TTD - Therapeutic Targets Database Full Data Download File Title - TTD targets information in raw format Version 10.1.01 (2024.01.10) Provided by IDRB Lab of Innovative Drug Reasearch and Bioinformatics College of Pharmaceutical Sciences Zhejiang University https://idrblab.org/ Provided by BIDD BioInformatic and Drug Design Group Department of Pharmacy National Unviersity of Singapore https://bidd.group/ Any question about data provided here, please contact with: Dr. Zhou (zhou_ying@zju.edu.cn) and Dr. Zhang (zhangyintao@zju.edu.cn) -------------------------------------------------------------------------------------------------------- Abbreviations: TARGETID TTD Target ID FORMERID TTD Former Target ID UNIPROID Uniprot ID TARGNAME Target Name GENENAME Target Gene Name TARGTYPE Target Type SYNONYMS Synonyms FUNCTION Function PDBSTRUC PDB Structure BIOCLASS BioChemical Class ECNUMBER EC Number SEQUENCE Sequence DRUGINFO TTD Drug ID Drug Name Highest Clinical Status -------------------------------------------------------------------------------------------------------- T47101 TARGETID T47101 T47101 FORMERID TTDC00024 T47101 UNIPROID FGFR1_HUMAN T47101 TARGNAME Fibroblast growth factor receptor 1 (FGFR1) T47101 GENENAME FGFR1 T47101 TARGTYPE Successful T47101 SYNONYMS c-fgr; bFGF-R-1; bFGF-R; N-sam; HBGFR; Fms-like tyrosine kinase 2; FLT2; FLT-2; FLG; FGFR-1; FGFBR; CEK; CD331 antigen; CD331; Basic fibroblast growth factor receptor 1; BFGFR T47101 FUNCTION Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. T47101 PDBSTRUC 6MZW; 6MZQ; 6C1O; 6C1C; 6C1B T47101 BIOCLASS Kinase T47101 ECNUMBER EC 2.7.10.1 T47101 SEQUENCE MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR T47101 DRUGINFO D0O6UY Pemigatinib Approved T47101 DRUGINFO D09HNV Intedanib Approved T47101 DRUGINFO D01PZD Romiplostim Approved T47101 DRUGINFO D07PQJ ARQ-087 Phase 3 T47101 DRUGINFO D05PWX Sulfatinib Phase 3 T47101 DRUGINFO D0A1AQ Rosiglitazone + metformin Phase 3 T47101 DRUGINFO D02WVT E-3810 Phase 3 T47101 DRUGINFO D0NU0U AZD4547 Phase 2/3 T47101 DRUGINFO D08DFF AM-001 Phase 2 T47101 DRUGINFO D08ZHL FGF-1 Phase 2 T47101 DRUGINFO D0U2DO FP-1039 Phase 2 T47101 DRUGINFO DR8CM0 MK-3655 Phase 2 T47101 DRUGINFO D0XT0W Debio 1347 Phase 2 T47101 DRUGINFO D00DRL MK-2461 Phase 1/2 T47101 DRUGINFO D0DJ0S NGM313 Phase 1 T47101 DRUGINFO D00ABO KW-2449 Phase 1 T47101 DRUGINFO D0LF0O BMS-695735 Preclinical T47101 DRUGINFO D0Z0KD PD-0183812 Terminated T47101 DRUGINFO D00JZS Anti-FGFR1 mab program Investigative T47101 DRUGINFO D01AVF SAR-106881 Investigative T47101 DRUGINFO D04FNY NP-506 Investigative T47101 DRUGINFO D06FFZ PMID26080733C7r Investigative T47101 DRUGINFO D06QUJ 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine Investigative T47101 DRUGINFO D07QMC 3-Benzimidazol-2-ylhydroquinolin-2-one Investigative T47101 DRUGINFO D0EE6A AAL-993 Investigative T47101 DRUGINFO D0OH3J PD-0179483 Investigative T47101 DRUGINFO D0R6OM ACTB-1003 Investigative T47101 DRUGINFO D0S1KJ PD-0173952 Investigative T47101 DRUGINFO D0XC6G 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole Investigative T47101 DRUGINFO D0Z7GH PD-0173958 Investigative T47101 DRUGINFO D03NPX PD-0173955 Investigative T47101 DRUGINFO D0D5EW HKI-9924129 Investigative T47101 DRUGINFO D0GW4Q PD-0173956 Investigative T47101 DRUGINFO D0P3JW PD-0166326 Investigative T47101 DRUGINFO D0E7VO PMID24900538C2c Investigative T47101 DRUGINFO D0C2GE PMID22765894C8h Investigative T47101 DRUGINFO D09XIL Ro-4396686 Investigative T59328 TARGETID T59328 T59328 FORMERID TTDS00355 T59328 UNIPROID EGFR_HUMAN T59328 TARGNAME Epidermal growth factor receptor (EGFR) T59328 GENENAME EGFR T59328 TARGTYPE Successful T59328 SYNONYMS Receptor tyrosine-protein kinase erbB-1; Proto-oncogene c-ErbB-1; HER1; ERBB1; ERBB T59328 FUNCTION Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance (By similarity). T59328 PDBSTRUC 6D8E; 6B3S; 6ARU; 5ZWJ; 5YU9 T59328 BIOCLASS Kinase T59328 ECNUMBER EC 2.7.10.1 T59328 SEQUENCE MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA T59328 DRUGINFO D03WPP Necitumumab Approved T59328 DRUGINFO D05GGP HEGF Approved T59328 DRUGINFO D07POC Erlotinib Approved T59328 DRUGINFO D09XZB Gefitinib Approved T59328 DRUGINFO D0HU9H Panitumumab Approved T59328 DRUGINFO D0N5OV Cetuximab Approved T59328 DRUGINFO D05UFG BIBW 2992 Approved T59328 DRUGINFO D07YDE Nitroglycerin Approved T59328 DRUGINFO D08TPS Epidermal growth factor Approved T59328 DRUGINFO D0O8GK Osimertinib Approved T59328 DRUGINFO D0U1ZV NERATINIB MALEATE Approved T59328 DRUGINFO DQ5X1Z Amivantamab Approved T59328 DRUGINFO D03MNN SKI-758 Approved T59328 DRUGINFO D06XXH Dacomitinib Approved T59328 DRUGINFO D08CDI Lapatinib Approved T59328 DRUGINFO D0F0ZE Merimepodib Approved T59328 DRUGINFO D0G6QF Vandetanib Approved T59328 DRUGINFO D0W5HK Sorafenib Approved T59328 DRUGINFO D06WRJ Icotinib hydrochloride Registered T59328 DRUGINFO D05FRP Rindopepimut Phase 3 T59328 DRUGINFO D0CR8H SYM-004 Phase 3 T59328 DRUGINFO D0FJ1W DE-766 Phase 3 T59328 DRUGINFO D0K7FY EGF816 Phase 3 T59328 DRUGINFO D0M4AV CO-1686 Phase 3 T59328 DRUGINFO D0R4PW Zalutumumab Phase 3 T59328 DRUGINFO DDH8L6 Almonertinib Phase 3 T59328 DRUGINFO DWK96T ASP1929 Phase 3 T59328 DRUGINFO DXZ31K A140 Phase 3 T59328 DRUGINFO D09BKY Bevacizumab + Erlotinib Phase 3 T59328 DRUGINFO D0Q9CY HKI-272 Phase 3 T59328 DRUGINFO D0F3KC Indium-111 Phase 2/3 T59328 DRUGINFO D00NYJ Varlitinib Phase 2/3 T59328 DRUGINFO D02BYZ ASP8273 Phase 2 T59328 DRUGINFO D06XIT ABT-414 Phase 2 T59328 DRUGINFO D0A6CC Depatuxizumab Phase 2 T59328 DRUGINFO D0BZ7V Matuzumab Phase 2 T59328 DRUGINFO D0C3LL HER1-VSSP vaccine Phase 2 T59328 DRUGINFO D0FN4T RM-1929 Phase 2 T59328 DRUGINFO D0K9MC CetuGEX Phase 2 T59328 DRUGINFO D0P9RG ABX-EGF Phase 2 T59328 DRUGINFO D0S3PO Pelitinib Phase 2 T59328 DRUGINFO D00YER HM-78136B Phase 2 T59328 DRUGINFO D03UKJ Pazopanib + Tyverb/Tykerb Phase 2 T59328 DRUGINFO D09BZJ MEHD-7945A Phase 2 T59328 DRUGINFO D0T5JS TT-100 Phase 2 T59328 DRUGINFO D0U4FF BMS-599626 Phase 2 T59328 DRUGINFO DUW81M Tarloxotinib Phase 2 T59328 DRUGINFO D0P6DJ VATALANIB Phase 2 T59328 DRUGINFO D0R6UV BMS-690514 Phase 2 T59328 DRUGINFO D0YB3W CI-1033 Phase 2 T59328 DRUGINFO D04DHZ CART-EGFR Phase 1/2 T59328 DRUGINFO D05ETC SN-32793 Phase 1/2 T59328 DRUGINFO D0G1ZU EGFR CART Phase 1/2 T59328 DRUGINFO D0S8BG EMD 55900 Phase 1/2 T59328 DRUGINFO DC1GH7 TAK-186 Phase 1/2 T59328 DRUGINFO DF0PR6 ZN-e4 Phase 1/2 T59328 DRUGINFO DWQ6J1 EMB-01 Phase 1/2 T59328 DRUGINFO D0B4OK Sym015 Phase 1/2 T59328 DRUGINFO D9FJ5V BDTX-189 Phase 1/2 T59328 DRUGINFO DK8QG3 AFM24 Phase 1/2 T59328 DRUGINFO D0FF2G Sym013 Phase 1/2 T59328 DRUGINFO D0V4XY S-222611 Phase 1b T59328 DRUGINFO D00KML SYN004 Phase 1 T59328 DRUGINFO D00RMC BIBX-1382 Phase 1 T59328 DRUGINFO D04HSH IMGN289 Phase 1 T59328 DRUGINFO D04OLK AST-1306 Phase 1 T59328 DRUGINFO D05LMC AMG 595 Phase 1 T59328 DRUGINFO D0E7RC HER-2/HER-1 vaccine Phase 1 T59328 DRUGINFO D0I7ZH EGFR806-specific CAR T cell Phase 1 T59328 DRUGINFO D0JS0W PF-05230907 Phase 1 T59328 DRUGINFO D0N3PC MR1-1 Phase 1 T59328 DRUGINFO D0T0SE Anti-EGFR CAR T Phase 1 T59328 DRUGINFO D0X7BN AP32788 Phase 1 T59328 DRUGINFO D68RMI CLN-081 Phase 1 T59328 DRUGINFO D01IJM LY3164530 Phase 1 T59328 DRUGINFO D01NAP MM-151 Phase 1 T59328 DRUGINFO D08JAN Cipatinib Phase 1 T59328 DRUGINFO D0JW2O Anti-HER3/EGFR DAF Phase 1 T59328 DRUGINFO D0U7XJ BCA101 Phase 1 T59328 DRUGINFO D0Z4RC CUDC-101 Phase 1 T59328 DRUGINFO D6JM8Z SI-B001 Phase 1 T59328 DRUGINFO D73FNL CX-904 Phase 1 T59328 DRUGINFO DN47VK AZD9592 Phase 1 T59328 DRUGINFO DR4ND6 D2C7 Phase 1 T59328 DRUGINFO DV8I4Q MCLA-158 Phase 1 T59328 DRUGINFO D0U3XL JNJ-26483327 Phase 1 T59328 DRUGINFO D0Z2PC Pyrrolo[2,3-d]pyrimidine derivative 24 Patented T59328 DRUGINFO D07GFF PKI166 Discontinued in Phase 2 T59328 DRUGINFO D0E2CQ RG7160 Discontinued in Phase 2 T59328 DRUGINFO D0Q7HO PD-153035 Discontinued in Phase 1 T59328 DRUGINFO D02RZL AZD4769 Discontinued in Phase 1 T59328 DRUGINFO D0A9OV TAK165 Discontinued in Phase 1 T59328 DRUGINFO D0V2FZ 111In-hEGF Preclinical T59328 DRUGINFO D0TI4U EGFR/IGFR tandem adnectin Preclinical T59328 DRUGINFO D02GFZ Heparin-EGF-like factor Terminated T59328 DRUGINFO D03QTP CGP-52411 Terminated T59328 DRUGINFO D0HO1S CGP-53353 Terminated T59328 DRUGINFO D0Y1YX AZD-9935 Terminated T59328 DRUGINFO D00TJF N4-(3-chlorophenyl)quinazoline-4,6-diamine Investigative T59328 DRUGINFO D00VZA 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile Investigative T59328 DRUGINFO D00WZG 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline Investigative T59328 DRUGINFO D01NTW 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide Investigative T59328 DRUGINFO D01SQP HM-61713B Investigative T59328 DRUGINFO D01WDI Benzyl-quinazolin-4-yl-amine Investigative T59328 DRUGINFO D01WXV 6,7-diethoxy-4-styrylquinazoline Investigative T59328 DRUGINFO D02FGG AFM-21 Investigative T59328 DRUGINFO D02GCE PD182905 Investigative T59328 DRUGINFO D02KVB AG 112 Investigative T59328 DRUGINFO D02RIG 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile Investigative T59328 DRUGINFO D02ZRO (3-Bromo-phenyl)-quinazolin-4-yl-amine Investigative T59328 DRUGINFO D03ATU PD-158780 Investigative T59328 DRUGINFO D03BJB EGFR inhibitor Investigative T59328 DRUGINFO D03CVQ 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline Investigative T59328 DRUGINFO D03MTY LA22-radioimmunoconjugates Investigative T59328 DRUGINFO D03WEN 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide Investigative T59328 DRUGINFO D03ZIW ICR 62 Investigative T59328 DRUGINFO D04GCH Bmab-200 Investigative T59328 DRUGINFO D04HGN HTS-00213 Investigative T59328 DRUGINFO D04LXG 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline Investigative T59328 DRUGINFO D05ARF N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine Investigative T59328 DRUGINFO D05MEY Epitinib Investigative T59328 DRUGINFO D06QEQ OSI-75 Investigative T59328 DRUGINFO D06UEK (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin Investigative T59328 DRUGINFO D07CZM HTS-02876 Investigative T59328 DRUGINFO D07IHD 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile Investigative T59328 DRUGINFO D07UYV PMID8568816C56 Investigative T59328 DRUGINFO D08RXW MT-062 Investigative T59328 DRUGINFO D09RXX Anti-EGFR mab Investigative T59328 DRUGINFO D0A0JL RG-50810 Investigative T59328 DRUGINFO D0AC7C IPS-01003 Investigative T59328 DRUGINFO D0AH2V RM-6427 Investigative T59328 DRUGINFO D0B4PH N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine Investigative T59328 DRUGINFO D0B8DE 3-Pyridin-4-yl-quinoline-6,7-diol Investigative T59328 DRUGINFO D0C5WE AGT-2000 Investigative T59328 DRUGINFO D0C9KC 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one Investigative T59328 DRUGINFO D0CY9O ON-128 Investigative T59328 DRUGINFO D0D0GS FHT-2107 Investigative T59328 DRUGINFO D0D0YK GI-3000 Investigative T59328 DRUGINFO D0DF3Z 6,7-dimethoxy-N-m-tolylquinazolin-4-amine Investigative T59328 DRUGINFO D0EH6L 5,6-Bis-p-tolylamino-isoindole-1,3-dione Investigative T59328 DRUGINFO D0EP1G HTS-05058 Investigative T59328 DRUGINFO D0F6FZ N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide Investigative T59328 DRUGINFO D0G4HR 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid Investigative T59328 DRUGINFO D0G9KD Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine Investigative T59328 DRUGINFO D0GB7F ARX-AHD Investigative T59328 DRUGINFO D0H3FX TGF alpha Investigative T59328 DRUGINFO D0H3UI AG 9 Investigative T59328 DRUGINFO D0HM5W N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine Investigative T59328 DRUGINFO D0I7RA 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline Investigative T59328 DRUGINFO D0J3EA Theliatinib Investigative T59328 DRUGINFO D0J9WO 4-(3-Bromo-phenylamino)-quinazoline-6,7-diol Investigative T59328 DRUGINFO D0K2VO 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline Investigative T59328 DRUGINFO D0K2YY 4-(2-nitroprop-1-enyl)benzene-1,2-diol Investigative T59328 DRUGINFO D0K3FG EDP-13 Investigative T59328 DRUGINFO D0K7GD N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine Investigative T59328 DRUGINFO D0KN1L (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate Investigative T59328 DRUGINFO D0L3SN 4-(2-nitrovinyl)benzene-1,2-diol Investigative T59328 DRUGINFO D0NH7M AG-538 Investigative T59328 DRUGINFO D0NJ3Q WZ-3146 Investigative T59328 DRUGINFO D0O9UR 2-methoxy-4-(2-nitrovinyl)phenol Investigative T59328 DRUGINFO D0P0JW MG-111 Investigative T59328 DRUGINFO D0P2GE 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline Investigative T59328 DRUGINFO D0R2RV Anti-EGFR humanized mabs Investigative T59328 DRUGINFO D0S9QP 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline Investigative T59328 DRUGINFO D0T7OS AL-6802 Investigative T59328 DRUGINFO D0U6WB BPIQ-I Investigative T59328 DRUGINFO D0V0JV mabionHER2 Investigative T59328 DRUGINFO D0W1BE 4-(2-nitrovinyl)phenol Investigative T59328 DRUGINFO D0W2PQ 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide Investigative T59328 DRUGINFO D0WD8R MDP-01 Investigative T59328 DRUGINFO D0X4UE N4-(3-methylphenyl)-4,6-quinazolinediamine Investigative T59328 DRUGINFO D0Y1LD RX-1792 Investigative T59328 DRUGINFO D0Y2AM (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine Investigative T59328 DRUGINFO D0Y6MD NRC-2694 Investigative T59328 DRUGINFO D0ZT9D Cochliobolic acid Investigative T59328 DRUGINFO D01VFR PD-168393 Investigative T59328 DRUGINFO D01WYI N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide Investigative T59328 DRUGINFO D03HLH 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline Investigative T59328 DRUGINFO D05QMN 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline Investigative T59328 DRUGINFO D0AM9O YH013 Investigative T59328 DRUGINFO D0D9TU LAVENDUSTIN A Investigative T59328 DRUGINFO D0J2CP PF 5208766 Investigative T59328 DRUGINFO D0J5SK 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine Investigative T59328 DRUGINFO D0N8TQ N-(4-(phenylamino)quinazolin-6-yl)acrylamide Investigative T59328 DRUGINFO D0Q3GG AG-213 Investigative T59328 DRUGINFO D0Q8GX SYM-011 Investigative T59328 DRUGINFO D0W6CE 10-hydroxy-18-methoxybetaenone Investigative T59328 DRUGINFO D0X4OU 4557W Investigative T59328 DRUGINFO D0ZH1U Tyrphostin ag-1478 Investigative T59328 DRUGINFO D00TZD CL-387785 Investigative T59328 DRUGINFO D05FFT HDS-029 Investigative T59328 DRUGINFO D0E5IP WHI-P154 Investigative T59328 DRUGINFO D06BJG PMID24915291C38 Investigative T59328 DRUGINFO D0D5EW HKI-9924129 Investigative T59328 DRUGINFO D0GW4Q PD-0173956 Investigative T59328 DRUGINFO D0P3JW PD-0166326 Investigative T59328 DRUGINFO D03EHM PP121 Investigative T59328 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T59328 DRUGINFO D09XIL Ro-4396686 Investigative T59328 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T59328 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T59328 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T89515 TARGETID T89515 T89515 FORMERID TTDS00208 T89515 UNIPROID DEFM_HUMAN T89515 TARGNAME Polypeptide deformylase (PDF) T89515 GENENAME PDF T89515 TARGTYPE Successful T89515 SYNONYMS PDF T89515 FUNCTION Bifunctional enzyme. Involved in de novo dTMP biosynthesis. Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, DNA precursor synthesis, and for the conversion of dUMP to dTMP. T89515 PDBSTRUC 3G5P; 3G5K T89515 BIOCLASS CH-NH donor oxidoreductase T89515 ECNUMBER EC 3.5.1.88 T89515 SEQUENCE MARLWGALSLWPLWAAVPWGGAAAVGVRACSSTAAPDGVEGPALRRSYWRHLRRLVLGPPEPPFSHVCQVGDPVLRGVAAPVERAQLGGPELQRLTQRLVQVMRRRRCVGLSAPQLGVPRQVLALELPEALCRECPPRQRALRQMEPFPLRVFVNPSLRVLDSRLVTFPEGCESVAGFLACVPRFQAVQISGLDPNGEQVVWQASGWAARIIQHEMDHLQGCLFIDKMDSRTFTNVYWMKVND T89515 DRUGINFO D02LWU Pralatrexate Approved T89515 DRUGINFO D0E3SF MCB-3837 Approved T89515 DRUGINFO D0P8RS Proguanil Approved T89515 DRUGINFO D0Y2DI Chlorproguanil Approved T89515 DRUGINFO D0Y7TS Trimetrexate Approved T89515 DRUGINFO D0A2UV Ustekinumab Approved T89515 DRUGINFO D0Y4AW Meprobamate Approved T89515 DRUGINFO D02AIM Metoprine Phase 2 T89515 DRUGINFO D0W3LI LY333531 Phase 2 T89515 DRUGINFO D0D2RN Aminopterin Withdrawn from market T89515 DRUGINFO D01ILN 6,7-Diphenyl-pteridine-2,4-diamine Investigative T89515 DRUGINFO D01UOO 3-Benzyl-2-ethylthio-6-nitro-quinazolin-4(3H)-one Investigative T89515 DRUGINFO D02ZCP 5-Phenylsulfanyl-2,4-Quinazolinediamine Investigative T89515 DRUGINFO D02ZPZ 5-((E)-Styryl)-quinazoline-2,4-diamine Investigative T89515 DRUGINFO D03DRF 2-Allylthio-3-benzyl-6-nitro-quinazolin-4(3H)-one Investigative T89515 DRUGINFO D03POU 8-(3,4-dimethoxyphenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D04MOZ NB3178 Investigative T89515 DRUGINFO D04UBQ 8-(3,4-dichlorophenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D05KJX 8-(2,4,6-trimethoxyphenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D05TPU 8-(2,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D05WHM Edatrexate Investigative T89515 DRUGINFO D06DIH Furo[2,3d]Pyrimidine Antifolate Investigative T89515 DRUGINFO D06QEN 7-Methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine Investigative T89515 DRUGINFO D06UPT Sri-9439 Investigative T89515 DRUGINFO D07BKE 8-(3,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D07XLJ N*6*-Benzyl-quinazoline-2,4,6-triamine Investigative T89515 DRUGINFO D08CMW 6-Phenylaminomethyl-quinazoline-2,4-diamine Investigative T89515 DRUGINFO D08GPU 5-Phenethyl-quinazoline-2,4-diamine Investigative T89515 DRUGINFO D09YVN Dihydrofolic Acid Investigative T89515 DRUGINFO D0A5GM 8-(2,5-dimethoxyphenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D0A6CS Bromo-WR99210 Investigative T89515 DRUGINFO D0A8HX 6-m-Tolyl-pteridine-2,4,7-triamine Investigative T89515 DRUGINFO D0A9WT 5-Formyl-6-Hydrofolic Acid Investigative T89515 DRUGINFO D0AT2Z 3-Phenylsulfanylmethyl-quinoxaline-5,7-diamine Investigative T89515 DRUGINFO D0B9MY 8-Pyridin-4-yl-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D0C1EF 5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine Investigative T89515 DRUGINFO D0C1UM Tylophorinidine Investigative T89515 DRUGINFO D0C9NE Biopterin Investigative T89515 DRUGINFO D0CH7U 2'-Monophosphoadenosine-5'-Diphosphate Investigative T89515 DRUGINFO D0D1ON Sri-9662 Investigative T89515 DRUGINFO D0DT4R Brodimoprim-4,6-Dicarboxylate Investigative T89515 DRUGINFO D0H2VY 8-benzyl-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D0H4NN NB3322 Investigative T89515 DRUGINFO D0H8AW GNF-PF-607 Investigative T89515 DRUGINFO D0J4KJ 5-p-Tolylsulfanyl-quinazoline-2,4-diamine Investigative T89515 DRUGINFO D0KY9B 5-Chloryl-2,4,6-Quinazolinetriamine Investigative T89515 DRUGINFO D0LH5P GNF-PF-173 Investigative T89515 DRUGINFO D0ME8Z 5-(2-fluorobenzyloxy)quinazoline-2,4-diamine Investigative T89515 DRUGINFO D0O9YG Cycloguanil Investigative T89515 DRUGINFO D0S1VJ 8-(3,5-dimethoxyphenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D0S4ZT 2-Allylthio-6-amino-3-benzyl-quinazolin-4(3H)-one Investigative T89515 DRUGINFO D0SB0W 8-(2,4-dimethoxyphenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D0U0KY 8-(2,6-Dichloro-phenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D0U7CJ 4-(2,6-diamino-9H-purin-8-yl)-2,6-dimethoxyphenol Investigative T89515 DRUGINFO D0UR9D 3-benzyl-2-mercapto-6-nitroquinazolin-4(3H)-one Investigative T89515 DRUGINFO D0V1UL 6-(2-Phenylsulfanyl-ethyl)-pteridine-2,4-diamine Investigative T89515 DRUGINFO D0V9US 6-Phenylsulfanylmethyl-pteridine-2,4-diamine Investigative T89515 DRUGINFO D0Y3TU 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine Investigative T89515 DRUGINFO D0Y5JB 8-(2,3,4-trimethoxyphenyl)-9H-purine-2,6-diamine Investigative T89515 DRUGINFO D06YIB DDATHF Investigative T89515 DRUGINFO D0B1PE Ro 5-4864 Investigative T89515 DRUGINFO D0T1XE Pergularinine Investigative T89515 DRUGINFO D0UZ9U PREMETREXED Investigative T89515 DRUGINFO D07KZA 2-(N-Morpholino)-Ethanesulfonic Acid Investigative T89515 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T89515 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T08391 TARGETID T08391 T08391 FORMERID TTDC00187 T08391 UNIPROID JAK2_HUMAN T08391 TARGNAME Janus kinase 2 (JAK-2) T08391 GENENAME JAK2 T08391 TARGTYPE Successful T08391 SYNONYMS Tyrosine-protein kinase JAK2 T08391 FUNCTION Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin. Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. T08391 PDBSTRUC 6M9H; 6E2Q; 6E2P; 6DRW; 6BSS T08391 BIOCLASS Kinase T08391 ECNUMBER EC 2.7.10.2 T08391 SEQUENCE MGMACLTMTEMEGTSTSSIYQNGDISGNANSMKQIDPVLQVYLYHSLGKSEADYLTFPSGEYVAEEICIAASKACGITPVYHNMFALMSETERIWYPPNHVFHIDESTRHNVLYRIRFYFPRWYCSGSNRAYRHGISRGAEAPLLDDFVMSYLFAQWRHDFVHGWIKVPVTHETQEECLGMAVLDMMRIAKENDQTPLAIYNSISYKTFLPKCIRAKIQDYHILTRKRIRYRFRRFIQQFSQCKATARNLKLKYLINLETLQSAFYTEKFEVKEPGSGPSGEEIFATIIITGNGGIQWSRGKHKESETLTEQDLQLYCDFPNIIDVSIKQANQEGSNESRVVTIHKQDGKNLEIELSSLREALSFVSLIDGYYRLTADAHHYLCKEVAPPAVLENIQSNCHGPISMDFAISKLKKAGNQTGLYVLRCSPKDFNKYFLTFAVERENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKCCPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHRNYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKNILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYEDRHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG T08391 DRUGINFO D0G8BM Fedratinib Approved T08391 DRUGINFO D0D5ZJ Momelotinib Approved T08391 DRUGINFO D04LKS Ruxolitinib Approved T08391 DRUGINFO D05PCM Abrocitinib Approved T08391 DRUGINFO D0Y7IC Baricitinib Approved T08391 DRUGINFO D05AJT XL019 Phase 3 T08391 DRUGINFO D0GH3Q ITF2357 Phase 3 T08391 DRUGINFO D05TSJ LY2784544 Phase 2 T08391 DRUGINFO D0DK8X BMS-911543 Phase 2 T08391 DRUGINFO D0MP0X AZD1480 Phase 2 T08391 DRUGINFO D01UAU CTP-543 Phase 2 T08391 DRUGINFO D09AFI INCB039110 Phase 2 T08391 DRUGINFO DH0A6O A223 Phase 2 T08391 DRUGINFO DU10JI CTP-543 Phase 2 T08391 DRUGINFO D2KTG5 TD-8236 Phase 2 T08391 DRUGINFO D0BI3N Cerdulatinib Phase 2 T08391 DRUGINFO D00MYW NS-018 Phase 1/2 T08391 DRUGINFO D2JZ3U ALXN2075 Phase 1/2 T08391 DRUGINFO D00RYA SB-1578 Phase 1 T08391 DRUGINFO D08CNP AC430 Phase 1 T08391 DRUGINFO D0S0NX Peginterferon beta Phase 1 T08391 DRUGINFO DI19BZ KN-002 Phase 1 T08391 DRUGINFO DX72LV AZD4604 Phase 1 T08391 DRUGINFO DXVA93 PF-07295324 Phase 1 T08391 DRUGINFO DZ2RH6 GDC-0214 Phase 1 T08391 DRUGINFO D0HS2J PMID27774824-Compound-Figure8Example99 Patented T08391 DRUGINFO D0KF8H PMID27774824-Compound-Figure8Example22 Patented T08391 DRUGINFO D00JUI Triazolo-pyridine derivative 1 Patented T08391 DRUGINFO D02VGC Pyrazolopyridine derivative 6 Patented T08391 DRUGINFO D03PBI Pyrrolo-pyridone derivative 2 Patented T08391 DRUGINFO D03TEE Tricyclic heterocycle derivative 2 Patented T08391 DRUGINFO D04OCD PMID27774822-Compound-Figure7Example63 Patented T08391 DRUGINFO D05GEL Cyclic cyanoethypypazole derivative 1 Patented T08391 DRUGINFO D06MQB Pyrrolo-pyridone derivative 1 Patented T08391 DRUGINFO D09RTW Aromatic bicyclic compound 6 Patented T08391 DRUGINFO D0A8BV PMID27774822-Compound-Figure10Compound12 Patented T08391 DRUGINFO D0AE0M PMID27774822-Compound-Figure10Compound4 Patented T08391 DRUGINFO D0B9TH PMID27774822-Compound-Figure8Example5 Patented T08391 DRUGINFO D0CD6Y Pyrimidopyridazinone derivative 1 Patented T08391 DRUGINFO D0D1QH Pyrazolopyridine derivative 7 Patented T08391 DRUGINFO D0E2WK PMID27774822-Compound-Figure2Example1-1left Patented T08391 DRUGINFO D0F3BK PMID27774824-Compound-Figure6Example6 Patented T08391 DRUGINFO D0H6XN Geminally-substituted cyanoethylpypazolo pyridone derivative 1 Patented T08391 DRUGINFO D0IC8O Curcumin analog 2 Patented T08391 DRUGINFO D0IQ6G PMID27774822-Compound-Figure2Example1-1right Patented T08391 DRUGINFO D0JZ2B Alkynyl-substituted pyrimidinyl-pyrrole derivative 1 Patented T08391 DRUGINFO D0K2RW Cyanomethyl pypazole carboxamide derivative 1 Patented T08391 DRUGINFO D0KI5F Geminally-substituted cyanoethylpypazolo pyridone derivative 2 Patented T08391 DRUGINFO D0M2OK Bis-aminopyrimidine derivative 5 Patented T08391 DRUGINFO D0M5AG Aromatic bicyclic compound 3 Patented T08391 DRUGINFO D0M9YZ Aromatic bicyclic compound 4 Patented T08391 DRUGINFO D0NP2W 1,2,4-triazolo[1,5a]pyridine derivative 2 Patented T08391 DRUGINFO D0NY6M PMID27774822-Compound-Figure3CompoundI-165 Patented T08391 DRUGINFO D0PB5X Cycloalkyl nitrile pyrazolo pyridone derivative 1 Patented T08391 DRUGINFO D0PM8K PMID27774824-Compound-Figure7Example10 Patented T08391 DRUGINFO D0Q5JV Aromatic bicyclic compound 5 Patented T08391 DRUGINFO D0QD5Y Aromatic bicyclic compound 1 Patented T08391 DRUGINFO D0S4TH Cycloalkyl nitrile pyrazolo pyridone derivative 2 Patented T08391 DRUGINFO D0V0KI Cycloalkyl nitrile pyrazole carboxamide derivative 1 Patented T08391 DRUGINFO D0VI7E Aromatic bicyclic compound 2 Patented T08391 DRUGINFO D0VQ7P Pyrrolo[2,3-d]pyrimidine derivative 11 Patented T08391 DRUGINFO D0W8DN PMID27774822-Compound-Figure10Example19 Patented T08391 DRUGINFO D0WD1Z Curcumin analog 1 Patented T08391 DRUGINFO D01EYJ Ruxolitinib derivative 2 Patented T08391 DRUGINFO D07XYI 1,2,4-triazolo[1,5a]pyridine derivative 1 Patented T08391 DRUGINFO D08WPB Five-and-six-membered heterocyclic compound 1 Patented T08391 DRUGINFO D09RUN Pyrazolopyridine derivative 4 Patented T08391 DRUGINFO D09UBE Pyrrole six-membered heteroaryl ring derivative 1 Patented T08391 DRUGINFO D0A6RG PMID27774824-Compound-Figure2Example4 Patented T08391 DRUGINFO D0G0FK Tricyclic compound 1 Patented T08391 DRUGINFO D0G9MM Isoxazole derivative 1 Patented T08391 DRUGINFO D0GH8D PMID27774822-Compound-Figure10Example1 Patented T08391 DRUGINFO D0M3CB PMID27774822-Compound-Figure1Example20 Patented T08391 DRUGINFO D0TX2G Isoxazole derivative 2 Patented T08391 DRUGINFO D0VR6E Pyrrolo-pyridine derivative 3 Patented T08391 DRUGINFO D0Y2IM N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 Patented T08391 DRUGINFO D0YJ4D Pyrrole derivative 7 Patented T08391 DRUGINFO D01CRX Benzimidazole derivative 7 Patented T08391 DRUGINFO D01FVC Bis-aminopyrimidine derivative 1 Patented T08391 DRUGINFO D03QAY Pyrazolopyridine derivative 3 Patented T08391 DRUGINFO D04BOW Tricyclic pyrrolopyridine compound 1 Patented T08391 DRUGINFO D05AXE Aminooxazole carboxamide derivative 1 Patented T08391 DRUGINFO D0FQ4Z Pyrrolo[2,3-d]pyrimidine derivative 6 Patented T08391 DRUGINFO D0GB7G PMID27774824-Compound-Figure6Example12 Patented T08391 DRUGINFO D0KL3B Pyrrolo[2,3-d]pyrimidine derivative 8 Patented T08391 DRUGINFO D0LR6J Bis-aminopyrimidine derivative 2 Patented T08391 DRUGINFO D0LS1O Tricyclic compound 11 Patented T08391 DRUGINFO D0M2WA Tricyclic heterocycle derivative 5 Patented T08391 DRUGINFO D0RJ3W PMID27774822-Compound-Figure11Example5 Patented T08391 DRUGINFO D0S6XT Bis-aminopyrimidine derivative 3 Patented T08391 DRUGINFO D0SJ1Q Bis-aminopyrimidine derivative 4 Patented T08391 DRUGINFO D0U1HA PMID27774824-Compound-Figure3Example18 Patented T08391 DRUGINFO D0U5FZ Pyrrolo[2,3-d]pyrimidine derivative 7 Patented T08391 DRUGINFO D0WA1V Pyrimidopyridazinone derivative 2 Patented T08391 DRUGINFO D0X1FD Tricyclic heterocycle derivative 1 Patented T08391 DRUGINFO D0WZ8N PMID27774824-Compound-Figure9Example2up Patented T08391 DRUGINFO D01DBB PMID27774824-Compound-Figure9Example2down Patented T08391 DRUGINFO D09ALF Aminotriazolopyridine derivative 1 Patented T08391 DRUGINFO D0VJ1R Imidazo[4,5-c]pyridine derivative 2 Patented T08391 DRUGINFO D0YR8S PMID27774824-Compound-Figure11Example1up Patented T08391 DRUGINFO D09PIS Pyrazolo[4,3-c]pyridine derivative 2 Patented T08391 DRUGINFO D0GZ7B AG490 Terminated T08391 DRUGINFO D00MAM AMG-JAK2-01 Investigative T08391 DRUGINFO D02UVS NSC-1771 Investigative T08391 DRUGINFO D09VZR SGI-1252 Investigative T08391 DRUGINFO D0I3EY 5-phenyl-1H-indazol-3-amine Investigative T08391 DRUGINFO D0I6QN K-454 Investigative T08391 DRUGINFO D0N8CN BVB-808 Investigative T08391 DRUGINFO D0OP3D AZ960 Investigative T08391 DRUGINFO DLW69V 1,2,3,4,5,6-hexabromocyclohexane Investigative T08391 DRUGINFO D05MHL Atropisomer 1 Investigative T08391 DRUGINFO D0A7XQ ON-044580 Investigative T08391 DRUGINFO D0IR6U CMP-6 Investigative T08391 DRUGINFO D0US9O PMID24359159C19a Investigative T08391 DRUGINFO D0E5IP WHI-P154 Investigative T08391 DRUGINFO D02NNT PMID21493067C1d Investigative T07663 TARGETID T07663 T07663 FORMERID TTDS00296 T07663 UNIPROID PDE5A_HUMAN T07663 TARGNAME Phosphodiesterase 5A (PDE5A) T07663 GENENAME PDE5A T07663 TARGTYPE Successful T07663 SYNONYMS cGMP-specific 3',5'-cyclic phosphodiesterase; PDE5A; CGMP-binding cGMP-specific phosphodiesterase; CGB-PDE T07663 FUNCTION Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP. Specifically regulates nitric-oxide-generated cGMP. T07663 PDBSTRUC 6ACB; 5ZZ2; 5JO3; 4OEX; 4OEW T07663 BIOCLASS Phosphoric diester hydrolase T07663 ECNUMBER EC 3.1.4.35 T07663 SEQUENCE MERAGPSFGQQRQQQQPQQQKQQQRDQDSVEAWLDDHWDFTFSYFVRKATREMVNAWFAERVHTIPVCKEGIRGHTESCSCPLQQSPRADNSAPGTPTRKISASEFDRPLRPIVVKDSEGTVSFLSDSEKKEQMPLTPPRFDHDEGDQCSRLLELVKDISSHLDVTALCHKIFLHIHGLISADRYSLFLVCEDSSNDKFLISRLFDVAEGSTLEEVSNNCIRLEWNKGIVGHVAALGEPLNIKDAYEDPRFNAEVDQITGYKTQSILCMPIKNHREEVVGVAQAINKKSGNGGTFTEKDEKDFAAYLAFCGIVLHNAQLYETSLLENKRNQVLLDLASLIFEEQQSLEVILKKIAATIISFMQVQKCTIFIVDEDCSDSFSSVFHMECEELEKSSDTLTREHDANKINYMYAQYVKNTMEPLNIPDVSKDKRFPWTTENTGNVNQQCIRSLLCTPIKNGKKNKVIGVCQLVNKMEENTGKVKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMAKQMVTLEVLSYHASAAEEETRELQSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWILSVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGVNNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAILATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAELVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCFPLLDGCRKNRQKWQALAEQQEKMLINGESGQAKRN T07663 DRUGINFO D01GUS Udenafil Approved T07663 DRUGINFO D05MQK Tadalafil Approved T07663 DRUGINFO D0C9SY Vardenafil Approved T07663 DRUGINFO D0F9GE Dipyridamole Approved T07663 DRUGINFO D0Y5JC Avanafil Approved T07663 DRUGINFO D0NJ3V Papaverine Approved T07663 DRUGINFO D0Z7ZM Rhucin Approved T07663 DRUGINFO D05OQG ICARIIN Phase 3 T07663 DRUGINFO D0M9VE EXISULIND Phase 3 T07663 DRUGINFO D0M9FQ PF-489791 Phase 2 T07663 DRUGINFO D09OCK UK-371800 Phase 1 T07663 DRUGINFO D00SPK E-4021 Discontinued in Phase 2 T07663 DRUGINFO D04NPP SLX-2101 Discontinued in Phase 2 T07663 DRUGINFO D0D7XW SINITRODIL Discontinued in Phase 2 T07663 DRUGINFO D0K2QG DASANTAFIL Discontinued in Phase 2 T07663 DRUGINFO D0X1LO EMR-62203 Discontinued in Phase 2 T07663 DRUGINFO D0K2BQ BRL-61063 Discontinued in Phase 2 T07663 DRUGINFO D0N5SC UK-369003 Discontinued in Phase 1/2 T07663 DRUGINFO D01FRF Trequinsin Terminated T07663 DRUGINFO D0W8OH SKF-96231 Terminated T07663 DRUGINFO D0W8QG FR-229934 Terminated T07663 DRUGINFO D00YPW ZAPRINAST Terminated T07663 DRUGINFO D09UMA IMAZODAN Terminated T07663 DRUGINFO D03BWH 7-(2-Hydroxyethyl)-3-O-rhamnosylicariin Investigative T07663 DRUGINFO D06TLQ Icariside II Investigative T07663 DRUGINFO D06URK CKD-533 Investigative T07663 DRUGINFO D08VGM Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine Investigative T07663 DRUGINFO D09WUP 3,7-Bis(2-hydroxyethyl)icaritin Investigative T07663 DRUGINFO D0H6ZC RWJ-387273 Investigative T07663 DRUGINFO D0KD6S SCH-57726 Investigative T07663 DRUGINFO D0LZ5R T0156 Investigative T07663 DRUGINFO D0O3QI Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine Investigative T07663 DRUGINFO D0V1CL Cartazolate Investigative T07663 DRUGINFO D0V3BI Aom-0890 Investigative T07663 DRUGINFO D0W2BI 8-prenylquercetin Investigative T07663 DRUGINFO D0X7SR 8-prenylapigenin Investigative T07663 DRUGINFO D0XQ8A TPN-729 Investigative T07663 DRUGINFO D0YZ0L LORNEIC ACID A Investigative T07663 DRUGINFO D0S8AV SOPHORAFLAVANONE B Investigative T07663 DRUGINFO D00QCL SOPHOFLAVESCENOL Investigative T07663 DRUGINFO D0T5PO ROLIPRAM Investigative T07663 DRUGINFO D0W4ZU KURARINOL Investigative T07663 DRUGINFO D04AWP Guanosine-5'-Monophosphate Investigative T07663 DRUGINFO D02VHD SCH51866 Investigative T07663 DRUGINFO D06GUJ KURAIDIN Investigative T07663 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T63505 TARGETID T63505 T63505 FORMERID TTDNS00592 T63505 UNIPROID ABL1_HUMAN T63505 TARGNAME Tyrosine-protein kinase ABL1 (ABL) T63505 GENENAME ABL1 T63505 TARGTYPE Successful T63505 SYNONYMS p150; Proto-oncogene tyrosine-protein kinase ABL1; Proto-oncogene c-Abl; JTK7; C-ABL; Abl; Abelson tyrosine-protein kinase 1; Abelson murine leukemia viral oncogene homolog 1 T63505 FUNCTION Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717'. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E. coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H. pylori, or AnkA (ankyrin repeat-containing protein A) of A. phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner. Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity. Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. T63505 PDBSTRUC 6NPV; 6NPU; 6NPE; 6BL8; 6AMW T63505 BIOCLASS Kinase T63505 ECNUMBER EC 2.7.10.2 T63505 SEQUENCE MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR T63505 DRUGINFO D01BYB Adenosine triphosphate Approved T63505 DRUGINFO D0OB0F Bosutinib Approved T63505 DRUGINFO D03MNN SKI-758 Approved T63505 DRUGINFO D0H0EQ Ponatinib Approved T63505 DRUGINFO D06JHV Flumatinib Phase 2 T63505 DRUGINFO D0M0XB Saracatinib Phase 2 T63505 DRUGINFO D0E0NM DCC-2036 Phase 1/2 T63505 DRUGINFO DC7P4Z IkT-148009 Phase 1 T63505 DRUGINFO D00ABO KW-2449 Phase 1 T63505 DRUGINFO D06CIJ ISIS-CRP Phase 1 T63505 DRUGINFO D03JXD PMID25656651-Compound-34c Patented T63505 DRUGINFO D05TYI Azaindole derivative 2 Patented T63505 DRUGINFO D06LHV PMID25656651-Compound-34a Patented T63505 DRUGINFO D0F4AW Indol-5-ol derivative 1 Patented T63505 DRUGINFO D0JD9Z PMID25656651-Compound-33b Patented T63505 DRUGINFO D0KM7V PMID25656651-Compound-34b Patented T63505 DRUGINFO D0O0RB 6,6-fused nitrogenous heterocyclic compound 1 Patented T63505 DRUGINFO D0QD6T 6,6-fused nitrogenous heterocyclic compound 2 Patented T63505 DRUGINFO D0RT8M PMID25656651-Compound-28b Patented T63505 DRUGINFO D0TX1S PMID25656651-Compound-33a Patented T63505 DRUGINFO D0X0VH PMID25656651-Compound-28a Patented T63505 DRUGINFO D0X9VH Azaindole derivative 1 Patented T63505 DRUGINFO D0XL1M 6,6-fused nitrogenous heterocyclic compound 3 Patented T63505 DRUGINFO D0Y0PE PMID25656651-Compound-46 Patented T63505 DRUGINFO D0ZH4I PMID25656651-Compound-42 Patented T63505 DRUGINFO D0WZ8N PMID27774824-Compound-Figure9Example2up Patented T63505 DRUGINFO D01DBB PMID27774824-Compound-Figure9Example2down Patented T63505 DRUGINFO D04GFO MC-2001 Preclinical T63505 DRUGINFO D0H3RD BAS-0338876 Investigative T63505 DRUGINFO D01GNF BAS-00387328 Investigative T63505 DRUGINFO D03GQI BAS-00387347 Investigative T63505 DRUGINFO D03PLP [1,1':2',1'']-terphenyl-4,3'',5''-triol Investigative T63505 DRUGINFO D04QUI BAS-00387275 Investigative T63505 DRUGINFO D07LYJ BAS-00672722 Investigative T63505 DRUGINFO D09QKH BAS-0338872 Investigative T63505 DRUGINFO D0A5MG BAS-09534324 Investigative T63505 DRUGINFO D0D8OY AP-24226 Investigative T63505 DRUGINFO D0D8ZN BAS-01373578 Investigative T63505 DRUGINFO D0O9NE TRISMETHOXYRESVERATROL Investigative T63505 DRUGINFO D0I3XZ Bis-(5-hydroxy-1H-indol-2-yl)-methanone Investigative T63505 DRUGINFO D0YZ7H JNJ-10198409 Investigative T63505 DRUGINFO D0GW4Q PD-0173956 Investigative T63505 DRUGINFO D0H1OK TG-100435 Investigative T63505 DRUGINFO D0P3JW PD-0166326 Investigative T63505 DRUGINFO D08OBF MYRISTIC ACID Investigative T63505 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T13201 TARGETID T13201 T13201 FORMERID TTDR01224 T13201 UNIPROID CAH1_HUMAN T13201 TARGNAME Carbonic anhydrase I (CA-I) T13201 GENENAME CA1 T13201 TARGTYPE Successful T13201 SYNONYMS Carbonic anhydrase B; Carbonic anhydrase 1; Carbonate dehydratase I; CAB T13201 FUNCTION Can hydrates cyanamide to urea. Reversible hydration of carbon dioxide. T13201 PDBSTRUC 6HWZ; 6G3V; 6FAG; 6FAF; 6F3B T13201 BIOCLASS Alpha-carbonic anhydrase T13201 ECNUMBER EC 4.2.1.1 T13201 SEQUENCE MASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEIINVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELHVAHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNFDPSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAVPMQHNNRPTQPLKGRTVRASF T13201 DRUGINFO D0C2II Methazolamide Approved T13201 DRUGINFO D0E1SW Acetazolamide Approved T13201 DRUGINFO D07INV Ethoxzolamide Approved T13201 DRUGINFO D0J4GO Dichlorphenamide Approved T13201 DRUGINFO D07HBX Salicyclic acid Approved T13201 DRUGINFO D0W2CX CG-100649 Phase 3 T13201 DRUGINFO D0A8JP PARABEN Phase 3 T13201 DRUGINFO D07SDQ Curcumin Phase 3 T13201 DRUGINFO D0L6HN PHENOL Phase 2/3 T13201 DRUGINFO D0Y6OA Coumate Phase 2 T13201 DRUGINFO D0V0UK SULFAMIDE Phase 1 T13201 DRUGINFO D03SLR FERULIC ACID Patented T13201 DRUGINFO D03LWY SULFATE Investigative T13201 DRUGINFO D04FXD CYANATE Investigative T13201 DRUGINFO D05EPY L-693612 Investigative T13201 DRUGINFO D09QHC BENZENESULFONAMIDE Investigative T13201 DRUGINFO D0CM3O [Au(CN)2]- Investigative T13201 DRUGINFO D0D1HC 5-oxo-1-tosyl-2,5-dihydro-1Hpyrrol-2-yl acetate Investigative T13201 DRUGINFO D0F7QZ Styrylboronic acid Investigative T13201 DRUGINFO D0T6VB Cynooxide anion Investigative T13201 DRUGINFO D0X0RE 4-methylstyrylboronic acid Investigative T13201 DRUGINFO D00RJT NITRATE Investigative T13201 DRUGINFO D00ZUQ ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE Investigative T13201 DRUGINFO D01GNQ Phenoxyarsonous acid Investigative T13201 DRUGINFO D04RCR 3-phenylprop-1-enylboronic acid Investigative T13201 DRUGINFO D05FMD 5-Chlorosalicylic Acid Investigative T13201 DRUGINFO D05WQF 2-Hydroxycinnamic acid Investigative T13201 DRUGINFO D06SME 5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one Investigative T13201 DRUGINFO D07OMY 3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide Investigative T13201 DRUGINFO D08RKK IODIDE Investigative T13201 DRUGINFO D08TBP 2-Acetylamino-indan-5-sulfonic acid hydrate Investigative T13201 DRUGINFO D0A8HW 4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide Investigative T13201 DRUGINFO D0BR1D 4,6-Dinitro salicylic acid Investigative T13201 DRUGINFO D0FD8G 2-(biphenyl-4-yl)vinylboronic acid Investigative T13201 DRUGINFO D0K5NQ N-[4-(trifluoromethyl)phenyl]sulfamide Investigative T13201 DRUGINFO D0L2GD [Cu(CN)2]- Investigative T13201 DRUGINFO D0M7QA N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE Investigative T13201 DRUGINFO D0O1QT 6-Amino-benzothiazole-2-sulfonic acid amide Investigative T13201 DRUGINFO D0S6CO 2,4-dichloro-5-sulfamoylbenzoic acid Investigative T13201 DRUGINFO D0U1AN 4-isothiocyanatobenzenesulfonamide Investigative T13201 DRUGINFO D0Y6EL Carbamoyl phosphate disodium Investigative T13201 DRUGINFO D00BMI N-1,3,4-thiadiazol-2-ylsulfamide Investigative T13201 DRUGINFO D00FGB 2-acetamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D00GVA 4-(2-Pyridin-4-ylacetamido)benzenesulfonamide Investigative T13201 DRUGINFO D00XIB 1-acetamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D01EEM 2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide Investigative T13201 DRUGINFO D01ISX 4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide Investigative T13201 DRUGINFO D01UDU 3-Chloro-4-hydrazino-benzenesulfonamide Investigative T13201 DRUGINFO D01YHK 3-Fluoro-4-hydrazino-benzenesulfonamide Investigative T13201 DRUGINFO D03EAQ N-hydroxysulfonamides Investigative T13201 DRUGINFO D04BKU Sulfamic acid 4-sulfamoyloxy-butyl ester Investigative T13201 DRUGINFO D05BMD 2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide Investigative T13201 DRUGINFO D05FNN Sulfamic acid 7-sulfamoyloxy-heptyl ester Investigative T13201 DRUGINFO D05NFU 4-butylphenylboronic acid Investigative T13201 DRUGINFO D05QEK Aminobenzolamide derivative Investigative T13201 DRUGINFO D06NDR 2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide Investigative T13201 DRUGINFO D06ORV Phenethylboronic acid Investigative T13201 DRUGINFO D06XNT 4-(2-Phenylacetamidomethyl)benzenesulfonamide Investigative T13201 DRUGINFO D07CBA Sulfamic acid 16-sulfamoyloxy-hexadecyl ester Investigative T13201 DRUGINFO D07IHP Sulfamic acid 3-sulfamoyloxy-phenyl ester Investigative T13201 DRUGINFO D07LYW 2-valproylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D07PNA 2-nonylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D07YSQ N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide Investigative T13201 DRUGINFO D07ZXR Sulfamic acid 12-sulfamoyloxy-dodecyl ester Investigative T13201 DRUGINFO D08AOA 2-ethylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D09CSP 3-(4-sulfamoylphenyl)propanoic acid Investigative T13201 DRUGINFO D09JHA Azide Investigative T13201 DRUGINFO D09LWR 4-(2-Phenylacetamidoethyl)benzenesulfonamide Investigative T13201 DRUGINFO D0A3JR 4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide Investigative T13201 DRUGINFO D0B4IN NSC-654077 Investigative T13201 DRUGINFO D0C8ZY Beta-naphthylboronic acid Investigative T13201 DRUGINFO D0D0BO 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide Investigative T13201 DRUGINFO D0D2JA 4-phenoxyphenylboronic acid Investigative T13201 DRUGINFO D0D5XC Sodium trithiocarbonate Investigative T13201 DRUGINFO D0DY9U 3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide Investigative T13201 DRUGINFO D0G0OP 2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide Investigative T13201 DRUGINFO D0G9NE 1-cyclohexylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D0HN0R 2-cyclohexylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D0I0RT Thioureido sulfonamide Investigative T13201 DRUGINFO D0J1PZ N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide Investigative T13201 DRUGINFO D0J3SP 2-pentafluorophenylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D0KZ2D 1-valproylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D0L4FM PHENYLSULFAMATE Investigative T13201 DRUGINFO D0LJ5P 4-ethynyl benzene sulfonamide Investigative T13201 DRUGINFO D0N7WP 4-(2-Pyridin-2-ylacetamido)benzenesulfonamide Investigative T13201 DRUGINFO D0O0UE 4-(2-Phenylacetamido)benzenesulfonamide Investigative T13201 DRUGINFO D0O4KL 1-pentafluorophenylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D0O8WV 2-propylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D0O9VU 4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide Investigative T13201 DRUGINFO D0Q0EK 4-Hydrazinocarbonyl-benzenesulfonamide Investigative T13201 DRUGINFO D0SF3B 2-butylamido-5-sulfonamidoindane Investigative T13201 DRUGINFO D0T0YI 4-nitrophenyl phosphate Investigative T13201 DRUGINFO D0T6ZX HYDROSULFIDE Investigative T13201 DRUGINFO D0W9VC 4-[2-(2-Thienyl)acetamido]benzenesulfonamide Investigative T13201 DRUGINFO D0X0PO Sulfamic acid 6-sulfamoyloxy-hexyl ester Investigative T13201 DRUGINFO D0X1MY 5-Amino-[1,3,4]thiadiazole-2-thiol Investigative T13201 DRUGINFO D0X9LJ 4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide Investigative T13201 DRUGINFO D0XL5K Benzothiazole-2-sulfonic acid amide Investigative T13201 DRUGINFO D0Z1CL 4-bromophenylboronic acid Investigative T13201 DRUGINFO D0Z5GE 4-(2-Phenylacetamido)-3-bromobenzenesulfonamide Investigative T13201 DRUGINFO D00IKQ 4-Methoxy-3-pyridinesulfonamide Investigative T13201 DRUGINFO D00NUK 4-Methanesulfonylamino-benzenesulfonamide Investigative T13201 DRUGINFO D01JTI 3-bromophenyl-difluoromethanesulfonamide Investigative T13201 DRUGINFO D02NQK 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide Investigative T13201 DRUGINFO D04JIN (2-bromophenyl)difluoromethanesulfonamide Investigative T13201 DRUGINFO D04PSK N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide Investigative T13201 DRUGINFO D04SNH 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide Investigative T13201 DRUGINFO D05EBZ 4-(4-Cyanophenoxy)-3-pyridinesulfonamide Investigative T13201 DRUGINFO D05RAB 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide Investigative T13201 DRUGINFO D06GPL 4-methylphenyl-difluoromethanesulfonamide Investigative T13201 DRUGINFO D06JVR N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T13201 DRUGINFO D06ZMH 3-(3-Phenyl-ureido)-benzenesulfonamide Investigative T13201 DRUGINFO D07SIA PHENYLMETHANESULFONAMIDE Investigative T13201 DRUGINFO D08JCC 4-(4-Fluorophenoxy)-3-pyridinesulfonamide Investigative T13201 DRUGINFO D09CXX N-hydroxysulfamide Investigative T13201 DRUGINFO D09LUD 4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide Investigative T13201 DRUGINFO D09OSN Biphenyl-4-ylboronic acid Investigative T13201 DRUGINFO D0A4HS 4-methoxyphenylboronic acid Investigative T13201 DRUGINFO D0E3VJ N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide Investigative T13201 DRUGINFO D0I5YQ 4-nitrophenyl-difluoromethanesulfonamide Investigative T13201 DRUGINFO D0IU3X (4-bromophenyl)difluoromethanesulfonamide Investigative T13201 DRUGINFO D0K3LN N-(4-Sulfamoyl-phenyl)-butyramide Investigative T13201 DRUGINFO D0KB6T N-(4-Sulfamoyl-phenyl)-benzamide Investigative T13201 DRUGINFO D0M4EV N-(4-cyanophenyl)sulfamide Investigative T13201 DRUGINFO D0N8LR N-(4-Sulfamoyl-phenyl)-propionamide Investigative T13201 DRUGINFO D0PA5L N-(pentafluorophenyl)sulfamide Investigative T13201 DRUGINFO D0Q0XO Pentanoic acid (4-sulfamoyl-phenyl)-amide Investigative T13201 DRUGINFO D0RK7J 2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide Investigative T13201 DRUGINFO D0S4NO N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T13201 DRUGINFO D0S8RD Trecadrine Investigative T13201 DRUGINFO D0T2VH N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T13201 DRUGINFO D0UN0E PHENYLDIFLUOROMETHANESULFONAMIDE Investigative T13201 DRUGINFO D0YD9F 4-Benzenesulfonylamino-benzenesulfonamide Investigative T13201 DRUGINFO D0Z6TM 4-azidobenzenesulfonamide Investigative T13201 DRUGINFO D00IAE Prop-2-ynyl 4-sulfamoylbenzoate Investigative T13201 DRUGINFO D01OTW 4-(Cyanomethylthio)pyridine-3-sulfonamide Investigative T13201 DRUGINFO D01XFH N-propynyl amidebenzenesulphonide Investigative T13201 DRUGINFO D02BMV 4-(2-Propynylthio)pyridine-3-sulfonamide Investigative T13201 DRUGINFO D03KRB 4,4'-thiodipyridine-3-sulfonamide Investigative T13201 DRUGINFO D03VDJ SULFAMATE Investigative T13201 DRUGINFO D04VSP 4-Ethoxy-3-pyridinesulfonamide Investigative T13201 DRUGINFO D05ETN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide Investigative T13201 DRUGINFO D05JAJ 4-(Quinolinoxy)-3-pyridinesulfonamide Investigative T13201 DRUGINFO D06DYP 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T13201 DRUGINFO D06IOI 4-Benzythiopyridine-3-sulfonamide Investigative T13201 DRUGINFO D09TKG 4-(Allylamino)-3-pyridinesulfonamide Investigative T13201 DRUGINFO D0A0YX SACCHARIN Investigative T13201 DRUGINFO D0C4QB 2-Amino-indan-5-sulfonic acid Investigative T13201 DRUGINFO D0J7GU 4-Methylthiopyridine-3-sulfonamide Investigative T13201 DRUGINFO D0LC0F 2,3-dihydro-1H-indene-5-sulfonamide Investigative T13201 DRUGINFO D0Q5VB 4-(Methylhydrazino)-3-pyridinesulfonamide Investigative T13201 DRUGINFO D0R4KQ 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide Investigative T13201 DRUGINFO D0RB0D 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid Investigative T13201 DRUGINFO D0TY8X 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide Investigative T13201 DRUGINFO D0UM1I 4-Hydrazino-3-pyridinesulfonamide Investigative T13201 DRUGINFO D0V5OW 4-(Carbamolymethylthio)pyridine-3-sulfonamide Investigative T13201 DRUGINFO D0X6IE 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide Investigative T13201 DRUGINFO D0Z1HY 4-amino-6-chlorobenzene-1,3-disulfonamide Investigative T13201 DRUGINFO D00XJA 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T13201 DRUGINFO D08XQI PARAOXON Investigative T13201 DRUGINFO D0D6UR 2-oxo-2H-thiochromene-3-carboxylic acid Investigative T13201 DRUGINFO D0EJ9B Phenyl Boronic acid Investigative T13201 DRUGINFO D0H3NS 2-oxo-2H-chromene-3-carboxylic acid Investigative T13201 DRUGINFO D04NSN 4-(2-AMINOETHYL)BENZENESULFONAMIDE Investigative T13201 DRUGINFO D05XZM 4-(hydroxymethyl)benzenesulfonamide Investigative T13201 DRUGINFO D09JPC Hexane-1,6-diamine Investigative T13201 DRUGINFO D09PWX Carzenide Investigative T13201 DRUGINFO D0G3BI 6-methyl-2-oxo-2H-chromene-3-carboxylic acid Investigative T13201 DRUGINFO D0Q2LL 6-Hydroxy-benzothiazole-2-sulfonic acid amide Investigative T13201 DRUGINFO D0U4BB HERNIARIN Investigative T13201 DRUGINFO D00YEF Decane-1,10-diyl disulfamate Investigative T13201 DRUGINFO D01STY 4-Amino-3-iodo-benzenesulfonamide Investigative T13201 DRUGINFO D02QGI Pentane-1,5-diamine Investigative T13201 DRUGINFO D03ZMQ COUMARIN Investigative T13201 DRUGINFO D04CVC 4-Amino-3-fluoro-benzenesulfonamide Investigative T13201 DRUGINFO D05TLB Octyl sulfamate Investigative T13201 DRUGINFO D09WSJ Decyl sulfamate Investigative T13201 DRUGINFO D0AU0M P-Coumaric Acid Investigative T13201 DRUGINFO D0D4OV Octane-1,8-diyl disulfamate Investigative T13201 DRUGINFO D0E8CC BENZOLAMIDE Investigative T13201 DRUGINFO D0M3PO 2,4-Disulfamyltrifluoromethylaniline Investigative T13201 DRUGINFO D0N1AW 6-(aminomethyl)-2H-chromen-2-one Investigative T13201 DRUGINFO D0NN3Q 4-Hydrazino-benzenesulfonamide Investigative T13201 DRUGINFO D0P6AM 4-Amino-3-bromo-benzenesulfonamide Investigative T13201 DRUGINFO D0Q7DJ Syringic Acid Investigative T13201 DRUGINFO D0VD7H CL-5343 Investigative T13201 DRUGINFO D0YU8J 4-Amino-3-chloro-benzenesulfonamide Investigative T13201 DRUGINFO D0V7AA CATECHIN Investigative T13201 DRUGINFO D0Y3TZ GALLICACID Investigative T13201 DRUGINFO D0A1CM ELLAGIC ACID Investigative T20401 TARGETID T20401 T20401 FORMERID TTDS00306 T20401 UNIPROID CAH2_HUMAN T20401 TARGNAME Carbonic anhydrase II (CA-II) T20401 GENENAME CA2 T20401 TARGTYPE Successful T20401 SYNONYMS Carbonic anhydrase C; Carbonic anhydrase 2; Carbonate dehydratase II; CAC T20401 FUNCTION Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate exchange activity of SLC26A6. Essential for bone resorption and osteoclast differentiation. T20401 PDBSTRUC 9CA2; 8CA2; 7CA2; 6QEB; 6MBY T20401 BIOCLASS Alpha-carbonic anhydrase T20401 ECNUMBER EC 4.2.1.1 T20401 SEQUENCE MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK T20401 DRUGINFO D03CNS Cyclothiazide Approved T20401 DRUGINFO D05UYW Dorzolamide Approved T20401 DRUGINFO D0CK3G Ethinamate Approved T20401 DRUGINFO D0L2MX Benzthiazide Approved T20401 DRUGINFO D0M9WM Chlorothiazide Approved T20401 DRUGINFO D07INV Ethoxzolamide Approved T20401 DRUGINFO D0J4GO Dichlorphenamide Approved T20401 DRUGINFO D0K1QD Sulfamylon Approved T20401 DRUGINFO D07HBX Salicyclic acid Approved T20401 DRUGINFO D02JUW GUAIACOL Phase 3 T20401 DRUGINFO D06PII SULTHIAME Phase 3 T20401 DRUGINFO D0W2CX CG-100649 Phase 3 T20401 DRUGINFO D0A8JP PARABEN Phase 3 T20401 DRUGINFO D07SDQ Curcumin Phase 3 T20401 DRUGINFO D0L6HN PHENOL Phase 2/3 T20401 DRUGINFO D07ZNI STX-140 Phase 2 T20401 DRUGINFO D0Y6OA Coumate Phase 2 T20401 DRUGINFO D0W1SL BUTYLATEDHYDROXYTOLUENE Phase 1 T20401 DRUGINFO D0V0UK SULFAMIDE Phase 1 T20401 DRUGINFO D03SLR FERULIC ACID Patented T20401 DRUGINFO D00SJT 4-Flourobenzenesulfonamide Investigative T20401 DRUGINFO D01KOO (2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate Investigative T20401 DRUGINFO D02DCD 4-(4-tert-butylbenzylideneamino)benzoic acid Investigative T20401 DRUGINFO D04GDW 2-methoxyestradiol-17-O-sulfamate Investigative T20401 DRUGINFO D04LNI Di(2,6-dimethylphenol) Investigative T20401 DRUGINFO D04MAM Sulfamic acid chroman-2-ylmethyl ester Investigative T20401 DRUGINFO D04XMZ Al7089a Investigative T20401 DRUGINFO D05DFJ 2,6-Difluorobenzenesulfonamide Investigative T20401 DRUGINFO D05DIH Methyl 4-(4-tert-butylbenzylideneamino)benzoate Investigative T20401 DRUGINFO D05NAR Allyl 4-(aminosulfonyl)benzoate Investigative T20401 DRUGINFO D06CGS Mercuribenzoic Acid Investigative T20401 DRUGINFO D06IYU PHENYLSULFAMIDE Investigative T20401 DRUGINFO D06MZK 2,6-di-t-butylphenol Investigative T20401 DRUGINFO D06OVA 1-pentenyl-4-(aminosulfonyl)benzoate Investigative T20401 DRUGINFO D07AUN Methyl 4-(4-hydroxybenzylideneamino)benzoate Investigative T20401 DRUGINFO D07JYF 6-Nitro-benzothiazole-2-sulfonic acid amide Investigative T20401 DRUGINFO D07QHM 4-(Hydroxymercury)Benzoic Acid Investigative T20401 DRUGINFO D07RZN N-Benzyl-4-Sulfamoyl-Benzamide Investigative T20401 DRUGINFO D08CNG AL5300 Investigative T20401 DRUGINFO D08ORD 2-(4-tert-butylbenzylideneamino)ethanesulfonamide Investigative T20401 DRUGINFO D09HNP AL4623 Investigative T20401 DRUGINFO D09LMH AL6528 Investigative T20401 DRUGINFO D09PUF 2-methoxyestrrone-3-O-sulfamate Investigative T20401 DRUGINFO D09SFY 2-(4-hydroxybenzylideneamino)ethanesulfonamide Investigative T20401 DRUGINFO D09ZUN 2,6-di-tert-butyl-4-methoxyphenol Investigative T20401 DRUGINFO D0A0RT Di(2,6-diisopropylphenol) Investigative T20401 DRUGINFO D0A2PD 3-Mercuri-4-Aminobenzenesulfonamide Investigative T20401 DRUGINFO D0A5XB Sulfamic acid benzo[1,3]dioxol-2-ylmethyl ester Investigative T20401 DRUGINFO D0A7ZH N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE Investigative T20401 DRUGINFO D0B8CU AL7182 Investigative T20401 DRUGINFO D0C3SL Di(2,6-di-t-butylphenol) Investigative T20401 DRUGINFO D0C9ZY 3-hydroxy-2-methoxybenzaldehyde Investigative T20401 DRUGINFO D0D6UL AL5424 Investigative T20401 DRUGINFO D0F4ZW SODIUM PERFLUOROHEXANESULFONAMIDE Investigative T20401 DRUGINFO D0G6OW Sodium 2,3,5,6-tetrafluorobenzoate Investigative T20401 DRUGINFO D0GI2R N-[(5-chloro-1-benzothien-3-yl)methyl]sulfamide Investigative T20401 DRUGINFO D0I1XT 4-((benzylideneamino)methyl)benzenesulfonamide Investigative T20401 DRUGINFO D0I8DW 4-nitrophenylsulfamide Investigative T20401 DRUGINFO D0K4IH 4-(benzylideneamino)benzoic acid Investigative T20401 DRUGINFO D0KK4F 4-Methylimidazole Investigative T20401 DRUGINFO D0L4KE N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide Investigative T20401 DRUGINFO D0LM8L N-[(4-bromo-1-benzothien-3-yl)methyl]sulfamide Investigative T20401 DRUGINFO D0M7DE N-(1-benzofuran-3-ylmethyl)sulfamide Investigative T20401 DRUGINFO D0M8HC AL5927 Investigative T20401 DRUGINFO D0M8UY 6-hydroxybenzo[d][1,3]oxathiol-2-one Investigative T20401 DRUGINFO D0N8RD N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide Investigative T20401 DRUGINFO D0O0HT 4-Sulfonamide-[1-(4-Aminobutane)]Benzamide Investigative T20401 DRUGINFO D0OT2H 1,2,4-Triazole Investigative T20401 DRUGINFO D0R6JK 4-(4-hydroxybenzylideneamino)benzoic acid Investigative T20401 DRUGINFO D0S5LS N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide Investigative T20401 DRUGINFO D0S6GK 3,5-Difluorobenzenesulfonamide Investigative T20401 DRUGINFO D0S7NH Dansylamide Investigative T20401 DRUGINFO D0T8SN 4-methoxyphenylsulfamide Investigative T20401 DRUGINFO D0U0QW 2-(benzylideneamino)ethanesulfonamide Investigative T20401 DRUGINFO D0U7GL N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide Investigative T20401 DRUGINFO D0XX9C AL7099A Investigative T20401 DRUGINFO D00CIW Phenyl-phosphonic acid Investigative T20401 DRUGINFO D00RJT NITRATE Investigative T20401 DRUGINFO D00ZUQ ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE Investigative T20401 DRUGINFO D01GNQ Phenoxyarsonous acid Investigative T20401 DRUGINFO D02KDH 2-(N''-Acetyl-hydrazino)-benzenesulfonamide Investigative T20401 DRUGINFO D03VUQ 4-(4-hydroxy-benzylideneamino)-benzenesulfonamide Investigative T20401 DRUGINFO D04RCR 3-phenylprop-1-enylboronic acid Investigative T20401 DRUGINFO D05FMD 5-Chlorosalicylic Acid Investigative T20401 DRUGINFO D05PRS 4-Thiocyanato-benzenesulfonamide Investigative T20401 DRUGINFO D05WQF 2-Hydroxycinnamic acid Investigative T20401 DRUGINFO D06KTD 2-Hydrazinocarbonyl-benzenesulfonamide Investigative T20401 DRUGINFO D06LVE 4-Nitro-benzenesulfonamide Investigative T20401 DRUGINFO D06SME 5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one Investigative T20401 DRUGINFO D07AGM 4-Methylamino-benzenesulfonamide Investigative T20401 DRUGINFO D07CQI 2-Sulfamoyl-benzoic acid methyl ester Investigative T20401 DRUGINFO D07OMY 3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide Investigative T20401 DRUGINFO D07ZHE 3-Nitro-benzenesulfonamide Investigative T20401 DRUGINFO D08RKK IODIDE Investigative T20401 DRUGINFO D08TBP 2-Acetylamino-indan-5-sulfonic acid hydrate Investigative T20401 DRUGINFO D09CZV Methyl Mercury Ion Investigative T20401 DRUGINFO D0A6HS 6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE Investigative T20401 DRUGINFO D0A8HW 4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide Investigative T20401 DRUGINFO D0BR1D 4,6-Dinitro salicylic acid Investigative T20401 DRUGINFO D0C6ED 1,4-phenylene disulfamate Investigative T20401 DRUGINFO D0F7SO Quinoline-8-sulfonamide Investigative T20401 DRUGINFO D0K5NQ N-[4-(trifluoromethyl)phenyl]sulfamide Investigative T20401 DRUGINFO D0L8ZG P-tolylboronic acid Investigative T20401 DRUGINFO D0M7QA N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE Investigative T20401 DRUGINFO D0M7VN 4-(N-Methyl-hydrazino)-benzenesulfonamide Investigative T20401 DRUGINFO D0N5KX Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester Investigative T20401 DRUGINFO D0O1QT 6-Amino-benzothiazole-2-sulfonic acid amide Investigative T20401 DRUGINFO D0R7QY EMATE Investigative T20401 DRUGINFO D0S2II 4-(benzylideneamino)benzenesulfonamide Investigative T20401 DRUGINFO D0S6CO 2,4-dichloro-5-sulfamoylbenzoic acid Investigative T20401 DRUGINFO D0SV6C PRONTOCIL Investigative T20401 DRUGINFO D0U1AN 4-isothiocyanatobenzenesulfonamide Investigative T20401 DRUGINFO D0Y1XM 2-(benzyloxyamino)-N-hydroxyhexanamide Investigative T20401 DRUGINFO D00BMI N-1,3,4-thiadiazol-2-ylsulfamide Investigative T20401 DRUGINFO D00FGB 2-acetamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D00GVA 4-(2-Pyridin-4-ylacetamido)benzenesulfonamide Investigative T20401 DRUGINFO D00XIB 1-acetamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D01EEM 2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide Investigative T20401 DRUGINFO D01ISX 4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide Investigative T20401 DRUGINFO D01UDU 3-Chloro-4-hydrazino-benzenesulfonamide Investigative T20401 DRUGINFO D01YHK 3-Fluoro-4-hydrazino-benzenesulfonamide Investigative T20401 DRUGINFO D03DAM 2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide Investigative T20401 DRUGINFO D03EAQ N-hydroxysulfonamides Investigative T20401 DRUGINFO D04BKU Sulfamic acid 4-sulfamoyloxy-butyl ester Investigative T20401 DRUGINFO D04HRS 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide Investigative T20401 DRUGINFO D04POB ACETYLSULFANILAMIDE Investigative T20401 DRUGINFO D05BMD 2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide Investigative T20401 DRUGINFO D05FNN Sulfamic acid 7-sulfamoyloxy-heptyl ester Investigative T20401 DRUGINFO D05NFU 4-butylphenylboronic acid Investigative T20401 DRUGINFO D05QEK Aminobenzolamide derivative Investigative T20401 DRUGINFO D06NDR 2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide Investigative T20401 DRUGINFO D06ORV Phenethylboronic acid Investigative T20401 DRUGINFO D06XNT 4-(2-Phenylacetamidomethyl)benzenesulfonamide Investigative T20401 DRUGINFO D07CBA Sulfamic acid 16-sulfamoyloxy-hexadecyl ester Investigative T20401 DRUGINFO D07IHP Sulfamic acid 3-sulfamoyloxy-phenyl ester Investigative T20401 DRUGINFO D07LYW 2-valproylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D07PNA 2-nonylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D07YSQ N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide Investigative T20401 DRUGINFO D07ZXR Sulfamic acid 12-sulfamoyloxy-dodecyl ester Investigative T20401 DRUGINFO D08AOA 2-ethylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D09CSP 3-(4-sulfamoylphenyl)propanoic acid Investigative T20401 DRUGINFO D09JHA Azide Investigative T20401 DRUGINFO D09LWR 4-(2-Phenylacetamidoethyl)benzenesulfonamide Investigative T20401 DRUGINFO D0A3JR 4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide Investigative T20401 DRUGINFO D0B4IN NSC-654077 Investigative T20401 DRUGINFO D0BD0K 3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide Investigative T20401 DRUGINFO D0C7WG 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide Investigative T20401 DRUGINFO D0C8ZY Beta-naphthylboronic acid Investigative T20401 DRUGINFO D0D0BO 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide Investigative T20401 DRUGINFO D0D2JA 4-phenoxyphenylboronic acid Investigative T20401 DRUGINFO D0D5XC Sodium trithiocarbonate Investigative T20401 DRUGINFO D0DY9U 3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide Investigative T20401 DRUGINFO D0G0OP 2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide Investigative T20401 DRUGINFO D0G9NE 1-cyclohexylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D0H4CF 3-((4-aminophenyl)diazenyl)benzenesulfonamide Investigative T20401 DRUGINFO D0HN0R 2-cyclohexylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D0I0RT Thioureido sulfonamide Investigative T20401 DRUGINFO D0J1PZ N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide Investigative T20401 DRUGINFO D0J3SP 2-pentafluorophenylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D0KZ2D 1-valproylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D0L4FM PHENYLSULFAMATE Investigative T20401 DRUGINFO D0LJ5P 4-ethynyl benzene sulfonamide Investigative T20401 DRUGINFO D0N7WP 4-(2-Pyridin-2-ylacetamido)benzenesulfonamide Investigative T20401 DRUGINFO D0O0UE 4-(2-Phenylacetamido)benzenesulfonamide Investigative T20401 DRUGINFO D0O4KL 1-pentafluorophenylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D0O8WV 2-propylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D0O9VU 4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide Investigative T20401 DRUGINFO D0Q0EK 4-Hydrazinocarbonyl-benzenesulfonamide Investigative T20401 DRUGINFO D0SF3B 2-butylamido-5-sulfonamidoindane Investigative T20401 DRUGINFO D0T0YI 4-nitrophenyl phosphate Investigative T20401 DRUGINFO D0T2YZ N-(4-Sulfamoyl-phenyl)-isobutyramide Investigative T20401 DRUGINFO D0T6ZX HYDROSULFIDE Investigative T20401 DRUGINFO D0W9VC 4-[2-(2-Thienyl)acetamido]benzenesulfonamide Investigative T20401 DRUGINFO D0X0PO Sulfamic acid 6-sulfamoyloxy-hexyl ester Investigative T20401 DRUGINFO D0X1MY 5-Amino-[1,3,4]thiadiazole-2-thiol Investigative T20401 DRUGINFO D0X9LJ 4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide Investigative T20401 DRUGINFO D0XL5K Benzothiazole-2-sulfonic acid amide Investigative T20401 DRUGINFO D0Z1CL 4-bromophenylboronic acid Investigative T20401 DRUGINFO D0Z5GE 4-(2-Phenylacetamido)-3-bromobenzenesulfonamide Investigative T20401 DRUGINFO D00IKQ 4-Methoxy-3-pyridinesulfonamide Investigative T20401 DRUGINFO D00IUB 4-CYANOPHENOL Investigative T20401 DRUGINFO D00NUK 4-Methanesulfonylamino-benzenesulfonamide Investigative T20401 DRUGINFO D01JTI 3-bromophenyl-difluoromethanesulfonamide Investigative T20401 DRUGINFO D02NQK 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide Investigative T20401 DRUGINFO D04JIN (2-bromophenyl)difluoromethanesulfonamide Investigative T20401 DRUGINFO D04PSK N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide Investigative T20401 DRUGINFO D04SNH 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide Investigative T20401 DRUGINFO D05EBZ 4-(4-Cyanophenoxy)-3-pyridinesulfonamide Investigative T20401 DRUGINFO D05RAB 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide Investigative T20401 DRUGINFO D06GPL 4-methylphenyl-difluoromethanesulfonamide Investigative T20401 DRUGINFO D06JVR N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T20401 DRUGINFO D06ZMH 3-(3-Phenyl-ureido)-benzenesulfonamide Investigative T20401 DRUGINFO D07QJJ CATECHOL Investigative T20401 DRUGINFO D07SIA PHENYLMETHANESULFONAMIDE Investigative T20401 DRUGINFO D08JCC 4-(4-Fluorophenoxy)-3-pyridinesulfonamide Investigative T20401 DRUGINFO D09CXX N-hydroxysulfamide Investigative T20401 DRUGINFO D09LUD 4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide Investigative T20401 DRUGINFO D09OSN Biphenyl-4-ylboronic acid Investigative T20401 DRUGINFO D09UQM 1-(3,4-dichlorophenyl)-3-hydroxyurea Investigative T20401 DRUGINFO D0A4HS 4-methoxyphenylboronic acid Investigative T20401 DRUGINFO D0E3VJ N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide Investigative T20401 DRUGINFO D0I5YQ 4-nitrophenyl-difluoromethanesulfonamide Investigative T20401 DRUGINFO D0IU3X (4-bromophenyl)difluoromethanesulfonamide Investigative T20401 DRUGINFO D0K3LN N-(4-Sulfamoyl-phenyl)-butyramide Investigative T20401 DRUGINFO D0KB6T N-(4-Sulfamoyl-phenyl)-benzamide Investigative T20401 DRUGINFO D0L6CN N-(phosphonacetyl)-L-aspartate Investigative T20401 DRUGINFO D0M4EV N-(4-cyanophenyl)sulfamide Investigative T20401 DRUGINFO D0N8LR N-(4-Sulfamoyl-phenyl)-propionamide Investigative T20401 DRUGINFO D0PA5L N-(pentafluorophenyl)sulfamide Investigative T20401 DRUGINFO D0Q0XO Pentanoic acid (4-sulfamoyl-phenyl)-amide Investigative T20401 DRUGINFO D0RK7J 2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide Investigative T20401 DRUGINFO D0S4NO N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T20401 DRUGINFO D0S8RD Trecadrine Investigative T20401 DRUGINFO D0T2VH N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T20401 DRUGINFO D0UN0E PHENYLDIFLUOROMETHANESULFONAMIDE Investigative T20401 DRUGINFO D0YD9F 4-Benzenesulfonylamino-benzenesulfonamide Investigative T20401 DRUGINFO D0Z6TM 4-azidobenzenesulfonamide Investigative T20401 DRUGINFO D00IAE Prop-2-ynyl 4-sulfamoylbenzoate Investigative T20401 DRUGINFO D01OTW 4-(Cyanomethylthio)pyridine-3-sulfonamide Investigative T20401 DRUGINFO D01XFH N-propynyl amidebenzenesulphonide Investigative T20401 DRUGINFO D02BMV 4-(2-Propynylthio)pyridine-3-sulfonamide Investigative T20401 DRUGINFO D02DBP RESORCINOL Investigative T20401 DRUGINFO D03KRB 4,4'-thiodipyridine-3-sulfonamide Investigative T20401 DRUGINFO D03VDJ SULFAMATE Investigative T20401 DRUGINFO D04VSP 4-Ethoxy-3-pyridinesulfonamide Investigative T20401 DRUGINFO D05ETN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide Investigative T20401 DRUGINFO D05JAJ 4-(Quinolinoxy)-3-pyridinesulfonamide Investigative T20401 DRUGINFO D06IOI 4-Benzythiopyridine-3-sulfonamide Investigative T20401 DRUGINFO D09TKG 4-(Allylamino)-3-pyridinesulfonamide Investigative T20401 DRUGINFO D0A0YX SACCHARIN Investigative T20401 DRUGINFO D0C4QB 2-Amino-indan-5-sulfonic acid Investigative T20401 DRUGINFO D0G0FJ 2-hydrazinylbenzenesulfonamide Investigative T20401 DRUGINFO D0J7GU 4-Methylthiopyridine-3-sulfonamide Investigative T20401 DRUGINFO D0LC0F 2,3-dihydro-1H-indene-5-sulfonamide Investigative T20401 DRUGINFO D0Q5VB 4-(Methylhydrazino)-3-pyridinesulfonamide Investigative T20401 DRUGINFO D0R4KQ 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide Investigative T20401 DRUGINFO D0TY8X 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide Investigative T20401 DRUGINFO D0UM1I 4-Hydrazino-3-pyridinesulfonamide Investigative T20401 DRUGINFO D0V5OW 4-(Carbamolymethylthio)pyridine-3-sulfonamide Investigative T20401 DRUGINFO D0X6IE 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide Investigative T20401 DRUGINFO D0Z1HY 4-amino-6-chlorobenzene-1,3-disulfonamide Investigative T20401 DRUGINFO D0ZC3W P-toluenesulfonamide Investigative T20401 DRUGINFO D00XJA 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T20401 DRUGINFO D04VLI 4-(2-Hydroxy-ethyl)-benzenesulfonamide Investigative T20401 DRUGINFO D08XQI PARAOXON Investigative T20401 DRUGINFO D0D6UR 2-oxo-2H-thiochromene-3-carboxylic acid Investigative T20401 DRUGINFO D0EJ9B Phenyl Boronic acid Investigative T20401 DRUGINFO D0J2AE 3-Amino-benzenesulfonamide Investigative T20401 DRUGINFO D0OI1H 2-Amino-benzenesulfonamide Investigative T20401 DRUGINFO D04NSN 4-(2-AMINOETHYL)BENZENESULFONAMIDE Investigative T20401 DRUGINFO D05XZM 4-(hydroxymethyl)benzenesulfonamide Investigative T20401 DRUGINFO D09PWX Carzenide Investigative T20401 DRUGINFO D0G3BI 6-methyl-2-oxo-2H-chromene-3-carboxylic acid Investigative T20401 DRUGINFO D0L5TZ 6-(hydroxymethyl)-2H-chromen-2-one Investigative T20401 DRUGINFO D0Q2LL 6-Hydroxy-benzothiazole-2-sulfonic acid amide Investigative T20401 DRUGINFO D00YEF Decane-1,10-diyl disulfamate Investigative T20401 DRUGINFO D01STY 4-Amino-3-iodo-benzenesulfonamide Investigative T20401 DRUGINFO D02QGI Pentane-1,5-diamine Investigative T20401 DRUGINFO D03ZMQ COUMARIN Investigative T20401 DRUGINFO D04CVC 4-Amino-3-fluoro-benzenesulfonamide Investigative T20401 DRUGINFO D05TLB Octyl sulfamate Investigative T20401 DRUGINFO D09WSJ Decyl sulfamate Investigative T20401 DRUGINFO D0AU0M P-Coumaric Acid Investigative T20401 DRUGINFO D0D4OV Octane-1,8-diyl disulfamate Investigative T20401 DRUGINFO D0E8CC BENZOLAMIDE Investigative T20401 DRUGINFO D0M3PO 2,4-Disulfamyltrifluoromethylaniline Investigative T20401 DRUGINFO D0N1AW 6-(aminomethyl)-2H-chromen-2-one Investigative T20401 DRUGINFO D0NN3Q 4-Hydrazino-benzenesulfonamide Investigative T20401 DRUGINFO D0P6AM 4-Amino-3-bromo-benzenesulfonamide Investigative T20401 DRUGINFO D0Q7DJ Syringic Acid Investigative T20401 DRUGINFO D0VD7H CL-5343 Investigative T20401 DRUGINFO D0YU8J 4-Amino-3-chloro-benzenesulfonamide Investigative T20401 DRUGINFO D0V7AA CATECHIN Investigative T20401 DRUGINFO D0Y3TZ GALLICACID Investigative T20401 DRUGINFO D06EWG Formic Acid Investigative T20401 DRUGINFO D0A4TC MMI270 Investigative T20401 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T20401 DRUGINFO D0A1CM ELLAGIC ACID Investigative T20401 DRUGINFO D0F2ME Acetate Ion Investigative T89534 TARGETID T89534 T89534 FORMERID TTDS00242 T89534 UNIPROID ESR1_HUMAN T89534 TARGNAME Estrogen receptor (ESR) T89534 GENENAME ESR1 T89534 TARGTYPE Successful T89534 SYNONYMS Nuclear receptor subfamily 3 group A member 1; NR3A1; Estradiol receptor; ESR; ER-alpha; ER T89534 FUNCTION Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1. T89534 PDBSTRUC 6IAR; 6HMU; 6HKF; 6HKB; 6HHP T89534 BIOCLASS Nuclear hormone receptor T89534 SEQUENCE MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAYEFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPFLQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV T89534 DRUGINFO D00ZFP Estrone Approved T89534 DRUGINFO D01ICU Conjugated estrogens b Approved T89534 DRUGINFO D01XBA Raloxifene Approved T89534 DRUGINFO D02CTS Ospemifene Approved T89534 DRUGINFO D03IUY Estropipate Approved T89534 DRUGINFO D04UZT Quinestrol Approved T89534 DRUGINFO D04VFJ Toremifene Approved T89534 DRUGINFO D06NXY Ethinyl Estradiol Approved T89534 DRUGINFO D07KSG Tamoxifen Approved T89534 DRUGINFO D07KUN Elacestrant Approved T89534 DRUGINFO D07VBA Estradiol Valerate Approved T89534 DRUGINFO D08QMX Estradiol Approved T89534 DRUGINFO D09IPV Danazol Approved T89534 DRUGINFO D09ZQN Dienestrol Approved T89534 DRUGINFO D0A2RG Conjugated estrogens a Approved T89534 DRUGINFO D0C4NY Promestriene Approved T89534 DRUGINFO D0CT9Y Clomifene Approved T89534 DRUGINFO D0I5WB Clomiphene Citrate Approved T89534 DRUGINFO D0J1ML Mestranol Approved T89534 DRUGINFO D0JO7Y Fulvestrant Approved T89534 DRUGINFO D0JO8Z Fosfestrol Approved T89534 DRUGINFO D0JY8T Bazedoxifene Approved T89534 DRUGINFO D0M5RF Gestrinone Approved T89534 DRUGINFO D0N6YV Cenestin Approved T89534 DRUGINFO D0R6RE Esterified estrogens Approved T89534 DRUGINFO D0S1UW Premarin/Trimegestone Approved T89534 DRUGINFO D0T7ZQ Estradiol Acetate Approved T89534 DRUGINFO D0U0XD Estradiol Cypionate Approved T89534 DRUGINFO D0V2JK Nomegestrol acetate Approved T89534 DRUGINFO D0W9GA Levormeloxifene Approved T89534 DRUGINFO D0X1EZ Cyclofenil Approved T89534 DRUGINFO D0Y2NE Diethylstilbestrol Approved T89534 DRUGINFO D0Z1FX Estriol Approved T89534 DRUGINFO D0Z5OE Mitotane Approved T89534 DRUGINFO D06LOQ ARZOXIFENE Approved T89534 DRUGINFO D09NMD Lasofoxifene Approved T89534 DRUGINFO D0M8PD Estrogen Approved T89534 DRUGINFO D02BAE Synthetic conjugated estrogen Phase 3 T89534 DRUGINFO D0C6XR Trimegestone/ethinyl estradiol Phase 3 T89534 DRUGINFO D0IC7A TZTX-001 Phase 3 T89534 DRUGINFO D0XB0T Acolbifene Phase 3 T89534 DRUGINFO D9I6QG NE3107 Phase 3 T89534 DRUGINFO DGW9U7 Giredestrant Phase 3 T89534 DRUGINFO DON71B Imlunestrant Phase 3 T89534 DRUGINFO D0VF3C NPC-01 Phase 3 T89534 DRUGINFO D0G7IV Premarin/Pravachol Phase 3 T89534 DRUGINFO D00JFE ARN-810 Phase 2 T89534 DRUGINFO D02PYN SR 16234 Phase 2 T89534 DRUGINFO D09NST Afimoxifene Phase 2 T89534 DRUGINFO D0E7FM GTx-758 Phase 2 T89534 DRUGINFO D0L0BX ICARITIN Phase 2 T89534 DRUGINFO D0L3TR Estetrol Phase 2 T89534 DRUGINFO D0W4EB Endoxifen Phase 2 T89534 DRUGINFO DATO92 AZD9833 Phase 2 T89534 DRUGINFO D0Z5VW H3B-6545 Phase 1/2 T89534 DRUGINFO DJ1W5R ZN-c5 Phase 1/2 T89534 DRUGINFO DZ91HE OP-1250 Phase 1/2 T89534 DRUGINFO D03YGP CC-8490 Phase 1 T89534 DRUGINFO D08OUV CHF-4227 Phase 1 T89534 DRUGINFO D09BQO ATD transdermal gel Phase 1 T89534 DRUGINFO D09OJI D-0502 Phase 1 T89534 DRUGINFO D0NZ3C TTC-352 Phase 1 T89534 DRUGINFO D0X1OW AZD9496 Phase 1 T89534 DRUGINFO DG38QS G1T-48 Phase 1 T89534 DRUGINFO DH4Y3O LY3484356 Phase 1 T89534 DRUGINFO DI9GC3 AC0682 Phase 1 T89534 DRUGINFO DNTW18 SCO-120 Phase 1 T89534 DRUGINFO DT4WU3 TTC-352 Phase 1 T89534 DRUGINFO D0X0KJ Chlorotrianisene Withdrawn from market T89534 DRUGINFO D0C4FT HEXESTROL Withdrawn from market T89534 DRUGINFO D0QQ1J BITHIONOL Withdrawn from market T89534 DRUGINFO D01OML IoGen Discontinued in Phase 3 T89534 DRUGINFO D02VFB Miproxifene Discontinued in Phase 3 T89534 DRUGINFO D0GR2J Idoxifene Discontinued in Phase 3 T89534 DRUGINFO D0MU0S EM-800 Discontinued in Phase 3 T89534 DRUGINFO D01AXT NP-50301 Discontinued in Phase 2 T89534 DRUGINFO D04BIG SR-90067 Discontinued in Phase 2 T89534 DRUGINFO D04HVB Panomifene Discontinued in Phase 2 T89534 DRUGINFO D04MNL SERM-3339 Discontinued in Phase 2 T89534 DRUGINFO D0R2JS Droloxifene Discontinued in Phase 2 T89534 DRUGINFO D0R8TB ERA-923 Discontinued in Phase 2 T89534 DRUGINFO D0B6HS HRT Discontinued in Phase 1 T89534 DRUGINFO D05BCA MX-4509 Discontinued in Phase 1 T89534 DRUGINFO D08DZZ HE2100 Discontinued in Phase 1 T89534 DRUGINFO D01EXY BN-AO-014 Preclinical T89534 DRUGINFO D06YGP BN-OD-026 Preclinical T89534 DRUGINFO D0N6YN BN-DF-037 Preclinical T89534 DRUGINFO D0P5NU BN-AA-003-NY Preclinical T89534 DRUGINFO D0QI9N BN-CB-045 Preclinical T89534 DRUGINFO D0QX9U BN-GU-005-DHP Preclinical T89534 DRUGINFO D0J4ZH Tamoxifen methyl iodide Terminated T89534 DRUGINFO D0TR4Z Zindoxifene Terminated T89534 DRUGINFO D09AAM ICI-164384 Terminated T89534 DRUGINFO D0H5CV ZK-119010 Terminated T89534 DRUGINFO D0SM0J LY-117018 Terminated T89534 DRUGINFO D00DJX JNJ-17148066 Investigative T89534 DRUGINFO D00XLU N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide Investigative T89534 DRUGINFO D00ZAJ 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE Investigative T89534 DRUGINFO D01NDN SNG-8006 Investigative T89534 DRUGINFO D01XCA N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide Investigative T89534 DRUGINFO D01ZRX 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL Investigative T89534 DRUGINFO D02GLM 2,4-diisobutylamino-6-isopentylpyrimidine Investigative T89534 DRUGINFO D02TPO JNJ-26529152 Investigative T89534 DRUGINFO D03AVA SNG-8033 Investigative T89534 DRUGINFO D03BOO 2,4-Dibenzylamino-6-isopentylpyrimidine Investigative T89534 DRUGINFO D03NWC SNG-8023 Investigative T89534 DRUGINFO D04PEM LTERHKILHRLLQEGSPSD Investigative T89534 DRUGINFO D04SAO GW7604 Investigative T89534 DRUGINFO D04TPC 4-benzyl-2,6-diisobutylamino-pyrimidine Investigative T89534 DRUGINFO D05QTG 7-Cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one Investigative T89534 DRUGINFO D07HBQ N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine Investigative T89534 DRUGINFO D07KXE Carboron Cluster with phenol Investigative T89534 DRUGINFO D07TGS 4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol Investigative T89534 DRUGINFO D07TGW MPrP Investigative T89534 DRUGINFO D08GWS Tamoxifen isopropyl bromide Investigative T89534 DRUGINFO D08JCJ 17-METHYL-17-ALPHA-DIHYDROEQUILENIN Investigative T89534 DRUGINFO D08LVT 4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide Investigative T89534 DRUGINFO D09BDK SNG-163 Investigative T89534 DRUGINFO D09NFD GSK-5182 Investigative T89534 DRUGINFO D09ULU N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide Investigative T89534 DRUGINFO D09UQU JNJ-19398990 Investigative T89534 DRUGINFO D09WEK 4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol Investigative T89534 DRUGINFO D0A8CS 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL Investigative T89534 DRUGINFO D0AD8G N-allyl-4-hydroxy-N-phenylbenzenesulfonamide Investigative T89534 DRUGINFO D0C4VX 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol Investigative T89534 DRUGINFO D0C6UR Tamoxifen ethyl bromide Investigative T89534 DRUGINFO D0C9XW 6-butyl-2,4-dipropylaminopyrimidine Investigative T89534 DRUGINFO D0E3UW RG6046 Investigative T89534 DRUGINFO D0E6AP STX Investigative T89534 DRUGINFO D0F8LS 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol Investigative T89534 DRUGINFO D0GH1I 3-(4-Hydroxyphenyl)-7-isobutoxychromen-4-one Investigative T89534 DRUGINFO D0GY3R SERMs Investigative T89534 DRUGINFO D0H6MZ 6-ethyl-2,4-diisobutylaminopyrimidine Investigative T89534 DRUGINFO D0H8ZT 4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol Investigative T89534 DRUGINFO D0I6QZ Org-37663 Investigative T89534 DRUGINFO D0J3PM 4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide Investigative T89534 DRUGINFO D0J6KN 4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol Investigative T89534 DRUGINFO D0K5LX 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL Investigative T89534 DRUGINFO D0K8QD 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol Investigative T89534 DRUGINFO D0L0RK 4-hydroxy-N-phenyl-N-propylbenzenesulfonamide Investigative T89534 DRUGINFO D0M4LQ N-butyl-4-hydroxy-N-phenylbenzenesulfonamide Investigative T89534 DRUGINFO D0O9UY 3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one Investigative T89534 DRUGINFO D0OV3S 4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol Investigative T89534 DRUGINFO D0Q4VG 4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol Investigative T89534 DRUGINFO D0Q6MS 4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol Investigative T89534 DRUGINFO D0S5RI Tamoxifen butyl bromide Investigative T89534 DRUGINFO D0V4DH Estriol E3 Investigative T89534 DRUGINFO D0V7OK 4-(1,2-Diphenyl-but-1-enyl)-phenol Investigative T89534 DRUGINFO D0V7ZI 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol Investigative T89534 DRUGINFO D0W1YZ TSERaM Investigative T89534 DRUGINFO D0X0RJ JNJ-26529126 Investigative T89534 DRUGINFO D0X6LK 5-hydroxy-2-phenylisoindoline-1,3-dione Investigative T89534 DRUGINFO D0XC3V 4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol Investigative T89534 DRUGINFO D0XF9F methyl-piperidino-pyrazole Investigative T89534 DRUGINFO D0Y8UF propylpyrazoletriol Investigative T89534 DRUGINFO D0Z9ZY 4-hydroxy-N,N-diphenylbenzenesulfonamide Investigative T89534 DRUGINFO D00AAU 3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol Investigative T89534 DRUGINFO D00CWN 2-(4-Hydroxy-phenyl)-quinolin-6-ol Investigative T89534 DRUGINFO D00FUO Nafoxidine Investigative T89534 DRUGINFO D00HUB [1,1':2',1'']Terphenyl-4'-carbaldehyde oxime Investigative T89534 DRUGINFO D00HZT 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol Investigative T89534 DRUGINFO D00IXB 6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol Investigative T89534 DRUGINFO D00NEK 4-(3-phenyl-1H-indol-2-yl)phenol Investigative T89534 DRUGINFO D00OLH 4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol Investigative T89534 DRUGINFO D00URP 4,10-dimethyl-6H-benzo[c]chromene-3,8-diol Investigative T89534 DRUGINFO D00ZBL 7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D01GPY 6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D01KJU 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL Investigative T89534 DRUGINFO D01KSR 5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol Investigative T89534 DRUGINFO D01QXL 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D01SWO 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol Investigative T89534 DRUGINFO D01UAO 3-chloro-4-(4-hydroxyphenyl)salicylaldoxime Investigative T89534 DRUGINFO D01WCA 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL Investigative T89534 DRUGINFO D02DML COUMESTROL Investigative T89534 DRUGINFO D02DVT 4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol Investigative T89534 DRUGINFO D02EJM 2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol Investigative T89534 DRUGINFO D02HGS 5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T89534 DRUGINFO D02JJU 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D02LCC 2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol Investigative T89534 DRUGINFO D02OKF 6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D02VIW DIHYDRORALOXIFENE Investigative T89534 DRUGINFO D03DVM 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol Investigative T89534 DRUGINFO D03EOD 4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol Investigative T89534 DRUGINFO D03GYS 7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D03QHG 8-(2,2-dimethylpropyl)naringenin Investigative T89534 DRUGINFO D03RYU 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol Investigative T89534 DRUGINFO D03XEU 2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol Investigative T89534 DRUGINFO D04EAY 3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol Investigative T89534 DRUGINFO D04SEX R,R-THC Investigative T89534 DRUGINFO D04WHH 2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol Investigative T89534 DRUGINFO D05FUY 1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D05JKC 6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D05JPW 2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol Investigative T89534 DRUGINFO D05KXP 8-n-undecylnaringenin Investigative T89534 DRUGINFO D05YIU 7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol Investigative T89534 DRUGINFO D06DDT BROUSSONIN A Investigative T89534 DRUGINFO D06DNN 4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol Investigative T89534 DRUGINFO D06OAL 7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D06SCS WAY200070 Investigative T89534 DRUGINFO D07LUI 6-(4-Hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D07VPM 2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol Investigative T89534 DRUGINFO D07XBD 6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol Investigative T89534 DRUGINFO D07XUY 8-methylnaringenin Investigative T89534 DRUGINFO D08FLV 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol Investigative T89534 DRUGINFO D08HCF 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol Investigative T89534 DRUGINFO D08VDX 8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D08WDN 4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol Investigative T89534 DRUGINFO D09CQC 2-(4-Hydroxy-phenyl)-benzooxazol-6-ol Investigative T89534 DRUGINFO D09DEK 7-(4-Hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D09NOH 8-(3-methylbutyl)naringenin Investigative T89534 DRUGINFO D09PXU 4,7-dimethyl-6H-benzo[c]chromene-3,8-diol Investigative T89534 DRUGINFO D09TQE 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D0A1JP 3'-Methoxy-4'Hydroxyclomiphene Investigative T89534 DRUGINFO D0AD3U 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol Investigative T89534 DRUGINFO D0B1HP 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol Investigative T89534 DRUGINFO D0B4VV Trans-hydroxytamoxifen Investigative T89534 DRUGINFO D0C5FY 3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one Investigative T89534 DRUGINFO D0C6AP 2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol Investigative T89534 DRUGINFO D0C9XK 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Investigative T89534 DRUGINFO D0CC6R 6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0D1LB 8-benzylnaringenin Investigative T89534 DRUGINFO D0DK9S 2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol Investigative T89534 DRUGINFO D0FD6Z 8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0H1CO 2-Naphthalen-1-yl-benzooxazol-6-ol Investigative T89534 DRUGINFO D0H2FI 6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol Investigative T89534 DRUGINFO D0H5HI 4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol Investigative T89534 DRUGINFO D0HM8Y 3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one Investigative T89534 DRUGINFO D0HR8L 6-(3-Hydroxy-phenyl)-naphthalen-1-ol Investigative T89534 DRUGINFO D0I1NX 4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol Investigative T89534 DRUGINFO D0I5HZ 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol Investigative T89534 DRUGINFO D0J0AG 5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T89534 DRUGINFO D0J2NG 8-n-heptylnaringenin Investigative T89534 DRUGINFO D0K0IC 4-(2-phenyl-1H-indol-3-yl)phenol Investigative T89534 DRUGINFO D0K1TW 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D0K6TE 6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0L2MU 7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol Investigative T89534 DRUGINFO D0L3AX 4-Naphthalen-2-yl-phenol Investigative T89534 DRUGINFO D0L6IQ 2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol Investigative T89534 DRUGINFO D0LI0M 8-n-pentylnaringenin Investigative T89534 DRUGINFO D0M0XL 6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol Investigative T89534 DRUGINFO D0MY8V 6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0N0OY 2-(4-Hydroxy-phenyl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D0NN0V 4',5,7-trihydroxy-6,8-dimethylisoflavone Investigative T89534 DRUGINFO D0O2KP 2-phenyl-1,2'-spirobi[1H-indene]-5'-ol Investigative T89534 DRUGINFO D0O5KR 4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol Investigative T89534 DRUGINFO D0O6FX 4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol Investigative T89534 DRUGINFO D0P0FN ZK-164015 Investigative T89534 DRUGINFO D0P6FN 6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0P7PK 2,3-diphenyl-1H-indole Investigative T89534 DRUGINFO D0R7AG 4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol Investigative T89534 DRUGINFO D0RI6O Doxorubicin-Formaldehyde Conjugate Investigative T89534 DRUGINFO D0S0SZ 7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D0S2ZJ 3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Investigative T89534 DRUGINFO D0S6NV 1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0S8EB 4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol Investigative T89534 DRUGINFO D0SR8Q 7-Phenyl-naphthalen-2-ol Investigative T89534 DRUGINFO D0U0ZE 3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one Investigative T89534 DRUGINFO D0U2VA 2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Investigative T89534 DRUGINFO D0U7KV 4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol Investigative T89534 DRUGINFO D0UV9G 6-Phenyl-naphthalen-2-ol Investigative T89534 DRUGINFO D0V6KJ 6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0V7QZ 2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T89534 DRUGINFO D0VN2R 6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol Investigative T89534 DRUGINFO D0W0LG 8-n-propylnaringenin Investigative T89534 DRUGINFO D0W2YR 3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Investigative T89534 DRUGINFO D0W3FF 2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Investigative T89534 DRUGINFO D0W4WF EFFUSOL Investigative T89534 DRUGINFO D0W5HT 8-n-nonylnaringenin Investigative T89534 DRUGINFO D0X2VK 2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol Investigative T89534 DRUGINFO D0X4VN 6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0X7DJ 6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0Y2LJ 8-(2-methylpropyl)naringenin Investigative T89534 DRUGINFO D0Y9BO WAY-169916 Investigative T89534 DRUGINFO D0YH4T 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Investigative T89534 DRUGINFO D0YW4C 2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol Investigative T89534 DRUGINFO D0Z0UC 1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol Investigative T89534 DRUGINFO D0ZT4U 1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D01IAT 7-(3-Hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D01TUB 4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T89534 DRUGINFO D03CBX 4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T89534 DRUGINFO D08SJL 4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T89534 DRUGINFO D09FWS 4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T89534 DRUGINFO D0H8PI 6-(4-Hydroxy-phenyl)-naphthalen-1-ol Investigative T89534 DRUGINFO D0K7HR 2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol Investigative T89534 DRUGINFO D0S8AV SOPHORAFLAVANONE B Investigative T89534 DRUGINFO D0H6OS Geldanamycin-estradiol hybrid Investigative T89534 DRUGINFO D0J7XZ CP-409069 Investigative T89534 DRUGINFO D0L5IC CP-394531 Investigative T89534 DRUGINFO D0P8PK 6-(3-Hydroxy-phenyl)-naphthalen-2-ol Investigative T89534 DRUGINFO D0SY2M daidzein Investigative T52450 TARGETID T52450 T52450 FORMERID TTDC00147 T52450 UNIPROID MMP1_HUMAN T52450 TARGNAME Matrix metalloproteinase-1 (MMP-1) T52450 GENENAME MMP1 T52450 TARGTYPE Successful T52450 SYNONYMS Interstitial collagenase; Fibroblast collagenase; CLG T52450 FUNCTION Cleaves collagens of types VII and X. In case of HIV infection, interacts and cleaves the secreted viral Tat protein, leading to a decrease in neuronal Tat's mediated neurotoxicity. Cleaves collagens of types I, II, and III at one site in the helical domain. T52450 PDBSTRUC 966C; 4AYK; 4AUO; 3SHI; 3AYK T52450 BIOCLASS Peptidase T52450 ECNUMBER EC 3.4.24.7 T52450 SEQUENCE MHSFPPLLLLLFWGVVSHSFPATLETQEQDVDLVQKYLEKYYNLKNDGRQVEKRRNSGPVVEKLKQMQEFFGLKVTGKPDAETLKVMKQPRCGVPDVAQFVLTEGNPRWEQTHLTYRIENYTPDLPRADVDHAIEKAFQLWSNVTPLTFTKVSEGQADIMISFVRGDHRDNSPFDGPGGNLAHAFQPGPGIGGDAHFDEDERWTNNFREYNLHRVAAHELGHSLGLSHSTDIGALMYPSYTFSGDVQLAQDDIDGIQAIYGRSQNPVQPIGPQTPKACDSKLTFDAITTIRGEVMFFKDRFYMRTNPFYPEVELNFISVFWPQLPNGLEAAYEFADRDEVRFFKGNKYWAVQGQNVLHGYPKDIYSSFGFPRTVKHIDAALSEENTGKTYFFVANKYWRYDEYKRSMDPGYPKMIAHDFPGIGHKVDAVFMKDGFFYFFHGTRQYKFDPKTKRILTLQKANSWFNCRKN T52450 DRUGINFO D00MDP Prinomastat Approved T52450 DRUGINFO D0MW3H CIPEMASTAT Phase 3 T52450 DRUGINFO D05VZE Marimastat Phase 3 T52450 DRUGINFO D0HG5M Apratastat Phase 2 T52450 DRUGINFO D05GAP PMID29130358-Compound-Figure10(2a) Patented T52450 DRUGINFO D0X6GG PMID29130358-Compound-Figure18(14a) Patented T52450 DRUGINFO D01EUF BMS 275291 Discontinued in Phase 3 T52450 DRUGINFO D0G4OT XL784 Discontinued in Phase 2 T52450 DRUGINFO D03BOZ RS-130830 Discontinued in Phase 2 T52450 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T52450 DRUGINFO D0EF7V Ro-31-4724 Terminated T52450 DRUGINFO D08CEE L-696418 Terminated T52450 DRUGINFO D08WBF BB-3644 Terminated T52450 DRUGINFO D0E5GY RO-319790 Terminated T52450 DRUGINFO D05VNG BB-1101 Terminated T52450 DRUGINFO D0Y1XT SC-44463 Terminated T52450 DRUGINFO D01QOB 4-Butoxy-N-hydroxycarbamoylmethyl-benzamide Investigative T52450 DRUGINFO D02BTV 3-Benzenesulfinyl-heptanoic acid hydroxyamide Investigative T52450 DRUGINFO D06BYR N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide Investigative T52450 DRUGINFO D08ZDD N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide Investigative T52450 DRUGINFO D09SYW N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide Investigative T52450 DRUGINFO D0L7AY N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3 Investigative T52450 DRUGINFO D0P2OA N-Hydroxycarbamoylmethyl-4-methoxy-benzamide Investigative T52450 DRUGINFO D0T4AN 4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide Investigative T52450 DRUGINFO D01OCR 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol Investigative T52450 DRUGINFO D09XUQ 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol Investigative T52450 DRUGINFO D0R2BO METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID Investigative T52450 DRUGINFO D0XE4B 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol Investigative T52450 DRUGINFO D0BI8T RS-39066 Investigative T52450 DRUGINFO D0D7UA 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol Investigative T52450 DRUGINFO D0K3RC 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol Investigative T52450 DRUGINFO D0N0FX 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol Investigative T52450 DRUGINFO D08ELY 3-Benzenesulfonyl-heptanoic acid hydroxyamide Investigative T52450 DRUGINFO D0N6CD 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide Investigative T52450 DRUGINFO D0H2PA PKF-242-484 Investigative T52450 DRUGINFO D0XL8K Ro-37-9790 Investigative T52450 DRUGINFO D03AMR SR-973 Investigative T52450 DRUGINFO D0A4TC MMI270 Investigative T53585 TARGETID T53585 T53585 FORMERID TTDS00195 T53585 UNIPROID HMDH_HUMAN T53585 TARGNAME HMG-CoA reductase (HMGCR) T53585 GENENAME HMGCR T53585 TARGTYPE Successful T53585 SYNONYMS 3-hydroxy-3-methylglutaryl-coenzyme A reductase T53585 FUNCTION Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins. T53585 PDBSTRUC 3CDB; 3CDA; 3CD7; 3CD5; 3CD0 T53585 BIOCLASS CH-OH donor oxidoreductase T53585 ECNUMBER EC 1.1.1.34 T53585 SEQUENCE MLSRLFRMHGLFVASHPWEVIVGTVTLTICMMSMNMFTGNNKICGWNYECPKFEEDVLSSDIIILTITRCIAILYIYFQFQNLRQLGSKYILGIAGLFTIFSSFVFSTVVIHFLDKELTGLNEALPFFLLLIDLSRASTLAKFALSSNSQDEVRENIARGMAILGPTFTLDALVECLVIGVGTMSGVRQLEIMCCFGCMSVLANYFVFMTFFPACVSLVLELSRESREGRPIWQLSHFARVLEEEENKPNPVTQRVKMIMSLGLVLVHAHSRWIADPSPQNSTADTSKVSLGLDENVSKRIEPSVSLWQFYLSKMISMDIEQVITLSLALLLAVKYIFFEQTETESTLSLKNPITSPVVTQKKVPDNCCRREPMLVRNNQKCDSVEEETGINRERKVEVIKPLVAETDTPNRATFVVGNSSLLDTSSVLVTQEPEIELPREPRPNEECLQILGNAEKGAKFLSDAEIIQLVNAKHIPAYKLETLMETHERGVSIRRQLLSKKLSEPSSLQYLPYRDYNYSLVMGACCENVIGYMPIPVGVAGPLCLDEKEFQVPMATTEGCLVASTNRGCRAIGLGGGASSRVLADGMTRGPVVRLPRACDSAEVKAWLETSEGFAVIKEAFDSTSRFARLQKLHTSIAGRNLYIRFQSRSGDAMGMNMISKGTEKALSKLHEYFPEMQILAVSGNYCTDKKPAAINWIEGRGKSVVCEAVIPAKVVREVLKTTTEAMIEVNINKNLVGSAMAGSIGGYNAHAANIVTAIYIACGQDAAQNVGSSNCITLMEASGPTNEDLYISCTMPSIEIGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLARIVCGTVMAGELSLMAALAAGHLVKSHMIHNRSKINLQDLQGACTKKTA T53585 DRUGINFO D01QIN Atorvastatin Approved T53585 DRUGINFO D02RQU Pravastatin Approved T53585 DRUGINFO D03KIA Cerivastatin Approved T53585 DRUGINFO D03VFL TOCOTRIENOL Approved T53585 DRUGINFO D04XGU Crestor/TriLipix Approved T53585 DRUGINFO D06WTZ Lovastatin Approved T53585 DRUGINFO D08GHB Fluvastatin Approved T53585 DRUGINFO D0G1WL PITAVASTATIN CALCIUM Approved T53585 DRUGINFO D0H0ND Simvastatin Approved T53585 DRUGINFO D0JE2E Rosuvastatin Approved T53585 DRUGINFO D0GY5Z Aspirin Approved T53585 DRUGINFO D07QFP Teriflunomide Approved T53585 DRUGINFO D0WL5V LAROPIPRANT Phase 4 T53585 DRUGINFO D0G7IV Premarin/Pravachol Phase 3 T53585 DRUGINFO D06BBV XZK-monascus Phase 2 T53585 DRUGINFO D0CC8L CRILVASTATIN Phase 2 T53585 DRUGINFO D0H0FX NCX-6560 Phase 1 T53585 DRUGINFO D00YVL PMID27537201-Compound-Figure15a Patented T53585 DRUGINFO D03HKN PMID27537201-Compound-Figure13b Patented T53585 DRUGINFO D04MFJ Quinoline derivative 17 Patented T53585 DRUGINFO D05SOY Hexahydro naphthalene derivative 3 Patented T53585 DRUGINFO D08FMC Sterol derivative 1 Patented T53585 DRUGINFO D09ZXW Atorvastatin lactole derivative 1 Patented T53585 DRUGINFO D0AP6V Poly-substituted azoles statin lactone derivative 2 Patented T53585 DRUGINFO D0AY4N Lactol derivative 1 Patented T53585 DRUGINFO D0CM4R Lactol derivative 2 Patented T53585 DRUGINFO D0CW2F Poly-substituted miazine derivative 1 Patented T53585 DRUGINFO D0EF9J PMID27537201-Compound-Figure13c Patented T53585 DRUGINFO D0G8JX Pitavastatin derivative 1 Patented T53585 DRUGINFO D0KU2T Pravastatin derivative 1 Patented T53585 DRUGINFO D0L3BE Hexahydro naphthalene derivative 1 Patented T53585 DRUGINFO D0LJ0M 2-cyclopropyl-4-substituted-phenoxy-quinoline derivative 1 Patented T53585 DRUGINFO D0M9ZW Hexahydro naphthalene derivative 2 Patented T53585 DRUGINFO D0O0OD Sterol derivative 3 Patented T53585 DRUGINFO D0QW7F Quinoline derivative 16 Patented T53585 DRUGINFO D0RW8J Poly-substituted azoles statin lactone derivative 1 Patented T53585 DRUGINFO D0S3BE PMID27537201-Compound-Figure17 Patented T53585 DRUGINFO D0SH0L PMID27537201-Compound-Figure15b Patented T53585 DRUGINFO D0U2CK Quinoline derivative 1 Patented T53585 DRUGINFO D0YX0O PMID27537201-Compound-Figure11 Patented T53585 DRUGINFO D0YZ3U Sterol derivative 2 Patented T53585 DRUGINFO D0Y9XD Dalvastatin Discontinued in Phase 3 T53585 DRUGINFO D02GSA RBx10558 Discontinued in Phase 2 T53585 DRUGINFO D04NCJ BMY-21950 Discontinued in Phase 2 T53585 DRUGINFO D0L1LJ Bervastatin Discontinued in Phase 2 T53585 DRUGINFO D0U5NU GLENVASTATIN Discontinued in Phase 2 T53585 DRUGINFO D0MF7U PF-3052334 Discontinued in Phase 1 T53585 DRUGINFO D07QSA CP-83101 Terminated T53585 DRUGINFO D0C7RV SR12813 Terminated T53585 DRUGINFO D0E2CO BMY-22089 Terminated T53585 DRUGINFO D0J9GD Mevastatin Terminated T53585 DRUGINFO D0Y3OR SQ-33600 Terminated T53585 DRUGINFO D0YQ9G GT-16-239 Terminated T53585 DRUGINFO D00RHH PMID17574411C41 Investigative T53585 DRUGINFO D00TBG PMID8246233C5ab Investigative T53585 DRUGINFO D00TIO PMID1656041C4ff Investigative T53585 DRUGINFO D00UOI PMID17574412C33 Investigative T53585 DRUGINFO D00VMO PMID1992149C13 Investigative T53585 DRUGINFO D00ZJG PMID2231594C3k Investigative T53585 DRUGINFO D01WQF FPYVAE peptide Investigative T53585 DRUGINFO D01XMY PMID1895299C1 Investigative T53585 DRUGINFO D01YQX 6-hydroxy-7,9-octadecadiynoic acid Investigative T53585 DRUGINFO D01ZAL PMID2296036C4i Investigative T53585 DRUGINFO D02EQL PMID2231594C3u Investigative T53585 DRUGINFO D02ITS PMID1992149C9 Investigative T53585 DRUGINFO D02MEX PMID2153213C2c Investigative T53585 DRUGINFO D02OET PMID1895299C4p Investigative T53585 DRUGINFO D02SRB BPL-001 Investigative T53585 DRUGINFO D02TIT PMID18412317C13b Investigative T53585 DRUGINFO D03CYY GFPDGG Investigative T53585 DRUGINFO D03EAN PMID2153213C1e Investigative T53585 DRUGINFO D03GRA (R)-Mevalonate Investigative T53585 DRUGINFO D03TKT o-hydroxyatorvastatin Investigative T53585 DRUGINFO D03ZIK MT-001 Investigative T53585 DRUGINFO D04XQG NCX-1067 Investigative T53585 DRUGINFO D05GWF PMID2153213C2d Investigative T53585 DRUGINFO D05UQC PMID2296036C2t Investigative T53585 DRUGINFO D05YUT PMID8426367C18 Investigative T53585 DRUGINFO D06BIF PMID2153213C13b Investigative T53585 DRUGINFO D06FRE PMID1656041C11dd Investigative T53585 DRUGINFO D06HNA PMID1875346C18 Investigative T53585 DRUGINFO D07QAX PMID15686906C17 Investigative T53585 DRUGINFO D07VEB PMID8246234C3h Investigative T53585 DRUGINFO D08SKU 3-(1,3 dodecadiynyl)-6-oxiranebutanoic acid Investigative T53585 DRUGINFO D09CSQ DFGYVAE Investigative T53585 DRUGINFO D09EBV 7,9-tetradecadiynoic acid Investigative T53585 DRUGINFO D09QIA 9-octadecynoic acid Investigative T53585 DRUGINFO D09TKN PMID2153213C13g Investigative T53585 DRUGINFO D0A6FX (E)-octadecan-9-ynoic acid Investigative T53585 DRUGINFO D0B2FM GLPTGG Investigative T53585 DRUGINFO D0C1RY GFPEGG Investigative T53585 DRUGINFO D0C5LO 7,9-octadecadiynoic acid Investigative T53585 DRUGINFO D0C8HK (E)-5-octadecen-7,9-diynoic acid Investigative T53585 DRUGINFO D0CU3I (Z)-7-octedecan-9-ynoic acid Investigative T53585 DRUGINFO D0FD8Q PMID8246237C18t Investigative T53585 DRUGINFO D0G2QW PMID1992138C8b Investigative T53585 DRUGINFO D0G4ZG PMID2153213C2f Investigative T53585 DRUGINFO D0G6PS PMID17574411C42 Investigative T53585 DRUGINFO D0I0IM 5-ketodihydromevinolin Investigative T53585 DRUGINFO D0I9TR PMID2296036C4d Investigative T53585 DRUGINFO D0IJ7H 3-Hydroxy-3-Methyl-Glutaric Acid Investigative T53585 DRUGINFO D0J8BD PMID2909732C7 Investigative T53585 DRUGINFO D0J9DY PMID2296027C25 Investigative T53585 DRUGINFO D0K1MB PMID7932551C9 Investigative T53585 DRUGINFO D0L6HX PMID18072721C50 Investigative T53585 DRUGINFO D0M4YT PMID1895299C6v Investigative T53585 DRUGINFO D0M9BZ PMID1656041C11nn Investigative T53585 DRUGINFO D0MU7C PMID2231594C3j Investigative T53585 DRUGINFO D0N7RK PMID19502059C25d Investigative T53585 DRUGINFO D0NJ5U PMID8246233C35 Investigative T53585 DRUGINFO D0NU6K (Z)-5-octadecen-7,9-diynoic acid Investigative T53585 DRUGINFO D0O1OC PMID2296036C2g Investigative T53585 DRUGINFO D0O2FD PMID1656041C11ff Investigative T53585 DRUGINFO D0O7AS PMID18155906C16f Investigative T53585 DRUGINFO D0O8XW PMID17560788C29f Investigative T53585 DRUGINFO D0Q2EH Brutieridin Investigative T53585 DRUGINFO D0Q6WP PMID15686906C29 Investigative T53585 DRUGINFO D0R1FP PMID2153213C1a Investigative T53585 DRUGINFO D0R8YV PMID1656041C74 Investigative T53585 DRUGINFO D0RA8F PMID2153213C1f Investigative T53585 DRUGINFO D0S1ER PMID8246233C28 Investigative T53585 DRUGINFO D0S1LA GFPTGG Investigative T53585 DRUGINFO D0T4PL PMID1656041C11jj Investigative T53585 DRUGINFO D0UQ6A PMID2231594C3q Investigative T53585 DRUGINFO D0W5FM PMID1527791C29 Investigative T53585 DRUGINFO D0W7VX Statin Investigative T53585 DRUGINFO D0X0GG PMID1656041C4rr Investigative T53585 DRUGINFO D0X0GV GLPDGG peptide Investigative T53585 DRUGINFO D0X1VL F(4-Fluoro)VAE Investigative T53585 DRUGINFO D0Y6DJ rawsonol Investigative T53585 DRUGINFO D0ZQ3B PMID2296027C29 Investigative T53585 DRUGINFO D01GMJ 1,4-Dithiothreitol Investigative T53585 DRUGINFO D0W3NA Coenzyme A Investigative T53585 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T53585 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T14597 TARGETID T14597 T14597 FORMERID TTDS00249 T14597 UNIPROID ERBB2_HUMAN T14597 TARGNAME Erbb2 tyrosine kinase receptor (HER2) T14597 GENENAME ERBB2 T14597 TARGTYPE Successful T14597 SYNONYMS p185erbB2; Tyrosine kinase-type cell surface receptor HER2; Receptor tyrosine-protein kinase erbB-2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; NGL; NEU; Metastatic lymph node gene 19 protein; MLN19; MLN 19; HER2; CD340 T14597 FUNCTION Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. T14597 PDBSTRUC 6OGE; 6J71; 6BGT; 6ATT; 5TQS T14597 BIOCLASS Kinase T14597 ECNUMBER EC 2.7.10.1 T14597 SEQUENCE MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV T14597 DRUGINFO D01YYP Margetuximab Approved T14597 DRUGINFO D04WFL Trastuzumab Approved T14597 DRUGINFO D09GRX Tucatinib Approved T14597 DRUGINFO D0CI4E Pertuzumab Approved T14597 DRUGINFO D0U3YB Masoprocol Approved T14597 DRUGINFO D05UFG BIBW 2992 Approved T14597 DRUGINFO D0U1ZV NERATINIB MALEATE Approved T14597 DRUGINFO D06XXH Dacomitinib Approved T14597 DRUGINFO D08CDI Lapatinib Approved T14597 DRUGINFO D0F0ZE Merimepodib Approved T14597 DRUGINFO D04VRB NeuVax Phase 3 T14597 DRUGINFO D0F8UV Nelipepimut S Phase 3 T14597 DRUGINFO D0HR7Z PF-05280014 Phase 3 T14597 DRUGINFO D0P4TH Trastuzumab-DM1 Phase 3 T14597 DRUGINFO DI0ED3 SYD985 Phase 3 T14597 DRUGINFO D04SLF Bevacizumab + Trastuzumab Phase 3 T14597 DRUGINFO D0J6PY Taxol/Paraplatin/Herceptin Phase 3 T14597 DRUGINFO D0Q9CY HKI-272 Phase 3 T14597 DRUGINFO D00NYJ Varlitinib Phase 2/3 T14597 DRUGINFO D06KOM DN24-02 Phase 2 T14597 DRUGINFO D09XHU HER-2 Protein AutoVac Phase 2 T14597 DRUGINFO D0B1TL Her2-targeted autologous T-cell therapy Phase 2 T14597 DRUGINFO D0BM7M AZD8931 Phase 2 T14597 DRUGINFO D0CN9Q CP-724714 Phase 2 T14597 DRUGINFO D0G5GB MGAH22 Phase 2 T14597 DRUGINFO D0P1DI MCLA-128 Phase 2 T14597 DRUGINFO D0P7KI Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells Phase 2 T14597 DRUGINFO D0Q2KM MM-111 Phase 2 T14597 DRUGINFO D0QF7Z HER2/neu peptide vaccine Phase 2 T14597 DRUGINFO DM7WY2 MRG002 Phase 2 T14597 DRUGINFO DV2N5P KN026 Phase 2 T14597 DRUGINFO D00YER HM-78136B Phase 2 T14597 DRUGINFO D03UKJ Pazopanib + Tyverb/Tykerb Phase 2 T14597 DRUGINFO D0U4FF BMS-599626 Phase 2 T14597 DRUGINFO D1J4CI Zenocutuzumab Phase 2 T14597 DRUGINFO DUW81M Tarloxotinib Phase 2 T14597 DRUGINFO D0O2JI Ertumaxomab Phase 2 T14597 DRUGINFO D0YB3W CI-1033 Phase 2 T14597 DRUGINFO D03TQB AU105 Phase 1/2 T14597 DRUGINFO D06KQG HER-2-targeting CAR T Cells Phase 1/2 T14597 DRUGINFO D08KCJ ABY-025 Phase 1/2 T14597 DRUGINFO D08QZH Anti-HER2 CAR-T Phase 1/2 T14597 DRUGINFO D0F3MT AVX901 Phase 1/2 T14597 DRUGINFO D0G4AJ AGN-208397 Phase 1/2 T14597 DRUGINFO D0NN7P CART-HER-2 Phase 1/2 T14597 DRUGINFO DD94ZN A166 Phase 1/2 T14597 DRUGINFO DY13WU TAS-0728 Phase 1/2 T14597 DRUGINFO D6SL3N Zenocutuzomab Phase 1/2 T14597 DRUGINFO D9FJ5V BDTX-189 Phase 1/2 T14597 DRUGINFO DNC79U ISB 1302 Phase 1/2 T14597 DRUGINFO D0FF2G Sym013 Phase 1/2 T14597 DRUGINFO D0V4XY S-222611 Phase 1b T14597 DRUGINFO D02UFQ TAK-285 Phase 1 T14597 DRUGINFO D05ATQ MVA HER-2 AutoVac Phase 1 T14597 DRUGINFO D06RCE HER2-specific T cells Phase 1 T14597 DRUGINFO D06XWD CAR-T Cells targeting HER2 Phase 1 T14597 DRUGINFO D07USV MM-302 Phase 1 T14597 DRUGINFO D08UDG MEDI4276 Phase 1 T14597 DRUGINFO D09UGG Zemab Phase 1 T14597 DRUGINFO D0H7ZN VM-206 Phase 1 T14597 DRUGINFO D0JI4M CAR-T cells targeting HER2 Phase 1 T14597 DRUGINFO D0M8AI ARRY-380 Phase 1 T14597 DRUGINFO D0O9HF TrasGEX Phase 1 T14597 DRUGINFO D0TN5W HER2-CAR T Cells Phase 1 T14597 DRUGINFO D0U2PS HER2p63-71 peptide vaccine Phase 1 T14597 DRUGINFO D0YF6K HER2-specific CAR T cell Phase 1 T14597 DRUGINFO D1C0WB DZD1516 Phase 1 T14597 DRUGINFO D56ECJ BB-1701 Phase 1 T14597 DRUGINFO D6IOB5 BAY 2701439 Phase 1 T14597 DRUGINFO DEI07S AIP-303 Phase 1 T14597 DRUGINFO DEX8D5 NJH395 Phase 1 T14597 DRUGINFO DH09QZ ZW49 Phase 1 T14597 DRUGINFO DQ04FJ MBS301 Phase 1 T14597 DRUGINFO DQ1RZ8 ACE1702 Phase 1 T14597 DRUGINFO DS60CK MT-5111 Phase 1 T14597 DRUGINFO DSOE74 GQ1001 Phase 1 T14597 DRUGINFO DU54BA MB-103 Phase 1 T14597 DRUGINFO DWS76U TT16 Phase 1 T14597 DRUGINFO D08JAN Cipatinib Phase 1 T14597 DRUGINFO D0DBS7 GBR1302 Phase 1 T14597 DRUGINFO D0UL7L Recombinant human Erbb3 fragment therapeutic tumor vaccine Phase 1 T14597 DRUGINFO D0Z4RC CUDC-101 Phase 1 T14597 DRUGINFO D3FYE1 M802 Phase 1 T14597 DRUGINFO DUA7P2 SBT6050 Phase 1 T14597 DRUGINFO DL6F3E SAR443216 Phase 1 T14597 DRUGINFO DCUQ32 Runimotamab Phase 1 T14597 DRUGINFO DCUQ32 Runimotamab Phase 1 T14597 DRUGINFO D0U3XL JNJ-26483327 Phase 1 T14597 DRUGINFO D05YLO Her-2-Bi-armed ATC Discontinued in Phase 2 T14597 DRUGINFO D0A9OV TAK165 Discontinued in Phase 1 T14597 DRUGINFO DO6UE8 227Th-labelled HER2-TTC Preclinical T14597 DRUGINFO D02YAQ GW-974 Terminated T14597 DRUGINFO D0NX2G (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine Investigative T14597 DRUGINFO D0O5CR TA1-RTA Investigative T14597 DRUGINFO D02ARA (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine Investigative T14597 DRUGINFO D0B1SW Redoxal Investigative T14597 DRUGINFO D0J2CP PF 5208766 Investigative T14597 DRUGINFO DKHL40 YH012 Investigative T07173 TARGETID T07173 T07173 FORMERID TTDC00318 T07173 UNIPROID NTRK1_HUMAN T07173 TARGNAME Tropomyosin-related kinase A (TrkA) T07173 GENENAME NTRK1 T07173 TARGTYPE Successful T07173 SYNONYMS gp140trk; Tyrosine kinase receptor A; Tyrosine kinase receptor; Trk-A; TRKA; TRK1-transforming tyrosine kinase protein; TRK1 transforming tyrosinekinase protein; TRK; P140-TrkA; Neurotrophic tyrosine kinase receptor type 1; NGF-trk receptor type A; MTC; High affinity nerve growth factor receptor T07173 FUNCTION High affinity receptor for NGF which is its primary ligand. Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that regulates cell differentiation and survival. Through PLCG1 controls NF-Kappa-B activation and the transcription of genes involved in cell survival. Through SHC1 and SH2B1 controls a Ras-PI3 kinase-AKT1 signaling cascade that is also regulating survival. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors. Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. T07173 PDBSTRUC 6NSS; 6NSP; 6NPT; 6DKW; 6DKI T07173 BIOCLASS Kinase T07173 ECNUMBER EC 2.7.10.1 T07173 SEQUENCE MLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACCPHGSSGLRCTRDGALDSLHHLPGAENLTELYIENQQHLQHLELRDLRGLGELRNLTIVKSGLRFVAPDAFHFTPRLSRLNLSFNALESLSWKTVQGLSLQELVLSGNPLHCSCALRWLQRWEEEGLGGVPEQKLQCHGQGPLAHMPNASCGVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTELEQSATVMKSGGLPSLGLTLANVTSDLNRKNVTCWAENDVGRAEVSVQVNVSFPASVQLHTAVEMHHWCIPFSVDGQPAPSLRWLFNGSVLNETSFIFTEFLEPAANETVRHGCLRLNQPTHVNNGNYTLLAANPFGQASASIMAAFMDNPFEFNPEDPIPVSFSPVDTNSTSGDPVEKKDETPFGVSVAVGLAVFACLFLSTLLLVLNKCGRRNKFGINRPAVLAPEDGLAMSLHFMTLGGSSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG T07173 DRUGINFO D05NFR Repotrectinib Approved T07173 DRUGINFO D07TOK Larotrectinib Approved T07173 DRUGINFO D0O0LS Entrectinib Approved T07173 DRUGINFO D0C2OR MIM-D3 Phase 3 T07173 DRUGINFO D04QYS SNA-120 Phase 2 T07173 DRUGINFO D0B7OY CT 327 Phase 2 T07173 DRUGINFO D0QP8X ONO-7579 Phase 1/2 T07173 DRUGINFO D03UDF LOXO-195 Phase 1 T07173 DRUGINFO D1ZD0N VMD-928 Phase 1 T07173 DRUGINFO D0N0DU DS-6051 Phase 1 T07173 DRUGINFO D07PSL PLX7486 Phase 1 T07173 DRUGINFO D0FA6S Altiratinib Phase 1 T07173 DRUGINFO D00DIZ Pyrazolo[1,5-a]pyrimidine derivative 17 Patented T07173 DRUGINFO D00EUL PMID28270021-Compound-WO2016054807Example82 Patented T07173 DRUGINFO D00FJH N-acylpiperidine ether derivative 4 Patented T07173 DRUGINFO D00ICS Pyrrolidinyl urea derivative 11 Patented T07173 DRUGINFO D00XXZ N-acylpiperidine ether derivative 1 Patented T07173 DRUGINFO D02ETU PMID28270021-Compound-WO2014152663 701 Patented T07173 DRUGINFO D02IBX Pyrrolo[2,3-b]pyridine derivative 3 Patented T07173 DRUGINFO D02OLJ N-acylpiperidine ether derivative 7 Patented T07173 DRUGINFO D02QWP N-arylmethyl-N-phenyl cyclic urea derivative 2 Patented T07173 DRUGINFO D02ZQN PMID28270021-Compound-WO2013009582Example16 Patented T07173 DRUGINFO D03BAY N-acylpiperidine ether derivative 5 Patented T07173 DRUGINFO D03USW Pyrazolo[1,5-a]pyrimidine derivative 25 Patented T07173 DRUGINFO D04BRW Five membered heterocyclic benzamide derivative 2 Patented T07173 DRUGINFO D04GCC N-acylpiperidine ether derivative 6 Patented T07173 DRUGINFO D04JCD Six-membered heterocyclic benzamide derivative 6 Patented T07173 DRUGINFO D04KQB Pyrazolo[1,5-a]pyrimidine derivative 24 Patented T07173 DRUGINFO D04QHI Imidazo[1,2-b]pyridazine derivative 7 Patented T07173 DRUGINFO D04RXX N-acylpiperidine ether derivative 2 Patented T07173 DRUGINFO D05AQT PMID28270021-Compound-WO2014078408Example1 Patented T07173 DRUGINFO D05KHT Pyrazolo[1,5-a]pyrimidine derivative 19 Patented T07173 DRUGINFO D05MRY Six-membered heterocyclic benzamide derivative 7 Patented T07173 DRUGINFO D05NBR PMID28270010-Compound-Figure16-a Patented T07173 DRUGINFO D05RKT Pyrazolo[1,5-a]pyrimidine derivative 18 Patented T07173 DRUGINFO D06GOT Pyrrolo[2,3-b]pyridine derivative 2 Patented T07173 DRUGINFO D06NPZ Pyrazolo[1,5-a]pyrimidine derivative 23 Patented T07173 DRUGINFO D06STX Thiadiazolyl carboxamide derivative 1 Patented T07173 DRUGINFO D06YON Pyrrolidinyl urea derivative 9 Patented T07173 DRUGINFO D07AJO Bicyclic heteroaryl benzamide derivative 9 Patented T07173 DRUGINFO D07CPL Bicyclic heteroaryl benzamide derivative 6 Patented T07173 DRUGINFO D07KVL PMID28270021-Compound-WO2010077680 811 Patented T07173 DRUGINFO D07VFQ Six-membered heterocyclic benzamide derivative 3 Patented T07173 DRUGINFO D08BIH N-acylpyrrolidine ether derivative 2 Patented T07173 DRUGINFO D08CZY PMID28270021-Compound-WO2016054807Example71 Patented T07173 DRUGINFO D08IWT Pyrazolo[1,5-a]pyrimidine derivative 27 Patented T07173 DRUGINFO D08SDJ Ureido-phenyl-substituted triazine derivative 1 Patented T07173 DRUGINFO D09SYD Pyrazolo[1,5-a]pyrimidine derivative 26 Patented T07173 DRUGINFO D0A4YR Pyrrolidinyl urea derivative 8 Patented T07173 DRUGINFO D0BI5I Pyrazolo[1,5-a]pyrimidine derivative 15 Patented T07173 DRUGINFO D0BO1H PMID28270021-Compound-WO2016054807Example80 Patented T07173 DRUGINFO D0BP9B N,N-bis(5-pyrazoyl)urea derivative 1 Patented T07173 DRUGINFO D0BZ0T Pyrazolo[1,5-a]pyrimidine derivative 16 Patented T07173 DRUGINFO D0C3RK N-(phenylpyrazolyl)benzamide derivative 1 Patented T07173 DRUGINFO D0CG8N Tri-substituted urea derivative 2 Patented T07173 DRUGINFO D0CY3U Five membered heterocyclic benzamide derivative 3 Patented T07173 DRUGINFO D0D6UF Pyrazolo[1,5-a]pyrimidine derivative 21 Patented T07173 DRUGINFO D0D7EG PMID28270010-Compound-Figure17-3 Patented T07173 DRUGINFO D0DN3Q Pyrazolo[1,5-a]pyridine derivative 1 Patented T07173 DRUGINFO D0DO4I Imidazo[1,2-b]pyridazine derivative 5 Patented T07173 DRUGINFO D0DQ5G Pyrrolo[3,2-c]pyridine derivative 1 Patented T07173 DRUGINFO D0DY5R Bicyclic heteroaryl benzamide derivative 8 Patented T07173 DRUGINFO D0EC4Z Six-membered heterocyclic benzamide derivative 4 Patented T07173 DRUGINFO D0F2BF PMID28270021-Compound-WO2010077680 803 Patented T07173 DRUGINFO D0F8BF Bicyclic heteroaryl benzamide derivative 2 Patented T07173 DRUGINFO D0FL8A PMID28270021-Compound-WO2010077680 481 Patented T07173 DRUGINFO D0FS4S Imidazo[1,2-b]pyridazine derivative 4 Patented T07173 DRUGINFO D0H3ZG Six-membered heterocyclic benzamide derivative 2 Patented T07173 DRUGINFO D0H8XH Pyrazolo[1,5-a]pyrimidine derivative 14 Patented T07173 DRUGINFO D0HF1A Bicyclic heteroaryl benzamide derivative 1 Patented T07173 DRUGINFO D0I2OO PMID28270021-Compound-WO2013161919Example85-117 Patented T07173 DRUGINFO D0I5DM N-arylmethyl-N-phenyl cyclic urea derivative 1 Patented T07173 DRUGINFO D0I8AY Pyrrolidinyl urea derivative 10 Patented T07173 DRUGINFO D0I9FU Bicyclic heteroaryl benzamide derivative 4 Patented T07173 DRUGINFO D0J4CA PMID28270021-Compound-WO2010077680 103 Patented T07173 DRUGINFO D0J5OO Pyrrolidinyl urea derivative 6 Patented T07173 DRUGINFO D0JJ0T Pyrrolidinyl urea derivative 2 Patented T07173 DRUGINFO D0JU4R Thiazole derivative 4 Patented T07173 DRUGINFO D0K2GH Pyrrolidinyl urea derivative 12 Patented T07173 DRUGINFO D0K3QT Pyrrolidinyl urea derivative 4 Patented T07173 DRUGINFO D0K6IM PMID28270021-Compound-WO2010077680 495 Patented T07173 DRUGINFO D0KC8X Bicyclic heteroaryl benzamide derivative 5 Patented T07173 DRUGINFO D0LB7Z Pyrrolidinyl urea derivative 3 Patented T07173 DRUGINFO D0LK8E PMID28270021-Compound-WO2016054807Example112 Patented T07173 DRUGINFO D0ME5D Pyrrolidinyl urea derivative 5 Patented T07173 DRUGINFO D0MZ7K Triazolo[4,3-b]pyridazine derivative 2 Patented T07173 DRUGINFO D0N6NG Bicyclic heteroaryl benzamide derivative 7 Patented T07173 DRUGINFO D0O0GZ Bicyclic heteroaryl benzamide derivative 3 Patented T07173 DRUGINFO D0O8SX Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1 Patented T07173 DRUGINFO D0P3VK PMID28270010-Compound-Figure17-1 Patented T07173 DRUGINFO D0P8SR Pyrrolo[2,3-b]pyridine derivative 1 Patented T07173 DRUGINFO D0PY0G PMID28270021-Compound-WO2010077680 201 Patented T07173 DRUGINFO D0QT8L PMID28270021-Compound-WO2014129431Example8-1 Patented T07173 DRUGINFO D0RK6W Pyrazolo[4,3-c]pyridine derivative 1 Patented T07173 DRUGINFO D0RR8O Pyrido[3,2-d]pyrimidine derivative 2 Patented T07173 DRUGINFO D0S0II Pyrrolo[2,3-d]pyrimidine derivative 3 Patented T07173 DRUGINFO D0T0HM PMID28270021-Compound-WO2010077680 109 Patented T07173 DRUGINFO D0T4CF Five membered heterocyclic benzamide derivative 1 Patented T07173 DRUGINFO D0T5OF PMID28270010-Compound-Figure17-2 Patented T07173 DRUGINFO D0U2GJ Pyrazolo[1,5-a]pyrimidine derivative 22 Patented T07173 DRUGINFO D0U3RD Pyrido[3,2-d]pyrimidine derivative 3 Patented T07173 DRUGINFO D0U5XI PMID28270021-Compound-WO2015042088Example11 Patented T07173 DRUGINFO D0UN4M Six-membered heterocyclic benzamide derivative 5 Patented T07173 DRUGINFO D0UQ2G Tri-substituted urea derivative 1 Patented T07173 DRUGINFO D0V7QU Ureido-phenyl-substituted triazine derivative 2 Patented T07173 DRUGINFO D0V9ZJ Pyrazolo[1,5-a]pyridine derivative 2 Patented T07173 DRUGINFO D0VD5J PMID28270021-Compound-WO2015042088Example12 Patented T07173 DRUGINFO D0W0UF Imidazo[1,2-b]pyridazine derivative 6 Patented T07173 DRUGINFO D0W9RH PMID28270010-Compound-Figure16-b-1 Patented T07173 DRUGINFO D0WI7N Imidazo pyridine derivative 1 Patented T07173 DRUGINFO D0X0YJ Pyrrolidinyl urea derivative 7 Patented T07173 DRUGINFO D0X1LP N-acylpiperidine ether derivative 3 Patented T07173 DRUGINFO D0X4LA N-acylpyrrolidine ether derivative 1 Patented T07173 DRUGINFO D0Y0XJ PMID28270021-Compound-WO2013009582Example76 Patented T07173 DRUGINFO D0YM2S PMID28270010-Compound-Figure16-b-2 Patented T07173 DRUGINFO D0YN0I PMID28270021-Compound-WO2014078408Example26 Patented T07173 DRUGINFO D0Z5PA Pyrazolo[1,5-a]pyrimidine derivative 20 Patented T07173 DRUGINFO D0Z6LB Pyrrolidinyl urea derivative 13 Patented T07173 DRUGINFO D0ZE6H Six-membered heterocyclic benzamide derivative 1 Patented T07173 DRUGINFO D0M8UO Imidazo[1,2-b]pyridazine derivative 2 Patented T07173 DRUGINFO D0N1CF Imidazo[1,2-b]pyridazine derivative 3 Patented T07173 DRUGINFO D0T3TZ Benzimidazole derivative 6 Patented T07173 DRUGINFO D0T8XD Imidazo[1,2-b]pyridazine derivative 1 Patented T07173 DRUGINFO D0X9VS PMID28270010-Compound-Figure24-a Patented T07173 DRUGINFO D00MGO PMID28270021-Compound-WO2016054807Example1 Patented T07173 DRUGINFO D07RLB PMID28270010-Compound-Figure24-b Patented T07173 DRUGINFO D0AG2A Pyrrolo[2,3-d]pyrimidine derivative 4 Patented T07173 DRUGINFO D0AU4G 3-amino-5-benzyl-substituted indazole derivative 1 Patented T07173 DRUGINFO D0J9ZG PMID28270010-Compound-Figure5-1 Patented T07173 DRUGINFO D0M8VS PMID28270021-Compound-WO2015042088Example4 Patented T07173 DRUGINFO D0T2OX PMID28270010-Compound-Figure5-2 Patented T07173 DRUGINFO D0V5AG PMID28270010-Compound-Figure5-3 Patented T07173 DRUGINFO D0Y1NH Azaindazole amide derivative 1 Patented T07173 DRUGINFO D0LX8D AZD6918 Discontinued in Phase 1 T07173 DRUGINFO D07SYN FX-007 Preclinical T07173 DRUGINFO D02RWK K-252a analogue Investigative T07173 DRUGINFO D0Z5TQ GW-5074 Investigative T07173 DRUGINFO D07IHM CEP-6331 Investigative T07173 DRUGINFO D09QBA CEP-5104 Investigative T85435 TARGETID T85435 T85435 FORMERID TTDS00292 T85435 UNIPROID INSR_HUMAN T85435 TARGNAME Insulin receptor (INSR) T85435 GENENAME INSR T85435 TARGTYPE Successful T85435 SYNONYMS IR; CD220 antigen; CD220 T85435 FUNCTION Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. T85435 PDBSTRUC 6HN5; 6HN4; 5U1M; 5KQV; 5J3H T85435 BIOCLASS Kinase T85435 ECNUMBER EC 2.7.10.1 T85435 SEQUENCE MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHLQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYALVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNEECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECLGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQGCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGCTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETLEIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQERNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFSDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWERQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQILKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAFPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYVSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCVSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSREKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKGFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMAAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDNCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEMEFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSNPS T85435 DRUGINFO D02EHV Human neutral insulin Approved T85435 DRUGINFO D03VXG Insulin Lyspro recombinant Approved T85435 DRUGINFO D05ELO Insulin, porcine Approved T85435 DRUGINFO D06SVW Insulin recombinant Approved T85435 DRUGINFO D09PPG Metformin arginine-hemisuccinimide Approved T85435 DRUGINFO D0L6JE Insulin-lispro Approved T85435 DRUGINFO D0M2XE Insulin-glulisine Approved T85435 DRUGINFO D0Y3VQ Ryzodeq Approved T85435 DRUGINFO D07MEH Meglitinides Approved T85435 DRUGINFO D0U8YK NN5401 Phase 3 T85435 DRUGINFO D0U3LK Metformin glycinate Phase 2/3 T85435 DRUGINFO D00AUX MSDC-0602 Phase 2 T85435 DRUGINFO D02SXZ S-707106 Phase 2 T85435 DRUGINFO D03VCJ NP-01 Phase 2 T85435 DRUGINFO D06MOY DM-99 Phase 2 T85435 DRUGINFO D07NKZ VVP-808 Phase 2 T85435 DRUGINFO D0A6OS TAK-379 Phase 2 T85435 DRUGINFO D0D4ZW EGS-21 Phase 2 T85435 DRUGINFO D0T5YX DM-71 Phase 2 T85435 DRUGINFO D0ZK7B Tesofensine Phase 2 T85435 DRUGINFO DJM3W0 RZ358 Phase 2 T85435 DRUGINFO D00SWQ Mitoglitazone Phase 2 T85435 DRUGINFO D06HPP AGT-182 Phase 1 T85435 DRUGINFO D07DLA ISF-402 Phase 1 T85435 DRUGINFO D08TGG Insulin transdermal Phase 1 T85435 DRUGINFO D08XFJ NN-1218 Phase 1 T85435 DRUGINFO D0D5EJ Insulin oral sublingual Phase 1 T85435 DRUGINFO D07HPJ AEW-541 Phase 1 T85435 DRUGINFO D05LSY AKP-020 Discontinued in Phase 2 T85435 DRUGINFO D0F1MU EML-336 Discontinued in Phase 2 T85435 DRUGINFO D0Z8UQ DM-83 Discontinued in Phase 2 T85435 DRUGINFO D0M3OR KW-2450 Discontinued in Phase 1/2 T85435 DRUGINFO D02IJP CLX-0900 Terminated T85435 DRUGINFO D03CMR TER-16998 Terminated T85435 DRUGINFO D02QOL XMetD Investigative T85435 DRUGINFO D03BCE FPT-038 Investigative T85435 DRUGINFO D08ZLL Quick-acting insulin Investigative T85435 DRUGINFO D0C7QW XMetS Investigative T85435 DRUGINFO D0I4LQ RHIIP Investigative T85435 DRUGINFO D0KC9V AD10-1025 Investigative T85435 DRUGINFO D0R2WK NVP-TAE684 Investigative T85435 DRUGINFO D0XQ0V DC-9703 Investigative T85435 DRUGINFO D0YN9H VVP-100X Investigative T85435 DRUGINFO D0L7MM 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol Investigative T85435 DRUGINFO D0W9KO 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol Investigative T85435 DRUGINFO D0G4CS PMID24900237C15 Investigative T85435 DRUGINFO D0UG4S L-betagamma-meATP Investigative T85435 DRUGINFO D06PJW GSK-1838705A Investigative T12499 TARGETID T12499 T12499 FORMERID TTDS00407 T12499 UNIPROID LCK_HUMAN T12499 TARGNAME LCK tyrosine protein kinase (LCK) T12499 GENENAME LCK T12499 TARGTYPE Successful T12499 SYNONYMS p56-LCK; Tyrosine-protein kinase Lck; T cell-specific protein-tyrosine kinase; Proto-oncogene tyrosine-protein kinase LCK; Proto-oncogene Lck; Protein YT16; Lymphocyte cell-specific protein-tyrosine kinase; Leukocyte C-terminal Src kinase; LSK; LCK p59-Fyn; LCK Protooncogene Syn T12499 FUNCTION Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated LCK protein to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAM) of the cytoplasmic tails of the TCR-gamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70, that becomes phosphorylated and activated by LCK. Following this, a large number of signaling molecules are recruited, ultimately leading to lymphokine production. LCK also contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, which leads to hyperphosphorylation and activation of LCK. Also plays a role in the IL2 receptor-linked signaling pathway that controls the T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR. Phosphorylates other substrates including RUNX3, PTK2B/PYK2, the microtubule-associated protein MAPT, RHOH or TYROBP. Interacts with FYB2. Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. T12499 PDBSTRUC 6H6A; 5MTN; 5MTM; 4D8K; 4C3F T12499 BIOCLASS Kinase T12499 ECNUMBER EC 2.7.10.2 T12499 SEQUENCE MGCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASPLQDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKANSLEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKHYKIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEVPRETLKLVERLGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRLVRLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIKLTINKLLDMAAQIAEGMAFIEERNYIHRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAPEAINYGTFTIKSDVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKERPEDRPTFDYLRSVLEDFFTATEGQYQPQP T12499 DRUGINFO D0E6XR Dasatinib Approved T12499 DRUGINFO D02XNW VX-680 Phase 2 T12499 DRUGINFO D06CIJ ISIS-CRP Phase 1 T12499 DRUGINFO D0U3XL JNJ-26483327 Phase 1 T12499 DRUGINFO D02BUW 2-(3,4,5-Trihydroxy-benzylidene)-malononitrile Investigative T12499 DRUGINFO D03AER A-641359 Investigative T12499 DRUGINFO D08DVL 3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide Investigative T12499 DRUGINFO D08WOG 4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline Investigative T12499 DRUGINFO D0L4HJ RPR-108518A Investigative T12499 DRUGINFO D0OZ2S Lck inhibitor Investigative T12499 DRUGINFO D06WGX A-770041 Investigative T12499 DRUGINFO D07ERV Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2 Investigative T12499 DRUGINFO D0A2LX Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2 Investigative T12499 DRUGINFO D0D5KZ PMID17280833C30 Investigative T12499 DRUGINFO D0D9TU LAVENDUSTIN A Investigative T12499 DRUGINFO D0IZ8M PMID21855335C19a Investigative T12499 DRUGINFO D0M3CT 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine Investigative T12499 DRUGINFO D0Y1SR WH-4-023 Investigative T12499 DRUGINFO D07AIB (4-Phenoxy-phenyl)-quinazolin-4-yl-amine Investigative T12499 DRUGINFO D0A7FQ CGP-57380 Investigative T12499 DRUGINFO D0BS6R A-420983 Investigative T12499 DRUGINFO D0C3AD GW-788388 Investigative T12499 DRUGINFO D00NWF ZM-336372 Investigative T12499 DRUGINFO D04TLI PMID17600705C23 Investigative T12499 DRUGINFO D09HXU 6-o-tolylquinazolin-2-amine Investigative T12499 DRUGINFO D06WJA L-779450 Investigative T12499 DRUGINFO D0CE3R SU 6656 Investigative T12499 DRUGINFO D0GT8N NM-PP1 Investigative T12499 DRUGINFO D0OH3J PD-0179483 Investigative T12499 DRUGINFO D0S1KJ PD-0173952 Investigative T12499 DRUGINFO D0Y4BL JNJ-28312141 Investigative T12499 DRUGINFO D0Z7GH PD-0173958 Investigative T12499 DRUGINFO D03NPX PD-0173955 Investigative T12499 DRUGINFO D0YZ7H JNJ-10198409 Investigative T12499 DRUGINFO D08RZB PMID15546730C2 Investigative T12499 DRUGINFO D09QBA CEP-5104 Investigative T12499 DRUGINFO D0D5EW HKI-9924129 Investigative T12499 DRUGINFO D0GW4Q PD-0173956 Investigative T12499 DRUGINFO D0H1OK TG-100435 Investigative T12499 DRUGINFO D0P3JW PD-0166326 Investigative T12499 DRUGINFO D0GB4V STAUROSPORINONE Investigative T12499 DRUGINFO D0M5FF Ro31-8220 Investigative T12499 DRUGINFO D00ICA AMP-PNP Investigative T12499 DRUGINFO D0M4SY BMS-536924 Investigative T12499 DRUGINFO D0N6ES KN-62 Investigative T12499 DRUGINFO D0B9BU CI-1040 Investigative T12499 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T12499 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T12499 DRUGINFO D0L8HO RO-316233 Investigative T60631 TARGETID T60631 T60631 FORMERID TTDS00348 T60631 UNIPROID RET_HUMAN T60631 TARGNAME Proto-oncogene c-Ret (RET) T60631 GENENAME RET T60631 TARGTYPE Successful T60631 SYNONYMS RET51; RET receptor tyrosine kinase; RET mutant Y791F; RET mutant V804M; RET mutant V804L; RET mutant S891A; RET mutant M918T; RET mutant G691S; Proto-oncogene tyrosine-protein kinase receptor Ret; PTC; Cadherin family member 12; CDHR16; CDHF12; C-ret T60631 FUNCTION Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. T60631 PDBSTRUC 6FEK; 5FM3; 5FM2; 5AMN; 4UX8 T60631 BIOCLASS Kinase T60631 ECNUMBER EC 2.7.10.1 T60631 SEQUENCE MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS T60631 DRUGINFO D01KOA Selpercatinib Approved T60631 DRUGINFO D0OD2I Pralsetinib Approved T60631 DRUGINFO D09GDD Regorafenib Approved T60631 DRUGINFO D0G6QF Vandetanib Approved T60631 DRUGINFO D0H0EQ Ponatinib Approved T60631 DRUGINFO D01PZD Romiplostim Approved T60631 DRUGINFO D05BLN MGCD516 Phase 2/3 T60631 DRUGINFO D05BLN MGCD516 Phase 2/3 T60631 DRUGINFO D04MXN CEP-32496 Phase 1/2 T60631 DRUGINFO DS7CY4 TPX-0046 Phase 1/2 T60631 DRUGINFO D0AX4H GSK3179106 Phase 1 T60631 DRUGINFO D1BG7C BOS172738 Phase 1 T60631 DRUGINFO DJVC36 A400 Phase 1 T60631 DRUGINFO D0S6TK tamatinib Clinical trial T60631 DRUGINFO D01BMX Pyrazolo[3,4-d]pyrimidine derivative 8 Patented T60631 DRUGINFO D03JZP Dihydropyridine compound 4 Patented T60631 DRUGINFO D03MMZ Pyrazolo[3,4-d]pyrimidine derivative 6 Patented T60631 DRUGINFO D03ORX Dihydropyridine compound 6 Patented T60631 DRUGINFO D05HYJ Pyrazolo[3,4-d]pyrimidine derivative 7 Patented T60631 DRUGINFO D05NBB Pyrrolo-pyridinone derivative 3 Patented T60631 DRUGINFO D06BNK Pyrazolo[3,4-d]pyrimidine derivative 5 Patented T60631 DRUGINFO D07OLQ Pyrrolo-pyrimidine derivative 6 Patented T60631 DRUGINFO D07QKP Pyrrolo-pyridinone derivative 4 Patented T60631 DRUGINFO D08LCQ Benzo(b)carbazol-11-one compound 1 Patented T60631 DRUGINFO D09FBJ Pyrrolo-pyrimidine derivative 2 Patented T60631 DRUGINFO D0A6RR Dihydropyridine compound 1 Patented T60631 DRUGINFO D0B3GX Quinazoline derivative 14 Patented T60631 DRUGINFO D0FU0I Pyrrolo-pyrimidine derivative 3 Patented T60631 DRUGINFO D0JY9S Dihydropyridine compound 2 Patented T60631 DRUGINFO D0NH2H Pyrrolo-pyrimidine derivative 5 Patented T60631 DRUGINFO D0P1AH Pyrrolo-pyrimidine derivative 4 Patented T60631 DRUGINFO D0QY6M Pyrrolo-pyridinone derivative 2 Patented T60631 DRUGINFO D0X7IS Dihydropyridine compound 5 Patented T60631 DRUGINFO D0XR9O Pyrrolo-pyridinone derivative 1 Patented T60631 DRUGINFO D0YC7C Dihydropyridine compound 3 Patented T60631 DRUGINFO D05PRG Quinazoline derivative 15 Patented T60631 DRUGINFO D0DV4X Quinazoline derivative 16 Patented T60631 DRUGINFO D0MX7B Carboxamide derivative 4 Patented T60631 DRUGINFO D0NB1V Pyridine derivative 20 Patented T60631 DRUGINFO D0O0AW Pyridine derivative 21 Patented T60631 DRUGINFO D0O4TA Pyridine derivative 22 Patented T60631 DRUGINFO D0T7BE Pyridine derivative 19 Patented T60631 DRUGINFO D0O9JD Benzo(b)carbazol-11-one compound 2 Patented T60631 DRUGINFO D0AK1F Pyridine derivative 18 Patented T60631 DRUGINFO D0J5TN CEP-751 Terminated T60631 DRUGINFO D02CFR GW-559768X Investigative T60631 DRUGINFO D0N5TB ITRI-305 Investigative T60631 DRUGINFO D0W4UQ (Z)-5-Amino-3-(4-methoxybenzylidene)indolin-2-one Investigative T60631 DRUGINFO D0Y1UL (E)-3-(4-hydroxybenzylidene)indolin-2-one Investigative T60631 DRUGINFO D00ATA (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one Investigative T60631 DRUGINFO D0N7AJ AST-487 Investigative T60631 DRUGINFO D02NNT PMID21493067C1d Investigative T60631 DRUGINFO D02BXJ PMID21561767C8h Investigative T60631 DRUGINFO D0H1OK TG-100435 Investigative T68251 TARGETID T68251 T68251 FORMERID TTDC00104 T68251 UNIPROID MMP2_HUMAN T68251 TARGNAME Matrix metalloproteinase-2 (MMP-2) T68251 GENENAME MMP2 T68251 TARGTYPE Successful T68251 SYNONYMS TBE-1; Matrix metalloproteinase 2; CLG4A; 72 kDa type IV collagenase; 72 kDa gelatinase T68251 FUNCTION As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14. Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. T68251 PDBSTRUC 3AYU; 1RTG; 1QIB; 1KS0; 1J7M T68251 BIOCLASS Peptidase T68251 ECNUMBER EC 3.4.24.24 T68251 SEQUENCE MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGCPKESCNLFVLKDTLKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWDKNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGDGYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFNGKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGTSYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKYESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGALMAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQIRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEYWIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYIFAGDKFWRYNEVKKKMDPGFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLENQSLKSVKFGSIKSDWLGC T68251 DRUGINFO D00MDP Prinomastat Approved T68251 DRUGINFO D05VZE Marimastat Phase 3 T68251 DRUGINFO D0U2BH Epigallocatechin gallate Phase 3 T68251 DRUGINFO D0IJ7O Metastat Phase 1 T68251 DRUGINFO D0T4BL Neovastat Phase 1 T68251 DRUGINFO D0A9ZW PMID29130358-Compound-Figure16(9b) Patented T68251 DRUGINFO D0DB0Z PMID29130358-Compound-SB-3CT Patented T68251 DRUGINFO D0LS4Y PMID29130358-Compound-Figure16(9a) Patented T68251 DRUGINFO D0O8RQ PMID29130358-Compound-Figure18(14) Patented T68251 DRUGINFO D0Q4QB PMID29130358-Compound-Figure13(4) Patented T68251 DRUGINFO D0S3PN PMID29130358-Compound-Figure16(9c) Patented T68251 DRUGINFO D0W7HO PMID29130358-Compound-LonimacranthoideVII Patented T68251 DRUGINFO D0Y1LO PMID29130358-Compound-Figure11(3) Patented T68251 DRUGINFO D05GAP PMID29130358-Compound-Figure10(2a) Patented T68251 DRUGINFO D0X6GG PMID29130358-Compound-Figure18(14a) Patented T68251 DRUGINFO D0Q1CD Tanomastat Discontinued in Phase 3 T68251 DRUGINFO D01EUF BMS 275291 Discontinued in Phase 3 T68251 DRUGINFO D05WTZ Galarubicin Discontinued in Phase 2 T68251 DRUGINFO D03BOZ RS-130830 Discontinued in Phase 2 T68251 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T68251 DRUGINFO D0C0ME RO-26-2853 Preclinical T68251 DRUGINFO D02GYD CDP-845 Terminated T68251 DRUGINFO D08CEE L-696418 Terminated T68251 DRUGINFO D08WBF BB-3644 Terminated T68251 DRUGINFO D05VNG BB-1101 Terminated T68251 DRUGINFO D0Y1XT SC-44463 Terminated T68251 DRUGINFO D06ALC Lithospermic acid Investigative T68251 DRUGINFO D08NSS SC-74020 Investigative T68251 DRUGINFO D0H9BL Clinopodic acid C Investigative T68251 DRUGINFO D0T1FR Cis-2-aminocyclohexylcarbamoylphosphonic acid Investigative T68251 DRUGINFO D01HKU Methotrexate gamma-L-proline-hydroxamic acid Investigative T68251 DRUGINFO D02EFQ PD-169469 Investigative T68251 DRUGINFO D05JPV 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid Investigative T68251 DRUGINFO D07LTB 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione Investigative T68251 DRUGINFO D0B0UI Methotrexate gamma-hydroxamic acid Investigative T68251 DRUGINFO D0E5MB 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid Investigative T68251 DRUGINFO D0F7BE PNU-107859 Investigative T68251 DRUGINFO D0K4TI 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione Investigative T68251 DRUGINFO D0Q9LC 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione Investigative T68251 DRUGINFO D0U7CD Roche 28-2653 Investigative T68251 DRUGINFO D0ZB6O Folate gamma-L-proline-hydroxamic acid Investigative T68251 DRUGINFO D00RNA N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide Investigative T68251 DRUGINFO D08ICI N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) Investigative T68251 DRUGINFO D0A5MV 3-(4-Phenylethynylbenzoyl)nonanoic acid Investigative T68251 DRUGINFO D0P8EY Folate gamma-hydroxamic acid Investigative T68251 DRUGINFO D0Y7NV 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione Investigative T68251 DRUGINFO D0G3YZ (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid Investigative T68251 DRUGINFO D0L4EO 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid Investigative T68251 DRUGINFO D0NP8A UK-356618 Investigative T68251 DRUGINFO D0XL8K Ro-37-9790 Investigative T68251 DRUGINFO D05THD 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide Investigative T68251 DRUGINFO D07MJD [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid Investigative T68251 DRUGINFO D0S9OL N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide Investigative T68251 DRUGINFO D03AMR SR-973 Investigative T68251 DRUGINFO D0W2UK IK-862 Investigative T68251 DRUGINFO D0A4TC MMI270 Investigative T00140 TARGETID T00140 T00140 FORMERID TTDS00112 T00140 UNIPROID LOX5_HUMAN T00140 TARGNAME Arachidonate 5-lipoxygenase (5-LOX) T00140 GENENAME ALOX5 T00140 TARGTYPE Successful T00140 SYNONYMS LOG5; 5-lipoxygenase; 5-LO T00140 FUNCTION Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes. T00140 PDBSTRUC 3V99; 3V98; 3V92; 3O8Y; 2ABV T00140 BIOCLASS Oxygenase T00140 ECNUMBER EC 1.13.11.34 T00140 SEQUENCE MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDEELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLARDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVLNYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNGCNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDPCTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDFHVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECGLFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWEAIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYLTVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCWHLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPYYYLSPDRIPNSVAI T00140 DRUGINFO D06RCB Diethylcarbamazine Approved T00140 DRUGINFO D09JUG Zileuton Approved T00140 DRUGINFO D0AZ8C Silymarin Phase 4 T00140 DRUGINFO D0V9EN 3,4-Dihydroxycinnamic Acid Phase 4 T00140 DRUGINFO D02RQT Tenidap Phase 3 T00140 DRUGINFO D02YEY FPL-62064 Phase 3 T00140 DRUGINFO D08PXR ABT-761 Phase 3 T00140 DRUGINFO D0X8VV Flobufen Phase 3 T00140 DRUGINFO D0C0NH Avastin+/-Tarceva Phase 3 T00140 DRUGINFO D0AL8T Darbufelone Phase 2/3 T00140 DRUGINFO D00RJB Rilopirox Phase 2 T00140 DRUGINFO D0A7JH WY-50295-tromethamine Phase 2 T00140 DRUGINFO D0L4SL TA-270 Phase 2 T00140 DRUGINFO D0L5XG PF-4191834 Phase 2 T00140 DRUGINFO D0S2PY MK-866 Phase 2 T00140 DRUGINFO DES36M Q301 Phase 2 T00140 DRUGINFO D04FNQ BIM23A760 Phase 2 T00140 DRUGINFO D04JIM UCB-35440 Phase 2 T00140 DRUGINFO D04WMR Tepoxalin Phase 2 T00140 DRUGINFO D05VVX PTC299 Phase 2 T00140 DRUGINFO D0D5ZV CMI-392 Phase 2 T00140 DRUGINFO D0K9UK E-6700 Phase 2 T00140 DRUGINFO D0Q7UG Tipelukast Phase 2 T00140 DRUGINFO D00YEV BAICALEIN Phase 2 T00140 DRUGINFO D0L6VH BF-389 Phase 1 T00140 DRUGINFO D0Y4OI SKF-105809 Phase 1 T00140 DRUGINFO D0U2CB Ibuproxam Withdrawn from market T00140 DRUGINFO D00HFD E-6080 Discontinued in Phase 2 T00140 DRUGINFO D01DAD CJ-13610 Discontinued in Phase 2 T00140 DRUGINFO D04QVN FPL-64170 Discontinued in Phase 2 T00140 DRUGINFO D06UVO DuP-654 Discontinued in Phase 2 T00140 DRUGINFO D0H7GH ETH615 Discontinued in Phase 2 T00140 DRUGINFO D0JY4Y E-3040 Discontinued in Phase 2 T00140 DRUGINFO D0K2ER MK-886 Discontinued in Phase 2 T00140 DRUGINFO D0M0QX MK-591 Discontinued in Phase 2 T00140 DRUGINFO D0P1TZ MLN-977 Discontinued in Phase 2 T00140 DRUGINFO D0U5EU SC-45662 Discontinued in Phase 2 T00140 DRUGINFO D0V3HG CV-6504 Discontinued in Phase 2 T00140 DRUGINFO D0E8UV Linetastine Discontinued in Phase 2 T00140 DRUGINFO D0G5GJ R-68151 Discontinued in Phase 2 T00140 DRUGINFO D08ORO OPC-21268 Discontinued in Phase 2 T00140 DRUGINFO D0P3KA TEBUFELONE Discontinued in Phase 2 T00140 DRUGINFO D0F5NB CD-581 Discontinued in Phase 1 T00140 DRUGINFO D0N1SU Licofelone Discontinued in Phase 1 T00140 DRUGINFO D0P3CF AZD-4407 Discontinued in Phase 1 T00140 DRUGINFO D01QAR LY-221068 Terminated T00140 DRUGINFO D02QGM CGS-26529 Terminated T00140 DRUGINFO D06MPF Sch-40120 Terminated T00140 DRUGINFO D06XRQ AA-861 Terminated T00140 DRUGINFO D06YOD ZD-7717 Terminated T00140 DRUGINFO D09JYF Epocarbazolin-A Terminated T00140 DRUGINFO D09SCI SKF-104351 Terminated T00140 DRUGINFO D0C5HV R zileuton Terminated T00140 DRUGINFO D0C9RZ BU-4601A Terminated T00140 DRUGINFO D0D8MD ZM-230487 Terminated T00140 DRUGINFO D0DP8P BW755C Terminated T00140 DRUGINFO D0H2RB NAFAZATROM Terminated T00140 DRUGINFO D0HJ1Y BW B70C Terminated T00140 DRUGINFO D0J8RS PD-146176 Terminated T00140 DRUGINFO D0L1IH A-79175 Terminated T00140 DRUGINFO D0L8RG CI-986 Terminated T00140 DRUGINFO D0O8ZE REV-5901 Terminated T00140 DRUGINFO D0QI8I CGS 8515 Terminated T00140 DRUGINFO D0S5DY R-85355 Terminated T00140 DRUGINFO D0SZ3B ER-34122 Terminated T00140 DRUGINFO D0T4EL A-80263 Terminated T00140 DRUGINFO D0U6AL BI-L-357 Terminated T00140 DRUGINFO D0X9KE A-78773 Terminated T00140 DRUGINFO D01LXG KC-11425 Terminated T00140 DRUGINFO D04APY KC-11404 Terminated T00140 DRUGINFO D05WPQ BW A4C Terminated T00140 DRUGINFO D08JKK RWJ-63556 Terminated T00140 DRUGINFO D0H0IA WY-28342 Terminated T00140 DRUGINFO D0V4GT CMI-206 Terminated T00140 DRUGINFO D00BSX 1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one Investigative T00140 DRUGINFO D00ENR 1,8-Dihydroxy-2-propionyl-10H-anthracen-9-one Investigative T00140 DRUGINFO D00JPV N-Phenylbenzo[d]oxazol-2-amine Investigative T00140 DRUGINFO D00MIM FR-122788 Investigative T00140 DRUGINFO D00OWE L-652,343 Investigative T00140 DRUGINFO D00XKA SC-41661A Investigative T00140 DRUGINFO D01QDG 4-Hydroxy-5-methoxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D01SQY TZI-41127 Investigative T00140 DRUGINFO D01VLQ 15-hydroxyeicosatetraenoic acid Investigative T00140 DRUGINFO D02HQK 2-Biphenyl-4-yl-N-hydroxy-N-methyl-acetamide Investigative T00140 DRUGINFO D02RBU 4-Butoxy-N-hydroxy-N-methyl-benzamide Investigative T00140 DRUGINFO D02TLZ 3-Biphenyl-4-yl-N-hydroxy-N-methyl-acrylamide Investigative T00140 DRUGINFO D02YPE 1,2-Dihydroxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D03QNE BW A360C Investigative T00140 DRUGINFO D04IFV 5-Methyl-2-p-tolyl-thiazol-4-ol Investigative T00140 DRUGINFO D04MBD 1,8-Dichloro-10H-anthracen-9-one Investigative T00140 DRUGINFO D04RQG 1-Benzyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D04UJI Naphthalene-2-carboxylic acid hydroxyamide Investigative T00140 DRUGINFO D04XPJ Biphenyl-4-carboxylic acid hydroxyamide Investigative T00140 DRUGINFO D04ZGR Phenanthrene-3-carboxylic acid hydroxyamide Investigative T00140 DRUGINFO D05GZI N-(4-Ethylphenyl)benzo[d]oxazol-2-amine Investigative T00140 DRUGINFO D05KCN 2-Pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D05PHI 2-(4-Methoxy-phenyl)-5-phenyl-thiazol-4-ol Investigative T00140 DRUGINFO D05QBX Biphenyl-3-carboxylic acid hydroxyamide Investigative T00140 DRUGINFO D05RIE 3-Benzoyl-N-hydroxy-benzamide Investigative T00140 DRUGINFO D06AFD N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide Investigative T00140 DRUGINFO D06CWX 1-Hydroxy-8-methoxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D06GRW N-Hydroxy-N-methyl-2,3,3-triphenyl-acrylamide Investigative T00140 DRUGINFO D06KQD N-Hydroxy-N-methyl-3-naphthalen-2-yl-propionamide Investigative T00140 DRUGINFO D06MUA N-Hydroxy-4-iodo-benzamide Investigative T00140 DRUGINFO D06TPF PYROGALLOL Investigative T00140 DRUGINFO D06XYZ 10-Benzoyl-1,8-dihydroxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D07LMV SK&F 107649 Investigative T00140 DRUGINFO D07MYE N-Hydroxy-3-phenyl-acrylamide Investigative T00140 DRUGINFO D07OKS 1,8,9-Trimethoxy-9,10-dihydro-anthracene Investigative T00140 DRUGINFO D07PCS N-Hydroxy-N-methyl-2-naphthalen-2-yl-propionamide Investigative T00140 DRUGINFO D07XMM N-(4-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine Investigative T00140 DRUGINFO D08BNV 4,5-Dimethoxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D08FPY 10-Acetyl-1,8-dihydroxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D08HFK 5-Chloro-N-phenylbenzo[d]oxazol-2-amine Investigative T00140 DRUGINFO D08MCE 2-(4-Phenyl-butyl)-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D08NDV 4-(1H-indol-3-yl)-1-morpholinobutan-1-one Investigative T00140 DRUGINFO D08UXT 3-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acrylamide Investigative T00140 DRUGINFO D09PDD N-Hydroxy-3-naphthalen-2-yl-acrylamide Investigative T00140 DRUGINFO D09WYM 3-Biphenyl-3-yl-N-hydroxy-N-methyl-acrylamide Investigative T00140 DRUGINFO D0A2QP N-Hydroxy-N-methyl-benzamide Investigative T00140 DRUGINFO D0A9HL 1-Methyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0B0XK 1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3) Investigative T00140 DRUGINFO D0C1XI Acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester Investigative T00140 DRUGINFO D0C4KD N-(3-Bromophenyl)-5-methoxybenzo[d]oxazol-2-amine Investigative T00140 DRUGINFO D0C6BU ANTHRONE Investigative T00140 DRUGINFO D0C7GT N-Hydroxy-N-methyl-3-phenanthren-2-yl-acrylamide Investigative T00140 DRUGINFO D0CT9V Anthracene-2-carboxylic acid hydroxyamide Investigative T00140 DRUGINFO D0DP9F Phenanthrene-2-carboxylic acid hydroxyamide Investigative T00140 DRUGINFO D0E1NK N-Hydroxy-N-methyl-3-phenanthren-3-yl-acrylamide Investigative T00140 DRUGINFO D0E3CO N-(2-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine Investigative T00140 DRUGINFO D0E4JU N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide Investigative T00140 DRUGINFO D0F1ZE 2-Naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0F4HT ICI-211965 Investigative T00140 DRUGINFO D0G3VE Acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester Investigative T00140 DRUGINFO D0H4MV 5-Methyl-N-phenylbenzo[d]oxazol-2-amine Investigative T00140 DRUGINFO D0H6JC 1,2-Dihydro-indazol-3-one Investigative T00140 DRUGINFO D0H7UQ N-Hydroxy-3-naphthalen-2-yl-propionamide Investigative T00140 DRUGINFO D0HZ9X 2-Pyridin-3-ylmethyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0I9RY N-Hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide Investigative T00140 DRUGINFO D0IF2H 2-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acetamide Investigative T00140 DRUGINFO D0J5OV Chebulagic acid Investigative T00140 DRUGINFO D0J7AM 4-Bromo-N-hydroxy-benzamide Investigative T00140 DRUGINFO D0K3AO CYLINDOL A Investigative T00140 DRUGINFO D0K7XU N-Hydroxy-4-naphthalen-2-yl-benzamide Investigative T00140 DRUGINFO D0KB6Q N-Hydroxy-2-naphthalen-2-yl-acetamide Investigative T00140 DRUGINFO D0L3BQ N-Hydroxy-4-isobutyl-benzamide Investigative T00140 DRUGINFO D0M6UM BW-A137C Investigative T00140 DRUGINFO D0N6CN 2-(4-Butoxy-phenoxy)-N-hydroxy-propionamide Investigative T00140 DRUGINFO D0O6OJ N-Hydroxy-N-methyl-3-phenanthren-9-yl-acrylamide Investigative T00140 DRUGINFO D0O7SM BUDDLEDIN A Investigative T00140 DRUGINFO D0P8IX 1-Hydroxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D0PD7X 2'-Nitro-biphenyl-4-carboxylic acid hydroxyamide Investigative T00140 DRUGINFO D0PU1J BW B218C Investigative T00140 DRUGINFO D0R1ER 2-(1H-Indol-3-ylmethyl)-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0R2MQ BW-858C Investigative T00140 DRUGINFO D0R2XE 4-Pentadeca-1,3,6-trienylsulfanyl-butyric acid Investigative T00140 DRUGINFO D0S6XY 4,5-Dihydroxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D0S8UP 3,4-Dihydroxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D0T0CY 2-(4-Butoxy-phenoxy)-N-hydroxy-N-methyl-acetamide Investigative T00140 DRUGINFO D0T1HY N-Hydroxy-3-naphthalen-2-yl-N-phenyl-acrylamide Investigative T00140 DRUGINFO D0T8TS Hexanoic acid 2,5-diphenyl-thiazol-4-yl ester Investigative T00140 DRUGINFO D0U2YL CGS-23885 Investigative T00140 DRUGINFO D0U9UL 5-Chloro-N-(4-ethylphenyl)benzo[d]oxazol-2-amine Investigative T00140 DRUGINFO D0V8UV N-Hydroxy-N-methyl-3-naphthalen-1-yl-acrylamide Investigative T00140 DRUGINFO D0WW1K 2-(4-hydroxylphenyl)-3-(3,5-dihydroxylphenyl) propenoic acid (NNU-hdpa) Investigative T00140 DRUGINFO D0X8BS 2-(4-Butoxy-phenoxy)-N-hydroxy-acetamide Investigative T00140 DRUGINFO D0X9RM 2-Thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0XL5D 5-Methoxy-N-phenylbenzo[d]oxazol-2-amine Investigative T00140 DRUGINFO D0XQ8P 2-Thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0Y0KF 1,5-Dihydroxy-10H-anthracen-9-one Investigative T00140 DRUGINFO D0Z0ZM SB-202235 Investigative T00140 DRUGINFO D0Z5XD 2-Pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D03HNC N-hydroxy-4-(naphthalen-1-yl)benzamide Investigative T00140 DRUGINFO D09CXQ Acanthus ilicifolius Linn Investigative T00140 DRUGINFO D0AS0V 5,8-Dihydroxy-1,4-naphthoquinone Investigative T00140 DRUGINFO D0K7XQ N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea Investigative T00140 DRUGINFO D02COM 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30) Investigative T00140 DRUGINFO D06HUQ 2-Phenethyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D07CJR 5S-HETE Investigative T00140 DRUGINFO D09VTJ Hyperforin Investigative T00140 DRUGINFO D0J7YU 2-Benzyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0L4TM 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0NS1S ACACETIN Investigative T00140 DRUGINFO D0P1LP PHENIDONE Investigative T00140 DRUGINFO D0S0PB 2-Phenyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0SJ3W 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0U8CM 2-Methyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0X6SA 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one Investigative T00140 DRUGINFO D0UU1I Heme Investigative T57700 TARGETID T57700 T57700 FORMERID TTDS00270 T57700 UNIPROID KIT_HUMAN T57700 TARGNAME Tyrosine-protein kinase Kit (KIT) T57700 GENENAME KIT T57700 TARGTYPE Successful T57700 SYNONYMS v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; p145 c-kit; Proto-oncogene tyrosine-protein kinase Kit; Proto-oncogene c-Kit; Piebald trait protein; PBT; Mast/stem cell growth factor receptor Kit; CD117 antigen; CD117; C-kit T57700 FUNCTION In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. T57700 PDBSTRUC 6GQM; 6GQL; 6GQK; 6GQJ; 4U0I T57700 BIOCLASS Kinase T57700 ECNUMBER EC 2.7.10.1 T57700 SEQUENCE MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTPLLIGFVIVAGMMCIIVMILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELKVLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAALYKNLLHSKESSCSDSTNEYMDMKPGVSYVVPTKADKRRSVRIGSYIERDVTPAIMEDDELALDLEDLLSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLARDIKNDSNYVVKGNARLPVKWMAPESIFNCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMLSPEHAPAEMYDIMKTCWDADPLKRPTFKQIVQLIEKQISESTNHIYSNLANCSPNRQKPVVDHSVRINSVGSTASSSQPLLVHDDV T57700 DRUGINFO D09AAK Ripretinib Approved T57700 DRUGINFO D09GDD Regorafenib Approved T57700 DRUGINFO D09TAB Pexidartinib Approved T57700 DRUGINFO D0F0ZY Pazopanib HCl Approved T57700 DRUGINFO D0AZ3C Imatinib Approved T57700 DRUGINFO D0H0EQ Ponatinib Approved T57700 DRUGINFO D0W5HK Sorafenib Approved T57700 DRUGINFO D01PZD Romiplostim Approved T57700 DRUGINFO D0T1GF MP470 Phase 2 T57700 DRUGINFO D00NSD XL-820 Phase 2 T57700 DRUGINFO D0Z6MT Famitinib Phase 2 T57700 DRUGINFO D03MDY PLX9486 Phase 1/2 T57700 DRUGINFO DB8G4D JSP191 Phase 1/2 T57700 DRUGINFO D05CFQ AMG-191 Phase 1 T57700 DRUGINFO D0E0SH CART-117 cells Phase 1 T57700 DRUGINFO D0N8RV OSI-930 Phase 1 T57700 DRUGINFO D0D3FB PMID25656651-Compound-21a Patented T57700 DRUGINFO D0XQ5F PMID25656651-Compound-21b Patented T57700 DRUGINFO D0NB1V Pyridine derivative 20 Patented T57700 DRUGINFO D0O0AW Pyridine derivative 21 Patented T57700 DRUGINFO D0O4TA Pyridine derivative 22 Patented T57700 DRUGINFO D0T7BE Pyridine derivative 19 Patented T57700 DRUGINFO D0AK1F Pyridine derivative 18 Patented T57700 DRUGINFO D00DQX Motesanib Discontinued in Phase 3 T57700 DRUGINFO D0TS2B CAR-T cells targeting CD117 Preclinical T57700 DRUGINFO D03SGF WBZ-7 Investigative T57700 DRUGINFO D08ZWJ 9-Bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole Investigative T57700 DRUGINFO D0T2UB APCK-110 Investigative T57700 DRUGINFO D0T4SL 9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole Investigative T57700 DRUGINFO D0BL0O PMID23521020C7k Investigative T57700 DRUGINFO D0T5OS Phosphonotyrosine Investigative T57700 DRUGINFO D05FFB 5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol Investigative T57700 DRUGINFO D05QBZ CP-673451 Investigative T57700 DRUGINFO D0Y9GK 4-(4-aminophenyl)-1H-indazol-3yl-amine Investigative T57700 DRUGINFO D08BJR Ki-20227 Investigative T57700 DRUGINFO D0N7AJ AST-487 Investigative T57700 DRUGINFO D0UN9O GTP-14564 Investigative T57700 DRUGINFO D0I3XZ Bis-(5-hydroxy-1H-indol-2-yl)-methanone Investigative T57700 DRUGINFO D0Y4BL JNJ-28312141 Investigative T57700 DRUGINFO D0GW4Q PD-0173956 Investigative T57700 DRUGINFO D0P3JW PD-0166326 Investigative T57700 DRUGINFO D0C2GE PMID22765894C8h Investigative T85943 TARGETID T85943 T85943 FORMERID TTDS00247 T85943 UNIPROID SRC_HUMAN T85943 TARGNAME Proto-oncogene c-Src (SRC) T85943 GENENAME SRC T85943 TARGTYPE Successful T85943 SYNONYMS pp60c-src; Tyrosine kinase (pp60(src)); Src tyrosine kinase; SRC1; Proto-oncogene tyrosine-protein kinase Src; Pp60(src); P60-Src; C-src TK; C-Src T85943 FUNCTION Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1. Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors. Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated calcium-activated chloride channel activation. Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of GRK2, leading to beta-arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor. Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus. Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances DDX58/RIG-I-elicited antiviral signaling. Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr-128'. Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3 activity. Involved in anchorage-independent cell growth. Required for podosome formation. Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. T85943 PDBSTRUC 6EHJ; 6C4S; 6ATE; 4MXZ; 4MXY T85943 BIOCLASS Kinase T85943 ECNUMBER EC 2.7.10.2 T85943 SEQUENCE MGSNKSKPKDASQRRRSLEPAENVHGAGGGAFPASQTPSKPASADGHRGPSAAFAPAAAEPKLFGGFNSSDTVTSPQRAGPLAGGVTTFVALYDYESRTETDLSFKKGERLQIVNNTEGDWWLAHSLSTGQTGYIPSNYVAPSDSIQAEEWYFGKITRRESERLLLNAENPRGTFLVRESETTKGAYCLSVSDFDNAKGLNVKHYKIRKLDSGGFYITSRTQFNSLQQLVAYYSKHADGLCHRLTTVCPTSKPQTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWMGTWNGTTRVAIKTLKPGTMSPEAFLQEAQVMKKLRHEKLVQLYAVVSEEPIYIVTEYMSKGSLLDFLKGETGKYLRLPQLVDMAAQIASGMAYVERMNYVHRDLRAANILVGENLVCKVADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELTTKGRVPYPGMVNREVLDQVERGYRMPCPPECPESLHDLMCQCWRKEPEERPTFEYLQAFLEDYFTSTEPQYQPGENL T85943 DRUGINFO D07DIM Herbimycin A Approved T85943 DRUGINFO D0OB0F Bosutinib Approved T85943 DRUGINFO D03MNN SKI-758 Approved T85943 DRUGINFO D0E6XR Dasatinib Approved T85943 DRUGINFO D0G2CG AL3818 Phase 3 T85943 DRUGINFO D0TY3L KX-01 Phase 3 T85943 DRUGINFO D0J1GR CP-868596 Phase 3 T85943 DRUGINFO D0MW0N Masitinib Phase 3 T85943 DRUGINFO D0M0XB Saracatinib Phase 2 T85943 DRUGINFO DS7CY4 TPX-0046 Phase 1/2 T85943 DRUGINFO D05YEI SUN-K0706 Phase 1 T85943 DRUGINFO D0RE4L KX2-361 Phase 1 T85943 DRUGINFO D7M8LI TPX-0022 Phase 1 T85943 DRUGINFO DG2EK3 PUR1800 Phase 1 T85943 DRUGINFO D06CIJ ISIS-CRP Phase 1 T85943 DRUGINFO D02VDD Deuterated 3-cyanoquinoline derivative 1 Patented T85943 DRUGINFO D07QBF PMID28460551-Compound-6 Patented T85943 DRUGINFO D09RTW Aromatic bicyclic compound 6 Patented T85943 DRUGINFO D0M5AG Aromatic bicyclic compound 3 Patented T85943 DRUGINFO D0M9YZ Aromatic bicyclic compound 4 Patented T85943 DRUGINFO D0Q5JV Aromatic bicyclic compound 5 Patented T85943 DRUGINFO D0QD5Y Aromatic bicyclic compound 1 Patented T85943 DRUGINFO D0VI7E Aromatic bicyclic compound 2 Patented T85943 DRUGINFO D0AK1F Pyridine derivative 18 Patented T85943 DRUGINFO D09WPN AP22408 Terminated T85943 DRUGINFO D0H8KG PD166285 Terminated T85943 DRUGINFO D00JID Ac-Cys-Ile-Tyr-Lys-Phe(4-Cl)-Tyr Investigative T85943 DRUGINFO D00TVY Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu Investigative T85943 DRUGINFO D01IDD BAS-4844343 Investigative T85943 DRUGINFO D01IZN Y-c[D-Pen-(2')Nal-GSFC]KR-NH2 Investigative T85943 DRUGINFO D01JJR RU90395 Investigative T85943 DRUGINFO D02HOG RU78300 Investigative T85943 DRUGINFO D02IYN RU82129 Investigative T85943 DRUGINFO D02SRA Y-c[D-Pen-D-(2')Nal-GSFC]KR-NH2 Investigative T85943 DRUGINFO D02TIO RU85053 Investigative T85943 DRUGINFO D03DEX N6-Benzyl Adenosine-5'-Diphosphate Investigative T85943 DRUGINFO D03NCK RU82197 Investigative T85943 DRUGINFO D03OKV BMS-279700 Investigative T85943 DRUGINFO D03XDN PD-174265 Investigative T85943 DRUGINFO D04QEW Ac-Cys-Ile-Tyr-Lys-Phe(4-I)-Tyr Investigative T85943 DRUGINFO D05GYO RU85493 Investigative T85943 DRUGINFO D05YQC ISO24 Investigative T85943 DRUGINFO D06CYG Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu Investigative T85943 DRUGINFO D06MYD Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Phe(4-NO2) Investigative T85943 DRUGINFO D06QUQ CGP 77675 Investigative T85943 DRUGINFO D07HBR PAS219 Investigative T85943 DRUGINFO D07RQB 7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine Investigative T85943 DRUGINFO D08AWZ Ac-Cys-Ile-Phe(4-NO2)-Lys-Phe(4-NO2)-Tyr Investigative T85943 DRUGINFO D08WEV BAS-0338868 Investigative T85943 DRUGINFO D08YUQ Ac-Cys-Ile-Tyr-Lys-Phe(4-N3)-Tyr Investigative T85943 DRUGINFO D09DVB Y-c[D-Pen-(2R,3R)-2-Me-(2')Nal-GSFC]KR-NH2 Investigative T85943 DRUGINFO D09NGN RU79256 Investigative T85943 DRUGINFO D09WNM PASBN Investigative T85943 DRUGINFO D0A5IW Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Tyr Investigative T85943 DRUGINFO D0AJ4T RU78262 Investigative T85943 DRUGINFO D0B4PI Y-c[D-Pen-(2R,3S)-2-Me-(2')Nal-GSFC]KR-NH2 Investigative T85943 DRUGINFO D0BU6T CGP-62464 Investigative T85943 DRUGINFO D0D1FK RU78299 Investigative T85943 DRUGINFO D0D9PD SKS-927 Investigative T85943 DRUGINFO D0GN1A Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Tyr-Phe Investigative T85943 DRUGINFO D0H3XF 5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol Investigative T85943 DRUGINFO D0J4RY BAS-450225 Investigative T85943 DRUGINFO D0K9TT Ac-Cys-Ile-cyclo[Phe-Lys]-Tyr-Tyr Investigative T85943 DRUGINFO D0KS2T RU81843 Investigative T85943 DRUGINFO D0L4NP RU84687 Investigative T85943 DRUGINFO D0LK4J Ac-Cys-Ile-Tyr-Lys-Tyr-Phe(4-NO2) Investigative T85943 DRUGINFO D0LP2M BAS-01047655 Investigative T85943 DRUGINFO D0M5RA RU78783 Investigative T85943 DRUGINFO D0M9QM CGP-191 Investigative T85943 DRUGINFO D0MI2W Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr] Investigative T85943 DRUGINFO D0N4FS DPI59 Investigative T85943 DRUGINFO D0O8BX Ac-Cys-Ile-Tyr-Lys-Phe(4-CN)-Tyr Investigative T85943 DRUGINFO D0OB0M Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe] Investigative T85943 DRUGINFO D0OG1Q 4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine Investigative T85943 DRUGINFO D0P2QG BAS-01047341 Investigative T85943 DRUGINFO D0P5ST 3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol Investigative T85943 DRUGINFO D0Q2UZ Y-c[D-Pen-(2S,3R)-2-Me-(2')Nal-GSFC]KR-NH2 Investigative T85943 DRUGINFO D0R1PD RU83876 Investigative T85943 DRUGINFO D0R2AT 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE Investigative T85943 DRUGINFO D0R7BX RU78191 Investigative T85943 DRUGINFO D0S3FW N-Phenyl-5-phenylimidazo[1,5-a]pyrazin-8-amine Investigative T85943 DRUGINFO D0S9LT Phenylphosphate Investigative T85943 DRUGINFO D0TC1E RU82209 Investigative T85943 DRUGINFO D0U1BA Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Phe(4-NO2) Investigative T85943 DRUGINFO D0U5KF RU79073 Investigative T85943 DRUGINFO D0U7BY Oxalic Acid Investigative T85943 DRUGINFO D0U8UH RU79072 Investigative T85943 DRUGINFO D0W6WU Cyclo[Ac-Cys-Ile-Phe]-Lys-Tyr-Tyr Investigative T85943 DRUGINFO D0W7LW Y-c[D-Pen-(2S,3S)-2-Me-(2')Nal-GSFC]KR-NH2 Investigative T85943 DRUGINFO D01GNF BAS-00387328 Investigative T85943 DRUGINFO D03GQI BAS-00387347 Investigative T85943 DRUGINFO D03YUW SBB007833 Investigative T85943 DRUGINFO D04QUI BAS-00387275 Investigative T85943 DRUGINFO D06WGX A-770041 Investigative T85943 DRUGINFO D07ERV Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2 Investigative T85943 DRUGINFO D07LYJ BAS-00672722 Investigative T85943 DRUGINFO D09QKH BAS-0338872 Investigative T85943 DRUGINFO D0A2LX Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2 Investigative T85943 DRUGINFO D0A5MG BAS-09534324 Investigative T85943 DRUGINFO D0D3RL AP-24163 Investigative T85943 DRUGINFO D0D8OY AP-24226 Investigative T85943 DRUGINFO D0D8ZN BAS-01373578 Investigative T85943 DRUGINFO D0N8TQ N-(4-(phenylamino)quinazolin-6-yl)acrylamide Investigative T85943 DRUGINFO D0T5OS Phosphonotyrosine Investigative T85943 DRUGINFO D0Y1SR WH-4-023 Investigative T85943 DRUGINFO D0BS6R A-420983 Investigative T85943 DRUGINFO D0Q7TO K00244 Investigative T85943 DRUGINFO D0VF6E PD173074 Investigative T85943 DRUGINFO D0V6UC Cysteine Sulfenic Acid Investigative T85943 DRUGINFO D0CE3R SU 6656 Investigative T85943 DRUGINFO D0GT8N NM-PP1 Investigative T85943 DRUGINFO D0OH3J PD-0179483 Investigative T85943 DRUGINFO D0S1KJ PD-0173952 Investigative T85943 DRUGINFO D0X7IC NG-25 Investigative T85943 DRUGINFO D0Z7GH PD-0173958 Investigative T85943 DRUGINFO D03NPX PD-0173955 Investigative T85943 DRUGINFO D0YZ7H JNJ-10198409 Investigative T85943 DRUGINFO D08RZB PMID15546730C2 Investigative T85943 DRUGINFO D0D5EW HKI-9924129 Investigative T85943 DRUGINFO D0GW4Q PD-0173956 Investigative T85943 DRUGINFO D0H1OK TG-100435 Investigative T85943 DRUGINFO D0P3JW PD-0166326 Investigative T85943 DRUGINFO D03EHM PP121 Investigative T85943 DRUGINFO D0C2GE PMID22765894C8h Investigative T51408 TARGETID T51408 T51408 FORMERID TTDC00184 T51408 UNIPROID ADRB3_HUMAN T51408 TARGNAME Adrenergic receptor beta-3 (ADRB3) T51408 GENENAME ADRB3 T51408 TARGTYPE Successful T51408 SYNONYMS Beta3AR; Beta3-AR; Beta-3 adrenoreceptor; Beta-3 adrenoceptor; Beta-3 adrenergic receptor; B3AR; ADRB3R T51408 FUNCTION Beta-3 is involved in the regulation of lipolysis and thermogenesis. Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. T51408 PDBSTRUC 2CDW T51408 BIOCLASS GPCR rhodopsin T51408 SEQUENCE MAPWPHENSSLAPWPDLPTLAPNTANTSGLPGVPWEAALAGALLALAVLATVGGNLLVIVAIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATGCELWTSVDVLCVTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVSFAPIMSQWWRVGADAEAQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARVFVVATRQLRLLRGELGRFPPEESPPAPSRSLAPAPVGTCAPPEGVPACGRRPARLLPLREHRALCTLGLIMGTFTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGYANSAFNPLIYCRSPDFRSAFRRLLCRCGRRLPPEPCAAARPALFPSGVPAARSSPAQPRLCQRLDGASWGVS T51408 DRUGINFO D03NOS Rimiterol Approved T51408 DRUGINFO D06RUL Bitolterol Approved T51408 DRUGINFO D09SSC Nipradilol Approved T51408 DRUGINFO D0DH5X Vibegron Approved T51408 DRUGINFO D0H5MB Bopindolol Approved T51408 DRUGINFO D0O5YZ Mepindolol Approved T51408 DRUGINFO D0X5UN Mirabegron Approved T51408 DRUGINFO D09GFL Trihexyphenidyl Approved T51408 DRUGINFO D0D0YM Amosulalol Approved T51408 DRUGINFO D00GZW ONO-2506 Phase 2/3 T51408 DRUGINFO D00NNI ASP-3652 Phase 2 T51408 DRUGINFO D01VAP YM-430 Phase 2 T51408 DRUGINFO D03FLT CP-331684 Phase 2 T51408 DRUGINFO D06UKG LY-377604 Phase 2 T51408 DRUGINFO D09PYV AZ-40140 Phase 2 T51408 DRUGINFO D0A5EF GW-427353 Phase 2 T51408 DRUGINFO D0D1FC LY-362884 Phase 2 T51408 DRUGINFO D0U7HL N-5984 Phase 2 T51408 DRUGINFO D0V9IE ZD2079 Phase 2 T51408 DRUGINFO DFS18G APD418 Phase 2 T51408 DRUGINFO D07WHS CL-316,243 Phase 2 T51408 DRUGINFO D0W3UH QLT-091568 Phase 1/2 T51408 DRUGINFO D03INQ Laevo-Bambuterol Phase 1 T51408 DRUGINFO D03QKW KUC-7483 Phase 1 T51408 DRUGINFO D05EPU ZD7114 Phase 1 T51408 DRUGINFO D07NFW BMS-196085 Phase 1 T51408 DRUGINFO D04UNO KUL-7211 Phase 1 T51408 DRUGINFO D01KKB PW-2101 Discontinued in Preregistration T51408 DRUGINFO D0Y0GG Epanolol Discontinued in Preregistration T51408 DRUGINFO D0E8CZ Amibegron Discontinued in Phase 3 T51408 DRUGINFO D01SWK Rafabegron Discontinued in Phase 2 T51408 DRUGINFO D02RHV PROXODOLOL Discontinued in Phase 2 T51408 DRUGINFO D02ZEM OBERADILOL MONOETHYL MALEATE Discontinued in Phase 2 T51408 DRUGINFO D06TVC Tienoxolol Discontinued in Phase 2 T51408 DRUGINFO D0D5DE ALPRENOXIME HYDROCHLORIDE Discontinued in Phase 2 T51408 DRUGINFO D0PU5L Adaprolol maleate-SME Discontinued in Phase 2 T51408 DRUGINFO D0X5ES NCX 950 Discontinued in Phase 1/2 T51408 DRUGINFO D00BKV SB 418790 Discontinued in Phase 1 T51408 DRUGINFO D03ISE PAFENOLOL Discontinued in Phase 1 T51408 DRUGINFO D04NXR RO-16-8714 Discontinued in Phase 1 T51408 DRUGINFO D0GT0Y MN-246 Discontinued in Phase 1 T51408 DRUGINFO D00MIX CP-114271 Preclinical T51408 DRUGINFO D03VGW GCR-1087 Preclinical T51408 DRUGINFO D08SIR CL-314698 Preclinical T51408 DRUGINFO D0MT5C L-742791 Preclinical T51408 DRUGINFO D0WS1V L-751250 Preclinical T51408 DRUGINFO D00TVI SR-58894A Terminated T51408 DRUGINFO D03GLM BMS-210285 Terminated T51408 DRUGINFO D04DZE BRL 26830A Terminated T51408 DRUGINFO D06XAK H-216/44 Terminated T51408 DRUGINFO D0I9QH SR-58878 Terminated T51408 DRUGINFO D0V4FK SM 11044 Terminated T51408 DRUGINFO D0Y1PG BRL 37344 Terminated T51408 DRUGINFO D00PLX MystiLol Investigative T51408 DRUGINFO D01OIK xamoterol Investigative T51408 DRUGINFO D01OIV T-0509 Investigative T51408 DRUGINFO D02DKX LK 204-545 Investigative T51408 DRUGINFO D02VPW [3H](-)CGP 12177 Investigative T51408 DRUGINFO D03VHK L-748337 Investigative T51408 DRUGINFO D04UNE NIHP Investigative T51408 DRUGINFO D07HTM (-)-Ro 363 Investigative T51408 DRUGINFO D07KMN Trimetoquinol Investigative T51408 DRUGINFO D07ZZG cicloprolol Investigative T51408 DRUGINFO D0A0KP zinterol Investigative T51408 DRUGINFO D0C4NF FMP-825 Investigative T51408 DRUGINFO D0G6RK ER-23006 Investigative T51408 DRUGINFO D0JK0I prenalterol Investigative T51408 DRUGINFO D0K6MI [125I]ICYP Investigative T51408 DRUGINFO D0R2JT iodocyanopindolol Investigative T51408 DRUGINFO D0U5HS L748328 Investigative T51408 DRUGINFO D0V5OS H87/07 Investigative T51408 DRUGINFO D0XR9Z SB251023 Investigative T51408 DRUGINFO D0A9ED Carazolol Investigative T51408 DRUGINFO D0F7BV 1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol Investigative T51408 DRUGINFO D03BZW [3H]CGP12177 Investigative T51408 DRUGINFO D04HXF 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol Investigative T51408 DRUGINFO D0A4FU 1-(2-allylphenoxy)-3-morpholinopropan-2-ol Investigative T51408 DRUGINFO D0S8RD Trecadrine Investigative T99089 TARGETID T99089 T99089 FORMERID TTDS00346 T99089 UNIPROID BRAF_HUMAN T99089 TARGNAME Serine/threonine-protein kinase B-raf (BRAF) T99089 GENENAME BRAF T99089 TARGTYPE Successful T99089 SYNONYMS V-Raf murine sarcoma viral oncogene homolog B1; RAFB1; Proto-oncogene B-Raf; P94; BRAF1; BRAF(V599E); BRAF serine/threonine kinase; B-raf protein; B-Raf T99089 FUNCTION May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway. Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. T99089 PDBSTRUC 6CAD; 6B8U; 5VYK; 5VR3; 5VAM T99089 BIOCLASS Kinase T99089 ECNUMBER EC 2.7.11.1 T99089 SEQUENCE MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH T99089 DRUGINFO D05ROI Dabrafenib Approved T99089 DRUGINFO D0TK7R LGX818 Approved T99089 DRUGINFO D0Y9EW Vemurafenib Approved T99089 DRUGINFO D05HTS PLX8394 Phase 2 T99089 DRUGINFO D0M5XN BGB-283 Phase 1/2 T99089 DRUGINFO D04MXN CEP-32496 Phase 1/2 T99089 DRUGINFO D04AZM ARQ 736 Phase 1 T99089 DRUGINFO D0G0PU RO-5212054 Phase 1 T99089 DRUGINFO D0XL8W ASN003 Phase 1 T99089 DRUGINFO D0Z2FD BMS-908662 Phase 1 T99089 DRUGINFO D6E1GI PF-07799933 Phase 1 T99089 DRUGINFO DIS4N5 ABM-1310 Phase 1 T99089 DRUGINFO DJ8QW7 PF-07284890 Phase 1 T99089 DRUGINFO D0RV7J RG-7256 Discontinued in Phase 1 T99089 DRUGINFO D03TTT AR-00341677 Investigative T99089 DRUGINFO D0C0ZC AZ-628 Investigative T26623 TARGETID T26623 T26623 FORMERID TTDS00115 T26623 UNIPROID ALDR_HUMAN T26623 TARGNAME Aldose reductase (AKR1B1) T26623 GENENAME AKR1B1 T26623 TARGTYPE Successful T26623 SYNONYMS Aldehyde reductase; AKR1B1 T26623 FUNCTION Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies. T26623 PDBSTRUC 6F8O; 6F84; 6F82; 6F81; 6F7R T26623 BIOCLASS Short-chain dehydrogenases reductase T26623 ECNUMBER EC 1.1.1.300 T26623 SEQUENCE MASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF T26623 DRUGINFO D0Z5IU Sulindac Approved T26623 DRUGINFO D03KOZ Epalrestat Approved T26623 DRUGINFO D00EWR Fidarestat Phase 3 T26623 DRUGINFO D0K8TI Ranirestat Phase 3 T26623 DRUGINFO D4PL6G BNV-222 Phase 2/3 T26623 DRUGINFO D04PBH CONTIGOSIDE B Phase 2/3 T26623 DRUGINFO D04BFU LIDORESTAT Phase 2 T26623 DRUGINFO D0B4XX QR-333 Phase 2 T26623 DRUGINFO D0P7SO ADMVA Phase 2 T26623 DRUGINFO D0V4UO M-16209 Phase 2 T26623 DRUGINFO D00QKL T2c-003 Phase 1/2 T26623 DRUGINFO D07DIX ALO-1567 Phase 1 T26623 DRUGINFO D0Q7QY SSR-125047 Phase 1 T26623 DRUGINFO D0J6JZ MINALRESTAT Discontinued in Phase 3 T26623 DRUGINFO D0Q7AW IMIRESTAT Discontinued in Phase 3 T26623 DRUGINFO D0U9TM Ponalrestat Discontinued in Phase 3 T26623 DRUGINFO D03PIB Alrestatin Discontinued in Phase 2 T26623 DRUGINFO D06EDT ZOPOLRESTAT Discontinued in Phase 2 T26623 DRUGINFO D08VMO JTT-811 Discontinued in Phase 2 T26623 DRUGINFO D0E0FY CTL-102-GDEPT Discontinued in Phase 2 T26623 DRUGINFO D0O2ET AD-5467 Discontinued in Phase 2 T26623 DRUGINFO D0M9RE ARI-809 Preclinical T26623 DRUGINFO D02CGC Sorbinil Terminated T26623 DRUGINFO D09BHF WF-2421 Terminated T26623 DRUGINFO D0B0GC E-0722 Terminated T26623 DRUGINFO D0C7KK Zenarestat Terminated T26623 DRUGINFO D0E6LC SPR-210 Terminated T26623 DRUGINFO D0RZ0N FR-62765 Terminated T26623 DRUGINFO D00EPD 6-(2-Chloro-benzenesulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D00KCB Fidarestat(Stereoisomer) Investigative T26623 DRUGINFO D00VHG Inhibitor Idd 384 Investigative T26623 DRUGINFO D00WFB 7-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one Investigative T26623 DRUGINFO D01KAM O7-Nitrooxyethyl chrysin Investigative T26623 DRUGINFO D01LWJ Apigenin-7-O-beta-D-glucuronide Investigative T26623 DRUGINFO D01UNC 2-(4-aminophenylsulfonamido)acetic acid Investigative T26623 DRUGINFO D02AAH 6-(4-Chloro-benzenesulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D02DYB TRIPTOCALLINE A Investigative T26623 DRUGINFO D02WZA 6-(Benzothiazole-2-sulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D03DEO PALBINONE Investigative T26623 DRUGINFO D03LRQ 2-(3-benzoyl-1H-pyrrol-1-yl)acetic acid Investigative T26623 DRUGINFO D03NEF 6-methoxykaempferol 3-O-beta-D-robinobioside Investigative T26623 DRUGINFO D03YBR 6-Phenylmethanesulfonyl-2H-pyridazin-3-one Investigative T26623 DRUGINFO D04GYD 2-Benzhydryl-7-hydroxy-chromen-4-one Investigative T26623 DRUGINFO D04YIV 2-(Phenylsulfonamido)acetic Acid Investigative T26623 DRUGINFO D05HBF 6,7-Dihydroxy-2-phenyl-chromen-4-one Investigative T26623 DRUGINFO D05SLZ 7-Hydroxy-2-(4-methoxy-benzyl)-chromen-4-one Investigative T26623 DRUGINFO D06YQS 6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D07DJS QUERCITRIN Investigative T26623 DRUGINFO D07GTX (8-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid Investigative T26623 DRUGINFO D07JEY IDD552 Investigative T26623 DRUGINFO D07XXK 6-(Biphenyl-2-sulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D08DRD Patuletin 3-O-beta-D-robinobioside Investigative T26623 DRUGINFO D08JEI 6-(Naphthalene-2-sulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D08MHU 6-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one Investigative T26623 DRUGINFO D08NKL Isorhamnetin 3,7-disulfate Investigative T26623 DRUGINFO D08OYH O5-Acetyl-O7-nitrooxyethyl chrysin Investigative T26623 DRUGINFO D08ZZX 4-(3-Methoxy-phenyl)-isoxazolidine-3,5-dione Investigative T26623 DRUGINFO D09MYF N-Acetylalanine Investigative T26623 DRUGINFO D09PNQ 2,3-dihydroxypropanal Investigative T26623 DRUGINFO D0A2FM 6-(1H-Indole-2-sulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0A4LM EPALRESTATE Investigative T26623 DRUGINFO D0A9NE 2-(3,4-Dihydroxy-benzyl)-7-hydroxy-chromen-4-one Investigative T26623 DRUGINFO D0BH6B Apigenin-7-O-beta-D-glucuronide methyl ester Investigative T26623 DRUGINFO D0BU5K TINGENIN B Investigative T26623 DRUGINFO D0CX4E 3-(3-Benzoyl-1H-pyrrol-1-yl)propanoic acid Investigative T26623 DRUGINFO D0F6AI TINGENONE Investigative T26623 DRUGINFO D0F6TM (6-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid Investigative T26623 DRUGINFO D0FJ7G IDD594 Investigative T26623 DRUGINFO D0G1OW Quercetin 3-O-neohesperidoside Investigative T26623 DRUGINFO D0G4CJ 4-(3-Benzoyl-1H-pyrrol-1-yl)butanoic acid Investigative T26623 DRUGINFO D0IB8C 6-(Toluene-4-sulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0IF8Z (4-Methyl-2-oxo-2H-quinolin-1-yl)-acetic acid Investigative T26623 DRUGINFO D0J7MD (6-Methoxy-2-oxo-2H-quinolin-1-yl)-acetic acid Investigative T26623 DRUGINFO D0J7VA Isorhamnetin 3-O-rhamnoside Investigative T26623 DRUGINFO D0K8NO AK198 Investigative T26623 DRUGINFO D0L7MI 7-Hydroxy-6-nitro-2-phenyl-chromen-4-one Investigative T26623 DRUGINFO D0O9KV 6-(2-Bromo-benzenesulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0OC4B 7-Hydroxy-4-phenylcoumarin Investigative T26623 DRUGINFO D0OZ4C 6-Benzenesulfonyl-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0P1ZM 6-(Naphthalene-1-sulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0P3AU 6-(4-Methoxy-benzenesulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0QP9D 2-Benzyl-7-hydroxy-chromen-4-one Investigative T26623 DRUGINFO D0R3MB 6-(Benzofuran-2-sulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0R3OQ BNV-222 Investigative T26623 DRUGINFO D0R7IJ 6-(3-Chloro-benzenesulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0T2TW 3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid Investigative T26623 DRUGINFO D0U8GZ Tamarixetin 3-glucoside-7-sulfate Investigative T26623 DRUGINFO D0XD1Q 6-(4-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0Y7PW 6-(4-Bromo-benzenesulfonyl)-2H-pyridazin-3-one Investigative T26623 DRUGINFO D0YJ3Q 2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one Investigative T26623 DRUGINFO D0Z3FX Patuletin 3-O-beta-D-galactoside Investigative T26623 DRUGINFO D04UYB MANGIFERIN Investigative T26623 DRUGINFO D06SPO 3,5-dichlorosalicylic acid Investigative T26623 DRUGINFO D06YEV Hydroxydimethylarsine Oxide Investigative T26623 DRUGINFO D08BFU ASTRAGALIN Investigative T26623 DRUGINFO D01KKU NSC-94258 Investigative T26623 DRUGINFO D01AWD Alpha-D-Glucose-6-Phosphate Investigative T26623 DRUGINFO D01UYI Chrysin Investigative T26623 DRUGINFO D0SY2M daidzein Investigative T26623 DRUGINFO D00RIX APIGENIN Investigative T26623 DRUGINFO D0G3TK KAEMPFEROL Investigative T26623 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T53524 TARGETID T53524 T53524 FORMERID TTDC00311 T53524 UNIPROID PGFRA_HUMAN T53524 TARGNAME Platelet-derived growth factor receptor alpha (PDGFRA) T53524 GENENAME PDGFRA T53524 TARGTYPE Successful T53524 SYNONYMS RHEPDGFRA; Platelet-derived growth factor receptor 2; Platelet-derived growth factor alpha receptor; PDGFR2; PDGFR-alpha; PDGFR-2; PDGF-R-alpha; CD140a antigen; CD140a; CD140 antigen-like family member A; Alpha-type platelet-derived growth factor receptor; Alpha platelet-derived growth factor receptor T53524 FUNCTION Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. T53524 PDBSTRUC 5K5X; 5GRN; 1GQ5 T53524 BIOCLASS Kinase T53524 ECNUMBER EC 2.7.10.1 T53524 SEQUENCE MGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVAAAVLVLLVIVIISLIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKKELDIFGLNPADESTRSYVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKNLLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYIIPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDSSDLVEDSFL T53524 DRUGINFO D09QZS Olaratumab Approved T53524 DRUGINFO D0UO2P Avapritinib Approved T53524 DRUGINFO D09AAK Ripretinib Approved T53524 DRUGINFO D01PZD Romiplostim Approved T53524 DRUGINFO D0J1GR CP-868596 Phase 3 T53524 DRUGINFO D02WVT E-3810 Phase 3 T53524 DRUGINFO D0AG7N MEDI-575 Phase 2 T53524 DRUGINFO D0T1GF MP470 Phase 2 T53524 DRUGINFO D00NSD XL-820 Phase 2 T53524 DRUGINFO D0Z6MT Famitinib Phase 2 T53524 DRUGINFO D0IH3I PMID28460551-Compound-1 Patented T53524 DRUGINFO D0NB1V Pyridine derivative 20 Patented T53524 DRUGINFO D0O0AW Pyridine derivative 21 Patented T53524 DRUGINFO D0O4TA Pyridine derivative 22 Patented T53524 DRUGINFO D0T7BE Pyridine derivative 19 Patented T53524 DRUGINFO D0AK1F Pyridine derivative 18 Patented T53524 DRUGINFO D00QCB SRI-62-834 Discontinued in Phase 2 T53524 DRUGINFO D0KX1E CEP-2563 Discontinued in Phase 1 T53524 DRUGINFO D03WTT RG-13022 Terminated T53524 DRUGINFO D06GBK AG1295 Terminated T53524 DRUGINFO D03DJR D-65476 Investigative T53524 DRUGINFO D05EDW 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline Investigative T53524 DRUGINFO D0N4VR 5-Fluoro-3-thiophen-3-yl-quinoline Investigative T53524 DRUGINFO D00LRC 3-Cyclopentyl-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D00RBV 6,7-Dimethoxy-3-pyridin-3-yl-quinoline Investigative T53524 DRUGINFO D00YCU 1-Phenyl-1H-benzoimidazol-5-ol Investigative T53524 DRUGINFO D01FWD 1-Phenyl-1H-benzoimidazole Investigative T53524 DRUGINFO D01MUN 4-Benzoimidazol-1-yl-phenylamine Investigative T53524 DRUGINFO D01UYS 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one Investigative T53524 DRUGINFO D02CUF Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine Investigative T53524 DRUGINFO D02PZZ 7-Methoxy-3-pyridin-4-yl-quinoline Investigative T53524 DRUGINFO D02XKJ 5-Methoxy-1-phenyl-1H-benzoimidazole Investigative T53524 DRUGINFO D03MQI 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid Investigative T53524 DRUGINFO D04PQX 6-Methoxy-3-pyridin-4-yl-quinoline Investigative T53524 DRUGINFO D05GBY 3-Thiophen-3-yl-quinoline Investigative T53524 DRUGINFO D05SNG 7-Fluoro-3-thiophen-3-yl-quinoline Investigative T53524 DRUGINFO D06LLF 6,7-Dimethoxy-3-((E)-styryl)-quinoline Investigative T53524 DRUGINFO D06MCJ 3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D06VNR 3-Benzyloxy-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D07CFT 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline Investigative T53524 DRUGINFO D07JDY 3-((E)-Styryl)-quinoline Investigative T53524 DRUGINFO D07ZWN 5,7-Dimethyl-3-thiophen-3-yl-quinoline Investigative T53524 DRUGINFO D08JGS 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline Investigative T53524 DRUGINFO D08KWL 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D08SUH 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D0A6AA 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline Investigative T53524 DRUGINFO D0A6YP 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D0AO6T 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D0C1BE 6,7-Dimethoxy-3-p-tolyl-quinoline Investigative T53524 DRUGINFO D0CF9B 6,7-Dichloro-3-thiophen-3-yl-quinoline Investigative T53524 DRUGINFO D0FH3M RPR-108514A Investigative T53524 DRUGINFO D0G0KN 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline Investigative T53524 DRUGINFO D0G0ZQ 6,7-Dimethoxy-3-thiophen-2-yl-quinoline Investigative T53524 DRUGINFO D0G6SA 6,7-Dimethoxy-3-phenyl-quinoline Investigative T53524 DRUGINFO D0GN3E 3-(1H-Indol-3-yl)-quinoline Investigative T53524 DRUGINFO D0H4JB 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol Investigative T53524 DRUGINFO D0H9TO 3-Pyridin-4-yl-quinolin-7-ol Investigative T53524 DRUGINFO D0I0GL 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D0IR5I 3-Pyridin-3-yl-quinoline-6,7-diol Investigative T53524 DRUGINFO D0K2YG 4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine Investigative T53524 DRUGINFO D0K9ON 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D0K9VE 3-Pyridin-4-yl-quinoline-5,7-diol Investigative T53524 DRUGINFO D0KF3N 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D0P0RD 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D0P0WT 5,7-Dimethoxy-3-pyridin-4-yl-quinoline Investigative T53524 DRUGINFO D0Q3DS 3-Pyridin-4-yl-quinoline Investigative T53524 DRUGINFO D0QT4X 6,7-Difluoro-3-thiophen-3-yl-quinoline Investigative T53524 DRUGINFO D0RD5S 5,7-Dimethoxy-3-thiophen-3-yl-quinoline Investigative T53524 DRUGINFO D0SG0G 5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline Investigative T53524 DRUGINFO D0T9FQ 6,7-Dimethoxy-3-pyridin-4-yl-quinoline Investigative T53524 DRUGINFO D0V8QI 7-Methoxy-3-thiophen-3-yl-quinoline Investigative T53524 DRUGINFO D0W7IN 6-Methoxy-3-thiophen-3-yl-quinoline Investigative T53524 DRUGINFO D0W9BF RPR-101511 Investigative T53524 DRUGINFO D0WW8M 6,7-Dimethoxy-3-phenylethynyl-quinoline Investigative T53524 DRUGINFO D0YE1X 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline Investigative T53524 DRUGINFO D0Z4HV 7-Chloro-3-pyridin-4-yl-quinoline Investigative T53524 DRUGINFO D05FFB 5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol Investigative T53524 DRUGINFO D05QBZ CP-673451 Investigative T53524 DRUGINFO D09OLH (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone Investigative T53524 DRUGINFO D0D7ZL (1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone Investigative T53524 DRUGINFO D0G0KQ (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone Investigative T53524 DRUGINFO D0G5YI Di(1H-indol-2-yl)methanone Investigative T53524 DRUGINFO D0H7MF (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone Investigative T53524 DRUGINFO D0XS9E (5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone Investigative T53524 DRUGINFO D09LPL SU-11652 Investigative T53524 DRUGINFO D0I3XZ Bis-(5-hydroxy-1H-indol-2-yl)-methanone Investigative T53524 DRUGINFO D0OH3J PD-0179483 Investigative T53524 DRUGINFO D0S1KJ PD-0173952 Investigative T53524 DRUGINFO D0Z7GH PD-0173958 Investigative T53524 DRUGINFO D03NPX PD-0173955 Investigative T53524 DRUGINFO D0YZ7H JNJ-10198409 Investigative T53524 DRUGINFO D02BXJ PMID21561767C8h Investigative T53524 DRUGINFO D0D5EW HKI-9924129 Investigative T53524 DRUGINFO D0GW4Q PD-0173956 Investigative T53524 DRUGINFO D0P3JW PD-0166326 Investigative T53524 DRUGINFO D03EHM PP121 Investigative T53524 DRUGINFO D0C2GE PMID22765894C8h Investigative T53524 DRUGINFO D09XIL Ro-4396686 Investigative T53524 DRUGINFO D0M4SY BMS-536924 Investigative T83875 TARGETID T83875 T83875 FORMERID TTDS00289 T83875 UNIPROID AOFA_HUMAN T83875 TARGNAME Monoamine oxidase type A (MAO-A) T83875 GENENAME MAOA T83875 TARGTYPE Successful T83875 SYNONYMS Monoamine oxidase A; Amine oxidase [flavin-containing] A T83875 FUNCTION MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine. Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. T83875 PDBSTRUC 2Z5Y; 2Z5X; 2BXS; 2BXR; 1H8Q T83875 BIOCLASS CH-NH(2) donor oxidoreductase T83875 ECNUMBER EC 1.4.3.4 T83875 SEQUENCE MENQEKASIAGHMFDVVVIGGGISGLSAAKLLTEYGVSVLVLEARDRVGGRTYTIRNEHVDYVDVGGAYVGPTQNRILRLSKELGIETYKVNVSERLVQYVKGKTYPFRGAFPPVWNPIAYLDYNNLWRTIDNMGKEIPTDAPWEAQHADKWDKMTMKELIDKICWTKTARRFAYLFVNINVTSEPHEVSALWFLWYVKQCGGTTRIFSVTNGGQERKFVGGSGQVSERIMDLLGDQVKLNHPVTHVDQSSDNIIIETLNHEHYECKYVINAIPPTLTAKIHFRPELPAERNQLIQRLPMGAVIKCMMYYKEAFWKKKDYCGCMIIEDEDAPISITLDDTKPDGSLPAIMGFILARKADRLAKLHKEIRKKKICELYAKVLGSQEALHPVHYEEKNWCEEQYSGGCYTAYFPPGIMTQYGRVIRQPVGRIFFAGTETATKWSGYMEGAVEAGERAAREVLNGLGKVTEKDIWVQEPESKDVPAVEITHTFWERNLPSVSGLLKIIGFSTSVTALGFVLYKYKLLPRS T83875 DRUGINFO D0I2VK Isocarboxazid Approved T83875 DRUGINFO D01ZSO Moclobemide Approved T83875 DRUGINFO D09QDP Clorgyline Approved T83875 DRUGINFO D0H0HJ Tranylcypromine Approved T83875 DRUGINFO D00VUI Psoralen Phase 3 T83875 DRUGINFO D08CJK TRYPTAMINE Phase 3 T83875 DRUGINFO D00RWQ CX157 Phase 2 T83875 DRUGINFO D04RCT CHF-3381 Phase 2 T83875 DRUGINFO D0C3UC Ladostigil Phase 2 T83875 DRUGINFO D0H7PW PIPERINE Phase 1/2 T83875 DRUGINFO D0T5AW Desoxypeganine Phase 1 T83875 DRUGINFO D01OGR Secondary and tertiary (hetero)arylamide derivative 2 Patented T83875 DRUGINFO D03EHC PMID25399762-Compound-Table 5-8 Patented T83875 DRUGINFO D03QMA PMID25399762-Compound-Figure2-Artoxanthochromane Patented T83875 DRUGINFO D03VGN PMID25399762-Compound-Table 5-O-methyl-M30 Patented T83875 DRUGINFO D03YOU GypensapogeninA Patented T83875 DRUGINFO D05GWJ PMID25399762-Compound-Figure1-Sarcaboside A Patented T83875 DRUGINFO D05MYL PMID25399762-Compound-Figure1-Sarcaboside B Patented T83875 DRUGINFO D07MEE PhyllanthoidA Patented T83875 DRUGINFO D08HOV PMID25399762-Compound-Figure3-Aspeverin Patented T83875 DRUGINFO D0AH9P PMID29324067-Compound-25 Patented T83875 DRUGINFO D0E7OQ PMID25399762-Compound-Figure3-Lycojaponicumin B Patented T83875 DRUGINFO D0G3TH KadcoccitoneA Patented T83875 DRUGINFO D0H7HH PMID25399762-Compound-Figure3-Lycojaponicumin C Patented T83875 DRUGINFO D0I5DV PMID25399762-Compound-Figure2-Spirooliganone B Patented T83875 DRUGINFO D0I9CK MyriberineA Patented T83875 DRUGINFO D0K3UV PMID25399762-Compound-Figure1-Chukrasone A Patented T83875 DRUGINFO D0KW7O PMID25399762-Compound-Figure3-Fluevirosine A Patented T83875 DRUGINFO D0LZ2M IncarviatoneA Patented T83875 DRUGINFO D0M0EP PMID25399762-Compound-Figure3-Lycojaponicumin A Patented T83875 DRUGINFO D0N1CG PMID25399762-Compound-Figure1-Eryngiolide A Patented T83875 DRUGINFO D0P1PC HouttuynoidA Patented T83875 DRUGINFO D0R2YC GypensapogeninB Patented T83875 DRUGINFO D0TX9E PMID25399762-Compound-Figure1-Aphanamixoid A Patented T83875 DRUGINFO D0V6TF PMID25399762-Compound-Figure1-Neonectrolide A Patented T83875 DRUGINFO D0XY6I AphanamgrandiolA Patented T83875 DRUGINFO D0Y9VB PMID25399762-Compound-Figure1-Chukrasone B Patented T83875 DRUGINFO D05RJG Schiff base compound 1 Patented T83875 DRUGINFO D0T9JB Tacrine-coumarin hybrid derivative 1 Patented T83875 DRUGINFO D04OEV Cyclic peptide derivative 1 Patented T83875 DRUGINFO D07NTA Heteroaryl-cyclopropylamine derivative 1 Patented T83875 DRUGINFO D08IOP N-(2-phenylcyclopropyl) amino acid derivative 3 Patented T83875 DRUGINFO D0AA7U PMID29757691-Compound-4 Patented T83875 DRUGINFO D00OWF Harmine Patented T83875 DRUGINFO D02EME Tetra-hydro-isoquinoline derivative 3 Patented T83875 DRUGINFO D04AXC Tetra-hydro-isoquinoline derivative 1 Patented T83875 DRUGINFO D04OHC Tarnylcypromine derivative 2 Patented T83875 DRUGINFO D0NB7Z Tetra-hydro-isoquinoline derivative 2 Patented T83875 DRUGINFO D0O7IH Tarnylcypromine derivative 3 Patented T83875 DRUGINFO D0R6RT Tetra-hydro-isoquinoline derivative 4 Patented T83875 DRUGINFO D05WEP Befloxatone Discontinued in Phase 3 T83875 DRUGINFO D06QOJ RS-8359 Discontinued in Phase 2 T83875 DRUGINFO D0H9DE CS-722 Discontinued in Phase 2 T83875 DRUGINFO D0IZ1D Brofaromine Discontinued in Phase 2 T83875 DRUGINFO D0ZM5W Esuprone Discontinued in Phase 2 T83875 DRUGINFO D0E8UJ BW-1370U87 Discontinued in Phase 1 T83875 DRUGINFO D01OLO AS602868 Discontinued in Phase 1 T83875 DRUGINFO D02CGY Bifemelane Terminated T83875 DRUGINFO D0G9AP E-2011 Terminated T83875 DRUGINFO D00JUD 4-methyl-2H-benzofuro[3,2-g]chromen-2-one Investigative T83875 DRUGINFO D00KQB 1-(4-butoxyphenyl)propan-2-amine Investigative T83875 DRUGINFO D00YVE 1-(2-Naphthyl)-2-aminopropane Investigative T83875 DRUGINFO D01UPT FA-70 Investigative T83875 DRUGINFO D02AQG N-Benzyl-(6-butoxy-2-naphthyl)-2-aminopropane Investigative T83875 DRUGINFO D02PSR N'-(2-phenylallyl)hydrazine hydrochloride Investigative T83875 DRUGINFO D02ZZA (S)-2-amino-1-(4-ethylthiophenyl)-propane Investigative T83875 DRUGINFO D04EDK 6-Fluoro-N-(2-morpholinoethyl)nicotinamide Investigative T83875 DRUGINFO D04SJC 6-Chloro-N-(3-morpholinopropyl)nicotinamide Investigative T83875 DRUGINFO D04UYZ (R,S)-N-(R-phenylethyl)-1H-pyrrole-2-carboxamide Investigative T83875 DRUGINFO D05GGH 6-Chloro-N-(2-morpholinoethyl)nicotinamide Investigative T83875 DRUGINFO D05HJT Ethyl 4-(2-oxo-2H-chromene-3-carboxamido)benzoate Investigative T83875 DRUGINFO D05OXR N-Phenyl-1-methyl-1H-indole-2-carboxamide Investigative T83875 DRUGINFO D06FXI 5-Methoxymethyl-3-pyrrol-1-yl-oxazolidin-2-one Investigative T83875 DRUGINFO D06IAE 4-Chloro-N-(3-morpholinopropyl)nicotinamide Investigative T83875 DRUGINFO D07LCW 5-Azidomethyl-3-pyrrol-1-yl-oxazolidin-2-one Investigative T83875 DRUGINFO D07ULQ N-methyl-N-(prop-2-ynyl)-1H-pyrrole-2-carboxamide Investigative T83875 DRUGINFO D07WFU Trans-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine Investigative T83875 DRUGINFO D08PEW N-(1H-Indol-2-ylmethyl)-N-(4-phenylbutyl)amine Investigative T83875 DRUGINFO D08QZP N-((1H-indol-2-yl)methyl)(phenyl)methanamine Investigative T83875 DRUGINFO D0A4FA N-benzyl-1H-pyrrole-2-carboxamide Investigative T83875 DRUGINFO D0B0JK DECYL(DIMETHYL)PHOSPHINE OXIDE Investigative T83875 DRUGINFO D0B5CR 1-(3-(4-chlorobenzyl)quinoxalin-2-yl)hydrazine Investigative T83875 DRUGINFO D0BE0S 1-(1-Naphthyl)-2-aminopropane Investigative T83875 DRUGINFO D0C0MP 2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole Investigative T83875 DRUGINFO D0C8RD N-benzyl,N-methyl-1H-pyrrole-2-carboxamide Investigative T83875 DRUGINFO D0C9RO N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine Investigative T83875 DRUGINFO D0D0SC 6-Hydroxy-N-(2-morpholinoethyl)nicotinamide Investigative T83875 DRUGINFO D0E5VT 6,11-dihydro-5H-benzo[a]carbazole Investigative T83875 DRUGINFO D0H1GQ 2-(3-benzylquinoxalin-2-ylamino)ethanol Investigative T83875 DRUGINFO D0H1VT Cis-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine Investigative T83875 DRUGINFO D0H5MV N-propargyl-1H-pyrrole-2-carboxamide Investigative T83875 DRUGINFO D0H6UA 1-(4-propoxyphenyl)propan-2-amine Investigative T83875 DRUGINFO D0J3IA 5,6-Dichloro-N-(2-morpholinoethyl)nicotinamide Investigative T83875 DRUGINFO D0K8SK 2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole Investigative T83875 DRUGINFO D0KB2R N-(1-Methyl-1H-indol-2-ylmethyl)-N-phenylamine Investigative T83875 DRUGINFO D0KU2D N-phenyl-1H-pyrrole-2-carboxamide Investigative T83875 DRUGINFO D0KW6V 3-benzyl-N-(2-morpholinoethyl)quinoxalin-2-amine Investigative T83875 DRUGINFO D0M0HM N-Benzyl-(6-methoxy-2-naphthyl)-2-aminopropane Investigative T83875 DRUGINFO D0O0QN 3-aminoacetamido-4'-methylfuro[3,2-g]coumarin Investigative T83875 DRUGINFO D0O4XF 1-(3-benzylquinoxalin-2-yl)hydrazine Investigative T83875 DRUGINFO D0P0XO 3-methyl-2(1H)-thioxo-4(3H)-quinazolinone Investigative T83875 DRUGINFO D0P3DV N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide Investigative T83875 DRUGINFO D0Q2QA (S)-2-amino-1-(4-methylthiophenyl)-propane Investigative T83875 DRUGINFO D0R4PR 7-acetonyloxy-3-acetylamino-8-methoxycoumarin Investigative T83875 DRUGINFO D0R4TI (6-methylthio-2-naphthyl)isopropylamine Investigative T83875 DRUGINFO D0S9JC 4-Chloro-N-(2-morpholinoethyl)nicotinamide Investigative T83875 DRUGINFO D0SN3L N-2-phenylethyl-1H-pyrrole-2-carboxamide Investigative T83875 DRUGINFO D0U9VX 9-(3-aminopropoxy)-7H-furo[3,2-g]chromen-7-one Investigative T83875 DRUGINFO D0V7RM (6-Butoxy-2-naphthyl)-2-aminopropane Investigative T83875 DRUGINFO D0W3BX 2-phenyl-5H-indeno[1,2-d]pyrimidine Investigative T83875 DRUGINFO D0WI3V 1-(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine Investigative T83875 DRUGINFO D0X0PA 1-(4-ethoxyphenyl)propan-2-amine Investigative T83875 DRUGINFO D0Y0LQ N-((1H-indol-2-yl)methyl)-2-phenylethanamine Investigative T83875 DRUGINFO D0Y1XS 3,4-Benzo-7-acetonyloxy-8-methylcoumarin Investigative T83875 DRUGINFO D0Y4JQ N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide Investigative T83875 DRUGINFO D0ZA4J 5,6-Dichloro-N-(3-morpholinopropyl)nicotinamide Investigative T83875 DRUGINFO D00KDZ N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine Investigative T83875 DRUGINFO D00OLX 8-(3-Methylbenzyloxy)caffeine Investigative T83875 DRUGINFO D00OQL 7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin Investigative T83875 DRUGINFO D00WSM 2-oxo-N-m-tolyl-2H-chromene-3-carboxamide Investigative T83875 DRUGINFO D00WVG 2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole Investigative T83875 DRUGINFO D01LUB 4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin Investigative T83875 DRUGINFO D01PES N-(1H-Indol-2-ylmethyl)-N-phenylamine Investigative T83875 DRUGINFO D01SBZ 1-(4-(benzyloxy)phenyl)propan-2-amine Investigative T83875 DRUGINFO D02BBT 2-Bromo-N-(2-morpholinoethyl)nicotinamide Investigative T83875 DRUGINFO D02FJX 8-[(3-Trifluoromethyl)benzyloxy]caffeine Investigative T83875 DRUGINFO D02IDM (6-Methoxy-2-naphthyl)-2-aminopropane Investigative T83875 DRUGINFO D02QBV N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide Investigative T83875 DRUGINFO D02TFD (7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile Investigative T83875 DRUGINFO D02UVG 7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83875 DRUGINFO D03HXD (6-Benzyloxy-2-naphthyl)-2-aminopropane Investigative T83875 DRUGINFO D03KDD N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine Investigative T83875 DRUGINFO D03LGV Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine Investigative T83875 DRUGINFO D03PXS 2-oxo-N-phenyl-2H-chromene-3-carboxamide Investigative T83875 DRUGINFO D03XKJ N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide Investigative T83875 DRUGINFO D04FLL (+/-)-2-Phenylthiomorpholin-5-one Investigative T83875 DRUGINFO D04GVX 6-Bromo-4,9-dihydro-3H-beta-carboline Investigative T83875 DRUGINFO D04LPY 8-(3-Fluorobenzyloxy)caffeine Investigative T83875 DRUGINFO D04QRS PNU-22394 Investigative T83875 DRUGINFO D04ZPU 2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole Investigative T83875 DRUGINFO D05ANK N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine Investigative T83875 DRUGINFO D05FMZ C-(1H-Indol-3-yl)-methylamine Investigative T83875 DRUGINFO D05FQN 7-Methoxy-9H-beta-carboline Investigative T83875 DRUGINFO D05GQQ 6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83875 DRUGINFO D05WQN N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide Investigative T83875 DRUGINFO D06AJP (E)-5-(3-Chlorostyryl)isatin Investigative T83875 DRUGINFO D07LCU N-(3-Phenylpropyl)-1H-indole-2-carboxamide Investigative T83875 DRUGINFO D07NBB 8-(3-Bromobenzyloxy)caffeine Investigative T83875 DRUGINFO D08CNS IPRONIAZIDE Investigative T83875 DRUGINFO D08FFH 7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin Investigative T83875 DRUGINFO D08FXH (+/-)-2-(4'-Propoxyphenyl)thiomorpholine Investigative T83875 DRUGINFO D08HAM 5-Bromo-4,9-dihydro-3H-beta-carboline Investigative T83875 DRUGINFO D08HNJ N-(4-Phenylbutyl)-1H-indole-2-carboxamide Investigative T83875 DRUGINFO D08PHY Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine Investigative T83875 DRUGINFO D08QVY 5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one Investigative T83875 DRUGINFO D08SRB Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate Investigative T83875 DRUGINFO D08SSS (S)-2-amino-1-(4-propylthiophenyl)-propane Investigative T83875 DRUGINFO D08TFN (+/-)-2-(4'-Methoxyphenyl)thiomorpholine Investigative T83875 DRUGINFO D08YCE 8-(3-Chlorobenzyloxy)caffeine Investigative T83875 DRUGINFO D09HBX Trans-2-fluoro-2-phenylcyclopropylamin Investigative T83875 DRUGINFO D09NNZ 3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide Investigative T83875 DRUGINFO D09XSB (E)-5-Styrylisatin Investigative T83875 DRUGINFO D09ZDQ 2-Furan-2-yl-4,5-dihydro-1H-imidazole Investigative T83875 DRUGINFO D0A1RE 4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one Investigative T83875 DRUGINFO D0A4AB 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline Investigative T83875 DRUGINFO D0A4IY HYDRAZINECARBOXAMIDE Investigative T83875 DRUGINFO D0B1WD N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide Investigative T83875 DRUGINFO D0B4CA NSC-656158 Investigative T83875 DRUGINFO D0B6MV 8-(3-Methoxybenzyloxy)caffeine Investigative T83875 DRUGINFO D0C7PD 6-Methoxy-4,9-dihydro-3H-beta-carboline Investigative T83875 DRUGINFO D0C9WW 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin Investigative T83875 DRUGINFO D0D1PE CGS-19281A Investigative T83875 DRUGINFO D0D2YR 9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83875 DRUGINFO D0D5KD (+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one Investigative T83875 DRUGINFO D0D6OR (+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine Investigative T83875 DRUGINFO D0D6QI 3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide Investigative T83875 DRUGINFO D0E8IE 4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid Investigative T83875 DRUGINFO D0F2DC Trans-2-fluoro-2-p-tolylcyclopropanamine Investigative T83875 DRUGINFO D0F7JK N-Methyl,N-phenyl-1H-indole-2-carboxamide Investigative T83875 DRUGINFO D0G4BG N-(propargyl),N-(pyrrol-2-ylmethyl)amine Investigative T83875 DRUGINFO D0G8BT 4,9-Dihydro-3H-beta-carboline Investigative T83875 DRUGINFO D0H0GZ 2-oxo-N-p-tolyl-2H-chromene-3-carboxamide Investigative T83875 DRUGINFO D0HU4J (+/-)-2-Phenylthiomorpholine Investigative T83875 DRUGINFO D0ID3Y (+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one Investigative T83875 DRUGINFO D0IP7L (6-Propoxy-2-naphthyl)-2-aminopropane Investigative T83875 DRUGINFO D0J0QW (+/-)-2-(4'-Ethoxyphenyl)thiomorpholine Investigative T83875 DRUGINFO D0JN9R 8-Benzyloxycaffeine Investigative T83875 DRUGINFO D0K9UN N-Phenyl-1H-indole-2-carboxamide Investigative T83875 DRUGINFO D0L5EW (6-Ethoxy-2-naphthyl)-2-aminopropane Investigative T83875 DRUGINFO D0M0XR (R/R)BEFLOXATONE Investigative T83875 DRUGINFO D0M4GR (+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one Investigative T83875 DRUGINFO D0M7WE 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole Investigative T83875 DRUGINFO D0MO1O N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine Investigative T83875 DRUGINFO D0N8UE N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine Investigative T83875 DRUGINFO D0N9FH 2-Phenoxymethyl-4,5-dihydro-1H-imidazole Investigative T83875 DRUGINFO D0NS9X 2-Chloro-N-(3-morpholinopropyl)nicotinamide Investigative T83875 DRUGINFO D0O2UK N-(benzyl),N-(pyrrol-2-ylmethyl)amine Investigative T83875 DRUGINFO D0P1UC 2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole Investigative T83875 DRUGINFO D0P4GF 3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin Investigative T83875 DRUGINFO D0Q1IP 2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole Investigative T83875 DRUGINFO D0Q9NC 2-phenyl-9H-indeno[2,1-d]pyrimidine Investigative T83875 DRUGINFO D0R5EW 2-Chloro-N-(2-morpholinoethyl)nicotinamide Investigative T83875 DRUGINFO D0S0JH 6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one Investigative T83875 DRUGINFO D0S3QN 2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide Investigative T83875 DRUGINFO D0S7FP (R)-Indan-1-yl-methyl-prop-2-ynyl-amine Investigative T83875 DRUGINFO D0T1FJ 4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one Investigative T83875 DRUGINFO D0T3XC (+/-)-2-(4'-Butoxyphenyl)thiomorpholine Investigative T83875 DRUGINFO D0T6XC N2-[4-(benzyloxy)benzyl]glycinamide Investigative T83875 DRUGINFO D0TL3S 3,4-Benzo-7-acetonyloxy-8-methoxycoumarin Investigative T83875 DRUGINFO D0V0TN N-Benzyl,N-methyl-1H-indole-2-carboxamide Investigative T83875 DRUGINFO D0V3NT TOLOXATONE Investigative T83875 DRUGINFO D0W4TW 7-Bromo-4,9-dihydro-3H-beta-carboline Investigative T83875 DRUGINFO D0X8HH (E)-5-(3-Fluorostyryl)isatin Investigative T83875 DRUGINFO D0X8RN Cis-2-phenylcyclopropylamine Investigative T83875 DRUGINFO D0YO7C N-(2-Phenylethyl)-1H-indole-2-carboxamide Investigative T83875 DRUGINFO D0Z0ZU (S)-2-amino-1-(4-butylthiophenyl)-propane Investigative T83875 DRUGINFO D0Z5BU (+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one Investigative T83875 DRUGINFO D0Z5YO N-Benzyl-1H-indole-2-carboxamide Investigative T83875 DRUGINFO D0Z7NC 2-Phenethyl-4,5-dihydro-1H-imidazole Investigative T83875 DRUGINFO D00NSA 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83875 DRUGINFO D06BAC 8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83875 DRUGINFO D0G2EF 8-Bromo-4,9-dihydro-3H-beta-carboline Investigative T83875 DRUGINFO D0J3SN 6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83875 DRUGINFO D0L8ND 5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83875 DRUGINFO D0Q3VI 8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83875 DRUGINFO D0V6XA 5-Methoxy-4,9-dihydro-3H-beta-carboline Investigative T83875 DRUGINFO D0Y1GL 8-Methoxy-4,9-dihydro-3H-beta-carboline Investigative T83875 DRUGINFO D08SCH 2-Amino-1-(4-methylthiophenyl)propane Investigative T83875 DRUGINFO D09BIV TRACIZOLINE Investigative T83875 DRUGINFO D0LI3J 2-BFi Investigative T83875 DRUGINFO D03LPH TRYPTOLINE Investigative T83875 DRUGINFO D05GDP 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83875 DRUGINFO D0C1SE 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole Investigative T83875 DRUGINFO D0I4ME MMDA Investigative T83875 DRUGINFO D0R7ZC Beta-methoxyamphetamine Investigative T83875 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T58454 TARGETID T58454 T58454 FORMERID TTDS00171 T58454 UNIPROID FGFR2_HUMAN T58454 TARGNAME Fibroblast growth factor receptor 2 (FGFR2) T58454 GENENAME FGFR2 T58454 TARGTYPE Successful T58454 SYNONYMS Keratinocyte growth factor receptor 2; Keratinocyte growth factor receptor; KSAM; KGFR; K-sam; FGFR-2; FGF-2 receptor; CD332; BEK T58454 FUNCTION Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. T58454 PDBSTRUC 5UI0; 5UHN; 5UGX; 5UGL; 5EG3 T58454 BIOCLASS Kinase T58454 ECNUMBER EC 2.7.10.1 T58454 SEQUENCE MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSINHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVLPAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTKRIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDKLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT T58454 DRUGINFO D09PMV Interferon Alfa-2a, Recombinant Approved T58454 DRUGINFO D0O7GU Palifermin Approved T58454 DRUGINFO D0O6UY Pemigatinib Approved T58454 DRUGINFO D0KV1Q Trafermin Phase 3 T58454 DRUGINFO D02WVT E-3810 Phase 3 T58454 DRUGINFO D0D4VV LY2874455 Phase 2 T58454 DRUGINFO D0XT0W Debio 1347 Phase 2 T58454 DRUGINFO D0G2QH AEE-788 Phase 1/2 T58454 DRUGINFO D00DRL MK-2461 Phase 1/2 T58454 DRUGINFO D0L6RF BAY1179470 Phase 1 T58454 DRUGINFO D47MOS Alofanib Phase 1 T58454 DRUGINFO DU1DL0 RLY-4008 Phase 1 T58454 DRUGINFO D0Z0KD PD-0183812 Terminated T58454 DRUGINFO D02VPS Anti-FGFR2 humanized mab Investigative T58454 DRUGINFO D0IE6Z Platelet factor 4 (PF-4) Investigative T58454 DRUGINFO D0VN4K PK 11195 Investigative T58454 DRUGINFO D0R6OM ACTB-1003 Investigative T58454 DRUGINFO D0H1OK TG-100435 Investigative T58454 DRUGINFO D09XIL Ro-4396686 Investigative T30082 TARGETID T30082 T30082 FORMERID TTDS00140 T30082 UNIPROID ACES_HUMAN T30082 TARGNAME Acetylcholinesterase (AChE) T30082 GENENAME ACHE T30082 TARGTYPE Successful T30082 SYNONYMS YT; N-ACHE; ARACHE T30082 FUNCTION Role in neuronal apoptosis. Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. T30082 PDBSTRUC 6O69; 6F25; 6CQZ; 6CQY; 6CQX T30082 BIOCLASS Carboxylic ester hydrolase T30082 ECNUMBER EC 3.1.1.7 T30082 SEQUENCE MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKNQFDHYSKQDRCSDL T30082 DRUGINFO D00WVW YM443 Approved T30082 DRUGINFO D06IAQ Ambenonium Approved T30082 DRUGINFO D06IDT Demecarium bromide Approved T30082 DRUGINFO D08USJ Neostigmine Approved T30082 DRUGINFO D0B2OT Isoflurophate Approved T30082 DRUGINFO D0E6YQ Tacrine Approved T30082 DRUGINFO D0K3LW Malathion Approved T30082 DRUGINFO D0NS6H Donepezil Approved T30082 DRUGINFO D0O2WB Pyridostigmine Approved T30082 DRUGINFO D0R9VR Galantamine Approved T30082 DRUGINFO D0S5LH Edrophonium Approved T30082 DRUGINFO D0U8AT Echothiophate Iodide Approved T30082 DRUGINFO D0WY5Q Rivastigmine Approved T30082 DRUGINFO D0X7NU Pralidoxime Chloride Approved T30082 DRUGINFO D06XWB Huperzine A Approved T30082 DRUGINFO D05UXU INM-176 Phase 3 T30082 DRUGINFO D0SH2X Amocarzine Phase 3 T30082 DRUGINFO D01LYX Eptastigmine Phase 3 T30082 DRUGINFO D07CIN (-)-Phenserine Phase 3 T30082 DRUGINFO D0MZ9A Suronacrine maleate Phase 3 T30082 DRUGINFO D0O5GK R-phenserine Phase 2 T30082 DRUGINFO D0PC1V T-82 Phase 2 T30082 DRUGINFO D0W3BA Methanesulfonyl fluoride Phase 2 T30082 DRUGINFO D67DST AD-35 Phase 2 T30082 DRUGINFO D0C3UC Ladostigil Phase 2 T30082 DRUGINFO D01KDM GTP-004 Phase 1 T30082 DRUGINFO D05REB ZT-1 Phase 1 T30082 DRUGINFO D08ZRR KW-5092 Phase 1 T30082 DRUGINFO D0JA7V PRX-105 Phase 1 T30082 DRUGINFO D0WI9W CPC-250 Phase 1 T30082 DRUGINFO D0X1XK CPC-212 Phase 1 T30082 DRUGINFO D0T5AW Desoxypeganine Phase 1 T30082 DRUGINFO D00AQW PMID27967267-Compound-36 Patented T30082 DRUGINFO D01EGC PMID27967267-Compound-47 Patented T30082 DRUGINFO D01FRI PMID27967267-Compound-15 Patented T30082 DRUGINFO D01RZG Amidine oxime derivative 1 Patented T30082 DRUGINFO D02GCZ PMID27967267-Compound-stenine Patented T30082 DRUGINFO D02SQQ PMID27967267-Compound-13 Patented T30082 DRUGINFO D03VUN Lycorine dimer salt derivative 1 Patented T30082 DRUGINFO D03WGA PMID27967267-Compound-neostenine Patented T30082 DRUGINFO D04TGJ PMID27967267-Compound-3 Patented T30082 DRUGINFO D04XHE PMID27967267-Compound-39 Patented T30082 DRUGINFO D05QVX Tacrine-indole hybrid derivative 3 Patented T30082 DRUGINFO D05WPG Tacrine-caffeic acid hybrid derivative 1 Patented T30082 DRUGINFO D06GSR PMID27967267-Compound-52 Patented T30082 DRUGINFO D07HNU PMID27967267-Compound-42 Patented T30082 DRUGINFO D0AH3R Fluorinated donepezil derivative 2 Patented T30082 DRUGINFO D0C0LQ 2-PAM derivative 1 Patented T30082 DRUGINFO D0C1UA Tacrine-dihydropyridine hybrid derivative 1 Patented T30082 DRUGINFO D0G4YS 4-PAM derivative 1 Patented T30082 DRUGINFO D0G9HY Tacrine-indole hybrid derivative 1 Patented T30082 DRUGINFO D0HI1R PMID27967267-Compound-48 Patented T30082 DRUGINFO D0I2FM Tacrine-phenothiazine hybrid derivative 1 Patented T30082 DRUGINFO D0I6UA PMID27967267-Compound-27 Patented T30082 DRUGINFO D0I7KU Tacrine-indole hybrid derivative 2 Patented T30082 DRUGINFO D0OG8Z PMID27967267-Compound-49 Patented T30082 DRUGINFO D0QJ5H PMID27967267-Compound-12 Patented T30082 DRUGINFO D0SW0V Tacrine-caffeic acid hybrid derivative 2 Patented T30082 DRUGINFO D0T0CB PMID27967267-Compound-7 Patented T30082 DRUGINFO D0UX5I PMID27967267-Compound-14 Patented T30082 DRUGINFO D0V2JR PMID27967267-Compound-neotuberostemonine Patented T30082 DRUGINFO D0W9ZU Galantamine analog 1 Patented T30082 DRUGINFO D0X5KA PMID27967267-Compound-51 Patented T30082 DRUGINFO D0XS3N Fluorinated donepezil derivative 1 Patented T30082 DRUGINFO D0YF7A PMID27967267-Compound-43 Patented T30082 DRUGINFO D0ZX8C PMID27967267-Compound-28 Patented T30082 DRUGINFO D01SQO Quinazoline alkaloid derivative 1 Patented T30082 DRUGINFO D03DIQ Egonol compound 1 Patented T30082 DRUGINFO D04FAS PMID29757691-Compound-8b Patented T30082 DRUGINFO D0B9TI PMID29757691-Compound-8d Patented T30082 DRUGINFO D0CB1C Tacrine heterodimer derivative 1 Patented T30082 DRUGINFO D0H3YG PMID29757691-Compound-2a Patented T30082 DRUGINFO D0J3OD Indoline derivative 1 Patented T30082 DRUGINFO D0K3EB Di-substituted piperidine derivative 2 Patented T30082 DRUGINFO D0OE6G Isochroman-4-ketone derivative 1 Patented T30082 DRUGINFO D0RS6O PMID29757691-Compound-8a Patented T30082 DRUGINFO D0VQ2N PMID29757691-Compound-8c Patented T30082 DRUGINFO D0W9OC PMID29757691-Compound-7 Patented T30082 DRUGINFO D0WD0M PMID29757691-Compound-2a-i Patented T30082 DRUGINFO D0X9CR PMID29757691-Compound-10 Patented T30082 DRUGINFO D0Y4CG Decyle nelycorine dibromo salt derivative 1 Patented T30082 DRUGINFO D0AA7U PMID29757691-Compound-4 Patented T30082 DRUGINFO D02EME Tetra-hydro-isoquinoline derivative 3 Patented T30082 DRUGINFO D04AXC Tetra-hydro-isoquinoline derivative 1 Patented T30082 DRUGINFO D0NB7Z Tetra-hydro-isoquinoline derivative 2 Patented T30082 DRUGINFO D0R6RT Tetra-hydro-isoquinoline derivative 4 Patented T30082 DRUGINFO D0AM8W Zanapezil Discontinued in Phase 3 T30082 DRUGINFO D0L8QQ VELNACRINE Discontinued in Phase 3 T30082 DRUGINFO D03GAX TAK-802 Discontinued in Phase 2 T30082 DRUGINFO D05UHJ SM-10888 Discontinued in Phase 2 T30082 DRUGINFO D09JVV Physostigmine Discontinued in Phase 2 T30082 DRUGINFO D09PTA HP-290 Discontinued in Phase 2 T30082 DRUGINFO D0B2BQ Icopezil maleate Discontinued in Phase 2 T30082 DRUGINFO D0F1VQ ZIFROSILONE Discontinued in Phase 2 T30082 DRUGINFO D0F3FB S-9977 Discontinued in Phase 2 T30082 DRUGINFO D0R5UZ Caracemide Discontinued in Phase 2 T30082 DRUGINFO D04UKJ NP-61 Discontinued in Phase 1 T30082 DRUGINFO D0SR4T PHENSERINE TARTRATE Preclinical T30082 DRUGINFO D0V7FG SPH-1285 Preclinical T30082 DRUGINFO D02UQU ABS-301 Terminated T30082 DRUGINFO D03DFY NP-7557 Terminated T30082 DRUGINFO D06ZAM MF268 Terminated T30082 DRUGINFO D09IUG F-3796 Terminated T30082 DRUGINFO D0J4GQ FR-152558 Terminated T30082 DRUGINFO D0K0XG MF-8615 Terminated T30082 DRUGINFO D0M2GI CI-1002 Terminated T30082 DRUGINFO D0S1VV 7-methoxytacrine Terminated T30082 DRUGINFO D0TK0W Ro-46-5934 Terminated T30082 DRUGINFO D00AJB Voacangine Investigative T30082 DRUGINFO D00FEH Mesuagenin D Investigative T30082 DRUGINFO D00RLO (3-Bromo-propyl)-trimethyl-ammonium Investigative T30082 DRUGINFO D00YHI N-(14-methylallyl)norgalanthamine Investigative T30082 DRUGINFO D01MVX TACRINE(8)-4-AMINOQUINOLINE Investigative T30082 DRUGINFO D01RUH LYSICAMINE Investigative T30082 DRUGINFO D01XRG CRYPTADINE B Investigative T30082 DRUGINFO D01ZHK N-isopropylnorlitebamine Investigative T30082 DRUGINFO D02DUJ GENESERINE Investigative T30082 DRUGINFO D02ELG 4-formylphenyl-O-beta-Dglucopyranoside Investigative T30082 DRUGINFO D02VFM DECIDIUM Investigative T30082 DRUGINFO D03EPB BIS(18)-HUPERZINE B Investigative T30082 DRUGINFO D03FHV MESUAGENIN A Investigative T30082 DRUGINFO D03FZK (4-Bromo-butyl)-trimethyl-ammonium Investigative T30082 DRUGINFO D03JRX N-n-dodecyl-7-methoxytacrine hydrochloride Investigative T30082 DRUGINFO D03KMG 1-benzene sulfonyl-cis-2,6-dimethyl piperidine Investigative T30082 DRUGINFO D03PQH 3-hydroxy-N,N,N-trimethylbenzenaminium iodide Investigative T30082 DRUGINFO D03WOS 5-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine Investigative T30082 DRUGINFO D03XXV 6-Methyl-4-(4-phenylpiperazin-1-yl)coumarin Investigative T30082 DRUGINFO D04JAX 6-Methyl-4-(4-o-tolylpiperazin-1-yl)coumarin Investigative T30082 DRUGINFO D04KWA Bis(14)-Huperzine B Investigative T30082 DRUGINFO D04LMJ MMB-4 Investigative T30082 DRUGINFO D04OUJ 1-Deoxy-1-Thio-Heptaethylene Glycol Investigative T30082 DRUGINFO D04XXE CORONARIDINE Investigative T30082 DRUGINFO D04ZJK BIS(20)-HUPERZINE B Investigative T30082 DRUGINFO D04ZJO (-)-huperzine B Investigative T30082 DRUGINFO D04ZQL But-3-enyl-trimethyl-ammonium bromide Investigative T30082 DRUGINFO D05CCT 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM Investigative T30082 DRUGINFO D05EPI Isosorbide-di-(4-nitrophenyl carbamate) Investigative T30082 DRUGINFO D05KZH (5-Bromo-pentyl)-trimethyl-ammonium Investigative T30082 DRUGINFO D05QXU 1,3-Bis-(3-imidazolidin-2-yl-phenyl)-urea Investigative T30082 DRUGINFO D06ACI BZYX Investigative T30082 DRUGINFO D06EJS BIS(12)-HUPERZINE B Investigative T30082 DRUGINFO D06LRC Isosorbide-di-phenylcarbamate Investigative T30082 DRUGINFO D07EMX (1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE Investigative T30082 DRUGINFO D07FFB Carinatumins B (2) Investigative T30082 DRUGINFO D07YQY N-benzylnorlitebamine Investigative T30082 DRUGINFO D08JOR (3-Hydroxy-2-methyl-phenyl)-trimethyl-ammonium Investigative T30082 DRUGINFO D08LBC N-butylnorlitebamine Investigative T30082 DRUGINFO D08PWL N-n-propyl-7-methoxytacrine hydrochloride Investigative T30082 DRUGINFO D08QQR Beta-L-fucose Investigative T30082 DRUGINFO D08TRN (2-Ethoxy-ethyl)-trimethyl-ammonium iodide Investigative T30082 DRUGINFO D08UET Propidium Investigative T30082 DRUGINFO D08WRG 3-(4-o-Tolylpiperazine-1-carbonyl)coumarin Investigative T30082 DRUGINFO D08XPP 9-hydrazino-1,2,3,4-tetrahydroacridine Investigative T30082 DRUGINFO D09DJX (S,S)-(-)-bis(12)-hupyridone Investigative T30082 DRUGINFO D09JAB 3-(2,5-Dioxo-pyrrolidin-1-yl)-benzoic acid Investigative T30082 DRUGINFO D09JZY Cis-2,6-dimethyl-1-methyl sulfonyl piperidine Investigative T30082 DRUGINFO D09NEH 6-Methyl-4-(4-benzoylpiperazin-1-yl)coumarin Investigative T30082 DRUGINFO D09ZGN 2-Hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole Investigative T30082 DRUGINFO D0A0FK Huprine Y Investigative T30082 DRUGINFO D0A6MF MESUAGENIN B Investigative T30082 DRUGINFO D0A9IM (R)-tacrine(10)-hupyridone Investigative T30082 DRUGINFO D0B2JV N-propylnorlitebamine Investigative T30082 DRUGINFO D0C0NS 4ALPHA-(HYDROXYMETHYL)-4ALPHA-DEMETHYLTERRITREM B Investigative T30082 DRUGINFO D0C6QF 2-Hex-5-enyl-5-non-8-enyl-pyrrolidine Investigative T30082 DRUGINFO D0D3TB N-ALLYLNORGALANTHAMINE Investigative T30082 DRUGINFO D0D3TG 5-Hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole Investigative T30082 DRUGINFO D0D4SK 6,8-Dichloro-1,2,3,4-tetrahydro-acridin-9-ylamine Investigative T30082 DRUGINFO D0D5QT 1-(3-Bromomethyl-phenyl)-2,2,2-trifluoro-ethanone Investigative T30082 DRUGINFO D0D9PI Tetraethylene Glycol Investigative T30082 DRUGINFO D0DV9Z 6-methoxy-2,9-dimethyl-9H-beta-carbolin-2-ium Investigative T30082 DRUGINFO D0E0ZV 3-(2-N-Piperidyl-acetamino)-rutaecarpine Investigative T30082 DRUGINFO D0E2LR 3-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1H-indazole Investigative T30082 DRUGINFO D0E3OZ OBIDOXIME Investigative T30082 DRUGINFO D0ER5C 6-hydroxy-2,9-dimethyl-9H-beta-carbolin-2-ium Investigative T30082 DRUGINFO D0FI9G 10-Hydroxy-infractopicrin Investigative T30082 DRUGINFO D0FS3L 4-formylphenyl-O-beta-D-ribopyranoside Investigative T30082 DRUGINFO D0FY2N NPRx-30 Investigative T30082 DRUGINFO D0G2WI CP-126998 Investigative T30082 DRUGINFO D0G5QX TRIMEDOXIME Investigative T30082 DRUGINFO D0GT6I (2-Mercapto-ethyl)-trimethyl-ammonium iodide Investigative T30082 DRUGINFO D0H4DW 9-Ethyl-beta-carboline Investigative T30082 DRUGINFO D0H5XD 3-(3-Carboxy-propionylamino)-benzoic acid Investigative T30082 DRUGINFO D0H7OP N-allylnorlitebamine Investigative T30082 DRUGINFO D0I0EN TURBINATINE Investigative T30082 DRUGINFO D0J3EU (2-Chloro-ethyl)-trimethyl-ammonium chloride Investigative T30082 DRUGINFO D0J9FT 3-[(1s)-1-(Dimethylamino)Ethyl]Phenol Investigative T30082 DRUGINFO D0K8AU 2-morpholino-N-phenethylpyrimidin-4-amine Investigative T30082 DRUGINFO D0L0ZH TASPINE Investigative T30082 DRUGINFO D0L4OW GANSTIGMINE Investigative T30082 DRUGINFO D0L8UL Pseudopalmatine trifluoroacetate Investigative T30082 DRUGINFO D0M1CG Allyl-trimethyl-ammonium Investigative T30082 DRUGINFO D0M5ES CHLORPYRIFOS Investigative T30082 DRUGINFO D0M8SQ Trimethyl-(3-nitro-phenyl)-ammonium iodide Investigative T30082 DRUGINFO D0M9JF Petrosamine Investigative T30082 DRUGINFO D0MB3S 7-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine Investigative T30082 DRUGINFO D0N8EC BIS(8)-HUPERZINE B Investigative T30082 DRUGINFO D0N9DB 9-amino-7H-dibenzo[de,h]quinolin-7-one Investigative T30082 DRUGINFO D0O1JC 2-Hex-5-enyl-5-nonyl-pyrrolidine Investigative T30082 DRUGINFO D0O1QB BW284C51 Investigative T30082 DRUGINFO D0O6AH Trimethyl-(4-oxo-pentyl)-ammonium iodide Investigative T30082 DRUGINFO D0O9OW N-isobutylnorlitebamine Investigative T30082 DRUGINFO D0P5CV BIS(16)-HUPERZINE B Investigative T30082 DRUGINFO D0P5YS TERRITREM B Investigative T30082 DRUGINFO D0P8KQ (4-Iodo-butyl)-trimethyl-ammonium iodide Investigative T30082 DRUGINFO D0PF3Z N-isopropylnorlitebamineN-methoiodide Investigative T30082 DRUGINFO D0Q2DE CHOLINE IODIDE Investigative T30082 DRUGINFO D0R1FR (3R)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine Investigative T30082 DRUGINFO D0R2QC 4-[4-(benzhydryloxy)piperidino]butyl benzoate Investigative T30082 DRUGINFO D0RA5T Pseudocolumbamine trifluoroacetate Investigative T30082 DRUGINFO D0S2DW AP-2238 Investigative T30082 DRUGINFO D0S7HC 3-(4-Phenylpiperazin-1-carbonyl)coumarin Investigative T30082 DRUGINFO D0SE8T (2-Butyryloxy-ethyl)-trimethyl-ammonium iodide Investigative T30082 DRUGINFO D0ST5U Galanthamine derivative Investigative T30082 DRUGINFO D0T4UO (S)-tacrine(10)-hupyridone Investigative T30082 DRUGINFO D0T7ZN Dimethyl-pent-4-enyl-ammonium bromide Investigative T30082 DRUGINFO D0U1SE Hexyl-trimethyl-ammonium Investigative T30082 DRUGINFO D0UF9K BIS(9)-HUPERZINE B Investigative T30082 DRUGINFO D0V0PS 9-Amino-1,2,3,4-tetrahydro-acridine-1,7-diol Investigative T30082 DRUGINFO D0V7EA 3-(4-Benzoylpiperazine-1-carbonyl)coumarin Investigative T30082 DRUGINFO D0VI6N Isosorbide-2-benzylcarbamate-5-tosylate Investigative T30082 DRUGINFO D0W8RP Monoisopropylphosphorylserine Investigative T30082 DRUGINFO D0X4EV 8-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine Investigative T30082 DRUGINFO D0XL1R ETHYLPHENSERINE Investigative T30082 DRUGINFO D0XN8A Infractopicrin Investigative T30082 DRUGINFO D0Y3LO (S,S)-(-)-bis(10)-hupyridone Investigative T30082 DRUGINFO D0Z4OS N-benzyl-2-morpholinopyrimidin-4-amine Investigative T30082 DRUGINFO D0Z6GG N-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine Investigative T30082 DRUGINFO D00FPI 1,4-Di(berberine-9-O-yl)ethane dibromide Investigative T30082 DRUGINFO D00MFR 6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium Investigative T30082 DRUGINFO D00NIX 9-O-[3-(Phenylamino)propyl]-berberine bromide Investigative T30082 DRUGINFO D01AJQ Isosorbide-di-(benzylcarbamate) Investigative T30082 DRUGINFO D01DHW 9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide Investigative T30082 DRUGINFO D01EZC 3-[4-(benzylmethylamino)butoxy]xanthen-9-one Investigative T30082 DRUGINFO D01GWN (24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol Investigative T30082 DRUGINFO D01KVT MEMOQUIN Investigative T30082 DRUGINFO D01OND 3-(dimethylamino)phenyl phenylcarbamate Investigative T30082 DRUGINFO D01QRR Isosorbide-2-benzylcarbamate-5-cyclopentanoate Investigative T30082 DRUGINFO D01TLN 9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide Investigative T30082 DRUGINFO D02AFZ 2-Propyl-beta-carboline-2-ium iodide Investigative T30082 DRUGINFO D02DWE 3,6,9,12,15-Pentaoxaheptadecane Investigative T30082 DRUGINFO D02JXK N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP Investigative T30082 DRUGINFO D02LWX 6-hydroxy-2-methyl-9H-beta-carbolin-2-ium Investigative T30082 DRUGINFO D02QMU 9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide Investigative T30082 DRUGINFO D02WKB 9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide Investigative T30082 DRUGINFO D03DIP 3-(2-Diethylamino-propionamino)-rutaecarpine Investigative T30082 DRUGINFO D04FHZ (-)-Tolserine Investigative T30082 DRUGINFO D04GTP CHF-2819 Investigative T30082 DRUGINFO D04SYM Isosorbide-2-(methylcarbamate)-5-mononitrate Investigative T30082 DRUGINFO D05QNR N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP Investigative T30082 DRUGINFO D05UJV N-n-pentyl-7-methoxytacrine hydrochloride Investigative T30082 DRUGINFO D07VIO 3-(2-Diethylamino-acetamino)-rutaecarpine Investigative T30082 DRUGINFO D07YJG 1,11-bis(pyridinium)-undecane dibromide Investigative T30082 DRUGINFO D09CGV 6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium Investigative T30082 DRUGINFO D09FAU (RS)-tacrine(10)-hupyridone Investigative T30082 DRUGINFO D09GXM 3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one Investigative T30082 DRUGINFO D09JCF Huprine-Tacrine Heterodimer Investigative T30082 DRUGINFO D09MCN Haloxysterol D Investigative T30082 DRUGINFO D09QDC Iso-OMPA Investigative T30082 DRUGINFO D09RJH Huprine X Investigative T30082 DRUGINFO D09XSI 9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide Investigative T30082 DRUGINFO D0A2BE CLEBOPRIDE Investigative T30082 DRUGINFO D0A8OX N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP Investigative T30082 DRUGINFO D0B4DT 3-[8-(benzylmethylamino)octyloxy]xanthen-9-one Investigative T30082 DRUGINFO D0C0XU N-n-heptyl-7-methoxytacrine hydrochloride Investigative T30082 DRUGINFO D0C3IS 3-(2-N-Piperidyl-propionamino)-rutaecarpine Investigative T30082 DRUGINFO D0E0LL Haloxysterol C Investigative T30082 DRUGINFO D0E4BT N-benzyl-2-thiomorpholinopyrimidin-4-amine Investigative T30082 DRUGINFO D0EX1R N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP Investigative T30082 DRUGINFO D0F0PY N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP Investigative T30082 DRUGINFO D0F5EJ LIPOCRINE Investigative T30082 DRUGINFO D0F6VM 3-(2-N-Pyrrolyl-propionamino)-rutaecarpine Investigative T30082 DRUGINFO D0G0GZ N-Methyl-1'H-phenothiazine-1'-carboxamide Investigative T30082 DRUGINFO D0G5SM HALOXYSTEROL A Investigative T30082 DRUGINFO D0G5TL 6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium Investigative T30082 DRUGINFO D0H2UG N-n-nonyl-7-methoxytacrine hydrochloride Investigative T30082 DRUGINFO D0H3BC 3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one Investigative T30082 DRUGINFO D0I3UA 7-Oxo-7H-dibenzo[de,g]quinoline Investigative T30082 DRUGINFO D0J4LR 24-ethyl-cholest-7-ene-3,5,6-triol Investigative T30082 DRUGINFO D0J4QH Methyl Phosphinic Acid Investigative T30082 DRUGINFO D0K2FQ 1,2-Di(berberine-9-O-yl)ethane dibromide Investigative T30082 DRUGINFO D0K6GY Ethyl octylfluorophosphonate Investigative T30082 DRUGINFO D0K8BT Isosorbide-2-(methylcarbamate)-5-benzoate Investigative T30082 DRUGINFO D0L3IS 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE Investigative T30082 DRUGINFO D0L5QJ 1,9-bis(pyridinium)-nonane dibromide Investigative T30082 DRUGINFO D0L9YJ 3-[3-(benzylmethylamino)propoxy]xanthen-9-one Investigative T30082 DRUGINFO D0LT0T 3-(2-N-Pyrrolyl-acetamino)-rutaecarpine Investigative T30082 DRUGINFO D0M0BM 6-chlorotacrine hydrochloride Investigative T30082 DRUGINFO D0M2EM BENZOQUINONE Investigative T30082 DRUGINFO D0MC3U N,N'-(1',10'-decylene)-bis-(-)-nor-MEP Investigative T30082 DRUGINFO D0MV0T 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine Investigative T30082 DRUGINFO D0NJ5W CAPROCTAMINE Investigative T30082 DRUGINFO D0O2OH 4-ISOPROPYLPHENSERINE Investigative T30082 DRUGINFO D0O8AQ Isosorbide-di-(ethylcarbamate) Investigative T30082 DRUGINFO D0O8DZ 3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one Investigative T30082 DRUGINFO D0O9YQ N-n-hexyl-7-methoxytacrine hydrochloride Investigative T30082 DRUGINFO D0P2VL 9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide Investigative T30082 DRUGINFO D0P5BT 1,3-Di(berberine-9-O-yl)ethane dibromide Investigative T30082 DRUGINFO D0P6PQ THIOCTIC ACID Investigative T30082 DRUGINFO D0PF7F TOLSERINE Investigative T30082 DRUGINFO D0Q3EV N-n-octyl-7-methoxytacrine hydrochloride Investigative T30082 DRUGINFO D0S1MC AP-2243 Investigative T30082 DRUGINFO D0T5MD Isosorbide-2-benzylcarbamate-5-cyclopropanoate Investigative T30082 DRUGINFO D0V3LC 24-ethylcholest-6-ene-3,5-diol Investigative T30082 DRUGINFO D0W7XL 9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide Investigative T30082 DRUGINFO D0W8NK 9-Ethyl-2-methyl-beta-carboline-2-ium iodide Investigative T30082 DRUGINFO D0X3FF HALOXYSTEROL B Investigative T30082 DRUGINFO D0X4HG XANTHOSTIGMINE Investigative T30082 DRUGINFO D0XI4U 6-methoxy-2-methyl-9H-beta-carbolin-2-ium Investigative T30082 DRUGINFO D0Y0VQ N,N'-(1',8'-octylene)-bis-(-)-nor-MEP Investigative T30082 DRUGINFO D0Y7UG N,N'-(1',6-hexylene)-bis-(-)-nor-MEP Investigative T30082 DRUGINFO D0Z6RT LAWSARITOL Investigative T30082 DRUGINFO D0Z6WU 1,10-bis(pyridinium)-decane dibromide Investigative T30082 DRUGINFO D0ZI7F 6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole Investigative T30082 DRUGINFO D0ZL9I 9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide Investigative T30082 DRUGINFO D0ZY4C N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine Investigative T30082 DRUGINFO D06IEN 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose Investigative T30082 DRUGINFO D0D0BI CHLORANIL Investigative T30082 DRUGINFO D0F5VY NSC-23180 Investigative T30082 DRUGINFO D0HQ4M Isopropyl dodecylfluorophosphonate Investigative T30082 DRUGINFO D0M4IE Bis-7-tacrine Investigative T30082 DRUGINFO D0N0HK 3,4,5,6-Tetrachloro-[1,2]benzoquinone Investigative T30082 DRUGINFO D0W6PT Chlorphrifos oxon Investigative T30082 DRUGINFO D0WX6R 5,6-dinitroacenaphthoquinone Investigative T30082 DRUGINFO D0W9VA 1,2-NAPHTHOQUINONE Investigative T30082 DRUGINFO D08XQI PARAOXON Investigative T30082 DRUGINFO D07KZA 2-(N-Morpholino)-Ethanesulfonic Acid Investigative T30082 DRUGINFO D0G6XS Fucose Investigative T30082 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T53378 TARGETID T53378 T53378 FORMERID TTDR00209 T53378 UNIPROID CAH4_HUMAN T53378 TARGNAME Carbonic anhydrase IV (CA-IV) T53378 GENENAME CA4 T53378 TARGTYPE Successful T53378 SYNONYMS Carbonic anhydrase 4; Carbonate dehydratase IV; CAIV T53378 FUNCTION May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid. Reversible hydration of carbon dioxide. T53378 PDBSTRUC 5KU6; 5JNC; 5JNA; 5JN9; 5JN8 T53378 BIOCLASS Alpha-carbonic anhydrase T53378 ECNUMBER EC 4.2.1.1 T53378 SEQUENCE MRMLLALLALSAARPSASAESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTKAKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSDLPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGFQPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFREPIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKSGAPGRPLPWALPALLGPMLACLLAGFLR T53378 DRUGINFO D01MUR Brinzolamide Approved T53378 DRUGINFO D0K1QD Sulfamylon Approved T53378 DRUGINFO D07HBX Salicyclic acid Approved T53378 DRUGINFO D0A8JP PARABEN Phase 3 T53378 DRUGINFO D07SDQ Curcumin Phase 3 T53378 DRUGINFO D0L6HN PHENOL Phase 2/3 T53378 DRUGINFO D0Y6OA Coumate Phase 2 T53378 DRUGINFO D02ECG Sodium pyruvate Phase 1/2 T53378 DRUGINFO D0V0UK SULFAMIDE Phase 1 T53378 DRUGINFO D03SLR FERULIC ACID Patented T53378 DRUGINFO D0LD9S SPERMINE Terminated T53378 DRUGINFO D01DOW Trisodium phosphate Investigative T53378 DRUGINFO D01ENA [Fe(CN)6]4- Investigative T53378 DRUGINFO D03MXZ Malonate sodium Investigative T53378 DRUGINFO D04HQK N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-benzamide Investigative T53378 DRUGINFO D05KTE SODIUM CITRATE Investigative T53378 DRUGINFO D0EX9Q 2-Propyl-pentanoic acid 4-sulfamoyl-benzyl ester Investigative T53378 DRUGINFO D0GQ9A Sodium phenylarsonate Investigative T53378 DRUGINFO D0H0PQ Aminocarbonyl dihydrogen phosphate Investigative T53378 DRUGINFO D0H7JJ Sodium sulfamate Investigative T53378 DRUGINFO D0Q4VO SODIUM PHOSPHATE, DIBASIC, ANHYDROUS Investigative T53378 DRUGINFO D0R3DQ SYL-040003 Investigative T53378 DRUGINFO D0S1OY 2-Propyl-pentanoic acid 4-sulfamoyl-benzylamide Investigative T53378 DRUGINFO D00CIW Phenyl-phosphonic acid Investigative T53378 DRUGINFO D0L2GD [Cu(CN)2]- Investigative T53378 DRUGINFO D0M6RM Phenylarsonic acid Investigative T53378 DRUGINFO D0Y6EL Carbamoyl phosphate disodium Investigative T53378 DRUGINFO D00BMI N-1,3,4-thiadiazol-2-ylsulfamide Investigative T53378 DRUGINFO D03EAQ N-hydroxysulfonamides Investigative T53378 DRUGINFO D0D5XC Sodium trithiocarbonate Investigative T53378 DRUGINFO D04PSK N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide Investigative T53378 DRUGINFO D06JVR N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T53378 DRUGINFO D07QJJ CATECHOL Investigative T53378 DRUGINFO D09UQM 1-(3,4-dichlorophenyl)-3-hydroxyurea Investigative T53378 DRUGINFO D0E3VJ N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide Investigative T53378 DRUGINFO D0L6CN N-(phosphonacetyl)-L-aspartate Investigative T53378 DRUGINFO D0S4NO N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T53378 DRUGINFO D0S8RD Trecadrine Investigative T53378 DRUGINFO D0T2VH N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T53378 DRUGINFO D00RNZ 7-(benzyloxy)-2H-chromen-2-one Investigative T53378 DRUGINFO D03VDJ SULFAMATE Investigative T53378 DRUGINFO D07TAJ Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate Investigative T53378 DRUGINFO D0EJ9B Phenyl Boronic acid Investigative T53378 DRUGINFO D0H3NS 2-oxo-2H-chromene-3-carboxylic acid Investigative T53378 DRUGINFO D0J2AE 3-Amino-benzenesulfonamide Investigative T53378 DRUGINFO D0X5HL N1-(naphthalen-1-yl)ethane-1,2-diamine Investigative T53378 DRUGINFO D04NSN 4-(2-AMINOETHYL)BENZENESULFONAMIDE Investigative T53378 DRUGINFO D09JPC Hexane-1,6-diamine Investigative T53378 DRUGINFO D0G3BI 6-methyl-2-oxo-2H-chromene-3-carboxylic acid Investigative T53378 DRUGINFO D0L5TZ 6-(hydroxymethyl)-2H-chromen-2-one Investigative T53378 DRUGINFO D0U4BB HERNIARIN Investigative T53378 DRUGINFO D00YEF Decane-1,10-diyl disulfamate Investigative T53378 DRUGINFO D01STY 4-Amino-3-iodo-benzenesulfonamide Investigative T53378 DRUGINFO D02QGI Pentane-1,5-diamine Investigative T53378 DRUGINFO D03ZMQ COUMARIN Investigative T53378 DRUGINFO D04CVC 4-Amino-3-fluoro-benzenesulfonamide Investigative T53378 DRUGINFO D05TLB Octyl sulfamate Investigative T53378 DRUGINFO D09WSJ Decyl sulfamate Investigative T53378 DRUGINFO D0AU0M P-Coumaric Acid Investigative T53378 DRUGINFO D0D4OV Octane-1,8-diyl disulfamate Investigative T53378 DRUGINFO D0E8CC BENZOLAMIDE Investigative T53378 DRUGINFO D0M3PO 2,4-Disulfamyltrifluoromethylaniline Investigative T53378 DRUGINFO D0N1AW 6-(aminomethyl)-2H-chromen-2-one Investigative T53378 DRUGINFO D0NN3Q 4-Hydrazino-benzenesulfonamide Investigative T53378 DRUGINFO D0P6AM 4-Amino-3-bromo-benzenesulfonamide Investigative T53378 DRUGINFO D0Q7DJ Syringic Acid Investigative T53378 DRUGINFO D0VD7H CL-5343 Investigative T53378 DRUGINFO D0YU8J 4-Amino-3-chloro-benzenesulfonamide Investigative T53378 DRUGINFO D0V7AA CATECHIN Investigative T53378 DRUGINFO D0Y3TZ GALLICACID Investigative T53378 DRUGINFO D0A1CM ELLAGIC ACID Investigative T80975 TARGETID T80975 T80975 FORMERID TTDS00008 T80975 UNIPROID VGFR2_HUMAN T80975 TARGNAME Vascular endothelial growth factor receptor 2 (KDR) T80975 GENENAME KDR T80975 TARGTYPE Successful T80975 SYNONYMS VEGFR2; VEGFR-2; VEGF-2 receptor; Protein-tyrosine kinase receptor flk-1; Kinase insert domain receptor; Fetal liver kinase 1; FLK1; FLK-1; CD309 T80975 FUNCTION Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. T80975 PDBSTRUC 6GQQ; 6GQP; 6GQO; 5OYJ; 5EW3 T80975 BIOCLASS Kinase T80975 ECNUMBER EC 2.7.10.1 T80975 SEQUENCE MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWLLLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPLGRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVNLLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLKRRLDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLASRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTMLDCWHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVSCMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDSGMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYSSEEAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV T80975 DRUGINFO D01ZRI Axitinib Approved T80975 DRUGINFO D09HVD Ramucirumab Approved T80975 DRUGINFO D0R0FO Lenvatinib Approved T80975 DRUGINFO D0R0MW Sunitinib Approved T80975 DRUGINFO D0SZ6E YN-968D1 Approved T80975 DRUGINFO D0IQ6P Cabozantinib Approved T80975 DRUGINFO D09GDD Regorafenib Approved T80975 DRUGINFO D0F0ZY Pazopanib HCl Approved T80975 DRUGINFO D0G6QF Vandetanib Approved T80975 DRUGINFO D0W7JZ Tivozanib Approved T80975 DRUGINFO D0W5HK Sorafenib Approved T80975 DRUGINFO D01PZD Romiplostim Approved T80975 DRUGINFO D09VMI Cediranib Phase 3 T80975 DRUGINFO D0D7BX Rivoceranib Phase 3 T80975 DRUGINFO D0HS5V Brivanib Phase 3 T80975 DRUGINFO D0Q9CY HKI-272 Phase 3 T80975 DRUGINFO D05PWX Sulfatinib Phase 3 T80975 DRUGINFO D0A1AQ Rosiglitazone + metformin Phase 3 T80975 DRUGINFO D02WVT E-3810 Phase 3 T80975 DRUGINFO D05BLN MGCD516 Phase 2/3 T80975 DRUGINFO D00YPR CP-547632 Phase 2 T80975 DRUGINFO D03AND RAF265 Phase 2 T80975 DRUGINFO D09LOZ TTAC-0001 Phase 2 T80975 DRUGINFO D0HN7I Alacizumab pegol Phase 2 T80975 DRUGINFO D0ZN1R Delphinidin Phase 2 T80975 DRUGINFO DN3Z5D L-DOS47 Phase 2 T80975 DRUGINFO D0D1GF XL880 Phase 2 T80975 DRUGINFO D07NOI BAY-57-9352 Phase 2 T80975 DRUGINFO D0P6DJ VATALANIB Phase 2 T80975 DRUGINFO D0R6UV BMS-690514 Phase 2 T80975 DRUGINFO D0Z6MT Famitinib Phase 2 T80975 DRUGINFO D0Q0HZ Elpamotide Phase 1/2 T80975 DRUGINFO D04NOE OTSGC-A24 Phase 1/2 T80975 DRUGINFO D0U6BQ Anti-VEGFR2 CD8 cell therapy Phase 1/2 T80975 DRUGINFO D00DRL MK-2461 Phase 1/2 T80975 DRUGINFO D07HRU KRN633 Phase 1 T80975 DRUGINFO D07PNT XL999 Phase 1 T80975 DRUGINFO D0GM6E Pegdinetanib Phase 1 T80975 DRUGINFO D0L9PU A168 Phase 1 T80975 DRUGINFO D0ZI5A PF-00337210 Phase 1 T80975 DRUGINFO D09ETH E-7050 Phase 1 T80975 DRUGINFO D0F5JZ PLX-4720 Phase 1 T80975 DRUGINFO D0N8RV OSI-930 Phase 1 T80975 DRUGINFO D0T2ER TAK-593 Phase 1 T80975 DRUGINFO D0CY1B CYC116 Phase 1 T80975 DRUGINFO D0FD6D CEP-11981 Phase 1 T80975 DRUGINFO D0FA6S Altiratinib Phase 1 T80975 DRUGINFO D01AXK Antibodie derivative 10 Patented T80975 DRUGINFO D06BTN Pyrimidine derivative 14 Patented T80975 DRUGINFO D06HEO Pyrimidine derivative 4 Patented T80975 DRUGINFO D08OXH Quinoline and quinazoline derivative 1 Patented T80975 DRUGINFO D08XAY Antibodie derivative 6 Patented T80975 DRUGINFO D0G1YI Pyrimidine derivative 13 Patented T80975 DRUGINFO D0JU8E Pyrimidine derivative 12 Patented T80975 DRUGINFO D05PRG Quinazoline derivative 15 Patented T80975 DRUGINFO D0DV4X Quinazoline derivative 16 Patented T80975 DRUGINFO D0AK1F Pyridine derivative 18 Patented T80975 DRUGINFO D00DQX Motesanib Discontinued in Phase 3 T80975 DRUGINFO D09DJU SU-14813 Discontinued in Phase 2 T80975 DRUGINFO D0E8VF IMC-1C11 Discontinued in Phase 1 T80975 DRUGINFO D0H4GI CEP-5214 Terminated T80975 DRUGINFO D06GBK AG1295 Terminated T80975 DRUGINFO D00GVV Indolin-2-one deriv. 4b Investigative T80975 DRUGINFO D00MCJ 6-(1H-Benzoimidazol-2-yl)-benzocyclohepten-7-one Investigative T80975 DRUGINFO D00YWZ 3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine Investigative T80975 DRUGINFO D01LEV 3-((3-bromothiophen-2-yl)methylene)indolin-2-one Investigative T80975 DRUGINFO D02AOT Isoindolinone Urea derivative Investigative T80975 DRUGINFO D04RQU 8-methyl-4H,7H-indolo[6,5,4-cd]indol-5-one Investigative T80975 DRUGINFO D05GMB BIBF-1202 Investigative T80975 DRUGINFO D07OIZ R-84 Investigative T80975 DRUGINFO D07OSK VEGF receptor 2 kinase inhibitor I Investigative T80975 DRUGINFO D07SRX AG-E-85378 Investigative T80975 DRUGINFO D08JSJ 4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide Investigative T80975 DRUGINFO D09AKX 4-(4-m-Tolylamino-phthalazin-1-yl)-benzamide Investigative T80975 DRUGINFO D09LKM Pyrazolo[1,5-a]pyrimidine 3G Investigative T80975 DRUGINFO D09TQP 3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole Investigative T80975 DRUGINFO D0A9ZQ (3-Phenoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine Investigative T80975 DRUGINFO D0AK4H AMG-429 Investigative T80975 DRUGINFO D0E3HC L000021649 Investigative T80975 DRUGINFO D0F0AU 3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide Investigative T80975 DRUGINFO D0J3OZ 2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile Investigative T80975 DRUGINFO D0Q4EQ JNJ-38158471 Investigative T80975 DRUGINFO D0R3IK EPI-0030 Investigative T80975 DRUGINFO D0ST4P IM-023911 Investigative T80975 DRUGINFO D0U3ZP 5-(4-Methoxy-phenyl)-1-phenyl-1H-benzoimidazole Investigative T80975 DRUGINFO D0UX3T 3-(5-Thiophen-3-yl-pyridin-3-yl)-1H-indole Investigative T80975 DRUGINFO D02RWK K-252a analogue Investigative T80975 DRUGINFO D03HTT 4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine Investigative T80975 DRUGINFO D06BVH 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile Investigative T80975 DRUGINFO D0A9ZP IM-094882 Investigative T80975 DRUGINFO D0D3QA 4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine Investigative T80975 DRUGINFO D0E9DI 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile Investigative T80975 DRUGINFO D0KH5T 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline Investigative T80975 DRUGINFO D0M9OF 3-(1H-Indol-2-yl)-1H-quinolin-2-one Investigative T80975 DRUGINFO D0Z7TM BMS-645737 Investigative T80975 DRUGINFO D0Z8TR IM-094261 Investigative T80975 DRUGINFO D03HQK 2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile Investigative T80975 DRUGINFO D05THI 4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide Investigative T80975 DRUGINFO D06GJO (2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine Investigative T80975 DRUGINFO D07AIB (4-Phenoxy-phenyl)-quinazolin-4-yl-amine Investigative T80975 DRUGINFO D07QMC 3-Benzimidazol-2-ylhydroquinolin-2-one Investigative T80975 DRUGINFO D07XBW N-(2,4-Dichloro-benzoyl)-benzenesulfonamide Investigative T80975 DRUGINFO D09LEK 4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide Investigative T80975 DRUGINFO D09MSA 4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide Investigative T80975 DRUGINFO D0BM4F Phenyl-(5-phenyl-oxazol-2-yl)-amine Investigative T80975 DRUGINFO D0C6KI CB-676475 Investigative T80975 DRUGINFO D0C6OD 4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide Investigative T80975 DRUGINFO D0D3YL (5-Phenyl-oxazol-2-yl)-m-tolyl-amine Investigative T80975 DRUGINFO D0J2XD 3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile Investigative T80975 DRUGINFO D0M2QA N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide Investigative T80975 DRUGINFO D0UZ5W 4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide Investigative T80975 DRUGINFO D0V4BR 4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide Investigative T80975 DRUGINFO D0V9DQ [3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol Investigative T80975 DRUGINFO D0Y9GK 4-(4-aminophenyl)-1H-indazol-3yl-amine Investigative T80975 DRUGINFO D0YN1E 3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine Investigative T80975 DRUGINFO D08BJR Ki-20227 Investigative T80975 DRUGINFO D09HXU 6-o-tolylquinazolin-2-amine Investigative T80975 DRUGINFO D09LPL SU-11652 Investigative T80975 DRUGINFO D0EE6A AAL-993 Investigative T80975 DRUGINFO D0N7AJ AST-487 Investigative T80975 DRUGINFO D0XC6G 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole Investigative T80975 DRUGINFO D0IX7Y BX-912 Investigative T80975 DRUGINFO D0PP6Y PMID23639540C13a Investigative T80975 DRUGINFO D0RG0Z BX-795 Investigative T80975 DRUGINFO D09QBA CEP-5104 Investigative T80975 DRUGINFO D0H1OK TG-100435 Investigative T80975 DRUGINFO D03EHM PP121 Investigative T80975 DRUGINFO D0C2GE PMID22765894C8h Investigative T80975 DRUGINFO D09XIL Ro-4396686 Investigative T80975 DRUGINFO D0M4SY BMS-536924 Investigative T80975 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T80975 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T80975 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T74312 TARGETID T74312 T74312 FORMERID TTDS00090 T74312 UNIPROID FLT3_HUMAN T74312 TARGNAME Fms-like tyrosine kinase 3 (FLT-3) T74312 GENENAME FLT3 T74312 TARGTYPE Successful T74312 SYNONYMS Stem cell tyrosine kinase 1; STK1; STK-1; Receptor-type tyrosine-protein kinase FLT3; Fetal liver kinase-2; FLT-3; FLK2; FLK-2; FL cytokine receptor; CD135 T74312 FUNCTION Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways. T74312 PDBSTRUC 6IL3; 5X02; 4XUF; 4RT7; 3QS9 T74312 BIOCLASS Kinase T74312 ECNUMBER EC 2.7.10.1 T74312 SEQUENCE MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESPEDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDLQNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQDALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRECTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEMSTYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYEIDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHAENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITEGVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQDNISFYATIGVCLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKADSSEREALMSELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLLNYLRSKREKFHRTWTEIFKEHNFSFYPTFQSHPNSSMPGSREVQIHPDSDQISGLHGNSFHSEDEIEYENQKRLEEEEDLNVLTFEDLLCFAYQVAKGMEFLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDSNYVVRGNARLPVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYKLIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADAEEAMYQNVDGRVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS T74312 DRUGINFO D07KYT Quizartinib Approved T74312 DRUGINFO D0V9WF Lestaurtinib Approved (orphan drug) T74312 DRUGINFO D01XYJ Zidovudine Approved T74312 DRUGINFO D04KZY Gilteritinib Approved T74312 DRUGINFO D07NVU Midostaurin Approved T74312 DRUGINFO D0PN8H Pacritinib Approved T74312 DRUGINFO D09TAB Pexidartinib Approved T74312 DRUGINFO D09HNV Intedanib Approved T74312 DRUGINFO D0H0EQ Ponatinib Approved T74312 DRUGINFO D0Q8CV CDX-301 Phase 2 T74312 DRUGINFO D06KTJ TAK-659 Phase 2 T74312 DRUGINFO D0R6UV BMS-690514 Phase 2 T74312 DRUGINFO D0Z6MT Famitinib Phase 2 T74312 DRUGINFO D28HJI FF-10101 Phase 1/2 T74312 DRUGINFO D0V2ZC SEL24 Phase 1/2 T74312 DRUGINFO D0X8ID SEL-24 Phase 1/2 T74312 DRUGINFO DI1VM3 HM43239 Phase 1/2 T74312 DRUGINFO D00DRL MK-2461 Phase 1/2 T74312 DRUGINFO D07UUB 4SC-203 Phase 1 T74312 DRUGINFO D07ZNF IMC-EB10 Phase 1 T74312 DRUGINFO D0D1HS Ki23819 Phase 1 T74312 DRUGINFO D0YQ9I FF-10101-01 Phase 1 T74312 DRUGINFO DIA08F SKI-G-801 Phase 1 T74312 DRUGINFO D10LNV MRX-2843 Phase 1 T74312 DRUGINFO D91CMX AMG 427 Phase 1 T74312 DRUGINFO D00ABO KW-2449 Phase 1 T74312 DRUGINFO DKCU40 FN-1501 Phase 1 T74312 DRUGINFO D0MX7B Carboxamide derivative 4 Patented T74312 DRUGINFO D0AK1F Pyridine derivative 18 Patented T74312 DRUGINFO D0IT6Q Tandutinib Discontinued in Phase 2 T74312 DRUGINFO D04GFO MC-2001 Preclinical T74312 DRUGINFO D01MIP SU5614 Terminated T74312 DRUGINFO D06GBK AG1295 Terminated T74312 DRUGINFO D0D0TQ AKN-028 Investigative T74312 DRUGINFO D0X1JO IN1479 Investigative T74312 DRUGINFO D0X6KS N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide Investigative T74312 DRUGINFO D0X7JK TCS-359 Investigative T74312 DRUGINFO D0ZO8Z 2-(3,4-dimethoxybenzamido)thiophene-3-carboxamide Investigative T74312 DRUGINFO D02OBA Bis(5-hydroxybenzo[b]furan-2-yl)methanone Investigative T74312 DRUGINFO D03VAA Bis(6-hydroxybenzo[b]furan-2-yl)methanone Investigative T74312 DRUGINFO D07AXL Bis(5-aminobenzo[b]furan-2-yl)methanone Investigative T74312 DRUGINFO D0I7QX (benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone Investigative T74312 DRUGINFO D0L0MZ Bis(5-acetoxybenzo[b]furan-2-yl)methanone Investigative T74312 DRUGINFO D0N3XP G749 Investigative T74312 DRUGINFO D0Z3DW Bis(benzo[b]furan-2-yl)methanone Investigative T74312 DRUGINFO D09OLH (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone Investigative T74312 DRUGINFO D0D7ZL (1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone Investigative T74312 DRUGINFO D0G0KQ (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone Investigative T74312 DRUGINFO D0G5YI Di(1H-indol-2-yl)methanone Investigative T74312 DRUGINFO D0H7MF (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone Investigative T74312 DRUGINFO D0XS9E (5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone Investigative T74312 DRUGINFO D0Y9GK 4-(4-aminophenyl)-1H-indazol-3yl-amine Investigative T74312 DRUGINFO D0N7AJ AST-487 Investigative T74312 DRUGINFO D0UN9O GTP-14564 Investigative T74312 DRUGINFO D06UKS PMID21982499C14k Investigative T74312 DRUGINFO D0I3XZ Bis-(5-hydroxy-1H-indol-2-yl)-methanone Investigative T74312 DRUGINFO D0Y4BL JNJ-28312141 Investigative T74312 DRUGINFO D07ADX URMC-099 Investigative T74312 DRUGINFO D0E7VO PMID24900538C2c Investigative T74312 DRUGINFO D0C2GE PMID22765894C8h Investigative T75243 TARGETID T75243 T75243 FORMERID TTDS00265 T75243 UNIPROID MTOR_HUMAN T75243 TARGNAME Serine/threonine-protein kinase mTOR (mTOR) T75243 GENENAME MTOR T75243 TARGTYPE Successful T75243 SYNONYMS Target of rapamycin; TOR kinase; Rapamycin target protein 1; Rapamycin target protein; Rapamycin and FKBP12 target 1; RAPT1; RAFT1; Mechanistic target of rapamycin; Mammalian target of rapamycin; FRAP2; FRAP1; FRAP; FKBP12-rapamycin complex-associated protein; FKBP-rapamycin associated protein; FK506-binding protein 12-rapamycin complex-associated protein 1 T75243 FUNCTION MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4. Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex. Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor. In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1. To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A. mTORC1 also negatively regulates autophagy through phosphorylation of ULK1. Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1. Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP. Also prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich conditions. mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor. Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules. As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton. Plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1. mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B. mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422'. Regulates osteoclastogenesis by adjusting the expression of CEBPB isoforms. Plays an important regulatory role in the circadian clock function; regulates period length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and liver clocks. Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. T75243 PDBSTRUC 6BCX; 6BCU; 5ZCS; 5WBY; 5WBU T75243 BIOCLASS Kinase T75243 ECNUMBER EC 2.7.11.1 T75243 SEQUENCE MLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFW T75243 DRUGINFO D03FCF Novolimus Approved T75243 DRUGINFO D0ES1Q Temsirolimus Approved T75243 DRUGINFO D0K3QS Everolimus Approved T75243 DRUGINFO D0V7WS Zotarolimus Approved T75243 DRUGINFO D03LJR Sirolimus Approved T75243 DRUGINFO D0S5LO PF-04449913 Approved T75243 DRUGINFO D0O3CV Ridaforolimus Phase 3 T75243 DRUGINFO D03DPZ INK128 Phase 2 T75243 DRUGINFO D0H7XL OSI-027 Phase 2 T75243 DRUGINFO D0W3UV ABI-009 Phase 2 T75243 DRUGINFO D00KTV Salirasib Phase 2 T75243 DRUGINFO D01PGR SAR245409 Phase 2 T75243 DRUGINFO D03NJY SF1126 Phase 2 T75243 DRUGINFO D0D8JB PF-05212384 Phase 2 T75243 DRUGINFO D0H1WC LY3023414 Phase 2 T75243 DRUGINFO D0N5JZ PF-04691502 Phase 2 T75243 DRUGINFO D0O6VZ GDC-0980/RG7422 Phase 2 T75243 DRUGINFO D0VG0D BEZ235 Phase 2 T75243 DRUGINFO D00BUO MM-141 Phase 2 T75243 DRUGINFO D0TU7B PQR309 Phase 2 T75243 DRUGINFO D0Z2UQ AZD2014 Phase 2 T75243 DRUGINFO D05EXN CC-223 Phase 1/2 T75243 DRUGINFO D0X7IN BGT226 Phase 1/2 T75243 DRUGINFO D03IXK ME-344 Phase 1/2 T75243 DRUGINFO D08PSC BI 860585 Phase 1 T75243 DRUGINFO D0QN5M LAM-001 Phase 1 T75243 DRUGINFO D0R9VX DS-3078 Phase 1 T75243 DRUGINFO D0U8QH GDC-0349 Phase 1 T75243 DRUGINFO D1RLY2 CERC 006 Phase 1 T75243 DRUGINFO D0X4RT DS-7423 Phase 1 T75243 DRUGINFO D0Y0FE PWT-33597 Phase 1 T75243 DRUGINFO D0U3DP VS-5584 Phase 1 T75243 DRUGINFO D07TVO PMID25726713-Compound-49 Patented T75243 DRUGINFO D0KH7Q PMID25726713-Compound-51 Patented T75243 DRUGINFO D0WJ3W PMID25726713-Compound-48 Patented T75243 DRUGINFO D0X5VI PMID25726713-Compound-47 Patented T75243 DRUGINFO D0Y8JF PMID25726713-Compound-50 Patented T75243 DRUGINFO D0K1VK AZD8055 Discontinued in Phase 1/2 T75243 DRUGINFO D0H5MX TAFA-93 Discontinued in Phase 1 T75243 DRUGINFO D05SXC SCR-44001 Terminated T75243 DRUGINFO D00GQM (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol Investigative T75243 DRUGINFO D01AQN Rapamycin complexed with immunophilin FKBP12 Investigative T75243 DRUGINFO D02TCF C-16-(S)-3-methylindolerapamycin Investigative T75243 DRUGINFO D03XRZ PF-05094037 Investigative T75243 DRUGINFO D05SOW SX-MTR1 Investigative T75243 DRUGINFO D07JKB 2-(6-morpholino-9H-purin-2-yl)phenol Investigative T75243 DRUGINFO D07NFT P-2281 Investigative T75243 DRUGINFO D08BTX X-387 Investigative T75243 DRUGINFO D09FBN 4-(6-morpholino-9H-purin-2-yl)phenol Investigative T75243 DRUGINFO D09VHS EM-101 Investigative T75243 DRUGINFO D0A8ES EC-0845 Investigative T75243 DRUGINFO D0AH8Q 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine Investigative T75243 DRUGINFO D0E1YN SB-2280 Investigative T75243 DRUGINFO D0F1SI 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine Investigative T75243 DRUGINFO D0H0HR torin 1 Investigative T75243 DRUGINFO D0H4KF EC-0565 Investigative T75243 DRUGINFO D0J9PK OXA-01 Investigative T75243 DRUGINFO D0N9TK AR-mTOR-26 Investigative T75243 DRUGINFO D0P0UV 2-chloro-N-(6-cyanopyridin-3-yl)propanamide Investigative T75243 DRUGINFO D0TC5H 3-(6-morpholino-9H-purin-2-yl)phenol Investigative T75243 DRUGINFO D0U8GR AP-21967 Investigative T75243 DRUGINFO D0Y1DR 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine Investigative T75243 DRUGINFO D2B7WM Torin2 Investigative T75243 DRUGINFO D02ELN HM-5016699 Investigative T75243 DRUGINFO D05RSS PF-03772304 Investigative T75243 DRUGINFO D0H2CM PP-242 Investigative T75243 DRUGINFO D0JD4S CU-906 Investigative T75243 DRUGINFO D0QE9F P-6915 Investigative T75243 DRUGINFO D0T0BY 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one Investigative T75243 DRUGINFO D0X7TB 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one Investigative T75243 DRUGINFO D0W1ST Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate Investigative T75243 DRUGINFO D03EHM PP121 Investigative T25005 TARGETID T25005 T25005 FORMERID TTDR00233 T25005 UNIPROID BTK_HUMAN T25005 TARGNAME Tyrosine-protein kinase BTK (ATK) T25005 GENENAME BTK T25005 TARGTYPE Successful T25005 SYNONYMS Bruton's tyrosine kinase; Bruton tyrosine kinase; BPK; B-cell progenitor kinase; B cell progenitor kinase; Agammaglobulinemia tyrosine kinase; Agammaglobulinaemia tyrosine kinase; AGMX1 T25005 FUNCTION Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members. PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK. BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways. Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway. The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense. Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells. Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation. BTK plays also a critical role in transcription regulation. Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes. BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR. GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression. ARID3A and NFAT are other transcriptional target of BTK. BTK is required for the formation of functional ARID3A DNA-binding complexes. There is however no evidence that BTK itself binds directly to DNA. BTK has a dual role in the regulation of apoptosis. Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. T25005 PDBSTRUC 6O8I; 6NFI; 6NFH; 6N9P; 6HRT T25005 BIOCLASS Kinase T25005 ECNUMBER EC 2.7.10.2 T25005 SEQUENCE MAAVILESIFLKRSQQKKKTSPLNFKKRLFLLTVHKLSYYEYDFERGRRGSKKGSIDVEKITCVETVVPEKNPPPERQIPRRGEESSEMEQISIIERFPYPFQVVYDEGPLYVFSPTEELRKRWIHQLKNVIRYNSDLVQKYHPCFWIDGQYLCCSQTAKNAMGCQILENRNGSLKPGSSHRKTKKPLPPTPEEDQILKKPLPPEPAAAPVSTSELKKVVALYDYMPMNANDLQLRKGDEYFILEESNLPWWRARDKNGQEGYIPSNYVTEAEDSIEMYEWYSKHMTRSQAEQLLKQEGKEGGFIVRDSSKAGKYTVSVFAKSTGDPQGVIRHYVVCSTPQSQYYLAEKHLFSTIPELINYHQHNSAGLISRLKYPVSQQNKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES T25005 DRUGINFO D09KTS Ibrutinib Approved T25005 DRUGINFO D09PQZ Acalabrutinib Approved T25005 DRUGINFO D0UT4W Zanubrutinib Approved T25005 DRUGINFO DXP04H Pirtobrutinib Approved T25005 DRUGINFO D0A9PN GDC-0853 Phase 3 T25005 DRUGINFO D7OZC3 Tolebrutinib Phase 3 T25005 DRUGINFO DUTJ12 ICP-022 Phase 3 T25005 DRUGINFO D04BFC CC-292 Phase 2 T25005 DRUGINFO D08AOZ BMS-986142 Phase 2 T25005 DRUGINFO D0C0OB LOU064 Phase 2 T25005 DRUGINFO D0E8PG BGB-3112 Phase 2 T25005 DRUGINFO D0GH7L PRN1008 Phase 2 T25005 DRUGINFO D0H0KH GS-4059 Phase 2 T25005 DRUGINFO D0KQ7M ARQ 531 Phase 2 T25005 DRUGINFO D0QX8X M2951 Phase 2 T25005 DRUGINFO DE3VU1 Branebrutinib Phase 2 T25005 DRUGINFO DS6V8H SAR 444727 Phase 2 T25005 DRUGINFO DVS81T DTRM-555 Phase 2 T25005 DRUGINFO D0UF0N ACP-319 Phase 1/2 T25005 DRUGINFO D0YI4F Vecabrutinib Phase 1/2 T25005 DRUGINFO DT3BA1 CG-806 Phase 1/2 T25005 DRUGINFO D02MRX ONO-4059 Phase 1 T25005 DRUGINFO D05SGI BGB-3113 Phase 1 T25005 DRUGINFO D08SGE M7583 Phase 1 T25005 DRUGINFO D09NVR PRN2246 Phase 1 T25005 DRUGINFO D0KT8D AC0058TA Phase 1 T25005 DRUGINFO D0VS3U TAK-020 Phase 1 T25005 DRUGINFO D0WP9A BIIB068 Phase 1 T25005 DRUGINFO D3Q4SZ DTRMWXHS-12 Phase 1 T25005 DRUGINFO D7GTX4 BIIB091 Phase 1 T25005 DRUGINFO DB2Q4X HMPL-760 Phase 1 T25005 DRUGINFO DBO39X JNJ-64264681 Phase 1 T25005 DRUGINFO DDEI09 TT-01488 Phase 1 T25005 DRUGINFO DELW64 NX-5948 Phase 1 T25005 DRUGINFO DJ6ZB0 BGB-16673 Phase 1 T25005 DRUGINFO DQ21NM TG-1701 Phase 1 T25005 DRUGINFO DTF20P HM71224 Phase 1 T25005 DRUGINFO D7YN4H NX-2127 Phase 1 T25005 DRUGINFO D00KEX Pyrrolo[2,3-d]pyrimidine derivative 14 Patented T25005 DRUGINFO D00KPQ Pyrrolo[2,3-d]pyrimidine derivative 19 Patented T25005 DRUGINFO D03ULH Pyrrolo[2,3-d]pyrimidine derivative 13 Patented T25005 DRUGINFO D05UXK Pyrrolo[2,3-d]pyrimidine derivative 29 Patented T25005 DRUGINFO D05YNZ Pyrrolo[2,3-d]pyrimidine derivative 30 Patented T25005 DRUGINFO D06ZNU Pyrrolo[2,3-d]pyrimidine derivative 16 Patented T25005 DRUGINFO D09IOW Pyrrolo[2,3-d]pyrimidine derivative 23 Patented T25005 DRUGINFO D09TKO Pyrrolo[2,3-d]pyrimidine derivative 15 Patented T25005 DRUGINFO D0CG3V Pyrrolo[2,3-d]pyrimidine derivative 25 Patented T25005 DRUGINFO D0IX7O Pyrrolo[2,3-d]pyrimidine derivative 27 Patented T25005 DRUGINFO D0J8UO Pyrrolo[2,3-d]pyrimidine derivative 33 Patented T25005 DRUGINFO D0Q1BE Pyrrolo[2,3-d]pyrimidine derivative 20 Patented T25005 DRUGINFO D0Q8LH Pyrrolo[2,3-d]pyrimidine derivative 32 Patented T25005 DRUGINFO D0QW4H Pyrrolo[2,3-d]pyrimidine derivative 12 Patented T25005 DRUGINFO D0R9HP Pyrrolo[2,3-d]pyrimidine derivative 26 Patented T25005 DRUGINFO D0SR0U Pyrrolo[2,3-d]pyrimidine derivative 22 Patented T25005 DRUGINFO D0TI0R Pyrrolo[2,3-d]pyrimidine derivative 21 Patented T25005 DRUGINFO D0V8JZ Pyrrolo[2,3-d]pyrimidine derivative 17 Patented T25005 DRUGINFO D0W3BE Pyrrolo[2,3-d]pyrimidine derivative 31 Patented T25005 DRUGINFO D0WN2X Pyrrolo[2,3-d]pyrimidine derivative 18 Patented T25005 DRUGINFO D00BYK PMID27774824-Compound-Figure12Example61 Patented T25005 DRUGINFO D00GTY Pyrrolo[2,3-d]pyrimidine derivative 28 Patented T25005 DRUGINFO D0NK1R PMID27774824-Compound-Figure12Example1 Patented T25005 DRUGINFO D0P3UH Imidazopyridine derivative 4 Patented T25005 DRUGINFO D0UH8J PMID27774824-Compound-Figure12Example10 Patented T25005 DRUGINFO D09PIS Pyrazolo[4,3-c]pyridine derivative 2 Patented T25005 DRUGINFO D0D4AQ PCI-45292 Preclinical T25005 DRUGINFO D03FUO GDC-0834 Terminated T25005 DRUGINFO D08NTB LFM-A13 Investigative T25005 DRUGINFO D0H3JH CGI-1316 Investigative T25005 DRUGINFO D0MH9X Inositol 1,3,4,5-Tetrakisphosphate Investigative T25005 DRUGINFO D0N0LN RN486 Investigative T25005 DRUGINFO D01RHR PMID24915291C31 Investigative T25005 DRUGINFO D06BJG PMID24915291C38 Investigative T25005 DRUGINFO D0E7VO PMID24900538C2c Investigative T01318 TARGETID T01318 T01318 FORMERID TTDS00059 T01318 UNIPROID PYRD_PLAF7 T01318 TARGNAME Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) T01318 GENENAME Malaria DHOdehase T01318 TARGTYPE Successful T01318 SYNONYMS PFF0160c; Mitochondrially bound dihydroorotate-ubiqui oxidoreductase; Dihydroorotate oxidase of Plasmodium falciparum; Dihydroorotate dehydrogenase of Plasmodium falciparum; DHOdehase of Plasmodium falciparum; DHODase; DHODH of Plasmodium falciparum; DHOD T01318 FUNCTION Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor. T01318 PDBSTRUC 6GJG; 6E0B; 5TBO; 5FI8; 5DEL T01318 BIOCLASS CH-CH donor oxidoreductase T01318 ECNUMBER EC 1.3.5.2 T01318 SEQUENCE MISKLKPQFMFLPKKHILSYCRKDVLNLFEQKFYYTSKRKESNNMKNESLLRLINYNRYYNKIDSNNYYNGGKILSNDRQYIYSPLCEYKKKINDISSYVSVPFKINIRNLGTSNFVNNKKDVLDNDYIYENIKKEKSKHKKIIFLLFVSLFGLYGFFESYNPEFFLYDIFLKFCLKYIDGEICHDLFLLLGKYNILPYDTSNDSIYACTNIKHLDFINPFGVAAGFDKNGVCIDSILKLGFSFIEIGTITPRGQTGNAKPRIFRDVESRSIINSCGFNNMGCDKVTENLILFRKRQEEDKLLSKHIVGVSIGKNKDTVNIVDDLKYCINKIGRYADYIAINVSSPNTPGLRDNQEAGKLKNIILSVKEEIDNLEKNNIMNDESTYNEDNKIVEKKNNFNKNNSHMMKDAKDNFLWFNTTKKKPLVFVKLAPDLNQEQKKEIADVLLETNIDGMIISNTTTQINDIKSFENKKGGVSGAKLKDISTKFICEMYNYTNKQIPIIASGGIFSGLDALEKIEAGASVCQLYSCLVFNGMKSAVQIKRELNHLLYQRGYYNLKEAIGRKHSKS T01318 DRUGINFO D06ZEE Atovaquone Approved T01318 DRUGINFO D08ROP Leflunomide Approved T01318 DRUGINFO D0S3WH Artemisinin Approved T01318 DRUGINFO D07QFP Teriflunomide Approved T01318 DRUGINFO D0C0NH Avastin+/-Tarceva Phase 3 T01318 DRUGINFO D00CQT Dichloroallyl lawsone Investigative T01318 DRUGINFO D00LCE Antiproliferative Agent A771726 Investigative T01318 DRUGINFO D00YPH 3-hydroxy-2-phenylquinoline-4-carboxylic acid Investigative T01318 DRUGINFO D01NWQ N-(4-bromo-2-methylphenyl)-2-naphthamide Investigative T01318 DRUGINFO D02TJY Triazine Investigative T01318 DRUGINFO D02YDM Dichloroally-lawsone Investigative T01318 DRUGINFO D03QKF 2-(3-(3,5-dichlorophenyl)ureido)benzoic acid Investigative T01318 DRUGINFO D04FYN Diethyl 2-((biphenyl-3-ylamino)methylene)malonate Investigative T01318 DRUGINFO D04HZA 2-(2-bromo-2-naphthamido)benzoic acid Investigative T01318 DRUGINFO D04LBT Antimycin A Investigative T01318 DRUGINFO D05SXU 2-(2-naphthamido)benzoic acid Investigative T01318 DRUGINFO D05YJP Ethyl 3-(biphenyl-3-ylamino)-2-cyanoacrylate Investigative T01318 DRUGINFO D06IPT N-(Biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide Investigative T01318 DRUGINFO D07NYQ Cinchoninic acid Investigative T01318 DRUGINFO D07PUS DSM1 Investigative T01318 DRUGINFO D07TKG NSC 665564 Investigative T01318 DRUGINFO D08LMT 3,6,9,12,15-PENTAOXATRICOSAN-1-OL Investigative T01318 DRUGINFO D09EAO LY214352 Investigative T01318 DRUGINFO D09WBQ DSM2 Investigative T01318 DRUGINFO D0C1LW 5,8-hydroxy-naphthoquinone Investigative T01318 DRUGINFO D0C1NU N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide Investigative T01318 DRUGINFO D0H6QL Salicylhydroxamic acid Investigative T01318 DRUGINFO D0HQ1I GNF-PF-85 Investigative T01318 DRUGINFO D0P0IE Plumbagin Investigative T01318 DRUGINFO D0R1GF 2-[(biphenyl-4-carbonyl)-amino]-benzoic acid Investigative T01318 DRUGINFO D0S7BK Orotic acid Investigative T01318 DRUGINFO D0S8AC 1-hydroxy-2-dodecyl-4(1H)quinolone Investigative T01318 DRUGINFO D0S8YD Decylamine-N,N-Dimethyl-N-Oxide Investigative T01318 DRUGINFO D0V8EH Isoxazol Investigative T01318 DRUGINFO D0WV5R Cyanide Investigative T01318 DRUGINFO D0X4NX Polyporic acid Investigative T01318 DRUGINFO D0YQ2A Undecylamine-n,n-dimethyl-n-oxide Investigative T01318 DRUGINFO D0AZ4T Dihydroorotate Investigative T01318 DRUGINFO D0B1SW Redoxal Investigative T01318 DRUGINFO D0B1TS Orotate Investigative T01318 DRUGINFO D0DQ6Z 1,4-Naphthoquinone Investigative T01318 DRUGINFO D0E2WX 5-Fluoro orotate Investigative T01318 DRUGINFO D0YN5P 8-aminoquinolines Investigative T01318 DRUGINFO D0C7PY Lauryl Dimethylamine-N-Oxide Investigative T01318 DRUGINFO D02UVH B-Octylglucoside Investigative T01318 DRUGINFO D0F2ME Acetate Ion Investigative T68547 TARGETID T68547 T68547 FORMERID TTDS00095 T68547 UNIPROID HDAC1_HUMAN T68547 TARGNAME Histone deacetylase 1 (HDAC1) T68547 GENENAME HDAC1 T68547 TARGTYPE Successful T68547 SYNONYMS RPD3L1; HD1 T68547 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Deacetylates SP proteins, SP1 and SP3, and regulates their function. Component of the BRG1-RB1-HDAC1 complex, which negatively regulates the CREST-mediated transcription in resting neurons. Upon calcium stimulation, HDAC1 is released from the complex and CREBBP is recruited, which facilitates transcriptional activation. Deacetylates TSHZ3 and regulates its transcriptional repressor activity. Deacetylates 'Lys-310' in RELA and thereby inhibits the transcriptional activity of NF-kappa-B. Deacetylates NR1D2 and abrogates the effect of KAT5-mediated relieving of NR1D2 transcription repression activity. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. Involved in CIART-mediated transcriptional repression of the circadian transcriptional activator: CLOCK-ARNTL/BMAL1 heterodimer. Required for the transcriptional repression of circadian target genes, such as PER1, mediated by the large PER complex or CRY1 through histone deacetylation. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). T68547 PDBSTRUC 5ICN; 4BKX; 1TYI T68547 BIOCLASS Carbon-nitrogen hydrolase T68547 ECNUMBER EC 3.5.1.98 T68547 SEQUENCE MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKANAEEMTKYHSDDYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVASAVKLNKQQTDIAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNYPLRDGIDDESYEAIFKPVMSKVMEMFQPSAVVLQCGSDSLSGDRLGCFNLTIKGHAKCVEFVKSFNLPMLMLGGGGYTIRNVARCWTYETAVALDTEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTNEYLEKIKQRLFENLRMLPHAPGVQMQAIPEDAIPEESGDEDEDDPDKRISICSSDKRIACEEEFSDSEEEGEGGRKNSSNFKKAKRVKTEDEKEKDPEEKKEVTEEEKTKEEKPEAKGVKEEVKLA T68547 DRUGINFO D0E3SH Panobinostat Approved T68547 DRUGINFO D0E7PQ Vorinostat Approved T68547 DRUGINFO D0L7LC Romidepsin Approved T68547 DRUGINFO D00SQN HBI-8000 Registered T68547 DRUGINFO D0B3FV NVP-LAQ824 Phase 3 T68547 DRUGINFO D0M8FD SNDX-275 Phase 3 T68547 DRUGINFO D0GH3Q ITF2357 Phase 3 T68547 DRUGINFO D01UXJ Resminostat Phase 2 T68547 DRUGINFO D0I7IB Sodium butyrate Phase 2 T68547 DRUGINFO D0VE1W SB-623 Phase 2 T68547 DRUGINFO D00FHR MGCD-0103 Phase 2 T68547 DRUGINFO D0B7CH Phenylbutyrate Phase 2 T68547 DRUGINFO D06TKI CHR-3996 Phase 1/2 T68547 DRUGINFO D07FPY SB-639 Phase 1 T68547 DRUGINFO D0GE5B RG-2833 Phase 1 T68547 DRUGINFO D00SSZ OBP-801 Phase 1 T68547 DRUGINFO D0YT8O PMID29671355-Compound-42 Patented T68547 DRUGINFO D00ACL PMID28092474-Compound-33d Patented T68547 DRUGINFO D00GLJ PMID28092474-Compound-32u Patented T68547 DRUGINFO D00LLN PMID28092474-Compound-33a Patented T68547 DRUGINFO D00XWZ PMID28092474-Compound-32a Patented T68547 DRUGINFO D01LCZ PMID28092474-Compound-32j Patented T68547 DRUGINFO D02YDG PMID28092474-Compound-32z Patented T68547 DRUGINFO D03EUD PMID28092474-Compound-32g Patented T68547 DRUGINFO D04AMI PMID28092474-Compound-34c Patented T68547 DRUGINFO D04KQU PMID28092474-Compound-32x Patented T68547 DRUGINFO D04MVN PMID28092474-Compound-33b Patented T68547 DRUGINFO D04VQE PMID28092474-Compound-32b Patented T68547 DRUGINFO D06IIL PMID28092474-Compound-32o Patented T68547 DRUGINFO D08GBR PMID28092474-Compound-33g Patented T68547 DRUGINFO D08GQL PMID28092474-Compound-33j Patented T68547 DRUGINFO D08SNJ PMID28092474-Compound-33p Patented T68547 DRUGINFO D08XLK PMID28092474-Compound-33m Patented T68547 DRUGINFO D08ZJZ PMID28092474-Compound-32v Patented T68547 DRUGINFO D09PVH PMID29671355-Compound-24 Patented T68547 DRUGINFO D0BY1R PMID28092474-Compound-34b Patented T68547 DRUGINFO D0CH4M PMID28092474-Compound-33e Patented T68547 DRUGINFO D0CX1Y PMID28092474-Compound-32t Patented T68547 DRUGINFO D0DH7R PMID28092474-Compound-32c Patented T68547 DRUGINFO D0E5CO PMID28092474-Compound-33i Patented T68547 DRUGINFO D0ET4U PMID28092474-Compound-32r Patented T68547 DRUGINFO D0EU5A PMID28092474-Compound-32h Patented T68547 DRUGINFO D0F3TB PMID29671355-Compound-65a Patented T68547 DRUGINFO D0HM6Y PMID28092474-Compound-32y Patented T68547 DRUGINFO D0JN0A PMID28092474-Compound-33h Patented T68547 DRUGINFO D0JR9L PMID29671355-Compound-38a Patented T68547 DRUGINFO D0K2UF PMID28092474-Compound-33f Patented T68547 DRUGINFO D0KA3X Diaryl amine derivative 3 Patented T68547 DRUGINFO D0L3CU PMID28092474-Compound-33c Patented T68547 DRUGINFO D0L7HG PMID29671355-Compound-39 Patented T68547 DRUGINFO D0LV6K PMID29671355-Compound-19 Patented T68547 DRUGINFO D0M7XL PMID28092474-Compound-32e Patented T68547 DRUGINFO D0MQ2D PMID28092474-Compound-32m Patented T68547 DRUGINFO D0MR7U PMID28092474-Compound-32p Patented T68547 DRUGINFO D0N1RX PMID28092474-Compound-32d Patented T68547 DRUGINFO D0O6SJ PMID28092474-Compound-32n Patented T68547 DRUGINFO D0Q9XK PMID28092474-Compound-33k Patented T68547 DRUGINFO D0QF0Y PMID28092474-Compound-32k Patented T68547 DRUGINFO D0QN8W PMID28092474-Compound-34a Patented T68547 DRUGINFO D0QR1Z Isosteric imidazolyl pyrimidine derivative 1 Patented T68547 DRUGINFO D0QX3G PMID29671355-Compound-22 Patented T68547 DRUGINFO D0R3RJ PMID29671355-Compound-26 Patented T68547 DRUGINFO D0RD7T PMID28092474-Compound-33o Patented T68547 DRUGINFO D0S3ZB PMID28092474-Compound-32f Patented T68547 DRUGINFO D0S7NE Diaryl amine derivative 2 Patented T68547 DRUGINFO D0SF8N PMID28092474-Compound-33l Patented T68547 DRUGINFO D0SK9K PMID28092474-Compound-32i Patented T68547 DRUGINFO D0TH3L PMID28092474-Compound-32q Patented T68547 DRUGINFO D0TN6E PMID29671355-Compound-18 Patented T68547 DRUGINFO D0UD9R PMID29671355-Compound-57 Patented T68547 DRUGINFO D0V5IQ PMID29671355-Compound-27 Patented T68547 DRUGINFO D0W1AX PMID28092474-Compound-32l Patented T68547 DRUGINFO D0YC2M PMID28092474-Compound-32s Patented T68547 DRUGINFO D0YD7B PMID29671355-Compound-38b Patented T68547 DRUGINFO D0Z7QI PMID29671355-Compound-28 Patented T68547 DRUGINFO D0C9NX PMID29671355-Compound-59 Patented T68547 DRUGINFO D0OU0J PMID29671355-Compound-55 Patented T68547 DRUGINFO D0T7OQ PMID29671355-Compound-73 Patented T68547 DRUGINFO D0ZG5X PMID29671355-Compound-13 Patented T68547 DRUGINFO D0EH2K PMID29671355-Compound-11 Patented T68547 DRUGINFO D0Q1QY PMID29671355-Compound-9 Patented T68547 DRUGINFO D0LN1T PMID29671355-Compound-8 Patented T68547 DRUGINFO D0JB4S PMID29671355-Compound-61 Patented T68547 DRUGINFO D00HXJ PMID29671355-Compound-23 Patented T68547 DRUGINFO D0N2DK PMID29671355-Compound-44 Patented T68547 DRUGINFO D0CH8Q PMID29671355-Compound-56 Patented T68547 DRUGINFO D0M0RE PMID29671355-Compound-67 Patented T68547 DRUGINFO D0DI9S PMID29671355-Compound-31 Patented T68547 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T68547 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T68547 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T68547 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T68547 DRUGINFO D0MP2U AN-9 Discontinued in Phase 2 T68547 DRUGINFO D0W9NH Tacedinaline Discontinued in Phase 2 T68547 DRUGINFO D0N3SH Pyroxamide Discontinued in Phase 1 T68547 DRUGINFO D03SZR M-carboxycinnamic acid bishydroxamide Preclinical T68547 DRUGINFO D06RQU HC-Toxin Preclinical T68547 DRUGINFO D0DO5U SK-7068 Preclinical T68547 DRUGINFO D0J8OC Scriptaid Preclinical T68547 DRUGINFO D0L5DZ 4SC-202 Preclinical T68547 DRUGINFO D0UC6H Chlamydocin Preclinical T68547 DRUGINFO D0UL5X SK-7041 Preclinical T68547 DRUGINFO D0W8JE Depudecin Preclinical T68547 DRUGINFO D03YVR Oxamflatin Terminated T68547 DRUGINFO D00GBB 6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide Investigative T68547 DRUGINFO D00LSZ N,8-dihydroxy-8-(naphthalen-2-yl)octanamide Investigative T68547 DRUGINFO D00PLM N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide Investigative T68547 DRUGINFO D00RGD N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide Investigative T68547 DRUGINFO D01EDB NSC-746457 Investigative T68547 DRUGINFO D02VVU 4-Benzenesulfonylamino-N-hydroxy-benzamide Investigative T68547 DRUGINFO D03FFI N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide Investigative T68547 DRUGINFO D03FOD 4-tert-butyl-N-hydroxybenzamide Investigative T68547 DRUGINFO D03OYL N-hydroxy-7-(naphthalen-2-yloxy)heptanamide Investigative T68547 DRUGINFO D03ZUZ 8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide Investigative T68547 DRUGINFO D04XPZ N-hydroxy-8-(naphthalen-2-yl)non-8-enamide Investigative T68547 DRUGINFO D05PYF N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide Investigative T68547 DRUGINFO D06NVX N-hydroxy-5-phenylthiophene-2-carboxamide Investigative T68547 DRUGINFO D06ONC Azithromycin-N-benzyltriazolyldecahydroxamic Acid Investigative T68547 DRUGINFO D07HUH 7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide Investigative T68547 DRUGINFO D0A6CB 8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide Investigative T68547 DRUGINFO D0A7IF N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide Investigative T68547 DRUGINFO D0B1YM Gymnochrome E Investigative T68547 DRUGINFO D0CJ7L N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide Investigative T68547 DRUGINFO D0D3XC N-hydroxybenzo[b]thiophene-2-carboxamide Investigative T68547 DRUGINFO D0G0OF 7-(1H-indol-5-yloxy)-N-hydroxyheptanamide Investigative T68547 DRUGINFO D0GJ1E 8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide Investigative T68547 DRUGINFO D0K8MF N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide Investigative T68547 DRUGINFO D0KM7H N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide Investigative T68547 DRUGINFO D0L4ML N-hydroxy-6-oxo-6-phenylhexanamide Investigative T68547 DRUGINFO D0L5WI N-hydroxy-8-(naphthalen-2-yl)octanamide Investigative T68547 DRUGINFO D0M0QJ ADS-102550 Investigative T68547 DRUGINFO D0O7UF N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide Investigative T68547 DRUGINFO D0P1RQ N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide Investigative T68547 DRUGINFO D0PP3Q N-hydroxy-2,2'-bithiophene-5-carboxamide Investigative T68547 DRUGINFO D0Q8QA ADS-100380 Investigative T68547 DRUGINFO D0QX6R N-hydroxy-7-oxo-7-phenylheptanamide Investigative T68547 DRUGINFO D0T0BE 7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide Investigative T68547 DRUGINFO D0U3MB SK-683 Investigative T68547 DRUGINFO D0Z2VP N-hydroxy-9-oxo-9-phenylnonanamide Investigative T68547 DRUGINFO D00HFS N-Hydroxy-N'-(4-methylphenyl)octanediamide Investigative T68547 DRUGINFO D01AMS N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T68547 DRUGINFO D01FYB N-(2-aminophenyl)quinoxaline-6-carboxamide Investigative T68547 DRUGINFO D01RJY 7-Biphenyl-4-yl-heptanoic acid hydroxyamide Investigative T68547 DRUGINFO D01ZMJ N-(2-Ethylphenyl)-N'-hydroxyoctanediamide Investigative T68547 DRUGINFO D03XXI 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid Investigative T68547 DRUGINFO D04ETX 1,1,1-Trifluoro-8-phenoxy-octan-2-one Investigative T68547 DRUGINFO D04LLD 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide Investigative T68547 DRUGINFO D05GRZ N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T68547 DRUGINFO D05ZGM 7-Phenoxy-heptanoic acid hydroxyamide Investigative T68547 DRUGINFO D06BKA 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one Investigative T68547 DRUGINFO D06FAK 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide Investigative T68547 DRUGINFO D06THS Desclasinose Azithromycinarylalkyl Hydroxamate Investigative T68547 DRUGINFO D08ICY N-(4-Ethylphenyl)-N'-hydroxyoctanediamide Investigative T68547 DRUGINFO D08TIJ N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T68547 DRUGINFO D08XMS N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide Investigative T68547 DRUGINFO D0B8RC N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T68547 DRUGINFO D0D7KH Azithromycin-N-benzyltriazolyloctahydroxamic Acid Investigative T68547 DRUGINFO D0E0TA N-(4-hydroxybiphenyl-3-yl)benzamide Investigative T68547 DRUGINFO D0E9DD AZUMAMIDE E Investigative T68547 DRUGINFO D0H3RO Azithromycin-N-benzyltriazolylnonahydroxamic Acid Investigative T68547 DRUGINFO D0H7QA N-Hydroxy-N'-(3-methylphenyl)octanediamide Investigative T68547 DRUGINFO D0H9DS 8-Phenyl-octanoic acid hydroxyamide Investigative T68547 DRUGINFO D0I5XM Azithromycin-N-benzyltriazolylhexahydroxamic Acid Investigative T68547 DRUGINFO D0J3CY N-(3-Ethylphenyl)-N'-hydroxyoctanediamide Investigative T68547 DRUGINFO D0L5KP N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T68547 DRUGINFO D0L6YF N-Hydroxy-N'-(4-methoxyphenyl)octanediamide Investigative T68547 DRUGINFO D0M1ZI AZUMAMIDE B Investigative T68547 DRUGINFO D0NL6C 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one Investigative T68547 DRUGINFO D0P9CQ Azithromycinarylalkylhydroxamic Acid Investigative T68547 DRUGINFO D0Q2CC N-Hydroxy-N'-(2-methylphenyl)octanediamide Investigative T68547 DRUGINFO D0Q5DI nexturastat A Investigative T68547 DRUGINFO D0Q9PO AZUMAMIDE C Investigative T68547 DRUGINFO D0SQ1F N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T68547 DRUGINFO D0YP4F N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide Investigative T68547 DRUGINFO D0Z8PX LARGAZOLE Investigative T68547 DRUGINFO D00XTC Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) Investigative T68547 DRUGINFO D02HVH 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide Investigative T68547 DRUGINFO D02NAF Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) Investigative T68547 DRUGINFO D02NVY Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) Investigative T68547 DRUGINFO D03PRG Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) Investigative T68547 DRUGINFO D04CDZ Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) Investigative T68547 DRUGINFO D04DOL N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide Investigative T68547 DRUGINFO D04UVL N-(2-aminophenyl)nicotinamide Investigative T68547 DRUGINFO D0E8UH Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) Investigative T68547 DRUGINFO D0G1EX Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) Investigative T68547 DRUGINFO D0M9LJ N-(4-aminobiphenyl-3-yl)nicotinamide Investigative T68547 DRUGINFO D0N5RV Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) Investigative T68547 DRUGINFO D0Q2GM N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide Investigative T68547 DRUGINFO D0R3XO Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) Investigative T68547 DRUGINFO D0U0EZ Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) Investigative T68547 DRUGINFO D0X4QC Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) Investigative T68547 DRUGINFO D0YO6M N-(2-aminophenyl)-4-methoxybenzamide Investigative T68547 DRUGINFO D0Z6HR Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) Investigative T68547 DRUGINFO D0Z6MI Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) Investigative T68547 DRUGINFO D02NWS 4-Phenylbutyrohydroxamic acid Investigative T68547 DRUGINFO D0S0WK 8-Oxo-8-phenyl-octanoic acid hydroxyamide Investigative T68547 DRUGINFO D01YBR ST-3050 Investigative T68547 DRUGINFO D07YZZ Octanedioic acid bis-hydroxyamide Investigative T68547 DRUGINFO D0N9AK ST-2986 Investigative T68547 DRUGINFO D00KFF 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative T68547 DRUGINFO D00SEE 7-Mercapto-heptanoic acid phenylamide Investigative T68547 DRUGINFO D00ZSD 6-benzenesulfinylhexanoic acid hydroxamide Investigative T68547 DRUGINFO D01MFV N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative T68547 DRUGINFO D01XWZ 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative T68547 DRUGINFO D01XXN N-Hydroxy-4-phenylacetylamino-benzamide Investigative T68547 DRUGINFO D02MQM 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative T68547 DRUGINFO D02UTC N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative T68547 DRUGINFO D02WZK 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T68547 DRUGINFO D04GGW Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative T68547 DRUGINFO D04HSS N-(6-Mercapto-hexyl)-benzamide Investigative T68547 DRUGINFO D04NSP 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T68547 DRUGINFO D04ZDI N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative T68547 DRUGINFO D05AHZ 6-benzenesulfonylhexanoic acid hydroxamide Investigative T68547 DRUGINFO D05FEJ 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative T68547 DRUGINFO D05GVY Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative T68547 DRUGINFO D05LLX 4-Butyrylamino-N-hydroxy-benzamide Investigative T68547 DRUGINFO D05VFP 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T68547 DRUGINFO D05XAN 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative T68547 DRUGINFO D06IQB 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative T68547 DRUGINFO D06VBN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative T68547 DRUGINFO D06XNP 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative T68547 DRUGINFO D07FJU 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative T68547 DRUGINFO D09YBN 6-Phenoxy-hexane-1-thiol Investigative T68547 DRUGINFO D09ZNU 4-Benzoylamino-N-hydroxy-benzamide Investigative T68547 DRUGINFO D0A5LS 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T68547 DRUGINFO D0AX7B 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative T68547 DRUGINFO D0B2ZJ 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T68547 DRUGINFO D0B3ZM 6-Mercapto-hexanoic acid phenylamide Investigative T68547 DRUGINFO D0C0VP Cyclostellettamine derivative Investigative T68547 DRUGINFO D0C2KD N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative T68547 DRUGINFO D0D2KE 5-Mercapto-pentanoic acid phenylamide Investigative T68547 DRUGINFO D0E8KR Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative T68547 DRUGINFO D0F0KS N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative T68547 DRUGINFO D0H1FZ 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative T68547 DRUGINFO D0KE3I (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative T68547 DRUGINFO D0QO0L N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative T68547 DRUGINFO D0R4BS N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative T68547 DRUGINFO D0R5VG N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative T68547 DRUGINFO D0RU1X 8-Oxo-8-phenyl-octanoic acid Investigative T68547 DRUGINFO D0S7WQ N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative T68547 DRUGINFO D0S9JF 6-phenylsulfanylhexanoic acid hydroxamide Investigative T68547 DRUGINFO D0T0SK ST-2987 Investigative T68547 DRUGINFO D0T4IY 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative T68547 DRUGINFO D0V2ZO 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative T68547 DRUGINFO D0XZ9Q 8-Mercapto-octanoic acid phenylamide Investigative T68547 DRUGINFO D0YY9M N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative T68547 DRUGINFO D0Z3BM 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative T68547 DRUGINFO D0Z5KX 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative T68547 DRUGINFO D0Z7YS N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative T68547 DRUGINFO D0N0TS PSAMMAPLIN A Investigative T93344 TARGETID T93344 T93344 FORMERID TTDS00302 T93344 UNIPROID ERG1_HUMAN T93344 TARGNAME Squalene monooxygenase (SQLE) T93344 GENENAME SQLE T93344 TARGTYPE Successful T93344 SYNONYMS Squalene epoxidase; SQLE; SE; Oxidosqaulene cyclase T93344 FUNCTION Catalyzes the first oxygenation step in sterol biosynthesis and is suggested to be one of the rate-limiting enzymes in this pathway. T93344 PDBSTRUC 6C6R; 6C6P; 6C6N T93344 BIOCLASS Paired donor oxygen oxidoreductase T93344 ECNUMBER EC 1.14.14.17 T93344 SEQUENCE MWTFLGIATFTYFYKKFGDFITLANREVLLCVLVFLSLGLVLSYRCRHRNGGLLGRQQSGSQFALFSDILSGLPFIGFFWAKSPPESENKEQLEARRRRKGTNISETSLIGTAACTSTSSQNDPEVIIVGAGVLGSALAAVLSRDGRKVTVIERDLKEPDRIVGEFLQPGGYHVLKDLGLGDTVEGLDAQVVNGYMIHDQESKSEVQIPYPLSENNQVQSGRAFHHGRFIMSLRKAAMAEPNAKFIEGVVLQLLEEDDVVMGVQYKDKETGDIKELHAPLTVVADGLFSKFRKSLVSNKVSVSSHFVGFLMKNAPQFKANHAELILANPSPVLIYQISSSETRVLVDIRGEMPRNLREYMVEKIYPQIPDHLKEPFLEATDNSHLRSMPASFLPPSSVKKRGVLLLGDAYNMRHPLTGGGMTVAFKDIKLWRKLLKGIPDLYDDAAIFEAKKSFYWARKTSHSFVVNILAQALYELFSATDDSLHQLRKACFLYFKLGGECVAGPVGLLSVLSPNPLVLIGHFFAVAIYAVYFCFKSEPWITKPRALLSSGAVLYKACSVIFPLIYSEMKYMVH T93344 DRUGINFO D00HPK Naftifine Approved T93344 DRUGINFO D02NTO Tolnaftate Approved T93344 DRUGINFO D0U2BH Epigallocatechin gallate Phase 3 T93344 DRUGINFO D04DMO FR-194738 Terminated T93344 DRUGINFO D06MUZ SDZ-87-469 Terminated T93344 DRUGINFO D0I3XW NB-598 Terminated T93344 DRUGINFO D01VEP N-cetylgallate Investigative T93344 DRUGINFO D02ZSX OCTYL_GALLATE Investigative T93344 DRUGINFO D03RKP Trisnorsqualene difluoromethylidene Investigative T93344 DRUGINFO D05UWZ Mallotinic acid Investigative T93344 DRUGINFO D06CPD ETHYLGALLATE Investigative T93344 DRUGINFO D06YCQ Procyanidin B-2 3,3'-di-O-gallate Investigative T93344 DRUGINFO D07WLU 1,2,6-tri-O-galloyl-beta-D-glucose Investigative T93344 DRUGINFO D0A1QJ Tellurium Investigative T93344 DRUGINFO D0C6QS GERANIIN Investigative T93344 DRUGINFO D0F3KP Thiocarbamate Investigative T93344 DRUGINFO D0F9KV 1(beta)-O-galloylpedunculagin Investigative T93344 DRUGINFO D0F9RE Allylamines Investigative T93344 DRUGINFO D0G3SL FUROSIN Investigative T93344 DRUGINFO D0J1DW Trisnorsqualene cyclopropylamine Investigative T93344 DRUGINFO D0J1QQ Sanguiin H-6 Investigative T93344 DRUGINFO D0K2XJ EUGENIIN Investigative T93344 DRUGINFO D0QN6H Mallotusinic acid Investigative T93344 DRUGINFO D0T0XY THEASINENSIN A Investigative T93344 DRUGINFO D0VS1V N-dodecylgallate Investigative T93344 DRUGINFO D0Z9PB Trisnorsqualene alcohol Investigative T93344 DRUGINFO D0Z9YK Chebulinic acid Investigative T93344 DRUGINFO D03SPJ CORILAGIN Investigative T93344 DRUGINFO D0L1XR Green tea Investigative T93344 DRUGINFO D0Z2TG Pedunculagin Investigative T93344 DRUGINFO D00QDR 1,2,3,4,6-penta-O-galloyl-beta-D-glucose Investigative T93344 DRUGINFO D0A1CM ELLAGIC ACID Investigative T92057 TARGETID T92057 T92057 FORMERID TTDC00114 T92057 UNIPROID ERBB4_HUMAN T92057 TARGNAME Erbb4 tyrosine kinase receptor (Erbb-4) T92057 GENENAME ERBB4 T92057 TARGTYPE Successful T92057 SYNONYMS Tyrosine kinase-type cell surface receptor HER4; Receptor tyrosine-protein kinase erbB-4; Proto-oncogene-like protein c-ErbB-4; P180erbB4; HER4 T92057 FUNCTION Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis. Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. T92057 PDBSTRUC 3U9U; 3U7U; 3U2P; 3BCE; 3BBW T92057 BIOCLASS Kinase T92057 ECNUMBER EC 2.7.10.1 T92057 SEQUENCE MKPATGLWVWVSLLVAAGTVQPSDSQSVCAGTENKLSSLSDLEQQYRALRKYYENCEVVMGNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGTKLYEDRYALAIFLNYRKDGNFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTLVSTNGSSGCGRCHKSCTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPYVSDCCHRECAGGCSGPKDTDCFACMNFNDSGACVTQCPQTFVYNPTTFQLEHNFNAKYTYGAFCVKKCPHNFVVDSSSCVRACPSSKMEVEENGIKMCKPCTDICPKACDGIGTGSLMSAQTVDSSNIDKFINCTKINGNLIFLVTGIHGDPYNAIEAIDPEKLNVFRTVREITGFLNIQSWPPNMTDFSVFSNLVTIGGRVLYSGLSLLILKQQGITSLQFQSLKEISAGNIYITDNSNLCYYHTINWTTLFSTINQRIVIRDNRKAENCTAEGMVCNHLCSSDGCWGPGPDQCLSCRRFSRGRICIESCNLYDGEFREFENGSICVECDPQCEKMEDGLLTCHGPGPDNCTKCSHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCNGPTSHDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRALRRFLETELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETTGPKANVEFMDEALIMASMDHPHLVRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHKDNIGSQLLLNWCVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLEGDEKEYNADGGKMPIKWMALECIHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKGERLPQPPICTIDVYMVMVKCWMIDADSRPKFKELAAEFSRMARDPQRYLVIQGDDRMKLPSPNDSKFFQNLLDEEDLEDMMDAEEYLVPQAFNIPPPIYTSRARIDSNRSEIGHSPPPAYTPMSGNQFVYRDGGFAAEQGVSVPYRAPTSTIPEAPVAQGATAEIFDDSCCNGTLRKPVAPHVQEDSSTQRYSADPTVFAPERSPRGELDEEGYMTPMRDKPKQEYLNPVEENPFVSRRKNGDLQALDNPEYHNASNGPPKAEDEYVNEPLYLNTFANTLGKAEYLKNNILSMPEKAKKAFDNPDYWNHSLPPRSTLQHPDYLQEYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV T92057 DRUGINFO D06XXH Dacomitinib Approved T92057 DRUGINFO D0OC4O RG7388 Phase 3 T92057 DRUGINFO D0Z7IW JI-101 Phase 2 T92057 DRUGINFO D0YB3W CI-1033 Phase 2 T92057 DRUGINFO D0U3XL JNJ-26483327 Phase 1 T92057 DRUGINFO D05FFT HDS-029 Investigative T92057 DRUGINFO D06BJG PMID24915291C38 Investigative T67849 TARGETID T67849 T67849 FORMERID TTDR00930 T67849 UNIPROID PK3CD_HUMAN T67849 TARGNAME PI3-kinase delta (PIK3CD) T67849 GENENAME PIK3CD T67849 TARGTYPE Successful T67849 SYNONYMS PtdIns-3-kinase subunit p110-delta; PtdIns-3-kinase subunit delta; Phosphoinositide 3-kinase delta; Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PI3Kdelta; PI3K-delta; PI3-kinase subunit delta; PI3-kinase p110 subunit delta; P110delta T67849 FUNCTION Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Have a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Have important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity. T67849 PDBSTRUC 6G6W; 5VLR; 5UBT; 5T8F; 5M6U T67849 BIOCLASS Kinase T67849 ECNUMBER EC 2.7.1.153 T67849 SEQUENCE MPPGVDCPMEFWTKEENQSVVVDFLLPTGVYLNFPVSRNANLSTIKQLLWHRAQYEPLFHMLSGPEAYVFTCINQTAEQQELEDEQRRLCDVQPFLPVLRLVAREGDRVKKLINSQISLLIGKGLHEFDSLCDPEVNDFRAKMCQFCEEAAARRQQLGWEAWLQYSFPLQLEPSAQTWGPGTLRLPNRALLVNVKFEGSEESFTFQVSTKDVPLALMACALRKKATVFRQPLVEQPEDYTLQVNGRHEYLYGSYPLCQFQYICSCLHSGLTPHLTMVHSSSILAMRDEQSNPAPQVQKPRAKPPPIPAKKPSSVSLWSLEQPFRIELIQGSKVNADERMKLVVQAGLFHGNEMLCKTVSSSEVSVCSEPVWKQRLEFDINICDLPRMARLCFALYAVIEKAKKARSTKKKSKKADCPIAWANLMLFDYKDQLKTGERCLYMWPSVPDEKGELLNPTGTVRSNPNTDSAAALLICLPEVAPHPVYYPALEKILELGRHSECVHVTEEEQLQLREILERRGSGELYEHEKDLVWKLRHEVQEHFPEALARLLLVTKWNKHEDVAQMLYLLCSWPELPVLSALELLDFSFPDCHVGSFAIKSLRKLTDDELFQYLLQLVQVLKYESYLDCELTKFLLDRALANRKIGHFLFWHLRSEMHVPSVALRFGLILEAYCRGSTHHMKVLMKQGEALSKLKALNDFVKLSSQKTPKPQTKELMHLCMRQEAYLEALSHLQSPLDPSTLLAEVCVEQCTFMDSKMKPLWIMYSNEEAGSGGSVGIIFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLRMTPYGCLPTGDRTGLIEVVLRSDTIANIQLNKSNMAATAAFNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMIRESGQLFHIDFGHFLGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTILRRHGLLFLHLFALMRAAGLPELSCSKDIQYLKDSLALGKTEEEALKHFRVKFNEALRESWKTKVNWLAHNVSKDNRQ T67849 DRUGINFO D0J5VR Idelalisib Approved T67849 DRUGINFO DGO2C1 Leniolisib Approved T67849 DRUGINFO D0O8SJ Umbralisib Approved T67849 DRUGINFO D0RU0O IPI-145 Approved T67849 DRUGINFO D0S5LD BAY 80-6946 Approved T67849 DRUGINFO D01QSO Buparlisib Phase 3 T67849 DRUGINFO D07RHP INCB50465 Phase 2 T67849 DRUGINFO D0LG7X RP6530 Phase 2 T67849 DRUGINFO DP1SE6 Parsaclisib Phase 2 T67849 DRUGINFO DQ62LM AZD8154 Phase 2 T67849 DRUGINFO D07CWH INCB40093 Phase 1/2 T67849 DRUGINFO DHX7S8 ZX-101A Phase 1/2 T67849 DRUGINFO D05CBJ PA-799 Phase 1/2 T67849 DRUGINFO D03FOP AMG 319 Phase 1 T67849 DRUGINFO D03IJO GS-9820 Phase 1 T67849 DRUGINFO D08WLY ME-401 Phase 1 T67849 DRUGINFO D0U5PT GS-9901 Phase 1 T67849 DRUGINFO DA02DE BGB-10188 Phase 1 T67849 DRUGINFO DDE3Z4 HMPL-689 Phase 1 T67849 DRUGINFO DDE6F1 GSK2292767 Phase 1 T67849 DRUGINFO D00GTY Pyrrolo[2,3-d]pyrimidine derivative 28 Patented T67849 DRUGINFO D08TAB XL-499 Preclinical T67849 DRUGINFO D0P1JI Wortmannin Terminated T67849 DRUGINFO D00ZIK IC87114 Investigative T67849 DRUGINFO D0O2HL IC980033 Investigative T67849 DRUGINFO DOR1I0 ETP-46321 Investigative T67849 DRUGINFO D07APP LY-292223 Investigative T67849 DRUGINFO D0W1ST Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate Investigative T10897 TARGETID T10897 T10897 FORMERID TTDS00516 T10897 UNIPROID ACOD_HUMAN T10897 TARGNAME Acyl-CoA desaturase (SCD) T10897 GENENAME SCD T10897 TARGTYPE Successful T10897 SYNONYMS hSCD1; Stearoyl-coenzyme A (Delta9) desaturase; Stearoyl-CoA desaturase; Membrane-bound 9 desaturase; Fatty acid desaturase; DesA3; Des A3; Delta-9-stearoyl desaturase; Delta-9 desaturase; Delta(9)-desaturase; 9 stearoyl-desaturase T10897 FUNCTION Catalyzes the insertion of a cis double bond at the delta-9 position into fatty acyl-CoA substrates including palmitoyl-CoA and stearoyl-CoA. Gives rise to a mixture of 16:1 and 18:1 unsaturated fatty acids. Plays an important role in lipid biosynthesis. Plays an important role in regulating the expression of genes that are involved in lipogenesis and in regulating mitochondrial fatty acid oxidation. Plays an important role in body energy homeostasis. Contributes to the biosynthesis of membrane phospholipids, cholesterol esters and triglycerides. Stearyl-CoA desaturase that utilizes O(2) and electrons from reduced cytochrome b5 to introduce the first double bond into saturated fatty acyl-CoA substrates. T10897 PDBSTRUC 4ZYO T10897 BIOCLASS Paired donor oxygen oxidoreductase T10897 ECNUMBER EC 1.14.19.1 T10897 SEQUENCE MPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEGPSPKVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLRLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLDLSDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAHLFGYRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYDRKKVSKAAILARIKRTGDGNYKSG T10897 DRUGINFO D0I8CA Isoxyl Approved T10897 DRUGINFO D09PVO Aramchol Phase 2/3 T10897 DRUGINFO D0S0RS MK-8245 Phase 2 T10897 DRUGINFO D00GQC Sterculic acid Investigative T10897 DRUGINFO D0D9QN ISIS 147919 Investigative T10897 DRUGINFO D0N1QW 2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide Investigative T10897 DRUGINFO D0O3TT MF-152 Investigative T10897 DRUGINFO D0O7DP CVT-12012 Investigative T16987 TARGETID T16987 T16987 FORMERID TTDR00212 T16987 UNIPROID CAH12_HUMAN T16987 TARGNAME Carbonic anhydrase XII (CA-XII) T16987 GENENAME CA12 T16987 TARGTYPE Successful T16987 SYNONYMS Tumor antigen HOM-RCC-3.1.3; Carbonic anhydrase 12; Carbonate dehydratase XII T16987 FUNCTION Reversible hydration of carbon dioxide. T16987 PDBSTRUC 6G7A; 6G5L; 5MSB; 5MSA; 5LLP T16987 BIOCLASS Alpha-carbonic anhydrase T16987 ECNUMBER EC 4.2.1.1 T16987 SEQUENCE MPRRSLHAAAVLLLVILKEQPSSPAPVNGSKWTYFGPDGENSWSKKYPSCGGLLQSPIDLHSDILQYDASLTPLEFQGYNLSANKQFLLTNNGHSVKLNLPSDMHIQGLQSRYSATQLHLHWGNPNDPHGSEHTVSGQHFAAELHIVHYNSDLYPDASTASNKSEGLAVLAVLIEMGSFNPSYDKIFSHLQHVKYKGQEAFVPGFNIEELLPERTAEYYRYRGSLTTPPCNPTVLWTVFRNPVQISQEQLLALETALYCTHMDDPSPREMINNFRQVQKFDERLVYTSFSQVQVCTAAGLSLGIILSLALAGILGICIVVVVSIWLFRRKSIKKGDNKGVIYKPATKMETEAHA T16987 DRUGINFO D0K1QD Sulfamylon Approved T16987 DRUGINFO D07HBX Salicyclic acid Approved T16987 DRUGINFO D0A8JP PARABEN Phase 3 T16987 DRUGINFO D07SDQ Curcumin Phase 3 T16987 DRUGINFO D0L6HN PHENOL Phase 2/3 T16987 DRUGINFO D0Y6OA Coumate Phase 2 T16987 DRUGINFO D03SLR FERULIC ACID Patented T16987 DRUGINFO D00RDE 4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide Investigative T16987 DRUGINFO D07AGM 4-Methylamino-benzenesulfonamide Investigative T16987 DRUGINFO D07UCQ Sodium phenylaminomethanesulfonate Investigative T16987 DRUGINFO D0M7VN 4-(N-Methyl-hydrazino)-benzenesulfonamide Investigative T16987 DRUGINFO D0M9IQ Sodium N-methylphenylaminomethanesulfonate Investigative T16987 DRUGINFO D03DAM 2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide Investigative T16987 DRUGINFO D04HRS 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide Investigative T16987 DRUGINFO D04POB ACETYLSULFANILAMIDE Investigative T16987 DRUGINFO D07CYN 2-amino-2,3-dihydro-1H-indene-5-sulfonamide Investigative T16987 DRUGINFO D09TES 2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid Investigative T16987 DRUGINFO D0BD0K 3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide Investigative T16987 DRUGINFO D0C7WG 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide Investigative T16987 DRUGINFO D0H4CF 3-((4-aminophenyl)diazenyl)benzenesulfonamide Investigative T16987 DRUGINFO D0I0RT Thioureido sulfonamide Investigative T16987 DRUGINFO D0T2YZ N-(4-Sulfamoyl-phenyl)-isobutyramide Investigative T16987 DRUGINFO D00IKQ 4-Methoxy-3-pyridinesulfonamide Investigative T16987 DRUGINFO D00IUB 4-CYANOPHENOL Investigative T16987 DRUGINFO D00NUK 4-Methanesulfonylamino-benzenesulfonamide Investigative T16987 DRUGINFO D02NQK 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide Investigative T16987 DRUGINFO D04SNH 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide Investigative T16987 DRUGINFO D05EBZ 4-(4-Cyanophenoxy)-3-pyridinesulfonamide Investigative T16987 DRUGINFO D05QUG 7-phenethoxy-2H-chromen-2-one Investigative T16987 DRUGINFO D05RAB 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide Investigative T16987 DRUGINFO D05VSK ETHOXYCOUMARIN Investigative T16987 DRUGINFO D06ZMH 3-(3-Phenyl-ureido)-benzenesulfonamide Investigative T16987 DRUGINFO D07QJJ CATECHOL Investigative T16987 DRUGINFO D08JCC 4-(4-Fluorophenoxy)-3-pyridinesulfonamide Investigative T16987 DRUGINFO D09CXX N-hydroxysulfamide Investigative T16987 DRUGINFO D09LUD 4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide Investigative T16987 DRUGINFO D0K3LN N-(4-Sulfamoyl-phenyl)-butyramide Investigative T16987 DRUGINFO D0KB6T N-(4-Sulfamoyl-phenyl)-benzamide Investigative T16987 DRUGINFO D0M4EV N-(4-cyanophenyl)sulfamide Investigative T16987 DRUGINFO D0N8LR N-(4-Sulfamoyl-phenyl)-propionamide Investigative T16987 DRUGINFO D0PA5L N-(pentafluorophenyl)sulfamide Investigative T16987 DRUGINFO D0Q0XO Pentanoic acid (4-sulfamoyl-phenyl)-amide Investigative T16987 DRUGINFO D0RK7J 2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide Investigative T16987 DRUGINFO D0YD9F 4-Benzenesulfonylamino-benzenesulfonamide Investigative T16987 DRUGINFO D00IAE Prop-2-ynyl 4-sulfamoylbenzoate Investigative T16987 DRUGINFO D00RNZ 7-(benzyloxy)-2H-chromen-2-one Investigative T16987 DRUGINFO D01OTW 4-(Cyanomethylthio)pyridine-3-sulfonamide Investigative T16987 DRUGINFO D01XFH N-propynyl amidebenzenesulphonide Investigative T16987 DRUGINFO D02BMV 4-(2-Propynylthio)pyridine-3-sulfonamide Investigative T16987 DRUGINFO D02DBP RESORCINOL Investigative T16987 DRUGINFO D03KRB 4,4'-thiodipyridine-3-sulfonamide Investigative T16987 DRUGINFO D04VSP 4-Ethoxy-3-pyridinesulfonamide Investigative T16987 DRUGINFO D05ETN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide Investigative T16987 DRUGINFO D05JAJ 4-(Quinolinoxy)-3-pyridinesulfonamide Investigative T16987 DRUGINFO D06DYP 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T16987 DRUGINFO D06IOI 4-Benzythiopyridine-3-sulfonamide Investigative T16987 DRUGINFO D09TKG 4-(Allylamino)-3-pyridinesulfonamide Investigative T16987 DRUGINFO D09WVV N1-(2-aminoethyl)ethane-1,2-diamine Investigative T16987 DRUGINFO D0A0YX SACCHARIN Investigative T16987 DRUGINFO D0C4QB 2-Amino-indan-5-sulfonic acid Investigative T16987 DRUGINFO D0G0FJ 2-hydrazinylbenzenesulfonamide Investigative T16987 DRUGINFO D0J7GU 4-Methylthiopyridine-3-sulfonamide Investigative T16987 DRUGINFO D0LC0F 2,3-dihydro-1H-indene-5-sulfonamide Investigative T16987 DRUGINFO D0LU4S 7-butoxy-2H-chromen-2-one Investigative T16987 DRUGINFO D0OT5L 7-propoxy-2H-chromen-2-one Investigative T16987 DRUGINFO D0Q5VB 4-(Methylhydrazino)-3-pyridinesulfonamide Investigative T16987 DRUGINFO D0R4KQ 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide Investigative T16987 DRUGINFO D0RB0D 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid Investigative T16987 DRUGINFO D0UM1I 4-Hydrazino-3-pyridinesulfonamide Investigative T16987 DRUGINFO D0V5OW 4-(Carbamolymethylthio)pyridine-3-sulfonamide Investigative T16987 DRUGINFO D0ZC3W P-toluenesulfonamide Investigative T16987 DRUGINFO D00XJA 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T16987 DRUGINFO D04VLI 4-(2-Hydroxy-ethyl)-benzenesulfonamide Investigative T16987 DRUGINFO D07TAJ Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate Investigative T16987 DRUGINFO D0D6UR 2-oxo-2H-thiochromene-3-carboxylic acid Investigative T16987 DRUGINFO D0H3NS 2-oxo-2H-chromene-3-carboxylic acid Investigative T16987 DRUGINFO D0J2AE 3-Amino-benzenesulfonamide Investigative T16987 DRUGINFO D0OI1H 2-Amino-benzenesulfonamide Investigative T16987 DRUGINFO D0X5HL N1-(naphthalen-1-yl)ethane-1,2-diamine Investigative T16987 DRUGINFO D04NSN 4-(2-AMINOETHYL)BENZENESULFONAMIDE Investigative T16987 DRUGINFO D05XZM 4-(hydroxymethyl)benzenesulfonamide Investigative T16987 DRUGINFO D09JPC Hexane-1,6-diamine Investigative T16987 DRUGINFO D09PWX Carzenide Investigative T16987 DRUGINFO D0G3BI 6-methyl-2-oxo-2H-chromene-3-carboxylic acid Investigative T16987 DRUGINFO D0L5TZ 6-(hydroxymethyl)-2H-chromen-2-one Investigative T16987 DRUGINFO D0Q2LL 6-Hydroxy-benzothiazole-2-sulfonic acid amide Investigative T16987 DRUGINFO D0U4BB HERNIARIN Investigative T16987 DRUGINFO D00YEF Decane-1,10-diyl disulfamate Investigative T16987 DRUGINFO D01STY 4-Amino-3-iodo-benzenesulfonamide Investigative T16987 DRUGINFO D02QGI Pentane-1,5-diamine Investigative T16987 DRUGINFO D03ZMQ COUMARIN Investigative T16987 DRUGINFO D04CVC 4-Amino-3-fluoro-benzenesulfonamide Investigative T16987 DRUGINFO D05TLB Octyl sulfamate Investigative T16987 DRUGINFO D09WSJ Decyl sulfamate Investigative T16987 DRUGINFO D0AU0M P-Coumaric Acid Investigative T16987 DRUGINFO D0D4OV Octane-1,8-diyl disulfamate Investigative T16987 DRUGINFO D0E8CC BENZOLAMIDE Investigative T16987 DRUGINFO D0M3PO 2,4-Disulfamyltrifluoromethylaniline Investigative T16987 DRUGINFO D0N1AW 6-(aminomethyl)-2H-chromen-2-one Investigative T16987 DRUGINFO D0NN3Q 4-Hydrazino-benzenesulfonamide Investigative T16987 DRUGINFO D0P6AM 4-Amino-3-bromo-benzenesulfonamide Investigative T16987 DRUGINFO D0Q7DJ Syringic Acid Investigative T16987 DRUGINFO D0VD7H CL-5343 Investigative T16987 DRUGINFO D0YU8J 4-Amino-3-chloro-benzenesulfonamide Investigative T16987 DRUGINFO D0V7AA CATECHIN Investigative T16987 DRUGINFO D0Y3TZ GALLICACID Investigative T16987 DRUGINFO D0A1CM ELLAGIC ACID Investigative T19433 TARGETID T19433 T19433 FORMERID TTDS00192 T19433 UNIPROID HPGDS_HUMAN T19433 TARGNAME Glutathione-dependent PGD synthase (HPGDS) T19433 GENENAME HPGDS T19433 TARGTYPE Successful T19433 SYNONYMS HPGDS; Glutathione-S-transferase; GST class-alpha T19433 FUNCTION Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the conjugation of glutathione with a widerange of aryl halides and organic isothiocyanates. Also exhibits low glutathione-peroxidase activity towards cumene hydroperoxide. T19433 PDBSTRUC 6N4E; 5YX1; 5YWX; 5YWE; 5AIX T19433 BIOCLASS Intramolecular oxidoreductases T19433 ECNUMBER EC 5.3.99.2 T19433 SEQUENCE MPNYKLTYFNMRGRAEIIRYIFAYLDIQYEDHRIEQADWPEIKSTLPFGKIPILEVDGLTLHQSLAIARYLTKNTDLAGNTEMEQCHVDAIVDTLDDFMSCFPWAEKKQDVKEQMFNELLTYNAPHLMQDLDTYLGGREWLIGNSVTWADFYWEICSTTLLVFKPDLLDNHPRLVTLRKKVQAIPAVANWIKRRPQTKL T19433 DRUGINFO D0L9ZR Praziquantel Approved T19433 DRUGINFO D02AOD HF-0220 Phase 2 T19433 DRUGINFO D06GJP Cibacron blue Investigative T19433 DRUGINFO D08IXW S-hexylglutathione Investigative T19433 DRUGINFO D0AF3A Protoporphyrin IX Investigative T19433 DRUGINFO D0PI1C HQL-79 Investigative T19433 DRUGINFO D06EWG Formic Acid Investigative T94033 TARGETID T94033 T94033 FORMERID TTDS00202 T94033 UNIPROID THRB_HUMAN T94033 TARGNAME Coagulation factor IIa (F2) T94033 GENENAME F2 T94033 TARGTYPE Successful T94033 SYNONYMS Prothrombin; Coagulation factor II T94033 FUNCTION Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing. T94033 PDBSTRUC 8KME; 7KME; 6EO9; 6EO8; 6EO7 T94033 BIOCLASS Peptidase T94033 ECNUMBER EC 3.4.21.5 T94033 SEQUENCE MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE T94033 DRUGINFO D03LWO Desirudin Recombinant Approved T94033 DRUGINFO D07KFG Human prothrombin complex concentrate Approved T94033 DRUGINFO D07UWV Argatroban Approved T94033 DRUGINFO D09LPN Lepirudin Approved T94033 DRUGINFO D09WKB Anisindione Approved T94033 DRUGINFO D0AW9T ATryn antithrombin Approved T94033 DRUGINFO D0M7JT Dabigatran Approved T94033 DRUGINFO D06JGH Pyridoxal Phosphate Approved T94033 DRUGINFO D09HVL Bivalirudin Approved T94033 DRUGINFO D0B5LF Ximelegatran Approved T94033 DRUGINFO D0F3SZ Hirudin Phase 4 T94033 DRUGINFO D01MUU MELAGATRAN Phase 3 T94033 DRUGINFO D0VL4V SR-123781A Phase 2/3 T94033 DRUGINFO D09DFB EFEGATRAN SULFATE HYDRATE Phase 2 T94033 DRUGINFO D0GG5I Recombinant RGD-hirudin Phase 2 T94033 DRUGINFO D0H9RN NU-172 Phase 2 T94033 DRUGINFO D0I7MX LB-30870 Phase 2 T94033 DRUGINFO D0K8FI Pegmusirudin Phase 2 T94033 DRUGINFO D0N6EA Odiparcil Phase 2 T94033 DRUGINFO D0PX0N TF0023 Phase 2 T94033 DRUGINFO D0UK1L EP-217609 Phase 2 T94033 DRUGINFO D00LOB RWJ-671818 Phase 1 T94033 DRUGINFO D05HAD DP-4088 Phase 1 T94033 DRUGINFO D0K4FP AZD-8165 Phase 1 T94033 DRUGINFO D0L2XU Solulin Phase 1 T94033 DRUGINFO D02UIC SSR-128428 Phase 1 T94033 DRUGINFO D0G6UQ EP-42675 Phase 1 T94033 DRUGINFO D0JQ7Y Ximelagatran Withdrawn from market T94033 DRUGINFO D06DUO SSR-182289 Discontinued in Phase 2 T94033 DRUGINFO D07MZC Vasoflux Discontinued in Phase 2 T94033 DRUGINFO D0B1KK AZD0837 Discontinued in Phase 2 T94033 DRUGINFO D0H4UJ INOGATRAN Discontinued in Phase 2 T94033 DRUGINFO D0Q3WN Napsagatran Discontinued in Phase 2 T94033 DRUGINFO D0B9EH Dermolastin Discontinued in Phase 2 T94033 DRUGINFO D01IBO BCX-1470 Discontinued in Phase 1 T94033 DRUGINFO D02MHE CVS-1123 Discontinued in Phase 1 T94033 DRUGINFO D05KTK CJC-1004 Discontinued in Phase 1 T94033 DRUGINFO D05MXK GW-473178 Discontinued in Phase 1 T94033 DRUGINFO D09CKF Licostinel Discontinued in Phase 1 T94033 DRUGINFO D0G0XN UK-156406 Discontinued in Phase 1 T94033 DRUGINFO D0H2ZQ S-18326 Discontinued in Phase 1 T94033 DRUGINFO D0UF5I MPC-0920 Discontinued in Phase 1 T94033 DRUGINFO D0W5XT ARC-183 Discontinued in Phase 1 T94033 DRUGINFO D02QTV Efegatran Terminated T94033 DRUGINFO D02ZWG SR-80027A Terminated T94033 DRUGINFO D05WYW L-373890 Terminated T94033 DRUGINFO D06ALB BCH-2763 Terminated T94033 DRUGINFO D0G7YZ BMS-189664 Terminated T94033 DRUGINFO D0J6VU CVS-995 Terminated T94033 DRUGINFO D0L6UZ L-374,087 Terminated T94033 DRUGINFO D0RP8F PPACK Terminated T94033 DRUGINFO D0S2JG LB30057 Terminated T94033 DRUGINFO D0S6XJ GS-522 Terminated T94033 DRUGINFO D0SF5F Org-34092 Terminated T94033 DRUGINFO D0WL1C Hementin Terminated T94033 DRUGINFO D0Y5EX DuP 714 Terminated T94033 DRUGINFO D01ARY Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir Investigative T94033 DRUGINFO D01NEZ CHLORODYSINOSIN A Investigative T94033 DRUGINFO D01RTU METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE Investigative T94033 DRUGINFO D01WDB S-2238 Investigative T94033 DRUGINFO D02KKL Hemi-Babim Investigative T94033 DRUGINFO D03KFJ TB-102 Investigative T94033 DRUGINFO D03LGM Beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide Investigative T94033 DRUGINFO D03MYL Lysophosphotidylserine Investigative T94033 DRUGINFO D04CQG Heparin-Cantithrombin III Investigative T94033 DRUGINFO D04PPE VE-04051645 Investigative T94033 DRUGINFO D04VYT Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir Investigative T94033 DRUGINFO D05BMA D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide Investigative T94033 DRUGINFO D05NRZ N4-(N,N-diphenylcarbamoyl)-aminoguanidine Investigative T94033 DRUGINFO D05RFC Tumor vascular thrombogen Investigative T94033 DRUGINFO D06KCW 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE Investigative T94033 DRUGINFO D06YJX Enoxaprin Investigative T94033 DRUGINFO D07BJZ Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir Investigative T94033 DRUGINFO D07BMA Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir Investigative T94033 DRUGINFO D07NYX BENZOTHIAZOLE Investigative T94033 DRUGINFO D07QPA Vitamin K Investigative T94033 DRUGINFO D07YNF D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide Investigative T94033 DRUGINFO D08EUH D-phenylalanyl-N-benzyl-L-prolinamide Investigative T94033 DRUGINFO D08MEC Melogatran Investigative T94033 DRUGINFO D08YGD Haempatch Investigative T94033 DRUGINFO D09CVG 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE Investigative T94033 DRUGINFO D09HFC Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir Investigative T94033 DRUGINFO D09QZJ AC-(D)PHE-PRO-BOROHOMOLYS-OH Investigative T94033 DRUGINFO D0CF3B Cyclotheonamide E5 Investigative T94033 DRUGINFO D0CV4F Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir Investigative T94033 DRUGINFO D0D8AK Cyclotheonamide E Investigative T94033 DRUGINFO D0D9NT 4-TERT-BUTYLBENZENESULFONIC ACID Investigative T94033 DRUGINFO D0E1NH 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE Investigative T94033 DRUGINFO D0E9ON AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH Investigative T94033 DRUGINFO D0F4VK TB-101 Investigative T94033 DRUGINFO D0H5WV OSCILLARIN Investigative T94033 DRUGINFO D0H8OB Desirudine Investigative T94033 DRUGINFO D0I0NY L-370,518 Investigative T94033 DRUGINFO D0I6DO bufrudin Investigative T94033 DRUGINFO D0I8WD Methyl L-phenylalaninate Investigative T94033 DRUGINFO D0K3JC D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide Investigative T94033 DRUGINFO D0KQ1K Bbs-Arg-(D-Pip)-Gly-(SPH(pY)EKVS)-Gly-Hir Investigative T94033 DRUGINFO D0M1AC Cyclotheonamide E4 Investigative T94033 DRUGINFO D0N0PI 2-NAPHTHALENESULFONIC ACID Investigative T94033 DRUGINFO D0N1HV 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL Investigative T94033 DRUGINFO D0O1DU D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide Investigative T94033 DRUGINFO D0P0LG Bbs-Arg-(D-Pip)-Gly-(SPHYEKVS)-Gly-Hir Investigative T94033 DRUGINFO D0P1JQ D-leucyl-N-(3-chlorobenzyl)-L-prolinamide Investigative T94033 DRUGINFO D0QQ4Z LB30812 Investigative T94033 DRUGINFO D0R4AV AC-(D)PHE-PRO-BOROLYS-OH Investigative T94033 DRUGINFO D0T5WR Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir Investigative T94033 DRUGINFO D0U4HG COCHINCHINENIN B Investigative T94033 DRUGINFO D0V7RD DYSINOSIN A Investigative T94033 DRUGINFO D0W5AW SC-79407 Investigative T94033 DRUGINFO D0WF2C Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir Investigative T94033 DRUGINFO D0X0IF COCHINCHINENENE B Investigative T94033 DRUGINFO D0Y8QU CVS-1578 Investigative T94033 DRUGINFO D02NHS L-375378 Investigative T94033 DRUGINFO D07HWB 5-desgalloylstachyurin Investigative T94033 DRUGINFO D07IBU GR-133686 Investigative T94033 DRUGINFO D09OBJ RWJ-50353 Investigative T94033 DRUGINFO D0E6SO Tellimagrandin II Investigative T94033 DRUGINFO D0G6RI 4-hydroxyphenylpyruvic acid Investigative T94033 DRUGINFO D0I1UF CASUARIIN Investigative T94033 DRUGINFO D0JU9N BMS-740808 Investigative T94033 DRUGINFO D0K7YL CRA_8696 Investigative T94033 DRUGINFO D0N0YX Beta-(2-Naphthyl)-Alanine Investigative T94033 DRUGINFO D0P3OH 3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate Investigative T94033 DRUGINFO D0RQ2T Macrocyclic tripeptide motif Investigative T94033 DRUGINFO D00WFQ (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone Investigative T94033 DRUGINFO D05MJU 4-iodobenzo[b]thiophene 2-carboxamidine Investigative T94033 DRUGINFO D06LPR (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone Investigative T94033 DRUGINFO D06UUK Gamma-Carboxy-Glutamic Acid Investigative T94033 DRUGINFO D08WQJ (3-nitro-1H-pyrazol-1-yl)(phenyl)methanone Investigative T94033 DRUGINFO D0CT8A 4-(3,4-Diethoxy-benzylamino)-benzamidine Investigative T94033 DRUGINFO D0J1QT BMS-344577 Investigative T94033 DRUGINFO D0SP2I 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine Investigative T94033 DRUGINFO D0Z2TG Pedunculagin Investigative T94033 DRUGINFO D00QDR 1,2,3,4,6-penta-O-galloyl-beta-D-glucose Investigative T94033 DRUGINFO D02XPB 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine Investigative T94033 DRUGINFO D05ZIP (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative T94033 DRUGINFO D08OCS (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative T94033 DRUGINFO D0IU5E 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide Investigative T94033 DRUGINFO D0M4VZ D-Pro-Phe-Arg chloromethyl ketone Investigative T94033 DRUGINFO D0ON2Z RAZAXABAN Investigative T94033 DRUGINFO D0X1OY (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone Investigative T94033 DRUGINFO D08OLP 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine Investigative T83369 TARGETID T83369 T83369 FORMERID TTDC00078 T83369 UNIPROID FA9_HUMAN T83369 TARGNAME Coagulation factor IX (F9) T83369 GENENAME F9 T83369 TARGTYPE Successful T83369 SYNONYMS Plasma thromboplastin component; PTC protein; Factor IX; Christmas factor T83369 FUNCTION Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa. T83369 PDBSTRUC 6MV4; 5VYG; 5TNT; 5TNO; 5JBC T83369 BIOCLASS Peptidase T83369 ECNUMBER EC 3.4.21.22 T83369 SEQUENCE MQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT T83369 DRUGINFO D0P8QN Recombinant Factor IX Approved T83369 DRUGINFO D09XTN Emicizumab Approved T83369 DRUGINFO D04AYZ CSL-654 Phase 3 T83369 DRUGINFO D08YTF RG6013 Phase 3 T83369 DRUGINFO DBHO19 AMT-061 Phase 3 T83369 DRUGINFO DN87BL Fidanacogene elaparvovec Phase 3 T83369 DRUGINFO D2AK6X Mim8 Phase 3 T83369 DRUGINFO D0VT1S TTP889 Phase 2 T83369 DRUGINFO D0A9PW AMT-060 Phase 1/2 T83369 DRUGINFO DH40QT SB-FIX Phase 1/2 T83369 DRUGINFO D00TXL AAV2-hFIX16 Phase 1 T83369 DRUGINFO D05RBH N9-GP Phase 1 T83369 DRUGINFO DA5J0E RG6512 Phase 1 T83369 DRUGINFO D03MCV RB-006 Discontinued in Phase 3 T83369 DRUGINFO D03PJP Trenonacog alfa Discontinued in Phase 3 T83369 DRUGINFO D07JQO SB 249417 Discontinued in Phase 1 T83369 DRUGINFO D0K9KS Draculin Terminated T83369 DRUGINFO D06IGE Factor IX-XTEN Investigative T83369 DRUGINFO D09PDK F-9TG Investigative T83369 DRUGINFO D0EK9T 4-Phenyl-benzo[b]thiophene-2-carboxamidine Investigative T83369 DRUGINFO D0G4LX PMID20121197C57 Investigative T83369 DRUGINFO D0LX0D 6-Benzyloxybenzo[b]thiophene-2-carboxamidine Investigative T83369 DRUGINFO D0Q4XG MOD-3012 Investigative T83369 DRUGINFO D0Y4KJ 5-Benzyloxy-benzo[b]thiophene-2-carboxamidine Investigative T83369 DRUGINFO D0YX8X MG-1104 Investigative T83369 DRUGINFO D0Z2PJ 4-Benzyloxybenzo[b]thiophene-2-carboxamidine Investigative T83369 DRUGINFO D0Z2UT BNP-FIX Investigative T83369 DRUGINFO D05MJU 4-iodobenzo[b]thiophene 2-carboxamidine Investigative T83369 DRUGINFO D06UUK Gamma-Carboxy-Glutamic Acid Investigative T83369 DRUGINFO D0ON2Z RAZAXABAN Investigative T84631 TARGETID T84631 T84631 FORMERID TTDS00203 T84631 UNIPROID FA10_HUMAN T84631 TARGNAME Coagulation factor Xa (F10) T84631 GENENAME F10 T84631 TARGTYPE Successful T84631 SYNONYMS Fxa; Factor Xa; F10; Activated coagulation factor X T84631 FUNCTION Factor Xa is avitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting. T84631 PDBSTRUC 6RK9; 5VOF; 5VOE; 5K0H; 5JZU T84631 BIOCLASS Peptidase T84631 ECNUMBER EC 3.4.21.6 T84631 SEQUENCE MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEETCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKNCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERRKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK T84631 DRUGINFO D08PSU Lmw heparin Approved T84631 DRUGINFO D0C3BS DU-176b Approved T84631 DRUGINFO D0I5HF Apixaban Approved T84631 DRUGINFO D0J0BU BETRIXABAN Approved T84631 DRUGINFO D0KG3R Rivaroxaban Approved T84631 DRUGINFO D0N2BX Nadroparin calcium Approved T84631 DRUGINFO D0NE9T Fondaparinux sodium Approved T84631 DRUGINFO D0P3SY Danaparoid Approved T84631 DRUGINFO D0Q5KL Coagulation Factor IX Approved T84631 DRUGINFO D0U7HJ Certoparin sodium Approved T84631 DRUGINFO D09XTN Emicizumab Approved T84631 DRUGINFO D07JEW Human coagulation factor X BLA submitted T84631 DRUGINFO D00ITC PRT4445 Phase 3 T84631 DRUGINFO D0P2RO SSR-126517E Phase 3 T84631 DRUGINFO D2AK6X Mim8 Phase 3 T84631 DRUGINFO D01MUU MELAGATRAN Phase 3 T84631 DRUGINFO D0VL4V SR-123781A Phase 2/3 T84631 DRUGINFO D01FFG Antistasin Phase 2 T84631 DRUGINFO D07BRZ LY-517717 Phase 2 T84631 DRUGINFO D0ID3W GW-813893 Phase 2 T84631 DRUGINFO D0UK1L EP-217609 Phase 2 T84631 DRUGINFO D00RGF GCC-4401 Phase 1 T84631 DRUGINFO D00ZPT BI-11634 Phase 1 T84631 DRUGINFO D08UUD R-1663 Phase 1 T84631 DRUGINFO D0X2NN BIBT986 Phase 1 T84631 DRUGINFO D02UIC SSR-128428 Phase 1 T84631 DRUGINFO D0G6UQ EP-42675 Phase 1 T84631 DRUGINFO DA5J0E RG6512 Phase 1 T84631 DRUGINFO D07OGZ Darexaban maleate Discontinued in Phase 3 T84631 DRUGINFO D0CY3A Idraparinux Discontinued in Phase 3 T84631 DRUGINFO D0E2MJ Otamixaban Discontinued in Phase 3 T84631 DRUGINFO D09TGX Valspodar Discontinued in Phase 3 T84631 DRUGINFO D0L9YS Octopamine Discontinued in Phase 2a T84631 DRUGINFO D0D5RH TAK-442 Discontinued in Phase 2 T84631 DRUGINFO D0JH6W DX-9065a Discontinued in Phase 2 T84631 DRUGINFO D0T4UL PD-348292 Discontinued in Phase 2 T84631 DRUGINFO D0V2OS DX-9065 Discontinued in Phase 2 T84631 DRUGINFO D0G5GJ R-68151 Discontinued in Phase 2 T84631 DRUGINFO D00CIF EMD-503982 Discontinued in Phase 1 T84631 DRUGINFO D03QJN DPC 423 Discontinued in Phase 1 T84631 DRUGINFO D0G6UP YM-75466 Discontinued in Phase 1 T84631 DRUGINFO D0L4PM AVE-3247 Discontinued in Phase 1 T84631 DRUGINFO D0N8JP JTV-803 Discontinued in Phase 1 T84631 DRUGINFO D0PG5J ZD-4927 Discontinued in Phase 1 T84631 DRUGINFO D0K5WM CS-3030 Preclinical T84631 DRUGINFO D0X1ZV Trimidox Preclinical T84631 DRUGINFO D0J9UI YM60828 Terminated T84631 DRUGINFO D0Q1JW Hirufaxin Terminated T84631 DRUGINFO D0K9KS Draculin Terminated T84631 DRUGINFO D01AUI SF303 Investigative T84631 DRUGINFO D02AVL ZK-813039 Investigative T84631 DRUGINFO D03QAQ SN429 Investigative T84631 DRUGINFO D04QZF SK554 Investigative T84631 DRUGINFO D06BPU SC-83157 Investigative T84631 DRUGINFO D06HOI BMS-269223 Investigative T84631 DRUGINFO D07NYR YM-96765 Investigative T84631 DRUGINFO D08CEU Recombinant Factor X Investigative T84631 DRUGINFO D09KKU Lefaxin Investigative T84631 DRUGINFO D09TXU DT-831j Investigative T84631 DRUGINFO D0ES5A Molecule 11 Investigative T84631 DRUGINFO D0FV9Y PhSO2-Gly-(Me-Gly)-Arg-(2-thiazole) Investigative T84631 DRUGINFO D0I8WY M55113 Investigative T84631 DRUGINFO D0K7NJ Recombinant coagulation factors Investigative T84631 DRUGINFO D0Q2VA EP-37 Investigative T84631 DRUGINFO D0QR3J GC-2107 Investigative T84631 DRUGINFO D0R5KV CI-1031 Investigative T84631 DRUGINFO D0SP5Q PRT-064445 Investigative T84631 DRUGINFO D0Z8VP Beta-Hydroxy Aspartic Acid Investigative T84631 DRUGINFO D0Z9TY SK549 Investigative T84631 DRUGINFO D00MZS SK509 Investigative T84631 DRUGINFO D07HWB 5-desgalloylstachyurin Investigative T84631 DRUGINFO D0E6SO Tellimagrandin II Investigative T84631 DRUGINFO D0I1UF CASUARIIN Investigative T84631 DRUGINFO D0JU9N BMS-740808 Investigative T84631 DRUGINFO D0P3OH 3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate Investigative T84631 DRUGINFO D0R9CH ZK-810388 Investigative T84631 DRUGINFO D02PAU ZK-814048 Investigative T84631 DRUGINFO D06UUK Gamma-Carboxy-Glutamic Acid Investigative T84631 DRUGINFO D0J1QT BMS-344577 Investigative T84631 DRUGINFO D0Z2TG Pedunculagin Investigative T84631 DRUGINFO D00QDR 1,2,3,4,6-penta-O-galloyl-beta-D-glucose Investigative T84631 DRUGINFO D02XPB 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine Investigative T84631 DRUGINFO D0M4VZ D-Pro-Phe-Arg chloromethyl ketone Investigative T84631 DRUGINFO D0ON2Z RAZAXABAN Investigative T89034 TARGETID T89034 T89034 FORMERID TTDS00392 T89034 UNIPROID PLMN_HUMAN T89034 TARGNAME Plasminogen (PLG) T89034 GENENAME PLG T89034 TARGTYPE Successful T89034 SYNONYMS Plasmin T89034 FUNCTION In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. T89034 PDBSTRUC 6D40; 6D3Z; 6D3Y; 6D3X; 5UGG T89034 BIOCLASS Peptidase T89034 ECNUMBER EC 3.4.21.7 T89034 SEQUENCE MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFTCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTEQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEEDCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGGPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN T89034 DRUGINFO D03HYQ Ranolazine Approved T89034 DRUGINFO D04URO Streptokinase Approved T89034 DRUGINFO D05HXX Tranexamic Acid Approved T89034 DRUGINFO D07BQE Alteplase Approved T89034 DRUGINFO D0FX8A Tenecteplase Approved T89034 DRUGINFO D0K4DI Anistreplase Approved T89034 DRUGINFO D0T1UJ Reteplase Approved T89034 DRUGINFO D0FD0H Aminocaproic Acid Approved T89034 DRUGINFO D0TC4R Desmoteplase Phase 3 T89034 DRUGINFO D01MUU MELAGATRAN Phase 3 T89034 DRUGINFO D0S4YT Plasminogen Phase 2/3 T89034 DRUGINFO D09IOF Troplasminogen alfa Phase 2 T89034 DRUGINFO DEV2G0 BIIB131 Phase 2 T89034 DRUGINFO D0RD0Y RetinoStat Phase 2 T89034 DRUGINFO D0PK7J bis-triazole derivative 10 Clinical trial T89034 DRUGINFO D04DYA SMTP-0 Investigative T89034 DRUGINFO D0A9HM 1-(2-Oxo-2-p-tolyl-ethyl)-1H-indole-2,3-dione Investigative T89034 DRUGINFO D0LJ7R M5 Investigative T89034 DRUGINFO D0M9XH XP-21510 Investigative T89034 DRUGINFO D0ND8N Textilinin Investigative T89034 DRUGINFO D0V2MR Bicine Investigative T89034 DRUGINFO D01JUI N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine Investigative T89034 DRUGINFO D0K4PK 1-guanidino-7-isoquinolinesulphonamide Investigative T89034 DRUGINFO D0VP6M 1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione Investigative T89034 DRUGINFO D00PEJ 1-guanidino-N-phenyl-7-isoquinolinesulphonamide Investigative T89034 DRUGINFO D08OLP 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine Investigative T89034 DRUGINFO D0Y5IQ Grassystatin a Investigative T17758 TARGETID T17758 T17758 FORMERID TTDC00312 T17758 UNIPROID UROK_HUMAN T17758 TARGNAME Urokinase-type plasminogen activator (PLAU) T17758 GENENAME PLAU T17758 TARGTYPE Successful T17758 SYNONYMS UPA; U-plasminogen activator T17758 FUNCTION Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. T17758 PDBSTRUC 6NMB; 5ZC5; 5ZAJ; 5ZAH; 5ZAG T17758 BIOCLASS Peptidase T17758 ECNUMBER EC 3.4.21.73 T17758 SEQUENCE MRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL T17758 DRUGINFO D03VNX Pro-urokinase Approved T17758 DRUGINFO D0E8UO Urokinase Approved T17758 DRUGINFO D03ZJE PAI-1 Phase 4 T17758 DRUGINFO D0G6ZG Amediplase Phase 3 T17758 DRUGINFO D03KGH Upamostat Phase 2 T17758 DRUGINFO D0G5UW Saruplase Phase 2 T17758 DRUGINFO D01HHJ HTU-PA Phase 1/2 T17758 DRUGINFO D00EPS PMID18163548C4 Clinical trial T17758 DRUGINFO D0G0YZ UK-356202 Clinical trial T17758 DRUGINFO D0D3VA PAI-2 Discontinued in Phase 2 T17758 DRUGINFO D08INO WX-UK1 Discontinued in Phase 1/2 T17758 DRUGINFO D0K1PR B-428 Terminated T17758 DRUGINFO D00LDI UPA-targeted oncolytic Sendai virus Investigative T17758 DRUGINFO D01LCS CRA_10655 Investigative T17758 DRUGINFO D02XJW 5-Methylsulfanyl-thiophene-2-carboxamidine Investigative T17758 DRUGINFO D03BWQ ATN-658 Investigative T17758 DRUGINFO D03NLL (2R)-1-(2,6-dimethylphenoxy)propan-2-amine Investigative T17758 DRUGINFO D05DNW B-623 Investigative T17758 DRUGINFO D06CJP 4-chloro-1-guanidino-7-isoquinolinesulphonamide Investigative T17758 DRUGINFO D09KKF 2-Amino-5-Hydroxy-Benzimidazole Investigative T17758 DRUGINFO D0A8WP 6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine Investigative T17758 DRUGINFO D0B1AK Thieno[2,3-B]Pyridine-2-Carboxamidine Investigative T17758 DRUGINFO D0D1TX Recombinant human pro-urokinase Investigative T17758 DRUGINFO D0EV6B N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea Investigative T17758 DRUGINFO D0F6EZ (4-guanidino-benzyl)-carbamic acid benzyl ester Investigative T17758 DRUGINFO D0ZM9M 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine Investigative T17758 DRUGINFO D02AKP 4-methoxy-N'-(2-phenylacetyl)benzohydrazide Investigative T17758 DRUGINFO D05ABK ATF-HI-8 Investigative T17758 DRUGINFO D0K4PK 1-guanidino-7-isoquinolinesulphonamide Investigative T17758 DRUGINFO D0K7YL CRA_8696 Investigative T17758 DRUGINFO D00PEJ 1-guanidino-N-phenyl-7-isoquinolinesulphonamide Investigative T17758 DRUGINFO D00WFQ (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone Investigative T17758 DRUGINFO D05MJU 4-iodobenzo[b]thiophene 2-carboxamidine Investigative T17758 DRUGINFO D06LPR (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone Investigative T17758 DRUGINFO D0SP2I 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine Investigative T17758 DRUGINFO D05ZIP (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative T17758 DRUGINFO D07SFI Benzamidine Investigative T17758 DRUGINFO D08OCS (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative T17758 DRUGINFO D0IU5E 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide Investigative T17758 DRUGINFO D0X1OY (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone Investigative T17758 DRUGINFO D08OLP 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine Investigative T17758 DRUGINFO D0G6XS Fucose Investigative T61622 TARGETID T61622 T61622 FORMERID TTDS00451 T61622 UNIPROID RENI_HUMAN T61622 TARGNAME Angiotensinogenase renin (REN) T61622 GENENAME REN T61622 TARGTYPE Successful T61622 SYNONYMS Renin; Angiotensinogenase T61622 FUNCTION Renin is a highly specific endopeptidase, whose only knownfunction is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney. T61622 PDBSTRUC 6I3F; 5VRP; 5VPM; 5V8V; 5TMK T61622 BIOCLASS Peptidase T61622 ECNUMBER EC 3.4.23.15 T61622 SEQUENCE MDGWRRMPRWGLLLLLWGSCTFGLPTDTTTFKRIFLKRMPSIRESLKERGVDMARLGPEWSQPMKRLTLGNTTSSVILTNYMDTQYYGEIGIGTPPQTFKVVFDTGSSNVWVPSSKCSRLYTACVYHKLFDASDSSSYKHNGTELTLRYSTGTVSGFLSQDIITVGGITVTQMFGEVTEMPALPFMLAEFDGVVGMGFIEQAIGRVTPIFDNIISQGVLKEDVFSFYYNRDSENSQSLGGQIVLGGSDPQHYEGNFHYINLIKTGVWQIQMKGVSVGSSTLLCEDGCLALVDTGASYISGSTSSIEKLMEALGAKKRLFDYVVKCNEGPTLPDISFHLGGKEYTLTSADYVFQESYSSKKLCTLAIHAMDIPPPTGPTWALGATFIRKFYTEFDRRNNRIGFALAR T61622 DRUGINFO D03SVX Aliskiren Approved T61622 DRUGINFO D0C2EP Remikiren Approved T61622 DRUGINFO D07JXN SPP-600 Phase 2 T61622 DRUGINFO D0A5SA TAK-272 Phase 2 T61622 DRUGINFO D0H8WZ SR-43845 Phase 2 T61622 DRUGINFO D0V3UN CP-80794 Phase 2 T61622 DRUGINFO DN9DB6 SPH3127 Phase 2 T61622 DRUGINFO D01QSG VTP-27999 Phase 1 T61622 DRUGINFO D03XHS ACT-178882 Phase 1 T61622 DRUGINFO D0U7OS CARD-024 Phase 1 T61622 DRUGINFO D01SGM FK-906 Discontinued in Phase 2 T61622 DRUGINFO D09ELW Enalkiren Discontinued in Phase 2 T61622 DRUGINFO D0J5GT ZANKIREN Discontinued in Phase 2 T61622 DRUGINFO D02KEY SPP-676 Discontinued in Phase 1 T61622 DRUGINFO D0L4VZ SPP-1148 Discontinued in Phase 1 T61622 DRUGINFO D0V4LG RS-8891 Discontinued in Phase 1 T61622 DRUGINFO D00MIF JTP-4761 Terminated T61622 DRUGINFO D01EZY JTP-2724 Terminated T61622 DRUGINFO D02KBO Ciprokiren Terminated T61622 DRUGINFO D05FTY ES-1005 Terminated T61622 DRUGINFO D06ZKG SC-56525 Terminated T61622 DRUGINFO D08IDQ BILA-2157BS Terminated T61622 DRUGINFO D0K1AF A-74273 Terminated T61622 DRUGINFO D0M7HO SQ-33800 Terminated T61622 DRUGINFO D0V5XL KRI-1314 Terminated T61622 DRUGINFO D00FHV Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2 Investigative T61622 DRUGINFO D01FJQ Pro-His-Pro-His-Phe-Phe-Val-Tyr Investigative T61622 DRUGINFO D02MBW 2-Methyl-3-(2-Aminothiazolo)Propanal Investigative T61622 DRUGINFO D02MME N-Methyl-N-(Methylbenzyl)Formamide Investigative T61622 DRUGINFO D04DZP (H-261)Boc-His-Pro-Phe-His-Leu(OH)-Val-Ile-His-OH Investigative T61622 DRUGINFO D04GXL Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O) Investigative T61622 DRUGINFO D04QIA Ro-66-1168 Investigative T61622 DRUGINFO D06JQM SPP-800 Investigative T61622 DRUGINFO D06OBP 1-Hydroxy-2-Amino-3-Cyclohexylpropane Investigative T61622 DRUGINFO D08BRJ Pro-His-Pro-His-Leu-Phe-Val-Tyr Investigative T61622 DRUGINFO D09PZT Iva-His-Pro-Phe-His-Sta-Leu-Phe-NH2 Investigative T61622 DRUGINFO D09QXR 3-Phenyl-1,2-Propandiol Investigative T61622 DRUGINFO D09RQD 2-Cyclopropylmethylenepropanal Investigative T61622 DRUGINFO D0A3LJ Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp Investigative T61622 DRUGINFO D0A9BK 1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine Investigative T61622 DRUGINFO D0E5QB Ro-65-7219 Investigative T61622 DRUGINFO D0G9DJ Iva-His-Pro-Phe-His-AHPPA-Leu-Phe-NH2 Investigative T61622 DRUGINFO D0J6QC PP1-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O) Investigative T61622 DRUGINFO D0K0OY Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro Investigative T61622 DRUGINFO D0KH9Z Pro-His-Pro-Phe-His-Leu(CH2NH)Val-Ile-His-Lys Investigative T61622 DRUGINFO D0P7NP CP-305202 Investigative T61622 DRUGINFO D0Q3IE Pro-His-Pro-His-Phe-Phe-Val-Tyr-Lys Investigative T61622 DRUGINFO D0Q8VT JT-2724 Investigative T61622 DRUGINFO D0TD2F ES-6864 Investigative T61622 DRUGINFO D0V4EK 1-Hydroxy-3-Methylbutane Investigative T61622 DRUGINFO D0VI7P PP2-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O) Investigative T61622 DRUGINFO D0E1KX Dimethylformamide Investigative T56915 TARGETID T56915 T56915 FORMERID TTDS00320 T56915 UNIPROID POL_HV1B1 T56915 TARGNAME Human immunodeficiency virus Protease (HIV PR) T56915 GENENAME HIV PR T56915 TARGTYPE Successful T56915 SYNONYMS HIV Retropepsin; HIV PR T56915 FUNCTION Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation. T56915 PDBSTRUC 6OE3; 6HAK; 6ELI; 6DUH; 6DUG T56915 BIOCLASS Peptidase T56915 ECNUMBER EC 3.4.23.16 T56915 SEQUENCE PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF T56915 DRUGINFO D03IGH Darunavir Approved T56915 DRUGINFO D07IQS Atazanavir Approved T56915 DRUGINFO D0A0OO Amprenavir Approved T56915 DRUGINFO D0EV6T Tipranavir Approved T56915 DRUGINFO D0F5MT Fosamprenavir Approved T56915 DRUGINFO D0V7CF Indinavir Approved T56915 DRUGINFO D0WI3T Saquinavir Approved T56915 DRUGINFO D0ZU9R Ritonavir Approved T56915 DRUGINFO D06KJQ BI 201335 Phase 3 T56915 DRUGINFO D01RXW Vaniprevir Phase 2 T56915 DRUGINFO D01ZNQ TMC-310911 Phase 2 T56915 DRUGINFO D04MCY BMS 650032 Phase 2 T56915 DRUGINFO D05TKB GS-9256 Phase 2 T56915 DRUGINFO D07OHT ABT-450 Phase 2 T56915 DRUGINFO D07SMH MK-5172 Phase 2 T56915 DRUGINFO D07ZAH ACH-1625 Phase 2 T56915 DRUGINFO D0R9MN Danoprevir Phase 2 T56915 DRUGINFO D0W9JM KNI-272 Phase 2 T56915 DRUGINFO D0Y3JI DG-17 Phase 2 T56915 DRUGINFO D02MMP VX-500 Phase 1 T56915 DRUGINFO D04CJN CTP-298 Phase 1 T56915 DRUGINFO D08FYH PF-04776548 Phase 1 T56915 DRUGINFO D09QKI PPL-100 Phase 1 T56915 DRUGINFO D0W6LW BIT225 Phase 1 T56915 DRUGINFO D04GWY Telinavir Discontinued in Phase 2 T56915 DRUGINFO D05UMD R-87366 Discontinued in Phase 2 T56915 DRUGINFO D07FJM BRECANAVIR Discontinued in Phase 2 T56915 DRUGINFO D07MPJ A-75925 Discontinued in Phase 2 T56915 DRUGINFO D0E4FG Mozenavir Discontinued in Phase 2 T56915 DRUGINFO D0J9AK MK-944a Discontinued in Phase 2 T56915 DRUGINFO D09HEV GS-9005 Discontinued in Phase 1/2 T56915 DRUGINFO D01KIS CGP-53437 Discontinued in Phase 1 T56915 DRUGINFO D03MIP SPI-256 Discontinued in Phase 1 T56915 DRUGINFO D06KPW U-103017 Discontinued in Phase 1 T56915 DRUGINFO D07JJC DPC-684 Discontinued in Phase 1 T56915 DRUGINFO D08JTU R-944 Discontinued in Phase 1 T56915 DRUGINFO D09CAC U-96988 Discontinued in Phase 1 T56915 DRUGINFO D0N3ZY DPC-681 Discontinued in Phase 1 T56915 DRUGINFO D0PB4P XM-323 Discontinued in Phase 1 T56915 DRUGINFO D0R5AU LASINAVIR Discontinued in Phase 1 T56915 DRUGINFO D0U7WN A-80987 Discontinued in Phase 1 T56915 DRUGINFO D0U8AR DMP-851 Discontinued in Phase 1 T56915 DRUGINFO D0X8AU KNI-764 Discontinued in Phase 1 T56915 DRUGINFO D00XRK BMS-182193 Terminated T56915 DRUGINFO D01RCC BMS-186318 Terminated T56915 DRUGINFO D02TGW GE-20372A Terminated T56915 DRUGINFO D05GQL KNI-102 Terminated T56915 DRUGINFO D05UMO BAY-793 Terminated T56915 DRUGINFO D06FMY CGP-70726 Terminated T56915 DRUGINFO D07PIA AG-1350 Terminated T56915 DRUGINFO D07PSP U-75875 Terminated T56915 DRUGINFO D0GM4S AG-1284 Terminated T56915 DRUGINFO D0P6DF PD-153103 Terminated T56915 DRUGINFO D0QH0R SB-206343 Terminated T56915 DRUGINFO D0R3JE GS-2992 Terminated T56915 DRUGINFO D0T4OE Palinavir Terminated T56915 DRUGINFO D0V8PN Droxinavir hydrochloride Terminated T56915 DRUGINFO D0B0XX KH-164 Investigative T56915 DRUGINFO D0G6HC JG-365 Investigative T31595 TARGETID T31595 T31595 FORMERID TTDS00174 T31595 UNIPROID NRAM_I33A0 T31595 TARGNAME Influenza Neuraminidase (Influ NA) T31595 GENENAME Influ NA T31595 TARGTYPE Successful T31595 SYNONYMS STNA; NEU1; NANase; N-acylneuraminate glycohydrolase; Influ Sialidase T31595 FUNCTION Unlike other strains, A/WSN/33 neuraminidase binds and activates plasminogen into plasmin in the vicinity of HA so that activated plasmin cleaves HA rendering the virus infectious. T31595 BIOCLASS Glycosylase T31595 ECNUMBER EC 3.2.1.18 T31595 SEQUENCE MNPNQKIITIGSICMVVGIISLILQIGNIISIWISHSIQTGNQNHTGICNQGIITYNVVAGQDSTSVILTGNSSLCPIRGWAIHSKDNGIRIGSKGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRALMSCPVGEAPSPYNSRFESVAWSASACHDGMGWLTIGISGPDNGAVAVLKYNGIITETIKSWRKKILRTQESECTCVNGSCFTIMTDGPSNGLASYKIFKIEKGKVTKSIELNAPNSHYEECSCYPDTGKVMCVCRDNWHGSNRPWVSFDQNLDYQIGYICSGVFGDNPRPKDGPGSCGPVSADGANGVKGFSYRYGNGVWIGRTKSDSSRHGFEMIWDPNGWTETDSRFSVRQDVVAMTDRSGYSGSFVQHPELTGLDCMRPCFWVELIRGRPEEETIWTSGSIISFCGVNSDTVDWSWPDGAELPFTIDK T31595 DRUGINFO D00NPP Zanamivir Approved T31595 DRUGINFO D0O5NK Oseltamivir Approved T31595 DRUGINFO D0P2IW Peramivir Approved T31595 DRUGINFO D04VSM CS-8958 Phase 3 T31595 DRUGINFO D03ZKM UX-001 Phase 3 T31595 DRUGINFO D0YO7Y DAS-181 Phase 2 T31595 DRUGINFO D0Q3ZN GS-3435 Terminated T31595 DRUGINFO D0XJ0P BCX-140 Terminated T31595 DRUGINFO D00LEQ FANA Investigative T31595 DRUGINFO D00PAS Cristacarpin Investigative T31595 DRUGINFO D00PZM Erythribyssin D Investigative T31595 DRUGINFO D01FEA 8-DEOXYGARTANIN Investigative T31595 DRUGINFO D01FQZ Erythribyssin O Investigative T31595 DRUGINFO D01WTQ MANGOSTANIN Investigative T31595 DRUGINFO D02HYW CUDRATRICUSXANTHONE Investigative T31595 DRUGINFO D02NRI Eryvarin D Investigative T31595 DRUGINFO D02QCC Erythribyssin M Investigative T31595 DRUGINFO D03XVT (S)-1,7-Diphenyl-6(E)-hepten-3-ol Investigative T31595 DRUGINFO D05BUX Cyclopentane amide derivatives 1 Investigative T31595 DRUGINFO D05FLL CALOPOCARPIN Investigative T31595 DRUGINFO D05GSS ISONEORAUTENOL Investigative T31595 DRUGINFO D05KWF Cudraxanthone M Investigative T31595 DRUGINFO D06BSN 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid Investigative T31595 DRUGINFO D06IDO GS4071 Investigative T31595 DRUGINFO D06LUX A-315675 Investigative T31595 DRUGINFO D07TDM PHASEOLIN Investigative T31595 DRUGINFO D08UEU 4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID Investigative T31595 DRUGINFO D09YOY Cyclopentane amide derivatives 2 Investigative T31595 DRUGINFO D09YVT HERBACETIN Investigative T31595 DRUGINFO D0A2OH Cudraxanthone L Investigative T31595 DRUGINFO D0A9CZ PHASEOLLIDIN Investigative T31595 DRUGINFO D0B1NY Cyclopentane amide derivatives 3 Investigative T31595 DRUGINFO D0C4GE 4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid Investigative T31595 DRUGINFO D0D8WQ 2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid Investigative T31595 DRUGINFO D0D9NX (E,E)-5-Hydroxy-1,7-diphenyl-4,6-heptadien-3-one Investigative T31595 DRUGINFO D0E8VD Erythribyssin L Investigative T31595 DRUGINFO D0F8CH 4-(Acetylamino)-3-Amino Benzoic Acid Investigative T31595 DRUGINFO D0G5MS MANGOSTANOL Investigative T31595 DRUGINFO D0G5PT DEMETHYLMEDICARPIN Investigative T31595 DRUGINFO D0I0WF RHODIOLININ Investigative T31595 DRUGINFO D0I1BA BCX-1898 Investigative T31595 DRUGINFO D0I6EH Cudraxanthone D Investigative T31595 DRUGINFO D0IH6W (E,E)-1,7-Diphenyl-4,6-heptadien-3-one Investigative T31595 DRUGINFO D0J7YV MANGOSTENONE F Investigative T31595 DRUGINFO D0K6FM SMEATHXANTHONE A Investigative T31595 DRUGINFO D0K8XC Lactose Investigative T31595 DRUGINFO D0MA3M MANGOSTENONE G Investigative T31595 DRUGINFO D0O8EB GARTANIN Investigative T31595 DRUGINFO D0P3BL A-192558 Investigative T31595 DRUGINFO D0P5MJ ERYSTAGALLIN A Investigative T31595 DRUGINFO D0PE5T BCX-1827 Investigative T31595 DRUGINFO D0Q8HV 4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID Investigative T31595 DRUGINFO D0R6YP BCX-1923 Investigative T31595 DRUGINFO D0U8AU MACLURAXANTHONE Investigative T31595 DRUGINFO D0UD1U Erysubin D Investigative T31595 DRUGINFO D0UK4O KATSUMADAIN A Investigative T31595 DRUGINFO D0UR7U Cudratricusxanthone F Investigative T31595 DRUGINFO D0W0BO Cyclopentane amide derivatives 4 Investigative T31595 DRUGINFO D01EJH NEORAUTENOL Investigative T31595 DRUGINFO D04UYB MANGIFERIN Investigative T31595 DRUGINFO D05IWY Gamma-mangostin Investigative T31595 DRUGINFO D05YJR GARCINONE D Investigative T31595 DRUGINFO D0M7ZZ Erysubin E Investigative T31595 DRUGINFO D0Z7EL GOSSYPETIN Investigative T31595 DRUGINFO D06PRC MANGOSTIN Investigative T31595 DRUGINFO D08WQM O-Sialic Acid Investigative T31595 DRUGINFO D0SD9H Beta-D-Mannose Investigative T31595 DRUGINFO D00RIX APIGENIN Investigative T31595 DRUGINFO D0G3TK KAEMPFEROL Investigative T31595 DRUGINFO D0G6XS Fucose Investigative T31595 DRUGINFO D07LUR Alpha-D-Mannose Investigative T31479 TARGETID T31479 T31479 FORMERID TTDS00065 T31479 UNIPROID PA21B_HUMAN T31479 TARGNAME Phospholipase A2 (PLA2G1B) T31479 GENENAME PLA2G1B T31479 TARGTYPE Successful T31479 SYNONYMS Secreted phospholipase A(2); Phosphatidylcholine 2-acylhydrolase 1B; PLA2G1B; Group IB phospholipase A2 T31479 FUNCTION PA2 catalyzes the calcium-dependent hydrolysis of the 2- acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules. T31479 PDBSTRUC 3ELO; 1YSK T31479 BIOCLASS Carboxylic ester hydrolase T31479 ECNUMBER EC 3.1.1.4 T31479 SEQUENCE MKLLVLAVLLTVAAADSGISPRAVWQFRKMIKCVIPGSDPFLEYNNYGCYCGLGGSGTPVDELDKCCQTHDNCYDQAKKLDSCKFLLDNPYTHTYSYSCSGSAITCSSKNKECEAFICNCDRNAAICFSKAPYNKAHKNLDTKKYCQS T31479 DRUGINFO D00FGR Miltefosine Approved T31479 DRUGINFO D00GOS Clocortolone Approved T31479 DRUGINFO D0FL5V Clobetasol Approved T31479 DRUGINFO D0G7KJ Diflorasone Approved T31479 DRUGINFO D0OR2L Cholic Acid Approved T31479 DRUGINFO D0C0KP AllerB Phase 2b T31479 DRUGINFO D00XQO MANOALIDE Phase 2 T31479 DRUGINFO D03VYZ MRX-4 Phase 2 T31479 DRUGINFO D07RKO MRX-6 Phase 2 T31479 DRUGINFO D74PRE Varespladib Phase 2 T31479 DRUGINFO D07LUJ URSOLIC ACID Phase 2 T31479 DRUGINFO D05GZD Rilapladib Phase 1 T31479 DRUGINFO D0L5UO Darapladib Discontinued in Phase 3 T31479 DRUGINFO D03RNX EPC-K1 Discontinued in Phase 2 T31479 DRUGINFO D08VGT BMY-30129 Discontinued in Phase 2 T31479 DRUGINFO D0D3KY SC-106 Discontinued in Phase 2 T31479 DRUGINFO D0MF3C WAY-123641 Discontinued in Phase 2 T31479 DRUGINFO D08YFD PF-05212372 Discontinued in Phase 1 T31479 DRUGINFO D09NBM SB-435495 Discontinued in Phase 1 T31479 DRUGINFO D07OGR YM-26734 Terminated T31479 DRUGINFO D00XNF LY256548 Investigative T31479 DRUGINFO D02COQ Petrosaspongiolide P Investigative T31479 DRUGINFO D02FVV HELENAQUINONE Investigative T31479 DRUGINFO D03IDX WA-8242-A1 Investigative T31479 DRUGINFO D05DUX Petrosaspongiolide M Investigative T31479 DRUGINFO D05SQA 4'-hydroxy-6,3',5'-triprenylisoflavonone Investigative T31479 DRUGINFO D06PLG SB-203347 Investigative T31479 DRUGINFO D07IRQ P-Anisic Acid Investigative T31479 DRUGINFO D0H1JX 3,9-dihydroxy-2,10-diprenylpterocap-6a-ene Investigative T31479 DRUGINFO D0H2RZ Heptanoic Acid Investigative T31479 DRUGINFO D0HZ3Q AGN-190383 Investigative T31479 DRUGINFO D0L3IQ ABYSSINONE V Investigative T31479 DRUGINFO D0O2DQ Mepacrine Investigative T31479 DRUGINFO D0P0DA BM-162115 Investigative T31479 DRUGINFO D0SS5D Lpc-Ether Investigative T31479 DRUGINFO D0TN4X LY178002 Investigative T31479 DRUGINFO D0V4NV folipastatin Investigative T31479 DRUGINFO D0YD6H Hyrtiosulawesine Investigative T31479 DRUGINFO D02IVU CACOSPONGIONOLIDE Investigative T31479 DRUGINFO D03BAB Cacospongionolide E Investigative T31479 DRUGINFO D06YGT N-Tridecanoic Acid Investigative T31479 DRUGINFO D0B9VV CACOSPONGIONOLIDE B Investigative T31479 DRUGINFO D0G4CI methylglyoxal Investigative T31479 DRUGINFO D0O0ZU Hexane-1,6-Diol Investigative T31479 DRUGINFO D0T3CM BOLINAQUINONE Investigative T31479 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T31479 DRUGINFO D0F2ME Acetate Ion Investigative T31479 DRUGINFO D07LUR Alpha-D-Mannose Investigative T40016 TARGETID T40016 T40016 FORMERID TTDS00283 T40016 UNIPROID GCR_HUMAN T40016 TARGNAME Glucocorticoid receptor (NR3C1) T40016 GENENAME NR3C1 T40016 TARGTYPE Successful T40016 SYNONYMS Nuclear receptor subfamily 3 group C member 1; GRL; GR T40016 FUNCTION Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling. Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity). T40016 PDBSTRUC 6EL9; 6EL7; 6EL6; 6DXK; 6CFN T40016 BIOCLASS Nuclear hormone receptor T40016 SEQUENCE MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRRLLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLKLLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGNVKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGNSNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTVYCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVGSENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKLCLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRKCLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIEPEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSWMFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSYEEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTKLLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK T40016 DRUGINFO D02QJH Fluocinolone Acetonide Approved T40016 DRUGINFO D03BLF Triamcinolone Approved T40016 DRUGINFO D03HYX Mometasone Approved T40016 DRUGINFO D03SXE Betamethasone Valerate Approved T40016 DRUGINFO D05RXI Hydrocortamate Approved T40016 DRUGINFO D06CWH Betamethasone Benzoate Approved T40016 DRUGINFO D08PIQ Methylprednisolone Approved T40016 DRUGINFO D09WYX Deflazacort Approved T40016 DRUGINFO D0CW1P Betamethasone Approved T40016 DRUGINFO D0D1SG Prednisolone Approved T40016 DRUGINFO D0FM2P Flunisolide Approved T40016 DRUGINFO D0I5DS Meprednisone Approved T40016 DRUGINFO D0IL7L Prednisone Approved T40016 DRUGINFO D0IT2G Dexamethasone Approved T40016 DRUGINFO D0KR5B Hydrocortisone Approved T40016 DRUGINFO D0LC6K Fluticasone Approved T40016 DRUGINFO D0NA8U Dexamethasone sodium phosphate Approved T40016 DRUGINFO D0P0HT Fluorometholone Approved T40016 DRUGINFO D0Y7IU Budesonide Approved T40016 DRUGINFO D0Y7JU GW685698X Approved T40016 DRUGINFO D0Z4EI Mifepristone Approved T40016 DRUGINFO D00TPW FST-201 Phase 3 T40016 DRUGINFO D01IUS Mapracorat Phase 3 T40016 DRUGINFO D03WNG CORT-125134 Phase 3 T40016 DRUGINFO D4R1JE TLC599 Phase 3 T40016 DRUGINFO D01HYQ IONIS-GCCRRX Phase 2 T40016 DRUGINFO D05MDJ ORG-34517 Phase 2 T40016 DRUGINFO D05RXW LAS-41002 Phase 2 T40016 DRUGINFO D06XSB GW-870086-X Phase 2 T40016 DRUGINFO D0I1DZ DE-110 Phase 2 T40016 DRUGINFO D0M8VL GW-870086-X Phase 2 T40016 DRUGINFO D0OR8W ETIPREDNOL DICLOACETATE Phase 2 T40016 DRUGINFO D0T5TU TPI-1020 Phase 2 T40016 DRUGINFO DWSG41 CORT113176 Phase 2 T40016 DRUGINFO D0E2WF ORG 34517/34850 Phase 2 T40016 DRUGINFO D0L3HU BAY 86-5044 Phase 2 T40016 DRUGINFO D0J6UV IBI-20089 Phase 1 T40016 DRUGINFO D0OS8C NCX-1015 Phase 1 T40016 DRUGINFO D9HQE2 PT-150 Phase 1 T40016 DRUGINFO D01NUG GSK870086 Discontinued in Phase 2 T40016 DRUGINFO D03RCP NM-135 Discontinued in Phase 2 T40016 DRUGINFO D09UFV AZD-5423 Discontinued in Phase 2 T40016 DRUGINFO D0G2CQ WC-3027 Discontinued in Phase 2 T40016 DRUGINFO D03CHE PF-251802 Discontinued in Phase 1 T40016 DRUGINFO D0I7EX Org-34116 Terminated T40016 DRUGINFO D0O0ZU Hexane-1,6-Diol Investigative T40016 DRUGINFO D02UVH B-Octylglucoside Investigative T30081 TARGETID T30081 T30081 FORMERID TTDR00500 T30081 UNIPROID KITH_HUMAN T30081 TARGNAME Thymidine kinase 1 (TK1) T30081 GENENAME TK1 T30081 TARGTYPE Successful T30081 SYNONYMS Thymidine kinase, cytosolic T30081 FUNCTION cytosol, identical protein binding, thymidine kinase activity, zinc ion binding, DNA metabolic process, nucleobase-containing compound metabolic process, protein homotetramerization, pyrimidine nucleoside salvage, thymidine metabolic process T30081 PDBSTRUC 2WVJ; 2ORV; 1XBT; 1W4R T30081 BIOCLASS Kinase T30081 ECNUMBER EC 2.7.1.21 T30081 SEQUENCE MSCINLPTVLPGSPSKTRGQIQVILGPMFSGKSTELMRRVRRFQIAQYKCLVIKYAKDTRYSSSFCTHDRNTMEALPACLLRDVAQEALGVAVIGIDEGQFFPDIVEFCEAMANAGKTVIVAALDGTFQRKPFGAILNLVPLAESVVKLTAVCMECFREAAYTKRLGTEKEVEVIGGADKYHSVCRLCYFKKASGQPAGPDNKENCPVPGKPGEAVAARKLFAPQQILQCSPAN T30081 DRUGINFO D0RX7Z DEOXYCYTIDINE Approved T30081 DRUGINFO D07BYK Penciclovir Approved T30081 DRUGINFO D08AMJ TK-DLI Preregistration T30081 DRUGINFO D04QPD FV-100 Phase 3 T30081 DRUGINFO D0X4NF Radiosensitizer gene therapy Phase 3 T30081 DRUGINFO D0Z9LP RP101 Phase 2/3 T30081 DRUGINFO D05RRA HQK-1004 Phase 2 T30081 DRUGINFO D02KBE Ad-OC-hsvTK/valacyclovir Phase 1 T30081 DRUGINFO D0FY1W Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy Phase 1 T30081 DRUGINFO D05GZD Rilapladib Phase 1 T30081 DRUGINFO D0W8RX Sitimagene ceradenovec Discontinued in Phase 3 T30081 DRUGINFO D00CEO 6-Hydroxypropylthymine Investigative T30081 DRUGINFO D01CUJ 3-(2-propyn-1-yl)thymidine Investigative T30081 DRUGINFO D01VKE ITdU Investigative T30081 DRUGINFO D04GXW 5-Iodo-2'-Deoxyuridine-5'-Monophosphate Investigative T30081 DRUGINFO D07GKK 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine Investigative T30081 DRUGINFO D07OOW (South)-Methanocarba-Thymidine Investigative T30081 DRUGINFO D08AOD 6-(Dihydroxy-Isobutyl)-Thymine Investigative T30081 DRUGINFO D0C7YS 5-propyl-2'-deoxyuridine Investigative T30081 DRUGINFO D0D7FB L-5-(bromovinyl)deoxyuridine Investigative T30081 DRUGINFO D0G5VO 9-(4-Hydroxybutyl)-N2-Phenylguanine Investigative T30081 DRUGINFO D0HO0W L-5-iodo-2'-deoxyuridine Investigative T30081 DRUGINFO D0O7GD 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine Investigative T30081 DRUGINFO D0PC2Y BVDU-MP Investigative T30081 DRUGINFO D0R0EI 9-Hydroxypropyladenine, S-Isomer Investigative T30081 DRUGINFO D0S4SQ 2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine Investigative T30081 DRUGINFO D0ST5A 5-Bromothienyldeoxyuridine Investigative T30081 DRUGINFO D0W8AD 1-[7-(triphenylmethoxy)heptyl]thymine Investigative T30081 DRUGINFO D0X1HX 9-Hydroxypropyladenine, R-Isomer Investigative T30081 DRUGINFO D0Y4MD Edoxudine Investigative T30081 DRUGINFO D0YJ5W N2-(3-trifluoromethylphenyl)guanine Investigative T30081 DRUGINFO D00CVB 2'-Deoxyuridine Investigative T30081 DRUGINFO D00KWL 1-[5-(triphenylmethoxy)pentyl]thymine Investigative T30081 DRUGINFO D01GLG Deoxythymidine Investigative T30081 DRUGINFO D02CCD 1-[6-(triphenylmethoxy)hexyl]thymine Investigative T30081 DRUGINFO D04BBF P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate Investigative T30081 DRUGINFO D0I6UV 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine Investigative T30081 DRUGINFO D0ZH0I Thymidine-5'-Phosphate Investigative T30081 DRUGINFO D09WYY 2'-deoxythymidine triphosphate Investigative T89041 TARGETID T89041 T89041 FORMERID TTDS00241 T89041 UNIPROID CP17A_HUMAN T89041 TARGNAME Steroid 17-alpha-monooxygenase (S17AH) T89041 GENENAME CYP17A1 T89041 TARGTYPE Successful T89041 SYNONYMS Steroid 17-alpha-hydroxylase/17,20 lyase; P450c17; P450-C17; P450 17; CYPXVII; CYP17A1; CYP 17; 17 alpha-Hydroxylase/C17-20-lyase T89041 FUNCTION Conversion of pregnenolone and progesterone to their 17- alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty. T89041 PDBSTRUC 6CIZ; 6CIR; 6CHI; 5UYS; 5IRV T89041 BIOCLASS Paired donor oxygen oxidoreductase T89041 ECNUMBER EC 1.14.14.19 T89041 SEQUENCE MWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAHWQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVISLICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRNDLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIFGAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREVLRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNPAGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIPKVVFLIDSFKVKIKVRQAWREAQAEGST T89041 DRUGINFO D02STN ABIRATERONE Approved T89041 DRUGINFO D06CNP Abiraterone acetate Approved T89041 DRUGINFO D0X3OI TAK-700 Phase 3 T89041 DRUGINFO D78CME TAVT-45 Phase 3 T89041 DRUGINFO D0Q9KR Seviteronel Phase 2 T89041 DRUGINFO D05RVA CFG920 Phase 1/2 T89041 DRUGINFO D01ARU DST-2970 Phase 1 T89041 DRUGINFO D00GIK 1-(3-(4-chlorophenyl)propyl)-1H-imidazole Investigative T89041 DRUGINFO D00GIW 1-(3,5-dibromobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D00IUN 1-(1-(4-thiophen-3-ylphenyl)ethyl)-1H-imidazole Investigative T89041 DRUGINFO D00YHD 4'-(2-methyl-1-(pyridin-4-yl)propyl)biphenyl-3-ol Investigative T89041 DRUGINFO D00ZME 1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole Investigative T89041 DRUGINFO D01JZO 1-(4-chlorobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D02HTG 1-(3,5-difluorobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D02ZQK N-3-(4-bromophenyl)propyl imidazole Investigative T89041 DRUGINFO D03EDD VN/107-1 Investigative T89041 DRUGINFO D04SHY Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,5-diol Investigative T89041 DRUGINFO D05LXA 1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole Investigative T89041 DRUGINFO D05PKT 4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine Investigative T89041 DRUGINFO D05VLU 2,3,4,5-Tetrafluoro-6-pentafluorophenylazo-phenol Investigative T89041 DRUGINFO D06AKB 3-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine Investigative T89041 DRUGINFO D07ORY 1-(3,5-dichlorobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D08OHU 1-(3,5-bis(trifluoromethyl)benzyl)-1H-imidazole Investigative T89041 DRUGINFO D08YCD 1-(1-Biphenyl-4-yl-ethyl)-1H-imidazole Investigative T89041 DRUGINFO D09GEH 1-(1-Biphenyl-4-yl-propyl)-1H-imidazole Investigative T89041 DRUGINFO D09TTR 1-(3-phenylpropyl)-1H-imidazole Investigative T89041 DRUGINFO D0AL3G 1-(3,4-dichlorobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D0B9XL 1-(1-(4-thiophen-3-yl-phenyl)propyl)-1Himidazole Investigative T89041 DRUGINFO D0GJ7J ISOCONAZOLE Investigative T89041 DRUGINFO D0J4VA 3-fluoro-4'-(1-(pyridin-4-yl)propyl)biphenyl-4-ol Investigative T89041 DRUGINFO D0L6HY 1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole Investigative T89041 DRUGINFO D0LC7Z 6-(3-(pyridin-4-yl)phenyl)naphthalen-2-ol Investigative T89041 DRUGINFO D0M1YW ANG-3407 Investigative T89041 DRUGINFO D0M8JE 1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole Investigative T89041 DRUGINFO D0MM7G 1-((9H-Fluoren-2-yl)methyl)-1H-imidazole Investigative T89041 DRUGINFO D0N5GZ 1-(4-methyl-benzyl)-1H-imidazole Investigative T89041 DRUGINFO D0N7CQ Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,4-diol Investigative T89041 DRUGINFO D0P5CT 4'-(Pyridin-4-ylmethyl)biphenyl-4-carboxamide Investigative T89041 DRUGINFO D0P8PG 1-(4-bromophenethyl)-1H-imidazole Investigative T89041 DRUGINFO D0Q1FX Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3-ol Investigative T89041 DRUGINFO D0Q1LG 1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole Investigative T89041 DRUGINFO D0QW7W 4-((1H-imidazol-1-yl)methyl)phenol Investigative T89041 DRUGINFO D0RD3C 1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole Investigative T89041 DRUGINFO D0RI7T 1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole Investigative T89041 DRUGINFO D0S0EP 1-(4-nitrobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D0SM4F Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-4-ol Investigative T89041 DRUGINFO D0SU0Y 1-(1-Biphenyl-4-yl-butyl)-1H-imidazole Investigative T89041 DRUGINFO D0T1CH 4-[1-(4'-Methoxybiphenyl-4-yl)propyl]pyridine Investigative T89041 DRUGINFO D0T3BL 1-(4-chlorophenethyl)-1H-imidazole Investigative T89041 DRUGINFO D0U5GF 2-(1-Imidazol-1-yl-ethyl)-9H-carbazole Investigative T89041 DRUGINFO D0U6JI 4'-(1-(pyridin-4-yl)propyl)biphenyl-3-ol Investigative T89041 DRUGINFO D0U6QM 1-(4-iodobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D0X1DV 1-(1-(4'-Ethylbiphenyl-4-yl)propyl)-1H-imidazole Investigative T89041 DRUGINFO D0X4XX 1-(3,4-difluorobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D00DSE 4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine Investigative T89041 DRUGINFO D01SZX 1-Imidazol-1-ylmethylxanthen-9-one Investigative T89041 DRUGINFO D02ALK 6-Pyridin-3-yl-naphthalen-2-ol Investigative T89041 DRUGINFO D02BXS 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine Investigative T89041 DRUGINFO D03VRC 1-(4-Bromobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D04CFP 5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole Investigative T89041 DRUGINFO D04ISG 3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine Investigative T89041 DRUGINFO D05QPR 1-(4-fluorobenzyl)-1H-imidazole Investigative T89041 DRUGINFO D06FHE 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole Investigative T89041 DRUGINFO D07CTI 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one Investigative T89041 DRUGINFO D07IQG 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one Investigative T89041 DRUGINFO D07VGT 6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol Investigative T89041 DRUGINFO D09GJI 7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol Investigative T89041 DRUGINFO D09VPA 4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine Investigative T89041 DRUGINFO D09VQZ 4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine Investigative T89041 DRUGINFO D0D0DR 1-(3-(4-fluorophenyl)propyl)-1H-imidazole Investigative T89041 DRUGINFO D0E0ZS N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide Investigative T89041 DRUGINFO D0E8DX 6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione Investigative T89041 DRUGINFO D0L1JF 3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T89041 DRUGINFO D0LJ9D 4-(4-(thiophen-2-yl)benzyl)pyridine Investigative T89041 DRUGINFO D0N1GH 6-(pyridin-3-yl)-2-naphthonitrile Investigative T89041 DRUGINFO D0Y5KX 4'-(Pyridin-4-ylmethyl)biphenyl-4-amine Investigative T89041 DRUGINFO D0Z3GX 4-(4-(thiophen-3-yl)benzyl)pyridine Investigative T89041 DRUGINFO D01REI 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol Investigative T89041 DRUGINFO D02CSU 4-Indan-(1Z)-ylidenemethyl-pyridine Investigative T89041 DRUGINFO D03EXD 4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine Investigative T89041 DRUGINFO D03MKT 4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Investigative T89041 DRUGINFO D06HFV 5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine Investigative T89041 DRUGINFO D07ZNR 2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol Investigative T89041 DRUGINFO D09HEA 4-((1H-imidazol-1-yl)methyl)benzonitrile Investigative T89041 DRUGINFO D09HOE 4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T89041 DRUGINFO D0D9FR 4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine Investigative T89041 DRUGINFO D0F5YU 4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T89041 DRUGINFO D0I1YH 4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine Investigative T89041 DRUGINFO D0K5KG 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine Investigative T89041 DRUGINFO D0MA9G 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine Investigative T89041 DRUGINFO D0N1PQ 3-(6-methoxynaphthalen-2-yl)pyridine Investigative T89041 DRUGINFO D0NX0M 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine Investigative T89041 DRUGINFO D0Q0BK 3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol Investigative T89041 DRUGINFO D0R0TE 3-(6-Ethoxy-naphthalen-2-yl)-pyridine Investigative T89041 DRUGINFO D0WN9P 4'-(Pyridin-4-ylmethyl)biphenyl-3-amine Investigative T89041 DRUGINFO D0YD9J 4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine Investigative T47107 TARGETID T47107 T47107 FORMERID TTDC00015 T47107 UNIPROID KPCG_HUMAN T47107 TARGNAME Protein kinase C gamma (PRKCG) T47107 GENENAME PRKCG T47107 TARGTYPE Successful T47107 SYNONYMS PRKCG; PKCG; PKC-gamma T47107 FUNCTION Calcium-activated, phospholipid-and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensitivity to opiates, pain and alcohol, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. Binds and phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its function by increasing plasma membrane-associated GRIA4 expression. In primary cerebellar neurons treated with the agonist 3,5-dihyidroxyphenylglycine, functions downstream of the metabotropic glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor which plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. May be involved in the regulation of hippocampal long-term potentiation (LTP), but may be not necessary for the process of synaptic plasticity. May be involved in desensitization of mu-type opioid receptor-mediated G-protein activation in the spinal cord, and may be critical for the development and/or maintenance ofmorphine-induced reinforcing effects in the limbic forebrain. May modulate the functionality of mu-type-opioid receptors by participating in a signaling pathway which leads to the phosphorylation anddegradation of opioid receptors. May also contributes to chronic morphine-induced changes in nociceptive processing. Plays a role in neuropathic pain mechanisms and contributes to the maintenance of the allodynia pain produced by peripheral inflammation. Plays an important role in initial sensitivity and tolerance to ethanol, by mediating the behavioral effects of ethanol as well as the effects of this drug on the GABA(A) receptors. During and after cerebral ischemia modulate neurotransmission and cell survival in synaptic membranes, and is involved in insulin-induced inhibition of necrosis, an important mechanism for minimizing ischemic injury. Required for the elimination of multiple climbing fibers during innervation of Purkinje cells in developing cerebellum. Is activated in lens epithelial cells upon hydrogen peroxide treatment, and phosphorylates connexin-43 (GJA1/CX43), resulting in disassembly of GJA1 gap junction plaques and inhibition of gap junction activity which could provide a protective effect against oxidative stress. Phosphorylates p53/TP53 and promotes p53/TP53-dependent apoptosis in response to DNA damage. Involved in the phase resetting of the cerebral cortex circadian clock during temporally restricted feeding. Stabilizes the core clock component ARNTL/BMAL1 by interfering with its ubiquitination, thus suppressing its degradation, resultingin phase resetting of the cerebral cortex clock. T47107 PDBSTRUC 2UZP; 2.00E+73 T47107 BIOCLASS Kinase T47107 ECNUMBER EC 2.7.11.13 T47107 SEQUENCE MAGLGPGVGDSEGGPRPLFCRKGALRQKVVHEVKSHKFTARFFKQPTFCSHCTDFIWGIGKQGLQCQVCSFVVHRRCHEFVTFECPGAGKGPQTDDPRNKHKFRLHSYSSPTFCDHCGSLLYGLVHQGMKCSCCEMNVHRRCVRSVPSLCGVDHTERRGRLQLEIRAPTADEIHVTVGEARNLIPMDPNGLSDPYVKLKLIPDPRNLTKQKTRTVKATLNPVWNETFVFNLKPGDVERRLSVEVWDWDRTSRNDFMGAMSFGVSELLKAPVDGWYKLLNQEEGEYYNVPVADADNCSLLQKFEACNYPLELYERVRMGPSSSPIPSPSPSPTDPKRCFFGASPGRLHISDFSFLMVLGKGSFGKVMLAERRGSDELYAIKILKKDVIVQDDDVDCTLVEKRVLALGGRGPGGRPHFLTQLHSTFQTPDRLYFVMEYVTGGDLMYHIQQLGKFKEPHAAFYAAEIAIGLFFLHNQGIIYRDLKLDNVMLDAEGHIKITDFGMCKENVFPGTTTRTFCGTPDYIAPEIIAYQPYGKSVDWWSFGVLLYEMLAGQPPFDGEDEEELFQAIMEQTVTYPKSLSREAVAICKGFLTKHPGKRLGSGPDGEPTIRAHGFFRWIDWERLERLEIPPPFRPRPCGRSGENFDKFFTRAAPALTPPDRLVLASIDQADFQGFTYVNPDFVHPDARSPTSPVPVPVM T47107 DRUGINFO D07NVU Midostaurin Approved T47107 DRUGINFO D0X0HN LY-317644 Terminated T47107 DRUGINFO D0R5ZR RO-320432 Terminated T47107 DRUGINFO D0R2TM BALANOL Terminated T47107 DRUGINFO D08GFG Monoctanoin component C Investigative T47107 DRUGINFO D04OHM 4-cyclopentyliden(4-hydroxyphenyl)methylphenol Investigative T47107 DRUGINFO D0L1YA (-)-Cercosporamide Investigative T47107 DRUGINFO D04AXH 8-Octyl-benzolactam-V9 Investigative T47107 DRUGINFO D06TLL Go 6983 Investigative T47107 DRUGINFO D00TWA [2,2':5',2'']Terthiophen-4-yl-methanol Investigative T47107 DRUGINFO D02PUV 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol Investigative T47107 DRUGINFO D02QME 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile Investigative T47107 DRUGINFO D05LRV [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde Investigative T47107 DRUGINFO D09TSC Ro-32-0557 Investigative T47107 DRUGINFO D09XIE 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile Investigative T47107 DRUGINFO D0A8MN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile Investigative T47107 DRUGINFO D0D3MR [2,2':5',2'']Terthiophene-4-carbaldehyde Investigative T47107 DRUGINFO D0Q3GQ 4-cycloheptyliden(4-hydroxyphenyl)methylphenol Investigative T47107 DRUGINFO D0S9UK 2,3,3-Triphenyl-acrylonitrile Investigative T47107 DRUGINFO D0T0UH 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile Investigative T47107 DRUGINFO D0V9SW 4-cyclohexyliden(4-hydroxyphenyl)methylphenol Investigative T47107 DRUGINFO D04JNZ PROSTRATIN Investigative T47107 DRUGINFO D06ZCX LY-326449 Investigative T47107 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T47107 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T47107 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T47107 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T47107 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T47107 DRUGINFO D0L8HO RO-316233 Investigative T17980 TARGETID T17980 T17980 FORMERID TTDS00406 T17980 UNIPROID FYN_HUMAN T17980 TARGNAME Fyn tyrosine protein kinase (FYN) T17980 GENENAME FYN T17980 TARGTYPE Successful T17980 SYNONYMS Tyrosine-protein kinase Fyn; Src-like kinase; SLK; Proto-oncogene tyrosine-protein kinase Fyn; Proto-oncogene c-Fyn; Proto-oncogene Syn; Fyn p59-Fyn; Fyn Protooncogene Syn T17980 FUNCTION Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions. Involved in the regulation of cell adhesion and motility through phosphorylation of CTNNB1 (beta-catenin) and CTNND1 (delta-catenin). Regulates cytoskeletal remodeling by phosphorylating several proteins including the actin regulator WAS and the microtubule-associated proteins MAP2 and MAPT. Promotes cell survival by phosphorylating AGAP2/PIKE-A and preventing its apoptotic cleavage. Participates in signal transduction pathways that regulate the integrity of the glomerular slit diaphragm (an essential part of the glomerular filter of the kidney) by phosphorylating several slit diaphragm components including NPHS1, KIRREL1 and TRPC6. Plays a role in neural processes by phosphorylating DPYSL2, a multifunctional adapter protein within the central nervous system, ARHGAP32, a regulator for Rho family GTPases implicated in various neural functions, and SNCA, a small pre-synaptic protein. Participates in the downstream signaling pathways that lead to T-cell differentiation and proliferation following T-cell receptor (TCR) stimulation. Phosphorylates PTK2B/PYK2 in response to T-cell receptor activation. Also participates in negative feedback regulation of TCR signaling through phosphorylation of PAG1, thereby promoting interaction between PAG1 and CSK and recruitment of CSK to lipid rafts. CSK maintains LCK and FYN in an inactive form. Promotes CD28-induced phosphorylation of VAV1. Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. T17980 PDBSTRUC 6IPZ; 6IPY; 6EDF; 4ZNX; 4U1P T17980 BIOCLASS Kinase T17980 ECNUMBER EC 2.7.10.2 T17980 SEQUENCE MGCVQCKDKEATKLTEERDGSLNQSSGYRYGTDPTPQHYPSFGVTSIPNYNNFHAAGGQGLTVFGGVNSSSHTGTLRTRGGTGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDWWEARSLTTGETGYIPSNYVAPVDSIQAEEWYFGKLGRKDAERQLLSFGNPRGTFLIRESETTKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFETLQQLVQHYSERAAGLCCRLVVPCHKGMPRLTDLSVKTKDVWEIPRESLQLIKRLGNGQFGEVWMGTWNGNTKVAIKTLKPGTMSPESFLEEAQIMKKLKHDKLVQLYAVVSEEPIYIVTEYMNKGSLLDFLKDGEGRALKLPNLVDMAAQVAAGMAYIERMNYIHRDLRSANILVGNGLICKIADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELVTKGRVPYPGMNNREVLEQVERGYRMPCPQDCPISLHELMIHCWKKDPEERPTFEYLQSFLEDYFTATEPQYQPGENL T17980 DRUGINFO D0E6XR Dasatinib Approved T17980 DRUGINFO D0U3XL JNJ-26483327 Phase 1 T17980 DRUGINFO D0OD8N 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane Investigative T17980 DRUGINFO D07IHM CEP-6331 Investigative T17980 DRUGINFO D0YZ7H JNJ-10198409 Investigative T17980 DRUGINFO D08RZB PMID15546730C2 Investigative T17980 DRUGINFO D09QBA CEP-5104 Investigative T17980 DRUGINFO D09XIL Ro-4396686 Investigative T27602 TARGETID T27602 T27602 FORMERID TTDS00282 T27602 UNIPROID TRY1_HUMAN T27602 TARGNAME Cationic trypsinogen (PRSS1) T27602 GENENAME PRSS1 T27602 TARGTYPE Successful T27602 SYNONYMS Trypsin-1; Trypsin I; TRYP1; TRY1; TRP1; Serine protease 1; Beta-trypsin T27602 FUNCTION Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form against all of these substrates. T27602 PDBSTRUC 4WXV; 4WWY; 2RA3; 1TRN; 1FXY T27602 BIOCLASS Peptidase T27602 ECNUMBER EC 3.4.21.4 T27602 SEQUENCE MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVINARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIKNTIAANS T27602 DRUGINFO D0SH3I Bortezomib Approved T27602 DRUGINFO D0DF1R Ulinastatin Phase 3 T27602 DRUGINFO D01MUU MELAGATRAN Phase 3 T27602 DRUGINFO D04TEF Alpha-1 antitrypsin Phase 2 T27602 DRUGINFO D0B9EH Dermolastin Discontinued in Phase 2 T27602 DRUGINFO D05QMJ RWJ-56423 Discontinued in Phase 1 T27602 DRUGINFO D0CV7T Patamostat Terminated T27602 DRUGINFO D0GR2H BMY-44621 Terminated T27602 DRUGINFO D00POF 6-Styryl-naphthalene-2-carboxamidine Investigative T27602 DRUGINFO D03ZUM Tert-butyloxy carbonyl-D-Phe-pro-Arg-H Investigative T27602 DRUGINFO D05ICF 1,3-Di-p-tolyl-[1,3]diazetidine-2,4-dione Investigative T27602 DRUGINFO D08OCL 4-(5-Nitro-indol-1-ylmethyl)-benzamidine Investigative T27602 DRUGINFO D08SKX recAAT, PPL Therapeutics/Bayer Investigative T27602 DRUGINFO D09TNA 1-(3-Amino-benzyl)-1H-indole-5-carboxamidine Investigative T27602 DRUGINFO D0C1TS CVS-2359 Investigative T27602 DRUGINFO D0EH1F 1-(3-Nitro-benzyl)-1H-indole-5-carboxamidine Investigative T27602 DRUGINFO D0J2SM 2-(2-Iodo-phenyl)-benzo[d][1,3]oxazin-4-one Investigative T27602 DRUGINFO D0K0GU 8-Furan-3-yl-6-styryl-naphthalene-2-carboxamidine Investigative T27602 DRUGINFO D0M1LO Piperidine-1-carboxamidine Investigative T27602 DRUGINFO D0M2PE 1-Benzyl-1H-indole-5-carboxamidine Investigative T27602 DRUGINFO D0N1PW 4-Indol-1-ylmethyl-benzamidine Investigative T27602 DRUGINFO D0O0GT CVS-2139 Investigative T27602 DRUGINFO D0S4MQ 8-Bromo-6-styryl-naphthalene-2-carboxamidine Investigative T27602 DRUGINFO D0Z7YI 2-Propionyl-1H-indole-6-carboxamidine Investigative T27602 DRUGINFO D02NHS L-375378 Investigative T27602 DRUGINFO D05ABK ATF-HI-8 Investigative T27602 DRUGINFO D07IBU GR-133686 Investigative T27602 DRUGINFO D09OBJ RWJ-50353 Investigative T27602 DRUGINFO D0F2YC 1,3-Dibenzyl-[1,3]diazetidine-2,4-dione Investigative T27602 DRUGINFO D0F9YV PMID3514912C9 Investigative T27602 DRUGINFO D0RQ2T Macrocyclic tripeptide motif Investigative T27602 DRUGINFO D08SMN POP-1 Investigative T27602 DRUGINFO D0CT8A 4-(3,4-Diethoxy-benzylamino)-benzamidine Investigative T27602 DRUGINFO D0JR9V JBP-1 Investigative T27602 DRUGINFO D02XPB 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine Investigative T27602 DRUGINFO D07SFI Benzamidine Investigative T27602 DRUGINFO D08OLP 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine Investigative T27602 DRUGINFO D0Y5IQ Grassystatin a Investigative T18477 TARGETID T18477 T18477 FORMERID TTDC00018 T18477 UNIPROID HS90A_HUMAN T18477 TARGNAME Heat shock protein 90 alpha (HSP90A) T18477 GENENAME HSP90AA1 T18477 TARGTYPE Successful T18477 SYNONYMS Renal carcinoma antigen NY-REN-38; Lipopolysaccharide-associated protein 2; LPS-associated protein 2; LAP-2; Heat shock protein HSP 90-alpha; Heat shock 86 kDa; HSPCA; HSPC1; HSP90A; HSP86; HSP 86 T18477 FUNCTION Undergoes a functional cycle that is linked to its ATPase activity which is essential for its chaperone activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function. Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself. Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle. Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels. In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues(). Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment. Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression. Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation. Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. T18477 PDBSTRUC 6GR5; 6GR4; 6GR3; 6GR1; 6GQU T18477 BIOCLASS Heat shock protein T18477 SEQUENCE MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEKEDKEEEKEKEEKESEDKPEIEDVGSDEEEEKKDGDKKKKKKIKEKYIDQEELNKTKPIWTRNPDDITNEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFVPRRAPFDLFENRKKKNNIKLYVRRVFIMDNCEELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNLVKKCLELFTELAEDKENYKKFYEQFSKNIKLGIHEDSQNRKKLSELLRYYTSASGDEMVSLKDYCTRMKENQKHIYYITGETKDQVANSAFVERLRKHGLEVIYMIEPIDEYCVQQLKEFEGKTLVSVTKEGLELPEDEEEKKKQEEKKTKFENLCKIMKDILEKKVEKVVVSNRLVTSPCCIVTSTYGWTANMERIMKAQALRDNSTMGYMAAKKHLEINPDHSIIETLRQKAEADKNDKSVKDLVILLYETALLSSGFSLEDPQTHANRIYRMIKLGLGIDEDDPTADDTSAAVTEEMPPLEGDDDTSRMEEVD T18477 DRUGINFO D06NSS Cromoglicate Approved T18477 DRUGINFO D0G5UB Amlexanox Approved T18477 DRUGINFO D05BYA NVP-AUY922 Phase 2 T18477 DRUGINFO D05HWN BIIB-021 Phase 2 T18477 DRUGINFO D08PYO KW-2478 Phase 2 T18477 DRUGINFO D09XGB VER 50589 Phase 2 T18477 DRUGINFO D0SC2J Tanespimycin Phase 2 T18477 DRUGINFO D0Y9PZ Efungumab Phase 2 T18477 DRUGINFO D07MPL SNX-5422 Phase 1/2 T18477 DRUGINFO D02PGP PU3 Phase 1 T18477 DRUGINFO D02TTL Debio 0932 Phase 1 T18477 DRUGINFO D03LRU Alvespimycin hydrochloride Phase 1 T18477 DRUGINFO D06YSP AT13387 Phase 1 T18477 DRUGINFO D0H3VK BIIB 028 Phase 1 T18477 DRUGINFO D0ME2T RTA-901 Phase 1 T18477 DRUGINFO D0V9MT PU-AD Phase 1 T18477 DRUGINFO D03IKZ HBP-347 Discontinued in Phase 3 T18477 DRUGINFO D03PKI Geldanamycin Discontinued in Phase 2 T18477 DRUGINFO D0BM6S IPI-493 Discontinued in Phase 1 T18477 DRUGINFO D00OCB CCT-018159 Preclinical T18477 DRUGINFO D0X5YU KOS-2484 Preclinical T18477 DRUGINFO D0KC7K EC-154 Terminated T18477 DRUGINFO D00PMS 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- Investigative T18477 DRUGINFO D01GGU 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine Investigative T18477 DRUGINFO D02IIL KOSN1559 Investigative T18477 DRUGINFO D05GKC ZEARALANONE Investigative T18477 DRUGINFO D05RTH 17-desmethoxy-17-aminogeldanamycin Investigative T18477 DRUGINFO D05UTX 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine Investigative T18477 DRUGINFO D07WDQ GNF-PF-67 Investigative T18477 DRUGINFO D08CZD 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine Investigative T18477 DRUGINFO D0D3BP 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE Investigative T18477 DRUGINFO D0D5KQ PU24S Investigative T18477 DRUGINFO D0H0KA Macbecin Investigative T18477 DRUGINFO D0K0TJ SNX-2112 Investigative T18477 DRUGINFO D0K4RN 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol Investigative T18477 DRUGINFO D0M2TY RHEIN Investigative T18477 DRUGINFO D0T4MS VER-49009 Investigative T18477 DRUGINFO D0ZA6G Radicicol Investigative T18477 DRUGINFO D0H6OS Geldanamycin-estradiol hybrid Investigative T18477 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T48069 TARGETID T48069 T48069 FORMERID TTDS00269 T48069 UNIPROID IGF1R_HUMAN T48069 TARGNAME Insulin-like growth factor I receptor (IGF1R) T48069 GENENAME IGF1R T48069 TARGTYPE Successful T48069 SYNONYMS Type 1 insulin-like growth factor receptor; Insulin-like growth factor 1 receptor; IGF-IR; IGF-I receptor; IGF-1R; IGF-1 receptor; CD221 antigen; CD221 T48069 FUNCTION Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R. Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). T48069 PDBSTRUC 5U8R; 5U8Q; 5HZN; 5FXS; 5FXR T48069 BIOCLASS Kinase T48069 ECNUMBER EC 2.7.10.1 T48069 SEQUENCE MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLHILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGDLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCSAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHDGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTRNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDGQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSEILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRHNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFESRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTWEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGNYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHRKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRHSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC T48069 DRUGINFO D0EN0W Teprotumumab Approved T48069 DRUGINFO D0F3JT Mecasermin Approved T48069 DRUGINFO D0N3NZ Somatomedin-1 Approved T48069 DRUGINFO D01GFX OSI-906 Phase 3 T48069 DRUGINFO D06APK Rinfabate Phase 2/3 T48069 DRUGINFO D00AKR AMG 479 Phase 2 T48069 DRUGINFO D00VKK VPI-2690B Phase 2 T48069 DRUGINFO D01SJS AXL-1717 Phase 2 T48069 DRUGINFO D03BHM R1507 Phase 2 T48069 DRUGINFO D0E5DP Cixutumumab Phase 2 T48069 DRUGINFO D0T5JS TT-100 Phase 2 T48069 DRUGINFO D00BUO MM-141 Phase 2 T48069 DRUGINFO D01OYS Cyclolignan picropodophyllin Phase 1 T48069 DRUGINFO D03WNN RG-7010 Phase 1 T48069 DRUGINFO D0L1ZM HF-0299 Phase 1 T48069 DRUGINFO D0O7QQ BIIB 022 Phase 1 T48069 DRUGINFO D4JYH3 FPI-1434 Phase 1 T48069 DRUGINFO D07HPJ AEW-541 Phase 1 T48069 DRUGINFO D10KTZ SAR446159 Phase 1 T48069 DRUGINFO D00BPE AVE-1642 Discontinued in Phase 2 T48069 DRUGINFO D0M3OR KW-2450 Discontinued in Phase 1/2 T48069 DRUGINFO D0U6KH Figitumumab Discontinued in Phase 1 T48069 DRUGINFO D0LF0O BMS-695735 Preclinical T48069 DRUGINFO D0TI4U EGFR/IGFR tandem adnectin Preclinical T48069 DRUGINFO D06NMZ NVP-ADW742 Investigative T48069 DRUGINFO D0O0RY JB-1 Investigative T48069 DRUGINFO D0L7MM 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol Investigative T48069 DRUGINFO D0W9KO 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol Investigative T48069 DRUGINFO D00ICA AMP-PNP Investigative T48069 DRUGINFO D0M4SY BMS-536924 Investigative T48069 DRUGINFO D0G6XS Fucose Investigative T48069 DRUGINFO D07LUR Alpha-D-Mannose Investigative T40474 TARGETID T40474 T40474 FORMERID TTDC00110 T40474 UNIPROID MET_HUMAN T40474 TARGNAME Proto-oncogene c-Met (MET) T40474 GENENAME MET T40474 TARGTYPE Successful T40474 SYNONYMS Tyrosine-protein kinase Met; Scatter factor receptor; SF receptor; Met proto-oncogene tyrosine kinase; Hepatocyte growth factor receptor; HGF/SF receptor; HGF-SF receptor; HGF receptor; C-met; C-Met receptor tyrosine kinase T40474 FUNCTION Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. T40474 PDBSTRUC 6I04; 6GCU; 5YA5; 5UAF; 5UAD T40474 BIOCLASS Kinase T40474 ECNUMBER EC 2.7.10.1 T40474 SEQUENCE MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKKTRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDLLKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQIKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGSCRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVDTRPASFWETS T40474 DRUGINFO D07OJZ Capmatinib Approved T40474 DRUGINFO D0R8QG Tepotinib Approved T40474 DRUGINFO D0IQ6P Cabozantinib Approved T40474 DRUGINFO DQ5X1Z Amivantamab Approved T40474 DRUGINFO D03ZBT Crizotinib Approved T40474 DRUGINFO D0H9PT RG3638 Phase 3 T40474 DRUGINFO D0LW0T Savolitinib Phase 3 T40474 DRUGINFO D0N1YF Beperminogene perplasmid Phase 3 T40474 DRUGINFO D0ZI1F Tivantinib Phase 3 T40474 DRUGINFO D05BLN MGCD516 Phase 2/3 T40474 DRUGINFO D05BLN MGCD516 Phase 2/3 T40474 DRUGINFO D03SXS LY-2875358 Phase 2 T40474 DRUGINFO D07ARN SAR-125844 Phase 2 T40474 DRUGINFO D0FE7D Emibetuzumab Phase 2 T40474 DRUGINFO D0G0BL AMG 337 Phase 2 T40474 DRUGINFO D0OK2N AMG 208 Phase 2 T40474 DRUGINFO D0R0YW HM-5016504 Phase 2 T40474 DRUGINFO D42TUS Telisotuzumab vedotin Phase 2 T40474 DRUGINFO DV3Y7F APL-101 Phase 2 T40474 DRUGINFO D01TBJ CMX-2043 Phase 2 T40474 DRUGINFO D06EGV LY2801653 Phase 2 T40474 DRUGINFO D0D1GF XL880 Phase 2 T40474 DRUGINFO D09ZNL ChronSeal Phase 1/2 T40474 DRUGINFO D0A3OE Anti-C-met CAR-T cells Phase 1/2 T40474 DRUGINFO D0O6WV BMS-777607 Phase 1/2 T40474 DRUGINFO D0B4OK Sym015 Phase 1/2 T40474 DRUGINFO D00DRL MK-2461 Phase 1/2 T40474 DRUGINFO D01FSX REGN5093 Phase 1 T40474 DRUGINFO D01LCC PF-4217903 Phase 1 T40474 DRUGINFO D02EOR ABBV-399 Phase 1 T40474 DRUGINFO D04XUJ CBT-101 Phase 1 T40474 DRUGINFO D05OMT MK-8033 Phase 1 T40474 DRUGINFO D0D1HI Autologous T Cells Expressing MET scFv CAR Phase 1 T40474 DRUGINFO D0I2IY ABT-700 Phase 1 T40474 DRUGINFO D0N6VK Hepapoietin Phase 1 T40474 DRUGINFO D0Y8UV EMD-1204831 Phase 1 T40474 DRUGINFO D0YT8P JNJ-38877605 Phase 1 T40474 DRUGINFO D0ZU5F SGX523 Phase 1 T40474 DRUGINFO DU6H8Z TR1801-ADC Phase 1 T40474 DRUGINFO D01IJM LY3164530 Phase 1 T40474 DRUGINFO D03GTO C-Met/PD-L1 CAR-T Cell Phase 1 T40474 DRUGINFO D09ETH E-7050 Phase 1 T40474 DRUGINFO D1TNJ2 XL092 Phase 1 T40474 DRUGINFO D95YSW BPI-9016 M Phase 1 T40474 DRUGINFO DN47VK AZD9592 Phase 1 T40474 DRUGINFO D7M8LI TPX-0022 Phase 1 T40474 DRUGINFO D7HZ3T RXDX-106 Phase 1 T40474 DRUGINFO D0FA6S Altiratinib Phase 1 T40474 DRUGINFO D0NO6E Mteron-F1 Preclinical T40474 DRUGINFO D1AD6L NPS-1034 Preclinical T40474 DRUGINFO D00FZA ALD-805 Investigative T40474 DRUGINFO D00TBD PHA-665752 Investigative T40474 DRUGINFO D03LZK APS-3010 Investigative T40474 DRUGINFO D05GSI LA-480 Investigative T40474 DRUGINFO D07CFW Anti-cMET mab Investigative T40474 DRUGINFO D07OXC AM7 Investigative T40474 DRUGINFO D0AD6Z mab 224G11 Investigative T40474 DRUGINFO D0BS6B TP-801 Investigative T40474 DRUGINFO D0E1QI SU11274 Investigative T40474 DRUGINFO D0G3ZN PF-00614435 Investigative T40474 DRUGINFO D0I2PS CMET Avimer polypeptides Investigative T40474 DRUGINFO D0M0SV PRS-110 Investigative T40474 DRUGINFO D0N5XG 1-benzyl-1H-pyrrolo[3,2-b]pyridine Investigative T40474 DRUGINFO D0N6QO RP-1040 Investigative T40474 DRUGINFO D0NX6F BAY-85-3474 Investigative T40474 DRUGINFO D0PS7U GE-137 Investigative T40474 DRUGINFO D0S0GT 3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine Investigative T40474 DRUGINFO D0S1II 1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine Investigative T40474 DRUGINFO D0T1YH ALD-806 Investigative T40474 DRUGINFO D0U4JW 1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine Investigative T40474 DRUGINFO D0W8GP DP-3590 Investigative T40474 DRUGINFO D0Z4RX HuMax-cMet Investigative T40474 DRUGINFO D0AM9O YH013 Investigative T40474 DRUGINFO D04CUA PMID24210504C1o Investigative T40474 DRUGINFO D0RO9R PMID21123062C27 Investigative T40474 DRUGINFO D00EMH PMID21967808CR-16 Investigative T40474 DRUGINFO D0M4SY BMS-536924 Investigative T43332 TARGETID T43332 T43332 FORMERID TTDR00947 T43332 UNIPROID FA7_HUMAN T43332 TARGNAME Coagulation factor VII (F7) T43332 GENENAME F7 T43332 TARGTYPE Successful T43332 SYNONYMS Serum prothrombin conversion accelerator; SPCA; Proconvertin; Eptacog alfa T43332 FUNCTION Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium. T43332 PDBSTRUC 5U6J; 5TQG; 5TQF; 5TQE; 5PB6 T43332 BIOCLASS Peptidase T43332 ECNUMBER EC 3.4.21.21 T43332 SEQUENCE MVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRRANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP T43332 DRUGINFO D0C9IW Factor viia Approved T43332 DRUGINFO D00VMA Vatreptacog alfa (activated) Phase 3 T43332 DRUGINFO D09SHH BAX-817 Phase 3 T43332 DRUGINFO D0C0CE Activated recombinant FVII-albumin fusion protein Phase 2/3 T43332 DRUGINFO D0HZ2A Recombinant factor VIIa PEGylated liposomal Phase 1/2 T43332 DRUGINFO D00EYC F-7TG Phase 1 T43332 DRUGINFO D05GPB Eptacog alfa Phase 1 T43332 DRUGINFO D0R4YQ CB-813 Phase 1 T43332 DRUGINFO D0J3YX BAY 86-6150 Discontinued in Phase 2/3 T43332 DRUGINFO D0K3LX RNAPc2 Discontinued in Phase 2 T43332 DRUGINFO D01NCC Factor-VIIa-XTEN Investigative T43332 DRUGINFO D02PKV Human recombinant factor VIIa Investigative T43332 DRUGINFO D0O9RV MOD-5023 Investigative T43332 DRUGINFO D0R9UQ Long-acting Factor VII conjugate Investigative T43332 DRUGINFO D0CT8A 4-(3,4-Diethoxy-benzylamino)-benzamidine Investigative T43332 DRUGINFO D02XPB 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine Investigative T43332 DRUGINFO D0G6XS Fucose Investigative T33489 TARGETID T33489 T33489 FORMERID TTDC00149 T33489 UNIPROID STS_HUMAN T33489 TARGNAME Steryl-sulfatase (STS) T33489 GENENAME STS T33489 TARGTYPE Successful T33489 SYNONYMS Steryl-sulfate sulfohydrolase; Steroid sulfatase; STS; Estrone sulfatase; Arylsulfatase C; ASC T33489 FUNCTION Conversion of sulfated steroid precursors to estrogens during pregnancy. T33489 PDBSTRUC 1P49 T33489 BIOCLASS Sulfuric ester hydrolase T33489 ECNUMBER EC 3.1.6.2 T33489 SEQUENCE MPLRKMKIPFLLLFFLWEAESHAASRPNIILVMADDLGIGDPGCYGNKTIRTPNIDRLASGGVKLTQHLAASPLCTPSRAAFMTGRYPVRSGMASWSRTGVFLFTASSGGLPTDEITFAKLLKDQGYSTALIGKWHLGMSCHSKTDFCHHPLHHGFNYFYGISLTNLRDCKPGEGSVFTTGFKRLVFLPLQIVGVTLLTLAALNCLGLLHVPLGVFFSLLFLAALILTLFLGFLHYFRPLNCFMMRNYEIIQQPMSYDNLTQRLTVEAAQFIQRNTETPFLLVLSYLHVHTALFSSKDFAGKSQHGVYGDAVEEMDWSVGQILNLLDELRLANDTLIYFTSDQGAHVEEVSSKGEIHGGSNGIYKGGKANNWEGGIRVPGILRWPRVIQAGQKIDEPTSNMDIFPTVAKLAGAPLPEDRIIDGRDLMPLLEGKSQRSDHEFLFHYCNAYLNAVRWHPQNSTSIWKAFFFTPNFNPVGSNGCFATHVCFCFGSYVTHHDPPLLFDISKDPRERNPLTPASEPRFYEILKVMQEAADRHTQTLPEVPDQFSWNNFLWKPWLQLCCPSTGLSCQCDREKQDKRLSR T33489 DRUGINFO D0E6OC Tranilast Approved T33489 DRUGINFO D04ZND PGL-2001 Phase 2 T33489 DRUGINFO D0I3RN PGL-2 Phase 2 T33489 DRUGINFO D07ZNI STX-140 Phase 2 T33489 DRUGINFO D0Y6OA Coumate Phase 2 T33489 DRUGINFO D05NJI STX 64 Phase 1 T33489 DRUGINFO D00AON Sulfamic acid 2-nonyl-4-oxo-4H-chromen-6-yl ester Investigative T33489 DRUGINFO D00LFX Estradiol 17-O-sulfamate Investigative T33489 DRUGINFO D00OZS 4-Sulfamoyloxy-benzoic acid pentyl ester Investigative T33489 DRUGINFO D01ACT 4-Sulfamoyloxy-benzoic acid propyl ester Investigative T33489 DRUGINFO D02RJA Sulfamic acid 3-(3-methoxy-benzoyl)-phenyl ester Investigative T33489 DRUGINFO D03NUT 4-Sulfamoyloxy-benzoic acid octyl ester Investigative T33489 DRUGINFO D03XJE 2-Adamantan-2-ylidenemethyl-benzooxazol-6-ol Investigative T33489 DRUGINFO D04HNO 3-{3-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate Investigative T33489 DRUGINFO D04YVS 3-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate Investigative T33489 DRUGINFO D05KKB Sulfamic acid 3-(4-methoxy-benzoyl)-phenyl ester Investigative T33489 DRUGINFO D05TRN 4-Sulfamoyloxy-benzoic acid cycloheptyl ester Investigative T33489 DRUGINFO D06ADL Sulfamic acid 4-(3-methoxy-benzoyl)-phenyl ester Investigative T33489 DRUGINFO D06DVJ Sulfamic acid 3-(3-hydroxy-benzoyl)-phenyl ester Investigative T33489 DRUGINFO D06IMK 3-(4-cyclohexylthiosemicarbazono)methyl-phenol Investigative T33489 DRUGINFO D06SMY 4-Sulfamoyloxy-benzoic acid nonyl ester Investigative T33489 DRUGINFO D06YDQ 4-Sulfamoyloxy-benzoic acid heptyl ester Investigative T33489 DRUGINFO D07GRM 2-Amino-3-Oxo-4-Sulfo-Butyric Acid Investigative T33489 DRUGINFO D08BTV 2-(4-cyclohexylthiosemicarbazono)methyl-phenol Investigative T33489 DRUGINFO D09BUM 4-(4-cyclohexylthiosemicarbazono)methyl-phenol Investigative T33489 DRUGINFO D09ROV Nortropinyl-arylsulfonylurea 3 Investigative T33489 DRUGINFO D0AL2D 4-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate Investigative T33489 DRUGINFO D0B1JM Sulfamic acid 4-(2-methoxy-benzoyl)-phenyl ester Investigative T33489 DRUGINFO D0B2XN Sulfamic acid 4-benzoyl-phenyl ester Investigative T33489 DRUGINFO D0D1CV 4-Sulfamoyloxy-benzoic acid hexyl ester Investigative T33489 DRUGINFO D0FH1V 2-methylsulfanylestradiol 3,17-O,O-bis-sulfamate Investigative T33489 DRUGINFO D0G1XC MHL cyclohexylthiosemicarbazone Investigative T33489 DRUGINFO D0G8HD Sulfamic acid 3-benzoyl-phenyl ester Investigative T33489 DRUGINFO D0I4LL 2',4'-dicyanobiphenyl-4-yl sulfamate Investigative T33489 DRUGINFO D0M2WG Sulfamic acid 4-(2-hydroxy-benzoyl)-phenyl ester Investigative T33489 DRUGINFO D0N8VZ 2-ethylestradiol 3,17-O,O-bis-sulfamate Investigative T33489 DRUGINFO D0P6IO 4-Sulfamoyloxy-benzoic acid butyl ester Investigative T33489 DRUGINFO D0P9ZV 4-Sulfamoyloxy-benzoic acid cyclohexyl ester Investigative T33489 DRUGINFO D0S3RZ Estradiol 3,17-O,O-bis-sulfamate Investigative T33489 DRUGINFO D0S5BA Sulfamic acid 3-(4-hydroxy-benzoyl)-phenyl ester Investigative T33489 DRUGINFO D0T5OD 4-Sulfamoyloxy-benzoic acid cyclooctyl ester Investigative T33489 DRUGINFO D0U7PV 4-Sulfamoyloxy-benzoic acid cyclopentyl ester Investigative T33489 DRUGINFO D0W6GB Benzomate Investigative T33489 DRUGINFO D0Y9SI 3-(4-hexylthiosemicarbazono)methyl-benzoic acid Investigative T33489 DRUGINFO D0R7QY EMATE Investigative T33489 DRUGINFO D02UVH B-Octylglucoside Investigative T69128 TARGETID T69128 T69128 FORMERID TTDNS00597 T69128 UNIPROID ROS1_HUMAN T69128 TARGNAME Proto-oncogene c-Ros (ROS1) T69128 GENENAME ROS1 T69128 TARGTYPE Successful T69128 SYNONYMS c-Ros receptor tyrosine kinase; Receptor tyrosine kinase c-ros oncogene 1; ROS; Proto-oncogene tyrosine-protein kinase ROS; Proto-oncogene c-Ros-1; MCF3 T69128 FUNCTION Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2. T69128 PDBSTRUC 4UXL; 3ZBF T69128 BIOCLASS Kinase T69128 ECNUMBER EC 2.7.10.1 T69128 SEQUENCE MKNIYCLIPKLVNFATLGCLWISVVQCTVLNSCLKSCVTNLGQQLDLGTPHNLSEPCIQGCHFWNSVDQKNCALKCRESCEVGCSSAEGAYEEEVLENADLPTAPFASSIGSHNMTLRWKSANFSGVKYIIQWKYAQLLGSWTYTKTVSRPSYVVKPLHPFTEYIFRVVWIFTAQLQLYSPPSPSYRTHPHGVPETAPLIRNIESSSPDTVEVSWDPPQFPGGPILGYNLRLISKNQKLDAGTQRTSFQFYSTLPNTIYRFSIAAVNEVGEGPEAESSITTSSSAVQQEEQWLFLSRKTSLRKRSLKHLVDEAHCLRLDAIYHNITGISVDVHQQIVYFSEGTLIWAKKAANMSDVSDLRIFYRGSGLISSISIDWLYQRMYFIMDELVCVCDLENCSNIEEITPPSISAPQKIVADSYNGYVFYLLRDGIYRADLPVPSGRCAEAVRIVESCTLKDFAIKPQAKRIIYFNDTAQVFMSTFLDGSASHLILPRIPFADVKSFACENNDFLVTDGKVIFQQDALSFNEFIVGCDLSHIEEFGFGNLVIFGSSSQLHPLPGRPQELSVLFGSHQALVQWKPPALAIGANVILISDIIELFELGPSAWQNWTYEVKVSTQDPPEVTHIFLNISGTMLNVPELQSAMKYKVSVRASSPKRPGPWSEPSVGTTLVPASEPPFIMAVKEDGLWSKPLNSFGPGEFLSSDIGNVSDMDWYNNSLYYSDTKGDVFVWLLNGTDISENYHLPSIAGAGALAFEWLGHFLYWAGKTYVIQRQSVLTGHTDIVTHVKLLVNDMVVDSVGGYLYWTTLYSVESTRLNGESSLVLQTQPWFSGKKVIALTLDLSDGLLYWLVQDSQCIHLYTAVLRGQSTGDTTITEFAAWSTSEISQNALMYYSGRLFWINGFRIITTQEIGQKTSVSVLEPARFNQFTIIQTSLKPLPGNFSFTPKVIPDSVQESSFRIEGNASSFQILWNGPPAVDWGVVFYSVEFSAHSKFLASEQHSLPVFTVEGLEPYALFNLSVTPYTYWGKGPKTSLSLRAPETVPSAPENPRIFILPSGKCCNKNEVVVEFRWNKPKHENGVLTKFEIFYNISNQSITNKTCEDWIAVNVTPSVMSFQLEGMSPRCFIAFQVRAFTSKGPGPYADVVKSTTSEINPFPHLITLLGNKIVFLDMDQNQVVWTFSAERVISAVCYTADNEMGYYAEGDSLFLLHLHNRSSSELFQDSLVFDITVITIDWISRHLYFALKESQNGMQVFDVDLEHKVKYPREVKIHNRNSTIISFSVYPLLSRLYWTEVSNFGYQMFYYSIISHTLHRILQPTATNQQNKRNQCSCNVTEFELSGAMAIDTSNLEKPLIYFAKAQEIWAMDLEGCQCWRVITVPAMLAGKTLVSLTVDGDLIYWIITAKDSTQIYQAKKGNGAIVSQVKALRSRHILAYSSVMQPFPDKAFLSLASDTVEPTILNATNTSLTIRLPLAKTNLTWYGITSPTPTYLVYYAEVNDRKNSSDLKYRILEFQDSIALIEDLQPFSTYMIQIAVKNYYSDPLEHLPPGKEIWGKTKNGVPEAVQLINTTVRSDTSLIISWRESHKPNGPKESVRYQLAISHLALIPETPLRQSEFPNGRLTLLVTRLSGGNIYVLKVLACHSEEMWCTESHPVTVEMFNTPEKPYSLVPENTSLQFNWKAPLNVNLIRFWVELQKWKYNEFYHVKTSCSQGPAYVCNITNLQPYTSYNVRVVVVYKTGENSTSLPESFKTKAGVPNKPGIPKLLEGSKNSIQWEKAEDNGCRITYYILEIRKSTSNNLQNQNLRWKMTFNGSCSSVCTWKSKNLKGIFQFRVVAANNLGFGEYSGISENIILVGDDFWIPETSFILTIIVGIFLVVTIPLTFVWHRRLKNQKSAKEGVTVLINEDKELAELRGLAAGVGLANACYAIHTLPTQEEIENLPAFPREKLTLRLLLGSGAFGEVYEGTAVDILGVGSGEIKVAVKTLKKGSTDQEKIEFLKEAHLMSKFNHPNILKQLGVCLLNEPQYIILELMEGGDLLTYLRKARMATFYGPLLTLVDLVDLCVDISKGCVYLERMHFIHRDLAARNCLVSVKDYTSPRIVKIGDFGLARDIYKNDYYRKRGEGLLPVRWMAPESLMDGIFTTQSDVWSFGILIWEILTLGHQPYPAHSNLDVLNYVQTGGRLEPPRNCPDDLWNLMTQCWAQEPDQRPTFHRIQDQLQLFRNFFLNSIYKSRDEANNSGVINESFEGEDGDVICLNSDDIMPVALMETKNREGLNYMVLATECGQGEEKSEGPLGSQESESCGLRKEEKEPHADKDFCQEKQVAYCPSGKPEGLNYACLTHSGYGDGSD T69128 DRUGINFO D05NFR Repotrectinib Approved T69128 DRUGINFO D0AF6O Lorlatinib Approved T69128 DRUGINFO D03ZBT Crizotinib Approved T69128 DRUGINFO D0O0LS Entrectinib Approved T69128 DRUGINFO D2KV8B AB-106 Phase 2 T69128 DRUGINFO D0N0DU DS-6051 Phase 1 T69128 DRUGINFO D0M8UO Imidazo[1,2-b]pyridazine derivative 2 Patented T69128 DRUGINFO D0N1CF Imidazo[1,2-b]pyridazine derivative 3 Patented T69128 DRUGINFO D0N8YJ PMID28270010-Compound-Figure21-b Patented T69128 DRUGINFO D0T8XD Imidazo[1,2-b]pyridazine derivative 1 Patented T69128 DRUGINFO D0MX7B Carboxamide derivative 4 Patented T69128 DRUGINFO D0K5UF PMID24432909C8e Investigative T73475 TARGETID T73475 T73475 FORMERID TTDR00029 T73475 UNIPROID MMP7_HUMAN T73475 TARGNAME Matrix metalloproteinase-7 (MMP-7) T73475 GENENAME MMP7 T73475 TARGTYPE Successful T73475 SYNONYMS Uterine metalloproteinase; Pump-1 protease; PUMP1; Matrin; Matrilysin; MPSL1 T73475 FUNCTION Activates procollagenase. Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. T73475 PDBSTRUC 5UE5; 5UE2; 2Y6D; 2Y6C; 2MZI T73475 BIOCLASS Peptidase T73475 ECNUMBER EC 3.4.24.23 T73475 SEQUENCE MRLTVLCAVCLLPGSLALPLPQEAGGMSELQWEQAQDYLKRFYLYDSETKNANSLEAKLKEMQKFFGLPITGMLNSRVIEIMQKPRCGVPDVAEYSLFPNSPKWTSKVVTYRIVSYTRDLPHITVDRLVSKALNMWGKEIPLHFRKVVWGTADIMIGFARGAHGDSYPFDGPGNTLAHAFAPGTGLGGDAHFDEDERWTDGSSLGINFLYAATHELGHSLGMGHSSDPNAVMYPTYGNGDPQNFKLSQDDIKGIQKLYGKRSNSRKK T73475 DRUGINFO D00MDP Prinomastat Approved T73475 DRUGINFO D05VZE Marimastat Phase 3 T73475 DRUGINFO D01EUF BMS 275291 Discontinued in Phase 3 T73475 DRUGINFO D08WBF BB-3644 Terminated T73475 DRUGINFO D0Y1XT SC-44463 Terminated T73475 DRUGINFO D06HSC Folate gamma-L-phenylalaninehydroxamic acid Investigative T73475 DRUGINFO D0ZB6O Folate gamma-L-proline-hydroxamic acid Investigative T73475 DRUGINFO D07SPC N-hydroxy-2,3-bis(phenylsulfonamido)propanamide Investigative T73475 DRUGINFO D0BI8T RS-39066 Investigative T73475 DRUGINFO D0P8EY Folate gamma-hydroxamic acid Investigative T73475 DRUGINFO D08ELY 3-Benzenesulfonyl-heptanoic acid hydroxyamide Investigative T73475 DRUGINFO D0N6CD 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide Investigative T73475 DRUGINFO D07GEL SL422 Investigative T73475 DRUGINFO D03AMR SR-973 Investigative T73475 DRUGINFO D0W2UK IK-862 Investigative T73475 DRUGINFO D0A4TC MMI270 Investigative T59102 TARGETID T59102 T59102 FORMERID TTDR01217 T59102 UNIPROID PGFRB_HUMAN T59102 TARGNAME Platelet-derived growth factor receptor beta (PDGFRB) T59102 GENENAME PDGFRB T59102 TARGTYPE Successful T59102 SYNONYMS Platelet-derived growth factor receptor 1; PDGFR1; PDGFR-beta; PDGFR-1; PDGFR; PDGF-R-beta; CD140b antigen; CD140b; CD140 antigen-like family member B; Beta-type platelet-derived growth factor receptor; Beta-PDGFR; Beta platelet-derived growth factor receptor T59102 FUNCTION Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. T59102 PDBSTRUC 3MJG; 2PLE; 2PLD; 2L6W; 2IUI T59102 BIOCLASS Kinase T59102 ECNUMBER EC 2.7.10.1 T59102 SEQUENCE MRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPVVWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFVPDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFSGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGNEVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDHQDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDSSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVLELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNVTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQVEPEPELEQLPDSGCPAPRAEAEDSFL T59102 DRUGINFO D0T5QT Becaplermin Approved T59102 DRUGINFO D0W5HK Sorafenib Approved T59102 DRUGINFO D01PZD Romiplostim Approved T59102 DRUGINFO D02WVT E-3810 Phase 3 T59102 DRUGINFO D00NSD XL-820 Phase 2 T59102 DRUGINFO D0Z6MT Famitinib Phase 2 T59102 DRUGINFO D0GB2L SNN-0031 Phase 1/2 T59102 DRUGINFO D00DRL MK-2461 Phase 1/2 T59102 DRUGINFO D0T2ER TAK-593 Phase 1 T59102 DRUGINFO D0YX2B PMID28460551-Compound-2 Patented T59102 DRUGINFO D0D3FB PMID25656651-Compound-21a Patented T59102 DRUGINFO D0XQ5F PMID25656651-Compound-21b Patented T59102 DRUGINFO D0AK1F Pyridine derivative 18 Patented T59102 DRUGINFO D08PAV CDP-860 Discontinued in Phase 2 T59102 DRUGINFO D00QCB SRI-62-834 Discontinued in Phase 2 T59102 DRUGINFO D0KX1E CEP-2563 Discontinued in Phase 1 T59102 DRUGINFO D03WTT RG-13022 Terminated T59102 DRUGINFO D06GBK AG1295 Terminated T59102 DRUGINFO D00QPG 3-(4-dimethylamino-benzylidenyl)-2-indolinone Investigative T59102 DRUGINFO D00YNJ XB-387 Investigative T59102 DRUGINFO D01XDV 6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline Investigative T59102 DRUGINFO D02QBH 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine Investigative T59102 DRUGINFO D03FCU 4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D03IPZ 4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D05WTI (2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine Investigative T59102 DRUGINFO D06ZUA Ki-11502 Investigative T59102 DRUGINFO D09PUW Bis(5-methoxybenzo[b]furan-2-yl)methanone Investigative T59102 DRUGINFO D09QTC 6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline Investigative T59102 DRUGINFO D0BW4G PDGF receptor tyrosine kinase inhibitor III Investigative T59102 DRUGINFO D0C2KK 4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0CW1Q 6,7-Dimethoxy-4-phenoxy-quinoline Investigative T59102 DRUGINFO D0F1RU 4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0K3CJ 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol Investigative T59102 DRUGINFO D0R8BC 6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline Investigative T59102 DRUGINFO D0U3WQ AGL 2043 Investigative T59102 DRUGINFO D0VJ5W 6,7-Dimethoxy-4-m-tolyloxy-quinoline Investigative T59102 DRUGINFO D0Y1CJ 4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0ZS3F 6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline Investigative T59102 DRUGINFO D00LRC 3-Cyclopentyl-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D00RBV 6,7-Dimethoxy-3-pyridin-3-yl-quinoline Investigative T59102 DRUGINFO D00YCU 1-Phenyl-1H-benzoimidazol-5-ol Investigative T59102 DRUGINFO D01FWD 1-Phenyl-1H-benzoimidazole Investigative T59102 DRUGINFO D01MUN 4-Benzoimidazol-1-yl-phenylamine Investigative T59102 DRUGINFO D01UYS 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one Investigative T59102 DRUGINFO D02CUF Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine Investigative T59102 DRUGINFO D02OBA Bis(5-hydroxybenzo[b]furan-2-yl)methanone Investigative T59102 DRUGINFO D02PZZ 7-Methoxy-3-pyridin-4-yl-quinoline Investigative T59102 DRUGINFO D02XKJ 5-Methoxy-1-phenyl-1H-benzoimidazole Investigative T59102 DRUGINFO D03HLH 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline Investigative T59102 DRUGINFO D03MQI 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid Investigative T59102 DRUGINFO D03VAA Bis(6-hydroxybenzo[b]furan-2-yl)methanone Investigative T59102 DRUGINFO D04PQX 6-Methoxy-3-pyridin-4-yl-quinoline Investigative T59102 DRUGINFO D05GBY 3-Thiophen-3-yl-quinoline Investigative T59102 DRUGINFO D05QMN 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D05SNG 7-Fluoro-3-thiophen-3-yl-quinoline Investigative T59102 DRUGINFO D06LLF 6,7-Dimethoxy-3-((E)-styryl)-quinoline Investigative T59102 DRUGINFO D06MCJ 3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D06VNR 3-Benzyloxy-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D07AXL Bis(5-aminobenzo[b]furan-2-yl)methanone Investigative T59102 DRUGINFO D07CFT 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline Investigative T59102 DRUGINFO D07JDY 3-((E)-Styryl)-quinoline Investigative T59102 DRUGINFO D07ZWN 5,7-Dimethyl-3-thiophen-3-yl-quinoline Investigative T59102 DRUGINFO D08JGS 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline Investigative T59102 DRUGINFO D08KWL 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D08SUH 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0A6AA 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline Investigative T59102 DRUGINFO D0A6YP 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0AO6T 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0C1BE 6,7-Dimethoxy-3-p-tolyl-quinoline Investigative T59102 DRUGINFO D0CF9B 6,7-Dichloro-3-thiophen-3-yl-quinoline Investigative T59102 DRUGINFO D0FH3M RPR-108514A Investigative T59102 DRUGINFO D0G0KN 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline Investigative T59102 DRUGINFO D0G0ZQ 6,7-Dimethoxy-3-thiophen-2-yl-quinoline Investigative T59102 DRUGINFO D0G6SA 6,7-Dimethoxy-3-phenyl-quinoline Investigative T59102 DRUGINFO D0GN3E 3-(1H-Indol-3-yl)-quinoline Investigative T59102 DRUGINFO D0H4JB 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol Investigative T59102 DRUGINFO D0H9TO 3-Pyridin-4-yl-quinolin-7-ol Investigative T59102 DRUGINFO D0I0GL 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0I7QX (benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone Investigative T59102 DRUGINFO D0IR5I 3-Pyridin-3-yl-quinoline-6,7-diol Investigative T59102 DRUGINFO D0K2YG 4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine Investigative T59102 DRUGINFO D0K9ON 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0K9VE 3-Pyridin-4-yl-quinoline-5,7-diol Investigative T59102 DRUGINFO D0KF3N 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0L0MZ Bis(5-acetoxybenzo[b]furan-2-yl)methanone Investigative T59102 DRUGINFO D0P0RD 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0P0WT 5,7-Dimethoxy-3-pyridin-4-yl-quinoline Investigative T59102 DRUGINFO D0Q3DS 3-Pyridin-4-yl-quinoline Investigative T59102 DRUGINFO D0QT4X 6,7-Difluoro-3-thiophen-3-yl-quinoline Investigative T59102 DRUGINFO D0RD5S 5,7-Dimethoxy-3-thiophen-3-yl-quinoline Investigative T59102 DRUGINFO D0SG0G 5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline Investigative T59102 DRUGINFO D0T9FQ 6,7-Dimethoxy-3-pyridin-4-yl-quinoline Investigative T59102 DRUGINFO D0V8QI 7-Methoxy-3-thiophen-3-yl-quinoline Investigative T59102 DRUGINFO D0W7IN 6-Methoxy-3-thiophen-3-yl-quinoline Investigative T59102 DRUGINFO D0W9BF RPR-101511 Investigative T59102 DRUGINFO D0WW8M 6,7-Dimethoxy-3-phenylethynyl-quinoline Investigative T59102 DRUGINFO D0YE1X 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline Investigative T59102 DRUGINFO D0Z3DW Bis(benzo[b]furan-2-yl)methanone Investigative T59102 DRUGINFO D0Z4HV 7-Chloro-3-pyridin-4-yl-quinoline Investigative T59102 DRUGINFO D05QBZ CP-673451 Investigative T59102 DRUGINFO D07QMC 3-Benzimidazol-2-ylhydroquinolin-2-one Investigative T59102 DRUGINFO D09OLH (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone Investigative T59102 DRUGINFO D0D7ZL (1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone Investigative T59102 DRUGINFO D0G0KQ (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone Investigative T59102 DRUGINFO D0G5YI Di(1H-indol-2-yl)methanone Investigative T59102 DRUGINFO D0H7MF (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone Investigative T59102 DRUGINFO D0XS9E (5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone Investigative T59102 DRUGINFO D08BJR Ki-20227 Investigative T59102 DRUGINFO D09LPL SU-11652 Investigative T59102 DRUGINFO D0UN9O GTP-14564 Investigative T59102 DRUGINFO D0I3XZ Bis-(5-hydroxy-1H-indol-2-yl)-methanone Investigative T59102 DRUGINFO D0OH3J PD-0179483 Investigative T59102 DRUGINFO D0S1KJ PD-0173952 Investigative T59102 DRUGINFO D0XC6G 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole Investigative T59102 DRUGINFO D0Z7GH PD-0173958 Investigative T59102 DRUGINFO D03NPX PD-0173955 Investigative T59102 DRUGINFO D0YZ7H JNJ-10198409 Investigative T59102 DRUGINFO D0D5EW HKI-9924129 Investigative T59102 DRUGINFO D0GW4Q PD-0173956 Investigative T59102 DRUGINFO D0H1OK TG-100435 Investigative T59102 DRUGINFO D0P3JW PD-0166326 Investigative T59102 DRUGINFO D0C2GE PMID22765894C8h Investigative T59102 DRUGINFO D09XIL Ro-4396686 Investigative T59102 DRUGINFO D0M4SY BMS-536924 Investigative T76024 TARGETID T76024 T76024 FORMERID TTDC00085 T76024 UNIPROID C1S_HUMAN T76024 TARGNAME Complement C1s component (C1S) T76024 GENENAME C1S T76024 TARGTYPE Successful T76024 SYNONYMS Complement component 1 subcomponent s; Complement C1s subcomponent; C1-esterase; C1 esterase T76024 FUNCTION C1r activates C1s so that it can, in turn, activate C2 and C4. C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. T76024 PDBSTRUC 6F1H; 6F1C; 4LOT; 4LOS; 4LOR T76024 BIOCLASS Peptidase T76024 ECNUMBER EC 3.4.21.42 T76024 SEQUENCE MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIELSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERFTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVFTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVFVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTPNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCGIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPKCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGNREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVKMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKVEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCGTYGLYTRVKNYVDWIMKTMQENSTPRED T76024 DRUGINFO DJ0L4K Sutimlimab Approved T76024 DRUGINFO D0BK4X Cinryze Approved T76024 DRUGINFO DHQI14 SAR445088 Phase 2 T76024 DRUGINFO D05TDJ TS01 Phase 1 T76024 DRUGINFO D06SHZ SHP616 Phase 1 T76024 DRUGINFO D0OC5T ANX005 Phase 1 T76024 DRUGINFO D0X1EV TNT009 Phase 1 T76024 DRUGINFO D0J1CC PMID16460935C28 Investigative T76024 DRUGINFO D0G6XS Fucose Investigative T06273 TARGETID T06273 T06273 FORMERID TTDS00191 T06273 UNIPROID PARP1_HUMAN T06273 TARGNAME Poly [ADP-ribose] polymerase 1 (PARP1) T06273 GENENAME PARP1 T06273 TARGTYPE Successful T06273 SYNONYMS Protein poly-ADP-ribosyltransferase PARP1; Poly[ADP-ribose] synthetase-1; Poly[ADP-ribose] synthase 1; Poly(ADP-ribose)polymerase-1; PPOL; PARP-1; NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1; NAD(+) ADP-ribosyltransferase-1; NAD(+) ADP-ribosyltransferase 1; DNA ADP-ribosyltransferase PARP1; ARTD1; ADPRT 1; ADPRT; ADP-ribosyltransferase diphtheria toxin-like 1 T06273 FUNCTION Mainly mediates glutamate and aspartate ADP-ribosylation of target proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of glutamate and aspartate residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. Mediates the poly(ADP-ribosyl)ation of a number of proteins, including itself, APLF and CHFR. Also mediates serine ADP-ribosylation of target proteins following interaction with HPF1; HPF1 conferring serine specificity. Probably also catalyzes tyrosine ADP-ribosylation of target proteins following interaction with HPF1. Catalyzes the poly-ADP-ribosylation of histones in a HPF1-dependent manner. Involved in the base excision repair (BER) pathway by catalyzing the poly-ADP-ribosylation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. ADP-ribosylation follows DNA damage and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. In addition to base excision repair (BER) pathway, also involved in double-strand breaks (DSBs) repair: together with TIMELESS, accumulates at DNA damage sites and promotes homologous recombination repair by mediating poly-ADP-ribosylation. In addition to proteins, also able to ADP-ribosylate DNA: catalyzes ADP-ribosylation of DNA strand break termini containing terminal phosphates and a 2'-OH group in single- and double-stranded DNA, respectively. Required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites. Acts as a regulator of transcription: positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. With EEF1A1 and TXK, forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFN-gamma to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production. Involved in the synthesis of ATP in the nucleus, together with NMNAT1, PARG and NUDT5. Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming. Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. T06273 PDBSTRUC 6GHK; 6BHV; 5XSU; 5XST; 5XSR T06273 BIOCLASS Glycosyltransferases T06273 ECNUMBER EC 2.4.2.30 T06273 SEQUENCE MAESSDKLYRVEYAKSGRASCKKCSESIPKDSLRMAIMVQSPMFDGKVPHWYHFSCFWKVGHSIRHPDVEVDGFSELRWDDQQKVKKTAEAGGVTGKGQDGIGSKAEKTLGDFAAEYAKSNRSTCKGCMEKIEKGQVRLSKKMVDPEKPQLGMIDRWYHPGCFVKNREELGFRPEYSASQLKGFSLLATEDKEALKKQLPGVKSEGKRKGDEVDGVDEVAKKKSKKEKDKDSKLEKALKAQNDLIWNIKDELKKVCSTNDLKELLIFNKQQVPSGESAILDRVADGMVFGALLPCEECSGQLVFKSDAYYCTGDVTAWTKCMVKTQTPNRKEWVTPKEFREISYLKKLKVKKQDRIFPPETSASVAATPPPSTASAPAAVNSSASADKPLSNMKILTLGKLSRNKDEVKAMIEKLGGKLTGTANKASLCISTKKEVEKMNKKMEEVKEANIRVVSEDFLQDVSASTKSLQELFLAHILSPWGAEVKAEPVEVVAPRGKSGAALSKKSKGQVKEEGINKSEKRMKLTLKGGAAVDPDSGLEHSAHVLEKGGKVFSATLGLVDIVKGTNSYYKLQLLEDDKENRYWIFRSWGRVGTVIGSNKLEQMPSKEDAIEHFMKLYEEKTGNAWHSKNFTKYPKKFYPLEIDYGQDEEAVKKLTVNPGTKSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKVEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKTSLW T06273 DRUGINFO D06NVJ Nicotinamide Approved T06273 DRUGINFO D09LSX KU-0058948 Approved T06273 DRUGINFO D0DN0W Niraparib Tosylate Approved T06273 DRUGINFO D0Z2UW Nicaraven Phase 3 T06273 DRUGINFO D09NTC CC-486 Phase 3 T06273 DRUGINFO D06KZL AG140699 Phase 2 T06273 DRUGINFO D0YTM9 AZD5305 Phase 2 T06273 DRUGINFO D0F5TD PMID27841036-Compound-37 Phase 2 T06273 DRUGINFO DP48WE Stenoparib Phase 2 T06273 DRUGINFO D8TE4F AMXI 5001 Phase 1/2 T06273 DRUGINFO DO0LP3 NMS-03305293 Phase 1 T06273 DRUGINFO D01KFW 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1 Patented T06273 DRUGINFO D01PYO Benzimidazole carboxamide derivative 1 Patented T06273 DRUGINFO D02KMI PMID27841036-Compound-33 Patented T06273 DRUGINFO D02QFM 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4 Patented T06273 DRUGINFO D05ZBB Phthalazine ketone derivative 1 Patented T06273 DRUGINFO D08KAH Quinazolinedione derivative 3 Patented T06273 DRUGINFO D08YPU 4-Carboxamido-isoindolinone derivative 2 Patented T06273 DRUGINFO D09HUV 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3 Patented T06273 DRUGINFO D09WUA 7-azaindole derivative 8 Patented T06273 DRUGINFO D09ZIM 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5 Patented T06273 DRUGINFO D0AN7Z Phthalazine ketone derivative 3 Patented T06273 DRUGINFO D0B3QI Dihydropyrido phthalazinone derivative 1 Patented T06273 DRUGINFO D0B4FV Phthalazine ketone derivative 2 Patented T06273 DRUGINFO D0E9JI Tricyclic indole compound 13 Patented T06273 DRUGINFO D0G8HX 3-phenyl isoquinolin-1(2H) derivative 2 Patented T06273 DRUGINFO D0GH4V 4-Carboxamido-isoindolinone derivative 5 Patented T06273 DRUGINFO D0IX2C Quinazolinedione derivative 2 Patented T06273 DRUGINFO D0J2SR Quinazolinedione derivative 1 Patented T06273 DRUGINFO D0J4GY Dihydropyrido phthalazinone derivative 2 Patented T06273 DRUGINFO D0M0WS 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2 Patented T06273 DRUGINFO D0M9TG Phthalazine derivative 3 Patented T06273 DRUGINFO D0MP4W Tetra-hydro-quinoline derivative 1 Patented T06273 DRUGINFO D0O9FC 4-Carboxamido-isoindolinone derivative 1 Patented T06273 DRUGINFO D0R0PO 4-Carboxamido-isoindolinone derivative 3 Patented T06273 DRUGINFO D0Z5DI 4-Carboxamido-isoindolinone derivative 4 Patented T06273 DRUGINFO D0P3YA Dihydrodiazepinocarbazolone derivative 1 Patented T06273 DRUGINFO D0Z8IR Tetra-cyclic pyridophthalazinone derivative 1 Patented T06273 DRUGINFO D0TD8R 3-phenyl isoquinolin-1(2H) derivative 1 Patented T06273 DRUGINFO D04ABS CPH-102 Preclinical T06273 DRUGINFO D04WDX PJ34 Preclinical T06273 DRUGINFO D0O3FX NU1025 Terminated T06273 DRUGINFO D00OZA 3-Ethynylquinoline-8-carboxamide Investigative T06273 DRUGINFO D00TUB 2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one Investigative T06273 DRUGINFO D00WMC N-(4-Phenylthiazol-2-yl)isonicotinamide Investigative T06273 DRUGINFO D01EVX 5-Chloro-2-methyl-3H-quinazolin-4-one Investigative T06273 DRUGINFO D01RXM BZ3 Investigative T06273 DRUGINFO D01YIR 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide Investigative T06273 DRUGINFO D02GPJ CEP-6800 Investigative T06273 DRUGINFO D02JHW ANG-2864 Investigative T06273 DRUGINFO D02MPP 3-Methoxybenzamide Investigative T06273 DRUGINFO D02QZF 2-Benzyl-2H-indazole-7-carboxamide Investigative T06273 DRUGINFO D02XLC 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Investigative T06273 DRUGINFO D03JTS 4-amino-1,8-naphthalimide Investigative T06273 DRUGINFO D03VNZ Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione Investigative T06273 DRUGINFO D04ATU 8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative T06273 DRUGINFO D04AYN EB-47 Investigative T06273 DRUGINFO D04LDH BZ6 Investigative T06273 DRUGINFO D04TDX 2-(4-methoxyphenyl)quinoline-8-carboxamide Investigative T06273 DRUGINFO D04UPQ 9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative T06273 DRUGINFO D04ZQJ (E)-N-(4-Phenylthiazol-2-yl) cinnamamide Investigative T06273 DRUGINFO D05APM ANG-2684 Investigative T06273 DRUGINFO D05GMW 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Investigative T06273 DRUGINFO D05HJG 2,3-dihydro-1H-benzo[de]isoquinolin-1-one Investigative T06273 DRUGINFO D05RXG 5-amino-3,4-dihydroisoquinolin-1(2H)-one Investigative T06273 DRUGINFO D05SYO KR-33889 Investigative T06273 DRUGINFO D05WYN 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one Investigative T06273 DRUGINFO D05XMG AG-014376 Investigative T06273 DRUGINFO D05ZTI 3-Hydroxy-benzamide Investigative T06273 DRUGINFO D06NKJ 8-Methoxy-2-phenyl-3H-quinazolin-4-one Investigative T06273 DRUGINFO D07AGU Quinoline-8-carboxamide Investigative T06273 DRUGINFO D07BBR 9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative T06273 DRUGINFO D07BPT 8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one Investigative T06273 DRUGINFO D07CRG 2H-Isoquinolin-1-one Investigative T06273 DRUGINFO D07QPV KU-58684 Investigative T06273 DRUGINFO D07SRJ 2,8-Dimethyl-3H-quinazolin-4-one Investigative T06273 DRUGINFO D07WPL 5-aminoisoquinolin-1(2H)-one Investigative T06273 DRUGINFO D08AOV INO-1002 Investigative T06273 DRUGINFO D08GMO 3-(4-aminophenyl)quinoxaline-5-carboxamide Investigative T06273 DRUGINFO D08OUR 2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide Investigative T06273 DRUGINFO D08QWR 4-benzylphthalazin-1(2H)-one Investigative T06273 DRUGINFO D08XPZ 3-Methylquinoline-8-carboxamide Investigative T06273 DRUGINFO D08ZVM 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide Investigative T06273 DRUGINFO D0B2WX 2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0CA2S HYDAMTIQ Investigative T06273 DRUGINFO D0E0QT 8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative T06273 DRUGINFO D0E2VC PD-128763 Investigative T06273 DRUGINFO D0E5EW 8-Methyl-2-phenyl-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0E7UW TI3 Investigative T06273 DRUGINFO D0EI6X 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one Investigative T06273 DRUGINFO D0EQ1J S-111 Investigative T06273 DRUGINFO D0EW8Y Thieno-phenanthridin-6-one Investigative T06273 DRUGINFO D0F8ZI 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one Investigative T06273 DRUGINFO D0FF4M 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one Investigative T06273 DRUGINFO D0G5VD 8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0GA0Y 2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0GJ8U 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one Investigative T06273 DRUGINFO D0I2AF 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide Investigative T06273 DRUGINFO D0IX3I 2-phenyl-2H-indazole-7-carboxamide Investigative T06273 DRUGINFO D0JD1O Carba-Nicotinamide-Adenine-Dinucleotide Investigative T06273 DRUGINFO D0K2PD 3-aminobenzamide Investigative T06273 DRUGINFO D0K7JT 3-Ethenylquinoline-8-carboxamide Investigative T06273 DRUGINFO D0L1NQ 3-Phenylquinoline-8-carboxamide Investigative T06273 DRUGINFO D0L1RZ 3-(4-methoxyphenyl)quinoxaline-5-carboxamide Investigative T06273 DRUGINFO D0L6LO TI4 Investigative T06273 DRUGINFO D0M6WJ Benzo[c][1,5]naphthyridin-6(5H)-one Investigative T06273 DRUGINFO D0M9TW 3-(4-cyanophenyl)quinoxaline-5-carboxamide Investigative T06273 DRUGINFO D0NU5Z 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione Investigative T06273 DRUGINFO D0O0GA 8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative T06273 DRUGINFO D0O6WW 8-Hydroxy-2-phenyl-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0OF1I 8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0PT1K 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide Investigative T06273 DRUGINFO D0R7FS BPI-704001 Investigative T06273 DRUGINFO D0R7HU Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Investigative T06273 DRUGINFO D0S8HZ 2-Methylquinoline-8-carboxamide Investigative T06273 DRUGINFO D0T3SY 8-Methoxy-2-methyl-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0T5TT 3-Prop-1-ynylquinoline-8-carboxamide Investigative T06273 DRUGINFO D0TH7S 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide Investigative T06273 DRUGINFO D0U5WY 2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0UF0U 3-Ethylquinoline-8-carboxamide Investigative T06273 DRUGINFO D0VY5O A-620223 Investigative T06273 DRUGINFO D0W7XH DR2313 Investigative T06273 DRUGINFO D0WO3P 2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0XZ5D 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide Investigative T06273 DRUGINFO D0Y1MH 2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one Investigative T06273 DRUGINFO D0Z3PB 2-ethylquinoline-8-carboxamide Investigative T06273 DRUGINFO D0Z9DY 2-phenylquinoline-8-carboxamide Investigative T06273 DRUGINFO D0ZK3L BZ5 Investigative T06273 DRUGINFO D04QRM ME0328 Investigative T06273 DRUGINFO D09SZG [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala Investigative T06273 DRUGINFO D0P4DG S-070 Investigative T03691 TARGETID T03691 T03691 FORMERID TTDC00130 T03691 UNIPROID LKHA4_HUMAN T03691 TARGNAME Leukotriene A-4 hydrolase (LTA4H) T03691 GENENAME LTA4H T03691 TARGTYPE Successful T03691 SYNONYMS Leukotriene A4 hydrolase; Leukotriene A(4)Leukotriene A-4 hydrolase hydrolase; Leukotriene A(4) hydrolase; LTA4; LTA-H; LTA-4hydrolase; LTA-4 hydrolase T03691 FUNCTION Has also aminopeptidase activity. Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. T03691 PDBSTRUC 6END; 6ENC; 6ENB; 5NIE; 5NID T03691 BIOCLASS Ether bond hydrolase T03691 ECNUMBER EC 3.3.2.6 T03691 SEQUENCE MPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD T03691 DRUGINFO D0RA5Q Bestatin Approved T03691 DRUGINFO DI2KZ7 LYS006 Phase 2 T03691 DRUGINFO D07VNH Acebilustat Phase 1 T03691 DRUGINFO D06XEL DG051 Discontinued in Phase 2 T03691 DRUGINFO D00FCJ N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide Investigative T03691 DRUGINFO D00FDS (R)-2-((4-phenoxyphenoxy)methyl)piperidine Investigative T03691 DRUGINFO D00TNN (R/S)-2-((4-phenoxyphenoxy)methyl)piperidine Investigative T03691 DRUGINFO D00TWK 5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol Investigative T03691 DRUGINFO D00YCG 5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole Investigative T03691 DRUGINFO D01QWO 4-(4-butoxyphenoxy)phenol Investigative T03691 DRUGINFO D01RVF (R)-N-benzyl-4-(pyrrolidin-2-ylmethoxy)aniline Investigative T03691 DRUGINFO D01YJJ N5-[4-(3-Phenylpropoxy)phenyl]-L-glutamine Investigative T03691 DRUGINFO D02TMR N5-[(4-Phenoxy)-3-pyridyl]-L-glutamamide Investigative T03691 DRUGINFO D03GON 2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzooxazole Investigative T03691 DRUGINFO D03UIF SA-6541 Investigative T03691 DRUGINFO D04CZF N5-[4-(Phenylmethoxy)phenyl]-L-glutamamide Investigative T03691 DRUGINFO D04DRM N1-[4-(Phenylmethoxy)phenyl]-D-glutamine Investigative T03691 DRUGINFO D04ZLZ N4-[4-(Phenylmethoxy)phenyl]-L-aspartamine Investigative T03691 DRUGINFO D05NXQ (S)-2-((4-phenoxyphenoxy)methyl)piperidine Investigative T03691 DRUGINFO D06RWH 2-Amino-N-[4-(phenylmethoxy)phenyl]-acetamide Investigative T03691 DRUGINFO D06SMN (R)-2-(4-Benzylphenoxymethyl)pyrrolidine Investigative T03691 DRUGINFO D07KBF N5-[4-(2-methylphenoxy)phenyl]-L-glutamamide Investigative T03691 DRUGINFO D07LTR 1-(pentyloxy)-4-phenoxybenzene Investigative T03691 DRUGINFO D07TVA 1-butoxy-4-phenoxybenzene Investigative T03691 DRUGINFO D07ZJS (R/S)-2-((4-benzylphenoxy)methyl)piperidine Investigative T03691 DRUGINFO D08TNQ N5-[4-(Phenylmethoxy)phenyl]-L-glutamine Investigative T03691 DRUGINFO D08UIO 2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzothiazole Investigative T03691 DRUGINFO D08WZB N5-[4-(1H-pyrrol-1-yl)phenyl]-L-glutamamide Investigative T03691 DRUGINFO D09BWE 1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-ol Investigative T03691 DRUGINFO D09MDO 4-amino-N-[4-(benzyloxy)phenyl]butanamide Investigative T03691 DRUGINFO D09OWF N5-(4-Phenoxyphenyl)-L-glutamine Investigative T03691 DRUGINFO D09PGC 2-[4-(2-Morpholin-4-ylethoxy)phenoxy]benzooxazole Investigative T03691 DRUGINFO D0A2YG N-methyl-1-(2-thiophen-2-ylphenyl)methanamine Investigative T03691 DRUGINFO D0B0DP N6-[4-(4-methylphenoxy)phenyl]-L-homoglutamine Investigative T03691 DRUGINFO D0B9UW N5-[4-(4-(3-Furyl)phenoxy)phenyl]-L-glutamamide Investigative T03691 DRUGINFO D0C1XE (R)-2-((4-benzylphenoxy)methyl)piperidine Investigative T03691 DRUGINFO D0DI4I N5-[4-(2-Oxo-3-phenylpropoxy)phenyl]-L-glutamine Investigative T03691 DRUGINFO D0G0JC N-(pyridin-3-ylmethyl)aniline Investigative T03691 DRUGINFO D0G8SW N5-[4-(4-methylphenoxy)phenyl]-L-glutamamide Investigative T03691 DRUGINFO D0H9NZ (R/S)-2-((4-benzylphenoxy)methyl)piperazine Investigative T03691 DRUGINFO D0HA1K N1-[4-(Phenylmethoxy)phenyl]-L-glutamine Investigative T03691 DRUGINFO D0I4OV (4-(thiophen-2-yl)phenyl)methanamine Investigative T03691 DRUGINFO D0I7MC 4-(4-(pentyloxy)phenoxy)phenol Investigative T03691 DRUGINFO D0J0WO (4-fluorophenyl)(pyridin-4-yl)methanone Investigative T03691 DRUGINFO D0LZ3O N1-[4-(Phenylmethoxy)phenyl]-L-aspartamine Investigative T03691 DRUGINFO D0M2CY 4S-4,5-Diamino-N-(4-phenoxyphenyl)pentanamide Investigative T03691 DRUGINFO D0N6TC N5-[4-(2-phenylethoxy)phenyl]-L-glutamine Investigative T03691 DRUGINFO D0P7DF 1-[4-(4-Iodophenoxy)phenyl]piperazine Investigative T03691 DRUGINFO D0PF9Q 2-(4-Piperidin-1-ylmethylphenoxy)benzothiazole Investigative T03691 DRUGINFO D0R7BT 1-(2,2'-bithiophen-5-yl)methanamine Investigative T03691 DRUGINFO D0SZ9E 8(S)-amino-2(R)-methyl-7-oxononanoic acid Investigative T03691 DRUGINFO D0U1EV N5-[4-(Phenylmethoxy)phenyl]-D-glutamine Investigative T03691 DRUGINFO D0U1UV N1-[4-(Phenylmethoxy)phenyl]-D-aspartamine Investigative T03691 DRUGINFO D0U2AM N5-[4-Benzylphenyl]-L-glutamamide Investigative T03691 DRUGINFO D0V0MH 1-(4-Phenoxyphenyl)piperazine Investigative T03691 DRUGINFO D0VN8V 4-[2-(4-Benzylphenoxy)ethyl]pyridine Investigative T03691 DRUGINFO D0W2OP 2-(4-benzylphenoxy)ethanamine Investigative T03691 DRUGINFO D0Y6IV 4-(4-propoxyphenoxy)phenol Investigative T03691 DRUGINFO D0Z6DL N5-[4-(N-Phenylamino)phenyl]-L-glutamine Investigative T03691 DRUGINFO D01KOI 4-(2-amino-1,3-thiazol-4-yl)phenol Investigative T03691 DRUGINFO D02AYI 2-(4-phenoxyphenoxy)ethanamine Investigative T03691 DRUGINFO D09DRF 3-(Benzyloxy)Pyridin-2-Amine Investigative T03691 DRUGINFO D0C8MT 2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine Investigative T03691 DRUGINFO D0Q8LS 2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole Investigative T03691 DRUGINFO D00UIN JNJ-10392980 Investigative T03691 DRUGINFO D0F2ME Acetate Ion Investigative T11211 TARGETID T11211 T11211 FORMERID TTDS00367 T11211 UNIPROID ANDR_HUMAN T11211 TARGNAME Androgen receptor (AR) T11211 GENENAME AR T11211 TARGTYPE Successful T11211 SYNONYMS Testosterone receptor; Nuclear receptor subfamily 3 group C member 4; NR3C4; Dihydrotestosterone receptor; DHTR T11211 FUNCTION Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation. Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. T11211 PDBSTRUC 5VO4; 5V8Q; 5T8J; 5T8E; 5JJM T11211 BIOCLASS Nuclear hormone receptor T11211 SEQUENCE MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ T11211 DRUGINFO D00YWP Nandrolone Approved T11211 DRUGINFO D06AEO Cyproterone Approved T11211 DRUGINFO D06XMU Testosterone Approved T11211 DRUGINFO D08TEJ Clascoterone Approved T11211 DRUGINFO D09NNA Dromostanolone Approved T11211 DRUGINFO D0BC2E Hydroxyflutamide Approved T11211 DRUGINFO D0DV6D Darolutamide Approved T11211 DRUGINFO D0L2LS Fluoxymesterone Approved T11211 DRUGINFO D0QK5X Enzalutamide Approved T11211 DRUGINFO D0S7LG ARN-509 Approved T11211 DRUGINFO D0SC8F Ethylestrenol Approved T11211 DRUGINFO D0SN9T Nilutamide Approved T11211 DRUGINFO D0U3GL Oxandrolone Approved T11211 DRUGINFO D0V9BD Bicalutamide Approved T11211 DRUGINFO D0Y0SW Flutamide Approved T11211 DRUGINFO D0K0EK Prasterone Approved T11211 DRUGINFO D0R7JT Fludrocortisone Approved T11211 DRUGINFO D0B2WJ Flufenamic Acid Approved T11211 DRUGINFO D04DJN Dihydrotestosterone Phase 4 T11211 DRUGINFO D04NNJ ZANOTERONE Phase 3 T11211 DRUGINFO DE4AO8 HC-1119 Phase 3 T11211 DRUGINFO D04KYB ASCJ-9 Phase 2 T11211 DRUGINFO D0C9EN AZD5312 Phase 2 T11211 DRUGINFO D0G1IV Testogen TDS Phase 2 T11211 DRUGINFO D0RV6F MK-0773 Phase 2 T11211 DRUGINFO D0U0BU TOK-001 Phase 2 T11211 DRUGINFO DZTX12 ASC-J9 Phase 2 T11211 DRUGINFO D03CVT ONC1-13B Phase 1/2 T11211 DRUGINFO D0N7DQ APC-100 Phase 1/2 T11211 DRUGINFO D3XE7Y ARV-766 Phase 1/2 T11211 DRUGINFO D3ZY1K ARV-110 Phase 1/2 T11211 DRUGINFO DS41PJ ARV-471 Phase 1/2 T11211 DRUGINFO D04XWX PS-178990 Phase 1 T11211 DRUGINFO D05VNP TESTOSTERONE BUCICLATE Phase 1 T11211 DRUGINFO D08AAV AZD-3514 Phase 1 T11211 DRUGINFO D09ZLZ RAD-140 Phase 1 T11211 DRUGINFO D0C4FS DT-200 Phase 1 T11211 DRUGINFO D0D3FP Drug 2881078 Phase 1 T11211 DRUGINFO D0N5NC TAS3681 Phase 1 T11211 DRUGINFO D8C1OA AC0176 Phase 1 T11211 DRUGINFO DNY63Z CC-94676 Phase 1 T11211 DRUGINFO DY7Q1O EPI-7386 Phase 1 T11211 DRUGINFO D08NNR Testosterone glucoside Discontinued in Phase 2 T11211 DRUGINFO D09IZX GW-275919 Discontinued in Phase 2 T11211 DRUGINFO D0E3EK NP-619 Discontinued in Phase 2 T11211 DRUGINFO D0F7WQ HE-2000 Discontinued in Phase 2 T11211 DRUGINFO D00ABW Opterone Discontinued in Phase 1 T11211 DRUGINFO D03KTE LGD2941 Discontinued in Phase 1 T11211 DRUGINFO D03SHP GSK2849466 Discontinued in Phase 1 T11211 DRUGINFO D0S7UU PF-06260414 Discontinued in Phase 1 T11211 DRUGINFO D05BCA MX-4509 Discontinued in Phase 1 T11211 DRUGINFO D0BJ7W GLPG-0492 Preclinical T11211 DRUGINFO D07VUD ZD-3980 Terminated T11211 DRUGINFO D0G6PL LG-2293 Terminated T11211 DRUGINFO D00QVP 6,11-dihydrothiochromeno[4,3-b]indol-8-ol Investigative T11211 DRUGINFO D02RZC ASC-JMX2 Investigative T11211 DRUGINFO D03KYW Calusterone Investigative T11211 DRUGINFO D04MFW DL-3 Investigative T11211 DRUGINFO D04QFY GTx-027 Investigative T11211 DRUGINFO D07KOY RU-59063 Investigative T11211 DRUGINFO D07TLT 11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol Investigative T11211 DRUGINFO D09HQH Boldenone Investigative T11211 DRUGINFO D09XGK Testetrol Investigative T11211 DRUGINFO D0A7YH Palodesangren C Investigative T11211 DRUGINFO D0C1UP SX-ARPC Investigative T11211 DRUGINFO D0D8QN ARN34 Investigative T11211 DRUGINFO D0I3LL Palodesangren D Investigative T11211 DRUGINFO D0JC4J SARMs Investigative T11211 DRUGINFO D0JI4G Palodesangren E Investigative T11211 DRUGINFO D0MM9P OXENDLONE Investigative T11211 DRUGINFO D0NH0U HYG-440 Investigative T11211 DRUGINFO D0O0II ASC-JMZ1 Investigative T11211 DRUGINFO D0T1DZ EPI-001 Investigative T11211 DRUGINFO D0W5IF CH-4933468 Investigative T11211 DRUGINFO D0W8AI Andromustine Investigative T11211 DRUGINFO D0Z3WA Delta1-dihydrotestosterone Investigative T11211 DRUGINFO D06BLF 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane Investigative T11211 DRUGINFO D06VZE [3H]mibolerone Investigative T11211 DRUGINFO D01ETZ [3H]methyltrienolone Investigative T63484 TARGETID T63484 T63484 FORMERID TTDR00008 T63484 UNIPROID G6PD_HUMAN T63484 TARGNAME Glucose-6-phosphate dehydrogenase (G6PD) T63484 GENENAME G6PD T63484 TARGTYPE Successful T63484 SYNONYMS Glucose-6-phosphate 1-dehydrogenase T63484 FUNCTION The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis. Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis. T63484 PDBSTRUC 6.00E+08; 6.00E+07; 5UKW; 2BHL; 2BH9 T63484 BIOCLASS CH-OH donor oxidoreductase T63484 ECNUMBER EC 1.1.1.49 T63484 SEQUENCE MAEQVALSRTQVCGILREELFQGDAFHQSDTHIFIIMGASGDLAKKKIYPTIWWLFRDGLLPENTFIVGYARSRLTVADIRKQSEPFFKATPEEKLKLEDFFARNSYVAGQYDDAASYQRLNSHMNALHLGSQANRLFYLALPPTVYEAVTKNIHESCMSQIGWNRIIVEKPFGRDLQSSDRLSNHISSLFREDQIYRIDHYLGKEMVQNLMVLRFANRIFGPIWNRDNIACVILTFKEPFGTEGRGGYFDEFGIIRDVMQNHLLQMLCLVAMEKPASTNSDDVRDEKVKVLKCISEVQANNVVLGQYVGNPDGEGEATKGYLDDPTVPRGSTTATFAAVVLYVENERWDGVPFILRCGKALNERKAEVRLQFHDVAGDIFHQQCKRNELVIRVQPNEAVYTKMMTKKPGMFFNPEESELDLTYGNRYKNVKLPDAYERLILDVFCGSQMHFVRSDELREAWRIFTPLLHQIELEKPKPIPYIYGSRGPTEADELMKRVGFQYEGTYKWVNPHKL T63484 DRUGINFO D0K0EK Prasterone Approved T63484 DRUGINFO D0O8FW EPIANDROSTERONE Phase 3 T63484 DRUGINFO D05JCG CBF-BS2 Discontinued in Phase 2 T63484 DRUGINFO D01HNP Hydroxyacetic Acid Investigative T63484 DRUGINFO D0FF3D Metazamide Investigative T63484 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T34234 TARGETID T34234 T34234 FORMERID TTDS00251 T34234 UNIPROID VDR_HUMAN T34234 TARGNAME Vitamin D3 receptor (VDR) T34234 GENENAME VDR T34234 TARGTYPE Successful T34234 SYNONYMS Vitamin D(3) receptor; Nuclear vitamin D receptor; Nuclear receptor subfamily 1 group I member 1; NR1I1; 1,25-dihydroxyvitamin D3 receptor T34234 FUNCTION Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR. The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes. Plays a central role in calcium homeostasis. Nuclear receptor for calcitriol, the active form of vitamin D3 which mediates the action of this vitamin on cells. T34234 PDBSTRUC 5YT2; 5YSY; 5V39; 5GT4; 4ITF T34234 BIOCLASS Nuclear hormone receptor T34234 SEQUENCE MEAMAASTSLPDPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRRSMKRKALFTCPFNGDCRITKDNRRHCQACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEALKDSLRPKLSEEQQRIIAILLDAHHKTYDPTYSDFCQFRPPVRVNDGGGSHPSRPNSRHTPSFSGDSSSSCSDHCITSSDMMDSSSFSNLDLSEEDSDDPSVTLELSQLSMLPHLADLVSYSIQKVIGFAKMIPGFRDLTSEDQIVLLKSSAIEVIMLRSNESFTMDDMSWTCGNQDYKYRVSDVTKAGHSLELIEPLIKFQVGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLSNTLQTYIRCRHPPPGSHLLYAKMIQKLADLRSLNEEHSKQYRCLSFQPECSMKLTPLVLEVFGNEIS T34234 DRUGINFO D01QUS Calcipotriol Approved T34234 DRUGINFO D01UFN Falecalcitrol Approved T34234 DRUGINFO D02VPX Calcidiol Approved T34234 DRUGINFO D06JPB Ergocalciferol Approved T34234 DRUGINFO D0G5CF Doxercalciferol Approved T34234 DRUGINFO D0G8OC Dihydrotachysterol Approved T34234 DRUGINFO D0K5WS Cholecalciferol Approved T34234 DRUGINFO D0N1TP Paricalcitol Approved T34234 DRUGINFO D0T2PL Calcitriol Approved T34234 DRUGINFO D09ZJQ Seocalcitol Phase 3 T34234 DRUGINFO D0U8CR S-06911 Phase 3 T34234 DRUGINFO D0R8IE Inecalcitol oral Phase 2 T34234 DRUGINFO D00CGH RO-23-7553 Phase 1 T34234 DRUGINFO D05SOH CTAP-201 Phase 1 T34234 DRUGINFO D00SZR PMID27454349-Compound-98 Patented T34234 DRUGINFO D03ZXP PMID27454349-Compound-97 Patented T34234 DRUGINFO D09KWM PMID27454349-Compound-93 Patented T34234 DRUGINFO D0JC8M PMID27454349-Compound-95 Patented T34234 DRUGINFO D0O2HK PMID27454349-Compound-102 Patented T34234 DRUGINFO D0P1KV PMID27454349-Compound-100 Patented T34234 DRUGINFO D0P8CM PMID27454349-Compound-92 Patented T34234 DRUGINFO D0PJ2C PMID27454349-Compound-99 Patented T34234 DRUGINFO D0UK7K PMID27454349-Compound-91 Patented T34234 DRUGINFO D0UY3J PMID27454349-Compound-96 Patented T34234 DRUGINFO D0WT4I PMID27454349-Compound-101 Patented T34234 DRUGINFO D0WV1W PMID27454349-Compound-94 Patented T34234 DRUGINFO D06SBK Atocalcitol Discontinued in Phase 2 T34234 DRUGINFO D07BDY Tisocalcitate Discontinued in Phase 2 T34234 DRUGINFO D0I4GI RO-26-9228 Discontinued in Phase 2 T34234 DRUGINFO D0RF9T Lexacalcitol Discontinued in Phase 2 T34234 DRUGINFO D08KZR BXL-746 Discontinued in Phase 1 T34234 DRUGINFO D0KK4U CB-1267 Terminated T34234 DRUGINFO D0O6WJ Ecalcidene Terminated T34234 DRUGINFO D0T9SJ CEP-4186 Terminated T34234 DRUGINFO D02EHY 2MD Investigative T34234 DRUGINFO D06DEL calcitriol-26,23-lactone Investigative T34234 DRUGINFO D07AHG LG190178 Investigative T34234 DRUGINFO D0C7NV MC-1301 Investigative T34234 DRUGINFO D0D6XV TEI-9647 Investigative T34234 DRUGINFO D0K8VA gemini Investigative T34234 DRUGINFO D0X0AM ZK159222 Investigative T34234 DRUGINFO D0X3DK KSP-BCS-1-alpha-CHF2-1624F2-2 Investigative T34234 DRUGINFO D0XZ2P KSP-BCS-1-alpha-CHF2-20-epi-22-oxabishomo-26-OH Investigative T34234 DRUGINFO D06RBG 3-keto-lithocholic acid Investigative T13260 TARGETID T13260 T13260 FORMERID TTDS00252 T13260 UNIPROID CP19A_HUMAN T13260 TARGNAME Aromatase (CYP19A1) T13260 GENENAME CYP19A1 T13260 TARGTYPE Successful T13260 SYNONYMS P-450AROM; Estrogen synthetase; Estrogen synthase; Cytochrome P450 19A1; Cytochrome P-450AROM; CYPXIX; CYP19; CYAR; ARO1 T13260 FUNCTION Catalyzes the formation of aromatic C18 estrogens from C19 androgens. T13260 PDBSTRUC 5JL9; 5JL7; 5JL6; 5JKW; 5JKV T13260 BIOCLASS Paired donor oxygen oxidoreductase T13260 ECNUMBER EC 1.14.14.14 T13260 SEQUENCE MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH T13260 DRUGINFO D0C1WH Letrozole Approved T13260 DRUGINFO D0C7JF Testolactone Approved T13260 DRUGINFO D0D2VS Exemestane Approved T13260 DRUGINFO D0W0BF Anastrozole Approved T13260 DRUGINFO D0M6DO Aminoglutethimide Approved T13260 DRUGINFO D0ZX1P FADROZOLE Approved T13260 DRUGINFO D0B4ES Atamestane + Toremifene Phase 3 T13260 DRUGINFO D08UGX LIAROZOLE Phase 2/3 T13260 DRUGINFO D02XMD BGS-649 Phase 2 T13260 DRUGINFO D0J8RR Dextromethorphan+quinidine Phase 2 T13260 DRUGINFO D0Y6OA Coumate Phase 2 T13260 DRUGINFO D02ABO NARINGENIN Phase 1 T13260 DRUGINFO D0B6PZ FORMESTANE Withdrawn from market T13260 DRUGINFO D04PSL FINROZOLE Discontinued in Phase 2 T13260 DRUGINFO D0D3PF VOROZOLE Discontinued in Phase 2 T13260 DRUGINFO D0U9LL NKS-01 Discontinued in Phase 2 T13260 DRUGINFO D0Y2OG YM-511 Discontinued in Phase 2 T13260 DRUGINFO D06JUR Rogletimide Terminated T13260 DRUGINFO D0FS9K MINAMESTANE Terminated T13260 DRUGINFO D00AVS MR-20814 Investigative T13260 DRUGINFO D00BVP 3-(imidazolylmethyl)-4'-methoxyflavone Investigative T13260 DRUGINFO D00GCK 3-Fluoren-9-ylidenemethyl-pyridine Investigative T13260 DRUGINFO D00VUO 3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D00ZPJ NSC-12999 Investigative T13260 DRUGINFO D01IJX 1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole Investigative T13260 DRUGINFO D01LOU 4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one Investigative T13260 DRUGINFO D01MPK 3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione Investigative T13260 DRUGINFO D01OQW ALBANOL A Investigative T13260 DRUGINFO D02BWQ 3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D02LTV MR-20494 Investigative T13260 DRUGINFO D02QSH NSC-368280 Investigative T13260 DRUGINFO D02SIT 1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole Investigative T13260 DRUGINFO D02XTS 3-(2,2-Diphenyl-vinyl)-pyridine Investigative T13260 DRUGINFO D03FBI 3,5-Diamino-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D04DZZ N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide Investigative T13260 DRUGINFO D04HVL 4-(3,4,5-Trimethoxyphenethyl)aniline Investigative T13260 DRUGINFO D04IJE 4-Fluoren-9-ylidenemethyl-pyridine Investigative T13260 DRUGINFO D04REX 5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine Investigative T13260 DRUGINFO D04TBB 11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B Investigative T13260 DRUGINFO D04VRY 3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone Investigative T13260 DRUGINFO D04WJN 3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one Investigative T13260 DRUGINFO D05HRP 3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione Investigative T13260 DRUGINFO D05PXK 4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone Investigative T13260 DRUGINFO D05YNW 4-Indan-(1E)-ylidenemethyl-pyridine Investigative T13260 DRUGINFO D05ZPO 7-hydroxy-2-phenylchroman-4-one Investigative T13260 DRUGINFO D06AZC NSC-131736 Investigative T13260 DRUGINFO D06GIV NSC-356483 Investigative T13260 DRUGINFO D06HJB LUDARTIN Investigative T13260 DRUGINFO D06WPP 4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone Investigative T13260 DRUGINFO D07FGX 2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one Investigative T13260 DRUGINFO D07JKK 3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one Investigative T13260 DRUGINFO D07PHT NSC-289311 Investigative T13260 DRUGINFO D07PHV 1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one Investigative T13260 DRUGINFO D07SOM 3-(imidazolylmethyl)flavone Investigative T13260 DRUGINFO D07TIJ 1-(9H-fluoren-9-yl)-1H-imidazole Investigative T13260 DRUGINFO D07TUX 7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one Investigative T13260 DRUGINFO D07UVN 3-Methoxyl-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D07ZCD 4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D07ZYL 4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D08AAP NSC-75308 Investigative T13260 DRUGINFO D08ARY NSC-368272 Investigative T13260 DRUGINFO D08EZA 3-(imidazolylmethyl)-4'-nitroflavone Investigative T13260 DRUGINFO D08FOJ 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one Investigative T13260 DRUGINFO D08IIW MR-16089 Investigative T13260 DRUGINFO D08KLN 3,4'-(Ethane-1,2-diyl)dibenzenamine Investigative T13260 DRUGINFO D08TKB 1-(2-phenoxybenzyl)-1H-imidazole Investigative T13260 DRUGINFO D08UQH 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone Investigative T13260 DRUGINFO D09HGK 4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D09MYQ NSC-93358 Investigative T13260 DRUGINFO D09OPA (2S)-euchrenone a7 Investigative T13260 DRUGINFO D09XKH (2S)-5,7,2',4'-tetrahydroxyflavanone Investigative T13260 DRUGINFO D09ZHX 4'-bromo-3-(imidazolylmethyl)flavone Investigative T13260 DRUGINFO D09ZIW Isogemichalcone C Investigative T13260 DRUGINFO D0A7PA 2,4-Dimethoxy-3'-amino-trans-stilbene Investigative T13260 DRUGINFO D0AH1B 3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0AM2Z 3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione Investigative T13260 DRUGINFO D0AW7Q 2-Imidazol-1-ylmethylxanthen-9-one Investigative T13260 DRUGINFO D0AY4E 3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0B8PE 2-(3-hydroxyphenyl)-7-methoxychroman-4-one Investigative T13260 DRUGINFO D0C3XU 10-EPI-8-DEOXY-CUMAMBRIN B Investigative T13260 DRUGINFO D0C5ZP N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide Investigative T13260 DRUGINFO D0C8EO 5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole Investigative T13260 DRUGINFO D0CR6B 4'-cyano-3-(imidazolylmethyl)flavone Investigative T13260 DRUGINFO D0D7GG 1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole Investigative T13260 DRUGINFO D0D8GU 4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0DJ3R 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one Investigative T13260 DRUGINFO D0DO1T MR-20492 Investigative T13260 DRUGINFO D0E2RV 3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione Investigative T13260 DRUGINFO D0E3IK N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide Investigative T13260 DRUGINFO D0E5FV ISOLICOFLAVONOL Investigative T13260 DRUGINFO D0F4MF 2,3-Dimethoxy-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0F4WQ 1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole Investigative T13260 DRUGINFO D0F5AC 4-Imidazol-1-ylmethylxanthen-9-one Investigative T13260 DRUGINFO D0F8IB MONODICTYOCHROMONE B Investigative T13260 DRUGINFO D0F9MQ N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide Investigative T13260 DRUGINFO D0G2JV 2,3,5-Trimethoxy-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0GL0L 1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole Investigative T13260 DRUGINFO D0H1LK 3-(4-Amino-phenyl)-pyrrolidine-2,5-dione Investigative T13260 DRUGINFO D0HC9U 4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one Investigative T13260 DRUGINFO D0HR9S NSC-683634 Investigative T13260 DRUGINFO D0I1SI 2,4-Dimethoxy-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0I2UE 4-Imidazol-1-ylmethylthioxanthen-9-one Investigative T13260 DRUGINFO D0I5PY 1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole Investigative T13260 DRUGINFO D0J2WW 4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0J3PK 4-Imidazol-1-yl-2-phenyl-chroman-7-ol Investigative T13260 DRUGINFO D0J4VR 3,5-Dihydroxyl-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0J8FS 3-Nitro-4'-nitro-trans-stilbene Investigative T13260 DRUGINFO D0K3CE 4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0K5GG 2,3,4-Trimethoxy-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0K5JU 4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one Investigative T13260 DRUGINFO D0L9BT 7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one Investigative T13260 DRUGINFO D0M0FE N-[2-(4'-Nitrophenyl)ethyl]-imidazole Investigative T13260 DRUGINFO D0M2IB MDL-18962 Investigative T13260 DRUGINFO D0M4CX NSC-613604 Investigative T13260 DRUGINFO D0M5EW 4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one Investigative T13260 DRUGINFO D0N7QV 4-(1-Imidazol-1-yl-vinyl)-benzonitrile Investigative T13260 DRUGINFO D0NB8V 3,4,5-Trimethoxy-3'-amino-trans-stilbene Investigative T13260 DRUGINFO D0NH6T (2S)-abyssinone II Investigative T13260 DRUGINFO D0O0BL 2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol Investigative T13260 DRUGINFO D0O1ZM 3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione Investigative T13260 DRUGINFO D0O6ZM 4-(3,4-Dimethoxyphenethyl)aniline Investigative T13260 DRUGINFO D0OY1J 7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one Investigative T13260 DRUGINFO D0P3ND 1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole Investigative T13260 DRUGINFO D0P5ZV NSC-94891 Investigative T13260 DRUGINFO D0PU5V 7-((1H-imidazol-1-yl)methyl)isoquinoline Investigative T13260 DRUGINFO D0Q6XB 3-Amino-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0QL1V Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine Investigative T13260 DRUGINFO D0R2YN NSC-122427 Investigative T13260 DRUGINFO D0R4WW MR-20496 Investigative T13260 DRUGINFO D0S0OV 1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole Investigative T13260 DRUGINFO D0S7VY 3,5-Diacetoxy-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0S8MJ NSC-356781 Investigative T13260 DRUGINFO D0SY6C 7,4'-Dihydroxyflavone Investigative T13260 DRUGINFO D0T0CK 3,4-Dimethoxy-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0T2IX 6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione Investigative T13260 DRUGINFO D0T3ED NSC-666292 Investigative T13260 DRUGINFO D0TM4K 3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0U6IT 5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole Investigative T13260 DRUGINFO D0U6NJ 4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one Investigative T13260 DRUGINFO D0U8JC MORACHALCONE A Investigative T13260 DRUGINFO D0U9QB DEHYDROLEUCODIN Investigative T13260 DRUGINFO D0UI8Q 5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one Investigative T13260 DRUGINFO D0V0DB 9-Hydroxy-7,8-benzoflavone Investigative T13260 DRUGINFO D0V1UY CGS-18320B Investigative T13260 DRUGINFO D0V3MV 1-(4-nitro-2-phenoxybenzyl)-1H-imidazole Investigative T13260 DRUGINFO D0V8SM 8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one Investigative T13260 DRUGINFO D0W3LG Broussoflavonol F Investigative T13260 DRUGINFO D0W3LM 2-(4-hydroxyphenyl)-7-methoxychroman-4-one Investigative T13260 DRUGINFO D0W4IB 2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one Investigative T13260 DRUGINFO D0W7GU 2,5-Dimethoxy-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0W9PF ANDROSTENEDONE Investigative T13260 DRUGINFO D0W9ZC 4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one Investigative T13260 DRUGINFO D0WK9Q 4-(3,5-Dimethoxyphenethyl)benzenamine Investigative T13260 DRUGINFO D0X8UK 5-(2-(1H-imidazol-1-yl)ethyl)quinoline Investigative T13260 DRUGINFO D0XS6T 1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone Investigative T13260 DRUGINFO D0Y0CT 3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0Y0EK 7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one Investigative T13260 DRUGINFO D0Y0QI 5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline Investigative T13260 DRUGINFO D0Y1EX Org-33201 Investigative T13260 DRUGINFO D0Y4TE NSC-369087 Investigative T13260 DRUGINFO D0Y7RB 3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0Y8XJ Docosapentaenoic acid Investigative T13260 DRUGINFO D0Y9HD NSC-625409 Investigative T13260 DRUGINFO D0Z1OI 3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione Investigative T13260 DRUGINFO D0Z4GR 4-(2,2-Diphenyl-vinyl)-pyridine Investigative T13260 DRUGINFO D00HVZ (+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one Investigative T13260 DRUGINFO D01SUE 3-Indan-(1E)-ylidenemethyl-pyridine Investigative T13260 DRUGINFO D01SZX 1-Imidazol-1-ylmethylxanthen-9-one Investigative T13260 DRUGINFO D02NAG 3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D02XHH 5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole Investigative T13260 DRUGINFO D03KLN 1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole Investigative T13260 DRUGINFO D03TRM 5-Indan-(1E)-ylidenemethyl-1H-imidazole Investigative T13260 DRUGINFO D04CLL 3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D04ELJ 3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D04IBH 3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine Investigative T13260 DRUGINFO D04QPK 3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D05FFY 1-(4-Cyanobenzyl)-5-methyl-1H-imidazole Investigative T13260 DRUGINFO D05IWY Gamma-mangostin Investigative T13260 DRUGINFO D05MQE 3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D05YJR GARCINONE D Investigative T13260 DRUGINFO D06FHE 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole Investigative T13260 DRUGINFO D07CTI 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one Investigative T13260 DRUGINFO D07IQG 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one Investigative T13260 DRUGINFO D07PYC 3-Indan-(1Z)-ylidenemethyl-pyridine Investigative T13260 DRUGINFO D08AZK 3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D08FAB 3-(naphthalen-2-yl)pyridine Investigative T13260 DRUGINFO D08HPU 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine Investigative T13260 DRUGINFO D08PKR 6-Imidazol-1-yl-isoquinoline Investigative T13260 DRUGINFO D08PNF 3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D08ZTZ 3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine Investigative T13260 DRUGINFO D09MQF 3,4,5-Trimethoxy-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D09QDY 5-Indan-(1Z)-ylidenemethyl-1H-imidazole Investigative T13260 DRUGINFO D09YXV 3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0A2FO (+/-)-7-methoxy-2-phenylchroman-4-one Investigative T13260 DRUGINFO D0A2GB 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione Investigative T13260 DRUGINFO D0B5MZ 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione Investigative T13260 DRUGINFO D0D0DR 1-(3-(4-fluorophenyl)propyl)-1H-imidazole Investigative T13260 DRUGINFO D0E9WX 5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole Investigative T13260 DRUGINFO D0G6QL 1-Naphthalen-2-yl-1H-imidazole Investigative T13260 DRUGINFO D0G9WP 5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one Investigative T13260 DRUGINFO D0I5NW 3-(3,4-dihydronaphthalen-2-yl)pyridine Investigative T13260 DRUGINFO D0I7GE ALPHA-NAPHTHOFLAVONE Investigative T13260 DRUGINFO D0K2DR 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one Investigative T13260 DRUGINFO D0K4PY LIQUIRTIGENIN Investigative T13260 DRUGINFO D0L1JF 3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0M7FS 3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0N9PY 3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0Q3JZ 3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0Q8UZ 3,5-Dimethoxy-4'-amino-trans-stilbene Investigative T13260 DRUGINFO D0U7RR 3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0V3YH 3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0V8CR 3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0X1QS 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine Investigative T13260 DRUGINFO D0YS2F 3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0Z7EL GOSSYPETIN Investigative T13260 DRUGINFO D01KKU NSC-94258 Investigative T13260 DRUGINFO D01REI 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol Investigative T13260 DRUGINFO D02CSU 4-Indan-(1Z)-ylidenemethyl-pyridine Investigative T13260 DRUGINFO D03EXD 4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine Investigative T13260 DRUGINFO D03MKT 4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D06HFV 5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine Investigative T13260 DRUGINFO D09HEA 4-((1H-imidazol-1-yl)methyl)benzonitrile Investigative T13260 DRUGINFO D09HOE 4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0D9FR 4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0F5YU 4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0I1YH 4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine Investigative T13260 DRUGINFO D0K5KG 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine Investigative T13260 DRUGINFO D0MA9G 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine Investigative T13260 DRUGINFO D0N1PQ 3-(6-methoxynaphthalen-2-yl)pyridine Investigative T13260 DRUGINFO D0NX0M 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine Investigative T13260 DRUGINFO D0Q0BK 3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol Investigative T13260 DRUGINFO D0R0TE 3-(6-Ethoxy-naphthalen-2-yl)-pyridine Investigative T13260 DRUGINFO D0WN9P 4'-(Pyridin-4-ylmethyl)biphenyl-3-amine Investigative T13260 DRUGINFO D0YD9J 4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine Investigative T13260 DRUGINFO D0M8RO 4-ANDROSTENE-3-17-DIONE Investigative T13260 DRUGINFO D01UYI Chrysin Investigative T13260 DRUGINFO D0S9YX biochanin A Investigative T13260 DRUGINFO D0S0RK flavone Investigative T13260 DRUGINFO D00RIX APIGENIN Investigative T85799 TARGETID T85799 T85799 FORMERID TTDC00165 T85799 UNIPROID CDK4_HUMAN T85799 TARGNAME Cyclin-dependent kinase 4 (CDK4) T85799 GENENAME CDK4 T85799 TARGTYPE Successful T85799 SYNONYMS PSK-J3; Cell division protein kinase 4 T85799 FUNCTION Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. T85799 PDBSTRUC 5FWP; 5FWM; 5FWL; 5FWK; 3G33 T85799 BIOCLASS Kinase T85799 ECNUMBER EC 2.7.11.22 T85799 SEQUENCE MATSRYEPVAEIGVGAYGTVYKARDPHSGHFVALKSVRVPNGGGGGGGLPISTVREVALLRRLEAFEHPNVVRLMDVCATSRTDREIKVTLVFEHVDQDLRTYLDKAPPPGLPAETIKDLMRQFLRGLDFLHANCIVHRDLKPENILVTSGGTVKLADFGLARIYSYQMALTPVVVTLWYRAPEVLLQSTYATPVDMWSVGCIFAEMFRRKPLFCGNSEADQLGKIFDLIGLPPEDDWPRDVSLPRGAFPPRGPRPVQSVVPEMEESGAQLLLEMLTFNPHKRISAFRALQHSYLHKDEGNPE T85799 DRUGINFO D00UZR Palbociclib Approved T85799 DRUGINFO D01HVT Ribociclib Succinate Approved T85799 DRUGINFO D05SBO LY2835219 Approved T85799 DRUGINFO D0AP9E Trilaciclib Approved T85799 DRUGINFO D07ESC Apremilast Approved T85799 DRUGINFO D08MXP LEE011 Phase 3 T85799 DRUGINFO D0W8IY P-276 Phase 2 T85799 DRUGINFO D0WU1O G1T38 Phase 2 T85799 DRUGINFO D01UMT Ro 31-7453 Phase 2 T85799 DRUGINFO D05IRT P276-00 Phase 2 T85799 DRUGINFO D4IS0G GLR2007 Phase 1/2 T85799 DRUGINFO D8ZV2Q FCN-437 Phase 1/2 T85799 DRUGINFO D70HZT NUV-422 Phase 1/2 T85799 DRUGINFO D0DX4J P1446A-05 Phase 1 T85799 DRUGINFO DZJ3D5 PF-07220060 Phase 1 T85799 DRUGINFO D01XZG G1T28-1 Phase 1 T85799 DRUGINFO D0IX4B AG-024322 Phase 1 T85799 DRUGINFO D0P1CV PHA-793887 Phase 1 T85799 DRUGINFO DYH94Z RGT-419B Phase 1 T85799 DRUGINFO DKCU40 FN-1501 Phase 1 T85799 DRUGINFO D03DKV RGB-286638 Phase 1 T85799 DRUGINFO D0WT7D Imidazo pyridine derivative 3 Patented T85799 DRUGINFO D03HED Palbociclib/ribociclib analog 1 Patented T85799 DRUGINFO D04AKA Pyrrolo[2,3-d]pyrimidine derivative 10 Patented T85799 DRUGINFO D0FQ6V PMID26161698-Compound-17 Patented T85799 DRUGINFO D08KKC Pyrrolo[2,3-d]pyrimidine derivative 9 Patented T85799 DRUGINFO D07TVO PMID25726713-Compound-49 Patented T85799 DRUGINFO D0KH7Q PMID25726713-Compound-51 Patented T85799 DRUGINFO D0LX6X Indole-based analog 13 Patented T85799 DRUGINFO D0W4MN Isoquinoline 1,3-dione derivative 1 Patented T85799 DRUGINFO D0WJ3W PMID25726713-Compound-48 Patented T85799 DRUGINFO D0X5VI PMID25726713-Compound-47 Patented T85799 DRUGINFO D0Y8JF PMID25726713-Compound-50 Patented T85799 DRUGINFO D0H4HD PMID25991433-Compound-A1 Patented T85799 DRUGINFO D0M5DX Oxazolyl methylthiothiazole derivative 1 Patented T85799 DRUGINFO D0NV9O BAY 10-00394 Discontinued in Phase 2 T85799 DRUGINFO D04FHB R547 Discontinued in Phase 1 T85799 DRUGINFO D00VBT ZK 304709 Discontinued in Phase 1 T85799 DRUGINFO D07ZJC INOC-005 Preclinical T85799 DRUGINFO D0Y6HA CYC-103 Terminated T85799 DRUGINFO D0Z0KD PD-0183812 Terminated T85799 DRUGINFO D03VDM N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide Investigative T85799 DRUGINFO D0G4JS 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea Investigative T85799 DRUGINFO D0M8CO 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea Investigative T85799 DRUGINFO D0T2VG 1-Pyridin-2-yl-3-quinolin-5-yl-urea Investigative T85799 DRUGINFO D0X1NW 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea Investigative T85799 DRUGINFO D07HPE Cdk4 inhibitor III Investigative T85799 DRUGINFO D09OAH Fascaplysin Investigative T85799 DRUGINFO D09RYV Ro-0505124 Investigative T85799 DRUGINFO D0VD8B NSC-625987 Investigative T85799 DRUGINFO D0W6CE 10-hydroxy-18-methoxybetaenone Investigative T85799 DRUGINFO D02DLC PYRAZOLOPYRIDAZINE 1 Investigative T85799 DRUGINFO D0D5HQ K00024 Investigative T85799 DRUGINFO D0O0VP PYRAZOLOPYRIDAZINE 2 Investigative T85799 DRUGINFO D0P6JS PMID18986805C9b Investigative T85799 DRUGINFO D0Y5RO NU-6102 Investigative T85799 DRUGINFO D04WFN NU6140 Investigative T85799 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T85799 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T85799 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T85799 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T85799 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T60366 TARGETID T60366 T60366 FORMERID TTDS00313 T60366 UNIPROID DCOR_HUMAN T60366 TARGNAME Ornithine decarboxylase (ODC1) T60366 GENENAME ODC1 T60366 TARGTYPE Successful T60366 SYNONYMS ODC T60366 FUNCTION Polyamines are essential for cell proliferation and are implicated in cellular processes, ranging from DNA replication to apoptosis. Catalyzes the first and rate-limiting step of polyamine biosynthesis that converts ornithine into putrescine, which is the precursor for the polyamines, spermidine and spermine. T60366 PDBSTRUC 5BWA; 4ZGY; 2OO0; 2ON3; 1D7K T60366 BIOCLASS Carbon-carbon lyase T60366 ECNUMBER EC 4.1.1.17 T60366 SEQUENCE MNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYANPCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKFGATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPDEKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQRPTIYYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV T60366 DRUGINFO D0X7JR Eflornithine Approved T60366 DRUGINFO D00FMV Putrescine Discontinued in Phase 2 T60366 DRUGINFO D01IGU APA Investigative T60366 DRUGINFO D01OHD AMXT-1501 Investigative T60366 DRUGINFO D02XYV (2R,5R)-delta-methyl-alpha-acetylenic putrescine Investigative T60366 DRUGINFO D04FIN ZAPOTIN Investigative T60366 DRUGINFO D04ZDD LONCHOCARPUSONE Investigative T60366 DRUGINFO D08CKE Alpha-monofluoromethyl-3,4-dehydroornithine methyl ester Investigative T60366 DRUGINFO D08TLJ Alpha-monofluoromethyl-3,4-dehydroornithine Investigative T60366 DRUGINFO D09AHL N-Pyridoxyl-Glycine-5-Monophosphate Investigative T60366 DRUGINFO D0F3QP 4-hydroxylonchocarpin Investigative T60366 DRUGINFO D0H2OA Alpha-monofluoromethyl-3,4-dehydroornithine ethyl ester Investigative T60366 DRUGINFO D0K6WI 3-(Aminooxy)propan-1-amine hydrochloride Investigative T60366 DRUGINFO D0N4YR 3-methoxy-4-hydroxylonchocarpin Investigative T60366 DRUGINFO D0XR2J 1-Amino-3-(aminoxy)-2-propanol Dihydrochloride Investigative T60366 DRUGINFO D03LMM G418 Investigative T60366 DRUGINFO D0B8JD Pyridoxine-5'-Phosphate Investigative T60366 DRUGINFO D0I5PZ N'-Pyridoxyl-Lysine-5'-Monophosphate Investigative T52227 TARGETID T52227 T52227 FORMERID TTDS00301 T52227 UNIPROID TYSY_CANAL T52227 TARGNAME Candida Thymidylate synthase (Candi TMP1) T52227 GENENAME Candi TMP1 T52227 TARGTYPE Successful T52227 SYNONYMS Tsase of Candida albicans; TS of Candida albicans; TMP1; Human recombinant thymidylate synthase; HrTS T52227 FUNCTION Contributes to thede novo mitochondrial thymidylate biosynthesis pathway. T52227 BIOCLASS Methyltransferase T52227 ECNUMBER EC 2.1.1.45 T52227 SEQUENCE MTVSPNTAEQAYLDLCKRIIDEGEHRPDRTGTGTKSLFAPPQLRFDLSNDTFPLLTTKKVFSKGIIHELLWFVAGSTDAKILSEKGVKIWEGNGSREFLDKLGLTHRREGDLGPVYGFQWRHFGAEYKDCDSDYTGQGFDQLQDVIKKLKTNPYDRRIIMSAWNPPDFAKMALPPCHVFCQFYVNFPTSSPDPNNPKQAKTAKPKLSCLLYQRSCDMGLGVPFNIASYALLTKMIAHVVDMDCGEFIHTLGDAHVYLDHIDALKEQFERIPKQFPKLVIKEERKNEIKSIDDFKFEDFEIVGYEPYPPIKMKMSV T52227 DRUGINFO D00HCQ Capecitabine Approved T52227 DRUGINFO D01KKQ Raltitrexed Approved T52227 DRUGINFO D05RHI Trifluridine Approved T52227 DRUGINFO D0M3MN Leucovorin/5-fluorouracil Approved T52227 DRUGINFO D0S5WG Flucytosine Approved T52227 DRUGINFO D0TS1Z Floxuridine Approved T52227 DRUGINFO D0Y4GO Pemetrexed Approved T52227 DRUGINFO D05LEO Fluorouracil Approved T52227 DRUGINFO D0O1WX Ciprofloxacin XR Approved T52227 DRUGINFO D06WQT Nolatrexed Phase 3 T52227 DRUGINFO D0I9GR Plevitrexed Phase 2 T52227 DRUGINFO D0Q0UA UFT/leucovorin calcium Phase 2 T52227 DRUGINFO D04FYZ Plevitrexed (R)-isomer Phase 2 T52227 DRUGINFO D05CQS NB1011 Phase 1/2 T52227 DRUGINFO D0S9MD DFP-11207 Phase 1 T52227 DRUGINFO D0U2CT EMITEFUR Discontinued in Preregistration T52227 DRUGINFO D0Y4AZ Galocitabine Discontinued in Phase 3 T52227 DRUGINFO D0B6GJ TT-62 Discontinued in Phase 2 T52227 DRUGINFO D0E8JO FO-152 Discontinued in Phase 2 T52227 DRUGINFO D0C4YA AG-331 Discontinued in Phase 1 T52227 DRUGINFO D03BTP Fosfluridine tidoxil Terminated T52227 DRUGINFO D0L0AU DMPDDF Terminated T52227 DRUGINFO D00BNE (6s)-5,6,7,8-Tetrahydrofolate Investigative T52227 DRUGINFO D01FCH Sp-722 Investigative T52227 DRUGINFO D01OVV OVI-117 Investigative T52227 DRUGINFO D02MUO 4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN Investigative T52227 DRUGINFO D04IRR Ly231514 Tetra Glu Investigative T52227 DRUGINFO D05HOO 2-bromophenol Investigative T52227 DRUGINFO D06FMH 2'-Deoxycytidine-5'-Monophosphate Investigative T52227 DRUGINFO D07LML Tosyl-D-Proline Investigative T52227 DRUGINFO D08STR 2'-5'dideoxyuridine Investigative T52227 DRUGINFO D09QPT 3-Methyl-2H-benzo[f]quinazolin-1-one Investigative T52227 DRUGINFO D0A6BH 5,10-Methylene-6-Hydrofolic Acid Investigative T52227 DRUGINFO D0F1LA N,O-Didansyl-L-Tyrosine Investigative T52227 DRUGINFO D0F2VL 3-Amino-5,6-dihydro-2H-benzo[f]quinazolin-1-one Investigative T52227 DRUGINFO D0G6CU 1,3-propanediphosphonic acid Investigative T52227 DRUGINFO D0G9XX 2'-Deoxyguanosine-5'-Monophosphate Investigative T52227 DRUGINFO D0I0OH 5-Fluoro-2'-Deoxyuridine-5'-Monophosphate Investigative T52227 DRUGINFO D0JY6J 6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE Investigative T52227 DRUGINFO D0K7CR Sp-876 Investigative T52227 DRUGINFO D0U0VO N-[Tosyl-D-Prolinyl]Amino-Ethanethiol Investigative T52227 DRUGINFO D0UL7N 3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE Investigative T52227 DRUGINFO D0VZ0I ZD1604 Investigative T52227 DRUGINFO D0X9QV LY341770 Investigative T52227 DRUGINFO D0YX9D N-Carboxymethionine Investigative T52227 DRUGINFO D00CVB 2'-Deoxyuridine Investigative T52227 DRUGINFO D0CZ3C 2'-deoxyuridylic acid Investigative T52227 DRUGINFO D0H9DJ Uridine-5'-Monophosphate Investigative T52227 DRUGINFO D0PG5D 10-Propargyl-5,8-Dideazafolic Acid Investigative T52227 DRUGINFO D0XV3B Methionine Sulfoxide Investigative T52227 DRUGINFO D01GMJ 1,4-Dithiothreitol Investigative T52227 DRUGINFO D0UZ9U PREMETREXED Investigative T52227 DRUGINFO D0ZH0I Thymidine-5'-Phosphate Investigative T52227 DRUGINFO D0P7JE S,S-(2-Hydroxyethyl)Thiocysteine Investigative T52227 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T82577 TARGETID T82577 T82577 FORMERID TTDS00181 T82577 UNIPROID ACE_HUMAN T82577 TARGNAME Angiotensin-converting enzyme (ACE) T82577 GENENAME SLC33A1 T82577 TARGTYPE Successful T82577 SYNONYMS Kininase II; Dipeptidyl carboxypeptidase I; DCP1; DCP; CD143 antigen; CD143; ACE T82577 FUNCTION Able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. T82577 PDBSTRUC 6QS1; 6H5X; 6H5W; 6F9V; 6F9U T82577 BIOCLASS Glycosylase T82577 ECNUMBER EC 3.2.1.- T82577 SEQUENCE MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFAQSYNSSAEQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRIIGAVRTLGSANLPLAKRQQYNALLSNMSRIYSTAKVCLPNKTATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWNATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQFHEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLLKYFQPVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDRTSQVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTTIKRIIKKVQDLERAALPAQELEEYNKILLDMETTYSVATVCHPNGSCLQLEPDLTNVMATSRKYEDLLWAWEGWRDKAGRAILQFYPKYVELINQAARLNGYVDAGDSWRSMYETPSLEQDLERLFQELQPLYLNLHAYVRRALHRHYGAQHINLEGPIPAHLLGNMWAQTWSNIYDLVVPFPSAPSMDTTEAMLKQGWTPRRMFKEADDFFTSLGLLPVPPEFWNKSMLEKPTDGREVVCHASAWDFYNGKDFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVALREGANPGFHEAIGDVLALSVSTPKHLHSLNLLSSEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGSITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPSSVPYIRYFVSFIIQFQFHEALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSYFKPLLDWLRTENELHGEKLGWPQYNWTPNSARSEGPLPDSGRVSFLGLDLDAQQARVGQWLLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHGPQFGSEVELRHS T82577 DRUGINFO D00HDU Moexipril Approved T82577 DRUGINFO D00SEB Enalapril Approved T82577 DRUGINFO D01STB Ramipril Approved T82577 DRUGINFO D02DSZ Temocapril hydrochloride Approved T82577 DRUGINFO D03KYG Perindopril Approved T82577 DRUGINFO D04GKO Cilazapril Approved T82577 DRUGINFO D05MFG Spirapril Approved T82577 DRUGINFO D07HGR Lisinopril Approved T82577 DRUGINFO D09HDR Deserpidine Approved T82577 DRUGINFO D0G8NJ Rescinnamine Approved T82577 DRUGINFO D0G8QW Delapril Approved T82577 DRUGINFO D0I0EG Captopril Approved T82577 DRUGINFO D0I7SZ Quinapril Approved T82577 DRUGINFO D0M5OC Trandolapril Approved T82577 DRUGINFO D0N5HJ Enalaprilat Approved T82577 DRUGINFO D0S0ES Imidapril Approved T82577 DRUGINFO D0U3EC Benazepril Approved T82577 DRUGINFO D0U4UQ Hydrochlorothiazide Approved T82577 DRUGINFO D0X5SJ Alacepril Approved T82577 DRUGINFO D0X8KY Fosinopril Approved T82577 DRUGINFO D04PBH CONTIGOSIDE B Phase 2/3 T82577 DRUGINFO D00ERV Gallopamil Phase 2 T82577 DRUGINFO D0C1AY GW-796406 Phase 1 T82577 DRUGINFO D0K6SM Ilepatril Discontinued in Phase 2/3 T82577 DRUGINFO D00FHI Zabiciprilat Discontinued in Phase 2 T82577 DRUGINFO D02JUM METIAPRIL Discontinued in Phase 2 T82577 DRUGINFO D03DRW UTIBAPRIL Discontinued in Phase 2 T82577 DRUGINFO D05NRI Ceronapril Discontinued in Phase 2 T82577 DRUGINFO D08DWH Idrapril Discontinued in Phase 2 T82577 DRUGINFO D0N5HN M-100240 Discontinued in Phase 2 T82577 DRUGINFO D05COG DU-1777 Terminated T82577 DRUGINFO D04MBS BMS-182657 Terminated T82577 DRUGINFO D05UQD Omapatrilat Terminated T82577 DRUGINFO D0F9BX GW-660511 Terminated T82577 DRUGINFO D0I5QZ SQ-26332 Terminated T82577 DRUGINFO D0KR3X CGS-30440 Terminated T82577 DRUGINFO D0K9YR SCH-54470 Terminated T82577 DRUGINFO D02FMN RXP-407 Investigative T82577 DRUGINFO D07BNP BRL-36378 Investigative T82577 DRUGINFO D0A1RG RIP Investigative T82577 DRUGINFO D0B8WQ lisinopril-tryptophan Investigative T82577 DRUGINFO D0HC9P Kaempferol-3-O-(2''-O-galloyl)-glucoside Investigative T82577 DRUGINFO D0K8ED N-Carboxymethyl-N-cyclopentyl-phthalamic acid Investigative T82577 DRUGINFO D0OZ3S RJM-0035-K002 Investigative T82577 DRUGINFO D0R6KV moexiprilat Investigative T82577 DRUGINFO D0U7TM [Cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid Investigative T82577 DRUGINFO D04DHD fasidotrilat Investigative T82577 DRUGINFO D08BFU ASTRAGALIN Investigative T82577 DRUGINFO D09GXF RB-105 Investigative T82577 DRUGINFO D0EW3L BUTEIN Investigative T82577 DRUGINFO D06IEN 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose Investigative T82577 DRUGINFO D07APP LY-292223 Investigative T82577 DRUGINFO D0F2ME Acetate Ion Investigative T97587 TARGETID T97587 T97587 FORMERID TTDS00445 T97587 UNIPROID ITA4_HUMAN T97587 TARGNAME Integrin alpha-4 (ITGA4) T97587 GENENAME ITGA4 T97587 TARGTYPE Successful T97587 SYNONYMS Very late antigen 4; VLA4 subunit alpha; VLA-4 subunit alpha; VLA-4; Integrin alphaIV; Integrin alpha4; Integrin alpha-IV; CD49d; CD49 antigenlike family member D; CD49 antigen-like family member D T97587 FUNCTION Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGA4:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. T97587 PDBSTRUC 5FPI; 5C7Z; 4HKC; 3V4V; 3V4P T97587 BIOCLASS Integrin T97587 SEQUENCE MAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD T97587 DRUGINFO D09EBL Antegren Approved T97587 DRUGINFO D3LWJ7 Natalizumab Approved T97587 DRUGINFO D0N5ZS Vedolizmab Approved T97587 DRUGINFO DWKI46 PB006 Phase 3 T97587 DRUGINFO D0Q5LF BIO-1211 Phase 2 T97587 DRUGINFO D04WQJ AMG-181 Phase 2 T97587 DRUGINFO D05ZWG Senktide Phase 2 T97587 DRUGINFO D0C9XA GSK683699 Phase 2 T97587 DRUGINFO D01CYT ELND-002 Phase 1 T97587 DRUGINFO D05JPJ ELND-004 Phase 1 T97587 DRUGINFO D0FU1J PTG-100 Phase 1 T97587 DRUGINFO D00GWR CT301 Investigative T97587 DRUGINFO D05SHQ ASP-2002 Investigative T84621 TARGETID T84621 T84621 FORMERID TTDS00420 T84621 UNIPROID C11B1_HUMAN T84621 TARGNAME Steroid 11-beta-hydroxylase (CYP11B1) T84621 GENENAME CYP11B1 T84621 TARGTYPE Successful T84621 SYNONYMS S11BH; P450C11; P-450c11; CYPXIB1; CYP11B1 T84621 FUNCTION Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB. T84621 PDBSTRUC 6M7X T84621 BIOCLASS Paired donor oxygen oxidoreductase T84621 ECNUMBER EC 1.14.15.4 T84621 SEQUENCE MALRAKAEVCMAVPWLSLQRAQALGTRAARVPRTVLPFEAMPRRPGNRWLRLLQIWREQGYEDLHLEVHQTFQELGPIFRYDLGGAGMVCVMLPEDVEKLQQVDSLHPHRMSLEPWVAYRQHRGHKCGVFLLNGPEWRFNRLRLNPEVLSPNAVQRFLPMVDAVARDFSQALKKKVLQNARGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFMPRSLSRWTSPKVWKEHFEAWDCIFQYGDNCIQKIYQELAFSRPQQYTSIVAELLLNAELSPDAIKANSMELTAGSVDTTVFPLLMTLFELARNPNVQQALRQESLAAAASISEHPQKATTELPLLRAALKETLRLYPVGLFLERVASSDLVLQNYHIPAGTLVRVFLYSLGRNPALFPRPERYNPQRWLDIRGSGRNFYHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHLQVETLTQEDIKMVYSFILRPSMFPLLTFRAIN T84621 DRUGINFO D03AJU Osilodrostat Approved T84621 DRUGINFO D0Q9JT Metyrapone Approved T84621 DRUGINFO D0ZX1P FADROZOLE Approved T84621 DRUGINFO D00DUJ 3-Phenanthren-9-yl-pyridine Investigative T84621 DRUGINFO D00PXF 1-(4-Cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole Investigative T84621 DRUGINFO D00RRV 3-Imidazol-1-ylmethyl-1H-indole Investigative T84621 DRUGINFO D01CGR 3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole Investigative T84621 DRUGINFO D02FRA 3-(2-Chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine Investigative T84621 DRUGINFO D02JUJ 5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol Investigative T84621 DRUGINFO D02LWB 3-(1H-inden-2-yl)pyridine Investigative T84621 DRUGINFO D02PSL 1-(4-Cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole Investigative T84621 DRUGINFO D02UZI 3-[(Z)-2-phenylvinyl]pyridine Investigative T84621 DRUGINFO D02ZQM 6-Pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol Investigative T84621 DRUGINFO D03CWL Methyl 3-(1-Benzyl-1H-imidazol-5-yl)-propanoate Investigative T84621 DRUGINFO D03YHZ 6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one Investigative T84621 DRUGINFO D04MEE 2-Methyl-1,2-di-pyridin-3-yl-propyliodide Investigative T84621 DRUGINFO D04PKP 3-(1,2-dihydroacenaphthylen-5-yl)pyridine Investigative T84621 DRUGINFO D04QWX 2-Methyl-1,2-di-pyridin-3-yl-propylchloride Investigative T84621 DRUGINFO D05IXU 3-(3-Benzylnaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D05VAN 1-Ethyl-3-imidazol-1-ylmethyl-1H-indole Investigative T84621 DRUGINFO D06NFC 1-(4-Fluorobenzyl)-5-phenyl-1H-imidazole Investigative T84621 DRUGINFO D06RSD 1-(4-Cyanobenzyl)-5-(4-pyridyl)-1H-imidazole Investigative T84621 DRUGINFO D07DQJ 1-(4-Bromobenzyl)-5-phenyl-1H-imidazole Investigative T84621 DRUGINFO D07EJK 1-(4-Cyanobenzyl)-5-formyl-1H-imidazole Investigative T84621 DRUGINFO D07JCO 3-Imidazol-1-yl-quinoline Investigative T84621 DRUGINFO D07JMO 1-(3-Bromobenzyl)-1H-imidazole Investigative T84621 DRUGINFO D07NAH 5-Naphthalen-2-yl-1H-imidazole Investigative T84621 DRUGINFO D07SAF 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol Investigative T84621 DRUGINFO D08HHA 1-(3-Fluorobenzyl)-1H-imidazole Investigative T84621 DRUGINFO D08ORG 1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole Investigative T84621 DRUGINFO D08UWI 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-one Investigative T84621 DRUGINFO D08WHC (3-((1H-imidazol-1-yl)methyl)phenyl)methanol Investigative T84621 DRUGINFO D08YGW 1-Benzyl-5-phenyl-1H-imidazole Investigative T84621 DRUGINFO D0AK9S 3-[1-(4-Bromobenzyl)-1H-imidazol-5-yl]-1-propanol Investigative T84621 DRUGINFO D0B2UM 3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine Investigative T84621 DRUGINFO D0C6US 4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D0C7YL 3-((1H-imidazol-1-yl)methyl)aniline Investigative T84621 DRUGINFO D0D7YL 3-(1,2-dihydroacenaphthylen-3-yl)pyridine Investigative T84621 DRUGINFO D0D8KN 3-(1-Benzyl-1H-imidazol-5-yl)-1-propanol Investigative T84621 DRUGINFO D0D8YE 3-(5-methoxy-1H-inden-2-yl)pyridine Investigative T84621 DRUGINFO D0G3RD 2-Methyl-1,2-di-pyridin-3-yl-propane Investigative T84621 DRUGINFO D0HL9S 1-(4-Aminobenzyl)-1H-imidazole Investigative T84621 DRUGINFO D0HV5D 2-Methyl-1,2-di-pyridin-3-yl-propan-1-one oxime Investigative T84621 DRUGINFO D0I0NP SL125 Investigative T84621 DRUGINFO D0I2UH 1-(4-Cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole Investigative T84621 DRUGINFO D0I9PA 3-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine Investigative T84621 DRUGINFO D0JE1I R-fadrozole Investigative T84621 DRUGINFO D0L2QD 1-(4-Cyanobenzyl)-5-bromo-1H-imidazole Investigative T84621 DRUGINFO D0L4NG 3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D0L8KL 5-Naphthalen-2-yl-oxazole Investigative T84621 DRUGINFO D0M9VK 1-(6-Methoxy-naphthalen-2-yl)-1H-imidazole Investigative T84621 DRUGINFO D0N4VI 1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole Investigative T84621 DRUGINFO D0N8QD (4-((1H-imidazol-1-yl)methyl)phenyl)methanol Investigative T84621 DRUGINFO D0NV7W 1-(4-Cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole Investigative T84621 DRUGINFO D0O7TC 7-Pyridin-3-yl-2H-1,4-benzothiazin-3(4H)-one Investigative T84621 DRUGINFO D0P1UO 1-(4-Cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole Investigative T84621 DRUGINFO D0P9JF 2-Methyl-1,2-di-pyridin-3-yl-1-methoxypropane Investigative T84621 DRUGINFO D0PH1G 3-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]-1-propanol Investigative T84621 DRUGINFO D0Q3CX 6-(4-Methylpyridin-3-yl)-2-naphthonitrile Investigative T84621 DRUGINFO D0Q5ZZ 3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D0Q6BJ 3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine Investigative T84621 DRUGINFO D0Q8KM 1-(4-Cyanobenzyl)-5-phenyl-1H-imidazole Investigative T84621 DRUGINFO D0R8NE 1-(2-Phenoxy-ethyl)-1H-imidazole Investigative T84621 DRUGINFO D0RJ6S 3-(6-Bromo-naphthalen-2-yl)-pyridine Investigative T84621 DRUGINFO D0S4KP 4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline Investigative T84621 DRUGINFO D0S4WQ 1-(3-Chlorobenzyl)-1H-imidazole Investigative T84621 DRUGINFO D0S8FV 3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D0T8JU 1-(4-Methoxybenzyl)-5-phenyl-1H-imidazole Investigative T84621 DRUGINFO D0V6QN 1-(4-Cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole Investigative T84621 DRUGINFO D0V9JS 3-(1,1-Dimethyl-2-phenyl-ethyl)-pyridine Investigative T84621 DRUGINFO D0VL3R 3-(5,6,7,8-Tetrahydronaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D0W8IZ 1-(4-Chlorobenzyl)-5-phenyl-1H-imidazole Investigative T84621 DRUGINFO D0WW4F METYRAPOL Investigative T84621 DRUGINFO D0X0IH BENZYLIMIDAZOLE Investigative T84621 DRUGINFO D0X4LQ 3-MeSO2-DDE Investigative T84621 DRUGINFO D0Y1YZ 4-(2-Imidazol-1-yl-ethoxy)-benzamide Investigative T84621 DRUGINFO D0Y2AK 1-Phenyl-2-pyridin-3-yl-propan-1-one Investigative T84621 DRUGINFO D0Y3AV 3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D00DSE 4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine Investigative T84621 DRUGINFO D01SUE 3-Indan-(1E)-ylidenemethyl-pyridine Investigative T84621 DRUGINFO D02ALK 6-Pyridin-3-yl-naphthalen-2-ol Investigative T84621 DRUGINFO D02BXS 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine Investigative T84621 DRUGINFO D02GFK 3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine Investigative T84621 DRUGINFO D02NAG 3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D02XHH 5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole Investigative T84621 DRUGINFO D03KLN 1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole Investigative T84621 DRUGINFO D03TRM 5-Indan-(1E)-ylidenemethyl-1H-imidazole Investigative T84621 DRUGINFO D03VRC 1-(4-Bromobenzyl)-1H-imidazole Investigative T84621 DRUGINFO D04CFP 5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole Investigative T84621 DRUGINFO D04CLL 3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D04ELJ 3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D04IBH 3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine Investigative T84621 DRUGINFO D04ISG 3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine Investigative T84621 DRUGINFO D04QPK 3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D05FFY 1-(4-Cyanobenzyl)-5-methyl-1H-imidazole Investigative T84621 DRUGINFO D05MQE 3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D05QPR 1-(4-fluorobenzyl)-1H-imidazole Investigative T84621 DRUGINFO D06CWR 4-(6-Methoxynaphthalen-2-yl)isoquinoline Investigative T84621 DRUGINFO D06JYY 3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine Investigative T84621 DRUGINFO D07PYC 3-Indan-(1Z)-ylidenemethyl-pyridine Investigative T84621 DRUGINFO D07VGT 6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol Investigative T84621 DRUGINFO D07WLT 6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one Investigative T84621 DRUGINFO D08AZK 3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D08FAB 3-(naphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D08HPU 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D08IDC 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D08PNF 3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D08ZTZ 3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine Investigative T84621 DRUGINFO D09CPC 6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one Investigative T84621 DRUGINFO D09GJI 7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol Investigative T84621 DRUGINFO D09QDY 5-Indan-(1Z)-ylidenemethyl-1H-imidazole Investigative T84621 DRUGINFO D09VPA 4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D09VQZ 4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine Investigative T84621 DRUGINFO D09YXV 3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0E0ZS N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide Investigative T84621 DRUGINFO D0E8DX 6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione Investigative T84621 DRUGINFO D0E9WX 5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole Investigative T84621 DRUGINFO D0G6QL 1-Naphthalen-2-yl-1H-imidazole Investigative T84621 DRUGINFO D0G9WP 5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one Investigative T84621 DRUGINFO D0I5NW 3-(3,4-dihydronaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D0K2DR 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one Investigative T84621 DRUGINFO D0LJ9D 4-(4-(thiophen-2-yl)benzyl)pyridine Investigative T84621 DRUGINFO D0M7FS 3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0N1GH 6-(pyridin-3-yl)-2-naphthonitrile Investigative T84621 DRUGINFO D0N9PY 3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0Q3JZ 3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0U7RR 3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0V3YH 3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0V8CR 3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0X1QS 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D0Y5KX 4'-(Pyridin-4-ylmethyl)biphenyl-4-amine Investigative T84621 DRUGINFO D0YS2F 3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0Z3GX 4-(4-(thiophen-3-yl)benzyl)pyridine Investigative T84621 DRUGINFO D01REI 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol Investigative T84621 DRUGINFO D02CSU 4-Indan-(1Z)-ylidenemethyl-pyridine Investigative T84621 DRUGINFO D03EXD 4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine Investigative T84621 DRUGINFO D03MKT 4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D06HFV 5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine Investigative T84621 DRUGINFO D09HEA 4-((1H-imidazol-1-yl)methyl)benzonitrile Investigative T84621 DRUGINFO D09HOE 4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0D9FR 4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0F5YU 4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine Investigative T84621 DRUGINFO D0I1YH 4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine Investigative T84621 DRUGINFO D0K5KG 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine Investigative T84621 DRUGINFO D0MA9G 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine Investigative T84621 DRUGINFO D0N1PQ 3-(6-methoxynaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D0NX0M 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine Investigative T84621 DRUGINFO D0Q0BK 3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol Investigative T84621 DRUGINFO D0R0TE 3-(6-Ethoxy-naphthalen-2-yl)-pyridine Investigative T84621 DRUGINFO D0WN9P 4'-(Pyridin-4-ylmethyl)biphenyl-3-amine Investigative T84621 DRUGINFO D0YD9J 4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine Investigative T55922 TARGETID T55922 T55922 FORMERID TTDR00414 T55922 UNIPROID DCAM_HUMAN T55922 TARGNAME S-adenosylmethionine decarboxylase proenzyme (AMD1) T55922 GENENAME AMD1 T55922 TARGTYPE Successful T55922 SYNONYMS SamDC; S-adenosylmethioninedecarboxylase; AdoMetDC; AMD T55922 FUNCTION Promotes maintenance and self-renewal of embryonic stem cells, by maintaining spermine levels. Essential for biosynthesis of the polyamines spermidine and spermine. T55922 PDBSTRUC 3H0W; 3H0V; 3EPB; 3EPA; 3EP9 T55922 BIOCLASS Carbon-carbon lyase T55922 ECNUMBER EC 4.1.1.50 T55922 SEQUENCE MEAAHFFEGTEKLLEVWFSRQQPDANQGSGDLRTIPRSEWDILLKDVQCSIISVTKTDKQEAYVLSESSMFVSKRRFILKTCGTTLLLKALVPLLKLARDYSGFDSIQSFFYSRKNFMKPSHQGYPHRNFQEEIEFLNAIFPNGAAYCMGRMNSDCWYLYTLDFPESRVISQPDQTLEILMSELDPAVMDQFYMKDGVTAKDVTRESGIRDLIPGSVIDATMFNPCGYSMNGMKSDGTYWTIHITPEPEFSYVSFETNLSQTSYDDLIRKVVEVFKPGKFVTTLFVNQSSKCRTVLASPQKIEGFKRLDCQSAMFNDYNFVFTSFAKKQQQQQS T55922 DRUGINFO D03ZFN Tromethamine Approved T55922 DRUGINFO D0E2WF ORG 34517/34850 Phase 2 T55922 DRUGINFO D00FMV Putrescine Discontinued in Phase 2 T55922 DRUGINFO D05FFR MGBG Terminated T55922 DRUGINFO D0S6VX CGP-40215A Terminated T55922 DRUGINFO D03OLX 5'-Deoxy-5'-(N,N-dimethylamino)adenosine Investigative T55922 DRUGINFO D0BI4H Hydroxyalanine Investigative T55922 DRUGINFO D0I7IA 5'-Deoxy-5'-dimethylsulfonioadenosine chloride Investigative T55922 DRUGINFO D0P5YR [(2-aminooxyethyl)methylamino]-5'-deoxyadenosine Investigative T55922 DRUGINFO D0Y7YL 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine Investigative T55922 DRUGINFO D0YM6B 5'-Deoxy-5'-(N,N-dimethylamino)-8-methyladenosine Investigative T55922 DRUGINFO D0V2QF 5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine Investigative T59929 TARGETID T59929 T59929 FORMERID TTDR00251 T59929 UNIPROID TYPH_HUMAN T59929 TARGNAME Thymidine phosphorylase (TYMP) T59929 GENENAME TYMP T59929 TARGTYPE Successful T59929 SYNONYMS TdRPase; TYMP; TP; Platelet-derived endothelial cell growth factor; PDECGF; PD-ECGF; Gliostatin T59929 FUNCTION Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis. T59929 PDBSTRUC 2WK6; 2WK5; 2J0F; 1UOU T59929 BIOCLASS Pentosyltransferase T59929 ECNUMBER EC 2.4.2.4 T59929 SEQUENCE MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPEPKQLPELIRMKRDGGRLSEADIRGFVAAVVNGSAQGAQIGAMLMAIRLRGMDLEETSVLTQALAQSGQQLEWPEAWRQQLVDKHSTGGVGDKVSLVLAPALAACGCKVPMISGRGLGHTGGTLDKLESIPGFNVIQSPEQMQVLLDQAGCCIVGQSEQLVPADGILYAARDVTATVDSLPLITASILSKKLVEGLSALVVDVKFGGAAVFPNQEQARELAKTLVGVGASLGLRVAAALTAMDKPLGRCVGHALEVEEALLCMDGAGPPDLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAAQGVDPGLARALCSGSPAERRQLLPRAREQEELLAPADGTVELVRALPLALVLHELGAGRSRAGEPLRLGVGAELLVDVGQRLRRGTPWLRVHRDGPALSGPQSRALQEALVLSDRAPFAAPSPFAELVLPPQQ T59929 DRUGINFO D0Y7DP Uridine Approved T59929 DRUGINFO D00PMF 5-bromo-6-hydrazinouracil hydrochloride Investigative T59929 DRUGINFO D01DAQ 5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil Investigative T59929 DRUGINFO D01IGW 6-chloro-5-phenylpyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D03IMY 6-chloro-5-heptylpyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D03ITH 1-(cyclohexyl)methyl-5'-O-tritylinosine Investigative T59929 DRUGINFO D04OWX 1-(cyclopropyl)methyl-5'-O-tritylinosine Investigative T59929 DRUGINFO D05OUP 1-propyl-5'-O-tritylinosine Investigative T59929 DRUGINFO D06BMN 1-allyl-5'-O-tritylinosine Investigative T59929 DRUGINFO D09TBA 5-benzyl-6-chloropyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D0C0HN 6-chloro-5-(2-thienyl)pyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D0CO5S 6-chloro-5-hexylpyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D0CQ1J 2'-aminoimidazolylmethyluracils Investigative T59929 DRUGINFO D0DX8A 6-chloro-5-propylpyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D0E7SH 6-chloro-5-pentylpyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D0E9PL 6-fluoro-5-phenylpyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D0F4KL Thymine Investigative T59929 DRUGINFO D0G1DS 5-chloro-6-hydrazinouracil hydrochloride Investigative T59929 DRUGINFO D0I7IF 6-bromo-5-phenylpyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D0RE9X 5-butyl-6-chloropyrimidine-2,4(1H,3H)-dione Investigative T59929 DRUGINFO D0VW6H 6-amino-5-chlorouracil hydrochloride Investigative T59929 DRUGINFO D0W6LJ 1-benzyl-5'-O-tritylinosine Investigative T59929 DRUGINFO D0X5RA 6-amino-5-bromouracil Investigative T59929 DRUGINFO D0Y5UF 5-bromo-6-(cyclopropylamino)uracil hydrochloride Investigative T67684 TARGETID T67684 T67684 FORMERID TTDS00004 T67684 UNIPROID ACM3_HUMAN T67684 TARGNAME Muscarinic acetylcholine receptor M3 (CHRM3) T67684 GENENAME CHRM3 T67684 TARGTYPE Successful T67684 SYNONYMS M3 receptor; CHRM3 T67684 FUNCTION The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. T67684 PDBSTRUC 2CSA T67684 BIOCLASS GPCR rhodopsin T67684 SEQUENCE MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPLGGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVISMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKRTTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAFYMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSMKRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSETRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSFPKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKRMSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVNPVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL T67684 DRUGINFO D04LHJ Methscopolamine Bromide Approved T67684 DRUGINFO D07KHH LAS-34273 Approved T67684 DRUGINFO D0BZ7W Tolterodine Approved T67684 DRUGINFO D0L4YD Solifenacin Approved T67684 DRUGINFO D0Q4CS Cevimeline Approved T67684 DRUGINFO D0Q7ZQ Succinylcholine Approved T67684 DRUGINFO D0S0AS Ipratropium Approved T67684 DRUGINFO D0P1WA Tiotropium Approved T67684 DRUGINFO D0Y5AM Darifenacin Approved T67684 DRUGINFO D04MWJ Methacholine Chloride Approved T67684 DRUGINFO D05KZK SMT-D002 Approved T67684 DRUGINFO D0M6VK Methylscopolamine Approved T67684 DRUGINFO D0R7WU ACECLIDINE Approved T67684 DRUGINFO D02TXV TRN-157 Phase 2 T67684 DRUGINFO D04YEW Tarafenacin Phase 2 T67684 DRUGINFO D0V0JQ CHF 5407 Phase 1 T67684 DRUGINFO D04SBH Zamifenacin Discontinued in Phase 3 T67684 DRUGINFO D06GCP PSD-506 Discontinued in Phase 2 T67684 DRUGINFO D09LMX Revatropate Discontinued in Phase 1 T67684 DRUGINFO D0X8MZ Alvameline Terminated T67684 DRUGINFO D05YBO Nocardimicin C Investigative T67684 DRUGINFO D06UOE 3-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenylethyl)pyrrolidine (APP) Investigative T67684 DRUGINFO D07QGQ Noccardimicin E Investigative T67684 DRUGINFO D07TDE Olterodine Investigative T67684 DRUGINFO D09YBC NOCARDIMICIN A Investigative T67684 DRUGINFO D0A2KT 4-DAMP Investigative T67684 DRUGINFO D0BP7C J-104135 Investigative T67684 DRUGINFO D0F5LH Oxybutynine Investigative T67684 DRUGINFO D0I2XG Nocardimicin D Investigative T67684 DRUGINFO D0IM7C AE-9C90CB Investigative T67684 DRUGINFO D0J4DJ Nocardimicin F Investigative T67684 DRUGINFO D00NRJ silahexocyclium Investigative T67684 DRUGINFO D00WNA ML381 Investigative T67684 DRUGINFO D02BOW McN-A-343 Investigative T67684 DRUGINFO D02IIN WIN 62,577 Investigative T67684 DRUGINFO D02MJE NNC 11-1314 Investigative T67684 DRUGINFO D02UNX VU0255035 Investigative T67684 DRUGINFO D02VGM [3H]QNB Investigative T67684 DRUGINFO D03DMR lithocholylcholine Investigative T67684 DRUGINFO D03LSH UH-AH 37 Investigative T67684 DRUGINFO D05EEV DAU-5750 Investigative T67684 DRUGINFO D05PSD WIN 51,708 Investigative T67684 DRUGINFO D05WXF thiochrome Investigative T67684 DRUGINFO D07CAB NNC 11-1585 Investigative T67684 DRUGINFO D07GPQ tripitramine Investigative T67684 DRUGINFO D07LDP hexahydrosiladifenidol Investigative T67684 DRUGINFO D07OAK Go7874 Investigative T67684 DRUGINFO D08BGK N-chloromethyl-brucine Investigative T67684 DRUGINFO D08KNP N-benzyl brucine Investigative T67684 DRUGINFO D08XBQ NNC 11-1607 Investigative T67684 DRUGINFO D0G4CG [3H]oxotremorine-M Investigative T67684 DRUGINFO D0H2UT brucine Investigative T67684 DRUGINFO D0I9AL guanylpirenzepine Investigative T67684 DRUGINFO D0I9LU arecaidine propargyl ester Investigative T67684 DRUGINFO D0K3VR p-F-HHSiD Investigative T67684 DRUGINFO D0PL0Y furtrethonium Investigative T67684 DRUGINFO D0R8AZ DAU-5884 Investigative T67684 DRUGINFO D0S4DT vinburnine Investigative T67684 DRUGINFO D0T6ID pentylthio-TZTP Investigative T67684 DRUGINFO D0W8XI hexahydrodifenidol Investigative T67684 DRUGINFO D0WO3A methylfurmethide Investigative T67684 DRUGINFO D00JTE 1,1-diphenyl-2-(3-tropanyl)ethanol Investigative T67684 DRUGINFO D09AAZ PTAC Investigative T67684 DRUGINFO D02ZPV UCB-101333-3 Investigative T67684 DRUGINFO D04XNH Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T67684 DRUGINFO D0Z5RQ Cremastrine Investigative T67684 DRUGINFO D01UDC Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T67684 DRUGINFO D02EXX GNF-PF-5618 Investigative T67684 DRUGINFO D02PFJ 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea Investigative T67684 DRUGINFO D05EML 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione Investigative T67684 DRUGINFO D05MDY 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one Investigative T67684 DRUGINFO D06IUC FM1-10 Investigative T67684 DRUGINFO D06VST 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one Investigative T67684 DRUGINFO D07DEY 3-(3-benzylamino)-piperidin-2-one Investigative T67684 DRUGINFO D07VZG BRL-55473 Investigative T67684 DRUGINFO D08ZTA 6-Dimethylamino-2-methyl-hex-4-ynal oxime Investigative T67684 DRUGINFO D0AR0H FM1-43 Investigative T67684 DRUGINFO D0B8AQ 7-Pyrrolidin-1-yl-hept-5-yn-2-one Investigative T67684 DRUGINFO D0C9VH N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide Investigative T67684 DRUGINFO D0C9ZE Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T67684 DRUGINFO D0O1BN SULFOARECOLINE Investigative T67684 DRUGINFO D0OE0K 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane Investigative T67684 DRUGINFO D0QL1X 7-Dimethylamino-3-methyl-hept-5-yn-2-one Investigative T67684 DRUGINFO D0R2JE N-methoxyquinuclidine-3-carboximidoyl chloride Investigative T67684 DRUGINFO D0R8FS 7-Dimethylamino-hept-5-yn-2-one Investigative T67684 DRUGINFO D0U2IL 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime Investigative T67684 DRUGINFO D0X2JU N-methoxyquinuclidine-3-carboximidoyl fluoride Investigative T67684 DRUGINFO D0HV3A FLUMEZAPINE Investigative T67684 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T67684 DRUGINFO D0F9QT A-987306 Investigative T67684 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T67684 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T62193 TARGETID T62193 T62193 FORMERID TTDS00361 T62193 UNIPROID DDC_HUMAN T62193 TARGNAME Aromatic-L-amino-acid decarboxylase (DDC) T62193 GENENAME DDC T62193 TARGTYPE Successful T62193 SYNONYMS DOPA decarboxylase; AADC T62193 FUNCTION Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine. T62193 PDBSTRUC 3RCH; 3RBL; 3RBF T62193 BIOCLASS Carbon-carbon lyase T62193 ECNUMBER EC 4.1.1.28 T62193 SEQUENCE MNASEFRRRGKEMVDYMANYMEGIEGRQVYPDVEPGYLRPLIPAAAPQEPDTFEDIINDVEKIIMPGVTHWHSPYFFAYFPTASSYPAMLADMLCGAIGCIGFSWAASPACTELETVMMDWLGKMLELPKAFLNEKAGEGGGVIQGSASEATLVALLAARTKVIHRLQAASPELTQAAIMEKLVAYSSDQAHSSVERAGLIGGVKLKAIPSDGNFAMRASALQEALERDKAAGLIPFFMVATLGTTTCCSFDNLLEVGPICNKEDIWLHVDAAYAGSAFICPEFRHLLNGVEFADSFNFNPHKWLLVNFDCSAMWVKKRTDLTGAFRLDPTYLKHSHQDSGLITDYRHWQIPLGRRFRSLKMWFVFRMYGVKGLQAYIRKHVQLSHEFESLVRQDPRFEICVEVILGLVCFRLKGSNKVNEALLQRINSAKKIHLVPCHLRDKFVLRFAICSRTVESAHVQRAWEHIKELAADVLRAERE T62193 DRUGINFO D07MUN Vitamin B6 Approved T62193 DRUGINFO D0P7JZ Carbidopa Approved T62193 DRUGINFO D03QFN Patrome Phase 3 T62193 DRUGINFO D0X8ED Benserazide Phase 3 T62193 DRUGINFO D02ITL AV-201 Phase 2 T62193 DRUGINFO D4X6SZ PTC-AADC Phase 2 T62193 DRUGINFO DH1W0G VY-AADC Phase 2 T62193 DRUGINFO DX9KC2 GT-AADC Phase 2 T62193 DRUGINFO D05ICS ProSavin Phase 1/2 T62193 DRUGINFO D72UDH OXB-102 Phase 1/2 T62193 DRUGINFO DZ4LX5 VY-AADC01 Phase 1 T62193 DRUGINFO D0IB8N Noradrenalone (arterenone) Investigative T62193 DRUGINFO D0P9BM 3-hydroxybenzylhydrazine Investigative T13852 TARGETID T13852 T13852 FORMERID TTDC00258 T13852 UNIPROID S1PR1_HUMAN T13852 TARGNAME Sphingosine-1-phosphate receptor 1 (S1PR1) T13852 GENENAME S1PR1 T13852 TARGTYPE Successful T13852 SYNONYMS Sphingosine 1-phosphate receptor Edg-1; S1P1; S1P receptor Edg-1; S1P receptor 1; Endothelial differentiation G-protein coupled receptor 1; CHEDG1; CD363 T13852 FUNCTION Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. Plays an important role in cell migration, probably via its role in the reorganization of the actin cytoskeleton and the formation of lamellipodia in response to stimuli that increase the activity of the sphingosine kinase SPHK1. Required for normal chemotaxis toward sphingosine 1-phosphate. Required for normal embryonic heart development and normal cardiac morphogenesis. Plays an important role in the regulation of sprouting angiogenesis and vascular maturation. Inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development. Required for normal egress of mature T-cells from the thymus into the blood stream and into peripheral lymphoid organs. Plays a role in the migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis. Plays a role in responses to oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine by pulmonary endothelial cells and in the protection against ventilator-induced lung injury. G-protein coupled receptor for the bioactive lysosphingolipid sphingosine 1-phosphate (S1P) that seems to be coupled to the G(i) subclass of heteromeric G proteins. T13852 PDBSTRUC 3V2Y; 3V2W T13852 BIOCLASS GPCR rhodopsin T13852 SEQUENCE MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISADKENSIKLTSVVFILICCFIILENIFVLLTIWKTKKFHRPMYYFIGNLALSDLLAGVAYTANLLLSGATTYKLTPAQWFLREGSMFVALSASVFSLLAIAIERYITMLKMKLHNGSNNFRLFLLISACWVISLILGGLPIMGWNCISALSSCSTVLPLYHKHYILFCTTVFTLLLLSIVILYCRIYSLVRTRSRRLTFRKNISKASRSSEKSLALLKTVIIVLSVFIACWAPLFILLLLDVGCKVKTCDILFRAEYFLVLAVLNSGTNPIIYTLTNKEMRRAFIRIMSCCKCPSGDSAGKFKRPIIAGMEFSRSKSDNSSHPQKDEGDNPETIMSSGNVNSSS T13852 DRUGINFO D07EDB Ozanimod Approved T13852 DRUGINFO D07UHS Fingolimod Approved T13852 DRUGINFO D0L9KH Etrasimod Approved T13852 DRUGINFO D0Y4SI Ponesimod Approved T13852 DRUGINFO D07FKQ Siponimod Approved T13852 DRUGINFO D00ISN MT-1303 Phase 2 T13852 DRUGINFO D0I2RB ONO-4641 Phase 2 T13852 DRUGINFO D0Y5ZT KRP-203 Phase 2 T13852 DRUGINFO D6C7FG VTX-002 Phase 2 T13852 DRUGINFO DLK93N CBP-307 Phase 2 T13852 DRUGINFO D07UGA Sphingosine-1-phosphate Phase 1 T13852 DRUGINFO D0B4CD GSK-2018682 Phase 1 T13852 DRUGINFO D0GG7L BMS-986104 Phase 1 T13852 DRUGINFO D0KV2E Sonepcizumab Phase 1 T13852 DRUGINFO D0X8XT CS-0777 Phase 1 T13852 DRUGINFO D0XE5M SAR247799 Phase 1 T13852 DRUGINFO D0Q0JI ASP-4058 Phase 1 T13852 DRUGINFO D0N8AB PF-4629991 Discontinued in Phase 1 T13852 DRUGINFO D0Y0BC XL-541 Terminated T13852 DRUGINFO D00VHN 3-(N-alkylamino) propylphosphonic acid derivative Investigative T13852 DRUGINFO D00ZXX CYM5442 Investigative T13852 DRUGINFO D02LTS NIBR-0213 Investigative T13852 DRUGINFO D02OCD NIBR-785 Investigative T13852 DRUGINFO D03AAC W146 Investigative T13852 DRUGINFO D04XCB 3-amino-5-(4-octylphenyl)pentanoic acid Investigative T13852 DRUGINFO D05SYL CYM5181 Investigative T13852 DRUGINFO D06XMB (3-Tetradecylamino-cyclohexyl)-phosphonic acid Investigative T13852 DRUGINFO D07EAB 1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid Investigative T13852 DRUGINFO D08VLT 4-amino-6-(4-octylphenyl)hexanoic acid Investigative T13852 DRUGINFO D09NWW AMG-247 Investigative T13852 DRUGINFO D0D5QS [3-(4-Nonyl-benzylamino)-propyl]-phosphonic acid Investigative T13852 DRUGINFO D0G6KH NOX-S91 Investigative T13852 DRUGINFO D0IL7V KRP-107 Investigative T13852 DRUGINFO D0LO4T 1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid Investigative T13852 DRUGINFO D0N0BN (3-Tetradecylamino-cyclopentyl)-phosphonic acid Investigative T13852 DRUGINFO D0O4JU (S)-FTY720P Investigative T13852 DRUGINFO D0P1TY 3-(tetradecylamino)propylphosphonic acid Investigative T13852 DRUGINFO D0P2AZ 1-(4-nonylbenzyl)azetidine-3-carboxylic acid Investigative T13852 DRUGINFO D0T4LT GSK-1842799C Investigative T13852 DRUGINFO D0YC1R BMS-520 Investigative T13852 DRUGINFO D0ZU0O SEW2871 Investigative T13852 DRUGINFO D05EDD VPC23019 Investigative T13852 DRUGINFO D09ESF GNF-PF-78 Investigative T13852 DRUGINFO D0R2ZN GNF-PF-826 Investigative T13852 DRUGINFO D0U7YK KRP 203-phosphate Investigative T13852 DRUGINFO D06GFH VPC44116 Investigative T13852 DRUGINFO D05KEE AFD(R) Investigative T13852 DRUGINFO D06DYN FTY720-phosphate Investigative T13852 DRUGINFO D0W1ZW VPC03090-P Investigative T13852 DRUGINFO D03BRM AUY954 Investigative T13852 DRUGINFO D0X0UR LPA Investigative T76904 TARGETID T76904 T76904 FORMERID TTDS00362 T76904 UNIPROID COMT_HUMAN T76904 TARGNAME Catechol-O-methyl-transferase (COMT) T76904 GENENAME COMT T76904 TARGTYPE Successful T76904 SYNONYMS S-COMT; MB-COMT; Catechol-O-methyltransferase; COMT T76904 FUNCTION Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol. T76904 PDBSTRUC 5LSA; 4XUE; 4XUD; 4XUC; 4PYK T76904 BIOCLASS Methyltransferase T76904 ECNUMBER EC 2.1.1.6 T76904 SEQUENCE MPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLLMGDTKEQRILNHVLQHAEPGNAQSVLEAIDTYCEQKEWAMNVGDKKGKIVDAVIQEHQPSVLLELGAYCGYSAVRMARLLSPGARLITIEINPDCAAITQRMVDFAGVKDKVTLVVGASQDIIPQLKKKYDVDTLDMVFLDHWKDRYLPDTLLLEECGLLRKGTVLLADNVICPGAPDFLAHVRGSSCFECTHYQSFLEYREVVDGLEKAIYKGPGSEAGP T76904 DRUGINFO D01SGK Opicapone Approved T76904 DRUGINFO D0J1VY Entacapone Approved T76904 DRUGINFO D0Y7PG Tolcapone Approved T76904 DRUGINFO D0R2NE Entacapone+levodopa+carbidopa Phase 3 T76904 DRUGINFO D0G4DE BIA 3-202 Phase 2 T76904 DRUGINFO D0P5TR CGP-28014 Phase 2 T76904 DRUGINFO D08LVF Nitecapone Discontinued in Phase 2 T76904 DRUGINFO D0U1CL PGX-200097 Preclinical T76904 DRUGINFO D01AFH 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone Investigative T76904 DRUGINFO D06LED 7,8-dihydroxy-4-phenyl-2H-chromen-2-one Investigative T76904 DRUGINFO D09AYR 3,5-Dinitrocatechol Investigative T76904 DRUGINFO D0C0OT 1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone Investigative T76904 DRUGINFO D0HW3Y 5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one Investigative T76904 DRUGINFO D0M3PG 6,7-dihydroxy-8-nitro-1-tetralone Investigative T76904 DRUGINFO D0OE1R (3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE Investigative T76904 DRUGINFO D0XT0I BIA Investigative T76369 TARGETID T76369 T76369 FORMERID TTDR00274 T76369 UNIPROID EST1_HUMAN T76369 TARGNAME Liver carboxylesterase (CES1) T76369 GENENAME CES1 T76369 TARGTYPE Successful T76369 SYNONYMS Serine esterase 1; Monocyte/macrophage serine esterase; Human carboxylesterase 1; HMSE; HCE1; CES1; Brain carboxylesterase hBr1; Acyl coenzyme A:cholesterol acyltransferase T76369 FUNCTION Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl coa ester. T76369 PDBSTRUC 5A7H; 5A7G; 5A7F; 4AB1; 3K9B T76369 BIOCLASS Carboxylic ester hydrolase T76369 ECNUMBER EC 3.1.1.1 T76369 SEQUENCE MWLRAFILATLSASAAWGHPSSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPLGPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLNIYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFSTGDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNLFHRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLKMKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIPMQLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDLIADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPFLKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLKDKEVAFWTNLFAKKAVEKPPQTEHIEL T76369 DRUGINFO D0OR2L Cholic Acid Approved T76369 DRUGINFO D02GWF PACTIMIBE Phase 2/3 T76369 DRUGINFO D03PYD K-604 Phase 2 T76369 DRUGINFO D0YB4D Eldacimibe Phase 2 T76369 DRUGINFO D05EMV GR148672X Clinical trial T76369 DRUGINFO D0O1KX Avasimibe Discontinued in Phase 3 T76369 DRUGINFO D01IDE E-5324 Discontinued in Phase 2 T76369 DRUGINFO D07DBS RP-64477 Discontinued in Phase 2 T76369 DRUGINFO D0D1XG CI-976 Discontinued in Phase 2 T76369 DRUGINFO D0E1UZ CL-283796 Discontinued in Phase 2 T76369 DRUGINFO D0W0ED Eflucimibe Discontinued in Phase 2 T76369 DRUGINFO D03QZB F-1394 Discontinued in Phase 1 T76369 DRUGINFO D04ODQ 447C88 Discontinued in Phase 1 T76369 DRUGINFO D06FCR CL-277082 Discontinued in Phase 1 T76369 DRUGINFO D0D9AD YM-750 Discontinued in Phase 1 T76369 DRUGINFO D0IZ7T YM-17E Discontinued in Phase 1 T76369 DRUGINFO D09MJO HL-004 Preclinical T76369 DRUGINFO D00KQT FR-129169 Terminated T76369 DRUGINFO D03EHR Lecimibide Terminated T76369 DRUGINFO D03JRJ NTE-122 Terminated T76369 DRUGINFO D03YPL RP-70676 Terminated T76369 DRUGINFO D06KFR RP-73163 Terminated T76369 DRUGINFO D0J8TH CEB-925 Terminated T76369 DRUGINFO D0K8KJ DuP-129 Terminated T76369 DRUGINFO D0O2AC FR-145237 Terminated T76369 DRUGINFO D0OK8M TEI-6522 Terminated T76369 DRUGINFO D0PG0S CI-999 Terminated T76369 DRUGINFO D00PLH 1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D01GSO Diethyl 2,2,2-trifluoro-1-phenylethyl phosphate Investigative T76369 DRUGINFO D01HRG 1-phenyl-1H-indole-2,3-dione Investigative T76369 DRUGINFO D01HZN 1,2-bis(3,4,5-trifluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D01VAU 1,2-Bis-(3-methoxy-phenyl)-ethane-1,2-dione Investigative T76369 DRUGINFO D01VCS 1,2-bis(2,6-difluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D02EZF SMP-797 Investigative T76369 DRUGINFO D02GJG 1,2-bis(2-fluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D02HQS 1,2-bis(2,4-difluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D02TLP 1-Phenyl-propane-1,2-dione Investigative T76369 DRUGINFO D02VYI Dibutyl 2,2,2-trifluoro-1-phenylethyl phosphate Investigative T76369 DRUGINFO D03HZT 1,2-Bis-(2-chloro-phenyl)-ethane-1,2-dione Investigative T76369 DRUGINFO D03TPH 5-chloro-1H-indole-2,3-dione Investigative T76369 DRUGINFO D03WOU 1,2-Di-naphthalen-2-yl-ethane-1,2-dione Investigative T76369 DRUGINFO D04AXR 4-chloro-1H-indole-2,3-dione Investigative T76369 DRUGINFO D04CDV 1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D04EXR 4,6-dichloro-1H-indole-2,3-dione Investigative T76369 DRUGINFO D04JVA 1,1,1-trifluoro-3-(hexylsulfonyl)propan-2-one Investigative T76369 DRUGINFO D05AVX Heptane-2,3-dione Investigative T76369 DRUGINFO D05EMT 1,2-bis(2,5-difluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D05EYA 1,2-Bis-(4-chloro-phenyl)-ethane-1,2-dione Investigative T76369 DRUGINFO D05PNO 1-(2-iodoethyl)-1H-indole-2,3-dione Investigative T76369 DRUGINFO D05VUC 1,2-bis(2-fluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D05XRY 11,12-dihydro-dibenzo[a,e]cyclooctene-5,6-dione Investigative T76369 DRUGINFO D05ZCX Thieno[3,2-e][1]benzothiophene-4,5-dione Investigative T76369 DRUGINFO D06FFD 1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione Investigative T76369 DRUGINFO D06GYH 1,2-bis(2,3,4-trifluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D06ZPI N-Methylnaloxonium Investigative T76369 DRUGINFO D07CFJ 1-propionyl-1H-indole-2,3-dione Investigative T76369 DRUGINFO D07WHV 4-Piperidino-Piperidine Investigative T76369 DRUGINFO D08AOG 2,2-Dimethoxy-1,2-diphenyl-ethanone Investigative T76369 DRUGINFO D08UOB 1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D09LSR 1,2-bis(3,5-difluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D0AW4P 1,2-bis(3-fluorophenyl)-2-hydroxyethanon Investigative T76369 DRUGINFO D0B1TQ 4-chloro-7-methyl-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0B8YX 1-Phenyl-2-p-tolyl-ethane-1,2-dione Investigative T76369 DRUGINFO D0BB2U 4-(2-Oxo-2-phenyl-acetyl)-benzoic acid Investigative T76369 DRUGINFO D0C9AD 1-(4-chlorobenzyl)-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0CN8Z 1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D0D2HH 1,2-bis(2,3,5-trifluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D0D7FN 1-(4-Nitro-phenyl)-2-phenyl-ethane-1,2-dione Investigative T76369 DRUGINFO D0DW9J 1,2-bis(4-fluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D0E2IG 1,2-bis(2,3,6-trifluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D0E5ZP 7-(trifluoromethyl)-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0EK7H 4,7-dichloro-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0F0JI (E)-Octadec-9-enoic acid phenylamide Investigative T76369 DRUGINFO D0F3RN 1-(4-Chloro-phenyl)-2-phenyl-ethane-1,2-dione Investigative T76369 DRUGINFO D0F4QX Thenoyltrifluoroacetone Investigative T76369 DRUGINFO D0F7NU 1,1,1-trifluoro-3-(hexylsulfinyl)propan-2-one Investigative T76369 DRUGINFO D0FO4J 3-(butylthio)-1,1,1-trifluoropropan-2-one Investigative T76369 DRUGINFO D0H5II 2-methoxy-3,4-methylenedioxybenzophenone Investigative T76369 DRUGINFO D0JH7C 1,10-phenanthroline-5,6-dione Investigative T76369 DRUGINFO D0JI0H 1-(2-bromoethyl)-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0K6OM 1,2-bis(3,4-difluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D0K6PO Acenanthrene-9,10-dione Investigative T76369 DRUGINFO D0L1ST 1-(4-Chloro-phenyl)-2-p-tolyl-ethane-1,2-dione Investigative T76369 DRUGINFO D0L4MF 1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D0LJ2F 1,2-dicyclohexylethane-1,2-dione Investigative T76369 DRUGINFO D0M2ZD 1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D0M5NR 1-butyryl-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0N8YZ 1-(3,4-Dimethyl-phenyl)-2-phenyl-ethane-1,2-dione Investigative T76369 DRUGINFO D0N9ZR 6-bromo-5-methyl-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0NJ4G 5,7-dichloro-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0O0LU 1-benzyl-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0O9EB 3-(butylsulfinyl)-1,1,1-trifluoropropan-2-one Investigative T76369 DRUGINFO D0OH1O VULM-1457 Investigative T76369 DRUGINFO D0P1IK 1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D0T5XC 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione Investigative T76369 DRUGINFO D0U0BV 1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D0U3JD 1-methyl-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0UK5A 1,2-Di-p-tolyl-ethane-1,2-dione Investigative T76369 DRUGINFO D0UT1X 1,2-Bis-(3-nitro-phenyl)-ethane-1,2-dione Investigative T76369 DRUGINFO D0UZ8R 1,2-Bis-(4-methoxy-phenyl)-ethane-1,2-dione Investigative T76369 DRUGINFO D0V9MG KY-382 Investigative T76369 DRUGINFO D0W0PH SCH-48375 Investigative T76369 DRUGINFO D0X0ER 7-chloro-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0XP0J Dimethyl 2,2,2-trifluoro-1-phenylethyl phosphate Investigative T76369 DRUGINFO D0Y6RZ 1,2-bis(3-fluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D0Y7FX BENZIL Investigative T76369 DRUGINFO D0Z1WQ 3,5-Di-tert-butyl-[1,2]benzoquinone Investigative T76369 DRUGINFO D0Z5KQ Benzoin Investigative T76369 DRUGINFO D0Z6CZ 4,5-dichloro-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0Z8HX 6,7-dichloro-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0ZL6B 1-hexadecyl-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0ZR2T 5-(trifluoromethoxy)-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0ZT5C 1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone Investigative T76369 DRUGINFO D00ANJ 1-dodecyl-1H-indole-2,3-dione Investigative T76369 DRUGINFO D00IAK 1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one Investigative T76369 DRUGINFO D00VKB 3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one Investigative T76369 DRUGINFO D01NDE 2,2-dimethyl-3-methyleneheptadecane Investigative T76369 DRUGINFO D01XGP 1,2-indanedione Investigative T76369 DRUGINFO D02SDT 3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one Investigative T76369 DRUGINFO D04UEN 1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one Investigative T76369 DRUGINFO D05LTW 1,2-bis(2,3-fluorophenyl)ethane-1,2-dione Investigative T76369 DRUGINFO D06VGD ACENAPHTHOQUINONE Investigative T76369 DRUGINFO D07EDG 1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione Investigative T76369 DRUGINFO D0A2NK PYRIPYROPENE A Investigative T76369 DRUGINFO D0B4GJ 3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one Investigative T76369 DRUGINFO D0E5CF 3-(decylthio)-1,1,1-trifluoropropan-2-one Investigative T76369 DRUGINFO D0I7FF 1,1,1-trifluorododecan-2-one Investigative T76369 DRUGINFO D0Q2YJ Phenanthrene-9,10-dione Investigative T76369 DRUGINFO D0Q3GH 1,1,1-trifluoro-3-(octylthio)propan-2-one Investigative T76369 DRUGINFO D0T7YM Oleic acid anilide Investigative T76369 DRUGINFO D0Y0FN 3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one Investigative T76369 DRUGINFO D0Y8RM (1r)-1,2,2-trimethylpropyl (r)-methylphosphinate Investigative T76369 DRUGINFO D0Z7WK 1,1,1-trifluoro-3-(hexylthio)propan-2-one Investigative T76369 DRUGINFO D0D0BI CHLORANIL Investigative T76369 DRUGINFO D0F5VY NSC-23180 Investigative T76369 DRUGINFO D0N0HK 3,4,5,6-Tetrachloro-[1,2]benzoquinone Investigative T76369 DRUGINFO D0WX6R 5,6-dinitroacenaphthoquinone Investigative T76369 DRUGINFO D08WQM O-Sialic Acid Investigative T76369 DRUGINFO D0W9VA 1,2-NAPHTHOQUINONE Investigative T76369 DRUGINFO D07LUR Alpha-D-Mannose Investigative T60529 TARGETID T60529 T60529 FORMERID TTDS00040 T60529 UNIPROID PGH1_HUMAN T60529 TARGNAME Prostaglandin G/H synthase 1 (COX-1) T60529 GENENAME PTGS1 T60529 TARGTYPE Successful T60529 SYNONYMS Prostaglandin-endoperoxide synthase 1; Prostaglandin H2 synthase 1; PHS 1; PGHS-1; PGH synthase 1; Cyclooxygenase-1; COX1; COX-1 T60529 FUNCTION Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells. T60529 BIOCLASS Paired donor oxygen oxidoreductase T60529 ECNUMBER EC 1.14.99.1 T60529 SEQUENCE MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTRTGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRSNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRFLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQYQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLYATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKFDPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEALVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQELVGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICSPEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL T60529 DRUGINFO D00IBN Piroxicam Approved T60529 DRUGINFO D07BPS Suprofen Approved T60529 DRUGINFO D0A6KR Balsalazide Approved T60529 DRUGINFO D0C4YC Mesalazine Approved T60529 DRUGINFO D0O1TC Gamma-Homolinolenic acid Approved T60529 DRUGINFO D0U1OM Bromfenac Approved T60529 DRUGINFO D0Y0JH Salsalate Approved T60529 DRUGINFO D06LHG FENBUFEN Approved T60529 DRUGINFO D0DJ1B Naproxen Approved T60529 DRUGINFO D0MN9K Meclofenamate Sodium Approved T60529 DRUGINFO D0Q5XX Eicosapentaenoic acid/docosa-hexaenoic acid Approved T60529 DRUGINFO D01WJL Aminosalicylic Acid Approved T60529 DRUGINFO D0B2WJ Flufenamic Acid Approved T60529 DRUGINFO D07HBX Salicyclic acid Approved T60529 DRUGINFO D0AL8M IMRECOXIB Phase 4 T60529 DRUGINFO D0G2IC (S)-FLURBIPROFEN Preregistration T60529 DRUGINFO D0C4DZ ThermoProfen Phase 3 T60529 DRUGINFO D0U3EP Resveratrol Phase 3 T60529 DRUGINFO D07SDQ Curcumin Phase 3 T60529 DRUGINFO D0F5BL EXO-230 Phase 1/2 T60529 DRUGINFO D05TPI EPICATECHIN Phase 1/2 T60529 DRUGINFO D0S8TB Carbamate derivative 2 Patented T60529 DRUGINFO D06JRD Metamizole Withdrawn from market T60529 DRUGINFO D0O2IE Phenacetin Withdrawn from market T60529 DRUGINFO D0Q5PL INDOPROFEN Withdrawn from market T60529 DRUGINFO D0BZ1Q CRx-401 Discontinued in Phase 2 T60529 DRUGINFO D0P3KA TEBUFELONE Discontinued in Phase 2 T60529 DRUGINFO D0ZL4F R-ketoprofen Discontinued in Phase 2 T60529 DRUGINFO D03AKL ATLIPROFEN METHYL ESTER Terminated T60529 DRUGINFO D0O9JX SC-58451 Terminated T60529 DRUGINFO D00RCV Acetic acid 2-hex-2-ynylsulfanyl-phenyl ester Investigative T60529 DRUGINFO D00VHS 4-(5-(4-Hydroxyphenyl)isothiazol-4-yl)phenol Investigative T60529 DRUGINFO D00XIX 5-(4-Chlorophenyl)-4-p-tolyl-3H-1,2-dithiol-3-one Investigative T60529 DRUGINFO D01EWD Acetic acid 2-heptylselanyl-phenyl ester Investigative T60529 DRUGINFO D01HXN TRL-382 Investigative T60529 DRUGINFO D02GZX 2-(3'-Ethylsulfanyl-biphenyl-4-yl)-propionic acid Investigative T60529 DRUGINFO D02HSZ IODOINDOMETHACIN Investigative T60529 DRUGINFO D02HVL (3-Chloro-4-Propoxy-Phenyl)-Acetic Acid Investigative T60529 DRUGINFO D02PLG 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiole-3-thione Investigative T60529 DRUGINFO D02VLR Acetic acid 2-hept-2-ynylsulfanyl-phenyl ester Investigative T60529 DRUGINFO D03EDF DEMETHOXYCURCUMIN Investigative T60529 DRUGINFO D03IRR Phenazone Investigative T60529 DRUGINFO D03TLR 5-(4-Chlorophenyl)-4-p-tolylisothiazole Investigative T60529 DRUGINFO D04KAM Acetic acid 2-hexylsulfanyl-phenyl ester Investigative T60529 DRUGINFO D04ORY 4-amino-N-p-tolylbenzenesulfonamide Investigative T60529 DRUGINFO D05DOM 2-Bromoacetyl Group Investigative T60529 DRUGINFO D05KYE 2'-epi-guianin Investigative T60529 DRUGINFO D06FTI 2-(1,1'-Biphenyl-4-Yl)Propanoic Acid Investigative T60529 DRUGINFO D06GSY P-(2'-Iodo-5'-Thenoyl)Hydrotropic Acid Investigative T60529 DRUGINFO D07OAV 5-(2-1H-indenyl)-1,3-benzodioxole Investigative T60529 DRUGINFO D07SAI Protoporphyrin Ix Containing Co Investigative T60529 DRUGINFO D08BPE (-)-3-O-acetylspectaline Investigative T60529 DRUGINFO D08QAH 2-(3'-Ethyl-biphenyl-4-yl)-propionic acid Investigative T60529 DRUGINFO D08RCQ 5-(4-Methoxyphenyl)-4-p-tolylisothiazole Investigative T60529 DRUGINFO D09CMJ FR122047 Investigative T60529 DRUGINFO D09XYZ Acetic Acid Salicyloyl-Amino-Ester Investigative T60529 DRUGINFO D0G7RA 4-(4-Chlorophenyl)-5-p-tolyl-3H-1,2-dithiol-3-one Investigative T60529 DRUGINFO D0HD9P Arachidonic Acid Investigative T60529 DRUGINFO D0IB5L O-Acetylserine Investigative T60529 DRUGINFO D0J6TU 5-(4-Chlorophenyl)-4-(4-methoxyphenyl)isothiazole Investigative T60529 DRUGINFO D0JQ1T 2-[4-(1H-Indol-5-yl)-phenyl]-propionic acid Investigative T60529 DRUGINFO D0L6TP N-(3-phenoxy-4-pyridinyl)propanesulfonamide Investigative T60529 DRUGINFO D0M5MI SC-560 Investigative T60529 DRUGINFO D0M7EI Acetic acid 2-pentylsulfanyl-phenyl ester Investigative T60529 DRUGINFO D0M9RL 2-(3'-Allyl-biphenyl-4-yl)-propionic acid Investigative T60529 DRUGINFO D0N7OP 2-(2-methoxyphenyl)-1H-indene Investigative T60529 DRUGINFO D0O8XG Acetic acid 2-hept-3-ynylsulfanyl-phenyl ester Investigative T60529 DRUGINFO D0OW4W 4-(4-Chlorophenyl)-5-p-tolylisothiazole Investigative T60529 DRUGINFO D0PQ3Q 4-(4-Chlorophenyl)-5-(4-methoxyphenyl)isothiazole Investigative T60529 DRUGINFO D0Q8TK 1-(4-aminosulfonylphenyl)-2-(4-pyridyl)acetylene Investigative T60529 DRUGINFO D0R1UO 2-(2-Methylpropanoyl)-1,3,5-benzenetriol Investigative T60529 DRUGINFO D0T5DO IODOSUPROFEN Investigative T60529 DRUGINFO D0VF6F N-(3-phenoxypyridin-4-yl)methanesulfonamide Investigative T60529 DRUGINFO D0X9VY Acetic acid 2-heptylsulfanyl-phenyl ester Investigative T60529 DRUGINFO D0Y7ND 4-amino-N-(2-chlorophenyl)benzenesulfonamide Investigative T60529 DRUGINFO D0YI3V 2-(3'-Vinyl-biphenyl-4-yl)-propionic acid Investigative T60529 DRUGINFO D00GBX Prifelone Investigative T60529 DRUGINFO D00VBX 2-(p-Methylsulfonylbenzoyl)furan Investigative T60529 DRUGINFO D01VRB 4,5-Bis(4-chlorophenyl)isothiazole Investigative T60529 DRUGINFO D01WLL N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide Investigative T60529 DRUGINFO D02CCB 2-(2,3,4-trimethoxyphenyl)-1H-indene Investigative T60529 DRUGINFO D02DYG 4-amino-N-(4-chlorophenyl)benzenesulfonamide Investigative T60529 DRUGINFO D02FGY 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid Investigative T60529 DRUGINFO D04TNI Nitroflurbiprofen Investigative T60529 DRUGINFO D04YPP 5-Methyl-3,4-diphenyl-isoxazole Investigative T60529 DRUGINFO D06DRL N-(3-phenylamino-4-pyridinyl)methanesulfonamide Investigative T60529 DRUGINFO D06WML 5-Ethyl-3,4-diphenyl-isoxazole Investigative T60529 DRUGINFO D07ARK 5-Phenyl-pentanoic acid benzyl-hydroxy-amide Investigative T60529 DRUGINFO D07RTV 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole Investigative T60529 DRUGINFO D07STC 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid Investigative T60529 DRUGINFO D08RYB 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole Investigative T60529 DRUGINFO D09HWQ 3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone Investigative T60529 DRUGINFO D09MDB 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole Investigative T60529 DRUGINFO D0A4LW (R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide Investigative T60529 DRUGINFO D0BO9W N-(3-phenoxy-4-pyridinyl)ethanesulfonamide Investigative T60529 DRUGINFO D0CW3A Resveratrol Potassium3-Sulfate Investigative T60529 DRUGINFO D0D0JE 4,5-Bis(4-methoxyphenyl)-1,2-selenazole Investigative T60529 DRUGINFO D0D6UC (Z)-2'-des-methyl sulindac sulfide Investigative T60529 DRUGINFO D0E5MK 4,5-Bis(4-chlorophenyl)-1,2-selenazole Investigative T60529 DRUGINFO D0F0JU 4,5-Bis(4-methoxyphenyl)isothiazole Investigative T60529 DRUGINFO D0GF9J (11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid Investigative T60529 DRUGINFO D0J7YE N-(1H-indazol-5-yl)acetamide Investigative T60529 DRUGINFO D0LL9E 1-(4-(methylsulfonyl)phenyl)-3-phenylurea Investigative T60529 DRUGINFO D0N0YS (11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid Investigative T60529 DRUGINFO D0OX0B 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene Investigative T60529 DRUGINFO D0S7ZQ 4'-Methoxy-5,3'-dipropyl-biphenyl-2ol Investigative T60529 DRUGINFO D0T4VL Primary alcohol metabolite of celecoxib Investigative T60529 DRUGINFO D0T7BP 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea Investigative T60529 DRUGINFO D0T9QW Oxametacin Investigative T60529 DRUGINFO D0U0YE 2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid Investigative T60529 DRUGINFO D0V9AU 1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene Investigative T60529 DRUGINFO D0X4LI 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one Investigative T60529 DRUGINFO D0X5RR (11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid Investigative T60529 DRUGINFO D0ZI8Y 3 beta-O-acetyloleanolic acid Investigative T60529 DRUGINFO D01JYF 2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl Investigative T60529 DRUGINFO D01OFH METHYLHONOKIOL Investigative T60529 DRUGINFO D04DQJ HONOKIOL Investigative T60529 DRUGINFO D04JZY Resveratrol Potassium4,-Sulfate Investigative T60529 DRUGINFO D04ZGF 5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline Investigative T60529 DRUGINFO D06HUQ 2-Phenethyl-1,2-dihydro-indazol-3-one Investigative T60529 DRUGINFO D09VTJ Hyperforin Investigative T60529 DRUGINFO D0J7YU 2-Benzyl-1,2-dihydro-indazol-3-one Investigative T60529 DRUGINFO D0L4TM 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one Investigative T60529 DRUGINFO D0P1LP PHENIDONE Investigative T60529 DRUGINFO D0R6ZC 5,3'-Dipropyl-biphenyl-2,4'-diol Investigative T60529 DRUGINFO D0S0PB 2-Phenyl-1,2-dihydro-indazol-3-one Investigative T60529 DRUGINFO D0SJ3W 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one Investigative T60529 DRUGINFO D0U8CM 2-Methyl-1,2-dihydro-indazol-3-one Investigative T60529 DRUGINFO D0X6SA 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one Investigative T60529 DRUGINFO D02DBP RESORCINOL Investigative T60529 DRUGINFO D0SD9H Beta-D-Mannose Investigative T60529 DRUGINFO D07ONX Beta-D-Glucose Investigative T60529 DRUGINFO D0V7AA CATECHIN Investigative T60529 DRUGINFO D0UU1I Heme Investigative T60529 DRUGINFO D02UVH B-Octylglucoside Investigative T60529 DRUGINFO D07LUR Alpha-D-Mannose Investigative T06569 TARGETID T06569 T06569 FORMERID TTDR00210 T06569 UNIPROID CAH6_HUMAN T06569 TARGNAME Carbonic anhydrase VI (CA-VI) T06569 GENENAME CA6 T06569 TARGTYPE Successful T06569 SYNONYMS Secreted carbonic anhydrase; Salivary carbonic anhydrase; Carbonic anhydrase 6; Carbonate dehydratase VI T06569 FUNCTION Its role in saliva is unknown. Reversible hydration of carbon dioxide. T06569 PDBSTRUC 3FE4 T06569 BIOCLASS Alpha-carbonic anhydrase T06569 ECNUMBER EC 4.2.1.1 T06569 SEQUENCE MRALVLLLSLFLLGGQAQHVSDWTYSEGALDEAHWPQHYPACGGQRQSPINLQRTKVRYNPSLKGLNMTGYETQAGEFPMVNNGHTVQISLPSTMRMTVADGTVYIAQQMHFHWGGASSEISGSEHTVDGIRHVIEIHIVHYNSKYKSYDIAQDAPDGLAVLAAFVEVKNYPENTYYSNFISHLANIKYPGQRTTLTGLDVQDMLPRNLQHYYTYHGSLTTPPCTENVHWFVLADFVKLSRTQVWKLENSLLDHRNKTIHNDYRRTQPLNHRVVESNFPNQEYTLGSEFQFYLHKIEEILDYLRRALN T06569 DRUGINFO D0K1QD Sulfamylon Approved T06569 DRUGINFO D07HBX Salicyclic acid Approved T06569 DRUGINFO D0A8JP PARABEN Phase 3 T06569 DRUGINFO D07SDQ Curcumin Phase 3 T06569 DRUGINFO D43GZX SAR566658 Phase 2 T06569 DRUGINFO D0Y6OA Coumate Phase 2 T06569 DRUGINFO D03SLR FERULIC ACID Patented T06569 DRUGINFO D0LD9S SPERMINE Terminated T06569 DRUGINFO D00IUB 4-CYANOPHENOL Investigative T06569 DRUGINFO D09WVV N1-(2-aminoethyl)ethane-1,2-diamine Investigative T06569 DRUGINFO D0G0FJ 2-hydrazinylbenzenesulfonamide Investigative T06569 DRUGINFO D0LU4S 7-butoxy-2H-chromen-2-one Investigative T06569 DRUGINFO D0OT5L 7-propoxy-2H-chromen-2-one Investigative T06569 DRUGINFO D0TY8X 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide Investigative T06569 DRUGINFO D0X6IE 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide Investigative T06569 DRUGINFO D0Z1HY 4-amino-6-chlorobenzene-1,3-disulfonamide Investigative T06569 DRUGINFO D0ZC3W P-toluenesulfonamide Investigative T06569 DRUGINFO D04VLI 4-(2-Hydroxy-ethyl)-benzenesulfonamide Investigative T06569 DRUGINFO D07TAJ Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate Investigative T06569 DRUGINFO D0OI1H 2-Amino-benzenesulfonamide Investigative T06569 DRUGINFO D0X5HL N1-(naphthalen-1-yl)ethane-1,2-diamine Investigative T06569 DRUGINFO D05XZM 4-(hydroxymethyl)benzenesulfonamide Investigative T06569 DRUGINFO D09JPC Hexane-1,6-diamine Investigative T06569 DRUGINFO D09PWX Carzenide Investigative T06569 DRUGINFO D0L5TZ 6-(hydroxymethyl)-2H-chromen-2-one Investigative T06569 DRUGINFO D0Q2LL 6-Hydroxy-benzothiazole-2-sulfonic acid amide Investigative T06569 DRUGINFO D0U4BB HERNIARIN Investigative T06569 DRUGINFO D00YEF Decane-1,10-diyl disulfamate Investigative T06569 DRUGINFO D01STY 4-Amino-3-iodo-benzenesulfonamide Investigative T06569 DRUGINFO D02QGI Pentane-1,5-diamine Investigative T06569 DRUGINFO D03ZMQ COUMARIN Investigative T06569 DRUGINFO D04CVC 4-Amino-3-fluoro-benzenesulfonamide Investigative T06569 DRUGINFO D05TLB Octyl sulfamate Investigative T06569 DRUGINFO D09WSJ Decyl sulfamate Investigative T06569 DRUGINFO D0AU0M P-Coumaric Acid Investigative T06569 DRUGINFO D0D4OV Octane-1,8-diyl disulfamate Investigative T06569 DRUGINFO D0E8CC BENZOLAMIDE Investigative T06569 DRUGINFO D0M3PO 2,4-Disulfamyltrifluoromethylaniline Investigative T06569 DRUGINFO D0N1AW 6-(aminomethyl)-2H-chromen-2-one Investigative T06569 DRUGINFO D0NN3Q 4-Hydrazino-benzenesulfonamide Investigative T06569 DRUGINFO D0P6AM 4-Amino-3-bromo-benzenesulfonamide Investigative T06569 DRUGINFO D0Q7DJ Syringic Acid Investigative T06569 DRUGINFO D0VD7H CL-5343 Investigative T06569 DRUGINFO D0YU8J 4-Amino-3-chloro-benzenesulfonamide Investigative T06569 DRUGINFO D0V7AA CATECHIN Investigative T06569 DRUGINFO D0Y3TZ GALLICACID Investigative T06569 DRUGINFO D0A1CM ELLAGIC ACID Investigative T68334 TARGETID T68334 T68334 FORMERID TTDS00438 T68334 UNIPROID FSHR_HUMAN T68334 TARGNAME Follicle-stimulating hormone receptor (FSHR) T68334 GENENAME FSHR T68334 TARGTYPE Successful T68334 SYNONYMS LGR1; Follitropin receptor; FSH-R T68334 FUNCTION G protein-coupled receptor for follitropin, the follicle-stimulating hormone. Through cAMP production activates the downstream PI3K-AKT and ERK1/ERK2 signaling pathways. T68334 PDBSTRUC 4MQW; 4AY9; 1XWD; 1XUN T68334 BIOCLASS GPCR rhodopsin T68334 SEQUENCE MALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRVIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLPNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKNGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLENLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQEVDYMTQARGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIMGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIASVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCKVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVLAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVPLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSSTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN T68334 DRUGINFO D02SBQ Urofollitropin Approved T68334 DRUGINFO D04WBY Menotropins Approved T68334 DRUGINFO D0OM3A Follitropin beta Approved T68334 DRUGINFO D0H2UB Suramin Phase 1 T68334 DRUGINFO D02FTU Recombinant follicle stimulating hormone Investigative T68334 DRUGINFO D08MVV PRX-111 Investigative T68334 DRUGINFO D09HCE Long-acting FSH conjugate Investigative T68334 DRUGINFO D0W3SX FSHR NAM Investigative T83011 TARGETID T83011 T83011 FORMERID TTDS00341 T83011 UNIPROID AOFB_HUMAN T83011 TARGNAME Monoamine oxidase type B (MAO-B) T83011 GENENAME MAOB T83011 TARGTYPE Successful T83011 SYNONYMS MAO-B; Amine oxidase [flavin-containing] B T83011 FUNCTION Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine. T83011 PDBSTRUC 6FWC; 6FW0; 6FVZ; 5MRL; 4CRT T83011 BIOCLASS CH-NH(2) donor oxidoreductase T83011 ECNUMBER EC 1.4.3.4 T83011 SEQUENCE MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSYVGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWRTMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEVSALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQTRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVYYKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEERLKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDRIYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTTFLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV T83011 DRUGINFO D06OMW Rasagiline Approved T83011 DRUGINFO D07TGY Indeloxazine Approved T83011 DRUGINFO D0J2MJ Selegiline Hydrochloride Approved T83011 DRUGINFO D0RM9Q Budipine Approved T83011 DRUGINFO D0TV6I Safinamide Approved T83011 DRUGINFO D0XM1A Safinamide mesylate Approved T83011 DRUGINFO D07PAO Sulphadoxine Approved T83011 DRUGINFO D0P9AC Phenelzine Approved T83011 DRUGINFO D0R0UJ Pargyline Approved T83011 DRUGINFO D0H0HJ Tranylcypromine Approved T83011 DRUGINFO D0S2UG Selegiline Approved T83011 DRUGINFO D00VUI Psoralen Phase 3 T83011 DRUGINFO D01NKW P2B-001 Phase 3 T83011 DRUGINFO D08CJK TRYPTAMINE Phase 3 T83011 DRUGINFO D02PSS RG1577 Phase 2 T83011 DRUGINFO D06PHS EVT302 Phase 2 T83011 DRUGINFO DL50ZE ORY-2001 Phase 2 T83011 DRUGINFO D04RCT CHF-3381 Phase 2 T83011 DRUGINFO D0C3UC Ladostigil Phase 2 T83011 DRUGINFO D0D1UQ Neu-120 Phase 1/2 T83011 DRUGINFO D0H7PW PIPERINE Phase 1/2 T83011 DRUGINFO D0W7LO PF9601N Phase 1 T83011 DRUGINFO D00KTI PMID25399762-Compound-Table1-C17 Patented T83011 DRUGINFO D00NDF 3-Hydroxy-2-butanone Patented T83011 DRUGINFO D00VSX PMID25399762-Compound-Table1-C10 Patented T83011 DRUGINFO D00YBT PMID25399762-Compound-Table1-C3 Patented T83011 DRUGINFO D01JDK PMID25399762-Compound-Table1-C13 Patented T83011 DRUGINFO D01PCI PMID25399762-Compound-Table1-C19 Patented T83011 DRUGINFO D02FRR PMID25399762-Compound-Table1-C18 Patented T83011 DRUGINFO D03VOJ 3,4-Dihydroxybenzaldehyde Patented T83011 DRUGINFO D03ZOH 4-Hydroxy-2,5-dimethyl-3(2H)-furanone Patented T83011 DRUGINFO D04FJY PMID25399762-Compound-Table1-C24 Patented T83011 DRUGINFO D04OXC PMID29324067-Compound-38 Patented T83011 DRUGINFO D05UNM PMID25399762-Compound-Table1-C12 Patented T83011 DRUGINFO D06BFA PMID25399762-Compound-Table1-C5 Patented T83011 DRUGINFO D06EIP PMID25399762-Compound-Table1-C9 Patented T83011 DRUGINFO D07GZU PMID25399762-Compound-Table1-C22 Patented T83011 DRUGINFO D07UZL PMID29324067-Compound-40 Patented T83011 DRUGINFO D08YYW PMID25399762-Compound-Table1-C15 Patented T83011 DRUGINFO D09SWE 4-Methoxybenzaldehyde Patented T83011 DRUGINFO D0AF7J PMID25399762-Compound-Table1-C16 Patented T83011 DRUGINFO D0B2YJ PMID25399762-Compound-Table1-C11 Patented T83011 DRUGINFO D0BT3Y Coumaricacid Patented T83011 DRUGINFO D0C2EW PMID25399762-Compound-Table1-C7 Patented T83011 DRUGINFO D0C7LB Lazabemide analog 1 Patented T83011 DRUGINFO D0DM9L PMID25399762-Compound-Table1-C6 Patented T83011 DRUGINFO D0DW5P Schiff base compound 2 Patented T83011 DRUGINFO D0GY4F PMID25399762-Compound-Table1-C8 Patented T83011 DRUGINFO D0HR6P PMID25399762-Compound-Table1-C23 Patented T83011 DRUGINFO D0J3JY PMID25399762-Compound-Table1-C25 Patented T83011 DRUGINFO D0J7HR Secondary and tertiary (hetero)arylamide derivative 1 Patented T83011 DRUGINFO D0K2LB PMID25399762-Compound-Table1-C2 Patented T83011 DRUGINFO D0L9FL Coumarin/resveratrol hybrid derivative 1 Patented T83011 DRUGINFO D0ME4N PMID25399762-Compound-Table 7-Vanillyl alcohol Patented T83011 DRUGINFO D0N3SU Piperonal Patented T83011 DRUGINFO D0N9JJ Ethylvanillin Patented T83011 DRUGINFO D0NH9P 4-Hydroxybenzoicacid Patented T83011 DRUGINFO D0Q1MN PMID25399762-Compound-Table1-C4 Patented T83011 DRUGINFO D0S2LV PMID25399762-Compound-Table1-C21 Patented T83011 DRUGINFO D0TR7N PMID25399762-Compound-Table 7-Veratraldehyde Patented T83011 DRUGINFO D0UA3V PMID25399762-Compound-Table 7-Vanillic acid Patented T83011 DRUGINFO D0UL2R PMID25399762-Compound-Table1-C20 Patented T83011 DRUGINFO D0V2NC PMID25399762-Compound-Table1-C14 Patented T83011 DRUGINFO D0X7BT 4-Hydroxybenzylalcohol Patented T83011 DRUGINFO D0XV2A Benzylcinnamate Patented T83011 DRUGINFO D0Z5VD Coumarin/resveratrol hybrid derivative 2 Patented T83011 DRUGINFO D0Z6ZH PMID25399762-Compound-Table1-C1 Patented T83011 DRUGINFO D00BRD 4-hydroxybenzaldehyde Patented T83011 DRUGINFO D02WXS PMID25399762-Compound-Table 6-11 Patented T83011 DRUGINFO D05RJG Schiff base compound 1 Patented T83011 DRUGINFO D06KBT PMID25399762-Compound-Table 6-13 Patented T83011 DRUGINFO D06QRW Lazabemide Patented T83011 DRUGINFO D06VMN Heteroaryl-cyclopropylamine derivative 3 Patented T83011 DRUGINFO D0AI6J PMID25399762-Compound-Table 6-10 Patented T83011 DRUGINFO D0DL1O Tetra-hydro-oxazolopyridine derivative 2 Patented T83011 DRUGINFO D0E7SF PMID25399762-Compound-Table 6-12 Patented T83011 DRUGINFO D0GQ2Z Tetra-hydro-oxazolopyridine derivative 1 Patented T83011 DRUGINFO D0IO2A PMID25399762-Compound-Table 6-9 Patented T83011 DRUGINFO D0O4QB EUGENOL Patented T83011 DRUGINFO D0PM2S PMID25399762-Compound-Table 6-14 Patented T83011 DRUGINFO D0Q1EG PMID25399762-Compound-Table 6-15 Patented T83011 DRUGINFO D0T9JB Tacrine-coumarin hybrid derivative 1 Patented T83011 DRUGINFO D04OEV Cyclic peptide derivative 1 Patented T83011 DRUGINFO D07NTA Heteroaryl-cyclopropylamine derivative 1 Patented T83011 DRUGINFO D08IOP N-(2-phenylcyclopropyl) amino acid derivative 3 Patented T83011 DRUGINFO D0AA7U PMID29757691-Compound-4 Patented T83011 DRUGINFO D0B5YS T83193 Patented T83011 DRUGINFO D0UL9U N-(2-phenylcyclopropyl) amino acid derivative 1 Patented T83011 DRUGINFO D02EME Tetra-hydro-isoquinoline derivative 3 Patented T83011 DRUGINFO D04AXC Tetra-hydro-isoquinoline derivative 1 Patented T83011 DRUGINFO D04OHC Tarnylcypromine derivative 2 Patented T83011 DRUGINFO D0NB7Z Tetra-hydro-isoquinoline derivative 2 Patented T83011 DRUGINFO D0O7IH Tarnylcypromine derivative 3 Patented T83011 DRUGINFO D0R6RT Tetra-hydro-isoquinoline derivative 4 Patented T83011 DRUGINFO D03SLR FERULIC ACID Patented T83011 DRUGINFO D01LAC MOFEGILINE Discontinued in Phase 3 T83011 DRUGINFO D0E3JL SL-25.1188 Discontinued in Phase 1 T83011 DRUGINFO D0O5QL HT-1067 Discontinued in Phase 1 T83011 DRUGINFO D0P1WB EVT-301 Discontinued in Phase 1 T83011 DRUGINFO D01OLO AS602868 Discontinued in Phase 1 T83011 DRUGINFO D0I9LO RWJ-416457 Preclinical T83011 DRUGINFO D07OLO Milacemide Terminated T83011 DRUGINFO D00AHV SKL-PD Investigative T83011 DRUGINFO D00PJT (S)(+)-7-fluoro-2-p-tolylchroman-4-one Investigative T83011 DRUGINFO D01DEU 2-p-tolyl-4,5-dihydro-1H-imidazole Investigative T83011 DRUGINFO D01FTB 2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole Investigative T83011 DRUGINFO D01GAX 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Investigative T83011 DRUGINFO D01HQV 3-(4-hydroxyphenyl)-6-methyl-2H-chromen-2-one Investigative T83011 DRUGINFO D01JMW 2-Bromo-N-(3-morpholinopropyl)nicotinamide Investigative T83011 DRUGINFO D01KZF (S)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one Investigative T83011 DRUGINFO D01UFM N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide Investigative T83011 DRUGINFO D01VPZ 2-p-tolyl-4H-chromene-4-thione Investigative T83011 DRUGINFO D02AQM VAR-10300 Investigative T83011 DRUGINFO D02KGZ N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide Investigative T83011 DRUGINFO D02KXU (+/-)-7-methoxy-2-p-tolylchroman-4-one Investigative T83011 DRUGINFO D02VIV 2-Hydrazino-3-methyl-4(3H)-quinazolinone Investigative T83011 DRUGINFO D02WOQ (R)(+)-7-fluoro-2-p-tolylchroman-4-one Investigative T83011 DRUGINFO D03BQJ 2-p-tolyl-4H-chromen-4-one Investigative T83011 DRUGINFO D03KYZ (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide Investigative T83011 DRUGINFO D03XQB (+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one Investigative T83011 DRUGINFO D04DCW (+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one Investigative T83011 DRUGINFO D04TGN 4-oxo-4H-chromene-3-carboxylic acid Investigative T83011 DRUGINFO D04TZI Cis-2-fluoro-2-phenylcyclopropanamine Investigative T83011 DRUGINFO D05HVV (R)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide Investigative T83011 DRUGINFO D05ILO (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide Investigative T83011 DRUGINFO D05LMT 2-Phenyl-cyclopropylamine hydrochloride Investigative T83011 DRUGINFO D05OTR (S)-N2-[4-(benzyloxy)benzyl]alaninamide Investigative T83011 DRUGINFO D06AAA Cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine Investigative T83011 DRUGINFO D06ERH CHALCONE Investigative T83011 DRUGINFO D06ETG 4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN Investigative T83011 DRUGINFO D06QNN N-benzyl-2-oxo-2H-chromene-3-carboxamide Investigative T83011 DRUGINFO D07AAZ 4-phenyl-1,2,3,6-tetrahydropyridine Investigative T83011 DRUGINFO D07BAO (R)-3-Prop-2-ynylamino-indan-5-ol Investigative T83011 DRUGINFO D07GUX (E)-6-Styrylisatin Investigative T83011 DRUGINFO D07HFF 7-methoxy-2-p-tolyl-4H-chromene-4-thione Investigative T83011 DRUGINFO D07KCC Butyl-methyl-prop-2-ynyl-amine hydrochloride Investigative T83011 DRUGINFO D07KIB 4-fluoroselegiline Investigative T83011 DRUGINFO D07WIJ (R)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one Investigative T83011 DRUGINFO D07YZD 2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole Investigative T83011 DRUGINFO D08BUB N2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide Investigative T83011 DRUGINFO D08HKC 7-methyl-2-p-tolyl-4H-chromene-4-thione Investigative T83011 DRUGINFO D08IDJ 3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one Investigative T83011 DRUGINFO D08ILX N-(2-Methyl-1H-indol-5-yl)benzamide Investigative T83011 DRUGINFO D09FAD N-isobutyl-2-oxo-2H-chromene-3-carboxamide Investigative T83011 DRUGINFO D09GCE (S)-N2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide Investigative T83011 DRUGINFO D09GQS JD-0100 Investigative T83011 DRUGINFO D09PBW (R)(+)-7-fluoro-2-phenylchroman-4-one Investigative T83011 DRUGINFO D0A2AF N-Methyl-N-Propargyl-1(R)-Aminoindan Investigative T83011 DRUGINFO D0B1XZ (+/-)-2-(4-fluorophenyl)-7-methoxychroman-4-one Investigative T83011 DRUGINFO D0B2TV Cis-2-Fluoro-2-(4-methoxyphenyl)cyclopropylamine Investigative T83011 DRUGINFO D0B3QN (R)(+)-7-methyl-2-phenylchroman-4-one Investigative T83011 DRUGINFO D0BV8Y LU-53439 Investigative T83011 DRUGINFO D0C9GI 7-fluoro-2-p-tolyl-4H-chromen-4-one Investigative T83011 DRUGINFO D0D2JH (+/-)-7-fluoro-2-(4-fluorophenyl)chroman-4-one Investigative T83011 DRUGINFO D0E4HB 2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole Investigative T83011 DRUGINFO D0EX4L Methyl piperate Investigative T83011 DRUGINFO D0F2SM (R)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one Investigative T83011 DRUGINFO D0F7KG L-136662 Investigative T83011 DRUGINFO D0FH5A 2-methyl-9H-indeno[2,1-d]pyrimidin-9-one Investigative T83011 DRUGINFO D0FR3X (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide Investigative T83011 DRUGINFO D0G2LF [(1e)-4-Phenylbut-1-Enyl]Benzene Investigative T83011 DRUGINFO D0G5YA (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide Investigative T83011 DRUGINFO D0G6MA 2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one Investigative T83011 DRUGINFO D0H3RQ 8-Bromo-6-methyl-3-(4'-methoxyphenyl)coumarin Investigative T83011 DRUGINFO D0I2GP 2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole Investigative T83011 DRUGINFO D0I5CZ (S)(+)-7-fluoro-2-phenylchroman-4-one Investigative T83011 DRUGINFO D0I6GH 3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one Investigative T83011 DRUGINFO D0I9AA 7-fluoro-2-p-tolyl-4H-chromene-4-thione Investigative T83011 DRUGINFO D0IK2S (+/-)-7-fluoro-2-phenylchroman-4-one Investigative T83011 DRUGINFO D0IN0X (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide Investigative T83011 DRUGINFO D0J0MX 1,4-diphenyl-(1E,3E)-1,3-butadiene Investigative T83011 DRUGINFO D0JY9B (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide Investigative T83011 DRUGINFO D0K0SA N-(2-aminoethyl)-p-chlorobenzamide Investigative T83011 DRUGINFO D0K1FE 8-Bromo-6-methyl-3-phenylcoumarin Investigative T83011 DRUGINFO D0K4GD RS-1636 Investigative T83011 DRUGINFO D0K5LJ N-Propargyl-1(S)-Aminoindan Investigative T83011 DRUGINFO D0K8EE NSC-93405 Investigative T83011 DRUGINFO D0L6HE (S)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one Investigative T83011 DRUGINFO D0M0CF Farnesol Investigative T83011 DRUGINFO D0MX1T Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine Investigative T83011 DRUGINFO D0N4DR (S)(+)-7-methyl-2-phenylchroman-4-one Investigative T83011 DRUGINFO D0N6JE Methyl-pentyl-prop-2-ynyl-amine oxalic acid Investigative T83011 DRUGINFO D0O0MY (+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one Investigative T83011 DRUGINFO D0O1GE 3-(3-methoxyphenyl)-6-methyl-2H-chromen-2-one Investigative T83011 DRUGINFO D0OW5Y NW-1772 Investigative T83011 DRUGINFO D0P1YC (R)(+)-7-methyl-2-p-tolylchroman-4-one Investigative T83011 DRUGINFO D0P7SY 2-(4-methoxyphenyl)-4H-chromene-4-thione Investigative T83011 DRUGINFO D0Q3VS 2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole Investigative T83011 DRUGINFO D0R3LP (+/-)-2-p-tolylchroman-4-one Investigative T83011 DRUGINFO D0R7UO 5-Aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one Investigative T83011 DRUGINFO D0R9TX 3-(4-methoxyphenyl)-6-methyl-2H-chromen-2-one Investigative T83011 DRUGINFO D0SP2O 1H-Indole-2,3-dione Investigative T83011 DRUGINFO D0T1GP (+/-)-7-methyl-2-phenylchroman-4-one Investigative T83011 DRUGINFO D0T3ZS (+/-)-2-(4'-Benzyloxyphenyl)thiomorpholin-5-one Investigative T83011 DRUGINFO D0T7EJ N2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide Investigative T83011 DRUGINFO D0T7VA NSC-50187 Investigative T83011 DRUGINFO D0T8AD (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide Investigative T83011 DRUGINFO D0TB1E (S)(+)-7-methyl-2-p-tolylchroman-4-one Investigative T83011 DRUGINFO D0U4JD (S)-N2-[4-(benzyloxy)benzyl]serinamide Investigative T83011 DRUGINFO D0U8ET 3-(2-Bromophenyl)-6-methylcoumarin Investigative T83011 DRUGINFO D0UF1R 1,2,3,4-Tetrahydro-naphthalen-1-ylamine Investigative T83011 DRUGINFO D0UL6Y Cis-2-(para-fluorophenyl)cyclopropylamine Investigative T83011 DRUGINFO D0US0J CORDOIN Investigative T83011 DRUGINFO D0V4KL VAR-10200 Investigative T83011 DRUGINFO D0W1WE N-Methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide Investigative T83011 DRUGINFO D0W7XK 7-fluoro-2-(4-methoxyphenyl)-4H-chromen-4-one Investigative T83011 DRUGINFO D0X3SE Isopropyl-methyl-prop-2-ynyl-amine hydrochloride Investigative T83011 DRUGINFO D0Y0JM Benzyl-methyl-[1-(1H-pyrrol-2-yl)-vinyl]-amine Investigative T83011 DRUGINFO D0Y0KU (+/-)-7-fluoro-2-p-tolylchroman-4-one Investigative T83011 DRUGINFO D0Y5OB 7-fluoro-2-(4-fluorophenyl)-4H-chromene-4-thione Investigative T83011 DRUGINFO D0Y8AN Deprenyl Investigative T83011 DRUGINFO D0Z2NN Heptyl-methyl-prop-2-ynyl-amine hydrochloride Investigative T83011 DRUGINFO D0Z2XR (+/-)-7-methyl-2-p-tolylchroman-4-one Investigative T83011 DRUGINFO D0ZH0T (+/-)-2-(4-fluorophenyl)chroman-4-one Investigative T83011 DRUGINFO D0ZI0S 7-methoxy-2-p-tolyl-4H-chromen-4-one Investigative T83011 DRUGINFO D00HVZ (+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one Investigative T83011 DRUGINFO D00KDZ N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine Investigative T83011 DRUGINFO D00OLX 8-(3-Methylbenzyloxy)caffeine Investigative T83011 DRUGINFO D00OQL 7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin Investigative T83011 DRUGINFO D00WSM 2-oxo-N-m-tolyl-2H-chromene-3-carboxamide Investigative T83011 DRUGINFO D00WVG 2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole Investigative T83011 DRUGINFO D01LUB 4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin Investigative T83011 DRUGINFO D01PES N-(1H-Indol-2-ylmethyl)-N-phenylamine Investigative T83011 DRUGINFO D01SBZ 1-(4-(benzyloxy)phenyl)propan-2-amine Investigative T83011 DRUGINFO D02BBT 2-Bromo-N-(2-morpholinoethyl)nicotinamide Investigative T83011 DRUGINFO D02FJX 8-[(3-Trifluoromethyl)benzyloxy]caffeine Investigative T83011 DRUGINFO D02IDM (6-Methoxy-2-naphthyl)-2-aminopropane Investigative T83011 DRUGINFO D02QBV N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide Investigative T83011 DRUGINFO D02TFD (7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile Investigative T83011 DRUGINFO D02UVG 7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83011 DRUGINFO D03HXD (6-Benzyloxy-2-naphthyl)-2-aminopropane Investigative T83011 DRUGINFO D03KDD N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine Investigative T83011 DRUGINFO D03LGV Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine Investigative T83011 DRUGINFO D03PXS 2-oxo-N-phenyl-2H-chromene-3-carboxamide Investigative T83011 DRUGINFO D03XKJ N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide Investigative T83011 DRUGINFO D04FLL (+/-)-2-Phenylthiomorpholin-5-one Investigative T83011 DRUGINFO D04GVX 6-Bromo-4,9-dihydro-3H-beta-carboline Investigative T83011 DRUGINFO D04LPY 8-(3-Fluorobenzyloxy)caffeine Investigative T83011 DRUGINFO D04QRS PNU-22394 Investigative T83011 DRUGINFO D04ZPU 2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole Investigative T83011 DRUGINFO D05ANK N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine Investigative T83011 DRUGINFO D05FMZ C-(1H-Indol-3-yl)-methylamine Investigative T83011 DRUGINFO D05FQN 7-Methoxy-9H-beta-carboline Investigative T83011 DRUGINFO D05GQQ 6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83011 DRUGINFO D05WQN N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide Investigative T83011 DRUGINFO D06AJP (E)-5-(3-Chlorostyryl)isatin Investigative T83011 DRUGINFO D07LCU N-(3-Phenylpropyl)-1H-indole-2-carboxamide Investigative T83011 DRUGINFO D07NBB 8-(3-Bromobenzyloxy)caffeine Investigative T83011 DRUGINFO D08CNS IPRONIAZIDE Investigative T83011 DRUGINFO D08FFH 7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin Investigative T83011 DRUGINFO D08FXH (+/-)-2-(4'-Propoxyphenyl)thiomorpholine Investigative T83011 DRUGINFO D08HAM 5-Bromo-4,9-dihydro-3H-beta-carboline Investigative T83011 DRUGINFO D08HNJ N-(4-Phenylbutyl)-1H-indole-2-carboxamide Investigative T83011 DRUGINFO D08NQM 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE Investigative T83011 DRUGINFO D08PHY Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine Investigative T83011 DRUGINFO D08QVY 5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one Investigative T83011 DRUGINFO D08SRB Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate Investigative T83011 DRUGINFO D08SSS (S)-2-amino-1-(4-propylthiophenyl)-propane Investigative T83011 DRUGINFO D08TFN (+/-)-2-(4'-Methoxyphenyl)thiomorpholine Investigative T83011 DRUGINFO D08YCE 8-(3-Chlorobenzyloxy)caffeine Investigative T83011 DRUGINFO D09HBX Trans-2-fluoro-2-phenylcyclopropylamin Investigative T83011 DRUGINFO D09NNZ 3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide Investigative T83011 DRUGINFO D09XSB (E)-5-Styrylisatin Investigative T83011 DRUGINFO D09ZDQ 2-Furan-2-yl-4,5-dihydro-1H-imidazole Investigative T83011 DRUGINFO D0A1RE 4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one Investigative T83011 DRUGINFO D0A2FO (+/-)-7-methoxy-2-phenylchroman-4-one Investigative T83011 DRUGINFO D0A4AB 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline Investigative T83011 DRUGINFO D0A4IY HYDRAZINECARBOXAMIDE Investigative T83011 DRUGINFO D0B1WD N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide Investigative T83011 DRUGINFO D0B4VE Flavanone Investigative T83011 DRUGINFO D0B6MV 8-(3-Methoxybenzyloxy)caffeine Investigative T83011 DRUGINFO D0C7PD 6-Methoxy-4,9-dihydro-3H-beta-carboline Investigative T83011 DRUGINFO D0C9WW 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin Investigative T83011 DRUGINFO D0D1PE CGS-19281A Investigative T83011 DRUGINFO D0D2YR 9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83011 DRUGINFO D0D5KD (+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one Investigative T83011 DRUGINFO D0D6OR (+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine Investigative T83011 DRUGINFO D0D6QI 3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide Investigative T83011 DRUGINFO D0E8IE 4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid Investigative T83011 DRUGINFO D0F2DC Trans-2-fluoro-2-p-tolylcyclopropanamine Investigative T83011 DRUGINFO D0F7JK N-Methyl,N-phenyl-1H-indole-2-carboxamide Investigative T83011 DRUGINFO D0G4BG N-(propargyl),N-(pyrrol-2-ylmethyl)amine Investigative T83011 DRUGINFO D0G8BT 4,9-Dihydro-3H-beta-carboline Investigative T83011 DRUGINFO D0H0GZ 2-oxo-N-p-tolyl-2H-chromene-3-carboxamide Investigative T83011 DRUGINFO D0HU4J (+/-)-2-Phenylthiomorpholine Investigative T83011 DRUGINFO D0ID3Y (+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one Investigative T83011 DRUGINFO D0IP7L (6-Propoxy-2-naphthyl)-2-aminopropane Investigative T83011 DRUGINFO D0J0QW (+/-)-2-(4'-Ethoxyphenyl)thiomorpholine Investigative T83011 DRUGINFO D0JN9R 8-Benzyloxycaffeine Investigative T83011 DRUGINFO D0K9UN N-Phenyl-1H-indole-2-carboxamide Investigative T83011 DRUGINFO D0L5EW (6-Ethoxy-2-naphthyl)-2-aminopropane Investigative T83011 DRUGINFO D0M0XR (R/R)BEFLOXATONE Investigative T83011 DRUGINFO D0M4GR (+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one Investigative T83011 DRUGINFO D0M7WE 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole Investigative T83011 DRUGINFO D0MO1O N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine Investigative T83011 DRUGINFO D0N8UE N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine Investigative T83011 DRUGINFO D0N9FH 2-Phenoxymethyl-4,5-dihydro-1H-imidazole Investigative T83011 DRUGINFO D0NS9X 2-Chloro-N-(3-morpholinopropyl)nicotinamide Investigative T83011 DRUGINFO D0O2UK N-(benzyl),N-(pyrrol-2-ylmethyl)amine Investigative T83011 DRUGINFO D0P1UC 2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole Investigative T83011 DRUGINFO D0P4GF 3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin Investigative T83011 DRUGINFO D0Q1IP 2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole Investigative T83011 DRUGINFO D0Q9NC 2-phenyl-9H-indeno[2,1-d]pyrimidine Investigative T83011 DRUGINFO D0R5EW 2-Chloro-N-(2-morpholinoethyl)nicotinamide Investigative T83011 DRUGINFO D0S0JH 6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one Investigative T83011 DRUGINFO D0S3QN 2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide Investigative T83011 DRUGINFO D0S7FP (R)-Indan-1-yl-methyl-prop-2-ynyl-amine Investigative T83011 DRUGINFO D0T1FJ 4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one Investigative T83011 DRUGINFO D0T3XC (+/-)-2-(4'-Butoxyphenyl)thiomorpholine Investigative T83011 DRUGINFO D0T6XC N2-[4-(benzyloxy)benzyl]glycinamide Investigative T83011 DRUGINFO D0TL3S 3,4-Benzo-7-acetonyloxy-8-methoxycoumarin Investigative T83011 DRUGINFO D0V0TN N-Benzyl,N-methyl-1H-indole-2-carboxamide Investigative T83011 DRUGINFO D0V3NT TOLOXATONE Investigative T83011 DRUGINFO D0W4TW 7-Bromo-4,9-dihydro-3H-beta-carboline Investigative T83011 DRUGINFO D0X8HH (E)-5-(3-Fluorostyryl)isatin Investigative T83011 DRUGINFO D0X8RN Cis-2-phenylcyclopropylamine Investigative T83011 DRUGINFO D0YO7C N-(2-Phenylethyl)-1H-indole-2-carboxamide Investigative T83011 DRUGINFO D0Z0ZU (S)-2-amino-1-(4-butylthiophenyl)-propane Investigative T83011 DRUGINFO D0Z5BU (+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one Investigative T83011 DRUGINFO D0Z5YO N-Benzyl-1H-indole-2-carboxamide Investigative T83011 DRUGINFO D0Z7NC 2-Phenethyl-4,5-dihydro-1H-imidazole Investigative T83011 DRUGINFO D00NSA 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83011 DRUGINFO D06BAC 8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83011 DRUGINFO D0C7PY Lauryl Dimethylamine-N-Oxide Investigative T83011 DRUGINFO D0G2EF 8-Bromo-4,9-dihydro-3H-beta-carboline Investigative T83011 DRUGINFO D0J3SN 6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83011 DRUGINFO D0L8ND 5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83011 DRUGINFO D0Q3VI 8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83011 DRUGINFO D0V6XA 5-Methoxy-4,9-dihydro-3H-beta-carboline Investigative T83011 DRUGINFO D0Y1GL 8-Methoxy-4,9-dihydro-3H-beta-carboline Investigative T83011 DRUGINFO D0TU7I (E)-8-(3-chlorostyryl)-caffeine Investigative T83011 DRUGINFO D09BIV TRACIZOLINE Investigative T83011 DRUGINFO D0LI3J 2-BFi Investigative T83011 DRUGINFO D03LPH TRYPTOLINE Investigative T83011 DRUGINFO D05GDP 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T83011 DRUGINFO D0C1SE 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole Investigative T83011 DRUGINFO D0I4ME MMDA Investigative T83011 DRUGINFO D0R7ZC Beta-methoxyamphetamine Investigative T83011 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T31391 TARGETID T31391 T31391 FORMERID TTDS00093 T31391 UNIPROID DPP4_HUMAN T31391 TARGNAME Dipeptidyl peptidase 4 (DPP-4) T31391 GENENAME DPP4 T31391 TARGTYPE Successful T31391 SYNONYMS Tcell activation antigen CD26; TP103; T-cell activation antigen CD26; Dipeptidyl peptidase IV; Dipeptidyl peptidase 4 soluble form; DPP-IV; DPP IV; DPP 4; CD26; Adenosine deaminase complexing protein-2; Adenosine deaminase complexing protein 2; ADCP2; ADCP-2; ADABP T31391 FUNCTION Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones. Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline. Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. T31391 PDBSTRUC 6B1O; 6B1E; 5ZID; 5Y7K; 5Y7J T31391 BIOCLASS Peptidase T31391 ECNUMBER EC 3.4.14.5 T31391 SEQUENCE MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLKNTYRLKLYSLRWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSFYSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKYPLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP T31391 DRUGINFO D02EYG Linagliptin Approved T31391 DRUGINFO D05IPF Kombiglyze XR/Komboglyze FDC Approved T31391 DRUGINFO D0K9MY Saxagliptin Approved T31391 DRUGINFO D0L3DK Vildagliptin Approved T31391 DRUGINFO D0NJ5H Alogliptin Approved T31391 DRUGINFO D0T8XB Anagliptin Approved T31391 DRUGINFO D0U2JP Sitagliptin Approved T31391 DRUGINFO D0Y6QC Dapagliflozin Propanediol; Saxagliptin Hydrochloride Approved T31391 DRUGINFO D02ZBW LC-150444 Phase 3 T31391 DRUGINFO D04XIO Dutogliptin Phase 3 T31391 DRUGINFO D0M3XR MK-3102 Phase 3 T31391 DRUGINFO D0N6SO SYR-472 Phase 3 T31391 DRUGINFO D0N7JZ SAND-26 Phase 3 T31391 DRUGINFO D0V0KJ IDDBCP161883 Phase 3 T31391 DRUGINFO D0ZD3C Gemigliptin Phase 3 T31391 DRUGINFO D09XMX SaxaDapa FDC Phase 3 T31391 DRUGINFO D06VCN Denagliptin Phase 2/3 T31391 DRUGINFO D03SKC KRP-104 Phase 2 T31391 DRUGINFO D06VMJ Melogliptin Phase 2 T31391 DRUGINFO D07HZG PF-00734200 Phase 2 T31391 DRUGINFO D0H2IO P32/98 Phase 2 T31391 DRUGINFO D0E3HY IP10 C8 Phase 2 T31391 DRUGINFO D05VXF YSCMA Phase 1/2 T31391 DRUGINFO D03JWU REC-01 Phase 1 T31391 DRUGINFO D05LPW DA-1229 Phase 1 T31391 DRUGINFO D07EPV Teneligliptin Phase 1 T31391 DRUGINFO D0BA5E ZYDPLA 1 Phase 1 T31391 DRUGINFO D0Z1OS ARI-2243 Phase 1 T31391 DRUGINFO D00GNP Triazole piperazine derivative 1 Patented T31391 DRUGINFO D01MMT PMID25482888-Compound-13 Patented T31391 DRUGINFO D02LNB PMID25482888-Compound-15 Patented T31391 DRUGINFO D02SUS Imidazo cyclohexylamine derivative 1 Patented T31391 DRUGINFO D02UOW Beta-phe compound 2 Patented T31391 DRUGINFO D04MAZ Pyrimidine derivative 33 Patented T31391 DRUGINFO D04UXC Imidazo cyclohexylamine derivative 3 Patented T31391 DRUGINFO D04XXF Peptide analog 49 Patented T31391 DRUGINFO D05GEY PMID25482888-Compound-21 Patented T31391 DRUGINFO D05HLQ Quinazoline derivative 1 Patented T31391 DRUGINFO D05LJQ Peptide analog 48 Patented T31391 DRUGINFO D06GQG PMID25482888-Compound-16 Patented T31391 DRUGINFO D06PDK PMID25482888-Compound-52 Patented T31391 DRUGINFO D06PIP Aminopiperidine derivative 2 Patented T31391 DRUGINFO D07JJT Pyrimidine derivative 31 Patented T31391 DRUGINFO D0A5QV PMID25482888-Compound-34 Patented T31391 DRUGINFO D0A6LI Aminopiperidine derivative 1 Patented T31391 DRUGINFO D0B4CH Peptide analog 45 Patented T31391 DRUGINFO D0BJ2X PMID25482888-Compound-37 Patented T31391 DRUGINFO D0BY2H Peptide analog 50 Patented T31391 DRUGINFO D0CW9H Pyrimidine derivative 32 Patented T31391 DRUGINFO D0E8AS Tricyclic heterocycle derivative 6 Patented T31391 DRUGINFO D0E8WW Peptide analog 46 Patented T31391 DRUGINFO D0E9MO PMID25482888-Compound-14 Patented T31391 DRUGINFO D0EL5B Pyrrolo[1,2-f]triazine derivative 2 Patented T31391 DRUGINFO D0G1CF PMID25482888-Compound-71 Patented T31391 DRUGINFO D0G3IL PMID25482888-Compound-17 Patented T31391 DRUGINFO D0IO0M Beta-phe compound 3 Patented T31391 DRUGINFO D0J0UN PMID25482888-Compound-69 Patented T31391 DRUGINFO D0J4KQ Peptide analog 51 Patented T31391 DRUGINFO D0J5EW Pyrimidinedione derivative 1 Patented T31391 DRUGINFO D0JP6A PMID25482888-Compound-6 Patented T31391 DRUGINFO D0K2ZQ Xanthine/amino piperidine compound 1 Patented T31391 DRUGINFO D0K5YJ PMID25482888-Compound-50 Patented T31391 DRUGINFO D0KR7R PMID25482888-Compound-18 Patented T31391 DRUGINFO D0KS8Y Imidazo cyclohexylamine derivative 2 Patented T31391 DRUGINFO D0LG1I PMID25482888-Compound-12 Patented T31391 DRUGINFO D0N9CV PMID25482888-Compound-11 Patented T31391 DRUGINFO D0ND5K Xanthine derivative 1 Patented T31391 DRUGINFO D0O6SK Triazolo-pyrimidinedione derivative 2 Patented T31391 DRUGINFO D0P3DS Pyrrolo[1,2-f]triazine derivative 1 Patented T31391 DRUGINFO D0PF2W PMID25482888-Compound-72 Patented T31391 DRUGINFO D0PM4N Triazolo-pyrimidinedione derivative 1 Patented T31391 DRUGINFO D0QE8Z Peptide analog 44 Patented T31391 DRUGINFO D0RT1R Pyrimidine derivative 30 Patented T31391 DRUGINFO D0T1WB PMID25482888-Compound-70 Patented T31391 DRUGINFO D0T6SD PMID25482888-Compound-56 Patented T31391 DRUGINFO D0UV3I Imidazo pyridine derivative 2 Patented T31391 DRUGINFO D0W6HL Beta-phe compound 1 Patented T31391 DRUGINFO D0WE8K Peptide analog 47 Patented T31391 DRUGINFO D0XB0Q Dihydropyrrolopyrazole derivative 1 Patented T31391 DRUGINFO D0XN3O PMID25482888-Compound-38 Patented T31391 DRUGINFO D06HJX Thiomorpholine derivative 1 Patented T31391 DRUGINFO D0D4BP Thiomorpholine derivative 2 Patented T31391 DRUGINFO D00FYF NVP-DPP728 Discontinued in Phase 2 T31391 DRUGINFO D0E4EZ R-1438 Discontinued in Phase 2 T31391 DRUGINFO D0FD0B PSN-9301 Discontinued in Phase 2 T31391 DRUGINFO D0H2KV ALS 2-0426 Discontinued in Phase 2 T31391 DRUGINFO D0JA1Z TA-6666 Discontinued in Phase 2 T31391 DRUGINFO D0A1NU ABT-279 Discontinued in Phase 1 T31391 DRUGINFO D0Q4YP TAK-100 Discontinued in Phase 1 T31391 DRUGINFO D0X5ZO SSR-162369 Discontinued in Phase 1 T31391 DRUGINFO D0O6DC LY-2463665 Preclinical T31391 DRUGINFO D0Q6ED ASP8497 Preclinical T31391 DRUGINFO D0XL4I ER-319711-15 Preclinical T31391 DRUGINFO D7K0GP PT630 Preclinical T31391 DRUGINFO D0F3TI PT-630 Terminated T31391 DRUGINFO D0M9SL DSP-7238 Terminated T31391 DRUGINFO D00HSG (2-(2-chlorophenyl)pyridin-3-yl)methanamine Investigative T31391 DRUGINFO D00KMP 3-butyl-1-(naphthalen-1-yl)piperidin-4-amine Investigative T31391 DRUGINFO D01KRQ EMC-0901 Investigative T31391 DRUGINFO D01OUJ D-Val-L-boroPro Investigative T31391 DRUGINFO D01ZWF BPI-711001 Investigative T31391 DRUGINFO D02RIE 4-(2,4-dichlorophenyl)-1-tosylpyrrolidin-3-amine Investigative T31391 DRUGINFO D02WBC 2-(2-chlorophenyl)-2-morpholinoethanamine Investigative T31391 DRUGINFO D03FDC Diisopropylphosphono Group Investigative T31391 DRUGINFO D04CAR (R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid Investigative T31391 DRUGINFO D04QDB ABT-341 Investigative T31391 DRUGINFO D05LYC KR-62436 Investigative T31391 DRUGINFO D05TKO Retagliptin Investigative T31391 DRUGINFO D05UUA (+/-)-6-(2-chlorophenyl)cyclohex-3-enamine Investigative T31391 DRUGINFO D05WKT PK-44 Investigative T31391 DRUGINFO D05XWX FE 999011 Investigative T31391 DRUGINFO D06AUB 1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine Investigative T31391 DRUGINFO D06NRU C-(2'-Chloro-biphenyl-2-yl)-methylamine Investigative T31391 DRUGINFO D06UKY 4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine Investigative T31391 DRUGINFO D07HWI (1R,2S)-1,2-diphenylethane-1,2-diamine Investigative T31391 DRUGINFO D07IJU (S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone Investigative T31391 DRUGINFO D07VDJ (2s)-Pyrrolidin-2-Ylmethylamine Investigative T31391 DRUGINFO D09BYA (3S,4R)-3-butyl-1-phenylpiperidin-4-amine Investigative T31391 DRUGINFO D09MVE 1-biphenyl-2-ylmethanamine Investigative T31391 DRUGINFO D0C2NQ L-Val-L-boroPro Investigative T31391 DRUGINFO D0D9ON Iodo-Phenylalanine Investigative T31391 DRUGINFO D0FH8R DB-160 Investigative T31391 DRUGINFO D0IQ4S L-Ala-L-boroPro Investigative T31391 DRUGINFO D0JI3S 1-benzhydryl-3-butylpiperidin-4-amine Investigative T31391 DRUGINFO D0L1NF D-420720 Investigative T31391 DRUGINFO D0L5RI (S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione Investigative T31391 DRUGINFO D0L9XR 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One Investigative T31391 DRUGINFO D0N1FU N-isoleucylthiazolidine Investigative T31391 DRUGINFO D0N1QQ DIPROTIN A Investigative T31391 DRUGINFO D0N3YL ASC-201 Investigative T31391 DRUGINFO D0N5CI (5-phenyl-3H-benzo[d]imidazol-4-yl)methanamine Investigative T31391 DRUGINFO D0O9RD (S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone Investigative T31391 DRUGINFO D0P5OE (1R,2R)-1,2-diphenylethane-1,2-diamine Investigative T31391 DRUGINFO D0PB2M 4-iodophenyl-alaninyl-(S)-2-cyano-pyrrolidine Investigative T31391 DRUGINFO D0R5OE (S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone Investigative T31391 DRUGINFO D0T2EW Cyclohexylglycine-(2S)-cyanopyrrolidine Investigative T31391 DRUGINFO D0T8UH E-3024 Investigative T31391 DRUGINFO D0W4GM (1-phenylcyclopentyl)methanamine Investigative T31391 DRUGINFO D0X2JG (2-chloro-6-phenoxyphenyl)methanamine Investigative T31391 DRUGINFO D07ALM N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine Investigative T31391 DRUGINFO D08NMS PMID20684603C24dd Investigative T31391 DRUGINFO D0G6XS Fucose Investigative T31391 DRUGINFO D07LUR Alpha-D-Mannose Investigative T61744 TARGETID T61744 T61744 FORMERID TTDS00280 T61744 UNIPROID PDE4A_HUMAN T61744 TARGNAME Phosphodiesterase 4A (PDE4A) T61744 GENENAME PDE4A T61744 TARGTYPE Successful T61744 SYNONYMS cAMP-specific 3',5'-cyclic phosphodiesterase 4A; Type 4A cAMP phosphodiesterase; PDE46; DPDE2 T61744 FUNCTION Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. T61744 PDBSTRUC 3TVX; 3I8V; 2QYK T61744 BIOCLASS Phosphoric diester hydrolase T61744 ECNUMBER EC 3.1.4.53 T61744 SEQUENCE MEPPTVPSERSLSLSLPGPREGQATLKPPPQHLWRQPRTPIRIQQRGYSDSAERAERERQPHRPIERADAMDTSDRPGLRTTRMSWPSSFHGTGTGSGGAGGGSSRRFEAENGPTPSPGRSPLDSQASPGLVLHAGAATSQRRESFLYRSDSDYDMSPKTMSRNSSVTSEAHAEDLIVTPFAQVLASLRSVRSNFSLLTNVPVPSNKRSPLGGPTPVCKATLSEETCQQLARETLEELDWCLEQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNEVEIPSPTMKEREKQQAPRPRPSQPPPPPVPHLQPMSQITGLKKLMHSNSLNNSNIPRFGVKTDQEELLAQELENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPCTAQEALTAQGLSGVEEALDATIAWEASPAQESLEVMAQEASLEAELEAVYLTQQAQSTGSAPVAPDEFSSREEFVVAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLPSTAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT T61744 DRUGINFO D02PWM Dyphylline Approved T61744 DRUGINFO D09AMZ Enprofylline Approved T61744 DRUGINFO D01XHG DENBUFYLLINE Phase 3 T61744 DRUGINFO D06VFP SOTB07 Phase 3 T61744 DRUGINFO D00JED AN-2898 Phase 2 T61744 DRUGINFO D01XFZ GPD-1116 Phase 2 T61744 DRUGINFO D02POH TA-7906 Phase 2 T61744 DRUGINFO D07OCV HT-0712 Phase 2 T61744 DRUGINFO D09TFB TOFIMILAST Phase 2 T61744 DRUGINFO D0F4TV AWD-12-281 Phase 2 T61744 DRUGINFO D0F5IY LIRIMILAST Phase 2 T61744 DRUGINFO D0L8KJ Oglemilast Phase 2 T61744 DRUGINFO D0M7CB MK-0873 Phase 2 T61744 DRUGINFO D0RJ1W OX-914 Phase 2 T61744 DRUGINFO D0U2DH CC-1088 Phase 2 T61744 DRUGINFO D0X0PW Revamilast Phase 2 T61744 DRUGINFO D0Z2FB Piclamilast Phase 2 T61744 DRUGINFO DB82TO Tofisopam Phase 2 T61744 DRUGINFO D01WZL AVE-8112 Phase 1 T61744 DRUGINFO D03CWX MEM-1414 Phase 1 T61744 DRUGINFO D0K9DI GSK-356278 Phase 1 T61744 DRUGINFO D0O8JW Ronomilast Phase 1 T61744 DRUGINFO D02EMR Cilomilast Discontinued in Phase 3 T61744 DRUGINFO D0U7PS GSK256066 Discontinued in Phase 2 T61744 DRUGINFO D00DBE CI-1018 Discontinued in Phase 2 T61744 DRUGINFO D03ZVD KW-4490 Discontinued in Phase 2 T61744 DRUGINFO D08SNX V-11294A Discontinued in Phase 2 T61744 DRUGINFO D0I0GM Daxalipram Discontinued in Phase 2 T61744 DRUGINFO D0UG4T CDP840 Discontinued in Phase 2 T61744 DRUGINFO D0V2CN LAS-37779 Discontinued in Phase 2 T61744 DRUGINFO D01FXD SCH-351591 Discontinued in Phase 1 T61744 DRUGINFO D0C7JT YM-976 Discontinued in Phase 1 T61744 DRUGINFO D0K1OA D-4418 Discontinued in Phase 1 T61744 DRUGINFO D01OUA TJN-598 Terminated T61744 DRUGINFO D01QUF GW-3600 Terminated T61744 DRUGINFO D07UHY NIK-616 Terminated T61744 DRUGINFO D0F7TV Torbafylline Terminated T61744 DRUGINFO D0R1QJ D-22888 Terminated T61744 DRUGINFO D01CAY 2,5-Bis-(3,4-dimethoxy-phenyl)-furan Investigative T61744 DRUGINFO D04XRV 6-Azido-8-(3-iodo-phenyl)-quinoline Investigative T61744 DRUGINFO D0J4AT 4-(2,5-Diphenyl-furan-3-yl)-morpholine Investigative T61744 DRUGINFO D0K4HG 8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline Investigative T61744 DRUGINFO D0L0NY 6-Imidazol-1-ylmethyl-8-phenyl-quinoline Investigative T61744 DRUGINFO D0N2KP 2,5-Bis-(3-cyclopentyloxy-4-methoxy-phenyl)-furan Investigative T61744 DRUGINFO D0V1IM L-791943 Investigative T61744 DRUGINFO D0V8DB 8-(3-Azido-phenyl)-6-iodo-quinoline Investigative T61744 DRUGINFO D0W7BI (2,5-Diphenyl-furan-3-yl)-phenyl-methanone Investigative T61744 DRUGINFO D0Y3PP NIS-62949 Investigative T61744 DRUGINFO D0Z5SB 8-(3-Azido-phenyl)-6-pyridin-4-ylmethyl-quinoline Investigative T61744 DRUGINFO D00JBC 1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione Investigative T61744 DRUGINFO D00TQR 1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione Investigative T61744 DRUGINFO D02NKD 8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine Investigative T61744 DRUGINFO D02NWF Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine Investigative T61744 DRUGINFO D09AUL Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine Investigative T61744 DRUGINFO D0DL6J CI-1044 Investigative T61744 DRUGINFO D0O3BL RS-14491 Investigative T61744 DRUGINFO D0V5BX NITRAQUAZONE Investigative T61744 DRUGINFO D01RUN (R)-Rolipram Investigative T61744 DRUGINFO D01TOR Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine Investigative T61744 DRUGINFO D02FZD (S)-Rolipram Investigative T61744 DRUGINFO D04BMR AL-59640 Investigative T61744 DRUGINFO D04JNC ZL-N-91 Investigative T61744 DRUGINFO D05YEL CH-3697 Investigative T61744 DRUGINFO D0E5VP KF-66490 Investigative T61744 DRUGINFO D0J7GF Benzyl-(2-phenyl-quinazolin-4-yl)-amine Investigative T61744 DRUGINFO D0JD4C L-454560 Investigative T61744 DRUGINFO D0K9PS CHF-5480 Investigative T61744 DRUGINFO D0N7HS ASP-3258 Investigative T61744 DRUGINFO D0S1HX TAS-203 Investigative T61744 DRUGINFO D0S6MA OCID-2987 Investigative T61744 DRUGINFO D0U4SS CD-160130 Investigative T61744 DRUGINFO D0U8YQ Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine Investigative T61744 DRUGINFO D0W7WV L-869298 Investigative T61744 DRUGINFO D00QCL SOPHOFLAVESCENOL Investigative T61744 DRUGINFO D02ZPV UCB-101333-3 Investigative T61744 DRUGINFO D0P2HX RS-25344 Investigative T61744 DRUGINFO D0T5PO ROLIPRAM Investigative T61744 DRUGINFO D0W4ZU KURARINOL Investigative T61744 DRUGINFO D06GUJ KURAIDIN Investigative T61744 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T92072 TARGETID T92072 T92072 FORMERID TTDS00186 T92072 UNIPROID AA1R_HUMAN T92072 TARGNAME Adenosine A1 receptor (ADORA1) T92072 GENENAME ADORA1 T92072 TARGTYPE Successful T92072 SYNONYMS Adenosine receptor A1; A(1) adenosine receptor T92072 FUNCTION The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Receptor for adenosine. T92072 PDBSTRUC 6D9H; 5UEN; 5N2S T92072 BIOCLASS GPCR rhodopsin T92072 SEQUENCE MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGALVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVTPRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYMVYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALILFLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFLKIWNDHFRCQPAPPIDEDLPEERPDD T92072 DRUGINFO D0B3HD Caffeine Approved T92072 DRUGINFO D0X0IY Rolofylline Phase 3 T92072 DRUGINFO D04YAJ SELODENOSON Phase 2 T92072 DRUGINFO D0BA5K Apaxifylline Phase 2 T92072 DRUGINFO D0F5UN SLV320 Phase 2 T92072 DRUGINFO D0I1EX DTI-0009 Phase 2 T92072 DRUGINFO D0I3YX Capadenoson Phase 2 T92072 DRUGINFO D0M7BL BAY 1067197 Phase 2 T92072 DRUGINFO D0QH7H AMP-579 Phase 2 T92072 DRUGINFO D00SUK Tonapofylline Phase 2 T92072 DRUGINFO D05KBP INO-8875 Phase 1/2 T92072 DRUGINFO D0Z9RJ GS 9667 Phase 1 T92072 DRUGINFO D7FJX0 AST-004 Phase 1 T92072 DRUGINFO D02YQO SCH-442416 Phase 1 T92072 DRUGINFO D0L5VS KF-17837 Phase 1 T92072 DRUGINFO D0T0YA PMID27387065-Compound-6 Patented T92072 DRUGINFO D07VZV N-0861 Discontinued in Phase 3 T92072 DRUGINFO D09GGJ CVT-124 Discontinued in Phase 3 T92072 DRUGINFO D00YSJ Tecadenoson Discontinued in Phase 3 T92072 DRUGINFO D01VPK FK-453 Discontinued in Phase 2 T92072 DRUGINFO D03JHJ FK-352 Discontinued in Phase 2 T92072 DRUGINFO D0EK6D FK-838 Discontinued in Phase 2 T92072 DRUGINFO D0UH4T GW-493838 Discontinued in Phase 2 T92072 DRUGINFO D0K2BQ BRL-61063 Discontinued in Phase 2 T92072 DRUGINFO D08ZBT SDZ-WAG-994 Discontinued in Phase 1 T92072 DRUGINFO D0V5DX GR-79236 Discontinued in Phase 1 T92072 DRUGINFO D0HE1P BAY 60-6583 Preclinical T92072 DRUGINFO D0I7BL ARISTEROMYCIN Terminated T92072 DRUGINFO D0NQ5I METRIFUDIL Terminated T92072 DRUGINFO D0Y6GJ ZM-241385 Terminated T92072 DRUGINFO D0E4WF METHYLTHIOADENOSINE Terminated T92072 DRUGINFO D00JXL N-(4-Phenyl-thiazol-2-yl)-benzamide Investigative T92072 DRUGINFO D00UFJ 4-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide Investigative T92072 DRUGINFO D00WFU LUF-5737 Investigative T92072 DRUGINFO D01EHP Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine Investigative T92072 DRUGINFO D01GUK Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine Investigative T92072 DRUGINFO D01MOQ 7-Methyl-2-propyl-[1,8]naphthyridin-4-ol Investigative T92072 DRUGINFO D03KLO 2,6-dimethyl-8-ethyl-1-deazapurine Investigative T92072 DRUGINFO D04LPX 4-Bromo-N-(4-phenyl-thiazol-2-yl)-benzamide Investigative T92072 DRUGINFO D04QAD 4-tert-Butyl-N-(4-phenyl-thiazol-2-yl)-benzamide Investigative T92072 DRUGINFO D05MCK 7-Chloro-2-phenyl-[1,8]naphthyridin-4-ol Investigative T92072 DRUGINFO D05SYY 7-Bromo-2-phenyl-[1,8]naphthyridin-4-ol Investigative T92072 DRUGINFO D05ZYN Cyclopentyl-(9-ethyl-9H-purin-6-yl)-amine Investigative T92072 DRUGINFO D06QRI 7-Dimethylamino-2-phenyl-[1,8]naphthyridin-4-ol Investigative T92072 DRUGINFO D06TSQ LUF5831 Investigative T92072 DRUGINFO D06ZWQ 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one Investigative T92072 DRUGINFO D07DGH Pentanoic acid (4,6-diphenylpyrimidin-2-yl)amide Investigative T92072 DRUGINFO D07DTC L-97-1 intravenous Investigative T92072 DRUGINFO D07HXL PD-81723 Investigative T92072 DRUGINFO D08VXF Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine Investigative T92072 DRUGINFO D09ETC Cyclohexyl-(9-ethyl-9H-purin-6-yl)-amine Investigative T92072 DRUGINFO D09FUO (1-Phenyl-propyl)-(9-phenyl-9H-purin-6-yl)-amine Investigative T92072 DRUGINFO D09KUY 4-Chloro-7-methyl-2-phenyl-[1,8]naphthyridine Investigative T92072 DRUGINFO D0BZ3S Phenyl-(9-phenyl-9H-purin-6-yl)-amine Investigative T92072 DRUGINFO D0C3ID N-(4,6-diphenylpyrimidin-2-yl)benzamide Investigative T92072 DRUGINFO D0D8WN (9-Methyl-9H-purin-6-yl)-phenyl-amine Investigative T92072 DRUGINFO D0G6SL MRS1062 Investigative T92072 DRUGINFO D0G8GA 9-Phenyl-9H-purin-6-ylamine Investigative T92072 DRUGINFO D0G8XJ 5-Cl-5-deoxy-(+/-)-ENBA Investigative T92072 DRUGINFO D0H2VA LUF-5853 Investigative T92072 DRUGINFO D0H3QX 4-Nitro-N-(4-phenyl-thiazol-2-yl)-benzamide Investigative T92072 DRUGINFO D0J3TY 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one Investigative T92072 DRUGINFO D0J4SW 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one Investigative T92072 DRUGINFO D0K2QF 3,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide Investigative T92072 DRUGINFO D0L4TY N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutyramide Investigative T92072 DRUGINFO D0L5JL 8-cyclopentyltheophylline Investigative T92072 DRUGINFO D0L7DL 8-cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine Investigative T92072 DRUGINFO D0L8DZ 8-Phenyl-3,7-dihydro-purine-2,6-dione Investigative T92072 DRUGINFO D0L8SN P-IODOAMPHETAMINE Investigative T92072 DRUGINFO D0N0OE 7-(3,6,9,12-tetraoxatricos-22-enyl)theophylline Investigative T92072 DRUGINFO D0N1PS Cyclopentyl-(9-cyclopentyl-9H-purin-6-yl)-amine Investigative T92072 DRUGINFO D0N9WG N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide Investigative T92072 DRUGINFO D0NH5X 2-(6-Cyclopentylamino-purin-9-yl)-ethanol Investigative T92072 DRUGINFO D0PD0F Paeoniflorin Investigative T92072 DRUGINFO D0S2MO FR194921 Investigative T92072 DRUGINFO D0T5FY 2,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide Investigative T92072 DRUGINFO D0U8KW LUF-6258 Investigative T92072 DRUGINFO D0UM4R (2-Chloro-9-methyl-9H-purin-6-yl)-phenyl-amine Investigative T92072 DRUGINFO D0W0QF 4-Methyl-N-(4-phenyl-thiazol-2-yl)-benzamide Investigative T92072 DRUGINFO D0WN3O N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide Investigative T92072 DRUGINFO D0XE8T Anthoptilide C Investigative T92072 DRUGINFO D0YB3X 3-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide Investigative T92072 DRUGINFO D0YV1R WRC-0571 Investigative T92072 DRUGINFO D0Z3BT LUF-5764 Investigative T92072 DRUGINFO D0Z3YY LUF-5735 Investigative T92072 DRUGINFO D0Z7BC VCP-28 Investigative T92072 DRUGINFO D0ZO1R Cirsimarin Investigative T92072 DRUGINFO D00CJJ 8-Bromo-9-phenylethyl-9H-adenine Investigative T92072 DRUGINFO D00HYS 2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile Investigative T92072 DRUGINFO D00MPA 6-(furan-2-yl)-9H-purin-2-amine Investigative T92072 DRUGINFO D00NYG 4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile Investigative T92072 DRUGINFO D00OFN 4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine Investigative T92072 DRUGINFO D00YOM 3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol Investigative T92072 DRUGINFO D01WXR N-(4,5-diphenylpyrimidin-2-yl)acetamide Investigative T92072 DRUGINFO D02BGA 9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine Investigative T92072 DRUGINFO D02HHW CP608,039 Investigative T92072 DRUGINFO D02HZJ N-(2,6-diphenylpyrimidin-4-yl)benzamide Investigative T92072 DRUGINFO D02NBB 9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine Investigative T92072 DRUGINFO D02RBK 9-Benzyl-8-bromo-9H-adenine Investigative T92072 DRUGINFO D02TEW 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine Investigative T92072 DRUGINFO D02WTN Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide Investigative T92072 DRUGINFO D03JFX 9-Ethyl-9H-adenine Investigative T92072 DRUGINFO D04AGC Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol Investigative T92072 DRUGINFO D04GFX MRS1132 Investigative T92072 DRUGINFO D04JIR 9-Methyl-9H-adenine Investigative T92072 DRUGINFO D04MMG N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine Investigative T92072 DRUGINFO D04PJO 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine Investigative T92072 DRUGINFO D04PLH VUF-8507 Investigative T92072 DRUGINFO D04RHI MRS1086 Investigative T92072 DRUGINFO D04XLX 2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide Investigative T92072 DRUGINFO D04ZTH 2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile Investigative T92072 DRUGINFO D05TFM 2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine Investigative T92072 DRUGINFO D05ZRR 9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine Investigative T92072 DRUGINFO D06NQD 2-amino-6-phenyl-4-p-tolylnicotinonitrile Investigative T92072 DRUGINFO D07DOE 2'-Me-tecadenoson Investigative T92072 DRUGINFO D07FGB 2,6-bis(4-tolyl)-9H-purine Investigative T92072 DRUGINFO D07FZA AS99 Investigative T92072 DRUGINFO D07HKU DEPX Investigative T92072 DRUGINFO D07RSH MRS923 Investigative T92072 DRUGINFO D07YKU 2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine Investigative T92072 DRUGINFO D08AJS 3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one Investigative T92072 DRUGINFO D08AXT 9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine Investigative T92072 DRUGINFO D08CIY 2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine Investigative T92072 DRUGINFO D08FOT PSB-1115 Investigative T92072 DRUGINFO D08INY 2,6-Diphenyl-pyrimidin-4-ylamine Investigative T92072 DRUGINFO D08RGW 3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol Investigative T92072 DRUGINFO D08RSU [3H]DPCPX Investigative T92072 DRUGINFO D09HAM 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine Investigative T92072 DRUGINFO D09TBE MRS1065 Investigative T92072 DRUGINFO D09UDF 2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine Investigative T92072 DRUGINFO D0A4MK AS100 Investigative T92072 DRUGINFO D0A5KG 2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine Investigative T92072 DRUGINFO D0BA7Q 1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione Investigative T92072 DRUGINFO D0BC7P 2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile Investigative T92072 DRUGINFO D0CB9B 4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine Investigative T92072 DRUGINFO D0D3WR 9-benzyl-6-(furan-2-yl)-9H-purin-2-amine Investigative T92072 DRUGINFO D0F9JF FR-166124 Investigative T92072 DRUGINFO D0G2JG CPFPX Investigative T92072 DRUGINFO D0HK5B SCH-63390 Investigative T92072 DRUGINFO D0I6MT N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine Investigative T92072 DRUGINFO D0J6ME 2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine Investigative T92072 DRUGINFO D0KM0Y 2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile Investigative T92072 DRUGINFO D0L3BI MRS1084 Investigative T92072 DRUGINFO D0M8NW Kuanoniamine D Investigative T92072 DRUGINFO D0N1PT 2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T92072 DRUGINFO D0N2DP N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine Investigative T92072 DRUGINFO D0N2VO 2-Amino-4,6-diphenyl-nicotinonitrile Investigative T92072 DRUGINFO D0O8QS 4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide Investigative T92072 DRUGINFO D0P1JJ 6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D0Q5HW N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine Investigative T92072 DRUGINFO D0Q9GL AS70 Investigative T92072 DRUGINFO D0QD3O 2-Amino-4,6-diphenyl-pyrimidine Investigative T92072 DRUGINFO D0QN5I 4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine Investigative T92072 DRUGINFO D0R4LZ 2-(4-methoxyphenyl)-6-phenyl-9H-purine Investigative T92072 DRUGINFO D0T6XM 1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione Investigative T92072 DRUGINFO D0UM6O 2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine Investigative T92072 DRUGINFO D0W5CZ 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine Investigative T92072 DRUGINFO D0W8RB 8-Bromo-9-(but-3-enyl)-9H-adenine Investigative T92072 DRUGINFO D0Y7AV 2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine Investigative T92072 DRUGINFO D0Y8SB L-249313 Investigative T92072 DRUGINFO D0Z3IZ N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine Investigative T92072 DRUGINFO D0ZV1T N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide Investigative T92072 DRUGINFO D00ASZ 2-(3''-pyrrolylethyloxy)adenosine Investigative T92072 DRUGINFO D00GQI N-(2,6-diphenylpyrimidin-4-yl)isobutyramide Investigative T92072 DRUGINFO D00IOF PSB36 Investigative T92072 DRUGINFO D00NFW 2,6-diphenyl-8-ethyl-1-deazapurine Investigative T92072 DRUGINFO D01AAI VUF5574 Investigative T92072 DRUGINFO D01NHH 2,6-diphenyl-8-tButyl-1-deazapurine Investigative T92072 DRUGINFO D01PGY 2-(hex-1-ynyl)-N6-methoxyadenosine Investigative T92072 DRUGINFO D01QBK 8-Bromo-9-cyclohexyl-9H-adenine Investigative T92072 DRUGINFO D01VEU 9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine Investigative T92072 DRUGINFO D01VXC N-(4,6-diphenylpyrimidin-2-yl)propionamide Investigative T92072 DRUGINFO D01VXP 2-ethynyl-N6-methoxyadenosine Investigative T92072 DRUGINFO D01WNA 8-Bromo-9-ethyl-9H-adenine Investigative T92072 DRUGINFO D02EAO N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine Investigative T92072 DRUGINFO D02FLH 2,6-dphenyl-8-propyl-1-deazapurine Investigative T92072 DRUGINFO D02HOL 8-Bromo-9-propyl-9H-adenine Investigative T92072 DRUGINFO D02HYT N-(2,6-diphenylpyrimidin-4-yl)propionamide Investigative T92072 DRUGINFO D02JCM N(6)-cyclohexyladenosine Investigative T92072 DRUGINFO D02JMR 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D02RMR 1,3-Diethyl-3,7-dihydro-purine-2,6-dione Investigative T92072 DRUGINFO D02SKN MRS1041 Investigative T92072 DRUGINFO D02VQK LUF-5433 Investigative T92072 DRUGINFO D03FVK N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine Investigative T92072 DRUGINFO D03HBG 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D03KKK 1,3-Dipropyl-3,7-dihydro-purine-2,6-dione Investigative T92072 DRUGINFO D03POP N6-methoxy-2-phenylethynyladenosine Investigative T92072 DRUGINFO D04TTP 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol Investigative T92072 DRUGINFO D04WHE 9-Propyl-9H-adenine Investigative T92072 DRUGINFO D05QNV ATL802 Investigative T92072 DRUGINFO D05XGF PSB-0788 Investigative T92072 DRUGINFO D06KMJ MRS5151 Investigative T92072 DRUGINFO D06RCT 2-(3''-indolylethyloxy)adenosine Investigative T92072 DRUGINFO D07DNX PD-115199 Investigative T92072 DRUGINFO D07HNM 1,3-Diallyl-3,7-dihydro-purine-2,6-dione Investigative T92072 DRUGINFO D07IPZ 2-(4-hydroxypent-1-yl)-N6-methoxyadenosine Investigative T92072 DRUGINFO D07PPM PSB-10 Investigative T92072 DRUGINFO D07VCN 4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one Investigative T92072 DRUGINFO D08BCH TCPA Investigative T92072 DRUGINFO D08EBT [3H]HEMADO Investigative T92072 DRUGINFO D08EZI N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide Investigative T92072 DRUGINFO D08HBH N-(2,6-diphenylpyrimidin-4-yl)butyramide Investigative T92072 DRUGINFO D08JUQ 2-tolyl-6-phenyl-9H-purine Investigative T92072 DRUGINFO D08JYX 2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine Investigative T92072 DRUGINFO D08LZN Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine Investigative T92072 DRUGINFO D08MRB 1H-Imidazo[4,5-c]quinolin-4-ylamine HCl Investigative T92072 DRUGINFO D09IRV LUF-5957 Investigative T92072 DRUGINFO D09RKX PSB-11 Investigative T92072 DRUGINFO D09VOP 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D09VRX 2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T92072 DRUGINFO D0A6IO MRE 3008F20 Investigative T92072 DRUGINFO D0A6JX 9-Cyclobutyl-9H-adenine Investigative T92072 DRUGINFO D0A9BZ PSB-601 Investigative T92072 DRUGINFO D0B0QW N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine Investigative T92072 DRUGINFO D0B1RV 2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine Investigative T92072 DRUGINFO D0B1YW 8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione Investigative T92072 DRUGINFO D0B3NZ N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide Investigative T92072 DRUGINFO D0B3UE 9-Cyclopentyl-9H-adenine Investigative T92072 DRUGINFO D0B7OW sakuranetin Investigative T92072 DRUGINFO D0B8DR MRS1093 Investigative T92072 DRUGINFO D0B8RQ LUF-5767 Investigative T92072 DRUGINFO D0C2UJ 2-chloroadenosine Investigative T92072 DRUGINFO D0DB7A 9-Isopropyl-9H-adenine Investigative T92072 DRUGINFO D0E4LB 2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine Investigative T92072 DRUGINFO D0E7YE 2,6,8-triphenyl-9H-purine Investigative T92072 DRUGINFO D0E8RA 8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine Investigative T92072 DRUGINFO D0E9QX (S)-PIA Investigative T92072 DRUGINFO D0F1AS 1-METHYLXANTHINE Investigative T92072 DRUGINFO D0F4XB 2-Amino-4,6-di-furan-2-yl-nicotinonitrile Investigative T92072 DRUGINFO D0G5ZF N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine Investigative T92072 DRUGINFO D0G6BI 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D0G6VT 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D0H9BP xanthine amine congener Investigative T92072 DRUGINFO D0I1EP MRS928 Investigative T92072 DRUGINFO D0I1IW 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D0I2EQ 2,6-diphenyl-8-methyl-1-deazapurine Investigative T92072 DRUGINFO D0I3HE KF26777 Investigative T92072 DRUGINFO D0I7HL 2-phenylpropoxyadenosine Investigative T92072 DRUGINFO D0J1BA MRS1191 Investigative T92072 DRUGINFO D0KJ3H 2-(2''-indolylethyloxy)adenosine Investigative T92072 DRUGINFO D0KT3L 2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine Investigative T92072 DRUGINFO D0L0VU MRE 2029F20 Investigative T92072 DRUGINFO D0L2MN 2-(4-chlorophenyl)-6-phenyl-9H-purine Investigative T92072 DRUGINFO D0L6YI 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D0LD0X 1-Propyl-3,7-dihydro-purine-2,6-dione Investigative T92072 DRUGINFO D0LP5G 2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine Investigative T92072 DRUGINFO D0LP5V LUF-5956 Investigative T92072 DRUGINFO D0N1QO N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine Investigative T92072 DRUGINFO D0N1QP 2,6-diphenyl-1-deazapurine Investigative T92072 DRUGINFO D0O0FP ST-1535 Investigative T92072 DRUGINFO D0O1CW GNF-PF-2700 Investigative T92072 DRUGINFO D0OX0V 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline Investigative T92072 DRUGINFO D0P0BV 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D0P7CS LUF-5417 Investigative T92072 DRUGINFO D0P7FK 2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile Investigative T92072 DRUGINFO D0P8MK 2-(6-amino-8-bromo-9H-purin-9-yl)ethanol Investigative T92072 DRUGINFO D0PU6F 2-(1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T92072 DRUGINFO D0Q1RD 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D0Q3LM N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine Investigative T92072 DRUGINFO D0Q5CS 6-guanidino-2-(3''-indolylethyloxy)adenosine Investigative T92072 DRUGINFO D0QN4U 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine Investigative T92072 DRUGINFO D0R8OK 8-Bromo-9-methyl-9H-adenine Investigative T92072 DRUGINFO D0RZ2M 2,6-diphenyl-9H-purine Investigative T92072 DRUGINFO D0S5XP 9-Allyl-8-bromo-9H-adenine Investigative T92072 DRUGINFO D0S6QA 8-Bromo-9-(2-butyl)-9H-adenine Investigative T92072 DRUGINFO D0T7GG LUF-5816 Investigative T92072 DRUGINFO D0TC7N PENECA Investigative T92072 DRUGINFO D0U8DW 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione Investigative T92072 DRUGINFO D0V9EE 2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile Investigative T92072 DRUGINFO D0V9OO (R,S)-PHPNECA Investigative T92072 DRUGINFO D0VB6X (1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl Investigative T92072 DRUGINFO D0W3MT 8-propyl-2,6-diphenyl-9H-purine Investigative T92072 DRUGINFO D0W6FC 8-Bromo-9-(2-hydroxypropyl)-9H-adenine Investigative T92072 DRUGINFO D0WI4D LUF-5962 Investigative T92072 DRUGINFO D0XC9U MRS1042 Investigative T92072 DRUGINFO D0Y2RM Isoguanosine Investigative T92072 DRUGINFO D0Y5WQ PSB603 Investigative T92072 DRUGINFO D0Y6HQ N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine Investigative T92072 DRUGINFO D0Z1WY 2-chloro-2'-C-methyl-tecadenoson Investigative T92072 DRUGINFO D0Z3XC N-(2,6-diphenylpyrimidin-4-yl)acetamide Investigative T92072 DRUGINFO D0ZL2A MRS1523 Investigative T92072 DRUGINFO D0ZW9L 5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol Investigative T92072 DRUGINFO D00GNW 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine Investigative T92072 DRUGINFO D00JWA N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide Investigative T92072 DRUGINFO D02PBY 3-noradamantyl-1,3-dipropylxanthine Investigative T92072 DRUGINFO D04LZN 8-Bromo-9-cyclobutyl-9H-adenine Investigative T92072 DRUGINFO D05KEF LUF-5978 Investigative T92072 DRUGINFO D06KYP 8-Bromo-9-isopropyl-9H-adenine Investigative T92072 DRUGINFO D0AI8F 8-Bromo-9-cyclopentyl-9H-adenine Investigative T92072 DRUGINFO D0B0TX 8-bromo-9-isobutyl-9H-purin-6-amine Investigative T92072 DRUGINFO D0CX7N 8-Bromo-9-(3-hydroxypropyl)-9H-adenine Investigative T92072 DRUGINFO D0IG5E 2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine Investigative T92072 DRUGINFO D0JJ6T N6-((+/-)-endo-norborn-2-yl)adenosine Investigative T92072 DRUGINFO D0K6ZA [3H]OSIP339391 Investigative T92072 DRUGINFO D0K8ZZ [3H]NECA Investigative T92072 DRUGINFO D0M3CG R-N6-(phenylisopropyl)adenosine Investigative T92072 DRUGINFO D0NO5E Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate Investigative T92072 DRUGINFO D0O4KI 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine Investigative T92072 DRUGINFO D0R1XY [3H]CCPA Investigative T92072 DRUGINFO D0TU7I (E)-8-(3-chlorostyryl)-caffeine Investigative T92072 DRUGINFO D0V8MD 8-PHENYL THEOPHYLLINE Investigative T92072 DRUGINFO D0W1PF LUF-5980 Investigative T92072 DRUGINFO D0Y9WZ SB-298 Investigative T92072 DRUGINFO D0Z8NC LUF-5981 Investigative T92072 DRUGINFO D0Z8VU 8-Bromo-9-(sec-butyl)-9H-adenine Investigative T92072 DRUGINFO D0K0OT GNF-PF-2224 Investigative T92072 DRUGINFO D03RFA N6-CYCLOPENTYLADENOSINE Investigative T92072 DRUGINFO D0S0RK flavone Investigative T92072 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T92072 DRUGINFO D0F9QT A-987306 Investigative T92072 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T74456 TARGETID T74456 T74456 FORMERID TTDS00267 T74456 UNIPROID AGTR1_HUMAN T74456 TARGNAME Angiotensin II receptor type-1 (AGTR1) T74456 GENENAME AGTR1 T74456 TARGTYPE Successful T74456 SYNONYMS Type-1 angiotensin II receptor; Angiotensin II type-1 receptor; Angiotensin II receptor 1; Angiotensin 1 receptor; AT2R1B; AT2R1; AT1BR; AT1AR; AT1; AGTR1B; AGTR1A T74456 FUNCTION Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Receptor for angiotensin II. T74456 PDBSTRUC 6DO1; 4ZUD; 4YAY; 1ZV0 T74456 BIOCLASS GPCR rhodopsin T74456 SEQUENCE MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLKTVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNYLCKIASASVSFNLYASVFLLTCLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLLAGLASLPAIIHRNVFFIENTNITVCAFHYESQNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDDIFKIIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPITICIAYFNNCLNPLFYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCFEVE T74456 DRUGINFO D00JAU Irbesartan Approved T74456 DRUGINFO D00NVX Forasartan Approved T74456 DRUGINFO D00VFE Saralasin Acetate Approved T74456 DRUGINFO D05FGG Azilsartan Approved T74456 DRUGINFO D06UDG Valsartan Approved T74456 DRUGINFO D07UBG Olmesartan medoxomil Approved T74456 DRUGINFO D0B9AO Saprisartan Approved T74456 DRUGINFO D0D5SQ Candesartan Approved T74456 DRUGINFO D0DD0K Losartan Approved T74456 DRUGINFO D0I7PO Micardis telmisartan Approved T74456 DRUGINFO D0M7TO Tasosartan Approved T74456 DRUGINFO D0N6RF Telmisartan Approved T74456 DRUGINFO D0T7US Eprosartan Approved T74456 DRUGINFO D0G6SE ANGIOTENSIN II Approved T74456 DRUGINFO D0K0AT SARALASIN Approved T74456 DRUGINFO D0YS1U Sparsentan Approved T74456 DRUGINFO D05FUU Pratosartan Phase 3 T74456 DRUGINFO D0A2RA TAK-491 Phase 3 T74456 DRUGINFO D0H9QC S-474474 Phase 3 T74456 DRUGINFO D02BBC CL-329167 Phase 2 T74456 DRUGINFO D06LRG TRV027 Phase 2 T74456 DRUGINFO D0C3BA YM-358 Phase 2 T74456 DRUGINFO D06TZT RIPISARTAN Discontinued in Phase 2 T74456 DRUGINFO D0DL2S MILFASARTAN Discontinued in Phase 2 T74456 DRUGINFO D0E3XG Zolasartan Discontinued in Phase 2 T74456 DRUGINFO D0J2NB KRH-594 Discontinued in Phase 2 T74456 DRUGINFO D00XZP UR-7198 Discontinued in Phase 1 T74456 DRUGINFO D0A8EG TAK-591 Discontinued in Phase 1 T74456 DRUGINFO D00XTS CR-3834 Terminated T74456 DRUGINFO D06EQN XR-510 Terminated T74456 DRUGINFO D0N0JE UP-275-22 Terminated T74456 DRUGINFO D0Q7SO RS-66252 Terminated T74456 DRUGINFO D00UBK L-159689 Terminated T74456 DRUGINFO D06MUI A-81988 Terminated T74456 DRUGINFO D0GS7N L-158809 Terminated T74456 DRUGINFO D0Q6YP HELENALIN Terminated T74456 DRUGINFO D00DIJ CGP-49870 Investigative T74456 DRUGINFO D00LWG [Sar1,Tdf8]AngII Investigative T74456 DRUGINFO D00TWV [125I]EXP985 Investigative T74456 DRUGINFO D01YPD GNF-PF-3832 Investigative T74456 DRUGINFO D04FQA 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone Investigative T74456 DRUGINFO D05EQC LY301875 Investigative T74456 DRUGINFO D06DRC [Sar1,Tdf3]AngII Investigative T74456 DRUGINFO D06PJZ [Sar1,Bpa2]AngII Investigative T74456 DRUGINFO D07EWK [Sar1,Bpa3]AngII Investigative T74456 DRUGINFO D0AD7P LY303336 Investigative T74456 DRUGINFO D0D1FT EXP3174 Investigative T74456 DRUGINFO D0F3VE GNF-PF-2812 Investigative T74456 DRUGINFO D0I6HJ INC-106 Investigative T74456 DRUGINFO D0I9IB 5-butyl-methyl immidazole carboxylate 30 Investigative T74456 DRUGINFO D0K0TY N,N`-bis-alkyl butylimmidazole 12b Investigative T74456 DRUGINFO D0L2HK 5-oxo-1-2-4-oxadiazol biphenyl Investigative T74456 DRUGINFO D0N2WA [Bpa1]AngII Investigative T74456 DRUGINFO D0N7HN (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n Investigative T74456 DRUGINFO D0O1YO [Sar1,Tdf2]AngII Investigative T74456 DRUGINFO D0OO4P CV-11194 Investigative T74456 DRUGINFO D0T1YO GNF-PF-2307 Investigative T74456 DRUGINFO D0T6WV 4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol Investigative T74456 DRUGINFO D0U3WW L-163,101 Investigative T74456 DRUGINFO D0U7QE [Tdf1]AngII Investigative T74456 DRUGINFO D0XO1T [Sar1,Bpa8]AngII Investigative T74456 DRUGINFO D0Z7AF L-162782 Investigative T74456 DRUGINFO D04SVT L-159093 Investigative T74456 DRUGINFO D07OOI [3H]GBR12935 Investigative T74456 DRUGINFO D0A4NO L-162313 Investigative T74456 DRUGINFO D0D9AS angiotensin III Investigative T74456 DRUGINFO D0RE7T 4-[(diphenylmethyl)amino]-2-phenylquinazoline Investigative T38301 TARGETID T38301 T38301 FORMERID TTDS00421 T38301 UNIPROID RIR2_HUMAN T38301 TARGNAME Ribonucleoside-diphosphate reductase M2 (RRM2) T38301 GENENAME RRM2 T38301 TARGTYPE Successful T38301 SYNONYMS Ribonucleotide reductase small subunit; Ribonucleotide reductase small chain; Ribonucleoside-diphosphate reductase subunit M2; RR2 T38301 FUNCTION Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signaling. Provides the precursors necessary for DNA synthesis. T38301 PDBSTRUC 3VPO; 3VPN; 3VPM; 3OLJ; 2UW2 T38301 BIOCLASS CH/CH(2) oxidoreductase T38301 ECNUMBER EC 1.17.4.1 T38301 SEQUENCE MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARRIFQEPTEPKTKAAAPGVEDEPLLRENPRRFVIFPIEYHDIWQMYKKAEASFWTAEEVDLSKDIQHWESLKPEERYFISHVLAFFAASDGIVNENLVERFSQEVQITEARCFYGFQIAMENIHSEMYSLLIDTYIKDPKEREFLFNAIETMPCVKKKADWALRWIGDKEATYGERVVAFAAVEGIFFSGSFASIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFKHLVHKPSEERVREIIINAVRIEQEFLTEALPVKLIGMNCTLMKQYIEFVADRLMLELGFSKVFRVENPFDFMENISLEGKTNFFEKRVGEYQRMGVMSSPTENSFTLDADF T38301 DRUGINFO D03UVS Gemcitabine Approved T38301 DRUGINFO D07CWD Hydroxyurea Approved T38301 DRUGINFO D0DT1R Triapine Phase 2 T38301 DRUGINFO D0V0CJ CO-101 Phase 2 T38301 DRUGINFO D0A1GR CALAA-01 Phase 1 T38301 DRUGINFO D0F2JY LY-2334737 Phase 1 T38301 DRUGINFO D05ACQ Gallium maltolate Discontinued in Phase 2 T38301 DRUGINFO D05HZI MDL 101,731 Discontinued in Phase 2 T38301 DRUGINFO D0V2RK NKP-46 Preclinical T05849 TARGETID T05849 T05849 FORMERID TTDS00043 T05849 UNIPROID GASR_HUMAN T05849 TARGNAME Gastrin/cholecystokinin type B receptor (CCKBR) T05849 GENENAME CCKBR T05849 TARGTYPE Successful T05849 SYNONYMS Cholecystokinin-2 receptor; CCKRB; CCK2-R; CCK-BR; CCK-B receptor T05849 FUNCTION The CCK-B receptors occur throughout the central nervous system where they modulate anxiety, analgesia, arousal, and neuroleptic activity. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Receptor for gastrin and cholecystokinin. T05849 PDBSTRUC 1L4T T05849 BIOCLASS GPCR rhodopsin T05849 SEQUENCE MELLKLNRSVQGTGPGPGASLCRPGAPLLNSSSVGNLSCEPPRIRGAGTRELELAIRITLYAVIFLMSVGGNMLIIVVLGLSRRLRTVTNAFLLSLAVSDLLLAVACMPFTLLPNLMGTFIFGTVICKAVSYLMGVSVSVSTLSLVAIALERYSAICRPLQARVWQTRSHAARVIVATWLLSGLLMVPYPVYTVVQPVGPRVLQCVHRWPSARVRQTWSVLLLLLLFFIPGVVMAVAYGLISRELYLGLRFDGDSDSDSQSRVRNQGGLPGAVHQNGRCRPETGAVGEDSDGCYVQLPRSRPALELTALTAPGPGSGSRPTQAKLLAKKRVVRMLLVIVVLFFLCWLPVYSANTWRAFDGPGAHRALSGAPISFIHLLSYASACVNPLVYCFMHRRFRQACLETCARCCPRPPRARPRALPDEDPPTPSIASLSRLSYTTISTLGPG T05849 DRUGINFO D0O5TQ Pentagastrin Approved T05849 DRUGINFO D0Y9TS Ceruletide Approved T05849 DRUGINFO D09XUH GASTRAZOLE Phase 3 T05849 DRUGINFO D02FYE TT-223 Phase 2 T05849 DRUGINFO D02RPK Z 360 Phase 2 T05849 DRUGINFO D0H5WM S-0509 Phase 2 T05849 DRUGINFO D0H7FW YF-476 Phase 2 T05849 DRUGINFO D0K2RY Itriglumide Phase 2 T05849 DRUGINFO D0TL7L Dexloxiglumide Phase 2 T05849 DRUGINFO D04KHY Spiroglumide Phase 2 T05849 DRUGINFO D0QJ6L Demogastrin Phase 1 T05849 DRUGINFO D0X4AV GV-150013 Discontinued in Phase 2 T05849 DRUGINFO D0XJ0S PD-134308 Discontinued in Phase 2 T05849 DRUGINFO D0Z1RQ L-365260 Discontinued in Phase 2 T05849 DRUGINFO D07YHY CR-2093 Discontinued in Phase 1 T05849 DRUGINFO D0E8QK JNJ-26070109 Preclinical T05849 DRUGINFO D06DPS PD-170292 Preclinical T05849 DRUGINFO D0W4OZ GG-8573 Preclinical T05849 DRUGINFO D00COB PD136450 Terminated T05849 DRUGINFO D00UEG LY288513 Terminated T05849 DRUGINFO D05HYL YM-022 Terminated T05849 DRUGINFO D07SXO AG-041R Terminated T05849 DRUGINFO D0EG1F GR-199114X Terminated T05849 DRUGINFO D01ZDR FR-208419 Terminated T05849 DRUGINFO D05HGU IQM-95333 Terminated T05849 DRUGINFO D0I3BT PD-135666 Terminated T05849 DRUGINFO D0W8TS SNF-9007 Terminated T05849 DRUGINFO D00UPU RPR-107836 Investigative T05849 DRUGINFO D02VGS desulfated cholecystokinin-8 Investigative T05849 DRUGINFO D02ZWC [125I]PD142308 Investigative T05849 DRUGINFO D06WOQ RP-72540 Investigative T05849 DRUGINFO D08VRJ PD-149164 Investigative T05849 DRUGINFO D09TNC RB-400 Investigative T05849 DRUGINFO D0A7RT Cholecystokinin-9 Investigative T05849 DRUGINFO D0A9EA PD-138917 Investigative T05849 DRUGINFO D0F5WV [3H]JB-93182 Investigative T05849 DRUGINFO D0IU6I [3H]PD140376 Investigative T05849 DRUGINFO D0J0NS [3H]PBC-264 Investigative T05849 DRUGINFO D0L9RP PBC-264 Investigative T05849 DRUGINFO D0O0AR RP-71483 Investigative T05849 DRUGINFO D0R4TA tetronothiodin Investigative T05849 DRUGINFO D0U5NA RP-69758 Investigative T05849 DRUGINFO D0Y8KY RP73870 Investigative T05849 DRUGINFO D0Z4HK BC-264 Investigative T05849 DRUGINFO D0Z4SS [125I]-BDZ2 Investigative T05849 DRUGINFO D00FLQ PD-140547 Investigative T05849 DRUGINFO D02MIN PD-138915 Investigative T05849 DRUGINFO D02ZML GW-5823 Investigative T05849 DRUGINFO D04VOM PD-136621 Investigative T05849 DRUGINFO D05OUQ CCK-33 Investigative T05849 DRUGINFO D05XXE Tetragastrin Investigative T05849 DRUGINFO D06NIP Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D08EYZ PD-140548 Investigative T05849 DRUGINFO D0C2KS CI-1015 Investigative T05849 DRUGINFO D0CE9U Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe Investigative T05849 DRUGINFO D0D2ZM PD-135158 Investigative T05849 DRUGINFO D0E4JX PD-137337 Investigative T05849 DRUGINFO D0ES2U TP-680 Investigative T05849 DRUGINFO D0G1CK PD-140723 Investigative T05849 DRUGINFO D0G7RE PD-137342 Investigative T05849 DRUGINFO D0I8AF CCK-8 Investigative T05849 DRUGINFO D0L9OU PD-138916 Investigative T05849 DRUGINFO D0M6ZF Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2 Investigative T05849 DRUGINFO D0O0IZ PD-135118 Investigative T05849 DRUGINFO D01ADK Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D03WGS H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac Investigative T05849 DRUGINFO D08QKT Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D0S7SO H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo Investigative T05849 DRUGINFO D0V0RB Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D0X7LC Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D01AQC Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D03EPA Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D06BRA Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D07ICW Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D07LQQ Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D09EMR Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D0E2OG Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D0J7GJ H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H Investigative T05849 DRUGINFO D0N6DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc Investigative T05849 DRUGINFO D0QP2S Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc Investigative T05849 DRUGINFO D0R4GI Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D0TR0U Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D0U6OA Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T05849 DRUGINFO D0V9DY H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H Investigative T05849 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T72458 TARGETID T72458 T72458 FORMERID TTDC00072 T72458 UNIPROID MC4R_HUMAN T72458 TARGNAME Melanocortin receptor 4 (MC4R) T72458 GENENAME MC4R T72458 TARGTYPE Successful T72458 SYNONYMS MC4-R T72458 FUNCTION Plays a central role in energy homeostasis and somatic growth. This receptor is mediated by G proteins that stimulate adenylate cyclase (cAMP). Receptor specific to the heptapeptide core common to adrenocorticotropic hormone and alpha-, beta-, and gamma-MSH. T72458 PDBSTRUC 2IQW; 2IQV; 2IQU; 2IQS; 2IQR T72458 BIOCLASS GPCR rhodopsin T72458 SEQUENCE MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIVITLLNSTDTDAQSFTVNIDNVIDSVICSSLLASICSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQNPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY T72458 DRUGINFO D0YP7B Setmelanotide Approved T72458 DRUGINFO D03YVO Methylnaltrexone bromide Approved T72458 DRUGINFO D0X9PF Bremelanotide Approved T72458 DRUGINFO D0PI8W Amylin Phase 4 T72458 DRUGINFO D0K8NR AMG 386 Phase 3 T72458 DRUGINFO D04QUX PF-446687 Phase 2 T72458 DRUGINFO D0G2XE PMX-53 Phase 2 T72458 DRUGINFO D0H3HV AP-1030 Phase 1/2 T72458 DRUGINFO D39UDP PF-07258669 Phase 1 T72458 DRUGINFO D09XVQ PT-14 Discontinued in Phase 2 T72458 DRUGINFO D0J9CF IDDBCP-150101 Preclinical T72458 DRUGINFO D0N0IQ Ro-27-3225 Preclinical T72458 DRUGINFO D06SDP Melanotetan II Preclinical T72458 DRUGINFO D00GCC MCL0129 Investigative T72458 DRUGINFO D00XMP 1-Methyl-4-(1-phenyl-ethyl)-piperazine Investigative T72458 DRUGINFO D02TOS AMSH Investigative T72458 DRUGINFO D04BOG C[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D07IBF Ac-YR[CE(1-Me-H)dFRWC]-NH2 Investigative T72458 DRUGINFO D07RRN C[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro] Investigative T72458 DRUGINFO D07SRW His-DPhe-Arg-Trp Investigative T72458 DRUGINFO D08EBV C[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro] Investigative T72458 DRUGINFO D08QRO BL-6020 Investigative T72458 DRUGINFO D09HHW ML-253764 Investigative T72458 DRUGINFO D09LHF C(his-D-phe-arg-trp-Aoc) Investigative T72458 DRUGINFO D0D1BC Melanocortin-4 Receptor antagonist Investigative T72458 DRUGINFO D0D7ZA Ser-Tyr-Ser-Nle-Glu-His-Dphe-Arg Investigative T72458 DRUGINFO D0D8YP 1-Benzyl-4-methyl-piperazine Investigative T72458 DRUGINFO D0GH5N NDP-alpha-MSH Investigative T72458 DRUGINFO D0J0ZG HS014 Investigative T72458 DRUGINFO D0M2QK C(his-D-phe-arg-trp-Ahp) Investigative T72458 DRUGINFO D0N6AS AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2 Investigative T72458 DRUGINFO D0N6KO THIQ Investigative T72458 DRUGINFO D0QW4A C[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2 Investigative T72458 DRUGINFO D0R5KO C(his-D-phe-arg-trp-Ahx) Investigative T72458 DRUGINFO D0U1UZ C(his-D-phe-arg-trp-Abu) Investigative T72458 DRUGINFO D0V5YV C(his-L-phe-arg-trp-Aoc) Investigative T72458 DRUGINFO D0Z1QU MCL-129 Investigative T72458 DRUGINFO D09XCH Ac-YR[CEHFRWC]-NH2 Investigative T72458 DRUGINFO D0R3GC D-Phe-Arg-2-Nal-NHCH3 Investigative T72458 DRUGINFO D0U5KM Ac-His-DPhe-Arg-Trp-NH2 Investigative T72458 DRUGINFO D0U6XP Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2 Investigative T72458 DRUGINFO D00HAJ Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2 Investigative T72458 DRUGINFO D00NOG MK-11 Investigative T72458 DRUGINFO D00TSX C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D00VYC Ac-YR[CEHdFRWC]-NH2 Investigative T72458 DRUGINFO D01HTX C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D02MPZ C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D04YZZ C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T72458 DRUGINFO D05WNC C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D05XRI Ac-R[CEHdFRWC]-NH2 Investigative T72458 DRUGINFO D06PNU Tic-D-Phe-Arg-2-Nal-NHCH3 Investigative T72458 DRUGINFO D07DWH Ac-dR[CEHdFRWC]-NH2 Investigative T72458 DRUGINFO D07UXW C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D08DND C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2 Investigative T72458 DRUGINFO D09OMI Ac-YK[CEHdFRWC]-NH2 Investigative T72458 DRUGINFO D09UUC MK-10 Investigative T72458 DRUGINFO D0A8ME Ac-[CEHdFRWC]-NH2 Investigative T72458 DRUGINFO D0B8GR Ac-His-D-Phe-Arg-2-Nal-NHCH3 Investigative T72458 DRUGINFO D0C7VI Ac-YR[CEHdFRWC]SPPKD-NH2 Investigative T72458 DRUGINFO D0F6GX Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3 Investigative T72458 DRUGINFO D0M4EF C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D0P4GI C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D0VD7R C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D0ZD3M Ac-YCit[CEHdFRWC]-NH2 Investigative T72458 DRUGINFO D02JVA C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D03AZC Ac-YRMEHdFRWG-NH2 Investigative T72458 DRUGINFO D05LLI C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D06RTP C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D07SFD C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D07TBR Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 Investigative T72458 DRUGINFO D09PDT C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T72458 DRUGINFO D0AU4C AEKKDEGPYRMEHFRWGSPPKD Investigative T72458 DRUGINFO D0B4OL Ac-YRMEHdFRWGSPPKD-NH2 Investigative T72458 DRUGINFO D0CK0K Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 Investigative T72458 DRUGINFO D0I8SJ NDP-SYSMEHFRWGKPVG Investigative T72458 DRUGINFO D0ID5M GPYRMEHFRWGSPPKD-NH2 Investigative T72458 DRUGINFO D0L1MJ C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T72458 DRUGINFO D0R0BY Ac-YR[CEH(pCl-dF)RWC]-NH2 Investigative T72458 DRUGINFO D0WG8P Ac-YR[CEH(pF-dF)RWC]-NH2 Investigative T72458 DRUGINFO D0WI8M C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T72458 DRUGINFO D0X1YL Ac-YRC(Me)*EHdFRWC(Me)NH2 Investigative T72458 DRUGINFO D0YB7F MT-II Investigative T72458 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T11288 TARGETID T11288 T11288 FORMERID TTDS00288 T11288 UNIPROID MRP1_HUMAN T11288 TARGNAME Multidrug resistance-associated protein 1 (ABCC1) T11288 GENENAME ABCC1 T11288 TARGTYPE Successful T11288 SYNONYMS MRP1; MRP; Leukotriene C(4) transporter; LTC4 transporter; ATP-binding cassette sub-family C member 1 T11288 FUNCTION Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency. Mediates export of organic anions and drugs from the cytoplasm. T11288 PDBSTRUC 4C3Z; 2CBZ T11288 BIOCLASS ABC transporter T11288 ECNUMBER EC 7.6.2.2 T11288 SEQUENCE MALRGFCSADGSDPLWDWNVTWNTSNPDFTKCFQNTVLVWVPCFYLWACFPFYFLYLSRHDRGYIQMTPLNKTKTALGFLLWIVCWADLFYSFWERSRGIFLAPVFLVSPTLLGITMLLATFLIQLERRKGVQSSGIMLTFWLVALVCALAILRSKIMTALKEDAQVDLFRDITFYVYFSLLLIQLVLSCFSDRSPLFSETIHDPNPCPESSASFLSRITFWWITGLIVRGYRQPLEGSDLWSLNKEDTSEQVVPVLVKNWKKECAKTRKQPVKVVYSSKDPAQPKESSKVDANEEVEALIVKSPQKEWNPSLFKVLYKTFGPYFLMSFFFKAIHDLMMFSGPQILKLLIKFVNDTKAPDWQGYFYTVLLFVTACLQTLVLHQYFHICFVSGMRIKTAVIGAVYRKALVITNSARKSSTVGEIVNLMSVDAQRFMDLATYINMIWSAPLQVILALYLLWLNLGPSVLAGVAVMVLMVPVNAVMAMKTKTYQVAHMKSKDNRIKLMNEILNGIKVLKLYAWELAFKDKVLAIRQEELKVLKKSAYLSAVGTFTWVCTPFLVALCTFAVYVTIDENNILDAQTAFVSLALFNILRFPLNILPMVISSIVQASVSLKRLRIFLSHEELEPDSIERRPVKDGGGTNSITVRNATFTWARSDPPTLNGITFSIPEGALVAVVGQVGCGKSSLLSALLAEMDKVEGHVAIKGSVAYVPQQAWIQNDSLRENILFGCQLEEPYYRSVIQACALLPDLEILPSGDRTEIGEKGVNLSGGQKQRVSLARAVYSNADIYLFDDPLSAVDAHVGKHIFENVIGPKGMLKNKTRILVTHSMSYLPQVDVIIVMSGGKISEMGSYQELLARDGAFAEFLRTYASTEQEQDAEENGVTGVSGPGKEAKQMENGMLVTDSAGKQLQRQLSSSSSYSGDISRHHNSTAELQKAEAKKEETWKLMEADKAQTGQVKLSVYWDYMKAIGLFISFLSIFLFMCNHVSALASNYWLSLWTDDPIVNGTQEHTKVRLSVYGALGISQGIAVFGYSMAVSIGGILASRCLHVDLLHSILRSPMSFFERTPSGNLVNRFSKELDTVDSMIPEVIKMFMGSLFNVIGACIVILLATPIAAIIIPPLGLIYFFVQRFYVASSRQLKRLESVSRSPVYSHFNETLLGVSVIRAFEEQERFIHQSDLKVDENQKAYYPSIVANRWLAVRLECVGNCIVLFAALFAVISRHSLSAGLVGLSVSYSLQVTTYLNWLVRMSSEMETNIVAVERLKEYSETEKEAPWQIQETAPPSSWPQVGRVEFRNYCLRYREDLDFVLRHINVTINGGEKVGIVGRTGAGKSSLTLGLFRINESAEGEIIIDGINIAKIGLHDLRFKITIIPQDPVLFSGSLRMNLDPFSQYSDEEVWTSLELAHLKDFVSALPDKLDHECAEGGENLSVGQRQLVCLARALLRKTKILVLDEATAAVDLETDDLIQSTIRTQFEDCTVLTIAHRLNTIMDYTRVIVLDKGEIQEYGAPSDLLQQRGLFYSMAKDAGLV T11288 DRUGINFO D03DEI Sulfinpyrazone Approved T11288 DRUGINFO D0Z3DY Benzbromarone Approved T11288 DRUGINFO D0KX3H Pyrrolopyrimidine Investigative T11288 DRUGINFO D04GYT XR-9456 Investigative T11288 DRUGINFO D09HIM XR-9504 Investigative T11288 DRUGINFO D0A4TF XR-9544 Investigative T11288 DRUGINFO D0S8CE XR-9577 Investigative T37693 TARGETID T37693 T37693 FORMERID TTDC00314 T37693 UNIPROID CNR2_HUMAN T37693 TARGNAME Cannabinoid receptor 2 (CB2) T37693 GENENAME CNR2 T37693 TARGTYPE Successful T37693 SYNONYMS hCB2; Cannabinoid CB2 receptor; CX5; CB2B; CB2A; CB-2 T37693 FUNCTION May function in inflammatory response, nociceptive transmission and bone homeostasis. Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. T37693 PDBSTRUC 5ZTY; 2KI9 T37693 BIOCLASS GPCR rhodopsin T37693 SEQUENCE MEECWVTEIANGSKDGLDSNPMKDYMILSGPQKTAVAVLCTLLGLLSALENVAVLYLILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAVFLLKIGSVTMTFTASVGSLLLTAIDRYLCLRYPPSYKALLTRGRALVTLGIMWVLSALVSYLPLMGWTCCPRPCSELFPLIPNDYLLSWLLFIAFLFSGIIYTYGHVLWKAHQHVASLSGHQDRQVPGMARMRLDVRLAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINSMVNPVIYALRSGEIRSSAHHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWPDSRDLDLSDC T37693 DRUGINFO D0L7AS NABILONE Approved T37693 DRUGINFO D07ILQ Guanfacine extended release Approved T37693 DRUGINFO D00FBC KHK-6188 Phase 2 T37693 DRUGINFO D06UIS LY-2828360 Phase 2 T37693 DRUGINFO D0I4PW APD371 Phase 2 T37693 DRUGINFO D0J6KZ S-777469 Phase 2 T37693 DRUGINFO D0Q7NB 842166X Phase 2 T37693 DRUGINFO D53QMP Beta-caryophyllene Phase 2 T37693 DRUGINFO DMJ2N9 Vicasinabin Phase 2 T37693 DRUGINFO D05BMC GW-42004 Phase 2 T37693 DRUGINFO D0Q8WG Tedalinab Phase 1 T37693 DRUGINFO DK3WQ5 NTRX-07 Phase 1 T37693 DRUGINFO D00TIB PMID27215781-Compound-34 Patented T37693 DRUGINFO D01PUS PMID27215781-Compound-32 Patented T37693 DRUGINFO D03YAA PMID27215781-Compound-28 Patented T37693 DRUGINFO D03YWY PMID27215781-Compound-30 Patented T37693 DRUGINFO D07IHT N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1 Patented T37693 DRUGINFO D07ULI PMID27215781-Compound-25 Patented T37693 DRUGINFO D08XES PMID27215781-Compound-4 Patented T37693 DRUGINFO D0CR0Y PMID27215781-Compound-31 Patented T37693 DRUGINFO D0D1TS Isoquinoline derivative 2 Patented T37693 DRUGINFO D0E6YT PMID27215781-Compound-27 Patented T37693 DRUGINFO D0EX1T PMID27215781-Compound-11 Patented T37693 DRUGINFO D0HG0F 1,3,5-triazine derivative 1 Patented T37693 DRUGINFO D0O2TY PMID27215781-Compound-13 Patented T37693 DRUGINFO D0OE0D PMID27215781-Compound-33 Patented T37693 DRUGINFO D0Q9TO PMID27215781-Compound-12 Patented T37693 DRUGINFO D0SR5L PMID27215781-Compound-19 Patented T37693 DRUGINFO D0T9OL Adamantyl derivative 1 Patented T37693 DRUGINFO D0TC7X Isoquinoline derivative 1 Patented T37693 DRUGINFO D0XG7K PMID27215781-Compound-29 Patented T37693 DRUGINFO D0YZ8I JWH-015 Patented T37693 DRUGINFO D0ZM1H Isoquinoline derivative 3 Patented T37693 DRUGINFO D02TOI Tricyclic phytocannabinoid derivative 2 Patented T37693 DRUGINFO D05CEL 2-cycloalkyl resorcinol cannabinoid ligand derivative 1 Patented T37693 DRUGINFO D07BFP PMID27215781-Compound-37 Patented T37693 DRUGINFO D09GJQ Tricyclic phytocannabinoid derivative 1 Patented T37693 DRUGINFO D09WPA Phytocannabinoid/aminoalkylindole derivative 2 Patented T37693 DRUGINFO D0FA2L N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3 Patented T37693 DRUGINFO D0GQ8W Carbazole-3-carboxamide analog 1 Patented T37693 DRUGINFO D0H0XC 2-cycloalkyl resorcinol cannabinoid ligand derivative 2 Patented T37693 DRUGINFO D0LN9D Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1 Patented T37693 DRUGINFO D0RZ4M Phytocannabinoid/aminoalkylindole derivative 1 Patented T37693 DRUGINFO D0W9PY PMID27215781-Compound-2 Patented T37693 DRUGINFO D0WJ3F N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2 Patented T37693 DRUGINFO D0X5ZS Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2 Patented T37693 DRUGINFO D03ACT PRS-211375 iv Discontinued in Phase 2 T37693 DRUGINFO D0LF5B KN-38-7271 Discontinued in Phase 2 T37693 DRUGINFO D03KTK TAK-937 Discontinued in Phase 1 T37693 DRUGINFO D01DTQ PXS-2076 Terminated T37693 DRUGINFO D07XGT AM-577 Terminated T37693 DRUGINFO D0A4XN PRS-639058 Terminated T37693 DRUGINFO D0J7RW WIN-55212-2 Terminated T37693 DRUGINFO D00ECV SCH-225336 Investigative T37693 DRUGINFO D00TPO JWH-201 Investigative T37693 DRUGINFO D01IUI JWH-253 Investigative T37693 DRUGINFO D01JTY JWH-313 Investigative T37693 DRUGINFO D02GTT AR-XYZ Investigative T37693 DRUGINFO D02INF L-759,656 Investigative T37693 DRUGINFO D02UEJ JWH-311 Investigative T37693 DRUGINFO D03DDL JWH-303 Investigative T37693 DRUGINFO D03SCD 5-Biphenyl-4-ylmethyl-1-isobutyl-1H-tetrazole Investigative T37693 DRUGINFO D04EOZ JWH-294 Investigative T37693 DRUGINFO D04XGX 2-(2-Methoxybenzyl)-3H-benzo[f]chromen-3-one Investigative T37693 DRUGINFO D05DXW JWH-251 Investigative T37693 DRUGINFO D05EWD JWH-167 Investigative T37693 DRUGINFO D05RKV Sch-036 Investigative T37693 DRUGINFO D05TQX O-oleoyl-N-(2-hydroxyethyl)hydroxylamine Investigative T37693 DRUGINFO D06GAF N1-(4-bromophenyl)-N2,N2-dipentylphthalamide Investigative T37693 DRUGINFO D06JFN N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide Investigative T37693 DRUGINFO D06SRX MDA-19 Investigative T37693 DRUGINFO D08BGZ JWH-315 Investigative T37693 DRUGINFO D08JCV JWH-204 Investigative T37693 DRUGINFO D08JFL 3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one Investigative T37693 DRUGINFO D08RYN RQ-00202730 Investigative T37693 DRUGINFO D09DSK JWH-051 Investigative T37693 DRUGINFO D0BS7G L-759,633 Investigative T37693 DRUGINFO D0D4HH JWH-250 Investigative T37693 DRUGINFO D0EC6B Dodeca-2E,4E-dienoic acid isobutylamide Investigative T37693 DRUGINFO D0F3CH JWH-151 Investigative T37693 DRUGINFO D0G9EU JWH-295 Investigative T37693 DRUGINFO D0GD9G JWH-207 Investigative T37693 DRUGINFO D0I9XR JWH-302 Investigative T37693 DRUGINFO D0IW4Q JWH-305 Investigative T37693 DRUGINFO D0J8KW SR144528 Investigative T37693 DRUGINFO D0L5IM JWH-306 Investigative T37693 DRUGINFO D0M1MQ JWH-203 Investigative T37693 DRUGINFO D0M1ZC JWH-343 Investigative T37693 DRUGINFO D0P6NA JWH-202 Investigative T37693 DRUGINFO D0P9KU JWH-252 Investigative T37693 DRUGINFO D0PC1Z JWH-323 Investigative T37693 DRUGINFO D0Q4IM JWH-237 Investigative T37693 DRUGINFO D0Q4YR JWH-296 Investigative T37693 DRUGINFO D0Q6FF JWH-249 Investigative T37693 DRUGINFO D0Q8QH N-oleoyl-N-(2-hydroxyethyl)hydroxylamine Investigative T37693 DRUGINFO D0Q8SO JWH-208 Investigative T37693 DRUGINFO D0R1UA GNF-PF-5188 Investigative T37693 DRUGINFO D0RI8G JWH-312 Investigative T37693 DRUGINFO D0T3CP N-oleoyl-O-(2-hydroxyethyl)hydroxylamine Investigative T37693 DRUGINFO D0U3ME 4'-(1,1-dimethyl-heptyl)-3,5-dimethyl-biphenyl Investigative T37693 DRUGINFO D0UX4A HU-433 Investigative T37693 DRUGINFO D0W9BD JWH-314 Investigative T37693 DRUGINFO D0WD1F JWH-205 Investigative T37693 DRUGINFO D0X0FB JWH-206 Investigative T37693 DRUGINFO D0X1EC JWH-248 Investigative T37693 DRUGINFO D0X1FX JWH-441 Investigative T37693 DRUGINFO D0YM8O JWH-209 Investigative T37693 DRUGINFO D00DNT JWH-406 Investigative T37693 DRUGINFO D00LZJ JWH-405 Investigative T37693 DRUGINFO D00TRZ JWH-407 Investigative T37693 DRUGINFO D01JHA 2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol Investigative T37693 DRUGINFO D01JQX JWH-342 Investigative T37693 DRUGINFO D01MJF JWH-404 Investigative T37693 DRUGINFO D01PEC (2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D01RWS 3-Benzyl-5-isopropyl-8-methylchromen-2-one Investigative T37693 DRUGINFO D01VIA (4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone Investigative T37693 DRUGINFO D02NAW N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D02POA 5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol Investigative T37693 DRUGINFO D02QTB JWH-307 Investigative T37693 DRUGINFO D02VSL JWH-133 Investigative T37693 DRUGINFO D03AWH AM-4768 Investigative T37693 DRUGINFO D03GDP AM-1715 Investigative T37693 DRUGINFO D03HFM (1R,2R)-N-Arachidonoylcyclopropanolamide Investigative T37693 DRUGINFO D03REA 5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one Investigative T37693 DRUGINFO D03RGV JWH-156 Investigative T37693 DRUGINFO D03SRV JWH-292 Investigative T37693 DRUGINFO D04AMC N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine Investigative T37693 DRUGINFO D04AUM AM-1710 Investigative T37693 DRUGINFO D04ECZ Rac-trans-N-oleoylcyclopropanolamide Investigative T37693 DRUGINFO D04GDY DELTA 8-TETRAHYDROCANNOBINOL Investigative T37693 DRUGINFO D04ICJ 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide Investigative T37693 DRUGINFO D04LZA JWH-370 Investigative T37693 DRUGINFO D04TSL JWH-392 Investigative T37693 DRUGINFO D06BXT [3H]WIN55212-2 Investigative T37693 DRUGINFO D06DTC (2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D06EHU JWH-268 Investigative T37693 DRUGINFO D06SKK JWH-440 Investigative T37693 DRUGINFO D07KZW JWH-364 Investigative T37693 DRUGINFO D07QUV JWH-345 Investigative T37693 DRUGINFO D08BNY (E)-N-(4-methoxyphenyl)undec-2-enamide Investigative T37693 DRUGINFO D08GLU 4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol Investigative T37693 DRUGINFO D08OAQ 4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol Investigative T37693 DRUGINFO D08TXL A-796260 Investigative T37693 DRUGINFO D08VLG 4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol Investigative T37693 DRUGINFO D09BYO N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D09CKZ AM-411 Investigative T37693 DRUGINFO D09FMK AM-630 Investigative T37693 DRUGINFO D09JER JWH-344 Investigative T37693 DRUGINFO D09KFJ JWH-229 Investigative T37693 DRUGINFO D09PIQ JWH-367 Investigative T37693 DRUGINFO D0A2BC JWH-385 Investigative T37693 DRUGINFO D0B8AN JWH-347 Investigative T37693 DRUGINFO D0C4CG N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide Investigative T37693 DRUGINFO D0CO6T NAPHTHYRIDINONE Investigative T37693 DRUGINFO D0D7OR KM-233-M Investigative T37693 DRUGINFO D0DE9L JWH-368 Investigative T37693 DRUGINFO D0DQ3F JWH-365 Investigative T37693 DRUGINFO D0E0AA N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D0E0JU JWH-401 Investigative T37693 DRUGINFO D0E3ET AM-1714 Investigative T37693 DRUGINFO D0E3OY JWH-372 Investigative T37693 DRUGINFO D0E4OT JWH-325 Investigative T37693 DRUGINFO D0EE0Q JWH-366 Investigative T37693 DRUGINFO D0EX7J JWH-442 Investigative T37693 DRUGINFO D0F3XG JWH-346 Investigative T37693 DRUGINFO D0F4BE O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine Investigative T37693 DRUGINFO D0G2EQ (1S,2S)-N-Arachidonoylcyclopropanolamide Investigative T37693 DRUGINFO D0G4VV SCH-356036 Investigative T37693 DRUGINFO D0G7GF 3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol Investigative T37693 DRUGINFO D0GG4T JWH-150 Investigative T37693 DRUGINFO D0I4AF N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D0I7MW JWH-244 Investigative T37693 DRUGINFO D0J3XJ N-(3-Phenyl)propyl-2-(4-bromophenylacetamide) Investigative T37693 DRUGINFO D0J7CR Rac-cis-N-arachidonoylcyclopropanolamide Investigative T37693 DRUGINFO D0K4PV 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D0K7QP (1S,2S)-N-Oleoylcyclopropanolamide Investigative T37693 DRUGINFO D0K8MN 5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole Investigative T37693 DRUGINFO D0K8VR [3H]HU-243 Investigative T37693 DRUGINFO D0L6RT PRAVADOLINE Investigative T37693 DRUGINFO D0N0ME 4-benzhydryl-N-butylpiperazine-1-carboxamide Investigative T37693 DRUGINFO D0N5VO JWH-403 Investigative T37693 DRUGINFO D0O3NY AM-1241 Investigative T37693 DRUGINFO D0O7ZJ JWH-120 Investigative T37693 DRUGINFO D0O8IC JWH-309 Investigative T37693 DRUGINFO D0P5VJ KM-233 Investigative T37693 DRUGINFO D0PE8U N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide Investigative T37693 DRUGINFO D0Q0XV (1R,2S)-N-Oleoylcyclopropanolamide Investigative T37693 DRUGINFO D0Q9FB JWH-308 Investigative T37693 DRUGINFO D0R1NR JWH-371 Investigative T37693 DRUGINFO D0R3GN JWH-373 Investigative T37693 DRUGINFO D0R6MB 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D0R7QF (1R,2S)-N-Arachidonoylcyclopropanolamide Investigative T37693 DRUGINFO D0R9VY 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D0S2ZR JWH-147 Investigative T37693 DRUGINFO D0S3UA JWH-145 Investigative T37693 DRUGINFO D0T4SE (E)-N-(4-methoxyphenethyl)undec-2-enamide Investigative T37693 DRUGINFO D0T5WY JWH-293 Investigative T37693 DRUGINFO D0TN1L JWH-146 Investigative T37693 DRUGINFO D0TS5I JWH-245 Investigative T37693 DRUGINFO D0U4JI JWH-337 Investigative T37693 DRUGINFO D0UD9H AM-281 Investigative T37693 DRUGINFO D0V3TO JWH-348 Investigative T37693 DRUGINFO D0V3YB 3,4-diarylpyrazoline derivative Investigative T37693 DRUGINFO D0V7QA 1,4-dihydroindeno[1,2-c]-pyrazole Investigative T37693 DRUGINFO D0Y0MY JWH-402 Investigative T37693 DRUGINFO D0Y1MM N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine Investigative T37693 DRUGINFO D0Y6MS JWH-297 Investigative T37693 DRUGINFO D0Y9HT JWH-363 Investigative T37693 DRUGINFO D0Z1NH Cis-N-oleoylcyclopropanolamide Investigative T37693 DRUGINFO D0Z1XE JWH-324 Investigative T37693 DRUGINFO D0Z5CX N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide Investigative T37693 DRUGINFO D0Z6BY JWH-243 Investigative T37693 DRUGINFO D0Z7FF JWH-246 Investigative T37693 DRUGINFO D0Z7OB (E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide Investigative T37693 DRUGINFO D0ZL2P JWH-369 Investigative T37693 DRUGINFO D0ZM1T VER-156085 Investigative T37693 DRUGINFO D01MCD (2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D02GOH AM-404 Investigative T37693 DRUGINFO D06NXC N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX) Investigative T37693 DRUGINFO D0D6OH [3H]CP55940 Investigative T37693 DRUGINFO D0FJ1I N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D0L1UA N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide Investigative T37693 DRUGINFO D0OQ5H 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T37693 DRUGINFO D0PC5A VER-156084 Investigative T77913 TARGETID T77913 T77913 FORMERID TTDS00086 T77913 UNIPROID HRH1_HUMAN T77913 TARGNAME Histamine H1 receptor (H1R) T77913 GENENAME HRH1 T77913 TARGTYPE Successful T77913 SYNONYMS HH1R; H1R T77913 FUNCTION In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system. T77913 PDBSTRUC 3RZE T77913 BIOCLASS GPCR rhodopsin T77913 SEQUENCE MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHTVGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFILCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKCETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLRPENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKLYCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSRTDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFIMAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFKRILHIRS T77913 DRUGINFO D00FGV Carbinoxamine Approved T77913 DRUGINFO D00JVR Azelastine Approved T77913 DRUGINFO D00TLN Cyproheptadine Approved T77913 DRUGINFO D01GBY Desloratadine Approved T77913 DRUGINFO D01KPV Fexofenadine Approved T77913 DRUGINFO D01NJI Mepyramine maleate Approved T77913 DRUGINFO D02WIW Dexbrompheniramine Approved T77913 DRUGINFO D02XJI Emedastine Approved T77913 DRUGINFO D03XSJ Buclizine Approved T77913 DRUGINFO D04OBB Pheniramine Approved T77913 DRUGINFO D04USC Ergotidine Approved T77913 DRUGINFO D05GPO Olopatadine Approved T77913 DRUGINFO D05ZGQ Dexchlorpheniramine Maleate Approved T77913 DRUGINFO D06ABF Loratadine Approved T77913 DRUGINFO D06EQP Aceprometazine Approved T77913 DRUGINFO D06FES Doxepin Approved T77913 DRUGINFO D06FZX Antazoline Approved T77913 DRUGINFO D06MAJ Mizolastine Approved T77913 DRUGINFO D06UDO Phenindamine Approved T77913 DRUGINFO D08CTT Dimethindene Approved T77913 DRUGINFO D08HRJ Cyclizine Approved T77913 DRUGINFO D08HZL Trimeprazine Approved T77913 DRUGINFO D08JZS Mepyramine Approved T77913 DRUGINFO D08SEI Levocabastine Approved T77913 DRUGINFO D08VXO Brompheniramine Approved T77913 DRUGINFO D09IMS Mequitazine Approved T77913 DRUGINFO D0AJ5L Oxatomide Approved T77913 DRUGINFO D0B4JQ Tripelennamine Approved T77913 DRUGINFO D0B7NG Chlorpheniramine Approved T77913 DRUGINFO D0C5XC Clemastine Approved T77913 DRUGINFO D0DK8V Cetirizine Approved T77913 DRUGINFO D0DV3O Epinastine Approved T77913 DRUGINFO D0E8CI Triprolidine Approved T77913 DRUGINFO D0EC6Q Chlophedianol Approved T77913 DRUGINFO D0K5LQ Pemirolast Approved T77913 DRUGINFO D0LR0R Methdilazine Approved T77913 DRUGINFO D0M8PW Levocetirizine dihydrochloride Approved T77913 DRUGINFO D0N7AD Azatadine Approved T77913 DRUGINFO D0O4EU Acrivastine Approved T77913 DRUGINFO D0O6SX Hydroxyzine Approved T77913 DRUGINFO D0O7JW Alcaftadine Approved T77913 DRUGINFO D0Q0RC Ethopropazine Approved T77913 DRUGINFO D0Q3YO Cinnarizine Approved T77913 DRUGINFO D0R9ZB Propiomazine Approved T77913 DRUGINFO D0T2XU Promethazine Approved T77913 DRUGINFO D0U5VZ Bepotastine Approved T77913 DRUGINFO D0U8UV Dimenhydrinate Approved T77913 DRUGINFO D0W6DY Diphenylpyraline Approved T77913 DRUGINFO D0Y2LR Doxylamine Approved T77913 DRUGINFO D0Y5GK Bromodiphenhydramine Approved T77913 DRUGINFO D0YG7M Ketotifen Approved T77913 DRUGINFO D0ZJ1C (S)-(+)-Dimethindene maleate Approved T77913 DRUGINFO D01FGR Diphenhydramine Approved T77913 DRUGINFO D0E6OC Tranilast Approved T77913 DRUGINFO D0S1CQ RUPATADINE Phase 4 T77913 DRUGINFO D01JFM AC-170 Phase 3 T77913 DRUGINFO D0LK4X Carebastine Phase 3 T77913 DRUGINFO D03DRR Noberastine Phase 2 T77913 DRUGINFO D04HAF LY-2624803 Phase 2 T77913 DRUGINFO D08TLI E-4716 Phase 2 T77913 DRUGINFO D08WOJ OBE-101 Phase 2 T77913 DRUGINFO D0E8ZY Vapitadine Phase 2 T77913 DRUGINFO D04JIM UCB-35440 Phase 2 T77913 DRUGINFO D05XEA RP5063 Phase 2 T77913 DRUGINFO D0R6LF Citalopram derivative 1 Patented T77913 DRUGINFO D0FA3G PMID29334795-Compound-61 Patented T77913 DRUGINFO D0VX6P Piperidine derivative 1 Patented T77913 DRUGINFO D08SOF Terfenadine Withdrawn from market T77913 DRUGINFO D0Y2HR Astemizole Withdrawn from market T77913 DRUGINFO D0I5UU Norastemizole Discontinued in Preregistration T77913 DRUGINFO D00WJE SUN-1334H Discontinued in Phase 2 T77913 DRUGINFO D02YBP Mequitamium iodide Discontinued in Phase 2 T77913 DRUGINFO D08RZV HSR-609 Discontinued in Phase 2 T77913 DRUGINFO D09TEI ReN-1869 Discontinued in Phase 2 T77913 DRUGINFO D04IFU GSK835726 Discontinued in Phase 2 T77913 DRUGINFO D09UXP AZD-1744 Discontinued in Phase 1 T77913 DRUGINFO D0B4TT GSK1004723 Discontinued in Phase 1 T77913 DRUGINFO D0FQ4M Selenotifen Terminated T77913 DRUGINFO D0VZ8S KA-398 Terminated T77913 DRUGINFO D01HUN UR-PG131A Investigative T77913 DRUGINFO D01XZI (-)-trans-H2-PAT Investigative T77913 DRUGINFO D05IHR 9-Phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine Investigative T77913 DRUGINFO D06QQS Hydroxyclemastine Investigative T77913 DRUGINFO D08NXC 1-[(Furan-2(5H)-one)-4-methyl]-desloratadine Investigative T77913 DRUGINFO D08TBU Diphenyl(piperidin-4-yl)methanol Investigative T77913 DRUGINFO D0A6IQ 2-(3-iodophenyl)histamine Investigative T77913 DRUGINFO D0B0PP 3,3-diphenylpropan-1-amine Investigative T77913 DRUGINFO D0B9TV (+/-)-cis-H2-PAT Investigative T77913 DRUGINFO D0BT1A 2-pyridylethylamine Investigative T77913 DRUGINFO D0G3OY methylhistaprodifen Investigative T77913 DRUGINFO D0K9KJ BU-E 47 Investigative T77913 DRUGINFO D0PB6B dimethylhistaprodifen Investigative T77913 DRUGINFO D0PC7A (+)-trans-H2-PAT Investigative T77913 DRUGINFO D0QW5N (+)-cis-H2-PAT Investigative T77913 DRUGINFO D0RG8O histaprodifen Investigative T77913 DRUGINFO D0T7AR 2-(3-chlorophenyl)histamine Investigative T77913 DRUGINFO D0UG1U UR-PG55B Investigative T77913 DRUGINFO D0XY3G 2-(2-thiazolyl)ethanamine Investigative T77913 DRUGINFO D0Y5QR 8R-Lisuride Investigative T77913 DRUGINFO D0Y9IB UR-PG153 Investigative T77913 DRUGINFO D0Z1WW (S)-cetirizine Investigative T77913 DRUGINFO D01CXD 9-(Aminomethyl)-9,10-dihydroanthracene Investigative T77913 DRUGINFO D01HJZ N,N-dimethyl-2,2-diphenylethanamine Investigative T77913 DRUGINFO D02GNN N-methyl-3,3-diphenylpropan-1-amine Investigative T77913 DRUGINFO D02SDX N,N-Dimethyl-3,3-diphenylpropan-1-amine Investigative T77913 DRUGINFO D02YSX DIMEBOLIN Investigative T77913 DRUGINFO D03SNI VUF-10148 Investigative T77913 DRUGINFO D03VUU 2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine Investigative T77913 DRUGINFO D04SCQ 4,4-Diphenylbutan-1-amine Investigative T77913 DRUGINFO D04WXI oxo-arpromidine Investigative T77913 DRUGINFO D05RKS N-methyl-4,4-diphenylbutan-1-amine Investigative T77913 DRUGINFO D05YFZ 9-(2-aminoethyl)-9,10-dihydroanthracene Investigative T77913 DRUGINFO D08RCH KF-A6 Investigative T77913 DRUGINFO D08SLS arpromidine Investigative T77913 DRUGINFO D0A1DE MDL-28163 Investigative T77913 DRUGINFO D0AU0F UR-PG146 Investigative T77913 DRUGINFO D0G6AQ 2-(3-bromophenyl)histamine Investigative T77913 DRUGINFO D0I0UW 1-(4-p-Tolyl-butyl)-piperidine Investigative T77913 DRUGINFO D0S0WX 9-(2-aminopropyl)-9,10-dihydroanthracene Investigative T77913 DRUGINFO D0S3WR N,N-dimethyl-4,4-diphenylbutan-1-amine Investigative T77913 DRUGINFO D0H8XV R-dimethindene Investigative T77913 DRUGINFO D0B4SF impromidine Investigative T77913 DRUGINFO D0Y4MC 9-OH-risperidone Investigative T77913 DRUGINFO D0D3YN OCTOCLOTHEPIN Investigative T77913 DRUGINFO D0PN9R R-226161 Investigative T77913 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T58921 TARGETID T58921 T58921 FORMERID TTDS00338 T58921 UNIPROID PPARG_HUMAN T58921 TARGNAME Peroxisome proliferator-activated receptor gamma (PPAR-gamma) T58921 GENENAME PPARG T58921 TARGTYPE Successful T58921 SYNONYMS PPAR-gamma; Nuclear receptor subfamily 1 group C member 3; NR1C3 T58921 FUNCTION Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity). T58921 PDBSTRUC 6MD4; 6MD2; 6MD1; 6MD0; 6MCZ T58921 BIOCLASS Nuclear hormone receptor T58921 SEQUENCE MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY T58921 DRUGINFO D03OFF Pioglitazone Approved T58921 DRUGINFO D06XZW Troglitazone Approved T58921 DRUGINFO D0K5ER Rosiglitazone XR Approved T58921 DRUGINFO D0K8IX Thiazolidinedione Approved T58921 DRUGINFO D04BCB Lobeglitazone Approved T58921 DRUGINFO D0S2BV Glitazone Phase 4 T58921 DRUGINFO D08PFA Rivoglitazone Phase 3 T58921 DRUGINFO D0F3NH Balaglitazone Phase 3 T58921 DRUGINFO D0M0SS FARGLITAZAR Phase 3 T58921 DRUGINFO D0Q6IW Rosiglitazone + simvastatin Phase 3 T58921 DRUGINFO DCA13V Leriglitazone Phase 3 T58921 DRUGINFO D02NHD Ragaglitazar Phase 3 T58921 DRUGINFO D0F5JH CS-038 Phase 3 T58921 DRUGINFO D0H1NL TESAGLITAZAR Phase 3 T58921 DRUGINFO D0M3UT MURAGLITAZAR Phase 3 T58921 DRUGINFO D0T7MN ZYH-1 Phase 3 T58921 DRUGINFO D0VU5M Imiglitazar Phase 3 T58921 DRUGINFO D0A1AQ Rosiglitazone + metformin Phase 3 T58921 DRUGINFO D0X7VB MBX-102 Phase 2/3 T58921 DRUGINFO D00PJJ FK-614 Phase 2 T58921 DRUGINFO D02TGD Netoglitazone Phase 2 T58921 DRUGINFO D08NPG MBX-2044 Phase 2 T58921 DRUGINFO D0E6ME GED-0507-34-Levo Phase 2 T58921 DRUGINFO D0P5SU CHS-131 Phase 2 T58921 DRUGINFO D0W0JP OMS405 Phase 2 T58921 DRUGINFO D04BPS Naveglitazar Phase 2 T58921 DRUGINFO D0PP8G ONO-5129 Phase 2 T58921 DRUGINFO D53BEH T3D‐959 Phase 2 T58921 DRUGINFO D0ZT8A T3D-959 Phase 1/2 T58921 DRUGINFO D06TWE CLX-0921 Phase 1 T58921 DRUGINFO D07IGC DSP-8658 Phase 1 T58921 DRUGINFO D08EEU Englitazone sodium Phase 1 T58921 DRUGINFO D03RJZ Oxeglitazar Phase 1 T58921 DRUGINFO D0AX9S GW-409544 Phase 1 T58921 DRUGINFO D03GFB Spirolaxine derivative 1 Patented T58921 DRUGINFO D09OXG Phenylpropionic acid derivative 1 Patented T58921 DRUGINFO D0E9GF A-substituted phenylpropionic acid derivative 1 Patented T58921 DRUGINFO D0G3KY PMID25416646-Compound-Figure2-K Patented T58921 DRUGINFO D0GG5K PMID25416646-Compound-Figure2-N Patented T58921 DRUGINFO D0H5FI MRL24 Patented T58921 DRUGINFO D0HT9C Sulfonamide derivative 18 Patented T58921 DRUGINFO D0M4RD Crystalline anhydrous toluene derivative 1 Patented T58921 DRUGINFO D0M5YQ A-substituted phenylpropionic acid derivative 2 Patented T58921 DRUGINFO D0O8PR Biaromatic compound 1 Patented T58921 DRUGINFO D0PO7F MRL20 Patented T58921 DRUGINFO D0SL0K Fused ring compound 1 Patented T58921 DRUGINFO D0SV6U 3-phenyl acrylic acid derivative 1 Patented T58921 DRUGINFO D0TF0T Thiazolidine dione crystalline derivative 1 Patented T58921 DRUGINFO D0UG1W Fused aromatic compound 1 Patented T58921 DRUGINFO D0UH5B PMID25416646-Compound-Figure2-J Patented T58921 DRUGINFO D0ZO0D Cannabinoid quinone derivative 1 Patented T58921 DRUGINFO D05AUY PMID25416646-Compound-Figure5-H Patented T58921 DRUGINFO D0HW6Y Flavonoid derivative 8 Patented T58921 DRUGINFO D0LA6O PMID25416646-Compound-Figure5-E Patented T58921 DRUGINFO D0NF8V Phenylpyridine derivative 3 Patented T58921 DRUGINFO D0O5IN PMID25416646-Compound-Figure5-A Patented T58921 DRUGINFO D0U6AW 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 Patented T58921 DRUGINFO D0V0JN PMID25416646-Compound-Figure5-C Patented T58921 DRUGINFO D0KL3K YM-440 Discontinued in Phase 2 T58921 DRUGINFO D02RAU KRP-297 Discontinued in Phase 2 T58921 DRUGINFO D02ZKL Reglixane Discontinued in Phase 2 T58921 DRUGINFO D0W2IU AVE-0847 Discontinued in Phase 2 T58921 DRUGINFO D01JGG Sodelglitazar Discontinued in Phase 2 T58921 DRUGINFO D09OHP Indeglitazar Discontinued in Phase 2 T58921 DRUGINFO D0S6KX GSK-677954 Discontinued in Phase 2 T58921 DRUGINFO D0Z6OI DS-6930 Discontinued in Phase 1 T58921 DRUGINFO D06PHO E-3030 Discontinued in Phase 1 T58921 DRUGINFO D0B0EB LY-929 Discontinued in Phase 1 T58921 DRUGINFO D03GWY Ciglitazone Preclinical T58921 DRUGINFO D08WOE MC-3002 Preclinical T58921 DRUGINFO D00YGA SB-219994 Terminated T58921 DRUGINFO D04JVX AKP-320 Terminated T58921 DRUGINFO D08VKZ Edaglitazone Terminated T58921 DRUGINFO D0N1EF DARGLITAZONE Terminated T58921 DRUGINFO D0I0RF BVT-142 Terminated T58921 DRUGINFO D0LB4T AD-5075 Terminated T58921 DRUGINFO D0OW6Z Sipoglitazar Terminated T58921 DRUGINFO D0V0TT CS-204 Terminated T58921 DRUGINFO D01PGU 15-deoxy-Delta(12, 14)-prostaglandin J(2) Investigative T58921 DRUGINFO D06MDX (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid Investigative T58921 DRUGINFO D0E5HC 3-(5-methoxy-1H-indol-3-yl)propanoic acid Investigative T58921 DRUGINFO D0H4US (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid Investigative T58921 DRUGINFO D0J3UU (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid Investigative T58921 DRUGINFO D0O2US GW7845 Investigative T58921 DRUGINFO D0Z5TV (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid Investigative T58921 DRUGINFO D01POG GW-2331 Investigative T58921 DRUGINFO D0SZ4T 9-hydroxyoctadecadienoic acid Investigative T58921 DRUGINFO D0Z4MH ZY H2 Investigative T58921 DRUGINFO D00ACX 2-chloro-5-nitro-N-phenylbenzamide Investigative T58921 DRUGINFO D01ARG DB-900 Investigative T60857 TARGETID T60857 T60857 FORMERID TTDR00033 T60857 UNIPROID AK1C3_HUMAN T60857 TARGNAME Dihydrodiol dehydrogenase type I (AKR1C3) T60857 GENENAME AKR1C3 T60857 TARGTYPE Successful T60857 SYNONYMS Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; Testosterone 17-beta-dehydrogenase 5; Prostaglandin F synthase; PGFS; KIAA0119; Indanol dehydrogenase; HSD17B5; HA1753; Dihydrodiol dehydrogenase 3; DDH1; DD3; DD-3; Chlordecone reductase homolog HAKRb; Aldo-keto reductase family 1 member C3; 3-alpha-hydroxysteroid dehydrogenase type 2; 3-alpha-HSD type II, brain; 3-alpha-HSD type 2; 17-beta-hydroxysteroid dehydrogenase type 5; 17-beta-HSD 5 T60857 FUNCTION Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone. T60857 PDBSTRUC 6GXK; 6F78; 6F2U; 5JM5; 5HNU T60857 BIOCLASS Short-chain dehydrogenases reductase T60857 ECNUMBER EC 1.-.-.- T60857 SEQUENCE MDSKHQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLDRNLHYFNSDSFASHPNYPYSDEY T60857 DRUGINFO D0B2WJ Flufenamic Acid Approved T60857 DRUGINFO D0H7XJ ASP-9521 Phase 1/2 T60857 DRUGINFO D02JPV N-(benzimidazole/indole) benzoic acid derivative 2 Patented T60857 DRUGINFO D05GKS N-(phenylamino)-benzoate derivative 1 Patented T60857 DRUGINFO D0E2TY Indomethacin analog 3 Patented T60857 DRUGINFO D0F0PK Indomethacin analog 2 Patented T60857 DRUGINFO D0G8VB Beta-naphthylacetic acids derivative 1 Patented T60857 DRUGINFO D0GY2Z Indomethacin analog 1 Patented T60857 DRUGINFO D0M6LX N-(naphthylamino)-benzoate derivative 1 Patented T60857 DRUGINFO D0N3XY N-(benzimidazolylcarbonyl)-piperidine derivative 1 Patented T60857 DRUGINFO D0PI1W Nitrogen/sulfur-substituted estrene derivative 1 Patented T60857 DRUGINFO D0Q8RC N-(indolylcarbonyl)-piperidine derivative 1 Patented T60857 DRUGINFO D0S6TL N-(benzimidazole/indole) benzoic acid derivative 1 Patented T60857 DRUGINFO D0SM2O N-(pyridinepyrroylylcarbonyl)-piperidine derivative 1 Patented T60857 DRUGINFO D0Y7XJ Isoquinolone derivative 1 Patented T60857 DRUGINFO D00DDO 3-Bromo-5-phenylsalicylc acid Investigative T60857 DRUGINFO D00XMO 2-(4-chlorobenzylidene)cyclopentyl ethyl ether Investigative T60857 DRUGINFO D03POE 2-[(2,2-diphenylacetyl)amino]benzoic acid Investigative T60857 DRUGINFO D09ALJ Rutin Investigative T60857 DRUGINFO D0DF1Z M-Phenoxybenzoic Acid For Cis-Isomer Investigative T60857 DRUGINFO D0K9YS EM1396 Investigative T60857 DRUGINFO D0MC5H 2-(4-Chlorobenzylidene)cyclopentanone Investigative T60857 DRUGINFO D0Q9RA 2-(4-chlorobenzylidene)cyclopentylmethyl ether Investigative T60857 DRUGINFO D0V5AQ 2,2-Dibenzylcyclopentanol Investigative T60857 DRUGINFO D0Z0IR 3-Phenylcyclopentanecarboxylic acid Investigative T60857 DRUGINFO D0ZR1V EM-1424 Investigative T60857 DRUGINFO D0M8RO 4-ANDROSTENE-3-17-DIONE Investigative T60857 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T60857 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T60857 DRUGINFO D0F2ME Acetate Ion Investigative T80276 TARGETID T80276 T80276 FORMERID TTDNC00388 T80276 UNIPROID PK3CA_HUMAN T80276 TARGNAME PI3-kinase alpha (PIK3CA) T80276 GENENAME PIK3CA T80276 TARGTYPE Successful T80276 SYNONYMS p110alpha; Serine/threonine protein kinase PIK3CA; PtdIns3kinase subunit p110alpha; PtdIns3kinase subunit alpha; PtdIns-3-kinase subunit p110-alpha; PtdIns-3-kinase subunit alpha; Phosphoinositide3kinase catalytic alpha polypeptide; Phosphoinositide-3-kinase catalytic alpha polypeptide; Phosphatidylinositol 4,5bisphosphate 3kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5bisphosphate 3kinase 110 kDa catalytic subunit alpha; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; PI3kinase subunit alpha; PI3Kalpha; PI3K-alpha; PI3-kinase subunit alpha T80276 FUNCTION Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Also has serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS. Plays a role in the positive regulation of phagocytosis and pinocytosis. T80276 PDBSTRUC 6NCT; 5XGJ; 5XGI; 5XGH; 5UL1 T80276 BIOCLASS Kinase T80276 ECNUMBER EC 2.7.1.153 T80276 SEQUENCE MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN T80276 DRUGINFO D0W7HE Alpelisib Approved T80276 DRUGINFO D0S5LD BAY 80-6946 Approved T80276 DRUGINFO D0UP1Z GDC-0032 Phase 3 T80276 DRUGINFO D01QSO Buparlisib Phase 3 T80276 DRUGINFO D0H1WC LY3023414 Phase 2 T80276 DRUGINFO D0Y2NS MLN1117 Phase 1/2 T80276 DRUGINFO D05CBJ PA-799 Phase 1/2 T80276 DRUGINFO D01LMM BLY719 Phase 1 T80276 DRUGINFO D8IJR1 LY3849524 Phase 1 T80276 DRUGINFO DYF2N4 HHCYH33 Phase 1 T80276 DRUGINFO D0Y0FE PWT-33597 Phase 1 T80276 DRUGINFO DOR1I0 ETP-46321 Investigative T62431 TARGETID T62431 T62431 FORMERID TTDC00156 T62431 UNIPROID KSYK_HUMAN T62431 TARGNAME Tyrosine-protein kinase SYK (SYK) T62431 GENENAME SYK T62431 TARGTYPE Successful T62431 SYNONYMS p72-Syk; Spleen tyrosine kinase T62431 FUNCTION Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK. Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition. Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR plays also a role in T-cell receptor signaling. Plays also a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF-kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade. Required for the stimulation of neutrophil phagocytosis by IL15. Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Involved in interleukin-3/IL3-mediated signaling pathway in basophils. Also functions downstream of receptors mediating cell adhesion. Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG-mediated recruitment of leukocytes to inflammatory loci. Plays also a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen. Together with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response. Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). T62431 PDBSTRUC 6HM7; 6HM6; 5Y5U; 5Y5T; 5TT7 T62431 BIOCLASS Kinase T62431 ECNUMBER EC 2.7.10.2 T62431 SEQUENCE MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRKAHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPFEDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQIVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQLVEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPATWSAGGIISRIKSYSFPKPGHRKSSPAQGNRQESTVSFNPYEPELAPWAADKGPQREALPMDTEVYESPYADPEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN T62431 DRUGINFO D0V8HJ Fostamatinib Approved T62431 DRUGINFO D00OPX Fostamatinib disodium Phase 3 T62431 DRUGINFO D0BW6F GS-9876 Phase 2 T62431 DRUGINFO D0G9AW GS-9973 Phase 2 T62431 DRUGINFO DY57LN Cevidoplenib Phase 2 T62431 DRUGINFO D06KTJ TAK-659 Phase 2 T62431 DRUGINFO D0BI3N Cerdulatinib Phase 2 T62431 DRUGINFO DI1VM3 HM43239 Phase 1/2 T62431 DRUGINFO D2JZ3U ALXN2075 Phase 1/2 T62431 DRUGINFO D01IDW SKI-O-703 Phase 1 T62431 DRUGINFO D0C0SZ PRT6207 Phase 1 T62431 DRUGINFO D0H2HZ GSK2646264 Phase 1 T62431 DRUGINFO D0R9IU PRT-062607 Phase 1 T62431 DRUGINFO D7CI9P BI 894416 Phase 1 T62431 DRUGINFO DODG42 HMPL-523 Phase 1 T62431 DRUGINFO DG2EK3 PUR1800 Phase 1 T62431 DRUGINFO D0S6TK tamatinib Clinical trial T62431 DRUGINFO D0CD6Y Pyrimidopyridazinone derivative 1 Patented T62431 DRUGINFO D0JU1R Pyrrolo-pyrazine derivative 3 Patented T62431 DRUGINFO D0Y6ON Pyrrolo-pyrazine derivative 4 Patented T62431 DRUGINFO D0WA1V Pyrimidopyridazinone derivative 2 Patented T62431 DRUGINFO D08DBE R-343 Discontinued in Phase 2 T62431 DRUGINFO D0Y2XQ PF-3526299 Discontinued in Phase 1 T62431 DRUGINFO D00EIL CG-103065 Investigative T62431 DRUGINFO D04LGK VRT-750018 Investigative T62431 DRUGINFO D09KEB PRT-060318 Investigative T62431 DRUGINFO D0C7AS N-Benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide Investigative T62431 DRUGINFO D0J3FK DNX-2000 Investigative T62431 DRUGINFO D03YUW SBB007833 Investigative T62431 DRUGINFO D0O6OH PMID23312943C21 Investigative T62431 DRUGINFO D0T4MJ K00592a Investigative T62431 DRUGINFO D04TLI PMID17600705C23 Investigative T62431 DRUGINFO D0A1CM ELLAGIC ACID Investigative T97613 TARGETID T97613 T97613 FORMERID TTDI01766 T97613 UNIPROID MTR1A_HUMAN T97613 TARGNAME Melatonin receptor type 1A (MTNR1A) T97613 GENENAME MTNR1A T97613 TARGTYPE Successful T97613 SYNONYMS Mel1a receptor; Mel1AR; Mel-1A-R T97613 FUNCTION Likely to mediate the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity. High affinity receptor for melatonin. T97613 PDBSTRUC 6ME5; 6ME4; 6ME3; 6ME2 T97613 BIOCLASS GPCR rhodopsin T97613 SEQUENCE MQGNGSALPNASQPVLRGDGARPSWLASALACVLIFTIVVDILGNLLVILSVYRNKKLRNAGNIFVVSLAVADLVVAIYPYPLVLMSIFNNGWNLGYLHCQVSGFLMGLSVIGSIFNITGIAINRYCYICHSLKYDKLYSSKNSLCYVLLIWLLTLAAVLPNLRAGTLQYDPRIYSCTFAQSVSSAYTIAVVVFHFLVPMIIVIFCYLRIWILVLQVRQRVKPDRKPKLKPQDFRNFVTMFVVFVLFAICWAPLNFIGLAVASDPASMVPRIPEWLFVASYYMAYFNSCLNAIIYGLLNQNFRKEYRRIIVSLCTARVFFVDSSNDVADRVKWKPSPLMTNNNVVKVDSV T97613 DRUGINFO D0AN7B Melatonin Approved T97613 DRUGINFO D0Q5MQ Tasimelteon Approved T97613 DRUGINFO D0U0KW Ramelteon Approved T97613 DRUGINFO D0D8FN LY-156735 Phase 2 T97613 DRUGINFO D00CVJ Neu-P11 Phase 2 T97613 DRUGINFO D0Y8UB Agomelatine Withdrawn from market T97613 DRUGINFO D01ESJ Luzindole Terminated T97613 DRUGINFO D05GOM S-20928 Terminated T97613 DRUGINFO D0B1VQ GR-133347 Terminated T97613 DRUGINFO D0B2CQ GR-131663 Terminated T97613 DRUGINFO D0T4XV SL-18.1616 Terminated T97613 DRUGINFO D01SNS IIK7 Investigative T97613 DRUGINFO D01YDR [125I]SD6 Investigative T97613 DRUGINFO D02VIZ GR 196429 Investigative T97613 DRUGINFO D03OGA 2-methoxy-alpha,beta-didehydro-agomelatine Investigative T97613 DRUGINFO D04BLO difluoroagomelatine Investigative T97613 DRUGINFO D04VGL 4P-PDOT Investigative T97613 DRUGINFO D04YWX S22153 Investigative T97613 DRUGINFO D06AUM S26284 Investigative T97613 DRUGINFO D07BKH (hydroxymethylphenyl)agomelatine Investigative T97613 DRUGINFO D07EOD S24773 Investigative T97613 DRUGINFO D07FDL N-(2,3-Dihydro-1H-phenalen-2-yl)-acetamide Investigative T97613 DRUGINFO D07MFG CBOBNEA Investigative T97613 DRUGINFO D07YFL EFPPEA Investigative T97613 DRUGINFO D08SGV 5-HEAT Investigative T97613 DRUGINFO D08TBF BOMPPA Investigative T97613 DRUGINFO D08WOV 2-[125I]melatonin Investigative T97613 DRUGINFO D08ZJM isoamyl-agomelatine Investigative T97613 DRUGINFO D09HWZ [125I]S70254 Investigative T97613 DRUGINFO D09LPG GR 128107 Investigative T97613 DRUGINFO D0B8PD 6-Cl-MLT Investigative T97613 DRUGINFO D0F9ZW N-acetylserotonin Investigative T97613 DRUGINFO D0I4DJ AAE-M-PBP-amine Investigative T97613 DRUGINFO D0K1HD UCM 793 Investigative T97613 DRUGINFO D0OY8Y UCM 549 Investigative T97613 DRUGINFO D0Q0LH S24014 Investigative T97613 DRUGINFO D0Q3WV [125I]DIV880 Investigative T97613 DRUGINFO D0R5JD S26131 Investigative T97613 DRUGINFO D0RF4L 5-methoxy-luzindole Investigative T97613 DRUGINFO D0S3NS 2-(indolin-1yl)-melatonin Investigative T97613 DRUGINFO D0S6SN 6-hydroxymelatonin Investigative T97613 DRUGINFO D0TM0N UCM 765 Investigative T97613 DRUGINFO D0WE4C K185 Investigative T97613 DRUGINFO D0XX9Y DH97 Investigative T97613 DRUGINFO D0Y2JY CIFEA Investigative T97613 DRUGINFO D0YN8Q UCM 724 Investigative T97613 DRUGINFO D01FVY N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide Investigative T97613 DRUGINFO D01LAU 5-methoxycarbonylamino-N-acetyltryptamine Investigative T97613 DRUGINFO D01UIY N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide Investigative T97613 DRUGINFO D05EDR Beta-methylmelatonin Investigative T97613 DRUGINFO D05WKI UCM-454 Investigative T97613 DRUGINFO D07ZQU N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide Investigative T97613 DRUGINFO D09ETU N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide Investigative T97613 DRUGINFO D0D6IK N-(3-(3-methoxyphenyl)propyl)propionamide Investigative T97613 DRUGINFO D0F6VI N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide Investigative T97613 DRUGINFO D0O2GK N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide Investigative T97613 DRUGINFO D0Q6HT Beta,beta-dimethylmelatonin Investigative T97613 DRUGINFO D0U8OS N-(3-(3-methoxyphenyl)propyl)acetamide Investigative T97613 DRUGINFO D0V7VF N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide Investigative T97613 DRUGINFO D0W7ZB N-(3-(2,5-dimethoxyphenyl)propyl)acetamide Investigative T97613 DRUGINFO D0H6YF 2-iodo-melatonin Investigative T97613 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T95913 TARGETID T95913 T95913 FORMERID TTDR00356 T95913 UNIPROID PK3CG_HUMAN T95913 TARGNAME PI3-kinase gamma (PIK3CG) T95913 GENENAME PIK3CG T95913 TARGTYPE Successful T95913 SYNONYMS p120-PI3K; p110gamma; Serine/threonine protein kinase PIK3CG; PtdIns-3-kinase subunit p110-gamma; PtdIns-3-kinase subunit gamma; PtdIns-3-kinase p110; Phosphoinositol-3 kinase; Phosphoinositide-3-kinase catalytic gamma polypeptide; Phosphoinositide 3-Kinase gamma; Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma; PI3Kgamma; PI3K-gamma; PI3K; PI3-kinase subunit gamma; PI3-kinase p110 subunit gamma T95913 FUNCTION Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G-protein coupled receptor activation to PIP3 production. Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarization and migration by regulating the spatial accumulation of PIP3 and by regulating the organization of F-actin formation and integrin-based adhesion at the leading edge. Controls motility of dendritic cells. Together with PIK3CD is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in T-lymphocyte migration. Regulates T-lymphocyte proliferation and cytokine production. Together with PIK3CD participates in T-lymphocyte development. Required for B-lymphocyte development and signaling. Together with PIK3CD participates in neutrophil respiratory burst. Together with PIK3CD is involved in neutrophil chemotaxis and extravasation. Together with PIK3CB promotes platelet aggregation and thrombosis. Regulates alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) adhesive function in platelets downstream of P2Y12 through a lipid kinase activity-independent mechanism. May have also a lipid kinase activity-dependent function in platelet aggregation. Involved in endothelial progenitor cell migration. Negative regulator of cardiac contractility. Modulates cardiac contractility by anchoring protein kinase A (PKA) and PDE3B activation, reducing cAMP levels. Regulates cardiac contractility also by promoting beta-adrenergic receptor internalization by binding to GRK2 and by non-muscle tropomyosin phosphorylation. Also has serine/threonine protein kinase activity: both lipid and protein kinase activities are required for beta-adrenergic receptor endocytosis. May also have a scaffolding role in modulating cardiac contractility. Contributes to cardiac hypertrophy under pathological stress. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis. T95913 PDBSTRUC 6GQ7; 6FH5; 6C1S; 6AUD; 5T23 T95913 BIOCLASS Kinase T95913 ECNUMBER EC 2.7.1.153 T95913 SEQUENCE MELENYKQPVVLREDNCRRRRRMKPRSAAASLSSMELIPIEFVLPTSQRKCKSPETALLHVAGHGNVEQMKAQVWLRALETSVAADFYHRLGPHHFLLLYQKKGQWYEIYDKYQVVQTLDCLRYWKATHRSPGQIHLVQRHPPSEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSEQDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVQLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSA T95913 DRUGINFO D0RU0O IPI-145 Approved T95913 DRUGINFO D0S5LD BAY 80-6946 Approved T95913 DRUGINFO D0KF9Q Rigosertib Phase 3 T95913 DRUGINFO D0UP1Z GDC-0032 Phase 3 T95913 DRUGINFO D0I6VU Enzastaurin Phase 3 T95913 DRUGINFO D01QSO Buparlisib Phase 3 T95913 DRUGINFO D03KAC XL147 Phase 2 T95913 DRUGINFO D03KHN CLR-1404 Phase 2 T95913 DRUGINFO D07BGC GDC-0084 Phase 2 T95913 DRUGINFO D08QGT GDC0941 Phase 2 T95913 DRUGINFO D0AW5T PX-866 Phase 2 T95913 DRUGINFO D0GW8X GDC-0077 Phase 2 T95913 DRUGINFO D0I3LO IPI-549 Phase 2 T95913 DRUGINFO D01PGR SAR245409 Phase 2 T95913 DRUGINFO D03NJY SF1126 Phase 2 T95913 DRUGINFO D0D8JB PF-05212384 Phase 2 T95913 DRUGINFO D0N5JZ PF-04691502 Phase 2 T95913 DRUGINFO D0O6VZ GDC-0980/RG7422 Phase 2 T95913 DRUGINFO D0VG0D BEZ235 Phase 2 T95913 DRUGINFO DQ62LM AZD8154 Phase 2 T95913 DRUGINFO D0TU7B PQR309 Phase 2 T95913 DRUGINFO D07ACZ CLR457 Phase 1/2 T95913 DRUGINFO D07MEX CLR-1401 Phase 1/2 T95913 DRUGINFO D0C3ZR TG100-115 Phase 1/2 T95913 DRUGINFO D0E6UZ CUDC-907 Phase 1/2 T95913 DRUGINFO D0X7IN BGT226 Phase 1/2 T95913 DRUGINFO DHX7S8 ZX-101A Phase 1/2 T95913 DRUGINFO D05CBJ PA-799 Phase 1/2 T95913 DRUGINFO D03EZE GSK2126458 Phase 1 T95913 DRUGINFO D09SFV LY294002 Phase 1 T95913 DRUGINFO D0J8MA KA2237 Phase 1 T95913 DRUGINFO D0O1LD ZSTK474 Phase 1 T95913 DRUGINFO D0R1VU Perifosine Phase 1 T95913 DRUGINFO D0R8ID P-7170 Phase 1 T95913 DRUGINFO D03BHZ AZD8186 Phase 1 T95913 DRUGINFO D0X4RT DS-7423 Phase 1 T95913 DRUGINFO D0U3DP VS-5584 Phase 1 T95913 DRUGINFO D02CQL Adyvia Discontinued in Phase 2 T95913 DRUGINFO D0L0ZC GSK1059615 Discontinued in Phase 1 T95913 DRUGINFO D0T5IN PX-867 Terminated T95913 DRUGINFO D05SXC SCR-44001 Terminated T95913 DRUGINFO D0P1JI Wortmannin Terminated T95913 DRUGINFO D00JIV PF-4989216 Investigative T95913 DRUGINFO D00LZO CZC-19091 Investigative T95913 DRUGINFO D02WGD LOR-220 Investigative T95913 DRUGINFO D03DRM AS-604850 Investigative T95913 DRUGINFO D03FIE AEZS-126 Investigative T95913 DRUGINFO D04DBA BAG956 Investigative T95913 DRUGINFO D06PWI CZC 24832 Investigative T95913 DRUGINFO D07PMP PKI-402 Investigative T95913 DRUGINFO D08RBS WX-037 Investigative T95913 DRUGINFO D0J1CF Her2- and PSA-targeted TGX-D1 Investigative T95913 DRUGINFO D0O6JE Multiform PI3K inhibitors Investigative T95913 DRUGINFO D0R2UG HS-173 Investigative T95913 DRUGINFO D0T3PW Myricetin Investigative T95913 DRUGINFO D0W8XH PI-103 Investigative T95913 DRUGINFO D01SSI PI-3065 Investigative T95913 DRUGINFO D02ELN HM-5016699 Investigative T95913 DRUGINFO D05BPX 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol Investigative T95913 DRUGINFO D05RSS PF-03772304 Investigative T95913 DRUGINFO D06DNH TGX-221 Investigative T95913 DRUGINFO D08NQM 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE Investigative T95913 DRUGINFO D0JD4S CU-906 Investigative T95913 DRUGINFO D0QE9F P-6915 Investigative T95913 DRUGINFO D00HSJ PIK-75 Investigative T95913 DRUGINFO D0R0TW KU-0060648 Investigative T95913 DRUGINFO D07APP LY-292223 Investigative T95913 DRUGINFO D0W1ST Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate Investigative T95913 DRUGINFO D03EHM PP121 Investigative T48268 TARGETID T48268 T48268 FORMERID TTDS00422 T48268 UNIPROID MTR1B_HUMAN T48268 TARGNAME Melatonin receptor type 1B (MTNR1B) T48268 GENENAME MTNR1B T48268 TARGTYPE Successful T48268 SYNONYMS Mel1b receptor; Mel1b melatonin receptor; Mel-1B-R T48268 FUNCTION Likely to mediate the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity. High affinity receptor for melatonin. T48268 PDBSTRUC 6ME9; 6ME8; 6ME7; 6ME6 T48268 BIOCLASS GPCR rhodopsin T48268 SEQUENCE MSENGSFANCCEAGGWAVRPGWSGAGSARPSRTPRPPWVAPALSAVLIVTTAVDVVGNLLVILSVLRNRKLRNAGNLFLVSLALADLVVAFYPYPLILVAIFYDGWALGEEHCKASAFVMGLSVIGSVFNITAIAINRYCYICHSMAYHRIYRRWHTPLHICLIWLLTVVALLPNFFVGSLEYDPRIYSCTFIQTASTQYTAAVVVIHFLLPIAVVSFCYLRIWVLVLQARRKAKPESRLCLKPSDLRSFLTMFVVFVIFAICWAPLNCIGLAVAINPQEMAPQIPEGLFVTSYLLAYFNSCLNAIVYGLLNQNFRREYKRILLALWNPRHCIQDASKGSHAEGLQSPAPPIIGVQHQADAL T48268 DRUGINFO D0Q5MQ Tasimelteon Approved T48268 DRUGINFO D0U0KW Ramelteon Approved T48268 DRUGINFO D0RL5B VLB-01 Phase 3 T48268 DRUGINFO D03AJW N-(3-Benzooxazol-7-yl-propyl)-butyramide Investigative T48268 DRUGINFO D03NND N-(3-Benzooxazol-7-yl-propyl)-propionamide Investigative T48268 DRUGINFO D05TRX N-[3-(2-Ethyl-benzooxazol-7-yl)-propyl]-acetamide Investigative T48268 DRUGINFO D0L9YA N-(3-Benzooxazol-7-yl-propyl)-acetamide Investigative T48268 DRUGINFO D01FVY N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide Investigative T48268 DRUGINFO D01LAU 5-methoxycarbonylamino-N-acetyltryptamine Investigative T48268 DRUGINFO D01UIY N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide Investigative T48268 DRUGINFO D05EDR Beta-methylmelatonin Investigative T48268 DRUGINFO D05WKI UCM-454 Investigative T48268 DRUGINFO D07ZQU N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide Investigative T48268 DRUGINFO D09ETU N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide Investigative T48268 DRUGINFO D0D6IK N-(3-(3-methoxyphenyl)propyl)propionamide Investigative T48268 DRUGINFO D0F6VI N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide Investigative T48268 DRUGINFO D0O2GK N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide Investigative T48268 DRUGINFO D0Q6HT Beta,beta-dimethylmelatonin Investigative T48268 DRUGINFO D0U8OS N-(3-(3-methoxyphenyl)propyl)acetamide Investigative T48268 DRUGINFO D0V7VF N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide Investigative T48268 DRUGINFO D0W7ZB N-(3-(2,5-dimethoxyphenyl)propyl)acetamide Investigative T48268 DRUGINFO D0H6YF 2-iodo-melatonin Investigative T76910 TARGETID T76910 T76910 FORMERID TTDS00136 T76910 UNIPROID GSK3A_HUMAN T76910 TARGNAME Glycogen synthase kinase-3 alpha (GSK-3A) T76910 GENENAME GSK3A T76910 TARGTYPE Successful T76910 SYNONYMS Serine/threonineprotein kinase GSK3A; Serine/threonine-protein kinase GSK3A; Glycogen synthase kinase3 alpha; Glycogen synthase kinase 3; GSK3 alpha; GSK-3 alpha; GSK-3 T76910 FUNCTION Requires primed phosphorylation of the majority of its substrates. Contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. Regulates glycogen metabolism in liver, but not in muscle. May also mediate the development of insulin resistance by regulating activation of transcription factors. In Wnt signaling, regulates the level and transcriptional activity of nuclear CTNNB1/beta-catenin. Facilitates amyloid precursor protein (APP) processing and the generation of APP-derived amyloid plaques found in Alzheimer disease. May be involved in the regulation of replication in pancreatic beta-cells. Is necessary for the establishment of neuronal polarity and axon outgrowth. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, leading to activate KAT5/TIP60 acetyltransferase activity and promote acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer. Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), CTNNB1/beta-catenin, APC and AXIN1. T76910 PDBSTRUC 2DFM T76910 BIOCLASS Kinase T76910 ECNUMBER EC 2.7.11.26 T76910 SEQUENCE MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGVGASSSGGGPGGSGGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYTDIKVIGNGSFGVVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGVCHRDIKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFKSRTPPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRCLGTQLPNNRPLPPLFNFSAGELSIQPSLNAILIPPHLRSPAGTTTLTPSSQALTETPTSSDWQSTDATPTLTNSS T76910 DRUGINFO D0Y3KG Valproate Approved T76910 DRUGINFO D0Z1DH LY2090314 Phase 2 T76910 DRUGINFO D5MF8Y Lithium Phase 2 T76910 DRUGINFO D01WAJ PMID27828716-Compound-21 Patented T76910 DRUGINFO D02OGA Thiadiazolidindione derivative 2 Patented T76910 DRUGINFO D03ETN PMID27828716-Compound-18 Patented T76910 DRUGINFO D03SNE PMID27828716-Compound-BIO-acetoxime Patented T76910 DRUGINFO D04RDR Quinoline derivative 15 Patented T76910 DRUGINFO D06ZRL Quinolinyl pyrazinyl urea derivative 1 Patented T76910 DRUGINFO D08CWE PMID27828716-Compound-19 Patented T76910 DRUGINFO D09PGW Spiroquinolone derivative 1 Patented T76910 DRUGINFO D0A4QD Quinoline derivative 14 Patented T76910 DRUGINFO D0CR2E Thiadiazolidindione derivative 3 Patented T76910 DRUGINFO D0FV9Z Pyrazolodihydropyridine derivative 1 Patented T76910 DRUGINFO D0I2RF Indirubin derivative 2 Patented T76910 DRUGINFO D0J6UW Maleimides derivative 3 Patented T76910 DRUGINFO D0J9YX PMID27828716-Compound-17 Patented T76910 DRUGINFO D0M9JE Pyrazole and benzimidazole derivative 1 Patented T76910 DRUGINFO D0NG2F Maleimides derivative 1 Patented T76910 DRUGINFO D0NO7V PMID27828716-Compound-20 Patented T76910 DRUGINFO D0P8RK PMID27828716-Compound-16 Patented T76910 DRUGINFO D0QE2H Thiadiazolidindione derivative 1 Patented T76910 DRUGINFO D0QW6B Maleimides derivative 2 Patented T76910 DRUGINFO D0RD9V Quinolinyl pyrazinyl urea derivative 2 Patented T76910 DRUGINFO D0UL2V PMID27828716-Compound-15 Patented T76910 DRUGINFO D0UZ7I N-naphtyl-N-benzylurea derivative 1 Patented T76910 DRUGINFO D0WX0K Indazole derivative 6 Patented T76910 DRUGINFO D0XR7S Tricyclic 5-quinolone derivative 1 Patented T76910 DRUGINFO D06KNK TDZD-8 Patented T76910 DRUGINFO D0A3MV AR-A014418 Patented T76910 DRUGINFO D0YK9D CHIR-99021 Patented T76910 DRUGINFO D00PWQ KENPAULLONE Patented T76910 DRUGINFO D02BIK AR-534 Investigative T76910 DRUGINFO D07WXT Lithium chloride Investigative T76910 DRUGINFO D0A1YQ SB216763 Investigative T76910 DRUGINFO D0S7ZZ Benzofuran-3-yl-(indol-3-yl)maleimides Investigative T76910 DRUGINFO D06OAH 6-bromoindirubin-3-oxime Investigative T09960 TARGETID T09960 T09960 FORMERID TTDS00326 T09960 UNIPROID CCR5_HUMAN T09960 TARGNAME C-C chemokine receptor type 5 (CCR5) T09960 GENENAME CCR5 T09960 TARGTYPE Successful T09960 SYNONYMS HIV-1 fusion coreceptor; HIV-1 fusion co-receptor; Chemokine receptor CCR5; CMKBR5; CHEMR13; CD195 antigen; CD195; CCR-5; CC-CKR-5; C-C CKR-5 T09960 FUNCTION May play a role in the control of granulocytic lineage proliferation or differentiation. Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. T09960 PDBSTRUC 6MET; 6MEO; 6FGP; 5YY4; 5YD5 T09960 BIOCLASS GPCR rhodopsin T09960 SEQUENCE MDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVILILINCKRLKSMTDIYLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFIILLTIDRYLAVVHAVFALKARTVTFGVVTSVITWVVAVFASLPGIIFTRSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIVILGLVLPLLVMVICYSGILKTLLRCRNEKKRHRAVRLIFTIMIVYFLFWAPYNIVLLLNTFQEFFGLNNCSSSNRLDQAMQVTETLGMTHCCINPIIYAFVGEKFRNYLLVFFQKHIAKRFCKCCSIFQQEAPERASSVYTRSTGEQEISVGL T09960 DRUGINFO D0NR6S Maraviroc Approved T09960 DRUGINFO D09JLI Vicriviroc Phase 3 T09960 DRUGINFO D0CG0N PRO-140 Phase 3 T09960 DRUGINFO D0J7QU E-913 Phase 3 T09960 DRUGINFO D1M8GC PRO 140 Phase 2/3 T09960 DRUGINFO D0Y7NA INCB9471 Phase 2a T09960 DRUGINFO D06FIT SB-728-T Phase 2 T09960 DRUGINFO D0F7PZ PF-232798 Phase 2 T09960 DRUGINFO D0UV4H GSK-706769 Phase 2 T09960 DRUGINFO D0B1SG BMS-813160 Phase 2 T09960 DRUGINFO D0YQ7U Cenicriviroc Phase 2 T09960 DRUGINFO D0A0BK Cal-1 Phase 1/2 T09960 DRUGINFO D06KNE INCB15050 Phase 1 T09960 DRUGINFO D09XXH VCH-286 Phase 1 T09960 DRUGINFO D0K1OK CCR5 mab Phase 1 T09960 DRUGINFO D0O9UC Tak-220 Phase 1 T09960 DRUGINFO D0G6SZ GW873140 Discontinued in Phase 3 T09960 DRUGINFO D06EMW AZD8566 Discontinued in Phase 1 T09960 DRUGINFO D0G6JE SCH-C Discontinued in Phase 1 T09960 DRUGINFO D07GIB AZD5672 Terminated T09960 DRUGINFO D0O9AZ CCR5Qb Terminated T09960 DRUGINFO D0W0LS TAK-779 Terminated T09960 DRUGINFO D01LRC ANIBAMINE Investigative T09960 DRUGINFO D01TYO SCH-210971 Investigative T09960 DRUGINFO D06TQD CMPD-167 Investigative T09960 DRUGINFO D06XIC VARIECOLIN Investigative T09960 DRUGINFO D06XRS N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine Investigative T09960 DRUGINFO D0BD3G 4-(2-(4-chlorobenzyloxy)-5-bromobenzyl)morpholine Investigative T09960 DRUGINFO D0BD6A GT-1282 Investigative T09960 DRUGINFO D0I3IZ (2-(4-chlorobenzyloxy)-5-bromophenyl)methanamine Investigative T09960 DRUGINFO D0J3BT NIFEVIROC Investigative T23172 TARGETID T23172 T23172 FORMERID TTDC00084 T23172 UNIPROID JAK3_HUMAN T23172 TARGNAME Janus kinase 3 (JAK-3) T23172 GENENAME JAK3 T23172 TARGTYPE Successful T23172 SYNONYMS Tyrosine-protein kinase JAK3; Leukocyte janus kinase; L-JAK T23172 FUNCTION Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion. Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. T23172 PDBSTRUC 6NY4; 6GLB; 6GLA; 6GL9; 6DUD T23172 BIOCLASS Kinase T23172 ECNUMBER EC 2.7.10.2 T23172 SEQUENCE MAPPSEETPLIPQRSCSLLSTEAGALHVLLPARGPGPPQRLSFSFGDHLAEDLCVQAAKASGILPVYHSLFALATEDLSCWFPPSHIFSVEDASTQVLLYRIRFYFPNWFGLEKCHRFGLRKDLASAILDLPVLEHLFAQHRSDLVSGRLPVGLSLKEQGECLSLAVLDLARMAREQAQRPGELLKTVSYKACLPPSLRDLIQGLSFVTRRRIRRTVRRALRRVAACQADRHSLMAKYIMDLERLDPAGAAETFHVGLPGALGGHDGLGLLRVAGDGGIAWTQGEQEVLQPFCDFPEIVDISIKQAPRVGPAGEHRLVTVTRTDNQILEAEFPGLPEALSFVALVDGYFRLTTDSQHFFCKEVAPPRLLEEVAEQCHGPITLDFAINKLKTGGSRPGSYVLRRSPQDFDSFLLTVCVQNPLGPDYKGCLIRRSPTGTFLLVGLSRPHSSLRELLATCWDGGLHVDGVAVTLTSCCIPRPKEKSNLIVVQRGHSPPTSSLVQPQSQYQLSQMTFHKIPADSLEWHENLGHGSFTKIYRGCRHEVVDGEARKTEVLLKVMDAKHKNCMESFLEAASLMSQVSYRHLVLLHGVCMAGDSTMVQEFVHLGAIDMYLRKRGHLVPASWKLQVVKQLAYALNYLEDKGLPHGNVSARKVLLAREGADGSPPFIKLSDPGVSPAVLSLEMLTDRIPWVAPECLREAQTLSLEADKWGFGATVWEVFSGVTMPISALDPAKKLQFYEDRQQLPAPKWTELALLIQQCMAYEPVQRPSFRAVIRDLNSLISSDYELLSDPTPGALAPRDGLWNGAQLYACQDPTIFEERHLKYISQLGKGNFGSVELCRYDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRLVMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRDLAARNILVESEAHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYELFTYCDKSCSPSAEFLRMMGCERDVPALCRLLELLEEGQRLPAPPACPAEVHELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLSFS T23172 DRUGINFO D02TUL Ritlecitinib Approved T23172 DRUGINFO D0EG1I Tofacitinib Approved T23172 DRUGINFO D0PN8H Pacritinib Approved T23172 DRUGINFO D05PCM Abrocitinib Approved T23172 DRUGINFO D06EIC ASP-015K Phase 3 T23172 DRUGINFO D04QWQ VX-509 Phase 2/3 T23172 DRUGINFO D6INZ9 ATI-501 Phase 2 T23172 DRUGINFO D6N5UC ATI-502 Phase 2 T23172 DRUGINFO D2KTG5 TD-8236 Phase 2 T23172 DRUGINFO D0BI3N Cerdulatinib Phase 2 T23172 DRUGINFO D2JZ3U ALXN2075 Phase 1/2 T23172 DRUGINFO D0Q0IM SNA-125 Phase 1 T23172 DRUGINFO DI19BZ KN-002 Phase 1 T23172 DRUGINFO DX72LV AZD4604 Phase 1 T23172 DRUGINFO DXVA93 PF-07295324 Phase 1 T23172 DRUGINFO DZ2RH6 GDC-0214 Phase 1 T23172 DRUGINFO D00ZVY Pyrazolopyridine derivative 2 Patented T23172 DRUGINFO D09JLL PMID27774822-Compound-Figure6Example3 Patented T23172 DRUGINFO D0EX5C Pyrrolo-pyrazine derivative 1 Patented T23172 DRUGINFO D0HL5C Pyrrolo-pyrazine derivative 2 Patented T23172 DRUGINFO D0QL7J Tricyclic compound 2 Patented T23172 DRUGINFO D0SX1B Benzimidazole derivative 5 Patented T23172 DRUGINFO D0T5AF PMID27774824-Compound-Figure5Example13 Patented T23172 DRUGINFO D0VJ5M Pyrazolopyridine derivative 1 Patented T23172 DRUGINFO D0WB5U PMID27774822-Compound-Figure2Example4-3 Patented T23172 DRUGINFO D0X6DL PMID27774822-Compound-Figure6Example2 Patented T23172 DRUGINFO D00BYK PMID27774824-Compound-Figure12Example61 Patented T23172 DRUGINFO D00PTE Imidazopyridazine derivative 2 Patented T23172 DRUGINFO D02IET PMID27774824-Compound-Figure3Example7 Patented T23172 DRUGINFO D02VGC Pyrazolopyridine derivative 6 Patented T23172 DRUGINFO D03TEE Tricyclic heterocycle derivative 2 Patented T23172 DRUGINFO D07BND Imidazopyridazine derivative 1 Patented T23172 DRUGINFO D0B9TH PMID27774822-Compound-Figure8Example5 Patented T23172 DRUGINFO D0D1QH Pyrazolopyridine derivative 7 Patented T23172 DRUGINFO D0E2WK PMID27774822-Compound-Figure2Example1-1left Patented T23172 DRUGINFO D0IQ6G PMID27774822-Compound-Figure2Example1-1right Patented T23172 DRUGINFO D0JU1R Pyrrolo-pyrazine derivative 3 Patented T23172 DRUGINFO D0NK1R PMID27774824-Compound-Figure12Example1 Patented T23172 DRUGINFO D0P3UH Imidazopyridine derivative 4 Patented T23172 DRUGINFO D0UH8J PMID27774824-Compound-Figure12Example10 Patented T23172 DRUGINFO D0W8DN PMID27774822-Compound-Figure10Example19 Patented T23172 DRUGINFO D0Y6ON Pyrrolo-pyrazine derivative 4 Patented T23172 DRUGINFO D01EYJ Ruxolitinib derivative 2 Patented T23172 DRUGINFO D07XYI 1,2,4-triazolo[1,5a]pyridine derivative 1 Patented T23172 DRUGINFO D08WPB Five-and-six-membered heterocyclic compound 1 Patented T23172 DRUGINFO D09RUN Pyrazolopyridine derivative 4 Patented T23172 DRUGINFO D09UBE Pyrrole six-membered heteroaryl ring derivative 1 Patented T23172 DRUGINFO D0A6RG PMID27774824-Compound-Figure2Example4 Patented T23172 DRUGINFO D0G0FK Tricyclic compound 1 Patented T23172 DRUGINFO D0G9MM Isoxazole derivative 1 Patented T23172 DRUGINFO D0GH8D PMID27774822-Compound-Figure10Example1 Patented T23172 DRUGINFO D0M3CB PMID27774822-Compound-Figure1Example20 Patented T23172 DRUGINFO D0TX2G Isoxazole derivative 2 Patented T23172 DRUGINFO D0VR6E Pyrrolo-pyridine derivative 3 Patented T23172 DRUGINFO D0XH7H N-methylmethanesulfonamide derivative 1 Patented T23172 DRUGINFO D0Y2IM N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 Patented T23172 DRUGINFO D01CRX Benzimidazole derivative 7 Patented T23172 DRUGINFO D01FVC Bis-aminopyrimidine derivative 1 Patented T23172 DRUGINFO D03QAY Pyrazolopyridine derivative 3 Patented T23172 DRUGINFO D04BOW Tricyclic pyrrolopyridine compound 1 Patented T23172 DRUGINFO D05AXE Aminooxazole carboxamide derivative 1 Patented T23172 DRUGINFO D0FQ4Z Pyrrolo[2,3-d]pyrimidine derivative 6 Patented T23172 DRUGINFO D0GB7G PMID27774824-Compound-Figure6Example12 Patented T23172 DRUGINFO D0KL3B Pyrrolo[2,3-d]pyrimidine derivative 8 Patented T23172 DRUGINFO D0LR6J Bis-aminopyrimidine derivative 2 Patented T23172 DRUGINFO D0LS1O Tricyclic compound 11 Patented T23172 DRUGINFO D0M2WA Tricyclic heterocycle derivative 5 Patented T23172 DRUGINFO D0RJ3W PMID27774822-Compound-Figure11Example5 Patented T23172 DRUGINFO D0S6XT Bis-aminopyrimidine derivative 3 Patented T23172 DRUGINFO D0SJ1Q Bis-aminopyrimidine derivative 4 Patented T23172 DRUGINFO D0U1HA PMID27774824-Compound-Figure3Example18 Patented T23172 DRUGINFO D0U5FZ Pyrrolo[2,3-d]pyrimidine derivative 7 Patented T23172 DRUGINFO D0WA1V Pyrimidopyridazinone derivative 2 Patented T23172 DRUGINFO D0X1FD Tricyclic heterocycle derivative 1 Patented T23172 DRUGINFO D07PTU Imidazo[4,5-c]pyridine derivative 1 Patented T23172 DRUGINFO D0WZ8N PMID27774824-Compound-Figure9Example2up Patented T23172 DRUGINFO D01DBB PMID27774824-Compound-Figure9Example2down Patented T23172 DRUGINFO D09ALF Aminotriazolopyridine derivative 1 Patented T23172 DRUGINFO D0VJ1R Imidazo[4,5-c]pyridine derivative 2 Patented T23172 DRUGINFO D0YR8S PMID27774824-Compound-Figure11Example1up Patented T23172 DRUGINFO D09PIS Pyrazolo[4,3-c]pyridine derivative 2 Patented T23172 DRUGINFO D01XEQ R348 Terminated T23172 DRUGINFO D0Z1HQ PNU156804 Terminated T23172 DRUGINFO D0GZ7B AG490 Terminated T23172 DRUGINFO D0G7YF VX-467 Investigative T23172 DRUGINFO D0M2AN AD-412 Investigative T23172 DRUGINFO D0P1BK NC1153 Investigative T23172 DRUGINFO D0V6VQ PF-956980 Investigative T23172 DRUGINFO D05MHL Atropisomer 1 Investigative T23172 DRUGINFO D0YX5U ZM-39923 Investigative T23172 DRUGINFO D0IR6U CMP-6 Investigative T23172 DRUGINFO D0US9O PMID24359159C19a Investigative T23172 DRUGINFO D09HXU 6-o-tolylquinazolin-2-amine Investigative T23172 DRUGINFO D0E5IP WHI-P154 Investigative T23172 DRUGINFO D02NNT PMID21493067C1d Investigative T23172 DRUGINFO D08RZB PMID15546730C2 Investigative T89361 TARGETID T89361 T89361 FORMERID TTDC00169 T89361 UNIPROID CDK6_HUMAN T89361 TARGNAME Cyclin-dependent kinase 6 (CDK6) T89361 GENENAME CDK6 T89361 TARGTYPE Successful T89361 SYNONYMS Serine/threonine-protein kinase PLSTIRE; Serine/threonine protein kinase PLSTIRE; Cell division protein kinase 6; CDKN6 T89361 FUNCTION Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase at G1 to form a pRB/RB1 kinase and controls the entrance into the cell cycle. Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation and regulates negatively cell differentiation, but is required for the proliferation of specific cell types (e. g. erythroid and hematopoietic cells). Essential for cell proliferation within the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles. Required during thymocyte development. Promotes the production of newborn neurons, probably by modulating G1 length. Promotes, at least in astrocytes, changes in patterns of gene expression, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. Prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation activity, but promotes proliferation of normal myeloid progenitors. Delays senescence. Promotes the proliferation of beta-cells in pancreatic islets of Langerhans. May play a role in the centrosome organization during the cell cycle phases. Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition. T89361 PDBSTRUC 5L2T; 5L2S; 5L2I; 4TTH; 4EZ5 T89361 BIOCLASS Kinase T89361 ECNUMBER EC 2.7.11.22 T89361 SEQUENCE MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRVQTGEEGMPLSTIREVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPGVPTETIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLARIYSFQMALTSVVVTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFRRKPLFRGSSDVDQLGKILDVIGLPGEEDWPRDVALPRQAFHSKSAQPIEKFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYFQDLERCKENLDSHLPPSQNTSELNTA T89361 DRUGINFO D00UZR Palbociclib Approved T89361 DRUGINFO D01HVT Ribociclib Succinate Approved T89361 DRUGINFO D05SBO LY2835219 Approved T89361 DRUGINFO D0AP9E Trilaciclib Approved T89361 DRUGINFO D07ESC Apremilast Approved T89361 DRUGINFO D08MXP LEE011 Phase 3 T89361 DRUGINFO D0WU1O G1T38 Phase 2 T89361 DRUGINFO D4IS0G GLR2007 Phase 1/2 T89361 DRUGINFO D8ZV2Q FCN-437 Phase 1/2 T89361 DRUGINFO D70HZT NUV-422 Phase 1/2 T89361 DRUGINFO D01XZG G1T28-1 Phase 1 T89361 DRUGINFO DYH94Z RGT-419B Phase 1 T89361 DRUGINFO DKCU40 FN-1501 Phase 1 T89361 DRUGINFO D07TVO PMID25726713-Compound-49 Patented T89361 DRUGINFO D0KH7Q PMID25726713-Compound-51 Patented T89361 DRUGINFO D0W4MN Isoquinoline 1,3-dione derivative 1 Patented T89361 DRUGINFO D0WJ3W PMID25726713-Compound-48 Patented T89361 DRUGINFO D0X5VI PMID25726713-Compound-47 Patented T89361 DRUGINFO D0Y8JF PMID25726713-Compound-50 Patented T89361 DRUGINFO D0M5DX Oxazolyl methylthiothiazole derivative 1 Patented T89361 DRUGINFO D07ZJC INOC-005 Preclinical T89361 DRUGINFO D0Y6HA CYC-103 Terminated T89361 DRUGINFO D0Z0KD PD-0183812 Terminated T89361 DRUGINFO D09OAH Fascaplysin Investigative T89361 DRUGINFO D0CI3C Deschloroflavopiridol Investigative T89361 DRUGINFO D0J4ON RGB-286147 Investigative T89361 DRUGINFO D01UYI Chrysin Investigative T89361 DRUGINFO D0MF5Y 3,7,3',4'-TETRAHYDROXYFLAVONE Investigative T89361 DRUGINFO D00RIX APIGENIN Investigative T89361 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T89361 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T89361 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T38338 TARGETID T38338 T38338 FORMERID TTDS00529 T38338 UNIPROID CAC1B_HUMAN T38338 TARGNAME Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) T38338 GENENAME CACNA1B T38338 TARGTYPE Successful T38338 SYNONYMS Voltage-gated calcium channel alpha subunit Cav2.2; Voltage-dependent N-type calcium channel alpha-1B subunit; N-type Ca2+ channel; Calcium channel, L type, alpha-1 polypeptide isoform 5; CACNA1B; Brain calcium channel III; BIII T38338 FUNCTION Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by omega-conotoxin-GVIA (omega-CTx-GVIA) and by omega-agatoxin- IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1B subunit may play a role in directed migration of immature neurons. T38338 PDBSTRUC 2LCM T38338 BIOCLASS Voltage-gated ion channel T38338 SEQUENCE MVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSIAQRARTMALYNPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWPPFEYMILATIIANCIVLALEQHLPDGDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFVFHKGSYLRNGWNVMDFVVVLTGILATAGTDFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMVPLLQIGLLLFFAILMFAIIGLEFYMGKFHKACFPNSTDAEPVGDFPCGKEAPARLCEGDTECREYWPGPNFGITNFDNILFAILTVFQCITMEGWTDILYNTNDAAGNTWNWLYFIPLIIIGSFFMLNLVLGVLSGEFAKERERVENRRAFLKLRRQQQIERELNGYLEWIFKAEEVMLAEEDRNAEEKSPLDVLKRAATKKSRNDLIHAEEGEDRFADLCAVGSPFARASLKSGKTESSSYFRRKEKMFRFFIRRMVKAQSFYWVVLCVVALNTLCVAMVHYNQPRRLTTTLYFAEFVFLGLFLTEMSLKMYGLGPRSYFRSSFNCFDFGVIVGSVFEVVWAAIKPGSSFGISVLRALRLLRIFKVTKYWSSLRNLVVSLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFQDETPTTNFDTFPAAILTVFQILTGEDWNAVMYHGIESQGGVSKGMFSSFYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTKDEEEMEEAANQKLALQKAKEVAEVSPMSAANISIAARQQNSAKARSVWEQRASQLRLQNLRASCEALYSEMDPEERLRFATTRHLRPDMKTHLDRPLVVELGRDGARGPVGGKARPEAAEAPEGVDPPRRHHRHRDKDKTPAAGDQDRAEAPKAESGEPGAREERPRPHRSHSKEAAGPPEARSERGRGPGPEGGRRHHRRGSPEEAAEREPRRHRAHRHQDPSKECAGAKGERRARHRGGPRAGPREAESGEEPARRHRARHKAQPAHEAVEKETTEKEATEKEAEIVEADKEKELRNHQPREPHCDLETSGTVTVGPMHTLPSTCLQKVEEQPEDADNQRNVTRMGSQPPDPNTIVHIPVMLTGPLGEATVVPSGNVDLESQAEGKKEVEADDVMRSGPRPIVPYSSMFCLSPTNLLRRFCHYIVTMRYFEVVILVVIALSSIALAAEDPVRTDSPRNNALKYLDYIFTGVFTFEMVIKMIDLGLLLHPGAYFRDLWNILDFIVVSGALVAFAFSGSKGKDINTIKSLRVLRVLRPLKTIKRLPKLKAVFDCVVNSLKNVLNILIVYMLFMFIFAVIAVQLFKGKFFYCTDESKELERDCRGQYLDYEKEEVEAQPRQWKKYDFHYDNVLWALLTLFTVSTGEGWPMVLKHSVDATYEEQGPSPGYRMELSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKVMSECSLEKNERACIDFAISAKPLTRYMPQNRQSFQYKTWTFVVSPPFEYFIMAMIALNTVVLMMKFYDAPYEYELMLKCLNIVFTSMFSMECVLKIIAFGVLNYFRDAWNVFDFVTVLGSITDILVTEIAETNNFINLSFLRLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQVFGNIALDDDTSINRHNNFRTFLQALMLLFRSATGEAWHEIMLSCLSNQACDEQANATECGSDFAYFYFVSFIFLCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEFIRVWAEYDPAACGRISYNDMFEMLKHMSPPLGLGKKCPARVAYKRLVRMNMPISNEDMTVHFTSTLMALIRTALEIKLAPAGTKQHQCDAELRKEISVVWANLPQKTLDLLVPPHKPDEMTVGKVYAALMIFDFYKQNKTTRDQMQQAPGGLSQMGPVSLFHPLKATLEQTQPAVLRGARVFLRQKSSTSLSNGGAIQNQESGIKESVSWGTQRTQDAPHEARPPLERGHSTEIPVGRSGALAVDVQMQSITRRGPDGEPQPGLESQGRAASMPRLAAETQPVTDASPMKRSISTLAQRPRGTHLCSTTPDRPPPSQASSHHHHHRCHRRRDRKQRSLEKGPSLSADMDGAPSSAVGPGLPPGEGPTGCRRERERRQERGRSQERRQPSSSSSEKQRFYSCDRFGGREPPKPKPSLSSHPTSPTAGQEPGPHPQGSGSVNGSPLLSTSGASTPGRGGRRQLPQTPLTPRPSITYKTANSSPIHFAGAQTSLPAFSPGRLSRGLSEHNALLQRDPLSQPLAPGSRIGSDPYLGQRLDSEASVHALPEDTLTFEEAVATNSGRSSRTSYVSSLTSQSHPLRRVPNGYHCTLGLSSGGRARHSYHHPDQDHWC T38338 DRUGINFO D01NLB Ziconotide Approved T38338 DRUGINFO D0I9HF Hesperidin Approved T38338 DRUGINFO D0N3ZJ LOMERIZINE Approved T38338 DRUGINFO D00GEG Ralfinamide Phase 3 T38338 DRUGINFO D0N3SR Cilnidipine Phase 3 T38338 DRUGINFO D01UDS CNV-2197944 Phase 2 T38338 DRUGINFO D0K8NW Ritanserin Discontinued in Phase 3 T38338 DRUGINFO D0T4YZ CNSB-004 Preclinical T38338 DRUGINFO D03QMS PD-157667 Terminated T38338 DRUGINFO D04BSZ PD-0204318 Terminated T38338 DRUGINFO D0G6HZ PD-29361 Terminated T38338 DRUGINFO D0QQ7N TH-9229 Terminated T38338 DRUGINFO D06NHS TROX-1 Investigative T38338 DRUGINFO D07BDQ PD-151307 Investigative T38338 DRUGINFO D0C3VI PD-167341 Investigative T38338 DRUGINFO D0GX2A NSC-87509 Investigative T38338 DRUGINFO D0K4ZX Conotoxin Investigative T38338 DRUGINFO D00PVO GNF-PF-3464 Investigative T38338 DRUGINFO D09LRA omega-conotoxin GVIA Investigative T38338 DRUGINFO D0WN7V NSC-180246 Investigative T38338 DRUGINFO D0X7VM KYS-05090 Investigative T38338 DRUGINFO D09YTH CPU-228 Investigative T38338 DRUGINFO D08RJC PD-32577 Investigative T00895 TARGETID T00895 T00895 FORMERID TTDC00066 T00895 UNIPROID KPCE_HUMAN T00895 TARGNAME Protein kinase C epsilon (PRKCE) T00895 GENENAME PRKCE T00895 TARGTYPE Successful T00895 SYNONYMS Protein kinase C epsilon type; PKCE; PKC epsilon; NPKC-epsilon T00895 FUNCTION Mediates cell adhesion to the extracellular matrix via integrin-dependent signaling, by mediating angiotensin-2-induced activation of integrin beta-1 (ITGB1) in cardiac fibroblasts. Phosphorylates MARCKS, which phosphorylates and activates PTK2/FAK, leading to the spread of cardiomyocytes. Involved in the control of the directional transport of ITGB1 in mesenchymal cells by phosphorylating vimentin (VIM), an intermediate filament (IF) protein. In epithelial cells, associates with and phosphorylates keratin-8 (KRT8), which induces targeting of desmoplakin at desmosomes and regulates cell-cell contact. Phosphorylates IQGAP1, which binds to CDC42, mediating epithelial cell-cell detachment prior to migration. In HeLa cells, contributes to hepatocyte growth factor (HGF)-induced cell migration, and in human corneal epithelial cells, plays a critical role in wound healing after activation by HGF. During cytokinesis, forms a complex with YWHAB, which is crucial for daughter cell separation, and facilitates abscission by a mechanism which may implicate the regulation of RHOA. In cardiac myocytes, regulates myofilament function and excitation coupling at the Z-lines, where it is indirectly associated with F-actin via interaction with COPB1. During endothelin-induced cardiomyocyte hypertrophy, mediates activation of PTK2/FAK, which is critical for cardiomyocyte survival and regulation of sarcomere length. Plays a role in the pathogenesis of dilated cardiomyopathy via persistent phosphorylation of troponin I (TNNI3). Involved in nerve growth factor (NFG)-induced neurite outgrowth and neuron morphological change independently of its kinase activity, by inhibition of RHOA pathway, activation of CDC42 and cytoskeletal rearrangement. May be involved in presynaptic facilitation by mediating phorbol ester-induced synaptic potentiation. Phosphorylates gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2), which reduces the response of GABA receptors to ethanol and benzodiazepines and may mediate acute tolerance to the intoxicating effects of ethanol. Upon PMA treatment, phosphorylates the capsaicin- and heat-activated cation channel TRPV1, which is required for bradykinin-induced sensitization of the heat response in nociceptive neurons. Is able to form a complex with PDLIM5 and N-type calcium channel, and may enhance channel activities and potentiates fast synaptic transmission by phosphorylating the pore-forming alpha subunit CACNA1B (CaV2. 2). In prostate cancer cells, interacts with and phosphorylates STAT3, which increases DNA-binding and transcriptional activity of STAT3 and seems to be essential for prostate cancer cell invasion. Downstream of TLR4, plays an important role in the lipopolysaccharide (LPS)-induced immune response by phosphorylating and activating TICAM2/TRAM, which in turn activates the transcription factor IRF3 and subsequent cytokines production. In differentiating erythroid progenitors, is regulated by EPO and controls the protection against the TNFSF10/TRAIL-mediated apoptosis, via BCL2. May be involved in the regulation of the insulin-induced phosphorylation and activation of AKT1. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motility, migration and cell cycle, functions in neuron growth and ion channel regulation, and is involved in immune response, cancer cell invasion and regulation of apoptosis. T00895 PDBSTRUC 5LIH; 2WH0 T00895 BIOCLASS Kinase T00895 ECNUMBER EC 2.7.11.13 T00895 SEQUENCE MVVFNGLLKIKICEAVSLKPTAWSLRHAVGPRPQTFLLDPYIALNVDDSRIGQTATKQKTNSPAWHDEFVTDVCNGRKIELAVFHDAPIGYDDFVANCTIQFEELLQNGSRHFEDWIDLEPEGRVYVIIDLSGSSGEAPKDNEERVFRERMRPRKRQGAVRRRVHQVNGHKFMATYLRQPTYCSHCRDFIWGVIGKQGYQCQVCTCVVHKRCHELIITKCAGLKKQETPDQVGSQRFSVNMPHKFGIHNYKVPTFCDHCGSLLWGLLRQGLQCKVCKMNVHRRCETNVAPNCGVDARGIAKVLADLGVTPDKITNSGQRRKKLIAGAESPQPASGSSPSEEDRSKSAPTSPCDQEIKELENNIRKALSFDNRGEEHRAASSPDGQLMSPGENGEVRQGQAKRLGLDEFNFIKVLGKGSFGKVMLAELKGKDEVYAVKVLKKDVILQDDDVDCTMTEKRILALARKHPYLTQLYCCFQTKDRLFFVMEYVNGGDLMFQIQRSRKFDEPRSRFYAAEVTSALMFLHQHGVIYRDLKLDNILLDAEGHCKLADFGMCKEGILNGVTTTTFCGTPDYIAPEILQELEYGPSVDWWALGVLMYEMMAGQPPFEADNEDDLFESILHDDVLYPVWLSKEAVSILKAFMTKNPHKRLGCVASQNGEDAIKQHPFFKEIDWVLLEQKKIKPPFKPRIKTKRDVNNFDQDFTREEPVLTLVDEAIVKQINQEEFKGFSYFGEDLMP T00895 DRUGINFO D0Y4AW Meprobamate Approved T00895 DRUGINFO D0E6AH Bryostatin-1 Phase 2 T00895 DRUGINFO D0J7CE CDE-6960 Terminated T00895 DRUGINFO D0X0HN LY-317644 Terminated T00895 DRUGINFO D0R5ZR RO-320432 Terminated T00895 DRUGINFO D0D4ZL Phorbol 12-myristate Investigative T00895 DRUGINFO D00TWA [2,2':5',2'']Terthiophen-4-yl-methanol Investigative T00895 DRUGINFO D02PUV 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol Investigative T00895 DRUGINFO D02QME 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile Investigative T00895 DRUGINFO D05LRV [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde Investigative T00895 DRUGINFO D09TSC Ro-32-0557 Investigative T00895 DRUGINFO D09XIE 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile Investigative T00895 DRUGINFO D0A8MN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile Investigative T00895 DRUGINFO D0D3MR [2,2':5',2'']Terthiophene-4-carbaldehyde Investigative T00895 DRUGINFO D0Q3GQ 4-cycloheptyliden(4-hydroxyphenyl)methylphenol Investigative T00895 DRUGINFO D0S9UK 2,3,3-Triphenyl-acrylonitrile Investigative T00895 DRUGINFO D0T0UH 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile Investigative T00895 DRUGINFO D0V9SW 4-cyclohexyliden(4-hydroxyphenyl)methylphenol Investigative T00895 DRUGINFO D06ZCX LY-326449 Investigative T00895 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T00895 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T00895 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T00895 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T00895 DRUGINFO D0L8HO RO-316233 Investigative T97071 TARGETID T97071 T97071 FORMERID TTDS00441 T97071 UNIPROID FOLH1_HUMAN T97071 TARGNAME Glutamate carboxypeptidase II (GCPII) T97071 GENENAME FOLH1 T97071 TARGTYPE Successful T97071 SYNONYMS Pteroylpoly-gamma-glutamate carboxypeptidase; Prostate-specific membrane antigen; PSMA; PSM; NAALADase I; NAALAD1; N-acetylated-alpha-linked acidic dipeptidase I; Membrane glutamate carboxypeptidase; MGCP; Glutamate carboxypeptidase 2; GIG27; Folylpoly-gamma-glutamate carboxypeptidase; Folate hydrolase 1; FOLH; FGCP; Cell growth-inhibiting gene 27 protein T97071 FUNCTION Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Involved in prostate tumor progression. Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. T97071 PDBSTRUC 6HKZ; 6HKJ; 6H7Z; 6H7Y; 6FE5 T97071 BIOCLASS Peptidase T97071 ECNUMBER EC 3.4.17.21 T97071 SEQUENCE MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA T97071 DRUGINFO D09PGL Capromab Approved T97071 DRUGINFO DBG46D PSMA-11 Ga-68 Approved T97071 DRUGINFO DGQW52 Lutetium Lu-177 vipivotide tetraxetan Approved T97071 DRUGINFO DENO78 BAY 2315497 Phase 3 T97071 DRUGINFO DSM5X9 177-Lu-PSMA-617 Phase 3 T97071 DRUGINFO D02EEK J 591 Lu-177 Phase 2 T97071 DRUGINFO D05MOZ G-202 Phase 2 T97071 DRUGINFO D06URI ATL101 Phase 2 T97071 DRUGINFO D08FTP 99mTc-MIP-1404 Phase 2 T97071 DRUGINFO D0H5ER MLN-591RL Phase 2 T97071 DRUGINFO D0RO2L CAR-T cells targeting PSMA Phase 1/2 T97071 DRUGINFO D0VI8T 4SCAR-PSMA Phase 1/2 T97071 DRUGINFO D0W7FC MLN-2704 Phase 1/2 T97071 DRUGINFO D1CZ8K 177-Lu-PSMA-R2 Phase 1/2 T97071 DRUGINFO D4GH1L 67Cu-SAR-bisPSMA Phase 1/2 T97071 DRUGINFO DBHQ20 64Cu-SAR-bisPSMA Phase 1/2 T97071 DRUGINFO DP6J5K 177Lu-labelled PSMA-R2 Phase 1/2 T97071 DRUGINFO DR8JH4 LAVA-1207 Phase 1/2 T97071 DRUGINFO D5MV0R Acapatamab Phase 1/2 T97071 DRUGINFO D6L5YT REGN4336 Phase 1/2 T97071 DRUGINFO D8UZM7 REGN5678 Phase 1/2 T97071 DRUGINFO D03JTL APVO414 Phase 1 T97071 DRUGINFO D04KRV Iofolastat I-124 Phase 1 T97071 DRUGINFO D07KHR PSMA-VRP Phase 1 T97071 DRUGINFO D08JYV PSMA subunit vaccine Phase 1 T97071 DRUGINFO D0F5KN 99mTc-MIP-1405 Phase 1 T97071 DRUGINFO D0H4IU GPI-16072 Phase 1 T97071 DRUGINFO D0N6QB MT-112 Phase 1 T97071 DRUGINFO D0O0JB PSMA-targeted tubulysin B conjugates Phase 1 T97071 DRUGINFO D0TN7S BAY-1075553 Phase 1 T97071 DRUGINFO D2Y9IG JNJ-63898081 Phase 1 T97071 DRUGINFO D48MDS HPN424 Phase 1 T97071 DRUGINFO DA03JS MIP-1095 Phase 1 T97071 DRUGINFO DAS4D6 PSMA CAR-T cell therapy Phase 1 T97071 DRUGINFO DH5S6Z CTT1403 Phase 1 T97071 DRUGINFO DJME35 225Ac-PSMA-617 Phase 1 T97071 DRUGINFO DM6CE2 177Lu-labelled CTT-1403 Phase 1 T97071 DRUGINFO DXOR23 225Ac-J591 Phase 1 T97071 DRUGINFO DXV67Q 227Th-labelled PSMA-TTC Phase 1 T97071 DRUGINFO DKX1U6 AMG 340 Phase 1 T97071 DRUGINFO DOY4E6 AMG 160 Phase 1 T97071 DRUGINFO DY4X5W CCW702 Phase 1 T97071 DRUGINFO D04UWG Autologous T-cell therapy Phase 1 T97071 DRUGINFO D03ZHE MDX-070 Discontinued in Phase 2 T97071 DRUGINFO D0M8PM IRX-4 Preclinical T97071 DRUGINFO D02CYQ 2-Hydroxycarbamoyl-pentanedioic acid Investigative T97071 DRUGINFO D03JFL 2-(2-carboxy-7-mercaptoheptyl)benzoic acid Investigative T97071 DRUGINFO D03RMT 3-(2-carboxy-6-mercaptohexyl)benzoic acid Investigative T97071 DRUGINFO D04SZR 4-(2-carboxy-5-mercaptopentyl)benzoic acid Investigative T97071 DRUGINFO D04VFS 3-(2-carboxy-4-mercaptobutyl)benzoic acid Investigative T97071 DRUGINFO D05SNS 2-(2-Hydroxycarbamoyl-ethyl)-pentanedioic acid Investigative T97071 DRUGINFO D05UAO J591-Ac-225 Investigative T97071 DRUGINFO D05VWZ 2-(3-carboxybenzyl)succinic acid Investigative T97071 DRUGINFO D06JOJ PMID15027864C8d Investigative T97071 DRUGINFO D06LAX PGI-02749 Investigative T97071 DRUGINFO D08CYU 2-Mercapto-pentanedioic acid Investigative T97071 DRUGINFO D08TDE 2-(4-Mercapto-butyl)-pentanedioic acid Investigative T97071 DRUGINFO D0A1FL 2-Phosphonooxy-pentanedioic acid Investigative T97071 DRUGINFO D0B9YO 2-benzyl-5-mercaptopentanoic acid Investigative T97071 DRUGINFO D0C2FS 2-(2-Mercapto-ethyl)-pentanedioic acid Investigative T97071 DRUGINFO D0C5JP 3-(2-carboxy-3-phosphonopropyl)benzoic acid Investigative T97071 DRUGINFO D0D8NM 2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid Investigative T97071 DRUGINFO D0E0HK 2-Mercaptomethyl-pentanedioic acid Investigative T97071 DRUGINFO D0E3OH 2-(3-cyanobenzyl)-5-mercaptopentanoic acid Investigative T97071 DRUGINFO D0F8TZ 3-(2-carboxy-5-mercaptopentyl)benzoic acid Investigative T97071 DRUGINFO D0FU7Y 2-Hydroxycarbamoylmethyl-pentanedioic acid Investigative T97071 DRUGINFO D0IW9Q MDX-1147 Investigative T97071 DRUGINFO D0JX2S 3-(2-carbamoyl-5-mercaptopentyl)benzoic acid Investigative T97071 DRUGINFO D0K3GB 99mTc-MIP-1340 Investigative T97071 DRUGINFO D0M1NS CTT-54 Investigative T97071 DRUGINFO D0ND1C 3-(1-carboxy-4-mercaptobutoxy)benzoic acid Investigative T97071 DRUGINFO D0Q2OH 2-(3-Methylsulfanyl-propyl)-pentanedioic acid Investigative T97071 DRUGINFO D0Q3KD 2-(5-Mercapto-pentyl)-pentanedioic acid Investigative T97071 DRUGINFO D0QA5U 2-(2-carboxy-5-mercaptopentyl)benzoic acid Investigative T97071 DRUGINFO D0T8ZL 3-(2-carboxy-3-mercaptopropyl)benzoic acid Investigative T97071 DRUGINFO D0X1DO 3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid Investigative T97071 DRUGINFO D0Y6UB 2-PMPA Investigative T97071 DRUGINFO D0Y7AN 2-(3-Mercapto-propyl)-pentanedioic acid Investigative T97071 DRUGINFO D0Z0UQ 5-Mercapto-pentanoic acid Investigative T97071 DRUGINFO D0Z5UD MIP-1375 Investigative T97071 DRUGINFO D0Z5VI 2-(2-Phosphonooxy-ethyl)-pentanedioic acid Investigative T97071 DRUGINFO D0Z9BU 99mTc-EC-0652 Investigative T97071 DRUGINFO D0ZJ9S 2-(3-Hydroxycarbamoyl-propyl)-pentanedioic acid Investigative T97071 DRUGINFO D06DUE [3H]quisqualate Investigative T86591 TARGETID T86591 T86591 FORMERID TTDS00340 T86591 UNIPROID PPARA_HUMAN T86591 TARGNAME Peroxisome proliferator-activated receptor alpha (PPARA) T86591 GENENAME PPARA T86591 TARGTYPE Successful T86591 SYNONYMS Peroxisome proliferater-activated receptor alpha; PPARalpha; PPAR-alpha; PPAR; Nuclear receptor subfamily 1 group C member 1; NR1C1 T86591 FUNCTION Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2. Ligand-activated transcription factor. T86591 PDBSTRUC 5HYK; 5AZT; 4CI4; 4BCR; 3VI8 T86591 BIOCLASS Nuclear hormone receptor T86591 SEQUENCE MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSCPGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACEGCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSEKAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFVIHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANLDLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFDFAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDIFLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY T86591 DRUGINFO D00WCX Bezafibrate Approved T86591 DRUGINFO D04QIE Pemafibrate Approved T86591 DRUGINFO D07XGR Fenofibrate Approved T86591 DRUGINFO D0EJ6O Ciprofibrate Approved T86591 DRUGINFO D04BCB Lobeglitazone Approved T86591 DRUGINFO D02NHD Ragaglitazar Phase 3 T86591 DRUGINFO D0F5JH CS-038 Phase 3 T86591 DRUGINFO D0H1NL TESAGLITAZAR Phase 3 T86591 DRUGINFO D0LW1Y GFT-505 Phase 3 T86591 DRUGINFO D0M3UT MURAGLITAZAR Phase 3 T86591 DRUGINFO D0T7MN ZYH-1 Phase 3 T86591 DRUGINFO D0VU5M Imiglitazar Phase 3 T86591 DRUGINFO D0I5IM LY-518674 Phase 2 T86591 DRUGINFO D0RJ0V GFT14 Phase 2 T86591 DRUGINFO DE6GF4 ZYH7 Phase 2 T86591 DRUGINFO D04BPS Naveglitazar Phase 2 T86591 DRUGINFO D0PP8G ONO-5129 Phase 2 T86591 DRUGINFO D00HYD CDT-fenofibrate Phase 1 T86591 DRUGINFO D01UJK AVE0897 Phase 1 T86591 DRUGINFO DF8M1T TPST-1120 Phase 1 T86591 DRUGINFO D03RJZ Oxeglitazar Phase 1 T86591 DRUGINFO D0AX9S GW-409544 Phase 1 T86591 DRUGINFO D05AUY PMID25416646-Compound-Figure5-H Patented T86591 DRUGINFO D0HW6Y Flavonoid derivative 8 Patented T86591 DRUGINFO D0O5IN PMID25416646-Compound-Figure5-A Patented T86591 DRUGINFO D0B9EN Aleglitazar Discontinued in Phase 3 T86591 DRUGINFO D08LZI NS-220 Discontinued in Phase 2 T86591 DRUGINFO D0B8JQ KRP-101 Discontinued in Phase 2 T86591 DRUGINFO D0Q8UU BM-17.0744 Discontinued in Phase 2 T86591 DRUGINFO D0R5QQ AVE-8134 Discontinued in Phase 2 T86591 DRUGINFO D02RAU KRP-297 Discontinued in Phase 2 T86591 DRUGINFO D02ZKL Reglixane Discontinued in Phase 2 T86591 DRUGINFO D0W2IU AVE-0847 Discontinued in Phase 2 T86591 DRUGINFO D01JGG Sodelglitazar Discontinued in Phase 2 T86591 DRUGINFO D09OHP Indeglitazar Discontinued in Phase 2 T86591 DRUGINFO D0S6KX GSK-677954 Discontinued in Phase 2 T86591 DRUGINFO D04FTB AR-H049020 Discontinued in Phase 1 T86591 DRUGINFO D09SLU LG-101280 Discontinued in Phase 1 T86591 DRUGINFO D0W3YW DRF 10945 Discontinued in Phase 1 T86591 DRUGINFO D0Z3XO MP-136 Discontinued in Phase 1 T86591 DRUGINFO D06PHO E-3030 Discontinued in Phase 1 T86591 DRUGINFO D0B0EB LY-929 Discontinued in Phase 1 T86591 DRUGINFO D04PBS MC-3001 Preclinical T86591 DRUGINFO D09XCX PIRINIXIC ACID Preclinical T86591 DRUGINFO D0U2FN Romazarit Preclinical T86591 DRUGINFO D08WOE MC-3002 Preclinical T86591 DRUGINFO D03CUS CS-207 Terminated T86591 DRUGINFO D0BB1X KRP-105 Terminated T86591 DRUGINFO D0I0RF BVT-142 Terminated T86591 DRUGINFO D0OW6Z Sipoglitazar Terminated T86591 DRUGINFO D0V0TT CS-204 Terminated T86591 DRUGINFO D00TFA GW7647 Investigative T86591 DRUGINFO D01KPN CP-775146 Investigative T86591 DRUGINFO D05CLM GSK-9578 Investigative T86591 DRUGINFO D06RRD Fibrates Investigative T86591 DRUGINFO D08UWZ BMS-687453 Investigative T86591 DRUGINFO D0EN7T pristanic acid Investigative T86591 DRUGINFO D0G9IP eicosatetranoic acid Investigative T86591 DRUGINFO D0K6TI 8S-HETE Investigative T86591 DRUGINFO D0K8HA LL-6531 Investigative T86591 DRUGINFO D0S4GK Deoxy-Bigchap Investigative T86591 DRUGINFO D00AII (E)-4-(3,5-dimethoxystyryl)phenol Investigative T86591 DRUGINFO D00EOP AD-5061 Investigative T86591 DRUGINFO D01POG GW-2331 Investigative T86591 DRUGINFO D04JOG TZD18 Investigative T86591 DRUGINFO D06GYO (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid Investigative T86591 DRUGINFO D08XGH reglitazar Investigative T86591 DRUGINFO D0M8VN DRF 2519 Investigative T86591 DRUGINFO D0M9LL (E)-12-Nitrooctadec-12-enoic Acid Investigative T86591 DRUGINFO D0P5QM (E)-13-Nitrooctadec-12-enoic Acid Investigative T86591 DRUGINFO D0Z4MH ZY H2 Investigative T86591 DRUGINFO D0Z7OX LY-465608 Investigative T86591 DRUGINFO D01ARG DB-900 Investigative T86591 DRUGINFO D09JII L-796449 Investigative T86591 DRUGINFO D0F0MP L-165461 Investigative T86591 DRUGINFO D07MBC N-oleoylethanolamide Investigative T25464 TARGETID T25464 T25464 FORMERID TTDS00363 T25464 UNIPROID PP2BA_HUMAN T25464 TARGNAME Calcineurin (PPP3CA) T25464 GENENAME PPP3CA T25464 TARGTYPE Successful T25464 SYNONYMS Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform; Calmodulin-dependent calcineurin A subunit alpha isoform; CNA; CAM-PRP catalytic subunit; CALNA T25464 FUNCTION Many of the substrates contain a PxIxIT motif and/or a LxVP motif. In response to increased Ca(2+) levels, dephosphorylates and activates phosphatase SSH1 which results in cofilin dephosphorylation. In response to increased Ca(2+) levels following mitochondrial depolarization, dephosphorylates DNM1L inducing DNM1L translocation to the mitochondrion. Dephosphorylates heat shock protein HSPB1. Dephosphorylates and activates transcription factor NFATC1. In response to increased Ca(2+) levels, regulates NFAT-mediated transcription probably by dephosphorylating NFAT and promoting its nuclear translocation. Dephosphorylates and inactivates transcription factor ELK1. Dephosphorylates DARPP32. May dephosphorylate CRTC2 at 'Ser-171' resulting in CRTC2 dissociation from 14-3-3 proteins. Calcium-dependent, calmodulin-stimulated protein phosphatase which plays an essential role in the transduction of intracellular Ca(2+)-mediated signals. T25464 PDBSTRUC 5SVE; 5C1V; 4Q5U; 4F0Z; 3LL8 T25464 BIOCLASS Phosphoric monoester hydrolase T25464 ECNUMBER EC 3.1.3.16 T25464 SEQUENCE MSEPKAIDPKLSTTDRVVKAVPFPPSHRLTAKEVFDNDGKPRVDILKAHLMKEGRLEESVALRIITEGASILRQEKNLLDIDAPVTVCGDIHGQFFDLMKLFEVGGSPANTRYLFLGDYVDRGYFSIECVLYLWALKILYPKTLFLLRGNHECRHLTEYFTFKQECKIKYSERVYDACMDAFDCLPLAALMNQQFLCVHGGLSPEINTLDDIRKLDRFKEPPAYGPMCDILWSDPLEDFGNEKTQEHFTHNTVRGCSYFYSYPAVCEFLQHNNLLSILRAHEAQDAGYRMYRKSQTTGFPSLITIFSAPNYLDVYNNKAAVLKYENNVMNIRQFNCSPHPYWLPNFMDVFTWSLPFVGEKVTEMLVNVLNICSDDELGSEEDGFDGATAAARKEVIRNKIRAIGKMARVFSVLREESESVLTLKGLTPTGMLPSGVLSGGKQTLQSATVEAIEADEAIKGFSPQHKITSFEEAKGLDRINERMPPRRDAMPSDANLNSINKALTSETNGTDSNGSNSSNIQ T25464 DRUGINFO D06OMK Tacrolimus Approved T25464 DRUGINFO D0L9HX Voclosporin Approved T25464 DRUGINFO D0O3YF Ciclosporin Approved T25464 DRUGINFO D0Z4UN Pimecrolimus Approved T25464 DRUGINFO D08IGF L-685,818 Investigative T88975 TARGETID T88975 T88975 FORMERID TTDS00390 T88975 UNIPROID PDE3A_HUMAN T88975 TARGNAME Phosphodiesterase 3A (PDE3A) T88975 GENENAME PDE3A T88975 TARGTYPE Successful T88975 SYNONYMS cGMP-inhibited 3',5'-cyclic phosphodiesterase A; Phosphodiesterase 3A; Cyclic GMP-inhibited phosphodiesterase A; Cyclic GMP inhibited phosphodiesterase A; CGI-PDE A T88975 FUNCTION Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. T88975 PDBSTRUC 1LRC T88975 BIOCLASS Phosphoric diester hydrolase T88975 ECNUMBER EC 3.1.4.17 T88975 SEQUENCE MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ T88975 DRUGINFO D03TYI Aminophylline Approved T88975 DRUGINFO D0D1HW Anagrelide Approved T88975 DRUGINFO D03VPC Cilostazol Approved T88975 DRUGINFO D0E0SW Enoximone Approved T88975 DRUGINFO D0L0ZF VESNARINONE Approved T88975 DRUGINFO D08HKT BEMORADAN Phase 2 T88975 DRUGINFO D0BK6B CI-930 Discontinued in Phase 2 T88975 DRUGINFO D0Y6HV EMD-53998 Discontinued in Phase 1 T88975 DRUGINFO D01OFY LAS-31180 Terminated T88975 DRUGINFO D08NXX BMY-20844 Terminated T88975 DRUGINFO D09UMA IMAZODAN Terminated T88975 DRUGINFO D00YPO TETRAHYDROBENXIMIDAZOLE Investigative T88975 DRUGINFO D03GAQ 8-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one Investigative T88975 DRUGINFO D04BXL 2-morpholino-7-(2-phenylethynyl)-4H-chromen-4-one Investigative T88975 DRUGINFO D04KDB 6-Imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one Investigative T88975 DRUGINFO D05HFD 7-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one Investigative T88975 DRUGINFO D06XVV BENZOYLENUREA Investigative T88975 DRUGINFO D07BFF 8-methyl-2-morpholino-7-phenyl-4H-chromen-4-one Investigative T88975 DRUGINFO D07LCE 1,3,9,9a-Tetrahydro-imidazo[4,5-b]quinolin-2-one Investigative T88975 DRUGINFO D08WIJ 8-methyl-2-morpholino-7-phenoxy-4H-chromen-4-one Investigative T88975 DRUGINFO D08XKO 8-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one Investigative T88975 DRUGINFO D09GTN 7-Fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one Investigative T88975 DRUGINFO D0DX3V 7-Ethoxy-1,3-dihydro-imidazo[4,5-b]quinolin-2-one Investigative T88975 DRUGINFO D0E3ID 7-Iodo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one Investigative T88975 DRUGINFO D0J7NR 5-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one Investigative T88975 DRUGINFO D0MJ1L 2-morpholino-7-phenyl-4H-chromen-4-one Investigative T88975 DRUGINFO D0N6MR 1,3-Dihydro-imidazo[4,5-b]quinolin-2-one Investigative T88975 DRUGINFO D0NI4Z 7-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one Investigative T88975 DRUGINFO D0T3UP 1,3-Dihydro-naphtho[2,3-d]imidazol-2-one Investigative T88975 DRUGINFO D0TE6A 1,5-Dihydro-imidazo[2,1-b]quinazolin-2-one Investigative T88975 DRUGINFO D0TZ8C 6-(2-Imidazol-1-yl-vinyl)-1H-quinolin-2-one Investigative T88975 DRUGINFO D09CPC 6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one Investigative T88975 DRUGINFO D0W3RR 2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one Investigative T88975 DRUGINFO D00QCL SOPHOFLAVESCENOL Investigative T88975 DRUGINFO D0W4ZU KURARINOL Investigative T88975 DRUGINFO D06GUJ KURAIDIN Investigative T88975 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T14558 TARGETID T14558 T14558 FORMERID TTDS00130 T14558 UNIPROID TRYB1_HUMAN T14558 TARGNAME Tryptase alpha/beta-1 (Tryptase) T14558 GENENAME TPSAB1 T14558 TARGTYPE Successful T14558 SYNONYMS Tryptase-1; Tryptase alpha-1; Tryptase I; TPSB1; TPS2; TPS1 T14558 FUNCTION May play a role in innate immunity. Isoform 2 cleaves large substrates, such as fibronectin, more efficiently than isoform 1, but seems less efficient toward small substrates. Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type. T14558 PDBSTRUC 5WI6; 5F03; 4MQA; 4MPX; 4MPW T14558 BIOCLASS Peptidase T14558 ECNUMBER EC 3.4.21.59 T14558 SEQUENCE MLNLLLLALPVLASRAYAAPAPGQALQRVGIVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYTAQIGADIALLELEEPVNVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKVNGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP T14558 DRUGINFO D05EAM Pentamidine Approved T14558 DRUGINFO D0O5WD Lactoferrin Approved T14558 DRUGINFO D08RMH APC-2059 Discontinued in Phase 2 T14558 DRUGINFO D0N9WB APC-366 Discontinued in Phase 2 T14558 DRUGINFO D02INZ BABIM Terminated T14558 DRUGINFO D0L7ZX BAY-17-1998 Terminated T14558 DRUGINFO D0W7DD BAY-44-3428 Terminated T14558 DRUGINFO D07IZR AMG-126737 Investigative T14558 DRUGINFO D0NZ3Q Lactoferrin Investigative T14558 DRUGINFO D0Q4PB MOL 6131 Investigative T14558 DRUGINFO D09YQM BMS-262084 Investigative T14558 DRUGINFO D0Y5IQ Grassystatin a Investigative T51076 TARGETID T51076 T51076 FORMERID TTDI01807 T51076 UNIPROID NTRK3_HUMAN T51076 TARGNAME NT-3 growth factor receptor (TrkC) T51076 GENENAME NTRK3 T51076 TARGTYPE Successful T51076 SYNONYMS TrkC tyrosine kinase; Trk-C; TRKC; Neurotrophic tyrosine kinase receptor type 3; NT3 growth factor receptor; GP145TrkC; GP145-TrkC T51076 FUNCTION Upon binding of its ligand NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the phosphatidylinositol 3-kinase/AKT and the MAPK pathways, that control cell survival and differentiation. Receptor tyrosine kinase involved in nervous system and probably heart development. T51076 PDBSTRUC 4YMJ; 3V5Q; 1WWC T51076 BIOCLASS Kinase T51076 ECNUMBER EC 2.7.10.1 T51076 SEQUENCE MDVSLCPAKCSFWRIFLLGSVWLDYVGSVLACPANCVCSKTEINCRRPDDGNLFPLLEGQDSGNSNGNASINITDISRNITSIHIENWRSLHTLNAVDMELYTGLQKLTIKNSGLRSIQPRAFAKNPHLRYINLSSNRLTTLSWQLFQTLSLRELQLEQNFFNCSCDIRWMQLWQEQGEAKLNSQNLYCINADGSQLPLFRMNISQCDLPEISVSHVNLTVREGDNAVITCNGSGSPLPDVDWIVTGLQSINTHQTNLNWTNVHAINLTLVNVTSEDNGFTLTCIAENVVGMSNASVALTVYYPPRVVSLEEPELRLEHCIEFVVRGNPPPTLHWLHNGQPLRESKIIHVEYYQEGEISEGCLLFNKPTHYNNGNYTLIAKNPLGTANQTINGHFLKEPFPESTDNFILFDEVSPTPPITVTHKPEEDTFGVSIAVGLAAFACVLLVVLFVMINKYGRRSKFGMKGPVAVISGEEDSASPLHHINHGITTPSSLDAGPDTVVIGMTRIPVIENPQYFRQGHNCHKPDTYVQHIKRRDIVLKRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLAARKDFQREAELLTNLQHEHIVKFYGVCGDGDPLIMVFEYMKHGDLNKFLRAHGPDAMILVDGQPRQAKGELGLSQMLHIASQIASGMVYLASQHFVHRDLATRNCLVGANLLVKIGDFGMSRDVYSTDYYRLFNPSGNDFCIWCEVGGHTMLPIRWMPPESIMYRKFTTESDVWSFGVILWEIFTYGKQPWFQLSNTEVIECITQGRVLERPRVCPKEVYDVMLGCWQREPQQRLNIKEIYKILHALGKATPIYLDILG T51076 DRUGINFO D07TOK Larotrectinib Approved T51076 DRUGINFO D0O0LS Entrectinib Approved T51076 DRUGINFO D00DRL MK-2461 Phase 1/2 T51076 DRUGINFO D0FA6S Altiratinib Phase 1 T51076 DRUGINFO D0NS6S Cyclopenta[d]pyrimidine derivative 1 Patented T51076 DRUGINFO D00MGO PMID28270021-Compound-WO2016054807Example1 Patented T51076 DRUGINFO D07RLB PMID28270010-Compound-Figure24-b Patented T51076 DRUGINFO D0AG2A Pyrrolo[2,3-d]pyrimidine derivative 4 Patented T51076 DRUGINFO D0AU4G 3-amino-5-benzyl-substituted indazole derivative 1 Patented T51076 DRUGINFO D0J9ZG PMID28270010-Compound-Figure5-1 Patented T51076 DRUGINFO D0M8VS PMID28270021-Compound-WO2015042088Example4 Patented T51076 DRUGINFO D0T2OX PMID28270010-Compound-Figure5-2 Patented T51076 DRUGINFO D0V5AG PMID28270010-Compound-Figure5-3 Patented T51076 DRUGINFO D0Y1NH Azaindazole amide derivative 1 Patented T51076 DRUGINFO D0KX1E CEP-2563 Discontinued in Phase 1 T51076 DRUGINFO D02RWC GNF-5837 Investigative T51076 DRUGINFO D0MH1X AZD1332 Investigative T51076 DRUGINFO D0Y4BL JNJ-28312141 Investigative T51076 DRUGINFO D02NNT PMID21493067C1d Investigative T51076 DRUGINFO D0E7VO PMID24900538C2c Investigative T80896 TARGETID T80896 T80896 FORMERID TTDS00250 T80896 UNIPROID ESR2_HUMAN T80896 TARGNAME Estrogen receptor beta (ESR2) T80896 GENENAME ESR2 T80896 TARGTYPE Successful T80896 SYNONYMS Oestrogen receptor beta; Nuclear receptor subfamily 3 group A member 2; NR3A2; Erbeta; ESTRB; ER-beta; Beta-1 T80896 FUNCTION Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner. Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by ESR1 and ESR2 is rapidly lost at 37 degrees Celsius in the absence of ligand while in the presence of 17 beta-estradiol and 4-hydroxy-tamoxifen loss in DNA-binding at elevated temperature is more gradual. Nuclear hormone receptor. T80896 PDBSTRUC 5TOA; 4ZI1; 4J26; 4J24; 3OMQ T80896 BIOCLASS Nuclear hormone receptor T80896 SEQUENCE MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHHEYPAMTFYSPAVMNYSIPSNVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAEPQKSPWCEARSLEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHYGVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMMGLMWRSIDHPGKLIFAPDLVLDRDEGKCVEGILEIFDMLLATTSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDADSSRKLAHLLNAVTDALVWVIAKSGISSQQQSMRLANLLMLLSHVRHASNKGMEHLLNMKCKNVVPVYDLLLEMLNAHVLRGCKSSITGSECSPAEDSKSKEGSQNPQSQ T80896 DRUGINFO D03XOC Trilostane Approved T80896 DRUGINFO D0T0LU Conjugated Estrogens Approved T80896 DRUGINFO D06LOQ ARZOXIFENE Approved T80896 DRUGINFO D0M8PD Estrogen Approved T80896 DRUGINFO D02GLD MF-101 Phase 3 T80896 DRUGINFO D0G7IV Premarin/Pravachol Phase 3 T80896 DRUGINFO D0L4FS Genistein Phase 2/3 T80896 DRUGINFO D01HXA AUS-131 Phase 2 T80896 DRUGINFO D07LZH ERB-041 Phase 2 T80896 DRUGINFO D0R2SK Erteberel Phase 2 T80896 DRUGINFO D01PTS VG-101 Phase 1/2 T80896 DRUGINFO D05KUP ERB-257 Phase 1 T80896 DRUGINFO D02ABO NARINGENIN Phase 1 T80896 DRUGINFO D0C4FT HEXESTROL Withdrawn from market T80896 DRUGINFO D0QQ1J BITHIONOL Withdrawn from market T80896 DRUGINFO D0MU0S EM-800 Discontinued in Phase 3 T80896 DRUGINFO D0R8TB ERA-923 Discontinued in Phase 2 T80896 DRUGINFO D08HIH ERB-196 Discontinued in Phase 1 T80896 DRUGINFO D08DZZ HE2100 Discontinued in Phase 1 T80896 DRUGINFO D09AAM ICI-164384 Terminated T80896 DRUGINFO D0H5CV ZK-119010 Terminated T80896 DRUGINFO D0SM0J LY-117018 Terminated T80896 DRUGINFO D00FPJ 3,4,6-Trihydroxy-2-(4-hydroxy-phenyl)-inden-1-one Investigative T80896 DRUGINFO D01AHL 7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one Investigative T80896 DRUGINFO D01CYI 7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one Investigative T80896 DRUGINFO D01IRO 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME Investigative T80896 DRUGINFO D01MWF GTx-878 Investigative T80896 DRUGINFO D02EIK Para-Mercury-Benzenesulfonic Acid Investigative T80896 DRUGINFO D02WRU PHTPP Investigative T80896 DRUGINFO D02WSA 5,7-dihydroxy-3-phenyl-3H-quinazolin-4-one Investigative T80896 DRUGINFO D02XVV 3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one Investigative T80896 DRUGINFO D05EOW diarylpropionitril Investigative T80896 DRUGINFO D05LQD 3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one Investigative T80896 DRUGINFO D05PNP TUPICHINOL C Investigative T80896 DRUGINFO D05QIZ GTx-822 Investigative T80896 DRUGINFO D09FWP 6-(2-Hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0H4RV NDC-1022 Investigative T80896 DRUGINFO D0I5VJ THIOGENISTEIN Investigative T80896 DRUGINFO D0K0TR 3-(4-Hydroxy-phenyl)-4H-chromen-7-ol Investigative T80896 DRUGINFO D0OX6I KB-9520 Investigative T80896 DRUGINFO D0P4SR 2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol Investigative T80896 DRUGINFO D0V3OR 3,6-Dihydroxy-2-(4-hydroxy-phenyl)-inden-1-one Investigative T80896 DRUGINFO D0WP6A 3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one Investigative T80896 DRUGINFO D0XD4N ERB-002 Investigative T80896 DRUGINFO D0Z3NC HPTE Investigative T80896 DRUGINFO D00AAU 3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol Investigative T80896 DRUGINFO D00CWN 2-(4-Hydroxy-phenyl)-quinolin-6-ol Investigative T80896 DRUGINFO D00FUO Nafoxidine Investigative T80896 DRUGINFO D00HUB [1,1':2',1'']Terphenyl-4'-carbaldehyde oxime Investigative T80896 DRUGINFO D00HZT 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol Investigative T80896 DRUGINFO D00IXB 6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol Investigative T80896 DRUGINFO D00NEK 4-(3-phenyl-1H-indol-2-yl)phenol Investigative T80896 DRUGINFO D00OLH 4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol Investigative T80896 DRUGINFO D00URP 4,10-dimethyl-6H-benzo[c]chromene-3,8-diol Investigative T80896 DRUGINFO D00ZBL 7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D01GPY 6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D01KJU 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL Investigative T80896 DRUGINFO D01KSR 5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol Investigative T80896 DRUGINFO D01QXL 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D01SWO 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol Investigative T80896 DRUGINFO D01UAO 3-chloro-4-(4-hydroxyphenyl)salicylaldoxime Investigative T80896 DRUGINFO D01WCA 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL Investigative T80896 DRUGINFO D02DML COUMESTROL Investigative T80896 DRUGINFO D02DVT 4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol Investigative T80896 DRUGINFO D02EJM 2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol Investigative T80896 DRUGINFO D02HGS 5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T80896 DRUGINFO D02JJU 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D02LCC 2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol Investigative T80896 DRUGINFO D02OKF 6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D02RQP bisphenol A Investigative T80896 DRUGINFO D02VIW DIHYDRORALOXIFENE Investigative T80896 DRUGINFO D03DVM 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol Investigative T80896 DRUGINFO D03EOD 4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol Investigative T80896 DRUGINFO D03GYS 7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D03QHG 8-(2,2-dimethylpropyl)naringenin Investigative T80896 DRUGINFO D03RYU 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol Investigative T80896 DRUGINFO D03XEU 2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol Investigative T80896 DRUGINFO D04EAY 3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol Investigative T80896 DRUGINFO D04SEX R,R-THC Investigative T80896 DRUGINFO D04WHH 2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol Investigative T80896 DRUGINFO D05FUY 1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D05JKC 6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D05JPW 2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol Investigative T80896 DRUGINFO D05KXP 8-n-undecylnaringenin Investigative T80896 DRUGINFO D05YIU 7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol Investigative T80896 DRUGINFO D06DDT BROUSSONIN A Investigative T80896 DRUGINFO D06DNN 4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol Investigative T80896 DRUGINFO D06OAL 7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D06SCS WAY200070 Investigative T80896 DRUGINFO D07LUI 6-(4-Hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D07VPM 2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol Investigative T80896 DRUGINFO D07XBD 6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol Investigative T80896 DRUGINFO D07XUY 8-methylnaringenin Investigative T80896 DRUGINFO D08FLV 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol Investigative T80896 DRUGINFO D08HCF 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol Investigative T80896 DRUGINFO D08VDX 8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D08WDN 4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol Investigative T80896 DRUGINFO D09CQC 2-(4-Hydroxy-phenyl)-benzooxazol-6-ol Investigative T80896 DRUGINFO D09DEK 7-(4-Hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D09NOH 8-(3-methylbutyl)naringenin Investigative T80896 DRUGINFO D09PXU 4,7-dimethyl-6H-benzo[c]chromene-3,8-diol Investigative T80896 DRUGINFO D09TQE 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D0A1JP 3'-Methoxy-4'Hydroxyclomiphene Investigative T80896 DRUGINFO D0AD3U 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol Investigative T80896 DRUGINFO D0B1HP 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol Investigative T80896 DRUGINFO D0B4VV Trans-hydroxytamoxifen Investigative T80896 DRUGINFO D0C5FY 3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one Investigative T80896 DRUGINFO D0C6AP 2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol Investigative T80896 DRUGINFO D0C9XK 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Investigative T80896 DRUGINFO D0CC6R 6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0D1LB 8-benzylnaringenin Investigative T80896 DRUGINFO D0DK9S 2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol Investigative T80896 DRUGINFO D0FD6Z 8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0H1CO 2-Naphthalen-1-yl-benzooxazol-6-ol Investigative T80896 DRUGINFO D0H2FI 6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol Investigative T80896 DRUGINFO D0H5HI 4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol Investigative T80896 DRUGINFO D0HM8Y 3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one Investigative T80896 DRUGINFO D0HR8L 6-(3-Hydroxy-phenyl)-naphthalen-1-ol Investigative T80896 DRUGINFO D0I1NX 4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol Investigative T80896 DRUGINFO D0I5HZ 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol Investigative T80896 DRUGINFO D0J0AG 5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T80896 DRUGINFO D0J2NG 8-n-heptylnaringenin Investigative T80896 DRUGINFO D0K0IC 4-(2-phenyl-1H-indol-3-yl)phenol Investigative T80896 DRUGINFO D0K1TW 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D0K6TE 6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0L2MU 7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol Investigative T80896 DRUGINFO D0L3AX 4-Naphthalen-2-yl-phenol Investigative T80896 DRUGINFO D0L6IQ 2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol Investigative T80896 DRUGINFO D0LI0M 8-n-pentylnaringenin Investigative T80896 DRUGINFO D0M0XL 6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol Investigative T80896 DRUGINFO D0MY8V 6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0N0OY 2-(4-Hydroxy-phenyl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D0NN0V 4',5,7-trihydroxy-6,8-dimethylisoflavone Investigative T80896 DRUGINFO D0O2KP 2-phenyl-1,2'-spirobi[1H-indene]-5'-ol Investigative T80896 DRUGINFO D0O5KR 4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol Investigative T80896 DRUGINFO D0O6FX 4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol Investigative T80896 DRUGINFO D0P0FN ZK-164015 Investigative T80896 DRUGINFO D0P6FN 6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0P7PK 2,3-diphenyl-1H-indole Investigative T80896 DRUGINFO D0P8XE GNF-PF-3037 Investigative T80896 DRUGINFO D0R7AG 4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol Investigative T80896 DRUGINFO D0RI6O Doxorubicin-Formaldehyde Conjugate Investigative T80896 DRUGINFO D0S0SZ 7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D0S2ZJ 3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Investigative T80896 DRUGINFO D0S6NV 1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0S8EB 4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol Investigative T80896 DRUGINFO D0SR8Q 7-Phenyl-naphthalen-2-ol Investigative T80896 DRUGINFO D0U0ZE 3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one Investigative T80896 DRUGINFO D0U2VA 2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Investigative T80896 DRUGINFO D0U7KV 4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol Investigative T80896 DRUGINFO D0UV9G 6-Phenyl-naphthalen-2-ol Investigative T80896 DRUGINFO D0V6KJ 6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0V7QZ 2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol Investigative T80896 DRUGINFO D0VN2R 6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol Investigative T80896 DRUGINFO D0W0LG 8-n-propylnaringenin Investigative T80896 DRUGINFO D0W2YR 3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Investigative T80896 DRUGINFO D0W3FF 2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Investigative T80896 DRUGINFO D0W4WF EFFUSOL Investigative T80896 DRUGINFO D0W5HT 8-n-nonylnaringenin Investigative T80896 DRUGINFO D0X2VK 2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol Investigative T80896 DRUGINFO D0X4VN 6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0X7DJ 6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0Y2LJ 8-(2-methylpropyl)naringenin Investigative T80896 DRUGINFO D0Y9BO WAY-169916 Investigative T80896 DRUGINFO D0YH4T 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Investigative T80896 DRUGINFO D0YW4C 2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol Investigative T80896 DRUGINFO D0Z0UC 1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol Investigative T80896 DRUGINFO D0ZT4U 1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D01IAT 7-(3-Hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D01TUB 4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T80896 DRUGINFO D03CBX 4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T80896 DRUGINFO D08SJL 4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T80896 DRUGINFO D09FWS 4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T80896 DRUGINFO D0H8PI 6-(4-Hydroxy-phenyl)-naphthalen-1-ol Investigative T80896 DRUGINFO D0K7HR 2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol Investigative T80896 DRUGINFO D0S8AV SOPHORAFLAVANONE B Investigative T80896 DRUGINFO D0H6OS Geldanamycin-estradiol hybrid Investigative T80896 DRUGINFO D0J7XZ CP-409069 Investigative T80896 DRUGINFO D0L5IC CP-394531 Investigative T80896 DRUGINFO D0P8PK 6-(3-Hydroxy-phenyl)-naphthalen-2-ol Investigative T80896 DRUGINFO D0NJ4H MORIN Investigative T80896 DRUGINFO D0SY2M daidzein Investigative T80896 DRUGINFO D0F2ME Acetate Ion Investigative T46360 TARGETID T46360 T46360 FORMERID TTDS00129 T46360 UNIPROID SGMR1_HUMAN T46360 TARGNAME Opioid receptor sigma 1 (OPRS1) T46360 GENENAME SIGMAR1 T46360 TARGTYPE Successful T46360 SYNONYMS hSigmaR1; Sigma1R; Sigma1-receptor; Sigma non-opioid intracellular receptor 1; Sigma 1-type opioid receptor; SRBP; SR31747-binding protein; SR31747 binding protein 1; SR-BP; SIG-1R; Opioid receptor, sigma 1, isoform 1; OPRS1 protein; Aging-associated gene 8 protein; AAG8 T46360 FUNCTION Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitter release. Plays a role in calcium signaling through modulation together with ANK2 of the ITP3R-dependent calcium efflux at the endoplasmic reticulum. Plays a role in several other cell functions including proliferation, survival and death. Originally identified for its ability to bind various psychoactive drugs it is involved in learning processes, memory and mood alteration. Necessary for proper mitochondrial axonal transport in motor neurons, in particular the retrograde movement of mitochondria. Plays a role in protecting cells against oxidative stress-induced cell death via its interaction with RNF112. Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. T46360 PDBSTRUC 6DK1; 6DK0; 6DJZ; 5HK2; 5HK1 T46360 BIOCLASS GPCR rhodopsin T46360 SEQUENCE MQWAVGRRWAWAALLLAVAAVLTQVVWLWLGTQSFVFQREEIAQLARQYAGLDHELAFSRLIVELRRLHPGHVLPDEELQWVFVNAGGWMGAMCLLHASLSEYVLLFGTALGSRGHSGRYWAEISDTIISGTFHQWREGTTKSEVFYPGETVVHGPGEATAVEWGPNTWMVEYGRGVIPSTLAFALADTVFSTQDFLTLFYTLRSYARGLRLELTTYLFGQDP T46360 DRUGINFO D09OBB Dextromethorphan Approved T46360 DRUGINFO D00KFB Dextromethorphan Polistirex Approved T46360 DRUGINFO D0GW6K ADX N05 Phase 3 T46360 DRUGINFO D0Z6IB AVP-786 Phase 3 T46360 DRUGINFO D0X6XH CM-2395 Phase 3 T46360 DRUGINFO D0N5LJ Igmesine Phase 2 T46360 DRUGINFO D0R8GR OPC-14523 Phase 2 T46360 DRUGINFO D0G9SH SA-5845 Phase 1 T46360 DRUGINFO D0T6ES SSR-125329A Phase 1 T46360 DRUGINFO D09AOO ANAVEX 2-73 Phase 1 T46360 DRUGINFO D0Q7QY SSR-125047 Phase 1 T46360 DRUGINFO DZ02CQ ANAVEX 3-71 Phase 1 T46360 DRUGINFO D04PCA Pyrazole derivative 86 Patented T46360 DRUGINFO D07XVQ Aryl alkanolamine derivative 2 Patented T46360 DRUGINFO D08RUG 1,2,4-triazole derivative 4 Patented T46360 DRUGINFO D0A0DV Phenylpropylamine derivative 4 Patented T46360 DRUGINFO D0C1YW Phenylpropylamine derivative 3 Patented T46360 DRUGINFO D0E9CK Aryl alkanolamine derivative 1 Patented T46360 DRUGINFO D0G4GT Phenylpropylamine derivative 1 Patented T46360 DRUGINFO D0G7GN Phenylpropylamine derivative 5 Patented T46360 DRUGINFO D0L0CD Phenylpropylamine derivative 2 Patented T46360 DRUGINFO D0MD6P 1,2,4-triazole derivative 3 Patented T46360 DRUGINFO D0X5FS Piperidine derivative 4 Patented T46360 DRUGINFO D03MKY Benzamide derivative 9 Patented T46360 DRUGINFO D05YFF Benzamide derivative 10 Patented T46360 DRUGINFO D0DW1D PMID30185082-Compound-57 Patented T46360 DRUGINFO D0EO9Z PMID28051882-Compound-XIV Patented T46360 DRUGINFO D0H2SE Benzamide derivative 8 Patented T46360 DRUGINFO D0J9SL Piperazine derivative 7 Patented T46360 DRUGINFO D0RS2J Benzamide derivative 7 Patented T46360 DRUGINFO D0SG9W PMID30185082-Compound-64 Patented T46360 DRUGINFO D0T5SO Piperidine derivative 6 Patented T46360 DRUGINFO D0W3TS Benzamide derivative 11 Patented T46360 DRUGINFO D0X9RA Piperidine derivative 5 Patented T46360 DRUGINFO D02NPB Isoindoline derivative 5 Patented T46360 DRUGINFO D06FNA Isoindoline derivative 3 Patented T46360 DRUGINFO D0EK3Z Isoindoline derivative 4 Patented T46360 DRUGINFO D0F8XU Isoindoline derivative 2 Patented T46360 DRUGINFO D0S3ON Isoindoline derivative 1 Patented T46360 DRUGINFO D01YOC BMS-181100 Discontinued in Phase 3 T46360 DRUGINFO D00EZE Panamesine Discontinued in Phase 2 T46360 DRUGINFO D0L4PY KB-5492 Discontinued in Phase 2 T46360 DRUGINFO D02JNX OxycoDex Discontinued in Phase 2 T46360 DRUGINFO D0L7BV Gevotroline Discontinued in Phase 1 T46360 DRUGINFO D0Z4QV DUP-734 Discontinued in Phase 1 T46360 DRUGINFO D00KVE Cutamesine Preclinical T46360 DRUGINFO D0T0UC ANAVEX 1-41 Preclinical T46360 DRUGINFO D0M6OW ANAVEX 1007 Preclinical T46360 DRUGINFO D00IRU E-5842 Terminated T46360 DRUGINFO D01KIU PRE-084 Terminated T46360 DRUGINFO D09DRG NE-100 Terminated T46360 DRUGINFO D09OTG MS-377 Terminated T46360 DRUGINFO D0B1PD NPC-16377 Terminated T46360 DRUGINFO D0B7BX E-6276 Terminated T46360 DRUGINFO D0L1YS NE-033 Terminated T46360 DRUGINFO D0M9GE Rimcazole Terminated T46360 DRUGINFO D0MK2C SR-31742A Terminated T46360 DRUGINFO D0T8BP AH-9700 Terminated T46360 DRUGINFO D0T8HU LU-29252 Terminated T46360 DRUGINFO D0U7VO CNS-1307 Terminated T46360 DRUGINFO D0Z5HB FH-510 Terminated T46360 DRUGINFO D0Q7OA HydrocoDex Terminated T46360 DRUGINFO D05BLG MC-116 Investigative T46360 DRUGINFO D07LVT (RS)-PPCC Investigative T46360 DRUGINFO D09AUU Dimemorfan Investigative T46360 DRUGINFO D09CGH BD-1047 Investigative T46360 DRUGINFO D0A3XA CNS-1169 Investigative T46360 DRUGINFO D0F1WD C-10068 Investigative T46360 DRUGINFO D0G4KB [3H]pentazocine Investigative T46360 DRUGINFO D0G5RT MC-113 Investigative T46360 DRUGINFO D0IZ1X (+)-SK&F10047 Investigative T46360 DRUGINFO D0J9VK CM-156 Investigative T46360 DRUGINFO D03DLZ 2-(1H-indol-3-yl)-N,N-dimethylethanamine Investigative T46360 DRUGINFO D02WJT 1,3-ditolylguanidine Investigative T66505 TARGETID T66505 T66505 FORMERID TTDNS00536 T66505 UNIPROID SMO_HUMAN T66505 TARGNAME Smoothened homolog (SMO) T66505 GENENAME SMO T66505 TARGTYPE Successful T66505 SYNONYMS Smo-D473H; SMOH; Protein Gx T66505 FUNCTION Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7, GLI2 and GLI3 in the cilia. Interacts with DLG5 at the ciliary base to induce the accumulation of KIF7 and GLI2 at the ciliary tip for GLI2 activation. G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. T66505 PDBSTRUC 5V57; 5V56; 5L7I; 5L7D; 4QIN T66505 BIOCLASS GPCR frizzled T66505 SEQUENCE MAAARPARGPELPLLGLLLLLLLGDPGRGAASSGNATGPGPRSAGGSARRSAAVTGPPPPLSHCGRAAPCEPLRYNVCLGSVLPYGATSTLLAGDSDSQEEAHGKLVLWSGLRNAPRCWAVIQPLLCAVYMPKCENDRVELPSRTLCQATRGPCAIVERERGWPDFLRCTPDRFPEGCTNEVQNIKFNSSGQCEVPLVRTDNPKSWYEDVEGCGIQCQNPLFTEAEHQDMHSYIAAFGAVTGLCTLFTLATFVADWRNSNRYPAVILFYVNACFFVGSIGWLAQFMDGARREIVCRADGTMRLGEPTSNETLSCVIIFVIVYYALMAGVVWFVVLTYAWHTSFKALGTTYQPLSGKTSYFHLLTWSLPFVLTVAILAVAQVDGDSVSGICFVGYKNYRYRAGFVLAPIGLVLIVGGYFLIRGVMTLFSIKSNHPGLLSEKAASKINETMLRLGIFGFLAFGFVLITFSCHFYDFFNQAEWERSFRDYVLCQANVTIGLPTKQPIPDCEIKNRPSLLVEKINLFAMFGTGIAMSTWVWTKATLLIWRRTWCRLTGQSDDEPKRIKKSKMIAKAFSKRHELLQNPGQELSFSMHTVSHDGPVAGLAFDLNEPSADVSSAWAQHVTKMVARRGAILPQDISVTPVATPVPPEEQANLWLVEAEISPELQKRLGRKKKRRKRKKEVCPLAPPPELHPPAPAPSTIPRLPQLPRQKCLVAAGAWGAGDSCRQGAWTLVSNPFCPEPSPPQDPFLPSAPAPVAWAHGRRQGLGPIHSRTNLMDTELMDADSDF T66505 DRUGINFO D03EDQ Vismodegib Approved T66505 DRUGINFO D0S5LO PF-04449913 Approved T66505 DRUGINFO D09BNZ LDE225 Phase 2 T66505 DRUGINFO D0W0SL LY2940680 Phase 1/2 T66505 DRUGINFO D03DUY BMS-833923 Phase 1b T66505 DRUGINFO D09UMN LEQ-506 Phase 1 T66505 DRUGINFO D0Q4JM TAK-441 Phase 1 T66505 DRUGINFO D00GMI PMID25726713-Compound-36 Patented T66505 DRUGINFO D00ITT PMID25726713-Compound-43 Patented T66505 DRUGINFO D01AJO Imidazo bicyclic iminium derivative 9 Patented T66505 DRUGINFO D01AWH PMID25726713-Compound-45 Patented T66505 DRUGINFO D02JSW PMID25726713-Compound-58 Patented T66505 DRUGINFO D03HMW Pyrimidine derivative 20 Patented T66505 DRUGINFO D03QAU PMID25726713-Compound-42 Patented T66505 DRUGINFO D03SCM PMID25726713-Compound-62 Patented T66505 DRUGINFO D05CWM PMID25726713-Compound-12 Patented T66505 DRUGINFO D05MIG PMID25726713-Compound-31 Patented T66505 DRUGINFO D05QCM PMID25726713-Compound-60 Patented T66505 DRUGINFO D05QYN PMID25726713-Compound-15 Patented T66505 DRUGINFO D06ELK PMID25726713-Compound-32 Patented T66505 DRUGINFO D06MXI PMID25726713-Compound-63 Patented T66505 DRUGINFO D06NBL PMID25726713-Compound-23 Patented T66505 DRUGINFO D07ZUO PMID25726713-Compound-28 Patented T66505 DRUGINFO D08LBZ PMID25726713-Compound-56 Patented T66505 DRUGINFO D0AB3D Imidazo bicyclic iminium derivative 5 Patented T66505 DRUGINFO D0B3FN PMID25726713-Compound-35 Patented T66505 DRUGINFO D0B3XW Cyclic sulfonamide derivative 2 Patented T66505 DRUGINFO D0B6GA PMID25726713-Compound-37 Patented T66505 DRUGINFO D0B9ML PMID25726713-Compound-24 Patented T66505 DRUGINFO D0C4PD PMID25726713-Compound-38 Patented T66505 DRUGINFO D0C4VR PMID25726713-Compound-16 Patented T66505 DRUGINFO D0CD8G PMID25726713-Compound-19 Patented T66505 DRUGINFO D0DH0O PMID25726713-Compound-30 Patented T66505 DRUGINFO D0E4TO PMID25726713-Compound-13 Patented T66505 DRUGINFO D0FS1J Imidazo bicyclic iminium derivative 4 Patented T66505 DRUGINFO D0FT1X PMID25726713-Compound-59 Patented T66505 DRUGINFO D0I8RK Bicyclic hexapeptide derivative 2 Patented T66505 DRUGINFO D0IS8B PMID25726713-Compound-33 Patented T66505 DRUGINFO D0IW7A Cyclic sulfonamide derivative 1 Patented T66505 DRUGINFO D0J0AT PMID25726713-Compound-25 Patented T66505 DRUGINFO D0J9JS Pyrimidine derivative 22 Patented T66505 DRUGINFO D0K0IO Pyrimidine derivative 21 Patented T66505 DRUGINFO D0K2FK Cyclic sulfonamide derivative 3 Patented T66505 DRUGINFO D0K6XL PMID25726713-Compound-29 Patented T66505 DRUGINFO D0K8HU PMID25726713-Compound-39 Patented T66505 DRUGINFO D0KC6Y PMID25726713-Compound-21 Patented T66505 DRUGINFO D0KS3J PMID25726713-Compound-64 Patented T66505 DRUGINFO D0KX5G Imidazo bicyclic iminium derivative 8 Patented T66505 DRUGINFO D0LH6R Imidazo bicyclic iminium derivative 6 Patented T66505 DRUGINFO D0O7BH PMID25726713-Compound-46 Patented T66505 DRUGINFO D0P8IR Bicyclic hexapeptide derivative 1 Patented T66505 DRUGINFO D0PG1G PMID25726713-Compound-57 Patented T66505 DRUGINFO D0QA9Q PMID25726713-Compound-14 Patented T66505 DRUGINFO D0QO1Y PMID25726713-Compound-22 Patented T66505 DRUGINFO D0R3UI PMID25726713-Compound-61 Patented T66505 DRUGINFO D0R8UO PMID25726713-Compound-26 Patented T66505 DRUGINFO D0RH3O PMID25726713-Compound-27 Patented T66505 DRUGINFO D0RV9D PMID25726713-Compound-20 Patented T66505 DRUGINFO D0SO6T PMID25726713-Compound-44 Patented T66505 DRUGINFO D0TK2O PMID25726713-Compound-10 Patented T66505 DRUGINFO D0V9AB Cyclic sulfonamide derivative 4 Patented T66505 DRUGINFO D0VR8N Imidazo bicyclic iminium derivative 3 Patented T66505 DRUGINFO D0WB2S Pyrimidine derivative 19 Patented T66505 DRUGINFO D0XH5O Imidazo bicyclic iminium derivative 7 Patented T66505 DRUGINFO D0Y6EY PMID25726713-Compound-18 Patented T66505 DRUGINFO D0Y8SC PMID25726713-Compound-34 Patented T66505 DRUGINFO D0ZF1N PMID25726713-Compound-11 Patented T66505 DRUGINFO D00RRB Isoflavone derivative 1 Patented T66505 DRUGINFO D01BGG Isoflavone derivative 5 Patented T66505 DRUGINFO D04IFL Isoflavone derivative 7 Patented T66505 DRUGINFO D05NRG Isoflavone derivative 8 Patented T66505 DRUGINFO D07BIQ PMID25726713-Compound-17 Patented T66505 DRUGINFO D09VIE Isoflavone derivative 9 Patented T66505 DRUGINFO D0J1RB Isoflavone derivative 6 Patented T66505 DRUGINFO D0TP0S Isoflavone derivative 3 Patented T66505 DRUGINFO D0WI1G Isoflavone derivative 2 Patented T66505 DRUGINFO D0Z6IS Isoflavone derivative 4 Patented T66505 DRUGINFO D07TVO PMID25726713-Compound-49 Patented T66505 DRUGINFO D0KH7Q PMID25726713-Compound-51 Patented T66505 DRUGINFO D0WJ3W PMID25726713-Compound-48 Patented T66505 DRUGINFO D0X5VI PMID25726713-Compound-47 Patented T66505 DRUGINFO D0Y8JF PMID25726713-Compound-50 Patented T66505 DRUGINFO D05UKJ CYCLOPAMINE Investigative T66505 DRUGINFO D06MUB SMOi2-17 Investigative T66505 DRUGINFO D0R8DO 1-Benzyl-4-(4-phenylpiperazin-1-yl)phthalazine Investigative T66505 DRUGINFO D0V8GX AZD8542 Investigative T31992 TARGETID T31992 T31992 FORMERID TTDR00213 T31992 UNIPROID CAH14_HUMAN T31992 TARGNAME Carbonic anhydrase XIV (CA-XIV) T31992 GENENAME CA14 T31992 TARGTYPE Successful T31992 SYNONYMS UNQ690/PRO1335; Carbonic anhydrase 14; Carbonate dehydratase XIV T31992 FUNCTION Reversible hydration of carbon dioxide. T31992 PDBSTRUC 5CJF; 4LU3 T31992 BIOCLASS Alpha-carbonic anhydrase T31992 ECNUMBER EC 4.2.1.1 T31992 SEQUENCE MLFSALLLEVIWILAADGGQHWTYEGPHGQDHWPASYPECGNNAQSPIDIQTDSVTFDPDLPALQPHGYDQPGTEPLDLHNNGHTVQLSLPSTLYLGGLPRKYVAAQLHLHWGQKGSPGGSEHQINSEATFAELHIVHYDSDSYDSLSEAAERPQGLAVLGILIEVGETKNIAYEHILSHLHEVRHKDQKTSVPPFNLRELLPKQLGQYFRYNGSLTTPPCYQSVLWTVFYRRSQISMEQLEKLQGTLFSTEEEPSKLLVQNYRALQPLNQRMVFASFIQAGSSYTTGEMLSLGVGILVGCLCLLLAVYFIARKIRKKRLENRKSVVFTSAQATTEA T31992 DRUGINFO D09VAZ TRIENTINE Approved T31992 DRUGINFO D0K1QD Sulfamylon Approved T31992 DRUGINFO D0A8JP PARABEN Phase 3 T31992 DRUGINFO D07SDQ Curcumin Phase 3 T31992 DRUGINFO D0L6HN PHENOL Phase 2/3 T31992 DRUGINFO D0Y6OA Coumate Phase 2 T31992 DRUGINFO D03SLR FERULIC ACID Patented T31992 DRUGINFO D0LD9S SPERMINE Terminated T31992 DRUGINFO D07MTM 4-AMINOPHENOL Investigative T31992 DRUGINFO D07CYN 2-amino-2,3-dihydro-1H-indene-5-sulfonamide Investigative T31992 DRUGINFO D09TES 2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid Investigative T31992 DRUGINFO D05QUG 7-phenethoxy-2H-chromen-2-one Investigative T31992 DRUGINFO D05VSK ETHOXYCOUMARIN Investigative T31992 DRUGINFO D00IAE Prop-2-ynyl 4-sulfamoylbenzoate Investigative T31992 DRUGINFO D00RNZ 7-(benzyloxy)-2H-chromen-2-one Investigative T31992 DRUGINFO D01OTW 4-(Cyanomethylthio)pyridine-3-sulfonamide Investigative T31992 DRUGINFO D01XFH N-propynyl amidebenzenesulphonide Investigative T31992 DRUGINFO D02BMV 4-(2-Propynylthio)pyridine-3-sulfonamide Investigative T31992 DRUGINFO D02DBP RESORCINOL Investigative T31992 DRUGINFO D03KRB 4,4'-thiodipyridine-3-sulfonamide Investigative T31992 DRUGINFO D04VSP 4-Ethoxy-3-pyridinesulfonamide Investigative T31992 DRUGINFO D05ETN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide Investigative T31992 DRUGINFO D05JAJ 4-(Quinolinoxy)-3-pyridinesulfonamide Investigative T31992 DRUGINFO D06DYP 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T31992 DRUGINFO D06IOI 4-Benzythiopyridine-3-sulfonamide Investigative T31992 DRUGINFO D09TKG 4-(Allylamino)-3-pyridinesulfonamide Investigative T31992 DRUGINFO D09WVV N1-(2-aminoethyl)ethane-1,2-diamine Investigative T31992 DRUGINFO D0C4QB 2-Amino-indan-5-sulfonic acid Investigative T31992 DRUGINFO D0J7GU 4-Methylthiopyridine-3-sulfonamide Investigative T31992 DRUGINFO D0LC0F 2,3-dihydro-1H-indene-5-sulfonamide Investigative T31992 DRUGINFO D0LU4S 7-butoxy-2H-chromen-2-one Investigative T31992 DRUGINFO D0OT5L 7-propoxy-2H-chromen-2-one Investigative T31992 DRUGINFO D0Q5VB 4-(Methylhydrazino)-3-pyridinesulfonamide Investigative T31992 DRUGINFO D0R4KQ 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide Investigative T31992 DRUGINFO D0RB0D 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid Investigative T31992 DRUGINFO D0SD9H Beta-D-Mannose Investigative T31992 DRUGINFO D0UM1I 4-Hydrazino-3-pyridinesulfonamide Investigative T31992 DRUGINFO D0V5OW 4-(Carbamolymethylthio)pyridine-3-sulfonamide Investigative T31992 DRUGINFO D00XJA 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T31992 DRUGINFO D04VLI 4-(2-Hydroxy-ethyl)-benzenesulfonamide Investigative T31992 DRUGINFO D07TAJ Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate Investigative T31992 DRUGINFO D0D6UR 2-oxo-2H-thiochromene-3-carboxylic acid Investigative T31992 DRUGINFO D0H3NS 2-oxo-2H-chromene-3-carboxylic acid Investigative T31992 DRUGINFO D0J2AE 3-Amino-benzenesulfonamide Investigative T31992 DRUGINFO D0OI1H 2-Amino-benzenesulfonamide Investigative T31992 DRUGINFO D0X5HL N1-(naphthalen-1-yl)ethane-1,2-diamine Investigative T31992 DRUGINFO D04NSN 4-(2-AMINOETHYL)BENZENESULFONAMIDE Investigative T31992 DRUGINFO D05XZM 4-(hydroxymethyl)benzenesulfonamide Investigative T31992 DRUGINFO D09JPC Hexane-1,6-diamine Investigative T31992 DRUGINFO D09PWX Carzenide Investigative T31992 DRUGINFO D0G3BI 6-methyl-2-oxo-2H-chromene-3-carboxylic acid Investigative T31992 DRUGINFO D0L5TZ 6-(hydroxymethyl)-2H-chromen-2-one Investigative T31992 DRUGINFO D0Q2LL 6-Hydroxy-benzothiazole-2-sulfonic acid amide Investigative T31992 DRUGINFO D0U4BB HERNIARIN Investigative T31992 DRUGINFO D00YEF Decane-1,10-diyl disulfamate Investigative T31992 DRUGINFO D01STY 4-Amino-3-iodo-benzenesulfonamide Investigative T31992 DRUGINFO D02QGI Pentane-1,5-diamine Investigative T31992 DRUGINFO D03ZMQ COUMARIN Investigative T31992 DRUGINFO D04CVC 4-Amino-3-fluoro-benzenesulfonamide Investigative T31992 DRUGINFO D05TLB Octyl sulfamate Investigative T31992 DRUGINFO D09WSJ Decyl sulfamate Investigative T31992 DRUGINFO D0AU0M P-Coumaric Acid Investigative T31992 DRUGINFO D0D4OV Octane-1,8-diyl disulfamate Investigative T31992 DRUGINFO D0E8CC BENZOLAMIDE Investigative T31992 DRUGINFO D0M3PO 2,4-Disulfamyltrifluoromethylaniline Investigative T31992 DRUGINFO D0N1AW 6-(aminomethyl)-2H-chromen-2-one Investigative T31992 DRUGINFO D0NN3Q 4-Hydrazino-benzenesulfonamide Investigative T31992 DRUGINFO D0P6AM 4-Amino-3-bromo-benzenesulfonamide Investigative T31992 DRUGINFO D0Q7DJ Syringic Acid Investigative T31992 DRUGINFO D0VD7H CL-5343 Investigative T31992 DRUGINFO D0YU8J 4-Amino-3-chloro-benzenesulfonamide Investigative T31992 DRUGINFO D0V7AA CATECHIN Investigative T31992 DRUGINFO D0Y3TZ GALLICACID Investigative T31992 DRUGINFO D0A1CM ELLAGIC ACID Investigative T56418 TARGETID T56418 T56418 FORMERID TTDI02271 T56418 UNIPROID ALK_HUMAN T56418 TARGNAME ALK tyrosine kinase receptor (ALK) T56418 GENENAME ALK T56418 TARGTYPE Successful T56418 SYNONYMS CD246; Anaplastic lymphoma kinase T56418 FUNCTION Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. T56418 PDBSTRUC 6MX8; 6EDL; 6EBW; 6E0R; 6CDT T56418 BIOCLASS Kinase T56418 ECNUMBER EC 2.7.10.1 T56418 SEQUENCE MGAIGLLWLLPLLLSTAAVGSGMGTGQRAGSPAAGPPLQPREPLSYSRLQRKSLAVDFVVPSLFRVYARDLLLPPSSSELKAGRPEARGSLALDCAPLLRLLGPAPGVSWTAGSPAPAEARTLSRVLKGGSVRKLRRAKQLVLELGEEAILEGCVGPPGEAAVGLLQFNLSELFSWWIRQGEGRLRIRLMPEKKASEVGREGRLSAAIRASQPRLLFQIFGTGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGLECSFDFPCELEYSPPLHDLRNQSWSWRRIPSEEASQMDLLDGPGAERSKEMPRGSFLLLNTSADSKHTILSPWMRSSSEHCTLAVSVHRHLQPSGRYIAQLLPHNEAAREILLMPTPGKHGWTVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFYCNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSLVLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERNPNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKGGKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLIIAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGGGCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQPGP T56418 DRUGINFO D04LVK Ceritinib Approved T56418 DRUGINFO D08PIE Brigatinib Approved T56418 DRUGINFO D0U3SY Alectinib Approved T56418 DRUGINFO D0AF6O Lorlatinib Approved T56418 DRUGINFO D03ZBT Crizotinib Approved T56418 DRUGINFO D0O0LS Entrectinib Approved T56418 DRUGINFO D0KX7I Ensartinib Phase 3 T56418 DRUGINFO D04DYC PF-06463922 Phase 2 T56418 DRUGINFO D0O9PQ AP26113 Phase 2 T56418 DRUGINFO D01HKZ TSR-011 Phase 1/2 T56418 DRUGINFO D0L9PA X-396 Phase 1/2 T56418 DRUGINFO D09GEK ASP3026 Phase 1 T56418 DRUGINFO D0N8YJ PMID28270010-Compound-Figure21-b Patented T56418 DRUGINFO D0NP2W 1,2,4-triazolo[1,5a]pyridine derivative 2 Patented T56418 DRUGINFO D0T3TZ Benzimidazole derivative 6 Patented T56418 DRUGINFO D0MX7B Carboxamide derivative 4 Patented T56418 DRUGINFO D03IDK CEP-18050 Investigative T56418 DRUGINFO D09PTP CEP-28122 Investigative T56418 DRUGINFO D0D2SU DLX-521 Investigative T56418 DRUGINFO D0I3TD CRL-37212 Investigative T56418 DRUGINFO D02NZE PMID20483621C5m Investigative T56418 DRUGINFO D0H0LP PMID20483621C5g Investigative T56418 DRUGINFO D0O7LU AZD3463 Investigative T56418 DRUGINFO D08TVU PMID20483621C5n Investigative T56418 DRUGINFO D0G4CS PMID24900237C15 Investigative T56418 DRUGINFO D06PJW GSK-1838705A Investigative T56418 DRUGINFO D0K5UF PMID24432909C8e Investigative T56418 DRUGINFO D09AID PMID22564207C25b Investigative T47623 TARGETID T47623 T47623 FORMERID TTDC00060 T47623 UNIPROID HPSE_HUMAN T47623 TARGNAME Heparanase (HPSE) T47623 GENENAME HPSE T47623 TARGTYPE Successful T47623 SYNONYMS Hpa1; Heparanase-1; Heparanase 8 kDa subunit; Heparanase 50 kDa subunit; HSE1; HPSE1; HPR1; HPA; HEP protein; Endo-glucoronidase T47623 FUNCTION Participates in extracellular matrix (ECM) degradation and remodeling. Selectively cleaves the linkage between a glucuronic acid unit and an N-sulfo glucosamine unit carrying either a 3-O-sulfo or a 6-O-sulfo group. Can also cleave the linkage between a glucuronic acid unit and an N-sulfo glucosamine unit carrying a 2-O-sulfo group, but not linkages between a glucuronic acid unit and a 2-O-sulfated iduronic acid moiety. It is essentially inactive at neutral pH but becomes active under acidic conditions such as during tumor invasion and in inflammatory processes. Facilitates cell migration associated with metastasis, wound healing and inflammation. Enhances shedding of syndecans, and increases endothelial invasion and angiogenesis in myelomas. Acts as procoagulant by increasing the generation of activation factor X in the presence of tissue factor and activation factor VII. Increases cell adhesion to the extracellular matrix (ECM), independent of its enzymatic activity. Induces AKT1/PKB phosphorylation via lipid rafts increasing cell mobility and invasion. Heparin increases this AKT1/PKB activation. Regulates osteogenesis. Enhances angiogenesis through up-regulation of SRC-mediated activation of VEGF. Implicated in hair follicle inner root sheath differentiation and hair homeostasis. Endoglycosidase that cleaves heparan sulfate proteoglycans (HSPGs) into heparan sulfate side chains and core proteoglycans. T47623 PDBSTRUC 5LA7; 5LA4; 5L9Z; 5L9Y; 5E9C T47623 BIOCLASS Glycosylase T47623 ECNUMBER EC 3.2.1.166 T47623 SEQUENCE MLLRSKPALPPPLMLLLLGPLGPLSPGALPRPAQAQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKESTFEERSYWQSQVNQDICKYGSIPPDVEEKLRLEWPYQEQLLLREHYQKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATKEDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI T47623 DRUGINFO D04KNL PG-545 Phase 1 T47623 DRUGINFO D0H2UB Suramin Phase 1 T47623 DRUGINFO D0G9LP Neutralase Discontinued in Phase 3 T80782 TARGETID T80782 T80782 FORMERID TTDC00334 T80782 UNIPROID VGFR1_HUMAN T80782 TARGNAME VEGFR1 messenger RNA (VEGFR1 mRNA) T80782 GENENAME FLT1 T80782 TARGTYPE Successful T80782 SYNONYMS Vascular permeability factor receptor (mRNA); VEGFR1 (mRNA); VEGFR-1 (mRNA); VEGF-1 receptor (mRNA); Tyrosine-protein kinase receptor FLT (mRNA); Tyrosine-protein kinase FRT (mRNA); Fms-like tyrosine kinase 1 (mRNA); FRT (mRNA); FLT (mRNA) T80782 FUNCTION May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. T80782 PDBSTRUC 5T89; 5EX3; 5ABD; 4CL7; 4CKV T80782 BIOCLASS mRNA target T80782 ECNUMBER EC 2.7.10.1 T80782 SEQUENCE MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDEGVYHCKATNQKGSVESSAYLTVQGTSDKSNLELITLTCTCVAATLFWLLLTLFIRKMKRSSSEIKTDYLSIIMDPDEVPLDEQCERLPYDASKWEFARERLKLGKSLGRGAFGKVVQASAFGIKKSPTCRTVAVKMLKEGATASEYKALMTELKILTHIGHHLNVVNLLGACTKQGGPLMVIVEYCKYGNLSNYLKSKRDLFFLNKDAALHMEPKKEKMEPGLEQGKKPRLDSVTSSESFASSGFQEDKSLSDVEEEEDSDGFYKEPITMEDLISYSFQVARGMEFLSSRKCIHRDLAARNILLSENNVVKICDFGLARDIYKNPDYVRKGDTRLPLKWMAPESIFDKIYSTKSDVWSYGVLLWEIFSLGGSPYPGVQMDEDFCSRLREGMRMRAPEYSTPEIYQIMLDCWHRDPKERPRFAELVEKLGDLLQANVQQDGKDYIPINAILTGNSGFTYSTPAFSEDFFKESISAPKFNSGSSDDVRYVNAFKFMSLERIKTFEELLPNATSMFDDYQGDSSTLLASPMLKRFTWTDSKPKASLKIDLRVTSKSKESGLSDVSRPSFCHSSCGHVSEGKRRFTYDHAELERKIACCSPPPDYNSVVLYSTPPI T80782 DRUGINFO D01PZD Romiplostim Approved T80782 DRUGINFO D0P6DJ VATALANIB Phase 2 T80782 DRUGINFO D04WIE Sirna-027 Phase 1/2 T80782 DRUGINFO D00DRL MK-2461 Phase 1/2 T80782 DRUGINFO D02MFX C[homoPhe-Hca-Glu-Gly-Leu-Glu-Glu]-NH2 Investigative T80782 DRUGINFO D02NZG C[YYDEKLEE]-NH2 Investigative T80782 DRUGINFO D03ZHK LYCOGARUBIN B Investigative T80782 DRUGINFO D04NYQ N3-GHQMFYYPra-NH2 Investigative T80782 DRUGINFO D0K7FA C[YYAEGLEE]-NH2 Investigative T80782 DRUGINFO D0R0XY C[YYDEGLEE]-NH2 Investigative T80782 DRUGINFO D03HTT 4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine Investigative T80782 DRUGINFO D0A9ZP IM-094882 Investigative T80782 DRUGINFO D0D3QA 4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine Investigative T80782 DRUGINFO D0Z8TR IM-094261 Investigative T80782 DRUGINFO D00ERW PMID17935989C25 Investigative T80782 DRUGINFO D03HQK 2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile Investigative T80782 DRUGINFO D05THI 4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide Investigative T80782 DRUGINFO D06GJO (2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine Investigative T80782 DRUGINFO D07OCA Cdk1/2 inhibitor III Investigative T80782 DRUGINFO D07XBW N-(2,4-Dichloro-benzoyl)-benzenesulfonamide Investigative T80782 DRUGINFO D09LEK 4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide Investigative T80782 DRUGINFO D09MSA 4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide Investigative T80782 DRUGINFO D0BM4F Phenyl-(5-phenyl-oxazol-2-yl)-amine Investigative T80782 DRUGINFO D0C6KI CB-676475 Investigative T80782 DRUGINFO D0C6OD 4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide Investigative T80782 DRUGINFO D0D3YL (5-Phenyl-oxazol-2-yl)-m-tolyl-amine Investigative T80782 DRUGINFO D0J2XD 3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile Investigative T80782 DRUGINFO D0M2QA N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide Investigative T80782 DRUGINFO D0UZ5W 4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide Investigative T80782 DRUGINFO D0V4BR 4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide Investigative T80782 DRUGINFO D0V9DQ [3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol Investigative T80782 DRUGINFO D0YN1E 3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine Investigative T80782 DRUGINFO D0EE6A AAL-993 Investigative T80782 DRUGINFO D0XC6G 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole Investigative T80782 DRUGINFO D0C2GE PMID22765894C8h Investigative T89529 TARGETID T89529 T89529 FORMERID TTDR01437 T89529 UNIPROID PTN1_HUMAN T89529 TARGNAME PTPN1 messenger RNA (PTPN1 mRNA) T89529 GENENAME PTPN1 T89529 TARGTYPE Successful T89529 SYNONYMS Tyrosine-protein phosphatase non-receptor type 1 (mRNA); PTP-1B (mRNA) T89529 FUNCTION Mediates dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase activity of EIF2AK3/PERK. May play an important role in CKII- and p60c-src-induced signal transduction cascades. May regulate the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET. Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response. T89529 PDBSTRUC 6CWV; 6CWU; 6BAI; 6B95; 6B90 T89529 BIOCLASS mRNA target T89529 ECNUMBER EC 3.1.3.48 T89529 SEQUENCE MEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEPPPEHIPPPPRPPKRILEPHNGKCREFFPNHQWVKEETQEDKDCPIKEEKGSPLNAAPYGIESMSQDTEVRSRVVGGSLRGAQAASPAKGEPSLPEKDEDHALSYWKPFLVNMCVATVLTAGAYLCYRFLFNSNT T89529 DRUGINFO D03IDU Hydrogen peroxide Approved T89529 DRUGINFO D03TTQ TRYPAN BLUE Approved T89529 DRUGINFO D0J1WO ISIS 113715 Phase 2 T89529 DRUGINFO D0SM6N ISIS-PTP1Brx Phase 2 T89529 DRUGINFO D07LUJ URSOLIC ACID Phase 2 T89529 DRUGINFO D06WBE ERTIPROTAFIB Terminated T89529 DRUGINFO D00BLD 1,2,3,4,6-penta-O-galloyl-D-glucopyranose Investigative T89529 DRUGINFO D00KZO Erybreadin C Investigative T89529 DRUGINFO D00MNE Abyssinone-IV Investigative T89529 DRUGINFO D00RZN Abyssinin II Investigative T89529 DRUGINFO D00VNC 3beta-hydroxyolean-12-en-27-oic acid Investigative T89529 DRUGINFO D01BZE MASLINIC ACID Investigative T89529 DRUGINFO D01NUT Mulberrofuran D Investigative T89529 DRUGINFO D01TNT Sanggenon G Investigative T89529 DRUGINFO D03BHQ FORMYLCHROMONE Investigative T89529 DRUGINFO D03CBD Isoxazolecarboxylic acid Investigative T89529 DRUGINFO D03EGZ OHIOENSIN A Investigative T89529 DRUGINFO D03KGX Rotungenic acid Investigative T89529 DRUGINFO D03KJL 1-Iodyl-4-nitro-benzene Investigative T89529 DRUGINFO D03NTG Sp7343-Sp7964 Investigative T89529 DRUGINFO D03ZIH Oxalylaminobenzoic acid Investigative T89529 DRUGINFO D04TTB 3alpha,24-dihydroxyolean-12-en-27-oic acid Investigative T89529 DRUGINFO D05AOH 1-Iodyl-3-nitro-benzene Investigative T89529 DRUGINFO D05SEV 3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol Investigative T89529 DRUGINFO D05WJI ISIS 107792 Investigative T89529 DRUGINFO D05YZE Abyssinoflavanone VI Investigative T89529 DRUGINFO D06AWX CAULERPIN Investigative T89529 DRUGINFO D06BFB 3beta,6beta-dihydroxyolean-12-en-27-oic acid Investigative T89529 DRUGINFO D06LNL Iodyl-benzene Investigative T89529 DRUGINFO D06NGA 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE Investigative T89529 DRUGINFO D07DNK 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid Investigative T89529 DRUGINFO D07VEP USIMINE A Investigative T89529 DRUGINFO D08ABU 18alpha-Glycyrrhetic acid Investigative T89529 DRUGINFO D08AHA PARA-(BENZOYL)-PHENYLALANINE Investigative T89529 DRUGINFO D08BSQ RK-682 Investigative T89529 DRUGINFO D08GDJ ISOTHIAZOLIDINONE ANALOG Investigative T89529 DRUGINFO D08GEN LICOAGROCHACONE A Investigative T89529 DRUGINFO D08NUF 3-oxoolean-12-en-27-oic acid Investigative T89529 DRUGINFO D08SAG Ohioensin F Investigative T89529 DRUGINFO D08VRV Kuwanon V Investigative T89529 DRUGINFO D09GPV Spathodic acid Investigative T89529 DRUGINFO D09HAX SIGMOIDIN B Investigative T89529 DRUGINFO D09JSD USNIC ACID Investigative T89529 DRUGINFO D09OWE UVAOL Investigative T89529 DRUGINFO D09TUB LICOAGROCHALCONE A Investigative T89529 DRUGINFO D09WED Kuwanon R Investigative T89529 DRUGINFO D09YKH BURTTINONE Investigative T89529 DRUGINFO D0A1QK Isochroman mono-carboxylic acid Investigative T89529 DRUGINFO D0A4ML 4'-(2-butylbenzofuran-3-yl)biphenyl-4-ol Investigative T89529 DRUGINFO D0A8WJ Kuwanon L Investigative T89529 DRUGINFO D0AL8P ISIS 107772 Investigative T89529 DRUGINFO D0D4SI 24-hydroxyursolic acid Investigative T89529 DRUGINFO D0D8QO Kuwanon J Investigative T89529 DRUGINFO D0DU3J 5-deoxyabyssinin II Investigative T89529 DRUGINFO D0E0BU 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid Investigative T89529 DRUGINFO D0E1UG Methyl3beta-hydroxyolean-12-en-27-oate Investigative T89529 DRUGINFO D0E1ZS ALBAFURAN A Investigative T89529 DRUGINFO D0G7HN 4-Iodyl-benzoic acid Investigative T89529 DRUGINFO D0H1WV Mulberrofuran W Investigative T89529 DRUGINFO D0J1GM 3beta-hydroxyurs-12-en-27-oic acid Investigative T89529 DRUGINFO D0J5KG Methyl 3beta-hydroxyolean-12-en-28-oate Investigative T89529 DRUGINFO D0J7EN KR61639 Investigative T89529 DRUGINFO D0JB4G CHROMOTROPATE Investigative T89529 DRUGINFO D0JL8I ERYTHRIBYSSIN A Investigative T89529 DRUGINFO D0K0PR 19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid Investigative T89529 DRUGINFO D0K3TS SIGMOIDIN A Investigative T89529 DRUGINFO D0L1ZD ISIS 107791 Investigative T89529 DRUGINFO D0M0XS 3beta-acetoxyolean-12-en-27-oic acid Investigative T89529 DRUGINFO D0M6KC Abyssinin I Investigative T89529 DRUGINFO D0M7IA Sanggenon C Investigative T89529 DRUGINFO D0MG9O PHELLIGRIDIN I Investigative T89529 DRUGINFO D0N8OO Sigmoidin F Investigative T89529 DRUGINFO D0O7ZL Augustic acid Investigative T89529 DRUGINFO D0O8PQ [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid, Investigative T89529 DRUGINFO D0OJ1V 16-alphaH,17-isovaleryloxy-ent-kauran-19-oic acid Investigative T89529 DRUGINFO D0OK8N 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID Investigative T89529 DRUGINFO D0OY2V 3,9-Dihydroxy-4-prenyl-[6aR,11aR]pterocarpan Investigative T89529 DRUGINFO D0P2TB ISIS 107773 Investigative T89529 DRUGINFO D0P9SW Erybreadin D Investigative T89529 DRUGINFO D0Q0XJ ISIS 107774 Investigative T89529 DRUGINFO D0Q3KF 4'-((2-butylbenzofuran-3-yl)methyl)biphenyl-4-ol Investigative T89529 DRUGINFO D0Q5PQ FOLITENOL Investigative T89529 DRUGINFO D0Q8AT 3-epi-masilinic acid Investigative T89529 DRUGINFO D0QQ7A Abyssinone-VI-4-O-methyl ether Investigative T89529 DRUGINFO D0QV8M ISIS 107776 Investigative T89529 DRUGINFO D0S0XV ISIS 107775 Investigative T89529 DRUGINFO D0S9GU Abyssinoflavanone VII Investigative T89529 DRUGINFO D0U2WU 3-Iodyl-benzoic acid Investigative T89529 DRUGINFO D0V0LU Ohioensin C Investigative T89529 DRUGINFO D0VA9F Mulberrofuran C Investigative T89529 DRUGINFO D0X2OD 18beta-Glycyrrhetic acid Investigative T89529 DRUGINFO D0XB7H PNU177836 Investigative T89529 DRUGINFO D0Y1RO Novo Nordisk a/S Compound Investigative T89529 DRUGINFO D0Y5SB 2-(Oxalyl-Amino)-Benzoic Acid Investigative T89529 DRUGINFO D0Z1HV Pomolic acid Investigative T89529 DRUGINFO D0ZE8C Ohioensin G Investigative T89529 DRUGINFO D0ZS7M Erybreadin b Investigative T89529 DRUGINFO D01EJH NEORAUTENOL Investigative T89529 DRUGINFO D02KKU Oleanonic acid Investigative T89529 DRUGINFO D0M7ZZ Erysubin E Investigative T89529 DRUGINFO D0U9HN DYSIDINE Investigative T89529 DRUGINFO D08GWQ 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione Investigative T89529 DRUGINFO D0N7YT 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione Investigative T89529 DRUGINFO D0SJ2Q OLEANOLIC_ACID Investigative T89529 DRUGINFO D05AMX Cysteinesulfonic Acid Investigative T89529 DRUGINFO D0V6UC Cysteine Sulfenic Acid Investigative T89529 DRUGINFO D0W9VA 1,2-NAPHTHOQUINONE Investigative T89529 DRUGINFO D0H1GU Double Oxidized Cysteine Investigative T89529 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T89529 DRUGINFO D02UVH B-Octylglucoside Investigative T89529 DRUGINFO D0F2ME Acetate Ion Investigative T08922 TARGETID T08922 T08922 FORMERID TTDS00357 T08922 UNIPROID ACACB_HUMAN T08922 TARGNAME Acetyl-CoA carboxylase 2 (ACACB) T08922 GENENAME ACACB T08922 TARGTYPE Successful T08922 SYNONYMS Acetyl-Coenzyme A carboxylase beta; Acetyl CoA carboxylase beta; ACCbeta; ACC2; ACC-beta; ACACB T08922 FUNCTION Catalyzes the ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA. Carries out three functions: biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase. Involved in inhibition of fatty acid and glucose oxidation and enhancement of fat storage. May play a role in regulation of mitochondrial fatty acid oxidation through malonyl- CoA-dependent inhibition of carnitine palmitoyltransferase 1. T08922 PDBSTRUC 5KKN; 4HQ6; 3TDC; 3JRX; 3JRW T08922 BIOCLASS Carbon-carbon ligase T08922 ECNUMBER EC 6.4.1.2 T08922 SEQUENCE MVLLLCLSCLIFSCLTFSWLKIWGKMTDSKPITKSKSEANLIPSQEPFPASDNSGETPQRNGEGHTLPKTPSQAEPASHKGPKDAGRRRNSLPPSHQKPPRNPLSSSDAAPSPELQANGTGTQGLEATDTNGLSSSARPQGQQAGSPSKEDKKQANIKRQLMTNFILGSFDDYSSDEDSVAGSSRESTRKGSRASLGALSLEAYLTTGEAETRVPTMRPSMSGLHLVKRGREHKKLDLHRDFTVASPAEFVTRFGGDRVIEKVLIANNGIAAVKCMRSIRRWAYEMFRNERAIRFVVMVTPEDLKANAEYIKMADHYVPVPGGPNNNNYANVELIVDIAKRIPVQAVWAGWGHASENPKLPELLCKNGVAFLGPPSEAMWALGDKIASTVVAQTLQVPTLPWSGSGLTVEWTEDDLQQGKRISVPEDVYDKGCVKDVDEGLEAAERIGFPLMIKASEGGGGKGIRKAESAEDFPILFRQVQSEIPGSPIFLMKLAQHARHLEVQILADQYGNAVSLFGRDCSIQRRHQKIVEEAPATIAPLAIFEFMEQCAIRLAKTVGYVSAGTVEYLYSQDGSFHFLELNPRLQVEHPCTEMIADVNLPAAQLQIAMGVPLHRLKDIRLLYGESPWGVTPISFETPSNPPLARGHVIAARITSENPDEGFKPSSGTVQELNFRSSKNVWGYFSVAATGGLHEFADSQFGHCFSWGENREEAISNMVVALKELSIRGDFRTTVEYLINLLETESFQNNDIDTGWLDYLIAEKVQAEKPDIMLGVVCGALNVADAMFRTCMTDFLHSLERGQVLPADSLLNLVDVELIYGGVKYILKVARQSLTMFVLIMNGCHIEIDAHRLNDGGLLLSYNGNSYTTYMKEEVDSYRITIGNKTCVFEKENDPTVLRSPSAGKLTQYTVEDGGHVEAGSSYAEMEVMKMIMTLNVQERGRVKYIKRPGAVLEAGCVVARLELDDPSKVHPAEPFTGELPAQQTLPILGEKLHQVFHSVLENLTNVMSGFCLPEPVFSIKLKEWVQKLMMTLRHPSLPLLELQEIMTSVAGRIPAPVEKSVRRVMAQYASNITSVLCQFPSQQIATILDCHAATLQRKADREVFFINTQSIVQLVQRYRSGIRGYMKTVVLDLLRRYLRVEHHFQQAHYDKCVINLREQFKPDMSQVLDCIFSHAQVAKKNQLVIMLIDELCGPDPSLSDELISILNELTQLSKSEHCKVALRARQILIASHLPSYELRHNQVESIFLSAIDMYGHQFCPENLKKLILSETTIFDVLPTFFYHANKVVCMASLEVYVRRGYIAYELNSLQHRQLPDGTCVVEFQFMLPSSHPNRMTVPISITNPDLLRHSTELFMDSGFSPLCQRMGAMVAFRRFEDFTRNFDEVISCFANVPKDTPLFSEARTSLYSEDDCKSLREEPIHILNVSIQCADHLEDEALVPILRTFVQSKKNILVDYGLRRITFLIAQEKEFPKFFTFRARDEFAEDRIYRHLEPALAFQLELNRMRNFDLTAVPCANHKMHLYLGAAKVKEGVEVTDHRFFIRAIIRHSDLITKEASFEYLQNEGERLLLEAMDELEVAFNNTSVRTDCNHIFLNFVPTVIMDPFKIEESVRYMVMRYGSRLWKLRVLQAEVKINIRQTTTGSAVPIRLFITNESGYYLDISLYKEVTDSRSGNIMFHSFGNKQGPQHGMLINTPYVTKDLLQAKRFQAQTLGTTYIYDFPEMFRQALFKLWGSPDKYPKDILTYTELVLDSQGQLVEMNRLPGGNEVGMVAFKMRFKTQEYPEGRDVIVIGNDITFRIGSFGPGEDLLYLRASEMARAEGIPKIYVAANSGARIGMAEEIKHMFHVAWVDPEDPHKGFKYLYLTPQDYTRISSLNSVHCKHIEEGGESRYMITDIIGKDDGLGVENLRGSGMIAGESSLAYEEIVTISLVTCRAIGIGAYLVRLGQRVIQVENSHIILTGASALNKVLGREVYTSNNQLGGVQIMHYNGVSHITVPDDFEGVYTILEWLSYMPKDNHSPVPIITPTDPIDREIEFLPSRAPYDPRWMLAGRPHPTLKGTWQSGFFDHGSFKEIMAPWAQTVVTGRARLGGIPVGVIAVETRTVEVAVPADPANLDSEAKIIQQAGQVWFPDSAYKTAQAVKDFNREKLPLMIFANWRGFSGGMKDMYDQVLKFGAYIVDGLRQYKQPILIYIPPYAELRGGSWVVIDATINPLCIEMYADKESRGGVLEPEGTVEIKFRKKDLIKSMRRIDPAYKKLMEQLGEPDLSDKDRKDLEGRLKAREDLLLPIYHQVAVQFADFHDTPGRMLEKGVISDILEWKTARTFLYWRLRRLLLEDQVKQEILQASGELSHVHIQSMLRRWFVETEGAVKAYLWDNNQVVVQWLEQHWQAGDGPRSTIRENITYLKHDSVLKTIRGLVEENPEVAVDCVIYLSQHISPAERAQVVHLLSTMDSPAST T08922 DRUGINFO D0D7LA Metformin Approved T08922 DRUGINFO D03KHO PF-05175157 Phase 2 T08922 DRUGINFO D01OKS Axokine Discontinued in Phase 3 T08922 DRUGINFO D08FSR QLT-091382 Investigative T08922 DRUGINFO D0K4WI 2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid Investigative T08922 DRUGINFO D0WD1E Soraphen A Investigative T08922 DRUGINFO D07WIC CP-640186 Investigative T08922 DRUGINFO D0IY5Y A-80040 Investigative T08922 DRUGINFO D0P7HI AC-8632 Investigative T21334 TARGETID T21334 T21334 FORMERID TTDC00224 T21334 UNIPROID TNF11_HUMAN T21334 TARGNAME Osteoclast differentiation factor (ODF) T21334 GENENAME TNFSF11 T21334 TARGTYPE Successful T21334 SYNONYMS Tumor necrosis factor ligand superfamily member 11; TRANCE; TNF-related activation-induced cytokine; Receptor activatorof nuclear factor kappa B ligand; Receptor activator of nuclear factor kappa-B ligand; RANKL; Osteoprotegerin ligand; OPGL; CD254 T21334 FUNCTION Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation. Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. T21334 PDBSTRUC 5BNQ; 3URF T21334 BIOCLASS Cytokine: tumor necrosis factor T21334 SEQUENCE MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPPAPHQPPAASRSMFVALLGLGLGQVVCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIKQAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSHKVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLDPDQDATYFGAFKVRDID T21334 DRUGINFO D08WSY Denosumab Approved T21334 DRUGINFO D09QWD CEP-37251 Phase 1 T21334 DRUGINFO D0MG2R ALX-0141 Phase 1 T92777 TARGETID T92777 T92777 FORMERID TTDS00291 T92777 UNIPROID MGA_HUMAN T92777 TARGNAME Intestinal maltase-glucoamylase (MGAM) T92777 GENENAME MGAM T92777 TARGTYPE Successful T92777 SYNONYMS MGAM T92777 FUNCTION May serve as an alternate pathway for starch digestion when luminal alpha-amylase activity is reduced because of immaturity or malnutrition. May play a unique role in the digestion of malted dietary oligosaccharides used in food manufacturing. T92777 PDBSTRUC 3TOP; 3TON; 3L4Z; 3L4Y; 3L4X T92777 BIOCLASS Glycosylase T92777 SEQUENCE MARKKLKKFTTLEIVLSVLLLVLFIISIVLIVLLAKESLKSTAPDPGTTGTPDPGTTGTPDPGTTGTTHARTTGPPDPGTTGTTPVSAECPVVNELERINCIPDQPPTKATCDQRGCCWNPQGAVSVPWCYYSKNHSYHVEGNLVNTNAGFTARLKNLPSSPVFGSNVDNVLLTAEYQTSNRFHFKLTDQTNNRFEVPHEHVQSFSGNAAASLTYQVEISRQPFSIKVTRRSNNRVLFDSSIGPLLFADQFLQLSTRLPSTNVYGLGEHVHQQYRHDMNWKTWPIFNRDTTPNGNGTNLYGAQTFFLCLEDASGLSFGVFLMNSNAMEVVLQPAPAITYRTIGGILDFYVFLGNTPEQVVQEYLELIGRPALPSYWALGFHLSRYEYGTLDNMREVVERNRAAQLPYDVQHADIDYMDERRDFTYDSVDFKGFPEFVNELHNNGQKLVIIVDPAISNNSSSSKPYGPYDRGSDMKIWVNSSDGVTPLIGEVWPGQTVFPDYTNPNCAVWWTKEFELFHNQVEFDGIWIDMNEVSNFVDGSVSGCSTNNLNNPPFTPRILDGYLFCKTLCMDAVQHWGKQYDIHNLYGYSMAVATAEAAKTVFPNKRSFILTRSTFAGSGKFAAHWLGDNTATWDDLRWSIPGVLEFNLFGIPMVGPDICGFALDTPEELCRRWMQLGAFYPFSRNHNGQGYKDQDPASFGADSLLLNSSRHYLNIRYTLLPYLYTLFFRAHSRGDTVARPLLHEFYEDNSTWDVHQQFLWGPGLLITPVLDEGAEKVMAYVPDAVWYDYETGSQVRWRKQKVEMELPGDKIGLHLRGGYIFPTQQPNTTTLASRKNPLGLIIALDENKEAKGELFWDNGETKDTVANKVYLLCEFSVTQNRLEVNISQSTYKDPNNLAFNEIKILGTEEPSNVTVKHNGVPSQTSPTVTYDSNLKVAIITDIDLLLGEAYTVEWSIKIRDEEKIDCYPDENGASAENCTARGCIWEASNSSGVPFCYFVNDLYSVSDVQYNSHGATADISLKSSVYANAFPSTPVNPLRLDVTYHKNEMLQFKIYDPNKNRYEVPVPLNIPSMPSSTPEGQLYDVLIKKNPFGIEIRRKSTGTIIWDSQLLGFTFSDMFIRISTRLPSKYLYGFGETEHRSYRRDLEWHTWGMFSRDQPPGYKKNSYGVHPYYMGLEEDGSAHGVLLLNSNAMDVTFQPLPALTYRTTGGVLDFYVFLGPTPELVTQQYTELIGRPVMVPYWSLGFQLCRYGYQNDSEIASLYDEMVAAQIPYDVQYSDIDYMERQLDFTLSPKFAGFPALINRMKADGMRVILILDPAISGNETQPYPAFTRGVEDDVFIKYPNDGDIVWGKVWPDFPDVVVNGSLDWDSQVELYRAYVAFPDFFRNSTAKWWKREIEELYNNPQNPERSLKFDGMWIDMNEPSSFVNGAVSPGCRDASLNHPPYMPHLESRDRGLSSKTLCMESQQILPDGSLVQHYNVHNLYGWSQTRPTYEAVQEVTGQRGVVITRSTFPSSGRWAGHWLGDNTAAWDQLKKSIIGMMEFSLFGISYTGADICGFFQDAEYEMCVRWMQLGAFYPFSRNHNTIGTRRQDPVSWDVAFVNISRTVLQTRYTLLPYLYTLMHKAHTEGVTVVRPLLHEFVSDQVTWDIDSQFLLGPAFLVSPVLERNARNVTAYFPRARWYDYYTGVDINARGEWKTLPAPLDHINLHVRGGYILPWQEPALNTHLSRQKFMGFKIALDDEGTAGGWLFWDDGQSIDTYGKGLYYLASFSASQNTMQSHIIFNNYITGTNPLKLGYIEIWGVGSVPVTSVSISVSGMVITPSFNNDPTTQVLSIDVTDRNISLHNFTSLTWISTL T92777 DRUGINFO D04ZTY Voglibose Approved T92777 DRUGINFO D0AD5C Acarbose Approved T92777 DRUGINFO D0D0ZD Miglitol Approved T92777 DRUGINFO D0M1CZ Rh-alphaglucosidase Approved T92777 DRUGINFO D0Y2SE Alpha-glucosidase Phase 3 T92777 DRUGINFO D0S5LT Deoxynojirimycin Phase 3 T92777 DRUGINFO D0H9WY PAZ-320 Phase 2 T92777 DRUGINFO D0O1HL SC-49483 Phase 2 T92777 DRUGINFO D08CDE Celgosivir Phase 1/2 T92777 DRUGINFO D04RYY Maltose Phase 1/2 T92777 DRUGINFO D07TSW SALACINOL Phase 1/2 T92777 DRUGINFO D0H9SF A-76202M Terminated T92777 DRUGINFO D05GYF PONKORANOL Investigative T92777 DRUGINFO D0F9YZ KOTALANOL Investigative T92777 DRUGINFO D0GS0O 1,4-dideoxy-1,4-imino-D-arabinito Investigative T92777 DRUGINFO D0O6OI 4'-(p-toluenesulfonamide)-3,4-dihydroxy chalcone Investigative T92777 DRUGINFO D0R5HV 2,5-Dideoxy-2,5-imino-D-mannitol Investigative T92777 DRUGINFO D0T0EJ 2-Cyclopentylaminomethyl-pyrrolidine-3,4-diol Investigative T92777 DRUGINFO D0T9YU Imino sugars Investigative T92777 DRUGINFO D0U8XY 3-(4-(4-hydroxyphenyl)phthalazin-1-ylamino)phenol Investigative T92777 DRUGINFO D0V3WN BMN-103 Investigative T92777 DRUGINFO D0W8GU De-O-sulfonated kotalanol Investigative T92777 DRUGINFO D0Z2RR 2-Aminomethyl-pyrrolidine-3,4-diol Investigative T92777 DRUGINFO D0Z7LK GSC-1 Investigative T92777 DRUGINFO D0H1GU Double Oxidized Cysteine Investigative T92777 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T00494 TARGETID T00494 T00494 FORMERID TTDR00288 T00494 UNIPROID ABCA1_HUMAN T00494 TARGNAME ATP-binding cassette transporter A1 (ABCA1) T00494 GENENAME ABCA1 T00494 TARGTYPE Successful T00494 SYNONYMS Cholesterol mobilizing transporter ABCA1; Cholesterol efflux regulatory protein; CERP; ATP-binding cassette transporter (ABCA1) transmembrane protein; ATP-binding cassette sub-family A member 1; ATP-binding cassette 1; ABC1; ABC-1 T00494 FUNCTION Involved in the efflux of intracellular cholesterol and phospholipids and their transfer to apoliproteins to form nascent high density lipoproteins/HDLs. cAMP-dependent and sulfonylurea-sensitive anion transporter. T00494 PDBSTRUC 5XJY T00494 BIOCLASS ABC transporter T00494 ECNUMBER EC 7.6.2.1 T00494 SEQUENCE MACWPQLRLLLWKNLTFRRRQTCQLLLEVAWPLFIFLILISVRLSYPPYEQHECHFPNKAMPSAGTLPWVQGIICNANNPCFRYPTPGEAPGVVGNFNKSIVARLFSDARRLLLYSQKDTSMKDMRKVLRTLQQIKKSSSNLKLQDFLVDNETFSGFLYHNLSLPKSTVDKMLRADVILHKVFLQGYQLHLTSLCNGSKSEEMIQLGDQEVSELCGLPREKLAAAERVLRSNMDILKPILRTLNSTSPFPSKELAEATKTLLHSLGTLAQELFSMRSWSDMRQEVMFLTNVNSSSSSTQIYQAVSRIVCGHPEGGGLKIKSLNWYEDNNYKALFGGNGTEEDAETFYDNSTTPYCNDLMKNLESSPLSRIIWKALKPLLVGKILYTPDTPATRQVMAEVNKTFQELAVFHDLEGMWEELSPKIWTFMENSQEMDLVRMLLDSRDNDHFWEQQLDGLDWTAQDIVAFLAKHPEDVQSSNGSVYTWREAFNETNQAIRTISRFMECVNLNKLEPIATEVWLINKSMELLDERKFWAGIVFTGITPGSIELPHHVKYKIRMDIDNVERTNKIKDGYWDPGPRADPFEDMRYVWGGFAYLQDVVEQAIIRVLTGTEKKTGVYMQQMPYPCYVDDIFLRVMSRSMPLFMTLAWIYSVAVIIKGIVYEKEARLKETMRIMGLDNSILWFSWFISSLIPLLVSAGLLVVILKLGNLLPYSDPSVVFVFLSVFAVVTILQCFLISTLFSRANLAAACGGIIYFTLYLPYVLCVAWQDYVGFTLKIFASLLSPVAFGFGCEYFALFEEQGIGVQWDNLFESPVEEDGFNLTTSVSMMLFDTFLYGVMTWYIEAVFPGQYGIPRPWYFPCTKSYWFGEESDEKSHPGSNQKRISEICMEEEPTHLKLGVSIQNLVKVYRDGMKVAVDGLALNFYEGQITSFLGHNGAGKTTTMSILTGLFPPTSGTAYILGKDIRSEMSTIRQNLGVCPQHNVLFDMLTVEEHIWFYARLKGLSEKHVKAEMEQMALDVGLPSSKLKSKTSQLSGGMQRKLSVALAFVGGSKVVILDEPTAGVDPYSRRGIWELLLKYRQGRTIILSTHHMDEADVLGDRIAIISHGKLCCVGSSLFLKNQLGTGYYLTLVKKDVESSLSSCRNSSSTVSYLKKEDSVSQSSSDAGLGSDHESDTLTIDVSAISNLIRKHVSEARLVEDIGHELTYVLPYEAAKEGAFVELFHEIDDRLSDLGISSYGISETTLEEIFLKVAEESGVDAETSDGTLPARRNRRAFGDKQSCLRPFTEDDAADPNDSDIDPESRETDLLSGMDGKGSYQVKGWKLTQQQFVALLWKRLLIARRSRKGFFAQIVLPAVFVCIALVFSLIVPPFGKYPSLELQPWMYNEQYTFVSNDAPEDTGTLELLNALTKDPGFGTRCMEGNPIPDTPCQAGEEEWTTAPVPQTIMDLFQNGNWTMQNPSPACQCSSDKIKKMLPVCPPGAGGLPPPQRKQNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWVNEFRYGGFSLGVSNTQALPPSQEVNDAIKQMKKHLKLAKDSSADRFLNSLGRFMTGLDTKNNVKVWFNNKGWHAISSFLNVINNAILRANLQKGENPSHYGITAFNHPLNLTKQQLSEVALMTTSVDVLVSICVIFAMSFVPASFVVFLIQERVSKAKHLQFISGVKPVIYWLSNFVWDMCNYVVPATLVIIIFICFQQKSYVSSTNLPVLALLLLLYGWSITPLMYPASFVFKIPSTAYVVLTSVNLFIGINGSVATFVLELFTDNKLNNINDILKSVFLIFPHFCLGRGLIDMVKNQAMADALERFGENRFVSPLSWDLVGRNLFAMAVEGVVFFLITVLIQYRFFIRPRPVNAKLSPLNDEDEDVRRERQRILDGGGQNDILEIKELTKIYRRKRKPAVDRICVGIPPGECFGLLGVNGAGKSSTFKMLTGDTTVTRGDAFLNKNSILSNIHEVHQNMGYCPQFDAITELLTGREHVEFFALLRGVPEKEVGKVGEWAIRKLGLVKYGEKYAGNYSGGNKRKLSTAMALIGGPPVVFLDEPTTGMDPKARRFLWNCALSVVKEGRSVVLTSHSMEECEALCTRMAIMVNGRFRCLGSVQHLKNRFGDGYTIVVRIAGSNPDLKPVQDFFGLAFPGSVLKEKHRNMLQYQLPSSLSSLARIFSILSQSKKRLHIEDYSVSQTTLDQVFVNFAKDQSDDDHLKDLSLHKNQTVVDVAVLTSFLQDEKVKESYV T00494 DRUGINFO D0H2DQ Probucol Approved T00494 DRUGINFO D03JQR RG-7273 Discontinued in Phase 1 T00494 DRUGINFO D01WMW RG7232 Investigative T17345 TARGETID T17345 T17345 FORMERID TTDI00931 T17345 UNIPROID DYR_HUMAN T17345 TARGNAME Dihydrofolate reductase (DHFR) T17345 GENENAME DHFR T17345 TARGTYPE Successful T17345 SYNONYMS DYR; DHFRP1 T17345 FUNCTION Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFR2. Key enzyme in folate metabolism. T17345 PDBSTRUC 6DE4; 6DAV; 6A7E; 6A7C; 5HVE T17345 BIOCLASS CH-NH donor oxidoreductase T17345 ECNUMBER EC 1.5.1.3 T17345 SEQUENCE MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND T17345 DRUGINFO D0AO5H Trimethoprim Approved T17345 DRUGINFO D0B6TW Leucovorin Calcium Approved T17345 DRUGINFO D0D3DU Methotrexate Sodium Approved T17345 DRUGINFO D01WJL Aminosalicylic Acid Approved T17345 DRUGINFO D04LBC Iclaprim Phase 3 T17345 DRUGINFO D02OTK CH-4051 Phase 2 T17345 DRUGINFO D09AYQ PIRITREXIM Phase 2 T17345 DRUGINFO D0DO5J MDAM (y-methylene-10-deazaaminopterin) Phase 1 T17345 DRUGINFO D0S9OH L-MDAM Phase 1 T17345 DRUGINFO D9ZQ7T VYR 006 Phase 1 T17345 DRUGINFO D00CQW TNP-351 Discontinued in Phase 2 T17345 DRUGINFO D05HCO 1954U89 Preclinical T45299 TARGETID T45299 T45299 FORMERID TTDR01233 T45299 UNIPROID TPA_HUMAN T45299 TARGNAME Tissue-type plasminogen activator (PLAT) T45299 GENENAME PLAT T45299 TARGTYPE Successful T45299 SYNONYMS TPA; T-plasminogen activator; T-PA; Reteplase; Alteplase T45299 FUNCTION By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Plays a direct role in facilitating neuronal migration. Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. T45299 PDBSTRUC 5ZLZ; 5BRR; 1TPN; 1TPM; 1TPK T45299 BIOCLASS Peptidase T45299 ECNUMBER EC 3.4.21.68 T45299 SEQUENCE MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP T45299 DRUGINFO D0FD0H Aminocaproic Acid Approved T45299 DRUGINFO D03CKG 5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID Investigative T45299 DRUGINFO D07PSW N-(4-Phenyl-pyridin-2-yl)-guanidine Investigative T45299 DRUGINFO D09YLF N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine Investigative T45299 DRUGINFO D0C3QE N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine Investigative T45299 DRUGINFO D01JUI N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine Investigative T45299 DRUGINFO D00PEJ 1-guanidino-N-phenyl-7-isoquinolinesulphonamide Investigative T45299 DRUGINFO D0J1QT BMS-344577 Investigative T45299 DRUGINFO D08OLP 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine Investigative T03661 TARGETID T03661 T03661 FORMERID TTDS00092 T03661 UNIPROID ADA_HUMAN T03661 TARGNAME Adenosine deaminase (ADA) T03661 GENENAME ADA T03661 TARGTYPE Successful T03661 SYNONYMS Adenosine aminohydrolase; ADA1 T03661 FUNCTION Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion. Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion. Enhances CD4+ T-cell differentiation and proliferation. Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change. Stimulates plasminogen activation. Plays a role in male fertility. Plays a protective role in early postimplantation embryonic development. Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. T03661 PDBSTRUC 3IAR; 1M7M T03661 BIOCLASS Carbon-nitrogen hydrolase T03661 ECNUMBER EC 3.5.4.4 T03661 SEQUENCE MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNL T03661 DRUGINFO D01VEJ Elapegademase Approved T03661 DRUGINFO D05GJW Cladribine Approved T03661 DRUGINFO D0F2XQ Fludarabine Approved T03661 DRUGINFO D0T3AD Pentostatin Approved T03661 DRUGINFO D0F4QV GSK2696273 Preregistration T03661 DRUGINFO D47RIS OTL-101 Phase 3 T03661 DRUGINFO D05YUI Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy Phase 1/2 T03661 DRUGINFO D00FIT 3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol Investigative T03661 DRUGINFO D01XFT 3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol Investigative T03661 DRUGINFO D03PLV 1-Deaza-Adenosine Investigative T03661 DRUGINFO D04GWR FR117016 Investigative T03661 DRUGINFO D05RDO 3-(6-Amino-purin-9-yl)-4-butoxy-butan-2-ol Investigative T03661 DRUGINFO D06EHE 6-Hydroxy-1,6-Dihydro Purine Nucleoside Investigative T03661 DRUGINFO D06QTC FR230513 Investigative T03661 DRUGINFO D08FWE 3-(6-Amino-purin-9-yl)-non-5-en-2-ol Investigative T03661 DRUGINFO D08ZMX FR239087 Investigative T03661 DRUGINFO D09JNN 3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol Investigative T03661 DRUGINFO D0D2OM 3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol Investigative T03661 DRUGINFO D0D7CM FR233623 Investigative T03661 DRUGINFO D0D8YG 3-(6-Amino-purin-9-yl)-4-phenethyloxy-butan-2-ol Investigative T03661 DRUGINFO D0E6ON 3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol Investigative T03661 DRUGINFO D0G0TP 3-(6-Amino-purin-9-yl)-non-5-yn-2-ol Investigative T03661 DRUGINFO D0KC9E 3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol Investigative T03661 DRUGINFO D0L5XY FR221647 Investigative T03661 DRUGINFO D0R7RB Purine Riboside Investigative T03661 DRUGINFO D0V4UU 6-Hydroxy-7,8-Dihydro Purine Nucleoside Investigative T03661 DRUGINFO D0V4WB (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol Investigative T03661 DRUGINFO D0V6TX FR236913 Investigative T03661 DRUGINFO D05ZHQ EHNA Investigative T20178 TARGETID T20178 T20178 FORMERID TTDS00131 T20178 UNIPROID TNFA_HUMAN T20178 TARGNAME Tumor necrosis factor (TNF) T20178 GENENAME TNF T20178 TARGTYPE Successful T20178 SYNONYMS Tumour necrosis factor alpha; Tumour necrosis factor; Tumor necrosis factor ligand superfamily member 2; TNFalpha; TNFSF2; TNFA; TNF-alpha; TNF-a; TNF alpha; Cachectin T20178 FUNCTION It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line. Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. T20178 PDBSTRUC 5YOY; 5WUX; 5UUI; 5TSW; 5MU8 T20178 BIOCLASS Cytokine: tumor necrosis factor T20178 SEQUENCE MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL T20178 DRUGINFO D05LTY Enbrel Approved T20178 DRUGINFO D09FSG Golimumab Approved T20178 DRUGINFO D09QEI Pentoxifylline Approved T20178 DRUGINFO D0CA0P Certolizumab Approved T20178 DRUGINFO D0I5QX Etanercept Approved T20178 DRUGINFO D0K5KS Adalimumab Approved T20178 DRUGINFO D0PG5G Infliximab Approved T20178 DRUGINFO D0Q5NX Lenalidomide Approved T20178 DRUGINFO D0U7GK Thalidomide Approved T20178 DRUGINFO D07XHO Nafamostat Approved T20178 DRUGINFO D03QBT Golnerminogene pradenovac Phase 3 T20178 DRUGINFO D06FMO ABP 501 Phase 3 T20178 DRUGINFO D08DGC CPL-7075 Phase 3 T20178 DRUGINFO D0D9HZ PF-06438179 Phase 3 T20178 DRUGINFO D0Y8TZ PF-06410293 Phase 3 T20178 DRUGINFO DI0CX8 AVT02 Phase 3 T20178 DRUGINFO D03VPJ AN0128 Phase 2 T20178 DRUGINFO D04GTA Pegsunercept Phase 2 T20178 DRUGINFO D04ZHJ TNF alpha kinoid Phase 2 T20178 DRUGINFO D05CJU DLX-105 Phase 2 T20178 DRUGINFO D0A8JM RDP58 Phase 2 T20178 DRUGINFO D0G9ZU ESBA-105 Phase 2 T20178 DRUGINFO D0Q5CH AP-301-IH Phase 2 T20178 DRUGINFO D2AQW7 ABBV-154 Phase 2 T20178 DRUGINFO D0OX5H ABT-122 Phase 2 T20178 DRUGINFO D0YX7E Ortataxel Phase 2 T20178 DRUGINFO D00YEV BAICALEIN Phase 2 T20178 DRUGINFO D00BPH COVA322 Phase 1/2a T20178 DRUGINFO D08KCK ART621 Phase 1/2 T20178 DRUGINFO DU7G5P XTMAB-16 Phase 1/2 T20178 DRUGINFO D02PTI AST-005 Phase 1 T20178 DRUGINFO D04DUH PMI-005 Phase 1 T20178 DRUGINFO D0DC8J CYT-609 Phase 1 T20178 DRUGINFO D0Y0FZ PF-05230905 Phase 1 T20178 DRUGINFO D1ROU2 IA-14069 Phase 1 T20178 DRUGINFO DQA23T SAR441566 Phase 1 T20178 DRUGINFO DR5LW8 INB03 Phase 1 T20178 DRUGINFO D03HIG AVX-470 Phase 1 T20178 DRUGINFO D04DQO ABBV-257 Phase 1 T20178 DRUGINFO D31CPE SAR442970 Phase 1 T20178 DRUGINFO DKX8W5 SAR444419 Phase 1 T20178 DRUGINFO D07AWM Segard Discontinued in Phase 3 T20178 DRUGINFO D0S2GT CDP571 Discontinued in Phase 3 T20178 DRUGINFO D0Q9ZD Camobucol Discontinued in Phase 2 T20178 DRUGINFO D0VA2I CRx-191 Discontinued in Phase 2 T20178 DRUGINFO D04VGY CYT-007-TNFQb Discontinued in Phase 1/2 T20178 DRUGINFO D05RTF AME-527 Discontinued in Phase 1/2 T20178 DRUGINFO D05NUT ALS-00T2-0501 Discontinued in Phase 1 T20178 DRUGINFO D0D1RF ABX-0401 Preclinical T20178 DRUGINFO D0I9XH Celastrol Preclinical T20178 DRUGINFO D01ZEY MDL-201112 Terminated T20178 DRUGINFO D06MJP TNFQb therapeutic vaccines Terminated T20178 DRUGINFO D04SVB FR-133605 Terminated T20178 DRUGINFO D06VXD DOM-0215 Investigative T20178 DRUGINFO D06YWZ Y-39041 Investigative T20178 DRUGINFO D02UYR PKF-241-466 Investigative T20178 DRUGINFO D0H2PA PKF-242-484 Investigative T20178 DRUGINFO D0W7LK 2-Propanol, Isopropanol Investigative T20178 DRUGINFO D0W2UK IK-862 Investigative T77664 TARGETID T77664 T77664 FORMERID TTDC00096 T77664 UNIPROID IFNG_HUMAN T77664 TARGNAME Interferon-gamma (IFNG) T77664 GENENAME IFNG T77664 TARGTYPE Successful T77664 SYNONYMS Interferon gamma; Immune interferon; IFN-gamma T77664 FUNCTION Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. T77664 PDBSTRUC 6E3L; 6E3K; 3BES; 1HIG; 1FYH T77664 BIOCLASS Cytokine: interferon T77664 SEQUENCE MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ T77664 DRUGINFO D0UI7K Emapalumab Approved T77664 DRUGINFO D03GOO Fumaric acid Phase 3 T77664 DRUGINFO D0I5QV VIR-201 Phase 1/2 T77664 DRUGINFO D06FLP AMG 811 Phase 1 T77664 DRUGINFO D06NDP CIGB-128 Phase 1 T77664 DRUGINFO D0H6PX TAK-603 Discontinued in Phase 2 T77664 DRUGINFO D0N4ND Fontolizumab Discontinued in Phase 2 T77664 DRUGINFO D0Z9MR TG-1042 Discontinued in Phase 2 T77664 DRUGINFO D0VA2I CRx-191 Discontinued in Phase 2 T77664 DRUGINFO D0WD6K VPM-4-001 Preclinical T42000 TARGETID T42000 T42000 FORMERID TTDS00447 T42000 UNIPROID IL1B_HUMAN T42000 TARGNAME Interleukin-1 beta (IL1B) T42000 GENENAME IL1B T42000 TARGTYPE Successful T42000 SYNONYMS IL1F2; IL-1beta; IL-1 beta; Catabolin T42000 FUNCTION Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. Potent proinflammatory cytokine. T42000 PDBSTRUC 9ILB; 7I1B; 6I1B; 5MVZ; 5I1B T42000 BIOCLASS Cytokine: interleukin T42000 SEQUENCE MAEVPELASEMMAYYSGNEDDLFFEADGPKQMKCSFQDLDLCPLDGGIQLRISDHHYSKGFRQAASVVVAMDKLRKMLVPCPQTFQENDLSTFFPFIFEEEPIFFDTWDNEAYVHDAPVRSLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKDDKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYISTSQAENMPVFLGGTKGGQDITDFTMQFVSS T42000 DRUGINFO D07NSU Glucosamine Approved T42000 DRUGINFO D09DBY Rilonacept Approved T42000 DRUGINFO D0R4ZT Gallium nitrate Approved T42000 DRUGINFO D0TD2G Canakinumab Approved T42000 DRUGINFO D0N1FS Diacerein Phase 4 T42000 DRUGINFO D0C4KT XOMA 052 Phase 3 T42000 DRUGINFO D02DJG LY-2189102 Phase 2 T42000 DRUGINFO D01WQQ ABT-981 Phase 2 T42000 DRUGINFO D0WP2R AC-201 Phase 2 T42000 DRUGINFO D00EHX TT-301 Phase 1 T42000 DRUGINFO D09YAS CYT-013-IL1bQb Phase 1 T42000 DRUGINFO D05FVX CDP-484 Discontinued in Phase 1/2 T42000 DRUGINFO D0I9XH Celastrol Preclinical T42000 DRUGINFO D0K8YK DVD-Ig Investigative T03313 TARGETID T03313 T03313 FORMERID TTDR01101 T03313 UNIPROID IL2RA_HUMAN T03313 TARGNAME Interleukin 2 receptor alpha (IL2RA) T03313 GENENAME IL2RA T03313 TARGTYPE Successful T03313 SYNONYMS TAC antigen; Interleukin-2 receptor subunit alpha; IL2-RA; IL-2R subunit alpha; IL-2-RA; IL-2 receptor subunit alpha; IL-2 receptor alpha subunit; CD25 antigen; CD25 T03313 FUNCTION The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells. Receptor for interleukin-2. T03313 PDBSTRUC 3NFP; 3IU3; 2ERJ; 2B5I; 1Z92 T03313 BIOCLASS Cytokine receptor T03313 SEQUENCE MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQASLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQPQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI T03313 DRUGINFO D06SBB Basiliximab Approved T03313 DRUGINFO D0OX9W Inolimomab Phase 3 T03313 DRUGINFO D06EIJ RFT-5.dgA Phase 2 T03313 DRUGINFO D0X0IU LMB-2 Phase 2 T03313 DRUGINFO D0U3UJ CHT-25 Phase 1 T03313 DRUGINFO DK52QX RG6292 Phase 1 T03313 DRUGINFO D0Q4DT HuMax-TAC Terminated T10191 TARGETID T10191 T10191 FORMERID TTDC00265 T10191 UNIPROID CD4_HUMAN T10191 TARGNAME T-cell surface glycoprotein CD4 (CD4) T10191 GENENAME CD4 T10191 TARGTYPE Successful T10191 SYNONYMS T-cell surface antigen T4/Leu-3 T10191 FUNCTION In T-cells, functions primarily as a coreceptor for MHC class II molecule:peptide complex. The antigens presented by class II peptides are derived from extracellular proteins while class I peptides are derived from cytosolic proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class II presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of T-helper cells. In other cells such as macrophages or NK cells, plays a role in differentiation/activation, cytokine expression and cell migration in a TCR/LCK-independent pathway. Participates in the development of T-helper cells in the thymus and triggers the differentiation of monocytes into functional mature macrophages. Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. T10191 PDBSTRUC 6MET; 6MEO; 6EDU; 6CM3; 5VN3 T10191 BIOCLASS Immunoglobulin T10191 SEQUENCE MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMRATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQVLLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQAERMSQIKRLLSEKKTCQCPHRFQKTCSPI T10191 DRUGINFO D0E7AD Ibalizumab Approved T10191 DRUGINFO D00UBX TNX-355 Phase 3 T10191 DRUGINFO D0Z8KS Zanolimumab Phase 3 T10191 DRUGINFO DN5CM6 Magrolimab Phase 3 T10191 DRUGINFO D0NQ0V BT-061 Phase 2 T10191 DRUGINFO D0C8AL Fluoropeptide vaccine Phase 2 T10191 DRUGINFO DFQ17Y TMB-365 Phase 1 T10191 DRUGINFO DO7MC9 CD4CAR Phase 1 T10191 DRUGINFO DRGC82 VRC07-523LS Phase 1 T10191 DRUGINFO D0T7LV LIPO-4 Phase 1 T10191 DRUGINFO DO61WZ Combinectin Phase 1 T10191 DRUGINFO D04ZLG IDEC-151 Discontinued in Phase 2 T10191 DRUGINFO D0F3VI CEL-1000 Investigative T39087 TARGETID T39087 T39087 FORMERID TTDC00211 T39087 UNIPROID POL_HV1B1 T39087 TARGNAME Human immunodeficiency virus Integrase (HIV IN) T39087 GENENAME HIV IN T39087 TARGTYPE Successful T39087 SYNONYMS HIV IN T39087 FUNCTION Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation. T39087 PDBSTRUC 6OE3; 6HAK; 6ELI; 6DUH; 6DUG T39087 BIOCLASS Integrase T39087 ECNUMBER EC 2.7.7.- T39087 SEQUENCE FLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTSATVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED T39087 DRUGINFO D00YZD Dolutegravir Approved T39087 DRUGINFO D0I1FQ Raltegravir Approved T39087 DRUGINFO D0QD1G Elvitegravir Approved T39087 DRUGINFO D01IRG Bictegravir, emtricitabine and tenofovir alafenamide Approved T39087 DRUGINFO D08LDB GSK1265744 Phase 3 T39087 DRUGINFO D02DMW S-1360 Phase 2 T39087 DRUGINFO D09HOW S-364735 Phase 2 T39087 DRUGINFO D0C1WL C-2507 Phase 1 T39087 DRUGINFO D0N3NL Acriflavine Phase 1 T39087 DRUGINFO D0P0PC S-265744 LAP Phase 1 T39087 DRUGINFO D7PY9O VH4524184 Phase 1 T39087 DRUGINFO D0F0OJ JTK-656 Discontinued in Phase 1 T39087 DRUGINFO D06SIG AR177 Terminated T39087 DRUGINFO D0V8HF GS-9160 Terminated T39087 DRUGINFO D01HGV L-708,906 Investigative T39087 DRUGINFO D05KKV Dicaffeoylquinic acids Investigative T39087 DRUGINFO D05PMU Dicaffeoyltartaric acids Investigative T39087 DRUGINFO D07ECH V-165 Investigative T39087 DRUGINFO D08FSC L-731,988 Investigative T39087 DRUGINFO D09OSF L17 Investigative T39087 DRUGINFO D0XJ7I Purpurin Investigative T77195 TARGETID T77195 T77195 FORMERID TTDS00469 T77195 UNIPROID NU3M_HUMAN T77195 TARGNAME NADH dehydrogenase (MT-ND3) T77195 GENENAME MT-ND3 T77195 TARGTYPE Successful T77195 SYNONYMS ND; NADH-ubiquinone oxidoreductase; NADH; MTND; MT-ND3; MT-ND T77195 FUNCTION Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in thetransfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone. T77195 PDBSTRUC 5XTD; 5XTC T77195 BIOCLASS NADH/NADPH oxidoreductase T77195 ECNUMBER EC 7.1.1.2 T77195 SEQUENCE MNFALILMINTLLALLLMIITFWLPQLNGYMEKSTPYECGFDPMSPARVPFSMKFFLVAITFLLFDLEIALLLPLPWALQTTNLPLMVMSSLLLIIILALSLAYEWLQKGLDWTE T77195 DRUGINFO D0B8SV NADH Approved T77195 DRUGINFO D07FRX 6-Thiophen-3-yl-imidazo[2,1-b]thiazole Investigative T77195 DRUGINFO D0J3TS 6-Thiophen-2-yl-imidazo[2,1-b]thiazole Investigative T77195 DRUGINFO D0GV9Q N-Formylmethionine Investigative T82739 TARGETID T82739 T82739 FORMERID TTDC00013 T82739 UNIPROID KLKB1_HUMAN T82739 TARGNAME Plasma kallikrein (KLKB1) T82739 GENENAME KLKB1 T82739 TARGTYPE Successful T82739 SYNONYMS Plasma prekallikrein; Plasma kallikrein light chain; Plasma kallikrein heavy chain; PKK; Kininogenin; KLK3; Fletcher factor T82739 FUNCTION It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin. The enzyme cleaves Lys-Arg and Arg-Ser bonds. T82739 PDBSTRUC 6O1S; 6O1G; 6I44; 5TJX; 5F8Z T82739 BIOCLASS Peptidase T82739 ECNUMBER EC 3.4.21.34 T82739 SEQUENCE MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA T82739 DRUGINFO D08LEY Lanadelumab Approved T82739 DRUGINFO DQ1S0B Berotralstat Approved T82739 DRUGINFO D0P5AE Ecallantide Approved T82739 DRUGINFO D03GSN KVD001 Phase 2 T82739 DRUGINFO D9SMF2 KVD824 Phase 2 T82739 DRUGINFO DA8W3Q THR-149 Phase 2 T82739 DRUGINFO D0R9CH ZK-810388 Investigative T82739 DRUGINFO D02PAU ZK-814048 Investigative T82739 DRUGINFO D08WQJ (3-nitro-1H-pyrazol-1-yl)(phenyl)methanone Investigative T82739 DRUGINFO D05ZIP (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative T82739 DRUGINFO D08OCS (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative T82739 DRUGINFO D0IU5E 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide Investigative T82739 DRUGINFO D0M4VZ D-Pro-Phe-Arg chloromethyl ketone Investigative T82739 DRUGINFO D0X1OY (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone Investigative T84173 TARGETID T84173 T84173 FORMERID TTDC00014 T84173 UNIPROID GLCM_HUMAN T84173 TARGNAME Glucosylceramidase (GBA) T84173 GENENAME GBA T84173 TARGTYPE Successful T84173 SYNONYMS SGTase; Lysosomal acid glucosylceramidase; Lysosomal acid GCase; Imiglucerase; GLUC; GC; D-glucosyl-N-acylsphingosine glucohydrolase; Cholesteryl-beta-glucosidase; Cholesterol glucosyltransferase; Beta-glucocerebrosidase; Beta-GC; Alglucerase; Acid beta-glucosidase T84173 FUNCTION Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramide/GlcCer into free ceramide and glucose. Thereby, plays a central role in the degradation of complex lipids and the turnover of cellular membranes. Through the production of ceramides, participates to the PKC-activated salvage pathway of ceramide formation. Also plays a role in cholesterol metabolism. May either catalyze the glucosylation of cholesterol, through a transglucosylation reaction that transfers glucose from glucosylceramide to cholesterol. The short chain saturated C8:0-GlcCer and the mono-unsaturated C18:0-GlcCer being the most effective glucose donors for that transglucosylation reaction. Under specific conditions, may alternatively catalyze the reverse reaction, transferring glucose from cholesteryl-beta-D-glucoside to ceramide. Finally, may also hydrolyze cholesteryl-beta-D-glucoside to produce D-glucose and cholesterol. T84173 PDBSTRUC 6Q6N; 6Q6L; 6Q6K; 5LVX; 3RIL T84173 BIOCLASS Glycosylase T84173 ECNUMBER EC 3.2.1.45 T84173 SEQUENCE MEFSSPSREECPKPLSRVSIMAGSLTGLLLLQAVSWASGARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ T84173 DRUGINFO D0G5ET Velaglucerase alfa Approved T84173 DRUGINFO D0G6HA Taliglucerase alfa Approved T84173 DRUGINFO D04BQV Isofagomine tartrate Phase 2 T84173 DRUGINFO D1SWN3 Afegostat Discontinued in Phase 2 T84173 DRUGINFO DJK0W9 NCGC607 Preclinical T84173 DRUGINFO DPUF69 N-Octyl-beta-valienamine Preclinical T84173 DRUGINFO D00MFZ L-Isofagomine Investigative T84173 DRUGINFO D06YQR (2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol Investigative T84173 DRUGINFO D09IWI N-(Propylamide-acetophenone)-1-deoxynojirimycin Investigative T84173 DRUGINFO D0B1WB (2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol Investigative T84173 DRUGINFO D0Q7SF N-(Propylamide-benzophenone)-1-deoxynojirimycin Investigative T84173 DRUGINFO D0R4JZ (2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol Investigative T84173 DRUGINFO D0R8TR 1,5-Dideoxy-1,5-imino-D-xylitol Investigative T84173 DRUGINFO D06IEN 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose Investigative T24836 TARGETID T24836 T24836 FORMERID TTDS00470 T24836 UNIPROID PROC_HUMAN T24836 TARGNAME Vitamin K-dependent protein C (PROC) T24836 GENENAME PROC T24836 TARGTYPE Successful T24836 SYNONYMS Vitamin K-dependent protein C light chain; Vitamin K-dependent protein C heavy chain; PROC; Blood coagulation factor XIV; Autoprothrombin IIA; Anticoagulant protein C; Activation peptide T24836 FUNCTION Protein C is avitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids. T24836 PDBSTRUC 4DT7; 3JTC; 3F6U; 2PCT; 1PCU T24836 BIOCLASS Peptidase T24836 ECNUMBER EC 3.4.21.69 T24836 SEQUENCE MWQLTSLLLFVATWGISGTPAPLDSVFSSSERAHQVLRIRKRANSFLEELRHSSLERECIEEICDFEEAKEIFQNVDDTLAFWSKHVDGDQCLVLPLEHPCASLCCGHGTCIDGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHLKRDTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP T24836 DRUGINFO D0Z5SM Sodium Tetradecyl Sulfate Approved T24836 DRUGINFO D05BII Ancrod Phase 3 T24836 DRUGINFO D0UT7F 3K3A-APC Phase 2 T24836 DRUGINFO D0F8RK GED-aPC Discontinued in Phase 1 T24836 DRUGINFO D00KJP RPR-120844 Investigative T24836 DRUGINFO D0MQ6K RPR-118071 Investigative T24836 DRUGINFO D0V7TH PMID24418773C37 Investigative T40800 TARGETID T40800 T40800 FORMERID TTDS00045 T40800 UNIPROID AT1A1_HUMAN T40800 TARGNAME Sodium pump subunit alpha-1 (ATP1A1) T40800 GENENAME ATP1A1 T40800 TARGTYPE Successful T40800 SYNONYMS Sodium/potassium-transporting ATPase alpha1; Sodium pump 1; Na+/K+ ATPase 1; ATP1A1 T40800 FUNCTION This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of atp coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions. T40800 BIOCLASS Acid anhydrides hydrolase T40800 ECNUMBER EC 7.2.2.13 T40800 SEQUENCE MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDELHRKYGTDLSRGLTSARAAEILARDGPNALTPPPTTPEWIKFCRQLFGGFSMLLWIGAILCFLAYSIQAATEEEPQNDNLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEKMSINAEEVVVGDLVEVKGGDRIPADLRIISANGCKVDNSSLTGESEPQTRSPDFTNENPLETRNIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAAEIEHFIHIITGVAVFLGVSFFILSLILEYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKNLEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTENQSGVSFDKTSATWLALSRIAGLCNRAVFQANQENLPILKRAVAGDASESALLKCIELCCGSVKEMRERYAKIVEIPFNSTNKYQLSIHKNPNTSEPQHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQNAYLELGGLGERVLGFCHLFLPDEQFPEGFQFDTDDVNFPIDNLCFVGLISMIDPPRAAVPDAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDAKACVVHGSDLKDMTSEQLDDILKYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKKADIGVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTLTSNIPEITPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPKTDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPIHLLGLRVDWDDRWINDVEDSYGQQWTYEQRKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFEETALAAFLSYCPGMGVALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKETYY T40800 DRUGINFO D06MQM Lumefantrine Approved T40800 DRUGINFO D07NAJ Chloroprocaine Approved T40800 DRUGINFO D07TGN Deslanoside Approved T40800 DRUGINFO D0AR3J Acocantherin Approved T40800 DRUGINFO D0D9NA Almitrine Approved T40800 DRUGINFO D0M9BW Artemether Approved T40800 DRUGINFO D0V3GA Acetyldigitoxin Approved T40800 DRUGINFO D0V8TQ Aluminium Approved T40800 DRUGINFO D04TSO UNBS-1450 Phase 1 T40800 DRUGINFO D08ZNS DIGITOXIGENIN Investigative T87024 TARGETID T87024 T87024 FORMERID TTDC00180 T87024 UNIPROID A4_HUMAN T87024 TARGNAME Amyloid beta A4 protein (APP) T87024 GENENAME APP T87024 TARGTYPE Successful T87024 SYNONYMS Protease nexin-II; PreA4; PN-II; Cerebral vascular amyloid peptide; CVAP; Amyloid-beta precursor protein; Amyloid-beta A4 protein; Alzheimer disease amyloid protein; APPI; APP; AD1; ABPP; A4 T87024 FUNCTION Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1. T87024 PDBSTRUC 6IYC; 6GFI; 6CO3; 5W3P; 5VZY T87024 BIOCLASS Amyloid beta-protein peptide T87024 SEQUENCE MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN T87024 DRUGINFO D00RRU Aducanumab Approved T87024 DRUGINFO D06XVR Lecanemab Approved T87024 DRUGINFO D09CGE Florbetapir F-18 Approved T87024 DRUGINFO D00CZT Solanezumab Phase 3 T87024 DRUGINFO D09DLP Tramiprosate Phase 3 T87024 DRUGINFO D0A1MX Bapineuzumab Phase 3 T87024 DRUGINFO D0CH6B ALZT-OP1 Phase 3 T87024 DRUGINFO D0Q7YZ Gantenerumab Phase 3 T87024 DRUGINFO D0R7EQ Crenezumab Phase 3 T87024 DRUGINFO D0Z2GF NI-101 Phase 3 T87024 DRUGINFO D1KR3N GV-971 Phase 3 T87024 DRUGINFO D2ZP0A Donanemab Phase 3 T87024 DRUGINFO D2ZP0A Donanemab Phase 3 T87024 DRUGINFO D07SDQ Curcumin Phase 3 T87024 DRUGINFO D0I3VT CAD-106 Phase 2/3 T87024 DRUGINFO D02XKK FRM-0962 Phase 2 T87024 DRUGINFO D07VAI ALZ-801 Phase 2 T87024 DRUGINFO D0B5EB Ponezumab Phase 2 T87024 DRUGINFO D0NR6T UB-311 Phase 2 T87024 DRUGINFO D0T6KV GSK933776A Phase 2 T87024 DRUGINFO D0W0NU NIC5-15 Phase 2 T87024 DRUGINFO D0X4ZL AN-1792 Phase 2 T87024 DRUGINFO D3XP8N Trontinemab Phase 2 T87024 DRUGINFO DY6DS3 ABBV-916 Phase 2 T87024 DRUGINFO D03SHD Myo-inositol Phase 2 T87024 DRUGINFO D0E8HA T-817MA Phase 2 T87024 DRUGINFO D67DST AD-35 Phase 2 T87024 DRUGINFO D0R6UR ACI-24 Phase 1/2 T87024 DRUGINFO D0TU1E EB-101 Phase 1/2 T87024 DRUGINFO D01ZSP AAB-003/PF-05236812 Phase 1 T87024 DRUGINFO D05ORO Anti-N3pG-Abeta antibody Phase 1 T87024 DRUGINFO D06KWU DWP-09031 Phase 1 T87024 DRUGINFO D08QDF Systebryl Phase 1 T87024 DRUGINFO D0HRC9 ANVS301 Phase 1 T87024 DRUGINFO D0N9JB SAR228810 Phase 1 T87024 DRUGINFO D0V0VI 11C-AZD-2184 Phase 1 T87024 DRUGINFO D0X2UK Affitope AD-01 Phase 1 T87024 DRUGINFO D0ZX2D 11C-6-Me-BTA-1 Phase 1 T87024 DRUGINFO D4YD7V LY3372993 Phase 1 T87024 DRUGINFO DCP0I8 ACU193 Phase 1 T87024 DRUGINFO DFM7X6 BEY2153 Phase 1 T87024 DRUGINFO D06BVT Affitope AD-02 Discontinued in Phase 2 T87024 DRUGINFO D0Z1VS RN6G Discontinued in Phase 2 T87024 DRUGINFO D0K3SV PF-05236812 Discontinued in Phase 1 T87024 DRUGINFO D01QLM AAB-002 Phase 0 T87024 DRUGINFO D09OUT NN-818 Preclinical T87024 DRUGINFO D0G7LP Pepticlere Preclinical T87024 DRUGINFO D00BTZ CT-003230 Investigative T87024 DRUGINFO D01BJK Mimovax Investigative T87024 DRUGINFO D01GAZ 123I-DRM-106 Investigative T87024 DRUGINFO D01HHL Gelsolin Investigative T87024 DRUGINFO D01MMU 5-methoxy-2-(4-methylaminophenyl)benzofuran Investigative T87024 DRUGINFO D02BBJ 5-hydroxy-2-(4-methylaminophenyl)benzofuran Investigative T87024 DRUGINFO D02DFT 4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol Investigative T87024 DRUGINFO D02FZQ 2,5-bis(4-methoxyphenyl)thiophene Investigative T87024 DRUGINFO D03RJH 2,5-bis(2-methoxyphenyl)thiophene Investigative T87024 DRUGINFO D03THP 4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine Investigative T87024 DRUGINFO D03TOK 1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene Investigative T87024 DRUGINFO D04LBV AZ4800 Investigative T87024 DRUGINFO D04QXW ARC-069 Investigative T87024 DRUGINFO D04TPS A-887755 Investigative T87024 DRUGINFO D04ZTA ANA-5 Investigative T87024 DRUGINFO D05GRI DEHYDROZINGERONE Investigative T87024 DRUGINFO D06CTD IN-N01 Investigative T87024 DRUGINFO D06DRD Chrysamine -G Investigative T87024 DRUGINFO D06LRQ TKP-1001 Investigative T87024 DRUGINFO D06MBR ACI-636 Investigative T87024 DRUGINFO D07DNV ARN-2966 Investigative T87024 DRUGINFO D07JKA SEN-1500 Investigative T87024 DRUGINFO D07LFZ 4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine Investigative T87024 DRUGINFO D07SNW 1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene Investigative T87024 DRUGINFO D07YAC Anticalin Investigative T87024 DRUGINFO D07ZDG EDN-OL1 Investigative T87024 DRUGINFO D08GHI 18F-AV-45 dimer Investigative T87024 DRUGINFO D08GKL 6-iodo-4'-methylaminoflavone Investigative T87024 DRUGINFO D08TME 2,5-bis(4-nitrophenyl)thiophene Investigative T87024 DRUGINFO D09MQZ 4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol Investigative T87024 DRUGINFO D09MRY ACU-0101979 Investigative T87024 DRUGINFO D09RAM 4-(5-(4-aminophenyl)thiophen-2-yl)phenol Investigative T87024 DRUGINFO D09UWI 2,5-bis(4-Hydroxyphenyl)thiophene Investigative T87024 DRUGINFO D0B1CL 5-methoxy-2-(4-aminophenyl)benzofuran Investigative T87024 DRUGINFO D0B4AH RECALL-VAX Investigative T87024 DRUGINFO D0C1AU 1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene Investigative T87024 DRUGINFO D0C4WY SP-08 Investigative T87024 DRUGINFO D0C9QW 5-hydroxy-2-(4-dimethylaminophenyl)benzofuran Investigative T87024 DRUGINFO D0E5CX Abloid Investigative T87024 DRUGINFO D0F5UO KMS-88009 Investigative T87024 DRUGINFO D0G4AE KNX-Monoclonal204 Investigative T87024 DRUGINFO D0H0AT 2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene Investigative T87024 DRUGINFO D0HK7G DBT-1339 Investigative T87024 DRUGINFO D0I8XD SB-13 Investigative T87024 DRUGINFO D0I9NH 5-hydroxy-2-(4-aminophenyl)benzofuran Investigative T87024 DRUGINFO D0J5SD Gamma-secretase modulators Investigative T87024 DRUGINFO D0K4WW 11A1 Investigative T87024 DRUGINFO D0K9ZU CD45RB Investigative T87024 DRUGINFO D0L7MD 6-iodo-4'-methoxyflavone Investigative T87024 DRUGINFO D0O5FK 2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol Investigative T87024 DRUGINFO D0O7XG SEM-606 Investigative T87024 DRUGINFO D0P0CB 6-iodo-4'-dimethyaminoflavone Investigative T87024 DRUGINFO D0Q2XN Turmeric extracts Investigative T87024 DRUGINFO D0Q5VC BAN-2203 Investigative T87024 DRUGINFO D0Q6ZQ ELND-007 Investigative T87024 DRUGINFO D0R0LQ 5-methoxy-2-(4-dimethylaminophenyl)benzofuran Investigative T87024 DRUGINFO D0S7CP VK-12 Investigative T87024 DRUGINFO D0U6KE 1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene Investigative T87024 DRUGINFO D0V5PR AS-602704 Investigative T87024 DRUGINFO D0W0WL 1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene Investigative T87024 DRUGINFO D0W8VC PA-1637 Investigative T87024 DRUGINFO D0X1EY 6-iodo-4'-hydroxyflavone Investigative T87024 DRUGINFO D0Y4TQ VK-11 Investigative T87024 DRUGINFO D0Y9ES AD-0802 Investigative T87024 DRUGINFO D0XV3B Methionine Sulfoxide Investigative T87024 DRUGINFO D03AMR SR-973 Investigative T23145 TARGETID T23145 T23145 FORMERID TTDS00419 T23145 UNIPROID CP11A_HUMAN T23145 TARGNAME Cholesterol desmolase (CYP11A1) T23145 GENENAME CYP11A1 T23145 TARGTYPE Successful T23145 SYNONYMS P450(scc); Cytochrome P450(scc); Cytochrome P450 11A1; Cholesterol side-chain cleavage enzyme, mitochondrial; CYPXIA1; CYP11A T23145 FUNCTION Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone, the precursor of most steroid hormones. T23145 PDBSTRUC 3NA1; 3NA0; 3N9Z; 3N9Y T23145 BIOCLASS Paired donor oxygen oxidoreductase T23145 ECNUMBER EC 1.14.15.6 T23145 SEQUENCE MLAKGLPPRSVLVKGCQTFLSAPREGLGRLRVPTGEGAGISTRSPRPFNEIPSPGDNGWLNLYHFWRETGTHKVHLHHVQNFQKYGPIYREKLGNVESVYVIDPEDVALLFKSEGPNPERFLIPPWVAYHQYYQRPIGVLLKKSAAWKKDRVALNQEVMAPEATKNFLPLLDAVSRDFVSVLHRRIKKAGSGNYSGDISDDLFRFAFESITNVIFGERQGMLEEVVNPEAQRFIDAIYQMFHTSVPMLNLPPDLFRLFRTKTWKDHVAAWDVIFSKADIYTQNFYWELRQKGSVHHDYRGILYRLLGDSKMSFEDIKANVTEMLAGGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAARHQAQGDMATMLQLVPLLKASIKETLRLHPISVTLQRYLVNDLVLRDYMIPAKTLVQVAIYALGREPTFFFDPENFDPTRWLSKDKNITYFRNLGFGWGVRQCLGRRIAELEMTIFLINMLENFRVEIQHLSDVGTTFNLILMPEKPISFTFWPFNQEATQQ T23145 DRUGINFO D0M6DO Aminoglutethimide Approved T23145 DRUGINFO DL73JW MK-5684 Phase 1/2 T23145 DRUGINFO D0A2GB 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione Investigative T23145 DRUGINFO D0B5MZ 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione Investigative T78585 TARGETID T78585 T78585 FORMERID TTDR00088 T78585 UNIPROID IL5_HUMAN T78585 TARGNAME Interleukin-5 (IL5) T78585 GENENAME IL5 T78585 TARGTYPE Successful T78585 SYNONYMS TRF protein; T-cell replacing factor; IL-5; Eosinophil differentiation factor; B-cell differentiation factor I; B cell differentiation factor I T78585 FUNCTION Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells. T78585 PDBSTRUC 3VA2; 3QT2; 1HUL T78585 BIOCLASS Cytokine: interleukin T78585 SEQUENCE MRMLLHLSLLALGAAYVYAIPTEIPTSALVKETLALLSTHRTLLIANETLRIPVPVHKNHQLCTEEIFQGIGTLESQTVQGGTVERLFKNLSLIKKYIDGQKKKCGEERRRVNQFLDYLQEFLGVMNTEWIIES T78585 DRUGINFO D03MTN Mepolizumab Approved T78585 DRUGINFO D0O8KX Reslizumab Approved T78585 DRUGINFO D02PIO Benralizumab Approved T78585 DRUGINFO DP8AS7 GSK3511294 Phase 3 T78585 DRUGINFO DS9J7L Depemokimab Phase 3 T78585 DRUGINFO D07CEU SOPHORICOSIDE Investigative T09538 TARGETID T09538 T09538 FORMERID TTDS00256 T09538 UNIPROID PPBT_HUMAN T09538 TARGNAME Alkaline phosphatase tissue-nonspecific (ALPL) T09538 GENENAME ALPL T09538 TARGTYPE Successful T09538 SYNONYMS TNSALP; Liver/bone/kidney isozyme; Alkaline phosphatase, tissue-nonspecific isozyme; Alkaline phosphatase liver/bone/kidney isozyme; AP-TNAP T09538 FUNCTION This isozyme plays a key role in skeletal mineralization by regulating levels of diphosphate (PPi). T09538 BIOCLASS Phosphoric monoester hydrolase T09538 ECNUMBER EC 3.1.3.1 T09538 SEQUENCE MISPFLVLAIGTCLTNSLVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSAGSLAAGPLLLALALYPLSVLF T09538 DRUGINFO D05XSJ Asfotase alfa Approved T09538 DRUGINFO D0CF2Q Levamisole Approved T09538 DRUGINFO D29GPF DS-1211 Phase 2 T09538 DRUGINFO D2DX6Z ALXN1910 Phase 1 T09538 DRUGINFO DNW79M ALXN1850 Phase 1 T32578 TARGETID T32578 T32578 FORMERID TTDC00080 T32578 UNIPROID IL6_HUMAN T32578 TARGNAME Interleukin-6 (IL6) T32578 GENENAME IL6 T32578 TARGTYPE Successful T32578 SYNONYMS Interferon beta-2; IL-6; IFNB2; IFN-beta-2; Hybridoma growth factor; CTL differentiation factor; CDF; BSF-2; B-cell stimulatory factor 2 T32578 FUNCTION It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation. Cytokine with a wide variety of biological functions. T32578 PDBSTRUC 5FUC; 4ZS7; 4O9H; 4NI9; 4NI7 T32578 BIOCLASS Cytokine: interleukin T32578 SEQUENCE MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKKAKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKEFLQSSLRALRQM T32578 DRUGINFO D07NJN Siltuximab Approved T32578 DRUGINFO D00NUG Olokizumab Phase 3 T32578 DRUGINFO DF86OC Ziltivekimab Phase 3 T32578 DRUGINFO DWJM12 RG6179 Phase 3 T32578 DRUGINFO D01XVF Sirukumab Phase 3 T32578 DRUGINFO D04RMM Clazakizumab Phase 2 T32578 DRUGINFO D07TCS CDP-6038 Phase 2 T32578 DRUGINFO D0N0BW ALD-518 Phase 2 T32578 DRUGINFO D0VS2W YSIL6 Phase 2 T32578 DRUGINFO D06NXG PF-04236921 Phase 2 T32578 DRUGINFO D07IVS Gerilimzumab Phase 1 T32578 DRUGINFO D0DT8Y MEDI5117 Phase 1 T32578 DRUGINFO D0GJ1U C326 Phase 1 T32578 DRUGINFO D0OK5R OP-R003 Phase 1 T32578 DRUGINFO DKX8W5 SAR444419 Phase 1 T99799 TARGETID T99799 T99799 FORMERID TTDS00143 T99799 UNIPROID CHLE_HUMAN T99799 TARGNAME Cholinesterase (BCHE) T99799 GENENAME BCHE T99799 TARGTYPE Successful T99799 SYNONYMS Pseudocholinesterase; Choline esterase II; CHE1; Butyrylcholine esterase; Acylcholine acylhydrolase T99799 FUNCTION Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters. T99799 PDBSTRUC 6QAE; 6QAD; 6QAC; 6QAB; 6QAA T99799 BIOCLASS Type-B carboxylesterase/lipase T99799 ECNUMBER EC 3.1.1.8 T99799 SEQUENCE MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCVGL T99799 DRUGINFO D0Q2MH Hexafluronium bromide Approved T99799 DRUGINFO D0S5YC MEPTAZINOL Approved T99799 DRUGINFO D01LYX Eptastigmine Phase 3 T99799 DRUGINFO D07CIN (-)-Phenserine Phase 3 T99799 DRUGINFO D04JMI Plasma derived human butyrylcholinesterase Phase 1 T99799 DRUGINFO D06FGJ Protexia Phase 1 T99799 DRUGINFO D09MEV JES-9501 Phase 1 T99799 DRUGINFO D0S1KR RVT-103+RVT-104 Phase 1 T99799 DRUGINFO D00GSF Di-substituted piperidine derivative 3 Patented T99799 DRUGINFO D0BS8I Di-substituted piperidine derivative 1 Patented T99799 DRUGINFO D0WR9T Oxime derivative 1 Patented T99799 DRUGINFO D01SQO Quinazoline alkaloid derivative 1 Patented T99799 DRUGINFO D03DIQ Egonol compound 1 Patented T99799 DRUGINFO D04FAS PMID29757691-Compound-8b Patented T99799 DRUGINFO D0B9TI PMID29757691-Compound-8d Patented T99799 DRUGINFO D0CB1C Tacrine heterodimer derivative 1 Patented T99799 DRUGINFO D0H3YG PMID29757691-Compound-2a Patented T99799 DRUGINFO D0J3OD Indoline derivative 1 Patented T99799 DRUGINFO D0K3EB Di-substituted piperidine derivative 2 Patented T99799 DRUGINFO D0OE6G Isochroman-4-ketone derivative 1 Patented T99799 DRUGINFO D0RS6O PMID29757691-Compound-8a Patented T99799 DRUGINFO D0VQ2N PMID29757691-Compound-8c Patented T99799 DRUGINFO D0W9OC PMID29757691-Compound-7 Patented T99799 DRUGINFO D0WD0M PMID29757691-Compound-2a-i Patented T99799 DRUGINFO D0X9CR PMID29757691-Compound-10 Patented T99799 DRUGINFO D0Y4CG Decyle nelycorine dibromo salt derivative 1 Patented T99799 DRUGINFO D02EME Tetra-hydro-isoquinoline derivative 3 Patented T99799 DRUGINFO D04AXC Tetra-hydro-isoquinoline derivative 1 Patented T99799 DRUGINFO D0NB7Z Tetra-hydro-isoquinoline derivative 2 Patented T99799 DRUGINFO D0R6RT Tetra-hydro-isoquinoline derivative 4 Patented T99799 DRUGINFO D00AHD Anthracen-10-yl(10H-phenothiazin-10-yl)methanone Investigative T99799 DRUGINFO D00KTT Isopropyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D00QLR (-)-DEBROMOFLUSTRAMINE B Investigative T99799 DRUGINFO D00VXE N-(Adamant-1-yl)-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D00XHC N,N-Diisopropyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D01FNH 4-methoxyphenyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D01LVY (10H-phenothiazin-10-yl)(p-tolyl)methanone Investigative T99799 DRUGINFO D01MAC Isosorbide-2-(butylcarbamate)-5-mononitrate Investigative T99799 DRUGINFO D01XKY (4-bromophenyl)(10H-phenothiazin-10-yl)methanone Investigative T99799 DRUGINFO D02XHM 3-[10-(benzylmethylamino)decyloxy]xanthen-9-one Investigative T99799 DRUGINFO D03NTO Isosorbide-2-benzylcarbamate-5-nicotinate Investigative T99799 DRUGINFO D03OGO Cyclosal-d4TMP Investigative T99799 DRUGINFO D03UCC ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE Investigative T99799 DRUGINFO D04AWS N-Cyclopentyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D04CTO 2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone Investigative T99799 DRUGINFO D04IXN 4-chlorophenyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D04JCW Isosorbide-2-benzylcarbamate-5-pentanoate Investigative T99799 DRUGINFO D04PKD Isosorbide-2-benzylcarbamate-5-propionate Investigative T99799 DRUGINFO D04ZWS DEMETHYLDEBROMOFLUSTRAMINE B Investigative T99799 DRUGINFO D04ZZU 3-chlorophenyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D05DIN 2-methoxyphenyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D05GPI 3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one Investigative T99799 DRUGINFO D05QFR Isosorbide-2-(cyclohexylcarbamate)-5-mononitrate Investigative T99799 DRUGINFO D05VLV (10H-phenothiazin-10-yl)(m-tolyl)methanone Investigative T99799 DRUGINFO D05XPL 2-Methyl-beta-carboline-2-ium iodide Investigative T99799 DRUGINFO D05XPW Isosorbide-di-(butylcarbamate) Investigative T99799 DRUGINFO D06BDB Isosorbide-2-benzylcarbamate-5-acetate Investigative T99799 DRUGINFO D06HUH Recombinant human butyrylcholinesterase Investigative T99799 DRUGINFO D06KQH 4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate Investigative T99799 DRUGINFO D06RTA N,N'-(1',4'-butylene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D06SWV Diethylphosphono Group Investigative T99799 DRUGINFO D06YEB 1-(10H-phenothiazin-10-yl)-3-phenylbutan-1-one Investigative T99799 DRUGINFO D07AYF Methyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D07MNG Ethyl Dihydrogen Phosphate Investigative T99799 DRUGINFO D07YXP 9-[5-(beta-Carboline-9-yl)pentyl]-beta-carboline Investigative T99799 DRUGINFO D08BKE Isosorbide-2-benzylcarbamate-5-triflate Investigative T99799 DRUGINFO D08FQW M-tolyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D08LNT Butyrylthiocholine Investigative T99799 DRUGINFO D08NNF N-Cyclobutyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D08TBI Cyclopentyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D08ZLS N-Benzyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D09DQV (1S)-MENTHYL HEXYL PHOSPHONATE GROUP Investigative T99799 DRUGINFO D09DWA (10H-phenothiazin-10-yl)(o-tolyl)methanone Investigative T99799 DRUGINFO D09GKY N-Cyclohexyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D09HZE Morpholino(1'H-phenothiazin-1'-yl)methanone Investigative T99799 DRUGINFO D09OPL (1'H-Phenothiazin-1'-yl)(piperidin-1-yl)methanone Investigative T99799 DRUGINFO D09YLY Isosorbide-2-benzylcarbamate-5-isonicotinate Investigative T99799 DRUGINFO D0A5FO 1,2-di(10H-phenothiazin-10-yl)ethane-1,2-dione Investigative T99799 DRUGINFO D0AQ3K 3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one Investigative T99799 DRUGINFO D0B0ZM N,N-Dipropyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0B6IQ N,N-Dimethyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0D7MN Naphthalen-1-yl(10H-phenothiazin-10-yl)methanone Investigative T99799 DRUGINFO D0D8IH N-Phenyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0DB9T N-tert-Butyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0DR7A N-p-Tolyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0E4GM 3-isopr-sal-cyclosal-d4TMP Investigative T99799 DRUGINFO D0EI5V Bis-cyclosal-d4TMP Investigative T99799 DRUGINFO D0EQ1Z Isosorbide-2-benzylcarbamate-5-(o-toluate) Investigative T99799 DRUGINFO D0FP5F Isosorbide-di-(propylcarbamate) Investigative T99799 DRUGINFO D0G0ED 3-sal-cyclosal-d4TMP Investigative T99799 DRUGINFO D0G6WQ (1R)-MENTHYL HEXYL PHOSPHONATE GROUP Investigative T99799 DRUGINFO D0H1NU 4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate Investigative T99799 DRUGINFO D0H3WJ 1-(10H-phenothiazin-10-yl)-2-phenylpropan-1-one Investigative T99799 DRUGINFO D0I4LX AS-1397 Investigative T99799 DRUGINFO D0I5LV 3-methoxyphenyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D0I7BX Naphthalen-1-yl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D0IC5U Isosorbide-2-(benzylcarbamate)-5-mononitrate Investigative T99799 DRUGINFO D0J1IX 1-(10H-phenothiazin-10-yl)-2-phenylethanone Investigative T99799 DRUGINFO D0J5AU Isosorbide-2-(ethylcarbamate)-5-mononitrate Investigative T99799 DRUGINFO D0J8LQ (3-bromophenyl)(10H-phenothiazin-10-yl)methanone Investigative T99799 DRUGINFO D0K3YM N-Isopropyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0K7EC N,N-Diethyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0L0SD N,N'-(1',3'-propylene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D0L1EI 4-[4-(benzyloxy)piperidino]butyl benzoate Investigative T99799 DRUGINFO D0L3EE (10H-phenothiazin-10-yl)(phenyl)methanone Investigative T99799 DRUGINFO D0LL8H Isosorbide-2-(benzylcarbamate)-5-benzoate Investigative T99799 DRUGINFO D0M2EH Non-PEGylated butyrylcholinesterase Investigative T99799 DRUGINFO D0M6IJ Naphthalen-2-yl(10H-phenothiazin-10-yl)methanone Investigative T99799 DRUGINFO D0M7SD MF-8623 Investigative T99799 DRUGINFO D0N4QQ VAGANINE D Investigative T99799 DRUGINFO D0N6XS 1-(10H-phenothiazin-10-yl)-2-phenylbutan-1-one Investigative T99799 DRUGINFO D0NU3J NOSTOCARBOLINE Investigative T99799 DRUGINFO D0O8LK 3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one Investigative T99799 DRUGINFO D0OJ9P 1-methyl-3-(phenylcarbamoyloxy)pyridinium bromide Investigative T99799 DRUGINFO D0P3VH 1-(10H-phenothiazin-10-yl)-3-phenylpropan-1-one Investigative T99799 DRUGINFO D0P7TN 5-methyl-cyclosal-d4TMP Investigative T99799 DRUGINFO D0PQ5R P-tolyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D0Q0BV Naphthalen-2-yl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D0R2GR N-Neopentyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0RO8V 9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE Investigative T99799 DRUGINFO D0RW1Y 9-N-Phenylmethylamino-Tacrine Investigative T99799 DRUGINFO D0S3WF 4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate Investigative T99799 DRUGINFO D0S8AS Tert-butyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D0T4JQ Butanoic Acid Investigative T99799 DRUGINFO D0U7BQ O-tolyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D0U9AU (-)-Phenethylcymserine Investigative T99799 DRUGINFO D0V4RD (4-nitrophenyl)(10H-phenothiazin-10-yl)methanone Investigative T99799 DRUGINFO D0V7EK Phenyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D0V8PE Butyl 10H-phenothiazine-10-carboxylate Investigative T99799 DRUGINFO D0W2SX NP-0336 Investigative T99799 DRUGINFO D0W4WB Isosorbide-2-benzyl carbamate Investigative T99799 DRUGINFO D0WB1D 4-[4-(benzyloxy)piperidino]butyl-4-fluorobenzoate Investigative T99799 DRUGINFO D0WH4J Isosorbide-2-(propylcarbamate)-5-mononitrate Investigative T99799 DRUGINFO D0X7CW 3-phenyl-cyclosal-d4TMP Investigative T99799 DRUGINFO D0X9TF N,N'-(1',2'-ethylene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D0Y0UV N-o-Tolyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0Y2TE 4-[4-(benzyloxy)piperidino]butyl-4-nitrobenzoate Investigative T99799 DRUGINFO D0Y4SO 9-[9-(beta-Carboline-9-yl)nonyl]-beta-carboline Investigative T99799 DRUGINFO D0Y5KN Isosorbide-2-(butylcarbamate)-5-benzoate Investigative T99799 DRUGINFO D0Y7WJ Dodecanesulfonate ion Investigative T99799 DRUGINFO D0YZ3E 1-(10H-phenothiazin-10-yl)-4-phenylbutan-1-one Investigative T99799 DRUGINFO D00FPI 1,4-Di(berberine-9-O-yl)ethane dibromide Investigative T99799 DRUGINFO D00MFR 6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium Investigative T99799 DRUGINFO D00NIX 9-O-[3-(Phenylamino)propyl]-berberine bromide Investigative T99799 DRUGINFO D01AJQ Isosorbide-di-(benzylcarbamate) Investigative T99799 DRUGINFO D01DHW 9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide Investigative T99799 DRUGINFO D01EZC 3-[4-(benzylmethylamino)butoxy]xanthen-9-one Investigative T99799 DRUGINFO D01GWN (24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol Investigative T99799 DRUGINFO D01KVT MEMOQUIN Investigative T99799 DRUGINFO D01OND 3-(dimethylamino)phenyl phenylcarbamate Investigative T99799 DRUGINFO D01QRR Isosorbide-2-benzylcarbamate-5-cyclopentanoate Investigative T99799 DRUGINFO D01TLN 9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide Investigative T99799 DRUGINFO D01XGP 1,2-indanedione Investigative T99799 DRUGINFO D02AFZ 2-Propyl-beta-carboline-2-ium iodide Investigative T99799 DRUGINFO D02JXK N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D02LWX 6-hydroxy-2-methyl-9H-beta-carbolin-2-ium Investigative T99799 DRUGINFO D02QMU 9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide Investigative T99799 DRUGINFO D02WKB 9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide Investigative T99799 DRUGINFO D03DIP 3-(2-Diethylamino-propionamino)-rutaecarpine Investigative T99799 DRUGINFO D04FHZ (-)-Tolserine Investigative T99799 DRUGINFO D04GTP CHF-2819 Investigative T99799 DRUGINFO D04SYM Isosorbide-2-(methylcarbamate)-5-mononitrate Investigative T99799 DRUGINFO D05LTW 1,2-bis(2,3-fluorophenyl)ethane-1,2-dione Investigative T99799 DRUGINFO D05QNR N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D05UJV N-n-pentyl-7-methoxytacrine hydrochloride Investigative T99799 DRUGINFO D06VGD ACENAPHTHOQUINONE Investigative T99799 DRUGINFO D07EDG 1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione Investigative T99799 DRUGINFO D07VIO 3-(2-Diethylamino-acetamino)-rutaecarpine Investigative T99799 DRUGINFO D07YJG 1,11-bis(pyridinium)-undecane dibromide Investigative T99799 DRUGINFO D09CGV 6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium Investigative T99799 DRUGINFO D09FAU (RS)-tacrine(10)-hupyridone Investigative T99799 DRUGINFO D09GXM 3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one Investigative T99799 DRUGINFO D09JCF Huprine-Tacrine Heterodimer Investigative T99799 DRUGINFO D09MCN Haloxysterol D Investigative T99799 DRUGINFO D09QDC Iso-OMPA Investigative T99799 DRUGINFO D09RJH Huprine X Investigative T99799 DRUGINFO D09XSI 9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide Investigative T99799 DRUGINFO D0A8OX N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D0B4DT 3-[8-(benzylmethylamino)octyloxy]xanthen-9-one Investigative T99799 DRUGINFO D0C0XU N-n-heptyl-7-methoxytacrine hydrochloride Investigative T99799 DRUGINFO D0C3IS 3-(2-N-Piperidyl-propionamino)-rutaecarpine Investigative T99799 DRUGINFO D0E0LL Haloxysterol C Investigative T99799 DRUGINFO D0E4BT N-benzyl-2-thiomorpholinopyrimidin-4-amine Investigative T99799 DRUGINFO D0EX1R N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D0F0PY N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D0F5EJ LIPOCRINE Investigative T99799 DRUGINFO D0F6VM 3-(2-N-Pyrrolyl-propionamino)-rutaecarpine Investigative T99799 DRUGINFO D0G0GZ N-Methyl-1'H-phenothiazine-1'-carboxamide Investigative T99799 DRUGINFO D0G5SM HALOXYSTEROL A Investigative T99799 DRUGINFO D0G5TL 6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium Investigative T99799 DRUGINFO D0H2UG N-n-nonyl-7-methoxytacrine hydrochloride Investigative T99799 DRUGINFO D0H3BC 3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one Investigative T99799 DRUGINFO D0I3UA 7-Oxo-7H-dibenzo[de,g]quinoline Investigative T99799 DRUGINFO D0J4LR 24-ethyl-cholest-7-ene-3,5,6-triol Investigative T99799 DRUGINFO D0J4QH Methyl Phosphinic Acid Investigative T99799 DRUGINFO D0K2FQ 1,2-Di(berberine-9-O-yl)ethane dibromide Investigative T99799 DRUGINFO D0K8BT Isosorbide-2-(methylcarbamate)-5-benzoate Investigative T99799 DRUGINFO D0L5QJ 1,9-bis(pyridinium)-nonane dibromide Investigative T99799 DRUGINFO D0L9YJ 3-[3-(benzylmethylamino)propoxy]xanthen-9-one Investigative T99799 DRUGINFO D0LT0T 3-(2-N-Pyrrolyl-acetamino)-rutaecarpine Investigative T99799 DRUGINFO D0M0BM 6-chlorotacrine hydrochloride Investigative T99799 DRUGINFO D0M2EM BENZOQUINONE Investigative T99799 DRUGINFO D0MC3U N,N'-(1',10'-decylene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D0MV0T 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine Investigative T99799 DRUGINFO D0NJ5W CAPROCTAMINE Investigative T99799 DRUGINFO D0NL4Z Monoisopropyl Ester Phosphonic Acid Group Investigative T99799 DRUGINFO D0O2OH 4-ISOPROPYLPHENSERINE Investigative T99799 DRUGINFO D0O8AQ Isosorbide-di-(ethylcarbamate) Investigative T99799 DRUGINFO D0O8DZ 3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one Investigative T99799 DRUGINFO D0O9YQ N-n-hexyl-7-methoxytacrine hydrochloride Investigative T99799 DRUGINFO D0P2VL 9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide Investigative T99799 DRUGINFO D0P5BT 1,3-Di(berberine-9-O-yl)ethane dibromide Investigative T99799 DRUGINFO D0PF7F TOLSERINE Investigative T99799 DRUGINFO D0Q2YJ Phenanthrene-9,10-dione Investigative T99799 DRUGINFO D0Q3EV N-n-octyl-7-methoxytacrine hydrochloride Investigative T99799 DRUGINFO D0T5MD Isosorbide-2-benzylcarbamate-5-cyclopropanoate Investigative T99799 DRUGINFO D0V3LC 24-ethylcholest-6-ene-3,5-diol Investigative T99799 DRUGINFO D0W7XL 9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide Investigative T99799 DRUGINFO D0W8NK 9-Ethyl-2-methyl-beta-carboline-2-ium iodide Investigative T99799 DRUGINFO D0X3FF HALOXYSTEROL B Investigative T99799 DRUGINFO D0X4HG XANTHOSTIGMINE Investigative T99799 DRUGINFO D0XI4U 6-methoxy-2-methyl-9H-beta-carbolin-2-ium Investigative T99799 DRUGINFO D0Y0VQ N,N'-(1',8'-octylene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D0Y7UG N,N'-(1',6-hexylene)-bis-(-)-nor-MEP Investigative T99799 DRUGINFO D0Z6RT LAWSARITOL Investigative T99799 DRUGINFO D0Z6WU 1,10-bis(pyridinium)-decane dibromide Investigative T99799 DRUGINFO D0ZI7F 6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole Investigative T99799 DRUGINFO D0ZL9I 9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide Investigative T99799 DRUGINFO D0ZY4C N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine Investigative T99799 DRUGINFO D0D0BI CHLORANIL Investigative T99799 DRUGINFO D0F5VY NSC-23180 Investigative T99799 DRUGINFO D0M4IE Bis-7-tacrine Investigative T99799 DRUGINFO D0N0HK 3,4,5,6-Tetrachloro-[1,2]benzoquinone Investigative T99799 DRUGINFO D0WX6R 5,6-dinitroacenaphthoquinone Investigative T99799 DRUGINFO D0SD9H Beta-D-Mannose Investigative T99799 DRUGINFO D0W9VA 1,2-NAPHTHOQUINONE Investigative T99799 DRUGINFO D07KZA 2-(N-Morpholino)-Ethanesulfonic Acid Investigative T99799 DRUGINFO D0G6XS Fucose Investigative T99799 DRUGINFO D07LUR Alpha-D-Mannose Investigative T21678 TARGETID T21678 T21678 FORMERID TTDC00016 T21678 UNIPROID AGAL_HUMAN T21678 TARGNAME Alpha-galactosidase A (GLA) T21678 GENENAME GLA T21678 TARGTYPE Successful T21678 SYNONYMS Melibiase; INN=Agalsidase; Alpha-D-galactoside galactohydrolase; Alpha-D-galactosidase A T21678 FUNCTION A homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. Predominantly hydrolyzes ceramide trihexoside, and can catalyze the hydrolysis of melibiose into galactose and glucose. T21678 PDBSTRUC 4NXS; 3TV8; 3S5Z; 3S5Y; 3LXC T21678 BIOCLASS Glycosylase T21678 ECNUMBER EC 3.2.1.22 T21678 SEQUENCE MQLRNPELHLGCALALRFLALVSWDIPGARALDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL T21678 DRUGINFO D07URD Pegunigalsidase alfa Approved T21678 DRUGINFO D0MU9L Migalastat Approved T21678 DRUGINFO DE3M8U ST-920 Phase 1/2 T21678 DRUGINFO DT28NV AVR-RD-01 Phase 1/2 T21678 DRUGINFO DX5HW2 isaralgagene civaparvovec Phase 1/2 T21678 DRUGINFO DZ97RW 4D-310 Phase 1/2 T21678 DRUGINFO D07RRH Beta-1-C-Butyl-1-deoxygalactonojirimycin Investigative T21678 DRUGINFO D0RU5N Beta-1-C-butenyl-1-deoxygalactonojirimycin Investigative T21678 DRUGINFO D0S4DV CALYSTEGINE B2 Investigative T21678 DRUGINFO D0V0WB (+)-5-deoxyadeenophorine Investigative T21678 DRUGINFO D0SQ1T 2,5-dideoxy-2,5-imino-D-altritol Investigative T21678 DRUGINFO D0G6XS Fucose Investigative T21678 DRUGINFO D07LUR Alpha-D-Mannose Investigative T22939 TARGETID T22939 T22939 FORMERID TTDS00245 T22939 UNIPROID PRGR_HUMAN T22939 TARGNAME Progesterone receptor (PGR) T22939 GENENAME PGR T22939 TARGTYPE Successful T22939 SYNONYMS PR; Nuclear receptor subfamily 3 group C member 3; NR3C3 T22939 FUNCTION Depending on the isoform, progesterone receptor functions as transcriptional activator or repressor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. T22939 PDBSTRUC 5CC0; 4OAR; 4APU; 4A2J; 3ZRB T22939 BIOCLASS Nuclear hormone receptor T22939 SEQUENCE MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLFPRPCQGQDPSDEKTQDQQSLSDVEGAYSRAEATRGAGGSSSSPPEKDSGLLDSVLDTLLAPSGPGQSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAAAHKVLPRGLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGKPRALGGAAAGGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTVMDFIHVPILPLNHALLAARTRQLLEDESYDGGAGAASAFAPPRSSPCASSTPVAVGDFPDCAYPPDAEPKDDAYPLYSDFQPPALKIKEEEEGAEASARSPRSYLVAGANPAAFPDFPLGPPPPLPPRATPSRPGEAAVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPCKAPGASGCLLPRDGLPSTSASAAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPPYLNYLRPDSEASQSPQYSFESLPQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHNYLCAGRNDCIVDKIRRKNCPACRLRKCCQAGMVLGGRKFKKFNKVRVVRALDAVALPQPVGVPNESQALSQRFTFSPGQDIQLIPPLINLLMSIEPDVIYAGHDNTKPDTSSSLLTSLNQLGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYSWMSLMVFGLGWRSYKHVSGQMLYFAPDLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQEEFLCMKVLLLLNTIPLEGLRSQTQFEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKLLDNLHDLVKQLHLYCLNTFIQSRALSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK T22939 DRUGINFO D02KIU Etonogestrel Approved T22939 DRUGINFO D04GJN Megestrol Approved T22939 DRUGINFO D06CGB Desogestrel Approved T22939 DRUGINFO D06RFG Estradiol valerate/dienogest Approved T22939 DRUGINFO D07BSQ Progesterone Approved T22939 DRUGINFO D09QZI Norgestimate Approved T22939 DRUGINFO D0BA9U Levonorgestrel Approved T22939 DRUGINFO D0F1UL Dydrogesterone Approved T22939 DRUGINFO D0GL7U Norethindrone Approved T22939 DRUGINFO D0I2SD Medroxyprogesterone Approved T22939 DRUGINFO D0R2KY Ethynodiol Diacetate Approved T22939 DRUGINFO D0V4WD Ulipristal Approved T22939 DRUGINFO D06LDT Segesterone acetate; ethinyl estradiol Approved T22939 DRUGINFO D02HUB Nestorone Phase 3 T22939 DRUGINFO D0VF3C NPC-01 Phase 3 T22939 DRUGINFO D01KMY MK-8342 Phase 2 T22939 DRUGINFO D07MON ONAPRISTONE Phase 2 T22939 DRUGINFO D07YGK Vilaprisan Phase 2 T22939 DRUGINFO D0H5BC Tosagestin Phase 2 T22939 DRUGINFO D0J0EM Virexxa Phase 2 T22939 DRUGINFO D0S1YX S-PRAnt Phase 2 T22939 DRUGINFO D0U8AS Telapristone Phase 2 T22939 DRUGINFO D0L3HU BAY 86-5044 Phase 2 T22939 DRUGINFO D0K2HA PF-2413873 Phase 1 T22939 DRUGINFO D0W5RL Asoprisnil Discontinued in Phase 3 T22939 DRUGINFO D03AZU Org-31710 Discontinued in Phase 1 T22939 DRUGINFO D0N4PC RU-46556 Terminated T22939 DRUGINFO D0O1PU BAY-39-9624 Terminated T22939 DRUGINFO D00ZGW GSK-325971A Investigative T22939 DRUGINFO D01NVD GSK-1564023A Investigative T22939 DRUGINFO D01OYG ZK-136798 Investigative T22939 DRUGINFO D01UFF ORG2058 Investigative T22939 DRUGINFO D02WQR GSK-008A Investigative T22939 DRUGINFO D05CND 6-(3-Nitro-phenyl)-3H-benzothiazol-2-one Investigative T22939 DRUGINFO D06DSF 5-(2-oxoindolin-5-yl)-1H-pyrrole-2-carbonitrile Investigative T22939 DRUGINFO D07XCB 1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione Investigative T22939 DRUGINFO D09GQF 5,N-Dihydroxythalidomide Investigative T22939 DRUGINFO D09VWK 3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one Investigative T22939 DRUGINFO D09XAM GTPL8662 Investigative T22939 DRUGINFO D0D6HI 4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile Investigative T22939 DRUGINFO D0E9CG 3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione Investigative T22939 DRUGINFO D0F1SS Lecanindole D Investigative T22939 DRUGINFO D0H2MF PF-02367982 Investigative T22939 DRUGINFO D0KX6D ZK-112993 Investigative T22939 DRUGINFO D0N1RQ 2-(4-Amino-3'-chloro-biphenyl-3-yl)-propan-2-ol Investigative T22939 DRUGINFO D0V4PL 3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile Investigative T22939 DRUGINFO D0V9NE Tanaproget Investigative T22939 DRUGINFO D0VJ7A ZK-114043 Investigative T22939 DRUGINFO D0ZM6R 2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline Investigative T22939 DRUGINFO D01ETZ [3H]methyltrienolone Investigative T22939 DRUGINFO D0G5OV WAY-255348 Investigative T22939 DRUGINFO D08KQM LGD-5552 Investigative T22939 DRUGINFO D0GR5L AL-43 Investigative T95678 TARGETID T95678 T95678 FORMERID TTDS00175 T95678 UNIPROID M2_I34A1 T95678 TARGNAME Influenza M2 protein (Influ M) T95678 GENENAME Influ M T95678 TARGTYPE Successful T95678 SYNONYMS Matrix protein M2; M2 proton channel; M T95678 FUNCTION Forms a proton-selective ion channel that is necessary for the efficient release of the viral genome during virus entry. After attaching to the cell surface, the virion enters the cell by endocytosis. Acidification of the endosome triggers M2 ion channel activity. The influx of protons into virion interior is believed to disrupt interactions between the viral ribonucleoprotein (RNP), matrix protein 1 (M1), and lipid bilayers, thereby freeing the viral genome from interaction with viral proteins and enabling RNA segments to migrate to the host cell nucleus, where influenza virus RNA transcription and replication occur. Also plays a role in viral proteins secretory pathway. Elevates the intravesicular pH of normally acidic compartments, such as trans-Golgi network, preventing newly formed hemagglutinin from premature switching to the fusion-active conformation. T95678 PDBSTRUC 5DLM T95678 BIOCLASS Influenza viruses matrix protein T95678 SEQUENCE MSLLTEVETPIRNEWGCRCNGSSDPLAIAANIIGILHLILWILDRLFFKCIYRRFKYGLKGGPSTEGVPKSMREEYRKEQQSAVDADDGHFVSIELE T95678 DRUGINFO D02KRS Amantadine Approved T95678 DRUGINFO D0TQ1G Rimantadine Approved T95678 DRUGINFO D0L1HK TCN-032 Phase 2 T95678 DRUGINFO D00SOM Spiro[piperidine-2,2-adamantane] Investigative T95678 DRUGINFO D03FAX 2-(1-adamantyl) piperidine Investigative T95678 DRUGINFO D04LRA Rimantadine isomer 2 Investigative T95678 DRUGINFO D04WWM 2-(1-adamantyl) pyrrolidine Investigative T95678 DRUGINFO D06IGJ 3-(2-adamantyl) pyrrolidine Investigative T95678 DRUGINFO D07FOH Spiro[pyrrolidine-2,2-adamantane] Investigative T95678 DRUGINFO D07IGD 2-(1-adamantyl)-2-methyl-pyrrolidine Investigative T95678 DRUGINFO D0B0PI 2-(2-adamantyl) piperidine Investigative T95678 DRUGINFO D0O6GL Spiro[cyclopropane-1,2-adamantan]-2-amine Investigative T95678 DRUGINFO D0P2NN Rimantadine isomer 1 Investigative T95678 DRUGINFO D02UVH B-Octylglucoside Investigative T28692 TARGETID T28692 T28692 FORMERID TTDS00066 T28692 UNIPROID LIPL_HUMAN T28692 TARGNAME Lipoprotein lipase (LPL) T28692 GENENAME LPL T28692 TARGTYPE Successful T28692 SYNONYMS LIPD T28692 FUNCTION Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage. Mediates margination of triglyceride-rich lipoprotein particles in capillaries. Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans. Key enzyme in triglyceride metabolism. T28692 PDBSTRUC 6OB0; 6OAZ; 6OAU; 6E7K T28692 BIOCLASS Carboxylic ester hydrolase T28692 ECNUMBER EC 3.1.1.34 T28692 SEQUENCE MESKALLVLTLAVWLQSLTASRGGVAAADQRRDFIDIESKFALRTPEDTAEDTCHLIPGVAESVATCHFNHSSKTFMVIHGWTVTGMYESWVPKLVAALYKREPDSNVIVVDWLSRAQEHYPVSAGYTKLVGQDVARFINWMEEEFNYPLDNVHLLGYSLGAHAAGIAGSLTNKKVNRITGLDPAGPNFEYAEAPSRLSPDDADFVDVLHTFTRGSPGRSIGIQKPVGHVDIYPNGGTFQPGCNIGEAIRVIAERGLGDVDQLVKCSHERSIHLFIDSLLNEENPSKAYRCSSKEAFEKGLCLSCRKNRCNNLGYEINKVRAKRSSKMYLKTRSQMPYKVFHYQVKIHFSGTESETHTNQAFEISLYGTVAESENIPFTLPEVSTNKTYSFLIYTEVDIGELLMLKLKWKSDSYFSWSDWWSSPGFAIQKIRVKAGETQKKVIFCSREKVSHLQKGKAPAVFVKCHDKSLNKKSG T28692 DRUGINFO D05VIX Gemfibrozil Approved T28692 DRUGINFO D0J5DC Clofibrate Approved T28692 DRUGINFO D01RNV AMT-011 Phase 3 T28692 DRUGINFO D0SA3J Ibrolipim Phase 2 T28692 DRUGINFO D0OH9B WS-070117 Investigative T62390 TARGETID T62390 T62390 FORMERID TTDS00365 T62390 UNIPROID TY3H_HUMAN T62390 TARGNAME Tyrosine 3-monooxygenase (TH) T62390 GENENAME TH T62390 TARGTYPE Successful T62390 SYNONYMS Tyrosine 3-hydroxylase; TH T62390 FUNCTION Plays an important role in the physiology of adrenergic neurones. T62390 PDBSTRUC 4J6S; 2XSN T62390 BIOCLASS Paired donor oxygen oxidoreductase T62390 ECNUMBER EC 1.14.16.2 T62390 SEQUENCE MPTPDATTPQAKGFRRAVSELDAKQAEAIMVRGQGAPGPSLTGSPWPGTAAPAASYTPTPRSPRFIGRRQSLIEDARKEREAAVAAAAAAVPSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQRPRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLVTKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLKGLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFLASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASDEEIEKLSTLYWFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQPYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDVLDSPQAVRRSLEGVQDELDTLAHALSAIG T62390 DRUGINFO D01CRB L-Tyrosine Approved T62390 DRUGINFO D0B3QM Metyrosine Approved T62390 DRUGINFO D0Q9YT Tetrahydrobiopterin Approved T62390 DRUGINFO D0R1CR L-Phenylalanine Approved T62390 DRUGINFO DI7SP5 L1-79 Phase 2 T62390 DRUGINFO D05ICS ProSavin Phase 1/2 T62390 DRUGINFO D72UDH OXB-102 Phase 1/2 T62390 DRUGINFO D05XGI Meta-Tyrosine Investigative T62390 DRUGINFO D0CI3A 3-iodotyrosine Investigative T62390 DRUGINFO D0X6LZ 3-chlorotyrosine Investigative T62390 DRUGINFO D0F3XT 7,8-dihydrobiopterin Investigative T62390 DRUGINFO D0IT5D alpha-propyldopacetamide Investigative T51120 TARGETID T51120 T51120 FORMERID TTDS00380 T51120 UNIPROID PERT_HUMAN T51120 TARGNAME Thyroid peroxidase (TPO) T51120 GENENAME TPO T51120 TARGTYPE Successful T51120 SYNONYMS Thyroperoxidase; TPO T51120 FUNCTION Iodination and coupling of the hormonogenic tyrosines in thyroglobulin to yield the thyroid hormones T(3) and T(4). T51120 BIOCLASS Peroxidases T51120 ECNUMBER EC 1.11.1.8 T51120 SEQUENCE MRALAVLSVTLVMACTEAFFPFISRGKELLWGKPEESRVSSVLEESKRLVDTAMYATMQRNLKKRGILSPAQLLSFSKLPEPTSGVIARAAEIMETSIQAMKRKVNLKTQQSQHPTDALSEDLLSIIANMSGCLPYMLPPKCPNTCLANKYRPITGACNNRDHPRWGASNTALARWLPPVYEDGFSQPRGWNPGFLYNGFPLPPVREVTRHVIQVSNEVVTDDDRYSDLLMAWGQYIDHDIAFTPQSTSKAAFGGGADCQMTCENQNPCFPIQLPEEARPAAGTACLPFYRSSAACGTGDQGALFGNLSTANPRQQMNGLTSFLDASTVYGSSPALERQLRNWTSAEGLLRVHARLRDSGRAYLPFVPPRAPAACAPEPGIPGETRGPCFLAGDGRASEVPSLTALHTLWLREHNRLAAALKALNAHWSADAVYQEARKVVGALHQIITLRDYIPRILGPEAFQQYVGPYEGYDSTANPTVSNVFSTAAFRFGHATIHPLVRRLDASFQEHPDLPGLWLHQAFFSPWTLLRGGGLDPLIRGLLARPAKLQVQDQLMNEELTERLFVLSNSSTLDLASINLQRGRDHGLPGYNEWREFCGLPRLETPADLSTAIASRSVADKILDLYKHPDNIDVWLGGLAENFLPRARTGPLFACLIGKQMKALRDGDWFWWENSHVFTDAQRRELEKHSLSRVICDNTGLTRVPMDAFQVGKFPEDFESCDSITGMNLEAWRETFPQDDKCGFPESVENGDFVHCEESGRRVLVYSCRHGYELQGREQLTCTQEGWDFQPPLCKDVNECADGAHPPCHASARCRNTKGGFQCLCADPYELGDDGRTCVDSGRLPRVTWISMSLAALLIGGFAGLTSTVICRWTRTGTKSTLPISETGGGTPELRCGKHQAVGTSPQRAAAQDSEQESAGMEGRDTHRLPRAL T51120 DRUGINFO D02CKX Carbimazole Approved T51120 DRUGINFO D0S4BR Methimazole Approved T51120 DRUGINFO D00MIN Propylthiouracil Approved T51120 DRUGINFO D0M9ZL TPO gene plasmid Investigative T52522 TARGETID T52522 T52522 FORMERID TTDS00037 T52522 UNIPROID ADRB2_HUMAN T52522 TARGNAME Adrenergic receptor beta-2 (ADRB2) T52522 GENENAME ADRB2 T52522 TARGTYPE Successful T52522 SYNONYMS Beta-2 adrenoreceptor; Beta-2 adrenoceptor; Beta-2 adrenergic receptor; B2AR; ADRB2R T52522 FUNCTION The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. T52522 PDBSTRUC 6MXT; 5X7D; 5JQH; 5D6L; 5D5B T52522 BIOCLASS GPCR rhodopsin T52522 SEQUENCE MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRFHVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL T52522 DRUGINFO D00LFB Ritodrine Approved T52522 DRUGINFO D02UFG Metaproterenol Sulfate Approved T52522 DRUGINFO D02ZJI Levalbuterol Approved T52522 DRUGINFO D03DJL Indacaterol Approved T52522 DRUGINFO D04KJO Formoterol Approved T52522 DRUGINFO D04UTT Olodaterol Approved T52522 DRUGINFO D04XEG Fenoterol Approved T52522 DRUGINFO D07XYV Bambuterol Approved T52522 DRUGINFO D08HUC Isoetharine Approved T52522 DRUGINFO D0D1DI Arformoterol Approved T52522 DRUGINFO D0FG6M GW642444 Approved T52522 DRUGINFO D0K5CB Salbutamol Approved T52522 DRUGINFO D0L0GM Vilanterol Approved T52522 DRUGINFO D0L5YV Salmeterol Approved T52522 DRUGINFO D0M8RC Terbutaline Approved T52522 DRUGINFO D0SS4P Pirbuterol Approved T52522 DRUGINFO D0X5NX Clenbuterol Approved T52522 DRUGINFO D0Z1WA Procaterol Approved T52522 DRUGINFO D0I8FI Isoproterenol Approved T52522 DRUGINFO D04DJS ICI 118,551 Phase 3 T52522 DRUGINFO D0Q5AT QVA-149 Phase 3 T52522 DRUGINFO D0T6TW GSK642444 Phase 3 T52522 DRUGINFO D0YS2W PT005 Phase 3 T52522 DRUGINFO D03MZJ BUCINDOLOL Phase 2/3 T52522 DRUGINFO D03LQC APD-209 Phase 2 T52522 DRUGINFO D04GRB THRX-198321 Phase 2 T52522 DRUGINFO D09CMK R-salbutamol sulphate Phase 2 T52522 DRUGINFO D0G0RT Carmoterol Phase 2 T52522 DRUGINFO D0GP8P GSK961081 Phase 2 T52522 DRUGINFO D0J1AV LAS 100977 Phase 2 T52522 DRUGINFO D0L6LD AZD-3199 Phase 2 T52522 DRUGINFO D0VU2M TA-2005 Phase 2 T52522 DRUGINFO D0YF4I MN-221 Phase 2 T52522 DRUGINFO D0L9CD AZD-2115 Phase 2 T52522 DRUGINFO D04UNO KUL-7211 Phase 1 T52522 DRUGINFO D0I2XM L-796568 Phase 1 T52522 DRUGINFO D0P0TR Meluadrine Discontinued in Preregistration T52522 DRUGINFO D0OR2S Broxaterol Discontinued in Phase 3 T52522 DRUGINFO D0C5PA Sibenadet Discontinued in Phase 3 T52522 DRUGINFO D02KMG Milveterol Discontinued in Phase 2 T52522 DRUGINFO D04MOF Milveterol+Fluticasone Discontinued in Phase 2 T52522 DRUGINFO D0AQ3H PF-610355 Discontinued in Phase 2 T52522 DRUGINFO D0GP4R Picumeterol Discontinued in Phase 2 T52522 DRUGINFO D0YL3E GSK159802 Discontinued in Phase 2 T52522 DRUGINFO D0N8MQ GSK-159797 Discontinued in Phase 2 T52522 DRUGINFO D08HDD RP-58802B Terminated T52522 DRUGINFO D0F6AB AR-C-89855 Terminated T52522 DRUGINFO D05ZGW DPI-201-106 Terminated T52522 DRUGINFO D04YJU L-755507 Terminated T52522 DRUGINFO D04UOP Butoxamine Investigative T52522 DRUGINFO D05RWZ 2-fluoronorepinehprine Investigative T52522 DRUGINFO D08JOS D 2343 Investigative T52522 DRUGINFO D0C6CZ GNF-PF-1694 Investigative T52522 DRUGINFO D0OL3X (S,R)-(+)-fenoterol Investigative T52522 DRUGINFO D02QPP (R,S)-(-)-fenoterol Investigative T52522 DRUGINFO D04JGC (R,R)-(-)-fenoterol Investigative T52522 DRUGINFO D0XX5S Dichloroisoproterenol Investigative T52522 DRUGINFO D03BZW [3H]CGP12177 Investigative T52522 DRUGINFO D04HXF 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol Investigative T52522 DRUGINFO D0A4FU 1-(2-allylphenoxy)-3-morpholinopropan-2-ol Investigative T50942 TARGETID T50942 T50942 FORMERID TTDC00189 T50942 UNIPROID TNR16_HUMAN T50942 TARGNAME Low-affinity nerve growth factor receptor (NGFR) T50942 GENENAME NGFR T50942 TARGTYPE Successful T50942 SYNONYMS p75 ICD; Tumor necrosis factor receptor superfamily member 16; TNFRSF16; P75neurotrophin receptor (p75(NTR)); P75NTR; P75ICD; NGFreceptor; NGF-P75 receptor; NGF receptor; Lowaffinity neurotrophin receptor p75NTR; Low affinity neurotrophin receptor p75NTR; Gp80-LNGFR; CD271; 75kD-neurotrophin receptor T50942 FUNCTION Low affinity receptor which can bind to NGF, BDNF, NT-3, and NT-4. Can mediate cell survival as well as cell death of neural cells. Necessary for the circadian oscillation of the clock genes ARNTL/BMAL1, PER1, PER2 and NR1D1 in the suprachiasmatic nucleus (SCN) of the brain and in liver and of the genes involved in glucose and lipid metabolism in the liver. Plays a role in the regulation of the translocation of GLUT4 to the cell surface in adipocytes and skeletal muscle cells in response to insulin, probably by regulating RAB31 activity, and thereby contributes to the regulation of insulin-dependent glucose uptake. T50942 PDBSTRUC 5ZGG; 3EWV; 2N97; 2N83; 2N80 T50942 BIOCLASS Cytokine receptor T50942 SEQUENCE MGAGATGRAMDGPRLLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKRWNSCKQNKQGANSRPVNQTPPPEGEKLHSDSGISVDSQSLHDQQPHTQTASGQALKGDGGLYSSLPPAKREEVEKLLNGSAGDTWRHLAGELGYQPEHIDSFTHEACPVRALLASWATQDSATLDALLAALRRIQRADLVESLCSESTATSPV T50942 DRUGINFO D02KUO Cenegermin Approved T50942 DRUGINFO D0O1GS Fulranumab Phase 3 T50942 DRUGINFO D0XR0B SPI-205 Phase 2 T50942 DRUGINFO D02XJJ LM11A-31 Phase 1/2 T50942 DRUGINFO D82DMK LM11A-31 Phase 1/2 T50942 DRUGINFO D00KEF Org-2766 Discontinued in Phase 3 T50942 DRUGINFO D0L8TN BU-4514N Terminated T50942 DRUGINFO D0M9FF ReN-1820 Terminated T50942 DRUGINFO D0O7DN CEP-427 Terminated T50942 DRUGINFO D04LRQ TDI-0059 Investigative T50942 DRUGINFO D07UZX Nerve growth factor conjugated RAP peptide Investigative T50942 DRUGINFO D0A0ZY ALD-901 Investigative T50942 DRUGINFO D0F2QP CRB-0022 Investigative T50942 DRUGINFO D0Q8ZP TDI-0033 Investigative T50942 DRUGINFO D0V1QX Axogenesis Factor-1 Investigative T46185 TARGETID T46185 T46185 FORMERID TTDS00003 T46185 UNIPROID ACM2_HUMAN T46185 TARGNAME Muscarinic acetylcholine receptor M2 (CHRM2) T46185 GENENAME CHRM2 T46185 TARGTYPE Successful T46185 SYNONYMS M2 receptor; CHRM2 T46185 FUNCTION The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol. T46185 PDBSTRUC 6OIK; 5ZKC; 5ZKB; 5ZK8; 5ZK3 T46185 BIOCLASS GPCR rhodopsin T46185 SEQUENCE MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNYFLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQFFSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRIVKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDEITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNIVARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNTVWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR T46185 DRUGINFO D05SJW Gallamine Triethiodide Approved T46185 DRUGINFO D04MWJ Methacholine Chloride Approved T46185 DRUGINFO D05KZK SMT-D002 Approved T46185 DRUGINFO D0M6VK Methylscopolamine Approved T46185 DRUGINFO D0R7WU ACECLIDINE Approved T46185 DRUGINFO D02MMF FP-1097 Phase 2 T46185 DRUGINFO D0A2OW Otenzepad Discontinued in Phase 2 T46185 DRUGINFO D06GCP PSD-506 Discontinued in Phase 2 T46185 DRUGINFO D08YVT SCH-211803 Discontinued in Phase 1 T46185 DRUGINFO D02JNY BIBN-140 Terminated T46185 DRUGINFO D07IZF Sch-57790 Terminated T46185 DRUGINFO D0R1VL BIBN-99 Terminated T46185 DRUGINFO D0VZ3D AQ-RA-741 Terminated T46185 DRUGINFO D06ACX HIMBACINE Terminated T46185 DRUGINFO D0X8MZ Alvameline Terminated T46185 DRUGINFO D0W3KR (R)-4-[2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl]piperidine-1-carboxylic acid amide (Ro-320-6206) Investigative T46185 DRUGINFO D04AAV 2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione Investigative T46185 DRUGINFO D06UXW METHOCTRAMINE Investigative T46185 DRUGINFO D08CTL CMI-936 Investigative T46185 DRUGINFO D09TDI CARAMIPEN Investigative T46185 DRUGINFO D0L1XR Green tea Investigative T46185 DRUGINFO D0MW7H CMI-1145 Investigative T46185 DRUGINFO D00JTE 1,1-diphenyl-2-(3-tropanyl)ethanol Investigative T46185 DRUGINFO D09AAZ PTAC Investigative T46185 DRUGINFO D0HP1O AF-DX-384 Investigative T46185 DRUGINFO D04XNH Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T46185 DRUGINFO D01UDC Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T46185 DRUGINFO D02EXX GNF-PF-5618 Investigative T46185 DRUGINFO D02PFJ 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea Investigative T46185 DRUGINFO D05EML 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione Investigative T46185 DRUGINFO D05MDY 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one Investigative T46185 DRUGINFO D06IUC FM1-10 Investigative T46185 DRUGINFO D06VST 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one Investigative T46185 DRUGINFO D07DEY 3-(3-benzylamino)-piperidin-2-one Investigative T46185 DRUGINFO D07VZG BRL-55473 Investigative T46185 DRUGINFO D08ZTA 6-Dimethylamino-2-methyl-hex-4-ynal oxime Investigative T46185 DRUGINFO D0AR0H FM1-43 Investigative T46185 DRUGINFO D0B8AQ 7-Pyrrolidin-1-yl-hept-5-yn-2-one Investigative T46185 DRUGINFO D0C9VH N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide Investigative T46185 DRUGINFO D0C9ZE Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T46185 DRUGINFO D0O1BN SULFOARECOLINE Investigative T46185 DRUGINFO D0OE0K 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane Investigative T46185 DRUGINFO D0QL1X 7-Dimethylamino-3-methyl-hept-5-yn-2-one Investigative T46185 DRUGINFO D0R2JE N-methoxyquinuclidine-3-carboximidoyl chloride Investigative T46185 DRUGINFO D0R8FS 7-Dimethylamino-hept-5-yn-2-one Investigative T46185 DRUGINFO D0U2IL 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime Investigative T46185 DRUGINFO D0X2JU N-methoxyquinuclidine-3-carboximidoyl fluoride Investigative T46185 DRUGINFO D0HV3A FLUMEZAPINE Investigative T46185 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T46185 DRUGINFO D0F9QT A-987306 Investigative T46185 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T46185 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T20709 TARGETID T20709 T20709 FORMERID TTDS00005 T20709 UNIPROID ACM4_HUMAN T20709 TARGNAME Muscarinic acetylcholine receptor M4 (CHRM4) T20709 GENENAME CHRM4 T20709 TARGTYPE Successful T20709 SYNONYMS M4 receptor; CHRM4 T20709 FUNCTION The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase. T20709 PDBSTRUC 6D9H; 5DSG T20709 BIOCLASS GPCR rhodopsin T20709 SEQUENCE MANFTPVNGSSGNQSVRLVTSSSHNRYETVEMVFIATVTGSLSLVTVVGNILVMLSIKVNRQLQTVNNYFLFSLACADLIIGAFSMNLYTVYIIKGYWPLGAVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTYPARRTTKMAGLMIAAAWVLSFVLWAPAILFWQFVVGKRTVPDNQCFIQFLSNPAVTFGTAIAAFYLPVVIMTVLYIHISLASRSRVHKHRPEGPKEKKAKTLAFLKSPLMKQSVKKPPPGEAAREELRNGKLEEAPPPALPPPPRPVADKDTSNESSSGSATQNTKERPATELSTTEATTPAMPAPPLQPRALNPASRWSKIQIVTKQTGNECVTAIEIVPATPAGMRPAANVARKFASIARNQVRKKRQMAARERKVTRTIFAILLAFILTWTPYNVMVLVNTFCQSCIPDTVWSIGYWLCYVNSTINPACYALCNATFKKTFRHLLLCQYRNIGTAR T20709 DRUGINFO D09PNY Tropicamide Approved T20709 DRUGINFO D0W9VB Diphenidol Approved T20709 DRUGINFO D04MWJ Methacholine Chloride Approved T20709 DRUGINFO D0R7WU ACECLIDINE Approved T20709 DRUGINFO D04BBK VU10007 Investigative T20709 DRUGINFO D0N2VN VU10010 Investigative T20709 DRUGINFO D08CTL CMI-936 Investigative T20709 DRUGINFO D0MW7H CMI-1145 Investigative T20709 DRUGINFO D09AAZ PTAC Investigative T20709 DRUGINFO D0HP1O AF-DX-384 Investigative T20709 DRUGINFO D04XNH Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T20709 DRUGINFO D0Z5RQ Cremastrine Investigative T20709 DRUGINFO D01UDC Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T20709 DRUGINFO D02EXX GNF-PF-5618 Investigative T20709 DRUGINFO D02PFJ 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea Investigative T20709 DRUGINFO D05EML 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione Investigative T20709 DRUGINFO D05MDY 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one Investigative T20709 DRUGINFO D06IUC FM1-10 Investigative T20709 DRUGINFO D06VST 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one Investigative T20709 DRUGINFO D07DEY 3-(3-benzylamino)-piperidin-2-one Investigative T20709 DRUGINFO D07VZG BRL-55473 Investigative T20709 DRUGINFO D08ZTA 6-Dimethylamino-2-methyl-hex-4-ynal oxime Investigative T20709 DRUGINFO D0AR0H FM1-43 Investigative T20709 DRUGINFO D0B8AQ 7-Pyrrolidin-1-yl-hept-5-yn-2-one Investigative T20709 DRUGINFO D0C9VH N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide Investigative T20709 DRUGINFO D0C9ZE Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T20709 DRUGINFO D0N2KU PF-3409409 Investigative T20709 DRUGINFO D0O1BN SULFOARECOLINE Investigative T20709 DRUGINFO D0OE0K 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane Investigative T20709 DRUGINFO D0QL1X 7-Dimethylamino-3-methyl-hept-5-yn-2-one Investigative T20709 DRUGINFO D0R2JE N-methoxyquinuclidine-3-carboximidoyl chloride Investigative T20709 DRUGINFO D0R8FS 7-Dimethylamino-hept-5-yn-2-one Investigative T20709 DRUGINFO D0U2IL 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime Investigative T20709 DRUGINFO D0X2JU N-methoxyquinuclidine-3-carboximidoyl fluoride Investigative T20709 DRUGINFO D0HV3A FLUMEZAPINE Investigative T20709 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T20709 DRUGINFO D0F9QT A-987306 Investigative T20709 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T20709 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T72168 TARGETID T72168 T72168 FORMERID TTDS00206 T72168 UNIPROID MCR_HUMAN T72168 TARGNAME Mineralocorticoid receptor (MR) T72168 GENENAME NR3C2 T72168 TARGTYPE Successful T72168 SYNONYMS Nuclear receptor subfamily 3 group C member 2; Mineralocorticoid receptor; MLR; MCR; Inner ear mineralocorticoid receptor; Delta T72168 FUNCTION Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels. Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. T72168 PDBSTRUC 6GGG; 6GG8; 6GEV; 5MWY; 5MWP T72168 BIOCLASS Nuclear hormone receptor T72168 SEQUENCE METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNSTQGSSKEKQELLPCLQQDNNRPGILTSDIKTELESKELSATVAESMGLYMDSVRDADYSYEQQNQQGSMSPAKIYQNVEQLVKFYKGNGHRPSTLSCVNTPLRSFMSDSGSSVNGGVMRAVVKSPIMCHEKSPSVCSPLNMTSSVCSPAGINSVSSTTASFGSFPVHSPITQGTPLTCSPNVENRGSRSHSPAHASNVGSPLSSPLSSMKSSISSPPSHCSVKSPVSSPNNVTLRSSVSSPANINNSRCSVSSPSNTNNRSTLSSPAASTVGSICSPVNNAFSYTASGTSAGSSTLRDVVPSPDTQEKGAQEVPFPKTEEVESAISNGVTGQLNIVQYIKPEPDGAFSSSCLGGNSKINSDSSFSVPIKQESTKHSCSGTSFKGNPTVNPFPFMDGSYFSFMDDKDYYSLSGILGPPVPGFDGNCEGSGFPVGIKQEPDDGSYYPEASIPSSAIVGVNSGGQSFHYRIGAQGTISLSRSARDQSFQHLSSFPPVNTLVESWKSHGDLSSRRSDGYPVLEYIPENVSSSTLRSVSTGSSRPSKICLVCGDEASGCHYGVVTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRLQKCLQAGMNLGARKSKKLGKLKGIHEEQPQQQQPPPPPPPPQSPEEGTTYIAPAKEPSVNTALVPQLSTISRALTPSPVMVLENIEPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQVVKWAKVLPGFKNLPLEDQITLIQYSWMCLSSFALSWRSYKHTNSQFLYFAPDLVFNEEKMHQSAMYELCQGMHQISLQFVRLQLTFEEYTIMKVLLLLSTIPKDGLKSQAAFEEMRTNYIKELRKMVTKCPNNSGQSWQRFYQLTKLLDSMHDLVSDLLEFCFYTFRESHALKVEFPAMLVEIISDQLPKVESGNAKPLYFHRK T72168 DRUGINFO D02CJX Desoxycorticosterone Acetate Approved T72168 DRUGINFO D0EP0C Spironolactone Approved T72168 DRUGINFO D0NV5O Finerenone Approved T72168 DRUGINFO D0Q4SD Eplerenone Approved T72168 DRUGINFO D0W5LS Desoxycorticosterone Pivalate Approved T72168 DRUGINFO D0Z4ZT Drospirenone Approved T72168 DRUGINFO D0I1LH Aldosterone Approved T72168 DRUGINFO D0R7JT Fludrocortisone Approved T72168 DRUGINFO D01JIO ZK-91587 Phase 2 T72168 DRUGINFO D03MSF Nerenone Phase 2 T72168 DRUGINFO D05RZE LY-2623091 Phase 2 T72168 DRUGINFO D0G4YR MT-3995 Phase 2 T72168 DRUGINFO D0OH2H BR-4628 Phase 2 T72168 DRUGINFO DP6AO8 AZD9977 Phase 2 T72168 DRUGINFO D00DFP KBP-5074 Phase 1/2 T72168 DRUGINFO D09UKH XL550 Phase 1 T72168 DRUGINFO DS4A5E SP 20202 Clinical trial T72168 DRUGINFO D01VJR PMID27551786-Compound-138 Patented T72168 DRUGINFO D02LAD PMID27551786-Compound-IV Patented T72168 DRUGINFO D08NNH PMID27551786-Compound-106 Patented T72168 DRUGINFO D0LZ4V PMID27551786-Compound-II Patented T72168 DRUGINFO D0NC3Q PMID27551786-Compound-III Patented T72168 DRUGINFO D0W5ZQ PMID27551786-Compound-I Patented T72168 DRUGINFO D02KAU PF-03882845 Terminated T72168 DRUGINFO D02SLV CB-1922 Investigative T72168 DRUGINFO D09WWY RU28318 Investigative T72168 DRUGINFO D04SQY deoxycorticosterone Investigative T72168 DRUGINFO D03TNT (11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE Investigative T72168 DRUGINFO D09OKK LG-120838 Investigative T72168 DRUGINFO D0G5OV WAY-255348 Investigative T72168 DRUGINFO D0XS0R Epierenone Investigative T72168 DRUGINFO D08KQM LGD-5552 Investigative T72168 DRUGINFO D0GR5L AL-43 Investigative T72168 DRUGINFO D02UVH B-Octylglucoside Investigative T78709 TARGETID T78709 T78709 FORMERID TTDS00098 T78709 UNIPROID 5HT1A_HUMAN T78709 TARGNAME 5-HT 1A receptor (HTR1A) T78709 GENENAME HTR1A T78709 TARGTYPE Successful T78709 SYNONYMS Serotonin receptor 1A; G-21; ADRBRL1; ADRB2RL1; 5-hydroxytryptamine receptor 1A; 5-HT1A receptor; 5-HT1A; 5-HT-1A T78709 FUNCTION Functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli. G-protein coupled receptor for 5-hydroxytryptamine (serotonin). T78709 BIOCLASS GPCR rhodopsin T78709 SEQUENCE MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAAIALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPEDRSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADTRHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGNSKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLPFFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFCRQ T78709 DRUGINFO D03SFU TERTATOLOL Approved T78709 DRUGINFO D07NJI Treximet Approved T78709 DRUGINFO D0R5GS Gepirone Approved T78709 DRUGINFO D0U2OO Buspirone Approved T78709 DRUGINFO D00USF Trazodone Approved T78709 DRUGINFO D0K0VO Urapidil Approved T78709 DRUGINFO D0P0OU OPC-34712 Approved T78709 DRUGINFO D0S9CB Flibanserin Approved T78709 DRUGINFO D0X6BV Vilazodone Approved T78709 DRUGINFO D02OJC Xaliproden Phase 3 T78709 DRUGINFO D04ZKY SEP-363856 Phase 3 T78709 DRUGINFO D06FKC Eltoprazine Phase 3 T78709 DRUGINFO D0X6XH CM-2395 Phase 3 T78709 DRUGINFO D0E2IN LECOZOTAN HYDROCHLORIDE Phase 2/3 T78709 DRUGINFO D0W5EH Sarizotan Phase 2/3 T78709 DRUGINFO D00CQQ TGFK09SD Phase 2 T78709 DRUGINFO D00KIE Ensaculin hydrochloride Phase 2 T78709 DRUGINFO D00QOF ORG-13011 Phase 2 T78709 DRUGINFO D09OOQ TGFK08AA Phase 2 T78709 DRUGINFO D09UMP MN-305 Phase 2 T78709 DRUGINFO D0F6TD SUN N4057 Phase 2 T78709 DRUGINFO D0OP8W Zalospirone Phase 2 T78709 DRUGINFO D0P2QO S-15535 Phase 2 T78709 DRUGINFO D0T6BA S-16924 Phase 2 T78709 DRUGINFO D04FVD TGBA01AD Phase 2 T78709 DRUGINFO D04JZP Mazapertine succinate Phase 2 T78709 DRUGINFO D08FKX SDZ-MAR-327 Phase 2 T78709 DRUGINFO D0R8GR OPC-14523 Phase 2 T78709 DRUGINFO D0S8DU TGWOOAA Phase 2 T78709 DRUGINFO D0SQ6A FKW00GA Phase 2 T78709 DRUGINFO D00CVJ Neu-P11 Phase 2 T78709 DRUGINFO D0MT8G FKB01MD Phase 2 T78709 DRUGINFO D0Z4FE MIN-117 Phase 2 T78709 DRUGINFO D05XEA RP5063 Phase 2 T78709 DRUGINFO D09CEY SKL-PSY Phase 1 T78709 DRUGINFO D0EH0C AV-965 Phase 1 T78709 DRUGINFO D0F2NF GSK-958108 Phase 1 T78709 DRUGINFO D0F8HS NLX-101 Phase 1 T78709 DRUGINFO D0Y2GJ DSP-1053 Phase 1 T78709 DRUGINFO D00ZEG Umespirone Phase 1 T78709 DRUGINFO D0K0GF SSR-181507 Phase 1 T78709 DRUGINFO D0C7WO 1192U90 Phase 1 T78709 DRUGINFO D0F9TY Aryl piperazine derivative 16 Patented T78709 DRUGINFO D0M9LM Aryl piperazine derivative 14 Patented T78709 DRUGINFO D0T7HK Aryl piperazine derivative 15 Patented T78709 DRUGINFO D0E7FT PMID30124346-Compound-60TABLE5 Patented T78709 DRUGINFO D0SG8X PMID30124346-Compound-LDT66 Patented T78709 DRUGINFO D0EO8F PMID30124346-Compound-LDT8 Patented T78709 DRUGINFO D0M1UF Aryl piperazine derivative 1 Patented T78709 DRUGINFO D0Z9WY Aryl piperazine derivative 6 Patented T78709 DRUGINFO D09BCJ PMID30124346-Compound-34TABLE4 Patented T78709 DRUGINFO D0F4NB PMID30124346-Compound-13TABLE4 Patented T78709 DRUGINFO D0M7LV LYSERGIC ACID DIETHYLAMIDE Withdrawn from market T78709 DRUGINFO D02VZP Flesinoxan Discontinued in Phase 3 T78709 DRUGINFO D01DAW Bifeprunox Discontinued in Phase 3 T78709 DRUGINFO D01YOC BMS-181100 Discontinued in Phase 3 T78709 DRUGINFO D03ITI Sunepitron Discontinued in Phase 3 T78709 DRUGINFO D01RCS TIOSPIRONE Discontinued in Phase 3 T78709 DRUGINFO D01QKR ALNESPIRONE Discontinued in Phase 2 T78709 DRUGINFO D01XAR AP-521 Discontinued in Phase 2 T78709 DRUGINFO D04HXS REC-15/3079 Discontinued in Phase 2 T78709 DRUGINFO D08AWI PRX-00023 Discontinued in Phase 2 T78709 DRUGINFO D08JAP Robalzotan Discontinued in Phase 2 T78709 DRUGINFO D0B7SP GSK163090 Discontinued in Phase 2 T78709 DRUGINFO D0G5TU LESOPITRON DIHYDROCHLORIDE Discontinued in Phase 2 T78709 DRUGINFO D0U4FW DU 125530 Discontinued in Phase 2 T78709 DRUGINFO D0X2TO Adatanserin Discontinued in Phase 2 T78709 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T78709 DRUGINFO D01DOY GR-127607 Discontinued in Phase 1 T78709 DRUGINFO D05AAM BINOSPIRONE MESYLATE Discontinued in Phase 1 T78709 DRUGINFO D05DSK E2101 Discontinued in Phase 1 T78709 DRUGINFO D0BN4Y Ebalzotan Discontinued in Phase 1 T78709 DRUGINFO D0G5ZL U-93385 Discontinued in Phase 1 T78709 DRUGINFO D0O9EM Eptapirone Discontinued in Phase 1 T78709 DRUGINFO D0S2WC Nerisopam Discontinued in Phase 1 T78709 DRUGINFO D0T8KF SUN-8399 Discontinued in Phase 1 T78709 DRUGINFO D03ZZH SLV-313 Discontinued in Phase 1 T78709 DRUGINFO D09WHM DU-29894 Discontinued in Phase 1 T78709 DRUGINFO D02CJA CM-2236 Preclinical T78709 DRUGINFO D04UXX PD-158771 Preclinical T78709 DRUGINFO D02FNU Ipsapirone Terminated T78709 DRUGINFO D02OKK SDZ 216-525 Terminated T78709 DRUGINFO D07BCO WAY-100635 Terminated T78709 DRUGINFO D07RPB HT-90B Terminated T78709 DRUGINFO D0A6PL S-14506 Terminated T78709 DRUGINFO D0L9SN NAN-190 Terminated T78709 DRUGINFO D0Q2PF LY-293284 Terminated T78709 DRUGINFO D0R1DP A-74283 Terminated T78709 DRUGINFO D0RJ6R Du-123015 Terminated T78709 DRUGINFO D0T0BS CGS-18102A Terminated T78709 DRUGINFO D0Z7AW CP-293019 Terminated T78709 DRUGINFO D02ZPM Anpirtoline Terminated T78709 DRUGINFO D05IPO BTS-79018 Terminated T78709 DRUGINFO D0R9PL RWJ-25730 Terminated T78709 DRUGINFO D0U4WG SLV-307 Terminated T78709 DRUGINFO D00KZF BMY-7378 Terminated T78709 DRUGINFO D03QMR WB-4101 Terminated T78709 DRUGINFO D0K9JP A-80426 Terminated T78709 DRUGINFO D00FHZ CP 93129 Investigative T78709 DRUGINFO D00XVV [11C]WAY100635 Investigative T78709 DRUGINFO D01WWC N-methyllaurotetanine Investigative T78709 DRUGINFO D02CTZ LY433221 Investigative T78709 DRUGINFO D02MVR 3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole Investigative T78709 DRUGINFO D03DKG EMD 56551 Investigative T78709 DRUGINFO D03ESA P-MPPI Investigative T78709 DRUGINFO D03FKF repinotan Investigative T78709 DRUGINFO D03ICS NPT-500 Investigative T78709 DRUGINFO D03LDH 1-Benzyl-4-chroman-2-ylmethyl-piperazine Investigative T78709 DRUGINFO D04JZJ 3-(4-Benzyl-piperidin-1-ylmethyl)-chromen-4-one Investigative T78709 DRUGINFO D04YJO CGS-19480A Investigative T78709 DRUGINFO D05CGI 2-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one Investigative T78709 DRUGINFO D06BYY S-14671 Investigative T78709 DRUGINFO D06DSX ESCHOLTZINE Investigative T78709 DRUGINFO D06FWM N-(3-(1H-indol-4-yloxy)propyl)cyclohexanamine Investigative T78709 DRUGINFO D06JVZ SR-59026 Investigative T78709 DRUGINFO D07ROK N-(3-(1H-indol-4-yloxy)propyl)cyclopentanamine Investigative T78709 DRUGINFO D07XUM FG-5893 Investigative T78709 DRUGINFO D08VUQ 1-(2-methoxyphenyl)-4-pentylpiperazine Investigative T78709 DRUGINFO D09BJW 9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine Investigative T78709 DRUGINFO D09BYW N-[4-(4-Phenyl-piperazin-1-yl)-butyl]-benzamide Investigative T78709 DRUGINFO D0B5ST 2-(3-Bromophenylthio)-N,N-dimethylethanamine Investigative T78709 DRUGINFO D0C9TZ 3-(3-Methanesulfonyl-phenyl)-1-propyl-pyrrolidine Investigative T78709 DRUGINFO D0E1PL [3H]NLX-112 Investigative T78709 DRUGINFO D0H3YR [3H]robalzotan Investigative T78709 DRUGINFO D0K6XD 4-(1H-indol-4-yloxy)-1-(isopropylamino)butan-2-ol Investigative T78709 DRUGINFO D0KJ4Q p-[18F]MPPF Investigative T78709 DRUGINFO D0KL1P PB-28 Investigative T78709 DRUGINFO D0L5YC 8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine Investigative T78709 DRUGINFO D0MA8C GR 125,743 Investigative T78709 DRUGINFO D0MS3V 2-(Biphenyl-3-ylthio)-N,N-dimethylethanamine Investigative T78709 DRUGINFO D0Q1HK 2-Dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol Investigative T78709 DRUGINFO D0U0VH U92016A Investigative T78709 DRUGINFO D0XK0T WAY 100135 Investigative T78709 DRUGINFO D0Z1LY [3H]p-MPPF Investigative T78709 DRUGINFO D0Z7KW RS-30199 Investigative T78709 DRUGINFO D00JJO 1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene Investigative T78709 DRUGINFO D00VHW 4-Benzyl-1-chroman-3-ylmethyl-piperidine Investigative T78709 DRUGINFO D01YBD 2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine Investigative T78709 DRUGINFO D02AVN (3-Chloro-phenyl)-piperazin-1-yl-methanone Investigative T78709 DRUGINFO D02PLD 1-(2-Butoxy-phenyl)-piperazine Investigative T78709 DRUGINFO D02XXA 3-Phenyl-1-propyl-pyrrolidine Investigative T78709 DRUGINFO D02YCY (R)-11-Amino-2-methoxyaporphine Investigative T78709 DRUGINFO D02YFZ 2-Piperazin-1-yl-benzonitrile Investigative T78709 DRUGINFO D03CEZ AGROCLAVINE Investigative T78709 DRUGINFO D03NWV 1-(2-Ethoxy-phenyl)-piperazine Investigative T78709 DRUGINFO D03PAH 1-(2-Methoxy-phenyl)-4-propyl-piperazine Investigative T78709 DRUGINFO D03XYG 1-Methyl-1,3-dihydro-indol-2-one Investigative T78709 DRUGINFO D04TQF 1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene Investigative T78709 DRUGINFO D04ZMS 3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one Investigative T78709 DRUGINFO D07IWZ (R)-2,11-Diaminoaporphine Investigative T78709 DRUGINFO D07LSC 1-(3-Fluoro-phenyl)-piperazine Investigative T78709 DRUGINFO D08YJP 1-(2-Fluoro-phenyl)-piperazine Investigative T78709 DRUGINFO D09MGF 1-(benzyloxy)-2-(2-phenylethyl)benzene Investigative T78709 DRUGINFO D09WIL SB-656104 Investigative T78709 DRUGINFO D0A7AK 3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine Investigative T78709 DRUGINFO D0CA9H N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide Investigative T78709 DRUGINFO D0E2FY 1-(2-Isopropoxy-phenyl)-piperazine Investigative T78709 DRUGINFO D0I0ML 2-(2'-methyl-biphenyl-3-yl)-ethylamine Investigative T78709 DRUGINFO D0J3ZK (R)-flurocarazolol Investigative T78709 DRUGINFO D0ND2Y 1-(3-Nitro-phenyl)-piperazine Investigative T78709 DRUGINFO D0O8QJ (S)-flurocarazolol Investigative T78709 DRUGINFO D0P6LN 3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol Investigative T78709 DRUGINFO D0PC2C 3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol Investigative T78709 DRUGINFO D0R5QM 1-Butyl-4-(2-methoxy-phenyl)-piperazine Investigative T78709 DRUGINFO D0R5WX 4-Benzyl-1-chroman-2-ylmethyl-piperidine Investigative T78709 DRUGINFO D0RQ8R 2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine Investigative T78709 DRUGINFO D0T4PS LY 165,163 Investigative T78709 DRUGINFO D0U1MN 1-Ethyl-4-(2-methoxy-phenyl)-piperazine Investigative T78709 DRUGINFO D0Z5GR 1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine Investigative T78709 DRUGINFO D00CGJ 2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine Investigative T78709 DRUGINFO D00FMX 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine Investigative T78709 DRUGINFO D00FUS 2-(2-Methoxy-phenyl)-1-methyl-ethylamine Investigative T78709 DRUGINFO D00GSD LP-211 Investigative T78709 DRUGINFO D00QSV 2-(3-Methoxy-phenyl)-1-methyl-ethylamine Investigative T78709 DRUGINFO D00UIN JNJ-10392980 Investigative T78709 DRUGINFO D00WEQ Brolamfetamine Investigative T78709 DRUGINFO D01HRV L-772,405 Investigative T78709 DRUGINFO D02OZB 2-Piperazin-1-yl-phenol Investigative T78709 DRUGINFO D02SAF 1-(2,5-Dimethoxy-phenyl)-piperazine Investigative T78709 DRUGINFO D03DET SB 714786 Investigative T78709 DRUGINFO D04CTN 3-(1-Propyl-pyrrolidin-3-yl)-phenol Investigative T78709 DRUGINFO D04MVL (R)-(-)-10-methyl-11-hydroxyaporphine Investigative T78709 DRUGINFO D06OJI 2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol Investigative T78709 DRUGINFO D06PKJ 1-(2,5-dimethoxyphenyl)propan-2-amine Investigative T78709 DRUGINFO D07DWS 1-(2-(2-fluorobenzyloxy)phenyl)piperazine Investigative T78709 DRUGINFO D08HOJ 1,2,3,4-Tetrahydro-naphthalen-2-ylamine Investigative T78709 DRUGINFO D09JOE 1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine Investigative T78709 DRUGINFO D09YVA 8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline Investigative T78709 DRUGINFO D0B2GS 3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one Investigative T78709 DRUGINFO D0D2PL 8-Methoxy-quinolin-2-ylamine Investigative T78709 DRUGINFO D0D3OF 1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine Investigative T78709 DRUGINFO D0I9FI 2-(4-Bromo-phenyl)-1-methyl-ethylamine Investigative T78709 DRUGINFO D0K0FI 7-methoxy-1-naphthylpiperazine Investigative T78709 DRUGINFO D0K6ZT 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine Investigative T78709 DRUGINFO D0KX3X MCL-516 Investigative T78709 DRUGINFO D0N0LZ 3-Naphthalen-1-yl-pyrrolidine Investigative T78709 DRUGINFO D0N2RJ 1-(2-(3-fluorophenoxy)phenyl)piperazine Investigative T78709 DRUGINFO D0O3GF [3H]8-OH-DPAT Investigative T78709 DRUGINFO D0O9HS 1-(2-Chloro-phenyl)-piperazine Investigative T78709 DRUGINFO D0PN8D 1-(7-Methoxy-naphthalen-2-yl)-piperazine Investigative T78709 DRUGINFO D0QM3E SB 272183 Investigative T78709 DRUGINFO D0R3GW SB 649915 Investigative T78709 DRUGINFO D0R3XC 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane Investigative T78709 DRUGINFO D0S5ZY 3-Naphthalen-1-yl-1-propyl-pyrrolidine Investigative T78709 DRUGINFO D0TH8D 8-Methoxy-2-piperazin-1-yl-quinoline Investigative T78709 DRUGINFO D0X4RC PHENYLPIPERAZINE Investigative T78709 DRUGINFO D0Y5CG 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine Investigative T78709 DRUGINFO D0YG1E Etisulergine Investigative T78709 DRUGINFO D0ZU5W 1-(2-(benzyloxy)phenyl)piperazine Investigative T78709 DRUGINFO D00CCV 1,6-bis(4-m-tolylpiperazin-1-yl)hexane Investigative T78709 DRUGINFO D00DEH 4-(2-(3-chlorophenoxy)phenyl)piperidine Investigative T78709 DRUGINFO D00HCC 1-(2-phenoxyphenyl)piperazine Investigative T78709 DRUGINFO D00KRQ 4-(2-phenoxyphenyl)piperidine Investigative T78709 DRUGINFO D01MBF 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine Investigative T78709 DRUGINFO D01YNZ 4-(2-(benzyloxy)phenyl)piperidine Investigative T78709 DRUGINFO D02NNS SNAP-8719 Investigative T78709 DRUGINFO D03DQQ 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine Investigative T78709 DRUGINFO D03PIP 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane Investigative T78709 DRUGINFO D03XKL 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane Investigative T78709 DRUGINFO D03ZHB 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine Investigative T78709 DRUGINFO D04NDO 4-(2-(2-fluorobenzyloxy)phenyl)piperidine Investigative T78709 DRUGINFO D04NKQ 4-(2-(4-fluorophenoxy)phenyl)piperidine Investigative T78709 DRUGINFO D04ZPF 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine Investigative T78709 DRUGINFO D05LJC 4-(2-(benzyloxy)-3-fluorophenyl)piperidine Investigative T78709 DRUGINFO D08EFH 2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine Investigative T78709 DRUGINFO D08JLB 4-(2-(benzyloxy)-6-fluorophenyl)piperidine Investigative T78709 DRUGINFO D09IIH 4-(3-fluoro-2-phenoxyphenyl)piperidine Investigative T78709 DRUGINFO D0C6BP 1,6-bis(4-phenylpiperazin-1-yl)hexane Investigative T78709 DRUGINFO D0CG2Y 2-phenoxy-3-(piperidin-4-yl)pyridine Investigative T78709 DRUGINFO D0E6PQ 4-(2-fluoro-6-phenoxyphenyl)piperidine Investigative T78709 DRUGINFO D0F6GB 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine Investigative T78709 DRUGINFO D0G7NW cyamemazine Investigative T78709 DRUGINFO D0I4VT 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine Investigative T78709 DRUGINFO D0IC4J 4-(2-(3-fluorophenoxy)phenyl)piperidine Investigative T78709 DRUGINFO D0KT2M 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine Investigative T78709 DRUGINFO D0M2ZE UH-232 Investigative T78709 DRUGINFO D0M3TK 1-(2-(4-fluorophenoxy)phenyl)piperazine Investigative T78709 DRUGINFO D0O4BC 3-(2-Benzylamino-ethoxy)-phenol Investigative T78709 DRUGINFO D0R3TA 4-(2-(4-fluorobenzyloxy)phenyl)piperidine Investigative T78709 DRUGINFO D0S4JT 1-(2-(phenoxymethyl)phenyl)piperazine Investigative T78709 DRUGINFO D0S8KA 3-(2-Amino-propyl)-1H-indol-5-ol Investigative T78709 DRUGINFO D0W1HM nafadotride Investigative T78709 DRUGINFO D0W2YN 1-Naphthalen-2-yl-piperazine Investigative T78709 DRUGINFO D0W8YO 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine Investigative T78709 DRUGINFO D0X4PH LP-44 Investigative T78709 DRUGINFO D0Z1OF LP-12 Investigative T78709 DRUGINFO D04TPO 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T78709 DRUGINFO D06ROA UH-301 Investigative T78709 DRUGINFO D0MU4A spiroxatrine Investigative T78709 DRUGINFO D0P1XQ SEL-73 Investigative T78709 DRUGINFO D0XX2U 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T78709 DRUGINFO D07GQP PG-01037 Investigative T78709 DRUGINFO D07GXY piribedil Investigative T78709 DRUGINFO D0CK9K EDMT Investigative T78709 DRUGINFO D0D9YW SB 216641 Investigative T78709 DRUGINFO D0V3XU CHLOROPHENYLPIPERAZINE Investigative T78709 DRUGINFO D0Y4MC 9-OH-risperidone Investigative T78709 DRUGINFO D06VPR WAY-466 Investigative T78709 DRUGINFO D08BCF QUIPAZINE Investigative T78709 DRUGINFO D0C5GF MPDT Investigative T78709 DRUGINFO D0LG8A 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine Investigative T78709 DRUGINFO D0V4RP 1-(2-Methoxy-phenyl)-piperazine Investigative T78709 DRUGINFO D0Y9TL 5-chloro-3,4-dihydroquinazolin-2-amine Investigative T78709 DRUGINFO D01KAX 1-((S)-2-aminopropyl)-1H-indazol-6-ol Investigative T78709 DRUGINFO D05EQG [3H]spiperone Investigative T78709 DRUGINFO D08VGJ 5,6-dichloro-3,4-dihydroquinazolin-2-amine Investigative T78709 DRUGINFO D03TDN 1-naphthylpiperazine Investigative T78709 DRUGINFO D04TVG BRL-15572 Investigative T78709 DRUGINFO D07LRJ SB-271046 Investigative T78709 DRUGINFO D02UWB 5-CT Investigative T78709 DRUGINFO D0V5HV TFMPP Investigative T78709 DRUGINFO D0F6CD SEROTONIN Investigative T78709 DRUGINFO D0F9QT A-987306 Investigative T78709 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T88240 TARGETID T88240 T88240 FORMERID TTDS00237 T88240 UNIPROID DHPS_ECOLI T88240 TARGNAME Bacterial Dihydropteroate synthetase (Bact folP) T88240 GENENAME Bact folP T88240 TARGTYPE Successful T88240 SYNONYMS folP; H2Pte synthase; Dihydropteroate synthase; Dihydropteroate pyrophosphorylase; DHPS T88240 FUNCTION Dhps catalyzes the formation of the immediate precursor of folic acid. It is implicated in resistance to sulfonamide. T88240 PDBSTRUC 1AJZ; 1AJ2; 1AJ0 T88240 BIOCLASS Alkyl aryl transferase T88240 ECNUMBER EC 2.5.1.15 T88240 SEQUENCE MKLFAQGTSLDLSHPHVMGILNVTPDSFSDGGTHNSLIDAVKHANLMINAGATIIDVGGESTRPGAAEVSVEEELQRVIPVVEAIAQRFEVWISVDTSKPEVIRESAKVGAHIINDIRSLSEPGALEAAAETGLPVCLMHMQGNPKTMQEAPKYDDVFAEVNRYFIEQIARCEQAGIAKEKLLLDPGFGFGKNLSHNYSLLARLAEFHHFNLPLLVGMSRKSMIGQLLNVGPSERLSGSLACAVIAAMQGAHIIRVHDVKETVEAMRVVEATLSAKENKRYE T88240 DRUGINFO D02IBU Oritavancin Approved T88240 DRUGINFO D02IIW Faropenem Approved T88240 DRUGINFO D03QWT Doripenem Approved T88240 DRUGINFO D05HPI Daptomycin Approved T88240 DRUGINFO D05LKP Sulfadiazine Approved T88240 DRUGINFO D07JJS Sulfamethizole Approved T88240 DRUGINFO D08JCA Silver sulfadiazine Approved T88240 DRUGINFO D09OOV Polymyxin B Sulfate Approved T88240 DRUGINFO D09TBD Sulfisoxazole Approved T88240 DRUGINFO D0B5FZ Cefozopran Approved T88240 DRUGINFO D0D4CY Sulfapyridine Approved T88240 DRUGINFO D0H1GJ Sulfamerazine Approved T88240 DRUGINFO D0J7XL Gramicidin D Approved T88240 DRUGINFO D0K7NQ Colistin Approved T88240 DRUGINFO D0L4JT Sulfanilamide Approved T88240 DRUGINFO D0Q3BV Colistimethate Approved T88240 DRUGINFO D0R9OH Sulfamethoxazole Approved T88240 DRUGINFO D0T1EO Sulfonamides Approved T88240 DRUGINFO D0T1GT Sulfacytine Approved T88240 DRUGINFO D0V4GY Chlorhexidine Approved T88240 DRUGINFO D0V9YR Sulfamethazine Approved T88240 DRUGINFO D07PAO Sulphadoxine Approved T88240 DRUGINFO D0F0OK Sulfametopyrazine Withdrawn from market T88240 DRUGINFO D00DBR 6-Methylamino-5-Nitroisocytosine Investigative T88240 DRUGINFO D01LEP 2-amino-8-methyl-7,8-dihydropteridin-4(3H)-one Investigative T88240 DRUGINFO D03GJB Pteroic Acid Investigative T88240 DRUGINFO D04TLB 2,6-diamino-5-nitrosopyrimidin-4(3H)-one Investigative T88240 DRUGINFO D0E4UI 2,6-diamino-5-nitropyrimidin-4(3H)-one Investigative T88240 DRUGINFO D0WT6A Ethylene diamine Investigative T88240 DRUGINFO D0YX4U Pterin-6-Yl-Methyl-Monophosphate Investigative T88240 DRUGINFO D03BIT [Pterin-6-Yl Methanyl]-Phosphonophosphate Investigative T88240 DRUGINFO D0D5EW HKI-9924129 Investigative T22658 TARGETID T22658 T22658 FORMERID TTDR00205 T22658 UNIPROID IL8_HUMAN T22658 TARGNAME Interleukin-8 (IL8) T22658 GENENAME CXCL8 T22658 TARGTYPE Successful T22658 SYNONYMS T-cell chemotactic factor; Protein 3-10C; Neutrophil-activating protein 1; NAP-1; Monocyte-derived neutrophil-activating peptide; Monocyte-derived neutrophil chemotactic factor; MONAP; MDNCF; IL8; IL-8; Granulocyte chemotactic protein 1; GCP-1; Emoctakin; Chemokine (C-X-C motif) ligand 8; C-X-C motif chemokine 8 T22658 FUNCTION IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively. T22658 PDBSTRUC 5WDZ; 5D14; 4XDX; 3IL8; 2IL8 T22658 BIOCLASS Cytokine: interleukin T22658 SEQUENCE MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPFHPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS T22658 DRUGINFO D0R1QE Ibuprofen Approved T22658 DRUGINFO D0BF9K ABX-IL8 Phase 2 T22658 DRUGINFO DJ2N3L BMS-986253 Phase 2 T22658 DRUGINFO D0W4HA MDX-018 Phase 1 T22658 DRUGINFO D0ZL4F R-ketoprofen Discontinued in Phase 2 T22658 DRUGINFO D05EMX 2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid Investigative T22658 DRUGINFO D08GOT 2-(2-(2-chlorophenylamino)phenyl)acetic acid Investigative T22658 DRUGINFO D0I8YN 2-(2-(2-fluorophenylamino)phenyl)acetic acid Investigative T22658 DRUGINFO D0Q8ZV 2-(2-(2-chlorophenoxy)phenyl)acetic acid Investigative T22658 DRUGINFO D0T8RL 2-(2-(2-fluorophenoxy)phenyl)acetic acid Investigative T31309 TARGETID T31309 T31309 FORMERID TTDC00319 T31309 UNIPROID BCL2_HUMAN T31309 TARGNAME Apoptosis regulator Bcl-2 (BCL-2) T31309 GENENAME BCL2 T31309 TARGTYPE Successful T31309 SYNONYMS Bcl-2 T31309 FUNCTION Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release. Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. T31309 PDBSTRUC 6GL8; 5VAY; 5VAX; 5VAU; 5JSN T31309 BIOCLASS B-cell lymphoma Bcl-2 T31309 SEQUENCE MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPAASRDPVARTSPLQTPAAPGAAAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFAEMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK T31309 DRUGINFO D00PBX GDC-0199 Approved T31309 DRUGINFO D06DLI MCI-186 Approved T31309 DRUGINFO D0C4RB Taxol Approved T31309 DRUGINFO D05RJP Oblimersen Phase 3 T31309 DRUGINFO D0I6OI RG7601 Phase 3 T31309 DRUGINFO D0J6PY Taxol/Paraplatin/Herceptin Phase 3 T31309 DRUGINFO D06ETI ABT-263 Phase 3 T31309 DRUGINFO DY4OZ6 Thymoquinone Phase 2/3 T31309 DRUGINFO D0Z0HH Gossypol Phase 2 T31309 DRUGINFO D0K8LB PI-88/Taxotere Phase 2 T31309 DRUGINFO D02OZK Obatoclax Phase 2 T31309 DRUGINFO D2Y7ZG APG-2575 Phase 1/2 T31309 DRUGINFO D4WN2M APG-1252 Phase 1/2 T31309 DRUGINFO DQ1P6X AZD0466 Phase 1/2 T31309 DRUGINFO D0C6YQ BCL201 Phase 1 T31309 DRUGINFO D0L2YF Pc4 Phase 1 T31309 DRUGINFO D74BRK BGB-11417 Phase 1 T31309 DRUGINFO DBY42T LP-108 Phase 1 T31309 DRUGINFO DJLX87 LOXO-338 Phase 1 T31309 DRUGINFO DP63FS VOB560 Phase 1 T31309 DRUGINFO D03UDW AI-850 Phase 1 T31309 DRUGINFO D05CHN Irofulven/Taxotere Phase 1 T31309 DRUGINFO D0C2DV Indole-based analog 2 Patented T31309 DRUGINFO D0IS8R PMID27744724-Compound-10 Patented T31309 DRUGINFO D0J9FN PMID27744724-Compound-21 Patented T31309 DRUGINFO D0MZ7I Indole-based analog 3 Patented T31309 DRUGINFO D0TU3N PMID27744724-Compound-18 Patented T31309 DRUGINFO D0L8WH ABT-737 Terminated T31309 DRUGINFO D04HAA WL-276 Investigative T31309 DRUGINFO D04RTY N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide Investigative T31309 DRUGINFO D06AQG 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine Investigative T31309 DRUGINFO D0S0YV modified HA14-1 compounds (cancer) Investigative T31309 DRUGINFO D0V7PX Apogossypol Investigative T31309 DRUGINFO D0X0CS 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide Investigative T31309 DRUGINFO D0D6BH 4,5-dibenzylbenzene-1,2-diol Investigative T31309 DRUGINFO D00LHS TW-37 Investigative T31309 DRUGINFO D0S6IW QEDIIRNIARHLAQVGDSMDR Investigative T57392 TARGETID T57392 T57392 FORMERID TTDS00475 T57392 UNIPROID CP2D6_HUMAN T57392 TARGNAME Debrisoquine 4-hydroxylase (CYP2D6) T57392 GENENAME CYP2D6 T57392 TARGTYPE Successful T57392 SYNONYMS P450-DB1; Cytochrome P450-DB1; Cytochrome P450 2D6; CYPIID6; CYP2DL1 T57392 FUNCTION It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants. Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. T57392 PDBSTRUC 6CSD; 6CSB; 5TFU; 5TFT; 4XRZ T57392 BIOCLASS Paired donor oxygen oxidoreductase T57392 ECNUMBER EC 1.14.14.- T57392 SEQUENCE MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPR T57392 DRUGINFO D0Z9NZ Glutethimide Approved T57392 DRUGINFO D03GNI ISOQUINE Phase 1 T57392 DRUGINFO D00AEX 2-Hexyloxy-5-imidazol-1-yl-pyridine Investigative T57392 DRUGINFO D00XOQ SB-210313 Investigative T57392 DRUGINFO D01DAU 4-(3-Pent-1-ynyl-benzyl)-1H-imidazole Investigative T57392 DRUGINFO D05ROV GNF-PF-5411 Investigative T57392 DRUGINFO D06QFO (5-(pyridin-3-yl)furan-2-yl)methanamine Investigative T57392 DRUGINFO D0C7PK (2-hydroxy-3-phenoxypropyl)(propan-2-yl)amine Investigative T57392 DRUGINFO D0FF0Z 4-(3-Phenylethynyl-benzyl)-1H-imidazole Investigative T57392 DRUGINFO D0FQ1Z GNF-PF-4292 Investigative T57392 DRUGINFO D0G8KT GBR-12289 Investigative T57392 DRUGINFO D0IM5E Desethyl isoquine Investigative T57392 DRUGINFO D0IO0I Go-Y022 Investigative T57392 DRUGINFO D0J6RQ 1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one Investigative T57392 DRUGINFO D0J9SO BS 7840 Investigative T57392 DRUGINFO D0M0IQ Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine Investigative T57392 DRUGINFO D0P2DU Prodipine Investigative T57392 DRUGINFO D0QH6F 4-methylaminomethyl-7-methoxycoumarin Investigative T57392 DRUGINFO D0S6NP Kaempferol-3-O-methyl ether Investigative T57392 DRUGINFO D0SE3C BS 7581 Investigative T57392 DRUGINFO D0X4DE GBR 12530 Investigative T57392 DRUGINFO D0YQ8U (5-phenylfuran-2-yl)methanamine Investigative T57392 DRUGINFO D0ZY7X GNF-PF-2094 Investigative T57392 DRUGINFO D0ZZ2L BS 9106 Investigative T57392 DRUGINFO D00PYW 4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine Investigative T57392 DRUGINFO D00TOF DIHYDROCUBEBIN Investigative T57392 DRUGINFO D01ARE Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine Investigative T57392 DRUGINFO D02DTR 3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine Investigative T57392 DRUGINFO D02GFK 3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine Investigative T57392 DRUGINFO D03KXT 4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine Investigative T57392 DRUGINFO D05MSG BMS-694153 Investigative T57392 DRUGINFO D07ANY 1H-1,2,3-benzotriazol-1-amine Investigative T57392 DRUGINFO D07VHB 1-(4-Butoxy-phenyl)-1H-imidazole Investigative T57392 DRUGINFO D0B0LC 2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine Investigative T57392 DRUGINFO D0C4XQ GB-12819 Investigative T57392 DRUGINFO D0G6BJ 1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX) Investigative T57392 DRUGINFO D0J4CB 1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX) Investigative T57392 DRUGINFO D0K3EW 6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX) Investigative T57392 DRUGINFO D0U7BJ 2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine Investigative T57392 DRUGINFO D0YP4A (5-pyridin-3-yl-furan-2-yl)methanethiol Investigative T57392 DRUGINFO D01RZP 4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol Investigative T57392 DRUGINFO D0M0KX 2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol Investigative T57392 DRUGINFO D0Y2RL 4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol Investigative T57392 DRUGINFO D01JXM 2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole Investigative T57392 DRUGINFO D03SAV ICI-199441 Investigative T57392 DRUGINFO D08DSJ ML-3163 Investigative T57392 DRUGINFO D0L9YP 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide Investigative T28893 TARGETID T28893 T28893 FORMERID TTDS00002 T28893 UNIPROID ACM1_HUMAN T28893 TARGNAME Muscarinic acetylcholine receptor M1 (CHRM1) T28893 GENENAME CHRM1 T28893 TARGTYPE Successful T28893 SYNONYMS M1 receptor T28893 FUNCTION Primary transducing effect is Pi turnover. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. T28893 PDBSTRUC 6OIJ; 5CXV T28893 BIOCLASS GPCR rhodopsin T28893 SEQUENCE MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISFKVNTELKTVNNYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALDYVASNASVMNLLLISFDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLAGQCYIQFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSETPGKGGGSSSSSERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEVVIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKEKKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYALCNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQC T28893 DRUGINFO D00BLL Fesoterodine fumarate Approved T28893 DRUGINFO D02LRQ Cycrimine Approved T28893 DRUGINFO D07XJM Dicyclomine Approved T28893 DRUGINFO D0B4TN Biperiden Approved T28893 DRUGINFO D0D1MA Oxyphenonium Approved T28893 DRUGINFO D0HQ6N Benztropine Approved T28893 DRUGINFO D0M0AM Glycopyrrolate Approved T28893 DRUGINFO D0NF0W Metixene Approved T28893 DRUGINFO D0OK5Q Diphemanil Methylsulfate Approved T28893 DRUGINFO D0T0LM Pirenzepine Approved T28893 DRUGINFO D0V5ZZ Propantheline Approved T28893 DRUGINFO D09GFL Trihexyphenidyl Approved T28893 DRUGINFO D0Q1BT Clidinium Approved T28893 DRUGINFO D05KZK SMT-D002 Approved T28893 DRUGINFO D0R7WU ACECLIDINE Approved T28893 DRUGINFO D0DY7W Nebracetam Phase 3 T28893 DRUGINFO D0H0UB Darotropium + 642444 Phase 3 T28893 DRUGINFO D07QAK Xanomeline tartrate Phase 2 T28893 DRUGINFO D0E0AS (S)-oxybutynin Phase 2 T28893 DRUGINFO D0K4HW N-DESMETHYLCLOZAPINE Phase 2 T28893 DRUGINFO D0L5WA SR-46559A Phase 2 T28893 DRUGINFO D0R1YL NGX-267 Phase 2 T28893 DRUGINFO D02MMF FP-1097 Phase 2 T28893 DRUGINFO D03TDW Thiopilocarpine Phase 1 T28893 DRUGINFO D04GGJ WST-057 Phase 1 T28893 DRUGINFO D04SIU MCD-386 Phase 1 T28893 DRUGINFO D07EFM Arecoline Phase 1 T28893 DRUGINFO D09BBA TAK-071 Phase 1 T28893 DRUGINFO D0FP0D AZD-6088 Phase 1 T28893 DRUGINFO D0RO8H AC-262271 Phase 1 T28893 DRUGINFO D01QXY B7-2/GM-CSF Phase 1 T28893 DRUGINFO D09AOO ANAVEX 2-73 Phase 1 T28893 DRUGINFO DZ02CQ ANAVEX 3-71 Phase 1 T28893 DRUGINFO D0FX4J Telenzepine Discontinued in Preregistration T28893 DRUGINFO D03STA Darotropium Discontinued in Phase 2 T28893 DRUGINFO D06ODM Talsaclidine fumarate Discontinued in Phase 2 T28893 DRUGINFO D0F8BS YM-796 Discontinued in Phase 2 T28893 DRUGINFO D0XE5L Rispenzepine Discontinued in Phase 2 T28893 DRUGINFO D09EEV Declopramide Discontinued in Phase 2 T28893 DRUGINFO D07MVE PD-151832 Discontinued in Phase 1/2 T28893 DRUGINFO D09FYQ Sabcomeline Discontinued in Phase 1 T28893 DRUGINFO D0D1VJ SDZ-210-086 Discontinued in Phase 1 T28893 DRUGINFO D0IE4H TAZOMELINE Discontinued in Phase 1 T28893 DRUGINFO D0JN3M ITAMELINE Discontinued in Phase 1 T28893 DRUGINFO D0J8UV AC-260584 Terminated T28893 DRUGINFO D0PZ9R WAY-132983 Terminated T28893 DRUGINFO D06ACX HIMBACINE Terminated T28893 DRUGINFO D0X8MZ Alvameline Terminated T28893 DRUGINFO D03FZG LY-593039 Investigative T28893 DRUGINFO D06BSD Bo(15)PZ Investigative T28893 DRUGINFO D08TRD hexocyclium Investigative T28893 DRUGINFO D09HXG RR(17)PZ Investigative T28893 DRUGINFO D0M2LD BQCA Investigative T28893 DRUGINFO D0Q6BG DAU-6202 Investigative T28893 DRUGINFO D0ZZ9M AF150(S) Investigative T28893 DRUGINFO D03WGD AMINOBENZTROPINE Investigative T28893 DRUGINFO D04AAV 2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione Investigative T28893 DRUGINFO D05EEV DAU-5750 Investigative T28893 DRUGINFO D09TDI CARAMIPEN Investigative T28893 DRUGINFO D0R8AZ DAU-5884 Investigative T28893 DRUGINFO D00JTE 1,1-diphenyl-2-(3-tropanyl)ethanol Investigative T28893 DRUGINFO D0H8XV R-dimethindene Investigative T28893 DRUGINFO D04XNH Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T28893 DRUGINFO D0F0BS 3alpha-(bis-chloro-phenylmethoxy)tropane Investigative T28893 DRUGINFO D0Y8UC Difluorobenztropine Investigative T28893 DRUGINFO D0Z5RQ Cremastrine Investigative T28893 DRUGINFO D01UDC Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T28893 DRUGINFO D02EXX GNF-PF-5618 Investigative T28893 DRUGINFO D02PFJ 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea Investigative T28893 DRUGINFO D05EML 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione Investigative T28893 DRUGINFO D05MDY 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one Investigative T28893 DRUGINFO D06IUC FM1-10 Investigative T28893 DRUGINFO D06VST 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one Investigative T28893 DRUGINFO D07DEY 3-(3-benzylamino)-piperidin-2-one Investigative T28893 DRUGINFO D07VZG BRL-55473 Investigative T28893 DRUGINFO D08ZTA 6-Dimethylamino-2-methyl-hex-4-ynal oxime Investigative T28893 DRUGINFO D0AR0H FM1-43 Investigative T28893 DRUGINFO D0B8AQ 7-Pyrrolidin-1-yl-hept-5-yn-2-one Investigative T28893 DRUGINFO D0C9VH N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide Investigative T28893 DRUGINFO D0C9ZE Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T28893 DRUGINFO D0O1BN SULFOARECOLINE Investigative T28893 DRUGINFO D0OE0K 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane Investigative T28893 DRUGINFO D0QL1X 7-Dimethylamino-3-methyl-hept-5-yn-2-one Investigative T28893 DRUGINFO D0R2JE N-methoxyquinuclidine-3-carboximidoyl chloride Investigative T28893 DRUGINFO D0R8FS 7-Dimethylamino-hept-5-yn-2-one Investigative T28893 DRUGINFO D0U2IL 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime Investigative T28893 DRUGINFO D0X2JU N-methoxyquinuclidine-3-carboximidoyl fluoride Investigative T28893 DRUGINFO D0HV3A FLUMEZAPINE Investigative T28893 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T28893 DRUGINFO D0F9QT A-987306 Investigative T28893 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T28893 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T09826 TARGETID T09826 T09826 FORMERID TTDNC00422 T09826 UNIPROID TOP1_HUMAN T09826 TARGNAME DNA topoisomerase I (TOP1) T09826 GENENAME TOP1 T09826 TARGTYPE Successful T09826 SYNONYMS DNA topoisomerase I T09826 FUNCTION Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component ARNTL/BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the ARNTL/BMAL1 promoter. Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. T09826 PDBSTRUC 1TL8; 1T8I; 1SEU; 1SC7; 1RRJ T09826 BIOCLASS Topoisomerase T09826 ECNUMBER EC 5.6.2.2 T09826 SEQUENCE MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKKHKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEPEDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKDKDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKFYYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKCDFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGLFRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENIQGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALYFIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNKVPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQQLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLADARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF T09826 DRUGINFO D02PMO Topotecan Approved T09826 DRUGINFO D06VYE Belotecan hydrocholoride Approved T09826 DRUGINFO D07HOB Irinotecan Approved T09826 DRUGINFO D0Z4XW Topetecan Approved T09826 DRUGINFO D04AIT B-Lactams Approved T09826 DRUGINFO D01FUC Exatecan Phase 3 T09826 DRUGINFO D09YDM Camptothecin Phase 3 T09826 DRUGINFO D0H5IZ Etirinotecan pegol Phase 3 T09826 DRUGINFO D0I1DW Edotecarin Phase 3 T09826 DRUGINFO D0Y1FO Rubitecan Phase 3 T09826 DRUGINFO DP41HV Datopotamab deruxtecan Phase 3 T09826 DRUGINFO D02CZK Karenitecin Phase 3 T09826 DRUGINFO D00BZS Gimatecan Phase 2 T09826 DRUGINFO D00XCX DIFLOMOTECAN Phase 2 T09826 DRUGINFO D02PAW TLC-388 Phase 2 T09826 DRUGINFO D05UFP PEG-SN38 Phase 2 T09826 DRUGINFO D06XCF EQ-917 Phase 2 T09826 DRUGINFO D07UHX 9-AMINOCAMPTOTHECIN Phase 2 T09826 DRUGINFO D0B6YB LE-SN38 Phase 2 T09826 DRUGINFO D0D4CX Pegamotecan Phase 2 T09826 DRUGINFO D0K0IS Polyglutamate camptothecin Phase 2 T09826 DRUGINFO D0M6BA AR-67 Phase 2 T09826 DRUGINFO D0ND9T CRLX101 Phase 2 T09826 DRUGINFO D0U6ML CKD602 Phase 2 T09826 DRUGINFO D0W0VD Beta-Lapachone Phase 2 T09826 DRUGINFO DX5A8D Patritumab deruxtecan Phase 2 T09826 DRUGINFO D08EES XR-5000 Phase 2 T09826 DRUGINFO D0RS4X PEN-866 Phase 1/2 T09826 DRUGINFO DT8R1L DS-7300 Phase 1/2 T09826 DRUGINFO D04TIJ Namitecan Phase 1 T09826 DRUGINFO D05GUK INTOPLICINE Phase 1 T09826 DRUGINFO D07PMG Afeletecan Phase 1 T09826 DRUGINFO D09CZS DRF-1042 Phase 1 T09826 DRUGINFO D0A1LS Genz-644282 Phase 1 T09826 DRUGINFO D0BW2N GZ402674 Phase 1 T09826 DRUGINFO D0E1VV ELOMOTECAN HYDROCHLORIDE Phase 1 T09826 DRUGINFO D0K6QU IT-141 Phase 1 T09826 DRUGINFO D0U0BP DFP 13318 Phase 1 T09826 DRUGINFO D0Z5VG CZ-48 Phase 1 T09826 DRUGINFO D0Z7FK XMT-1001 Phase 1 T09826 DRUGINFO DD90AS DAN-222 Phase 1 T09826 DRUGINFO DDXH71 LMP744 Phase 1 T09826 DRUGINFO DV3WF1 LMP400 Phase 1 T09826 DRUGINFO D07BXE Daniquidone Phase 1 T09826 DRUGINFO D07DAU Tafluposide Phase 1 T09826 DRUGINFO D0Y1GJ MLN-576 Phase 1 T09826 DRUGINFO DJ4X7D DS-6157 Phase 1 T09826 DRUGINFO D0P4KU ABI-011 Phase 1 T09826 DRUGINFO D0M8KY (S)-DRF-1042 Clinical trial T09826 DRUGINFO D0N1FR BECATECARIN Discontinued in Phase 3 T09826 DRUGINFO D05ZQV NK-611 Discontinued in Phase 2 T09826 DRUGINFO D07YCR S-16020-2 Discontinued in Phase 2 T09826 DRUGINFO D08ODH Atiratecan Discontinued in Phase 2 T09826 DRUGINFO D0Q7FC Lurtotecan Discontinued in Phase 2 T09826 DRUGINFO D0H2DN DE-310 Discontinued in Phase 1 T09826 DRUGINFO D06UFH CZ-112 Terminated T09826 DRUGINFO D0B3CT BE-13793C Terminated T09826 DRUGINFO D0G9RW TAN-1496 Terminated T09826 DRUGINFO D0J7AI BN-80245 Terminated T09826 DRUGINFO D0OH5V PIROXANTRONE Terminated T09826 DRUGINFO D0T6VU ED-110 Terminated T09826 DRUGINFO D0T7WQ Datelliptium chloride Terminated T09826 DRUGINFO D00QTU TH-1320 Investigative T09826 DRUGINFO D00SSW 7-amino-4-hydroxy-2-naphthalenesulfonic acid Investigative T09826 DRUGINFO D01EGN 4-(4,6-diphenylpyridin-2-yl)phenol Investigative T09826 DRUGINFO D01ILT CRISNATOL MESILATE Investigative T09826 DRUGINFO D01JEX ROSETTACIN Investigative T09826 DRUGINFO D01QKX (5Z,9Z)-5,9-heptacosadienoic acid Investigative T09826 DRUGINFO D02MMY 2,3-Dimethoxybenzo[i]phenanthridines Investigative T09826 DRUGINFO D02VPC 5-hydroxy-1H-indole-3-acetic acid Investigative T09826 DRUGINFO D03QAS E-758 Investigative T09826 DRUGINFO D03RLA Nogalamycin Investigative T09826 DRUGINFO D04DJM 4-hydroxysaprothoquinone Investigative T09826 DRUGINFO D04VPP ATI-1150 Investigative T09826 DRUGINFO D06VGG KT6528 Investigative T09826 DRUGINFO D07ILP 10-hydroxycamptothecin Investigative T09826 DRUGINFO D07VJK IDN-6384 Investigative T09826 DRUGINFO D08VGL KT6006 Investigative T09826 DRUGINFO D0A6NP A35566-A Investigative T09826 DRUGINFO D0C0AA DTS-108 Investigative T09826 DRUGINFO D0DW4J Dibenzo-p-dioxin-2-carboxylic acid Investigative T09826 DRUGINFO D0E6QI MEN-14295 Investigative T09826 DRUGINFO D0G8ZX Homocamptothecins (hCPTs) Investigative T09826 DRUGINFO D0I6EJ 3-(4-phenyl-2,4'-bipyridin-6-yl)phenol Investigative T09826 DRUGINFO D0K0WK NSC-341622 Investigative T09826 DRUGINFO D0M0WX 3-(6-phenyl-2,4'-bipyridin-4-yl)phenol Investigative T09826 DRUGINFO D0N0VW IDN-5174 Investigative T09826 DRUGINFO D0RL8X CHO793076 Investigative T09826 DRUGINFO D0TH1I 4-(6-phenyl-2,4'-bipyridin-4-yl)phenol Investigative T09826 DRUGINFO D0Y6OK Quinizarin Investigative T09826 DRUGINFO D0Z1VE SER-203 Investigative T09826 DRUGINFO D00WYS 3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol Investigative T09826 DRUGINFO D03JZQ 3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol Investigative T09826 DRUGINFO D0MI5C 3,3'-(4-phenylpyridine-2,6-diyl)diphenol Investigative T09826 DRUGINFO D0L8BN TOPOSTATIN Investigative T72841 TARGETID T72841 T72841 FORMERID TTDR00270 T72841 UNIPROID ERR1_HUMAN T72841 TARGNAME Estrogen-related receptor-alpha (ESRRA) T72841 GENENAME ESRRA T72841 TARGTYPE Successful T72841 SYNONYMS Nuclear receptor subfamily 3 group B member 1; NR3B1; Estrogen-relatedreceptor, alpha; Estrogen-relatedreceptor alpha; Estrogen-related receptor alpha; Estrogen receptor-like 1; ESRL1; ERRalpha; ERR1; ERR-alpha T72841 FUNCTION Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces the expression of PERM1 in the skeletal muscle. Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'. T72841 PDBSTRUC 3K6P; 3D24; 2PJL; 1XB7 T72841 BIOCLASS Nuclear hormone receptor T72841 SEQUENCE MSSQVVGIEPLYIKAEPASPDSPKGSSETETEPPVALAPGPAPTRCLPGHKEEEDGEGAGPGEQGGGKLVLSSLPKRLCLVCGDVASGYHYGVASCEACKAFFKRTIQGSIEYSCPASNECEITKRRRKACQACRFTKCLRVGMLKEGVRLDRVRGGRQKYKRRPEVDPLPFPGPFPAGPLAVAGGPRKTAAPVNALVSHLLVVEPEKLYAMPDPAGPDGHLPAVATLCDLFDREIVVTISWAKSIPGFSSLSLSDQMSVLQSVWMEVLVLGVAQRSLPLQDELAFAEDLVLDEEGARAAGLGELGAALLQLVRRLQALRLEREEYVLLKALALANSDSVHIEDAEAVEQLREALHEALLEYEAGRAGPGGGAERRRAGRLLLTLPLLRQTAGKVLAHFYGVKLEGKVPMHKLFLEMLEAMMD T72841 DRUGINFO D0D2TN Rimexolone Approved T72841 DRUGINFO D0B4RU Pregnenolone Phase 4 T72841 DRUGINFO D0W8CW D-5519 Phase 3 T72841 DRUGINFO D07MME Dexamethasone palmitate Phase 1/2 T72841 DRUGINFO D09UGP RPR-106541 Discontinued in Phase 2 T72841 DRUGINFO D0G9FP Rofleponide Discontinued in Phase 2 T72841 DRUGINFO D06YFO AD-121 Discontinued in Phase 1/2 T72841 DRUGINFO D01EDO GW-250495 Discontinued in Phase 1 T72841 DRUGINFO D02WUW PLD-177 Terminated T72841 DRUGINFO D03RZM Steroid hormone conjugates Terminated T72841 DRUGINFO D00QDE 7-bromo-6H-chromeno[4,3-b]quinoline-3,9-diol Investigative T72841 DRUGINFO D01MFT chlordane Investigative T72841 DRUGINFO D06PFK TDT-044 Investigative T72841 DRUGINFO D07XJC 7-ethyl-6H-chromeno[4,3-b]quinoline-3,9-diol Investigative T72841 DRUGINFO D0E7RI PMID17556356C1a Investigative T72841 DRUGINFO D0I1AF 7-vinyl-6H-chromeno[4,3-b]quinoline-3,9-diol Investigative T72841 DRUGINFO D0LV7F NCX-1047 Investigative T72841 DRUGINFO D0RD6G 7-ethynyl-6H-chromeno[4,3-b]quinoline-3,9-diol Investigative T72841 DRUGINFO D0W1YT 7-chloro-6H-chromeno[4,3-b]quinoline-3,9-diol Investigative T72841 DRUGINFO D0X6OV toxaphene Investigative T72841 DRUGINFO D0ZB7Z XCT790 Investigative T72841 DRUGINFO D01TUB 4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T72841 DRUGINFO D03CBX 4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T72841 DRUGINFO D08SJL 4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T72841 DRUGINFO D09FWS 4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Investigative T72841 DRUGINFO D0K7HR 2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol Investigative T72841 DRUGINFO D0S9YX biochanin A Investigative T72841 DRUGINFO D0SY2M daidzein Investigative T73215 TARGETID T73215 T73215 FORMERID TTDS00268 T73215 UNIPROID CD20_HUMAN T73215 TARGNAME Leukocyte surface antigen Leu-16 (CD20) T73215 GENENAME MS4A1 T73215 TARGTYPE Successful T73215 SYNONYMS Membrane-spanning 4-domains subfamily A member 1; Leu-16; Bp35; B-lymphocyte surface antigen B1; B-lymphocyte antigen CD20 T73215 FUNCTION Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. T73215 PDBSTRUC 3PP4; 3BKY; 2OSL; 1S8B T73215 BIOCLASS CD20 calcium channel T73215 SEQUENCE MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP T73215 DRUGINFO D01TVQ Ibritumomab Approved T73215 DRUGINFO D09EXD Rituximab Approved T73215 DRUGINFO D0A8GM Ublituximab Approved T73215 DRUGINFO D0I2AV Tositumomab Approved T73215 DRUGINFO D0S8WA Obinutuzumab Approved T73215 DRUGINFO D0Y8ZN Ofatumumab Approved T73215 DRUGINFO D0YM7U Rituximab Approved T73215 DRUGINFO D0YV4F Ocrelizumab Approved T73215 DRUGINFO D0IM6T Tisagenlecleucel Approved T73215 DRUGINFO D2HDB8 Mosunetuzumab Approved T73215 DRUGINFO DB4M9J Epcoritamab Approved T73215 DRUGINFO DKF7G0 Glofitamab Approved T73215 DRUGINFO D07PML Ublituximab + umbralisib Phase 3 T73215 DRUGINFO D0GP8N MK-8808 Phase 3 T73215 DRUGINFO D0O9DK PF-05280586 Phase 3 T73215 DRUGINFO DJ5E7O SAIT101 Phase 3 T73215 DRUGINFO D08CGU Bevacizumab + Rituximab Phase 3 T73215 DRUGINFO D03RRJ Iodine-131-tositumomab Phase 2 T73215 DRUGINFO D07NBA Veltuzumab Phase 2 T73215 DRUGINFO D0A6DY ATM AVI Phase 2 T73215 DRUGINFO D0AU2T REGN1979 Phase 2 T73215 DRUGINFO D0KA9L AME-133v Phase 2 T73215 DRUGINFO D0KX6E DI-Leu16-IL2 Phase 2 T73215 DRUGINFO D0M6GC TRU-015 Phase 2 T73215 DRUGINFO D0OR6L CAR-T cells targeting CD20 Phase 2 T73215 DRUGINFO D0W9QG SBI-087 Phase 2 T73215 DRUGINFO D0Y3HP CD20 CAR T cells Phase 2 T73215 DRUGINFO DZNH43 MT-3724 Phase 2 T73215 DRUGINFO DDIO36 Odronextamab Phase 2 T73215 DRUGINFO DLM8G6 Plamotamab Phase 2 T73215 DRUGINFO D00FIO Anti-CD20-CAR-transduced T cells Phase 1/2 T73215 DRUGINFO D05PZI MB-CART20.1 Phase 1/2 T73215 DRUGINFO D09GSV FBT-A05 Phase 1/2 T73215 DRUGINFO D0E0RP CART20 Phase 1/2 T73215 DRUGINFO D0Q0RX CD20-Specific CAR T Cells Phase 1/2 T73215 DRUGINFO D0V6VD Anti-CD20-CAR vector-transduced autologous T cells Phase 1/2 T73215 DRUGINFO DT6EN8 PBCAR20A Phase 1/2 T73215 DRUGINFO D03ZCH 4SCAR19 and 4SCAR20 Phase 1/2 T73215 DRUGINFO D04GIO Anti-CD19 and Anti-CD20 CAR-T Cells Phase 1/2 T73215 DRUGINFO D0MA4O Anti-CD20 CAR-T cells Phase 1/2 T73215 DRUGINFO D0QB1O CD19 and CD20 CAR-T Cells Phase 1/2 T73215 DRUGINFO D9OMQ3 GEN3013 Phase 1/2 T73215 DRUGINFO D01SXH CD20-CAR-T Cells Phase 1 T73215 DRUGINFO D05YQL BM-ca Phase 1 T73215 DRUGINFO D0A0UU RG7828 Phase 1 T73215 DRUGINFO D0E8ZL CD20-CART Phase 1 T73215 DRUGINFO D0FL5S CART-20 cells Phase 1 T73215 DRUGINFO D0L2JE XmAb13676 Phase 1 T73215 DRUGINFO D7X8CB RG6035 Phase 1 T73215 DRUGINFO D07TCV Anti-CD19 anti-CD20 Bispecific CAR-T Phase 1 T73215 DRUGINFO D0NU9L CAR-20/19-T Cells Phase 1 T73215 DRUGINFO D0TW3L CD20Bi aATC Phase 1 T73215 DRUGINFO D51HBQ CD20-CD19 cCAR Phase 1 T73215 DRUGINFO DI6BK9 KITE-363 Phase 1 T73215 DRUGINFO DN91RC IGM-2323 Phase 1 T73215 DRUGINFO D0J2VB Iboctadekin + rituximab Phase 1 T73215 DRUGINFO D0NL9N Anti-CD19/20-CAR vector-transduced T cells Clinical trial T73215 DRUGINFO DY2EJ1 ATA2431 Preclinical T73215 DRUGINFO D00GLQ 2LM20-4 Investigative T73215 DRUGINFO D00RTU 227Th-rituximab Investigative T73215 DRUGINFO D05QGH DXL-625 Investigative T73215 DRUGINFO D08CWX BVX-20-CD20 Investigative T73215 DRUGINFO D08KAL MEDI-552 Investigative T73215 DRUGINFO D0K9HF BLX-301 Investigative T73215 DRUGINFO D0S4OH Anti-CD20 engineered toxin bodies Investigative T73215 DRUGINFO D0SN8K Anti-CD-20 mab Investigative T89360 TARGETID T89360 T89360 FORMERID TTDS00063 T89360 UNIPROID IMDH2_HUMAN T89360 TARGNAME Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) T89360 GENENAME IMPDH2 T89360 TARGTYPE Successful T89360 SYNONYMS IMPDH-II; IMPDH 2; IMPD2; IMPD 2; IMP dehydrogenase 2 T89360 FUNCTION Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumors. Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. T89360 PDBSTRUC 6I0O; 6I0M; 1NFB; 1NF7; 1B3O T89360 BIOCLASS CH-OH donor oxidoreductase T89360 ECNUMBER EC 1.1.1.205 T89360 SEQUENCE MADYLISGGTSYVPDDGLTAQQLFNCGDGLTYNDFLILPGYIDFTADQVDLTSALTKKITLKTPLVSSPMDTVTEAGMAIAMALTGGIGFIHHNCTPEFQANEVRKVKKYEQGFITDPVVLSPKDRVRDVFEAKARHGFCGIPITDTGRMGSRLVGIISSRDIDFLKEEEHDCFLEEIMTKREDLVVAPAGITLKEANEILQRSKKGKLPIVNEDDELVAIIARTDLKKNRDYPLASKDAKKQLLCGAAIGTHEDDKYRLDLLAQAGVDVVVLDSSQGNSIFQINMIKYIKDKYPNLQVIGGNVVTAAQAKNLIDAGVDALRVGMGSGSICITQEVLACGRPQATAVYKVSEYARRFGVPVIADGGIQNVGHIAKALALGASTVMMGSLLAATTEAPGEYFFSDGIRLKKYRGMGSLDAMDKHLSSQNRYFSEADKIKVAQGVSGAVQDKGSIHKFVPYLIAGIQHSCQDIGAKSLTQVRAMMYSGELKFEKRTSSAQVEGGVHSLHSYEKRLF T89360 DRUGINFO D04FBR Mycophenolate mofetil Approved T89360 DRUGINFO D09HTY Urea and carbamate bioisostere derivative 1 Patented T89360 DRUGINFO D00FPG 1-methyl-1H-indole-3-carboxamide Investigative T89360 DRUGINFO D02YMQ 6-phenyl-3-(pyridin-4-yl)-1H-indole Investigative T89360 DRUGINFO D03HDS C4-MAD Investigative T89360 DRUGINFO D04LRN 2-Benzyl-6-methoxy-5-oxazol-5-yl-1H-indole Investigative T89360 DRUGINFO D05AJZ 6-bromo-1-methyl-3-(pyridin-4-yl)-1H-indole Investigative T89360 DRUGINFO D05SKE 6-bromo-3-(pyridin-4-yl)-1H-indole Investigative T89360 DRUGINFO D06FSR 1-methyl-1H-indole-3-carbonitrile Investigative T89360 DRUGINFO D06RQV 2-methyl-3-(pyridin-4-yl)-1H-indol-6-amine Investigative T89360 DRUGINFO D07HZQ Selenazole-4-Carboxyamide-Adenine Dinucleotide Investigative T89360 DRUGINFO D08OSM 3-(furan-3-yl)-1H-indole Investigative T89360 DRUGINFO D0A0UW 6-Methoxy-5-oxazol-5-yl-2-phenyl-1H-indole Investigative T89360 DRUGINFO D0A4AL C2-MAD Investigative T89360 DRUGINFO D0AL2E 3-(pyridin-4-yl)-1H-indol-7-amine Investigative T89360 DRUGINFO D0D1KZ 1-methyl-1H-indole-3-carbaldehyde Investigative T89360 DRUGINFO D0D2ST 2-methyl-3-(pyridin-4-yl)-1H-indole Investigative T89360 DRUGINFO D0G3BY 3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea Investigative T89360 DRUGINFO D0H1II 1-(3-cyano-1-methyl-1H-indol-6-yl)-3-phenylurea Investigative T89360 DRUGINFO D0J9OS 3-(furan-3-yl)-1-methyl-1H-indole Investigative T89360 DRUGINFO D0K4EM 3-(pyridin-4-yl)-1H-indol-6-amine Investigative T89360 DRUGINFO D0L0MJ Rockout Investigative T89360 DRUGINFO D0L0ZP 3-methoxy-4-(oxazol-5-yl)aniline Investigative T89360 DRUGINFO D0Q3WC 1-methoxy-3-(3-(pyridin-4-yl)-1H-indol-6-yl)urea Investigative T89360 DRUGINFO D0V0YP 3-(thiophen-3-yl)-1H-indol-6-amine Investigative T89360 DRUGINFO D0Z0YB N-benzyl-9-oxo-9,10-dihydroacridine-3-carboxamide Investigative T89360 DRUGINFO D0ZG3O Ethyl 3-(pyridin-4-yl)-1H-indole-6-carboxylate Investigative T89360 DRUGINFO D01LDQ Mycophenolic hydroxamic acid Investigative T89360 DRUGINFO D0S4BK Tiazofurin adenine dinucleotide Investigative T89360 DRUGINFO D0T4UE Mycophenolic bis(sulfonamide) Investigative T89360 DRUGINFO D0VD5N 6-Chloropurine Riboside, 5'-Monophosphate Investigative T89360 DRUGINFO D0H2YT Inosinic Acid Investigative T89360 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T82146 TARGETID T82146 T82146 FORMERID TTDS00075 T82146 UNIPROID RARG_HUMAN T82146 TARGNAME Retinoic acid receptor gamma (RARG) T82146 GENENAME RARG T82146 TARGTYPE Successful T82146 SYNONYMS RAR-gamma; Nuclear receptor subfamily 1 group B member 3; NR1B3 T82146 FUNCTION Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. Required for limb bud development. In concert with RARA or RARB, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). T82146 PDBSTRUC 6FX0; 5M24; 4LBD; 3LBD; 2LBD T82146 BIOCLASS Nuclear hormone receptor T82146 SEQUENCE MATNKERLFAAGALGPGSGYPGAGFPFAFPGALRGSPPFEMLSPSFRGLGQPDLPKEMASLSVETQSTSSEEMVPSSPSPPPPPRVYKPCFVCNDKSSGYHYGVSSCEGCKGFFRRSIQKNMVYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKEAVRNDRNKKKKEVKEEGSPDSYELSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCIIKIVEFAKRLPGFTGLSIADQITLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVDKLQEPLLEALRLYARRRRPSQPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLENPEMFEDDSSQPGPHPNASSEDEVPGGQGKGGLKSPA T82146 DRUGINFO D06FOU Trifarotene Approved T82146 DRUGINFO D0BM5G Tazarotene Approved T82146 DRUGINFO D0H8OH Palovarotene Approved T82146 DRUGINFO D02DGU Tretinoin Approved T82146 DRUGINFO D0G3PI Alitretinoin Approved T82146 DRUGINFO D01OYE PMID27336223-Compound-13 Patented T82146 DRUGINFO D09YFJ PMID27336223-Compound-12 Patented T82146 DRUGINFO D0MC3J PMID27336223-Compound-14 Patented T82146 DRUGINFO D0W8JK PMID27336223-Compound-11 Patented T82146 DRUGINFO D0YP0T PMID27336223-Compound-15 Patented T82146 DRUGINFO D0ZQ0X PMID27336223-Compound-9 Patented T82146 DRUGINFO D05DWG Dodecyl-Alpha-D-Maltoside Investigative T82146 DRUGINFO D06RAM MM 11253 Investigative T82146 DRUGINFO D0A6NQ AHPN Investigative T82146 DRUGINFO D0E3SB SR11254 Investigative T82146 DRUGINFO D0M3LK BMS270394 Investigative T82146 DRUGINFO D0O6QU CD564 Investigative T82146 DRUGINFO D0OM2S BMS184394 Investigative T82146 DRUGINFO D0Y6WJ CD2665 Investigative T82146 DRUGINFO D0F8CC CD666 Investigative T82146 DRUGINFO D0Q0IR AGN193109 Investigative T67162 TARGETID T67162 T67162 FORMERID TTDS00012 T67162 UNIPROID DRD2_HUMAN T67162 TARGNAME Dopamine D2 receptor (D2R) T67162 GENENAME DRD2 T67162 TARGTYPE Successful T67162 SYNONYMS Dopamine receptor 2; D(2) dopamine receptor T67162 FUNCTION Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. T67162 PDBSTRUC 6CM4; 5AER; 1I15 T67162 BIOCLASS GPCR rhodopsin T67162 SEQUENCE MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVFGNVLVCMAVSREKALQTTTNYLIVSLAVADLLVATLVMPWVVYLEVVGEWKFSRIHCDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNNADQNECIIANPAFVVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVNTKRSSRAFRAHLRAPLKGNCTHPEDMKLCTVIMKSNGSFPVNRRRVEAARRAQELEMEMLSSTSPPERTRYSPIPPSHHQLTLPDPSHHGLHSTPDSPAKPEKNGHAKDHPKIAKIFEIQTMPNGKTRTSLKTMSRRKLSQQKEKKATQMLAIVLGVFIICWLPFFITHILNIHCDCNIPPVLYSAFTWLGYVNSAVNPIIYTTFNIEFRKAFLKILHC T67162 DRUGINFO D00HHS Pseudoephedrine Approved T67162 DRUGINFO D00KHM Pimozide Approved T67162 DRUGINFO D01AZG Risperidone Approved T67162 DRUGINFO D01JUF Phentolamine Approved T67162 DRUGINFO D01QML Carphenazine Approved T67162 DRUGINFO D01SAT Bevantolol Approved T67162 DRUGINFO D01ZII Chlorpromazine Approved T67162 DRUGINFO D02HED Perphenazine Approved T67162 DRUGINFO D03CJL Droperidol Approved T67162 DRUGINFO D03ELL Amisulpride Approved T67162 DRUGINFO D03QGM Sulpiride Approved T67162 DRUGINFO D03RZV Tolazoline Approved T67162 DRUGINFO D04AAN Mesoridazine Approved T67162 DRUGINFO D04EGX Cabergoline Approved T67162 DRUGINFO D04EYC Metaraminol Approved T67162 DRUGINFO D06YFA Bromocriptine Approved T67162 DRUGINFO D07JWT Perazine Approved T67162 DRUGINFO D08HVR Levodopa Approved T67162 DRUGINFO D08VYV Metoclopramide Approved T67162 DRUGINFO D09LZT Levomepromazine Approved T67162 DRUGINFO D09OQV N-0923 Approved T67162 DRUGINFO D09TPF Molindone Approved T67162 DRUGINFO D0AO6B Piperacetazine Approved T67162 DRUGINFO D0AV3G Domperidone Approved T67162 DRUGINFO D0B0CP Chlorprothixene Approved T67162 DRUGINFO D0B2UZ Prochlorperazine Approved T67162 DRUGINFO D0BA6T Methyldopa Approved T67162 DRUGINFO D0C1IW Ergonovine Approved T67162 DRUGINFO D0D1AL Haloperidol Approved T67162 DRUGINFO D0E0LQ Thiothixene Approved T67162 DRUGINFO D0G1OZ Mephentermine Approved T67162 DRUGINFO D0H3HM Aripiprazole Approved T67162 DRUGINFO D0H6QU Apomorphine Approved T67162 DRUGINFO D0H7KF Quetiapine Approved T67162 DRUGINFO D0I8LU Zuclopenthixol Approved T67162 DRUGINFO D0IN7I Nemonapride Approved T67162 DRUGINFO D0K2TB Docarpamine Approved T67162 DRUGINFO D0L0MB Acetophenazine Approved T67162 DRUGINFO D0LG8E Ephedrine Approved T67162 DRUGINFO D0O6IU Phenylephrine Approved T67162 DRUGINFO D0O6IZ Naphazoline Approved T67162 DRUGINFO D0Q9ON Denopamine Approved T67162 DRUGINFO D0T2IA Dapiprazole Approved T67162 DRUGINFO D0T7OW Dopamine Approved T67162 DRUGINFO D0U1OE Thioridazine Approved T67162 DRUGINFO D0U5FS Fluspirilene Approved T67162 DRUGINFO D0U5OE Loxapine Approved T67162 DRUGINFO D0U9QU Ibopamine hci Approved T67162 DRUGINFO D0V3ZA Dihydroergotamine Approved T67162 DRUGINFO D0V4QS Olanzapine Approved T67162 DRUGINFO D0V7XF Dopexamine Approved T67162 DRUGINFO D0W9ZF Quinagolide Approved T67162 DRUGINFO D0X2DK Phenoxybenzamine Approved T67162 DRUGINFO D0X7KB Lisuride Approved T67162 DRUGINFO D0Y0ER Thiethylperazine Approved T67162 DRUGINFO D01QGX Lurasidone hydrochloride Approved T67162 DRUGINFO D02DPU Aniracetam Approved T67162 DRUGINFO D02LCR Tiapride Approved T67162 DRUGINFO D04JCN Pergolide Approved T67162 DRUGINFO D05XGO Cariprazine Approved T67162 DRUGINFO D07MEH Meglitinides Approved T67162 DRUGINFO D0G8NN Pramipexole Approved T67162 DRUGINFO D0M8VE Iloperidone Approved T67162 DRUGINFO D0P0OU OPC-34712 Approved T67162 DRUGINFO D0P6UB Methamphetamine Approved T67162 DRUGINFO D0R1JV Ziprasidone Approved T67162 DRUGINFO D0R9EQ Ropinirole Approved T67162 DRUGINFO D0SP3D Dihydroergotoxine Approved T67162 DRUGINFO D1CWL0 lumateperone tosylate Approved T67162 DRUGINFO D0KS6W Phenyltoloxamine Approved T67162 DRUGINFO D0Y7XC Talipexole Phase 4 T67162 DRUGINFO D04NPR Lu AF35700 Phase 3 T67162 DRUGINFO D07GJZ CQA 206-291 Phase 3 T67162 DRUGINFO D07YVK Sumanirole Phase 3 T67162 DRUGINFO D0F4SY Pridopidine Phase 3 T67162 DRUGINFO D0O5TR RBP-7000 Phase 3 T67162 DRUGINFO DB6IM8 esamisulpride Phase 3 T67162 DRUGINFO D05UAV Bis(olanzapine) pamoate monohydrate Phase 3 T67162 DRUGINFO D08GJH Blonanserin Phase 3 T67162 DRUGINFO D0R2NE Entacapone+levodopa+carbidopa Phase 3 T67162 DRUGINFO D01NKW P2B-001 Phase 3 T67162 DRUGINFO D02YVM Zicronapine Phase 3 T67162 DRUGINFO D0W5EH Sarizotan Phase 2/3 T67162 DRUGINFO D01GEB ROXINDOLE Phase 2 T67162 DRUGINFO D02UJD PD-143188 Phase 2 T67162 DRUGINFO D06MNF Pardoprunox Phase 2 T67162 DRUGINFO D09QAD CGS-15873A Phase 2 T67162 DRUGINFO D0C8PE JNJ-37822681 Phase 2 T67162 DRUGINFO D0P3SJ XP-21279 Phase 2 T67162 DRUGINFO D0T1HE APD-403 Phase 2 T67162 DRUGINFO D0XE0X Aplindore fumarate Phase 2 T67162 DRUGINFO D04FNQ BIM23A760 Phase 2 T67162 DRUGINFO D04JZP Mazapertine succinate Phase 2 T67162 DRUGINFO D04VHK CLR-3001 Phase 2 T67162 DRUGINFO D08FKX SDZ-MAR-327 Phase 2 T67162 DRUGINFO D0L6OA BL-1020 Phase 2 T67162 DRUGINFO D2L8NT TBR-760 Phase 2 T67162 DRUGINFO DD5VO3 TAK-906 Phase 2 T67162 DRUGINFO DS31JZ SEP--4199 Phase 2 T67162 DRUGINFO D01FQR Ocaperidone Phase 2 T67162 DRUGINFO D07XQS ONC201 Phase 2 T67162 DRUGINFO D05XEA RP5063 Phase 2 T67162 DRUGINFO D0B9DI Lu-AE04621 Phase 1 T67162 DRUGINFO D0CH4T Lu-02-750 Phase 1 T67162 DRUGINFO D0J0WX (-)-3PPP, Maryland Phase 1 T67162 DRUGINFO D0K2PS Carmoxirole Phase 1 T67162 DRUGINFO D6P9OU ONC206 Phase 1 T67162 DRUGINFO D00ZEG Umespirone Phase 1 T67162 DRUGINFO D02JGD SKL-10406 Phase 1 T67162 DRUGINFO D0A7KI Abaperidone Phase 1 T67162 DRUGINFO D0K0GF SSR-181507 Phase 1 T67162 DRUGINFO D0N4NJ YKP-1358 Phase 1 T67162 DRUGINFO DJ2OV7 Lu AF28996 Phase 1 T67162 DRUGINFO D06NOF ATI-9242 Phase 1 T67162 DRUGINFO D0AI8V DSP-1200 Phase 1 T67162 DRUGINFO D0C7WO 1192U90 Phase 1 T67162 DRUGINFO D05KKZ PMID29334795-Compound-67 Patented T67162 DRUGINFO D0BZ0N Benzo[d]oxazol-2(3H)-one derivative 2 Patented T67162 DRUGINFO D0D5AH PMID29334795-Compound-62 Patented T67162 DRUGINFO D0N8CU Benzo[d]oxazol-2(3H)-one derivative 3 Patented T67162 DRUGINFO D0RP1J PMID29334795-Compound-66 Patented T67162 DRUGINFO D0SO4O Benzo[d]oxazol-2(3H)-one derivative 1 Patented T67162 DRUGINFO D0E7FT PMID30124346-Compound-60TABLE5 Patented T67162 DRUGINFO D0J4AZ L-piperazino-3-phenyl-indane derivative 1 Patented T67162 DRUGINFO D0M1UF Aryl piperazine derivative 1 Patented T67162 DRUGINFO D0Z9WY Aryl piperazine derivative 6 Patented T67162 DRUGINFO D09BCJ PMID30124346-Compound-34TABLE4 Patented T67162 DRUGINFO D0F4NB PMID30124346-Compound-13TABLE4 Patented T67162 DRUGINFO D01PIL Remoxipride Withdrawn from market T67162 DRUGINFO D06BPG Nomifensine Withdrawn from market T67162 DRUGINFO D0OC3J Flupenthixol Withdrawn from market T67162 DRUGINFO D0OS6O Sertindole Withdrawn from market T67162 DRUGINFO D0P3DM Fencamfamine Withdrawn from market T67162 DRUGINFO D0QU8H (S)-amisulpride Discontinued in Phase 4 T67162 DRUGINFO D0Q6SD Lamectacin Discontinued in Phase 3 T67162 DRUGINFO D01DAW Bifeprunox Discontinued in Phase 3 T67162 DRUGINFO D02ALD NOLOMIROLE HYDROCHLORIDE Discontinued in Phase 3 T67162 DRUGINFO D0C5PA Sibenadet Discontinued in Phase 3 T67162 DRUGINFO D01RCS TIOSPIRONE Discontinued in Phase 3 T67162 DRUGINFO D02JMI SLV-310 Discontinued in Phase 2 T67162 DRUGINFO D02VUX PF-217830 Discontinued in Phase 2 T67162 DRUGINFO D0K1DC Romergoline Discontinued in Phase 2 T67162 DRUGINFO D0N8NC SAVOXEPIN MESYLATE Discontinued in Phase 2 T67162 DRUGINFO D0TH1Z Naxagolide Discontinued in Phase 2 T67162 DRUGINFO D0X8QP FOSOPAMINE Discontinued in Phase 2 T67162 DRUGINFO D02KKQ BAM-1110 Discontinued in Phase 2 T67162 DRUGINFO D09EEV Declopramide Discontinued in Phase 2 T67162 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T67162 DRUGINFO D0A8FD S-18327 Discontinued in Phase 1 T67162 DRUGINFO D0OZ4F Ordopidine Discontinued in Phase 1 T67162 DRUGINFO D03ZZH SLV-313 Discontinued in Phase 1 T67162 DRUGINFO D09WHM DU-29894 Discontinued in Phase 1 T67162 DRUGINFO D0LE7P SDZ-GLC-756 Discontinued in Phase 1 T67162 DRUGINFO D0A8IE AM-831 Discontinued in Phase 1 T67162 DRUGINFO D0Q3GV S32504 Preclinical T67162 DRUGINFO D0R1PZ F-15063 Preclinical T67162 DRUGINFO D0U1CL PGX-200097 Preclinical T67162 DRUGINFO D04UXX PD-158771 Preclinical T67162 DRUGINFO D0N5NM Org-23366 Preclinical T67162 DRUGINFO D0F6WV PD-157695 Preclinical T67162 DRUGINFO D01TSN PD-128483 Terminated T67162 DRUGINFO D02ONK Y-20024 Terminated T67162 DRUGINFO D04LFG CGP-25454A Terminated T67162 DRUGINFO D05KTV NGD-93-1 Terminated T67162 DRUGINFO D07VMC LY-243062 Terminated T67162 DRUGINFO D0A7PW CP-903397 Terminated T67162 DRUGINFO D0CQ8D AMR-103 Terminated T67162 DRUGINFO D0LS4U Etrabamine Terminated T67162 DRUGINFO D0Q0HR Y-931 Terminated T67162 DRUGINFO D03NPZ NNC-22-0031 Terminated T67162 DRUGINFO D08IRR Org-10490 Terminated T67162 DRUGINFO D0G3MH PNU-96391A Terminated T67162 DRUGINFO D0N1WM A-68930 Terminated T67162 DRUGINFO D0R9PL RWJ-25730 Terminated T67162 DRUGINFO D0U4WG SLV-307 Terminated T67162 DRUGINFO D05RMW ZD-3638 Terminated T67162 DRUGINFO D0A3OF GMC-283 Terminated T67162 DRUGINFO D0EH2O BIMG80 Terminated T67162 DRUGINFO D0P3IZ E-2040 Terminated T67162 DRUGINFO D0N5UA Dianicline+rimonabant Terminated T67162 DRUGINFO D0K9JP A-80426 Terminated T67162 DRUGINFO D00CPI 1-(3-Hydroxyphenyl)-4-propylpiperazine Investigative T67162 DRUGINFO D00DHM SDZ-208911 Investigative T67162 DRUGINFO D00HHK PD-135478 Investigative T67162 DRUGINFO D01ADA N-Propyl-2-methylnorapomorphine hydrochloride Investigative T67162 DRUGINFO D01HZE BRL-25594 Investigative T67162 DRUGINFO D01KLI 1-Propyl-3-m-tolyl-piperidine hydrochloride Investigative T67162 DRUGINFO D01KWU Uinagolide Investigative T67162 DRUGINFO D01YNL PD-137789 Investigative T67162 DRUGINFO D02OEI 3-(2,3-Dimethyl-phenyl)-piperidine Investigative T67162 DRUGINFO D02RMS Ethyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine Investigative T67162 DRUGINFO D03KUH ETICLOPRIDE Investigative T67162 DRUGINFO D03TYT PF-03800130 Investigative T67162 DRUGINFO D04AAI 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperazine Investigative T67162 DRUGINFO D04HPX MCL-515 Investigative T67162 DRUGINFO D04JUJ 1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol Investigative T67162 DRUGINFO D04LWD 4-Benzyl-1-indan-2-ylmethyl-piperidine Investigative T67162 DRUGINFO D04PBD MLS1547 Investigative T67162 DRUGINFO D04ZYA 3-(Octahydro-indolizin-8-yl)-phenol Investigative T67162 DRUGINFO D05AIN 1-Benzyl-4-(3-hydroxyphenyl)piperidine Investigative T67162 DRUGINFO D05ARI Propyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine Investigative T67162 DRUGINFO D05DTJ 3-Phenyl-1-propyl-piperidine hydrochloride Investigative T67162 DRUGINFO D05EHE (S,R)-pseudoxandrine hydrochloride Investigative T67162 DRUGINFO D05GBE 3-(Octahydro-quinolizin-3-yl)-phenol Investigative T67162 DRUGINFO D05NET PD-137821 Investigative T67162 DRUGINFO D05NZI BRL-26175 Investigative T67162 DRUGINFO D05TZE SKF-89124A Investigative T67162 DRUGINFO D05XNR 2,3-Dihydro-1H-indol-5-ol Investigative T67162 DRUGINFO D06CXG PD-135540 Investigative T67162 DRUGINFO D06FUV Preclamol Investigative T67162 DRUGINFO D06GGB N-Ethyl-2-phenylnorapomorphine hydrochloride Investigative T67162 DRUGINFO D06XKX N-Propyl-2-phenylnorapomorphine hydrochloride Investigative T67162 DRUGINFO D06YYJ Bis-{[R-(-)-apomorphine-2-oxy]ethyl} ether Investigative T67162 DRUGINFO D08OUX IODOPRIDE Investigative T67162 DRUGINFO D09CFW ML321 Investigative T67162 DRUGINFO D0A3XB PD-135188 Investigative T67162 DRUGINFO D0B1FV (S,R)-isotetrandrine hydrochloride Investigative T67162 DRUGINFO D0BN9C (S)-secoantioquine hydrochloride Investigative T67162 DRUGINFO D0C6KQ IODOSULPIRIDE Investigative T67162 DRUGINFO D0C8WL EPIDEPRIDE Investigative T67162 DRUGINFO D0E3AL UNC0006 Investigative T67162 DRUGINFO D0E4JL Rotigitine Investigative T67162 DRUGINFO D0G2HT 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperidine Investigative T67162 DRUGINFO D0G5PK 3-Cyclohexyl-1-propyl-piperidine hydrochloride Investigative T67162 DRUGINFO D0G8CV SLV-314 Investigative T67162 DRUGINFO D0G8VU PD-168077 Investigative T67162 DRUGINFO D0GI7S 3-Phenyl-pyrrolidine Investigative T67162 DRUGINFO D0H2GH 3-(3,4-Dimethyl-phenyl)-1-propyl-piperidine Investigative T67162 DRUGINFO D0H2IT PD-172939 Investigative T67162 DRUGINFO D0H7RN PD-135146 Investigative T67162 DRUGINFO D0H9GP PD-135111 Investigative T67162 DRUGINFO D0J2NS Anti-D Investigative T67162 DRUGINFO D0J8RP 3-(2,3-Dimethyl-phenyl)-1-propyl-piperidine Investigative T67162 DRUGINFO D0K6QX 3-(2,6-Dimethyl-phenyl)-1-propyl-piperidine Investigative T67162 DRUGINFO D0L1IS NOR-ROEFRACTINE Investigative T67162 DRUGINFO D0L4FJ PD-135385 Investigative T67162 DRUGINFO D0L7ZD UNC9975 Investigative T67162 DRUGINFO D0L8NG (5-Methoxy-chroman-3-yl)-dipropyl-amine Investigative T67162 DRUGINFO D0M9TM 3-(3,5-Dimethyl-phenyl)-1-propyl-piperidine Investigative T67162 DRUGINFO D0MT1N N-Ethyl-2-methylnorapomorphine hydrochloride Investigative T67162 DRUGINFO D0N6FZ WS-50030 Investigative T67162 DRUGINFO D0N7WB CLR-151 Investigative T67162 DRUGINFO D0P7OB PD-172938 Investigative T67162 DRUGINFO D0Q0KD 1-Propyl-3-o-tolyl-piperidine hydrochloride Investigative T67162 DRUGINFO D0Q2MX UNC9994 Investigative T67162 DRUGINFO D0Q4BK PD-135222 Investigative T67162 DRUGINFO D0R5ZL S-(-)-sulpiride Investigative T67162 DRUGINFO D0R6LU 1-Propyl-3-p-tolyl-piperidine hydrochloride Investigative T67162 DRUGINFO D0R9KV 3-(2,5-Dimethyl-phenyl)-1-propyl-piperidine Investigative T67162 DRUGINFO D0S1GB 3-(3,4-Dimethyl-phenyl)-piperidine Investigative T67162 DRUGINFO D0U6BT Rolicyclidine Investigative T67162 DRUGINFO D0UL6I 3-(Octahydro-quinolizin-1-yl)-phenol Investigative T67162 DRUGINFO D0V3WS (S,R)-antioquine hydrochloride Investigative T67162 DRUGINFO D0VE4Z 7-(2-Dipropylamino-ethyl)-3H-benzothiazol-2-one Investigative T67162 DRUGINFO D0X3JB 1-[3-(Methylsulfonyl)phenyl]-4-propylpiperazine Investigative T67162 DRUGINFO D0X5LJ 3-(N-propylpiperidin-4-yl)phenol Investigative T67162 DRUGINFO D0Y2BL 7-(2-Amino-ethyl)-4-hydroxy-3H-benzothiazol-2-one Investigative T67162 DRUGINFO D0Y3UL 3-(3,5-Dimethyl-phenyl)-piperidine Investigative T67162 DRUGINFO D0Z4VD 3-(2,4-Dimethyl-phenyl)-1-propyl-piperidine Investigative T67162 DRUGINFO D00CDM PD 128907 Investigative T67162 DRUGINFO D00JJO 1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene Investigative T67162 DRUGINFO D00QMQ D-220 Investigative T67162 DRUGINFO D00SDJ A-706149 Investigative T67162 DRUGINFO D00VHW 4-Benzyl-1-chroman-3-ylmethyl-piperidine Investigative T67162 DRUGINFO D02RAY GLAUCINE Investigative T67162 DRUGINFO D02XXA 3-Phenyl-1-propyl-pyrrolidine Investigative T67162 DRUGINFO D03EDW D-193 Investigative T67162 DRUGINFO D03PYX [3H]7-OH-DPAT Investigative T67162 DRUGINFO D03RMB 2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol Investigative T67162 DRUGINFO D03YXB (+)-(1R,1'S)-berbamunine hydrochloride Investigative T67162 DRUGINFO D03ZOJ D-189 Investigative T67162 DRUGINFO D04GRS (S)-BULBOCAPNINE Investigative T67162 DRUGINFO D04IIK (R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine Investigative T67162 DRUGINFO D04PBA 3-(4-Benzyl-piperazin-1-yl)-phenol Investigative T67162 DRUGINFO D04RBU D-366 Investigative T67162 DRUGINFO D04TQF 1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene Investigative T67162 DRUGINFO D04TTN (+)-(1R,1'S)-thaligrisine hydrochloride Investigative T67162 DRUGINFO D04ZMS 3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one Investigative T67162 DRUGINFO D05HMW 2-(4-Dipropylamino-cyclohexylidene)-malononitrile Investigative T67162 DRUGINFO D05HWC PUKATEINE Investigative T67162 DRUGINFO D05NBK 1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol Investigative T67162 DRUGINFO D05NED D-190 Investigative T67162 DRUGINFO D05OHF (R)-(+)-coclaurine Investigative T67162 DRUGINFO D06AIQ IBZM Investigative T67162 DRUGINFO D06HTJ D-264 Investigative T67162 DRUGINFO D07ISL D-210 Investigative T67162 DRUGINFO D08DLP 3-Chloroboldine Investigative T67162 DRUGINFO D08EMG (S)APOMORPHINE Investigative T67162 DRUGINFO D08HTJ 2-methoxyapomorphine Investigative T67162 DRUGINFO D08UQU (R)-(-)-2-methoxy-11-hydroxyaporphine Investigative T67162 DRUGINFO D09AQJ D-203 Investigative T67162 DRUGINFO D09MGF 1-(benzyloxy)-2-(2-phenylethyl)benzene Investigative T67162 DRUGINFO D09PJF D-315 Investigative T67162 DRUGINFO D09QRL 2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline Investigative T67162 DRUGINFO D0A2BE CLEBOPRIDE Investigative T67162 DRUGINFO D0A4GE 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol Investigative T67162 DRUGINFO D0A7AK 3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine Investigative T67162 DRUGINFO D0B4SL D-218 Investigative T67162 DRUGINFO D0C7SE SNAP-94847 Investigative T67162 DRUGINFO D0CA9H N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide Investigative T67162 DRUGINFO D0D1PR (R)-(-)-2-methoxy-N-npropylnorapomorphine Investigative T67162 DRUGINFO D0D2CU (R)-(-)-2-Methyl-apomorphine hydrochloride Investigative T67162 DRUGINFO D0FU2V D-237 Investigative T67162 DRUGINFO D0G3MD (4-Quinolin-2-ylpiperazin-1-yl)acetic Acid Investigative T67162 DRUGINFO D0H9QG SB-258719 Investigative T67162 DRUGINFO D0HG4U (R)-(-)-2-Phenyl-apomorphine hydrochloride Investigative T67162 DRUGINFO D0HO7I ANONAINE Investigative T67162 DRUGINFO D0I7CE SK&F-89626 Investigative T67162 DRUGINFO D0M1OE ANOLOBINE Investigative T67162 DRUGINFO D0M5XV D-219 Investigative T67162 DRUGINFO D0M7SY SB269652 Investigative T67162 DRUGINFO D0M8LN A-690344 Investigative T67162 DRUGINFO D0N9DY 3-Iodoboldine Investigative T67162 DRUGINFO D0NA2T (R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine Investigative T67162 DRUGINFO D0ND8J (-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride Investigative T67162 DRUGINFO D0P4BY SCH-24518 Investigative T67162 DRUGINFO D0P6LN 3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol Investigative T67162 DRUGINFO D0P8AW Ro-21-7767 Investigative T67162 DRUGINFO D0PC2C 3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol Investigative T67162 DRUGINFO D0PV6G (+)-S-14297 Investigative T67162 DRUGINFO D0Q7FM Azaperone Investigative T67162 DRUGINFO D0R5WX 4-Benzyl-1-chroman-2-ylmethyl-piperidine Investigative T67162 DRUGINFO D0RQ8R 2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine Investigative T67162 DRUGINFO D0S5ZE D-192 Investigative T67162 DRUGINFO D0S7WZ (-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile Investigative T67162 DRUGINFO D0TA8F (S,S)-oxandrine hydrochloride Investigative T67162 DRUGINFO D0U6IL 1-Aminomethyl-isochroman-5,6-diol Investigative T67162 DRUGINFO D0V3DO 1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane Investigative T67162 DRUGINFO D0YB0K 7-trans-OH-PIPAT Investigative T67162 DRUGINFO D0Z9JY [R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether Investigative T67162 DRUGINFO D00GSD LP-211 Investigative T67162 DRUGINFO D00HUV [2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine Investigative T67162 DRUGINFO D01KIH 4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole Investigative T67162 DRUGINFO D03GES 1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine Investigative T67162 DRUGINFO D03JOS 3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole Investigative T67162 DRUGINFO D04CTN 3-(1-Propyl-pyrrolidin-3-yl)-phenol Investigative T67162 DRUGINFO D04KGP (R)-(-)-11-hydroxy-N-n-propylnoraporphine Investigative T67162 DRUGINFO D04MVL (R)-(-)-10-methyl-11-hydroxyaporphine Investigative T67162 DRUGINFO D05BCJ 1-Benzyl-4-pyrrol-1-yl-piperidine Investigative T67162 DRUGINFO D05QJK Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine Investigative T67162 DRUGINFO D06FLU 3,8-dibromoboldine Investigative T67162 DRUGINFO D06NTB 3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole Investigative T67162 DRUGINFO D06WLB Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine Investigative T67162 DRUGINFO D09BSE 3-bromoboldine Investigative T67162 DRUGINFO D0H3KU 5-OH-DPAT Investigative T67162 DRUGINFO D0IU8V 4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one Investigative T67162 DRUGINFO D0KX3X MCL-516 Investigative T67162 DRUGINFO D0LV7U 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one Investigative T67162 DRUGINFO D0M3PV L-741626 Investigative T67162 DRUGINFO D0N0LZ 3-Naphthalen-1-yl-pyrrolidine Investigative T67162 DRUGINFO D0O1PM (4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine Investigative T67162 DRUGINFO D0O9BZ 4-(4-Benzyl-piperazin-1-yl)-1H-indole Investigative T67162 DRUGINFO D0Q5IP 3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole Investigative T67162 DRUGINFO D0R3XC 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane Investigative T67162 DRUGINFO D0S1XN 4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole Investigative T67162 DRUGINFO D0S5ZY 3-Naphthalen-1-yl-1-propyl-pyrrolidine Investigative T67162 DRUGINFO D0T1TU Etoloxamine Investigative T67162 DRUGINFO D0T3IH [3H]N-methylspiperone Investigative T67162 DRUGINFO D0TU5W 4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole Investigative T67162 DRUGINFO D00CCV 1,6-bis(4-m-tolylpiperazin-1-yl)hexane Investigative T67162 DRUGINFO D03PIP 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane Investigative T67162 DRUGINFO D03XKL 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane Investigative T67162 DRUGINFO D06LQH N-propylnorapomorphine Investigative T67162 DRUGINFO D07UUQ 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine Investigative T67162 DRUGINFO D0B9DR 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine Investigative T67162 DRUGINFO D0C6BP 1,6-bis(4-phenylpiperazin-1-yl)hexane Investigative T67162 DRUGINFO D0H2WQ QUINPIROLE Investigative T67162 DRUGINFO D0I4VT 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine Investigative T67162 DRUGINFO D0LH4L BOLDINE Investigative T67162 DRUGINFO D0M2BB 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine Investigative T67162 DRUGINFO D0M2ZE UH-232 Investigative T67162 DRUGINFO D0O4BC 3-(2-Benzylamino-ethoxy)-phenol Investigative T67162 DRUGINFO D0O7DA (+)-BUTACLAMOL Investigative T67162 DRUGINFO D0V4NW N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide Investigative T67162 DRUGINFO D0W1HM nafadotride Investigative T67162 DRUGINFO D0WD6J 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine Investigative T67162 DRUGINFO D0X4PH LP-44 Investigative T67162 DRUGINFO D0Z1OF LP-12 Investigative T67162 DRUGINFO D01TOU FLUANISONE Investigative T67162 DRUGINFO D05UUW 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine Investigative T67162 DRUGINFO D06ROA UH-301 Investigative T67162 DRUGINFO D0E1RX 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine Investigative T67162 DRUGINFO D0L7OM STEPHOLIDINE Investigative T67162 DRUGINFO D0MC2R FLUTROLINE Investigative T67162 DRUGINFO D0OG0R WAY-208466 Investigative T67162 DRUGINFO D0P1XQ SEL-73 Investigative T67162 DRUGINFO D0R8UU 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine Investigative T67162 DRUGINFO D07GQP PG-01037 Investigative T67162 DRUGINFO D07GXY piribedil Investigative T67162 DRUGINFO D0D3YN OCTOCLOTHEPIN Investigative T67162 DRUGINFO D05EQG [3H]spiperone Investigative T67162 DRUGINFO D07LRJ SB-271046 Investigative T67162 DRUGINFO D0HV3A FLUMEZAPINE Investigative T67162 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T67162 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T67162 DRUGINFO D0L5MW (+/-)-nantenine Investigative T67162 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T97035 TARGETID T97035 T97035 FORMERID TTDS00373 T97035 UNIPROID TYRO_HUMAN T97035 TARGNAME Tyrosinase (TYR) T97035 GENENAME TYR T97035 TARGTYPE Successful T97035 SYNONYMS Tumor rejection antigen AB; SK29-AB; Monophenol monooxygenase; LB24-AB T97035 FUNCTION Catalyzes the initial and rate limiting step in the cascade of reactions leading to melanin production from tyrosine. In addition to hydroxylating tyrosine to DOPA (3,4-dihydroxyphenylalanine), also catalyzes the oxidation of DOPA to DOPA-quinone, and possibly the oxidation of DHI (5,6-dihydroxyindole) to indole-5,6 quinone. This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. T97035 BIOCLASS Paired donor oxygen oxidoreductase T97035 ECNUMBER EC 1.14.18.1 T97035 SEQUENCE MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGSCQNILLSNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFWGPNCTERRLLVRRNIFDLSAPEKDKFFAYLTLAKHTISSDYVIPIGTYGQMKNGSTPMFNDINIYDLFVWMHYYVSMDALLGGSEIWRDIDFAHEAPAFLPWHRLFLLRWEQEIQKLTGDENFTIPYWDWRDAEKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRLEEYNSHQSLCNGTPEGPLRRNPGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDKAANFSFRNTLEGFASPLTGIADASQSSMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLQEVYPEANAPIGHNRESYMVPFIPLYRNGDFFISSKDLGYDYSYLQDSDPDSFQDYIKSYLEQASRIWSWLLGAAMVGAVLTALLAGLVSLLCRHKRKQLPEEKQPLLMEKEDYHSLYQSHL T97035 DRUGINFO D0H6TP Monobenzone Approved T97035 DRUGINFO D03UOT Hydroquinone Approved T97035 DRUGINFO D0P5TG Multi-epitope peptide melanoma vaccine Phase 3 T97035 DRUGINFO D0U9MJ Melanoma vaccine Phase 3 T97035 DRUGINFO D0J7MQ MKC-1106-MT Phase 2 T97035 DRUGINFO D0N7FD Multi-epitope tyrosinase/gp100 vaccine Phase 2 T97035 DRUGINFO D00DSV Polynoma-1 Phase 2 T97035 DRUGINFO D00DYI Benzothiazole analog 1 Patented T97035 DRUGINFO D00EGV Monoamine derivative 2 Patented T97035 DRUGINFO D00JQA Benzimidazole derivative 3 Patented T97035 DRUGINFO D00LSQ PMID26815044-Compound-126 Patented T97035 DRUGINFO D00QVY Resorcinol compound 23 Patented T97035 DRUGINFO D00YRS PMID26815044-Compound-H Patented T97035 DRUGINFO D01CFL Benzothiazoline derivative 1 Patented T97035 DRUGINFO D01EVP Resorcinol compound 17 Patented T97035 DRUGINFO D01NJW PMID26815044-Compound-31 Patented T97035 DRUGINFO D01QYA Diamine derivative 1 Patented T97035 DRUGINFO D01RTO Polyhydroxy benzamide derivative 4 Patented T97035 DRUGINFO D01VTT P-coumaric acid derivative 6 Patented T97035 DRUGINFO D01ZCC PMID26815044-Compound-118 Patented T97035 DRUGINFO D02CXZ PMID26815044-Compound-123 Patented T97035 DRUGINFO D02EGY Aromatic hydrazine carboxyimidoamide derivative 6 Patented T97035 DRUGINFO D02JVX Resorcinol compound 7 Patented T97035 DRUGINFO D02SGL PMID26815044-Compound-49 Patented T97035 DRUGINFO D02TIY Monoamine derivative 1 Patented T97035 DRUGINFO D02WJB PMID26815044-Compound-124 Patented T97035 DRUGINFO D03BRP Aromatic hydrazine carboxyimidoamide derivative 5 Patented T97035 DRUGINFO D03FQY PMID26815044-Compound-121 Patented T97035 DRUGINFO D03KNZ Monoamine derivative 3 Patented T97035 DRUGINFO D03MKE Resorcinol compound 15 Patented T97035 DRUGINFO D03NCL Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3 Patented T97035 DRUGINFO D03PLQ Benzothiazole analog 3 Patented T97035 DRUGINFO D03PYA Cyclohexyl carbamate derivative 3 Patented T97035 DRUGINFO D03PZZ Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7 Patented T97035 DRUGINFO D04HEW PMID26815044-Compound-32 Patented T97035 DRUGINFO D04ZZM Resorcinol compound 21 Patented T97035 DRUGINFO D05NHA Resorcinol compound 20 Patented T97035 DRUGINFO D05XAH Aromatic hydrazine carboxyimidoamide derivative 4 Patented T97035 DRUGINFO D06FUM PMID26815044-Compound-114 Patented T97035 DRUGINFO D06KKO PMID26815044-Compound-50 Patented T97035 DRUGINFO D06LIQ Cyclohexyl carbamate derivative 8 Patented T97035 DRUGINFO D06LMS P-coumaric acid derivative 4 Patented T97035 DRUGINFO D06WGO Resorcinol compound 8 Patented T97035 DRUGINFO D06YKN Resorcinol compound 22 Patented T97035 DRUGINFO D07DFC Aromatic hydrazine carboxyimidoamide derivative 1 Patented T97035 DRUGINFO D07PNX PMID26815044-Compound-115 Patented T97035 DRUGINFO D07PSJ Resorcinol compound 24 Patented T97035 DRUGINFO D07RJD Resorcinol compound 2 Patented T97035 DRUGINFO D07RUH Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14 Patented T97035 DRUGINFO D07UBZ Thiazoline derivative 2 Patented T97035 DRUGINFO D08OJB Benzoic acid linked peptide analog 4 Patented T97035 DRUGINFO D09EFW Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13 Patented T97035 DRUGINFO D09JLP Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10 Patented T97035 DRUGINFO D09MHU Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6 Patented T97035 DRUGINFO D09QZB Resorcinol compound 32 Patented T97035 DRUGINFO D09VRO Cyclohexyl carbamate derivative 6 Patented T97035 DRUGINFO D09YKI Polyhydroxy benzamide derivative 1 Patented T97035 DRUGINFO D0A0RM PMID26815044-Compound-51 Patented T97035 DRUGINFO D0A2RI PMID26815044-Compound-127 Patented T97035 DRUGINFO D0A8UJ Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9 Patented T97035 DRUGINFO D0AE8D Benzothiazole analog 4 Patented T97035 DRUGINFO D0AG7M Benzoic acid linked peptide analog 6 Patented T97035 DRUGINFO D0CH3F Resorcinol compound 16 Patented T97035 DRUGINFO D0CI2U Benzoic acid linked peptide analog 3 Patented T97035 DRUGINFO D0CP6B 3-(phenoxymethyl) benzylamine derivative 5 Patented T97035 DRUGINFO D0D2JW Polyhydroxy benzamide derivative 3 Patented T97035 DRUGINFO D0DW3Z PMID26815044-Compound-93 Patented T97035 DRUGINFO D0E6LU Resorcinol compound 10 Patented T97035 DRUGINFO D0EH4P PMID26815044-Compound-117 Patented T97035 DRUGINFO D0EQ3V Resorcinol compound 4 Patented T97035 DRUGINFO D0F0VF Benzoic acid linked peptide analog 2 Patented T97035 DRUGINFO D0F3HA Cyclohexyl carbamate derivative 2 Patented T97035 DRUGINFO D0FL1E Resorcinol compound 33 Patented T97035 DRUGINFO D0FQ3D Nicotinyl hydroxamic acid derivative 1 Patented T97035 DRUGINFO D0G5CV Resorcinol compound 1 Patented T97035 DRUGINFO D0G7XW Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2 Patented T97035 DRUGINFO D0GW5H Polyhydroxy benzamide derivative 5 Patented T97035 DRUGINFO D0H0UC Resorcinol compound 12 Patented T97035 DRUGINFO D0H4LK Thiazoline derivative 1 Patented T97035 DRUGINFO D0HH4L Thiazolidine derivative 1 Patented T97035 DRUGINFO D0HO0I Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12 Patented T97035 DRUGINFO D0I3KT PMID26815044-Compound-64 Patented T97035 DRUGINFO D0IB3Z Thiazolidine derivative 3 Patented T97035 DRUGINFO D0IH6G Resorcinol compound 26 Patented T97035 DRUGINFO D0J0BB Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11 Patented T97035 DRUGINFO D0J2HH Cyclohexyl carbamate derivative 1 Patented T97035 DRUGINFO D0J4YH P-coumaric acid derivative 3 Patented T97035 DRUGINFO D0J6DS Thiazolidine derivative 2 Patented T97035 DRUGINFO D0JC3U Resorcinol compound 11 Patented T97035 DRUGINFO D0JR0P Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4 Patented T97035 DRUGINFO D0K1UO Resorcinol compound 30 Patented T97035 DRUGINFO D0K2XK PMID26815044-Compound-I Patented T97035 DRUGINFO D0K5JG Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5 Patented T97035 DRUGINFO D0K6TN Resorcinol compound 25 Patented T97035 DRUGINFO D0K7LI Resorcinol compound 31 Patented T97035 DRUGINFO D0KR9E PMID26815044-Compound-122 Patented T97035 DRUGINFO D0KU5J Resorcinol compound 5 Patented T97035 DRUGINFO D0L0CV Diamine derivative 2 Patented T97035 DRUGINFO D0L1SV Cyclohexyl carbamate derivative 4 Patented T97035 DRUGINFO D0LA2R Dihydroxyfumaric acid derivative 1 Patented T97035 DRUGINFO D0LC2G Cyclohexyl carbamate derivative 7 Patented T97035 DRUGINFO D0M4EQ PMID26815044-Compound-48 Patented T97035 DRUGINFO D0MA7A 3-(phenoxymethyl) benzylamine derivative 4 Patented T97035 DRUGINFO D0MM1Y Polyhydroxy benzamide derivative 2 Patented T97035 DRUGINFO D0MT3J Benzimidazole derivative 4 Patented T97035 DRUGINFO D0N7BW Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1 Patented T97035 DRUGINFO D0NR2A Resorcinol compound 6 Patented T97035 DRUGINFO D0O3JR P-coumaric acid derivative 1 Patented T97035 DRUGINFO D0P0PT Aromatic hydrazine carboxyimidoamide derivative 3 Patented T97035 DRUGINFO D0P6ZB Resorcinol compound 14 Patented T97035 DRUGINFO D0PI1Z Resorcinol compound 13 Patented T97035 DRUGINFO D0PN6U PMID26815044-Compound-52 Patented T97035 DRUGINFO D0Q1HU Resorcinol compound 28 Patented T97035 DRUGINFO D0Q1NF 3-(phenoxymethyl) benzylamine derivative 6 Patented T97035 DRUGINFO D0QC9I Benzoic acid linked peptide analog 1 Patented T97035 DRUGINFO D0QR0E Resorcinol compound 27 Patented T97035 DRUGINFO D0QU3G Diamine derivative 3 Patented T97035 DRUGINFO D0RC7R Resorcinol compound 9 Patented T97035 DRUGINFO D0SD9L Monoamine derivative 5 Patented T97035 DRUGINFO D0SF6C P-coumaric acid derivative 2 Patented T97035 DRUGINFO D0SJ1U Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8 Patented T97035 DRUGINFO D0SJ4S P-coumaric acid derivative 5 Patented T97035 DRUGINFO D0T7BH Resorcinol compound 34 Patented T97035 DRUGINFO D0TL2C Resorcinol compound 18 Patented T97035 DRUGINFO D0U5GU PMID26815044-Compound-125 Patented T97035 DRUGINFO D0UT0X Aromatic hydrazine carboxyimidoamide derivative 2 Patented T97035 DRUGINFO D0UT9H Cyclohexyl carbamate derivative 5 Patented T97035 DRUGINFO D0VY9O 3-(phenoxymethyl) benzylamine derivative 2 Patented T97035 DRUGINFO D0W6ZO PMID26815044-Compound-30 Patented T97035 DRUGINFO D0W8RV PMID26815044-Compound-116 Patented T97035 DRUGINFO D0WT1C Benzothiazole analog 2 Patented T97035 DRUGINFO D0X0RV PMID26815044-Compound-47 Patented T97035 DRUGINFO D0X4EC Benzoic acid linked peptide analog 5 Patented T97035 DRUGINFO D0X5VH Monoamine derivative 4 Patented T97035 DRUGINFO D0X7EQ Resorcinol compound 19 Patented T97035 DRUGINFO D0XO4I 3-(phenoxymethyl) benzylamine derivative 3 Patented T97035 DRUGINFO D0YX1C Thiazole derivative 1 Patented T97035 DRUGINFO D0Z0DX Benzothiazole analog 5 Patented T97035 DRUGINFO D0Z1LJ 3-(phenoxymethyl) benzylamine derivative 1 Patented T97035 DRUGINFO D0ZJ4M Resorcinol compound 3 Patented T97035 DRUGINFO D0ZT3U Resorcinol compound 29 Patented T97035 DRUGINFO D0Y1LO PMID29130358-Compound-Figure11(3) Patented T97035 DRUGINFO D00GRN 5-hydroxy-2-(pentylthiomethyl)-4H-pyran-4-one Investigative T97035 DRUGINFO D00LMT 1'-(4-Methyl-benzyl)-[1,4']bipiperidinyl Investigative T97035 DRUGINFO D00MPM Broussonin C Investigative T97035 DRUGINFO D00OUF 1-(3-phenoxypropyl)-4-(piperidin-1-yl)piperidine Investigative T97035 DRUGINFO D00VQZ 1-hydroxy-3-(4-nitrophenyl)urea Investigative T97035 DRUGINFO D01IFR 5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione Investigative T97035 DRUGINFO D01SLA ETHISTERONE Investigative T97035 DRUGINFO D01VOU 2,2',4,4',6'-pentahydroxychalcone Investigative T97035 DRUGINFO D02CFH PHENYLTHIOUREA Investigative T97035 DRUGINFO D02IJM DAEDALIN A Investigative T97035 DRUGINFO D02JWY SRI-224 Investigative T97035 DRUGINFO D02LHQ 3-(2,4-dihydroxyphenyl)propionic acid Investigative T97035 DRUGINFO D02PWZ N-(2,4-dihydroxybenzyl)-3,5-dihydroxybenzamide Investigative T97035 DRUGINFO D02UKE 5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione Investigative T97035 DRUGINFO D02UUK KAZINOL S Investigative T97035 DRUGINFO D02VKX 4-adamantyl resorcinol Investigative T97035 DRUGINFO D03ESC 5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol Investigative T97035 DRUGINFO D03TYV 5,5'-methylenebis(1,3,4-thiadiazole-2(3H)-thione) Investigative T97035 DRUGINFO D04KCX 5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione Investigative T97035 DRUGINFO D04QFU 2-(cyclohexylthiomethyl)-5-hydroxy-4H-pyran-4-one Investigative T97035 DRUGINFO D04QYN 5-(pyridin-4-yl)-1,3,4-oxadiazole-2(3H)-thione Investigative T97035 DRUGINFO D04WLH 5-{8(Z),11(Z)-pentadecadienyl}resorcinol Investigative T97035 DRUGINFO D04XED Crocusatin-K Investigative T97035 DRUGINFO D04ZQC 3-hydroxyphenethyl 3,4,5-trihydroxybenzoate Investigative T97035 DRUGINFO D05OML 5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione Investigative T97035 DRUGINFO D06MNV 1-(1-phenylethylidene)thiosemicarbazide Investigative T97035 DRUGINFO D06ZRX OXYRESVERATROL Investigative T97035 DRUGINFO D07DAP 4,4'-(ethane-1,2-diyl)dibenzene-1,3-diol Investigative T97035 DRUGINFO D07EFI 1-(4-Methylpent-3-en-2-ylidene)thiosemicarbazide Investigative T97035 DRUGINFO D07EGB 4-hexyl resorcinol Investigative T97035 DRUGINFO D07FKO N-(2,4-dihydroxybenzyl)-3,4,5-trihydroxybenzamide Investigative T97035 DRUGINFO D07HYL 2,4,3',5'-tetrahydroxybibenzyl Investigative T97035 DRUGINFO D07KXZ 5-phenyl-1,3,4-oxadiazole-2(3H)-thione Investigative T97035 DRUGINFO D07RGP ASKENDOSIDE B Investigative T97035 DRUGINFO D07ZAV 2-(butylthiomethyl)-5-hydroxy-4H-pyran-4-one Investigative T97035 DRUGINFO D07ZVP 1-(2,5-Dimethyl-1H-pyrrol-1-yl)thiourea Investigative T97035 DRUGINFO D08EJQ 1-hydroxy-3-(4-(trifluoromethyl)phenyl)urea Investigative T97035 DRUGINFO D08OFD 1-(1-p-tolylethylidene)thiosemicarbazide Investigative T97035 DRUGINFO D08UHS 1-(1,4-diacetylphenyl)dithiosemicarbazide Investigative T97035 DRUGINFO D08UML 1-(Butan-2-ylidene)thiosemicarbazide Investigative T97035 DRUGINFO D09FDZ 7,8,4'-trihydroxyisoflavone Investigative T97035 DRUGINFO D09OGW 4'-(4-Nitrobenzensulfonamide)-4-hydroxychalcone Investigative T97035 DRUGINFO D09SIW 2-(hexylthiomethyl)-5-hydroxy-4H-pyran-4-one Investigative T97035 DRUGINFO D09YGD 4'-(4-Aminobenzensulfonamide)-4-hydroxychalcone Investigative T97035 DRUGINFO D09YJS 2-hydroxyphenethyl 3,4,5-trihydroxybenzoate Investigative T97035 DRUGINFO D0A3QM 1-(1-(pyridin-3-yl)ethylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0A6ZK 2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one Investigative T97035 DRUGINFO D0A7WB 7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol Investigative T97035 DRUGINFO D0AZ0Y 5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol Investigative T97035 DRUGINFO D0B9IX 1-(3-Phenylallylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0BH2T 2,2',4,4'-tetrahydroxychalcone Investigative T97035 DRUGINFO D0BR1V 4'-(Benzensulfonamide)-4-hydroxychalcone Investigative T97035 DRUGINFO D0D5OG Kazinol C Investigative T97035 DRUGINFO D0D7ES 1-(4-(benzyloxy)phenyl)-3-hydroxyurea Investigative T97035 DRUGINFO D0D7GL TROPOLONE Investigative T97035 DRUGINFO D0D7KE 4'-(4-Fluorobenzensulfonamide)-4-hydroxychalcone Investigative T97035 DRUGINFO D0DU4B 1-Propylidenethiosemicarbazide Investigative T97035 DRUGINFO D0E7TO 1-(1-(4-bromophenyl)ethylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0EB9U 1-Cyclohexylidenethiosemicarbazide Investigative T97035 DRUGINFO D0EN7L 1-(But-2-enylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0F1XE 1-(3-Methylbutylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0F3CO KOJIC ACID Investigative T97035 DRUGINFO D0F6RH 2-(heptylthiomethyl)-5-hydroxy-4H-pyran-4-one Investigative T97035 DRUGINFO D0G6IO 1-(4-bromophenyl)-3-hydroxyurea Investigative T97035 DRUGINFO D0G9WX 5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione Investigative T97035 DRUGINFO D0H4YW HINOKITIOL Investigative T97035 DRUGINFO D0H5WY 5,5'-methylenebis(1,3,4-oxadiazole-2(3H)-thione) Investigative T97035 DRUGINFO D0H5XP 2-(ethylthiomethyl)-5-hydroxy-4H-pyran-4-one Investigative T97035 DRUGINFO D0HS3M 1-(1-(pyrazin-2-yl)ethylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0J5DN 7,3',4'-trihydroxyisoflavone Investigative T97035 DRUGINFO D0L3KR 2,2',4,4'-tetrahydroxy-6'-methoxychalcone Investigative T97035 DRUGINFO D0M2EN N-butylresorcinol Investigative T97035 DRUGINFO D0M4XH 1-Ethylidenethiosemicarbazide Investigative T97035 DRUGINFO D0M7LC 4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol Investigative T97035 DRUGINFO D0N3DW 5-phenyl-1,3,4-thiadiazole-2(3H)-thione Investigative T97035 DRUGINFO D0O7CX 4'-Amino-4-hydroxychalcone Investigative T97035 DRUGINFO D0O9BS S-2-(o-toluidino)-2-oxoethyl carbamothioate Investigative T97035 DRUGINFO D0OE5N 5-{8(Z),-pentadecenyl}resorcinol Investigative T97035 DRUGINFO D0OG4X 1-(1-(4-fluorophenyl)ethylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0PG8M 4',4-Dihydroxychalcone Investigative T97035 DRUGINFO D0Q5RG 1-(1-(thiophen-2-yl)ethylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0Q6UT 5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione Investigative T97035 DRUGINFO D0QS2N 3hydroxy-1-methyl-1-phenylurea Investigative T97035 DRUGINFO D0S5OR (+/-)-Daedalin A Investigative T97035 DRUGINFO D0S7TM 2,2'-bi(1,3,4-thiadiazole)-5,5'(4H,4'H)-dithione Investigative T97035 DRUGINFO D0SE1R 4'-(p-Toluenesulfonamide)-4-hydroxychalcone Investigative T97035 DRUGINFO D0T2WM N-(2,4-dihydroxybenzyl)-3,4-dihydroxybenzamide Investigative T97035 DRUGINFO D0T4WL 1-hydroxy-3-phenylurea Investigative T97035 DRUGINFO D0T7DV SODIUM ZINC DIHYDROLIPOYLHISTIDINATE Investigative T97035 DRUGINFO D0TS8S 1-Cyclopentylidenethiosemicarbazide Investigative T97035 DRUGINFO D0U1MF 3,4-dihydroxybenzaldehyde-O-ethyloxime Investigative T97035 DRUGINFO D0UN0R Kazinol F Investigative T97035 DRUGINFO D0X3SO 1-(Propan-2-ylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0X6PH 5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol Investigative T97035 DRUGINFO D0X9DP 5-hydroxy-2-(propylthiomethyl)-4H-pyran-4-one Investigative T97035 DRUGINFO D0Z1XR 2-hydroxy-5-isopropyl-2,4,6-cycloheptatrien-1-one Investigative T97035 DRUGINFO D0Z8MX 5-benzyl-1,3,4-oxadiazole-2(3H)-thione Investigative T97035 DRUGINFO D0Z9JS 1-(3-Oxocyclohexylidene)thiosemicarbazide Investigative T97035 DRUGINFO D0ZK2F Kojic acid-phenylalanine amide Investigative T97035 DRUGINFO D0ZR4M 4-hydroxyphenethyl 3,4,5-trihydroxybenzoate Investigative T97035 DRUGINFO D05PTT ROSMARINIC ACID Investigative T97035 DRUGINFO D0P8PK 6-(3-Hydroxy-phenyl)-naphthalen-2-ol Investigative T81900 TARGETID T81900 T81900 FORMERID TTDS00134 T81900 UNIPROID IDE_HUMAN T81900 TARGNAME Insulin-degrading enzyme (IDE) T81900 GENENAME IDE T81900 TARGTYPE Successful T81900 SYNONYMS Insulysin; Insulinase; Insulin protease; Abeta-degrading protease T81900 FUNCTION Substrate binding induces important conformation changes, making it possible to bind and degrade larger substrates, such as insulin. Contributes to the regulation of peptide hormone signaling cascades and regulation of blood glucose homeostasis via its role in the degradation of insulin, glucagon and IAPP. Plays a role in the degradation and clearance of APP-derived amyloidogenic peptides that are secreted by neurons and microglia. Involved in antigen processing. Produces both the N terminus and the C terminus of MAGEA3-derived antigenic peptide (EVDPIGHLY) that is presented to cytotoxic T lymphocytes by MHC class I. Plays a role in the cellular breakdown of insulin, APP peptides, IAPP peptides, glucagon, bradykinin, kallidin and other peptides, and thereby plays a role in intercellular peptide signaling. T81900 PDBSTRUC 6MQ3; 6EDS; 6BYZ; 6BFC; 6BF9 T81900 BIOCLASS Peptidase T81900 ECNUMBER EC 3.4.24.56 T81900 SEQUENCE MRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPEDKREYRGLELANGIKVLLISDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKKYPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKDREVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQELLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQLYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLVGGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAVAFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAIVSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPLEKEATPYPALIKDTAMSKLWFKQDDKFFLPKACLNFEFFSPFAYVDPLHCNMAYLYLELLKDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFEIIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLLSRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQQRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRANGIQGLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKLSAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLAREMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL T81900 DRUGINFO D0M1IO Bacitracin Approved T81900 DRUGINFO D0K6HE PRO-001 Phase 2 T81900 DRUGINFO D0E9JD quinoline 2 Investigative T81900 DRUGINFO D0N0ED NTE-2 Investigative T81900 DRUGINFO D0N9YP NTE-1 Investigative T81900 DRUGINFO D06DKB GNF-PF-4478 Investigative T72515 TARGETID T72515 T72515 FORMERID TTDS00138 T72515 UNIPROID IL1R1_HUMAN T72515 TARGNAME Interleukin 1 receptor type 1 (IL1R1) T72515 GENENAME IL1R1 T72515 TARGTYPE Successful T72515 SYNONYMS p80; Interleukin-1 receptor type I; Interleukin-1 receptor type 1; Interleukin-1 receptor alpha; IL1RT1; IL1RA; IL1R; IL-1RT1; IL-1RT-1; IL-1R-alpha; IL-1R-1; CD121a; CD121 antigen-like family member A T72515 FUNCTION Receptor for IL1A, IL1B and IL1RN. After binding to interleukin-1 associates with the coreceptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Binds ligands with comparable affinity and binding of antagonist IL1RN prevents association with IL1RAP to form a signaling complex. Involved in IL1B-mediated costimulation of IFNG production from T-helper 1 (Th1) cells. T72515 PDBSTRUC 4GAF; 4DEP; 1ITB; 1IRA; 1G0Y T72515 BIOCLASS Cytokine receptor T72515 SEQUENCE MKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKHMIGICVTLTVIIVCSVFIYKIFKIDIVLWYRDSCYDFLPIKASDGKTYDAYILYPKTVGEGSTSDCDIFVFKVLPEVLEKQCGYKLFIYGRDDYVGEDIVEVINENVKKSRRLIIILVRETSGFSWLGGSSEEQIAMYNALVQDGIKVVLLELEKIQDYEKMPESIKFIKQKHGAIRWSGDFTQGPQSAKTRFWKNVRYHMPVQRRSPSSKHQLLSPATKEKLQREAHVPLG T72515 DRUGINFO D02DES Anakinra Approved T72515 DRUGINFO D0F8DL SB 203580 Terminated T51487 TARGETID T51487 T51487 FORMERID TTDS00403 T51487 UNIPROID GBRA1_HUMAN T51487 TARGNAME GABA(A) receptor alpha-1 (GABRA1) T51487 GENENAME GABRA1 T51487 TARGTYPE Successful T51487 SYNONYMS Gamma-aminobutyric acid receptor subunit alpha-1; GABA(A) receptor subunit alpha-1 T51487 FUNCTION Ligand-gated chloride channel which is a component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the brain. Plays an important role in the formation of functional inhibitory GABAergic synapses in addition to mediating synaptic inhibition as a GABA-gated ion channel. The gamma2 subunit is necessary but not sufficient for a rapid formation of active synaptic contacts and the synaptogenic effect of this subunit is influenced by the type of alpha and beta subunits present in the receptor pentamer (By similarity). The alpha1/beta2/gamma2 receptor and the alpha1/beta3/gamma2 receptor exhibit synaptogenic activity. GABRA1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Functions also as histamine receptor and mediates cellular responses to histamine (By similarity). T51487 PDBSTRUC 6I53; 6D6U; 6D6T; 6D1S; 6CDU T51487 BIOCLASS Ligand-gated ion channel T51487 SEQUENCE MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPGLGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASKIWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHACPLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDPLIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKIDRLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ T51487 DRUGINFO D00AMQ Ethanol Approved T51487 DRUGINFO D00ETS Hexobarbital Approved T51487 DRUGINFO D00SJE Secobarbital Approved T51487 DRUGINFO D05BQK Butalbital Approved T51487 DRUGINFO D05OQJ Methyprylon Approved T51487 DRUGINFO D07SOO Methoxyflurane Approved T51487 DRUGINFO D08UMH Methylphenobarbital Approved T51487 DRUGINFO D09DWL Zaleplon Approved T51487 DRUGINFO D0A4JK Butabarbital Approved T51487 DRUGINFO D0E0WQ Barbital Approved T51487 DRUGINFO D0F0YZ Pentobarbital Approved T51487 DRUGINFO D0GA5T Indiplon Approved T51487 DRUGINFO D0KR9U Picrotoxin Approved T51487 DRUGINFO D0O3AB Butethal Approved T51487 DRUGINFO D0R6BR Amobarbital Approved T51487 DRUGINFO D0S8TD Methohexital Approved T51487 DRUGINFO D0T5WK Nitrazepam Approved T51487 DRUGINFO D0U5RT Primidone Approved T51487 DRUGINFO D03VZH Ethchlorvynol Approved T51487 DRUGINFO D0S9MC Clobazam - Lundbeck Approved T51487 DRUGINFO D0T1WN Zolpidem Approved T51487 DRUGINFO D0WB9V Barbiturate Approved T51487 DRUGINFO D0Y4AW Meprobamate Approved T51487 DRUGINFO D00VZZ Allopregnanolone approved T51487 DRUGINFO D0IG4I THIOCOLCHICOSIDE Approved T51487 DRUGINFO D07ZCK ZK-93423 Phase 3 T51487 DRUGINFO D00OVC EVT-201 Phase 2 T51487 DRUGINFO D0C9XA GSK683699 Phase 2 T51487 DRUGINFO D0B8YZ ELTANOLONE Discontinued in Phase 3 T51487 DRUGINFO D05EVI U-78875 Discontinued in Phase 1 T51487 DRUGINFO D01BCQ Divaplon Terminated T51487 DRUGINFO D0V4GI CGS-9896 Terminated T51487 DRUGINFO D00ASA 2-(3-Chloro-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D02ANG (2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid Investigative T51487 DRUGINFO D02CHG 6-Chloro-2-phenyl-chromen-4-one Investigative T51487 DRUGINFO D02HEK 1-(9H-beta-Carbolin-3-yl)-ethanone Investigative T51487 DRUGINFO D02HRB RWJ-16979 Investigative T51487 DRUGINFO D02LLU 2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one Investigative T51487 DRUGINFO D02ONZ 6-Bromo-2-(4-nitro-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D03EQH RIPAZEPAM Investigative T51487 DRUGINFO D03NWH 2-(3-Bromo-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D04JTK (6-Benzylamino-9H-beta-carbolin-3-yl)-methanol Investigative T51487 DRUGINFO D04JUH NSC-73613 Investigative T51487 DRUGINFO D04UUT 2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one Investigative T51487 DRUGINFO D04WIA 2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one Investigative T51487 DRUGINFO D04YHZ 3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium Investigative T51487 DRUGINFO D05AEG N-(9H-beta-Carbolin-3-yl)-acetamide Investigative T51487 DRUGINFO D05LXP 7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene Investigative T51487 DRUGINFO D05YQE 3-(2,2-Dimethyl-propoxy)-9H-beta-carboline Investigative T51487 DRUGINFO D06BNI (9H-beta-Carbolin-3-yl)-methanol Investigative T51487 DRUGINFO D06DTT RO-054520 Investigative T51487 DRUGINFO D06JBP Benzyl-(9H-beta-carbolin-6-yl)-amine Investigative T51487 DRUGINFO D07CUW 6-Bromo-2-(3-nitro-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D07LCC 4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline Investigative T51487 DRUGINFO D07MRF 3-Nitro-9H-beta-carboline Investigative T51487 DRUGINFO D08LJJ 6-Bromo-2-(2-nitro-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D09NNI 3-Methoxy-9H-beta-carboline Investigative T51487 DRUGINFO D09PKJ 2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline Investigative T51487 DRUGINFO D0A4UQ 6-Bromo-2-(3-bromo-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D0A6AX (9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester Investigative T51487 DRUGINFO D0AU7Y 2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one Investigative T51487 DRUGINFO D0C5XB NSC-93394 Investigative T51487 DRUGINFO D0C8CR 9H-beta-Carbolin-6-ylamine Investigative T51487 DRUGINFO D0D2NV Pyrrolidin-3-yl-acetic acid Investigative T51487 DRUGINFO D0F8AP 9H-beta-Carbolin-3-ol Investigative T51487 DRUGINFO D0K6WD (9H-beta-Carbolin-3-yl)-ethyl-amine Investigative T51487 DRUGINFO D0N9DG 3-Isopropoxy-9H-beta-carboline Investigative T51487 DRUGINFO D0O4MK 3-Chloro-9H-beta-carboline Investigative T51487 DRUGINFO D0P2DB 7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene Investigative T51487 DRUGINFO D0Q6CJ 2-(3-Bromo-phenyl)-6-nitro-chromen-4-one Investigative T51487 DRUGINFO D0R2ES 2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline Investigative T51487 DRUGINFO D0R2HJ Isoquinoline-3-carboxylic acid methyl ester Investigative T51487 DRUGINFO D0R6FJ NORHARMANE Investigative T51487 DRUGINFO D0S4RQ 3-sec-Butoxy-9H-beta-carboline Investigative T51487 DRUGINFO D0S6GS 6-Bromo-2-phenyl-chromen-4-one Investigative T51487 DRUGINFO D0T4ZI 6-Chloro-2-(3-nitro-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D0V4AR 2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline Investigative T51487 DRUGINFO D0W3FQ 6-Nitro-2-phenyl-chromen-4-one Investigative T51487 DRUGINFO D0W7ND 2-Phenyl-3H-imidazo[4,5-c]quinoline Investigative T51487 DRUGINFO D0W9WW 6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D0X2CC 1-(9H-beta-Carbolin-3-yl)-butan-1-one Investigative T51487 DRUGINFO D0ZJ5V N-(9H-beta-Carbolin-3-yl)-formamide Investigative T51487 DRUGINFO D00OAN 9H-beta-Carboline-3-carboxylic acid propyl ester Investigative T51487 DRUGINFO D00SXO 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one Investigative T51487 DRUGINFO D01BVR 5-(4-piperidyl)-4-propylisothiazol-3-ol Investigative T51487 DRUGINFO D02XUD 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol Investigative T51487 DRUGINFO D04PQN N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide Investigative T51487 DRUGINFO D05WEF N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide Investigative T51487 DRUGINFO D06QOX 1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one Investigative T51487 DRUGINFO D06ZOM 3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one Investigative T51487 DRUGINFO D07BIF [3H]CGP27492 Investigative T51487 DRUGINFO D09AVL 4-benzyl-5-(4-piperidyl)isothiazol-3-ol Investigative T51487 DRUGINFO D0D6IU 2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide Investigative T51487 DRUGINFO D0GE4A N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide Investigative T51487 DRUGINFO D0J9SS 6-Nitro-2-(3-nitro-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D0JV5L 4-Methyl-5-(4-piperidyl)isothiazol-3-ol Investigative T51487 DRUGINFO D0KS2X CGS-9895 Investigative T51487 DRUGINFO D0P3FZ 5-(piperidin-4-yl)isothiazol-3-ol Investigative T51487 DRUGINFO D0S9YE (beta-CCE)9H-beta-Carboline-3-carboxylic acid Investigative T51487 DRUGINFO D0V2LK 6-Nitro-2-(4-nitro-phenyl)-chromen-4-one Investigative T51487 DRUGINFO D00CQR 6-Methyl-2-oxa-spiro[4.4]nonan-1-one Investigative T51487 DRUGINFO D00VWR 3,3-Diethyl-dihydro-furan-2-one Investigative T51487 DRUGINFO D00WON 3-Ethyl-3-methyl-dihydro-furan-2-one Investigative T51487 DRUGINFO D01OZS 3,3-Diisopropyl-dihydro-furan-2-one Investigative T51487 DRUGINFO D01PPZ Ridine-5-carboxylic acid ethyl ester Investigative T51487 DRUGINFO D01UZT 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole Investigative T51487 DRUGINFO D02FXS 3-carboxy-6-ethyl-4-quinolone Investigative T51487 DRUGINFO D02RUV 3-Isopropyl-3-methyl-dihydro-furan-2-one Investigative T51487 DRUGINFO D02XXK (9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine Investigative T51487 DRUGINFO D03CKN 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone Investigative T51487 DRUGINFO D03EOK N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide Investigative T51487 DRUGINFO D03FBS 6-ethyl-3-propoxycarbonyl-4-quinolone Investigative T51487 DRUGINFO D03OEN N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide Investigative T51487 DRUGINFO D03OQG 1-Methyl-5-oxa-spiro[2.4]heptan-4-one Investigative T51487 DRUGINFO D03YLX 3-Methyl-9H-beta-carboline Investigative T51487 DRUGINFO D04EOV 3-ethoxycarbonyl-6-propyl-4-quinolone Investigative T51487 DRUGINFO D05OOA 6-ethyl-3-pentoxycarbonyl-4-quinolone Investigative T51487 DRUGINFO D05SVA 5-(piperidin-4-yl)isoxazol-3-ol Investigative T51487 DRUGINFO D05TVT 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone Investigative T51487 DRUGINFO D06EUJ 3-butoxycarbonyl-4-quinolone Investigative T51487 DRUGINFO D06GAI 1-(4-chlorophenyl)-4-phenyl-1H-imidazole Investigative T51487 DRUGINFO D06OSB 6-ethyl-3-i-propoxycarbonyl-4-quinolone Investigative T51487 DRUGINFO D07OON 3-Ethyl-3-isopropyl-dihydro-furan-2-one Investigative T51487 DRUGINFO D07QGN CGS-13767 Investigative T51487 DRUGINFO D08AID 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone Investigative T51487 DRUGINFO D08HGK N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide Investigative T51487 DRUGINFO D09AYK 3-ethoxycarbonyl-4-quinolone Investigative T51487 DRUGINFO D09CQO 2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline Investigative T51487 DRUGINFO D09RWW 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone Investigative T51487 DRUGINFO D0AR4P 2-(9-Benzyl-9H-purin-6-ylamino)-ethanol Investigative T51487 DRUGINFO D0B4CQ 6-benzyl-3-propylaminocarbonyl-4-quinolone Investigative T51487 DRUGINFO D0B4WR 2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline Investigative T51487 DRUGINFO D0CR6M 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone Investigative T51487 DRUGINFO D0D2PJ GNF-PF-4421 Investigative T51487 DRUGINFO D0ER0L 4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T51487 DRUGINFO D0FQ2N 3-Isothiocyanato-9H-beta-carboline Investigative T51487 DRUGINFO D0FR4S 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol Investigative T51487 DRUGINFO D0G6IG 3-butoxycarbonyl-6-ethyl-4-quinolone Investigative T51487 DRUGINFO D0H0DP 3-amino-3-demethoxythiocolchicine Investigative T51487 DRUGINFO D0H0NE 6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one Investigative T51487 DRUGINFO D0I4HT 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol Investigative T51487 DRUGINFO D0J0CA BETA-CCM Investigative T51487 DRUGINFO D0J9VP 3-tert-Butyl-3-ethyl-dihydro-furan-2-one Investigative T51487 DRUGINFO D0K2CZ 1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one Investigative T51487 DRUGINFO D0KS3X U-89267 Investigative T51487 DRUGINFO D0L2KB RO-145974 Investigative T51487 DRUGINFO D0M0ZX 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone Investigative T51487 DRUGINFO D0M2AY 6-ethyl-3-propylaminocarbonyl-4-quinolone Investigative T51487 DRUGINFO D0O9SG 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one Investigative T51487 DRUGINFO D0Q8UV RO-145975 Investigative T51487 DRUGINFO D0R1IL 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol Investigative T51487 DRUGINFO D0S6ME 6-benzyl-3-propoxycarbonyl-4-quinolone Investigative T51487 DRUGINFO D0TJ2L RO-147437 Investigative T51487 DRUGINFO D0U9ET 6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one Investigative T51487 DRUGINFO D0UQ6J RO-194603 Investigative T51487 DRUGINFO D0W5IP GNF-PF-3645 Investigative T51487 DRUGINFO D0WC5L 3-butylaminocarbonyl-6-ethyl-4-quinolone Investigative T51487 DRUGINFO D0X4OW 2-Oxa-spiro[4.4]nonan-1-one Investigative T51487 DRUGINFO D0YS9E 4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T51487 DRUGINFO D01UAS 6-bromo-3-ethoxycarbonyl-4-quinolone Investigative T51487 DRUGINFO D02CZO 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone Investigative T51487 DRUGINFO D03LMR 6-benzyl-3-ethoxycarbonyl-4-quinolone Investigative T51487 DRUGINFO D0H4GQ RY-066 Investigative T51487 DRUGINFO D01CUR 3-Ethoxy-9H-beta-carboline Investigative T51487 DRUGINFO D01RLF 9H-beta-Carboline-3-carboxylic acid ethyl ester Investigative T51487 DRUGINFO D03PPZ Beta-Carboline-3-carboxylic acid t-butyl ester Investigative T51487 DRUGINFO D03TMD Barbituric acid derivative Investigative T51487 DRUGINFO D04RVA 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine Investigative T51487 DRUGINFO D06WMM 3-Butoxy-9H-beta-carboline Investigative T51487 DRUGINFO D06XGL 3-demethoxy-3-D-xylopyranosylaminothiocolchicine Investigative T51487 DRUGINFO D08BOP 3-Propoxy-9H-beta-carboline Investigative T51487 DRUGINFO D08BXK 3-(3-Methyl-butoxy)-9H-beta-carboline Investigative T51487 DRUGINFO D08YLW 3-demethoxy-3-L-fucopyranosylaminothiocolchicine Investigative T51487 DRUGINFO D09MHS 3-demethoxy-3D-glucopyranosylaminothiocolchicine Investigative T51487 DRUGINFO D09MYJ 3-Isobutoxy-9H-beta-carboline Investigative T51487 DRUGINFO D0C6WO Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate Investigative T51487 DRUGINFO D0D4MM Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate Investigative T51487 DRUGINFO D0E7PY Ro-4938581 Investigative T51487 DRUGINFO D0LP2K 3-demethoxy-3-D-mannopyranosylaminothiocolchicine Investigative T51487 DRUGINFO D0O9MG L-655708 Investigative T51487 DRUGINFO D0P3BU 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole Investigative T51487 DRUGINFO D0R5OU 3-(benzyloxy)-9H-pyrido[3,4-b]indole Investigative T51487 DRUGINFO D01IHM CI-218872 Investigative T51487 DRUGINFO D07NKO 5-[(1R)-1-ammonioethyl]isoxazol-3-olate Investigative T51487 DRUGINFO D09ACO (2E,4S)-4-ammoniopent-2-enoate Investigative T51487 DRUGINFO D0A8EU (4R)-4-ammoniopentanoate Investigative T51487 DRUGINFO D0N0ZK (4S)-4-ammoniopentanoate Investigative T51487 DRUGINFO D0S0RK flavone Investigative T51487 DRUGINFO D0S5PS 5-[(1S)-1-ammonioethyl]isoxazol-3-olate Investigative T51487 DRUGINFO D00WHO Ro-15-3505 Investigative T51487 DRUGINFO D0M4CP [3H]Ro154513 Investigative T51487 DRUGINFO D0M9RM [3H]CGS8216 Investigative T51487 DRUGINFO D06HRX AMENTOFLAVONE Investigative T89697 TARGETID T89697 T89697 FORMERID TTDS00476 T89697 UNIPROID I23O1_HUMAN T89697 TARGNAME Indoleamine 2,3-dioxygenase 1 (IDO1) T89697 GENENAME IDO1 T89697 TARGTYPE Successful T89697 SYNONYMS Indoleamine-pyrrole 2,3-dioxygenase; INDO; IDO-1; IDO T89697 FUNCTION Involved in the peripheral immune tolerance, contributing to maintain homeostasis by preventing autoimmunity or immunopathology that would result from uncontrolled and overreacting immune responses. Tryptophan shortage inhibits T lymphocytes division and accumulation of tryptophan catabolites induces T-cell apoptosis and differentiation of regulatory T-cells. Acts as a suppressor of anti-tumor immunity. Limits the growth of intracellular pathogens by depriving tryptophan. Protects the fetus from maternal immune rejection. Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway. T89697 PDBSTRUC 6MQ6; 6F0A; 6DPR; 6DPQ; 6CXV T89697 BIOCLASS Oxygenase T89697 ECNUMBER EC 1.13.11.52 T89697 SEQUENCE MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIESGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVLPRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGFFLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGNPQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMPPAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQQPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLKEG T89697 DRUGINFO D05EJG L-Tryptophan Approved T89697 DRUGINFO D0DP5I BMS-986205 Phase 3 T89697 DRUGINFO D0G7MV INCB24360 Phase 3 T89697 DRUGINFO D0C0NH Avastin+/-Tarceva Phase 3 T89697 DRUGINFO D0B5HS NLG8189 Phase 2/3 T89697 DRUGINFO D08XDL KHK2455 Phase 1 T89697 DRUGINFO D0C4PB LY3381916 Phase 1 T89697 DRUGINFO D0J1HB PF-06840003 Phase 1 T89697 DRUGINFO D0N4VB NLG802 Phase 1 T89697 DRUGINFO DGCQ13 MK-7162 Phase 1 T89697 DRUGINFO D9S7XO DN1406131 Phase 1 T89697 DRUGINFO DB53NH HTI-1090 Phase 1 T89697 DRUGINFO D00JLX Sulfonamide derivative 6 Patented T89697 DRUGINFO D01NST Monofluorine derivative 1 Patented T89697 DRUGINFO D02XQE PMID29473428-Compound-39 Patented T89697 DRUGINFO D03CTR PMID29473428-Compound-50 Patented T89697 DRUGINFO D03CYB Aryl 1,2-diamine derivative 1 Patented T89697 DRUGINFO D03JQL PMID29473428-Compound-6 Patented T89697 DRUGINFO D03NHO Monoaryl-1,2-diamine derivative 1 Patented T89697 DRUGINFO D03PQB Imidazoleisoindoles derivative 1 Patented T89697 DRUGINFO D03TZE PMID29473428-Compound-22 Patented T89697 DRUGINFO D03ZMX Monoaryl-1,2-diamine derivative 3 Patented T89697 DRUGINFO D04VUH PMID29473428-Compound-48 Patented T89697 DRUGINFO D04WCW Hydoxyamidine derivative 1 Patented T89697 DRUGINFO D05BYE Hydroxy amidine derivative 2 Patented T89697 DRUGINFO D05CNJ Five-membered heteroaromatic compound 1 Patented T89697 DRUGINFO D05QAL Hydroxy amidine derivative 1 Patented T89697 DRUGINFO D06FHJ Sulfonamide derivative 8 Patented T89697 DRUGINFO D06HOA Indazole derivative 2 Patented T89697 DRUGINFO D06SKI Sulfamic acid ester derivative 1 Patented T89697 DRUGINFO D07JFY PMID29473428-Compound-43 Patented T89697 DRUGINFO D07NFQ PMID29473428-Compound-16 Patented T89697 DRUGINFO D08XQG PMID29473428-Compound-59 Patented T89697 DRUGINFO D09FPV PMID29473428-Compound-4 Patented T89697 DRUGINFO D09HVV PMID29473428-Compound-58 Patented T89697 DRUGINFO D09LKN PMID29473428-Compound-53 Patented T89697 DRUGINFO D09TSM Imidazoleisoindoles derivative 2 Patented T89697 DRUGINFO D0B5FA Benzimidazole and imadazopyridine carboximidamide compound 2 Patented T89697 DRUGINFO D0B7LR Biphenyl derivative 3 Patented T89697 DRUGINFO D0BK2I Pyridine derivative 1 Patented T89697 DRUGINFO D0CE7G Cyclohexyl-ethyl-substituted diaza and triaza-tricyclic compound 1 Patented T89697 DRUGINFO D0DA8D Hexahydro quinoline derivative 1 Patented T89697 DRUGINFO D0DW4P PMID29473428-Compound-15 Patented T89697 DRUGINFO D0E4BN Monoaryl-1,2-diamine derivative 4 Patented T89697 DRUGINFO D0F3VN Sulfamoylamide derivative 1 Patented T89697 DRUGINFO D0FY1Q PMID29473428-Compound-52 Patented T89697 DRUGINFO D0GV6B Monoaryl-1,2-diamine derivative 2 Patented T89697 DRUGINFO D0H3ZZ PMID29473428-Compound-71 Patented T89697 DRUGINFO D0IE8M Cyclic hydroxamate derivative 1 Patented T89697 DRUGINFO D0IS1M PMID29473428-Compound-34 Patented T89697 DRUGINFO D0IT3V Thieno[2,3-c]pyridine derivative 1 Patented T89697 DRUGINFO D0IY1Z Azetidine derivative 5 Patented T89697 DRUGINFO D0JR2C PMID29473428-Compound-29 Patented T89697 DRUGINFO D0K4KM PMID29473428-Compound-60 Patented T89697 DRUGINFO D0K8EV PMID29473428-Compound-11 Patented T89697 DRUGINFO D0L4GL Biphenyl derivative 2 Patented T89697 DRUGINFO D0L8KM PMID29473428-Compound-14 Patented T89697 DRUGINFO D0L9BG PMID29473428-Compound-10 Patented T89697 DRUGINFO D0M8KB Amide derivative 2 Patented T89697 DRUGINFO D0MO3W Pyridino tricyclic compound 1 Patented T89697 DRUGINFO D0N6UO PMID29473428-Compound-47 Patented T89697 DRUGINFO D0OZ8W Biphenyl derivative 1 Patented T89697 DRUGINFO D0P1HR PMID29473428-Compound-21 Patented T89697 DRUGINFO D0Q3SU Benzimidazole and imadazopyridine carboximidamide compound 1 Patented T89697 DRUGINFO D0QZ8K Acyl piperidine derivative 1 Patented T89697 DRUGINFO D0R0QY Pyrrolo[1,2-c]pyrazole derivative 1 Patented T89697 DRUGINFO D0R8OW Sulfonamide derivative 7 Patented T89697 DRUGINFO D0RH9K Imidazo[1,5-a]pyridine derivative 2 Patented T89697 DRUGINFO D0S7BW PMID29473428-Compound-33 Patented T89697 DRUGINFO D0T5WX Biphenyl 1,2-diamine derivative 1 Patented T89697 DRUGINFO D0T9XC Five-membered heteroaromatic compound 2 Patented T89697 DRUGINFO D0U3KX PMID29473428-Compound-70 Patented T89697 DRUGINFO D0UC2S Indazole derivative 4 Patented T89697 DRUGINFO D0UI9T Carbamide derivative 13 Patented T89697 DRUGINFO D0UZ6C Five-membered heteroaromatic compound 3 Patented T89697 DRUGINFO D0V3KH PMID29473428-Compound-41 Patented T89697 DRUGINFO D0WR7B Imidazo isoindole derivative 1 Patented T89697 DRUGINFO D0XT4V PMID29473428-Compound-17 Patented T89697 DRUGINFO D0YV6X PMID29473428-Compound-72 Patented T89697 DRUGINFO D0YW4T Aryl sulphoxide imine derivative 1 Patented T89697 DRUGINFO D0YY4R PMID29473428-Compound-54 Patented T89697 DRUGINFO D0Z5PM PMID29473428-Compound-80 Patented T89697 DRUGINFO D0ZV6F Imidazo[1,5-a]pyridine derivative 1 Patented T89697 DRUGINFO D0E8XV 2,3-diamino-benzo[b]thiophene derivative 3 Patented T89697 DRUGINFO D0F4MN PMID29473428-Compound-76 Patented T89697 DRUGINFO D0JB1V Indazole derivative 3 Patented T89697 DRUGINFO D04BZI 2,3-diamino-benzo[b]thiophene derivative 4 Patented T89697 DRUGINFO D04MIQ PMID27172114-Compound-30 Patented T89697 DRUGINFO D05TIP 2,3-diamino-benzo[b]thiophene derivative 2 Patented T89697 DRUGINFO D05ZGX 2,3-diamino-benzo[b]thiophene derivative 8 Patented T89697 DRUGINFO D0F4VD 2,3-diamino-benzo[b]thiophene derivative 7 Patented T89697 DRUGINFO D0FF6H 2,3-diamino-benzo[b]thiophene derivative 6 Patented T89697 DRUGINFO D0HV0Y 2,3-diamino-benzo[b]thiophene derivative 5 Patented T89697 DRUGINFO D0RA7I 2,3-diamino-benzo[b]thiophene derivative 1 Patented T89697 DRUGINFO D06YFT 1-methyl-L-tryptophan Preclinical T89697 DRUGINFO D9P8LE RG70099 Preclinical T89697 DRUGINFO DZK24C EPL-1410 Preclinical T89697 DRUGINFO D00BGN 2-(1H-Imidazol-4-yl)benzene-1,3-diol Investigative T89697 DRUGINFO D00GYX BENZENEMETHANETHIOL Investigative T89697 DRUGINFO D00UIK 4-(Benzylamino)-1-naphthol Investigative T89697 DRUGINFO D00XOT 4-(2-Hydroxyethoxy)-1-naphthol Investigative T89697 DRUGINFO D01CSZ 5-(isopropylamino)quinolin-8-ol Investigative T89697 DRUGINFO D01HST amg-1 Investigative T89697 DRUGINFO D02DRL S-(2-Chlorobenzyl)isothiourea hydrochloride Investigative T89697 DRUGINFO D02IVJ S-(4-Fluorobenzyl)isothiourea hydrochloride Investigative T89697 DRUGINFO D02SRL 4-phenylthiazole-2-thiol Investigative T89697 DRUGINFO D02XRG 4-(ethylamino)naphthalen-1-ol Investigative T89697 DRUGINFO D03ETX S-Benzyl-brassinin Investigative T89697 DRUGINFO D03JAE S-(4-Bromobenzyl)isothiourea hydrobromide Investigative T89697 DRUGINFO D03JMD S-(4-Cyanobenzyl)isothiourea hydrobromide Investigative T89697 DRUGINFO D04OXY 2-methoxy-1,4-naphthoquinone Investigative T89697 DRUGINFO D05AFW S-(4-Ethylbenzyl)isothiourea hydrochloride Investigative T89697 DRUGINFO D05LFV S-(4-Methylbenzyl)isothiourea hydrochloride Investigative T89697 DRUGINFO D06BBF BLV-0801 Investigative T89697 DRUGINFO D06MUL N-[2-(Indol-3-yl)ethyl]-S-benzyl-dithiocarbamate Investigative T89697 DRUGINFO D06OUR 4-(2-(diethylamino)ethylamino)-1-naphthol Investigative T89697 DRUGINFO D07NSZ S-(3-Chlorobenzyl)isothiourea hydrochloride Investigative T89697 DRUGINFO D07RGV ANNULIN B Investigative T89697 DRUGINFO D08GZK EXIGUAMINE B Investigative T89697 DRUGINFO D08MOG 4-(Pent-3-ylamino)-1-naphthol Investigative T89697 DRUGINFO D08MRL 4-(propylamino)naphthalen-1-ol Investigative T89697 DRUGINFO D08PIF 4-Methoxybenzenemethanethiol Investigative T89697 DRUGINFO D08XXD 4-aminonaphthalen-1-ol Investigative T89697 DRUGINFO D08YHA 2,2-dimethyl-2H-benzo[g]chromene-5,10-dione Investigative T89697 DRUGINFO D09BVH Naphthalene-1,4-diol Investigative T89697 DRUGINFO D09DSZ 2,3-dihydrobenzo[d]thiazole-2-thiol Investigative T89697 DRUGINFO D09JOM S-(2,4-Dichlorobenzyl)isothiourea hydrobromide Investigative T89697 DRUGINFO D09ZJW 4-Chlorobenzenemethanethiol Investigative T89697 DRUGINFO D0A7NH 4-(Cyclohexylamino)-1-naphthol Investigative T89697 DRUGINFO D0B9IA ANNULIN C Investigative T89697 DRUGINFO D0DB2N ANNULIN A Investigative T89697 DRUGINFO D0DR7W Seco-exiguamine Investigative T89697 DRUGINFO D0G0EE 3-(1H-Imidazol-4-yl)benzenethiol Investigative T89697 DRUGINFO D0G3RO 3-(4H-Imidazol-4-yl)benzenethiol Investigative T89697 DRUGINFO D0G8IH 4-(methylamino)naphthalen-1-ol Investigative T89697 DRUGINFO D0I2RW 2,3-dichloro-1,4-naphthoquinone Investigative T89697 DRUGINFO D0I9AT tryptanthrin Investigative T89697 DRUGINFO D0J9DD 4-Phenylimidazole Investigative T89697 DRUGINFO D0J9JH GARVEATIN A Investigative T89697 DRUGINFO D0K3SZ 4-Methylbenzenemethanethiol Investigative T89697 DRUGINFO D0K4MG 2-HYDROXYGARVIN A Investigative T89697 DRUGINFO D0MC4U Exiguamine A Investigative T89697 DRUGINFO D0N1ZJ 4-(tert-butylamino)naphthalen-1-ol Investigative T89697 DRUGINFO D0N6QU 2-hydroxygarveatin E Investigative T89697 DRUGINFO D0NI8W 2-(1H-Imidazol-4-yl)phenol Investigative T89697 DRUGINFO D0O3IE 5-phenyl-1H-1,2,3-triazole Investigative T89697 DRUGINFO D0O9QG S-(4-Chlorobenzyl)isothiourea hydrochloride Investigative T89697 DRUGINFO D0P1CO S-(3,4-Dichlorobenzyl)isothiourea hydrochloride Investigative T89697 DRUGINFO D0P2ET Garveatin E Investigative T89697 DRUGINFO D0P3XW 2-Chlorobenzenemethanethiol Investigative T89697 DRUGINFO D0PR7L 4-Fluorobenzenemethanethiol Investigative T89697 DRUGINFO D0Q9JG S-(4-Methoxybenzyl)isothiourea hydrochloride Investigative T89697 DRUGINFO D0S1FF 4-(Isopropylamino)-1-naphthol Investigative T89697 DRUGINFO D0SZ9F 2,4-Dichlorobenzenemethanethiol Investigative T89697 DRUGINFO D0TM0Z 1H-indole-4,7-dione Investigative T89697 DRUGINFO D0UV8T 4-(1H-1,2,3-triazol-5-yl)pyridine Investigative T89697 DRUGINFO D0W3ON 5-aminoquinolin-8-ol Investigative T89697 DRUGINFO D0W3OY S-(4-Nitrobenzyl)isothiourea hydrochloride Investigative T89697 DRUGINFO D0W3XP Garveatin C Investigative T89697 DRUGINFO D0YU9L 4-amino-1,2,5-oxadiazole-3-carboximidamide Investigative T89697 DRUGINFO D0Z0BB 3,4-Dichlorobenzenemethanethiol Investigative T89697 DRUGINFO D0Z3NE PMID24099220C5i Investigative T89697 DRUGINFO D0Z4JG 4-methoxynaphthalen-1-amine Investigative T89697 DRUGINFO D0DQ6Z 1,4-Naphthoquinone Investigative T89697 DRUGINFO D0W9VA 1,2-NAPHTHOQUINONE Investigative T56365 TARGETID T56365 T56365 FORMERID TTDC00135 T56365 UNIPROID CD19_HUMAN T56365 TARGNAME B-lymphocyte surface antigen B4 (CD19) T56365 GENENAME CD19 T56365 TARGTYPE Successful T56365 SYNONYMS T-cell surface antigen Leu-12; Leu-12; Differentiation antigen CD19; B-lymphocyte antigen CD19 T56365 FUNCTION Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge. Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. T56365 PDBSTRUC 6AL5 T56365 BIOCLASS Immunoglobulin T56365 SEQUENCE MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRMGTWSTR T56365 DRUGINFO D0DK5R Axicabtagene ciloleucel Approved T56365 DRUGINFO D0M4WU Lisocabtagene maraleucel Approved T56365 DRUGINFO D0XH3V Inebilizumab Approved T56365 DRUGINFO D18SHN Tecartus Approved T56365 DRUGINFO D8L5PA Loncastuximab tesirine Approved T56365 DRUGINFO D0IM6T Tisagenlecleucel Approved T56365 DRUGINFO D0K4RK Blinatumomab Approved T56365 DRUGINFO D4I3HU Obexelimab Phase 3 T56365 DRUGINFO D02CYL MOR-208 Phase 2/3 T56365 DRUGINFO D03IOM CART-19 Phase 2/3 T56365 DRUGINFO D04YSC CD19 CAR T cells Phase 2/3 T56365 DRUGINFO D00UNK Coltuximab ravtansine Phase 2 T56365 DRUGINFO D05MGQ MDX-1342 Phase 2 T56365 DRUGINFO D06TKR CART 19 Phase 2 T56365 DRUGINFO D07FGK SAR-3419 Phase 2 T56365 DRUGINFO D09BWG CAR-T cells targeting CD19 Phase 2 T56365 DRUGINFO D0F1HT MB-CART19.1 Phase 2 T56365 DRUGINFO D0G4IW CART-19 Phase 2 T56365 DRUGINFO D0HM1V KYMRIAH Phase 2 T56365 DRUGINFO D0I0NJ CART-19 cells Phase 2 T56365 DRUGINFO D0I0UM CTL019 Phase 2 T56365 DRUGINFO D0I8OY XLCART001 Phase 2 T56365 DRUGINFO D0K3XB JCAR015 Phase 2 T56365 DRUGINFO D0L5HM CD19 CAR T cells Phase 2 T56365 DRUGINFO D0R3ZE MEDI-551 Phase 2 T56365 DRUGINFO D0RA1R CD19-targeting CAR T cells Phase 2 T56365 DRUGINFO DLN4R8 Minjuvi Phase 2 T56365 DRUGINFO D00NXT Xmab 5871 Phase 2 T56365 DRUGINFO D02BCY CD19 CART Phase 1/2 T56365 DRUGINFO D02BHW IM19 CAR-T Phase 1/2 T56365 DRUGINFO D03JOA Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes Phase 1/2 T56365 DRUGINFO D03UNT Anti-CD19-CAR vector-transduced T cells Phase 1/2 T56365 DRUGINFO D04FPN CD19 CAR-T lymphocytes Phase 1/2 T56365 DRUGINFO D04JHH CAR-T cells targeting CD19 Phase 1/2 T56365 DRUGINFO D05LIH Anti-CD19 CAR-T cells Phase 1/2 T56365 DRUGINFO D07NHZ CD19 CAR T cells Phase 1/2 T56365 DRUGINFO D08BPS JCAR017 Phase 1/2 T56365 DRUGINFO D0B3HF SCRI-huCAR19v1 Phase 1/2 T56365 DRUGINFO D0CE0Y Anti-CD19-CAR-T cells Phase 1/2 T56365 DRUGINFO D0D9BL Anti-CD19 CAR-T cells Phase 1/2 T56365 DRUGINFO D0EH1J CD19.CAR-T cells Phase 1/2 T56365 DRUGINFO D0FF0N TBI-1501 Phase 1/2 T56365 DRUGINFO D0FR3J CD19 specific CAR T cells Phase 1/2 T56365 DRUGINFO D0G5WV KTE-C19 CAR Phase 1/2 T56365 DRUGINFO D0GT3R Anti-CD19 CAR-T cells Phase 1/2 T56365 DRUGINFO D0HO1A CD19 CAR Gene Transduced T Lymphocytes Phase 1/2 T56365 DRUGINFO D0J3DN Anti-CD19-CAR PBL Phase 1/2 T56365 DRUGINFO D0JD4T Anti-CD19 CAR transduced T cells Phase 1/2 T56365 DRUGINFO D0JV4R TriCAR-T-CD19 Phase 1/2 T56365 DRUGINFO D0KF9T Anti-CD19 CAR-T Phase 1/2 T56365 DRUGINFO D0LF6M Chimeric Antigen Receptor Modified T cells Targeting CD19 Phase 1/2 T56365 DRUGINFO D0M0CO PCAR-019 Phase 1/2 T56365 DRUGINFO D0MV4T CD19.CAR T Cells Phase 1/2 T56365 DRUGINFO D0N3GE CD19 CART Phase 1/2 T56365 DRUGINFO D0NJ3T CART-19 cells Phase 1/2 T56365 DRUGINFO D0O6LR Autologous CD19-targeting CAR T cells Phase 1/2 T56365 DRUGINFO D0OP7I CARCIK-CD19 Phase 1/2 T56365 DRUGINFO D0OZ5H CD19-CAR T cell Phase 1/2 T56365 DRUGINFO D0PN3M CD19-directed CAR-T cells Phase 1/2 T56365 DRUGINFO D0Q5EH Anti-CD19 CAR-T cells Phase 1/2 T56365 DRUGINFO D0QF0L CD19 CAR-T Cells Phase 1/2 T56365 DRUGINFO D0R3IG SJCAR19 Phase 1/2 T56365 DRUGINFO D0S4IR PBCAR0191 Phase 1/2 T56365 DRUGINFO D0SV4A CD19 targeted chimeric antigen receptor T cells Phase 1/2 T56365 DRUGINFO D0TE0L 4SCAR19 cells Phase 1/2 T56365 DRUGINFO D0U0BN JCAR014 Phase 1/2 T56365 DRUGINFO D0UM8Q UCART019 Phase 1/2 T56365 DRUGINFO D0W8WG CD19-targeting CAR T Cells Phase 1/2 T56365 DRUGINFO D0XG0L Anti-CD19 CAR T cells Phase 1/2 T56365 DRUGINFO D0XY6T Humanized CD19 CAR-T cells Phase 1/2 T56365 DRUGINFO D0YY6O CLIC-1901 Phase 1/2 T56365 DRUGINFO D0Z8GD CD19 CAR T Cells Phase 1/2 T56365 DRUGINFO D1HID7 ALLO-501A Phase 1/2 T56365 DRUGINFO DN2MC5 AUTO1 Phase 1/2 T56365 DRUGINFO DN71VY TAK-007 Phase 1/2 T56365 DRUGINFO DS53MJ TC-110 Phase 1/2 T56365 DRUGINFO D02ONA AUTO3 Phase 1/2 T56365 DRUGINFO D02YRD 4SCAR19 and 4SCAR70 Phase 1/2 T56365 DRUGINFO D03ZCH 4SCAR19 and 4SCAR20 Phase 1/2 T56365 DRUGINFO D04GIO Anti-CD19 and Anti-CD20 CAR-T Cells Phase 1/2 T56365 DRUGINFO D05OAI CART-19/22 Phase 1/2 T56365 DRUGINFO D05VNS CD19 and CD22 CAR-T Cells Phase 1/2 T56365 DRUGINFO D08FVH 4SCAR19/22 T cells Phase 1/2 T56365 DRUGINFO D08JTI Anti-CD19/22-CAR vector-transduced T cells Phase 1/2 T56365 DRUGINFO D0AC9S CART-19/BCMA Phase 1/2 T56365 DRUGINFO D0BH2M 4SCAR19 and 4SCAR123 Phase 1/2 T56365 DRUGINFO D0E2CS CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells Phase 1/2 T56365 DRUGINFO D0I4HG 4SCAR19 and 4SCAR38 Phase 1/2 T56365 DRUGINFO D0J7VH 4SCAR19 and 4SCAR22 Phase 1/2 T56365 DRUGINFO D0K8YX 4SCAR19 and 4SCAR30 Phase 1/2 T56365 DRUGINFO D0MA4O Anti-CD20 CAR-T cells Phase 1/2 T56365 DRUGINFO D0QB1O CD19 and CD20 CAR-T Cells Phase 1/2 T56365 DRUGINFO D0W4SM CD19 and CD22 CAR-T Cells Phase 1/2 T56365 DRUGINFO D00MUC CD19 CAR-T cells Phase 1 T56365 DRUGINFO D00YUQ CART-19 T cells Phase 1 T56365 DRUGINFO D01HAT CD19.CAR-aNKT cells Phase 1 T56365 DRUGINFO D02NFE Anti-CD19 CART Cells Phase 1 T56365 DRUGINFO D02XYW CD19-directed CAR-T cells Phase 1 T56365 DRUGINFO D03EIA Anti-CD19-CAR T Phase 1 T56365 DRUGINFO D03LFA Allogeneic CART-19 Phase 1 T56365 DRUGINFO D04BVL IM19 Phase 1 T56365 DRUGINFO D04KWO MEDl-551 Phase 1 T56365 DRUGINFO D05DKT CART19 cell Phase 1 T56365 DRUGINFO D05UOU CD19-CAR-T2 Cells Phase 1 T56365 DRUGINFO D05XPZ JWCAR029 Phase 1 T56365 DRUGINFO D06TNO CD19 CAR T-cells Phase 1 T56365 DRUGINFO D06UTM Anti-CD19-CAR T cells Phase 1 T56365 DRUGINFO D07ITH 4SCAR19 cells Phase 1 T56365 DRUGINFO D07TMJ EGFRt/19-28z/4-1BBL CAR T cells Phase 1 T56365 DRUGINFO D08LLB Human CD19 targeted T Cells Phase 1 T56365 DRUGINFO D09SAH PZ01 CAR-T cells Phase 1 T56365 DRUGINFO D0A2RX 19-28z T CELLS Phase 1 T56365 DRUGINFO D0A6XC CD19-targeted CART cells Phase 1 T56365 DRUGINFO D0B1CU CD19 CAR T-cells Phase 1 T56365 DRUGINFO D0BQ0C CD19 CAR-T cells Phase 1 T56365 DRUGINFO D0C5FA Duvortuxizumab Phase 1 T56365 DRUGINFO D0CS3A CART-19 Phase 1 T56365 DRUGINFO D0DR6N CART-19 cells Phase 1 T56365 DRUGINFO D0DU4T IC9-CAR19 cells Phase 1 T56365 DRUGINFO D0E2VF CD19 Redirected Autologous T Cells Phase 1 T56365 DRUGINFO D0EO6G Anti-CD19-CAR Phase 1 T56365 DRUGINFO D0F1OH CD19CAT-41BBZ CAR T-cells Phase 1 T56365 DRUGINFO D0G8YJ CD19-TriCAR-T Phase 1 T56365 DRUGINFO D0GC3U CD19-directed CAR-T cells Phase 1 T56365 DRUGINFO D0J6WE CD19-CAR-T Cells Phase 1 T56365 DRUGINFO D0JD6Y CD19 CAR T Phase 1 T56365 DRUGINFO D0KZ0V CD19 CAR T Cells Phase 1 T56365 DRUGINFO D0M5II CART-19 autologous T-cells Phase 1 T56365 DRUGINFO D0MWS2 YTB323 Phase 1 T56365 DRUGINFO D0NV6I Anti-CD19 CAR-T cells Phase 1 T56365 DRUGINFO D0O7VZ AntiCD19 CART Phase 1 T56365 DRUGINFO D0OC5C ICAR19 CAR-T cells Phase 1 T56365 DRUGINFO D0OD8T CD19 CAR T cells Phase 1 T56365 DRUGINFO D0PE3J CAR-T Cells targeting CD19 Phase 1 T56365 DRUGINFO D0PH6Z CD19+ CAR T Cells Phase 1 T56365 DRUGINFO D0PY5I IC9-CAR19 T cells Phase 1 T56365 DRUGINFO D0Q8XO CART-19 Phase 1 T56365 DRUGINFO D0S5BC CART-19 cells Phase 1 T56365 DRUGINFO D0SD9R ARI-0001 cells Phase 1 T56365 DRUGINFO D0TD0O Anti-CD19 CAR-T Phase 1 T56365 DRUGINFO D0U7VS CAR-T cells targeting CD19 Phase 1 T56365 DRUGINFO D0U8PE CAR19 T cells carrying cytoplasmic activated PD-1 Phase 1 T56365 DRUGINFO D0V7BD HuCART19 Phase 1 T56365 DRUGINFO D0X6FU C-CAR011 Phase 1 T56365 DRUGINFO D2KB3W ALLO-501 Phase 1 T56365 DRUGINFO D2PFY3 AMG 562 Phase 1 T56365 DRUGINFO D3DPR8 Sleeping Beauty CAR-TCR Phase 1 T56365 DRUGINFO D5DBU7 CarVAC Phase 1 T56365 DRUGINFO D67TOB TAK-940 Phase 1 T56365 DRUGINFO D6ONY2 KUR-502 Phase 1 T56365 DRUGINFO DA0Q5P ET019002 Phase 1 T56365 DRUGINFO DB93YI ET019003 Phase 1 T56365 DRUGINFO DFJO04 NKX019 Phase 1 T56365 DRUGINFO DH19QJ CTX-101 Phase 1 T56365 DRUGINFO DJVH04 CC-97540 Phase 1 T56365 DRUGINFO DP0G9N Anti-CD19 EBV CTL therapy Phase 1 T56365 DRUGINFO DR15DO FT-819 Phase 1 T56365 DRUGINFO DV3ZI0 CD19t-haNK Phase 1 T56365 DRUGINFO D00JCB CD19/CD22 CAR T cells Phase 1 T56365 DRUGINFO D02BAA Patient-derived CD19- and CD22 specific CAR Phase 1 T56365 DRUGINFO D02LNU CART22-65s cells and huCART19 Cells Phase 1 T56365 DRUGINFO D03YEM CD19/CD22 CAR T-Cells Phase 1 T56365 DRUGINFO D06RUK Combotox Phase 1 T56365 DRUGINFO D07TCV Anti-CD19 anti-CD20 Bispecific CAR-T Phase 1 T56365 DRUGINFO D0D7FV CD19/CD22 Chimeric Antigen Receptor T Cells Phase 1 T56365 DRUGINFO D0MD8S CARTmeso/19 Phase 1 T56365 DRUGINFO D0NU9L CAR-20/19-T Cells Phase 1 T56365 DRUGINFO D0QE4F CD19-CAR and CD28-CAR T Cells Phase 1 T56365 DRUGINFO D0T8RV BCMA CART and huCART19 Phase 1 T56365 DRUGINFO D0U1HR Donor-derived CD19/22 bispecific CAR-T cells Phase 1 T56365 DRUGINFO D0U7WY Anti-CD19/BCMA CAR-T cells Phase 1 T56365 DRUGINFO D0V5DD CART-meso-19 T cells Phase 1 T56365 DRUGINFO D0ZX6F RG6333 Phase 1 T56365 DRUGINFO D51HBQ CD20-CD19 cCAR Phase 1 T56365 DRUGINFO D7LN0E TNB-486 Phase 1 T56365 DRUGINFO D8UNG2 TG-1801 Phase 1 T56365 DRUGINFO DI6BK9 KITE-363 Phase 1 T56365 DRUGINFO DTR05Z BCMA-CD19 cCAR Phase 1 T56365 DRUGINFO DVOB28 AFM11 Phase 1 T56365 DRUGINFO DZD4R6 RO7443904 Phase 1 T56365 DRUGINFO D01JCT CD19-CAR T Cells Clinical trial T56365 DRUGINFO D04PDI CD19-targeted CAR-T cells Clinical trial T56365 DRUGINFO D05FZM CD19-UCART Clinical trial T56365 DRUGINFO D09IAN Anti-CD19 Chimeric Antigen Receptor T Cells Clinical trial T56365 DRUGINFO D09VYT CD19-targeted CAR-T cells Clinical trial T56365 DRUGINFO D0B8BZ CD19CART Clinical trial T56365 DRUGINFO D0U5NO CAR-CD19 T cell Clinical trial T56365 DRUGINFO D0NL9N Anti-CD19/20-CAR vector-transduced T cells Clinical trial T56365 DRUGINFO D0G5SK Anti-CD19 CAR T cells Phase 0 T56365 DRUGINFO D0P4KP CART19 cells Phase 0 T56365 DRUGINFO D0L4WO SGN-19A Preclinical T56365 DRUGINFO D28JEC ATA3219 Preclinical T56365 DRUGINFO DY2EJ1 ATA2431 Preclinical T56365 DRUGINFO D0V2QU Anti-CD22/CD19 mab-toxin conjugate Investigative T75498 TARGETID T75498 T75498 FORMERID TTDC00138 T75498 UNIPROID NQO2_HUMAN T75498 TARGNAME Quinone reductase 2 (NQO2) T75498 GENENAME NQO2 T75498 TARGTYPE Successful T75498 SYNONYMS Quinone oxidoreductase 2; Qui reductase 2; QR2; NRH:quinone oxidoreductase 2; NRH:qui oxidoreductase 2; NQO2; NAD(P)H qui oxidoreductase 2 T75498 FUNCTION The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis. T75498 PDBSTRUC 5LBZ; 5LBY; 5LBW; 5LBU; 5LBT T75498 BIOCLASS Diphenol donor oxidoreductase T75498 ECNUMBER EC 1.10.5.1 T75498 SEQUENCE MAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNLEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ T75498 DRUGINFO D0AN7B Melatonin Approved T75498 DRUGINFO D07JTD NSC-645809 Phase 2 T75498 DRUGINFO D0C6VV Prolarix Phase 2 T75498 DRUGINFO D07ZHV CB1954 Discontinued in Phase 2 T75498 DRUGINFO D00DSW NSC-640559 Investigative T75498 DRUGINFO D00GIU NSC-238146 Investigative T75498 DRUGINFO D00GUG NSC-665126 Investigative T75498 DRUGINFO D00OTC NSC-381864 Investigative T75498 DRUGINFO D00SNO NSC-645833 Investigative T75498 DRUGINFO D01DYZ NSC-204996 Investigative T75498 DRUGINFO D01JID NSC-660841 Investigative T75498 DRUGINFO D01WRT NSC-300853 Investigative T75498 DRUGINFO D01ZKN NSC-645836 Investigative T75498 DRUGINFO D02DOX NSC-677939 Investigative T75498 DRUGINFO D02GDG NSC-640353 Investigative T75498 DRUGINFO D02NED NSC-637991 Investigative T75498 DRUGINFO D03GWA NSC-669977 Investigative T75498 DRUGINFO D03QRT NSC-645812 Investigative T75498 DRUGINFO D03SBI NSC-660838 Investigative T75498 DRUGINFO D04KTJ NSC-645834 Investigative T75498 DRUGINFO D04LWL 1,4-Dimethylquinolin-2(1H)-one Investigative T75498 DRUGINFO D04PMX NSC-115890 Investigative T75498 DRUGINFO D04UGI NSC-645835 Investigative T75498 DRUGINFO D05GDD NSC-645831 Investigative T75498 DRUGINFO D05TZK NSC-693571 Investigative T75498 DRUGINFO D05YCI 6,7,8-Trimethoxy-4-methylquinolin-2(1H)-one Investigative T75498 DRUGINFO D06CHV NSC-77833 Investigative T75498 DRUGINFO D06GRP NSC-640583 Investigative T75498 DRUGINFO D06UQR 5,6,8-Trimethoxy-4-methylquinolin-2(1H)-one Investigative T75498 DRUGINFO D07OAH NSC-78021 Investigative T75498 DRUGINFO D08FHU 6,7,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one Investigative T75498 DRUGINFO D08ISK 6,8-Dimethoxy-4-methylquinolin-2(1H)-one Investigative T75498 DRUGINFO D08NCP NSC-660839 Investigative T75498 DRUGINFO D08NWU NSC-660840 Investigative T75498 DRUGINFO D08WKQ NSC-640566 Investigative T75498 DRUGINFO D09DRS 6,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one Investigative T75498 DRUGINFO D09XVU NSC-306843 Investigative T75498 DRUGINFO D0A0DN NSC-637994 Investigative T75498 DRUGINFO D0C8KC 5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one Investigative T75498 DRUGINFO D0G7MJ NSC-640556 Investigative T75498 DRUGINFO D0G8VF NSC-676468 Investigative T75498 DRUGINFO D0H3LU NSC-86715 Investigative T75498 DRUGINFO D0I3PD NSC-649091 Investigative T75498 DRUGINFO D0K0TO NSC-78017 Investigative T75498 DRUGINFO D0L3AJ 8-Methoxy-1,4-dimethylquinolin-2(1H)-one Investigative T75498 DRUGINFO D0M7RM NSC-640558 Investigative T75498 DRUGINFO D0O4YS 6-Methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one Investigative T75498 DRUGINFO D0O6NU NSC-637992 Investigative T75498 DRUGINFO D0OT1Z NSC-356820 Investigative T75498 DRUGINFO D0Q8JE NSC-637993 Investigative T75498 DRUGINFO D0S1AY 5,8-Dimethoxy-4-methylquinolin-2(1H)-one Investigative T75498 DRUGINFO D0S6RL NSC-99495 Investigative T75498 DRUGINFO D0T5NO 5,6,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one Investigative T75498 DRUGINFO D0TT3K NSC-645811 Investigative T75498 DRUGINFO D0UB3V NSC-640584 Investigative T75498 DRUGINFO D0W8VX NSC-180969 Investigative T75498 DRUGINFO D0W9ZH NSC-720622 Investigative T75498 DRUGINFO D0WW2D NSC-356819 Investigative T75498 DRUGINFO D0XQ6T 7,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one Investigative T75498 DRUGINFO D0Z9MG NSC-359466 Investigative T75498 DRUGINFO D09MQF 3,4,5-Trimethoxy-4'-amino-trans-stilbene Investigative T75498 DRUGINFO D0E0DQ NSC-645808 Investigative T75498 DRUGINFO D0I5YK decynium 22 Investigative T75498 DRUGINFO D0J3RB NSC-106080 Investigative T75498 DRUGINFO D0M0WT NSC-99528 Investigative T75498 DRUGINFO D0PG5D 10-Propargyl-5,8-Dideazafolic Acid Investigative T75498 DRUGINFO D0Q8UZ 3,5-Dimethoxy-4'-amino-trans-stilbene Investigative T75498 DRUGINFO D0H6YF 2-iodo-melatonin Investigative T75498 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T94309 TARGETID T94309 T94309 FORMERID TTDC00295 T94309 UNIPROID LIPP_HUMAN T94309 TARGNAME Pancreatic triacylglycerol lipase (PNLIP) T94309 GENENAME PNLIP T94309 TARGTYPE Successful T94309 SYNONYMS Pancreatic lipase; PTL; PL T94309 FUNCTION Catalyses the following chemical reaction: triacylglycerol + H2O diacylglycerol + a carboxylate. Acts only on an ester-water interface. T94309 PDBSTRUC 1N8S; 1LPB; 1LPA; 1GPL T94309 BIOCLASS Carboxylic ester hydrolase T94309 ECNUMBER EC 3.1.1.3 T94309 SEQUENCE MLPLWTLSLLLGAVAGKEVCYERLGCFSDDSPWSGITERPLHILPWSPKDVNTRFLLYTNENPNNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGEENWLANVCKNLFKVESVNCICVDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGRRTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGHLDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDGFAGFPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKVSVTLSGKKVTGHILVSLFGNKGNSKQYEIFKGTLKPDSTHSNEFDSDVDVGDLQMVKFIWYNNVINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC T94309 DRUGINFO D07QAR Dalbavancin Approved T94309 DRUGINFO D0T9TJ Orlistat Approved T94309 DRUGINFO D0A5DJ Pancrecarb NDA filed T94309 DRUGINFO D0T9LR Liprotamase Phase 3 T94309 DRUGINFO D0D7AM MS-1819 Phase 1/2 T94309 DRUGINFO D09VRZ AZM-131 Terminated T94309 DRUGINFO D04HWJ METHOXYUNDECYLPHOSPHINIC ACID Investigative T94309 DRUGINFO D09CGL Daio-Orengedokuto (DOT) Investigative T94309 DRUGINFO D06PVF (Hydroxyethyloxy)Tri(Ethyloxy)Octane Investigative T94309 DRUGINFO D0K1UI B-Nonylglucoside Investigative T94309 DRUGINFO D02UVH B-Octylglucoside Investigative T15000 TARGETID T15000 T15000 FORMERID TTDC00259 T15000 UNIPROID CTLA4_HUMAN T15000 TARGNAME Cytotoxic T-lymphocyte protein 4 (CTLA-4) T15000 GENENAME CTLA4 T15000 TARGTYPE Successful T15000 SYNONYMS Cytotoxic T-lymphocyte-associated antigen 4; CTLA-4; CD152 T15000 FUNCTION Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. T15000 PDBSTRUC 5XJ3; 5TRU; 5GGV; 3OSK; 3BX7 T15000 BIOCLASS Immunoglobulin T15000 SEQUENCE MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFLLTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN T15000 DRUGINFO D07BVI Ipilimumab Approved T15000 DRUGINFO D0J6DQ Tremelimumab Approved T15000 DRUGINFO D2ELZ3 AK04 Phase 3 T15000 DRUGINFO DLOQ25 KN046 Phase 3 T15000 DRUGINFO DJX61M Vudalimab Phase 2 T15000 DRUGINFO DR05IX Lorigerlimab Phase 2 T15000 DRUGINFO DXJH93 AK104 Phase 2 T15000 DRUGINFO D09SFX AGEN1884 Phase 1/2 T15000 DRUGINFO D42SLV Zalifrelimab Phase 1/2 T15000 DRUGINFO D7BF8Y BMS-986288 Phase 1/2 T15000 DRUGINFO DZ1IL2 MK-1308 Phase 1/2 T15000 DRUGINFO D02RPO BMS-986249 Phase 1 T15000 DRUGINFO D1YXQ4 YH001 Phase 1 T15000 DRUGINFO D2P8LR AGEN1181 Phase 1 T15000 DRUGINFO D3B1MS ONC-392 Phase 1 T15000 DRUGINFO DH6GK7 ADG116 Phase 1 T15000 DRUGINFO D0BOM7 XmAb22841 Phase 1 T15000 DRUGINFO D0U0EC TRemelimumab + MEDI0562 Phase 1 T15000 DRUGINFO D1PYC8 MGD019 Phase 1 T15000 DRUGINFO D1S7EP SI-B003 Phase 1 T15000 DRUGINFO D7L1MP MEDI5752 Phase 1 T15000 DRUGINFO D82UVG ALPN-202 Phase 1 T15000 DRUGINFO DD1TJ8 XmAb20717 Phase 1 T15000 DRUGINFO DL97UQ A337 Phase 1 T15000 DRUGINFO D02YSO GX-C4 Investigative T15000 DRUGINFO D03FSU Concatameric CTLA4Ig Investigative T15000 DRUGINFO D0EZ9C CTLA-4-XTEN Investigative T15000 DRUGINFO D0W7ZS Del 60 tetramer Investigative T15000 DRUGINFO DZ7EG5 YH006 Investigative T15000 DRUGINFO D0G6XS Fucose Investigative T15000 DRUGINFO D07LUR Alpha-D-Mannose Investigative T41201 TARGETID T41201 T41201 FORMERID TTDS00230 T41201 UNIPROID DPEP1_HUMAN T41201 TARGNAME Dehydropeptidase I (DPEP1) T41201 GENENAME DPEP1 T41201 TARGTYPE Successful T41201 SYNONYMS hRDP; Renal dipeptidase; RDP; Microsomal dipeptidase; MDP; Dipeptidase 1; Dehydropeptidase-I T41201 FUNCTION Implicated in the renal metabolism of glutathione and its conjugates. Converts leukotriene D4 to leukotriene E4; it may play an important role in the regulation of leukotriene activity. Hydrolyzes a wide range of dipeptides. T41201 PDBSTRUC 1ITU; 1ITQ T41201 BIOCLASS Peptidase T41201 ECNUMBER EC 3.4.13.19 T41201 SEQUENCE MWSGWWLWPLVAVCTADFFRDEAERIMRDSPVIDGHNDLPWQLLDMFNNRLQDERANLTTLAGTHTNIPKLRAGFVGGQFWSVYTPCDTQNKDAVRRTLEQMDVVHRMCRMYPETFLYVTSSAGIRQAFREGKVASLIGVEGGHSIDSSLGVLRALYQLGMRYLTLTHSCNTPWADNWLVDTGDSEPQSQGLSPFGQRVVKELNRLGVLIDLAHVSVATMKATLQLSRAPVIFSHSSAYSVCASRRNVPDDVLRLVKQTDSLVMVNFYNNYISCTNKANLSQVADHLDHIKEVAGARAVGFGGDFDGVPRVPEGLEDVSKYPDLIAELLRRNWTEAEVKGALADNLLRVFEAVEQASNLTQAPEEEPIPLDQLGGSCRTHYGYSSGASSLHRHWGLLLASLAPLVLCLSLL T41201 DRUGINFO D02GIU Cilastatin Approved T12808 TARGETID T12808 T12808 FORMERID TTDC00182 T12808 UNIPROID KPCA_HUMAN T12808 TARGNAME Protein kinase C alpha (PRKCA) T12808 GENENAME PRKCA T12808 TARGTYPE Successful T12808 SYNONYMS Protein kinase C alpha type; PRKACA; PKCalpha; PKCA; PKC-alpha; PKC-A T12808 FUNCTION Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. During chemokine-induced CD4(+) T cell migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting in its dissociation from LRCH1 and the activation of GTPase CDC42. Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. T12808 PDBSTRUC 4RA4; 4DNL; 3IW4; 2ELI T12808 BIOCLASS Kinase T12808 ECNUMBER EC 2.7.11.13 T12808 SEQUENCE MADVFPGNDSTASQDVANRFARKGALRQKNVHEVKDHKFIARFFKQPTFCSHCTDFIWGFGKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPDTDDPRSKHKFKIHTYGSPTFCDHCGSLLYGLIHQGMKCDTCDMNVHKQCVINVPSLCGMDHTEKRGRIYLKAEVADEKLHVTVRDAKNLIPMDPNGLSDPYVKLKLIPDPKNESKQKTKTIRSTLNPQWNESFTFKLKPSDKDRRLSVEIWDWDRTTRNDFMGSLSFGVSELMKMPASGWYKLLNQEEGEYYNVPIPEGDEEGNMELRQKFEKAKLGPAGNKVISPSEDRKQPSNNLDRVKLTDFNFLMVLGKGSFGKVMLADRKGTEELYAIKILKKDVVIQDDDVECTMVEKRVLALLDKPPFLTQLHSCFQTVDRLYFVMEYVNGGDLMYHIQQVGKFKEPQAVFYAAEISIGLFFLHKRGIIYRDLKLDNVMLDSEGHIKIADFGMCKEHMMDGVTTRTFCGTPDYIAPEIIAYQPYGKSVDWWAYGVLLYEMLAGQPPFDGEDEDELFQSIMEHNVSYPKSLSKEAVSVCKGLMTKHPAKRLGCGPEGERDVREHAFFRRIDWEKLENREIQPPFKPKVCGKGAENFDKFFTRGQPVLTPPDQLVIANIDQSDFEGFSYVNPQFVHPILQSAV T12808 DRUGINFO D0P2GK Sodium phenylbutyrate Approved T12808 DRUGINFO D0F5HB Sotrastaurin acetate Phase 2 T12808 DRUGINFO D0ZG7E PMID28460551-Compound-3 Patented T12808 DRUGINFO D04DDM ISIS 3521 Discontinued in Phase 2 T12808 DRUGINFO D05XMY Acteoside Terminated T12808 DRUGINFO D0X0HN LY-317644 Terminated T12808 DRUGINFO D0R5ZR RO-320432 Terminated T12808 DRUGINFO D0R2TM BALANOL Terminated T12808 DRUGINFO D07ANB 1,2-dioctanoyl-sn-glycerol Investigative T12808 DRUGINFO D07TPU LEUCOSCEPTOSIDE A Investigative T12808 DRUGINFO D0L0UY Plantainoside D Investigative T12808 DRUGINFO D0L8CK CALCEOLARIOSIDE A Investigative T12808 DRUGINFO D0P4JO FORSYTHIASIDE Investigative T12808 DRUGINFO D0W7JA CALCEOLARIOSIDE B Investigative T12808 DRUGINFO D05SLL Diheptan-3-yl 5-(hydroxymethyl)isophthalate Investigative T12808 DRUGINFO D0B1SO TANNIN Investigative T12808 DRUGINFO D0J4NI Dihexan-3-yl 5-(hydroxymethyl)isophthalate Investigative T12808 DRUGINFO D0Q3XB PUNICAFOLIN Investigative T12808 DRUGINFO D0X2DH 3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione Investigative T12808 DRUGINFO D04OHM 4-cyclopentyliden(4-hydroxyphenyl)methylphenol Investigative T12808 DRUGINFO D0L1YA (-)-Cercosporamide Investigative T12808 DRUGINFO D06TLL Go 6983 Investigative T12808 DRUGINFO D00TWA [2,2':5',2'']Terthiophen-4-yl-methanol Investigative T12808 DRUGINFO D02PUV 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol Investigative T12808 DRUGINFO D02QME 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile Investigative T12808 DRUGINFO D05LRV [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde Investigative T12808 DRUGINFO D09TSC Ro-32-0557 Investigative T12808 DRUGINFO D09XIE 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile Investigative T12808 DRUGINFO D0A8MN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile Investigative T12808 DRUGINFO D0D3MR [2,2':5',2'']Terthiophene-4-carbaldehyde Investigative T12808 DRUGINFO D0Q3GQ 4-cycloheptyliden(4-hydroxyphenyl)methylphenol Investigative T12808 DRUGINFO D0S9UK 2,3,3-Triphenyl-acrylonitrile Investigative T12808 DRUGINFO D0T0UH 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile Investigative T12808 DRUGINFO D0V9SW 4-cyclohexyliden(4-hydroxyphenyl)methylphenol Investigative T12808 DRUGINFO D04JNZ PROSTRATIN Investigative T12808 DRUGINFO D0G2VC KT-5720 Investigative T12808 DRUGINFO D06ZCX LY-326449 Investigative T12808 DRUGINFO D0GB4V STAUROSPORINONE Investigative T12808 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T12808 DRUGINFO D0M5FF Ro31-8220 Investigative T12808 DRUGINFO D0N6ES KN-62 Investigative T12808 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T12808 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T12808 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T12808 DRUGINFO D0B9BU CI-1040 Investigative T12808 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T12808 DRUGINFO D0L8HO RO-316233 Investigative T08910 TARGETID T08910 T08910 FORMERID TTDS00428 T08910 UNIPROID GBRG2_HUMAN T08910 TARGNAME GABA(A) receptor gamma-2 (GABRG2) T08910 GENENAME GABRG2 T08910 TARGTYPE Successful T08910 SYNONYMS Gamma-aminobutyric acid receptor subunit gamma-2; GABA(A) receptor subunit gamma-2 T08910 FUNCTION Plays an important role in the formation of functional inhibitory GABAergic synapses in addition to mediating synaptic inhibition as a GABA-gated ion channel. The gamma2 subunit is necessary but not sufficient for a rapid formation of active synaptic contacts and the synaptogenic effect of this subunit is influenced by the type of alpha and beta subunits present in the receptor pentamer. The alpha1/beta2/gamma2 receptor and the alpha1/beta3/gamma2 receptor exhibit synaptogenic activity. The alpha2/beta2/gamma2 receptor exhibits synatogenic activity whereas the alpha2/beta3/gamma2 receptor shows very little or no synaptogenic activity. Functions also as histamine receptor and mediates cellular responses to histamine. Ligand-gated chloride channel which is a component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the brain. T08910 PDBSTRUC 6I53; 6HUP; 6HUO; 6HUK; 6HUJ T08910 BIOCLASS Neurotransmitter receptor T08910 SEQUENCE MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLTPKVPEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYVNSIGPVNAINMEYTIDIFFAQTWYDRRLKFNSTIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWNDGRVLYTLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWKRSSVEVGDTRSWRLYQFSFVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLSWVSFWINKDAVPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFSALVEYGTLHYFVSNRKPSKDKDKKKKNPAPTIDIRPRSATIQMNNATHLQERDEEYGYECLDGKDCASFFCCFEDCRTGAWRHGRIHIRIAKMDSYARIFFPTAFCLFNLVYWVSYLYL T08910 DRUGINFO D00VZZ Allopregnanolone approved T08910 DRUGINFO D0IG4I THIOCOLCHICOSIDE Approved T08910 DRUGINFO D07ZCK ZK-93423 Phase 3 T08910 DRUGINFO D0C9XA GSK683699 Phase 2 T08910 DRUGINFO D0B8YZ ELTANOLONE Discontinued in Phase 3 T08910 DRUGINFO D05EVI U-78875 Discontinued in Phase 1 T08910 DRUGINFO D06BFP CGS-17867A Terminated T08910 DRUGINFO D0V4GI CGS-9896 Terminated T08910 DRUGINFO D00OAN 9H-beta-Carboline-3-carboxylic acid propyl ester Investigative T08910 DRUGINFO D00SXO 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one Investigative T08910 DRUGINFO D01BVR 5-(4-piperidyl)-4-propylisothiazol-3-ol Investigative T08910 DRUGINFO D02XUD 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol Investigative T08910 DRUGINFO D04PQN N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide Investigative T08910 DRUGINFO D05WEF N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide Investigative T08910 DRUGINFO D06QOX 1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one Investigative T08910 DRUGINFO D06ZOM 3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one Investigative T08910 DRUGINFO D09AVL 4-benzyl-5-(4-piperidyl)isothiazol-3-ol Investigative T08910 DRUGINFO D0D6IU 2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide Investigative T08910 DRUGINFO D0GE4A N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide Investigative T08910 DRUGINFO D0J9SS 6-Nitro-2-(3-nitro-phenyl)-chromen-4-one Investigative T08910 DRUGINFO D0JV5L 4-Methyl-5-(4-piperidyl)isothiazol-3-ol Investigative T08910 DRUGINFO D0KS2X CGS-9895 Investigative T08910 DRUGINFO D0P3FZ 5-(piperidin-4-yl)isothiazol-3-ol Investigative T08910 DRUGINFO D0S9YE (beta-CCE)9H-beta-Carboline-3-carboxylic acid Investigative T08910 DRUGINFO D0V2LK 6-Nitro-2-(4-nitro-phenyl)-chromen-4-one Investigative T08910 DRUGINFO D00CQR 6-Methyl-2-oxa-spiro[4.4]nonan-1-one Investigative T08910 DRUGINFO D00VWR 3,3-Diethyl-dihydro-furan-2-one Investigative T08910 DRUGINFO D00WON 3-Ethyl-3-methyl-dihydro-furan-2-one Investigative T08910 DRUGINFO D01OZS 3,3-Diisopropyl-dihydro-furan-2-one Investigative T08910 DRUGINFO D01PPZ Ridine-5-carboxylic acid ethyl ester Investigative T08910 DRUGINFO D01UZT 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole Investigative T08910 DRUGINFO D02FXS 3-carboxy-6-ethyl-4-quinolone Investigative T08910 DRUGINFO D02RUV 3-Isopropyl-3-methyl-dihydro-furan-2-one Investigative T08910 DRUGINFO D02XXK (9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine Investigative T08910 DRUGINFO D03CKN 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone Investigative T08910 DRUGINFO D03EOK N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide Investigative T08910 DRUGINFO D03FBS 6-ethyl-3-propoxycarbonyl-4-quinolone Investigative T08910 DRUGINFO D03OEN N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide Investigative T08910 DRUGINFO D03OQG 1-Methyl-5-oxa-spiro[2.4]heptan-4-one Investigative T08910 DRUGINFO D03YLX 3-Methyl-9H-beta-carboline Investigative T08910 DRUGINFO D04EOV 3-ethoxycarbonyl-6-propyl-4-quinolone Investigative T08910 DRUGINFO D05OOA 6-ethyl-3-pentoxycarbonyl-4-quinolone Investigative T08910 DRUGINFO D05SVA 5-(piperidin-4-yl)isoxazol-3-ol Investigative T08910 DRUGINFO D05TVT 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone Investigative T08910 DRUGINFO D06EUJ 3-butoxycarbonyl-4-quinolone Investigative T08910 DRUGINFO D06GAI 1-(4-chlorophenyl)-4-phenyl-1H-imidazole Investigative T08910 DRUGINFO D06OSB 6-ethyl-3-i-propoxycarbonyl-4-quinolone Investigative T08910 DRUGINFO D07OON 3-Ethyl-3-isopropyl-dihydro-furan-2-one Investigative T08910 DRUGINFO D07QGN CGS-13767 Investigative T08910 DRUGINFO D08AID 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone Investigative T08910 DRUGINFO D08HGK N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide Investigative T08910 DRUGINFO D09AYK 3-ethoxycarbonyl-4-quinolone Investigative T08910 DRUGINFO D09CQO 2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline Investigative T08910 DRUGINFO D09RWW 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone Investigative T08910 DRUGINFO D0AR4P 2-(9-Benzyl-9H-purin-6-ylamino)-ethanol Investigative T08910 DRUGINFO D0B4CQ 6-benzyl-3-propylaminocarbonyl-4-quinolone Investigative T08910 DRUGINFO D0B4WR 2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline Investigative T08910 DRUGINFO D0CR6M 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone Investigative T08910 DRUGINFO D0D2PJ GNF-PF-4421 Investigative T08910 DRUGINFO D0ER0L 4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T08910 DRUGINFO D0FQ2N 3-Isothiocyanato-9H-beta-carboline Investigative T08910 DRUGINFO D0FR4S 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol Investigative T08910 DRUGINFO D0G6IG 3-butoxycarbonyl-6-ethyl-4-quinolone Investigative T08910 DRUGINFO D0H0DP 3-amino-3-demethoxythiocolchicine Investigative T08910 DRUGINFO D0H0NE 6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one Investigative T08910 DRUGINFO D0I4HT 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol Investigative T08910 DRUGINFO D0J0CA BETA-CCM Investigative T08910 DRUGINFO D0J9VP 3-tert-Butyl-3-ethyl-dihydro-furan-2-one Investigative T08910 DRUGINFO D0K2CZ 1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one Investigative T08910 DRUGINFO D0KS3X U-89267 Investigative T08910 DRUGINFO D0L2KB RO-145974 Investigative T08910 DRUGINFO D0M0ZX 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone Investigative T08910 DRUGINFO D0M2AY 6-ethyl-3-propylaminocarbonyl-4-quinolone Investigative T08910 DRUGINFO D0O9SG 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one Investigative T08910 DRUGINFO D0Q8UV RO-145975 Investigative T08910 DRUGINFO D0R1IL 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol Investigative T08910 DRUGINFO D0S6ME 6-benzyl-3-propoxycarbonyl-4-quinolone Investigative T08910 DRUGINFO D0TJ2L RO-147437 Investigative T08910 DRUGINFO D0U9ET 6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one Investigative T08910 DRUGINFO D0UQ6J RO-194603 Investigative T08910 DRUGINFO D0W5IP GNF-PF-3645 Investigative T08910 DRUGINFO D0WC5L 3-butylaminocarbonyl-6-ethyl-4-quinolone Investigative T08910 DRUGINFO D0X4OW 2-Oxa-spiro[4.4]nonan-1-one Investigative T08910 DRUGINFO D0YS9E 4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T08910 DRUGINFO D01UAS 6-bromo-3-ethoxycarbonyl-4-quinolone Investigative T08910 DRUGINFO D02CZO 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone Investigative T08910 DRUGINFO D03LMR 6-benzyl-3-ethoxycarbonyl-4-quinolone Investigative T08910 DRUGINFO D0H4GQ RY-066 Investigative T08910 DRUGINFO D01CUR 3-Ethoxy-9H-beta-carboline Investigative T08910 DRUGINFO D01RLF 9H-beta-Carboline-3-carboxylic acid ethyl ester Investigative T08910 DRUGINFO D03PPZ Beta-Carboline-3-carboxylic acid t-butyl ester Investigative T08910 DRUGINFO D04RVA 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine Investigative T08910 DRUGINFO D06WMM 3-Butoxy-9H-beta-carboline Investigative T08910 DRUGINFO D06XGL 3-demethoxy-3-D-xylopyranosylaminothiocolchicine Investigative T08910 DRUGINFO D08BOP 3-Propoxy-9H-beta-carboline Investigative T08910 DRUGINFO D08BXK 3-(3-Methyl-butoxy)-9H-beta-carboline Investigative T08910 DRUGINFO D08YLW 3-demethoxy-3-L-fucopyranosylaminothiocolchicine Investigative T08910 DRUGINFO D09MHS 3-demethoxy-3D-glucopyranosylaminothiocolchicine Investigative T08910 DRUGINFO D09MYJ 3-Isobutoxy-9H-beta-carboline Investigative T08910 DRUGINFO D0C6WO Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate Investigative T08910 DRUGINFO D0D4MM Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate Investigative T08910 DRUGINFO D0E7PY Ro-4938581 Investigative T08910 DRUGINFO D0LP2K 3-demethoxy-3-D-mannopyranosylaminothiocolchicine Investigative T08910 DRUGINFO D0O9MG L-655708 Investigative T08910 DRUGINFO D0P3BU 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole Investigative T08910 DRUGINFO D0R5OU 3-(benzyloxy)-9H-pyrido[3,4-b]indole Investigative T08910 DRUGINFO D01IHM CI-218872 Investigative T08910 DRUGINFO D07NKO 5-[(1R)-1-ammonioethyl]isoxazol-3-olate Investigative T08910 DRUGINFO D09ACO (2E,4S)-4-ammoniopent-2-enoate Investigative T08910 DRUGINFO D0A8EU (4R)-4-ammoniopentanoate Investigative T08910 DRUGINFO D0N0ZK (4S)-4-ammoniopentanoate Investigative T08910 DRUGINFO D0S5PS 5-[(1S)-1-ammonioethyl]isoxazol-3-olate Investigative T08910 DRUGINFO D00WHO Ro-15-3505 Investigative T08910 DRUGINFO D0M4CP [3H]Ro154513 Investigative T08910 DRUGINFO D0M9RM [3H]CGS8216 Investigative T08910 DRUGINFO D06HRX AMENTOFLAVONE Investigative T08910 DRUGINFO D0P0TI TBPS Investigative T65197 TARGETID T65197 T65197 FORMERID TTDS00144 T65197 UNIPROID EPOR_HUMAN T65197 TARGNAME Erythropoietin Receptor (EPOR) T65197 GENENAME EPOR T65197 TARGTYPE Successful T65197 SYNONYMS Full-length form; EPO-R T65197 FUNCTION Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Receptor for erythropoietin. T65197 PDBSTRUC 6E2Q; 4Y5Y; 4Y5X; 4Y5V; 2MV6 T65197 BIOCLASS Cytokine receptor T65197 SEQUENCE MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDLVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPLELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRYEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPVSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTHKGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVGSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGASAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGLSDGPYSNPYENSLIPAAEPLPPSYVACS T65197 DRUGINFO D02LVZ Darbepoetin alfa Approved T65197 DRUGINFO D07PBZ Epoetin alfa Approved T65197 DRUGINFO D0K3XP Methoxy polyethylene glycol-epoetin beta Approved T65197 DRUGINFO D0U1TA RHuEPO Approved T65197 DRUGINFO D04YHG ErepoXen Phase 3 T65197 DRUGINFO D0DV3T Epoetin zeta Phase 3 T65197 DRUGINFO D0S7KQ Hematide Phase 3 T65197 DRUGINFO D0F5AR Cibinetide Phase 2 T65197 DRUGINFO D03PVY GlycoPEGylated erythropoietin Discontinued in Phase 2 T65197 DRUGINFO D0ZV6W Albupoietin Terminated T65197 DRUGINFO D01ESC BBT-009 Investigative T65197 DRUGINFO D06QIW EPO peptide mimetics Investigative T65197 DRUGINFO D0C7KB Nova-EPO Investigative T65197 DRUGINFO D0D5FB EPO-derived peptide Investigative T65197 DRUGINFO D0G5JW Erythropoietin Investigative T65197 DRUGINFO D0J0GJ P-1116 Investigative T65197 DRUGINFO D0L6PZ PT-401 Investigative T65197 DRUGINFO D0O6TD BBT-021 Investigative T65197 DRUGINFO D0R3JO PEG-EPO Investigative T65197 DRUGINFO D0U9PX 3,5 DIBROMOTYROSINE Investigative T37539 TARGETID T37539 T37539 FORMERID TTDS00480 T37539 UNIPROID CD22_HUMAN T37539 TARGNAME B-cell receptor CD22 (CD22) T37539 GENENAME CD22 T37539 TARGTYPE Successful T37539 SYNONYMS T-cell surface antigen Leu-14; Siglec-2; Sialic acid-binding Ig-like lectin 2; SIGLEC2; Leu-14; BL-CAM; B-lymphocyte cell adhesion molecule T37539 FUNCTION May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. Mediates B-cell B-cell interactions. T37539 PDBSTRUC 5VL3; 5VKM; 5VKJ T37539 BIOCLASS Immunoglobulin T37539 SEQUENCE MHLLGPWLLLLVLEYLAFSDSSKWVFEHPETLYAWEGACVWIPCTYRALDGDLESFILFHNPEYNKNTSKFDGTRLYESTKDGKVPSEQKRVQFLGDKNKNCTLSIHPVHLNDSGQLGLRMESKTEKWMERIHLNVSERPFPPHIQLPPEIQESQEVTLTCLLNFSCYGYPIQLQWLLEGVPMRQAAVTSTSLTIKSVFTRSELKFSPQWSHHGKIVTCQLQDADGKFLSNDTVQLNVKHTPKLEIKVTPSDAIVREGDSVTMTCEVSSSNPEYTTVSWLKDGTSLKKQNTFTLNLREVTKDQSGKYCCQVSNDVGPGRSEEVFLQVQYAPEPSTVQILHSPAVEGSQVEFLCMSLANPLPTNYTWYHNGKEMQGRTEEKVHIPKILPWHAGTYSCVAENILGTGQRGPGAELDVQYPPKKVTTVIQNPMPIREGDTVTLSCNYNSSNPSVTRYEWKPHGAWEEPSLGVLKIQNVGWDNTTIACAACNSWCSWASPVALNVQYAPRDVRVRKIKPLSEIHSGNSVSLQCDFSSSHPKEVQFFWEKNGRLLGKESQLNFDSISPEDAGSYSCWVNNSIGQTASKAWTLEVLYAPRRLRVSMSPGDQVMEGKSATLTCESDANPPVSHYTWFDWNNQSLPYHSQKLRLEPVKVQHSGAYWCQGTNSVGKGRSPLSTLTVYYSPETIGRRVAVGLGSCLAILILAICGLKLQRRWKRTQSQQGLQENSSGQSFFVRNKKVRRAPLSEGPHSLGCYNPMMEDGISYTTLRFPEMNIPRTGDAESSEMQRPPPDCDDTVTYSALHKRQVGDYENVIPDFPEDEGIHYSELIQFGVGERPQAQENVDYVILKH T37539 DRUGINFO D00HPD Moxetumomab pasudotox Approved T37539 DRUGINFO D00QEP Inotuzumab ozogamicin Approved T37539 DRUGINFO D0W9OR OspA lipoprotein Approved T37539 DRUGINFO D0I9VO Epratuzumab Phase 3 T37539 DRUGINFO D01AAH CAR-T cells targeting CD22 Phase 2 T37539 DRUGINFO D0M3GQ BL-22 Phase 2 T37539 DRUGINFO D03IHD Anti-CD22-CAR-transduced T cells Phase 1/2 T37539 DRUGINFO D0IN2K CD22 CAR-T Phase 1/2 T37539 DRUGINFO D0P0NS CD22-Targeted CAR-T cells Phase 1/2 T37539 DRUGINFO D0PD4C CAR-T cells targeting CD22 Phase 1/2 T37539 DRUGINFO D0ZQ3K Anti-CD22 CAR-T cells Phase 1/2 T37539 DRUGINFO D02ONA AUTO3 Phase 1/2 T37539 DRUGINFO D05OAI CART-19/22 Phase 1/2 T37539 DRUGINFO D05VNS CD19 and CD22 CAR-T Cells Phase 1/2 T37539 DRUGINFO D08FVH 4SCAR19/22 T cells Phase 1/2 T37539 DRUGINFO D08JTI Anti-CD19/22-CAR vector-transduced T cells Phase 1/2 T37539 DRUGINFO D0E2CS CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells Phase 1/2 T37539 DRUGINFO D0J7VH 4SCAR19 and 4SCAR22 Phase 1/2 T37539 DRUGINFO D0W4SM CD19 and CD22 CAR-T Cells Phase 1/2 T37539 DRUGINFO D01HGT Anti-CD22 Phase 1 T37539 DRUGINFO D02NSS CART-22 cells Phase 1 T37539 DRUGINFO D09AXQ CD22-CART Phase 1 T37539 DRUGINFO D09DIQ CART22 cells expressing anti-CD22 scFv TCRz:41BB Phase 1 T37539 DRUGINFO D0GJ2G Anti-CD22 CAR-T cells Phase 1 T37539 DRUGINFO D0GR9H CD22-specific CAR T-cells also expressing an EGFRt Phase 1 T37539 DRUGINFO D0JG2X JCAR018 Phase 1 T37539 DRUGINFO D0PO0L Retroviral vector-transduced autologous T cells to express CD22-specific CARs Phase 1 T37539 DRUGINFO D0QV9Q CART22 cells Phase 1 T37539 DRUGINFO D0ZP8Z CART22-65s cells Phase 1 T37539 DRUGINFO D7C3JA UCART-22 Phase 1 T37539 DRUGINFO DNML54 Lumoxiti Phase 1 T37539 DRUGINFO DQC80I TRPH-222 Phase 1 T37539 DRUGINFO D00JCB CD19/CD22 CAR T cells Phase 1 T37539 DRUGINFO D02BAA Patient-derived CD19- and CD22 specific CAR Phase 1 T37539 DRUGINFO D02LNU CART22-65s cells and huCART19 Cells Phase 1 T37539 DRUGINFO D03YEM CD19/CD22 CAR T-Cells Phase 1 T37539 DRUGINFO D06RUK Combotox Phase 1 T37539 DRUGINFO D0D7FV CD19/CD22 Chimeric Antigen Receptor T Cells Phase 1 T37539 DRUGINFO D0U1HR Donor-derived CD19/22 bispecific CAR-T cells Phase 1 T37539 DRUGINFO DH7ZV4 JNJ-75348780 Phase 1 T37539 DRUGINFO D0EI1U DCDT-2980S Discontinued in Phase 2 T37539 DRUGINFO D0J9UB RG7593 Discontinued in Phase 2 T37539 DRUGINFO DY2EJ1 ATA2431 Preclinical T37539 DRUGINFO D0Q3WP MEDI-553 Investigative T37539 DRUGINFO D0V2QU Anti-CD22/CD19 mab-toxin conjugate Investigative T51666 TARGETID T51666 T51666 FORMERID TTDS00044 T51666 UNIPROID ATP4A_HUMAN T51666 TARGNAME Gastric H(+)/K(+) ATPase alpha (ATP4A) T51666 GENENAME ATP4A T51666 TARGTYPE Successful T51666 SYNONYMS Gastric H+/K+ ATPase alpha subunit; Gastric H(+)/K(+)-ATPase; ATP4A T51666 FUNCTION Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach. T51666 BIOCLASS Acid anhydrides hydrolase T51666 ECNUMBER EC 7.2.2.19 T51666 SEQUENCE MGKAENYELYSVELGPGPGGDMAAKMSKKKKAGGGGGKRKEKLENMKKEMEINDHQLSVAELEQKYQTSATKGLSASLAAELLLRDGPNALRPPRGTPEYVKFARQLAGGLQCLMWVAAAICLIAFAIQASEGDLTTDDNLYLAIALIAVVVVTGCFGYYQEFKSTNIIASFKNLVPQQATVIRDGDKFQINADQLVVGDLVEMKGGDRVPADIRILAAQGCKVDNSSLTGESEPQTRSPECTHESPLETRNIAFFSTMCLEGTVQGLVVNTGDRTIIGRIASLASGVENEKTPIAIEIEHFVDIIAGLAILFGATFFIVAMCIGYTFLRAMVFFMAIVVAYVPEGLLATVTVCLSLTAKRLASKNCVVKNLEAVETLGSTSVICSDKTGTLTQNRMTVSHLWFDNHIHTADTTEDQSGQTFDQSSETWRALCRVLTLCNRAAFKSGQDAVPVPKRIVIGDASETALLKFSELTLGNAMGYRDRFPKVCEIPFNSTNKFQLSIHTLEDPRDPRHLLVMKGAPERVLERCSSILIKGQELPLDEQWREAFQTAYLSLGGLGERVLGFCQLYLNEKDYPPGYAFDVEAMNFPSSGLCFAGLVSMIDPPRATVPDAVLKCRTAGIRVIMVTGDHPITAKAIAASVGIISEGSETVEDIAARLRVPVDQVNRKDARACVINGMQLKDMDPSELVEALRTHPEMVFARTSPQQKLVIVESCQRLGAIVAVTGDGVNDSPALKKADIGVAMGIAGSDAAKNAADMILLDDNFASIVTGVEQGRLIFDNLKKSIAYTLTKNIPELTPYLIYITVSVPLPLGCITILFIELCTDIFPSVSLAYEKAESDIMHLRPRNPKRDRLVNEPLAAYSYFQIGAIQSFAGFTDYFTAMAQEGWFPLLCVGLRAQWEDHHLQDLQDSYGQEWTFGQRLYQQYTCYTVFFISIEVCQIADVLIRKTRRLSAFQQGFFRNKILVIAIVFQVCIGCFLCYCPGMPNIFNFMPIRFQWWLVPLPYGILIFVYDEIRKLGVRCCPGSWWDQELYY T51666 DRUGINFO D0KL4J Rabeprazole Approved T51666 DRUGINFO D06YYD Dexlansoprazole Approved T51666 DRUGINFO D0B2ZZ Esomeprazole magnesium + Aspirin Phase 3 T51666 DRUGINFO D0V3ZN AG-SPT201 Phase 3 T51666 DRUGINFO D0Z9NY API-023 Phase 1 T51666 DRUGINFO D0K1UF Saliphenylhalamide Preclinical T51666 DRUGINFO D03SSG PA-10040 Investigative T51666 DRUGINFO D06ZAK CA-50040 Investigative T51666 DRUGINFO D0E2MI ARH-1029 Investigative T51666 DRUGINFO D0K6LA OPC-22575 Investigative T51666 DRUGINFO D0N0KG CDRI-85/92 Investigative T35640 TARGETID T35640 T35640 FORMERID TTDS00444 T35640 UNIPROID ITAL_HUMAN T35640 TARGNAME Integrin alpha-L (ITGAL) T35640 GENENAME ITGAL T35640 TARGTYPE Successful T35640 SYNONYMS Lymphocyte Function-associated Antigen-1; Leukocyte function-associated molecule 1 alpha chain; Leukocyte function associated molecule 1, alpha chain; Leukocyte adhesion glycoprotein LFA-1 alpha chain; LFA-1A; LFA-1; CD11a; CD11 antigen-like family member A T35640 FUNCTION Integrin ITGAL/ITGB2 is a receptor for F11R. Integin ITGAL/ITGB2 is a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL. Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Required for generation of common lymphoid progenitor cells in bone marrow, indicating a role in lymphopoiesis. Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages. Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. T35640 PDBSTRUC 6CKB; 6BXJ; 6BXF; 6BXB; 5E6U T35640 BIOCLASS Integrin T35640 SEQUENCE MKDSCITVMAMALLSGFFFFAPASSYNLDVRGARSFSPPRAGRHFGYRVLQVGNGVIVGAPGEGNSTGSLYQCQSGTGHCLPVTLRGSNYTSKYLGMTLATDPTDGSILACDPGLSRTCDQNTYLSGLCYLFRQNLQGPMLQGRPGFQECIKGNVDLVFLFDGSMSLQPDEFQKILDFMKDVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYVATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLHKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEGTSKQDLTSFNMELSSSGISADLSRGHAVVGAVGAKDWAGGFLDLKADLQDDTFIGNEPLTPEVRAGYLGYTVTWLPSRQKTSLLASGAPRYQHMGRVLLFQEPQGGGHWSQVQTIHGTQIGSYFGGELCGVDVDQDGETELLLIGAPLFYGEQRGGRVFIYQRRQLGFEEVSELQGDPGYPLGRFGEAITALTDINGDGLVDVAVGAPLEEQGAVYIFNGRHGGLSPQPSQRIEGTQVLSGIQWFGRSIHGVKDLEGDGLADVAVGAESQMIVLSSRPVVDMVTLMSFSPAEIPVHEVECSYSTSNKMKEGVNITICFQIKSLIPQFQGRLVANLTYTLQLDGHRTRRRGLFPGGRHELRRNIAVTTSMSCTDFSFHFPVCVQDLISPINVSLNFSLWEEEGTPRDQRAQGKDIPPILRPSLHSETWEIPFEKNCGEDKKCEANLRVSFSPARSRALRLTAFASLSVELSLSNLEEDAYWVQLDLHFPPGLSFRKVEMLKPHSQIPVSCEELPEESRLLSRALSCNVSSPIFKAGHSVALQMMFNTLVNSSWGDSVELHANVTCNNEDSDLLEDNSATTIIPILYPINILIQDQEDSTLYVSFTPKGPKIHQVKHMYQVRIQPSIHDHNIPTLEAVVGVPQPPSEGPITHQWSVQMEPPVPCHYEDLERLPDAAEPCLPGALFRCPVVFRQEILVQVIGTLELVGEIEASSMFSLCSSLSISFNSSKHFHLYGSNASLAQVVMKVDVVYEKQMLYLYVLSGIGGLLLLLLIFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDSEQLASGQEAGDPGCLKPLHEKDSESGGGKD T35640 DRUGINFO D03SGR Efalizumab Approved T35640 DRUGINFO D0Q9EV lifitegrast Approved T35640 DRUGINFO D0W7GH IC-747 Discontinued in Phase 2 T35640 DRUGINFO D0GT8W BMS-587101 Discontinued in Phase 2 T35640 DRUGINFO D03RYN Cytolin Preclinical T35640 DRUGINFO D00FIV Leukotoxin Investigative T35640 DRUGINFO D0W3WW LFA703 Investigative T35640 DRUGINFO D07XCA A-286982 Investigative T76685 TARGETID T76685 T76685 FORMERID TTDS00334 T76685 UNIPROID CNR1_HUMAN T76685 TARGNAME Cannabinoid receptor 1 (CB1) T76685 GENENAME CNR1 T76685 TARGTYPE Successful T76685 SYNONYMS Cannabinoid CB1 receptor; CNR; CB-R; CANN6 T76685 FUNCTION Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP. In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission. In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner. In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone. Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes. In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism. In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism. In response to cannabinoid anandamide, elicits a proinflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion. In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells. G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC). T76685 PDBSTRUC 6N4B; 5XRA; 5XR8; 5U09; 5TGZ T76685 BIOCLASS GPCR rhodopsin T76685 SEQUENCE MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPLTSFRGSPFQEKMTAGDNPQLVPADQVNITEFYNKSLSSFKENEENIQCGENFMDIECFMVLNPSQQLAIAVLSLTLGTFTVLENLLVLCVILHSRSLRCRPSYHFIGSLAVADLLGSVIFVYSFIDFHVFHRKDSRNVFLFKLGGVTASFTASVGSLFLTAIDRYISIHRPLAYKRIVTRPKAVVAFCLMWTIAIVIAVLPLLGWNCEKLQSVCSDIFPHIDETYLMFWIGVTSVLLLFIVYAYMYILWKAHSHAVRMIQRGTQKSIIIHTSEDGKVQVTRPDQARMDIRLAKTLVLILVVLIICWGPLLAIMVYDVFGKMNKLIKTVFAFCSMLCLLNSTVNPIIYALRSKDLRHAFRSMFPSCEGTAQPLDNSMGDSDCLHKHANNAASVHRAAESCIKSTVKIAKVTMSVSTDTSAEAL T76685 DRUGINFO D0O3OS SR141716A Approved T76685 DRUGINFO D0P1FO Marinol Approved T76685 DRUGINFO D0L7AS NABILONE Approved T76685 DRUGINFO D0T9TJ Orlistat Approved T76685 DRUGINFO D0Y6MH Tebipenem Phase 3 T76685 DRUGINFO D0W3GL SR-147778 Phase 2 T76685 DRUGINFO DA6NG5 Nimacimab Phase 2 T76685 DRUGINFO DN8VS3 AEF0117 Phase 2 T76685 DRUGINFO D05BMC GW-42004 Phase 2 T76685 DRUGINFO D00WME Conatumumab Phase 2 T76685 DRUGINFO D09KYZ V-24343 Phase 1 T76685 DRUGINFO D0D3UI ZY01 Phase 1 T76685 DRUGINFO D0VH3H TM38837 Phase 1 T76685 DRUGINFO DJ8B6F GFB-024 Phase 1 T76685 DRUGINFO D00BXK Pyrazole derivative 39 Patented T76685 DRUGINFO D00TBI Imidazole derivative 7 Patented T76685 DRUGINFO D00TMQ Azetidine-1-carboxamide derivative 3 Patented T76685 DRUGINFO D00XDN Pyrazole derivative 40 Patented T76685 DRUGINFO D00XFT Pyrazole derivative 53 Patented T76685 DRUGINFO D01HJQ Aminoazetidine derivative 1 Patented T76685 DRUGINFO D01KJZ Pyrazole derivative 4 Patented T76685 DRUGINFO D01RIT Pyrazole derivative 20 Patented T76685 DRUGINFO D01WWN Pyrazole derivative 57 Patented T76685 DRUGINFO D01XVK Pyrazoline derivative 2 Patented T76685 DRUGINFO D02NNZ 1,2,4-triazole derivative 1 Patented T76685 DRUGINFO D02OBW Aminoazetidine derivative 2 Patented T76685 DRUGINFO D02SNQ Pyrazole derivative 8 Patented T76685 DRUGINFO D02XYT Furopyridine derivative 1 Patented T76685 DRUGINFO D02ZVY Diphenyl purine derivative 4 Patented T76685 DRUGINFO D03FDN PMID26161824-Compound-69 Patented T76685 DRUGINFO D03GLK Imidazole derivative 1 Patented T76685 DRUGINFO D03HHD Pyrazoline derivative 4 Patented T76685 DRUGINFO D03TDK Sulfonamide derivative 1 Patented T76685 DRUGINFO D03WCJ 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1 Patented T76685 DRUGINFO D04BXA Pyrazole derivative 32 Patented T76685 DRUGINFO D04KUJ Purine derivative 1 Patented T76685 DRUGINFO D04MPV Pyrazole derivative 15 Patented T76685 DRUGINFO D04QVK 1,2,4-tri-substituted imidazoline derivative 1 Patented T76685 DRUGINFO D04ZLC N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1 Patented T76685 DRUGINFO D05GDS N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2 Patented T76685 DRUGINFO D05NUN Pyrazole derivative 36 Patented T76685 DRUGINFO D05TQG Pyrazole derivative 30 Patented T76685 DRUGINFO D05VIN Imidazole derivative 2 Patented T76685 DRUGINFO D06CEA Purine derivative 3 Patented T76685 DRUGINFO D06FOF Imidazole derivative 5 Patented T76685 DRUGINFO D06IPV Pyrazolo[1,5-a]pyrimidine derivative 2 Patented T76685 DRUGINFO D06MIW Pyrazole derivative 37 Patented T76685 DRUGINFO D06MPH Pyrazole derivative 28 Patented T76685 DRUGINFO D06STK Purine derivative 2 Patented T76685 DRUGINFO D07GJH PMID26161824-Compound-68 Patented T76685 DRUGINFO D07NAA Sulfonylated piperazine derivative 4 Patented T76685 DRUGINFO D07PIH Pyrazole derivative 60 Patented T76685 DRUGINFO D07PND Diphenyl purine derivative 1 Patented T76685 DRUGINFO D07QLD Pyrazole derivative 7 Patented T76685 DRUGINFO D07SYY Pyrazolo[1,5-a]pyrimidine derivative 3 Patented T76685 DRUGINFO D08RCV Pyrido[2,3-d]pyrimidine derivative 2 Patented T76685 DRUGINFO D08WTW Pyrazole derivative 12 Patented T76685 DRUGINFO D09IYH Pyrazole derivative 58 Patented T76685 DRUGINFO D09XUI 1,5-diphenylpyrrolidin-2-one derivative 2 Patented T76685 DRUGINFO D0A2PY Pyrazole derivative 35 Patented T76685 DRUGINFO D0AM1D Diaryl piperazine derivative 2 Patented T76685 DRUGINFO D0B6NT Pyrazolo[1,5-a]pyrimidine derivative 11 Patented T76685 DRUGINFO D0BB2F Pyrazole derivative 26 Patented T76685 DRUGINFO D0BI0F Imidazole derivative 3 Patented T76685 DRUGINFO D0C0KI Aminoazetidine derivative 7 Patented T76685 DRUGINFO D0C4TB Pyrazole derivative 22 Patented T76685 DRUGINFO D0CF8Y Pyrazoline derivative 3 Patented T76685 DRUGINFO D0CW1J Pyrrole derivative 5 Patented T76685 DRUGINFO D0CX1F Sulfonylated piperazine derivative 1 Patented T76685 DRUGINFO D0D1EI Diphenyl purine derivative 5 Patented T76685 DRUGINFO D0D5MQ Pyrazole derivative 27 Patented T76685 DRUGINFO D0D7AJ Pyrazoline derivative 11 Patented T76685 DRUGINFO D0D7ZU Pyrazole derivative 23 Patented T76685 DRUGINFO D0DE0C Diphenyl purine derivative 2 Patented T76685 DRUGINFO D0DF6B Azetidine-1-carboxamide derivative 1 Patented T76685 DRUGINFO D0EQ3O Pyrazolo[1,5-a]pyrimidine derivative 4 Patented T76685 DRUGINFO D0ET9U Pyrazoline derivative 1 Patented T76685 DRUGINFO D0F0VY Pyrazolo[1,5-a]pyrimidine derivative 5 Patented T76685 DRUGINFO D0F1DK Pyridotriazolopyrimidine derivative 1 Patented T76685 DRUGINFO D0FC8P Pyrazole derivative 19 Patented T76685 DRUGINFO D0FR1Q Sulfonylated piperazine derivative 3 Patented T76685 DRUGINFO D0FS0D 1,2,3-triazole derivative 2 Patented T76685 DRUGINFO D0FZ5R Imidazolidine-2,4-dione derivative 1 Patented T76685 DRUGINFO D0G8LH Pyrazolo[1,5-a]pyrimidine derivative 8 Patented T76685 DRUGINFO D0GH4B Pyrazolo[1,5-a]pyrimidine derivative 13 Patented T76685 DRUGINFO D0GW8L Pyrrole derivative 2 Patented T76685 DRUGINFO D0GX6V Pyrazole derivative 1 Patented T76685 DRUGINFO D0H1IX Pyrazole derivative 5 Patented T76685 DRUGINFO D0H2GT Pyrrole derivative 3 Patented T76685 DRUGINFO D0HD6C Tetra-hydro-1H-1,2,6-triazaazulene derivative 1 Patented T76685 DRUGINFO D0HD7S Pyrrole derivative 6 Patented T76685 DRUGINFO D0I0VJ Pyrazole derivative 3 Patented T76685 DRUGINFO D0I1VK Heterocyclic-substituted 3-alkyl azetidine derivative 2 Patented T76685 DRUGINFO D0I1XE Diphenyl purine derivative 3 Patented T76685 DRUGINFO D0I5SD Azetidine derivative 1 Patented T76685 DRUGINFO D0IC3K N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1 Patented T76685 DRUGINFO D0IG6J Piperazine derivative 1 Patented T76685 DRUGINFO D0J5NB Pyrazole derivative 25 Patented T76685 DRUGINFO D0J5XM Pyrido[2,3-d]pyrimidine derivative 1 Patented T76685 DRUGINFO D0J8GO Aminoazetidine derivative 4 Patented T76685 DRUGINFO D0JK3V Imidazole derivative 4 Patented T76685 DRUGINFO D0JW7T Amide derivative 1 Patented T76685 DRUGINFO D0K0DV N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2 Patented T76685 DRUGINFO D0K3FJ Imidazole derivative 6 Patented T76685 DRUGINFO D0K6GI Benzimidazole derivative 2 Patented T76685 DRUGINFO D0K7XA Pyrazole derivative 21 Patented T76685 DRUGINFO D0KD5X Pyrazole derivative 31 Patented T76685 DRUGINFO D0KT1Q Pyrazole derivative 11 Patented T76685 DRUGINFO D0KX2W 1,2,4,5-tetra-substituted imidazole derivative 1 Patented T76685 DRUGINFO D0KX8N Diaryl morpholine derivative 1 Patented T76685 DRUGINFO D0L2MA Pyrazolo[1,5-a]pyrimidine derivative 12 Patented T76685 DRUGINFO D0LH9E Imidazolidine-2,4-dione derivative 2 Patented T76685 DRUGINFO D0LU7K Pyrazolo[1,5-a]pyrimidine derivative 6 Patented T76685 DRUGINFO D0LX2Y Aminoazetidine derivative 8 Patented T76685 DRUGINFO D0LZ1Z Pyrazolo[1,5-a]pyrimidine derivative 7 Patented T76685 DRUGINFO D0M2RT Pyrazole derivative 2 Patented T76685 DRUGINFO D0M6PB Pyrrole derivative 1 Patented T76685 DRUGINFO D0M9FZ Pyrazole derivative 6 Patented T76685 DRUGINFO D0N0XU Pyrazole derivative 29 Patented T76685 DRUGINFO D0N6GL Pyrazoline derivative 10 Patented T76685 DRUGINFO D0NB2K Pyrrole derivative 4 Patented T76685 DRUGINFO D0NJ0S Pyrazole derivative 34 Patented T76685 DRUGINFO D0O4RN Sulfonylated piperazine derivative 5 Patented T76685 DRUGINFO D0OT3G Pyrazolo[1,5-a]pyrimidine derivative 10 Patented T76685 DRUGINFO D0P7HQ Pyrazole derivative 13 Patented T76685 DRUGINFO D0P7LP Azetidine derivative 3 Patented T76685 DRUGINFO D0P7QA Pyrazole derivative 14 Patented T76685 DRUGINFO D0PK0R Piperazine derivative 2 Patented T76685 DRUGINFO D0Q5FS Pyrazole derivative 18 Patented T76685 DRUGINFO D0Q9AD Pyrazole derivative 59 Patented T76685 DRUGINFO D0QH5I N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3 Patented T76685 DRUGINFO D0R1PX Pyrano[2,3-b]pyridine derivative 1 Patented T76685 DRUGINFO D0R9PD Hydrazide derivative 1 Patented T76685 DRUGINFO D0RC5I Azetidine derivative 4 Patented T76685 DRUGINFO D0RV2E Pyrazole derivative 17 Patented T76685 DRUGINFO D0S2ME Pyrazoline derivative 5 Patented T76685 DRUGINFO D0S3RX 1,2,3-triazole derivative 1 Patented T76685 DRUGINFO D0S5NS Pyrazole derivative 24 Patented T76685 DRUGINFO D0SV6D Heterocyclic-substituted 3-alkyl azetidine derivative 1 Patented T76685 DRUGINFO D0SW2Q Tetra-hydro-1H-1,2,6-triazaazulene derivative 2 Patented T76685 DRUGINFO D0T0OQ Furopyridine derivative 2 Patented T76685 DRUGINFO D0T7QY Pyrazole derivative 38 Patented T76685 DRUGINFO D0T8VE Aminoazetidine derivative 5 Patented T76685 DRUGINFO D0TI3Q 1,2,4,5-tetra-substituted imidazole derivative 2 Patented T76685 DRUGINFO D0TS3S Heterocyclic-substituted 3-alkyl azetidine derivative 3 Patented T76685 DRUGINFO D0TT0B 1,2,4-triazole derivative 2 Patented T76685 DRUGINFO D0U3VU Aminoazetidine derivative 9 Patented T76685 DRUGINFO D0U3YY Pyrano[2,3-b]pyridine derivative 2 Patented T76685 DRUGINFO D0U6PA Pyrazolo[1,5-a]pyrimidine derivative 9 Patented T76685 DRUGINFO D0UA6W Pyrazole derivative 33 Patented T76685 DRUGINFO D0UW5J PMID27215781-Compound-1 Patented T76685 DRUGINFO D0V0UW Pyridotriazolopyrimidine derivative 2 Patented T76685 DRUGINFO D0V5BV Benzimidazole derivative 1 Patented T76685 DRUGINFO D0VB2M 1,5-diphenylpyrrolidin-2-one derivative 1 Patented T76685 DRUGINFO D0VL5E Aminoazetidine derivative 3 Patented T76685 DRUGINFO D0WK8I Sulfonylated piperazine derivative 2 Patented T76685 DRUGINFO D0X7DZ Pyrazolo[1,5-a]pyrimidine derivative 1 Patented T76685 DRUGINFO D0YN2I Pyrazole derivative 54 Patented T76685 DRUGINFO D0YW3K Pyrazole derivative 16 Patented T76685 DRUGINFO D0Z7EV Carboxamide derivative 1 Patented T76685 DRUGINFO D0Z8WF Pyridotriazolopyrimidine derivative 3 Patented T76685 DRUGINFO D0ZE8B Azetidine-1-carboxamide derivative 2 Patented T76685 DRUGINFO D0ZY6C Diaryl piperazine derivative 1 Patented T76685 DRUGINFO D02TOI Tricyclic phytocannabinoid derivative 2 Patented T76685 DRUGINFO D05CEL 2-cycloalkyl resorcinol cannabinoid ligand derivative 1 Patented T76685 DRUGINFO D07BFP PMID27215781-Compound-37 Patented T76685 DRUGINFO D09GJQ Tricyclic phytocannabinoid derivative 1 Patented T76685 DRUGINFO D09WPA Phytocannabinoid/aminoalkylindole derivative 2 Patented T76685 DRUGINFO D0FA2L N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3 Patented T76685 DRUGINFO D0GQ8W Carbazole-3-carboxamide analog 1 Patented T76685 DRUGINFO D0H0XC 2-cycloalkyl resorcinol cannabinoid ligand derivative 2 Patented T76685 DRUGINFO D0LN9D Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1 Patented T76685 DRUGINFO D0RZ4M Phytocannabinoid/aminoalkylindole derivative 1 Patented T76685 DRUGINFO D0W9PY PMID27215781-Compound-2 Patented T76685 DRUGINFO D0WJ3F N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2 Patented T76685 DRUGINFO D0X5ZS Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2 Patented T76685 DRUGINFO D06TGE Taranabant Discontinued in Phase 3 T76685 DRUGINFO D0J0AE CP-945598 Discontinued in Phase 3 T76685 DRUGINFO D0A9OR SLV319 Discontinued in Phase 2 T76685 DRUGINFO D0J1TS AZD2207 Discontinued in Phase 2 T76685 DRUGINFO D0OM0M AVE1625 Discontinued in Phase 2 T76685 DRUGINFO D0P8MG KDS-2000 Discontinued in Phase 2 T76685 DRUGINFO D0LF5B KN-38-7271 Discontinued in Phase 2 T76685 DRUGINFO D0H1FL PF-514273 Discontinued in Phase 1 T76685 DRUGINFO D0M7LQ CBD cannabis derivative Discontinued in Phase 1 T76685 DRUGINFO D0N0UY AZD1704 Discontinued in Phase 1 T76685 DRUGINFO D0N5SS AZD1175 Discontinued in Phase 1 T76685 DRUGINFO D03KTK TAK-937 Discontinued in Phase 1 T76685 DRUGINFO D00GES JD-5037 Preclinical T76685 DRUGINFO D0H4GB CB1 antagonist, Bayer Preclinical T76685 DRUGINFO D0J7RW WIN-55212-2 Terminated T76685 DRUGINFO D0N5UA Dianicline+rimonabant Terminated T76685 DRUGINFO D00VCW ACEA Investigative T76685 DRUGINFO D01PZU N-ethyl-5,6-dip-tolylpyrazine-2-carboxamide Investigative T76685 DRUGINFO D02MBV [123I]AM251 Investigative T76685 DRUGINFO D03FAI {[(9Z)-octadec-9-en-1-yl]sulfamoyl}amine Investigative T76685 DRUGINFO D03LVT SEMIPLENAMIDE B Investigative T76685 DRUGINFO D03RFS N-(3,3-Diphenyl)propyl-2-phenylacetamide Investigative T76685 DRUGINFO D03RTC BMS-812204 Investigative T76685 DRUGINFO D03TPB 1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea Investigative T76685 DRUGINFO D04YLU AZ-599 Investigative T76685 DRUGINFO D05ACE 1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole Investigative T76685 DRUGINFO D05DFO N-(4-methoxyphenyl)oleamide Investigative T76685 DRUGINFO D05QTX Org27569 Investigative T76685 DRUGINFO D05RGU N-(4-methoxyphenethyl)oleamide Investigative T76685 DRUGINFO D06RIK N-(3,5-dimethoxyphenethyl)oleamide Investigative T76685 DRUGINFO D06RKK SEMIPLENAMIDE A Investigative T76685 DRUGINFO D06YQD N-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide Investigative T76685 DRUGINFO D08DZK N-(2,4-dimethoxyphenethyl)oleamide Investigative T76685 DRUGINFO D08EGA N-(cis-9-cis-12-octadecadienyl)sulfamide Investigative T76685 DRUGINFO D08JHR N-(2-adamantyl)-N'-propylsulfamide Investigative T76685 DRUGINFO D08MON 3-Benzyl-5-methoxy-7-methylchromen-2-one Investigative T76685 DRUGINFO D08UKF N-(3,5-dimethoxyphenethyl)docos-13-enamide Investigative T76685 DRUGINFO D08WRU N-octadecyl-N'-propylsulfamide Investigative T76685 DRUGINFO D08YQT AM251 Investigative T76685 DRUGINFO D09CJO CXB-029 Investigative T76685 DRUGINFO D09DFD CP-4497 Investigative T76685 DRUGINFO D09LVP O-1812 Investigative T76685 DRUGINFO D09QLR Dibenzothiazepines Investigative T76685 DRUGINFO D0A2KW 1-(bis(4-bromophenyl)methyl)-3-phenylurea Investigative T76685 DRUGINFO D0A9PS Anandamide Investigative T76685 DRUGINFO D0B8EP 1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)- Investigative T76685 DRUGINFO D0B8GY N-methyl-5,6-dip-tolylpyrazine-2-carboxamide Investigative T76685 DRUGINFO D0B9RI 3-Benzyl-5-methoxychromen-2-one Investigative T76685 DRUGINFO D0D5SP Semiplenamide G Investigative T76685 DRUGINFO D0E9HC 1-(bis(4-chlorophenyl)methyl)-3-phenylurea Investigative T76685 DRUGINFO D0F4BX HU210 Investigative T76685 DRUGINFO D0G6BG 2-Benzylbenzo[f]chromen-3-one Investigative T76685 DRUGINFO D0GS1B 1-(2-morpholinoethyl)-1H-indol-3-yl acetate Investigative T76685 DRUGINFO D0H1DV N-phenyl-5,6-dip-tolylpyrazine-2-carboxamide Investigative T76685 DRUGINFO D0H6DL 1,3,5-triphenylimidazolidine-2,4-dione Investigative T76685 DRUGINFO D0I1OJ N-(4-morpholinophenyl)docos-13-enamide Investigative T76685 DRUGINFO D0I4YK Methanandamide Investigative T76685 DRUGINFO D0J5KA N-(2,4-dimethoxyphenethyl)docos-13-enamide Investigative T76685 DRUGINFO D0K0EW N-(1-adamantyl)-N'-propylsulfamide Investigative T76685 DRUGINFO D0K5DA N-(4-methoxybenzyl)oleamide Investigative T76685 DRUGINFO D0LX4U 1-[bis(4-bromophenyl)methyl]-3-phenylthiourea Investigative T76685 DRUGINFO D0M4UK PMID26161824C70 Investigative T76685 DRUGINFO D0O4LO 1-(4-CHLOROPHENYL)-2-(2,4-DICHLOROPHENYL)-5-(METHYLSULFINYL)-N-(PIPERIDIN-1-YL)-1H-IMIDAZOLE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D0V0YM MK-5596 Investigative T76685 DRUGINFO D0V2NQ N-(3-Phenyl)propyl-2,2-diphenylacetamide Investigative T76685 DRUGINFO D0WO8A 1,3,5-tris(4-chlorophenyl)imidazolidine-2,4-dione Investigative T76685 DRUGINFO D0X8FV N-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide Investigative T76685 DRUGINFO D0Z9GI 1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea Investigative T76685 DRUGINFO D0ZU9Z LY320135 Investigative T76685 DRUGINFO D00DNT JWH-406 Investigative T76685 DRUGINFO D00LZJ JWH-405 Investigative T76685 DRUGINFO D00QUN Isopropyl 4-nitrophenyl dodecylphosphonate Investigative T76685 DRUGINFO D00TRZ JWH-407 Investigative T76685 DRUGINFO D01JHA 2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol Investigative T76685 DRUGINFO D01JQX JWH-342 Investigative T76685 DRUGINFO D01MJF JWH-404 Investigative T76685 DRUGINFO D01PEC (2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D01RWS 3-Benzyl-5-isopropyl-8-methylchromen-2-one Investigative T76685 DRUGINFO D01VIA (4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone Investigative T76685 DRUGINFO D02HDI arachidonylcyclopropylamide Investigative T76685 DRUGINFO D02NAW N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D02POA 5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol Investigative T76685 DRUGINFO D02QTB JWH-307 Investigative T76685 DRUGINFO D02VSL JWH-133 Investigative T76685 DRUGINFO D03AWH AM-4768 Investigative T76685 DRUGINFO D03GDP AM-1715 Investigative T76685 DRUGINFO D03HFM (1R,2R)-N-Arachidonoylcyclopropanolamide Investigative T76685 DRUGINFO D03REA 5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one Investigative T76685 DRUGINFO D03RGV JWH-156 Investigative T76685 DRUGINFO D03SRV JWH-292 Investigative T76685 DRUGINFO D03ZBS 4-cyanophenyl ethyl dodecylphosphonate Investigative T76685 DRUGINFO D04AMC N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine Investigative T76685 DRUGINFO D04AUM AM-1710 Investigative T76685 DRUGINFO D04ECZ Rac-trans-N-oleoylcyclopropanolamide Investigative T76685 DRUGINFO D04GDY DELTA 8-TETRAHYDROCANNOBINOL Investigative T76685 DRUGINFO D04ICJ 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide Investigative T76685 DRUGINFO D04LZA JWH-370 Investigative T76685 DRUGINFO D04TSL JWH-392 Investigative T76685 DRUGINFO D04YUA Octane-1-sulfonyl fluoride Investigative T76685 DRUGINFO D06BXT [3H]WIN55212-2 Investigative T76685 DRUGINFO D06DTC (2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D06EHU JWH-268 Investigative T76685 DRUGINFO D06SKK JWH-440 Investigative T76685 DRUGINFO D07KZW JWH-364 Investigative T76685 DRUGINFO D07QUV JWH-345 Investigative T76685 DRUGINFO D08BNY (E)-N-(4-methoxyphenyl)undec-2-enamide Investigative T76685 DRUGINFO D08GLU 4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol Investigative T76685 DRUGINFO D08OAQ 4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol Investigative T76685 DRUGINFO D08TXL A-796260 Investigative T76685 DRUGINFO D08VLG 4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol Investigative T76685 DRUGINFO D09BYO N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D09CKZ AM-411 Investigative T76685 DRUGINFO D09FMK AM-630 Investigative T76685 DRUGINFO D09JER JWH-344 Investigative T76685 DRUGINFO D09KFJ JWH-229 Investigative T76685 DRUGINFO D09PIQ JWH-367 Investigative T76685 DRUGINFO D0A2BC JWH-385 Investigative T76685 DRUGINFO D0B8AN JWH-347 Investigative T76685 DRUGINFO D0C4CG N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide Investigative T76685 DRUGINFO D0CO6T NAPHTHYRIDINONE Investigative T76685 DRUGINFO D0D7OR KM-233-M Investigative T76685 DRUGINFO D0DE9L JWH-368 Investigative T76685 DRUGINFO D0DQ3F JWH-365 Investigative T76685 DRUGINFO D0E0AA N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D0E0JU JWH-401 Investigative T76685 DRUGINFO D0E3ET AM-1714 Investigative T76685 DRUGINFO D0E3OY JWH-372 Investigative T76685 DRUGINFO D0E4OT JWH-325 Investigative T76685 DRUGINFO D0EE0Q JWH-366 Investigative T76685 DRUGINFO D0EX7J JWH-442 Investigative T76685 DRUGINFO D0F3XG JWH-346 Investigative T76685 DRUGINFO D0F4BE O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine Investigative T76685 DRUGINFO D0G2EQ (1S,2S)-N-Arachidonoylcyclopropanolamide Investigative T76685 DRUGINFO D0G4VV SCH-356036 Investigative T76685 DRUGINFO D0G7GF 3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol Investigative T76685 DRUGINFO D0GG4T JWH-150 Investigative T76685 DRUGINFO D0I4AF N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D0I7MW JWH-244 Investigative T76685 DRUGINFO D0J3XJ N-(3-Phenyl)propyl-2-(4-bromophenylacetamide) Investigative T76685 DRUGINFO D0J7CR Rac-cis-N-arachidonoylcyclopropanolamide Investigative T76685 DRUGINFO D0K4PV 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D0K7QP (1S,2S)-N-Oleoylcyclopropanolamide Investigative T76685 DRUGINFO D0K8MN 5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole Investigative T76685 DRUGINFO D0K8VR [3H]HU-243 Investigative T76685 DRUGINFO D0L6RT PRAVADOLINE Investigative T76685 DRUGINFO D0N0ME 4-benzhydryl-N-butylpiperazine-1-carboxamide Investigative T76685 DRUGINFO D0N5VO JWH-403 Investigative T76685 DRUGINFO D0O3NY AM-1241 Investigative T76685 DRUGINFO D0O7ZJ JWH-120 Investigative T76685 DRUGINFO D0O8IC JWH-309 Investigative T76685 DRUGINFO D0P5VJ KM-233 Investigative T76685 DRUGINFO D0PE8U N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide Investigative T76685 DRUGINFO D0Q0XV (1R,2S)-N-Oleoylcyclopropanolamide Investigative T76685 DRUGINFO D0Q9FB JWH-308 Investigative T76685 DRUGINFO D0R1NR JWH-371 Investigative T76685 DRUGINFO D0R3GN JWH-373 Investigative T76685 DRUGINFO D0R6MB 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D0R7QF (1R,2S)-N-Arachidonoylcyclopropanolamide Investigative T76685 DRUGINFO D0R9VY 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D0S2ZR JWH-147 Investigative T76685 DRUGINFO D0S3UA JWH-145 Investigative T76685 DRUGINFO D0T4HB Methyl icosylphosphonofluoridate Investigative T76685 DRUGINFO D0T4SE (E)-N-(4-methoxyphenethyl)undec-2-enamide Investigative T76685 DRUGINFO D0T5WY JWH-293 Investigative T76685 DRUGINFO D0TN1L JWH-146 Investigative T76685 DRUGINFO D0TS5I JWH-245 Investigative T76685 DRUGINFO D0U0CV Dodecane-1-sulfonyl fluoride Investigative T76685 DRUGINFO D0U4JI JWH-337 Investigative T76685 DRUGINFO D0U5LL cannabinol Investigative T76685 DRUGINFO D0UD9H AM-281 Investigative T76685 DRUGINFO D0V3TO JWH-348 Investigative T76685 DRUGINFO D0V3YB 3,4-diarylpyrazoline derivative Investigative T76685 DRUGINFO D0V7QA 1,4-dihydroindeno[1,2-c]-pyrazole Investigative T76685 DRUGINFO D0Y0MY JWH-402 Investigative T76685 DRUGINFO D0Y1MM N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine Investigative T76685 DRUGINFO D0Y6MS JWH-297 Investigative T76685 DRUGINFO D0Y9HT JWH-363 Investigative T76685 DRUGINFO D0Z1NH Cis-N-oleoylcyclopropanolamide Investigative T76685 DRUGINFO D0Z1XE JWH-324 Investigative T76685 DRUGINFO D0Z5CX N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide Investigative T76685 DRUGINFO D0Z6BY JWH-243 Investigative T76685 DRUGINFO D0Z7FF JWH-246 Investigative T76685 DRUGINFO D0Z7OB (E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide Investigative T76685 DRUGINFO D0ZL2P JWH-369 Investigative T76685 DRUGINFO D0ZM1T VER-156085 Investigative T76685 DRUGINFO D01MCD (2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D02GOH AM-404 Investigative T76685 DRUGINFO D06NXC N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX) Investigative T76685 DRUGINFO D0D6OH [3H]CP55940 Investigative T76685 DRUGINFO D0FJ1I N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D0HQ4M Isopropyl dodecylfluorophosphonate Investigative T76685 DRUGINFO D0L1UA N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide Investigative T76685 DRUGINFO D0OQ5H 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T76685 DRUGINFO D0PC5A VER-156084 Investigative T76685 DRUGINFO D0W6PT Chlorphrifos oxon Investigative T76685 DRUGINFO D07MBC N-oleoylethanolamide Investigative T76685 DRUGINFO D08XQI PARAOXON Investigative T76685 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T22118 TARGETID T22118 T22118 FORMERID TTDS00011 T22118 UNIPROID DRD1_HUMAN T22118 TARGNAME Dopamine D1 receptor (D1R) T22118 GENENAME DRD1 T22118 TARGTYPE Successful T22118 SYNONYMS D(1A) dopamine receptor T22118 FUNCTION Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase. T22118 PDBSTRUC 1OZ5 T22118 BIOCLASS GPCR rhodopsin T22118 SEQUENCE MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTNFFVISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVDRYWAISSPFRYERKMTPKAAFILISVAWTLSVLISFIPVQLSWHKAKPTSPSDGNATSLAETIDNCDSSLSRTYAISSSVISFYIPVAIMIVTYTRIYRIAQKQIRRIAALERAAVHAKNCQTTTGNGKPVECSQPESSFKMSFKRETKVLKTLSVIMGVFVCCWLPFFILNCILPFCGSGETQPFCIDSNTFDVFVWFGWANSSLNPIIYAFNADFRKAFSTLLGCYRLCPATNNAIETVSINNNGAAMFSSHHEPRGSISKECNLVYLIPHAVGSSEDLKKEEAAGIARPLEKLSPALSVILDYDTDVSLEKIQPITQNGQHPT T22118 DRUGINFO D05AHE Methylergonovine Approved T22118 DRUGINFO D0R6BI Fenoldopam Approved T22118 DRUGINFO D04JCN Pergolide Approved T22118 DRUGINFO D0KS6W Phenyltoloxamine Approved T22118 DRUGINFO D0Y6HW Ecopipam Phase 3 T22118 DRUGINFO D02YVM Zicronapine Phase 3 T22118 DRUGINFO D0BJ2W DAS-431 Phase 2 T22118 DRUGINFO D0D3VT Dihydrexidine Phase 1/2 T22118 DRUGINFO DJ2OV7 Lu AF28996 Phase 1 T22118 DRUGINFO D09ORU ZELANDOPAM HYDROCHLORIDE Discontinued in Phase 2 T22118 DRUGINFO D0N5JJ ADROGOLIDE HYDROCHLORIDE Discontinued in Phase 2 T22118 DRUGINFO D0S0GM ADX-10061 Discontinued in Phase 2 T22118 DRUGINFO D02KKQ BAM-1110 Discontinued in Phase 2 T22118 DRUGINFO D0BQ8M CY-208243 Discontinued in Phase 2 T22118 DRUGINFO D03DXS Odapipam Discontinued in Phase 1 T22118 DRUGINFO D03PTZ BTS-73947 Discontinued in Phase 1 T22118 DRUGINFO D0X8MI Berupipam Discontinued in Phase 1 T22118 DRUGINFO D0LE7P SDZ-GLC-756 Discontinued in Phase 1 T22118 DRUGINFO D0J7WO BSF-78438 Preclinical T22118 DRUGINFO D01TCM CEE-03-320 Terminated T22118 DRUGINFO D02DHU SKF-81297 Terminated T22118 DRUGINFO D0DX6L SDZ-PSD-958 Terminated T22118 DRUGINFO D0OQ4H A-69024 Terminated T22118 DRUGINFO D0OU7P SKF 38393 Terminated T22118 DRUGINFO D0P2YS A 77636 Terminated T22118 DRUGINFO D03NPZ NNC-22-0031 Terminated T22118 DRUGINFO D08IRR Org-10490 Terminated T22118 DRUGINFO D0N1WM A-68930 Terminated T22118 DRUGINFO D0EH2O BIMG80 Terminated T22118 DRUGINFO D00MLN (R,S)-homoaromaline hydrochloride Investigative T22118 DRUGINFO D02BPV 5-(2-Amino-ethyl)-2-chloro-phenol hydrobromide Investigative T22118 DRUGINFO D03OUU 6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol Investigative T22118 DRUGINFO D05QOF 1-Aminomethyl-3-phenyl-isochroman-5,6-diol Investigative T22118 DRUGINFO D06VYA 6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol Investigative T22118 DRUGINFO D08YYX 6-(2-Amino-ethyl)-biphenyl-2,3-diol Investigative T22118 DRUGINFO D0A9UF 1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol Investigative T22118 DRUGINFO D0I0AQ MELOSMINE Investigative T22118 DRUGINFO D0L3MJ SKF-83959 Investigative T22118 DRUGINFO D0L8PI SCH-23390 Investigative T22118 DRUGINFO D0NY6P TEPA (possesses cytotoxic activity) Investigative T22118 DRUGINFO D0O1EY 9-Aminomethyl-9H-fluorene-2,5,6-triol Investigative T22118 DRUGINFO D0P2YV SCH-12679 Investigative T22118 DRUGINFO D0V1EJ 6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol Investigative T22118 DRUGINFO D0V4FZ SKF-75670 Investigative T22118 DRUGINFO D0X7ZC 9-Aminomethyl-9H-fluorene-3,4-diol Investigative T22118 DRUGINFO D00YEB 11-Butyryloxy-N-n-propylnoraporphine Investigative T22118 DRUGINFO D02RAY GLAUCINE Investigative T22118 DRUGINFO D02YCY (R)-11-Amino-2-methoxyaporphine Investigative T22118 DRUGINFO D03RMB 2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol Investigative T22118 DRUGINFO D03YXB (+)-(1R,1'S)-berbamunine hydrochloride Investigative T22118 DRUGINFO D04GRS (S)-BULBOCAPNINE Investigative T22118 DRUGINFO D04IIK (R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine Investigative T22118 DRUGINFO D04TTN (+)-(1R,1'S)-thaligrisine hydrochloride Investigative T22118 DRUGINFO D05HWC PUKATEINE Investigative T22118 DRUGINFO D05NBK 1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol Investigative T22118 DRUGINFO D05OHF (R)-(+)-coclaurine Investigative T22118 DRUGINFO D06AIQ IBZM Investigative T22118 DRUGINFO D07CZJ 11-valeryloxynoraporphine Investigative T22118 DRUGINFO D07IWZ (R)-2,11-Diaminoaporphine Investigative T22118 DRUGINFO D08DLP 3-Chloroboldine Investigative T22118 DRUGINFO D08EMG (S)APOMORPHINE Investigative T22118 DRUGINFO D08HTJ 2-methoxyapomorphine Investigative T22118 DRUGINFO D08UQU (R)-(-)-2-methoxy-11-hydroxyaporphine Investigative T22118 DRUGINFO D09CVV NORSTEPHALAGINE Investigative T22118 DRUGINFO D09KRA [125I]SCH23982 Investigative T22118 DRUGINFO D09QRL 2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline Investigative T22118 DRUGINFO D0A4GE 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol Investigative T22118 DRUGINFO D0B1GJ 11-Propionyloxy-N-n-propylnoraporphine Investigative T22118 DRUGINFO D0D1PR (R)-(-)-2-methoxy-N-npropylnorapomorphine Investigative T22118 DRUGINFO D0I2WQ 11-Heptanoyloxy-N-n-propylnoraporphine Investigative T22118 DRUGINFO D0I7CE SK&F-89626 Investigative T22118 DRUGINFO D0LR8X SKF-83556 Investigative T22118 DRUGINFO D0N9DY 3-Iodoboldine Investigative T22118 DRUGINFO D0NA2T (R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine Investigative T22118 DRUGINFO D0ND8J (-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride Investigative T22118 DRUGINFO D0P4BY SCH-24518 Investigative T22118 DRUGINFO D0P8AW Ro-21-7767 Investigative T22118 DRUGINFO D0R8PL 11-Hexanoyloxy-N-n-propylnoraporphine Investigative T22118 DRUGINFO D0TA8F (S,S)-oxandrine hydrochloride Investigative T22118 DRUGINFO D0U6IL 1-Aminomethyl-isochroman-5,6-diol Investigative T22118 DRUGINFO D0V3DO 1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane Investigative T22118 DRUGINFO D0X2NO (+)-ADTN Investigative T22118 DRUGINFO D0Z9JY [R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether Investigative T22118 DRUGINFO D01ENR 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine Investigative T22118 DRUGINFO D04CPW N-(4-Propylaminobutyl)-4-biphenylcarboxamide Investigative T22118 DRUGINFO D04KGP (R)-(-)-11-hydroxy-N-n-propylnoraporphine Investigative T22118 DRUGINFO D04MVL (R)-(-)-10-methyl-11-hydroxyaporphine Investigative T22118 DRUGINFO D06FLU 3,8-dibromoboldine Investigative T22118 DRUGINFO D09BSE 3-bromoboldine Investigative T22118 DRUGINFO D0KX3X MCL-516 Investigative T22118 DRUGINFO D0T1TU Etoloxamine Investigative T22118 DRUGINFO D06LQH N-propylnorapomorphine Investigative T22118 DRUGINFO D07RYR 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine Investigative T22118 DRUGINFO D07UUQ 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine Investigative T22118 DRUGINFO D0B9DR 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine Investigative T22118 DRUGINFO D0H2WQ QUINPIROLE Investigative T22118 DRUGINFO D0LH4L BOLDINE Investigative T22118 DRUGINFO D0M2BB 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine Investigative T22118 DRUGINFO D0O7DA (+)-BUTACLAMOL Investigative T22118 DRUGINFO D0V4NW N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide Investigative T22118 DRUGINFO D0WD6J 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine Investigative T22118 DRUGINFO D05UUW 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine Investigative T22118 DRUGINFO D08UOX FALCARINDIOL Investigative T22118 DRUGINFO D0E1RX 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine Investigative T22118 DRUGINFO D0L7OM STEPHOLIDINE Investigative T22118 DRUGINFO D0MC2R FLUTROLINE Investigative T22118 DRUGINFO D0R8UU 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine Investigative T22118 DRUGINFO D07LRJ SB-271046 Investigative T22118 DRUGINFO D0HV3A FLUMEZAPINE Investigative T22118 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T22118 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T22118 DRUGINFO D0L5MW (+/-)-nantenine Investigative T22118 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T76198 TARGETID T76198 T76198 FORMERID TTDS00395 T76198 UNIPROID TA2R_HUMAN T76198 TARGNAME Thromboxane A2 receptor (TBXA2R) T76198 GENENAME TBXA2R T76198 TARGTYPE Successful T76198 SYNONYMS TXA2-R; TXA2 receptor; Prostanoid TP receptor T76198 FUNCTION The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. In the kidney, the binding of TXA2 to glomerular TP receptors causes intense vasoconstriction. Activates phospholipase C. Isoform 1 activates adenylyl cyclase. Isoform 2 inhibits adenylyl cyclase. Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. T76198 PDBSTRUC 1LBN T76198 BIOCLASS GPCR rhodopsin T76198 SEQUENCE MWPNGSSLGPCFRPTNITLEERRLIASPWFAASFCVVGLASNLLALSVLAGARQGGSHTRSSFLTFLCGLVLTDFLGLLVTGTIVVSQHAALFEWHAVDPGCRLCRFMGVVMIFFGLSPLLLGAAMASERYLGITRPFSRPAVASQRRAWATVGLVWAAALALGLLPLLGVGRYTVQYPGSWCFLTLGAESGDVAFGLLFSMLGGLSVGLSFLLNTVSVATLCHVYHGQEAAQQRPRDSEVEMMAQLLGIMVVASVCWLPLLVFIAQTVLRNPPAMSPAGQLSRTTEKELLIYLRVATWNQILDPWVYILFRRAVLRRLQPRLSTRPRSLSLQPQLTQRSGLQ T76198 DRUGINFO D0E3BH Ridogrel Approved T76198 DRUGINFO D0I4DQ Alprostadil Approved T76198 DRUGINFO D0WL5V LAROPIPRANT Phase 4 T76198 DRUGINFO D0GC5H Ramatroban Phase 2/3 T76198 DRUGINFO D00KHD TAK-128 Phase 2 T76198 DRUGINFO D0B2WK Ifetroban sodium Phase 2 T76198 DRUGINFO D8N9VF Ifetroban Phase 2 T76198 DRUGINFO D07JKY KP-496 Phase 2 T76198 DRUGINFO D0WH9U FK-070 Phase 2 T76198 DRUGINFO D0D9LB BIBV 308 Phase 1 T76198 DRUGINFO D0YP0C DT-TX-30 Phase 1 T76198 DRUGINFO D0K2NA YM-57158 Phase 1 T76198 DRUGINFO D0RU7T G-619 Phase 1 T76198 DRUGINFO D00HTY PGF2alpha Clinical trial T76198 DRUGINFO D01HRR Domitroban Discontinued in Preregistration T76198 DRUGINFO D03QGL DALTROBAN Discontinued in Phase 3 T76198 DRUGINFO D04SPK Seratrodast Discontinued in Phase 3 T76198 DRUGINFO D0Z5VQ Terutroban sodium Discontinued in Phase 3 T76198 DRUGINFO D00VQI SQ-30741 Discontinued in Phase 2 T76198 DRUGINFO D01LPX Linotroban Discontinued in Phase 2 T76198 DRUGINFO D06UCV Z-335 Discontinued in Phase 2 T76198 DRUGINFO D0B9NA ICI-192605 Discontinued in Phase 2 T76198 DRUGINFO D03KST KT2-962 Discontinued in Phase 1 T76198 DRUGINFO D0H5KO KW-3635 Discontinued in Phase 1 T76198 DRUGINFO D0H5PG CGS-22652 Discontinued in Phase 1 T76198 DRUGINFO D03ZVW Vapiprost Terminated T76198 DRUGINFO D07JSK Sulotroban Terminated T76198 DRUGINFO D0E3UM L-657925 Terminated T76198 DRUGINFO D0E8JL ZT-386 Terminated T76198 DRUGINFO D0J5QW ON-579 Terminated T76198 DRUGINFO D0U7HD SQ-33961 Terminated T76198 DRUGINFO D0X8QI UP-116-77 Terminated T76198 DRUGINFO D00OXH U-44069 Investigative T76198 DRUGINFO D02IBM SQ-29548 Investigative T76198 DRUGINFO D03BNO PGH2 Investigative T76198 DRUGINFO D05LWE [125I]BOP Investigative T76198 DRUGINFO D07FLX AGN 191976 Investigative T76198 DRUGINFO D08TWT AGN192093 Investigative T76198 DRUGINFO D09IRF [125I]PTA-OH Investigative T76198 DRUGINFO D09NFY [125I]SQ-29548 Investigative T76198 DRUGINFO D09TWW EP 171 Investigative T76198 DRUGINFO D09XLT SQ 26655 Investigative T76198 DRUGINFO D09YJR S 18204 Investigative T76198 DRUGINFO D0LC8Z [125I]SAP Investigative T76198 DRUGINFO D0OE2Z ONO-8809 Investigative T76198 DRUGINFO D0P3HG ONO-3708 Investigative T76198 DRUGINFO D0Q9SC 10,10-difluoro TXA2 Investigative T76198 DRUGINFO D0RI3H I-SAP Investigative T76198 DRUGINFO D0XB3U BM-573 Investigative T76198 DRUGINFO D0Y6LS carbocyclic thromboxane A2 Investigative T76198 DRUGINFO D00GTU STA2 Investigative T76198 DRUGINFO D07WQV AH23848 Investigative T76198 DRUGINFO D05TNX fluprostenol Investigative T76198 DRUGINFO D0X5MA I-BOP Investigative T76198 DRUGINFO D0O9ES cloprostenol Investigative T76198 DRUGINFO D08MNO butaprost (free acid form) Investigative T76198 DRUGINFO D0BN1U M&B 28767 Investigative T76198 DRUGINFO D0W7RI carbacyclin Investigative T76198 DRUGINFO D03PLH U46619 Investigative T24983 TARGETID T24983 T24983 FORMERID TTDC00291 T24983 UNIPROID DRD4_HUMAN T24983 TARGNAME Dopamine D4 receptor (D4R) T24983 GENENAME DRD4 T24983 TARGTYPE Successful T24983 SYNONYMS DRD4; D(2C)D(4) dopamine receptor dopamine receptor T24983 FUNCTION Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells. T24983 PDBSTRUC 5WIV; 5WIU T24983 BIOCLASS GPCR rhodopsin T24983 SEQUENCE MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLAGNSLVCVSVATERALQTPTNSFIVSLAAADLLLALLVLPLFVYSEVQGGAWLLSPRLCDALMAMDVMLCTASIFNLCAISVDRFVAVAVPLRYNRQGGSRRQLLLIGATWLLSAAVAAPVLCGLNDVRGRDPAVCRLEDRDYVVYSSVCSFFLPCPLMLLLYWATFRGLQRWEVARRAKLHGRAPRRPSGPGPPSPTPPAPRLPQDPCGPDCAPPAPGLPRGPCGPDCAPAAPSLPQDPCGPDCAPPAPGLPPDPCGSNCAPPDAVRAAALPPQTPPQTRRRRRAKITGRERKAMRVLPVVVGAFLLCWTPFFVVHITQALCPACSVPPRLVSAVTWLGYVNSALNPVIYTVFNAEFRNVFRKALRACC T24983 DRUGINFO D0Z1RV Clozapine Approved T24983 DRUGINFO D0KS6W Phenyltoloxamine Approved T24983 DRUGINFO D0X6XH CM-2395 Phase 3 T24983 DRUGINFO D0N1HW L-745,870 Phase 2 T24983 DRUGINFO D05XEA RP5063 Phase 2 T24983 DRUGINFO D0L3JI NGD 94-1 Phase 1 T24983 DRUGINFO D03TNA ABT-724 Discontinued in Phase 2 T24983 DRUGINFO D0T5MB Lu-35138 Discontinued in Phase 2 T24983 DRUGINFO D0Q5YH NGD-94-4 Discontinued in Phase 1 T24983 DRUGINFO D00MQS PD-165167 Preclinical T24983 DRUGINFO D04PVN SPI-376 Preclinical T24983 DRUGINFO D0WQ5S U-99363E Preclinical T24983 DRUGINFO D01RAE Sonepiprazole Terminated T24983 DRUGINFO D0I2OP Belaperidone Terminated T24983 DRUGINFO D0OW1R YM-43611 Terminated T24983 DRUGINFO D0EH2O BIMG80 Terminated T24983 DRUGINFO D0K9JP A-80426 Terminated T24983 DRUGINFO D00NQV RBI257 Investigative T24983 DRUGINFO D00VSQ E-1455 Investigative T24983 DRUGINFO D03VPS ABT-670 Investigative T24983 DRUGINFO D07VBS A412997 Investigative T24983 DRUGINFO D08QPU ML398 Investigative T24983 DRUGINFO D08ZTK Ro 10-4548 Investigative T24983 DRUGINFO D09WBJ FAUC213 Investigative T24983 DRUGINFO D0A2KN [125I]L750667 Investigative T24983 DRUGINFO D0AX0K U101958 Investigative T24983 DRUGINFO D0B0UZ A-425444 Investigative T24983 DRUGINFO D0F0IA A-381393 Investigative T24983 DRUGINFO D0G0IQ JL-18 Investigative T24983 DRUGINFO D0G2CP FAUC 113 Investigative T24983 DRUGINFO D0K3UL CP-226269 Investigative T24983 DRUGINFO D0Q4DP L-750,667 Investigative T24983 DRUGINFO D0S7XR TKP-1002 Investigative T24983 DRUGINFO D01URS PF-592379 Investigative T24983 DRUGINFO D09FTZ (4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine Investigative T24983 DRUGINFO D00HUV [2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine Investigative T24983 DRUGINFO D01ENR 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine Investigative T24983 DRUGINFO D01KIH 4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole Investigative T24983 DRUGINFO D03GES 1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine Investigative T24983 DRUGINFO D03JOS 3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole Investigative T24983 DRUGINFO D04CPW N-(4-Propylaminobutyl)-4-biphenylcarboxamide Investigative T24983 DRUGINFO D05BCJ 1-Benzyl-4-pyrrol-1-yl-piperidine Investigative T24983 DRUGINFO D05QJK Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine Investigative T24983 DRUGINFO D06NTB 3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole Investigative T24983 DRUGINFO D06WLB Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine Investigative T24983 DRUGINFO D0IU8V 4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one Investigative T24983 DRUGINFO D0M3PV L-741626 Investigative T24983 DRUGINFO D0O1PM (4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine Investigative T24983 DRUGINFO D0O9BZ 4-(4-Benzyl-piperazin-1-yl)-1H-indole Investigative T24983 DRUGINFO D0Q5IP 3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole Investigative T24983 DRUGINFO D0S1XN 4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole Investigative T24983 DRUGINFO D0T3IH [3H]N-methylspiperone Investigative T24983 DRUGINFO D0TU5W 4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole Investigative T24983 DRUGINFO D07RYR 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine Investigative T24983 DRUGINFO D07UUQ 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine Investigative T24983 DRUGINFO D0B9DR 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine Investigative T24983 DRUGINFO D0H2WQ QUINPIROLE Investigative T24983 DRUGINFO D0M2BB 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine Investigative T24983 DRUGINFO D0M2ZE UH-232 Investigative T24983 DRUGINFO D0O4BC 3-(2-Benzylamino-ethoxy)-phenol Investigative T24983 DRUGINFO D0V4NW N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide Investigative T24983 DRUGINFO D0W1HM nafadotride Investigative T24983 DRUGINFO D0WD6J 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine Investigative T24983 DRUGINFO D0WU9R L-741742 Investigative T24983 DRUGINFO D05UUW 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine Investigative T24983 DRUGINFO D0E1RX 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine Investigative T24983 DRUGINFO D0L7OM STEPHOLIDINE Investigative T24983 DRUGINFO D0MC2R FLUTROLINE Investigative T24983 DRUGINFO D0R8UU 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine Investigative T24983 DRUGINFO D07GQP PG-01037 Investigative T24983 DRUGINFO D07GXY piribedil Investigative T24983 DRUGINFO D05EQG [3H]spiperone Investigative T24983 DRUGINFO D07LRJ SB-271046 Investigative T24983 DRUGINFO D0HV3A FLUMEZAPINE Investigative T24983 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T24983 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T24983 DRUGINFO D0L5MW (+/-)-nantenine Investigative T15569 TARGETID T15569 T15569 FORMERID TTDS00482 T15569 UNIPROID MUTA_HUMAN T15569 TARGNAME Methylmalonyl-CoA mutase (MMUT) T15569 GENENAME MUT T15569 TARGTYPE Successful T15569 SYNONYMS Methylmalonyl-CoA isomerase; MUT; MCM T15569 FUNCTION Involved in the degradation of several amino acids, odd- chain fatty acids and cholesterol via propionyl-CoA to the tricarboxylic acid cycle. MCM has different functions in other species. T15569 PDBSTRUC 3BIC; 2XIQ; 2XIJ T15569 BIOCLASS Intramolecular transferases T15569 ECNUMBER EC 5.4.99.2 T15569 SEQUENCE MLRAKNQLFLLSPHYLRQVKESSGSRLIQQRLLHQQQPLHPEWAALAKKQLKGKNPEDLIWHTPEGISIKPLYSKRDTMDLPEELPGVKPFTRGPYPTMYTFRPWTIRQYAGFSTVEESNKFYKDNIKAGQQGLSVAFDLATHRGYDSDNPRVRGDVGMAGVAIDTVEDTKILFDGIPLEKMSVSMTMNGAVIPVLANFIVTGEEQGVPKEKLTGTIQNDILKEFMVRNTYIFPPEPSMKIIADIFEYTAKHMPKFNSISISGYHMQEAGADAILELAYTLADGLEYSRTGLQAGLTIDEFAPRLSFFWGIGMNFYMEIAKMRAGRRLWAHLIEKMFQPKNSKSLLLRAHCQTSGWSLTEQDPYNNIVRTAIEAMAAVFGGTQSLHTNSFDEALGLPTVKSARIARNTQIIIQEESGIPKVADPWGGSYMMECLTNDVYDAALKLINEIEEMGGMAKAVAEGIPKLRIEECAARRQARIDSGSEVIVGVNKYQLEKEDAVEVLAIDNTSVRNRQIEKLKKIKSSRDQALAERCLAALTECAASGDGNILALAVDASRARCTVGEITDALKKVFGEHKANDRMVSGAYRQEFGESKEITSAIKRVHKFMEREGRRPRLLVAKMGQDGHDRGAKVIATGFADLGFDVDIGPLFQTPREVAQQAVDADVHAVGISTLAAGHKTLVPELIKELNSLGRPDILVMCGGVIPPQDYEFLFEVGVSNVFGPGTRIPKAAVQVLDDIEKCLEKKQQSV T15569 DRUGINFO D0VF4H Hydroxocobalamin Approved T15569 DRUGINFO DJN3E2 mRNA-3704 Phase 1/2 T62460 TARGETID T62460 T62460 FORMERID TTDNS00611 T62460 UNIPROID JAK1_HUMAN T62460 TARGNAME Janus kinase 1 (JAK-1) T62460 GENENAME JAK1 T62460 TARGTYPE Successful T62460 SYNONYMS Tyrosine-protein kinase JAK1; JAK1B; JAK1A T62460 FUNCTION Kinase partner for the interleukin (IL)-2 receptor as well as interleukin (IL)-10 receptor. Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. T62460 PDBSTRUC 6N7D; 6N7C; 6N7B; 6N7A; 6N79 T62460 BIOCLASS Kinase T62460 ECNUMBER EC 2.7.10.2 T62460 SEQUENCE MQYLNIKEDCNAMAFCAKMRSSKKTEVNLEAPEPGVEVIFYLSDREPLRLGSGEYTAEELCIRAAQACRISPLCHNLFALYDENTKLWYAPNRTITVDDKMSLRLHYRMRFYFTNWHGTNDNEQSVWRHSPKKQKNGYEKKKIPDATPLLDASSLEYLFAQGQYDLVKCLAPIRDPKTEQDGHDIENECLGMAVLAISHYAMMKKMQLPELPKDISYKRYIPETLNKSIRQRNLLTRMRINNVFKDFLKEFNNKTICDSSVSTHDLKVKYLATLETLTKHYGAEIFETSMLLISSENEMNWFHSNDGGNVLYYEVMVTGNLGIQWRHKPNVVSVEKEKNKLKRKKLENKHKKDEEKNKIREEWNNFSYFPEITHIVIKESVVSINKQDNKKMELKLSSHEEALSFVSLVDGYFRLTADAHHYLCTDVAPPLIVHNIQNGCHGPICTEYAINKLRQEGSEEGMYVLRWSCTDFDNILMTVTCFEKSEQVQGAQKQFKNFQIEVQKGRYSLHGSDRSFPSLGDLMSHLKKQILRTDNISFMLKRCCQPKPREISNLLVATKKAQEWQPVYPMSQLSFDRILKKDLVQGEHLGRGTRTHIYSGTLMDYKDDEGTSEEKKIKVILKVLDPSHRDISLAFFEAASMMRQVSHKHIVYLYGVCVRDVENIMVEEFVEGGPLDLFMHRKSDVLTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNLLLAREGIDSECGPFIKLSDPGIPITVLSRQECIERIPWIAPECVEDSKNLSVAADKWSFGTTLWEICYNGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRCMNYDPNQRPFFRAIMRDINKLEEQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK T62460 DRUGINFO D07JAG Upadacitinib Approved T62460 DRUGINFO D0D5ZJ Momelotinib Approved T62460 DRUGINFO D04LKS Ruxolitinib Approved T62460 DRUGINFO D05PCM Abrocitinib Approved T62460 DRUGINFO D0Y7IC Baricitinib Approved T62460 DRUGINFO DFK8Z5 SHR0302 Phase 3 T62460 DRUGINFO D06EIC ASP-015K Phase 3 T62460 DRUGINFO D06HZA GSK2586184 Phase 2 T62460 DRUGINFO D0HJ1R INCB54707 Phase 2 T62460 DRUGINFO D0SG7B GLPG-0634 Phase 2 T62460 DRUGINFO DD6A7P EQ121 Phase 2 T62460 DRUGINFO D01UAU CTP-543 Phase 2 T62460 DRUGINFO D09AFI INCB039110 Phase 2 T62460 DRUGINFO D0V4DX PF-06700841 Phase 2 T62460 DRUGINFO D6INZ9 ATI-501 Phase 2 T62460 DRUGINFO D6N5UC ATI-502 Phase 2 T62460 DRUGINFO DH0A6O A223 Phase 2 T62460 DRUGINFO DU10JI CTP-543 Phase 2 T62460 DRUGINFO D2KTG5 TD-8236 Phase 2 T62460 DRUGINFO D0BI3N Cerdulatinib Phase 2 T62460 DRUGINFO D2JZ3U ALXN2075 Phase 1/2 T62460 DRUGINFO D63WFO AZD0449 Phase 1 T62460 DRUGINFO DI19BZ KN-002 Phase 1 T62460 DRUGINFO DX72LV AZD4604 Phase 1 T62460 DRUGINFO DXVA93 PF-07295324 Phase 1 T62460 DRUGINFO DZ2RH6 GDC-0214 Phase 1 T62460 DRUGINFO D00GJY Cyclohexyl azetidine derivative 1 Patented T62460 DRUGINFO D0H3KF Bipyrazole derivative 1 Patented T62460 DRUGINFO D0OS1N Tricyclic compound 3 Patented T62460 DRUGINFO D00JUI Triazolo-pyridine derivative 1 Patented T62460 DRUGINFO D00PTE Imidazopyridazine derivative 2 Patented T62460 DRUGINFO D03PBI Pyrrolo-pyridone derivative 2 Patented T62460 DRUGINFO D04OCD PMID27774822-Compound-Figure7Example63 Patented T62460 DRUGINFO D05GEL Cyclic cyanoethypypazole derivative 1 Patented T62460 DRUGINFO D06MQB Pyrrolo-pyridone derivative 1 Patented T62460 DRUGINFO D07BND Imidazopyridazine derivative 1 Patented T62460 DRUGINFO D0F3BK PMID27774824-Compound-Figure6Example6 Patented T62460 DRUGINFO D0H6XN Geminally-substituted cyanoethylpypazolo pyridone derivative 1 Patented T62460 DRUGINFO D0K2RW Cyanomethyl pypazole carboxamide derivative 1 Patented T62460 DRUGINFO D0KI5F Geminally-substituted cyanoethylpypazolo pyridone derivative 2 Patented T62460 DRUGINFO D0PB5X Cycloalkyl nitrile pyrazolo pyridone derivative 1 Patented T62460 DRUGINFO D0PM8K PMID27774824-Compound-Figure7Example10 Patented T62460 DRUGINFO D0S4TH Cycloalkyl nitrile pyrazolo pyridone derivative 2 Patented T62460 DRUGINFO D0T6CY Pyrrolo-pyridone derivative 3 Patented T62460 DRUGINFO D0V0KI Cycloalkyl nitrile pyrazole carboxamide derivative 1 Patented T62460 DRUGINFO D0VQ7P Pyrrolo[2,3-d]pyrimidine derivative 11 Patented T62460 DRUGINFO D01EYJ Ruxolitinib derivative 2 Patented T62460 DRUGINFO D08WPB Five-and-six-membered heterocyclic compound 1 Patented T62460 DRUGINFO D09RUN Pyrazolopyridine derivative 4 Patented T62460 DRUGINFO D09UBE Pyrrole six-membered heteroaryl ring derivative 1 Patented T62460 DRUGINFO D0A6RG PMID27774824-Compound-Figure2Example4 Patented T62460 DRUGINFO D0G0FK Tricyclic compound 1 Patented T62460 DRUGINFO D0G9MM Isoxazole derivative 1 Patented T62460 DRUGINFO D0M3CB PMID27774822-Compound-Figure1Example20 Patented T62460 DRUGINFO D0TX2G Isoxazole derivative 2 Patented T62460 DRUGINFO D0VR6E Pyrrolo-pyridine derivative 3 Patented T62460 DRUGINFO D0XH7H N-methylmethanesulfonamide derivative 1 Patented T62460 DRUGINFO D0Y2IM N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 Patented T62460 DRUGINFO D0YJ4D Pyrrole derivative 7 Patented T62460 DRUGINFO D01CRX Benzimidazole derivative 7 Patented T62460 DRUGINFO D01FVC Bis-aminopyrimidine derivative 1 Patented T62460 DRUGINFO D03QAY Pyrazolopyridine derivative 3 Patented T62460 DRUGINFO D04BOW Tricyclic pyrrolopyridine compound 1 Patented T62460 DRUGINFO D05AXE Aminooxazole carboxamide derivative 1 Patented T62460 DRUGINFO D0FQ4Z Pyrrolo[2,3-d]pyrimidine derivative 6 Patented T62460 DRUGINFO D0GB7G PMID27774824-Compound-Figure6Example12 Patented T62460 DRUGINFO D0KL3B Pyrrolo[2,3-d]pyrimidine derivative 8 Patented T62460 DRUGINFO D0LR6J Bis-aminopyrimidine derivative 2 Patented T62460 DRUGINFO D0LS1O Tricyclic compound 11 Patented T62460 DRUGINFO D0M2WA Tricyclic heterocycle derivative 5 Patented T62460 DRUGINFO D0RJ3W PMID27774822-Compound-Figure11Example5 Patented T62460 DRUGINFO D0S6XT Bis-aminopyrimidine derivative 3 Patented T62460 DRUGINFO D0SJ1Q Bis-aminopyrimidine derivative 4 Patented T62460 DRUGINFO D0U1HA PMID27774824-Compound-Figure3Example18 Patented T62460 DRUGINFO D0U5FZ Pyrrolo[2,3-d]pyrimidine derivative 7 Patented T62460 DRUGINFO D0WA1V Pyrimidopyridazinone derivative 2 Patented T62460 DRUGINFO D0X1FD Tricyclic heterocycle derivative 1 Patented T62460 DRUGINFO D07PTU Imidazo[4,5-c]pyridine derivative 1 Patented T62460 DRUGINFO D0WZ8N PMID27774824-Compound-Figure9Example2up Patented T62460 DRUGINFO D01DBB PMID27774824-Compound-Figure9Example2down Patented T62460 DRUGINFO D09ALF Aminotriazolopyridine derivative 1 Patented T62460 DRUGINFO D0VJ1R Imidazo[4,5-c]pyridine derivative 2 Patented T62460 DRUGINFO D0YR8S PMID27774824-Compound-Figure11Example1up Patented T62460 DRUGINFO D09PIS Pyrazolo[4,3-c]pyridine derivative 2 Patented T62460 DRUGINFO D0HB4E INCB47986 Discontinued in Phase 2 T62460 DRUGINFO D0YX5U ZM-39923 Investigative T62460 DRUGINFO D0US9O PMID24359159C19a Investigative T62460 DRUGINFO D0E5IP WHI-P154 Investigative T03346 TARGETID T03346 T03346 FORMERID TTDC00081 T03346 UNIPROID IL4RA_HUMAN T03346 TARGNAME Interleukin 4 receptor alpha (IL4R) T03346 GENENAME IL4R T03346 TARGTYPE Successful T03346 SYNONYMS Interleukin-4 receptor subunit alpha; IL4RA; IL-4RA; IL-4R-alpha; IL-4R subunit alpha; IL-4 receptor subunit alpha; CD124 antigen; CD124; 582J2.1 T03346 FUNCTION Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2. Receptor for both interleukin 4 and interleukin 13. T03346 PDBSTRUC 5E4E; 3BPO; 3BPN; 3BPL; 1ITE T03346 BIOCLASS Cytokine receptor T03346 SEQUENCE MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPDNYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRARVRAWAQCYNTTWSEWSPSTKWHNSYREPFEQHLLLGVSVSCIVILAVCLLCYVSITKIKKEWWDQIPNPARSRLVAIIIQDAQGSQWEKRSRGQEPAKCPHWKNCLTKLLPCFLEHNMKRDEDPHKAAKEMPFQGSGKSAWCPVEISKTVLWPESISVVRCVELFEAPVECEEEEEVEEEKGSFCASPESSRDDFQEGREGIVARLTESLFLDLLGEENGGFCQQDMGESCLLPPSGSTSAHMPWDEFPSAGPKEAPPWGKEQPLHLEPSPPASPTQSPDNLTCTETPLVIAGNPAYRSFSNSLSQSPCPRELGPDPLLARHLEEVEPEMPCVPQLSEPTTVPQPEPETWEQILRRNVLQHGAAAAPVSAPTSGYQEFVHAVEQGGTQASAVVGLGPPGEAGYKAFSSLLASSAVSPEKCGFGASSGEEGYKPFQDLIPGCPGDPAPVPVPLFTFGLDREPPRSPQSSHLPSSSPEHLGLEPGEKVEDMPKPPLPQEQATDPLVDSLGSGIVYSALTCHLCGHLKQCHGQEDGGQTPVMASPCCGCCCGDRSSPPTTPLRAPDPSPGGVPLEASLCPASLAPSGISEKSKSSSSFHPAPGNAQSSSQTPKIVNFVSVGPTYMRVS T03346 DRUGINFO D07FUP Dupilumab Approved T03346 DRUGINFO D0O9UN SAR231893 Phase 3 T03346 DRUGINFO DF7Y9S CBP-201 Phase 3 T03346 DRUGINFO D0BW3P Aerovant Phase 2a T03346 DRUGINFO D0C5VQ PRX-321 Phase 2 T03346 DRUGINFO D0O5KH Altrakincept Phase 2 T03346 DRUGINFO DZGI51 AZD1402 Phase 2 T03346 DRUGINFO D0O4SH SAR-156597 Phase 2 T03346 DRUGINFO D09MKQ AMG 317 Discontinued in Phase 1 T03346 DRUGINFO D01BEX PRS-060 Investigative T03346 DRUGINFO D0Y1BF APG-201 Investigative T00884 TARGETID T00884 T00884 FORMERID TTDC00190 T00884 UNIPROID CXCR1_HUMAN T00884 TARGNAME C-X-C chemokine receptor type 1 (CXCR1) T00884 GENENAME CXCR1 T00884 TARGTYPE Successful T00884 SYNONYMS Interleukin-8 receptor A; IL8RA; IL-8R A; IL-8 receptor type 1; High affinity interleukin-8 receptor A; CXCR-1; CXC-R1; CMKAR1; CDw128a; CD181 T00884 FUNCTION Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activate a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity. Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. T00884 PDBSTRUC 2LNL; 1ILQ; 1ILP T00884 BIOCLASS GPCR rhodopsin T00884 SEQUENCE MSNITDPQMWDFDDLNFTGMPPADEDYSPCMLETETLNKYVVIIAYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALTLPIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLLACISVDRYLAIVHATRTLTQKRHLVKFVCLGCWGLSMNLSLPFFLFRQAYHPNNSSPVCYEVLGNDTAKWRMVLRILPHTFGFIVPLFVMLFCYGFTLRTLFKAHMGQKHRAMRVIFAVVLIFLLCWLPYNLVLLADTLMRTQVIQESCERRNNIGRALDATEILGFLHSCLNPIIYAFIGQNFRHGFLKILAMHGLVSKEFLARHRVTSYTSSSVNVSSNL T00884 DRUGINFO D0R1QE Ibuprofen Approved T00884 DRUGINFO D0LJ1B Reparixin Phase 3 T00884 DRUGINFO D00QKI SCH-527123 Phase 2 T00884 DRUGINFO DAY4L1 SX-682 Phase 1 T00884 DRUGINFO D0Q5PL INDOPROFEN Withdrawn from market T00884 DRUGINFO D0ZL4F R-ketoprofen Discontinued in Phase 2 T00884 DRUGINFO D0Q8TD 1-(2-Bromo-phenyl)-3-(2,4-dihydroxy-phenyl)-urea Investigative T00884 DRUGINFO D00IPO 2-(3-Isopropyl-phenyl)-propionic acid Investigative T00884 DRUGINFO D00PWV 2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid Investigative T00884 DRUGINFO D05OUY (R)-2-(4-Isobutyl-phenyl)-propionamide Investigative T00884 DRUGINFO D06BBI (R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide Investigative T00884 DRUGINFO D08BRR 2-[3-(2-Methyl-butyl)-phenyl]-propionic acid Investigative T00884 DRUGINFO D09FHA (R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide Investigative T00884 DRUGINFO D09LFY Il-8((3-73))K11R Investigative T00884 DRUGINFO D0F8YO 2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid Investigative T00884 DRUGINFO D0O5YE 2-(3-Isobutyl-phenyl)-propionic acid Investigative T00884 DRUGINFO D0U2UJ 1-(2-hydroxy-4-nitrophenyl)-3-phenylurea Investigative T00884 DRUGINFO D0W1WQ (R)-3-(4-Isobutyl-phenyl)-butan-2-one Investigative T56923 TARGETID T56923 T56923 FORMERID TTDC00087 T56923 UNIPROID CXCR2_HUMAN T56923 TARGNAME C-X-C chemokine receptor type 2 (CXCR2) T56923 GENENAME CXCR2 T56923 TARGTYPE Successful T56923 SYNONYMS Interleukin-8 receptor B; IL8RB; IL-8R B; IL-8 receptor type 2; High affinity interleukin-8 receptor B; GRO/MGSA receptor; CXCR-2; CXC-R2; CDw128b; CD182 T56923 FUNCTION Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. Binds to IL-8 with high affinity. Also binds with high affinity to CXCL3, GRO/MGSA and NAP-2. Receptor for interleukin-8 which is a powerful neutrophil chemotactic factor. T56923 PDBSTRUC 5TYT; 4Q3H T56923 BIOCLASS GPCR rhodopsin T56923 SEQUENCE MEDFNMESDSFEDFWKGEDLSNYSYSSTLPPFLLDAAPCEPESLEINKYFVVIIYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALTLPIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLLACISVDRYLAIVHATRTLTQKRYLVKFICLSIWGLSLLLALPVLLFRRTVYSSNVSPACYEDMGNNTANWRMLLRILPQSFGFIVPLLIMLFCYGFTLRTLFKAHMGQKHRAMRVIFAVVLIFLLCWLPYNLVLLADTLMRTQVIQETCERRNHIDRALDATEILGILHSCLNPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVGSSSGHTSTTL T56923 DRUGINFO D09GOS Clotrimazole Approved T56923 DRUGINFO D0R1QE Ibuprofen Approved T56923 DRUGINFO D0LJ1B Reparixin Phase 3 T56923 DRUGINFO D02JXG SB-265610 Phase 2 T56923 DRUGINFO D0E6SX AZD-5069 Phase 2 T56923 DRUGINFO D0H8GW PS-938285 Phase 2 T56923 DRUGINFO D0R7XD GSK1325756 Phase 2 T56923 DRUGINFO D0SN7I SB-656933 Phase 2 T56923 DRUGINFO DW8Z1M RIST4721 Phase 2 T56923 DRUGINFO D00QKI SCH-527123 Phase 2 T56923 DRUGINFO D0N3QF AZD-5122 Phase 1 T56923 DRUGINFO D0Q0RK AZD4721 Phase 1 T56923 DRUGINFO DAY4L1 SX-682 Phase 1 T56923 DRUGINFO D0Q5PL INDOPROFEN Withdrawn from market T56923 DRUGINFO D0ZL4F R-ketoprofen Discontinued in Phase 2 T56923 DRUGINFO D03PDY SB-332235 Discontinued in Phase 1 T56923 DRUGINFO D0F6WV PD-157695 Preclinical T56923 DRUGINFO D05AZU 1-(4-cyano-2-hydroxyphenyl)-3-phenylurea Investigative T56923 DRUGINFO D05CCF 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea Investigative T56923 DRUGINFO D05SNR 5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-ol Investigative T56923 DRUGINFO D06WVV 1-(2-Hydroxy-3-nitro-phenyl)-3-phenyl-urea Investigative T56923 DRUGINFO D09MAZ SX-517 Investigative T56923 DRUGINFO D0D8LQ 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea Investigative T56923 DRUGINFO D0J1XP 1-(2-Hydroxy-5-nitro-phenyl)-3-phenyl-urea Investigative T56923 DRUGINFO D0Q6VK SB 272844 Investigative T56923 DRUGINFO D0T4KC 1-(3-cyano-2-hydroxyphenyl)-3-phenylurea Investigative T56923 DRUGINFO D00IPO 2-(3-Isopropyl-phenyl)-propionic acid Investigative T56923 DRUGINFO D00PWV 2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid Investigative T56923 DRUGINFO D05OUY (R)-2-(4-Isobutyl-phenyl)-propionamide Investigative T56923 DRUGINFO D06BBI (R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide Investigative T56923 DRUGINFO D07PHS CXCL8 Investigative T56923 DRUGINFO D08BRR 2-[3-(2-Methyl-butyl)-phenyl]-propionic acid Investigative T56923 DRUGINFO D09FHA (R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide Investigative T56923 DRUGINFO D09LFY Il-8((3-73))K11R Investigative T56923 DRUGINFO D0F8YO 2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid Investigative T56923 DRUGINFO D0O5YE 2-(3-Isobutyl-phenyl)-propionic acid Investigative T56923 DRUGINFO D0U2UJ 1-(2-hydroxy-4-nitrophenyl)-3-phenylurea Investigative T56923 DRUGINFO D0W1WQ (R)-3-(4-Isobutyl-phenyl)-butan-2-one Investigative T47094 TARGETID T47094 T47094 FORMERID TTDS00194 T47094 UNIPROID NK1R_HUMAN T47094 TARGNAME Substance-P receptor (TACR1) T47094 GENENAME TACR1 T47094 TARGTYPE Successful T47094 SYNONYMS Tachykinin receptor 1; Tachykinin neurokinin 1 receptor; Tachykinin 1 receptor; TACR1; Substance P receptor; SPR; Neurokinin 1 receptor; NK-1R; NK-1 receptor T47094 FUNCTION This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K. T47094 PDBSTRUC 6HLP; 6HLO; 6HLL; 6.00E+59; 2KSB T47094 BIOCLASS GPCR rhodopsin T47094 SEQUENCE MDNVLPVDSDLSPNISTNTSEPNQFVQPAWQIVLWAAAYTVIVVTSVVGNVVVMWIILAHKRMRTVTNYFLVNLAFAEASMAAFNTVVNFTYAVHNEWYYGLFYCKFHNFFPIAAVFASIYSMTAVAFDRYMAIIHPLQPRLSATATKVVICVIWVLALLLAFPQGYYSTTETMPSRVVCMIEWPEHPNKIYEKVYHICVTVLIYFLPLLVIGYAYTVVGITLWASEIPGDSSDRYHEQVSAKRKVVKMMIVVVCTFAICWLPFHIFFLLPYINPDLYLKKFIQQVYLAIMWLAMSSTMYNPIIYCCLNDRFRLGFKHAFRCCPFISAGDYEGLEMKSTRYLQTQGSVYKVSRLETTISTVVGAHEEEPEDGPKATPSSLDLTSNCSSRSDSKTMTESFSFSSNVLS T47094 DRUGINFO D0CF0Y Rolapitant Approved T47094 DRUGINFO D0GU4K Aprepitant Approved T47094 DRUGINFO D0K5IP Palonosetron + fosnetupitant Approved T47094 DRUGINFO D0S2UG Selegiline Approved T47094 DRUGINFO D0CB2B Serlopitant Phase 3 T47094 DRUGINFO D0G3YC Netupitant Phase 3 T47094 DRUGINFO D0N8UY LY-686017 Phase 3 T47094 DRUGINFO DKZ07O Elinzanetant Phase 3 T47094 DRUGINFO D02DLP VOFOPITANT HYDROCHLORIDE Phase 2 T47094 DRUGINFO D05SLM LY-2590443 Phase 2 T47094 DRUGINFO D06HCC LANEPITANT Phase 2 T47094 DRUGINFO D0DM6I DAPITANT Phase 2 T47094 DRUGINFO D0E6ZN TKA-731 Phase 2 T47094 DRUGINFO D0F1WX SSR240600 Phase 2 T47094 DRUGINFO D0J4PB GW 597599 Phase 2 T47094 DRUGINFO D0P1YE Orvepitant Phase 2 T47094 DRUGINFO D0P3JF SCH-900978 Phase 2 T47094 DRUGINFO D0T0PN CP-122721 Phase 2 T47094 DRUGINFO D0V7US NKP 608 Phase 2 T47094 DRUGINFO D09XLS FR139317 Phase 2 T47094 DRUGINFO D07XDQ Figopitant Phase 1 T47094 DRUGINFO D0E5GI CJ-12255 Phase 1 T47094 DRUGINFO D0P2KG GSK1144814 Phase 1 T47094 DRUGINFO D00ZGA Casopitant Withdrawn from market T47094 DRUGINFO D00XPA L-759274 Discontinued in Phase 3 T47094 DRUGINFO D05KFA BL-1832 Discontinued in Phase 3 T47094 DRUGINFO D01TBN Ezlopitant Discontinued in Phase 2 T47094 DRUGINFO D05UKK FK-888 Discontinued in Phase 2 T47094 DRUGINFO D09RNP GSK 679769 Discontinued in Phase 2 T47094 DRUGINFO D0J5CX TAK-637 Discontinued in Phase 2 T47094 DRUGINFO D0N1PA CGP-49823 Discontinued in Phase 2 T47094 DRUGINFO D0ST5P TA-5538 Discontinued in Phase 2 T47094 DRUGINFO D0UT3F Nolpitantium besilate Discontinued in Phase 2 T47094 DRUGINFO D02FIJ FK-224 Discontinued in Phase 2 T47094 DRUGINFO D0C9FF DNK-333 Discontinued in Phase 2 T47094 DRUGINFO D03ZKE CS-003 Discontinued in Phase 2 T47094 DRUGINFO D0Y4GJ AVE-5883 Discontinued in Phase 1/2 T47094 DRUGINFO D00VPU SLV-323 Discontinued in Phase 1 T47094 DRUGINFO D04RUP SDZ-NKT-343 Discontinued in Phase 1 T47094 DRUGINFO D00CQB CI-1021 Terminated T47094 DRUGINFO D02TKI L-733060 Terminated T47094 DRUGINFO D03SXN CP-96345 Terminated T47094 DRUGINFO D04VDY L-741671 Terminated T47094 DRUGINFO D05REL GR-82334 Terminated T47094 DRUGINFO D07PLK WIN-64821 Terminated T47094 DRUGINFO D08KXE RP-67580 Terminated T47094 DRUGINFO D0KD4U FK-355 Terminated T47094 DRUGINFO D0L0UF MEN-11467 Terminated T47094 DRUGINFO D0T4IQ MEN-11149 Terminated T47094 DRUGINFO D0T6MU FR-113680 Terminated T47094 DRUGINFO D08ZBV L-732138 Terminated T47094 DRUGINFO D00EEU Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2 Investigative T47094 DRUGINFO D00HUY L-708568 Investigative T47094 DRUGINFO D00IQV Homspera Investigative T47094 DRUGINFO D00XCC (D)-Phe-(D)-Phe-NH2 Investigative T47094 DRUGINFO D01MND EU-C-001 Investigative T47094 DRUGINFO D01PAC [125I]L703,606 Investigative T47094 DRUGINFO D01VKI physalaemin Investigative T47094 DRUGINFO D02BOG H-Tyr(OMe)-Phe(2-Me)-NH2 Investigative T47094 DRUGINFO D02SNO 2-Phenyl-3-(1-phenyl-ethoxy)-piperidine Investigative T47094 DRUGINFO D03DLD H-Tyr-Ala-Phe-Phe-NH2 Investigative T47094 DRUGINFO D03FQU H-Tyr-Pro-Phe-Ala-NH2 Investigative T47094 DRUGINFO D03UVR [18F]SPA-RQ Investigative T47094 DRUGINFO D04LHG SP-SAP Investigative T47094 DRUGINFO D05BTG 3,6-Diphenyl-1-oxa-7-aza-spiro[4.5]decane Investigative T47094 DRUGINFO D05ETM CP-99,994 Investigative T47094 DRUGINFO D05GAT H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH Investigative T47094 DRUGINFO D05MTD Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 Investigative T47094 DRUGINFO D05RGO H-Pro-Phe-Phe-NH2 Investigative T47094 DRUGINFO D06IZZ Arg-Pro-Lys-Pro-Ala-Gln-Phe-Phe-Gly-Leu-Met-NH2 Investigative T47094 DRUGINFO D07ARO WIN-66306 Investigative T47094 DRUGINFO D07FUN spantide II Investigative T47094 DRUGINFO D07KDH [Sar9,Met(O2)11]-SP Investigative T47094 DRUGINFO D07YFY Ac-Phe-Phe-NH2 Investigative T47094 DRUGINFO D08CHK WIN-64745 Investigative T47094 DRUGINFO D09JDH Septide Investigative T47094 DRUGINFO D0A7SR H-Leu-Phe-NH2 Investigative T47094 DRUGINFO D0BV8M (D)-Phe-(L)-Phe-NH2 Investigative T47094 DRUGINFO D0DB8W H-Tyr-Pro-Phe-Phe-OH Investigative T47094 DRUGINFO D0I8HY Arg-Pro-Lys-Pro-Gln-Ser-Phe-Phe-Gly-Leu-Met-NH2 Investigative T47094 DRUGINFO D0J6SX (L)-Phe-(D)-Phe-NH2 Investigative T47094 DRUGINFO D0J8SU Substance P Investigative T47094 DRUGINFO D0K9GG L-703,606 Investigative T47094 DRUGINFO D0L1ME H-Phe-NH2 Investigative T47094 DRUGINFO D0L3SA T2328 Investigative T47094 DRUGINFO D0LA6S R116031 Investigative T47094 DRUGINFO D0M0ZB H-Ala-Pro-Phe-Phe-NH2 Investigative T47094 DRUGINFO D0N0GT 3-Benzyloxy-2-phenyl-piperidine Investigative T47094 DRUGINFO D0N3RM befetupitant Investigative T47094 DRUGINFO D0P1XM L-736281 Investigative T47094 DRUGINFO D0Q7MQ CP-100263 Investigative T47094 DRUGINFO D0T0IL WIN-68577 Investigative T47094 DRUGINFO D0T4JO 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (3,5-BIS-TRIFLUOROMETHYL-BENZYL)-METHYL-AMIDE (STRUCTURAL MIX) Investigative T47094 DRUGINFO D0TL4O 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(S)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX) Investigative T47094 DRUGINFO D0U8CB SPANTIDE Investigative T47094 DRUGINFO D0U8EA S-41744 Investigative T47094 DRUGINFO D0UG6N 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(R)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX) Investigative T47094 DRUGINFO D0XR4J H-Phe-Phe-NH2 Investigative T47094 DRUGINFO D0A1DE MDL-28163 Investigative T47094 DRUGINFO D0D2JB kassinin Investigative T47094 DRUGINFO D0U9IB eledoisin Investigative T47094 DRUGINFO D0Y9RD H-Tyr-Pro-Ala-Phe-NH2 Investigative T47094 DRUGINFO D0Z6TG ZD-6021 Investigative T47094 DRUGINFO D01NPA neurokinin A Investigative T47094 DRUGINFO D07JAN SCH 206272 Investigative T47094 DRUGINFO D08KSJ H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2 Investigative T47094 DRUGINFO D0C6RQ H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2 Investigative T47094 DRUGINFO D0CK8C H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl Investigative T47094 DRUGINFO D0G6GC Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl Investigative T47094 DRUGINFO D0L2CT H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2 Investigative T47094 DRUGINFO D0P0RB H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl Investigative T47094 DRUGINFO D0Q7HG H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl Investigative T47094 DRUGINFO D00TNR ENDOMORPHIN 2 Investigative T47094 DRUGINFO D0PN9R R-226161 Investigative T47094 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T87023 TARGETID T87023 T87023 FORMERID TTDR01165 T87023 UNIPROID PTAFR_HUMAN T87023 TARGNAME Platelet-activating factor receptor (PTAFR) T87023 GENENAME PTAFR T87023 TARGTYPE Successful T87023 SYNONYMS PTAFR; PAF-R T87023 FUNCTION Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth- muscle contractile and hypotensive activity. Seems to mediate its action via a G protein that activates a phosphatidylinositol- calcium second messenger system. T87023 PDBSTRUC 2B0X T87023 BIOCLASS GPCR rhodopsin T87023 SEQUENCE MEPHDSSHMDSEFRYTLFPIVYSIIFVLGVIANGYVLWVFARLYPCKKFNEIKIFMVNLTMADMLFLITLPLWIVYYQNQGNWILPKFLCNVAGCLFFINTYCSVAFLGVITYNRFQAVTRPIKTAQANTRKRGISLSLVIWVAIVGAASYFLILDSTNTVPDSAGSGNVTRCFEHYEKGSVPVLIIHIFIVFSFFLVFLIILFCNLVIIRTLLMQPVQQQRNAEVKRRALWMVCTVLAVFIICFVPHHVVQLPWTLAELGFQDSKFHQAINDAHQVTLCLLSTNCVLDPVIYCFLTKKFRKHLTEKFYSMRSSRKCSRATTDTVTEVVVPFNQIPGNSLKN T87023 DRUGINFO D05LBU Ticlopidine Approved T87023 DRUGINFO D0S1CQ RUPATADINE Phase 4 T87023 DRUGINFO D0D4ZM ISRAPAFANT Phase 3 T87023 DRUGINFO D0W6AF YM-264 Phase 2 T87023 DRUGINFO D0ZI0C Dersalazine Phase 2 T87023 DRUGINFO DA85NC 60P002 Phase 2 T87023 DRUGINFO D0D5ZV CMI-392 Phase 2 T87023 DRUGINFO D0I0UE Lexipafant Phase 2 T87023 DRUGINFO D0C2HI PegCNTF Phase 1 T87023 DRUGINFO D05YUK FOROPAFANT Discontinued in Phase 3 T87023 DRUGINFO D0G2RE BN 50730 Discontinued in Phase 3 T87023 DRUGINFO D01KZC Minopafant Discontinued in Phase 2 T87023 DRUGINFO D04ENK TCV-309 Discontinued in Phase 2 T87023 DRUGINFO D05KQE MK-287 Discontinued in Phase 2 T87023 DRUGINFO D0CB8W DE-081 Discontinued in Phase 2 T87023 DRUGINFO D0I6UU UK-74505 Discontinued in Phase 2 T87023 DRUGINFO D0R0EV E-6123 Discontinued in Phase 2 T87023 DRUGINFO D0R0TF BN50727 Discontinued in Phase 2 T87023 DRUGINFO D0S4JY Ro-24-4736 Discontinued in Phase 2 T87023 DRUGINFO D0U7DI SM-10661 Discontinued in Phase 2 T87023 DRUGINFO D02DVB AGN-191743 Discontinued in Phase 1 T87023 DRUGINFO D07SGB ABT-299 Discontinued in Phase 1 T87023 DRUGINFO D0C7LF DACOPAFANT Discontinued in Phase 1 T87023 DRUGINFO D0W5OV DF-1111301 Discontinued in Phase 1 T87023 DRUGINFO D0XQ1W SDZ-62-434 Discontinued in Phase 1 T87023 DRUGINFO D01RFI Ro-24-0238 Terminated T87023 DRUGINFO D02HCU WEB-2347 Terminated T87023 DRUGINFO D05CEK CV 6209 Terminated T87023 DRUGINFO D05RBL CL-184005 Terminated T87023 DRUGINFO D08EVM FR-128998 Terminated T87023 DRUGINFO D09FQB UR-12460 Terminated T87023 DRUGINFO D0BD3U SDZ-64-412 Terminated T87023 DRUGINFO D0H3XB TULOPAFANT Terminated T87023 DRUGINFO D0KW2A BN50739 Terminated T87023 DRUGINFO D0MA3D L-659989 Terminated T87023 DRUGINFO D0Q1UR TIAPAFANT Terminated T87023 DRUGINFO D0Q8YN Sch-40338 Terminated T87023 DRUGINFO D0V7HD BN-50726 Terminated T87023 DRUGINFO D0Y2ES Bepafant Terminated T87023 DRUGINFO D01LXG KC-11425 Terminated T87023 DRUGINFO D04APY KC-11404 Terminated T87023 DRUGINFO D0V4GT CMI-206 Terminated T87023 DRUGINFO D00JJP UR-12519 Investigative T87023 DRUGINFO D01CDL L-652731 Investigative T87023 DRUGINFO D02QUS RP-52770 Investigative T87023 DRUGINFO D03WIK 2-O-ethyl-PAF C-16 Investigative T87023 DRUGINFO D04FHG PAF Investigative T87023 DRUGINFO D04GGK KO-286011 Investigative T87023 DRUGINFO D05BJY 7alpha-OCOCH2Ph-ginkgolide B Investigative T87023 DRUGINFO D05MWB UR-10324 Investigative T87023 DRUGINFO D05XSV 7alpha-OAc-ginkgolide B Investigative T87023 DRUGINFO D06AUX enantio PAF C-16 Investigative T87023 DRUGINFO D07DAK 7-epi-ginkgolide C Investigative T87023 DRUGINFO D07FPS 7alpha-Cl-ginkgolide B Investigative T87023 DRUGINFO D07TQF 7alpha-F-ginkgolide B Investigative T87023 DRUGINFO D09BLB methylcarbamyl PAF Investigative T87023 DRUGINFO D09FQT 7alpha-N3-ginkgolide B Investigative T87023 DRUGINFO D09PTR FR-900452 Investigative T87023 DRUGINFO D0A8PD 2-O-methyl-PAF C-18 Investigative T87023 DRUGINFO D0AN6L A 137491 Investigative T87023 DRUGINFO D0BV8A 7alpha-NHMe-ginkgolide B Investigative T87023 DRUGINFO D0D1NQ 7alpha-NH2-ginkgolide B Investigative T87023 DRUGINFO D0G1AK UR-12510 Investigative T87023 DRUGINFO D0HJ9U LAU-0901 Investigative T87023 DRUGINFO D0I7RF 10-OBn-ginkgolide B Investigative T87023 DRUGINFO D0J6WM 10-OBn-ginkgolide C Investigative T87023 DRUGINFO D0N0IV VERAGUENSIN Investigative T87023 DRUGINFO D0N2WK CV-3988 Investigative T87023 DRUGINFO D0NB4Q 10-OBn-7alpha-F-gingkolide B Investigative T87023 DRUGINFO D0OT3H UR-11353 Investigative T87023 DRUGINFO D0Q6EK 7alpha-NHEt-ginkgolide B Investigative T87023 DRUGINFO D0WJ1N SRI-63-675 Investigative T87023 DRUGINFO D0X9RL BB-823 Investigative T87023 DRUGINFO D0Z6BO 10-OBn-epi-ginkgolide C Investigative T36483 TARGETID T36483 T36483 FORMERID TTDC00071 T36483 UNIPROID PAR1_HUMAN T36483 TARGNAME Proteinase activated receptor 1 (F2R) T36483 GENENAME F2R T36483 TARGTYPE Successful T36483 SYNONYMS Thrombin receptor; Proteinase-activated receptor 1; Protease-activated receptor-1; Protease activated receptor 1; PAR1; PAR-1; Coagulation factor II receptor; CF2R T36483 FUNCTION May play a role in platelets activation and in vascular development. High affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. T36483 PDBSTRUC 3VW7; 3LU9; 3HKJ; 3HKI; 3BEF T36483 BIOCLASS GPCR rhodopsin T36483 SEQUENCE MGPRRLLLVAACFSLCGPLLSARTRARRPESKATNATLDPRSFLLRNPNDKYEPFWEDEEKNESGLTEYRLVSINKSSPLQKQLPAFISEDASGYLTSSWLTLFVPSVYTGVFVVSLPLNIMAIVVFILKMKVKKPAVVYMLHLATADVLFVSVLPFKISYYFSGSDWQFGSELCRFVTAAFYCNMYASILLMTVISIDRFLAVVYPMQSLSWRTLGRASFTCLAIWALAIAGVVPLLLKEQTIQVPGLNITTCHDVLNETLLEGYYAYYFSAFSAVFFFVPLIISTVCYVSIIRCLSSSAVANRSKKSRALFLSAAVFCIFIICFGPTNVLLIAHYSFLSHTSTTEAAYFAYLLCVCVSSISCCIDPLIYYYASSECQRYVYSILCCKESSDPSSYNSSGQLMASKMDTCSSNLNNSIYKKLLT T36483 DRUGINFO D0VA0I Vorapaxar Approved T36483 DRUGINFO D0PU8T E5555 Phase 2 T36483 DRUGINFO D2F7JC PZ-128 Phase 2 T36483 DRUGINFO D08ELM RWJ-58259 Terminated T36483 DRUGINFO D0Z4NX FR-171113 Terminated T36483 DRUGINFO D0BV3B SCH-602539 Investigative T36483 DRUGINFO D0I2VE RWJ-56110 Investigative T36483 DRUGINFO D0QK2E SCH-205831 Investigative T14065 TARGETID T14065 T14065 FORMERID TTDC00031 T14065 UNIPROID ITB7_HUMAN T14065 TARGNAME Integrin beta-7 (ITGB7) T14065 GENENAME ITGB7 T14065 TARGTYPE Successful T14065 SYNONYMS Gut homing receptor beta subunit T14065 FUNCTION Integrin alpha-4/beta-7 interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interacts also with VCAM1 and fibronectin, an extracellular matrix component. It recognizes one or more domains within the alternatively spliced CS-1 region of fibronectin. Interactions involves the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. Binds to HIV-1 gp120, thereby allowing the virus to enter GALT, which is thought to be the major trigger of AIDS disease. Interaction would involve a tripeptide L-D-I in HIV-1 gp120. Integrin alpha-E/beta-7 (HML-1) is a receptor for E-cadherin. Integrin alpha-4/beta-7 (Peyer patches-specific homing receptor LPAM-1) is an adhesion molecule that mediates lymphocyte migration and homing to gut-associated lymphoid tissue (GALT). T14065 PDBSTRUC 3V4V; 3V4P; 2BRQ T14065 BIOCLASS Integrin T14065 SEQUENCE MVALPMVLVLLLVLSRGESELDAKIPSTGDATEWRNPHLSMLGSCQPAPSCQKCILSHPSCAWCKQLNFTASGEAEARRCARREELLARGCPLEELEEPRGQQEVLQDQPLSQGARGEGATQLAPQRVRVTLRPGEPQQLQVRFLRAEGYPVDLYYLMDLSYSMKDDLERVRQLGHALLVRLQEVTHSVRIGFGSFVDKTVLPFVSTVPSKLRHPCPTRLERCQSPFSFHHVLSLTGDAQAFEREVGRQSVSGNLDSPEGGFDAILQAALCQEQIGWRNVSRLLVFTSDDTFHTAGDGKLGGIFMPSDGHCHLDSNGLYSRSTEFDYPSVGQVAQALSAANIQPIFAVTSAALPVYQELSKLIPKSAVGELSEDSSNVVQLIMDAYNSLSSTVTLEHSSLPPGVHISYESQCEGPEKREGKAEDRGQCNHVRINQTVTFWVSLQATHCLPEPHLLRLRALGFSEELIVELHTLCDCNCSDTQPQAPHCSDGQGHLQCGVCSCAPGRLGRLCECSVAELSSPDLESGCRAPNGTGPLCSGKGHCQCGRCSCSGQSSGHLCECDDASCERHEGILCGGFGRCQCGVCHCHANRTGRACECSGDMDSCISPEGGLCSGHGRCKCNRCQCLDGYYGALCDQCPGCKTPCERHRDCAECGAFRTGPLATNCSTACAHTNVTLALAPILDDGWCKERTLDNQLFFFLVEDDARGTVVLRVRPQEKGADHTQAIVLGCVGGIVAVGLGLVLAYRLSVEIYDRREYSRFEKEQQQLNWKQDSNPLYKSAITTTINPRFQEADSPTL T14065 DRUGINFO D0N5ZS Vedolizmab Approved T14065 DRUGINFO D06PFT Rhumab Beta7 Phase 3 T14065 DRUGINFO D04WQJ AMG-181 Phase 2 T14065 DRUGINFO D0FU1J PTG-100 Phase 1 T40492 TARGETID T40492 T40492 FORMERID TTDR00103 T40492 UNIPROID POLG_HCV1 T40492 TARGNAME Hepatitis C virus NS3 helicase (HCV NS3) T40492 GENENAME HCV NS3 T40492 TARGTYPE Successful T40492 SYNONYMS HCV Hepacivirin; HCV NS3P; HCV p70 T40492 FUNCTION Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity). T40492 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T40492 BIOCLASS Peptidase T40492 ECNUMBER EC 3.4.21.98 T40492 SEQUENCE APITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVVT T40492 DRUGINFO D0T9TE Ombitasvir + paritaprevir + ritonavir Approved T40492 DRUGINFO D02HTD GS-9451 Phase 2 T40492 DRUGINFO D07TYE GS-9857 Phase 2 T40492 DRUGINFO D0OZ7P BILN-2061 Phase 2 T40492 DRUGINFO D02YEG VBY-376 Phase 1 T40492 DRUGINFO D06KUY ACH-2684 Phase 1 T40492 DRUGINFO D0N8XL BMS-605339 Terminated T40492 DRUGINFO D02HVT AcAsp-D-Gla-Leu-Ile-Cha-Cys Investigative T40492 DRUGINFO D02IYE Cbz-Ile-Leu-L-(difluoro)aminobutyric acid Investigative T40492 DRUGINFO D04DXC AcGlu-Dif-Ile-Cha-Cys Investigative T40492 DRUGINFO D04LUF AcGlu-Dif-Glu-Cha-Cys Investigative T40492 DRUGINFO D05EDA AcAsp-Glu-Cha-Val-Prb-Cys Investigative T40492 DRUGINFO D06KJR AcAsp-Glu-Dif-Glu-Cha-Fab Investigative T40492 DRUGINFO D07XFT Ribavirin-TP Investigative T40492 DRUGINFO D08AXB Ac-Glu-Cha-Cys Investigative T40492 DRUGINFO D08NOS AcAsp-Glu-Dif-Ile-Cha-Cys Investigative T40492 DRUGINFO D09JCT AcAsp-Glu-Met-Glu-Glu-Cys Investigative T40492 DRUGINFO D09KTN Asp-D-Glu-Leu-Glu-Cha-Cys Investigative T40492 DRUGINFO D0B3FI Boc-Ile-Leu-L-(difluoro)aminobutyric aid Investigative T40492 DRUGINFO D0BP1S AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Nle-Asp-ValNH2 Investigative T40492 DRUGINFO D0C9GO AcAsp-Glu-Leu-Glu-Cha-Cys Investigative T40492 DRUGINFO D0D2WV Azapeptide Investigative T40492 DRUGINFO D0D3OV AcAsp-Glu-Cha-Val-Prb-Cpg Investigative T40492 DRUGINFO D0FR8Z AcAsp-Glu-Met-Glu-Nal-Cyse Investigative T40492 DRUGINFO D0H1VY 2,4,6-Trihydroxy-3-nitro-N-tridecyl-benzamide Investigative T40492 DRUGINFO D0H9AV AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Cha-Asp-ValNH2 Investigative T40492 DRUGINFO D0HT2D AcAsp-Glu-Met-Glu-Cha-Cys Investigative T40492 DRUGINFO D0I8WU AcDif-Glu-Cha-Cys Investigative T40492 DRUGINFO D0K9BF AcAsp-Glu-Dif-Glu-Cha-Cys Investigative T40492 DRUGINFO D0L7DB SCH-68631 Investigative T40492 DRUGINFO D0L7PQ AcDif-Ile-Cha-Cys Investigative T40492 DRUGINFO D0LB4A PATULIN Investigative T40492 DRUGINFO D0M2RI AcAsp-Gla-Leu-Ile-Cha-Cys Investigative T40492 DRUGINFO D0PT8O AcAsp-Glu-Dif-Lys-Cha-Cys Investigative T40492 DRUGINFO D0R5QX AcAsp-Glu-Dif-Ile-Cha-Cys-Iqc-Nle-Thr-TyrNH2 Investigative T40492 DRUGINFO D0S8BU SE RNA Investigative T40492 DRUGINFO D0VM0N AcAsp-D-Glu-Leu-Glu-Cha-Cys Investigative T40492 DRUGINFO D0VN0H AcGlu-Asp-Val-Val-Leu-Cys-Iqc-Nle-Thr-TyrNH2 Investigative T40492 DRUGINFO D00PVO GNF-PF-3464 Investigative T05152 TARGETID T05152 T05152 FORMERID TTDI01926 T05152 UNIPROID POLG_HCV1 T05152 TARGNAME Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) T05152 GENENAME HCV NS5B T05152 TARGTYPE Successful T05152 SYNONYMS HCV NS5B; HCV p68 T05152 FUNCTION Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity). T05152 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T05152 BIOCLASS Peptidase T05152 ECNUMBER EC 2.7.7.48 T05152 SEQUENCE SMSYSWTGALVTPCAAEEQKLPINALSNSLLRHHNLVYSTTSRSACQRQKKVTFDRLQVLDSHYQDVLKEVKAAASKVKANLLSVEEACSLTPPHSAKSKFGYGAKDVRCHARKAVTHINSVWKDLLEDNVTPIDTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMALYDVVTKLPLAVMGSSYGFQYSPGQRVEFLVQAWKSKKTPMGFSYDTRCFDSTVTESDIRTEEAIYQCCDLDPQARVAIKSLTERLYVGGPLTNSRGENCGYRRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCTMLVCGDDLVVICESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDGAGKRVYYLTRDPTTPLARAAWETARHTPVNSWLGNIIMFAPTLWARMILMTHFFSVLIARDQLEQALDCEIYGACYSIEPLDLPPIIQRLHGLSAFSLHSYSPGEINRVAACLRKLGVPPLRAWRHRARSVRARLLARGGRAAICGKYLFNWAVRTKLKLTPIAAAGQLDLSGWFTAGYSGGDIYHSVSHARPRWIWFCLLLLAAGVGIYLLPNR T05152 DRUGINFO D0D4YZ PSI-7977 Approved T05152 DRUGINFO D0RM5Z Sofosbuvir + velpatasvir + voxilaprevir Approved T05152 DRUGINFO D06PGZ Setrobuvir Phase 2 T05152 DRUGINFO D07QAF BI 207127 Phase 2 T05152 DRUGINFO D08GBB Valopicitabine dihydrochloride Phase 2 T05152 DRUGINFO D08TQP INX-189 Phase 2 T05152 DRUGINFO D09RVI Tegobuvir Phase 2 T05152 DRUGINFO D09ZZW VX-759 Phase 2 T05152 DRUGINFO D0BG3B VX-135 Phase 2 T05152 DRUGINFO D0F4NH VX-222 Phase 2 T05152 DRUGINFO D0H7QU BMS 791325 Phase 2 T05152 DRUGINFO D0U0GZ Filibuvir Phase 2 T05152 DRUGINFO DD5NX2 AT-777 Phase 1/2 T05152 DRUGINFO D01FUL Balapiravir Phase 1 T05152 DRUGINFO D02RVC PPI-383 Phase 1 T05152 DRUGINFO D04KJT ABT-333 Phase 1 T05152 DRUGINFO D06IPZ MK-3281 Phase 1 T05152 DRUGINFO D06QOA PSI-938 Phase 1 T05152 DRUGINFO D08DPN GSK-625433 Phase 1 T05152 DRUGINFO D09APB IDX-189 Phase 1 T05152 DRUGINFO D0B5RZ GS-6620 Phase 1 T05152 DRUGINFO D0HN6Q RG-7348 Phase 1 T05152 DRUGINFO D0J2OC MBX-700 Phase 1 T05152 DRUGINFO D0L0HV VX-916 Phase 1 T05152 DRUGINFO D0NR7H A-837093 Phase 1 T05152 DRUGINFO D0Y7CO ABT-072 Phase 1 T05152 DRUGINFO D0Y8BW TMC-647055 Phase 1 T05152 DRUGINFO D0Z3BU Drug 2878175 Phase 1 T05152 DRUGINFO D0Z6GW TMC649128 Phase 1 T05152 DRUGINFO DO2LE6 CC-31244 Phase 1 T05152 DRUGINFO DXO1V4 AT-787 Phase 1 T05152 DRUGINFO D02IRL IDX375 Discontinued in Phase 2 T05152 DRUGINFO D05DDN HCV-796 Discontinued in Phase 2 T05152 DRUGINFO D06QOF R7128 Discontinued in Phase 2 T05152 DRUGINFO D0M2SR R-803 Discontinued in Phase 1/2 T05152 DRUGINFO D00JNT HCV-086 Discontinued in Phase 1 T05152 DRUGINFO D01ZGH JTK-853 Discontinued in Phase 1 T05152 DRUGINFO D0A1KR JTK-652 Discontinued in Phase 1 T05152 DRUGINFO D0FY6Q JTK-109 Discontinued in Phase 1 T05152 DRUGINFO D0QH7G RG-7432 Discontinued in Phase 1 T05152 DRUGINFO D0ZM5B AG-021541 Discontinued in Phase 1 T05152 DRUGINFO D00RFZ PSI-6130 Terminated T05152 DRUGINFO D0GE2F GSK-2485852 Terminated T05152 DRUGINFO D0K6ZH PSI-661 Terminated T05152 DRUGINFO D00QTA A-058 Investigative T05152 DRUGINFO D01GJI GS-9256 + tegobuvir Investigative T05152 DRUGINFO D0A6OO PSI 7851 Investigative T07806 TARGETID T07806 T07806 FORMERID TTDS00099 T07806 UNIPROID 5HT1B_HUMAN T07806 TARGNAME 5-HT 1B receptor (HTR1B) T07806 GENENAME HTR1B T07806 TARGTYPE Successful T07806 SYNONYMS Serotonin receptor 1B; Serotonin 1D beta receptor; S12; HTR1DB; 5-hydroxytryptamine receptor 1B; 5-HT1B receptor; 5-HT1B; 5-HT-1D-beta; 5-HT-1B T07806 FUNCTION Functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries. G-protein coupled receptor for 5-hydroxytryptamine (serotonin). T07806 PDBSTRUC 6G79; 5V54; 4IAR; 4IAQ; 2G1X T07806 BIOCLASS GPCR rhodopsin T07806 SEQUENCE MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALITLATTLSNAFVIATVYRTRKLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQVVCDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISISLPPFFWRQAKAEEEVSECVVNTDHILYTVYSTVGAFYFPTLLLIALYGRIYVEARSRILKQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSESGSPVYVNQVKVRVSDALLEKKKLMAARERKATKTLGIILGAFIVCWLPFFIISLVMPICKDACWFHLAIFDFFTWLGYLNSLINPIIYTMSNEDFKQAFHKLIRFKCTS T07806 DRUGINFO D03NTJ Prolixin decanoate Approved T07806 DRUGINFO D0P5SA Fluphenazine Approved T07806 DRUGINFO D0T3KI Naratriptan Approved T07806 DRUGINFO D02DMQ Eletriptan Approved T07806 DRUGINFO D06FPQ Frovatriptan Approved T07806 DRUGINFO D0NG7O Zolmitriptan Approved T07806 DRUGINFO D0UA0I Metergolin Approved T07806 DRUGINFO D06FKC Eltoprazine Phase 3 T07806 DRUGINFO D0O2XJ NXN-188 Phase 2 T07806 DRUGINFO D0C1ZO [N-methyl-3H(3)]AZ-10419369 Phase 1 T07806 DRUGINFO D0Y0RW Alniditan Discontinued in Phase 3 T07806 DRUGINFO D03SFN Elzasonan hydrochloride Discontinued in Phase 2 T07806 DRUGINFO D09WCE IS-159 Discontinued in Phase 2 T07806 DRUGINFO D0G5ML Donitriptan Preclinical T07806 DRUGINFO D0E4HZ F-12682 Terminated T07806 DRUGINFO D0K4PN AZD-1134 Terminated T07806 DRUGINFO D0Q1ER CGS-12066B Terminated T07806 DRUGINFO D02ZPM Anpirtoline Terminated T07806 DRUGINFO D02ZSO L-775606 Terminated T07806 DRUGINFO D06DZI GR-127935 Terminated T07806 DRUGINFO D0UO9T VR-147 Terminated T07806 DRUGINFO D04DLR GR55562 Investigative T07806 DRUGINFO D09PIN SB 224289 Investigative T07806 DRUGINFO D0A8NB CP-94,253 Investigative T07806 DRUGINFO D0P6IV [11C]AZ10419369 Investigative T07806 DRUGINFO D0V9XE SB236057 Investigative T07806 DRUGINFO D00TYX [3H]sumatriptan Investigative T07806 DRUGINFO D03KPA 5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole Investigative T07806 DRUGINFO D03MVY 2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine Investigative T07806 DRUGINFO D03XAE [2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine Investigative T07806 DRUGINFO D09AVG 5-amino-3-(N-methylpiperidin-4-yl)-1H-indole Investigative T07806 DRUGINFO D0A2SY [3H]GR 125,743 Investigative T07806 DRUGINFO D0B6WH [3H]eletriptan Investigative T07806 DRUGINFO D0C3EX 2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine Investigative T07806 DRUGINFO D0H6KD [125I]GTI Investigative T07806 DRUGINFO D0J3ZK (R)-flurocarazolol Investigative T07806 DRUGINFO D0K9MT 5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole Investigative T07806 DRUGINFO D0KQ9H L-747201 Investigative T07806 DRUGINFO D0O8QJ (S)-flurocarazolol Investigative T07806 DRUGINFO D01APL lysergol Investigative T07806 DRUGINFO D01HRV L-772,405 Investigative T07806 DRUGINFO D03DET SB 714786 Investigative T07806 DRUGINFO D0H3KU 5-OH-DPAT Investigative T07806 DRUGINFO D0K0FI 7-methoxy-1-naphthylpiperazine Investigative T07806 DRUGINFO D0O3GF [3H]8-OH-DPAT Investigative T07806 DRUGINFO D0PN8D 1-(7-Methoxy-naphthalen-2-yl)-piperazine Investigative T07806 DRUGINFO D0QM3E SB 272183 Investigative T07806 DRUGINFO D0R3GW SB 649915 Investigative T07806 DRUGINFO D0D3PZ dipropyl-5-CT Investigative T07806 DRUGINFO D0W2YN 1-Naphthalen-2-yl-piperazine Investigative T07806 DRUGINFO D0D9YW SB 216641 Investigative T07806 DRUGINFO D0Y4MC 9-OH-risperidone Investigative T07806 DRUGINFO D06VPR WAY-466 Investigative T07806 DRUGINFO D0LG8A 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine Investigative T07806 DRUGINFO D00CRA 2-methyl-5-HT Investigative T07806 DRUGINFO D03TDN 1-naphthylpiperazine Investigative T07806 DRUGINFO D04TVG BRL-15572 Investigative T07806 DRUGINFO D02UWB 5-CT Investigative T07806 DRUGINFO D0V5HV TFMPP Investigative T07806 DRUGINFO D0F6CD SEROTONIN Investigative T07806 DRUGINFO D0F9QT A-987306 Investigative T07806 DRUGINFO D0L5MW (+/-)-nantenine Investigative T32060 TARGETID T32060 T32060 FORMERID TTDS00103 T32060 UNIPROID 5HT2A_HUMAN T32060 TARGNAME 5-HT 2A receptor (HTR2A) T32060 GENENAME HTR2A T32060 TARGTYPE Successful T32060 SYNONYMS Serotonin receptor 2A; HTR2; 5-hydroxytryptamine receptor 2A; 5-HT-2A; 5-HT-2 T32060 FUNCTION G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction. T32060 PDBSTRUC 6A94; 6A93 T32060 BIOCLASS GPCR rhodopsin T32060 SEQUENCE MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGCLSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIADMLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNPIHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSFVSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIHREPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGALLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYKSSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV T32060 DRUGINFO D0G6VL Sarpogrelate Approved T32060 DRUGINFO D0J8JP Pimavanserin Approved T32060 DRUGINFO D0T6QX ZOTEPINE Approved T32060 DRUGINFO D01QGX Lurasidone hydrochloride Approved T32060 DRUGINFO D02DPU Aniracetam Approved T32060 DRUGINFO D0M8VE Iloperidone Approved T32060 DRUGINFO D0S9CB Flibanserin Approved T32060 DRUGINFO D1CWL0 lumateperone tosylate Approved T32060 DRUGINFO D0UA0I Metergolin Approved T32060 DRUGINFO D04PLI SR46349B Phase 3 T32060 DRUGINFO D08GJH Blonanserin Phase 3 T32060 DRUGINFO D0L7TA MIN-101 Phase 3 T32060 DRUGINFO D0NN8N TNX-102 Phase 3 T32060 DRUGINFO D02YVM Zicronapine Phase 3 T32060 DRUGINFO D08CJK TRYPTAMINE Phase 3 T32060 DRUGINFO D0HZ2E M100907 Phase 3 T32060 DRUGINFO D0Q0EF ITI-007 Phase 3 T32060 DRUGINFO D00TLM PRUVANSERIN Phase 2 T32060 DRUGINFO D03IGB BVT.28949 Phase 2 T32060 DRUGINFO D0GJ7B NELOTANSERIN Phase 2 T32060 DRUGINFO D0SQ6A FKW00GA Phase 2 T32060 DRUGINFO D9I3WE SYN120 Phase 2 T32060 DRUGINFO DDI6B0 Nuplazid Phase 2 T32060 DRUGINFO D01FQR Ocaperidone Phase 2 T32060 DRUGINFO D05XEA RP5063 Phase 2 T32060 DRUGINFO D0R9KG Temanogrel Phase 1 T32060 DRUGINFO D02JGD SKL-10406 Phase 1 T32060 DRUGINFO D0A7KI Abaperidone Phase 1 T32060 DRUGINFO D0N4NJ YKP-1358 Phase 1 T32060 DRUGINFO D06NOF ATI-9242 Phase 1 T32060 DRUGINFO D0AI8V DSP-1200 Phase 1 T32060 DRUGINFO D0C7WO 1192U90 Phase 1 T32060 DRUGINFO D00PLP Pyrazole derivative 72 Patented T32060 DRUGINFO D02GTU Benzoyl-piperidine derivative 2 Patented T32060 DRUGINFO D03IAB Pyrazole derivative 68 Patented T32060 DRUGINFO D06RIO Piperazine derivative 3 Patented T32060 DRUGINFO D09WFK Pyrazole derivative 75 Patented T32060 DRUGINFO D0AQ1T Pyrazole derivative 73 Patented T32060 DRUGINFO D0DW6V Pyrazole derivative 67 Patented T32060 DRUGINFO D0FR1P Benzoyl-piperidine derivative 1 Patented T32060 DRUGINFO D0H5XC Pyrazole derivative 69 Patented T32060 DRUGINFO D0H8IH PMID26609882-Compound-36 Patented T32060 DRUGINFO D0HY3K 3-phenyl pyrazole derivative 1 Patented T32060 DRUGINFO D0J7SD Piperazine derivative 4 Patented T32060 DRUGINFO D0JT3F PMID26609882-Compound-35 Patented T32060 DRUGINFO D0KM0T Pyrazole derivative 74 Patented T32060 DRUGINFO D0N8PF Pyrazole derivative 70 Patented T32060 DRUGINFO D0O3BR Diarylamine and arylheteroarylamine pyrazole derivative 3 Patented T32060 DRUGINFO D0OR4G Diarylamine and arylheteroarylamine pyrazole derivative 2 Patented T32060 DRUGINFO D0R6HF Pyrazole derivative 71 Patented T32060 DRUGINFO D0WC8M Diarylamine and arylheteroarylamine pyrazole derivative 1 Patented T32060 DRUGINFO D0ZF0Z PMID26609882-Compound-34 Patented T32060 DRUGINFO D0BU6K Aryl piperazine derivative 9 Patented T32060 DRUGINFO D00YGY Pyrimidine derivative 29 Patented T32060 DRUGINFO D08DJY Pyrimidine derivative 26 Patented T32060 DRUGINFO D0B7NS Pyrimidine derivative 23 Patented T32060 DRUGINFO D0J4AZ L-piperazino-3-phenyl-indane derivative 1 Patented T32060 DRUGINFO D0N2VA Pyrimidine derivative 25 Patented T32060 DRUGINFO D0P9VX Pyrimidine derivative 27 Patented T32060 DRUGINFO D0SE9K Pyrimidine derivative 28 Patented T32060 DRUGINFO D0U9UH Pyrimidine derivative 24 Patented T32060 DRUGINFO D0EO8F PMID30124346-Compound-LDT8 Patented T32060 DRUGINFO D0M1UF Aryl piperazine derivative 1 Patented T32060 DRUGINFO D0Z9WY Aryl piperazine derivative 6 Patented T32060 DRUGINFO D09BCJ PMID30124346-Compound-34TABLE4 Patented T32060 DRUGINFO D0F4NB PMID30124346-Compound-13TABLE4 Patented T32060 DRUGINFO D0M7LV LYSERGIC ACID DIETHYLAMIDE Withdrawn from market T32060 DRUGINFO D05MFO MDL-11939 Discontinued in Phase 3 T32060 DRUGINFO D0B1GX Iferanserin-Ventrus Discontinued in Phase 3 T32060 DRUGINFO D0E6UA Deramciclane Discontinued in Phase 3 T32060 DRUGINFO D01RCS TIOSPIRONE Discontinued in Phase 3 T32060 DRUGINFO D0K8NW Ritanserin Discontinued in Phase 3 T32060 DRUGINFO D0B4JL SERAZAPINE HYDROCHLORIDE Discontinued in Phase 2 T32060 DRUGINFO D0OQ3L SL65.0472 Discontinued in Phase 2 T32060 DRUGINFO D0S5ZJ SERGOLEXOLE MALEATE Discontinued in Phase 2 T32060 DRUGINFO D0V7MA AMESERGIDE Discontinued in Phase 2 T32060 DRUGINFO D01ESB YM-992 Discontinued in Phase 2 T32060 DRUGINFO D02SKA FCE-22716 Discontinued in Phase 2 T32060 DRUGINFO D0X2TO Adatanserin Discontinued in Phase 2 T32060 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T32060 DRUGINFO D0Z4QV DUP-734 Discontinued in Phase 1 T32060 DRUGINFO D0A8IE AM-831 Discontinued in Phase 1 T32060 DRUGINFO D0N5NM Org-23366 Preclinical T32060 DRUGINFO D00PXQ Fananserin Terminated T32060 DRUGINFO D07MWD MDL-28161 Terminated T32060 DRUGINFO D0EN4G R-102444 Terminated T32060 DRUGINFO D0ES4S RP-68303 Terminated T32060 DRUGINFO D0F6XR DV-7028 Terminated T32060 DRUGINFO D0V4JO AMPEROZIDE Terminated T32060 DRUGINFO D05KHN ICI-169369 Terminated T32060 DRUGINFO D05RMW ZD-3638 Terminated T32060 DRUGINFO D0A3OF GMC-283 Terminated T32060 DRUGINFO D0B4BN Ro-60-0175 Terminated T32060 DRUGINFO D0PA6K LY53857 Terminated T32060 DRUGINFO D0K9JP A-80426 Terminated T32060 DRUGINFO D00FJT [11C]volinanserin Investigative T32060 DRUGINFO D00SNJ N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide Investigative T32060 DRUGINFO D01CGM ALTANSERIN Investigative T32060 DRUGINFO D01GWH N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide Investigative T32060 DRUGINFO D01TSX (R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine Investigative T32060 DRUGINFO D01WNO 7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole Investigative T32060 DRUGINFO D02IEO LY108742 Investigative T32060 DRUGINFO D02JPD 3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole Investigative T32060 DRUGINFO D02SFJ 4-(10H-Anthracen-9-ylidene)-1-methyl-piperidine Investigative T32060 DRUGINFO D03IWX 2-methoxy-9-aminomethyl-9,10-dihydroanthracene Investigative T32060 DRUGINFO D03JEW N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide Investigative T32060 DRUGINFO D04NAL LY314228 Investigative T32060 DRUGINFO D04SIT 1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane Investigative T32060 DRUGINFO D04TWX (R)-3-(4-propylmorpholin-2-yl)phenol Investigative T32060 DRUGINFO D04UCV 8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole Investigative T32060 DRUGINFO D05LJF N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide Investigative T32060 DRUGINFO D05ULV 4-methoxy-9-aminomethyl-9,10-dihydroanthracene Investigative T32060 DRUGINFO D05USH 4-(4-Fluoro-benzyl)-piperidine hydrochloride Investigative T32060 DRUGINFO D07QMR N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide Investigative T32060 DRUGINFO D08AGH [18F]altanserin Investigative T32060 DRUGINFO D08CNN 1-(3-(phenylthio)propyl)-4-m-tolylpiperazine Investigative T32060 DRUGINFO D08MNG C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine Investigative T32060 DRUGINFO D08VLD Racemic DOTFM Investigative T32060 DRUGINFO D08XGI (1-Phenethyl-piperidin-4-yl)-phenyl-methanone Investigative T32060 DRUGINFO D08XYR DOM Investigative T32060 DRUGINFO D08ZWM PSILOCIN Investigative T32060 DRUGINFO D09CKT LY433222 Investigative T32060 DRUGINFO D09FZD N-(1-phenethylpiperidin-4-yl)-2-naphthamide Investigative T32060 DRUGINFO D09HFT (E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine Investigative T32060 DRUGINFO D0AW4X N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide Investigative T32060 DRUGINFO D0B3WX CINANSERIN Investigative T32060 DRUGINFO D0B9ZK 3-methoxy-9-aminomethyl-9,10-dihydroanthracene Investigative T32060 DRUGINFO D0BI5Y C-(9H-Thioxanthen-9-yl)-methylamine Investigative T32060 DRUGINFO D0C0LG N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide Investigative T32060 DRUGINFO D0C7FL 2,2-Diphenyl-ethylamine Investigative T32060 DRUGINFO D0EH5Z 2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine Investigative T32060 DRUGINFO D0F1CP EPLIVANSERIN MESILATE Investigative T32060 DRUGINFO D0F1FN (2-Indol-1-yl-ethyl)-dimethyl-amine Investigative T32060 DRUGINFO D0FK5Z N-(1-phenethylpiperidin-4-yl)-1-naphthamide Investigative T32060 DRUGINFO D0H0PL LY215840 Investigative T32060 DRUGINFO D0I6KF (S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine Investigative T32060 DRUGINFO D0I8MP N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide Investigative T32060 DRUGINFO D0IX1V 1-(10-Bromoanthracen-9-yl)-2-aminopropane Investigative T32060 DRUGINFO D0K6VR 6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole Investigative T32060 DRUGINFO D0K8DY 9-(N-benzylaminomethyl)-9,10-dihydroanthracene Investigative T32060 DRUGINFO D0L0MU C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine Investigative T32060 DRUGINFO D0L0SF LY320954 Investigative T32060 DRUGINFO D0L8MR MESCALINE Investigative T32060 DRUGINFO D0L9GR Very low dose (VLD) cyclobenzaprine Investigative T32060 DRUGINFO D0M2JA ACP-106 Investigative T32060 DRUGINFO D0Q1ZC 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole Investigative T32060 DRUGINFO D0Q6PI PHENETHYLAMINE Investigative T32060 DRUGINFO D0R5WB 2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole Investigative T32060 DRUGINFO D0S0PA C-(9H-Xanthen-9-yl)-methylamine Investigative T32060 DRUGINFO D0U3GZ 2,5-dimethoxy-4-bromophenethylamine Investigative T32060 DRUGINFO D0U5HQ [2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine Investigative T32060 DRUGINFO D0V5OY N-(1-benzylpiperidine-4-yl)-2-naphthamide Investigative T32060 DRUGINFO D0V7YD 4-Benzyl-1-methyl-piperidine hydrochloride Investigative T32060 DRUGINFO D0W1CC (R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine Investigative T32060 DRUGINFO D0XP5P LY063518 Investigative T32060 DRUGINFO D0Y1UV 1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine Investigative T32060 DRUGINFO D0ZF1W N-1-isopropyltryptamine Investigative T32060 DRUGINFO D0ZP2D N-1-isopropyl-5-MeOT Investigative T32060 DRUGINFO D0ZQ3Q 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine Investigative T32060 DRUGINFO D0ZZ4S 1-methoxy-9-aminomethyl-9,10-dihydroanthracene Investigative T32060 DRUGINFO D00AVR Aplysinopsin Investigative T32060 DRUGINFO D00LXH (R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D00NST (2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D00OCV 3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol Investigative T32060 DRUGINFO D00YEB 11-Butyryloxy-N-n-propylnoraporphine Investigative T32060 DRUGINFO D01CXD 9-(Aminomethyl)-9,10-dihydroanthracene Investigative T32060 DRUGINFO D01HJZ N,N-dimethyl-2,2-diphenylethanamine Investigative T32060 DRUGINFO D01YBD 2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine Investigative T32060 DRUGINFO D02GNN N-methyl-3,3-diphenylpropan-1-amine Investigative T32060 DRUGINFO D02SDX N,N-Dimethyl-3,3-diphenylpropan-1-amine Investigative T32060 DRUGINFO D02XAX LY86057 Investigative T32060 DRUGINFO D03PAH 1-(2-Methoxy-phenyl)-4-propyl-piperazine Investigative T32060 DRUGINFO D03VUU 2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine Investigative T32060 DRUGINFO D03XYG 1-Methyl-1,3-dihydro-indol-2-one Investigative T32060 DRUGINFO D04SCQ 4,4-Diphenylbutan-1-amine Investigative T32060 DRUGINFO D05JIO (2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D05RKS N-methyl-4,4-diphenylbutan-1-amine Investigative T32060 DRUGINFO D05YFZ 9-(2-aminoethyl)-9,10-dihydroanthracene Investigative T32060 DRUGINFO D07CZJ 11-valeryloxynoraporphine Investigative T32060 DRUGINFO D07GBV 3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole Investigative T32060 DRUGINFO D07XTU Racemic DOI Investigative T32060 DRUGINFO D08CZT 2-Phenyl-3-piperidin-4-yl-1H-indole Investigative T32060 DRUGINFO D08FUK (R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D0A6LB 2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline Investigative T32060 DRUGINFO D0B1GJ 11-Propionyloxy-N-n-propylnoraporphine Investigative T32060 DRUGINFO D0I2WQ 11-Heptanoyloxy-N-n-propylnoraporphine Investigative T32060 DRUGINFO D0J2ID 6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide Investigative T32060 DRUGINFO D0J2UA 6-bromoaplysinopsin Investigative T32060 DRUGINFO D0J8RI (R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D0KU6D (R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D0NM6R N-3'-ethylaplysinopsin Investigative T32060 DRUGINFO D0Q3OK (R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D0Q9FU (S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D0Q9KP (2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D0R5QM 1-Butyl-4-(2-methoxy-phenyl)-piperazine Investigative T32060 DRUGINFO D0R8PL 11-Hexanoyloxy-N-n-propylnoraporphine Investigative T32060 DRUGINFO D0S0WX 9-(2-aminopropyl)-9,10-dihydroanthracene Investigative T32060 DRUGINFO D0S3WR N,N-dimethyl-4,4-diphenylbutan-1-amine Investigative T32060 DRUGINFO D0U1MN 1-Ethyl-4-(2-methoxy-phenyl)-piperazine Investigative T32060 DRUGINFO D0U7UD 5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide Investigative T32060 DRUGINFO D00APD 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol Investigative T32060 DRUGINFO D00CGJ 2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine Investigative T32060 DRUGINFO D00EMF SB 242084 Investigative T32060 DRUGINFO D00FUS 2-(2-Methoxy-phenyl)-1-methyl-ethylamine Investigative T32060 DRUGINFO D00GOY VER-3323 Investigative T32060 DRUGINFO D00NSA 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T32060 DRUGINFO D00QSV 2-(3-Methoxy-phenyl)-1-methyl-ethylamine Investigative T32060 DRUGINFO D00WEQ Brolamfetamine Investigative T32060 DRUGINFO D00ZCU BW723C86 Investigative T32060 DRUGINFO D01BGW (2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine Investigative T32060 DRUGINFO D01NTM VER-5593 Investigative T32060 DRUGINFO D01SJL 1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol Investigative T32060 DRUGINFO D02OZB 2-Piperazin-1-yl-phenol Investigative T32060 DRUGINFO D02SAF 1-(2,5-Dimethoxy-phenyl)-piperazine Investigative T32060 DRUGINFO D03DLZ 2-(1H-indol-3-yl)-N,N-dimethylethanamine Investigative T32060 DRUGINFO D04AQE 5-METHOXYTRYPTAMINE Investigative T32060 DRUGINFO D04KGP (R)-(-)-11-hydroxy-N-n-propylnoraporphine Investigative T32060 DRUGINFO D04YCJ 1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol Investigative T32060 DRUGINFO D05NWH SB 228357 Investigative T32060 DRUGINFO D05SWY 3-Dimethylaminomethyl-1H-indol-4-ol Investigative T32060 DRUGINFO D06ABJ [2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine Investigative T32060 DRUGINFO D06BAC 8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T32060 DRUGINFO D06OJI 2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol Investigative T32060 DRUGINFO D06PKJ 1-(2,5-dimethoxyphenyl)propan-2-amine Investigative T32060 DRUGINFO D07LJH [125I]DOI Investigative T32060 DRUGINFO D08GJS 3-(2-Dimethylamino-propyl)-1H-indol-4-ol Investigative T32060 DRUGINFO D08HOJ 1,2,3,4-Tetrahydro-naphthalen-2-ylamine Investigative T32060 DRUGINFO D08JCU (E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine Investigative T32060 DRUGINFO D08OFG BARETTIN Investigative T32060 DRUGINFO D09HJL AL-37350A Investigative T32060 DRUGINFO D09JOE 1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine Investigative T32060 DRUGINFO D09YVA 8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline Investigative T32060 DRUGINFO D0AP6N 1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol Investigative T32060 DRUGINFO D0B2GS 3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one Investigative T32060 DRUGINFO D0D3OF 1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine Investigative T32060 DRUGINFO D0DY5G SB 221284 Investigative T32060 DRUGINFO D0E6NW VER-5384 Investigative T32060 DRUGINFO D0F5WP 1-(2-aminoethyl)-1H-indazol-6-ol Investigative T32060 DRUGINFO D0G2EF 8-Bromo-4,9-dihydro-3H-beta-carboline Investigative T32060 DRUGINFO D0H5XR YM-348 Investigative T32060 DRUGINFO D0I9FI 2-(4-Bromo-phenyl)-1-methyl-ethylamine Investigative T32060 DRUGINFO D0I9RW 1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol Investigative T32060 DRUGINFO D0J3SN 6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T32060 DRUGINFO D0KH5R SB 215505 Investigative T32060 DRUGINFO D0L8ND 5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T32060 DRUGINFO D0M1YU VER-2692 Investigative T32060 DRUGINFO D0N0LZ 3-Naphthalen-1-yl-pyrrolidine Investigative T32060 DRUGINFO D0N7HY Org 12962 Investigative T32060 DRUGINFO D0N8YG 1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol Investigative T32060 DRUGINFO D0O5KK 7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine Investigative T32060 DRUGINFO D0Q3VI 8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T32060 DRUGINFO D0R3XC 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane Investigative T32060 DRUGINFO D0R8VT 3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol Investigative T32060 DRUGINFO D0S5ZY 3-Naphthalen-1-yl-1-propyl-pyrrolidine Investigative T32060 DRUGINFO D0T3IH [3H]N-methylspiperone Investigative T32060 DRUGINFO D0T7RY 6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine Investigative T32060 DRUGINFO D0T8UR 3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol Investigative T32060 DRUGINFO D0TH8D 8-Methoxy-2-piperazin-1-yl-quinoline Investigative T32060 DRUGINFO D0V5SQ spiramide Investigative T32060 DRUGINFO D0V6XA 5-Methoxy-4,9-dihydro-3H-beta-carboline Investigative T32060 DRUGINFO D0W7GQ EGIS-7625 Investigative T32060 DRUGINFO D0W8EB 3-(3-Dimethylamino-propyl)-1H-indol-4-ol Investigative T32060 DRUGINFO D0X4RC PHENYLPIPERAZINE Investigative T32060 DRUGINFO D0XX7J 7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine Investigative T32060 DRUGINFO D0Y0SA 1-((R)-2-aminopropyl)-1H-indazol-6-ol Investigative T32060 DRUGINFO D0Y1GL 8-Methoxy-4,9-dihydro-3H-beta-carboline Investigative T32060 DRUGINFO D0YG1E Etisulergine Investigative T32060 DRUGINFO D0ZZ4Z 3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol Investigative T32060 DRUGINFO D00CCV 1,6-bis(4-m-tolylpiperazin-1-yl)hexane Investigative T32060 DRUGINFO D03PIP 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane Investigative T32060 DRUGINFO D03XKL 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane Investigative T32060 DRUGINFO D08EFH 2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine Investigative T32060 DRUGINFO D0C2NK norfluoxetine Investigative T32060 DRUGINFO D0C5XQ 5-MEO-DMT Investigative T32060 DRUGINFO D0C6BP 1,6-bis(4-phenylpiperazin-1-yl)hexane Investigative T32060 DRUGINFO D0G7NW cyamemazine Investigative T32060 DRUGINFO D0I4VT 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine Investigative T32060 DRUGINFO D0S8KA 3-(2-Amino-propyl)-1H-indol-5-ol Investigative T32060 DRUGINFO D0W2YN 1-Naphthalen-2-yl-piperazine Investigative T32060 DRUGINFO D0X4PH LP-44 Investigative T32060 DRUGINFO D0Z1OF LP-12 Investigative T32060 DRUGINFO D01TOU FLUANISONE Investigative T32060 DRUGINFO D0OG0R WAY-208466 Investigative T32060 DRUGINFO D0P1XQ SEL-73 Investigative T32060 DRUGINFO D0SP2J bufotenine Investigative T32060 DRUGINFO D03LPH TRYPTOLINE Investigative T32060 DRUGINFO D05GDP 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T32060 DRUGINFO D07GQP PG-01037 Investigative T32060 DRUGINFO D0C1SE 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole Investigative T32060 DRUGINFO D0D9YW SB 216641 Investigative T32060 DRUGINFO D0V3XU CHLOROPHENYLPIPERAZINE Investigative T32060 DRUGINFO D0Y4MC 9-OH-risperidone Investigative T32060 DRUGINFO D08BCF QUIPAZINE Investigative T32060 DRUGINFO D0C5GF MPDT Investigative T32060 DRUGINFO D0F5NJ METHYLENEDIOXYMETHAMPHETAMINE Investigative T32060 DRUGINFO D0I4ME MMDA Investigative T32060 DRUGINFO D0J6JT m-chlorophenylpiperazine Investigative T32060 DRUGINFO D0LG8A 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine Investigative T32060 DRUGINFO D0V4RP 1-(2-Methoxy-phenyl)-piperazine Investigative T32060 DRUGINFO D0Y9TL 5-chloro-3,4-dihydroquinazolin-2-amine Investigative T32060 DRUGINFO D01KAX 1-((S)-2-aminopropyl)-1H-indazol-6-ol Investigative T32060 DRUGINFO D05EQG [3H]spiperone Investigative T32060 DRUGINFO D08VGJ 5,6-dichloro-3,4-dihydroquinazolin-2-amine Investigative T32060 DRUGINFO D09OYA alpha-methyl-5-HT Investigative T32060 DRUGINFO D03TDN 1-naphthylpiperazine Investigative T32060 DRUGINFO D04TVG BRL-15572 Investigative T32060 DRUGINFO D07LRJ SB-271046 Investigative T32060 DRUGINFO D02UWB 5-CT Investigative T32060 DRUGINFO D0V5HV TFMPP Investigative T32060 DRUGINFO D0F6CD SEROTONIN Investigative T32060 DRUGINFO D0F9QT A-987306 Investigative T32060 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T32060 DRUGINFO D0L5MW (+/-)-nantenine Investigative T32060 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T83813 TARGETID T83813 T83813 FORMERID TTDS00105 T83813 UNIPROID 5HT2C_HUMAN T83813 TARGNAME 5-HT 2C receptor (HTR2C) T83813 GENENAME HTR2C T83813 TARGTYPE Successful T83813 SYNONYMS Serotonin receptor 2C; HTR1C; 5HT-1C; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1C; 5-HTR2C; 5-HT2C receptor; 5-HT2C; 5-HT1C; 5-HT-2C; 5-HT-1C T83813 FUNCTION Functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis. G-protein coupled receptor for 5-hydroxytryptamine (serotonin). T83813 PDBSTRUC 6BQH; 6BQG T83813 BIOCLASS GPCR rhodopsin T83813 SEQUENCE MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSIVIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVWPLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWAISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYVLRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTMQAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVCSGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTNEPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV T83813 DRUGINFO D01JMC Lorcaserin Approved T83813 DRUGINFO D05GKD Tramadol Approved T83813 DRUGINFO D05ZIK Mirtazapine Approved T83813 DRUGINFO D0O6GC Methysergide Approved T83813 DRUGINFO D0X7DE Nefazodone Approved T83813 DRUGINFO D0UA0I Metergolin Approved T83813 DRUGINFO D04PLI SR46349B Phase 3 T83813 DRUGINFO D06FKC Eltoprazine Phase 3 T83813 DRUGINFO D0HZ2E M100907 Phase 3 T83813 DRUGINFO D03TYJ ATHX-105 Phase 2 T83813 DRUGINFO D08QHX PRX00933 Phase 2 T83813 DRUGINFO D0I7MT Puerarin Phase 2 T83813 DRUGINFO D02BRJ Vabicaserin Phase 2 T83813 DRUGINFO DDI6B0 Nuplazid Phase 2 T83813 DRUGINFO D01XUE Tedatioxetine Phase 1 T83813 DRUGINFO D00DFK Heteroaryl-azepine derivative 10 Patented T83813 DRUGINFO D00YRD Heteroaryl-azepine derivative 7 Patented T83813 DRUGINFO D01PAP PMID26609882-Compound-83 Patented T83813 DRUGINFO D03IZY Benzazepine derivative 4 Patented T83813 DRUGINFO D06VJM Heteroaryl-azepine derivative 14 Patented T83813 DRUGINFO D06YCW PMID26609882-Compound-58 Patented T83813 DRUGINFO D07KZR Heteroaryl-azepine derivative 2 Patented T83813 DRUGINFO D09EPG Heteroaryl-azepine derivative 12 Patented T83813 DRUGINFO D0A5FR Benzazepine derivative 1 Patented T83813 DRUGINFO D0AA9F Tricyclic pyrrolidine derivative 3 Patented T83813 DRUGINFO D0AI8S Heteroaryl-azepine derivative 1 Patented T83813 DRUGINFO D0AJ0O Heteroaryl-azepine derivative 5 Patented T83813 DRUGINFO D0AV8R Tricyclic pyrrolidine derivative 2 Patented T83813 DRUGINFO D0BD3M Heteroaryl-azepine derivative 4 Patented T83813 DRUGINFO D0FK0Y Heteroaryl-azepine derivative 8 Patented T83813 DRUGINFO D0FS3J Heteroaryl-azepine derivative 15 Patented T83813 DRUGINFO D0GW5F Benzazepine derivative 5 Patented T83813 DRUGINFO D0HV0D Aryl piperazine derivative 10 Patented T83813 DRUGINFO D0I3QY Benzazepine derivative 6 Patented T83813 DRUGINFO D0KO2E Heteroaryl-azepine derivative 11 Patented T83813 DRUGINFO D0L4UC Benzazepine derivative 3 Patented T83813 DRUGINFO D0MQ7F Heteroaryl-azepine derivative 13 Patented T83813 DRUGINFO D0OA6W Aryl piperazine derivative 8 Patented T83813 DRUGINFO D0R6EF Heteroaryl-azepine derivative 9 Patented T83813 DRUGINFO D0SO0F Tricyclic pyrrolidine derivative 1 Patented T83813 DRUGINFO D0T5ER Benzazepine derivative 2 Patented T83813 DRUGINFO D0UL9W Heteroaryl-azepine derivative 3 Patented T83813 DRUGINFO D0WR7F Chromene derivative 1 Patented T83813 DRUGINFO D0WS6Y Tricyclic pyrrolidine derivative 4 Patented T83813 DRUGINFO D0YO2O Heteroaryl-azepine derivative 6 Patented T83813 DRUGINFO D01LVT Quinoline derivative 2 Patented T83813 DRUGINFO D0BU6K Aryl piperazine derivative 9 Patented T83813 DRUGINFO D00YGY Pyrimidine derivative 29 Patented T83813 DRUGINFO D08DJY Pyrimidine derivative 26 Patented T83813 DRUGINFO D0B7NS Pyrimidine derivative 23 Patented T83813 DRUGINFO D0N2VA Pyrimidine derivative 25 Patented T83813 DRUGINFO D0P9VX Pyrimidine derivative 27 Patented T83813 DRUGINFO D0SE9K Pyrimidine derivative 28 Patented T83813 DRUGINFO D0U9UH Pyrimidine derivative 24 Patented T83813 DRUGINFO D0E6UA Deramciclane Discontinued in Phase 3 T83813 DRUGINFO D0K8NW Ritanserin Discontinued in Phase 3 T83813 DRUGINFO D0S5FQ MCPP Discontinued in Phase 2 T83813 DRUGINFO D04DGE SB-247853 Discontinued in Phase 1 T83813 DRUGINFO D0I5LM R-1065 Discontinued in Phase 1 T83813 DRUGINFO D0U5EY Org-37684 Terminated T83813 DRUGINFO D0Z4QC SDZ-SER-082 Terminated T83813 DRUGINFO D05KHN ICI-169369 Terminated T83813 DRUGINFO D0B4BN Ro-60-0175 Terminated T83813 DRUGINFO D0PA6K LY53857 Terminated T83813 DRUGINFO D00BWZ N-(pyridin-3-yl)indoline-1-carboxamide Investigative T83813 DRUGINFO D00DHV 4-(piperazin-1-yl)thieno[3,2-d]pyrimidine Investigative T83813 DRUGINFO D00OBS Cyclo[(6-bromotryptophan)arginine] Investigative T83813 DRUGINFO D01FOM 4-(piperazin-1-yl)thieno[2,3-d]pyrimidine Investigative T83813 DRUGINFO D02ESW MK-212 Investigative T83813 DRUGINFO D02YNH CP-809101 Investigative T83813 DRUGINFO D03MHA FR260010 Investigative T83813 DRUGINFO D03NKE 6-bromo-2'-de-N-methylaplysinopsin Investigative T83813 DRUGINFO D04VXP 4-(piperazin-1-yl)furo[3,2-c]pyridine Investigative T83813 DRUGINFO D05FKE 6-(piperazin-1-yl)-9-propyl-9H-purine Investigative T83813 DRUGINFO D05RKH 6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine Investigative T83813 DRUGINFO D06VDN SB 243213 Investigative T83813 DRUGINFO D07DQO N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide Investigative T83813 DRUGINFO D07LHD 1-(2-Dimethylamino-ethyl)-1H-indol-4-ol Investigative T83813 DRUGINFO D08YZM 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Investigative T83813 DRUGINFO D0A2GI LY334362 Investigative T83813 DRUGINFO D0J1VB 4-(piperazin-1-yl)thieno[3,2-c]pyridine Investigative T83813 DRUGINFO D0KV4G 1-(piperazin-1-yl)isoquinoline Investigative T83813 DRUGINFO D0Q4AQ 6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine Investigative T83813 DRUGINFO D0SZ8Q CSC-500297 Investigative T83813 DRUGINFO D0U3EA BVT 933 Investigative T83813 DRUGINFO D0U9HE RS-102,221 Investigative T83813 DRUGINFO D0W6RV WAY-163909 Investigative T83813 DRUGINFO D00AVR Aplysinopsin Investigative T83813 DRUGINFO D00LXH (R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D00NST (2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D00OCV 3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol Investigative T83813 DRUGINFO D04AZE SB 204741 Investigative T83813 DRUGINFO D05JIO (2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D08FUK (R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D0A6LB 2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline Investigative T83813 DRUGINFO D0J2ID 6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide Investigative T83813 DRUGINFO D0J2UA 6-bromoaplysinopsin Investigative T83813 DRUGINFO D0J8RI (R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D0KU6D (R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D0NM6R N-3'-ethylaplysinopsin Investigative T83813 DRUGINFO D0Q3OK (R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D0Q9FU (S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D0Q9KP (2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D0U7UD 5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide Investigative T83813 DRUGINFO D0U8OK [3H]mesulergine Investigative T83813 DRUGINFO D00APD 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol Investigative T83813 DRUGINFO D00EMF SB 242084 Investigative T83813 DRUGINFO D00GOY VER-3323 Investigative T83813 DRUGINFO D00ZCU BW723C86 Investigative T83813 DRUGINFO D01BGW (2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine Investigative T83813 DRUGINFO D01NTM VER-5593 Investigative T83813 DRUGINFO D01SJL 1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol Investigative T83813 DRUGINFO D04YCJ 1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol Investigative T83813 DRUGINFO D05NWH SB 228357 Investigative T83813 DRUGINFO D05SWY 3-Dimethylaminomethyl-1H-indol-4-ol Investigative T83813 DRUGINFO D06ABJ [2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine Investigative T83813 DRUGINFO D07LJH [125I]DOI Investigative T83813 DRUGINFO D08GJS 3-(2-Dimethylamino-propyl)-1H-indol-4-ol Investigative T83813 DRUGINFO D08JCU (E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine Investigative T83813 DRUGINFO D08OFG BARETTIN Investigative T83813 DRUGINFO D08YCS TQ-1017 Investigative T83813 DRUGINFO D09HJL AL-37350A Investigative T83813 DRUGINFO D0AP6N 1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol Investigative T83813 DRUGINFO D0DY5G SB 221284 Investigative T83813 DRUGINFO D0E6NW VER-5384 Investigative T83813 DRUGINFO D0F5WP 1-(2-aminoethyl)-1H-indazol-6-ol Investigative T83813 DRUGINFO D0H5XR YM-348 Investigative T83813 DRUGINFO D0I9RW 1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol Investigative T83813 DRUGINFO D0KH5R SB 215505 Investigative T83813 DRUGINFO D0M1YU VER-2692 Investigative T83813 DRUGINFO D0N7HY Org 12962 Investigative T83813 DRUGINFO D0N8YG 1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol Investigative T83813 DRUGINFO D0O5KK 7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine Investigative T83813 DRUGINFO D0R8VT 3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol Investigative T83813 DRUGINFO D0T7RY 6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine Investigative T83813 DRUGINFO D0T8UR 3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol Investigative T83813 DRUGINFO D0V5SQ spiramide Investigative T83813 DRUGINFO D0W7GQ EGIS-7625 Investigative T83813 DRUGINFO D0W8EB 3-(3-Dimethylamino-propyl)-1H-indol-4-ol Investigative T83813 DRUGINFO D0XX7J 7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine Investigative T83813 DRUGINFO D0Y0SA 1-((R)-2-aminopropyl)-1H-indazol-6-ol Investigative T83813 DRUGINFO D0ZZ4Z 3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol Investigative T83813 DRUGINFO D03ZHB 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine Investigative T83813 DRUGINFO D07HQZ [3H]LSD Investigative T83813 DRUGINFO D08EFH 2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine Investigative T83813 DRUGINFO D0C2NK norfluoxetine Investigative T83813 DRUGINFO D0C5XQ 5-MEO-DMT Investigative T83813 DRUGINFO D0G7NW cyamemazine Investigative T83813 DRUGINFO D0S8KA 3-(2-Amino-propyl)-1H-indol-5-ol Investigative T83813 DRUGINFO D04TPO 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T83813 DRUGINFO D0OG0R WAY-208466 Investigative T83813 DRUGINFO D0XX2U 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T83813 DRUGINFO D07GQP PG-01037 Investigative T83813 DRUGINFO D0D9YW SB 216641 Investigative T83813 DRUGINFO D0V3XU CHLOROPHENYLPIPERAZINE Investigative T83813 DRUGINFO D06VPR WAY-466 Investigative T83813 DRUGINFO D0C5GF MPDT Investigative T83813 DRUGINFO D0D3YN OCTOCLOTHEPIN Investigative T83813 DRUGINFO D0F5NJ METHYLENEDIOXYMETHAMPHETAMINE Investigative T83813 DRUGINFO D0J6JT m-chlorophenylpiperazine Investigative T83813 DRUGINFO D0Y9TL 5-chloro-3,4-dihydroquinazolin-2-amine Investigative T83813 DRUGINFO D01KAX 1-((S)-2-aminopropyl)-1H-indazol-6-ol Investigative T83813 DRUGINFO D08VGJ 5,6-dichloro-3,4-dihydroquinazolin-2-amine Investigative T83813 DRUGINFO D09OYA alpha-methyl-5-HT Investigative T83813 DRUGINFO D04TVG BRL-15572 Investigative T83813 DRUGINFO D07LRJ SB-271046 Investigative T83813 DRUGINFO D02UWB 5-CT Investigative T83813 DRUGINFO D0V5HV TFMPP Investigative T83813 DRUGINFO D0F6CD SEROTONIN Investigative T83813 DRUGINFO D0L5MW (+/-)-nantenine Investigative T83813 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T10877 TARGETID T10877 T10877 FORMERID TTDNC00424 T10877 UNIPROID CD38_HUMAN T10877 TARGNAME Cyclic ADP-ribose hydrolase 1 (CD38) T10877 GENENAME CD38 T10877 TARGTYPE Successful T10877 SYNONYMS cADPr hydrolase 1; T10; Cyclic ADPribose hydrolase 1; ADPribosyl cyclase 1; ADPRC 1; ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; ADP-ribosyl cyclase 1; 2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-ADP-ribosyl cyclase T10877 FUNCTION Has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system. Synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger for glucose-induced insulin secretion. T10877 PDBSTRUC 6EDR; 5F21; 5F1O; 5F1K; 4XJT T10877 BIOCLASS Glycosylase T10877 ECNUMBER EC 3.2.2.6 T10877 SEQUENCE MANCEFSPVSGDKPCCRLSRRAQLCLGVSILVLILVVVLAVVVPRWRQQWSGPGTTKRFPETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCNITEEDYQPLMKLGTQTVPCNKILLWSRIKDLAHQFTQVQRDMFTLEDTLLGYLADDLTWCGEFNTSKINYQSCPDWRKDCSNNPVSVFWKTVSRRFAEAACDVVHVMLNGSRSKIFDKNSTFGSVEVHNLQPEKVQTLEAWVIHGGREDSRDLCQDPTIKELESIISKRNIQFSCKNIYRPDKFLQCVKNPEDSSCTSEI T10877 DRUGINFO D0RV4P Daratumumab Approved T10877 DRUGINFO D54QKH Mezagitamab Phase 2 T10877 DRUGINFO D09UFZ CD38 CAR T cells Phase 1/2 T10877 DRUGINFO D0M8EF CD38 CAR-T Cell Phase 1/2 T10877 DRUGINFO D0NS1X SAR-650984 Phase 1/2 T10877 DRUGINFO D0O4IN MOR-202 Phase 1/2 T10877 DRUGINFO D0OO1S Anti-CD38 CAR-T cells Phase 1/2 T10877 DRUGINFO D0UJ3C CD38-specific gene-engineered T cells Phase 1/2 T10877 DRUGINFO D0G0PI CD38 and BCMA CAR-T Cells Phase 1/2 T10877 DRUGINFO D0I4HG 4SCAR19 and 4SCAR38 Phase 1/2 T10877 DRUGINFO DE0L6O ISB 1342 Phase 1/2 T10877 DRUGINFO D05WET Anti-CD38 CAR-T cells Phase 1 T10877 DRUGINFO D06OES CART-38 cells Phase 1 T10877 DRUGINFO D0GP9M SAR444559 Phase 1 T10877 DRUGINFO D0ZDP2 TAK-573 Phase 1 T10877 DRUGINFO D2HE9I TAK-169 Phase 1 T10877 DRUGINFO D5VE7C SAR442085 Phase 1 T10877 DRUGINFO DECJ17 KP1237 Phase 1 T10877 DRUGINFO DK1PA2 225Ac-labelled aCD38 Phase 1 T10877 DRUGINFO DSWZ60 CD38 CAR-T Phase 1 T10877 DRUGINFO DLY65X AMG 424 Phase 1 T10877 DRUGINFO DBP9Q5 SAR442257 Phase 1 T10877 DRUGINFO D0V6WU CAR-T cells targeting CD38 Clinical trial T10877 DRUGINFO D0N1QH HuMax-CD38b Investigative T77365 TARGETID T77365 T77365 FORMERID TTDS00187 T77365 UNIPROID AA2AR_HUMAN T77365 TARGNAME Adenosine A2a receptor (ADORA2A) T77365 GENENAME ADORA2A T77365 TARGTYPE Successful T77365 SYNONYMS Adenosine receptor A2a; ADORA2; A2a Adenosine receptor; A(2A) adenosine receptor T77365 FUNCTION The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Receptor for adenosine. T77365 PDBSTRUC 6MH8; 6GDG; 6AQF; 5WF6; 5WF5 T77365 BIOCLASS GPCR rhodopsin T77365 SEQUENCE MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAIPFAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAIDRYIAIRIPLRYNGLVTGTRAKGIIAICWVLSFAIGLTPMLGWNNCGQPKEGKNHSQGCGEGQVACLFEDVVPMNYMVYFNFFACVLVPLLLMLGVYLRIFLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVGLFALCWLPLHIINCFTFFCPDCSHAPLWLMYLAIVLSHTNSVVNPFIYAYRIREFRQTFRKIIRSHVLRQQEPFKAAGTSARVLAAHGSDGEQVSLRLNGHPPGVWANGSAPHPERRPNGYALGLVSGGSAQESQGNTGLPDVELLSHELKGVCPEPPGLDDPLAQDGAGVS T77365 DRUGINFO D0F4ZY Istradefylline Approved T77365 DRUGINFO D0XE1C Regadenoson Approved T77365 DRUGINFO D0B3HD Caffeine Approved T77365 DRUGINFO D03OQI Tozadenant Phase 3 T77365 DRUGINFO D08TJM Binodenoson Phase 3 T77365 DRUGINFO D0QG9A Apadenoson Phase 3 T77365 DRUGINFO D06MIQ MRE-0094 Phase 2 T77365 DRUGINFO D07TEP SCH 420814 Phase 2 T77365 DRUGINFO D0D5VJ UK-432097 Phase 2 T77365 DRUGINFO D0J4XV AZD4635 Phase 2 T77365 DRUGINFO D0Z3PO BIIB014 Phase 2 T77365 DRUGINFO D03QWO Dexefaroxan Phase 2 T77365 DRUGINFO D0QH7H AMP-579 Phase 2 T77365 DRUGINFO D00SUK Tonapofylline Phase 2 T77365 DRUGINFO D04AEQ V81444 Phase 1/2 T77365 DRUGINFO D08FHZ ATL-313 Phase 1/2 T77365 DRUGINFO D0E4IB PBF509 Phase 1/2 T77365 DRUGINFO D0J6NG OPA-6566 Phase 1/2 T77365 DRUGINFO D04UBI AB928 Phase 1/2 T77365 DRUGINFO D00OAU GW-328267 Phase 1 T77365 DRUGINFO DS2J7Q EOS100850 Phase 1 T77365 DRUGINFO DJ0P6A PBF-999 Phase 1 T77365 DRUGINFO D02YQO SCH-442416 Phase 1 T77365 DRUGINFO D0L5VS KF-17837 Phase 1 T77365 DRUGINFO D07ESH PF-1913539 Discontinued in Phase 3 T77365 DRUGINFO D09NEE BVT-115959 Discontinued in Phase 2 T77365 DRUGINFO D0L3YX T-62 Discontinued in Phase 1 T77365 DRUGINFO D0LJ0L Lu-AA47070 Discontinued in Phase 1 T77365 DRUGINFO D0I7BL ARISTEROMYCIN Terminated T77365 DRUGINFO D0NQ5I METRIFUDIL Terminated T77365 DRUGINFO D0Y6GJ ZM-241385 Terminated T77365 DRUGINFO D0E4WF METHYLTHIOADENOSINE Terminated T77365 DRUGINFO D01RPD (E,E)-8-(4-Phenylbutadien-1-yl)caffeine Investigative T77365 DRUGINFO D01VJT 1-amino-2,4-bis(phenylthio)anthracene-9,10-dione Investigative T77365 DRUGINFO D01XFR 7-Allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D01XGG N-(7-methoxy-4-phenylbenzofuran-2-yl)acetamide Investigative T77365 DRUGINFO D02XMQ 1-amino-4-methoxyanthracene-9,10-dione Investigative T77365 DRUGINFO D02XPR (S)-DHPA Investigative T77365 DRUGINFO D03LJX (3-amino-5-bromobenzofuran-2-yl)(phenyl)methanone Investigative T77365 DRUGINFO D04JDQ 6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine Investigative T77365 DRUGINFO D04WBU 1-Ethyl-3-methyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D04WCH 1,3,7-Tripropyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D04YUM 9-Butyl-9H-adenine Investigative T77365 DRUGINFO D05OUG 1-amino-2-phenoxyanthracene-9,10-dione Investigative T77365 DRUGINFO D06ETD LUF-5437 Investigative T77365 DRUGINFO D06PYV 2-amino-3-(m-tolylamino)naphthalene-1,4-dione Investigative T77365 DRUGINFO D06YJN 1,3-Diallyl-7-methyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D06ZLL (E,E)-8-[4-(3-Bromophenyl)butadien-1-yl]caffeine Investigative T77365 DRUGINFO D07ETD N6-(4-hydroxybenzyl)adenine riboside Investigative T77365 DRUGINFO D08DPH (E,E)-8-[4-(3-Chlorophenyl)butadien-1-yl]caffeine Investigative T77365 DRUGINFO D08GLJ 1,3,8-Trimethyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D08SJF 5-Azido-6-benzyl-2-methyl-[1,8]naphthyridine Investigative T77365 DRUGINFO D08ZOV Methyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate Investigative T77365 DRUGINFO D0A0VT 7-Propyl-7H-adenine Investigative T77365 DRUGINFO D0C1PS 9-(3-Hydroxypropyl)-9H-adenine Investigative T77365 DRUGINFO D0C8ON 1-aminoanthracene-9,10-dione Investigative T77365 DRUGINFO D0E2FV 9-Phenylethyl-9H-adenine Investigative T77365 DRUGINFO D0E4UT 9-But-3-enyl-9H-adenine Investigative T77365 DRUGINFO D0G5NE (Z)-8-(3-chlorostyryl)caffeine Investigative T77365 DRUGINFO D0H0AO Phenyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate Investigative T77365 DRUGINFO D0H5HP 1-amino-4-chloroanthracene-9,10-dione Investigative T77365 DRUGINFO D0J6PQ 6-Furan-2-yl-9-phenyl-9H-purin-2-ylamine Investigative T77365 DRUGINFO D0K1UA 1-Allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D0L4WN 1,4-diaminoanthracene-9,10-dione Investigative T77365 DRUGINFO D0LM1Q 1,3-Dibenzyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D0M7AX 3-Isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D0MG3U (E,E)-8-[4-(3-Fluorophenyl)butadien-1-yl]caffeine Investigative T77365 DRUGINFO D0N5IE 1-Phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea Investigative T77365 DRUGINFO D0N8RM 9-(2-Hydroxyethyl)-9H-adenine Investigative T77365 DRUGINFO D0O6NS 8-Br-adenine Investigative T77365 DRUGINFO D0OR5V 9-Cyclopropyl-9H-adenine Investigative T77365 DRUGINFO D0P7MU N-(4-Pyridin-2-yl-thiazol-2-yl)-benzamide Investigative T77365 DRUGINFO D0Q6KO 9-(2-Hydroxypropyl)-9H-adenine Investigative T77365 DRUGINFO D0RZ5U 7-Allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D0S4JI 9-BENZYL-9H-ADENINE Investigative T77365 DRUGINFO D0V7MX 9-Cycloheptyl-9H-adenine Investigative T77365 DRUGINFO D0W4HJ MSX-3 Investigative T77365 DRUGINFO D0YE5K N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-benzamide Investigative T77365 DRUGINFO D0Z2QM 7-Isopropyl-7H-adenine Investigative T77365 DRUGINFO D0ZD4M 4-amino-2-p-tolylisoindoline-1,3-dione Investigative T77365 DRUGINFO D00CJJ 8-Bromo-9-phenylethyl-9H-adenine Investigative T77365 DRUGINFO D00HYS 2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile Investigative T77365 DRUGINFO D00MFV 9-(sec-Butyl)-9H-adenine Investigative T77365 DRUGINFO D00MPA 6-(furan-2-yl)-9H-purin-2-amine Investigative T77365 DRUGINFO D00NYG 4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile Investigative T77365 DRUGINFO D00OFN 4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine Investigative T77365 DRUGINFO D00YOM 3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol Investigative T77365 DRUGINFO D02BGA 9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine Investigative T77365 DRUGINFO D02NBB 9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine Investigative T77365 DRUGINFO D02RBK 9-Benzyl-8-bromo-9H-adenine Investigative T77365 DRUGINFO D02TEW 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine Investigative T77365 DRUGINFO D03JFX 9-Ethyl-9H-adenine Investigative T77365 DRUGINFO D04AGC Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol Investigative T77365 DRUGINFO D04JIR 9-Methyl-9H-adenine Investigative T77365 DRUGINFO D04MMG N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine Investigative T77365 DRUGINFO D04PJO 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine Investigative T77365 DRUGINFO D04XLX 2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide Investigative T77365 DRUGINFO D04ZTH 2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile Investigative T77365 DRUGINFO D05TFM 2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine Investigative T77365 DRUGINFO D05ZRR 9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine Investigative T77365 DRUGINFO D06NQD 2-amino-6-phenyl-4-p-tolylnicotinonitrile Investigative T77365 DRUGINFO D07HVJ 2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine Investigative T77365 DRUGINFO D07YKU 2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine Investigative T77365 DRUGINFO D08AXT 9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine Investigative T77365 DRUGINFO D08CIY 2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine Investigative T77365 DRUGINFO D08INY 2,6-Diphenyl-pyrimidin-4-ylamine Investigative T77365 DRUGINFO D08RGW 3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol Investigative T77365 DRUGINFO D09HAM 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine Investigative T77365 DRUGINFO D09UDF 2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine Investigative T77365 DRUGINFO D0BA7Q 1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D0BC7P 2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile Investigative T77365 DRUGINFO D0CB9B 4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine Investigative T77365 DRUGINFO D0D3WR 9-benzyl-6-(furan-2-yl)-9H-purin-2-amine Investigative T77365 DRUGINFO D0F9JF FR-166124 Investigative T77365 DRUGINFO D0HK5B SCH-63390 Investigative T77365 DRUGINFO D0I6MT N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine Investigative T77365 DRUGINFO D0J2UW CGS 21680 Investigative T77365 DRUGINFO D0J6ME 2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine Investigative T77365 DRUGINFO D0KM0Y 2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile Investigative T77365 DRUGINFO D0M8NW Kuanoniamine D Investigative T77365 DRUGINFO D0N2VO 2-Amino-4,6-diphenyl-nicotinonitrile Investigative T77365 DRUGINFO D0P5ZE Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine Investigative T77365 DRUGINFO D0QD3O 2-Amino-4,6-diphenyl-pyrimidine Investigative T77365 DRUGINFO D0QN5I 4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine Investigative T77365 DRUGINFO D0T6XM 1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D0UM6O 2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine Investigative T77365 DRUGINFO D0W5CZ 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine Investigative T77365 DRUGINFO D0W6TG PSB-09120 Investigative T77365 DRUGINFO D0W8RB 8-Bromo-9-(but-3-enyl)-9H-adenine Investigative T77365 DRUGINFO D0Y5TL Alloxazine Investigative T77365 DRUGINFO D0Y7AV 2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine Investigative T77365 DRUGINFO D0YR1V 5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine Investigative T77365 DRUGINFO D0ZV1T N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide Investigative T77365 DRUGINFO D00ASZ 2-(3''-pyrrolylethyloxy)adenosine Investigative T77365 DRUGINFO D00GQI N-(2,6-diphenylpyrimidin-4-yl)isobutyramide Investigative T77365 DRUGINFO D00NFW 2,6-diphenyl-8-ethyl-1-deazapurine Investigative T77365 DRUGINFO D01NHH 2,6-diphenyl-8-tButyl-1-deazapurine Investigative T77365 DRUGINFO D01PGY 2-(hex-1-ynyl)-N6-methoxyadenosine Investigative T77365 DRUGINFO D01QBK 8-Bromo-9-cyclohexyl-9H-adenine Investigative T77365 DRUGINFO D01VEU 9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine Investigative T77365 DRUGINFO D01VXC N-(4,6-diphenylpyrimidin-2-yl)propionamide Investigative T77365 DRUGINFO D01VXP 2-ethynyl-N6-methoxyadenosine Investigative T77365 DRUGINFO D01WNA 8-Bromo-9-ethyl-9H-adenine Investigative T77365 DRUGINFO D02EAO N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine Investigative T77365 DRUGINFO D02FLH 2,6-dphenyl-8-propyl-1-deazapurine Investigative T77365 DRUGINFO D02HOL 8-Bromo-9-propyl-9H-adenine Investigative T77365 DRUGINFO D02HYT N-(2,6-diphenylpyrimidin-4-yl)propionamide Investigative T77365 DRUGINFO D02JMR 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D02RMR 1,3-Diethyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D02VQK LUF-5433 Investigative T77365 DRUGINFO D03FVK N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine Investigative T77365 DRUGINFO D03HBG 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D03KKK 1,3-Dipropyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D03POP N6-methoxy-2-phenylethynyladenosine Investigative T77365 DRUGINFO D04TTP 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol Investigative T77365 DRUGINFO D04WHE 9-Propyl-9H-adenine Investigative T77365 DRUGINFO D05XGF PSB-0788 Investigative T77365 DRUGINFO D06RCT 2-(3''-indolylethyloxy)adenosine Investigative T77365 DRUGINFO D07DNX PD-115199 Investigative T77365 DRUGINFO D07HNM 1,3-Diallyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D07IPZ 2-(4-hydroxypent-1-yl)-N6-methoxyadenosine Investigative T77365 DRUGINFO D08EZI N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide Investigative T77365 DRUGINFO D08HBH N-(2,6-diphenylpyrimidin-4-yl)butyramide Investigative T77365 DRUGINFO D08JUQ 2-tolyl-6-phenyl-9H-purine Investigative T77365 DRUGINFO D08JYX 2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine Investigative T77365 DRUGINFO D08LZN Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine Investigative T77365 DRUGINFO D08MRB 1H-Imidazo[4,5-c]quinolin-4-ylamine HCl Investigative T77365 DRUGINFO D09IRV LUF-5957 Investigative T77365 DRUGINFO D09VOP 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D09VRX 2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T77365 DRUGINFO D0A6JX 9-Cyclobutyl-9H-adenine Investigative T77365 DRUGINFO D0A9BZ PSB-601 Investigative T77365 DRUGINFO D0B0QW N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine Investigative T77365 DRUGINFO D0B1RV 2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine Investigative T77365 DRUGINFO D0B1YW 8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D0B3NZ N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide Investigative T77365 DRUGINFO D0B3UE 9-Cyclopentyl-9H-adenine Investigative T77365 DRUGINFO D0B8RQ LUF-5767 Investigative T77365 DRUGINFO D0DB7A 9-Isopropyl-9H-adenine Investigative T77365 DRUGINFO D0E4LB 2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine Investigative T77365 DRUGINFO D0E7YE 2,6,8-triphenyl-9H-purine Investigative T77365 DRUGINFO D0E8RA 8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine Investigative T77365 DRUGINFO D0F1AS 1-METHYLXANTHINE Investigative T77365 DRUGINFO D0F4XB 2-Amino-4,6-di-furan-2-yl-nicotinonitrile Investigative T77365 DRUGINFO D0G5ZF N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine Investigative T77365 DRUGINFO D0G6BI 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D0G6VT 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D0I1IW 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D0I2EQ 2,6-diphenyl-8-methyl-1-deazapurine Investigative T77365 DRUGINFO D0I6XA (2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol Investigative T77365 DRUGINFO D0I7HL 2-phenylpropoxyadenosine Investigative T77365 DRUGINFO D0KJ3H 2-(2''-indolylethyloxy)adenosine Investigative T77365 DRUGINFO D0KT3L 2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine Investigative T77365 DRUGINFO D0L2MN 2-(4-chlorophenyl)-6-phenyl-9H-purine Investigative T77365 DRUGINFO D0L6YI 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D0LP5G 2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine Investigative T77365 DRUGINFO D0LP5V LUF-5956 Investigative T77365 DRUGINFO D0N1QO N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine Investigative T77365 DRUGINFO D0N1QP 2,6-diphenyl-1-deazapurine Investigative T77365 DRUGINFO D0O0FP ST-1535 Investigative T77365 DRUGINFO D0O1CW GNF-PF-2700 Investigative T77365 DRUGINFO D0OX0V 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline Investigative T77365 DRUGINFO D0P0BV 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D0P7CS LUF-5417 Investigative T77365 DRUGINFO D0P7FK 2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile Investigative T77365 DRUGINFO D0P8MK 2-(6-amino-8-bromo-9H-purin-9-yl)ethanol Investigative T77365 DRUGINFO D0PU6F 2-(1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T77365 DRUGINFO D0Q1RD 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D0Q3LM N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine Investigative T77365 DRUGINFO D0Q5CS 6-guanidino-2-(3''-indolylethyloxy)adenosine Investigative T77365 DRUGINFO D0QN4U 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine Investigative T77365 DRUGINFO D0R8OK 8-Bromo-9-methyl-9H-adenine Investigative T77365 DRUGINFO D0RZ2M 2,6-diphenyl-9H-purine Investigative T77365 DRUGINFO D0S5XP 9-Allyl-8-bromo-9H-adenine Investigative T77365 DRUGINFO D0S6QA 8-Bromo-9-(2-butyl)-9H-adenine Investigative T77365 DRUGINFO D0U8DW 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione Investigative T77365 DRUGINFO D0V9EE 2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile Investigative T77365 DRUGINFO D0VB6X (1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl Investigative T77365 DRUGINFO D0W3MT 8-propyl-2,6-diphenyl-9H-purine Investigative T77365 DRUGINFO D0W6FC 8-Bromo-9-(2-hydroxypropyl)-9H-adenine Investigative T77365 DRUGINFO D0WI4D LUF-5962 Investigative T77365 DRUGINFO D0Y2RM Isoguanosine Investigative T77365 DRUGINFO D0Y6HQ N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine Investigative T77365 DRUGINFO D0Y7HG Galangin Investigative T77365 DRUGINFO D0Z3XC N-(2,6-diphenylpyrimidin-4-yl)acetamide Investigative T77365 DRUGINFO D0ZW9L 5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol Investigative T77365 DRUGINFO D00GNW 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine Investigative T77365 DRUGINFO D00JWA N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide Investigative T77365 DRUGINFO D02PBY 3-noradamantyl-1,3-dipropylxanthine Investigative T77365 DRUGINFO D04LZN 8-Bromo-9-cyclobutyl-9H-adenine Investigative T77365 DRUGINFO D05KEF LUF-5978 Investigative T77365 DRUGINFO D06KYP 8-Bromo-9-isopropyl-9H-adenine Investigative T77365 DRUGINFO D0AI8F 8-Bromo-9-cyclopentyl-9H-adenine Investigative T77365 DRUGINFO D0B0TX 8-bromo-9-isobutyl-9H-purin-6-amine Investigative T77365 DRUGINFO D0CX7N 8-Bromo-9-(3-hydroxypropyl)-9H-adenine Investigative T77365 DRUGINFO D0IG5E 2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine Investigative T77365 DRUGINFO D0JJ6T N6-((+/-)-endo-norborn-2-yl)adenosine Investigative T77365 DRUGINFO D0K6ZA [3H]OSIP339391 Investigative T77365 DRUGINFO D0K8ZZ [3H]NECA Investigative T77365 DRUGINFO D0M3CG R-N6-(phenylisopropyl)adenosine Investigative T77365 DRUGINFO D0NO5E Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate Investigative T77365 DRUGINFO D0O4KI 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine Investigative T77365 DRUGINFO D0R1XY [3H]CCPA Investigative T77365 DRUGINFO D0V8MD 8-PHENYL THEOPHYLLINE Investigative T77365 DRUGINFO D0W1PF LUF-5980 Investigative T77365 DRUGINFO D0Y9WZ SB-298 Investigative T77365 DRUGINFO D0Z8NC LUF-5981 Investigative T77365 DRUGINFO D0Z8VU 8-Bromo-9-(sec-butyl)-9H-adenine Investigative T77365 DRUGINFO D0K0OT GNF-PF-2224 Investigative T77365 DRUGINFO D03RFA N6-CYCLOPENTYLADENOSINE Investigative T77365 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T77365 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T13251 TARGETID T13251 T13251 FORMERID TTDC00033 T13251 UNIPROID IL12A_HUMAN T13251 TARGNAME Interleukin-12 alpha (IL12A) T13251 GENENAME IL12A T13251 TARGTYPE Successful T13251 SYNONYMS NKSF1; NKSF; NK cell stimulatory factor chain 1; NK cell stimulatory factor; Interleukin-12 subunit alpha; IL-12A; IL-12 subunit p35; IL-12; Cytotoxic lymphocyte maturation factor 35 kDa subunit; CLMF p35 T13251 FUNCTION Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC. T13251 PDBSTRUC 3HMX; 1F45 T13251 BIOCLASS Cytokine: interleukin T13251 SEQUENCE MCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS T13251 DRUGINFO D0E7QB Mirikizumab Approved T13251 DRUGINFO D0A2UV Ustekinumab Approved T13251 DRUGINFO D0C9NJ STA-5326 Phase 2 T82383 TARGETID T82383 T82383 FORMERID TTDNR00764 T82383 UNIPROID UFO_HUMAN T82383 TARGNAME Tyrosine-protein kinase UFO (AXL) T82383 GENENAME AXL T82383 TARGTYPE Successful T82383 SYNONYMS UFO; Tyrosine-protein kinase receptor UFO; AXL oncogene T82383 FUNCTION Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, ALX binds and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. T82383 PDBSTRUC 5VXZ; 5U6B; 4RA0; 2C5D T82383 BIOCLASS Kinase T82383 ECNUMBER EC 2.7.10.1 T82383 SEQUENCE MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEESPFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRDGQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSDTGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPEDRTVAANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHGPQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQQPRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLSDDGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHPHTPYHIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENISATRNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEVLMDIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGPWSLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWYVLLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVDRHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWELNPQDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRYVLCPSTTPSPAQPADRGSPAAPGQEDGA T82383 DRUGINFO D04KZY Gilteritinib Approved T82383 DRUGINFO D0U8XE Bemcentinib Phase 2 T82383 DRUGINFO D0X9VR BGB-324 Phase 2 T82383 DRUGINFO DYI4L2 Mecbotamab vedotin Phase 2 T82383 DRUGINFO D08FDX MGCD265 Phase 2 T82383 DRUGINFO D0Q7OE BI-505 Phase 2 T82383 DRUGINFO D00LGR TP-0903 Phase 1/2 T82383 DRUGINFO DI0ZA3 Enapotamab vedotin Phase 1/2 T82383 DRUGINFO DA1MG8 ONO-7475 Phase 1/2 T82383 DRUGINFO D06THG DS-1205 Phase 1 T82383 DRUGINFO D0Y5QA AVB-S6-500 Phase 1 T82383 DRUGINFO DMLY68 A416 Phase 1 T82383 DRUGINFO D0VH4T ONO-7475 Phase 1 T82383 DRUGINFO D95YSW BPI-9016 M Phase 1 T82383 DRUGINFO DP4KH3 PF-07265807 Phase 1 T82383 DRUGINFO DQX83Z INCB81776 Phase 1 T82383 DRUGINFO D7HZ3T RXDX-106 Phase 1 T82383 DRUGINFO D4JS3A Cu-anti-hAXL Preclinical T82383 DRUGINFO D4K2CQ DP-3975 Preclinical T82383 DRUGINFO D50NHR YW327.6S2 Preclinical T82383 DRUGINFO DU9RB1 GL21.T Preclinical T82383 DRUGINFO D09TFN LDC1267 Investigative T75440 TARGETID T75440 T75440 FORMERID TTDS00454 T75440 UNIPROID TSPO_HUMAN T75440 TARGNAME Translocator protein (TSPO) T75440 GENENAME TSPO T75440 TARGTYPE Successful T75440 SYNONYMS Peripheral-type benzodiazepine receptor; Peripheral benzodiazepine receptor; PKBS; PBR; Mitochondrial benzodiazepine receptor; MBR; BZRP T75440 FUNCTION Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism, but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benzodiazepine receptor; can also bind isoquinoline carboxamides. Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme. T75440 BIOCLASS Cholesterol/porphyrin uptake translocator T75440 SEQUENCE MAPPWVPAMGFTLAPSLGCFVGSRFVHGEGLRWYAGLQKPSWHPPHWVLGPVWGTLYSAMGYGSYLVWKELGGFTEKAVVPLGLYTGQLALNWAWPPIFFGARQMGWALVDLLLVSGAAAATTVAWYQVSPLAARLLYPYLAWLAFTTTLNYCVWRDNHGWRGGRRLPE T75440 DRUGINFO D03NPH Quazepam Approved T75440 DRUGINFO D04BNP Temazepam Approved T75440 DRUGINFO D06BEP Chlordiazepoxide Approved T75440 DRUGINFO D06FWC Fludiazepam Approved T75440 DRUGINFO D06ZII Eszopiclone Approved T75440 DRUGINFO D07JVL Diazepam Approved T75440 DRUGINFO D08XFV Flurazepam Approved T75440 DRUGINFO D09LDR Oxazepam Approved T75440 DRUGINFO D0E0OG Lorazepam Approved T75440 DRUGINFO D0E7FS Adinazolam Approved T75440 DRUGINFO D0G3AQ Prazepam Approved T75440 DRUGINFO D0L9GG Alprazolam Approved T75440 DRUGINFO D0P2CK Estazolam Approved T75440 DRUGINFO D0P3JU Clorazepate Approved T75440 DRUGINFO D0Q9WO Cinolazepam Approved T75440 DRUGINFO D0R4DP Clotiazepam Approved T75440 DRUGINFO D0S1OE Chlormezanone Approved T75440 DRUGINFO D0U3LS Triazolam Approved T75440 DRUGINFO D0U6LM Midazolam Approved T75440 DRUGINFO D0W2NM Flunitrazepam Approved T75440 DRUGINFO D0Z9VB Halazepam Approved T75440 DRUGINFO D01XOD Alpidem Approved T75440 DRUGINFO D0D5GD Flumazenil Approved T75440 DRUGINFO D04LTF TLN-4601 Phase 2 T75440 DRUGINFO D05CMZ ONO-2952 Phase 2 T75440 DRUGINFO D09OTU SSR-180575 Phase 2 T75440 DRUGINFO D0G4YZ 11C-PBR-28 Phase 2 T75440 DRUGINFO D07TXJ Dextofisopam Phase 2 T75440 DRUGINFO D06OFD BAY-85-8102 Phase 1 T75440 DRUGINFO D0U1US 18F-FEDAA-1106 Phase 1 T75440 DRUGINFO D00EBN Imidazopyridine acetamide analog 7 Patented T75440 DRUGINFO D00UDJ Indole-based analog 5 Patented T75440 DRUGINFO D01BXA PMID27607364-Compound-65 Patented T75440 DRUGINFO D01DWN PMID27599163-Compound-79 Patented T75440 DRUGINFO D01KPW Isoquinoline carboxamide derivative 1 Patented T75440 DRUGINFO D01LOJ Pyrazolopyrimidine acetamide analog 1 Patented T75440 DRUGINFO D01PXI Indole-based analog 10 Patented T75440 DRUGINFO D01WQX Imidazopyridine derivative 2 Patented T75440 DRUGINFO D02UMS Quinazoline derivative 5 Patented T75440 DRUGINFO D02VRI Tricyclic indole compound 11 Patented T75440 DRUGINFO D03ENW Benzothiazepine analog 3 Patented T75440 DRUGINFO D03PTY PMID27607364-Compound-64 Patented T75440 DRUGINFO D04ESE Imidazo[1,2-b]pyridazine acetamide derivative 4 Patented T75440 DRUGINFO D04JEH Aryl oxyanilide derivative 1 Patented T75440 DRUGINFO D04SWU Tricyclic indole compound 12 Patented T75440 DRUGINFO D05GJL Benzothiazepine analog 6 Patented T75440 DRUGINFO D05ZAV PMID27607364-Compound-141 Patented T75440 DRUGINFO D06HIJ PMID27607364-Compound-60 Patented T75440 DRUGINFO D06PPD Imidazopyridine acetamide analog 2 Patented T75440 DRUGINFO D06RNU Quinazoline derivative 2 Patented T75440 DRUGINFO D06WUT Quinoline carboxamide derivative 8 Patented T75440 DRUGINFO D07KTM Quinoline carboxamide derivative 9 Patented T75440 DRUGINFO D07RRL PMID27599163-Compound-76 Patented T75440 DRUGINFO D07RWQ Imidazo[1,2-b]pyridazine acetamide derivative 5 Patented T75440 DRUGINFO D08DPU Benzimidazolone acetamide derivative 1 Patented T75440 DRUGINFO D08RNV Aryl oxyanilide derivative 2 Patented T75440 DRUGINFO D08RTY Imidazo[1,2-b]pyridazine acetamide derivative 3 Patented T75440 DRUGINFO D08XOA Benzothiazepine analog 2 Patented T75440 DRUGINFO D08ZHA PMID27599163-Compound-78 Patented T75440 DRUGINFO D09AKT Imidazo[1,2-b]pyridazine acetamide derivative 6 Patented T75440 DRUGINFO D09GSO PMID27599163-Compound-82 Patented T75440 DRUGINFO D09JTT Quinazoline derivative 3 Patented T75440 DRUGINFO D0A5RG PMID27607364-Compound-58 Patented T75440 DRUGINFO D0AC4P Benzimidazolone acetamide derivative 2 Patented T75440 DRUGINFO D0AP1F PMID27599163-Compound-81 Patented T75440 DRUGINFO D0AW8P Quinoline carboxamide derivative 7 Patented T75440 DRUGINFO D0B3RK Indole-based analog 9 Patented T75440 DRUGINFO D0CL2E Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 3 Patented T75440 DRUGINFO D0E2XN PMID27607364-Compound-59 Patented T75440 DRUGINFO D0E6TQ Tricyclic indole compound 14 Patented T75440 DRUGINFO D0EG4F Imidazopyridine acetamide analog 6 Patented T75440 DRUGINFO D0EI2Q Tricyclic indole compound 7 Patented T75440 DRUGINFO D0EY2Q Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 2 Patented T75440 DRUGINFO D0FF5C Quinoline carboxamide derivative 4 Patented T75440 DRUGINFO D0FR9I Aryl oxyanilide derivative 3 Patented T75440 DRUGINFO D0G5FS Bidentate pyrazolopyrimidine acetamide analog 3 Patented T75440 DRUGINFO D0G7HK Benzothiazepine analog 8 Patented T75440 DRUGINFO D0GN5R Benzothiazepine analog 7 Patented T75440 DRUGINFO D0GY0E Benzothiazepine analog 5 Patented T75440 DRUGINFO D0H2RG Phenylpurine acetamide analog 2 Patented T75440 DRUGINFO D0HS8T Imidazopyridine derivative 1 Patented T75440 DRUGINFO D0I6CF Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 1 Patented T75440 DRUGINFO D0IY5H PMID27607364-Compound-62 Patented T75440 DRUGINFO D0JN7L PMID27599163-Compound-77 Patented T75440 DRUGINFO D0K3MV Imidazo[1,2-b]pyridazine acetamide derivative 7 Patented T75440 DRUGINFO D0K3QX Tricyclic indole compound 6 Patented T75440 DRUGINFO D0K3ZB Quinazoline derivative 6 Patented T75440 DRUGINFO D0K4UF Imidazopyridine acetamide analog 4 Patented T75440 DRUGINFO D0K4VT Benzoxazepine analog 1 Patented T75440 DRUGINFO D0KZ5O Bidentate pyrazolopyrimidine acetamide analog 2 Patented T75440 DRUGINFO D0L5EG Tricyclic indole compound 2 Patented T75440 DRUGINFO D0LB3J Pyrazolopyrimidine acetamide analog 2 Patented T75440 DRUGINFO D0LE6B PMID27599163-Compound-75 Patented T75440 DRUGINFO D0M9PB Imidazo[1,2-b]pyridazine acetamide derivative 1 Patented T75440 DRUGINFO D0MR8D Imidazopyridine acetamide analog 3 Patented T75440 DRUGINFO D0N5LW Phenylpurine acetamide analog 1 Patented T75440 DRUGINFO D0N9DS PMID27607364-Compound-4 Patented T75440 DRUGINFO D0NF3Y Tricyclic indole compound 5 Patented T75440 DRUGINFO D0O8DG Benzothiazepine analog 9 Patented T75440 DRUGINFO D0OB0Q Quinoline carboxamide derivative 6 Patented T75440 DRUGINFO D0P1TH Imidazo[1,2-b]pyridazine acetamide derivative 2 Patented T75440 DRUGINFO D0PE1K Quinoline carboxamide derivative 5 Patented T75440 DRUGINFO D0PO3M Imidazopyridine acetamide analog 1 Patented T75440 DRUGINFO D0Q5JO Tricyclic indole compound 9 Patented T75440 DRUGINFO D0R0OA Tricyclic indole compound 3 Patented T75440 DRUGINFO D0R2XX Benzodiazepine derivative 1 Patented T75440 DRUGINFO D0RH7L PMID27607364-Compound-162 Patented T75440 DRUGINFO D0RT5D Tricyclic indole compound 10 Patented T75440 DRUGINFO D0S2SS Quinazoline derivative 4 Patented T75440 DRUGINFO D0TB2L PMID27607364-Compound-61 Patented T75440 DRUGINFO D0TP7S Quinazoline derivative 7 Patented T75440 DRUGINFO D0TQ8V Tricyclic indole compound 4 Patented T75440 DRUGINFO D0U0IH PMID27599163-Compound-52 Patented T75440 DRUGINFO D0V9GL Imidazopyridine acetamide analog 5 Patented T75440 DRUGINFO D0WL7F Tricyclic indole compound 1 Patented T75440 DRUGINFO D0X1MJ Bidentate pyrazolopyrimidine acetamide analog 1 Patented T75440 DRUGINFO D0X8TY Bidentate pyrazolopyrimidine acetamide analog 4 Patented T75440 DRUGINFO D0XB2O Tricyclic indole compound 8 Patented T75440 DRUGINFO D0Y0FR Quinoline carboxamide derivative 10 Patented T75440 DRUGINFO D0Y2ZS PMID27607364-Compound-63 Patented T75440 DRUGINFO D0Z1KU Benzothiazepine analog 1 Patented T75440 DRUGINFO D0Z6RI Benzothiazepine analog 4 Patented T75440 DRUGINFO D0ZK2Q PMID27607364-Compound-10 Patented T75440 DRUGINFO D0B3LP Ro-16-6028 Discontinued in Phase 3 T75440 DRUGINFO D00TNC S-8510 Discontinued in Phase 2 T75440 DRUGINFO D05UXF Emapunil Discontinued in Phase 2 T75440 DRUGINFO D0D5ZR TRO-40303 Discontinued in Phase 2 T75440 DRUGINFO D0O0DF Lirequinil Discontinued in Phase 2 T75440 DRUGINFO D06BYS Imepitoin Discontinued in Phase 1 T75440 DRUGINFO D02UOE Miltirone Terminated T75440 DRUGINFO D03XPV Ginkgolide B (GKB) Terminated T75440 DRUGINFO D0K5IQ DAA-1097 Terminated T75440 DRUGINFO D0S8KE NS-2979 Terminated T75440 DRUGINFO D0Y6LO NNC-13-8119 Terminated T75440 DRUGINFO D01HGI TGSC01AA(4) Investigative T75440 DRUGINFO D04EGE 11C-PBR-170 Investigative T75440 DRUGINFO D05CYJ N,N-Dimethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide Investigative T75440 DRUGINFO D07WPM 6-Thia-10b-aza-benzo[e]azulen-4-one Investigative T75440 DRUGINFO D08AWL 5-Phenyl-6-thia-10b-aza-benzo[e]azulen-4-one Investigative T75440 DRUGINFO D08XEQ N,N-Dihexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide Investigative T75440 DRUGINFO D0A0ED FGIN-1-27 Investigative T75440 DRUGINFO D0A3TE 5-Phenyl-6-thia-10b-aza-benzo[e]azulene Investigative T75440 DRUGINFO D0CS6N Benzodiazepine Investigative T75440 DRUGINFO D0L2NV U-89854 Investigative T75440 DRUGINFO D0M1JT 4-Methoxy-5-phenyl-6-thia-10b-aza-benzo[e]azulene Investigative T75440 DRUGINFO D0N6IL N-Hexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide Investigative T75440 DRUGINFO D0O6JQ (R)PK-11195 Investigative T75440 DRUGINFO D0T6NJ N,N-Diethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide Investigative T75440 DRUGINFO D0Z4SA 2-(2-Phenyl-1H-indol-3-yl)-N,N-dipropyl-acetamide Investigative T75440 DRUGINFO D0B1PE Ro 5-4864 Investigative T75440 DRUGINFO D0VN4K PK 11195 Investigative T32247 TARGETID T32247 T32247 FORMERID TTDS00485 T32247 UNIPROID CALCR_HUMAN T32247 TARGNAME Calcitonin receptor (CALCR) T32247 GENENAME CALCR T32247 TARGTYPE Successful T32247 SYNONYMS CT-R T32247 FUNCTION The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin. This is a receptor for calcitonin. T32247 PDBSTRUC 6NIY; 5UZ7; 5II0 T32247 BIOCLASS GPCR secretin T32247 SEQUENCE MRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYVVGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDFDPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFTLVISLGIFVFFRSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVVPNGELVRRDPVSCKILHFFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTKMRETHEAESHMYLKAVKATMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFFVATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQEPRNEPANNQGEESAEIIPLNIIEQESSA T32247 DRUGINFO D02QCM Calcitonin Human Approved T32247 DRUGINFO D0I1XG Salmon Calcitonin Approved T32247 DRUGINFO D93YJK LY 3541105 Phase 1 T32247 DRUGINFO DW3J9N DACRA 089 Phase 1 T32247 DRUGINFO D00XRI TJN-220 Terminated T32247 DRUGINFO D00JEO CSNLSTCVLGKLSQELc[DKLHK]YPRTNTGSGTP-amide Investigative T32247 DRUGINFO D03CEP CGNLSTCMLGTYTQDFNKPHTFPQTAIGVGAP-amide Investigative T32247 DRUGINFO D03DPD CGNLSTCMLGTYTQDFc[DKFHK]FPQTAIGVGAP-amide Investigative T32247 DRUGINFO D05AIM CSNLSTCVLGKLSQELc[DKLHO]YPRTNTGSGTP-amide Investigative T32247 DRUGINFO D08URJ CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-amide Investigative T32247 DRUGINFO D0A8VZ CGNLSTCBLGTYTQDF[DKFHO]YPQTAIGVGAP-amide Investigative T32247 DRUGINFO D0G0WP CGNLSTCBLGTYTQDFNKFHZYPQTAIGVGAP-amide Investigative T32247 DRUGINFO D0H0GJ CSNLSTCVLGKLSQELNKLHBYPRTNTGSGTP-amide Investigative T32247 DRUGINFO D0J2UD CGNLSTCMLGTYTQDFc[DKFHO]FPQTAIGVGAP-amide Investigative T32247 DRUGINFO D0J7CK CSNLSTCVLGKLSQELc[DKLQK]YPRTNTGSGTP-amide Investigative T32247 DRUGINFO D0K1IE CGNLSTCMLGTYTQDFNPFHTFPQTAIGVGAP-amide Investigative T32247 DRUGINFO D0O9WG CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-amide Investigative T32247 DRUGINFO D0Y0NM CGNLSTCMLGTYTQDFNPKHTFPQTAIGVGAP-amide Investigative T26368 TARGETID T26368 T26368 FORMERID TTDR01042 T26368 UNIPROID GBRA5_HUMAN T26368 TARGNAME GABA(A) receptor alpha-5 (GABRA5) T26368 GENENAME GABRA5 T26368 TARGTYPE Successful T26368 SYNONYMS GABRA5; GABAA alpha 5; GABA-A alpha-5 T26368 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. T26368 PDBSTRUC 6A96; 5OJM; 5O8F T26368 BIOCLASS Ligand-gated ion channel T26368 SEQUENCE MDNGMFSGFIMIKNLLLFCISMNLSSHFGFSQMPTSSVKDETNDNITIFTRILDGLLDGYDNRLRPGLGERITQVRTDIYVTSFGPVSDTEMEYTIDVFFRQSWKDERLRFKGPMQRLPLNNLLASKIWTPDTFFHNGKKSIAHNMTTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDFPMDAHACPLKFGSYAYPNSEVVYVWTNGSTKSVVVAEDGSRLNQYHLMGQTVGTENISTSTGEYTIMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKKALEAAKIKKKREVILNKSTNAFTTGKMSHPPNIPKEQTPAGTSNTTSVSVKPSEEKTSESKKTYNSISKIDKMSRIVFPVLFGTFNLVYWATYLNREPVIKGAASPK T26368 DRUGINFO D0D5GD Flumazenil Approved T26368 DRUGINFO D0CH7C Basmisanil Phase 2 T26368 DRUGINFO D0C9XA GSK683699 Phase 2 T26368 DRUGINFO D09TOL RG-7816 Phase 1 T26368 DRUGINFO D0D9RF RY024 Investigative T26368 DRUGINFO D0GQ2G [3H]RY80 Investigative T26368 DRUGINFO D0LE1F [3H]L655708 Investigative T26368 DRUGINFO D0YZ0B HT-2678 Investigative T26368 DRUGINFO D03PBN tetrahydrodeoxycorticosterone Investigative T26368 DRUGINFO D03ZWB alpha3IA Investigative T26368 DRUGINFO D06SOQ alpha5IA Investigative T26368 DRUGINFO D07JXC [18F]fluoroethylflumazenil Investigative T26368 DRUGINFO D0GQ1S DMCM Investigative T26368 DRUGINFO D0Q1ZT TP003 Investigative T26368 DRUGINFO D0T9DS [35S]TBPS Investigative T26368 DRUGINFO D01CUR 3-Ethoxy-9H-beta-carboline Investigative T26368 DRUGINFO D01RLF 9H-beta-Carboline-3-carboxylic acid ethyl ester Investigative T26368 DRUGINFO D03PPZ Beta-Carboline-3-carboxylic acid t-butyl ester Investigative T26368 DRUGINFO D03TMD Barbituric acid derivative Investigative T26368 DRUGINFO D06WMM 3-Butoxy-9H-beta-carboline Investigative T26368 DRUGINFO D08BOP 3-Propoxy-9H-beta-carboline Investigative T26368 DRUGINFO D08BXK 3-(3-Methyl-butoxy)-9H-beta-carboline Investigative T26368 DRUGINFO D09MYJ 3-Isobutoxy-9H-beta-carboline Investigative T26368 DRUGINFO D0C6WO Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate Investigative T26368 DRUGINFO D0D4MM Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate Investigative T26368 DRUGINFO D0E7PY Ro-4938581 Investigative T26368 DRUGINFO D0O9MG L-655708 Investigative T26368 DRUGINFO D0P3BU 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole Investigative T26368 DRUGINFO D0R5OU 3-(benzyloxy)-9H-pyrido[3,4-b]indole Investigative T26368 DRUGINFO D01IHM CI-218872 Investigative T26368 DRUGINFO D07NKO 5-[(1R)-1-ammonioethyl]isoxazol-3-olate Investigative T26368 DRUGINFO D09ACO (2E,4S)-4-ammoniopent-2-enoate Investigative T26368 DRUGINFO D0A8EU (4R)-4-ammoniopentanoate Investigative T26368 DRUGINFO D0N0ZK (4S)-4-ammoniopentanoate Investigative T26368 DRUGINFO D0S5PS 5-[(1S)-1-ammonioethyl]isoxazol-3-olate Investigative T26368 DRUGINFO D0VW5M piperidine-4-sulphonic acid Investigative T26368 DRUGINFO D00WHO Ro-15-3505 Investigative T26368 DRUGINFO D0AC2H isonipecotic acid Investigative T26368 DRUGINFO D0M4CP [3H]Ro154513 Investigative T26368 DRUGINFO D0M9RM [3H]CGS8216 Investigative T26368 DRUGINFO D06HRX AMENTOFLAVONE Investigative T26368 DRUGINFO D0P0TI TBPS Investigative T27812 TARGETID T27812 T27812 FORMERID TTDC00255 T27812 UNIPROID SC6A4_HUMAN T27812 TARGNAME Serotonin transporter (SERT) T27812 GENENAME SLC6A4 T27812 TARGTYPE Successful T27812 SYNONYMS Solute carrier family 6 member 4; HTT; 5HTT; 5HT transporter T27812 FUNCTION Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner. Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. T27812 PDBSTRUC 6DZZ; 6DZY; 6DZW; 6DZV; 6AWQ T27812 BIOCLASS Neurotransmitter:sodium symporter T27812 SEQUENCE METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTRHSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLPYTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIMAWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIHRSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGATLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQDALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPASTFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVTLTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRICWVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIITPGTFKERIIKSITPETPTEIPCGDIRLNAV T27812 DRUGINFO D03HFG Fluvoxamine Approved T27812 DRUGINFO D03WEX Vortioxetine Approved T27812 DRUGINFO D04WFD Nortriptyline Approved T27812 DRUGINFO D06CDO Chlorphentermine Hydrochloride Approved T27812 DRUGINFO D06CVT Tianeptine Approved T27812 DRUGINFO D06GDY Paroxetine Approved T27812 DRUGINFO D08RBC Escitalopram Approved T27812 DRUGINFO D0K0TC Sertraline Approved T27812 DRUGINFO D0M5JI Luvox Approved T27812 DRUGINFO D0O3FG Desvenlafaxine Approved T27812 DRUGINFO D0TR5X Fluoxetine Approved T27812 DRUGINFO D0Y5DO Citalopram Approved T27812 DRUGINFO D0ZS8P Clomipramine Approved T27812 DRUGINFO D00KFB Dextromethorphan Polistirex Approved T27812 DRUGINFO D00USF Trazodone Approved T27812 DRUGINFO D01AXB Duloxetine Approved T27812 DRUGINFO D02XOK Levomilnacipran Approved T27812 DRUGINFO D08KVZ Sibutramine Approved T27812 DRUGINFO D0B7OD Amfepramone Approved T27812 DRUGINFO D0P1UX Venlafaxine Approved T27812 DRUGINFO D0X4ZR Bupropion Approved T27812 DRUGINFO D0X6BV Vilazodone Approved T27812 DRUGINFO D0Y5UG Amitriptyline Approved T27812 DRUGINFO D04XPW Cocaine Approved T27812 DRUGINFO D0U5QK Acetaminophen Approved T27812 DRUGINFO D0W6KM Dasotraline Approved T27812 DRUGINFO D03QIE Bicifadine Phase 3 T27812 DRUGINFO D07AHC LITOXETINE Phase 3 T27812 DRUGINFO D0Z6IB AVP-786 Phase 3 T27812 DRUGINFO D04PXS Amitifadine Phase 3 T27812 DRUGINFO D0Q0EF ITI-007 Phase 3 T27812 DRUGINFO D05BXO Brasofensine Phase 2 T27812 DRUGINFO D0F8HN DA-8031 Phase 2 T27812 DRUGINFO D02JKY TD-9855 Phase 2 T27812 DRUGINFO D04VHK CLR-3001 Phase 2 T27812 DRUGINFO D0A8QM Lu-AA34893 Phase 2 T27812 DRUGINFO D07QXU NS 2359 Phase 2 T27812 DRUGINFO D0Z4FE MIN-117 Phase 2 T27812 DRUGINFO D02ZCE AD-337 Phase 1 T27812 DRUGINFO D03PRV BGC-20-1259 Phase 1 T27812 DRUGINFO D08SHE SEP-228432 Phase 1 T27812 DRUGINFO D0FM7Z BL-1021 Phase 1 T27812 DRUGINFO D0K7OW GSK-1360707 Phase 1 T27812 DRUGINFO D0R6LF Citalopram derivative 1 Patented T27812 DRUGINFO D0FA3G PMID29334795-Compound-61 Patented T27812 DRUGINFO D0VX6P Piperidine derivative 1 Patented T27812 DRUGINFO D0C1XS ZIMELIDINE Withdrawn from market T27812 DRUGINFO D0F9SG Dexfenfluramine Withdrawn from market T27812 DRUGINFO D01ESB YM-992 Discontinued in Phase 2 T27812 DRUGINFO D0B2OC R-sibutramine metabolite Discontinued in Phase 2 T27812 DRUGINFO D02JNX OxycoDex Discontinued in Phase 2 T27812 DRUGINFO D0H9GQ DOV-216303 Discontinued in Phase 2 T27812 DRUGINFO D0LU6N SPD-473 Discontinued in Phase 2 T27812 DRUGINFO D0M9LB NS-2389 Discontinued in Phase 2 T27812 DRUGINFO D04VUY RG-7166 Discontinued in Phase 1 T27812 DRUGINFO D08UNQ NSD-644 Discontinued in Phase 1 T27812 DRUGINFO D0I9UH MOXIFETIN HYDROGEN MALEATE Terminated T27812 DRUGINFO D0S6PJ 6-nitroquipazine Terminated T27812 DRUGINFO D0V9HI Irindalone Terminated T27812 DRUGINFO D0Q7OA HydrocoDex Terminated T27812 DRUGINFO D0K9JP A-80426 Terminated T27812 DRUGINFO D00DDT 2-N,N-Dimethylamino-1-(4-methylthiophenyl)propane Investigative T27812 DRUGINFO D00EUD 2-Amino-1-(4-methylthiophenyl)butane Investigative T27812 DRUGINFO D00RTM 3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine Investigative T27812 DRUGINFO D01OGZ TEFLUDAZINE Investigative T27812 DRUGINFO D02GSL 4-Iodo-6-nitro-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D02HOP 6-Iodo-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D02JOZ 4-Bromo-6-nitro-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D02JVG 2-Amino-1-(4-ethylthiophenyl)propane Investigative T27812 DRUGINFO D02MMS 2-N-(n-Propyl)amino-1-(4-methylthiophenyl)butane Investigative T27812 DRUGINFO D02NMY 6-Bromo-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D02PKR 3-Bromo-6-nitro-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D02VHZ 2-Amino-1-(4-ethylthiophenyl)butane Investigative T27812 DRUGINFO D03ETK 2-N-Hydroxyamino-1-(4-methylthiophenyl)propane Investigative T27812 DRUGINFO D03FGM 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzamide Investigative T27812 DRUGINFO D03HFH 1-(4-Benzylsulfanyl-phenyl)-propylamine Investigative T27812 DRUGINFO D04GHK 2-N-Hydroxyamino-1-(4-methylthiophenyl)butane Investigative T27812 DRUGINFO D04IZU 4-(2-((dimethylamino)methyl)phenoxy)benzonitrile Investigative T27812 DRUGINFO D04RUF 2-N-Ethylamino-1-(4-ethylthiophenyl)butane Investigative T27812 DRUGINFO D04VNR 2-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole Investigative T27812 DRUGINFO D05FMK 2-N-Propargylamino-1-(4-methylthiophenyl)propane Investigative T27812 DRUGINFO D05LLP 2-N-Hydroxyamino-1-(4-ethylthiophenyl)propane Investigative T27812 DRUGINFO D05MJO 2-(3-Methyl-piperazin-1-yl)-6-nitro-quinoline Investigative T27812 DRUGINFO D05REQ 3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile Investigative T27812 DRUGINFO D05UHO 2-N-Ethylamino-1-(4-ethylthiophenyl)propane Investigative T27812 DRUGINFO D05YHP 2-N-Propargylamino-1-(4-methylthiophenyl)butane Investigative T27812 DRUGINFO D07GLO 4-Allyl-6-nitro-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D07SZF 2-N-Ethylamino-1-(4-methylthiophenyl)butane Investigative T27812 DRUGINFO D07TEJ 1-(1-phenyl-2-(pyridin-4-yl)ethyl)piperazine Investigative T27812 DRUGINFO D09NVT 4-Benzyl-6-nitro-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D09PEZ 6,8-Dinitro-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D09YHS 1-Methyl-2-(4-phenylsulfanyl-phenyl)-ethylamine Investigative T27812 DRUGINFO D09ZAL 6,6-dimethyl-1-phenyl-3-aza-bicyclo[3.1.0]hexane Investigative T27812 DRUGINFO D0A0UC Cyclopentyl-(3,4-dichloro-phenyl)-acetonitrile Investigative T27812 DRUGINFO D0A3YK 1-(2-(naphthalen-2-yl)-1-phenylethyl)piperazine Investigative T27812 DRUGINFO D0B8BC 6-Chloro-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D0D2WN 2-N-Methylamino-1-(4-methylthiophenyl)butane Investigative T27812 DRUGINFO D0E2XW 1-fluoro-5-phenyl-3-aza-bicyclo[3.1.0]hexane Investigative T27812 DRUGINFO D0GZ5F CX-1001 Investigative T27812 DRUGINFO D0H7PI 2-N-Cyclopropylamino-1-(4-methylthiophenyl)butane Investigative T27812 DRUGINFO D0J1VS 4-Furan-2-yl-6-nitro-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D0J8DC 1-(2-(naphthalen-1-yl)-1-phenylethyl)piperazine Investigative T27812 DRUGINFO D0L4HU Cyclohexyl-(3,4-dichloro-phenyl)-acetonitrile Investigative T27812 DRUGINFO D0N1AZ 1-Methyl-4-p-tolyl-piperidine-4-carbonitrile Investigative T27812 DRUGINFO D0N7IH N*1*-(6-Nitro-quinolin-2-yl)-ethane-1,2-diamine Investigative T27812 DRUGINFO D0O8QM 2-N-Allylamino-1-(4-methylthiophenyl)propan Investigative T27812 DRUGINFO D0P0US 4-Chloro-6-nitro-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D0Q3EJ 2-N-Hydroxyamino-1-(4-ethylthiophenyl)butane Investigative T27812 DRUGINFO D0R8XV 2-N-Methylamino-1-(4-ethylthiophenyl)propane Investigative T27812 DRUGINFO D0SA1G 2-N-Ethylamino-1-(4-methylthiophenyl)propane Investigative T27812 DRUGINFO D0SD4O 2-N-Methylamino-1-(4-methylthiophenyl)propane Investigative T27812 DRUGINFO D0T7VU 2-N-(Isopropyl)amino-1-(4-methylthiophenyl)butane Investigative T27812 DRUGINFO D0VD4L 2-[1,4]Diazepan-1-yl-6-nitro-quinoline Investigative T27812 DRUGINFO D0VX1V 2-N-Methoxyamino-1-(4-methylthiophenyl)propane Investigative T27812 DRUGINFO D0W6WL 1-(1,3-diphenylpropyl)piperazine Investigative T27812 DRUGINFO D0X4FO 6-Nitro-2-piperazin-1-yl-4-vinyl-quinoline Investigative T27812 DRUGINFO D0X8DW 6-Nitro-4-phenyl-2-piperazin-1-yl-quinoline Investigative T27812 DRUGINFO D0X8GC N-cyclobutyl-N-(piperidin-4-yl)-2-naphthamide Investigative T27812 DRUGINFO D0Y6GQ 1-(1-phenyl-2-(pyridin-2-yl)ethyl)piperazine Investigative T27812 DRUGINFO D0Y7UJ 1-(2-(naphthalen-2-yl)ethyl)piperazine Investigative T27812 DRUGINFO D00KKN (2S,3S)-iodoreboxetine Investigative T27812 DRUGINFO D01BPR 1-benzylpiperidine hydrochloride Investigative T27812 DRUGINFO D01EIS 1-(1,2-diphenylethyl)piperazine Investigative T27812 DRUGINFO D01GSG (R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile Investigative T27812 DRUGINFO D01JVP (2R,3R)-iodoreboxetine Investigative T27812 DRUGINFO D01SHR ((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine Investigative T27812 DRUGINFO D02ANE 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane Investigative T27812 DRUGINFO D02LQG WIN-35065 Investigative T27812 DRUGINFO D03BUG 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane Investigative T27812 DRUGINFO D03MYV 2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile Investigative T27812 DRUGINFO D03ZDY 1-(2-(2-bromophenyl)-1-phenylethyl)piperazine Investigative T27812 DRUGINFO D04EXA Erythro-3,4-dichloromethylphenidate hydrochloride Investigative T27812 DRUGINFO D05VTT 3-(4-Trifluoromethylphenyl)-2-nortropene Investigative T27812 DRUGINFO D05WFQ norzotepine Investigative T27812 DRUGINFO D05ZFG (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane Investigative T27812 DRUGINFO D06PJD 3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine Investigative T27812 DRUGINFO D08IFQ 3-Phenyl-2-nortropene Investigative T27812 DRUGINFO D08LAY 1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine Investigative T27812 DRUGINFO D08MEN KF-A5 Investigative T27812 DRUGINFO D08MUX S33005 Investigative T27812 DRUGINFO D08RCH KF-A6 Investigative T27812 DRUGINFO D09DWM Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine Investigative T27812 DRUGINFO D09JRN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile Investigative T27812 DRUGINFO D09RCL (2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine Investigative T27812 DRUGINFO D09WVS 10R-hydroxylobelane Investigative T27812 DRUGINFO D09ZIU 1-phenyl-3-aza-bicyclo[3.1.0]hexane Investigative T27812 DRUGINFO D0A1HH 1-(1-phenyl-2-o-tolylethyl)piperazine Investigative T27812 DRUGINFO D0A7GW N-(piperidin-4-yl)-N-propyl-2-naphthamide Investigative T27812 DRUGINFO D0A9QT JNJ-28583867 Investigative T27812 DRUGINFO D0B1FM 3-(3,4-dichlorophenyl)-2-nortropene Investigative T27812 DRUGINFO D0B6UU 8R-hydroxylobel-9-ene Investigative T27812 DRUGINFO D0D8YY N-benzyl-N-isobutylpiperidin-4-amine Investigative T27812 DRUGINFO D0D9FA (2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine Investigative T27812 DRUGINFO D0E3DF (2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine Investigative T27812 DRUGINFO D0EO5P 1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine Investigative T27812 DRUGINFO D0EX2M 1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine Investigative T27812 DRUGINFO D0F8SA 8S-hydroxylobelane Investigative T27812 DRUGINFO D0I1ME 10R-hydroxylobel-7-ene Investigative T27812 DRUGINFO D0I4TO (S)-NORDULOXETINE Investigative T27812 DRUGINFO D0J4EF 1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane Investigative T27812 DRUGINFO D0KD9M (S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile Investigative T27812 DRUGINFO D0M4KN 10S-hydroxylobelane Investigative T27812 DRUGINFO D0N4YP 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline Investigative T27812 DRUGINFO D0NM1F (R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide Investigative T27812 DRUGINFO D0NW3Z COCAINE.HCL Investigative T27812 DRUGINFO D0P6SY MDL-28618 Investigative T27812 DRUGINFO D0Q0MN Threo-3,4-dichlororitalinol hydrochloride Investigative T27812 DRUGINFO D0S0EE 3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane Investigative T27812 DRUGINFO D0S9IO N-(2-oxazolemethyl)milnacipran Investigative T27812 DRUGINFO D0T5VG 2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran Investigative T27812 DRUGINFO D0T6XD 10S-hydroxylobel-7-ene Investigative T27812 DRUGINFO D0TE5Q Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride Investigative T27812 DRUGINFO D0TO4N 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane Investigative T27812 DRUGINFO D0US2X 3-(4-Fluorophenyl)-2-nortropene Investigative T27812 DRUGINFO D0VC1K N,N-dimethyl(2-phenoxyphenyl)methanamine Investigative T27812 DRUGINFO D0W9JK (S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide Investigative T27812 DRUGINFO D0Y0BB 3-(4-Chlorophenyl)-2-nortropene Investigative T27812 DRUGINFO D0Z0LP 8R-hydroxylobelane Investigative T27812 DRUGINFO D0Z4IH 8S-hydroxylobel-9-ene Investigative T27812 DRUGINFO D0Z6YA 1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine Investigative T27812 DRUGINFO D00FMX 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine Investigative T27812 DRUGINFO D00GDI 2-(N-tert-Butylamino)-3',4'-dichloropropiophenone Investigative T27812 DRUGINFO D00VUT D-257C Investigative T27812 DRUGINFO D01AOI 6-(piperidin-4-ylmethoxy)-2-naphthonitrile Investigative T27812 DRUGINFO D02ENH (R)-Norfluoxetine Investigative T27812 DRUGINFO D02ICX PYROVALERONE Investigative T27812 DRUGINFO D02TMK METHYLENEDIOXYAMPHETAMINE Investigative T27812 DRUGINFO D02UUC 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane Investigative T27812 DRUGINFO D02YOO NISOXETINE Investigative T27812 DRUGINFO D02YSN 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran Investigative T27812 DRUGINFO D02ZIQ 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one Investigative T27812 DRUGINFO D03BQV 1S,2R-milnacipran Investigative T27812 DRUGINFO D03HQF 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran Investigative T27812 DRUGINFO D03JOX 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T27812 DRUGINFO D03ZFX D-254C Investigative T27812 DRUGINFO D04KZX 2-(tert-Butylamino)-3',4'-dichlorobutyrophenone Investigative T27812 DRUGINFO D05LKO 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine Investigative T27812 DRUGINFO D05UMA (R)-DULOXETINE Investigative T27812 DRUGINFO D06CMJ Para-chloroamphetamine Investigative T27812 DRUGINFO D06EMC PF-18298 Investigative T27812 DRUGINFO D06KNV [3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine Investigative T27812 DRUGINFO D06QGD 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T27812 DRUGINFO D06UDU 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine Investigative T27812 DRUGINFO D06WIV Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine Investigative T27812 DRUGINFO D07DMN 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine Investigative T27812 DRUGINFO D07DWS 1-(2-(2-fluorobenzyloxy)phenyl)piperazine Investigative T27812 DRUGINFO D07RQT 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane Investigative T27812 DRUGINFO D07SAA 2-(N-Cyclopropylamino)-3-chloropropiophenone Investigative T27812 DRUGINFO D07ZOP 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T27812 DRUGINFO D08AWN (S)-Norfluoxetine Investigative T27812 DRUGINFO D08TJY D-257A Investigative T27812 DRUGINFO D09QZM 2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran Investigative T27812 DRUGINFO D09ZAT 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol Investigative T27812 DRUGINFO D0G1XP 2-(tert-Butylamino)-3',4'-dichloropentanophenone Investigative T27812 DRUGINFO D0G5RH WIN-35066-2 Investigative T27812 DRUGINFO D0G8UA (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol Investigative T27812 DRUGINFO D0GG2J 1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T27812 DRUGINFO D0H2TS 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine Investigative T27812 DRUGINFO D0H4AD 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one Investigative T27812 DRUGINFO D0I9KV 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T27812 DRUGINFO D0IB6Y 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran Investigative T27812 DRUGINFO D0J0ES 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol Investigative T27812 DRUGINFO D0J5AR 2-(2'-Aminoethyl)-5-benzyltetrahydrofuran Investigative T27812 DRUGINFO D0K6ZT 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine Investigative T27812 DRUGINFO D0L0AY 2-(Aminomethyl)-5-phenethyltetrahydrofuran Investigative T27812 DRUGINFO D0L7BK 1-(1,4-diphenylbutan-2-yl)piperazine Investigative T27812 DRUGINFO D0LD1X D-211B Investigative T27812 DRUGINFO D0N0TQ 2-Aminomethyl-5-(phenyl)tetrahydrofuran Investigative T27812 DRUGINFO D0N2RJ 1-(2-(3-fluorophenoxy)phenyl)piperazine Investigative T27812 DRUGINFO D0N3DD [3H]WIN35428 Investigative T27812 DRUGINFO D0NY4W 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T27812 DRUGINFO D0O9BL 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T27812 DRUGINFO D0Q6SH 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine Investigative T27812 DRUGINFO D0R8EV 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one Investigative T27812 DRUGINFO D0RT9B 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran Investigative T27812 DRUGINFO D0S9AY 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine Investigative T27812 DRUGINFO D0SB6Y D-211A Investigative T27812 DRUGINFO D0SN6R (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine Investigative T27812 DRUGINFO D0T8BU 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol Investigative T27812 DRUGINFO D0V0PR 4-(2-(phenoxymethyl)phenyl)piperidine Investigative T27812 DRUGINFO D0V3LR D-166A Investigative T27812 DRUGINFO D0W8BJ Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine Investigative T27812 DRUGINFO D0WB6P R-NORDULOXETINE Investigative T27812 DRUGINFO D0X8LG 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one Investigative T27812 DRUGINFO D0Y3BI 2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran Investigative T27812 DRUGINFO D0Y5CG 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine Investigative T27812 DRUGINFO D0Z4UF RTI-219 Investigative T27812 DRUGINFO D0Z9OX 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine Investigative T27812 DRUGINFO D0ZE4C 2-(N-Cyclopentylamino)-3'-methoxypropiophenone Investigative T27812 DRUGINFO D0ZU5W 1-(2-(benzyloxy)phenyl)piperazine Investigative T27812 DRUGINFO D00DEH 4-(2-(3-chlorophenoxy)phenyl)piperidine Investigative T27812 DRUGINFO D00HCC 1-(2-phenoxyphenyl)piperazine Investigative T27812 DRUGINFO D00KRQ 4-(2-phenoxyphenyl)piperidine Investigative T27812 DRUGINFO D01ABR 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine Investigative T27812 DRUGINFO D01FFX 4-((naphthalen-2-yloxy)methyl)piperidine Investigative T27812 DRUGINFO D01JYY (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide Investigative T27812 DRUGINFO D01MBF 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine Investigative T27812 DRUGINFO D01YNZ 4-(2-(benzyloxy)phenyl)piperidine Investigative T27812 DRUGINFO D03DQQ 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine Investigative T27812 DRUGINFO D04NDO 4-(2-(2-fluorobenzyloxy)phenyl)piperidine Investigative T27812 DRUGINFO D04NKQ 4-(2-(4-fluorophenoxy)phenyl)piperidine Investigative T27812 DRUGINFO D04ZPF 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine Investigative T27812 DRUGINFO D05LJC 4-(2-(benzyloxy)-3-fluorophenyl)piperidine Investigative T27812 DRUGINFO D08EKQ 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T27812 DRUGINFO D08JLB 4-(2-(benzyloxy)-6-fluorophenyl)piperidine Investigative T27812 DRUGINFO D08SCH 2-Amino-1-(4-methylthiophenyl)propane Investigative T27812 DRUGINFO D09FIC 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T27812 DRUGINFO D09IIH 4-(3-fluoro-2-phenoxyphenyl)piperidine Investigative T27812 DRUGINFO D0CG2Y 2-phenoxy-3-(piperidin-4-yl)pyridine Investigative T27812 DRUGINFO D0D5QV O-DESMETHYL TRAMADOL Investigative T27812 DRUGINFO D0E3DM (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine Investigative T27812 DRUGINFO D0E6PQ 4-(2-fluoro-6-phenoxyphenyl)piperidine Investigative T27812 DRUGINFO D0F0BS 3alpha-(bis-chloro-phenylmethoxy)tropane Investigative T27812 DRUGINFO D0F6GB 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine Investigative T27812 DRUGINFO D0IC4J 4-(2-(3-fluorophenoxy)phenyl)piperidine Investigative T27812 DRUGINFO D0KT2M 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine Investigative T27812 DRUGINFO D0M3TK 1-(2-(4-fluorophenoxy)phenyl)piperazine Investigative T27812 DRUGINFO D0R3TA 4-(2-(4-fluorobenzyloxy)phenyl)piperidine Investigative T27812 DRUGINFO D0S4JT 1-(2-(phenoxymethyl)phenyl)piperazine Investigative T27812 DRUGINFO D0U7OD PF-526014 Investigative T27812 DRUGINFO D0W8YO 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine Investigative T27812 DRUGINFO D0XF5P (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine Investigative T27812 DRUGINFO D0Y8UC Difluorobenztropine Investigative T27812 DRUGINFO D06QIQ 7-(piperidin-4-ylmethoxy)-2-naphthonitrile Investigative T27812 DRUGINFO D0FU5E S-34324 Investigative T27812 DRUGINFO D0N2KU PF-3409409 Investigative T27812 DRUGINFO D08BCF QUIPAZINE Investigative T27812 DRUGINFO D0F5NJ METHYLENEDIOXYMETHAMPHETAMINE Investigative T27812 DRUGINFO D0I4ME MMDA Investigative T27812 DRUGINFO D0R7ZC Beta-methoxyamphetamine Investigative T27812 DRUGINFO D0PN9R R-226161 Investigative T27812 DRUGINFO D0L5MW (+/-)-nantenine Investigative T27812 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T07137 TARGETID T07137 T07137 FORMERID TTDS00314 T07137 UNIPROID HPPD_HUMAN T07137 TARGNAME Hydroxyphenylpyruvate dioxygenase (HPD) T07137 GENENAME HPD T07137 TARGTYPE Successful T07137 SYNONYMS HPPDase; HPD; F Alloantigen; 4HPPD T07137 FUNCTION Key enzyme in the degradation of tyrosine. T07137 PDBSTRUC 5EC3; 3ISQ T07137 BIOCLASS Single donor oxidoreductase T07137 ECNUMBER EC 1.13.11.27 T07137 SEQUENCE MTTYSDKGAKPERGRFLHFHSVTFWVGNAKQAASFYCSKMGFEPLAYRGLETGSREVVSHVIKQGKIVFVLSSALNPWNKEMGDHLVKHGDGVKDIAFEVEDCDYIVQKARERGAKIMREPWVEQDKFGKVKFAVLQTYGDTTHTLVEKMNYIGQFLPGYEAPAFMDPLLPKLPKCSLEMIDHIVGNQPDQEMVSASEWYLKNLQFHRFWSVDDTQVHTEYSSLRSIVVANYEESIKMPINEPAPGKKKSQIQEYVDYNGGAGVQHIALKTEDIITAIRHLRERGLEFLSVPSTYYKQLREKLKTAKIKVKENIDALEELKILVDYDEKGYLLQIFTKPVQDRPTLFLEVIQRHNHQGFGAGNFNSLFKAFEEEQNLRGNLTNMETNGVVPGM T07137 DRUGINFO D0V1UW Nitisinone Approved T07137 DRUGINFO D08QTP BMS-433771 Terminated T07137 DRUGINFO D01TZT 2-(2-Nitro-benzoyl)-cyclohexane-1,3-dione Investigative T07137 DRUGINFO D02CAT 2-(2-Iodo-benzoyl)-cyclohexane-1,3-dione Investigative T07137 DRUGINFO D03FPH 2-(2-Bromo-benzoyl)-cyclohexane-1,3-dione Investigative T07137 DRUGINFO D04QZR Diketonitrile Investigative T07137 DRUGINFO D07IWD 2-(2-Methoxy-benzoyl)-cyclohexane-1,3-dione Investigative T07137 DRUGINFO D0A2EE 3-Hydroxy-4-phenyl-5H-furan-2-one Investigative T07137 DRUGINFO D0B7WF (4-Hydroxy-phenoxy)-acetic acid Investigative T07137 DRUGINFO D0C2WX 2-(2-Chloro-benzoyl)-cyclohexane-1,3-dione Investigative T07137 DRUGINFO D0I6SI 3-hydroxy-2-propionylcyclohex-2-enone Investigative T07137 DRUGINFO D0K3BO 2-Acetyl-cyclohexane-1,3-dione Investigative T07137 DRUGINFO D0L8FW 2-(2-Methyl-benzoyl)-cyclohexane-1,3-dione Investigative T07137 DRUGINFO D0MZ9D 2-Propionyl-cyclohexane-1,3-dione Investigative T07137 DRUGINFO D0Q7OY 2-Cyclopropanecarbonyl-cyclohexane-1,3-dione Investigative T07137 DRUGINFO D0R0XE 2-acetyl-3-hydroxycyclohex-2-enone Investigative T07137 DRUGINFO D0F2ME Acetate Ion Investigative T62292 TARGETID T62292 T62292 FORMERID TTDR01178 T62292 UNIPROID GBRA3_HUMAN T62292 TARGNAME GABA(A) receptor alpha-3 (GABRA3) T62292 GENENAME GABRA3 T62292 TARGTYPE Successful T62292 SYNONYMS Gamma-aminobutyric acid receptor subunit alpha-3; GABA-A receptor alpha 3; GABA(A)Gamma-aminobutyric-acid receptor alpha-3 subunit precursor receptor; GABA(A) receptor subunit alpha-3 T62292 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. T62292 BIOCLASS Neurotransmitter receptor T62292 SEQUENCE MIITQTSHCYMTSLGILFLINILPGTTGQGESRRQEPGDFVKQDIGGLSPKHAPDIPDDSTDNITIFTRILDRLLDGYDNRLRPGLGDAVTEVKTDIYVTSFGPVSDTDMEYTIDVFFRQTWHDERLKFDGPMKILPLNNLLASKIWTPDTFFHNGKKSVAHNMTTPNKLLRLVDNGTLLYTMRLTIHAECPMHLEDFPMDVHACPLKFGSYAYTTAEVVYSWTLGKNKSVEVAQDGSRLNQYDLLGHVVGTEIIRSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRSWAWEGKKVPEALEMKKKTPAAPAKKTSTTFNIVGTTYPINLAKDTEFSTISKGAAPSASSTPTIIASPKATYVQDSPTETKTYNSVSKVDKISRIIFPVLFAIFNLVYWATYVNRESAIKGMIRKQ T62292 DRUGINFO D0D5GD Flumazenil Approved T62292 DRUGINFO D0B9OG Adipiplon Phase 2 T62292 DRUGINFO D0M2WZ NS-2710 Phase 2 T62292 DRUGINFO D0C9XA GSK683699 Phase 2 T62292 DRUGINFO D0Z9HW AZD6280 Discontinued in Phase 1 T62292 DRUGINFO D09IHE MRK016 Investigative T62292 DRUGINFO D09YOU MK-0343 Investigative T62292 DRUGINFO D03PBN tetrahydrodeoxycorticosterone Investigative T62292 DRUGINFO D03ZWB alpha3IA Investigative T62292 DRUGINFO D06SOQ alpha5IA Investigative T62292 DRUGINFO D07JXC [18F]fluoroethylflumazenil Investigative T62292 DRUGINFO D0GQ1S DMCM Investigative T62292 DRUGINFO D0Q1ZT TP003 Investigative T62292 DRUGINFO D0T9DS [35S]TBPS Investigative T62292 DRUGINFO D01UAS 6-bromo-3-ethoxycarbonyl-4-quinolone Investigative T62292 DRUGINFO D02CZO 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone Investigative T62292 DRUGINFO D03LMR 6-benzyl-3-ethoxycarbonyl-4-quinolone Investigative T62292 DRUGINFO D0H4GQ RY-066 Investigative T62292 DRUGINFO D01CUR 3-Ethoxy-9H-beta-carboline Investigative T62292 DRUGINFO D01RLF 9H-beta-Carboline-3-carboxylic acid ethyl ester Investigative T62292 DRUGINFO D03PPZ Beta-Carboline-3-carboxylic acid t-butyl ester Investigative T62292 DRUGINFO D03TMD Barbituric acid derivative Investigative T62292 DRUGINFO D06WMM 3-Butoxy-9H-beta-carboline Investigative T62292 DRUGINFO D08BOP 3-Propoxy-9H-beta-carboline Investigative T62292 DRUGINFO D08BXK 3-(3-Methyl-butoxy)-9H-beta-carboline Investigative T62292 DRUGINFO D09MYJ 3-Isobutoxy-9H-beta-carboline Investigative T62292 DRUGINFO D0C6WO Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate Investigative T62292 DRUGINFO D0D4MM Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate Investigative T62292 DRUGINFO D0E7PY Ro-4938581 Investigative T62292 DRUGINFO D0O9MG L-655708 Investigative T62292 DRUGINFO D0P3BU 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole Investigative T62292 DRUGINFO D0R5OU 3-(benzyloxy)-9H-pyrido[3,4-b]indole Investigative T62292 DRUGINFO D01IHM CI-218872 Investigative T62292 DRUGINFO D07NKO 5-[(1R)-1-ammonioethyl]isoxazol-3-olate Investigative T62292 DRUGINFO D09ACO (2E,4S)-4-ammoniopent-2-enoate Investigative T62292 DRUGINFO D0A8EU (4R)-4-ammoniopentanoate Investigative T62292 DRUGINFO D0N0ZK (4S)-4-ammoniopentanoate Investigative T62292 DRUGINFO D0S5PS 5-[(1S)-1-ammonioethyl]isoxazol-3-olate Investigative T62292 DRUGINFO D0VW5M piperidine-4-sulphonic acid Investigative T62292 DRUGINFO D00WHO Ro-15-3505 Investigative T62292 DRUGINFO D0AC2H isonipecotic acid Investigative T62292 DRUGINFO D0M4CP [3H]Ro154513 Investigative T62292 DRUGINFO D0M9RM [3H]CGS8216 Investigative T62292 DRUGINFO D06HRX AMENTOFLAVONE Investigative T62292 DRUGINFO D0P0TI TBPS Investigative T77796 TARGETID T77796 T77796 FORMERID TTDR01197 T77796 UNIPROID TRFR_HUMAN T77796 TARGNAME Thyrotropin-releasing hormone receptor (TRHR) T77796 GENENAME TRHR T77796 TARGTYPE Successful T77796 SYNONYMS Thyroliberin receptor; TRH-R T77796 FUNCTION Receptor for thyrotropin-releasing hormone. This receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. T77796 BIOCLASS GPCR rhodopsin T77796 SEQUENCE MENETVSELNQTQLQPRAVVALEYQVVTILLVLIICGLGIVGNIMVVLVVMRTKHMRTPTNCYLVSLAVADLMVLVAAGLPNITDSIYGSWVYGYVGCLCITYLQYLGINASSCSITAFTIERYIAICHPIKAQFLCTFSRAKKIIIFVWAFTSLYCMLWFFLLDLNISTYKDAIVISCGYKISRNYYSPIYLMDFGVFYVVPMILATVLYGFIARILFLNPIPSDPKENSKTWKNDSTHQNTNLNVNTSNRCFNSTVSSRKQVTKMLAVVVILFALLWMPYRTLVVVNSFLSSPFQENWFLLFCRICIYLNSAINPVIYNLMSQKFRAAFRKLCNCKQKPTEKPANYSVALNYSVIKESDHFSTELDDITVTDTYLSATKVSFDDTCLASEVSFSQS T77796 DRUGINFO D08BTB protirelin Approved T77796 DRUGINFO D02QBT AZETIRELIN Phase 3 T77796 DRUGINFO D05NBD MONTIRELIN TETRAHYDRATE Discontinued in Preregistration T77796 DRUGINFO D0J8RM Posatirelin Discontinued in Phase 3 T77796 DRUGINFO D03BHO JTP-2942 Discontinued in Phase 2 T77796 DRUGINFO D04JSS MK-771 Investigative T77796 DRUGINFO D06UIU CORYMBONE B Investigative T77796 DRUGINFO D0S9VG C4X-101 Investigative T77796 DRUGINFO D0YA7R MeTRH Investigative T45262 TARGETID T45262 T45262 FORMERID TTDC00073 T45262 UNIPROID CRFR1_HUMAN T45262 TARGNAME Corticotropin-releasing factor receptor 1 (CRHR1) T45262 GENENAME CRHR1 T45262 TARGTYPE Successful T45262 SYNONYMS Corticotropin-releasing hormone type 1 receptor; Corticotropin-releasing hormone receptor 1; CRHR1; CRH-R 1; CRF1; CRF-R1; CRF-R; CRF-1 receptor; CRF receptor T45262 FUNCTION G-protein coupled receptor for CRH (corticotropin- releasing factor) and UCN (urocortin). Has high affinity for CRH and UCN. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and down-stream effectors, such as adenylate cyclase. Promotes the activation of adenylate cyclase, leading to increased intracellular cAMP levels. Inhibits the activity of the calcium channel CACNA1H. Required for normal embryonic development of the adrenal gland and for normal hormonal responses to stress. Plays a role in the response to anxiogenic stimuli. T45262 PDBSTRUC 4Z9G; 4K5Y; 3EHU; 3EHT; 3EHS T45262 BIOCLASS GPCR secretin T45262 SEQUENCE MGGHPQLRLVKALLLLGLNPVSASLQDQHCESLSLASNISGLQCNASVDLIGTCWPRSPAGQLVVRPCPAFFYGVRYNTTNNGYRECLANGSWAARVNYSECQEILNEEKKSKVHYHVAVIINYLGHCISLVALLVAFVLFLRLRPGCTHWGDQADGALEVGAPWSGAPFQVRRSIRCLRNIIHWNLISAFILRNATWFVVQLTMSPEVHQSNVGWCRLVTAAYNYFHVTNFFWMFGEGCYLHTAIVLTYSTDRLRKWMFICIGWGVPFPIIVAWAIGKLYYDNEKCWFGKRPGVYTDYIYQGPMILVLLINFIFLFNIVRILMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDEVSRVVFIYFNSFLESFQGFFVSVFYCFLNSEVRSAIRKRWHRWQDKHSIRARVARAMSIPTSPTRVSFHSIKQSTAV T45262 DRUGINFO D0B9JO Telavancin Approved T45262 DRUGINFO D0ZM5O Pexacerfont Phase 2/3 T45262 DRUGINFO D05IIN SSR125543 Phase 2 T45262 DRUGINFO D08UYM ONO-2333Ms Phase 2 T45262 DRUGINFO D0ZC0M GSK561679 Phase 2 T45262 DRUGINFO DF91UW Tildacerfont Phase 2 T45262 DRUGINFO D0J1FB GSK586529 Phase 1 T45262 DRUGINFO D01KKE GW876008 Discontinued in Phase 2 T45262 DRUGINFO D0R2KV CP-316,311 Discontinued in Phase 2 T45262 DRUGINFO D0M5DH CRA1000 Preclinical T45262 DRUGINFO D00PYP NBI-37582 Terminated T45262 DRUGINFO D03KJS Antalarmin Terminated T45262 DRUGINFO D0G0GI DMP-696 Terminated T45262 DRUGINFO D02BYS N-mesityl-6-methyl-3-tosylpyridin-2-amine Investigative T45262 DRUGINFO D02IOC CP154,526 Investigative T45262 DRUGINFO D03KTU BMS-561388 Investigative T45262 DRUGINFO D06FIF CP-376395 Investigative T45262 DRUGINFO D0B2AH DMP-695/696 Investigative T45262 DRUGINFO D0C0AS PD-171729 Investigative T45262 DRUGINFO D0C9BZ N-mesityl-4,6-dimethyl-3-tosylpyridin-2-amine Investigative T45262 DRUGINFO D04KWH Des-Arg(9)-[Leu(8)]-BK Investigative T47768 TARGETID T47768 T47768 FORMERID TTDS00126 T47768 UNIPROID OPRM_HUMAN T47768 TARGNAME Opioid receptor mu (MOP) T47768 GENENAME OPRM1 T47768 TARGTYPE Successful T47768 SYNONYMS hMOP; Mu-type opioid receptor; Mu opioid receptor; Mu opiate receptor; MOR1A; MOR1; MOR-1; M-OR-1 T47768 FUNCTION Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity. Receptor for endogenous opioids such as beta-endorphin and endomorphin. T47768 BIOCLASS GPCR rhodopsin T47768 SEQUENCE MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCPPTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIYVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP T47768 DRUGINFO D03HCZ Propoxyphene Hydrochloride Approved T47768 DRUGINFO D05PIZ Levomethadyl Acetate Approved T47768 DRUGINFO D05ZTJ Anileridine Hydrochloride Approved T47768 DRUGINFO D06AWE Buprenorphine Approved T47768 DRUGINFO D07LCF Naloxegol Approved T47768 DRUGINFO D0D7KC Alvimopan Approved T47768 DRUGINFO D0E1WI Fentanyl Approved T47768 DRUGINFO D0G5QB Alfentanil Approved T47768 DRUGINFO D0GR0T Methadyl Acetate Approved T47768 DRUGINFO D0H2JP Buprenorphine + naloxone Approved T47768 DRUGINFO D0J2TN Diphenoxylate Approved T47768 DRUGINFO D0Q2HO Naldemedine Tosylate Approved T47768 DRUGINFO D0T5OX Remifentanil Approved T47768 DRUGINFO D0WE3O Morphine Approved T47768 DRUGINFO D0X3FX Naloxone Approved T47768 DRUGINFO D0X5KF Hydrocodone Approved T47768 DRUGINFO D0X6HD Anileridine Approved T47768 DRUGINFO D02RXG Nalfurafine hcl Approved T47768 DRUGINFO D03SKD Oxycodone Approved T47768 DRUGINFO D03YVO Methylnaltrexone bromide Approved T47768 DRUGINFO D04JHN Hydromorphone Approved T47768 DRUGINFO D09ZXR Eluxadoline Approved T47768 DRUGINFO D0HF0W Levopropoxyphene Napsylate Anhydrous Approved T47768 DRUGINFO D0K4MH Tapentadol hydrochloride Approved T47768 DRUGINFO D01UXW Morphine-6-glucuronide Phase 3 T47768 DRUGINFO D03TBJ GRT-6005 Phase 3 T47768 DRUGINFO D0K2ID NKTR-181 Phase 3 T47768 DRUGINFO D02INX TD-1211 Phase 2 T47768 DRUGINFO D04PUO OPNT001 Phase 2 T47768 DRUGINFO D0T0ZW ALKS33 Phase 2 T47768 DRUGINFO D0V5WL Met-enkephalin Phase 2 T47768 DRUGINFO DW7OF1 ORP-101 Phase 2 T47768 DRUGINFO D03PJU Carfentanil Phase 2 T47768 DRUGINFO D0LU5Q TPM-1/Morphine Phase 2 T47768 DRUGINFO D05ONA Cyt-1010 Phase 1 T47768 DRUGINFO D0G1YO GSK1521498 Phase 1 T47768 DRUGINFO D0OK6F TRV734 Phase 1 T47768 DRUGINFO D0W4YO NOCICEPTIN Phase 1 T47768 DRUGINFO D00HBR AIKO-150 Phase 1 T47768 DRUGINFO D01AKU MCP-201 Phase 1 T47768 DRUGINFO D06EXA SALVINORIN A Phase 1 T47768 DRUGINFO D01PCE BCH-2687 Discontinued in Phase 2 T47768 DRUGINFO D01SJC Transdur-sufentanil Discontinued in Phase 2 T47768 DRUGINFO D09MTC ADL-5945 Discontinued in Phase 2 T47768 DRUGINFO D0IW4R TREFENTANIL HYDROCHLORIDE Discontinued in Phase 2 T47768 DRUGINFO D0N1HL Frakefamide Discontinued in Phase 2 T47768 DRUGINFO D0O0AH MIRFENTANIL HYDROCHLORIDE Discontinued in Phase 2 T47768 DRUGINFO D0G1YN DPI-3290 Discontinued in Phase 2 T47768 DRUGINFO D0Y8SK Dynorphin a Discontinued in Phase 2 T47768 DRUGINFO D03MNS ADL-7445 Discontinued in Phase 1 T47768 DRUGINFO D0T9MQ KN-203 Discontinued in Phase 1 T47768 DRUGINFO D0J5XZ VP004 Discontinued in Phase 1 T47768 DRUGINFO D0X6SZ GNTI Preclinical T47768 DRUGINFO D0C2QF LY-25582 Preclinical T47768 DRUGINFO D0E8SE 443C81 Terminated T47768 DRUGINFO D0J8XO BCH-150 Terminated T47768 DRUGINFO D0K9TC Sameridine Terminated T47768 DRUGINFO D0PE1A DBO-11 Terminated T47768 DRUGINFO D0XH1H DBO-17 Terminated T47768 DRUGINFO D0LX5D BIPHALIN Terminated T47768 DRUGINFO D08YUP SB-213698 Terminated T47768 DRUGINFO D0W8TS SNF-9007 Terminated T47768 DRUGINFO D00NZP Dmt-Sar-Phe-D-2-Nal-NH Investigative T47768 DRUGINFO D00PQS NE-2 Investigative T47768 DRUGINFO D00PYB CODEINONE Investigative T47768 DRUGINFO D00YMN AIKO-152 Investigative T47768 DRUGINFO D01ESN [Tyr-Pro-Phe-Phe-NH-]2 Investigative T47768 DRUGINFO D01MHO DC6S Investigative T47768 DRUGINFO D01MKM Tyr-Pro-Hfe-Phe-NH2 Investigative T47768 DRUGINFO D02VUL AIKO-151 Investigative T47768 DRUGINFO D02YXR MM3A6S Investigative T47768 DRUGINFO D03BUD BREMAZOCINE Investigative T47768 DRUGINFO D03NCF Tyr-Pro-Hfe-Pro-NH2 Investigative T47768 DRUGINFO D03PCP NCT-400 Investigative T47768 DRUGINFO D04IHL Tyr-Pro-D-(NMe)Phe-D-Pro-NH2 Investigative T47768 DRUGINFO D04JCJ 6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide Investigative T47768 DRUGINFO D04MYP Tyr-Pro-Phe-Phg-NH2 Investigative T47768 DRUGINFO D05CRC SL-3111 Investigative T47768 DRUGINFO D05ETG Tyr-Pro-Phe-D-Phg-NH2 Investigative T47768 DRUGINFO D05HOH Tyr-Sar-Phe-D-2-Nal-NH2 Investigative T47768 DRUGINFO D05XCV Ac-D-pro-L-Phe-D-trp-L-Phe-NH2 Investigative T47768 DRUGINFO D05XPU [D-Ala2]Met-enkephalinamide Investigative T47768 DRUGINFO D05YXS ORIPAVINE Investigative T47768 DRUGINFO D06ESC YGGWL-NH2 Investigative T47768 DRUGINFO D06LCW KIN-4044 Investigative T47768 DRUGINFO D06QLG Tyr-D-Ala-Gly-NMePhe Investigative T47768 DRUGINFO D06YVE M3B6S Investigative T47768 DRUGINFO D07GZG Endomorphins Investigative T47768 DRUGINFO D07UJV DM3A6S Investigative T47768 DRUGINFO D07XXX Tyr-Pro-Phe-Hfe-NH2 Investigative T47768 DRUGINFO D08QSN (+/-)-TRANS-U-50488 METHANESULFONATE Investigative T47768 DRUGINFO D08UZJ 3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol Investigative T47768 DRUGINFO D09FVG AKUAMMINE Investigative T47768 DRUGINFO D09MXM Semorphone Investigative T47768 DRUGINFO D09TCT YGWFL-NH2 Investigative T47768 DRUGINFO D0A1XG YRFB Investigative T47768 DRUGINFO D0C0FG NRT-300 Investigative T47768 DRUGINFO D0C1AN H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2 Investigative T47768 DRUGINFO D0C2ZW Tyr-Pro-Phg-Pro-NH2 Investigative T47768 DRUGINFO D0D0XP C6S Investigative T47768 DRUGINFO D0D1VB Tyr-Pro-Phe-D-2-Nal-NH2 Investigative T47768 DRUGINFO D0E7CA Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2 Investigative T47768 DRUGINFO D0F8CD Tyr-Pro-Phe-D-Ala-Bn Investigative T47768 DRUGINFO D0G1IF naloxonazine Investigative T47768 DRUGINFO D0G2BN Tyr-Pro-Phg-Phe-NH2 Investigative T47768 DRUGINFO D0G2YV KNT-5 Investigative T47768 DRUGINFO D0HL7Q N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2 Investigative T47768 DRUGINFO D0I1ZN Ac-L-Phe-D-trp-L-Phe-D-pro-NH2 Investigative T47768 DRUGINFO D0IC5F DM3B6S Investigative T47768 DRUGINFO D0IQ0S Tyr-Pro-Phe-Ala-Bn Investigative T47768 DRUGINFO D0IU2K YPAA-NH2 Investigative T47768 DRUGINFO D0J0ZU KIN-3031 Investigative T47768 DRUGINFO D0J5IR Tyr-Pro-Phe-D-Val-Bn Investigative T47768 DRUGINFO D0J9DO [Tyr-Pro-Phe-NH-CH2-]2 Investigative T47768 DRUGINFO D0JX3P YAWF-NH2 Investigative T47768 DRUGINFO D0KQ8A Tyr-Pro-Trp-D-Val-Bn Investigative T47768 DRUGINFO D0KW4Y H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2 Investigative T47768 DRUGINFO D0N3GU YPWA-NH2 Investigative T47768 DRUGINFO D0N5QC Ethylmorphine Investigative T47768 DRUGINFO D0O2LD THEBAINE Investigative T47768 DRUGINFO D0O7XU [Tyr-Pro-Phe-Phe-NH-CH2-]2 Investigative T47768 DRUGINFO D0P2DF Ac-YGGFL-NH2 Investigative T47768 DRUGINFO D0P2QV Tyr-(R)-spiro-Aba-Gly-Phe-NH2 Investigative T47768 DRUGINFO D0P7YV D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2 Investigative T47768 DRUGINFO D0R0OZ MORPHICEPTIN Investigative T47768 DRUGINFO D0R1MB DIHYDROAKUAMMINE Investigative T47768 DRUGINFO D0R2VL 6-(2-benzylisoindolin-5-yloxy)nicotinamide Investigative T47768 DRUGINFO D0R6VX Tyr-Pro-Trp-Gly-Bn Investigative T47768 DRUGINFO D0S3TZ CYPRODIME Investigative T47768 DRUGINFO D0S5BJ MORPHINONE Investigative T47768 DRUGINFO D0S6BX PL017 Investigative T47768 DRUGINFO D0TA3V ADC-5510 Investigative T47768 DRUGINFO D0TT5V MM3B6S Investigative T47768 DRUGINFO D0V0PY M3S Investigative T47768 DRUGINFO D0W3PR Tyr-Pro-Trp-D-Ala-Bn Investigative T47768 DRUGINFO D0WT7H Beta-funaltrexamine Investigative T47768 DRUGINFO D0WX3N KRP-110 Investigative T47768 DRUGINFO D0X1SN H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2 Investigative T47768 DRUGINFO D0X4RU KRP-100 Investigative T47768 DRUGINFO D0Z9YE [Tyr-Pro-Phe-NH-]2 Investigative T47768 DRUGINFO D00FXL H-Aba-ser-Gly-Phe-Leu-Thr-OH Investigative T47768 DRUGINFO D00FZN Tyr-(R)-Aba-Gly-Phe-NH2 Investigative T47768 DRUGINFO D00LLO H-Dmt-Tic-Lys-NH-Ph Investigative T47768 DRUGINFO D00MEM H-Dmt-Tic-Gly-NH-CH2-Bid Investigative T47768 DRUGINFO D00QLH H-Dmt-Tic-D-Asp-N(Me)-Ph Investigative T47768 DRUGINFO D00WBU H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid Investigative T47768 DRUGINFO D00WEV H-Dmt-Tic-Glu-Dap(6DMN)-NH(2) Investigative T47768 DRUGINFO D00XQV Tyr-Pro-D-Phe-Pro-NH2 Investigative T47768 DRUGINFO D01HOP H-mCpa-ala-Gly-Phe-leu-OH Investigative T47768 DRUGINFO D01JSA H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2 Investigative T47768 DRUGINFO D01MFM H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH Investigative T47768 DRUGINFO D01SDX H-Aba-ala-Gly-Phe-Met-OH Investigative T47768 DRUGINFO D01TKS Tyr-D-Ala-Gly-Phe-Met-NH2 Investigative T47768 DRUGINFO D02GMU Tyr-Pro-3,5Dmp-Phe-NH2 Investigative T47768 DRUGINFO D02IQG H-Dmt-Tic-NH-CH2-CH2-NH2 Investigative T47768 DRUGINFO D02TPK Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG Investigative T47768 DRUGINFO D02WUZ Tyr-Pro-Phe-Phe-OCH2CH3 Investigative T47768 DRUGINFO D03BFH N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2 Investigative T47768 DRUGINFO D03BRB (H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2) Investigative T47768 DRUGINFO D03CKF H-Tyr-c[D-Orn-Aic-Glu]-NH2 Investigative T47768 DRUGINFO D03HXN 3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone Investigative T47768 DRUGINFO D03KAQ 2-Benzylaminomethyl-3-hydroxymorphinan Investigative T47768 DRUGINFO D03PMB PTI-601 Investigative T47768 DRUGINFO D03RSA M6S Investigative T47768 DRUGINFO D03VSJ Antanal 1 Investigative T47768 DRUGINFO D03WYO KETOCYCLAZOCINE Investigative T47768 DRUGINFO D03YDG UFP-502 Investigative T47768 DRUGINFO D04BII H-Dmt-Tic-D-Asp-NH-Ph Investigative T47768 DRUGINFO D04EZN Dimethylthiambutene Investigative T47768 DRUGINFO D04IIB H-Dmt-Tic-Asp-NH-Bzl Investigative T47768 DRUGINFO D04JCK Etorphine Investigative T47768 DRUGINFO D04KHE H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H Investigative T47768 DRUGINFO D04POA Tyr-Pro-L-Phe-Pro-NH2 Investigative T47768 DRUGINFO D04QXM Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2 Investigative T47768 DRUGINFO D04RPI Dmt-Pro-Trp-D-2-Nal-NH2 Investigative T47768 DRUGINFO D04SFK H-Tyr-Tic-Phe-Phe-OH Investigative T47768 DRUGINFO D04VJE 6-(2-phenethylisoindolin-5-yloxy)nicotinamide Investigative T47768 DRUGINFO D05AFV UFP-512 Investigative T47768 DRUGINFO D05EWZ SPIROINDANYLOXYMORPHONE Investigative T47768 DRUGINFO D05GFM Tyr-(NMe)Ala-L-Phe-D-Pro-NH2 Investigative T47768 DRUGINFO D05KIQ H-Dmt-Tic-Gly-N(Me)-Ph Investigative T47768 DRUGINFO D05KIS H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H Investigative T47768 DRUGINFO D05NYR H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH Investigative T47768 DRUGINFO D05ZYZ NalBzOH Investigative T47768 DRUGINFO D06BAU CTAP Investigative T47768 DRUGINFO D06EES Leucine-enkephalin Investigative T47768 DRUGINFO D06SZI MCL-457 Investigative T47768 DRUGINFO D06YMS DADLE Investigative T47768 DRUGINFO D07AUG H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Investigative T47768 DRUGINFO D07BPA 1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol Investigative T47768 DRUGINFO D07BXN Tyr-Pro-Dmt-Phe-NH2 Investigative T47768 DRUGINFO D07DTN H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2 Investigative T47768 DRUGINFO D07GQE Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 Investigative T47768 DRUGINFO D07JIQ H-Aba-Gly-Gly-Phe-Leu-OH Investigative T47768 DRUGINFO D07LXZ Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 Investigative T47768 DRUGINFO D07QUY C[L-Phe-D-pro-L-Tyr(OMe)-D-trp] Investigative T47768 DRUGINFO D08BOD D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP) Investigative T47768 DRUGINFO D08BST N-isobutylnoroxymorphone Investigative T47768 DRUGINFO D08CJB H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H Investigative T47768 DRUGINFO D08COK 1,10-bis-(Dmt-Tic-amino)decane Investigative T47768 DRUGINFO D08CXZ H-Dmt-Tic-NH-CH2-Bta Investigative T47768 DRUGINFO D08FGQ Tyr-Pro-D-Phg-Phe-NH2 Investigative T47768 DRUGINFO D08FYQ KNT-63 Investigative T47768 DRUGINFO D08LIT SB-0304 Investigative T47768 DRUGINFO D08SCK H-Dmt-Aba-Gly-NH-CH2-Ph Investigative T47768 DRUGINFO D08STW Tyr-Pro-L-(NMe)Phe-Pro-NH2 Investigative T47768 DRUGINFO D08VOC 3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone Investigative T47768 DRUGINFO D09BWX C[L-Phe-D-pro-L-Phe-D-trp] Investigative T47768 DRUGINFO D09CTG Ac-RYYRIK-K-(NH2)-YRFB Investigative T47768 DRUGINFO D09DAM H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph Investigative T47768 DRUGINFO D09GQP H-2',6'-dimethyltyrosine-Tic-OH Investigative T47768 DRUGINFO D09GSD H-Dmt-Aba-Gly-NH-CH2-Bid Investigative T47768 DRUGINFO D09KBQ FLUPERAMIDE Investigative T47768 DRUGINFO D09MBV H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me) Investigative T47768 DRUGINFO D09SBU C[L-Ala-D-pro-L-Phe-D-trp] Investigative T47768 DRUGINFO D0A9AJ H-mCpa-ser-Gly-Phe-Leu-Thr-OH Investigative T47768 DRUGINFO D0AJ9D H-Dmt-Tic-Lys(Z)-NH-Ph Investigative T47768 DRUGINFO D0B1JC Tyr-Pro-Phe-Phe-N(CH3)2 Investigative T47768 DRUGINFO D0C4QH Tyr-Pro-Mmp-Phe-NH Investigative T47768 DRUGINFO D0C5RC N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2 Investigative T47768 DRUGINFO D0C9XB D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 Investigative T47768 DRUGINFO D0D1WB Dynorphin(1-8) Investigative T47768 DRUGINFO D0D5VD C[L-Phe-D-pro-L-Tyr-D-trp] Investigative T47768 DRUGINFO D0D6KZ KNT-62 Investigative T47768 DRUGINFO D0D6OA DM6S Investigative T47768 DRUGINFO D0D8DZ H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid Investigative T47768 DRUGINFO D0D9RL (-)-eseroline Investigative T47768 DRUGINFO D0DN6A 1,4-bis-(Dmt-Tic-amino)butane Investigative T47768 DRUGINFO D0DO6P MR-2034 Investigative T47768 DRUGINFO D0E3RQ Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG Investigative T47768 DRUGINFO D0E7NL H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH Investigative T47768 DRUGINFO D0ED2I H-Dmt-Tic-Gly-NH-Ph Investigative T47768 DRUGINFO D0EG7I H-Dmt-Tic-Lys(Ac)-NH-Ph Investigative T47768 DRUGINFO D0EM9A DSLET Investigative T47768 DRUGINFO D0ES7P H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2 Investigative T47768 DRUGINFO D0F1XY H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc Investigative T47768 DRUGINFO D0F8AX 1-benzhydryl-4-cyclopropylpiperidin-4-ol Investigative T47768 DRUGINFO D0FT9J Tyr-Pro-Tmp-Phe-NH Investigative T47768 DRUGINFO D0H1BU H-Dmt-Tic-Gly-NH-Bzl Investigative T47768 DRUGINFO D0H2RF Tyr-Pro-Imp-Phe-NH2 Investigative T47768 DRUGINFO D0H3QK AMINOFENTANYL Investigative T47768 DRUGINFO D0H6AA M3Pr6S Investigative T47768 DRUGINFO D0H8WV Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2 Investigative T47768 DRUGINFO D0HF0I Tyr-Pro-Phe-Phe-NHCH3 Investigative T47768 DRUGINFO D0I1BJ Dmt-Pro-Phe-D-1-Nal-NH2 Investigative T47768 DRUGINFO D0I9IX Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2 Investigative T47768 DRUGINFO D0J2IK 3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone Investigative T47768 DRUGINFO D0J7XM DELTORPHIN-II Investigative T47768 DRUGINFO D0K0XT MR-1029 Investigative T47768 DRUGINFO D0K2OK Tyr-Pro-Dmp-Phe-NH2 Investigative T47768 DRUGINFO D0K4AC DELTORPHIN Investigative T47768 DRUGINFO D0L3DM Tyr-Pro-D-Phe-D-Pro-NH2 Investigative T47768 DRUGINFO D0L9NB H-Dmt-Tic-NH-CH2-ImidPh Investigative T47768 DRUGINFO D0M4DI MR-2266 Investigative T47768 DRUGINFO D0M6BL H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2 Investigative T47768 DRUGINFO D0M6CZ H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH Investigative T47768 DRUGINFO D0MP7Z Dmt-Pro-Phe-D-2-Nal-NH2 Investigative T47768 DRUGINFO D0MZ2A CTOP Investigative T47768 DRUGINFO D0N1AO H-Dmt-Tic-NH-CH2-Indn Investigative T47768 DRUGINFO D0N5TL Antanal 2 Investigative T47768 DRUGINFO D0NB7S Tyr-Pro-Phe-Phe-OC(CH3)3 Investigative T47768 DRUGINFO D0NE3U DERMORPHIN Investigative T47768 DRUGINFO D0O4KY Tyr-Pro-Phe-Phe-OCH3 Investigative T47768 DRUGINFO D0O7NC H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid Investigative T47768 DRUGINFO D0P1CP H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2 Investigative T47768 DRUGINFO D0P2GB MR-1526 Investigative T47768 DRUGINFO D0P2KV H-Dmt-Tic-Asp-N(Me)-Ph Investigative T47768 DRUGINFO D0P2LE 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide Investigative T47768 DRUGINFO D0P4PM H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2 Investigative T47768 DRUGINFO D0P5EI H-Dmt-Tic-Glu-NH-(CH2)5-NH2 Investigative T47768 DRUGINFO D0P5IH C[L-Tyr(OMe)-D-pro-L-Phe-D-trp] Investigative T47768 DRUGINFO D0P6AR Tyr-Pro-L-(NMe)Phe-D-Pro-NH2 Investigative T47768 DRUGINFO D0P8NZ H-Dmt-Tic-NH-CH2-Indl Investigative T47768 DRUGINFO D0PN1A H-Dmt-Tic-Asp-NH-Ph Investigative T47768 DRUGINFO D0PN3P H-Aba-ala-Gly-Phe-leu-OH Investigative T47768 DRUGINFO D0Q0UQ H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Investigative T47768 DRUGINFO D0Q1PN H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac Investigative T47768 DRUGINFO D0Q2HZ H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me) Investigative T47768 DRUGINFO D0Q6CF C[L-Tyr-D-pro-L-Phe-D-trp] Investigative T47768 DRUGINFO D0Q7SS Tyr-(S)-Aba-Gly-Phe-NH2 Investigative T47768 DRUGINFO D0R1DY H-Dmt-Tic-Lys-NH-CH2-Ph Investigative T47768 DRUGINFO D0R3GD H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid Investigative T47768 DRUGINFO D0R4KJ H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH Investigative T47768 DRUGINFO D0R4YD H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH Investigative T47768 DRUGINFO D0R9AP H-Apa-ala-Gly-Phe-leu-OH Investigative T47768 DRUGINFO D0R9LV 1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane Investigative T47768 DRUGINFO D0R9XD H-Dmt-Tic-Lys(Z)-NH-CH2-Ph Investigative T47768 DRUGINFO D0RR4X H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Investigative T47768 DRUGINFO D0S3LK 1,6-bis-(Dmt-Tic-amino)hexane Investigative T47768 DRUGINFO D0S9UH ZYKLOPHIN Investigative T47768 DRUGINFO D0TH8E M3P6S Investigative T47768 DRUGINFO D0U3ZL CARBOXYFENTANYL Investigative T47768 DRUGINFO D0U4LU H-Dmt-Tic-NH-(CH2)6-NH-Phe-H Investigative T47768 DRUGINFO D0U5OP 1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol Investigative T47768 DRUGINFO D0U8YU Tyr-Pro-Phe-Phe-OCH2OH Investigative T47768 DRUGINFO D0UV1C 3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone Investigative T47768 DRUGINFO D0V2PM H-Dmt-Tic-NH-CH2-Imid Investigative T47768 DRUGINFO D0V3GN Tyr-Pro-Phe-Phe-NHNH2 Investigative T47768 DRUGINFO D0V3OY [3H]U69593 Investigative T47768 DRUGINFO D0V8UG H-Dmt-Tic-NH-CH2-Boa Investigative T47768 DRUGINFO D0W8MP H-Dmt-Tic-Glu-NH2 Investigative T47768 DRUGINFO D0WZ7J M3A6S Investigative T47768 DRUGINFO D0X2HA H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid Investigative T47768 DRUGINFO D0X2HT M3IBu6S Investigative T47768 DRUGINFO D0X4YC H-Dmt-Tic-NH-(CH2)6-NH-Tic-H Investigative T47768 DRUGINFO D0X5TB H-Cdp-ser-Gly-Phe-Leu-Thr-OH Investigative T47768 DRUGINFO D0X9SP D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP) Investigative T47768 DRUGINFO D0X9TT Tyr-(S)-spiro-Aba-Gly-Phe-NH2 Investigative T47768 DRUGINFO D0Y2HI H-Dmt-Aba-Gly-NH-Ph Investigative T47768 DRUGINFO D0Y2MT Ac-RYYRIK-K-(NH2)-YAFGYPS Investigative T47768 DRUGINFO D0Y5TF Tyr-Pro-Emp-Phe-NH2 Investigative T47768 DRUGINFO D0Y5UN Tyr-Pro-L-Phe-D-Pro-NH2 Investigative T47768 DRUGINFO D0Y9RD H-Tyr-Pro-Ala-Phe-NH2 Investigative T47768 DRUGINFO D0YK5E Oxymorphone semicarbazone hydrochloride Investigative T47768 DRUGINFO D0Z5UG H-Tyr-Tic-Cha-Phe-OH Investigative T47768 DRUGINFO D0ZI5Z H-Tyr-Pro-Dap(6DMN)-Phe-NH2 Investigative T47768 DRUGINFO D0ZQ7L H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2 Investigative T47768 DRUGINFO D00HIG 3-Methylthiofentanyl Investigative T47768 DRUGINFO D00JAT (-)-cyclorphan Investigative T47768 DRUGINFO D00JPB 5-(4-((phenethylamino)methyl)phenoxy)picolinamide Investigative T47768 DRUGINFO D00NRB MCL-117 Investigative T47768 DRUGINFO D00SDP 17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine Investigative T47768 DRUGINFO D00XZH 1-benzhydryl-4-isopropylpiperidin-4-ol Investigative T47768 DRUGINFO D01ADK Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D01EPU BUTORPHAN Investigative T47768 DRUGINFO D01MUV 1-benzhydryl-4-tert-butylpiperidin-4-ol Investigative T47768 DRUGINFO D01RFG 8-carboxamidocyclazocine Investigative T47768 DRUGINFO D02BER quadazocine Investigative T47768 DRUGINFO D02FZW 17-methyl-4'-methyldihydromorphinone Investigative T47768 DRUGINFO D02IMZ MCL-443 Investigative T47768 DRUGINFO D02PIG H-Cpa-Gly-Gly-Phe-Met-OH Investigative T47768 DRUGINFO D02RYZ MCL-450 Investigative T47768 DRUGINFO D03QWP Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Investigative T47768 DRUGINFO D03UFD OXYMORPHINDOLE Investigative T47768 DRUGINFO D03UHT MCL-458 Investigative T47768 DRUGINFO D03WGS H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac Investigative T47768 DRUGINFO D04JFL Naltrexone-6-alpha-ol Investigative T47768 DRUGINFO D04PPP MCL-139 Investigative T47768 DRUGINFO D04UFM Dmt-Pro-Dmt-Phe-NH2 Investigative T47768 DRUGINFO D04UIK MCL-429 Investigative T47768 DRUGINFO D05ANN naltriben Investigative T47768 DRUGINFO D05EZE Dmt-Pro-Phe-Phe-NH2 Investigative T47768 DRUGINFO D05FEQ CYCLORPHAN Investigative T47768 DRUGINFO D05JSY MCL-145 Investigative T47768 DRUGINFO D05QJS NORBINALTORPHIMINE Investigative T47768 DRUGINFO D05RII 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole Investigative T47768 DRUGINFO D05TOY Dmt-Pro-3,5Dmp-Phe-NH2 Investigative T47768 DRUGINFO D05YNT [3H]diprenorphine Investigative T47768 DRUGINFO D05ZIH 6beta-naltrexol HCl Investigative T47768 DRUGINFO D06IXE MCL-153 Investigative T47768 DRUGINFO D06KFX C[L-Phe-D-pro-L-Phe-L-trp] Investigative T47768 DRUGINFO D06MWG Dmt-Pro-Mmp-Phe-NH2 Investigative T47768 DRUGINFO D06NST CYCLAZOCINE Investigative T47768 DRUGINFO D06OKE MCL-433 Investigative T47768 DRUGINFO D06PVO 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol Investigative T47768 DRUGINFO D06WTI NRP290 Investigative T47768 DRUGINFO D07AAK M6G thiosaccharide analogue Investigative T47768 DRUGINFO D07DFD MCL-434 Investigative T47768 DRUGINFO D07FCB 4-phenyl-1-(1-phenylethyl)piperidin-4-ol Investigative T47768 DRUGINFO D07HFU MCL-446 Investigative T47768 DRUGINFO D07JZS H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2 Investigative T47768 DRUGINFO D08IWF MCL-435 Investigative T47768 DRUGINFO D08KSJ H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2 Investigative T47768 DRUGINFO D08NJB Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Investigative T47768 DRUGINFO D08ORS 6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol Investigative T47768 DRUGINFO D08QKT Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D08RPH MCL-182 Investigative T47768 DRUGINFO D08YCS TQ-1017 Investigative T47768 DRUGINFO D09DUE MCL-447 Investigative T47768 DRUGINFO D09FLC 17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate Investigative T47768 DRUGINFO D09RUY N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine Investigative T47768 DRUGINFO D09UKS MCL-183 Investigative T47768 DRUGINFO D0A5MU Deprotected cogener of M6G Investigative T47768 DRUGINFO D0B8MY MCL-144 Investigative T47768 DRUGINFO D0C2UQ MCL-428 Investigative T47768 DRUGINFO D0C6RQ H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2 Investigative T47768 DRUGINFO D0C7MP MCL-448 Investigative T47768 DRUGINFO D0CK8C H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl Investigative T47768 DRUGINFO D0CX0I [Dcp1]Dyn A(1-11)-NH2 Investigative T47768 DRUGINFO D0D3UB SN-23 Investigative T47768 DRUGINFO D0D8AN 6-desoxonaltrexone Investigative T47768 DRUGINFO D0D9BB 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol Investigative T47768 DRUGINFO D0E0TD 4-(4-((phenethylamino)methyl)phenoxy)benzamide Investigative T47768 DRUGINFO D0E1FQ Dmt-Pro-Imp-Phe-NH2 Investigative T47768 DRUGINFO D0E6GH 14-O-phenylpropylnaltrexone Investigative T47768 DRUGINFO D0F1EB MC-CAM Investigative T47768 DRUGINFO D0F4AN MCL-432 Investigative T47768 DRUGINFO D0F8CV DAMGO Investigative T47768 DRUGINFO D0G4NM DPDPE Investigative T47768 DRUGINFO D0G6GC Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl Investigative T47768 DRUGINFO D0G7FB MCL-147 Investigative T47768 DRUGINFO D0H0KP 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide Investigative T47768 DRUGINFO D0H0OO dynorphin B Investigative T47768 DRUGINFO D0HB6O H-Cdp-Gly-Gly-Phe-Leu-OH Investigative T47768 DRUGINFO D0HC3H Dimepheptanol Investigative T47768 DRUGINFO D0HV6H H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2 Investigative T47768 DRUGINFO D0I1NG 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide Investigative T47768 DRUGINFO D0I2CE C[L-mTyr-D-pro-L-Phe-D-trp] Investigative T47768 DRUGINFO D0I9PH H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H Investigative T47768 DRUGINFO D0I9SX PHENAZOCINE Investigative T47768 DRUGINFO D0IL9H 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol Investigative T47768 DRUGINFO D0IY2V MCL-445 Investigative T47768 DRUGINFO D0J3NK MCL-449 Investigative T47768 DRUGINFO D0K1BV N-(17-Methylmorphinan-3-yl)-N'-phenylurea Investigative T47768 DRUGINFO D0K4XQ MCL-431 Investigative T47768 DRUGINFO D0KL5N Dmt-Pro-Tmp-Phe-NH2 Investigative T47768 DRUGINFO D0L0NI Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Investigative T47768 DRUGINFO D0L2CT H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2 Investigative T47768 DRUGINFO D0L5DN MCL-149 Investigative T47768 DRUGINFO D0L6QN LOFENTANIL Investigative T47768 DRUGINFO D0L8LX H-Tyr-Gly-Gly-Phe-Met-NH2 Investigative T47768 DRUGINFO D0M1YV ELAEOCARPENINE Investigative T47768 DRUGINFO D0N8LP Beta-endorphin Investigative T47768 DRUGINFO D0NA7G MCL-451 Investigative T47768 DRUGINFO D0NV5N normorphine Investigative T47768 DRUGINFO D0O1JD 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide Investigative T47768 DRUGINFO D0O6SB Diprenorphine Investigative T47768 DRUGINFO D0P0RB H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl Investigative T47768 DRUGINFO D0P5QI 2-Hydroxymethyl-3-hydroxymorphinan Investigative T47768 DRUGINFO D0P6FF N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine Investigative T47768 DRUGINFO D0Q5AJ MCL-154 Investigative T47768 DRUGINFO D0Q7HG H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl Investigative T47768 DRUGINFO D0R1AB H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH Investigative T47768 DRUGINFO D0R4QF HERKINORIN Investigative T47768 DRUGINFO D0R5TA ENDOMORPHIN-1 Investigative T47768 DRUGINFO D0R6VF Clocinnamox Investigative T47768 DRUGINFO D0R7LY Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Investigative T47768 DRUGINFO D0S5FN H-Cdp-ala-Gly-Phe-leu-OH Investigative T47768 DRUGINFO D0S7SO H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo Investigative T47768 DRUGINFO D0SC3W Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate Investigative T47768 DRUGINFO D0T5EI ethylketocyclazocine Investigative T47768 DRUGINFO D0T6OQ 3-desoxy-3-carboxamidonaltrexone Investigative T47768 DRUGINFO D0TB4A Dmt-Pro-Emp-Phe-NH2 Investigative T47768 DRUGINFO D0TN0D METAZOCINE Investigative T47768 DRUGINFO D0TO0E SN-28 Investigative T47768 DRUGINFO D0U3UM ETONITAZENE Investigative T47768 DRUGINFO D0U7JS H-Cpa-Gly-Gly-Phe-Met-NH2 Investigative T47768 DRUGINFO D0UG8H SN-11 Investigative T47768 DRUGINFO D0UR7D Benzyl derivative of M6G Investigative T47768 DRUGINFO D0V0RB Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D0VO7C HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 Investigative T47768 DRUGINFO D0W0CO 17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine Investigative T47768 DRUGINFO D0W2DN MCL-444 Investigative T47768 DRUGINFO D0W6OP H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 Investigative T47768 DRUGINFO D0X0XV Dmt-Pro-Dmp-Phe-NH2 Investigative T47768 DRUGINFO D0X6BU H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 Investigative T47768 DRUGINFO D0X7LC Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D0Y5ZP N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea Investigative T47768 DRUGINFO D0Y7KE 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol Investigative T47768 DRUGINFO D0Y8NO RTI-5989-31 Investigative T47768 DRUGINFO D0YU5H 6-(4-((benzylamino)methyl)phenoxy)nicotinamide Investigative T47768 DRUGINFO D0Z5JD [Leu5]enkephalin Investigative T47768 DRUGINFO D0Z8JX C[L-Phe-D-pro-L-mTyr-D-trp] Investigative T47768 DRUGINFO D0ZH3G 3-Methylfentanyl Investigative T47768 DRUGINFO D00TNR ENDOMORPHIN 2 Investigative T47768 DRUGINFO D00YCW 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol Investigative T47768 DRUGINFO D01AQC Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D01WMU 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol Investigative T47768 DRUGINFO D02EIB 4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol Investigative T47768 DRUGINFO D03EPA Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D03PTV 1-benzhydryl-4-ethoxy-4-phenylpiperidine Investigative T47768 DRUGINFO D03RBD 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide Investigative T47768 DRUGINFO D03UJW 1-benzhydryl-4-butylpiperidin-4-ol Investigative T47768 DRUGINFO D04ZQX 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol Investigative T47768 DRUGINFO D06BRA Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D06MQG 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol Investigative T47768 DRUGINFO D06PHT 1-benzhydryl-4-phenylpiperidin-4-ol Investigative T47768 DRUGINFO D07CIU 1-benzhydryl-4-p-tolylpiperidin-4-ol Investigative T47768 DRUGINFO D07ICW Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D07LQQ Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D07NMH 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol Investigative T47768 DRUGINFO D08DVV 1-benzhydryl-4-hexylpiperidin-4-ol Investigative T47768 DRUGINFO D08QBU 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol Investigative T47768 DRUGINFO D08TFY 1-benzhydryl-4-cyclohexylpiperidin-4-ol Investigative T47768 DRUGINFO D09BYD 1-benzhydryl-4-o-tolylpiperidin-4-ol Investigative T47768 DRUGINFO D09EMR Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D09FJY 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol Investigative T47768 DRUGINFO D09LRO 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol Investigative T47768 DRUGINFO D09VRT 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol Investigative T47768 DRUGINFO D0B7GU Dihydromorphine Investigative T47768 DRUGINFO D0D0UP 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol Investigative T47768 DRUGINFO D0D5QV O-DESMETHYL TRAMADOL Investigative T47768 DRUGINFO D0E2OG Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D0G4FA 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol Investigative T47768 DRUGINFO D0G7DF 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol Investigative T47768 DRUGINFO D0J5JO 1-benzhydryl-4-m-tolylpiperidin-4-ol Investigative T47768 DRUGINFO D0J7GJ H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H Investigative T47768 DRUGINFO D0JH5D 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol Investigative T47768 DRUGINFO D0N6DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc Investigative T47768 DRUGINFO D0O7JV 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol Investigative T47768 DRUGINFO D0P3FP 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol Investigative T47768 DRUGINFO D0Q9TQ 1-benzhydryl-4-methoxy-4-phenylpiperidine Investigative T47768 DRUGINFO D0QH4A 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol Investigative T47768 DRUGINFO D0QP2S Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc Investigative T47768 DRUGINFO D0R4GI Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D0T4ZY 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol Investigative T47768 DRUGINFO D0T9KE 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol Investigative T47768 DRUGINFO D0TR0U Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D0U6OA Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T47768 DRUGINFO D0V9DY H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H Investigative T47768 DRUGINFO D0W3VT 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol Investigative T47768 DRUGINFO D0X4SX 1-benzhydryl-4-phenyl-4-propoxypiperidine Investigative T47768 DRUGINFO D0XX1Y 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol Investigative T47768 DRUGINFO D0Y5LJ 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol Investigative T47768 DRUGINFO D0ZE2W 1-benzhydryl-4-benzylpiperidin-4-ol Investigative T47768 DRUGINFO D03SAV ICI-199441 Investigative T47768 DRUGINFO D08UOX FALCARINDIOL Investigative T47768 DRUGINFO D0L9YP 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide Investigative T47768 DRUGINFO D0T5RO SOMATOSTATIN Investigative T47768 DRUGINFO D0L5MW (+/-)-nantenine Investigative T47768 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T02551 TARGETID T02551 T02551 FORMERID TTDS00013 T02551 UNIPROID DRD3_HUMAN T02551 TARGNAME Dopamine D3 receptor (D3R) T02551 GENENAME DRD3 T02551 TARGTYPE Successful T02551 SYNONYMS D(3) dopamine receptor T02551 FUNCTION Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation. T02551 PDBSTRUC 3PBL T02551 BIOCLASS GPCR rhodopsin T02551 SEQUENCE MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERALQTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTVCSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQQTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRKLSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHVSPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC T02551 DRUGINFO D05XGO Cariprazine Approved T02551 DRUGINFO D0G8NN Pramipexole Approved T02551 DRUGINFO D0R9EQ Ropinirole Approved T02551 DRUGINFO D01NKW P2B-001 Phase 3 T02551 DRUGINFO D0X6XH CM-2395 Phase 3 T02551 DRUGINFO D03RIO GSK598809 Phase 2 T02551 DRUGINFO DD5VO3 TAK-906 Phase 2 T02551 DRUGINFO D07XQS ONC201 Phase 2 T02551 DRUGINFO D05XEA RP5063 Phase 2 T02551 DRUGINFO D0H3ID Pfizer 10 Phase 1 T02551 DRUGINFO D0HI1K GSK618334 Phase 1 T02551 DRUGINFO D0M1UF Aryl piperazine derivative 1 Patented T02551 DRUGINFO D0Z9WY Aryl piperazine derivative 6 Patented T02551 DRUGINFO D0Z2WQ Quinelorane Discontinued in Phase 3 T02551 DRUGINFO D0EE6L BP-897 Discontinued in Phase 2 T02551 DRUGINFO D0FH3X A-437203 Discontinued in Phase 2 T02551 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T02551 DRUGINFO D06ZWG AVE-5997EF Discontinued in Phase 1 T02551 DRUGINFO D0UZ1I S-33138 Discontinued in Phase 1 T02551 DRUGINFO D0K5EE S-33084 Preclinical T02551 DRUGINFO D0Q2VL PD-157533 Preclinical T02551 DRUGINFO D0T3JW U-99194A Preclinical T02551 DRUGINFO D0Q3GV S32504 Preclinical T02551 DRUGINFO D0R1PZ F-15063 Preclinical T02551 DRUGINFO D04UXX PD-158771 Preclinical T02551 DRUGINFO D0F6WV PD-157695 Preclinical T02551 DRUGINFO D01ZSF GR-218231 Terminated T02551 DRUGINFO D03AZY PNU-177864 Terminated T02551 DRUGINFO D0G2LT RGH-1756 Terminated T02551 DRUGINFO D0Y6SN SB-277011 Terminated T02551 DRUGINFO D05IPO BTS-79018 Terminated T02551 DRUGINFO D08KDP AS-8112 Terminated T02551 DRUGINFO D0G3MH PNU-96391A Terminated T02551 DRUGINFO D0OW1R YM-43611 Terminated T02551 DRUGINFO D0P3IZ E-2040 Terminated T02551 DRUGINFO D0V1SD BP4.879a Terminated T02551 DRUGINFO D0N5UA Dianicline+rimonabant Terminated T02551 DRUGINFO D00XEN NGB 2904 Investigative T02551 DRUGINFO D02YDU 4-Dipropylamino-cyclohex-1-enecarbonitrile Investigative T02551 DRUGINFO D05NQX PD-152255 Investigative T02551 DRUGINFO D08TCX (2-Benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine Investigative T02551 DRUGINFO D0C0UM (4-Dipropylamino-cyclohexylidene)-acetonitrile Investigative T02551 DRUGINFO D0J1HP (R)-2-(Benzylamino-methyl)-chroman-7-ol Investigative T02551 DRUGINFO D0T2MV AS-9705 Investigative T02551 DRUGINFO D0X1QW (+)-AJ76 Investigative T02551 DRUGINFO D00CDM PD 128907 Investigative T02551 DRUGINFO D00QMQ D-220 Investigative T02551 DRUGINFO D00SDJ A-706149 Investigative T02551 DRUGINFO D01URS PF-592379 Investigative T02551 DRUGINFO D03EDW D-193 Investigative T02551 DRUGINFO D03PYX [3H]7-OH-DPAT Investigative T02551 DRUGINFO D03ZOJ D-189 Investigative T02551 DRUGINFO D04PBA 3-(4-Benzyl-piperazin-1-yl)-phenol Investigative T02551 DRUGINFO D04RBU D-366 Investigative T02551 DRUGINFO D05HMW 2-(4-Dipropylamino-cyclohexylidene)-malononitrile Investigative T02551 DRUGINFO D05NED D-190 Investigative T02551 DRUGINFO D06HTJ D-264 Investigative T02551 DRUGINFO D07ISL D-210 Investigative T02551 DRUGINFO D09AQJ D-203 Investigative T02551 DRUGINFO D09FTZ (4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine Investigative T02551 DRUGINFO D09PJF D-315 Investigative T02551 DRUGINFO D0B4SL D-218 Investigative T02551 DRUGINFO D0D2CU (R)-(-)-2-Methyl-apomorphine hydrochloride Investigative T02551 DRUGINFO D0FU2V D-237 Investigative T02551 DRUGINFO D0HG4U (R)-(-)-2-Phenyl-apomorphine hydrochloride Investigative T02551 DRUGINFO D0M5XV D-219 Investigative T02551 DRUGINFO D0M7SY SB269652 Investigative T02551 DRUGINFO D0M8LN A-690344 Investigative T02551 DRUGINFO D0PV6G (+)-S-14297 Investigative T02551 DRUGINFO D0Q7FM Azaperone Investigative T02551 DRUGINFO D0S5ZE D-192 Investigative T02551 DRUGINFO D0S7WZ (-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile Investigative T02551 DRUGINFO D0YB0K 7-trans-OH-PIPAT Investigative T02551 DRUGINFO D00HUV [2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine Investigative T02551 DRUGINFO D01KIH 4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole Investigative T02551 DRUGINFO D03GES 1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine Investigative T02551 DRUGINFO D03JOS 3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole Investigative T02551 DRUGINFO D04CPW N-(4-Propylaminobutyl)-4-biphenylcarboxamide Investigative T02551 DRUGINFO D04CTN 3-(1-Propyl-pyrrolidin-3-yl)-phenol Investigative T02551 DRUGINFO D05BCJ 1-Benzyl-4-pyrrol-1-yl-piperidine Investigative T02551 DRUGINFO D05QJK Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine Investigative T02551 DRUGINFO D06NTB 3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole Investigative T02551 DRUGINFO D06WLB Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine Investigative T02551 DRUGINFO D0H3KU 5-OH-DPAT Investigative T02551 DRUGINFO D0IU8V 4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one Investigative T02551 DRUGINFO D0LV7U 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one Investigative T02551 DRUGINFO D0M3PV L-741626 Investigative T02551 DRUGINFO D0O1PM (4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine Investigative T02551 DRUGINFO D0O9BZ 4-(4-Benzyl-piperazin-1-yl)-1H-indole Investigative T02551 DRUGINFO D0Q5IP 3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole Investigative T02551 DRUGINFO D0S1XN 4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole Investigative T02551 DRUGINFO D0T1TU Etoloxamine Investigative T02551 DRUGINFO D0TU5W 4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole Investigative T02551 DRUGINFO D06LQH N-propylnorapomorphine Investigative T02551 DRUGINFO D07RYR 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine Investigative T02551 DRUGINFO D07UUQ 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine Investigative T02551 DRUGINFO D0B9DR 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine Investigative T02551 DRUGINFO D0H2WQ QUINPIROLE Investigative T02551 DRUGINFO D0I4VT 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine Investigative T02551 DRUGINFO D0M2BB 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine Investigative T02551 DRUGINFO D0M2ZE UH-232 Investigative T02551 DRUGINFO D0O4BC 3-(2-Benzylamino-ethoxy)-phenol Investigative T02551 DRUGINFO D0O7DA (+)-BUTACLAMOL Investigative T02551 DRUGINFO D0V4NW N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide Investigative T02551 DRUGINFO D0W1HM nafadotride Investigative T02551 DRUGINFO D0WD6J 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine Investigative T02551 DRUGINFO D0WU9R L-741742 Investigative T02551 DRUGINFO D05UUW 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine Investigative T02551 DRUGINFO D0E1RX 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine Investigative T02551 DRUGINFO D0L7OM STEPHOLIDINE Investigative T02551 DRUGINFO D0MC2R FLUTROLINE Investigative T02551 DRUGINFO D0R8UU 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine Investigative T02551 DRUGINFO D07GQP PG-01037 Investigative T02551 DRUGINFO D07GXY piribedil Investigative T02551 DRUGINFO D05EQG [3H]spiperone Investigative T02551 DRUGINFO D07LRJ SB-271046 Investigative T02551 DRUGINFO D0PN9R R-226161 Investigative T02551 DRUGINFO D0HV3A FLUMEZAPINE Investigative T02551 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T02551 DRUGINFO D0F9QT A-987306 Investigative T02551 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T02551 DRUGINFO D0L5MW (+/-)-nantenine Investigative T02551 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T79232 TARGETID T79232 T79232 FORMERID TTDS00109 T79232 UNIPROID V1AR_HUMAN T79232 TARGNAME Vasopressin V1a receptor (V1AR) T79232 GENENAME AVPR1A T79232 TARGTYPE Successful T79232 SYNONYMS Vascular/hepatic-type arginine vasopressin receptor; V1aR; V1a vasopressin receptor; Antidiuretic hormone receptor 1a; AVPR1; AVPR V1a T79232 FUNCTION The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment. Receptor for arginine vasopressin. T79232 PDBSTRUC 1YTV T79232 BIOCLASS GPCR rhodopsin T79232 SEQUENCE MRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAVTFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGPDWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFVLSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFICYNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAYIVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCVQSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST T79232 DRUGINFO D0H3MG Felypressin Approved T79232 DRUGINFO D0P4VX Terlipressin Approved T79232 DRUGINFO D0VU2X Conivaptan Approved T79232 DRUGINFO D0F4NS Mozavaptan Approved T79232 DRUGINFO D0M3FJ Oxytocin Approved T79232 DRUGINFO D0U7SH Desmopressin Approved T79232 DRUGINFO D0D8XY ATOSIBAN Phase 4 T79232 DRUGINFO DY7MH5 Balovaptan Phase 3 T79232 DRUGINFO D00LSW VA-111913 Phase 2 T79232 DRUGINFO D0F4VW SRX-246 Phase 2 T79232 DRUGINFO D0L4HL RG7314 Phase 2 T79232 DRUGINFO D0S3YN FE-202158 Phase 2 T79232 DRUGINFO DNS58L SRX246 Phase 2 T79232 DRUGINFO D0SY9B SSR149415 Phase 2 T79232 DRUGINFO D0G2XE PMX-53 Phase 2 T79232 DRUGINFO D0PB0D SRX-251 Phase 1 T79232 DRUGINFO D8TO6D NMRA-511 Phase 1 T79232 DRUGINFO D01GCI PMID25776143-Compound-7 Patented T79232 DRUGINFO D03TLQ PMID25776143-Compound-1 Patented T79232 DRUGINFO D07WNO Tetra-azabenzo[e]azulene derivative 1 Patented T79232 DRUGINFO D0GT5M Tetra-azabenzo[e]azulene derivative 2 Patented T79232 DRUGINFO D0H9AU PMID25776143-Compound-8 Patented T79232 DRUGINFO D0LZ5Q PMID25776143-Compound-4 Patented T79232 DRUGINFO D0MQ6T PMID25776143-Compound-3 Patented T79232 DRUGINFO D0TV9B PMID25776143-Compound-2 Patented T79232 DRUGINFO D0BU3L Pyrrolidine derivative 13 Patented T79232 DRUGINFO D0H0QR PMID28906174-Compound-figure1g Patented T79232 DRUGINFO D08ORO OPC-21268 Discontinued in Phase 2 T79232 DRUGINFO D0A1KU PF-3274167 Discontinued in Phase 1 T79232 DRUGINFO D09KAK NOX-F37 Preclinical T79232 DRUGINFO D02RDE JTV-605 Terminated T79232 DRUGINFO D08PAC L-371257 Terminated T79232 DRUGINFO D0D9OM V1A F/U Investigative T79232 DRUGINFO D0I8ZZ Relcovaptan Investigative T79232 DRUGINFO D0Q3VN HO-LVA Investigative T79232 DRUGINFO D01WHI L023103 Investigative T79232 DRUGINFO D02FXZ DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT Investigative T79232 DRUGINFO D03QUQ LS-192629 Investigative T79232 DRUGINFO D09HMT [HO1][Orn8(5/6C-Rhm)]VT Investigative T79232 DRUGINFO D0BS2Q [Thr4,Gly7]OT Investigative T79232 DRUGINFO D0K5NV [Lys8(Alexa 546) ]PVA Investigative T79232 DRUGINFO D0Q0OR SSR126768A Investigative T79232 DRUGINFO D0T3YS CL-385004 Investigative T79232 DRUGINFO D0Y0SO DVDAVP Investigative T79232 DRUGINFO D0Y1AJ D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT Investigative T79232 DRUGINFO D0YG0D 1'-tosylspiro[indene-1,4'-piperidine] Investigative T79232 DRUGINFO D00HAJ Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2 Investigative T79232 DRUGINFO D00NIT YM 471 Investigative T79232 DRUGINFO D00SGZ YM 218 Investigative T79232 DRUGINFO D02VVG D[Orn8(5/6C-Flu)]VT Investigative T79232 DRUGINFO D02YBV [Val4]AVP Investigative T79232 DRUGINFO D03EBH D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT Investigative T79232 DRUGINFO D04JXX d[Pen1,Tyr(Me)2]AVP Investigative T79232 DRUGINFO D05YHE D[Thr4,Lys8(5/6C-Flu)]VT Investigative T79232 DRUGINFO D09BWP [HO1][Orn8(5/6C-Flu)]VT Investigative T79232 DRUGINFO D09OML D[D-3-Pal2]AVP Investigative T79232 DRUGINFO D0C8XX D[Thr4,Orn8(5/6C-Flu)]VT Investigative T79232 DRUGINFO D0K0JJ [HO1][Lys8(5/6C-Flu)]VT Investigative T79232 DRUGINFO D0L0RP [Lys8(Alexa 488) ]PVA Investigative T79232 DRUGINFO D0M3BJ D[Lys8(5/6-Flu)]VT Investigative T79232 DRUGINFO D0O6WN [HO1][Thr4,Orn8(5/6C-Flu)]VT Investigative T79232 DRUGINFO D0T4ML L-372662 Investigative T79232 DRUGINFO D0Y4HL [Phe3]OT Investigative T79232 DRUGINFO D0Y5FO [HO1][Thr4,Lys8(5/6C-Flu)]VT Investigative T79232 DRUGINFO D01FDW ARGENINE VASOPRESSIN Investigative T79232 DRUGINFO D03BVC D[Arg4,Orn8]VP Investigative T79232 DRUGINFO D03DXK D[Leu4,Lys8]VP Investigative T79232 DRUGINFO D04MMD D[Arg4,Lys8]VP Investigative T79232 DRUGINFO D05BHL D[Cha4,Lys8]VP Investigative T79232 DRUGINFO D05RNF D[Cha4,Orn8]VP Investigative T79232 DRUGINFO D06SDG D[Leu4,Dab8]VP Investigative T79232 DRUGINFO D09RIE D[Cha4]AVP Investigative T79232 DRUGINFO D09XWA D[Cha4,Dap8]VP Investigative T79232 DRUGINFO D0A6FK D[Leu4]AVP Investigative T79232 DRUGINFO D0HI2N D[Cha4,Dab8]VP Investigative T79232 DRUGINFO D0M4QM d(CH2)5[Tyr(Me)2]AVP Investigative T79232 DRUGINFO D0O5TK D[Leu4,Dap8]VP Investigative T79232 DRUGINFO D0O8OF D[Orn4,Lys8]VP Investigative T79232 DRUGINFO D0R7QC D[Arg4]AVP Investigative T79232 DRUGINFO D0UK0O D[Arg4,Dab8]VP Investigative T79232 DRUGINFO D0V3FF D[Leu4,Orn8]VP Investigative T79232 DRUGINFO D0W3IQ D[Val4]AVP Investigative T79232 DRUGINFO D0YJ6C D[Orn4,Orn8]VP Investigative T79232 DRUGINFO D0ZD0W D[Orn4]AVP Investigative T79232 DRUGINFO D0F9QT A-987306 Investigative T73495 TARGETID T73495 T73495 FORMERID TTDS00122 T73495 UNIPROID GRIK1_HUMAN T73495 TARGNAME Glutamate receptor ionotropic kainate 1 (GRIK1) T73495 GENENAME GRIK1 T73495 TARGTYPE Successful T73495 SYNONYMS Glutamate receptor 5; GluR5 kainate receptor; GluR5; GluR-5; GRIK1; Excitatory amino acid receptor 3; EAA3 T73495 FUNCTION Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L- glutamate induces a conformation change, leading tothe opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. May be involved in the transmission of light information from the retina to the hypothalamus. T73495 PDBSTRUC 4MF3; 3FVO; 3FVN; 3FVK; 3FVG T73495 BIOCLASS Glutamate-gated ion channel T73495 SEQUENCE MEHGTLLAQPGLWTRDTSWALLYFLCYILPQTAPQVLRIGGIFETVENEPVNVEELAFKFAVTSINRNRTLMPNTTLTYDIQRINLFDSFEASRRACDQLALGVAALFGPSHSSSVSAVQSICNALEVPHIQTRWKHPSVDNKDLFYINLYPDYAAISRAILDLVLYYNWKTVTVVYEDSTGLIRLQELIKAPSRYNIKIKIRQLPSGNKDAKPLLKEMKKGKEFYVIFDCSHETAAEILKQILFMGMMTEYYHYFFTTLDLFALDLELYRYSGVNMTGFRLLNIDNPHVSSIIEKWSMERLQAPPRPETGLLDGMMTTEAALMYDAVYMVAIASHRASQLTVSSLQCHRHKPWRLGPRFMNLIKEARWDGLTGHITFNKTNGLRKDFDLDIISLKEEGTEKAAGEVSKHLYKVWKKIGIWNSNSGLNMTDSNKDKSSNITDSLANRTLIVTTILEEPYVMYRKSDKPLYGNDRFEGYCLDLLKELSNILGFIYDVKLVPDGKYGAQNDKGEWNGMVKELIDHRADLAVAPLTITYVREKVIDFSKPFMTLGISILYRKPNGTNPGVFSFLNPLSPDIWMYVLLACLGVSCVLFVIARFTPYEWYNPHPCNPDSDVVENNFTLLNSFWFGVGALMQQGSELMPKALSTRIVGGIWWFFTLIIISSYTANLAAFLTVERMESPIDSADDLAKQTKIEYGAVRDGSTMTFFKKSKISTYEKMWAFMSSRQQTALVRNSDEGIQRVLTTDYALLMESTSIEYVTQRNCNLTQIGGLIDSKGYGVGTPIGSPYRDKITIAILQLQEEGKLHMMKEKWWRGNGCPEEDNKEASALGVENIGGIFIVLAAGLVLSVFVAIGEFIYKSRKNNDIEQAFCFFYGLQCKQTHPTNSTSGTTLSTDLECGKLIREERGIRKQSSVHTV T73495 DRUGINFO D07VDZ Topiramate Approved T73495 DRUGINFO D0B0NQ LY293558 Phase 2 T73495 DRUGINFO D0H7GQ NS 1209 Phase 2 T73495 DRUGINFO D02VKC NBQX Phase 1 T73495 DRUGINFO D02TTF YM-90K Discontinued in Phase 2 T73495 DRUGINFO D01BAG ACET Investigative T73495 DRUGINFO D01DMS (S)-5-iodowillardiine Investigative T73495 DRUGINFO D01HOO 8-deoxy-neodysiherbaine Investigative T73495 DRUGINFO D01KEH Domoric acid Investigative T73495 DRUGINFO D01RSH 2-(3-bromobenzoylamino)-4-chlorobenzoic acid Investigative T73495 DRUGINFO D02RGB LY339434 Investigative T73495 DRUGINFO D03NDD LY466195 Investigative T73495 DRUGINFO D03UIR (2S,4R)-4-(3-Methoxy-3-oxopropyl)glutamic Acid Investigative T73495 DRUGINFO D04XZP DIHYDROKAINATE Investigative T73495 DRUGINFO D05ERF TQX-173 Investigative T73495 DRUGINFO D05FZE ATPA Investigative T73495 DRUGINFO D09VYB UBP-302 Investigative T73495 DRUGINFO D0B2VW 2S,4R-4-METHYLGLUTAMATE Investigative T73495 DRUGINFO D0BN4U MSVIII-19 Investigative T73495 DRUGINFO D0KD6O (S)-4-AHCP Investigative T73495 DRUGINFO D0N1CL 2-(3-(3-bromophenyl)ureido)-4-chlorobenzoic acid Investigative T73495 DRUGINFO D0T1MK LY382884 Investigative T73495 DRUGINFO D0T8IK S-ATPO Investigative T73495 DRUGINFO D0TT9H NS3763 Investigative T73495 DRUGINFO D00VEZ 2,4-epi-neodysiherbaine Investigative T73495 DRUGINFO D0J1PG 2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX) Investigative T73495 DRUGINFO D0K5UI UBP310 Investigative T73495 DRUGINFO D09KRH domoic acid Investigative T73495 DRUGINFO D0K6AF dysiherbaine Investigative T73495 DRUGINFO D05KQC DNQX Investigative T73495 DRUGINFO D0S8AN SYM2081 Investigative T73495 DRUGINFO D04PFN [3H]kainate Investigative T73495 DRUGINFO D06DUE [3H]quisqualate Investigative T29130 TARGETID T29130 T29130 FORMERID TTDS00275 T29130 UNIPROID STAT3_HUMAN T29130 TARGNAME Signal transducer and activator of transcription 3 (STAT3) T29130 GENENAME STAT3 T29130 TARGTYPE Successful T29130 SYNONYMS Acute-phase response factor; APRF T29130 FUNCTION Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the interleukin-6 (IL-6)-responsive elements identified in the promoters of various acute-phase protein genes. Activated by IL31 through IL31RA. Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): deacetylation and oxidation of lysine residues by LOXL3, leads to disrupt STAT3 dimerization and inhibit its transcription activity. Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1. Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation (By similarity). May play an apoptotic role by transctivating BIRC5 expression under LEP activation. Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity. Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion (By similarity). T29130 PDBSTRUC 5U5S; 5AX3 T29130 BIOCLASS Transcription factor T29130 SEQUENCE MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM T29130 DRUGINFO D05QDC Acitretin Approved T29130 DRUGINFO D01IGZ Napabucasin Phase 3 T29130 DRUGINFO D02MRN Golotimod Phase 2 T29130 DRUGINFO D0D9LJ Atiprimod Phase 1/2 T29130 DRUGINFO D0E7IM OPB-31121 Phase 1/2 T29130 DRUGINFO D0H7DM IMX-110 Phase 1/2 T29130 DRUGINFO D0P7IL GLG-801 Phase 1/2 T29130 DRUGINFO D0IV4C WP-1066 Phase 1/2 T29130 DRUGINFO DUI59O NT219 Phase 1/2 T29130 DRUGINFO D01FFC OPB-51602 Phase 1 T29130 DRUGINFO D01RCM TAK-114 Phase 1 T29130 DRUGINFO D3U8YR WP1220 Phase 1 T29130 DRUGINFO DLJN17 DSP-0337 Phase 1 T29130 DRUGINFO DN81JB OPB-111077 Phase 1 T29130 DRUGINFO D00FUZ Quinoline carboxamide derivative 2 Patented T29130 DRUGINFO D02CJU Peptidomimetic analog 3 Patented T29130 DRUGINFO D02ILH PMID26394986-Compound-11 Patented T29130 DRUGINFO D02KDA Flavonoid derivative 5 Patented T29130 DRUGINFO D03ARS Salicylic acid derivative 6 Patented T29130 DRUGINFO D03HEP Gold-complexed thiosaccharide derivative 2 Patented T29130 DRUGINFO D03VMP Peptidomimetic analog 1 Patented T29130 DRUGINFO D03XAK Quinoline carboxamide derivative 1 Patented T29130 DRUGINFO D04ANB Salicylic acid derivative 4 Patented T29130 DRUGINFO D04GVY PMID26394986-Compound-12 Patented T29130 DRUGINFO D06RBL PMID26394986-Compound-21 Patented T29130 DRUGINFO D08EID Salicylic acid derivative 5 Patented T29130 DRUGINFO D08ETA PMID26394986-Compound-20 Patented T29130 DRUGINFO D08SEP PMID26394986-Compound-43 Patented T29130 DRUGINFO D09BOL PMID26394986-Compound-50 Patented T29130 DRUGINFO D09CKU PMID26394986-Compound-44 Patented T29130 DRUGINFO D09SYX PMID26394986-Compound-51 Patented T29130 DRUGINFO D09ZCV Salicylic acid derivative 3 Patented T29130 DRUGINFO D0D8RR Quinoline carboxamide derivative 3 Patented T29130 DRUGINFO D0DC3S Pyrazole derivative 62 Patented T29130 DRUGINFO D0ET3L Pyrazole derivative 63 Patented T29130 DRUGINFO D0EV5U Flavonoid derivative 3 Patented T29130 DRUGINFO D0EW9W Peptide analog 7 Patented T29130 DRUGINFO D0EX9O Salicylic acid derivative 1 Patented T29130 DRUGINFO D0FH4G Gold-complexed thiosaccharide derivative 1 Patented T29130 DRUGINFO D0J1US Gold-complexed thiosaccharide derivative 3 Patented T29130 DRUGINFO D0KP0U PMID26394986-Compound-22 Patented T29130 DRUGINFO D0M5AR Pyrazole derivative 65 Patented T29130 DRUGINFO D0M8OV Pyrazole derivative 64 Patented T29130 DRUGINFO D0MA8T PMID26394986-Compound-42 Patented T29130 DRUGINFO D0QR1I Peptidomimetic analog 2 Patented T29130 DRUGINFO D0S0UL Pyrazole derivative 66 Patented T29130 DRUGINFO D0T1GB PMID26394986-Compound-52 Patented T29130 DRUGINFO D0U7LL Salicylic acid derivative 2 Patented T29130 DRUGINFO D0V3PA Salicylic acid derivative 7 Patented T29130 DRUGINFO D0V7HS PMID26394986-Compound-53 Patented T29130 DRUGINFO D0V7NH Flavonoid derivative 1 Patented T29130 DRUGINFO D0WW1Z PMID26394986-Compound-54 Patented T29130 DRUGINFO D0X6QQ Peptidomimetic analog 4 Patented T29130 DRUGINFO D0Y0OQ PMID26394986-Compound-13 Patented T29130 DRUGINFO D0Y2PO Tri-substituted purine derivative 1 Patented T29130 DRUGINFO D0Y3DN Flavonoid derivative 4 Patented T29130 DRUGINFO D0Z8BD Flavonoid derivative 2 Patented T29130 DRUGINFO D0ZQ8T PMID26394986-Compound-Figure16 Patented T29130 DRUGINFO D0ZS8Q PMID26394986-Compound-Figure17 Patented T29130 DRUGINFO D0EZ6V Oxazole derivative 1 Patented T29130 DRUGINFO D0IC8O Curcumin analog 2 Patented T29130 DRUGINFO D0WD1Z Curcumin analog 1 Patented T29130 DRUGINFO D0XQ3F Peptidomimetic analog 5 Patented T29130 DRUGINFO D01BVU Platinum IV complexe 1 Patented T29130 DRUGINFO D0TU0X PMID26394986-Compound-10 Patented T29130 DRUGINFO D06PZK GNF-PF-1399 Investigative T58992 TARGETID T58992 T58992 FORMERID TTDS00128 T58992 UNIPROID OPRD_HUMAN T58992 TARGNAME Opioid receptor delta (OPRD1) T58992 GENENAME OPRD1 T58992 TARGTYPE Successful T58992 SYNONYMS OPRD; Delta-type opioid receptor; Delta opioid receptor; DOR-1; D-OR-1 T58992 FUNCTION Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine. G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. T58992 PDBSTRUC 4RWD; 4RWA; 4N6H; 2IQM; 1OZC T58992 BIOCLASS GPCR rhodopsin T58992 SEQUENCE MEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAIAITALYSAVCAVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELLCKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVGVPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRLRSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAALHLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTACTPSDGPGGGAAA T58992 DRUGINFO D03DIG Codeine Approved T58992 DRUGINFO D0CS2F Loperamide Approved T58992 DRUGINFO D0X9RG Butorphanol Approved T58992 DRUGINFO D03SKD Oxycodone Approved T58992 DRUGINFO D04JHN Hydromorphone Approved T58992 DRUGINFO D09ZXR Eluxadoline Approved T58992 DRUGINFO D04DQZ AZD-2327 Phase 2 T58992 DRUGINFO D0N9VZ ADL-5747 Phase 2 T58992 DRUGINFO D0W9ZT ADL-5859 Phase 2 T58992 DRUGINFO D0V5WL Met-enkephalin Phase 2 T58992 DRUGINFO D03PJU Carfentanil Phase 2 T58992 DRUGINFO D0LU5Q TPM-1/Morphine Phase 2 T58992 DRUGINFO D09FOP MCP-202 Phase 1 T58992 DRUGINFO D0Q1HD TRV250 Phase 1 T58992 DRUGINFO D00HBR AIKO-150 Phase 1 T58992 DRUGINFO D01AKU MCP-201 Phase 1 T58992 DRUGINFO D06EXA SALVINORIN A Phase 1 T58992 DRUGINFO D0G1YN DPI-3290 Discontinued in Phase 2 T58992 DRUGINFO D0Y8SK Dynorphin a Discontinued in Phase 2 T58992 DRUGINFO D0R1XI TRK-851 Discontinued in Phase 1 T58992 DRUGINFO D0J5XZ VP004 Discontinued in Phase 1 T58992 DRUGINFO D01WVJ BIO-306 Preclinical T58992 DRUGINFO D0N1RG SoRI-9409 Preclinical T58992 DRUGINFO D0C2QF LY-25582 Preclinical T58992 DRUGINFO D0K5KL BW 373U86 Terminated T58992 DRUGINFO D0Y0ZB SB-219825 Terminated T58992 DRUGINFO D0LX5D BIPHALIN Terminated T58992 DRUGINFO D08YUP SB-213698 Terminated T58992 DRUGINFO D0W8TS SNF-9007 Terminated T58992 DRUGINFO D00BXG TIPPpsi Investigative T58992 DRUGINFO D00HDC MCP-204 Investigative T58992 DRUGINFO D01GYS Tyr-Gly-Gly-Phe-leu-c(Cys-Arg-Ile-Arg-Cys)-lys Investigative T58992 DRUGINFO D02ALI H-Tyr-c[pen-Gly-Phe-pen]OH Investigative T58992 DRUGINFO D02REM DPI-221 Investigative T58992 DRUGINFO D03VEQ Tyr-Gly-Gly-Phe-c(Cys-Arg-Arg-Ile-Cys)-Arg-lys Investigative T58992 DRUGINFO D04EQE N-methylstephisoferulin Investigative T58992 DRUGINFO D05EXX AKNADILACTAM Investigative T58992 DRUGINFO D05JHA H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2 Investigative T58992 DRUGINFO D06DDA 6-cinnamoylhernandine Investigative T58992 DRUGINFO D06XDA Grandisine F Investigative T58992 DRUGINFO D07ZIG H-Tyr-Tic-OH Investigative T58992 DRUGINFO D08IXN [3H]naltrindole Investigative T58992 DRUGINFO D09RJT Grandisine C Investigative T58992 DRUGINFO D09RZB BBI-11008 Investigative T58992 DRUGINFO D09WKT ARD-412 Investigative T58992 DRUGINFO D0A3YH H-Tyr-NMe-D-Ala-Phe-Sar-NH2 Investigative T58992 DRUGINFO D0B3BJ ICI-174864 Investigative T58992 DRUGINFO D0D4AU PROSTEPHABYSSINE Investigative T58992 DRUGINFO D0E4YP SB 227122 Investigative T58992 DRUGINFO D0E6IT H-mCpa-Gly-Gly-Phe-Leu-OH Investigative T58992 DRUGINFO D0FT5V (-)-isoelaeocarpiline Investigative T58992 DRUGINFO D0G1XL DSTBULET Investigative T58992 DRUGINFO D0H8ID Tonazocine mesylate Investigative T58992 DRUGINFO D0J7VL H-Cxp-ala-Gly-Phe-leu-OH Investigative T58992 DRUGINFO D0LL4C TIP Investigative T58992 DRUGINFO D0M8YB PERIPENTADENINE Investigative T58992 DRUGINFO D0N6ZO 6-cinnamoyl-N-methylstephasunoline Investigative T58992 DRUGINFO D0N7FU D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2(CTOP) Investigative T58992 DRUGINFO D0O7NF MCP-205 Investigative T58992 DRUGINFO D0OH7D 7-benzylidenenaltrexone Investigative T58992 DRUGINFO D0P2TT H-Cpa-c[pen-Gly-Phe-pen]OH Investigative T58992 DRUGINFO D0Q3XK LONGANINE Investigative T58992 DRUGINFO D0QA1M MCP-203 Investigative T58992 DRUGINFO D0U5QL Grandisine D Investigative T58992 DRUGINFO D0U7PT ANALOG OF DYNORPHIN A Investigative T58992 DRUGINFO D0UA3E N-methylstephuline Investigative T58992 DRUGINFO D0W1YD H-Poa-ser-Gly-Phe-Leu-Thr-OH Investigative T58992 DRUGINFO D0Y4SP ICI 154129 Investigative T58992 DRUGINFO D0Y7CI SNC-80 Investigative T58992 DRUGINFO D0Z6DK Isoelaeocarpine Investigative T58992 DRUGINFO D0ZY3C Lophocladine a Investigative T58992 DRUGINFO D00FXL H-Aba-ser-Gly-Phe-Leu-Thr-OH Investigative T58992 DRUGINFO D00FZN Tyr-(R)-Aba-Gly-Phe-NH2 Investigative T58992 DRUGINFO D00LLO H-Dmt-Tic-Lys-NH-Ph Investigative T58992 DRUGINFO D00MEM H-Dmt-Tic-Gly-NH-CH2-Bid Investigative T58992 DRUGINFO D00QLH H-Dmt-Tic-D-Asp-N(Me)-Ph Investigative T58992 DRUGINFO D00WBU H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid Investigative T58992 DRUGINFO D00WEV H-Dmt-Tic-Glu-Dap(6DMN)-NH(2) Investigative T58992 DRUGINFO D00XQV Tyr-Pro-D-Phe-Pro-NH2 Investigative T58992 DRUGINFO D01HOP H-mCpa-ala-Gly-Phe-leu-OH Investigative T58992 DRUGINFO D01JSA H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2 Investigative T58992 DRUGINFO D01MFM H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH Investigative T58992 DRUGINFO D01SDX H-Aba-ala-Gly-Phe-Met-OH Investigative T58992 DRUGINFO D01TKS Tyr-D-Ala-Gly-Phe-Met-NH2 Investigative T58992 DRUGINFO D02GMU Tyr-Pro-3,5Dmp-Phe-NH2 Investigative T58992 DRUGINFO D02IQG H-Dmt-Tic-NH-CH2-CH2-NH2 Investigative T58992 DRUGINFO D02WUZ Tyr-Pro-Phe-Phe-OCH2CH3 Investigative T58992 DRUGINFO D03BFH N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2 Investigative T58992 DRUGINFO D03BRB (H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2) Investigative T58992 DRUGINFO D03CKF H-Tyr-c[D-Orn-Aic-Glu]-NH2 Investigative T58992 DRUGINFO D03HXN 3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone Investigative T58992 DRUGINFO D03VSJ Antanal 1 Investigative T58992 DRUGINFO D03YDG UFP-502 Investigative T58992 DRUGINFO D04BII H-Dmt-Tic-D-Asp-NH-Ph Investigative T58992 DRUGINFO D04EZN Dimethylthiambutene Investigative T58992 DRUGINFO D04IIB H-Dmt-Tic-Asp-NH-Bzl Investigative T58992 DRUGINFO D04JCK Etorphine Investigative T58992 DRUGINFO D04KHE H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H Investigative T58992 DRUGINFO D04POA Tyr-Pro-L-Phe-Pro-NH2 Investigative T58992 DRUGINFO D04QXM Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2 Investigative T58992 DRUGINFO D04RPI Dmt-Pro-Trp-D-2-Nal-NH2 Investigative T58992 DRUGINFO D04SFK H-Tyr-Tic-Phe-Phe-OH Investigative T58992 DRUGINFO D04VJE 6-(2-phenethylisoindolin-5-yloxy)nicotinamide Investigative T58992 DRUGINFO D05AFV UFP-512 Investigative T58992 DRUGINFO D05GFM Tyr-(NMe)Ala-L-Phe-D-Pro-NH2 Investigative T58992 DRUGINFO D05KIQ H-Dmt-Tic-Gly-N(Me)-Ph Investigative T58992 DRUGINFO D05KIS H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H Investigative T58992 DRUGINFO D05NYR H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH Investigative T58992 DRUGINFO D06BAU CTAP Investigative T58992 DRUGINFO D06EES Leucine-enkephalin Investigative T58992 DRUGINFO D06NIP Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D06YMS DADLE Investigative T58992 DRUGINFO D07AUG H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Investigative T58992 DRUGINFO D07BPA 1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol Investigative T58992 DRUGINFO D07BXN Tyr-Pro-Dmt-Phe-NH2 Investigative T58992 DRUGINFO D07DTN H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2 Investigative T58992 DRUGINFO D07GQE Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 Investigative T58992 DRUGINFO D07JIQ H-Aba-Gly-Gly-Phe-Leu-OH Investigative T58992 DRUGINFO D07LXZ Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 Investigative T58992 DRUGINFO D07PPK 4-phenyl-4-[1H-imidazol-2-yl]-piperidine Investigative T58992 DRUGINFO D08BOD D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP) Investigative T58992 DRUGINFO D08CJB H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H Investigative T58992 DRUGINFO D08COK 1,10-bis-(Dmt-Tic-amino)decane Investigative T58992 DRUGINFO D08CXZ H-Dmt-Tic-NH-CH2-Bta Investigative T58992 DRUGINFO D08FGQ Tyr-Pro-D-Phg-Phe-NH2 Investigative T58992 DRUGINFO D08LIT SB-0304 Investigative T58992 DRUGINFO D08SCK H-Dmt-Aba-Gly-NH-CH2-Ph Investigative T58992 DRUGINFO D08STW Tyr-Pro-L-(NMe)Phe-Pro-NH2 Investigative T58992 DRUGINFO D08VOC 3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone Investigative T58992 DRUGINFO D09DAM H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph Investigative T58992 DRUGINFO D09GQP H-2',6'-dimethyltyrosine-Tic-OH Investigative T58992 DRUGINFO D09GSD H-Dmt-Aba-Gly-NH-CH2-Bid Investigative T58992 DRUGINFO D09MBV H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me) Investigative T58992 DRUGINFO D0A9AJ H-mCpa-ser-Gly-Phe-Leu-Thr-OH Investigative T58992 DRUGINFO D0AJ9D H-Dmt-Tic-Lys(Z)-NH-Ph Investigative T58992 DRUGINFO D0B1JC Tyr-Pro-Phe-Phe-N(CH3)2 Investigative T58992 DRUGINFO D0C4QH Tyr-Pro-Mmp-Phe-NH Investigative T58992 DRUGINFO D0C5RC N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2 Investigative T58992 DRUGINFO D0C9XB D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 Investigative T58992 DRUGINFO D0D5SK ethyketazocine Investigative T58992 DRUGINFO D0D8DZ H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid Investigative T58992 DRUGINFO D0D9RL (-)-eseroline Investigative T58992 DRUGINFO D0DN6A 1,4-bis-(Dmt-Tic-amino)butane Investigative T58992 DRUGINFO D0E7NL H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH Investigative T58992 DRUGINFO D0ED2I H-Dmt-Tic-Gly-NH-Ph Investigative T58992 DRUGINFO D0EG7I H-Dmt-Tic-Lys(Ac)-NH-Ph Investigative T58992 DRUGINFO D0EM9A DSLET Investigative T58992 DRUGINFO D0ES7P H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2 Investigative T58992 DRUGINFO D0F1XY H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc Investigative T58992 DRUGINFO D0FT9J Tyr-Pro-Tmp-Phe-NH Investigative T58992 DRUGINFO D0H1BU H-Dmt-Tic-Gly-NH-Bzl Investigative T58992 DRUGINFO D0H2RF Tyr-Pro-Imp-Phe-NH2 Investigative T58992 DRUGINFO D0H3QK AMINOFENTANYL Investigative T58992 DRUGINFO D0H8WV Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2 Investigative T58992 DRUGINFO D0HF0I Tyr-Pro-Phe-Phe-NHCH3 Investigative T58992 DRUGINFO D0I1BJ Dmt-Pro-Phe-D-1-Nal-NH2 Investigative T58992 DRUGINFO D0I3XV RTI-5989-25 Investigative T58992 DRUGINFO D0I9IX Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2 Investigative T58992 DRUGINFO D0J2IK 3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone Investigative T58992 DRUGINFO D0J7XM DELTORPHIN-II Investigative T58992 DRUGINFO D0K2OK Tyr-Pro-Dmp-Phe-NH2 Investigative T58992 DRUGINFO D0K4AC DELTORPHIN Investigative T58992 DRUGINFO D0L3DM Tyr-Pro-D-Phe-D-Pro-NH2 Investigative T58992 DRUGINFO D0L9NB H-Dmt-Tic-NH-CH2-ImidPh Investigative T58992 DRUGINFO D0M6BL H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2 Investigative T58992 DRUGINFO D0M6CZ H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH Investigative T58992 DRUGINFO D0MP7Z Dmt-Pro-Phe-D-2-Nal-NH2 Investigative T58992 DRUGINFO D0MZ2A CTOP Investigative T58992 DRUGINFO D0N0JC RTI-5989-23 Investigative T58992 DRUGINFO D0N1AO H-Dmt-Tic-NH-CH2-Indn Investigative T58992 DRUGINFO D0N5TL Antanal 2 Investigative T58992 DRUGINFO D0NB7S Tyr-Pro-Phe-Phe-OC(CH3)3 Investigative T58992 DRUGINFO D0NE3U DERMORPHIN Investigative T58992 DRUGINFO D0O4KY Tyr-Pro-Phe-Phe-OCH3 Investigative T58992 DRUGINFO D0O7NC H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid Investigative T58992 DRUGINFO D0P1CP H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2 Investigative T58992 DRUGINFO D0P2KV H-Dmt-Tic-Asp-N(Me)-Ph Investigative T58992 DRUGINFO D0P4PM H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2 Investigative T58992 DRUGINFO D0P5EI H-Dmt-Tic-Glu-NH-(CH2)5-NH2 Investigative T58992 DRUGINFO D0P6AR Tyr-Pro-L-(NMe)Phe-D-Pro-NH2 Investigative T58992 DRUGINFO D0P8NZ H-Dmt-Tic-NH-CH2-Indl Investigative T58992 DRUGINFO D0PN1A H-Dmt-Tic-Asp-NH-Ph Investigative T58992 DRUGINFO D0PN3P H-Aba-ala-Gly-Phe-leu-OH Investigative T58992 DRUGINFO D0Q0UQ H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Investigative T58992 DRUGINFO D0Q1PN H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac Investigative T58992 DRUGINFO D0Q2HZ H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me) Investigative T58992 DRUGINFO D0Q7SS Tyr-(S)-Aba-Gly-Phe-NH2 Investigative T58992 DRUGINFO D0R1DY H-Dmt-Tic-Lys-NH-CH2-Ph Investigative T58992 DRUGINFO D0R3GD H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid Investigative T58992 DRUGINFO D0R4KJ H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH Investigative T58992 DRUGINFO D0R4YD H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH Investigative T58992 DRUGINFO D0R9AP H-Apa-ala-Gly-Phe-leu-OH Investigative T58992 DRUGINFO D0R9LV 1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane Investigative T58992 DRUGINFO D0R9XD H-Dmt-Tic-Lys(Z)-NH-CH2-Ph Investigative T58992 DRUGINFO D0RR4X H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Investigative T58992 DRUGINFO D0S3LK 1,6-bis-(Dmt-Tic-amino)hexane Investigative T58992 DRUGINFO D0U3ZL CARBOXYFENTANYL Investigative T58992 DRUGINFO D0U4LU H-Dmt-Tic-NH-(CH2)6-NH-Phe-H Investigative T58992 DRUGINFO D0U5OP 1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol Investigative T58992 DRUGINFO D0U8YU Tyr-Pro-Phe-Phe-OCH2OH Investigative T58992 DRUGINFO D0UV1C 3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone Investigative T58992 DRUGINFO D0V2PM H-Dmt-Tic-NH-CH2-Imid Investigative T58992 DRUGINFO D0V3GN Tyr-Pro-Phe-Phe-NHNH2 Investigative T58992 DRUGINFO D0V8UG H-Dmt-Tic-NH-CH2-Boa Investigative T58992 DRUGINFO D0W8MP H-Dmt-Tic-Glu-NH2 Investigative T58992 DRUGINFO D0X2HA H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid Investigative T58992 DRUGINFO D0X4YC H-Dmt-Tic-NH-(CH2)6-NH-Tic-H Investigative T58992 DRUGINFO D0X5TB H-Cdp-ser-Gly-Phe-Leu-Thr-OH Investigative T58992 DRUGINFO D0X9SP D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP) Investigative T58992 DRUGINFO D0X9TT Tyr-(S)-spiro-Aba-Gly-Phe-NH2 Investigative T58992 DRUGINFO D0Y2HI H-Dmt-Aba-Gly-NH-Ph Investigative T58992 DRUGINFO D0Y5TF Tyr-Pro-Emp-Phe-NH2 Investigative T58992 DRUGINFO D0Y5UN Tyr-Pro-L-Phe-D-Pro-NH2 Investigative T58992 DRUGINFO D0Z5UG H-Tyr-Tic-Cha-Phe-OH Investigative T58992 DRUGINFO D0ZI5Z H-Tyr-Pro-Dap(6DMN)-Phe-NH2 Investigative T58992 DRUGINFO D0ZQ7L H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2 Investigative T58992 DRUGINFO D00HIG 3-Methylthiofentanyl Investigative T58992 DRUGINFO D00JAT (-)-cyclorphan Investigative T58992 DRUGINFO D00JPB 5-(4-((phenethylamino)methyl)phenoxy)picolinamide Investigative T58992 DRUGINFO D00NRB MCL-117 Investigative T58992 DRUGINFO D00SDP 17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine Investigative T58992 DRUGINFO D01ADK Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D01EPU BUTORPHAN Investigative T58992 DRUGINFO D01RFG 8-carboxamidocyclazocine Investigative T58992 DRUGINFO D02BER quadazocine Investigative T58992 DRUGINFO D02FZW 17-methyl-4'-methyldihydromorphinone Investigative T58992 DRUGINFO D02IMZ MCL-443 Investigative T58992 DRUGINFO D02PIG H-Cpa-Gly-Gly-Phe-Met-OH Investigative T58992 DRUGINFO D02RYZ MCL-450 Investigative T58992 DRUGINFO D03QWP Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Investigative T58992 DRUGINFO D03UFD OXYMORPHINDOLE Investigative T58992 DRUGINFO D03UHT MCL-458 Investigative T58992 DRUGINFO D03WGS H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac Investigative T58992 DRUGINFO D04JFL Naltrexone-6-alpha-ol Investigative T58992 DRUGINFO D04PPP MCL-139 Investigative T58992 DRUGINFO D04UFM Dmt-Pro-Dmt-Phe-NH2 Investigative T58992 DRUGINFO D04UIK MCL-429 Investigative T58992 DRUGINFO D05ANN naltriben Investigative T58992 DRUGINFO D05EZE Dmt-Pro-Phe-Phe-NH2 Investigative T58992 DRUGINFO D05FEQ CYCLORPHAN Investigative T58992 DRUGINFO D05JSY MCL-145 Investigative T58992 DRUGINFO D05QJS NORBINALTORPHIMINE Investigative T58992 DRUGINFO D05TOY Dmt-Pro-3,5Dmp-Phe-NH2 Investigative T58992 DRUGINFO D05YNT [3H]diprenorphine Investigative T58992 DRUGINFO D05ZIH 6beta-naltrexol HCl Investigative T58992 DRUGINFO D06IXE MCL-153 Investigative T58992 DRUGINFO D06KFX C[L-Phe-D-pro-L-Phe-L-trp] Investigative T58992 DRUGINFO D06MWG Dmt-Pro-Mmp-Phe-NH2 Investigative T58992 DRUGINFO D06NST CYCLAZOCINE Investigative T58992 DRUGINFO D06OKE MCL-433 Investigative T58992 DRUGINFO D06WTI NRP290 Investigative T58992 DRUGINFO D07AAK M6G thiosaccharide analogue Investigative T58992 DRUGINFO D07DFD MCL-434 Investigative T58992 DRUGINFO D07HFU MCL-446 Investigative T58992 DRUGINFO D07JZS H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2 Investigative T58992 DRUGINFO D08IWF MCL-435 Investigative T58992 DRUGINFO D08KSJ H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2 Investigative T58992 DRUGINFO D08NJB Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Investigative T58992 DRUGINFO D08ORS 6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol Investigative T58992 DRUGINFO D08QKT Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D08RPH MCL-182 Investigative T58992 DRUGINFO D09DUE MCL-447 Investigative T58992 DRUGINFO D09FLC 17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate Investigative T58992 DRUGINFO D09RUY N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine Investigative T58992 DRUGINFO D09UKS MCL-183 Investigative T58992 DRUGINFO D0A5MU Deprotected cogener of M6G Investigative T58992 DRUGINFO D0B8MY MCL-144 Investigative T58992 DRUGINFO D0C2UQ MCL-428 Investigative T58992 DRUGINFO D0C6RQ H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2 Investigative T58992 DRUGINFO D0C7MP MCL-448 Investigative T58992 DRUGINFO D0CK8C H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl Investigative T58992 DRUGINFO D0CX0I [Dcp1]Dyn A(1-11)-NH2 Investigative T58992 DRUGINFO D0D3UB SN-23 Investigative T58992 DRUGINFO D0D8AN 6-desoxonaltrexone Investigative T58992 DRUGINFO D0E0TD 4-(4-((phenethylamino)methyl)phenoxy)benzamide Investigative T58992 DRUGINFO D0E1FQ Dmt-Pro-Imp-Phe-NH2 Investigative T58992 DRUGINFO D0E6GH 14-O-phenylpropylnaltrexone Investigative T58992 DRUGINFO D0F1EB MC-CAM Investigative T58992 DRUGINFO D0F4AN MCL-432 Investigative T58992 DRUGINFO D0F8CV DAMGO Investigative T58992 DRUGINFO D0G4NM DPDPE Investigative T58992 DRUGINFO D0G6GC Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl Investigative T58992 DRUGINFO D0G7FB MCL-147 Investigative T58992 DRUGINFO D0H0KP 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide Investigative T58992 DRUGINFO D0H0OO dynorphin B Investigative T58992 DRUGINFO D0H3GI 4-(p-Tolyl)spiro[chromene-2,4'-piperidine] Investigative T58992 DRUGINFO D0HB6O H-Cdp-Gly-Gly-Phe-Leu-OH Investigative T58992 DRUGINFO D0HC3H Dimepheptanol Investigative T58992 DRUGINFO D0HV6H H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2 Investigative T58992 DRUGINFO D0I1NG 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide Investigative T58992 DRUGINFO D0I2CE C[L-mTyr-D-pro-L-Phe-D-trp] Investigative T58992 DRUGINFO D0I9PH H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H Investigative T58992 DRUGINFO D0I9SX PHENAZOCINE Investigative T58992 DRUGINFO D0IY2V MCL-445 Investigative T58992 DRUGINFO D0J3NK MCL-449 Investigative T58992 DRUGINFO D0K1BV N-(17-Methylmorphinan-3-yl)-N'-phenylurea Investigative T58992 DRUGINFO D0K4XQ MCL-431 Investigative T58992 DRUGINFO D0KL5N Dmt-Pro-Tmp-Phe-NH2 Investigative T58992 DRUGINFO D0L0NI Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Investigative T58992 DRUGINFO D0L2CT H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2 Investigative T58992 DRUGINFO D0L5DN MCL-149 Investigative T58992 DRUGINFO D0L6QN LOFENTANIL Investigative T58992 DRUGINFO D0L8LX H-Tyr-Gly-Gly-Phe-Met-NH2 Investigative T58992 DRUGINFO D0M1YV ELAEOCARPENINE Investigative T58992 DRUGINFO D0N2DN 4-Phenylspiro[chromene-2,4'-piperidine] Investigative T58992 DRUGINFO D0N8LP Beta-endorphin Investigative T58992 DRUGINFO D0NA7G MCL-451 Investigative T58992 DRUGINFO D0NV5N normorphine Investigative T58992 DRUGINFO D0O1JD 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide Investigative T58992 DRUGINFO D0O6SB Diprenorphine Investigative T58992 DRUGINFO D0P0RB H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl Investigative T58992 DRUGINFO D0P5QI 2-Hydroxymethyl-3-hydroxymorphinan Investigative T58992 DRUGINFO D0P6FF N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine Investigative T58992 DRUGINFO D0Q5AJ MCL-154 Investigative T58992 DRUGINFO D0Q7HG H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl Investigative T58992 DRUGINFO D0R1AB H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH Investigative T58992 DRUGINFO D0R4QF HERKINORIN Investigative T58992 DRUGINFO D0R5TA ENDOMORPHIN-1 Investigative T58992 DRUGINFO D0R6VF Clocinnamox Investigative T58992 DRUGINFO D0R7LY Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Investigative T58992 DRUGINFO D0S2OA 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine Investigative T58992 DRUGINFO D0S5FN H-Cdp-ala-Gly-Phe-leu-OH Investigative T58992 DRUGINFO D0S7SO H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo Investigative T58992 DRUGINFO D0SC3W Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate Investigative T58992 DRUGINFO D0T5EI ethylketocyclazocine Investigative T58992 DRUGINFO D0T6OQ 3-desoxy-3-carboxamidonaltrexone Investigative T58992 DRUGINFO D0TB4A Dmt-Pro-Emp-Phe-NH2 Investigative T58992 DRUGINFO D0TN0D METAZOCINE Investigative T58992 DRUGINFO D0TO0E SN-28 Investigative T58992 DRUGINFO D0U3UM ETONITAZENE Investigative T58992 DRUGINFO D0U7JS H-Cpa-Gly-Gly-Phe-Met-NH2 Investigative T58992 DRUGINFO D0UG8H SN-11 Investigative T58992 DRUGINFO D0UR7D Benzyl derivative of M6G Investigative T58992 DRUGINFO D0V0RB Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D0VO7C HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 Investigative T58992 DRUGINFO D0W0CO 17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine Investigative T58992 DRUGINFO D0W2DN MCL-444 Investigative T58992 DRUGINFO D0W6OP H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 Investigative T58992 DRUGINFO D0X0XV Dmt-Pro-Dmp-Phe-NH2 Investigative T58992 DRUGINFO D0X6BU H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 Investigative T58992 DRUGINFO D0X7LC Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D0Y5ZP N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea Investigative T58992 DRUGINFO D0Y8NO RTI-5989-31 Investigative T58992 DRUGINFO D0YU5H 6-(4-((benzylamino)methyl)phenoxy)nicotinamide Investigative T58992 DRUGINFO D0Z5JD [Leu5]enkephalin Investigative T58992 DRUGINFO D0Z8JX C[L-Phe-D-pro-L-mTyr-D-trp] Investigative T58992 DRUGINFO D0ZH3G 3-Methylfentanyl Investigative T58992 DRUGINFO D00TNR ENDOMORPHIN 2 Investigative T58992 DRUGINFO D00YCW 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol Investigative T58992 DRUGINFO D01AQC Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D01WMU 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol Investigative T58992 DRUGINFO D02EIB 4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol Investigative T58992 DRUGINFO D03EPA Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D03PTV 1-benzhydryl-4-ethoxy-4-phenylpiperidine Investigative T58992 DRUGINFO D03RBD 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide Investigative T58992 DRUGINFO D03UJW 1-benzhydryl-4-butylpiperidin-4-ol Investigative T58992 DRUGINFO D04ZQX 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol Investigative T58992 DRUGINFO D06BRA Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D06MQG 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol Investigative T58992 DRUGINFO D06PHT 1-benzhydryl-4-phenylpiperidin-4-ol Investigative T58992 DRUGINFO D07CIU 1-benzhydryl-4-p-tolylpiperidin-4-ol Investigative T58992 DRUGINFO D07ICW Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D07LQQ Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D07NMH 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol Investigative T58992 DRUGINFO D08DVV 1-benzhydryl-4-hexylpiperidin-4-ol Investigative T58992 DRUGINFO D08QBU 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol Investigative T58992 DRUGINFO D08TFY 1-benzhydryl-4-cyclohexylpiperidin-4-ol Investigative T58992 DRUGINFO D09BYD 1-benzhydryl-4-o-tolylpiperidin-4-ol Investigative T58992 DRUGINFO D09EMR Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D09FJY 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol Investigative T58992 DRUGINFO D09LRO 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol Investigative T58992 DRUGINFO D09VRT 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol Investigative T58992 DRUGINFO D0B7GU Dihydromorphine Investigative T58992 DRUGINFO D0D0UP 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol Investigative T58992 DRUGINFO D0D5QV O-DESMETHYL TRAMADOL Investigative T58992 DRUGINFO D0E2OG Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D0G4FA 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol Investigative T58992 DRUGINFO D0G7DF 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol Investigative T58992 DRUGINFO D0J5JO 1-benzhydryl-4-m-tolylpiperidin-4-ol Investigative T58992 DRUGINFO D0J7GJ H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H Investigative T58992 DRUGINFO D0JH5D 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol Investigative T58992 DRUGINFO D0N6DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc Investigative T58992 DRUGINFO D0O7JV 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol Investigative T58992 DRUGINFO D0P3FP 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol Investigative T58992 DRUGINFO D0Q9TQ 1-benzhydryl-4-methoxy-4-phenylpiperidine Investigative T58992 DRUGINFO D0QH4A 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol Investigative T58992 DRUGINFO D0QP2S Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc Investigative T58992 DRUGINFO D0R4GI Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D0T4ZY 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol Investigative T58992 DRUGINFO D0T9KE 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol Investigative T58992 DRUGINFO D0TR0U Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D0U6OA Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T58992 DRUGINFO D0V9DY H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H Investigative T58992 DRUGINFO D0W3VT 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol Investigative T58992 DRUGINFO D0X4SX 1-benzhydryl-4-phenyl-4-propoxypiperidine Investigative T58992 DRUGINFO D0XX1Y 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol Investigative T58992 DRUGINFO D0Y5LJ 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol Investigative T58992 DRUGINFO D0ZE2W 1-benzhydryl-4-benzylpiperidin-4-ol Investigative T58992 DRUGINFO D03SAV ICI-199441 Investigative T58992 DRUGINFO D08UOX FALCARINDIOL Investigative T58992 DRUGINFO D0L9YP 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide Investigative T58992 DRUGINFO D0T5RO SOMATOSTATIN Investigative T60693 TARGETID T60693 T60693 FORMERID TTDS00127 T60693 UNIPROID OPRK_HUMAN T60693 TARGNAME Opioid receptor kappa (OPRK1) T60693 GENENAME OPRK1 T60693 TARGTYPE Successful T60693 SYNONYMS OPRK; Kappa-type opioid receptor; Kappa opioid receptor; KOR-1; KOR; K-OR-1 T60693 FUNCTION Functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions. G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. T60693 PDBSTRUC 6B73; 4DJH; 2IQN; 2A0D T60693 BIOCLASS GPCR rhodopsin T60693 SEQUENCE MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEPAHISPAIPVIITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSTVYLMNSWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINICIWLLSSSVGISAIVLGGTKVREDVDVIECSLQFPDDDYSWWDLFMKICVFIFAFVIPVLIIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVFVVCWTPIHIFILVEALGSTSHSTAALSSYYFCIALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRVRNTVQDPAYLRDIDGMNKPV T60693 DRUGINFO D01KQA Nalbuphine Approved T60693 DRUGINFO D02HWP CHLOROXINE Approved T60693 DRUGINFO D0K3OK Difelikefalin Approved T60693 DRUGINFO D0P6VV Dezocine Approved T60693 DRUGINFO D02RXG Nalfurafine hcl Approved T60693 DRUGINFO D07TQN Asimadoline Phase 3 T60693 DRUGINFO DSNA01 JNJ 67953964 Phase 3 T60693 DRUGINFO D06ZXH PHN-131 Phase 2/3 T60693 DRUGINFO D08NJE CR-845 Phase 2/3 T60693 DRUGINFO D01HBG Apadoline Phase 2 T60693 DRUGINFO D07YHM LY-2456302 Phase 2 T60693 DRUGINFO D09ALE Enadoline Phase 2 T60693 DRUGINFO D0L1KX CR-665 Phase 2 T60693 DRUGINFO D0PW4C Niravoline Phase 2 T60693 DRUGINFO DDK53C BTRX-335140 Phase 2 T60693 DRUGINFO DDQH94 A277 Phase 2 T60693 DRUGINFO DW7OF1 ORP-101 Phase 2 T60693 DRUGINFO D03PJU Carfentanil Phase 2 T60693 DRUGINFO D0LU5Q TPM-1/Morphine Phase 2 T60693 DRUGINFO D00SVP PF-4455242 Phase 1 T60693 DRUGINFO D0RN6V BRL-52656 Phase 1 T60693 DRUGINFO D00HBR AIKO-150 Phase 1 T60693 DRUGINFO D01AKU MCP-201 Phase 1 T60693 DRUGINFO D06EXA SALVINORIN A Phase 1 T60693 DRUGINFO D06ABW CLIOQUINOL Withdrawn from market T60693 DRUGINFO D00KUD ADL 10-0101 Discontinued in Phase 2 T60693 DRUGINFO D04OXU E-2078 Discontinued in Phase 2 T60693 DRUGINFO D0N7SG R-84760 Discontinued in Phase 2 T60693 DRUGINFO D0Y8SK Dynorphin a Discontinued in Phase 2 T60693 DRUGINFO D0J5XZ VP004 Discontinued in Phase 1 T60693 DRUGINFO D0X6SZ GNTI Preclinical T60693 DRUGINFO D0C2QF LY-25582 Preclinical T60693 DRUGINFO D02PIN GR-94839 Terminated T60693 DRUGINFO D03EFD KT-95 Terminated T60693 DRUGINFO D06FEF Fedotozine Terminated T60693 DRUGINFO D0M7BW GR-89696 Terminated T60693 DRUGINFO D08YUP SB-213698 Terminated T60693 DRUGINFO D01BPI Salvinorin B fluoromethyl ether Investigative T60693 DRUGINFO D01EKO GR-86014 Investigative T60693 DRUGINFO D01FPD Salvinorin B 2-fluoroethoxymethyl ether Investigative T60693 DRUGINFO D02JHE [U-13C]ascomycin Investigative T60693 DRUGINFO D03PIF Salvinorin B tetrahydropyran-2-yl ether Investigative T60693 DRUGINFO D04FBZ Nalorphine Investigative T60693 DRUGINFO D04QUB 12-EPI-SALVINORIN A Investigative T60693 DRUGINFO D04TZR ICI-204448 Investigative T60693 DRUGINFO D04YNW BRL 52537 hydrochloride Investigative T60693 DRUGINFO D05BCY 2-EPI-2-THIOSALVINORIN B Investigative T60693 DRUGINFO D05BZQ DEOXY SALVINORIN A Investigative T60693 DRUGINFO D05COL SALVINORIN B Investigative T60693 DRUGINFO D06QGJ 3-(1-benzylpiperidin-4-yloxy)benzamide Investigative T60693 DRUGINFO D06TQU GR-45809 Investigative T60693 DRUGINFO D06UTW Salvinorin B butoxymethyl ether Investigative T60693 DRUGINFO D07GMY BRL 52974 Investigative T60693 DRUGINFO D07KTF Salvinorin B ethoxymethyl ether Investigative T60693 DRUGINFO D08HTW Drug 7684380 Investigative T60693 DRUGINFO D08TDQ Morphinan Cyclic Imine analogue Investigative T60693 DRUGINFO D08VVC N,N-dibenzyl[D-Pro-10]Dyn A-(1-11) Investigative T60693 DRUGINFO D09JXT N-allyl[D-Pro-10]Dyn A-(1-11) Investigative T60693 DRUGINFO D09RSU N-CPM[D-Pro-10]Dyn A-(1-11) Investigative T60693 DRUGINFO D09WSG Salvinorin B benzyloxymethyl ether Investigative T60693 DRUGINFO D0A3KA Salvinorin B 2,2,2-trifluoroethoxymethyl ether Investigative T60693 DRUGINFO D0B6VF GR-91272 Investigative T60693 DRUGINFO D0C7EI GR-38414 Investigative T60693 DRUGINFO D0C9II Salvinorin B 1-ethoxyethyl ether Investigative T60693 DRUGINFO D0E0OF Salvinorin B tert-butoxymethyl ether Investigative T60693 DRUGINFO D0E9HW Salvinorin B propoxymethyl ether Investigative T60693 DRUGINFO D0ET0T 2-EPI-2-THIOSALVINORIN A Investigative T60693 DRUGINFO D0G0HP SALVINICIN B Investigative T60693 DRUGINFO D0GX3K N,N-diallyl[D-Pro-10]Dyn A-(1-11) Investigative T60693 DRUGINFO D0H2CI Salvinorin B methoxymethyl ether Investigative T60693 DRUGINFO D0H3VZ Salvinorin B methylthiomethyl ether Investigative T60693 DRUGINFO D0HQ0E spiradoline Investigative T60693 DRUGINFO D0I3AH N-benzyl[D-Pro-10]Dyn A-(1-11) Investigative T60693 DRUGINFO D0IL7F N,N-diCPM[D-Pro-10]Dyn A-(1-11) Investigative T60693 DRUGINFO D0J1PJ U50,488H Investigative T60693 DRUGINFO D0K9HE Nor-binaltorphimine dihydrochloride Investigative T60693 DRUGINFO D0M9GO tifluadom Investigative T60693 DRUGINFO D0O7RK Salvinorin B 2-methoxyethoxymethyl ether Investigative T60693 DRUGINFO D0P8TI Salvinicin A Investigative T60693 DRUGINFO D0Q3CD Salvinorin B 2-methoxy-2-propyl ether Investigative T60693 DRUGINFO D0R7OE Salvinorin B isopropoxymethyl ether Investigative T60693 DRUGINFO D0S1MA ANISOCOUMARIN H Investigative T60693 DRUGINFO D0W7DM 2-THIOSALVINORIN B Investigative T60693 DRUGINFO D0ZG9I Salvinorin A (ester) Investigative T60693 DRUGINFO D03KAQ 2-Benzylaminomethyl-3-hydroxymorphinan Investigative T60693 DRUGINFO D03RSA M6S Investigative T60693 DRUGINFO D03WYO KETOCYCLAZOCINE Investigative T60693 DRUGINFO D05EWZ SPIROINDANYLOXYMORPHONE Investigative T60693 DRUGINFO D05ZYZ NalBzOH Investigative T60693 DRUGINFO D06SZI MCL-457 Investigative T60693 DRUGINFO D07PPK 4-phenyl-4-[1H-imidazol-2-yl]-piperidine Investigative T60693 DRUGINFO D07QUY C[L-Phe-D-pro-L-Tyr(OMe)-D-trp] Investigative T60693 DRUGINFO D08BST N-isobutylnoroxymorphone Investigative T60693 DRUGINFO D08FYQ KNT-63 Investigative T60693 DRUGINFO D08IGF L-685,818 Investigative T60693 DRUGINFO D08QBS MK-1925 Investigative T60693 DRUGINFO D09BWX C[L-Phe-D-pro-L-Phe-D-trp] Investigative T60693 DRUGINFO D09SBU C[L-Ala-D-pro-L-Phe-D-trp] Investigative T60693 DRUGINFO D0D1WB Dynorphin(1-8) Investigative T60693 DRUGINFO D0D5SK ethyketazocine Investigative T60693 DRUGINFO D0D5VD C[L-Phe-D-pro-L-Tyr-D-trp] Investigative T60693 DRUGINFO D0D6KZ KNT-62 Investigative T60693 DRUGINFO D0D6OA DM6S Investigative T60693 DRUGINFO D0DO6P MR-2034 Investigative T60693 DRUGINFO D0H6AA M3Pr6S Investigative T60693 DRUGINFO D0I3XV RTI-5989-25 Investigative T60693 DRUGINFO D0K0XT MR-1029 Investigative T60693 DRUGINFO D0M4DI MR-2266 Investigative T60693 DRUGINFO D0N0JC RTI-5989-23 Investigative T60693 DRUGINFO D0P2GB MR-1526 Investigative T60693 DRUGINFO D0P2LE 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide Investigative T60693 DRUGINFO D0P5IH C[L-Tyr(OMe)-D-pro-L-Phe-D-trp] Investigative T60693 DRUGINFO D0Q6CF C[L-Tyr-D-pro-L-Phe-D-trp] Investigative T60693 DRUGINFO D0S9UH ZYKLOPHIN Investigative T60693 DRUGINFO D0TH8E M3P6S Investigative T60693 DRUGINFO D0V3OY [3H]U69593 Investigative T60693 DRUGINFO D0WZ7J M3A6S Investigative T60693 DRUGINFO D0X2HT M3IBu6S Investigative T60693 DRUGINFO D0YK5E Oxymorphone semicarbazone hydrochloride Investigative T60693 DRUGINFO D00HIG 3-Methylthiofentanyl Investigative T60693 DRUGINFO D00JAT (-)-cyclorphan Investigative T60693 DRUGINFO D00JPB 5-(4-((phenethylamino)methyl)phenoxy)picolinamide Investigative T60693 DRUGINFO D00NRB MCL-117 Investigative T60693 DRUGINFO D00SDP 17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine Investigative T60693 DRUGINFO D00XZH 1-benzhydryl-4-isopropylpiperidin-4-ol Investigative T60693 DRUGINFO D01EPU BUTORPHAN Investigative T60693 DRUGINFO D01MUV 1-benzhydryl-4-tert-butylpiperidin-4-ol Investigative T60693 DRUGINFO D01RFG 8-carboxamidocyclazocine Investigative T60693 DRUGINFO D02BER quadazocine Investigative T60693 DRUGINFO D02FZW 17-methyl-4'-methyldihydromorphinone Investigative T60693 DRUGINFO D02IMZ MCL-443 Investigative T60693 DRUGINFO D02PIG H-Cpa-Gly-Gly-Phe-Met-OH Investigative T60693 DRUGINFO D02RYZ MCL-450 Investigative T60693 DRUGINFO D03QWP Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Investigative T60693 DRUGINFO D03UFD OXYMORPHINDOLE Investigative T60693 DRUGINFO D03UHT MCL-458 Investigative T60693 DRUGINFO D04JFL Naltrexone-6-alpha-ol Investigative T60693 DRUGINFO D04PPP MCL-139 Investigative T60693 DRUGINFO D04UFM Dmt-Pro-Dmt-Phe-NH2 Investigative T60693 DRUGINFO D04UIK MCL-429 Investigative T60693 DRUGINFO D05ANN naltriben Investigative T60693 DRUGINFO D05EZE Dmt-Pro-Phe-Phe-NH2 Investigative T60693 DRUGINFO D05FEQ CYCLORPHAN Investigative T60693 DRUGINFO D05JSY MCL-145 Investigative T60693 DRUGINFO D05QJS NORBINALTORPHIMINE Investigative T60693 DRUGINFO D05RII 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole Investigative T60693 DRUGINFO D05TOY Dmt-Pro-3,5Dmp-Phe-NH2 Investigative T60693 DRUGINFO D05YNT [3H]diprenorphine Investigative T60693 DRUGINFO D05ZIH 6beta-naltrexol HCl Investigative T60693 DRUGINFO D06IXE MCL-153 Investigative T60693 DRUGINFO D06KFX C[L-Phe-D-pro-L-Phe-L-trp] Investigative T60693 DRUGINFO D06MWG Dmt-Pro-Mmp-Phe-NH2 Investigative T60693 DRUGINFO D06NST CYCLAZOCINE Investigative T60693 DRUGINFO D06OKE MCL-433 Investigative T60693 DRUGINFO D06PVO 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol Investigative T60693 DRUGINFO D06WTI NRP290 Investigative T60693 DRUGINFO D07AAK M6G thiosaccharide analogue Investigative T60693 DRUGINFO D07DFD MCL-434 Investigative T60693 DRUGINFO D07FCB 4-phenyl-1-(1-phenylethyl)piperidin-4-ol Investigative T60693 DRUGINFO D07HFU MCL-446 Investigative T60693 DRUGINFO D07JZS H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2 Investigative T60693 DRUGINFO D08IWF MCL-435 Investigative T60693 DRUGINFO D08NJB Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Investigative T60693 DRUGINFO D08ORS 6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol Investigative T60693 DRUGINFO D08RPH MCL-182 Investigative T60693 DRUGINFO D09DUE MCL-447 Investigative T60693 DRUGINFO D09FLC 17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate Investigative T60693 DRUGINFO D09RUY N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine Investigative T60693 DRUGINFO D09UKS MCL-183 Investigative T60693 DRUGINFO D0A5MU Deprotected cogener of M6G Investigative T60693 DRUGINFO D0B8MY MCL-144 Investigative T60693 DRUGINFO D0C2UQ MCL-428 Investigative T60693 DRUGINFO D0C7MP MCL-448 Investigative T60693 DRUGINFO D0CX0I [Dcp1]Dyn A(1-11)-NH2 Investigative T60693 DRUGINFO D0D3UB SN-23 Investigative T60693 DRUGINFO D0D8AN 6-desoxonaltrexone Investigative T60693 DRUGINFO D0D9BB 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol Investigative T60693 DRUGINFO D0E0TD 4-(4-((phenethylamino)methyl)phenoxy)benzamide Investigative T60693 DRUGINFO D0E1FQ Dmt-Pro-Imp-Phe-NH2 Investigative T60693 DRUGINFO D0E6GH 14-O-phenylpropylnaltrexone Investigative T60693 DRUGINFO D0F1EB MC-CAM Investigative T60693 DRUGINFO D0F4AN MCL-432 Investigative T60693 DRUGINFO D0F8CV DAMGO Investigative T60693 DRUGINFO D0G4NM DPDPE Investigative T60693 DRUGINFO D0G7FB MCL-147 Investigative T60693 DRUGINFO D0H0KP 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide Investigative T60693 DRUGINFO D0H0OO dynorphin B Investigative T60693 DRUGINFO D0H3GI 4-(p-Tolyl)spiro[chromene-2,4'-piperidine] Investigative T60693 DRUGINFO D0HB6O H-Cdp-Gly-Gly-Phe-Leu-OH Investigative T60693 DRUGINFO D0HC3H Dimepheptanol Investigative T60693 DRUGINFO D0HV6H H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2 Investigative T60693 DRUGINFO D0I1NG 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide Investigative T60693 DRUGINFO D0I2CE C[L-mTyr-D-pro-L-Phe-D-trp] Investigative T60693 DRUGINFO D0I9SX PHENAZOCINE Investigative T60693 DRUGINFO D0IL9H 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol Investigative T60693 DRUGINFO D0IY2V MCL-445 Investigative T60693 DRUGINFO D0J3NK MCL-449 Investigative T60693 DRUGINFO D0K1BV N-(17-Methylmorphinan-3-yl)-N'-phenylurea Investigative T60693 DRUGINFO D0K4XQ MCL-431 Investigative T60693 DRUGINFO D0KL5N Dmt-Pro-Tmp-Phe-NH2 Investigative T60693 DRUGINFO D0L0NI Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Investigative T60693 DRUGINFO D0L5DN MCL-149 Investigative T60693 DRUGINFO D0L6QN LOFENTANIL Investigative T60693 DRUGINFO D0L8LX H-Tyr-Gly-Gly-Phe-Met-NH2 Investigative T60693 DRUGINFO D0M1YV ELAEOCARPENINE Investigative T60693 DRUGINFO D0N2DN 4-Phenylspiro[chromene-2,4'-piperidine] Investigative T60693 DRUGINFO D0N8LP Beta-endorphin Investigative T60693 DRUGINFO D0NA7G MCL-451 Investigative T60693 DRUGINFO D0NV5N normorphine Investigative T60693 DRUGINFO D0O1JD 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide Investigative T60693 DRUGINFO D0O6SB Diprenorphine Investigative T60693 DRUGINFO D0P5QI 2-Hydroxymethyl-3-hydroxymorphinan Investigative T60693 DRUGINFO D0P6FF N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine Investigative T60693 DRUGINFO D0Q5AJ MCL-154 Investigative T60693 DRUGINFO D0R1AB H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH Investigative T60693 DRUGINFO D0R4QF HERKINORIN Investigative T60693 DRUGINFO D0R5TA ENDOMORPHIN-1 Investigative T60693 DRUGINFO D0R6VF Clocinnamox Investigative T60693 DRUGINFO D0R7LY Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Investigative T60693 DRUGINFO D0S2OA 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine Investigative T60693 DRUGINFO D0S5FN H-Cdp-ala-Gly-Phe-leu-OH Investigative T60693 DRUGINFO D0SC3W Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate Investigative T60693 DRUGINFO D0T5EI ethylketocyclazocine Investigative T60693 DRUGINFO D0T6OQ 3-desoxy-3-carboxamidonaltrexone Investigative T60693 DRUGINFO D0TB4A Dmt-Pro-Emp-Phe-NH2 Investigative T60693 DRUGINFO D0TN0D METAZOCINE Investigative T60693 DRUGINFO D0TO0E SN-28 Investigative T60693 DRUGINFO D0U3UM ETONITAZENE Investigative T60693 DRUGINFO D0U7JS H-Cpa-Gly-Gly-Phe-Met-NH2 Investigative T60693 DRUGINFO D0UG8H SN-11 Investigative T60693 DRUGINFO D0UR7D Benzyl derivative of M6G Investigative T60693 DRUGINFO D0VO7C HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 Investigative T60693 DRUGINFO D0W0CO 17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine Investigative T60693 DRUGINFO D0W2DN MCL-444 Investigative T60693 DRUGINFO D0W6OP H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 Investigative T60693 DRUGINFO D0X0XV Dmt-Pro-Dmp-Phe-NH2 Investigative T60693 DRUGINFO D0X6BU H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 Investigative T60693 DRUGINFO D0Y5ZP N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea Investigative T60693 DRUGINFO D0Y7KE 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol Investigative T60693 DRUGINFO D0Y8NO RTI-5989-31 Investigative T60693 DRUGINFO D0YU5H 6-(4-((benzylamino)methyl)phenoxy)nicotinamide Investigative T60693 DRUGINFO D0Z5JD [Leu5]enkephalin Investigative T60693 DRUGINFO D0Z8JX C[L-Phe-D-pro-L-mTyr-D-trp] Investigative T60693 DRUGINFO D0ZH3G 3-Methylfentanyl Investigative T60693 DRUGINFO D00TNR ENDOMORPHIN 2 Investigative T60693 DRUGINFO D00YCW 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol Investigative T60693 DRUGINFO D01WMU 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol Investigative T60693 DRUGINFO D02EIB 4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol Investigative T60693 DRUGINFO D03PTV 1-benzhydryl-4-ethoxy-4-phenylpiperidine Investigative T60693 DRUGINFO D03RBD 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide Investigative T60693 DRUGINFO D03UJW 1-benzhydryl-4-butylpiperidin-4-ol Investigative T60693 DRUGINFO D04ZQX 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol Investigative T60693 DRUGINFO D06MQG 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol Investigative T60693 DRUGINFO D06PHT 1-benzhydryl-4-phenylpiperidin-4-ol Investigative T60693 DRUGINFO D07CIU 1-benzhydryl-4-p-tolylpiperidin-4-ol Investigative T60693 DRUGINFO D07NMH 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol Investigative T60693 DRUGINFO D08DVV 1-benzhydryl-4-hexylpiperidin-4-ol Investigative T60693 DRUGINFO D08QBU 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol Investigative T60693 DRUGINFO D08TFY 1-benzhydryl-4-cyclohexylpiperidin-4-ol Investigative T60693 DRUGINFO D09BYD 1-benzhydryl-4-o-tolylpiperidin-4-ol Investigative T60693 DRUGINFO D09FJY 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol Investigative T60693 DRUGINFO D09LRO 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol Investigative T60693 DRUGINFO D09VRT 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol Investigative T60693 DRUGINFO D0B7GU Dihydromorphine Investigative T60693 DRUGINFO D0D0UP 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol Investigative T60693 DRUGINFO D0D5QV O-DESMETHYL TRAMADOL Investigative T60693 DRUGINFO D0G4FA 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol Investigative T60693 DRUGINFO D0G7DF 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol Investigative T60693 DRUGINFO D0J5JO 1-benzhydryl-4-m-tolylpiperidin-4-ol Investigative T60693 DRUGINFO D0JH5D 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol Investigative T60693 DRUGINFO D0O7JV 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol Investigative T60693 DRUGINFO D0P3FP 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol Investigative T60693 DRUGINFO D0Q9TQ 1-benzhydryl-4-methoxy-4-phenylpiperidine Investigative T60693 DRUGINFO D0QH4A 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol Investigative T60693 DRUGINFO D0T4ZY 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol Investigative T60693 DRUGINFO D0T9KE 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol Investigative T60693 DRUGINFO D0W3VT 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol Investigative T60693 DRUGINFO D0X4SX 1-benzhydryl-4-phenyl-4-propoxypiperidine Investigative T60693 DRUGINFO D0XX1Y 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol Investigative T60693 DRUGINFO D0Y5LJ 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol Investigative T60693 DRUGINFO D0ZE2W 1-benzhydryl-4-benzylpiperidin-4-ol Investigative T60693 DRUGINFO D03SAV ICI-199441 Investigative T60693 DRUGINFO D08UOX FALCARINDIOL Investigative T60693 DRUGINFO D0L9YP 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide Investigative T92076 TARGETID T92076 T92076 FORMERID TTDS00164 T92076 UNIPROID CASR_HUMAN T92076 TARGNAME Extracellular calcium-sensing receptor (CASR) T92076 GENENAME CASR T92076 TARGTYPE Successful T92076 SYNONYMS hCasR; Parathyroid cell calciumreceptor; Parathyroid cell calcium-sensing receptor 1; Parathyroid calcium receptor; Parathyroid Cell calcium-sensing receptor; PCaR1; GPRC2A; CaSR T92076 FUNCTION Senses fluctuations in the circulating calcium concentration and modulates the production of parathyroid hormone (PTH) in parathyroid glands. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. The G-protein-coupled receptor activity is activated by a co-agonist mechanism: aromatic amino acids, such as Trp or Phe, act concertedly with divalent cations, such as calcium or magnesium, to achieve full receptor activation. G-protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis. T92076 PDBSTRUC 5K5T; 5K5S; 5FBK; 5FBH T92076 BIOCLASS GPCR glutamate T92076 SEQUENCE MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPFSNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPDDFWSNENHTSCIAKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLLCCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWWGLNLQFLLVFLCTFMQIVICVIWLYTAPPSSYRNQELEDEIIFITCHEGSLMALGFLIGYTCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVIAILAASFGLLACIFFNKIYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRKRSSSLGGSTGSTPSSSISSKSNSEDPFPQPERQKQQQPLALTQQEQQQQPLTLPQQQRSQQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSTHQNSLEAQKSSDTLTRHEPLLPLQCGETDLDLTVQETGLQGPVGGDQRPEVEDPEELSPALVVSSSQSFVISGGGSTVTENVVNS T92076 DRUGINFO D03YGR Cinacalcet Approved T92076 DRUGINFO D07RYI Etelcalcetide Approved T92076 DRUGINFO DKP2I0 Encaleret Phase 3 T92076 DRUGINFO D07YRW ASP7991 Phase 2 T92076 DRUGINFO D0H8OA MK-5442 Phase 2 T92076 DRUGINFO D04CJE ATF-936 Phase 1 T92076 DRUGINFO D0S7VI AXT-914 Phase 1 T92076 DRUGINFO D03XIS R-568 Discontinued in Phase 2 T92076 DRUGINFO D07XPT Ronacaleret Discontinued in Phase 2 T92076 DRUGINFO D0G1RH NPS-2143 Discontinued in Phase 2 T92076 DRUGINFO D0W0XM NPS-2390 Preclinical T92076 DRUGINFO D02BCM 2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one Investigative T92076 DRUGINFO D04HDO 3-Phenethyl-2-phenyl-3H-quinazolin-4-one Investigative T92076 DRUGINFO D04PHG 2-methyl-3-phenethyl-3H-pyrimidin-4-one Investigative T92076 DRUGINFO D0F4MI TAK-075 Investigative T92076 DRUGINFO D0I1GV 1-arylmethylpyrrolidin-2-yl ethanol amine Investigative T92076 DRUGINFO D0R7SM PMID15686947C(S)-3h Investigative T92076 DRUGINFO D0UO2Q calhex 231 Investigative T92076 DRUGINFO D0Z5HX PMID15300839C17 Investigative T92076 DRUGINFO D0Z8YZ AC265347 Investigative T92076 DRUGINFO D0HS5P calindol Investigative T31204 TARGETID T31204 T31204 FORMERID TTDS00104 T31204 UNIPROID 5HT2B_HUMAN T31204 TARGNAME 5-HT 2B receptor (HTR2B) T31204 GENENAME HTR2B T31204 TARGTYPE Successful T31204 SYNONYMS Serotonin receptor 2B; 5-hydroxytryptamine receptor 2B; 5-HT2B; 5-HT-2B; 5-HT 2B T31204 FUNCTION Functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine uptake and in the regulation of extracellular dopamine and 5-hydroxytryptamine levels, and thereby affects neural activity. May play a role in the perception of pain. Plays a role in the regulation of behavior, including impulsive behavior. Required for normal proliferation of embryonic cardiac myocytes and normal heart development. Protects cardiomyocytes against apoptosis. Plays a role in the adaptation of pulmonary arteries to chronic hypoxia. Plays a role in vasoconstriction. Required for normal osteoblast function and proliferation, and for maintaining normal bone density. Required for normal proliferation of the interstitial cells of Cajal in the intestine. G-protein coupled receptor for 5-hydroxytryptamine (serotonin). T31204 PDBSTRUC 6DS0; 6DRZ; 6DRY; 6DRX; 5TVN T31204 BIOCLASS GPCR rhodopsin T31204 SEQUENCE MALSYRVSELQSTIPEHILQSTFVHVISSNWSGLQTESIPEEMKQIVEEQGNKLHWAALLILMVIIPTIGGNTLVILAVSLEKKLQYATNYFLMSLAVADLLVGLFVMPIALLTIMFEAMWPLPLVLCPAWLFLDVLFSTASIMHLCAISVDRYIAIKKPIQANQYNSRATAFIKITVVWLISIGIAIPVPIKGIETDVDNPNNITCVLTKERFGDFMLFGSLAAFFTPLAIMIVTYFLTIHALQKKAYLVKNKPPQRLTWLTVSTVFQRDETPCSSPEKVAMLDGSRKDKALPNSGDETLMRRTSTIGKKSVQTISNEQRASKVLGIVFFLFLLMWCPFFITNITLVLCDSCNQTTLQMLLEIFVWIGYVSSGVNPLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNPMAENSKFFKKHGIRNGINPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEGDKTEEQVSYV T31204 DRUGINFO D05NOS Triflupromazine Approved T31204 DRUGINFO D0W8SJ Minaprine Approved T31204 DRUGINFO D0UA0I Metergolin Approved T31204 DRUGINFO DRL5Y7 SPN-812 Phase 4 T31204 DRUGINFO D0W4XY PRX-08066 Phase 2 T31204 DRUGINFO D02BRJ Vabicaserin Phase 2 T31204 DRUGINFO D0D3BL Pyrazole-3-carboxamide derivative 1 Patented T31204 DRUGINFO D01LVT Quinoline derivative 2 Patented T31204 DRUGINFO D00YGY Pyrimidine derivative 29 Patented T31204 DRUGINFO D08DJY Pyrimidine derivative 26 Patented T31204 DRUGINFO D0B7NS Pyrimidine derivative 23 Patented T31204 DRUGINFO D0N2VA Pyrimidine derivative 25 Patented T31204 DRUGINFO D0P9VX Pyrimidine derivative 27 Patented T31204 DRUGINFO D0SE9K Pyrimidine derivative 28 Patented T31204 DRUGINFO D0U9UH Pyrimidine derivative 24 Patented T31204 DRUGINFO D02FEA FENDILINE Withdrawn from market T31204 DRUGINFO D0K8NW Ritanserin Discontinued in Phase 3 T31204 DRUGINFO D0QF4Z MT-500 Discontinued in Phase 1 T31204 DRUGINFO D03YPJ SB 206553 Terminated T31204 DRUGINFO D0B4BN Ro-60-0175 Terminated T31204 DRUGINFO D0PA6K LY53857 Terminated T31204 DRUGINFO D07RIQ ADRENOGLOMERULOTROPIN Investigative T31204 DRUGINFO D0GM9E RQ-00310941 Investigative T31204 DRUGINFO D0H3MO (-)-norfenfluramine Investigative T31204 DRUGINFO D0N6AY norfenfluramine Investigative T31204 DRUGINFO D0O7MW (5-methoxy-1H-indol-3-yl)methanamine Investigative T31204 DRUGINFO D0U7BH (+)-norfenfluramine Investigative T31204 DRUGINFO D0Y4WR R-1 Investigative T31204 DRUGINFO D0Z7GS 6-Fluoromelatonin Investigative T31204 DRUGINFO D01NOZ ADS-103274 Investigative T31204 DRUGINFO D02XAX LY86057 Investigative T31204 DRUGINFO D04AZE SB 204741 Investigative T31204 DRUGINFO D07XTU Racemic DOI Investigative T31204 DRUGINFO D0U8OK [3H]mesulergine Investigative T31204 DRUGINFO D0UI3L dihydroergocryptine Investigative T31204 DRUGINFO D00APD 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol Investigative T31204 DRUGINFO D00EMF SB 242084 Investigative T31204 DRUGINFO D00GOY VER-3323 Investigative T31204 DRUGINFO D00ZCU BW723C86 Investigative T31204 DRUGINFO D01BGW (2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine Investigative T31204 DRUGINFO D01NTM VER-5593 Investigative T31204 DRUGINFO D01SJL 1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol Investigative T31204 DRUGINFO D04YCJ 1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol Investigative T31204 DRUGINFO D05NWH SB 228357 Investigative T31204 DRUGINFO D05SWY 3-Dimethylaminomethyl-1H-indol-4-ol Investigative T31204 DRUGINFO D06ABJ [2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine Investigative T31204 DRUGINFO D07LJH [125I]DOI Investigative T31204 DRUGINFO D08GJS 3-(2-Dimethylamino-propyl)-1H-indol-4-ol Investigative T31204 DRUGINFO D09HJL AL-37350A Investigative T31204 DRUGINFO D0AP6N 1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol Investigative T31204 DRUGINFO D0DY5G SB 221284 Investigative T31204 DRUGINFO D0E6NW VER-5384 Investigative T31204 DRUGINFO D0F5WP 1-(2-aminoethyl)-1H-indazol-6-ol Investigative T31204 DRUGINFO D0H5XR YM-348 Investigative T31204 DRUGINFO D0I9RW 1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol Investigative T31204 DRUGINFO D0KH5R SB 215505 Investigative T31204 DRUGINFO D0M1YU VER-2692 Investigative T31204 DRUGINFO D0N6OL ADS-103253 Investigative T31204 DRUGINFO D0N7HY Org 12962 Investigative T31204 DRUGINFO D0N8YG 1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol Investigative T31204 DRUGINFO D0O5KK 7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine Investigative T31204 DRUGINFO D0R8VT 3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol Investigative T31204 DRUGINFO D0T7RY 6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine Investigative T31204 DRUGINFO D0T8UR 3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol Investigative T31204 DRUGINFO D0V5SQ spiramide Investigative T31204 DRUGINFO D0W7GQ EGIS-7625 Investigative T31204 DRUGINFO D0W8EB 3-(3-Dimethylamino-propyl)-1H-indol-4-ol Investigative T31204 DRUGINFO D0XX7J 7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine Investigative T31204 DRUGINFO D0Y0SA 1-((R)-2-aminopropyl)-1H-indazol-6-ol Investigative T31204 DRUGINFO D0ZZ4Z 3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol Investigative T31204 DRUGINFO D07HQZ [3H]LSD Investigative T31204 DRUGINFO D08EFH 2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine Investigative T31204 DRUGINFO D0C2NK norfluoxetine Investigative T31204 DRUGINFO D0C5XQ 5-MEO-DMT Investigative T31204 DRUGINFO D0N8BJ [3H]5-HT Investigative T31204 DRUGINFO D0S8KA 3-(2-Amino-propyl)-1H-indol-5-ol Investigative T31204 DRUGINFO D0Z7EA [3H]rauwolscine Investigative T31204 DRUGINFO D0MU4A spiroxatrine Investigative T31204 DRUGINFO D07GXY piribedil Investigative T31204 DRUGINFO D0D9YW SB 216641 Investigative T31204 DRUGINFO D0V3XU CHLOROPHENYLPIPERAZINE Investigative T31204 DRUGINFO D0F5NJ METHYLENEDIOXYMETHAMPHETAMINE Investigative T31204 DRUGINFO D0J6JT m-chlorophenylpiperazine Investigative T31204 DRUGINFO D0LG8A 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine Investigative T31204 DRUGINFO D00CRA 2-methyl-5-HT Investigative T31204 DRUGINFO D01KAX 1-((S)-2-aminopropyl)-1H-indazol-6-ol Investigative T31204 DRUGINFO D09OYA alpha-methyl-5-HT Investigative T31204 DRUGINFO D03TDN 1-naphthylpiperazine Investigative T31204 DRUGINFO D04TVG BRL-15572 Investigative T31204 DRUGINFO D02UWB 5-CT Investigative T31204 DRUGINFO D0V5HV TFMPP Investigative T31204 DRUGINFO D0F6CD SEROTONIN Investigative T31204 DRUGINFO D0F9QT A-987306 Investigative T31204 DRUGINFO D0L5MW (+/-)-nantenine Investigative T31204 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T50912 TARGETID T50912 T50912 FORMERID TTDS00490 T50912 UNIPROID CD86_HUMAN T50912 TARGNAME T-lymphocyte activation antigen CD86 (FUN1) T50912 GENENAME CD86 T50912 TARGTYPE Successful T50912 SYNONYMS FUN-1; CTLA-4 counter-receptor B7.2; CD86; CD28LG2; BU63; B70; Activation B7-2 antigen T50912 FUNCTION Receptor involved in the costimulatory signal essential for t-lymphocyte proliferation and interleukin-2 production, by binding cd28 or ctla-4. May play a critical role in the early events of t-cell activation and costimulationof naive t-cells, such as deciding between immunity and anergy that is made by t-cells within 24 hours after activation. Isoform 2 interferes with the formation of cd86 clusters, and thus acts as a negative regulator of t-cell activation. T50912 PDBSTRUC 5YXK; 1NCN; 1I85 T50912 BIOCLASS Immunoglobulin T50912 SEQUENCE MDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGVMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQPPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTMEREESEQTKKREKIHIPERSDEAQRVFKSSKTSSCDKSDTCF T50912 DRUGINFO D0EW4L Abatacept Approved T50912 DRUGINFO D0T2EO MAXY-4 Phase 1 T50912 DRUGINFO D0V4PH Tolerimab Terminated T99954 TARGETID T99954 T99954 FORMERID TTDS00170 T99954 UNIPROID PI2R_HUMAN T99954 TARGNAME Prostacyclin receptor (PTGIR) T99954 GENENAME PTGIR T99954 TARGTYPE Successful T99954 SYNONYMS Prostanoid IP receptor; Prostaglandin I2 receptor; PRIPR; PGI2 receptor; PGI receptor; IP prostanoid receptor T99954 FUNCTION The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase. Receptor for prostacyclin (prostaglandin I2 or PGI2). T99954 BIOCLASS GPCR rhodopsin T99954 SEQUENCE MADSCRNLTYVRGSVGPATSTLMFVAGVVGNGLALGILSARRPARPSAFAVLVTGLAATDLLGTSFLSPAVFVAYARNSSLLGLARGGPALCDAFAFAMTFFGLASMLILFAMAVERCLALSHPYLYAQLDGPRCARLALPAIYAFCVLFCALPLLGLGQHQQYCPGSWCFLRMRWAQPGGAAFSLAYAGLVALLVAAIFLCNGSVTLSLCRMYRQQKRHQGSLGPRPRTGEDEVDHLILLALMTVVMAVCSLPLTIRCFTQAVAPDSSSEMGDLLAFRFYAFNPILDPWVFILFRKAVFQRLKLWVCCLCLGPAHGDSQTPLSQLASGRRDPRAPSAPVGKEGSCVPLSAWGEGQVEPLPPTQQSSGSAVGTSSKAEASVACSLC T99954 DRUGINFO D01WUA Treprostinil Approved T99954 DRUGINFO D04RGA Dinoprost Tromethamine Approved T99954 DRUGINFO D09ANG Misoprostol Approved T99954 DRUGINFO D0N2SR Selexipag Approved T99954 DRUGINFO D0V0IX Epoprostenol Approved T99954 DRUGINFO D4Q5AW Beraprost Phase 4 T99954 DRUGINFO D0WL5V LAROPIPRANT Phase 4 T99954 DRUGINFO D0CO3N esuberaprost Phase 3 T99954 DRUGINFO D0M4TJ Ralinepag Phase 2 T99954 DRUGINFO D0X8DU Clinprost Discontinued in Preregistration T99954 DRUGINFO D00LWS Ataprost Discontinued in Phase 3 T99954 DRUGINFO D00QFY YM533 Discontinued in Phase 3 T99954 DRUGINFO D0G2GR OP-2507 Discontinued in Phase 2 T99954 DRUGINFO D0G2XM AP-227 Terminated T99954 DRUGINFO D0M4LC EPTALOPROST Terminated T99954 DRUGINFO D06ENH Prostacyclin analog Investigative T99954 DRUGINFO D08WBB BAY-73-1449 Investigative T99954 DRUGINFO D09AZM TEI-9063 Investigative T99954 DRUGINFO D0O2WX AFP-07 Investigative T99954 DRUGINFO D0U1SF BMY 45778 Investigative T99954 DRUGINFO D0W4JS RO3244794 Investigative T99954 DRUGINFO D0X6PY EP 157 Investigative T99954 DRUGINFO D0Y1IF FR-193262 Investigative T99954 DRUGINFO D0Z9XV RO1138452 Investigative T99954 DRUGINFO D02YIJ isocarbacyclin Investigative T99954 DRUGINFO D0TA0L FR-181157 Investigative T99954 DRUGINFO D05SFA cicaprost Investigative T99954 DRUGINFO D08MNO butaprost (free acid form) Investigative T99954 DRUGINFO D0W7RI carbacyclin Investigative T99954 DRUGINFO D03PLH U46619 Investigative T36075 TARGETID T36075 T36075 FORMERID TTDS00440 T36075 UNIPROID GLP1R_HUMAN T36075 TARGNAME Glucagon-like peptide 1 receptor (GLP1R) T36075 GENENAME GLP1R T36075 TARGTYPE Successful T36075 SYNONYMS GLP-1R; GLP-1-R; GLP-1 receptor T36075 FUNCTION Ligand binding triggers activation of a signaling cascade that leads to the activation of adenylyl cyclase and increased intracellular cAMP levels. Plays a role in regulating insulin secretion in response to GLP-1. G-protein coupled receptor for glucagon-like peptide 1 (GLP-1). T36075 PDBSTRUC 6GB1; 6B3J; 5VEX; 5VEW; 5OTX T36075 BIOCLASS GPCR secretin T36075 SEQUENCE MAGAPGPLRLALLLLGMVGRAGPRPQGATVSLWETVQKWREYRRQCQRSLTEDPPPATDLFCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASSVPQGHVYRFCTAEGLWLQKDNSSLPWRDLSECEESKRGERSSPEEQLLFLYIIYTVGYALSFSALVIASAILLGFRHLHCTRNYIHLNLFASFILRALSVFIKDAALKWMYSTAAQQHQWDGLLSYQDSLSCRLVFLLMQYCVAANYYWLLVEGVYLYTLLAFSVLSEQWIFRLYVSIGWGVPLLFVVPWGIVKYLYEDEGCWTRNSNMNYWLIIRLPILFAIGVNFLIFVRVICIVVSKLKANLMCKTDIKCRLAKSTLTLIPLLGTHEVIFAFVMDEHARGTLRFIKLFTELSFTSFQGLMVAILYCFVNNEVQLEFRKSWERWRLEHLHIQRDSSMKPLKCPTSSLSSGATAGSSMYTATCQASCS T36075 DRUGINFO D00YVF Exenatide Approved T36075 DRUGINFO D02ULU Semaglutide Approved T36075 DRUGINFO D03GOI Liraglutide Approved T36075 DRUGINFO D03NAW Dulaglutide Approved T36075 DRUGINFO D05MKA Lixisenatide Approved T36075 DRUGINFO D0C4AM Pramlintide Approved T36075 DRUGINFO D0F1DY Albiglutide Approved T36075 DRUGINFO DA69JF Tirzepatide Approved T36075 DRUGINFO D05OZQ Efpeglenatide Phase 3 T36075 DRUGINFO D08NXW GLP-1 Phase 3 T36075 DRUGINFO D0B1EQ Taspoglutide Phase 3 T36075 DRUGINFO D0H1UW LATIN T1D Phase 3 T36075 DRUGINFO DK1MX0 GMA102 Phase 3 T36075 DRUGINFO DO78YZ GMA105 Phase 3 T36075 DRUGINFO DULR78 PB-119 Phase 3 T36075 DRUGINFO DI9P5G Orforglipron Phase 3 T36075 DRUGINFO DI9P5G Orforglipron Phase 3 T36075 DRUGINFO DG7N3W Retatrutide Phase 3 T36075 DRUGINFO D05XXF ORMD-0901 Phase 2 T36075 DRUGINFO D06QWM OI338GT Phase 2 T36075 DRUGINFO D09FTJ TTP-054 Phase 2 T36075 DRUGINFO D0DI1B TTP273 Phase 2 T36075 DRUGINFO D0G4QL UNI-rE-4 Phase 2 T36075 DRUGINFO D0O3DK GTP-010 Phase 2 T36075 DRUGINFO D0U9LV LY-2428757 Phase 2 T36075 DRUGINFO D5XV9K PF-06882961 Phase 2 T36075 DRUGINFO DAJI68 Avexitide Phase 2 T36075 DRUGINFO DH08CI RGT-075 Phase 2 T36075 DRUGINFO DM61KY PF-07081532 Phase 2 T36075 DRUGINFO DX1U3C BI 456906 Phase 2 T36075 DRUGINFO D03MSV PB-1023 Phase 2 T36075 DRUGINFO D08FMK LY2944876 Phase 2 T36075 DRUGINFO D0Q8VM TT-401 Phase 2 T36075 DRUGINFO D7A5LO NLY01 Phase 2 T36075 DRUGINFO D7A5LO NLY01 Phase 2 T36075 DRUGINFO D96UBZ Semorinemab Phase 2 T36075 DRUGINFO DY67HC Efinopegdutide Phase 2 T36075 DRUGINFO DR76TW LY3437943 Phase 2 T36075 DRUGINFO D00BZZ PF-4603629 Phase 1 T36075 DRUGINFO D00TED JNJ-54728518 Phase 1 T36075 DRUGINFO D08NIN NN-9926 Phase 1 T36075 DRUGINFO D08PCR CM3.1-AC100 Phase 1 T36075 DRUGINFO D0A0FB ZYOG1 Phase 1 T36075 DRUGINFO D0FC4R CVX 096 Phase 1 T36075 DRUGINFO D0U9NN OG987SC Phase 1 T36075 DRUGINFO D0W7SX CNTO-3649 Phase 1 T36075 DRUGINFO DN5O8K GZR18 Phase 1 T36075 DRUGINFO DPFY92 AZD0186 Phase 1 T36075 DRUGINFO D0FY4L SAR438335 Phase 1 T36075 DRUGINFO D53BVX Pemvidutide Phase 1 T36075 DRUGINFO D5V1CL DD01 Phase 1 T36075 DRUGINFO D6ZGP9 LY3305677 Phase 1 T36075 DRUGINFO DEC8O3 CT 868 Phase 1 T36075 DRUGINFO DQO46V CT-388 Phase 1 T36075 DRUGINFO D02URD SAR425899 Phase 1 T36075 DRUGINFO D0FW0B ZP2929 Phase 1 T36075 DRUGINFO D0L1JE CJC-1131 Discontinued in Phase 2 T36075 DRUGINFO D0Q9HT LY-307161 Discontinued in Phase 2 T36075 DRUGINFO D0M4RX RG7685 Discontinued in Phase 2 T36075 DRUGINFO D00NSM CM-GLP-1 Discontinued in Phase 1/2 T36075 DRUGINFO D0K5HD LY-315902 Discontinued in Phase 1 T36075 DRUGINFO D7FL3H CIN-209 Preclinical T36075 DRUGINFO D0D2JD TH-0318 Terminated T36075 DRUGINFO D0I0TD AZM-134 Terminated T36075 DRUGINFO D00UCX HAEGTFTSDVSSYLEGQAAKEIFAWLVKGR Investigative T36075 DRUGINFO D01TMK GX-G6 Investigative T36075 DRUGINFO D02TKT HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-NH2 Investigative T36075 DRUGINFO D03JQD BETP Investigative T36075 DRUGINFO D03YDP C[Glu22-Orn26][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D04LSW C[Glu21-Lys25][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D04NUZ C[Glu26-Lys30][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D06PZJ [Gly8, aib22]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D07MBQ CNTO-736 Investigative T36075 DRUGINFO D08HSQ C[Glu22-Lys26][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D09RUJ SX-GLP1 Investigative T36075 DRUGINFO D0B3BS C[Asp22-Lys26][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0B4WW C[Glu18-Lys22][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0BL8S [Gly8,Glu22]GLP-1(7,37)-NH2 Investigative T36075 DRUGINFO D0D9KV SKL-18287 Investigative T36075 DRUGINFO D0ED6E CAM-2036 Investigative T36075 DRUGINFO D0F2GY Glu20-Lys24][Gly8][GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0I7WD C[hGlu22-Lys26][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0M7LZ C[Glu23-Lys27][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0NY1R AC-3174 Investigative T36075 DRUGINFO D0O0LF F-18 exendin-4 derivative PET tracers Investigative T36075 DRUGINFO D0O1DS [123I] iodobenzoyl 12-Ex4 Investigative T36075 DRUGINFO D0Q4AR Glucagon-like peptide-1 analog Investigative T36075 DRUGINFO D0R1NH C[Glu24-Lys28][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0R2ZG [Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0S2GY C[Glu19-Lys23][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0U2XB PGC GLP-1 Investigative T36075 DRUGINFO D0W2EI C[Glu21-Lys26][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0W8BP C[Cpa19-Lys26][Gly8]GLP-1(7-37)-NH2 Investigative T36075 DRUGINFO D0XL7R GLP-17-(7-36) derivative Investigative T36075 DRUGINFO D0Z9WP ZP-3022 Investigative T36075 DRUGINFO D0D7YR AMPE4L Investigative T70967 TARGETID T70967 T70967 FORMERID TTDS00141 T70967 UNIPROID ACHA4_HUMAN T70967 TARGNAME Neuronal acetylcholine receptor alpha-4 (CHRNA4) T70967 GENENAME CHRNA4 T70967 TARGTYPE Successful T70967 SYNONYMS Nicotinic acetylcholine receptor alpha4; CHRNA4; Alpha-4 nAChR T70967 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasmamembrane permeable to sodium ions. T70967 PDBSTRUC 6CNK; 6CNJ; 5KXI; 2LLY; 2GVT T70967 BIOCLASS Neurotransmitter receptor T70967 SEQUENCE MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISDVVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWRPDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFGSWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKRPSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGPSCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEGGVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSVSPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDRIFLWMFIIVCLLGTVGLFLPPWLAGMI T70967 DRUGINFO D0B6CC Trimethaphan Approved T70967 DRUGINFO D0IX1A Pentolinium Approved T70967 DRUGINFO D08XPW CYTISINE Phase 3 T70967 DRUGINFO D04HYP ABT-594 Discontinued in Phase 2 T70967 DRUGINFO D09ADT ABT-418 Discontinued in Phase 2 T70967 DRUGINFO D0C9KD HOMOEPIBATIDINE Terminated T70967 DRUGINFO D03FEV N-methyl-2-(pyridin-3-yloxy)ethanamine Investigative T70967 DRUGINFO D03SYO N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine Investigative T70967 DRUGINFO D04HQP N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine Investigative T70967 DRUGINFO D06KYM N-methyl-N-(pyridin-3-ylmethyl)ethanamine Investigative T70967 DRUGINFO D0A7HM N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine Investigative T70967 DRUGINFO D0P9ED CMI-489 Investigative T70967 DRUGINFO D0R8YJ N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine Investigative T70967 DRUGINFO D0U2HZ 6'-methylepibatidine Investigative T70967 DRUGINFO D0UX5M N,N-dimethyl(pyridin-3-yl)methanamine Investigative T70967 DRUGINFO D0V2KB Predicentrine methiodide Investigative T70967 DRUGINFO D0V7HJ 3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine Investigative T70967 DRUGINFO D0LH4L BOLDINE Investigative T70967 DRUGINFO D00QCP (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol Investigative T70967 DRUGINFO D03YQY (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol Investigative T70967 DRUGINFO D03TMD Barbituric acid derivative Investigative T70967 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T88887 TARGETID T88887 T88887 FORMERID TTDS00226 T88887 UNIPROID RPOB_STAA8 T88887 TARGNAME Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB) T88887 GENENAME Stap-coc rpoB T88887 TARGTYPE Successful T88887 SYNONYMS Transcriptase beta chain; RpoB; RNAP beta subunit; RNA polymerase beta subunit; DNA-directed RNA polymerase beta chain T88887 FUNCTION DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. T88887 BIOCLASS Kinase T88887 ECNUMBER EC 2.7.7.6 T88887 SEQUENCE MAGQVVQYGRHRKRRNYARISEVLELPNLIEIQTKSYEWFLREGLIEMFRDISPIEDFTGNLSLEFVDYRLGEPKYDLEESKNRDATYAAPLRVKVRLIIKETGEVKEQEVFMGDFPLMTDTGTFVINGAERVIVSQLVRSPSVYFNEKIDKNGRENYDATIIPNRGAWLEYETDAKDVVYVRIDRTRKLPLTVLLRALGFSSDQEIVDLLGDNEYLRNTLEKDGTENTEQALLEIYERLRPGEPPTVENAKSLLYSRFFDPKRYDLASVGRYKTNKKLHLKHRLFNQKLAEPIVNTETGEIVVEEGTVLDRRKIDEIMDVLESNANSEVFELHGSVIDEPVEIQSIKVYVPNDDEGRTTTVIGNAFPDSEVKCITPADIIASMSYFFNLLSGIGYTDDIDHLGNRRLRSVGELLQNQFRIGLSRMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMDQANPLAELTHKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLINSLSSYARVNEFGFIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRFRGNNTVMAKEKMDYMDVSPKQVVSAATACIPFLENDDSNRALMGANMQRQAVPLMNPEAPFVGTGMEHVAARDSGAAITAKHRGRVEHVESNEILVRRLVEENGVEHEGELDRYPLAKFKRSNSGTCYNQRPIVAVGDVVEYNEILADGPSMELGEMALGRNVVVGFMTWDGYNYEDAVIMSERLVKDDVYTSIHIEEYESEARDTKLGPEEITRDIPNVSESALKNLDDRGIVYIGAEVKDGDILVGKVTPKGVTELTAEERLLHAIFGEKAREVRDTSLRVPHGAGGIVLDVKVFNREEGDDTLSPGVNQLVRVYIVQKRKIHVGDKMCGRHGNKGVISKIVPEEDMPYLPDGRPIDIMLNPLGVPSRMNIGQVLELHLGMAAKNLGIHVASPVFDGANDDDVWSTIEEAGMARDGKTVLYDGRTGEPFDNRISVGVMYMLKLAHMVDDKLHARSTGPYSLVTQQPLGGKAQFGGQRFGEMEVWALEAYGAAYTLQEILTYKSDDTVGRVKTYEAIVKGENISRPSVPESFRVLMKELQSLGLDVKVMDEQDNEIEMTDVDDDDVVERKVDLQQNDAPETQKEVTD T88887 DRUGINFO D0FX2Q Rifamycin Approved T88887 DRUGINFO D07NQQ Tagetitoxin Investigative T88887 DRUGINFO D0T6ED Myxopyronin B Investigative T80387 TARGETID T80387 T80387 FORMERID TTDS00410 T80387 UNIPROID GBRB2_HUMAN T80387 TARGNAME GABA(A) receptor beta-2 (GABRB2) T80387 GENENAME GABRB2 T80387 TARGTYPE Successful T80387 SYNONYMS GABRB2; GABA(A) receptor subunit beta-2 T80387 FUNCTION Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand- gated chloride channel. T80387 PDBSTRUC 6D6U; 6D6T T80387 BIOCLASS Neurotransmitter receptor T80387 SEQUENCE MWRVRKRGYFGIWSFPLIIAAVCAQSVNDPSNMSLVKETVDRLLKGYDIRLRPDFGGPPVAVGMNIDIASIDMVSEVNMDYTLTMYFQQAWRDKRLSYNVIPLNLTLDNRVADQLWVPDTYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWRGDDNAVTGVTKIELPQFSIVDYKLITKKVVFSTGSYPRLSLSFKLKRNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKIPYVKAIDMYLMGCFVFVFMALLEYALVNYIFFGRGPQRQKKAAEKAASANNEKMRLDVNKIFYKDIKQNGTQYRSLWDPTGNLSPTRRTTNYDFSLYTMDPHENILLSTLEIKNEMATSEAVMGLGDPRSTMLAYDASSIQYRKAGLPRHSFGRNALERHVAQKKSRLRRRASQLKITIPDLTDVNAIDRWSRIFFPVVFSFFNIVYWLYYVN T80387 DRUGINFO D03VZH Ethchlorvynol Approved T80387 DRUGINFO D00VZZ Allopregnanolone approved T80387 DRUGINFO D0IG4I THIOCOLCHICOSIDE Approved T80387 DRUGINFO D07ZCK ZK-93423 Phase 3 T80387 DRUGINFO D0C9XA GSK683699 Phase 2 T80387 DRUGINFO D0B8YZ ELTANOLONE Discontinued in Phase 3 T80387 DRUGINFO D05EVI U-78875 Discontinued in Phase 1 T80387 DRUGINFO D0V4GI CGS-9896 Terminated T80387 DRUGINFO D02XUD 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol Investigative T80387 DRUGINFO D04PQN N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide Investigative T80387 DRUGINFO D05WEF N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide Investigative T80387 DRUGINFO D0GE4A N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide Investigative T80387 DRUGINFO D00CQR 6-Methyl-2-oxa-spiro[4.4]nonan-1-one Investigative T80387 DRUGINFO D00VWR 3,3-Diethyl-dihydro-furan-2-one Investigative T80387 DRUGINFO D00WON 3-Ethyl-3-methyl-dihydro-furan-2-one Investigative T80387 DRUGINFO D01OZS 3,3-Diisopropyl-dihydro-furan-2-one Investigative T80387 DRUGINFO D01PPZ Ridine-5-carboxylic acid ethyl ester Investigative T80387 DRUGINFO D01UZT 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole Investigative T80387 DRUGINFO D02FXS 3-carboxy-6-ethyl-4-quinolone Investigative T80387 DRUGINFO D02RUV 3-Isopropyl-3-methyl-dihydro-furan-2-one Investigative T80387 DRUGINFO D02XXK (9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine Investigative T80387 DRUGINFO D03CKN 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone Investigative T80387 DRUGINFO D03EOK N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide Investigative T80387 DRUGINFO D03FBS 6-ethyl-3-propoxycarbonyl-4-quinolone Investigative T80387 DRUGINFO D03OEN N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide Investigative T80387 DRUGINFO D03OQG 1-Methyl-5-oxa-spiro[2.4]heptan-4-one Investigative T80387 DRUGINFO D03YLX 3-Methyl-9H-beta-carboline Investigative T80387 DRUGINFO D04EOV 3-ethoxycarbonyl-6-propyl-4-quinolone Investigative T80387 DRUGINFO D05OOA 6-ethyl-3-pentoxycarbonyl-4-quinolone Investigative T80387 DRUGINFO D05SVA 5-(piperidin-4-yl)isoxazol-3-ol Investigative T80387 DRUGINFO D05TVT 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone Investigative T80387 DRUGINFO D06EUJ 3-butoxycarbonyl-4-quinolone Investigative T80387 DRUGINFO D06GAI 1-(4-chlorophenyl)-4-phenyl-1H-imidazole Investigative T80387 DRUGINFO D06OSB 6-ethyl-3-i-propoxycarbonyl-4-quinolone Investigative T80387 DRUGINFO D07OON 3-Ethyl-3-isopropyl-dihydro-furan-2-one Investigative T80387 DRUGINFO D07QGN CGS-13767 Investigative T80387 DRUGINFO D08AID 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone Investigative T80387 DRUGINFO D08HGK N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide Investigative T80387 DRUGINFO D09AYK 3-ethoxycarbonyl-4-quinolone Investigative T80387 DRUGINFO D09CQO 2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline Investigative T80387 DRUGINFO D09RWW 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone Investigative T80387 DRUGINFO D0AR4P 2-(9-Benzyl-9H-purin-6-ylamino)-ethanol Investigative T80387 DRUGINFO D0B4CQ 6-benzyl-3-propylaminocarbonyl-4-quinolone Investigative T80387 DRUGINFO D0B4WR 2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline Investigative T80387 DRUGINFO D0CR6M 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone Investigative T80387 DRUGINFO D0D2PJ GNF-PF-4421 Investigative T80387 DRUGINFO D0ER0L 4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T80387 DRUGINFO D0FQ2N 3-Isothiocyanato-9H-beta-carboline Investigative T80387 DRUGINFO D0FR4S 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol Investigative T80387 DRUGINFO D0G6IG 3-butoxycarbonyl-6-ethyl-4-quinolone Investigative T80387 DRUGINFO D0H0DP 3-amino-3-demethoxythiocolchicine Investigative T80387 DRUGINFO D0H0NE 6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one Investigative T80387 DRUGINFO D0I4HT 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol Investigative T80387 DRUGINFO D0J0CA BETA-CCM Investigative T80387 DRUGINFO D0J9VP 3-tert-Butyl-3-ethyl-dihydro-furan-2-one Investigative T80387 DRUGINFO D0K2CZ 1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one Investigative T80387 DRUGINFO D0KS3X U-89267 Investigative T80387 DRUGINFO D0L2KB RO-145974 Investigative T80387 DRUGINFO D0M0ZX 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone Investigative T80387 DRUGINFO D0M2AY 6-ethyl-3-propylaminocarbonyl-4-quinolone Investigative T80387 DRUGINFO D0O9SG 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one Investigative T80387 DRUGINFO D0Q8UV RO-145975 Investigative T80387 DRUGINFO D0R1IL 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol Investigative T80387 DRUGINFO D0S6ME 6-benzyl-3-propoxycarbonyl-4-quinolone Investigative T80387 DRUGINFO D0TJ2L RO-147437 Investigative T80387 DRUGINFO D0U9ET 6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one Investigative T80387 DRUGINFO D0UQ6J RO-194603 Investigative T80387 DRUGINFO D0W5IP GNF-PF-3645 Investigative T80387 DRUGINFO D0WC5L 3-butylaminocarbonyl-6-ethyl-4-quinolone Investigative T80387 DRUGINFO D0X4OW 2-Oxa-spiro[4.4]nonan-1-one Investigative T80387 DRUGINFO D0YS9E 4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T80387 DRUGINFO D01UAS 6-bromo-3-ethoxycarbonyl-4-quinolone Investigative T80387 DRUGINFO D02CZO 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone Investigative T80387 DRUGINFO D03LMR 6-benzyl-3-ethoxycarbonyl-4-quinolone Investigative T80387 DRUGINFO D04RVA 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine Investigative T80387 DRUGINFO D06XGL 3-demethoxy-3-D-xylopyranosylaminothiocolchicine Investigative T80387 DRUGINFO D08YLW 3-demethoxy-3-L-fucopyranosylaminothiocolchicine Investigative T80387 DRUGINFO D09MHS 3-demethoxy-3D-glucopyranosylaminothiocolchicine Investigative T80387 DRUGINFO D0LP2K 3-demethoxy-3-D-mannopyranosylaminothiocolchicine Investigative T80387 DRUGINFO D01IHM CI-218872 Investigative T80387 DRUGINFO D07NKO 5-[(1R)-1-ammonioethyl]isoxazol-3-olate Investigative T80387 DRUGINFO D09ACO (2E,4S)-4-ammoniopent-2-enoate Investigative T80387 DRUGINFO D0A8EU (4R)-4-ammoniopentanoate Investigative T80387 DRUGINFO D0N0ZK (4S)-4-ammoniopentanoate Investigative T80387 DRUGINFO D0S5PS 5-[(1S)-1-ammonioethyl]isoxazol-3-olate Investigative T80387 DRUGINFO D00WHO Ro-15-3505 Investigative T80387 DRUGINFO D0M4CP [3H]Ro154513 Investigative T80387 DRUGINFO D0M9RM [3H]CGS8216 Investigative T80387 DRUGINFO D06HRX AMENTOFLAVONE Investigative T80387 DRUGINFO D0P0TI TBPS Investigative T60182 TARGETID T60182 T60182 FORMERID TTDS00439 T60182 UNIPROID GLR_HUMAN T60182 TARGNAME Glucagon receptor (GCGR) T60182 GENENAME GCGR T60182 TARGTYPE Successful T60182 SYNONYMS GLR; GL-R T60182 FUNCTION Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system. G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. T60182 PDBSTRUC 5XEZ; 5EE7; 4LF3; 4L6R; 4ERS T60182 BIOCLASS GPCR secretin T60182 SEQUENCE MPPCQPQRPLLLLLLLLACQPQVPSAQVMDFLFEKWKLYGDQCHHNLSLLPPPTELVCNRTFDKYSCWPDTPANTTANISCPWYLPWHHKVQHRFVFKRCGPDGQWVRGPRGQPWRDASQCQMDGEEIEVQKEVAKMYSSFQVMYTVGYSLSLGALLLALAILGGLSKLHCTRNAIHANLFASFVLKASSVLVIDGLLRTRYSQKIGDDLSVSTWLSDGAVAGCRVAAVFMQYGIVANYCWLLVEGLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVVPWAVVKCLFENVQCWTSNDNMGFWWILRFPVFLAILINFFIFVRIVQLLVAKLRARQMHHTDYKFRLAKSTLTLIPLLGVHEVVFAFVTDEHAQGTLRSAKLFFDLFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRWRLGKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGGSQDSSAETPLAGGLPRLAESPF T60182 DRUGINFO D0H8WF Glucagon recombinant Approved T60182 DRUGINFO DE5N3K Dasiglucagon Approved T60182 DRUGINFO DG7N3W Retatrutide Phase 3 T60182 DRUGINFO D0D8VU LGD-6972 Phase 2 T60182 DRUGINFO D0V7SO PF-06291874 Phase 2 T60182 DRUGINFO D0ZW5D LY-2409021 Phase 2 T60182 DRUGINFO DLV0Z8 REMD 477 Phase 2 T60182 DRUGINFO D04CQK MK-8521 Phase 2 T60182 DRUGINFO D08FMK LY2944876 Phase 2 T60182 DRUGINFO D0Q8VM TT-401 Phase 2 T60182 DRUGINFO DY67HC Efinopegdutide Phase 2 T60182 DRUGINFO DR76TW LY3437943 Phase 2 T60182 DRUGINFO DJCN38 REGN1193 Phase 1 T60182 DRUGINFO D53BVX Pemvidutide Phase 1 T60182 DRUGINFO D5V1CL DD01 Phase 1 T60182 DRUGINFO D6ZGP9 LY3305677 Phase 1 T60182 DRUGINFO D02URD SAR425899 Phase 1 T60182 DRUGINFO D0FW0B ZP2929 Phase 1 T60182 DRUGINFO D00NCJ Heterocycle-containing compound 5 Patented T60182 DRUGINFO D00QJA Biphenyl carboxamidopropanoic acid derivative 4 Patented T60182 DRUGINFO D01EWH Quinolinyl compound 1 Patented T60182 DRUGINFO D01TGE Heterocycle-containing compound 2 Patented T60182 DRUGINFO D03KUD Pyrrolidine derivative 6 Patented T60182 DRUGINFO D04ELA Picolinamido propanoic acid derivative 2 Patented T60182 DRUGINFO D04NUS Spiroimidazolone derivative 4 Patented T60182 DRUGINFO D05AWM Spiroimidazolone derivative 6 Patented T60182 DRUGINFO D05EON Quinolinyl compound 2 Patented T60182 DRUGINFO D06HMY Biphenyl carboxamidopropanoic acid derivative 2 Patented T60182 DRUGINFO D07AMZ Spiroimidazolone derivative 5 Patented T60182 DRUGINFO D07CLY Heterocycle-containing compound 3 Patented T60182 DRUGINFO D07ZDJ Aromatic ring compound 4 Patented T60182 DRUGINFO D09IGN Pyrrolidine derivative 8 Patented T60182 DRUGINFO D0AJ3F Spiroimidazolone derivative 7 Patented T60182 DRUGINFO D0DE4E Spiroimidazolone derivative 2 Patented T60182 DRUGINFO D0F9RK Spiroimidazolone derivative 3 Patented T60182 DRUGINFO D0FA5D Aromatic ring compound 3 Patented T60182 DRUGINFO D0FS8K Biphenyl carboxamidopropanoic acid derivative 3 Patented T60182 DRUGINFO D0FW5U PMID25828189-Compound-21 Patented T60182 DRUGINFO D0HS9X 3-substituted-2-furancarboxylic acid hydrazide derivative 1 Patented T60182 DRUGINFO D0HV7T Picolinamido propanoic acid derivative 3 Patented T60182 DRUGINFO D0IL0U Heterocycle-containing compound 4 Patented T60182 DRUGINFO D0IT9C Picolinamido propanoic acid derivative 1 Patented T60182 DRUGINFO D0JA0A PMID25828189-Compound-22 Patented T60182 DRUGINFO D0JY2I Pyrrolidine derivative 7 Patented T60182 DRUGINFO D0O0DJ Spiroimidazolone derivative 1 Patented T60182 DRUGINFO D0SA6K Biphenyl carboxamidopropanoic acid derivative 1 Patented T60182 DRUGINFO D0TR5T Heterocycle-containing compound 1 Patented T60182 DRUGINFO D0UA4Y PMID25828189-Compound-19 Patented T60182 DRUGINFO D0XT3V Aromatic ring compound 1 Patented T60182 DRUGINFO D0Y5DU Aromatic ring compound 2 Patented T60182 DRUGINFO D0YP5U 3-substituted-2-furancarboxylic acid hydrazide derivative 5 Patented T60182 DRUGINFO D04MRA BAY-73-7977 Discontinued in Phase 1 T60182 DRUGINFO D0N2LY NN-2501 Discontinued in Phase 1 T60182 DRUGINFO D0Z6AX BAY-27-9955 Discontinued in Phase 1 T60182 DRUGINFO D09MOD NNC-252504 Terminated T60182 DRUGINFO D0V3LD DIO-901 Terminated T60182 DRUGINFO D03OYY MAR-531 Investigative T60182 DRUGINFO D04IUW BI-32169 Investigative T60182 DRUGINFO D05OBK DwLIP-GCGRrx Investigative T60182 DRUGINFO D06ARL [des-His1,Tyr5,Glu9,D-Tyr10]glucagon-NH2 Investigative T60182 DRUGINFO D07SIV [des-His1,Tyr5,Glu9]glucagon-NH2 Investigative T60182 DRUGINFO D08RTR [des-His1,Tyr5,Glu9,D-Ala10]glucagon-NH2 Investigative T60182 DRUGINFO D08SYL [des-His1,Tyr5,Glu9,D-Phe10]glucagon-NH2 Investigative T60182 DRUGINFO D08XLL hGCGR antagonist Investigative T60182 DRUGINFO D0E0UC DSR-17759 Investigative T60182 DRUGINFO D0I6HV NNC 92-1687 Investigative T60182 DRUGINFO D0J4BF glucagon-(1-6) Investigative T60182 DRUGINFO D0M3AR L-168049 Investigative T60182 DRUGINFO D0V9BB Des-His1[Glu9]glucagon-NH2 Investigative T40954 TARGETID T40954 T40954 FORMERID TTDS00056 T40954 UNIPROID XDH_HUMAN T40954 TARGNAME Xanthine dehydrogenase/oxidase (XDH) T40954 GENENAME XDH T40954 TARGTYPE Successful T40954 SYNONYMS Xanthine oxidase; Xanthine dehydrogenase; XDHA T40954 FUNCTION Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro). Key enzyme in purine degradation. T40954 PDBSTRUC 2E1Q; 2CKJ T40954 BIOCLASS CH/CH(2) oxidoreductase T40954 SEQUENCE MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDRLQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGIVMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCCMNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQASTLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFGAACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISDLNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSAFKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKEELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLDPTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRYENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDKVTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDLKKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKMLGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGRHPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGRLCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKLEGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGALLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAASVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLGYSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAFVQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAVGEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVTGVPENCKPWSVRV T40954 DRUGINFO D04KYY Allopurinol Approved T40954 DRUGINFO D07GTW Fosdenopterin Approved T40954 DRUGINFO D0A5SE Febuxostat Approved T40954 DRUGINFO D07SDQ Curcumin Phase 3 T40954 DRUGINFO D08FWK Oxypurinol Phase 2/3 T40954 DRUGINFO D0WK0P Topiroxostat Phase 2 T40954 DRUGINFO D5BMY9 TMX-049 Phase 2 T40954 DRUGINFO D00YEV BAICALEIN Phase 2 T40954 DRUGINFO D0I5JM LC-350189 Phase 1 T40954 DRUGINFO D00GMJ Azaindole derivative 5 Patented T40954 DRUGINFO D01FMW Fused heterocyclic compound 3 Patented T40954 DRUGINFO D02VYR Azaindole derivative 7 Patented T40954 DRUGINFO D03JDR Fused heterocyclic compound 4 Patented T40954 DRUGINFO D04BAQ Fused heterocyclic compound 11 Patented T40954 DRUGINFO D04IGE PMID27841045-Compound-130 Patented T40954 DRUGINFO D06XJG Azole benzene derivative 2 Patented T40954 DRUGINFO D07TTT PMID27841045-Compound-137 Patented T40954 DRUGINFO D08KAT Fused heterocyclic compound 9 Patented T40954 DRUGINFO D0AJ5T PMID27841045-Compound-144 Patented T40954 DRUGINFO D0AU8E PMID27841045-Compound-133 Patented T40954 DRUGINFO D0AV1B Fused heterocyclic compound 2 Patented T40954 DRUGINFO D0B5QZ PMID27841045-Compound-132 Patented T40954 DRUGINFO D0D6UT Azaindole derivative 3 Patented T40954 DRUGINFO D0DQ6C Fused heterocyclic compound 5 Patented T40954 DRUGINFO D0EZ5O PMID27841045-Compound-145 Patented T40954 DRUGINFO D0FM8Q PMID27841045-Compound-134 Patented T40954 DRUGINFO D0G9OT Fused heterocyclic compound 7 Patented T40954 DRUGINFO D0GQ0V PMID27841045-Compound-131 Patented T40954 DRUGINFO D0J0JH PMID27841045-Compound-156 Patented T40954 DRUGINFO D0J3ZM Azole benzene derivative 3 Patented T40954 DRUGINFO D0J5GS Azaindole derivative 6 Patented T40954 DRUGINFO D0LX9F PMID27841045-Compound-157 Patented T40954 DRUGINFO D0N0MV Fused heterocyclic compound 8 Patented T40954 DRUGINFO D0NS7W Fused heterocyclic compound 6 Patented T40954 DRUGINFO D0QY4O PMID27841045-Compound-136 Patented T40954 DRUGINFO D0RK1R Azaindole derivative 4 Patented T40954 DRUGINFO D0RK3S Fused heterocyclic compound 10 Patented T40954 DRUGINFO D0RN2X PMID27841045-Compound-129 Patented T40954 DRUGINFO D0S0EM PMID27841045-Compound-155 Patented T40954 DRUGINFO D0SY6J Fused heterocyclic compound 1 Patented T40954 DRUGINFO D0VY5N Azole benzene derivative 1 Patented T40954 DRUGINFO D0XY7C Azole benzene derivative 4 Patented T40954 DRUGINFO D0YX0S PMID27841045-Compound-135 Patented T40954 DRUGINFO D0Z2IO PMID27841045-Compound-143 Patented T40954 DRUGINFO D0B8SC BOF-4272 Discontinued in Phase 2 T40954 DRUGINFO D0E4FM Y-700 Discontinued in Phase 2 T40954 DRUGINFO D00LMG SCUTELLAREIN Investigative T40954 DRUGINFO D02CWE Dioxothiomolybdenum(VI) ion Investigative T40954 DRUGINFO D05KKF NC-2500 Investigative T40954 DRUGINFO D07NAY ROBINETIN Investigative T40954 DRUGINFO D08NIT FUKUGETIN Investigative T40954 DRUGINFO D0C9ZN 3,5-bis(2-methylpyridin-4-yl)-1H-1,2,4-triazole Investigative T40954 DRUGINFO D0D9OC 2-chloro-6(methylamino)purine Investigative T40954 DRUGINFO D0E5IM PERSICARIN Investigative T40954 DRUGINFO D0G8XL 1-(3-Cyano-phenyl)-1H-pyrazole-4-carboxylic acid Investigative T40954 DRUGINFO D0IW5C 3,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine Investigative T40954 DRUGINFO D0L9EF 3-O-METHYLQUERCETIN Investigative T40954 DRUGINFO D0R4FM DIHYDROKAEMPFEROL Investigative T40954 DRUGINFO D0Z2NY Aom-0763 Investigative T40954 DRUGINFO D0ZC8K 3,5-di(pyridin-4-yl)-1H-1,2,4-triazole Investigative T40954 DRUGINFO D00MXS Wogonin Investigative T40954 DRUGINFO D01FGM CHRYSOERIOL Investigative T40954 DRUGINFO D0K4PY LIQUIRTIGENIN Investigative T40954 DRUGINFO D0NS1S ACACETIN Investigative T40954 DRUGINFO D00QDR 1,2,3,4,6-penta-O-galloyl-beta-D-glucose Investigative T40954 DRUGINFO D06HRX AMENTOFLAVONE Investigative T40954 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T46456 TARGETID T46456 T46456 FORMERID TTDR01075 T46456 UNIPROID RXRG_HUMAN T46456 TARGNAME Retinoic acid receptor RXR-gamma (RXRG) T46456 GENENAME RXRG T46456 TARGTYPE Successful T46456 SYNONYMS Retinoid X receptor gamma; Nuclear receptor subfamily 2 group B member 3; NR2B3 T46456 FUNCTION Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. Receptor for retinoic acid. T46456 PDBSTRUC 2GL8 T46456 BIOCLASS Nuclear hormone receptor T46456 SEQUENCE MYGNYSHFMKFPAGYGGSPGHTGSTSMSPSAALSTGKPMDSHPSYTDTPVSAPRTLSAVGTPLNALGSPYRVITSAMGPPSGALAAPPGINLVAPPSSQLNVVNSVSSSEDIKPLPGLPGIGNMNYPSTSPGSLVKHICAICGDRSSGKHYGVYSCEGCKGFFKRTIRKDLIYTCRDNKDCLIDKRQRNRCQYCRYQKCLVMGMKREAVQEERQRSRERAESEAECATSGHEDMPVERILEAELAVEPKTESYGDMNMENSTNDPVTNICHAADKQLFTLVEWAKRIPHFSDLTLEDQVILLRAGWNELLIASFSHRSVSVQDGILLATGLHVHRSSAHSAGVGSIFDRVLTELVSKMKDMQMDKSELGCLRAIVLFNPDAKGLSNPSEVETLREKVYATLEAYTKQKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLETPLQIT T46456 DRUGINFO D0S7WX Vitamin A Approved T46456 DRUGINFO D0G3PI Alitretinoin Approved T46456 DRUGINFO D06QXI NRX-4204 Phase 2 T46456 DRUGINFO D07OSS 9cUAB-30 Phase 1 T46456 DRUGINFO D09DJC IRX4204 Phase 1 T46456 DRUGINFO D09YUQ SR-11237 Terminated T46456 DRUGINFO D0GR9O AGN-34 Investigative T46456 DRUGINFO D0Q9FZ LG100754 Investigative T16514 TARGETID T16514 T16514 FORMERID TTDS00295 T16514 UNIPROID FAS_HUMAN T16514 TARGNAME Fatty acid synthase (FASN) T16514 GENENAME FASN T16514 TARGTYPE Successful T16514 SYNONYMS Yeast fatty acid synthase; Fatty-acyl-CoA synthase; Fatty acyl-CoA synthetase enzyme; FAS T16514 FUNCTION Fatty acid synthetase catalyzes the formation of long-chain fatty acids from acetyl-CoA, malonyl-CoA and NADPH. This multifunctional protein has 7 catalytic activities as an acyl carrier protein. T16514 PDBSTRUC 6NNA; 5C37; 4Z49; 4W9N; 4W82 T16514 BIOCLASS Acyltransferase T16514 ECNUMBER EC 2.3.1.85 T16514 SEQUENCE MEEVVIAGMSGKLPESENLQEFWDNLIGGVDMVTDDDRRWKAGLYGLPRRSGKLKDLSRFDASFFGVHPKQAHTMDPQLRLLLEVTYEAIVDGGINPDSLRGTHTGVWVGVSGSETSEALSRDPETLVGYSMVGCQRAMMANRLSFFFDFRGPSIALDTACSSSLMALQNAYQAIHSGQCPAAIVGGINVLLKPNTSVQFLRLGMLSPEGTCKAFDTAGNGYCRSEGVVAVLLTKKSLARRVYATILNAGTNTDGFKEQGVTFPSGDIQEQLIRSLYQSAGVAPESFEYIEAHGTGTKVGDPQELNGITRALCATRQEPLLIGSTKSNMGHPEPASGLAALAKVLLSLEHGLWAPNLHFHSPNPEIPALLDGRLQVVDQPLPVRGGNVGINSFGFGGSNVHIILRPNTQPPPAPAPHATLPRLLRASGRTPEAVQKLLEQGLRHSQDLAFLSMLNDIAAVPATAMPFRGYAVLGGERGGPEVQQVPAGERPLWFICSGMGTQWRGMGLSLMRLDRFRDSILRSDEAVKPFGLKVSQLLLSTDESTFDDIVHSFVSLTAIQIGLIDLLSCMGLRPDGIVGHSLGEVACGYADGCLSQEEAVLAAYWRGQCIKEAHLPPGAMAAVGLSWEECKQRCPPGVVPACHNSKDTVTISGPQAPVFEFVEQLRKEGVFAKEVRTGGMAFHSYFMEAIAPPLLQELKKVIREPKPRSARWLSTSIPEAQWHSSLARTSSAEYNVNNLVSPVLFQEALWHVPEHAVVLEIAPHALLQAVLKRGLKPSCTIIPLMKKDHRDNLEFFLAGIGRLHLSGIDANPNALFPPVEFPAPRGTPLISPLIKWDHSLAWDVPAAEDFPNGSGSPSAAIYNIDTSSESPDHYLVDHTLDGRVLFPATGYLSIVWKTLARALGLGVEQLPVVFEDVVLHQATILPKTGTVSLEVRLLEASRAFEVSENGNLVVSGKVYQWDDPDPRLFDHPESPTPNPTEPLFLAQAEVYKELRLRGYDYGPHFQGILEASLEGDSGRLLWKDNWVSFMDTMLQMSILGSAKHGLYLPTRVTAIHIDPATHRQKLYTLQDKAQVADVVVSRWLRVTVAGGVHISGLHTESAPRRQQEQQVPILEKFCFTPHTEEGCLSERAALQEELQLCKGLVQALQTKVTQQGLKMVVPGLDGAQIPRDPSQQELPRLLSAACRLQLNGNLQLELAQVLAQERPKLPEDPLLSGLLDSPALKACLDTAVENMPSLKMKVVEVLAGHGHLYSRIPGLLSPHPLLQLSYTATDRHPQALEAAQAELQQHDVAQGQWDPADPAPSALGSADLLVCNCAVAALGDPASALSNMVAALREGGFLLLHTLLRGHPLGDIVAFLTSTEPQYGQGILSQDAWESLFSRVSLRLVGLKKSFYGSTLFLCRRPTPQDSPIFLPVDDTSFRWVESLKGILADEDSSRPVWLKAINCATSGVVGLVNCLRREPGGNRLRCVLLSNLSSTSHVPEVDPGSAELQKVLQGDLVMNVYRDGAWGAFRHFLLEEDKPEEPTAHAFVSTLTRGDLSSIRWVCSSLRHAQPTCPGAQLCTVYYASLNFRDIMLATGKLSPDAIPGKWTSQDSLLGMEFSGRDASGKRVMGLVPAKGLATSVLLSPDFLWDVPSNWTLEEAASVPVVYSTAYYALVVRGRVRPGETLLIHSGSGGVGQAAIAIALSLGCRVFTTVGSAEKRAYLQARFPQLDSTSFANSRDTSFEQHVLWHTGGKGVDLVLNSLAEEKLQASVRCLATHGRFLEIGKFDLSQNHPLGMAIFLKNVTFHGVLLDAFFNESSADWREVWALVQAGIRDGVVRPLKCTVFHGAQVEDAFRYMAQGKHIGKVVVQVLAEEPEAVLKGAKPKLMSAISKTFCPAHKSYIIAGGLGGFGLELAQWLIQRGVQKLVLTSRSGIRTGYQAKQVRRWRRQGVQVQVSTSNISSLEGARGLIAEAAQLGPVGGVFNLAVVLRDGLLENQTPEFFQDVCKPKYSGTLNLDRVTREACPELDYFVVFSSVSCGRGNAGQSNYGFANSAMERICEKRRHEGLPGLAVQWGAIGDVGILVETMSTNDTIVSGTLPQRMASCLEVLDLFLNQPHMVLSSFVLAEKAAAYRDRDSQRDLVEAVAHILGIRDLAAVNLDSSLADLGLDSLMSVEVRQTLERELNLVLSVREVRQLTLRKLQELSSKADEASELACPTPKEDGLAQQQTQLNLRSLLVNPEGPTLMRLNSVQSSERPLFLVHPIEGSTTVFHSLASRLSIPTYGLQCTRAAPLDSIHSLAAYYIDCIRQVQPEGPYRVAGYSYGACVAFEMCSQLQAQQSPAPTHNSLFLFDGSPTYVLAYTQSYRAKLTPGCEAEAETEAICFFVQQFTDMEHNRVLEALLPLKGLEERVAAAVDLIIKSHQGLDRQELSFAARSFYYKLRAAEQYTPKAKYHGNVMLLRAKTGGAYGEDLGADYNLSQVCDGKVSVHVIEGDHRTLLEGSGLESIISIIHSSLAEPRVSVREG T16514 DRUGINFO D03ZFG Cerulenin Approved T16514 DRUGINFO D0U2BH Epigallocatechin gallate Phase 3 T16514 DRUGINFO D0K9BV TVB-2640 Phase 2 T16514 DRUGINFO DE2U5N TVB-2640 Phase 2 T16514 DRUGINFO D04RSI FAS1 Preclinical T16514 DRUGINFO D0R2SW FSA2 Preclinical T16514 DRUGINFO D03VGO GSK2194069 Investigative T16514 DRUGINFO D06SYA MT-061 Investigative T16514 DRUGINFO D07WAF Anti-Fas mabs Investigative T16514 DRUGINFO D09IGF MG-28 Investigative T16514 DRUGINFO D0BY6E 4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one Investigative T16514 DRUGINFO D0QP7C 4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one Investigative T16514 DRUGINFO D0X6AU FAS-031 Investigative T16514 DRUGINFO D07MXA C75 Investigative T16514 DRUGINFO D05HRK 2-Hexadecynoic acid Investigative T16514 DRUGINFO D07KXK GALLOCATECHIN GALLATE Investigative T16514 DRUGINFO D0MF5Y 3,7,3',4'-TETRAHYDROXYFLAVONE Investigative T16514 DRUGINFO D0RB1V (-)-CATECHINGALLATE Investigative T16514 DRUGINFO D0S9YX biochanin A Investigative T16514 DRUGINFO D0NJ4H MORIN Investigative T09909 TARGETID T09909 T09909 FORMERID TTDS00525 T09909 UNIPROID AGTR2_HUMAN T09909 TARGNAME Angiotensin II receptor type-2 (AGTR2) T09909 GENENAME AGTR2 T09909 TARGTYPE Successful T09909 SYNONYMS Type-2 angiotensin II receptor; Angiotensin II type-2 receptor; Angiotensin II receptor 2; AT2 T09909 FUNCTION Cooperates with MTUS1 to inhibit ERK2 activation and cell proliferation. Receptor for angiotensin II. T09909 PDBSTRUC 5UNH; 5UNG; 5UNF T09909 BIOCLASS GPCR rhodopsin T09909 SEQUENCE MKGNSTLATTSKNITSGLHFGLVNISGNNESTLNCSQKPSDKHLDAIPILYYIIFVIGFLVNIVVVTLFCCQKGPKKVSSIYIFNLAVADLLLLATLPLWATYYSYRYDWLFGPVMCKVFGSFLTLNMFASIFFITCMSVDRYQSVIYPFLSQRRNPWQASYIVPLVWCMACLSSLPTFYFRDVRTIEYLGVNACIMAFPPEKYAQWSAGIALMKNILGFIIPLIFIATCYFGIRKHLLKTNSYGKNRITRDQVLKMAAAVVLAFIICWLPFHVLTFLDALAWMGVINSCEVIAVIDLALPFAILLGFTNSCVNPFLYCFVGNRFQQKLRSVFRVPITWLQGKRESMSCRKSSSLREMETFVS T09909 DRUGINFO D0G6SE ANGIOTENSIN II Approved T09909 DRUGINFO D0K0AT SARALASIN Approved T09909 DRUGINFO D0O0JP EMA-401 Phase 2 T09909 DRUGINFO D03VWB MP-157 Phase 1 T09909 DRUGINFO D0LA6O PMID25416646-Compound-Figure5-E Patented T09909 DRUGINFO D0NF8V Phenylpyridine derivative 3 Patented T09909 DRUGINFO D0U6AW 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 Patented T09909 DRUGINFO D08CKJ Fonsartan Discontinued in Phase 2 T09909 DRUGINFO D0A9BX L-158282 Discontinued in Phase 2 T09909 DRUGINFO D0A8EG TAK-591 Discontinued in Phase 1 T09909 DRUGINFO D04AOA SC-51895 Terminated T09909 DRUGINFO D09TED L-162234 Terminated T09909 DRUGINFO D0F5VB PD-123319 Terminated T09909 DRUGINFO D0RG2P SC-50560 Terminated T09909 DRUGINFO D00UBK L-159689 Terminated T09909 DRUGINFO D0GS7N L-158809 Terminated T09909 DRUGINFO D00UWL Sar-Arg-Val-Tyr-Ile-His-Pro-Ile Investigative T09909 DRUGINFO D04UJZ [125I]CGP42112 Investigative T09909 DRUGINFO D09FRL PD123177 Investigative T09909 DRUGINFO D0K2EX PMID22802221C21 Investigative T09909 DRUGINFO D0K7DW Sar-Arg-Val-Tyr-Ile-His-Pro-Ala Investigative T09909 DRUGINFO D0MH1K SC-55634 Investigative T09909 DRUGINFO D0O0SH SC-52892 Investigative T09909 DRUGINFO D0OF3M Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH Investigative T09909 DRUGINFO D04SVT L-159093 Investigative T09909 DRUGINFO D0A4NO L-162313 Investigative T09909 DRUGINFO D0D9AS angiotensin III Investigative T17448 TARGETID T17448 T17448 FORMERID TTDS00089 T17448 UNIPROID HNMT_HUMAN T17448 TARGNAME Histamine N-methyltransferase (HNMT) T17448 GENENAME HNMT T17448 TARGTYPE Successful T17448 SYNONYMS Histamine-N-methyltransferase; HNMT; HMT T17448 FUNCTION Inactivates histamine by N-methylation. Plays an important role in degrading histamine and in regulating the airway response to histamine. T17448 PDBSTRUC 2AOX; 2AOW; 2AOV; 2AOU; 2AOT T17448 BIOCLASS Methyltransferase T17448 ECNUMBER EC 2.1.1.8 T17448 SEQUENCE MASSMRSLFSDHGKYVESFRRFLNHSTEHQCMQEFMDKKLPGIIGRIGDTKSEIKILSIGGGAGEIDLQILSKVQAQYPGVCINNEVVEPSAEQIAKYKELVAKTSNLENVKFAWHKETSSEYQSRMLEKKELQKWDFIHMIQMLYYVKDIPATLKFFHSLLGTNAKMLIIVVSGSSGWDKLWKKYGSRFPQDDLCQYITSDDLTQMLDNLGLKYECYDLLSTMDISDCFIDGNENGDLLWDFLTETCNFNATAPPDLRAELGKDLQEPEFSAKKEGKVLFNNTLSFIVIEA T17448 DRUGINFO D04NQI Amodiaquine Approved T17448 DRUGINFO D01FGR Diphenhydramine Approved T17448 DRUGINFO D02AIM Metoprine Phase 2 T17448 DRUGINFO D0F0ZX 4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE Investigative T17448 DRUGINFO D09CLP (L-)-S-adenosyl-L-homocysteine Investigative T65291 TARGETID T65291 T65291 FORMERID TTDS00053 T65291 UNIPROID AL3A2_HUMAN T65291 TARGNAME Fatty aldehyde dehydrogenase (ALDH3A2) T65291 GENENAME ALDH3A2 T65291 TARGTYPE Successful T65291 SYNONYMS Microsomal aldehyde dehydrogenase; Aldehyde dehydrogenase family 3 member A2; Aldehyde dehydrogenase 10; ALDH10 T65291 FUNCTION Catalyzes the oxidation of medium and long chain aliphatic aldehydes to fatty acids. Active on a variety of saturated and unsaturated aliphatic aldehydes between 6 and 24 carbons in length. Responsible for conversion of the sphingosine 1-phosphate (S1P) degradation product hexadecenal to hexadecenoic acid. T65291 PDBSTRUC 4QGK T65291 BIOCLASS Aldehyde/oxo donor oxidoreductase T65291 ECNUMBER EC 1.2.1.3 T65291 SEQUENCE MELEVRRVRQAFLSGRSRPLRFRLQQLEALRRMVQEREKDILTAIAADLCKSEFNVYSQEVITVLGEIDFMLENLPEWVTAKPVKKNVLTMLDEAYIQPQPLGVVLIIGAWNYPFVLTIQPLIGAIAAGNAVIIKPSELSENTAKILAKLLPQYLDQDLYIVINGGVEETTELLKQRFDHIFYTGNTAVGKIVMEAAAKHLTPVTLELGGKSPCYIDKDCDLDIVCRRITWGKYMNCGQTCIAPDYILCEASLQNQIVWKIKETVKEFYGENIKESPDYERIINLRHFKRILSLLEGQKIAFGGETDEATRYIAPTVLTDVDPKTKVMQEEIFGPILPIVPVKNVDEAINFINEREKPLALYVFSHNHKLIKRMIDETSSGGVTGNDVIMHFTLNSFPFGGVGSSGMGAYHGKHSFDTFSHQRPCLLKSLKREGANKLRYPPNSQSKVDWGKFFLLKRFNKEKLGLLLLTFLGIVAAVLVKAEYY T65291 DRUGINFO D0X5SD Disulfiram Approved T65291 DRUGINFO D00DBH NPS 1776 Discontinued in Phase 2 T65291 DRUGINFO D04DKX NSC-527035 Investigative T65291 DRUGINFO D09BUG Aloe-emodin Investigative T65291 DRUGINFO D0M0YO S-methyl 4-methyl-4-morpholinopent-2-ynethioate Investigative T13259 TARGETID T13259 T13259 FORMERID TTDS00054 T13259 UNIPROID SSDH_HUMAN T13259 TARGNAME Succinate-semialdehyde dehydrogenase (ALDH5A1) T13259 GENENAME ALDH5A1 T13259 TARGTYPE Successful T13259 SYNONYMS Succinic dehydrogenase; Succinate-semialdehyde dehydrogenase, mitochondrial; SSADH; NAD(+)-dependent succinic semialdehyde dehydrogenase; Aldehyde dehydrogenase family 5 member A1 T13259 FUNCTION Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). T13259 PDBSTRUC 2W8R; 2W8Q; 2W8P; 2W8O; 2W8N T13259 BIOCLASS Aldehyde/oxo donor oxidoreductase T13259 ECNUMBER EC 1.2.1.24 T13259 SEQUENCE MATCIWLRSCGARRLGSTFPGCRLRPRAGGLVPASGPAPGPAQLRCYAGRLAGLSAALLRTDSFVGGRWLPAAATFPVQDPASGAALGMVADCGVREARAAVRAAYEAFCRWREVSAKERSSLLRKWYNLMIQNKDDLARIITAESGKPLKEAHGEILYSAFFLEWFSEEARRVYGDIIHTPAKDRRALVLKQPIGVAAVITPWNFPSAMITRKVGAALAAGCTVVVKPAEDTPFSALALAELASQAGIPSGVYNVIPCSRKNAKEVGEAICTDPLVSKISFTGSTTTGKILLHHAANSVKRVSMELGGLAPFIVFDSANVDQAVAGAMASKFRNTGQTCVCSNQFLVQRGIHDAFVKAFAEAMKKNLRVGNGFEEGTTQGPLINEKAVEKVEKQVNDAVSKGATVVTGGKRHQLGKNFFEPTLLCNVTQDMLCTHEETFGPLAPVIKFDTEEEAIAIANAADVGLAGYFYSQDPAQIWRVAEQLEVGMVGVNEGLISSVECPFGGVKQSGLGREGSKYGIDEYLELKYVCYGGL T13259 DRUGINFO D06EMT Chlormerodrin Approved T13259 DRUGINFO D06VNK Succinic acid Approved T13259 DRUGINFO D0B5YS T83193 Patented T13259 DRUGINFO D0L7RB 1-(4-hydroxyphenyl)prop-2-en-1-one Investigative T49526 TARGETID T49526 T49526 FORMERID TTDS00148 T49526 UNIPROID KCNQ1_HUMAN T49526 TARGNAME Voltage-gated potassium channel Kv7.1 (KCNQ1) T49526 GENENAME KCNQ1 T49526 TARGTYPE Successful T49526 SYNONYMS Voltage-gated potassium channel subunit Kv7.1; Potassium voltage-gated channel subfamily KQT member 1; Kv7.1; KVLQT1; KQT-like 1; KCNQ1 channel; KCNA9; KCNA8; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; IKs producing slow voltage-gated potassium channel alpha subunit KvLQT1 T49526 FUNCTION Associates with KCNE beta subunits that modulates current kinetics. Induces a voltage-dependent by rapidly activating and slowly deactivating potassium-selective outward current. Promotes also a delayed voltage activated potassium current showing outward rectification characteristic. During beta-adrenergic receptor stimulation participates in cardiac repolarization by associating with KCNE1 to form the I(Ks) cardiac potassium current that increases the amplitude and slows down the activation kinetics of outward potassium current I(Ks). Muscarinic agonist oxotremorine-M strongly suppresses KCNQ1/KCNE1 current. When associated with KCNE3, forms the potassium channel that is important for cyclic AMP-stimulated intestinal secretion of chloride ions. This interaction with KCNE3 is reduced by 17beta-estradiol, resulting in the reduction of currents. During conditions of increased substrate load, maintains the driving force for proximal tubular and intestinal sodium ions absorption, gastric acid secretion, and cAMP-induced jejunal chloride ions secretion. Allows the provision of potassium ions to the luminal membrane of the secretory canaliculus in the resting state as well as during stimulated acid secretion. When associated with KCNE2, forms a heterooligomer complex leading to currents with an apparently instantaneous activation, a rapid deactivation process and a linear current-voltage relationship and decreases the amplitude of the outward current. When associated with KCNE4, inhibits voltage-gated potassium channel activity. When associated with KCNE5, this complex only conducts current upon strong and continued depolarization. Also forms a heterotetramer with KCNQ5; has a voltage-gated potassium channel activity. Binds with phosphatidylinositol 4,5-bisphosphate. Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon. T49526 PDBSTRUC 4V0C; 4UMO; 3HFE; 3HFC; 3BJ4 T49526 BIOCLASS Voltage-gated ion channel T49526 SEQUENCE MAAASSPPRAERKRWGWGRLPGARRGSAGLAKKCPFSLELAEGGPAGGALYAPIAPGAPGPAPPASPAAPAAPPVASDLGPRPPVSLDPRVSIYSTRRPVLARTHVQGRVYNFLERPTGWKCFVYHFAVFLIVLVCLIFSVLSTIEQYAALATGTLFWMEIVLVVFFGTEYVVRLWSAGCRSKYVGLWGRLRFARKPISIIDLIVVVASMVVLCVGSKGQVFATSAIRGIRFLQILRMLHVDRQGGTWRLLGSVVFIHRQELITTLYIGFLGLIFSSYFVYLAEKDAVNESGRVEFGSYADALWWGVVTVTTIGYGDKVPQTWVGKTIASCFSVFAISFFALPAGILGSGFALKVQQKQRQKHFNRQIPAAASLIQTAWRCYAAENPDSSTWKIYIRKAPRSHTLLSPSPKPKKSVVVKKKKFKLDKDNGVTPGEKMLTVPHITCDPPEERRLDHFSVDGYDSSVRKSPTLLEVSMPHFMRTNSFAEDLDLEGETLLTPITHISQLREHHRATIKVIRRMQYFVAKKKFQQARKPYDVRDVIEQYSQGHLNLMVRIKELQRRLDQSIGKPSLFISVSEKSKDRGSNTIGARLNRVEDKVTQLDQRLALITDMLHQLLSLHGGSTPGSGGPPREGGAHITQPCGSGGSVDPELFLPSNTLPTYEQLTVPRRGPDEGS T49526 DRUGINFO D0H8FH Indapamide Approved T49526 DRUGINFO D03OFO L-768673 Terminated T49526 DRUGINFO D00CAU N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide Investigative T49526 DRUGINFO D01JJH (3R,4S)-293B Investigative T49526 DRUGINFO D04UYO HMR-1556 Investigative T49526 DRUGINFO D05GQK R-L3 Investigative T49526 DRUGINFO D08HPL 3S,4R-293B Investigative T49526 DRUGINFO D0D0OD N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide Investigative T49526 DRUGINFO D0M1BJ L-735,821 Investigative T49526 DRUGINFO D0MS4Z N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide Investigative T49526 DRUGINFO D0W2FU ML277 Investigative T49526 DRUGINFO D0X2ZW IKs124 Investigative T49526 DRUGINFO D0X8DF N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide Investigative T49526 DRUGINFO D07FTI zinc pyrithione Investigative T49526 DRUGINFO D0P8PH XE991 Investigative T76497 TARGETID T76497 T76497 FORMERID TTDR00910 T76497 UNIPROID 6PGD_HUMAN T76497 TARGNAME Phosphogluconate dehydrogenase (PGD) T76497 GENENAME PGD T76497 TARGTYPE Successful T76497 SYNONYMS PGDH; 6PGDH; 6-phosphogluconate dehydrogenase, decarboxylating; 6-phosphogluconate dehydrogenase T76497 FUNCTION Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH. T76497 PDBSTRUC 5UQ9; 4GWK; 4GWG; 2JKV T76497 BIOCLASS CH-OH donor oxidoreductase T76497 ECNUMBER EC 1.1.1.44 T76497 SEQUENCE MAQADIALIGLAVMGQNLILNMNDHGFVVCAFNRTVSKVDDFLANEAKGTKVVGAQSLKEMVSKLKKPRRIILLVKAGQAVDDFIEKLVPLLDTGDIIIDGGNSEYRDTTRRCRDLKAKGILFVGSGVSGGEEGARYGPSLMPGGNKEAWPHIKTIFQGIAAKVGTGEPCCDWVGDEGAGHFVKMVHNGIEYGDMQLICEAYHLMKDVLGMAQDEMAQAFEDWNKTELDSFLIEITANILKFQDTDGKHLLPKIRDSAGQKGTGKWTAISALEYGVPVTLIGEAVFARCLSSLKDERIQASKKLKGPQKFQFDGDKKSFLEDIRKALYASKIISYAQGFMLLRQAATEFGWTLNYGGIALMWRGGCIIRSVFLGKIKDAFDRNPELQNLLLDDFFKSAVENCQDSWRRAVSTGVQAGIPMPCFTTALSFYDGYRHEMLPASLIQAQRDYFGAHTYELLAKPGQFIHTNWTGHGGTVSSSSYNA T76497 DRUGINFO D08VRX GHRP-2 Approved T76497 DRUGINFO D04LDP 5-deoxy-5-phosphono-D-arabinonate Investigative T76497 DRUGINFO D0C4VG 4-phospho-D-erythronate Investigative T76497 DRUGINFO D0E4AN 6-Phosphogluconic Acid Investigative T76497 DRUGINFO D0P9DD (2R)-2-Methyl-4,5-dideoxy Investigative T76497 DRUGINFO D0A1DU Pyrophosphate 2- Investigative T79798 TARGETID T79798 T79798 FORMERID TTDC00044 T79798 UNIPROID MK12_HUMAN T79798 TARGNAME MAP kinase p38 (MAPK12) T79798 GENENAME MAPK12 T79798 TARGTYPE Successful T79798 SYNONYMS Stress-activated protein kinase 3; SAPK3; Mitogen-activated proteinkinase p38 gamma; Mitogen-activated proteinkinase 12; MAPK12; Extracellular signal-regulated kinase 6; ERK6; ERK5; ERK-6 T79798 FUNCTION Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK12 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors such as ELK1 and ATF2. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases such as MAPKAPK2, which are activated through phosphorylation and further phosphorylate additional targets. Plays a role in myoblast differentiation and also in the down-regulation of cyclin D1 in response to hypoxia in adrenal cells suggesting MAPK12 may inhibit cell proliferation while promoting differentiation. Phosphorylates DLG1. Following osmotic shock, MAPK12 in the cell nucleus increases its association with nuclear DLG1, thereby causing dissociation of DLG1-SFPQ complexes. This function is independent of its catalytic activity and could affect mRNA processing and/or gene transcription to aid cell adaptation to osmolarity changes in the environment. Regulates UV-induced checkpoint signaling and repair of UV-induced DNA damage and G2 arrest after gamma- radiation exposure. MAPK12 is involved in the regulation of SLC2A1 expression and basal glucose uptake in L6 myotubes; and negatively regulates SLC2A4 expression and contraction-mediated glucose uptake in adult skeletal muscle. C-Jun (JUN) phosphorylation is stimulated by MAPK14 and inhibited by MAPK12, leading to a distinct AP-1 regulation. MAPK12 is required for the normal kinetochore localization of PLK1, prevents chromosomal instability and supports mitotic cell viability. MAPK12-signaling is also positively regulating the expansion of transient amplifying myogenic precursor cells during muscle growth and regeneration. T79798 PDBSTRUC 4QUM; 1CM8 T79798 BIOCLASS Kinase T79798 ECNUMBER EC 2.7.11.24 T79798 SEQUENCE MSSPPPARSGFYRQEVTKTAWEVRAVYRDLQPVGSGAYGAVCSAVDGRTGAKVAIKKLYRPFQSELFAKRAYRELRLLKHMRHENVIGLLDVFTPDETLDDFTDFYLVMPFMGTDLGKLMKHEKLGEDRIQFLVYQMLKGLRYIHAAGIIHRDLKPGNLAVNEDCELKILDFGLARQADSEMTGYVVTRWYRAPEVILNWMRYTQTVDIWSVGCIMAEMITGKTLFKGSDHLDQLKEIMKVTGTPPAEFVQRLQSDEAKNYMKGLPELEKKDFASILTNASPLAVNLLEKMLVLDAEQRVTAGEALAHPYFESLHDTEDEPQVQKYDDSFDDVDRTLDEWKRVTYKEVLSFKPPRQLGARVSKETPL T79798 DRUGINFO D0H6VY SM-101 Approved (orphan drug) T79798 DRUGINFO D02LBK ARRY-797 Phase 2 T79798 DRUGINFO D02NNV VX-745 Phase 2 T79798 DRUGINFO D0Y2HH KC706 Discontinued in Phase 2 T79798 DRUGINFO D0W0AM SB 235699 Discontinued in Phase 1 T79798 DRUGINFO D06NUL RWJ-68354 Investigative T79798 DRUGINFO D09HBZ ML-3375 Investigative T79798 DRUGINFO D0W4FF ML-3403 Investigative T79798 DRUGINFO D08DSJ ML-3163 Investigative T79798 DRUGINFO D05BHG Phosphonothreonine Investigative T79798 DRUGINFO D0G2VC KT-5720 Investigative T79798 DRUGINFO D0GB4V STAUROSPORINONE Investigative T79798 DRUGINFO D0M5FF Ro31-8220 Investigative T79798 DRUGINFO D00ICA AMP-PNP Investigative T79798 DRUGINFO D0N6ES KN-62 Investigative T79798 DRUGINFO D0B9BU CI-1040 Investigative T79798 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T79798 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T79798 DRUGINFO D0L8HO RO-316233 Investigative T53103 TARGETID T53103 T53103 FORMERID TTDS00495 T53103 UNIPROID ANAG_HUMAN T53103 TARGNAME Alpha-N-acetylglucosaminidase (NAGLU) T53103 GENENAME NAGLU T53103 TARGTYPE Successful T53103 SYNONYMS UFHSD1; NAGLU; NAG; N-acetyl-alpha-glucosaminidase; Alpha-N-acetylglucosaminidase82 kDa form; Alpha-N-acetylglucosaminidase77 kDa form T53103 FUNCTION Involved in the degradation of heparan sulfate. T53103 PDBSTRUC 4XWH T53103 BIOCLASS Glycosylase T53103 ECNUMBER EC 3.2.1.50 T53103 SEQUENCE MEAVAVAAAVGVLLLAGAGGAAGDEAREAAAVRALVARLLGPGPAADFSVSVERALAAKPGLDTYSLGGGGAARVRVRGSTGVAAAAGLHRYLRDFCGCHVAWSGSQLRLPRPLPAVPGELTEATPNRYRYYQNVCTQSYSFVWWDWARWEREIDWMALNGINLALAWSGQEAIWQRVYLALGLTQAEINEFFTGPAFLAWGRMGNLHTWDGPLPPSWHIKQLYLQHRVLDQMRSFGMTPVLPAFAGHVPEAVTRVFPQVNVTKMGSWGHFNCSYSCSFLLAPEDPIFPIIGSLFLRELIKEFGTDHIYGADTFNEMQPPSSEPSYLAAATTAVYEAMTAVDTEAVWLLQGWLFQHQPQFWGPAQIRAVLGAVPRGRLLVLDLFAESQPVYTRTASFQGQPFIWCMLHNFGGNHGLFGALEAVNGGPEAARLFPNSTMVGTGMAPEGISQNEVVYSLMAELGWRKDPVPDLAAWVTSFAARRYGVSHPDAGAAWRLLLRSVYNCSGEACRGHNRSPLVRRPSLQMNTSIWYNRSDVFEAWRLLLTSAPSLATSPAFRYDLLDLTRQAVQELVSLYYEEARSAYLSKELASLLRAGGVLAYELLPALDEVLASDSRFLLGSWLEQARAAAVSEAEADFYEQNSRYQLTLWGPEGNILDYANKQLAGLVANYYTPRWRLFLEALVDSVAQGIPFQQHQFDKNVFQLEQAFVLSKQRYPSQPRGDTVDLAKKIFLKYYPRWVAGSW T53103 DRUGINFO D05ZYM N-Acetyl-D-glucosamine Approved T53103 DRUGINFO DG1CX7 ABO-101 Phase 1/2 T53103 DRUGINFO DK3U6C BMN 250 Phase 1/2 T96079 TARGETID T96079 T96079 FORMERID TTDC00121 T96079 UNIPROID CXCR4_HUMAN T96079 TARGNAME C-X-C chemokine receptor type 4 (CXCR4) T96079 GENENAME CXCR4 T96079 TARGTYPE Successful T96079 SYNONYMS Stromal cell-derived factor 1 receptor; SDF-1 receptor; NPYRL; Lipopolysaccharide-associated protein 3; Leukocyte-derived seven transmembrane domain receptor; LPS-associated protein 3; LESTR; LCR1; LAP-3; HM89; Fusin; FB22; Chemokine receptor CXCR4; CXCR-4; CXC-R4; CD184 antigen; CD184 T96079 FUNCTION Involved in the AKT signaling cascade. Plays a role in regulation of cell migration, e. g. during wound healing. Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival. Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. T96079 PDBSTRUC 4RWS; 3OE9; 3OE8; 3OE6; 3OE0 T96079 BIOCLASS GPCR rhodopsin T96079 SEQUENCE MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFLTGIVGNGLVILVMGYQKKLRSMTDKYRLHLSVADLLFVITLPFWAVDAVANWYFGNFLCKAVHVIYTVNLYSSVLILAFISLDRYLAIVHATNSQRPRKLLAEKVVYVGVWIPALLLTIPDFIFANVSEADDRYICDRFYPNDLWVVVFQFQHIMVGLILPGIVILSCYCIIISKLSHSKGHQKRKALKTTVILILAFFACWLPYYIGISIDSFILLEIIKQGCEFENTVHKWISITEALAFFHCCLNPILYAFLGAKFKTSAQHALTSVSRGSSLKILSKGKRGGHSSVSTESESSSFHSS T96079 DRUGINFO D0L5RW Plerixafor Approved T96079 DRUGINFO D0T6CN Motixafortide Approved T96079 DRUGINFO D0C3LQ Ulocuplumab Phase 3 T96079 DRUGINFO D0GG9P Balixafortide Phase 3 T96079 DRUGINFO D0O2XQ AMD-070 Phase 3 T96079 DRUGINFO D06KGI TG-0054 Phase 2 T96079 DRUGINFO D0FV8P POL-6326 Phase 2 T96079 DRUGINFO D01TJM CTCE-9908 Phase 1/2 T96079 DRUGINFO D08XQV USL311 Phase 1/2 T96079 DRUGINFO D09MPD ALX-0651 Phase 1 T96079 DRUGINFO D0AZ3Y CTCE-0214 Phase 1 T96079 DRUGINFO D0E5JC MSX-122 Phase 1 T96079 DRUGINFO D0LC5L PF-06747143 Phase 1 T96079 DRUGINFO D0Z8JR BMS-936564 Phase 1 T96079 DRUGINFO D3KZ6M LY2624587 Phase 1 T96079 DRUGINFO DBDW09 GMI-1359 Phase 1 T96079 DRUGINFO D0H5KK Garnocestim Discontinued in Phase 1 T96079 DRUGINFO D0I4OX SURADISTA Discontinued in Phase 1 T96079 DRUGINFO D2NU0H MAb173 Preclinical T96079 DRUGINFO D00FJS KRH-2731 Terminated T96079 DRUGINFO D00GII Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-) Investigative T96079 DRUGINFO D00XBM Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-) Investigative T96079 DRUGINFO D02UES Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-) Investigative T96079 DRUGINFO D03QJA GSK-812397 Investigative T96079 DRUGINFO D04ATE AT-009 Investigative T96079 DRUGINFO D04BVW Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-) Investigative T96079 DRUGINFO D04PDF Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-) Investigative T96079 DRUGINFO D04TED Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-) Investigative T96079 DRUGINFO D04TIO Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-) Investigative T96079 DRUGINFO D04XHX Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-) Investigative T96079 DRUGINFO D05IXH KUR-CXCR4 Investigative T96079 DRUGINFO D05VQJ isothiourea-1t Investigative T96079 DRUGINFO D05YHT Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-) Investigative T96079 DRUGINFO D06EBJ CX-02 Investigative T96079 DRUGINFO D06MBD isothiourea-1a Investigative T96079 DRUGINFO D07IZP ND-401 Investigative T96079 DRUGINFO D07VDF CXCR4 gene disrupted T cells Investigative T96079 DRUGINFO D08NJD T134 Investigative T96079 DRUGINFO D08XRM Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-) Investigative T96079 DRUGINFO D08YYV Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-) Investigative T96079 DRUGINFO D0A7GH ATI-2341 Investigative T96079 DRUGINFO D0B8VW Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-) Investigative T96079 DRUGINFO D0BH8K Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-) Investigative T96079 DRUGINFO D0FQ3G Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-) Investigative T96079 DRUGINFO D0I6AN T140 Investigative T96079 DRUGINFO D0K0SO Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-) Investigative T96079 DRUGINFO D0K9KQ Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-) Investigative T96079 DRUGINFO D0L3GH CTCE-0324 Investigative T96079 DRUGINFO D0M6RQ Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-) Investigative T96079 DRUGINFO D0P7UV Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-) Investigative T96079 DRUGINFO D0Q3MM Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-) Investigative T96079 DRUGINFO D0Q7XS LP-0067 Investigative T96079 DRUGINFO D0R4WT NB-325 Investigative T96079 DRUGINFO D0S0GV Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-) Investigative T96079 DRUGINFO D0S0PU Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-) Investigative T96079 DRUGINFO D0ST1U Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-) Investigative T96079 DRUGINFO D0TL6C T22 Investigative T96079 DRUGINFO D0Y3OX TN-14003 Investigative T96079 DRUGINFO D0ZO3C Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-) Investigative T96079 DRUGINFO D07PHS CXCL8 Investigative T96079 DRUGINFO D09PZD viral macrophage inflammatory protein-II Investigative T76059 TARGETID T76059 T76059 FORMERID TTDC00307 T76059 UNIPROID FKB1A_HUMAN T76059 TARGNAME FK506-binding protein 1A (FKBP1A) T76059 GENENAME FKBP1A T76059 TARGTYPE Successful T76059 SYNONYMS Rotamase; Peptidyl-prolyl cis-trans isomerase FKBP1A; PPIase FKBP1A; Immunophillin FKBP; Immunophilin FKBP12; FKBP12; FKBP1; FKBP-1A; FKBP-12; FK-binding protein 12; Calstabin-1; 12 kDa FKBP; 12 kDa FK506-binding protein T76059 FUNCTION Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. T76059 PDBSTRUC 5I7Q; 5I7P; 4ODR; 4ODQ; 4ODP T76059 BIOCLASS Cis-trans-isomerase T76059 ECNUMBER EC 5.2.1.8 T76059 SEQUENCE MGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE T76059 DRUGINFO D0N0AR GPI-1485 Phase 2 T76059 DRUGINFO D0O5OF SDZ-281-240 Phase 2 T76059 DRUGINFO D0K8TO AP1903 Phase 1/2 T76059 DRUGINFO D04PGB Gpi-1046 Terminated T76059 DRUGINFO D04NBE 4-Hydroxy-2-Butanone Investigative T76059 DRUGINFO D04OSU L-709,587 Investigative T76059 DRUGINFO D08GFY Methyl Methylsulfinylmethyl Sulfide Investigative T76059 DRUGINFO D0Q5YP Rapamycin Immunosuppressant Drug Investigative T76059 DRUGINFO D0X2LN FKB-001 Investigative T76059 DRUGINFO D06IBV Heptyl-Beta-D-Glucopyranoside Investigative T76059 DRUGINFO D08OBF MYRISTIC ACID Investigative T59045 TARGETID T59045 T59045 FORMERID TTDS00024 T59045 UNIPROID GABT_HUMAN T59045 TARGNAME GABA transaminase (ABAT) T59045 GENENAME ABAT T59045 TARGTYPE Successful T59045 SYNONYMS L-AIBAT; Gamma-amino-N-butyrate transaminase; GABA-T; GABA-AT; GABA aminotransferase; ABAT; (S)-3-amino-2-methylpropionate transaminase T59045 FUNCTION Catalyzes the conversion of gamma-aminobutyrate and L- beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate andbeta-alanine. T59045 BIOCLASS Transaminase T59045 ECNUMBER EC 2.6.1.19 T59045 SEQUENCE MASMLLAQRLACSFQHSYRLLVPGSRHISQAAAKVDVEFDYDGPLMKTEVPGPRSQELMKQLNIIQNAEAVHFFCNYEESRGNYLVDVDGNRMLDLYSQISSVPIGYSHPALLKLIQQPQNASMFVNRPALGILPPENFVEKLRQSLLSVAPKGMSQLITMACGSCSNENALKTIFMWYRSKERGQRGFSQEELETCMINQAPGCPDYSILSFMGAFHGRTMGCLATTHSKAIHKIDIPSFDWPIAPFPRLKYPLEEFVKENQQEEARCLEEVEDLIVKYRKKKKTVAGIIVEPIQSEGGDNHASDDFFRKLRDIARKHGCAFLVDEVQTGGGCTGKFWAHEHWGLDDPADVMTFSKKMMTGGFFHKEEFRPNAPYRIFNTWLGDPSKNLLLAEVINIIKREDLLNNAAHAGKALLTGLLDLQARYPQFISRVRGRGTFCSFDTPDDSIRNKLILIARNKGVVLGGCGDKSIRFRPTLVFRDHHAHLFLNIFSDILADFK T59045 DRUGINFO D03LGY Divalproex sodium Approved T59045 DRUGINFO D09PUL L-Alanine Approved T59045 DRUGINFO D0G4JI Pyruvic acid Approved T59045 DRUGINFO D0R3QY Vigabatrin Approved T59045 DRUGINFO D06JGH Pyridoxal Phosphate Approved T59045 DRUGINFO D0EJ7U CPP-115 Phase 2 T59045 DRUGINFO D0YC4F K-828-AB Phase 2 T59045 DRUGINFO D0TP1P CPP -15 Phase 1 T59045 DRUGINFO D00BRD 4-hydroxybenzaldehyde Patented T59045 DRUGINFO D0B5YS T83193 Patented T59045 DRUGINFO D03VZF 4-hydroxy-3-nitrobenzaldehyde Investigative T59045 DRUGINFO D05TEW (4e)-4-Aminohex-4-Enoic Acid Investigative T59045 DRUGINFO D07ZBH 4-hydroxybenzylamine Investigative T59045 DRUGINFO D09IHN Gamma-acetylenic GABA Investigative T59045 DRUGINFO D0L5IN 4-Amino Hexanoic Acid Investigative T59045 DRUGINFO D0R5HK Sodium valproate Investigative T59045 DRUGINFO D0UT2X 3-chloro-1-(4-hydroxyphenyl)propan-1-one Investigative T59045 DRUGINFO D0L7RB 1-(4-hydroxyphenyl)prop-2-en-1-one Investigative T59045 DRUGINFO D0LP2H OXAMATE Investigative T59045 DRUGINFO D0RF2M NIPECOTIC ACID Investigative T59045 DRUGINFO D0F2ME Acetate Ion Investigative T79068 TARGETID T79068 T79068 FORMERID TTDS00384 T79068 UNIPROID INHA_MYCTU T79068 TARGNAME Bacterial Fatty acid synthetase I (Bact inhA) T79068 GENENAME Bact inhA T79068 TARGTYPE Successful T79068 SYNONYMS Enoyl-[acyl-carrier-protein] reductase [NADH]; Bacterial InhA T79068 FUNCTION Involved in the resistance against the antituberculosis drugs isoniazid and ethionamide. T79068 PDBSTRUC 6GHN; 6GH4; 6GH1; 6GGM; 6EP8 T79068 BIOCLASS CH-CH donor oxidoreductase T79068 SEQUENCE MTGLLDGKRILVSGIITDSSIAFHIARVAQEQGAQLVLTGFDRLRLIQRITDRLPAKAPLLELDVQNEEHLASLAGRVTEAIGAGNKLDGVVHSIGFMPQTGMGINPFFDAPYADVSKGIHISAYSYASMAKALLPIMNPGGSIVGMDFDPSRAMPAYNWMTVAKSALESVNRFVAREAGKYGVRSNLVAAGPIRTLAMSAIVGGALGEEAGAQIQLLEEGWDQRAPIGWNMKDATPVAKTVCALLSDWLPATTGDIIYADGGAHTQLL T79068 DRUGINFO D09XQF Isoniazid Approved T79068 DRUGINFO D0L7UQ Prothionamide Approved T79068 DRUGINFO D0P0HB Ethionamide Approved T79068 DRUGINFO D0XF8W Pyrazinamide Approved T79068 DRUGINFO D0X6NZ AFN-1720 Phase 2 T79068 DRUGINFO D0K1UD MMV00/0053 Terminated T79068 DRUGINFO D01EFQ 2-(4,6-dimethoxypyrimidin-2-yloxy)-5-hexylphenol Investigative T79068 DRUGINFO D01MLQ (4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone Investigative T79068 DRUGINFO D03PJO Diclosan Investigative T79068 DRUGINFO D04BHQ N-(2,4-dimethylphenyl)-2-nitrobenzamide Investigative T79068 DRUGINFO D04XUV 5-hexyl-2-(3-nitrophenoxy)phenol Investigative T79068 DRUGINFO D05DRQ N-(4-(diethylamino)phenyl)-2-nitrobenzamide Investigative T79068 DRUGINFO D05MLT 2-(4-aminophenoxy)-5-hexylphenol Investigative T79068 DRUGINFO D05NWQ 4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide Investigative T79068 DRUGINFO D05OQF N-(3,5-dichlorophenyl)-2-nitrobenzamide Investigative T79068 DRUGINFO D05SWR N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide Investigative T79068 DRUGINFO D07UTV 2-nitro-N-(2,4,5-trichlorophenyl)benzamide Investigative T79068 DRUGINFO D07WJX C16-Fatty-Acyl-Substrate-Mimic Investigative T79068 DRUGINFO D08AFZ (4-benzylpiperidin-1-yl)(p-tolyl)methanone Investigative T79068 DRUGINFO D08KWS 5-hexyl-2-phenoxyphenol Investigative T79068 DRUGINFO D08VHO 5-hexyl-2-(pyridin-3-yloxy)phenol Investigative T79068 DRUGINFO D08ZCM 5-octyl-2-phenoxyphenol Investigative T79068 DRUGINFO D09ABM 5-PENTYL-2-PHENOXYPHENOL Investigative T79068 DRUGINFO D09JHY N-(4-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide Investigative T79068 DRUGINFO D09LQF N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide Investigative T79068 DRUGINFO D0E9CT Genz-10850 Investigative T79068 DRUGINFO D0FI4X 2-(3-aminophenoxy)-5-hexylphenol Investigative T79068 DRUGINFO D0G7MC 5-hexyl-2-(pyridin-2-yloxy)phenol Investigative T79068 DRUGINFO D0I1RG (4-phenylpiperazin-1-yl)(p-tolyl)methanone Investigative T79068 DRUGINFO D0IA7R 2-(2-aminophenoxy)-5-hexylphenol Investigative T79068 DRUGINFO D0J1PL 5-hexyl-2-(4-nitrophenoxy)phenol Investigative T79068 DRUGINFO D0JQ7W 2-bromo-4-methylphenyl 2-nitrobenzoate Investigative T79068 DRUGINFO D0K9LT 5-hexyl-2-(pyrazin-2-yloxy)phenol Investigative T79068 DRUGINFO D0K9LV 5-hexyl-2-(pyrimidin-2-yloxy)phenol Investigative T79068 DRUGINFO D0M0EE N-(2-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide Investigative T79068 DRUGINFO D0M5EU (4-benzylpiperidin-1-yl)(m-tolyl)methanone Investigative T79068 DRUGINFO D0N0IC N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide Investigative T79068 DRUGINFO D0N4IT N-(2,4-dichlorophenyl)-2-nitrobenzamide Investigative T79068 DRUGINFO D0O1BT 2-(4-hexyl-2-methoxyphenoxy)pyrimidine Investigative T79068 DRUGINFO D0P9AP 5-hexyl-2-(pyridin-4-yloxy)phenol Investigative T79068 DRUGINFO D0TH7L 5-hexyl-2-(2-nitrophenoxy)phenol Investigative T79068 DRUGINFO D0X8JE N-(3-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide Investigative T79068 DRUGINFO D0YK5U N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide Investigative T79068 DRUGINFO D0ZM1Q (4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone Investigative T79068 DRUGINFO D0B3UG 4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole Investigative T79068 DRUGINFO D0Z7SL Indole Naphthyridinone Investigative T79068 DRUGINFO D05HRK 2-Hexadecynoic acid Investigative T79068 DRUGINFO D07ONX Beta-D-Glucose Investigative T79068 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T12187 TARGETID T12187 T12187 FORMERID TTDS00474 T12187 UNIPROID DDL_MYCTU T12187 TARGNAME Mycobacterium D-alanine-D-alanine ligase A (MycB ddl) T12187 GENENAME MycB ddl T12187 TARGTYPE Successful T12187 SYNONYMS ddlA; D-alanylalanine synthetase A; D-Ala-D-Ala ligase A T12187 FUNCTION Cell wall formation. T12187 PDBSTRUC 3LWB T12187 BIOCLASS Carbon-nitrogen ligase T12187 ECNUMBER EC 6.3.2.4 T12187 SEQUENCE MSANDRRDRRVRVAVVFGGRSNEHAISCVSAGSILRNLDSRRFDVIAVGITPAGSWVLTDANPDALTITNRELPQVKSGSGTELALPADPRRGGQLVSLPPGAGEVLESVDVVFPVLHGPYGEDGTIQGLLELAGVPYVGAGVLASAVGMDKEFTKKLLAADGLPVGAYAVLRPPRSTLHRQECERLGLPVFVKPARGGSSIGVSRVSSWDQLPAAVARARRHDPKVIVEAAISGRELECGVLEMPDGTLEASTLGEIRVAGVRGREDSFYDFATKYLDDAAELDVPAKVDDQVAEAIRQLAIRAFAAIDCRGLARVDFFLTDDGPVINEINTMPGFTTISMYPRMWAASGVDYPTLLATMIETTLARGVGLH T12187 DRUGINFO D02WFK Cycloserine Approved T85733 TARGETID T85733 T85733 FORMERID TTDR01192 T85733 UNIPROID TOP2B_HUMAN T85733 TARGNAME DNA topoisomerase II beta (TOP2B) T85733 GENENAME TOP2B T85733 TARGTYPE Successful T85733 SYNONYMS Topo IIbeta; TOP2beta; TOP2B T85733 FUNCTION Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. T85733 PDBSTRUC 5ZRF; 5ZQF; 5ZEN; 5ZAD; 5GWJ T85733 BIOCLASS ATP-hydrolyzing DNA topoisomerase T85733 ECNUMBER EC 5.6.2.3 T85733 SEQUENCE MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKNMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNNMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKENMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILNMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN T85733 DRUGINFO D07XVN Dexrazoxane Approved T85733 DRUGINFO D04FMB XK-469 Phase 1 T85733 DRUGINFO D06SJZ XB-947 Phase 1 T85733 DRUGINFO D0Q1RC A-62176 Terminated T85733 DRUGINFO D02MKW 3'-THIO-THYMIDINE-5'-PHOSPHATE Investigative T85733 DRUGINFO D00ICA AMP-PNP Investigative T62276 TARGETID T62276 T62276 FORMERID TTDR01259 T62276 UNIPROID NMDZ1_HUMAN T62276 TARGNAME Glutamate receptor ionotropic NMDA 1 (NMDAR1) T62276 GENENAME GRIN1 T62276 TARGTYPE Successful T62276 SYNONYMS NmethylDaspartate receptor subunit NR1; NMDR1; NMD-R1; N-methyl-D-aspartate receptor subunit NR1; Glutamate receptor ionotropic, NMDA 1; Glutamate [NMDA] receptor subunit zeta1; Glutamate [NMDA] receptor subunit zeta-1; GluN1 T62276 FUNCTION Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition. Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. T62276 PDBSTRUC 6IRH; 6IRG; 6IRF; 6IRA; 5TPA T62276 BIOCLASS Glutamate-gated ion channel T62276 SEQUENCE MSTMRLLTLALLFSCSVARAACDPKIVNIGAVLSTRKHEQMFREAVNQANKRHGSWKIQLNATSVTHKPNAIQMALSVCEDLISSQVYAILVSHPPTPNDHFTPTPVSYTAGFYRIPVLGLTTRMSIYSDKSIHLSFLRTVPPYSHQSSVWFEMMRVYSWNHIILLVSDDHEGRAAQKRLETLLEERESKAEKVLQFDPGTKNVTALLMEAKELEARVIILSASEDDAATVYRAAAMLNMTGSGYVWLVGEREISGNALRYAPDGILGLQLINGKNESAHISDAVGVVAQAVHELLEKENITDPPRGCVGNTNIWKTGPLFKRVLMSSKYADGVTGRVEFNEDGDRKFANYSIMNLQNRKLVQVGIYNGTHVIPNDRKIIWPGGETEKPRGYQMSTRLKIVTIHQEPFVYVKPTLSDGTCKEEFTVNGDPVKKVICTGPNDTSPGSPRHTVPQCCYGFCIDLLIKLARTMNFTYEVHLVADGKFGTQERVNNSNKKEWNGMMGELLSGQADMIVAPLTINNERAQYIEFSKPFKYQGLTILVKKEIPRSTLDSFMQPFQSTLWLLVGLSVHVVAVMLYLLDRFSPFGRFKVNSEEEEEDALTLSSAMWFSWGVLLNSGIGEGAPRSFSARILGMVWAGFAMIIVASYTANLAAFLVLDRPEERITGINDPRLRNPSDKFIYATVKQSSVDIYFRRQVELSTMYRHMEKHNYESAAEAIQAVRDNKLHAFIWDSAVLEFEASQKCDLVTTGELFFRSGFGIGMRKDSPWKQNVSLSILKSHENGFMEDLDKTWVRYQECDSRSNAPATLTFENMAGVFMLVAGGIVAGIFLIFIEIAYKRHKDARRKQMQLAFAAVNVWRKNLQDRKSGRAEPDPKKKATFRAITSTLASSFKRRRSSKDTSTGGGRGALQNQKDTVLPRRAIEREEGQLQLCSRHRES T62276 DRUGINFO D02WFK Cycloserine Approved T62276 DRUGINFO D02UDJ D-Serine Phase 4 T62276 DRUGINFO D0S8CI ELIPRODIL Phase 2 T62276 DRUGINFO D02VKC NBQX Phase 1 T62276 DRUGINFO D02TTF YM-90K Discontinued in Phase 2 T62276 DRUGINFO D03KGJ AM-92016 Terminated T62276 DRUGINFO D01PWK RPR-104632 Terminated T62276 DRUGINFO D03CNT L-698532 Terminated T62276 DRUGINFO D03WYF L-695902 Terminated T62276 DRUGINFO D0M1WN L-701324 Terminated T62276 DRUGINFO D0UB6U L-687414 Terminated T62276 DRUGINFO D0X5PX MDL-105519 Terminated T62276 DRUGINFO D02KLW DIZOCILPINE Terminated T62276 DRUGINFO D0AZ5V L-698544 Terminated T62276 DRUGINFO D03UNN L-689560 Terminated T62276 DRUGINFO D0LD9S SPERMINE Terminated T62276 DRUGINFO D04DHB 5,7-Dichlorokynurenic Acid Investigative T62276 DRUGINFO D06NYB 5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione Investigative T62276 DRUGINFO D07DHN 5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione Investigative T62276 DRUGINFO D0D4IG 5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione Investigative T62276 DRUGINFO D0P0GT Cycloleucine Investigative T62276 DRUGINFO D0S6TW 6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione Investigative T62276 DRUGINFO D0X7BP 3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid Investigative T62276 DRUGINFO D00HET 6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole Investigative T62276 DRUGINFO D01BQD 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine Investigative T62276 DRUGINFO D04ZFH 2-(4-Phenoxy-benzyl)-1H-benzoimidazole Investigative T62276 DRUGINFO D05IGJ 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol Investigative T62276 DRUGINFO D06NIS 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol Investigative T62276 DRUGINFO D07RFM 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol Investigative T62276 DRUGINFO D09BZV 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol Investigative T62276 DRUGINFO D0J1AE Phenethyl-(4-phenyl-butyl)-amine Investigative T62276 DRUGINFO D0J8PY 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine Investigative T62276 DRUGINFO D0P1YK 6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole Investigative T62276 DRUGINFO D0Q8PE 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol Investigative T62276 DRUGINFO D0QV0K 4-Benzyl-1-phenethyl-piperidine hydrochloride Investigative T62276 DRUGINFO D0T0GA 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol Investigative T62276 DRUGINFO D0T1GZ Phenethyl-(3-phenyl-propyl)-amine Investigative T62276 DRUGINFO D0V5IZ 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol Investigative T62276 DRUGINFO D00KGK 4-Bromo-3-hydroxy-1H-quinolin-2-one Investigative T62276 DRUGINFO D01JHR H-Gly-dmP-Glu-OH Investigative T62276 DRUGINFO D01LDO (R)-2-Amino-7-phosphono-heptanoic acid Investigative T62276 DRUGINFO D01MSM 3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione Investigative T62276 DRUGINFO D01SHB TRANSTORINE Investigative T62276 DRUGINFO D01XWL 3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione Investigative T62276 DRUGINFO D03CAE 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol Investigative T62276 DRUGINFO D03LWV Nle-Pro-Glu Investigative T62276 DRUGINFO D03NWI Ala-Pro-Glu Investigative T62276 DRUGINFO D04JJL N,N'-Bis-(4-ethyl-phenyl)-guanidine Investigative T62276 DRUGINFO D04ZJL 8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T62276 DRUGINFO D05RRK Phe-Pro-Glu Investigative T62276 DRUGINFO D05WZA 4-[3-(4-Phenyl-butylamino)-propyl]-phenol Investigative T62276 DRUGINFO D06QXT 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol Investigative T62276 DRUGINFO D06RFW N,N'-Bis-(4-isopropyl-phenyl)-guanidine Investigative T62276 DRUGINFO D06SZG 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione Investigative T62276 DRUGINFO D07OBI H-Gly-D-dmP-Glu-OH Investigative T62276 DRUGINFO D07QBQ 6-Chloro-1,4-dihydro-quinoxaline-2,3-dione Investigative T62276 DRUGINFO D08FBB 8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T62276 DRUGINFO D08TAN (+)-HA966 Investigative T62276 DRUGINFO D09ISB (R)-2-Amino-5-phosphono-pentanoic acid Investigative T62276 DRUGINFO D0A5ET 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol Investigative T62276 DRUGINFO D0BC2N Gly-Pip-Glu Investigative T62276 DRUGINFO D0D5HM 4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one Investigative T62276 DRUGINFO D0E9KB N,N'-Bis-(4-butoxy-phenyl)-guanidine Investigative T62276 DRUGINFO D0FU0K 5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione Investigative T62276 DRUGINFO D0H5JV 4-Chloro-3-hydroxy-1H-quinolin-2-one Investigative T62276 DRUGINFO D0H7PR 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one Investigative T62276 DRUGINFO D0J3EZ 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione Investigative T62276 DRUGINFO D0K7EZ N-(2-methoxybenzyl)cinnamamidine Investigative T62276 DRUGINFO D0L4QC 3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione Investigative T62276 DRUGINFO D0L7RU 5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one Investigative T62276 DRUGINFO D0LE0E 8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T62276 DRUGINFO D0OZ2F AP-7 Investigative T62276 DRUGINFO D0P3MF Gly-Hyp-Glu Investigative T62276 DRUGINFO D0P4RL 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione Investigative T62276 DRUGINFO D0Q5PC PHENCYCLIDINE Investigative T62276 DRUGINFO D0Q6QW 3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one Investigative T62276 DRUGINFO D0Q8NW 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one Investigative T62276 DRUGINFO D0S3TY N,N'-Bis-(4-butyl-phenyl)-guanidine Investigative T62276 DRUGINFO D0S5OQ (D)-Ala-Pro-Glu Investigative T62276 DRUGINFO D0S5RV 3-Hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T62276 DRUGINFO D0T7TB Gly-Amp-Glu Investigative T62276 DRUGINFO D0U8BM N,N'-Bis-(4-sec-butyl-phenyl)-guanidine Investigative T62276 DRUGINFO D0U8ZQ Benzyl 4-aminobutyl(3-aminopropyl)carbamate Investigative T62276 DRUGINFO D0V1PE 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T62276 DRUGINFO D0W0HN 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol Investigative T62276 DRUGINFO D0W0VK 3-phenyl-4-hydroxyquinolin-2(1H)-one Investigative T62276 DRUGINFO D0ZD4F N,N'-Bis-(4-hexyl-phenyl)-guanidine Investigative T62276 DRUGINFO D0ZL5U Gly-b7Pro-Glu Investigative T62276 DRUGINFO D03GBO 4,6-Dichloro-1H-indole-2-carboxylic acid Investigative T62276 DRUGINFO D00ZKW [3H]CPP Investigative T62276 DRUGINFO D02WJT 1,3-ditolylguanidine Investigative T62276 DRUGINFO D03PGF RPR-118723 Investigative T62276 DRUGINFO D05VVC 7-chloro-3-hydroxyquinazoline-2,4-dione Investigative T62276 DRUGINFO D06GKL 2-Methylamino-succinic acid(NMDA) Investigative T62276 DRUGINFO D07COG [3H]MDL105519 Investigative T62276 DRUGINFO D08UDC [3H]CGP39653 Investigative T62276 DRUGINFO D0B4DP 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline Investigative T62276 DRUGINFO D0B5ZA homoquinolinic acid Investigative T62276 DRUGINFO D0D2ZH [3H]dizocilpine Investigative T62276 DRUGINFO D0F5ZW CGP61594 Investigative T62276 DRUGINFO D0FW8K (RS)-(tetrazol-5-yl)glycine Investigative T62276 DRUGINFO D0K9NW 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline Investigative T62276 DRUGINFO D0KO6Y [3H]CGS19755 Investigative T62276 DRUGINFO D0OT9B L-aspartic acid Investigative T62276 DRUGINFO D05KQC DNQX Investigative T62276 DRUGINFO D08CAB D-aspartic acid Investigative T94444 TARGETID T94444 T94444 FORMERID TTDS00078 T94444 UNIPROID AOXA_HUMAN T94444 TARGNAME Aldehyde oxidase (AOX1) T94444 GENENAME AOX1 T94444 TARGTYPE Successful T94444 SYNONYMS AOX1 T94444 FUNCTION Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N- methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyzing the oxidation step from 6-deoxypenciclovir topenciclovir, which is a potent antiviral agent. Is probably involved in the regulation of reactive oxygen species homeostasis. May be a prominent source of superoxide generation via the one-electron reduction of molecular oxygen. Also may catalyze nitric oxide (NO) production via the reduction of nitrite to NO with NADH or aldehyde as electron donor. May play a role in adipogenesis. T94444 PDBSTRUC 6Q6Q; 5EPG; 4UHX; 4UHW T94444 BIOCLASS Aldehyde/oxo donor oxidoreductase T94444 ECNUMBER EC 1.2.3.1 T94444 SEQUENCE MDRASELLFYVNGRKVIEKNVDPETMLLPYLRKKLRLTGTKYGCGGGGCGACTVMISRYNPITKRIRHHPANACLIPICSLYGAAVTTVEGIGSTHTRIHPVQERIAKCHGTQCGFCTPGMVMSIYTLLRNHPEPTLDQLTDALGGNLCRCTGYRPIIDACKTFCKTSGCCQSKENGVCCLDQGINGLPEFEEGSKTSPKLFAEEEFLPLDPTQELIFPPELMIMAEKQSQRTRVFGSERMMWFSPVTLKELLEFKFKYPQAPVIMGNTSVGPEVKFKGVFHPVIISPDRIEELSVVNHAYNGLTLGAGLSLAQVKDILADVVQKLPEEKTQMYHALLKHLGTLAGSQIRNMASLGGHIISRHPDSDLNPILAVGNCTLNLLSKEGKRQIPLNEQFLSKCPNADLKPQEILVSVNIPYSRKWEFVSAFRQAQRQENALAIVNSGMRVFFGEGDGIIRELCISYGGVGPATICAKNSCQKLIGRHWNEQMLDIACRLILNEVSLLGSAPGGKVEFKRTLIISFLFKFYLEVSQILKKMDPVHYPSLADKYESALEDLHSKHHCSTLKYQNIGPKQHPEDPIGHPIMHLSGVKHATGEAIYCDDMPLVDQELFLTFVTSSRAHAKIVSIDLSEALSMPGVVDIMTAEHLSDVNSFCFFTEAEKFLATDKVFCVGQLVCAVLADSEVQAKRAAKRVKIVYQDLEPLILTIEESIQHNSSFKPERKLEYGNVDEAFKVVDQILEGEIHMGGQEHFYMETQSMLVVPKGEDQEMDVYVSTQFPKYIQDIVASTLKLPANKVMCHVRRVGGAFGGKVLKTGIIAAVTAFAANKHGRAVRCVLERGEDMLITGGRHPYLGKYKAGFMNDGRILALDMEHYSNAGASLDESLFVIEMGLLKMDNAYKFPNLRCRGWACRTNLPSNTAFRGFGFPQAALITESCITEVAAKCGLSPEKVRIINMYKEIDQTPYKQEINAKNLIQCWRECMAMSSYSLRKVAVEKFNAENYWKKKGLAMVPLKFPVGLGSRAAGQAAALVHIYLDGSVLVTHGGIEMGQGVHTKMIQVVSRELRMPMSNVHLRGTSTETVPNANISGGSVVADLNGLAVKDACQTLLKRLEPIISKNPKGTWKDWAQTAFDESINLSAVGYFRGYESDMNWEKGEGQPFEYFVYGAACSEVEIDCLTGDHKNIRTDIVMDVGCSINPAIDIGQIEGAFIQGMGLYTIEELNYSPQGILHTRGPDQYKIPAICDMPTELHIALLPPSQNSNTLYSSKGLGESGVFLGCSVFFAIHDAVSAARQERGLHGPLTLNSPLTPEKIRMACEDKFTKMIPRDEPGSYVPWNVPI T94444 DRUGINFO D0E9CD Isovanillin Approved T94444 DRUGINFO D03GET Menadione Approved T02001 TARGETID T02001 T02001 FORMERID TTDS00499 T02001 UNIPROID PDE4D_HUMAN T02001 TARGNAME Phosphodiesterase 4D (PDE4D) T02001 GENENAME PDE4D T02001 TARGTYPE Successful T02001 SYNONYMS cAMP-specific 3',5'-cyclic phosphodiesterase 4D; PDE43; DPDE3 T02001 FUNCTION Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. T02001 PDBSTRUC 6NJJ; 6NJI; 6NJH; 6FW3; 6FTW T02001 BIOCLASS Phosphoric diester hydrolase T02001 ECNUMBER EC 3.1.4.53 T02001 SEQUENCE MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQYPLRQPQFRLLHPHHHLPPPPPPSPQPQPQCPLQPPPPPPLPPPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRAMDRTSYAVETGHRPGLKKSRMSWPSSFQGLRRFDVDNGTSAGRSPLDPMTSPGSGLILQANFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRTVRNNFAALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQTRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKEKKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELSGNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGMEISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQSPSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSESTEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT T02001 DRUGINFO D0NJ3V Papaverine Approved T02001 DRUGINFO D01XHG DENBUFYLLINE Phase 3 T02001 DRUGINFO D06VFP SOTB07 Phase 3 T02001 DRUGINFO D0IZ8X BPN14770 Phase 2 T02001 DRUGINFO D00JED AN-2898 Phase 2 T02001 DRUGINFO D01XFZ GPD-1116 Phase 2 T02001 DRUGINFO D02POH TA-7906 Phase 2 T02001 DRUGINFO D07OCV HT-0712 Phase 2 T02001 DRUGINFO D09TFB TOFIMILAST Phase 2 T02001 DRUGINFO D0F4TV AWD-12-281 Phase 2 T02001 DRUGINFO D0F5IY LIRIMILAST Phase 2 T02001 DRUGINFO D0L8KJ Oglemilast Phase 2 T02001 DRUGINFO D0M7CB MK-0873 Phase 2 T02001 DRUGINFO D0RJ1W OX-914 Phase 2 T02001 DRUGINFO D0U2DH CC-1088 Phase 2 T02001 DRUGINFO D0X0PW Revamilast Phase 2 T02001 DRUGINFO D0Z2FB Piclamilast Phase 2 T02001 DRUGINFO D01WZL AVE-8112 Phase 1 T02001 DRUGINFO D03CWX MEM-1414 Phase 1 T02001 DRUGINFO D0K9DI GSK-356278 Phase 1 T02001 DRUGINFO D0O8JW Ronomilast Phase 1 T02001 DRUGINFO D00DBE CI-1018 Discontinued in Phase 2 T02001 DRUGINFO D03ZVD KW-4490 Discontinued in Phase 2 T02001 DRUGINFO D08SNX V-11294A Discontinued in Phase 2 T02001 DRUGINFO D0I0GM Daxalipram Discontinued in Phase 2 T02001 DRUGINFO D0UG4T CDP840 Discontinued in Phase 2 T02001 DRUGINFO D0V2CN LAS-37779 Discontinued in Phase 2 T02001 DRUGINFO D01FXD SCH-351591 Discontinued in Phase 1 T02001 DRUGINFO D0C7JT YM-976 Discontinued in Phase 1 T02001 DRUGINFO D0K1OA D-4418 Discontinued in Phase 1 T02001 DRUGINFO D00YPW ZAPRINAST Terminated T02001 DRUGINFO D01OUA TJN-598 Terminated T02001 DRUGINFO D01QUF GW-3600 Terminated T02001 DRUGINFO D07UHY NIK-616 Terminated T02001 DRUGINFO D0F7TV Torbafylline Terminated T02001 DRUGINFO D0R1QJ D-22888 Terminated T02001 DRUGINFO D00JBC 1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione Investigative T02001 DRUGINFO D00TQR 1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione Investigative T02001 DRUGINFO D04BMR AL-59640 Investigative T02001 DRUGINFO D04JNC ZL-N-91 Investigative T02001 DRUGINFO D05YEL CH-3697 Investigative T02001 DRUGINFO D0E5VP KF-66490 Investigative T02001 DRUGINFO D0JD4C L-454560 Investigative T02001 DRUGINFO D0K9PS CHF-5480 Investigative T02001 DRUGINFO D0N7HS ASP-3258 Investigative T02001 DRUGINFO D0S1HX TAS-203 Investigative T02001 DRUGINFO D0S6MA OCID-2987 Investigative T02001 DRUGINFO D0U4SS CD-160130 Investigative T02001 DRUGINFO D0W7WV L-869298 Investigative T02001 DRUGINFO D02ZPV UCB-101333-3 Investigative T02001 DRUGINFO D0P2HX RS-25344 Investigative T02001 DRUGINFO D0T5PO ROLIPRAM Investigative T02001 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T91480 TARGETID T91480 T91480 FORMERID TTDS00331 T91480 UNIPROID ABCC8_HUMAN T91480 TARGNAME ATP-binding cassette transporter C8 (ABCC8) T91480 GENENAME ABCC8 T91480 TARGTYPE Successful T91480 SYNONYMS Sulfonylurea receptor 1; SUR1-type K(ATP) channel; SUR1; Kir6.2/SUR1; ATPbinding cassette subfamily C member 8; ABCC8 T91480 FUNCTION Putative subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release. T91480 PDBSTRUC 6C3P; 6C3O T91480 BIOCLASS ABC transporter T91480 SEQUENCE MPLAFCGSENHSAAYRVDQGVLNNGCFVDALNVVPHVFLLFITFPILFIGWGSQSSKVHIHHSTWLHFPGHNLRWILTFMLLFVLVCEIAEGILSDGVTESHHLHLYMPAGMAFMAAVTSVVYYHNIETSNFPKLLIALLVYWTLAFITKTIKFVKFLDHAIGFSQLRFCLTGLLVILYGMLLLVEVNVIRVRRYIFFKTPREVKPPEDLQDLGVRFLQPFVNLLSKGTYWWMNAFIKTAHKKPIDLRAIGKLPIAMRALTNYQRLCEAFDAQVRKDIQGTQGARAIWQALSHAFGRRLVLSSTFRILADLLGFAGPLCIFGIVDHLGKENDVFQPKTQFLGVYFVSSQEFLANAYVLAVLLFLALLLQRTFLQASYYVAIETGINLRGAIQTKIYNKIMHLSTSNLSMGEMTAGQICNLVAIDTNQLMWFFFLCPNLWAMPVQIIVGVILLYYILGVSALIGAAVIILLAPVQYFVATKLSQAQRSTLEYSNERLKQTNEMLRGIKLLKLYAWENIFRTRVETTRRKEMTSLRAFAIYTSISIFMNTAIPIAAVLITFVGHVSFFKEADFSPSVAFASLSLFHILVTPLFLLSSVVRSTVKALVSVQKLSEFLSSAEIREEQCAPHEPTPQGPASKYQAVPLRVVNRKRPAREDCRGLTGPLQSLVPSADGDADNCCVQIMGGYFTWTPDGIPTLSNITIRIPRGQLTMIVGQVGCGKSSLLLAALGEMQKVSGAVFWSSLPDSEIGEDPSPERETATDLDIRKRGPVAYASQKPWLLNATVEENIIFESPFNKQRYKMVIEACSLQPDIDILPHGDQTQIGERGINLSGGQRQRISVARALYQHANVVFLDDPFSALDIHLSDHLMQAGILELLRDDKRTVVLVTHKLQYLPHADWIIAMKDGTIQREGTLKDFQRSECQLFEHWKTLMNRQDQELEKETVTERKATEPPQGLSRAMSSRDGLLQDEEEEEEEAAESEEDDNLSSMLHQRAEIPWRACAKYLSSAGILLLSLLVFSQLLKHMVLVAIDYWLAKWTDSALTLTPAARNCSLSQECTLDQTVYAMVFTVLCSLGIVLCLVTSVTVEWTGLKVAKRLHRSLLNRIILAPMRFFETTPLGSILNRFSSDCNTIDQHIPSTLECLSRSTLLCVSALAVISYVTPVFLVALLPLAIVCYFIQKYFRVASRDLQQLDDTTQLPLLSHFAETVEGLTTIRAFRYEARFQQKLLEYTDSNNIASLFLTAANRWLEVRMEYIGACVVLIAAVTSISNSLHRELSAGLVGLGLTYALMVSNYLNWMVRNLADMELQLGAVKRIHGLLKTEAESYEGLLAPSLIPKNWPDQGKIQIQNLSVRYDSSLKPVLKHVNALIAPGQKIGICGRTGSGKSSFSLAFFRMVDTFEGHIIIDGIDIAKLPLHTLRSRLSIILQDPVLFSGTIRFNLDPERKCSDSTLWEALEIAQLKLVVKALPGGLDAIITEGGENFSQGQRQLFCLARAFVRKTSIFIMDEATASIDMATENILQKVVMTAFADRTVVTIAHRVHTILSADLVIVLKRGAILEFDKPEKLLSRKDSVFASFVRADK T91480 DRUGINFO D05LYX Glibenclamide Approved T91480 DRUGINFO D07WFK Acetohexamide Approved T91480 DRUGINFO D0M2MR Gliclazide Approved T91480 DRUGINFO D06OIV Tolbutamide Approved T91480 DRUGINFO D0B2GI Glimepiride Approved T91480 DRUGINFO D0N5YA Repaglinide Approved T91480 DRUGINFO D02ZPN NN-414 Phase 1 T91480 DRUGINFO D0H4BF NS-11757 Investigative T91480 DRUGINFO D0U1XJ HBR-985 Investigative T20251 TARGETID T20251 T20251 FORMERID TTDS00147 T20251 UNIPROID KCNH2_HUMAN T20251 TARGNAME Voltage-gated potassium channel Kv11.1 (KCNH2) T20251 GENENAME KCNH2 T20251 TARGTYPE Successful T20251 SYNONYMS hERG1; hERG-1; Voltage-gated potassium channel subunit Kv11.1; Potassium voltage-gated channel subfamily H member 2; HERG K+ channel; HERG; H-ERG; Ether-a-go-go-related protein 1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go related protein 1; Ether-a-go-go related gene potassium channel 1; Eag related protein 1; Eag homolog; ERG-1; ERG T20251 FUNCTION Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. T20251 PDBSTRUC 5VA3; 5VA2; 5VA1; 4HQA; 4HP9 T20251 BIOCLASS Voltage-gated ion channel T20251 SEQUENCE MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCELCGYSRAEVMQRPCTCDFLHGPRTQRRAAAQIAQALLGAEERKVEIAFYRKDGSCFLCLVDVVPVKNEDGAVIMFILNFEVVMEKDMVGSPAHDTNHRGPPTSWLAPGRAKTFRLKLPALLALTARESSVRSGGAGGAGAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSPPRSAPGQLPSPRAHSLNPDASGSSCSLARTRSRESCASVRRASSADDIEAMRAGVLPPPPRHASTGAMHPLRSGLLNSTSDSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDREIIAPKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLLVIYTAVFTPYSAAFLLKETEEGPPATECGYACQPLAVVDLIVDIMFIVDILINFRTTYVNANEEVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGSGSEELIGLLKTARLLRLVRVARKLDRYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSRIGWLHNLGDQIGKPYNSSGLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFGNVSAIIQRLYSGTARYHTQMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGFPECLQADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALYFISRGSIEILRGDVVVAILGKNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLEVLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGGFSRQRKRKLSFRRRTDKDTEQPGEVSALGPGRAGAGPSSRGRPGGPWGESPSSGPSSPESSEDEGPGRSSSPLRLVPFSSPRPPGEPPGGEPLMEDCEKSSDTCNPLSGAFSGVSNIFSFWGDSRGRQYQELPRCPAPTPSLLNIPLSSPGRRPRGDVESRLDALQRQLNRLETRLSADMATVLQLLQRQMTLVPPAYSAVTTPGPGPTSTSPLLPVSPLPTLTLDSLSQVSQFMACEELPPGAPELPQEGPTRRLSLPGQLGALTSQPLHRHGSDPGS T20251 DRUGINFO D0L0ZF VESNARINONE Approved T20251 DRUGINFO D0HZ2E M100907 Phase 3 T20251 DRUGINFO D07MKL ABT-229 Phase 2 T20251 DRUGINFO D02TIK HP-184 Phase 2 T20251 DRUGINFO D0LI1C NITD609 Phase 2 T20251 DRUGINFO D03GNI ISOQUINE Phase 1 T20251 DRUGINFO D01EBW Quinoline derivative 12 Patented T20251 DRUGINFO D0B7KM Quinoline derivative 13 Patented T20251 DRUGINFO D0L2KM Quinoline derivative 11 Patented T20251 DRUGINFO D01LSP Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 Patented T20251 DRUGINFO D02NPB Isoindoline derivative 5 Patented T20251 DRUGINFO D06FNA Isoindoline derivative 3 Patented T20251 DRUGINFO D0EK3Z Isoindoline derivative 4 Patented T20251 DRUGINFO D0F8XU Isoindoline derivative 2 Patented T20251 DRUGINFO D0S3ON Isoindoline derivative 1 Patented T20251 DRUGINFO D0T8WU Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 Patented T20251 DRUGINFO D02NGR MK-499 Discontinued in Phase 2 T20251 DRUGINFO D00YQZ L-702958 Terminated T20251 DRUGINFO D0AX4E Bertosamil Terminated T20251 DRUGINFO D00FAY 4-(3-thienyl)benzene-1,2-diamine) Investigative T20251 DRUGINFO D01BKS ginsenoside Rg3 Investigative T20251 DRUGINFO D01IWD MDL-74156 Investigative T20251 DRUGINFO D01PIU 5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole Investigative T20251 DRUGINFO D01PYU 3-(1-Phenethyl-piperidin-3-yl)-2-phenyl-1H-indole Investigative T20251 DRUGINFO D01WVE KB-130015 Investigative T20251 DRUGINFO D02DCM 5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole Investigative T20251 DRUGINFO D03NRJ 4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine Investigative T20251 DRUGINFO D03PSY 3 9-DIHYDRO-N-DESMETHYL-N-ISOPROPYLERYTHROMYCIN A Investigative T20251 DRUGINFO D03WAE VU0405601 Investigative T20251 DRUGINFO D04MLU [1-(4-p-Tolyl-butyl)-piperidin-4-yl]-methanol Investigative T20251 DRUGINFO D05KUM DESMETHYLOLANZAPINE Investigative T20251 DRUGINFO D06EGM PD-307243 Investigative T20251 DRUGINFO D07ETF 3-(1-Methyl-piperidin-3-yl)-2-phenyl-1H-indole Investigative T20251 DRUGINFO D07LFR 3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine Investigative T20251 DRUGINFO D08ZIS 4-(2-thienyl)benzene-1,2-diamine Investigative T20251 DRUGINFO D09GZH (R)-ONDANSETRON Investigative T20251 DRUGINFO D09ICL PD-118057 Investigative T20251 DRUGINFO D0BW0V 3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine Investigative T20251 DRUGINFO D0C9UF Desmethylastemizole Investigative T20251 DRUGINFO D0DM6F (1R,5R)-30-OXO-19-OXA-2,6,10,12-TETRAAZAHEXACYCLO[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]TRIACONTA-8,10,14(29),15,17,20(28),21,23(27)-OCTAENE-17-CARBONITRILE (STRUCTURAL MIX) Investigative T20251 DRUGINFO D0FL1D 3-(1-Benzyl-piperidin-3-yl)-2-phenyl-1H-indole Investigative T20251 DRUGINFO D0G7LE 4-Benzenesulfonyl-1-phenethyl-piperidine Investigative T20251 DRUGINFO D0I2UC 5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole Investigative T20251 DRUGINFO D0JY2K NS-1643 Investigative T20251 DRUGINFO D0LM5H RPR260243 Investigative T20251 DRUGINFO D0ND5D 3-(1-Methyl-piperidin-2-yl)-2-phenyl-1H-indole Investigative T20251 DRUGINFO D0NM7S A-935142 Investigative T20251 DRUGINFO D0RC9T 2-Phenyl-3-piperidin-3-yl-1H-indole Investigative T20251 DRUGINFO D0S1XC 5-(3-butylpyrrolidin-3-yl)-1H-indole Investigative T20251 DRUGINFO D0ZC3Q 5-(3-benzylpyrrolidin-3-yl)-1h-indole (structural mix) Investigative T20251 DRUGINFO D00AWM GW803430 Investigative T20251 DRUGINFO D06NXK (R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline Investigative T20251 DRUGINFO D07GBV 3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole Investigative T20251 DRUGINFO D07MAF 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one Investigative T20251 DRUGINFO D07SGS N-(4-(benzyloxy)phenethyl)pyridin-4-amine Investigative T20251 DRUGINFO D08CZT 2-Phenyl-3-piperidin-4-yl-1H-indole Investigative T20251 DRUGINFO D08QBS MK-1925 Investigative T20251 DRUGINFO D0A7GW N-(piperidin-4-yl)-N-propyl-2-naphthamide Investigative T20251 DRUGINFO D0I0UW 1-(4-p-Tolyl-butyl)-piperidine Investigative T20251 DRUGINFO D0Q8LS 2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole Investigative T20251 DRUGINFO D0XH1N ICA-105574 Investigative T20251 DRUGINFO D0Z7TM BMS-645737 Investigative T20251 DRUGINFO D00UIN JNJ-10392980 Investigative T20251 DRUGINFO D01MCD (2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T20251 DRUGINFO D06NXC N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX) Investigative T20251 DRUGINFO D08JCU (E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine Investigative T20251 DRUGINFO D0FJ1I N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Investigative T20251 DRUGINFO D0GG2J 1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T20251 DRUGINFO D0H3GI 4-(p-Tolyl)spiro[chromene-2,4'-piperidine] Investigative T20251 DRUGINFO D0H8XV R-dimethindene Investigative T20251 DRUGINFO D0N2DN 4-Phenylspiro[chromene-2,4'-piperidine] Investigative T20251 DRUGINFO D0N6OL ADS-103253 Investigative T20251 DRUGINFO D0OQ5H 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative T20251 DRUGINFO D0S9AY 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine Investigative T20251 DRUGINFO D00CCV 1,6-bis(4-m-tolylpiperazin-1-yl)hexane Investigative T20251 DRUGINFO D01ABR 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine Investigative T20251 DRUGINFO D01FFX 4-((naphthalen-2-yloxy)methyl)piperidine Investigative T20251 DRUGINFO D01JYY (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide Investigative T20251 DRUGINFO D02EIB 4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol Investigative T20251 DRUGINFO D03PIP 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane Investigative T20251 DRUGINFO D03RBD 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide Investigative T20251 DRUGINFO D03XKL 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane Investigative T20251 DRUGINFO D08EKQ 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T20251 DRUGINFO D09FIC 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T20251 DRUGINFO D0C6BP 1,6-bis(4-phenylpiperazin-1-yl)hexane Investigative T20251 DRUGINFO D0E3DM (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine Investigative T20251 DRUGINFO D0U7OD PF-526014 Investigative T20251 DRUGINFO D0XF5P (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine Investigative T20251 DRUGINFO D06QIQ 7-(piperidin-4-ylmethoxy)-2-naphthonitrile Investigative T20251 DRUGINFO D0L9YP 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide Investigative T22285 TARGETID T22285 T22285 FORMERID TTDS00123 T22285 UNIPROID NMDE1_HUMAN T22285 TARGNAME Glutamate receptor ionotropic NMDA 2A (NMDAR2A) T22285 GENENAME GRIN2A T22285 TARGTYPE Successful T22285 SYNONYMS NR2A; NMDA receptor NR2A; N-methyl D-aspartate receptor subtype 2A; HNR2A; Glutamate receptor ionotropic, NMDA 2A; Glutamate [NMDA] receptor subunit epsilon-1; GluN2A T22285 FUNCTION Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition; channels containing GRIN1 and GRIN2A have higher sensitivity to glutamate and faster kinetics than channels formed by GRIN1 and GRIN2B. Contributes to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning. Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. T22285 PDBSTRUC 6IRH; 6IRG; 6IRF; 6IRA; 5TPA T22285 BIOCLASS Glutamate-gated ion channel T22285 SEQUENCE MGRVGYWTLLVLPALLVWRGPAPSAAAEKGPPALNIAVMLGHSHDVTERELRTLWGPEQAAGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLVFGDDTDQEAVAQMLDFISSHTFVPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVMLKIMQDYDWHVFSLVTTIFPGYREFISFVKTTVDNSFVGWDMQNVITLDTSFEDAKTQVQLKKIHSSVILLYCSKDEAVLILSEARSLGLTGYDFFWIVPSLVSGNTELIPKEFPSGLISVSYDDWDYSLEARVRDGIGILTTAASSMLEKFSYIPEAKASCYGQMERPEVPMHTLHPFMVNVTWDGKDLSFTEEGYQVHPRLVVIVLNKDREWEKVGKWENHTLSLRHAVWPRYKSFSDCEPDDNHLSIVTLEEAPFVIVEDIDPLTETCVRNTVPCRKFVKINNSTNEGMNVKKCCKGFCIDILKKLSRTVKFTYDLYLVTNGKHGKKVNNVWNGMIGEVVYQRAVMAVGSLTINEERSEVVDFSVPFVETGISVMVSRSNGTVSPSAFLEPFSASVWVMMFVMLLIVSAIAVFVFEYFSPVGYNRNLAKGKAPHGPSFTIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEFVDQVTGLSDKKFQRPHDYSPPFRFGTVPNGSTERNIRNNYPYMHQYMTKFNQKGVEDALVSLKTGKLDAFIYDAAVLNYKAGRDEGCKLVTIGSGYIFATTGYGIALQKGSPWKRQIDLALLQFVGDGEMEELETLWLTGICHNEKNEVMSSQLDIDNMAGVFYMLAAAMALSLITFIWEHLFYWKLRFCFTGVCSDRPGLLFSISRGIYSCIHGVHIEEKKKSPDFNLTGSQSNMLKLLRSAKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQGKESIFGDNMNELQTFVANRQKDNLNNYVFQGQHPLTLNESNPNTVEVAVSTESKANSRPRQLWKKSVDSIRQDSLSQNPVSQRDEATAENRTHSLKSPRYLPEEMAHSDISETSNRATCHREPDNSKNHKTKDNFKRSVASKYPKDCSEVERTYLKTKSSSPRDKIYTIDGEKEPGFHLDPPQFVENVTLPENVDFPDPYQDPSENFRKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPHSETSERYRQNSTHCRSCLSNMPTYSGHFTMRSPFKCDACLRMGNLYDIDEDQMLQETGNPATGEQVYQQDWAQNNALQLQKNKLRISRQHSYDNIVDKPRELDLSRPSRSISLKDRERLLEGNFYGSLFSVPSSKLSGKKSSLFPQGLEDSKRSKSLLPDHTSDNPFLHSHRDDQRLVIGRCPSDPYKHSLPSQAVNDSYLRSSLRSTASYCSRDSRGHNDVYISEHVMPYAANKNNMYSTPRVLNSCSNRRVYKKMPSIESDV T22285 DRUGINFO D0M8AB Glycine Approved T22285 DRUGINFO D02VKC NBQX Phase 1 T22285 DRUGINFO D02TTF YM-90K Discontinued in Phase 2 T22285 DRUGINFO D01PWK RPR-104632 Terminated T22285 DRUGINFO D03CNT L-698532 Terminated T22285 DRUGINFO D03WYF L-695902 Terminated T22285 DRUGINFO D0M1WN L-701324 Terminated T22285 DRUGINFO D0UB6U L-687414 Terminated T22285 DRUGINFO D0X5PX MDL-105519 Terminated T22285 DRUGINFO D02KLW DIZOCILPINE Terminated T22285 DRUGINFO D0AZ5V L-698544 Terminated T22285 DRUGINFO D03UNN L-689560 Terminated T22285 DRUGINFO D0LD9S SPERMINE Terminated T22285 DRUGINFO D09HXX TCN-201 Investigative T22285 DRUGINFO D0IX7S MDL 100,453 Investigative T22285 DRUGINFO D00VKV Tenocyclidine Investigative T22285 DRUGINFO D08OMB NVP-AAM077 Investigative T22285 DRUGINFO D0Z2EV Conantokin-R Investigative T22285 DRUGINFO D00KGK 4-Bromo-3-hydroxy-1H-quinolin-2-one Investigative T22285 DRUGINFO D01JHR H-Gly-dmP-Glu-OH Investigative T22285 DRUGINFO D01LDO (R)-2-Amino-7-phosphono-heptanoic acid Investigative T22285 DRUGINFO D01MSM 3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione Investigative T22285 DRUGINFO D01SHB TRANSTORINE Investigative T22285 DRUGINFO D01XWL 3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione Investigative T22285 DRUGINFO D03CAE 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol Investigative T22285 DRUGINFO D03LWV Nle-Pro-Glu Investigative T22285 DRUGINFO D03NWI Ala-Pro-Glu Investigative T22285 DRUGINFO D04JJL N,N'-Bis-(4-ethyl-phenyl)-guanidine Investigative T22285 DRUGINFO D04ZJL 8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T22285 DRUGINFO D05RRK Phe-Pro-Glu Investigative T22285 DRUGINFO D05WZA 4-[3-(4-Phenyl-butylamino)-propyl]-phenol Investigative T22285 DRUGINFO D06QXT 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol Investigative T22285 DRUGINFO D06RFW N,N'-Bis-(4-isopropyl-phenyl)-guanidine Investigative T22285 DRUGINFO D06SZG 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione Investigative T22285 DRUGINFO D07OBI H-Gly-D-dmP-Glu-OH Investigative T22285 DRUGINFO D07QBQ 6-Chloro-1,4-dihydro-quinoxaline-2,3-dione Investigative T22285 DRUGINFO D08FBB 8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T22285 DRUGINFO D08TAN (+)-HA966 Investigative T22285 DRUGINFO D09ISB (R)-2-Amino-5-phosphono-pentanoic acid Investigative T22285 DRUGINFO D0A5ET 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol Investigative T22285 DRUGINFO D0BC2N Gly-Pip-Glu Investigative T22285 DRUGINFO D0D5HM 4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one Investigative T22285 DRUGINFO D0E9KB N,N'-Bis-(4-butoxy-phenyl)-guanidine Investigative T22285 DRUGINFO D0FU0K 5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione Investigative T22285 DRUGINFO D0H5JV 4-Chloro-3-hydroxy-1H-quinolin-2-one Investigative T22285 DRUGINFO D0H7PR 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one Investigative T22285 DRUGINFO D0J3EZ 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione Investigative T22285 DRUGINFO D0K7EZ N-(2-methoxybenzyl)cinnamamidine Investigative T22285 DRUGINFO D0L4QC 3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione Investigative T22285 DRUGINFO D0L7RU 5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one Investigative T22285 DRUGINFO D0LE0E 8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T22285 DRUGINFO D0OZ2F AP-7 Investigative T22285 DRUGINFO D0P3MF Gly-Hyp-Glu Investigative T22285 DRUGINFO D0P4RL 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione Investigative T22285 DRUGINFO D0Q5PC PHENCYCLIDINE Investigative T22285 DRUGINFO D0Q6QW 3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one Investigative T22285 DRUGINFO D0Q8NW 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one Investigative T22285 DRUGINFO D0S3TY N,N'-Bis-(4-butyl-phenyl)-guanidine Investigative T22285 DRUGINFO D0S5OQ (D)-Ala-Pro-Glu Investigative T22285 DRUGINFO D0S5RV 3-Hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T22285 DRUGINFO D0T7TB Gly-Amp-Glu Investigative T22285 DRUGINFO D0U8BM N,N'-Bis-(4-sec-butyl-phenyl)-guanidine Investigative T22285 DRUGINFO D0U8ZQ Benzyl 4-aminobutyl(3-aminopropyl)carbamate Investigative T22285 DRUGINFO D0V1PE 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T22285 DRUGINFO D0W0HN 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol Investigative T22285 DRUGINFO D0W0VK 3-phenyl-4-hydroxyquinolin-2(1H)-one Investigative T22285 DRUGINFO D0ZD4F N,N'-Bis-(4-hexyl-phenyl)-guanidine Investigative T22285 DRUGINFO D0ZL5U Gly-b7Pro-Glu Investigative T22285 DRUGINFO D02PXN N1-dansyl-spermine Investigative T22285 DRUGINFO D03GBO 4,6-Dichloro-1H-indole-2-carboxylic acid Investigative T22285 DRUGINFO D03XLS d-CCPene Investigative T22285 DRUGINFO D04NPE UBP141 Investigative T22285 DRUGINFO D08RVB LY233053 Investigative T22285 DRUGINFO D0FT0J d-AP5 Investigative T22285 DRUGINFO D00ZKW [3H]CPP Investigative T22285 DRUGINFO D02WJT 1,3-ditolylguanidine Investigative T22285 DRUGINFO D03PGF RPR-118723 Investigative T22285 DRUGINFO D05VVC 7-chloro-3-hydroxyquinazoline-2,4-dione Investigative T22285 DRUGINFO D06GKL 2-Methylamino-succinic acid(NMDA) Investigative T22285 DRUGINFO D07COG [3H]MDL105519 Investigative T22285 DRUGINFO D08UDC [3H]CGP39653 Investigative T22285 DRUGINFO D0B5ZA homoquinolinic acid Investigative T22285 DRUGINFO D0D2ZH [3H]dizocilpine Investigative T22285 DRUGINFO D0F5ZW CGP61594 Investigative T22285 DRUGINFO D0FW8K (RS)-(tetrazol-5-yl)glycine Investigative T22285 DRUGINFO D0KO6Y [3H]CGS19755 Investigative T22285 DRUGINFO D0OT9B L-aspartic acid Investigative T22285 DRUGINFO D05KQC DNQX Investigative T22285 DRUGINFO D08CAB D-aspartic acid Investigative T76414 TARGETID T76414 T76414 FORMERID TTDC00299 T76414 UNIPROID NMDE2_HUMAN T76414 TARGNAME Glutamate receptor ionotropic NMDA 2B (NMDAR2B) T76414 GENENAME GRIN2B T76414 TARGTYPE Successful T76414 SYNONYMS NR3; NR2B; NMDA receptor subunit 2B; NMDA receptor NR2B; NMDA NR2B receptor; N-methylD-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; N-methyl D-aspartate receptor subtype 2B; HNR3; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor NR2B subunit; Glutamate [NMDA] receptor subunit epsilon-2; GluN2B T76414 FUNCTION Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death. Contributes to neural pattern formation in the developing brain. Plays a role in long-term depression (LTD) of hippocampus membrane currents and in synaptic plasticity. Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. T76414 PDBSTRUC 5EWM; 5EWL; 5EWJ; 2IPV; 1S2S T76414 BIOCLASS Glutamate-gated ion channel T76414 SEQUENCE MKPRAECCSPKFWLVLAVLAVSGSRARSQKSPPSIGIAVILVGTSDEVAIKDAHEKDDFHHLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVVFADDTDQEAIAQILDFISAQTLTPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEEYDWYIFSIVTTYFPGYQDFVNKIRSTIENSFVGWELEEVLLLDMSLDDGDSKIQNQLKKLQSPIILLYCTKEEATYIFEVANSVGLTGYGYTWIVPSLVAGDTDTVPAEFPTGLISVSYDEWDYGLPARVRDGIAIITTAASDMLSEHSFIPEPKSSCYNTHEKRIYQSNMLNRYLINVTFEGRNLSFSEDGYQMHPKLVIILLNKERKWERVGKWKDKSLQMKYYVWPRMCPETEEQEDDHLSIVTLEEAPFVIVESVDPLSGTCMRNTVPCQKRIVTENKTDEEPGYIKKCCKGFCIDILKKISKSVKFTYDLYLVTNGKHGKKINGTWNGMIGEVVMKRAYMAVGSLTINEERSEVVDFSVPFIETGISVMVSRSNGTVSPSAFLEPFSADVWVMMFVMLLIVSAVAVFVFEYFSPVGYNRCLADGREPGGPSFTIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEYVDQVSGLSDKKFQRPNDFSPPFRFGTVPNGSTERNIRNNYAEMHAYMGKFNQRGVDDALLSLKTGKLDAFIYDAAVLNYMAGRDEGCKLVTIGSGKVFASTGYGIAIQKDSGWKRQVDLAILQLFGDGEMEELEALWLTGICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEHLFYWQFRHCFMGVCSGKPGMVFSISRGIYSCIHGVAIEERQSVMNSPTATMNNTHSNILRLLRTAKNMANLSGVNGSPQSALDFIRRESSVYDISEHRRSFTHSDCKSYNNPPCEENLFSDYISEVERTFGNLQLKDSNVYQDHYHHHHRPHSIGSASSIDGLYDCDNPPFTTQSRSISKKPLDIGLPSSKHSQLSDLYGKFSFKSDRYSGHDDLIRSDVSDISTHTVTYGNIEGNAAKRRKQQYKDSLKKRPASAKSRREFDEIELAYRRRPPRSPDHKRYFRDKEGLRDFYLDQFRTKENSPHWEHVDLTDIYKERSDDFKRDSVSGGGPCTNRSHIKHGTGDKHGVVSGVPAPWEKNLTNVEWEDRSGGNFCRSCPSKLHNYSTTVTGQNSGRQACIRCEACKKAGNLYDISEDNSLQELDQPAAPVAVTSNASTTKYPQSPTNSKAQKKNRNKLRRQHSYDTFVDLQKEEAALAPRSVSLKDKGRFMDGSPYAHMFEMSAGESTFANNKSSVPTAGHHHHNNPGGGYMLSKSLYPDRVTQNPFIPTFGDDQCLLHGSKSYFFRQPTVAGASKARPDFRALVTNKPVVSALHGAVPARFQKDICIGNQSNPCVPNNKNPRAFNGSSNGHVYEKLSSIESDV T76414 DRUGINFO D0I0DL Alpha 1-PI Approved T76414 DRUGINFO D04WUA CP-101,606 Phase 2 T76414 DRUGINFO D06EMM CERC-301 Phase 2 T76414 DRUGINFO D0N3EJ RGH-896 Phase 2 T76414 DRUGINFO DD9VR3 MIJ821 Phase 2 T76414 DRUGINFO D0S8CI ELIPRODIL Phase 2 T76414 DRUGINFO D0JY2X Neu-2000 Phase 1 T76414 DRUGINFO D0S3EK EVT100 Phase 1 T76414 DRUGINFO D02VKC NBQX Phase 1 T76414 DRUGINFO D0A5TS EVT-101 Discontinued in Phase 2 T76414 DRUGINFO D02TTF YM-90K Discontinued in Phase 2 T76414 DRUGINFO D06RCS Besonprodil Discontinued in Phase 1 T76414 DRUGINFO D07YKJ EVT-103 Discontinued in Phase 1 T76414 DRUGINFO D0K0DB RO-25-6981 Terminated T76414 DRUGINFO D01PWK RPR-104632 Terminated T76414 DRUGINFO D03CNT L-698532 Terminated T76414 DRUGINFO D03WYF L-695902 Terminated T76414 DRUGINFO D0M1WN L-701324 Terminated T76414 DRUGINFO D0UB6U L-687414 Terminated T76414 DRUGINFO D0X5PX MDL-105519 Terminated T76414 DRUGINFO D02KLW DIZOCILPINE Terminated T76414 DRUGINFO D0AZ5V L-698544 Terminated T76414 DRUGINFO D03UNN L-689560 Terminated T76414 DRUGINFO D00JNH Conantokins G Investigative T76414 DRUGINFO D01ORL 2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol Investigative T76414 DRUGINFO D04GDI NP93-31 Investigative T76414 DRUGINFO D05ZQO N-(3-phenethoxybenzyl)-4-hydroxybenzamide Investigative T76414 DRUGINFO D06QJM Ro 63-1908 Investigative T76414 DRUGINFO D09TQO Conantokin-G Investigative T76414 DRUGINFO D0HB5V CN-2097 Investigative T76414 DRUGINFO D0N3LY Conantokins T Investigative T76414 DRUGINFO D00HET 6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole Investigative T76414 DRUGINFO D00VKV Tenocyclidine Investigative T76414 DRUGINFO D01BQD 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine Investigative T76414 DRUGINFO D04ZFH 2-(4-Phenoxy-benzyl)-1H-benzoimidazole Investigative T76414 DRUGINFO D05IGJ 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol Investigative T76414 DRUGINFO D06NIS 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol Investigative T76414 DRUGINFO D07RFM 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol Investigative T76414 DRUGINFO D07SGS N-(4-(benzyloxy)phenethyl)pyridin-4-amine Investigative T76414 DRUGINFO D08OMB NVP-AAM077 Investigative T76414 DRUGINFO D09BZV 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol Investigative T76414 DRUGINFO D0J1AE Phenethyl-(4-phenyl-butyl)-amine Investigative T76414 DRUGINFO D0J8PY 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine Investigative T76414 DRUGINFO D0P1YK 6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole Investigative T76414 DRUGINFO D0Q8PE 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol Investigative T76414 DRUGINFO D0QV0K 4-Benzyl-1-phenethyl-piperidine hydrochloride Investigative T76414 DRUGINFO D0T0GA 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol Investigative T76414 DRUGINFO D0T1GZ Phenethyl-(3-phenyl-propyl)-amine Investigative T76414 DRUGINFO D0V5IZ 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol Investigative T76414 DRUGINFO D0Z2EV Conantokin-R Investigative T76414 DRUGINFO D00KGK 4-Bromo-3-hydroxy-1H-quinolin-2-one Investigative T76414 DRUGINFO D01JHR H-Gly-dmP-Glu-OH Investigative T76414 DRUGINFO D01LDO (R)-2-Amino-7-phosphono-heptanoic acid Investigative T76414 DRUGINFO D01MSM 3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione Investigative T76414 DRUGINFO D01SHB TRANSTORINE Investigative T76414 DRUGINFO D01XWL 3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione Investigative T76414 DRUGINFO D03CAE 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol Investigative T76414 DRUGINFO D03LWV Nle-Pro-Glu Investigative T76414 DRUGINFO D03NWI Ala-Pro-Glu Investigative T76414 DRUGINFO D04JJL N,N'-Bis-(4-ethyl-phenyl)-guanidine Investigative T76414 DRUGINFO D04ZJL 8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T76414 DRUGINFO D05RRK Phe-Pro-Glu Investigative T76414 DRUGINFO D05WZA 4-[3-(4-Phenyl-butylamino)-propyl]-phenol Investigative T76414 DRUGINFO D06QXT 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol Investigative T76414 DRUGINFO D06RFW N,N'-Bis-(4-isopropyl-phenyl)-guanidine Investigative T76414 DRUGINFO D06SZG 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione Investigative T76414 DRUGINFO D07OBI H-Gly-D-dmP-Glu-OH Investigative T76414 DRUGINFO D07QBQ 6-Chloro-1,4-dihydro-quinoxaline-2,3-dione Investigative T76414 DRUGINFO D08FBB 8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T76414 DRUGINFO D08TAN (+)-HA966 Investigative T76414 DRUGINFO D09ISB (R)-2-Amino-5-phosphono-pentanoic acid Investigative T76414 DRUGINFO D0A5ET 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol Investigative T76414 DRUGINFO D0BC2N Gly-Pip-Glu Investigative T76414 DRUGINFO D0D5HM 4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one Investigative T76414 DRUGINFO D0E9KB N,N'-Bis-(4-butoxy-phenyl)-guanidine Investigative T76414 DRUGINFO D0FU0K 5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione Investigative T76414 DRUGINFO D0H5JV 4-Chloro-3-hydroxy-1H-quinolin-2-one Investigative T76414 DRUGINFO D0H7PR 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one Investigative T76414 DRUGINFO D0HF0A DQP-1105 Investigative T76414 DRUGINFO D0J3EZ 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione Investigative T76414 DRUGINFO D0K7EZ N-(2-methoxybenzyl)cinnamamidine Investigative T76414 DRUGINFO D0L4QC 3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione Investigative T76414 DRUGINFO D0L7RU 5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one Investigative T76414 DRUGINFO D0LE0E 8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T76414 DRUGINFO D0OZ2F AP-7 Investigative T76414 DRUGINFO D0P3MF Gly-Hyp-Glu Investigative T76414 DRUGINFO D0P4RL 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione Investigative T76414 DRUGINFO D0Q5PC PHENCYCLIDINE Investigative T76414 DRUGINFO D0Q6QW 3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one Investigative T76414 DRUGINFO D0Q8NW 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one Investigative T76414 DRUGINFO D0S3TY N,N'-Bis-(4-butyl-phenyl)-guanidine Investigative T76414 DRUGINFO D0S5OQ (D)-Ala-Pro-Glu Investigative T76414 DRUGINFO D0S5RV 3-Hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T76414 DRUGINFO D0T7TB Gly-Amp-Glu Investigative T76414 DRUGINFO D0U8BM N,N'-Bis-(4-sec-butyl-phenyl)-guanidine Investigative T76414 DRUGINFO D0U8ZQ Benzyl 4-aminobutyl(3-aminopropyl)carbamate Investigative T76414 DRUGINFO D0V1PE 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione Investigative T76414 DRUGINFO D0W0HN 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol Investigative T76414 DRUGINFO D0W0VK 3-phenyl-4-hydroxyquinolin-2(1H)-one Investigative T76414 DRUGINFO D0ZD4F N,N'-Bis-(4-hexyl-phenyl)-guanidine Investigative T76414 DRUGINFO D0ZL5U Gly-b7Pro-Glu Investigative T76414 DRUGINFO D02PXN N1-dansyl-spermine Investigative T76414 DRUGINFO D03GBO 4,6-Dichloro-1H-indole-2-carboxylic acid Investigative T76414 DRUGINFO D03XLS d-CCPene Investigative T76414 DRUGINFO D04NPE UBP141 Investigative T76414 DRUGINFO D08RVB LY233053 Investigative T76414 DRUGINFO D0FT0J d-AP5 Investigative T76414 DRUGINFO D00ZKW [3H]CPP Investigative T76414 DRUGINFO D02WJT 1,3-ditolylguanidine Investigative T76414 DRUGINFO D03PGF RPR-118723 Investigative T76414 DRUGINFO D05VVC 7-chloro-3-hydroxyquinazoline-2,4-dione Investigative T76414 DRUGINFO D06GKL 2-Methylamino-succinic acid(NMDA) Investigative T76414 DRUGINFO D07COG [3H]MDL105519 Investigative T76414 DRUGINFO D08UDC [3H]CGP39653 Investigative T76414 DRUGINFO D0B4DP 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline Investigative T76414 DRUGINFO D0B5ZA homoquinolinic acid Investigative T76414 DRUGINFO D0D2ZH [3H]dizocilpine Investigative T76414 DRUGINFO D0F5ZW CGP61594 Investigative T76414 DRUGINFO D0FW8K (RS)-(tetrazol-5-yl)glycine Investigative T76414 DRUGINFO D0K9NW 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline Investigative T76414 DRUGINFO D0KO6Y [3H]CGS19755 Investigative T76414 DRUGINFO D0OT9B L-aspartic acid Investigative T76414 DRUGINFO D05KQC DNQX Investigative T76414 DRUGINFO D08CAB D-aspartic acid Investigative T10147 TARGETID T10147 T10147 FORMERID TTDS00360 T10147 UNIPROID PTPRS_HUMAN T10147 TARGNAME Protein-tyrosine phosphatase sigma (R-PTP-sigma) T10147 GENENAME PTPRS T10147 TARGTYPE Successful T10147 SYNONYMS Receptor-type tyrosine-protein phosphatase sigma; Receptor-type tyrosine-protein phosphatase S; R-PTP-S T10147 FUNCTION Binding to chondroitin sulfate and heparan sulfate proteoglycans has opposite effects on PTPRS oligomerization and regulation of neurite outgrowth. Contributes to the inhibition of neurite and axonal outgrowth by chondroitin sulfate proteoglycans, also after nerve transection. Plays a role in stimulating neurite outgrowth in response to the heparan sulfate proteoglycan GPC2. Required for normal brain development, especially for normal development of the pituitary gland and the olfactory bulb. Functions as tyrosine phosphatase. Mediates dephosphorylation of NTRK1, NTRK2 and NTRK3. Plays a role in down-regulation of signaling cascades that lead to the activation of Akt and MAP kinases. Down-regulates TLR9-mediated activation of NF-kappa-B, as well as production of TNF, interferon alpha and interferon beta. Cell surface receptor that binds to glycosaminoglycans, including chondroitin sulfate proteoglycans and heparan sulfate proteoglycan. T10147 PDBSTRUC 4PBX; 4BPC; 2YD9; 2YD3; 2YD2 T10147 BIOCLASS Phosphoric monoester hydrolase T10147 ECNUMBER EC 3.1.3.48 T10147 SEQUENCE MAPTWGPGMVSVVGPMGLLVVLLVGGCAAEEPPRFIKEPKDQIGVSGGVASFVCQATGDPKPRVTWNKKGKKVNSQRFETIEFDESAGAVLRIQPLRTPRDENVYECVAQNSVGEITVHAKLTVLREDQLPSGFPNIDMGPQLKVVERTRTATMLCAASGNPDPEITWFKDFLPVDPSASNGRIKQLRSETFESTPIRGALQIESSEETDQGKYECVATNSAGVRYSSPANLYVRELREVRRVAPRFSILPMSHEIMPGGNVNITCVAVGSPMPYVKWMQGAEDLTPEDDMPVGRNVLELTDVKDSANYTCVAMSSLGVIEAVAQITVKSLPKAPGTPMVTENTATSITITWDSGNPDPVSYYVIEYKSKSQDGPYQIKEDITTTRYSIGGLSPNSEYEIWVSAVNSIGQGPPSESVVTRTGEQAPASAPRNVQARMLSATTMIVQWEEPVEPNGLIRGYRVYYTMEPEHPVGNWQKHNVDDSLLTTVGSLLEDETYTVRVLAFTSVGDGPLSDPIQVKTQQGVPGQPMNLRAEARSETSITLSWSPPRQESIIKYELLFREGDHGREVGRTFDPTTSYVVEDLKPNTEYAFRLAARSPQGLGAFTPVVRQRTLQSKPSAPPQDVKCVSVRSTAILVSWRPPPPETHNGALVGYSVRYRPLGSEDPEPKEVNGIPPTTTQILLEALEKWTQYRITTVAHTEVGPGPESSPVVVRTDEDVPSAPPRKVEAEALNATAIRVLWRSPAPGRQHGQIRGYQVHYVRMEGAEARGPPRIKDVMLADAQWETDDTAEYEMVITNLQPETAYSITVAAYTMKGDGARSKPKVVVTKGAVLGRPTLSVQQTPEGSLLARWEPPAGTAEDQVLGYRLQFGREDSTPLATLEFPPSEDRYTASGVHKGATYVFRLAARSRGGLGEEAAEVLSIPEDTPRGHPQILEAAGNASAGTVLLRWLPPVPAERNGAIVKYTVAVREAGALGPARETELPAAAEPGAENALTLQGLKPDTAYDLQVRAHTRRGPGPFSPPVRYRTFLRDQVSPKNFKVKMIMKTSVLLSWEFPDNYNSPTPYKIQYNGLTLDVDGRTTKKLITHLKPHTFYNFVLTNRGSSLGGLQQTVTAWTAFNLLNGKPSVAPKPDADGFIMVYLPDGQSPVPVQSYFIVMVPLRKSRGGQFLTPLGSPEDMDLEELIQDISRLQRRSLRHSRQLEVPRPYIAARFSVLPPTFHPGDQKQYGGFDNRGLEPGHRYVLFVLAVLQKSEPTFAASPFSDPFQLDNPDPQPIVDGEEGLIWVIGPVLAVVFIICIVIAILLYKNKPDSKRKDSEPRTKCLLNNADLAPHHPKDPVEMRRINFQTPDSGLRSPLREPGFHFESMLSHPPIPIADMAEHTERLKANDSLKLSQEYESIDPGQQFTWEHSNLEVNKPKNRYANVIAYDHSRVILQPIEGIMGSDYINANYVDGYRCQNAYIATQGPLPETFGDFWRMVWEQRSATIVMMTRLEEKSRIKCDQYWPNRGTETYGFIQVTLLDTIELATFCVRTFSLHKNGSSEKREVRQFQFTAWPDHGVPEYPTPFLAFLRRVKTCNPPDAGPIVVHCSAGVGRTGCFIVIDAMLERIKPEKTVDVYGHVTLMRSQRNYMVQTEDQYSFIHEALLEAVGCGNTEVPARSLYAYIQKLAQVEPGEHVTGMELEFKRLANSKAHTSRFISANLPCNKFKNRLVNIMPYESTRVCLQPIRGVEGSDYINASFIDGYRQQKAYIATQGPLAETTEDFWRMLWENNSTIVVMLTKLREMGREKCHQYWPAERSARYQYFVVDPMAEYNMPQYILREFKVTDARDGQSRTVRQFQFTDWPEQGVPKSGEGFIDFIGQVHKTKEQFGQDGPISVHCSAGVGRTGVFITLSIVLERMRYEGVVDIFQTVKMLRTQRPAMVQTEDEYQFCYQAALEYLGSFDHYAT T10147 DRUGINFO D00NNC Etidronic acid Approved T10147 DRUGINFO D0N4XG Orthovanadate Investigative T59679 TARGETID T59679 T59679 FORMERID TTDS00107 T59679 UNIPROID 5HT4R_HUMAN T59679 TARGNAME 5-HT 4 receptor (HTR4) T59679 GENENAME HTR4 T59679 TARGTYPE Successful T59679 SYNONYMS Serotonin receptor 4; 5-hydroxytryptamine receptor 4; 5-HT4 receptor; 5-HT4; 5-HT-4 T59679 FUNCTION The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. T59679 PDBSTRUC 5EM9 T59679 BIOCLASS GPCR rhodopsin T59679 SEQUENCE MDKLDANVSSEEGFGSVEKVVLLTFLSTVILMAILGNLLVMVAVCWDRQLRKIKTNYFIVSLAFADLLVSVLVMPFGAIELVQDIWIYGEVFCLVRTSLDVLLTTASIFHLCCISLDRYYAICCQPLVYRNKMTPLRIALMLGGCWVIPTFISFLPIMQGWNNIGIIDLIEKRKFNQNSNSTYCVFMVNKPYAITCSVVAFYIPFLLMVLAYYRIYVTAKEHAHQIQMLQRAGASSESRPQSADQHSTHRMRTETKAAKTLCIIMGCFCLCWAPFFVTNIVDPFIDYTVPGQVWTAFLWLGYINSGLNPFLYAFLNKSFRRAFLIILCCDDERYRRPSILGQTVPCSTTTINGSTHVLRDAVECGGQWESQCHPPATSPLVAAQPSDT T59679 DRUGINFO D00XWD Tegaserod Approved T59679 DRUGINFO D04QSJ R0-93877 Approved T59679 DRUGINFO D0BD8D Cisapride Approved T59679 DRUGINFO D0O2YE HTF 919 Approved T59679 DRUGINFO D06PZN Mosapride Phase 4 T59679 DRUGINFO D04MKJ Renzapride Phase 3 T59679 DRUGINFO D01HVZ TD-8954 Phase 2 T59679 DRUGINFO D01MBV SB-207266A Phase 2 T59679 DRUGINFO D02ORS YKP-GI Phase 2 T59679 DRUGINFO D04GMY TD-5108 Phase 2 T59679 DRUGINFO D05BWH PRX-3140 Phase 2 T59679 DRUGINFO D06HCF SPD-557 Phase 2 T59679 DRUGINFO D07SKN PF-885706 Phase 2 T59679 DRUGINFO D0D7YA DSP-6952 Phase 2 T59679 DRUGINFO D0X2XF Piboserod Phase 2 T59679 DRUGINFO D0Q8MI Lintopride Phase 2 T59679 DRUGINFO D00ZGF DA-6886 Phase 1 T59679 DRUGINFO D02YKI PF-04995274 Phase 1 T59679 DRUGINFO D03MIN M-0004 Phase 1 T59679 DRUGINFO D0M9RI SUVN-D4010 Phase 1 T59679 DRUGINFO D0S6GY SER-101 Phase 1 T59679 DRUGINFO D01CDE BIMU-1 Phase 1 T59679 DRUGINFO D08HGY Naronapride Discontinued in Phase 2 T59679 DRUGINFO D09ZQX SL65.0155 Discontinued in Phase 2 T59679 DRUGINFO D04DMQ Fabesetron Discontinued in Phase 2 T59679 DRUGINFO D0K1SZ Norcisapride Discontinued in Phase 2 T59679 DRUGINFO D0Y0SY E-3620 Discontinued in Phase 2 T59679 DRUGINFO D0U7VZ TD-2749 Discontinued in Phase 1 T59679 DRUGINFO D04GSA DAU-6285 Terminated T59679 DRUGINFO D09BHA LY-353433 Terminated T59679 DRUGINFO D0E8KS SB 203186 Terminated T59679 DRUGINFO D0PN9E SK-951 Terminated T59679 DRUGINFO D0ZG9N SC-53116 Terminated T59679 DRUGINFO D00LWD AF-3473 Investigative T59679 DRUGINFO D01EAG MDDR 287569 Investigative T59679 DRUGINFO D01KMI RS 116 0086 Investigative T59679 DRUGINFO D03KNI GR 125487 Investigative T59679 DRUGINFO D06DMV ER-21018 Investigative T59679 DRUGINFO D06HYB ML-10302 Investigative T59679 DRUGINFO D07OSA RS67506 Investigative T59679 DRUGINFO D07QMY ML 10375 Investigative T59679 DRUGINFO D08JLW GR-113808 Investigative T59679 DRUGINFO D08MVY R-116712 Investigative T59679 DRUGINFO D0AK9V VRX-03011 Investigative T59679 DRUGINFO D0B5MU SB-207710 Investigative T59679 DRUGINFO D0F3XQ RS 57639 Investigative T59679 DRUGINFO D0FE7A RS 67333 Investigative T59679 DRUGINFO D0H1UY RQ-00000010 Investigative T59679 DRUGINFO D0HA6Y [11C]SB207145 Investigative T59679 DRUGINFO D0M5ZE RS 100235 Investigative T59679 DRUGINFO D0N8EL SB 204070 Investigative T59679 DRUGINFO D0O3PE RO 116 1148 Investigative T59679 DRUGINFO D0R6UI [123I]SB 207710 Investigative T59679 DRUGINFO D0TU7G SUVN-1004028 Investigative T59679 DRUGINFO D0W8EP SDZ-205-557 Investigative T59679 DRUGINFO D00JKB SC-54750 Investigative T59679 DRUGINFO D03TPY SC-52491 Investigative T59679 DRUGINFO D0AJ3C (R)-zacopride Investigative T59679 DRUGINFO D08OFG BARETTIN Investigative T59679 DRUGINFO D01KAX 1-((S)-2-aminopropyl)-1H-indazol-6-ol Investigative T59679 DRUGINFO D09OYA alpha-methyl-5-HT Investigative T59679 DRUGINFO D0F6CD SEROTONIN Investigative T59679 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T39716 TARGETID T39716 T39716 FORMERID TTDS00402 T39716 UNIPROID SCN5A_HUMAN T39716 TARGNAME Voltage-gated sodium channel alpha Nav1.5 (SCN5A) T39716 GENENAME SCN5A T39716 TARGTYPE Successful T39716 SYNONYMS Voltage-gated sodium channel subunit alpha Nav1.5; Sodium channel protein type V subunit alpha; Sodium channel protein type 5 subunit alpha; Sodium channel protein cardiac muscle subunit alpha; HH1 T39716 FUNCTION Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is responsible for the initial upstroke of the action potential. Channel inactivation is regulated by intracellular calcium levels. This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. T39716 PDBSTRUC 6MUD; 5DBR; 4OVN; 4JQ0; 4DJC T39716 BIOCLASS Voltage-gated ion channel T39716 SEQUENCE MANFLLPRGTSSFRRFTRESLAAIEKRMAEKQARGSTTLQESREGLPEEEAPRPQLDLQASKKLPDLYGNPPQELIGEPLEDLDPFYSTQKTFIVLNKGKTIFRFSATNALYVLSPFHPIRRAAVKILVHSLFNMLIMCTILTNCVFMAQHDPPPWTKYVEYTFTAIYTFESLVKILARGFCLHAFTFLRDPWNWLDFSVIIMAYTTEFVDLGNVSALRTFRVLRALKTISVISGLKTIVGALIQSVKKLADVMVLTVFCLSVFALIGLQLFMGNLRHKCVRNFTALNGTNGSVEADGLVWESLDLYLSDPENYLLKNGTSDVLLCGNSSDAGTCPEGYRCLKAGENPDHGYTSFDSFAWAFLALFRLMTQDCWERLYQQTLRSAGKIYMIFFMLVIFLGSFYLVNLILAVVAMAYEEQNQATIAETEEKEKRFQEAMEMLKKEHEALTIRGVDTVSRSSLEMSPLAPVNSHERRSKRRKRMSSGTEECGEDRLPKSDSEDGPRAMNHLSLTRGLSRTSMKPRSSRGSIFTFRRRDLGSEADFADDENSTAGESESHHTSLLVPWPLRRTSAQGQPSPGTSAPGHALHGKKNSTVDCNGVVSLLGAGDPEATSPGSHLLRPVMLEHPPDTTTPSEEPGGPQMLTSQAPCVDGFEEPGARQRALSAVSVLTSALEELEESRHKCPPCWNRLAQRYLIWECCPLWMSIKQGVKLVVMDPFTDLTITMCIVLNTLFMALEHYNMTSEFEEMLQVGNLVFTGIFTAEMTFKIIALDPYYYFQQGWNIFDSIIVILSLMELGLSRMSNLSVLRSFRLLRVFKLAKSWPTLNTLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKNYSELRDSDSGLLPRWHMMDFFHAFLIIFRILCGEWIETMWDCMEVSGQSLCLLVFLLVMVIGNLVVLNLFLALLLSSFSADNLTAPDEDREMNNLQLALARIQRGLRFVKRTTWDFCCGLLRQRPQKPAALAAQGQLPSCIATPYSPPPPETEKVPPTRKETRFEEGEQPGQGTPGDPEPVCVPIAVAESDTDDQEEDEENSLGTEEESSKQQESQPVSGGPEAPPDSRTWSQVSATASSEAEASASQADWRQQWKAEPQAPGCGETPEDSCSEGSTADMTNTAELLEQIPDLGQDVKDPEDCFTEGCVRRCPCCAVDTTQAPGKVWWRLRKTCYHIVEHSWFETFIIFMILLSSGALAFEDIYLEERKTIKVLLEYADKMFTYVFVLEMLLKWVAYGFKKYFTNAWCWLDFLIVDVSLVSLVANTLGFAEMGPIKSLRTLRALRPLRALSRFEGMRVVVNALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFGRCINQTEGDLPLNYTIVNNKSQCESLNLTGELYWTKVKVNFDNVGAGYLALLQVATFKGWMDIMYAAVDSRGYEEQPQWEYNLYMYIYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKYQGFIFDIVTKQAFDVTIMFLICLNMVTMMVETDDQSPEKINILAKINLLFVAIFTGECIVKLAALRHYYFTNSWNIFDFVVVILSIVGTVLSDIIQKYFFSPTLFRVIRLARIGRILRLIRGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMANFAYVKWEAGIDDMFNFQTFANSMLCLFQITTSAGWDGLLSPILNTGPPYCDPTLPNSNGSRGDCGSPAVGILFFTTYIIISFLIVVNMYIAIILENFSVATEESTEPLSEDDFDMFYEIWEKFDPEATQFIEYSVLSDFADALSEPLRIAKPNQISLINMDLPMVSGDRIHCMDILFAFTKRVLGESGEMDALKIQMEEKFMAANPSKISYEPITTTLRRKHEEVSAMVIQRAFRRHLLQRSLKHASFLFRQQAGSGLSEEDAPEREGLIAYVMSENFSRPLGPPSSSSISSTSFPPSYDSVTRATSDNLQVRGSDYSHSEDLADFPPSPDRDRESIV T39716 DRUGINFO D04QLR Dyclonine Approved T39716 DRUGINFO D04VPA Moricizine Approved T39716 DRUGINFO D05EPM Ethotoin Approved T39716 DRUGINFO D06LYG Prilocaine Approved T39716 DRUGINFO D07RGW Mephenytoin Approved T39716 DRUGINFO D08MRN Hexylcaine Approved T39716 DRUGINFO D0J5YC Fosphenytoin Approved T39716 DRUGINFO D0K4CQ Indecainide Approved T39716 DRUGINFO D0M4YC Disopyramide Approved T39716 DRUGINFO D0P5GE Dibucaine Approved T39716 DRUGINFO D0Q2ES Benzonatate Approved T39716 DRUGINFO D0X0RI Mexiletine Approved T39716 DRUGINFO D0C7ET Tetrodotoxin Approved T39716 DRUGINFO D0N3ZJ LOMERIZINE Approved T39716 DRUGINFO D00XWB F-15845 Phase 1 T39716 DRUGINFO D03WBS Aryl carboxamide derivative 3 Patented T39716 DRUGINFO D0UL0K Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 Patented T39716 DRUGINFO D0M8WO Aryl carboxamide derivative 1 Patented T39716 DRUGINFO D0OP5F Aryl carboxamide derivative 2 Patented T39716 DRUGINFO D06PAZ Encainide Withdrawn from market T39716 DRUGINFO D08LDS LUBELUZOLE Discontinued in Preregistration T39716 DRUGINFO D04BQR Acecainide Discontinued in Phase 3 T39716 DRUGINFO D0EC2K SIPATRIGINE Discontinued in Phase 2 T39716 DRUGINFO D02NLI PD-85639 Terminated T39716 DRUGINFO D01SAX KC-12291 Investigative T39716 DRUGINFO D06GQO N-Butyl-N'-(4-methyl-benzoyl)-guanidine Investigative T39716 DRUGINFO D0O2RN N-(4-Methyl-benzoyl)-N'-phenethyl-guanidine Investigative T39716 DRUGINFO D01AGR 1-[5-(4-Chlorophenyl)-2-furoyl]piperazine Investigative T39716 DRUGINFO D0A1MW aconitine Investigative T39716 DRUGINFO D0G9WE batrachotoxin Investigative T39716 DRUGINFO D0S4MN veratridine Investigative T22095 TARGETID T22095 T22095 FORMERID TTDC00214 T22095 UNIPROID IL17_HUMAN T22095 TARGNAME Interleukin-17 (IL17) T22095 GENENAME IL17A T22095 TARGTYPE Successful T22095 SYNONYMS Interleukin-17A; IL-17A; IL-17; Cytotoxic T-lymphocyte-associated antigen 8; Cytotoxic T lymphocyte-associated antigen 8; CTLA8; CTLA-8 T22095 FUNCTION The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC. Involved in inducing stromal cells to produce proinflammatory and hematopoietic cytokines. Ligand for IL17RA and IL17RC. T22095 PDBSTRUC 5VB9; 5NAN; 5N92; 5N7W; 5HI5 T22095 BIOCLASS Cytokine: interleukin T22095 SEQUENCE MTPGKTSLVSLLLLLSLEAIVKAGITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVA T22095 DRUGINFO D08NMV Ixekizumab Approved T22095 DRUGINFO D05CEO Brodalumab Approved T22095 DRUGINFO D0WJ5M Bimekizumab Approved T22095 DRUGINFO D0T5TN CJM112 Phase 2 T22095 DRUGINFO D0A7NZ CNTO-6785 Phase 2 T22095 DRUGINFO D0OX5H ABT-122 Phase 2 T22095 DRUGINFO D00BPH COVA322 Phase 1/2a T22095 DRUGINFO D04EJG SHR-1314 Phase 1/2 T22095 DRUGINFO D08YWY SCH-900117 Phase 1 T22095 DRUGINFO D04DQO ABBV-257 Phase 1 T22095 DRUGINFO D0B5UH ALX-0761 Phase 1 T22095 DRUGINFO D0J8JF RG-4934 Discontinued in Phase 1 T22095 DRUGINFO DFU4B0 RO7040547 Discontinued in Phase 1 T84703 TARGETID T84703 T84703 FORMERID TTDNR00649 T84703 UNIPROID NTRK2_HUMAN T84703 TARGNAME BDNF/NT-3 growth factors receptor (TrkB) T84703 GENENAME NTRK2 T84703 TARGTYPE Successful T84703 SYNONYMS Tropomyosin-related kinase B; TrkB tyrosine kinase; Trk-B; TRKB; Neurotrophic tyrosine kinase receptor type 2; GP145-TrkB T84703 FUNCTION Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia. Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. T84703 PDBSTRUC 5MO9; 4AT5; 4AT4; 4AT3; 4ASZ T84703 BIOCLASS Kinase T84703 ECNUMBER EC 2.7.10.1 T84703 SEQUENCE MSSWIRWHGPAMARLWGFCWLVVGFWRAAFACPTSCKCSASRIWCSDPSPGIVAFPRLEPNSVDPENITEIFIANQKRLEIINEDDVEAYVGLRNLTIVDSGLKFVAHKAFLKNSNLQHINFTRNKLTSLSRKHFRHLDLSELILVGNPFTCSCDIMWIKTLQEAKSSPDTQDLYCLNESSKNIPLANLQIPNCGLPSANLAAPNLTVEEGKSITLSCSVAGDPVPNMYWDVGNLVSKHMNETSHTQGSLRITNISSDDSGKQISCVAENLVGEDQDSVNLTVHFAPTITFLESPTSDHHWCIPFTVKGNPKPALQWFYNGAILNESKYICTKIHVTNHTEYHGCLQLDNPTHMNNGDYTLIAKNEYGKDEKQISAHFMGWPGIDDGANPNYPDVIYEDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFCLLVMLFLLKLARHSKFGMKGPASVISNDDDSASPLHHISNGSNTPSSSEGGPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFVQHIKRHNIVLKRELGEGAFGKVFLAECYNLCPEQDKILVAVKTLKDASDNARKDFHREAELLTNLQHEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLRAHGPDAVLMAEGNPPTELTQSQMLHIAQQIAAGMVYLASQHFVHRDLATRNCLVGENLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSLGVVLWEIFTYGKQPWYQLSNNEVIECITQGRVLQRPRTCPQEVYELMLGCWQREPHMRKNIKGIHTLLQNLAKASPVYLDILG T84703 DRUGINFO D07TOK Larotrectinib Approved T84703 DRUGINFO D0O0LS Entrectinib Approved T84703 DRUGINFO D00DRL MK-2461 Phase 1/2 T84703 DRUGINFO D00DXC Macrocycle derivative 13 Patented T84703 DRUGINFO D0NS6S Cyclopenta[d]pyrimidine derivative 1 Patented T84703 DRUGINFO D00MGO PMID28270021-Compound-WO2016054807Example1 Patented T84703 DRUGINFO D07RLB PMID28270010-Compound-Figure24-b Patented T84703 DRUGINFO D0AG2A Pyrrolo[2,3-d]pyrimidine derivative 4 Patented T84703 DRUGINFO D0AU4G 3-amino-5-benzyl-substituted indazole derivative 1 Patented T84703 DRUGINFO D0J9ZG PMID28270010-Compound-Figure5-1 Patented T84703 DRUGINFO D0M8VS PMID28270021-Compound-WO2015042088Example4 Patented T84703 DRUGINFO D0T2OX PMID28270010-Compound-Figure5-2 Patented T84703 DRUGINFO D0V5AG PMID28270010-Compound-Figure5-3 Patented T84703 DRUGINFO D0Y1NH Azaindazole amide derivative 1 Patented T84703 DRUGINFO D0D1HR TrkB NAM Investigative T84703 DRUGINFO D02RWC GNF-5837 Investigative T84703 DRUGINFO D0MH1X AZD1332 Investigative T84703 DRUGINFO D0K5UF PMID24432909C8e Investigative T69619 TARGETID T69619 T69619 FORMERID TTDR00742 T69619 UNIPROID AOC3_HUMAN T69619 TARGNAME Membrane copper amine oxidase (AOC3) T69619 GENENAME AOC3 T69619 TARGTYPE Successful T69619 SYNONYMS Vascular adhesion protein-1; Vascular adhesion protein 1; VAP1; VAP-1; Semicarbazide-sensitive amine oxidase; SSAO; Membrane primary amine oxidase; HPAO; Copper amine oxidase T69619 FUNCTION Has semicarbazide-sensitive (SSAO) monoamine oxidase activity. May play a role in adipogenesis. Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion. T69619 PDBSTRUC 4BTY; 4BTX; 4BTW; 3ALA; 2Y74 T69619 BIOCLASS CH-NH(2) donor oxidoreductase T69619 ECNUMBER EC 1.4.3.21 T69619 SEQUENCE MNQKTILVLLILAVITIFALVCVLLVGRGGDGGEPSQLPHCPSVSPSAQPWTHPGQSQLFADLSREELTAVMRFLTQRLGPGLVDAAQARPSDNCVFSVELQLPPKAAALAHLDRGSPPPAREALAIVFFGRQPQPNVSELVVGPLPHPSYMRDVTVERHGGPLPYHRRPVLFQEYLDIDQMIFNRELPQASGLLHHCCFYKHRGRNLVTMTTAPRGLQSGDRATWFGLYYNISGAGFFLHHVGLELLVNHKALDPARWTIQKVFYQGRYYDSLAQLEAQFEAGLVNVVLIPDNGTGGSWSLKSPVPPGPAPPLQFYPQGPRFSVQGSRVASSLWTFSFGLGAFSGPRIFDVRFQGERLVYEISLQEALAIYGGNSPAAMTTRYVDGGFGMGKYTTPLTRGVDCPYLATYVDWHFLLESQAPKTIRDAFCVFEQNQGLPLRRHHSDLYSHYFGGLAETVLVVRSMSTLLNYDYVWDTVFHPSGAIEIRFYATGYISSAFLFGATGKYGNQVSEHTLGTVHTHSAHFKVDLDVAGLENWVWAEDMVFVPMAVPWSPEHQLQRLQVTRKLLEMEEQAAFLVGSATPRYLYLASNHSNKWGHPRGYRIQMLSFAGEPLPQNSSMARGFSWERYQLAVTQRKEEEPSSSSVFNQNDPWAPTVDFSDFINNETIAGKDLVAWVTAGFLHIPHAEDIPNTVTVGNGVGFFLRPYNFFDEDPSFYSADSIYFRGDQDAGACEVNPLACLPQAAACAPDLPAFSHGGFSHN T69619 DRUGINFO D0K1XK Hydralazine Approved T69619 DRUGINFO D03SKR Clonidine Approved T69619 DRUGINFO D01VLT ASP8232 Phase 2 T69619 DRUGINFO D06GUG BTT-1023 Phase 2 T69619 DRUGINFO DM3J5I BI 1467335 Discontinued in Phase 2 T69619 DRUGINFO D05YHW Vapaliximab Terminated T69619 DRUGINFO D00LPZ Vapill Investigative T69619 DRUGINFO D00WKL PSX-4206 Investigative T69619 DRUGINFO D0F8KR RTU-1096 Investigative T69619 DRUGINFO D0I1TM FP-1102 Investigative T69619 DRUGINFO D0M9YH 6-hydroxydopa quinone Investigative T69619 DRUGINFO D0R0FU PXS-4159 Investigative T69619 DRUGINFO D0V6DF LJP-1207 Investigative T40696 TARGETID T40696 T40696 FORMERID TTDS00083 T40696 UNIPROID PARC_STAAS T40696 TARGNAME Staphylococcus Topoisomerase IV (Stap-coc parC) T40696 GENENAME Stap-coc parC T40696 TARGTYPE Successful T40696 SYNONYMS Topoisomerase IV subunit A; DNA topoisomerase 4 subunit A T40696 FUNCTION Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule. T40696 PDBSTRUC 2INR T40696 BIOCLASS Topoisomerase GyrA ParC T40696 ECNUMBER EC 5.6.2.3 T40696 SEQUENCE MSEIIQDLSLEDVLGDRFGRYSKYIIQERALPDVRDGLKPVQRRILYAMYSSGNTHDKNFRKSAKTVGDVIGQYHPHGDSSVYEAMVRLSQDWKLRHVLIEMHGNNGSIDNDPPAAMRYTEAKLSLLAEELLRDINKETVSFIPNYDDTTLEPMVLPSRFPNLLVNGSTGISAGYATDIPPHNLAEVIQATLKYIDNPDITVNQLMKYIKGPDFPTGGIIQGIDGIKKAYESGKGRIIVRSKVEEETLRNGRKQLIITEIPYEVNKSSLVKRIDELRADKKVDGIVEVRDETDRTGLRIAIELKKDVNSESIKNYLYKNSDLQISYNFNMVAISDGRPKLMGIRQIIDSYLNHQIEVVANRTKFELDNAEKRMHIVEGLIKALSILDKVIELIRSSKNKRDAKENLIEVYEFTEEQAEAIVMLQLYRLTNTDIVALEGEHKELEALIKQLRHILDNHDALLNVIKEELNEIKKKFKSERLSLIEAEIEEIKIDKEVMVPSEEVILSMTRHGYIKRTSIRSFNASGVEDIGLKDGDSLLKHQEVNTQDTVLVFTNKGRYLFIPVHKLADIRWKELGQHVSQIVPIEEDEVVINVFNEKDFNTDAFYVFATQNGMIKKSTVPLFKTTRFNKPLIATKVKENDDLISVMRFEKDQLITVITNKGMSLTYNTSELSDTGLRAAGVKSINLKAEDFVVVTEGVSENDTILMATQRGSLKRISFKILQVAKRAQRGITLLKELKKNPHRIVAAHVVTGEHSQYTLYSKSNEEHGLINDIHKSEQYTNGSFIVDTDDFGEVIDMYIS T40696 DRUGINFO D00TRV Besifloxacin Approved T40696 DRUGINFO D01IXD Finafloxacin Approved T40696 DRUGINFO D02RSN Levofloxacin Approved T40696 DRUGINFO D03CQE Gatifloxacin Approved T40696 DRUGINFO D04XDT Delafloxacin Meglumine Approved T40696 DRUGINFO D0K6GZ Sparfloxacin Approved T40696 DRUGINFO D0VR7W Gemifloxacin Approved T40696 DRUGINFO D0ZV0Z Moxifloxacin Approved T40696 DRUGINFO D0O1WX Ciprofloxacin XR Approved T40696 DRUGINFO D0X1HE Ozenoxacin Approved T40696 DRUGINFO D04ETV Nemonaxacin Phase 3 T40696 DRUGINFO D0V9BU ABT-492 Phase 3 T40696 DRUGINFO D07MXF Zabofloxacin Phase 3 T40696 DRUGINFO D0E9RP WCK-2349 Phase 2 T40696 DRUGINFO D07NTC WCK-771 Phase 2 T40696 DRUGINFO D0Q6GD WCK-1152 Phase 1 T40696 DRUGINFO D07AOY Avarofloxacin Discontinued in Phase 2 T40696 DRUGINFO D0T3VO DX-619 Discontinued in Phase 2 T40696 DRUGINFO D0QW7D DK-507k Discontinued in Phase 1 T40696 DRUGINFO D01ZLI CBR-2092 Terminated T40696 DRUGINFO D08ZRP NSFQ-105 Investigative T40696 DRUGINFO D0PC5N Premafloxacin Investigative T73676 TARGETID T73676 T73676 FORMERID TTDC00246 T73676 UNIPROID SV2A_HUMAN T73676 TARGNAME Synaptic vesicle glycoprotein 2A (SV2A) T73676 GENENAME SV2A T73676 TARGTYPE Successful T73676 SYNONYMS SV2A T73676 FUNCTION Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles. T73676 PDBSTRUC 4V11 T73676 BIOCLASS Major facilitator superfamily T73676 SEQUENCE MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFEEEDDDDDFPAPSDGYYRGEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPRAESGGKGERMADGAPLAGVRGGLSDGEGPPGGRGEAQRRKEREELAQQYEAILRECGHGRFQWTLYFVLGLALMADGVEVFVVGFVLPSAEKDMCLSDSNKGMLGLIVYLGMMVGAFLWGGLADRLGRRQCLLISLSVNSVFAFFSSFVQGYGTFLFCRLLSGVGIGGSIPIVFSYFSEFLAQEKRGEHLSWLCMFWMIGGVYAAAMAWAIIPHYGWSFQMGSAYQFHSWRVFVLVCAFPSVFAIGALTTQPESPRFFLENGKHDEAWMVLKQVHDTNMRAKGHPERVFSVTHIKTIHQEDELIEIQSDTGTWYQRWGVRALSLGGQVWGNFLSCFGPEYRRITLMMMGVWFTMSFSYYGLTVWFPDMIRHLQAVDYASRTKVFPGERVEHVTFNFTLENQIHRGGQYFNDKFIGLRLKSVSFEDSLFEECYFEDVTSSNTFFRNCTFINTVFYNTDLFEYKFVNSRLINSTFLHNKEGCPLDVTGTGEGAYMVYFVSFLGTLAVLPGNIVSALLMDKIGRLRMLAGSSVMSCVSCFFLSFGNSESAMIALLCLFGGVSIASWNALDVLTVELYPSDKRTTAFGFLNALCKLAAVLGISIFTSFVGITKAAPILFASAALALGSSLALKLPETRGQVLQ T73676 DRUGINFO D0CT4D Brivaracetam Approved T73676 DRUGINFO D0E1XL Levetiracetam Approved T73676 DRUGINFO DCA5M2 Padsevonil Phase 2/3 T73676 DRUGINFO D0L9AJ Seletracetam Discontinued in Phase 3 T62206 TARGETID T62206 T62206 FORMERID TTDR01164 T62206 UNIPROID PCSK9_HUMAN T62206 TARGNAME Proprotein convertase subtilisin/kexin type 9 (PCSK9) T62206 GENENAME PCSK9 T62206 TARGTYPE Successful T62206 SYNONYMS Subtilisin/kexin-like protease PC9; Proprotein convertase 9; PC9; Neural apoptosis-regulated convertase 1; NARC1; NARC-1 T62206 FUNCTION Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. T62206 PDBSTRUC 6MV5; 6F5G; 6E4Z; 6E4Y; 5VLP T62206 BIOCLASS Peptidase T62206 ECNUMBER EC 3.4.21.- T62206 SEQUENCE MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEELVLALRSEEDGLAEAPEHGTTATFHRCAKDPWRLPGTYVVVLKEETHLSQSERTARRLQAQAARRGYLTKILHVFHGLLPGFLVKMSGDLLELALKLPHVDYIEEDSSVFAQSIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMVTDFENVPEEDGTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRSLRVLNCQGKGTVSGTLIGLEFIRKSQLVQPVGPLVVLLPLAGGYSRVLNAACQRLARAGVVLVTAAGNFRDDACLYSPASAPEVITVGATNAQDQPVTLGTLGTNFGRCVDLFAPGEDIIGASSDCSTCFVSQSGTSQAAAHVAGIAAMMLSAEPELTLAELRQRLIHFSAKDVINEAWFPEDQRVLTPNLVAALPPSTHGAGWQLFCRTVWSAHSGPTRMATAVARCAPDEELLSCSSFSRSGKRRGERMEAQGGKLVCRAHNAFGGEGVYAIARCCLLPQANCSVHTAPPAEASMGTRVHCHQQGHVLTGCSSHWEVEDLGTHKPPVLRPRGQPNQCVGHREASIHASCCHAPGLECKVKEHGIPAPQEQVTVACEEGWTLTGCSALPGTSHVLGAYAVDNTCVVRSRDVSTTGSTSEGAVTAVAICCRSRHLAQASQELQ T62206 DRUGINFO D00GNI REGN-727 Approved T62206 DRUGINFO D8MNH5 Evolocumab Approved T62206 DRUGINFO D03DJT Bococizumab Phase 3 T62206 DRUGINFO D03FBV PF-04950615 Phase 3 T62206 DRUGINFO D0OW2S AMG 145 Phase 3 T62206 DRUGINFO D93UYR LIB003 Phase 3 T62206 DRUGINFO D07SKJ LY3015014 Phase 2 T62206 DRUGINFO D4DMS3 MK-0616 Phase 2 T62206 DRUGINFO D05EBY PCSK9 Adnectin Phase 1 T62206 DRUGINFO D0U3GA SPC5001 Phase 1 T62206 DRUGINFO D2EF8M AZD0780 Phase 1 T62206 DRUGINFO DL69MN NNC-0385-0434 Phase 1 T62206 DRUGINFO D0R0RW 1D05 Investigative T51426 TARGETID T51426 T51426 FORMERID TTDS00272 T51426 UNIPROID NR1H4_HUMAN T51426 TARGNAME Farnesoid X-activated receptor (FXR) T51426 GENENAME NR1H4 T51426 TARGTYPE Successful T51426 SYNONYMS Retinoid X receptor-interacting protein 14; RXR-interacting protein 14; RIP14; Nuclear receptor subfamily 1 group H member 4; HRR1; Farnesol receptor HRR-1; FXR; Bile acid receptor; BAR T51426 FUNCTION Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). Plays a essential role in BA homeostasis through the regulation of genes involved in BA synthesis, conjugation and enterohepatic circulation. Also regulates lipid and glucose homeostasis and is involved innate immune response. The FXR-RXR heterodimer binds predominantly to farnesoid X receptor response elements (FXREs) containing two inverted repeats of the consensus sequence 5'-AGGTCA-3' in which the monomers are spaced by 1 nucleotide (IR-1) but also to tandem repeat DR1 sites with lower affinity, and can be activated by either FXR or RXR-specific ligands. It is proposed that monomeric nuclear receptors such as NR5A2/LRH-1 bound to coregulatory nuclear responsive element (NRE) halfsites located in close proximity to FXREs modulate transcriptional activity (By similarity). In the liver activates transcription of the corepressor NR0B2 thereby indirectly inhibiting CYP7A1 and CYP8B1 (involved in BA synthesis) implicating at least in part histone demethylase KDM1A resulting in epigenomic repression, and SLC10A1/NTCP (involved in hepatic uptake of conjugated BAs). Activates transcription of the repressor MAFG (involved in regulation of BA synthesis) (By similarity). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine). In the intestine activates FGF19 expression and secretion leading to hepatic CYP7A1 repression. The function also involves the coordinated induction of hepatic KLB/beta-klotho expression (By similarity). Regulates transcription of liver UGT2B4 and SULT2A1 involved in BA detoxification; binding to the UGT2B4 promoter seems to imply a monomeric transactivation independent of RXRA. Modulates lipid homeostasis by activating liver NR0B2/SHP-mediated repression of SREBF1 (involved in de novo lipogenesis), expression of PLTP (involved in HDL formation), SCARB1 (involved in HDL hepatic uptake), APOE, APOC1, APOC4, PPARA (involved in beta-oxidation of fatty acids), VLDLR and SDC1 (involved in the hepatic uptake of LDL and IDL remnants), and inhibiting expression of MTTP (involved in VLDL assembly. Increases expression of APOC2 (promoting lipoprotein lipase activity implicated in triglyceride clearance). Transrepresses APOA1 involving a monomeric competition with NR2A1 for binding to a DR1 element. Also reduces triglyceride clearance by inhibiting expression of ANGPTL3 and APOC3 (both involved in inhibition of lipoprotein lipase). Involved in glucose homeostasis by modulating hepatic gluconeogenesis through activation of NR0B2/SHP-mediated repression of respective genes. Modulates glycogen synthesis (inducing phosphorylation of glycogen synthase kinase-3) (By similarity). Modulates glucose-stimulated insulin secretion and is involved in insulin resistance. Involved in intestinal innate immunity. Plays a role in protecting the distal small intestine against bacterial overgrowth and preservation of the epithelial barrier (By similarity). Down-regulates inflammatory cytokine expression in several types of immune cells including macrophages and mononuclear cells. Mediates trans-repression of TLR4-induced cytokine expression; the function seems to require its sumoylation and prevents N-CoR nuclear receptor corepressor clearance from target genes such as IL1B and NOS2. Involved in the TLR9-mediated protective mechanism in intestinal inflammation. Plays an anti-inflammatory role in liver inflammation; proposed to inhibit proinflammatory (but not antiapoptotic) NF-kappa-B signaling) (By similarity). T51426 PDBSTRUC 6A60; 6A5Z; 6A5Y; 6A5X; 6A5W T51426 BIOCLASS Nuclear hormone receptor T51426 SEQUENCE MVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAKGVLTEQVAGPLGQNLEVEPYSQYSNVQFPQVQPQISSSSYYSNLGFYPQQPEEWYSPGIYELRRMPAETLYQGETEVAEMPVTKKPRMGASAGRIKGDELCVVCGDRASGYHYNALTCEGCKGFFRRSITKNAVYKCKNGGNCVMDMYMRRKCQECRLRKCKEMGMLAECMYTGLLTEIQCKSKRLRKNVKQHADQTVNEDSEGRDLRQVTSTTKSCREKTELTPDQQTLLHFIMDSYNKQRMPQEITNKILKEEFSAEENFLILTEMATNHVQVLVEFTKKLPGFQTLDHEDQIALLKGSAVEAMFLRSAEIFNKKLPSGHSDLLEERIRNSGISDEYITPMFSFYKSIGELKMTQEEYALLTAIVILSPDRQYIKDREAVEKLQEPLLDVLQKLCKIHQPENPQHFACLLGRLTELRTFNHHHAEMLMSWRVNDHKFTPLLCEIWDVQ T51426 DRUGINFO D03ZTE Chenodiol Approved T51426 DRUGINFO D0G8BV Guggulsterone Approved T51426 DRUGINFO D0M4WA obeticholic acid Approved T51426 DRUGINFO DBND71 GS-9674 Phase 3 T51426 DRUGINFO D04SLF Bevacizumab + Trastuzumab Phase 3 T51426 DRUGINFO D00HTO Apomine Phase 2 T51426 DRUGINFO D05EUR LJN452 Phase 2 T51426 DRUGINFO DBU2W3 EYP001 Phase 2 T51426 DRUGINFO DM4K9V EDP-305 Phase 2 T51426 DRUGINFO DW9ML8 LMB763 Phase 2 T51426 DRUGINFO DX56JK MET409 Phase 2 T51426 DRUGINFO D01SYU Turofexorate isopropyl Phase 1 T51426 DRUGINFO D4PV0B AGN-242266 Phase 1 T51426 DRUGINFO D7LQJ8 PX-102 Phase 1 T51426 DRUGINFO D01QNX PMID29649907-Compound-15 Patented T51426 DRUGINFO D01XIW PMID29649907-Compound-22 Patented T51426 DRUGINFO D02OJH PMID29649907-Compound-26 Patented T51426 DRUGINFO D02RCY PMID29649907-Compound-41 Patented T51426 DRUGINFO D03DZQ PMID30259754-Compound-WAY-362450 Patented T51426 DRUGINFO D03IMJ PMID29649907-Compound-20 Patented T51426 DRUGINFO D04QBY PMID29649907-Compound-27 Patented T51426 DRUGINFO D05QJY PMID29649907-Compound-9 Patented T51426 DRUGINFO D07EDS PMID29649907-Compound-29 Patented T51426 DRUGINFO D07NTP PMID29649907-Compound-14 Patented T51426 DRUGINFO D08MBD PMID29649907-Compound-24 Patented T51426 DRUGINFO D08MYA PMID29649907-Compound-31 Patented T51426 DRUGINFO D08ZAW PMID29649907-Compound-12 Patented T51426 DRUGINFO D09FOM PMID30259754-Compound-pyrrole[2,3-d]azepines Patented T51426 DRUGINFO D0A4LL PMID29649907-Compound-25 Patented T51426 DRUGINFO D0BN9E PMID29649907-Compound-13 Patented T51426 DRUGINFO D0E0MH PMID30259754-Compound-INT-767 Patented T51426 DRUGINFO D0E5ED PMID29649907-Compound-5 Patented T51426 DRUGINFO D0EB7G PMID29649907-Compound-3 Patented T51426 DRUGINFO D0F2OO PMID29649907-Compound-18 Patented T51426 DRUGINFO D0F3SQ PMID29649907-Compound-2 Patented T51426 DRUGINFO D0F5MF PMID29649907-Compound-33 Patented T51426 DRUGINFO D0FC0B PMID29649907-Compound-21 Patented T51426 DRUGINFO D0HR8Y PMID29649907-Compound-10 Patented T51426 DRUGINFO D0J4CL PMID29649907-Compound-19 Patented T51426 DRUGINFO D0JD0G PMID29649907-Compound-4 Patented T51426 DRUGINFO D0K3UO PMID29649907-Compound-39 Patented T51426 DRUGINFO D0KB4T PMID29649907-Compound-44 Patented T51426 DRUGINFO D0N4PL PMID29649907-Compound-36 Patented T51426 DRUGINFO D0OM2M PMID29649907-Compound-28 Patented T51426 DRUGINFO D0R8GK PMID30259754-Compound-Px-102 Patented T51426 DRUGINFO D0RL3M PMID29649907-Compound-35 Patented T51426 DRUGINFO D0TH6M PMID30259754-Compound-LY2562175 Patented T51426 DRUGINFO D0TL4F PMID29649907-Compound-23 Patented T51426 DRUGINFO D0U0CC PMID29649907-Compound-11 Patented T51426 DRUGINFO D0UW8Q PMID29649907-Compound-32 Patented T51426 DRUGINFO D0WA9U PMID29649907-Compound-1 Patented T51426 DRUGINFO D0WT7M PMID29649907-Compound-38 Patented T51426 DRUGINFO D0Y0LI PMID29649907-Compound-40 Patented T51426 DRUGINFO D0Y3NZ PMID29649907-Compound-42 Patented T51426 DRUGINFO D0YK9Q PMID29649907-Compound-37 Patented T51426 DRUGINFO D0Z0FP PMID29649907-Compound-34 Patented T51426 DRUGINFO D0ZG3D PMID29649907-Compound-30 Patented T51426 DRUGINFO D08LIB PMID29649907-Compound-INT767 Patented T51426 DRUGINFO D0AA3P PMID29649907-Compound-8 Patented T51426 DRUGINFO D03LFR SB-756050 Discontinued in Phase 2 T51426 DRUGINFO D08TKV SKF-97426 Discontinued in Phase 2 T51426 DRUGINFO DNZ96J INT-767 Preclinical T51426 DRUGINFO D01GUG 12-O-deacetyl-12-epi-19-deoxy-21-hydroxyscalarin Investigative T51426 DRUGINFO D01MYO Fexaramine Investigative T51426 DRUGINFO D0HH9N cholesten Investigative T51426 DRUGINFO D0IO8G GW4065 Investigative T51426 DRUGINFO D0X4YY 1,1-bisphosphonate esters Investigative T51426 DRUGINFO D01RNA desmosterol Investigative T51426 DRUGINFO D0K4GK 22R-hydroxycholesterol Investigative T51426 DRUGINFO D0GR9O AGN-34 Investigative T98913 TARGETID T98913 T98913 FORMERID TTDS00411 T98913 UNIPROID CSF3R_HUMAN T98913 TARGNAME Granulocyte colony-stimulating factor receptor (G-CSF-R) T98913 GENENAME CSF3R T98913 TARGTYPE Successful T98913 SYNONYMS c-fms; GCSFR; GCSF receptor; G-CSF receptor; Fms proto-oncogene; CD114 T98913 FUNCTION Plays a crucial role in the proliferation, differientation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface. Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. T98913 PDBSTRUC 2D9Q; 1AZ7 T98913 BIOCLASS Cytokine receptor T98913 SEQUENCE MARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAGYPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPKDGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPEAAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPATAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVPLEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPTPVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRMEQNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGKTWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHLMAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWPSVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGLPTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGLTPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF T98913 DRUGINFO D09WDK Tbo-Filgrastim Approved T98913 DRUGINFO D0AT8C Pegfilgrastim Approved T98913 DRUGINFO D03ZAE Peg-G-CSF Phase 3 T98913 DRUGINFO D01LRM SBC-014 Phase 2 T98913 DRUGINFO D03GRD AX-200 Phase 2 T98913 DRUGINFO D05ZXS MAXY-G34 Phase 2 T98913 DRUGINFO D08NDE BLZ-945 Phase 2 T98913 DRUGINFO D08YGY MK-6302 Phase 1 T98913 DRUGINFO D0W1YV PLX-5622 Phase 1 T98913 DRUGINFO D0I8DX AMG 820 Phase 1 T98913 DRUGINFO D07PSL PLX7486 Phase 1 T98913 DRUGINFO D0B6BQ ZD-6003 Terminated T98913 DRUGINFO D00WSN N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide Investigative T98913 DRUGINFO D01QXW CSL-324 Investigative T98913 DRUGINFO D02ILI ZP-G-CSF Investigative T98913 DRUGINFO D06CWM AZD-7507 Investigative T98913 DRUGINFO D07CNF G-CSF Investigative T98913 DRUGINFO D0LD8U TG-3003 Investigative T98913 DRUGINFO D0V4EX AC-710 Investigative T11843 TARGETID T11843 T11843 FORMERID TTDS00398 T11843 UNIPROID VKOR1_HUMAN T11843 TARGNAME Vitamin K epoxide reductase complex 1 (VKORC1) T11843 GENENAME VKORC1 T11843 TARGTYPE Successful T11843 SYNONYMS Vitamin K1 2,3-epoxide reductase subunit 1; VKORC1; VKOR; UNQ308/PRO351; MSTP576; MSTP134 T11843 FUNCTION Involved invitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. T11843 BIOCLASS Short-chain dehydrogenases reductase T11843 ECNUMBER EC 1.17.4.4 T11843 SEQUENCE MGSTWGSPGWVRLALCLTGLVLSLYALHVKAARARDRDYRALCDVGTAISCSRVFSSRWGRGFGLVEHVLGQDSILNQSNSIFGCIFYTLQLLLGCLRTRWASVLMLLSSLVSLAGSVYLAWILFFVLYDFCIVCITTYAINVSLMWLSFRKVQEPQGKAKRH T11843 DRUGINFO D02TJS Dicumarol Approved T11843 DRUGINFO D05HFY Acenocoumarol Approved T11843 DRUGINFO D08FTG Phenindione Approved T11843 DRUGINFO D0E3OF Warfarin Approved T11843 DRUGINFO D0QV5T Phenprocoumon Approved T11843 DRUGINFO D07VIB Tecarfarin Phase 3 T56556 TARGETID T56556 T56556 FORMERID TTDS00528 T56556 UNIPROID ABCG2_HUMAN T56556 TARGNAME ATP-binding cassette transporter G2 (ABCG2) T56556 GENENAME ABCG2 T56556 TARGTYPE Successful T56556 SYNONYMS Urate exporter; Placenta-specific ATP-binding cassette transporter; Mitoxantrone resistance-associated protein; MXR; CDw338; CD338; Breast cancer resistance protein; BCRP1; BCRP; ABCP T56556 FUNCTION Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin. High-capacity urate exporter functioning in both renal and extrarenal urate excretion. T56556 PDBSTRUC 6HZM; 6HIJ; 6HCO; 6HBU; 6FFC T56556 BIOCLASS ABC transporter T56556 SEQUENCE MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVEKEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCNSGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGTQFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIFSIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIINGDSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKKITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDSTGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLPMRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLLMTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGNNPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS T56556 DRUGINFO D02ZTJ Sulfasalazine Approved T02318 TARGETID T02318 T02318 FORMERID TTDC00196 T02318 UNIPROID TN13B_HUMAN T02318 TARGNAME B-cell-activating factor (TNFSF13B) T02318 GENENAME TNFSF13B T02318 TARGTYPE Successful T02318 SYNONYMS ZTNF4; UNQ401/PRO738; Tumor necrosis factor ligand superfamily member 13B; TNFSF20; TNF-and APOL-related leukocyte expressed ligand 1; TNF- and APOL-related leukocyte expressed ligand 1; TALL1; TALL-1; Dendritic cell-derived TNF-like molecule; CD257; BLyS; BAFF; B lymphocyte stimulator; B cell-activating factor T02318 FUNCTION TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response. Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. T02318 PDBSTRUC 6FXN; 5Y9J; 4ZCH; 4V46; 3V56 T02318 BIOCLASS Cytokine: tumor necrosis factor T02318 SEQUENCE MDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLSCCLTVVSFYQVAALQGDLASLRAELQGHHAEKLPAGAGAPKAGLEEAPAVTAGLKIFEPPAPGEGNSSQNSRNKRAVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL T02318 DRUGINFO D05IQX Belimumab Approved T02318 DRUGINFO D0I5WJ Blisibimod Phase 3 T02318 DRUGINFO D0U6UK Tabalumab Phase 3 T02318 DRUGINFO DV2CR7 AMG 570 Phase 2 T02318 DRUGINFO D0YA0N BR3-Fc Discontinued in Phase 2 T02318 DRUGINFO D0T8YV LymphoRad-131 Discontinued in Phase 1 T02318 DRUGINFO D04IEK Receptor-Fc fusion proteins Investigative T02318 DRUGINFO D08AMH 1,4-Diethylene Dioxide Investigative T48945 TARGETID T48945 T48945 FORMERID TTDR00459 T48945 UNIPROID TERT_HUMAN T48945 TARGNAME TERT messenger RNA (TERT mRNA) T48945 GENENAME TERT T48945 TARGTYPE Successful T48945 SYNONYMS Telomerase-associated protein 2 (mRNA); Telomerase catalytic subunit (mRNA); TRT (mRNA); TP2 (mRNA); TCS1 (mRNA); HEST2 (mRNA); EST2 (mRNA) T48945 FUNCTION Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis. Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. T48945 PDBSTRUC 5UGW; 5MER; 5MEQ; 5MEP; 5MEO T48945 BIOCLASS mRNA target T48945 ECNUMBER EC 2.7.7.49 T48945 SEQUENCE MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD T48945 DRUGINFO D07VLY Doxorubicin Approved T48945 DRUGINFO D05LEO Fluorouracil Approved T48945 DRUGINFO D00EWP 2,7-Bis(acetamido)anthraquinone Investigative T48945 DRUGINFO D00FCF 2,7-Bis(cyclohexanecarbonamido)anthraquinone Investigative T48945 DRUGINFO D00SLR 2,7-Bis[2-(isopropylamino)acetamido]anthraquinone Investigative T48945 DRUGINFO D01AAD NSC-745884 Investigative T48945 DRUGINFO D01BAK 2,7-Bis[3-(piperidino)propionamido]anthraquinone Investigative T48945 DRUGINFO D01MWX 2,7-Bis(cyclopropanecarbonamido)anthraquinone Investigative T48945 DRUGINFO D01TRI 2,7-Bis(phenylacetamido)anthraquinone Investigative T48945 DRUGINFO D02CSC NSC-745887 Investigative T48945 DRUGINFO D02ZIO 2,7-Bis[2-(butylamino)acetamido]anthraquinone Investigative T48945 DRUGINFO D03SFB 2-Methyl-1(3)H-anthrasimidazole-6,11-dione Investigative T48945 DRUGINFO D04KDW 2,7-Bis[3-(pyrrolidino)propionamido]anthraquinone Investigative T48945 DRUGINFO D04LTV 2,3-Dimethylnaphtho[2,3-f]quinoxaline-7,12-dione Investigative T48945 DRUGINFO D04SKW 2,7-Bis[3-(ethylamino)propionamido]anthraquinone Investigative T48945 DRUGINFO D04STF NSC-745798 Investigative T48945 DRUGINFO D05IBW 2,7-Bis(3-chloropropionamido)anthraquinone Investigative T48945 DRUGINFO D05RCG 2,7-Bis[2-(piperazino)acetamido]anthraquinone Investigative T48945 DRUGINFO D06GHM 2,7-Bis[3-(butylamino)propionamido]anthraquinone Investigative T48945 DRUGINFO D06TSI 2,7-Bis[3-(propylamino)propionamido]anthraquinone Investigative T48945 DRUGINFO D07DAX 2,7-Dinitroantraquinone Investigative T48945 DRUGINFO D07SQW LIVIDOMYCIN A Investigative T48945 DRUGINFO D07ZRU 2,7-Bis(chloroacetamido)anthraquinone Investigative T48945 DRUGINFO D08ZRW Cantide + Cisplatin Investigative T48945 DRUGINFO D09IJN NSC-745886 Investigative T48945 DRUGINFO D09PHV AURASPERONE A Investigative T48945 DRUGINFO D09VFQ NSC-745794 Investigative T48945 DRUGINFO D0B2YF 2,7-Bis[2-(piperidino)acetamido]anthraquinone Investigative T48945 DRUGINFO D0C0TI 2,7-Bis[3-(piperazino)propionamido]anthraquinone Investigative T48945 DRUGINFO D0C9HB 2,7-Bis[2-(isobutylamino)acetamido]anthraquinone Investigative T48945 DRUGINFO D0D0OX 2,7-Bis(propionamido)anthraquinone Investigative T48945 DRUGINFO D0E8ZH HOE-33258 Investigative T48945 DRUGINFO D0EB4X 2-Butyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione Investigative T48945 DRUGINFO D0F5MA 2,7-Bis(4-chlorobutyramido)anthraquinone Investigative T48945 DRUGINFO D0G6CD 2,7-Bis[2-(diethylamino)acetamido]anthraquinone Investigative T48945 DRUGINFO D0G7NE 2,7-diaminoanthraquinone Investigative T48945 DRUGINFO D0I0CU NSC-745888 Investigative T48945 DRUGINFO D0I6UM NSC-745885 Investigative T48945 DRUGINFO D0IT1P 2,7-Bis[2-(pyrrolidino)acetamido]anthraquinone Investigative T48945 DRUGINFO D0JR3Y 2-Heptyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione Investigative T48945 DRUGINFO D0KQ6U 2,7-Bis(phenylpropionamido)anthraquinone Investigative T48945 DRUGINFO D0M6GY NSC-745799 Investigative T48945 DRUGINFO D0M7VY NSC-745796 Investigative T48945 DRUGINFO D0P7KL NSC-745795 Investigative T48945 DRUGINFO D0Q8SP NSC-745797 Investigative T48945 DRUGINFO D0S6JQ 2,7-Bis(benzoamido)anthraquinone Investigative T48945 DRUGINFO D0T1ZM NSC-745883 Investigative T48945 DRUGINFO D0T2JN 2,7-Bis(cyclopentanecarbonamido)anthraquinone Investigative T48945 DRUGINFO D0VR4A 2,7-Bis[2-(dimethylamino)acetamido]anthraquinone Investigative T48945 DRUGINFO D0WJ5T 2,7-Bis(butyramido)anthraquinone Investigative T48945 DRUGINFO D0X5LN 7,8,3',4'-tetrahydroxyflavone Investigative T48945 DRUGINFO D0Y2RR 1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one Investigative T48945 DRUGINFO D0Y5IW 2,7-Bis[2-(ethylamino)acetamido]anthraquinone Investigative T48945 DRUGINFO D0Z5AO 2,7-Bis[2-(propylamino)acetamido]anthraquinone Investigative T57011 TARGETID T57011 T57011 FORMERID TTDC00192 T57011 UNIPROID ICAM1_HUMAN T57011 TARGNAME ICAM1 messenger RNA (ICAM1 mRNA) T57011 GENENAME ICAM1 T57011 TARGTYPE Successful T57011 SYNONYMS Major group rhinovirus receptor (mRNA); Intercellular adhesion molecule 1 (mRNA); ICAM-1 (mRNA); CD54 (mRNA) T57011 FUNCTION During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation. ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). T57011 PDBSTRUC 6EIT; 5MZA; 3TCX; 2OZ4; 1Z7Z T57011 BIOCLASS mRNA target T57011 SEQUENCE MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPGNWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQGEVTRKVTVNVLSPRYEIVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP T57011 DRUGINFO D00OTT ISIS 1570 Approved T57011 DRUGINFO D0P9BT Alicaforsen Phase 3 T57011 DRUGINFO D0M0UV INXC-ICAM1 Terminated T57011 DRUGINFO D00FAL ISIS 11159 Investigative T57011 DRUGINFO D02TKV ISIS 3224 Investigative T57011 DRUGINFO D02ZMH ISIS 1931 Investigative T57011 DRUGINFO D03YAG PIPERROLEIN B Investigative T57011 DRUGINFO D06SDT ISIS 2974 Investigative T57011 DRUGINFO D0H0FG Dehydropipernonaline Investigative T57011 DRUGINFO D0J1FW ISIS 3067 Investigative T57011 DRUGINFO D0K7HI ISIS 11665 Investigative T57011 DRUGINFO D0S2UZ PIPERNONALINE Investigative T57011 DRUGINFO D0V8KH ISIS 11158 Investigative T57011 DRUGINFO D0ZH9W Pellitorin Investigative T57011 DRUGINFO D07XCA A-286982 Investigative T92494 TARGETID T92494 T92494 UNIPROID EF2K_HUMAN T92494 TARGNAME Eukaryotic elongation factor 2 kinase (eEF-2K) T92494 GENENAME EEF2K T92494 TARGTYPE Successful T92494 SYNONYMS eEF-2K; eEF-2 kinase; Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase T92494 FUNCTION Threonine kinase that regulates protein synthesis by controlling the rate of peptide chain elongation. Upon activation by a variety of upstream kinases including AMPK or TRPM7, phosphorylates the elongation factor EEF2 at a single site, renders it unable to bind ribosomes and thus inactive. In turn, the rate of protein synthesis is reduced. T92494 PDBSTRUC 5KS5; 5J8H T92494 BIOCLASS Kinase T92494 ECNUMBER EC 2.7.11.20 T92494 SEQUENCE MADEDLIFRLEGVDGGQSPRAGHDGDSDGDSDDEEGYFICPITDDPSSNQNVNSKVNKYYSNLTKSERYSSSGSPANSFHFKEAWKHAIQKAKHMPDPWAEFHLEDIATERATRHRYNAVTGEWLDDEVLIKMASQPFGRGAMRECFRTKKLSNFLHAQQWKGASNYVAKRYIEPVDRDVYFEDVRLQMEAKLWGEEYNRHKPPKQVDIMQMCIIELKDRPGKPLFHLEHYIEGKYIKYNSNSGFVRDDNIRLTPQAFSHFTFERSGHQLIVVDIQGVGDLYTDPQIHTETGTDFGDGNLGVRGMALFFYSHACNRICESMGLAPFDLSPRERDAVNQNTKLLQSAKTILRGTEEKCGSPQVRTLSGSRPPLLRPLSENSGDENMSDVTFDSLPSSPSSATPHSQKLDHLHWPVFSDLDNMASRDHDHLDNHRESENSGDSGYPSEKRGELDDPEPREHGHSYSNRKYESDEDSLGSSGRVCVEKWNLLNSSRLHLPRASAVALEVQRLNALDLEKKIGKSILGKVHLAMVRYHEGGRFCEKGEEWDQESAVFHLEHAANLGELEAIVGLGLMYSQLPHHILADVSLKETEENKTKGFDYLLKAAEAGDRQSMILVARAFDSGQNLSPDRCQDWLEALHWYNTALEMTDCDEGGEYDGMQDEPRYMMLAREAEMLFTGGYGLEKDPQRSGDLYTQAAEAAMEAMKGRLANQYYQKAEEAWAQMEE T92494 DRUGINFO D08CDI Lapatinib Approved T15023 TARGETID T15023 T15023 FORMERID TTDC00183 T15023 UNIPROID NRP1_HUMAN T15023 TARGNAME Neuropilin-1 (NRP1) T15023 GENENAME NRP1 T15023 TARGTYPE Successful T15023 SYNONYMS Vascular endothelial cell growth factor 165 receptor; VEGF165R; Platelet-derived endothelial cell growth factor receptor; NRP; Membrane-bound; CD304 T15023 FUNCTION It mediates the chemorepulsant activity of semaphorins. It binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF165 isoform of VEGFA and VEGFB. Coexpression with KDR results in increased VEGF165 binding to KDR as well as increased chemotaxis. Regulate VEGF-induced angiogenesis. Binding to VEGFA initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. The membrane-bound isoform 1 is a receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. T15023 PDBSTRUC 6FMF; 6FMC; 5L73; 5JHK; 5JGQ T15023 BIOCLASS Neuropilin and tolloid-like T15023 SEQUENCE MERGLPLLCAVLALVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHPSEKCEWLIQAPDPYQRIMINFNPHFDLEDRDCKYDYVEVFDGENENGHFRGKFCGKIAPPPVVSSGPFLFIKFVSDYETHGAGFSIRYEIFKRGPECSQNYTTPSGVIKSPGFPEKYPNSLECTYIVFVPKMSEIILEFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTDSAIAKEGFSANYSVLQSSVSEDFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPAPHSYINEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRKFKIGYSNNGSDWKMIMDDSKRKAKSFEGNNNYDTPELRTFPALSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLVDECDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSEFPTYGFNCEFGWGSHKTFCHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADENQKGKVARLVSPVVYSQNSAHCMTFWYHMSGSHVGTLRVKLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVIFEGEIGKGNLGGIAVDDISINNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEGDKNISRKPGNVLKTLDPILITIIAMSALGVLLGAVCGVVLYCACWHNGMSERNLSALENYNFELVDGVKLKKDKLNTQSTYSEA T15023 DRUGINFO D0UF9W Pegaptanib Approved T15023 DRUGINFO D0YH8F RG7347 Phase 1 T15023 DRUGINFO D4JV0H ASP1948 Phase 1 T15023 DRUGINFO D0GD5G H-KPPR-OH Investigative T64795 TARGETID T64795 T64795 FORMERID TTDS00161 T64795 UNIPROID CAC1G_HUMAN T64795 TARGNAME Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) T64795 GENENAME CACNA1G T64795 TARGTYPE Successful T64795 SYNONYMS Voltage-gated calcium channel alpha subunit Cav3.1; Voltage-dependent T-type calcium channel; NBR13; Cav3.1c; CACNA1G T64795 FUNCTION Voltage-sensitive calcium channels (vscc) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release and gene expression. T64795 BIOCLASS Voltage-gated ion channel T64795 SEQUENCE MDEEEDGAGAEESGQPRSFMRLNDLSGAGGRPGPGSAEKDPGSADSEAEGLPYPALAPVVFFYLSQDSRPRSWCLRTVCNPWFERISMLVILLNCVTLGMFRPCEDIACDSQRCRILQAFDDFIFAFFAVEMVVKMVALGIFGKKCYLGDTWNRLDFFIVIAGMLEYSLDLQNVSFSAVRTVRVLRPLRAINRVPSMRILVTLLLDTLPMLGNVLLLCFFVFFIFGIVGVQLWAGLLRNRCFLPENFSLPLSVDLERYYQTENEDESPFICSQPRENGMRSCRSVPTLRGDGGGGPPCGLDYEAYNSSSNTTCVNWNQYYTNCSAGEHNPFKGAINFDNIGYAWIAIFQVITLEGWVDIMYFVMDAHSFYNFIYFILLIIVGSFFMINLCLVVIATQFSETKQRESQLMREQRVRFLSNASTLASFSEPGSCYEELLKYLVYILRKAARRLAQVSRAAGVRVGLLSSPAPLGGQETQPSSSCSRSHRRLSVHHLVHHHHHHHHHYHLGNGTLRAPRASPEIQDRDANGSRRLMLPPPSTPALSGAPPGGAESVHSFYHADCHLEPVRCQAPPPRSPSEASGRTVGSGKVYPTVHTSPPPETLKEKALVEVAASSGPPTLTSLNIPPGPYSSMHKLLETQSTGACQSSCKISSPCLKADSGACGPDSCPYCARAGAGEVELADREMPDSDSEAVYEFTQDAQHSDLRDPHSRRQRSLGPDAEPSSVLAFWRLICDTFRKIVDSKYFGRGIMIAILVNTLSMGIEYHEQPEELTNALEISNIVFTSLFALEMLLKLLVYGPFGYIKNPYNIFDGVIVVISVWEIVGQQGGGLSVLRTFRLMRVLKLVRFLPALQRQLVVLMKTMDNVATFCMLLMLFIFIFSILGMHLFGCKFASERDGDTLPDRKNFDSLLWAIVTVFQILTQEDWNKVLYNGMASTSSWAALYFIALMTFGNYVLFNLLVAILVEGFQAEEISKREDASGQLSCIQLPVDSQGGDANKSESEPDFFSPSLDGDGDRKKCLALVSLGEHPELRKSLLPPLIIHTAATPMSLPKSTSTGLGEALGPASRRTSSSGSAEPGAAHEMKSPPSARSSPHSPWSAASSWTSRRSSRNSLGRAPSLKRRSPSGERRSLLSGEGQESQDEEESSEEERASPAGSDHRHRGSLEREAKSSFDLPDTLQVPGLHRTASGRGSASEHQDCNGKSASGRLARALRPDDPPLDGDDADDEGNLSKGERVRAWIRARLPACCLERDSWSAYIFPPQSRFRLLCHRIITHKMFDHVVLVIIFLNCITIAMERPKIDPHSAERIFLTLSNYIFTAVFLAEMTVKVVALGWCFGEQAYLRSSWNVLDGLLVLISVIDILVSMVSDSGTKILGMLRVLRLLRTLRPLRVISRAQGLKLVVETLMSSLKPIGNIVVICCAFFIIFGILGVQLFKGKFFVCQGEDTRNITNKSDCAEASYRWVRHKYNFDNLGQALMSLFVLASKDGWVDIMYDGLDAVGVDQQPIMNHNPWMLLYFISFLLIVAFFVLNMFVGVVVENFHKCRQHQEEEEARRREEKRLRRLEKKRRNLMLDDVIASGSSASAASEAQCKPYYSDYSRFRLLVHHLCTSHYLDLFITGVIGLNVVTMAMEHYQQPQILDEALKICNYIFTVIFVLESVFKLVAFGFRRFFQDRWNQLDLAIVLLSIMGITLEEIEVNASLPINPTIIRIMRVLRIARVLKLLKMAVGMRALLDTVMQALPQVGNLGLLFMLLFFIFAALGVELFGDLECDETHPCEGLGRHATFRNFGMAFLTLFRVSTGDNWNGIMKDTLRDCDQESTCYNTVISPIYFVSFVLTAQFVLVNVVIAVLMKHLEESNKEAKEEAELEAELELEMKTLSPQPHSPLGSPFLWPGVEGPDSPDSPKPGALHPAAHARSASHFSLEHPTDRQLFDTISLLIQGSLEWELKLMDELAGPGGQPSAFPSAPSLGGSDPQIPLAEMEALSLTSEIVSEPSCSLALTDDSLPDDMHTLLLSALESNMQPHPTELPGPDLLTVRKSGVSRTHSLPNDSYMCRHGSTAEGPLGHRGWGLPKAQSGSVLSVHSQPADTSYILQLPKDAPHLLQPHSAPTWGTIPKLPPPGRSPLAQRPLRRQAAIRTDSLDVQGLGSREDLLAEVSGPSPPLARAYSFWGQSSTQAQQHSRSHSKISKHMTPPAPCPGPEPNWGKGPPETRSSLELDTELSWISGDLLPPGGQEEPPSPRDLKKCYSVEAQSCQRRPTSWLDEQRRHSIAVSCLDSGSQPHLGTDPSNLGGQPLGGPGSRPKKKLSPPSITIDPPESQGPRTPPSPGICLRRRAPSSDSKDPLASGPPDSMAASPSPKKDVLSLSGLSSDPADLDP T64795 DRUGINFO D08EOD Methsuximide Approved T64795 DRUGINFO D09JBP Paramethadione Approved T64795 DRUGINFO D0CQ0Z Penfluridol Approved T64795 DRUGINFO D0Q4XQ Ethosuximide Approved T64795 DRUGINFO D0R0FE Verapamil Approved T64795 DRUGINFO D0U4VT Trimethadione Approved T64795 DRUGINFO D07CMN PD-200390 Phase 2 T64795 DRUGINFO D0L3JI NGD 94-1 Phase 1 T64795 DRUGINFO D02DDI KYS-05064 Investigative T64795 DRUGINFO D03HCT KKHT-10608 Investigative T64795 DRUGINFO D04CUL KKHT-10613 Investigative T64795 DRUGINFO D05MYH KYS-05065 Investigative T64795 DRUGINFO D06EPZ KKHT-20718 Investigative T64795 DRUGINFO D06FWY KYS-05070 Investigative T64795 DRUGINFO D06ORM KYS-05055 Investigative T64795 DRUGINFO D08MKF Nickel chloride Investigative T64795 DRUGINFO D09QCD KYS-05056 Investigative T64795 DRUGINFO D0A4DR Alpha-methyl-alpha-phenylsuccinimide (MPS) Investigative T64795 DRUGINFO D0JO8Q KYS-05071 Investigative T64795 DRUGINFO D0K9NK KKHT-20818 Investigative T64795 DRUGINFO D0QM9Y KKHT-20918 Investigative T64795 DRUGINFO D0R5FO KYS-05057 Investigative T64795 DRUGINFO D0V3NI KYS-05074 Investigative T64795 DRUGINFO D0V9CG KKHT-10318 Investigative T64795 DRUGINFO D0X3HB KKHT-10609 Investigative T64795 DRUGINFO D0Y4WI KKHT-11018 Investigative T64795 DRUGINFO D0Z4JL KKHT-10618 Investigative T64795 DRUGINFO D02DUO KYS-05001 Investigative T64795 DRUGINFO D02SSG KYS-05077 Investigative T64795 DRUGINFO D06UAX KYS-05080 Investigative T64795 DRUGINFO D07UBR Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide Investigative T64795 DRUGINFO D0K5RX KYS-05050 Investigative T64795 DRUGINFO D0M2EZ KYS-05042 Investigative T64795 DRUGINFO D0N5RQ KYS-05041 Investigative T64795 DRUGINFO D0R6PX (-)-(R)-efonidipine Investigative T64795 DRUGINFO D0S5QB KYS-05040 Investigative T64795 DRUGINFO D0X7VM KYS-05090 Investigative T64795 DRUGINFO D09PWJ ML218 Investigative T69485 TARGETID T69485 T69485 FORMERID TTDR01056 T69485 UNIPROID OX2R_HUMAN T69485 TARGNAME Orexin receptor type 2 (HCRTR2) T69485 GENENAME HCRTR2 T69485 TARGTYPE Successful T69485 SYNONYMS Ox2r; Ox2-R; Ox-2-R; Orexin-2 receptor; Hypocretin receptor type 2; HFGANP T69485 FUNCTION Triggers an increase in cytoplasmic Ca(2+) levels in response to orexin-A binding. Nonselective, high-affinity receptor for both orexin-A and orexin-B neuropeptides. T69485 PDBSTRUC 5WS3; 5WQC; 4S0V T69485 BIOCLASS GPCR rhodopsin T69485 SEQUENCE MSGTKLEDSPPCRNWSSASELNETQEPFLNPTDYDDEEFLRYLWREYLHPKEYEWVLIAGYIIVFVVALIGNVLVCVAVWKNHHMRTVTNYFIVNLSLADVLVTITCLPATLVVDITETWFFGQSLCKVIPYLQTVSVSVSVLTLSCIALDRWYAICHPLMFKSTAKRARNSIVIIWIVSCIIMIPQAIVMECSTVFPGLANKTTLFTVCDERWGGEIYPKMYHICFFLVTYMAPLCLMVLAYLQIFRKLWCRQIPGTSSVVQRKWKPLQPVSQPRGPGQPTKSRMSAVAAEIKQIRARRKTARMLMIVLLVFAICYLPISILNVLKRVFGMFAHTEDRETVYAWFTFSHWLVYANSAANPIIYNFLSGKFREEFKAAFSCCCLGVHHRQEDRLTRGRTSTESRKSLTTQISNFDNISKLSEQVVLTSISTLPAANGAGPLQNW T69485 DRUGINFO D00OVU Suvorexant Approved T69485 DRUGINFO D08SCL MK-3697 Phase 2 T69485 DRUGINFO D0FK6O MIN-202 Phase 2 T69485 DRUGINFO DZ35AP TAK-861 Phase 2 T69485 DRUGINFO DZ2PC5 TAK-925 Phase 1 T69485 DRUGINFO D00VEM 1,2-diamino cyclopentane-based derivative 25 Patented T69485 DRUGINFO D01NWU 1,2-diamino cyclopentane-based derivative 5 Patented T69485 DRUGINFO D02CCF 1,2-diamino cyclopentane-based derivative 20 Patented T69485 DRUGINFO D02LWJ 1,2-diamino cyclopentane-based derivative 15 Patented T69485 DRUGINFO D03JAZ 1,2-diamino cyclopentane-based derivative 13 Patented T69485 DRUGINFO D04DCO 1,2-diamino cyclopentane-based derivative 9 Patented T69485 DRUGINFO D04JLF 1,2-diamino cyclopentane-based derivative 8 Patented T69485 DRUGINFO D05PMY 1,2-diamino cyclopentane-based derivative 26 Patented T69485 DRUGINFO D05QWJ 1,2-diamino cyclopentane-based derivative 2 Patented T69485 DRUGINFO D05WDQ 1,2-diamino cyclopentane-based derivative 12 Patented T69485 DRUGINFO D06NRQ 1,2-diamino cyclopentane-based derivative 18 Patented T69485 DRUGINFO D06OTA 1,2-diamino cyclopentane-based derivative 29 Patented T69485 DRUGINFO D08KYM 1,2-diamino cyclopentane-based derivative 22 Patented T69485 DRUGINFO D08ZRN 1,2-diamino cyclopentane-based derivative 27 Patented T69485 DRUGINFO D09XLY 1,2-diamino cyclopentane-based derivative 31 Patented T69485 DRUGINFO D0AL3I 1,2-diamino cyclopentane-based derivative 16 Patented T69485 DRUGINFO D0C6GE 1,2-diamino cyclopentane-based derivative 21 Patented T69485 DRUGINFO D0CG0D 1,2-diamino cyclopentane-based derivative 33 Patented T69485 DRUGINFO D0DO4J 1,2-diamino cyclopentane-based derivative 11 Patented T69485 DRUGINFO D0EG3N 1,2-diamino cyclopentane-based derivative 34 Patented T69485 DRUGINFO D0FI1W 1,2-diamino cyclopentane-based derivative 10 Patented T69485 DRUGINFO D0J4YW 1,2-diamino cyclopentane-based derivative 24 Patented T69485 DRUGINFO D0L0YA 1,2-diamino cyclopentane-based derivative 19 Patented T69485 DRUGINFO D0NX4W 1,2-diamino cyclopentane-based derivative 14 Patented T69485 DRUGINFO D0P8AX 1,2-diamino cyclopentane-based derivative 23 Patented T69485 DRUGINFO D0S4UG 1,2-diamino cyclopentane-based derivative 32 Patented T69485 DRUGINFO D0U7VC 1,2-diamino cyclopentane-based derivative 7 Patented T69485 DRUGINFO D0U9WX 1,2-diamino cyclopentane-based derivative 30 Patented T69485 DRUGINFO D0VE3H 1,2-diamino cyclopentane-based derivative 17 Patented T69485 DRUGINFO D0VR1K 1,2-diamino cyclopentane-based derivative 3 Patented T69485 DRUGINFO D0WX1B 1,2-diamino cyclopentane-based derivative 1 Patented T69485 DRUGINFO D0YI3Z 1,2-diamino cyclopentane-based derivative 4 Patented T69485 DRUGINFO D0ZC1O 1,2-diamino cyclopentane-based derivative 6 Patented T69485 DRUGINFO D01SUL JNJ-10397049 Investigative T69485 DRUGINFO D02MDC EMPA Investigative T69485 DRUGINFO D0U0TS TCS-OX2-29 Investigative T69485 DRUGINFO D08MXD [3H]SB-674042 Investigative T69485 DRUGINFO D0J3PJ SB-408124 Investigative T69485 DRUGINFO D0MY0E orexin-B Investigative T69485 DRUGINFO D0R4BT PMID15261275C1 Investigative T69485 DRUGINFO D0UZ4J SB-334867 Investigative T84040 TARGETID T84040 T84040 FORMERID TTDS00465 T84040 UNIPROID TRPA1_HUMAN T84040 TARGNAME Transformation-sensitive protein p120 (TRPA1) T84040 GENENAME TRPA1 T84040 TARGTYPE Successful T84040 SYNONYMS TRPA1; Ankyrin-like with transmembrane domains protein 1; ANKTM1 T84040 FUNCTION Receptor-activated non-selective cation channel involved in detection of pain and possibly also in cold perception and inner ear function. Has a central role in the pain response to endogenous inflammatory mediators and to a diverse array of volatile irritants, such as mustard oil, garlic and acrolein, an irritant from tears gas and vehicule exhaust fumes. Acts also as a ionotropic cannabinoid receptor by being activated by delta(9)- tetrahydrocannabinol (THC), the psychoactive component of marijuana. Not involved in menthol sensation. May be a component for the mechanosensitive transduction channel of hair cells in inner ear, thereby participating in the perception of sounds. Probably operated by a phosphatidylinositol second messenger system. T84040 PDBSTRUC 3J9P T84040 BIOCLASS Transient receptor potential catioin channel T84040 SEQUENCE MKRSLRKMWRPGEKKEPQGVVYEDVPDDTEDFKESLKVVFEGSAYGLQNFNKQKKLKRCDDMDTFFLHYAAAEGQIELMEKITRDSSLEVLHEMDDYGNTPLHCAVEKNQIESVKFLLSRGANPNLRNFNMMAPLHIAVQGMNNEVMKVLLEHRTIDVNLEGENGNTAVIIACTTNNSEALQILLKKGAKPCKSNKWGCFPIHQAAFSGSKECMEIILRFGEEHGYSRQLHINFMNNGKATPLHLAVQNGDLEMIKMCLDNGAQIDPVEKGRCTAIHFAATQGATEIVKLMISSYSGSVDIVNTTDGCHETMLHRASLFDHHELADYLISVGADINKIDSEGRSPLILATASASWNIVNLLLSKGAQVDIKDNFGRNFLHLTVQQPYGLKNLRPEFMQMQQIKELVMDEDNDGCTPLHYACRQGGPGSVNNLLGFNVSIHSKSKDKKSPLHFAASYGRINTCQRLLQDISDTRLLNEGDLHGMTPLHLAAKNGHDKVVQLLLKKGALFLSDHNGWTALHHASMGGYTQTMKVILDTNLKCTDRLDEDGNTALHFAAREGHAKAVALLLSHNADIVLNKQQASFLHLALHNKRKEVVLTIIRSKRWDECLKIFSHNSPGNKCPITEMIEYLPECMKVLLDFCMLHSTEDKSCRDYYIEYNFKYLQCPLEFTKKTPTQDVIYEPLTALNAMVQNNRIELLNHPVCKEYLLMKWLAYGFRAHMMNLGSYCLGLIPMTILVVNIKPGMAFNSTGIINETSDHSEILDTTNSYLIKTCMILVFLSSIFGYCKEAGQIFQQKRNYFMDISNVLEWIIYTTGIIFVLPLFVEIPAHLQWQCGAIAVYFYWMNFLLYLQRFENCGIFIVMLEVILKTLLRSTVVFIFLLLAFGLSFYILLNLQDPFSSPLLSIIQTFSMMLGDINYRESFLEPYLRNELAHPVLSFAQLVSFTIFVPIVLMNLLIGLAVGDIAEVQKHASLKRIAMQVELHTSLEKKLPLWFLRKVDQKSTIVYPNKPRSGGMLFHIFCFLFCTGEIRQEIPNADKSLEMEILKQKYRLKDLTFLLEKQHELIKLIIQKMEIISETEDDDSHCSFQDRFKKEQMEQRNSRWNTVLRAVKAKTHHLEP T84040 DRUGINFO D04CSZ Menthol Approved T84040 DRUGINFO D40GBC LY3526318 Phase 2 T84040 DRUGINFO D0I3QJ HX-100 Phase 1 T84040 DRUGINFO D01RUO morphanthridine Investigative T84040 DRUGINFO D02XOP 2-methyl-1-(thiophen-2-yl)pent-1-en-3-one oxime Investigative T84040 DRUGINFO D03LVI AMG-2504 Investigative T84040 DRUGINFO D04NOT bromoacetone Investigative T84040 DRUGINFO D04PKE 2-methyl-1-(pyridin-4-yl)pent-1-en-3-one oxime Investigative T84040 DRUGINFO D05CRM AMG-9090 Investigative T84040 DRUGINFO D05DTN 4-oxo-nonenal Investigative T84040 DRUGINFO D06IOP 2-methyl-1-(thiophen-3-yl)pent-1-en-3-one oxime Investigative T84040 DRUGINFO D06OLJ AMG-7160 Investigative T84040 DRUGINFO D07FLG dibutyl phthalate Investigative T84040 DRUGINFO D07HHD resolvin D2 Investigative T84040 DRUGINFO D07LNY prostaglandin A2 Investigative T84040 DRUGINFO D07PNM methyl isocyanate Investigative T84040 DRUGINFO D08MUZ 2-pentenal Investigative T84040 DRUGINFO D09SVQ dibenzoxazepine Investigative T84040 DRUGINFO D0C7WN acetaldehyde Investigative T84040 DRUGINFO D0G4GB omega-chloroacetophenone Investigative T84040 DRUGINFO D0I0AA acrolein Investigative T84040 DRUGINFO D0I0BV 1'-acetoxychavicol acetate Investigative T84040 DRUGINFO D0J0BV TCS 5861528 Investigative T84040 DRUGINFO D0J2UJ chloropicrin Investigative T84040 DRUGINFO D0K4ZR oleocanthal Investigative T84040 DRUGINFO D0K6RG benzyl bromide Investigative T84040 DRUGINFO D0MZ7C isovelleral Investigative T84040 DRUGINFO D0N3CZ super cinnamaldehyde Investigative T84040 DRUGINFO D0O3FC AMG-5445 Investigative T84040 DRUGINFO D0S2GF chlorobenzylidene malononitrile Investigative T84040 DRUGINFO D0T1YY 3-Methyl-4-phenylbut-3-en-2-one oxime Investigative T84040 DRUGINFO D0T3NP methyl p-hydroxybenzoate Investigative T84040 DRUGINFO D0U4VL artepillin C Investigative T84040 DRUGINFO D0U9UF A-967079 Investigative T84040 DRUGINFO D0UD7H 1,6-hexamethylene diisocyanate Investigative T84040 DRUGINFO D0V6OH MTSEA Investigative T84040 DRUGINFO D0V8DH PF-4840154 Investigative T84040 DRUGINFO D0Y1YR gingerol Investigative T84040 DRUGINFO D0YI4T 2-methyl-1-(pyridin-3-yl)pent-1-en-3-one oxime Investigative T84040 DRUGINFO D0Z0AA methyl salicylate Investigative T84040 DRUGINFO D01KEE Formaldehyde Investigative T84040 DRUGINFO D04ULU icilin Investigative T84040 DRUGINFO D09CSB crotylaldehyde Investigative T84040 DRUGINFO D0G4CI methylglyoxal Investigative T84040 DRUGINFO D0PJ3M cinnamaldehyde Investigative T84040 DRUGINFO D0P0KG [3H]resolvin D1 Investigative T84040 DRUGINFO D08DQL NPPB Investigative T69563 TARGETID T69563 T69563 FORMERID TTDI02094 T69563 UNIPROID IDHC_HUMAN T69563 TARGNAME Oxalosuccinate decarboxylase (IDH1) T69563 GENENAME IDH1 T69563 TARGTYPE Successful T69563 SYNONYMS PICD; NADP(+)-specific ICDH; Isocitrate dehydrogenase [NADP] cytoplasmic; IDP; IDH; Cytosolic NADP-isocitrate dehydrogenase T69563 FUNCTION Catalyses the NADPH-dependent reduction of alpha-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). T69563 PDBSTRUC 6BL2; 6BL1; 6BL0; 6BKZ; 6BKY T69563 BIOCLASS Short-chain dehydrogenases reductase T69563 ECNUMBER EC 1.1.1.42 T69563 SEQUENCE MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGRHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL T69563 DRUGINFO D07DCG Ivosidenib Approved T69563 DRUGINFO D07VYP Olutasidenib Approved T69563 DRUGINFO D0RZ9V IDH305 Phase 1 T69563 DRUGINFO D6AHO2 LY3410738 Phase 1 T16688 TARGETID T16688 T16688 FORMERID TTDS00466 T16688 UNIPROID DGAT1_HUMAN T16688 TARGNAME Diacylglycerol acyltransferase 1 (DGAT1) T16688 GENENAME DGAT1 T16688 TARGTYPE Successful T16688 SYNONYMS Retinol O-fatty-acyltransferase; Diglyceride acyltransferase; Diacylglycerol O-acyltransferase 1; DGAT; Acyl-CoA retinol O-fatty-acyltransferase; ARAT; AGRP1; ACAT-related gene product 1 T16688 FUNCTION Catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. In contrast to DGAT2 it is not essential for survival. May be involved in VLDL (very low density lipoprotein) assembly. In liver, plays a role in esterifying exogenous fatty acids to glycerol. Functions as the major acyl-CoA retinol acyltransferase (ARAT) in the skin, where it acts to maintain retinoid homeostasis and prevent retinoid toxicity leading to skin and hair disorders. T16688 BIOCLASS Acyltransferase T16688 ECNUMBER EC 2.3.1.20 T16688 SEQUENCE MGDRGSSRRRRTGSRPSSHGGGGPAAAEEEVRDAAAGPDVGAAGDAPAPAPNKDGDAGVGSGHWELRCHRLQDSLFSSDSGFSNYRGILNWCVVMLILSNARLFLENLIKYGILVDPIQVVSLFLKDPYSWPAPCLVIAANVFAVAAFQVEKRLAVGALTEQAGLLLHVANLATILCFPAAVVLLVESITPVGSLLALMAHTILFLKLFSYRDVNSWCRRARAKAASAGKKASSAAAPHTVSYPDNLTYRDLYYFLFAPTLCYELNFPRSPRIRKRFLLRRILEMLFFTQLQVGLIQQWMVPTIQNSMKPFKDMDYSRIIERLLKLAVPNHLIWLIFFYWLFHSCLNAVAELMQFGDREFYRDWWNSESVTYFWQNWNIPVHKWCIRHFYKPMLRRGSSKWMARTGVFLASAFFHEYLVSVPLRMFRLWAFTGMMAQIPLAWFVGRFFQGNYGNAAVWLSLIIGQPIAVLMYVHDYYVLNYEAPAAEA T16688 DRUGINFO D07MGA Hesperetin Approved T16688 DRUGINFO D0F1CE LCQ908 Phase 3 T16688 DRUGINFO D0EY0A AZD7687 Phase 1 T16688 DRUGINFO D0M4HL P-7435 Phase 1 T16688 DRUGINFO D01DHT Azole derivative 7 Patented T16688 DRUGINFO D02CTG Carbamide derivative 3 Patented T16688 DRUGINFO D02NRD T863 Patented T16688 DRUGINFO D04EFQ Benzamide derivative 19 Patented T16688 DRUGINFO D04QGW Lactam derivative 5 Patented T16688 DRUGINFO D05REP Pyridine-carboximide derivative 2 Patented T16688 DRUGINFO D08UCB PMID25470667-Compound-BAY744113 Patented T16688 DRUGINFO D0A8SI Lactam derivative 4 Patented T16688 DRUGINFO D0F6VD Lactam derivative 1 Patented T16688 DRUGINFO D0H2WY Pyrazine carboxamide derivative 1 Patented T16688 DRUGINFO D0H9RP Lactam derivative 3 Patented T16688 DRUGINFO D0MX3Y PMID25470667-Compound-AZD3988 Patented T16688 DRUGINFO D0N0WE amidepsines Patented T16688 DRUGINFO D0OT8R Pyridine-carboximide derivative 1 Patented T16688 DRUGINFO D0QT3C Azole derivative 6 Patented T16688 DRUGINFO D0U0MZ Lactam derivative 2 Patented T16688 DRUGINFO D0UY7A Pyridine-amide derivative 1 Patented T16688 DRUGINFO D0WR6N Pyrazolo[1,5-a]pyrimidine derivative 28 Patented T16688 DRUGINFO D0XT7O Pyrazolo[1,5-a]pyrimidine derivative 29 Patented T16688 DRUGINFO D0Z7VF PMID25470667-Compound-PF-04620110 Patented T16688 DRUGINFO D0L5DV PMID25470667-Compound-Figure4-1A Patented T16688 DRUGINFO D0U5NY JTT-553 Discontinued in Phase 1 T16688 DRUGINFO D0Z2QR DS-7250 Discontinued in Phase 1 T16688 DRUGINFO D0M0NT PF-04620110 Terminated T54644 TARGETID T54644 T54644 FORMERID TTDS00413 T54644 UNIPROID CAC1H_HUMAN T54644 TARGNAME Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) T54644 GENENAME CACNA1H T54644 TARGTYPE Successful T54644 SYNONYMS Voltage-gated calcium channel subunit alpha Cav3.2; Voltage-dependent T-type calcium channel subunit alpha-1H; Low-voltage-activated calcium channel alpha1 3.2 subunit T54644 FUNCTION Voltage-sensitive calcium channel that gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group. A particularity of this type of channel is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle (Probable). They may also be involved in the modulation of firing patterns of neurons. In the adrenal zona glomerulosa, participates in the signaling pathway leading to aldosterone production in response to either AGT/angiotensin II, or hyperkalemia. T54644 BIOCLASS Voltage-gated ion channel T54644 SEQUENCE MTEGARAADEVRVPLGAPPPGPAALVGASPESPGAPGREAERGSELGVSPSESPAAERGAELGADEEQRVPYPALAATVFFCLGQTTRPRSWCLRLVCNPWFEHVSMLVIMLNCVTLGMFRPCEDVECGSERCNILEAFDAFIFAFFAVEMVIKMVALGLFGQKCYLGDTWNRLDFFIVVAGMMEYSLDGHNVSLSAIRTVRVLRPLRAINRVPSMRILVTLLLDTLPMLGNVLLLCFFVFFIFGIVGVQLWAGLLRNRCFLDSAFVRNNNLTFLRPYYQTEEGEENPFICSSRRDNGMQKCSHIPGRRELRMPCTLGWEAYTQPQAEGVGAARNACINWNQYYNVCRSGDSNPHNGAINFDNIGYAWIAIFQVITLEGWVDIMYYVMDAHSFYNFIYFILLIIVGSFFMINLCLVVIATQFSETKQRESQLMREQRARHLSNDSTLASFSEPGSCYEELLKYVGHIFRKVKRRSLRLYARWQSRWRKKVDPSAVQGQGPGHRQRRAGRHTASVHHLVYHHHHHHHHHYHFSHGSPRRPGPEPGACDTRLVRAGAPPSPPSPGRGPPDAESVHSIYHADCHIEGPQERARVAHAAATAAASLRLATGLGTMNYPTILPSGVGSGKGSTSPGPKGKWAGGPPGTGGHGPLSLNSPDPYEKIPHVVGEHGLGQAPGHLSGLSVPCPLPSPPAGTLTCELKSCPYCTRALEDPEGELSGSESGDSDGRGVYEFTQDVRHGDRWDPTRPPRATDTPGPGPGSPQRRAQQRAAPGEPGWMGRLWVTFSGKLRRIVDSKYFSRGIMMAILVNTLSMGVEYHEQPEELTNALEISNIVFTSMFALEMLLKLLACGPLGYIRNPYNIFDGIIVVISVWEIVGQADGGLSVLRTFRLLRVLKLVRFLPALRRQLVVLVKTMDNVATFCTLLMLFIFIFSILGMHLFGCKFSLKTDTGDTVPDRKNFDSLLWAIVTVFQILTQEDWNVVLYNGMASTSSWAALYFVALMTFGNYVLFNLLVAILVEGFQAEGDANRSDTDEDKTSVHFEEDFHKLRELQTTELKMCSLAVTPNGHLEGRGSLSPPLIMCTAATPMPTPKSSPFLDAAPSLPDSRRGSSSSGDPPLGDQKPPASLRSSPCAPWGPSGAWSSRRSSWSSLGRAPSLKRRGQCGERESLLSGEGKGSTDDEAEDGRAAPGPRATPLRRAESLDPRPLRPAALPPTKCRDRDGQVVALPSDFFLRIDSHREDAAELDDDSEDSCCLRLHKVLEPYKPQWCRSREAWALYLFSPQNRFRVSCQKVITHKMFDHVVLVFIFLNCVTIALERPDIDPGSTERVFLSVSNYIFTAIFVAEMMVKVVALGLLSGEHAYLQSSWNLLDGLLVLVSLVDIVVAMASAGGAKILGVLRVLRLLRTLRPLRVISRAPGLKLVVETLISSLRPIGNIVLICCAFFIIFGILGVQLFKGKFYYCEGPDTRNISTKAQCRAAHYRWVRRKYNFDNLGQALMSLFVLSSKDGWVNIMYDGLDAVGVDQQPVQNHNPWMLLYFISFLLIVSFFVLNMFVGVVVENFHKCRQHQEAEEARRREEKRLRRLERRRRSTFPSPEAQRRPYYADYSPTRRSIHSLCTSHYLDLFITFIICVNVITMSMEHYNQPKSLDEALKYCNYVFTIVFVFEAALKLVAFGFRRFFKDRWNQLDLAIVLLSLMGITLEEIEMSAALPINPTIIRIMRVLRIARVLKLLKMATGMRALLDTVVQALPQVGNLGLLFMLLFFIYAALGVELFGRLECSEDNPCEGLSRHATFSNFGMAFLTLFRVSTGDNWNGIMKDTLRECSREDKHCLSYLPALSPVYFVTFVLVAQFVLVNVVVAVLMKHLEESNKEAREDAELDAEIELEMAQGPGSARRVDADRPPLPQESPGARDAPNLVARKVSVSRMLSLPNDSYMFRPVVPASAPHPRPLQEVEMETYGAGTPLGSVASVHSPPAESCASLQIPLAVSSPARSGEPLHALSPRGTARSPSLSRLLCRQEAVHTDSLEGKIDSPRDTLDPAEPGEKTPVRPVTQGGSLQSPPRSPRPASVRTRKHTFGQRCVSSRPAAPGGEEAEASDPADEEVSHITSSACPWQPTAEPHGPEASPVAGGERDLRRLYSVDAQGFLDKPGRADEQWRPSAELGSGEPGEAKAWGPEAEPALGARRKKKMSPPCISVEPPAEDEGSARPSAAEGGSTTLRRRTPSCEATPHRDSLEPTEGSGAGGDPAAKGERWGQASCRAEHLTVPSFAFEPLDLGVPSGDPFLDGSHSVTPESRASSSGAIVPLEPPESEPPMPVGDPPEKRRGLYLTVPQCPLEKPGSPSATPAPGGGADDPV T54644 DRUGINFO D02FLB Sodium bicarbonate Approved T54644 DRUGINFO D05CEU Flunarizine Approved T54644 DRUGINFO D04TNT ABT-639 Phase 2 T54644 DRUGINFO D0W8XT Mibefradil Phase 1 T54644 DRUGINFO D0X5OV TTA-A8 Preclinical T54644 DRUGINFO D0OW2O U-92032 Terminated T54644 DRUGINFO D05NSP GNF-PF-4599 Investigative T54644 DRUGINFO D06HWI GNF-PF-1967 Investigative T54644 DRUGINFO D08NRG HYP-10 Investigative T54644 DRUGINFO D0T6NE Z 944 Investigative T54644 DRUGINFO D0TW1Q DP-3005 Investigative T54644 DRUGINFO D0Y5WL TTL-1177 Investigative T54644 DRUGINFO D0YF6L KST-5468 Investigative T54644 DRUGINFO D02DUO KYS-05001 Investigative T54644 DRUGINFO D02SSG KYS-05077 Investigative T54644 DRUGINFO D06UAX KYS-05080 Investigative T54644 DRUGINFO D07UBR Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide Investigative T54644 DRUGINFO D0K5RX KYS-05050 Investigative T54644 DRUGINFO D0M2EZ KYS-05042 Investigative T54644 DRUGINFO D0N5RQ KYS-05041 Investigative T54644 DRUGINFO D0S5QB KYS-05040 Investigative T54644 DRUGINFO D09PWJ ML218 Investigative T31751 TARGETID T31751 T31751 FORMERID TTDS00236 T31751 UNIPROID DXR_PLAFX T31751 TARGNAME Plasmodium DOXP reductoisomerase (Malaria DXR) T31751 GENENAME Malaria DXR T31751 TARGTYPE Successful T31751 SYNONYMS IspC; DXR; DXP reductoisomerase; DOXP reductoisomerase; 2-C-Methyl-d-erythritol 4-phosphate synthase; 1-deoxyxylulose-5-phosphate reductoisomerase T31751 FUNCTION Catalyzes the NADP-dependent rearrangement and reduction of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methyl-D-erythritol 4-phosphate (MEP). T31751 PDBSTRUC 4KP7; 4GAE; 3WQS; 3WQR; 3WQQ T31751 BIOCLASS Short-chain dehydrogenases reductase T31751 ECNUMBER EC 1.1.1.267 T31751 SEQUENCE MKKYIYIYFFFITITINDLVINNTSKCVSIERRKNNAYINYGIGYNGPDNKITKSRRCKRIKLCKKDLIDIGAIKKPINVAIFGSTGSIGTNALNIIRECNKIENVFNVKALYVNKSVNELYEQAREFLPEYLCIHDKSVYEELKELVKNIKDYKPIILCGDEGMKEICSSNSIDKIVIGIDSFQGLYSTMYAIMNNKIVALANKESIVSAGFFLKKLLNIHKNAKIIPVDSEHSAIFQCLDNNKVLKTKCLQDNFSKINNINKIFLCSSGGPFQNLTMDELKNVTSENALKHPKWKMGKKITIDSATMMNKGLEVIETHFLFDVDYNDIEVIVHKECIIHSCVEFIDKSVISQMYYPDMQIPILYSLTWPDRIKTNLKPLDLAQVSTLTFHKPSLEHFPCIKLAYQAGIKGNFYPTVLNASNEIANNLFLNNKIKYFDISSIISQVLESFNSQKVSENSEDLMKQILQIHSWAKDKATDIYNKHNSS T31751 DRUGINFO D09UXE Fosmidomycin Approved T31751 DRUGINFO D05MNV Fosclin Phase 3 T76213 TARGETID T76213 T76213 FORMERID TTDI01963 T76213 UNIPROID PH4H_HUMAN T76213 TARGNAME Phenylalanine hydroxylase (PAH) T76213 GENENAME PAH T76213 TARGTYPE Successful T76213 SYNONYMS Phenylalanine4hydroxylase; Phenylalanine-4-hydroxylase; Phe4monooxygenase; Phe-4-monooxygenase T76213 FUNCTION Catalyzes the hydroxylation of L-phenylalanine to L-tyrosine. T76213 PDBSTRUC 6PAH; 6N1K; 5PAH; 5FII; 4PAH T76213 BIOCLASS Paired donor oxygen oxidoreductase T76213 ECNUMBER EC 1.14.16.1 T76213 SEQUENCE MSTAVLENPGLGRKLSDFGQETSYIEDNCNQNGAISLIFSLKEEVGALAKVLRLFEENDVNLTHIESRPSRLKKDEYEFFTHLDKRSLPALTNIIKILRHDIGATVHELSRDKKKDTVPWFPRTIQELDRFANQILSYGAELDADHPGFKDPVYRARRKQFADIAYNYRHGQPIPRVEYMEEEKKTWGTVFKTLKSLYKTHACYEYNHIFPLLEKYCGFHEDNIPQLEDVSQFLQTCTGFRLRPVAGLLSSRDFLGGLAFRVFHCTQYIRHGSKPMYTPEPDICHELLGHVPLFSDRSFAQFSQEIGLASLGAPDEYIEKLATIYWFTVEFGLCKQGDSIKAYGAGLLSSFGELQYCLSEKPKLLPLELEKTAIQNYTVTEFQPLYYVAESFNDAKEKVRNFAATIPRPFSVRYDPYTQRIEVLDNTQQLKILADSINSEIGILCSALQKIK T76213 DRUGINFO D0S2IQ Sapropterin hydrochloride Approved T76213 DRUGINFO D0T8HZ Pegvaliase Approved T76213 DRUGINFO D00IDR Phenylalanine hydroxylase Phase 2 T76213 DRUGINFO D05XZQ HepaStem Phase 2 T76213 DRUGINFO D5SZK9 HMI-102 Phase 1/2 T76213 DRUGINFO D94DTN BMN-307 Phase 1/2 T76213 DRUGINFO D05TXS BMN-168 Investigative T76213 DRUGINFO D07GET ALTU-236 Investigative T76213 DRUGINFO D08URY alpha-methylphenylalanine Investigative T76213 DRUGINFO D0F9XO BH4 Investigative T76213 DRUGINFO D0F2GG fenclonine Investigative T14602 TARGETID T14602 T14602 FORMERID TTDS00205 T14602 UNIPROID FA8_HUMAN T14602 TARGNAME Coagulation factor VIII (F8) T14602 GENENAME F8 T14602 TARGTYPE Successful T14602 SYNONYMS Procoagulant component; F8C; Antihemophilic factor; AHF T14602 FUNCTION Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa. T14602 PDBSTRUC 5K8D; 4XZU; 4PT6; 4KI5; 4BDV T14602 SEQUENCE MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRPGKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY T14602 DRUGINFO D0M2BR Factor 8 Approved T14602 DRUGINFO D0UQ1R Eloctate Approved T14602 DRUGINFO DMU9P2 Efanesoctocog alfa Approved T14602 DRUGINFO D0PG0G Drotrecogin alfa Approved T14602 DRUGINFO D0ZL1T SK-NBP601 Preregistration T14602 DRUGINFO D00UUL N8-GP Phase 3 T14602 DRUGINFO D03SIA OBI-1 Phase 3 T14602 DRUGINFO D05LDQ BAY 94-9027 Phase 3 T14602 DRUGINFO D09APA Plasma derived factor VIII PEGylated liposomal Phase 3 T14602 DRUGINFO D0ML8G Turoctocog alfa Phase 3 T14602 DRUGINFO D7HLI1 Valoctocogene roxaparvovec Phase 3 T14602 DRUGINFO DGB7W9 Milademetan Phase 3 T14602 DRUGINFO DZ9AJ3 PF-07055480 Phase 3 T14602 DRUGINFO D0B3XG Recombinant von Willebrand factor/recombinant Factor VIII complex Phase 3 T14602 DRUGINFO D00LHI BAY 794980 Phase 2 T14602 DRUGINFO D09UAI TB-402 Phase 2 T14602 DRUGINFO D8BYU3 BAY2599023 Phase 1/2 T14602 DRUGINFO DJ5I6L SPK-8016 Phase 1/2 T14602 DRUGINFO DW7PT6 SPK-8011 Phase 1/2 T14602 DRUGINFO DX0NW9 TAK-754 Phase 1/2 T14602 DRUGINFO D01FRK LA-N8 Investigative T14602 DRUGINFO D07LRB Factor VIII-XTEN Investigative T14602 DRUGINFO D08VFX Full-length Factor VIII molecule Investigative T14602 DRUGINFO D09CTF Human recombinant factor VIII Investigative T14602 DRUGINFO D0B6EG Simoctocog alfa Investigative T14602 DRUGINFO D0C7GJ Long-acting factor VIII Investigative T14602 DRUGINFO D0D7XS GPG-290 Investigative T14602 DRUGINFO D0P8ME LG-889 Investigative T14602 DRUGINFO D0Q7XA LG-888 Investigative T14602 DRUGINFO D0Q9UL IATX-FVIII Investigative T14602 DRUGINFO D0XK6O SMaRT FVIII Investigative T38179 TARGETID T38179 T38179 FORMERID TTDS00228 T38179 UNIPROID BLAC_STAAU T38179 TARGNAME Staphylococcus Beta-lactamase (Stap-coc blaZ) T38179 GENENAME Stap-coc blaZ T38179 TARGTYPE Successful T38179 SYNONYMS blaZ; Cephalosporinase T38179 FUNCTION This protein is a serine beta-lactamase with a substrate specificity for cephalosporins. T38179 PDBSTRUC 3BLM; 1PIO; 1OME; 1KGG; 1KGF T38179 BIOCLASS Carbon-nitrogen hydrolase T38179 ECNUMBER EC 3.5.2.6 T38179 SEQUENCE MKKLIFLIVIALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKEVKFNSDKRFAYASTSKAINSAILLEQVPYNKLNKKVHINKDDIVAYSPILEKYVGKDITLKALIEASMTYSDNTANNKIIKEIGGIKKVKQRLKELGDKVTNPVRYEIELNYYSPKSKKDTSTPAAFGKTLNKLIANGKLSKENKKFLLDLMLNNKSGDTLIKDGVPKDYKVADKSGQAITYASRNDVAFVYPKGQSEPIVLVIFTNKDNKSDKPNDKLISETAKSVMKEF T38179 DRUGINFO D0F7AJ Ceftolozane/tazobactam Approved T38179 DRUGINFO D0N5KF Meropenem + vaborbactam Approved T38179 DRUGINFO D0QQ7D Tazobactam Approved T38179 DRUGINFO D0X7JN Clavulanate Approved T38179 DRUGINFO D0S3EM CAZ AVI Phase 3 T38179 DRUGINFO D1MEH5 Enmetazobactam Phase 3 T38179 DRUGINFO DR6BU1 Vaborbactam Phase 3 T38179 DRUGINFO D02VSP MK-7655 Phase 2 T38179 DRUGINFO D08DGW CXL Phase 2 T38179 DRUGINFO D0EX1C RASV-Sp Phase 1 T38179 DRUGINFO D0V3BZ ME-1071 Phase 1 T38179 DRUGINFO D2UE8B QPX7831 Phase 1 T38179 DRUGINFO DD36YG OP-0595 Phase 1 T38179 DRUGINFO DMQ86J QPX7728 Phase 1 T38179 DRUGINFO DNI5M0 XNW4107 Phase 1 T38179 DRUGINFO DO57QB ETX0282 Phase 1 T38179 DRUGINFO DT30FV VNRX-5133 Phase 1 T38179 DRUGINFO D0I0VY DA-7101 Discontinued in Phase 3 T38179 DRUGINFO D0J6TN 2085-P Discontinued in Phase 3 T38179 DRUGINFO D0R4ML P1A Discontinued in Phase 2 T38179 DRUGINFO D03YIT CL-186659 Terminated T38179 DRUGINFO D08VWL BRL-42715 Terminated T38179 DRUGINFO D0H3CV Ro-48-8724 Terminated T38179 DRUGINFO D0OM5M Ro-48-1220 Terminated T38179 DRUGINFO D0P5NW SB-236049 Terminated T38179 DRUGINFO D0Y6IJ Ro-48-5545 Terminated T38179 DRUGINFO D00WZI 5-methyl-benzo[b]thiophen-2-ylboronic acid Investigative T38179 DRUGINFO D00YUO 4-iodo-acetamido phenylboronic acid Investigative T38179 DRUGINFO D00ZBH Alpha-Sulfanyl(4-fluorobenzyl)phosphonic acid Investigative T38179 DRUGINFO D01ULE Alpha-Sulfanylbenzylphosphonic acid Investigative T38179 DRUGINFO D02DOQ Diisopropyl 2-(sulfanylmethyl)phenylphosphonate Investigative T38179 DRUGINFO D02OVN Acylated Ceftazidime Investigative T38179 DRUGINFO D03JFU Alpha-Sulfanylpropylphosphonic acid Investigative T38179 DRUGINFO D03XOB 5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid Investigative T38179 DRUGINFO D05BCF Clavulanate+Amoxicillin Investigative T38179 DRUGINFO D05LMB Alpha-Sulfanyl(2-methoxybenzyl)phosphonic acid Investigative T38179 DRUGINFO D05PVX Thiophene-2-ylboronic acid Investigative T38179 DRUGINFO D06BUM 4-Carboxyphenylboronic Acid Investigative T38179 DRUGINFO D06CUF Hydrolyzed Cephalothin Investigative T38179 DRUGINFO D06GYI N-2-Thiophen-2-Yl-Acetamide Boronic Acid Investigative T38179 DRUGINFO D06OGZ Degraded Cephaloridine Investigative T38179 DRUGINFO D06UHZ 2-mercaptophenylphosphonic acid Investigative T38179 DRUGINFO D07OSW 2-(Sulfanylmethyl)phenylphosphonic acid Investigative T38179 DRUGINFO D08KUO 1-Aminopropane-1,2,3-tricarboxylic acid Investigative T38179 DRUGINFO D08LLS 4-(Carboxyvin-2-Yl)Phenylboronic Acid Investigative T38179 DRUGINFO D08TCV Sucrose Investigative T38179 DRUGINFO D09EHR 5-Fluoro-2-sulfanyl-phenylphosphonic acid Investigative T38179 DRUGINFO D0E1XD M-Aminophenylboronic Acid Investigative T38179 DRUGINFO D0EK8U [[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate Investigative T38179 DRUGINFO D0F1RL Alpha-Sulfanyl(4-bromobenzyl)phosphonic acid Investigative T38179 DRUGINFO D0H9UT Carbamic Acid Investigative T38179 DRUGINFO D0I6QE Alpha-Sulfanyl(4-chlorobenzyl)phosphonic acid Investigative T38179 DRUGINFO D0I7DN Tribenzyl 2-aminopropane-1,2,3-tricarboxylate Investigative T38179 DRUGINFO D0IN7A Alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid Investigative T38179 DRUGINFO D0J7EL 3-Nitrophenylboronic Acid Investigative T38179 DRUGINFO D0N5WV 4-[(METHYLSULFONYL)AMINO]BENZOIC ACID Investigative T38179 DRUGINFO D0R5FE (P-Iodophenylacetylamino)Methylphosphinic Acid Investigative T38179 DRUGINFO D0R6DA 3-ethoxycarbonylpyroglutamate Investigative T38179 DRUGINFO D0W4OF Diisopropyl mercapto(phenyl)methylphosphonate Investigative T38179 DRUGINFO D0W9RM 4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid Investigative T38179 DRUGINFO D0X0KZ 4,4'-Biphenyldiboronic Acid Investigative T38179 DRUGINFO D0XF5X 3-Amino-3-(methoxycarbonyl)-1,5-pentandioic acid Investigative T38179 DRUGINFO D0XF6C 2-phenyl-1H-imidazole-4-carboxylic acid Investigative T38179 DRUGINFO D0YY2L Diisopropyl 1-mercaptopropylphosphonate Investigative T38179 DRUGINFO D0Z7IJ Triethyl 2-aminopropane-1,2,3-tricarboxylate Investigative T38179 DRUGINFO D04BWH Benzo[b]thiophen-2-ylboronic acid Investigative T38179 DRUGINFO D08JUW PCNOTAXIME GROUP Investigative T38179 DRUGINFO D07KZA 2-(N-Morpholino)-Ethanesulfonic Acid Investigative T38179 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T38179 DRUGINFO D0F2ME Acetate Ion Investigative T27445 TARGETID T27445 T27445 FORMERID TTDS00223 T27445 UNIPROID SYI_ECOLI T27445 TARGNAME Bacterial Isoleucyl-tRNA synthetase (Bact ileS) T27445 GENENAME Bact ileS T27445 TARGTYPE Successful T27445 SYNONYMS ileS; Isoleucine--tRNA ligase of Escherichia coli; IRS of Escherichia coli T27445 FUNCTION Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS can inadvertently accommodate and process structurally similar amino acids such as valine, to avoid such errors it has two additional distinct tRNA(Ile)-dependent editing activities. One activity is designated as 'pretransfer' editing and involves the hydrolysis of activated Val-AMP. The other activity is designated 'posttransfer' editing and involves deacylation of mischarged Val-tRNA(Ile). T27445 BIOCLASS Carbon-oxygen ligase T27445 ECNUMBER EC 6.1.1.5 T27445 SEQUENCE MSDYKSTLNLPETGFPMRGDLAKREPGMLARWTDDDLYGIIRAAKKGKKTFILHDGPPYANGSIHIGHSVNKILKDIIVKSKGLSGYDSPYVPGWDCHGLPIELKVEQEYGKPGEKFTAAEFRAKCREYAATQVDGQRKDFIRLGVLGDWSHPYLTMDFKTEANIIRALGKIIGNGHLHKGAKPVHWCVDCRSALAEAEVEYYDKTSPSIDVAFQAVDQDALKAKFAVSNVNGPISLVIWTTTPWTLPANRAISIAPDFDYALVQIDGQAVILAKDLVESVMQRIGVTDYTILGTVKGAELELLRFTHPFMGFDVPAILGDHVTLDAGTGAVHTAPGHGPDDYVIGQKYGLETANPVGPDGTYLPGTYPTLDGVNVFKANDIVVALLQEKGALLHVEKMQHSYPCCWRHKTPIIFRATPQWFVSMDQKGLRAQSLKEIKGVQWIPDWGQARIESMVANRPDWCISRQRTWGVPMSLFVHKDTEELHPRTLELMEEVAKRVEVDGIQAWWDLDAKEILGDEADQYVKVPDTLDVWFDSGSTHSSVVDVRPEFAGHAADMYLEGSDQHRGWFMSSLMISTAMKGKAPYRQVLTHGFTVDGQGRKMSKSIGNTVSPQDVMNKLGADILRLWVASTDYTGEMAVSDEILKRAADSYRRIRNTARFLLANLNGFDPAKDMVKPEEMVVLDRWAVGCAKAAQEDILKAYEAYDFHEVVQRLMRFCSVEMGSFYLDIIKDRQYTAKADSVARRSCQTALYHIAEALVRWMAPILSFTADEVWGYLPGEREKYVFTGEWYEGLFGLADSEAMNDAFWDELLKVRGEVNKVIEQARADKKVGGSLEAAVTLYAEPELSAKLTALGDELRFVLLTSGATVADYNDAPADAQQSEVLKGLKVALSKAEGEKCPRCWHYTQDVGKVAEHAEICGRCVSNVAGDGEKRKFA T27445 DRUGINFO D03JSJ Mupirocin Approved T27445 DRUGINFO D0N1BC Reveromycin A Terminated T73476 TARGETID T73476 T73476 FORMERID TTDS00467 T73476 UNIPROID ANT3_HUMAN T73476 TARGNAME Antithrombin-III (ATIII) T73476 GENENAME SERPINC1 T73476 TARGTYPE Successful T73476 SYNONYMS SERPINC1; ATIII; AT3 T73476 FUNCTION Most important serine protease inhibitorin plasma that regulates the blood coagulation cascade. At-iii inhibits thrombin as well as factors ixa, xa and xia. Its inhibitory activity is greatly enhanced in the presence of heparin. T73476 PDBSTRUC 4EB1; 3KCG; 3EVJ; 2ZNH; 2HIJ T73476 BIOCLASS Serpin protein T73476 SEQUENCE MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK T73476 DRUGINFO D01ZJK Ardeparin Approved T73476 DRUGINFO D0A2GM Heparin Calcium Approved T73476 DRUGINFO D0E9TP Sulodexide Approved T73476 DRUGINFO D0UX6Z Heparin Sodium Approved T73476 DRUGINFO D02WST Unfractionated heparin Phase 3 T73476 DRUGINFO D0C3YN Heparin low molecular weight Phase 3 T73476 DRUGINFO D0C6ZX KW-3357 Phase 3 T73476 DRUGINFO D00AKQ O-desulfated heparin Phase 2 T73476 DRUGINFO D07XJJ M118 Phase 2 T73476 DRUGINFO D08HXG PMX-60056 Phase 2 T73476 DRUGINFO D06LEA MER-102 Phase 1 T73476 DRUGINFO D08FNJ RO-14 Phase 1 T73476 DRUGINFO D0O8SB OPK-0018 Phase 1 T73476 DRUGINFO D09EDW Deligoparin sodium Discontinued in Phase 3 T73476 DRUGINFO D02JGZ Heparin Pentasaccharide Investigative T73476 DRUGINFO D0A3WQ Org-36764 Investigative T73476 DRUGINFO D0AZ5O LHD-4 Investigative T73476 DRUGINFO D0X5SQ PNU-87663 Investigative T73476 DRUGINFO D0GV9Q N-Formylmethionine Investigative T73476 DRUGINFO D07LUR Alpha-D-Mannose Investigative T28265 TARGETID T28265 T28265 FORMERID TTDS00285 T28265 UNIPROID A1AT_HUMAN T28265 TARGNAME Alpha-1-antitrypsin (SERPINA1) T28265 GENENAME SERPINA1 T28265 TARGTYPE Successful T28265 SYNONYMS SERPINA1; PRO0684/PRO2209; Alpha1-proteinase; Alpha-1-antiproteinase; Alpha-1 protease inhibitor T28265 FUNCTION Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. T28265 PDBSTRUC 9API; 8API; 7API; 5NBV; 5NBU T28265 BIOCLASS Serpin protein T28265 SEQUENCE MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK T28265 DRUGINFO D04ELD Glassia Approved T28265 DRUGINFO D9EC0G Zemaira Approved T28265 DRUGINFO D0QF2W AGTC-0106 Phase 2 T28265 DRUGINFO D0N5LJ Igmesine Phase 2 T28265 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T94692 TARGETID T94692 T94692 FORMERID TTDR00225 T94692 UNIPROID LDLR_HUMAN T94692 TARGNAME Low-density lipoprotein receptor (LDL-R) T94692 GENENAME LDLR T94692 TARGTYPE Successful T94692 SYNONYMS LDL receptor T94692 FUNCTION In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. T94692 PDBSTRUC 5OYL; 5OY9; 4NE9; 3SO6; 3P5C T94692 BIOCLASS Low density lipoprotein receptor T94692 SEQUENCE MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA T94692 DRUGINFO D02JDL Porfimer Sodium Approved T94692 DRUGINFO D07LUR Alpha-D-Mannose Investigative T97257 TARGETID T97257 T97257 FORMERID TTDR00511 T97257 UNIPROID TGFB1_HUMAN T97257 TARGNAME Transforming growth factor beta 1 (TGFB1) T97257 GENENAME TGFB1 T97257 TARGTYPE Successful T97257 SYNONYMS Transforming growth factor beta-1 proprotein; Transforming growth factor beta-1; TGFB; TGF-beta1; TGF-beta 1 T97257 FUNCTION Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively. T97257 PDBSTRUC 5VQP; 5FFO; 4KV5; 3KFD; 1KLD T97257 BIOCLASS Growth factor T97257 SEQUENCE MPPSGLRLLLLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS T97257 DRUGINFO D02WCI Pirfenidone Approved T97257 DRUGINFO D8UKA4 A435 IND submitted T97257 DRUGINFO D0DP3V TG-C Phase 3 T97257 DRUGINFO D06TFI LY2157299 Phase 2/3 T97257 DRUGINFO D0C4WC Disitertide Phase 2 T97257 DRUGINFO D8NZ7T ACE-1334 Phase 1 T97257 DRUGINFO DFZJ79 SRK-181 Phase 1 T97257 DRUGINFO DKCI94 ABBV-151 Phase 1 T97257 DRUGINFO D0U3DX Mannose phosphate Discontinued in Phase 2 T97257 DRUGINFO D08OLR ART-144 Investigative T63934 TARGETID T63934 T63934 FORMERID TTDI01921 T63934 UNIPROID IFNA2_HUMAN T63934 TARGNAME Interferon-alpha 2 (IFNA2) T63934 GENENAME IFNA2 T63934 TARGTYPE Successful T63934 SYNONYMS LeIF A; Interferon alphaA; Interferon alpha2; Interferon alpha-A; Interferon alpha-2; IFNalpha2; IFNA2C; IFNA2B; IFNA2A; IFN-alpha-2 T63934 FUNCTION Produced by macrophages, IFN-alpha have antiviral activities. T63934 PDBSTRUC 4Z5R; 4YPG; 3SE3; 3S9D; 2LMS T63934 BIOCLASS Cytokine: interferon T63934 SEQUENCE MALTFALLVALLVLSCKSSCSVGCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE T63934 DRUGINFO D08NWC Peginterferon alfa-2b Approved T63934 DRUGINFO D0P0WV Interferon Alfa-2b Approved T63934 DRUGINFO D0Y8OK Peginterferon alfa-2a Approved T63934 DRUGINFO D00TJX Albinterferon alfa-2b Phase 3 T63934 DRUGINFO D05DZK Interferon alpha 2a Phase 3 T63934 DRUGINFO D0M2IS Hebergel Phase 3 T63934 DRUGINFO D0V8KD P-1101 Phase 3 T63934 DRUGINFO D00EFO Interferon alpha-2b Phase 2 T63934 DRUGINFO D04PIH Novaferon Phase 2 T63934 DRUGINFO D07CNY Instiladrin Phase 2 T63934 DRUGINFO D0NI0X SCH-721015 Phase 1 T63934 DRUGINFO D06NDP CIGB-128 Phase 1 T63934 DRUGINFO D04DVA HAp-IFN Investigative T63934 DRUGINFO D0Q5UM subalin Investigative T02808 TARGETID T02808 T02808 FORMERID TTDI01922 T02808 UNIPROID IFNB_HUMAN T02808 TARGNAME Interferon-beta (IFNB1) T02808 GENENAME IFNB1 T02808 TARGTYPE Successful T02808 SYNONYMS Interferon beta; IFNbeta; IFNB; IFN-beta; IFB; Fibroblast interferon T02808 FUNCTION Has antiviral, antibacterial and anticancer activities. T02808 PDBSTRUC 1AU1 T02808 BIOCLASS Cytokine: interferon T02808 SEQUENCE MTNKCLLQIALLLCFSTTALSMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN T02808 DRUGINFO D04YXL PEGylated IFN beta 1-a Approved T02808 DRUGINFO D0LW4O PLEGRIDY Approved T02808 DRUGINFO D0V4JQ Interferon beta-1a Approved T02808 DRUGINFO D05LOB FP-1201 Phase 3 T02808 DRUGINFO D0D0LH NU-100 Phase 3 T02808 DRUGINFO D0L8PH Biferonex Phase 3 T02808 DRUGINFO D04HJE AZ-01, PEGylated interferon-beta Phase 2 T02808 DRUGINFO D08RDD PF-06823859 Phase 2 T02808 DRUGINFO D0V5KJ Interferon beta 1a Phase 2 T02808 DRUGINFO D0F7ZR ARX-424 Phase 1 T02808 DRUGINFO D0Q3BG Gene therapy, IFN-b Phase 1 T02808 DRUGINFO D00TEN TV-1390 Preclinical T02808 DRUGINFO D05BIT Maxy-10 Terminated T63068 TARGETID T63068 T63068 FORMERID TTDS00336 T63068 UNIPROID ALBU_HUMAN T63068 TARGNAME Serum albumin (ALB) T63068 GENENAME ALB T63068 TARGTYPE Successful T63068 SYNONYMS Serum albumin T63068 FUNCTION Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc. T63068 PDBSTRUC 6JE7; 6EZQ; 6A7P; 5Z0B; 5YOQ T63068 SEQUENCE MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL T63068 DRUGINFO D01OIL Gadobenate Dimeglumine Approved T63068 DRUGINFO D05ATI Sodium lauryl sulfate Approved T63068 DRUGINFO D06ZPS Oxyphenbutazone Approved T63068 DRUGINFO D07OIX Iodipamide Approved T63068 DRUGINFO D0B1FE SPI-1005 Approved T63068 DRUGINFO D0H0WK Gadofosveset Approved T63068 DRUGINFO D0I0VI Albumin Human Approved T63068 DRUGINFO D0OG5K Bismuth Approved T63068 DRUGINFO D0P2CS EVANS BLUE Approved T63068 DRUGINFO D0C0CE Activated recombinant FVII-albumin fusion protein Phase 2/3 T63068 DRUGINFO D9J6XV Vobarilizumab Phase 2 T63068 DRUGINFO D0YW6P RU-101 Phase 1/2 T14342 TARGETID T14342 T14342 FORMERID TTDS00317 T14342 UNIPROID POL_HV1B1 T14342 TARGNAME Human immunodeficiency virus Reverse transcriptase (HIV RT) T14342 GENENAME HIV RT T14342 TARGTYPE Successful T14342 SYNONYMS HIV p66 RT; HIV Exoribonuclease H T14342 FUNCTION Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation. T14342 PDBSTRUC 6OE3; 6HAK; 6ELI; 6DUH; 6DUG T14342 ECNUMBER EC 2.7.7.49 T14342 SEQUENCE PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKIL T14342 DRUGINFO D03TGJ Sorivudine Approved T14342 DRUGINFO D06FDR Didanosine Approved T14342 DRUGINFO D07HVY Efavirenz Approved T14342 DRUGINFO D07TQV Lamivudine Approved T14342 DRUGINFO D0A4IJ Abacavir Approved T14342 DRUGINFO D0BP9C Etravirine Approved T14342 DRUGINFO D0D1BR GS-7340 Approved T14342 DRUGINFO D0D9HW Tenofovir Approved T14342 DRUGINFO D0G6SD Delavirdine Approved T14342 DRUGINFO D0O2EM Nevirapine Approved T14342 DRUGINFO D0R0TS MK-1439 Approved T14342 DRUGINFO D0R3FP Tenofovir disoproxil fumarate Approved T14342 DRUGINFO D0S9SD Emtricitabine Approved T14342 DRUGINFO D0Z8EX Stavudine Approved T14342 DRUGINFO D0Z9QR Zalcitabine Approved T14342 DRUGINFO D01IRG Bictegravir, emtricitabine and tenofovir alafenamide Approved T14342 DRUGINFO D01XYJ Zidovudine Approved T14342 DRUGINFO D0T6WN Rilpivirine Approved T14342 DRUGINFO D0I0ZP Glyminox Phase 3 T14342 DRUGINFO D0V9QR Apricitabine Phase 3 T14342 DRUGINFO D0ZL0Z PT-304 Phase 3 T14342 DRUGINFO D0U2BH Epigallocatechin gallate Phase 3 T14342 DRUGINFO D01BBB VM-1500 Phase 2/3 T14342 DRUGINFO D02SPX IDX899 Phase 2 T14342 DRUGINFO D02SUR L-697,661 Phase 2 T14342 DRUGINFO D05NDN Alovudine Phase 2 T14342 DRUGINFO D06ZWL Amdoxovir Phase 2 T14342 DRUGINFO D08SSP Lersivirine Phase 2 T14342 DRUGINFO D0GK4E EMIVIRINE Phase 2 T14342 DRUGINFO D0L6KC BILR-355 Phase 2 T14342 DRUGINFO D0ML2V RALURIDINE Phase 2 T14342 DRUGINFO D0O4WB OBP-601 Phase 2 T14342 DRUGINFO D0I0UE Lexipafant Phase 2 T14342 DRUGINFO D05GBH F4co vaccine Phase 2 T14342 DRUGINFO D04GSV TRICIRIBINE Phase 1/2 T14342 DRUGINFO D0DC6U Dapivirine Phase 1/2 T14342 DRUGINFO D0W9IH Ad35-GRIN Phase 1/2 T14342 DRUGINFO D00BTW UC-781 Phase 1 T14342 DRUGINFO D01JTL KM-023 Phase 1 T14342 DRUGINFO D03MLA PT-302 Phase 1 T14342 DRUGINFO D03PKJ MK-6186 Phase 1 T14342 DRUGINFO D05HGL GW-695634 Phase 1 T14342 DRUGINFO D06KXS PT-112 Phase 1 T14342 DRUGINFO D08DFU CMX-157 Phase 1 T14342 DRUGINFO D09PRN TROVIRDINE HYDROCHLORIDE Phase 1 T14342 DRUGINFO D0D0PB AIC-292 Phase 1 T14342 DRUGINFO D0KR5K Capravirine Phase 1 T14342 DRUGINFO D0S0OI ATEVIRDINE Phase 1 T14342 DRUGINFO D0S6KA CALANOLIDE A Phase 1 T14342 DRUGINFO D0XB1M MSH-372 Phase 1 T14342 DRUGINFO D3NTA9 MK-8504 Phase 1 T14342 DRUGINFO DF6Y1J MK-8583 Phase 1 T14342 DRUGINFO D09ZKB Ad35-GRIN/ENV Phase 1 T14342 DRUGINFO D0V4RH Lobucavir Discontinued in Phase 3 T14342 DRUGINFO D05SFD DMP-961 Discontinued in Phase 2 T14342 DRUGINFO D06HKB Lodenosine Discontinued in Phase 2 T14342 DRUGINFO D07QWZ AZT-P-DDI Discontinued in Phase 2 T14342 DRUGINFO D09TYS Loviride Discontinued in Phase 2 T14342 DRUGINFO D0A0MU FOZIVUDINE TIDOXIL Discontinued in Phase 2 T14342 DRUGINFO D0E3NZ L-696229 Discontinued in Phase 2 T14342 DRUGINFO D0K2PH Elvucitabine Discontinued in Phase 2 T14342 DRUGINFO D0Q1KP R-18893 Discontinued in Phase 2 T14342 DRUGINFO D0V3CM Opaviraline Discontinued in Phase 2 T14342 DRUGINFO D01AUL L-697639 Discontinued in Phase 1 T14342 DRUGINFO D09PSB DPC-082 Discontinued in Phase 1 T14342 DRUGINFO D09SFH R-82150 Discontinued in Phase 1 T14342 DRUGINFO D0L9PF LY-73497 Discontinued in Phase 1 T14342 DRUGINFO D0T5SZ PNU-142721 Discontinued in Phase 1 T14342 DRUGINFO D0V6HS R-82913 Discontinued in Phase 1 T14342 DRUGINFO D01VCW MEN-10690 Terminated T14342 DRUGINFO D04AUA MIV-170 Terminated T14342 DRUGINFO D04NFB DMP-963 Terminated T14342 DRUGINFO D05DNH A-79296 Terminated T14342 DRUGINFO D05IZG BAY-Z-4305 Terminated T14342 DRUGINFO D05MQO BEA-005 Terminated T14342 DRUGINFO D05SVQ C-AFG Terminated T14342 DRUGINFO D0A8BK MEN-10979 Terminated T14342 DRUGINFO D0B0QX MSC-204 Terminated T14342 DRUGINFO D0JI1S RDEA-640 Terminated T14342 DRUGINFO D0K3YG ANX-201 Terminated T14342 DRUGINFO D0L0NE DPC-A78277 Terminated T14342 DRUGINFO D0L2QJ UC-84 Terminated T14342 DRUGINFO D0L9PL UC-38 Terminated T14342 DRUGINFO D0M0UJ GS-9148 Terminated T14342 DRUGINFO D0M4HM MEN-10880 Terminated T14342 DRUGINFO D0M9VZ Navuridine Terminated T14342 DRUGINFO D0S7DS SPD-756 Terminated T14342 DRUGINFO D0T9KF RDEA-427 Terminated T14342 DRUGINFO D0U6NV ISIS-1082 Terminated T14342 DRUGINFO D00DSQ HI-244 Investigative T14342 DRUGINFO D00JWR PT-312 Investigative T14342 DRUGINFO D00NNP HI-172 Investigative T14342 DRUGINFO D01KPX PT-315 Investigative T14342 DRUGINFO D01VSM 6-Benzyl-2-isobutylsulfanyl-3H-pyrimidin-4-one Investigative T14342 DRUGINFO D01YRL 6-Benzyl-2-cyclohexylsulfanyl-3H-pyrimidin-4-one Investigative T14342 DRUGINFO D02MIH PT-104 Investigative T14342 DRUGINFO D02MJN 2-Amino-6-(3-cyano-benzenesulfonyl)-benzonitrile Investigative T14342 DRUGINFO D02MZZ 2-Amino-6-(toluene-2-sulfonyl)-benzonitrile Investigative T14342 DRUGINFO D02POV 1-(2-Phenyl-propyl)-3-thiazol-2-yl-thiourea Investigative T14342 DRUGINFO D02PPQ Ethyl 1-[(1H-benzimidazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate Investigative T14342 DRUGINFO D02VFQ HI-241 Investigative T14342 DRUGINFO D03BNC HI-240 Investigative T14342 DRUGINFO D03DZP HI-242 Investigative T14342 DRUGINFO D03KLW PT-109 Investigative T14342 DRUGINFO D03OQK NSC-380292 Investigative T14342 DRUGINFO D03TYE PT-108 Investigative T14342 DRUGINFO D03VYO 10-Ethyl-10H-dibenzo[b,f][1,4]oxazepin-11-one Investigative T14342 DRUGINFO D03XBA PT-102 Investigative T14342 DRUGINFO D04AQW 10-Isopropyl-10H-dibenzo[b,f][1,4]oxazepin-11-one Investigative T14342 DRUGINFO D04BHR PT-313 Investigative T14342 DRUGINFO D04JYI 1-Benzothiazol-2-yl-3-phenethyl-thiourea Investigative T14342 DRUGINFO D04MYC NSC-625487 Investigative T14342 DRUGINFO D04PGW [(40-OH)MeLeu]4-Cyclosporin A Investigative T14342 DRUGINFO D04PHR UK-129485 Investigative T14342 DRUGINFO D05DQF Indole N -acetamide Investigative T14342 DRUGINFO D05GOC PT-306 Investigative T14342 DRUGINFO D05NBU 2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine Investigative T14342 DRUGINFO D05UTC PT-103 Investigative T14342 DRUGINFO D06DTQ 2-Amino-6-(3-bromo-benzenesulfinyl)-benzonitrile Investigative T14342 DRUGINFO D06PAA 1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea Investigative T14342 DRUGINFO D06ZGS 1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea Investigative T14342 DRUGINFO D07ABJ [(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A Investigative T14342 DRUGINFO D07BXD HI-281 Investigative T14342 DRUGINFO D07DPX 2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile Investigative T14342 DRUGINFO D07DQD Tetrahydroimidazo[4,5,1-jk]-[1,4]benzodiazepin-2(1H)-one Investigative T14342 DRUGINFO D07HEZ 2-Amino-6-phenylsulfanyl-benzonitrile Investigative T14342 DRUGINFO D07IUX 2-Amino-6-(3-methoxy-phenylsulfanyl)-benzonitrile Investigative T14342 DRUGINFO D07TYK 2'-3'-dideoxy-7-deaza-guaninetriphosphate Investigative T14342 DRUGINFO D08CZE Dihydropyrone Investigative T14342 DRUGINFO D08EXA 2-Amino-6-(3-cyano-phenylsulfanyl)-benzonitrile Investigative T14342 DRUGINFO D08FZQ E-EBU-dM Investigative T14342 DRUGINFO D08QLC 2-Amino-6-(2-cyano-phenylsulfanyl)-benzonitrile Investigative T14342 DRUGINFO D08TVG PT-307 Investigative T14342 DRUGINFO D08ZZJ R-87027 Investigative T14342 DRUGINFO D09CNT 1-(2-Furan-2-yl-ethyl)-3-thiazol-2-yl-thiourea Investigative T14342 DRUGINFO D09GBA Ethyl 1-[(1H-benzotriazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate Investigative T14342 DRUGINFO D09GYC 2-Amino-6-(2-cyano-benzenesulfinyl)-benzonitrile Investigative T14342 DRUGINFO D09UTR 2-Amino-6-(4-chloro-phenylsulfanyl)-benzonitrile Investigative T14342 DRUGINFO D09WOX 2-Amino-6-(naphthalene-1-sulfonyl)-benzonitrile Investigative T14342 DRUGINFO D09XKC PT-113 Investigative T14342 DRUGINFO D0A2SA 10-Allyl-10H-dibenzo[b,f][1,4]oxazepin-11-one Investigative T14342 DRUGINFO D0A3CB 2-Amino-6-(2-chloro-phenylsulfanyl)-benzonitrile Investigative T14342 DRUGINFO D0A8BJ 2-Amino-6-(toluene-3-sulfinyl)-benzonitrile Investigative T14342 DRUGINFO D0A9LX Deoxyfluorothymidine Investigative T14342 DRUGINFO D0A9WC PT-319 Investigative T14342 DRUGINFO D0AZ7V PT-309 Investigative T14342 DRUGINFO D0B2BD 1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea Investigative T14342 DRUGINFO D0B8FZ 1-(3-Phenyl-propyl)-3-thiazol-2-yl-thiourea Investigative T14342 DRUGINFO D0BT5E PT-314 Investigative T14342 DRUGINFO D0C0PL PT-115 Investigative T14342 DRUGINFO D0C5HP 2-Amino-6-(3-bromo-phenylsulfanyl)-benzonitrile Investigative T14342 DRUGINFO D0C9VN 10-Propyl-10H-dibenzo[b,f][1,4]oxazepin-11-one Investigative T14342 DRUGINFO D0D4QL Benzimidazole 5-carboxamide Investigative T14342 DRUGINFO D0D6FR 2-Amino-6-(naphthalene-2-sulfonyl)-benzonitrile Investigative T14342 DRUGINFO D0E3PF PT-320 Investigative T14342 DRUGINFO D0E9TU ISODISPAR B Investigative T14342 DRUGINFO D0ET0J PT-322 Investigative T14342 DRUGINFO D0F0RO [(40-OH) MeLeu]4-CsA derivatives Investigative T14342 DRUGINFO D0F9KX PT-101 Investigative T14342 DRUGINFO D0H0WL PT-106 Investigative T14342 DRUGINFO D0H4PN 1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea Investigative T14342 DRUGINFO D0I5TQ 2-Amino-6-(toluene-4-sulfonyl)-benzonitrile Investigative T14342 DRUGINFO D0I7HP PT-308 Investigative T14342 DRUGINFO D0J0CU 2-Amino-6-(2-cyano-benzenesulfonyl)-benzonitrile Investigative T14342 DRUGINFO D0JZ8P 10-Propyl-10H-dibenzo[b,f][1,4]thiazepin-11-one Investigative T14342 DRUGINFO D0K8EZ 2-Amino-6-(3-fluoro-phenylsulfanyl)-benzonitrile Investigative T14342 DRUGINFO D0KF0N 1-Benzenesulfonyl-2-nitro-benzene Investigative T14342 DRUGINFO D0L2CG 1-Benzyl-3-thiazol-2-yl-thiourea Investigative T14342 DRUGINFO D0MR4N 1-(4-Butyl-thiazol-2-yl)-3-phenethyl-thiourea Investigative T14342 DRUGINFO D0N8KZ 1-nitro-2-(2-nitrophenylsulfonyl)benzene Investigative T14342 DRUGINFO D0N8MN TNK-651 Investigative T14342 DRUGINFO D0N8PI 2-Amino-6-(3-chloro-phenylsulfanyl)-benzonitrile Investigative T14342 DRUGINFO D0O6JB HI-443 Investigative T14342 DRUGINFO D0OV0I 2-Amino-6-m-tolylsulfanyl-benzonitrile Investigative T14342 DRUGINFO D0P0CX 2-Amino-6-(toluene-3-sulfonyl)-benzonitrile Investigative T14342 DRUGINFO D0P7CD 1-(4-Cyano-thiazol-2-yl)-3-phenethyl-thiourea Investigative T14342 DRUGINFO D0PJ9J 1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea Investigative T14342 DRUGINFO D0Q0IE PT-110 Investigative T14342 DRUGINFO D0Q9OR HI-445 Investigative T14342 DRUGINFO D0QU1E PT-311 Investigative T14342 DRUGINFO D0QW6X 3'thiacytidine Investigative T14342 DRUGINFO D0RD5U PT-114 Investigative T14342 DRUGINFO D0T7IG RTI-20 Investigative T14342 DRUGINFO D0T9PE PT-310 Investigative T14342 DRUGINFO D0U0LL PT-316 Investigative T14342 DRUGINFO D0U3GH 2-Amino-6-p-tolylsulfanyl-benzonitrile Investigative T14342 DRUGINFO D0U4BQ 2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile Investigative T14342 DRUGINFO D0UO3I HEPT Investigative T14342 DRUGINFO D0V9EH PT-317 Investigative T14342 DRUGINFO D0W8JP 1-Phenethyl-3-[1,3,4]thiadiazol-2-yl-thiourea Investigative T14342 DRUGINFO D0W9YC 2-Amino-6-(2-methoxy-phenylsulfanyl)-benzonitrile Investigative T14342 DRUGINFO D0WT5M 3-Benzylamino-5-ethyl-6-methyl-1H-pyridin-2-one Investigative T14342 DRUGINFO D0WZ3T 1-(2-Pyridin-2-yl-ethyl)-3-thiazol-2-yl-thiourea Investigative T14342 DRUGINFO D0X2IG 2-Amino-6-benzenesulfonyl-benzonitrile Investigative T14342 DRUGINFO D0X4SF 2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile Investigative T14342 DRUGINFO D0XO2E HI-236 Investigative T14342 DRUGINFO D0Y2FF 1-Thiazol-2-yl-3-(2-o-tolyl-ethyl)-thiourea Investigative T14342 DRUGINFO D0Y4ZF 6-Benzyl-2-cyclopentylsulfanyl-3H-pyrimidin-4-one Investigative T14342 DRUGINFO D0YP0P 2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile Investigative T14342 DRUGINFO D0Z2MJ 2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile Investigative T14342 DRUGINFO D0Z8XJ 6-Benzyl-2-sec-butylsulfanyl-3H-pyrimidin-4-one Investigative T14342 DRUGINFO D0ZY8H HI-280 Investigative T14342 DRUGINFO D03SPJ CORILAGIN Investigative T14342 DRUGINFO D0BK8V 2',3'-ddATP Investigative T14342 DRUGINFO D09WYY 2'-deoxythymidine triphosphate Investigative T14342 DRUGINFO D0W1ST Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate Investigative T86674 TARGETID T86674 T86674 FORMERID TTDC00002 T86674 UNIPROID HEMA_I34A1 T86674 TARGNAME Influenza Hemagglutinin (Influ HA) T86674 GENENAME Influ HA T86674 TARGTYPE Successful T86674 SYNONYMS Hemagglutinin T86674 FUNCTION Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. This attachment induces virion internalization either through clathrin-dependent endocytosis or through clathrin- and caveolin-independent pathway. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induces an irreversible conformational change in HA2, releasing the fusion hydrophobic peptide. Several trimers are required to form a competent fusion pore. T86674 PDBSTRUC 1RVZ; 1RVX; 1RU7 T86674 BIOCLASS Influenza viruses hemagglutinin T86674 SEQUENCE MKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI T86674 DRUGINFO D02VIT Arbidol Approved T86674 DRUGINFO D0B1IC CR8020 Phase 2 T86674 DRUGINFO D0Q1WI RG7745 Phase 2 T86674 DRUGINFO DQ45GY VIS410 Phase 2 T86674 DRUGINFO D01AYF ND-1.1 Phase 1 T86674 DRUGINFO D03TAY VGX-3400 Phase 1 T86674 DRUGINFO D0LF3K A/Anhui/05 Phase 1 T86674 DRUGINFO D3G2BO VIR-2482 Phase 1 T86674 DRUGINFO D04HHR BMY-27709 Investigative T86674 DRUGINFO D08UNZ PXVX-0103 Investigative T86674 DRUGINFO D0DQ2G 2-tert-butylbenzene-1,4-diol Investigative T86674 DRUGINFO D0LH1A CL 385319 Investigative T86674 DRUGINFO D0Z2SL Stachyflin Investigative T86674 DRUGINFO D07LUR Alpha-D-Mannose Investigative T74002 TARGETID T74002 T74002 FORMERID TTDR00322 T74002 UNIPROID CSF2_HUMAN T74002 TARGNAME Granulocyte-macrophage colony-stimulating factor (CSF2) T74002 GENENAME CSF2 T74002 TARGTYPE Successful T74002 SYNONYMS Sargramostim; Molgramostin; GM-CSF; Colony-stimulating factor; CSF2; CSF T74002 FUNCTION Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. T74002 PDBSTRUC 6BFS; 6BFQ; 5D72; 5D71; 5D70 T74002 BIOCLASS Growth factor T74002 SEQUENCE MWLQSLLLLGTVACSISAPARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE T74002 DRUGINFO D05BXY Talimogene Laherparepvec Approved T74002 DRUGINFO D0HB0V JX-594 Phase 3 T74002 DRUGINFO D02SYV Lenzilumab Phase 2 T74002 DRUGINFO D09SJE KB002/003 Phase 2 T74002 DRUGINFO D0C7ZB GSK3196165 Phase 2 T74002 DRUGINFO D0F0ZK KB-003 Phase 2 T74002 DRUGINFO D0H6SH MT203 Phase 2 T74002 DRUGINFO D06KCF Mavrilimumab Phase 2 T74002 DRUGINFO D0YO4B Cabiralizumab Phase 2 T74002 DRUGINFO D07RIJ Autologous melanoma cell vaccine Phase 1 T74002 DRUGINFO D09JCH CDNA vaccine Phase 1 T74002 DRUGINFO D0F4NN CGTG-102 Phase 1 T74002 DRUGINFO D0B0VD MORAb-022 Phase 1 T74002 DRUGINFO D09CRQ RPK-739 Terminated T74002 DRUGINFO D06TJO human monoclonal antibodies (GM-CSF) Investigative T26203 TARGETID T26203 T26203 FORMERID TTDI01933 T26203 UNIPROID ICAM1_HUMAN T26203 TARGNAME Intercellular adhesion molecule ICAM-1 (ICAM1) T26203 GENENAME ICAM1 T26203 TARGTYPE Successful T26203 SYNONYMS Major group rhinovirus receptor; Intercellular adhesion molecule 1; ICAM-1; CD54 T26203 FUNCTION During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation. ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). T26203 PDBSTRUC 6EIT; 5MZA; 3TCX; 2OZ4; 1Z7Z T26203 BIOCLASS Immunoglobulin T26203 SEQUENCE MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPGNWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQGEVTRKVTVNVLSPRYEIVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP T26203 DRUGINFO D0Q9EV lifitegrast Approved T26203 DRUGINFO D0P9BT Alicaforsen Phase 3 T26203 DRUGINFO D0XH8X APC-8015F Phase 2 T26203 DRUGINFO D0Q7OE BI-505 Phase 2 T26203 DRUGINFO DP0NU9 AIC100 Phase 1 T26203 DRUGINFO D09GGO A-252444.0 Terminated T26203 DRUGINFO D0M8JF MOR-102 Terminated T26203 DRUGINFO D0RR4T GI-270384X Terminated T26203 DRUGINFO D02BRA ISIS-1939 Investigative T60433 TARGETID T60433 T60433 FORMERID TTDS00472 T60433 UNIPROID CD1A_HUMAN T60433 TARGNAME T-cell surface glycoprotein CD1a (CD1A) T60433 GENENAME CD1A T60433 TARGTYPE Successful T60433 SYNONYMS hTa1 thymocyteantigen; hTa1 thymocyte antigen; T-cell surfaceantigen T6/Leu-6; T-cell surface antigen T6/Leu-6; CD1a T60433 FUNCTION Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells. T60433 PDBSTRUC 5J1A; 4X6F; 4X6E; 4X6D; 4X6C T60433 BIOCLASS Immunoglobulin T60433 SEQUENCE MLFLLLPLLAVLPGDGNADGLKEPLSFHVTWIASFYNHSWKQNLVSGWLSDLQTHTWDSNSSTIVFLCPWSRGNFSNEEWKELETLFRIRTIRSFEGIRRYAHELQFEYPFEIQVTGGCELHSGKVSGSFLQLAYQGSDFVSFQNNSWLPYPVAGNMAKHFCKVLNQNQHENDITHNLLSDTCPRFILGLLDAGKAHLQRQVKPEAWLSHGPSPGPGHLQLVCHVSGFYPKPVWVMWMRGEQEQQGTQRGDILPSADGTWYLRATLEVAAGEAADLSCRVKHSSLEGQDIVLYWEHHSSVGFIILAVIVPLLLLIGLALWFRKRCFC T60433 DRUGINFO D0M7XS Antithymocyte globulin Approved T60433 DRUGINFO DUJ16L PF-07242813 Phase 1 T87075 TARGETID T87075 T87075 FORMERID TTDS00473 T87075 UNIPROID CD3E_HUMAN T87075 TARGNAME T-cell surface glycoprotein CD3 epsilon (CD3E) T87075 GENENAME CD3E T87075 TARGTYPE Successful T87075 SYNONYMS T3E; T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e T87075 FUNCTION When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways. In addition of this role of signal transduction in T-cell activation, CD3E plays an essential role in correct T-cell development. Initiates the TCR-CD3 complex assembly by forming the two heterodimers CD3D/CD3E and CD3G/CD3E. Participates also in internalization and cell surface down-regulation of TCR-CD3 complexes via endocytosis sequences present in CD3E cytosolic region. Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. T87075 PDBSTRUC 2ROL; 1XIW; 1SY6; 1A81 T87075 SEQUENCE MQSGTHWRVLGLCLLSVGVWGQDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPPVPNPDYEPIRKGQRDLYSGLNQRRI T87075 DRUGINFO D0C6PS Muromonab Approved T87075 DRUGINFO D0C3TI Resimmune Phase 2 T87075 DRUGINFO D0O2JI Ertumaxomab Phase 2 T87075 DRUGINFO D00YOV MT-110 Phase 1 T87075 DRUGINFO D04UWG Autologous T-cell therapy Phase 1 T88452 TARGETID T88452 T88452 FORMERID TTDS00068 T88452 UNIPROID CBG_HUMAN T88452 TARGNAME Corticosteroid-binding globulin (SERPINA6) T88452 GENENAME SERPINA6 T88452 TARGTYPE Successful T88452 SYNONYMS Transcortin; SERPINA6; CBG T88452 FUNCTION Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species. T88452 PDBSTRUC 4C49; 4C41; 4BB2; 2VDY; 2VDX T88452 BIOCLASS Serpin protein T88452 SEQUENCE MPLLLYTCLLWLPTSGLWTVQAMDPNAAYVNMSNHHRGLASANVDFAFSLYKHLVALSPKKNIFISPVSISMALAMLSLGTCGHTRAQLLQGLGFNLTERSETEIHQGFQHLHQLFAKSDTSLEMTMGNALFLDGSLELLESFSADIKHYYESEVLAMNFQDWATASRQINSYVKNKTQGKIVDLFSGLDSPAILVLVNYIFFKGTWTQPFDLASTREENFYVDETTVVKVPMMLQSSTISYLHDSELPCQLVQMNYVGNGTVFFILPDKGKMNTVIAALSRDTINRWSAGLTSSQVDLYIPKVTISGVYDLGDVLEEMGIADLFTNQANFSRITQDAQLKSSKVVHKAVLQLNEEGVDTAGSTGVTLNLTSKPIILRFNQPFIIMIFDHFTWSSLFLARVMNPV T88452 DRUGINFO D03IKT Paramethasone Approved T88452 DRUGINFO D0F1EX Alclometasone Approved T88452 DRUGINFO D0K7HU Ciclesonide Approved T88452 DRUGINFO D09TSD I-vation Phase 2 T44068 TARGETID T44068 T44068 FORMERID TTDS00036 T44068 UNIPROID ADRB1_HUMAN T44068 TARGNAME Adrenergic receptor beta-1 (ADRB1) T44068 GENENAME ADRB1 T44068 TARGTYPE Successful T44068 SYNONYMS Beta-1 adrenoreceptor; Beta-1 adrenoceptor; Beta-1 adrenergic receptor; B1AR; ADRB1R T44068 FUNCTION Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling. T44068 PDBSTRUC 2LSQ T44068 BIOCLASS GPCR rhodopsin T44068 SEQUENCE MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAGMGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVVWGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVCTVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIMAFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAPLANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFVFFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGPPPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV T44068 DRUGINFO D00IUG Levobunolol Approved T44068 DRUGINFO D01JFT Dipivefrin Approved T44068 DRUGINFO D01JGV Ajmalicine Approved T44068 DRUGINFO D01UXC Atenolol Approved T44068 DRUGINFO D02FCQ Protokylol Hydrochloride Approved T44068 DRUGINFO D02YYF Bretylium Approved T44068 DRUGINFO D03GCJ Carteolol Approved T44068 DRUGINFO D03ROX Betaxolol Approved T44068 DRUGINFO D03XTC Esmolol Approved T44068 DRUGINFO D04JEE Propranolol Approved T44068 DRUGINFO D04PHC Epinephrine Approved T44068 DRUGINFO D04VMT Sotalol Approved T44068 DRUGINFO D05SHK Nadolol Approved T44068 DRUGINFO D05UVD Timolol Approved T44068 DRUGINFO D06KYN Arbutamine Approved T44068 DRUGINFO D06VFO Anisodamine Approved T44068 DRUGINFO D07MOX Norepinephrine Approved T44068 DRUGINFO D0A6CQ Levobetaxolol Approved T44068 DRUGINFO D0F2PO Pindolol Approved T44068 DRUGINFO D0HD9K Acebutolol Approved T44068 DRUGINFO D0I2MK Metoprolol Approved T44068 DRUGINFO D0J7RK Dobutamine Approved T44068 DRUGINFO D0K3ZR Bisoprolol Approved T44068 DRUGINFO D0KD1U Practolol Approved T44068 DRUGINFO D0L5FY Metipranolol Approved T44068 DRUGINFO D0W8SB Penbutolol Approved T44068 DRUGINFO D0X2MB Oxprenolol Approved T44068 DRUGINFO D0Z1UA Nebivolol Approved T44068 DRUGINFO D05ZJG Anisodine Approved T44068 DRUGINFO D0I8FI Isoproterenol Approved T44068 DRUGINFO D03MZJ BUCINDOLOL Phase 2/3 T44068 DRUGINFO D05NZV BRL 35135 Phase 2 T44068 DRUGINFO D0H9MA COR-1 Phase 2 T44068 DRUGINFO D0P5FA Galnobax Phase 1/2 T44068 DRUGINFO D0I2XM L-796568 Phase 1 T44068 DRUGINFO D0P9KA YM-16151-4 Phase 1 T44068 DRUGINFO D01VAB Alprenolol Withdrawn from market T44068 DRUGINFO D0JP4H Bethanidine Withdrawn from market T44068 DRUGINFO D0CY4V Cetamolol Terminated T44068 DRUGINFO D04YJU L-755507 Terminated T44068 DRUGINFO D0D6AC Cebutolol Investigative T44068 DRUGINFO D0J2CR CGP 20712A Investigative T44068 DRUGINFO D02QPP (R,S)-(-)-fenoterol Investigative T44068 DRUGINFO D04JGC (R,R)-(-)-fenoterol Investigative T44068 DRUGINFO D0A9ED Carazolol Investigative T44068 DRUGINFO D0F7BV 1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol Investigative T44068 DRUGINFO D0XX5S Dichloroisoproterenol Investigative T44068 DRUGINFO D03BZW [3H]CGP12177 Investigative T44068 DRUGINFO D04HXF 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol Investigative T44068 DRUGINFO D0A4FU 1-(2-allylphenoxy)-3-morpholinopropan-2-ol Investigative T44068 DRUGINFO D0L5MW (+/-)-nantenine Investigative T44068 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T28076 TARGETID T28076 T28076 FORMERID TTDI01961 T28076 UNIPROID FGF4_HUMAN T28076 TARGNAME Fibroblast growth factor-4 (FGF4) T28076 GENENAME FGF4 T28076 TARGTYPE Successful T28076 SYNONYMS Transforming protein KS3; Heparinbinding growth factor 4; Heparin secretorytransforming protein 1; HST1; HST; HBGF4; Fibroblast growth factor 4; FGF4 T28076 FUNCTION Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal limb and cardiac valve development during embryogenesis. T28076 PDBSTRUC 1IJT T28076 BIOCLASS Heparin-binding growth factors family T28076 SEQUENCE MSGPGTAAVALLPAVLLALLAPWAGRGGAAAPTAPNGTLEAELERRWESLVALSLARLPVAAQPKEAAVQSGAGDYLLGIKRLRRLYCNVGIGFHLQALPDGRIGGAHADTRDSLLELSPVERGVVSIFGVASRFFVAMSSKGKLYGSPFFTDECTFKEILLPNNYNAYESYKYPGMFIALSKNGKTKKGNRVSPTMKVTHFLPRL T28076 DRUGINFO D0F8CM Pentosan Polysulfate Approved T28076 DRUGINFO D0ER5F Ad5FGF-4 Phase 3 T28076 DRUGINFO D0G8UL Alferminogene tadenovec Phase 3 T28076 DRUGINFO DZ0DT2 Generx Phase 3 T93440 TARGETID T93440 T93440 FORMERID TTDS00521 T93440 UNIPROID IL6RA_HUMAN; IL6RB_HUMAN T93440 TARGNAME Interleukin 6 receptor (IL6R) T93440 GENENAME IL6R; IL6ST T93440 TARGTYPE Successful T93440 SYNONYMS Membrane glycoprotein; Interleukin-6 receptor; IL-6R; IL-6 receptor T93440 FUNCTION Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity. T93440 BIOCLASS Cytokine receptor T93440 SEQUENCE MLAVGCALLAALLAAPGAALAPRRCPAQEVARGVLTSLPGDSVTLTCPGVEPEDNATVHWVLRKPAAGSHPSRWAGMGRRLLLRSVQLHDSGNYSCYRAGRPAGTVHLLVDVPPEEPQLSCFRKSPLSNVVCEWGPRSTPSLTTKAVLLVRKFQNSPAEDFQEPCQYSQESQKFSCQLAVPEGDSSFYIVSMCVASSVGSKFSKTQTFQGCGILQPDPPANITVTAVARNPRWLSVTWQDPHSWNSSFYRLRFELRYRAERSKTFTTWMVKDLQHHCVIHDAWSGLRHVVQLRAQEEFGQGEWSEWSPEAMGTPWTESRSPPAENEVSTPMQALTTNKDDDNILFRDSANATSLPVQDSSSVPLPTFLVAGGSLAFGTLLCIAIVLRFKKTWKLRALKEGKTSMHPPYSLGQLVPERPRPTPVLVPLISPPVSPSSLGSDNTSSHNRPDARDPRSPYDISNTDYFFPR T93440 DRUGINFO D08HPZ Tocilizumab Approved T93440 DRUGINFO D0Z8CQ Sarilumab Approved T93440 DRUGINFO D09HTB SAR153191 Phase 3 T93440 DRUGINFO D0Y1ZU SA-237 Phase 3 T93440 DRUGINFO D01XVF Sirukumab Phase 3 T93440 DRUGINFO D05NIR ALX-0061 Phase 2 T93440 DRUGINFO D9J6XV Vobarilizumab Phase 2 T93440 DRUGINFO D0G0UZ SBP-002 Terminated T93440 DRUGINFO D07CIX FM-101 Investigative T93440 DRUGINFO D07VQW Sant7 Investigative T93440 DRUGINFO D09PLZ NI-1201 Investigative T93440 DRUGINFO D07LUR Alpha-D-Mannose Investigative T11448 TARGETID T11448 T11448 FORMERID TTDS00032 T11448 UNIPROID ADA2A_HUMAN T11448 TARGNAME Adrenergic receptor alpha-2A (ADRA2A) T11448 GENENAME ADRA2A T11448 TARGTYPE Successful T11448 SYNONYMS Alpha-2AAR; Alpha-2A adrenoreceptor; Alpha-2A adrenoceptor; Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptor subtype C10; ADRAR; ADRA2R T11448 FUNCTION The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol. Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. T11448 PDBSTRUC 1HOF; 1HOD; 1HO9; 1HLL T11448 BIOCLASS GPCR rhodopsin T11448 SEQUENCE MFRQEQPLAEGSFAPMGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFTSRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSSIVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGGPQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVAAPPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSDHAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKASRWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSSLNPVIYTIFNHDFRRAFKKILCRGDRKRIV T11448 DRUGINFO D0WD8M Connexyn Approved T11448 DRUGINFO D0K0MW Lofexidine Approved T11448 DRUGINFO D0E9PK MOXONIDINE Approved T11448 DRUGINFO DJC4L7 A295 IND submitted T11448 DRUGINFO D8NY3J Guanfacine Phase 3 T11448 DRUGINFO D0F2ML MEDETOMIDINE Phase 2 T11448 DRUGINFO D0AI8V DSP-1200 Phase 1 T11448 DRUGINFO D0ZI0K NMI-870 Discontinued in Phase 2 T11448 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T11448 DRUGINFO D0KC5X S-18616 Terminated T11448 DRUGINFO D08OWQ SK&F-104078 Terminated T11448 DRUGINFO D03QMR WB-4101 Terminated T11448 DRUGINFO D06HRY SNAP-5089 Terminated T11448 DRUGINFO D0K9JP A-80426 Terminated T11448 DRUGINFO D01SRL 7-Nitro-1,2,3,4-tetrahydro-isoquinoline Investigative T11448 DRUGINFO D01SRS 3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline Investigative T11448 DRUGINFO D03DMN AKUAMMIGINE Investigative T11448 DRUGINFO D08OLL BRL 44408 Investigative T11448 DRUGINFO D0H1WR SK&F-29661 Investigative T11448 DRUGINFO D05QTJ Chloroethylclonidine Investigative T11448 DRUGINFO D0S4VR (1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine Investigative T11448 DRUGINFO D0ZC4S (1H-Imidazol-2-yl)-quinoxalin-6-yl-amine Investigative T11448 DRUGINFO D02KIS (S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline Investigative T11448 DRUGINFO D02QXT 8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline Investigative T11448 DRUGINFO D03EPY 1,2,3,4-tetrahydroisoquinoline Investigative T11448 DRUGINFO D03HBZ (3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine Investigative T11448 DRUGINFO D03LRY C-(6-Methoxy-naphthalen-1-yl)-methylamine Investigative T11448 DRUGINFO D04PYQ PIPEROXAN Investigative T11448 DRUGINFO D04RBQ 1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol Investigative T11448 DRUGINFO D06BWZ MEZILAMINE Investigative T11448 DRUGINFO D06SYS METHYLNORADRENALINE Investigative T11448 DRUGINFO D07ICV GNF-PF-3878 Investigative T11448 DRUGINFO D07RLW 5-Aminomethyl-naphthalen-2-ol Investigative T11448 DRUGINFO D07SYG 2,3-Dihydro-1H-isoindole Investigative T11448 DRUGINFO D08ZRA C-Naphthalen-1-yl-methylamine Investigative T11448 DRUGINFO D09JZG 1,2,3,4,5,6-Hexahydro-benzo[c]azocine Investigative T11448 DRUGINFO D0AE9M Butyl-indol-1-yl-pyridin-4-yl-amine Investigative T11448 DRUGINFO D0B2BO 6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene Investigative T11448 DRUGINFO D0C9DC SK&F-64139 Investigative T11448 DRUGINFO D0D1RU Indol-1-yl-pyridin-4-yl-amine Investigative T11448 DRUGINFO D0E0KG (R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline Investigative T11448 DRUGINFO D0E3OL GNF-PF-2857 Investigative T11448 DRUGINFO D0E8HU 3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline Investigative T11448 DRUGINFO D0F5TA Ethyl-indol-1-yl-pyridin-4-yl-amine Investigative T11448 DRUGINFO D0K0KR AR-129330 Investigative T11448 DRUGINFO D0L7IZ JP1302 Investigative T11448 DRUGINFO D0M8FL 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine Investigative T11448 DRUGINFO D0P3HP 1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline Investigative T11448 DRUGINFO D0P8BE (3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine Investigative T11448 DRUGINFO D0QH0X 2,3,4,5-Tetrahydro-1H-benzo[c]azepine Investigative T11448 DRUGINFO D0QO8X 1,2,3,4-Tetrahydro-isoquinolin-7-ol Investigative T11448 DRUGINFO D0R1XT Indol-1-yl-methyl-pyridin-4-yl-amine Investigative T11448 DRUGINFO D0TN2R 3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline Investigative T11448 DRUGINFO D0V0NJ 2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine Investigative T11448 DRUGINFO D0V3IT SNAP-5150 Investigative T11448 DRUGINFO D0W5IN (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine Investigative T11448 DRUGINFO D0Y8DJ (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol Investigative T11448 DRUGINFO D0Z7XI 3-Methyl-1,2,3,4-tetrahydro-isoquinoline Investigative T11448 DRUGINFO D0ZS3M Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine Investigative T11448 DRUGINFO D0ZT8D Tramazoline Investigative T11448 DRUGINFO D08UDY 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl Investigative T11448 DRUGINFO D0I3XA Ciproxifan Investigative T11448 DRUGINFO D0MH0S 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine Investigative T11448 DRUGINFO D06HHJ (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine Investigative T11448 DRUGINFO D07JMN 1-(pyridin-2-yl)piperazine Investigative T11448 DRUGINFO D09BIV TRACIZOLINE Investigative T11448 DRUGINFO D0A6GK (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine Investigative T11448 DRUGINFO D0FU5E S-34324 Investigative T11448 DRUGINFO D0H3NA 4-Benzo[b]thiophen-4-yl-1H-imidazole Investigative T11448 DRUGINFO D0LI3J 2-BFi Investigative T11448 DRUGINFO D03LPH TRYPTOLINE Investigative T11448 DRUGINFO D05GDP 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T11448 DRUGINFO D08KLH [3H]RX821002 Investigative T11448 DRUGINFO D0C1SE 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole Investigative T11448 DRUGINFO D0L9WN 4-(4-Methyl-indan-1-yl)-1H-imidazole Investigative T11448 DRUGINFO D0P5PW 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole Investigative T11448 DRUGINFO D01KAX 1-((S)-2-aminopropyl)-1H-indazol-6-ol Investigative T11448 DRUGINFO D0R7ZC Beta-methoxyamphetamine Investigative T11448 DRUGINFO D0PN9R R-226161 Investigative T11448 DRUGINFO D0L5MW (+/-)-nantenine Investigative T11448 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T31621 TARGETID T31621 T31621 FORMERID TTDR00567 T31621 UNIPROID FGF2_HUMAN T31621 TARGNAME Fibroblast growth factor-2 (FGF2) T31621 GENENAME FGF2 T31621 TARGTYPE Successful T31621 SYNONYMS bFGF; Heparin-binding growth factor 2; HBGF-2; Fibroblast growth factor 2; FGFB; FGF-2; Basic fibroblast growth factor T31621 FUNCTION Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signaling. Binds to integrin ITGAV:ITGB3. Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration. Functions as a potent mitogen in vitro. Can induce angiogenesis. T31621 PDBSTRUC 5X1O; 4OEG; 4OEF; 4OEE; 4FGF T31621 BIOCLASS Growth factor T31621 SEQUENCE MVGVGGGDVEDVTPRPGGCQISGRGARGCNGIPGAAAWEAALPRRRPRRHPSVNPRSRAAGSPRTRGRRTEERPSGSRLGDRGRGRALPGGRLGGRGRGRAPERVGGRGRGRGTAAPRAAPAARGSRPGPAGTMAAGSITTLPALPEDGGSGAFPPGHFKDPKRLYCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEERGVVSIKGVCANRYLAMKEDGRLLASKCVTDECFFFERLESNNYNTYRSRKYTSWYVALKRTGQYKLGSKTGPGQKAILFLPMSAKS T31621 DRUGINFO D06ULU Sucralfate Approved T31621 DRUGINFO D07PVB Squalamine Phase 3 T31621 DRUGINFO D00IZD DVC1-0101 Phase 2 T31621 DRUGINFO D05ISO Bemarituzumab Phase 2 T31621 DRUGINFO D06NND FPA144 Phase 1 T31621 DRUGINFO D0B4XU TGP-580 Discontinued in Phase 2 T31621 DRUGINFO D09ZAV RG-8803 Terminated T31621 DRUGINFO D0KL1I 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid Investigative T31621 DRUGINFO D0X4AL 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid Investigative T31621 DRUGINFO D0N1RE BIBF100 Investigative T31621 DRUGINFO D0B0SV N,O6-Disulfo-Glucosamine Investigative T31621 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T19615 TARGETID T19615 T19615 FORMERID TTDR01234 T19615 UNIPROID CSF3_HUMAN T19615 TARGNAME Granulocyte colony-stimulating factor (CSF3) T19615 GENENAME CSF3 T19615 TARGTYPE Successful T19615 SYNONYMS Pluripoietin; Lenograstim; G-CSF; CSF3 T19615 FUNCTION Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes. T19615 PDBSTRUC 5ZO6; 5GW9; 2D9Q; 1RHG; 1PGR T19615 BIOCLASS Cytokine: interleukin T19615 SEQUENCE MAGPATQSPMKLMALQLLLWHSALWTVQEATPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLVSECATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP T19615 DRUGINFO D07BUH Efbemalenograstim Approved T19615 DRUGINFO D0CH1U Interleukin-3 Approved T19615 DRUGINFO D0FP8S Neugranin Preregistration T19615 DRUGINFO D01REE DA-3031 Phase 3 T19615 DRUGINFO D07FPJ MK-4214 Phase 3 T19615 DRUGINFO D07JZT LA-EP2006 Phase 3 T24634 TARGETID T24634 T24634 FORMERID TTDS00233 T24634 UNIPROID MURA_ECOLI T24634 TARGNAME Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) T24634 GENENAME Bact murA T24634 TARGTYPE Successful T24634 SYNONYMS UDP-N-acetylglucosamine enolpyruvyl transferase; UDP-GlcNAcenolpyruvyl transferase; MurA protein; MurA; Enoylpyruvate transferase; EPT T24634 FUNCTION Cell wall formation. Adds enolpyruvyl to UDP-n- acetylglucosamine. Target for the antibiotic phosphomycin. T24634 PDBSTRUC 3SWD; 3KR6; 3KQJ; 3ISS; 2Z2C T24634 BIOCLASS Alkyl aryl transferase T24634 SEQUENCE MDKFRVQGPTKLQGEVTISGAKNAALPILFAALLAEEPVEIQNVPKLKDVDTSMKLLSQLGAKVERNGSVHIDARDVNVFCAPYDLVKTMRASIWALGPLVARFGQGQVSLPGGCTIGARPVDLHISGLEQLGATIKLEEGYVKASVDGRLKGAHIVMDKVSVGATVTIMCAATLAEGTTIIENAAREPEIVDTANFLITLGAKISGQGTDRIVIEGVERLGGGVYRVLPDRIETGTFLVAAAISRGKIICRNAQPDTLDAVLAKLRDAGADIEVGEDWISLDMHGKRPKAVNVRTAPHPAFPTDMQAQFTLLNLVAEGTGFITETVFENRFMHVPELSRMGAHAEIESNTVICHGVEKLSGAQVMATDLRASASLVLAGCIAEGTTVVDRIYHIDRGYERIEDKLRALGANIERVKGE T24634 DRUGINFO D01GYT Fosfomycin Approved T24634 DRUGINFO D04SDN RWJ-3981 Investigative T24634 DRUGINFO D05BIJ RWJ-140998 Investigative T24634 DRUGINFO D06FHW Aminomethylcyclohexane Investigative T24634 DRUGINFO D06HIW EUPATORIOPICRIN Investigative T24634 DRUGINFO D09RZX CNICIN Investigative T24634 DRUGINFO D0E9IM L-Iso-Aspartate Investigative T24634 DRUGINFO D0G2MM Cyclohexylammonium Ion Investigative T24634 DRUGINFO D0S2TZ CYNAROPICRIN Investigative T24634 DRUGINFO D0KC2Z Uridine-Diphosphate-N-Acetylglucosamine Investigative T61657 TARGETID T61657 T61657 FORMERID TTDR01191 T61657 UNIPROID RARB_HUMAN T61657 TARGNAME Retinoic acid receptor beta (RARB) T61657 GENENAME RARB T61657 TARGTYPE Successful T61657 SYNONYMS RAR-epsilon; RAR-beta; Nuclear receptor subfamily 1 group B member 2; NR1B2; HBV-activated protein; HAP T61657 FUNCTION Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function. Receptor for retinoic acid. T61657 PDBSTRUC 5UAN; 4JYI; 4JYH; 4JYG; 4DM8 T61657 BIOCLASS Nuclear hormone receptor T61657 SEQUENCE MTTSGHACPVPAVNGHMTHYPATPYPLLFPPVIGGLSLPPLHGLHGHPPPSGCSTPSPATIETQSTSSEELVPSPPSPLPPPRVYKPCFVCQDKSSGYHYGVSACEGCKGFFRRSIQKNMIYTCHRDKNCVINKVTRNRCQYCRLQKCFEVGMSKESVRNDRNKKKKETSKQECTESYEMTAELDDLTEKIRKAHQETFPSLCQLGKYTTNSSADHRVRLDLGLWDKFSELATKCIIKIVEFAKRLPGFTGLTIADQITLLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFTFANQLLPLEMDDTETGLLSAICLICGDRQDLEEPTKVDKLQEPLLEALKIYIRKRRPSKPHMFPKILMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGHEPLTPSSSGNTAEHSPSISPSSVENSGVSQSPLVQ T61657 DRUGINFO D0G3PI Alitretinoin Approved T61657 DRUGINFO D02GTY Tamibarotene Phase 3 T61657 DRUGINFO D0E2AD PMID27336223-Compound-10 Patented T61657 DRUGINFO D0M5EC PMID27336223-Compound-8 Patented T61657 DRUGINFO D0PU1L PMID27336223-Compound-7 Patented T61657 DRUGINFO D05QYR AC55649 Investigative T61657 DRUGINFO D09RNF BMS641 Investigative T61657 DRUGINFO D09RRF AC261066 Investigative T61657 DRUGINFO D0G6JM TTNPB Investigative T61657 DRUGINFO D0F8CC CD666 Investigative T61657 DRUGINFO D0Q0IR AGN193109 Investigative T79591 TARGETID T79591 T79591 FORMERID TTDS00381 T79591 UNIPROID THA_HUMAN T79591 TARGNAME Thyroid hormone receptor alpha (THRA) T79591 GENENAME THRA T79591 TARGTYPE Successful T79591 SYNONYMS V-erbA-related protein 7; THRA2; THRA1; Nuclear receptor subfamily 1 group A member 1; NR1A1; ERBA1; EAR7; EAR-7; C-erbA-alpha; C-erbA-1 T79591 FUNCTION High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine. Isoform Alpha-1: Nuclear hormone receptor that can act as a repressor or activator of transcription. T79591 PDBSTRUC 4LNX; 4LNW; 3JZB; 3ILZ; 3HZF T79591 BIOCLASS Nuclear hormone receptor T79591 SEQUENCE MEQKPSKVECGSDPEENSARSPDGKRKRKNGQCSLKTSMSGYIPSYLDKDEQCVVCGDKATGYHYRCITCEGCKGFFRRTIQKNLHPTYSCKYDSCCVIDKITRNQCQLCRFKKCIAVGMAMDLVLDDSKRVAKRKLIEQNRERRRKEEMIRSLQQRPEPTPEEWDLIHIATEAHRSTNAQGSHWKQRRKFLPDDIGQSPIVSMPDGDKVDLEAFSEFTKIITPAITRVVDFAKKLPMFSELPCEDQIILLKGCCMEIMSLRAAVRYDPESDTLTLSGEMAVKREQLKNGGLGVVSDAIFELGKSLSAFNLDDTEVALLQAVLLMSTDRSGLLCVDKIEKSQEAYLLAFEHYVNHRKHNIPHFWPKLLMKEREVQSSILYKGAAAEGRPGGSLGVHPEGQQLLGMHVVQGPQVRQLEQQLGEAGSLQGPVLQHQSPKSPQQRLLELLHRSGILHARAVCGEDDSSEADSPSSSEEEPEVCEDLAGNAASP T79591 DRUGINFO D06RGG Levothyroxine Approved T79591 DRUGINFO D0S6JG Liothyronine Approved T79591 DRUGINFO D03TPR Dextrothyroxine Sodium Approved T79591 DRUGINFO D03KVY BCT303 Phase 2 T79591 DRUGINFO D0J6XC tiratricol Clinical trial T79591 DRUGINFO D01HAZ 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one Investigative T79591 DRUGINFO D01NTN 3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid Investigative T79591 DRUGINFO D03VOM 3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one Investigative T79591 DRUGINFO D04FQZ 4-(4-hexylphenyl)-4-oxobut-2-enoic acid Investigative T79591 DRUGINFO D05FRX (3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid Investigative T79591 DRUGINFO D06IJW 1-(4-hexylphenyl)-3-morpholinopropan-1-one Investigative T79591 DRUGINFO D09XOC 3-bromo-1-(4-hexylphenyl)propan-1-one Investigative T79591 DRUGINFO D0I2GK Detrothyronine Investigative T79591 DRUGINFO D0I7DH (E)-1-(4-heptylphenyl)but-2-en-1-one Investigative T79591 DRUGINFO D0J0MD (Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid Investigative T79591 DRUGINFO D0Q0YS rT3 Investigative T79591 DRUGINFO D0Q9ZN 3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid Investigative T79591 DRUGINFO D0ZX0Y 4-hexylphenyl propiolate Investigative T98933 TARGETID T98933 T98933 FORMERID TTDR01227 T98933 UNIPROID THB_HUMAN T98933 TARGNAME Thyroid hormone receptor beta (THRB) T98933 GENENAME THRB T98933 TARGTYPE Successful T98933 SYNONYMS c-erbA-beta; c-erbA-2; THR1; Nuclear receptor subfamily 1 group A member 2; NR1A2; ERBA2 T98933 FUNCTION High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine. Nuclear hormone receptor that can act as a repressor or activator of transcription. T98933 PDBSTRUC 4ZO1; 3JZC; 3IMY; 3GWS; 3D57 T98933 BIOCLASS Nuclear hormone receptor T98933 SEQUENCE MTPNSMTENGLTAWDKPKHCPDREHDWKLVGMSEACLHRKSHSERRSTLKNEQSSPHLIQTTWTSSIFHLDHDDVNDQSVSSAQTFQTEEKKCKGYIPSYLDKDELCVVCGDKATGYHYRCITCEGCKGFFRRTIQKNLHPSYSCKYEGKCVIDKVTRNQCQECRFKKCIYVGMATDLVLDDSKRLAKRKLIEENREKRRREELQKSIGHKPEPTDEEWELIKTVTEAHVATNAQGSHWKQKRKFLPEDIGQAPIVNAPEGGKVDLEAFSHFTKIITPAITRVVDFAKKLPMFCELPCEDQIILLKGCCMEIMSLRAAVRYDPESETLTLNGEMAVTRGQLKNGGLGVVSDAIFDLGMSLSSFNLDDTEVALLQAVLLMSSDRPGLACVERIEKYQDSFLLAFEHYINYRKHHVTHFWPKLLMKVTDLRMIGACHASRFLHMKVECPTELFPPLFLEVFED T98933 DRUGINFO D03TPR Dextrothyroxine Sodium Approved T98933 DRUGINFO D03MYO MGL-3196 Phase 2 T98933 DRUGINFO D07ZTD MB-07811 Phase 2 T98933 DRUGINFO D0E7AK VK-2809 Phase 2 T98933 DRUGINFO D03KVY BCT303 Phase 2 T98933 DRUGINFO D05DCL ZYT-1 Phase 1 T98933 DRUGINFO D0V5FQ Axitirome Phase 1 T98933 DRUGINFO DJ74CB VK-0214 Phase 1 T98933 DRUGINFO D0J6XC tiratricol Clinical trial T98933 DRUGINFO D02CGG 2-hexylphenyl acrylate Investigative T98933 DRUGINFO D03XCG 1-(4-hexylphenyl)-3-(propylamino)propan-1-one Investigative T98933 DRUGINFO D05XMM 4-(3-(Dimethylamino)propanoyl)-N-hexylbenzamide Investigative T98933 DRUGINFO D05ZJC (3,5-Dibromo-4-butoxy-phenyl)-acetic acid Investigative T98933 DRUGINFO D06WJC GC-24 Investigative T98933 DRUGINFO D08BQI (3,5-Dibromo-4-pentyloxy-phenyl)-acetic acid Investigative T98933 DRUGINFO D0G7HF (4-hexylphenyl)(oxiran-2-yl)methanone Investigative T98933 DRUGINFO D0H6BV 1-(4-(Hexyloxy)phenyl)-3-morpholinopropan-1-one Investigative T98933 DRUGINFO D0U0GY 1-(4-heptylphenyl)prop-2-en-1-one Investigative T98933 DRUGINFO D0U9JC 1-(4-octylphenyl)prop-2-en-1-one Investigative T98933 DRUGINFO D0YU9Z 1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE Investigative T98933 DRUGINFO D01HAZ 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one Investigative T98933 DRUGINFO D01NTN 3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid Investigative T98933 DRUGINFO D03VOM 3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one Investigative T98933 DRUGINFO D04FQZ 4-(4-hexylphenyl)-4-oxobut-2-enoic acid Investigative T98933 DRUGINFO D05FRX (3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid Investigative T98933 DRUGINFO D06IJW 1-(4-hexylphenyl)-3-morpholinopropan-1-one Investigative T98933 DRUGINFO D07MAF 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one Investigative T98933 DRUGINFO D09XOC 3-bromo-1-(4-hexylphenyl)propan-1-one Investigative T98933 DRUGINFO D0I2GK Detrothyronine Investigative T98933 DRUGINFO D0I7DH (E)-1-(4-heptylphenyl)but-2-en-1-one Investigative T98933 DRUGINFO D0J0MD (Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid Investigative T98933 DRUGINFO D0Q0YS rT3 Investigative T98933 DRUGINFO D0Q9ZN 3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid Investigative T98933 DRUGINFO D0ZX0Y 4-hexylphenyl propiolate Investigative T98933 DRUGINFO D09TVP Cacodylate Ion Investigative T02333 TARGETID T02333 T02333 FORMERID TTDS00076 T02333 UNIPROID GHR_HUMAN T02333 TARGNAME Growth hormone receptor (GHR) T02333 GENENAME GHR T02333 TARGTYPE Successful T02333 SYNONYMS Somatotropin receptor; Serum bindingprotein; GH receptor T02333 FUNCTION On ligand binding, couples to the JAK2/STAT5 pathway. Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. T02333 PDBSTRUC 5OHD; 5OEK; 3HHR; 2AEW; 1KF9 T02333 BIOCLASS Cytokine receptor T02333 SEQUENCE MDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPERETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTSIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRNADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNYGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEESDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGEADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSSLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADAKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHIVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP T02333 DRUGINFO D0D6VE Pegvisomant Approved T02333 DRUGINFO D0P4DJ Somatropin recombinant Approved T02333 DRUGINFO D05ECK SKF-110679 Phase 2 T02333 DRUGINFO D0K1SR PH-794428 Phase 2 T02333 DRUGINFO DU26QH IONIS-GHR-LRx Phase 2 T02333 DRUGINFO D03MWZ Syntropin Phase 1 T02333 DRUGINFO D0O1LU EP-51389 Phase 1 T02333 DRUGINFO D0Z6WI EP-51216 Phase 1 T02333 DRUGINFO D0O7XO AOD-9604 Discontinued in Phase 2 T02333 DRUGINFO D00LWR BVT-A Preclinical T02333 DRUGINFO D0BW2C NNC-26-0194 Investigative T06455 TARGETID T06455 T06455 FORMERID TTDR01443 T06455 UNIPROID CP2A6_HUMAN T06455 TARGNAME Cytochrome P450 2A6 (CYP2A6) T06455 GENENAME CYP2A6 T06455 TARGTYPE Successful T06455 SYNONYMS Cytochrome P450(I); Cytochrome P450 IIA3; Coumarin 7-hydroxylase; CYPIIA6; CYP2A6; CYP2A3 T06455 FUNCTION Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Possesses low phenacetin O-deethylation activity. T06455 PDBSTRUC 4RUI; 4EJJ; 3T3R; 3T3Q; 3EBS T06455 BIOCLASS Paired donor oxygen oxidoreductase T06455 ECNUMBER EC 1.14.13.- T06455 SEQUENCE MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMKISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSNGERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDALRGTGGANIDPTFFLSRTVSNVISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQLLQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFIGGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVYPMLGSVLRDPSFFSNPQDFNPQHFLNEKGQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGFATIPRNYTMSFLPR T06455 DRUGINFO D08SKH Methoxsalen Approved T37510 TARGETID T37510 T37510 FORMERID TTDS00204 T37510 UNIPROID FA5_HUMAN T37510 TARGNAME Coagulation factor Va (F5) T37510 GENENAME F5 T37510 TARGTYPE Successful T37510 SYNONYMS Factor Va; F5 T37510 FUNCTION Central regulator of hemostasis. It serves as a critical cofactor for the prothrombinase activity of factor Xa that results in the activation of prothrombin to thrombin. T37510 PDBSTRUC 3S9C; 3P70; 3P6Z; 1Y61; 1FV4 T37510 SEQUENCE MFPGCPRLWVLVVLGTSWVGWGSQGTEAAQLRQFYVAAQGISWSYRPEPTNSSLNLSVTSFKKIVYREYEPYFKKEKPQSTISGLLGPTLYAEVGDIIKVHFKNKADKPLSIHPQGIRYSKLSEGASYLDHTFPAEKMDDAVAPGREYTYEWSISEDSGPTHDDPPCLTHIYYSHENLIEDFNSGLIGPLLICKKGTLTEGGTQKTFDKQIVLLFAVFDESKSWSQSSSLMYTVNGYVNGTMPDITVCAHDHISWHLLGMSSGPELFSIHFNGQVLEQNHHKVSAITLVSATSTTANMTVGPEGKWIISSLTPKHLQAGMQAYIDIKNCPKKTRNLKKITREQRRHMKRWEYFIAAEEVIWDYAPVIPANMDKKYRSQHLDNFSNQIGKHYKKVMYTQYEDESFTKHTVNPNMKEDGILGPIIRAQVRDTLKIVFKNMASRPYSIYPHGVTFSPYEDEVNSSFTSGRNNTMIRAVQPGETYTYKWNILEFDEPTENDAQCLTRPYYSDVDIMRDIASGLIGLLLICKSRSLDRRGIQRAADIEQQAVFAVFDENKSWYLEDNINKFCENPDEVKRDDPKFYESNIMSTINGYVPESITTLGFCFDDTVQWHFCSVGTQNEILTIHFTGHSFIYGKRHEDTLTLFPMRGESVTVTMDNVGTWMLTSMNSSPRSKKLRLKFRDVKCIPDDDEDSYEIFEPPESTVMATRKMHDRLEPEDEESDADYDYQNRLAAALGIRSFRNSSLNQEEEEFNLTALALENGTEFVSSNTDIIVGSNYSSPSNISKFTVNNLAEPQKAPSHQQATTAGSPLRHLIGKNSVLNSSTAEHSSPYSEDPIEDPLQPDVTGIRLLSLGAGEFKSQEHAKHKGPKVERDQAAKHRFSWMKLLAHKVGRHLSQDTGSPSGMRPWEDLPSQDTGSPSRMRPWKDPPSDLLLLKQSNSSKILVGRWHLASEKGSYEIIQDTDEDTAVNNWLISPQNASRAWGESTPLANKPGKQSGHPKFPRVRHKSLQVRQDGGKSRLKKSQFLIKTRKKKKEKHTHHAPLSPRTFHPLRSEAYNTFSERRLKHSLVLHKSNETSLPTDLNQTLPSMDFGWIASLPDHNQNSSNDTGQASCPPGLYQTVPPEEHYQTFPIQDPDQMHSTSDPSHRSSSPELSEMLEYDRSHKSFPTDISQMSPSSEHEVWQTVISPDLSQVTLSPELSQTNLSPDLSHTTLSPELIQRNLSPALGQMPISPDLSHTTLSPDLSHTTLSLDLSQTNLSPELSQTNLSPALGQMPLSPDLSHTTLSLDFSQTNLSPELSHMTLSPELSQTNLSPALGQMPISPDLSHTTLSLDFSQTNLSPELSQTNLSPALGQMPLSPDPSHTTLSLDLSQTNLSPELSQTNLSPDLSEMPLFADLSQIPLTPDLDQMTLSPDLGETDLSPNFGQMSLSPDLSQVTLSPDISDTTLLPDLSQISPPPDLDQIFYPSESSQSLLLQEFNESFPYPDLGQMPSPSSPTLNDTFLSKEFNPLVIVGLSKDGTDYIEIIPKEEVQSSEDDYAEIDYVPYDDPYKTDVRTNINSSRDPDNIAAWYLRSNNGNRRNYYIAAEEISWDYSEFVQRETDIEDSDDIPEDTTYKKVVFRKYLDSTFTKRDPRGEYEEHLGILGPIIRAEVDDVIQVRFKNLASRPYSLHAHGLSYEKSSEGKTYEDDSPEWFKEDNAVQPNSSYTYVWHATERSGPESPGSACRAWAYYSAVNPEKDIHSGLIGPLLICQKGILHKDSNMPMDMREFVLLFMTFDEKKSWYYEKKSRSSWRLTSSEMKKSHEFHAINGMIYSLPGLKMYEQEWVRLHLLNIGGSQDIHVVHFHGQTLLENGNKQHQLGVWPLLPGSFKTLEMKASKPGWWLLNTEVGENQRAGMQTPFLIMDRDCRMPMGLSTGIISDSQIKASEFLGYWEPRLARLNNGGSYNAWSVEKLAAEFASKPWIQVDMQKEVIITGIQTQGAKHYLKSCYTTEFYVAYSSNQINWQIFKGNSTRNVMYFNGNSDASTIKENQFDPPIVARYIRISPTRAYNRPTLRLELQGCEVNGCSTPLGMENGKIENKQITASSFKKSWWGDYWEPFRARLNAQGRVNAWQAKANNNKQWLEIDLLKIKKITAIITQGCKSLSSEMYVKSYTIHYSEQGVEWKPYRLKSSMVDKIFEGNTNTKGHVKNFFNPPIISRFIRVIPKTWNQSIALRLELFGCDIY T37510 DRUGINFO D0PG0G Drotrecogin alfa Approved T37510 DRUGINFO D0MY1A Phenylmercury Investigative T37510 DRUGINFO D0ON2Z RAZAXABAN Investigative T22212 TARGETID T22212 T22212 FORMERID TTDS00515 T22212 UNIPROID FCG2A_HUMAN T22212 TARGNAME Immunoglobulin gamma Fc receptor IIA (FCGR2A) T22212 GENENAME FCGR2A T22212 TARGTYPE Successful T22212 SYNONYMS Low affinity immunoglobulin gamma Fc region receptor II-a; IgG Fc receptor II-a; FcRII-a; Fc-gamma-RIIa; Fc-gamma RII-a; FCGR2A1; FCG2A; CDw32 A; CD32 A T22212 FUNCTION Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens. T22212 PDBSTRUC 3RY6; 3RY5; 3RY4; 3D5O; 1H9V T22212 BIOCLASS Immunoglobulin T22212 SEQUENCE MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTLTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDDKNIYLTLPPNDHVNSNN T22212 DRUGINFO D0H6VY SM-101 Approved (orphan drug) T55654 TARGETID T55654 T55654 FORMERID TTDNS00605 T55654 UNIPROID CFTR_HUMAN T55654 TARGNAME cAMP-dependent chloride channel (CFTR) T55654 GENENAME CFTR T55654 TARGTYPE Successful T55654 SYNONYMS cAMPdependent chloride channel; Cystic fibrosis transmembrane conductance regulator; Channel conductancecontrolling ATPase; ATPbinding cassette subfamily C member 7; ATP-binding cassette sub-family C member 7; ABCC7 T55654 FUNCTION Mediates the transport of chloride ions across the cell membrane. Channel activity is coupled to ATP hydrolysis. The ion channel is also permeable to HCO(3-); selectivity depends on the extracellular chloride concentration. Exerts its function also by modulating the activity of other ion channels and transporters. Plays an important role in airway fluid homeostasis. Contributes to the regulation of the pH and the ion content of the airway surface fluid layer and thereby plays an important role in defense against pathogens. Modulates the activity of the epithelial sodium channel (ENaC) complex, in part by regulating the cell surface expression of the ENaC complex. Inhibits the activity of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G. Inhibits the activity of the ENaC channel containing subunits SCNN1D, SCNN1B and SCNN1G, but not of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the transporter SLC4A7. Can inhibit the chloride channel activity of ANO1. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation. Epithelial ion channel that plays an important role in the regulation of epithelial ion and water transport and fluid homeostasis. T55654 PDBSTRUC 6MSM; 6HEP; 5UAK; 5TGK; 5TFJ T55654 BIOCLASS ABC transporter T55654 ECNUMBER EC 5.6.1.6 T55654 SEQUENCE MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELASKKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIAIYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQTWYDSLGAINKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRFSLEGDAPVSWTETKKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQMNGIEEDSDEPLERRLSLVPDSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQGQNIHRKTTASTRKVSLAPQANLTELDIYSRRLSQETGLEISEEINEEDLKECFFDDMESIPAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAASLVVLWLLGNTPLQDKGNSTHSRNNSYAVIITSTSSYYVFYIYVGVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVLQAPMSTLNTLKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYFLQTSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHKALNLHTANWFLYLSTLRWFQMRIEMIFVIFFIAVTFISILTTGEGEGRVGIILTLAMNIMSTLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYKNGQLSKVMIIENSHVKKDDIWPSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLSAFLRLLNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVADEVGLRSVIEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPVTYQIIRRTLKQAFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQAISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEVQDTRL T55654 DRUGINFO D0E1HC Tezacaftor and ivacaftor Approved T55654 DRUGINFO D0W7WC Ivacaftor Approved T55654 DRUGINFO D09VXM Crofelemer Approved T55654 DRUGINFO D0S9WB Lumacaftor + ivacaftor Approved T55654 DRUGINFO D0Z5HR VX-661 Phase 3 T55654 DRUGINFO D01DGZ ABBV-2222 Phase 2 T55654 DRUGINFO D0E0JO GLPG-1837 Phase 2 T55654 DRUGINFO D0N4PW iOWH032 Phase 2 T55654 DRUGINFO D0X0CB Lumacaftor Phase 2 T55654 DRUGINFO DFV1I4 QBW251 Phase 2 T55654 DRUGINFO D0A1YF ABBV-3067 Phase 1 T55654 DRUGINFO D0U0QC ABBV-2737 Phase 1 T55654 DRUGINFO D0VT6X ABBV-2451 Phase 1 T55654 DRUGINFO D62RIY VX-522 Phase 1 T55654 DRUGINFO D03PGV phenylglycine-01 Investigative T55654 DRUGINFO D04ZIP CBIQ Investigative T55654 DRUGINFO D05PDF sulfonamide-01 Investigative T55654 DRUGINFO D0C6YC UCCF-339 Investigative T55654 DRUGINFO D0P3ZK CFTRinh-172 Investigative T55654 DRUGINFO D0S0NB UCCF-853 Investigative T55654 DRUGINFO D0S1FV GlyH-101 Investigative T55654 DRUGINFO D0T9DI UCCF-029 Investigative T20514 TARGETID T20514 T20514 FORMERID TTDS00342 T20514 UNIPROID HEM2_HUMAN T20514 TARGNAME Delta-aminolevulinic acid dehydratase (ALAD) T20514 GENENAME ALAD T20514 TARGTYPE Successful T20514 SYNONYMS Porphobilinogen synthase; Delta-aminolevulinate dehydratase; ALADH; ALAD T20514 FUNCTION Catalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen. T20514 PDBSTRUC 5HNR; 5HMS; 1PV8; 1.00E+51 T20514 BIOCLASS Alpha-carbonic anhydrase T20514 ECNUMBER EC 4.2.1.24 T20514 SEQUENCE MQPQSVLHSGYFHPLLRAWQTATTTLNASNLIYPIFVTDVPDDIQPITSLPGVARYGVKRLEEMLRPLVEEGLRCVLIFGVPSRVPKDERGSAADSEESPAIEAIHLLRKTFPNLLVACDVCLCPYTSHGHCGLLSENGAFRAEESRQRLAEVALAYAKAGCQVVAPSDMMDGRVEAIKEALMAHGLGNRVSVMSYSAKFASCFYGPFRDAAKSSPAFGDRRCYQLPPGARGLALRAVDRDVREGADMLMVKPGMPYLDIVREVKDKHPDLPLAVYHVSGEFAMLWHGAQAGAFDLKAAVLEAMTAFRRAGADIIITYYTPQLLQWLKEE T20514 DRUGINFO D0Y7ZD Aminolevulinic acid hci Approved T20514 DRUGINFO D0U6QC Porphobilinogen Phase 2 T20514 DRUGINFO D06KOT Delta-Amino Valeric Acid Investigative T20514 DRUGINFO D06UYC 4,7-Dioxosebacic Acid Investigative T20514 DRUGINFO D0A1PW Laevulinic Acid Investigative T20514 DRUGINFO D0MD4U 3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid Investigative T20514 DRUGINFO D0NV2V 5-Fluorolevulinic Acid Investigative T20514 DRUGINFO D0VG6L 4-Oxosebacic Acid Investigative T20514 DRUGINFO D0Y4TF 5-hydroxyvaleric acid Investigative T20514 DRUGINFO D0P7JE S,S-(2-Hydroxyethyl)Thiocysteine Investigative T20514 DRUGINFO D06EWG Formic Acid Investigative T20514 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T86528 TARGETID T86528 T86528 FORMERID TTDI02575 T86528 UNIPROID FPPS_HUMAN T86528 TARGNAME Geranyltranstransferase (FDPS) T86528 GENENAME FDPS T86528 TARGTYPE Successful T86528 SYNONYMS KIAA1293; Geranylgeranyl pyrophosphate synthase; Geranylgeranyl diphosphate synthase; GGPS1; GGPPSase; GGPP synthase; Farnesyltranstransferase; Farnesyl pyrophosphate synthase; Farnesyl diphosphate synthase; FPS protein; FPP synthase; Dimethylallyltranstransferase; (2E,6E)-farnesyl diphosphate synthase T86528 FUNCTION FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate. Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. T86528 PDBSTRUC 5YGI; 5KSX; 5JV2; 5JV1; 5JV0 T86528 BIOCLASS Alkyl aryl transferase T86528 ECNUMBER EC 2.5.1.10 T86528 SEQUENCE MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCWCQAWTEEPRALCSSLRMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK T86528 DRUGINFO D00NPT Minodronate Approved T86528 DRUGINFO D08SJZ Ibandronate Approved T86528 DRUGINFO D09KLR Alendronate Approved T86528 DRUGINFO D0BF8G Pamidronate Approved T86528 DRUGINFO D0N4PZ Incadronate Approved T86528 DRUGINFO D0PA5S Risedronate Approved T86528 DRUGINFO D0V8PA NERIDRONIC ACID Approved T86528 DRUGINFO D0VM2L Zoledronate Approved T86528 DRUGINFO D07NPS Zarnestra Phase 3 T86528 DRUGINFO D00ZMS 1-(but-2-ylamino)ethyl 1,I-bisphosphonic acid Investigative T86528 DRUGINFO D01GAR 1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid Investigative T86528 DRUGINFO D01WWK (2E, 6E)-farnesylbisphosphonate Investigative T86528 DRUGINFO D01XBZ Dimethylallyl Diphosphate Investigative T86528 DRUGINFO D02CYZ [2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid Investigative T86528 DRUGINFO D02PVD PMID12014956C12 Investigative T86528 DRUGINFO D02QWB [2-(Imidazol-1-yl)ethyl]-bisphosphonic acid Investigative T86528 DRUGINFO D02SNU NE97220 Investigative T86528 DRUGINFO D02YHA Geranyl Diphosphate Investigative T86528 DRUGINFO D03ZDC NE21650 Investigative T86528 DRUGINFO D04TIS PMID18800762C11 Investigative T86528 DRUGINFO D05DDS Isopentyl Pyrophosphate Investigative T86528 DRUGINFO D05ONZ PMID17975902C5e Investigative T86528 DRUGINFO D05XLD Piridronic acid Investigative T86528 DRUGINFO D05YIK (1-hydroxy-1-phosphono-heptyl)-phosphonic acid Investigative T86528 DRUGINFO D06III NE10790 Investigative T86528 DRUGINFO D06MYN PMID18295483C2 Investigative T86528 DRUGINFO D06QJG PG-1014491 Investigative T86528 DRUGINFO D06UVF 1-[(n-but-1-ylamino)ethyl]-1,1-bisphosphonic acid Investigative T86528 DRUGINFO D08CSK PMID18800762C16 Investigative T86528 DRUGINFO D09KGN PMID18800762C51 Investigative T86528 DRUGINFO D09USO (biphenyl-3-ylamino)methylenediphosphonic acid Investigative T86528 DRUGINFO D0A4MM NE-10575 Investigative T86528 DRUGINFO D0B0LU [2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid Investigative T86528 DRUGINFO D0B2YN 1-[(cyclohexylamino)ethyl]-1,1-bisphosphonicacid Investigative T86528 DRUGINFO D0B6DV CT-10 Investigative T86528 DRUGINFO D0B9ZZ 1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid Investigative T86528 DRUGINFO D0C9LF PMID18800762C19 Investigative T86528 DRUGINFO D0DC3N digeranyl bisphosphonate Investigative T86528 DRUGINFO D0DL1F 1-[(tert-butylamino)ethyl]-1,1-bisphosphonicacid Investigative T86528 DRUGINFO D0E3GI BPH-629 Investigative T86528 DRUGINFO D0E4DR [2-(Purin-9-yl)ethyl]-bisphosphonic acid Investigative T86528 DRUGINFO D0E9AL BPH-628 Investigative T86528 DRUGINFO D0F4NK BPH-676 Investigative T86528 DRUGINFO D0H4MO NE58027 Investigative T86528 DRUGINFO D0I6YD BPH-252 Investigative T86528 DRUGINFO D0J1XZ BPH-675 Investigative T86528 DRUGINFO D0L1RM 1-[(prop-1-ylamino)ethyl]-1,1-bisphosphonic acid Investigative T86528 DRUGINFO D0L8QX Homorisedronate Investigative T86528 DRUGINFO D0MY0R [2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid Investigative T86528 DRUGINFO D0N0JL diphosphoric acid Investigative T86528 DRUGINFO D0N4AH BPH-608 Investigative T86528 DRUGINFO D0OJ5M OLPADRONIC ACID SODIUM SALT Investigative T86528 DRUGINFO D0P2BY [2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid Investigative T86528 DRUGINFO D0R0UV PMID17963374C31 Investigative T86528 DRUGINFO D0R9ZY 3-azageranylgeranyl diphosphate Investigative T86528 DRUGINFO D0S7YD NE58062 Investigative T86528 DRUGINFO D0TK4X PMID18800762C47 Investigative T86528 DRUGINFO D0U9LD PMID18800762C14 Investigative T86528 DRUGINFO D0W0FX NE11808 Investigative T86528 DRUGINFO D0X1FT BPH-715 Investigative T86528 DRUGINFO D0X8YK BPH-742 Investigative T86528 DRUGINFO D0Y3XR NE58043 Investigative T86528 DRUGINFO D0Y7XQ 1-[(prop-2-ylamino)ethyl]-1,1-bisphosphonicacid Investigative T86528 DRUGINFO D0Z8EU NE58018 Investigative T86528 DRUGINFO D0J8KR ISOPENTENYL PYROPHOSPHATE Investigative T86528 DRUGINFO D0QX6B GERANYLGERANYL DIPHOSPHATE Investigative T83386 TARGETID T83386 T83386 FORMERID TTDI01918 T83386 UNIPROID FOLR1_HUMAN T83386 TARGNAME Folate receptor alpha (FOLR1) T83386 GENENAME FOLR1 T83386 TARGTYPE Successful T83386 SYNONYMS Ovarian tumorassociated antigen MOv18; KB cells FBP; Folate receptor, adult; Folate receptor 1; FRalpha; FOLR1; Adult folatebinding protein T83386 FUNCTION Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pHafter receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for normal embryonic development and normal cell proliferation. T83386 PDBSTRUC 5IZQ; 4LRH; 4KMX; 4KM7; 4KM6 T83386 BIOCLASS Folate receptor T83386 SEQUENCE MAQRMTTQLLLLLVWVAVVGEAQTRIAWARTELLNVCMNAKHHKEKPGPEDKLHEQCRPWRKNACCSTNTSQEAHKDVSYLYRFNWNHCGEMAPACKRHFIQDTCLYECSPNLGPWIQQVDQSWRKERVLNVPLCKEDCEQWWEDCRTSYTCKSNWHKGWNWTSGFNKCAVGAACQPFHFYFPTPTVLCNEIWTHSYKVSNYSRGSGRCIQMWFDPAQGNPNEEVARFYAAAMSGAGPWAAWPFLLSLALMLLWLLS T83386 DRUGINFO D0C0SK Pyrimethamine Approved T83386 DRUGINFO D0RP2W Mirvetuximab soravtansine Approved T83386 DRUGINFO D00BHL EC20 Phase 3 T83386 DRUGINFO D02TJT MK-8109 Phase 3 T83386 DRUGINFO D06XVN Farletuzumab Phase 3 T83386 DRUGINFO D09JGH EC-145 Phase 2 T83386 DRUGINFO D0N8JG FolateImmune Phase 2 T83386 DRUGINFO D0GL7H Talotrexin Phase 1/2 T83386 DRUGINFO D0N2GC BMS-753493 Phase 1/2 T83386 DRUGINFO D06CVN EC0489 Phase 1 T83386 DRUGINFO D07DPC IMGN-853 Phase 1 T83386 DRUGINFO D10GPJ STRO-002 Phase 1 T73097 TARGETID T73097 T73097 FORMERID TTDS00442 T73097 UNIPROID CSF2R_HUMAN T73097 TARGNAME GMCSFR-alpha (CSF2RA) T73097 GENENAME CSF2RA T73097 TARGTYPE Successful T73097 SYNONYMS GMR; GM-CSFR; GM-CSF-R-alpha; CSF2RA; CDw116; CD116 antigen T73097 FUNCTION Low affinity receptor for granulocyte-macrophage colony- stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells. T73097 PDBSTRUC 4RS1; 4NKQ T73097 BIOCLASS Type I cytokine receptor family T73097 SEQUENCE MLLLVTSLLLCELPHPAFLLIPEKSDLRTVAPASSLNVRFDSRTMNLSWDCQENTTFSKCFLTDKKNRVVEPRLSNNECSCTFREICLHEGVTFEVHVNTSQRGFQQKLLYPNSGREGTAAQNFSCFIYNADLMNCTWARGPTAPRDVQYFLYIRNSKRRREIRCPYYIQDSGTHVGCHLDNLSGLTSRNYFLVNGTSREIGIQFFDSLLDTKKIERFNPPSNVTVRCNTTHCLVRWKQPRTYQKLSYLDFQYQLDVHRKNTQPGTENLLINVSGDLENRYNFPSSEPRAKHSVKIRAADVRILNWSSWSEAIEFGSDDGNLGSVYIYVLLIVGTLVCGIVLGFLFKRFLRIQRLFPPVPQIKDKLNDNHEVEDEIIWEEFTPEEGKGYREEVLTVKEIT T73097 DRUGINFO D0XT5Y Sargramostim Approved T73097 DRUGINFO D0A5SJ B-cell lymphoma vaccine Preregistration T73097 DRUGINFO D04INP Pixykine Phase 3 T73097 DRUGINFO D0U0HX Molgramostim Phase 3 T73097 DRUGINFO D09SHX GM-CSF cancer vaccine Phase 2 T73097 DRUGINFO D0M0OT Leukemia cancer vaccine Phase 2 T73097 DRUGINFO D0U0NS Myeloma cancer vaccine Phase 2 T73097 DRUGINFO D05YFL AFTVac Phase 2 T73097 DRUGINFO D06KCF Mavrilimumab Phase 2 T73097 DRUGINFO D05ORA MOR-103 Phase 1/2 T73097 DRUGINFO D0C4BD KH-901 Phase 1 T73097 DRUGINFO D0C5YQ SDZ-62-826 Terminated T73097 DRUGINFO D0B6OG BBT-007 Investigative T20761 TARGETID T20761 T20761 FORMERID TTDNS00542 T20761 UNIPROID VEGFA_HUMAN T20761 TARGNAME Vascular endothelial growth factor A (VEGFA) T20761 GENENAME VEGFA T20761 TARGTYPE Successful T20761 SYNONYMS Vascular permeability factor; VPF; VEGF-A; VEGF T20761 FUNCTION Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. T20761 PDBSTRUC 6D3O; 6BFT; 5T89; 5O4E; 5HHD T20761 BIOCLASS Growth factor T20761 SEQUENCE MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGPHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR T20761 DRUGINFO D04EYG Ranibizumab Approved T20761 DRUGINFO D04KBL Bevacizumab Approved T20761 DRUGINFO D5DO9L Brolucizumab Approved T20761 DRUGINFO D9MWL4 Faricimab Approved T20761 DRUGINFO D0C9ET Aflibercept Approved T20761 DRUGINFO D08CGU Bevacizumab + Rituximab Phase 3 T20761 DRUGINFO D09BKY Bevacizumab + Erlotinib Phase 3 T20761 DRUGINFO D04SLF Bevacizumab + Trastuzumab Phase 3 T20761 DRUGINFO D0C0NH Avastin+/-Tarceva Phase 3 T20761 DRUGINFO D0CJ7Z Abicipar pegol Phase 2 T20761 DRUGINFO D05VVX PTC299 Phase 2 T20761 DRUGINFO D06FTM RG7221 Phase 2 T20761 DRUGINFO D0I8YS RO5520985 Phase 2 T20761 DRUGINFO D0E7RQ SNN-0029 Phase 1/2 T20761 DRUGINFO D0ME7Q MP0250 Phase 1/2 T20761 DRUGINFO D0NO1A AT001/r84 Phase 1 T20761 DRUGINFO D0V3HP MP-0112 Phase 1 T20761 DRUGINFO D00IVN Navicixizumab Phase 1 T20761 DRUGINFO D0YZ4T SFLT-01 Phase 1 T20761 DRUGINFO D0P4KU ABI-011 Phase 1 T20761 DRUGINFO D00ZFY Carbamide derivative 17 Patented T20761 DRUGINFO D01CKB Carbamide derivative 16 Patented T20761 DRUGINFO D01DJZ Indoline derivative 18 Patented T20761 DRUGINFO D01IFD Antibodie derivative 11 Patented T20761 DRUGINFO D01OEF Pyridine derivative 2 Patented T20761 DRUGINFO D03HPW Indoline derivative 16 Patented T20761 DRUGINFO D03SZN Carbamide derivative 22 Patented T20761 DRUGINFO D03VXQ Oxetane 3,3-dicarboxamide compound 1 Patented T20761 DRUGINFO D04PKQ Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 Patented T20761 DRUGINFO D04UKD 1,6-naphyridine-4-ketone fused heterocyclic derivative 1 Patented T20761 DRUGINFO D05GVV Pyrimidine derivative 5 Patented T20761 DRUGINFO D05LBH PMID28621580-Compound-WO2013112959C68 Patented T20761 DRUGINFO D05WTW Carbamide derivative 23 Patented T20761 DRUGINFO D06ARD Quinoline and quinazoline derivative 7 Patented T20761 DRUGINFO D07AVU PMID28621580-Compound-WO2015089220C70 Patented T20761 DRUGINFO D07ESG Pyrimidine derivative 9 Patented T20761 DRUGINFO D07UJJ Quinoline and quinazoline derivative 4 Patented T20761 DRUGINFO D08INZ Pyridine derivative 5 Patented T20761 DRUGINFO D08XDA Carbamide derivative 15 Patented T20761 DRUGINFO D09GWR Antibodie derivative 3 Patented T20761 DRUGINFO D09KYB Pyrimidine derivative 7 Patented T20761 DRUGINFO D0A5NC Carbamide derivative 18 Patented T20761 DRUGINFO D0A8SH Indoline derivative 21 Patented T20761 DRUGINFO D0A9RY Pyrimidine derivative 10 Patented T20761 DRUGINFO D0BA5J Pyridine derivative 7 Patented T20761 DRUGINFO D0BL4H Quinoline and quinazoline derivative 6 Patented T20761 DRUGINFO D0CE1R Antibodie derivative 7 Patented T20761 DRUGINFO D0D0AX Antibodie derivative 2 Patented T20761 DRUGINFO D0D7SL Pyridine derivative 3 Patented T20761 DRUGINFO D0DA6B Pyridine derivative 8 Patented T20761 DRUGINFO D0DI5S Carbamide derivative 19 Patented T20761 DRUGINFO D0E5IJ Indoline derivative 13 Patented T20761 DRUGINFO D0EE3P Pyrimidine derivative 11 Patented T20761 DRUGINFO D0FK5P Pyrimidine derivative 8 Patented T20761 DRUGINFO D0FK6Y Quinoline and quinazoline derivative 10 Patented T20761 DRUGINFO D0FL6P Quinoline and quinazoline derivative 8 Patented T20761 DRUGINFO D0FY2Q Pyridine derivative 10 Patented T20761 DRUGINFO D0HO5B Indoline derivative 14 Patented T20761 DRUGINFO D0HX9S PMID28621580-Compound-WO2014079545C69 Patented T20761 DRUGINFO D0I6WJ Carbamide derivative 14 Patented T20761 DRUGINFO D0IZ8B Pyridine derivative 11 Patented T20761 DRUGINFO D0KW0F Pyridine derivative 9 Patented T20761 DRUGINFO D0M2XJ Quinoline and quinazoline derivative 5 Patented T20761 DRUGINFO D0M9KZ Pyridine derivative 4 Patented T20761 DRUGINFO D0MA6I Quinoline and quinazoline derivative 3 Patented T20761 DRUGINFO D0O5IA Quinoline and quinazoline derivative 2 Patented T20761 DRUGINFO D0O8RZ Indoline derivative 17 Patented T20761 DRUGINFO D0Q4XV Indoline derivative 19 Patented T20761 DRUGINFO D0S4XH Pyridine derivative 6 Patented T20761 DRUGINFO D0SH2Y Quinoline and quinazoline derivative 9 Patented T20761 DRUGINFO D0T1GG 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1 Patented T20761 DRUGINFO D0T9DV PMID28621580-Compound-WO2013036866C66 Patented T20761 DRUGINFO D0U6PW Antibodie derivative 8 Patented T20761 DRUGINFO D0V7OF Pyrimidine derivative 6 Patented T20761 DRUGINFO D0VI1V Carbamide derivative 20 Patented T20761 DRUGINFO D0VX5Y Indoline derivative 15 Patented T20761 DRUGINFO D0WL5P Antibodie derivative 9 Patented T20761 DRUGINFO D0X2BP Antibodie derivative 1 Patented T20761 DRUGINFO D0X2MF Indoline derivative 20 Patented T20761 DRUGINFO D0XS0Z Carbamide derivative 21 Patented T20761 DRUGINFO D0Y2IV Antibodie derivative 4 Patented T20761 DRUGINFO D0Z0SY Indoline derivative 12 Patented T20761 DRUGINFO D0ZE2J Oxetane 3,3-dicarboxamide compound 2 Patented T20761 DRUGINFO D0YG4I Bevasiranib Discontinued in Phase 3 T60606 TARGETID T60606 T60606 FORMERID TTDS00452 T60606 UNIPROID TSHR_HUMAN T60606 TARGNAME Thyrotropin receptor (TSHR) T60606 GENENAME TSHR T60606 TARGTYPE Successful T60606 SYNONYMS Thyroid stimulating hormone receptor; TSHR; TSH-R; TSH receptor T60606 FUNCTION Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a receptor for thyrostimulin (gpa2+gpb5). T60606 PDBSTRUC 3G04; 2XWT; 1XUM T60606 BIOCLASS GPCR rhodopsin T60606 SEQUENCE MRPADLLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLIETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPDALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETLTLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTALPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLMCNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQEDEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMGYKFLRIVVWFVSLLALLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSEYYNHAIDWQTGPGCNTAGFFTVFASELSVYTLTVITLERWYAITFAMRLDRKIRLRHACAIMVGGWVCCFLLALLPLVGISSYAKVSICLPMDTETPLALAYIVFVLTLNIVAFVIVCCCYVKIYITVRNPQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLITVSNSKILLVLFYPLNSCANPFLYAIFTKAFQRDVFILLSKFGICKRQAQAYRGQRVPPKNSTDIQVQKVTHDMRQGLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL T60606 DRUGINFO D03EER Thyrotropin Approved T60606 DRUGINFO D0H4TQ Thyrotropin Alfa Approved T60606 DRUGINFO D0U2DY Recombinant TSH superagonists Investigative T41580 TARGETID T41580 T41580 FORMERID TTDC00293 T41580 UNIPROID ADA2B_HUMAN T41580 TARGNAME Adrenergic receptor alpha-2B (ADRA2B) T41580 GENENAME ADRA2B T41580 TARGTYPE Successful T41580 SYNONYMS Subtype C2; Alpha-2BAR; Alpha-2B adrenoreceptor; Alpha-2B adrenoceptor; Alpha-2B adrenergic receptor; Alpha-2 adrenergic receptor subtype C2; ADRA2RL1; ADRA2L1 T41580 FUNCTION The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol. Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. T41580 PDBSTRUC 2CVA T41580 BIOCLASS GPCR rhodopsin T41580 SEQUENCE MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLFLVSLAAADILVATLIIPFSLANELLGYWYFRRTWCEVYLALDVLFCTSSIVHLCAISLDRYWAVSRALEYNSKRTPRRIKCIILTVWLIAAVISLPPLIYKGDQGPQPRGRPQCKLNQEAWYILASSIGSFFAPCLIMILVYLRIYLIAKRSNRRGPRAKGGPGQGESKQPRPDHGGALASAKLPALASVASAREVNGHSKSTGEKEEGETPEDTGTRALPPSWAALPNSGQGQKEGVCGASPEDEAEEEEEEEEEEEECEPQAVPVSPASACSPPLQQPQGSRVLATLRGQVLLGRGVGAIGGQWWRRRAQLTREKRFTFVLAVVIGVFVLCWFPFFFSYSLGAICPKHCKVPHGLFQFFFWIGYCNSSLNPVIYTIFNQDFRRAFRRILCRPWTQTAW T41580 DRUGINFO D0E9PK MOXONIDINE Approved T41580 DRUGINFO D05CFH AGN-199981 Phase 2 T41580 DRUGINFO D0F2ML MEDETOMIDINE Phase 2 T41580 DRUGINFO D02LHR INDORAMIN Withdrawn from market T41580 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T41580 DRUGINFO D08OWQ SK&F-104078 Terminated T41580 DRUGINFO D03QMR WB-4101 Terminated T41580 DRUGINFO D06HRY SNAP-5089 Terminated T41580 DRUGINFO D0K9JP A-80426 Terminated T41580 DRUGINFO D03IVG imiloxan Investigative T41580 DRUGINFO D0GP1I [3H]MK-912 Investigative T41580 DRUGINFO D0Y2JI xylazine Investigative T41580 DRUGINFO D02KIS (S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline Investigative T41580 DRUGINFO D02QXT 8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline Investigative T41580 DRUGINFO D03EPY 1,2,3,4-tetrahydroisoquinoline Investigative T41580 DRUGINFO D03HBZ (3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine Investigative T41580 DRUGINFO D03LRY C-(6-Methoxy-naphthalen-1-yl)-methylamine Investigative T41580 DRUGINFO D04PYQ PIPEROXAN Investigative T41580 DRUGINFO D04RBQ 1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol Investigative T41580 DRUGINFO D06BWZ MEZILAMINE Investigative T41580 DRUGINFO D06SYS METHYLNORADRENALINE Investigative T41580 DRUGINFO D07ICV GNF-PF-3878 Investigative T41580 DRUGINFO D07RLW 5-Aminomethyl-naphthalen-2-ol Investigative T41580 DRUGINFO D07SYG 2,3-Dihydro-1H-isoindole Investigative T41580 DRUGINFO D08ZRA C-Naphthalen-1-yl-methylamine Investigative T41580 DRUGINFO D09JZG 1,2,3,4,5,6-Hexahydro-benzo[c]azocine Investigative T41580 DRUGINFO D0AE9M Butyl-indol-1-yl-pyridin-4-yl-amine Investigative T41580 DRUGINFO D0B2BO 6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene Investigative T41580 DRUGINFO D0C9DC SK&F-64139 Investigative T41580 DRUGINFO D0D1RU Indol-1-yl-pyridin-4-yl-amine Investigative T41580 DRUGINFO D0E0KG (R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline Investigative T41580 DRUGINFO D0E3OL GNF-PF-2857 Investigative T41580 DRUGINFO D0E8HU 3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline Investigative T41580 DRUGINFO D0F5TA Ethyl-indol-1-yl-pyridin-4-yl-amine Investigative T41580 DRUGINFO D0L7IZ JP1302 Investigative T41580 DRUGINFO D0M8FL 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine Investigative T41580 DRUGINFO D0P3HP 1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline Investigative T41580 DRUGINFO D0P8BE (3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine Investigative T41580 DRUGINFO D0QH0X 2,3,4,5-Tetrahydro-1H-benzo[c]azepine Investigative T41580 DRUGINFO D0QO8X 1,2,3,4-Tetrahydro-isoquinolin-7-ol Investigative T41580 DRUGINFO D0R1XT Indol-1-yl-methyl-pyridin-4-yl-amine Investigative T41580 DRUGINFO D0TN2R 3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline Investigative T41580 DRUGINFO D0V0NJ 2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine Investigative T41580 DRUGINFO D0V3IT SNAP-5150 Investigative T41580 DRUGINFO D0W5IN (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine Investigative T41580 DRUGINFO D0Y8DJ (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol Investigative T41580 DRUGINFO D0Z7XI 3-Methyl-1,2,3,4-tetrahydro-isoquinoline Investigative T41580 DRUGINFO D0ZS3M Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine Investigative T41580 DRUGINFO D0ZT8D Tramazoline Investigative T41580 DRUGINFO D08UDY 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl Investigative T41580 DRUGINFO D0MH0S 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine Investigative T41580 DRUGINFO D0Z7EA [3H]rauwolscine Investigative T41580 DRUGINFO D07JMN 1-(pyridin-2-yl)piperazine Investigative T41580 DRUGINFO D09BIV TRACIZOLINE Investigative T41580 DRUGINFO D0FU5E S-34324 Investigative T41580 DRUGINFO D0H3NA 4-Benzo[b]thiophen-4-yl-1H-imidazole Investigative T41580 DRUGINFO D0LI3J 2-BFi Investigative T41580 DRUGINFO D0MU4A spiroxatrine Investigative T41580 DRUGINFO D03LPH TRYPTOLINE Investigative T41580 DRUGINFO D05GDP 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T41580 DRUGINFO D08KLH [3H]RX821002 Investigative T41580 DRUGINFO D0C1SE 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole Investigative T41580 DRUGINFO D0L9WN 4-(4-Methyl-indan-1-yl)-1H-imidazole Investigative T41580 DRUGINFO D0P5PW 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole Investigative T41580 DRUGINFO D0PN9R R-226161 Investigative T41580 DRUGINFO D0L5MW (+/-)-nantenine Investigative T01777 TARGETID T01777 T01777 FORMERID TTDR01180 T01777 UNIPROID ADA2C_HUMAN T01777 TARGNAME Adrenergic receptor alpha-2C (ADRA2C) T01777 GENENAME ADRA2C T01777 TARGTYPE Successful T01777 SYNONYMS Subtype C4; Alpha-2CAR; Alpha-2C adrenoreceptor; Alpha-2C adrenoceptor; Alpha-2C adrenergic receptor; Alpha-2 adrenergic receptor subtype C4; ADRA2RL2; ADRA2L2 T01777 FUNCTION Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. T01777 BIOCLASS GPCR rhodopsin T01777 SEQUENCE MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGFLIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFGQVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISAVISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLRTRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGALRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRRRRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFKFFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ T01777 DRUGINFO D00DPJ Amezinium Approved T01777 DRUGINFO D03DVJ Propylhexedrine Approved T01777 DRUGINFO D05IHU Tetrahydrozoline Approved T01777 DRUGINFO D06OFS Rilmenidine Approved T01777 DRUGINFO D09NNH Dihydroergocristine Approved T01777 DRUGINFO D0AE3X Brimonidine Approved T01777 DRUGINFO D0D0YM Amosulalol Approved T01777 DRUGINFO D0E9PK MOXONIDINE Approved T01777 DRUGINFO D0Y4DY Xylometazoline Phase 4 T01777 DRUGINFO D01ZNH IDAZOXAN HYDROCHLORIDE Phase 3 T01777 DRUGINFO D0NN8N TNX-102 Phase 3 T01777 DRUGINFO D00BWF AGN-XX/YY Phase 2 T01777 DRUGINFO D01BVI V-101 Phase 2 T01777 DRUGINFO D02VTB BAY1193397 Phase 2 T01777 DRUGINFO D0B3ZF ORM-12741 Phase 2 T01777 DRUGINFO D0U1NA Fadolmidine Phase 2 T01777 DRUGINFO D0F2ML MEDETOMIDINE Phase 2 T01777 DRUGINFO D02LHR INDORAMIN Withdrawn from market T01777 DRUGINFO D0Y0ZQ Ecabapide Discontinued in Preregistration T01777 DRUGINFO D02VCK FLUPAROXAN Discontinued in Phase 3 T01777 DRUGINFO D0L7SY Delequamine hydrochloride Discontinued in Phase 3 T01777 DRUGINFO D02ALD NOLOMIROLE HYDROCHLORIDE Discontinued in Phase 3 T01777 DRUGINFO D0A5TM SGB-1534 Discontinued in Phase 2 T01777 DRUGINFO D0Y4LU MK-912 Discontinued in Phase 2 T01777 DRUGINFO D03ABH Deriglidole Discontinued in Phase 2 T01777 DRUGINFO D06WOJ JTH-601 Discontinued in Phase 2 T01777 DRUGINFO D0U0QI GYKI-16084 Discontinued in Phase 2 T01777 DRUGINFO D0ZI0K NMI-870 Discontinued in Phase 2 T01777 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T01777 DRUGINFO D0M6YW GYKI-12743 Discontinued in Phase 1 T01777 DRUGINFO D02YIW 5-(N,N-hexamethylene)-amiloride Preclinical T01777 DRUGINFO D02XMM Midaglizole Terminated T01777 DRUGINFO D07SZJ A-75169 Terminated T01777 DRUGINFO D08VJI F-14413 Terminated T01777 DRUGINFO D0V8NS ARC239 Terminated T01777 DRUGINFO D08OWQ SK&F-104078 Terminated T01777 DRUGINFO D03QMR WB-4101 Terminated T01777 DRUGINFO D06HRY SNAP-5089 Terminated T01777 DRUGINFO D0K9JP A-80426 Terminated T01777 DRUGINFO D06QKW cirazoline Investigative T01777 DRUGINFO D07OAF A61603 Investigative T01777 DRUGINFO D09CUJ 6-fluoro-noradrenaline Investigative T01777 DRUGINFO D0B6FM SKF 89748 Investigative T01777 DRUGINFO D0F8NE V-103 Investigative T01777 DRUGINFO D0R2HZ ETHOXY-IDAZOXAN Investigative T01777 DRUGINFO D0SG6A amidephrine Investigative T01777 DRUGINFO D0U9IJ indanidine Investigative T01777 DRUGINFO D02EMH all-trans-4-oxo-retinoic acid Investigative T01777 DRUGINFO D03YLQ [125I]BE-2254 Investigative T01777 DRUGINFO D05QTJ Chloroethylclonidine Investigative T01777 DRUGINFO D09DKC [125I]HEAT Investigative T01777 DRUGINFO D0GP1I [3H]MK-912 Investigative T01777 DRUGINFO D0S4VR (1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine Investigative T01777 DRUGINFO D0V6DJ 5-methylurapidil Investigative T01777 DRUGINFO D0Y2JI xylazine Investigative T01777 DRUGINFO D0ZC4S (1H-Imidazol-2-yl)-quinoxalin-6-yl-amine Investigative T01777 DRUGINFO D02KIS (S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline Investigative T01777 DRUGINFO D02QXT 8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline Investigative T01777 DRUGINFO D03EPY 1,2,3,4-tetrahydroisoquinoline Investigative T01777 DRUGINFO D03HBZ (3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine Investigative T01777 DRUGINFO D03LRY C-(6-Methoxy-naphthalen-1-yl)-methylamine Investigative T01777 DRUGINFO D04PYQ PIPEROXAN Investigative T01777 DRUGINFO D04RBQ 1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol Investigative T01777 DRUGINFO D06BWZ MEZILAMINE Investigative T01777 DRUGINFO D06SYS METHYLNORADRENALINE Investigative T01777 DRUGINFO D07ICV GNF-PF-3878 Investigative T01777 DRUGINFO D07RLW 5-Aminomethyl-naphthalen-2-ol Investigative T01777 DRUGINFO D07SYG 2,3-Dihydro-1H-isoindole Investigative T01777 DRUGINFO D08ZRA C-Naphthalen-1-yl-methylamine Investigative T01777 DRUGINFO D09JZG 1,2,3,4,5,6-Hexahydro-benzo[c]azocine Investigative T01777 DRUGINFO D0AE9M Butyl-indol-1-yl-pyridin-4-yl-amine Investigative T01777 DRUGINFO D0B2BO 6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene Investigative T01777 DRUGINFO D0C9DC SK&F-64139 Investigative T01777 DRUGINFO D0D1RU Indol-1-yl-pyridin-4-yl-amine Investigative T01777 DRUGINFO D0E0KG (R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline Investigative T01777 DRUGINFO D0E3OL GNF-PF-2857 Investigative T01777 DRUGINFO D0E8HU 3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline Investigative T01777 DRUGINFO D0F5TA Ethyl-indol-1-yl-pyridin-4-yl-amine Investigative T01777 DRUGINFO D0L7IZ JP1302 Investigative T01777 DRUGINFO D0M8FL 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine Investigative T01777 DRUGINFO D0M9IC CONESSINE Investigative T01777 DRUGINFO D0P3HP 1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline Investigative T01777 DRUGINFO D0P8BE (3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine Investigative T01777 DRUGINFO D0QH0X 2,3,4,5-Tetrahydro-1H-benzo[c]azepine Investigative T01777 DRUGINFO D0QO8X 1,2,3,4-Tetrahydro-isoquinolin-7-ol Investigative T01777 DRUGINFO D0R1XT Indol-1-yl-methyl-pyridin-4-yl-amine Investigative T01777 DRUGINFO D0TN2R 3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline Investigative T01777 DRUGINFO D0V0NJ 2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine Investigative T01777 DRUGINFO D0V3IT SNAP-5150 Investigative T01777 DRUGINFO D0W5IN (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine Investigative T01777 DRUGINFO D0Y8DJ (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol Investigative T01777 DRUGINFO D0Z7XI 3-Methyl-1,2,3,4-tetrahydro-isoquinoline Investigative T01777 DRUGINFO D0ZS3M Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine Investigative T01777 DRUGINFO D0ZT8D Tramazoline Investigative T01777 DRUGINFO D0I3XA Ciproxifan Investigative T01777 DRUGINFO D0Z7EA [3H]rauwolscine Investigative T01777 DRUGINFO D06HHJ (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine Investigative T01777 DRUGINFO D09BIV TRACIZOLINE Investigative T01777 DRUGINFO D0A6GK (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine Investigative T01777 DRUGINFO D0FU5E S-34324 Investigative T01777 DRUGINFO D0LI3J 2-BFi Investigative T01777 DRUGINFO D0MU4A spiroxatrine Investigative T01777 DRUGINFO D03LPH TRYPTOLINE Investigative T01777 DRUGINFO D05GDP 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Investigative T01777 DRUGINFO D07GXY piribedil Investigative T01777 DRUGINFO D08KLH [3H]RX821002 Investigative T01777 DRUGINFO D0C1SE 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole Investigative T01777 DRUGINFO D0L9WN 4-(4-Methyl-indan-1-yl)-1H-imidazole Investigative T01777 DRUGINFO D0P5PW 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole Investigative T01777 DRUGINFO D01KAX 1-((S)-2-aminopropyl)-1H-indazol-6-ol Investigative T01777 DRUGINFO D0PN9R R-226161 Investigative T01777 DRUGINFO D0L5MW (+/-)-nantenine Investigative T13726 TARGETID T13726 T13726 FORMERID TTDR01073 T13726 UNIPROID RXRA_HUMAN T13726 TARGNAME Retinoic acid receptor RXR-alpha (RXRA) T13726 GENENAME RXRA T13726 TARGTYPE Successful T13726 SYNONYMS Retinoid X receptor alpha; RXRalpha; Nuclear receptor subfamily 2 group B member 1; NR2B1 T13726 FUNCTION Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes. Receptor for retinoic acid. T13726 PDBSTRUC 6HN6; 6FBR; 6FBQ; 6A60; 6A5Z T13726 BIOCLASS Nuclear hormone receptor T13726 SEQUENCE MDTKHFLPLDFSTQVNSSLTSPTGRGSMAAPSLHPSLGPGIGSPGQLHSPISTLSSPINGMGPPFSVISSPMGPHSMSVPTTPTLGFSTGSPQLSSPMNPVSSSEDIKPPLGLNGVLKVPAHPSGNMASFTKHICAICGDRSSGKHYGVYSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQYCRYQKCLAMGMKREAVQEERQRGKDRNENEVESTSSANEDMPVERILEAELAVEPKTETYVEANMGLNPSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSELPLDDQVILLRAGWNELLIASFSHRSIAVKDGILLATGLHVHRNSAHSAGVGAIFDRVLTELVSKMRDMQMDKTELGCLRAIVLFNPDSKGLSNPAEVEALREKVYASLEAYCKHKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQMT T13726 DRUGINFO D0N0RU Bexarotene Approved T13726 DRUGINFO D0G3PI Alitretinoin Approved T13726 DRUGINFO D03ZEL CD3254 Investigative T13726 DRUGINFO D05JXE phytanic acid Investigative T13726 DRUGINFO D09IEN UVI3003 Investigative T13726 DRUGINFO D0CQ3A Tributylstannanyl Investigative T13726 DRUGINFO D0CT1F methoprene acid Investigative T13726 DRUGINFO D0IY9H PA451 Investigative T13726 DRUGINFO D05DMH (5BETA)-PREGNANE-3,20-DIONE Investigative T13726 DRUGINFO D00ACX 2-chloro-5-nitro-N-phenylbenzamide Investigative T13726 DRUGINFO D0GR9O AGN-34 Investigative T13726 DRUGINFO D0Q9FZ LG100754 Investigative T83145 TARGETID T83145 T83145 FORMERID TTDC00046 T83145 UNIPROID NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN T83145 TARGNAME Nuclear factor NF-kappa-B (NFKB) T83145 GENENAME NFKB1; NFKB2; RELA; RELB; REL T83145 TARGTYPE Successful T83145 SYNONYMS Nuclear factor of kappa light polypeptide gene enhancer in B-cells; DNA-binding factor KBF T83145 FUNCTION NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. T83145 SEQUENCE MAEDDPYLGRPEQMFHLDPSLTHTIFNPEVFQPQMALPTDGPYLQILEQPKQRGFRFRYVCEGPSHGGLPGASSEKNKKSYPQVKICNYVGPAKVIVQLVTNGKNIHLHAHSLVGKHCEDGICTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACIRGYNPGLLVHPDLAYLQAEGGGDRQLGDREKELIRQAALQQTKEMDLSVVRLMFTAFLPDSTGSFTRRLEPVVSDAIYDSKAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGFGDFSPTDVHRQFAIVFKTPKYKDINITKPASVFVQLRRKSDLETSEPKPFLYYPEIKDKEEVQRKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGGTGSTGPGYSFPHYGFPTYGGITFHPGTTKSNAGMKHGTMDTESKKDPEGCDKSDDKNTVNLFGKVIETTEQDQEPSEATVGNGEVTLTYATGTKEESAGVQDNLFLEKAMQLAKRHANALFDYAVTGDVKMLLAVQRHLTAVQDENGDSVLHLAIIHLHSQLVRDLLEVTSGLISDDIINMRNDLYQTPLHLAVITKQEDVVEDLLRAGADLSLLDRLGNSVLHLAAKEGHDKVLSILLKHKKAALLLDHPNGDGLNAIHLAMMSNSLPCLLLLVAAGADVNAQEQKSGRTALHLAVEHDNISLAGCLLLEGDAHVDSTTYDGTTPLHIAAGRGSTRLAALLKAAGADPLVENFEPLYDLDDSWENAGEDEGVVPGTTPLDMATSWQVFDILNGKPYEPEFTSDDLLAQGDMKQLAEDVKLQLYKLLEIPDPDKNWATLAQKLGLGILNNAFRLSPAPSKTLMDNYEVSGGTVRELVEALRQMGYTEAIEVIQAASSPVKTTSQAHSLPLSPASTRQQIDELRDSDSVCDSGVETSFRKLSFTESLTSGASLLTLNKMPHDYGQEGPLEGKI T83145 DRUGINFO D02ZTJ Sulfasalazine Approved T83145 DRUGINFO D0I6LH Triptolide Phase 3 T83145 DRUGINFO D0JN5N Laquinimod Phase 3 T83145 DRUGINFO D0QR3X Edasalonexent Phase 3 T83145 DRUGINFO D0R7UL MD1003 Phase 3 T83145 DRUGINFO D00SBD Recoflavone Phase 2 T83145 DRUGINFO D01KHW CZEN-002 Phase 2 T83145 DRUGINFO D02RDX XP-23829 Phase 2 T83145 DRUGINFO D05MJS PRO22 Phase 2 T83145 DRUGINFO D06HFI L-ornithine phenylacetate Phase 2 T83145 DRUGINFO D08UOY Vadimezan Phase 2 T83145 DRUGINFO D06TZZ CAT 1004 Phase 2 T83145 DRUGINFO D0M4KE Parthenolide Phase 2 T83145 DRUGINFO D08JOY Avrina Phase 1/2 T83145 DRUGINFO D0V5AL LC-1 Phase 1 T83145 DRUGINFO D00THJ 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3 Patented T83145 DRUGINFO D01LTK PMID25553724-Compound-WO2011152671 2 Patented T83145 DRUGINFO D02CEY PMID25553724-Compound-WO2013082253 33 Patented T83145 DRUGINFO D02WOW PMID25553724-Compound-WO2011127048 32 Patented T83145 DRUGINFO D03WHA N-quinolin-benzene sulphonamide derivative 1 Patented T83145 DRUGINFO D04GMP N-quinolin-benzene sulphonamide derivative 3 Patented T83145 DRUGINFO D04NKE Tihourea derivative 1 Patented T83145 DRUGINFO D04NMJ PMID25553724-Compound-US2012830453910 Patented T83145 DRUGINFO D05CGR PMID25553724-Compound-WO2013082253 31 Patented T83145 DRUGINFO D05UGL 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1 Patented T83145 DRUGINFO D05WCW Quinoxaline derivative 6 Patented T83145 DRUGINFO D06YEK 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4 Patented T83145 DRUGINFO D07NCJ PMID25553724-Compound-EP20132578214 2 Patented T83145 DRUGINFO D08NGV PMID25553724-Compound-US2012820715110 Patented T83145 DRUGINFO D08RUK PMID25553724-Compound-WO2011127048 31 Patented T83145 DRUGINFO D08YMD Quinoxaline derivative 5 Patented T83145 DRUGINFO D09OGV PMID25553724-Compound-WO2011127048 34 Patented T83145 DRUGINFO D09VXA Quinoxaline derivative 1 Patented T83145 DRUGINFO D0BL3X PMID25553724-Compound-US2011799419010 Patented T83145 DRUGINFO D0BQ8A PMID25553724-Compound-US2011796857710 Patented T83145 DRUGINFO D0D6DE PMID25553724-Compound-US20138552206 4 Patented T83145 DRUGINFO D0DL3R PMID25553724-Compound-US2011801300410 Patented T83145 DRUGINFO D0E7ZN PMID25553724-Compound-US2011000295210 Patented T83145 DRUGINFO D0ED5S PMID25553724-Compound-US20130116324 2 Patented T83145 DRUGINFO D0F5TR PMID25553724-Compound-US2012832440110 Patented T83145 DRUGINFO D0F9GL PMID25553724-Compound-US2011806744710 Patented T83145 DRUGINFO D0GN7U PMID25553724-Compound-US2011803494010 Patented T83145 DRUGINFO D0J2VS 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2 Patented T83145 DRUGINFO D0K0TL PMID25553724-Compound-WO2013082253 34 Patented T83145 DRUGINFO D0KO3I Olenolic acid acetate derivative 1 Patented T83145 DRUGINFO D0LT6Z PMID25553724-Compound-US2012810604610 Patented T83145 DRUGINFO D0O5TC Quinoxaline derivative 2 Patented T83145 DRUGINFO D0OY0Q Tihotungstate derivative 1 Patented T83145 DRUGINFO D0P0KY PMID25553724-Compound-WO2011127048 33 Patented T83145 DRUGINFO D0PB2J PMID25553724-Compound-WO2013082253 32 Patented T83145 DRUGINFO D0Q5YJ PMID25553724-Compound-US2012819831110 Patented T83145 DRUGINFO D0Q6JK Quinoxaline derivative 3 Patented T83145 DRUGINFO D0R4RV PMID25553724-Compound-US20138552206 5 Patented T83145 DRUGINFO D0X2ZY N-quinolin-benzene sulphonamide derivative 2 Patented T83145 DRUGINFO D0XQ5E Quinoxaline derivative 4 Patented T83145 DRUGINFO D0Y2RN PMID25553724-Compound-US2011788838110 Patented T83145 DRUGINFO D03HVN P-1 Discontinued in Phase 3 T83145 DRUGINFO D0W7ZN SIM-916 Discontinued in Phase 1 T83145 DRUGINFO D01OLO AS602868 Discontinued in Phase 1 T83145 DRUGINFO D00ARN Tyloxapol Terminated T83145 DRUGINFO D0N1XD Gliotoxin Terminated T83145 DRUGINFO D0P1YO MOL-218 Terminated T83145 DRUGINFO D0Q6YP HELENALIN Terminated T83145 DRUGINFO D00EOD Centratherin Investigative T83145 DRUGINFO D00RAO 4,5-ISOBUDLEIN A Investigative T83145 DRUGINFO D00SRS BUDLEIN A Investigative T83145 DRUGINFO D01FYY SP-650003 Investigative T83145 DRUGINFO D01NVL 9-chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide Investigative T83145 DRUGINFO D02EHZ 5-chloro-N-(quinolin-8-yl)thiophene-2-sulfonamide Investigative T83145 DRUGINFO D03VYU Isohelenin Investigative T83145 DRUGINFO D04VQM 5-bromo-N-(quinolin-8-yl)thiophene-2-sulfonamide Investigative T83145 DRUGINFO D04YTE ROCAGLAMIDE Investigative T83145 DRUGINFO D05DHX HELENALINMETHACRYLATE Investigative T83145 DRUGINFO D05OPF 4-nitro-N-(quinolin-8-yl)benzenesulfonamide Investigative T83145 DRUGINFO D05RCK Miller-9E-enolide Investigative T83145 DRUGINFO D06FRZ 15-ACETOXY-EREMANTHOLIDE B Investigative T83145 DRUGINFO D06MAL ATRIPLICIOLIDTIGLATE Investigative T83145 DRUGINFO D06YGF Caffeic acid phenethyl ester Investigative T83145 DRUGINFO D06ZIE SCANDENOLIDE Investigative T83145 DRUGINFO D06ZYQ 2beta-methoxy-2-deethoxyphantomolin Investigative T83145 DRUGINFO D07JDD ARTORIGIDIN A Investigative T83145 DRUGINFO D07PWA IkappaB-alphaM Investigative T83145 DRUGINFO D08KJM 9-methyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide Investigative T83145 DRUGINFO D08ZBD 9-fluoro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide Investigative T83145 DRUGINFO D09FBD MOLEPHANTIN Investigative T83145 DRUGINFO D09SZJ Pycnogenol Investigative T83145 DRUGINFO D0B0IJ Pyrrolidine dithiocarbamate Investigative T83145 DRUGINFO D0B7EP 1beta-methoxy-miller-9Z-enolide Investigative T83145 DRUGINFO D0B8RN 4beta,15-epoxy-miller-9E-enolide Investigative T83145 DRUGINFO D0CQ5F 3,4-epoxydehydroleucodin Investigative T83145 DRUGINFO D0E7FU 2-amino-N-(quinolin-8-yl)benzenesulfonamide Investigative T83145 DRUGINFO D0F0VD ACHP Investigative T83145 DRUGINFO D0F7UW 4beta,15-epoxy-miller-9Z-enolide Investigative T83145 DRUGINFO D0G8GL Miller-9Z-enolide Investigative T83145 DRUGINFO D0J0ZF 15-isobutyrylmiguanin Investigative T83145 DRUGINFO D0J2PO ARTOBILOXANTHONE Investigative T83145 DRUGINFO D0J7XB ENHYDRIN Investigative T83145 DRUGINFO D0L2XO BAY11-7082 Investigative T83145 DRUGINFO D0LH9A ISOGOIAZENSOLIDE Investigative T83145 DRUGINFO D0M6DV MOLEPHANTININ Investigative T83145 DRUGINFO D0MY0M 15-DEOXYBUDLEIN A Investigative T83145 DRUGINFO D0N2GO 7-hydroxycostunolide Investigative T83145 DRUGINFO D0O5HF Helenalin-2-methylbutyrate Investigative T83145 DRUGINFO D0Q2KK 5H-6-thia-4,5-diaza-chrysene 6,6-dioxide Investigative T83145 DRUGINFO D0R2MO 2-oxoguaia-1,4,11(13)-trien-12,8alpha-olide Investigative T83145 DRUGINFO D0V4PJ 9alpha-acetoxy-miller-1(10)Z-enolide Investigative T83145 DRUGINFO D0V6QZ 2-nitro-N-(quinolin-8-yl)benzenesulfonamide Investigative T83145 DRUGINFO D0VD3M 15-deoxygoiazensolide Investigative T83145 DRUGINFO D0X8OL N-(quinolin-8-yl)thiophene-2-sulfonamide Investigative T83145 DRUGINFO D0Y0CA 2-oxoguaia-1,4(15), 11(13)-trien-12,8beta-olide Investigative T83145 DRUGINFO D0Y0LD DTD Investigative T83145 DRUGINFO D07MQC PS-1145 Investigative T83145 DRUGINFO D08JPU G6976 Investigative T38950 TARGETID T38950 T38950 FORMERID TTDS00091 T38950 UNIPROID CD33_HUMAN T38950 TARGNAME Myeloid cell surface antigen CD33 (CD33) T38950 GENENAME CD33 T38950 TARGTYPE Successful T38950 SYNONYMS Siglec-3; Sialic acid-binding Ig-like lectin 3; SIGLEC3; Gp67 T38950 FUNCTION Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. T38950 PDBSTRUC 6D4A; 6D49; 6D48; 5J0B; 5J06 T38950 BIOCLASS Immunoglobulin T38950 SEQUENCE MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTHPTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSEVRTQ T38950 DRUGINFO D06EWO Gemtuzumab ozogamicin Approved T38950 DRUGINFO D0W2BF Vadastuximab talirine Phase 3 T38950 DRUGINFO D03HSA Actimab-A Phase 2 T38950 DRUGINFO D04MGW BI-836858 Phase 2 T38950 DRUGINFO DSIT20 Actimab-MDS Phase 2 T38950 DRUGINFO D01KKI SGN-CD33A Phase 1/2 T38950 DRUGINFO D04VCQ CART33 cells Phase 1/2 T38950 DRUGINFO D0G9MY CD33-specific gene-engineered T cells Phase 1/2 T38950 DRUGINFO D0K8WE Anti-CD33 CAR-T cells Phase 1/2 T38950 DRUGINFO D0TV6H HuM-195-Ac-225 Phase 1/2 T38950 DRUGINFO D9O7GC GTB-3550 Phase 1/2 T38950 DRUGINFO D06JQS HuM195/rGel Phase 1 T38950 DRUGINFO D0C4GN CD33-CAR-T Cell Phase 1 T38950 DRUGINFO D0LP7U AMV564 Phase 1 T38950 DRUGINFO D0P6YN CART-33 cells Phase 1 T38950 DRUGINFO D0XE4W Actimab-M Phase 1 T38950 DRUGINFO D0ZL3U Allogeneic CART-33 Phase 1 T38950 DRUGINFO D5QKY2 AL003 Phase 1 T38950 DRUGINFO D9OZ3B JNJ-67571244 Phase 1 T38950 DRUGINFO DSI4G9 225Ac-labelled aCD33 Phase 1 T38950 DRUGINFO D5T9GZ CLL1-CD33 cCART cell therapy Phase 1 T38950 DRUGINFO D8AOC1 AMG 330 Phase 1 T38950 DRUGINFO DB4C5H CD123-CD33 Ccar Phase 1 T38950 DRUGINFO DNS2P1 AMG 673 Phase 1 T38950 DRUGINFO DQD1T2 GEM333 Phase 1 T38950 DRUGINFO D01RNL Lintuzumab Discontinued in Phase 2 T38950 DRUGINFO D0IJ1D HuM-195-Bi-213 Discontinued in Phase 1/2 T38950 DRUGINFO D0E4EP Oncolysin M Discontinued in Phase 1 T38950 DRUGINFO D0JT0U CAR-T cells targeting CD33 Preclinical T40111 TARGETID T40111 T40111 FORMERID TTDS00062 T40111 UNIPROID IMDH1_HUMAN T40111 TARGNAME Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) T40111 GENENAME IMPDH1 T40111 TARGTYPE Successful T40111 SYNONYMS Superoxide-inducible protein 12; SOI12; Probable inosine-5'-monophosphate dehydrogenase IMD1; NAD-dependent inosine monophosphate dehydrogenase; Inosine dehydrogenase; IMPDH-I; IMPDH 1; IMPDH; IMPD1; IMPD 1; IMPD; IMP dehydrogenase 1; IMP dehydrogenase T40111 FUNCTION Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumors. Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. T40111 PDBSTRUC 1JCN T40111 BIOCLASS CH-OH donor oxidoreductase T40111 ECNUMBER EC 1.1.1.205 T40111 SEQUENCE MADYLISGGTGYVPEDGLTAQQLFASADGLTYNDFLILPGFIDFIADEVDLTSALTRKITLKTPLISSPMDTVTEADMAIAMALMGGIGFIHHNCTPEFQANEVRKVKKFEQGFITDPVVLSPSHTVGDVLEAKMRHGFSGIPITETGTMGSKLVGIVTSRDIDFLAEKDHTTLLSEVMTPRIELVVAPAGVTLKEANEILQRSKKGKLPIVNDCDELVAIIARTDLKKNRDYPLASKDSQKQLLCGAAVGTREDDKYRLDLLTQAGVDVIVLDSSQGNSVYQIAMVHYIKQKYPHLQVIGGNVVTAAQAKNLIDAGVDGLRVGMGCGSICITQEVMACGRPQGTAVYKVAEYARRFGVPIIADGGIQTVGHVVKALALGASTVMMGSLLAATTEAPGEYFFSDGVRLKKYRGMGSLDAMEKSSSSQKRYFSEGDKVKIAQGVSGSIQDKGSIQKFVPYLIAGIQHGCQDIGARSLSVLRSMMYSGELKFEKRTMSAQIEGGVHGLHSYEKRLY T40111 DRUGINFO D0G5AG Mizoribine Approved T40111 DRUGINFO D0H3WI Ribavirin Approved T40111 DRUGINFO D0S7DV Tiazofurin Approved T40111 DRUGINFO D09UZO Mercaptopurine Approved T40111 DRUGINFO D0F0ZE Merimepodib Approved T40111 DRUGINFO D09XUB Viramidine Phase 3 T40111 DRUGINFO D05QIS VX-944 Phase 2 T40111 DRUGINFO D00RJA VX-148 Patented T40111 DRUGINFO D00XRN PMID28074661-Compound-US20100022547C81 Patented T40111 DRUGINFO D01FPR PMID28074661-Compound-US20120264760C80 Patented T40111 DRUGINFO D01XUI Carbamide derivative 9 Patented T40111 DRUGINFO D03GSK Carbamide derivative 7 Patented T40111 DRUGINFO D03KFN PMID28074661-Compound-US20100022547C88 Patented T40111 DRUGINFO D03XKM PMID28074661-Compound-US20100022547C82 Patented T40111 DRUGINFO D04DRI Mycophenolic acid/nucleotide derivative 10 Patented T40111 DRUGINFO D05BGS Urea and carbamate bioisostere derivative 7 Patented T40111 DRUGINFO D05QMA Urea and carbamate bioisostere derivative 18 Patented T40111 DRUGINFO D05YHV Mycophenolic acid/nucleotide derivative 11 Patented T40111 DRUGINFO D06HLW PMID28074661-Compound-US20120264760C82 Patented T40111 DRUGINFO D06KXL Quinazolinone derivative 2 Patented T40111 DRUGINFO D06UKM PMID28074661-Compound-US20120264760C87 Patented T40111 DRUGINFO D07IOO Urea and carbamate bioisostere derivative 11 Patented T40111 DRUGINFO D07NDT PMID28074661-Compound-US20100022547C80 Patented T40111 DRUGINFO D07WXU Urea and carbamate bioisostere derivative 6 Patented T40111 DRUGINFO D07ZCP Carbamide derivative 4 Patented T40111 DRUGINFO D08EIA Carbamide derivative 6 Patented T40111 DRUGINFO D0B7FH PMID28074661-Compound-US20120264760C88 Patented T40111 DRUGINFO D0C8GW Quinolone derivative 1 Patented T40111 DRUGINFO D0D5YK Urea and carbamate bioisostere derivative 16 Patented T40111 DRUGINFO D0EX3N PMID28074661-Compound-WO2009018344C78 Patented T40111 DRUGINFO D0FY8B Carbamide derivative 8 Patented T40111 DRUGINFO D0FZ1H Mycophenolic acid/nucleotide derivative 4 Patented T40111 DRUGINFO D0G9BO Mycophenolic acid/nucleotide derivative 8 Patented T40111 DRUGINFO D0GR7W Mycophenolic acid/nucleotide derivative 2 Patented T40111 DRUGINFO D0H5UL PMID28074661-Compound-US20128202889C90 Patented T40111 DRUGINFO D0HO8C Urea and carbamate bioisostere derivative 2 Patented T40111 DRUGINFO D0IQ5V PMID28074661-Compound-US20100022547C86 Patented T40111 DRUGINFO D0J0EP PMID28074661-Compound-US20120264760C86 Patented T40111 DRUGINFO D0J4CI Mycophenolic acid/nucleotide derivative 12 Patented T40111 DRUGINFO D0J9WP PMID28074661-Compound-US20100022547C87 Patented T40111 DRUGINFO D0K4AQ Mycophenolic acid/nucleotide derivative 6 Patented T40111 DRUGINFO D0KN3S Carbamide derivative 5 Patented T40111 DRUGINFO D0L5UM Urea and carbamate bioisostere derivative 9 Patented T40111 DRUGINFO D0L7QE Mycophenolic acid/nucleotide derivative 9 Patented T40111 DRUGINFO D0LH0O Carbamide derivative 11 Patented T40111 DRUGINFO D0NK9Y Quinazolinone derivative 1 Patented T40111 DRUGINFO D0NN4P Urea and carbamate bioisostere derivative 5 Patented T40111 DRUGINFO D0OI4X Mycophenolic acid/nucleotide derivative 1 Patented T40111 DRUGINFO D0OS2M Mycophenolic acid/nucleotide derivative 5 Patented T40111 DRUGINFO D0P6WN Carbamide derivative 10 Patented T40111 DRUGINFO D0P8WC PMID28074661-Compound-US20169447134C85 Patented T40111 DRUGINFO D0PN7H PMID28074661-Compound-US20120264760C83 Patented T40111 DRUGINFO D0QA8T Urea and carbamate bioisostere derivative 4 Patented T40111 DRUGINFO D0QL7X Urea and carbamate bioisostere derivative 10 Patented T40111 DRUGINFO D0R3QC PMID28074661-Compound-WO2009018344C79 Patented T40111 DRUGINFO D0S7VL Urea and carbamate bioisostere derivative 15 Patented T40111 DRUGINFO D0SG2L PMID28074661-Compound-US20120264760C81 Patented T40111 DRUGINFO D0TZ1Y Mycophenolic acid/nucleotide derivative 7 Patented T40111 DRUGINFO D0UD3K Urea and carbamate bioisostere derivative 3 Patented T40111 DRUGINFO D0V3HE PMID28074661-Compound-US20158969342C84 Patented T40111 DRUGINFO D0W3KK Urea and carbamate bioisostere derivative 13 Patented T40111 DRUGINFO D0X6FX PMID28074661-Compound-US20100022547C83 Patented T40111 DRUGINFO D0XQ3W Mycophenolic acid/nucleotide derivative 3 Patented T40111 DRUGINFO D0Z7SK Urea and carbamate bioisostere derivative 14 Patented T40111 DRUGINFO D0O2IE Phenacetin Withdrawn from market T40111 DRUGINFO D03LIS Selenazofurin Investigative T40111 DRUGINFO D0F5TV TAD Investigative T40111 DRUGINFO D05EHM 6-Cl-IMP Investigative T40111 DRUGINFO D0H2YT Inosinic Acid Investigative T46828 TARGETID T46828 T46828 FORMERID TTDS00015 T46828 UNIPROID DRD5_HUMAN T46828 TARGNAME Dopamine D5 receptor (D5R) T46828 GENENAME DRD5 T46828 TARGTYPE Successful T46828 SYNONYMS Dopamine receptor 5; DRD5; D1beta dopamine receptor; D(5)D(1B) dopamine receptor dopamine receptor; D(5) dopamine receptor T46828 FUNCTION Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase. T46828 BIOCLASS GPCR rhodopsin T46828 SEQUENCE MLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLLIIWTLLGNVLVCAAIVRSRHLRANMTNVFIVSLAVSDLFVALLVMPWKAVAEVAGYWPFGAFCDVWVAFDIMCSTASILNLCVISVDRYWAISRPFRYKRKMTQRMALVMVGLAWTLSILISFIPVQLNWHRDQAASWGGLDLPNNLANWTPWEEDFWEPDVNAENCDSSLNRTYAISSSLISFYIPVAIMIVTYTRIYRIAQVQIRRISSLERAAEHAQSCRSSAACAPDTSLRASIKKETKVLKTLSVIMGVFVCCWLPFFILNCMVPFCSGHPEGPPAGFPCVSETTFDVFVWFGWANSSLNPVIYAFNADFQKVFAQLLGCSHFCSRTPVETVNISNELISYNQDIVFHKEIAAAYIHMMPNAVTPGNREVDNDEEEGPFDRMFQIYQTSPDGDPVAESVWELDCEGEISLDKITPFTPNGFH T46828 DRUGINFO D0KS6W Phenyltoloxamine Approved T46828 DRUGINFO D07YLK LE-300 Preclinical T46828 DRUGINFO D05RMW ZD-3638 Terminated T46828 DRUGINFO D0A3OF GMC-283 Terminated T46828 DRUGINFO D08EXR beta-ergocriptine Investigative T46828 DRUGINFO D09KRA [125I]SCH23982 Investigative T46828 DRUGINFO D0LR8X SKF-83556 Investigative T46828 DRUGINFO D0X2NO (+)-ADTN Investigative T46828 DRUGINFO D01ENR 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine Investigative T46828 DRUGINFO D0LV7U 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one Investigative T46828 DRUGINFO D06LQH N-propylnorapomorphine Investigative T46828 DRUGINFO D07RYR 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine Investigative T46828 DRUGINFO D05UUW 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine Investigative T46828 DRUGINFO D0E1RX 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine Investigative T46828 DRUGINFO D0L7OM STEPHOLIDINE Investigative T46828 DRUGINFO D0MC2R FLUTROLINE Investigative T46828 DRUGINFO D0R8UU 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine Investigative T46828 DRUGINFO D0HV3A FLUMEZAPINE Investigative T46828 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T46828 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T46828 DRUGINFO D0L5MW (+/-)-nantenine Investigative T28993 TARGETID T28993 T28993 FORMERID TTDI02286 T28993 UNIPROID IDS_HUMAN T28993 TARGNAME Iduronate 2-sulfatase (IDS) T28993 GENENAME IDS T28993 TARGTYPE Successful T28993 SYNONYMS Idursulfase; Iduronate 2sulfatase 14 kDa chain; IDS; AlphaLiduronate sulfate sulfatase T28993 FUNCTION Required for the lysosomal degradation ofheparan sulfate and dermatan sulfate. T28993 PDBSTRUC 6IOZ; 5FQL T28993 BIOCLASS Sulfuric ester hydrolase T28993 ECNUMBER EC 3.1.6.13 T28993 SEQUENCE MPPPRTGRGLLWLGLVLSSVCVALGSETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPVDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQREDVQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPGNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP T28993 DRUGINFO D06CZJ Idursulfase Approved T28993 DRUGINFO D0L1DR Recombinant human iduronate-2-sulfatase Phase 3 T28993 DRUGINFO DTV58L DNL310 Phase 2/3 T28993 DRUGINFO DY21QW RGX-121 Phase 1/2 T28993 DRUGINFO DY9DX8 SB-913 Phase 1/2 T17569 TARGETID T17569 T17569 FORMERID TTDC00303 T17569 UNIPROID KCNA5_HUMAN T17569 TARGNAME Voltage-gated potassium channel Kv1.5 (KCNA5) T17569 GENENAME KCNA5 T17569 TARGTYPE Successful T17569 SYNONYMS Voltage-gatedpotassium channel subunit Kv1.5; Voltage-gated potassium channel subunit Kv1.5; Voltage-gated potassium channel HK2; Potassium voltage-gated channel subfamily A member 5; Potassium channel Kv1.5; HPCN1; HK2; 02-Sensitive Potassium Channel Kv1.5 T17569 FUNCTION Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation. Homotetrameric channels display rapid activation and slow inactivation. May play a role in regulating the secretion of insulin in normal pancreatic islets. Isoform 2 exhibits a voltage-dependent recovery from inactivation and an excessive cumulative inactivation. Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. T17569 BIOCLASS Voltage-gated ion channel T17569 SEQUENCE MEIALVPLENGGAMTVRGGDEARAGCGQATGGELQCPPTAGLSDGPKEPAPKGRGAQRDADSGVRPLPPLPDPGVRPLPPLPEELPRPRRPPPEDEEEEGDPGLGTVEDQALGTASLHHQRVHINISGLRFETQLGTLAQFPNTLLGDPAKRLRYFDPLRNEYFFDRNRPSFDGILYYYQSGGRLRRPVNVSLDVFADEIRFYQLGDEAMERFREDEGFIKEEEKPLPRNEFQRQVWLIFEYPESSGSARAIAIVSVLVILISIITFCLETLPEFRDERELLRHPPAPHQPPAPAPGANGSGVMAPPSGPTVAPLLPRTLADPFFIVETTCVIWFTFELLVRFFACPSKAGFSRNIMNIIDVVAIFPYFITLGTELAEQQPGGGGGGQNGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGKTLQASMRELGLLIFFLFIGVILFSSAVYFAEADNQGTHFSSIPDAFWWAVVTMTTVGYGDMRPITVGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETDHEEPAVLKEEQGTQSQGPGLDRGVQRKVSGSRGSFCKAGGTLENADSARRGSCPLEKCNVKAKSNVDLRRSLYALCLDTSRETDL T17569 DRUGINFO D05CPV Dronedarone Approved T17569 DRUGINFO D04LOR BMS-919373 Phase 2 T17569 DRUGINFO D00RNB IQB-9302 Phase 1 T17569 DRUGINFO D05DXT XEN-D0103 Phase 1 T17569 DRUGINFO D06ERY BMS-394136 Phase 1 T17569 DRUGINFO D0X6ZG XEN-D0101 Phase 1 T17569 DRUGINFO D0TV4N T-226296 Preclinical T17569 DRUGINFO D0NR3V Zatebradine Terminated T17569 DRUGINFO D00UCP N-Phenethyl-2-(toluene-4-sulfonylamino)-benzamide Investigative T17569 DRUGINFO D00WKK 2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol Investigative T17569 DRUGINFO D06BMZ 2-morpholino-1,1,2-triphenylethanol Investigative T17569 DRUGINFO D07VWP S-9947 Investigative T17569 DRUGINFO D08LZZ DPO-1 Investigative T17569 DRUGINFO D0A5KP 2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol Investigative T17569 DRUGINFO D0D8JU 2-phenyl-1,1-di(pyridin-3-yl)ethanol Investigative T17569 DRUGINFO D0H7JE RS-100302 Investigative T17569 DRUGINFO D0I2NX N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide Investigative T17569 DRUGINFO D0J0OY 3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one Investigative T17569 DRUGINFO D0K7RO 2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol Investigative T17569 DRUGINFO D0QG6A NIP-142 Investigative T17569 DRUGINFO D0R5OF 3-methyl-2-morpholino-1,1-diphenylbutan-1-ol Investigative T17569 DRUGINFO D0T0VZ XEN-D0104 Investigative T17569 DRUGINFO D0U9DD 2-phenoxy-1-(2-p-tolylthiazolidin-3-yl)ethanone Investigative T17569 DRUGINFO D0XB2Z 3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one Investigative T17569 DRUGINFO D0Y8AB 2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol Investigative T17569 DRUGINFO D02QJW clofilium Investigative T17569 DRUGINFO D0R9CF 4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one Investigative T17569 DRUGINFO D06PZZ [14C]TEA Investigative T42822 TARGETID T42822 T42822 FORMERID TTDS00437 T42822 UNIPROID HEMH_HUMAN T42822 TARGNAME Ferrochelatase (FECH) T42822 GENENAME FECH T42822 TARGTYPE Successful T42822 SYNONYMS Protoheme ferro-lyase; Heme synthetase; FECH T42822 FUNCTION Catalyzes the ferrous insertion into protoporphyrin IX. T42822 PDBSTRUC 4MK4; 4KMM; 4KLR; 4KLC; 4KLA T42822 BIOCLASS Ferrochelatase T42822 ECNUMBER EC 4.99.1.1 T42822 SEQUENCE MRSLGANMAAALRAAGVLLRDPLASSSWRVCQPWRWKSGAAAAAVTTETAQHAQGAKPQVQPQKRKPKTGILMLNMGGPETLGDVHDFLLRLFLDRDLMTLPIQNKLAPFIAKRRTPKIQEQYRRIGGGSPIKIWTSKQGEGMVKLLDELSPNTAPHKYYIGFRYVHPLTEEAIEEMERDGLERAIAFTQYPQYSCSTTGSSLNAIYRYYNQVGRKPTMKWSTIDRWPTHHLLIQCFADHILKELDHFPLEKRSEVVILFSAHSLPMSVVNRGDPYPQEVSATVQKVMERLEYCNPYRLVWQSKVGPMPWLGPQTDESIKGLCERGRKNILLVPIAFTSDHIETLYELDIEYSQVLAKECGVENIRRAESLNGNPLFSKALADLVHSHIQSNELCSKQLTLSCPLCVNPVCRETKSFFTSQQL T42822 DRUGINFO D0OL6O Methyl aminolevulinate Approved T42822 DRUGINFO D0OR2L Cholic Acid Approved T42822 DRUGINFO D00GJZ N-Methylmesoporphyrin Containing Copper Investigative T42822 DRUGINFO D0S4VW Lead acetate Investigative T42822 DRUGINFO D0X5ZA N-Methylmesoporphyrin Investigative T79473 TARGETID T79473 T79473 FORMERID TTDS00254 T79473 UNIPROID LSHR_HUMAN T79473 TARGNAME Luteinizing hormone receptor (LHCGR) T79473 GENENAME LHCGR T79473 TARGTYPE Successful T79473 SYNONYMS Luteinizing hormone-releasing hormone receptor; LSH-R; LHRH receptor; LHCGR; LH/CG-R T79473 FUNCTION Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. T79473 PDBSTRUC 1XUL; 1LUT T79473 BIOCLASS GPCR rhodopsin T79473 SEQUENCE MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLPVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFINLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLKLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSYGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENFSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYDFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDSQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRLRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFFIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLITVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYTSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC T79473 DRUGINFO D0J0LI Chorionic Gonadotropin Approved T79473 DRUGINFO D0W6SS Choriogonadotropin alfa Approved T79473 DRUGINFO D0Z2CM Lutropin alfa Approved T79473 DRUGINFO D08DOE ML-04 Phase 2 T79473 DRUGINFO D0M3TD Org-43902 Phase 1 T79473 DRUGINFO D0K0GN LDI-200 Discontinued in Phase 3 T79473 DRUGINFO D00TTS Human chorionic gonadotropin Terminated T79473 DRUGINFO D04CTP EP-200 Investigative T25847 TARGETID T25847 T25847 FORMERID TTDS00417 T25847 UNIPROID PPIB_HUMAN T25847 TARGNAME Rotamase B (PPIB) T25847 GENENAME PPIB T25847 TARGTYPE Successful T25847 SYNONYMS SCYLP; S-cyclophilin; Peptidyl-prolyl cis-trans isomerase B; PPIase B; Cyclophilin B; CYPB; CYP-S1 T25847 FUNCTION PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. T25847 PDBSTRUC 3ICI; 3ICH; 1CYN T25847 BIOCLASS Cis-trans-isomerase T25847 ECNUMBER EC 5.2.1.8 T25847 SEQUENCE MLRLSERNMKVLLAAALIAGSVFFLLLPGPSAADEKKKGPKVTVKVYFDLRIGDEDVGRVIFGLFGKTVPKTVDNFVALATGEKGFGYKNSKFHRVIKDFMIQGGDFTRGDGTGGKSIYGERFPDENFKLKHYGPGWVSMANAGKDTNGSQFFITTVKTAWLDGKHVVFGKVLEGMEVVRKVESTKTDSRDKPLKDVIIADCGKIEVEKPFAIAKE T25847 DRUGINFO D0DZ3X L-Proline Approved T25847 DRUGINFO D01GMJ 1,4-Dithiothreitol Investigative T50269 TARGETID T50269 T50269 FORMERID TTDR00771 T50269 UNIPROID GLRA1_HUMAN T50269 TARGNAME Strychnine-binding glycine receptor (GLRA1) T50269 GENENAME GLRA1 T50269 TARGTYPE Successful T50269 SYNONYMS Strychnine-insensitive glycine receptor; Strychnine binding subunit; Glycine receptor 48 kDa subunit; GLRA1 T50269 FUNCTION The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing). T50269 PDBSTRUC 4X5T; 2M6I; 2M6B; 1VRY; 1MOT T50269 BIOCLASS Neurotransmitter receptor T50269 SEQUENCE MYSFNTLRLYLWETIVFFSLAASKEAEAARSAPKPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVSCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYNEYPDDSLDLDPSMLDSIWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLTLACPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQEQGAVQVADGLTLPQFILKEEKDLRYCTKHYNTGKFTCIEARFHLERQMGYYLIQMYIPSLLIVILSWISFWINMDAAPARVGLGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRQHKELLRFRRKRRHHKSPMLNLFQEDEAGEGRFNFSAYGMGPACLQAKDGISVKGANNSNTTNPPPAPSKSPEEMRKLFIQRAKKIDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ T50269 DRUGINFO D0IG4I THIOCOLCHICOSIDE Approved T50269 DRUGINFO D02UDJ D-Serine Phase 4 T50269 DRUGINFO D04ZCZ GINKOLIDE B Terminated T50269 DRUGINFO D04IEW GINKGOLIDE A Investigative T50269 DRUGINFO D0D1EE Ginkgolide J Investigative T50269 DRUGINFO D0G2OJ Ginkgolide C Investigative T50269 DRUGINFO D0H0BD [3H]strychnine Investigative T50269 DRUGINFO D0JU4G Ginkgolide M Investigative T50269 DRUGINFO D0M4ZK 10-methoxy-ginkgolide C Investigative T50269 DRUGINFO D0X3TL 3,14-DIDEHYDROGINKGOLIDE A Investigative T50269 DRUGINFO D04RVA 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine Investigative T50269 DRUGINFO D06XGL 3-demethoxy-3-D-xylopyranosylaminothiocolchicine Investigative T50269 DRUGINFO D08YLW 3-demethoxy-3-L-fucopyranosylaminothiocolchicine Investigative T50269 DRUGINFO D09MHS 3-demethoxy-3D-glucopyranosylaminothiocolchicine Investigative T50269 DRUGINFO D0LP2K 3-demethoxy-3-D-mannopyranosylaminothiocolchicine Investigative T55285 TARGETID T55285 T55285 FORMERID TTDC00039 T55285 UNIPROID GLRA1_HUMAN; GLRA2_HUMAN; GLRA3_HUMAN; GLRA4_HUMAN; GLRB_HUMAN T55285 TARGNAME Glycine receptor (GlyR) T55285 GENENAME GLRA1; GLRA2; GLRA3; GLRA4; GLRB T55285 TARGTYPE Successful T55285 SYNONYMS Glycine receptor T55285 FUNCTION The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing). T55285 BIOCLASS Neurotransmitter receptor T55285 SEQUENCE MYSFNTLRLYLWETIVFFSLAASKEAEAARSAPKPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVSCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYNEYPDDSLDLDPSMLDSIWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLTLACPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQEQGAVQVADGLTLPQFILKEEKDLRYCTKHYNTGKFTCIEARFHLERQMGYYLIQMYIPSLLIVILSWISFWINMDAAPARVGLGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRQHKELLRFRRKRRHHKSPMLNLFQEDEAGEGRFNFSAYGMGPACLQAKDGISVKGANNSNTTNPPPAPSKSPEEMRKLFIQRAKKIDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ T55285 DRUGINFO D0IG4I THIOCOLCHICOSIDE Approved T55285 DRUGINFO D06RYY ZD-9379 Phase 1 T55285 DRUGINFO D0N7BL UK-240455 Phase 1 T55285 DRUGINFO D0TT5K MDL-27531 Phase 1 T55285 DRUGINFO D05ERT GV-196771 Discontinued in Phase 2 T55285 DRUGINFO D0O0FF GW 468816 Discontinued in Phase 2 T55285 DRUGINFO D0O6AQ Gavestinel Discontinued in Phase 2 T55285 DRUGINFO D02NVF M-241247 Terminated T55285 DRUGINFO D04ZCZ GINKOLIDE B Terminated T55285 DRUGINFO D05OAE (12E,20Z,18S)-8-hydroxyvariabilin Investigative T55285 DRUGINFO D07QEH ginkgolide X Investigative T55285 DRUGINFO D09BKM alkylbenzene sulfonate Investigative T55285 DRUGINFO D09SZL NV-31 Investigative T55285 DRUGINFO D0AD1L PMBA Investigative T55285 DRUGINFO D0C6IE taurine Investigative T55285 DRUGINFO D0H2XJ alpha-Emtbl Investigative T55285 DRUGINFO D0V9XF PICROTIN Investigative T55285 DRUGINFO D0Z3FP NBBCC Investigative T55285 DRUGINFO D04IEW GINKGOLIDE A Investigative T55285 DRUGINFO D0D1EE Ginkgolide J Investigative T55285 DRUGINFO D0G2OJ Ginkgolide C Investigative T55285 DRUGINFO D0H0BD [3H]strychnine Investigative T55285 DRUGINFO D0JU4G Ginkgolide M Investigative T55285 DRUGINFO D0M4ZK 10-methoxy-ginkgolide C Investigative T55285 DRUGINFO D0X3TL 3,14-DIDEHYDROGINKGOLIDE A Investigative T55285 DRUGINFO D0B0TK bilobalide Investigative T55285 DRUGINFO D04RVA 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine Investigative T55285 DRUGINFO D06XGL 3-demethoxy-3-D-xylopyranosylaminothiocolchicine Investigative T55285 DRUGINFO D08YLW 3-demethoxy-3-L-fucopyranosylaminothiocolchicine Investigative T55285 DRUGINFO D09MHS 3-demethoxy-3D-glucopyranosylaminothiocolchicine Investigative T55285 DRUGINFO D0LP2K 3-demethoxy-3-D-mannopyranosylaminothiocolchicine Investigative T21945 TARGETID T21945 T21945 FORMERID TTDC00304 T21945 UNIPROID SC6A2_HUMAN T21945 TARGNAME Norepinephrine transporter (NET) T21945 GENENAME SLC6A2 T21945 TARGTYPE Successful T21945 SYNONYMS Solute carrier family 6 member 2; Sodium-dependent noradrenaline transporter; SLC6A2; NET1; NET; NAT1 T21945 FUNCTION Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals. T21945 BIOCLASS Neurotransmitter:sodium symporter T21945 SEQUENCE MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWGKKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYNREGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTWNSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLCLMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFYRLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFAIFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSSMGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTSILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINFKPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHLVAQRDIRQFQLQHWLAI T21945 DRUGINFO D00HZV Trimipramine Approved T21945 DRUGINFO D00MYQ Protriptyline Approved T21945 DRUGINFO D01UTL Desipramine Approved T21945 DRUGINFO D02JIS Iobenguane I-123 Approved T21945 DRUGINFO D03CEF Desvenalfaxine succinate Approved T21945 DRUGINFO D03KQF Maprotiline Approved T21945 DRUGINFO D04CRN Atomoxetine Approved T21945 DRUGINFO D06ZUK Imipramine Approved T21945 DRUGINFO D09IOI Amoxapine Approved T21945 DRUGINFO D09VGC Milnacipran Approved T21945 DRUGINFO D0H8QL Mazindol Approved T21945 DRUGINFO D0N8FQ Reboxetine Approved T21945 DRUGINFO D0U0RZ Phentermine Approved T21945 DRUGINFO D01AXB Duloxetine Approved T21945 DRUGINFO D02XOK Levomilnacipran Approved T21945 DRUGINFO D08KVZ Sibutramine Approved T21945 DRUGINFO D0B7OD Amfepramone Approved T21945 DRUGINFO D0K4MH Tapentadol hydrochloride Approved T21945 DRUGINFO D0M2MC Phenmetrazine Approved T21945 DRUGINFO D0P1UX Venlafaxine Approved T21945 DRUGINFO D0X4ZR Bupropion Approved T21945 DRUGINFO D0Y5UG Amitriptyline Approved T21945 DRUGINFO D04WYX Netarsudil Approved T21945 DRUGINFO D04XPW Cocaine Approved T21945 DRUGINFO D0U5QK Acetaminophen Approved T21945 DRUGINFO D0W6KM Dasotraline Approved T21945 DRUGINFO D08BYK Hypericum Phase 4 T21945 DRUGINFO DRL5Y7 SPN-812 Phase 4 T21945 DRUGINFO D03QIE Bicifadine Phase 3 T21945 DRUGINFO D0BN7W Roclatan Phase 3 T21945 DRUGINFO D0MZ9A Suronacrine maleate Phase 3 T21945 DRUGINFO D01TMQ Bupropion+naltrexone Phase 3 T21945 DRUGINFO D04PXS Amitifadine Phase 3 T21945 DRUGINFO D01BAU SPN-812 Phase 2 T21945 DRUGINFO D02GWJ MCT-125 Phase 2 T21945 DRUGINFO D04IKF 18F-LMI-1195 Phase 2 T21945 DRUGINFO D05FQD Metaiodobenzylguanidine I-131 Phase 2 T21945 DRUGINFO D0E2EY BLI-1005 Phase 2 T21945 DRUGINFO D0U2XU XEN-2174 Phase 2 T21945 DRUGINFO DC2DO5 PDC-1421 Phase 2 T21945 DRUGINFO D02JKY TD-9855 Phase 2 T21945 DRUGINFO D04KHY Spiroglumide Phase 2 T21945 DRUGINFO D07QXU NS 2359 Phase 2 T21945 DRUGINFO D0FM7Z BL-1021 Phase 1 T21945 DRUGINFO D0K7OW GSK-1360707 Phase 1 T21945 DRUGINFO D01NJT Esreboxetine Discontinued in Phase 2 T21945 DRUGINFO D06KOL Napitane mesilate Discontinued in Phase 2 T21945 DRUGINFO D0A5RD Radafaxine Discontinued in Phase 2 T21945 DRUGINFO D0B2OC R-sibutramine metabolite Discontinued in Phase 2 T21945 DRUGINFO D0O6QW Manifaxine Discontinued in Phase 2 T21945 DRUGINFO D0H9GQ DOV-216303 Discontinued in Phase 2 T21945 DRUGINFO D0LU6N SPD-473 Discontinued in Phase 2 T21945 DRUGINFO D0M9LB NS-2389 Discontinued in Phase 2 T21945 DRUGINFO D04VUY RG-7166 Discontinued in Phase 1 T21945 DRUGINFO D08UNQ NSD-644 Discontinued in Phase 1 T21945 DRUGINFO D05CBG 4-(3'-furyl)-aniline Investigative T21945 DRUGINFO D0D1KK (R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol Investigative T21945 DRUGINFO D0GE9U 3-(3'-furyl)-aniline Investigative T21945 DRUGINFO D0H3CQ [3H]nisoxetine Investigative T21945 DRUGINFO D0KS0I WAY-256805 Investigative T21945 DRUGINFO D0TH6L N-desalkylquetiapine Investigative T21945 DRUGINFO D0V4FW {2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine Investigative T21945 DRUGINFO D0V9SV POLYGALATENOSIDE B Investigative T21945 DRUGINFO D0X5AA AMIFLAMINE Investigative T21945 DRUGINFO D00WMS 2-(N-tert-Butylamino)propiophenone Investigative T21945 DRUGINFO D01EIS 1-(1,2-diphenylethyl)piperazine Investigative T21945 DRUGINFO D01GSG (R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile Investigative T21945 DRUGINFO D01RWY 2-(N-tert-Butylamino)-3'-chloroheptanophenone Investigative T21945 DRUGINFO D01SHR ((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine Investigative T21945 DRUGINFO D01YED 2-(N-Pyrrolidinyl)-3'-methoxypropiophenone Investigative T21945 DRUGINFO D03MYV 2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile Investigative T21945 DRUGINFO D03PMB PTI-601 Investigative T21945 DRUGINFO D03ZDY 1-(2-(2-bromophenyl)-1-phenylethyl)piperazine Investigative T21945 DRUGINFO D05WFQ norzotepine Investigative T21945 DRUGINFO D06GFV 1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine Investigative T21945 DRUGINFO D06LCK 2-(N-Pyrrolidinyl)-3'-fluoropropiophenone Investigative T21945 DRUGINFO D06PJD 3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine Investigative T21945 DRUGINFO D07IOX 2-(N-tert-Butylamino)-3'-chlorooctanophenone Investigative T21945 DRUGINFO D08LAY 1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine Investigative T21945 DRUGINFO D08MEN KF-A5 Investigative T21945 DRUGINFO D08MUX S33005 Investigative T21945 DRUGINFO D09BYB 2-(tert-butylamino)-1-p-tolylpropan-1-one Investigative T21945 DRUGINFO D09DWM Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine Investigative T21945 DRUGINFO D09JRN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile Investigative T21945 DRUGINFO D09XWL 2-(N-Cyclopentylamino)-3'-fluoropropiophenone Investigative T21945 DRUGINFO D0A1HH 1-(1-phenyl-2-o-tolylethyl)piperazine Investigative T21945 DRUGINFO D0B4FN 2pyrrolidin-1-yl-1-phenylpentan-1-one Investigative T21945 DRUGINFO D0B5AG Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine Investigative T21945 DRUGINFO D0C0GL 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one Investigative T21945 DRUGINFO D0D8YY N-benzyl-N-isobutylpiperidin-4-amine Investigative T21945 DRUGINFO D0EO5P 1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine Investigative T21945 DRUGINFO D0EX2M 1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine Investigative T21945 DRUGINFO D0G0CJ 2-(N-Cyclopentylamino)-3'-bromopropiophenone Investigative T21945 DRUGINFO D0G0NB 2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine Investigative T21945 DRUGINFO D0GY8R 2-(N-Pyrrolidinyl)-3'-methylpropiophenone Investigative T21945 DRUGINFO D0I4TO (S)-NORDULOXETINE Investigative T21945 DRUGINFO D0KD9M (S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile Investigative T21945 DRUGINFO D0L6RY 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T21945 DRUGINFO D0M4AQ 2-((2-iodophenoxy)(phenyl)methyl)morpholine Investigative T21945 DRUGINFO D0NM1F (R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide Investigative T21945 DRUGINFO D0O2LC 2-(N-Cyclopentylamino)-3'-chloropropiophenone Investigative T21945 DRUGINFO D0P6SY MDL-28618 Investigative T21945 DRUGINFO D0P9EO 2-(N-Cyclopentylamino)-3'-methylpropiophenone Investigative T21945 DRUGINFO D0Q8IQ 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one Investigative T21945 DRUGINFO D0Q9UZ 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine Investigative T21945 DRUGINFO D0R5AD 2-(N,N-Diethylamino)-3'-chloropropiophenone Investigative T21945 DRUGINFO D0S9IO N-(2-oxazolemethyl)milnacipran Investigative T21945 DRUGINFO D0T5VG 2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran Investigative T21945 DRUGINFO D0U3SB 2-(N-Pyrrolidinyl)-3'-bromopropiophenone Investigative T21945 DRUGINFO D0V8IZ 2-(N-tert-Butylamino)-3'-chlorohexanophenone Investigative T21945 DRUGINFO D0VC1K N,N-dimethyl(2-phenoxyphenyl)methanamine Investigative T21945 DRUGINFO D0VY9K 2-(N-Pyrrolidinyl)-3'-nitropropiophenone Investigative T21945 DRUGINFO D0W9JK (S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide Investigative T21945 DRUGINFO D0XY9E 2-(N-tert-Butylamino)-3'-chloropentanophenone Investigative T21945 DRUGINFO D0Y7CS 2-(tert-butylamino)-1-m-tolylpropan-1-one Investigative T21945 DRUGINFO D0Z5GR 1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine Investigative T21945 DRUGINFO D0Z6YA 1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine Investigative T21945 DRUGINFO D00FMX 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine Investigative T21945 DRUGINFO D00GDI 2-(N-tert-Butylamino)-3',4'-dichloropropiophenone Investigative T21945 DRUGINFO D00VUT D-257C Investigative T21945 DRUGINFO D01AOI 6-(piperidin-4-ylmethoxy)-2-naphthonitrile Investigative T21945 DRUGINFO D02ENH (R)-Norfluoxetine Investigative T21945 DRUGINFO D02ICX PYROVALERONE Investigative T21945 DRUGINFO D02TMK METHYLENEDIOXYAMPHETAMINE Investigative T21945 DRUGINFO D02UUC 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane Investigative T21945 DRUGINFO D02YOO NISOXETINE Investigative T21945 DRUGINFO D02YSN 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran Investigative T21945 DRUGINFO D02ZIQ 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one Investigative T21945 DRUGINFO D03BQV 1S,2R-milnacipran Investigative T21945 DRUGINFO D03HQF 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran Investigative T21945 DRUGINFO D03JOX 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T21945 DRUGINFO D03ZFX D-254C Investigative T21945 DRUGINFO D04KZX 2-(tert-Butylamino)-3',4'-dichlorobutyrophenone Investigative T21945 DRUGINFO D05LKO 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine Investigative T21945 DRUGINFO D05UMA (R)-DULOXETINE Investigative T21945 DRUGINFO D06CMJ Para-chloroamphetamine Investigative T21945 DRUGINFO D06EMC PF-18298 Investigative T21945 DRUGINFO D06KNV [3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine Investigative T21945 DRUGINFO D06QGD 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T21945 DRUGINFO D06UDU 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine Investigative T21945 DRUGINFO D06WIV Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine Investigative T21945 DRUGINFO D07DMN 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine Investigative T21945 DRUGINFO D07DWS 1-(2-(2-fluorobenzyloxy)phenyl)piperazine Investigative T21945 DRUGINFO D07RQT 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane Investigative T21945 DRUGINFO D07SAA 2-(N-Cyclopropylamino)-3-chloropropiophenone Investigative T21945 DRUGINFO D07ZOP 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T21945 DRUGINFO D08AWN (S)-Norfluoxetine Investigative T21945 DRUGINFO D08TJY D-257A Investigative T21945 DRUGINFO D08YCS TQ-1017 Investigative T21945 DRUGINFO D09QZM 2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran Investigative T21945 DRUGINFO D09ZAT 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol Investigative T21945 DRUGINFO D0G1XP 2-(tert-Butylamino)-3',4'-dichloropentanophenone Investigative T21945 DRUGINFO D0G5RH WIN-35066-2 Investigative T21945 DRUGINFO D0G8UA (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol Investigative T21945 DRUGINFO D0GG2J 1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T21945 DRUGINFO D0H2TS 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine Investigative T21945 DRUGINFO D0H4AD 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one Investigative T21945 DRUGINFO D0I9KV 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T21945 DRUGINFO D0IB6Y 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran Investigative T21945 DRUGINFO D0J0ES 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol Investigative T21945 DRUGINFO D0J5AR 2-(2'-Aminoethyl)-5-benzyltetrahydrofuran Investigative T21945 DRUGINFO D0K6ZT 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine Investigative T21945 DRUGINFO D0L0AY 2-(Aminomethyl)-5-phenethyltetrahydrofuran Investigative T21945 DRUGINFO D0L7BK 1-(1,4-diphenylbutan-2-yl)piperazine Investigative T21945 DRUGINFO D0LD1X D-211B Investigative T21945 DRUGINFO D0N0TQ 2-Aminomethyl-5-(phenyl)tetrahydrofuran Investigative T21945 DRUGINFO D0N2RJ 1-(2-(3-fluorophenoxy)phenyl)piperazine Investigative T21945 DRUGINFO D0N3DD [3H]WIN35428 Investigative T21945 DRUGINFO D0NY4W 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T21945 DRUGINFO D0O9BL 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T21945 DRUGINFO D0Q6SH 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine Investigative T21945 DRUGINFO D0R8EV 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one Investigative T21945 DRUGINFO D0RT9B 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran Investigative T21945 DRUGINFO D0S9AY 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine Investigative T21945 DRUGINFO D0SB6Y D-211A Investigative T21945 DRUGINFO D0SN6R (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine Investigative T21945 DRUGINFO D0T8BU 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol Investigative T21945 DRUGINFO D0V0PR 4-(2-(phenoxymethyl)phenyl)piperidine Investigative T21945 DRUGINFO D0V3LR D-166A Investigative T21945 DRUGINFO D0W8BJ Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine Investigative T21945 DRUGINFO D0WB6P R-NORDULOXETINE Investigative T21945 DRUGINFO D0X8LG 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one Investigative T21945 DRUGINFO D0Y3BI 2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran Investigative T21945 DRUGINFO D0Y5CG 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine Investigative T21945 DRUGINFO D0Z4UF RTI-219 Investigative T21945 DRUGINFO D0Z9OX 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine Investigative T21945 DRUGINFO D0ZE4C 2-(N-Cyclopentylamino)-3'-methoxypropiophenone Investigative T21945 DRUGINFO D0ZU5W 1-(2-(benzyloxy)phenyl)piperazine Investigative T21945 DRUGINFO D00DEH 4-(2-(3-chlorophenoxy)phenyl)piperidine Investigative T21945 DRUGINFO D00HCC 1-(2-phenoxyphenyl)piperazine Investigative T21945 DRUGINFO D00KRQ 4-(2-phenoxyphenyl)piperidine Investigative T21945 DRUGINFO D01ABR 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine Investigative T21945 DRUGINFO D01FFX 4-((naphthalen-2-yloxy)methyl)piperidine Investigative T21945 DRUGINFO D01JYY (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide Investigative T21945 DRUGINFO D01MBF 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine Investigative T21945 DRUGINFO D01YNZ 4-(2-(benzyloxy)phenyl)piperidine Investigative T21945 DRUGINFO D03DQQ 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine Investigative T21945 DRUGINFO D04NDO 4-(2-(2-fluorobenzyloxy)phenyl)piperidine Investigative T21945 DRUGINFO D04NKQ 4-(2-(4-fluorophenoxy)phenyl)piperidine Investigative T21945 DRUGINFO D04ZPF 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine Investigative T21945 DRUGINFO D05LJC 4-(2-(benzyloxy)-3-fluorophenyl)piperidine Investigative T21945 DRUGINFO D08EKQ 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T21945 DRUGINFO D08JLB 4-(2-(benzyloxy)-6-fluorophenyl)piperidine Investigative T21945 DRUGINFO D08SCH 2-Amino-1-(4-methylthiophenyl)propane Investigative T21945 DRUGINFO D09FIC 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T21945 DRUGINFO D09IIH 4-(3-fluoro-2-phenoxyphenyl)piperidine Investigative T21945 DRUGINFO D0CG2Y 2-phenoxy-3-(piperidin-4-yl)pyridine Investigative T21945 DRUGINFO D0E3DM (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine Investigative T21945 DRUGINFO D0E6PQ 4-(2-fluoro-6-phenoxyphenyl)piperidine Investigative T21945 DRUGINFO D0F0BS 3alpha-(bis-chloro-phenylmethoxy)tropane Investigative T21945 DRUGINFO D0F6GB 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine Investigative T21945 DRUGINFO D0IC4J 4-(2-(3-fluorophenoxy)phenyl)piperidine Investigative T21945 DRUGINFO D0KT2M 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine Investigative T21945 DRUGINFO D0M3TK 1-(2-(4-fluorophenoxy)phenyl)piperazine Investigative T21945 DRUGINFO D0R3TA 4-(2-(4-fluorobenzyloxy)phenyl)piperidine Investigative T21945 DRUGINFO D0S4JT 1-(2-(phenoxymethyl)phenyl)piperazine Investigative T21945 DRUGINFO D0U7OD PF-526014 Investigative T21945 DRUGINFO D0W8YO 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine Investigative T21945 DRUGINFO D0XF5P (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine Investigative T21945 DRUGINFO D0Y8UC Difluorobenztropine Investigative T21945 DRUGINFO D00QCP (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol Investigative T21945 DRUGINFO D03YQY (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol Investigative T21945 DRUGINFO D06QIQ 7-(piperidin-4-ylmethoxy)-2-naphthonitrile Investigative T21945 DRUGINFO D0FU5E S-34324 Investigative T21945 DRUGINFO D0N2KU PF-3409409 Investigative T21945 DRUGINFO D0F5NJ METHYLENEDIOXYMETHAMPHETAMINE Investigative T21945 DRUGINFO D0I4ME MMDA Investigative T21945 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T92828 TARGETID T92828 T92828 FORMERID TTDS00199 T92828 UNIPROID EDNRB_HUMAN T92828 TARGNAME Endothelin B receptor (EDNRB) T92828 GENENAME EDNRB T92828 TARGTYPE Successful T92828 SYNONYMS Endothelin receptor type B; Endothelin receptor Non-selective type; Endothelin receptor B; ETRB; ET-BR; ET-B T92828 FUNCTION Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Non-specific receptor for endothelin 1, 2, and 3. T92828 PDBSTRUC 6IGL; 6IGK; 5XPR; 5X93; 5GLI T92828 BIOCLASS GPCR rhodopsin T92828 SEQUENCE MQPPPSLCGRALVALVLACGLSRIWGEERGFPPDRATPLLQTAEIMTPPTKTLWPKGSNASLARSLAPAEVPKGDRTAGSPPRTISPPPCQGPIEIKETFKYINTVVSCLVFVLGIIGNSTLLRIIYKNKCMRNGPNILIASLALGDLLHIVIDIPINVYKLLAEDWPFGAEMCKLVPFIQKASVGITVLSLCALSIDRYRAVASWSRIKGIGVPKWTAVEIVLIWVVSVVLAVPEAIGFDIITMDYKGSYLRICLLHPVQKTAFMQFYKTAKDWWLFSFYFCLPLAITAFFYTLMTCEMLRKKSGMQIALNDHLKQRREVAKTVFCLVLVFALCWLPLHLSRILKLTLYNQNDPNRCELLSFLLVLDYIGINMASLNSCINPIALYLVSKRFKNCFKSCLCCWCQSFEEKQSLEEKQSCLKFKANDHGYDNFRSSNKYSSS T92828 DRUGINFO D0S7JH Macitentan Approved T92828 DRUGINFO D0U4CE Bosentan Approved T92828 DRUGINFO D08IXA BQ788 Phase 3 T92828 DRUGINFO D07WYI SPI-1620 Phase 2 T92828 DRUGINFO D0OW4A PD-145065 Phase 2 T92828 DRUGINFO DUOX13 ENB003 Phase 1/2 T92828 DRUGINFO D05VZJ J-104132 Discontinued in Phase 2 T92828 DRUGINFO D07YHT ENRASENTAN Discontinued in Phase 2 T92828 DRUGINFO D0W6XL SB-209670 Discontinued in Phase 2 T92828 DRUGINFO D05OEO ET-1 Phase 0 T92828 DRUGINFO D01EDE IRL-2500 Terminated T92828 DRUGINFO D03ATH RES-701-1 Terminated T92828 DRUGINFO D0S9JH PD142893 Terminated T92828 DRUGINFO D05GYG BQ 3020 Investigative T92828 DRUGINFO D05HIH Linear peptide of RES-701-1 Investigative T92828 DRUGINFO D05KPH Endothelin-3 Investigative T92828 DRUGINFO D07TIH RES-701-1-C-terminal analogue Investigative T92828 DRUGINFO D0G5UD Ro 46-8443 Investigative T92828 DRUGINFO D0I1ZB ENDG-4010 Investigative T92828 DRUGINFO D0M6CC Sarafotoxin 6C Investigative T92828 DRUGINFO D0MS8T IRL-1722 Investigative T92828 DRUGINFO D0T1BU [125I]IRL1620 Investigative T92828 DRUGINFO D0X1ZC IRL-1841 Investigative T92828 DRUGINFO D0Y1HN A192621 Investigative T92828 DRUGINFO D00RGL W-F-F-N--Y-Y-W Investigative T92828 DRUGINFO D06OSN Bhg-F-N-Y-Y-W Investigative T92828 DRUGINFO D07OMS PD-163140 Investigative T92828 DRUGINFO D0F8BZ Ac-bhg-F-N-Y-Y-W Investigative T92828 DRUGINFO D0M2TB Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys) Investigative T92828 DRUGINFO D0NI1W Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys) Investigative T92828 DRUGINFO D0X1XM LU302872 Investigative T92828 DRUGINFO D0Y8UY Ac-w-F-F-N-Y-Y-W Investigative T30985 TARGETID T30985 T30985 FORMERID TTDS00087 T30985 UNIPROID HRH2_HUMAN T30985 TARGNAME Histamine H2 receptor (H2R) T30985 GENENAME HRH2 T30985 TARGTYPE Successful T30985 SYNONYMS Histamine receptor 2; HH2R; Gastric receptor I T30985 FUNCTION Appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway. The H2 subclass of histamine receptors mediates gastric acid secretion. T30985 BIOCLASS GPCR rhodopsin T30985 SEQUENCE MAPNGTASSFCLDSTACKITITVVLAVLILITVAGNVVVCLAVGLNRRLRNLTNCFIVSLAITDLLLGLLVLPFSAIYQLSCKWSFGKVFCNIYTSLDVMLCTASILNLFMISLDRYCAVMDPLRYPVLVTPVRVAISLVLIWVISITLSFLSIHLGWNSRNETSKGNHTTSKCKVQVNEVYGLVDGLVTFYLPLLIMCITYYRIFKVARDQAKRINHISSWKAATIREHKATVTLAAVMGAFIICWFPYFTAFVYRGLRGDDAINEVLEAIVLWLGYANSALNPILYAALNRDFRTGYQQLFCCRLANRNSHKTSLRSNASQLSRTQSREPRQQEEKPLKLQVWSGTEVTAPQGATDR T30985 DRUGINFO D01OUE Betazole Approved T30985 DRUGINFO D02DPA Cimetidine Approved T30985 DRUGINFO D0B8WN Ranitidine Approved T30985 DRUGINFO D0K0OZ Famotidine Approved T30985 DRUGINFO D0Q9DK Nizatidine Approved T30985 DRUGINFO D0R8FM Ebrotidine Withdrawn from market T30985 DRUGINFO D01YDF Pibutidine Discontinued in Phase 3 T30985 DRUGINFO D09YTY Osutidine Discontinued in Phase 3 T30985 DRUGINFO D0A2IH KU-1257 Discontinued in Phase 3 T30985 DRUGINFO D08OQQ Lavoltidine Discontinued in Phase 2 T30985 DRUGINFO D0D1YY IGN-2098 Discontinued in Phase 2 T30985 DRUGINFO D0L9PY CP-66948 Discontinued in Phase 1 T30985 DRUGINFO D0N3TO TRM-115 Discontinued in Phase 1 T30985 DRUGINFO D0T2MN Z-300 Discontinued in Phase 1 T30985 DRUGINFO D03RGO CP-331 Terminated T30985 DRUGINFO D0J0JC FRG-8701 Terminated T30985 DRUGINFO D02NWL [125I]iodoaminopotentidine Investigative T30985 DRUGINFO D0E7AZ tiotidine Investigative T30985 DRUGINFO D0I5CT amthamine Investigative T30985 DRUGINFO D0O3NG Dimaprit Investigative T30985 DRUGINFO D0W9LJ Metiamide Investigative T30985 DRUGINFO D0Z9WK iodoaminopotentidine Investigative T30985 DRUGINFO D03SNI VUF-10148 Investigative T30985 DRUGINFO D04WXI oxo-arpromidine Investigative T30985 DRUGINFO D08SLS arpromidine Investigative T30985 DRUGINFO D0AU0F UR-PG146 Investigative T30985 DRUGINFO D06RNM burimamide Investigative T30985 DRUGINFO D0C7LY WAY-207024 Investigative T30985 DRUGINFO D0B4SF impromidine Investigative T30985 DRUGINFO D0L5MW (+/-)-nantenine Investigative T30985 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T97947 TARGETID T97947 T97947 FORMERID TTDC00171 T97947 UNIPROID GUC2C_HUMAN T97947 TARGNAME Guanylyl cyclase C (GUCY2C) T97947 GENENAME GUCY2C T97947 TARGTYPE Successful T97947 SYNONYMS hSTAR; STA receptor; Intestinal guanylate cyclase; Heat-stable enterotoxin receptor; GUC2C; GC-C T97947 FUNCTION Receptor for the E.coli heat-stable enterotoxin (E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GC-C). Also activated by the endogenous peptides guanylin and uroguanylin. T97947 BIOCLASS Phosphorus-oxygen lyase T97947 ECNUMBER EC 4.6.1.2 T97947 SEQUENCE MKTLLLDLALWSLLFQPGWLSFSSQVSQNCHNGSYEISVLMMGNSAFAEPLKNLEDAVNEGLEIVRGRLQNAGLNVTVNATFMYSDGLIHNSGDCRSSTCEGLDLLRKISNAQRMGCVLIGPSCTYSTFQMYLDTELSYPMISAGSFGLSCDYKETLTRLMSPARKLMYFLVNFWKTNDLPFKTYSWSTSYVYKNGTETEDCFWYLNALEASVSYFSHELGFKVVLRQDKEFQDILMDHNRKSNVIIMCGGPEFLYKLKGDRAVAEDIVIILVDLFNDQYFEDNVTAPDYMKNVLVLTLSPGNSLLNSSFSRNLSPTKRDFALAYLNGILLFGHMLKIFLENGENITTPKFAHAFRNLTFEGYDGPVTLDDWGDVDSTMVLLYTSVDTKKYKVLLTYDTHVNKTYPVDMSPTFTWKNSKLPNDITGRGPQILMIAVFTLTGAVVLLLLVALLMLRKYRKDYELRQKKWSHIPPENIFPLETNETNHVSLKIDDDKRRDTIQRLRQCKYDKKRVILKDLKHNDGNFTEKQKIELNKLLQIDYYNLTKFYGTVKLDTMIFGVIEYCERGSLREVLNDTISYPDGTFMDWEFKISVLYDIAKGMSYLHSSKTEVHGRLKSTNCVVDSRMVVKITDFGCNSILPPKKDLWTAPEHLRQANISQKGDVYSYGIIAQEIILRKETFYTLSCRDRNEKIFRVENSNGMKPFRPDLFLETAEEKELEVYLLVKNCWEEDPEKRPDFKKIETTLAKIFGLFHDQKNESYMDTLIRRLQLYSRNLEHLVEERTQLYKAERDRADRLNFMLLPRLVVKSLKEKGFVEPELYEEVTIYFSDIVGFTTICKYSTPMEVVDMLNDIYKSFDHIVDHHDVYKVETIGDAYMVASGLPKRNGNRHAIDIAKMALEILSFMGTFELEHLPGLPIWIRIGVHSGPCAAGVVGIKMPRYCLFGDTVNTASRMESTGLPLRIHVSGSTIAILKRTECQFLYEVRGETYLKGRGNETTYWLTGMKDQKFNLPTPPTVENQQRLQAEFSDMIANSLQKRQAAGIRSQKPRRVASYKKGTLEYLQLNTTDKESTYF T97947 DRUGINFO D00GNJ Linaclotide Approved T97947 DRUGINFO D06WKA MD-1100 Approved T97947 DRUGINFO D07FEC Plecanatide Approved T97947 DRUGINFO D05YLP SP-333 Phase 2 T97947 DRUGINFO D0U7VU MLN0264 Phase 2 T97947 DRUGINFO DK87UQ PF-07062119 Phase 1 T23499 TARGETID T23499 T23499 FORMERID TTDS00198 T23499 UNIPROID EDNRA_HUMAN T23499 TARGNAME Endothelin A receptor (EDNRA) T23499 GENENAME EDNRA T23499 TARGTYPE Successful T23499 SYNONYMS HET-AR; Endothelin-1 receptor; Endothelin receptor type A; Endothelin receptor A; ETRA; ETA-R; ETA receptor; ETA; ET-A T23499 FUNCTION Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3. Receptor for endothelin-1. T23499 BIOCLASS GPCR rhodopsin T23499 SEQUENCE METLCLRASFWLALVGCVISDNPERYSTNLSNHVDDFTTFRGTELSFLVTTHQPTNLVLPSNGSMHNYCPQQTKITSAFKYINTVISCTIFIVGMVGNATLLRIIYQNKCMRNGPNALIASLALGDLIYVVIDLPINVFKLLAGRWPFDHNDFGVFLCKLFPFLQKSSVGITVLNLCALSVDRYRAVASWSRVQGIGIPLVTAIEIVSIWILSFILAIPEAIGFVMVPFEYRGEQHKTCMLNATSKFMEFYQDVKDWWLFGFYFCMPLVCTAIFYTLMTCEMLNRRNGSLRIALSEHLKQRREVAKTVFCLVVIFALCWFPLHLSRILKKTVYNEMDKNRCELLSFLLLMDYIGINLATMNSCINPIALYFVSKKFKNCFQSCLCCCCYQSKSLMTSVPMNGTSIQWKNHDQNNHNTDRSSHKDSMN T23499 DRUGINFO D0X5ZI Ambrisentan Approved T23499 DRUGINFO D0Y7OJ LU302146 Approved T23499 DRUGINFO D0S7JH Macitentan Approved T23499 DRUGINFO D0U4CE Bosentan Approved T23499 DRUGINFO D0YS1U Sparsentan Approved T23499 DRUGINFO D08JWJ PF-1228305 Phase 3 T23499 DRUGINFO D0R7YY Darusentan Phase 3 T23499 DRUGINFO D0Y6UU Atrasentan Phase 3 T23499 DRUGINFO D0H2RJ Clazosentan Phase 3 T23499 DRUGINFO D03LAB TBC-3711 Phase 2 T23499 DRUGINFO D09LQK BQ-123 Phase 2 T23499 DRUGINFO D0XR7C YM-598 Phase 2 T23499 DRUGINFO D09XLS FR139317 Phase 2 T23499 DRUGINFO D0OW4A PD-145065 Phase 2 T23499 DRUGINFO D04OXG PMZ-2123 Phase 1 T23499 DRUGINFO D02EAS TBC 11251 (TBC) Withdrawn from market T23499 DRUGINFO D0T1RG Sitaxsentan Withdrawn from market T23499 DRUGINFO D02HVW Zibotentan Discontinued in Phase 3 T23499 DRUGINFO D03FVI 97-139 Discontinued in Phase 2 T23499 DRUGINFO D03MUM EDONENTAN HYDRATE Discontinued in Phase 2 T23499 DRUGINFO D0B5PU BMS-193884 Discontinued in Phase 2 T23499 DRUGINFO D0J2IH Avosentan Discontinued in Phase 2 T23499 DRUGINFO D05VZJ J-104132 Discontinued in Phase 2 T23499 DRUGINFO D07YHT ENRASENTAN Discontinued in Phase 2 T23499 DRUGINFO D0W6XL SB-209670 Discontinued in Phase 2 T23499 DRUGINFO D02QQB A-216546 Discontinued in Phase 1 T23499 DRUGINFO D04NPX ZD-1611 Discontinued in Phase 1 T23499 DRUGINFO D08AMQ SB-234551 Discontinued in Phase 1 T23499 DRUGINFO D05OEO ET-1 Phase 0 T23499 DRUGINFO D01VUE BMS-182874 Terminated T23499 DRUGINFO D07DGM BQ-518 Terminated T23499 DRUGINFO D0H0KK PD-155080 Terminated T23499 DRUGINFO D0L3AR PD156707 Terminated T23499 DRUGINFO D0NC1D MX-6120 Terminated T23499 DRUGINFO D0P5UE 50-235 Terminated T23499 DRUGINFO D0Q9XI BQ610 Terminated T23499 DRUGINFO D0S9JH PD142893 Terminated T23499 DRUGINFO D02OPG [3H]BQ123 Investigative T23499 DRUGINFO D07QBJ HJP-272 Investigative T23499 DRUGINFO D0A8MD 2-HYDROXY-3,5-DIIODOBENZOIC ACID Investigative T23499 DRUGINFO D0F6TS Endothelin-2 Investigative T23499 DRUGINFO D0I7OD Asterric acid Investigative T23499 DRUGINFO D0M2YL [125I]PD151242 Investigative T23499 DRUGINFO D0NA5S [3H]S0139 Investigative T23499 DRUGINFO D0OC1W sarafotoxin S6b Investigative T23499 DRUGINFO D0W1HZ PD164333 Investigative T23499 DRUGINFO D0W4UX BMS-187308 Investigative T23499 DRUGINFO D00RGL W-F-F-N--Y-Y-W Investigative T23499 DRUGINFO D06OSN Bhg-F-N-Y-Y-W Investigative T23499 DRUGINFO D07OMS PD-163140 Investigative T23499 DRUGINFO D0F8BZ Ac-bhg-F-N-Y-Y-W Investigative T23499 DRUGINFO D0M2TB Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys) Investigative T23499 DRUGINFO D0NI1W Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys) Investigative T23499 DRUGINFO D0X1XM LU302872 Investigative T23499 DRUGINFO D0Y8UY Ac-w-F-F-N-Y-Y-W Investigative T23499 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T30372 TARGETID T30372 T30372 FORMERID TTDR00982 T30372 UNIPROID CYSP_TRYCR T30372 TARGNAME Trypanosoma Cruzipain (Trypano CYSP) T30372 GENENAME Trypano CYSP T30372 TARGTYPE Successful T30372 SYNONYMS Cruzaine; Major cysteine proteinase T30372 FUNCTION The cysteine protease may play an important role in the development and differentiation of the parasites at several stages of their life cycle. T30372 PDBSTRUC 4XUI; 4W5C; 4W5B; 4QH6; 4PI3 T30372 BIOCLASS Peptidase T30372 ECNUMBER EC 3.4.22.51 T30372 SEQUENCE MSGWARALLLAAVLVVMACLVPAATASLHAEETLTSQFAEFKQKHGRVYESAAEEAFRLSVFRENLFLARLHAAANPHATFGVTPFSDLTREEFRSRYHNGAAHFAAAQERARVPVKVEVVGAPAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVSCDKTDSGCSGGLMNNAFEWIVQENNGAVYTEDSYPYASGEGISPPCTTSGHTVGATITGHVELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQLDHGVLLVGYNDSAAVPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVGGPGPTPEPTTTTTTSAPGPSPSYFVQMSCTDAACIVGCENVTLPTGQCLLTTSGVSAIVTCGAETLTEEVFLTSTHCSGPSVRSSVPLNKCNRLLRGSVEFFCGSSSSGRLADVDRQRRHQPYHSRHRRL T30372 DRUGINFO D02VMJ TRICLABENDAZOLE Approved T30372 DRUGINFO D08TVA MANIDIPINE Phase 3 T30372 DRUGINFO D04YJU L-755507 Terminated T30372 DRUGINFO D01BQI 1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione Investigative T30372 DRUGINFO D04FMU 3-amino-5-(furan-2-yl)biphenyl-2,4-dicarbonitrile Investigative T30372 DRUGINFO D05VOH VITAMIN K2 Investigative T30372 DRUGINFO D06LSC WRR-204 Investigative T30372 DRUGINFO D07LMK 2-(trifluoromethyl)benzaldehyde thiosemicarbazone Investigative T30372 DRUGINFO D07NVK 1-(1-(3-nitrophenyl)propylidene)thiosemicarbazide Investigative T30372 DRUGINFO D07PZF 1-(bis(3-bromophenyl)methylene)thiosemicarbazide Investigative T30372 DRUGINFO D07XQR N1,N4-bis(5-chloro-2-methylphenyl)succinamide Investigative T30372 DRUGINFO D08DEG 5-(3,4-dichlorophenyl)-1H-pyrazol-3-ol Investigative T30372 DRUGINFO D08NYF 5-(4-bromophenyl)-2-furaldehyde thiosemicarbazone Investigative T30372 DRUGINFO D09BXH 2-(cycloheptylamino)-2-oxoethyl 2-aminonicotinate Investigative T30372 DRUGINFO D0DT5K 2-methoxy-1-naphthaldehyde thiosemicarbazone Investigative T30372 DRUGINFO D0J3HR 1-(3,4-dihydronaphthalen-1-yl)ethanone Investigative T30372 DRUGINFO D0L7GI 3-chloro-N-(4-(phenyldiazenyl)phenyl)benzamide Investigative T30372 DRUGINFO D0N2QX 3-(trifluoromethyl)benzaldehyde thiosemicarbazone Investigative T30372 DRUGINFO D0O5TA 5-Chloro-1-(4-chloro-benzyl)-1H-indole-2,3-dione Investigative T30372 DRUGINFO D0S2IS 3'-bromopropiophenonethiosemicarbazone Investigative T30372 DRUGINFO D0S2NU 3,5-dichlorobenzaldehyde thiosemicarbazone Investigative T30372 DRUGINFO D0TZ5V (3Z)-1H-indole-2,3-dione 3-thiosemicarbazone Investigative T30372 DRUGINFO D0UL6C 3,4-dichlorobenzaldehyde thiosemicarbazone Investigative T30372 DRUGINFO D0V8DQ 3',4'-dichloroacetophenonethiosemicarbazone Investigative T30372 DRUGINFO D06DKB GNF-PF-4478 Investigative T30372 DRUGINFO D08TMM K-777 Investigative T30372 DRUGINFO D0B5IL WRR-99 Investigative T30372 DRUGINFO D0L5WS Benzoyl-Arginine-Alanine-Methyl Ketone Investigative T30372 DRUGINFO D0PB3X Vinylsulphones Investigative T30372 DRUGINFO D0T0IX WRR-112 Investigative T71377 TARGETID T71377 T71377 FORMERID TTDR00012 T71377 UNIPROID IL3RA_HUMAN T71377 TARGNAME Interleukin 3 receptor alpha (IL3RA) T71377 GENENAME IL3RA T71377 TARGTYPE Successful T71377 SYNONYMS Interleukin-3 receptor subunit alpha; IL3R; IL-3RA; IL-3R-alpha; IL-3R subunit alpha; IL-3 receptor subunit alpha; CD123 antigen; CD123 T71377 FUNCTION This is a receptor for interleukin-3. T71377 PDBSTRUC 5UWC; 5UV8; 4JZJ T71377 BIOCLASS Cytokine receptor T71377 SEQUENCE MVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSMPAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFLSCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSSHILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYELQIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGANTRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAGKAGLEECLVTEVQVVQKT T71377 DRUGINFO D0R7NI Tagraxofusp Approved T71377 DRUGINFO D04GGG CD123/CLL1 CAR-T Cells Phase 2/3 T71377 DRUGINFO D07MGC Talacotuzumab Phase 2 T71377 DRUGINFO D0C3JB MB-102 Phase 2 T71377 DRUGINFO D0YA1B Flotetuzumab Phase 2 T71377 DRUGINFO D04MLR CD123-specific gene-engineered T cells Phase 1/2 T71377 DRUGINFO D0N6PE CART-123 cells Phase 1/2 T71377 DRUGINFO D0S1CR Anti-CD123-CAR-transduced T cells Phase 1/2 T71377 DRUGINFO D0BH2M 4SCAR19 and 4SCAR123 Phase 1/2 T71377 DRUGINFO DL1FG3 SAR440234 Phase 1/2 T71377 DRUGINFO D00HAN IM23 Phase 1 T71377 DRUGINFO D02SAC Anti-CD123 CAR-T cells Phase 1 T71377 DRUGINFO D0AW4T CART-123 cells Phase 1 T71377 DRUGINFO D0JX7M CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells Phase 1 T71377 DRUGINFO D0P2GU CSL-362-AML Phase 1 T71377 DRUGINFO D0R5NU CART123 cells Phase 1 T71377 DRUGINFO D0UP8U Anti-CD123 CAR-T treatment Phase 1 T71377 DRUGINFO D0Z7QK UCART123 Phase 1 T71377 DRUGINFO D00JDL MGD006 Phase 1 T71377 DRUGINFO D2GY5C APVO436 Phase 1 T71377 DRUGINFO D3Q0FU CSL311 Phase 1 T71377 DRUGINFO D9TG4H JNJ-63709178 Phase 1 T71377 DRUGINFO DB4C5H CD123-CD33 Ccar Phase 1 T71377 DRUGINFO D0H8UT Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes Phase 0 T71377 DRUGINFO D0N4VG CAR-T cells targeting CD123 Preclinical T71377 DRUGINFO D0D4XF Daniplestim Terminated T11072 TARGETID T11072 T11072 FORMERID TTDS00100 T11072 UNIPROID 5HT1D_HUMAN T11072 TARGNAME 5-HT 1D receptor (HTR1D) T11072 GENENAME HTR1D T11072 TARGTYPE Successful T11072 SYNONYMS Serotonin receptor 1D; Serotonin 1D alpha receptor; HTRL; HTR1DA; 5HT1D; 5-hydroxytryptamine receptor 1D; 5-HT1D receptor; 5-HT1D; 5-HT-1D-alpha; 5-HT-1D T11072 FUNCTION Functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction. G-protein coupled receptor for 5-hydroxytryptamine (serotonin). T11072 BIOCLASS GPCR rhodopsin T11072 SEQUENCE MSPLNQSAEGLPQEASNRSLNATETSEAWDPRTLQALKISLAVVLSVITLATVLSNAFVLTTILLTRKLHTPANYLIGSLATTDLLVSILVMPISIAYTITHTWNFGQILCDIWLSSDITCCTASILHLCVIALDRYWAITDALEYSKRRTAGHAATMIAIVWAISICISIPPLFWRQAKAQEEMSDCLVNTSQISYTIYSTCGAFYIPSVLLIILYGRIYRAARNRILNPPSLYGKRFTTAHLITGSAGSSLCSLNSSLHEGHSHSAGSPLFFNHVKIKLADSALERKRISAARERKATKILGIILGAFIICWLPFFVVSLVLPICRDSCWIHPALFDFFTWLGYLNSLINPIIYTVFNEEFRQAFQKIVPFRKAS T11072 DRUGINFO D0P0SM Almogran Approved T11072 DRUGINFO D0S9MU Rizatriptan Approved T11072 DRUGINFO D0Z6UC Sumatriptan Approved T11072 DRUGINFO D02DMQ Eletriptan Approved T11072 DRUGINFO D06FPQ Frovatriptan Approved T11072 DRUGINFO D0NG7O Zolmitriptan Approved T11072 DRUGINFO D0UA0I Metergolin Approved T11072 DRUGINFO D0E8IZ Tonabersat Phase 2 T11072 DRUGINFO D04FVD TGBA01AD Phase 2 T11072 DRUGINFO D00CVJ Neu-P11 Phase 2 T11072 DRUGINFO D0MT8G FKB01MD Phase 2 T11072 DRUGINFO D0O2XJ NXN-188 Phase 2 T11072 DRUGINFO D01BPF Avitriptan Discontinued in Phase 3 T11072 DRUGINFO D0Y0RW Alniditan Discontinued in Phase 3 T11072 DRUGINFO D00QXV BMS-181101 Discontinued in Phase 2 T11072 DRUGINFO D03SWH PNU-142633 Discontinued in Phase 2 T11072 DRUGINFO D0SU1F CP-122288 Discontinued in Phase 2 T11072 DRUGINFO D03SFN Elzasonan hydrochloride Discontinued in Phase 2 T11072 DRUGINFO D09WCE IS-159 Discontinued in Phase 2 T11072 DRUGINFO D03JSS Tidembersat Discontinued in Phase 1 T11072 DRUGINFO D08XWZ ALX-0646 Discontinued in Phase 1 T11072 DRUGINFO D0G5ML Donitriptan Preclinical T11072 DRUGINFO D00NLD L-741604 Terminated T11072 DRUGINFO D0G1RT L-694247 Terminated T11072 DRUGINFO D0Q7TH BMS-181885 Terminated T11072 DRUGINFO D0T1SF PNU-109291 Terminated T11072 DRUGINFO D02ZSO L-775606 Terminated T11072 DRUGINFO D06DZI GR-127935 Terminated T11072 DRUGINFO D0UO9T VR-147 Terminated T11072 DRUGINFO D02EPZ 2-(2,6-Dimethyl-benzyl)-4,5-dihydro-1H-imidazole Investigative T11072 DRUGINFO D0V7OO L-760790 Investigative T11072 DRUGINFO D00TYX [3H]sumatriptan Investigative T11072 DRUGINFO D02AVN (3-Chloro-phenyl)-piperazin-1-yl-methanone Investigative T11072 DRUGINFO D02PLD 1-(2-Butoxy-phenyl)-piperazine Investigative T11072 DRUGINFO D02YFZ 2-Piperazin-1-yl-benzonitrile Investigative T11072 DRUGINFO D03CEZ AGROCLAVINE Investigative T11072 DRUGINFO D03KPA 5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole Investigative T11072 DRUGINFO D03MVY 2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine Investigative T11072 DRUGINFO D03NWV 1-(2-Ethoxy-phenyl)-piperazine Investigative T11072 DRUGINFO D03XAE [2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine Investigative T11072 DRUGINFO D07LSC 1-(3-Fluoro-phenyl)-piperazine Investigative T11072 DRUGINFO D08YJP 1-(2-Fluoro-phenyl)-piperazine Investigative T11072 DRUGINFO D09AVG 5-amino-3-(N-methylpiperidin-4-yl)-1H-indole Investigative T11072 DRUGINFO D0A2SY [3H]GR 125,743 Investigative T11072 DRUGINFO D0B6WH [3H]eletriptan Investigative T11072 DRUGINFO D0C3EX 2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine Investigative T11072 DRUGINFO D0E2FY 1-(2-Isopropoxy-phenyl)-piperazine Investigative T11072 DRUGINFO D0H6KD [125I]GTI Investigative T11072 DRUGINFO D0K9MT 5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole Investigative T11072 DRUGINFO D0KQ9H L-747201 Investigative T11072 DRUGINFO D0L9ZQ lysergic acid Investigative T11072 DRUGINFO D0ND2Y 1-(3-Nitro-phenyl)-piperazine Investigative T11072 DRUGINFO D0P4KF 2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole Investigative T11072 DRUGINFO D00CGJ 2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine Investigative T11072 DRUGINFO D00FUS 2-(2-Methoxy-phenyl)-1-methyl-ethylamine Investigative T11072 DRUGINFO D00QSV 2-(3-Methoxy-phenyl)-1-methyl-ethylamine Investigative T11072 DRUGINFO D00WEQ Brolamfetamine Investigative T11072 DRUGINFO D01APL lysergol Investigative T11072 DRUGINFO D01HRV L-772,405 Investigative T11072 DRUGINFO D02OZB 2-Piperazin-1-yl-phenol Investigative T11072 DRUGINFO D02SAF 1-(2,5-Dimethoxy-phenyl)-piperazine Investigative T11072 DRUGINFO D03DET SB 714786 Investigative T11072 DRUGINFO D06OJI 2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol Investigative T11072 DRUGINFO D06PKJ 1-(2,5-dimethoxyphenyl)propan-2-amine Investigative T11072 DRUGINFO D08HOJ 1,2,3,4-Tetrahydro-naphthalen-2-ylamine Investigative T11072 DRUGINFO D09JOE 1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine Investigative T11072 DRUGINFO D09YVA 8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline Investigative T11072 DRUGINFO D0B2GS 3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one Investigative T11072 DRUGINFO D0D2PL 8-Methoxy-quinolin-2-ylamine Investigative T11072 DRUGINFO D0D3OF 1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine Investigative T11072 DRUGINFO D0I9FI 2-(4-Bromo-phenyl)-1-methyl-ethylamine Investigative T11072 DRUGINFO D0K0FI 7-methoxy-1-naphthylpiperazine Investigative T11072 DRUGINFO D0O3GF [3H]8-OH-DPAT Investigative T11072 DRUGINFO D0PN8D 1-(7-Methoxy-naphthalen-2-yl)-piperazine Investigative T11072 DRUGINFO D0QM3E SB 272183 Investigative T11072 DRUGINFO D0R3GW SB 649915 Investigative T11072 DRUGINFO D0TH8D 8-Methoxy-2-piperazin-1-yl-quinoline Investigative T11072 DRUGINFO D0X4RC PHENYLPIPERAZINE Investigative T11072 DRUGINFO D0YG1E Etisulergine Investigative T11072 DRUGINFO D0D3PZ dipropyl-5-CT Investigative T11072 DRUGINFO D0N8BJ [3H]5-HT Investigative T11072 DRUGINFO D0W2YN 1-Naphthalen-2-yl-piperazine Investigative T11072 DRUGINFO D04TPO 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T11072 DRUGINFO D08PJK [3H]5-CT Investigative T11072 DRUGINFO D0SP2J bufotenine Investigative T11072 DRUGINFO D0XX2U 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T11072 DRUGINFO D0CK9K EDMT Investigative T11072 DRUGINFO D0D9YW SB 216641 Investigative T11072 DRUGINFO D0V3XU CHLOROPHENYLPIPERAZINE Investigative T11072 DRUGINFO D0Y4MC 9-OH-risperidone Investigative T11072 DRUGINFO D06VPR WAY-466 Investigative T11072 DRUGINFO D08BCF QUIPAZINE Investigative T11072 DRUGINFO D0C5GF MPDT Investigative T11072 DRUGINFO D0J6JT m-chlorophenylpiperazine Investigative T11072 DRUGINFO D0LG8A 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine Investigative T11072 DRUGINFO D0V4RP 1-(2-Methoxy-phenyl)-piperazine Investigative T11072 DRUGINFO D0Y9TL 5-chloro-3,4-dihydroquinazolin-2-amine Investigative T11072 DRUGINFO D00CRA 2-methyl-5-HT Investigative T11072 DRUGINFO D01KAX 1-((S)-2-aminopropyl)-1H-indazol-6-ol Investigative T11072 DRUGINFO D08VGJ 5,6-dichloro-3,4-dihydroquinazolin-2-amine Investigative T11072 DRUGINFO D09OYA alpha-methyl-5-HT Investigative T11072 DRUGINFO D03TDN 1-naphthylpiperazine Investigative T11072 DRUGINFO D04TVG BRL-15572 Investigative T11072 DRUGINFO D02UWB 5-CT Investigative T11072 DRUGINFO D0V5HV TFMPP Investigative T11072 DRUGINFO D0F6CD SEROTONIN Investigative T11072 DRUGINFO D0L5MW (+/-)-nantenine Investigative T86679 TARGETID T86679 T86679 FORMERID TTDS00188 T86679 UNIPROID AA2BR_HUMAN T86679 TARGNAME Adenosine A2b receptor (ADORA2B) T86679 GENENAME ADORA2B T86679 TARGTYPE Successful T86679 SYNONYMS Adenosine receptor A2b; A2b Adenosine receptor T86679 FUNCTION The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Receptor for adenosine. T86679 BIOCLASS GPCR rhodopsin T86679 SEQUENCE MLLETQDALYVALELVIAALSVAGNVLVCAAVGTANTLQTPTNYFLVSLAAADVAVGLFAIPFAITISLGFCTDFYGCLFLACFVLVLTQSSIFSLLAVAVDRYLAICVPLRYKSLVTGTRARGVIAVLWVLAFGIGLTPFLGWNSKDSATNNCTEPWDGTTNESCCLVKCLFENVVPMSYMVYFNFFGCVLPPLLIMLVIYIKIFLVACRQLQRTELMDHSRTTLQREIHAAKSLAMIVGIFALCWLPVHAVNCVTLFQPAQGKNKPKWAMNMAILLSHANSVVNPIVYAYRNRDFRYTFHKIISRYLLCQADVKSGNGQAGVQPALGVGL T86679 DRUGINFO D06IAR Adenosine Approved T86679 DRUGINFO D0NI0C Vidarabine Approved T86679 DRUGINFO DJC4L7 A295 IND submitted T86679 DRUGINFO D0W9NO YT-146 Phase 2 T86679 DRUGINFO D00SUK Tonapofylline Phase 2 T86679 DRUGINFO D04UBI AB928 Phase 1/2 T86679 DRUGINFO D0G4CF CVT-6883 Phase 1 T86679 DRUGINFO D0HF2D PBF-1129 Phase 1 T86679 DRUGINFO D0M3IN Xanthine Phase 1 T86679 DRUGINFO D0L5VS KF-17837 Phase 1 T86679 DRUGINFO D07ESH PF-1913539 Discontinued in Phase 3 T86679 DRUGINFO D08ECB LAS-101057 Preclinical T86679 DRUGINFO D0HE1P BAY 60-6583 Preclinical T86679 DRUGINFO D0Y6GJ ZM-241385 Terminated T86679 DRUGINFO D0E4WF METHYLTHIOADENOSINE Terminated T86679 DRUGINFO D01CQU MRS1706 Investigative T86679 DRUGINFO D01KNZ [125I]ABOPX Investigative T86679 DRUGINFO D01QYQ ATL-844 Investigative T86679 DRUGINFO D02UHS CGS 24012 Investigative T86679 DRUGINFO D03NVE CVT-6694 Investigative T86679 DRUGINFO D03NXZ CV-1674 Investigative T86679 DRUGINFO D03WPE AB-NECA Investigative T86679 DRUGINFO D04DVT XCC Investigative T86679 DRUGINFO D06GOE AS74 Investigative T86679 DRUGINFO D06GTI AS96 Investigative T86679 DRUGINFO D06NRX CV-1808 Investigative T86679 DRUGINFO D06SGU CVT-7124 Investigative T86679 DRUGINFO D0A8EK APNEA Investigative T86679 DRUGINFO D0I2MU 3-isobutyl-8-pyrrolidinoxanthine Investigative T86679 DRUGINFO D0J4EZ AS95 Investigative T86679 DRUGINFO D0M5TM 8-(3-Fluoro-phenyl)-9-methyl-9H-purin-6-ylamine Investigative T86679 DRUGINFO D0O0HR KF 17837S Investigative T86679 DRUGINFO D0O3SA ATL-801 Investigative T86679 DRUGINFO D0PB2W BETA-HYDROXYETHYL THEOPHYLLINE Investigative T86679 DRUGINFO D0U7TR [125I]ZM-241385 Investigative T86679 DRUGINFO D0W4JC [3H]ZM 241385 Investigative T86679 DRUGINFO D0X5PJ AS16 Investigative T86679 DRUGINFO D0Y8LD AS94 Investigative T86679 DRUGINFO D00MFV 9-(sec-Butyl)-9H-adenine Investigative T86679 DRUGINFO D04GFX MRS1132 Investigative T86679 DRUGINFO D04RHI MRS1086 Investigative T86679 DRUGINFO D07DOE 2'-Me-tecadenoson Investigative T86679 DRUGINFO D07FZA AS99 Investigative T86679 DRUGINFO D07HKU DEPX Investigative T86679 DRUGINFO D07RSH MRS923 Investigative T86679 DRUGINFO D08FOT PSB-1115 Investigative T86679 DRUGINFO D08RSU [3H]DPCPX Investigative T86679 DRUGINFO D09NEP MRS1088 Investigative T86679 DRUGINFO D09TBE MRS1065 Investigative T86679 DRUGINFO D0A4MK AS100 Investigative T86679 DRUGINFO D0B9CC 3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione Investigative T86679 DRUGINFO D0D9YL 1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione Investigative T86679 DRUGINFO D0G2JG CPFPX Investigative T86679 DRUGINFO D0J2UW CGS 21680 Investigative T86679 DRUGINFO D0L3BI MRS1084 Investigative T86679 DRUGINFO D0MH4R visnagin Investigative T86679 DRUGINFO D0PM5R AB-MECA Investigative T86679 DRUGINFO D0Q9GL AS70 Investigative T86679 DRUGINFO D0W6TG PSB-09120 Investigative T86679 DRUGINFO D0X3PD I-ABOPX Investigative T86679 DRUGINFO D0Y5TL Alloxazine Investigative T86679 DRUGINFO D00IOF PSB36 Investigative T86679 DRUGINFO D01AAI VUF5574 Investigative T86679 DRUGINFO D01WNA 8-Bromo-9-ethyl-9H-adenine Investigative T86679 DRUGINFO D02HOL 8-Bromo-9-propyl-9H-adenine Investigative T86679 DRUGINFO D02JCM N(6)-cyclohexyladenosine Investigative T86679 DRUGINFO D02RMR 1,3-Diethyl-3,7-dihydro-purine-2,6-dione Investigative T86679 DRUGINFO D02SKN MRS1041 Investigative T86679 DRUGINFO D03KKK 1,3-Dipropyl-3,7-dihydro-purine-2,6-dione Investigative T86679 DRUGINFO D04WHE 9-Propyl-9H-adenine Investigative T86679 DRUGINFO D05QNV ATL802 Investigative T86679 DRUGINFO D05XGF PSB-0788 Investigative T86679 DRUGINFO D06KMJ MRS5151 Investigative T86679 DRUGINFO D07DNX PD-115199 Investigative T86679 DRUGINFO D07HNM 1,3-Diallyl-3,7-dihydro-purine-2,6-dione Investigative T86679 DRUGINFO D07PPM PSB-10 Investigative T86679 DRUGINFO D07VCN 4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one Investigative T86679 DRUGINFO D08BCH TCPA Investigative T86679 DRUGINFO D08EBT [3H]HEMADO Investigative T86679 DRUGINFO D08MRB 1H-Imidazo[4,5-c]quinolin-4-ylamine HCl Investigative T86679 DRUGINFO D09RKX PSB-11 Investigative T86679 DRUGINFO D0A6IO MRE 3008F20 Investigative T86679 DRUGINFO D0A6JX 9-Cyclobutyl-9H-adenine Investigative T86679 DRUGINFO D0A9BZ PSB-601 Investigative T86679 DRUGINFO D0B1RV 2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine Investigative T86679 DRUGINFO D0B1YW 8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione Investigative T86679 DRUGINFO D0B7OW sakuranetin Investigative T86679 DRUGINFO D0B8DR MRS1093 Investigative T86679 DRUGINFO D0C2UJ 2-chloroadenosine Investigative T86679 DRUGINFO D0DB7A 9-Isopropyl-9H-adenine Investigative T86679 DRUGINFO D0E8RA 8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine Investigative T86679 DRUGINFO D0E9QX (S)-PIA Investigative T86679 DRUGINFO D0F1AS 1-METHYLXANTHINE Investigative T86679 DRUGINFO D0F4XB 2-Amino-4,6-di-furan-2-yl-nicotinonitrile Investigative T86679 DRUGINFO D0H9BP xanthine amine congener Investigative T86679 DRUGINFO D0I1EP MRS928 Investigative T86679 DRUGINFO D0I3HE KF26777 Investigative T86679 DRUGINFO D0J1BA MRS1191 Investigative T86679 DRUGINFO D0L0VU MRE 2029F20 Investigative T86679 DRUGINFO D0LD0X 1-Propyl-3,7-dihydro-purine-2,6-dione Investigative T86679 DRUGINFO D0LP5G 2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine Investigative T86679 DRUGINFO D0O0FP ST-1535 Investigative T86679 DRUGINFO D0O1CW GNF-PF-2700 Investigative T86679 DRUGINFO D0P7FK 2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile Investigative T86679 DRUGINFO D0P8MK 2-(6-amino-8-bromo-9H-purin-9-yl)ethanol Investigative T86679 DRUGINFO D0R8OK 8-Bromo-9-methyl-9H-adenine Investigative T86679 DRUGINFO D0S5XP 9-Allyl-8-bromo-9H-adenine Investigative T86679 DRUGINFO D0S6QA 8-Bromo-9-(2-butyl)-9H-adenine Investigative T86679 DRUGINFO D0T7GG LUF-5816 Investigative T86679 DRUGINFO D0TC7N PENECA Investigative T86679 DRUGINFO D0U8DW 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione Investigative T86679 DRUGINFO D0V9EE 2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile Investigative T86679 DRUGINFO D0V9OO (R,S)-PHPNECA Investigative T86679 DRUGINFO D0VB6X (1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl Investigative T86679 DRUGINFO D0W6FC 8-Bromo-9-(2-hydroxypropyl)-9H-adenine Investigative T86679 DRUGINFO D0XC9U MRS1042 Investigative T86679 DRUGINFO D0Y2RM Isoguanosine Investigative T86679 DRUGINFO D0Y5WQ PSB603 Investigative T86679 DRUGINFO D0Z1WY 2-chloro-2'-C-methyl-tecadenoson Investigative T86679 DRUGINFO D0ZL2A MRS1523 Investigative T86679 DRUGINFO D00GNW 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine Investigative T86679 DRUGINFO D00JWA N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide Investigative T86679 DRUGINFO D02PBY 3-noradamantyl-1,3-dipropylxanthine Investigative T86679 DRUGINFO D04LZN 8-Bromo-9-cyclobutyl-9H-adenine Investigative T86679 DRUGINFO D05KEF LUF-5978 Investigative T86679 DRUGINFO D06KYP 8-Bromo-9-isopropyl-9H-adenine Investigative T86679 DRUGINFO D0AI8F 8-Bromo-9-cyclopentyl-9H-adenine Investigative T86679 DRUGINFO D0B0TX 8-bromo-9-isobutyl-9H-purin-6-amine Investigative T86679 DRUGINFO D0CX7N 8-Bromo-9-(3-hydroxypropyl)-9H-adenine Investigative T86679 DRUGINFO D0IG5E 2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine Investigative T86679 DRUGINFO D0JJ6T N6-((+/-)-endo-norborn-2-yl)adenosine Investigative T86679 DRUGINFO D0K6ZA [3H]OSIP339391 Investigative T86679 DRUGINFO D0K8ZZ [3H]NECA Investigative T86679 DRUGINFO D0M3CG R-N6-(phenylisopropyl)adenosine Investigative T86679 DRUGINFO D0NO5E Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate Investigative T86679 DRUGINFO D0O4KI 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine Investigative T86679 DRUGINFO D0R1XY [3H]CCPA Investigative T86679 DRUGINFO D0TU7I (E)-8-(3-chlorostyryl)-caffeine Investigative T86679 DRUGINFO D0V8MD 8-PHENYL THEOPHYLLINE Investigative T86679 DRUGINFO D0W1PF LUF-5980 Investigative T86679 DRUGINFO D0Y9WZ SB-298 Investigative T86679 DRUGINFO D0Z8NC LUF-5981 Investigative T86679 DRUGINFO D0Z8VU 8-Bromo-9-(sec-butyl)-9H-adenine Investigative T86679 DRUGINFO D0K0OT GNF-PF-2224 Investigative T86679 DRUGINFO D03RFA N6-CYCLOPENTYLADENOSINE Investigative T86679 DRUGINFO D0S0RK flavone Investigative T86679 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T95385 TARGETID T95385 T95385 FORMERID TTDI01746 T95385 UNIPROID IL12B_HUMAN T95385 TARGNAME Interleukin-12 beta (IL12B) T95385 GENENAME IL12B T95385 TARGTYPE Successful T95385 SYNONYMS NKSF2; NK cell stimulatory factor chain 2; Interleukin12 subunit beta; Interleukin-12 subunit beta; IL12 subunit p40; IL-12B; IL-12 subunit p40; Cytotoxic lymphocyte maturation factor 40 kDa subunit; CLMF p40 T95385 FUNCTION Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC. T95385 PDBSTRUC 5NJD; 5MZV; 5MXA; 5MJ4; 5MJ3 T95385 BIOCLASS Cytokine: interleukin T95385 SEQUENCE MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCS T95385 DRUGINFO D0I8FI Isoproterenol Approved T95385 DRUGINFO D0H1TL ABT-874 Phase 3 T95385 DRUGINFO D0OS7K EGEN-001 Phase 2 T95385 DRUGINFO D0P7MO SFV IL-12 gene therapy Phase 2 T95385 DRUGINFO D06LUI Ad-IL-12 DNA therapeutic Phase 1/2 T95385 DRUGINFO D00BVJ NHS-IL 12 Phase 1 T95385 DRUGINFO DMA7E5 PF-07261271 Phase 1 T23714 TARGETID T23714 T23714 FORMERID TTDC00111 T23714 UNIPROID BKRB2_HUMAN T23714 TARGNAME B2 bradykinin receptor (BDKRB2) T23714 GENENAME BDKRB2 T23714 TARGTYPE Successful T23714 SYNONYMS Bradykinin B2 receptor; BKR2; BK-2 receptor; BK B(2) receptor; B2R T23714 FUNCTION It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. Receptor for bradykinin. T23714 BIOCLASS GPCR rhodopsin T23714 SEQUENCE MFSPWKISMFLSVREDSVPTTASFSADMLNVTLQGPTLNGTFAQSKCPQVEWLGWLNTIQPPFLWVLFVLATLENIFVLSVFCLHKSSCTVAEIYLGNLAAADLILACGLPFWAITISNNFDWLFGETLCRVVNAIISMNLYSSICFLMLVSIDRYLALVKTMSMGRMRGVRWAKLYSLVIWGCTLLLSSPMLVFRTMKEYSDEGHNVTACVISYPSLIWEVFTNMLLNVVGFLLPLSVITFCTMQIMQVLRNNEMQKFKEIQTERRATVLVLVVLLLFIICWLPFQISTFLDTLHRLGILSSCQDERIIDVITQIASFMAYSNSCLNPLVYVIVGKRFRKKSWEVYQGVCQKGGCRSEPIQMENSMGTLRTSISVERQIHKLQDWAGSRQ T23714 DRUGINFO D04ZBT Icatibant Approved T23714 DRUGINFO D05ENJ Fasitibant chloride Phase 2 T23714 DRUGINFO D05XTQ DELTIBANT Phase 2 T23714 DRUGINFO D09BPN Anatibant Phase 2 T23714 DRUGINFO DS70MP DM199 Phase 2 T23714 DRUGINFO D0X0BI BRADYKININ Phase 1 T23714 DRUGINFO D03ZBM NPC-567 Discontinued in Phase 2 T23714 DRUGINFO D0G0IZ Labradimil Discontinued in Phase 2 T23714 DRUGINFO D03WMY NPC-17731 Terminated T23714 DRUGINFO D07OCC JSM-10292 Terminated T23714 DRUGINFO D0H5PD CP-0597 Terminated T23714 DRUGINFO D0NN5B FR-172357 Terminated T23714 DRUGINFO D0ON2X FR-173657 Terminated T23714 DRUGINFO D00FUT [Leu8,des-Arg9]bradykinin Investigative T23714 DRUGINFO D01APZ (D)Arg-Arg-Pro-Hyp-Gly-Thi-Cys-(D)Phe-Phe-Cys-Arg Investigative T23714 DRUGINFO D03RYY NPC-349 Investigative T23714 DRUGINFO D04ULY bradyzide Investigative T23714 DRUGINFO D04WHO PMID12812482C11 Investigative T23714 DRUGINFO D05IBQ (D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Tic-Arg Investigative T23714 DRUGINFO D06JXH Met-Lys-bradykinin Investigative T23714 DRUGINFO D06QYV FR167344 Investigative T23714 DRUGINFO D07COX T-kinin Investigative T23714 DRUGINFO D08HBN kallidin Investigative T23714 DRUGINFO D09IEO [des-Arg9]bradykinin Investigative T23714 DRUGINFO D0A3YN FR191413 Investigative T23714 DRUGINFO D0BR7M Breceptin Investigative T23714 DRUGINFO D0DU5S Quinapril analogue Investigative T23714 DRUGINFO D0GW6V [Sar,D-Phe8,des-Arg9]bradykinin Investigative T23714 DRUGINFO D0I8HL (D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Aoc-Arg Investigative T23714 DRUGINFO D0J4GG LF-160335 Investigative T23714 DRUGINFO D0L3GT chroman 28 Investigative T23714 DRUGINFO D0LL7N FR190997 Investigative T23714 DRUGINFO D0LM7P (D)Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(d)Phe-Phe-Arg Investigative T23714 DRUGINFO D0NY1V WIN 64338 Investigative T23714 DRUGINFO D0U4SG PMID12723943C12 Investigative T23714 DRUGINFO D0VF5V PS020990 Investigative T23714 DRUGINFO D00FAE H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638) Investigative T23714 DRUGINFO D02DGP H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669) Investigative T23714 DRUGINFO D0C3KW H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645) Investigative T23714 DRUGINFO D0N2GM JMV1431 Investigative T66237 TARGETID T66237 T66237 FORMERID TTDS00111 T66237 UNIPROID V2R_HUMAN T66237 TARGNAME Vasopressin V2 receptor (V2R) T66237 GENENAME AVPR2 T66237 TARGTYPE Successful T66237 SYNONYMS Renal-type arginine vasopressin receptor; DIR3; DIR; Antidiuretic hormone receptor; AVPR V2; ADHR T66237 FUNCTION The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption. Receptor for arginine vasopressin. T66237 PDBSTRUC 4JQI T66237 BIOCLASS GPCR rhodopsin T66237 SEQUENCE MLMASTTSAVPGHPSLPSLPSNSSQERPLDTRDPLLARAELALLSIVFVAVALSNGLVLAALARRGRRGHWAPIHVFIGHLCLADLAVALFQVLPQLAWKATDRFRGPDALCRAVKYLQMVGMYASSYMILAMTLDRHRAICRPMLAYRHGSGAHWNRPVLVAWAFSLLLSLPQLFIFAQRNVEGGSGVTDCWACFAEPWGRRTYVTWIALMVFVAPTLGIAACQVLIFREIHASLVPGPSERPGGRRRGRRTGSPGEGAHVSAAVAKTVRMTLVIVVVYVLCWAPFFLVQLWAAWDPEAPLEGAPFVLLMLLASLNSCTNPWIYASFSSSVSSELRSLLCCARGRTPPSLGPQDESCTTASSSLAKDTSS T66237 DRUGINFO D03KZM Tolvaptan Approved T66237 DRUGINFO D0N4OW Vasopressin Approved T66237 DRUGINFO D0VU2X Conivaptan Approved T66237 DRUGINFO D0F4NS Mozavaptan Approved T66237 DRUGINFO D0M3FJ Oxytocin Approved T66237 DRUGINFO D0U7SH Desmopressin Approved T66237 DRUGINFO D0D8XY ATOSIBAN Phase 4 T66237 DRUGINFO D0L9NX Satavaptan Phase 3 T66237 DRUGINFO D07EEN Lixivaptan Phase 3 T66237 DRUGINFO D01OXH ASP-7035 Phase 2 T66237 DRUGINFO D06VWL VA-106483 Phase 2 T66237 DRUGINFO D0Z8DO SPD-556 Phase 2 T66237 DRUGINFO D0SY9B SSR149415 Phase 2 T66237 DRUGINFO D03RYS VNA-932 Discontinued in Phase 1 T66237 DRUGINFO D0AV0O OPC-51803 Discontinued in Phase 1 T66237 DRUGINFO D0DI0B OX 19 Discontinued in Phase 1 T66237 DRUGINFO D02RDE JTV-605 Terminated T66237 DRUGINFO D05WHD FR161282 Investigative T66237 DRUGINFO D08JNK d(CH2)5[D-Ile2,Ile4]AVP Investigative T66237 DRUGINFO D0KU5D YM-35278 Investigative T66237 DRUGINFO D0ZJ5K VP-343 Investigative T66237 DRUGINFO D0T3YS CL-385004 Investigative T66237 DRUGINFO D0Y0SO DVDAVP Investigative T66237 DRUGINFO D00NIT YM 471 Investigative T66237 DRUGINFO D00SGZ YM 218 Investigative T66237 DRUGINFO D02YBV [Val4]AVP Investigative T66237 DRUGINFO D03EBH D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT Investigative T66237 DRUGINFO D04JXX d[Pen1,Tyr(Me)2]AVP Investigative T66237 DRUGINFO D09OML D[D-3-Pal2]AVP Investigative T66237 DRUGINFO D0T4ML L-372662 Investigative T66237 DRUGINFO D0Y4HL [Phe3]OT Investigative T66237 DRUGINFO D01FDW ARGENINE VASOPRESSIN Investigative T66237 DRUGINFO D03BVC D[Arg4,Orn8]VP Investigative T66237 DRUGINFO D03DXK D[Leu4,Lys8]VP Investigative T66237 DRUGINFO D04MMD D[Arg4,Lys8]VP Investigative T66237 DRUGINFO D05BHL D[Cha4,Lys8]VP Investigative T66237 DRUGINFO D05RNF D[Cha4,Orn8]VP Investigative T66237 DRUGINFO D06SDG D[Leu4,Dab8]VP Investigative T66237 DRUGINFO D09RIE D[Cha4]AVP Investigative T66237 DRUGINFO D09XWA D[Cha4,Dap8]VP Investigative T66237 DRUGINFO D0A6FK D[Leu4]AVP Investigative T66237 DRUGINFO D0HI2N D[Cha4,Dab8]VP Investigative T66237 DRUGINFO D0M4QM d(CH2)5[Tyr(Me)2]AVP Investigative T66237 DRUGINFO D0O5TK D[Leu4,Dap8]VP Investigative T66237 DRUGINFO D0O8OF D[Orn4,Lys8]VP Investigative T66237 DRUGINFO D0R7QC D[Arg4]AVP Investigative T66237 DRUGINFO D0UK0O D[Arg4,Dab8]VP Investigative T66237 DRUGINFO D0V3FF D[Leu4,Orn8]VP Investigative T66237 DRUGINFO D0W3IQ D[Val4]AVP Investigative T66237 DRUGINFO D0YJ6C D[Orn4,Orn8]VP Investigative T66237 DRUGINFO D0ZD0W D[Orn4]AVP Investigative T62184 TARGETID T62184 T62184 FORMERID TTDR01179 T62184 UNIPROID SC6A1_HUMAN T62184 TARGNAME GABA transporter GAT-1 (SLC6A1) T62184 GENENAME SLC6A1 T62184 TARGTYPE Successful T62184 SYNONYMS Solute carrier family 6 member 1; Sodium- and chloride-dependent GABA transporter 1; GAT1; GAT-1; GABT1; GABATR; GABA transporter 1 T62184 FUNCTION Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals. T62184 BIOCLASS Neurotransmitter:sodium symporter T62184 SEQUENCE MATNGSKVADGQISTEVSEAPVANDKPKTLVVKVQKKAADLPDRDTWKGRFDFLMSCVGYAIGLGNVWRFPYLCGKNGGGAFLIPYFLTLIFAGVPLFLLECSLGQYTSIGGLGVWKLAPMFKGVGLAAAVLSFWLNIYYIVIISWAIYYLYNSFTTTLPWKQCDNPWNTDRCFSNYSMVNTTNMTSAVVEFWERNMHQMTDGLDKPGQIRWPLAITLAIAWILVYFCIWKGVGWTGKVVYFSATYPYIMLIILFFRGVTLPGAKEGILFYITPNFRKLSDSEVWLDAATQIFFSYGLGLGSLIALGSYNSFHNNVYRDSIIVCCINSCTSMFAGFVIFSIVGFMAHVTKRSIADVAASGPGLAFLAYPEAVTQLPISPLWAILFFSMLLMLGIDSQFCTVEGFITALVDEYPRLLRNRRELFIAAVCIISYLIGLSNITQGGIYVFKLFDYYSASGMSLLFLVFFECVSISWFYGVNRFYDNIQEMVGSRPCIWWKLCWSFFTPIIVAGVFIFSAVQMTPLTMGNYVFPKWGQGVGWLMALSSMVLIPGYMAYMFLTLKGSLKQRIQVMVQPSEDIVRPENGPEQPQAGSSTSKEAYI T62184 DRUGINFO D0YH0N Metadoxine Approved T62184 DRUGINFO D0ED7U Tiagabine Approved T62184 DRUGINFO D0C9XA GSK683699 Phase 2 T62184 DRUGINFO D08ESA CI-966 Phase 1 T62184 DRUGINFO D03IWW (S)-Piperidine-3-carboxylic acid Investigative T62184 DRUGINFO D08YGM SKF89976A Investigative T62184 DRUGINFO D02SDM LU32-176B Investigative T62184 DRUGINFO D0D2EF (R)-nipecotic acid Investigative T62184 DRUGINFO D0ER1G 4-Hydroxy-piperidine-3-carboxylic acid Investigative T62184 DRUGINFO D0H2HC (R/S) EF-1500 Investigative T62184 DRUGINFO D0I7AL (R)-EF-1520 Investigative T62184 DRUGINFO D0WT5D (S)-EF-1520 Investigative T62184 DRUGINFO D09TTI 2,4-Diamino-butyric acid(GABA) Investigative T62184 DRUGINFO D0RF2M NIPECOTIC ACID Investigative T16633 TARGETID T16633 T16633 FORMERID TTDC00112 T16633 UNIPROID SSR1_HUMAN T16633 TARGNAME Somatostatin receptor type 1 (SSTR1) T16633 GENENAME SSTR1 T16633 TARGTYPE Successful T16633 SYNONYMS Sst(1); Somatostatin receptor 1; SSTR1; SS1R; SRIF-2 T16633 FUNCTION Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphataseand Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins. T16633 BIOCLASS GPCR rhodopsin T16633 SEQUENCE MFPNGTASSPSSSPSPSPGSCGEGGGSRGPGAGAADGMEEPGRNASQNGTLSEGQGSAILISFIYSVVCLVGLCGNSMVIYVILRYAKMKTATNIYILNLAIADELLMLSVPFLVTSTLLRHWPFGALLCRLVLSVDAVNMFTSIYCLTVLSVDRYVAVVHPIKAARYRRPTVAKVVNLGVWVLSLLVILPIVVFSRTAANSDGTVACNMLMPEPAQRWLVGFVLYTFLMGFLLPVGAICLCYVLIIAKMRMVALKAGWQQRKRSERKITLMVMMVVMVFVICWMPFYVVQLVNVFAEQDDATVSQLSVILGYANSCANPILYGFLSDNFKRSFQRILCLSWMDNAAEEPVDYYATALKSRAYSVEDFQPENLESGGVFRNGTCTSRITTL T16633 DRUGINFO D0DQ7V Lutetium Lu 177 dotatate Approved T16633 DRUGINFO D0TV0C Pasireotide Approved T16633 DRUGINFO D06JFI ODT-8 Phase 3 T16633 DRUGINFO D05EKM FR-121196 Terminated T16633 DRUGINFO D00MGT SRA880 Investigative T16633 DRUGINFO D01NID Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Ser13]SRIF Investigative T16633 DRUGINFO D03SXC Des-AA1,2,5-[(NalphaMe)D-Nal8,IAmp9]SRIF Investigative T16633 DRUGINFO D03VHX Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9,Tyr11]SRIF Investigative T16633 DRUGINFO D04EWA Des-AA1,2,5-[(NalphaMe)Lys4,D-Nal8,IAmp9]SRIF Investigative T16633 DRUGINFO D05XZA Des-AA1,2,5-[(NalphaMe)Cys3,D-Trp8,IAmp9]SRIF Investigative T16633 DRUGINFO D06JWT Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Thr12]SRIF Investigative T16633 DRUGINFO D07DUF Des-AA1,2,5-[D-Nal8,IAmp9]SRIF Investigative T16633 DRUGINFO D07OSF Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Phe11]SRIF Investigative T16633 DRUGINFO D0A0DO Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Cys14]SRIF Investigative T16633 DRUGINFO D0BE3D Des-AA1,2,5-[D-Trp8,IAmp9,Tyr11]Cbm-SRIF Investigative T16633 DRUGINFO D0CC1P Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9]SRIF Investigative T16633 DRUGINFO D0I9ME Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9,Tyr11]SRIF Investigative T16633 DRUGINFO D0N4LH Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Cys14]SRIF Investigative T16633 DRUGINFO D0O2DN L-797,591 Investigative T16633 DRUGINFO D0R4IS Des-AA1,2,5-[(NalphaMe)Cys3,D-Nal8,IAmp9]SRIF Investigative T16633 DRUGINFO D0S7YR Des-AA1,5-[Tyr2,D-Trp8,IAmp9]SRIF CH-288 Investigative T16633 DRUGINFO D0Z1XY Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Ser13]SRIF Investigative T16633 DRUGINFO D02WOX Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275 Investigative T16633 DRUGINFO D03DRL Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF Investigative T16633 DRUGINFO D04FPW Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF Investigative T16633 DRUGINFO D05PKR L-817,818 Investigative T16633 DRUGINFO D09LHN Des-AA1,2,5-[IAmp9,Tyr11]-SRIF Investigative T16633 DRUGINFO D0A1XX Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF Investigative T16633 DRUGINFO D0N2MA Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF Investigative T16633 DRUGINFO D0R0OX Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF Investigative T16633 DRUGINFO D0Z0OF Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF Investigative T16633 DRUGINFO D02NJV Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF Investigative T16633 DRUGINFO D0W0AF Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF Investigative T16633 DRUGINFO D02OJQ Des-AA1,2,5-[D-Trp8,Tyr11]SRIF Investigative T16633 DRUGINFO D04ORV Des-AA1,2,5,12,13-[D-Trp8]SRIF Investigative T16633 DRUGINFO D06WCI SRIF-28 Investigative T16633 DRUGINFO D06WYG 99mTc-MIP-1407 Investigative T16633 DRUGINFO D09DAC Des-AA1,2,4,12,13-[D-Trp8]SRIF Investigative T16633 DRUGINFO D0B5AZ Cytotoxin Peptide Conjugate Investigative T16633 DRUGINFO D0C5RH Des-AA1,2,4,13-[D-Trp8]SRIF Investigative T16633 DRUGINFO D0H4WH Des-AA5-[D-Trp8]SRIF Investigative T16633 DRUGINFO D0J5OY Des-AA1,2,4,5-[D-Trp8]SRIF Investigative T16633 DRUGINFO D0P3WF CGP 23996 Investigative T16633 DRUGINFO D0R7OD SRIF-14 Investigative T16633 DRUGINFO D0Z3LZ Des-AA1,2,4,5,13-[D-Trp8]-SRIF Investigative T16633 DRUGINFO D0T5RO SOMATOSTATIN Investigative T53024 TARGETID T53024 T53024 FORMERID TTDS00394 T53024 UNIPROID SSR2_HUMAN T53024 TARGNAME Somatostatin receptor type 2 (SSTR2) T53024 GENENAME SSTR2 T53024 TARGTYPE Successful T53024 SYNONYMS Sst(2); Somatostatin receptor 2; SS2R; SS2-R; SS-2-R; SRIF-1 T53024 FUNCTION Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. Inhibits cell growth through enhancement of MAPK1 and MAPK2 phosphorylation and subsequent up-regulation of CDKN1B. Stimulates neuronal migration and axon outgrowth and may participate in neuron development and maturation during brain development. Mediates negative regulation of insulin receptor signaling through PTPN6. Inactivates SSTR3 receptor function following heterodimerization. T53024 BIOCLASS GPCR rhodopsin T53024 SEQUENCE MDMADEPLNGSHTWLSIPFDLNGSVVSTNTSNQTEPYYDLTSNAVLTFIYFVVCIIGLCGNTLVIYVILRYAKMKTITNIYILNLAIADELFMLGLPFLAMQVALVHWPFGKAICRVVMTVDGINQFTSIFCLTVMSIDRYLAVVHPIKSAKWRRPRTAKMITMAVWGVSLLVILPIMIYAGLRSNQWGRSSCTINWPGESGAWYTGFIIYTFILGFLVPLTIICLCYLFIIIKVKSSGIRVGSSKRKKSEKKVTRMVSIVVAVFIFCWLPFYIFNVSSVSMAISPTPALKGMFDFVVVLTYANSCANPILYAFLSDNFKKSFQNVLCLVKVSGTDDGERSDSKQDKSRLNETTETQRTLLNGDLQTSI T53024 DRUGINFO D02XIY Octreotide Approved T53024 DRUGINFO D0M2YE Lanreotide acetate Approved T53024 DRUGINFO D1HEN2 Ga-68-DOTATOC Approved T53024 DRUGINFO D9E6KQ Copper dotatate Cu-64 Approved T53024 DRUGINFO D0TV0C Pasireotide Approved T53024 DRUGINFO DHTL97 Paltusotine Phase 3 T53024 DRUGINFO D06JFI ODT-8 Phase 3 T53024 DRUGINFO D2L8NT TBR-760 Phase 2 T53024 DRUGINFO D0PX7X Re-188-P-2045 Phase 1/2 T53024 DRUGINFO D0Z4CY PEN-221 Phase 1/2 T53024 DRUGINFO D05EKM FR-121196 Terminated T53024 DRUGINFO D00OSB Ala7-SRIF-14-amide Investigative T53024 DRUGINFO D02EWR L-779,976 Investigative T53024 DRUGINFO D05CRG L-054852 Investigative T53024 DRUGINFO D07WRP L-054,522 Investigative T53024 DRUGINFO D0HY4Q 98mTc-CIM-ANT Investigative T53024 DRUGINFO D0M5LA Des-AA1,2,4,5,11,12,13-[D-Trp8]SRIF Investigative T53024 DRUGINFO D0P6ZZ H-c[Cys-Phe-DTrp-Lys-Thr-Cys]-OH Investigative T53024 DRUGINFO D02IXC D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2 Investigative T53024 DRUGINFO D09EIG Pyz6-D-Trp8-SRIF Investigative T53024 DRUGINFO D0GN3M Ala11-SRIF-14-amide Investigative T53024 DRUGINFO D0K9TS Pyz11-D-Trp8-SRIF Investigative T53024 DRUGINFO D0O4GU H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 Investigative T53024 DRUGINFO D0WG0O Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF Investigative T53024 DRUGINFO D0Y1PT Ala6-SRIF-14-amide Investigative T53024 DRUGINFO D02CQW H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2 Investigative T53024 DRUGINFO D05COQ H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2 Investigative T53024 DRUGINFO D02OJQ Des-AA1,2,5-[D-Trp8,Tyr11]SRIF Investigative T53024 DRUGINFO D04ORV Des-AA1,2,5,12,13-[D-Trp8]SRIF Investigative T53024 DRUGINFO D06WCI SRIF-28 Investigative T53024 DRUGINFO D06WYG 99mTc-MIP-1407 Investigative T53024 DRUGINFO D09DAC Des-AA1,2,4,12,13-[D-Trp8]SRIF Investigative T53024 DRUGINFO D0B5AZ Cytotoxin Peptide Conjugate Investigative T53024 DRUGINFO D0C5RH Des-AA1,2,4,13-[D-Trp8]SRIF Investigative T53024 DRUGINFO D0H4WH Des-AA5-[D-Trp8]SRIF Investigative T53024 DRUGINFO D0J5OY Des-AA1,2,4,5-[D-Trp8]SRIF Investigative T53024 DRUGINFO D0P3WF CGP 23996 Investigative T53024 DRUGINFO D0R7OD SRIF-14 Investigative T53024 DRUGINFO D0Z3LZ Des-AA1,2,4,5,13-[D-Trp8]-SRIF Investigative T53024 DRUGINFO D0T5RO SOMATOSTATIN Investigative T12475 TARGETID T12475 T12475 FORMERID TTDS00273 T12475 UNIPROID GNRHR_HUMAN T12475 TARGNAME Gonadotropin-releasing hormone receptor (GNRHR) T12475 GENENAME GNRHR T12475 TARGTYPE Successful T12475 SYNONYMS Hypothalamic gonadotropin-releasing hormone receptor; Gonadotrophin releasing hormone receptor; GnRH-R; GnRH receptor; GRHR T12475 FUNCTION Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling. T12475 BIOCLASS GPCR rhodopsin T12475 SEQUENCE MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKLQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYLKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRMIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTRVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRLSDPVNHFFFLFAFLNPCFDPLIYGYFSL T12475 DRUGINFO D00RJJ Ganirelix Approved T12475 DRUGINFO D01AHO Abarelix Approved T12475 DRUGINFO D03QRS Triptorelin Approved T12475 DRUGINFO D04ASH Leuprorelin acetate Approved T12475 DRUGINFO D04ODH Gonadorelin Approved T12475 DRUGINFO D08WYM Nafarelin Approved T12475 DRUGINFO D09OLZ Cetrorelix Approved T12475 DRUGINFO D0F2WP Relugolix Approved T12475 DRUGINFO D0VG7Y Elagolix sodium Approved T12475 DRUGINFO D0Y7KH Degarelix Approved T12475 DRUGINFO D02HBB AEZS-108 Phase 3 T12475 DRUGINFO D0R9VC GnRH Phase 3 T12475 DRUGINFO D0UI3T Elagolix Phase 3 T12475 DRUGINFO D02ROU ASP-1707 Phase 2 T12475 DRUGINFO D08FKH KLH-2109 Phase 2 T12475 DRUGINFO D0F0UT ACYLINE Phase 2 T12475 DRUGINFO D0S9BH Ozarelix Phase 2 T12475 DRUGINFO D0S8HD PEP-223/CoVaccine HT Phase 1/2 T12475 DRUGINFO D49LPT VERU-100 Phase 1/2 T12475 DRUGINFO D00VPV TAK-013 Discontinued in Phase 2 T12475 DRUGINFO D07RYX Antide Discontinued in Phase 2 T12475 DRUGINFO D0Z5AC Gonadimmune Discontinued in Phase 2 T12475 DRUGINFO D09MON A-75998 Discontinued in Phase 1 T12475 DRUGINFO D0B7PY Prostate cancer vaccine Discontinued in Phase 1 T12475 DRUGINFO D0D3ZP NBI-42902 Discontinued in Phase 1 T12475 DRUGINFO D0S6AQ Ramorelix Discontinued in Phase 1 T12475 DRUGINFO D02YIW 5-(N,N-hexamethylene)-amiloride Preclinical T12475 DRUGINFO D01WJM D-26344 Terminated T12475 DRUGINFO D0Y3ZX D-21775 Terminated T12475 DRUGINFO D00HNG furan-1 Investigative T12475 DRUGINFO D00JYL [D-Ncy(isopropyl)7]acyline Investigative T12475 DRUGINFO D00TSY [D-Dap(CO-NH-OCH3)3]degarelix Investigative T12475 DRUGINFO D01BUT LXT-101 Investigative T12475 DRUGINFO D01DBW [Ncy(isopropyl)7]acyline Investigative T12475 DRUGINFO D01XHU AN-207 Investigative T12475 DRUGINFO D02NCO T-98475 Investigative T12475 DRUGINFO D03JDY [Ncy(SO,methyl)4]acyline Investigative T12475 DRUGINFO D03YHT [Ncy(SO,methyl)10]acyline Investigative T12475 DRUGINFO D04BVX [D-Ncy(SO,methyl)10]acyline Investigative T12475 DRUGINFO D04HPP [D-Gln3,D-Ncy(isopropyl)7]acyline Investigative T12475 DRUGINFO D04LMF [125I]cetrorelix Investigative T12475 DRUGINFO D04TDF [4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix Investigative T12475 DRUGINFO D05ELQ [Ncy(SO,isopropyl)7]acyline Investigative T12475 DRUGINFO D05UTO [D-Dap(CO-NH-OH)3]degarelix Investigative T12475 DRUGINFO D05VEH detirelix Investigative T12475 DRUGINFO D07DPW [D-Ncy(SO,isopropyl)7]acyline Investigative T12475 DRUGINFO D07NBK AZALINE B Investigative T12475 DRUGINFO D07XFF [4Aph(CO-NH-OH)5]degarelix Investigative T12475 DRUGINFO D08JEK Org-30850 Investigative T12475 DRUGINFO D08XDH [4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix Investigative T12475 DRUGINFO D08XFR AEZS-115 Investigative T12475 DRUGINFO D09UXO [D-Dab(CO-NH-OCH3)3]degarelix Investigative T12475 DRUGINFO D0B2PW antarelix Investigative T12475 DRUGINFO D0B4NU PGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 Investigative T12475 DRUGINFO D0B6LL [4Aph(CO-NH-OCH3)5]degarelix Investigative T12475 DRUGINFO D0C0HP IN-3 Investigative T12475 DRUGINFO D0C2JJ [D-4Aph(CO-NH-OCH3)6]degarelix Investigative T12475 DRUGINFO D0G6IX [D-Gln3,Ncy(SO,isopropyl)7]acyline Investigative T12475 DRUGINFO D0I9JL [Ncy(methyl)4]acyline Investigative T12475 DRUGINFO D0K1AT [D-Ncy(methyl)4]acyline Investigative T12475 DRUGINFO D0K2MC [D-Ncy(methyl)10] acyline Investigative T12475 DRUGINFO D0K8AP [4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix Investigative T12475 DRUGINFO D0KA9Y [Ncy(methyl)10]acyline Investigative T12475 DRUGINFO D0L8WJ [D-4Aph(CO-NH-OH)6]degarelix Investigative T12475 DRUGINFO D0O5VA PGlu-His-Trp-Ser-His-D-Tyr-Leu-Arg-Pro-Gly-NH2 Investigative T12475 DRUGINFO D0R9JG [D-Dab(CO-NH-OH)3]degarelix Investigative T12475 DRUGINFO D0RB5Z [Ncy(2-naphthyl)1]acyline Investigative T12475 DRUGINFO D0V6KF LHRH Investigative T12475 DRUGINFO D0W5JT [D-Gln3,Ncy(isopropyl)7]acyline Investigative T12475 DRUGINFO D0WG8L [D-Gln3,D-Ncy(SO,isopropyl)7]acyline Investigative T12475 DRUGINFO D0X1RZ [D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix Investigative T12475 DRUGINFO D0XL0H [D-Gln3,D-Ncy(SO2,isopropyl)7]acyline Investigative T12475 DRUGINFO D0Y1WD [D-Ncy(2-naphthyl)1]acyline Investigative T12475 DRUGINFO D0Y2NA [D-Gln3,Ncy(SO2,isopropyl)7]acyline Investigative T12475 DRUGINFO D0Z5TP [D-Ncy(SO,methyl)4]acyline Investigative T12475 DRUGINFO D0Z5WP FD-1 Investigative T12475 DRUGINFO D0C7LY WAY-207024 Investigative T71390 TARGETID T71390 T71390 FORMERID TTDR01183 T71390 UNIPROID S5A2_HUMAN T71390 TARGNAME Steroid 5-alpha-reductase 2 (SRD5A2) T71390 GENENAME SRD5A2 T71390 TARGTYPE Successful T71390 SYNONYMS Type 2 steroid 5alpha-reductase (5alpha-R); SRD5A2; SR type 2; 5-alpha reductase 2; 5 alpha-SR2 T71390 FUNCTION Converts testosterone (T) into 5-alpha- dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology. T71390 BIOCLASS CH-CH donor oxidoreductase T71390 ECNUMBER EC 1.3.1.22 T71390 SEQUENCE MQVQCQQSPVLAGSATLVALGALALYVAKPSGYGKHTESLKPAATRLPARAAWFLQELPSFAVPAGILARQPLSLFGPPGTVLLGLFCVHYFHRTFVYSLLNRGRPYPAILILRGTAFCTGNGVLQGYYLIYCAEYPDGWYTDIRFSLGVFLFILGMGINIHSDYILRQLRKPGEISYRIPQGGLFTYVSGANFLGEIIEWIGYALATWSLPALAFAFFSLCFLGLRAFHHHRFYLKMFEDYPKSRKALIPFIF T71390 DRUGINFO D08IWD Finasteride Approved T71390 DRUGINFO D04GZD 4-(4-phenoxybenzoyl)phenylacetic acid Investigative T71390 DRUGINFO D04LXR 3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid Investigative T71390 DRUGINFO D05JGX 4-[4-(benzylamino)benzoyl]benzoic acid Investigative T71390 DRUGINFO D09XLZ 4-[4-(benzoylamino)benzoyl]benzoic acid Investigative T71390 DRUGINFO D0Z6BT 4-[3-(benzyloxy)benzoyl]benzoic acid Investigative T71390 DRUGINFO D01AUS 4-[4-benzyloxy)benzoyl]benzoic acid Investigative T71390 DRUGINFO D04AED 4-[4-(benzhydryloxy)benzoyl]benzoic acid Investigative T71390 DRUGINFO D05XPT (3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid Investigative T71390 DRUGINFO D07BHS (3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid Investigative T71390 DRUGINFO D07BQG {4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid Investigative T71390 DRUGINFO D0Q4GH (E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid Investigative T71390 DRUGINFO D0VR9L 4,4'-dihydroxyoctafluoroazobenzene Investigative T71390 DRUGINFO D0W6HB 4-(4-phenoxybenzoyl)benzoic acid Investigative T71390 DRUGINFO D07OAC GP515 Investigative T71390 DRUGINFO D07ZNR 2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol Investigative T25163 TARGETID T25163 T25163 FORMERID TTDS00533 T25163 UNIPROID CPSM_HUMAN T25163 TARGNAME Carbamoyl-phosphate synthetase I (CPS1) T25163 GENENAME CPS1 T25163 TARGTYPE Successful T25163 SYNONYMS Carbamoyl-phosphate synthase [ammonia], mitochondrial; CPSase I; CPS1 T25163 FUNCTION Involved in the urea cycle of ureotelic animals where the enzyme plays an important role in removing excess ammonia from the cell. T25163 PDBSTRUC 5OJO; 5DOU; 5DOT; 4UUB; 4UUA T25163 BIOCLASS Carbon-nitrogen ligase T25163 ECNUMBER EC 6.3.4.16 T25163 SEQUENCE MTRILTAFKVVRTLKTGFGFTNVTAHQKWKFSRPGIRLLSVKAQTAHIVLEDGTKMKGYSFGHPSSVAGEVVFNTGLGGYPEAITDPAYKGQILTMANPIIGNGGAPDTTALDELGLSKYLESNGIKVSGLLVLDYSKDYNHWLATKSLGQWLQEEKVPAIYGVDTRMLTKIIRDKGTMLGKIEFEGQPVDFVDPNKQNLIAEVSTKDVKVYGKGNPTKVVAVDCGIKNNVIRLLVKRGAEVHLVPWNHDFTKMEYDGILIAGGPGNPALAEPLIQNVRKILESDRKEPLFGISTGNLITGLAAGAKTYKMSMANRGQNQPVLNITNKQAFITAQNHGYALDNTLPAGWKPLFVNVNDQTNEGIMHESKPFFAVQFHPEVTPGPIDTEYLFDSFFSLIKKGKATTITSVLPKPALVASRVEVSKVLILGSGGLSIGQAGEFDYSGSQAVKAMKEENVKTVLMNPNIASVQTNEVGLKQADTVYFLPITPQFVTEVIKAEQPDGLILGMGGQTALNCGVELFKRGVLKEYGVKVLGTSVESIMATEDRQLFSDKLNEINEKIAPSFAVESIEDALKAADTIGYPVMIRSAYALGGLGSGICPNRETLMDLSTKAFAMTNQILVEKSVTGWKEIEYEVVRDADDNCVTVCNMENVDAMGVHTGDSVVVAPAQTLSNAEFQMLRRTSINVVRHLGIVGECNIQFALHPTSMEYCIIEVNARLSRSSALASKATGYPLAFIAAKIALGIPLPEIKNVVSGKTSACFEPSLDYMVTKIPRWDLDRFHGTSSRIGSSMKSVGEVMAIGRTFEESFQKALRMCHPSIEGFTPRLPMNKEWPSNLDLRKELSEPSSTRIYAIAKAIDDNMSLDEIEKLTYIDKWFLYKMRDILNMEKTLKGLNSESMTEETLKRAKEIGFSDKQISKCLGLTEAQTRELRLKKNIHPWVKQIDTLAAEYPSVTNYLYVTYNGQEHDVNFDDHGMMVLGCGPYHIGSSVEFDWCAVSSIRTLRQLGKKTVVVNCNPETVSTDFDECDKLYFEELSLERILDIYHQEACGGCIISVGGQIPNNLAVPLYKNGVKIMGTSPLQIDRAEDRSIFSAVLDELKVAQAPWKAVNTLNEALEFAKSVDYPCLLRPSYVLSGSAMNVVFSEDEMKKFLEEATRVSQEHPVVLTKFVEGAREVEMDAVGKDGRVISHAISEHVEDAGVHSGDATLMLPTQTISQGAIEKVKDATRKIAKAFAISGPFNVQFLVKGNDVLVIECNLRASRSFPFVSKTLGVDFIDVATKVMIGENVDEKHLPTLDHPIIPADYVAIKAPMFSWPRLRDADPILRCEMASTGEVACFGEGIHTAFLKAMLSTGFKIPQKGILIGIQQSFRPRFLGVAEQLHNEGFKLFATEATSDWLNANNVPATPVAWPSQEGQNPSLSSIRKLIRDGSIDLVINLPNNNTKFVHDNYVIRRTAVDSGIPLLTNFQVTKLFAEAVQKSRKVDSKSLFHYRQYSAGKAA T25163 DRUGINFO D0LW9U Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co Approved T25163 DRUGINFO D0Z0MG Carglumic acid Approved T13644 TARGETID T13644 T13644 FORMERID TTDC00254 T13644 UNIPROID SSR3_HUMAN T13644 TARGNAME Somatostatin receptor type 3 (SSTR3) T13644 GENENAME SSTR3 T13644 TARGTYPE Successful T13644 SYNONYMS SSTR3; SSR-28; SS3R T13644 FUNCTION Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. T13644 BIOCLASS GPCR rhodopsin T13644 SEQUENCE MDMLHPSSVSTTSEPENASSAWPPDATLGNVSAGPSPAGLAVSGVLIPLVYLVVCVVGLLGNSLVIYVVLRHTASPSVTNVYILNLALADELFMLGLPFLAAQNALSYWPFGSLMCRLVMAVDGINQFTSIFCLTVMSVDRYLAVVHPTRSARWRTAPVARTVSAAVWVASAVVVLPVVVFSGVPRGMSTCHMQWPEPAAAWRAGFIIYTAALGFFGPLLVICLCYLLIVVKVRSAGRRVWAPSCQRRRRSERRVTRMVVAVVALFVLCWMPFYVLNIVNVVCPLPEEPAFFGLYFLVVALPYANSCANPILYGFLSYRFKQGFRRVLLRPSRRVRSQEPTVGPPEKTEEEDEEEEDGEESREGGKGKEMNGRVSQITQPGTSGQERPPSRVASKEQQLLPQEASTGEKSSTMRISYL T13644 DRUGINFO D0TV0C Pasireotide Approved T13644 DRUGINFO D06JFI ODT-8 Phase 3 T13644 DRUGINFO D05EKM FR-121196 Terminated T13644 DRUGINFO D01BWV BN-81,644 Investigative T13644 DRUGINFO D02MLI NVP ACQ090 Investigative T13644 DRUGINFO D05JKQ L-796,778 Investigative T13644 DRUGINFO D05JMJ BN-81,674 Investigative T13644 DRUGINFO D02WOX Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275 Investigative T13644 DRUGINFO D04FPW Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF Investigative T13644 DRUGINFO D0H0DC Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF Investigative T13644 DRUGINFO D0N2MA Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF Investigative T13644 DRUGINFO D0Z0OF Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF Investigative T13644 DRUGINFO D02CQW H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2 Investigative T13644 DRUGINFO D02NJV Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF Investigative T13644 DRUGINFO D05COQ H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2 Investigative T13644 DRUGINFO D0W0AF Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF Investigative T13644 DRUGINFO D02OJQ Des-AA1,2,5-[D-Trp8,Tyr11]SRIF Investigative T13644 DRUGINFO D04ORV Des-AA1,2,5,12,13-[D-Trp8]SRIF Investigative T13644 DRUGINFO D06WCI SRIF-28 Investigative T13644 DRUGINFO D06WYG 99mTc-MIP-1407 Investigative T13644 DRUGINFO D09DAC Des-AA1,2,4,12,13-[D-Trp8]SRIF Investigative T13644 DRUGINFO D0B5AZ Cytotoxin Peptide Conjugate Investigative T13644 DRUGINFO D0C5RH Des-AA1,2,4,13-[D-Trp8]SRIF Investigative T13644 DRUGINFO D0H4WH Des-AA5-[D-Trp8]SRIF Investigative T13644 DRUGINFO D0J5OY Des-AA1,2,4,5-[D-Trp8]SRIF Investigative T13644 DRUGINFO D0P3WF CGP 23996 Investigative T13644 DRUGINFO D0R7OD SRIF-14 Investigative T13644 DRUGINFO D0Z3LZ Des-AA1,2,4,5,13-[D-Trp8]-SRIF Investigative T13644 DRUGINFO D0T5RO SOMATOSTATIN Investigative T58238 TARGETID T58238 T58238 FORMERID TTDS00453 T58238 UNIPROID CD80_HUMAN T58238 TARGNAME Activation B7-1 antigen (CD80) T58238 GENENAME CD80 T58238 TARGTYPE Successful T58238 SYNONYMS T-lymphocyte activation antigen CD80; LAB7; CTLA-4 counter-receptor B7.1; CD28LG1; CD28LG; BB1; B7 T58238 FUNCTION T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation. Involved in the costimulatory signal essential for T-lymphocyte activation. T58238 PDBSTRUC 1I8L; 1DR9 T58238 SEQUENCE MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV T58238 DRUGINFO D0EW4L Abatacept Approved T58238 DRUGINFO D0J0KT RhuDex Phase 2a T58238 DRUGINFO D0P2SI Galiximab Phase 2 T58238 DRUGINFO D0F3EO HS-110 Phase 2 T58238 DRUGINFO D0T6KI CAR-T cells targeting CD80/86 Phase 1 T58238 DRUGINFO D0T2EO MAXY-4 Phase 1 T58238 DRUGINFO D0V4PH Tolerimab Terminated T23292 TARGETID T23292 T23292 FORMERID TTDI02272 T23292 UNIPROID GALNS_HUMAN T23292 TARGNAME N-acetylgalactosamine 6 sulfatase (GALNS) T23292 GENENAME GALNS T23292 TARGTYPE Successful T23292 SYNONYMS N-acetylgalactosamine-6-sulfate sulfatase; N-acetylgalactosamine-6-sulfatase; Galactose-6-sulfate sulfatase; GalNAc6S sulfatase; GalN6S; Chondroitinsulfatase; Chondroitinase T23292 FUNCTION Catalyzes the chemical reaction of cleaving off the 6-sulfate groups of the N-acetyl-D-galactosamine 6-sulfate units of the macromolecule chondroitin sulfate and, similarly, of the D-galactose 6-sulfate units of the macromolecule keratan sulfate. T23292 PDBSTRUC 4FDJ; 4FDI T23292 BIOCLASS Sulfuric ester hydrolase T23292 ECNUMBER EC 3.1.6.4 T23292 SEQUENCE MAAVVAATRWWQLLLVLSAAGMGASGAPQPPNILLLLMDDMGWGDLGVYGEPSRETPNLDRMAAEGLLFPNFYSANPLCSPSRAALLTGRLPIRNGFYTTNAHARNAYTPQEIVGGIPDSEQLLPELLKKAGYVSKIVGKWHLGHRPQFHPLKHGFDEWFGSPNCHFGPYDNKARPNIPVYRDWEMVGRYYEEFPINLKTGEANLTQIYLQEALDFIKRQARHHPFFLYWAVDATHAPVYASKPFLGTSQRGRYGDAVREIDDSIGKILELLQDLHVADNTFVFFTSDNGAALISAPEQGGSNGPFLCGKQTTFEGGMREPALAWWPGHVTAGQVSHQLGSIMDLFTTSLALAGLTPPSDRAIDGLNLLPTLLQGRLMDRPIFYYRGDTLMAATLGQHKAHFWTWTNSWENFRQGIDFCPGQNVSGVTTHNLEDHTKLPLIFHLGRDPGERFPLSFASAEYQEALSRITSVVQQHQEALVPAQPQLNVCNWAVMNWAPPGCEKLGKCLTPPESIPKKCLWSH T23292 DRUGINFO D0J1UA Elosulfase alfa Approved T23292 DRUGINFO D0OQ9V BMN-110 Phase 3 T64830 TARGETID T64830 T64830 FORMERID TTDC00253 T64830 UNIPROID SSR5_HUMAN T64830 TARGNAME Somatostatin receptor type 5 (SSTR5) T64830 GENENAME SSTR5 T64830 TARGTYPE Successful T64830 SYNONYMS Somatostatin receptor 5; SSTR5; SS5R T64830 FUNCTION Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerization. T64830 BIOCLASS GPCR rhodopsin T64830 SEQUENCE MEPLFPASTPSWNASSPGAASGGGDNRTLVGPAPSAGARAVLVPVLYLLVCAAGLGGNTLVIYVVLRFAKMKTVTNIYILNLAVADVLYMLGLPFLATQNAASFWPFGPVLCRLVMTLDGVNQFTSVFCLTVMSVDRYLAVVHPLSSARWRRPRVAKLASAAAWVLSLCMSLPLLVFADVQEGGTCNASWPEPVGLWGAVFIIYTAVLGFFAPLLVICLCYLLIVVKVRAAGVRVGCVRRRSERKVTRMVLVVVLVFAGCWLPFFTVNIVNLAVALPQEPASAGLYFFVVILSYANSCANPVLYGFLSDNFRQSFQKVLCLRKGSGAKDADATEPRPDRIRQQQEATPPAHRAAANGLMQTSKL T64830 DRUGINFO D0TV0C Pasireotide Approved T64830 DRUGINFO D06JFI ODT-8 Phase 3 T64830 DRUGINFO D05EKM FR-121196 Terminated T64830 DRUGINFO D0H6LR PTR-3046 Investigative T64830 DRUGINFO D02IXC D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2 Investigative T64830 DRUGINFO D05PKR L-817,818 Investigative T64830 DRUGINFO D0O4GU H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 Investigative T64830 DRUGINFO D02CQW H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2 Investigative T64830 DRUGINFO D05COQ H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2 Investigative T64830 DRUGINFO D02OJQ Des-AA1,2,5-[D-Trp8,Tyr11]SRIF Investigative T64830 DRUGINFO D04ORV Des-AA1,2,5,12,13-[D-Trp8]SRIF Investigative T64830 DRUGINFO D06WCI SRIF-28 Investigative T64830 DRUGINFO D06WYG 99mTc-MIP-1407 Investigative T64830 DRUGINFO D09DAC Des-AA1,2,4,12,13-[D-Trp8]SRIF Investigative T64830 DRUGINFO D0B5AZ Cytotoxin Peptide Conjugate Investigative T64830 DRUGINFO D0C5RH Des-AA1,2,4,13-[D-Trp8]SRIF Investigative T64830 DRUGINFO D0H4WH Des-AA5-[D-Trp8]SRIF Investigative T64830 DRUGINFO D0J5OY Des-AA1,2,4,5-[D-Trp8]SRIF Investigative T64830 DRUGINFO D0P3WF CGP 23996 Investigative T64830 DRUGINFO D0R7OD SRIF-14 Investigative T64830 DRUGINFO D0Z3LZ Des-AA1,2,4,5,13-[D-Trp8]-SRIF Investigative T64830 DRUGINFO D0T5RO SOMATOSTATIN Investigative T92609 TARGETID T92609 T92609 FORMERID TTDC00292 T92609 UNIPROID ADA1A_HUMAN T92609 TARGNAME Adrenergic receptor alpha-1A (ADRA1A) T92609 GENENAME ADRA1A T92609 TARGTYPE Successful T92609 SYNONYMS Alpha-adrenergic receptor 1c; Alpha-1C adrenergic receptor; Alpha-1A adrenoreceptor; Alpha-1A adrenoceptor; Alpha-1A adrenergic receptor; Alpha adrenergic receptor 1c; Alpha 1A-adrenoreceptor; Alpha 1A-adrenoceptor; ADRA1C T92609 FUNCTION Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes. This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. T92609 BIOCLASS GPCR rhodopsin T92609 SEQUENCE MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPDFKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTLHPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCTTARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV T92609 DRUGINFO D04DKH NAFTOPIDIL Approved T92609 DRUGINFO D05MBZ Tamsulosin Approved T92609 DRUGINFO D0H1YQ Xatral Approved T92609 DRUGINFO D0U0VU SILODOSIN Approved T92609 DRUGINFO D0C6QQ Besipirdine Phase 3 T92609 DRUGINFO D09JFY Dutasteride + tamsulosin Phase 3 T92609 DRUGINFO D0F2ML MEDETOMIDINE Phase 2 T92609 DRUGINFO D0SG8X PMID30124346-Compound-LDT66 Patented T92609 DRUGINFO D0EO8F PMID30124346-Compound-LDT8 Patented T92609 DRUGINFO D03ITI Sunepitron Discontinued in Phase 3 T92609 DRUGINFO D01RCS TIOSPIRONE Discontinued in Phase 3 T92609 DRUGINFO D0LL9K L-771688 Discontinued in Phase 2 T92609 DRUGINFO D0S1PM RBx-2258 Discontinued in Phase 2 T92609 DRUGINFO D0V9HH Taprizosin Discontinued in Phase 2 T92609 DRUGINFO D0P9FT REC-15-2739 Discontinued in Phase 2 T92609 DRUGINFO D08OJU SOU-001 Discontinued in Phase 2 T92609 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T92609 DRUGINFO D0C3CF SDZ-NVI-085 Discontinued in Phase 1 T92609 DRUGINFO D0Z2UD RS-100975 Discontinued in Phase 1 T92609 DRUGINFO D02CJA CM-2236 Preclinical T92609 DRUGINFO D04XCQ SNAP-6201 Terminated T92609 DRUGINFO D09YUS KRG-3332 Terminated T92609 DRUGINFO D0L5TJ A-131701 Terminated T92609 DRUGINFO D0M4HC L-757464 Terminated T92609 DRUGINFO D0O7DB A-204176 Terminated T92609 DRUGINFO D0BC6Q AGN-193080 Terminated T92609 DRUGINFO D0N7LZ SK&F-104856 Terminated T92609 DRUGINFO D0U3HP ABANOQUIL Terminated T92609 DRUGINFO D0XK2K Siramesine Terminated T92609 DRUGINFO D00KZF BMY-7378 Terminated T92609 DRUGINFO D05IML NIGULDIPINE Terminated T92609 DRUGINFO D08OWQ SK&F-104078 Terminated T92609 DRUGINFO D03QMR WB-4101 Terminated T92609 DRUGINFO D06HRY SNAP-5089 Terminated T92609 DRUGINFO D00MCY REC2615 Investigative T92609 DRUGINFO D01BJZ SNAP-5036 Investigative T92609 DRUGINFO D09ZUW L-765314 Investigative T92609 DRUGINFO D0A0JU A-315456 Investigative T92609 DRUGINFO D0D8GV SNAP-7915 Investigative T92609 DRUGINFO D0N0SN RWJ-68141 Investigative T92609 DRUGINFO D0O6MG RS-100329 Investigative T92609 DRUGINFO D0R4MH RS-513815 Investigative T92609 DRUGINFO D0V8XD (-)-SNAP-5399 Investigative T92609 DRUGINFO D0XL9J Ro-11-04253 Investigative T92609 DRUGINFO D0Z1PA GG-818 Investigative T92609 DRUGINFO D00RLE 4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one Investigative T92609 DRUGINFO D0C7SE SNAP-94847 Investigative T92609 DRUGINFO D0E5CI 8-Piperazin-1-yl-imidazo[1,2-a]pyrazine Investigative T92609 DRUGINFO D0EO4F A-123189 Investigative T92609 DRUGINFO D0J9ZF 4-benzyl-2-methylphthalazin-1(2H)-one Investigative T92609 DRUGINFO D0JC4Q 4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one Investigative T92609 DRUGINFO D0P4KF 2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole Investigative T92609 DRUGINFO D0Q2SI 4-(4-chlorobenzyl)phthalazin-1(2H)-one Investigative T92609 DRUGINFO D0Q7ZR A-119637 Investigative T92609 DRUGINFO D0R2YM 5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine Investigative T92609 DRUGINFO D0Z8OD RWJ-38063 Investigative T92609 DRUGINFO D02TQC N-(5-Bromo-quinoxalin-6-yl)-guanidine Investigative T92609 DRUGINFO D06QKD 4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol Investigative T92609 DRUGINFO D06UBB SK&F-86466 Investigative T92609 DRUGINFO D07QCC SK&F-106686 Investigative T92609 DRUGINFO D07XDL 4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole Investigative T92609 DRUGINFO D08XTL RWJ-69736 Investigative T92609 DRUGINFO D09NXU 4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole Investigative T92609 DRUGINFO D09PIF Imidazolidin-2-ylidene-o-tolyl-amine Investigative T92609 DRUGINFO D0E9VU LEVONORDEFRIN Investigative T92609 DRUGINFO D0F3AR 4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole Investigative T92609 DRUGINFO D0H3CW SK&F-105854 Investigative T92609 DRUGINFO D0L6JS AGN-192172 Investigative T92609 DRUGINFO D0N7UE Imidazolidin-2-ylidene-quinoxalin-6-yl-amine Investigative T92609 DRUGINFO D0O9HS 1-(2-Chloro-phenyl)-piperazine Investigative T92609 DRUGINFO D0Q4PY RWJ-68157 Investigative T92609 DRUGINFO D0RX6I 4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole Investigative T92609 DRUGINFO D0S1GH 4-Morpholin-2-yl-benzene-1,2-diol Investigative T92609 DRUGINFO D0T5KJ 4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol Investigative T92609 DRUGINFO D0ZP5X 4-(1-Naphthalen-1-yl-propyl)-1H-imidazole Investigative T92609 DRUGINFO D02NNS SNAP-8719 Investigative T92609 DRUGINFO D08UDY 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl Investigative T92609 DRUGINFO D09CKI CORYNANTHEINE Investigative T92609 DRUGINFO D0MH0S 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine Investigative T92609 DRUGINFO D01TOU FLUANISONE Investigative T92609 DRUGINFO D06HHJ (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine Investigative T92609 DRUGINFO D06ROA UH-301 Investigative T92609 DRUGINFO D07JMN 1-(pyridin-2-yl)piperazine Investigative T92609 DRUGINFO D0A6GK (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine Investigative T92609 DRUGINFO D0B4DP 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline Investigative T92609 DRUGINFO D0H3NA 4-Benzo[b]thiophen-4-yl-1H-imidazole Investigative T92609 DRUGINFO D0K9NW 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline Investigative T92609 DRUGINFO D08KLH [3H]RX821002 Investigative T92609 DRUGINFO D0L9WN 4-(4-Methyl-indan-1-yl)-1H-imidazole Investigative T92609 DRUGINFO D0P5PW 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole Investigative T92609 DRUGINFO D0D3YN OCTOCLOTHEPIN Investigative T92609 DRUGINFO D0V4RP 1-(2-Methoxy-phenyl)-piperazine Investigative T92609 DRUGINFO D05EQG [3H]spiperone Investigative T92609 DRUGINFO D0R7ZC Beta-methoxyamphetamine Investigative T92609 DRUGINFO D0PN9R R-226161 Investigative T92609 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T92609 DRUGINFO D0L5MW (+/-)-nantenine Investigative T92609 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T66665 TARGETID T66665 T66665 UNIPROID PGH2_HUMAN T66665 TARGNAME Prostaglandin G/H synthase 2 (COX-2) T66665 GENENAME PTGS2 T66665 TARGTYPE Successful T66665 SYNONYMS Prostaglandin-endoperoxide synthase 2; Prostaglandin H2 synthase 2; PHS II; PGHS-2; PGH synthase 2; Cyclooxygenase-2; COX2; COX-2 T66665 FUNCTION Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis. During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs), especially 15-R-lipoxin A4, that regulates phagocytic microglia (By similarity). T66665 PDBSTRUC 5KIR; 5IKV; 5IKT; 5IKR; 5IKQ T66665 BIOCLASS Paired donor oxygen oxidoreductase T66665 ECNUMBER EC 1.14.99.1 T66665 SEQUENCE MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKERSTEL T66665 DRUGINFO D00HGB Niflumic Acid Approved T66665 DRUGINFO D03RTS Celecoxib Approved T66665 DRUGINFO D04YMH Lumiracoxib Approved T66665 DRUGINFO D05CKR Nabumetone Approved T66665 DRUGINFO D05FTJ Mefenamic acid Approved T66665 DRUGINFO D05VLS Rofecoxib Approved T66665 DRUGINFO D07VHR Phenylbutazone Approved T66665 DRUGINFO D08LFZ Diflunisal Approved T66665 DRUGINFO D09BHB Tolmetin Approved T66665 DRUGINFO D09MGR Etoricoxib Approved T66665 DRUGINFO D0A1PX Flurbiprofen Approved T66665 DRUGINFO D0G7FJ Meloxicam Approved T66665 DRUGINFO D0I6IB Tenoxicam Approved T66665 DRUGINFO D0IT2X Carprofen Approved T66665 DRUGINFO D0L6DA Valdecoxib Approved T66665 DRUGINFO D0N1WU Etodolac Approved T66665 DRUGINFO D0R1RS Indomethacin Approved T66665 DRUGINFO D0S7VO Tiaprofenic acid Approved T66665 DRUGINFO D0W9WF Ketoprofen Approved T66665 DRUGINFO D06LHG FENBUFEN Approved T66665 DRUGINFO D0DJ1B Naproxen Approved T66665 DRUGINFO D0MN9K Meclofenamate Sodium Approved T66665 DRUGINFO D0Q5XX Eicosapentaenoic acid/docosa-hexaenoic acid Approved T66665 DRUGINFO D01WJL Aminosalicylic Acid Approved T66665 DRUGINFO D0B2WJ Flufenamic Acid Approved T66665 DRUGINFO D0R1QE Ibuprofen Approved T66665 DRUGINFO D0AL8M IMRECOXIB Phase 4 T66665 DRUGINFO D0G2IC (S)-FLURBIPROFEN Preregistration T66665 DRUGINFO D0C4DZ ThermoProfen Phase 3 T66665 DRUGINFO D0W2CX CG-100649 Phase 3 T66665 DRUGINFO D07SDQ Curcumin Phase 3 T66665 DRUGINFO D0AL8T Darbufelone Phase 2/3 T66665 DRUGINFO D02DYU SC-75416 Phase 2 T66665 DRUGINFO D0U8OD CIMICOXIB Phase 2 T66665 DRUGINFO D0Z9YW FK-3311 Phase 2 T66665 DRUGINFO D06OZJ RWJ-67657 Phase 1 T66665 DRUGINFO DTYP21 CA102N Phase 1 T66665 DRUGINFO D0JE1M PMID29130358-Compound-LonimacranthoideVI Patented T66665 DRUGINFO D0S8TB Carbamate derivative 2 Patented T66665 DRUGINFO D0Q5PL INDOPROFEN Withdrawn from market T66665 DRUGINFO D00RSK GW-406381 Discontinued in Phase 3 T66665 DRUGINFO D0V7HI PRINOMIDE TROMETHAMINE Discontinued in Phase 3 T66665 DRUGINFO D0I9LH PMI-001 Discontinued in Phase 3 T66665 DRUGINFO D02HLL RQ-00317076 Discontinued in Phase 2 T66665 DRUGINFO D04DUJ S-2474 Discontinued in Phase 2 T66665 DRUGINFO D05HVY GSK-644784 Discontinued in Phase 2 T66665 DRUGINFO D0S7IZ Apricoxib Discontinued in Phase 2 T66665 DRUGINFO D0Z5LZ Tilmacoxib Discontinued in Phase 2 T66665 DRUGINFO D0BZ1Q CRx-401 Discontinued in Phase 2 T66665 DRUGINFO D0P3KA TEBUFELONE Discontinued in Phase 2 T66665 DRUGINFO D0ZL4F R-ketoprofen Discontinued in Phase 2 T66665 DRUGINFO D02OHR SC-57666 Discontinued in Phase 1 T66665 DRUGINFO D07RUC E-6087 Discontinued in Phase 1 T66665 DRUGINFO D08GRY DUP 697 Discontinued in Phase 1 T66665 DRUGINFO D0C2HF GR-253035 Discontinued in Phase 1 T66665 DRUGINFO D01QRG RPR 200765A Terminated T66665 DRUGINFO D02KQE ON-09300 Terminated T66665 DRUGINFO D03NZV SC-236 Terminated T66665 DRUGINFO D05EYG L-745337 Terminated T66665 DRUGINFO D05REH Flosulide Terminated T66665 DRUGINFO D07TZM SC-58125 Terminated T66665 DRUGINFO D09BKE NS398 Terminated T66665 DRUGINFO D0B0TO L-768277 Terminated T66665 DRUGINFO D0DR3I S-33516 Terminated T66665 DRUGINFO D0R5TT FR-123826 Terminated T66665 DRUGINFO D0Z5OJ NMI-150 Terminated T66665 DRUGINFO D03AKL ATLIPROFEN METHYL ESTER Terminated T66665 DRUGINFO D08JKK RWJ-63556 Terminated T66665 DRUGINFO D0O9JX SC-58451 Terminated T66665 DRUGINFO D0C0JT Nimesulide Terminated T66665 DRUGINFO D0F8DL SB 203580 Terminated T66665 DRUGINFO D00LWQ 3-Bromo-2'-hydroxy-4-methoxychalcone Investigative T66665 DRUGINFO D00TKO 1-(4-(methylsulfonyl)phenyl)-1H-pyrrole Investigative T66665 DRUGINFO D01MFK DFU Investigative T66665 DRUGINFO D01SNR Firocoxib Investigative T66665 DRUGINFO D02FEF 4-(3-methoxy-benzylideneamino)-benzenesulfonamide Investigative T66665 DRUGINFO D02FYN (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide Investigative T66665 DRUGINFO D02IPX Prostaglandin G2 Investigative T66665 DRUGINFO D02VXW (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide Investigative T66665 DRUGINFO D03ETD Nectamazin C Investigative T66665 DRUGINFO D03FXI 4-(4-nitro-benzylideneamino)-benzenesulfonamide Investigative T66665 DRUGINFO D03GHR C-myb Investigative T66665 DRUGINFO D03KSL L-761000 Investigative T66665 DRUGINFO D03XZJ (E)-3-(4-(methylsulfonyl)styryl)thiophene Investigative T66665 DRUGINFO D04IXJ Bimetopyrole Investigative T66665 DRUGINFO D05JRZ NSC-27236 Investigative T66665 DRUGINFO D05UPM 4-benzyloxy-2'-hydroxychalcone Investigative T66665 DRUGINFO D05ZDQ 1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one Investigative T66665 DRUGINFO D06BHC 4-amino-N-(4-iodophenyl)benzenesulfonamide Investigative T66665 DRUGINFO D06JCT 5-thia-8,11,14,17-eicosatetraenoic acid Investigative T66665 DRUGINFO D07AFA 1-(4-(methylsulfonyl)phenyl)-1H-indole Investigative T66665 DRUGINFO D07HKJ CLEMATOMANDSHURICA SAPONIN A Investigative T66665 DRUGINFO D07QIU 4-(4-methoxy-benzylideneamino)-benzenesulfonamide Investigative T66665 DRUGINFO D08HRA (E)-2-(4-(methylsulfonyl)styryl)thiophene Investigative T66665 DRUGINFO D08LYB SB 239063 Investigative T66665 DRUGINFO D09DMR 4-phenyliminomethyl-benzenesulfonamide Investigative T66665 DRUGINFO D0C1GO SC-558 Investigative T66665 DRUGINFO D0C6WN 2,4-dimethoxy-2'-hydroxychalcone Investigative T66665 DRUGINFO D0EI8V GW-637185X Investigative T66665 DRUGINFO D0F3UR 4-(4-methyl-benzylideneamino)-benzenesulfonamide Investigative T66665 DRUGINFO D0FQ3N 3,4-dihydroxyxanthone Investigative T66665 DRUGINFO D0H4BT 2-(4-(methylsulfonyl)phenyl)pyridine Investigative T66665 DRUGINFO D0J1AW 4-(3-hydroxy-benzylideneamino)-benzenesulfonamide Investigative T66665 DRUGINFO D0JQ3X 4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline Investigative T66665 DRUGINFO D0JT8Y 4-(3-nitro-benzylideneamino)-benzenesulfonamide Investigative T66665 DRUGINFO D0K4QW 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate Investigative T66665 DRUGINFO D0KX7A CR-4174 Investigative T66665 DRUGINFO D0LB6L 2,3-dimethoxy-2'-hydroxychalcone Investigative T66665 DRUGINFO D0M6UZ NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B Investigative T66665 DRUGINFO D0N0GX (E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide Investigative T66665 DRUGINFO D0N8TM XGP-110 Investigative T66665 DRUGINFO D0NB0I 2,4'-Dimethoxy-5,3'-dipropyl-biphenyl Investigative T66665 DRUGINFO D0P4QS 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole Investigative T66665 DRUGINFO D0P9BG 3-benzyloxy-4-methoxy-2'-hydroxychalcone Investigative T66665 DRUGINFO D0Q4CT 2'-hydroxy-3,4,5-trimethoxychalcone Investigative T66665 DRUGINFO D0Q4FH L-748780 Investigative T66665 DRUGINFO D0Q4LI Furan-3-yl(4-(methylsulfonyl)phenyl)methanone Investigative T66665 DRUGINFO D0QV6M LM-4108 Investigative T66665 DRUGINFO D0S7LD 2,6-dihydroxy-1,7-dimethoxyxanthone Investigative T66665 DRUGINFO D0S9YA 2'-Hydroxychalcone Investigative T66665 DRUGINFO D0T2SD 4-(4-methyl-phenyliminomethyl)-benzenesulfonamide Investigative T66665 DRUGINFO D0T3KZ TENOSAL Investigative T66665 DRUGINFO D0U1IJ 6,7'-oxybis(2-phenyl-4H-chromen-4-one) Investigative T66665 DRUGINFO D0U1UP 3,4-dibenzyloxy-2'-hydroxychalcone Investigative T66665 DRUGINFO D0UD5X (E)-2-(4-(methylsulfonyl)styryl)furan Investigative T66665 DRUGINFO D0UH3D Fluoro loxoprofen Investigative T66665 DRUGINFO D0UH3W OCOPHYLLALS A Investigative T66665 DRUGINFO D0V2QP 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline Investigative T66665 DRUGINFO D0V8ZU 8alpha,19-dihydroxylabd-13 E-en-15-oic acid Investigative T66665 DRUGINFO D0X6RO 4-(4-fluoro-benzylideneamino)-benzenesulfonamide Investigative T66665 DRUGINFO D0XC1F CX-9051 Investigative T66665 DRUGINFO D0Y1UG Ocophyllals b Investigative T66665 DRUGINFO D0Y4ZI Silicon-modified indomethacin Investigative T66665 DRUGINFO D0Y9ZO 4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide Investigative T66665 DRUGINFO D0YK4L PAC-10649 Investigative T66665 DRUGINFO D0Z1WF 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide Investigative T66665 DRUGINFO D0Z7BK CLEMATOMANDSHURICA SAPONIN B Investigative T66665 DRUGINFO D00GBX Prifelone Investigative T66665 DRUGINFO D00MXS Wogonin Investigative T66665 DRUGINFO D00VBX 2-(p-Methylsulfonylbenzoyl)furan Investigative T66665 DRUGINFO D01VRB 4,5-Bis(4-chlorophenyl)isothiazole Investigative T66665 DRUGINFO D01WLL N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide Investigative T66665 DRUGINFO D02CCB 2-(2,3,4-trimethoxyphenyl)-1H-indene Investigative T66665 DRUGINFO D02DYG 4-amino-N-(4-chlorophenyl)benzenesulfonamide Investigative T66665 DRUGINFO D02FGY 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid Investigative T66665 DRUGINFO D03VUQ 4-(4-hydroxy-benzylideneamino)-benzenesulfonamide Investigative T66665 DRUGINFO D04TNI Nitroflurbiprofen Investigative T66665 DRUGINFO D04YPP 5-Methyl-3,4-diphenyl-isoxazole Investigative T66665 DRUGINFO D06DRL N-(3-phenylamino-4-pyridinyl)methanesulfonamide Investigative T66665 DRUGINFO D06WML 5-Ethyl-3,4-diphenyl-isoxazole Investigative T66665 DRUGINFO D07ARK 5-Phenyl-pentanoic acid benzyl-hydroxy-amide Investigative T66665 DRUGINFO D07RTV 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole Investigative T66665 DRUGINFO D07STC 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid Investigative T66665 DRUGINFO D08JML Microxine Investigative T66665 DRUGINFO D08RYB 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole Investigative T66665 DRUGINFO D09HWQ 3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone Investigative T66665 DRUGINFO D09MDB 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole Investigative T66665 DRUGINFO D0A4LW (R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide Investigative T66665 DRUGINFO D0BO9W N-(3-phenoxy-4-pyridinyl)ethanesulfonamide Investigative T66665 DRUGINFO D0CW3A Resveratrol Potassium3-Sulfate Investigative T66665 DRUGINFO D0D0JE 4,5-Bis(4-methoxyphenyl)-1,2-selenazole Investigative T66665 DRUGINFO D0D6UC (Z)-2'-des-methyl sulindac sulfide Investigative T66665 DRUGINFO D0E5MK 4,5-Bis(4-chlorophenyl)-1,2-selenazole Investigative T66665 DRUGINFO D0F0JU 4,5-Bis(4-methoxyphenyl)isothiazole Investigative T66665 DRUGINFO D0GF9J (11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid Investigative T66665 DRUGINFO D0J7YE N-(1H-indazol-5-yl)acetamide Investigative T66665 DRUGINFO D0LL9E 1-(4-(methylsulfonyl)phenyl)-3-phenylurea Investigative T66665 DRUGINFO D0N0YS (11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid Investigative T66665 DRUGINFO D0OX0B 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene Investigative T66665 DRUGINFO D0P6PQ THIOCTIC ACID Investigative T66665 DRUGINFO D0S2II 4-(benzylideneamino)benzenesulfonamide Investigative T66665 DRUGINFO D0T4VL Primary alcohol metabolite of celecoxib Investigative T66665 DRUGINFO D0T7BP 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea Investigative T66665 DRUGINFO D0T9QW Oxametacin Investigative T66665 DRUGINFO D0U0YE 2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid Investigative T66665 DRUGINFO D0V9AU 1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene Investigative T66665 DRUGINFO D0X4LI 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one Investigative T66665 DRUGINFO D0X5RR (11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid Investigative T66665 DRUGINFO D0ZI8Y 3 beta-O-acetyloleanolic acid Investigative T66665 DRUGINFO D01JYF 2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl Investigative T66665 DRUGINFO D01OFH METHYLHONOKIOL Investigative T66665 DRUGINFO D04DQJ HONOKIOL Investigative T66665 DRUGINFO D04JZY Resveratrol Potassium4,-Sulfate Investigative T66665 DRUGINFO D04ZGF 5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline Investigative T66665 DRUGINFO D06HUQ 2-Phenethyl-1,2-dihydro-indazol-3-one Investigative T66665 DRUGINFO D0C5SV alpha-linolenic acid Investigative T66665 DRUGINFO D0J7YU 2-Benzyl-1,2-dihydro-indazol-3-one Investigative T66665 DRUGINFO D0L4TM 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one Investigative T66665 DRUGINFO D0P1LP PHENIDONE Investigative T66665 DRUGINFO D0R6ZC 5,3'-Dipropyl-biphenyl-2,4'-diol Investigative T66665 DRUGINFO D0S0PB 2-Phenyl-1,2-dihydro-indazol-3-one Investigative T66665 DRUGINFO D0SJ3W 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one Investigative T66665 DRUGINFO D0U8CM 2-Methyl-1,2-dihydro-indazol-3-one Investigative T66665 DRUGINFO D0VC0I Oxindole 94 Investigative T66665 DRUGINFO D0X6SA 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one Investigative T66665 DRUGINFO D0UU1I Heme Investigative T66665 DRUGINFO D02UVH B-Octylglucoside Investigative T34429 TARGETID T34429 T34429 FORMERID TTDS00520 T34429 UNIPROID ACHA7_HUMAN T34429 TARGNAME Neuronal acetylcholine receptor alpha-7 (CHRNA7) T34429 GENENAME CHRNA7 T34429 TARGTYPE Successful T34429 SYNONYMS Nicotinic acetylcholine receptor subunit alpha 7; Nicotinic acetylcholine receptor alpha7; CHRNA7; Alpha7 nicotinic receptor; Alpha7 nAChR; Alpha-7 nAChR; Alpha(7) nicotinic receptor T34429 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. T34429 PDBSTRUC 5AFN; 5AFM; 5AFL; 5AFK; 5AFJ T34429 BIOCLASS Neurotransmitter receptor T34429 SEQUENCE MRCSPGGVWLALAASLLHVSLQGEFQRKLYKELVKNYNPLERPVANDSQPLTVYFSLSLLQIMDVDEKNQVLTTNIWLQMSWTDHYLQWNVSEYPGVKTVRFPDGQIWKPDILLYNSADERFDATFHTNVLVNSSGHCQYLPPGIFKSSCYIDVRWFPFDVQHCKLKFGSWSYGGWSLDLQMQEADISGYIPNGEWDLVGIPGKRSERFYECCKEPYPDVTFTVTMRRRTLYYGLNLLIPCVLISALALLVFLLPADSGEKISLGITVLLSLTVFMLLVAEIMPATSDSVPLIAQYFASTMIIVGLSVVVTVIVLQYHHHDPDGGKMPKWTRVILLNWCAWFLRMKRPGEDKVRPACQHKQRRCSLASVEMSAVAPPPASNGNLLYIGFRGLDGVHCVPTPDSGVVCGRMACSPTHDEHLLHGGQPPEGDPDLAKILEEVRYIANRFRCQDESEAVCSEWKFAACVVDRLCLMAFSVFTIICTIGILMSAPNFVEAVSKDFA T34429 DRUGINFO D0L1OY ALCURONIUM Approved T34429 DRUGINFO D0R1JV Ziprasidone Approved T34429 DRUGINFO D0D3TX EVP-6124 Phase 3 T34429 DRUGINFO D08XPW CYTISINE Phase 3 T34429 DRUGINFO D0K8NR AMG 386 Phase 3 T34429 DRUGINFO D02NTS JNJ-39393406 Phase 2 T34429 DRUGINFO D08XOY ABT-126 Phase 2 T34429 DRUGINFO D0G4GA TC-6987 Phase 2 T34429 DRUGINFO D0H1AY AQW-051 Phase 2 T34429 DRUGINFO D0U5JP MEM-3454 Phase 2 T34429 DRUGINFO D0ZC3C GTS-21 Phase 2 T34429 DRUGINFO D9PC0O Bradanicline Phase 2 T34429 DRUGINFO D05LRD BMS-933043 Phase 1 T34429 DRUGINFO D07FPR R4996 Phase 1 T34429 DRUGINFO D0C3ZZ BNC375 Phase 1 T34429 DRUGINFO D0O3OI AVL-3288 Phase 1 T34429 DRUGINFO D0Q9RR AZD0328 Discontinued in Phase 2 T34429 DRUGINFO D0F7FX AZD-9684 Discontinued in Phase 2 T34429 DRUGINFO D0Z0LJ ABT-107 Discontinued in Phase 1 T34429 DRUGINFO D0A5MD PHA-568487 Preclinical T34429 DRUGINFO D0I2LX RMG-40083 Preclinical T34429 DRUGINFO D06LKM PNU-282987 Terminated T34429 DRUGINFO D03FPQ PNU-120596 Investigative T34429 DRUGINFO D03JPN A-582941 Investigative T34429 DRUGINFO D04LJH [3H]A-585539 Investigative T34429 DRUGINFO D08HTF JNJ-1930942 Investigative T34429 DRUGINFO D0C9TY PSAB-OFP Investigative T34429 DRUGINFO D0F2XI 4BP-TQS Investigative T34429 DRUGINFO D0M8JZ TOXIFERINE Investigative T34429 DRUGINFO D0O7IS [3H]AZ11637326 Investigative T34429 DRUGINFO D0SR3T JN-711 Investigative T34429 DRUGINFO D0VE4O EVP-4473 Investigative T34429 DRUGINFO D0X2NB AZD-6319 Investigative T34429 DRUGINFO D0Z0EH PheTQS Investigative T34429 DRUGINFO D02LWF GCCSHPACAGNNQHIC* Investigative T34429 DRUGINFO D0IP9V PH-709829 Investigative T34429 DRUGINFO D0X7HD CP-810123 Investigative T34429 DRUGINFO D04MIG LY2087101 Investigative T34429 DRUGINFO D06FLU 3,8-dibromoboldine Investigative T34429 DRUGINFO D09BSE 3-bromoboldine Investigative T34429 DRUGINFO D09VJI [3H]methyllycaconitine Investigative T34429 DRUGINFO D0D4LF NS1738 Investigative T34429 DRUGINFO D0DA1E A-867744 Investigative T34429 DRUGINFO D0UH8F GCCSNPVCHLEHSNLC* Investigative T34429 DRUGINFO D0R4RN [125I]epibatidine Investigative T34429 DRUGINFO D03TMD Barbituric acid derivative Investigative T30284 TARGETID T30284 T30284 FORMERID TTDS00477 T30284 UNIPROID INGR2_HUMAN T30284 TARGNAME Interferon gamma receptor (IFNGR2) T30284 GENENAME IFNGR2 T30284 TARGTYPE Successful T30284 SYNONYMS Interferon gamma transducer 1; Interferon gamma receptor beta-chain; Interferon gamma receptor accessory factor 1; Interferon gamma receptor 2; IFNGT1; IFNGR; IFN-gamma-R2; IFN-gamma-R-beta; IFN-gamma-R; IFN-gamma receptor 2; CDw119; CD119; AF-1 T30284 FUNCTION Ligand binding stimulates activation of the JAK/STAT signaling pathway. Required for signal transduction in contrast to other receptor subunit responsible for ligand binding. Associates with IFNGR1 to form a receptor for the cytokine interferon gamma (IFNG) (, ,). T30284 PDBSTRUC 6E3L; 6E3K; 5EH1 T30284 BIOCLASS Cytokine receptor T30284 SEQUENCE MRPTLLWSLLLLLGVFAAAAAAPPDPLSQLPAPQHPKIRLYNAEQVLSWEPVALSNSTRPVVYQVQFKYTDSKWFTADIMSIGVNCTQITATECDFTAASPSAGFPMDFNVTLRLRAELGALHSAWVTMPWFQHYRNVTVGPPENIEVTPGEGSLIIRFSSPFDIADTSTAFFCYYVHYWEKGGIQQVKGPFRSNSISLDNLKPSRVYCLQVQAQLLWNKSNIFRVGHLSNISCYETMADASTELQQVILISVGTFSLLSVLAGACFFLVLKYRGLIKYWFHTPPSIPLQIEEYLKDPTQPILEALDKDSSPKDDVWDSVSIISFPEKEQEDVLQTL T30284 DRUGINFO D0U8US Interferon gamma-1b Approved T30284 DRUGINFO D0FU8R Anifrolumab Approved T99616 TARGETID T99616 T99616 FORMERID TTDR00585 T99616 UNIPROID TYTR_TRYBB T99616 TARGNAME Trypanosoma Trypanothione reductase (Trypano TPR) T99616 GENENAME Trypano TPR T99616 TARGTYPE Successful T99616 SYNONYMS TRYR; TPR; Parasite-specific trypanothione reductase; N(1),N(8)-bis(glutathionyl)spermidine reductase T99616 FUNCTION Trypanothione is the parasite analog of glutathione; this enzyme is the equivalent of glutathione reductase. T99616 PDBSTRUC 2WBA T99616 BIOCLASS Sulfur donor oxidoreductase T99616 ECNUMBER EC 1.8.1.12 T99616 SEQUENCE MSKIFDLVVIGAGSGGLEAGWNAATLYKKRVAVIDVQTHHGPPHYAALGGTCVNVGCVPKKLMVTGAQYMDHLRESAGFGWEFDGSSVKANWKKLIAAKNEAVLDINKSYEGMFNDTEGLDFFLGWGSLESKNVVVVRETADPKSAVKERLQADHILLATGSWPQMPAIPGVEHCISSNEAFYLPEPPRRVLTVGGGFISVEFAGIFNAYKPPGGKVTLCYRNNLILRGFDETIREEVTKQLTANGIEIMTNENPAKVSLNTDGSKHVTFESGKTLDVDVVMMAIGRIPRTNDLQLGNVGVKLTPKGGVQVDEFSRTNVPNIYAIGDITDRLMLTPVAINEGAALVDTVFGNKPRKTDHTRVASAVFSIPPIGTCGLIEEVAAKEFEKVAVYMSSFTPLMHNISGSKYKKFVAKIVTNHSDGTVLGVHLLGDGAPEIIQAVGVCLRLNAKISDFYNTIGVHPTSAEELCSMRTPSYYYLKGEKMETLPESSL T99616 DRUGINFO D09HVL Bivalirudin Approved T99616 DRUGINFO D0S7WX Vitamin A Approved T99616 DRUGINFO D0E0JN CEPHARANTINE Investigative T99616 DRUGINFO D0P4IP Trypanothione Investigative T99616 DRUGINFO D0P9YV N-(5-chloro-2-(phenylthio)phenyl)butyramide Investigative T99616 DRUGINFO D0R3TU N1,N2-bis(dihydrocaffeoyl)spermine Investigative T99616 DRUGINFO D0E7UH Maleic Acid Investigative T99616 DRUGINFO D0I8HK 1-(2'-chlorophenyl)penta-1,4-dien-3-one Investigative T99616 DRUGINFO D0M9IC CONESSINE Investigative T99616 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T16156 TARGETID T16156 T16156 FORMERID TTDS00524 T16156 UNIPROID TPOR_HUMAN T16156 TARGNAME Thrombopoietin receptor (MPL) T16156 GENENAME MPL T16156 TARGTYPE Successful T16156 SYNONYMS TPOR; TPO-R; Proto-oncogene c-Mpl; Myeloproliferative leukemia protein; CD110 antigen; CD110; C-mpl T16156 FUNCTION May represent a regulatory molecule specific for TPO-R-dependent immune responses. Receptor for thrombopoietin that acts as a primary regulator of megakaryopoiesis and platelet production. T16156 BIOCLASS Cytokine receptor T16156 SEQUENCE MPSWALFMVTSCLLLAPQNLAQVSSQDVSLLASDSEPLKCFSRTFEDLTCFWDEEEAAPSGTYQLLYAYPREKPRACPLSSQSMPHFGTRYVCQFPDQEEVRLFFPLHLWVKNVFLNQTRTQRVLFVDSVGLPAPPSIIKAMGGSQPGELQISWEEPAPEISDFLRYELRYGPRDPKNSTGPTVIQLIATETCCPALQRPHSASALDQSPCAQPTMPWQDGPKQTSPSREASALTAEGGSCLISGLQPGNSYWLQLRSEPDGISLGGSWGSWSLPVTVDLPGDAVALGLQCFTLDLKNVTCQWQQQDHASSQGFFYHSRARCCPRDRYPIWENCEEEEKTNPGLQTPQFSRCHFKSRNDSIIHILVEVTTAPGTVHSYLGSPFWIHQAVRLPTPNLHWREISSGHLELEWQHPSSWAAQETCYQLRYTGEGHQDWKVLEPPLGARGGTLELRPRSRYRLQLRARLNGPTYQGPWSSWSDPTRVETATETAWISLVTALHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLCSSQAQMDYRRLQPSCLGTMPLSVCPPMAESGSCCTTHIANHSYLPLSYWQQP T16156 DRUGINFO D00PEH Eltrombopag Approved T16156 DRUGINFO D08VSI Revolade/Promacta Approved T16156 DRUGINFO D0TD1R Lusutrombopag Approved T16156 DRUGINFO D0W1DI AS-1670542 Approved T16156 DRUGINFO D01PZD Romiplostim Approved T16156 DRUGINFO D04BFI LGD-4665 Phase 2 T16156 DRUGINFO D00CLM NIP-004 Phase 1 T16156 DRUGINFO D04KVA BVI-007 Phase 1 T16156 DRUGINFO D00OEG RhTPO Discontinued in Phase 3 T16156 DRUGINFO D04TJP Totrombopag Discontinued in Phase 1 T16156 DRUGINFO D00LWX Promegapoietin Terminated T16156 DRUGINFO D09WOY SB-559457 Investigative T16156 DRUGINFO D0C3GZ STS-T4 Investigative T16156 DRUGINFO D0EI7H ThromboMer Investigative T16156 DRUGINFO D0G6TR RI-TPO Investigative T16156 DRUGINFO D0GL7O HL-034 Investigative T16156 DRUGINFO D0KP0L SE-ET-TP020d Investigative T16156 DRUGINFO D0QI6W Non-peptide TPO mimics Investigative T33584 TARGETID T33584 T33584 FORMERID TTDC00250 T33584 UNIPROID GRIA1_HUMAN T33584 TARGNAME Glutamate receptor AMPA 1 (GRIA1) T33584 GENENAME GRIA1 T33584 TARGTYPE Successful T33584 SYNONYMS Glutamate receptor ionotropic, AMPA 1; Glutamate receptor 1; GluR-K1; GluR-A; GluR-1; GluA1; GLUR1; GLUH1; AMPA-selective glutamate receptor 1 T33584 FUNCTION L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate. Ionotropic glutamate receptor. T33584 BIOCLASS Glutamate-gated ion channel T33584 SEQUENCE MQHIFAFFCTGFLGAVVGANFPNNIQIGGLFPNQQSQEHAAFRFALSQLTEPPKLLPQIDIVNISDSFEMTYRFCSQFSKGVYAIFGFYERRTVNMLTSFCGALHVCFITPSFPVDTSNQFVLQLRPELQDALISIIDHYKWQKFVYIYDADRGLSVLQKVLDTAAEKNWQVTAVNILTTTEEGYRMLFQDLEKKKERLVVVDCESERLNAILGQIIKLEKNGIGYHYILANLGFMDIDLNKFKESGANVTGFQLVNYTDTIPAKIMQQWKNSDARDHTRVDWKRPKYTSALTYDGVKVMAEAFQSLRRQRIDISRRGNAGDCLANPAVPWGQGIDIQRALQQVRFEGLTGNVQFNEKGRRTNYTLHVIEMKHDGIRKIGYWNEDDKFVPAATDAQAGGDNSSVQNRTYIVTTILEDPYVMLKKNANQFEGNDRYEGYCVELAAEIAKHVGYSYRLEIVSDGKYGARDPDTKAWNGMVGELVYGRADVAVAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHSEEFEEGRDQTTSDQSNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLAKQTEIAYGTLEAGSTKEFFRRSKIAVFEKMWTYMKSAEPSVFVRTTEEGMIRVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSALRNPVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKDKTSALSLSNVAGVFYILIGGLGLAMLVALIEFCYKSRSESKRMKGFCLIPQQSINEAIRTSTLPRNSGAGASSGGSGENGRVVSHDFPKSMQSIPCMSHSSGMPLGATGL T33584 DRUGINFO D0U3ED E-2007 Approved T33584 DRUGINFO D02VKC NBQX Phase 1 T33584 DRUGINFO D02TTF YM-90K Discontinued in Phase 2 T33584 DRUGINFO D0Z4KX Farampator Discontinued in Phase 1 T33584 DRUGINFO D08QYJ SORETOLIDE Terminated T33584 DRUGINFO D0A9VO GYKI-52466 Terminated T33584 DRUGINFO D0M7MW GYKI-53655 Terminated T33584 DRUGINFO D0Z9CC Zonampanel Terminated T33584 DRUGINFO D08SCF Philanthotoxin-343 Investigative T33584 DRUGINFO D0O7OE Argiotoxin-636 Investigative T33584 DRUGINFO D04SMQ (S)-WILLARDIINE Investigative T33584 DRUGINFO D08SYX Piriqualone Investigative T33584 DRUGINFO D0AA9A N-(4-hydroxyphenylpropanyl)-spermine Investigative T33584 DRUGINFO D0T5SU (S)-AMPA Investigative T33584 DRUGINFO D0SB9H joro toxin Investigative T33584 DRUGINFO D03VBJ ATPO Investigative T33584 DRUGINFO D09LXQ (S)-5-fluorowillardiine Investigative T33584 DRUGINFO D0G1UE [3H]AMPA Investigative T33584 DRUGINFO D03PGF RPR-118723 Investigative T33584 DRUGINFO D05VVC 7-chloro-3-hydroxyquinazoline-2,4-dione Investigative T33584 DRUGINFO D0E5UQ [3H]CNQX Investigative T33584 DRUGINFO D05KQC DNQX Investigative T33584 DRUGINFO D04PFN [3H]kainate Investigative T42392 TARGETID T42392 T42392 FORMERID TTDI01970 T42392 UNIPROID GRIA2_HUMAN T42392 TARGNAME Glutamate receptor AMPA 2 (GRIA2) T42392 GENENAME GRIA2 T42392 TARGTYPE Successful T42392 SYNONYMS Glutamate receptor ionotropic, AMPA 2; Glutamate receptor 2; GluRK2; GluRB; GluR2; GluR-K2; GluR-B; GluR-2; GluA2; AMPAselective glutamate receptor 2; AMPA-selective glutamate receptor 2 T42392 FUNCTION L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate. Through complex formation with NSG1, GRIP1 and STX12 controls the intracellular fate of AMPAR and the endosomal sorting of the GRIA2 subunit toward recycling and membrane targeting. Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. T42392 PDBSTRUC 5ZG3; 5ZG2; 5ZG1; 5ZG0; 5YBG T42392 BIOCLASS Glutamate-gated ion channel T42392 SEQUENCE MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFGFYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINVGNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNIKFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRNAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKEKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSRAEAKRMKVAKNAQNINPSSSQNSQNFATYKEGYNVYGIESVKI T42392 DRUGINFO D0U3ED E-2007 Approved T42392 DRUGINFO D05KVC Paliroden Phase 2 T42392 DRUGINFO D03VBJ ATPO Investigative T42392 DRUGINFO D09LXQ (S)-5-fluorowillardiine Investigative T42392 DRUGINFO D0G1UE [3H]AMPA Investigative T42392 DRUGINFO D0E5UQ [3H]CNQX Investigative T75797 TARGETID T75797 T75797 FORMERID TTDS00169 T75797 UNIPROID PF2R_HUMAN T75797 TARGNAME Prostaglandin F2-alpha receptor (PTGFR) T75797 GENENAME PTGFR T75797 TARGTYPE Successful T75797 SYNONYMS Prostanoid FP receptor; PGF2-alpha receptor; PGF2 alpha receptor; PGF receptor; FP prostanoid receptor; FP prostaglandin receptor T75797 FUNCTION The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum. Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and isoform 5 are proposed to be a receptor for prostamides including the synthetic analog bimatoprost. Receptor for prostaglandin F2-alpha (PGF2-alpha). T75797 BIOCLASS GPCR rhodopsin T75797 SEQUENCE MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAILMKAYQRFRQKSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIRFDQSNVLCSIFGICMVFSGLCPLLLGSVMAIERCIGVTKPIFHSTKITSKHVKMMLSGVCLFAVFIALLPILGHRDYKIQASRTWCFYNTEDIKDWEDRFYLLLFSFLGLLALGVSLLCNAITGITLLRVKFKSQQHRQGRSHHLEMVIQLLAIMCVSCICWSPFLVTMANIGINGNHSLETCETTLFALRMATWNQILDPWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPVAEKSAST T75797 DRUGINFO D04LCQ Tafluprost Approved T75797 DRUGINFO D05LQX BOL-303259-X Approved T75797 DRUGINFO D07PCI Carboprost Tromethamine Approved T75797 DRUGINFO D09CZA Travoprost Approved T75797 DRUGINFO D0C6NM Latanoprost Approved T75797 DRUGINFO D06FEA Dinoprostone Approved T75797 DRUGINFO D0WL5V LAROPIPRANT Phase 4 T75797 DRUGINFO D00JRD PGF2ALPHA-IE Phase 3 T75797 DRUGINFO D0V5QH ONO-9054 Phase 2 T75797 DRUGINFO D0TJ7S PDC-41 Phase 1 T75797 DRUGINFO D08QWQ bimatoprost (free acid form) Clinical trial T75797 DRUGINFO D00HTY PGF2alpha Clinical trial T75797 DRUGINFO D0W2OT BUTAPROST Patented T75797 DRUGINFO D03OYD 13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha Investigative T75797 DRUGINFO D04ULI [3H]PGF2alpha Investigative T75797 DRUGINFO D05DRG PDC-31 Investigative T75797 DRUGINFO D05VOG AL-8810 Investigative T75797 DRUGINFO D08MXB NCX-125 Investigative T75797 DRUGINFO D0L4IV AL12180 Investigative T75797 DRUGINFO D0MR1B AS604872 Investigative T75797 DRUGINFO D05TNX fluprostenol Investigative T75797 DRUGINFO D0X5MA I-BOP Investigative T75797 DRUGINFO D0O9ES cloprostenol Investigative T75797 DRUGINFO D0BN1U M&B 28767 Investigative T75797 DRUGINFO D06KBO PGD2 Investigative T75797 DRUGINFO D0W7RI carbacyclin Investigative T75797 DRUGINFO D03PLH U46619 Investigative T38529 TARGETID T38529 T38529 FORMERID TTDS00168 T38529 UNIPROID PE2R2_HUMAN T38529 TARGNAME Prostaglandin E2 receptor EP2 (PTGER2) T38529 GENENAME PTGER2 T38529 TARGTYPE Successful T38529 SYNONYMS Prostanoid EP2 receptor; Prostaglandin E2 receptor EP2 subtype; PGE2 receptor EP2 subtype; PGE receptor, EP2 subtype; PGE receptor EP2 subtype; EP2 receptor T38529 FUNCTION The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle. Receptor for prostaglandin E2 (PGE2). T38529 BIOCLASS GPCR rhodopsin T38529 SEQUENCE MGNASNDSQSEDCETRQWLPPGESPAISSVMFSAGVLGNLIALALLARRWRGDVGCSAGRRSSLSLFHVLVTELVFTDLLGTCLISPVVLASYARNQTLVALAPESRACTYFAFAMTFFSLATMLMLFAMALERYLSIGHPYFYQRRVSRSGGLAVLPVIYAVSLLFCSLPLLDYGQYVQYCPGTWCFIRHGRTAYLQLYATLLLLLIVSVLACNFSVILNLIRMHRRSRRSRCGPSLGSGRGGPGARRRGERVSMAEETDHLILLAIMTITFAVCSLPFTIFAYMNETSSRKEKWDLQALRFLSINSIIDPWVFAILRPPVLRLMRSVLCCRISLRTQDATQTSCSTQSDASKQADL T38529 DRUGINFO D00SOZ Omidenepag isopropyl Approved T38529 DRUGINFO D05ZTH Iloprost Approved T38529 DRUGINFO D04FBR Mycophenolate mofetil Approved T38529 DRUGINFO D06FEA Dinoprostone Approved T38529 DRUGINFO D0I4DQ Alprostadil Approved T38529 DRUGINFO D0WL5V LAROPIPRANT Phase 4 T38529 DRUGINFO D0G6EI CP-533536 Phase 2 T38529 DRUGINFO D0Y3LL Taprenepag Phase 2 T38529 DRUGINFO D0U7WF 16,16-dimethyl-PGE2 Phase 2 T38529 DRUGINFO D0S5EF PF-4418948 Phase 1 T38529 DRUGINFO D54FYW TPST-1495 Phase 1 T38529 DRUGINFO D00HTY PGF2alpha Clinical trial T38529 DRUGINFO D01ERV PMID25772215-Compound-US02014179750TG7-170 Patented T38529 DRUGINFO D01FIM PMID25772215-Compound-WO2012177618M6 Patented T38529 DRUGINFO D01JJN PMID25772215-Compound-EP2149552diaminopyrimidines Patented T38529 DRUGINFO D03IKW PMID25772215-Compound-WO2012177618M4 Patented T38529 DRUGINFO D06ZEI PMID25772215-Compound-US02014179750TG8-15 Patented T38529 DRUGINFO D0A2VQ PMID25772215-Compound-US02014179750M2 Patented T38529 DRUGINFO D0D0PF PMID25772215-Compound-US02014179750TG7-112-2 Patented T38529 DRUGINFO D0G6UA PMID25772215-Compound-WO2012177618M5 Patented T38529 DRUGINFO D0H6QG PMID25772215-Compound-US02014179750TG7-74 Patented T38529 DRUGINFO D0HJ1O PMID25772215-Compound-US02014179750M1 Patented T38529 DRUGINFO D0NQ6N PMID25772215-Compound-US02014179750TG6-10-1 Patented T38529 DRUGINFO D0O2EN PMID25772215-Compound-US02014179750TG6-129 Patented T38529 DRUGINFO D0RD5O PMID25772215-Compound-US02014179750TG7-76 Patented T38529 DRUGINFO D0Y8GN PMID25772215-Compound-US02014179750M3 Patented T38529 DRUGINFO D0ZT9N PMID25772215-Compound-EP20082149552C9 Patented T38529 DRUGINFO D0W2OT BUTAPROST Patented T38529 DRUGINFO D02RUO ONO-8815Ly Terminated T38529 DRUGINFO D01IJD AH13205 Investigative T38529 DRUGINFO D03WTU TG4-155 Investigative T38529 DRUGINFO D06PVN R-65 Investigative T38529 DRUGINFO D0NY1J TG7-171 Investigative T38529 DRUGINFO D0ST1M PMID20080612C1 Investigative T38529 DRUGINFO D0YD9E PF-00212062 Investigative T38529 DRUGINFO D05MXO 19(R)-OH-PGE2 Investigative T38529 DRUGINFO D0CW4T ONO-AE-248 Investigative T38529 DRUGINFO D02LXJ 3-(2-cinnamylphenyl)acrylic acid Investigative T38529 DRUGINFO D02SAD 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid Investigative T38529 DRUGINFO D02YIJ isocarbacyclin Investigative T38529 DRUGINFO D06VZS ONO-AE1-329 Investigative T38529 DRUGINFO D0G5MT 11-deoxy-PGE1 Investigative T38529 DRUGINFO D0W4GQ 3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid Investigative T38529 DRUGINFO D0X2MQ 17-phenyl-omega-trinor-PGE2 Investigative T38529 DRUGINFO D0Z3XJ 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid Investigative T38529 DRUGINFO D0J9PG AH6809 Investigative T38529 DRUGINFO D05SFA cicaprost Investigative T38529 DRUGINFO D08MNO butaprost (free acid form) Investigative T38529 DRUGINFO D0BN1U M&B 28767 Investigative T38529 DRUGINFO D06KBO PGD2 Investigative T38529 DRUGINFO D0W7RI carbacyclin Investigative T38529 DRUGINFO D03PLH U46619 Investigative T64591 TARGETID T64591 T64591 FORMERID TTDS00399 T64591 UNIPROID 5HT3A_HUMAN T64591 TARGNAME 5-HT 3A receptor (HTR3A) T64591 GENENAME HTR3A T64591 TARGTYPE Successful T64591 SYNONYMS Serotonin-gated ion channel receptor; Serotonin receptor 3A; HTR3; 5HT3R; 5-hydroxytryptamine receptor 3A; 5-HT3RA; 5-HT3A; 5-HT3-A; 5-HT 3A T64591 FUNCTION This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel. T64591 BIOCLASS GPCR rhodopsin T64591 SEQUENCE MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVRPVRDWRKPTTVSIDVIVYAILNVDEKNQVLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSIWVPDILINEFVDVGKSPNIPYVYIRHQGEVQNYKPLQVVTACSLDIYNFPFDVQNCSLTFTSWLHTIQDINISLWRLPEKVKSDRSVFMNQGEWELLGVLPYFREFSMESSNYYAEMKFYVVIRRRPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITLLLGYSVFLIIVSDTLPATAIGTPLIGVYFVVCMALLVISLAETIFIVRLVHKQDLQQPVPAWLRHLVLERIAWLLCLREQSTSQRPPATSQATKTDDCSAMGNHCSHMGGPQDFEKSPRDRCSPPPPPREASLAVCGLLQELSSIRQFLEKRDEIREVARDWLRVGSVLDKLLFHIYLLAVLAYSITLVMLWSIWQYA T64591 DRUGINFO D00YLW Dolasetron Approved T64591 DRUGINFO D04FVU Palonosetron Approved T64591 DRUGINFO D06GKN Alosetron Approved T64591 DRUGINFO D0K0KH Tropisetron Approved T64591 DRUGINFO D0TZ1G Procaine Approved T64591 DRUGINFO D0E1XL Levetiracetam Approved T64591 DRUGINFO D0K5IP Palonosetron + fosnetupitant Approved T64591 DRUGINFO D0Z2MB Cilansetron Phase 3 T64591 DRUGINFO D0V3GT BEMESETRON Discontinued in Phase 3 T64591 DRUGINFO D02WGN YM-114 Discontinued in Phase 2 T64591 DRUGINFO D0K1SZ Norcisapride Discontinued in Phase 2 T64591 DRUGINFO D0M1YN ATI-17000 Preclinical T64591 DRUGINFO D08KDP AS-8112 Terminated T64591 DRUGINFO D0V1SD BP4.879a Terminated T64591 DRUGINFO D00EJS 5-hydroxyindole Investigative T64591 DRUGINFO D01WXA TMB-8 Investigative T64591 DRUGINFO D02OYL 1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea Investigative T64591 DRUGINFO D04KGK 10,11-dihydro-5H-dibenzo[b,f]azepine Investigative T64591 DRUGINFO D07ZZD 4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane Investigative T64591 DRUGINFO D0C3AJ 3alpha-(2'-Indolecarbonyloxy)-nortropane Investigative T64591 DRUGINFO D0M4RW FLUPENTIXOLE Investigative T64591 DRUGINFO D0O5PQ [3H]ramosetron Investigative T64591 DRUGINFO D0S8ZJ 3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane Investigative T64591 DRUGINFO D0T3QZ [3H]GR65630 Investigative T64591 DRUGINFO D0UV6L [3H](S)-zacopride Investigative T64591 DRUGINFO D00PCE BRL-24682 Investigative T64591 DRUGINFO D04AXY 6-(4-Methyl-piperazin-1-yl)-phenanthridine Investigative T64591 DRUGINFO D06IRE trichloroethanol Investigative T64591 DRUGINFO D0G3MD (4-Quinolin-2-ylpiperazin-1-yl)acetic Acid Investigative T64591 DRUGINFO D0H4NK 1-phenylbiguanide Investigative T64591 DRUGINFO D0I4BZ (S)-zacopride Investigative T64591 DRUGINFO D0IP9V PH-709829 Investigative T64591 DRUGINFO D0L1NS 2-(4-Benzyl-piperazin-1-yl)-benzothiazole Investigative T64591 DRUGINFO D0P2HR [3H]granisetron Investigative T64591 DRUGINFO D0SA4A meta-chlorphenylbiguanide Investigative T64591 DRUGINFO D0TJ6Z 2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole Investigative T64591 DRUGINFO D0X7HD CP-810123 Investigative T64591 DRUGINFO D0B0TK bilobalide Investigative T64591 DRUGINFO D0G2BS 2-(4-Methyl-piperazin-1-yl)-quinoline Investigative T64591 DRUGINFO D01FFX 4-((naphthalen-2-yloxy)methyl)piperidine Investigative T64591 DRUGINFO D0K5NZ MESULERGINE Investigative T64591 DRUGINFO D06QIQ 7-(piperidin-4-ylmethoxy)-2-naphthonitrile Investigative T64591 DRUGINFO D08BCF QUIPAZINE Investigative T64591 DRUGINFO D0Y9TL 5-chloro-3,4-dihydroquinazolin-2-amine Investigative T64591 DRUGINFO D00CRA 2-methyl-5-HT Investigative T64591 DRUGINFO D08VGJ 5,6-dichloro-3,4-dihydroquinazolin-2-amine Investigative T64591 DRUGINFO D0F6CD SEROTONIN Investigative T64591 DRUGINFO D0F9QT A-987306 Investigative T64591 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T59881 TARGETID T59881 T59881 FORMERID TTDC00298 T59881 UNIPROID V1BR_HUMAN T59881 TARGNAME Vasopressin V1b receptor (V1BR) T59881 GENENAME AVPR1B T59881 TARGTYPE Successful T59881 SYNONYMS Vasopressin V3 receptor; Vasopressin V(1b) Receptor; VPR3; V1bR; Antidiuretic hormone receptor 1b; AVPR3; AVPR V3; AVPR V1b T59881 FUNCTION The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Receptor for arginine vasopressin. T59881 BIOCLASS GPCR rhodopsin T59881 SEQUENCE MDSGPLWDANPTPRGTLSAPNATTPWLGRDEELAKVEIGVLATVLVLATGGNLAVLLTLGQLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLWDITYRFQGPDLLCRAVKYLQVLSMFASTYMLLAMTLDRYLAVCHPLRSLQQPGQSTYLLIAAPWLLAAIFSLPQVFIFSLREVIQGSGVLDCWADFGFPWGPRAYLTWTTLAIFVLPVTMLTACYSLICHEICKNLKVKTQAWRVGGGGWRTWDRPSPSTLAATTRGLPSRVSSINTISRAKIRTVKMTFVIVLAYIACWAPFFSVQMWSVWDKNAPDEDSTNVAFTISMLLGNLNSCCNPWIYMGFNSHLLPRPLRHLACCGGPQPRMRRRLSDGSLSSRHTTLLTRSSCPATLSLSLSLTLSGRPRPEESPRDLELADGEGTAETIIF T59881 DRUGINFO D0F4NS Mozavaptan Approved T59881 DRUGINFO D0M3FJ Oxytocin Approved T59881 DRUGINFO D0U7SH Desmopressin Approved T59881 DRUGINFO D0D8XY ATOSIBAN Phase 4 T59881 DRUGINFO D0RC0J ABT-436 Phase 2 T59881 DRUGINFO D0SY9B SSR149415 Phase 2 T59881 DRUGINFO D01CSM [3H]nelivaptan Investigative T59881 DRUGINFO D00NIT YM 471 Investigative T59881 DRUGINFO D00SGZ YM 218 Investigative T59881 DRUGINFO D02VVG D[Orn8(5/6C-Flu)]VT Investigative T59881 DRUGINFO D02YBV [Val4]AVP Investigative T59881 DRUGINFO D04JXX d[Pen1,Tyr(Me)2]AVP Investigative T59881 DRUGINFO D05YHE D[Thr4,Lys8(5/6C-Flu)]VT Investigative T59881 DRUGINFO D09BWP [HO1][Orn8(5/6C-Flu)]VT Investigative T59881 DRUGINFO D09OML D[D-3-Pal2]AVP Investigative T59881 DRUGINFO D0C8XX D[Thr4,Orn8(5/6C-Flu)]VT Investigative T59881 DRUGINFO D0K0JJ [HO1][Lys8(5/6C-Flu)]VT Investigative T59881 DRUGINFO D0L0RP [Lys8(Alexa 488) ]PVA Investigative T59881 DRUGINFO D0M3BJ D[Lys8(5/6-Flu)]VT Investigative T59881 DRUGINFO D0O6WN [HO1][Thr4,Orn8(5/6C-Flu)]VT Investigative T59881 DRUGINFO D0Y5FO [HO1][Thr4,Lys8(5/6C-Flu)]VT Investigative T59881 DRUGINFO D01FDW ARGENINE VASOPRESSIN Investigative T59881 DRUGINFO D03BVC D[Arg4,Orn8]VP Investigative T59881 DRUGINFO D03DXK D[Leu4,Lys8]VP Investigative T59881 DRUGINFO D04MMD D[Arg4,Lys8]VP Investigative T59881 DRUGINFO D05BHL D[Cha4,Lys8]VP Investigative T59881 DRUGINFO D05RNF D[Cha4,Orn8]VP Investigative T59881 DRUGINFO D06SDG D[Leu4,Dab8]VP Investigative T59881 DRUGINFO D09RIE D[Cha4]AVP Investigative T59881 DRUGINFO D09XWA D[Cha4,Dap8]VP Investigative T59881 DRUGINFO D0A6FK D[Leu4]AVP Investigative T59881 DRUGINFO D0HI2N D[Cha4,Dab8]VP Investigative T59881 DRUGINFO D0M4QM d(CH2)5[Tyr(Me)2]AVP Investigative T59881 DRUGINFO D0O5TK D[Leu4,Dap8]VP Investigative T59881 DRUGINFO D0O8OF D[Orn4,Lys8]VP Investigative T59881 DRUGINFO D0R7QC D[Arg4]AVP Investigative T59881 DRUGINFO D0UK0O D[Arg4,Dab8]VP Investigative T59881 DRUGINFO D0V3FF D[Leu4,Orn8]VP Investigative T59881 DRUGINFO D0W3IQ D[Val4]AVP Investigative T59881 DRUGINFO D0YJ6C D[Orn4,Orn8]VP Investigative T59881 DRUGINFO D0ZD0W D[Orn4]AVP Investigative T17163 TARGETID T17163 T17163 FORMERID TTDR00238 T17163 UNIPROID LEPR_HUMAN T17163 TARGNAME Leptin receptor (LEPR) T17163 GENENAME LEPR T17163 TARGTYPE Successful T17163 SYNONYMS OBR; OB-R; OB receptor; LEP-R; HuB219; DB; CD295 T17163 FUNCTION On ligand binding, mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade/FOS. In the hypothalamus, LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides, also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery, increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity. Control of energy homeostasis and melanocortin production (stimulation of POMC and full repression of AgRP transcription) is mediated by STAT3 signaling, whereas distinct signals regulate NPY and the control of fertility, growth and glucose homeostasis. Involved in the regulation of counter-regulatory response to hypoglycemia by inhibiting neurons of the parabrachial nucleus. Has a specific effect on T lymphocyte responses, differentially regulating the proliferation of naive and memory T -ells. Leptin increases Th1 and suppresses Th2 cytokine production. Receptor for hormone LEP/leptin. T17163 PDBSTRUC 6E2P; 3V6O T17163 BIOCLASS Cytokine receptor T17163 SEQUENCE MICQKFCVVLLHWEFIYVITAFNLSYPITPWRFKLSCMPPNSTYDYFLLPAGLSKNTSNSNGHYETAVEPKFNSSGTHFSNLSKTTFHCCFRSEQDRNCSLCADNIEGKTFVSTVNSLVFQQIDANWNIQCWLKGDLKLFICYVESLFKNLFRNYNYKVHLLYVLPEVLEDSPLVPQKGSFQMVHCNCSVHECCECLVPVPTAKLNDTLLMCLKITSGGVIFQSPLMSVQPINMVKPDPPLGLHMEITDDGNLKISWSSPPLVPFPLQYQVKYSENSTTVIREADKIVSATSLLVDSILPGSSYEVQVRGKRLDGPGIWSDWSTPRVFTTQDVIYFPPKILTSVGSNVSFHCIYKKENKIVPSKEIVWWMNLAEKIPQSQYDVVSDHVSKVTFFNLNETKPRGKFTYDAVYCCNEHECHHRYAELYVIDVNINISCETDGYLTKMTCRWSTSTIQSLAESTLQLRYHRSSLYCSDIPSIHPISEPKDCYLQSDGFYECIFQPIFLLSGYTMWIRINHSLGSLDSPPTCVLPDSVVKPLPPSSVKAEITINIGLLKISWEKPVFPENNLQFQIRYGLSGKEVQWKMYEVYDAKSKSVSLPVPDLCAVYAVQVRCKRLDGLGYWSNWSNPAYTVVMDIKVPMRGPEFWRIINGDTMKKEKNVTLLWKPLMKNDSLCSVQRYVINHHTSCNGTWSEDVGNHTKFTFLWTEQAHTVTVLAINSIGASVANFNLTFSWPMSKVNIVQSLSAYPLNSSCVIVSWILSPSDYKLMYFIIEWKNLNEDGEIKWLRISSSVKKYYIHDHFIPIEKYQFSLYPIFMEGVGKPKIINSFTQDDIEKHQSDAGLYVIVPVIISSSILLLGTLLISHQRMKKLFWEDVPNPKNCSWAQGLNFQKPETFEHLFIKHTASVTCGPLLLEPETISEDISVDTSWKNKDEMMPTTVVSLLSTTDLEKGSVCISDQFNSVNFSEAEGTEVTYEDESQRQPFVKYATLISNSKPSETGEEQGLINSSVTKCFSSKNSPLKDSFSNSSWEIEAQAFFILSDQHPNIISPHLTFSEGLDELLKLEGNFPEENNDKKSIYYLGVTSIKKRESGVLLTDKSRVSCPFPAPCLFTDIRVLQDSCSHFVENNINLGTSSKKTFASYMPQFQTCSTQTHKIMENKMCDLTV T17163 DRUGINFO D0Z9EO Metreleptin Approved T17163 DRUGINFO D06GZW PEGylated leptin Investigative T17163 DRUGINFO D07OED BL-5040 Investigative T17163 DRUGINFO D08HUB ANG-2004 Investigative T17163 DRUGINFO D0B3IZ AMPSL Investigative T17163 DRUGINFO D0C6TL Leptin Investigative T17163 DRUGINFO D0D1PQ EDP-21 Investigative T17163 DRUGINFO D0G8BE AMPPL Investigative T17163 DRUGINFO D0J3AV PEG-LPA-2 Investigative T17163 DRUGINFO D0D7YR AMPE4L Investigative T06421 TARGETID T06421 T06421 FORMERID TTDS00492 T06421 UNIPROID INAR2_HUMAN T06421 TARGNAME Interferon alpha/beta receptor 2 (IFNAR2) T06421 GENENAME IFNAR2 T06421 TARGTYPE Successful T06421 SYNONYMS Type I interferon receptor 2; Type I interferon receptor; Interferon alpha/beta receptor; Interferon alpha binding protein; IFNARB; IFNABR; IFN-alpha/beta receptor 2; IFN-alpha-REC; IFN-alpha binding protein; IFN-R-2; IFN-R T06421 FUNCTION Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity. Associates with IFNAR1 to form the type I interferon receptor. T06421 PDBSTRUC 3SE4; 3SE3; 3S9D; 3S8W; 2LAG T06421 BIOCLASS Cytokine receptor T06421 SEQUENCE MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHSIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLFSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKKHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAESAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMDMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLIDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGRITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPTFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR T06421 DRUGINFO D03QCW Interferon alfa-n1 Approved T06421 DRUGINFO D04RZD Interferon Alfa-2b, Recombinant Approved T06421 DRUGINFO D05NDR Sifalimumab Approved T06421 DRUGINFO D0CQ2O Interferon beta-1b Approved T06421 DRUGINFO D0GA0A Interferon alfacon-1 Approved T06421 DRUGINFO D0FU8R Anifrolumab Approved T06421 DRUGINFO D0SX9C Alfa-interferon Phase 1 T70792 TARGETID T70792 T70792 FORMERID TTDNS00541 T70792 UNIPROID PLGF_HUMAN T70792 TARGNAME Placenta growth factor (PlGF) T70792 GENENAME PGF T70792 TARGTYPE Successful T70792 SYNONYMS SHGC-10760; PlGF-2; PLGF; PGFL; D12S1900 T70792 FUNCTION It binds to the receptor FLT1/VEGFR-1. Isoform PlGF-2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth. Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. T70792 PDBSTRUC 1RV6; 1FZV T70792 BIOCLASS Growth factor T70792 SEQUENCE MPVMRLFPCFLQLLAGLALPAVPPQQWALSAGNGSSEVEVVPFQEVWGRSYCRALERLVDVVSEYPSEVEHMFSPSCVSLLRCTGCCGDENLHCVPVETANVTMQLLKIRSGDRPSYVELTFSQHVRCECRHSPGRQSPDMPGDFRADAPSFLPPRRSLPMLFRMEWGCALTGSQSAVWPSSPVPEEIPRMHPGRNGKKQQRKPLREKMKPERCGDAVPRR T70792 DRUGINFO D0C9ET Aflibercept Approved T70792 DRUGINFO D04TPU RO-5323441 Phase 2 T70792 DRUGINFO D06TWA TB-403 Phase 2 T70792 DRUGINFO D0E9HQ R7334 Phase 1 T70792 DRUGINFO D0YZ4T SFLT-01 Phase 1 T70792 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T30040 TARGETID T30040 T30040 FORMERID TTDR00926 T30040 UNIPROID VEGFB_HUMAN T30040 TARGNAME Vascular endothelial growth factor B (VEGFB) T30040 GENENAME VEGFB T30040 TARGTYPE Successful T30040 SYNONYMS VRF; VEGF-related factor; VEGF-B T30040 FUNCTION VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis. Growth factor for endothelial cells. T30040 PDBSTRUC 2XAC; 2VWE; 2C7W T30040 BIOCLASS Growth factor T30040 SEQUENCE MSPLLRRLLLAALLQLAPAQAPVSQPDAPGHQRKVVSWIDVYTRATCQPREVVVPLTVELMGTVAKQLVPSCVTVQRCGGCCPDDGLECVPTGQHQVRMQILMIRYPSSQLGEMSLEEHSQCECRPKKKDSAVKPDRAATPHHRPQPRSVPGWDSAPGAPSPADITHPTPAPGPSAHAAPSTTSALTPGPAAAAADAAASSVAKGGA T30040 DRUGINFO D0C9ET Aflibercept Approved T30040 DRUGINFO DD4E9T CSL346 Phase 2 T06955 TARGETID T06955 T06955 FORMERID TTDC00226 T06955 UNIPROID CCR4_HUMAN T06955 TARGNAME C-C chemokine receptor type 4 (CCR4) T06955 GENENAME CCR4 T06955 TARGTYPE Successful T06955 SYNONYMS K5-5; CMKBR4; CD194; CCR-4; CC-CKR-4; CC chemokine receptor 4; C-CCKR-4; C-C CKR-4 T06955 FUNCTION The activity of this receptor is mediated by G(i) proteins which activate a phosphatidylinositol-calcium second messenger system. Can function as a chemoattractant homing receptor on circulating memory lymphocytes and as a coreceptor for some primary HIV-2 isolates. In the CNS, could mediate hippocampal-neuron survival. High affinity receptor for the C-C type chemokines CCL17/TARC, CCL22/MDC and CKLF isoform 1/CKLF1. T06955 BIOCLASS GPCR rhodopsin T06955 SEQUENCE MNPTDIADTTLDESIYSNYYLYESIPKPCTKEGIKAFGELFLPPLYSLVFVFGLLGNSVVVLVLFKYKRLRSMTDVYLLNLAISDLLFVFSLPFWGYYAADQWVFGLGLCKMISWMYLVGFYSGIFFVMLMSIDRYLAIVHAVFSLRARTLTYGVITSLATWSVAVFASLPGFLFSTCYTERNHTYCKTKYSLNSTTWKVLSSLEINILGLVIPLGIMLFCYSMIIRTLQHCKNEKKNKAVKMIFAVVVLFLGFWTPYNIVLFLETLVELEVLQDCTFERYLDYAIQATETLAFVHCCLNPIIYFFLGEKFRKYILQLFKTCRGLFVLCQYCGLLQIYSADTPSSSYTQSTMDHDLHDAL T06955 DRUGINFO D0W2HD Mogamulizumab Approved T06955 DRUGINFO D5SDZ0 RPT193 Phase 2 T06955 DRUGINFO D0XD7V FLX475 Phase 1/2 T06955 DRUGINFO D00XBC GSK-2239633 Phase 1 T06955 DRUGINFO D0U5AQ ATLCAR.CD30.CCR4 cells Phase 1 T06955 DRUGINFO D0E2QN AZD-1678 Preclinical T06955 DRUGINFO D01RGG N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine Investigative T06955 DRUGINFO D02MTK AT-008 Investigative T06955 DRUGINFO D03VIS 4-tert-butyl-N-phenylthiazol-2-amine Investigative T06955 DRUGINFO D06AJH 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine Investigative T06955 DRUGINFO D0B3JB 4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine Investigative T06955 DRUGINFO D0CX7I 4-tert-butyl-N-m-tolylthiazol-2-amine Investigative T06955 DRUGINFO D0EV1I C-014C Investigative T06955 DRUGINFO D0G6NY 4-tert-butyl-N-(naphthalen-1-yl)thiazol-2-amine Investigative T06955 DRUGINFO D0K2UA 4-tert-butyl-N-(2-isopropylphenyl)thiazol-2-amine Investigative T06955 DRUGINFO D0M7HQ 4-isopropyl-N-(naphthalen-1-yl)thiazol-2-amine Investigative T06955 DRUGINFO D0U7FE N-(4-tert-butylthiazol-2-yl)quinolin-5-amine Investigative T06955 DRUGINFO D0W1VL N-(naphthalen-1-yl)-4-phenylthiazol-2-amine Investigative T06955 DRUGINFO D0W5OM 4-tert-butyl-N-o-tolylthiazol-2-amine Investigative T06955 DRUGINFO D0W6GE N-(naphthalen-1-yl)-4-neopentylthiazol-2-amine Investigative T06955 DRUGINFO D0XH2N RS-1748 Investigative T06955 DRUGINFO D0ZE9M N-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine Investigative T37046 TARGETID T37046 T37046 FORMERID TTDS00494 T37046 UNIPROID BIEA_HUMAN T37046 TARGNAME Biliverdin reductase A (BLVRA) T37046 GENENAME BLVRA T37046 TARGTYPE Successful T37046 SYNONYMS Biliverdin-IX alpha-reductase; BVR A; BVR; BLVRA; BLVR T37046 FUNCTION Reduces the gamma-methene bridge of the open tetrapyrrole, biliverdin IX alpha, to bilirubin with the concomitant oxidation of a NADH or NADPH cofactor. T37046 PDBSTRUC 2H63 T37046 BIOCLASS CH-CH donor oxidoreductase T37046 ECNUMBER EC 1.3.1.24 T37046 SEQUENCE MNAEPERKFGVVVVGVGRAGSVRMRDLRNPHPSSAFLNLIGFVSRRELGSIDGVQQISLEDALSSQEVEVAYICSESSSHEDYIRQFLNAGKHVLVEYPMTLSLAAAQELWELAEQKGKVLHEEHVELLMEEFAFLKKEVVGKDLLKGSLLFTAGPLEEERFGFPAFSGISRLTWLVSLFGELSLVSATLEERKEDQYMKMTVCLETEKKSPLSWIEEKGPGLKRNRYLSFHFKSGSLENVPNVGVNKNIFLKDQNIFVQKLLGQFSEKELAAEKKRILHCLGLAEEIQKYCCSRK T37046 DRUGINFO D0G3SH Ursodeoxycholic acid Approved T37046 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T84316 TARGETID T84316 T84316 FORMERID TTDS00415 T84316 UNIPROID CA2D1_HUMAN T84316 TARGNAME Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) T84316 GENENAME CACNA2D1 T84316 TARGTYPE Successful T84316 SYNONYMS Voltage-gated calcium channel subunit alpha-2/delta-1; Voltage-dependent calcium channel subunit delta-1; Voltage-dependent calcium channel subunit alpha-2-1; MHS3; CCHL2A; CACNL2A; CACNA2D1 T84316 FUNCTION The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling. T84316 BIOCLASS Voltage-gated ion channel T84316 SEQUENCE MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDIYEKYQDLYTVEPNNARQLVEIAARDIEKLLSNRSKALVRLALEAEKVQAAHQWREDFASNEVVYYNAKDDLDPEKNDSEPGSQRIKPVFIEDANFGRQISYQHAAVHIPTDIYEGSTIVLNELNWTSALDEVFKKNREEDPSLLWQVFGSATGLARYYPASPWVDNSRTPNKIDLYDVRRRPWYIQGAASPKDMLILVDVSGSVSGLTLKLIRTSVSEMLETLSDDDFVNVASFNSNAQDVSCFQHLVQANVRNKKVLKDAVNNITAKGITDYKKGFSFAFEQLLNYNVSRANCNKIIMLFTDGGEERAQEIFNKYNKDKKVRVFTFSVGQHNYDRGPIQWMACENKGYYYEIPSIGAIRINTQEYLDVLGRPMVLAGDKAKQVQWTNVYLDALELGLVITGTLPVFNITGQFENKTNLKNQLILGVMGVDVSLEDIKRLTPRFTLCPNGYYFAIDPNGYVLLHPNLQPKPIGVGIPTINLRKRRPNIQNPKSQEPVTLDFLDAELENDIKVEIRNKMIDGESGEKTFRTLVKSQDERYIDKGNRTYTWTPVNGTDYSLALVLPTYSFYYIKAKLEETITQARYSETLKPDNFEESGYTFIAPRDYCNDLKISDNNTEFLLNFNEFIDRKTPNNPSCNADLINRVLLDAGFTNELVQNYWSKQKNIKGVKARFVVTDGGITRVYPKEAGENWQENPETYEDSFYKRSLDNDNYVFTAPYFNKSGPGAYESGIMVSKAVEIYIQGKLLKPAVVGIKIDVNSWIENFTKTSIRDPCAGPVCDCKRNSDVMDCVILDDGGFLLMANHDDYTNQIGRFFGEIDPSLMRHLVNISVYAFNKSYDYQSVCEPGAAPKQGAGHRSAYVPSVADILQIGWWATAAAWSILQQFLLSLTFPRLLEAVEMEDDDFTASLSKQSCITEQTQYFFDNDSKSFSGVLDCGNCSRIFHGEKLMNTNLIFIMVESKGTCPCDTRLLIQAEQTSDGPNPCDMVKQPRYRKGPDVCFDNNVLEDYTDCGGVSGLNPSLWYIIGIQFLLLWLVSGSTHRLL T84316 DRUGINFO D00WUF Pregabalin Approved T84316 DRUGINFO D08JIV Amlodipine Approved T84316 DRUGINFO D0A1DH Nitrendipine Approved T84316 DRUGINFO D0OB1J Diltiazem Approved T84316 DRUGINFO D0P6ZH Lercanidipine Approved T84316 DRUGINFO D07VFD Mirogabalin Registered T84316 DRUGINFO D05DBY Imagabalin Phase 3 T84316 DRUGINFO D06FSC NP-118809 Discontinued in Phase 2 T84316 DRUGINFO D00XUE (S)-2-amino-3-cyclohexylpropanoic acid Investigative T84316 DRUGINFO D01PWO 4-(2-nitrobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D02ANL 4-(3-fluorobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D02IRC 4-(2-cyanobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D03KKH (S)-phenylglycine Investigative T84316 DRUGINFO D04YNS 2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid Investigative T84316 DRUGINFO D05JAZ 2-amino-2-(3-chloro-4-fluorophenyl)acetic acid Investigative T84316 DRUGINFO D05WDV 2-amino-2-(3-bromophenyl)acetic acid Investigative T84316 DRUGINFO D06EUM Rac-2-amino-5-cyclohexylpentanoic acid Investigative T84316 DRUGINFO D06NUU 1-benzhydryl-4-(3,3-diphenylpropyl)piperazine Investigative T84316 DRUGINFO D06RSF 4-(3-methoxybenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D06VUC 4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D07BMX (S)-2-amino-3-(benzylthio)propanoic acid Investigative T84316 DRUGINFO D07QDU 1-benzhydryl-4-(4,4-diphenylbutyl)piperazine Investigative T84316 DRUGINFO D07QGX 2-amino-2-(2,4-difluorophenyl)acetic acid Investigative T84316 DRUGINFO D08BOL 3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid Investigative T84316 DRUGINFO D08ZGW 2-amino-2-(3-chlorophenyl)acetic acid Investigative T84316 DRUGINFO D09CKV 4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D09EQN 4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D09QVD 4-(2-bromobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D09UXA Trans-dimethyl gababutin Investigative T84316 DRUGINFO D09VTR 4-(4-tert-butylbenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0C6FW 4-(3-nitrobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0CU9Y (S)-2-amino-2-o-tolylacetic acid Investigative T84316 DRUGINFO D0D7FX Rac-2-amino-4-phenylbutanoic acid Investigative T84316 DRUGINFO D0GB8J (S)-2-amino-2-cyclohexylacetic acid Investigative T84316 DRUGINFO D0GU5E 4-(3-cyanobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0H2VW N,4-dibenzhydrylpiperazine-1-carboxamide Investigative T84316 DRUGINFO D0I0SK 4-(4-chlorobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0J3NS 3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid Investigative T84316 DRUGINFO D0KZ7A 3-(aminomethyl)-4-(furan-2-yl)butanoic acid Investigative T84316 DRUGINFO D0L2VI 4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0L7AO Gababutin Investigative T84316 DRUGINFO D0LN2D ETHIONINE Investigative T84316 DRUGINFO D0N6QW 4-(3-bromobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0O6HW 4-(4-bromobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0OI6B 4-(2-methoxybenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0Q3KV 2-amino-2-(2,3-difluorophenyl)acetic acid Investigative T84316 DRUGINFO D0R1QW (R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid Investigative T84316 DRUGINFO D0RA0P 2-amino-2-(thiophen-2-yl)acetic acid Investigative T84316 DRUGINFO D0RC5X (S)-2-amino-2-p-tolylacetic acid Investigative T84316 DRUGINFO D0RS3R 2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid Investigative T84316 DRUGINFO D0S0WU 4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0T2VK 3-(aminomethyl)-4-(furan-3-yl)butanoic acid Investigative T84316 DRUGINFO D0T6YJ 4-(3-chlorobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0V2ZB 2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid Investigative T84316 DRUGINFO D0V6SS 2-amino-2-(2-fluorophenyl)acetic acid Investigative T84316 DRUGINFO D0VA2O 4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid Investigative T84316 DRUGINFO D0VQ4G N'-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine Investigative T84316 DRUGINFO D0W2EX (S)-2-amino-4-(benzylthio)butanoic acid Investigative T84316 DRUGINFO D0X1BT (S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid Investigative T84316 DRUGINFO D0Z0VF (S)-2-amino-2-phenylpropanoic acid Investigative T84316 DRUGINFO D0D1EU PD-144550 Investigative T84316 DRUGINFO D0T6DR 3-Aminomethyl-5-methyl-hexanoic acid Investigative T61698 TARGETID T61698 T61698 FORMERID TTDR00141 T61698 UNIPROID IL2_HUMAN T61698 TARGNAME Interleukin-2 (IL2) T61698 GENENAME IL2 T61698 TARGTYPE Successful T61698 SYNONYMS TCGF; T-cell growth factor; IL-2; Aldesleukin T61698 FUNCTION Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells. T61698 PDBSTRUC 5UTZ; 5M5E; 5LQB; 4NEM; 4NEJ T61698 BIOCLASS Cytokine: interleukin T61698 SEQUENCE MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT T61698 DRUGINFO D05PUD Aldesleukin Approved T61698 DRUGINFO D0P1BZ Daclizumab Approved T61698 DRUGINFO D0C6ND AIR-insulin Phase 3 T61698 DRUGINFO D0ZW3R TG-4010 Phase 2/3 T61698 DRUGINFO D00DAE Carboxyamidotriazole orotate Phase 2 T61698 DRUGINFO D01WHC Leuvectin Phase 2 T61698 DRUGINFO D04OJM Human interleukin-2 Phase 2 T61698 DRUGINFO D07KAQ L19-IL-2 fusion protein Phase 2 T61698 DRUGINFO D0J4LI Thymoctonan Phase 2 T61698 DRUGINFO D0NS7A APN-301 Phase 2 T61698 DRUGINFO D05RRU IL-2/CD40L-expressing leukemia vaccine Phase 2 T61698 DRUGINFO DE09IO BNZ-1 Phase 2 T61698 DRUGINFO D01VWB IL-2/gene-modified lymphocytes Phase 1/2 T61698 DRUGINFO D07XYT Medusa IL-2 Phase 1/2 T61698 DRUGINFO D08XFA IL-2 XL Phase 1/2 T61698 DRUGINFO D0ZM5E VCL-1M01 Phase 1 T61698 DRUGINFO DPJ70I SAR444245 Phase 1 T61698 DRUGINFO D1FUQ2 ASP9801 Phase 1 T61698 DRUGINFO D0PE0D Nuleusin Discontinued in Phase 3 T61698 DRUGINFO D0I9LH PMI-001 Discontinued in Phase 3 T61698 DRUGINFO D0C7OQ BIWB-1 Discontinued in Phase 2 T61698 DRUGINFO D0EY5A VLTS-587 Discontinued in Phase 2 T61698 DRUGINFO D01OWJ TG-1024 Discontinued in Phase 1 T61698 DRUGINFO D0G9ZW Roquinimex Discontinued in Phase 1 T61698 DRUGINFO D0WD6K VPM-4-001 Preclinical T61698 DRUGINFO D05NUC SP4160 Investigative T61698 DRUGINFO D08TGB interleukin-2, Roussel Uclaf Investigative T61698 DRUGINFO D0AJ7H TG-2001 Investigative T61698 DRUGINFO D0VS0Z SP2456 Investigative T61698 DRUGINFO D0Y9MP IL-2 antibody (anti-tumor) Investigative T61698 DRUGINFO D0GF2L TG-1031 Investigative T59845 TARGETID T59845 T59845 FORMERID TTDR00717 T59845 UNIPROID PP1A_HUMAN T59845 TARGNAME Serine/threonine PP1-alpha (PPP1CA) T59845 GENENAME PPP1CA T59845 TARGTYPE Successful T59845 SYNONYMS Serine/threonine-protein phosphatase PP1-alpha catalytic subunit; Protein phosphatase 1alpha; PPP1A; PP-1A T59845 FUNCTION Protein phosphatase 1 (PP1) is essential for cell division, and participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis. Involved in regulation of ionic conductances and long-term synaptic plasticity. May play an important role in dephosphorylating substrates such as the postsynaptic density-associated Ca(2+)/calmodulin dependent protein kinase II. Component of the PTW/PP1 phosphatase complex, which plays a role in the control of chromatin structure and cell cycle progression during the transition from mitosis into interphase. Regulates NEK2 function in terms of kinase activity and centrosome number and splitting, both in the presence and absence of radiation-induced DNA damage. Regulator of neural tube and optic fissure closure, and enteric neural crest cell (ENCCs) migration during development. In balance with CSNK1D and CSNK1E, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. May dephosphorylate CSNK1D and CSNK1E. Dephosphorylates the 'Ser-418' residue of FOXP3 in regulatory T-cells (Treg) from patients with rheumatoid arthritis, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Dephosphorylates CENPA. Dephosphorylates the 'Ser-139' residue of ATG16L1 causing dissociation of ATG12-ATG5-ATG16L1 complex, thereby inhibiting autophagy. Protein phosphatase that associates with over 200 regulatory proteins to form highly specific holoenzymes which dephosphorylate hundreds of biological targets. T59845 PDBSTRUC 6GHM; 6G0J; 6G0I; 6DNO; 6DCX T59845 BIOCLASS Phosphoric monoester hydrolase T59845 ECNUMBER EC 3.1.3.16 T59845 SEQUENCE MSDSEKLNLDSIIGRLLEVQGSRPGKNVQLTENEIRGLCLKSREIFLSQPILLELEAPLKICGDIHGQYYDLLRLFEYGGFPPESNYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFLLRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDLQSMEQIRRIMRPTDVPDQGLLCDLLWSDPDKDVQGWGENDRGVSFTFGAEVVAKFLHKHDLDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGAMMSVDETLMCSFQILKPADKNKGKYGQFSGLNPGGRPITPPRNSAKAKK T59845 DRUGINFO D0Z2RA Cantharidin Approved T59845 DRUGINFO D06EUA PALASONIN Investigative T59845 DRUGINFO D09CAI TAUTOMYCIN Investigative T59845 DRUGINFO D0M0TM CANTHARIDIC_ACID Investigative T59845 DRUGINFO D0O1BJ MICROCYSTIN-LR Investigative T59845 DRUGINFO D0W4IL NORCANTHARIDIN Investigative T47081 TARGETID T47081 T47081 FORMERID TTDS00323 T47081 UNIPROID PPIA_HUMAN T47081 TARGNAME Rotamase A (PPIA) T47081 GENENAME PPIA T47081 TARGTYPE Successful T47081 SYNONYMS PPIA; Cyclophilin A; CyPA T47081 FUNCTION Ppiases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. T47081 PDBSTRUC 6GJY; 6GJR; 6GJP; 6GJN; 6GJM T47081 BIOCLASS Cis-trans-isomerases T47081 ECNUMBER EC 5.2.1.8 T47081 SEQUENCE MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE T47081 DRUGINFO D0DZ3X L-Proline Approved T47081 DRUGINFO D07IQR 3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide Investigative T47081 DRUGINFO D0DQ4D (3r)-1-Acetyl-3-Methylpiperidine Investigative T47081 DRUGINFO D0L5XK 7-AMINO-4-METHYL-CHROMEN-2-ONE Investigative T47081 DRUGINFO D0P6TX 1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea Investigative T47081 DRUGINFO D0P8IK Ethyl Oxo(Piperidin-1-Yl)Acetate Investigative T47081 DRUGINFO D0X5JR 4-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide Investigative T49493 TARGETID T49493 T49493 FORMERID TTDS00498 T49493 UNIPROID HBA_HUMAN T49493 TARGNAME Hemoglobin (HB) T49493 GENENAME HBA2 T49493 TARGTYPE Successful T49493 SYNONYMS Hemoglobin subunit alpha; Hemoglobin alpha chain; HBA1; Alpha-globin T49493 FUNCTION Involved in oxygen transport from the lung to the various peripheral tissues. T49493 PDBSTRUC 6NBD; 6NBC; 6HBW; 6HAL; 6DI4 T49493 BIOCLASS Pore-forming globin T49493 SEQUENCE MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHGKKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR T49493 DRUGINFO D08OKJ Iron Dextran Approved T49493 DRUGINFO D09RII Voxelotor Approved T49493 DRUGINFO D0Y3TM Iron Approved T49493 DRUGINFO D00IWL PolyHeme Phase 3 T49493 DRUGINFO D03HVV Efaproxyn Phase 3 T49493 DRUGINFO D0H4CB Hemoglobin raffimer Phase 2/3 T49493 DRUGINFO DWR4I7 GBT021601 Phase 2/3 T49493 DRUGINFO D0D8TE FBS-0701 Phase 2 T49493 DRUGINFO D0E6SB HQK-1001 Phase 2 T49493 DRUGINFO D0E9BF 5-hydroxymethyl-2-furfural Phase 2 T49493 DRUGINFO D00YBW OXY-111A Phase 1/2 T49493 DRUGINFO D09VBN CTX110 Phase 1/2 T49493 DRUGINFO D0G6EO Hemoximer Discontinued in Phase 3 T49493 DRUGINFO D0AL3O VX-366 Discontinued in Phase 2 T49493 DRUGINFO D0S3WK HRC-302 Discontinued in Phase 1 T49493 DRUGINFO D00HNK RHb1.1 Terminated T49493 DRUGINFO D00XQK HRC-102 Terminated T49493 DRUGINFO D09ZCH HRC-201 Terminated T49493 DRUGINFO D09ZFF HRC-101 Terminated T49493 DRUGINFO D0Q5QE AN-10 Terminated T49493 DRUGINFO D0ZL9B Diaspirin crosslinked hemoglobin Terminated T49493 DRUGINFO D05QIT SEBACIC ACID Investigative T49493 DRUGINFO D06EEJ 4-Carboxycinnamic Acid Investigative T49493 DRUGINFO D06KMP 2,6-DICARBOXYNAPHTHALENE Investigative T49493 DRUGINFO D0A1GE 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine Investigative T49493 DRUGINFO D0F2WQ 1,3,5-BENZENETRICARBOXYLIC ACID Investigative T49493 DRUGINFO D0TM1Z 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine Investigative T49493 DRUGINFO D0UU1I Heme Investigative T55959 TARGETID T55959 T55959 FORMERID TTDS00017 T55959 UNIPROID SC6A3_HUMAN T55959 TARGNAME Dopamine transporter (DAT) T55959 GENENAME SLC6A3 T55959 TARGTYPE Successful T55959 SYNONYMS Solute carrier family 6 member 3; Sodium-dependent dopamine transporter; DAT1; DAT; DA transporter T55959 FUNCTION Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals. T55959 BIOCLASS Neurotransmitter:sodium symporter T55959 SEQUENCE MSKSKCSVGLMSSVVAPAKEPNAVGPKEVELILVKEQNGVQLTSSTLTNPRQSPVEAQDRETWGKKIDFLLSVIGFAVDLANVWRFPYLCYKNGGGAFLVPYLLFMVIAGMPLFYMELALGQFNREGAAGVWKICPILKGVGFTVILISLYVGFFYNVIIAWALHYLFSSFTTELPWIHCNNSWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLGPPRWQLTACLVLVIVLLYFSLWKGVKTSGKVVWITATMPYVVLTALLLRGVTLPGAIDGIRAYLSVDFYRLCEASVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDAIVTTSINSLTSFSSGFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLGIDSAMGGMESVITGLIDEFQLLHRHRELFTLFIVLATFLLSLFCVTNGGIYVFTLLDHFAAGTSILFGVLIEAIGVAWFYGVGQFSDDIQQMTGQRPSLYWRLCWKLVSPCFLLFVVVVSIVTFRPPHYGAYIFPDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYAIAPEKDRELVDRGEVRQFTLRHWLKV T55959 DRUGINFO D02GJZ Ioflupane i-123 Approved T55959 DRUGINFO D02PPN Methylphenidate Approved T55959 DRUGINFO D02QCD DEXMETHYLPHENIDATE HYDROCHLORIDE Approved T55959 DRUGINFO D07HQC Modafinil Approved T55959 DRUGINFO D0A8XY Altropane Approved T55959 DRUGINFO D0M2MC Phenmetrazine Approved T55959 DRUGINFO D04XPW Cocaine Approved T55959 DRUGINFO D0W6KM Dasotraline Approved T55959 DRUGINFO D0X8HB NAV5001 Phase 3 T55959 DRUGINFO D01TMQ Bupropion+naltrexone Phase 3 T55959 DRUGINFO D04PXS Amitifadine Phase 3 T55959 DRUGINFO D04KHY Spiroglumide Phase 2 T55959 DRUGINFO D07QXU NS 2359 Phase 2 T55959 DRUGINFO D0Z4FE MIN-117 Phase 2 T55959 DRUGINFO D04KWY RTI-336 Phase 1 T55959 DRUGINFO D0K7OW GSK-1360707 Phase 1 T55959 DRUGINFO D08QUV Amineptine Withdrawn from market T55959 DRUGINFO D0A5RD Radafaxine Discontinued in Phase 2 T55959 DRUGINFO D0O6QW Manifaxine Discontinued in Phase 2 T55959 DRUGINFO D0H9GQ DOV-216303 Discontinued in Phase 2 T55959 DRUGINFO D0LU6N SPD-473 Discontinued in Phase 2 T55959 DRUGINFO D0M9LB NS-2389 Discontinued in Phase 2 T55959 DRUGINFO D0N2HF Vanoxerine Discontinued in Phase 1 T55959 DRUGINFO D0W6WD KP106 Discontinued in Phase 1 T55959 DRUGINFO D04VUY RG-7166 Discontinued in Phase 1 T55959 DRUGINFO D08UNQ NSD-644 Discontinued in Phase 1 T55959 DRUGINFO D00JSG Fluoratec Terminated T55959 DRUGINFO D0U5PR Seridopidine Terminated T55959 DRUGINFO D00KIK 1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepane Investigative T55959 DRUGINFO D00NEE Bip-tyr-thr-pro-lys-thr Investigative T55959 DRUGINFO D00QGB O-2442 Investigative T55959 DRUGINFO D01DNN Bip-tyr(3bzl)-thr-pro-lys-thr Investigative T55959 DRUGINFO D01EOU (+/-)-threo-N-(3-Chlorobenzyl)methylphenidate Investigative T55959 DRUGINFO D01XHX (+/-)-threo-N-(2-Phenylethyl)methylphenidate Investigative T55959 DRUGINFO D02BXG 1-Benzo[b]thiophen-2-yl-cyclohexylamine Investigative T55959 DRUGINFO D02EHL 1-Benzo[b]thiophen-2-yl-cyclopentylamine Investigative T55959 DRUGINFO D02EKR 2-(N-Isopropylamino)-3'-chloropropiophenone Investigative T55959 DRUGINFO D02NUR 2-(tert-Butylamino)-3',5'-difluoropropiophenone Investigative T55959 DRUGINFO D02QWO HOMOAROMOLINE Investigative T55959 DRUGINFO D02XSH DIMETHYLGRISABINE Investigative T55959 DRUGINFO D02ZFN (+/-)-threo-3',4'-Dichlororitalinol methyl ether Investigative T55959 DRUGINFO D03EMO (RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidine Investigative T55959 DRUGINFO D03NUN (+/-)-threo-Methylphenidate amide Investigative T55959 DRUGINFO D05KJH COCLAURINE Investigative T55959 DRUGINFO D05PLF 2-(N-tert-Butylamino)-4'-chloropropiophenone Investigative T55959 DRUGINFO D05TWV (+/-)-threo-N-Methyl-30-methylmethylphenidate Investigative T55959 DRUGINFO D06FYY (+/-)-threo-3-Fluororitalinol Investigative T55959 DRUGINFO D06MFY (+/-)-threo-Benzylphenidate Investigative T55959 DRUGINFO D06OIU Threo-N-ethylritalinol hydrochloride Investigative T55959 DRUGINFO D06QDX Bip-tyr-thr-ala-pro-phe Investigative T55959 DRUGINFO D07CQD 1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine Investigative T55959 DRUGINFO D07LRZ (+/-)-threo-N-(6-Phenylhexyl)methylphenidate Investigative T55959 DRUGINFO D07PAT (RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidine Investigative T55959 DRUGINFO D07YGR (+/-)-threo-N-(4-Methylpyridine)methylphenidate Investigative T55959 DRUGINFO D08JCK 1-phenyl-1-(piperidin-2-yl)propan-2-one Investigative T55959 DRUGINFO D08NZE Indatraline Investigative T55959 DRUGINFO D08SLZ (RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidine Investigative T55959 DRUGINFO D08SWN (+/-)-threo-3',5'-Dimethylmethylphenidate Investigative T55959 DRUGINFO D08WVJ [N-[2-[(3'-N'-PROPYL-3''ALPHA-(BIS(4-FLUORORPHENYL)METHOXY)TROPANE-2''BETA-CARBOXYLIC ACID METHYL ESTER)(2-MERCAPTOETHYL)AMINO]ACETYL]-2-AMINOETHANETHIOLATO]RHENIUM(V) OXIDE (DIASTEREOMERIC MIX) Investigative T55959 DRUGINFO D08XGL (+/-)-threo-N-(3-Phenylpropyl)ritalinol Investigative T55959 DRUGINFO D08YJE (+/-)-threo-N-(4-Phenylbutyl)methylphenidate Investigative T55959 DRUGINFO D09BJN (+/-)-threo-3',4'-Dichloromethylphenidate amide Investigative T55959 DRUGINFO D09FTL (+/-)-threo-N-(3-Methylfuran)methylphenidate Investigative T55959 DRUGINFO D09GXL NORBOLDINE Investigative T55959 DRUGINFO D09OOO (+/-)-threo-N-(4-Methoxybenzyl)methylphenidate Investigative T55959 DRUGINFO D09QSO (+/-)-threo-N-(2-Phenylethyl)ritalinol Investigative T55959 DRUGINFO D09ZQW (+/-)-threo-3',5'-Dichloromethylphenidate Investigative T55959 DRUGINFO D0A0LZ (+/-)-threo-N-Benzylmethylphenidate amide Investigative T55959 DRUGINFO D0AN2Q ISOTETRANDRINE Investigative T55959 DRUGINFO D0B1KJ (+/-)-threo-4'-Ethylmethylphenidate Investigative T55959 DRUGINFO D0B1WF N-Benzylmethylphenidate Investigative T55959 DRUGINFO D0B9LI (+/-)-threo-N-(2-Methylpyridine)methylphenidate Investigative T55959 DRUGINFO D0BM0M N,Ndimethyl milnacipran Investigative T55959 DRUGINFO D0D3QE 4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile Investigative T55959 DRUGINFO D0DH9G 2-phenylpiperidine hydrochloride Investigative T55959 DRUGINFO D0DX0R ISOPILINE Investigative T55959 DRUGINFO D0E8FG 1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepane Investigative T55959 DRUGINFO D0FS4V Bip-tyr-thr-pro-thr(obzl)-gly Investigative T55959 DRUGINFO D0G8ZD (1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine Investigative T55959 DRUGINFO D0H2RD (+/-)-threo-N-(4-Phenylbutyl)ritalinol Investigative T55959 DRUGINFO D0H7RH ANTIOQUINE Investigative T55959 DRUGINFO D0I9ON (+/-)-threo-N-Allylmethylphenidate Investigative T55959 DRUGINFO D0IR0R (RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidine Investigative T55959 DRUGINFO D0J5EF 2-(tert-Butylamino)-3'-fluoropropiophenone Investigative T55959 DRUGINFO D0K9OK PSEUDOCOCAINE Investigative T55959 DRUGINFO D0L2JS (+/-)-threo-N-(2-Methylfuran)methylphenidate Investigative T55959 DRUGINFO D0M3YA (+/-)-threo-N-(2-Methylthiopene)methylphenidate Investigative T55959 DRUGINFO D0N6OH (+/-)-threo-N-Propargylmethylphenidate Investigative T55959 DRUGINFO D0O1WV Threo-ritalinol hydrochloride Investigative T55959 DRUGINFO D0O8MA (+/-)-threo-N-(3-Methylpyridine)methylphenidate Investigative T55959 DRUGINFO D0P1HA OBABERINE Investigative T55959 DRUGINFO D0P7NW (+/-)-threo-N-Benzyl-3'-chloromethylphenidate Investigative T55959 DRUGINFO D0P9MQ (+/-)-threo-N-(4-Nitrobenzyl)methylphenidate Investigative T55959 DRUGINFO D0Q9NW Threo-ritalinol methyl ether hydrochloride Investigative T55959 DRUGINFO D0R1AE Methyl 2-(naphthalen-2-yl)benzoate Investigative T55959 DRUGINFO D0R2BM 1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T55959 DRUGINFO D0R8TH (RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidine Investigative T55959 DRUGINFO D0R9ZS (+/-)-threo-N-(2-Chlorobenzyl)methylphenidate Investigative T55959 DRUGINFO D0S6CT (+/-)-threo-N-(5-Phenylpentyl)methylphenidate Investigative T55959 DRUGINFO D0U3PC 1-Benzo[b]thiophen-2-yl-cycloheptylamine Investigative T55959 DRUGINFO D0U5DH (+/-)-threo-N-(4-Chlorobenzyl)methylphenidate Investigative T55959 DRUGINFO D0U6PD Bip-tyr-ala-pro-lys-thr(obzl)-gly Investigative T55959 DRUGINFO D0UV1S O-methyldauricine Investigative T55959 DRUGINFO D0V0NO (+/-)-threo-N-(3-Methylthiopene)methylphenidate Investigative T55959 DRUGINFO D0V0RS SECOCULARIDINE Investigative T55959 DRUGINFO D0Y1MJ (RS/SR)-2-[1-(4-chlorophenyl)ethyl]piperidine Investigative T55959 DRUGINFO D0Y2YH (+/-)-threo-N-Benzyl-3',4'-dichlororitalinol Investigative T55959 DRUGINFO D0Y3DR 1-(1-Benzo[b]thiophen-2-yl-cyclopentyl)-azepane Investigative T55959 DRUGINFO D0Y5WA Bip-tyr-thr-pro-lys-thr(obzl)-gly Investigative T55959 DRUGINFO D0YD9W (+/-)-threo-N-(3-Phenylpropyl)methylphenidate Investigative T55959 DRUGINFO D0Z8DJ Bip-tyr-thr-pro-ala-thr(obzl)-gly Investigative T55959 DRUGINFO D00KKN (2S,3S)-iodoreboxetine Investigative T55959 DRUGINFO D00WMS 2-(N-tert-Butylamino)propiophenone Investigative T55959 DRUGINFO D01BPR 1-benzylpiperidine hydrochloride Investigative T55959 DRUGINFO D01JVP (2R,3R)-iodoreboxetine Investigative T55959 DRUGINFO D01RWY 2-(N-tert-Butylamino)-3'-chloroheptanophenone Investigative T55959 DRUGINFO D01YED 2-(N-Pyrrolidinyl)-3'-methoxypropiophenone Investigative T55959 DRUGINFO D02ANE 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane Investigative T55959 DRUGINFO D02LQG WIN-35065 Investigative T55959 DRUGINFO D03BUG 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane Investigative T55959 DRUGINFO D03WGD AMINOBENZTROPINE Investigative T55959 DRUGINFO D04EXA Erythro-3,4-dichloromethylphenidate hydrochloride Investigative T55959 DRUGINFO D05VTT 3-(4-Trifluoromethylphenyl)-2-nortropene Investigative T55959 DRUGINFO D05ZFG (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane Investigative T55959 DRUGINFO D06GFV 1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine Investigative T55959 DRUGINFO D06LCK 2-(N-Pyrrolidinyl)-3'-fluoropropiophenone Investigative T55959 DRUGINFO D07IOX 2-(N-tert-Butylamino)-3'-chlorooctanophenone Investigative T55959 DRUGINFO D07OOI [3H]GBR12935 Investigative T55959 DRUGINFO D08IFQ 3-Phenyl-2-nortropene Investigative T55959 DRUGINFO D09BYB 2-(tert-butylamino)-1-p-tolylpropan-1-one Investigative T55959 DRUGINFO D09CVV NORSTEPHALAGINE Investigative T55959 DRUGINFO D09RCL (2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine Investigative T55959 DRUGINFO D09WVS 10R-hydroxylobelane Investigative T55959 DRUGINFO D09XWL 2-(N-Cyclopentylamino)-3'-fluoropropiophenone Investigative T55959 DRUGINFO D09ZIU 1-phenyl-3-aza-bicyclo[3.1.0]hexane Investigative T55959 DRUGINFO D0B1FM 3-(3,4-dichlorophenyl)-2-nortropene Investigative T55959 DRUGINFO D0B4FN 2pyrrolidin-1-yl-1-phenylpentan-1-one Investigative T55959 DRUGINFO D0B5AG Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine Investigative T55959 DRUGINFO D0B6UU 8R-hydroxylobel-9-ene Investigative T55959 DRUGINFO D0C0GL 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one Investigative T55959 DRUGINFO D0C4XQ GB-12819 Investigative T55959 DRUGINFO D0D9FA (2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine Investigative T55959 DRUGINFO D0E3DF (2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine Investigative T55959 DRUGINFO D0F8SA 8S-hydroxylobelane Investigative T55959 DRUGINFO D0G0CJ 2-(N-Cyclopentylamino)-3'-bromopropiophenone Investigative T55959 DRUGINFO D0G0NB 2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine Investigative T55959 DRUGINFO D0GY8R 2-(N-Pyrrolidinyl)-3'-methylpropiophenone Investigative T55959 DRUGINFO D0HO7I ANONAINE Investigative T55959 DRUGINFO D0I1ME 10R-hydroxylobel-7-ene Investigative T55959 DRUGINFO D0J4EF 1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane Investigative T55959 DRUGINFO D0L6RY 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T55959 DRUGINFO D0M1OE ANOLOBINE Investigative T55959 DRUGINFO D0M4AQ 2-((2-iodophenoxy)(phenyl)methyl)morpholine Investigative T55959 DRUGINFO D0M4KN 10S-hydroxylobelane Investigative T55959 DRUGINFO D0M6UK PMID25037917C58 Investigative T55959 DRUGINFO D0N4YP 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline Investigative T55959 DRUGINFO D0NW3Z COCAINE.HCL Investigative T55959 DRUGINFO D0O2LC 2-(N-Cyclopentylamino)-3'-chloropropiophenone Investigative T55959 DRUGINFO D0P9EO 2-(N-Cyclopentylamino)-3'-methylpropiophenone Investigative T55959 DRUGINFO D0Q0MN Threo-3,4-dichlororitalinol hydrochloride Investigative T55959 DRUGINFO D0Q8IQ 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one Investigative T55959 DRUGINFO D0Q9UZ 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine Investigative T55959 DRUGINFO D0R5AD 2-(N,N-Diethylamino)-3'-chloropropiophenone Investigative T55959 DRUGINFO D0RE7T 4-[(diphenylmethyl)amino]-2-phenylquinazoline Investigative T55959 DRUGINFO D0S0EE 3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane Investigative T55959 DRUGINFO D0T6XD 10S-hydroxylobel-7-ene Investigative T55959 DRUGINFO D0TE5Q Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride Investigative T55959 DRUGINFO D0TO4N 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane Investigative T55959 DRUGINFO D0U3SB 2-(N-Pyrrolidinyl)-3'-bromopropiophenone Investigative T55959 DRUGINFO D0US2X 3-(4-Fluorophenyl)-2-nortropene Investigative T55959 DRUGINFO D0V8IZ 2-(N-tert-Butylamino)-3'-chlorohexanophenone Investigative T55959 DRUGINFO D0VY9K 2-(N-Pyrrolidinyl)-3'-nitropropiophenone Investigative T55959 DRUGINFO D0XY9E 2-(N-tert-Butylamino)-3'-chloropentanophenone Investigative T55959 DRUGINFO D0Y0BB 3-(4-Chlorophenyl)-2-nortropene Investigative T55959 DRUGINFO D0Y7CS 2-(tert-butylamino)-1-m-tolylpropan-1-one Investigative T55959 DRUGINFO D0Z0LP 8R-hydroxylobelane Investigative T55959 DRUGINFO D0Z4IH 8S-hydroxylobel-9-ene Investigative T55959 DRUGINFO D00GDI 2-(N-tert-Butylamino)-3',4'-dichloropropiophenone Investigative T55959 DRUGINFO D00VUT D-257C Investigative T55959 DRUGINFO D01AOI 6-(piperidin-4-ylmethoxy)-2-naphthonitrile Investigative T55959 DRUGINFO D02ENH (R)-Norfluoxetine Investigative T55959 DRUGINFO D02ICX PYROVALERONE Investigative T55959 DRUGINFO D02TMK METHYLENEDIOXYAMPHETAMINE Investigative T55959 DRUGINFO D02UUC 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane Investigative T55959 DRUGINFO D02YOO NISOXETINE Investigative T55959 DRUGINFO D02YSN 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran Investigative T55959 DRUGINFO D02ZIQ 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one Investigative T55959 DRUGINFO D03BQV 1S,2R-milnacipran Investigative T55959 DRUGINFO D03HQF 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran Investigative T55959 DRUGINFO D03JOX 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T55959 DRUGINFO D03ZFX D-254C Investigative T55959 DRUGINFO D04KZX 2-(tert-Butylamino)-3',4'-dichlorobutyrophenone Investigative T55959 DRUGINFO D05LKO 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine Investigative T55959 DRUGINFO D05UMA (R)-DULOXETINE Investigative T55959 DRUGINFO D06CMJ Para-chloroamphetamine Investigative T55959 DRUGINFO D06EMC PF-18298 Investigative T55959 DRUGINFO D06KNV [3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine Investigative T55959 DRUGINFO D06QGD 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T55959 DRUGINFO D06UDU 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine Investigative T55959 DRUGINFO D06WIV Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine Investigative T55959 DRUGINFO D07DMN 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine Investigative T55959 DRUGINFO D07RQT 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane Investigative T55959 DRUGINFO D07SAA 2-(N-Cyclopropylamino)-3-chloropropiophenone Investigative T55959 DRUGINFO D07ZOP 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T55959 DRUGINFO D08AWN (S)-Norfluoxetine Investigative T55959 DRUGINFO D08TJY D-257A Investigative T55959 DRUGINFO D09QZM 2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran Investigative T55959 DRUGINFO D09ZAT 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol Investigative T55959 DRUGINFO D0G1XP 2-(tert-Butylamino)-3',4'-dichloropentanophenone Investigative T55959 DRUGINFO D0G5RH WIN-35066-2 Investigative T55959 DRUGINFO D0G8UA (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol Investigative T55959 DRUGINFO D0H2TS 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine Investigative T55959 DRUGINFO D0H4AD 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one Investigative T55959 DRUGINFO D0I9KV 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T55959 DRUGINFO D0IB6Y 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran Investigative T55959 DRUGINFO D0J0ES 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol Investigative T55959 DRUGINFO D0J5AR 2-(2'-Aminoethyl)-5-benzyltetrahydrofuran Investigative T55959 DRUGINFO D0J7GF Benzyl-(2-phenyl-quinazolin-4-yl)-amine Investigative T55959 DRUGINFO D0L0AY 2-(Aminomethyl)-5-phenethyltetrahydrofuran Investigative T55959 DRUGINFO D0L7BK 1-(1,4-diphenylbutan-2-yl)piperazine Investigative T55959 DRUGINFO D0LD1X D-211B Investigative T55959 DRUGINFO D0N0TQ 2-Aminomethyl-5-(phenyl)tetrahydrofuran Investigative T55959 DRUGINFO D0N3DD [3H]WIN35428 Investigative T55959 DRUGINFO D0NY4W 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T55959 DRUGINFO D0O9BL 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one Investigative T55959 DRUGINFO D0Q6SH 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine Investigative T55959 DRUGINFO D0R8EV 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one Investigative T55959 DRUGINFO D0RT9B 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran Investigative T55959 DRUGINFO D0SB6Y D-211A Investigative T55959 DRUGINFO D0SN6R (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine Investigative T55959 DRUGINFO D0T8BU 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol Investigative T55959 DRUGINFO D0V0PR 4-(2-(phenoxymethyl)phenyl)piperidine Investigative T55959 DRUGINFO D0V3LR D-166A Investigative T55959 DRUGINFO D0W8BJ Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine Investigative T55959 DRUGINFO D0WB6P R-NORDULOXETINE Investigative T55959 DRUGINFO D0X8LG 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one Investigative T55959 DRUGINFO D0Y3BI 2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran Investigative T55959 DRUGINFO D0Z4UF RTI-219 Investigative T55959 DRUGINFO D0Z9OX 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine Investigative T55959 DRUGINFO D0ZE4C 2-(N-Cyclopentylamino)-3'-methoxypropiophenone Investigative T55959 DRUGINFO D00DEH 4-(2-(3-chlorophenoxy)phenyl)piperidine Investigative T55959 DRUGINFO D00HCC 1-(2-phenoxyphenyl)piperazine Investigative T55959 DRUGINFO D00KRQ 4-(2-phenoxyphenyl)piperidine Investigative T55959 DRUGINFO D01ABR 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine Investigative T55959 DRUGINFO D01JYY (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide Investigative T55959 DRUGINFO D01MBF 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine Investigative T55959 DRUGINFO D01YNZ 4-(2-(benzyloxy)phenyl)piperidine Investigative T55959 DRUGINFO D03DQQ 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine Investigative T55959 DRUGINFO D04NDO 4-(2-(2-fluorobenzyloxy)phenyl)piperidine Investigative T55959 DRUGINFO D04NKQ 4-(2-(4-fluorophenoxy)phenyl)piperidine Investigative T55959 DRUGINFO D04ZPF 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine Investigative T55959 DRUGINFO D05LJC 4-(2-(benzyloxy)-3-fluorophenyl)piperidine Investigative T55959 DRUGINFO D08EKQ 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T55959 DRUGINFO D08JLB 4-(2-(benzyloxy)-6-fluorophenyl)piperidine Investigative T55959 DRUGINFO D08SCH 2-Amino-1-(4-methylthiophenyl)propane Investigative T55959 DRUGINFO D09FIC 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) Investigative T55959 DRUGINFO D09IIH 4-(3-fluoro-2-phenoxyphenyl)piperidine Investigative T55959 DRUGINFO D0CG2Y 2-phenoxy-3-(piperidin-4-yl)pyridine Investigative T55959 DRUGINFO D0E3DM (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine Investigative T55959 DRUGINFO D0E6PQ 4-(2-fluoro-6-phenoxyphenyl)piperidine Investigative T55959 DRUGINFO D0F0BS 3alpha-(bis-chloro-phenylmethoxy)tropane Investigative T55959 DRUGINFO D0F6GB 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine Investigative T55959 DRUGINFO D0IC4J 4-(2-(3-fluorophenoxy)phenyl)piperidine Investigative T55959 DRUGINFO D0KT2M 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine Investigative T55959 DRUGINFO D0M3TK 1-(2-(4-fluorophenoxy)phenyl)piperazine Investigative T55959 DRUGINFO D0R3TA 4-(2-(4-fluorobenzyloxy)phenyl)piperidine Investigative T55959 DRUGINFO D0S4JT 1-(2-(phenoxymethyl)phenyl)piperazine Investigative T55959 DRUGINFO D0U7OD PF-526014 Investigative T55959 DRUGINFO D0W8YO 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine Investigative T55959 DRUGINFO D0XF5P (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine Investigative T55959 DRUGINFO D0Y8UC Difluorobenztropine Investigative T55959 DRUGINFO D00QCP (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol Investigative T55959 DRUGINFO D03YQY (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol Investigative T55959 DRUGINFO D06QIQ 7-(piperidin-4-ylmethoxy)-2-naphthonitrile Investigative T55959 DRUGINFO D0N2KU PF-3409409 Investigative T55959 DRUGINFO D0F5NJ METHYLENEDIOXYMETHAMPHETAMINE Investigative T55959 DRUGINFO D0I4ME MMDA Investigative T55959 DRUGINFO D0R7ZC Beta-methoxyamphetamine Investigative T55959 DRUGINFO D0PN9R R-226161 Investigative T55959 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T61400 TARGETID T61400 T61400 FORMERID TTDI00862 T61400 UNIPROID PYRD_HUMAN T61400 TARGNAME Dihydroorotate dehydrogenase (DHODH) T61400 GENENAME DHODH T61400 TARGTYPE Successful T61400 SYNONYMS Dihydroorotate oxidase; Dihydroorotate dehydrogenase (quinone), mitochondrial; DHOdehase; DHODH T61400 FUNCTION Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor. T61400 PDBSTRUC 6FMD; 6ET4; 6CJG; 6CJF; 5ZFB T61400 BIOCLASS CH-CH donor oxidoreductase T61400 ECNUMBER EC 1.3.5.2 T61400 SEQUENCE MAWRHLKKRAQDAVIILGGGGLLFASYLMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR T61400 DRUGINFO D07QFP Teriflunomide Approved T61400 DRUGINFO D00LSI Vidofludimus Phase 2 T61400 DRUGINFO D0N3XT BREQUINAR Phase 2 T61400 DRUGINFO D08DMH BAY2402234 Phase 1 T61400 DRUGINFO D0F1JY LAS-186323 Phase 1 T61400 DRUGINFO D0SX4K HR325 Discontinued in Phase 2 T61400 DRUGINFO D0X4IA FK778 Discontinued in Phase 2 T67710 TARGETID T67710 T67710 FORMERID TTDS00258 T67710 UNIPROID PTH1R_HUMAN T67710 TARGNAME Parathyroid hormone 1 receptor (PTH1R) T67710 GENENAME PTH1R T67710 TARGTYPE Successful T67710 SYNONYMS Parathyroid hormone-related peptide (PTHRP); PTH1R; PTH/PTHrP type I receptor; PTH/PTHr receptor T67710 FUNCTION This is a receptor for parathyroid hormone and for parathyroid hormone-related peptide. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system. T67710 PDBSTRUC 6NBI; 6NBH; 6NBF; 5EMB; 4Z8J T67710 BIOCLASS GPCR secretin T67710 SEQUENCE MGTARIAPGLALLLCCPVLSSAYALVDADDVMTKEEQIFLLHRAQAQCEKRLKEVLQRPASIMESDKGWTSASTSGKPRKDKASGKLYPESEEDKEAPTGSRYRGRPCLPEWDHILCWPLGAPGEVVAVPCPDYIYDFNHKGHAYRRCDRNGSWELVPGHNRTWANYSECVKFLTNETREREVFDRLGMIYTVGYSVSLASLTVAVLILAYFRRLHCTRNYIHMHLFLSFMLRAVSIFVKDAVLYSGATLDEAERLTEEELRAIAQAPPPPATAAAGYAGCRVAVTFFLYFLATNYYWILVEGLYLHSLIFMAFFSEKKYLWGFTVFGWGLPAVFVAVWVSVRATLANTGCWDLSSGNKKWIIQVPILASIVLNFILFINIVRVLATKLRETNAGRCDTRQQYRKLLKSTLVLMPLFGVHYIVFMATPYTEVSGTLWQVQMHYEMLFNSFQGFFVAIIYCFCNGEVQAEIKKSWSRWTLALDFKRKARSGSSSYSYGPMVSHTSVTNVGPRVGLGLPLSPRLLPTATTNGHPQLPGHAKPGTPALETLETTPPAMAAPKDDGFLNGSCSGLDEEASGPERPPALLQEEWETVM T67710 DRUGINFO D02CII Abaloparatide Approved T67710 DRUGINFO D03NHS PCO371 Phase 1 T55689 TARGETID T55689 T55689 FORMERID TTDR00917 T55689 UNIPROID LIPS_HUMAN T55689 TARGNAME Hormone sensitive lipase (LIPE) T55689 GENENAME LIPE T55689 TARGTYPE Successful T55689 SYNONYMS Hormone-sensitive lipase; HSL T55689 FUNCTION In adipose tissue and heart, it primarily hydrolyzes stored triglycerides to free fatty acids, while in steroidogenic tissues, it principally converts cholesteryl esters to free cholesterol for steroid hormone production. T55689 BIOCLASS Carboxylic ester hydrolase T55689 ECNUMBER EC 3.1.1.79 T55689 SEQUENCE MEPGSKSVSRSDWQPEPHQRPITPLEPGPEKTPIAQPESKTLQGSNTQQKPASNQRPLTQQETPAQHDAESQKEPRAQQKSASQEEFLAPQKPAPQQSPYIQRVLLTQQEAASQQGPGLGKESITQQEPALRQRHVAQPGPGPGEPPPAQQEAESTPAAQAKPGAKREPSAPTESTSQETPEQSDKQTTPVQGAKSKQGSLTELGFLTKLQELSIQRSALEWKALSEWVTDSESESDVGSSSDTDSPATMGGMVAQGVKLGFKGKSGYKVMSGYSGTSPHEKTSARNHRHYQDTASRLIHNMDLRTMTQSLVTLAEDNIAFFSSQGPGETAQRLSGVFAGVREQALGLEPALGRLLGVAHLFDLDPETPANGYRSLVHTARCCLAHLLHKSRYVASNRRSIFFRTSHNLAELEAYLAALTQLRALVYYAQRLLVTNRPGVLFFEGDEGLTADFLREYVTLHKGCFYGRCLGFQFTPAIRPFLQTISIGLVSFGEHYKRNETGLSVAASSLFTSGRFAIDPELRGAEFERITQNLDVHFWKAFWNITEMEVLSSLANMASATVRVSRLLSLPPEAFEMPLTADPTLTVTISPPLAHTGPGPVLVRLISYDLREGQDSEELSSLIKSNGQRSLELWPRPQQAPRSRSLIVHFHGGGFVAQTSRSHEPYLKSWAQELGAPIISIDYSLAPEAPFPRALEECFFAYCWAIKHCALLGSTGERICLAGDSAGGNLCFTVALRAAAYGVRVPDGIMAAYPATMLQPAASPSRLLSLMDPLLPLSVLSKCVSAYAGAKTEDHSNSDQKALGMMGLVRRDTALLLRDFRLGASSWLNSFLELSGRKSQKMSEPIAEPMRRSVSEAALAQPQGPLGTDSLKNLTLRDLSLRGNSETSSDTPEMSLSAETLSPSTPSDVNFLLPPEDAGEEAEAKNELSPMDRGLGVRAAFPEGFHPRRSSQGATQMPLYSSPIVKNPFMSPLLAPDSMLKSLPPVHIVACALDPMLDDSVMLARRLRNLGQPVTLRVVEDLPHGFLTLAALCRETRQAAELCVERIRLVLTPPAGAGPSGETGAAGVDGGCGGRH T55689 DRUGINFO D0G1VX BENZYL BENZOATE Approved T55689 DRUGINFO D0A8UP PMID15026062C41 Clinical trial T55689 DRUGINFO D02CWR OXYBENZONE Investigative T55689 DRUGINFO D02XQX ETHIOFENCARB Investigative T55689 DRUGINFO D0B4KG NCI-58425 Investigative T55689 DRUGINFO D0F3WR 2-(3-methoxybenzylthio)-2-phenylacetic acid Investigative T55689 DRUGINFO D0KH3M BIFENOX Investigative T55689 DRUGINFO D0R0AX NCI-159878 Investigative T55689 DRUGINFO D0T8QY PMI-008 Investigative T48873 TARGETID T48873 T48873 FORMERID TTDS00118 T48873 UNIPROID VMAT2_HUMAN T48873 TARGNAME Synaptic vesicle amine transporter (SLC18A2) T48873 GENENAME SLC18A2 T48873 TARGTYPE Successful T48873 SYNONYMS Vesicular amine transporter; Vesicular Monoamine Transporter; VMAT; VAT; Solute carrier family 18 member 2; SLC18A2; Monoamine transporter T48873 FUNCTION Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis. T48873 BIOCLASS Major facilitator superfamily T48873 SEQUENCE MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVVPIIPSYLYSIKHEKNATEIQTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQTATQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQLITNPFIGLLTNRIGYPIPIFAGFCIMFVSTIMFAFSSSYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEERGNVMGIALGGLAMGVLVGPPFGSVLYEFVGKTAPFLVLAALVLLDGAIQLFVLQPSRVQPESQKGTPLTTLLKDPYILIAAGSICFANMGIAMLEPALPIWMMETMCSRKWQLGVAFLPASISYLIGTNIFGILAHKMGRWLCALLGMIIVGVSILCIPFAKNIYGLIAPNFGVGFAIGMVDSSMMPIMGYLVDLRHVSVYGSVYAIADVAFCMGYAIGPSAGGAIAKAIGFPWLMTIIGIIDILFAPLCFFLRSPPAKEEKMAILMDHNCPIKTKMYTQNNIQSYPIGEDEESESD T48873 DRUGINFO D09PJX Tetrabenazine Approved T48873 DRUGINFO D0E7ZU Deutetrabenazine Approved T48873 DRUGINFO D0I3IG Alseroxylon Approved T48873 DRUGINFO D0J4JM Reserpine Approved T48873 DRUGINFO D0JJ7S Valbenazine Tosylate Approved T48873 DRUGINFO D0Y2MC Alkavervir Approved T48873 DRUGINFO D63WMQ Ingrezza Phase 4 T48873 DRUGINFO D09NAF AV 133 Phase 3 T48873 DRUGINFO D0IX1I NBI-98854 Phase 3 T48873 DRUGINFO D01IVE Lobeline Phase 2 T48873 DRUGINFO D0XT8W SOM3355 Phase 2 T48873 DRUGINFO D03TJJ [125I]7-azido-8-iodoketanserine Investigative T48873 DRUGINFO D07QQY [11C]DTBZ Investigative T48873 DRUGINFO D0F5NJ METHYLENEDIOXYMETHAMPHETAMINE Investigative T48873 DRUGINFO D0I4ME MMDA Investigative T48873 DRUGINFO D0R7ZC Beta-methoxyamphetamine Investigative T97713 TARGETID T97713 T97713 FORMERID TTDS00401 T97713 UNIPROID PUR1_HUMAN T97713 TARGNAME Amidophosphoribosyltransferase (PPAT) T97713 GENENAME PPAT T97713 TARGTYPE Successful T97713 SYNONYMS Glutamine phosphoribosylpyrophosphate amidotransferase; GPAT; ATase T97713 FUNCTION Catalyzes the conversion of 5-phosphoribosyl-1-pyrophosphate (PRPP) into 5-phosphoribosyl-1-amine (PRA), using the amine group from a glutamine side-chain. T97713 BIOCLASS Short-chain dehydrogenases reductase T97713 ECNUMBER EC 2.4.2.14 T97713 SEQUENCE MELEELGIREECGVFGCIASGEWPTQLDVPHVITLGLVGLQHRGQESAGIVTSDGSSVPTFKSHKGMGLVNHVFTEDNLKKLYVSNLGIGHTRYATTGKCELENCQPFVVETLHGKIAVAHNGELVNAARLRKKLLRHGIGLSTSSDSEMITQLLAYTPPQEQDDTPDWVARIKNLMKEAPTAYSLLIMHRDVIYAVRDPYGNRPLCIGRLIPVSDINDKEKKTSETEGWVVSSESCSFLSIGARYYREVLPGEIVEISRHNVQTLDIISRSEGNPVAFCIFEYVYFARPDSMFEDQMVYTVRYRCGQQLAIEAPVDADLVSTVPESATPAALAYAGKCGLPYVEVLCKNRYVGRTFIQPNMRLRQLGVAKKFGVLSDNFKGKRIVLVDDSIVRGNTISPIIKLLKESGAKEVHIRVASPPIKYPCFMGINIPTKEELIANKPEFDHLAEYLGANSVVYLSVEGLVSSVQEGIKFKKQKEKKHDIMIQENGNGLECFEKSGHCTACLTGKYPVELEW T97713 DRUGINFO D07QCE Azathioprine Approved T97713 DRUGINFO D09UZO Mercaptopurine Approved T97713 DRUGINFO D01LDQ Mycophenolic hydroxamic acid Investigative T97713 DRUGINFO D0S4BK Tiazofurin adenine dinucleotide Investigative T97713 DRUGINFO D0T4UE Mycophenolic bis(sulfonamide) Investigative T97713 DRUGINFO D0VD5N 6-Chloropurine Riboside, 5'-Monophosphate Investigative T63609 TARGETID T63609 T63609 FORMERID TTDS00500 T63609 UNIPROID ADCY1_HUMAN T63609 TARGNAME Adenylate cyclase type 1 (ADCY1) T63609 GENENAME ADCY1 T63609 TARGTYPE Successful T63609 SYNONYMS Ca(2+)/calmodulin-activated adenylyl cyclase; Adenylyl cyclase 1; Adenylate cyclase type I; ATP pyrophosphate-lyase 1 T63609 FUNCTION Mediates responses to increased cellular Ca(2+)/calmodulin levels. May be involved in regulatory processes in the central nervous system. May play a role in memory and learning. Plays a role in the regulation of the circadian rhythm of daytime contrast sensitivity probably by modulating the rhythmic synthesis of cyclic AMP in the retina. Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling. T63609 BIOCLASS Phosphorus-oxygen lyase T63609 ECNUMBER EC 4.6.1.1 T63609 SEQUENCE MAGAPRGGGGGGGGAGEPGGAERAAGTSRRRGLRACDEEFACPELEALFRGYTLRLEQAATLKALAVLSLLAGALALAELLGAPGPAPGLAKGSHPVHCVLFLALLVVTNVRSLQVPQLQQVGQLALLFSLTFALLCCPFALGGPARGSAGAAGGPATAEQGVWQLLLVTFVSYALLPVRSLLAIGFGLVVAASHLLVTATLVPAKRPRLWRTLGANALLFVGVNMYGVFVRILTERSQRKAFLQARSCIEDRLRLEDENEKQERLLMSLLPRNVAMEMKEDFLKPPERIFHKIYIQRHDNVSILFADIVGFTGLASQCTAQELVKLLNELFGKFDELATENHCRRIKILGDCYYCVSGLTQPKTDHAHCCVEMGLDMIDTITSVAEATEVDLNMRVGLHTGRVLCGVLGLRKWQYDVWSNDVTLANVMEAAGLPGKVHITKTTLACLNGDYEVEPGYGHERNSFLKTHNIETFFIVPSHRRKIFPGLILSDIKPAKRMKFKTVCYLLVQLMHCRKMFKAEIPFSNVMTCEDDDKRRALRTASEKLRNRSSFSTNVVYTTPGTRVNRYISRLLEARQTELEMADLNFFTLKYKHVEREQKYHQLQDEYFTSAVVLTLILAALFGLVYLLIFPQSVVVLLLLVFCICFLVACVLYLHITRVQCFPGCLTIQIRTVLCIFIVVLIYSVAQGCVVGCLPWAWSSKPNSSLVVLSSGGQRTALPTLPCESTHHALLCCLVGTLPLAIFFRVSSLPKMILLSGLTTSYILVLELSGYTRTGGGAVSGRSYEPIVAILLFSCALALHARQVDIRLRLDYLWAAQAEEEREDMEKVKLDNRRILFNLLPAHVAQHFLMSNPRNMDLYYQSYSQVGVMFASIPNFNDFYIELDGNNMGVECLRLLNEIIADFDELMEKDFYKDIEKIKTIGSTYMAAVGLAPTSGTKAKKSISSHLSTLADFAIEMFDVLDEINYQSYNDFVLRVGINVGPVVAGVIGARRPQYDIWGNTVNVASRMDSTGVQGRIQVTEEVHRLLRRCPYHFVCRGKVSVKGKGEMLTYFLEGRTDGNGSQIRSLGLDRKMCPFGRAGLQGRRPPVCPMPGVSVRAGLPPHSPGQYLPSAAAGKEA T63609 DRUGINFO D06ACW Adenosine monophosphate Approved T51115 TARGETID T51115 T51115 FORMERID TTDS00414 T51115 UNIPROID CAC1C_HUMAN T51115 TARGNAME Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) T51115 GENENAME CACNA1C T51115 TARGTYPE Successful T51115 SYNONYMS Voltage-gated calcium channel subunit alpha Cav1.2; Voltage-dependent L-type calcium channel subunit alpha-1C; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; CACNL1A1; CACN2; CACH2 T51115 FUNCTION Mediates influx of calcium ions into the cytoplasm, and thereby triggers calcium release from the sarcoplasm. Plays an important role in excitation-contraction coupling in the heart. Required for normal heart development and normal regulation of heart rhythm. Required for normal contraction of smooth muscle cells in blood vessels and in the intestine. Essential for normal blood pressure regulation via its role in the contraction of arterial smooth muscle cells. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents. T51115 PDBSTRUC 6DAF; 6DAE; 6DAD; 6C0A; 5V2Q T51115 BIOCLASS Voltage-gated ion channel T51115 SEQUENCE MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAALSWQAAIDAARQAKLMGSAGNATISTVSSTQRKRQQYGKPKKQGSTTATRPPRALLCLTLKNPIRRACISIVEWKPFEIIILLTIFANCVALAIYIPFPEDDSNATNSNLERVEYLFLIIFTVEAFLKVIAYGLLFHPNAYLRNGWNLLDFIIVVVGLFSAILEQATKADGANALGGKGAGFDVKALRAFRVLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFMGKMHKTCYNQEGIADVPAEDDPSPCALETGHGRQCQNGTVCKPGWDGPKHGITNFDNFAFAMLTVFQCITMEGWTDVLYWVNDAVGRDWPWIYFVTLIIIGSFFVLNLVLGVLSGEFSKEREKAKARGDFQKLREKQQLEEDLKGYLDWITQAEDIDPENEDEGMDEEKPRNMSMPTSETESVNTENVAGGDIEGENCGARLAHRISKSKFSRYWRRWNRFCRRKCRAAVKSNVFYWLVIFLVFLNTLTIASEHYNQPNWLTEVQDTANKALLALFTAEMLLKMYSLGLQAYFVSLFNRFDCFVVCGGILETILVETKIMSPLGISVLRCVRLLRIFKITRYWNSLSNLVASLLNSVRSIASLLLLLFLFIIIFSLLGMQLFGGKFNFDEMQTRRSTFDNFPQSLLTVFQILTGEDWNSVMYDGIMAYGGPSFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLADAESLTSAQKEEEEEKERKKLARTASPEKKQELVEKPAVGESKEEKIELKSITADGESPPATKINMDDLQPNENEDKSPYPNPETTGEEDEEEPEMPVGPRPRPLSELHLKEKAVPMPEASAFFIFSSNNRFRLQCHRIVNDTIFTNLILFFILLSSISLAAEDPVQHTSFRNHILFYFDIVFTTIFTIEIALKILGNADYVFTSIFTLEIILKMTAYGAFLHKGSFCRNYFNILDLLVVSVSLISFGIQSSAINVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIVIVTTLLQFMFACIGVQLFKGKLYTCSDSSKQTEAECKGNYITYKDGEVDHPIIQPRSWENSKFDFDNVLAAMMALFTVSTFEGWPELLYRSIDSHTEDKGPIYNYRVEISIFFIIYIIIIAFFMMNIFVGFVIVTFQEQGEQEYKNCELDKNQRQCVEYALKARPLRRYIPKNQHQYKVWYVVNSTYFEYLMFVLILLNTICLAMQHYGQSCLFKIAMNILNMLFTGLFTVEMILKLIAFKPKGYFSDPWNVFDFLIVIGSIIDVILSETNHYFCDAWNTFDALIVVGSIVDIAITEVNPAEHTQCSPSMNAEENSRISITFFRLFRVMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIVMLFFIYAVIGMQVFGKIALNDTTEINRNNNFQTFPQAVLLLFRCATGEAWQDIMLACMPGKKCAPESEPSNSTEGETPCGSSFAVFYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWAEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVSMNMPLNSDGTVMFNATLFALVRTALRIKTEGNLEQANEELRAIIKKIWKRTSMKLLDQVVPPAGDDEVTVGKFYATFLIQEYFRKFKKRKEQGLVGKPSQRNALSLQAGLRTLHDIGPEIRRAISGDLTAEEELDKAMKEAVSAASEDDIFRRAGGLFGNHVSYYQSDGRSAFPQTFTTQRPLHINKAGSSQGDTESPSHEKLVDSTFTPSSYSSTGSNANINNANNTALGRLPRPAGYPSTVSTVEGHGPPLSPAIRVQEVAWKLSSNRERHVPMCEDLELRRDSGSAGTQAHCLLLRKANPSRCHSRESQAAMAGQEETSQDETYEVKMNHDTEACSEPSLLSTEMLSYQDDENRQLTLPEEDKRDIRQSPKRGFLRSASLGRRASFHLECLKRQKDRGGDISQKTVLPLHLVHHQALAVAGLSPLLQRSHSPASFPRPFATPPATPGSRGWPPQPVPTLRLEGVESSEKLNSSFPSIHCGSWAETTPGGGGSSAARRVRPVSLMVPSQAGAPGRQFHGSASSLVEAVLISEGLGQFAQDPKFIEVTTQELADACDMTIEEMESAADNILSGGAPQSPNGALLPFVNCRDAGQDRAGGEEDAGCVRARGRPSEEELQDSRVYVSSL T51115 DRUGINFO D0U7GP RAUWOLFIA SERPENTINA ROOT Approved T51115 DRUGINFO D06GRK ARC029 Phase 3 T51115 DRUGINFO D08MJX R-56865 Terminated T51115 DRUGINFO D00JMZ CGS-27830 Terminated T51115 DRUGINFO D05IML NIGULDIPINE Terminated T51115 DRUGINFO D0QQ7N TH-9229 Terminated T51115 DRUGINFO D06HRY SNAP-5089 Terminated T51115 DRUGINFO D04ALU [3H](+)-cis-diltiazem Investigative T51115 DRUGINFO D04UDT MEBUDIPINE Investigative T51115 DRUGINFO D06XTT FPL64176 Investigative T51115 DRUGINFO D0I9VY CV-4093 Investigative T51115 DRUGINFO D0R6PX (-)-(R)-efonidipine Investigative T51115 DRUGINFO D0U7BI SZ(+)-(S)-202-791 Investigative T51115 DRUGINFO D03UJT [3H](-)devapamil Investigative T51115 DRUGINFO D0S3YP [3H](+)-isradipine Investigative T51115 DRUGINFO D02RIH (-)-(S)-BayK8644 Investigative T51115 DRUGINFO D09CKI CORYNANTHEINE Investigative T51115 DRUGINFO D09YTH CPU-228 Investigative T51115 DRUGINFO D08RJC PD-32577 Investigative T59631 TARGETID T59631 T59631 FORMERID TTDNC00489 T59631 UNIPROID PDCD1_HUMAN T59631 TARGNAME Programmed cell death protein 1 (PD-1) T59631 GENENAME PDCD1 T59631 TARGTYPE Successful T59631 SYNONYMS hPD1; hPD-1; Protein PD1; Protein PD-1; PD1; CD279 T59631 FUNCTION Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. T59631 PDBSTRUC 5WT9; 5JXE; 5IUS; 5GGS; 5GGR T59631 BIOCLASS Immunoglobulin T59631 SEQUENCE MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL T59631 DRUGINFO D00GOV Nivolumab Approved T59631 DRUGINFO D02KSP Tislelizumab Approved T59631 DRUGINFO D07DMY MK-3475 Approved T59631 DRUGINFO D08ANZ Pembrolizumab Approved T59631 DRUGINFO D0KG4Q Cemiplimab Approved T59631 DRUGINFO D0PG5O Retifanlimab Approved T59631 DRUGINFO D92OCI Toripalimab Approved in China T59631 DRUGINFO DFLK16 Sintilimab Approved T59631 DRUGINFO DGQU43 Dostarlimab Approved T59631 DRUGINFO D05BAJ PDR001 Phase 3 T59631 DRUGINFO D08HWV BGB-A317 Phase 3 T59631 DRUGINFO D08JLH Spartalizumab Phase 3 T59631 DRUGINFO D0B0UF IBI-308 Phase 3 T59631 DRUGINFO D0BO0K INCSHR1210 Phase 3 T59631 DRUGINFO D32ZQU Balstilimab Phase 3 T59631 DRUGINFO D4L5NW CS-1003 Phase 3 T59631 DRUGINFO DP2Z0X Sasanlimab Phase 3 T59631 DRUGINFO DX9GT7 Nofazinlimab Phase 3 T59631 DRUGINFO D2ELZ3 AK04 Phase 3 T59631 DRUGINFO D02XFH Peresolimab Phase 2 T59631 DRUGINFO D08UGS JNJ 63723283 Phase 2 T59631 DRUGINFO D0WJ7H AGEN2034 Phase 2 T59631 DRUGINFO DZMO76 JTX-4014 Phase 2 T59631 DRUGINFO D53YZV SAR445877 Phase 2 T59631 DRUGINFO DJX61M Vudalimab Phase 2 T59631 DRUGINFO DNI7E3 AZD7789 Phase 2 T59631 DRUGINFO DQM48O RO7121661 Phase 2 T59631 DRUGINFO DR05IX Lorigerlimab Phase 2 T59631 DRUGINFO DXJH93 AK104 Phase 2 T59631 DRUGINFO D05FPZ M7824 Phase 2 T59631 DRUGINFO D0MY0F MGD013 Phase 1/2 T59631 DRUGINFO DQ43PA Cetrelimab Phase 1/2 T59631 DRUGINFO D4RMC9 Rilvegostomig Phase 1/2 T59631 DRUGINFO D00JMY AMP-224 Phase 1 T59631 DRUGINFO D00NEL BI-754091 Phase 1 T59631 DRUGINFO D01CXW MEDI0680 Phase 1 T59631 DRUGINFO D03XRA GSK2661380 Phase 1 T59631 DRUGINFO D05BPO PF-06801591 Phase 1 T59631 DRUGINFO D0BX5L LZM009 Phase 1 T59631 DRUGINFO D0D4TC Sym021 Phase 1 T59631 DRUGINFO D0L5ZH CC-90006 Phase 1 T59631 DRUGINFO D0N5VK TSR-042 Phase 1 T59631 DRUGINFO D0Y3ZC CBT-501 Phase 1 T59631 DRUGINFO D5T6DY AMG 404 Phase 1 T59631 DRUGINFO D5WB0F RG6279 Phase 1 T59631 DRUGINFO DDKY53 BI 754091 Phase 1 T59631 DRUGINFO DG4YF6 SYN125 Phase 1 T59631 DRUGINFO DL1XC2 609A Phase 1 T59631 DRUGINFO DVO4H2 APL-501 Phase 1 T59631 DRUGINFO D1PYC8 MGD019 Phase 1 T59631 DRUGINFO D1S7EP SI-B003 Phase 1 T59631 DRUGINFO D28MNU CDX-527 Phase 1 T59631 DRUGINFO D4CGN3 RG6139 Phase 1 T59631 DRUGINFO D7L1MP MEDI5752 Phase 1 T59631 DRUGINFO D8FJ9K XmAb23104 Phase 1 T59631 DRUGINFO DD1TJ8 XmAb20717 Phase 1 T59631 DRUGINFO DMEQ73 ADPT01 Phase 1 T59631 DRUGINFO DX30BA IBI318 Phase 1 T59631 DRUGINFO D00ZRO Cyclic compound 3 Patented T59631 DRUGINFO D03PSA 1,2,4-oxadiazole derivative 2 Patented T59631 DRUGINFO D03XZT Cyclic compound 1 Patented T59631 DRUGINFO D07PJR Cyclic compound 2 Patented T59631 DRUGINFO D08VDV PMID30107136-Compound-Example15 Patented T59631 DRUGINFO D0K7NC PMID30107136-Compound-Example16 Patented T59631 DRUGINFO D0LM6D 1,3,4-oxadiazole derivative 1 Patented T59631 DRUGINFO D0MZ4V 1,2,4-oxadiazole derivative 1 Patented T59631 DRUGINFO D0P3EG 1,3,4-oxadiazole derivative 2 Patented T59631 DRUGINFO D04QQG AUNP-12 Preclinical T59631 DRUGINFO D04BON PMID30247903-Compound-General structure25 Investigative T59631 DRUGINFO D07FEF PMID30247903-Compound-General structure13 Investigative T59631 DRUGINFO D0BU2V PMID30247903-Compound-General structure22 Investigative T59631 DRUGINFO D0BX6Z PMID30247903-Compound-General structure20 Investigative T59631 DRUGINFO D0D8DV PMID30247903-Compound-General structure17 Investigative T59631 DRUGINFO D0E4UM PMID30247903-Compound-General structure14 Investigative T59631 DRUGINFO D0L0DQ PMID30247903-Compound-General structure24 Investigative T59631 DRUGINFO D0L1BZ PMID30247903-Compound-General structure21 Investigative T59631 DRUGINFO D0N6MD PMID30247903-Compound-General structure23 Investigative T59631 DRUGINFO D0T9HE PMID30247903-Compound-General structure15 Investigative T59631 DRUGINFO D0UJ9J PMID30247903-Compound-General structure16 Investigative T59631 DRUGINFO DH0JW9 YH008 Investigative T55815 TARGETID T55815 T55815 FORMERID TTDS00400 T55815 UNIPROID ACHA2_HUMAN T55815 TARGNAME Neuronal acetylcholine receptor alpha-2 (CHRNA2) T55815 GENENAME CHRNA2 T55815 TARGTYPE Successful T55815 SYNONYMS CHRNA2 T55815 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. T55815 PDBSTRUC 5FJV T55815 BIOCLASS Neurotransmitter receptor T55815 SEQUENCE MGPSCPVFLSFTKLSLWWLLLTPAGGEEAKRPPPRAPGDPLSSPSPTALPQGGSHTETEDRLFKHLFRGYNRWARPVPNTSDVVIVRFGLSIAQLIDVDEKNQMMTTNVWLKQEWSDYKLRWNPTDFGNITSLRVPSEMIWIPDIVLYNNADGEFAVTHMTKAHLFSTGTVHWVPPAIYKSSCSIDVTFFPFDQQNCKMKFGSWTYDKAKIDLEQMEQTVDLKDYWESGEWAIVNATGTYNSKKYDCCAEIYPDVTYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSDCGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPSTHTMPHWVRGALLGCVPRWLLMNRPPPPVELCHPLRLKLSPSYHWLESNVDAEEREVVVEEEDRWACAGHVAPSVGTLCSHGHLHSGASGPKAEALLQEGELLLSPHMQKALEGVHYIADHLRSEDADSSVKEDWKYVAMVIDRIFLWLFIIVCFLGTIGLFLPPFLAGMI T55815 DRUGINFO D04QWE Levallorphan Approved T55815 DRUGINFO D05HSC Tubocurarine Approved T55815 DRUGINFO D0L5CZ Rocuronium Approved T55815 DRUGINFO D0OB2M Mivacurium Approved T55815 DRUGINFO D0U7BW Carbachol Approved T55815 DRUGINFO D0XX6Y Pipecuronium Approved T55815 DRUGINFO D0Z8HG Vecuronium Approved T55815 DRUGINFO D08ALK Cisatracurium Approved T55815 DRUGINFO D08XPW CYTISINE Phase 3 T55815 DRUGINFO D03ZVM 5-(1-Methyl-pyrrolidin-2-yl)-2-phenethyl-pyridine Investigative T55815 DRUGINFO D08AGA 3-((S)-Azetidin-2-yloxy)-5-iodo-pyridine Investigative T55815 DRUGINFO D08DAE CHOLINE Investigative T55815 DRUGINFO D0A9RZ 1,1-Dimethyl-4-phenyl-piperazin-1-ium iodide Investigative T55815 DRUGINFO D0C7GB 1-(piperidin-3-ylmethyl)pyridin-2(1H)-one Investigative T55815 DRUGINFO D0L1IB (S)-3-(azetidin-2-ylmethoxy)-2-fluoropyridine Investigative T55815 DRUGINFO D0QE7J 1-(piperidin-4-ylmethyl)pyridin-2(1H)-one Investigative T55815 DRUGINFO D0R6YB 2-Pyridin-3-yl-7-aza-bicyclo[2.2.1]heptane Investigative T55815 DRUGINFO D04MIG LY2087101 Investigative T55815 DRUGINFO D0Y3DW [3H]cytisine Investigative T55815 DRUGINFO D0R4RN [125I]epibatidine Investigative T14908 TARGETID T14908 T14908 FORMERID TTDS00377 T14908 UNIPROID CEGT_HUMAN T14908 TARGNAME Ceramide glucosyltransferase (UGCG) T14908 GENENAME UGCG T14908 TARGTYPE Successful T14908 SYNONYMS UGCG; UDP-glucose:N-acylsphingosine D-glucosyltransferase; UDP-glucose ceramideglucosyltransferase; Glucosylceramide synthase; GLCT-1 T14908 FUNCTION Catalyzes the first glycosylation step in glycosphingolipid biosynthesis, the transfer of glucose to ceramide. May also serve as a "flippase". T14908 BIOCLASS Hexosyltransferase T14908 ECNUMBER EC 2.4.1.80 T14908 SEQUENCE MALLDLALEGMAVFGFVLFLVLWLMHFMAIIYTRLHLNKKATDKQPYSKLPGVSLLKPLKGVDPNLINNLETFFELDYPKYEVLLCVQDHDDPAIDVCKKLLGKYPNVDARLFIGGKKVGINPKINNLMPGYEVAKYDLIWICDSGIRVIPDTLTDMVNQMTEKVGLVHGLPYVADRQGFAATLEQVYFGTSHPRYYISANVTGFKCVTGMSCLMRKDVLDQAGGLIAFAQYIAEDYFMAKAIADRGWRFAMSTQVAMQNSGSYSISQFQSRMIRWTKLRINMLPATIICEPISECFVASLIIGWAAHHVFRWDIMVFFMCHCLAWFIFDYIQLRGVQGGTLCFSKLDYAVAWFIRESMTIYIFLSALWDPTISWRTGRYRLRCGGTAEEILDV T14908 DRUGINFO D0HR8Z Miglustat Approved T14908 DRUGINFO D0J8IJ Eliglustat tartrate Approved T14908 DRUGINFO D07WEN Venglustat Phase 2 T14908 DRUGINFO D00KJV N-butylgalactonojirimycin Investigative T84581 TARGETID T84581 T84581 FORMERID TTDS00276 T84581 UNIPROID TRXR1_HUMAN T84581 TARGNAME Cytoplasmic thioredoxin reductase (TXNRD1) T84581 GENENAME TXNRD1 T84581 TARGTYPE Successful T84581 SYNONYMS Thioredoxin reductase TR1; Thioredoxin reductase 1, cytoplasmic; KM-102-derived reductase-like factor; KDRF; Gene associated with retinoic and interferon-induced mortality 12 protein; Gene associated with retinoic and IFN-induced mortality 12 protein; GRIM12; GRIM-12 T84581 FUNCTION Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions. Isoform 4 enhances the transcriptional activity of estrogen receptors alpha and beta while isoform 5 enhances the transcriptional activity of the beta receptor only. Isoform 5 also mediates cell death induced by a combination of interferon-beta and retinoic acid. T84581 PDBSTRUC 3QFB; 3QFA; 2ZZC; 2ZZB; 2ZZ0 T84581 BIOCLASS Sulfur donor oxidoreductase T84581 ECNUMBER EC 1.8.1.9 T84581 SEQUENCE MGCAEGKAVAAAAPTELQTKGKNGDGRRRSAKDHHPGKTLPENPAGFTSTATADSRALLQAYIDGHSVVIFSRSTCTRCTEVKKLFKSLCVPYFVLELDQTEDGRALEGTLSELAAETDLPVVFVKQRKIGGHGPTLKAYQEGRLQKLLKMNGPEDLPKSYDYDLIIIGGGSGGLAAAKEAAQYGKKVMVLDFVTPTPLGTRWGLGGTCVNVGCIPKKLMHQAALLGQALQDSRNYGWKVEETVKHDWDRMIEAVQNHIGSLNWGYRVALREKKVVYENAYGQFIGPHRIKATNNKGKEKIYSAERFLIATGERPRYLGIPGDKEYCISSDDLFSLPYCPGKTLVVGASYVALECAGFLAGIGLDVTVMVRSILLRGFDQDMANKIGEHMEEHGIKFIRQFVPIKVEQIEAGTPGRLRVVAQSTNSEEIIEGEYNTVMLAIGRDACTRKIGLETVGVKINEKTGKIPVTDEEQTNVPYIYAIGDILEDKVELTPVAIQAGRLLAQRLYAGSTVKCDYENVPTTVFTPLEYGACGLSEEKAVEKFGEENIEVYHSYFWPLEWTIPSRDNNKCYAKIICNTKDNERVVGFHVLGPNAGEVTQGFAAALKCGLTKKQLDSTIGIHPVCAEVFTTLSVTKRSGASILQAGCUG T84581 DRUGINFO D0S1ZB Fotemustine Approved T84581 DRUGINFO D08BXT Spermidine Phase 3 T84581 DRUGINFO D00CLK PMID27977313-Compound-18 Patented T84581 DRUGINFO D00LBC Triazole gold complexe 1 Patented T84581 DRUGINFO D00TXZ 4-aryl quinol derivative 2 Patented T84581 DRUGINFO D01BXV PMID27977313-Compound-46 Patented T84581 DRUGINFO D01IPU Triazole gold complexe 2 Patented T84581 DRUGINFO D01PYM PMID27977313-Compound-48 Patented T84581 DRUGINFO D01WCU 4-aryl quinol derivative 4 Patented T84581 DRUGINFO D01XRW PMID27977313-Compound-31 Patented T84581 DRUGINFO D02ODA Palmarumycin derivative 4 Patented T84581 DRUGINFO D02UTG Binuclear gold(I) compound 1 Patented T84581 DRUGINFO D03CQQ PMID27977313-Compound-17 Patented T84581 DRUGINFO D04ONQ 4-aryl quinol derivative 7 Patented T84581 DRUGINFO D05HHG PMID27977313-Compound-32 Patented T84581 DRUGINFO D07CDS Metal complex derivative 3 Patented T84581 DRUGINFO D07PKU 4-aryl quinol derivative 3 Patented T84581 DRUGINFO D08BVX PMID27977313-Compound-27 Patented T84581 DRUGINFO D08VQU Metal complex derivative 1 Patented T84581 DRUGINFO D09ACU PMID27977313-Compound-8 Patented T84581 DRUGINFO D0CV1Q PMID27977313-Compound-5 Patented T84581 DRUGINFO D0D1LI PMID27977313-Compound-45 Patented T84581 DRUGINFO D0E0EF Terpyridineplatinum(II) complexe 5 Patented T84581 DRUGINFO D0F3BO Binuclear gold(I) compound 3 Patented T84581 DRUGINFO D0G9QO PMID27977313-Compound-7 Patented T84581 DRUGINFO D0HH1K Palmarumycin derivative 1 Patented T84581 DRUGINFO D0I2HK Bis-sulfonamide derivative 1 Patented T84581 DRUGINFO D0J4PE Acyl oxymethyl acrylamide ester derivative 2 Patented T84581 DRUGINFO D0K2GG PMID27977313-Compound-44 Patented T84581 DRUGINFO D0K8NP Terpyridineplatinum(II) complexe 1 Patented T84581 DRUGINFO D0KM8V PMID27977313-Compound-47 Patented T84581 DRUGINFO D0KV5Z Benzisoselenazolone difluorocytidine derivative 1 Patented T84581 DRUGINFO D0L2LF PMID27977313-Compound-42 Patented T84581 DRUGINFO D0L2NG 4-aryl quinol derivative 1 Patented T84581 DRUGINFO D0LB6Q PMID27977313-Compound-19 Patented T84581 DRUGINFO D0NM0B PMID27977313-Compound-Figure4b Patented T84581 DRUGINFO D0NU8U PMID27977313-Compound-Figure6C Patented T84581 DRUGINFO D0NX8E Triazole gold complexe 3 Patented T84581 DRUGINFO D0PT8T PMID27977313-Compound-29 Patented T84581 DRUGINFO D0Q6PR PMID27977313-Compound-39 Patented T84581 DRUGINFO D0QA9N PMID27977313-Compound-28 Patented T84581 DRUGINFO D0RC5J Disulfide compound 2 Patented T84581 DRUGINFO D0RE1D Terpyridineplatinum(II) complexe 2 Patented T84581 DRUGINFO D0RK3P Bis-sulfonamide derivative 2 Patented T84581 DRUGINFO D0RR2D Golden phosphorous acetyletic compound 3 Patented T84581 DRUGINFO D0S2AY PMID27977313-Compound-6 Patented T84581 DRUGINFO D0S3QX PMID27977313-Compound-30 Patented T84581 DRUGINFO D0SC3B Palmarumycin derivative 2 Patented T84581 DRUGINFO D0V1XY PMID27977313-Compound-43 Patented T84581 DRUGINFO D0VA1R 4-aryl quinol derivative 5 Patented T84581 DRUGINFO D0VK1L Metal complex derivative 2 Patented T84581 DRUGINFO D0WK9J Binuclear gold(I) compound 2 Patented T84581 DRUGINFO D0XV4L Disulfide compound 1 Patented T84581 DRUGINFO D0ZZ6N Palmarumycin derivative 3 Patented T84581 DRUGINFO D02NYT Golden phosphorous acetyletic compound 2 Patented T84581 DRUGINFO D03BPZ Terpyridineplatinum(II) complexe 3 Patented T84581 DRUGINFO D05SHW Terpyridineplatinum(II) complexe 4 Patented T84581 DRUGINFO D0W1DK Golden phosphorous acetyletic compound 1 Patented T84581 DRUGINFO D0Z2MX Acyl oxymethyl acrylamide ester derivative 1 Patented T84581 DRUGINFO D05ABT 3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide Investigative T84581 DRUGINFO D09GTJ Bis(2,4-dinitrophenyl)sulfane Investigative T84581 DRUGINFO D0AA8E 4,6-dinitrobenzo[c][1,2,5]thiadiazole Investigative T84581 DRUGINFO D0AS0V 5,8-Dihydroxy-1,4-naphthoquinone Investigative T84581 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T64410 TARGETID T64410 T64410 FORMERID TTDS00182 T64410 UNIPROID VANY_ENTFA T64410 TARGNAME Bacterial DD-carboxypeptidase (Bact vanYB) T64410 GENENAME Bact vanYB T64410 TARGTYPE Successful T64410 SYNONYMS vanYB; DD-peptidase; DD-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase-transpeptidase T64410 FUNCTION Vancomycin-inducible, penicillin-resistant, DD- carboxypeptidase that hydrolyzes depsipeptide- and D-alanyl-D- alanine-containing peptidoglycan precursors. Insensitive to beta- lactams. T64410 PDBSTRUC 6A6A; 5ZHW; 5ZHF; 5HNM T64410 BIOCLASS Peptidase T64410 ECNUMBER EC 3.4.16.4 T64410 SEQUENCE MEKSNYHSNVNHHKRHMKQSGEKRAFLWAFIISFTVCTLFLGWRLVSVLEATQLPPIPATHTGSGTGVAENPEENTLATAKEQGDEQEWSLILVNRQNPIPAQYDVELEQLSNGERIDIRISPYLQDLFDAARADGVYPIVASGYRTTEKQQEIMDEKVAEYKAKGYTSAQAKAEAETWVAVPGTSEHQLGLAVDINADGIHSTGNEVYRWLDENSYRFGFIRRYPPDKTEITGVSNEPWHYRYVGIEAATKIYHQGLCLEEYLNTEK T64410 DRUGINFO D01PLN Cefalotin Approved T64410 DRUGINFO D07JVS Cephalosporin Approved T64410 DRUGINFO D0D1HA Cefotaxime Approved T64410 DRUGINFO D04AIT B-Lactams Approved T64410 DRUGINFO D0Q6RG TD-1792 Phase 3 T64410 DRUGINFO D01BCI D-Alanine Investigative T64410 DRUGINFO D02KJI 3-boronobenzoic acid Investigative T64410 DRUGINFO D02TXD NITROCEFIN Investigative T64410 DRUGINFO D05PXD 2-[(Dioxidophosphino)Oxy]Benzoate Investigative T64410 DRUGINFO D07CUI Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine Investigative T64410 DRUGINFO D0G0ZI Benzo[c][1,2]oxaborol-1(3H)-ol Investigative T64410 DRUGINFO D0JV5J 5-boronothiophene-2-carboxylic acid Investigative T64410 DRUGINFO D01KEE Formaldehyde Investigative T64410 DRUGINFO D0O4TL Cephalosporin C Investigative T64410 DRUGINFO D0EJ9B Phenyl Boronic acid Investigative T78277 TARGETID T78277 T78277 FORMERID TTDI01982 T78277 UNIPROID ASGL1_HUMAN T78277 TARGNAME Asparaginase (ASRGL1) T78277 GENENAME ASRGL1 T78277 TARGTYPE Successful T78277 SYNONYMS Lasparagine amidohydrolase; Isoaspartyl peptidase/Lasparaginase beta chain; Isoaspartyl peptidase/Lasparaginase; Isoaspartyl dipeptidase; Betaaspartylpeptidase; Asparaginaselike protein 1; ASRGL1 T78277 FUNCTION Has both L-asparaginase and beta-aspartyl peptidase activity. May be involved in the production of L-aspartate, which can act as an excitatory neurotransmitter in some brain regions. Is highly active with L-Asp beta-methyl ester. Besides, has catalytic activity toward beta-aspartyl dipeptides and their methyl esters, including beta-L-Asp-L-Phe, beta-L-Asp-L-Phe methyl ester (aspartame), beta-L-Asp-L-Ala, beta-L-Asp-L-Leu and beta-L- Asp-L-Lys. Does not have aspartylglucosaminidase activity and is inactive toward GlcNAc-L-Asn. Likewise, has no activity toward glutamine. T78277 PDBSTRUC 4ZM9; 4PVS; 4PVR; 4PVQ; 4PVP T78277 BIOCLASS Peptidase T78277 ECNUMBER EC 3.4.19.5 T78277 SEQUENCE MNPIVVVHGGGAGPISKDRKERVHQGMVRAATVGYGILREGGSAVDAVEGAVVALEDDPEFNAGCGSVLNTNGEVEMDASIMDGKDLSAGAVSAVQCIANPIKLARLVMEKTPHCFLTDQGAAQFAAAMGVPEIPGEKLVTERNKKRLEKEKHEKGAQKTDCQKNLGTVGAVALDCKGNVAYATSTGGIVNKMVGRVGDSPCLGAGGYADNDIGAVSTTGHGESILKVNLARLTLFHIEQGKTVEEAADLSLGYMKSRVKGLGGLIVVSKTGDWVAKWTSTSMPWAAAKDGKLHFGIDPDDTTITDLP T78277 DRUGINFO D0C9DA Calaspargase pegol Approved T78277 DRUGINFO D09JKS GRASPA Phase 3 T83193 TARGETID T83193 T83193 FORMERID TTDC00049 T83193 UNIPROID TRPV1_HUMAN T83193 TARGNAME Transient receptor potential cation channel V1 (TRPV1) T83193 GENENAME TRPV1 T83193 TARGTYPE Successful T83193 SYNONYMS Vanilloid receptor 1; VR1; TrpV1; Transient receptor potential cation channel subfamily V member 1; Osm-9-like TRP channel 1; OTRPC1; Capsaicin receptor T83193 FUNCTION Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Activation by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6.5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis. T83193 BIOCLASS Transient receptor potential catioin channel T83193 SEQUENCE MKKWSSTDLGAAADPLQKDTCPDPLDGDPNSRPPPAKPQLSTAKSRTRLFGKGDSEEAFPVDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLRLYDRRSIFEAVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLHDGQNTTIPLLLEIARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGADVQAAAHGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNTVLHALVEVADNTADNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYYRPVDGLPPFKMEKTGDYFRVTGEILSVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLYFSHLKEYVASMVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIEDGKNDSLPSESTSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWNTNVGIINEDPGNCEGVKRTLSFSLRSSRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDAEVFKSPAASGEK T83193 DRUGINFO D0U5CE Capsaicin Approved T83193 DRUGINFO D0XW8Y CNTX-4975 Phase 3 T83193 DRUGINFO D04VQH XEN-D0501 Phase 2 T83193 DRUGINFO D05XJW Resiniferatoxin Phase 2 T83193 DRUGINFO D09BDE PAC-14028 Phase 2 T83193 DRUGINFO D0A3EX GRC-15300 Phase 2 T83193 DRUGINFO D0FC8O DWP-05195 Phase 2 T83193 DRUGINFO D0VJ5N SB-705498 Phase 2 T83193 DRUGINFO D00CMV ABT-102 Phase 1 T83193 DRUGINFO D01SZA MR-1817 Phase 1 T83193 DRUGINFO D02XGC PF-3864086 Phase 1 T83193 DRUGINFO D0EK1C PHE-377 Phase 1 T83193 DRUGINFO D0EM4S JNJ-39439335 Phase 1 T83193 DRUGINFO D0KK9D CA-011 Phase 1 T83193 DRUGINFO D0W8NP SAR-115740 Phase 1 T83193 DRUGINFO D00MAN GRC-6211 Phase 1 T83193 DRUGINFO DF63BG BIO-017 Phase 1 T83193 DRUGINFO D00KTN PMID25666693-Compound-121 Patented T83193 DRUGINFO D00ODY PMID25666693-Compound-95 Patented T83193 DRUGINFO D00OLY PMID25666693-Compound-149 Patented T83193 DRUGINFO D00QEZ PMID25666693-Compound-60 Patented T83193 DRUGINFO D00YXA PMID25666693-Compound-2 Patented T83193 DRUGINFO D01DNH PMID25666693-Compound-150 Patented T83193 DRUGINFO D01GEK PMID25666693-Compound-133 Patented T83193 DRUGINFO D01HED PMID25666693-Compound-158 Patented T83193 DRUGINFO D01LGQ PMID25666693-Compound-103 Patented T83193 DRUGINFO D01PLJ PMID25666693-Compound-58 Patented T83193 DRUGINFO D01RUK PMID25666693-Compound-104 Patented T83193 DRUGINFO D02EKO PMID25666693-Compound-126 Patented T83193 DRUGINFO D02JQB PMID25666693-Compound-140 Patented T83193 DRUGINFO D02OAH PMID25666693-Compound-5 Patented T83193 DRUGINFO D02QJE PMID25666693-Compound-23 Patented T83193 DRUGINFO D03EEA PMID25666693-Compound-70 Patented T83193 DRUGINFO D03FSF PMID25666693-Compound-73 Patented T83193 DRUGINFO D03QAW PMID25666693-Compound-61 Patented T83193 DRUGINFO D03SHM PMID25666693-Compound-88 Patented T83193 DRUGINFO D03VXP PMID25666693-Compound-145 Patented T83193 DRUGINFO D03YFL PMID25666693-Compound-71 Patented T83193 DRUGINFO D03ZOZ PMID25666693-Compound-97 Patented T83193 DRUGINFO D04FRL PMID25666693-Compound-44 Patented T83193 DRUGINFO D04HCS PMID25666693-Compound-93 Patented T83193 DRUGINFO D04TIU PMID25666693-Compound-154 Patented T83193 DRUGINFO D05RBF PMID25666693-Compound-99 Patented T83193 DRUGINFO D05SMP PMID25666693-Compound-116 Patented T83193 DRUGINFO D05SWL PMID25666693-Compound-28 Patented T83193 DRUGINFO D05ZWR PMID25666693-Compound-90 Patented T83193 DRUGINFO D06JHW PMID25666693-Compound-37 Patented T83193 DRUGINFO D06VYF PMID25666693-Compound-3 Patented T83193 DRUGINFO D07BZW PMID25666693-Compound-85 Patented T83193 DRUGINFO D07EAV PMID25666693-Compound-41 Patented T83193 DRUGINFO D07EGF PMID25666693-Compound-56 Patented T83193 DRUGINFO D07FIY PMID25666693-Compound-50 Patented T83193 DRUGINFO D07FWF PMID25666693-Compound-117 Patented T83193 DRUGINFO D07JNJ PMID25666693-Compound-17 Patented T83193 DRUGINFO D07MNI PMID25666693-Compound-127 Patented T83193 DRUGINFO D07RYM PMID25666693-Compound-131 Patented T83193 DRUGINFO D07XVL PMID25666693-Compound-119 Patented T83193 DRUGINFO D07XZR PMID25666693-Compound-134 Patented T83193 DRUGINFO D08CLA PMID25666693-Compound-123 Patented T83193 DRUGINFO D08ICT PMID25666693-Compound-13 Patented T83193 DRUGINFO D08UEC PMID25666693-Compound-135 Patented T83193 DRUGINFO D08YAL PMID25666693-Compound-111 Patented T83193 DRUGINFO D08ZBB PMID25666693-Compound-84 Patented T83193 DRUGINFO D09QXC PMID25666693-Compound-79 Patented T83193 DRUGINFO D09SMA PMID25666693-Compound-128 Patented T83193 DRUGINFO D09ZWU PMID25666693-Compound-40 Patented T83193 DRUGINFO D0A0YI PMID25666693-Compound-34 Patented T83193 DRUGINFO D0A3XC PMID25666693-Compound-25 Patented T83193 DRUGINFO D0A8LU PMID25666693-Compound-113 Patented T83193 DRUGINFO D0AQ3U PMID25666693-Compound-153 Patented T83193 DRUGINFO D0B0WJ PMID25666693-Compound-51 Patented T83193 DRUGINFO D0B4NI PMID25666693-Compound-77 Patented T83193 DRUGINFO D0C1MZ PMID25666693-Compound-10 Patented T83193 DRUGINFO D0C5NT PMID25666693-Compound-114 Patented T83193 DRUGINFO D0C8ZZ PMID25666693-Compound-12 Patented T83193 DRUGINFO D0C9FN PMID25666693-Compound-87 Patented T83193 DRUGINFO D0CR0H PMID25666693-Compound-138 Patented T83193 DRUGINFO D0CX4C PMID25666693-Compound-76 Patented T83193 DRUGINFO D0D2CF PMID25666693-Compound-115 Patented T83193 DRUGINFO D0D4NX PMID25666693-Compound-108 Patented T83193 DRUGINFO D0DC4O PMID25666693-Compound-74 Patented T83193 DRUGINFO D0DE5I PMID25666693-Compound-78 Patented T83193 DRUGINFO D0DE5K PMID25666693-Compound-42 Patented T83193 DRUGINFO D0DI1R PMID25666693-Compound-130 Patented T83193 DRUGINFO D0DT7M PMID25666693-Compound-124 Patented T83193 DRUGINFO D0E0SA PMID25666693-Compound-110 Patented T83193 DRUGINFO D0E8UP PMID25666693-Compound-69 Patented T83193 DRUGINFO D0EC3Z PMID25666693-Compound-82 Patented T83193 DRUGINFO D0EH2T PMID25666693-Compound-118 Patented T83193 DRUGINFO D0EV3G PMID25666693-Compound-26 Patented T83193 DRUGINFO D0F3HP PMID25666693-Compound-101 Patented T83193 DRUGINFO D0F4DI PMID25666693-Compound-30 Patented T83193 DRUGINFO D0F4YX PMID25666693-Compound-15 Patented T83193 DRUGINFO D0F5NQ PMID25666693-Compound-65 Patented T83193 DRUGINFO D0G3UV PMID25666693-Compound-55 Patented T83193 DRUGINFO D0G6IQ PMID25666693-Compound-143 Patented T83193 DRUGINFO D0GV5G PMID25666693-Compound-66 Patented T83193 DRUGINFO D0GZ4G PMID25666693-Compound-4 Patented T83193 DRUGINFO D0H4TR PMID25666693-Compound-80 Patented T83193 DRUGINFO D0H6CX PMID25666693-Compound-72 Patented T83193 DRUGINFO D0HE7X PMID25666693-Compound-11 Patented T83193 DRUGINFO D0HS1D PMID25666693-Compound-20 Patented T83193 DRUGINFO D0I3ZW PMID25666693-Compound-159 Patented T83193 DRUGINFO D0IK1S PMID25666693-Compound-102 Patented T83193 DRUGINFO D0IN5E PMID25666693-Compound-48 Patented T83193 DRUGINFO D0IP5E PMID25666693-Compound-9 Patented T83193 DRUGINFO D0IR7H PMID25666693-Compound-27 Patented T83193 DRUGINFO D0IT4N PMID25666693-Compound-94 Patented T83193 DRUGINFO D0IU1H PMID25666693-Compound-52 Patented T83193 DRUGINFO D0J9CS PMID25666693-Compound-59 Patented T83193 DRUGINFO D0JC8L PMID25666693-Compound-31 Patented T83193 DRUGINFO D0JK2N PMID25666693-Compound-22 Patented T83193 DRUGINFO D0JT8B PMID25666693-Compound-147 Patented T83193 DRUGINFO D0JX4I PMID25666693-Compound-62 Patented T83193 DRUGINFO D0K0ZI PMID25666693-Compound-141 Patented T83193 DRUGINFO D0K3KE PMID25666693-Compound-155 Patented T83193 DRUGINFO D0K3KM PMID25666693-Compound-148 Patented T83193 DRUGINFO D0K4SZ PMID25666693-Compound-46 Patented T83193 DRUGINFO D0KB2Z PMID25666693-Compound-1 Patented T83193 DRUGINFO D0KF3A PMID25666693-Compound-98 Patented T83193 DRUGINFO D0KM0W PMID25666693-Compound-137 Patented T83193 DRUGINFO D0LA0Q PMID25666693-Compound-162 Patented T83193 DRUGINFO D0M4WY PMID25666693-Compound-29 Patented T83193 DRUGINFO D0MU3S PMID25666693-Compound-47 Patented T83193 DRUGINFO D0MY3K PMID25666693-Compound-109 Patented T83193 DRUGINFO D0N0QN PMID25666693-Compound-146 Patented T83193 DRUGINFO D0N0TF PMID25666693-Compound-156 Patented T83193 DRUGINFO D0N2UQ PMID25666693-Compound-24 Patented T83193 DRUGINFO D0N9FJ PMID25666693-Compound-7 Patented T83193 DRUGINFO D0NB5M PMID25666693-Compound-35 Patented T83193 DRUGINFO D0NH2M PMID25666693-Compound-142 Patented T83193 DRUGINFO D0NM3D PMID25666693-Compound-19 Patented T83193 DRUGINFO D0NV2M PMID25666693-Compound-157 Patented T83193 DRUGINFO D0O0UG PMID25666693-Compound-86 Patented T83193 DRUGINFO D0O3TG PMID25666693-Compound-136 Patented T83193 DRUGINFO D0O6VU PMID25666693-Compound-92 Patented T83193 DRUGINFO D0O7IQ PMID25666693-Compound-6 Patented T83193 DRUGINFO D0O9GI PMID25666693-Compound-63 Patented T83193 DRUGINFO D0OA1P PMID25666693-Compound-53 Patented T83193 DRUGINFO D0OC6A PMID25666693-Compound-75 Patented T83193 DRUGINFO D0ON4M PMID25666693-Compound-8 Patented T83193 DRUGINFO D0P0MR PMID25666693-Compound-57 Patented T83193 DRUGINFO D0P5SB PMID25666693-Compound-49 Patented T83193 DRUGINFO D0P9KJ PMID25666693-Compound-43 Patented T83193 DRUGINFO D0PJ8O PMID25666693-Compound-129 Patented T83193 DRUGINFO D0PT0U PMID25666693-Compound-112 Patented T83193 DRUGINFO D0QP4N PMID25666693-Compound-81 Patented T83193 DRUGINFO D0R2QV PMID25666693-Compound-122 Patented T83193 DRUGINFO D0R2VB PMID25666693-Compound-106 Patented T83193 DRUGINFO D0R8GA PMID25666693-Compound-14 Patented T83193 DRUGINFO D0R9RP PMID25666693-Compound-32 Patented T83193 DRUGINFO D0RC7L PMID25666693-Compound-139 Patented T83193 DRUGINFO D0SD4G PMID25666693-Compound-16 Patented T83193 DRUGINFO D0TZ2W PMID25666693-Compound-38 Patented T83193 DRUGINFO D0U5CQ PMID25666693-Compound-54 Patented T83193 DRUGINFO D0U5ON PMID25666693-Compound-125 Patented T83193 DRUGINFO D0U8YZ PMID25666693-Compound-45 Patented T83193 DRUGINFO D0UE9K PMID25666693-Compound-83 Patented T83193 DRUGINFO D0V3PI PMID25666693-Compound-36 Patented T83193 DRUGINFO D0V9RM PMID25666693-Compound-89 Patented T83193 DRUGINFO D0W4AA PMID25666693-Compound-33 Patented T83193 DRUGINFO D0WJ8R PMID25666693-Compound-91 Patented T83193 DRUGINFO D0WT1W PMID25666693-Compound-132 Patented T83193 DRUGINFO D0WX4W PMID25666693-Compound-120 Patented T83193 DRUGINFO D0X1OO PMID25666693-Compound-39 Patented T83193 DRUGINFO D0XX8R PMID25666693-Compound-161 Patented T83193 DRUGINFO D0Y1SI PMID25666693-Compound-100 Patented T83193 DRUGINFO D0Y9ST PMID25666693-Compound-64 Patented T83193 DRUGINFO D0YM1M PMID25666693-Compound-67 Patented T83193 DRUGINFO D0YR4E PMID25666693-Compound-21 Patented T83193 DRUGINFO D0YU9B PMID25666693-Compound-151 Patented T83193 DRUGINFO D0Z4QQ PMID25666693-Compound-160 Patented T83193 DRUGINFO D0Z5HH PMID25666693-Compound-144 Patented T83193 DRUGINFO D0ZE1M PMID25666693-Compound-107 Patented T83193 DRUGINFO D0ZM8H PMID25666693-Compound-18 Patented T83193 DRUGINFO D0ZP2C PMID25666693-Compound-105 Patented T83193 DRUGINFO D0ZQ2W PMID25666693-Compound-96 Patented T83193 DRUGINFO D0ZS3E PMID25666693-Compound-152 Patented T83193 DRUGINFO D0ZZ8F PMID25666693-Compound-68 Patented T83193 DRUGINFO D00FJC Nuvanil Discontinued in Phase 2 T83193 DRUGINFO D04PMM AZD1386 Discontinued in Phase 2 T83193 DRUGINFO D06GDH DA-5018 Discontinued in Phase 2 T83193 DRUGINFO D06PYP JTS-653 Discontinued in Phase 2 T83193 DRUGINFO D0Z0PB NGD-8243 Discontinued in Phase 2 T83193 DRUGINFO D0L5XI AMG-517 Discontinued in Phase 1 T83193 DRUGINFO D07LRT A-425619 Preclinical T83193 DRUGINFO D01QIA BL-1872 Terminated T83193 DRUGINFO D07IEM AMG-8562 Terminated T83193 DRUGINFO D00RDS 4-tert-butyl-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D00XZZ 4-butyl-N-(pyridin-3-yl)benzamide Investigative T83193 DRUGINFO D00ZWU 4-butyl-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D01WDS 4-(cyclohexylamino)-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D02ANZ phenylacetylrinvanil Investigative T83193 DRUGINFO D02GNL KMJ-372 Investigative T83193 DRUGINFO D03SJY N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide Investigative T83193 DRUGINFO D04FFY AMG-8563 Investigative T83193 DRUGINFO D04IJB [125I]resiniferatoxin Investigative T83193 DRUGINFO D05APW ABT-116 Investigative T83193 DRUGINFO D05NTO 6'-Iodononivamide Investigative T83193 DRUGINFO D06CDW PPAHV Investigative T83193 DRUGINFO D06MRN 4-(methyl(octyl)amino)-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D07BKU A-795614 Investigative T83193 DRUGINFO D07LCG 4-butyl-N-phenylbenzamide Investigative T83193 DRUGINFO D08KRX 4-nonyl-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D08KYH 4-(hexyl(methyl)amino)-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D08WAW 4-pentyl-N-pyridin-3-yl benzamide Investigative T83193 DRUGINFO D08WTR 6-iodo-nordihydrocapsaicin Investigative T83193 DRUGINFO D09AZO 4-(3-methylpyridin-2-yl)-N-p-tolylbenzamide Investigative T83193 DRUGINFO D09BEW N-methyl-4-pentyl-N-(pyridin-3-yl)benzamide Investigative T83193 DRUGINFO D09SXM (R)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea Investigative T83193 DRUGINFO D09WYF 2-(4-pentylphenyl)-N-(pyridin-3-yl)acetamide Investigative T83193 DRUGINFO D0BB7F 4-butyl-N-(isoquinolin-5-yl)benzamide Investigative T83193 DRUGINFO D0BY9X A778317 Investigative T83193 DRUGINFO D0C3XF 4-decyl-N-(pyridin-3-yl)benzamide Investigative T83193 DRUGINFO D0D0DW 1-(4-Bromo-benzyl)-3-quinazolin-8-yl-urea Investigative T83193 DRUGINFO D0D2FP [3H]A778317 Investigative T83193 DRUGINFO D0D4SO 4-octyl-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D0D7QH arvanil Investigative T83193 DRUGINFO D0D9MW 4-propyl-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D0DJ6G 4-butyl-N-(7-hydroxynaphthalen-1-yl)benzamide Investigative T83193 DRUGINFO D0DL4Y (5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenal Investigative T83193 DRUGINFO D0DY4E JNJ-17203212 Investigative T83193 DRUGINFO D0E2XP N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]linoleamide Investigative T83193 DRUGINFO D0E4FJ (E)-Octadec-9-enal Investigative T83193 DRUGINFO D0F4LI LASSBio-881 Investigative T83193 DRUGINFO D0F4NA N-(4-iodophenyl)-4-(trifluoromethyl)benzamide Investigative T83193 DRUGINFO D0F9NL 12S-HPETE Investigative T83193 DRUGINFO D0GL2X 1,3-dibenzyl urea Investigative T83193 DRUGINFO D0H6GW 4-heptyl-N-(pyridin-3-yl)benzamide Investigative T83193 DRUGINFO D0H6TX (S)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea Investigative T83193 DRUGINFO D0J3VX 1-(isoquinolin-5-yl)-3-(4-morpholinobenzyl)urea Investigative T83193 DRUGINFO D0J8NC ASP-8370 Investigative T83193 DRUGINFO D0KH9W 15S-HPETE Investigative T83193 DRUGINFO D0L9DR SB-782443 Investigative T83193 DRUGINFO D0M7NA A-993610 Investigative T83193 DRUGINFO D0M7TC agatoxin 489 Investigative T83193 DRUGINFO D0N8EI 4-(butyl(methyl)amino)-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D0P0MN NE-28345 Investigative T83193 DRUGINFO D0P7VQ BCTC Investigative T83193 DRUGINFO D0Q2ZO 4-octyl-N-(pyridin-3-yl)benzamide Investigative T83193 DRUGINFO D0R8XX N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]lauramide Investigative T83193 DRUGINFO D0SH1L 1-benzhydryl-3-(isoquinolin-5-yl)urea Investigative T83193 DRUGINFO D0SO5A ATC-120 Investigative T83193 DRUGINFO D0T8DR 4-hexyl-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D0U3WK SB452533 Investigative T83193 DRUGINFO D0VM5U KJM429 Investigative T83193 DRUGINFO D0W3VM N-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide Investigative T83193 DRUGINFO D0W6TX N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide Investigative T83193 DRUGINFO D0W8UW AMG-628 Investigative T83193 DRUGINFO D0WK3N 4-(methyl(nonyl)amino)-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D0X8XU 1-(isoquinolin-5-yl)-3-(1-phenylpropyl)urea Investigative T83193 DRUGINFO D0XO2G AMG 9810 Investigative T83193 DRUGINFO D0Y7QY (E)-3-(4-tert-Butyl-phenyl)-N-phenyl-acrylamide Investigative T83193 DRUGINFO D0Y9EU 4-heptyl-N-(quinolin-3-yl)benzamide Investigative T83193 DRUGINFO D00ESG 4-Pyridin-2-yl-piperazine-1-carboxylic acid amide Investigative T83193 DRUGINFO D03KQG Pyrrolidin-1-yl-thiourea Investigative T83193 DRUGINFO D07YQG NADA Investigative T83193 DRUGINFO D0G8BN CAPSAZEPINE Investigative T83193 DRUGINFO D0Q2LG 5S-HPETE Investigative T83193 DRUGINFO D0X7AM SC-0030 Investigative T83193 DRUGINFO D03TWR diphenylboronic anhydride Investigative T83193 DRUGINFO D07CJR 5S-HETE Investigative T83193 DRUGINFO D00HCI 2-APB Investigative T75888 TARGETID T75888 T75888 FORMERID TTDS00433 T75888 UNIPROID CPT1B_HUMAN T75888 TARGNAME Carnitine O-palmitoyltransferase I (CPT1B) T75888 GENENAME CPT1B T75888 TARGTYPE Successful T75888 SYNONYMS KIAA1670; Carnitine palmitoyltransferase I-like protein; Carnitine palmitoyltransferase I; Carnitine palmitoyltransferase 1B; Carnitine palmitoyl-transferase I; Carnitine o-palmitoyltransferase-1; Carnitine O-palmitoyltransferase I, muscle isoform; Carnitine O-palmitoyltransferase 1, muscle isoform; CPTI-M; CPTI-L; CPT1-M; CPT-1; CPT I; CPT T75888 FUNCTION mitochondrial outer membrane, mitochondrion, carnitine O-palmitoyltransferase activity, carnitine metabolic process, carnitine shuttle, fatty acid beta-oxidation, long-chain fatty acid transport. T75888 BIOCLASS Acyltransferase T75888 ECNUMBER EC 2.3.1.21 T75888 SEQUENCE MAEAHQAVAFQFTVTPDGVDFRLSREALKHVYLSGINSWKKRLIRIKNGILRGVYPGSPTSWLVVIMATVGSSFCNVDISLGLVSCIQRCLPQGCGPYQTPQTRALLSMAIFSTGVWVTGIFFFRQTLKLLLCYHGWMFEMHGKTSNLTRIWAMCIRLLSSRHPMLYSFQTSLPKLPVPRVSATIQRYLESVRPLLDDEEYYRMELLAKEFQDKTAPRLQKYLVLKSWWASNYVSDWWEEYIYLRGRSPLMVNSNYYVMDLVLIKNTDVQAARLGNIIHAMIMYRRKLDREEIKPVMALGIVPMCSYQMERMFNTTRIPGKDTDVLQHLSDSRHVAVYHKGRFFKLWLYEGARLLKPQDLEMQFQRILDDPSPPQPGEEKLAALTAGGRVEWAQARQAFFSSGKNKAALEAIERAAFFVALDEESYSYDPEDEASLSLYGKALLHGNCYNRWFDKSFTLISFKNGQLGLNAEHAWADAPIIGHLWEFVLGTDSFHLGYTETGHCLGKPNPALAPPTRLQWDIPKQCQAVIESSYQVAKALADDVELYCFQFLPFGKGLIKKCRTSPDAFVQIALQLAHFRDRGKFCLTYEASMTRMFREGRTETVRSCTSESTAFVQAMMEGSHTKADLRDLFQKAAKKHQNMYRLAMTGAGIDRHLFCLYLVSKYLGVSSPFLAEVLSEPWRLSTSQIPQSQIRMFDPEQHPNHLGAGGGFGPVADDGYGVSYMIAGENTIFFHISSKFSSSETNAQRFGNHIRKALLDIADLFQVPKAYS T75888 DRUGINFO D00SBN Perhexiline Approved T75888 DRUGINFO D0G8SQ Levacecarnine hci Approved T75888 DRUGINFO D0I3PG SDZ-CPI-975 Discontinued in Phase 1 T75888 DRUGINFO D00UEQ Etomoxir Terminated T75888 DRUGINFO D0SG0N DB-200 Terminated T75888 DRUGINFO D07MXA C75 Investigative T59604 TARGETID T59604 T59604 FORMERID TTDC00127 T59604 UNIPROID GHSR_HUMAN T59604 TARGNAME Growth hormone secretagogue receptor 1 (GHSR) T59604 GENENAME GHSR T59604 TARGTYPE Successful T59604 SYNONYMS Growth hormone secretagogue receptor; Ghrelin receptor; GHSR; GHS-R; GHRP; GH-releasing peptide receptor T59604 FUNCTION Receptor for ghrelin, coupled to G-alpha-11 proteins. Stimulates growth hormone secretion. Binds also other growth hormone releasing peptides (GHRP) (e.g. Met-enkephalin and GHRP-6) as well as non-peptide, low molecular weight secretagogues (e.g. L-692,429, MK-0677, adenosine). T59604 BIOCLASS GPCR rhodopsin T59604 SEQUENCE MWNATPSEEPGFNLTLADLDWDASPGNDSLGDELLQLFPAPLLAGVTATCVALFVVGIAGNLLTMLVVSRFRELRTTTNLYLSSMAFSDLLIFLCMPLDLVRLWQYRPWNFGDLLCKLFQFVSESCTYATVLTITALSVERYFAICFPLRAKVVVTKGRVKLVIFVIWAVAFCSAGPIFVLVGVEHENGTDPWDTNECRPTEFAVRSGLLTVMVWVSSIFFFLPVFCLTVLYSLIGRKLWRRRRGDAVVGASLRDQNHKQTVKMLAVVVFAFILCWLPFHVGRYLFSKSFEPGSLEIAQISQYCNLVSFVLFYLSAAINPILYNIMSKKYRVAVFRLLGFEPFSQRKLSTLKDESSRAWTESSINT T59604 DRUGINFO D02NEH Ibutamoren Approved T59604 DRUGINFO D0BV3J Macimorelin Approved T59604 DRUGINFO D08VRX GHRP-2 Approved T59604 DRUGINFO D03WAU Anamorelin Phase 3 T59604 DRUGINFO D0W9VW TZP-101 Phase 2b T59604 DRUGINFO D03RFK GTP-200 Phase 2 T59604 DRUGINFO D0UO4B RQ-00000005 Phase 2 T59604 DRUGINFO D0XH9B Tabimorelin Phase 2 T59604 DRUGINFO D9OR7F Ibutamoren mesylate Phase 2 T59604 DRUGINFO D08BEA Ipamorelin Phase 1/2 T59604 DRUGINFO D01HLO PF-05190457 Phase 1 T59604 DRUGINFO D03BGG ST-1141 Phase 1 T59604 DRUGINFO D08KVK CYT-009-GhrQb Discontinued in Phase 1/2 T59604 DRUGINFO D0LR1M LY-444711 Discontinued in Phase 1 T59604 DRUGINFO D09DKY AEZS-123 Preclinical T59604 DRUGINFO D0N3RC TZP-301 Preclinical T59604 DRUGINFO D0T8YK EP-01492 Preclinical T59604 DRUGINFO D0G2VT SUN-11031 Terminated T59604 DRUGINFO D01LKO WFwGG-NH2 Investigative T59604 DRUGINFO D01WVV [35S]ibutamoren Investigative T59604 DRUGINFO D02NZI SM-130,686 Investigative T59604 DRUGINFO D06GIL JMV3008 Investigative T59604 DRUGINFO D07JZB RwFwLL-NH2 Investigative T59604 DRUGINFO D07QLZ AwFwLL-NH2 Investigative T59604 DRUGINFO D08GTH WFwLL-NH2 Investigative T59604 DRUGINFO D09QPV QwFwLL-NH2 Investigative T59604 DRUGINFO D0C3OY RPKPfQwFwLL-NH2 Investigative T59604 DRUGINFO D0C4BI EX-1314 Investigative T59604 DRUGINFO D0E7PZ NOX-B11 Investigative T59604 DRUGINFO D0G8TL HwFwLL-NH2 Investigative T59604 DRUGINFO D0J2YB YIL781 Investigative T59604 DRUGINFO D0L3AP DwFwLL-NH2 Investigative T59604 DRUGINFO D0L3EP GSK1614343 Investigative T59604 DRUGINFO D0PQ7A DprwFwLL-NH2 Investigative T59604 DRUGINFO D0U2QP 4-(3-hexylureido)-N-phenylbenzenesulfonamide Investigative T59604 DRUGINFO D0UV9F GSK-894281 Investigative T59604 DRUGINFO D0XR6A KwFwLL-NH2 Investigative T59604 DRUGINFO D0YJ5H EX-1311 Investigative T59604 DRUGINFO D0ZG7W Abbott 14c Investigative T46937 TARGETID T46937 T46937 FORMERID TTDS00113 T46937 UNIPROID P2Y12_HUMAN T46937 TARGNAME P2Y purinoceptor 12 (P2RY12) T46937 GENENAME P2RY12 T46937 TARGTYPE Successful T46937 SYNONYMS SP1999; P2Y12 platelet ADP receptor; P2Y12; P2Y(cyc); P2Y(ADP)P2Y purinoceptor 12; P2Y(ADP); P2Y(AC); P2T(AC); P2RY12; Nucleotide P2Y(12) receptor; Adenosine P2Y12 receptor; ADPG-R; ADP-glucose receptor T46937 FUNCTION Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation. T46937 PDBSTRUC 4PY0; 4PXZ; 4NTJ; 1Y9C; 1VZ1 T46937 BIOCLASS GPCR rhodopsin T46937 SEQUENCE MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIFFQIRSKSNFIIFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTFVCQVTSVIFYFTMYISISFLGLITIDRYQKTTRPFKTSNPKNLLGAKILSVVIWAFMFLLSLPNMILTNRQPRDKNVKKCSFLKSEFGLVWHEIVNYICQVIFWINFLIVIVCYTLITKELYRSYVRTRGVGKVPRKKVNVKVFIIIAVFFICFVPFHFARIPYTLSQTRDVFDCTAENTLFYVKESTLWLTSLNACLDPFIYFFLCKSFRNSLISMLKCPNSATSLSQDNRKKEQDGGDPNEETPM T46937 DRUGINFO D07IRF Prasugrel Approved T46937 DRUGINFO D09QBG Cangrelor Approved T46937 DRUGINFO D0N0TZ Clopidogrel Approved T46937 DRUGINFO D0WF7L Brilinta Approved T46937 DRUGINFO D0W4JI INS-50589 Phase 2 T46937 DRUGINFO D09VBE Elinogrel Phase 1 T46937 DRUGINFO D0KE4Z ARL-67085 Phase 1 T46937 DRUGINFO D00YAZ R-138727 Investigative T46937 DRUGINFO D01APA PMID22984835C20o Investigative T46937 DRUGINFO D01IEX PSB-0739 Investigative T46937 DRUGINFO D02TXW BX 667 Investigative T46937 DRUGINFO D03HLK PRT-060096 Investigative T46937 DRUGINFO D05KHS pCMPS Investigative T46937 DRUGINFO D08MDL INS49266 Investigative T46937 DRUGINFO D0E4YW ARL66096 Investigative T46937 DRUGINFO D0KF2P PMID22984835C4 Investigative T46937 DRUGINFO D0M7HH [3H]PSB-0413 Investigative T46937 DRUGINFO D0N3FL PSB-0702 Investigative T46937 DRUGINFO D0U2CJ PMID23083103C4 Investigative T46937 DRUGINFO D0U4VW BX 048 Investigative T46937 DRUGINFO D01GRB 2MeSAMP Investigative T46937 DRUGINFO D0BB0O 2MeSADP Investigative T46937 DRUGINFO D05NWF adenosine diphosphate Investigative T06841 TARGETID T06841 T06841 FORMERID TTDI01808 T06841 UNIPROID IL23A_HUMAN T06841 TARGNAME Interleukin-23 (IL23) T06841 GENENAME IL23A T06841 TARGTYPE Successful T06841 SYNONYMS UNQ2498/PRO5798; SGRF; P40 subunit of interleukin-23; Interleukin-23 subunit p19; Interleukin-23 subunit alpha; Interleukin 23 subunit alpha; IL-23p19; IL-23-A; IL-23 subunit alpha; IL-23 T06841 FUNCTION IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis. Associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. T06841 PDBSTRUC 5NJD; 5MZV; 5MXA; 5MJ4; 5MJ3 T06841 BIOCLASS Cytokine: interleukin T06841 SEQUENCE MLGSRAVMLLLLLPWTAQGRAVPGGSSPAWTQCQQLSQKLCTLAWSAHPLVGHMDLREEGDEETTNDVPHIQCGDGCDPQGLRDNSQFCLQRIHQGLIFYEKLLGSDIFTGEPSLLPDSPVGQLHASLLGLSQLLQPEGHHWETQQIPSLSPSQPWQRLLLRFKILRSLQAFVAVAARVFAHGAATLSP T06841 DRUGINFO D03HSN CNTO-1959 Approved T06841 DRUGINFO D0GP8Q Risankizumab Approved T06841 DRUGINFO D0FT3R Tildrakizumab Approved T06841 DRUGINFO D0A2UV Ustekinumab Approved T06841 DRUGINFO D0A0MS BI 655066 Phase 3 T06841 DRUGINFO D0P1ME MK-3222 Phase 3 T06841 DRUGINFO DMS12U Brazikumab Phase 3 T06841 DRUGINFO DVT8O0 ABP 654 Phase 3 T06841 DRUGINFO D0HT2X CNT0-1959 Phase 2 T06841 DRUGINFO D0G3EU AMG-139 Phase 1 T06841 DRUGINFO DC5A9Q mRNA-2752 Phase 1 T46482 TARGETID T46482 T46482 FORMERID TTDS00311 T46482 UNIPROID TLR7_HUMAN T46482 TARGNAME Toll-like receptor 7 (TLR7) T46482 GENENAME TLR7 T46482 TARGTYPE Successful T46482 SYNONYMS Toll-like receptor 7 T46482 FUNCTION Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR7 is a nucleotide-sensing TLR which is activated by single-stranded RNA. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (By similarity). T46482 BIOCLASS Toll-like receptor T46482 SEQUENCE MVFPMWTLKRQILILFNIILISKLLGARWFPKTLPCDVTLDVPKNHVIVDCTDKHLTEIPGGIPTNTTNLTLTINHIPDISPASFHRLDHLVEIDFRCNCVPIPLGSKNNMCIKRLQIKPRSFSGLTYLKSLYLDGNQLLEIPQGLPPSLQLLSLEANNIFSIRKENLTELANIEILYLGQNCYYRNPCYVSYSIEKDAFLNLTKLKVLSLKDNNVTAVPTVLPSTLTELYLYNNMIAKIQEDDFNNLNQLQILDLSGNCPRCYNAPFPCAPCKNNSPLQIPVNAFDALTELKVLRLHSNSLQHVPPRWFKNINKLQELDLSQNFLAKEIGDAKFLHFLPSLIQLDLSFNFELQVYRASMNLSQAFSSLKSLKILRIRGYVFKELKSFNLSPLHNLQNLEVLDLGTNFIKIANLSMFKQFKRLKVIDLSVNKISPSGDSSEVGFCSNARTSVESYEPQVLEQLHYFRYDKYARSCRFKNKEASFMSVNESCYKYGQTLDLSKNSIFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQPLAELRYLDFSNNRLDLLHSTAFEELHKLEVLDISSNSHYFQSEGITHMLNFTKNLKVLQKLMMNDNDISSSTSRTMESESLRTLEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISKNSLSFLPSGVFDGMPPNLKNLSLAKNGLKSFSWKKLQCLKNLETLDLSHNQLTTVPERLSNCSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQKTSFPENVLNNLKMLLLHHNRFLCTCDAVWFVWWVNHTEVTIPYLATDVTCVGPGAHKGQSVISLDLYTCELDLTNLILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTKDPAVTEWVLAELVAKLEDPREKHFNLCLEERDWLPGQPVLENLSQSIQLSKKTVFVMTDKYAKTENFKIAFYLSHQRLMDEKVDVIILIFLEKPFQKSKFLQLRKRLCGSSVLEWPTNPQAHPYFWQCLKNALATDNHVAYSQVFKETV T46482 DRUGINFO D06CTE Imiquimod Approved T46482 DRUGINFO D0OJ4L Hydroxychloroquine Approved T46482 DRUGINFO D04TIL ANA773 Phase 2a T46482 DRUGINFO D04EIF LOXORIBINE Phase 2 T46482 DRUGINFO D04PAU GSK2245035 Phase 2 T46482 DRUGINFO D04XCO AZD-8848 Phase 2 T46482 DRUGINFO D05AAD Isatoribine Phase 2 T46482 DRUGINFO D08JWC GS-9620 Phase 2 T46482 DRUGINFO D0T1FC PF-4878691 Phase 2 T46482 DRUGINFO D08OXU IMO-3100 Phase 2 T46482 DRUGINFO D0C8KF Resiquimod Phase 2 T46482 DRUGINFO DW0ZV1 Afimetoran Phase 2 T46482 DRUGINFO D52NOH BNT411 Phase 1/2 T46482 DRUGINFO DZL8S6 DSP-0509 Phase 1/2 T46482 DRUGINFO D8JN5H NKTR-262 Phase 1/2 T46482 DRUGINFO D12EFM RG7854 Phase 1 T46482 DRUGINFO D6QRJ2 RG6115 Phase 1 T46482 DRUGINFO DU2G0C LHC165 Phase 1 T46482 DRUGINFO D00CGX DV-1179 Phase 1 T46482 DRUGINFO D0L8HB MEDI9197 Phase 1 T46482 DRUGINFO D0G1TY CPG 52364 Phase 1 T46482 DRUGINFO DVU2H8 CV8102 Phase 1 T46482 DRUGINFO D0H4XV IM0-8400 Discontinued in Phase 1/2 T46482 DRUGINFO D03GNR ANA-975 Discontinued in Phase 1 T46482 DRUGINFO D0J3VV IPH-3201 Terminated T46482 DRUGINFO D05TCC TMX-202 Investigative T46482 DRUGINFO D0I2GT TMX-30X Investigative T46482 DRUGINFO D0Z2IY TMX-201 Investigative T99948 TARGETID T99948 T99948 FORMERID TTDNC00468 T99948 UNIPROID PD1L1_HUMAN T99948 TARGNAME Programmed cell death 1 ligand 1 (PD-L1) T99948 GENENAME CD274 T99948 TARGTYPE Successful T99948 SYNONYMS hPD-L1; Programmed death ligand 1; PDL1; PDCD1LG1; PDCD1L1; PDCD1 ligand 1; B7H1; B7-H1; B7 homolog 1 T99948 FUNCTION As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Plays a critical role in induction and maintenance of immune tolerance to self. T99948 PDBSTRUC 6R3K; 6NP9; 6NOS; 6NOJ; 6NNV T99948 BIOCLASS Immunoglobulin T99948 SEQUENCE MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET T99948 DRUGINFO D0K7SX Avelumab Approved T99948 DRUGINFO D0LS9E Durvalumab Approved T99948 DRUGINFO D0OZ4J RG-7446 Approved T99948 DRUGINFO D0W8HN Bavencio Approved T99948 DRUGINFO D0YM2K Atezolizumab Approved T99948 DRUGINFO DDZ48Y Sugemalimab Approved in China T99948 DRUGINFO D04RRZ MEDI4736 Phase 3 T99948 DRUGINFO D0Y5IH MPDL-3280A Phase 3 T99948 DRUGINFO D3MP1S CS1001 Phase 3 T99948 DRUGINFO DI89WD A167 Phase 3 T99948 DRUGINFO DLOQ25 KN046 Phase 3 T99948 DRUGINFO D09MRL Pidilizumab Phase 2 T99948 DRUGINFO D0GF2R KN035 Phase 2 T99948 DRUGINFO D0Z2BO CX-072 Phase 2 T99948 DRUGINFO DKM79E INCB86550 Phase 2 T99948 DRUGINFO D5J3BL Bintrafusp alfa Phase 2 T99948 DRUGINFO D05FPZ M7824 Phase 2 T99948 DRUGINFO DC5VW9 BGB-A333 Phase 1/2 T99948 DRUGINFO DS6VD0 GS-4224 Phase 1/2 T99948 DRUGINFO DUVH60 NM21-1480 Phase 1/2 T99948 DRUGINFO D08HSS LY3300054 Phase 1 T99948 DRUGINFO D0A8AU MSB2311 Phase 1 T99948 DRUGINFO D0KP9A Anti-PD-L1 Phase 1 T99948 DRUGINFO D0LU1O FAZ053 Phase 1 T99948 DRUGINFO D0W7UD Anti-PD-L1 CSR T cells Phase 1 T99948 DRUGINFO D0X1GN BMS-986189 Phase 1 T99948 DRUGINFO D17URP Cosibelimab Phase 1 T99948 DRUGINFO D2Z6WF CA-170 Phase 1 T99948 DRUGINFO DH42RF PD-L1 t-haNK Phase 1 T99948 DRUGINFO DJVR06 KD033 Phase 1 T99948 DRUGINFO D03GTO C-Met/PD-L1 CAR-T Cell Phase 1 T99948 DRUGINFO D09PPU CA-170 Phase 1 T99948 DRUGINFO D0XO9F FS118 Phase 1 T99948 DRUGINFO D1A7OP PF-07257876 Phase 1 T99948 DRUGINFO D2QY0Z MCLA-145 Phase 1 T99948 DRUGINFO D3HBJ1 GEN1046 Phase 1 T99948 DRUGINFO D82UVG ALPN-202 Phase 1 T99948 DRUGINFO D9SL1N TAK-252 Phase 1 T99948 DRUGINFO DA1X5W INBRX-105 Phase 1 T99948 DRUGINFO DC8HR6 LY3415244 Phase 1 T99948 DRUGINFO DL97UQ A337 Phase 1 T99948 DRUGINFO DX30BA IBI318 Phase 1 T99948 DRUGINFO D0OK1S PMID30107136-Compound-Example2 Patented T99948 DRUGINFO D0WQ9X PMID30107136-Compound-Example1 Patented T99948 DRUGINFO D01TGF PMID30247903-Compound-General structure7 Investigative T99948 DRUGINFO D04ILU CA-327 Investigative T99948 DRUGINFO D04QGF PMID30247903-Compound-General structure8 Investigative T99948 DRUGINFO D07BOF PMID30247903-Compound-General structure5 Investigative T99948 DRUGINFO D09BYN PMID30247903-Compound-General structure12 Investigative T99948 DRUGINFO D0GG6N PMID30247903-Compound-General structure9 Investigative T99948 DRUGINFO D0TN4F PMID30247903-Compound-General structure6 Investigative T99948 DRUGINFO D0XL3N PMID30247903-Compound-General structure10 Investigative T99948 DRUGINFO DA91UG YH011 Investigative T99948 DRUGINFO DBTI39 YH010 Investigative T42446 TARGETID T42446 T42446 FORMERID TTDS00022 T42446 UNIPROID GABR1_HUMAN; GABR2_HUMAN T42446 TARGNAME Gamma-aminobutyric acid B receptor (GABBR) T42446 GENENAME GABBR1; GABBR2 T42446 TARGTYPE Successful T42446 SYNONYMS Gamma-aminobutyric acid type B receptor; GPRC3; GABABR; GABA-BR; GABA-B-R; GABA-B receptor T42446 FUNCTION Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis. Plays a critical role in the fine-tuning of inhibitory synaptic transmission. Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials. Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception. Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. T42446 BIOCLASS GPCR glutamate T42446 SEQUENCE MLLLLLLAPLFLRPPGAGGAQTPNATSEGCQIIHPPWEGGIRYRGLTRDQVKAINFLPVDYEIEYVCRGEREVVGPKVRKCLANGSWTDMDTPSRCVRICSKSYLTLENGKVFLTGGDLPALDGARVDFRCDPDFHLVGSSRSICSQGQWSTPKPHCQVNRTPHSERRAVYIGALFPMSGGWPGGQACQPAVEMALEDVNSRRDILPDYELKLIHHDSKCDPGQATKYLYELLYNDPIKIILMPGCSSVSTLVAEAARMWNLIVLSYGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLFEKWGWKKIATIQQTTEVFTSTLDDLEERVKEAGIEITFRQSFFSDPAVPVKNLKRQDARIIVGLFYETEARKVFCEVYKERLFGKKYVWFLIGWYADNWFKIYDPSINCTVDEMTEAVEGHITTEIVMLNPANTRSISNMTSQEFVEKLTKRLKRHPEETGGFQEAPLAYDAIWALALALNKTSGGGGRSGVRLEDFNYNNQTITDQIYRAMNSSSFEGVSGHVVFDASGSRMAWTLIEQLQGGSYKKIGYYDSTKDDLSWSKTDKWIGGSPPADQTLVIKTFRFLSQKLFISVSVLSSLGIVLAVVCLSFNIYNSHVRYIQNSQPNLNNLTAVGCSLALAAVFPLGLDGYHIGRNQFPFVCQARLWLLGLGFSLGYGSMFTKIWWVHTVFTKKEEKKEWRKTLEPWKLYATVGLLVGMDVLTLAIWQIVDPLHRTIETFAKEEPKEDIDVSILPQLEHCSSRKMNTWLGIFYGYKGLLLLLGIFLAYETKSVSTEKINDHRAVGMAIYNVAVLCLITAPVTMILSSQQDAAFAFASLAIVFSSYITLVVLFVPKMRRLITRGEWQSEAQDTMKTGSSTNNNEEEKSRLLEKENRELEKIIAEKEERVSELRHQLQSRQQLRSRRHPPTPPEPSGGLPRGPPEPPDRLSCDGSRVHLLYK T42446 DRUGINFO D01AJY Baclofen Approved T42446 DRUGINFO D0EP8X Gamma Hydroxybutyric Acid Approved T42446 DRUGINFO D0J0ZS Gabapentin Approved T42446 DRUGINFO D0O5LA Progabide Approved T42446 DRUGINFO D0H5JW [3H](R)-(-)-baclofen Phase 3 T42446 DRUGINFO DV3H6T Arabaclofen Phase 3 T42446 DRUGINFO D0GX3L Arbaclofen placarbil Phase 3 T42446 DRUGINFO D01RBR SGS742 Phase 2 T42446 DRUGINFO D09YRA SSTarbaclofen Phase 2 T42446 DRUGINFO D0JM7Z ASP8062 Phase 2 T42446 DRUGINFO D0C9XA GSK683699 Phase 2 T42446 DRUGINFO D05VYJ SUN-09 Discontinued in Phase 3 T42446 DRUGINFO D03FFY AZD3355 Discontinued in Phase 2 T42446 DRUGINFO D01OYR AZD-9343 Discontinued in Phase 1 T42446 DRUGINFO D0B2RZ ADX-71943 Preclinical T42446 DRUGINFO D04KMO CGP-35348 Terminated T42446 DRUGINFO D0K9OL SCH 50911 Terminated T42446 DRUGINFO D00KXZ CGP 54626A Investigative T42446 DRUGINFO D00TYI TG-3030 Investigative T42446 DRUGINFO D02ALQ PMID25050158C14 Investigative T42446 DRUGINFO D02BBN 4-Amino-3-benzofuran-2-yl-butyric acid Investigative T42446 DRUGINFO D02HNM Phaclofen Investigative T42446 DRUGINFO D02WUY [125I]CGP 64213 Investigative T42446 DRUGINFO D03KZK CGP-34938 Investigative T42446 DRUGINFO D04LZJ (3-Amino-propyl)-phosphonic acid Investigative T42446 DRUGINFO D06NMP CGP-29030A Investigative T42446 DRUGINFO D06VMV BHF-177 Investigative T42446 DRUGINFO D06WWN AVE-1876 Investigative T42446 DRUGINFO D07KYZ GABA-B receptor PAM Investigative T42446 DRUGINFO D07YSJ (3-Amino-1-ethyl-propyl)-methyl-phosphinic acid Investigative T42446 DRUGINFO D08LFC CGP-35024 Investigative T42446 DRUGINFO D08PXU 4-Amino-3-(5-bromo-thiophen-2-yl)-butyric acid Investigative T42446 DRUGINFO D09IVS ((Z)-3-Amino-propenyl)-methyl-phosphinic acid Investigative T42446 DRUGINFO D09QOE CGP 55845 Investigative T42446 DRUGINFO D09WJO 4-Amino-3-thiophen-2-yl-butyric acid Investigative T42446 DRUGINFO D09YCW 4-Amino-3-(5-methyl-thiophen-2-yl)-butyric acid Investigative T42446 DRUGINFO D0AK9X 4-Amino-3-(5-chloro-thiophen-2-yl)-butyric acid Investigative T42446 DRUGINFO D0B8SE CGP 46381 Investigative T42446 DRUGINFO D0E0LI amino-propylphosphinic acid Investigative T42446 DRUGINFO D0E5QN CGP 71872 Investigative T42446 DRUGINFO D0E7YK (R)-5-Amino-3-(4-chloro-phenyl)-pentanoic acid Investigative T42446 DRUGINFO D0GK6Q [125I]CGP 71872 Investigative T42446 DRUGINFO D0H2IA CGP 56999A Investigative T42446 DRUGINFO D0H2LT 4-Amino-3-(2-chloro-phenyl)-butyric acid Investigative T42446 DRUGINFO D0H7KP (3-Amino-1-hydroxy-propyl)-methyl-phosphinic acid Investigative T42446 DRUGINFO D0J6PV CGP 47656 Investigative T42446 DRUGINFO D0L4CB CGP 64213 Investigative T42446 DRUGINFO D0N4WZ CGP-36216 Investigative T42446 DRUGINFO D0S5YH saclofen Investigative T42446 DRUGINFO D0T8SD 2-hydroxy-saclofen Investigative T42446 DRUGINFO D0U9XC (3-Amino-phenyl)-phosphonic acid diphenyl ester Investigative T42446 DRUGINFO D0V0LA CGP-35582 Investigative T42446 DRUGINFO D0VR3K 4-Amino-3-(4-fluoro-phenyl)-butyric acid Investigative T42446 DRUGINFO D0WZ9T CGP-44532 Investigative T42446 DRUGINFO D0XX9G (3-Amino-propyl)-hydroxymethyl-phosphinic acid Investigative T42446 DRUGINFO D0Y8YN (3-Amino-propyl)-hexyl-phosphinic acid Investigative T42446 DRUGINFO D0Z9QI CGP 62349 Investigative T42446 DRUGINFO D05WZL ((E)-3-Amino-propenyl)-methyl-phosphinic acid Investigative T42446 DRUGINFO D0N4EZ 3-ammoniopropane-1-sulfinate Investigative T42446 DRUGINFO D07BIF [3H]CGP27492 Investigative T33901 TARGETID T33901 T33901 FORMERID TTDS00328 T33901 UNIPROID NPCL1_HUMAN T33901 TARGNAME Niemann-Pick C1-like protein 1 (NPC1L1) T33901 GENENAME NPC1L1 T33901 TARGTYPE Successful T33901 SYNONYMS Niemann-Pick C1 Like 1; NPC1L1 T33901 FUNCTION Plays a major role in cholesterol homeostasis. Is critical for the uptake of cholesterol across the plasma membrane of the intestinal enterocyte. Is the direct molecular target of ezetimibe, a drug that inhibits cholesterol absorption. Lack of activity leads to multiple lipid transport defects. The protein may have a function in the transport of multiple lipids and their homeostasis, and may play a critical role in regulating lipid metabolism. Acts as a negative regulator of NPC2 and down- regulates its expression and secretion by inhibiting its maturation and accelerating its degradation. T33901 PDBSTRUC 3QNT T33901 SEQUENCE MAEAGLRGWLLWALLLRLAQSEPYTTIHQPGYCAFYDECGKNPELSGSLMTLSNVSCLSNTPARKITGDHLILLQKICPRLYTGPNTQACCSAKQLVSLEASLSITKALLTRCPACSDNFVNLHCHNTCSPNQSLFINVTRVAQLGAGQLPAVVAYEAFYQHSFAEQSYDSCSRVRVPAAATLAVGTMCGVYGSALCNAQRWLNFQGDTGNGLAPLDITFHLLEPGQAVGSGIQPLNEGVARCNESQGDDVATCSCQDCAASCPAIARPQALDSTFYLGQMPGSLVLIIILCSVFAVVTILLVGFRVAPARDKSKMVDPKKGTSLSDKLSFSTHTLLGQFFQGWGTWVASWPLTILVLSVIPVVALAAGLVFTELTTDPVELWSAPNSQARSEKAFHDQHFGPFFRTNQVILTAPNRSSYRYDSLLLGPKNFSGILDLDLLLELLELQERLRHLQVWSPEAQRNISLQDICYAPLNPDNTSLYDCCINSLLQYFQNNRTLLLLTANQTLMGQTSQVDWKDHFLYCANAPLTFKDGTALALSCMADYGAPVFPFLAIGGYKGKDYSEAEALIMTFSLNNYPAGDPRLAQAKLWEEAFLEEMRAFQRRMAGMFQVTFMAERSLEDEINRTTAEDLPIFATSYIVIFLYISLALGSYSSWSRVMVDSKATLGLGGVAVVLGAVMAAMGFFSYLGIRSSLVILQVVPFLVLSVGADNIFIFVLEYQRLPRRPGEPREVHIGRALGRVAPSMLLCSLSEAICFFLGALTPMPAVRTFALTSGLAVILDFLLQMSAFVALLSLDSKRQEASRLDVCCCVKPQELPPPGQGEGLLLGFFQKAYAPFLLHWITRGVVLLLFLALFGVSLYSMCHISVGLDQELALPKDSYLLDYFLFLNRYFEVGAPVYFVTTLGYNFSSEAGMNAICSSAGCNNFSFTQKIQYATEFPEQSYLAIPASSWVDDFIDWLTPSSCCRLYISGPNKDKFCPSTVNSLNCLKNCMSITMGSVRPSVEQFHKYLPWFLNDRPNIKCPKGGLAAYSTSVNLTSDGQVLDTVAILSPRLEYSGTISAHCNLYLLDSTSRFMAYHKPLKNSQDYTEALRAARELAANITADLRKVPGTDPAFEVFPYTITNVFYEQYLTILPEGLFMLSLCLVPTFAVSCLLLGLDLRSGLLNLLSIVMILVDTVGFMALWGISYNAVSLINLVSAVGMSVEFVSHITRSFAISTKPTWLERAKEATISMGSAVFAGVAMTNLPGILVLGLAKAQLIQIFFFRLNLLITLLGLLHGLVFLPVILSYVGPDVNPALALEQKRAEEAVAAVMVASCPNHPSRVSTADNIYVNHSFEGSIKGAGAISNFLPNNGRQF T33901 DRUGINFO D09LWS Ezetimibe Approved T33901 DRUGINFO D09XJH Ezetimibe-glucuronide Investigative T22839 TARGETID T22839 T22839 FORMERID TTDR00230 T22839 UNIPROID CELA1_HUMAN T22839 TARGNAME Pancreatic elastase 1 (CELA1) T22839 GENENAME CELA1 T22839 TARGTYPE Successful T22839 SYNONYMS Elastase; CELA1 T22839 FUNCTION Acts upon elastin. T22839 BIOCLASS Peptidase T22839 ECNUMBER EC 3.4.21.36 T22839 SEQUENCE MLVLYGHSTQDLPETNARVVGGTEAGRNSWPSQISLQYRSGGSRYHTCGGTLIRQNWVMTAAHCVDYQKTFRVVAGDHNLSQNDGTEQYVSVQKIVVHPYWNSDNVAAGYDIALLRLAQSVTLNSYVQLGVLPQEGAILANNSPCYITGWGKTKTNGQLAQTLQQAYLPSVDYAICSSSSYWGSTVKNTMVCAGGDGVRSGCQGDSGGPLHCLVNGKYSVHGVTSFVSSRGCNVSRKPTVFTQVSAYISWINNVIASN T22839 DRUGINFO D0K3VA Erdosteine Approved T22839 DRUGINFO D0I0DL Alpha 1-PI Approved T22839 DRUGINFO D0FT4R Sivelestat Phase 3 T22839 DRUGINFO D00AWA WIN-63759 Terminated T22839 DRUGINFO D0B3MV SSR-69071 Terminated T22839 DRUGINFO D0PQ3V SYN-1134 Terminated T22839 DRUGINFO D0V6LH PBI-1101 Terminated T22839 DRUGINFO D0O6GN Mdl 101,146 Terminated T22839 DRUGINFO D05UHB (Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine Investigative T22839 DRUGINFO D06RRT Acetyl-Pro-Ala-Pro-Ala-trifluoro methane Investigative T22839 DRUGINFO D08EBC (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE Investigative T22839 DRUGINFO D0D7HZ Para-Isopropylaniline Investigative T22839 DRUGINFO D0E9EH Acetyl-Ala-Ala-Pro-Ala-trifluromethane Investigative T22839 DRUGINFO D0W5EF MOLASSAMIDE Investigative T22839 DRUGINFO D0E1KX Dimethylformamide Investigative T22839 DRUGINFO D0Y5IQ Grassystatin a Investigative T22839 DRUGINFO D0F2ME Acetate Ion Investigative T71192 TARGETID T71192 T71192 FORMERID TTDS00183 T71192 UNIPROID CLTR1_HUMAN T71192 TARGNAME Leukotriene CysLT1 receptor (CYSLTR1) T71192 GENENAME CYSLTR1 T71192 TARGTYPE Successful T71192 SYNONYMS Leukotriene D4-receptor; LTD4 receptor; HMTMF81; HG55; G-protein coupled receptor HG55; Cysteinyl leukotriene receptor 1; Cysteinyl leukotriene D4 receptor; CysLTR1; CYSLT1 T71192 FUNCTION Stimulation by LTD4 results in the contraction and proliferation of smooth muscle, edema, eosinophil migration and damage to the mucus layer in the lung. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The rank order of affinities for the leukotrienes is LTD4 >> LTE4 = LTC4 >> LTB4. Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma. T71192 BIOCLASS GPCR rhodopsin T71192 SEQUENCE MDETGNLTVSSATCHDTIDDFRNQVYSTLYSMISVVGFFGNGFVLYVLIKTYHKKSAFQVYMINLAVADLLCVCTLPLRVVYYVHKGIWLFGDFLCRLSTYALYVNLYCSIFFMTAMSFFRCIAIVFPVQNINLVTQKKARFVCVGIWIFVILTSSPFLMAKPQKDEKNNTKCFEPPQDNQTKNHVLVLHYVSLFVGFIIPFVIIIVCYTMIILTLLKKSMKKNLSSHKKAIGMIMVVTAAFLVSFMPYHIQRTIHLHFLHNETKPCDSVLRMQKSVVITLSLAASNCCFDPLLYFFSGGNFRKRLSTFRKHSLSSVTYVPRKKASLPEKGEEICKV T71192 DRUGINFO D00QET Montelukast Approved T71192 DRUGINFO D05DVP Zafirlukast Approved T71192 DRUGINFO D06PEB Cinalukast Approved T71192 DRUGINFO D08QIP Pranlukast Approved T71192 DRUGINFO D0C2XI Claritin/Singulair Phase 3 T71192 DRUGINFO D05BHF Masilukast Phase 2 T71192 DRUGINFO D0OG6N LM-1507.NA Phase 2 T71192 DRUGINFO D0X9LK Iralukast Phase 2 T71192 DRUGINFO D07JKY KP-496 Phase 2 T71192 DRUGINFO D0GY0O BAY-X-7195 Phase 2 T71192 DRUGINFO D07ZUX CR-3465 Phase 1 T71192 DRUGINFO D0K2NA YM-57158 Phase 1 T71192 DRUGINFO D09DIG Ablukast Discontinued in Phase 3 T71192 DRUGINFO D04HHW FK-011 Discontinued in Phase 2 T71192 DRUGINFO D07GTB L-660771 Discontinued in Phase 2 T71192 DRUGINFO D09RON LY-2300559 Discontinued in Phase 2 T71192 DRUGINFO D0B6EU AS-35 Discontinued in Phase 2 T71192 DRUGINFO D0F4IG DS-4574 Discontinued in Phase 2 T71192 DRUGINFO D0G8UG Sulukast Discontinued in Phase 2 T71192 DRUGINFO D0B7KF RG-7152 Discontinued in Phase 1 T71192 DRUGINFO D00YOW LM-1376 Terminated T71192 DRUGINFO D0AB7G MCI-826 Terminated T71192 DRUGINFO D0J4EG L-648051 Terminated T71192 DRUGINFO D0PL5F OT-4003 Terminated T71192 DRUGINFO D0S8YL Tomelukast Terminated T71192 DRUGINFO D09ZVR MDL-43291 Terminated T71192 DRUGINFO D0D0XX LY-290154 Terminated T71192 DRUGINFO D0ZE5V FPL-55712 Terminated T71192 DRUGINFO D0J7UI ICI-198615 Terminated T71192 DRUGINFO D0R8IQ WY-46016 Investigative T71192 DRUGINFO D0X8PD XGP-510 Investigative T71192 DRUGINFO D03VGR N-methyl LTC4 Investigative T71192 DRUGINFO D04CZQ CGP-57698 Investigative T71192 DRUGINFO D05CNT BAYu9773 Investigative T71192 DRUGINFO D09JQU BayCysLT2 Investigative T71192 DRUGINFO D0G7OZ pobilukast Investigative T71192 DRUGINFO D03YBH LTD4 Investigative T71192 DRUGINFO D0EW6H LTC4 Investigative T71192 DRUGINFO D0C0KJ LTE4 Investigative T43739 TARGETID T43739 T43739 FORMERID TTDS00514 T43739 UNIPROID SCNAA_HUMAN T43739 TARGNAME Voltage-gated sodium channel alpha Nav1.8 (SCN10A) T43739 GENENAME SCN10A T43739 TARGTYPE Successful T43739 SYNONYMS hPN3; Voltage-gated sodium channel subunit alpha Nav1.8; Sodium channel protein type X subunit alpha; Sodium channel protein type 10 subunit alpha; Peripheral nerve sodium channel 3; PN3 T43739 FUNCTION Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms. T43739 BIOCLASS Voltage-gated ion channel T43739 SEQUENCE MEFPIGSLETNNFRRFTPESLVEIEKQIAAKQGTKKAREKHREQKDQEEKPRPQLDLKACNQLPKFYGELPAELIGEPLEDLDPFYSTHRTFMVLNKGRTISRFSATRALWLFSPFNLIRRTAIKVSVHSWFSLFITVTILVNCVCMTRTDLPEKIEYVFTVIYTFEALIKILARGFCLNEFTYLRDPWNWLDFSVITLAYVGTAIDLRGISGLRTFRVLRALKTVSVIPGLKVIVGALIHSVKKLADVTILTIFCLSVFALVGLQLFKGNLKNKCVKNDMAVNETTNYSSHRKPDIYINKRGTSDPLLCGNGSDSGHCPDGYICLKTSDNPDFNYTSFDSFAWAFLSLFRLMTQDSWERLYQQTLRTSGKIYMIFFVLVIFLGSFYLVNLILAVVTMAYEEQNQATTDEIEAKEKKFQEALEMLRKEQEVLAALGIDTTSLHSHNGSPLTSKNASERRHRIKPRVSEGSTEDNKSPRSDPYNQRRMSFLGLASGKRRASHGSVFHFRSPGRDISLPEGVTDDGVFPGDHESHRGSLLLGGGAGQQGPLPRSPLPQPSNPDSRHGEDEHQPPPTSELAPGAVDVSAFDAGQKKTFLSAEYLDEPFRAQRAMSVVSIITSVLEELEESEQKCPPCLTSLSQKYLIWDCCPMWVKLKTILFGLVTDPFAELTITLCIVVNTIFMAMEHHGMSPTFEAMLQIGNIVFTIFFTAEMVFKIIAFDPYYYFQKKWNIFDCIIVTVSLLELGVAKKGSLSVLRSFRLLRVFKLAKSWPTLNTLIKIIGNSVGALGNLTIILAIIVFVFALVGKQLLGENYRNNRKNISAPHEDWPRWHMHDFFHSFLIVFRILCGEWIENMWACMEVGQKSICLILFLTVMVLGNLVVLNLFIALLLNSFSADNLTAPEDDGEVNNLQVALARIQVFGHRTKQALCSFFSRSCPFPQPKAEPELVVKLPLSSSKAENHIAANTARGSSGGLQAPRGPRDEHSDFIANPTVWVSVPIAEGESDLDDLEDDGGEDAQSFQQEVIPKGQQEQLQQVERCGDHLTPRSPGTGTSSEDLAPSLGETWKDESVPQVPAEGVDDTSSSEGSTVDCLDPEEILRKIPELADDLEEPDDCFTEGCIRHCPCCKLDTTKSPWDVGWQVRKTCYRIVEHSWFESFIIFMILLSSGSLAFEDYYLDQKPTVKALLEYTDRVFTFIFVFEMLLKWVAYGFKKYFTNAWCWLDFLIVNISLISLTAKILEYSEVAPIKALRTLRALRPLRALSRFEGMRVVVDALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFWRCINYTDGEFSLVPLSIVNNKSDCKIQNSTGSFFWVNVKVNFDNVAMGYLALLQVATFKGWMDIMYAAVDSREVNMQPKWEDNVYMYLYFVIFIIFGGFFTLNLFVGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKFQGFVFDIVTRQAFDITIMVLICLNMITMMVETDDQSEEKTKILGKINQFFVAVFTGECVMKMFALRQYYFTNGWNVFDFIVVVLSIASLIFSAILKSLQSYFSPTLFRVIRLARIGRILRLIRAAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMSSFPHVRWEAGIDDMFNFQTFANSMLCLFQITTSAGWDGLLSPILNTGPPYCDPNLPNSNGTRGDCGSPAVGIIFFTTYIIISFLIMVNMYIAVILENFNVATEESTEPLSEDDFDMFYETWEKFDPEATQFITFSALSDFADTLSGPLRIPKPNRNILIQMDLPLVPGDKIHCLDILFAFTKNVLGESGELDSLKANMEEKFMATNLSKSSYEPIATTLRWKQEDISATVIQKAYRSYVLHRSMALSNTPCVPRAEEEAASLPDEGFVAFTANENCVLPDKSETASATSFPPSYESVTRGLSDRVNMRTSSSIQNEDEATSMELIAPGP T43739 DRUGINFO D08HQK Tetracaine Approved T43739 DRUGINFO D09RHQ Ropivacaine Approved T43739 DRUGINFO D0A0FL Bupivacaine Approved T43739 DRUGINFO D0Q7ZG Proparacaine Approved T43739 DRUGINFO D02LCR Tiapride Approved T43739 DRUGINFO D0T6WN Rilpivirine Approved T43739 DRUGINFO D01KWJ VX-150 Phase 2 T43739 DRUGINFO D00WME Conatumumab Phase 2 T43739 DRUGINFO D04JZH PF-01247324 Phase 1 T43739 DRUGINFO D0V5HA VX-128 Phase 1 T43739 DRUGINFO D0VE7B DSP-2230 Phase 1 T43739 DRUGINFO D08FZT Corus 1030 Discontinued in Phase 2 T43739 DRUGINFO D0EC2K SIPATRIGINE Discontinued in Phase 2 T43739 DRUGINFO D01EQU SCH-725739 Investigative T43739 DRUGINFO D02CQN 5-(4-chlorophenyl)-N-(2-methylbenzyl)nicotinamide Investigative T43739 DRUGINFO D09ZUM CR-4892 Investigative T43739 DRUGINFO D0F5WY SCH-725737 Investigative T43739 DRUGINFO D0FF6S A-803467 Investigative T43739 DRUGINFO D0O0JO N-(2-chlorobenzyl)-5-(4-chlorophenyl)nicotinamide Investigative T43739 DRUGINFO D0W2BP N-benzyl-5-(4-chlorophenyl)nicotinamide Investigative T43739 DRUGINFO D01AGR 1-[5-(4-Chlorophenyl)-2-furoyl]piperazine Investigative T43739 DRUGINFO D0B9UU BW-202W92 Investigative T43739 DRUGINFO D08RJC PD-32577 Investigative T43739 DRUGINFO D0G9WE batrachotoxin Investigative T43739 DRUGINFO D0S4MN veratridine Investigative T09507 TARGETID T09507 T09507 FORMERID TTDR01360 T09507 UNIPROID APOB_HUMAN T09507 TARGNAME APOB messenger RNA (APOB mRNA) T09507 GENENAME APOB T09507 TARGTYPE Successful T09507 SYNONYMS Apolipoprotein B48 (mRNA); Apolipoprotein B-100 (mRNA); Apo B48 (mRNA); Apo B100 (mRNA); Apo B-100 (mRNA) T09507 FUNCTION Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). T09507 BIOCLASS mRNA target T09507 SEQUENCE MDPPRPALLALLALPALLLLLLAGARAEEEMLENVSLVCPKDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKVELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEEFAAAMSRYELKLAIPEGKQVFLYPEKDEPTYILNIKRGIISALLVPPETEEAKQVLFLDTVYGNCSTHFTVKTRKGNVATEISTERDLGQCDRFKPIRTGISPLALIKGMTRPLSTLISSSQSCQYTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMVAQVTQTLKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPKQAEAVLKTLQELKKLTISEQNIQRANLFNKLVTELRGLSDEAVTSLLPQLIEVSSPITLQALVQCGQPQCSTHILQWLKRVHANPLLIDVVTYLVALIPEPSAQQLREIFNMARDQRSRATLYALSHAVNNYHKTNPTGTQELLDIANYLMEQIQDDCTGDEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPSLMIQKAAIQALRKMEPKDKDQEVLLQTFLDDASPGDKRLAAYLMLMRSPSQADINKIVQILPWEQNEQVKNFVASHIANILNSEELDIQDLKKLVKEALKESQLPTVMDFRKFSRNYQLYKSVSLPSLDPASAKIEGNLIFDPNNYLPKESMLKTTLTAFGFASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALYWVNGQVPDGVSKVLVDHFGYTKDDKHEQDMVNGIMLSVEKLIKDLKSKEVPEARAYLRILGEELGFASLHDLQLLGKLLLMGARTLQGIPQMIGEVIRKGSKNDFFLHYIFMENAFELPTGAGLQLQISSSGVIAPGAKAGVKLEVANMQAELVAKPSVSVEFVTNMGIIIPDFARSGVQMNTNFFHESGLEAHVALKAGKLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENRQSWSVCKQVFPGLNYCTSGAYSNASSTDSASYYPLTGDTRLELELRPTGEIEQYSVSATYELQREDRALVDTLKFVTQAEGAKQTEATMTFKYNRQSMTLSSEVQIPDFDVDLGTILRVNDESTEGKTSYRLTLDIQNKKITEVALMGHLSCDTKEERKIKGVISIPRLQAEARSEILAHWSPAKLLLQMDSSATAYGSTVSKRVAWHYDEEKIEFEWNTGTNVDTKKMTSNFPVDLSDYPKSLHMYANRLLDHRVPQTDMTFRHVGSKLIVAMSSWLQKASGSLPYTQTLQDHLNSLKEFNLQNMGLPDFHIPENLFLKSDGRVKYTLNKNSLKIEIPLPFGGKSSRDLKMLETVRTPALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDLSTNVYSNLYNWSASYSGGNTSTDHFSLRARYHMKADSVVDLLSYNVQGSGETTYDHKNTFTLSYDGSLRHKFLDSNIKFSHVEKLGNNPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHLFVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGESNLRFNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTASLKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRSEYQADYESLRFFSLLSGSLNSHGLELNADILGTDKINSGAHKATLRIGQDGISTSATTNLKCSLLVLENELNAELGLSGASMKLTTNGRFREHNAKFSLDGKAALTELSLGSAYQAMILGVDSKNIFNFKVSQEGLKLSNDMMGSYAEMKFDHTNSLNIAGLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTLNSDLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIYAISSAALSASYKADTVAKVQGVEFSHRLNTDIAGLASAIDMSTNYNSDSLHFSNVFRSVMAPFTMTIDAHTNGNGKLALWGEHTGQLYSKFLLKAEPLAFTFSHDYKGSTSHHLVSRKSISAALEHKVSALLTPAEQTGTWKLKTQFNNNEYSQDLDAYNTKDKIGVELTGRTLADLTLLDSPIKVPLLLSEPINIIDALEMRDAVEKPQEFTIVAFVKYDKNQDVHSINLPFFETLQEYFERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLPQQANDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIALDDAKINFNEKLSQLQTYMIQFDQYIKDSYDLHDLKIAIANIIDEIIEKLKSLDEHYHIRVNLVKTIHDLHLFIENIDFNKSGSSTASWIQNVDTKYQIRIQIQEKLQQLKRHIQNIDIQHLAGKLKQHIEAIDVRVLLDQLGTTISFERINDILEHVKHFVINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMDKLVELAHQYKLKETIQKLSNVLQQVKIKDYFEKLVGFIDDAVKKLNELSFKTFIEDVNKFLDMLIKKLKSFDYHQFVDETNDKIREVTQRLNGEIQALELPQKAEALKLFLEETKATVAVYLESLQDTKITLIINWLQEALSSASLAHMKAKFRETLEDTRDRMYQMDIQQELQRYLSLVGQVYSTLVTYISDWWTLAAKNLTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILGTMPAFEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIKIPSRFSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNSELQWPVPDIYLRDLKVEDIPLARITLPDFRLPEIAIPEFIIPTLNLNDFQVPDLHIPEFQLPHISHTIEVPTFGKLYSILKIQSPLFTLDANADIGNGTTSANEAGIAASITAKGESKLEVLNFDFQANAQLSNPKINPLALKESVKFSSKYLRTEHGSEMLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQLTLDSNTKYFHKLNIPKLDFSSQADLRNEIKTLLKAGHIAWTSSGKGSWKWACPRFSDEGTHESQISFTIEGPLTSFGLSNKINSKHLRVNQNLVYESGSLNFSKLEIQSQVDSQHVGHSVLTAKGMALFGEGKAEFTGRHDAHLNGKVIGTLKNSLFFSAQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALFLSPSAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGEANLDFLNIPLTIPEMRLPYTIITTPPLKDFSLWEKTGLKEFLKTTKQSFDLSVKAQYKKNKHRHSITNPLAVLCEFISQSIKSFDRHFEKNRNNALDFVTKSYNETKIKFDKYKAEKSHDELPRTFQIPGYTVPVVNVEVSPFTIEMSAFGYVFPKAVSMPSFSILGSDVRVPSYTLILPSLELPVLHVPRNLKLSLPDFKELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQSDIVAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALSLSNKFVEGSHNSTVSLTTKNMEVSVATTTKAQIPILRMNFKQELNGNTKSKPTVSSSMEFKYDFNSSMLYSTAKGAVDHKLSLESLTSYFSIESSTKGDVKGSVLSREYSGTIASEANTYLNSKSTRSSVKLQGTSKIDDIWNLEVKENFAGEATLQRIYSLWEHSTKNHLQLEGLFFTNGEHTSKATLELSPWQMSALVQVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRIHSGSFQSQVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVYDKSLWDFLKLDVTTSIGRRQHLRVSTAFVYTKNPNGYSFSIPVKVLADKFIIPGLKLNDLNSVLVMPTFHVPFTDLQVPSCKLDFREIQIYKKLRTSSFALNLPTLPEVKFPEVDVLTKYSQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAALDLNAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQALTARFEVDSPVYNATWSASLKNKADYVETVLDSTCSSTVQFLEYELNVLGTHKIEDGTLASKTKGTFAHRDFSAEYEEDGKYEGLQEWEGKAHLNIKSPAFTDLHLRYQKDKKGISTSAASPAVGTVGMDMDEDDDFSKWNFYYSPQSSPDKKLTIFKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVPKATGVLYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWVYQGAIRQIDDIDVRFQKAASGTTGTYQEWKDKAQNLYQELLTQEGQASFQGLKDNVFDGLVRVTQEFHMKVKHLIDSLIDFLNFPRFQFPGKPGIYTREELCTMFIREVGTVLSQVYSKVHNGSEILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEAQEVFKAIQSLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEMKFTYLINYIQDEINTIFSDYIPYVFKLLKENLCLNLHKFNEFIQNELQEASQELQQIHQYIMALREEYFDPSIVGWTVKYYELEEKIVSLIKNLLVALKDFHSEYIVSASNFTSQLSSQVEQFLHRNIQEYLSILTDPDGKGKEKIAELSATAQEIIKSQAIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRLIDLSIQNYHTFLIYITELLKKLQSTTVMNPYMKLAPGELTIIL T09507 DRUGINFO D08CVQ Mipomersen Approved T09507 DRUGINFO D04VOZ TKM-ApoB Phase 4 T09507 DRUGINFO D09YRP ISIS 147788 Investigative T09507 DRUGINFO D0S3JF ISIS 147483 Investigative T34949 TARGETID T34949 T34949 FORMERID TTDR00199 T34949 UNIPROID CAC1A_HUMAN T34949 TARGNAME Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) T34949 GENENAME CACNA1A T34949 TARGTYPE Successful T34949 SYNONYMS Voltage-gated calcium channel alpha subunit Cav2.1; Voltage-dependent P/Q-type calcium channel; RBA-I; RAT brain class A; Calcium channel, L type, alpha-1 polypeptide, isoform 4; Calcium channel, L type, alpha-1 polypeptide isoform 4; CACNA1A; Brain calcium channel I; BI T34949 FUNCTION Voltage-sensitive calcium channels (vscc) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release and gene expression. T34949 PDBSTRUC 3BXK T34949 BIOCLASS Voltage-gated ion channel T34949 SEQUENCE MARFGDEMPARYGGGGSGAAAGVVVGSGGGRGAGGSRQGGQPGAQRMYKQSMAQRARTMALYNPIPVRQNCLTVNRSLFLFSEDNVVRKYAKKITEWPPFEYMILATIIANCIVLALEQHLPDDDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFAFHKGSYLRNGWNVMDFVVVLTGILATVGTEFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMIPLLQIGLLLFFAILIFAIIGLEFYMGKFHTTCFEEGTDDIQGESPAPCGTEEPARTCPNGTKCQPYWEGPNNGITQFDNILFAVLTVFQCITMEGWTDLLYNSNDASGNTWNWLYFIPLIIIGSFFMLNLVLGVLSGEFAKERERVENRRAFLKLRRQQQIERELNGYMEWISKAEEVILAEDETDGEQRHPFDALRRTTIKKSKTDLLNPEEAEDQLADIASVGSPFARASIKSAKLENSTFFHKKERRMRFYIRRMVKTQAFYWTVLSLVALNTLCVAIVHYNQPEWLSDFLYYAEFIFLGLFMSEMFIKMYGLGTRPYFHSSFNCFDCGVIIGSIFEVIWAVIKPGTSFGISVLRALRLLRIFKVTKYWASLRNLVVSLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFDEGTPPTNFDTFPAAIMTVFQILTGEDWNEVMYDGIKSQGGVQGGMVFSIYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTKDEQEEEEAANQKLALQKAKEVAEVSPLSAANMSIAVKEQQKNQKPAKSVWEQRTSEMRKQNLLASREALYNEMDPDERWKAAYTRHLRPDMKTHLDRPLVVDPQENRNNNTNKSRAAEPTVDQRLGQQRAEDFLRKQARYHDRARDPSGSAGLDARRPWAGSQEAELSREGPYGRESDHHAREGSLEQPGFWEGEAERGKAGDPHRRHVHRQGGSRESRSGSPRTGADGEHRRHRAHRRPGEEGPEDKAERRARHREGSRPARGGEGEGEGPDGGERRRRHRHGAPATYEGDARREDKERRHRRRKENQGSGVPVSGPNLSTTRPIQQDLGRQDPPLAEDIDNMKNNKLATAESAAPHGSLGHAGLPQSPAKMGNSTDPGPMLAIPAMATNPQNAASRRTPNNPGNPSNPGPPKTPENSLIVTNPSGTQTNSAKTARKPDHTTVDIPPACPPPLNHTVVQVNKNANPDPLPKKEEEKKEEEEDDRGEDGPKPMPPYSSMFILSTTNPLRRLCHYILNLRYFEMCILMVIAMSSIALAAEDPVQPNAPRNNVLRYFDYVFTGVFTFEMVIKMIDLGLVLHQGAYFRDLWNILDFIVVSGALVAFAFTGNSKGKDINTIKSLRVLRVLRPLKTIKRLPKLKAVFDCVVNSLKNVFNILIVYMLFMFIFAVVAVQLFKGKFFHCTDESKEFEKDCRGKYLLYEKNEVKARDREWKKYEFHYDNVLWALLTLFTVSTGEGWPQVLKHSVDATFENQGPSPGYRMEMSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKMMEEYSLEKNERACIDFAISAKPLTRHMPQNKQSFQYRMWQFVVSPPFEYTIMAMIALNTIVLMMKFYGASVAYENALRVFNIVFTSLFSLECVLKVMAFGILNYFRDAWNIFDFVTVLGSITDILVTEFGNNFINLSFLRLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQVFGNIGIDVEDEDSDEDEFQITEHNNFRTFFQALMLLFRSATGEAWHNIMLSCLSGKPCDKNSGILTRECGNEFAYFYFVSFIFLCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEYVRVWAEYDPAAWGRMPYLDMYQMLRHMSPPLGLGKKCPARVAYKRLLRMDLPVADDNTVHFNSTLMALIRTALDIKIAKGGADKQQMDAELRKEMMAIWPNLSQKTLDLLVTPHKSTDLTVGKIYAAMMIMEYYRQSKAKKLQAMREEQDRTPLMFQRMEPPSPTQEGGPGQNALPSTQLDPGGALMAHESGLKESPSWVTQRAQEMFQKTGTWSPEQGPPTDMPNSQPNSQSVEMREMGRDGYSDSEHYLPMEGQGRAASMPRLPAENQRRRGRPRGNNLSTISDTSPMKRSASVLGPKARRLDDYSLERVPPEENQRHHQRRRDRSHRASERSLGRYTDVDTGLGTDLSMTTQSGDLPSKERDQERGRPKDRKHRQHHHHHHHHHHPPPPDKDRYAQERPDHGRARARDQRWSRSPSEGREHMAHRQGSSSVSGSPAPSTSGTSTPRRGRRQLPQTPSTPRPHVSYSPVIRKAGGSGPPQQQQQQQQQQQQQAVARPGRAATSGPRRYPGPTAEPLAGDRPPTGGHSSGRSPRMERRVPGPARSESPRACRHGGARWPASGPHVSEGPPGPRHHGYYRGSDYDEADGPGSGGGEEAMAGAYDAPPPVRHASSGATGRSPRTPRASGPACASPSRHGRRLPNGYYPAHGLARPRGPGSRKGLHEPYSESDDDWC T34949 DRUGINFO D05CEU Flunarizine Approved T34949 DRUGINFO D0A3MJ XEN007 Phase 1 T34949 DRUGINFO D0QQ7N TH-9229 Terminated T34949 DRUGINFO D0N1MY Alpha-eudesmol Investigative T34949 DRUGINFO D09LRA omega-conotoxin GVIA Investigative T34949 DRUGINFO D09YTH CPU-228 Investigative T27376 TARGETID T27376 T27376 FORMERID TTDI01909 T27376 UNIPROID GBRD_HUMAN T27376 TARGNAME GABA(A) receptor delta (GABRD) T27376 GENENAME GABRD T27376 TARGTYPE Successful T27376 SYNONYMS Gammaaminobutyric acid receptor subunit delta; GABRD; GABA(A) receptor subunit delta T27376 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. T27376 BIOCLASS Ligand-gated ion channel T27376 SEQUENCE MDAPARLLAPLLLLCAQQLRGTRAMNDIGDYVGSNLEISWLPNLDGLIAGYARNFRPGIGGPPVNVALALEVASIDHISEANMEYTMTVFLHQSWRDSRLSYNHTNETLGLDSRFVDKLWLPDTFIVNAKSAWFHDVTVENKLIRLQPDGVILYSIRITSTVACDMDLAKYPMDEQECMLDLESYGYSSEDIVYYWSESQEHIHGLDKLQLAQFTITSYRFTTELMNFKSAGQFPRLSLHFHLRRNRGVYIIQSYMPSVLLVAMSWVSFWISQAAVPARVSLGITTVLTMTTLMVSARSSLPRASAIKALDVYFWICYVFVFAALVEYAFAHFNADYRKKQKAKVKVSRPRAEMDVRNAIVLFSLSAAGVTQELAISRRQRRVPGNLMGSYRSVGVETGETKKEGAARSGGQGGIRARLRPIDADTIDIYARAVFPAAFAAVNVIYWAAYAM T27376 DRUGINFO D00EEL Gaboxadol Approved T27376 DRUGINFO D00VZZ Allopregnanolone approved T27376 DRUGINFO D05PDJ SAGE-217b Phase 2 T27376 DRUGINFO D00AJI PF-4480682 Discontinued in Phase 2 T27376 DRUGINFO D0T2QN PF-2393296 Discontinued in Phase 1 T27376 DRUGINFO D03ZGV Co-60549 Terminated T27376 DRUGINFO D0SE4D Org-20599 Terminated T27376 DRUGINFO D04TVU RU-5135 Investigative T27376 DRUGINFO D0P0TI TBPS Investigative T56262 TARGETID T56262 T56262 UNIPROID TPP1_HUMAN T56262 TARGNAME Tripeptidyl-peptidase I (TPP1) T56262 GENENAME TPP1 T56262 TARGTYPE Successful T56262 SYNONYMS TPP1 T56262 FUNCTION Lysosomal serine protease with tripeptidyl-peptidase I activity. May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases. Requires substrates with an unsubstituted N-terminus. T56262 PDBSTRUC 3EE6; 3EDY; 1R60 T56262 BIOCLASS Peptidase T56262 ECNUMBER EC 3.4.14.9 T56262 SEQUENCE MGLQACLLGLFALILSGKCSYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP T56262 DRUGINFO D06CAS Cerliponase Alfa Approved T56262 DRUGINFO DZ1XV8 LX1004 Phase 1/2 T02777 TARGETID T02777 T02777 FORMERID TTDS00332 T02777 UNIPROID ABCC9_HUMAN T02777 TARGNAME ATP-binding cassette transporter C9 (ABCC9) T02777 GENENAME ABCC9 T02777 TARGTYPE Successful T02777 SYNONYMS Sulfonylurea receptor 2; SUR2; ATP-binding cassette sub-family C member 9 T02777 FUNCTION Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation. T02777 BIOCLASS ABC transporter T02777 SEQUENCE MSLSFCGNNISSYNINDGVLQNSCFVDALNLVPHVFLLFITFPILFIGWGSQSSKVQIHHNTWLHFPGHNLRWILTFALLFVHVCEIAEGIVSDSRRESRHLHLFMPAVMGFVATTTSIVYYHNIETSNFPKLLLALFLYWVMAFITKTIKLVKYCQSGLDISNLRFCITGMMVILNGLLMAVEINVIRVRRYVFFMNPQKVKPPEDLQDLGVRFLQPFVNLLSKATYWWMNTLIISAHKKPIDLKAIGKLPIAMRAVTNYVCLKDAYEEQKKKVADHPNRTPSIWLAMYRAFGRPILLSSTFRYLADLLGFAGPLCISGIVQRVNETQNGTNNTTGISETLSSKEFLENAYVLAVLLFLALILQRTFLQASYYVTIETGINLRGALLAMIYNKILRLSTSNLSMGEMTLGQINNLVAIETNQLMWFLFLCPNLWAMPVQIIMGVILLYNLLGSSALVGAAVIVLLAPIQYFIATKLAEAQKSTLDYSTERLKKTNEILKGIKLLKLYAWEHIFCKSVEETRMKELSSLKTFALYTSLSIFMNAAIPIAAVLATFVTHAYASGNNLKPAEAFASLSLFHILVTPLFLLSTVVRFAVKAIISVQKLNEFLLSDEIGDDSWRTGESSLPFESCKKHTGVQPKTINRKQPGRYHLDSYEQSTRRLRPAETEDIAIKVTNGYFSWGSGLATLSNIDIRIPTGQLTMIVGQVGCGKSSLLLAILGEMQTLEGKVHWSNVNESEPSFEATRSRNRYSVAYAAQKPWLLNATVEENITFGSPFNKQRYKAVTDACSLQPDIDLLPFGDQTEIGERGINLSGGQRQRICVARALYQNTNIVFLDDPFSALDIHLSDHLMQEGILKFLQDDKRTLVLVTHKLQYLTHADWIIAMKDGSVLREGTLKDIQTKDVELYEHWKTLMNRQDQELEKDMEADQTTLERKTLRRAMYSREAKAQMEDEDEEEEEEEDEDDNMSTVMRLRTKMPWKTCWRYLTSGGFFLLILMIFSKLLKHSVIVAIDYWLATWTSEYSINNTGKADQTYYVAGFSILCGAGIFLCLVTSLTVEWMGLTAAKNLHHNLLNKIILGPIRFFDTTPLGLILNRFSADTNIIDQHIPPTLESLTRSTLLCLSAIGMISYATPVFLVALLPLGVAFYFIQKYFRVASKDLQELDDSTQLPLLCHFSETAEGLTTIRAFRHETRFKQRMLELTDTNNIAYLFLSAANRWLEVRTDYLGACIVLTASIASISGSSNSGLVGLGLLYALTITNYLNWVVRNLADLEVQMGAVKKVNSFLTMESENYEGTMDPSQVPEHWPQEGEIKIHDLCVRYENNLKPVLKHVKAYIKPGQKVGICGRTGSGKSSLSLAFFRMVDIFDGKIVIDGIDISKLPLHTLRSRLSIILQDPILFSGSIRFNLDPECKCTDDRLWEALEIAQLKNMVKSLPGGLDAVVTEGGENFSVGQRQLFCLARAFVRKSSILIMDEATASIDMATENILQKVVMTAFADRTVVTIAHRVSSIMDAGLVLVFSEGILVECDTVPNLLAHKNGLFSTLVMTNK T02777 DRUGINFO D0O2SR Nicorandil Approved T02777 DRUGINFO D06OIV Tolbutamide Approved T02777 DRUGINFO D0B2GI Glimepiride Approved T02777 DRUGINFO D0N5YA Repaglinide Approved T02777 DRUGINFO D0P2MH BTS-67582 Discontinued in Phase 2 T02777 DRUGINFO D0S6SU KRN-2391 Discontinued in Phase 2 T02777 DRUGINFO D04JGA BMS-191095 Discontinued in Phase 1 T02777 DRUGINFO D0MT0A CCX915 Discontinued in Phase 1 T20808 TARGETID T20808 T20808 FORMERID TTDI02095 T20808 UNIPROID IDHC_HUMAN; IDHP_HUMAN; IDH3A_HUMAN; IDH3B_HUMAN; IDH3G_HUMAN T20808 TARGNAME Isocitrate dehydrogenase (IDH) T20808 GENENAME IDH1; IDH2; IDH3A; IDH3B; IDH3G T20808 TARGTYPE Successful T20808 SYNONYMS Isocitrate dehydrogenase [NAD] T20808 FUNCTION It may tightly associate or interact with the pyruvate dehydrogenase complex. Plays a role in intermediary metabolism and energy production. T20808 BIOCLASS CH-OH donor oxidoreductase T20808 SEQUENCE MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGRHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL T20808 DRUGINFO D0WH4P ENASIDENIB MESYLATE Approved T20808 DRUGINFO D0K7FT AG-221 Phase 3 T20808 DRUGINFO D0K9PC AG-881 Phase 3 T34843 TARGETID T34843 T34843 FORMERID TTDNS00544 T34843 UNIPROID GLP2R_HUMAN T34843 TARGNAME Glucagon-like peptide 2 receptor (GLP2R) T34843 GENENAME GLP2R T34843 TARGTYPE Successful T34843 SYNONYMS GLP2R; GLP2 receptor T34843 FUNCTION This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. T34843 BIOCLASS GPCR secretin T34843 SEQUENCE MKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVSIKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPSYLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQLMYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYSKRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLWPRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLKILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFIQLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKKLSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTMANTMEEILEESEI T34843 DRUGINFO D00RCI Teduglutide Approved T34843 DRUGINFO D0EV1L Elsiglutide Phase 2 T34843 DRUGINFO D01JWH SAN-134 Phase 1 T34843 DRUGINFO D09NVU ZP-1848 Phase 1 T34843 DRUGINFO D0L2VB FE-203799 Investigative T34843 DRUGINFO D0P3PF AMX-256 Investigative T33425 TARGETID T33425 T33425 FORMERID TTDI01986 T33425 UNIPROID EGF_HUMAN T33425 TARGNAME Epidermal growth factor (EGF) T33425 GENENAME EGF T33425 TARGTYPE Successful T33425 SYNONYMS Proepidermal growth factor; Pro-epidermal growth factor T33425 FUNCTION Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro. EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. T33425 PDBSTRUC 3NJP; 2KV4; 1P9J; 1NQL; 1JL9 T33425 BIOCLASS Growth factor T33425 SEQUENCE MLLTLIILLPVVSKFSFVSLSAPQHWSCPEGTLAGNGNSTCVGPAPFLIFSHGNSIFRIDTEGTNYEQLVVDAGVSVIMDFHYNEKRIYWVDLERQLLQRVFLNGSRQERVCNIEKNVSGMAINWINEEVIWSNQQEGIITVTDMKGNNSHILLSALKYPANVAVDPVERFIFWSSEVAGSLYRADLDGVGVKALLETSEKITAVSLDVLDKRLFWIQYNREGSNSLICSCDYDGGSVHISKHPTQHNLFAMSLFGDRIFYSTWKMKTIWIANKHTGKDMVRINLHSSFVPLGELKVVHPLAQPKAEDDTWEPEQKLCKLRKGNCSSTVCGQDLQSHLCMCAEGYALSRDRKYCEDVNECAFWNHGCTLGCKNTPGSYYCTCPVGFVLLPDGKRCHQLVSCPRNVSECSHDCVLTSEGPLCFCPEGSVLERDGKTCSGCSSPDNGGCSQLCVPLSPVSWECDCFPGYDLQLDEKSCAASGPQPFLLFANSQDIRHMHFDGTDYGTLLSQQMGMVYALDHDPVENKIYFAHTALKWIERANMDGSQRERLIEEGVDVPEGLAVDWIGRRFYWTDRGKSLIGRSDLNGKRSKIITKENISQPRGIAVHPMAKRLFWTDTGINPRIESSSLQGLGRLVIASSDLIWPSGITIDFLTDKLYWCDAKQSVIEMANLDGSKRRRLTQNDVGHPFAVAVFEDYVWFSDWAMPSVMRVNKRTGKDRVRLQGSMLKPSSLVVVHPLAKPGADPCLYQNGGCEHICKKRLGTAWCSCREGFMKASDGKTCLALDGHQLLAGGEVDLKNQVTPLDILSKTRVSEDNITESQHMLVAEIMVSDQDDCAPVGCSMYARCISEGEDATCQCLKGFAGDGKLCSDIDECEMGVPVCPPASSKCINTEGGYVCRCSEGYQGDGIHCLDIDECQLGEHSCGENASCTNTEGGYTCMCAGRLSEPGLICPDSTPPPHLREDDHHYSVRNSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELRHAGHGQQQKVIVVAVCVVVLVMLLLLSLWGAHYYRTQKLLSKNPKNPYEESSRDVRSRRPADTEDGMSSCPQPWFVVIKEHQDLKNGGQPVAGEDGQAADGSMQPTSWRQEPQLCGMGTEQGCWIPVSSDKGSCPQVMERSFHMPSYGTQTLEGGVEKPHSLLSANPLWQQRALDPPHQMELTQ T33425 DRUGINFO D08TPS Epidermal growth factor Approved T33425 DRUGINFO D09SBY Hebervis Investigative T18950 TARGETID T18950 T18950 FORMERID TTDS00244 T18950 UNIPROID GON1_HUMAN T18950 TARGNAME Leutinizing-hormone-releasing hormone (GNRH1) T18950 GENENAME GNRH1 T18950 TARGTYPE Successful T18950 SYNONYMS Progonadoliberin-1; Progonadoliberin I; LHRH; GRH; GNRH T18950 FUNCTION Stimulates the secretion of gonadotropins; it stimulates the secretion of both luteinizing and follicle-stimulating hormones. T18950 PDBSTRUC 4D5M T18950 BIOCLASS Gonadotropin-releasing hormone T18950 SEQUENCE MKPIQKLLAGLILLTWCVEGCSSQHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAETQRFECTTHQPRSPLRDLKGALESLIEEETGQKKI T18950 DRUGINFO D00BCG Goserelin Approved T18950 DRUGINFO D0U5FF Leuprolide Approved T18950 DRUGINFO D01FDN NAL-GLU Phase 2/3 T18950 DRUGINFO D08LMS CG201 Phase 2 T18950 DRUGINFO D0B3DX Norelin Discontinued in Phase 2 T18950 DRUGINFO D06IYV TAK-810 Discontinued in Phase 1 T18950 DRUGINFO D07IAU Anti-GnRH Spiegelmer Investigative T98708 TARGETID T98708 T98708 FORMERID TTDI01944 T98708 UNIPROID PTHY_HUMAN T98708 TARGNAME Parathyroid hormone (PTH) T98708 GENENAME PTH T98708 TARGTYPE Successful T98708 SYNONYMS Parathyrin; Parathormone T98708 FUNCTION Stimulates [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblastic cells. PTH elevates calcium level by dissolving the salts in bone and preventing their renal excretion. T98708 PDBSTRUC 3C4M; 2L1X; 1ZWG; 1ZWF; 1ZWE T98708 SEQUENCE MIPAKDMAKVMIVMLAICFLTKSDGKSVKKRSVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTKAKSQ T98708 DRUGINFO D0YA2L Teriparatide Approved T98708 DRUGINFO D0F4SN KUR-111 Phase 2 T98708 DRUGINFO D0S7FR Ostabolin-C Phase 2 T98708 DRUGINFO D02RAI ABX-PTH Terminated T98708 DRUGINFO D0F2PZ SUN-E3001 Terminated T98708 DRUGINFO D01VGQ MG-1101 Investigative T98708 DRUGINFO D04PRM parathyroid hormone Investigative T82841 TARGETID T82841 T82841 FORMERID TTDNC00576 T82841 UNIPROID INS_HUMAN T82841 TARGNAME Insulin (INS) T82841 GENENAME INS T82841 TARGTYPE Successful T82841 SYNONYMS Insulin T82841 FUNCTION Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. T82841 PDBSTRUC 6HN5; 6CK2; 6CEB; 6CE9; 6CE7 T82841 SEQUENCE MALWMRLLPLLALLALWGPDPAAAFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN T82841 DRUGINFO D01IWS Inulin Approved T82841 DRUGINFO D03FIL Insulin Zinc Susp Recombinant Human Approved T82841 DRUGINFO D07NGZ Insulin-glargine Approved T82841 DRUGINFO D08ENK Insulin Susp Isophane Recombinant Human Approved T82841 DRUGINFO D0F3LS Insulin determir Approved T82841 DRUGINFO D0I1PY Insulin Susp Protamine Zinc Beef/Pork Approved T82841 DRUGINFO D0I3LE Insulin-aspart Approved T82841 DRUGINFO D0L2CI Insulin degludec Approved T82841 DRUGINFO D0QE5U Insulin-detemir Approved T82841 DRUGINFO D01LOE LY2963016 Phase 3 T82841 DRUGINFO D09VFX SAR342434 Phase 3 T82841 DRUGINFO D0L6NW LY2605541 Phase 3 T82841 DRUGINFO D0V2WO PC-DAC:Insulin Phase 3 T82841 DRUGINFO D0X5AN U300 Phase 3 T82841 DRUGINFO D00ARS MER-3001 Phase 2 T82841 DRUGINFO D0M2LI NNC-0123-0000-0338 Phase 2 T82841 DRUGINFO D0PT1Y SAR-161271 Phase 1/2 T82841 DRUGINFO D00KMQ OI362GT Phase 1 T82841 DRUGINFO D00ROY Adjustable basal insulin Phase 1 T82841 DRUGINFO D05NUP SBS-1000 Phase 1 T82841 DRUGINFO D0B2HF OI287GT Phase 1 T82841 DRUGINFO D0D6OO NP-500 Phase 1 T82841 DRUGINFO D0I8TW IBC-VS01 Phase 1 T82841 DRUGINFO D01VWR S-15261 Discontinued in Phase 2 T82841 DRUGINFO D0B3MX NBI-6024 Discontinued in Phase 2 T82841 DRUGINFO D0QX0K FT-105 Discontinued in Phase 1 T82841 DRUGINFO D0SG4W Oral insulin Terminated T82841 DRUGINFO D0AE1E Insulin molecules, Novo Investigative T56518 TARGETID T56518 T56518 FORMERID TTDR00970 T56518 UNIPROID DPOL_HBVA3 T56518 TARGNAME Hepatitis B virus Reverse transcriptase (HBV RT) T56518 GENENAME HBV RT T56518 TARGTYPE Successful T56518 SYNONYMS P; HBV reverse transcriptase T56518 FUNCTION Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3'- to 5'-endonucleasic mode. Neo-synthesized pregenomic RNA (pgRNA) are encapsidated together with the P protein, and reverse- transcribed inside the nucleocapsid. Initiation of reverse- transcription occurs first by binding the epsilon loop on the pgRNA genome, and is initiated by protein priming, thereby the 5'- end of (-)DNA is covalently linked to P protein. Partial (+)DNA is synthesized from the (-)DNA template and generates the relaxed circular DNA (RC-DNA) genome. After budding and infection, theRC- DNA migrates in the nucleus, and is converted into a plasmid-like covalently closed circular DNA (cccDNA). The activity of P protein does not seem to be necessary for cccDNA generation, and is presumably released from (+)DNA by host nuclear DNA repair machinery. T56518 BIOCLASS DNA-directed DNA polymerase T56518 ECNUMBER EC 2.7.7.49 T56518 SEQUENCE EHHIRIPRTPARVTGGVFLVDKNPHNTAESRLVVDFSQFSRGISRVSWPKFAVPNLQSLTNLLSSNLSWLSLDVSAAFYHIPLHPAAMPHLLIGSSGLSRYVARLSSNSRINNNQYGTMQNLHDSCSRQLYVSLMLLYKTYGWKLHLYSHPIVLGFRKIPMGVGLSPFLLAQFTSAICSVVRRAFPHCLAFSYMDDVVLGAKSVQHRESLYTAVTNFLLSLGIHLNPNKTKRWGYSLNFMGYII T56518 DRUGINFO D0KR2J Entecavir Approved T56518 DRUGINFO D0ML1F Adefovir Dipivoxil Approved T56518 DRUGINFO D0T1WY Clevudine Phase 3 T56518 DRUGINFO D0G9XP LB80380 Phase 2b T56518 DRUGINFO D02FCU MIV-210 Phase 2 T56518 DRUGINFO D0D5CY Pradefovir Phase 2 T83611 TARGETID T83611 T83611 FORMERID TTDS00471 T83611 UNIPROID 2B11_HUMAN T83611 TARGNAME MHC class II antigen DRB1*1 (HLA-DRB1) T83611 GENENAME HLA-DRB1 T83611 TARGTYPE Successful T83611 SYNONYMS HLA class II histocompatibility antigen, DRB1-1 beta chain; DR1; DR-1 T83611 FUNCTION Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading. T83611 PDBSTRUC 6CQR; 6CQJ; 4X5X; 4X5W; 4OV5 T83611 BIOCLASS MHC class II T83611 SEQUENCE MVCLKLPGGSCMTALTVTLMVLSSPLALSGDTRPRFLWQPKRECHFFNGTERVRFLDRYFYNQEESVRFDSDVGEFRAVTELGRPDAEYWNSQKDILEQARAAVDTYCRHNYGVVESFTVQRRVQPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFLNGQEEKAGMVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS T83611 DRUGINFO D04CRL Glatiramer Acetate Approved T03917 TARGETID T03917 T03917 FORMERID TTDS00046 T03917 UNIPROID AT1A1_HUMAN; AT1A2_HUMAN; AT1A3_HUMAN; AT1B1_HUMAN; AT1B2_HUMAN; AT1B3_HUMAN T03917 TARGNAME Sodium/potassium-transporting ATPase (SPT ATPase) T03917 GENENAME ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3 T03917 TARGTYPE Successful T03917 SYNONYMS Na(+)/K(+) ATPase T03917 FUNCTION Maintain resting potential, affects transport, and regulates cellular volume. Function as a signal transducer/integrator to regulate the MAPK pathway, ROS, as well as intracellular calcium. T03917 BIOCLASS Acid anhydrides hydrolase T03917 SEQUENCE MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDELHRKYGTDLSRGLTSARAAEILARDGPNALTPPPTTPEWIKFCRQLFGGFSMLLWIGAILCFLAYSIQAATEEEPQNDNLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEKMSINAEEVVVGDLVEVKGGDRIPADLRIISANGCKVDNSSLTGESEPQTRSPDFTNENPLETRNIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAAEIEHFIHIITGVAVFLGVSFFILSLILEYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKNLEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTENQSGVSFDKTSATWLALSRIAGLCNRAVFQANQENLPILKRAVAGDASESALLKCIELCCGSVKEMRERYAKIVEIPFNSTNKYQLSIHKNPNTSEPQHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQNAYLELGGLGERVLGFCHLFLPDEQFPEGFQFDTDDVNFPIDNLCFVGLISMIDPPRAAVPDAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDAKACVVHGSDLKDMTSEQLDDILKYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKKADIGVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTLTSNIPEITPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPKTDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPIHLLGLRVDWDDRWINDVEDSYGQQWTYEQRKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFEETALAAFLSYCPGMGVALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKETYY T03917 DRUGINFO D0M3QP Digitoxin Approved T03917 DRUGINFO D0T3NB Sanguinarine Approved T03917 DRUGINFO D02OZE Digoxin Approved T03917 DRUGINFO D08UUK Rostafuroxin Phase 2 T03917 DRUGINFO D0A4YK PBI-05204 Phase 2 T03917 DRUGINFO D3OUH0 RX108 Phase 1 T03917 DRUGINFO D06HIO Istaroxime Discontinued in Phase 2 T03917 DRUGINFO D0P6EL Cordil Terminated T73712 TARGETID T73712 T73712 FORMERID TTDR00634 T73712 UNIPROID FABPL_HUMAN T73712 TARGNAME Fatty acid-binding protein 1 (FABP1) T73712 GENENAME FABP1 T73712 TARGTYPE Successful T73712 SYNONYMS L-FABP; FABP1; 14-kDa fatty-acid binding protein; 14 kDa selenium-binding protein T73712 FUNCTION Binds free fatty acids andtheir coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. May be involved in intracellular lipid transport. T73712 PDBSTRUC 6DRG; 6DO7; 6DO6; 3VG7; 3VG6 T73712 SEQUENCE MSFSGKYQLQSQENFEAFMKAIGLPEELIQKGKDIKGVSEIVQNGKHFKFTITAGSKVIQNEFTVGEECELETMTGEKVKTVVQLEGDNKLVTTFKNIKSVTELNGDIITNTMTLGDIVFKRISKRI T73712 DRUGINFO D0NF1U FENOFIBRIC ACID Approved T73712 DRUGINFO D0Q5PL INDOPROFEN Withdrawn from market T73712 DRUGINFO D0C7RS 1-anilinonaphthalene-8-sulfonic acid Investigative T73712 DRUGINFO D0A4EA OLEIC ACID Investigative T96413 TARGETID T96413 T96413 FORMERID TTDI01288 T96413 UNIPROID BGLR_HUMAN T96413 TARGNAME Beta-glucuronidase (GUSB) T96413 GENENAME GUSB T96413 TARGTYPE Successful T96413 SYNONYMS Beta-G1 T96413 FUNCTION Plays an important role in the degradation of dermatan and keratan sulfates. T96413 PDBSTRUC 3HN3; 1BHG T96413 ECNUMBER EC 3.2.1.31 T96413 SEQUENCE MARGSAVAWAALGPLLWGCALGLQGGMLYPQESPSRECKELDGLWSFRADFSDNRRRGFEEQWYRRPLWESGPTVDMPVPSSFNDISQDWRLRHFVGWVWYEREVILPERWTQDLRTRVVLRIGSAHSYAIVWVNGVDTLEHEGGYLPFEADISNLVQVGPLPSRLRITIAINNTLTPTTLPPGTIQYLTDTSKYPKGYFVQNTYFDFFNYAGLQRSVLLYTTPTTYIDDITVTTSVEQDSGLVNYQISVKGSNLFKLEVRLLDAENKVVANGTGTQGQLKVPGVSLWWPYLMHERPAYLYSLEVQLTAQTSLGPVSDFYTLPVGIRTVAVTKSQFLINGKPFYFHGVNKHEDADIRGKGFDWPLLVKDFNLLRWLGANAFRTSHYPYAEEVMQMCDRYGIVVIDECPGVGLALPQFFNNVSLHHHMQVMEEVVRRDKNHPAVVMWSVANEPASHLESAGYYLKMVIAHTKSLDPSRPVTFVSNSNYAADKGAPYVDVICLNSYYSWYHDYGHLELIQLQLATQFENWYKKYQKPIIQSEYGAETIAGFHQDPPLMFTEEYQKSLLEQYHLGLDQKRRKYVVGELIWNFADFMTEQSPTRVLGNKKGIFTRQRQPKSAAFLLRERYWKIANETRYPHSVAKSQCLENSLFT T96413 DRUGINFO D0OY4K Vestronidase alfa Approved T96413 DRUGINFO D0U8IU PerioPatch Phase 2 T50688 TARGETID T50688 T50688 FORMERID TTDS00077 T50688 UNIPROID ITA2B_HUMAN; ITB3_HUMAN T50688 TARGNAME Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) T50688 GENENAME ITGA2B; ITGB3 T50688 TARGTYPE Successful T50688 SYNONYMS Platelet membrane glycoprotein IIb; Platelet membrane glycoprotein IIIa; GP T50688 FUNCTION Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha- IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface. T50688 SEQUENCE MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE T50688 DRUGINFO D09ZIO Eptifibatide Approved T50688 DRUGINFO D0BN9X Tirofiban Approved T50688 DRUGINFO D0P3TX Abciximab Approved T50688 DRUGINFO D03UOT Hydroquinone Approved T50688 DRUGINFO D04FYU DMP-444 Phase 3 T50688 DRUGINFO D0UZ4G 99mTc-rBitistatin Phase 1/2 T50688 DRUGINFO D02PYB SDZ-GPI-562 Phase 1 T50688 DRUGINFO D05MVA RGD-891 Phase 1 T50688 DRUGINFO D0V7PL Lefradafiban Phase 1 T50688 DRUGINFO D0VO7R AjvW2 Phase 1 T50688 DRUGINFO D00VAJ ORBOFIBAN Discontinued in Phase 3 T50688 DRUGINFO D01QQM LAMIFIBAN Discontinued in Phase 3 T50688 DRUGINFO D0N0BI SIBRAFIBAN Discontinued in Phase 3 T50688 DRUGINFO D0SV7D LOTRAFIBAN Discontinued in Phase 3 T50688 DRUGINFO D07EXV XEMILOFIBAN Discontinued in Phase 3 T50688 DRUGINFO D03CKX Cromafiban Discontinued in Phase 2 T50688 DRUGINFO D06LGC ZD-2486 Discontinued in Phase 2 T50688 DRUGINFO D09AFJ SR-121787 Discontinued in Phase 2 T50688 DRUGINFO D0H9WO Gantofiban Discontinued in Phase 2 T50688 DRUGINFO D0M5CU YM-337 Discontinued in Phase 2 T50688 DRUGINFO D0N6PV MK-852 Discontinued in Phase 2 T50688 DRUGINFO D0S3RB ELAROFIBAN Discontinued in Phase 2 T50688 DRUGINFO D0W4OL FK-633 Discontinued in Phase 2 T50688 DRUGINFO D05JXR SC-52012 Discontinued in Phase 1 T50688 DRUGINFO D0C7JH TP-9201 Discontinued in Phase 1 T50688 DRUGINFO D0D7GE TAK-029 Discontinued in Phase 1 T50688 DRUGINFO D0F8QM FR-158999 Discontinued in Phase 1 T50688 DRUGINFO D0H1PN ME-3277 Discontinued in Phase 1 T50688 DRUGINFO D0II5S DMP-728 Discontinued in Phase 1 T50688 DRUGINFO D0P8JX L-734217 Discontinued in Phase 1 T50688 DRUGINFO D0I7EU SB-208651 Terminated T50688 DRUGINFO D0J6MS BIBU-251 Terminated T50688 DRUGINFO D0LK9N Fradafiban Terminated T50688 DRUGINFO D0M6YE SKF-106760 Terminated T50688 DRUGINFO D0U6BB L-703014 Terminated T50688 DRUGINFO D0Y0AP GR-144053 Terminated T50688 DRUGINFO D0Z7PI GR-233548 Terminated T50688 DRUGINFO D0Z9LD SC-49992 Terminated T50688 DRUGINFO D06PYZ XV454 Investigative T50688 DRUGINFO D07WDB RGD Investigative T50688 DRUGINFO D0H3UO RGD-039 Investigative T82240 TARGETID T82240 T82240 FORMERID TTDS00518 T82240 UNIPROID FCG3A_HUMAN; FCG3B_HUMAN T82240 TARGNAME Immunoglobulin gamma Fc receptor III (FCGR3) T82240 GENENAME FCGR3A; FCGR3B T82240 TARGTYPE Successful T82240 SYNONYMS Low affinity immunoglobulin gamma Fc region receptor III; IgG Fc receptor III; IGFR3; FcRIIIb; FcRIIIa; FcRIII; FcR-10; Fc-gamma RIII; FCGR3; FCG3; CD16 T82240 FUNCTION Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis. T82240 BIOCLASS Immunoglobulin T82240 SEQUENCE MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKNVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDWKDHKFKWRKDPQDK T82240 DRUGINFO D09WZV GMA-161 Approved (orphan drug) T82240 DRUGINFO D9O7GC GTB-3550 Phase 1/2 T66040 TARGETID T66040 T66040 FORMERID TTDS00211 T66040 UNIPROID MRDA_ECOLI T66040 TARGNAME Bacterial Penicillin binding protein 2 (Bact mrdA) T66040 GENENAME Bact mrdA T66040 TARGTYPE Successful T66040 SYNONYMS PBP-2 T66040 FUNCTION Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. It synthesizes cross- linked peptidoglycan from lipid intermediates. T66040 PDBSTRUC 6G9S T66040 ECNUMBER EC 3.4.16.4 T66040 SEQUENCE MKLQNSFRDYTAESALFVRRALVAFLGILLLTGVLIANLYNLQIVRFTDYQTRSNENRIKLVPIAPSRGIIYDRNGIPLALNRTIYQIEMMPEKVDNVQQTLDALRSVVDLTDDDIAAFRKERARSHRFTSIPVKTNLTEVQVARFAVNQYRFPGVEVKGYKRRYYPYGSALTHVIGYVSKINDKDVERLNNDGKLANYAATHDIGKLGIERYYEDVLHGQTGYEEVEVNNRGRVIRQLKEVPPQAGHDIYLTLDLKLQQYIETLLAGSRAAVVVTDPRTGGVLALVSTPSYDPNLFVDGISSKDYSALLNDPNTPLVNRATQGVYPPASTVKPYVAVSALSAGVITRNTTLFDPGWWQLPGSEKRYRDWKKWGHGRLNVTRSLEESADTFFYQVAYDMGIDRLSEWMGKFGYGHYTGIDLAEERSGNMPTREWKQKRFKKPWYQGDTIPVGIGQGYWTATPIQMSKALMILINDGIVKVPHLLMSTAEDGKQVPWVQPHEPPVGDIHSGYWELAKDGMYGVANRPNGTAHKYFASAPYKIAAKSGTAQVFGLKANETYNAHKIAERLRDHKLMTAFAPYNNPQVAVAMILENGGAGPAVGTLMRQILDHIMLGDNNTDLPAENPAVAAAEDH T66040 DRUGINFO D0A1CB Cefepime Approved T66040 DRUGINFO D0H3TD Imipenem Approved T66040 DRUGINFO D0M1VC Amdinocillin Approved T33193 TARGETID T33193 T33193 FORMERID TTDS00212 T33193 UNIPROID FTSI_ECOLI T33193 TARGNAME Bacterial Penicillin binding protein 3 (Bact mrcA) T33193 GENENAME Bact mrcA T33193 TARGTYPE Successful T33193 SYNONYMS mrcA; Peptidoglycan synthetase ftsI; Peptidoglycan glycosyltransferase 3; Penicillin-binding protein 3; PSPB20; PBP-3; PBP 3 T33193 FUNCTION Cell wall formation. Essential for the formation of a septum of the murein sacculus. Synthesis of cross-linked peptidoglycan from the lipid intermediates. T33193 BIOCLASS Hexosyltransferase T33193 ECNUMBER EC 3.4.16.4 T33193 SEQUENCE MKAAAKTQKPKRQEEHANFISWRFALLCGCILLALAFLLGRVAWLQVISPDMLVKEGDMRSLRVQQVSTSRGMITDRSGRPLAVSVPVKAIWADPKEVHDAGGISVGDRWKALANALNIPLDQLSARINANPKGRFIYLARQVNPDMADYIKKLKLPGIHLREESRRYYPSGEVTAHLIGFTNVDSQGIEGVEKSFDKWLTGQPGERIVRKDRYGRVIEDISSTDSQAAHNLALSIDERLQALVYRELNNAVAFNKAESGSAVLVDVNTGEVLAMANSPSYNPNNLSGTPKEAMRNRTITDVFEPGSTVKPMVVMTALQRGVVRENSVLNTIPYRINGHEIKDVARYSELTLTGVLQKSSNVGVSKLALAMPSSALVDTYSRFGLGKATNLGLVGERSGLYPQKQRWSDIERATFSFGYGLMVTPLQLARVYATIGSYGIYRPLSITKVDPPVPGERVFPESIVRTVVHMMESVALPGGGGVKAAIKGYRIAIKTGTAKKVGPDGRYINKYIAYTAGVAPASQPRFALVVVINDPQAGKYYGGAVSAPVFGAIMGGVLRTMNIEPDALTTGDKNEFVINQGEGTGGRS T33193 DRUGINFO D00NJJ Mezlocillin Approved T33193 DRUGINFO D04VXN Moxalactam Disodium Approved T33193 DRUGINFO D05UBX Cefmetazole Approved T33193 DRUGINFO D06QCC Cefmenoxime Approved T33193 DRUGINFO D0F2XV Aztreonam Approved T33193 DRUGINFO D0K3DQ Cefotiam Approved T33193 DRUGINFO D0O5LU Latamoxef Approved T33193 DRUGINFO D00QAR Benzylpenicillin Phase 3 T33193 DRUGINFO DO75VX LYS228 Phase 2 T33193 DRUGINFO D0L7GN Acylureido penicillin mezlocillin Investigative T33193 DRUGINFO D08JUW PCNOTAXIME GROUP Investigative T33193 DRUGINFO D0O4TL Cephalosporin C Investigative T39610 TARGETID T39610 T39610 FORMERID TTDS00432 T39610 UNIPROID CALM1_HUMAN; CALM2_HUMAN; CALM3_HUMAN T39610 TARGNAME Calmodulin (CALM) T39610 GENENAME CALM T39610 TARGTYPE Successful T39610 SYNONYMS CaM; CALM2 T39610 FUNCTION Calmodulin mediates the control of a largenumber of enzymes by ca(2+). Among the enzymes to be stimulated by the calmodulin-ca(2+) complex are a number of protein kinases and phosphatases. T39610 BIOCLASS Calmodulin-dependent secretion T39610 SEQUENCE MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQMMTAK T39610 DRUGINFO D07MVK Halofantrine Approved T39610 DRUGINFO D0R4OM Trifluoperazine Approved T39610 DRUGINFO D0W7OE Aprindine Approved T39610 DRUGINFO D01UJL N-Trimethyllysine Investigative T39610 DRUGINFO DW56QV Calmidazolium Investigative T39610 DRUGINFO D0Q7LD 2-Methyl-2-Propanol Investigative T39610 DRUGINFO D09TVP Cacodylate Ion Investigative T39610 DRUGINFO D08OBF MYRISTIC ACID Investigative T39610 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T39610 DRUGINFO D0F2ME Acetate Ion Investigative T73726 TARGETID T73726 T73726 FORMERID TTDS00359 T73726 UNIPROID CP51_CANAL T73726 TARGNAME Candida Cytochrome P450 51 (Candi ERG11) T73726 GENENAME Candi ERG11 T73726 TARGTYPE Successful T73726 SYNONYMS Sterol 14alpha-demethylase; Sterol 14-alpha demethylase; P450LI; P450L1; P450-14DM; Lanosterol 14 alpha-demethylase; LDM; Erg11p; ERG11; Cytochrome P450-dependent lanosterol 14-demethylase; Cytochrome P-450 lanosterol 14-alpha-demethylase; Cyt P450 14DM; CYPLI; CYPL1 T73726 FUNCTION Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol. T73726 PDBSTRUC 5V5Z; 5TZ1; 5FSA T73726 BIOCLASS Paired donor oxygen oxidoreductase T73726 SEQUENCE MAIVETVIDGINYFLSLSVTQQISILLGVPFVYNLVWQYLYSLRKDRAPLVFYWIPWFGSAASYGQQPYEFFESCRQKYGDVFSFMLLGKIMTVYLGPKGHEFVFNAKLSDVSAEDAYKHLTTPVFGKGVIYDCPNSRLMEQKKFAKFALTTDSFKRYVPKIREEILNYFVTDESFKLKEKTHGVANVMKTQPEITIFTASRSLFGDEMRRIFDRSFAQLYSDLDKGFTPINFVFPNLPLPHYWRRDAAQKKISATYMKEIKSRRERGDIDPNRDLIDSLLIHSTYKDGVKMTDQEIANLLIGILMGGQHTSASTSAWFLLHLGEKPHLQDVIYQEVVELLKEKGGDLNDLTYEDLQKLPSVNNTIKETLRMHMPLHSIFRKVTNPLRIPETNYIVPKGHYVLVSPGYAHTSERYFDNPEDFDPTRWDTAAAKANSVSFNSSDEVDYGFGKVSKGVSSPYLPFGGGRHRCIGEQFAYVQLGTILTTFVYNLRWTIDGYKVPDPDYSSMVVLPTEPAEIIWEKRETCMF T73726 DRUGINFO D00AXJ Miconazole Approved T73726 DRUGINFO D01AQT Terconazole Approved T73726 DRUGINFO D04GYO Oxiconazole Approved T73726 DRUGINFO D07ABV Posaconazole Approved T73726 DRUGINFO D09LNI Fluconazole Approved T73726 DRUGINFO D0AA2D Bifonazole Approved T73726 DRUGINFO D0B4IF Ketoconazole Approved T73726 DRUGINFO D0CA6J Tioconazole Approved T73726 DRUGINFO D0EV8E Econazole Approved T73726 DRUGINFO D0G4BI Efinaconazole Approved T73726 DRUGINFO D0N3SP Butoconazole Approved T73726 DRUGINFO D0N3VR Voriconazole Approved T73726 DRUGINFO D0O6UZ Sertaconazole Approved T73726 DRUGINFO D0U4XJ Luliconazole Approved T73726 DRUGINFO DM8BN1 Oteseconazole Approved T73726 DRUGINFO D0V4IB Itraconazole Approved T73726 DRUGINFO D07QKK CHLORIDE Phase 3 T73726 DRUGINFO D01ZBF E-1224 Phase 2 T73726 DRUGINFO D0J1CL EcoNail Phase 2 T73726 DRUGINFO D0Y2HA Pramiconazole Phase 2 T73726 DRUGINFO D05QIU Embeconazole Phase 1 T73726 DRUGINFO D0CE8J Genaconazole Phase 1 T73726 DRUGINFO DUAI04 VT-1598 Phase 1 T73726 DRUGINFO D08MTG Abafungin Discontinued in Phase 3 T73726 DRUGINFO D0SX7F AZALANSTAT Discontinued in Phase 2 T73726 DRUGINFO D00UMG ANALOGUE A Investigative T73726 DRUGINFO D0S0AN CP-320626 Investigative T73726 DRUGINFO D02RTS citric acid Investigative T85529 TARGETID T85529 T85529 FORMERID TTDC00208 T85529 UNIPROID CD28_HUMAN T85529 TARGNAME T-cell-specific surface glycoprotein CD28 (CD28) T85529 GENENAME CD28 T85529 TARGTYPE Successful T85529 SYNONYMS TP44; CD28-S2 T85529 FUNCTION Enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L costimulation. Isoform 3 enhances CD40L-mediated activation of NF-kappa-B and kinases MAPK8 and PAK2 in T-cells. Involved in T-cell activation, the induction of cell proliferation and cytokine production and promotion of T-cell survival. T85529 PDBSTRUC 5GJI; 5GJH; 5AUL; 3WA4; 1YJD T85529 SEQUENCE MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLDSAVEVCVVYGNYSQQLQVYSKTGFNCDGKLGNESVTFYLQNLYVNQTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS T85529 DRUGINFO D0N4HB Belatacept Approved T85529 DRUGINFO D04HQJ AB-103 Phase 3 T85529 DRUGINFO D0GB5X Lulizumab pegol Phase 2 T85529 DRUGINFO D0T9JW AU101 Phase 1/2 T85529 DRUGINFO D8UZM7 REGN5678 Phase 1/2 T85529 DRUGINFO DT1R9E REGN5668 Phase 1/2 T85529 DRUGINFO D0JY0M CD28 and CD137 CAR-T Cells Phase 1 T85529 DRUGINFO D0QE4F CD19-CAR and CD28-CAR T Cells Phase 1 T85529 DRUGINFO D0ZX6F RG6333 Phase 1 T85529 DRUGINFO DZD4R6 RO7443904 Phase 1 T85529 DRUGINFO DBP9Q5 SAR442257 Phase 1 T85529 DRUGINFO DL6F3E SAR443216 Phase 1 T85529 DRUGINFO D00PNU TGN-1412 Discontinued in Phase 1 T85529 DRUGINFO D0A2MA FR-104 Investigative T85529 DRUGINFO D0V9LF Anti-CD28 Investigative T96144 TARGETID T96144 T96144 FORMERID TTDS00080 T96144 UNIPROID TOP2A_HUMAN; TOP2B_HUMAN T96144 TARGNAME DNA topoisomerase II (TOP2) T96144 GENENAME TOP2A; TOP2B T96144 TARGTYPE Successful T96144 SYNONYMS TOP2; DNA topoisomerase 2 T96144 FUNCTION Cut both strands of the DNA helix simultaneously in order to manage DNA tangles and supercoils. T96144 BIOCLASS ATP-hydrolyzing DNA topoisomerase T96144 SEQUENCE MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDNMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKENMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF T96144 DRUGINFO D01DBQ Teniposide Approved T96144 DRUGINFO D01UBX Aclarubicin Approved T96144 DRUGINFO D01XDL Idarubicin Approved T96144 DRUGINFO D02KOF Lomefloxacin Approved T96144 DRUGINFO D03KPZ Ciprofloxacin+dexamethasone Approved T96144 DRUGINFO D04NXQ Pefloxacin Approved T96144 DRUGINFO D06GAM Fleroxacin Approved T96144 DRUGINFO D07CPU Rosoxacin Approved T96144 DRUGINFO D07IPB Valrubicin Approved T96144 DRUGINFO D07JGT Nalidixic Acid Approved T96144 DRUGINFO D07UXP Cinoxacin Approved T96144 DRUGINFO D08FPM Dhaq diacetate Approved T96144 DRUGINFO D09OZC Lucanthone Approved T96144 DRUGINFO D0B7EB Etoposide Approved T96144 DRUGINFO D0C9XJ Epirubicin Approved T96144 DRUGINFO D0D4HN Podofilox Approved T96144 DRUGINFO D0G9YH Amsacrine Approved T96144 DRUGINFO D0Q0PR Novobiocin Approved T96144 DRUGINFO D0R3JB Mitoxantrone Approved T96144 DRUGINFO D0R8ER Enoxacin Approved T96144 DRUGINFO D0Z3EI Quinolones Approved T96144 DRUGINFO D07VLY Doxorubicin Approved T96144 DRUGINFO D07XVN Dexrazoxane Approved T96144 DRUGINFO D00NVM SNS-595 Phase 3 T96144 DRUGINFO D09XQU Tirapazamine Phase 3 T96144 DRUGINFO D0C3CZ Aldoxorubicin Phase 3 T96144 DRUGINFO D0Q4OW Pixantrone Phase 3 T96144 DRUGINFO D0R9US GSK2140944 Phase 3 T96144 DRUGINFO D0W9AI MTC-DOX Phase 2/3 T96144 DRUGINFO D01UGG Sabarubicin Phase 2 T96144 DRUGINFO D03AZR Berubicin Phase 2 T96144 DRUGINFO D03FVS Salvicine Phase 2 T96144 DRUGINFO D07QIT GPX-150D Phase 2 T96144 DRUGINFO D0E3EY Elsamitrucin Phase 2 T96144 DRUGINFO D0L5MF PYRAZOLOACRIDINE Phase 2 T96144 DRUGINFO D0M2WQ CAP-7.1 Phase 2 T96144 DRUGINFO D0M5CD Doxorubicin-eluting beads Phase 2 T96144 DRUGINFO D08EES XR-5000 Phase 2 T96144 DRUGINFO D0NS8T 13-DEOXYADRIAMYCIN HYDROCHLORIDE Phase 2 T96144 DRUGINFO D04BSV L-377202 Phase 1/2 T96144 DRUGINFO D05BIN F-14512 Phase 1/2 T96144 DRUGINFO D03OFN NK-314 Phase 1 T96144 DRUGINFO D0E2LA TAS-103 Phase 1 T96144 DRUGINFO D0GV0Q BMY-43748 Phase 1 T96144 DRUGINFO D0Q5TH XR-5944 Phase 1 T96144 DRUGINFO D00MAN GRC-6211 Phase 1 T96144 DRUGINFO D07BXE Daniquidone Phase 1 T96144 DRUGINFO D07DAU Tafluposide Phase 1 T96144 DRUGINFO D0F3PU Iboctadekin + Doxil Phase 1 T96144 DRUGINFO D0VO7R AjvW2 Phase 1 T96144 DRUGINFO D0Y1GJ MLN-576 Phase 1 T96144 DRUGINFO D00VZF Merbarone Discontinued in Phase 2 T96144 DRUGINFO D01ORM Mitonafide Discontinued in Phase 2 T96144 DRUGINFO D03WPI NC-190 Discontinued in Phase 2 T96144 DRUGINFO D04MRV Amifloxacin Discontinued in Phase 2 T96144 DRUGINFO D04ZLJ LOSOXANTRONE Discontinued in Phase 2 T96144 DRUGINFO D07BKL KW-2170 Discontinued in Phase 2 T96144 DRUGINFO D07HTX GL-331 Discontinued in Phase 2 T96144 DRUGINFO D07VPG BW-773U82 Discontinued in Phase 2 T96144 DRUGINFO D09WRI ELINAFIDE MESILATE Discontinued in Phase 2 T96144 DRUGINFO D0T3CE SUPER-LEU-DOX Discontinued in Phase 2 T96144 DRUGINFO D00PIE Banoxantrone Discontinued in Phase 1 T96144 DRUGINFO D0B7CZ Teloxantrone Discontinued in Phase 1 T96144 DRUGINFO D0H5NX TOP-53 Discontinued in Phase 1 T96144 DRUGINFO D0K2CR Nemorubicin Preclinical T96144 DRUGINFO D03RQI ER-37328 Terminated T96144 DRUGINFO D04OKJ Garenoxacin Terminated T96144 DRUGINFO D08IHF A-74932 Terminated T96144 DRUGINFO D0H1YE BE-22179 Terminated T96144 DRUGINFO D0FZ1Z Doxorubicin-CEA conjugate Terminated T96144 DRUGINFO D0Q1RC A-62176 Terminated T96144 DRUGINFO D0T7WQ Datelliptium chloride Terminated T96144 DRUGINFO D00DNY Ellipticine Investigative T96144 DRUGINFO D00FIE 2-(2-Hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one Investigative T96144 DRUGINFO D01QCJ 4,4'-(4-phenylpyridine-2,6-diyl)diphenol Investigative T96144 DRUGINFO D01VDB Howiinol A (GHM-10) Investigative T96144 DRUGINFO D02GSX 2-(2-Aminoethyl)anthra[1,9-cd]pyrazol-6(2H)-one Investigative T96144 DRUGINFO D02NCW Olean-12-en-3beta,15alpha-diol Investigative T96144 DRUGINFO D02PDP 3-(2,6-diphenylpyridin-4-yl)phenol Investigative T96144 DRUGINFO D03CVY 4-(furan-3-yl)-2,6-di(thiophen-2-yl)pyridine Investigative T96144 DRUGINFO D03NXV Ametantrone Investigative T96144 DRUGINFO D03YCW 4'-Demethyl-epipodophyllotoxin Investigative T96144 DRUGINFO D05HUX ICRF-154 Investigative T96144 DRUGINFO D06KOJ 1,3,7-trihydroxyacridone Investigative T96144 DRUGINFO D08NFP 3-(6-(furan-2-yl)-4-phenylpyridin-2-yl)-phenol Investigative T96144 DRUGINFO D08YKN 3-(2-phenyl-6-(thiophen-2-yl)pyridin-4-yl)-phenol Investigative T96144 DRUGINFO D0C9BH Clorobiocin Investigative T96144 DRUGINFO D0DS0O 1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one Investigative T96144 DRUGINFO D0I0HL DEMETHYLZEYLASTERONE Investigative T96144 DRUGINFO D0J8ZH 4'-Demethyl-4beta-amino-4-desoxypodophyllotoxin Investigative T96144 DRUGINFO D0O2CH Makaluvamine N Investigative T96144 DRUGINFO D0P0UM 7-chloro-1,3-dihydroxyacridone Investigative T96144 DRUGINFO D0RA6H LUPEOL Investigative T96144 DRUGINFO D0V2KV 3-(2-phenyl-6-(thiophen-3-yl)pyridin-4-yl)-phenol Investigative T96144 DRUGINFO D00WYS 3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol Investigative T96144 DRUGINFO D03JZQ 3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol Investigative T96144 DRUGINFO D04ACC doxorubicin-peptide-PEG conjugate Investigative T96144 DRUGINFO D0K4QL doxorubicin-LL2 conjugate Investigative T96144 DRUGINFO D0MI5C 3,3'-(4-phenylpyridine-2,6-diyl)diphenol Investigative T96144 DRUGINFO D0V6EY Pumiliotoxin 251D Investigative T96144 DRUGINFO D0L8BN TOPOSTATIN Investigative T96144 DRUGINFO D00ICA AMP-PNP Investigative T19244 TARGETID T19244 T19244 UNIPROID CP2C9_HUMAN T19244 TARGNAME S-mephenytoin 4-hydroxylase (CYP2C9) T19244 GENENAME CYP2C9 T19244 TARGTYPE Successful T19244 SYNONYMS Cytochrome P450 PB-1; Cytochrome P450 MP-8; Cytochrome P450 MP-4; Cytochrome P450 2C9; Cytochrome P-450MP; Cholesterol 25-hydroxylase; CYPIIC9; CYP2C10; (S)-limonene 7-monooxygenase; (S)-limonene 6-monooxygenase; (R)-limonene 6-monooxygenase T19244 FUNCTION In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan. Cytochromes P450 are a group of heme-thiolate monooxygenases. T19244 PDBSTRUC 5XXI; 5X24; 5X23; 5W0C; 5K7K T19244 BIOCLASS Paired donor oxygen oxidoreductase T19244 ECNUMBER EC 1.14.14.- T19244 SEQUENCE MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFMKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVPPFYQLCFIPV T19244 DRUGINFO D0A4YE Sulfaphenazole Approved T27999 TARGETID T27999 T27999 FORMERID TTDR00859 T27999 UNIPROID PAG_BACAN T27999 TARGNAME Bacterial Protective antigen (Bact pagA) T27999 GENENAME Bact pagA T27999 TARGTYPE Successful T27999 SYNONYMS pagA; PA of Bacillus anthracis; Bacterial toxins translocating protein; Bacterial anthracis protective antigen; Bact PA83; Bact PA-83 T27999 FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death wheninjected, PA associated with EF produces edema. PA induces immunity to infection with anthrax. T27999 PDBSTRUC 5FR3; 4NAM; 4H2A; 4EE2; 3TEZ T27999 BIOCLASS Bacillus anthracis protective antigen T27999 SEQUENCE MKKRKVLIPLMALSTILVSSTGNLEVIQAEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYFQSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQYQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSQTRTISKNTSTSRTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPNGNLQYQGKDITEFDFNFDQQTSQNIKNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG T27999 DRUGINFO D02JYA Raxibacumab Approved T27999 DRUGINFO D06FPF Valortim Phase 1 T27999 DRUGINFO D0L8OP AVP-21D9 Phase 1 T27999 DRUGINFO D09SZY IQ-DAA Phase 1 T27999 DRUGINFO D07TRV Anthrax vaccine Discontinued in Phase 1 T97621 TARGETID T97621 T97621 UNIPROID CFTR_HUMAN T97621 TARGNAME cAMP-dependent chloride channel F508 deletion (CFTR del F508) T97621 GENENAME CFTR T97621 TARGTYPE Successful T97621 SYNONYMS cAMP-dependent chloride channel (del F508); Cystic fibrosis transmembrane conductance regulator (del F508); Channel conductance-controlling ATPase; CFTR; ATP-binding cassette sub-family C member 7 (del F508); ABCC7 (del F508) T97621 FUNCTION Epithelial ion channel that plays an important role in the regulation of epithelial ion and water transport and fluid homeostasis. Mediates the transport of chloride ions across the cell membrane. Channel activity is coupled to ATP hydrolysis. The ion channel is also permeable to HCO(3-); selectivity depends on the extracellular chloride concentration. Exerts its function also by modulating the activity of other ion channels and transporters. Plays an important role in airway fluid homeostasis. Contributes to the regulation of the pH and the ion content of the airway surface fluid layer and thereby plays an important role in defense against pathogens. Modulates the activity of the epithelial sodium channel (ENaC) complex, in part by regulating the cell surface expression of the ENaC complex. Inhibits the activity of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G. Inhibits the activity of the ENaC channel containing subunits SCNN1D, SCNN1B and SCNN1G, but not of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the transporter SLC4A7. Can inhibit the chloride channel activity of ANO1. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation. T97621 PDBSTRUC 6MSM; 6HEP; 5UAK; 5TGK; 5TFJ T97621 BIOCLASS ABC transporter T97621 ECNUMBER EC 5.6.1.6 T97621 SEQUENCE MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELASKKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIAIYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQTWYDSLGAINKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRFSLEGDAPVSWTETKKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQMNGIEEDSDEPLERRLSLVPDSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQGQNIHRKTTASTRKVSLAPQANLTELDIYSRRLSQETGLEISEEINEEDLKECFFDDMESIPAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAASLVVLWLLGNTPLQDKGNSTHSRNNSYAVIITSTSSYYVFYIYVGVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVLQAPMSTLNTLKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYFLQTSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHKALNLHTANWFLYLSTLRWFQMRIEMIFVIFFIAVTFISILTTGEGEGRVGIILTLAMNIMSTLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYKNGQLSKVMIIENSHVKKDDIWPSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLSAFLRLLNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVADEVGLRSVIEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPVTYQIIRRTLKQAFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQAISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEVQDTRL T97621 DRUGINFO D0S9WB Lumacaftor + ivacaftor Approved T02119 TARGETID T02119 T02119 FORMERID TTDI02288 T02119 UNIPROID ARSB_HUMAN T02119 TARGNAME N-acetylgalactosamine-4-sulfatase (G4S) T02119 GENENAME ARSB T02119 TARGTYPE Successful T02119 SYNONYMS Nacetylgalactosamine4sulfatase; G4S; ASB; ARSB T02119 FUNCTION Removes sulfate groups from chondroitin-4-sulfate (C4S) and regulates its degradation (PubMed:19306108). Involved in the regulation of cell adhesion, cell migration and invasion in colonic epithelium (PubMed:19306108). In the central nervous system, is a regulator of neurite outgrowth and neuronal plasticity, acting through the control of sulfate glycosaminoglycans and neurocan levels. T02119 PDBSTRUC 1FSU T02119 BIOCLASS Sulfuric ester hydrolase T02119 ECNUMBER EC 3.1.6.12 T02119 SEQUENCE MGPRGAASLPRGPGPRRLLLPVVLPLLLLLLLAPPGSGAGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTNGTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM T02119 DRUGINFO D05UHF Galsulfase Approved T28869 TARGETID T28869 T28869 FORMERID TTDS00479 T28869 UNIPROID URE1_KLEAE T28869 TARGNAME Bacterial Urease (Bact ureC) T28869 GENENAME Bact ureC T28869 TARGTYPE Successful T28869 SYNONYMS Urease subunit alpha; Urea amidohydrolase subunit alpha T28869 FUNCTION Catalyzes the hydrolysis of urea, leading to the production of carbon dioxide and ammonia. Allows many soil bacteria to use urea as a nitrogen source. An important virulence factor that improves survival of pathogenic bacteria under acidic conditions within the host and can also cause direct damage to the host tissue due to ammonia, CO2 or alkali production. T28869 PDBSTRUC 4EPE; 4EPD; 4EPB; 4EP8; 2KAU T28869 BIOCLASS Carbon-nitrogen hydrolase T28869 SEQUENCE MSNISRQAYADMFGPTVGDKVRLADTELWIEVEDDLTTYGEEVKFGGGKVIRDGMGQGQMLAADCVDLVLTNALIVDHWGIVKADIGVKDGRIFAIGKAGNPDIQPNVTIPIGAATEVIAAEGKIVTAGGIDTHIHWICPQQAEEALVSGVTTMVGGGTGPAAGTHATTCTPGPWYISRMLQAADSLPVNIGLLGKGNVSQPDALREQVAAGVIGLKIHEDWGATPAAIDCALTVADEMDIQVALHSDTLNESGFVEDTLAAIGGRTIHTFHTEGAGGGHAPDIITACAHPNILPSSTNPTLPYTLNTIDEHLDMLMVCHHLDPDIAEDVAFAESRIRRETIAAEDVLHDLGAFSLTSSDSQAMGRVGEVILRTWQVAHRMKVQRGALAEETGDNDNFRVKRYIAKYTINPALTHGIAHEVGSIEVGKLADLVVWSPAFFGVKPATVIKGGMIAIAPMGDINASIPTPQPVHYRPMFGALGSARHHCRLTFLSQAAAANGVAERLNLRSAIAVVKGCRTVQKADMVHNSLQPNITVDAQTYEVRVDGELITSEPADVLPMAQRYFLF T28869 DRUGINFO D0R9BG Acetohydroxamic Acid Approved T28869 DRUGINFO D03NMB 3-(4-bromobenzyl)-1,1-dimethylselenourea Investigative T28869 DRUGINFO D03PVM 1-cyclohexyl-1-isopropyl-3,3-dimethylselenourea Investigative T28869 DRUGINFO D06KWQ 3-dodecyl-1,1-dimethylthiourea Investigative T28869 DRUGINFO D09YRL N-glycylglycinehydroxamic acid Investigative T28869 DRUGINFO D0RL0F 3-(4-bromophenyl)-1,1-dimethylthiourea Investigative T27265 TARGETID T27265 T27265 FORMERID TTDS00240 T27265 UNIPROID S5A1_HUMAN; S5A2_HUMAN; PORED_HUMAN T27265 TARGNAME Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) T27265 GENENAME SRD5A1; SRD5A2; SRD5A3 T27265 TARGTYPE Successful T27265 SYNONYMS Steroid 5-alpha-reductase; SR; S5AR; 3-oxo-5-alpha-steroid 4-dehydrogenase T27265 FUNCTION Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology. T27265 BIOCLASS CH-CH donor oxidoreductase T27265 SEQUENCE MATATGVAEERLLAALAYLQCAVGCAVFARNRQTNSVYGRHALPSHRLRVPARAAWVVQELPSLALPLYQYASESAPRLRSAPNCILLAMFLVHYGHRCLIYPFLMRGGKPMPLLACTMAIMFCTCNGYLQSRYLSHCAVYADDWVTDPRFLIGFGLWLTGMLINIHSDHILRNLRKPGDTGYKIPRGGLFEYVTAANYFGEIMEWCGYALASWSVQGAAFAFFTFCFLSGRAKEHHEWYLRKFEEYPKFRKIIIPFLF T27265 DRUGINFO D03DXN Polyestradiol Phosphate Approved T27265 DRUGINFO D0A9YA Dutasteride Approved T27265 DRUGINFO D0E4WR Azelaic Acid Approved T27265 DRUGINFO D08IWD Finasteride Approved T27265 DRUGINFO D02KRI Epristeride Phase 3 T27265 DRUGINFO D09JFY Dutasteride + tamsulosin Phase 3 T27265 DRUGINFO D0J3CT FK-143 Phase 2 T27265 DRUGINFO D0S3XE Turosteride Phase 2 T27265 DRUGINFO D07BXC IZONSTERIDE Phase 1/2 T27265 DRUGINFO D08JCL ONO-3805 Discontinued in Phase 3 T27265 DRUGINFO D06AVN CS-891B Discontinued in Phase 2 T27265 DRUGINFO D06AGD MK-0963 Discontinued in Phase 1 T27265 DRUGINFO D07UOS MK-434 Discontinued in Phase 1 T27265 DRUGINFO D0O8SY GI-197111 Terminated T97174 TARGETID T97174 T97174 FORMERID TTDS00481 T97174 UNIPROID MPRD_HUMAN T97174 TARGNAME Mannose-6-phosphate receptor (M6PR) T97174 GENENAME M6PR T97174 TARGTYPE Successful T97174 SYNONYMS MPRD; MPR46; MPR 46; Cation-dependent mannose-6-phosphate receptor; CDMan-6-P receptor; CD-MPR; CD Man-6-P receptor; 46kDa mannose 6-phosphate receptor; 46 kDa mannose 6-phosphate receptor T97174 FUNCTION Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. T97174 PDBSTRUC 1JUQ T97174 BIOCLASS Mannose 6-phosphate receptor T97174 SEQUENCE MFPFYSCWRTGLLLLLLAVAVRESWQTEEKTCDLVGEKGKESEKELALVKRLKPLFNKSFESTVGQGSDTYIYIFRVCREAGNHTSGAGLVQINKSNGKETVVGRLNETHIFNGSNWIMLIYKGGDEYDNHCGKEQRRAVVMISCNRHTLADNFNPVSEERGKVQDCFYLFEMDSSLACSPEISHLSVGSILLVTFASLVAVYVVGGFLYQRLVVGAKGMEQFPHLAFWQDLGNLVADGCDFVCRSKPRNVPAAYRGVGDDQLGEESEERDDHLLPM T97174 DRUGINFO D07DUU Alglucosidase alfa Approved T97174 DRUGINFO D06WSW 1-3 Sugar Ring of Pentamannosyl 6-Phosphate Investigative T97174 DRUGINFO D0Q0OH Alpha-D-Mannose-6-Phosphate Investigative T03403 TARGETID T03403 T03403 FORMERID TTDS00039 T03403 UNIPROID PGH1_HUMAN; PGH2_HUMAN T03403 TARGNAME Prostaglandin G/H synthase (COX) T03403 GENENAME PTGS1; PTGS2 T03403 TARGTYPE Successful T03403 SYNONYMS Prostaglandin-endoperoxide synthase; Prostaglandin H2 synthase; PHS; PGHS; PGH synthase; Cyclooxygenase; COX T03403 FUNCTION Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. PTGS1 is involved in the constitutive production of prostanoids in particular in the stomach and platelets. It is a key step in the generation of prostaglandins in gastric epithelial cells and the generation of thromboxane A2 (TXA2) in platelets. PTGS2 is constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. T03403 BIOCLASS Paired donor oxygen oxidoreductase T03403 SEQUENCE MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTRTGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRSNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRFLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQYQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLYATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKFDPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEALVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQELVGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICSPEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL T03403 DRUGINFO D00BDC Morniflumate Approved T03403 DRUGINFO D02IHW Nepafenac Approved T03403 DRUGINFO D03XYW Fenoprofen Approved T03403 DRUGINFO D06YPU Dexibuprofen Approved T03403 DRUGINFO D07OHO Ampiroxicam Approved T03403 DRUGINFO D08IFL Meclofenamic acid Approved T03403 DRUGINFO D0D9JW Ketorolac Approved T03403 DRUGINFO D0F3IP Asasantin Approved T03403 DRUGINFO D0G2MW Icosapent Approved T03403 DRUGINFO D0LR4B Loxoprofen gel Approved T03403 DRUGINFO D0M9DC Oxaprozin Approved T03403 DRUGINFO D0N3UL Fosfosal Approved T03403 DRUGINFO D0S5RZ Amtolmetin guacil Approved T03403 DRUGINFO D0T8VY Aceclofenac Approved T03403 DRUGINFO D0TG1H Diclofenac Approved T03403 DRUGINFO D0UL2L Lornoxicam Approved T03403 DRUGINFO D0X4JN Pelubiprofen Approved T03403 DRUGINFO D0Y7EM Felbinac Approved T03403 DRUGINFO D0GY5Z Aspirin Approved T03403 DRUGINFO D0U5QK Acetaminophen Approved T03403 DRUGINFO D0R4OI K-103-IP Phase 3 T03403 DRUGINFO D0U5OU Naproxcinod Phase 3 T03403 DRUGINFO D05OQX NCX-4016 Phase 2 T03403 DRUGINFO D0E8YH NCX 1022 Phase 2 T03403 DRUGINFO D0B6VN TZI-41078 Phase 2 T03403 DRUGINFO D0I8QS BN82451 Phase 2 T03403 DRUGINFO D0Q3QS 4-aminosalicylate sodium Phase 1 T03403 DRUGINFO D0Y4OI SKF-105809 Phase 1 T03403 DRUGINFO D0R6AB Droxicam Withdrawn from market T03403 DRUGINFO D0SU1G Zomepirac Withdrawn from market T03403 DRUGINFO D01IRW Bermoprofen Discontinued in Preregistration T03403 DRUGINFO D0E0JF Pirazolac Discontinued in Preregistration T03403 DRUGINFO D0S6GJ KC-764 Discontinued in Phase 3 T03403 DRUGINFO D03CFJ NCX-701 Discontinued in Phase 2 T03403 DRUGINFO D06FJO Benzydamine Discontinued in Phase 2 T03403 DRUGINFO D0E2CZ FS-205-397 Discontinued in Phase 2 T03403 DRUGINFO D0L7OY D-7193 Discontinued in Phase 2 T03403 DRUGINFO D0X4IV PSD-508 Discontinued in Phase 2 T03403 DRUGINFO D0E8MW D-1367 Discontinued in Phase 1 T03403 DRUGINFO D0JF6O Eltenac Discontinued in Phase 1 T03403 DRUGINFO D0O2EB F-11105 Discontinued in Phase 1 T03403 DRUGINFO D04SHO NMI-1182 Terminated T03403 DRUGINFO D0M6JP S-14080 Terminated T03403 DRUGINFO D0Y2MP E-5110 Terminated T03403 DRUGINFO D0Y7BV Florifenine Terminated T03403 DRUGINFO D05BBQ RP-66364 Terminated T03403 DRUGINFO D0H0IA WY-28342 Terminated T53381 TARGETID T53381 T53381 FORMERID TTDS00030 T53381 UNIPROID ADA1D_HUMAN T53381 TARGNAME Adrenergic receptor alpha-1D (ADRA1D) T53381 GENENAME ADRA1D T53381 TARGTYPE Successful T53381 SYNONYMS Alpha-adrenergic receptor 1a; Alpha-1D adrenoreceptor; Alpha-1D adrenoceptor; Alpha-1D adrenergic receptor; Alpha adrenergic receptor 1a; Alpha 1D-adrenoreceptor; Alpha 1D-adrenoceptor; ADRA1A T53381 FUNCTION This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium. T53381 BIOCLASS GPCR rhodopsin T53381 SEQUENCE MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGAGGGGGVVGAGSGEDNRSSAGEPGSAGAGGDVNGTAAVGGLVVSAQGVGVGVFLAAFILMAVAGNLLVILSVACNRHLQTVTNYFIVNLAVADLLLSATVLPFSATMEVLGFWAFGRAFCDVWAAVDVLCCTASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVPPDERFCGITEEAGYAVFSSVCSFYLPMAVIVVMYCRVYVVARSTTRSLEAGVKRERGKASEVVLRIHCRGAATGADGAHGMRSAKGHTFRSSLSVRLLKFSREKKAAKTLAIVVGVFVLCWFPFFFVLPLGSLFPQLKPSEGVFKVIFWLGYFNSCVNPLIYPCSSREFKRAFLRLLRCQCRRRRRRRPLWRVYGHHWRASTSGLRQDCAPSSGDAPPGAPLALTALPDPDPEPPGTPEMQAPVASRRKPPSAFREWRLLGPFRRPTTQLRAKVSSLSHKIRAGGAQRAEAACAQRSEVEAVSLGVPHEVAEGATCQAYELADYSNLRETDI T53381 DRUGINFO D03MIR Doxazosin Approved T53381 DRUGINFO D09MWJ Alfuzosin Approved T53381 DRUGINFO D0A7QN Moxisylyte Approved T53381 DRUGINFO D0J5RN Armodafinil Approved T53381 DRUGINFO D0P9RF Terazosin Approved T53381 DRUGINFO D0S0AF Bunazosin Approved T53381 DRUGINFO D0T4WA Trimazosin Approved T53381 DRUGINFO D0F2ML MEDETOMIDINE Phase 2 T53381 DRUGINFO D00POS DL-017 Phase 1 T53381 DRUGINFO D0SG8X PMID30124346-Compound-LDT66 Patented T53381 DRUGINFO D0EO8F PMID30124346-Compound-LDT8 Patented T53381 DRUGINFO D02LHR INDORAMIN Withdrawn from market T53381 DRUGINFO D03ITI Sunepitron Discontinued in Phase 3 T53381 DRUGINFO D01RCS TIOSPIRONE Discontinued in Phase 3 T53381 DRUGINFO D02ZSU NS-49 Discontinued in Phase 2 T53381 DRUGINFO D04CON SL-89.0591 Discontinued in Phase 2 T53381 DRUGINFO D06WJI OPC-28326 Discontinued in Phase 2 T53381 DRUGINFO D0A6VE FIDUXOSIN HYDROCHLORIDE Discontinued in Phase 2 T53381 DRUGINFO D0F0YL SL-25.1039 Discontinued in Phase 2 T53381 DRUGINFO D0Z3UP Dabuzalgron Discontinued in Phase 2 T53381 DRUGINFO D02SKA FCE-22716 Discontinued in Phase 2 T53381 DRUGINFO D03ABH Deriglidole Discontinued in Phase 2 T53381 DRUGINFO D06WOJ JTH-601 Discontinued in Phase 2 T53381 DRUGINFO D0P9FT REC-15-2739 Discontinued in Phase 2 T53381 DRUGINFO D0U0QI GYKI-16084 Discontinued in Phase 2 T53381 DRUGINFO D08OJU SOU-001 Discontinued in Phase 2 T53381 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T53381 DRUGINFO D0C1CU SUN-9221 Discontinued in Phase 1 T53381 DRUGINFO D01EWC CR-2991 Terminated T53381 DRUGINFO D0C5LI SL-91.0893 Terminated T53381 DRUGINFO D0BC6Q AGN-193080 Terminated T53381 DRUGINFO D0N7LZ SK&F-104856 Terminated T53381 DRUGINFO D0U3HP ABANOQUIL Terminated T53381 DRUGINFO D0XK2K Siramesine Terminated T53381 DRUGINFO D00KZF BMY-7378 Terminated T53381 DRUGINFO D05IML NIGULDIPINE Terminated T53381 DRUGINFO D08OWQ SK&F-104078 Terminated T53381 DRUGINFO D03QMR WB-4101 Terminated T53381 DRUGINFO D06HRY SNAP-5089 Terminated T53381 DRUGINFO D00YGP 6-hydroxy-3-(3',5'-dihydroxyphenyl)coumarin Investigative T53381 DRUGINFO D00RLE 4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one Investigative T53381 DRUGINFO D0E5CI 8-Piperazin-1-yl-imidazo[1,2-a]pyrazine Investigative T53381 DRUGINFO D0J9ZF 4-benzyl-2-methylphthalazin-1(2H)-one Investigative T53381 DRUGINFO D0JC4Q 4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one Investigative T53381 DRUGINFO D0Q2SI 4-(4-chlorobenzyl)phthalazin-1(2H)-one Investigative T53381 DRUGINFO D0R2YM 5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine Investigative T53381 DRUGINFO D0Z8OD RWJ-38063 Investigative T53381 DRUGINFO D02TQC N-(5-Bromo-quinoxalin-6-yl)-guanidine Investigative T53381 DRUGINFO D06QKD 4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol Investigative T53381 DRUGINFO D06UBB SK&F-86466 Investigative T53381 DRUGINFO D07QCC SK&F-106686 Investigative T53381 DRUGINFO D07XDL 4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole Investigative T53381 DRUGINFO D08XTL RWJ-69736 Investigative T53381 DRUGINFO D09NXU 4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole Investigative T53381 DRUGINFO D09PIF Imidazolidin-2-ylidene-o-tolyl-amine Investigative T53381 DRUGINFO D0E9VU LEVONORDEFRIN Investigative T53381 DRUGINFO D0F3AR 4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole Investigative T53381 DRUGINFO D0H3CW SK&F-105854 Investigative T53381 DRUGINFO D0L6JS AGN-192172 Investigative T53381 DRUGINFO D0N7UE Imidazolidin-2-ylidene-quinoxalin-6-yl-amine Investigative T53381 DRUGINFO D0O9HS 1-(2-Chloro-phenyl)-piperazine Investigative T53381 DRUGINFO D0Q4PY RWJ-68157 Investigative T53381 DRUGINFO D0RX6I 4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole Investigative T53381 DRUGINFO D0S1GH 4-Morpholin-2-yl-benzene-1,2-diol Investigative T53381 DRUGINFO D0T5KJ 4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol Investigative T53381 DRUGINFO D0ZP5X 4-(1-Naphthalen-1-yl-propyl)-1H-imidazole Investigative T53381 DRUGINFO D02NNS SNAP-8719 Investigative T53381 DRUGINFO D08UDY 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl Investigative T53381 DRUGINFO D09CKI CORYNANTHEINE Investigative T53381 DRUGINFO D0MH0S 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine Investigative T53381 DRUGINFO D01TOU FLUANISONE Investigative T53381 DRUGINFO D06HHJ (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine Investigative T53381 DRUGINFO D06ROA UH-301 Investigative T53381 DRUGINFO D07JMN 1-(pyridin-2-yl)piperazine Investigative T53381 DRUGINFO D0A6GK (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine Investigative T53381 DRUGINFO D0B4DP 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline Investigative T53381 DRUGINFO D0H3NA 4-Benzo[b]thiophen-4-yl-1H-imidazole Investigative T53381 DRUGINFO D0K9NW 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline Investigative T53381 DRUGINFO D08KLH [3H]RX821002 Investigative T53381 DRUGINFO D0L9WN 4-(4-Methyl-indan-1-yl)-1H-imidazole Investigative T53381 DRUGINFO D0P5PW 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole Investigative T53381 DRUGINFO D0D3YN OCTOCLOTHEPIN Investigative T53381 DRUGINFO D0V4RP 1-(2-Methoxy-phenyl)-piperazine Investigative T53381 DRUGINFO D0R7ZC Beta-methoxyamphetamine Investigative T53381 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T53381 DRUGINFO D0L5MW (+/-)-nantenine Investigative T53381 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T60077 TARGETID T60077 T60077 FORMERID TTDI03515 T60077 UNIPROID RXRB_HUMAN T60077 TARGNAME Retinoic acid receptor RXR-beta (RXRB) T60077 GENENAME RXRB T60077 TARGTYPE Successful T60077 SYNONYMS Retinoid X receptor beta; Nuclear receptor subfamily 2 group B member 2; NR2B2 T60077 FUNCTION Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE). Receptor for retinoic acid. T60077 PDBSTRUC 5KYJ; 5KYA; 5I4V; 5HJP; 1UHL T60077 BIOCLASS Nuclear hormone receptor T60077 SEQUENCE MSWAARPPFLPQRHAAGQCGPVGVRKEMHCGVASRWRRRRPWLDPAAAAAAAVAGGEQQTPEPEPGEAGRDGMGDSGRDSRSPDSSSPNPLPQGVPPPSPPGPPLPPSTAPSLGGSGAPPPPPMPPPPLGSPFPVISSSMGSPGLPPPAPPGFSGPVSSPQINSTVSLPGGGSGPPEDVKPPVLGVRGLHCPPPPGGPGAGKRLCAICGDRSSGKHYGVYSCEGCKGFFKRTIRKDLTYSCRDNKDCTVDKRQRNRCQYCRYQKCLATGMKREAVQEERQRGKDKDGDGEGAGGAPEEMPVDRILEAELAVEQKSDQGVEGPGGTGGSGSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSSLPLDDQVILLRAGWNELLIASFSHRSIDVRDGILLATGLHVHRNSAHSAGVGAIFDRVLTELVSKMRDMRMDKTELGCLRAIILFNPDAKGLSNPSEVEVLREKVYASLETYCKQKYPEQQGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQLA T60077 DRUGINFO D0G3PI Alitretinoin Approved T60077 DRUGINFO D0GR9O AGN-34 Investigative T60077 DRUGINFO D0Q9FZ LG100754 Investigative T77009 TARGETID T77009 T77009 FORMERID TTDI00956 T77009 UNIPROID PRDX5_HUMAN T77009 TARGNAME Thioredoxin reductase (PRDX5) T77009 GENENAME PRDX5 T77009 TARGTYPE Successful T77009 SYNONYMS Thioredoxin peroxidase PMP20; TPx type VI; SBBI10; PrxV; Prx-V; Peroxisomal antioxidant enzyme; Peroxiredoxin5, mitochondrial; Peroxiredoxin-5, mitochondrial; Peroxiredoxin V; PLP; Liver tissue 2Dpage spot 71B; Liver tissue 2D-page spot 71B; Antioxidant enzyme B166; Alu corepressor 1; AOEB166; ACR1 T77009 FUNCTION Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. T77009 PDBSTRUC 4MMM; 4K7O; 4K7N; 4K7I; 3MNG T77009 BIOCLASS Peroxide acceptor oxidoreductase T77009 ECNUMBER EC 1.11.1.15 T77009 SEQUENCE MGLAGVCALRRSAGYILVGGAGGQSAAAAARRYSEGEWASGGVRSFSRAAAAMAPIKVGDAIPAVEVFEGEPGNKVNLAELFKGKKGVLFGVPGAFTPGCSKTHLPGFVEQAEALKAKGVQVVACLSVNDAFVTGEWGRAHKAEGKVRLLADPTGAFGKETDLLLDDSLVSIFGNRRLKRFSMVVQDGIVKALNVEPDGTGLTCSLAPNIISQL T77009 DRUGINFO D05BJD Motexafin gadolinium Approved T77009 DRUGINFO DNXH76 Eptacog beta Phase 1/2 T77009 DRUGINFO D0CF4R Diterpene triepoxide derivative 1 Patented T84486 TARGETID T84486 T84486 FORMERID TTDS00264 T84486 UNIPROID OXYR_HUMAN T84486 TARGNAME Oxytocin receptor (OTR) T84486 GENENAME OXTR T84486 TARGTYPE Successful T84486 SYNONYMS OT-R T84486 FUNCTION The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Receptor for oxytocin. T84486 BIOCLASS GPCR rhodopsin T84486 SEQUENCE MEGALAANWSAEAANASAAPPGAEGNRTAGPPRRNEALARVEVAVLCLILLLALSGNACVLLALRTTRQKHSRLFFFMKHLSIADLVVAVFQVLPQLLWDITFRFYGPDLLCRLVKYLQVVGMFASTYLLLLMSLDRCLAICQPLRSLRRRTDRLAVLATWLGCLVASAPQVHIFSLREVADGVFDCWAVFIQPWGPKAYITWITLAVYIVPVIVLAACYGLISFKIWQNLRLKTAAAAAAEAPEGAAAGDGGRVALARVSSVKLISKAKIRTVKMTFIIVLAFIVCWTPFFFVQMWSVWDANAPKEASAFIIVMLLASLNSCCNPWIYMLFTGHLFHELVQRFLCCSASYLKGRRLGETSASKKSNSSSFVLSHRSSSQRSCSQPSTA T84486 DRUGINFO D08FJL Carbetocin Approved T84486 DRUGINFO D0M3FJ Oxytocin Approved T84486 DRUGINFO D0U7SH Desmopressin Approved T84486 DRUGINFO D0D8XY ATOSIBAN Phase 4 T84486 DRUGINFO D04QZI Retosiban Phase 3 T84486 DRUGINFO D04TQT Barusiban Phase 2 T84486 DRUGINFO D07LWT FE-202767 Phase 2 T84486 DRUGINFO D09WYL GSK-557296 Phase 2 T84486 DRUGINFO D0SY9B SSR149415 Phase 2 T84486 DRUGINFO D02CAU Triazole derivative 7 Patented T84486 DRUGINFO D03AOX Triazole derivative 5 Patented T84486 DRUGINFO D03ZGF Pyrrolidine derivative 10 Patented T84486 DRUGINFO D0J5IB Pyrrolidine derivative 11 Patented T84486 DRUGINFO D0J5QP Triazole derivative 6 Patented T84486 DRUGINFO D0LW9R Pyrrolidine derivative 9 Patented T84486 DRUGINFO D0N4RI Pyrrolidine derivative 12 Patented T84486 DRUGINFO D0RF1V Triazole derivative 4 Patented T84486 DRUGINFO D0BU3L Pyrrolidine derivative 13 Patented T84486 DRUGINFO D0H0QR PMID28906174-Compound-figure1g Patented T84486 DRUGINFO D0P6OS TT-235 Discontinued in Phase 1 T84486 DRUGINFO D0Q8RX L-368899 Discontinued in Phase 1 T84486 DRUGINFO D0A1KU PF-3274167 Discontinued in Phase 1 T84486 DRUGINFO D0SK1W AS-602305 Terminated T84486 DRUGINFO D08PAC L-371257 Terminated T84486 DRUGINFO D00TBJ PF-271836 Investigative T84486 DRUGINFO D01EDA [Mpa1, D-Tyr(Et)2, Pip7]OT Investigative T84486 DRUGINFO D03BDK L-366,948 Investigative T84486 DRUGINFO D05JIS L-365,209 Investigative T84486 DRUGINFO D06SMJ [Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT Investigative T84486 DRUGINFO D07HTH [Mpa1, D-Tyr(Et)2, D-Tic7]OT Investigative T84486 DRUGINFO D07KWZ L-367,773 Investigative T84486 DRUGINFO D07NPZ [Mpa1, D-Tyr(Et)2, Gly(But)7]OT Investigative T84486 DRUGINFO D07XKF [Mpa1, L-Tic7]OT Investigative T84486 DRUGINFO D08MTW [Pip7]OT Investigative T84486 DRUGINFO D08ZAK L-366,682 Investigative T84486 DRUGINFO D09LXI [Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT Investigative T84486 DRUGINFO D0D5QP L-366,509 Investigative T84486 DRUGINFO D0F9QJ [Gly(But)7]OT Investigative T84486 DRUGINFO D0H0MK [Mpa1, D-Tyr(Et)2, Aib7]OT Investigative T84486 DRUGINFO D0I3HV [Mpa1, D-Tyr(Et)2, L-Tic7]OT Investigative T84486 DRUGINFO D0IB4H [Mpa1, D-Tic7]OT Investigative T84486 DRUGINFO D0NC8V PMID16250654C37 Investigative T84486 DRUGINFO D0O1KA [Aib7]OT Investigative T84486 DRUGINFO D0O9FA [Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT Investigative T84486 DRUGINFO D0R1WH [L-Tic7]OT Investigative T84486 DRUGINFO D0R2JA [35S]-non-peptide OT antagonist Investigative T84486 DRUGINFO D0S3GE [D-Tic7]OT Investigative T84486 DRUGINFO D0YL6T [Mpa1, D-Tic2, Aib7]OT Investigative T84486 DRUGINFO D0ZV3Y [Mpa1, D-Tyr(Et)2, D-Tic7, Aib9]OT Investigative T84486 DRUGINFO D01WHI L023103 Investigative T84486 DRUGINFO D02FXZ DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT Investigative T84486 DRUGINFO D03QUQ LS-192629 Investigative T84486 DRUGINFO D09HMT [HO1][Orn8(5/6C-Rhm)]VT Investigative T84486 DRUGINFO D0BS2Q [Thr4,Gly7]OT Investigative T84486 DRUGINFO D0K5NV [Lys8(Alexa 546) ]PVA Investigative T84486 DRUGINFO D0Q0OR SSR126768A Investigative T84486 DRUGINFO D0Y1AJ D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT Investigative T84486 DRUGINFO D0YG0D 1'-tosylspiro[indene-1,4'-piperidine] Investigative T84486 DRUGINFO D02VVG D[Orn8(5/6C-Flu)]VT Investigative T84486 DRUGINFO D03EBH D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT Investigative T84486 DRUGINFO D05YHE D[Thr4,Lys8(5/6C-Flu)]VT Investigative T84486 DRUGINFO D09BWP [HO1][Orn8(5/6C-Flu)]VT Investigative T84486 DRUGINFO D0C8XX D[Thr4,Orn8(5/6C-Flu)]VT Investigative T84486 DRUGINFO D0K0JJ [HO1][Lys8(5/6C-Flu)]VT Investigative T84486 DRUGINFO D0L0RP [Lys8(Alexa 488) ]PVA Investigative T84486 DRUGINFO D0M3BJ D[Lys8(5/6-Flu)]VT Investigative T84486 DRUGINFO D0O6WN [HO1][Thr4,Orn8(5/6C-Flu)]VT Investigative T84486 DRUGINFO D0T4ML L-372662 Investigative T84486 DRUGINFO D0Y4HL [Phe3]OT Investigative T84486 DRUGINFO D0Y5FO [HO1][Thr4,Lys8(5/6C-Flu)]VT Investigative T84486 DRUGINFO D01FDW ARGENINE VASOPRESSIN Investigative T84486 DRUGINFO D03BVC D[Arg4,Orn8]VP Investigative T84486 DRUGINFO D03DXK D[Leu4,Lys8]VP Investigative T84486 DRUGINFO D04MMD D[Arg4,Lys8]VP Investigative T84486 DRUGINFO D05BHL D[Cha4,Lys8]VP Investigative T84486 DRUGINFO D05RNF D[Cha4,Orn8]VP Investigative T84486 DRUGINFO D06SDG D[Leu4,Dab8]VP Investigative T84486 DRUGINFO D09RIE D[Cha4]AVP Investigative T84486 DRUGINFO D09XWA D[Cha4,Dap8]VP Investigative T84486 DRUGINFO D0A6FK D[Leu4]AVP Investigative T84486 DRUGINFO D0HI2N D[Cha4,Dab8]VP Investigative T84486 DRUGINFO D0M4QM d(CH2)5[Tyr(Me)2]AVP Investigative T84486 DRUGINFO D0O5TK D[Leu4,Dap8]VP Investigative T84486 DRUGINFO D0O8OF D[Orn4,Lys8]VP Investigative T84486 DRUGINFO D0R7QC D[Arg4]AVP Investigative T84486 DRUGINFO D0UK0O D[Arg4,Dab8]VP Investigative T84486 DRUGINFO D0V3FF D[Leu4,Orn8]VP Investigative T84486 DRUGINFO D0W3IQ D[Val4]AVP Investigative T84486 DRUGINFO D0YJ6C D[Orn4,Orn8]VP Investigative T84486 DRUGINFO D0ZD0W D[Orn4]AVP Investigative T78656 TARGETID T78656 T78656 FORMERID TTDR01194 T78656 UNIPROID 5HT1F_HUMAN T78656 TARGNAME 5-HT 1F receptor (HTR1F) T78656 GENENAME HTR1F T78656 TARGTYPE Successful T78656 SYNONYMS Serotonin receptor 1F; HTR1EL; 5-hydroxytryptamine receptor 1F; 5-HT1F receptor; 5-HT1F; 5-HT-1F T78656 FUNCTION Functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for 5-hydroxytryptamine (serotonin). T78656 BIOCLASS GPCR rhodopsin T78656 SEQUENCE MDFLNSSDQNLTSEELLNRMPSKILVSLTLSGLALMTTTINSLVIAAIIVTRKLHHPANYLICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALDRYRAITDAVEYARKRTPKHAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIVSTIYSTFGAFYIPLALILILYYKIYRAAKTLYHKRQASRIAKEEVNGQVLLESGEKSTKSVSTSYVLEKSLSDPSTDFDKIHSTVRSLRSEFKHEKSWRRQKISGTRERKAATTLGLILGAFVICWLPFFVKELVVNVCDKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQKLVRCRC T78656 DRUGINFO D01NQM Lasmiditan Approved T78656 DRUGINFO D0UA0I Metergolin Approved T78656 DRUGINFO D09GHO LY-334370 Phase 2 T78656 DRUGINFO D0O9TT LY344864 Investigative T78656 DRUGINFO D03RHW 5-BODMT Investigative T78656 DRUGINFO D0BW9V [125I]LSD Investigative T78656 DRUGINFO D0D3PZ dipropyl-5-CT Investigative T78656 DRUGINFO D06VPR WAY-466 Investigative T78656 DRUGINFO D00CRA 2-methyl-5-HT Investigative T78656 DRUGINFO D09OYA alpha-methyl-5-HT Investigative T78656 DRUGINFO D03TDN 1-naphthylpiperazine Investigative T78656 DRUGINFO D04TVG BRL-15572 Investigative T78656 DRUGINFO D02UWB 5-CT Investigative T78656 DRUGINFO D0V5HV TFMPP Investigative T34287 TARGETID T34287 T34287 FORMERID TTDS00450 T34287 UNIPROID MPI_CANAL T34287 TARGNAME Candida Mannose-6-phosphate isomerase (Candi PMI1) T34287 GENENAME Candi PMI1 T34287 TARGTYPE Successful T34287 SYNONYMS Phosphomannose isomerase; Phosphohexomutase; PMI1; PMI T34287 FUNCTION Involved in the synthesis of the GDP-mannose and dolichol-phosphate-mannose required for a number of critical mannosyl transfer reactions. T34287 PDBSTRUC 5NW7; 1PMI T34287 BIOCLASS Intramolecular oxidoreductases T34287 SEQUENCE MSSEKLFRIQCGYQNYDWGKIGSSSAVAQFVHNSDPSITIDETKPYAELWMGTHPSVPSKAIDLNNQTLRDLVTAKPQEYLGESIITKFGSSKELPFLFKVLSIEKVLSIQAHPDKKLGAQLHAADPKNYPDDNHKPEMAIAVTDFEGFCGFKPLDQLAKTLATVPELNEIIGQELVDEFISGIKLPAEVGSQDDVNNRKLLQKVFGKLMNTDDDVIKQQTAKLLERTDREPQVFKDIDSRLPELIQRLNKQFPNDIGLFCGCLLLNHVGLNKGEAMFLQAKDPHAYISGDIIECMAASDNVVRAGFTPKFKDVKNLVEMLTYSYESVEKQKMPLQEFPRSKGDAVKSVLYDPPIAEFSVLQTIFDKSKGGKQVIEGLNGPSIVIATNGKGTIQITGDDSTKQKIDTGYVFFVAPGSSIELTADSANQDQDFTTYRAFVEA T34287 DRUGINFO D0M4VM Sulfacetamide Approved T34287 DRUGINFO D0PI2E Sulfoxone Approved T34287 DRUGINFO D0IK4V GNF-PF-5134 Investigative T34287 DRUGINFO D0P0CM GNF-PF-2272 Investigative T34287 DRUGINFO D0XU4Y NSC-66209 Investigative T34287 DRUGINFO D06EWG Formic Acid Investigative T34287 DRUGINFO D0F2ME Acetate Ion Investigative T82795 TARGETID T82795 T82795 FORMERID TTDR00713 T82795 UNIPROID CTNB1_HUMAN T82795 TARGNAME Beta-catenin (CTNNB1) T82795 GENENAME CTNNB1 T82795 TARGTYPE Successful T82795 SYNONYMS Wnt/beta-catenin signaling pathway; PRO2286; OK/SW-cl.35; Catenin beta-1; CTNNB T82795 FUNCTION In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion, as component of an E-cadherin:catenin adhesion complex. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML. Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle. Key downstream component of the canonical Wnt signaling pathway. T82795 PDBSTRUC 6M94; 6M93; 6M92; 6M91; 6M90 T82795 BIOCLASS Beta-catenin T82795 SEQUENCE MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL T82795 DRUGINFO D05YAG Recombinant human endostatin Approved T82795 DRUGINFO D00GBZ CEQ-508 Phase 1/2 T82795 DRUGINFO D0DA5M C 82 Phase 1/2 T82795 DRUGINFO D54WUR Tegavivint Phase 1 T29500 TARGETID T29500 T29500 FORMERID TTDS00029 T29500 UNIPROID ADA1B_HUMAN T29500 TARGNAME Adrenergic receptor alpha-1B (ADRA1B) T29500 GENENAME ADRA1B T29500 TARGTYPE Successful T29500 SYNONYMS Alpha-1B adrenoreceptor; Alpha-1B adrenoceptor; Alpha-1B adrenergic receptor; Alpha 1B-adrenoreceptor; Alpha 1B-adrenoceptor T29500 FUNCTION Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes. This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. T29500 BIOCLASS GPCR rhodopsin T29500 SEQUENCE MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGLVLGAFILFAIVGNILVILSVACNRHLRTPTNYFIVNLAMADLLLSFTVLPFSAALEVLGYWVLGRIFCDIWAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGPLLGWKEPAPNDDKECGVTEEPFYALFSSLGSFYIPLAVILVMYCRVYIVAKRTTKNLEAGVMKEMSNSKELTLRIHSKNFHEDTLSSTKAKGHNPRSSIAVKLFKFSREKKAAKTLGIVVGMFILCWLPFFIALPLGSLFSTLKPPDAVFKVVFWLGYFNSCLNPIIYPCSSKEFKRAFVRILGCQCRGRGRRRRRRRRRLGGCAYTYRPWTRGGSLERSQSRKDSLDDSGSCLSGSQRTLPSASPSPGYLGRGAPPPVELCAFPEWKAPGALLSLPAPEPPGRRGRHDSGPLFTFKLLTEPESPGTDGGASNGGCEAAADVANGQPGFKSNMPLAPGQF T29500 DRUGINFO D00AWT Propericiazine Approved T29500 DRUGINFO D09GYT Methoxamine Approved T29500 DRUGINFO D0T6SU Phendimetrazine Approved T29500 DRUGINFO D0P6UB Methamphetamine Approved T29500 DRUGINFO D0F2ML MEDETOMIDINE Phase 2 T29500 DRUGINFO D03ITI Sunepitron Discontinued in Phase 3 T29500 DRUGINFO D01RCS TIOSPIRONE Discontinued in Phase 3 T29500 DRUGINFO D08OJU SOU-001 Discontinued in Phase 2 T29500 DRUGINFO D01WJZ MAZAPERTINE Discontinued in Phase 2 T29500 DRUGINFO D0BC6Q AGN-193080 Terminated T29500 DRUGINFO D0N7LZ SK&F-104856 Terminated T29500 DRUGINFO D0U3HP ABANOQUIL Terminated T29500 DRUGINFO D0XK2K Siramesine Terminated T29500 DRUGINFO D00KZF BMY-7378 Terminated T29500 DRUGINFO D05IML NIGULDIPINE Terminated T29500 DRUGINFO D08OWQ SK&F-104078 Terminated T29500 DRUGINFO D03QMR WB-4101 Terminated T29500 DRUGINFO D06HRY SNAP-5089 Terminated T29500 DRUGINFO D04BYL 6-fluoronorepinehprine Investigative T29500 DRUGINFO D06ABL Rec 15/2615 Investigative T29500 DRUGINFO D0DP8I Cyclazosin Investigative T29500 DRUGINFO D0FH7B AH 11110 Investigative T29500 DRUGINFO D03YLQ [125I]BE-2254 Investigative T29500 DRUGINFO D09DKC [125I]HEAT Investigative T29500 DRUGINFO D0EO4F A-123189 Investigative T29500 DRUGINFO D0Q7ZR A-119637 Investigative T29500 DRUGINFO D0V6DJ 5-methylurapidil Investigative T29500 DRUGINFO D02TQC N-(5-Bromo-quinoxalin-6-yl)-guanidine Investigative T29500 DRUGINFO D06QKD 4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol Investigative T29500 DRUGINFO D06UBB SK&F-86466 Investigative T29500 DRUGINFO D07QCC SK&F-106686 Investigative T29500 DRUGINFO D07XDL 4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole Investigative T29500 DRUGINFO D08XTL RWJ-69736 Investigative T29500 DRUGINFO D09NXU 4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole Investigative T29500 DRUGINFO D09PIF Imidazolidin-2-ylidene-o-tolyl-amine Investigative T29500 DRUGINFO D0E9VU LEVONORDEFRIN Investigative T29500 DRUGINFO D0F3AR 4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole Investigative T29500 DRUGINFO D0H3CW SK&F-105854 Investigative T29500 DRUGINFO D0L6JS AGN-192172 Investigative T29500 DRUGINFO D0N7UE Imidazolidin-2-ylidene-quinoxalin-6-yl-amine Investigative T29500 DRUGINFO D0Q4PY RWJ-68157 Investigative T29500 DRUGINFO D0RX6I 4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole Investigative T29500 DRUGINFO D0S1GH 4-Morpholin-2-yl-benzene-1,2-diol Investigative T29500 DRUGINFO D0T5KJ 4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol Investigative T29500 DRUGINFO D0ZP5X 4-(1-Naphthalen-1-yl-propyl)-1H-imidazole Investigative T29500 DRUGINFO D02NNS SNAP-8719 Investigative T29500 DRUGINFO D09CKI CORYNANTHEINE Investigative T29500 DRUGINFO D01TOU FLUANISONE Investigative T29500 DRUGINFO D06HHJ (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine Investigative T29500 DRUGINFO D06ROA UH-301 Investigative T29500 DRUGINFO D0A6GK (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine Investigative T29500 DRUGINFO D0B4DP 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline Investigative T29500 DRUGINFO D0H3NA 4-Benzo[b]thiophen-4-yl-1H-imidazole Investigative T29500 DRUGINFO D0K9NW 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline Investigative T29500 DRUGINFO D0MU4A spiroxatrine Investigative T29500 DRUGINFO D08KLH [3H]RX821002 Investigative T29500 DRUGINFO D0L9WN 4-(4-Methyl-indan-1-yl)-1H-imidazole Investigative T29500 DRUGINFO D0P5PW 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole Investigative T29500 DRUGINFO D0D3YN OCTOCLOTHEPIN Investigative T29500 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T29500 DRUGINFO D0L5MW (+/-)-nantenine Investigative T29500 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T52173 TARGETID T52173 T52173 FORMERID TTDS00158 T52173 UNIPROID SCNNA_HUMAN; SCNNB_HUMAN; SCNNG_HUMAN; SCNND_HUMAN T52173 TARGNAME Amiloride-sensitive sodium channel (ENaC) T52173 GENENAME SCNN1A; SCNN1B; SCNN1G; SCNN1D T52173 TARGTYPE Successful T52173 SYNONYMS SCNE; Nonvoltage-gated sodium channel 1; NaCH; Epithelial Na(+) channel; ENaC T52173 FUNCTION Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. Controls the reabsorption ofsodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception. T52173 BIOCLASS Epithelial sodium channel T52173 SEQUENCE MEGNKLEEQDSSPPQSTPGLMKGNKREEQGLGPEPAAPQQPTAEEEALIEFHRSYRELFEFFCNNTTIHGAIRLVCSQHNRMKTAFWAVLWLCTFGMMYWQFGLLFGEYFSYPVSLNINLNSDKLVFPAVTICTLNPYRYPEIKEELEELDRITEQTLFDLYKYSSFTTLVAGSRSRRDLRGTLPHPLQRLRVPPPPHGARRARSVASSLRDNNPQVDWKDWKIGFQLCNQNKSDCFYQTYSSGVDAVREWYRFHYINILSRLPETLPSLEEDTLGNFIFACRFNQVSCNQANYSHFHHPMYGNCYTFNDKNNSNLWMSSMPGINNGLSLMLRAEQNDFIPLLSTVTGARVMVHGQDEPAFMDDGGFNLRPGVETSISMRKETLDRLGGDYGDCTKNGSDVPVENLYPSKYTQQVCIHSCFQESMIKECGCAYIFYPRPQNVEYCDYRKHSSWGYCYYKLQVDFSSDHLGCFTKCRKPCSVTSYQLSAGYSRWPSVTSQEWVFQMLSRQNNYTVNNKRNGVAKVNIFFKELNYKTNSESPSVTMVTLLSNLGSQWSLWFGSSVLSVVEMAELVFDLLVIMFLMLLRRFRSRYWSPGRGGRGAQEVASTLASSPPSHFCPHPMSLSLSQPGPAPSPALTAPPPAYATLGPRPSPGGSAGASSSTCPLGGP T52173 DRUGINFO D00NKB Triamterene Approved T52173 DRUGINFO DAD95G VX-371 Phase 2 T52173 DRUGINFO D0L9JE S3969 Investigative T52173 DRUGINFO D02ACL benzamil Investigative T88182 TARGETID T88182 T88182 FORMERID TTDS00486 T88182 UNIPROID VKGC_HUMAN T88182 TARGNAME Vitamin K-dependent gamma-carboxylase (GGCX) T88182 GENENAME GGCX T88182 TARGTYPE Successful T88182 SYNONYMS Vitamin K gamma glutamyl carboxylase; Gamma-glutamyl carboxylase; GGCX T88182 FUNCTION Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide. T88182 BIOCLASS Carbon-carbon lyase T88182 ECNUMBER EC 4.1.1.90 T88182 SEQUENCE MAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTDPASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYTIMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYWSVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSPFKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFSYVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRHQLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRTGELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQRIFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHLENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYMYVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFLRRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEVTYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF T88182 DRUGINFO D00FSV Phytonadione Approved T24373 TARGETID T24373 T24373 FORMERID TTDI02303 T24373 UNIPROID LICH_HUMAN T24373 TARGNAME Lysosomal acid lipase (LIPA) T24373 GENENAME LIPA T24373 TARGTYPE Successful T24373 SYNONYMS Sterol esterase; Lysosomal acid lipase/cholesteryl ester hydrolase; Lipase A; LIPA; LAL; Cholesteryl esterase; Acid cholesteryl ester hydrolase T24373 FUNCTION Crucial for the intracellular hydrolysis of cholesteryl esters and triglycerides that have been internalized via receptor- mediated endocytosis of lipoprotein particles. Important in mediating the effect of LDL (low density lipoprotein) uptake on suppression of hydroxymethylglutaryl-CoA reductase and activation of endogenous cellular cholesteryl ester formation. T24373 BIOCLASS Carboxylic ester hydrolase T24373 ECNUMBER EC 3.1.1.13 T24373 SEQUENCE MKMRFLGLVVCLVLWTLHSEGSGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ T24373 DRUGINFO D0CH4A SBC-102 Approved T73189 TARGETID T73189 T73189 FORMERID TTDI01942 T73189 UNIPROID FKS2_YEAST T73189 TARGNAME Fungal 1,3-beta-glucan synthase (Fung GSC2) T73189 GENENAME Fung GSC2 T73189 TARGTYPE Successful T73189 SYNONYMS GSC2 T73189 FUNCTION Alternate catalytic subunit of the 1,3-beta-glucan synthase (GS). Synthesizes 1,3-beta-glucan, a major structural component of the yeast cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling. T73189 BIOCLASS Hexosyltransferase T73189 ECNUMBER EC 2.4.1.34 T73189 SEQUENCE MSYNDPNLNGQYYSNGDGTGDGNYPTYQVTQDQSAYDEYGQPIYTQNQLDDGYYDPNEQYVDGTQFPQGQDPSQDQGPYNNDASYYNQPPNMMNPSSQDGENFSDFSSYGPPSGTYPNDQYTPSQMSYPDQDGSSGASTPYGNGVVNGNGQYYDPNAIEMALPNDPYPAWTADPQSPLPIEQIEDIFIDLTNKFGFQRDSMRNMFDHFMTLLDSRSSRMSPEQALLSLHADYIGGDTANYKKWYFAAQLDMDDEIGFRNMKLGKLSRKARKAKKKNKKAMQEASPEDTEETLNQIEGDNSLEAADFRWKSKMNQLSPFEMVRQIALFLLCWGEANQVRFTPECLCFIYKCASDYLDSAQCQQRPDPLPEGDFLNRVITPLYRFIRSQVYEIVDGRYVKSEKDHNKVIGYDDVNQLFWYPEGIAKIVMEDGTRLIDLPAEERYLKLGEIPWDDVFFKTYKETRSWLHLVTNFNRIWIMHISVYWMYCAYNAPTFYTHNYQQLVDNQPLAAYKWATAALGGTVASLIQVAATLCEWSFVPRKWAGAQHLSRRFWFLCVIMGINLGPVIFVFAYDKDTVYSTAAHVVGAVMFFVAVATLVFFSVMPLGGLFTSYMKKSTRSYVASQTFTASFAPLHGLDRWMSYLVWVTVFAAKYAESYFFLILSLRDPIRILSTTSMRCTGEYWWGNKICKVQPKIVLGLMIATDFILFFLDTYLWYIVVNTVFSVGKSFYLGISILTPWRNIFTRLPKRIYSKILATTDMEIKYKPKVLISQIWNAIIISMYREHLLAIDHVQKLLYHQVPSEIEGKRTLRAPTFFVSQDDNNFETEFFPRDSEAERRISFFAQSLSTPIPEPLPVDNMPTFTVLTPHYAERILLSLREIIREDDQFSRVTLLEYLKQLHPVEWDCFVKDTKILAEETAAYENNEDEPEKEDALKSQIDDLPFYCIGFKSAAPEYTLRTRIWASLRSQTLYRTISGFMNYSRAIKLLYRVENPEIVQMFGGNADGLERELEKMARRKFKFLVSMQRLAKFKPHELENAEFLLRAYPDLQIAYLDEEPPLNEGEEPRIYSALIDGHCEILENGRRRPKFRVQLSGNPILGDGKSDNQNHALIFYRGEYIQLIDANQDNYLEECLKIRSVLAEFEELGIEQIHPYTPGLKYEDQSTNHPVAIVGAREYIFSENSGVLGDVAAGKEQTFGTLFARTLAQIGGKLHYGHPDFINATFMTTRGGVSKAQKGLHLNEDIYAGMNAVLRGGRIKHCEYYQCGKGRDLGFGTILNFTTKIGAGMGEQMLSREYYYLGTQLPIDRFLTFYYAHPGFHLNNLFIQLSLQMFMLTLVNLHALAHESILCVYDRDKPITDVLYPIGCYNFHPAIDWVRRYTLSIFIVFWIAFVPIVVQELIERGLWKATQRFFRHILSLSPMFEVFAGQIYSSALLSDIAVGGARYISTGRGFATSRIPFSILYSRFAGSAIYMGSRSMLMLLFGTVAHWQAPLLWFWASLSALIFAPFIFNPHQFAWEDFFLDYRDYIRWLSRGNNKYHRNSWIGYVRMSRSRVTGFKRKLVGDESEKSAGDASRAHRTNLIMAEIIPCAIYAAGCFIAFTFINAQTGVKTTDEDRVNSTLRIIICTLAPIVIDIGVLFFCMGLSCCSGPLLGMCCKKTGSVMAGIAHGIAVVVHIVFFIVMWVLEGFSFVRMLIGVVTCIQCQRLIFHCMTVLLLTREFKNDHANTAFWTGKWYSTGLGYMAWTQPTRELTAKVIELSEFAADFVLGHVILIFQLPVICIPKIDKFHSIMLFWLKPSRQIRPPIYSLKQARLRKRMVRRYCSLYFLVLIIFAGCIVGPAVASAHVPKDLGSGLTGTFHNLVQPRNVSNNDTGSQMSTYKSHYYTHTPSLKTWSTIK T73189 DRUGINFO D00ZCN Caspofungin Approved T73189 DRUGINFO D02URM Rezafungin Approved T73189 DRUGINFO D06TOE Micafungin Approved T73189 DRUGINFO D07INL Ibrexafungerp Approved T73189 DRUGINFO D0F9BY Anidulafungin Approved T73189 DRUGINFO D07TDT L-733560 Terminated T51452 TARGETID T51452 T51452 FORMERID TTDR01177 T51452 UNIPROID GBRA2_HUMAN T51452 TARGNAME GABA(A) receptor alpha-2 (GABRA2) T51452 GENENAME GABRA2 T51452 TARGTYPE Successful T51452 SYNONYMS GABRA2; GABA-A receptor alpha 2; GABA(A)Gamma-aminobutyric-acid receptor alpha-2 subunit precursor receptor T51452 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. T51452 BIOCLASS Neurotransmitter receptor T51452 SEQUENCE MKTKLNIYNMQFLLFVFLVWDPARLVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPGLGDSITEVFTNIYVTSFGPVSDTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMASKIWTPDTFFHNGKKSVAHNMTMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAHSCPLKFGSYAYTTSEVTYIWTYNASDSVQVAPDGSRLNQYDLLGQSIGKETIKSSTGEYTVMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKSVVNDKKKEKASVMIQNNAYAVAVANYAPNLSKDPVLSTISKSATTPEPNKKPENKPAEAKKTFNSVSKIDRMSRIVFPVLFGTFNLVYWATYLNREPVLGVSP T51452 DRUGINFO D0D5GD Flumazenil Approved T51452 DRUGINFO D0C9XA GSK683699 Phase 2 T51452 DRUGINFO D00AJI PF-4480682 Discontinued in Phase 2 T51452 DRUGINFO D06BFP CGS-17867A Terminated T51452 DRUGINFO D09IHE MRK016 Investigative T51452 DRUGINFO D09YOU MK-0343 Investigative T51452 DRUGINFO D03PBN tetrahydrodeoxycorticosterone Investigative T51452 DRUGINFO D03ZWB alpha3IA Investigative T51452 DRUGINFO D06SOQ alpha5IA Investigative T51452 DRUGINFO D07JXC [18F]fluoroethylflumazenil Investigative T51452 DRUGINFO D0GQ1S DMCM Investigative T51452 DRUGINFO D0Q1ZT TP003 Investigative T51452 DRUGINFO D0T9DS [35S]TBPS Investigative T51452 DRUGINFO D0H4GQ RY-066 Investigative T51452 DRUGINFO D01CUR 3-Ethoxy-9H-beta-carboline Investigative T51452 DRUGINFO D01RLF 9H-beta-Carboline-3-carboxylic acid ethyl ester Investigative T51452 DRUGINFO D03PPZ Beta-Carboline-3-carboxylic acid t-butyl ester Investigative T51452 DRUGINFO D03TMD Barbituric acid derivative Investigative T51452 DRUGINFO D06WMM 3-Butoxy-9H-beta-carboline Investigative T51452 DRUGINFO D08BOP 3-Propoxy-9H-beta-carboline Investigative T51452 DRUGINFO D08BXK 3-(3-Methyl-butoxy)-9H-beta-carboline Investigative T51452 DRUGINFO D09MYJ 3-Isobutoxy-9H-beta-carboline Investigative T51452 DRUGINFO D0C6WO Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate Investigative T51452 DRUGINFO D0D4MM Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate Investigative T51452 DRUGINFO D0E7PY Ro-4938581 Investigative T51452 DRUGINFO D0O9MG L-655708 Investigative T51452 DRUGINFO D0P3BU 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole Investigative T51452 DRUGINFO D0R5OU 3-(benzyloxy)-9H-pyrido[3,4-b]indole Investigative T51452 DRUGINFO D01IHM CI-218872 Investigative T51452 DRUGINFO D07NKO 5-[(1R)-1-ammonioethyl]isoxazol-3-olate Investigative T51452 DRUGINFO D09ACO (2E,4S)-4-ammoniopent-2-enoate Investigative T51452 DRUGINFO D0A8EU (4R)-4-ammoniopentanoate Investigative T51452 DRUGINFO D0N0ZK (4S)-4-ammoniopentanoate Investigative T51452 DRUGINFO D0S5PS 5-[(1S)-1-ammonioethyl]isoxazol-3-olate Investigative T51452 DRUGINFO D0VW5M piperidine-4-sulphonic acid Investigative T51452 DRUGINFO D00WHO Ro-15-3505 Investigative T51452 DRUGINFO D0AC2H isonipecotic acid Investigative T51452 DRUGINFO D0M4CP [3H]Ro154513 Investigative T51452 DRUGINFO D0M9RM [3H]CGS8216 Investigative T51452 DRUGINFO D06HRX AMENTOFLAVONE Investigative T51452 DRUGINFO D0P0TI TBPS Investigative T15571 TARGETID T15571 T15571 FORMERID TTDR00565 T15571 UNIPROID 5HT5A_HUMAN T15571 TARGNAME 5-HT 5A receptor (HTR5A) T15571 GENENAME HTR5A T15571 TARGTYPE Successful T15571 SYNONYMS Serotonin receptor 5A; 5-hydroxytryptamine receptor 5A; 5-HT5A; 5-HT-5A; 5-HT-5; 5-HT 5A T15571 FUNCTION The activity of this receptor is mediated by G proteins. This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. T15571 BIOCLASS GPCR rhodopsin T15571 SEQUENCE MDLPVNLTSFSLSTPSPLETNHSLGKDDLRPSSPLLSVFGVLILTLLGFLVAATFAWNLLVLATILRVRTFHRVPHNLVASMAVSDVLVAALVMPLSLVHELSGRRWQLGRRLCQLWIACDVLCCTASIWNVTAIALDRYWSITRHMEYTLRTRKCVSNVMIALTWALSAVISLAPLLFGWGETYSEGSEECQVSREPSYAVFSTVGAFYLPLCVVLFVYWKIYKAAKFRVGSRKTNSVSPISEAVEVKDSAKQPQMVFTVRHATVTFQPEGDTWREQKEQRAALMVGILIGVFVLCWIPFFLTELISPLCSCDIPAIWKSIFLWLGYSNSFFNPLIYTAFNKNYNSAFKNFFSRQH T15571 DRUGINFO D0UA0I Metergolin Approved T15571 DRUGINFO D03XKU 4-ethyl-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D03XMD SB 699551 Investigative T15571 DRUGINFO D04UTQ N,N-dimethyl-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D06LIA N,4-dimethyl-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D07DLW 4-methyl-N-propyl-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D0C3AR 8-chloro-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D0E4ON N-butyl-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D0EA7Z 4-propyl-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D0I6II 3,4-dihydroquinazolin-2-amine hydrobromide Investigative T15571 DRUGINFO D0W1TU SB-699551-A Investigative T15571 DRUGINFO D0L9ZQ lysergic acid Investigative T15571 DRUGINFO D0X6MT METHIOTHEPIN Investigative T15571 DRUGINFO D03ZHB 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D0BW9V [125I]LSD Investigative T15571 DRUGINFO D04TPO 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D08PJK [3H]5-CT Investigative T15571 DRUGINFO D0SP2J bufotenine Investigative T15571 DRUGINFO D0XX2U 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D0CK9K EDMT Investigative T15571 DRUGINFO D0C5GF MPDT Investigative T15571 DRUGINFO D0Y9TL 5-chloro-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D08VGJ 5,6-dichloro-3,4-dihydroquinazolin-2-amine Investigative T15571 DRUGINFO D02UWB 5-CT Investigative T15571 DRUGINFO D0V5HV TFMPP Investigative T15571 DRUGINFO D0F6CD SEROTONIN Investigative T15571 DRUGINFO D0L5MW (+/-)-nantenine Investigative T59720 TARGETID T59720 T59720 FORMERID TTDR00659 T59720 UNIPROID FHIT_HUMAN T59720 TARGNAME Fragile histidine triad protein (FHIT) T59720 GENENAME FHIT T59720 TARGTYPE Successful T59720 SYNONYMS Fragile histidinetriad protein; Fragile histidinetriad (FHIT) gene; Dinucleosidetriphosphatase; Diadenosine 5',5'''-P1,P3-triphosphate hydrolase; Bis(5'-adenosyl)-triphosphatase; AP3AASE; AP3A hydrolase T59720 FUNCTION Can also hydrolyze P(1)-P(4)-bis(5'-adenosyl) tetraphosphate (Ap4A), but has extremely low activity with ATP. Modulates transcriptional activation by CTNNB1 and thereby contributes to regulate the expression of genes essential for cell proliferation and survival, such as CCND1 and BIRC5. Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways. Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a role in p53/TP53-mediated apoptosis. Induction of apoptosis depends on the ability of FHIT to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related compounds, but does not require its catalytic activity, it may in part come from the mitochondrial form, which sensitizes the low-affinity Ca(2+) transporters, enhancing mitochondrial calcium uptake. Functions as tumor suppressor. Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP. T59720 PDBSTRUC 6FIT; 5FIT; 4FIT; 3FIT; 2FIT T59720 BIOCLASS Acid anhydride hydrolase T59720 ECNUMBER EC 3.6.1.29 T59720 SEQUENCE MSFRFGQHLIKPSVVFLKTELSFALVNRKPVVPGHVLVCPLRPVERFHDLRPDEVADLFQTTQRVGTVVEKHFHGTSLTFSMQDGPEAGQTVKHVHVHVLPRKAGDFHRNDSIYEELQKHDKEDFPASWRSEEEMAAEAAALRVYFQ T59720 DRUGINFO D06HZY Fructose Approved T59720 DRUGINFO D08IHM Adenosine Monotungstate Investigative T59720 DRUGINFO D09KQT Ado-P-Ch2-P-Ps-Ado Investigative T34318 TARGETID T34318 T34318 FORMERID TTDNS00564 T34318 UNIPROID CAMP_HUMAN T34318 TARGNAME Cathelicidin antimicrobial peptide (CAMP) T34318 GENENAME CAMP T34318 TARGTYPE Successful T34318 SYNONYMS upregulating cAMP; hCAP18; CAP18; CAMP; Antibacterial protein LL37; 18 kDa cationic antimicrobial protein T34318 FUNCTION Binds to bacterial lipopolysaccharides (LPS), has antibacterial activity. T34318 BIOCLASS Cathelicidin family T34318 SEQUENCE MKTQRDGHSLGRWSLVLLLLGLVMPLAIIAQVLSYKEAVLRAIDGINQRSSDANLYRLLDLDPRPTMDGDPDTPKPVSFTVKETVCPRTTQQSPEDCDFKKDGLVKRCMGTVTLNQARGSFDISCDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES T34318 DRUGINFO D0H2MO Colforsin daropate hci Approved T66350 TARGETID T66350 T66350 FORMERID TTDR00036 T66350 UNIPROID RAB9A_HUMAN T66350 TARGNAME Ras-related protein Rab-9A (RAB9A) T66350 GENENAME RAB9A T66350 TARGTYPE Successful T66350 SYNONYMS RAB9A T66350 FUNCTION Involved in the transport of proteins between the endosomes and the trans Golgi network. T66350 PDBSTRUC 1WMS T66350 BIOCLASS Small GTPase superfamily T66350 SEQUENCE MAGKSSLFKVILLGDGGVGKSSLMNRYVTNKFDTQLFHTIGVEFLNKDLEVDGHFVTMQIWDTAGQERFRSLRTPFYRGSDCCLLTFSVDDSQSFQNLSNWKKEFIYYADVKEPESFPFVILGNKIDISERQVSTEEAQAWCRDNGDYPYFETSAKDATNVAAAFEEAVRRVLATEDRSDHLIQTDTVNLHRKPKPSSSCC T66350 DRUGINFO D0X9RY Benzoic Acid Approved T66350 DRUGINFO D0C7LS Guanosine-5'-Diphosphate Investigative T50066 TARGETID T50066 T50066 FORMERID TTDS00287 T50066 UNIPROID CLCN2_HUMAN T50066 TARGNAME Chloride channel protein 2 (CLC-2) T50066 GENENAME CLCN2 T50066 TARGTYPE Successful T50066 SYNONYMS ClC-2 chloride channel; ClC-2 Cl- channel; ClC-2; CLCN2 T50066 FUNCTION Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. T50066 BIOCLASS Chloride channel T50066 SEQUENCE MAAAAAEEGMEPRALQYEQTLMYGRYTQDLGAFAKEEAARIRLGGPEPWKGPPSSRAAPELLEYGRSRCARCRVCSVRCHKFLVSRVGEDWIFLVLLGLLMALVSWVMDYAIAACLQAQQWMSRGLNTSILLQYLAWVTYPVVLITFSAGFTQILAPQAVGSGIPEMKTILRGVVLKEYLTLKTFIAKVIGLTCALGSGMPLGKEGPFVHIASMCAALLSKFLSLFGGIYENESRNTEMLAAACAVGVGCCFAAPIGGVLFSIEVTSTFFAVRNYWRGFFAATFSAFIFRVLAVWNRDEETITALFKTRFRLDFPFDLQELPAFAVIGIASGFGGALFVYLNRKIVQVMRKQKTINRFLMRKRLLFPALVTLLISTLTFPPGFGQFMAGQLSQKETLVTLFDNRTWVRQGLVEELEPPSTSQAWNPPRANVFLTLVIFILMKFWMSALATTIPVPCGAFMPVFVIGAAFGRLVGESMAAWFPDGIHTDSSTYRIVPGGYAVVGAAALAGAVTHTVSTAVIVFELTGQIAHILPVMIAVILANAVAQSLQPSLYDSIIRIKKLPYLPELGWGRHQQYRVRVEDIMVRDVPHVALSCTFRDLRLALHRTKGRMLALVESPESMILLGSIERSQVVALLGAQLSPARRRQHMQERRATQTSPLSDQEGPPTPEASVCFQVNTEDSAFPAARGETHKPLKPALKRGPSVTRNLGESPTGSAESAGIALRSLFCGSPPPEAASEKLESCEKRKLKRVRISLASDADLEGEMSPEEILEWEEQQLDEPVNFSDCKIDPAPFQLVERTSLHKTHTIFSLLGVDHAYVTSIGRLIGIVTLKELRKAIEGSVTAQGVKVRPPLASFRDSATSSSDTETTEVHALWGPHSRHGLPREGSPSDSDDKCQ T50066 DRUGINFO D00CTS Lubiprostone Approved T50066 DRUGINFO D0E2QC RK-023 Phase 2 T50066 DRUGINFO D03APP diphenylamine-2-carboxylic acid Investigative T50066 DRUGINFO D0L1UK Acid-activated omeprazole Investigative T50066 DRUGINFO D08DQL NPPB Investigative T84886 TARGETID T84886 T84886 FORMERID TTDS00117 T84886 UNIPROID S12A3_HUMAN T84886 TARGNAME Solute carrier family 12 member 3 (SLC12A3) T84886 GENENAME SLC12A3 T84886 TARGTYPE Successful T84886 SYNONYMS Thiazide-sensitive sodium-chloride cotransporter; Thiazide-sensitive Na-Cl cotransporter; SLC12A3; Na-Cl symporter T84886 FUNCTION Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption. T84886 BIOCLASS Cation-chloride cotransporter T84886 SEQUENCE MAELPTTETPGDATLCSGRFTISTLLSSDEPSPPAAYDSSHPSHLTHSSTFCMRTFGYNTIDVVPTYEHYANSTQPGEPRKVRPTLADLHSFLKQEGRHLHALAFDSRPSHEMTDGLVEGEAGTSSEKNPEEPVRFGWVKGVMIRCMLNIWGVILYLRLPWITAQAGIVLTWIIILLSVTVTSITGLSISAISTNGKVKSGGTYFLISRSLGPELGGSIGLIFAFANAVGVAMHTVGFAETVRDLLQEYGAPIVDPINDIRIIAVVSVTVLLAISLAGMEWESKAQVLFFLVIMVSFANYLVGTLIPPSEDKASKGFFSYRADIFVQNLVPDWRGPDGTFFGMFSIFFPSATGILAGANISGDLKDPAIAIPKGTLMAIFWTTISYLAISATIGSCVVRDASGVLNDTVTPGWGACEGLACSYGWNFTECTQQHSCHYGLINYYQTMSMVSGFAPLITAGIFGATLSSALACLVSAAKVFQCLCEDQLYPLIGFFGKGYGKNKEPVRGYLLAYAIAVAFIIIAELNTIAPIISNFFLCSYALINFSCFHASITNSPGWRPSFQYYNKWAALFGAIISVVIMFLLTWWAALIAIGVVLFLLLYVIYKKPEVNWGSSVQAGSYNLALSYSVGLNEVEDHIKNYRPQCLVLTGPPNFRPALVDFVGTFTRNLSLMICGHVLIGPHKQRMPELQLIANGHTKWLNKRKIKAFYSDVIAEDLRRGVQILMQAAGLGRMKPNILVVGFKKNWQSAHPATVEDYIGILHDAFDFNYGVCVMRMREGLNVSKMMQAHINPVFDPAEDGKEASARVDPKALVKEEQATTIFQSEQGKKTIDIYWLFDDGGLTLLIPYLLGRKRRWSKCKIRVFVGGQINRMDQERKAIISLLSKFRLGFHEVHILPDINQNPRAEHTKRFEDMIAPFRLNDGFKDEATVNEMRRDCPWKISDEEITKNRVKSLRQVRLNEIVLDYSRDAALIVITLPIGRKGKCPSSLYMAWLETLSQDLRPPVILIRGNQENVLTFYCQ T84886 DRUGINFO D01WLC Metolazone Approved T84886 DRUGINFO D06TNG Polythiazide Approved T84886 DRUGINFO D02PAH Bendroflumethiazide Approved T46628 TARGETID T46628 T46628 FORMERID TTDC00123 T46628 UNIPROID MTP_HUMAN T46628 TARGNAME Microsomal triglyceride transfer protein (MTTP) T46628 GENENAME MTTP T46628 TARGTYPE Successful T46628 SYNONYMS Microsomal triglyceride transfer protein large subunit; MTP T46628 FUNCTION Required for the secretion of plasma lipoproteins that contain apolipoprotein B. Catalyzes the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces. T46628 SEQUENCE MILLAVLFLCFISSYSASVKGHTTGLSLNNDRLYKLTYSTEVLLDRGKGKLQDSVGYRISSNVDVALLWRNPDGDDDQLIQITMKDVNVENVNQQRGEKSIFKGKSPSKIMGKENLEALQRPTLLHLIHGKVKEFYSYQNEAVAIENIKRGLASLFQTQLSSGTTNEVDISGNCKVTYQAHQDKVIKIKALDSCKIARSGFTTPNQVLGVSSKATSVTTYKIEDSFVIAVLAEETHNFGLNFLQTIKGKIVSKQKLELKTTEAGPRLMSGKQAAAIIKAVDSKYTAIPIVGQVFQSHCKGCPSLSELWRSTRKYLQPDNLSKAEAVRNFLAFIQHLRTAKKEEILQILKMENKEVLPQLVDAVTSAQTSDSLEAILDFLDFKSDSSIILQERFLYACGFASHPNEELLRALISKFKGSIGSSDIRETVMIITGTLVRKLCQNEGCKLKAVVEAKKLILGGLEKAEKKEDTRMYLLALKNALLPEGIPSLLKYAEAGEGPISHLATTALQRYDLPFITDEVKKTLNRIYHQNRKVHEKTVRTAAAAIILNNNPSYMDVKNILLSIGELPQEMNKYMLAIVQDILRFEMPASKIVRRVLKEMVAHNYDRFSRSGSSSAYTGYIERSPRSASTYSLDILYSGSGILRRSNLNIFQYIGKAGLHGSQVVIEAQGLEALIAATPDEGEENLDSYAGMSAILFDVQLRPVTFFNGYSDLMSKMLSASGDPISVVKGLILLIDHSQELQLQSGLKANIEVQGGLAIDISGAMEFSLWYRESKTRVKNRVTVVITTDITVDSSFVKAGLETSTETEAGLEFISTVQFSQYPFLVCMQMDKDEAPFRQFEKKYERLSTGRGYVSQKRKESVLAGCEFPLHQENSEMCKVVFAPQPDSTSSGWF T46628 DRUGINFO D0H8VY BMS-201038 Approved T46628 DRUGINFO D05YTG SLx-4090 Phase 2 T46628 DRUGINFO D0F2KX Granotapide Phase 2 T46628 DRUGINFO D0F6YK Implitapide Phase 2 T46628 DRUGINFO D0M5WS JNJ-16269110 Phase 2 T46628 DRUGINFO D0S7AW KD020 Phase 1/2 T46628 DRUGINFO D0SS6J GR-328713 Discontinued in Phase 1 T46628 DRUGINFO D0J0TP DIRLOTAPIDE Investigative T71023 TARGETID T71023 T71023 FORMERID TTDS00496 T71023 UNIPROID SNP25_HUMAN T71023 TARGNAME Synaptosomal-associated protein 25 (SNAP25) T71023 GENENAME SNAP25 T71023 TARGTYPE Successful T71023 SYNONYMS Synaptosomal-associated 25 kDa protein; Super protein; SUP; SNAP-25; SNAP T71023 FUNCTION May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 in pancreatic beta cells. t-SNARE involved in the molecular regulation of neurotransmitter release. T71023 PDBSTRUC 5W7J; 5W7I; 3ZUR; 3RL0; 3RK3 T71023 BIOCLASS Synaptosomal vesicle fusion pore T71023 SEQUENCE MAEDADMRNELEEMQRRADQLADESLESTRRMLQLVEESKDAGIRTLVMLDEQGEQLERIEEGMDQINKDMKEAEKNLTDLGKFCGLCVCPCNKLKSSDAYKKAWGNNQDGVVASQPARVVDEREQMAISGGFIRRVTNDARENEMDENLEQVSGIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG T71023 DRUGINFO D0D1RM Botulinum Toxin Type A Approved T95479 TARGETID T95479 T95479 FORMERID TTDS00497 T95479 UNIPROID SMS_HUMAN T95479 TARGNAME Somatostatin (SST) T95479 GENENAME SST T95479 TARGTYPE Successful T95479 SYNONYMS Somatostatin-28; Somatostatin-14; SST; Growth hormone release-inhibiting factor T95479 FUNCTION Somatostatin inhibits the release of somatotropin. T95479 PDBSTRUC 2MI1; 1P2W T95479 BIOCLASS Somatostatin cortistatin T95479 SEQUENCE MLSCRLQCALAALSIVLALGCVTGAPSDPRLRQFLQKSLAAAAGKQELAKYFLAELLSEPNQTENDALEPEDLSQAAEQDEMRLELQRSANSNPAMAPRERKAGCKNFFWKTFTSC T95479 DRUGINFO D0V0LB Cysteamine Approved T12966 TARGETID T12966 T12966 FORMERID TTDS00409 T12966 UNIPROID TNNC1_HUMAN T12966 TARGNAME Troponin C (TN-C) T12966 GENENAME TNNC1 T12966 TARGTYPE Successful T12966 SYNONYMS Troponin C, slow skeletal and cardiac muscles; TNNC T12966 FUNCTION Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments. T12966 PDBSTRUC 6MV3; 5WCL; 5W88; 5VLN; 4Y99 T12966 SEQUENCE MDDIYKAAVEQLTEEQKNEFKAAFDIFVLGAEDGCISTKELGKVMRMLGQNPTPEELQEMIDEVDEDGSGTVDFDEFLVMMVRCMKDDSKGKSEEELSDLFRMFDKNADGYIDLDELKIMLQATGETITEDDIEELMKDGDKNNDGRIDYDEFLEFMKGVE T12966 DRUGINFO D0C4HG Levosimendan Approved T12966 DRUGINFO D0L9YX Dihydroxyaluminium Approved T09423 TARGETID T09423 T09423 FORMERID TTDS00431 T09423 UNIPROID KCJ10_HUMAN T09423 TARGNAME Inward rectifier potassium channel Kir1.2 (KCNJ10) T09423 GENENAME KCNJ10 T09423 TARGTYPE Successful T09423 SYNONYMS Potassiumchannel, inwardly rectifying, subfamily J, member 10; Potassium channel, inwardly rectifying subfamily J member 10; Inward rectifier K+ channel Kir1.2; Inward rectifier K(+) channel Kir1.2; ATP-sensitive inward rectifier potassium channel 10; ATP-dependent inwardly rectifying potassium channel Kir4.1; ATP dependent K+ channel T09423 FUNCTION Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium and cesium. In the kidney, together with KCNJ16, mediates basolateral K(+) recycling in distal tubules; this process is critical for Na(+) reabsorption at the tubules. May be responsible for potassium buffering action of glial cells in the brain. T09423 BIOCLASS Inward rectifier potassium channel T09423 SEQUENCE MTSVAKVYYSQTTQTESRPLMGPGIRRRRVLTKDGRSNVRMEHIADKRFLYLKDLWTTFIDMQWRYKLLLFSATFAGTWFLFGVVWYLVAVAHGDLLELDPPANHTPCVVQVHTLTGAFLFSLESQTTIGYGFRYISEECPLAIVLLIAQLVLTTILEIFITGTFLAKIARPKKRAETIRFSQHAVVASHNGKPCLMIRVANMRKSLLIGCQVTGKLLQTHQTKEGENIRLNQVNVTFQVDTASDSPFLILPLTFYHVVDETSPLKDLPLRSGEGDFELVLILSGTVESTSATCQVRTSYLPEEILWGYEFTPAISLSASGKYIADFSLFDQVVKVASPSGLRDSTVRYGDPEKLKLEESLREQAEKEGSALSVRISNV T09423 DRUGINFO D00BCP Chlorpropamide Approved T09423 DRUGINFO D03JAA Glycodiazine Approved T09423 DRUGINFO D04NTJ Glisoxepide Approved T09423 DRUGINFO D06HBQ Gliquidone Approved T09423 DRUGINFO D09FJB Tolazamide Approved T09423 DRUGINFO D0P2YU Mitiglinide Approved T09423 DRUGINFO D0Z4SB Glipizide Approved T09423 DRUGINFO D0K4HI Sulfonylthioureas Investigative T30578 TARGETID T30578 T30578 FORMERID TTDS00383 T30578 UNIPROID EMBC_MYCTU T30578 TARGNAME Mycobacterium Arabinosyltransferase C (MycB embC) T30578 GENENAME MycB embC T30578 TARGTYPE Successful T30578 SYNONYMS Probable arabinosyltransferase C T30578 FUNCTION Arabinosyl transferase responsible for the polymerization of arabinose into the arabinan of arabinogalactan. T30578 PDBSTRUC 3PTY T30578 ECNUMBER EC 2.4.2.- T30578 SEQUENCE MATEAAPPRIAVRLPSTSVRDAGANYRIARYVAVVAGLLGAVLAIATPLLPVNQTTAQLNWPQNGTFASVEAPLIGYVATDLNITVPCQAAAGLAGSQNTGKTVLLSTVPKQAPKAVDRGLLLQRANDDLVLVVRNVPLVTAPLSQVLGPTCQRLTFTAHADRVAAEFVGLVQGPNAEHPGAPLRGERSGYDFRPQIVGVFTDLAGPAPPGLSFSASVDTRYSSSPTPLKMAAMILGVALTGAALVALHILDTADGMRHRRFLPARWWSTGGLDTLVIAVLVWWHFVGANTSDDGYILTMARVSEHAGYMANYYRWFGTPEAPFGWYYDLLALWAHVSTASIWMRLPTLAMALTCWWVISREVIPRLGHAVKTSRAAAWTAAGMFLAVWLPLDNGLRPEPIIALGILLTWCSVERAVATSRLLPVAIACIIGALTLFSGPTGIASIGALLVAIGPLRTILHRRSRRFGVLPLVAPILAAATVTAIPIFRDQTFAGEIQANLLKRAVGPSLKWFDEHIRYERLFMASPDGSIARRFAVLALVLALAVSVAMSLRKGRIPGTAAGPSRRIIGITIISFLAMMFTPTKWTHHFGVFAGLAGSLGALAAVAVTGAAMRSRRNRTVFAAVVVFVLALSFASVNGWWYVSNFGVPWSNSFPKWRWSLTTALLELTVLVLLLAAWFHFVANGDGRRTARPTRFRARLAGIVQSPLAIATWLLVLFEVVSLTQAMISQYPAWSVGRSNLQALAGKTCGLAEDVLVELDPNAGMLAPVTAPLADALGAGLSEAFTPNGIPADVTADPVMERPGDRSFLNDDGLITGSEPGTEGGTTAAPGINGSRARLPYNLDPARTPVLGSWRAGVQVPAMLRSGWYRLPTNEQRDRAPLLVVTAAGRFDSREVRLQWATDEQAAAGHHGGSMEFADVGAAPAWRNLRAPLSAIPSTATQVRLVADDQDLAPQHWIALTPPRIPRVRTLQNVVGAADPVFLDWLVGLAFPCQRPFGHQYGVDETPKWRILPDRFGAEANSPVMDHNGGGPLGITELLMRATTVASYLKDDWFRDWGALQRLTPYYPDAQPADLNLGTVTRSGLWSPAPLRRG T30578 DRUGINFO D08QME Ethambutol Approved T68253 TARGETID T68253 T68253 FORMERID TTDR00165 T68253 UNIPROID DDL_MYCTO T68253 TARGNAME Mycobacterium D-alanine-D-alanine ligase (MycB ddl) T68253 GENENAME MycB ddl T68253 TARGTYPE Successful T68253 SYNONYMS ddl; D-alanylalanine synthetase; D-alanine:D-alanine ligase; D-Ala-D-Ala ligase T68253 FUNCTION Cell wall formation. T68253 BIOCLASS Carbon-nitrogen ligase T68253 ECNUMBER EC 6.3.2.4 T68253 SEQUENCE MSANDRRDRRVRVAVVFGGRSNEHAISCVSAGSILRNLDSRRFDVIAVGITPAGSWVLTDANPDALTITNRELPQVKSGSGTELALPADPRRGGQLVSLPPGAGEVLESVDVVFPVLHGPYGEDGTIQGLLELAGVPYVGAGVLASAVGMDKEFTKKLLAADGLPVGAYAVLRPPRSTLHRQECERLGLPVFVKPARGGSSIGVSRVSSWDQLPAAVARARRHDPKVIVEAAISGRELECGVLEMPDGTLEASTLGEIRVAGVRGREDSFYDFATKYLDDAAELDVPAKVDDQVAEAIRQLAIRAFAAIDCRGLARVDFFLTDDGPVINEINTMPGFTTISMYPRMWAASGVDYPTLLATMIETALARGVGLH T70449 TARGETID T70449 T70449 FORMERID TTDS00446 T70449 UNIPROID GHRHR_HUMAN T70449 TARGNAME Growth hormone-releasing hormone receptor (GHRHR) T70449 GENENAME GHRHR T70449 TARGTYPE Successful T70449 SYNONYMS GRFR; GRF receptor; GHRHR; GHRH receptor T70449 FUNCTION Receptor for GRF,coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion. T70449 PDBSTRUC 2XDG T70449 BIOCLASS GPCR secretin T70449 SEQUENCE MDRRMWGAHVFCVLSPLPTVLGHMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWDGLLCWPTAGSGEWVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLAEEESYFSTVKIIYTVGHSISIVALFVAITILVALRRLHCPRNYVHTQLFTTFILKAGAVFLKDAALFHSDDTDHCSFSTVLCKVSVAASHFATMTNFSWLLAEAVYLNCLLASTSPSSRRAFWWLVLAGWGLPVLFTGTWVSCKLAFEDIACWDLDDTSPYWWIIKGPIVLSVGVNFGLFLNIIRILVRKLEPAQGSLHTQSQYWRLSKSTLFLIPLFGIHYIIFNFLPDNAGLGIRLPLELGLGSFQGFIVAILYCFLNQEVRTEISRKWHGHDPELLPAWRTRAKWTTPSRSAAKVLTSMC T70449 DRUGINFO D04AQH Sermorelin Approved T70449 DRUGINFO D0UL9R Tesamorelin Approved T70449 DRUGINFO D09TGZ Examorelin Discontinued in Phase 2 T70449 DRUGINFO D0J8WJ AKL-0707 Discontinued in Phase 2 T70449 DRUGINFO D0B3CY L-692429 Discontinued in Phase 1 T70449 DRUGINFO D01GCY NNC-26-0762 Terminated T70449 DRUGINFO D0F2CH Mutated growth hormone Investigative T75890 TARGETID T75890 T75890 FORMERID TTDR01187 T75890 UNIPROID DPYD_HUMAN T75890 TARGNAME Dihydrothymine dehydrogenase (DPYD) T75890 GENENAME DPYD T75890 TARGTYPE Successful T75890 SYNONYMS Dihydrouracil dehydrogenase; Dihydropyrimidine dehydrogenase [NADP(+)]; Dihydropyrimidine dehydrogenase; DPD; DHPDHase T75890 FUNCTION Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil. Involved in pyrimidine base degradation. T75890 BIOCLASS CH/CH donor oxidoreductase T75890 ECNUMBER EC 1.3.1.2 T75890 SEQUENCE MAPVLSKDSADIESILALNPRTQTHATLCSTSAKKLDKKHWKRNPDKNCFNCEKLENNFDDIKHTTLGERGALREAMRCLKCADAPCQKSCPTNLDIKSFITSIANKNYYGAAKMIFSDNPLGLTCGMVCPTSDLCVGGCNLYATEEGPINIGGLQQFATEVFKAMSIPQIRNPSLPPPEKMSEAYSAKIALFGAGPASISCASFLARLGYSDITIFEKQEYVGGLSTSEIPQFRLPYDVVNFEIELMKDLGVKIICGKSLSVNEMTLSTLKEKGYKAAFIGIGLPEPNKDAIFQGLTQDQGFYTSKDFLPLVAKGSKAGMCACHSPLPSIRGVVIVLGAGDTAFDCATSALRCGARRVFIVFRKGFVNIRAVPEEMELAKEEKCEFLPFLSPRKVIVKGGRIVAMQFVRTEQDETGKWNEDEDQMVHLKADVVISAFGSVLSDPKVKEALSPIKFNRWGLPEVDPETMQTSEAWVFAGGDVVGLANTTVESVNDGKQASWYIHKYVQSQYGASVSAKPELPLFYTPIDLVDISVEMAGLKFINPFGLASATPATSTSMIRRAFEAGWGFALTKTFSLDKDIVTNVSPRIIRGTTSGPMYGPGQSSFLNIELISEKTAAYWCQSVTELKADFPDNIVIASIMCSYNKNDWTELAKKSEDSGADALELNLSCPHGMGERGMGLACGQDPELVRNICRWVRQAVQIPFFAKLTPNVTDIVSIARAAKEGGANGVTATNTVSGLMGLKSDGTPWPAVGIAKRTTYGGVSGTAIRPIALRAVTSIARALPGFPILATGGIDSAESGLQFLHSGASVLQVCSAIQNQDFTVIEDYCTGLKALLYLKSIEELQDWDGQSPATVSHQKGKPVPRIAELMDKKLPSFGPYLEQRKKIIAENKIRLKEQNVAFSPLKRNCFIPKRPIPTIKDVIGKALQYLGTFGELSNVEQVVAMIDEEMCINCGKCYMTCNDSGYQAIQFDPETHLPTITDTCTGCTLCLSVCPIVDCIKMVSRTTPYEPKRGVPLSVNPVC T75890 DRUGINFO D05LEO Fluorouracil Approved T75890 DRUGINFO D09QOR Eniluracil Phase 2 T75890 DRUGINFO D03GGN RO-09-4889 Phase 1 T75890 DRUGINFO D05YLL FL-386 Discontinued in Phase 2 T75890 DRUGINFO D08EZR 5-Iodouracil Investigative T75890 DRUGINFO D0HR8H (5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione Investigative T75890 DRUGINFO D0O0AI 6-Carboxymethyluracil Investigative T75890 DRUGINFO D0Y0DG Uracil Investigative T75890 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T93878 TARGETID T93878 T93878 FORMERID TTDS00116 T93878 UNIPROID S12A1_HUMAN T93878 TARGNAME Solute carrier family 12 member 1 (SLC12A1) T93878 GENENAME SLC12A1 T93878 TARGTYPE Successful T93878 SYNONYMS Solute carrier family 12 member; SLC12A1; Na+/K+/2CL- co-transporter; NKCC2; Kidney-specific Na-K-Cl symporter; Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2 T93878 FUNCTION Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume. T93878 BIOCLASS Cation-chloride cotransporter T93878 SEQUENCE MSLNNSSNVFLDSVPSNTNRFQVSVINENHESSAAADDNTDPPHYEETSFGDEAQKRLRISFRPGNQECYDNFLQSGETAKTDASFHAYDSHTNTYYLQTFGHNTMDAVPKIEYYRNTGSISGPKVNRPSLLEIHEQLAKNVAVTPSSADRVANGDGIPGDEQAENKEDDQAGVVKFGWVKGVLVRCMLNIWGVMLFIRLSWIVGEAGIGLGVLIILLSTMVTSITGLSTSAIATNGFVRGGGAYYLISRSLGPEFGGSIGLIFAFANAVAVAMYVVGFAETVVDLLKESDSMMVDPTNDIRIIGSITVVILLGISVAGMEWEAKAQVILLVILLIAIANFFIGTVIPSNNEKKSRGFFNYQASIFAENFGPRFTKGEGFFSVFAIFFPAATGILAGANISGDLEDPQDAIPRGTMLAIFITTVAYLGVAICVGACVVRDATGNMNDTIISGMNCNGSAACGLGYDFSRCRHEPCQYGLMNNFQVMSMVSGFGPLITAGIFSATLSSALASLVSAPKVFQALCKDNIYKALQFFAKGYGKNNEPLRGYILTFLIAMAFILIAELNTIAPIISNFFLASYALINFSCFHASYAKSPGWRPAYGIYNMWVSLFGAVLCCAVMFVINWWAAVITYVIEFFLYVYVTCKKPDVNWGSSTQALSYVSALDNALELTTVEDHVKNFRPQCIVLTGGPMTRPALLDITHAFTKNSGLCICCEVFVGPRKLCVKEMNSGMAKKQAWLIKNKIKAFYAAVAADCFRDGVRSLLQASGLGRMKPNTLVIGYKKNWRKAPLTEIENYVGIIHDAFDFEIGVVIVRISQGFDISQVLQVQEELERLEQERLALEATIKDNECEEESGGIRGLFKKAGKLNITKTTPKKDGSINTSQSMHVGEFNQKLVEASTQFKKKQEKGTIDVWWLFDDGGLTLLIPYILTLRKKWKDCKLRIYVGGKINRIEEEKIVMASLLSKFRIKFADIHIIGDINIRPNKESWKVFEEMIEPYRLHESCKDLTTAEKLKRETPWKITDAELEAVKEKSYRQVRLNELLQEHSRAANLIVLSLPVARKGSISDLLYMAWLEILTKNLPPVLLVRGNHKNVLTFYS T93878 DRUGINFO D00WAM Hydroflumethiazide Approved T93878 DRUGINFO D03GVC Methyclothiazide Approved T93878 DRUGINFO D06TNL Ethacrynic acid Approved T93878 DRUGINFO D09NIA Chlorthalidone Approved T93878 DRUGINFO D0E9JM Potassium Chloride Approved T93878 DRUGINFO D0J9XZ Torasemide Approved T93878 DRUGINFO D0PQ3G Furosemide Approved T93878 DRUGINFO D0R7HO Bumetanide Approved T93878 DRUGINFO D0W5UV Ethacrynate Sodium Approved T93878 DRUGINFO D0Y2IZ Trichlormethiazide Approved T93878 DRUGINFO D02PAH Bendroflumethiazide Approved T93878 DRUGINFO D0I1LH Aldosterone Approved T93878 DRUGINFO D07NWZ CL-301 Investigative T93878 DRUGINFO D09NNS Piretanide Investigative T93878 DRUGINFO D0O7ZE Calyculin-A Investigative T47610 TARGETID T47610 T47610 FORMERID TTDS00501 T47610 UNIPROID I11RA_HUMAN T47610 TARGNAME Interleukin 11 receptor alpha (IL11RA) T47610 GENENAME IL11RA T47610 TARGTYPE Successful T47610 SYNONYMS Interleukin-11 receptor subunit alpha; IL-11RA; IL-11R-alpha; IL-11R subunit alpha; IL-11 receptor subunit alpha T47610 FUNCTION The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells. Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and tooth number. Receptor for interleukin-11. T47610 BIOCLASS Cytokine receptor T47610 SEQUENCE MSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCPGVTAGDPVSWFRDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICQTLDGALGGTVTLQLGYPPARPVVSCQAADYENFSCTWSPSQISGLPTRYLTSYRKKTVLGADSQRRSPSTGPWPCPQDPLGAARCVVHGAEFWSQYRINVTEVNPLGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASWTYPASWPCQPHFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAVRVSARDFLDAGTWSTWSPEAWGTPSTGTIPKEIPAWGQLHTQPEVEPQVDSPAPPRPSLQPHPRLLDHRDSVEQVAVLASLGILSFLGLVAGALALGLWLRLRRGGKDGSPKPGFLASVIPVDRRPGAPNL T47610 DRUGINFO D0T1IJ Oprelvekin Approved T47610 DRUGINFO D0E2YL UNI-rhIL-11 Phase 3 T47610 DRUGINFO D0D2YZ BMTP-11 Phase 1 T69506 TARGETID T69506 T69506 FORMERID TTDS00351 T69506 UNIPROID NR1I3_HUMAN T69506 TARGNAME Orphan nuclear receptor NR1I3 (NR1I3) T69506 GENENAME NR1I3 T69506 TARGTYPE Successful T69506 SYNONYMS Orphan nuclear receptor MB67; Orphan nuclear receptor CAR; Nuclear receptor subfamily 1 group I member 3; Nuclear receptor CAR; Constitutive androstane receptor; Constitutive active response; Constitutive activator of retinoid response; CAR T69506 FUNCTION Transactivates both the phenobarbital responsive element module of the human CYP2B6 gene and the CYP3A4 xenobiotic response element. Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. T69506 PDBSTRUC 1XVP; 1XV9 T69506 BIOCLASS Nuclear hormone receptor T69506 SEQUENCE MASREDELRNCVVCGDQATGYHFNALTCEGCKGFFRRTVSKSIGPTCPFAGSCEVSKTQRRHCPACRLQKCLDAGMRKDMILSAEALALRRAKQAQRRAQQTPVQLSKEQEELIRTLLGAHTRHMGTMFEQFVQFRPPAHLFIHHQPLPTLAPVLPLVTHFADINTFMVLQVIKFTKDLPVFRSLPIEDQISLLKGAAVEICHIVLNTTFCLQTQNFLCGPLRYTIEDGARVSPTVGFQVEFLELLFHFHGTLRKLQLQEPEYVLLAAMALFSPDRPGVTQRDEIDQLQEEMALTLQSYIKGQQRRPRDRFLYAKLLGLLAELRSINEAYGYQIQHIQGLSAMMPLLQEICS T69506 DRUGINFO D0T1XW Meclizine Approved T69506 DRUGINFO D01BXE CITCO Investigative T69506 DRUGINFO D02BPI TCPOBOP Investigative T69506 DRUGINFO D08XML androstenol Investigative T69506 DRUGINFO D0V7WD androstanol Investigative T69506 DRUGINFO D05DMH (5BETA)-PREGNANE-3,20-DIONE Investigative T41955 TARGETID T41955 T41955 FORMERID TTDS00507 T41955 UNIPROID TRPM8_HUMAN T41955 TARGNAME Long transient receptor potential channel 8 (TRPM8) T41955 GENENAME TRPM8 T41955 TARGTYPE Successful T41955 SYNONYMS Trp-p8; Transient receptor potential-p8; Transient receptor potential cation channel subfamily M member 8; TRPP8; TRPM8; LTrpC6 T41955 FUNCTION Receptor-activated non-selective cation channel involved in detection of sensations such as coolness, by being activated by cold temperature below 25 degrees Celsius. Activated by icilin, eucalyptol, menthol, cold and modulation of intracellular pH. Involved in menthol sensation. Permeable for monovalent cations sodium, potassium, and cesium and divalent cation calcium. Temperature sensing is tightly linked to voltage-dependent gating. Activated upon depolarization, changes in temperature resulting in graded shifts of its voltage-dependent activation curves. The chemical agonist menthol functions as a gating modifier, shifting activation curves towards physiological membrane potentials. Temperature sensitivity arises from a tenfold difference in the activation energies associated with voltage-dependent opening and closing. In prostate cancer cells, shows strong inward rectification and high calcium selectivity in contrast to its behavior in normal cells which is characterized by outward rectification and poor cationic selectivity. Plays a role in prostate cancer cell migration (PubMed:25559186). Isoform 2 and isoform 3 negatively regulate menthol- and cold-induced channel activity by stabilizing the closed state of the channel. T41955 BIOCLASS Transient receptor potential catioin channel T41955 SEQUENCE MSFRAARLSMRNRRNDTLDSTRTLYSSASRSTDLSYSESDLVNFIQANFKKRECVFFTKDSKATENVCKCGYAQSQHMEGTQINQSEKWNYKKHTKEFPTDAFGDIQFETLGKKGKYIRLSCDTDAEILYELLTQHWHLKTPNLVISVTGGAKNFALKPRMRKIFSRLIYIAQSKGAWILTGGTHYGLMKYIGEVVRDNTISRSSEENIVAIGIAAWGMVSNRDTLIRNCDAEGYFLAQYLMDDFTRDPLYILDNNHTHLLLVDNGCHGHPTVEAKLRNQLEKYISERTIQDSNYGGKIPIVCFAQGGGKETLKAINTSIKNKIPCVVVEGSGQIADVIASLVEVEDALTSSAVKEKLVRFLPRTVSRLPEEETESWIKWLKEILECSHLLTVIKMEEAGDEIVSNAISYALYKAFSTSEQDKDNWNGQLKLLLEWNQLDLANDEIFTNDRRWESADLQEVMFTALIKDRPKFVRLFLENGLNLRKFLTHDVLTELFSNHFSTLVYRNLQIAKNSYNDALLTFVWKLVANFRRGFRKEDRNGRDEMDIELHDVSPITRHPLQALFIWAILQNKKELSKVIWEQTRGCTLAALGASKLLKTLAKVKNDINAAGESEELANEYETRAVELFTECYSSDEDLAEQLLVYSCEAWGGSNCLELAVEATDQHFIAQPGVQNFLSKQWYGEISRDTKNWKIILCLFIIPLVGCGFVSFRKKPVDKHKKLLWYYVAFFTSPFVVFSWNVVFYIAFLLLFAYVLLMDFHSVPHPPELVLYSLVFVLFCDEVRQWYVNGVNYFTDLWNVMDTLGLFYFIAGIVFRLHSSNKSSLYSGRVIFCLDYIIFTLRLIHIFTVSRNLGPKIIMLQRMLIDVFFFLFLFAVWMVAFGVARQGILRQNEQRWRWIFRSVIYEPYLAMFGQVPSDVDGTTYDFAHCTFTGNESKPLCVELDEHNLPRFPEWITIPLVCIYMLSTNILLVNLLVAMFGYTVGTVQENNDQVWKFQRYFLVQEYCSRLNIPFPFIVFAYFYMVVKKCFKCCCKEKNMESSVCCFKNEDNETLAWEGVMKENYLVKINTKANDTSEEMRHRFRQLDTKLNDLKGLLKEIANKIK T41955 DRUGINFO D04CSZ Menthol Approved T41955 DRUGINFO D04FKX D-3263 Phase 1 T41955 DRUGINFO D09NAW PF-05105679 Phase 1 T41955 DRUGINFO D00AVT Perillaldehyde Investigative T41955 DRUGINFO D01PZP hydroxycitronellal Investigative T41955 DRUGINFO D03NZW PMD38 Investigative T41955 DRUGINFO D04LSR thio-BCTC Investigative T41955 DRUGINFO D04NGL WS-12 Investigative T41955 DRUGINFO D05WZK frescolat ML Investigative T41955 DRUGINFO D05YAR eucalyptol Investigative T41955 DRUGINFO D06NGQ 5-Benzyloxytryptamine Investigative T41955 DRUGINFO D08KPQ M8-B Investigative T41955 DRUGINFO D09GBL isopulegol Investigative T41955 DRUGINFO D09QSY frescolat MGA Investigative T41955 DRUGINFO D0A1UL RQ-00203078 Investigative T41955 DRUGINFO D0A4TS WS-5 Investigative T41955 DRUGINFO D0B4ZT WS-23 Investigative T41955 DRUGINFO D0D8FW PBMC Investigative T41955 DRUGINFO D0G8FU CPS125 Investigative T41955 DRUGINFO D0J9CR AMTB Investigative T41955 DRUGINFO D0Q4GB geraniol Investigative T41955 DRUGINFO D0T6XB WS-3 Investigative T41955 DRUGINFO D0V1PD cooling agent 10 Investigative T41955 DRUGINFO D0X5DC linalool Investigative T41955 DRUGINFO D04ULU icilin Investigative T41955 DRUGINFO D05DAG 2-(5-fluoro-1H-indol-3-yl)ethanamine Investigative T41955 DRUGINFO D07YQG NADA Investigative T41955 DRUGINFO D0C8MT 2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine Investigative T41955 DRUGINFO D04AQE 5-METHOXYTRYPTAMINE Investigative T41955 DRUGINFO D0N7MS ACAA Investigative T41955 DRUGINFO D00HCI 2-APB Investigative T70680 TARGETID T70680 T70680 FORMERID TTDS00504 T70680 UNIPROID S22A8_HUMAN T70680 TARGNAME Solute carrier family 22 member 8 (SLC22A8) T70680 GENENAME SLC22A8 T70680 TARGTYPE Successful T70680 SYNONYMS hROAT1; hPAHT; hOAT1; Solute carrier family 22 member 6; SLC22A8; SLC22A6; Renal organic anion transporter 1; PAHT; PAH transporter; OAT1 T70680 FUNCTION Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). T70680 BIOCLASS Major facilitator superfamily T70680 SEQUENCE MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCRPPHNASTGPWVLPMGPNGKPERCLRFVHPPNASLPNDTQRAMEPCLDGWVYNSTKDSIVTEWDLVCNSNKLKEMAQSIFMAGILIGGLVLGDLSDRFGRRPILTCSYLLLAASGSGAAFSPTFPIYMVFRFLCGFGISGITLSTVILNVEWVPTRMRAIMSTALGYCYTFGQFILPGLAYAIPQWRWLQLTVSIPFFVFFLSSWWTPESIRWLVLSGKSSKALKILRRVAVFNGKKEEGERLSLEELKLNLQKEISLAKAKYTASDLFRIPMLRRMTFCLSLAWFATGFAYYSLAMGVEEFGVNLYILQIIFGGVDVPAKFITILSLSYLGRHTTQAAALLLAGGAILALTFVPLDLQTVRTVLAVFGKGCLSSSFSCLFLYTSELYPTVIRQTGMGVSNLWTRVGSMVSPLVKITGEVQPFIPNIIYGITALLGGSAALFLPETLNQPLPETIEDLENWSLRAKKPKQEPEVEKASQRIPLQPHGPGLGSS T70680 DRUGINFO D0L7FM Probenecid Approved T70680 DRUGINFO D06TJJ FLUORESCEIN Approved T70680 DRUGINFO D04LTQ Buproprion+zonisamide Phase 2 T70680 DRUGINFO D04DLM AMINOHIPPURIC ACID Investigative T70680 DRUGINFO D04XDS GLUTARATE Investigative T70680 DRUGINFO D05KFG ADIPATE Investigative T70680 DRUGINFO D0KN6Q 3R14S-OCHRATOXIN A Investigative T70680 DRUGINFO D0L7UB HEPTANOATE Investigative T88185 TARGETID T88185 T88185 FORMERID TTDC00317 T88185 UNIPROID HCAR2_HUMAN T88185 TARGNAME Nicotinic acid receptor (HCAR2) T88185 GENENAME HCAR2 T88185 TARGTYPE Successful T88185 SYNONYMS Niacin receptor 1; NIACR1; Hydroxycarboxylic acid receptor 2; HM74A; HCA2; GPR109A; G-protein coupled receptor HM74A; G-protein coupled receptor 109A T88185 FUNCTION Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide. T88185 BIOCLASS GPCR rhodopsin T88185 SEQUENCE MNRHHLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWKSSRIFLFNLAVADFLLIICLPFLMDNYVRRWDWKFGDIPCRLMLFMLAMNRQGSIIFLTVVAVDRYFRVVHPHHALNKISNRTAAIISCLLWGITIGLTVHLLKKKMPIQNGGANLCSSFSICHTFQWHEAMFLLEFFLPLGIILFCSARIIWSLRQRQMDRHAKIKRAITFIMVVAIVFVICFLPSVVVRIRIFWLLHTSGTQNCEVYRSVDLAFFITLSFTYMNSMLDPVVYYFSSPSFPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPWSPSYLGPTSP T88185 DRUGINFO D0N0ES Vitamin B3 Approved T88185 DRUGINFO D01DDN SCH-900271 Phase 2 T88185 DRUGINFO D04ODO GSK-256073 Phase 2 T88185 DRUGINFO D09TGC MK-1903 Phase 2 T88185 DRUGINFO D0A5MR MK-0354 Phase 2 T88185 DRUGINFO D01VMZ ARI-3037MO Phase 2 T88185 DRUGINFO D0V0WE NIA-114 Clinical trial T88185 DRUGINFO D0E5MJ INCB19602 Discontinued in Phase 2 T88185 DRUGINFO D00TPG 5-Benzyl-1H-pyrazole-3-carboxylic acid Investigative T88185 DRUGINFO D00WPU Sazetidine-A Investigative T88185 DRUGINFO D01AUX 2-(3-biphenyl-4-yl-propionylamino)-benzoic acid Investigative T88185 DRUGINFO D02EBQ 3-pyridine-acetic acid Investigative T88185 DRUGINFO D02YVZ 2-(6-phenylhexyl)pyrido[2,3-d]pyrimidin-4(3H)-one Investigative T88185 DRUGINFO D05VGC PMID21185185C21 Investigative T88185 DRUGINFO D06UZK 4,5,6,7-Tetrahydro-1H-indazole-3-carboxylic acid Investigative T88185 DRUGINFO D06WXN PMID20615702C8f Investigative T88185 DRUGINFO D07BFA 2-(2-(4-tert-butylphenoxy)acetamido)benzoic acid Investigative T88185 DRUGINFO D07NDW PMID18752940C9n Investigative T88185 DRUGINFO D07ONY 5-(3-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid Investigative T88185 DRUGINFO D07TVE PMID20363624C(+)17a Investigative T88185 DRUGINFO D07XKG 2-(4-phenylbutyl)pyrido[2,3-d]pyrimidin-4(3H)-one Investigative T88185 DRUGINFO D09UXZ 5-Phenethyl-1H-pyrazole-3-carboxylic acid Investigative T88185 DRUGINFO D09ZPN MK-6892 Investigative T88185 DRUGINFO D0ET2F 5-methyl nicotinic acid Investigative T88185 DRUGINFO D0FF9F 5-Butyl-1H-pyrazole-3-carboxylic acid Investigative T88185 DRUGINFO D0G2LQ 5-(4-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid Investigative T88185 DRUGINFO D0G8TM (+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid Investigative T88185 DRUGINFO D0IC7C 5-Isopropyl-1H-pyrazole-3-carboxylic acid Investigative T88185 DRUGINFO D0M4BZ 2-(3-(naphthalen-2-yl)propanamido)benzoic acid Investigative T88185 DRUGINFO D0M7DC 1H-Pyrazole-3-carboxylic acid Investigative T88185 DRUGINFO D0Q0PN PMID19309152C2g Investigative T88185 DRUGINFO D0R4GX beta-D-hydroxybutyric acid Investigative T88185 DRUGINFO D0S3XI monomethylfumarate Investigative T88185 DRUGINFO D0U6SQ 5-Propyl-1H-pyrazole-3-carboxylic acid Investigative T88185 DRUGINFO D0V9LR PMID22420767C42 Investigative T88185 DRUGINFO D0W5CQ ISONICOTINIC ACID Investigative T88185 DRUGINFO D0W5TY 5-(3-Phenyl-propyl)-1H-pyrazole-3-carboxylic acid Investigative T88185 DRUGINFO D0Y7XK 2-(cinnamyloxy)pyrido[2,3-d]pyrimidin-4(3H)-one Investigative T88185 DRUGINFO D0T2QL cinnamic acid Investigative T93788 TARGETID T93788 T93788 FORMERID TTDC00050 T93788 UNIPROID GP119_HUMAN T93788 TARGNAME Glucose-dependent insulinotropic receptor (GPR119) T93788 GENENAME GPR119 T93788 TARGTYPE Successful T93788 SYNONYMS GPR119; G-protein coupled receptor 119 T93788 FUNCTION Receptor for the endogenous fatty-acid ethanolamide oleoylethanolamide (OEA) and lysophosphatidylcholine (LPC). Functions as a glucose-dependent insulinotropic receptor. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Seems to act through a G(s) mediated pathway. T93788 BIOCLASS GPCR rhodopsin T93788 SEQUENCE MESSFSFGVILAVLASLIIATNTLVAVAVLLLIHKNDGVSLCFTLNLAVADTLIGVAISGLLTDQLSSPSRPTQKTLCSLRMAFVTSSAAASVLTVMLITFDRYLAIKQPFRYLKIMSGFVAGACIAGLWLVSYLIGFLPLGIPMFQQTAYKGQCSFFAVFHPHFVLTLSCVGFFPAMLLFVFFYCDMLKIASMHSQQIRKMEHAGAMAGGYRSPRTPSDFKALRTVSVLIGSFALSWTPFLITGIVQVACQECHLYLVLERYLWLLGVGNSLLNPLIYAYWQKEVRLQLYHMALGVKKVLTSFLLFLSARNCGPERPRESSCHIVTISSSEFDG T93788 DRUGINFO D07ILQ Guanfacine extended release Approved T93788 DRUGINFO D03AOP DS-8500 Phase 2 T93788 DRUGINFO D07QHF SAR-260093 Phase 2 T93788 DRUGINFO D0S4II GSK1292263 Phase 2 T93788 DRUGINFO D00WDY BMS-903452 Phase 1 T93788 DRUGINFO D0O9XN APD-597 Phase 1 T93788 DRUGINFO DX4A3Q DA-1241 Phase 1 T93788 DRUGINFO D0Q3ES APD668 Discontinued in Phase 1 T93788 DRUGINFO D0F1KP PSN821 Terminated T93788 DRUGINFO D00GTC AS1269574 Investigative T93788 DRUGINFO D00LMY RO-5212651 Investigative T93788 DRUGINFO D00WVI AS-1907417 Investigative T93788 DRUGINFO D01GPC PMID21273063C58 Investigative T93788 DRUGINFO D01URR PMID21939274C2 Investigative T93788 DRUGINFO D01VZL PSN632408 Investigative T93788 DRUGINFO D02GEQ lysophosphatidylethanolamine Investigative T93788 DRUGINFO D02HWL oleoyl-lysophosphatidylcholine Investigative T93788 DRUGINFO D02KIM PMID21536438C36j Investigative T93788 DRUGINFO D02UXK MBX-3254 Investigative T93788 DRUGINFO D02XKE 1-oleoyl glycerol Investigative T93788 DRUGINFO D03PVV 1-palmitoyl-lysophosphatidylcholine Investigative T93788 DRUGINFO D05FOV 2-oleoyl glycerol Investigative T93788 DRUGINFO D06KHW PMID21939274C1 Investigative T93788 DRUGINFO D06QYM PMID21310611C3 Investigative T93788 DRUGINFO D07TAL PMID21536438C20f Investigative T93788 DRUGINFO D08HOK PMID21444206C3a Investigative T93788 DRUGINFO D09ROS PMID21444206C23 Investigative T93788 DRUGINFO D0B8SS 1-stearoyl-lysophosphatidylcholine Investigative T93788 DRUGINFO D0HI5B PSN375963 Investigative T93788 DRUGINFO D0I2EL PMID21444206C3j Investigative T93788 DRUGINFO D0K0LA LC34AD3 Investigative T93788 DRUGINFO D0LX6R (S)-N-oleoyltyrosinol Investigative T93788 DRUGINFO D0NL5K SEA Investigative T93788 DRUGINFO D0R5QF AR231453 Investigative T93788 DRUGINFO D0R6PF PMID22545772C42 Investigative T93788 DRUGINFO D0S4FV (R)-N-oleoyltyrosinol Investigative T93788 DRUGINFO D0VA7C PMID21273063C1 Investigative T93788 DRUGINFO D0X3NW PMID21444206C8g Investigative T93788 DRUGINFO D0XM1U PMID21273063C36 Investigative T93788 DRUGINFO D0YT3Z AR-7947 Investigative T93788 DRUGINFO D0M1UA lysophosphatidylinositol Investigative T93788 DRUGINFO D07MBC N-oleoylethanolamide Investigative T53748 TARGETID T53748 T53748 FORMERID TTDS00235 T53748 UNIPROID Q965D5_PLAFA T53748 TARGNAME Plasmodium Enoyl-ACP reductase (Malaria fabI) T53748 GENENAME Malaria fabI T53748 TARGTYPE Successful T53748 SYNONYMS fabI; NADH-dependent enoyl-ACP reductase; Enoyl-acyl-carrier protein reductase; Enoyl-acyl carrier reductase; Enoyl-acyl carrier protein reductase; Enoyl-ACP reductase FabI T53748 FUNCTION Catalyzes the reduction of a carbon-carbon double bond in an enoyl moiety that is covalently linked to an acyl carrier protein (ACP). Involved in the elongation cycle of fatty acid which are used in the lipid metabolism and in the biotin biosynthesis. T53748 BIOCLASS CH-CH donor oxidoreductase T53748 ECNUMBER EC 1.3.1.9 T53748 SEQUENCE MNKISQRLLFLFLHFYTTVCFIQNNTQKTFHNVLQNEQIRGKEKAFYRKEKRENIFIGNKMKHVHNMNNTHNNNHYMEKEEQDASNINKIKEENKNEDICFIAGIGDTNGYGWGIAKELSKRNVKIIFGIWPPVYNIFMKNYKNGKFDNDMIIDKDKKMNILDMLPFDASFDTANDIDEETKNNKRYNMLQNYPIEDVANLIHQKYGKINMLVHSLANAKEVQKDLLNTSRKGYLDALSKSSYSLISLCKYFVNIMKPQSSIISLTYHASQKVVPGYGGGMSSAKAALESDTRVLAYHLGRNYNIRINTISAGPLKSRAATAINKLNNTYENNTNQNKNRNSHDVHNIMNNSGEKEEKKNSASQNYTFIDYAIEYSEKYAPLRQKLLSTDIGSVASFLLSRESRAITGQTIYVDNGLNIMFLPDDIYRNENE T53748 DRUGINFO D00CSQ Triclosan Approved T53748 DRUGINFO D0U2BH Epigallocatechin gallate Phase 3 T53748 DRUGINFO D00TWC 4-(2,4-dichloro-phenoxy)-2'-methyl-biphenyl-3-ol Investigative T53748 DRUGINFO D01DTE 5-chloro-2-(2-chloro-4-hydroxyphenoxy)phenol Investigative T53748 DRUGINFO D01TGI 4-(2,4-dichloro-phenoxy)-biphenyl-3-ol Investigative T53748 DRUGINFO D03DND 2-(2,4-dichlorophenoxy)-5-propylphenol Investigative T53748 DRUGINFO D05VXX 5-butyl-2-(2,4-dichlorophenoxy)phenol Investigative T53748 DRUGINFO D08EME 4-(2,4-dichlorophenoxy)-4'-methylbiphenyl-3-ol Investigative T53748 DRUGINFO D08FBM 2-(2,4-dichlorophenoxy)-5-phenethylphenol Investigative T53748 DRUGINFO D08KNJ 4-(2,4-dichlorophenoxy)-3'-methylbiphenyl-3-ol Investigative T53748 DRUGINFO D09QZL 3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide Investigative T53748 DRUGINFO D0A1XH 2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol Investigative T53748 DRUGINFO D0A7US 2-(2,4-dichlorophenoxy)-5-isopentylphenol Investigative T53748 DRUGINFO D0A9HU 2-(4-chloro-2-hydroxyphenoxy)benzenaminium Investigative T53748 DRUGINFO D0D9ES 2-(2-((benzylamino)methyl)phenoxy)-5-chlorophenol Investigative T53748 DRUGINFO D0FW2W 4-(2,4-dichloro-phenoxy)-4'-fluoro-biphenyl-3-ol Investigative T53748 DRUGINFO D0JL2T 3,7-dihydroxy-flavone Investigative T53748 DRUGINFO D0L0AZ 2-(2,4-dichlorophenoxy)-5-isobutylphenol Investigative T53748 DRUGINFO D0L7HD 5-benzyl-2-(2,4-dichlorophenoxy)phenol Investigative T53748 DRUGINFO D0LU2N 2-(2,4-dichlorophenoxy)-5-ethylphenol Investigative T53748 DRUGINFO D0O9UI 2-(2,4-dichlorophenoxy)-5-methylphenol Investigative T53748 DRUGINFO D0QV8V 2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol Investigative T53748 DRUGINFO D0U7MR 4-(2,4-dichlorophenoxy)-3-hydroxybenzonitrile Investigative T53748 DRUGINFO D0X4BJ 2-(4-amino-2-chlorophenoxy)-5-chlorophenol Investigative T53748 DRUGINFO D0Z7FM 5-chloro-2-(2-chloro-4-nitrophenoxy)phenol Investigative T53748 DRUGINFO D08BMM OROIDIN Investigative T53748 DRUGINFO D0B3UG 4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole Investigative T53748 DRUGINFO D0EW3L BUTEIN Investigative T53748 DRUGINFO D0Z7SL Indole Naphthyridinone Investigative T53748 DRUGINFO D07YDN ISORHAMNETIN Investigative T53748 DRUGINFO D04JTY Thiolactomycin Investigative T53748 DRUGINFO D07KXK GALLOCATECHIN GALLATE Investigative T53748 DRUGINFO D08ZHT Diazaborines Investigative T53748 DRUGINFO D0MF5Y 3,7,3',4'-TETRAHYDROXYFLAVONE Investigative T53748 DRUGINFO D0RB1V (-)-CATECHINGALLATE Investigative T53748 DRUGINFO D0NJ4H MORIN Investigative T53748 DRUGINFO D07ONX Beta-D-Glucose Investigative T53748 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T95558 TARGETID T95558 T95558 FORMERID TTDS00531 T95558 UNIPROID DGAT2_HUMAN T95558 TARGNAME Diacylglycerol O-acyltransferase 2 (DGAT2) T95558 GENENAME DGAT2 T95558 TARGTYPE Successful T95558 SYNONYMS UNQ738/PRO1433; HMFN1045; Diglyceride acyltransferase 2 T95558 FUNCTION Required for synthesis and storage of intracellular triglycerides. Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides. Functions also as an acyl-CoA retinol acyltransferase (ARAT). Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. T95558 BIOCLASS Acyltransferase T95558 ECNUMBER EC 2.3.1.20 T95558 SEQUENCE MKTLIAAYSGVLRGERQAEADRSQRSHGGPALSREGSGRWGTGSSILSALQDLFSVTWLNRSKVEKQLQVISVLQWVLSFLVLGVACSAILMYIFCTDCWLIAVLYFTWLVFDWNTPKKGGRRSQWVRNWAVWRYFRDYFPIQLVKTHNLLTTRNYIFGYHPHGIMGLGAFCNFSTEATEVSKKFPGIRPYLATLAGNFRMPVLREYLMSGGICPVSRDTIDYLLSKNGSGNAIIIVVGGAAESLSSMPGKNAVTLRNRKGFVKLALRHGADLVPIYSFGENEVYKQVIFEEGSWGRWVQKKFQKYIGFAPCIFHGRGLFSSDTWGLVPYSKPITTVVGEPITIPKLEHPTQQDIDLYHTMYMEALVKLFDKHKTKFGLPETEVLEVN T95558 DRUGINFO D0N0ES Vitamin B3 Approved T95558 DRUGINFO D8VP6R PF-06865571 Phase 2 T95558 DRUGINFO D01VMZ ARI-3037MO Phase 2 T95558 DRUGINFO D0UL2I PF-06427878 Phase 1 T95558 DRUGINFO D0Z4RS PMID25470667-Compound-roselipins Patented T95558 DRUGINFO D0L5DV PMID25470667-Compound-Figure4-1A Patented T99524 TARGETID T99524 T99524 FORMERID TTDI01906 T99524 UNIPROID TAAR1_HUMAN T99524 TARGNAME Trace amine-associated receptor-1 (TAAR1) T99524 GENENAME TAAR1 T99524 TARGTYPE Successful T99524 SYNONYMS Trace amine receptor 1; TaR-1; TAAR1 T99524 FUNCTION Receptor for trace amines, including beta- phenylethylamine (b-PEA), p-tyramine (p-TYR), octopamine and tryptamine, with highest affinity for b-PEA and p-TYR. Unresponsive to classical biogenic amines,such as epinephrine and histamine and only partially activated by dopamine and serotonine. Trace amines are biogenic amines present in very low levels in mammalian tissues. Although some trace amineshave clearly defined roles as neurotransmitters in invertebrates, the extent to which they function as true neurotransmitters in vertebrates has remained speculative. Trace amines are likely to be involved in a variety of physiological functions that have yet to be fully understood. The signal transduced by this receptor is mediated by the G(s)-class of G-proteins which activate adenylate cyclase. T99524 BIOCLASS GPCR rhodopsin T99524 SEQUENCE MMPFCHNIINISCVKNNWSNDVRASLYSLMVLIILTTLVGNLIVIVSISHFKQLHTPTNWLIHSMATVDFLLGCLVMPYSMVRSAEHCWYFGEVFCKIHTSTDIMLSSASIFHLSFISIDRYYAVCDPLRYKAKMNILVICVMIFISWSVPAVFAFGMIFLELNFKGAEEIYYKHVHCRGGCSVFFSKISGVLTFMTSFYIPGSIMLCVYYRIYLIAKEQARLISDANQKLQIGLEMKNGISQSKERKAVKTLGIVMGVFLICWCPFFICTVMDPFLHYIIPPTLNDVLIWFGYLNSTFNPMVYAFFYPWFRKALKMMLFGKIFQKDSSRCKLFLELSS T99524 DRUGINFO D00DEF Lisdexamfetamine Approved T99524 DRUGINFO D05BMG Amphetamine Approved T99524 DRUGINFO D0T3LF Dextroamphetamine Approved T99524 DRUGINFO D0W1RY Hydroxyamphetamine Hydrobromide Approved T99524 DRUGINFO D04IUB NT0202 Phase 3 T99524 DRUGINFO D0CZ5Z SPD-465 Phase 3 T99524 DRUGINFO D04ZKY SEP-363856 Phase 3 T99524 DRUGINFO D0L4ZK RG-7351 Phase 1 T99524 DRUGINFO D05GOP EPPTB Investigative T99524 DRUGINFO D07BAH R(-)amphetamine Investigative T99524 DRUGINFO D0C5RZ tyramine Investigative T99524 DRUGINFO D0HR1V 3-iodothyronamine Investigative T99524 DRUGINFO D0O9ZY RO5166017 Investigative T86057 TARGETID T86057 T86057 FORMERID TTDC00243 T86057 UNIPROID S22AC_HUMAN T86057 TARGNAME Urate anion exchanger 1 (URAT1) T86057 GENENAME SLC22A12 T86057 TARGTYPE Successful T86057 SYNONYMS UNQ6453/PRO34004; Solute carrier family 22 member 12; Renal-specific transporter; RST; Organic anion transporter 4-like protein; OATL4 T86057 FUNCTION Regulates blood urate levels. Mediates saturable urate uptake by facilitating the exchange of urate against organic anions. Required for efficient urate re-absorption in the kidney. T86057 BIOCLASS Major facilitator T86057 SEQUENCE MAFSELLDLVGGLGRFQVLQTMALMVSIMWLCTQSMLENFSAAVPSHRCWAPLLDNSTAQASILGSLSPEALLAISIPPGPNQRPHQCRRFRQPQWQLLDPNATATSWSEADTEPCVDGWVYDRSIFTSTIVAKWNLVCDSHALKPMAQSIYLAGILVGAAACGPASDRFGRRLVLTWSYLQMAVMGTAAAFAPAFPVYCLFRFLLAFAVAGVMMNTGTLLMEWTAARARPLVMTLNSLGFSFGHGLTAAVAYGVRDWTLLQLVVSVPFFLCFLYSWWLAESARWLLTTGRLDWGLQELWRVAAINGKGAVQDTLTPEVLLSAMREELSMGQPPASLGTLLRMPGLRFRTCISTLCWFAFGFTFFGLALDLQALGSNIFLLQMFIGVVDIPAKMGALLLLSHLGRRPTLAASLLLAGLCILANTLVPHEMGALRSALAVLGLGGVGAAFTCITIYSSELFPTVLRMTAVGLGQMAARGGAILGPLVRLLGVHGPWLPLLVYGTVPVLSGLAALLLPETQSLPLPDTIQDVQNQAVKKATHGTLGNSVLKSTQF T86057 DRUGINFO D0C3SW Lesinurad Approved T86057 DRUGINFO DA29IM Dotinurad Phase 3 T86057 DRUGINFO D03BSK URC102 Phase 2 T86057 DRUGINFO D06UTH RDEA-684 Phase 2 T86057 DRUGINFO D0P3ZN RDEA3170 Phase 2 T86057 DRUGINFO D62LZO AR882 Phase 2 T86057 DRUGINFO D02JOK Sulfonamide derivative 11 Patented T86057 DRUGINFO D02USA Cycloalkyl acid derivative 1 Patented T86057 DRUGINFO D03PZX 2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1 Patented T86057 DRUGINFO D03QGH Tihoacetate derivative 1 Patented T86057 DRUGINFO D03UNB Cycloalkyl acid derivative 2 Patented T86057 DRUGINFO D04ULX Succinamide derivative 1 Patented T86057 DRUGINFO D06LEZ Benzene sulfonamide derivative 16 Patented T86057 DRUGINFO D06RFO Benzofurans derivative 1 Patented T86057 DRUGINFO D07FCV PMID27414413-Compound-Figure6right Patented T86057 DRUGINFO D07IZC Ring-fused compound 1 Patented T86057 DRUGINFO D0CK1D 3-benzyloxyphenyloxoacetic acid derivative 1 Patented T86057 DRUGINFO D0D5YG PMID27414413-Compound-Figure8right Patented T86057 DRUGINFO D0FX9D Tetrazole acetic acid derivative 1 Patented T86057 DRUGINFO D0HG2S Sulfonamide derivative 10 Patented T86057 DRUGINFO D0JM7W Phenylthioacetate derivative 1 Patented T86057 DRUGINFO D0KD6U Benzoic acid derivative 1 Patented T86057 DRUGINFO D0ND8U Fused heterocyclic compound 12 Patented T86057 DRUGINFO D0R5DH Triazole propanedioic acid derivative 1 Patented T86057 DRUGINFO D0NJ4H MORIN Investigative T96215 TARGETID T96215 T96215 FORMERID TTDS00058 T96215 UNIPROID Q9NGT0_PLAFA T96215 TARGNAME Plasmodium Glutamate dehydrogenase (Malaria gdh) T96215 GENENAME Malaria gdh T96215 TARGTYPE Successful T96215 SYNONYMS Glutamate dehydrogenase T96215 FUNCTION Catalyses the reversible oxidative deamination of L-glutamate to form -ketoglutarate and ammonia using NADP(H) or NAD(H) as co-factors T96215 BIOCLASS CH-NH(2) donor oxidoreductase T96215 ECNUMBER EC 1.4.1.2 T96215 SEQUENCE MDIDRRSALSCSPNNMECGFGSGHFSNNSITWKEKYEQTKELLKSYNLFSDHLINYSIDFYFNKLGFNKFHFEETSPELISKVVVCIITAKINEQYSSDKYFPTFEETHDNVIFIITRVFADDNKTRLNYKMEKKIEEKYFNFSDMSKDCYRLKSFRSVHSVFDKEHTYQEPLRTYILELPTYNDDIIKENETDLKKLMDVNFYNYIKGTRSEQIYYELNKAVLYDLTGQFLQTHYYETSSSTFTLTIAVKRSNVISSIFSLIGDCLNMHRCFSYSKYVEPLKNGVLLIILNVKVIVNNEMEREKQKLDLKDKIYKVVKSLKTLCLFNDSKFIQLSVKRTFTAQESAYLFMIIKFITFFSTFTLSSYKNVEHALNLRNYNNNIMDTTTNSSSSPSSVLNDVYIIKEKLKSSKYTKEEILRCAQSNVRTIKMLFANFEKKLNHQRNKCNQMKYGENNMKNSGDLLKEYSTNNRNVDHPTLSSLASSSSSCSSSFSLHSYLSGSYESPYYHHNKDSKDIIDEIEDNHDKKILQYFYMFEKYALKTNFFLTHKISLAVAFDGALLKDSIYEAQPYSIIMILGLHFVGFHIRFSKISRGGVRIVISNNVNSYMHNSDNLFDEAYNLAYTQNFKNKDIPEGGSKGIILLDADVCNVANTKYIKNLSFYSYVNSILDLLINEDLNEERASSISVHSTKGANNTTITFDNVMSSVENMVDRGGVEGEHLNITLPYDANMACNNNTTNDNLSNMHDTYNLNNSGEATLDHHSVDNRIVSNSSGTNNMNAQKGEGEDEKAKDKEMSNNRKNEENERKRCDNVSNSNYNYVNGTTEDAVQKIMGSKCKGGRNNNGEEKDGDMNGHNNNNNDNNNIDDDEHIEECYKGAGCVINGENKTRKMILQEKMNEEEDLIFLGPDENTGSDQLMDWACIIAKREYIHIGKPFQQGKLRKNGGVPHDMYGMTTLGIETYISKLCEKLNIKEESISRSLVGGPDGDLGSNAILQSKTKIISIIDGSGILYDKQGLNKEELIRLAKRRNNKDKSKAITCCTLYDEKYFSKDGFKISIEDHNVDIFGNKIRNGLDFRNTFFLNPLNKCELFNPCGGRPHSINIFNVNNIIKNGECIYKYIVEGANVFISDDARNILESKNVILFKDAATNKGGVISSSLEVLAGLVLDDKQYIDYMCSPDSDILQVDENEINFVHQNQKMNHSLSFKRGSINNLEEDEKKDTSNNEKNKNIIKTVNKNDTQDNSHHHNNSNKCNEDQQDVSDFYKAYVKEIQKKITHYCELEFESLWKETRRTKTPISKAINILSNKISELKKDILSSDTLCRDYKLLKKVLERVIPPTLLKIVTFEQILERVPYVYIKSLLASARASKLLLFTTILE T96215 DRUGINFO D0ZX2G Hexachlorophene Approved T76937 TARGETID T76937 T76937 FORMERID TTDR01255 T76937 UNIPROID SCN3A_HUMAN T76937 TARGNAME Voltage-gated sodium channel alpha Nav1.3 (SCN3A) T76937 GENENAME SCN3A T76937 TARGTYPE Successful T76937 SYNONYMS Voltage-gated sodium channel subunit alpha Nav1.3; Voltage-gated sodium channel subtype III; Sodium channel protein, brain III subunit alpha; Sodium channel protein type III subunit alpha; Sodium channel protein type 3 subunit alpha; Sodium channel protein brain III subunit alpha; NAC3; KIAA1356 T76937 FUNCTION Assuming opened or closed conformations in response to the voltage difference across the membrane, forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. May contribute to the regulation of serotonin/5-hydroxytryptamine release by enterochromaffin cells. In pancreatic endocrine cells, required for both glucagon and glucose-induced insulin secretion. Mediates the voltage-dependent sodium ion permeability of excitable membranes. T76937 BIOCLASS Voltage-gated ion channel T76937 SEQUENCE MAQALLVPPGPESFRLFTRESLAAIEKRAAEEKAKKPKKEQDNDDENKPKPNSDLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVMNKGKAIFRFSATSALYILTPLNPVRKIAIKILVHSLFSMLIMCTILTNCVFMTLSNPPDWTKNVEYTFTGIYTFESLIKILARGFCLEDFTFLRDPWNWLDFSVIVMAYVTEFVSLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCLQWPPSDSAFETNTTSYFNGTMDSNGTFVNVTMSTFNWKDYIGDDSHFYVLDGQKDPLLCGNGSDAGQCPEGYICVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDYWENLYQLTLRAAGKTYMIFFVLVIFLGSFYLVNLILAVVAMAYEEQNQATLEEAEQKEAEFQQMLEQLKKQQEEAQAVAAASAASRDFSGIGGLGELLESSSEASKLSSKSAKEWRNRRKKRRQREHLEGNNKGERDSFPKSESEDSVKRSSFLFSMDGNRLTSDKKFCSPHQSLLSIRGSLFSPRRNSKTSIFSFRGRAKDVGSENDFADDEHSTFEDSESRRDSLFVPHRHGERRNSNVSQASMSSRMVPGLPANGKMHSTVDCNGVVSLVGGPSALTSPTGQLPPEGTTTETEVRKRRLSSYQISMEMLEDSSGRQRAVSIASILTNTMEELEESRQKCPPCWYRFANVFLIWDCCDAWLKVKHLVNLIVMDPFVDLAITICIVLNTLFMAMEHYPMTEQFSSVLTVGNLVFTGIFTAEMVLKIIAMDPYYYFQEGWNIFDGIIVSLSLMELGLSNVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKINDDCTLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQTMCLIVFMLVMVIGNLVVLNLFLALLLSSFSSDNLAATDDDNEMNNLQIAVGRMQKGIDYVKNKMRECFQKAFFRKPKVIEIHEGNKIDSCMSNNTGIEISKELNYLRDGNGTTSGVGTGSSVEKYVIDENDYMSFINNPSLTVTVPIAVGESDFENLNTEEFSSESELEESKEKLNATSSSEGSTVDVVLPREGEQAETEPEEDLKPEACFTEGCIKKFPFCQVSTEEGKGKIWWNLRKTCYSIVEHNWFETFIVFMILLSSGALAFEDIYIEQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGFQTYFTNAWCWLDFLIVDVSLVSLVANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYHCVNMTTGNMFDISDVNNLSDCQALGKQARWKNVKVNFDNVGAGYLALLQVATFKGWMDIMYAAVDSRDVKLQPVYEENLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPANKFQGMVFDFVTRQVFDISIMILICLNMVTMMVETDDQGKYMTLVLSRINLVFIVLFTGEFVLKLVSLRHYYFTIGWNIFDFVVVILSIVGMFLAEMIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKKEAGIDDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSAPPDCDPDTIHPGSSVKGDCGNPSVGIFFFVSYIIISFLVVVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALDPPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEDRFMASNPSKVSYEPITTTLKRKQEEVSAAIIQRNFRCYLLKQRLKNISSNYNKEAIKGRIDLPIKQDMIIDKLNGNSTPEKTDGSSSTTSPPSYDSVTKPDKEKFEKDKPEKESKGKEVRENQK T76937 DRUGINFO D0L7VL LIDOFLAZINE Approved T76937 DRUGINFO D03GPV Pyrimidine derivative 1 Patented T76937 DRUGINFO D06VYB Pyrrolo-pyridinone derivative 6 Patented T76937 DRUGINFO D09YJV Pyrrolo-pyridinone derivative 5 Patented T76937 DRUGINFO D0M8WO Aryl carboxamide derivative 1 Patented T76937 DRUGINFO D0OP5F Aryl carboxamide derivative 2 Patented T76937 DRUGINFO D0EC2K SIPATRIGINE Discontinued in Phase 2 T76937 DRUGINFO D02NLI PD-85639 Terminated T76937 DRUGINFO D0OW2O U-92032 Terminated T76937 DRUGINFO D0NC0G RQ-00203066 Investigative T76937 DRUGINFO D05XEF 5-Hexyl-5-phenyl-imidazolidine-2,4-dione Investigative T76937 DRUGINFO D08KBV 4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole Investigative T76937 DRUGINFO D08RNW 2-Hydroxy-2-phenyl-nonanoic acid amide Investigative T76937 DRUGINFO D08VUM 2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole Investigative T76937 DRUGINFO D08WQO 2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole Investigative T76937 DRUGINFO D0B8GI 5-Heptyl-5-phenyl-imidazolidine-2,4-dione Investigative T76937 DRUGINFO D0FL7O 4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole Investigative T76937 DRUGINFO D0K1UR 4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole Investigative T76937 DRUGINFO D0K8DH 4-Biphenyl-4-yl-2-hexyl-1H-imidazole Investigative T76937 DRUGINFO D0L5UC 5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione Investigative T76937 DRUGINFO D0N0KO CCNCSSKWCRDHSRCC Investigative T76937 DRUGINFO D0Q7GZ 5-Nonyl-5-phenyl-imidazolidine-2,4-dione Investigative T76937 DRUGINFO D0S7ZU 4-Biphenyl-4-yl-2-methyl-1H-imidazole Investigative T76937 DRUGINFO D0B9UU BW-202W92 Investigative T76937 DRUGINFO D0WU9R L-741742 Investigative T76937 DRUGINFO D0G9WE batrachotoxin Investigative T76937 DRUGINFO D0S4MN veratridine Investigative T96845 TARGETID T96845 T96845 UNIPROID IL37_HUMAN T96845 TARGNAME Interleukin-37 (IL37) T96845 GENENAME IL37 T96845 TARGTYPE Successful T96845 SYNONYMS Interleukin-1-related protein; Interleukin-1 zeta; Interleukin-1 homolog 4; Interleukin-1 family member 7; IL1RP1; IL1H4; IL1F7; IL-37; IL-1X; IL-1RP1; IL-1H4; IL-1H; IL-1F7; IL-1 zeta; FIL1Z; FIL1 zeta T96845 FUNCTION Suppressor of innate inflammatory and immune responses involved in curbing excessive inflammation. This function requires SMAD3. Suppresses, or reduces, proinflammatory cytokine production, including IL1A and IL6, as well as CCL12, CSF1, CSF2, CXCL13, IL1B, IL23A and IL1RN, but spares anti-inflammatory cytokines. Inhibits dendritic cell activation. T96845 PDBSTRUC 6NCU; 5HN1 T96845 BIOCLASS Cytokine: interleukin T96845 SEQUENCE MSFVGENSGVKMGSEDWEKDEPQCCLEDPAGSPLEPGPSLPTMNFVHTSPKVKNLNPKKFSIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEKGSPILLGVSKGEFCLYCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTSCNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD T96845 DRUGINFO D0FT3R Tildrakizumab Approved T98917 TARGETID T98917 T98917 UNIPROID MRM2_HUMAN T98917 TARGNAME Mitochondrial rRNA methyltransferase 2 (MRM2) T98917 GENENAME MRM2 T98917 TARGTYPE Successful T98917 SYNONYMS rRNA methyltransferase 2, mitochondrial; Protein ftsJ homolog 2; 16S rRNA [Um1369] 2'-O-methyltransferase; 16S rRNA (uridine(1369)-2'-O)-methyltransferase T98917 FUNCTION S-adenosyl-L-methionine-dependent 2'-O-ribose methyltransferase that catalyzes the formation of 2'-O-methyluridine at position 1369 (Um1369) in the 16S mitochondrial large subunit ribosomal RNA (mtLSU rRNA), a universally conserved modification in the peptidyl transferase domain of the mtLSU rRNA. T98917 PDBSTRUC 2NYU T98917 BIOCLASS Methyltransferase T98917 ECNUMBER EC 2.1.1.- T98917 SEQUENCE MAGYLKLVCVSFQRQGFHTVGSRCKNRTGAEHLWLTRHLRDPFVKAAKVESYRCRSAFKLLEVNERHQILRPGLRVLDCGAAPGAWSQVAVQKVNAAGTDPSSPVGFVLGVDLLHIFPLEGATFLCPADVTDPRTSQRILEVLPGRRADVILSDMAPNATGFRDLDHDRLISLCLTLLSVTPDILQPGGTFLCKTWAGSQSRRLQRRLTEEFQNVRIIKPEASRKESSEVYFLATQYHGRKGTVKQ T98917 DRUGINFO D0E6BB Plazomicin Approved T74500 TARGETID T74500 T74500 FORMERID TTDS00412 T74500 UNIPROID KCND3_HUMAN T74500 TARGNAME Voltage-gated potassium channel Kv4.3 (KCND3) T74500 GENENAME KCND3 T74500 TARGTYPE Successful T74500 SYNONYMS Voltage-gated potassium channel subunit Kv4.3; KCND3 T74500 FUNCTION Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits. T74500 PDBSTRUC 2NZ0; 1S1G T74500 BIOCLASS Voltage-gated ion channel T74500 SEQUENCE MAAGVAAWLPFARAAAIGWMPVANCPMPLAPADKNKRQDELIVLNVSGRRFQTWRTTLERYPDTLLGSTEKEFFFNEDTKEYFFDRDPEVFRCVLNFYRTGKLHYPRYECISAYDDELAFYGILPEIIGDCCYEEYKDRKRENAERLMDDNDSENNQESMPSLSFRQTMWRAFENPHTSTLALVFYYVTGFFIAVSVITNVVETVPCGTVPGSKELPCGERYSVAFFCLDTACVMIFTVEYLLRLFAAPSRYRFIRSVMSIIDVVAIMPYYIGLVMTNNEDVSGAFVTLRVFRVFRIFKFSRHSQGLRILGYTLKSCASELGFLLFSLTMAIIIFATVMFYAEKGSSASKFTSIPASFWYTIVTMTTLGYGDMVPKTIAGKIFGSICSLSGVLVIALPVPVIVSNFSRIYHQNQRADKRRAQKKARLARIRVAKTGSSNAYLHSKRNGLLNEALELTGTPEEEHMGKTTSLIESQHHHLLHCLEKTTGLSYLVDDPLLSVRTSTIKNHEFIDEQMFEQNCMESSMQNYPSTRSPSLSSHPGLTTTCCSRRSKKTTHLPNSNLPATRLRSMQELSTIHIQGSEQPSLTTSRSSLNLKADDGLRPNCKTSQITTAIISIPTPPALTPEGESRPPPASPGPNTNIPSIASNVVKVSAL T74500 DRUGINFO D02FLB Sodium bicarbonate Approved T74500 DRUGINFO D0N4MR CDE-5498 Terminated T23389 TARGETID T23389 T23389 FORMERID TTDC00329 T23389 UNIPROID TTHY_HUMAN T23389 TARGNAME Transthyretin messenger RNA (TTR mRNA) T23389 GENENAME TTR T23389 TARGTYPE Successful T23389 SYNONYMS Transthyretin (mRNA); TBPA (mRNA); Prealbumin (mRNA); PALB (mRNA); ATTR (mRNA) T23389 FUNCTION Probably transports thyroxine from the bloodstream to the brain. Thyroid hormone-binding protein. T23389 PDBSTRUC 6IMY; 6IMX; 6GRP; 6GR7; 6FZL T23389 BIOCLASS mRNA target T23389 SEQUENCE MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE T23389 DRUGINFO D02UYB Patisiran Approved T23389 DRUGINFO DE2CW9 Eplontersen Approved T23389 DRUGINFO DXRP68 Vutrisiran Approved T23389 DRUGINFO D01ZHB Revusiran Phase 3 T23389 DRUGINFO D0Y9HW ISIS-TTR Phase 3 T23389 DRUGINFO DJ0E7P ALN-TTR01 Phase 1 T65414 TARGETID T65414 T65414 FORMERID TTDC00283 T65414 UNIPROID ENV_HV1H2 T65414 TARGNAME Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA) T65414 GENENAME HIV env mRNA T65414 TARGTYPE Successful T65414 SYNONYMS HIV-1 HXB2 envelope glycoprotein gp160 (mRNA); HIV-1 HXB2 env polyprotein (mRNA) T65414 FUNCTION Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41. T65414 PDBSTRUC 6DLN; 6DE7; 6BXQ; 6BXP; 6B9K T65414 BIOCLASS mRNA target T65414 SEQUENCE MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL T65414 DRUGINFO D0L3MP VRX496 Approved T79249 TARGETID T79249 T79249 FORMERID TTDR01172 T79249 UNIPROID TYSY_HUMAN T79249 TARGNAME Thymidylate synthase messenger RNA (TYMS mRNA) T79249 GENENAME TYMS T79249 TARGTYPE Successful T79249 SYNONYMS TSase (mRNA); TS (mRNA); OK/SW-cl.29 (mRNA) T79249 FUNCTION Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. T79249 PDBSTRUC 6R2E; 6QYQ; 6QXH; 6QXG; 5X69 T79249 BIOCLASS mRNA target T79249 ECNUMBER EC 2.1.1.45 T79249 SEQUENCE MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV T79249 DRUGINFO D05LEO Fluorouracil Approved T79249 DRUGINFO D0V5YQ TS antisense + raltitrexed Investigative T72171 TARGETID T72171 T72171 FORMERID TTDI02236 T72171 UNIPROID CCR5_HUMAN T72171 TARGNAME CCR5 messenger RNA (CCR5 mRNA) T72171 GENENAME CCR5 T72171 TARGTYPE Successful T72171 SYNONYMS HIV-1 fusion coreceptor (mRNA); HIV-1 fusion co-receptor (mRNA); Chemokine receptor CCR5 (mRNA); CMKBR5 (mRNA); CHEMR13 (mRNA); CD195 antigen (mRNA); CD195 (mRNA); CCR-5 (mRNA); CC-CKR-5 (mRNA); C-C chemokine receptor type 5 (mRNA); C-C CKR-5 (mRNA) T72171 FUNCTION May play a role in the control of granulocytic lineage proliferation or differentiation. Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. T72171 PDBSTRUC 6MET; 6MEO; 6FGP; 5YY4; 5YD5 T72171 BIOCLASS mRNA target T72171 SEQUENCE MDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVILILINCKRLKSMTDIYLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFIILLTIDRYLAVVHAVFALKARTVTFGVVTSVITWVVAVFASLPGIIFTRSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIVILGLVLPLLVMVICYSGILKTLLRCRNEKKRHRAVRLIFTIMIVYFLFWAPYNIVLLLNTFQEFFGLNNCSSSNRLDQAMQVTETLGMTHCCINPIIYAFVGEKFRNYLLVFFQKHIAKRFCKCCSIFQQEAPERASSVYTRSTGEQEISVGL T72171 DRUGINFO D0NR6S Maraviroc Approved T72171 DRUGINFO D0O4RB DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells Phase 1/2 T72171 DRUGINFO D0G6JE SCH-C Discontinued in Phase 1 T72171 DRUGINFO D09PZD viral macrophage inflammatory protein-II Investigative T67282 TARGETID T67282 T67282 FORMERID TTDI01958 T67282 UNIPROID SYL_STAAE T67282 TARGNAME Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS) T67282 GENENAME Stap-coc leuS T67282 TARGTYPE Successful T67282 SYNONYMS Leucyl-tRNA synthetase; Leucine--tRNA ligase; LeuRS T67282 FUNCTION Catalyzes the chemical reaction: ATP + L-leucine + Trna = AMP + diphosphate + L-leucyl-tRNALeu T67282 BIOCLASS Carbon-oxygen ligase T67282 ECNUMBER EC 6.1.1.4 T67282 SEQUENCE MLNYNHNQIEKKWQDYWDENKTFKTNDNLGQKKFYALDMFPYPSGAGLHVGHPEGYTATDIISRYKRMQGYNVLHPMGWDAFGLPAEQYALDTGNDPREFTKKNIQTFKRQIKELGFSYDWDREVNTTDPEYYKWTQWIFIQLYNKGLAYVDEVAVNWCPALGTVLSNEEVIDGVSERGGHPVYRKPMKQWVLKITEYADQLLADLDDLDWPESLKDMQRNWIGRSEGAKVSFDVDNTEGKVEVFTTRPDTIYGASFLVLSPEHALVNSITTDEYKEKVKAYQTEASKKSDLERTDLAKDKSGVFTGAYATNPLSGEKVQIWIADYVLSTYGTGAIMAVPAHDDRDYEFAKKFDLPIIEVIEGGNVEEAAYTGEGKHINSGELDGLENEAAITKAIQLLEQKGAGEKKVNYKLRDWLFSRQRYWGEPIPVIHWEDGTMTTVPEEELPLLLPETDEIKPSGTGESPLANIDSFVNVVDEKTGMKGRRETNTMPQWAGSCWYYLRYIDPKNENMLADPEKLKHWLPVDLYIGGVEHAVLHLLYARFWHKVLYDLAIVPTKEPFQKLFNQGMILGEGNEKMSKSKGNVINPDDIVQSHGADTLRLYEMFMGPLDAAIAWSEKGLDGSRRFLDRVWRLMVNEDGTLSSKIVTTNNKSLDKVYNQTVKKVTEDFETLGFNTAISQLMVFINECYKVDEVYKPYIEGFVKMLAPIAPHIGEELWSKLGHEESITYQPWPTYDEALLVDDEVEIVVQVNGKLRAKIKIAKDTSKEEMQEIALSNDNVKASIEGKDIMKVIAVPQKLVNIVAK T67282 DRUGINFO D05VGL Tavaborole Approved T67282 DRUGINFO D00NXM GSK-2251052 Phase 2 T67282 DRUGINFO D09DUQ AN-2718 Phase 1 T72657 TARGETID T72657 T72657 FORMERID TTDS00219 T72657 UNIPROID F4NA87_STAAU T72657 TARGNAME Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) T72657 GENENAME Stap-coc pbp2 T72657 TARGTYPE Successful T72657 SYNONYMS Penicillin-binding protein 2; Penicillin-binding protein; Penicillin binding protein PBP 2 T72657 FUNCTION Subunite of bacterial 70s ribosomes. Invovled in protein biosynthesis. T72657 SEQUENCE MTENKGSSQPKKNGNNGGKSNSKKNRNVKRTIIKIIGFMIIAFFVVLLLGILLFAYYAWKAPAFTEAKLQDPIPAKIYDKNGELVKTLDNGQRHEHVNLKDVPKSMKDAVLATEDNRFYEHGALDYKRLFGAIGKNLTGGFGSEGASTLTQQVVKDAFLSQHKSIGRKAQEAYLSYRLEQEYSKDDIFQVYLNKIYYSDGVTGIKAAAKYYFNKDLKDLNLAEEAYLAGLPQVPNNYNIYDHPKAAEDRKNTVLYLMHYHKRITDKQWEDAKKIDLKANLVNRTAEERQNIDTNQDSEYNSYVNFVKSELMNNKAFKDENLGNVLQSGIKIYTNMDKDVQKTLQNDVDNGSFYKNKDQQVGATILDSKTGGLVAISGGRDFKDVVNRNQATDPHPTGSSLKPFLAYGPAIENMKWATNHAIQDESSYQVDGSTFRNYDVKSHGTVSIYDALRQSFNIPALKAWQSVKQNAGNDAPKKFAAKLGLNYEGDIGPSEVLGGSASEFSPTQLASAFAAIANGGTYNNAHSIQKVVTRDGETIEYDHTSHKAMSDYTAYMLAEMLKGTFKPYGSAYGHGVSGVNMGAKTGTGTYGAETYSQYNLPDNAAKDVWINGFTPQYTMSVWMGFSKVKQYGENSFVGHSQQEYPQFLYENVMSKISSRDGEDFKRPSSVSGSIPSINVSGSQDNNTTNRSTHGGSDTSANSSGTAQSNNNTRSQQSRNSGGLTGIFN T72657 DRUGINFO D02GAC Clomocycline Approved T72657 DRUGINFO D02PCR Spectinomycin Approved T72657 DRUGINFO D04NDM Paromomycin Approved T72657 DRUGINFO D04VEJ Lymecycline Approved T72657 DRUGINFO D05AFR Rolitetracycline Approved T72657 DRUGINFO D07JHH Meclocycline Approved T72657 DRUGINFO D07JZF Netilmicin Approved T72657 DRUGINFO D08LTU Minocycline Approved T72657 DRUGINFO D08NQZ Tetracycline Approved T72657 DRUGINFO D0G4OD Tigecycline Approved T72657 DRUGINFO D0H1AR Methacycline Approved T72657 DRUGINFO D0J2NK Oxytetracycline Approved T72657 DRUGINFO D0N0EQ Streptomycin Approved T72657 DRUGINFO D0R9WP Demeclocycline Approved T72657 DRUGINFO D0Y3MO Amikacin Approved T72657 DRUGINFO D0YV1Q Kanamycin Approved T72657 DRUGINFO D05JNI Framycetin Approved T31230 TARGETID T31230 T31230 FORMERID TTDS00307 T31230 UNIPROID FRDA_HELPY T31230 TARGNAME Bacterial Fumarate reductase flavoprotein (Bact frdA) T31230 GENENAME Bact frdA T31230 TARGTYPE Successful T31230 SYNONYMS Fumarate reductase; FRDA T31230 FUNCTION Two distinct, membrane-bound, fad-containing enzymes are responsible for the catalysis of fumarate and succinate interconversion; The fumarate reductase is used in anaerobic growth, and the succinate dehydrogenase is used in aerobic growth. T31230 BIOCLASS CH-CH donor oxidoreductase T31230 ECNUMBER EC 1.3.5.4 T31230 SEQUENCE MKITYCDALIIGGGLAGLRASIACKQKGLNTIVLSLVPVRRSHSAAAQGGMQASLANAKKSEGDNEDLHFLDTVKGSDWGCDQQVARMFVTTAPKAIRELASWGVPWTRIKKGDRPAVVNGEHVTITERDDRHGYILSRDFGGTKKWRTCFTADATGHTMLYAVANEALHHKVDIQDRKDMLAFIHHDNKCYGAVVRDLITGEISAYVSKGTLLATGGYGRVYKHTTNAVICDGAGAASALETGVAKLGNMEAVQFHPTALVPSGILMTEGCRGDGGVLRDKFGRRFMPAYEPEKKELASRDVVSRRILEHIQKGYGAKSPYGDHVWLDIAILGRNHVEKNLRDVRDIAMTFAGIDPADSKEQTKDNMQGVPANEPEYGQAMAKQKGWIPIKPMQHYSMGGVRTNPKGETHLKGLFCAGEAACWDLHGFNRLGGNSVSEAVVAGMIIGDYFASHCLEAQIEINTQKVEAFIKESQDYMHFLLHNEGKEDVYEIRERMKEVMDEKVGVFREGKRLEEALKELQELYARSKNICVKNKVLHNNPELEDAYRTKKMLKLALCITQGALLRTESRGAHTRIDYPKRDDEKWLNRTLASWPSAEQDMPTIEYEELDVMKMEISPDFRGYGKKGNFIPHPKKEERDAEILKTILELEKLGKDRIEVQHALMPFELQEKYKARNMRLEDEEVRARGEHLYSFNVHELLDQHNANLKGEHHE T31230 DRUGINFO D08PCE Oxantel pamoate Approved T31230 DRUGINFO D08QCJ Thiabendazole Approved T31230 DRUGINFO D0Q4TK Morantel tartrate Approved T31230 DRUGINFO D01MDE Fumarate Investigative T31230 DRUGINFO D05PZL 2,3-DIMETHYL-1,4-NAPHTHOQUINONE Investigative T31230 DRUGINFO D09KCU Citraconic acid Investigative T31230 DRUGINFO D0B9FP 2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL Investigative T31230 DRUGINFO D0BW1H 2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE Investigative T31230 DRUGINFO D0E0TK Malate Like Intermediate Investigative T31230 DRUGINFO D0UU1I Heme Investigative T31230 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T04689 TARGETID T04689 T04689 UNIPROID ACHA_HUMAN T04689 TARGNAME Neuronal acetylcholine receptor alpha-1 (CHRNA1) T04689 GENENAME CHRNA1 T04689 TARGTYPE Successful T04689 SYNONYMS CHNRA; Acetylcholine receptor subunit alpha; ACHRA T04689 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. T04689 PDBSTRUC 5HBT; 4ZJS; 1Y6C; 1Y5T; 1Y5P T04689 BIOCLASS Neurotransmitter receptor T04689 SEQUENCE MEPWPLLLLFSLCSAGLVLGSEHETRLVAKLFKDYSSVVRPVEDHRQVVEVTVGLQLIQLINVDEVNQIVTTNVRLKQGDMVDLPRPSCVTLGVPLFSHLQNEQWVDYNLKWNPDDYGGVKKIHIPSEKIWRPDLVLYNNADGDFAIVKFTKVLLQYTGHITWTPPAIFKSYCEIIVTHFPFDEQNCSMKLGTWTYDGSVVAINPESDQPDLSNFMESGEWVIKESRGWKHSVTYSCCPDTPYLDITYHFVMQRLPLYFIVNVIIPCLLFSFLTGLVFYLPTDSGEKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIGKYMLFTMVFVIASIIITVIVINTHHRSPSTHVMPNWVRKVFIDTIPNIMFFSTMKRPSREKQDKKIFTEDIDISDISGKPGPPPMGFHSPLIKHPEVKSAIEGIKYIAETMKSDQESNNAAAEWKYVAMVMDHILLGVFMLVCIIGTLAVFAGRLIELNQQG T04689 DRUGINFO D05QNO Decamethonium Approved T86462 TARGETID T86462 T86462 FORMERID TTDNC00670 T86462 UNIPROID TTHY_HUMAN T86462 TARGNAME Transthyretin (TTR) T86462 GENENAME TTR T86462 TARGTYPE Successful T86462 SYNONYMS TBPA; Prealbumin; PALB; ATTR T86462 FUNCTION Probably transports thyroxine from the bloodstream to the brain. Thyroid hormone-binding protein. T86462 PDBSTRUC 6IMY; 6IMX; 6GRP; 6GR7; 6FZL T86462 SEQUENCE MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE T86462 DRUGINFO D0R3BV Inotersen Approved T86462 DRUGINFO D0E9AF ALN-TTRsc Phase 3 T86462 DRUGINFO D5EHL4 Acoramidis Phase 3 T86462 DRUGINFO DW95VT NTLA-2001 Phase 1 T86462 DRUGINFO DZ1W4B NI006 Phase 1 T32369 TARGETID T32369 T32369 FORMERID TTDI01569 T32369 UNIPROID PA_I34A1 T32369 TARGNAME Influenza Polymerase acidic endonuclease (Influ PA) T32369 GENENAME Influ PA T32369 TARGTYPE Successful T32369 SYNONYMS RNA-directed RNA polymerase subunit P2; Polymerase acidic protein T32369 FUNCTION Plays an essential role in viral RNA transcription and replication by forming the heterotrimeric polymerase complex together with PB1 and PB2 subunits. The complex transcribes viral mRNAs by using a unique mechanism called cap-snatching. It consists in the hijacking and cleavage of host capped pre-mRNAs. These short capped RNAs are then used as primers for viral mRNAs. The PB2 subunit is responsible for the binding of the 5' cap of cellular pre-mRNAs which are subsequently cleaved after 10-13 nucleotides by the PA subunit that carries the endonuclease activity. T32369 PDBSTRUC 5JHV; 5JHT; 5I13; 5FDG; 5FDD T32369 ECNUMBER EC 3.1.-.- T32369 SEQUENCE MEDFVRQCFNPMIVELAEKTMKEYGEDLKIETNKFAAICTHLEVCFMYSDFHFINEQGESIIVELGDPNALLKHRFEIIEGRDRTMAWTVVNSICNTTGAEKPKFLPDLYDYKENRFIEIGVTRREVHIYYLEKANKIKSEKTHIHIFSFTGEEMATKADYTLDEESRARIKTRLFTIRQEMASRGLWDSFRQSERGEETIEERFEITGTMRKLADQSLPPNFSSLENFRAYVDGFEPNGYIEGKLSQMSKEVNARIEPFLKTTPRPLRLPNGPPCSQRSKFLLMDALKLSIEDPSHEGEGIPLYDAIKCMRTFFGWKEPNVVKPHEKGINPNYLLSWKQVLAELQDIENEEKIPKTKNMKKTSQLKWALGENMAPEKVDFDDCKDVGDLKQYDSDEPELRSLASWIQNEFNKACELTDSSWIELDEIGEDVAPIEHIASMRRNYFTSEVSHCRATEYIMKGVYINTALLNASCAAMDDFQLIPMISKCRTKEGRRKTNLYGFIIKGRSHLRNDTDVVNFVSMEFSLTDPRLEPHKWEKYCVLEIGDMLIRSAIGQVSRPMFLYVRTNGTSKIKMKWGMEMRRCLLQSLQQIESMIEAESSVKEKDMTKEFFENKSETWPIGESPKGVEESSIGKVCRTLLAKSVFNSLYASPQLEGFSAESRKLLLIVQALRDNLEPGTFDLGGLYEAIEECLINDPWVLLNASWFNSFLTHALS T32369 DRUGINFO D0O5AG Baloxavir marboxil Approved T37847 TARGETID T37847 T37847 FORMERID TTDS00310 T37847 UNIPROID DPOL_HHV11 T37847 TARGNAME Herpes simplex virus DNA polymerase UL30 (HSV UL30) T37847 GENENAME HSV UL30 T37847 TARGTYPE Successful T37847 SYNONYMS HSV DNA polymerase catalytic subunit T37847 FUNCTION Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. Additionally, the polymerase contains an intrinsic ribonuclease H (RNase H) activity that specifically degrades RNA/DNA heteroduplexes or duplex DNA substrates in the 5' to 3' direction. Therefore, it can catalyze the excision of the RNA primers that initiate the synthesis of Okazaki fragments at a replication fork during viral DNA replication. T37847 BIOCLASS DNA polymerase type-B T37847 SEQUENCE MFSGGGGPLSPGGKSAARAASGFFAPAGPRGASRGPPPCLRQNFYNPYLAPVGTQQKPTGPTQRHTYYSECDEFRFIAPRVLDEDAPPEKRAGVHDGHLKRAPKVYCGGDERDVLRVGSGGFWPRRSRLWGGVDHAPAGFNPTVTVFHVYDILENVEHAYGMRAAQFHARFMDAITPTGTVITLLGLTPEGHRVAVHVYGTRQYFYMNKEEVDRHLQCRAPRDLCERMAAALRESPGASFRGISADHFEAEVVERTDVYYYETRPALFYRVYVRSGRVLSYLCDNFCPAIKKYEGGVDATTRFILDNPGFVTFGWYRLKPGRNNTLAQPAAPMAFGTSSDVEFNCTADNLAIEGGMSDLPAYKLMCFDIECKAGGEDELAFPVAGHPEDLVIQISCLLYDLSTTALEHVLLFSLGSCDLPESHLNELAARGLPTPVVLEFDSEFEMLLAFMTLVKQYGPEFVTGYNIINFDWPFLLAKLTDIYKVPLDGYGRMNGRGVFRVWDIGQSHFQKRSKIKVNGMVNIDMYGIITDKIKLSSYKLNAVAEAVLKDKKKDLSYRDIPAYYAAGPAQRGVIGEYCIQDSLLVGQLFFKFLPHLELSAVARLAGINITRTIYDGQQIRVFTCLLRLADQKGFILPDTQGRFRGAGGEAPKRPAAAREDEERPEEEGEDEDEREEGGGEREPEGARETAGRHVGYQGARVLDPTSGFHVNPVVVFDFASLYPSIIQAHNLCFSTLSLRADAVAHLEAGKDYLEIEVGGRRLFFVKAHVRESLLSILLRDWLAMRKQIRSRIPQSSPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTIGREMLLATREYVHARWAAFEQLLADFPEAADMRAPGPYSMRIIYGDTDSIFVLCRGLTAAGLTAVGDKMASHISRALFLPPIKLECEKTFTKLLLIAKKKYIGVIYGGKMLIKGVDLVRKNNCAFINRTSRALVDLLFYDDTVSGAAAALAERPAEEWLARPLPEGLQAFGAVLVDAHRRITDPERDIQDFVLTAELSRHPRAYTNKRLAHLTVYYKLMARRAQVPSIKDRIPYVIVAQTREVEETVARLAALRELDAAAPGDEPAPPAALPSPAKRPRETPSPADPPGGASKPRKLLVSELAEDPAYAIAHGVALNTDYYFSHLLGAACVTFKALFGNNAKITESLLKRFIPEVWHPPDDVAARLRTAGFGAVGAGATAEETRRMLHRAFDTLA T37847 DRUGINFO D04AAW Cidofovir Approved T37847 DRUGINFO D04QJD Valaciclovir Approved T37847 DRUGINFO D05ARP Ganciclovir Approved T37847 DRUGINFO D05MFA Valacyclovir Hydrochloride Approved T37847 DRUGINFO D06GWF Valganciclovir Approved T37847 DRUGINFO D07XSN Cytarabine Approved T37847 DRUGINFO D0OT0O Foscavir Approved T37847 DRUGINFO D0VT8P Famciclovir Approved T37847 DRUGINFO D07BYK Penciclovir Approved T37847 DRUGINFO D0B5MP Aciclovir Approved T37847 DRUGINFO D04OXD Netivudine Phase 3 T37847 DRUGINFO D06CCR Fialuridine Phase 2 T37847 DRUGINFO D0M7DS Valomaciclovir stearate Phase 2 T37847 DRUGINFO D07LUJ URSOLIC ACID Phase 2 T37847 DRUGINFO D00LHF GS-9219 Phase 1/2 T37847 DRUGINFO D0R9YR BETULINIC ACID Phase 1 T37847 DRUGINFO D0V4YO ROCICLOVIR Phase 1 T37847 DRUGINFO D0H1OL Guanosine Phase 1 T37847 DRUGINFO D0WF1S Tomeglovir Discontinued in Phase 2 T37847 DRUGINFO D05RQB Aphidicolin Discontinued in Phase 1 T37847 DRUGINFO D0H5LC CHPMPC Discontinued in Phase 1 T37847 DRUGINFO D03LNN IDX136 Preclinical T37847 DRUGINFO D0T4HS GR-95168 Terminated T37847 DRUGINFO D0U0FH Amitivir Terminated T37847 DRUGINFO D00NQQ Alpha,beta-methylene-dATP Investigative T37847 DRUGINFO D00UUM PMEA Investigative T37847 DRUGINFO D00XVS 3beta-hydroxyrus-18,20(30)-dien-28-oic acid Investigative T37847 DRUGINFO D01NBF 3alpha-O-trans-p-coumaroyl-7-labden-15-oic acid Investigative T37847 DRUGINFO D02NCY 6-(4-Chloro-phenylamino)-1H-pyrimidine-2,4-dione Investigative T37847 DRUGINFO D05YDK PENICILLIOL A Investigative T37847 DRUGINFO D06CSI Alpha,beta-methylene-dTTP Investigative T37847 DRUGINFO D06GWR (24E)-3beta-hydroxy-7,24-euphadien-26-oic acid Investigative T37847 DRUGINFO D06QWO TALAROFLAVONE Investigative T37847 DRUGINFO D06WRC 3-cis-p-coumaroyl maslinic acid Investigative T37847 DRUGINFO D07GFI Gallic acid 5,6-dihydroxy-3-carboxyphenylester Investigative T37847 DRUGINFO D09OIO (+)-Myristinin A Investigative T37847 DRUGINFO D0B7WO 5-propenyl-arabinofuranosyluracil 5'-triphosphate Investigative T37847 DRUGINFO D0D8QY 6-(4-Bromo-phenylamino)-1H-pyrimidine-2,4-dione Investigative T37847 DRUGINFO D0H1VJ DdCTP SODIUM Investigative T37847 DRUGINFO D0MG5N Mahureone D Investigative T37847 DRUGINFO D0P9KI 5-propenyl-2'-deoxyuridine triphosphate Investigative T37847 DRUGINFO D0T7CB Alpha,beta-methylene-dCTP Investigative T37847 DRUGINFO D0TL0V 3-Oximo-olean-12-en-29-oic acid Investigative T37847 DRUGINFO D0U7XP Alpha,beta-methylene-dGTP Investigative T37847 DRUGINFO D0W1OQ 3beta-hydroxyrus-12,19(29)-dien-28-oic acid Investigative T37847 DRUGINFO D0WV3D (+)-Myristinin D Investigative T37847 DRUGINFO D0XS0X 3-trans-p-coumaroyl maslinic acid Investigative T37847 DRUGINFO D0H6VK 6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione Investigative T37847 DRUGINFO D0SJ2Q OLEANOLIC_ACID Investigative T37847 DRUGINFO D09WYY 2'-deoxythymidine triphosphate Investigative T37847 DRUGINFO D04AWP Guanosine-5'-Monophosphate Investigative T93783 TARGETID T93783 T93783 FORMERID TTDS00322 T93783 UNIPROID TAT_HV1H2 T93783 TARGNAME Human immunodeficiency virus Tat protein (HIV tat) T93783 GENENAME HIV tat T93783 TARGTYPE Successful T93783 SYNONYMS Transactivating regulatory protein; TAT protein T93783 FUNCTION Extracellular circulating Tat can be endocytosed by surrounding uninfected cells via the binding to several surface receptors such as CD26, CXCR4, heparan sulfate proteoglycans (HSPG) or LDLR. Neurons are rarely infected, but they internalize Tat via their LDLR. Endosomal low pH allows Tat to cross the endosome membrane to enter the cytosol and eventually further translocate into the nucleus, thereby inducing severe celldysfunctions ranging from cell activation to cell death. Through its interaction with nuclear HATs, Tat is potentially able to control the acetylation-dependent cellular gene expression. Tat seems toinhibit the HAT activity of KAT5/Tip60 and TAF1, and consequently modify the expression of specific cellular genes. Modulates the expression of many cellular genes involved in cell survival, proliferation or in coding for cytokines (such as IL10) or cytokine receptors. May be involved in the derepression of host interleukin IL2 expression. Mediates the activation of cyclin- dependent kinases and dysregulation of microtubule network. Tat plays a role in T-cell and neurons apoptosis. Tat induced neurotoxicity and apoptosis probably contribute to neuroAIDS. Host extracellular matrix metalloproteinase MMP1 cleaves Tat and decreases Tat's mediated neurotoxicity. Circulating Tat also acts as a chemokine-like and/or growth factor-like molecule that binds to specific receptors on the surface of the cells, affecting many cellular pathways. In the vascular system, Tat binds to ITGAV/ITGB3 and ITGA5/ITGB1 integrins dimers at the surface of endothelial cells and competes with bFGF for heparin-binding sites, leading to an excess of soluble bFGF. Binds to KDR/VEGFR-2. All these Tat-mediated effects enhance angiogenesis in Kaposi's sarcoma lesions. T93783 PDBSTRUC 6MCF; 6MCE; 5V61; 4OR5; 3MIA T93783 BIOCLASS Lentiviruses Tat family T93783 SEQUENCE MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKE T93783 DRUGINFO D08HZC Penicillamine Approved T93783 DRUGINFO D0XP3W Ro-24-7429 Phase 2 T93783 DRUGINFO D0Y2NU ALX-40-4C Phase 2 T93783 DRUGINFO D0W5QJ Anti-HIV ribozyme therapy Phase 1/2 T93783 DRUGINFO D09QOF EM-2487 Terminated T93783 DRUGINFO D0O7QV Durhamycin A Investigative T93783 DRUGINFO D0X3XE CGP 40336A Investigative T24211 TARGETID T24211 T24211 FORMERID TTDI02289 T24211 UNIPROID IC1_HUMAN T24211 TARGNAME C1 esterase inhibitor (SERPING1) T24211 GENENAME SERPING1 T24211 TARGTYPE Successful T24211 SYNONYMS Serpin G1; SERPING1; Plasma protease C1 inhibitor; C1inhibiting factor; C1Inh; C1 Inh T24211 FUNCTION Activation of the C1 complex is under control of the C1- inhibitor. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. May play a potentially crucial role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis and the generation of kinins. Very efficient inhibitor of FXIIa. Inhibits chymotrypsin and kallikrein. {ECO:0000269|PubMed:8495195}. T24211 PDBSTRUC 5DUQ; 5DU3; 2OAY; 1M6Q T24211 BIOCLASS Serpin protein T24211 SEQUENCE MASRLTLLTLLLLLLAGDRASSNPNATSSSSQDPESLQDRGEGKVATTVISKMLFVEPILEVSSLPTTNSTTNSATKITANTTDEPTTQPTTEPTTQPTIQPTQPTTQLPTDSPTQPTTGSFCPGPVTLCSDLESHSTEAVLGDALVDFSLKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYPKDFTCVHQALKGFTTKGVTSVSQIFHSPDLAIRDTFVNASRTLYSSSPRVLSNNSDANLELINTWVAKNTNNKISRLLDSLPSDTRLVLLNAIYLSAKWKTTFDPKKTRMEPFHFKNSVIKVPMMNSKKYPVAHFIDQTLKAKVGQLQLSHNLSLVILVPQNLKHRLEDMEQALSPSVFKAIMEKLEMSKFQPTLLTLPRIKVTTSQDMLSIMEKLEFFDFSYDLNLCGLTEDPDLQVSAMQHQTVLELTETGVEAAAASAISVARTLLVFEVQQPFLFVLWDQQHKFPVFMGRVYDPRA T24211 DRUGINFO D0BK4X Cinryze Approved T24211 DRUGINFO D0Z7ZM Rhucin Approved T65570 TARGETID T65570 T65570 UNIPROID ADH1A_HUMAN T65570 TARGNAME Alcohol dehydrogenase 1A (ADH1A) T65570 GENENAME ADH1A T65570 TARGTYPE Successful T65570 SYNONYMS Alcohol dehydrogenase subunit alpha; ADH1 T65570 FUNCTION Facilitates the interconversion between alcohols and aldehydes or ketones with the reduction of nicotinamide adenine dinucleotide (NAD+) to NADH. T65570 PDBSTRUC 1U3T; 1HSO T65570 ECNUMBER EC 1.1.1.1 T65570 SEQUENCE MSTAGKVIKCKAAVLWELKKPFSIEEVEVAPPKAHEVRIKMVAVGICGTDDHVVSGTMVTPLPVILGHEAAGIVESVGEGVTTVKPGDKVIPLAIPQCGKCRICKNPESNYCLKNDVSNPQGTLQDGTSRFTCRRKPIHHFLGISTFSQYTVVDENAVAKIDAASPLEKVCLIGCGFSTGYGSAVNVAKVTPGSTCAVFGLGGVGLSAIMGCKAAGAARIIAVDINKDKFAKAKELGATECINPQDYKKPIQEVLKEMTDGGVDFSFEVIGRLDTMMASLLCCHEACGTSVIVGVPPDSQNLSMNPMLLLTGRTWKGAILGGFKSKECVPKLVADFMAKKFSLDALITHVLPFEKINEGFDLLHSGKSIRTILMF T65570 DRUGINFO D02NJA Fomepizole Approved T79961 TARGETID T79961 T79961 FORMERID TTDI01755 T79961 UNIPROID ACM5_HUMAN T79961 TARGNAME Muscarinic acetylcholine receptor M5 (CHRM5) T79961 GENENAME CHRM5 T79961 TARGTYPE Successful T79961 SYNONYMS CHRM5 T79961 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. T79961 BIOCLASS GPCR rhodopsin T79961 SEQUENCE MEGDSYHNATTVNGTPVNHQPLERHRLWEVITIAAVTAVVSLITIVGNVLVMISFKVNSQLKTVNNYYLLSLACADLIIGIFSMNLYTTYILMGRWALGSLACDLWLALDYVASNASVMNLLVISFDRYFSITRPLTYRAKRTPKRAGIMIGLAWLISFILWAPAILCWQYLVGKRTVPLDECQIQFLSEPTITFGTAIAAFYIPVSVMTILYCRIYRETEKRTKDLADLQGSDSVTKAEKRKPAHRALFRSCLRCPRPTLAQRERNQASWSSSRRSTSTTGKPSQATGPSANWAKAEQLTTCSSYPSSEDEDKPATDPVLQVVYKSQGKESPGEEFSAEETEETFVKAETEKSDYDTPNYLLSPAAAHRPKSQKCVAYKFRLVVKADGNQETNNGCHKVKIMPCPFPVAKEPSTKGLNPNPSHQMTKRKRVVLVKERKAAQTLSAILLAFIITWTPYNIMVLVSTFCDKCVPVTLWHLGYWLCYVNSTVNPICYALCNRTFRKTFKMLLLCRWKKKKVEEKLYWQGNSKLP T79961 DRUGINFO D00NAX Promazine Approved T79961 DRUGINFO D00SLY Umeclidinium Approved T79961 DRUGINFO D02KIE Cimetropium bromide Approved T79961 DRUGINFO D05EMG Butylscopolamine Approved T79961 DRUGINFO D05TIB Trospium Approved T79961 DRUGINFO D06HLY Pilocarpine Approved T79961 DRUGINFO D06QDR Choline alfoscerate Approved T79961 DRUGINFO D07CNL Anisotropine Methylbromide Approved T79961 DRUGINFO D07ZTO Bethanechol Approved T79961 DRUGINFO D0B1EV Cyclopentolate Approved T79961 DRUGINFO D0D4IH Oxitropium bromide Approved T79961 DRUGINFO D0E8LT Prifinium Approved T79961 DRUGINFO D0F7AT Cryptenamine Acetates Approved T79961 DRUGINFO D0FV3V Mepenzolate Approved T79961 DRUGINFO D0H5DU Oxyphencyclimine Approved T79961 DRUGINFO D0J6WX Flutropium bromide Approved T79961 DRUGINFO D0JY5S Methantheline Approved T79961 DRUGINFO D0MG1Y Belladonna Approved T79961 DRUGINFO D0ND2J Flavoxate Approved T79961 DRUGINFO D0O5SZ Homatropine Methylbromide Approved T79961 DRUGINFO D0OK5I Tridihexethyl Approved T79961 DRUGINFO D0P7VJ Pramiracetam Approved (orphan drug) T79961 DRUGINFO D0Q0JG Ispaghula Approved T79961 DRUGINFO D0R1WR Procyclidine Approved T79961 DRUGINFO D0RD5W Hyoscyamine Approved T79961 DRUGINFO D0RG3O Atropine Approved T79961 DRUGINFO D0TV9K Propiverine Approved T79961 DRUGINFO D0VU8Q Mebeverine Approved T79961 DRUGINFO D0W2AN Emepronium Approved T79961 DRUGINFO D05ZJG Anisodine Approved T79961 DRUGINFO D0R7WU ACECLIDINE Approved T79961 DRUGINFO D05IIP L-651582 Phase 3 T79961 DRUGINFO D06CVO OrM3 Phase 2b T79961 DRUGINFO D05KXJ GSK233705 Phase 2 T79961 DRUGINFO D0L3CQ Dexpirronium Phase 1 T79961 DRUGINFO D07KYU Benactyzine Withdrawn from market T79961 DRUGINFO D04SOS BMS-181168 Discontinued in Phase 2 T79961 DRUGINFO D05PZZ DDP-200 Discontinued in Phase 2 T79961 DRUGINFO D0IJ2H FK-584 Discontinued in Phase 2 T79961 DRUGINFO D0A8IE AM-831 Discontinued in Phase 1 T79961 DRUGINFO D0N5NM Org-23366 Preclinical T79961 DRUGINFO D05HKB RS 86 Terminated T79961 DRUGINFO D0R5ZJ SU-740 Terminated T79961 DRUGINFO D00IDV CRTX-070 Investigative T79961 DRUGINFO D01OMY BHT-3034 Investigative T79961 DRUGINFO D03DKZ VU0238429 Investigative T79961 DRUGINFO D03IJZ Recombinant botulinum toxin Investigative T79961 DRUGINFO D04VNS alpha-conotoxin AuIB Investigative T79961 DRUGINFO D0B2JL JWB-1-84-1 Investigative T79961 DRUGINFO D0H4BJ Muscarine Investigative T79961 DRUGINFO D0I4PC alpha-conotoxin GI Investigative T79961 DRUGINFO D0JV2S VU0119498 Investigative T79961 DRUGINFO D0P1FJ Aprophen Investigative T79961 DRUGINFO D00YUX alpha-conotoxin PnIA Investigative T79961 DRUGINFO D0D4LF NS1738 Investigative T79961 DRUGINFO D0DA1E A-867744 Investigative T79961 DRUGINFO D0Y3DW [3H]cytisine Investigative T79961 DRUGINFO D0R4RN [125I]epibatidine Investigative T79961 DRUGINFO D0Z5RQ Cremastrine Investigative T79961 DRUGINFO D01UDC Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T79961 DRUGINFO D02EXX GNF-PF-5618 Investigative T79961 DRUGINFO D02PFJ 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea Investigative T79961 DRUGINFO D05EML 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione Investigative T79961 DRUGINFO D05MDY 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one Investigative T79961 DRUGINFO D06IUC FM1-10 Investigative T79961 DRUGINFO D06VST 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one Investigative T79961 DRUGINFO D07DEY 3-(3-benzylamino)-piperidin-2-one Investigative T79961 DRUGINFO D07VZG BRL-55473 Investigative T79961 DRUGINFO D08ZTA 6-Dimethylamino-2-methyl-hex-4-ynal oxime Investigative T79961 DRUGINFO D0AR0H FM1-43 Investigative T79961 DRUGINFO D0B8AQ 7-Pyrrolidin-1-yl-hept-5-yn-2-one Investigative T79961 DRUGINFO D0C9VH N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide Investigative T79961 DRUGINFO D0C9ZE Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester Investigative T79961 DRUGINFO D0N2KU PF-3409409 Investigative T79961 DRUGINFO D0O1BN SULFOARECOLINE Investigative T79961 DRUGINFO D0OE0K 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane Investigative T79961 DRUGINFO D0QL1X 7-Dimethylamino-3-methyl-hept-5-yn-2-one Investigative T79961 DRUGINFO D0R2JE N-methoxyquinuclidine-3-carboximidoyl chloride Investigative T79961 DRUGINFO D0R8FS 7-Dimethylamino-hept-5-yn-2-one Investigative T79961 DRUGINFO D0U2IL 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime Investigative T79961 DRUGINFO D0X2JU N-methoxyquinuclidine-3-carboximidoyl fluoride Investigative T79961 DRUGINFO D0HV3A FLUMEZAPINE Investigative T79961 DRUGINFO D0Q2GP ISOLOXAPINE Investigative T79961 DRUGINFO D0P0IX ISOCLOZAPINE Investigative T79961 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T46904 TARGETID T46904 T46904 FORMERID TTDS00491 T46904 UNIPROID SECR_HUMAN T46904 TARGNAME Secretin receptor (SCT) T46904 GENENAME SCT T46904 TARGTYPE Successful T46904 SYNONYMS SCTR; SCT-R; SCT T46904 FUNCTION This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. T46904 BIOCLASS GPCR secretin T46904 SEQUENCE MAPRPLLLLLLLLGGSAARPAPPRARRHSDGTFTSELSRLREGARLQRLLQGLVGKRSEQDAENSMAWTRLSAGLLCPSGSNMPILQAWMPLDGTWSPWLPPGPMVSEPAGAAAEGTLRPR T46904 DRUGINFO D0O8JB Secretin Approved T71690 TARGETID T71690 T71690 FORMERID TTDS00530 T71690 UNIPROID ODP1_ECOLI T71690 TARGNAME Bacterial Pyruvate decarboxylase (Bact aceE) T71690 GENENAME Bact aceE T71690 TARGTYPE Successful T71690 SYNONYMS aceE; Pyruvate decarboxylase E1 component T71690 FUNCTION The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-coa and co(2). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (e1), dihydrolipoamide acetyltransferase (e2) and lipoamide dehydrogenase. T71690 PDBSTRUC 2QTC; 2QTA; 2IEA; 2G67; 2G28 T71690 BIOCLASS Aldehyde/oxo donor oxidoreductase T71690 SEQUENCE MSERFPNDVDPIETRDWLQAIESVIREEGVERAQYLIDQLLAEARKGGVNVAAGTGISNYINTIPVEEQPEYPGNLELERRIRSAIRWNAIMTVLRASKKDLELGGHMASFQSSATIYDVCFNHFFRARNEQDGGDLVYFQGHISPGVYARAFLEGRLTQEQLDNFRQEVHGNGLSSYPHPKLMPEFWQFPTVSMGLGPIGAIYQAKFLKYLEHRGLKDTSKQTVYAFLGDGEMDEPESKGAITIATREKLDNLVFVINCNLQRLDGPVTGNGKIINELEGIFEGAGWNVIKVMWGSRWDELLRKDTSGKLIQLMNETVDGDYQTFKSKDGAYVREHFFGKYPETAALVADWTDEQIWALNRGGHDPKKIYAAFKKAQETKGKATVILAHTIKGYGMGDAAEGKNIAHQVKKMNMDGVRHIRDRFNVPVSDADIEKLPYITFPEGSEEHTYLHAQRQKLHGYLPSRQPNFTEKLELPSLQDFGALLEEQSKEISTTIAFVRALNVMLKNKSIKDRLVPIIADEARTFGMEGLFRQIGIYSPNGQQYTPQDREQVAYYKEDEKGQILQEGINELGAGCSWLAAATSYSTNNLPMIPFYIYYSMFGFQRIGDLCWAAGDQQARGFLIGGTSGRTTLNGEGLQHEDGHSHIQSLTIPNCISYDPAYAYEVAVIMHDGLERMYGEKQENVYYYITTLNENYHMPAMPEGAEEGIRKGIYKLETIEGSKGKVQLLGSGSILRHVREAAEILAKDYGVGSDVYSVTSFTELARDGQDCERWNMLHPLETPRVPYIAQVMNDAPAVASTDYMKLFAEQVRTYVPADDYRVLGTDGFGRSDSRENLRHHFEVDASYVVVAALGELAKRGEIDKKVVADAIAKFNIDADKVNPRLA T71690 DRUGINFO D06PQT Vitamin B1 Approved T68461 TARGETID T68461 T68461 FORMERID TTDS00405 T68461 UNIPROID ADT1_HUMAN T68461 TARGNAME Adenine nucleotide translocator 1 (SLC25A4) T68461 GENENAME SLC25A4 T68461 TARGTYPE Successful T68461 SYNONYMS Solute carrier family 25 member 4; SLC25A4; ANT1; ANT 1; ADP/ATP translocase 1; ADP,ATP carrier protein, heart/skeletal muscle isoform T1; ADP,ATP carrier protein 1 T68461 FUNCTION Catalyzes the exchange of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner membrane. T68461 BIOCLASS Mitochondrial carrier T68461 SEQUENCE MGDHAWSFLKDFLAGGVAAAVSKTAVAPIERVKLLLQVQHASKQISAEKQYKGIIDCVVRIPKEQGFLSFWRGNLANVIRYFPTQALNFAFKDKYKQLFLGGVDRHKQFWRYFAGNLASGGAAGATSLCFVYPLDFARTRLAADVGKGAAQREFHGLGDCIIKIFKSDGLRGLYQGFNVSVQGIIIYRAAYFGVYDTAKGMLPDPKNVHIFVSWMIAQSVTAVAGLVSYPFDTVRRRMMMQSGRKGADIMYTGTVDCWRKIAKDEGAKAFFKGAWSNVLRGMGGAFVLVLYDEIKKYV T68461 DRUGINFO D00HNB Clodronate Approved T68461 DRUGINFO D06LYY Di-Stearoyl-3-Sn-Phosphatidylcholine Investigative T68461 DRUGINFO D07GHW bongkrek acid Investigative T68461 DRUGINFO D0V6RT Cardiolipin Investigative T68461 DRUGINFO D0Z0VL Carboxyatractyloside Investigative T71230 TARGETID T71230 T71230 FORMERID TTDS00478 T71230 UNIPROID ANPRA_HUMAN T71230 TARGNAME Atrial natriuretic peptide receptor A (NPR1) T71230 GENENAME NPR1 T71230 TARGTYPE Successful T71230 SYNONYMS NPR1; NPR-A; GC-A; Atrial natriuretic peptide A-type receptor; ANPRA; ANP-A T71230 FUNCTION Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand. T71230 BIOCLASS Phosphorus-oxygen lyase T71230 ECNUMBER EC 4.6.1.2 T71230 SEQUENCE MPGPRRPAGSRLRLLLLLLLPPLLLLLRGSHAGNLTVAVVLPLANTSYPWSWARVGPAVELALAQVKARPDLLPGWTVRTVLGSSENALGVCSDTAAPLAAVDLKWEHNPAVFLGPGCVYAAAPVGRFTAHWRVPLLTAGAPALGFGVKDEYALTTRAGPSYAKLGDFVAALHRRLGWERQALMLYAYRPGDEEHCFFLVEGLFMRVRDRLNITVDHLEFAEDDLSHYTRLLRTMPRKGRVIYICSSPDAFRTLMLLALEAGLCGEDYVFFHLDIFGQSLQGGQGPAPRRPWERGDGQDVSARQAFQAAKIITYKDPDNPEYLEFLKQLKHLAYEQFNFTMEDGLVNTIPASFHDGLLLYIQAVTETLAHGGTVTDGENITQRMWNRSFQGVTGYLKIDSSGDRETDFSLWDMDPENGAFRVVLNYNGTSQELVAVSGRKLNWPLGYPPPDIPKCGFDNEDPACNQDHLSTLEVLALVGSLSLLGILIVSFFIYRKMQLEKELASELWRVRWEDVEPSSLERHLRSAGSRLTLSGRGSNYGSLLTTEGQFQVFAKTAYYKGNLVAVKRVNRKRIELTRKVLFELKHMRDVQNEHLTRFVGACTDPPNICILTEYCPRGSLQDILENESITLDWMFRYSLTNDIVKGMLFLHNGAICSHGNLKSSNCVVDGRFVLKITDYGLESFRDLDPEQGHTVYAKKLWTAPELLRMASPPVRGSQAGDVYSFGIILQEIALRSGVFHVEGLDLSPKEIIERVTRGEQPPFRPSLALQSHLEELGLLMQRCWAEDPQERPPFQQIRLTLRKFNRENSSNILDNLLSRMEQYANNLEELVEERTQAYLEEKRKAEALLYQILPHSVAEQLKRGETVQAEAFDSVTIYFSDIVGFTALSAESTPMQVVTLLNDLYTCFDAVIDNFDVYKVETIGDAYMVVSGLPVRNGRLHACEVARMALALLDAVRSFRIRHRPQEQLRLRIGIHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGEALKIHLSSETKAVLEEFGGFELELRGDVEMKGKGKVRTYWLLGERGSSTRG T71230 DRUGINFO D05GRY Nesiritide Approved T71230 DRUGINFO D0L5WD Ularitide Phase 3 T71230 DRUGINFO D0C2ZL Ataciguat Phase 2 T71230 DRUGINFO D0OK3O Cenderitide Phase 2 T71230 DRUGINFO D0X8QO PL-3994 Phase 2 T94429 TARGETID T94429 T94429 FORMERID TTDI02314 T94429 UNIPROID TRM1_HCMVA T94429 TARGNAME Cytomegalovirus Terminase UL56 (CMV TRM1) T94429 GENENAME CMV TRM1 T94429 TARGTYPE Successful T94429 SYNONYMS UL56; Tripartite terminase subunit UL28 homolog; TRM1; Protein HFLF0 T94429 FUNCTION Component of the terminase, molecular motor that packages genomic DNA in empty capsid during assembly. T94429 BIOCLASS Herpesviridae UL28 T94429 SEQUENCE MEMNLLQKLCVVCSKCNEYAMELECLKYCDPNVLLAESTPFKRNAAAIVYLYRKIYPEVVAQNRTQSSLLTLYLEMLLKALHEDTALLDRALMAYSRQPDRAAFYRTVLRLDRCDRHHTVELQFTDNVRFSVSLATLNDIERFLCKMNYVYGILAPEAGLEVCAQLLELLRRLCGISPVARQEVYVEGTTCAQCYEELTIIPNQGRSLNKRLQGLLCNHIAVHRPSSQSDVNIQTVEQDLLDLTTRIPHLAGVLSALKSLFSSSSAYHSYIQEAEEALREYNLFTDIPERIYSLSDFTYWSRTSEVIVKRVGITIQQLNVYHQLCRALMNGISRHLYGEDVEDIFVLGEKALDGEERMFVGSVFAAPNRIIDLITSLSIQAFEDNPVFNKLHESNEMYTKIKHILEEIRRPLPDGTGGDGPEGEAIHLRGREAMSGTGTTLMTASNSSNSSTHSQRNNGGGGRARGGGKKVVGGGVNGQDGDGSENGLRVRNCDEHEALDLVDARSRIHNVTREVNVRKRAYLQKVSEVGYGKVIRCIKTQERLTSKLIDVNLVGPLCLDFISKLMNGFLYRSQYHQDQDVVDVGDQFTYDEHLYVVNNLIHKSLPVESLPLLGQQIYELCNGPLFTHCTDRYPLSHNVDMAYACDNAGVLPHVKDDLVKCAEGTVYPSEWMVVKYMGFFNFSDCQDLNVLQKEMWMHVRELVLSVALYNETFGKQLSIACLRDELHPDRDVILTYNKEWPLLLRHEGSLYKSKDLYLLLYRHLSRPDESGDVPTAPVAKPSTLTAAAAVSGVFREPDRPWLPSPYPSSSTAGVSRRVRATRKRPRRASSLLDLARDEHGIQDLVPGSLR T94429 DRUGINFO D0G8PA MK-8228 Approved T14541 TARGETID T14541 T14541 UNIPROID TOXB_CLODI T14541 TARGNAME Clostridium difficile Toxin B (CD toxB) T14541 GENENAME CD toxB T14541 TARGTYPE Successful T14541 SYNONYMS Toxin B T14541 FUNCTION Cytotoxin. T14541 PDBSTRUC 6C0B; 6AR6; 5UQT; 5UQN; 5UQM T14541 ECNUMBER EC 3.4.22.- T14541 SEQUENCE MSLVNRKQLEKMANVRFRTQEDEYVAILDALEEYHNMSENTVVEKYLKLKDINSLTDIYIDTYKKSGRNKALKKFKEYLVTEVLELKNNNLTPVEKNLHFVWIGGQINDTAINYINQWKDVNSDYNVNVFYDSNAFLINTLKKTVVESAINDTLESFRENLNDPRFDYNKFFRKRMEIIYDKQKNFINYYKAQREENPELIIDDIVKTYLSNEYSKEIDELNTYIEESLNKITQNSGNDVRNFEEFKNGESFNLYEQELVERWNLAAASDILRISALKEIGGMYLDVDMLPGIQPDLFESIEKPSSVTVDFWEMTKLEAIMKYKEYIPEYTSEHFDMLDEEVQSSFESVLASKSDKSEIFSSLGDMEASPLEVKIAFNSKGIINQGLISVKDSYCSNLIVKQIENRYKILNNSLNPAISEDNDFNTTTNTFIDSIMAEANADNGRFMMELGKYLRVGFFPDVKTTINLSGPEAYAAAYQDLLMFKEGSMNIHLIEADLRNFEISKTNISQSTEQEMASLWSFDDARAKAQFEEYKRNYFEGSLGEDDNLDFSQNIVVDKEYLLEKISSLARSSERGYIHYIVQLQGDKISYEAACNLFAKTPYDSVLFQKNIEDSEIAYYYNPGDGEIQEIDKYKIPSIISDRPKIKLTFIGHGKDEFNTDIFAGFDVDSLSTEIEAAIDLAKEDISPKSIEINLLGCNMFSYSINVEETYPGKLLLKVKDKISELMPSISQDSIIVSANQYEVRINSEGRRELLDHSGEWINKEESIIKDISSKEYISFNPKENKITVKSKNLPELSTLLQEIRNNSNSSDIELEEKVMLTECEINVISNIDTQIVEERIEEAKNLTSDSINYIKDEFKLIESISDALCDLKQQNELEDSHFISFEDISETDEGFSIRFINKETGESIFVETEKTIFSEYANHITEEISKIKGTIFDTVNGKLVKKVNLDTTHEVNTLNAAFFIQSLIEYNSSKESLSNLSVAMKVQVYAQLFSTGLNTITDAAKVVELVSTALDETIDLLPTLSEGLPIIATIIDGVSLGAAIKELSETSDPLLRQEIEAKIGIMAVNLTTATTAIITSSLGIASGFSILLVPLAGISAGIPSLVNNELVLRDKATKVVDYFKHVSLVETEGVFTLLDDKIMMPQDDLVISEIDFNNNSIVLGKCEIWRMEGGSGHTVTDDIDHFFSAPSITYREPHLSIYDVLEVQKEELDLSKDLMVLPNAPNRVFAWETGWTPGLRSLENDGTKLLDRIRDNYEGEFYWRYFAFIADALITTLKPRYEDTNIRINLDSNTRSFIVPIITTEYIREKLSYSFYGSGGTYALSLSQYNMGINIELSESDVWIIDVDNVVRDVTIESDKIKKGDLIEGILSTLSIEENKIILNSHEINFSGEVNGSNGFVSLTFSILEGINAIIEVDLLSKSYKLLISGELKILMLNSNHIQQKIDYIGFNSELQKNIPYSFVDSEGKENGFINGSTKEGLFVSELPDVVLISKVYMDDSKPSFGYYSNNLKDVKVITKDNVNILTGYYLKDDIKISLSLTLQDEKTIKLNSVHLDESGVAEILKFMNRKGNTNTSDSLMSFLESMNIKSIFVNFLQSNIKFILDANFIISGTTSIGQFEFICDENDNIQPYFIKFNTLETNYTLYVGNRQNMIVEPNYDLDDSGDISSTVINFSQKYLYGIDSCVNKVVISPNIYTDEINITPVYETNNTYPEVIVLDANYINEKINVNINDLSIRYVWSNDGNDFILMSTSEENKVSQVKIRFVNVFKDKTLANKLSFNFSDKQDVPVSEIILSFTPSYYEDGLIGYDLGLVSLYNEKFYINNFGMMVSGLIYINDSLYYFKPPVNNLITGFVTVGDDKYYFNPINGGAASIGETIIDDKNYYFNQSGVLQTGVFSTEDGFKYFAPANTLDENLEGEAIDFTGKLIIDENIYYFDDNYRGAVEWKELDGEMHYFSPETGKAFKGLNQIGDYKYYFNSDGVMQKGFVSINDNKHYFDDSGVMKVGYTEIDGKHFYFAENGEMQIGVFNTEDGFKYFAHHNEDLGNEEGEEISYSGILNFNNKIYYFDDSFTAVVGWKDLEDGSKYYFDEDTAEAYIGLSLINDGQYYFNDDGIMQVGFVTINDKVFYFSDSGIIESGVQNIDDNYFYIDDNGIVQIGVFDTSDGYKYFAPANTVNDNIYGQAVEYSGLVRVGEDVYYFGETYTIETGWIYDMENESDKYYFNPETKKACKGINLIDDIKYYFDEKGIMRTGLISFENNNYYFNENGEMQFGYINIEDKMFYFGEDGVMQIGVFNTPDGFKYFAHQNTLDENFEGESINYTGWLDLDEKRYYFTDEYIAATGSVIIDGEEYYFDPDTAQLVISE T14541 DRUGINFO D09KRE Bezlotoxumab Approved T14541 DRUGINFO D06IBG MK-3415A Phase 3 T75273 TARGETID T75273 T75273 UNIPROID GYRA_STAAU T75273 TARGNAME Staphylococcus DNA gyrase A (Stap-coc gyrA) T75273 GENENAME Stap-coc gyrA T75273 TARGTYPE Successful T75273 SYNONYMS Stap-coc DNA gyrase subunit A T75273 FUNCTION A type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to modulate DNA topology and maintain chromosomes in an underwound state. Negative supercoiling favors strand separation, and DNA replication, transcription, recombination and repair, all of which involve strand separation. Also able to catalyze the interconversion of other topological isomers of dsDNA rings, including catenanes and knotted rings. Type II topoisomerases break and join 2 DNA strands simultaneously in an ATP-dependent manner. T75273 PDBSTRUC 5BS3; 4PLB T75273 ECNUMBER EC 5.6.2.3 T75273 SEQUENCE MAELPQSRINERNITSEMRESFLDYAMSVIVARALPDVRDGLKPVHRRILYGLNEQGMTPDKSYKKSARIVGDVMGKYHPHGDSSIYEAMVRMAQDFSYRYPLVDGQGNFGSMDGDGAAAMRYTEARMTKITLELLRDINKDTIDFIDNYDGNEREPSVLPARFPNLLANGASGIAVGMATNIPPHNLTELINGVLSLSKNPDISIAELMEDIEGPDFPTAGLILGKSGIRRAYETGRGSIQMRSRAVIEERGGGRQRIVVTEIPFQVNKARMIEKIAELVRDKKIDGITDLRDETSLRTGVRVVIDVRKDANASVILNNLYKQTPLQTSFGVNMIALVNGRPKLINLKEALVHYLEHQKTVVRRRTQYNLRKAKDRAHILEGLRIALDHIDEIISTIRESDTDKVAMESLQQRFKLSEKQAQAILDMRLRRLTGLERDKIEAEYNELLNYISELEAILADEEVLLQLVRDELTEIRDRFGDDRRTEIQLGGFEDLEDEDLIPEEQIVITLSHNNYIKRLPVSTYRAQNRGGRGVQGMNTLEEDFVSQLVTLSTHDHVLFFTNKGRVYKLKGYEVPELSRQSKGIPVVNAIELENDEVISTMIAVKDLESEDNFLVFATKRGVVKRSALSNFSRINRNGKIAISFREDDELIAVRLTSGQEDILIGTSHASLIRFPESTLRPLGRTATGVKGITLREGDEVVGLDVAHANSVDEVLVVTENGYGKRTPVNDYRLSNRGGKGIKTATITERNGNVVCITTVTGEEDLMIVTNAGVIIRLDVADISQNGRAAQGVRLIRLGDDQFVSTVAKVKEDAEDETNEDEQSTSTVSEDGTEQQREAVVNDETPGNAIHTEVIDSEENDEDGRIEVRQDFMDRVEEDIQQSLDEDEE T75273 DRUGINFO D0X1HE Ozenoxacin Approved T51146 TARGETID T51146 T51146 FORMERID TTDI01872 T51146 UNIPROID FUT4_HUMAN T51146 TARGNAME Fucosyltransferase IV (CD15) T51146 GENENAME FUT4 T51146 TARGTYPE Successful T51146 SYNONYMS Galactoside 3-L-fucosyltransferase; Fucosyltransferase 4; FucT-IV; Fuc-TIV; FCT3A; ELFT; ELAM-1 ligand fucosyltransferase; Alpha-(1,3)-fucosyltransferase 4 T51146 FUNCTION May catalyze alpha-1,3 glycosidic linkages involved in the expression of Lewis X/SSEA-1 and VIM-2 antigens. T51146 BIOCLASS Glycosyltransferases T51146 ECNUMBER EC 2.4.1.- T51146 SEQUENCE MRRLWGAARKPSGAGWEKEWAEAPQEAPGAWSGRLGPGRSGRKGRAVPGWASWPAHLALAARPARHLGGAGQGPRPLHSGTAPFHSRASGERQRRLEPQLQHESRCRSSTPADAWRAEAALPVRAMGAPWGSPTAAAGGRRGWRRGRGLPWTVCVLAAAGLTCTALITYACWGQLPPLPWASPTPSRPVGVLLWWEPFGGRDSAPRPPPDCRLRFNISGCRLLTDRASYGEAQAVLFHHRDLVKGPPDWPPPWGIQAHTAEEVDLRVLDYEEAAAAAEALATSSPRPPGQRWVWMNFESPSHSPGLRSLASNLFNWTLSYRADSDVFVPYGYLYPRSHPGDPPSGLAPPLSRKQGLVAWVVSHWDERQARVRYYHQLSQHVTVDVFGRGGPGQPVPEIGLLHTVARYKFYLAFENSQHLDYITEKLWRNALLAGAVPVVLGPDRANYERFVPRGAFIHVDDFPSASSLASYLLFLDRNPAVYRRYFHWRRSYAVHITSFWDEPWCRVCQAVQRAGDRPKSIRNLASWFER T51146 DRUGINFO D07WLI 99mTc-fanolesomab Approved T73342 TARGETID T73342 T73342 FORMERID TTDS00246 T73342 UNIPROID RIR1_HUMAN; RIR2_HUMAN; RIR2B_HUMAN T73342 TARGNAME Ribonucleotide reductase (RIR) T73342 GENENAME RIR T73342 TARGTYPE Successful T73342 SYNONYMS Ribonucleoside diphosphate reductase; RIR1 T73342 FUNCTION Ribonucleoside-diphosphate reductase holoenzyme provides the precursors necessary for viral DNA synthesis. Allows virus growth in non-dividing cells, as well as reactivation from latency in infected hosts. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. The N-terminal region confers antiapoptotic activity in differentiated cells such as neurons and is importantfor viral reactivation to increase neural survivability. T73342 BIOCLASS CH/CH(2) oxidoreductase T73342 SEQUENCE MHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSGVTTVELDTLAAETAATLTTKHPDYAILAARIAVSNLHKETKKVFSDVMEDLYNYINPHNGKHSPMVAKSTLDIVLANKDRLNSAIIYDRDFSYNYFGFKTLERSYLLKINGKVAERPQHMLMRVSVGIHKEDIDAAIETYNLLSERWFTHASPTLFNAGTNRPQLSSCFLLSMKDDSIEGIYDTLKQCALISKSAGGIGVAVSCIRATGSYIAGTNGNSNGLVPMLRVYNNTARYVDQGGNKRPGAFAIYLEPWHLDIFEFLDLKKNTGKEEQRARDLFFALWIPDLFMKRVETNQDWSLMCPNECPGLDEVWGEEFEKLYASYEKQGRVRKVVKAQQLWYAIIESQTETGTPYMLYKDSCNRKSNQQNLGTIKCSNLCTEIVEYTSKDEVAVCNLASLALNMYVTSEHTYDFKKLAEVTKVVVRNLNKIIDINYYPVPEACLSNKRHRPIGIGVQGLADAFILMRYPFESAEAQLLNKQIFETIYYGALEASCDLAKEQGPYETYEGSPVSKGILQYDMWNVTPTDLWDWKVLKEKIAKYGIRNSLLIAPMPTASTAQILGNNESIEPYTSNIYTRRVLSGEFQIVNPHLLKDLTERGLWHEEMKNQIIACNGSIQSIPEIPDDLKQLYKTVWEISQKTVLKMAAERGAFIDQSQSLNIHIAEPNYGKLTSMHFYGWKQGLKTGMYYLRTRPAANPIQFTLNKEKLKDKEKVSKEEEEKERNTAAMVCSLENRDECLMCGS T73342 DRUGINFO D0R5RR Clofarabine Approved T73342 DRUGINFO D7K3FB CPX-POM Phase 2 T73342 DRUGINFO D0YU1M G-207 virus construct Phase 1/2 T73342 DRUGINFO D0NS6Z COH29 Phase 1 T73342 DRUGINFO D04FXS Didox Discontinued in Phase 2 T73342 DRUGINFO D0X1ZV Trimidox Preclinical T73342 DRUGINFO D06PWA Amidox Terminated T40555 TARGETID T40555 T40555 FORMERID TTDC00322 T40555 UNIPROID POLG_HCV1 T40555 TARGNAME Hepatitis C virus Non-structural 5A (HCV NS5A) T40555 GENENAME HCV NS5A T40555 TARGTYPE Successful T40555 SYNONYMS HCV NS5A T40555 FUNCTION Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity). T40555 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T40555 BIOCLASS Hepacivirus polyprotein T40555 SEQUENCE SGSWLRDIWDWICEVLSDFKTWLKAKLMPQLPGIPFVSCQRGYKGVWRVDGIMHTRCHCGAEITGHVKNGTMRIVGPRTCRNMWSGTFPINAYTTGPCTPLPAPNYTFALWRVSAEEYVEIRQVGDFHYVTGMTTDNLKCPCQVPSPEFFTELDGVRLHRFAPPCKPLLREEVSFRVGLHEYPVGSQLPCEPEPDVAVLTSMLTDPSHITAEAAGRRLARGSPPSVASSSASQLSAPSLKATCTANHDSPDAELIEANLLWRQEMGGNITRVESENKVVILDSFDPLVAEEDEREISVPAEILRKSRRFAQALPVWARPDYNPPLVETWKKPDYEPPVVHGCPLPPPKSPPVPPPRKKRTVVLTESTLSTALAELATRSFGSSSTSGITGDNTTTSSEPAPSGCPPDSDAESYSSMPPLEGEPGDPDLSDGSWSTVSSEANAEDVVCC T40555 DRUGINFO D09SGV Daclatasvir Approved T40555 DRUGINFO D0C4DH Glecaprevir; pibrentasvir Approved T40555 DRUGINFO D0RM5Z Sofosbuvir + velpatasvir + voxilaprevir Approved T40555 DRUGINFO D03GCR MK-8742 Phase 3 T40555 DRUGINFO D0LF5Q ABT-267 Phase 3 T40555 DRUGINFO DGJD82 Ravidasvir Phase 2/3 T40555 DRUGINFO D06LUZ GS-5885 Phase 2 T40555 DRUGINFO D0D6MV PPI-668 Phase 2 T40555 DRUGINFO D0U6QN ACH-3102 Phase 2 T40555 DRUGINFO D0V1KS AZD-2836 Phase 1/2 T40555 DRUGINFO D0AR5N BMS-824383 Phase 1 T40555 DRUGINFO D0C0QT PPI-461 Phase 1 T40555 DRUGINFO D0D0KZ AV4025 Phase 1 T40555 DRUGINFO D0N9TY AZD-7295 Phase 1 T40555 DRUGINFO D0P6NP EDP-239 Phase 1 T40555 DRUGINFO DN18SP MB-110 Phase 1 T40555 DRUGINFO D01VCB ACH-2928 Discontinued in Phase 1 T84117 TARGETID T84117 T84117 FORMERID TTDR00564 T84117 UNIPROID 5HT1E_HUMAN T84117 TARGNAME 5-HT 1E receptor (HTR1E) T84117 GENENAME HTR1E T84117 TARGTYPE Successful T84117 SYNONYMS Serotonin receptor 1E; S31; 5-hydroxytryptamine receptor 1E; 5-HT1E; 5-HT-1E; 5-HT 1E T84117 FUNCTION Functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for 5-hydroxytryptamine (serotonin). T84117 BIOCLASS GPCR rhodopsin T84117 SEQUENCE MNITNCTTEASMAIRPKTITEKMLICMTLVVITTLTTLLNLAVIMAIGTTKKLHQPANYLICSLAVTDLLVAVLVMPLSIIYIVMDRWKLGYFLCEVWLSVDMTCCTCSILHLCVIALDRYWAITNAIEYARKRTAKRAALMILTVWTISIFISMPPLFWRSHRRLSPPPSQCTIQHDHVIYTIYSTLGAFYIPLTLILILYYRIYHAAKSLYQKRGSSRHLSNRSTDSQNSFASCKLTQTFCVSDFSTSDPTTEFEKFHASIRIPPFDNDLDHPGERQQISSTRERKAARILGLILGAFILSWLPFFIKELIVGLSIYTVSSEVADFLTWLGYVNSLINPLLYTSFNEDFKLAFKKLIRCREHT T84117 DRUGINFO D0UA0I Metergolin Approved T84117 DRUGINFO D0Q5SL BRL54443 Investigative T84117 DRUGINFO D0S2BB B173 Investigative T84117 DRUGINFO D03RHW 5-BODMT Investigative T84117 DRUGINFO D05DAG 2-(5-fluoro-1H-indol-3-yl)ethanamine Investigative T84117 DRUGINFO D01APL lysergol Investigative T84117 DRUGINFO D0N8BJ [3H]5-HT Investigative T84117 DRUGINFO D0CK9K EDMT Investigative T84117 DRUGINFO D0Y4MC 9-OH-risperidone Investigative T84117 DRUGINFO D0J6JT m-chlorophenylpiperazine Investigative T84117 DRUGINFO D00CRA 2-methyl-5-HT Investigative T84117 DRUGINFO D09OYA alpha-methyl-5-HT Investigative T84117 DRUGINFO D03TDN 1-naphthylpiperazine Investigative T84117 DRUGINFO D04TVG BRL-15572 Investigative T84117 DRUGINFO D02UWB 5-CT Investigative T84117 DRUGINFO D0V5HV TFMPP Investigative T88023 TARGETID T88023 T88023 FORMERID TTDR00192 T88023 UNIPROID TNR8_HUMAN T88023 TARGNAME Lymphocyte activation antigen CD30 (TNFRSF8) T88023 GENENAME TNFRSF8 T88023 TARGTYPE Successful T88023 SYNONYMS Tumor necrosis factor receptor superfamily member 8; KI-1 antigen; D1S166E; CD30L receptor; CD30 T88023 FUNCTION May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. Receptor for TNFSF8/CD30L. T88023 PDBSTRUC 1D01 T88023 SEQUENCE MRVLLAALGLLFLGALRAFPQDRPFEDTCHGNPSHYYDKAVRRCCYRCPMGLFPTQQCPQRPTDCRKQCEPDYYLDEADRCTACVTCSRDDLVEKTPCAWNSSRVCECRPGMFCSTSAVNSCARCFFHSVCPAGMIVKFPGTAQKNTVCEPASPGVSPACASPENCKEPSSGTIPQAKPTPVSPATSSASTMPVRGGTRLAQEAASKLTRAPDSPSSVGRPSSDPGLSPTQPCPEGSGDCRKQCEPDYYLDEAGRCTACVSCSRDDLVEKTPCAWNSSRTCECRPGMICATSATNSCARCVPYPICAAETVTKPQDMAEKDTTFEAPPLGTQPDCNPTPENGEAPASTSPTQSLLVDSQASKTLPIPTSAPVALSSTGKPVLDAGPVLFWVILVLVVVVGSSAFLLCHRRACRKRIRQKLHLCYPVQTSQPKLELVDSRPRRSSTQLRSGASVTEPVAEERGLMSQPLMETCHSVGAAYLESLPLQDASPAGGPSSPRDLPEPRVSTEHTNNKIEKIYIMKADTVIVGTVKAELPEGRGLAGPAEPELEEELEADHTPHYPEQETEPPLGSCSDVMLSVEEEGKEDPLPTAASGK T88023 DRUGINFO D03TIS Brentuximab vedotin Approved T88023 DRUGINFO D00MBR Iratumumab Phase 2 T88023 DRUGINFO D0J7KD TT11X Phase 2 T88023 DRUGINFO D0S0MP SGN-30 Phase 2 T88023 DRUGINFO D0T4FY CAR-T cells targeting CD30 Phase 2 T88023 DRUGINFO DIKA27 TT20X Phase 2 T88023 DRUGINFO DZM2L1 AFM13 Phase 2 T88023 DRUGINFO D04ACK Anti-CD30 CAR T cells Phase 1/2 T88023 DRUGINFO D0FZ1Y CART30 Phase 1/2 T88023 DRUGINFO D0I5GS CAR.CD30 cells Phase 1/2 T88023 DRUGINFO D0UA0U CAR-T cells targeting CD30 Phase 1/2 T88023 DRUGINFO D0W2MI Anti-CD30-CAR-transduced T cells Phase 1/2 T88023 DRUGINFO D0K8YX 4SCAR19 and 4SCAR30 Phase 1/2 T88023 DRUGINFO D06ALK Xmab-2513 Phase 1 T88023 DRUGINFO D08ZAC ICAR30 T cells Phase 1 T88023 DRUGINFO D0GA8I ATLCAR.CD30 cells Phase 1 T88023 DRUGINFO D0H2LC Anti-CD30 CAR-T cells Phase 1 T88023 DRUGINFO D0N2AM CAR CD30 T cells Phase 1 T88023 DRUGINFO D0S3YV CD30 CAR T Cells Phase 1 T88023 DRUGINFO D0TC6X Anti-CD30-CAR T cells Phase 1 T88023 DRUGINFO DDG8W9 SGN-CD30C Phase 1 T88023 DRUGINFO D0U5AQ ATLCAR.CD30.CCR4 cells Phase 1 T88023 DRUGINFO D0A9QL Ber-H2/saporin Terminated T88023 DRUGINFO D02SJG VT-362 Investigative T88023 DRUGINFO D0LE2E H22xKi-4 Investigative T95400 TARGETID T95400 T95400 FORMERID TTDS00484 T95400 UNIPROID FCERG_HUMAN T95400 TARGNAME Immunoglobulin epsilon Fc receptor gamma (FCERG) T95400 GENENAME FCER1G T95400 TARGTYPE Successful T95400 SYNONYMS IgE Fc receptor subunit gamma; High affinity immunoglobulin epsilon receptor subunit gamma; FceRI gamma; FcRgamma; Fc receptor gamma-chain T95400 FUNCTION As a component of the high-affinity immunoglobulin E (IgE) receptor, mediates allergic inflammatory signaling in mast cells. As a constitutive component of interleukin-3 receptor complex, selectively mediates interleukin 4/IL4 production by basophils, priming T-cells toward effector T-helper 2 subset. Associates with pattern recognition receptors CLEC4D and CLEC4E to form a functional signaling complex in myeloid cells. Binding of mycobacterial trehalose 6,6'-dimycolate (TDM) to this receptor complex leads to phosphorylation of ITAM, triggering activation of SYK, CARD9 and NF-kappa-B, consequently driving maturation of antigen-presenting cells and shaping antigen-specific priming of T-cells toward effector T-helper 1 and T-helper 17 cell subtypes. May function cooperatively with other activating receptors. Functionally linked to integrin beta-2/ITGB2-mediated neutrophil activation. Also involved in integrin alpha-2/ITGA2-mediated platelet activation. Adapter protein containing an immunoreceptor tyrosine-based activation motif (ITAM) that transduces activation signals from various immunoreceptors. T95400 BIOCLASS Immunoglobulin T95400 SEQUENCE MIPAVVLLLLLLVEQAAALGEPQLCYILDAILFLYGIVLTLLYCRLKIQVRKAAITSYEKSDGVYTGLSTRNQETYETLKHEKPPQ T95400 DRUGINFO D02GEC Omalizumab Approved T95400 DRUGINFO D0J7TM Benzylpenicilloyl Polylysine Approved T95400 DRUGINFO D0G6XS Fucose Investigative T95400 DRUGINFO D07LUR Alpha-D-Mannose Investigative T76630 TARGETID T76630 T76630 FORMERID TTDS00096 T76630 UNIPROID CD52_HUMAN T76630 TARGNAME Cambridge pathology 1 antigen (CD52) T76630 GENENAME CD52 T76630 TARGTYPE Successful T76630 SYNONYMS Epididymal secretory protein E5; CDW52; CD52 antigen; CD52 T76630 FUNCTION May play a role in carrying and orienting carbohydrate, as well as having a more specific role. T76630 SEQUENCE MKRFLFLLLTISLLVMVQIQTGLSGQNDTSQTSSPSASSNISGGIFLFFVANAIIHLFCFS T76630 DRUGINFO D01ZYG Alemtuzumab Approved T76630 DRUGINFO D0U0SK GZ402668 Phase 1 T30085 TARGETID T30085 T30085 FORMERID TTDNC00579 T30085 UNIPROID SC5A2_HUMAN T30085 TARGNAME Sodium/glucose cotransporter 2 (SGLT2) T30085 GENENAME SLC5A2 T30085 TARGTYPE Successful T30085 SYNONYMS Solute carrier family 5 member 2; Na(+)/glucose cotransporter 2; Low affinity sodium-glucose cotransporter T30085 FUNCTION Has a Na(+) to glucose coupling ratio of 1:1. Sodium-dependent glucose transporter. T30085 BIOCLASS Solute:sodium symporter T30085 SEQUENCE MEEHTEAGSAPEMGAQKALIDNPADILVIAAYFLLVIGVGLWSMCRTNRGTVGGYFLAGRSMVWWPVGASLFASNIGSGHFVGLAGTGAASGLAVAGFEWNALFVVLLLGWLFAPVYLTAGVITMPQYLRKRFGGRRIRLYLSVLSLFLYIFTKISVDMFSGAVFIQQALGWNIYASVIALLGITMIYTVTGGLAALMYTDTVQTFVILGGACILMGYAFHEVGGYSGLFDKYLGAATSLTVSEDPAVGNISSFCYRPRPDSYHLLRHPVTGDLPWPALLLGLTIVSGWYWCSDQVIVQRCLAGKSLTHIKAGCILCGYLKLTPMFLMVMPGMISRILYPDEVACVVPEVCRRVCGTEVGCSNIAYPRLVVKLMPNGLRGLMLAVMLAALMSSLASIFNSSSTLFTMDIYTRLRPRAGDRELLLVGRLWVVFIVVVSVAWLPVVQAAQGGQLFDYIQAVSSYLAPPVSAVFVLALFVPRVNEQGAFWGLIGGLLMGLARLIPEFSFGSGSCVQPSACPAFLCGVHYLYFAIVLFFCSGLLTLTVSLCTAPIPRKHLHRLVFSLRHSKEEREDLDADEQQGSSLPVQNGCPESAMEMNEPQAPAPSLFRQCLLWFCGMSRGGVGSPPPLTQEEAAAAARRLEDISEDPSWARVVNLNALLMMAVAVFLWGFYA T30085 DRUGINFO D01TNW Dapagliflozin Approved T30085 DRUGINFO D06ALD Empagliflozin Approved T30085 DRUGINFO D08DFX Canagliflozin Approved T30085 DRUGINFO D0Q3VE PF-04971729 Approved T30085 DRUGINFO D0U7IL Sotagliflozin Approved T30085 DRUGINFO D0Y6QC Dapagliflozin Propanediol; Saxagliptin Hydrochloride Approved T30085 DRUGINFO D07FBM ASP1941 Phase 3 T30085 DRUGINFO D0B6QZ AVE-2268 Phase 2 T30085 DRUGINFO D0H2NI YM-543 Phase 2 T30085 DRUGINFO D0U7SR RO-4998452 Phase 2 T30085 DRUGINFO D0V4MB Remogliflozin etabonate Phase 2 T30085 DRUGINFO D0X2UI LIK-066 Phase 2 T30085 DRUGINFO D6KEW7 YG1699 Phase 2 T30085 DRUGINFO D00SFY BI-44847 Phase 1 T30085 DRUGINFO D08OUL EGT-0001474 Phase 1 T30085 DRUGINFO D08WGZ TS-033 Discontinued in Phase 2 T30085 DRUGINFO D07UEJ Empagli ozin Investigative T30085 DRUGINFO D0X1TN sergliflozin Investigative T21890 TARGETID T21890 T21890 FORMERID TTDS00487 T21890 UNIPROID CEAM3_HUMAN T21890 TARGNAME Carcinoembryonic antigen CGM1 (CD66d) T21890 GENENAME CEACAM3 T21890 TARGTYPE Successful T21890 SYNONYMS CGM1; CEACAM3; CD66d T21890 FUNCTION Major granulocyte receptor mediating recognition and efficient opsonin-independent phagocytosis of CEACAM-binding microorganisms, including Neissiria, Moxarella and Haemophilus species, thus playing an important role in the clearance of pathogens by the innate immune system. Responsible for RAC1 stimulation in the course of pathogen phagocytosis. T21890 PDBSTRUC 6AW3; 6AW1; 6AW0; 6AVZ T21890 BIOCLASS Immunoglobulin T21890 SEQUENCE MGPPSASPHRECIPWQGLLLTASLLNFWNPPTTAKLTIESMPLSVAEGKEVLLLVHNLPQHLFGYSWYKGERVDGNSLIVGYVIGTQQATPGAAYSGRETIYTNASLLIQNVTQNDIGFYTLQVIKSDLVNEEATGQFHVYQENAPGLPVGAVAGIVTGVLVGVALVAALVCFLLLAKTGRTSIQRDLKEQQPQALAPGRGPSHSSAFSMSPLSTAQAPLPNPRTAASIYEELLKHDTNIYCRMDHKAEVAS T21890 DRUGINFO D06URS Arcitumomab Approved T62391 TARGETID T62391 T62391 FORMERID TTDI01974 T62391 UNIPROID GRIA3_HUMAN T62391 TARGNAME Glutamate receptor AMPA 3 (GRIA3) T62391 GENENAME GRIA3 T62391 TARGTYPE Successful T62391 SYNONYMS Glutamate receptor ionotropic, AMPA 3; GluRK3; GluRC; GluR3; GluA3; GRIA3; AMPAselective glutamate receptor 3 T62391 FUNCTION Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L- glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate. T62391 BIOCLASS Glutamate-gated ion channel T62391 SEQUENCE MARQKKMGQSVLRAVFFLVLGLLGHSHGGFPNTISIGGLFMRNTVQEHSAFRFAVQLYNTNQNTTEKPFHLNYHVDHLDSSNSFSVTNAFCSQFSRGVYAIFGFYDQMSMNTLTSFCGALHTSFVTPSFPTDADVQFVIQMRPALKGAILSLLGHYKWEKFVYLYDTERGFSILQAIMEAAVQNNWQVTARSVGNIKDVQEFRRIIEEMDRRQEKRYLIDCEVERINTILEQVVILGKHSRGYHYMLANLGFTDILLERVMHGGANITGFQIVNNENPMVQQFIQRWVRLDEREFPEAKNAPLKYTSALTHDAILVIAEAFRYLRRQRVDVSRRGSAGDCLANPAVPWSQGIDIERALKMVQVQGMTGNIQFDTYGRRTNYTIDVYEMKVSGSRKAGYWNEYERFVPFSDQQISNDSASSENRTIVVTTILESPYVMYKKNHEQLEGNERYEGYCVDLAYEIAKHVRIKYKLSIVGDGKYGARDPETKIWNGMVGELVYGRADIAVAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHLEDNNEEPRDPQSPPDPPNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLAKQTEIAYGTLDSGSTKEFFRRSKIAVYEKMWSYMKSAEPSVFTKTTADGVARVRKSKGKFAFLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGVATPKGSALRNAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKDKTSALSLSNVAGVFYILVGGLGLAMMVALIEFCYKSRAESKRMKLTKNTQNFKPAPATNTQNYATYREGYNVYGTESVKI T62391 DRUGINFO D0U3ED E-2007 Approved T62391 DRUGINFO D0SB9H joro toxin Investigative T62391 DRUGINFO D03VBJ ATPO Investigative T62391 DRUGINFO D09LXQ (S)-5-fluorowillardiine Investigative T62391 DRUGINFO D0G1UE [3H]AMPA Investigative T62391 DRUGINFO D0E5UQ [3H]CNQX Investigative T63967 TARGETID T63967 T63967 UNIPROID ACHA4_HUMAN; ACHB2_HUMAN T63967 TARGNAME Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) T63967 GENENAME CHRNA4-CHRNB2 T63967 TARGTYPE Successful T63967 SYNONYMS CHRN; nAChR T63967 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions. T63967 BIOCLASS Neurotransmitter receptor T63967 SEQUENCE MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISDVVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWRPDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFGSWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKRPSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGPSCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEGGVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSVSPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDRIFLWMFIIVCLLGTVGLFLPPWLAGMI T63967 DRUGINFO D0LM4A Varenicline Approved T63967 DRUGINFO D0Y6CE Metocurine Iodide Approved T63967 DRUGINFO D01MAU AZD-1446 Phase 2 T63967 DRUGINFO D04SHH TC-6499-12 Phase 2 T63967 DRUGINFO D05RSC Sofinicline Phase 2 T63967 DRUGINFO D0R7AK CP-601927 Phase 2 T63967 DRUGINFO D00EZO TC-2216 Phase 1 T63967 DRUGINFO D4AY6B SUVN 911 Phase 1 T63967 DRUGINFO D00LVA Dianicline Discontinued in Phase 3 T63967 DRUGINFO D05OFO TC-2696 Discontinued in Phase 2 T63967 DRUGINFO D0AB4Q Ispronicline Discontinued in Phase 2 T63967 DRUGINFO D0L1DP ABT-089 Discontinued in Phase 2 T63967 DRUGINFO D0TF1E A-366833 Preclinical T63967 DRUGINFO D0Y9HH SIB-1508Y Terminated T96235 TARGETID T96235 T96235 FORMERID TTDI01975 T96235 UNIPROID GRIA4_HUMAN T96235 TARGNAME Glutamate receptor AMPA 4 (GRIA4) T96235 GENENAME GRIA4 T96235 TARGTYPE Successful T96235 SYNONYMS Glutamate receptor ionotropic, AMPA 4; GluRD; GluR4; GluA4; GRIA4; AMPAselective glutamate receptor 4 T96235 FUNCTION Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the centralnervous system. Binding of the excitatory neurotransmitter L- glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate. T96235 BIOCLASS Glutamate-gated ion channel T96235 SEQUENCE MRIISRQIVLLFSGFWGLAMGAFPSSVQIGGLFIRNTDQEYTAFRLAIFLHNTSPNASEAPFNLVPHVDNIETANSFAVTNAFCSQYSRGVFAIFGLYDKRSVHTLTSFCSALHISLITPSFPTEGESQFVLQLRPSLRGALLSLLDHYEWNCFVFLYDTDRGYSILQAIMEKAGQNGWHVSAICVENFNDVSYRQLLEELDRRQEKKFVIDCEIERLQNILEQIVSVGKHVKGYHYIIANLGFKDISLERFIHGGANVTGFQLVDFNTPMVIKLMDRWKKLDQREYPGSETPPKYTSALTYDGVLVMAETFRSLRRQKIDISRRGNAGDCLANPAAPWGQGIDMERTLKQVRIQGLTGNVQFDHYGRRVNYTMDVFELKSTGPRKVGYWNDMDKLVLIQDVPTLGNDTAAIENRTVVVTTIMESPYVMYKKNHEMFEGNDKYEGYCVDLASEIAKHIGIKYKIAIVPDGKYGARDADTKIWNGMVGELVYGKAEIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEPEDGKEGPSDQPPNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLAKQTEIAYGTLDSGSTKEFFRRSKIAVYEKMWTYMRSAEPSVFTRTTAEGVARVRKSKGKFAFLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGVATPKGSSLRTPVNLAVLKLSEAGVLDKLKNKWWYDKGECGPKDSGSKDKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSRAEAKRMKLTFSEAIRNKARLSITGSVGENGRVLTPDCPKAVHTGTAIRQSSGLAVIASDLP T96235 DRUGINFO D0U3ED E-2007 Approved T96235 DRUGINFO D0W6EP AMG-889436 Investigative T96235 DRUGINFO D0SB9H joro toxin Investigative T96235 DRUGINFO D03VBJ ATPO Investigative T96235 DRUGINFO D09LXQ (S)-5-fluorowillardiine Investigative T96235 DRUGINFO D0G1UE [3H]AMPA Investigative T96235 DRUGINFO D0E5UQ [3H]CNQX Investigative T16792 TARGETID T16792 T16792 FORMERID TTDS00426 T16792 UNIPROID IOD1_HUMAN T16792 TARGNAME Iodothyronine deiodinase type I (DIO1) T16792 GENENAME DIO1 T16792 TARGTYPE Successful T16792 SYNONYMS Type-I 5'-deiodinase; Type I iodothyronine deiodinase; Type 1 DI; TXDI1; ITDI1; DIOI; 5DI T16792 FUNCTION Plays a role in providing a source of plasma T3 by deiodination of T4 in peripheral tissues such as liver and kidney. Responsible for the deiodination of T4 (3,5,3',5'-tetraiodothyronine) into T3 (3,5,3'-triiodothyronine) and of T3 into T2 (3,3'-diiodothyronine). T16792 ECNUMBER EC 1.21.99.4 T16792 SEQUENCE MGLPQPGLWLKRLWVLLEVAVHVVVGKVLLILFPDRVKRNILAMGEKTGMTRNPHFSHDNWIPTFFSTQYFWFVLKVRWQRLEDTTELGGLAPNCPVVRLSGQRCNIWEFMQGNRPLVLNFGSCTUPSFMFKFDQFKRLIEDFSSIADFLVIYIEEAHASDGWAFKNNMDIRNHQNLQDRLQAAHLLLARSPQCPVVVDTMQNQSSQLYAALPERLYIIQEGRILYKGKSGPWNYNPEEVRAVLEKLHS T16792 DRUGINFO D00MIN Propylthiouracil Approved T34239 TARGETID T34239 T34239 UNIPROID PPOX_HUMAN T34239 TARGNAME Protoporphyrinogen oxidase (PPOX) T34239 GENENAME PPOX T34239 TARGTYPE Successful T34239 SYNONYMS PPO T34239 FUNCTION Catalyzes the 6-electron oxidation of protoporphyrinogen-IX to form protoporphyrin-IX. T34239 PDBSTRUC 4IVO; 4IVM; 3NKS T34239 ECNUMBER EC 1.3.3.4 T34239 SEQUENCE MGRTVVVLGGGISGLAASYHLSRAPCPPKVVLVESSERLGGWIRSVRGPNGAIFELGPRGIRPAGALGARTLLLVSELGLDSEVLPVRGDHPAAQNRFLYVGGALHALPTGLRGLLRPSPPFSKPLFWAGLRELTKPRGKEPDETVHSFAQRRLGPEVASLAMDSLCRGVFAGNSRELSIRSCFPSLFQAEQTHRSILLGLLLGAGRTPQPDSALIRQALAERWSQWSLRGGLEMLPQALETHLTSRGVSVLRGQPVCGLSLQAEGRWKVSLRDSSLEADHVISAIPASVLSELLPAEAAPLARALSAITAVSVAVVNLQYQGAHLPVQGFGHLVPSSEDPGVLGIVYDSVAFPEQDGSPPGLRVTVMLGGSWLQTLEASGCVLSQELFQQRAQEAAATQLGLKEMPSHCLVHLHKNCIPQYTLGHWQKLESARQFLTAHRLPLTLAGASYEGVAVNDCIESGRQAAVSVLGTEPNS T34239 DRUGINFO D0O4GY Aminolevulinic Acid Hydrochloride Approved T55094 TARGETID T55094 T55094 FORMERID TTDR01256 T55094 UNIPROID ASIC1_HUMAN T55094 TARGNAME Acid-sensing ion channel 1 (ASIC1) T55094 GENENAME ASIC1 T55094 TARGTYPE Successful T55094 SYNONYMS Brain sodium channel 2; BNaC2; Amiloride-sensitive cation channel 2, neuronal; ASIC1; ACCN2 T55094 FUNCTION Isoform 1 does not display proton-gated cation channel activity. T55094 BIOCLASS Amiloride-sensitive sodium channel T55094 SEQUENCE MELKAEEEEVGGVQPVSIQAFASSSTLHGLAHIFSYERLSLKRALWALCFLGSLAVLLCVCTERVQYYFHYHHVTKLDEVAASQLTFPAVTLCNLNEFRFSQVSKNDLYHAGELLALLNNRYEIPDTQMADEKQLEILQDKANFRSFKPKPFNMREFYDRAGHDIRDMLLSCHFRGEVCSAEDFKVVFTRYGKCYTFNSGRDGRPRLKTMKGGTGNGLEIMLDIQQDEYLPVWGETDETSFEAGIKVQIHSQDEPPFIDQLGFGVAPGFQTFVACQEQRLIYLPPPWGTCKAVTMDSDLDFFDSYSITACRIDCETRYLVENCNCRMVHMPGDAPYCTPEQYKECADPALDFLVEKDQEYCVCEMPCNLTRYGKELSMVKIPSKASAKYLAKKFNKSEQYIGENILVLDIFFEVLNYETIEQKKAYEIAGLLGDIGGQMGLFIGASILTVLELFDYAYEVIKHKLCRRGKCQKEAKRSSADKGVALSLDDVKRHNPCESLRGHPAGMTYAANILPHHPARGTFEDFTC T55094 DRUGINFO D0I0RJ Amiloride Approved T55094 DRUGINFO D0E2ZA PPC-5650 Phase 1 T55094 DRUGINFO D0I8OE PcTx1 Investigative T14582 TARGETID T14582 T14582 FORMERID TTDR00158 T14582 UNIPROID ALR_MYCSM T14582 TARGNAME Mycobacterium Biosynthetic alanine racemase (MycB alr) T14582 GENENAME MycB alr T14582 TARGTYPE Successful T14582 SYNONYMS D-alanine racemase; Alr; Alanine racemase; AlaR T14582 FUNCTION Catalyzes the interconversion of L-alanine and D- alanine. Overexpression due to a natural mutation in the promoter is responsible for mediating resistance to D-cycloserine (DCS) in mycobacteria. T14582 BIOCLASS Racemases and epimerases T14582 ECNUMBER EC 5.1.1.1 T14582 SEQUENCE MQTTEPMTPPAPLASAQTVIDLGAIDHNVRVLRELAGSADVMAVVKADAYGHGALPVARTALAAGAAALGVATIPEALALREGGITAPVLAWLHPPGTDFAPAIAADVEVAVSSRRQLEQVTAAAAEVGRTATVTVKVDTGLSRNGVGAADYPEVLDVLRRAQADGAIRVRGLMSHLVHGDDPENPFNGLQGQRLADMRVYAREHGVDYEVAHLCNSPAAMTRPDLAFEMVRPGISLYGLSPIPERGDMGLRPAMTLKCPVALVRSVHAGDGVSYGHRWVADRDTTLGLLPIGYADGVYRALSGRIDVLIKGRRRRAVGRICMDQFVVDLGPDADDVAVGDDAILFGPGANGEPTAQDWAELLDTIHYEVVTSPRGRVTRTYLPAGQQD T14582 DRUGINFO D02WFK Cycloserine Approved T14582 DRUGINFO D02XZI Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate Investigative T14582 DRUGINFO D0B0SD Propionate Investigative T14582 DRUGINFO D0I7PG N-(5'-Phosphopyridoxyl)-D-Alanine Investigative T14582 DRUGINFO D0J1AY Pyridoxyl-Alanine-5-Phosphate Investigative T14582 DRUGINFO D0S5BG Propanoic Acid Investigative T14582 DRUGINFO D0T7UP 3-fluorovinylglycine Investigative T14582 DRUGINFO D01NBK Pyridoxamine-5'-Phosphate Investigative T14582 DRUGINFO D0CC0B Lysine Nz-Carboxylic Acid Investigative T14582 DRUGINFO D0F2ME Acetate Ion Investigative T90828 TARGETID T90828 T90828 UNIPROID IL5RA_HUMAN T90828 TARGNAME Interleukin 5 receptor alpha (IL5RA) T90828 GENENAME IL5RA T90828 TARGTYPE Successful T90828 SYNONYMS Interleukin-5 receptor subunit alpha; IL5R; IL-5RA; IL-5R-alpha; IL-5R subunit alpha; IL-5 receptor subunit alpha; CDw125; CD125 T90828 FUNCTION The alpha chain binds to IL5. This is the receptor for interleukin-5. T90828 PDBSTRUC 6H41; 3VA2; 3QT2; 1OBZ; 1OBX T90828 BIOCLASS Cytokine receptor T90828 SEQUENCE MIIVAHVLLILLGATEILQADLLPDEKISLLPPVNFTIKVTGLAQVLLQWKPNPDQEQRNVNLEYQVKINAPKEDDYETRITESKCVTILHKGFSASVRTILQNDHSLLASSWASAELHAPPGSPGTSIVNLTCTTNTTEDNYSRLRSYQVSLHCTWLVGTDAPEDTQYFLYYRYGSWTEECQEYSKDTLGRNIACWFPRTFILSKGRDWLAVLVNGSSKHSAIRPFDQLFALHAIDQINPPLNVTAEIEGTRLSIQWEKPVSAFPIHCFDYEVKIHNTRNGYLQIEKLMTNAFISIIDDLSKYDVQVRAAVSSMCREAGLWSEWSQPIYVGNDEHKPLREWFVIVIMATICFILLILSLICKICHLWIKLFPPIPAPKSNIKDLFVTTNYEKAGSSETEIEVICYIEKPGVETLEDSVF T90828 DRUGINFO D02PIO Benralizumab Approved T90828 DRUGINFO D3Q0FU CSL311 Phase 1 T90828 DRUGINFO D0S2TI YM90709 Investigative T08898 TARGETID T08898 T08898 FORMERID TTDS00286 T08898 UNIPROID ACTHR_HUMAN T08898 TARGNAME Melanocortin receptor 2 (MC2R) T08898 GENENAME MC2R T08898 TARGTYPE Successful T08898 SYNONYMS Melanocortin-2 receptor; MC2-R; Adrenocorticotropin receptor; Adrenocorticotropic hormone receptor; ACTHR; ACTH-R; ACTH receptor T08898 FUNCTION Receptor for corticotropin (ACTH). This receptor is mediated by G proteins (G(s)) which activate adenylate cyclase (cAMP). T08898 BIOCLASS GPCR rhodopsin T08898 SEQUENCE MKHIINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMYFFICSLAISDMLGSLYKILENILIILRNMGYLKPRGSFETTADDIIDSLFVLSLLGSIFSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMFLLARSHTRKISTLPRANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPSNPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW T08898 DRUGINFO D0W6LI Cosyntropin Approved T19693 TARGETID T19693 T19693 FORMERID TTDI03001 T19693 UNIPROID GUC2D_HUMAN T19693 TARGNAME Soluble guanylyl cyclase (GUCY2D) T19693 GENENAME GUCY2D T19693 TARGTYPE Successful T19693 SYNONYMS Rod outer segment membrane guanylate cyclase; Retinal guanylyl cyclase 1; ROS-GC; RETGC1; RETGC-1; RETGC; Guanylate cyclase 2D, retinal; GUC2D; GUC1A4; CORD6 T19693 FUNCTION Probably plays a specific functional role in the rods and/or cones of photoreceptors. It may be the enzyme involved in the resynthesis of cGMP required for recovery of the dark state after phototransduction. T19693 PDBSTRUC 1AWL T19693 ECNUMBER EC 4.6.1.2 T19693 SEQUENCE MTACARRAGGLPDPGLCGPAWWAPSLPRLPRALPRLPLLLLLLLLQPPALSAVFTVGVLGPWACDPIFSRARPDLAARLAAARLNRDPGLAGGPRFEVALLPEPCRTPGSLGAVSSALARVSGLVGPVNPAACRPAELLAEEAGIALVPWGCPWTQAEGTTAPAVTPAADALYALLRAFGWARVALVTAPQDLWVEAGRSLSTALRARGLPVASVTSMEPLDLSGAREALRKVRDGPRVTAVIMVMHSVLLGGEEQRYLLEAAEELGLTDGSLVFLPFDTIHYALSPGPEALAALANSSQLRRAHDAVLTLTRHCPSEGSVLDSLRRAQERRELPSDLNLQQVSPLFGTIYDAVFLLARGVAEARAAAGGRWVSGAAVARHIRDAQVPGFCGDLGGDEEPPFVLLDTDAAGDRLFATYMLDPARGSFLSAGTRMHFPRGGSAPGPDPSCWFDPNNICGGGLEPGLVFLGFLLVVGMGLAGAFLAHYVRHRLLHMQMVSGPNKIILTVDDITFLHPHGGTSRKVAQGSRSSLGARSMSDIRSGPSQHLDSPNIGVYEGDRVWLKKFPGDQHIAIRPATKTAFSKLQELRHENVALYLGLFLARGAEGPAALWEGNLAVVSEHCTRGSLQDLLAQREIKLDWMFKSSLLLDLIKGIRYLHHRGVAHGRLKSRNCIVDGRFVLKITDHGHGRLLEAQKVLPEPPRAEDQLWTAPELLRDPALERRGTLAGDVFSLAIIMQEVVCRSAPYAMLELTPEEVVQRVRSPPPLCRPLVSMDQAPVECILLMKQCWAEQPELRPSMDHTFDLFKNINKGRKTNIIDSMLRMLEQYSSNLEDLIRERTEELELEKQKTDRLLTQMLPPSVAEALKTGTPVEPEYFEQVTLYFSDIVGFTTISAMSEPIEVVDLLNDLYTLFDAIIGSHDVYKVETIGDAYMVASGLPQRNGQRHAAEIANMSLDILSAVGTFRMRHMPEVPVRIRIGLHSGPCVAGVVGLTMPRYCLFGDTVNTASRMESTGLPYRIHVNLSTVGILRALDSGYQVELRGRTELKGKGAEDTFWLVGRRGFNKPIPKPPDLQPGSSNHGISLQEIPPERRRKLEKARPGQFS T19693 DRUGINFO D04UKC Riociguat Approved T19693 DRUGINFO D06ZEO Vericiguat Approved T19693 DRUGINFO D0ZM8B FK-409 Phase 2 T19693 DRUGINFO D0O9CZ BAY412272 Investigative T19693 DRUGINFO D0R3FS ODQ Investigative T19693 DRUGINFO D0U3YQ NS 2028 Investigative T07289 TARGETID T07289 T07289 FORMERID TTDI01985 T07289 UNIPROID ACKR1_HUMAN T07289 TARGNAME Duffy antigen chemokine receptor (ACKR1) T07289 GENENAME ACKR1 T07289 TARGTYPE Successful T07289 SYNONYMS Plasmodium vivax receptor; GpFy; Glycoprotein D; Fy glycoprotein; Duffy antigen/chemokine receptor; DARC; CD234; ACKR1 T07289 FUNCTION Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Has a promiscuous chemokine-binding profile, interacting with inflammatory chemokines of both the CXC and the CC subfamilies but not with homeostatic chemokines. Acts as a receptor for chemokines including CCL2, CCL5, CCL7, CCL11, CCL13, CCL14, CCL17, CXCL5, CXCL6, IL8/CXCL8, CXCL11, GRO, RANTES, MCP-1, TARC and also for the malaria parasites P.vivax and P.knowlesi. May regulate chemokine bioavailability and, consequently, leukocyte recruitment through two distinct mechanisms: when expressed in endothelial cells, it sustains the abluminal to luminal transcytosis of tissue-derived chemokines and their subsequent presentation to circulating leukocytes; when expressed in erythrocytes, serves as blood reservoir of cognate chemokines but also as a chemokine sink, buffering potential surges in plasma chemokine levels. T07289 PDBSTRUC 4NUV; 4NUU T07289 BIOCLASS GPCR duffy T07289 SEQUENCE MGNCLHRAELSPSTENSSQLDFEDVWNSSYGVNDSFPDGDYGANLEAAAPCHSCNLLDDSALPFFILTSVLGILASSTVLFMLFRPLFRWQLCPGWPVLAQLAVGSALFSIVVPVLAPGLGSTRSSALCSLGYCVWYGSAFAQALLLGCHASLGHRLGAGQVPGLTLGLTVGIWGVAALLTLPVTLASGASGGLCTLIYSTELKALQATHTVACLAIFVLLPLGLFGAKGLKKALGMGPGPWMNILWAWFIFWWPHGVVLGLDFLVRSKLLLLSTCLAQQALDLLLNLAEALAILHCVATPLLLALFCHQATRTLLPSLPLPEGWSSHLDTLGSKS T07289 DRUGINFO D09EGZ Chloroquine Approved T07289 DRUGINFO D0L1VI AQ-13 Phase 2 T93955 TARGETID T93955 T93955 FORMERID TTDS00506 T93955 UNIPROID MTLD_ASPFU T93955 TARGNAME Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA) T93955 GENENAME Asperg mpdA T93955 TARGTYPE Successful T93955 SYNONYMS mpdA; MPDH; MPD; M1PDH T93955 FUNCTION Catalyzes the NAD(H)-dependent interconversion of D- fructose 6-phosphate and D-mannitol 1-phosphate in the mannitol metabolic pathway. Has a strong preference for NADH over NADPH. T93955 BIOCLASS Short-chain dehydrogenases reductase T93955 ECNUMBER EC 1.1.1.17 T93955 SEQUENCE MGKKAIQFGGGNIGRGFVAEFLHEAGYEVVFIDVVDKIIDALKSTPSYEVTEVSEEGEKTKTITNYRAINSKTNEEDVVKEIGTADVVTCAVGPNVLKFIAPVIAKGIDARTASKPVAVIACENAIGATDTLRGFIEQNTDKDRLSSMSERARFANSAIDRIVPNQPPNAGLNVRIEKFYEWTVEQTPFGEFGHPDIPAIHWVDDLKPYIERKLFTVNTGHATTAYYGHMRGKKMIADALADAEIRQIVHKVLEQTAKLITTKHEITEQEQNEYVDTIVKRMSNPFLEDNVERVGRAPLRKLSRNERFIGPASQLAEKGLPFDALLGSIEMALRFQNVPGDEESAELAKILKEMSAEEATGKLTGLEKHHPLYEPVQNVIAKVQKDSK T93955 DRUGINFO D0P7EK Mannitol Approved T71501 TARGETID T71501 T71501 FORMERID TTDS00309 T71501 UNIPROID Q67889_HBV T71501 TARGNAME Hepatitis B virus Polymerase (HBV P) T71501 GENENAME HBV P T71501 TARGTYPE Successful T71501 SYNONYMS Protein P T71501 FUNCTION Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3'- to 5'-endonucleasic mode. Neo-synthesized pregenomic RNA (pgRNA) are encapsidated together with the P protein, and reverse-transcribed inside the nucleocapsid. Initiation of reverse-transcription occurs first by binding the epsilon loop on the pgRNA genome, and is initiated by protein priming, thereby the 5'-end of (-)DNA is covalently linked to P protein. Partial (+)DNA is synthesized from the (-)DNA template and generates the relaxed circular DNA (RC-DNA) genome. After budding and infection, the RC-DNA migrates in the nucleus, and is converted into a plasmid-like covalently closed circular DNA (cccDNA). The activity of P protein does not seem to be necessary for cccDNA generation, and is presumably released from (+)DNA by host nuclear DNA repair machinery. T71501 BIOCLASS DNA-directed DNA polymerase T71501 SEQUENCE MPLSYQHFRKLLLLDDGTGPLEEELPRLADEGLNRRVAEDLNLGNLNVSIPWTHKVGNFTGLYSSTVPVFNPHWKTPSFPNIHLHQDIIKKCEQFVGPLTVNEKRRLQLIMPARFYPKVTKYLPLDKGIKPYYPEHLVNHYFQTRHYLHTLWKAGILYKRETTHSASFCGSPYSWEQDLQHGAESIHQQSSGILSRPPVGSSLQSKHRKSRLGLQSQQGHLARRQQGRSWSIRAGFHPTARRPFGVEPSGSGHTTNFASKSASCLHQSPVRKAAYPSVSTFEKHSSSGHAVELHNLPPNSARSKSERPVFPCWWLQFRNSKPCSDYCLSLIVNLREDWGPCDDHGEHHIRIPRTPARVRGGVFLVDKNPHNTAESRLVVDFSQFSRGNYRVSWPKFAVPNLPSLTNLLSSNLSWLSLDVSAAFYHIPLHPAAMPHLLVGSSGLSRYVARLSSNSRYFNNQHGTMQNLHDSCSRNLYVSLLLLYQTFGRKLHLYSHPIILGFRKIPMAVGLSPFLLAQFTSAICSVVRRAFPHCLGFSYMDDVVLGAKSVQHRESLYTAVTNFLLSLGIHLNPNKTKRWGYSLNFMGYIIGSWGTLPQDHIVQKIKHCFRKLPVNRPIDWKVWQRIVGLLGFAAPFTQCGYPALMPLYACIQAKQAFTFSPTYKAFLSKQYMNLYPVARQRPGLCQVFADATPTGWGLA T71501 DRUGINFO D0CL9S Telbivudine Approved T71501 DRUGINFO D5R6AG ATI-2173 Phase 2 T71501 DRUGINFO DY1H2Z NCO-48 Phase 1 T71501 DRUGINFO D0X3LD Valtorcitabine Discontinued in Phase 2 T09005 TARGETID T09005 T09005 FORMERID TTDS00532 T09005 UNIPROID Q6NK15_CORDI T09005 TARGNAME Corynebacterium Mutated CRM197 (Cory mTOX) T09005 GENENAME Cory mTOX T09005 TARGTYPE Successful T09005 SYNONYMS Diphtheria toxin; DIP0222 T09005 FUNCTION Contains a single base change in the structural gene resulting in the substitution of glutamic acid for glycine which blocks ADP-ribosylation. T09005 PDBSTRUC 5I82 T09005 ECNUMBER EC 2.4.2.36 T09005 SEQUENCE MSRKLFASILIGALLGIGAPPSAHAGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTQPFLHDGYAVSWNTVEDSIIRTGFQGESGHDIKITAENTPLPIAGVLLPTIPGKLDVNKSKTHISVNGRKIRMRCRAIDGDVTFCRPKSPVYVGNGVHANLHVAFHRSSSEKIHSNEISSDSIGVLGYQKTVDHTKVNSKLSLFFEIKS T09005 DRUGINFO D09LEN Pneumococcal 13-valent conjugate vaccine Approved T09005 DRUGINFO D0V7DW Meningococcal groups A, C, Y and W-135 conjugate vaccine Approved T38052 TARGETID T38052 T38052 FORMERID TTDR00758 T38052 UNIPROID PNO_CRYPV T38052 TARGNAME Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO) T38052 GENENAME Crypto CpPNO T38052 TARGTYPE Successful T38052 SYNONYMS Pyruvate:NADP+ oxidoreductase; PFOR; CpPNO T38052 FUNCTION May have an important role in respiratorymetabolism. Cryptosporidium have a relic mitochondrion with no function in energy metabolism so it is not known if PFOR has a function. T38052 BIOCLASS Aldehyde/oxo donor oxidoreductase T38052 ECNUMBER EC 1.2.1.51 T38052 SEQUENCE MGEKEIVDGCVAACHIAYACSEVAFTYPITPSSTISEVADSWMSRGRRNIFDQVVSVVEMQSEMGSAGALHGSLSVGCSTTTFTASQGLLLMIPNMYKIAGELWPCVFHVTARAIATSSLSIFGDHNDIMAARQTGWAFLGAMTVQEVMDLALVSHVSTFECSVPFVNFFDGFRTSHELQKIDMISYETIKKIFPYEKLKEFRERALNPTHPTLRGTATSSDVYFQLAEARNKYYESTPDIVQSVMDRLAKLIGRSYHLFDYYGHPDAEFLIVVMGSGGLTIEEMIDYLMEKSNEKVGMIKVRLFRPWSIDAFVKKIPKTTKRITVLERCKESGSLGEPLCLDVSTSIMRSELSSNNILVLGGRYGLASKEFTPGMALAVWENMISENPINNFSVGIDDDVTFKSLFVRQPRLDLLTSETKQCLFWGLGSDGTVSANKNAIKIIGESTDLQVQGYFAYDAKKAGGATMSHLRFGPKPIKSAYLLQRCDYVAVHHPSYVHKFDVLENIKQGGCFVLNCPWSTLEELNHELPSKIKHQIASRDVKFYVIDAQRIAQESNLGRRINNILMVVFFSLTNIIPLDLAIKLVKEAIKKTYGKKGDAVVNSNWKAVDLTLESLIQISYDKSQWISKDKCGEKSLPATAVETGNKDQEITKSTVLKQKPEHDVNQFVKDILGPVNALKGDELPVSMFEPTGTVPLGTTAYEKRGIAMSIPIVDMNKCTQCNYCSIVCPHAAIRPFLLDEAEFKNAPETMHIPKAKGGQEFSSYYYRIQVTPLDCTGCELCVHACPDDALHMEGLQKMEAVEKTHWDYLIGLPNKAEKFDRTTVKGSQFQQPLLEFSAACEGCGETPYVKLLTQLFGERMVIANATGCSSIWGASYPSVPYTKNQKGYGPAWGNSLFEDNAEYGLGMVVGYRQRRDRFRELVSNEILKDITEEEEFLKDDNASVQGRNEIITKYDHLKDYLRSWLKNIRNGEACQSLFEEISKLLEDNLINSNNFAQVLKKDRIELLEKLYDSRDLIPKISHWIVGGDGWAYDIGYAGLDHVLSFGEDVNIIILDTEVYSNTGGQASKSTPFGAIAKFAQSGNLRQKKDIGSIAMEYGSVYVASVALGANYSQTIKSLLEAEKYPGTSLIVAYSTCIEHGYTKYNLQQESVKLAVESGYWPLYRYNPELVRTEVVDNLTTIVSSGFTLDSKKVKVDIENFLKRENRFLQLIRSNPELASMAKDKLKAHSDKRFQKMKDMSENVTVTALKDQIKKLKDQLISIQNASKTGELAASGLINADLFIEQEMHVLYGTETGNSEEVAQYIQSQLVSRGYSSSSLNLDDLDIDEFLNPDKFSTVIIVTSTSGQGEFPGSSGILYEALLKKHLENQDDKFCSFMRFGIFGLGDSNYVFFNEAAKKWDKLLLDCGAVRIGAVGMGDDQSEEKYETELIEWLPDYLQLINAPEPKHDEKSEIPKATTFKVTILDSCRNDILNESTGTLCEKLDENNNIGNSHYKPIIPPNSVLLPVIENKRITNQDYDKDVRHIVFKLIGDGGDTPSLSYCLGDSLALYGQNPVNEAIKAIEMFGYNPYSLLRLSINEENEANNTNKVNQRYSSLFGYDITVLQLFVECLDLWGKPNRKFFQEFYRYCSNPEEKIQAKKWAQNEGKKLIEEFSSKTGTYLDVFKMFESARPTLAQLLDIVPFIKSRSYSIASCNKFVNGEKIELCVGIVDWKLESGEIRYGQCTGFLNRLPILDSESKIDSIPRLPSNIKASAFNLPFDYRSPVIMACMGTGIAPFRAFVQNKKYIRDVLKEEIGPVILYFGCRYYDNDYLYREELENYVKEGVITSLNIAFSRDPKGYKTSNCENIRYAQKMYVQHLMLENSQEIYENMIEKCGYFYLCGTKQVPIDIRKAIIQIIIKHSSTTEQVTSEEDANSILNSIQIMGRYNVEAWS T38052 DRUGINFO D08EBN Nitazoxanide Approved T33846 TARGETID T33846 T33846 FORMERID TTDI02425 T33846 UNIPROID I17RA_HUMAN; I17RB_HUMAN; I17RC_HUMAN; I17RD_HUMAN; I17RE_HUMAN T33846 TARGNAME Interleukin 17 receptor (IL17R) T33846 GENENAME IL17RA; IL17RB; IL17RC; IL17RD; IL17RE T33846 TARGTYPE Successful T33846 SYNONYMS Interleukin-17 receptor; IL-17R; IL-17 receptor T33846 FUNCTION Receptor for IL17A, IL17F and, in dimer withIL17RE, for IL17C. Binds its IL17A ligand with low affinity, suggesting that additional components are involved in IL17A-induced signaling. T33846 BIOCLASS Cytokine receptor T33846 SEQUENCE MGAARSPPSAVPGPLLGLLLLLLGVLAPGGASLRLLDHRALVCSQPGLNCTVKNSTCLDDSWIHPRNLTPSSPKDLQIQLHFAHTQQGDLFPVAHIEWTLQTDASILYLEGAELSVLQLNTNERLCVRFEFLSKLRHHHRRWRFTFSHFVVDPDQEYEVTVHHLPKPIPDGDPNHQSKNFLVPDCEHARMKVTTPCMSSGSLWDPNITVETLEAHQLRVSFTLWNESTHYQILLTSFPHMENHSCFEHMHHIPAPRPEEFHQRSNVTLTLRNLKGCCRHQVQIQPFFSSCLNDCLRHSATVSCPEMPDTPEPIPDYMPLWVYWFITGISILLVGSVILLIVCMTWRLAGPGSEKYSDDTKYTDGLPAADLIPPPLKPRKVWIIYSADHPLYVDVVLKFAQFLLTACGTEVALDLLEEQAISEAGVMTWVGRQKQEMVESNSKIIVLCSRGTRAKWQALLGRGAPVRLRCDHGKPVGDLFTAAMNMILPDFKRPACFGTYVVCYFSEVSCDGDVPDLFGAAPRYPLMDRFEEVYFRIQDLEMFQPGRMHRVGELSGDNYLRSPGGRQLRAALDRFRDWQVRCPDWFECENLYSADDQDAPSLDEEVFEEPLLPPGTGIVKRAPLVREPGSQACLAIDPLVGEEGGAAVAKLEPHLQPRGQPAPQPLHTLVLAAEEGALVAAVEPGPLADGAAVRLALAGEGEACPLLGSPGAGRNSVLFLPVDPEDSPLGSSTPMASPDLLPEDVREHLEGLMLSLFEQSLSCQAQGGCSRPAMVLTDPHTPYEEEQRQSVQSDQGYISRSSPQPPEGLTEMEEEEEEEQDPGKPALPLSPEDLESLRSLQRQLLFRQLQKNSGWDTMGSESEGPSA T33846 DRUGINFO D05CEO Brodalumab Approved T33846 DRUGINFO D0A7NZ CNTO-6785 Phase 2 T33846 DRUGINFO D00XNC CAT-2200 Investigative T33846 DRUGINFO D04PAF ANA-04 Investigative T33846 DRUGINFO D0LT4D NI-1401 Investigative T65236 TARGETID T65236 T65236 FORMERID TTDNR00682 T65236 UNIPROID GPER1_HUMAN T65236 TARGNAME G-protein coupled estrogen receptor 1 (GPER1) T65236 GENENAME GPER1 T65236 TARGTYPE Successful T65236 SYNONYMS Membrane estrogen receptor; Lymphocyte-derived G-protein coupled receptor; LYGPR; IL8-related receptor DRY12; GPER1; GPER; GPCR-BR; G-protein coupled receptor 30; Flow-induced endothelial G-protein coupled receptor 1; FEG-1; Chemoattractant receptor-like 2 T65236 FUNCTION Receptor for estrogen. . T65236 BIOCLASS GPCR rhodopsin T65236 SEQUENCE MDVTSQARGVGLEMYPGTAQPAAPNTTSPELNLSHPLLGTALANGTGELSEHQQYVIGLFLSCLYTIFLFPIGFVGNILILVVNISFREKMTIPDLYFINLAVADLILVADSLIEVFNLHERYYDIAVLCTFMSLFLQVNMYSSVFFLTWMSFDRYIALARAMRCSLFRTKHHARLSCGLIWMASVSATLVPFTAVHLQHTDEACFCFADVREVQWLEVTLGFIVPFAIIGLCYSLIVRVLVRAHRHRGLRPRRQKALRMILAVVLVFFVCWLPENVFISVHLLQRTQPGAAPCKQSFRHAHPLTGHIVNLAAFSNSCLNPLIYSFLGETFRDKLRLYIEQKTNLPALNRFCHAALKAVIPDSTEQSDVRFSSAV T65236 DRUGINFO D06LDT Segesterone acetate; ethinyl estradiol Approved T65236 DRUGINFO D0WM5O G1 Phase 1/2 T65236 DRUGINFO D02WIL G15 Investigative T65236 DRUGINFO D06CAL G36 Investigative T13491 TARGETID T13491 T13491 FORMERID TTDS00430 T13491 UNIPROID S29A1_HUMAN T13491 TARGNAME Solute carrier family 29 member 1 (SLC29A1) T13491 GENENAME SLC29A1 T13491 TARGTYPE Successful T13491 SYNONYMS SLC29A1; Nucleoside transporter, es-type; Nucleoside transporter 1; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; Equilibrative NBMPR-sensitive nucleoside transporter; ENT1 T13491 FUNCTION Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (nbmpr) and is sodium-independent. T13491 SEQUENCE MTTSHQPQDRYKAVWLIFFMLGLGTLLPWNFFMTATQYFTNRLDMSQNVSLVTAELSKDAQASAAPAAPLPERNSLSAIFNNVMTLCAMLPLLLFTYLNSFLHQRIPQSVRILGSLVAILLVFLITAILVKVQLDALPFFVITMIKIVLINSFGAILQGSLFGLAGLLPASYTAPIMSGQGLAGFFASVAMICAIASGSELSESAFGYFITACAVIILTIICYLGLPRLEFYRYYQQLKLEGPGEQETKLDLISKGEEPRAGKEESGVSVSNSQPTNESHSIKAILKNISVLAFSVCFIFTITIGMFPAVTVEVKSSIAGSSTWERYFIPVSCFLTFNIFDWLGRSLTAVFMWPGKDSRWLPSLVLARLVFVPLLLLCNIKPRRYLTVVFEHDAWFIFFMAAFAFSNGYLASLCMCFGPKKVKPAEAETAGAIMAFFLCLGLALGAVFSFLFRAIV T13491 DRUGINFO D0L7VL LIDOFLAZINE Approved T13491 DRUGINFO D00GUM Dilazep Investigative T13491 DRUGINFO D02TOP S6-nitrobenzyl mercaptopurine riboside Investigative T13491 DRUGINFO D07EVI [3H]nitrobenzylmercaptopurine ribonucleoside Investigative T13491 DRUGINFO D08GKT KF24345 Investigative T13491 DRUGINFO D09FHE NBTGR Investigative T13491 DRUGINFO D0I7ON 9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine Investigative T13491 DRUGINFO D0S0PI Nitrobenzylthioinosine Investigative T13491 DRUGINFO D0V8DJ 6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine Investigative T13491 DRUGINFO D03RFA N6-CYCLOPENTYLADENOSINE Investigative T28722 TARGETID T28722 T28722 FORMERID TTDI01774 T28722 UNIPROID GBRG3_HUMAN T28722 TARGNAME GABA(A) receptor gamma-3 (GABRG3) T28722 GENENAME GABRG3 T28722 TARGTYPE Successful T28722 SYNONYMS GABRG3 T28722 FUNCTION Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functionsas receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand- gated chloride channel. T28722 BIOCLASS Ligand-gated ion channel T28722 SEQUENCE MAPKLLLLLCLFSGLHARSRKVEEDEYEDSSSNQKWVLAPKSQDTDVTLILNKLLREYDKKLRPDIGIKPTVIDVDIYVNSIGPVSSINMEYQIDIFFAQTWTDSRLRFNSTMKILTLNSNMVGLIWIPDTIFRNSKTAEAHWITTPNQLLRIWNDGKILYTLRLTINAECQLQLHNFPMDEHSCPLIFSSYGYPKEEMIYRWRKNSVEAADQKSWRLYQFDFMGLRNTTEIVTTSAGDYVVMTIYFELSRRMGYFTIQTYIPCILTVVLSWVSFWIKKDATPARTALGITTVLTMTTLSTIARKSLPRVSYVTAMDLFVTVCFLFVFAALMEYATLNYYSSCRKPTTTKKTTSLLHPDSSRWIPERISLQAPSNYSLLDMRPPPTAMITLNNSVYWQEFEDTCVYECLDGKDCQSFFCCYEECKSGSWRKGRIHIDILELDSYSRVFFPTSFLLFNLVYWVGYLYL T28722 DRUGINFO D02KBD Mebutamate Approved T28722 DRUGINFO D02OZY Metharbital Approved T28722 DRUGINFO D02XSA Stiripentol Approved T28722 DRUGINFO D02YPG Etomidate Approved T28722 DRUGINFO D06NSA Thiamylal Approved T28722 DRUGINFO D0L5KU Remimazolam Approved T28722 DRUGINFO D0N8DP Bentazepam Approved T28722 DRUGINFO D0S5IR Zuranolone Approved T28722 DRUGINFO D0W0MF Talbutal Approved T28722 DRUGINFO D0S9MC Clobazam - Lundbeck Approved T28722 DRUGINFO D0T1WN Zolpidem Approved T28722 DRUGINFO D0D5GD Flumazenil Approved T28722 DRUGINFO D00VZZ Allopregnanolone approved T28722 DRUGINFO D0G3LM Clomethiazole Phase 3 T28722 DRUGINFO D0GX3L Arbaclofen placarbil Phase 3 T28722 DRUGINFO D0O0PY Pagoclone Phase 2/3 T28722 DRUGINFO D02XYB SARIPIDEM Phase 2 T28722 DRUGINFO D08KDK T-2007 Phase 2 T28722 DRUGINFO D0J6LN Etazolate Phase 2 T28722 DRUGINFO D00OVC EVT-201 Phase 2 T28722 DRUGINFO D04ZWQ Org-25435 Phase 1 T28722 DRUGINFO D05RWL NSD-788 Phase 1 T28722 DRUGINFO D06SUS AZD-3043 Phase 1 T28722 DRUGINFO D02HKL Suriclone Discontinued in Preregistration T28722 DRUGINFO D08YYY Ocinaplon Discontinued in Phase 3 T28722 DRUGINFO D0C9JL Y-23684 Discontinued in Phase 3 T28722 DRUGINFO D0ZE9C Pazinaclone Discontinued in Phase 3 T28722 DRUGINFO D01EDS SL-65.1498 Discontinued in Phase 2 T28722 DRUGINFO D07OMK RO-48-6791 Discontinued in Phase 2 T28722 DRUGINFO D08CLN Suritozole Discontinued in Phase 2 T28722 DRUGINFO D08LQD RESEQUINIL Discontinued in Phase 2 T28722 DRUGINFO D0H6PN LORECLEZOLE Discontinued in Phase 2 T28722 DRUGINFO D0S9KM NGD 91-3 Discontinued in Phase 2 T28722 DRUGINFO D04KCT Org-21465 Discontinued in Phase 1 T28722 DRUGINFO D04KZN CTP-354 Discontinued in Phase 1 T28722 DRUGINFO D0AM1S CCD-3693 Discontinued in Phase 1 T28722 DRUGINFO D0MT9G RO-48-8684 Discontinued in Phase 1 T28722 DRUGINFO D02VOJ RWJ-51204 Preclinical T28722 DRUGINFO D01SBP Co-152791 Terminated T28722 DRUGINFO D02UIE ZK-91296 Terminated T28722 DRUGINFO D05IVZ RU-33965 Terminated T28722 DRUGINFO D0II9K Girisopam Terminated T28722 DRUGINFO D0P3IE ZK-93426 Terminated T28722 DRUGINFO D0P6YO NSD-721 Terminated T28722 DRUGINFO D0Z7AN Ro-19-8022 Terminated T28722 DRUGINFO D00EFD C-21191 Investigative T28722 DRUGINFO D01FJA UC-2024 Investigative T28722 DRUGINFO D01VNL JM-1232(-) Investigative T28722 DRUGINFO D01YGY UC-1011 Investigative T28722 DRUGINFO D02FBG UC-2029 Investigative T28722 DRUGINFO D02ZMI AA-29504 Investigative T28722 DRUGINFO D04UMT CP-409092 Investigative T28722 DRUGINFO D06SAT HZ-166 Investigative T28722 DRUGINFO D09JET NGD 96-3 Investigative T28722 DRUGINFO D0D3TK PNU 101017 Investigative T28722 DRUGINFO D0O7NV DOV-51892 Investigative T28722 DRUGINFO D0SD3Q GIDAZEPAM Investigative T28722 DRUGINFO D03PBN tetrahydrodeoxycorticosterone Investigative T28722 DRUGINFO D03ZWB alpha3IA Investigative T28722 DRUGINFO D06SOQ alpha5IA Investigative T28722 DRUGINFO D07JXC [18F]fluoroethylflumazenil Investigative T28722 DRUGINFO D0GQ1S DMCM Investigative T28722 DRUGINFO D0Q1ZT TP003 Investigative T28722 DRUGINFO D0T9DS [35S]TBPS Investigative T28722 DRUGINFO D0VW5M piperidine-4-sulphonic acid Investigative T28722 DRUGINFO D00WHO Ro-15-3505 Investigative T28722 DRUGINFO D0AC2H isonipecotic acid Investigative T28722 DRUGINFO D0M4CP [3H]Ro154513 Investigative T28722 DRUGINFO D0M9RM [3H]CGS8216 Investigative T28722 DRUGINFO D0P0TI TBPS Investigative T14853 TARGETID T14853 T14853 FORMERID TTDI02072 T14853 UNIPROID FGF23_HUMAN T14853 TARGNAME Fibroblast growth factor-23 (FGF23) T14853 GENENAME FGF23 T14853 TARGTYPE Successful T14853 SYNONYMS Tumor-derived hypophosphatemia-inducing factor; Phosphatonin; HYPF; Fibroblast growth factor 23; FGF-23 T14853 FUNCTION Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL (By similarity). Acts directly on the parathyroid to decrease PTH secretion (By similarity). Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. T14853 PDBSTRUC 5W21; 2P39 T14853 BIOCLASS Growth factor T14853 SEQUENCE MLGARLRLWVCALCSVCSMSVLRAYPNASPLLGSSWGGLIHLYTATARNSYHLQIHKNGHVDGAPHQTIYSALMIRSEDAGFVVITGVMSRRYLCMDFRGNIFGSHYFDPENCRFQHQTLENGYDVYHSPQYHFLVSLGRAKRAFLPGMNPPPYSQFLSRRNEIPLIHFNTPIPRRHTRSAEDDSERDPLNVLKPRARMTPAPASCSQELPSAEDNSPMASDPLGVVRGGRVNTHAGGTGPEGCRPFAKFI T14853 DRUGINFO D0DJ9D Burosumab Approved T98052 TARGETID T98052 T98052 FORMERID TTDI02305 T98052 UNIPROID SLAF7_HUMAN T98052 TARGNAME SLAM family member 7 SLAMF7 (CS1) T98052 GENENAME SLAMF7 T98052 TARGTYPE Successful T98052 SYNONYMS UNQ576/PRO1138; SLAM family member 7; Protein 19A; Novel Ly9; Membrane protein FOAP-12; CRACC; CD319; CD2-like receptor-activating cytotoxic cells; CD2 subset 1 T98052 FUNCTION SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K. In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells. May play a role in lymphocyte adhesion. In LPS-activated monocytes negatively regulates production of proinflammatory cytokines. Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. T98052 BIOCLASS Immunoglobulin T98052 SEQUENCE MAGSPTCLTLIYILWQLTGSAASGPVKELVGSVGGAVTFPLKSKVKQVDSIVWTFNTTPLVTIQPEGGTIIVTQNRNRERVDFPDGGYSLKLSKLKKNDSGIYYVGIYSSSLQQPSTQEYVLHVYEHLSKPKVTMGLQSNKNGTCVTNLTCCMEHGEEDVIYTWKALGQAANESHNGSILPISWRWGESDMTFICVARNPVSRNFSSPILARKLCEGAADDPDSSMVLLCLLLVPLLLSLFVLGLFLWFLKRERQEEYIEEKKRVDICRETPNICPHSGENTEYDTIPHTNRTILKEDPANTVYSTVEIPKKMENPHSLLTMPDTPRLFAYENVI T98052 DRUGINFO D05DZR Elotuzumab Approved T98052 DRUGINFO D06DUS PVX-410 Phase 2 T98052 DRUGINFO D0B5RU CS1-CAR T Therapy Phase 1 T98052 DRUGINFO D0BB2V ABBV-838 Phase 1 T98052 DRUGINFO DRU0M6 MB-104 Phase 1 T98052 DRUGINFO DS6W8Z UCARTCS1 Phase 1 T98052 DRUGINFO DX1LD3 BCMA-CS1 cCAR Phase 1 T34123 TARGETID T34123 T34123 FORMERID TTDR01254 T34123 UNIPROID SCNBA_HUMAN T34123 TARGNAME Voltage-gated sodium channel alpha Nav1.9 (SCN11A) T34123 GENENAME SCN11A T34123 TARGTYPE Successful T34123 SYNONYMS hNaN; Sodium channel protein type XIsubunit alpha; Sodium channel protein type 11subunit alpha; Sensory neuron sodium channel 2; SNS2; SCN12A; SCN11A; Peripheral nerve sodium channel 5; PN5 T34123 FUNCTION This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant sodium channel isoform. Also involved, with the contribution of the receptor tyrosine kinase NTRK2, in rapid BDNF-evoked neuronal depolarization. T34123 BIOCLASS Voltage-gated ion channel T34123 SEQUENCE MDDRCYPVIFPDERNFRPFTSDSLAAIEKRIAIQKEKKKSKDQTGEVPQPRPQLDLKASRKLPKLYGDIPRELIGKPLEDLDPFYRNHKTFMVLNRKRTIYRFSAKHALFIFGPFNSIRSLAIRVSVHSLFSMFIIGTVIINCVFMATGPAKNSNSNNTDIAECVFTGIYIFEALIKILARGFILDEFSFLRDPWNWLDSIVIGIAIVSYIPGITIKLLPLRTFRVFRALKAISVVSRLKVIVGALLRSVKKLVNVIILTFFCLSIFALVGQQLFMGSLNLKCISRDCKNISNPEAYDHCFEKKENSPEFKMCGIWMGNSACSIQYECKHTKINPDYNYTNFDNFGWSFLAMFRLMTQDSWEKLYQQTLRTTGLYSVFFFIVVIFLGSFYLINLTLAVVTMAYEEQNKNVAAEIEAKEKMFQEAQQLLKEEKEALVAMGIDRSSLTSLETSYFTPKKRKLFGNKKRKSFFLRESGKDQPPGSDSDEDCQKKPQLLEQTKRLSQNLSLDHFDEHGDPLQRQRALSAVSILTITMKEQEKSQEPCLPCGENLASKYLVWNCCPQWLCVKKVLRTVMTDPFTELAITICIIINTVFLAMEHHKMEASFEKMLNIGNLVFTSIFIAEMCLKIIALDPYHYFRRGWNIFDSIVALLSFADVMNCVLQKRSWPFLRSFRVLRVFKLAKSWPTLNTLIKIIGNSVGALGSLTVVLVIVIFIFSVVGMQLFGRSFNSQKSPKLCNPTGPTVSCLRHWHMGDFWHSFLVVFRILCGEWIENMWECMQEANASSSLCVIVFILITVIGKLVVLNLFIALLLNSFSNEERNGNLEGEARKTKVQLALDRFRRAFCFVRHTLEHFCHKWCRKQNLPQQKEVAGGCAAQSKDIIPLVMEMKRGSETQEELGILTSVPKTLGVRHDWTWLAPLAEEEDDVEFSGEDNAQRITQPEPEQQAYELHQENKKPTSQRVQSVEIDMFSEDEPHLTIQDPRKKSDVTSILSECSTIDLQDGFGWLPEMVPKKQPERCLPKGFGCCFPCCSVDKRKPPWVIWWNLRKTCYQIVKHSWFESFIIFVILLSSGALIFEDVHLENQPKIQELLNCTDIIFTHIFILEMVLKWVAFGFGKYFTSAWCCLDFIIVIVSVTTLINLMELKSFRTLRALRPLRALSQFEGMKVVVNALIGAIPAILNVLLVCLIFWLVFCILGVYFFSGKFGKCINGTDSVINYTIITNKSQCESGNFSWINQKVNFDNVGNAYLALLQVATFKGWMDIIYAAVDSTEKEQQPEFESNSLGYIYFVVFIIFGSFFTLNLFIGVIIDNFNQQQKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKCQGLVFDIVTSQIFDIIIISLIILNMISMMAESYNQPKAMKSILDHLNWVFVVIFTLECLIKIFALRQYYFTNGWNLFDCVVVLLSIVSTMISTLENQEHIPFPPTLFRIVRLARIGRILRLVRAARGIRTLLFALMMSLPSLFNIGLLLFLIMFIYAILGMNWFSKVNPESGIDDIFNFKTFASSMLCLFQISTSAGWDSLLSPMLRSKESCNSSSENCHLPGIATSYFVSYIIISFLIVVNMYIAVILENFNTATEESEDPLGEDDFDIFYEVWEKFDPEATQFIKYSALSDFADALPEPLRVAKPNKYQFLVMDLPMVSEDRLHCMDILFAFTARVLGGSDGLDSMKAMMEEKFMEANPLKKLYEPIVTTTKRKEEERGAAIIQKAFRKYMMKVTKGDQGDQNDLENGPHSPLQTLCNGDLSSFGVAKGKVHCD T34123 DRUGINFO D03FLC Lamotrigine Approved T34123 DRUGINFO D0H0KB Riluzole Approved T34123 DRUGINFO D0QL3P Oxcarbazepine Approved T34123 DRUGINFO D0X4RN Lidocaine Approved T34123 DRUGINFO D0X0WU Tolperisone Approved T34123 DRUGINFO D04QZD Eslicarbazepine Approved T34123 DRUGINFO D05OFX Lacosamide Approved T34123 DRUGINFO D02TIK HP-184 Phase 2 T34123 DRUGINFO D0J2VB Iboctadekin + rituximab Phase 1 T34123 DRUGINFO D0C4JX QX-314 Terminated T34123 DRUGINFO D0D9CO SB-221420-A Investigative T34123 DRUGINFO D08RJC PD-32577 Investigative T87670 TARGETID T87670 T87670 FORMERID TTDNR00683 T87670 UNIPROID GPR55_HUMAN T87670 TARGNAME G-protein coupled receptor 55 (GPR55) T87670 GENENAME GPR55 T87670 TARGTYPE Successful T87670 SYNONYMS LPIR1 T87670 FUNCTION Receptor for L-alpha-lysophosphatidylinositol (LPI). LPI induces Ca(2+) release from intracellular stores via the heterotrimeric G protein GNA13 and RHOA. Putative cannabinoid receptor. May play a role in bone physiology by regulating osteoclast number and function. May be involved in hyperalgesia associated with inflammatory and neuropathic pain. T87670 BIOCLASS GPCR rhodopsin T87670 SEQUENCE MSQQNTSGDCLFDGVNELMKTLQFAVHIPTFVLGLLLNLLAIHGFSTFLKNRWPDYAATSIYMINLAVFDLLLVLSLPFKMVLSQVQSPFPSLCTLVECLYFVSMYGSVFTICFISMDRFLAIRYPLLVSHLRSPRKIFGICCTIWVLVWTGSIPIYSFHGKVEKYMCFHNMSDDTWSAKVFFPLEVFGFLLPMGIMGFCCSRSIHILLGRRDHTQDWVQQKACIYSIAASLAVFVVSFLPVHLGFFLQFLVRNSFIVECRAKQSISFFLQLSMCFSNVNCCLDVFCYYFVIKEFRMNIRAHRPSRVQLVLQDTTISRG T87670 DRUGINFO D07ILQ Guanfacine extended release Approved T87670 DRUGINFO DF63BG BIO-017 Phase 1 T87670 DRUGINFO D00UZO O-arachidonoyl ethanolamine Investigative T87670 DRUGINFO D02SMK CID1172084 Investigative T87670 DRUGINFO D04MAP CID16020046 Investigative T87670 DRUGINFO D08JYT 2-arachidonyl glyceryl ether Investigative T87670 DRUGINFO D09SCS CP55,244 Investigative T87670 DRUGINFO D0C2DN 2-arachidonoylglycerolphosphoinositol Investigative T87670 DRUGINFO D0G3TV CID2440433 Investigative T87670 DRUGINFO D0Q9GU CID1792197 Investigative T87670 DRUGINFO D0R1ZD GSK575594A Investigative T87670 DRUGINFO D0X2ZM T1117 Investigative T87670 DRUGINFO D0X3TF CP55,667 Investigative T87670 DRUGINFO D0Z0KY GSK494581A Investigative T87670 DRUGINFO D06NAM O-1602 Investigative T87670 DRUGINFO D0S3UM abnormal cannabidiol Investigative T87670 DRUGINFO D0D6OH [3H]CP55940 Investigative T87670 DRUGINFO D0M1UA lysophosphatidylinositol Investigative T87670 DRUGINFO D07MBC N-oleoylethanolamide Investigative T33765 TARGETID T33765 T33765 FORMERID TTDR01173 T33765 UNIPROID MCL1_HUMAN T33765 TARGNAME Mcl-1 messenger RNA (MCL-1 mRNA) T33765 GENENAME MCL1 T33765 TARGTYPE Successful T33765 SYNONYMS mcl1/EAT (mRNA); Induced myeloid leukemia cell differentiation protein Mcl-1 (mRNA); Bcl2-L-3 (mRNA); Bcl-2-related protein EAT/mcl1 (mRNA); Bcl-2-like protein 3 (mRNA); BCL2L3 (mRNA) T33765 FUNCTION Mediates its effects by interactions with a number of other regulators of apoptosis. Isoform 1 inhibits apoptosis. Isoform 2 promotes apoptosis. Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. T33765 PDBSTRUC 6OVC; 6OQN; 6OQD; 6OQC; 6OQB T33765 BIOCLASS mRNA target T33765 SEQUENCE MFGLKRNAVIGLNLYCGGAGLGAGSGGATRPGGRLLATEKEASARREIGGGEAGAVIGGSAGASPPSTLTPDSRRVARPPPIGAEVPDVTATPARLLFFAPTRRAAPLEEMEAPAADAIMSPEEELDGYEPEPLGKRPAVLPLLELVGESGNNTSTDGSLPSTPPPAEEEEDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGGIRNVLLAFAGVAGVGAGLAYLIR T33765 DRUGINFO D0AZ3C Imatinib Approved T33765 DRUGINFO D06GGT MCL-1-specific antisense oligonucleotide + nilotinib (AMN107) Investigative T33765 DRUGINFO D0KL7G MCL-1-specific antisense oligonucleotide + midostaurin(PKC412) Investigative T84972 TARGETID T84972 T84972 FORMERID TTDS00436 T84972 UNIPROID EFG_STRZJ T84972 TARGNAME Streptococcus Elongation factor G (Stre-coc fusA) T84972 GENENAME Stre-coc fusA T84972 TARGTYPE Successful T84972 SYNONYMS fusA; EF-G T84972 FUNCTION Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post- translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome. T84972 BIOCLASS Acid anhydrides hydrolase T84972 SEQUENCE MAREFSLEKTRNIGIMAHVDAGKTTTTERILYYTGKIHKIGETHEGASQMDWMEQEQERGITITSAATTAQWNNHRVNIIDTPGHVDFTIEVQRSLRVLDGAVTVLDSQSGVEPQTETVWRQATEYGVPRIVFANKMDKIGADFLYSVSTLHDRLQANAHPIQLPIGSEDDFRGIIDLIKMKAEIYTNDLGTDILEEDIPAEYLDQAQEYREKLIEAVAETDEELMMKYLEGEEITNEELKAGIRKATINVEFFPVLCGSAFKNKGVQLMLDAVIDYLPSPLDIPAIKGINPDTDAEETRPASDEEPFAALAFKIMTDPFVGRLTFFRVYSGVLQSGSYVLNTSKGKRERIGRILQMHANSRQEIDTVYSGDIAAAVGLKDTTTGDSLTDEKAKIILESINVPEPVIQLMVEPKSKADQDKMGIALQKLAEEDPTFRVETNVETGETVISGMGELHLDVLVDRMRREFKVEANVGAPQVSYRETFRASTQARGFFKRQSGGKGQFGDVWIEFTPNEEGKGFEFENAIVGGVVPREFIPAVEKGLVESMANGVLAGYPMVDVKAKLYDGSYHDVDSSETAFKIAASLSLKEAAKSAQPAILEPMMLVTITVPEENLGDVMGHVTARRGRVDGMEAHGNSQIVRAYVPLAEMFGYATVLRSASQGRGTFMMVFDHYEDVPKSVQEEIIKKNKGED T84972 DRUGINFO D0X7XG Fusidic Acid Approved T84972 DRUGINFO D0C7LS Guanosine-5'-Diphosphate Investigative T99641 TARGETID T99641 T99641 FORMERID TTDR01184 T99641 UNIPROID AL1A1_HUMAN; ALDH2_HUMAN; AL1B1_HUMAN T99641 TARGNAME Acetaldehyde dehydrogenase (ALDH) T99641 GENENAME ALDH1A1; ALDH2; ALDH1B1 T99641 TARGTYPE Successful T99641 SYNONYMS Aldehyde dehydrogenase; ALDH T99641 FUNCTION Catalyzes the conversion of acetaldehyde to acetyl-CoA, using NAD(+) and coenzyme A. Is the final enzyme in the meta- cleavage pathway for the degradation of 3-phenylpropanoate. Functionsas a chaperone protein for folding of MhpE. T99641 BIOCLASS Aldehyde/oxo donor oxidoreductase T99641 SEQUENCE MSSSGTPDLPVLLTDLKIQYTKIFINNEWHDSVSGKKFPVFNPATEEELCQVEEGDKEDVDKAVKAARQAFQIGSPWRTMDASERGRLLYKLADLIERDRLLLATMESMNGGKLYSNAYLNDLAGCIKTLRYCAGWADKIQGRTIPIDGNFFTYTRHEPIGVCGQIIPWNFPLVMLIWKIGPALSCGNTVVVKPAEQTPLTALHVASLIKEAGFPPGVVNIVPGYGPTAGAAISSHMDIDKVAFTGSTEVGKLIKEAAGKSNLKRVTLELGGKSPCIVLADADLDNAVEFAHHGVFYHQGQCCIAASRIFVEESIYDEFVRRSVERAKKYILGNPLTPGVTQGPQIDKEQYDKILDLIESGKKEGAKLECGGGPWGNKGYFVQPTVFSNVTDEMRIAKEEIFGPVQQIMKFKSLDDVIKRANNTFYGLSAGVFTKDIDKAITISSALQAGTVWVNCYGVVSAQCPFGGFKMSGNGRELGEYGFHEYTEVKTVTVKISQKNS T99641 DRUGINFO D0A9KF Calcium carbimide Approved T07485 TARGETID T07485 T07485 FORMERID TTDI01919 T07485 UNIPROID FUS_HRSVA T07485 TARGNAME Respiratory syncytial virus protein F (RSV F) T07485 GENENAME RSV F T07485 TARGTYPE Successful T07485 SYNONYMS Protein F; Fusion glycoprotein F1; Fusion glycoprotein F0; F T07485 FUNCTION Class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and plasma cell membrane fusion, the heptad repeat (HR) regions assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and plasma cell membranes. Directs fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm. This fusion is pH independent and occurs directly at the outer cell membrane. The trimer of F1-F2 (protein F) interacts with glycoprotein G at the virion surface. Upon binding of G to heparan sulfate, the hydrophobic fusion peptide is unmasked and interacts with the cellular membrane, inducing the fusion between host cell and virion membranes. Notably, RSV fusion protein is able to interact directly with heparan sulfate and therefore actively participates in virus attachment. Furthermore, the F2 subunit was identifed as the major determinant of RSV host cell specificity. Later in infection, proteins F expressed at the plasma membrane of infected cells mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis. The fusion protein is also able to trigger p53- dependent apoptosis. T07485 PDBSTRUC 6OE5; 6OE4; 6APD; 6APB; 5W23 T07485 SEQUENCE MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPPTNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEINLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGMDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN T07485 DRUGINFO D0A1AS Palivizumab Approved T07485 DRUGINFO D09NMD Lasofoxifene Approved T07485 DRUGINFO D08NAI SAR438584 Phase 3 T07485 DRUGINFO D0O3OK Motavizumab Phase 3 T07485 DRUGINFO DOST52 MK-1654 Phase 2/3 T07485 DRUGINFO D0QY1M GS-5806 Phase 2 T07485 DRUGINFO DENO49 RV521 Phase 2 T07485 DRUGINFO DRH80V JNJ-53718678 Phase 2 T07485 DRUGINFO D08DSF MEDI-557 Phase 1 T07485 DRUGINFO D02TNS TMC-353121 Preclinical T07485 DRUGINFO D0T7EZ CL-387626 Terminated T38161 TARGETID T38161 T38161 FORMERID TTDI01878 T38161 UNIPROID ANXA1_HUMAN T38161 TARGNAME Phospholipase A2 inhibitory protein (PA2IP) T38161 GENENAME ANXA1 T38161 TARGTYPE Successful T38161 SYNONYMS p35; Lipocortin I; LPC1; Chromobindin-9; Calpactin-2; Calpactin II; Annexin-1; Annexin I; Annexin A1; ANX1 T38161 FUNCTION Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity. Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Promotes resolution of inflammation and wound healing. Functions at least in part by activating the formyl peptide receptors and downstream signaling cascades. Promotes chemotaxis of granulocytes and monocytes via activation of the formyl peptide receptors. Contributes to the adaptive immune response by enhancing signaling cascades that are triggered by T-cell activation, regulates differentiation and proliferation of activated T-cells. Promotes the differentiation of T-cells into Th1 cells and negatively regulates differentiation into Th2 cells. Has no effect on unstimulated T cells. Promotes rearrangement of the actin cytoskeleton, cell polarization and cell migration. Negatively regulates hormone exocytosis via activation of the formyl peptide receptors and reorganization of the actin cytoskeleton. Has high affinity for Ca(2+) and can bind up to eight Ca(2+) ions (By similarity). Displays Ca(2+)-dependent binding to phospholipid membranes. Plays a role in the formation of phagocytic cups and phagosomes. Plays a role in phagocytosis by mediating the Ca(2+)-dependent interaction between phagosomes and the actin cytoskeleton (By similarity). T38161 PDBSTRUC 5VFW; 1QLS; 1BO9; 1AIN T38161 SEQUENCE MAMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAALHKAIMVKGVDEATIIDILTKRNNAQRQQIKAAYLQETGKPLDETLKKALTGHLEEVVLALLKTPAQFDADELRAAMKGLGTDEDTLIEILASRTNKEIRDINRVYREELKRDLAKDITSDTSGDFRNALLSLAKGDRSEDFGVNEDLADSDARALYEAGERRKGTDVNVFNTILTTRSYPQLRRVFQKYTKYSKHDMNKVLDLELKGDIEKCLTAIVKCATSKPAFFAEKLHQAMKGVGTRHKALIRIMVSRSEIDMNDIKAFYQKMYGISLCQAILDETKGDYEKILVALCGGN T38161 DRUGINFO D01ZOG Difluprednate Approved T06770 TARGETID T06770 T06770 FORMERID TTDS00325 T06770 UNIPROID ENV_HV1H2 T06770 TARGNAME Human immunodeficiency virus Glycoprotein 41 (HIV gp41) T06770 GENENAME HIV gp41 T06770 TARGTYPE Successful T06770 SYNONYMS Env polyprotein gp41 (33-511) T06770 FUNCTION Transmembrane protein gp41: Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin- dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm. T06770 PDBSTRUC 6DLN; 6DE7; 6BXQ; 6BXP; 6B9K T06770 SEQUENCE AVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL T06770 DRUGINFO D06GBQ Enfuvirtide Approved T06770 DRUGINFO D0CF3M Sifuvirtide Phase 3 T06770 DRUGINFO D03DAY ITV-1 Phase 2 T06770 DRUGINFO D08DUY T-1249 Phase 1/2 T06770 DRUGINFO D0IL0H MaC46/M87o Phase 1/2 T06770 DRUGINFO D0O4UZ Gp41 HIV-1 vaccine Phase 1 T06770 DRUGINFO D01NGH Multi-envelope HIV vaccine Phase 1 T06770 DRUGINFO DO61WZ Combinectin Phase 1 T91442 TARGETID T91442 T91442 FORMERID TTDI01984 T91442 UNIPROID DPOL_VZVD T91442 TARGNAME Varicella-zoster virus DNA polymerase (VZV ORF28) T91442 GENENAME VZV ORF28 T91442 TARGTYPE Successful T91442 SYNONYMS VZV DNA polymerase catalytic subunit; ORF28 T91442 FUNCTION Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA- binding protein. Additionally, the polymerase contains an intrinsic ribonuclease H (RNase H) activity that specifically degrades RNA/DNA heteroduplexes or duplex DNA substrates in the 5' to 3' direction. Therefore, it can catalyze the excision of the RNA primers that initiate the synthesis of Okazaki fragments at a replication fork during viral DNA replication. T91442 BIOCLASS Kinase T91442 SEQUENCE MAIRTGFCNPFLTQASGIKYNPRTGRGSNREFLHSYKTTMSSFQFLAPKCLDEDVPMEERKGVHVGTLSRPPKVYCNGKEVPILDFRCSSPWPRRVNIWGEIDFRGDKFDPRFNTFHVYDIVETTEAASNGDVSRFATATRPLGTVITLLGMSRCGKRVAVHVYGICQYFYINKAEVDTACGIRSGSELSVLLAECLRSSMITQNDATLNGDKNAFHGTSFKSASPESFRVEVIERTDVYYYDTQPCAFYRVYSPSSKFTNYLCDNFHPELKKYEGRVDATTRFLMDNPGFVSFGWYQLKPGVDGERVRVRPASRQLTLSDVEIDCMSDNLQAIPNDDSWPDYKLLCFDIECKSGGSNELAFPDATHLEDLVIQISCLLYSIPRQSLEHILLFSLGSCDLPQRYVQEMKDAGLPEPTVLEFDSEFELLIAFMTLVKQYAPEFATGYNIVNFDWAFIMEKLNSIYSLKLDGYGSINRGGLFKIWDVGKSGFQRRSKVKINGLISLDMYAIATEKLKLSSYKLDSVAREALNESKRDLPYKDIPGYYASGPNTRGIIGEYCIQDSALVGKLFFKYLPHLELSAVARLARITLTKAIYDGQQVRIYTCLLGLASSRGFILPDGGYPATFEYKDVIPDVGDVEEEMDEDESVSPTGTSSGRNVGYKGARVFDPDTGFYIDPVVVLDFASLYPSIIQAHNLCFTTLTLNFETVKRLNPSDYATFTVGGKRLFFVRSNVRESLLGVLLKDWLAMRKAIRARIPGSSSDEAVLLDKQQAAIKVVCNSVYGFTGVAQGFLPCLYVAATVTTIGRQMLLSTRDYIHNNWAAFERFITAFPDIESSVLSQKAYEVKVIYGDTDSVFIRFKGVSVEGIAKIGEKMAHIISTALFCPPIKLECEKTFIKLLLITKKKYIGVIYGGKVLMKGVDLVRKNNCQFINDYARKLVELLLYDDTVSRAAAEASCVSIAEWNRRAMPSGMAGFGRIIADAHRQITSPKLDINKFVMTAELSRPPSAYINRRLAHLTVYYKLVMRQGQIPNVRERIPYVIVAPTDEVEADAKSVALLRGDPLQNTAGKRCGEAKRKLIISDLAEDPIHVTSHGLSLNIDYYFSHLIGTASVTFKALFGNDTKLTERLLKRFIPETRVVNVKMLNRLQAAGFVCIHAPCWDNKMNTEAEITEEEQSHQIMRRVFCIPKAILHQS T91442 DRUGINFO D0B5MP Aciclovir Approved T42354 TARGETID T42354 T42354 UNIPROID SIGA_STAA8 T42354 TARGNAME Bacterial RNA polymerase sigma factor SigA (Bact sigA) T42354 GENENAME Bact sigA T42354 TARGTYPE Successful T42354 SYNONYMS RNA polymerase sigma factor SigA T42354 FUNCTION Sigma factors are initiation factors that promote the attachment of RNA polymerase to specific initiation sites and are then released. This sigma factor is the primary sigma factor during exponential growth. T42354 PDBSTRUC 4G94; 4G8X; 4G6D T42354 SEQUENCE MSDNTVKIKKQTIDPTLTLEDVKKQLIEKGKKEGHLSHEEIAEKLQNFDIDSDQMDDFFDQLNDNDISLVNEKDSSDTDEKLNPSDLSAPPGVKINDPVRMYLKEIGRVNLLSAQEEIELAKRIEQGDEVAKSRLAEANLRLVVSIAKRYVGRGMLFLDLIQEGNMGLIKAVEKFDFNKGFKFSTYATWWIRQAITRAIADQARTIRIPVHMVETINKLIRVQRQLLQDLGRDPAPEEIGEEMDLPAEKVREILKIAQEPVSLETPIGEEDDSHLGDFIEDQEAQSPSDHAAYELLKEQLEDVLDTLTDREENVLRLRFGLDDGRTRTLEEVGKVFGVTRERIRQIEAKALRKLRHPSRSKRLKDFMD T42354 DRUGINFO D0FX2Q Rifamycin Approved T38284 TARGETID T38284 T38284 UNIPROID BCR_HUMAN-ABL1_HUMAN T38284 TARGNAME Fusion protein Bcr-Abl (Bcr-Abl) T38284 GENENAME BCR-ABL1 T38284 TARGTYPE Successful T38284 SYNONYMS BCR-ABL fusion protein; BCR-ABL T38284 FUNCTION Activates downstream signaling pathways such as STAT5, PI3K/Akt, and Erk1/2 to lead to increased cell transformation, survival, and proliferation. T38284 BIOCLASS Kinase T38284 SEQUENCE MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEPRASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNVEFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPPWPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTYRMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQDGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTSQQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDAKDPTTKNSLETLLYKPVDRVTRSTLVLHDLLKHTPASHPDHPLLQDALRISQNFLSSINEEITPRRQSMTVKKGEHRQLLKDSFMVELVEGARKLRHVFLFTDLLLCTKLKKQSGGKTQQYDCKWYIPLTDLSFQMVDELEAVPNIPLVPDEELDALKIKISQIKNDIQREKRANKGSKATERLKKKLSEQESLLLLMSPSMAFRVHSRNGKSYTFLISSDYERAEWRENIREQQKKCFRSFSLTSVELQMLTNSCVKLQTVHSIPLTINKEDDESPGLYGFLNVIVHSATGFKQSSNLYCTLEVDSFGYFVNKAKTRVYRDTAEPNWNEEFEIELEGSQTLRILCYEKCYNKTKIPKEDGESTDRLMGKGQVQLDPQALQDRDWQRTVIAMNGIEVKLSVKFNSREFSLKRMPSRKQTGVFGVKIAVVTKRERSKVPYIVRQCVEEIERRGMEEVGIYRVSGVATDIQALKAAFDVNNKDVSVMMSEMDVNAIAGTLKLYFRELPEPLFTDEFYPNFAEGIALSDPVAKESCMLNLLLSLPEANLLTFLFLLDHLKRVAEKEAVNKMSLHNLATVFGPTLLRPSEKESKLPANPSQPITMTDSWSLEVMSQVQVLLYFLQLEAIPAPDSKRQSILFSTEVMLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR T38284 DRUGINFO D00STL Nilotinib Approved T38284 DRUGINFO DSHT18 Asciminib Approved T38284 DRUGINFO D0AZ3C Imatinib Approved T38284 DRUGINFO D0E6XR Dasatinib Approved T38284 DRUGINFO D01NIR Radotinib Phase 3 T38284 DRUGINFO D0LB3Z ABL 001 Phase 3 T38284 DRUGINFO DQ84IT ICLUSIG Phase 3 T38284 DRUGINFO D04BXX AN-019 Phase 2 T38284 DRUGINFO DH5RN1 HQP1351 Phase 2 T38284 DRUGINFO D0G0VV Bafetinib Phase 2 T38284 DRUGINFO D01SCR NPB-001-056 Phase 1/2 T38284 DRUGINFO D0Z1RJ Adaphostin Phase 1 T38284 DRUGINFO DL8T4I SCO-088 Phase 1 T38284 DRUGINFO D00AIO Pyridoindole derivative 3 Patented T38284 DRUGINFO D01OYY PMID25656651-Compound-16a Patented T38284 DRUGINFO D01UBA PMID25656651-Compound-30a Patented T38284 DRUGINFO D03EMY Pyrrolo[2,3-b]pyridine carboxamide derivative 1 Patented T38284 DRUGINFO D04UXO PMID25656651-Compound-15a Patented T38284 DRUGINFO D04ZXR PMID25656651-Compound-23a Patented T38284 DRUGINFO D05HDJ PMID25656651-Compound-20a Patented T38284 DRUGINFO D05YAD PMID25656651-Compound-11c Patented T38284 DRUGINFO D08PXF Aminopyrimidine derivative 1 Patented T38284 DRUGINFO D0AP4V Pyridoindole derivative 2 Patented T38284 DRUGINFO D0B0BJ Pyridoindole derivative 1 Patented T38284 DRUGINFO D0B5DX Aminopyrimidine derivative 3 Patented T38284 DRUGINFO D0BE9U Pyrimidinyl pyrazolamine derivative 1 Patented T38284 DRUGINFO D0BJ6M PMID25656651-Compound-25 Patented T38284 DRUGINFO D0C9ZW PMID25656651-Compound-26a Patented T38284 DRUGINFO D0CJ7F PMID25656651-Compound-15c Patented T38284 DRUGINFO D0DC7I PMID25656651-Compound-11b Patented T38284 DRUGINFO D0EF5T PMID25656651-Compound-10 Patented T38284 DRUGINFO D0F5HC PMID25656651-Compound-40 Patented T38284 DRUGINFO D0HF0R Aminopyrimidine derivative 4 Patented T38284 DRUGINFO D0I5VG PMID25656651-Compound-29b Patented T38284 DRUGINFO D0JR7X PMID25656651-Compound-29a Patented T38284 DRUGINFO D0K3BR PMID25656651-Compound-26b Patented T38284 DRUGINFO D0KL5M PMID25656651-Compound-38 Patented T38284 DRUGINFO D0KR7K PMID25656651-Compound-16b Patented T38284 DRUGINFO D0KT5W PMID25656651-Compound-30b Patented T38284 DRUGINFO D0L7XM PMID25656651-Compound-20b Patented T38284 DRUGINFO D0O0YI PMID25656651-Compound-7 Patented T38284 DRUGINFO D0O2HW PMID25656651-Compound-27 Patented T38284 DRUGINFO D0OY0U PMID25656651-Compound-26c Patented T38284 DRUGINFO D0PF2F PMID25656651-Compound-15b Patented T38284 DRUGINFO D0U2LO PMID25656651-Compound-23b Patented T38284 DRUGINFO D0VD5I Aminopyrimidine derivative 2 Patented T38284 DRUGINFO D0WL1U PMID25656651-Compound-5 Patented T38284 DRUGINFO D0XU3A PMID25656651-Compound-23c Patented T38284 DRUGINFO D0Y4EU PMID25656651-Compound-11a Patented T38284 DRUGINFO D0Z7DA PMID25656651-Compound-18 Patented T38284 DRUGINFO D01KIJ PMID25656651-Compound-37b Patented T38284 DRUGINFO D02KNW PMID25656651-Compound-36a Patented T38284 DRUGINFO D02VDD Deuterated 3-cyanoquinoline derivative 1 Patented T38284 DRUGINFO D08IUE PMID25656651-Compound-37c Patented T38284 DRUGINFO D09WKF PMID25656651-Compound-36d Patented T38284 DRUGINFO D09ZFM PMID25656651-Compound-36b Patented T38284 DRUGINFO D0BK6R PMID25656651-Compound-36c Patented T38284 DRUGINFO D0E6EP PMID25656651-Compound-19b Patented T38284 DRUGINFO D0IA4G PMID25656651-Compound-37a Patented T38284 DRUGINFO D0JY1I PMID25656651-Compound-19a Patented T38284 DRUGINFO D0D3FB PMID25656651-Compound-21a Patented T38284 DRUGINFO D0XQ5F PMID25656651-Compound-21b Patented T38284 DRUGINFO D0H4YH 4,3'',5''-trimethoxy-[1,1':3',1'']-terphenyl Investigative T38284 DRUGINFO D0PI0R 3'',5''-dimethoxy-[1,1':2',1'']-terphenyl-4-ol Investigative T38284 DRUGINFO D0QG6G 3'',5''-dimethoxy-[1,1':3',1'']-terphenyl-4-ol Investigative T38284 DRUGINFO D00AII (E)-4-(3,5-dimethoxystyryl)phenol Investigative T38284 DRUGINFO D0AW4W 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl Investigative T38284 DRUGINFO D03NPX PD-0173955 Investigative T38284 DRUGINFO D0D5EW HKI-9924129 Investigative T68066 TARGETID T68066 T68066 UNIPROID ERR1_HUMAN; ERR2_HUMAN; ERR3_HUMAN T68066 TARGNAME Steroid hormone receptor ERR (ESRR) T68066 GENENAME ESRRA; ESRRB; ESRRG T68066 TARGTYPE Successful T68066 SYNONYMS Nuclear receptor subfamily 3 group B; NR3B; ERR T68066 FUNCTION Intracellular receptors (typically cytoplasmic or nuclear). Initiates signal transduction for steroid hormones which lead to changes in gene expression over a time period of hours to days T68066 BIOCLASS Nuclear hormone receptor T68066 SEQUENCE MSSQVVGIEPLYIKAEPASPDSPKGSSETETEPPVALAPGPAPTRCLPGHKEEEDGEGAGPGEQGGGKLVLSSLPKRLCLVCGDVASGYHYGVASCEACKAFFKRTIQGSIEYSCPASNECEITKRRRKACQACRFTKCLRVGMLKEGVRLDRVRGGRQKYKRRPEVDPLPFPGPFPAGPLAVAGGPRKTAAPVNALVSHLLVVEPEKLYAMPDPAGPDGHLPAVATLCDLFDREIVVTISWAKSIPGFSSLSLSDQMSVLQSVWMEVLVLGVAQRSLPLQDELAFAEDLVLDEEGARAAGLGELGAALLQLVRRLQALRLEREEYVLLKALALANSDSVHIEDAEAVEQLREALHEALLEYEAGRAGPGGGAERRRAGRLLLTLPLLRQTAGKVLAHFYGVKLEGKVPMHKLFLEMLEAMMD T68066 DRUGINFO D00XPC Halobetasol Propionate Approved T68066 DRUGINFO D02JNM Desonide Approved T68066 DRUGINFO D03ZZK Fluocinonide Approved T68066 DRUGINFO D04SFH Medrysone Approved T68066 DRUGINFO D06IIB Halcinonide Approved T68066 DRUGINFO D06XHC Amcinonide Approved T68066 DRUGINFO D07DVK Beclomethasone Approved T68066 DRUGINFO D09IEE Prednicarbate Approved T68066 DRUGINFO D0CZ1Q Desoximetasone Approved T68066 DRUGINFO D0F7NQ Flumethasone Pivalate Approved T68066 DRUGINFO D0L2UN Auranofin Approved T68066 DRUGINFO D0X4RS Cortisone Acetate Approved T68066 DRUGINFO D0X6GN Loteprednol Etabonate Approved T68066 DRUGINFO D0Y2YP Flurandrenolide Approved T68066 DRUGINFO D0RR2E IDP-122 Phase 3 T68066 DRUGINFO D0Z7MJ Prednisolone sodium metazoate Discontinued in Phase 2 T30956 TARGETID T30956 T30956 FORMERID TTDI01685 T30956 UNIPROID PAG_BACAN T30956 TARGNAME Bacillus anthracis Protective antigen (Anthrax PA) T30956 GENENAME Anthrax PA T30956 TARGTYPE Successful T30956 SYNONYMS Protective antigen; Anthrax toxins translocating protein; Anthrax PA83; Anthrax PA-83; Anthrax PA T30956 FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax. T30956 PDBSTRUC 5FR3; 4NAM; 4H2A; 4EE2; 3TEZ T30956 SEQUENCE MKKRKVLIPLMALSTILVSSTGNLEVIQAEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYFQSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQYQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSQTRTISKNTSTSRTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPNGNLQYQGKDITEFDFNFDQQTSQNIKNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG T30956 DRUGINFO D09VOS ETI-204 Approved T30956 DRUGINFO D0P8MB AIGIV Phase 1/2 T07403 TARGETID T07403 T07403 UNIPROID ITA4_HUMAN-ITB7_HUMAN T07403 TARGNAME Integrin alpha-4/beta-7 (ITGA4/B7) T07403 GENENAME ITGA4-ITGB7 T07403 TARGTYPE Successful T07403 SYNONYMS alpha(4)beta(7) integrin; Alpha 4 beta 7 integrin T07403 FUNCTION It is expressed on lymphocytes and is responsible for T-cell homing into gut-associated lymphoid tissues through its binding to mucosal addressin cell adhesion molecule (MAdCAM), which is present on high endothelial venules of mucosal lymphoid organs. T07403 BIOCLASS Integrin T07403 SEQUENCE MVALPMVLVLLLVLSRGESELDAKIPSTGDATEWRNPHLSMLGSCQPAPSCQKCILSHPSCAWCKQLNFTASGEAEARRCARREELLARGCPLEELEEPRGQQEVLQDQPLSQGARGEGATQLAPQRVRVTLRPGEPQQLQVRFLRAEGYPVDLYYLMDLSYSMKDDLERVRQLGHALLVRLQEVTHSVRIGFGSFVDKTVLPFVSTVPSKLRHPCPTRLERCQSPFSFHHVLSLTGDAQAFEREVGRQSVSGNLDSPEGGFDAILQAALCQEQIGWRNVSRLLVFTSDDTFHTAGDGKLGGIFMPSDGHCHLDSNGLYSRSTEFDYPSVGQVAQALSAANIQPIFAVTSAALPVYQELSKLIPKSAVGELSEDSSNVVQLIMDAYNSLSSTVTLEHSSLPPGVHISYESQCEGPEKREGKAEDRGQCNHVRINQTVTFWVSLQATHCLPEPHLLRLRALGFSEELIVELHTLCDCNCSDTQPQAPHCSDGQGHLQCGVCSCAPGRLGRLCECSVAELSSPDLESGCRAPNGTGPLCSGKGHCQCGRCSCSGQSSGHLCECDDASCERHEGILCGGFGRCQCGVCHCHANRTGRACECSGDMDSCISPEGGLCSGHGRCKCNRCQCLDGYYGALCDQCPGCKTPCERHRDCAECGAFRTGPLATNCSTACAHTNVTLALAPILDDGWCKERTLDNQLFFFLVEDDARGTVVLRVRPQEKGADHTQAIVLGCVGGIVAVGLGLVLAYRLSVEIYDRREYSRFEKEQQQLNWKQDSNPLYKSAITTTINPRFQEADSPTLMAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD T07403 DRUGINFO D0PK5M MLN0002 Approved T07403 DRUGINFO D1W8RK PN-943 Phase 2 T07403 DRUGINFO DYZA20 MORF-057 Phase 2 T07403 DRUGINFO D0A2KH TRK-170 Phase 2 T07403 DRUGINFO D2MFD0 GS-1427 Phase 1 T07403 DRUGINFO D04XJM R1295 Discontinued in Phase 1 T07403 DRUGINFO D02WII TR-14035 Discontinued in Phase 1 T51593 TARGETID T51593 T51593 FORMERID TTDR01331 T51593 UNIPROID TPH1_HUMAN; TPH2_HUMAN T51593 TARGNAME Tryptophan hydroxylase (TPH) T51593 GENENAME TPH1; TPH2 T51593 TARGTYPE Successful T51593 SYNONYMS Tryptophan 5-monooxygenase; TPH T51593 FUNCTION Responsible for addition of the -HO group (hydroxylation) to the 5 position to form the amino acid 5-hydroxytryptophan (5-HTP), which is the initial and rate-limiting step in the synthesis of the neurotransmitter serotonin. T51593 BIOCLASS Paired donor oxygen oxidoreductase T51593 SEQUENCE MIEDNKENKDHSLERGRASLIFSLKNEVGGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIFHLLKSHTNVLSVNLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKDTKSITSAMNELQHDLDVVSDALAKVSRKPSI T51593 DRUGINFO D0RE6T Telotristat ethyl Approved T59122 TARGETID T59122 T59122 FORMERID TTDI02398 T59122 UNIPROID LFA3_HUMAN T59122 TARGNAME Surface glycoprotein LFA-3 (CD58) T59122 GENENAME CD58 T59122 TARGTYPE Successful T59122 SYNONYMS Surface glycoprotein LFA3; Lymphocyte functionassociated antigen 3; Lymphocyte function-associated antigen 3; LFA3; Ag3 T59122 FUNCTION Ligand of the T-lymphocyte CD2 glycoprotein. This interaction is important in mediating thymocyte interactions with thymic epithelial cells, antigen-independent and -dependent interactions of T-lymphocytes with target cells and antigen-presenting cells and the T-lymphocyte rosetting with erythrocytes. In addition, the LFA-3/CD2 interaction may prime response by both the CD2+ and LFA-3+ cells. T59122 PDBSTRUC 1QA9; 1CI5; 1CCZ T59122 SEQUENCE MVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN T59122 DRUGINFO D09ZSO Alefacept Approved T92687 TARGETID T92687 T92687 UNIPROID ATP4A_HUMAN; ATP4B_HUMAN T92687 TARGNAME Gastric H(+)/K(+) ATPase (Proton pump) T92687 GENENAME ATP4A; ATP4B T92687 TARGTYPE Successful T92687 SYNONYMS Proton pump; Potassium-transporting ATPase T92687 FUNCTION Proton pump of the stomach. Exchanges potassium from the intestinal lumen with cytoplasmic hydronium and is the enzyme primarily responsible for the acidification of the stomach contents and the activation of the digestive enzyme pepsin. T92687 SEQUENCE MGKAENYELYSVELGPGPGGDMAAKMSKKKKAGGGGGKRKEKLENMKKEMEINDHQLSVAELEQKYQTSATKGLSASLAAELLLRDGPNALRPPRGTPEYVKFARQLAGGLQCLMWVAAAICLIAFAIQASEGDLTTDDNLYLAIALIAVVVVTGCFGYYQEFKSTNIIASFKNLVPQQATVIRDGDKFQINADQLVVGDLVEMKGGDRVPADIRILAAQGCKVDNSSLTGESEPQTRSPECTHESPLETRNIAFFSTMCLEGTVQGLVVNTGDRTIIGRIASLASGVENEKTPIAIEIEHFVDIIAGLAILFGATFFIVAMCIGYTFLRAMVFFMAIVVAYVPEGLLATVTVCLSLTAKRLASKNCVVKNLEAVETLGSTSVICSDKTGTLTQNRMTVSHLWFDNHIHTADTTEDQSGQTFDQSSETWRALCRVLTLCNRAAFKSGQDAVPVPKRIVIGDASETALLKFSELTLGNAMGYRDRFPKVCEIPFNSTNKFQLSIHTLEDPRDPRHLLVMKGAPERVLERCSSILIKGQELPLDEQWREAFQTAYLSLGGLGERVLGFCQLYLNEKDYPPGYAFDVEAMNFPSSGLCFAGLVSMIDPPRATVPDAVLKCRTAGIRVIMVTGDHPITAKAIAASVGIISEGSETVEDIAARLRVPVDQVNRKDARACVINGMQLKDMDPSELVEALRTHPEMVFARTSPQQKLVIVESCQRLGAIVAVTGDGVNDSPALKKADIGVAMGIAGSDAAKNAADMILLDDNFASIVTGVEQGRLIFDNLKKSIAYTLTKNIPELTPYLIYITVSVPLPLGCITILFIELCTDIFPSVSLAYEKAESDIMHLRPRNPKRDRLVNEPLAAYSYFQIGAIQSFAGFTDYFTAMAQEGWFPLLCVGLRAQWEDHHLQDLQDSYGQEWTFGQRLYQQYTCYTVFFISIEVCQIADVLIRKTRRLSAFQQGFFRNKILVIAIVFQVCIGCFLCYCPGMPNIFNFMPIRFQWWLVPLPYGILIFVYDEIRKLGVRCCPGSWWDQELYY T92687 DRUGINFO D01XNB Omeprazole Approved T92687 DRUGINFO D02CPP Vonoprazan Approved T92687 DRUGINFO D0C6DT Esomeprazole Approved T92687 DRUGINFO D0T6XX Pantoprazole Approved T92687 DRUGINFO D06YYD Dexlansoprazole Approved T92687 DRUGINFO D05BCU RQ-00000004 Phase 3 T92687 DRUGINFO D03RVC YH-4808 Phase 2 T92687 DRUGINFO D0N1PZ S-tenatoprazole Phase 2 T92687 DRUGINFO D0S0EQ AZD-0865 Phase 2 T92687 DRUGINFO D0QZ4S LEMINOPRAZOLE Discontinued in Preregistration T92687 DRUGINFO D02THB SKF-96067 Discontinued in Phase 3 T92687 DRUGINFO D0M8HH PUMAPRAZOLE Discontinued in Phase 3 T92687 DRUGINFO D03EZB AR-H047108 Discontinued in Phase 2 T92687 DRUGINFO D0GY4V TY-11345 Discontinued in Phase 2 T92687 DRUGINFO D0Q0YN SORAPRAZAN Discontinued in Phase 2 T92687 DRUGINFO D0R2EY SKF-97574 Discontinued in Phase 1 T92687 DRUGINFO D0R7GH CS-526 Discontinued in Phase 1 T92687 DRUGINFO D03CCH SK&F-95601 Terminated T92687 DRUGINFO D0FN1P Saviprazole Terminated T92687 DRUGINFO D0C7SC YH-1238 Investigative T22348 TARGETID T22348 T22348 FORMERID TTDI01914 T22348 UNIPROID GYRA_STAAU; GYRB_STAAU T22348 TARGNAME Bacterial DNA gyrase (Bact gyrase) T22348 GENENAME Bact gyrA; Bact gyrB T22348 TARGTYPE Successful T22348 SYNONYMS DNA gyrase T22348 FUNCTION DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings. T22348 BIOCLASS ATP-hydrolyzing DNA topoisomerase T22348 SEQUENCE MAELPQSRINERNITSEMRESFLDYAMSVIVARALPDVRDGLKPVHRRILYGLNEQGMTPDKSYKKSARIVGDVMGKYHPHGDSSIYEAMVRMAQDFSYRYPLVDGQGNFGSMDGDGAAAMRYTEARMTKITLELLRDINKDTIDFIDNYDGNEREPSVLPARFPNLLANGASGIAVGMATNIPPHNLTELINGVLSLSKNPDISIAELMEDIEGPDFPTAGLILGKSGIRRAYETGRGSIQMRSRAVIEERGGGRQRIVVTEIPFQVNKARMIEKIAELVRDKKIDGITDLRDETSLRTGVRVVIDVRKDANASVILNNLYKQTPLQTSFGVNMIALVNGRPKLINLKEALVHYLEHQKTVVRRRTQYNLRKAKDRAHILEGLRIALDHIDEIISTIRESDTDKVAMESLQQRFKLSEKQAQAILDMRLRRLTGLERDKIEAEYNELLNYISELEAILADEEVLLQLVRDELTEIRDRFGDDRRTEIQLGGFEDLEDEDLIPEEQIVITLSHNNYIKRLPVSTYRAQNRGGRGVQGMNTLEEDFVSQLVTLSTHDHVLFFTNKGRVYKLKGYEVPELSRQSKGIPVVNAIELENDEVISTMIAVKDLESEDNFLVFATKRGVVKRSALSNFSRINRNGKIAISFREDDELIAVRLTSGQEDILIGTSHASLIRFPESTLRPLGRTATGVKGITLREGDEVVGLDVAHANSVDEVLVVTENGYGKRTPVNDYRLSNRGGKGIKTATITERNGNVVCITTVTGEEDLMIVTNAGVIIRLDVADISQNGRAAQGVRLIRLGDDQFVSTVAKVKEDAEDETNEDEQSTSTVSEDGTEQQREAVVNDETPGNAIHTEVIDSEENDEDGRIEVRQDFMDRVEEDIQQSLDEDEE T22348 DRUGINFO D03NHW Ofloxacin Approved T22348 DRUGINFO D03WPA Trovafloxacin Approved T22348 DRUGINFO D0JL2K Grepafloxacin Approved T22348 DRUGINFO D0P0RX Nemonoxacin Approved T22348 DRUGINFO D0Q2PE Norfloxacin Approved T22348 DRUGINFO D00TRV Besifloxacin Approved T22348 DRUGINFO D01IXD Finafloxacin Approved T22348 DRUGINFO D02RSN Levofloxacin Approved T22348 DRUGINFO D03CQE Gatifloxacin Approved T22348 DRUGINFO D0K6GZ Sparfloxacin Approved T22348 DRUGINFO D0VR7W Gemifloxacin Approved T22348 DRUGINFO D0ZV0Z Moxifloxacin Approved T22348 DRUGINFO DR36YB Prulifloxacin Approved T22348 DRUGINFO D0O1WX Ciprofloxacin XR Approved T22348 DRUGINFO D0X1HE Ozenoxacin Approved T22348 DRUGINFO D00HBE AZD0914 Phase 3 T22348 DRUGINFO D01ODU BAY-35-3377 Phase 3 T22348 DRUGINFO D05STQ Pazufloxacin Phase 3 T22348 DRUGINFO D07MXF Zabofloxacin Phase 3 T22348 DRUGINFO D07NTC WCK-771 Phase 2 T22348 DRUGINFO D2FCM4 VB 1953 Phase 2 T22348 DRUGINFO D39VXL JNJ-32729463 Phase 2 T22348 DRUGINFO D4M8RS TNP-2092 Phase 2 T22348 DRUGINFO D6DT3X Sitafloxacin Phase 2 T22348 DRUGINFO D04SBX Temafloxacin Withdrawn from market T22348 DRUGINFO D0Q0SZ OLAMUFLOXACIN MESILATE Discontinued in Phase 3 T22348 DRUGINFO D09CFM DANOFLOXACIN Discontinued in Phase 2 T22348 DRUGINFO D0D2SG 99mTc-ciprofloxacin Discontinued in Phase 2 T22348 DRUGINFO D0E6NR BAY-Y-3118 Discontinued in Phase 2 T22348 DRUGINFO D0K4ED Ro-23-9424 Discontinued in Phase 2 T22348 DRUGINFO D0Q4UY CFC-222 Discontinued in Phase 2 T22348 DRUGINFO D0R6MH Cadrofloxacin Discontinued in Phase 2 T22348 DRUGINFO D0W7KD FANDOFLOXACIN HYDROCHLORIDE Discontinued in Phase 2 T22348 DRUGINFO D0W8VY A-86719.1 Discontinued in Phase 2 T22348 DRUGINFO D0T3VO DX-619 Discontinued in Phase 2 T22348 DRUGINFO D03ESW Cetefloxacin Discontinued in Phase 1 T22348 DRUGINFO D06GMJ GSK945237 Discontinued in Phase 1 T22348 DRUGINFO D09KXA PD-131112 Discontinued in Phase 1 T22348 DRUGINFO D0D1LG AZD-5099 Discontinued in Phase 1 T22348 DRUGINFO D0T6PV DV-7751A Discontinued in Phase 1 T22348 DRUGINFO D0IY0R Viquidacin Preclinical T22348 DRUGINFO D00ITG Clinafloxacin Terminated T22348 DRUGINFO D00MLQ Protosufloxacin Terminated T22348 DRUGINFO D03GQC PD-117596 Terminated T22348 DRUGINFO D03HSF Ro-23-7777 Terminated T22348 DRUGINFO D03YLN CP-67015 Terminated T22348 DRUGINFO D0C7FN BMY-40062 Terminated T22348 DRUGINFO D0IA7K MF-5137 Terminated T22348 DRUGINFO D0L2BH S-34109 Terminated T22348 DRUGINFO D0PM9P KB-5246 Terminated T22348 DRUGINFO D0V2WK A-70826 Terminated T22348 DRUGINFO D01ZLI CBR-2092 Terminated T22348 DRUGINFO D0Q8YO PD-117558 Investigative T22348 DRUGINFO D08ZRP NSFQ-105 Investigative T61997 TARGETID T61997 T61997 FORMERID TTDR00362 T61997 UNIPROID PSA1_HUMAN; PSA2_HUMAN T61997 TARGNAME Core proteasome 20S complex (PS 20S) T61997 GENENAME PSMA1; PSMA2 T61997 TARGTYPE Successful T61997 SYNONYMS Proteasome subunit alpha; Proteasome component; PSC; Multicatalytic endopeptidase complex; Macropain; HC T61997 FUNCTION Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). T61997 BIOCLASS Peptidase T61997 SEQUENCE MFRNQYDNDVTVWSPQGRIHQIEYAMEAVKQGSATVGLKSKTHAVLVALKRAQSELAAHQKKILHVDNHIGISIAGLTADARLLCNFMRQECLDSRFVFDRPLPVSRLVSLIGSKTQIPTQRYGRRPYGVGLLIAGYDDMGPHIFQTCPSANYFDCRAMSIGARSQSARTYLERHMSEFMECNLNELVKHGLRALRETLPAEQDLTTKNVSIGIVGKDLEFTIYDDDDVSPFLEGLEERPQRKAQPAQPADEPAEKADEPMEH T03896 TARGETID T03896 T03896 UNIPROID POLG_HCV1 T03896 TARGNAME Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) T03896 GENENAME HCV NS3/4A T03896 TARGTYPE Successful T03896 SYNONYMS HCV Hepacivirin/NS4A; HCV NS3P/NS4A; HCV p70/NS4A T03896 FUNCTION Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity). T03896 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T03896 SEQUENCE APITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVVTSTWVLVGGVLAALAAYCLSTGCVVIVGRVVLSGKPAIIPDREVLYREFDEMEEC T03896 DRUGINFO D00TLP Simeprevir Approved T03896 DRUGINFO D0V3YT BOCEPREVIR Approved T03896 DRUGINFO D0X9CH Telaprevir Approved T03896 DRUGINFO D0C4DH Glecaprevir; pibrentasvir Approved T03896 DRUGINFO D0RM5Z Sofosbuvir + velpatasvir + voxilaprevir Approved T16761 TARGETID T16761 T16761 UNIPROID FOL1_PNECA T16761 TARGNAME Pneumocystis carinii Dihydropteroate synthase (PC DHPS) T16761 GENENAME PC DHPS T16761 TARGTYPE Successful T16761 SYNONYMS PC DHPS T16761 FUNCTION Catalyzes three sequential steps of tetrahydrofolate biosynthesis. T16761 ECNUMBER EC 2.5.1.15 T16761 SEQUENCE SFRSYKAPTYIMAILNLTPDSFFDGGIHSYDSVLIDVEKFINAGATIIDIGGQSTRPGSYIIPLEEEIFRVIPAIKYLQKTYPDILISIDTFRSEVAEQAVKAGASLVNDISGGRYDPKMFNTVARLKVPICIMHMRGNFLNMDNLTDYGTDIIEQITIELEKLLNSAEKSGIPRWNIILDPGLGFSKTLHQNIELLRRFNELKSKNCFNGLPWLLGPSRKRFTGFITGDNMPKDRIWGTVAAVVASISGGCDIIRVHDVYEMYKISKMSDAIWKEIY T16761 DRUGINFO D0MA9N Dapsone Approved T74166 TARGETID T74166 T74166 UNIPROID ACHA3_HUMAN-ACHB4_HUMAN T74166 TARGNAME Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4) T74166 GENENAME CHRNA3-CHRNB4 T74166 TARGTYPE Successful T74166 SYNONYMS Neuronal acetylcholine receptor T74166 FUNCTION A type of nicotinic acetylcholine receptor, consisting of 3 and 4 subunits. T74166 BIOCLASS Neurotransmitter receptor T74166 SEQUENCE MRRAPSLVLFFLVALCGRGNCRVANAEEKLMDDLLNKTRYNNLIRPATSSSQLISIKLQLSLAQLISVNEREQIMTTNVWLKQEWTDYRLTWNSSRYEGVNILRIPAKRIWLPDIVLYNNADGTYEVSVYTNLIVRSNGSVLWLPPAIYKSACKIEVKYFPFDQQNCTLKFRSWTYDHTEIDMVLMTPTASMDDFTPSGEWDIVALPGRRTVNPQDPSYVDVTYDFIIKRKPLFYTINLIIPCVLTTLLAILVFYLPSDCGEKMTLCISVLLALTFFLLLISKIVPPTSLDVPLIGKYLMFTMVLVTFSIVTSVCVLNVHHRSPSTHTMAPWVKRCFLHKLPTFLFMKRPGPDSSPARAFPPSKSCVTKPEATATSTSPSNFYGNSMYFVNPASAASKSPAGSTPVAIPRDFWLRSSGRFRQDVQEALEGVSFIAQHMKNDDEDQSVVEDWKYVAMVVDRLFLWVFMFVCVLGTVGLFLPPLFQTHAASEGPYAAQRDMGSGPLSLPLALSPPRLLLLLLLSLLPVARASEAEHRLFERLFEDYNEIIRPVANVSDPVIIHFEVSMSQLVKVDEVNQIMETNLWLKQIWNDYKLKWNPSDYGGAEFMRVPAQKIWKPDIVLYNNAVGDFQVDDKTKALLKYTGEVTWIPPAIFKSSCKIDVTYFPFDYQNCTMKFGSWSYDKAKIDLVLIGSSMNLKDYWESGEWAIIKAPGYKHDIKYNCCEEIYPDITYSLYIRRLPLFYTINLIIPCLLISFLTVLVFYLPSDCGEKVTLCISVLLSLTVFLLVITETIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHYRTPTTHTMPSWVKTVFLNLLPRVMFMTRPTSNEGNAQKPRPLYGAELSNLNCFSRAESKGCKEGYPCQDGMCGYCHHRRIKISNFSANLTRSSSSESVDAVLSLSALSPEIKEAIQSVKYIAENMKAQNEAKEIQDDWKYVAMVIDRIFLWVFTLVCILGTAGLFLQPLMAREDA T74166 DRUGINFO D0HF0W Levopropoxyphene Napsylate Anhydrous Approved T74166 DRUGINFO D0D7YW TC-5214 Phase 2 T74166 DRUGINFO D0DS3J 18-MC Phase 1 T14121 TARGETID T14121 T14121 FORMERID TTDI02064 T14121 UNIPROID F13_VAR67 T14121 TARGNAME Virus Major envelope p37 (Viru p37) T14121 GENENAME Viru p37 T14121 TARGTYPE Successful T14121 SYNONYMS Viru p37K; Viru Palmitoylated EV membrane protein; Viru Envelope protein F13; C17L, F13L; 37 kDa protein T14121 FUNCTION Envelope protein associated with the inner side of the enveloped virion (EV) membrane. T14121 BIOCLASS Phospholipase D phosphodiesterase T14121 SEQUENCE MWPFTSAPAGAKCRLVETLPENMDFRSDHLTTFECFNEIITLAKKYIYIASFCCNPLSTTRGALIFDKLKEASEKGIKIIVLLDERGKRNLGELQSHCPDINFITVNIDKKNNVGLLLGCFWVSDDERCYVGNASFTGGSIHTIKTLGVYSDYPPLATDLRRRFDTFKAFNSVKNSWLNLYSSACCLPVSTAYHIKNPIGGVFFTDSPEHLLGYSRDLDTDVVIDKLRSAKTSIDIEHLAIVPTTRVDGNSYYWPDIYNSIIEAAINRGVKIRLLVGNWDKNDVYSMATAESLDALCVQNDLSVKVFTIQNNTKLLIVDDEYVHITSANFDGTHYQNHGFVSFNSIDKQLVSEAKKIFERDWVSSHSKSLKI T23666 TARGETID T23666 T23666 FORMERID TTDI02013 T23666 UNIPROID AHR_HUMAN T23666 TARGNAME Aryl hydrocarbon receptor (AHR) T23666 GENENAME AHR T23666 TARGTYPE Successful T23666 SYNONYMS bHLHe76; Class E basic helixloophelix protein 76; Class E basic helix-loop-helix protein 76; AhR; Ah receptor T23666 FUNCTION Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene). Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. Involved in cell-cycle regulation. Likely to play an important role in the development and maturation of many tissues. Regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1. Inhibits PER1 by repressing the CLOCK-ARNTL/BMAL1 heterodimer mediated transcriptional activation of PER1. The heterodimer ARNT:AHR binds to core DNA sequence 5'-TGCGTG-3' within the dioxin response element (DRE) of target gene promoters and activates their transcription. Ligand-activated transcriptional activator. T23666 PDBSTRUC 5NJ8 T23666 SEQUENCE MNSSSANITYASRKRRKPVQKTVKPIPAEGIKSNPSKRHRDRLNTELDRLASLLPFPQDVINKLDKLSVLRLSVSYLRAKSFFDVALKSSPTERNGGQDNCRAANFREGLNLQEGEFLLQALNGFVLVVTTDALVFYASSTIQDYLGFQQSDVIHQSVYELIHTEDRAEFQRQLHWALNPSQCTESGQGIEEATGLPQTVVCYNPDQIPPENSPLMERCFICRLRCLLDNSSGFLAMNFQGKLKYLHGQKKKGKDGSILPPQLALFAIATPLQPPSILEIRTKNFIFRTKHKLDFTPIGCDAKGRIVLGYTEAELCTRGSGYQFIHAADMLYCAESHIRMIKTGESGMIVFRLLTKNNRWTWVQSNARLLYKNGRPDYIIVTQRPLTDEEGTEHLRKRNTKLPFMFTTGEAVLYEATNPFPAIMDPLPLRTKNGTSGKDSATTSTLSKDSLNPSSLLAAMMQQDESIYLYPASSTSSTAPFENNFFNESMNECRNWQDNTAPMGNDTILKHEQIDQPQDVNSFAGGHPGLFQDSKNSDLYSIMKNLGIDFEDIRHMQNEKFFRNDFSGEVDFRDIDLTDEILTYVQDSLSKSPFIPSDYQQQQSLALNSSCMVQEHLHLEQQQQHHQKQVVVEPQQQLCQKMKHMQVNGMFENWNSNQFVPFNCPQQDPQQYNVFTDLHGISQEFPYKSEMDSMPYTQNFISCNQPVLPQHSKCTELDYPMGSFEPSPYPTTSSLEDFVTCLQLPENQKHGLNPQSAIITPQTCYAGAVSMYQCQPEPQHTHVGQMQYNPVLPGQQAFLNKFQNGVLNETYPAELNNINNTQTTTHLQPLHHPSEARPFPDLTSSGFL T23666 DRUGINFO D03DMB Tapinarof Approved T23666 DRUGINFO D01PZD Romiplostim Approved T23666 DRUGINFO D0AF5P RVT-505 Phase 2 T23666 DRUGINFO D5D6ZM IK-175 Phase 1 T23666 DRUGINFO DMVR61 BAY 2416964 Phase 1 T23666 DRUGINFO DNEH27 AT-177 Clinical trial T23666 DRUGINFO D49AGF CB7993113 Preclinical T23666 DRUGINFO DQ3NC4 2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester Preclinical T23666 DRUGINFO DFBJ28 6-Formylindolo[3,2-b]carbazole Investigative T23666 DRUGINFO DL36FJ CH-223191 Investigative T35465 TARGETID T35465 T35465 FORMERID TTDI03511 T35465 UNIPROID S19A1_HUMAN T35465 TARGNAME Solute carrier family 19 member 1 (SLC19A1) T35465 GENENAME SLC19A1 T35465 TARGTYPE Successful T35465 SYNONYMS Reduced folate carrier protein; RFC1; RFC; Placental folate transporter; Intestinal folate carrier 1; IFC-1; Folate transporter 1; FOLT; FLOT1 T35465 FUNCTION Transporter for the intake of folate. Uptake of folate in human placental choriocarcinoma cells occurs by a novel mechanism called potocytosis which functionally couples three components, namely the folate receptor, the folate transporter, and a V-type H(+)-pump. T35465 SEQUENCE MVPSSPAVEKQVPVEPGPDPELRSWRHLVCYLCFYGFMAQIRPGESFITPYLLGPDKNFTREQVTNEITPVLSYSYLAVLVPVFLLTDYLRYTPVLLLQGLSFVSVWLLLLLGHSVAHMQLMELFYSVTMAARIAYSSYIFSLVRPARYQRVAGYSRAAVLLGVFTSSVLGQLLVTVGRVSFSTLNYISLAFLTFSVVLALFLKRPKRSLFFNRDDRGRCETSASELERMNPGPGGKLGHALRVACGDSVLARMLRELGDSLRRPQLRLWSLWWVFNSAGYYLVVYYVHILWNEVDPTTNSARVYNGAADAASTLLGAITSFAAGFVKIRWARWSKLLIAGVTATQAGLVFLLAHTRHPSSIWLCYAAFVLFRGSYQFLVPIATFQIASSLSKELCALVFGVNTFFATIVKTIITFIVSDVRGLGLPVRKQFQLYSVYFLILSIIYFLGAMLDGLRHCQRGHHPRQPPAQGLRSAAEEKAAQALSVQDKGLGGLQPAQSPPLSPEDSLGAVGPASLEQRQSDPYLAQAPAPQAAEFLSPVTTPSPCTLCSAQASGPEAADETCPQLAVHPPGVSKLGLQCLPSDGVQNVNQ T35465 DRUGINFO D0SV8E Methotrexate Approved T35465 DRUGINFO D0Z0DW Folic Acid Approved T30938 TARGETID T30938 T30938 FORMERID TTDI00934 T30938 UNIPROID RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU T30938 TARGNAME Mycobacterium RNA polymerase (MycB RNAP) T30938 GENENAME MycB rpoA; MycB rpoB; MycB rpoC; MycB rpoZ T30938 TARGTYPE Successful T30938 SYNONYMS Transcriptase; RNAP; RNA polymerase; Mycobacterium DNA-directed RNA polymerase T30938 FUNCTION DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. T30938 SEQUENCE MLISQRPTLSEDVLTDNRSQFVIEPLEPGFGYTLGNSLRRTLLSSIPGAAVTSIRIDGVLHEFTTVPGVKEDVTEIILNLKSLVVSSEEDEPVTMYLRKQGPGEVTAGDIVPPAGVTVHNPGMHIATLNDKGKLEVELVVERGRGYVPAVQNRASGAEIGRIPVDSIYSPVLKVTYKVDATRVEQRTDFDKLILDVETKNSISPRDALASAGKTLVELFGLARELNVEAEGIEIGPSPAEADHIASFALPIDDLDLTVRSYNCLKREGVHTVGELVARTESDLLDIRNFGQKSIDEVKIKLHQLGLSLKDSPPSFDPSEVAGYDVATGTWSTEGAYDEQDYAETEQL T30938 DRUGINFO D0FX2Q Rifamycin Approved T30938 DRUGINFO D0Y4LX Favipiravir Registered T30938 DRUGINFO D0OR5P TAS-106 Phase 2 T30938 DRUGINFO D00TQN JTK-003 Discontinued in Phase 2 T30938 DRUGINFO D01ZJM R-1479 Discontinued in Phase 1 T30938 DRUGINFO D0S5AL XTL-2125 Discontinued in Phase 1 T57680 TARGETID T57680 T57680 FORMERID TTDR00186 T57680 UNIPROID GCYA1_HUMAN; GCYB1_HUMAN T57680 TARGNAME Soluble guanylate cyclase (GCS) T57680 GENENAME GUCY1A1; GUCY1B1 T57680 TARGTYPE Successful T57680 SYNONYMS GUCY1; GUCS; GUC1; GCS T57680 FUNCTION Probably plays a specific functional role in the rods and/or cones of photoreceptors. It may be the enzyme involved in the resynthesis of cGMP required for recovery of the dark state after phototransduction. T57680 BIOCLASS Phosphorus-oxygen lyase T57680 SEQUENCE MFCTKLKDLKITGECPFSLLAPGQVPNESSEEAAGSSESCKATVPICQDIPEKNIQESLPQRKTSRSRVYLHTLAESICKLIFPEFERLNVALQRTLAKHKIKESRKSLEREDFEKTIAEQAVAAGVPVEVIKESLGEEVFKICYEEDENILGVVGGTLKDFLNSFSTLLKQSSHCQEAGKRGRLEDASILCLDKEDDFLHVYYFFPKRTTSLILPGIIKAAAHVLYETEVEVSLMPPCFHNDCSEFVNQPYLLYSVHMKSTKPSLSPSKPQSSLVIPTSLFCKTFPFHFMFDKDMTILQFGNGIRRLMNRRDFQGKPNFEEYFEILTPKINQTFSGIMTMLNMQFVVRVRRWDNSVKKSSRVMDLKGQMIYIVESSAILFLGSPCVDRLEDFTGRGLYLSDIPIHNALRDVVLIGEQARAQDGLKKRLGKLKATLEQAHQALEEEKKKTVDLLCSIFPCEVAQQLWQGQVVQAKKFSNVTMLFSDIVGFTAICSQCSPLQVITMLNALYTRFDQQCGELDVYKVETIGDAYCVAGGLHKESDTHAVQIALMALKMMELSDEVMSPHGEPIKMRIGLHSGSVFAGVVGVKMPRYCLFGNNVTLANKFESCSVPRKINVSPTTYRLLKDCPGFVFTPRSREELPPNFPSEIPGICHFLDAYQQGTNSKPCFQKKDVEDGNANFLGKASGID T57680 DRUGINFO D07XVR Sodium nitroprusside Approved T57680 DRUGINFO D07YDE Nitroglycerin Approved T57680 DRUGINFO D0A5FM Nitric Oxide Approved T57680 DRUGINFO D04EMB IW-1973 Phase 2 T57680 DRUGINFO D2RG4D Runcaciguat Phase 2 T57680 DRUGINFO DVCB87 MK-5475 Phase 2 T57680 DRUGINFO DW5UI2 CTI-1601 Phase 2 T57680 DRUGINFO DO37EF CY6463 Phase 2 T57680 DRUGINFO DO37EF CY6463 Phase 2 T57680 DRUGINFO D00REK (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol Investigative T74363 TARGETID T74363 T74363 FORMERID TTDR00369 T74363 UNIPROID UPAR_HUMAN T74363 TARGNAME Urokinase plasminogen activator surface receptor (PLAUR) T74363 GENENAME PLAUR T74363 TARGTYPE Successful T74363 SYNONYMS Urokinase-type plasminogen activator receptor; Urokinase plasminogen activator receptor; Monocyte activation antigenMo3; CD87 antigen; CD87 T74363 FUNCTION Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form. Acts as a receptor for urokinase plasminogen activator. T74363 PDBSTRUC 4QTI; 4K24; 3U74; 3U73; 3BT2 T74363 SEQUENCE MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT T74363 DRUGINFO D04LKS Ruxolitinib Approved T28661 TARGETID T28661 T28661 FORMERID TTDS00389 T28661 UNIPROID TBB2A_HUMAN T28661 TARGNAME Tubulin beta-2 chain (TUBB2) T28661 GENENAME TUBB2A T28661 TARGTYPE Successful T28661 SYNONYMS Tubulin beta-2A chain; Tubulin beta class IIa; TUBB4B; BetaII-Tubulin; Beta(II)-Tubulin; Beta(II) isotype of Tubulin T28661 FUNCTION It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. Tubulin is the major constituent of microtubules. T28661 SEQUENCE MREIVHIQAGQCGNQIGAKFWEVISDEHGIDPTGSYHGDSDLQLERINVYYNEAAGNKYVPRAILVDLEPGTMDSVRSGPFGQIFRPDNFVFGQSGAGNNWAKGHYTEGAELVDSVLDVVRKESESCDCLQGFQLTHSLGGGTGSGMGTLLISKIREEYPDRIMNTFSVMPSPKVSDTVVEPYNATLSVHQLVENTDETYSIDNEALYDICFRTLKLTTPTYGDLNHLVSATMSGVTTCLRFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTSRGSQQYRALTVPELTQQMFDSKNMMAACDPRHGRYLTVAAIFRGRMSMKEVDEQMLNVQNKNSSYFVEWIPNNVKTAVCDIPPRGLKMSATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESNMNDLVSEYQQYQDATADEQGEFEEEEGEDEA T28661 DRUGINFO D0W9MM Vinblastine Approved T28661 DRUGINFO D0PF3J DOLASTATIN-10 Phase 2 T28661 DRUGINFO D02XKD 3-bromo-4,4',5-trimethoxy-(Z)-stilbene Investigative T28661 DRUGINFO D03CYV 6-ile-ustiloxin Investigative T28661 DRUGINFO D03NTD 3,4',5-trimethoxy-(Z)-stilbene Investigative T28661 DRUGINFO D07UWD Ustiloxin D Investigative T28661 DRUGINFO D0C6EW Ustiloxin F Investigative T28661 DRUGINFO D0LH3S 3,4,4',5-tetramethoxy-(Z)-stilbene Investigative T28661 DRUGINFO D0OW6Q 2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene Investigative T28661 DRUGINFO D0S6FK USTILOXIN A Investigative T28661 DRUGINFO D0VH8A N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide Investigative T28661 DRUGINFO D0W5RQ 2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene Investigative T28661 DRUGINFO D0X9OV 2-amino-3,4',5-trimethoxy-(Z)-stillbene Investigative T82624 TARGETID T82624 T82624 FORMERID TTDS00502 T82624 UNIPROID ITPR1_HUMAN; ITPR2_HUMAN; ITPR3_HUMAN T82624 TARGNAME Inositol 1,4,5-trisphosphate receptor (ITPR) T82624 GENENAME ITPR1; ITPR2; ITPR3 T82624 TARGTYPE Successful T82624 SYNONYMS InsP3R; InsP3 receptor; IP3R; IP3 receptor T82624 FUNCTION Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate. T82624 SEQUENCE MSDKMSSFLHIGDICSLYAEGSTNGFISTLGLVDDRCVVQPETGDLNNPPKKFRDCLFKLCPMNRYSAQKQFWKAAKPGANSTTDAVLLNKLHHAADLEKKQNETENRKLLGTVIQYGNVIQLLHLKSNKYLTVNKRLPALLEKNAMRVTLDEAGNEGSWFYIQPFYKLRSIGDSVVIGDKVVLNPVNAGQPLHASSHQLVDNPGCNEVNSVNCNTSWKIVLFMKWSDNKDDILKGGDVVRLFHAEQEKFLTCDEHRKKQHVFLRTTGRQSATSATSSKALWEVEVVQHDPCRGGAGYWNSLFRFKHLATGHYLAAEVDPDFEEECLEFQPSVDPDQDASRSRLRNAQEKMVYSLVSVPEGNDISSIFELDPTTLRGGDSLVPRNSYVRLRHLCTNTWVHSTNIPIDKEEEKPVMLKIGTSPVKEDKEAFAIVPVSPAEVRDLDFANDASKVLGSIAGKLEKGTITQNERRSVTKLLEDLVYFVTGGTNSGQDVLEVVFSKPNRERQKLMREQNILKQIFKLLQAPFTDCGDGPMLRLEELGDQRHAPFRHICRLCYRVLRHSQQDYRKNQEYIAKQFGFMQKQIGYDVLAEDTITALLHNNRKLLEKHITAAEIDTFVSLVRKNREPRFLDYLSDLCVSMNKSIPVTQELICKAVLNPTNADILIETKLVLSRFEFEGVSSTGENALEAGEDEEEVWLFWRDSNKEIRSKSVRELAQDAKEGQKEDRDVLSYYRYQLNLFARMCLDRQYLAINEISGQLDVDLILRCMSDENLPYDLRASFCRLMLHMHVDRDPQEQVTPVKYARLWSEIPSEIAIDDYDSSGASKDEIKERFAQTMEFVEEYLRDVVCQRFPFSDKEKNKLTFEVVNLARNLIYFGFYNFSDLLRLTKILLAILDCVHVTTIFPISKMAKGEENKGNNDVEKLKSSNVMRSIHGVGELMTQVVLRGGGFLPMTPMAAAPEGNVKQAEPEKEDIMVMDTKLKIIEILQFILNVRLDYRISCLLCIFKREFDESNSQTSETSSGNSSQEGPSNVPGALDFEHIEEQAEGIFGGSEENTPLDLDDHGGRTFLRVLLHLTMHDYPPLVSGALQLLFRHFSQRQEVLQAFKQVQLLVTSQDVDNYKQIKQDLDQLRSIVEKSELWVYKGQGPDETMDGASGENEHKKTEEGNNKPQKHESTSSYNYRVVKEILIRLSKLCVQESASVRKSRKQQQRLLRNMGAHAVVLELLQIPYEKAEDTKMQEIMRLAHEFLQNFCAGNQQNQALLHKHINLFLNPGILEAVTMQHIFMNNFQLCSEINERVVQHFVHCIETHGRNVQYIKFLQTIVKAEGKFIKKCQDMVMAELVNSGEDVLVFYNDRASFQTLIQMMRSERDRMDENSPLMYHIHLVELLAVCTEGKNVYTEIKCNSLLPLDDIVRVVTHEDCIPEVKIAYINFLNHCYVDTEVEMKEIYTSNHMWKLFENFLVDICRACNNTSDRKHADSILEKYVTEIVMSIVTTFFSSPFSDQSTTLQTRQPVFVQLLQGVFRVYHCNWLMPSQKASVESCIRVLSDVAKSRAIAIPVDLDSQVNNLFLKSHSIVQKTAMNWRLSARNAARRDSVLAASRDYRNIIERLQDIVSALEDRLRPLVQAELSVLVDVLHRPELLFPENTDARRKCESGGFICKLIKHTKQLLEENEEKLCIKVLQTLREMMTKDRGYGEKLISIDELDNAELPPAPDSENATEELEPSPPLRQLEDHKRGEALRQVLVNRYYGNVRPSGRRESLTSFGNGPLSAGGPGKPGGGGGGSGSSSMSRGEMSLAEVQCHLDKEGASNLVIDLIMNASSDRVFHESILLAIALLEGGNTTIQHSFFCRLTEDKKSEKFFKVFYDRMKVAQQEIKATVTVNTSDLGNKKKDDEVDRDAPSRKKAKEPTTQITEEVRDQLLEASAATRKAFTTFRREADPDDHYQPGEGTQATADKAKDDLEMSAVITIMQPILRFLQLLCENHNRDLQNFLRCQNNKTNYNLVCETLQFLDCICGSTTGGLGLLGLYINEKNVALINQTLESLTEYCQGPCHENQNCIATHESNGIDIITALILNDINPLGKKRMDLVLELKNNASKLLLAIMESRHDSENAERILYNMRPKELVEVIKKAYMQGEVEFEDGENGEDGAASPRNVGHNIYILAHQLARHNKELQSMLKPGGQVDGDEALEFYAKHTAQIEIVRLDRTMEQIVFPVPSICEFLTKESKLRIYYTTERDEQGSKINDFFLRSEDLFNEMNWQKKLRAQPVLYWCARNMSFWSSISFNLAVLMNLLVAFFYPFKGVRGGTLEPHWSGLLWTAMLISLAIVIALPKPHGIRALIASTILRLIFSVGLQPTLFLLGAFNVCNKIIFLMSFVGNCGTFTRGYRAMVLDVEFLYHLLYLVICAMGLFVHEFFYSLLLFDLVYREETLLNVIKSVTRNGRSIILTAVLALILVYLFSIVGYLFFKDDFILEVDRLPNETAVPETGESLASEFLFSDVCRVESGENCSSPAPREELVPAEETEQDKEHTCETLLMCIVTVLSHGLRSGGGVGDVLRKPSKEEPLFAARVIYDLLFFFMVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVTFEEHIKEEHNMWHYLCFIVLVKVKDSTEYTGPESYVAEMIKERNLDWFPRMRAMSLVSSDSEGEQNELRNLQEKLESTMKLVTNLSGQLSELKDQMTEQRKQKQRIGLLGHPPHMNVNPQQPA T82624 DRUGINFO D00PLV Nitroprusside Approved T82624 DRUGINFO D0A0RR ADENOPHOSTIN A Investigative T82624 DRUGINFO D0G5CI 5'-Deoxy-5'-phenyladenophostin A Investigative T82624 DRUGINFO D0MR1K D-myo-inositol 1,4,5-trisphosphate Investigative T92078 TARGETID T92078 T92078 FORMERID TTDI01962 T92078 UNIPROID DPYL2_HUMAN T92078 TARGNAME Dihydropyrimidinase related protein 2 (DPYSL2) T92078 GENENAME DPYSL2 T92078 TARGTYPE Successful T92078 SYNONYMS Unc33like phosphoprotein 2; Unc-33-like phosphoprotein 2; ULIP2; ULIP-2; N2A3; Dihydropyrimidinaserelated protein 2; Dihydropyrimidinase-related protein 2; DRP2; DRP-2; Collapsin response mediator protein 2; CRMP2; CRMP-2 T92078 FUNCTION Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. May play a role in endocytosis. Plays a role in neuronal development and polarity, as well as in axon growth and guidance, neuronal growth cone collapse and cell migration. T92078 PDBSTRUC 5YZB; 5YZA; 5YZ5; 5X1D; 5X1C T92078 SEQUENCE MSYQGKKNIPRITSDRLLIKGGKIVNDDQSFYADIYMEDGLIKQIGENLIVPGGVKTIEAHSRMVIPGGIDVHTRFQMPDQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGTSLLAAFDQWREWADSKSCCDYSLHVDISEWHKGIQEEMEALVKDHGVNSFLVYMAFKDRFQLTDCQIYEVLSVIRDIGAIAQVHAENGDIIAEEQQRILDLGITGPEGHVLSRPEEVEAEAVNRAITIANQTNCPLYITKVMSKSSAEVIAQARKKGTVVYGEPITASLGTDGSHYWSKNWAKAAAFVTSPPLSPDPTTPDFLNSLLSCGDLQVTGSAHCTFNTAQKAVGKDNFTLIPEGTNGTEERMSVIWDKAVVTGKMDENQFVAVTSTNAAKVFNLYPRKGRIAVGSDADLVIWDPDSVKTISAKTHNSSLEYNIFEGMECRGSPLVVISQGKIVLEDGTLHVTEGSGRYIPRKPFPDFVYKRIKARSRLAELRGVPRGLYDGPVCEVSVTPKTVTPASSAKTSPAKQQAPPVRNLHQSGFSLSGAQIDDNIPRRTTQRIVAPPGGRANITSLG T92078 DRUGINFO D05OFX Lacosamide Approved T16047 TARGETID T16047 T16047 FORMERID TTDS00120 T16047 UNIPROID Q25634_ONCVO T16047 TARGNAME Onchocerca Glutamate-gated chloride channel (Onchoc GluCl) T16047 GENENAME Onchoc GluCl T16047 TARGTYPE Successful T16047 SYNONYMS Glutamate-gated chloride channel T16047 FUNCTION As postsynaptic receptors within the crustacean stomatogastric ganglion. T16047 BIOCLASS Ion transport T16047 SEQUENCE MNSFPIVCWNLAFLILVVAKKKLKEQEIIQRTLKDYDWRVRPRGNNLSWPDTGGPVLVSVNIYLRSISKIDDVNMEYSAQFTFREEWNDARLGYERLADENTQVPPFVVLAASEQPDLTQQIWMPDTFFQNEKEARRHLIDKPNVLIRIHPDGQILYSVRLSLVLSCPMSLEYYPLDRQTCLIDLASYAYTTDDIKYEWKVKNPIQQKEGLRQSLPSFELQDVLTEYCTSKTNTGEYSCARVLLLLRREYRFSYYLIQLYIPCIMLVVVSWVSFWLDKDAVPARVSLGVTTLLTMTTQASGINAKLPPVSYIKAVDVWIGVCLAFIFGALLEYALVNYHGRQEFLKKEKKK T16047 DRUGINFO D09YHJ Ivermectin Approved T16047 DRUGINFO D05AWP Moxidectin Approved T08735 TARGETID T08735 T08735 FORMERID TTDS00505 T08735 UNIPROID M2DH_ASPFU T08735 TARGNAME Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH) T08735 GENENAME Asperg M2DH T08735 TARGTYPE Successful T08735 SYNONYMS MDH; M2DH T08735 FUNCTION Catalyzes the NAD(H)-dependent interconversion of D- fructose and D-mannitol in the mannitol metabolic pathway. Has a preference for NADH over NADPH. T08735 BIOCLASS Short-chain dehydrogenases reductase T08735 SEQUENCE MAPLKLNSRNLSQIAAAGGALVKIPTYQRGRAVKEGIVHIGVGGFHRAHLAVYIDQLMQKHGVNDYAICGVGLQPFDSAMRDALASQDHLYTLIERSAKGSFAHVIGSINSYLFAPDNREAVIAKMAHPDTKIVSLTITESGYYYNENTHELQSEHPDIQFDLDPANEKAPRTTFGFLYAGLTRRYQQGLKPFTVMSCDNMQKNGSITRHMLESFARLRNPEVAEWIAEEGAFPNAMVDRITPQTSETDKTALAEKFGIVDSWPVVTEPFTQWVIEDQFSDGRPPFEKVGVQVVKDVHAVEQFEKHKLRLLNGSHSALGYPGQLAGFQYVHEVMANPLFRKFVWQMMQEEVKPLLPEIPGVDIDEYCNTLIERFTNPTIMDQLPRICLNASGKIPQFIMPSIAEAIWETGPFRRLCFVAAAWFHYIKGVDDRGKPFEVVDPMREELQAKARAGGNDPSELLSIKSLFGDDLRNDERFLREITTAMNDIARDGIMKTLPKYIN T08735 DRUGINFO D0P7EK Mannitol Approved T05089 TARGETID T05089 T05089 FORMERID TTDNS00606 T05089 UNIPROID ANO1_HUMAN T05089 TARGNAME Calcium-dependent chloride channel anoctamin (ANO) T05089 GENENAME ANO1 T05089 TARGTYPE Successful T05089 SYNONYMS Tumoramplified and overexpressed sequence 2; Tumor-amplified and overexpressed sequence 2; Transmembrane protein 16A; TMEM16A; TAOS2; Oral cancer overexpressed protein 2; ORAOV2; Discovered on gastrointestinal stromal tumors protein 1; DOG1; Anoctamin1; Anoctamin-1 T05089 FUNCTION Required for the normal functioning of the interstitial cells of Cajal (ICCs) which generate electrical pacemaker activity in gastrointestinal smooth muscles. Acts as a major contributor to basal and stimulated chloride conductance in airway epithelial cells and plays an important role in tracheal cartilage development. Calcium-activated chloride channel (CaCC) which plays a role in transepithelial anion transport and smooth muscle contraction. T05089 SEQUENCE MRVNEKYSTLPAEDRSVHIINICAIEDIGYLPSEGTLLNSLSVDPDAECKYGLYFRDGRRKVDYILVYHHKRPSGNRTLVRRVQHSDTPSGARSVKQDHPLPGKGASLDAGSGEPPMDYHEDDKRFRREEYEGNLLEAGLELERDEDTKIHGVGFVKIHAPWNVLCREAEFLKLKMPTKKMYHINETRGLLKKINSVLQKITDPIQPKVAEHRPQTMKRLSYPFSREKQHLFDLSDKDSFFDSKTRSTIVYEILKRTTCTKAKYSMGITSLLANGVYAAAYPLHDGDYNGENVEFNDRKLLYEEWARYGVFYKYQPIDLVRKYFGEKIGLYFAWLGVYTQMLIPASIVGIIVFLYGCATMDENIPSMEMCDQRHNITMCPLCDKTCSYWKMSSACATARASHLFDNPATVFFSVFMALWAATFMEHWKRKQMRLNYRWDLTGFEEEEEAVKDHPRAEYEARVLEKSLKKESRNKEKRRHIPEESTNKWKQRVKTAMAGVKLTDKVKLTWRDRFPAYLTNLVSIIFMIAVTFAIVLGVIIYRISMAAALAMNSSPSVRSNIRVTVTATAVIINLVVIILLDEVYGCIARWLTKIEVPKTEKSFEERLIFKAFLLKFVNSYTPIFYVAFFKGRFVGRPGDYVYIFRSFRMEECAPGGCLMELCIQLSIIMLGKQLIQNNLFEIGIPKMKKLIRYLKLKQQSPPDHEECVKRKQRYEVDYNLEPFAGLTPEYMEMIIQFGFVTLFVASFPLAPLFALLNNIIEIRLDAKKFVTELRRPVAVRAKDIGIWYNILRGIGKLAVIINAFVISFTSDFIPRLVYLYMYSKNGTMHGFVNHTLSSFNVSDFQNGTAPNDPLDLGYEVQICRYKDYREPPWSENKYDISKDFWAVLAARLAFVIVFQNLVMFMSDFVDWVIPDIPKDISQQIHKEKVLMVELFMREEQDKQQLLETWMEKERQKDEPPCNHHNTKACPDSLGSPAPSHAYHGGVL T05089 DRUGINFO D09VXM Crofelemer Approved T05089 DRUGINFO D0Z3DY Benzbromarone Approved T05089 DRUGINFO D02DAJ DCDPC Investigative T05089 DRUGINFO D0R4WJ tannic acid Investigative T05089 DRUGINFO D0W1GH Ins(3,4,5,6)P4 Investigative T05089 DRUGINFO D0A2UX SITS Investigative T05089 DRUGINFO D0O6KR 9-anthroic acid Investigative T05089 DRUGINFO D08DQL NPPB Investigative T05089 DRUGINFO D0PW7B DIDS Investigative T96914 TARGETID T96914 T96914 FORMERID TTDR00076 T96914 UNIPROID Q8I0X3_PLAF7 T96914 TARGNAME Plasmodium DNA gyrase (Malaria gyrase) T96914 GENENAME Malaria gyrase T96914 TARGTYPE Successful T96914 SYNONYMS Malaria DNA gyrase subunit A T96914 FUNCTION Essential for replication and transcription in prokaryotes. Catalyses ATP-dependent DNA supercoiling activity. T96914 ECNUMBER EC 5.99.1.3 T96914 SEQUENCE MSFKFSIVFVLYLLFLLKFNKRFIFLKSEKITSYINTQIPNYSSSPPFFLKKEAKNNIKKCYFIKREGYRNIGTKNASNAFVLNFKSNRSTYTDNAFSCTSLCSEKKERKKVQDPYDLKAKKKEKTYELNDIKNNEKKKDDIVNASNDITNDKLDNINNNINESRKLIKGEYYDVEICEILSKSFLSYANFLILNRCLCDYRDGLKTVQRRIIWSMYEINKGIDKKGYKKCARIVGEVIGKYHPHGDKSVYDALVRLAQKHHNNNLLIKGYGNFGSVEYNAAAMRYTEAKISSFCYDILLDEINDENVEYIKNFDGNEREPKVLCSKIPLLLINGCSGIAVSILSSIPCHNLIDVANCCINFLINENIRDDELFHIIKGPDFSTGGIIISKYDILKNIYNSGKGNFEIRSNVFFEYIKNDKKVITKHINDLSSIENSDIDKLTKKIIIKNLPPNVKPNELIENIINLLNDKKNEHDNILLRIRDESEKEDMRIVLELKKHSQIEQIHNFLSYLFKYTNMQISYHCNFVCIGYENTYTQFSLKSFIKLWCNNRIKFIKTNYEIKNKNLQKQLNIIDLYLIIQNKILDIITFFQKNQNIEQIQLYLKNNFKLNPEQIKYILSIKLQKLINIKNIDFISQRNKIMHQIKLNDEIINNVQNIKNLIIQELIYIKNKYGIHNLNKQCIIPSTPKYKYSYINSEYHPNFSKNKQIIDTYNTVSTNDNNINHSNYTHDLPNTDNVTKDKNVVETNVHKNIHISSDISNNIKNSDKNSSLTKNQDSDNMMPYRNTYIDSLDNNMKDIYNNDEVLILITYGGYIKKIKINEKLKNHSNNIIKLSNVKYILKENEEKLNENNKRLKFNDLQKGNEQEKYKDNEQKLNNDIGHNINIQNNNNDNNNNNNDNNNVLLLNEEEYNSYKIKKSILVRNRDKILLTDNYNKAFLLNVYDLHLSSYDSKGTPINQIIHSSKNITGITKFQENKKYLIVCSENGKMKVINNDVFLKRKKKGIKLFKNKKNIYFSYCNFNDNCIVGTKNGYIIQFPLSSFKISKKNSLGNKCISLAKNDKVVDLLSYENNEKNLKNYKIIFVTKNGFGKMINLNELKIQKKKGKGHRIMKFKKSKTRKDNKKDIEKKQINAINNKDKDKDIPSNNDDNNILHNTKVDEFLGFKLYDMNKQNEKDILIMITDHAVLIRKNMSLLKEKNKKHSSQIYAKMNKINQLVYFDII T96914 DRUGINFO D04XDT Delafloxacin Meglumine Approved T30653 TARGETID T30653 T30653 FORMERID TTDS00133 T30653 UNIPROID PCAT1_HUMAN; PCAT2_HUMAN T30653 TARGNAME Acetyl-CoA:lyso-PAF acetyltransferase (PCAT) T30653 GENENAME LPCAT1; LPCAT2 T30653 TARGTYPE Successful T30653 SYNONYMS Lysophosphatidylcholine acyltransferase; LysoPC acyltransferase; LysoPAFAT; Lyso-PAF acetyltransferase; LPCAT; LPC acyltransferase; Acyltransferase-like; Acetyl-CoA:lyso-platelet-activating factor acetyltransferase; AYTL; 1-alkylglycerophosphocholine O-acetyltransferase; 1-acylglycerophosphocholine O-acyltransferase T30653 FUNCTION Possesses both acyltransferase and acetyltransferase activities. Mediates the conversion of 1-acyl-sn-glycero-3-phosphocholine (LPC) into phosphatidylcholine (PC), a major component of cell membranes and a PAF precursor. T30653 SEQUENCE MRLRGCGPRAAPASSAGASDARLLAPPGRNPFVHELRLSALQKAQVALMTLTLFPVRLLVAAAMMLLAWPLALVASLGSAEKEPEQPPALWRKVVDFLLKAIMRTMWFAGGFHRVAVKGRQALPTEAAILTLAPHSSYFDAIPVTMTMSSIVMKAESRDIPIWGTLIQYIRPVFVSRSDQDSRRKTVEEIKRRAQSNGKWPQIMIFPEGTCTNRTCLITFKPGAFIPGAPVQPVVLRYPNKLDTITWTWQGPGALEILWLTLCQFHNQVEIEFLPVYSPSEEEKRNPALYASNVRRVMAEALGVSVTDYTFEDCQLALAEGQLRLPADTCLLEFARLVRGLGLKPEKLEKDLDRYSERARMKGGEKIGIAEFAASLEVPVSDLLEDMFSLFDESGSGEVDLRECVVALSVVCRPARTLDTIQLAFKMYGAQEDGSVGEGDLSCILKTALGVAELTVTDLFRAIDQEEKGKITFADFHRFAEMYPAFAEEYLYPDQTHFESCAETSPAPIPNGFCADFSPENSDAGRKPVRKKLD T30653 DRUGINFO D0K8KX Quercetin Approved T30653 DRUGINFO D04AIT B-Lactams Approved T78173 TARGETID T78173 T78173 UNIPROID ERG1_CANAL T78173 TARGNAME Candida Squalene epoxidase (Candi ERG1) T78173 GENENAME Candi ERG1 T78173 TARGTYPE Successful T78173 SYNONYMS Candi Squalene monooxygenase; Candi Squalene epoxidase; Candi SE T78173 FUNCTION Catalyzes the stereospecific oxidation of squalene to (S)-2,3-epoxysqualene, and is considered to be a rate-limiting enzyme in steroid biosynthesis. T78173 SEQUENCE MSSVKYDAIIIGAGVIGPTIATAFARQGRKVLIVERDWSKPDRIVGELMQPAGIKALRELGMIKAINNIRAVDCTGYYIKYYDETITIPYPLKKDACITNPVKPVPDAVDGVNDKLDSDSTLNVDDWDFDERVRGAAFHHGDFLMNLRQICRDEPNVTAVEATVTKILRDPSDPNTVIGVQTKQPSGTVDYHAKLTISCDGIYSKFRKELSPTNVPTIGSYFIGLYLKNAELPAKGKGHVLLGGHAPALIYSVSPTETRVLCVYVSSKPPSAANDAVYKYLRDNILPAIPKETVPAFKEALEERKFRIMPNQYLSAMKQGSENHKGFILLGDSLNMRHPLTGGGMTVGLNDSVLLAKLLHPKFVEDFDDHQLIAKRLKTFHRKRKNLDAVINTLSISLYSLFAADKKPLRILRNGCFKYFQRGGECVNGPIGLLSGMLPFPMLLFNHFFSVAFYSVYLNFIERGLLGFPLALFEAFEVLFTAIVIFTPYLWNEIVR T78173 DRUGINFO D01AYJ Terbinafine Approved T78173 DRUGINFO D0B4DC Butenafine Approved T08378 TARGETID T08378 T08378 FORMERID TTDS00513 T08378 UNIPROID S23A2_HUMAN T08378 TARGNAME Solute carrier family 23 member 2 (SLC23A2) T08378 GENENAME SLC23A2 T08378 TARGTYPE Successful T08378 SYNONYMS hSVCT2; Yolksac permease-like molecule 2; YSPL2; SVCT2; SLC23A2; Nucleobase transporter-like 1 protein; Na(+)/L-ascorbic acid transporter 2; NBTL1; KIAA0238 T08378 FUNCTION Sodium/ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate. T08378 BIOCLASS Nucleobase ascorbate transporter T08378 SEQUENCE MMGIGKNTTSKSMEAGSSTEGKYEDEAKHPAFFTLPVVINGGATSSGEQDNEDTELMAIYTTENGIAEKSSLAETLDSTGSLDPQRSDMIYTIEDVPPWYLCIFLGLQHYLTCFSGTIAVPFLLADAMCVGYDQWATSQLIGTIFFCVGITTLLQTTFGCRLPLFQASAFAFLAPARAILSLDKWKCNTTDVSVANGTAELLHTEHIWYPRIREIQGAIIMSSLIEVVIGLLGLPGALLKYIGPLTITPTVALIGLSGFQAAGERAGKHWGIAMLTIFLVLLFSQYARNVKFPLPIYKSKKGWTAYKLQLFKMFPIILAILVSWLLCFIFTVTDVFPPDSTKYGFYARTDARQGVLLVAPWFKVPYPFQWGLPTVSAAGVIGMLSAVVASIIESIGDYYACARLSCAPPPPIHAINRGIFVEGLSCVLDGIFGTGNGSTSSSPNIGVLGITKVGSRRVIQCGAALMLALGMIGKFSALFASLPDPVLGALFCTLFGMITAVGLSNLQFIDLNSSRNLFVLGFSIFFGLVLPSYLRQNPLVTGITGIDQVLNVLLTTAMFVGGCVAFILDNTIPGTPEERGIRKWKKGVGKGNKSLDGMESYNLPFGMNIIKKYRCFSYLPISPTFVGYTWKGLRKSDNSRSSDEDSQATG T08378 DRUGINFO D0G3SH Ursodeoxycholic acid Approved T08378 DRUGINFO D07AHW Vitamin C Approved T54055 TARGETID T54055 T54055 FORMERID TTDI01989 T54055 UNIPROID LYVE1_HUMAN T54055 TARGNAME Hyaluronic acid receptor (LYVE1) T54055 GENENAME LYVE1 T54055 TARGTYPE Successful T54055 SYNONYMS Lymphatic vessel endothelial hyaluronic acid receptor 1; LYVE1; Extracellular link domaincontaining protein 1; Cell surface retention sequencebindingprotein 1; CRSBP1 T54055 FUNCTION Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes. T54055 SEQUENCE MARCFSLVLLLTSIWTTRLLVQGSLRAEELSIQVSCRIMGITLVSKKANQQLNFTEAKEACRLLGLSLAGKDQVETALKASFETCSYGWVGDGFVVISRISPNPKCGKNGVGVLIWKVPVSRQFAAYCYNSSDTWTNSCIPEIITTKDPIFNTQTATQTTEFIVSDSTYSVASPYSTIPAPTTTPPAPASTSIPRRKKLICVTEVFMETSTMSTETEPFVENKAAFKNEAAGFGGVPTALLVLALLFFGAAAGLGFCYVKRYVKAFPFTNKNQQKEMIETKVVKEEKANDSNPNEESKKTDKNPEESKSPSKTTVRCLEAEV T54055 DRUGINFO D07BSE Hyaluronate sodium Approved T54055 DRUGINFO D0DC1I RG-7356 Discontinued in Phase 1 T07035 TARGETID T07035 T07035 FORMERID TTDS00526 T07035 UNIPROID VIE2_HCMVA T07035 TARGNAME Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) T07035 GENENAME CMV IE2 mRNA T07035 TARGTYPE Successful T07035 SYNONYMS Viral transcription factor IE2 (mRNA); UL122 (mRNA); Protein UL122 (mRNA); IE2 (mRNA) T07035 FUNCTION Stimulates viral early and late gene expression and thus play a crucial role in the regulation of productive infection. In addition, activates quiescent cells to reenter the cell cycle and upregulates several E2F-responsive genes, which are responsible for pushing the cell into S phase. In S-phase, inhibits cellular DNA synthesis and blocks further cell cycle progression. T07035 BIOCLASS mRNA target T07035 SEQUENCE MESSAKRKMDPDNPDEGPSSKVPRPETPVTKATTFLQTMLRKEVNSQLSLGDPLFPELAEESLKTFEQVTEDCNENPEKDVLAELGDILAQAVNHAGIDSSSTGPTLTTHSCSVSSAPLNKPTPTSVAVTNTPLPGASATPELSPRKKPRKTTRPFKVIIKPPVPPAPIMLPLIKQEDIKPEPDFTIQYRNKIIDTAGCIVISDSEEEQGEEVETRGATASSPSTGSGTPRVTSPTHPLSQMNHPPLPDPLGRPDEDSSSSSSSSCSSASDSESESEEMKCSSGGGASVTSSHHGRGGFGGAASSSLLSCGHQSSGGASTGPRKKKSKRISELDNEKVRNIMKDKNTPFCTPNVQTRRGRVKIDEVSRMFRNTNRSLEYKNLPFTIPSMHQVLDEAIKACKTMQVNNKGIQIIYTRNHEVKSEVDAVRCRLGTMCNLALSTPFLMEHTMPVTHPPEVAQRTADACNEGVKAAWSLKELHTHQLCPRSSDYRNMIIHAATPVDLLGALNLCLPLMQKFPKQVMVRIFSTNQGGFMLPIYETAAKAYAVGQFEQPTETPPEDLDTLSLAIEAAIQDLRNKSQ T07035 DRUGINFO D0ID4Z Fomivirsen sodium Approved T07035 DRUGINFO D00XFY ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine Investigative T07035 DRUGINFO D01LAP ISIS 2922 + Ganciclovir Investigative T07035 DRUGINFO D02DXY ISIS 12659 Investigative T07035 DRUGINFO D04WRK ISIS 2921 Investigative T07035 DRUGINFO D06REI ISIS 3246 Investigative T07035 DRUGINFO D08NVD ISIS 2919 Investigative T07035 DRUGINFO D09JXY ISIS 2920 Investigative T07035 DRUGINFO D0BY9R ISIS 2918 Investigative T07035 DRUGINFO D0HV7V ISIS 12660 Investigative T07035 DRUGINFO D0P0JE ISIS 3300 Investigative T52771 TARGETID T52771 T52771 FORMERID TTDNS00614 T52771 UNIPROID A0A1Q4HQH4_9MYCO T52771 TARGNAME Mycobacterium Proton pump (MycB Prop) T52771 GENENAME MycB Prop T52771 TARGTYPE Successful T52771 SYNONYMS Nicotinamide nucleotide transhydrogenase subunit beta; NAD(P) transhydrogenase subunit beta T52771 FUNCTION The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane. T52771 SEQUENCE MNYLVTVLYIISFALFIYGLMGLTGPKTAVRGNLIAAVGMAIAVAATLIKIRHTESWVLIIAGLVVGVALGVPPARYTKMTAMPQLVAFFNGVGGGTVALIALSEFIETKGFSAFQHGESPTVHIVVASLFAAIIGSISFWGSIIAFGKLQEIISGSPIGFGKAQQPINLLLLAAAVAAAVVIGLGAHPGTGGVALWWMIGLLAAAGVLGLMVVLPIGGADMPVVISLLNAMTGLSAAAAGLALNNTAMIVAGMIVGASGSILTNLMAKAMNRSIPAIVAGGFGGGGVAPSGGGGGDKHVKATSAADAAIQMAYANQVIVVPGYGLAVAQAQHAVKDMASLLEDKGVPVKYAIHPVAGRMPGHMNVLLAEAEVDYDAMKDMDDINDEFARTDVAIVIGANDVTNPAARNEQSSPIYGMPILNVDRAKSVIVLKRSMNSGFAGIDNPLFYADGTTMLFGDAKKSVTEVAEELKAL T52771 DRUGINFO D0Y4QG Bedaquiline Approved T63598 TARGETID T63598 T63598 FORMERID TTDI01884 T63598 UNIPROID E0VDF4_PEDHC T63598 TARGNAME Pediculus humanus Nicotinic acetylcholine receptor (Pedhc nAChR) T63598 GENENAME Pedhc nAChR T63598 TARGTYPE Successful T63598 SYNONYMS Acetylcholine receptor protein alpha 1, 2, 3, 4invertebrate, putative; Acetylcholine receptor protein alpha 1, 2, 3, 4 invertebrate, putative T63598 FUNCTION Mediates the fast actions ofacetylcholine (ACh) in the nervous system and at neuromuscular junctions. T63598 SEQUENCE MCLCLCLTPFLDIPGFKPVQMEANPDAKRLYDDLLSNYNRLIRPVVNNTETLTVRLGLKLSQLIEVNLKSQVMTTNVWVEQKWTDYKLRWNPEEYGGVEMLYVPSEHIWLPDIVLYNNADGNYEVTLMTKATLNYNGEVYWKPPAIYKSSCEINVLYFPFDEQSCYMKFGSWTYHGYQVDLKHMDQKPGTNLVPVGVDLKEFYLSVEWDILEVPARKNEEYYPCCAEPYSDITFNLKMRRKTLFYTVNLIIPCVGITFLTVLVFYLPSDSGEKVTLTVSILLSLTVFFLLLAEIIPPTSLAVPLLGKYLLFTMMLVTLSIFITVCVLNIYFRSPSTHKMSPWVRNVFLNFIPRLLMMRRPPYSVRRDGYDDSGDNGYASALDYRDGIGEPFPPELKGSPEFESVTTVCKSTFGTESDDNLGTTFRHAQPSDSENIIPRNLSSDVLSALQGVCFIAQHIRNADKDNEVIEDWKYVSMVLDRFFLWVFTLACIGGTCAIIFQAPSLYDQRIPIDQEISLIQFGKIFLNIPREQNSD T63598 DRUGINFO D09WCM Spinosad Approved T60708 TARGETID T60708 T60708 UNIPROID CO5_HUMAN T60708 TARGNAME Complement C5 (CO5) T60708 GENENAME C5 T60708 TARGTYPE Successful T60708 SYNONYMS C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 T60708 FUNCTION Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. T60708 BIOCLASS Complement system T60708 SEQUENCE MGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYPDKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPITYDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHIGIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGYKNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVTFDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATPLFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASFVLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGEHLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRLLVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWVALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANADDSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLVPRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQLKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTVLPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFPYRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFYVFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTAFALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEARENSLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDKTHPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLNLKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHKGALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLKIDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLKALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHRPDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYAYKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIMGKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC T60708 DRUGINFO D0NW7Y Ravulizumab Approved T60708 DRUGINFO D0W8BO Zilucoplan Approved T60708 DRUGINFO D4XBR9 Pozelimab Approved T60708 DRUGINFO D75AZJ Avacincaptad pegol Approved T60708 DRUGINFO D1O9XQ SKY59 Phase 3 T60708 DRUGINFO D2RTQ0 SB12 Phase 3 T60708 DRUGINFO DCOP72 Nomacopan Phase 3 T60708 DRUGINFO DH3YK4 Zimura Phase 3 T60708 DRUGINFO DRQ18X ABP959 Phase 3 T60708 DRUGINFO DY14KR ALXN1720 Phase 3 T60708 DRUGINFO DYG0W5 Coversin Phase 3 T60708 DRUGINFO D04HOT LFG-316 Phase 2 T60708 DRUGINFO D05YWJ IFX-1 Phase 2 T60708 DRUGINFO D0J4PM NNC-0151-0000-0000 Phase 2 T60708 DRUGINFO D76INB Tesidolumab Phase 2 T60708 DRUGINFO D08FMR ARC-1905 Phase 1 T60708 DRUGINFO D0H0ZV MEDI7814 Phase 1 T60708 DRUGINFO D0H6VZ REV-576 Phase 1 T60708 DRUGINFO D0P6MB Pexelizumab Discontinued in Phase 3 T60708 DRUGINFO D0H0ZU MP-435 Discontinued in Phase 2 T60708 DRUGINFO D0B1DA SAND-5 Preclinical T60708 DRUGINFO D0I1BX CGS-32359 Terminated T19414 TARGETID T19414 T19414 FORMERID TTDR01242 T19414 UNIPROID FIBA_HUMAN; FIBB_HUMAN T19414 TARGNAME Fibrin (FG) T19414 GENENAME FGA; FGB T19414 TARGTYPE Successful T19414 SYNONYMS Fibrinogen (31-44) T19414 FUNCTION A fibrous, non-globular protein involved in the clotting of blood. Formed by the action of the protease thrombin on fibrinogen which causes it to polymerize. T19414 SEQUENCE MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDWNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSANNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSCRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSSGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTWNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNVSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTKEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFSVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQRGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSHNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENGVVWVSFRGADYSLRAVRMKIRPLVTQ T19414 DRUGINFO D0DV4J Beriplast-P Approved T19414 DRUGINFO D0G3EC Baquting Approved T19414 DRUGINFO D0J0KD Fibrinolysin Approved T19414 DRUGINFO D0KT3X Thrombin/fibrinogen matrix patch Approved T19414 DRUGINFO D0M3AH TachoComb Approved T19414 DRUGINFO D09KRV Adhexil Phase 3 T19414 DRUGINFO D0O9UZ Alfimeprase Phase 3 T19414 DRUGINFO D04BHS Recombinant batroxobin Phase 2 T19414 DRUGINFO D09BAP KUR-212 Phase 2 T19414 DRUGINFO D0L9XS Plasmin Phase 2 T19414 DRUGINFO D0W4AR KUR-211 Phase 2 T19414 DRUGINFO D0YQ3M EP-2104R Discontinued in Phase 2 T19414 DRUGINFO D09WVR FX-107 Preclinical T07569 TARGETID T07569 T07569 UNIPROID CY1_HUMAN-CYB_HUMAN T07569 TARGNAME Electron transport complex III (Complex III) T07569 GENENAME CYC1-MT-CYB T07569 TARGTYPE Successful T07569 SYNONYMS Cytochrome bc1 complex; CoQH2-cytochrome c reductase T07569 FUNCTION Produces a transmembrane proton electrochemical gradient as a result of the redox reactions T07569 SEQUENCE MTPMRKTNPLMKLINHSFIDLPTPSNISAWWNFGSLLGACLILQITTGLFLAMHYSPDASTAFSSIAHITRDVNYGWIIRYLHANGASMFFICLFLHIGRGLYYGSFLYSETWNIGIILLLATMATAFMGYVLPWGQMSFWGATVITNLLSAIPYIGTDLVQWIWGGYSVDSPTLTRFFTFHFILPFIIAALATLHLLFLHETGSNNPLGITSHSDKITFHPYYTIKDALGLLLFLLSLMTLTLFSPDLLGDPDNYTLANPLNTPPHIKPEWYFLFAYTILRSVPNKLGGVLALLLSILILAMIPILHMSKQQSMMFRPLSQSLYWLLAADLLILTWIGGQPVSYPFTIIGQVASVLYFTTILILMPTISLIENKMLKWAMAAAAASLRGVVLGPRGAGLPGARARGLLCSARPGQLPLRTPQAVALSSKSGLSRGRKVMLSALGMLAAGGAGLAMALHSAVSASDLELHPPSYPWSHRGLLSSLDHTSIRRGFQVYKQVCASCHSMDFVAYRHLVGVCYTEDEAKELAAEVEVQDGPNEDGEMFMRPGKLFDYFPKPYPNSEAARAANNGALPPDLSYIVRARHGGEDYVFSLLTGYCEPPTGVSLREGLYFNPYFPGQAIAMAPPIYTDVLEFDDGTPATMSQIAKDVCTFLRWASEPEHDHRKRMGLKMLMMMALLVPLVYTIKRHKWSVLKSRKLAYRPPK T07569 DRUGINFO D07TWN Tafenoquine Approved T30028 TARGETID T30028 T30028 FORMERID TTDS00483 T30028 UNIPROID VAMP1_HUMAN; VAMP2_HUMAN T30028 TARGNAME Vesicle-associated membrane protein (VAMP) T30028 GENENAME VAMP1; VAMP2 T30028 TARGTYPE Successful T30028 SYNONYMS VAMP; Synaptobrevin; SYB T30028 FUNCTION Involved in the targeting and/or fusion of transport vesicles to their target membrane. T30028 SEQUENCE MSAPAQPPAEGTEGTAPGGGPPGPPPNMTSNRRLQQTQAQVEEVVDIIRVNVDKVLERDQKLSELDDRADALQAGASQFESSAAKLKRKYWWKNCKMMIMLGAICAIIVVVIVIYFFT T30028 DRUGINFO D02FXK Botulinum Toxin Type B Approved T27495 TARGETID T27495 T27495 UNIPROID F13_VAR67 T27495 TARGNAME Variola virus Envelope phospholipase F13 (VARV p37) T27495 GENENAME VARV p37 T27495 TARGTYPE Successful T27495 SYNONYMS Variola 37 kDa protein; VARV p37K; VARV Palmitoylated EV membrane protein; VARV Envelope protein F13 T27495 FUNCTION Envelope protein associated with the inner side of the enveloped virion (EV) membrane. T27495 SEQUENCE MWPFTSAPAGAKCRLVETLPENMDFRSDHLTTFECFNEIITLAKKYIYIASFCCNPLSTTRGALIFDKLKEASEKGIKIIVLLDERGKRNLGELQSHCPDINFITVNIDKKNNVGLLLGCFWVSDDERCYVGNASFTGGSIHTIKTLGVYSDYPPLATDLRRRFDTFKAFNSVKNSWLNLYSSACCLPVSTAYHIKNPIGGVFFTDSPEHLLGYSRDLDTDVVIDKLRSAKTSIDIEHLAIVPTTRVDGNSYYWPDIYNSIIEAAINRGVKIRLLVGNWDKNDVYSMATAESLDALCVQNDLSVKVFTIQNNTKLLIVDDEYVHITSANFDGTHYQNHGFVSFNSIDKQLVSEAKKIFERDWVSSHSKSLKI T27495 DRUGINFO D0MD8D Tecovirimat Approved T23459 TARGETID T23459 T23459 UNIPROID VGP3_EBVP3 T23459 TARGNAME Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1) T23459 GENENAME EBV BLLF1 T23459 TARGTYPE Successful T23459 SYNONYMS Membrane antigen; MA; Envelope glycoprotein GP340 T23459 FUNCTION Responsible for EBV binding to the CR2 receptor on human B-cells. T23459 SEQUENCE MEAALLVCQYTIQSLIQLTRDDPGFFNVEILEFPFYPACNVCTADVNATINFDVGGKKHKLNLDFGLLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINITTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLNTTGFAAPNTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAGTTSGASPVTPSPSPRDNGTESKAPDMTSPTSAVTTPTPNATSPTPAVTTPTPNATSPTLGKTSPTSAVTTPTPNATSPTPAVTTPTPNATIPTLGKTSPTSAVTTPTPNATSPTVGETSPQANTTNHTLGGTSSTPVVTSPPKNATSAVTTGQHNITSSSTSSMSLRPSSISETLSPSTSDNSTSHMPLLTSAHPTGGENITQVTPASTSTHHVSTSSPAPRPGTTSQASGPGNSSTSTKPGEVNVTKGTPPKNATSPQAPSGQKTAVPTVTSTGGKANSTTGGKHTTGHGARTSTEPTTDYGGDSTTPRTRYNATTYLPPSTSSKLRPRWTFTSPPVTTAQATVPVPPTSQPRFSNLSMLVLQWASLAVLTLLLLLVMADCAFRRNLSTSHTYTTPPYDDAETYV T23459 DRUGINFO D00AOJ Docosanol Approved T64258 TARGETID T64258 T64258 FORMERID TTDR01215 T64258 UNIPROID MAP1A_HUMAN; MAP1B_HUMAN T64258 TARGNAME Microtubule-associated protein (MAP) T64258 GENENAME MAP1A; MAP1B T64258 TARGTYPE Successful T64258 SYNONYMS Microtubule-associated protein 1; MAP-1 T64258 FUNCTION Binds to the tubulin subunits that make up microtubules to regulate their stability. Invovled in stabilizing and destabilizing microtubules, guiding microtubules towards specific cellular locations, cross-linking microtubules and mediating the interactions of microtubules with other proteins in the cell. T64258 SEQUENCE MDGVAEFSEYVSETVDVPSPFDLLEPPTSGGFLKLSKPCCYIFPGGRGDSALFAVNGFNILVDGGSDRKSCFWKLVRHLDRIDSVLLTHIGADNLPGINGLLQRKVAELEEEQSQGSSSYSDWVKNLISPELGVVFFNVPEKLRLPDASRKAKRSIEEACLTLQHLNRLGIQAEPLYRVVSNTIEPLTLFHKMGVGRLDMYVLNPVKDSKEMQFLMQKWAGNSKAKTGIVLPNGKEAEISVPYLTSITALVVWLPANPTEKIVRVLFPGNAPQNKILEGLEKLRHLDFLRYPVATQKDLASGAVPTNLKPSKIKQRADSKESLKATTKTAVSKLAKREEVVEEGAKEARSELAKELAKTEKKAKESSEKPPEKPAKPERVKTESSEALKAEKRKLIKDKVGKKHLKEKISKLEEKKDKEKKEIKKERKELKKDEGRKEEKKDAKKEEKRKDTKPELKKISKPDLKPFTPEVRKTLYKAKVPGRVKIDRSRAIRGEKELSSEPQTPPAQKGTVPLPTISGHRELVLSSPEDLTQDFEEMKREERALLAEQRDTGLGDKPFPLDTAEEGPPSTAIQGTPPSVPGLGQEEHVMKEKELVPEVPEEQGSKDRGLDSGAETEEEKDTWEEKKQREAERLPDRTEAREESEPEVKEDVIEKAELEEMEEVHPSDEEEEDATKAEGFYQKHMQEPLKVTPRSREAFGGRELGLQGKAPEKETSLFLSSLTTPAGATEHVSYIQDETIPGYSETEQTISDEEIHDEPEERPAPPRFHTSTYDLPGPEGAGPFEASQPADSAVPATSGKVYGTPETELTYPTNIVAAPLAEEEHVSSATSITECDKLSSFATSVAEDQSVASLTAPQTEETGKSSLLLDTVTSIPSSRTEATQGLDYVPSAGTISPTSSLEEDKGFKSPPCEDFSVTGESEKRGEIIGKGLSGERAVEEEEEETANVEMSEKLCSQYGTPVFSAPGHALHPGEPALGEAEERCLSPDDSTVKMASPPPSGPPSATHTPFHQSPVEEKSEPQDFQEADSWGDTKRTPGVGKEDAAEETVKPGPEEGTLEKEEKVPPPRSPQAQEAPVNIDEGLTGCTIQLLPAQDKAIVFEIMEAGEPTGPILGAEALPGGLRTLPQEPGKPQKDEVLRYPDRSLSPEDAESLSVLSVPSPDTANQEPTPKSPCGLTEQYLHKDRWPEVSPEDTQSLSLSEESPSKETSLDVSSKQLSPESLGTLQFGELNLGKEEMGHLMQAEDTSHHTAPMSVPEPHAATASPPTDGTTRYSAQTDITDDSLDRKSPASSFSHSTPSGNGKYLPGAITSPDEHILTPDSSFSKSPESLPGPALEDIAIKWEDKVPGLKDRTSEQKKEPEPKDEVLQQKDKTLEHKEVVEPKDTAIYQKDEALHVKNEAVKQQDKALEQKGRDLEQKDTALEQKDKALEPKDKDLEEKDKALEQKDKIPEEKDKALEQKDTALEQKDKALEPKDKDLEQKDRVLEQKEKIPEEKDKALDQKVRSVEHKAPEDTVAEMKDRDLEQTDKAPEQKHQAQEQKDKVSEKKDQALEQKYWALGQKDEALEQNIQALEENHQTQEQESLVQEDKTRKPKMLEEKSPEKVKAMEEKLEALLEKTKALGLEESLVQEGRAREQEEKYWRGQDVVQEWQETSPTREEPAGEQKELAPAWEDTSPEQDNRYWRGREDVALEQDTYWRELSCERKVWFPHELDGQGARPHYTEERESTFLDEGPDDEQEVPLREHATRSPWASDFKDFQESSPQKGLEVERWLAESPVGLPPEEEDKLTRSPFEIISPPASPPEMVGQRVPSAPGQESPIPDPKLMPHMKNEPTTPSWLADIPPWVPKDRPLPPAPLSPAPGPPTPAPESHTPAPFSWGTAEYDSVVAAVQEGAAELEGGPYSPLGKDYRKAEGEREEEGRAEAPDKSSHSSKVPEASKSHATTEPEQTEPEQREPTPYPDERSFQYADIYEQMMLTGLGPACPTREPPLGAAGDWPPCLSTKEAAAGRNTSAEKELSSPISPKSLQSDTPTFSYAALAGPTVPPRPEPGPSMEPSLTPPAVPPRAPILSKGPSPPLNGNILSCSPDRRSPSPKESGRSHWDDSTSDSELEKGAREQPEKEAQSPSPPHPIPMGSPTLWPETEAHVSPPLDSHLGPARPSLDFPASAFGFSSLQPAPPQLPSPAEPRSAPCGSLAFSGDRALALAPGPPTRTRHDEYLEVTKAPSLDSSLPQLPSPSSPGAPLLSNLPRPASPALSEGSSSEATTPVISSVAERFSPSLEAAEQESGELDPGMEPAAHSLWDLTPLSPAPPASLDLALAPAPSLPGDMGDGILPCHLECSEAATEKPSPFQVPSEDCAANGPTETSPNPPGPAPAKAENEEAAACPAWERGAWPEGAERSSRPDTLLSPEQPVCPAGGSGGPPSSASPEVEAGPQGCATEPRPHRGELSPSFLNPPLPPSIDDRDLSTEEVRLVGRGGRRRVGGPGTTGGPCPVTDETPPTSASDSGSSQSDSDVPPETEECPSITAEAALDSDEDGDFLPVDKAGGVSGTHHPRPGHDPPPLPQPDPRPSPPRPDVCMADPEGLSSESGRVERLREKEKVQGRVGRRAPGKAKPASPARRLDLRGKRSPTPGKGPADRASRAPPRPRSTTSQVTPAEEKDGHSPMSKGLVNGLKAGPMALSSKGSSGAPVYVDLAYIPNHCSGKTADLDFFRRVRASYYVVSGNDPANGEPSRAVLDALLEGKAQWGENLQVTLIPTHDTEVTREWYQQTHEQQQQLNVLVLASSSTVVMQDESFPACKIEF T64258 DRUGINFO D02LZB Demecolcine Approved T64258 DRUGINFO D06EFW RG7304 Phase 1 T64258 DRUGINFO D07KNG Costunolide Investigative T51282 TARGETID T51282 T51282 UNIPROID ROCK1_HUMAN T51282 TARGNAME Rho-associated protein kinase 1 (ROCK1) T51282 GENENAME ROCK1 T51282 TARGTYPE Successful T51282 SYNONYMS Rok; Rho-associated, coiled-coil containing protein kinase 1; Rho-associated kinase 1; Rho kinase; ROCK1; ROCK; P160ROCK; P160(rock); P160 ROCK-1; Let-502 kinase T51282 FUNCTION Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. Phosphorylates FHOD1 and acts synergistically with it to promote SRC-dependent non-apoptotic plasma membrane blebbing. Phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. Acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Required for centrosome positioning and centrosome-dependent exit from mitosis. Plays a role in terminal erythroid differentiation. May regulate closure of the eyelids and ventral body wall by inducing the assembly of actomyosin bundles. Promotes keratinocyte terminal differentiation. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization. T51282 BIOCLASS Kinase T51282 SEQUENCE MSTGDSFETRFEKMDNLLRDPKSEVNSDCLLDGLDALVYDLDFPALRKNKNIDNFLSRYKDTINKIRDLRMKAEDYEVVKVIGRGAFGEVQLVRHKSTRKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWARFYTAEVVLALDAIHSMGFIHRDVKPDNMLLDKSGHLKLADFGTCMKMNKEGMVRCDTAVGTPDYISPEVLKSQGGDGYYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMNHKNSLTFPDDNDISKEAKNLICAFLTDREVRLGRNGVEEIKRHLFFKNDQWAWETLRDTVAPVVPDLSSDIDTSNFDDLEEDKGEEETFPIPKAFVGNQLPFVGFTYYSNRRYLSSANPNDNRTSSNADKSLQESLQKTIYKLEEQLHNEMQLKDEMEQKCRTSNIKLDKIMKELDEEGNQRRNLESTVSQIEKEKMLLQHRINEYQRKAEQENEKRRNVENEVSTLKDQLEDLKKVSQNSQLANEKLSQLQKQLEEANDLLRTESDTAVRLRKSHTEMSKSISQLESLNRELQERNRILENSKSQTDKDYYQLQAILEAERRDRGHDSEMIGDLQARITSLQEEVKHLKHNLEKVEGERKEAQDMLNHSEKEKNNLEIDLNYKLKSLQQRLEQEVNEHKVTKARLTDKHQSIEEAKSVAMCEMEKKLKEEREAREKAENRVVQIEKQCSMLDVDLKQSQQKLEHLTGNKERMEDEVKNLTLQLEQESNKRLLLQNELKTQAFEADNLKGLEKQMKQEINTLLEAKRLLEFELAQLTKQYRGNEGQMRELQDQLEAEQYFSTLYKTQVKELKEEIEEKNRENLKKIQELQNEKETLATQLDLAETKAESEQLARGLLEEQYFELTQESKKAASRNRQEITDKDHTVSRLEEANSMLTKDIEILRRENEELTEKMKKAEEEYKLEKEEEISNLKAAFEKNINTERTLKTQAVNKLAEIMNRKDFKIDRKKANTQDLRKKEKENRKLQLELNQEREKFNQMVVKHQKELNDMQAQLVEECAHRNELQMQLASKESDIEQLRAKLLDLSDSTSVASFPSADETDGNLPESRIEGWLSVPNRGNIKRYGWKKQYVVVSSKKILFYNDEQDKEQSNPSMVLDIDKLFHVRPVTQGDVYRAETEEIPKIFQILYANEGECRKDVEMEPVQQAEKTNFQNHKGHEFIPTLYHFPANCDACAKPLWHVFKPPPALECRRCHVKCHRDHLDKKEDLICPCKVSYDVTSARDMLLLACSQDEQKKWVTHLVKKIPKNPPSGFVRASPRTLSTRSTANQSFRKVVKNTSGKTS T51282 DRUGINFO D04WYX Netarsudil Approved T51282 DRUGINFO D00UET SAR-407899 Phase 2 T51282 DRUGINFO D08ZPO H-1152 Phase 2 T51282 DRUGINFO D08JXW INS-117548 Phase 1 T51282 DRUGINFO D02ZQS GSK269962A Clinical trial T51282 DRUGINFO D08YGE PMID28048944-Compound-21 Patented T51282 DRUGINFO D0S0VF PMID28048944-Compound-20 Patented T51282 DRUGINFO D0CW9Q PMID28048944-Compound-19 Patented T51282 DRUGINFO D0DO1U PMID28048944-Compound-3 Patented T51282 DRUGINFO D0QC6H PMID28048944-Compound-7 Patented T51282 DRUGINFO D0QX0O PMID28048944-Compound-4 Patented T51282 DRUGINFO D0V6OK PMID28048944-Compound-5 Patented T51282 DRUGINFO D0VK6S PMID28048944-Compound-6 Patented T51282 DRUGINFO D0YV6S PMID28048944-Compound-2 Patented T51282 DRUGINFO D00ZNS CDE-5110 Terminated T51282 DRUGINFO D01WIH (4-Fluoro-phenyl)-(9H-purin-6-yl)-amine Investigative T51282 DRUGINFO D03KKR Fasudil Investigative T51282 DRUGINFO D07UBK AS-1892802 Investigative T51282 DRUGINFO D02RYE AMA-237 Investigative T51282 DRUGINFO D02WRE ATS-907 Investigative T51282 DRUGINFO D0J2GG SR-3850 Investigative T51282 DRUGINFO D0L1UK Acid-activated omeprazole Investigative T51282 DRUGINFO D0X8UW TRN-101 Investigative T51282 DRUGINFO D0I1FJ SB-747651A Investigative T51282 DRUGINFO D0R3MO PMID20684608C35 Investigative T51282 DRUGINFO D0V0KA PMID20462760C22 Investigative T51282 DRUGINFO D01YWE PMID19364658C33 Investigative T51282 DRUGINFO D03CPB RKI-1447 Investigative T51282 DRUGINFO D0G2VC KT-5720 Investigative T51282 DRUGINFO D0M5FF Ro31-8220 Investigative T51282 DRUGINFO D0N6ES KN-62 Investigative T51282 DRUGINFO D0B9BU CI-1040 Investigative T51282 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T51282 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T51282 DRUGINFO D0L8HO RO-316233 Investigative T36053 TARGETID T36053 T36053 FORMERID TTDI03425 T36053 UNIPROID SO4C1_HUMAN T36053 TARGNAME Organic anion transporter M1 (SLCO4C1) T36053 GENENAME SLCO4C1 T36053 TARGTYPE Successful T36053 SYNONYMS Solute carrier organic anion transporter family member 4C1; Solute carrier family 21 member 20; OATPX; OATP4C1; OATP-M1; OATP-H T36053 FUNCTION Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ouabain. Involved in the uptake of the dipeptidyl peptidase-4 inhibitor sitagliptin and hence may play a role in its transport into and out of renal proximal tubule cells. May be involved in the first step of the transport pathway of digoxin and various compounds into the urine in the kidney. May be involved in sperm maturation by enabling directed movement of organic anions and compounds within or between cells. This ion-transporting process is important to maintain the strict epididymal homeostasis necessary for sperm maturation. May have a role in secretory functions since seminal vesicle epithelial cells are assumed to secrete proteins involved in decapacitation by modifying surface proteins to facilitate the acquisition of the ability to fertilize the egg. T36053 SEQUENCE MKSAKGIENLAFVPSSPDILRRLSASPSQIEVSALSSDPQRENSQPQELQKPQEPQKSPEPSLPSAPPNVSEEKLRSLSLSEFEEGSYGWRNFHPQCLQRCNTPGGFLLHYCLLAVTQGIVVNGLVNISISTVEKRYEMKSSLTGLISSSYDISFCLLSLFVSFFGERGHKPRWLAFAAFMIGLGALVFSLPQFFSGEYKLGSLFEDTCVTTRNSTSCTSSTSSLSNYLYVFILGQLLLGAGGTPLYTLGTAFLDDSVPTHKSSLYIGTGYAMSILGPAIGYVLGGQLLTIYIDVAMGESTDVTEDDPRWLGAWWIGFLLSWIFAWSLIIPFSCFPKHLPGTAEIQAGKTSQAHQSNSNADVKFGKSIKDFPAALKNLMKNAVFMCLVLSTSSEALITTGFATFLPKFIENQFGLTSSFAATLGGAVLIPGAALGQILGGFLVSKFRMTCKNTMKFALFTSGVALTLSFVFMYAKCENEPFAGVSESYNGTGELGNLIAPCNANCNCSRSYYYPVCGDGVQYFSPCFAGCSNPVAHRKPKVYYNCSCIERKTEITSTAETFGFEAKAGKCETHCAKLPIFLCIFFIVIIFTFMAGTPITVSILRCVNHRQRSLALGIQFMVLRLLGTIPGPIIFGFTIDSTCILWDINDCGIKGACWIYDNIKMAHMLVAISVTCKVITMFFNGFAIFLYKPPPSATDVSFHKENAVVTNVLAEQDLNKIVKEG T36053 DRUGINFO D02OZE Digoxin Approved T41263 TARGETID T41263 T41263 FORMERID TTDNS00579 T41263 UNIPROID TS1R1_HUMAN; TS1R2_HUMAN; TS1R3_HUMAN T41263 TARGNAME Taste receptor (TASR) T41263 GENENAME TAS1R1; TAS1R2; TAS1R3 T41263 TARGTYPE Successful T41263 SYNONYMS TR; Sweet taste receptor; G-protein coupled receptor T41263 FUNCTION Putative taste receptor. TAS1R1/TAS1R3 responds to the umami taste stimulus (the taste of monosodium glutamate). TAS1R2/TAS1R3 recognizes diverse natural and synthetic sweeteners. TAS1R3 is essential for the recognition and response to the disaccharide trehalose (By similarity). Sequence differences within and between species can significantly influence the selectivity and specificity of taste responses. T41263 SEQUENCE MLLCTARLVGLQLLISCCWAFACHSTESSPDFTLPGDYLLAGLFPLHSGCLQVRHRPEVTLCDRSCSFNEHGYHLFQAMRLGVEEINNSTALLPNITLGYQLYDVCSDSANVYATLRVLSLPGQHHIELQGDLLHYSPTVLAVIGPDSTNRAATTAALLSPFLVPMISYAASSETLSVKRQYPSFLRTIPNDKYQVETMVLLLQKFGWTWISLVGSSDDYGQLGVQALENQATGQGICIAFKDIMPFSAQVGDERMQCLMRHLAQAGATVVVVFSSRQLARVFFESVVLTNLTGKVWVASEAWALSRHITGVPGIQRIGMVLGVAIQKRAVPGLKAFEEAYARADKKAPRPCHKGSWCSSNQLCRECQAFMAHTMPKLKAFSMSSAYNAYRAVYAVAHGLHQLLGCASGACSRGRVYPWQLLEQIHKVHFLLHKDTVAFNDNRDPLSSYNIIAWDWNGPKWTFTVLGSSTWSPVQLNINETKIQWHGKDNQVPKSVCSSDCLEGHQRVVTGFHHCCFECVPCGAGTFLNKSDLYRCQPCGKEEWAPEGSQTCFPRTVVFLALREHTSWVLLAANTLLLLLLLGTAGLFAWHLDTPVVRSAGGRLCFLMLGSLAAGSGSLYGFFGEPTRPACLLRQALFALGFTIFLSCLTVRSFQLIIIFKFSTKVPTFYHAWVQNHGAGLFVMISSAAQLLICLTWLVVWTPLPAREYQRFPHLVMLECTETNSLGFILAFLYNGLLSISAFACSYLGKDLPENYNEAKCVTFSLLFNFVSWIAFFTTASVYDGKYLPAANMMAGLSSLSSGFGGYFLPKCYVILCRPDLNSTEHFQASIQDYTRRCGST T41263 DRUGINFO D0KN2M Cynarin Approved T39676 TARGETID T39676 T39676 FORMERID TTDI03395 T39676 UNIPROID S47A1_HUMAN T39676 TARGNAME Solute carrier family 47 member 1 (SLC47A1) T39676 GENENAME SLC47A1 T39676 TARGTYPE Successful T39676 SYNONYMS hMATE-1; Multidrug and toxin extrusion protein 1; MATE1; MATE-1 T39676 FUNCTION Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport paraquat (PQ or N,N-dimethyl-4-4'-bipiridinium); a widely used herbicid. Responsible for the secretion of cationic drugs across the brush border membranes. T39676 SEQUENCE MEAPEEPAPVRGGPEATLEVRGSRCLRLSAFREELRALLVLAGPAFLVQLMVFLISFISSVFCGHLGKLELDAVTLAIAVINVTGVSVGFGLSSACDTLISQTYGSQNLKHVGVILQRSALVLLLCCFPCWALFLNTQHILLLFRQDPDVSRLTQTYVTIFIPALPATFLYMLQVKYLLNQGIVLPQIVTGVAANLVNALANYLFLHQLHLGVIGSALANLISQYTLALLLFLYILGKKLHQATWGGWSLECLQDWASFLRLAIPSMLMLCMEWWAYEVGSFLSGILGMVELGAQSIVYELAIIVYMVPAGFSVAASVRVGNALGAGDMEQARKSSTVSLLITVLFAVAFSVLLLSCKDHVGYIFTTDRDIINLVAQVVPIYAVSHLFEALACTSGGVLRGSGNQKVGAIVNTIGYYVVGLPIGIALMFATTLGVMGLWSGIIICTVFQAVCFLGFIIQLNWKKACQQAQVHANLKVNNVPRSGNSALPQDPLHPGCPENLEGILTNDVGKTGEPQSDQQMRQEEPLPEHPQDGAKLSRKQLVLRRGLLLLGVFLILLVGILVRFYVRIQ T39676 DRUGINFO D0D7LA Metformin Approved T39676 DRUGINFO D06PZZ [14C]TEA Investigative T19229 TARGETID T19229 T19229 FORMERID TTDI03501 T19229 UNIPROID PCFT_HUMAN T19229 TARGNAME Proton-coupled folate transporter (SLC46A1) T19229 GENENAME SLC46A1 T19229 TARGTYPE Successful T19229 SYNONYMS Solute carrier family 46 member 1; PCFT/HCP1; PCFT; Heme carrier protein 1; HCP1; G21 T19229 FUNCTION Has been shown to act both as an intestinal proton-coupled high-affinity folate transporter and as an intestinal heme transporter which mediates heme uptake from the gut lumen into duodenal epithelial cells. The iron is then released from heme and may be transported into the bloodstream. Dietary heme iron is an important nutritional source of iron. Shows a higher affinity for folate than heme. T19229 SEQUENCE MEGSASPPEKPRARPAAAVLCRGPVEPLVFLANFALVLQGPLTTQYLWHRFSADLGYNGTRQRGGCSNRSADPTMQEVETLTSHWTLYMNVGGFLVGLFSSTLLGAWSDSVGRRPLLVLASLGLLLQALVSVFVVQLQLHVGYFVLGRILCALLGDFGGLLAASFASVADVSSSRSRTFRMALLEASIGVAGMLASLLGGHWLRAQGYANPFWLALALLIAMTLYAAFCFGETLKEPKSTRLFTFRHHRSIVQLYVAPAPEKSRKHLALYSLAIFVVITVHFGAQDILTLYELSTPLCWDSKLIGYGSAAQHLPYLTSLLALKLLQYCLADAWVAEIGLAFNILGMVVFAFATITPLMFTGYGLLFLSLVITPVIRAKLSKLVRETEQGALFSAVACVNSLAMLTASGIFNSLYPATLNFMKGFPFLLGAGLLLIPAVLIGMLEKADPHLEFQQFPQSP T19229 DRUGINFO D0SV8E Methotrexate Approved T19229 DRUGINFO D0Z0DW Folic Acid Approved T19229 DRUGINFO D0C2VP [3H]N5-methylfolate Investigative T19229 DRUGINFO D0R4PS [3H]folinic acid Investigative T19229 DRUGINFO D0UZ9U PREMETREXED Investigative T63140 TARGETID T63140 T63140 FORMERID TTDS00510 T63140 UNIPROID Q9CDQ3_LACLA T63140 TARGNAME Bacterial Integral membrane LmrP (Bact lmrP) T63140 GENENAME Bact lmrP T63140 TARGTYPE Successful T63140 SYNONYMS lmrP; L24511; Integral membrane protein LmrP T63140 FUNCTION Major facilitator superfamily multidrug transporter from Lactococcus lactis that mediates the efflux of cationic amphiphilic substrates from the cell in a proton-motive force-dependent fashion. T63140 SEQUENCE MKEFWNLDKNLQLRLGIVFLGAFSYGTVFSSMTIYYNQHLGSAITGILLALSAVATFVAGILSGFFADRNGRKPVMVFGTVIQLLGALLAIDSNLPGHVNPWSTFIAFLLISFGYNLVITAGNAMIIDASNAENRKVVFMLDYWAQNLSVILGAALSAWLFRPAFEALLVILLLTVLVSFFLTTFVMTETFRPIVKAKEEAENIFQAYKTVLQDKTYMIFMGANIATTFIIMQFDNFLPVHLSNSFKTITFFGFEIYGQRMLTIYLILACVLVVLLMTTLNRLTKDWSHQKGFIWGSLFMAIGMIFSFLTTTFTPIFIAGIVYTLGEIVYTPSVQTLGVDLMNPEKIGSYNGVAAIKMPIASILAGLLVSISPMIKATGVSLVLALTEVLAIILVLIAVNRHQKTKIN T63140 DRUGINFO D0E2OU Quinupristin Approved T37382 TARGETID T37382 T37382 FORMERID TTDI03558 T37382 UNIPROID S23A1_HUMAN T37382 TARGNAME Solute carrier family 23 member 1 (SLC23A1) T37382 GENENAME SLC23A1 T37382 TARGTYPE Successful T37382 SYNONYMS hSVCT1; Yolk sac permease-like molecule 3; YSPL3; Sodium-dependent vitamin C transporter 1; SVCT1; Na(+)/L-ascorbic acid transporter 1 T37382 FUNCTION Sodium/ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate. T37382 SEQUENCE MRAQEDLEGRTQHETTRDPSTPLPTEPKFDMLYKIEDVPPWYLCILLGFQHYLTCFSGTIAVPFLLAEALCVGHDQHMVSQLIGTIFTCVGITTLIQTTVGIRLPLFQASAFAFLVPAKAILALERWKCPPEEEIYGNWSLPLNTSHIWHPRIREVQGAIMVSSVVEVVIGLLGLPGALLNYIGPLTVTPTVSLIGLSVFQAAGDRAGSHWGISACSILLIILFSQYLRNLTFLLPVYRWGKGLTLLRIQIFKMFPIMLAIMTVWLLCYVLTLTDVLPTDPKAYGFQARTDARGDIMAIAPWIRIPYPCQWGLPTVTAAAVLGMFSATLAGIIESIGDYYACARLAGAPPPPVHAINRGIFTEGICCIIAGLLGTGNGSTSSSPNIGVLGITKVGSRRVVQYGAAIMLVLGTIGKFTALFSSLPDPILGGMFCTLFGMITAVGLSNLQFVDMNSSRNLFVLGFSMFFGLTLPNYLESNPGAINTGILEVDQILIVLLTTEMFVGGCLAFILDNTVPGSPEERGLIQWKAGAHANSDMSSSLKSYDFPIGMGIVKRITFLKYIPICPVFKGFSSSSKDQIAIPEDTPENTETASVCTKV T37382 DRUGINFO D07AHW Vitamin C Approved T37382 DRUGINFO D0HD2G phloretin Investigative T62905 TARGETID T62905 T62905 UNIPROID SC5A6_HUMAN T62905 TARGNAME Sodium-dependent multivitamin transporter (SLC5A6) T62905 GENENAME SLC5A6 T62905 TARGTYPE Successful T62905 SYNONYMS Solute carrier family 5 member 6; SMVT; Na(+)-dependent multivitamin transporter T62905 FUNCTION Transports pantothenate, biotin and lipoate in the presence of sodium. T62905 SEQUENCE MSVGVSTSAPLSPTSGTSVGMSTFSIMDYVVFVLLLVLSLAIGLYHACRGWGRHTVGELLMADRKMGCLPVALSLLATFQSAVAILGVPSEIYRFGTQYWFLGCCYFLGLLIPAHIFIPVFYRLHLTSAYEYLELRFNKTVRVCGTVTFIFQMVIYMGVVLYAPSLALNAVTGFDLWLSVLALGIVCTVYTALGGLKAVIWTDVFQTLVMFLGQLAVIIVGSAKVGGLGRVWAVASQHGRISGFELDPDPFVRHTFWTLAFGGVFMMLSLYGVNQAQVQRYLSSRTEKAAVLSCYAVFPFQQVSLCVGCLIGLVMFAYYQEYPMSIQQAQAAPDQFVLYFVMDLLKGLPGLPGLFIACLFSGSLSTISSAFNSLATVTMEDLIRPWFPEFSEARAIMLSRGLAFGYGLLCLGMAYISSQMGPVLQAAISIFGMVGGPLLGLFCLGMFFPCANPPGAVVGLLAGLVMAFWIGIGSIVTSMGSSMPPSPSNGSSFSLPTNLTVATVTTLMPLTTFSKPTGLQRFYSLSYLWYSAHNSTTVIVVGLIVSLLTGRMRGRSLNPATIYPVLPKLLSLLPLSCQKRLHCRSYGQDHLDTGLFPEKPRNGVLGDSRDKEAMALDGTAYQGSSSTCILQETSL T62905 DRUGINFO D05KBU Gabapentin enacarbil Phase 2 T71905 TARGETID T71905 T71905 FORMERID TTDS00216 T71905 TARGNAME Bacterial 16S ribosomal RNA (Bact 16S rRNA) T71905 TARGTYPE Successful T71905 SYNONYMS RrnS; Plastid 16S rRNA; 16S rRNA T71905 DRUGINFO D05JNI Framycetin Approved T71905 DRUGINFO D0F9FR Oxazolidinones Phase 2 T71905 DRUGINFO D0B0FU Apramycin Phase 1 T71905 DRUGINFO D08PVY Ribostamycin Investigative T71905 DRUGINFO D0I1NU Neamine Investigative T71905 DRUGINFO D0KE3S Butirosin B Investigative T71905 DRUGINFO D0M5WG Aminodeoxykanamycin Investigative T71905 DRUGINFO D03LMM G418 Investigative T71905 DRUGINFO D0S6RD Hygromycin B Investigative T88338 TARGETID T88338 T88338 FORMERID TTDS00217 T88338 TARGNAME Bacterial 23S ribosomal RNA (Bact 23S rRNA) T88338 TARGTYPE Successful T88338 SYNONYMS RrnL; Plastid 23S rRNA T88338 DRUGINFO D03YLZ Thiamphenicol Approved T88338 DRUGINFO D07UYO Linezolid Approved T88338 DRUGINFO D0EB5N Lefamulin Approved T88338 DRUGINFO D0F5OR Spiramycin Approved T88338 DRUGINFO D0Q6OS Macrolides Approved T88338 DRUGINFO D0U5GB Lopinavir Approved T88338 DRUGINFO D0X6IU Chloramphenicol Approved T88338 DRUGINFO D0D7TD Cethromycin Phase 3 T88338 DRUGINFO D03PVQ EDP-420 Phase 2 T88338 DRUGINFO D0F9FR Oxazolidinones Phase 2 T88338 DRUGINFO D07IQU Micrococcin Investigative T88338 DRUGINFO D0G5FV Thiostrepton Investigative T53601 TARGETID T53601 T53601 FORMERID TTDI01915 T53601 TARGNAME Bacterial 50S ribosomal RNA (Bact 50S rRNA) T53601 TARGTYPE Successful T53601 FUNCTION Protein L1 is also a translational repressor protein, it controls the translation of the L11 operon by binding to its mRNA. T53601 DRUGINFO D02YIZ Erythromycin Approved T53601 DRUGINFO D03HJK Zithromax Approved T53601 DRUGINFO D03UQM Retapamulin Approved T53601 DRUGINFO D05AFC Dalfopristin Approved T53601 DRUGINFO D06IGU Troleandomycin Approved T53601 DRUGINFO D06ZUP Dirithromycin Approved T53601 DRUGINFO D08KBK Tedizolid Approved T53601 DRUGINFO D09HNR Telithromycin Approved T53601 DRUGINFO D09PEQ Gentamicine sulfate Approved T53601 DRUGINFO D0Q0EX Lincomycin Approved T53601 DRUGINFO D0R0ZL Clindamycin Approved T53601 DRUGINFO D0X1WJ Josamycin Approved T53601 DRUGINFO D0Z1ZM Clarithromycin Approved T53601 DRUGINFO D0W2FZ Solithromycin Phase 3 T53601 DRUGINFO DVA7X9 DARE-BV1 Phase 3 T53601 DRUGINFO D0J1GA GSK-1399686 Phase 2 T53601 DRUGINFO D0R6EC BC-7013 Phase 2 T53601 DRUGINFO D0T9FU BC-3205 Phase 1 T53601 DRUGINFO D0Y4FL Roxithromycin Withdrawn from market T53601 DRUGINFO D06FBB Azithromycin/chloroquine Discontinued in Phase 3 T53601 DRUGINFO D0LA5G Evernimicin Discontinued in Phase 3 T53601 DRUGINFO D0YE2N Eperezolid Discontinued in Phase 3 T53601 DRUGINFO D03VHI HMR-3562 Discontinued in Phase 1 T53601 DRUGINFO D01GHV RANBEZOLID HYDROCHLORIDE Preclinical T53601 DRUGINFO D02FHP RX-01-423 Preclinical T53601 DRUGINFO D03HTI HMR-3787 Terminated T53601 DRUGINFO D09XQR Erythromycin salnacedin Investigative T62094 TARGETID T62094 T62094 FORMERID TTDI01930 T62094 TARGNAME Bacterial 30S ribosomal RNA (Bact 30S rRNA) T62094 TARGTYPE Successful T62094 DRUGINFO D07BCT Tobramycin Approved T62094 DRUGINFO D09GUJ Omadacycline Approved T62094 DRUGINFO D0IE1E Nitrofurazone Approved T62094 DRUGINFO D0L9UU Gentamicin Approved T62094 DRUGINFO D0S0LZ Doxycycline Approved T62094 DRUGINFO D0T6EI Sarecycline Approved T62094 DRUGINFO D0LZ7E TP-434 Approved T62094 DRUGINFO D01CYK ME1100 Phase 1 T62094 DRUGINFO DA3F2X TP-6076 Phase 1 T62094 DRUGINFO DU3GQ9 TP-271 Phase 1 T62094 DRUGINFO DUI1N7 TP 6076 Phase 1 T62094 DRUGINFO D07ZXE Wetimicin Discontinued in Phase 1 T62094 DRUGINFO D07TNU DACTIMICIN Terminated T48472 TARGETID T48472 T48472 FORMERID TTDS00221 T48472 TARGNAME Bacterial 70S ribosomal RNA (Bact 70S rRNA) T48472 TARGTYPE Successful T48472 DRUGINFO D06EZI Capreomycin Sulfate Approved T48472 DRUGINFO D0E7MV Capreomycin Approved T48472 DRUGINFO D0Q8NJ Viomycin sulfate Approved T49814 TARGETID T49814 T49814 FORMERID TTDI01534 T49814 TARGNAME Bacterial Deoxyribonucleic acid (Bact DNA) T49814 TARGTYPE Successful T49814 DRUGINFO D02RIV Hydroxystilbamidine Isethionate Approved T49814 DRUGINFO D03CUF Furazolidone Approved T49814 DRUGINFO D08GSF Proflavine Approved T49814 DRUGINFO D0A2ZX Metronidazole Approved T49814 DRUGINFO D0R0BX Nitrofurantoin Approved T49814 DRUGINFO D0S5UH Clofazimine Approved T49814 DRUGINFO DIK8W5 MGB-BP-3 Phase 2 T74429 TARGETID T74429 T74429 TARGNAME Calcium (Ca) T74429 TARGTYPE Successful T74429 DRUGINFO D0V4AS Cellulose Sodium Phosphate Approved T74429 DRUGINFO D00XUN Etidronate Disodium Approved T32862 TARGETID T32862 T32862 TARGNAME Fungal Cell membrane ergosterol (Fung CME) T32862 TARGTYPE Successful T32862 DRUGINFO D02DWM Amphotericin B Approved T32862 DRUGINFO D08XAC Nystatin Approved T32862 DRUGINFO D0I6IP Candicidin Approved T86836 TARGETID T86836 T86836 FORMERID TTDI01911 T86836 TARGNAME Human Deoxyribonucleic acid (hDNA) T86836 TARGTYPE Successful T86836 DRUGINFO D00FGO Melphalan Approved T86836 DRUGINFO D01CYA Bendamustine hydrochloride Approved T86836 DRUGINFO D01HPY Melphalan flufenamide Approved T86836 DRUGINFO D01OXI DTI-015 Approved T86836 DRUGINFO D02LPF Altretamine Approved T86836 DRUGINFO D02TLO Ifosfamide Approved T86836 DRUGINFO D03FNJ Pipobroman Approved T86836 DRUGINFO D03SSE Mechlorethamine Approved T86836 DRUGINFO D04JPJ Lomustine Approved T86836 DRUGINFO D06UVD Bleomycin Approved T86836 DRUGINFO D07SUG Busulfan Approved T86836 DRUGINFO D08GYO Procarbazine Approved T86836 DRUGINFO D08IBS Adenine Approved T86836 DRUGINFO D0B9EJ Mitomycin A Approved T86836 DRUGINFO D0C8EU Temozolomide Approved T86836 DRUGINFO D0CT9C Cyclophosphamide Approved T86836 DRUGINFO D0E6AF Radium-223-Dichloride Approved T86836 DRUGINFO D0H0SJ Neocarzinostatin Approved T86836 DRUGINFO D0I8RR Streptozocin Approved T86836 DRUGINFO D0J9UN Uracil mustard Approved T86836 DRUGINFO D0JE4D Dornase Alfa Approved T86836 DRUGINFO D0P8IV Dactinomycin Approved T86836 DRUGINFO D0T8EH Pirarubicin Approved T86836 DRUGINFO D0U5HU Cisplatin Approved T86836 DRUGINFO D0X5XU Decitabine Approved T86836 DRUGINFO D0X7HM Carboplatin Approved T86836 DRUGINFO D0Y0GH Mitomycin Approved T86836 DRUGINFO D0Y3ME Oxaliplatin Approved T86836 DRUGINFO D0Y7ZU Dacarbazine Approved T86836 DRUGINFO D0Z4PE Zinostatin stimalamer Approved T86836 DRUGINFO D01XWG Daunorubicin Approved T86836 DRUGINFO D0V6OA Lurbinectedin Approved T86836 DRUGINFO D04ZXP Dicycloplatin Registered T86836 DRUGINFO D09DJO Pafuramidine Phase 3 T86836 DRUGINFO D0A1IL VAL-083 Phase 3 T86836 DRUGINFO D0E5DB Laromustine Phase 3 T86836 DRUGINFO D0FP0R Apaziquone Phase 3 T86836 DRUGINFO D0L9IA Glufosfamide Phase 3 T86836 DRUGINFO D0J6PY Taxol/Paraplatin/Herceptin Phase 3 T86836 DRUGINFO D00HUZ NDDP Phase 2 T86836 DRUGINFO D02ZZU DM-CHOC-PEN Phase 2 T86836 DRUGINFO D05XUY JM216 Phase 2 T86836 DRUGINFO D07WRW LADIRUBICIN Phase 2 T86836 DRUGINFO D08EUS CGC-11047 Phase 2 T86836 DRUGINFO D09WND TETRAPLATIN TETRANITRATE Phase 2 T86836 DRUGINFO D0D6SZ TROXACITABINE Phase 2 T86836 DRUGINFO D0H1EA TH-302 Phase 2 T86836 DRUGINFO D0M2QR TOL-3021 Phase 2 T86836 DRUGINFO D0M7PU PM-00104 Phase 2 T86836 DRUGINFO D0N3RK CYSTEMUSTINE Phase 2 T86836 DRUGINFO D0VO6J FAD-104 Phase 2 T86836 DRUGINFO D0X0PQ NHS-IL2-LT Phase 2 T86836 DRUGINFO DQ9OL5 OBI-3424 Phase 2 T86836 DRUGINFO D0NS8T 13-DEOXYADRIAMYCIN HYDROCHLORIDE Phase 2 T86836 DRUGINFO D0V0CJ CO-101 Phase 2 T86836 DRUGINFO D01MQP SECTA belomycin Phase 1/2 T86836 DRUGINFO D0AH6V BN-2629 Phase 1/2 T86836 DRUGINFO D0C3MW MBO7133 Phase 1/2 T86836 DRUGINFO D0P5SC GTU-TB vaccine Phase 1/2 T86836 DRUGINFO D00JJW RH 1 Phase 1 T86836 DRUGINFO D02ONT 5-FP Phase 1 T86836 DRUGINFO D03DKR GALAMUSTINE HYDROCHLORIDE Phase 1 T86836 DRUGINFO D05ZEW INO-3510 Phase 1 T86836 DRUGINFO D09HJS BIZELESIN Phase 1 T86836 DRUGINFO D09URP DABIS MALEATE Phase 1 T86836 DRUGINFO D0D7XM NC-4016 Phase 1 T86836 DRUGINFO D0E1HF FFC-14A Phase 1 T86836 DRUGINFO D0K6JQ INO-3401 Phase 1 T86836 DRUGINFO D0PR6H PENCLOMEDINE Phase 1 T86836 DRUGINFO D0SF5Q Pennvax-B Phase 1 T86836 DRUGINFO D0V5JO T-0128 Phase 1 T86836 DRUGINFO D0X0OF Pennvax-G Phase 1 T86836 DRUGINFO D0X3CD Thiarabine Phase 1 T86836 DRUGINFO D0F2JY LY-2334737 Phase 1 T86836 DRUGINFO DE8S2F DFP-14927 Phase 1 T86836 DRUGINFO D0L5BK KW-2149 Discontinued in Phase 3 T86836 DRUGINFO D0RT5T ARANOSE Discontinued in Phase 3 T86836 DRUGINFO D0WR3D Abetimus sodium Discontinued in Phase 3 T86836 DRUGINFO D01VPR BBR-3438 Discontinued in Phase 2 T86836 DRUGINFO D05BTR Tallimustine Discontinued in Phase 2 T86836 DRUGINFO D05UIL TV-4710 Discontinued in Phase 2 T86836 DRUGINFO D06DWQ TOPIXANTRONE HYDROCHLORIDE Discontinued in Phase 2 T86836 DRUGINFO D0H2JQ NB-506 Discontinued in Phase 2 T86836 DRUGINFO D0J0PR PIBROZELESIN HYDROCHLORIDE Discontinued in Phase 2 T86836 DRUGINFO D0M0VN BISNAFIDE MESILATE Discontinued in Phase 2 T86836 DRUGINFO D0O1MP CARZELESIN Discontinued in Phase 2 T86836 DRUGINFO D0U1IR AP-5346 Discontinued in Phase 2 T86836 DRUGINFO D0X5UH ADOZELESIN Discontinued in Phase 2 T86836 DRUGINFO D01GTB ZD-2767 Discontinued in Phase 1 T86836 DRUGINFO D07NGJ S-23906-1 Discontinued in Phase 1 T86836 DRUGINFO D0G6XC SW-33377 Discontinued in Phase 1 T86836 DRUGINFO D0K8HF PLD-147 Discontinued in Phase 1 T86836 DRUGINFO D0NK2U FK-973 Discontinued in Phase 1 T86836 DRUGINFO D0R3HX RB-6145 Discontinued in Phase 1 T86836 DRUGINFO D0S0XS SR-271425 Discontinued in Phase 1 T86836 DRUGINFO D0Y7HW Clomet Discontinued in Phase 1 T86836 DRUGINFO D0J6VN Indol-3-carbinol Preclinical T86836 DRUGINFO D0FT9P Talisomycin Terminated T86836 DRUGINFO D0G2JZ Bisbenzimide (Hoechst 33258) Terminated T86836 DRUGINFO D0R7GL BW-A502U Terminated T86836 DRUGINFO D0FZ1Z Doxorubicin-CEA conjugate Terminated T86836 DRUGINFO D02CWZ AMBAZONE Investigative T86836 DRUGINFO D04UPU 2-(3,4-Dihydroxyphenyl)Acetic Acid Investigative T86836 DRUGINFO D08ATQ Nitracrine Investigative T86836 DRUGINFO D0AU4H Thiamin Diphosphate Investigative T86836 DRUGINFO D0N6FL Lipid Fragment Investigative T86836 DRUGINFO D0P0WG Ethidium Investigative T86836 DRUGINFO D04ACC doxorubicin-peptide-PEG conjugate Investigative T86836 DRUGINFO D0K4QL doxorubicin-LL2 conjugate Investigative T86836 DRUGINFO D0O9GJ alphabeta-methyleneADP Investigative T86836 DRUGINFO D07ONX Beta-D-Glucose Investigative T75499 TARGETID T75499 T75499 FORMERID TTDNS00588 T75499 TARGNAME Human Deoxyribonucleic acid major groove (hDNA maj) T75499 TARGTYPE Successful T75499 DRUGINFO D0J5TS Carzinophilin Approved T51038 TARGETID T51038 T51038 FORMERID TTDI01874 T51038 TARGNAME Hyaluronic acid (HA) T51038 TARGTYPE Successful T51038 DRUGINFO D04GPZ Hyaluronidase (ovine) Approved T51038 DRUGINFO D0N3UG Hylenex Approved T02246 TARGETID T02246 T02246 FORMERID TTDI01910 T02246 TARGNAME Iron (Fe) T02246 TARGTYPE Successful T02246 DRUGINFO D0FJ8A Deferoxamine Mesylate Approved T02246 DRUGINFO D0N0OU Deferiprone Approved T02246 DRUGINFO D0Q5UQ Exjade Approved T02246 DRUGINFO D00XUN Etidronate Disodium Approved T02246 DRUGINFO D0Y2JM Soluble ferric pyrophosphate Phase 3 T02246 DRUGINFO D02SNJ SPD602 Phase 2 T02246 DRUGINFO D00DIM Monohydroxyethylrutoside Phase 1 T02246 DRUGINFO D7L8JC DpC Phase 1 T85889 TARGETID T85889 T85889 FORMERID TTDI01976 T85889 TARGNAME Phosphate (PHO) T85889 TARGTYPE Successful T85889 DRUGINFO D0H1LO Lanthanum carbonate Approved T28658 TARGETID T28658 T28658 FORMERID TTDS00460 T28658 TARGNAME Plasmodium 80S ribosome (Malaria 80S) T28658 TARGTYPE Successful T28658 DRUGINFO D0GQ7K Mefloquine Approved T20089 TARGETID T20089 T20089 FORMERID TTDI01265 T20089 TARGNAME Plasmodium Deoxyribonucleic acid (Malaria DNA) T20089 TARGTYPE Successful T20089 DRUGINFO D0T1LK Primaquine Approved T31133 TARGETID T31133 T31133 FORMERID TTDI01287 T31133 TARGNAME Potassium (K) T31133 TARGTYPE Successful T31133 DRUGINFO D03AZK Sodium zirconium cyclosilicate Approved T31133 DRUGINFO D0Z2YQ Patiromer calcium Approved T20796 TARGETID T20796 T20796 FORMERID TTDI01161 T20796 TARGNAME Reactive oxygen species (ROS) T20796 TARGTYPE Successful T20796 DRUGINFO D07TWN Tafenoquine Approved T20796 DRUGINFO D0M0UT Procysteine Phase 2 T20796 DRUGINFO D1FR3T Mitoquinone Phase 2 T20796 DRUGINFO D02ECG Sodium pyruvate Phase 1/2 T84575 TARGETID T84575 T84575 TARGNAME Samarium (SAM) T84575 TARGTYPE Successful T84575 DRUGINFO D04YHR Samarium Sm-153 Lexidronam Pentasodium Approved T66023 TARGETID T66023 T66023 TARGNAME Schistosoma Deoxyribonucleic acid (Schist DNA) T66023 TARGTYPE Successful T66023 DRUGINFO D0P4MT Oxamniquine Approved T62501 TARGETID T62501 T62501 FORMERID TTDI01889 T62501 TARGNAME Toxic methotrexate (TM) T62501 TARGTYPE Successful T62501 DRUGINFO D0P4PZ Glucarpidase Approved T89086 TARGETID T89086 T89086 FORMERID TTDI01846 T89086 TARGNAME Toxic reactive metabolite (TRM) T89086 TARGTYPE Successful T89086 DRUGINFO D06CIE Amifostine Approved T05196 TARGETID T05196 T05196 FORMERID TTDI01977 T05196 TARGNAME Uric acid (URA) T05196 TARGTYPE Successful T05196 DRUGINFO D06ZIT Pegloticase Approved T05196 DRUGINFO D0S3BF Pegadricase Phase 1 T28848 TARGETID T28848 T28848 FORMERID TTDI01148 T28848 TARGNAME Virus Deoxyribonucleic acid (Viru DNA) T28848 TARGTYPE Successful T28848 DRUGINFO D09PZO Idoxuridine Approved T63966 TARGETID T63966 T63966 FORMERID TTDS00007 T63966 UNIPROID VGFR1_HUMAN T63966 TARGNAME Vascular endothelial growth factor receptor 1 (FLT-1) T63966 GENENAME FLT1 T63966 TARGTYPE Successful T63966 SYNONYMS Vascular permeability factor receptor; VEGFR1; VEGFR-1; VEGF-1 receptor; Tyrosine-protein kinase receptor FLT; Tyrosine-protein kinase FRT; Fms-like tyrosine kinase 1; FRT; FLT T63966 FUNCTION May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. T63966 PDBSTRUC 5T89; 5EX3; 5ABD; 4CL7; 4CKV T63966 BIOCLASS Kinase T63966 ECNUMBER EC 2.7.10.1 T63966 SEQUENCE MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDEGVYHCKATNQKGSVESSAYLTVQGTSDKSNLELITLTCTCVAATLFWLLLTLFIRKMKRSSSEIKTDYLSIIMDPDEVPLDEQCERLPYDASKWEFARERLKLGKSLGRGAFGKVVQASAFGIKKSPTCRTVAVKMLKEGATASEYKALMTELKILTHIGHHLNVVNLLGACTKQGGPLMVIVEYCKYGNLSNYLKSKRDLFFLNKDAALHMEPKKEKMEPGLEQGKKPRLDSVTSSESFASSGFQEDKSLSDVEEEEDSDGFYKEPITMEDLISYSFQVARGMEFLSSRKCIHRDLAARNILLSENNVVKICDFGLARDIYKNPDYVRKGDTRLPLKWMAPESIFDKIYSTKSDVWSYGVLLWEIFSLGGSPYPGVQMDEDFCSRLREGMRMRAPEYSTPEIYQIMLDCWHRDPKERPRFAELVEKLGDLLQANVQQDGKDYIPINAILTGNSGFTYSTPAFSEDFFKESISAPKFNSGSSDDVRYVNAFKFMSLERIKTFEELLPNATSMFDDYQGDSSTLLASPMLKRFTWTDSKPKASLKIDLRVTSKSKESGLSDVSRPSFCHSSCGHVSEGKRRFTYDHAELERKIACCSPPPDYNSVVLYSTPPI T63966 DRUGINFO D0W7JZ Tivozanib Approved T63966 DRUGINFO D05PWX Sulfatinib Phase 3 T63966 DRUGINFO D02WVT E-3810 Phase 3 T63966 DRUGINFO D0LX8Z OCV-101 Phase 2 T63966 DRUGINFO D0X2RL LY3012212 Phase 2 T63966 DRUGINFO D0L2ZY X-82 Phase 2 T63966 DRUGINFO D0Z6MT Famitinib Phase 2 T63966 DRUGINFO D04NOE OTSGC-A24 Phase 1/2 T63966 DRUGINFO D04SQJ EW-A-401 Phase 1 T63966 DRUGINFO D0FD6D CEP-11981 Phase 1 T63966 DRUGINFO D07HAD Telbermin Discontinued in Phase 2 T63966 DRUGINFO D0M8PL Angiozyme Discontinued in Phase 2 T63966 DRUGINFO D09LPL SU-11652 Investigative T63966 DRUGINFO D0EE6A AAL-993 Investigative T91331 TARGETID T91331 T91331 FORMERID TTDC00131 T91331 UNIPROID FGFR3_HUMAN T91331 TARGNAME Fibroblast growth factor receptor 3 (FGFR3) T91331 GENENAME FGFR3 T91331 TARGTYPE Successful T91331 SYNONYMS JTK4; FGFR-3; CD333 T91331 FUNCTION Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. T91331 PDBSTRUC 4K33; 2LZL; 1RY7 T91331 BIOCLASS Kinase T91331 ECNUMBER EC 2.7.10.1 T91331 SEQUENCE MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGPDGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQVARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT T91331 DRUGINFO D0O6UY Pemigatinib Approved T91331 DRUGINFO D0U2CV Trapidil Phase 4 T91331 DRUGINFO D03WQS BMS-582664 Phase 3 T91331 DRUGINFO D07OZR TKI258 Phase 3 T91331 DRUGINFO D02WVT E-3810 Phase 3 T91331 DRUGINFO D0G6CF B-701 Phase 2 T91331 DRUGINFO DBA40S Recifercept Phase 2 T91331 DRUGINFO D0XT0W Debio 1347 Phase 2 T91331 DRUGINFO D0G2QH AEE-788 Phase 1/2 T91331 DRUGINFO D00DRL MK-2461 Phase 1/2 T91331 DRUGINFO D0V0BO Anti-FGFR3 Phase 1 T91331 DRUGINFO D9FMA2 SAR442501 Phase 1 T91331 DRUGINFO D0Z0KD PD-0183812 Terminated T91331 DRUGINFO D03HGW AV-370 Investigative T91331 DRUGINFO D0A4XJ SU5402 Investigative T91331 DRUGINFO D05FFB 5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol Investigative T91331 DRUGINFO D0R6OM ACTB-1003 Investigative T91331 DRUGINFO D02NNT PMID21493067C1d Investigative T91331 DRUGINFO D09XIL Ro-4396686 Investigative T67619 TARGETID T67619 T67619 FORMERID TTDI00350 T67619 UNIPROID AKT1_HUMAN T67619 TARGNAME RAC-alpha serine/threonine-protein kinase (AKT1) T67619 GENENAME AKT1 T67619 TARGTYPE Successful T67619 SYNONYMS RAC-PK-alpha; RAC; Proto-oncogene c-Akt; Protein kinase B alpha; PKB alpha T67619 FUNCTION AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53. T67619 PDBSTRUC 6NPZ; 6HHJ; 6HHI; 6HHH; 6HHG T67619 BIOCLASS Kinase T67619 ECNUMBER EC 2.7.11.1 T67619 SEQUENCE MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA T67619 DRUGINFO D01ZAQ Capivasertib Approved T67619 DRUGINFO D0I4TH GDC-0068 Phase 3 T67619 DRUGINFO D0I6VU Enzastaurin Phase 3 T67619 DRUGINFO D02NXM GSK2110183 Phase 2 T67619 DRUGINFO D07SYZ RX-0201 Phase 2 T67619 DRUGINFO D0S5WP Trametinib + 2141795 Phase 2 T67619 DRUGINFO D0X7CV PTX-200 Phase 2 T67619 DRUGINFO D01TBJ CMX-2043 Phase 2 T67619 DRUGINFO D07DWF ARQ 092 Phase 2 T67619 DRUGINFO D0YB3W CI-1033 Phase 2 T67619 DRUGINFO D09CCZ Triciribine prodrug Phase 1/2 T67619 DRUGINFO D02QWY BMS-754807 Phase 1 T67619 DRUGINFO D0L8PZ ARQ 751 Phase 1 T67619 DRUGINFO D06HYF M2698 Phase 1 T67619 DRUGINFO D07QBF PMID28460551-Compound-6 Patented T67619 DRUGINFO D0O1AV Squalestatin 1 Terminated T67619 DRUGINFO D07MQF MYRIOCIN Investigative T67619 DRUGINFO D09DGE LD-101 Investigative T67619 DRUGINFO D0CM6T A-674563 Investigative T67619 DRUGINFO D0F8HX Lactoquinomycin Investigative T67619 DRUGINFO D0N7CY VLI-27 Investigative T67619 DRUGINFO D0OX1T A-443654 Investigative T67619 DRUGINFO D0PX5F NU-1001-41 Investigative T67619 DRUGINFO D0RZ1H 4,5,6-trihydroxy-3-methylphthalide Investigative T67619 DRUGINFO D0V1ES ALM-301 Investigative T67619 DRUGINFO D0L5AB BX-517 Investigative T67619 DRUGINFO D0MH9X Inositol 1,3,4,5-Tetrakisphosphate Investigative T67619 DRUGINFO D00ATA (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one Investigative T67619 DRUGINFO D05APZ Akt inhibitor VIII Investigative T67619 DRUGINFO D0I1FJ SB-747651A Investigative T67619 DRUGINFO D0L2WP PMID20005102C1 Investigative T67619 DRUGINFO D0GB4V STAUROSPORINONE Investigative T67619 DRUGINFO D0M5FF Ro31-8220 Investigative T67619 DRUGINFO D0M4SY BMS-536924 Investigative T67619 DRUGINFO D0N6ES KN-62 Investigative T67619 DRUGINFO D0B9BU CI-1040 Investigative T67619 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T67619 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T67619 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T67619 DRUGINFO D0L8HO RO-316233 Investigative T31514 TARGETID T31514 T31514 FORMERID TTDC00023 T31514 UNIPROID LYAG_HUMAN T31514 TARGNAME Lysosomal alpha-glucosidase (GAA) T31514 GENENAME GAA T31514 TARGTYPE Successful T31514 SYNONYMS GAA; Aglucosidase alfa; Acid maltase T31514 FUNCTION Essential for the degradation of glygogen to glucose in lysosomes. T31514 PDBSTRUC 5NN8; 5NN6; 5NN5; 5NN4; 5NN3 T31514 BIOCLASS Glycosylase T31514 ECNUMBER EC 3.2.1.20 T31514 SEQUENCE MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC T31514 DRUGINFO D34SXJ Avalglucosidase alfa Approved T31514 DRUGINFO D05JEG BMN-701 Phase 3 T31514 DRUGINFO D0S5LT Deoxynojirimycin Phase 3 T31514 DRUGINFO DG4X8E AT845 Phase 2 T31514 DRUGINFO D3O5XK SPK-3006 Phase 1/2 T31514 DRUGINFO D07TSW SALACINOL Phase 1/2 T31514 DRUGINFO D0Q1UB GZ402666 Phase 1 T31514 DRUGINFO DW68KF 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one Preclinical T31514 DRUGINFO D03TYC Alpha-Homonojirimycin Investigative T31514 DRUGINFO D07JCA 7-O-b-D-Glucopyranosyl-a-homonojirimycin Investigative T31514 DRUGINFO D08TQA VALIOLAMINE Investigative T31514 DRUGINFO D0J2JM UNIFLORINE B Investigative T31514 DRUGINFO D0KE8R (-)-uniflorine A Investigative T31514 DRUGINFO D0N9IX N-adamantanemethyloxypentyl-1-deoxynojirimycin Investigative T31514 DRUGINFO D0Q1KL (R)-2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol Investigative T31514 DRUGINFO D0X6BK 2,5-imino-2,5,6-trideoxy-D-manno-heptitol Investigative T31514 DRUGINFO D0ZC7V Alpha-7-Deoxyhomonojirimycin Investigative T07303 TARGETID T07303 T07303 FORMERID TTDC00290 T07303 UNIPROID VGFR3_HUMAN T07303 TARGNAME Vascular endothelial growth factor receptor 3 (FLT-4) T07303 GENENAME FLT4 T07303 TARGTYPE Successful T07303 SYNONYMS VEGFR3; VEGFR-3; VEGF-3 receptor; Tyrosine-protein kinase receptor FLT4; Fms-like tyrosine kinase 4 T07303 FUNCTION Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. T07303 PDBSTRUC 4BSK; 4BSJ T07303 BIOCLASS Kinase T07303 ECNUMBER EC 2.7.10.1 T07303 SEQUENCE MQRGAALCLRLWLCLGLLDGLVSGYSMTPPTLNITEESHVIDTGDSLSISCRGQHPLEWAWPGAQEAPATGDKDSEDTGVVRDCEGTDARPYCKVLLLHEVHANDTGSYVCYYKYIKARIEGTTAASSYVFVRDFEQPFINKPDTLLVNRKDAMWVPCLVSIPGLNVTLRSQSSVLWPDGQEVVWDDRRGMLVSTPLLHDALYLQCETTWGDQDFLSNPFLVHITGNELYDIQLLPRKSLELLVGEKLVLNCTVWAEFNSGVTFDWDYPGKQAERGKWVPERRSQQTHTELSSILTIHNVSQHDLGSYVCKANNGIQRFRESTEVIVHENPFISVEWLKGPILEATAGDELVKLPVKLAAYPPPEFQWYKDGKALSGRHSPHALVLKEVTEASTGTYTLALWNSAAGLRRNISLELVVNVPPQIHEKEASSPSIYSRHSRQALTCTAYGVPLPLSIQWHWRPWTPCKMFAQRSLRRRQQQDLMPQCRDWRAVTTQDAVNPIESLDTWTEFVEGKNKTVSKLVIQNANVSAMYKCVVSNKVGQDERLIYFYVTTIPDGFTIESKPSEELLEGQPVLLSCQADSYKYEHLRWYRLNLSTLHDAHGNPLLLDCKNVHLFATPLAASLEEVAPGARHATLSLSIPRVAPEHEGHYVCEVQDRRSHDKHCHKKYLSVQALEAPRLTQNLTDLLVNVSDSLEMQCLVAGAHAPSIVWYKDERLLEEKSGVDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVAVEGSEDKGSMEIVILVGTGVIAVFFWVLLLLIFCNMRRPAHADIKTGYLSIIMDPGEVPLEEQCEYLSYDASQWEFPRERLHLGRVLGYGAFGKVVEASAFGIHKGSSCDTVAVKMLKEGATASEHRALMSELKILIHIGNHLNVVNLLGACTKPQGPLMVIVEFCKYGNLSNFLRAKRDAFSPCAEKSPEQRGRFRAMVELARLDRRRPGSSDRVLFARFSKTEGGARRASPDQEAEDLWLSPLTMEDLVCYSFQVARGMEFLASRKCIHRDLAARNILLSESDVVKICDFGLARDIYKDPDYVRKGSARLPLKWMAPESIFDKVYTTQSDVWSFGVLLWEIFSLGASPYPGVQINEEFCQRLRDGTRMRAPELATPAIRRIMLNCWSGDPKARPAFSELVEILGDLLQGRGLQEEEEVCMAPRSSQSSEEGSFSQVSTMALHIAQADAEDSPPSLQRHSLAARYYNWVSFPGCLARGAETRGSSRMKTFEEFPMTPTTYKGSVDNQTDSGMVLASEEFEQIESRHRQESGFSCKGPGQNVAVTRAHPDSQGRRRRPERGARGGQVFYNSEYGELSEPSEEDHCSPSARVTFFTDNSY T07303 DRUGINFO D0W7JZ Tivozanib Approved T07303 DRUGINFO D04ZJG PI-88 Phase 3 T07303 DRUGINFO D0GY4H Taberminogene vadenovec Phase 3 T07303 DRUGINFO D0M9QZ ABT-869 Phase 3 T07303 DRUGINFO D05PWX Sulfatinib Phase 3 T07303 DRUGINFO D02WVT E-3810 Phase 3 T07303 DRUGINFO D05BLN MGCD516 Phase 2/3 T07303 DRUGINFO D0P6DJ VATALANIB Phase 2 T07303 DRUGINFO D0Z6MT Famitinib Phase 2 T07303 DRUGINFO D00DRL MK-2461 Phase 1/2 T07303 DRUGINFO D09JSM IMC-3C5 Phase 1 T07303 DRUGINFO D0U3XL JNJ-26483327 Phase 1 T07303 DRUGINFO D07DJR Pyrimidine derivative 15 Patented T07303 DRUGINFO D07VCG Anti-VEGFR 3 mab Investigative T07303 DRUGINFO D08GBT SAR-131675 Investigative T07303 DRUGINFO D03HQK 2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile Investigative T07303 DRUGINFO D05THI 4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide Investigative T07303 DRUGINFO D06GJO (2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine Investigative T07303 DRUGINFO D07XBW N-(2,4-Dichloro-benzoyl)-benzenesulfonamide Investigative T07303 DRUGINFO D09LEK 4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide Investigative T07303 DRUGINFO D09MSA 4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide Investigative T07303 DRUGINFO D0BM4F Phenyl-(5-phenyl-oxazol-2-yl)-amine Investigative T07303 DRUGINFO D0C6KI CB-676475 Investigative T07303 DRUGINFO D0C6OD 4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide Investigative T07303 DRUGINFO D0D3YL (5-Phenyl-oxazol-2-yl)-m-tolyl-amine Investigative T07303 DRUGINFO D0J2XD 3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile Investigative T07303 DRUGINFO D0M2QA N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide Investigative T07303 DRUGINFO D0UZ5W 4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide Investigative T07303 DRUGINFO D0V4BR 4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide Investigative T07303 DRUGINFO D0V9DQ [3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol Investigative T07303 DRUGINFO D0YN1E 3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine Investigative T07303 DRUGINFO D07IHM CEP-6331 Investigative T07303 DRUGINFO D0C2GE PMID22765894C8h Investigative T71266 TARGETID T71266 T71266 FORMERID TTDI02016 T71266 UNIPROID AKT3_HUMAN T71266 TARGNAME RAC-gamma serine/threonine-protein kinase (AKT3) T71266 GENENAME AKT3 T71266 TARGTYPE Successful T71266 SYNONYMS STK-2; RAC-PK-gamma; Protein kinase B gamma; Protein kinase Akt-3; PKBG; PKB gamma T71266 FUNCTION AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. T71266 PDBSTRUC 2X18 T71266 BIOCLASS Kinase T71266 ECNUMBER EC 2.7.11.1 T71266 SEQUENCE MSDVTIVKEGWVQKRGEYIKNWRPRYFLLKTDGSFIGYKEKPQDVDLPYPLNNFSVAKCQLMKTERPKPNTFIIRCLQWTTVIERTFHVDTPEEREEWTEAIQAVADRLQRQEEERMNCSPTSQIDNIGEEEMDASTTHHKRKTMNDFDYLKLLGKGTFGKVILVREKASGKYYAMKILKKEVIIAKDEVAHTLTESRVLKNTRHPFLTSLKYSFQTKDRLCFVMEYVNGGELFFHLSRERVFSEDRTRFYGAEIVSALDYLHSGKIVYRDLKLENLMLDKDGHIKITDFGLCKEGITDAATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEDIKFPRTLSSDAKSLLSGLLIKDPNKRLGGGPDDAKEIMRHSFFSGVNWQDVYDKKLVPPFKPQVTSETDTRYFDEEFTAQTITITPPEKYDEDGMDCMDNERRPHFPQFSYSASGRE T71266 DRUGINFO D01ZAQ Capivasertib Approved T71266 DRUGINFO D01NEC GSK2141795 Phase 2 T71266 DRUGINFO D07DWF ARQ 092 Phase 2 T71266 DRUGINFO D0W3RW MK-2206 Phase 2 T71266 DRUGINFO D03AVS SR13668 Phase 1 T71266 DRUGINFO D07TWK TCN-P Phase 1 T71266 DRUGINFO D0MS3Z GSK690693 Phase 1 T71266 DRUGINFO D0S9IE BAY1125976 Phase 1 T71266 DRUGINFO D00DXH LYS-6KAKT1 Phase 1 T71266 DRUGINFO D0Q0PO LY2780301 Phase 1 T71266 DRUGINFO D0X2JM XL418 Phase 1 T71266 DRUGINFO D06HYF M2698 Phase 1 T71266 DRUGINFO D0C4JV ISC-4 Investigative T71266 DRUGINFO D05APZ Akt inhibitor VIII Investigative T71266 DRUGINFO D0L2WP PMID20005102C1 Investigative T21960 TARGETID T21960 T21960 FORMERID TTDC00210 T21960 UNIPROID ANGP2_HUMAN T21960 TARGNAME Angiopoietin-2 (ANGPT2) T21960 GENENAME ANGPT2 T21960 TARGTYPE Successful T21960 SYNONYMS ANG-2 T21960 FUNCTION Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1. In the absence of angiogenic inducers, such as VEGF, ANGPT2-mediated loosening of cell-matrix contacts may induce endothelial cell apoptosis with consequent vascular regression. In concert with VEGF, it may facilitate endothelial cell migration and proliferation, thus serving as a permissive angiogenic signal. Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling. T21960 PDBSTRUC 4ZFG; 4JZC; 2GY7; 1Z3U; 1Z3S T21960 BIOCLASS Fibrinogen protein T21960 SEQUENCE MWQIVFFTLSCDLVLAAAYNNFRKSMDSIGKKQYQVQHGSCSYTFLLPEMDNCRSSSSPYVSNAVQRDAPLEYDDSVQRLQVLENIMENNTQWLMKLENYIQDNMKKEMVEIQQNAVQNQTAVMIEIGTNLLNQTAEQTRKLTDVEAQVLNQTTRLELQLLEHSLSTNKLEKQILDQTSEINKLQDKNSFLEKKVLAMEDKHIIQLQSIKEEKDQLQVLVSKQNSIIEELEKKIVTATVNNSVLQKQQHDLMETVNNLLTMMSTSNSAKDPTVAKEEQISFRDCAEVFKSGHTTNGIYTLTFPNSTEEIKAYCDMEAGGGGWTIIQRREDGSVDFQRTWKEYKVGFGNPSGEYWLGNEFVSQLTNQQRYVLKIHLKDWEGNEAYSLYEHFYLSSEELNYRIHLKGLTGTAGKISSISQPGNDFSTKDGDNDKCICKCSQMLTGGWWFDACGPSNLNGMYYPQRQNTNKFNGIKWYYWKGSGYSLKATTMMIRPADF T21960 DRUGINFO D9MWL4 Faricimab Approved T21960 DRUGINFO D9NL3R Trebananib Phase 3 T21960 DRUGINFO D0K8NR AMG 386 Phase 3 T21960 DRUGINFO DS68GD REGN910-3 Phase 2 T21960 DRUGINFO D06FTM RG7221 Phase 2 T21960 DRUGINFO D0I8YS RO5520985 Phase 2 T21960 DRUGINFO D02WSY CVX-060 Phase 1/2 T21960 DRUGINFO D02EOS CVX-241 Phase 1 T21960 DRUGINFO D03WOQ LY3127804 Phase 1 T21960 DRUGINFO D03YEG REGN-910 Phase 1 T21960 DRUGINFO DP7J0Z MEDI3617 Phase 1 T21960 DRUGINFO DP7Z9Q Nesvacumab Phase 1 T21960 DRUGINFO D57NHD Zifibancimig Phase 1 T21960 DRUGINFO D62LKT BI 836880 Phase 1 T21960 DRUGINFO D1JS9X ABTAA Investigative T06093 TARGETID T06093 T06093 FORMERID TTDI02162 T06093 UNIPROID ROCK2_HUMAN T06093 TARGNAME Rho-associated protein kinase 2 (ROCK2) T06093 GENENAME ROCK2 T06093 TARGTYPE Successful T06093 SYNONYMS p164 ROCK-2; Rho-associated, coiled-coil-containing protein kinase II; Rho-associated, coiled-coil-containing protein kinase 2; Rho kinase 2; ROCK-II; KIAA0619 T06093 FUNCTION Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Positively regulates the activation of p42/MAPK1-p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays an important role in the timely initiation of centrosome duplication. Inhibits keratinocyte terminal differentiation. May regulate closure of the eyelids and ventral body wall through organization of actomyosin bundles. Plays a critical role in the regulation of spine and synaptic properties in the hippocampus. Plays an important role in generating the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and vascular contractility by modulating the myosin light chain phosphorylation. Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. T06093 PDBSTRUC 6ED6; 5U7R; 5U7Q; 4WOT; 4L6Q T06093 BIOCLASS Kinase T06093 ECNUMBER EC 2.7.11.1 T06093 SEQUENCE MSRPPPTGKMPGAPETAPGDGAGASRQRKLEALIRDPRSPINVESLLDGLNSLVLDLDFPALRKNKNIDNFLNRYEKIVKKIRGLQMKAEDYDVVKVIGRGAFGEVQLVRHKASQKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWAKFYTAEVVLALDAIHSMGLIHRDVKPDNMLLDKHGHLKLADFGTCMKMDETGMVHCDTAVGTPDYISPEVLKSQGGDGFYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMDHKNSLCFPEDAEISKHAKNLICAFLTDREVRLGRNGVEEIRQHPFFKNDQWHWDNIRETAAPVVPELSSDIDSSNFDDIEDDKGDVETFPIPKAFVGNQLPFIGFTYYRENLLLSDSPSCRETDSIQSRKNEESQEIQKKLYTLEEHLSNEMQAKEELEQKCKSVNTRLEKTAKELEEEITLRKSVESALRQLEREKALLQHKNAEYQRKADHEADKKRNLENDVNSLKDQLEDLKKRNQNSQISTEKVNQLQRQLDETNALLRTESDTAARLRKTQAESSKQIQQLESNNRDLQDKNCLLETAKLKLEKEFINLQSALESERRDRTHGSEIINDLQGRICGLEEDLKNGKILLAKVELEKRQLQERFTDLEKEKSNMEIDMTYQLKVIQQSLEQEEAEHKATKARLADKNKIYESIEEAKSEAMKEMEKKLLEERTLKQKVENLLLEAEKRCSLLDCDLKQSQQKINELLKQKDVLNEDVRNLTLKIEQETQKRCLTQNDLKMQTQQVNTLKMSEKQLKQENNHLMEMKMNLEKQNAELRKERQDADGQMKELQDQLEAEQYFSTLYKTQVRELKEECEEKTKLGKELQQKKQELQDERDSLAAQLEITLTKADSEQLARSIAEEQYSDLEKEKIMKELEIKEMMARHKQELTEKDATIASLEETNRTLTSDVANLANEKEELNNKLKDVQEQLSRLKDEEISAAAIKAQFEKQLLTERTLKTQAVNKLAEIMNRKEPVKRGNDTDVRRKEKENRKLHMELKSEREKLTQQMIKYQKELNEMQAQIAEESQIRIELQMTLDSKDSDIEQLRSQLQALHIGLDSSSIGSGPGDAEADDGFPESRLEGWLSLPVRNNTKKFGWVKKYVIVSSKKILFYDSEQDKEQSNPYMVLDIDKLFHVRPVTQTDVYRADAKEIPRIFQILYANEGESKKEQEFPVEPVGEKSNYICHKGHEFIPTLYHFPTNCEACMKPLWHMFKPPPALECRRCHIKCHKDHMDKKEEIIAPCKVYYDISTAKNLLLLANSTEEQQKWVSRLVKKIPKKPPAPDPFARSSPRTSMKIQQNQSIRRPSRQLAPNKPS T06093 DRUGINFO D0U5UC Belumosudil Approved T06093 DRUGINFO D08JXW INS-117548 Phase 1 T06093 DRUGINFO D02ZQS GSK269962A Clinical trial T06093 DRUGINFO D06RBE Tricyclic compound 7 Patented T06093 DRUGINFO D0E1KS Tricyclic compound 5 Patented T06093 DRUGINFO D0E9PE Tricyclic compound 6 Patented T06093 DRUGINFO D0G3DM Indazolyl-thiadiazolamine derivative 1 Patented T06093 DRUGINFO D0T0RV PMID28048944-Compound-11 Patented T06093 DRUGINFO D0U4LI Tricyclic compound 4 Patented T06093 DRUGINFO D0CW9Q PMID28048944-Compound-19 Patented T06093 DRUGINFO D0DO1U PMID28048944-Compound-3 Patented T06093 DRUGINFO D0QC6H PMID28048944-Compound-7 Patented T06093 DRUGINFO D0QX0O PMID28048944-Compound-4 Patented T06093 DRUGINFO D0V6OK PMID28048944-Compound-5 Patented T06093 DRUGINFO D0VK6S PMID28048944-Compound-6 Patented T06093 DRUGINFO D0YV6S PMID28048944-Compound-2 Patented T06093 DRUGINFO D00ZNS CDE-5110 Terminated T06093 DRUGINFO D02RYE AMA-237 Investigative T06093 DRUGINFO D02WRE ATS-907 Investigative T06093 DRUGINFO D0J2GG SR-3850 Investigative T06093 DRUGINFO D0X8UW TRN-101 Investigative T06093 DRUGINFO D0Y8DT Glycyl-H 1152 Investigative T06093 DRUGINFO D0N1UU PMID20471253C32 Investigative T06093 DRUGINFO D0R3MO PMID20684608C35 Investigative T06093 DRUGINFO D0V0KA PMID20462760C22 Investigative T06093 DRUGINFO D03CPB RKI-1447 Investigative T29143 TARGETID T29143 T29143 FORMERID TTDC00177 T29143 UNIPROID IL13_HUMAN T29143 TARGNAME Interleukin-13 (IL13) T29143 GENENAME IL13 T29143 TARGTYPE Successful T29143 SYNONYMS NC30; IL-13 T29143 FUNCTION Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses. Positively regulates IL31RA expression in macrophages. Cytokine. T29143 PDBSTRUC 5L6Y; 5E4E; 4PS4; 4I77; 3LB6 T29143 BIOCLASS Cytokine: interleukin T29143 SEQUENCE MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN T29143 DRUGINFO D0I1ZY Tralokinumab Approved T29143 DRUGINFO D0SM8S Lebrikizumab Phase 3 T29143 DRUGINFO D2R3ZX Cendakimab Phase 3 T29143 DRUGINFO DP2UR8 Dexpramipexole Phase 3 T29143 DRUGINFO D02QDQ QAX-576 Phase 2 T29143 DRUGINFO D03ING Anrukinzumab Phase 2 T29143 DRUGINFO DTQ3Z8 Dectrekumab Phase 2 T29143 DRUGINFO D00KQN PEGylated pitrakinra Phase 2 T29143 DRUGINFO DF5R7E Romilkimab Phase 2 T29143 DRUGINFO D0O4SH SAR-156597 Phase 2 T29143 DRUGINFO D0K0WA CNTO-5825 Phase 1 T29143 DRUGINFO D9TW0X SAR443765 Phase 1 T29143 DRUGINFO D1LP4B PF-07264660 Phase 1 T29143 DRUGINFO DIWU14 PF-07275315 Phase 1 T29143 DRUGINFO DFU4B0 RO7040547 Discontinued in Phase 1 T25265 TARGETID T25265 T25265 FORMERID TTDI02063 T25265 UNIPROID EZH2_HUMAN T25265 TARGNAME Enhancer of zeste homolog 2 (EZH2) T25265 GENENAME EZH2 T25265 TARGTYPE Successful T25265 SYNONYMS Lysine Nmethyltransferase 6; Lysine N-methyltransferase 6; KMT6; Histonelysine Nmethyltransferase EZH2; Histone-lysine N-methyltransferase EZH2; EZH2; ENX1; ENX-1 T25265 FUNCTION Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. Polycomb group (PcG) protein. T25265 PDBSTRUC 6C24; 6C23; 5WUK; 5WG6; 5U62 T25265 BIOCLASS Methyltransferase T25265 ECNUMBER EC 2.1.1.43 T25265 SEQUENCE MGQTGKKSEKGPVCWRKRVKSEYMRLRQLKRFRRADEVKSMFSSNRQKILERTEILNQEWKQRRIQPVHILTSVSSLRGTRECSVTSDLDFPTQVIPLKTLNAVASVPIMYSWSPLQQNFMVEDETVLHNIPYMGDEVLDQDGTFIEELIKNYDGKVHGDRECGFINDEIFVELVNALGQYNDDDDDDDGDDPEEREEKQKDLEDHRDDKESRPPRKFPSDKIFEAISSMFPDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPSTPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAEASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKIQLKKDGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSSECQNRFPGCRCKAQCNTKQCPCYLAVRECDPDLCLTCGAADHWDSKNVSCKNCSIQRGSKKHLLLAPSDVAGWGIFIKDPVQKNEFISEYCGEIISQDEADRRGKVYDKYMCSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAIQTGEELFFDYRYSQADALKYVGIEREMEIP T25265 DRUGINFO D00EQL Tazemetostat Approved T25265 DRUGINFO DNM79H DS-3201b Phase 2 T25265 DRUGINFO D0E6AG CPI-1205 Phase 1/2 T25265 DRUGINFO DM5X0L SHR2554 Phase 1/2 T25265 DRUGINFO DXL38G CPI-0209 Phase 1/2 T25265 DRUGINFO D05FIJ GSK2816126 Phase 1 T25265 DRUGINFO DI1L7M PF-06821497 Phase 1 T25265 DRUGINFO D0LG8T DS-3201 Phase 1 T25265 DRUGINFO D6EU7R HH2853 Phase 1 T25265 DRUGINFO D03MYI PMID28394193-Compound-33 Patented T25265 DRUGINFO D04PCW PMID28394193-Compound-Figure3bI Patented T25265 DRUGINFO D05MAR PMID28394193-Compound-35 Patented T25265 DRUGINFO D07CZI PMID28394193-Compound-54 Patented T25265 DRUGINFO D08MXO PMID28394193-Compound-24 Patented T25265 DRUGINFO D09GFF PMID28394193-Compound-27 Patented T25265 DRUGINFO D09PQQ PMID28394193-Compound-25 Patented T25265 DRUGINFO D0A0VH PMID28394193-Compound-50 Patented T25265 DRUGINFO D0B4TX PMID28394193-Compound-47 Patented T25265 DRUGINFO D0BL8W PMID28394193-Compound-21 Patented T25265 DRUGINFO D0BT6Y PMID28394193-Compound-41 Patented T25265 DRUGINFO D0CH4O PMID28394193-Compound-53 Patented T25265 DRUGINFO D0D1QD PMID28394193-Compound-Figure5aVIII Patented T25265 DRUGINFO D0DQ6N PMID28394193-Compound-38 Patented T25265 DRUGINFO D0FC9J PMID28394193-Compound-51 Patented T25265 DRUGINFO D0FI3A PMID28394193-Compound-31 Patented T25265 DRUGINFO D0H4HR PMID28394193-Compound-42 Patented T25265 DRUGINFO D0KR2T PMID28394193-Compound-15 Patented T25265 DRUGINFO D0LR5O PMID28394193-Compound-52 Patented T25265 DRUGINFO D0M1TG PMID28394193-Compound-32 Patented T25265 DRUGINFO D0M9BY PMID28394193-Compound-23 Patented T25265 DRUGINFO D0MH8G PMID28394193-Compound-29 Patented T25265 DRUGINFO D0MO2X PMID28394193-Compound-30 Patented T25265 DRUGINFO D0MZ8D PMID28394193-Compound-39 Patented T25265 DRUGINFO D0PB6T PMID28394193-Compound-49 Patented T25265 DRUGINFO D0PI5O PMID28394193-Compound-43 Patented T25265 DRUGINFO D0QH1J PMID28394193-Compound-40 Patented T25265 DRUGINFO D0R2TQ PMID28394193-Compound-Figure3bIII Patented T25265 DRUGINFO D0RD5P PMID28394193-Compound-36 Patented T25265 DRUGINFO D0S4OP PMID28394193-Compound-28 Patented T25265 DRUGINFO D0SQ1R PMID28394193-Compound-22 Patented T25265 DRUGINFO D0SY6P PMID28394193-Compound-18 Patented T25265 DRUGINFO D0T8QL PMID28394193-Compound-16 Patented T25265 DRUGINFO D0U9OH PMID28394193-Compound-44 Patented T25265 DRUGINFO D0UG5O PMID28394193-Compound-20 Patented T25265 DRUGINFO D0VF0M PMID28394193-Compound-19 Patented T25265 DRUGINFO D0W2KL PMID28394193-Compound-37 Patented T25265 DRUGINFO D0W4MW PMID28394193-Compound-Figure3bII Patented T25265 DRUGINFO D0Z0NC PMID28394193-Compound-26 Patented T25265 DRUGINFO D0Z0QS PMID28394193-Compound-17 Patented T25265 DRUGINFO D0Z7GN PMID28394193-Compound-34 Patented T25265 DRUGINFO D01PZZ PMID28394193-Compound-56 Patented T25265 DRUGINFO D0D4UH PMID28394193-Compound-46 Patented T25265 DRUGINFO D0G1JR PMID28394193-Compound-57 Patented T25265 DRUGINFO D0GT7A PMID28394193-Compound-14 Patented T25265 DRUGINFO D0H8VN PMID28394193-Compound-12 Patented T25265 DRUGINFO D0L1TA PMID26882240-Compound-1 Patented T25265 DRUGINFO D0M4LK PMID28394193-Compound-55 Patented T25265 DRUGINFO D0M8AA PMID28394193-Compound-45 Patented T25265 DRUGINFO D0TA4N PMID28394193-Compound-13 Patented T25265 DRUGINFO D02BBA EPZ005687 Investigative T25265 DRUGINFO D02CIT EI1 Investigative T25265 DRUGINFO D02YXP UNC1999 Investigative T25265 DRUGINFO D65IMT MS1943 Investigative T25265 DRUGINFO D02TVQ GSK343 Investigative T53904 TARGETID T53904 T53904 FORMERID TTDC00054 T53904 UNIPROID EGLN2_HUMAN T53904 TARGNAME HIF-prolyl hydroxylase 1 (HPH-1) T53904 GENENAME EGLN2 T53904 TARGTYPE Successful T53904 SYNONYMS Prolyl hydroxylase domain-containing protein 1; PHD1; Hypoxia-inducible factor prolyl hydroxylase 1; HPH-3; HIF-PH1; HIF-PH; Estrogen-induced tag6; Estrogen-induced tag 6; Egl nine homolog 2; EIT6; EIT-6 T53904 FUNCTION Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF2A. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN2 is involved in regulating hypoxia tolerance and apoptosis in cardiac and skeletal muscle. Also regulates susceptibility to normoxic oxidative neuronal death. Links oxygen sensing to cell cycle and primary cilia formation by hydroxylating the critical centrosome component CEP192 which promotes its ubiquitination and subsequent proteasomal degradation. Hydroxylates IKBKB, mediating NF-kappaB activation in hypoxic conditions. Target proteins are preferentially recognized via a LXXLAP motif. Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. T53904 PDBSTRUC 5V1B T53904 BIOCLASS Paired donor oxygen oxidoreductase T53904 ECNUMBER EC 1.14.11.29 T53904 SEQUENCE MDSPCQPQPLSQALPQLPGSSSEPLEPEPGRARMGVESYLPCPLLPSYHCPGVPSEASAGSGTPRATATSTTASPLRDGFGGQDGGELRPLQSEGAAALVTKGCQRLAAQGARPEAPKRKWAEDGGDAPSPSKRPWARQENQEAEREGGMSCSCSSGSGEASAGLMEEALPSAPERLALDYIVPCMRYYGICVKDSFLGAALGGRVLAEVEALKRGGRLRDGQLVSQRAIPPRSIRGDQIAWVEGHEPGCRSIGALMAHVDAVIRHCAGRLGSYVINGRTKAMVACYPGNGLGYVRHVDNPHGDGRCITCIYYLNQNWDVKVHGGLLQIFPEGRPVVANIEPLFDRLLIFWSDRRNPHEVKPAYATRYAITVWYFDAKERAAAKDKYQLASGQKGVQVPVSQPPTPT T53904 DRUGINFO D0F6JC Daprodustat Approved T53904 DRUGINFO D03YKE FG-4592 Phase 3 T53904 DRUGINFO D01SPD BAY-85-3934 Phase 2 T53904 DRUGINFO D07IOY Pyridine-2,4-dicarboxylic acid Investigative T53904 DRUGINFO D08IZY 2-(carboxymethylamino)-2-oxoacetic acid Investigative T64765 TARGETID T64765 T64765 FORMERID TTDC00079 T64765 UNIPROID HRH3_HUMAN T64765 TARGNAME Histamine H3 receptor (H3R) T64765 GENENAME HRH3 T64765 TARGTYPE Successful T64765 SYNONYMS Histamine receptor 3; HH3R; GPCR97; G-protein coupled receptor 97; G protein-coupled receptor 97 T64765 FUNCTION Signals through the inhibition of adenylate cyclase and displays high constitutive activity (spontaneous activity in the absence of agonist). Agonist stimulation of isoform 3 neither modified adenylate cyclase activity nor induced intracellular calcium mobilization. The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. T64765 BIOCLASS GPCR rhodopsin T64765 SEQUENCE MERAPPDGPLNASGALAGEAAAAGGARGFSAAWTAVLAALMALLIVATVLGNALVMLAFVADSSLRTQNNFFLLNLAISDFLVGAFCIPLYVPYVLTGRWTFGRGLCKLWLVVDYLLCTSSAFNIVLISYDRFLSVTRAVSYRAQQGDTRRAVRKMLLVWVLAFLLYGPAILSWEYLSGGSSIPEGHCYAEFFYNWYFLITASTLEFFTPFLSVTFFNLSIYLNIQRRTRLRLDGAREAAGPEPPPEAQPSPPPPPGCWGCWQKGHGEAMPLHRYGVGEAAVGAEAGEATLGGGGGGGSVASPTSSSGSSSRGTERPRSLKRGSKPSASSASLEKRMKMVSQSFTQRFRLSRDRKVAKSLAVIVSIFGLCWAPYTLLMIIRAACHGHCVPDYWYETSFWLLWANSAVNPVLYPLCHHSFRRAFTKLLCPQKLKIQPHSSLEHCWK T64765 DRUGINFO D01UUD Pitolisant Approved T64765 DRUGINFO D04KMP SUVN-G3031 Phase 3 T64765 DRUGINFO D02REJ JNJ-17216498 Phase 2 T64765 DRUGINFO D07YGH GSK239512 Phase 2 T64765 DRUGINFO D0EQ9T JNJ-39220675 Phase 2 T64765 DRUGINFO D0I6ZO AZD-5213 Phase 2 T64765 DRUGINFO D0M8OC Bavisant Phase 2 T64765 DRUGINFO D0N8QK ABT-288 Phase 2 T64765 DRUGINFO D0O0EX SAR-110894 Phase 2 T64765 DRUGINFO D0S5BV ABT-652 Phase 2 T64765 DRUGINFO D0XW6Y S-38093 Phase 2 T64765 DRUGINFO D00GCA MK-7288 Phase 1 T64765 DRUGINFO D04LSD ABT-239 Phase 1 T64765 DRUGINFO D0N1GB APD-916 Phase 1 T64765 DRUGINFO D0OW9L MK-3134 Phase 1 T64765 DRUGINFO D0P2OK HPP404 Phase 1 T64765 DRUGINFO D0R2OU Irdabisant Phase 1 T64765 DRUGINFO D0M9RQ MK-0249 Clinical trial T64765 DRUGINFO D01EHZ Piperazine carbamate/urea derivative 5 Patented T64765 DRUGINFO D01IJA Piperazine carbamate/urea derivative 3 Patented T64765 DRUGINFO D02SKQ PMID29334795-Compound-28 Patented T64765 DRUGINFO D03EHI Acrylamide compound 3 Patented T64765 DRUGINFO D04DUF Phenylsulfonyl derivative 2 Patented T64765 DRUGINFO D08EYN Acrylamide compound 2 Patented T64765 DRUGINFO D09AQZ PMID29334795-Compound-57 Patented T64765 DRUGINFO D09QCB PMID29334795-Compound-56 Patented T64765 DRUGINFO D09STY PMID29334795-Compound-55 Patented T64765 DRUGINFO D0A2ZO Phenoxypiperidine derivative 2 Patented T64765 DRUGINFO D0A8VU PMID29334795-Compound-58 Patented T64765 DRUGINFO D0AX9N Biphenyl derivative 4 Patented T64765 DRUGINFO D0B2NV PMID29334795-Compound-22 Patented T64765 DRUGINFO D0CE7X 4-benzylidene-1-(cyclobutylo)piperidine derivative 1 Patented T64765 DRUGINFO D0D8LP Phenylsulfonyl derivative 3 Patented T64765 DRUGINFO D0DS9D Acrylamide compound 4 Patented T64765 DRUGINFO D0EP0M PMID29334795-Compound-24 Patented T64765 DRUGINFO D0F7UB Triazolo-benzodiazepine derivative 1 Patented T64765 DRUGINFO D0F8PG PMID29334795-Compound-21 Patented T64765 DRUGINFO D0FJ3N Piperazine carbamate/urea derivative 2 Patented T64765 DRUGINFO D0GB3P Pyridazin-3(2H)-one derivative 1 Patented T64765 DRUGINFO D0H7OC Piperazine carbamate/urea derivative 4 Patented T64765 DRUGINFO D0K9MH Acrylamide compound 1 Patented T64765 DRUGINFO D0KP0I Piperazine carbamate/urea derivative 1 Patented T64765 DRUGINFO D0QV0P Phenoxypiperidine derivative 1 Patented T64765 DRUGINFO D0R0GY Piperazine carbamate/urea derivative 7 Patented T64765 DRUGINFO D0RV0O PMID29334795-Compound-23 Patented T64765 DRUGINFO D0SZ1L Triazolo-benzodiazepine derivative 2 Patented T64765 DRUGINFO D0TE2D PMID29334795-Compound-25 Patented T64765 DRUGINFO D0TM4R Piperazine carbamate/urea derivative 6 Patented T64765 DRUGINFO D0V2WE Steroidal carboxamide derivative 1 Patented T64765 DRUGINFO D0W3RA Phenylsulfonyl derivative 1 Patented T64765 DRUGINFO D0ZC7W Phenylsulfonyl derivative 4 Patented T64765 DRUGINFO D05KKZ PMID29334795-Compound-67 Patented T64765 DRUGINFO D0BZ0N Benzo[d]oxazol-2(3H)-one derivative 2 Patented T64765 DRUGINFO D0D5AH PMID29334795-Compound-62 Patented T64765 DRUGINFO D0N8CU Benzo[d]oxazol-2(3H)-one derivative 3 Patented T64765 DRUGINFO D0RP1J PMID29334795-Compound-66 Patented T64765 DRUGINFO D0SO4O Benzo[d]oxazol-2(3H)-one derivative 1 Patented T64765 DRUGINFO D0FA3G PMID29334795-Compound-61 Patented T64765 DRUGINFO D0VX6P Piperidine derivative 1 Patented T64765 DRUGINFO D0P9LO BP-2.94 Discontinued in Phase 2 T64765 DRUGINFO D0Q5YF Cipralisant Discontinued in Phase 2 T64765 DRUGINFO D04IFU GSK835726 Discontinued in Phase 2 T64765 DRUGINFO D02EVT SAR-152954 Discontinued in Phase 1 T64765 DRUGINFO D0B4TT GSK1004723 Discontinued in Phase 1 T64765 DRUGINFO D02KAF GT-2203 Terminated T64765 DRUGINFO D02YXQ GT-2016 Terminated T64765 DRUGINFO D06TEO UCL-1390 Terminated T64765 DRUGINFO D0N2CN GR-175737 Terminated T64765 DRUGINFO D05FYA Thioperamide Terminated T64765 DRUGINFO D00HWF Proxyfan Investigative T64765 DRUGINFO D00IIQ (S)-1-(4-nitrophenethyl)-2-methylpyrrolidine Investigative T64765 DRUGINFO D00PSJ 2-(3-Methyl-3H-imidazol-4-yl)-ethylamine Investigative T64765 DRUGINFO D00RUN 4-(7,7-Dimethyl-oct-3-ynyl)-1H-imidazole Investigative T64765 DRUGINFO D00SHX 1-[2-(2,4,6-trimethyl-phenyl)-ethyl]-pyrrolidine Investigative T64765 DRUGINFO D01CJZ VUF 5681 Investigative T64765 DRUGINFO D01RJV 4-((2S,3R)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole Investigative T64765 DRUGINFO D01RTR (R)-3-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine Investigative T64765 DRUGINFO D02BXA 2-(2-(pyrrolidin-1-yl)ethyl)pyridine Investigative T64765 DRUGINFO D02HNE 5-(2-(pyrrolidin-1-yl)ethyl)isothiazole Investigative T64765 DRUGINFO D02IJW (S)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine Investigative T64765 DRUGINFO D02INJ 4-(2-(Phenylamino)ethyl)-1H-imidazole Investigative T64765 DRUGINFO D02LZL 4-(6-Cyclohexyl-hex-3-ynyl)-1H-imidazole Investigative T64765 DRUGINFO D02SWF (1R,2R)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine Investigative T64765 DRUGINFO D03QGB JNJ-5207852 Investigative T64765 DRUGINFO D04ATN 4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole Investigative T64765 DRUGINFO D04FUZ 1-(3-(2-(3-methoxyphenoxy)ethoxy)propyl)azepane Investigative T64765 DRUGINFO D04LFK 2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole Investigative T64765 DRUGINFO D04MKB ST-1025 Investigative T64765 DRUGINFO D04NWI (R)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine Investigative T64765 DRUGINFO D04ZOI 4-(8-Phenyl-oct-3-ynyl)-1H-imidazole Investigative T64765 DRUGINFO D05ANV 1-(2-p-tolyl-ethyl)-pyrrolidine Investigative T64765 DRUGINFO D05BYD A-304121 Investigative T64765 DRUGINFO D05JZQ 2-(2-(pyrrolidin-1-yl)ethyl)phenol Investigative T64765 DRUGINFO D05OHN 4-isopropyl-2-(phenoxymethyl)morpholine Investigative T64765 DRUGINFO D05PBN (R)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine Investigative T64765 DRUGINFO D05RGW Methimepip Investigative T64765 DRUGINFO D06MGO (S)-1-(2-methoxyphenethyl)-2-methylpyrrolidine Investigative T64765 DRUGINFO D06RPY 2-[4-(1-Ethyl-propyl)-piperazin-1-yl]-quinoline Investigative T64765 DRUGINFO D06ZBV CARCININE Investigative T64765 DRUGINFO D07JHD VUF5391 Investigative T64765 DRUGINFO D07KTP SCH79687 Investigative T64765 DRUGINFO D07LCM 1-(3-methoxyphenethyl)pyrrolidine Investigative T64765 DRUGINFO D07PSG 5-phenyl-2-(4-(piperidin-1-yl)butyl)oxazole Investigative T64765 DRUGINFO D07TST 4-(2-(Cyclohexylamino)ethyl)-1H-imidazole Investigative T64765 DRUGINFO D07UCE 4-Benzyl-1-[3-phenylpropoxy)propyl]piperidine Investigative T64765 DRUGINFO D08BSG IODOPROXYFAN Investigative T64765 DRUGINFO D08HYX 4-Hex-3-ynyl-1H-imidazole Investigative T64765 DRUGINFO D09DDQ FUB-130 Investigative T64765 DRUGINFO D09JSA 1-(3-(3-phenylpropoxy)propyl)piperidine Investigative T64765 DRUGINFO D09NSH JB 98064 Investigative T64765 DRUGINFO D09ROG UCL-2138 Investigative T64765 DRUGINFO D09WQL Immethridine Investigative T64765 DRUGINFO D0A2WT 4-((2R,3S)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole Investigative T64765 DRUGINFO D0B5SF 4-(2-(3,4-Dimethylphenylamino)ethyl)-1H-imidazole Investigative T64765 DRUGINFO D0B6CA 4-(2-(pyrrolidin-1-yl)ethyl)pyridine Investigative T64765 DRUGINFO D0CI9W GSK-334429 Investigative T64765 DRUGINFO D0D0FV (R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine Investigative T64765 DRUGINFO D0D9JL 1-(2-m-tolyl-ethyl)-pyrrolidine Investigative T64765 DRUGINFO D0DC1P 1-(3-(4-(2-fluoroethyl)phenoxy)propyl)piperidine Investigative T64765 DRUGINFO D0DG5A 4-(7-Methyl-oct-3-ynyl)-1H-imidazole Investigative T64765 DRUGINFO D0E5EB impentamine Investigative T64765 DRUGINFO D0E5XM imbutamine Investigative T64765 DRUGINFO D0F2XZ (S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine Investigative T64765 DRUGINFO D0F9OP Aerophobin-1 Investigative T64765 DRUGINFO D0FK6T 2-(4-Cyclopentyl-piperazin-1-yl)-quinoline Investigative T64765 DRUGINFO D0FN7I Des-bromoaplysamine-1 Investigative T64765 DRUGINFO D0G3RN VUF-10214 Investigative T64765 DRUGINFO D0G5DU 4-Propyl-1-[3-(phenylpropoxy)propyl]piperidine Investigative T64765 DRUGINFO D0G5GV [123I]iodoproxyfan Investigative T64765 DRUGINFO D0G5TD (S)-1-(3-methoxyphenethyl)-2-methylpyrrolidine Investigative T64765 DRUGINFO D0H3DY VUF-5297 Investigative T64765 DRUGINFO D0H3LF 2-(4-Isopropyl-piperazin-1-yl)-quinoline Investigative T64765 DRUGINFO D0H4ID (S)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate Investigative T64765 DRUGINFO D0H4TP GSK189254A Investigative T64765 DRUGINFO D0H9IH (R)-1-(3-methoxyphenethyl)-2-methylpyrrolidine Investigative T64765 DRUGINFO D0HF4I 4-(2-(4-Methoxyphenylamino)ethyl)-1H-imidazole Investigative T64765 DRUGINFO D0HM7G SUVN-G1031 Investigative T64765 DRUGINFO D0I3TN (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopentylamine Investigative T64765 DRUGINFO D0I4BC 1-(2-(naphthalen-2-yl)ethyl)pyrrolidine Investigative T64765 DRUGINFO D0I4UU FUB 349 Investigative T64765 DRUGINFO D0J6NI 4-((1H-Imidazol-4-yl)methyl)-1-phenylpiperidine Investigative T64765 DRUGINFO D0J6XO A-331440 Investigative T64765 DRUGINFO D0K1PS (1R,2S)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine Investigative T64765 DRUGINFO D0K7XM APLYSAMINE Investigative T64765 DRUGINFO D0K8DZ VUF 5207 Investigative T64765 DRUGINFO D0K9WJ 2-(4-Cyclopropyl-piperazin-1-yl)-quinoline Investigative T64765 DRUGINFO D0KK4C 2-[2-(1H-Imidazol-4-yl)-cyclopropyl]-ethylamine Investigative T64765 DRUGINFO D0M2HC 4-(2-(4-Methylphenylamino)ethyl)-1H-imidazole Investigative T64765 DRUGINFO D0M4JK UCB-2892 Investigative T64765 DRUGINFO D0M7QR 5-ethyl-2-(2-(pyrrolidin-1-yl)ethyl)pyridine Investigative T64765 DRUGINFO D0M7TW PF-3900422 Investigative T64765 DRUGINFO D0MR0Z (R)-1-(4-methoxyphenethyl)-2-methylpyrrolidine Investigative T64765 DRUGINFO D0MX0Z (R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol Investigative T64765 DRUGINFO D0N3OH A-317920 Investigative T64765 DRUGINFO D0N6CB ST-1093 Investigative T64765 DRUGINFO D0N7KK 5-methoxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole Investigative T64765 DRUGINFO D0O3GR 4-[3-(4-Methoxy-phenoxy)-propyl]-1H-imidazole Investigative T64765 DRUGINFO D0O9LR 4-[3-(4-Butyl-phenoxy)-propyl]-1H-imidazole Investigative T64765 DRUGINFO D0O9YL (R)-1-(2-methoxyphenethyl)-2-methylpyrrolidine Investigative T64765 DRUGINFO D0OB7B 2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridine Investigative T64765 DRUGINFO D0OM9G Immepip Investigative T64765 DRUGINFO D0P2UM 2-(ethoxycarbonyl)-1H-indole-5-carboxylic acid Investigative T64765 DRUGINFO D0P8SU (R)-1-(4-nitrophenethyl)-2-methylpyrrolidine Investigative T64765 DRUGINFO D0P8UI (S)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine Investigative T64765 DRUGINFO D0Q0YC 2-(4-Propyl-piperazin-1-yl)-quinoline Investigative T64765 DRUGINFO D0Q6TU GT2394 Investigative T64765 DRUGINFO D0Q8CE 4-(2-(3-tert-Butylphenylamino)ethyl)-1H-imidazole Investigative T64765 DRUGINFO D0Q8LU 2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridine Investigative T64765 DRUGINFO D0Q8NO VUF 8328 Investigative T64765 DRUGINFO D0QP3A 1-(4-(benzyloxy)phenethyl)pyrrolidine Investigative T64765 DRUGINFO D0R2TU 4-(3-Phenoxy-propyl)-1H-imidazole Investigative T64765 DRUGINFO D0RP8X UCL1972 Investigative T64765 DRUGINFO D0S0HT 3-((1H-imidazol-4-yl)methyl)pyridine Investigative T64765 DRUGINFO D0S5ON 1-(4-nitrophenethyl)pyrrolidine Investigative T64765 DRUGINFO D0S5VI N-benzyl-4-cyclopentylpiperazine-1-carboxamide Investigative T64765 DRUGINFO D0SQ0T C-[2-(1H-Imidazol-4-yl)-cyclopropyl]-methylamine Investigative T64765 DRUGINFO D0T5KC (S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol Investigative T64765 DRUGINFO D0T6TH EVT-501 Investigative T64765 DRUGINFO D0T8MV (S)-1-(4-methoxyphenethyl)-2-methylpyrrolidine Investigative T64765 DRUGINFO D0TW9N 2-((2-ethoxyphenoxy)methyl)-4-isopropylmorpholine Investigative T64765 DRUGINFO D0U1DR VUF 4904 Investigative T64765 DRUGINFO D0UO2Z 4-(2-(4-Cyclohexylphenylamino)ethyl)-1H-imidazole Investigative T64765 DRUGINFO D0UW9I (S)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine Investigative T64765 DRUGINFO D0V4XA ATH-90879 Investigative T64765 DRUGINFO D0V7YQ 4-((1H-imidazol-4-yl)methyl)-1-heptylpiperidine Investigative T64765 DRUGINFO D0V8MJ 4-(6-Cyclopentyl-hex-3-ynyl)-1H-imidazole Investigative T64765 DRUGINFO D0V9AJ 1-(2-methoxyphenethyl)pyrrolidine Investigative T64765 DRUGINFO D0W1GR 4-Hept-3-ynyl-1H-imidazole Investigative T64765 DRUGINFO D0W2HJ 1-(4-methoxyphenethyl)pyrrolidine Investigative T64765 DRUGINFO D0W7OR 2-((1H-imidazol-4-yl)methyl)pyridine Investigative T64765 DRUGINFO D0X5DB 4-(2-(4-tert-Butylphenylamino)ethyl)-1H-imidazole Investigative T64765 DRUGINFO D0X6SR (R)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine Investigative T64765 DRUGINFO D0XW9U N-methyl-2-(pyridin-2-yl)ethanamine Investigative T64765 DRUGINFO D0Y5MS Verongamine Investigative T64765 DRUGINFO D0Y5WD 1-(3-(4-(fluoromethyl)phenoxy)propyl)piperidine Investigative T64765 DRUGINFO D0ZY8V 4-Butyl-1-[3-(phenylpropoxy)propyl]piperidine Investigative T64765 DRUGINFO D02RAN Imetit Investigative T64765 DRUGINFO D03ECU [125I]iodophenpropit Investigative T64765 DRUGINFO D03SAM (R)-alpha-methylhistamine Investigative T64765 DRUGINFO D06NXK (R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline Investigative T64765 DRUGINFO D08ECP N-[3H]alpha-methylhistamine Investigative T64765 DRUGINFO D0A4XL N-[3H]methylhistamine Investigative T64765 DRUGINFO D0A9QT JNJ-28583867 Investigative T64765 DRUGINFO D0C8IB (R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate Investigative T64765 DRUGINFO D0H2KD (1H-indol-2-yl)(piperazin-1-yl)methanone Investigative T64765 DRUGINFO D0Q8BS (S)-alpha-methylhistamine Investigative T64765 DRUGINFO D0T6SC N-methylhistamine Investigative T64765 DRUGINFO D0T8OD Clobenpropit Investigative T64765 DRUGINFO D06RNM burimamide Investigative T64765 DRUGINFO D0G2BS 2-(4-Methyl-piperazin-1-yl)-quinoline Investigative T64765 DRUGINFO D0M9IC CONESSINE Investigative T64765 DRUGINFO D01JXM 2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole Investigative T64765 DRUGINFO D0B4SF impromidine Investigative T64765 DRUGINFO D0I3XA Ciproxifan Investigative T64765 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T29024 TARGETID T29024 T29024 FORMERID TTDC00325 T29024 UNIPROID SODC_HUMAN T29024 TARGNAME SOD1 messenger RNA (SOD1 mRNA) T29024 GENENAME SOD1 T29024 TARGTYPE Successful T29024 SYNONYMS hSod1 (mRNA); Superoxide dismutase [Cu-Zn] (mRNA); Superoxide dismutase 1 (mRNA); Superoxide dismutase (mRNA) T29024 FUNCTION Destroys radicals which are normally produced within the cells and which are toxic to biological systems. T29024 PDBSTRUC 6FP6; 6FON; 6FOL; 6FOI; 6FLH T29024 BIOCLASS mRNA target T29024 ECNUMBER EC 1.15.1.1 T29024 SEQUENCE MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ T29024 DRUGINFO D0I1CQ Tofersen Approved T29024 DRUGINFO D05BYO ISIS-SOD1 Phase 1 T29024 DRUGINFO D05EJO ISIS 150463 Investigative T29024 DRUGINFO D05RSX ISIS 150454 Investigative T29024 DRUGINFO D07AGD ISIS 150450 Investigative T29024 DRUGINFO D07MGX ISIS 150451 Investigative T29024 DRUGINFO D0A3RM ISIS 150452 Investigative T29024 DRUGINFO D0BP6T ISIS 150464 Investigative T29024 DRUGINFO D0F4SF ISIS 150453 Investigative T30687 TARGETID T30687 T30687 FORMERID TTDR01436 T30687 UNIPROID GCR_HUMAN T30687 TARGNAME Glucocorticoid receptor messenger RNA (GCR mRNA) T30687 GENENAME NR3C1 T30687 TARGTYPE Successful T30687 SYNONYMS Nuclear receptor subfamily 3 group C member 1 (mRNA); Glucocorticoid receptor (mRNA); GRL (mRNA); GR (mRNA); Alpha-A (mRNA) T30687 FUNCTION Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling. Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Receptor for glucocorticoids (GC). T30687 PDBSTRUC 6EL9; 6EL7; 6EL6; 6DXK; 6CFN T30687 BIOCLASS mRNA target T30687 SEQUENCE MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRRLLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLKLLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGNVKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGNSNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTVYCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVGSENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKLCLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRKCLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIEPEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSWMFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSYEEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTKLLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK T30687 DRUGINFO D0F6YM Vamorolone Approved T30687 DRUGINFO D07UIS CORT125281 Phase 2 T30687 DRUGINFO D0F8XK ISIS-GCCR Phase 2 T30687 DRUGINFO D0HE7C ORIC-101 Phase 1 T30687 DRUGINFO D0SZ1G AZD9567 Phase 1 T30687 DRUGINFO D0W8OJ A-348441 Phase 1 T30687 DRUGINFO D05XVM 1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine Investigative T30687 DRUGINFO D06TOI RU26988 Investigative T30687 DRUGINFO D09FQL ENDIANDRIN A Investigative T30687 DRUGINFO D0D6GI 1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX) Investigative T30687 DRUGINFO D0EG5G 1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX) Investigative T30687 DRUGINFO D0N8UD 2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX) Investigative T30687 DRUGINFO D0O5ZG 1-Methoxy-6-phenyl-6H-benzo[c]chromene Investigative T30687 DRUGINFO D0PR2T DI-O-METHYLENDIANDRIN A Investigative T30687 DRUGINFO D0S9KH OXDEX Investigative T30687 DRUGINFO D0Z7YK RU28362 Investigative T30687 DRUGINFO D04SQY deoxycorticosterone Investigative T30687 DRUGINFO D07KWO RU-43044 Investigative T30687 DRUGINFO D03TNT (11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE Investigative T30687 DRUGINFO D09OKK LG-120838 Investigative T30687 DRUGINFO D0XS0R Epierenone Investigative T30687 DRUGINFO D08KQM LGD-5552 Investigative T30687 DRUGINFO D0GR5L AL-43 Investigative T30687 DRUGINFO D0J7XZ CP-409069 Investigative T30687 DRUGINFO D0L5IC CP-394531 Investigative T30687 DRUGINFO D0V4RZ WAY-214950 Investigative T30687 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T86652 TARGETID T86652 T86652 FORMERID TTDR01439 T86652 UNIPROID PCSK9_HUMAN T86652 TARGNAME PCSK9 messenger RNA (PCSK9 mRNA) T86652 GENENAME PCSK9 T86652 TARGTYPE Successful T86652 SYNONYMS Subtilisin/kexin-like protease PC9 (mRNA); Proprotein convertase subtilisin/kexin type 9 (mRNA); Proprotein convertase 9 (mRNA); PSEC0052 (mRNA); PC9 (mRNA); Neural apoptosis-regulated convertase 1 (mRNA); NARC1 (mRNA); NARC-1 (mRNA) T86652 FUNCTION Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. Crucial player in the regulation of plasma cholesterol homeostasis. T86652 PDBSTRUC 6MV5; 6F5G; 6E4Z; 6E4Y; 5VLP T86652 BIOCLASS mRNA target T86652 ECNUMBER EC 3.4.21.- T86652 SEQUENCE MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEELVLALRSEEDGLAEAPEHGTTATFHRCAKDPWRLPGTYVVVLKEETHLSQSERTARRLQAQAARRGYLTKILHVFHGLLPGFLVKMSGDLLELALKLPHVDYIEEDSSVFAQSIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMVTDFENVPEEDGTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRSLRVLNCQGKGTVSGTLIGLEFIRKSQLVQPVGPLVVLLPLAGGYSRVLNAACQRLARAGVVLVTAAGNFRDDACLYSPASAPEVITVGATNAQDQPVTLGTLGTNFGRCVDLFAPGEDIIGASSDCSTCFVSQSGTSQAAAHVAGIAAMMLSAEPELTLAELRQRLIHFSAKDVINEAWFPEDQRVLTPNLVAALPPSTHGAGWQLFCRTVWSAHSGPTRMATAVARCAPDEELLSCSSFSRSGKRRGERMEAQGGKLVCRAHNAFGGEGVYAIARCCLLPQANCSVHTAPPAEASMGTRVHCHQQGHVLTGCSSHWEVEDLGTHKPPVLRPRGQPNQCVGHREASIHASCCHAPGLECKVKEHGIPAPQEQVTVACEEGWTLTGCSALPGTSHVLGAYAVDNTCVVRSRDVSTTGSTSEGAVTAVAICCRSRHLAQASQELQ T86652 DRUGINFO D00COJ Inclisiran Approved T86652 DRUGINFO D0B1TI MPSK3169A Phase 2 T86652 DRUGINFO D81WHA AZD8233 Phase 2 T86652 DRUGINFO D0G9OC BMS-PCSK9 Preclinical T86652 DRUGINFO D0H5HJ ALN-PCS Preclinical T26851 TARGETID T26851 T26851 FORMERID TTDR01153 T26851 UNIPROID CO3_HUMAN T26851 TARGNAME Complement C3 (CO3) T26851 GENENAME C3 T26851 TARGTYPE Successful T26851 SYNONYMS C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1; C3 T26851 FUNCTION Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750). T26851 PDBSTRUC 6EHG; 5O35; 5O32; 5NBQ; 5M6W T26851 BIOCLASS Complement system T26851 SEQUENCE MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVHDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKVVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSLSSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTEKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEVVLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKTPKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPLSITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMDRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGASGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDKGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAELQCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEACKKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKEPPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVVRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVIVPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKEDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTPTVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTAYVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKDMALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMGRLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLRSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDAKNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSDRNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDGKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDEYIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSYIIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN T26851 DRUGINFO D0P5LH Pegcetacoplan Approved T26851 DRUGINFO D0P6MW Imprime PGG Phase 2/3 T26851 DRUGINFO D01SQI POT-4 Phase 2 T26851 DRUGINFO D4ME2Z NGM621 Phase 2 T26851 DRUGINFO DSI31T AMY-101 Phase 2 T26851 DRUGINFO D00BCO Ac-I[CV(Bta)QDWGAHRC]T Investigative T26851 DRUGINFO D00CYF Ac-I[CVWQDWGWHRC]T-NH2 Investigative T26851 DRUGINFO D01DQT Ac-ICVWQDWGAHRCT-NH2 Investigative T26851 DRUGINFO D01ZRJ Ac-I[CV(Bta)QDWGAHRC]T-NH2 Investigative T26851 DRUGINFO D02AWT Ac-I[CV(Bpa)QDWGAHRC]T Investigative T26851 DRUGINFO D02CSO Ac-I[CVWQDWG(Abu)HRC]T-NH2 Investigative T26851 DRUGINFO D03SHO Ac-I[CVVQDWGAHRC]T-NH2 Investigative T26851 DRUGINFO D05AIB Ac-I[CVHQDWGHHRC]T-NH2 Investigative T26851 DRUGINFO D05LJY Ac-I[CV(2Nal)QDWGAHRC]T Investigative T26851 DRUGINFO D07VEA Ac-ICV(1MeW)QDWGAHRCT-NH2 Investigative T26851 DRUGINFO D0B4JO Ac-I[CVWQDWGAHRC]T Investigative T26851 DRUGINFO D0D3VF Ac-ICV(5fW)QDWGAHRCT-NH2 Investigative T26851 DRUGINFO D0DR3X Ac-I[CV(2Igl)QDWGAHRC]T Investigative T26851 DRUGINFO D0G4VH Ac-I[CVSQDWGHHRC]T-NH2 Investigative T26851 DRUGINFO D0J3BV Ac-I[CV(Bpa)QDWGAHRC]T-NH2 Investigative T26851 DRUGINFO D0N6LH Ac-I[CV(1Nal)QDWGAHRC]T Investigative T26851 DRUGINFO D0O2BI Ac-I[CVWQDWGHHRC]T-NH2 Investigative T26851 DRUGINFO D0PD8G Ac-I[CV(Dht)QDWGAHRC]T Investigative T26851 DRUGINFO D0Q0HE Ac-I[CVTQDWGHHRC]T-NH2 Investigative T26851 DRUGINFO D0R1MR Ac-I[CVFQDWGHHRC]T-NH2 Investigative T26851 DRUGINFO D0R2FS Ac-I[CVWQDWGAHRC]dT Investigative T26851 DRUGINFO D0T0PR Ac-I[CV(Yphs)QDWGAHRC]I-NH2 Investigative T26851 DRUGINFO D0T6ST Ac-I[CV(2Nal)QDWGAHRC]T-NH2 Investigative T26851 DRUGINFO D0T7CN Ac-ICVWQD(5fW)GAHRCT-NH2 Investigative T26851 DRUGINFO D0UK9D Ac-I[CV(2Igl)QDWGAHRC]T-NH2 Investigative T26851 DRUGINFO D0V0RO Ac-I[CVYQDWGAHRC]T-NH2 Investigative T26851 DRUGINFO D0Y9TF Ac-ICV(5MeW)QDWGAHRCT-NH2 Investigative T26851 DRUGINFO D0V6UC Cysteine Sulfenic Acid Investigative T23348 TARGETID T23348 T23348 FORMERID TTDC00108 T23348 UNIPROID VWF_HUMAN T23348 TARGNAME von Willebrand factor (VWF) T23348 GENENAME VWF T23348 TARGTYPE Successful T23348 SYNONYMS vWF; F8VWF T23348 FUNCTION Acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. T23348 PDBSTRUC 6N29; 6FWN; 5BV8; 4NT5; 4DMU T23348 SEQUENCE MIPARFAGVLLALALILPGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYSFAGYCSYLLAGGCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQGDQRVSMPYASKGLYLETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFNKTCGLCGNFNIFAEDDFMTQEGTLTSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPLVDPEPFVALCEKTLCECAGGLECACPALLEYARTCAQEGMVLYGWTDHSACSPVCPAGMEYRQCVSPCARTCQSLHINEMCQERCVDGCSCPEGQLLDEGLCVESTECPCVHSGKRYPPGTSLSRDCNTCICRNSQWICSNEECPGECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQDHSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDGQDVQLPLLKGDLRIQHTVTASVRLSYGEDLQMDWDGRGRLLVKLSPVYAGKTCGLCGNYNGNQGDDFLTPSGLAEPRVEDFGNAWKLHGDCQDLQKQHSDPCALNPRMTRFSEEACAVLTSPTFEACHRAVSPLPYLRNCRYDVCSCSDGRECLCGALASYAAACAGRGVRVAWREPGRCELNCPKGQVYLQCGTPCNLTCRSLSYPDEECNEACLEGCFCPPGLYMDERGDCVPKAQCPCYYDGEIFQPEDIFSDHHTMCYCEDGFMHCTMSGVPGSLLPDAVLSSPLSHRSKRSLSCRPPMVKLVCPADNLRAEGLECTKTCQNYDLECMSMGCVSGCLCPPGMVRHENRCVALERCPCFHQGKEYAPGETVKIGCNTCVCQDRKWNCTDHVCDATCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGSNPGTFRILVGNKGCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVESGRYIILLLGKALSVVWDRHLSISVVLKQTYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVDFGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKLVDPEPYLDVCIYDTCSCESIGDCACFCDTIAAYAHVCAQHGKVVTWRTATLCPQSCEERNLRENGYECEWRYNSCAPACQVTCQHPEPLACPVQCVEGCHAHCPPGKILDELLQTCVDPEDCPVCEVAGRRFASGKKVTLNPSDPEHCQICHCDVVNLTCEACQEPGGLVVPPTDAPVSPTTLYVEDISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVEYHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRITLLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVLSSVDELEQQRDEIVSYLCDLAPEAPPPTLPPDMAQVTVGPGLLGVSTLGPKRNSMVLDVAFVLEGSDKIGEADFNRSKEFMEEVIQRMDVGQDSIHVTVLQYSYMVTVEYPFSEAQSKGDILQRVREIRYQGGNRTNTGLALRYLSDHSFLVSQGDREQAPNLVYMVTGNPASDEIKRLPGDIQVVPIGVGPNANVQELERIGWPNAPILIQDFETLPREAPDLVLQRCCSGEGLQIPTLSPAPDCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITTIDVPWNVVPEKAHLLSLVDVMQREGGPSQIGDALGFAVRYLTSEMHGARPGASKAVVILVTDVSVDSVDAAADAARSNRVTVFPIGIGDRYDAAQLRILAGPAGDSNVVKLQRIEDLPTMVTLGNSFLHKLCSGFVRICMDEDGNEKRPGDVWTLPDQCHTVTCQPDGQTLLKSHRVNCDRGLRPSCPNSQSPVKVEETCGCRWTCPCVCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNKEQDLEVILHNGACSPGARQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEVNVYGAIMHEVRFNHLGHIFTFTPQNNEFQLQLSPKTFASKTYGLCGICDENGANDFMLRDGTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSSHCQVLLLPLFAECHKVLAPATFYAICQQDSCHQEQVCEVIASYAHLCRTNGVCVDWRTPDFCAMSCPPSLVYNHCEHGCPRHCDGNVSSCGDHPSEGCFCPPDKVMLEGSCVPEEACTQCIGEDGVQHQFLEAWVPDHQPCQICTCLSGRKVNCTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCDPVSCDLPPVPHCERGLQPTLTNPGECRPNFTCACRKEECKRVSPPSCPPHRLPTLRKTQCCDEYECACNCVNSTVSCPLGYLASTATNDCGCTTTTCLPDKVCVHRSTIYPVGQFWEEGCDVCTCTDMEDAVMGLRVAQCSQKPCEDSCRSGFTYVLHEGECCGRCLPSACEVVTGSPRGDSQSSWKSVGSQWASPENPCLINECVRVKEEVFIQQRNVSCPQLEVPVCPSGFQLSCKTSACCPSCRCERMEACMLNGTVIGPGKTVMIDVCTTCRCMVQVGVISGFKLECRKTTCNPCPLGYKEENNTGECCGRCLPTACTIQLRGGQIMTLKRDETLQDGCDTHFCKVNERGEYFWEKRVTGCPPFDEHKCLAEGGKIMKIPGTCCDTCEEPECNDITARLQYVKVGSCKSEVEVDIHYCQGKCASKAMYSIDINDVQDQCSCCSPTRTEPMQVALHCTNGSVVYHEVLNAMECKCSPRKCSK T23348 DRUGINFO D4Y0SB Vonvendi Approved T23348 DRUGINFO DUCA08 Caplacizumab Approved T23348 DRUGINFO D08POF ALX-0081 Phase 3 T23348 DRUGINFO D0B3XG Recombinant von Willebrand factor/recombinant Factor VIII complex Phase 3 T23348 DRUGINFO D41PKY BT-200 Phase 2 T23348 DRUGINFO DH8FY6 ARC1779 Phase 2 T23348 DRUGINFO D0HX1T DA-697b Phase 1 T23348 DRUGINFO DYZ76K DTRI-031 Phase 1 T23348 DRUGINFO D0KN7H Mitoflaxone Terminated T23348 DRUGINFO D0F1EF Auryntricarboxylic acid (ATA) Investigative T20333 TARGETID T20333 T20333 UNIPROID CSF1R_HUMAN T20333 TARGNAME Macrophage colony-stimulating factor 1 receptor (CSF1R) T20333 GENENAME CSF1R T20333 TARGTYPE Successful T20333 SYNONYMS Proto-oncogene c-Fms; M-CSF-R; FMS; CSF-1R; CSF-1-R; CSF-1 receptor; CD115 T20333 FUNCTION Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone and tooth development. Required for normal male and female fertility, and for normal development of milk ducts and acinar structures in the mammary gland during pregnancy. Promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration, and promotes cancer cell invasion. Activates several signaling pathways in response to ligand binding. Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL. Activation of PLCG2 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, that then lead to the activation of protein kinase C family members, especially PRKCD. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to activation of the AKT1 signaling pathway. Activated CSF1R also mediates activation of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1, and of the SRC family kinases SRC, FYN and YES1. Activated CSF1R transmits signals both via proteins that directly interact with phosphorylated tyrosine residues in its intracellular domain, or via adapter proteins, such as GRB2. Promotes activation of STAT family members STAT3, STAT5A and/or STAT5B. Promotes tyrosine phosphorylation of SHC1 and INPP5D/SHIP-1. Receptor signaling is down-regulated by protein phosphatases, such as INPP5D/SHIP-1, that dephosphorylate the receptor and its downstream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. T20333 PDBSTRUC 4WRM; 4WRL; 4R7I; 4R7H; 4LIQ T20333 BIOCLASS Kinase T20333 ECNUMBER EC 2.7.10.1 T20333 SEQUENCE MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEWDGPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLYVKDPARPWNVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMRHTNYSFSPWHGFTIHRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIPGPPALTLVPAELVRIRGEAAQIVCSASSVDVNFDVFLQHNNTKLAIPQQSDFHNNRYQKVLTLNLDQVDFQHAGNYSCVASNVQGKHSTSMFFRVVESAYLNLSSEQNLIQEVTVGEGLNLKVMVEAYPGLQGFNWTYLGPFSDHQPEPKLANATTKDTYRHTFTLSLPRLKPSEAGRYSFLARNPGGWRALTFELTLRYPPEVSVIWTFINGSGTLLCAASGYPQPNVTWLQCSGHTDRCDEAQVLQVWDDPYPEVLSQEPFHKVTVQSLLTVETLEHNQTYECRAHNSVGSGSWAFIPISAGAHTHPPDEFLFTPVVVACMSIMALLLLLLLLLLYKYKQKPKYQVRWKIIESYEGNSYTFIDPTQLPYNEKWEFPRNNLQFGKTLGAGAFGKVVEATAFGLGKEDAVLKVAVKMLKSTAHADEKEALMSELKIMSHLGQHENIVNLLGACTHGGPVLVITEYCCYGDLLNFLRRKAEAMLGPSLSPGQDPEGGVDYKNIHLEKKYVRRDSGFSSQGVDTYVEMRPVSTSSNDSFSEQDLDKEDGRPLELRDLLHFSSQVAQGMAFLASKNCIHRDVAARNVLLTNGHVAKIGDFGLARDIMNDSNYIVKGNARLPVKWMAPESIFDCVYTVQSDVWSYGILLWEIFSLGLNPYPGILVNSKFYKLVKDGYQMAQPAFAPKNIYSIMQACWALEPTHRPTFQQICSFLQEQAQEDRRERDYTNLPSSSRSGGSGSSSSELEEESSSEHLTCCEQGDIAQPLLQPNNYQFC T20333 DRUGINFO D09TAB Pexidartinib Approved T20333 DRUGINFO D05PWX Sulfatinib Phase 3 T20333 DRUGINFO DWD3V2 AMB-05X Phase 2 T20333 DRUGINFO D05JAA ARRY-382 Phase 2 T20333 DRUGINFO D08NDE BLZ-945 Phase 2 T20333 DRUGINFO D0YO4B Cabiralizumab Phase 2 T20333 DRUGINFO D9RH0V DCC-3014 Phase 1/2 T20333 DRUGINFO D08ZQI FPA-008 Phase 1/2 T20333 DRUGINFO D04CTD SNDX-6352 Phase 1 T20333 DRUGINFO D0M5XJ DCC-3014 Phase 1 T20333 DRUGINFO D3ZN5U Axatilamab Phase 1 T20333 DRUGINFO D6FTN1 ABSK021 Phase 1 T20333 DRUGINFO DYK5U6 EI1071 Phase 1 T20333 DRUGINFO D07PSL PLX7486 Phase 1 T20333 DRUGINFO D7M8LI TPX-0022 Phase 1 T20333 DRUGINFO D0X9VS PMID28270010-Compound-Figure24-a Patented T20333 DRUGINFO D0NB1V Pyridine derivative 20 Patented T20333 DRUGINFO D0O0AW Pyridine derivative 21 Patented T20333 DRUGINFO D0O4TA Pyridine derivative 22 Patented T20333 DRUGINFO D0T7BE Pyridine derivative 19 Patented T20333 DRUGINFO D0AK1F Pyridine derivative 18 Patented T98157 TARGETID T98157 T98157 FORMERID TTDI02021 T98157 UNIPROID ARSA_HUMAN T98157 TARGNAME Cerebroside-sulfatase (ARSA) T98157 GENENAME ARSA T98157 TARGTYPE Successful T98157 SYNONYMS Cerebrosidesulfatase; Arylsulfatase A component C; ASA; ARSA T98157 FUNCTION Hydrolyzes cerebroside sulfate. T98157 PDBSTRUC 2HI8; 2AIK; 2AIJ; 1N2L; 1N2K T98157 BIOCLASS Sulfuric ester hydrolase T98157 ECNUMBER EC 3.1.6.8 T98157 SEQUENCE MGAPRSLLLALAAGLAVARPPNIVLIFADDLGYGDLGCYGHPSSTTPNLDQLAAGGLRFTDFYVPVSLCTPSRAALLTGRLPVRMGMYPGVLVPSSRGGLPLEEVTVAEVLAARGYLTGMAGKWHLGVGPEGAFLPPHQGFHRFLGIPYSHDQGPCQNLTCFPPATPCDGGCDQGLVPIPLLANLSVEAQPPWLPGLEARYMAFAHDLMADAQRQDRPFFLYYASHHTHYPQFSGQSFAERSGRGPFGDSLMELDAAVGTLMTAIGDLGLLEETLVIFTADNGPETMRMSRGGCSGLLRCGKGTTYEGGVREPALAFWPGHIAPGVTHELASSLDLLPTLAALAGAPLPNVTLDGFDLSPLLLGTGKSPRQSLFFYPSYPDEVRGVFAVRTGKYKAHFFTQGSAHSDTTADPACHASSSLTAHEPPLLYDLSKDPGENYNLLGGVAGATPEVLQALKQLQLLKAQLDAAVTFGPSQVARGEDPALQICCHPGCTPRPACCHCPDPHA T98157 DRUGINFO DQ4TO3 OTL-200 Approved T98157 DRUGINFO D0E5RA HGT-1111 Phase 2 T10965 TARGETID T10965 T10965 FORMERID TTDC00197 T10965 UNIPROID LYAM3_HUMAN T10965 TARGNAME P-selectin (SELP) T10965 GENENAME SELP T10965 TARGTYPE Successful T10965 SYNONYMS SELP; PADGEM; Leukocyte-endothelial cell adhesion molecule 3; LECAM3; Granule membrane protein 140; GMP-140; CD62P T10965 FUNCTION Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with PSGL1. T10965 PDBSTRUC 1KJD; 1HES; 1G1S; 1G1R; 1G1Q T10965 SEQUENCE MANCQIAILYQRFQRVVFGISQLLCFSALISELTNQKEVAAWTYHYSTKAYSWNISRKYCQNRYTDLVAIQNKNEIDYLNKVLPYYSSYYWIGIRKNNKTWTWVGTKKALTNEAENWADNEPNNKRNNEDCVEIYIKSPSAPGKWNDEHCLKKKHALCYTASCQDMSCSKQGECLETIGNYTCSCYPGFYGPECEYVRECGELELPQHVLMNCSHPLGNFSFNSQCSFHCTDGYQVNGPSKLECLASGIWTNKPPQCLAAQCPPLKIPERGNMTCLHSAKAFQHQSSCSFSCEEGFALVGPEVVQCTASGVWTAPAPVCKAVQCQHLEAPSEGTMDCVHPLTAFAYGSSCKFECQPGYRVRGLDMLRCIDSGHWSAPLPTCEAISCEPLESPVHGSMDCSPSLRAFQYDTNCSFRCAEGFMLRGADIVRCDNLGQWTAPAPVCQALQCQDLPVPNEARVNCSHPFGAFRYQSVCSFTCNEGLLLVGASVLQCLATGNWNSVPPECQAIPCTPLLSPQNGTMTCVQPLGSSSYKSTCQFICDEGYSLSGPERLDCTRSGRWTDSPPMCEAIKCPELFAPEQGSLDCSDTRGEFNVGSTCHFSCDNGFKLEGPNNVECTTSGRWSATPPTCKGIASLPTPGLQCPALTTPGQGTMYCRHHPGTFGFNTTCYFGCNAGFTLIGDSTLSCRPSGQWTAVTPACRAVKCSELHVNKPIAMNCSNLWGNFSYGSICSFHCLEGQLLNGSAQTACQENGHWSTTVPTCQAGPLTIQEALTYFGGAVASTIGLIMGGTLLALLRKRFRQKDDGKCPLNPHSHLGTYGVFTNAAFDPSP T10965 DRUGINFO DU47SF Crizanlizumab Approved T10965 DRUGINFO DWY87T Inclacumab Phase 3 T10965 DRUGINFO D0N4EO GMI-1070 Phase 3 T10965 DRUGINFO D0B7LK CY-1503 Phase 2/3 T10965 DRUGINFO D0A9ML SelG1 Phase 2 T10965 DRUGINFO D0Z6DE RPSGL-Ig Phase 2 T10965 DRUGINFO D00YEV BAICALEIN Phase 2 T10965 DRUGINFO D0Z0AM PSI-697 Phase 1 T10965 DRUGINFO D00WOT CDP-850 Discontinued in Phase 2 T10965 DRUGINFO D0G1MZ CY-1787 Discontinued in Phase 1 T10965 DRUGINFO D0L3XV SMART anti-E/P selectin Discontinued in Phase 1 T10965 DRUGINFO D0R7MJ PURPUROGALLIN Terminated T10965 DRUGINFO D08RYE Efomycine M Investigative T10965 DRUGINFO D0E9NT 2,3,4-trihydroxybenzoic acid Investigative T10965 DRUGINFO D0U7DO 1na Investigative T10965 DRUGINFO D08WQM O-Sialic Acid Investigative T10965 DRUGINFO D0Y3TZ GALLICACID Investigative T10965 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T10965 DRUGINFO D0G6XS Fucose Investigative T15439 TARGETID T15439 T15439 FORMERID TTDNC00518 T15439 UNIPROID C5AR1_HUMAN T15439 TARGNAME C5a anaphylatoxin chemotactic receptor (C5AR1) T15439 GENENAME C5AR1 T15439 TARGTYPE Successful T15439 SYNONYMS CD88; C5aR; C5a-R; C5a anaphylatoxin chemotactic receptor 1; C5R1 T15439 FUNCTION The ligand interacts with at least two sites on the receptor: a high-affinity site on the extracellular N-terminus, and a second site in the transmembrane region which activates downstream signaling events. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a. T15439 PDBSTRUC 6C1R; 6C1Q; 5O9H T15439 BIOCLASS GPCR rhodopsin T15439 SEQUENCE MDSFNYTTPDYGHYDDKDTLDLNTPVDKTSNTLRVPDILALVIFAVVFLVGVLGNALVVWVTAFEAKRTINAIWFLNLAVADFLSCLALPILFTSIVQHHHWPFGGAACSILPSLILLNMYASILLLATISADRFLLVFKPIWCQNFRGAGLAWIACAVAWGLALLLTIPSFLYRVVREEYFPPKVLCGVDYSHDKRRERAVAIVRLVLGFLWPLLTLTICYTFILLRTWSRRATRSTKTLKVVVAVVASFFIFWLPYQVTGIMMSFLEPSSPTFLLLKKLDSLCVSFAYINCCINPIIYVVAGQGFQGRLRKSLPSLLRNVLTEESVVRESKSFTRSTVDTMAQKTQAV T15439 DRUGINFO D0MR4Q Avacopan Approved T15439 DRUGINFO D0G2XE PMX-53 Phase 2 T15439 DRUGINFO D05ILZ NN8209 Discontinued in Phase 2 T15439 DRUGINFO D0MT7W NN8210 Discontinued in Phase 1 T15439 DRUGINFO DBA5M7 PMX205 Preclinical T15439 DRUGINFO D03TBA RPR121154 Investigative T15439 DRUGINFO D04JXA W54011 Investigative T15439 DRUGINFO D0G9EX C5aR pepducins Investigative T15439 DRUGINFO D0J3FH NDT9520492 Investigative T29683 TARGETID T29683 T29683 FORMERID TTDC00117 T29683 UNIPROID NK3R_HUMAN T29683 TARGNAME Neuromedin-K receptor (TACR3) T29683 GENENAME TACR3 T29683 TARGTYPE Successful T29683 SYNONYMS Tachykinin receptor 3; TACR3; Neuromedin K receptor; Neurokinin-3 receptor; Neurokinin B receptor; NKR; NK-3R; NK-3 receptor T29683 FUNCTION This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: neuromedin-K > substance K > substance P. T29683 BIOCLASS GPCR rhodopsin T29683 SEQUENCE MATLPAAETWIDGGGGVGADAVNLTASLAAGAATGAVETGWLQLLDQAGNLSSSPSALGLPVASPAPSQPWANLTNQFVQPSWRIALWSLAYGVVVAVAVLGNLIVIWIILAHKRMRTVTNYFLVNLAFSDASMAAFNTLVNFIYALHSEWYFGANYCRFQNFFPITAVFASIYSMTAIAVDRYMAIIDPLKPRLSATATKIVIGSIWILAFLLAFPQCLYSKTKVMPGRTLCFVQWPEGPKQHFTYHIIVIILVYCFPLLIMGITYTIVGITLWGGEIPGDTCDKYHEQLKAKRKVVKMMIIVVMTFAICWLPYHIYFILTAIYQQLNRWKYIQQVYLASFWLAMSSTMYNPIIYCCLNKRFRAGFKRAFRWCPFIKVSSYDELELKTTRFHPNRQSSMYTVTRMESMTVVFDPNDADTTRSSRKKRATPRDPSFNGCSRRNSKSASATSSFISSPYTSVDEYS T29683 DRUGINFO DUS06I Fezolinetant Approved T29683 DRUGINFO DKZ07O Elinzanetant Phase 3 T29683 DRUGINFO D02IWC AZD2624 Phase 2 T29683 DRUGINFO D0K5HI Talnetant Phase 2 T29683 DRUGINFO D05ZWG Senktide Phase 2 T29683 DRUGINFO D0P2KG GSK1144814 Phase 1 T29683 DRUGINFO D0IP6X Osanetant Discontinued in Phase 2b T29683 DRUGINFO D03ZKE CS-003 Discontinued in Phase 2 T29683 DRUGINFO D0C3AN SSR-146977 Discontinued in Phase 1 T29683 DRUGINFO D00VPT SB222200 Preclinical T29683 DRUGINFO D02CCA GSK-172981 Investigative T29683 DRUGINFO D02UCT R-820 Investigative T29683 DRUGINFO D02UJO GR138676 Investigative T29683 DRUGINFO D04TXE PD-157672 Investigative T29683 DRUGINFO D07NNN NEUROKININ B Investigative T29683 DRUGINFO D09FAO PD 154740 Investigative T29683 DRUGINFO D09NBN PD-161182 Investigative T29683 DRUGINFO D0G2AK 3-methoxy-N',2-diphenylquinoline-4-carbohydrazide Investigative T29683 DRUGINFO D0G4PZ N-phenethyl-2-phenylquinoline-4-carboxamide Investigative T29683 DRUGINFO D0J3AO PD-160946 Investigative T29683 DRUGINFO D0O8RG 2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide Investigative T29683 DRUGINFO D0S9CI N',2-diphenylquinoline-4-carbohydrazide 8m Investigative T29683 DRUGINFO D0W3XD N',2-diphenylquinoline-4-carbohydrazide Investigative T29683 DRUGINFO D0D2JB kassinin Investigative T29683 DRUGINFO D0U9IB eledoisin Investigative T29683 DRUGINFO D01NPA neurokinin A Investigative T29683 DRUGINFO D07JAN SCH 206272 Investigative T78932 TARGETID T78932 T78932 FORMERID TTDNC00412 T78932 UNIPROID TYK2_HUMAN T78932 TARGNAME TYK2 tyrosine kinase (TYK2) T78932 GENENAME TYK2 T78932 TARGTYPE Successful T78932 SYNONYMS Non-receptor tyrosine-protein kinase TYK2 T78932 FUNCTION Probably involved in intracellular signal transduction by being involved in the initiation of type I IFN signaling. Phosphorylates the interferon-alpha/beta receptor alpha chain. T78932 PDBSTRUC 6DBM; 6DBK; 6AAM; 5WAL; 5TKD T78932 BIOCLASS Kinase T78932 ECNUMBER EC 2.7.10.2 T78932 SEQUENCE MPLRHWGMARGSKPVGDGAQPMAAMGGLKVLLHWAGPGGGEPWVTFSESSLTAEEVCIHIAHKVGITPPCFNLFALFDAQAQVWLPPNHILEIPRDASLMLYFRIRFYFRNWHGMNPREPAVYRCGPPGTEASSDQTAQGMQLLDPASFEYLFEQGKHEFVNDVASLWELSTEEEIHHFKNESLGMAFLHLCHLALRHGIPLEEVAKKTSFKDCIPRSFRRHIRQHSALTRLRLRNVFRRFLRDFQPGRLSQQMVMVKYLATLERLAPRFGTERVPVCHLRLLAQAEGEPCYIRDSGVAPTDPGPESAAGPPTHEVLVTGTGGIQWWPVEEEVNKEEGSSGSSGRNPQASLFGKKAKAHKAVGQPADRPREPLWAYFCDFRDITHVVLKEHCVSIHRQDNKCLELSLPSRAAALSFVSLVDGYFRLTADSSHYLCHEVAPPRLVMSIRDGIHGPLLEPFVQAKLRPEDGLYLIHWSTSHPYRLILTVAQRSQAPDGMQSLRLRKFPIEQQDGAFVLEGWGRSFPSVRELGAALQGCLLRAGDDCFSLRRCCLPQPGETSNLIIMRGARASPRTLNLSQLSFHRVDQKEITQLSHLGQGTRTNVYEGRLRVEGSGDPEEGKMDDEDPLVPGRDRGQELRVVLKVLDPSHHDIALAFYETASLMSQVSHTHLAFVHGVCVRGPENIMVTEYVEHGPLDVWLRRERGHVPMAWKMVVAQQLASALSYLENKNLVHGNVCGRNILLARLGLAEGTSPFIKLSDPGVGLGALSREERVERIPWLAPECLPGGANSLSTAMDKWGFGATLLEICFDGEAPLQSRSPSEKEHFYQRQHRLPEPSCPQLATLTSQCLTYEPTQRPSFRTILRDLTRLQPHNLADVLTVNPDSPASDPTVFHKRYLKKIRDLGEGHFGKVSLYCYDPTNDGTGEMVAVKALKADCGPQHRSGWKQEIDILRTLYHEHIIKYKGCCEDQGEKSLQLVMEYVPLGSLRDYLPRHSIGLAQLLLFAQQICEGMAYLHAQHYIHRDLAARNVLLDNDRLVKIGDFGLAKAVPEGHEYYRVREDGDSPVFWYAPECLKEYKFYYASDVWSFGVTLYELLTHCDSSQSPPTKFLELIGIAQGQMTVLRLTELLERGERLPRPDKCPCEVYHLMKNCWETEASFRPTFENLIPILKTVHEKYQGQAPSVFSVC T78932 DRUGINFO D0S1XX Deucravacitinib Approved T78932 DRUGINFO D5XJ7F NDI-034858 Phase 2 T78932 DRUGINFO D7TA4P PF-06826647 Phase 2 T78932 DRUGINFO D0V4DX PF-06700841 Phase 2 T78932 DRUGINFO D0M3XE PF-06826647 Phase 1 T78932 DRUGINFO D01GNL Pyrazolopyridine derivative 5 Patented T78932 DRUGINFO D0C3HN PMID27774822-Compound-Figure9Example15 Patented T78932 DRUGINFO D0IB3R Imidazopyridine derivative 3 Patented T78932 DRUGINFO D0M2JK Aminopyridine derivative 1 Patented T78932 DRUGINFO D0M8YW Aminopyrimidine derivative 5 Patented T78932 DRUGINFO D0UG8S Thiazolopyridine derivative 1 Patented T78932 DRUGINFO D0M2OK Bis-aminopyrimidine derivative 5 Patented T78932 DRUGINFO D0NY6M PMID27774822-Compound-Figure3CompoundI-165 Patented T78932 DRUGINFO D0T6CY Pyrrolo-pyridone derivative 3 Patented T78932 DRUGINFO D0XH7H N-methylmethanesulfonamide derivative 1 Patented T78932 DRUGINFO D0YJ4D Pyrrole derivative 7 Patented T78932 DRUGINFO D01CRX Benzimidazole derivative 7 Patented T78932 DRUGINFO D01FVC Bis-aminopyrimidine derivative 1 Patented T78932 DRUGINFO D03QAY Pyrazolopyridine derivative 3 Patented T78932 DRUGINFO D04BOW Tricyclic pyrrolopyridine compound 1 Patented T78932 DRUGINFO D05AXE Aminooxazole carboxamide derivative 1 Patented T78932 DRUGINFO D0FQ4Z Pyrrolo[2,3-d]pyrimidine derivative 6 Patented T78932 DRUGINFO D0GB7G PMID27774824-Compound-Figure6Example12 Patented T78932 DRUGINFO D0KL3B Pyrrolo[2,3-d]pyrimidine derivative 8 Patented T78932 DRUGINFO D0LR6J Bis-aminopyrimidine derivative 2 Patented T78932 DRUGINFO D0LS1O Tricyclic compound 11 Patented T78932 DRUGINFO D0M2WA Tricyclic heterocycle derivative 5 Patented T78932 DRUGINFO D0RJ3W PMID27774822-Compound-Figure11Example5 Patented T78932 DRUGINFO D0S6XT Bis-aminopyrimidine derivative 3 Patented T78932 DRUGINFO D0SJ1Q Bis-aminopyrimidine derivative 4 Patented T78932 DRUGINFO D0U1HA PMID27774824-Compound-Figure3Example18 Patented T78932 DRUGINFO D0U5FZ Pyrrolo[2,3-d]pyrimidine derivative 7 Patented T78932 DRUGINFO D0X1FD Tricyclic heterocycle derivative 1 Patented T78932 DRUGINFO D07PTU Imidazo[4,5-c]pyridine derivative 1 Patented T78932 DRUGINFO D0WZ8N PMID27774824-Compound-Figure9Example2up Patented T78932 DRUGINFO D01DBB PMID27774824-Compound-Figure9Example2down Patented T78932 DRUGINFO D09ALF Aminotriazolopyridine derivative 1 Patented T78932 DRUGINFO D0VJ1R Imidazo[4,5-c]pyridine derivative 2 Patented T78932 DRUGINFO D0YR8S PMID27774824-Compound-Figure11Example1up Patented T78932 DRUGINFO D09PIS Pyrazolo[4,3-c]pyridine derivative 2 Patented T78932 DRUGINFO D0IR6U CMP-6 Investigative T41750 TARGETID T41750 T41750 FORMERID TTDI02342 T41750 UNIPROID GIPR_HUMAN T41750 TARGNAME Gastric inhibitory polypeptide receptor (GIPR) T41750 GENENAME GIPR T41750 TARGTYPE Successful T41750 SYNONYMS Glucosedependent insulinotropic polypeptide receptor; GIPR T41750 FUNCTION This is a receptor for GIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. T41750 PDBSTRUC 6DKJ; 4HJ0; 2QKH T41750 BIOCLASS GPCR secretin T41750 SEQUENCE MTTSPILQLLLRLSLCGLLLQRAETGSKGQTAGELYQRWERYRRECQETLAAAEPPSGLACNGSFDMYVCWDYAAPNATARASCPWYLPWHHHVAAGFVLRQCGSDGQWGLWRDHTQCENPEKNEAFLDQRLILERLQVMYTVGYSLSLATLLLALLILSLFRRLHCTRNYIHINLFTSFMLRAAAILSRDRLLPRPGPYLGDQALALWNQALAACRTAQIVTQYCVGANYTWLLVEGVYLHSLLVLVGGSEEGHFRYYLLLGWGAPALFVIPWVIVRYLYENTQCWERNEVKAIWWIIRTPILMTILINFLIFIRILGILLSKLRTRQMRCRDYRLRLARSTLTLVPLLGVHEVVFAPVTEEQARGALRFAKLGFEIFLSSFQGFLVSVLYCFINKEVQSEIRRGWHHCRLRRSLGEEQRQLPERAFRALPSGSGPGEVPTSRGLSSGTLPGPGNEASRELESYC T41750 DRUGINFO DA69JF Tirzepatide Approved T41750 DRUGINFO DG7N3W Retatrutide Phase 3 T41750 DRUGINFO DF58YX AMG 133 Phase 2 T41750 DRUGINFO DR76TW LY3437943 Phase 2 T41750 DRUGINFO D6V9SI LY3537021 Phase 1 T41750 DRUGINFO DEQW79 LY3532226 Phase 1 T41750 DRUGINFO D0FY4L SAR438335 Phase 1 T41750 DRUGINFO DEC8O3 CT 868 Phase 1 T41750 DRUGINFO DQO46V CT-388 Phase 1 T41750 DRUGINFO D00YFP RG7697 Discontinued in Phase 2 T41750 DRUGINFO D0M4RX RG7685 Discontinued in Phase 2 T92403 TARGETID T92403 T92403 FORMERID TTDR00035 T92403 UNIPROID SL9A3_HUMAN T92403 TARGNAME Sodium/hydrogen exchanger 3 (SLC9A3) T92403 GENENAME SLC9A3 T92403 TARGTYPE Successful T92403 SYNONYMS SLC9A3; Na(+)/H(+) exchanger 3; NHE-3 T92403 FUNCTION Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction. T92403 BIOCLASS Monovalent cation:proton antiporter T92403 SEQUENCE MWGLGARGPDRGLLLALALGGLARAGGVEVEPGGAHGESGGFQVVTFEWAHVQDPYVIALWILVASLAKIGFHLSHKVTSVVPESALLIVLGLVLGGIVWAADHIASFTLTPTVFFFYLLPPIVLDAGYFMPNRLFFGNLGTILLYAVVGTVWNAATTGLSLYGVFLSGLMGDLQIGLLDFLLFGSLMAAVDPVAVLAVFEEVHVNEVLFIIVFGESLLNDAVTVVLYNVFESFVALGGDNVTGVDCVKGIVSFFVVSLGGTLVGVVFAFLLSLVTRFTKHVRIIEPGFVFIISYLSYLTSEMLSLSAILAITFCGICCQKYVKANISEQSATTVRYTMKMLASSAETIIFMFLGISAVNPFIWTWNTAFVLLTLVFISVYRAIGVVLQTWLLNRYRMVQLEPIDQVVLSYGGLRGAVAFALVVLLDGDKVKEKNLFVSTTIIVVFFTVIFQGLTIKPLVQWLKVKRSEHREPRLNEKLHGRAFDHILSAIEDISGQIGHNYLRDKWSHFDRKFLSRVLMRRSAQKSRDRILNVFHELNLKDAISYVAEGERRGSLAFIRSPSTDNVVNVDFTPRSSTVEASVSYLLRENVSAVCLDMQSLEQRRRSIRDAEDMVTHHTLQQYLYKPRQEYKHLYSRHELTPTEDEKQDREIFHRTMRKRLESFKSTKLGLNQNKKAAKLYKRERAQKRRNSSIPNGKLPMESPAQNFTIKEKDLELSDTEEPPNYDEEMSGGIEFLASVTKDTASDSPAGIDNPVFSPDEALDRSLLARLPPWLSPGETVVPSQRARTQIPYSPGTFCRLMPFRLSSKSVDSFLQADGPEERPPAALPESTHM T92403 DRUGINFO D04TQO Tenapanor Approved T92403 DRUGINFO D01ICY AVE-0657 Phase 2 T92403 DRUGINFO D04AIB AZD1772//RDX5791 Phase 2 T92403 DRUGINFO D0N8QQ CARIPORIDE Discontinued in Phase 2 T92403 DRUGINFO D0V9RU ENIPORIDE Discontinued in Phase 2 T92403 DRUGINFO D0K2CV HOE-694 Terminated T92403 DRUGINFO D03AGV N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine Investigative T92403 DRUGINFO D04OTF N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine Investigative T92403 DRUGINFO D04UMY N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine Investigative T92403 DRUGINFO D05CQR N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine Investigative T92403 DRUGINFO D07DUW N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine Investigative T92403 DRUGINFO D0T1OG N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine Investigative T13127 TARGETID T13127 T13127 UNIPROID FNTA_HUMAN; FNTB_HUMAN T13127 TARGNAME Farnesyl protein transferase (Ftase) T13127 GENENAME FNTB; FNTA T13127 TARGTYPE Successful T13127 SYNONYMS Ras proteins prenyltransferase; Protein farnesyltransferase; Ftase; CAAX farnesyltransferase T13127 FUNCTION Essential subunit of both the farnesyltransferase and the geranylgeranyltransferase complex. Contributes to the transfer of a farnesyl or geranylgeranyl moiety from farnesyl or geranylgeranyl diphosphate to a cysteine at the fourth position from the C-terminus of several proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. May positively regulate neuromuscular junction development downstream of MUSK via its function in RAC1prenylation and activation. T13127 BIOCLASS Alkyl aryl transferase T13127 SEQUENCE MAATEGVGEAAQGGEPGQPAQPPPQPHPPPPQQQHKEEMAAEAGEAVASPMDDGFVSLDSPSYVLYRDRAEWADIDPVPQNDGPNPVVQIIYSDKFRDVYDYFRAVLQRDERSERAFKLTRDAIELNAANYTVWHFRRVLLKSLQKDLHEEMNYITAIIEEQPKNYQVWHHRRVLVEWLRDPSQELEFIADILNQDAKNYHAWQHRQWVIQEFKLWDNELQYVDQLLKEDVRNNSVWNQRYFVISNTTGYNDRAVLEREVQYTLEMIKLVPHNESAWNYLKGILQDRGLSKYPNLLNQLLDLQPSHSSPYLIAFLVDIYEDMLENQCDNKEDILNKALELCEILAKEKDTIRKEYWRYIGRSLQSKHSTENDSPTNVQQ T13127 DRUGINFO D0W4HZ Lonafarnib Approved T13127 DRUGINFO D07NPS Zarnestra Phase 3 T13127 DRUGINFO D07RKN GGTI-2418 Phase 1 T13127 DRUGINFO D0Z1NY BMS214662 Phase 1 T13127 DRUGINFO D0Q5VW L-778123 Phase 1 T13127 DRUGINFO D0NE3C AZD3409 Terminated T13127 DRUGINFO D04DYZ ABT-839 Terminated T13127 DRUGINFO D0C2UY MANUMYCIN A Terminated T13127 DRUGINFO D0EY9P SCH-44342 Terminated T13127 DRUGINFO D0H5VF RPR-113829 Terminated T13127 DRUGINFO D0L5AS RPR-114334 Terminated T13127 DRUGINFO D0W2ED L-731735 Terminated T13127 DRUGINFO D03OLA L-745631 Terminated T13127 DRUGINFO D00LAR BMS-404683 Investigative T13127 DRUGINFO D01DTW FARNESYL Investigative T13127 DRUGINFO D01OFD ACTINOPLANIC ACID A Investigative T13127 DRUGINFO D06JMV PB-27 Investigative T13127 DRUGINFO D0H4QM PB-80 Investigative T13127 DRUGINFO D0L4RX PB-81 Investigative T13127 DRUGINFO D0R3PD CLAVARINONE Investigative T13127 DRUGINFO D0TC4Z ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID Investigative T13127 DRUGINFO D0VD2C (Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid Investigative T13127 DRUGINFO D06DSE PD-83176 Investigative T13127 DRUGINFO D0QX6B GERANYLGERANYL DIPHOSPHATE Investigative T35842 TARGETID T35842 T35842 FORMERID TTDR00530 T35842 UNIPROID MSHR_HUMAN T35842 TARGNAME Melanocortin receptor 1 (MC1R) T35842 GENENAME MC1R T35842 TARGTYPE Successful T35842 SYNONYMS Melanotropin receptor; Melanocyte-stimulating hormone receptor; Melanocortin-1 receptor; MSHR; MSH-R; MC1-R T35842 FUNCTION The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Receptor for MSH (alpha, beta and gamma) and ACTH. T35842 BIOCLASS GPCR rhodopsin T35842 SEQUENCE MAVQGSQRRLLGSLNSTPTAIPQLGLAANQTGARCLEVSISDGLFLSLGLVSLVENALVVATIAKNRNLHSPMYCFICCLALSDLLVSGSNVLETAVILLLEAGALVARAAVLQQLDNVIDVITCSSMLSSLCFLGAIAVDRYISIFYALRYHSIVTLPRARRAVAAIWVASVVFSTLFIAYYDHVAVLLCLVVFFLAMLVLMAVLYVHMLARACQHAQGIARLHKRQRPVHQGFGLKGAVTLTILLGIFFLCWGPFFLHLTLIVLCPEHPTCGCIFKNFNLFLALIICNAIIDPLIYAFHSQELRRTLKEVLTCSW T35842 DRUGINFO D0V2OX Afamelanotide Approved T35842 DRUGINFO D0X9PF Bremelanotide Approved T35842 DRUGINFO D7M3WV Dersimelagon Phase 3 T35842 DRUGINFO DVI21W PL8177 Phase 2 T35842 DRUGINFO D0H3HV AP-1030 Phase 1/2 T35842 DRUGINFO D09QPE AP-1189 Investigative T35842 DRUGINFO D09XCH Ac-YR[CEHFRWC]-NH2 Investigative T35842 DRUGINFO D0GN9K C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2 Investigative T35842 DRUGINFO D0R3GC D-Phe-Arg-2-Nal-NHCH3 Investigative T35842 DRUGINFO D0U5KM Ac-His-DPhe-Arg-Trp-NH2 Investigative T35842 DRUGINFO D0U6XP Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2 Investigative T35842 DRUGINFO D00VYC Ac-YR[CEHdFRWC]-NH2 Investigative T35842 DRUGINFO D05XRI Ac-R[CEHdFRWC]-NH2 Investigative T35842 DRUGINFO D06PNU Tic-D-Phe-Arg-2-Nal-NHCH3 Investigative T35842 DRUGINFO D07DWH Ac-dR[CEHdFRWC]-NH2 Investigative T35842 DRUGINFO D09OMI Ac-YK[CEHdFRWC]-NH2 Investigative T35842 DRUGINFO D0A8ME Ac-[CEHdFRWC]-NH2 Investigative T35842 DRUGINFO D0B8GR Ac-His-D-Phe-Arg-2-Nal-NHCH3 Investigative T35842 DRUGINFO D0C7VI Ac-YR[CEHdFRWC]SPPKD-NH2 Investigative T35842 DRUGINFO D0F6GX Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3 Investigative T35842 DRUGINFO D0W1SM C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2 Investigative T35842 DRUGINFO D0XQ5U C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T35842 DRUGINFO D0ZD3M Ac-YCit[CEHdFRWC]-NH2 Investigative T35842 DRUGINFO D02JVA C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T35842 DRUGINFO D03AZC Ac-YRMEHdFRWG-NH2 Investigative T35842 DRUGINFO D05LLI C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T35842 DRUGINFO D06RTP C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T35842 DRUGINFO D07SFD C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 Investigative T35842 DRUGINFO D07TBR Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 Investigative T35842 DRUGINFO D09PDT C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T35842 DRUGINFO D0AU4C AEKKDEGPYRMEHFRWGSPPKD Investigative T35842 DRUGINFO D0B4OL Ac-YRMEHdFRWGSPPKD-NH2 Investigative T35842 DRUGINFO D0CK0K Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 Investigative T35842 DRUGINFO D0I8SJ NDP-SYSMEHFRWGKPVG Investigative T35842 DRUGINFO D0ID5M GPYRMEHFRWGSPPKD-NH2 Investigative T35842 DRUGINFO D0L1MJ C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T35842 DRUGINFO D0R0BY Ac-YR[CEH(pCl-dF)RWC]-NH2 Investigative T35842 DRUGINFO D0WG8P Ac-YR[CEH(pF-dF)RWC]-NH2 Investigative T35842 DRUGINFO D0WI8M C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T35842 DRUGINFO D0X1YL Ac-YRC(Me)*EHdFRWC(Me)NH2 Investigative T35842 DRUGINFO D0YB7F MT-II Investigative T88505 TARGETID T88505 T88505 FORMERID TTDNR00714 T88505 UNIPROID NF2L2_HUMAN T88505 TARGNAME Nuclear factor erythroid 2-related factor 2 (Nrf2) T88505 GENENAME NFE2L2 T88505 TARGTYPE Successful T88505 SYNONYMS Nuclear factor, erythroid derived 2, like 2; NRF2; NFE2-related factor 2; NF-E2-related factor 2; HEBP1 T88505 FUNCTION Important for the coordinated up-regulation of genes in response to oxidative stress and the regulation of cellular redox conditions. May be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. Transcription activator that binds to antioxidant response (ARE) elements in the promoter regions of target genes. T88505 PDBSTRUC 5WFV; 4IFL; 3ZGC; 2LZ1; 2FLU T88505 BIOCLASS Basic leucine zipper bZIP T88505 SEQUENCE MMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDEETGEFLPIQPAQHIQSETSGSANYSQVAHIPKSDALYFDDCMQLLAQTFPFVDDNEVSSATFQSLVPDIPGHIESPVFIATNQAQSPETSVAQVAPVDLDGMQQDIEQVWEELLSIPELQCLNIENDKLVETTMVPSPEAKLTEVDNYHFYSSIPSMEKEVGNCSPHFLNAFEDSFSSILSTEDPNQLTVNSLNSDATVNTDFGDEFYSAFIAEPSISNSMPSPATLSHSLSELLNGPIDVSDLSLCKAFNQNHPESTAEFNDSDSGISLNTSPSVASPEHSVESSSYGDTLLGLSDSEVEELDSAPGSVKQNGPKTPVHSSGDMVQPLSPSQGQSTHVHDAQCENTPEKELPVSPGHRKTPFTKDKHSSRLEAHLTRDELRAKALHIPFPVEKIINLPVVDFNEMMSKEQFNEAQLALIRDIRRRGKNKVAAQNCRKRKLENIVELEQDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLYLEVFSMLRDEDGKPYSPSEYSLQQTRDGNVFLVPKSKKPDVKKN T88505 DRUGINFO D0JB3H Omaveloxolone Approved T88505 DRUGINFO D02NMR SFX-01 Phase 2 T88505 DRUGINFO D0K7NI ABT-RTA-408 Phase 2 T88505 DRUGINFO D0P1IX OT-551 Phase 2 T88505 DRUGINFO DHG2O3 OT551 Phase 2 T88505 DRUGINFO DF1JO7 CXA10 Phase 2 T88505 DRUGINFO D9ZEM7 HPP971 Phase 1 T88505 DRUGINFO D00PGP Benzamide derivative 6 Patented T88505 DRUGINFO D03RTM Benzo[d]oxazole derivative 1 Patented T88505 DRUGINFO D04YKV PMID28454500-Compound-93 Patented T88505 DRUGINFO D05EMI PMID28454500-Compound-92 Patented T88505 DRUGINFO D06KOH 4-(2-cyclohexylethoxy) aniline derivative 3 Patented T88505 DRUGINFO D07TEZ Benzo[d]oxazole derivative 2 Patented T88505 DRUGINFO D0D8KO Thiazole derivative 3 Patented T88505 DRUGINFO D0DE0Y Benzamide derivative 5 Patented T88505 DRUGINFO D0G8CF Benzo[d]oxazole derivative 3 Patented T88505 DRUGINFO D0M2ZX Benzo[d]oxazole derivative 4 Patented T88505 DRUGINFO D0ND6T 4-(2-cyclohexylethoxy) aniline derivative 2 Patented T88505 DRUGINFO D0O5ZK PMID28454500-Compound-96 Patented T88505 DRUGINFO D0P9ZD PMID28454500-Compound-94 Patented T88505 DRUGINFO D0PF4H PMID28454500-Compound-91 Patented T88505 DRUGINFO D0R2AI 4-(2-cyclohexylethoxy) aniline derivative 1 Patented T88505 DRUGINFO D0RO7A PMID28454500-Compound-95 Patented T88505 DRUGINFO D0T2LN Thiazole derivative 2 Patented T88505 DRUGINFO D0T7WW 4-(2-cyclohexylethoxy) aniline derivative 4 Patented T88505 DRUGINFO D00TVL PMID28454500-Compound-57 Patented T88505 DRUGINFO D01GTU PMID28454500-Compound-8 Patented T88505 DRUGINFO D01MZI Pyrazino[2,1-a]isoquinolin derivative 4 Patented T88505 DRUGINFO D01PKZ PMID28454500-Compound-36 Patented T88505 DRUGINFO D02FWA Naphthalene derivative 1 Patented T88505 DRUGINFO D02JFV PMID28454500-Compound-58 Patented T88505 DRUGINFO D02SPI Chalcone derivative 4 Patented T88505 DRUGINFO D02YNU 2-hydroxybenzamide derivative 1 Patented T88505 DRUGINFO D04ILM Vinyl sulfone derivative 1 Patented T88505 DRUGINFO D06LEF Pyrazino[2,1-a]isoquinolin derivative 2 Patented T88505 DRUGINFO D09FZF Diterpenoid derivative 1 Patented T88505 DRUGINFO D09MSN 1-phenyl-1,3,4-triazole derivative 1 Patented T88505 DRUGINFO D0AJ2T PMID28454500-Compound-13 Patented T88505 DRUGINFO D0AR0L 1-phenyl-1,3,4-triazole derivative 2 Patented T88505 DRUGINFO D0AX4Q PMID28454500-Compound-12 Patented T88505 DRUGINFO D0AZ8T Pyrazino[2,1-a]isoquinolin derivative 1 Patented T88505 DRUGINFO D0C1PB PMID28454500-Compound-41 Patented T88505 DRUGINFO D0EO3S Chalcone derivative 2 Patented T88505 DRUGINFO D0FH6P PMID28454500-Compound-34 Patented T88505 DRUGINFO D0FM3Q PMID28454500-Compound-33 Patented T88505 DRUGINFO D0G1LS Chalcone derivative 3 Patented T88505 DRUGINFO D0G4EK PMID28454500-Compound-50 Patented T88505 DRUGINFO D0I2DV 1-phenyl-1,3,4-triazole derivative 3 Patented T88505 DRUGINFO D0JH8Z PMID28454500-Compound-3 Patented T88505 DRUGINFO D0KX0J Pyridyl compound 1 Patented T88505 DRUGINFO D0L1JQ PMID28454500-Compound-32 Patented T88505 DRUGINFO D0LL7V PMID28454500-Compound-60 Patented T88505 DRUGINFO D0MQ3X PMID28454500-Compound-40 Patented T88505 DRUGINFO D0MS7G 3-phenyl propanoic derivative 2 Patented T88505 DRUGINFO D0MX0Q PMID28454500-Compound-35 Patented T88505 DRUGINFO D0N1VC PMID28454500-Compound-49 Patented T88505 DRUGINFO D0N9GH PMID28454500-Compound-9 Patented T88505 DRUGINFO D0O3KN PMID28454500-Compound-59 Patented T88505 DRUGINFO D0O6LW 3-phenyl propanoic derivative 1 Patented T88505 DRUGINFO D0Q8JZ 3-phenyl propanoic derivative 3 Patented T88505 DRUGINFO D0Q9QQ Diterpenoid derivative 2 Patented T88505 DRUGINFO D0RM4V PMID28454500-Compound-11 Patented T88505 DRUGINFO D0SA1N PMID28454500-Compound-37 Patented T88505 DRUGINFO D0U9TR Chalcone derivative 1 Patented T88505 DRUGINFO D0VA2G Pyrazino[2,1-a]isoquinolin derivative 3 Patented T88505 DRUGINFO D0VW9H 2-hydroxybenzamide derivative 2 Patented T88505 DRUGINFO D0WN1Y PMID28454500-Compound-10 Patented T88505 DRUGINFO D0WR1I 1,2,3,4-tetrahydroisoquinoline derivative 1 Patented T88505 DRUGINFO D0XL2V Trepenoid derivative 1 Patented T88505 DRUGINFO D24EPJ CAT4001 Preclinical T88505 DRUGINFO DA85KQ M102 Preclinical T88505 DRUGINFO DPJ05C TFM735 Preclinical T32262 TARGETID T32262 T32262 FORMERID TTDC00093 T32262 UNIPROID CALRL_HUMAN T32262 TARGNAME Calcitonin gene-related peptide receptor (CGRPR) T32262 GENENAME CALCRL T32262 TARGTYPE Successful T32262 SYNONYMS Calcitonin receptor-like receptor; Calcitonin gene-related peptide type 1 receptor; CGRPR; CGRP type 1 receptor T32262 FUNCTION Receptor for calcitonin-gene-related peptide (CGRP) together with RAMP1 and receptor for adrenomedullin together with RAMP3 (By similarity). Receptor for adrenomedullin together with RAMP2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. T32262 PDBSTRUC 6E3Y; 6D1U; 5V6Y; 4RWG; 4RWF T32262 BIOCLASS GPCR secretin T32262 SEQUENCE MEKKCTLNFLVLLPFFMILVTAELEESPEDSIQLGVTRNKIMTAQYECYQKIMQDPIQQAEGVYCNRTWDGWLCWNDVAAGTESMQLCPDYFQDFDPSEKVTKICDQDGNWFRHPASNRTWTNYTQCNVNTHEKVKTALNLFYLTIIGHGLSIASLLISLGIFFYFKSLSCQRITLHKNLFFSFVCNSVVTIIHLTAVANNQALVATNPVSCKVSQFIHLYLMGCNYFWMLCEGIYLHTLIVVAVFAEKQHLMWYYFLGWGFPLIPACIHAIARSLYYNDNCWISSDTHLLYIIHGPICAALLVNLFFLLNIVRVLITKLKVTHQAESNLYMKAVRATLILVPLLGIEFVLIPWRPEGKIAEEVYDYIMHILMHFQGLLVSTIFCFFNGEVQAILRRNWNQYKIQFGNSFSNSEALRSASYTVSTISDGPGYSHDCPSEHLNGKSIHDIENVLLKPENLYN T32262 DRUGINFO D02ZUG Atogepant Approved T32262 DRUGINFO D07GXR Ubrogepant Approved T32262 DRUGINFO D08PLK Fremanezumab Approved T32262 DRUGINFO D0C8VF Galcanezumab Approved T32262 DRUGINFO D0IA9Y Zavegepant Approved T32262 DRUGINFO D0KX1Y Erenumab Approved T32262 DRUGINFO D0V9VG Rimegepant Approved T32262 DRUGINFO D00MXN MK-3207 Phase 2 T32262 DRUGINFO D04YLQ AMG 334 Phase 2 T32262 DRUGINFO D0G5ME Telcagepant Phase 2 T32262 DRUGINFO D0L5GH Olcegepant Phase 2 T32262 DRUGINFO D0VZ5X BI-44370 Phase 2 T32262 DRUGINFO D05YQT LBR-101 Phase 1 T32262 DRUGINFO D02NMK FVPTDVGAFAF Investigative T32262 DRUGINFO D03WBD FV-Hyp-TDVGPFAF Investigative T32262 DRUGINFO D07ZZZ FV-Tic-TDVGPFAF Investigative T32262 DRUGINFO D09TDY EPIMER A Investigative T32262 DRUGINFO D0B8HD FVPTDVGPFAF Investigative T32262 DRUGINFO D0E1YT ISOMER A Investigative T32262 DRUGINFO D0E7CV FVATDVGPFAF Investigative T32262 DRUGINFO D0G0YT HCGRPalpha Investigative T32262 DRUGINFO D0K8ZD FVPTDVG-Tic-FAF-Tic Investigative T32262 DRUGINFO D05MSG BMS-694153 Investigative T32262 DRUGINFO D0I2KW FV-Aib-TDVGPFAF Investigative T86115 TARGETID T86115 T86115 FORMERID TTDC00328 T86115 UNIPROID APOC3_HUMAN T86115 TARGNAME ApoC-III messenger RNA (APOC3 mRNA) T86115 GENENAME APOC3 T86115 TARGTYPE Successful T86115 SYNONYMS Apolipoprotein CIII (mRNA); Apolipoprotein C3 (mRNA); Apolipoprotein C-III (mRNA); ApoC-III (mRNA); Apo-CIII (mRNA) T86115 FUNCTION Plays a multifaceted role in triglyceride homeostasis. Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners. Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma. T86115 PDBSTRUC 2JQ3 T86115 BIOCLASS mRNA target T86115 SEQUENCE MQPRVLLVVALLALLASARASEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSEFWDLDPEVRPTSAVAA T86115 DRUGINFO D0A8TA Volanesorsen Approved T86115 DRUGINFO DNF8Z1 ARO-APOC3 Phase 3 T86115 DRUGINFO DVA8R9 Olezarsen Phase 3 T86115 DRUGINFO D0F6KM ISIS-APOCIII Phase 1 T81100 TARGETID T81100 T81100 FORMERID TTDC00336 T81100 UNIPROID SC5A2_HUMAN T81100 TARGNAME SLC5A2 messenger RNA (SLC5A2 mRNA) T81100 GENENAME SLC5A2 T81100 TARGTYPE Successful T81100 SYNONYMS Solute carrier family 5 member 2 (mRNA); Na(+)/glucose cotransporter 2 (mRNA); Low affinity sodium-glucose cotransporter (mRNA) T81100 FUNCTION Has a Na(+) to glucose coupling ratio of 1:1. Sodium-dependent glucose transporter. T81100 BIOCLASS mRNA target T81100 SEQUENCE MEEHTEAGSAPEMGAQKALIDNPADILVIAAYFLLVIGVGLWSMCRTNRGTVGGYFLAGRSMVWWPVGASLFASNIGSGHFVGLAGTGAASGLAVAGFEWNALFVVLLLGWLFAPVYLTAGVITMPQYLRKRFGGRRIRLYLSVLSLFLYIFTKISVDMFSGAVFIQQALGWNIYASVIALLGITMIYTVTGGLAALMYTDTVQTFVILGGACILMGYAFHEVGGYSGLFDKYLGAATSLTVSEDPAVGNISSFCYRPRPDSYHLLRHPVTGDLPWPALLLGLTIVSGWYWCSDQVIVQRCLAGKSLTHIKAGCILCGYLKLTPMFLMVMPGMISRILYPDEVACVVPEVCRRVCGTEVGCSNIAYPRLVVKLMPNGLRGLMLAVMLAALMSSLASIFNSSSTLFTMDIYTRLRPRAGDRELLLVGRLWVVFIVVVSVAWLPVVQAAQGGQLFDYIQAVSSYLAPPVSAVFVLALFVPRVNEQGAFWGLIGGLLMGLARLIPEFSFGSGSCVQPSACPAFLCGVHYLYFAIVLFFCSGLLTLTVSLCTAPIPRKHLHRLVFSLRHSKEEREDLDADEQQGSSLPVQNGCPESAMEMNEPQAPAPSLFRQCLLWFCGMSRGGVGSPPPLTQEEAAAAARRLEDISEDPSWARVVNLNALLMMAVAVFLWGFYA T81100 DRUGINFO D0OR3G Bexagliflozin Approved T81100 DRUGINFO D0G8LN ISIS-SGLT2 Phase 1 T81100 DRUGINFO D03AJS SERGLIFLOZIN A Investigative T81100 DRUGINFO D05ODW MAACKIAIN Investigative T81100 DRUGINFO D0M7BR FORMONONETIN Investigative T81100 DRUGINFO D0M8VV Acerogenin C Investigative T81100 DRUGINFO D00HFT 10-methoxy-N(1)-methylburnamine-17-O-veratrate Investigative T81100 DRUGINFO D01DIQ Alstiphyllanine F Investigative T81100 DRUGINFO D03VSQ Kushenol N Investigative T81100 DRUGINFO D05AZW Alstiphyllanine E Investigative T81100 DRUGINFO D0I2FC Burnamine-17-O-3',4',5'-trimethoxybenzoate Investigative T81100 DRUGINFO D0L8OJ Alstiphyllanine D Investigative T81100 DRUGINFO D0M8EH O-spiroketal glucoside Investigative T81100 DRUGINFO D0S1MI ACEROGENIN B Investigative T81100 DRUGINFO D0VE0Q Sophoraflavanone G Investigative T81100 DRUGINFO D01PNM KURARINONE Investigative T81100 DRUGINFO D06GUJ KURAIDIN Investigative T72702 TARGETID T72702 T72702 FORMERID TTDR00396 T72702 UNIPROID TF_HUMAN T72702 TARGNAME Tissue factor (F3) T72702 GENENAME F3 T72702 TARGTYPE Successful T72702 SYNONYMS Thromboplastin; TF; F3; Coagulation factor III; CD142 antigen T72702 FUNCTION Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assemblyand propagation of the coagulation protease cascade. T72702 PDBSTRUC 5W06; 4ZMA; 4Z6A; 4YLQ; 4M7L T72702 SEQUENCE METPAWPRVPRPETAVARTLLLGWVFAQVAGASGTTNTVAAYNLTWKSTNFKTILEWEPKPVNQVYTVQISTKSGDWKSKCFYTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVESTGSAGEPLYENSPEFTPYLETNLGQPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFGKDLIYTLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDSPVECMGQEKGEFREIFYIIGAVVFVVIILVIILAISLHKCRKAGVGQSWKENSPLNVS T72702 DRUGINFO D0A4GQ Tisotumab vedotin Approved T72702 DRUGINFO D04DKL ALT-836 Phase 2 T72702 DRUGINFO D0E2LH TT-173 Phase 2 T72702 DRUGINFO D0H8PX MORAb-066 Phase 1 T72702 DRUGINFO D0M4VZ D-Pro-Phe-Arg chloromethyl ketone Investigative T17234 TARGETID T17234 T17234 FORMERID TTDR00589 T17234 UNIPROID UL97_HCMVA T17234 TARGNAME Cytomegalovirus Ganciclovir kinase (CMV UL97) T17234 GENENAME CMV UL97 T17234 TARGTYPE Successful T17234 SYNONYMS UL97; Human cytomegalovirus UL97 protein kinase; HSRF3 protein T17234 FUNCTION Phosphorylates the antiviral nucleoside analog ganciclovir. T17234 BIOCLASS Kinase T17234 ECNUMBER EC 2.7.1.- T17234 SEQUENCE MSSALRSRARSASLGTTTQGWDPPPLRRPSRARRRQWMREAAQAAAQAAVQAAQAAAAQVAQAHVDENEVVDLMADEAGGGVTTLTTLSSVSTTTVLGHATFSACVRSDVMRDGEKEDAASDKENLRRPVVPSTSSRGSAASGDGYHGLRCRETSAMWSFEYDRDGDVTSVRRALFTGGSDPSDSVSGVRGGRKRPLRPPLVSLARTPLCRRRVGGVDAVLEENDVELRAESQDSAVASGPGRIPQPLSGSSGEESATAVEADSTSHDDVHCTCSNDQIITTSIRGLTCDPRMFLRLTHPELCELSISYLLVYVPKEDDFCHKICYAVDMSDESYRLGQGSFGEVWPLDRYRVVKVARKHSETVLTVWMSGLIRTRAAGEQQQPPSLVGTGVHRGLLTATGCCLLHNVTVHRRFHTDMFHHDQWKLACIDSYRRAFCTLADAIKFLNHQCRVCHFDITPMNVLIDVNPHNPSEIVRAALCDYSLSEPYPDYNERCVAVFQETGTARRIPNCSHRLRECYHPAFRPMPLQKLLICDPHARFPVAGLRRYCMSELSALGNVLGFCLMRLLDRRGLDEVRMGTEALLFKHAGAACRALENGKLTHCSDACLLILAAQMSYGACLLGEHGAALVSHTLRFVEAKMSSCRVRAFRRFYHECSQTMLHEYVRKNVERLLATSDGLYLYNAFRRTTSIICEEDLDGDCRQLFPE T17234 DRUGINFO D07WXI Maribavir Approved T08306 TARGETID T08306 T08306 FORMERID TTDNC00634 T08306 UNIPROID CD79B_HUMAN T08306 TARGNAME B-cell-specific glycoprotein B29 (CD79B) T08306 GENENAME CD79B T08306 TARGTYPE Successful T08306 SYNONYMS Immunoglobulinassociated B29 protein; Immunoglobulin-associated B29 protein; Igbeta; Ig-beta; IGB; CD79b; Bcellspecific glycoprotein B29; Bcell antigen receptor complexassociated protein beta chain; B29; B-cell antigen receptor complex-associated protein beta chain T08306 FUNCTION Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. T08306 PDBSTRUC 3KG5 T08306 BIOCLASS Immunoglobulin T08306 SEQUENCE MARLALSPVPSHWMVALLLLLSAEPVPAARSEDRYRNPKGSACSRIWQSPRFIARKRGFTVKMHCYMNSASGNVSWLWKQEMDENPQQLKLEKGRMEESQNESLATLTIQGIRFEDNGIYFCQQKCNNTSEVYQGCGTELRVMGFSTLAQLKQRNTLKDGIIMIQTLLIILFIIVPIFLLLDKDDSKAGMEEDHTYEGLDIDQTATYEDIVTLRTGEVKWSVGEHPGQE T08306 DRUGINFO D05QOL Polatuzumab vedotin Approved T08306 DRUGINFO D03KIZ RG7596 Phase 2 T08306 DRUGINFO D0PA1B DCDS-4501A Phase 2 T08306 DRUGINFO D50ESV Polivy Phase 2 T08306 DRUGINFO D0QO6N MGD010 Phase 1 T08306 DRUGINFO D0M7EP CD79-targeted immunotoxins Investigative T85857 TARGETID T85857 T85857 FORMERID TTDNC00460 T85857 UNIPROID TSLP_HUMAN T85857 TARGNAME Thymic stromal lymphopoietin (TSLP) T85857 GENENAME TSLP T85857 TARGTYPE Successful T85857 SYNONYMS Thymic stromal lymphopoietin T85857 FUNCTION Isoform 1: Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells. Can induce allergic inflammation by directly activating mast cells. T85857 PDBSTRUC 5J13; 5J12; 5J11 T85857 SEQUENCE MFPFALLYVLSVSFRKIFILQLVGLVLTYDFTNCDFEKIKAAYLSTISKDLITYMSGTKSTEFNNTVSCSNRPHCLTEIQSLTFNPTAGCASLAKEMFAMKTKAALAIWCPGYSETQINATQAMKKRRKRKVTTNKCLEQVSQLQGLWRRFNRPLLKQQ T85857 DRUGINFO DMOF95 Tezepelumab Approved T85857 DRUGINFO DX8M3T A378 IND submitted T85857 DRUGINFO D00CTZ MEDI9929 Phase 2 T85857 DRUGINFO DU6O4B CSJ117 Phase 2 T85857 DRUGINFO D94LRF AMG 104 Phase 1 T85857 DRUGINFO DYC40H AZD8630 Phase 1 T85857 DRUGINFO D9TW0X SAR443765 Phase 1 T85857 DRUGINFO DIWU14 PF-07275315 Phase 1 T99840 TARGETID T99840 T99840 FORMERID TTDC00051 T99840 UNIPROID APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN T99840 TARGNAME Gamma-secretase (GS) T99840 GENENAME APH1A; APH1B; NCSTN; PSENEN; PSEN1 T99840 TARGTYPE Successful T99840 SYNONYMS Presenilin-stabilization factor-like; PSFL; Aph-1beta T99840 FUNCTION Probable subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral proteins such as Notch receptors and APP (beta-amyloid precursor protein). It probably represents a stabilizing cofactor for the presenilin homodimer that promotes the formation of a stable complex. Probably present in a minority of gamma-secretase complexes compared to APH1A. T99840 SEQUENCE MGAAVFFGCTFVAFGPAFALFLITVAGDPLRVIILVAGAFFWLVSLLLASVVWFILVHVTDRSDARLQYGLLIFGAAVSVLLQEVFRFAYYKLLKKADEGLASLSEDGRSPISIRQMAYVSGLSFGIISGVFSVINILADALGPGVVGIHGDSPYYFLTSAFLTAAIILLHTFWGVVFFDACERRRYWALGLVVGSHLLTSGLTFLNPWYEASLLPIYAVTVSMGLWAFITAGGSLRSIQRSLLCRRQEDSRVMVYSALRIPPED T99840 DRUGINFO D00GPQ Nirogacestat Approved T99840 DRUGINFO D0G2IC (S)-FLURBIPROFEN Preregistration T99840 DRUGINFO D01LXD Semagacestat Phase 3 T99840 DRUGINFO D0K8NR AMG 386 Phase 3 T99840 DRUGINFO D02HNG MK-0752 Phase 2 T99840 DRUGINFO D02JOH BMS-708163 Phase 2 T99840 DRUGINFO D03MFQ CHF-5074 Phase 2 T99840 DRUGINFO D0I3WC RO-4929097 Phase 2 T99840 DRUGINFO DT3OE6 AL102 Phase 2 T99840 DRUGINFO D05FGR R-flurbiprofen Phase 2 T99840 DRUGINFO D08XKL SPI-014 Phase 1 T99840 DRUGINFO D09ZVC Begacestat Phase 1 T99840 DRUGINFO D0EV5O NGP 555 Phase 1 T99840 DRUGINFO D0F0JJ E2012 Phase 1 T99840 DRUGINFO D0I1OS E-2212 Phase 1 T99840 DRUGINFO D0TQ4Y PF-06648671 Phase 1 T99840 DRUGINFO D0U6FT GSI-136 Phase 1 T99840 DRUGINFO DZ76PB PF-06648671 Phase 1 T99840 DRUGINFO D00DFR (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone Investigative T99840 DRUGINFO D04TWU (5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone Investigative T99840 DRUGINFO D06TPT Drug 311951 Investigative T99840 DRUGINFO D09HAD Drug 311383 Investigative T99840 DRUGINFO D0I8BA 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one Investigative T99840 DRUGINFO D0M2LV (2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone Investigative T99840 DRUGINFO D0V7YM Drug 311952 Investigative T99840 DRUGINFO D0XQ2T Drug 311440 Investigative T06542 TARGETID T06542 T06542 UNIPROID IL17F_HUMAN T06542 TARGNAME Cytokine ML-1 (IL17F) T06542 GENENAME IL17F T06542 TARGTYPE Successful T06542 SYNONYMS Interleukin-17F; IL-17F T06542 FUNCTION The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC. Involved in stimulating the production of other cytokines such as IL6, IL8 and CSF2, and in regulation of cartilage matrix turnover. Also involved in stimulating the proliferation of peripheral blood mononuclear cells and T-cells and in inhibition of angiogenesis. Plays a role in the induction of neutrophilia in the lungs and in the exacerbation of antigen-induced pulmonary allergic inflammation. Ligand for IL17RA and IL17RC. T06542 PDBSTRUC 5NAN; 5N92; 3JVF; 1JPY T06542 BIOCLASS Cytokine: interleukin T06542 SEQUENCE MTVKTLHGPAMVKYLLLSILGLAFLSEAAARKIPKVGHTFFQKPESCPPVPGGSMKLDIGIINENQRVSMSRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNLGCINAQGKEDISMNSVPIQQETLVVRRKHQGCSVSFQLEKVLVTVGCTCVTPVIHHVQ T06542 DRUGINFO D0WJ5M Bimekizumab Approved T60724 TARGETID T60724 T60724 FORMERID TTDNC00461 T60724 UNIPROID SOST_HUMAN T60724 TARGNAME Sclerostin (SOST) T60724 GENENAME SOST T60724 TARGTYPE Successful T60724 SYNONYMS UNQ2976/PRO7455/PRO7476 T60724 FUNCTION Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. T60724 PDBSTRUC 3SOV; 2K8P T60724 SEQUENCE MQLPLALCLVCLLVHTAFRVVEGQGWQAFKNDATEIIPELGEYPEPPPELENNKTMNRAENGGRPPHHPFETKDVSEYSCRELHFTRYVTDGPCRSAKPVTELVCSGQCGPARLLPNAIGRGKWWRPSGPDFRCIPDRYRAQRVQLLCPGGEAPRARKVRLVASCKCKRLTRFHNQSELKDFGTEAARPQKGRKPRPRARSAKANQAELENAY T60724 DRUGINFO D0K3LO Romosozumab Approved T60724 DRUGINFO DG8VN2 UX143 Phase 3 T60724 DRUGINFO D08PKG LY2541546 Phase 2 T60724 DRUGINFO D0XY4A BPS-804 Phase 2 T60724 DRUGINFO D02DJR AMG 167 Phase 1 T46128 TARGETID T46128 T46128 FORMERID TTDI02331 T46128 UNIPROID PMEL_HUMAN T46128 TARGNAME Melanocytes lineage-specific antigen GP100 (PMEL) T46128 GENENAME PMEL T46128 TARGTYPE Successful T46128 SYNONYMS Silver locus protein homolog; SILV; Premelanosome protein; PMEL17; P100; P1; Melanomaassociated ME20 antigen; Melanoma-associated ME20 antigen; Melanocyte protein Pmel 17; Melanocyte protein PMEL; Mbeta; ME20S; ME20M; ME20-M; D12S53E T46128 FUNCTION Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. Plays a central role in the biogenesis of melanosomes. T46128 PDBSTRUC 5EU6; 5EU5; 5EU4; 5EU3; 4IS6 T46128 SEQUENCE MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAMLGTHTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQPLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAIPLTSCGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVLYRYGSFSVTLDIVQGIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQLVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIMPGQEAGLGQVPLIVGILLVLMAVVLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPRIFCSCPIGENSPLLSGQQV T46128 DRUGINFO D0S0BJ Tebentafusp Approved T46128 DRUGINFO D0P5TG Multi-epitope peptide melanoma vaccine Phase 3 T46128 DRUGINFO D0U9MJ Melanoma vaccine Phase 3 T46128 DRUGINFO D08DWM Gp100:209-217(210M) peptide vaccine Phase 2 T46128 DRUGINFO D0N7FD Multi-epitope tyrosinase/gp100 vaccine Phase 2 T46128 DRUGINFO D0F5GF AE-08 Phase 1 T46128 DRUGINFO D0C1EO Melanoma vaccine (ALVAC) Discontinued in Phase 2 T24982 TARGETID T24982 T24982 FORMERID TTDNC00442 T24982 UNIPROID NTCP2_HUMAN T24982 TARGNAME Ileal sodium/bile acid cotransporter (SLC10A2) T24982 GENENAME SLC10A2 T24982 TARGTYPE Successful T24982 SYNONYMS Solute carrier family 10 member 2; Sodium/taurocholate cotransporting polypeptide, ileal; SLC10A2; Na(+)dependent ileal bile acid transporter; Ileal sodiumdependent bile acid transporter; Ileal Na(+)/bile acid cotransporter; ISBT; IBAT; Apical sodiumdependent bile acid transporter; ASBT T24982 FUNCTION Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism. T24982 SEQUENCE MNDPNSCVDNATVCSGASCVVPESNFNNILSVVLSTVLTILLALVMFSMGCNVEIKKFLGHIKRPWGICVGFLCQFGIMPLTGFILSVAFDILPLQAVVVLIIGCCPGGTASNILAYWVDGDMDLSVSMTTCSTLLALGMMPLCLLIYTKMWVDSGSIVIPYDNIGTSLVSLVVPVSIGMFVNHKWPQKAKIILKIGSIAGAILIVLIAVVGGILYQSAWIIAPKLWIIGTIFPVAGYSLGFLLARIAGLPWYRCRTVAFETGMQNTQLCSTIVQLSFTPEELNVVFTFPLIYSIFQLAFAAIFLGFYVAYKKCHGKNKAEIPESKENGTEPESSFYKANGGFQPDEK T24982 DRUGINFO DEWC27 Odevixibat Approved T24982 DRUGINFO DZB84T Maralixibat Approved T24982 DRUGINFO D04BLE A-3309 Phase 3 T24982 DRUGINFO D02FEV S-8921 Phase 2 T24982 DRUGINFO D02JIN 264W94 Phase 2 T24982 DRUGINFO D0X8CH GSK2330672 Phase 2 T24982 DRUGINFO D09JXH LUM001 Phase 2 T24982 DRUGINFO D09NTG Taurocholic Acid Phase 1/2 T24982 DRUGINFO D0D2WX 1614235 + 2330672 Phase 1 T24982 DRUGINFO D06FCT AZD-7806 Investigative T99189 TARGETID T99189 T99189 UNIPROID NTCP_HUMAN T99189 TARGNAME Sodium/bile acid cotransporter (SLC10A1) T99189 GENENAME SLC10A1 T99189 TARGTYPE Successful T99189 SYNONYMS Solute carrier family 10 member 1; Sodium/taurocholate cotransporting polypeptide; Na(+)/taurocholate transport protein; Na(+)/bile acid cotransporter; Cell growth-inhibiting gene 29 protein T99189 FUNCTION The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium. T99189 BIOCLASS Bile acid:sodium symporter (BASS) (TC 2.A.28) family T99189 SEQUENCE MEAHNASAPFNFTLPPNFGKRPTDLALSVILVFMLFFIMLSLGCTMEFSKIKAHLWKPKGLAIALVAQYGIMPLTAFVLGKVFRLKNIEALAILVCGCSPGGNLSNVFSLAMKGDMNLSIVMTTCSTFCALGMMPLLLYIYSRGIYDGDLKDKVPYKGIVISLVLVLIPCTIGIVLKSKRPQYMRYVIKGGMIIILLCSVAVTVLSAINVGKSIMFAMTPLLIATSSLMPFIGFLLGYVLSALFCLNGRCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPLLYMIFQLGEGLLLIAIFWCYEKFKTPKDKTKMIYTAATTEETIPGALGNGTYKGEDCSPCTA T99189 DRUGINFO D2G4HB Bulevirtide Approved T99189 DRUGINFO D09JXH LUM001 Phase 2 T71907 TARGETID T71907 T71907 FORMERID TTDI02176 T71907 UNIPROID SMN_HUMAN T71907 TARGNAME Survival motor neuron protein (SMN1) T71907 GENENAME SMN1 T71907 TARGTYPE Successful T71907 SYNONYMS SMNT; SMNC; SMN2; SMN; Gemin-1; Component of gems 1 T71907 FUNCTION Thereby, plays an important role in the splicing of cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP. Dissociation by the SMN complex of CLNS1A from the trapped Sm proteins and their transfer to an SMN-Sm complex triggers the assembly of core snRNPs and their transport to the nucleus. Ensures the correct splicing of U12 intron-containing genes that may be important for normal motor and proprioceptive neurons development. Also required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs). The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. T71907 PDBSTRUC 5XJU; 5XJT; 5XJS; 5XJR; 5XJQ T71907 SEQUENCE MAMSSGGSGGGVPEQEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASFKHALKNGDICETSGKPKTTPKRKPAKKNKSQKKNTAASLQQWKVGDKCSAIWSEDGCIYPATIASIDFKRETCVVVYTGYGNREEQNLSDLLSPICEVANNIEQNAQENENESQVSTDESENSRSPGNKSDNIKPKSAPWNSFLPPPPPMPGPRLGPGKPGLKFNGPPPPPPPPPPHLLSCWLPPFPSGPPIIPPPPPICPDSLDDADALGSMLISWYMSGYHTGYYMGFRQNQKEGRCSHSLN T71907 DRUGINFO DP07NC Zolgensma Approved T71907 DRUGINFO D0CE6C LMI070 Phase 3 T71907 DRUGINFO D09OTX RG7800 Phase 1/2 T35591 TARGETID T35591 T35591 FORMERID TTDC00343 T35591 UNIPROID NECT4_HUMAN T35591 TARGNAME Nectin cell adhesion molecule 4 (NECTIN4) T35591 GENENAME NECTIN4 T35591 TARGTYPE Successful T35591 SYNONYMS Poliovirus receptor-related protein 4; PVRL4; PRR4; Nectin-4; LNIR; Ig superfamily receptor LNIR T35591 FUNCTION Does not act as receptor for alpha-herpesvirus entry into cells. Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. T35591 PDBSTRUC 4JJH; 4GJT; 4FRW T35591 SEQUENCE MPLSLGAEMWGPEAWLLLLLLLASFTGRCPAGELETSDVVTVVLGQDAKLPCFYRGDSGEQVGQVAWARVDAGEGAQELALLHSKYGLHVSPAYEGRVEQPPPPRNPLDGSVLLRNAVQADEGEYECRVSTFPAGSFQARLRLRVLVPPLPSLNPGPALEEGQGLTLAASCTAEGSPAPSVTWDTEVKGTTSSRSFKHSRSAAVTSEFHLVPSRSMNGQPLTCVVSHPGLLQDQRITHILHVSFLAEASVRGLEDQNLWHIGREGAMLKCLSEGQPPPSYNWTRLDGPLPSGVRVDGDTLGFPPLTTEHSGIYVCHVSNEFSSRDSQVTVDVLDPQEDSGKQVDLVSASVVVVGVIAALLFCLLVVVVVLMSRYHRRKAQQMTQKYEEELTLTRENSIRRLHSHHTDPRSQPEESVGLRAEGHPDSLKDNSSCSVMSEEPEGRSYSTLTTVREIETQTELLSPGSGRAEEEEDQDEGIKQAMNHFVQENGTLRAKPTGNGIYINGRGHLV T35591 DRUGINFO DAG87H Enfortumab vedotin Approved T35591 DRUGINFO DORB45 Enfortumab Approved T35591 DRUGINFO DC57TE BT8009 Phase 1/2 T35591 DRUGINFO D0R1CG ASG-22ME Phase 1 T21123 TARGETID T21123 T21123 UNIPROID EPAS1_HUMAN T21123 TARGNAME Hypoxia-inducible factor 2 alpha (HIF-2A) T21123 GENENAME EPAS1 T21123 TARGTYPE Successful T21123 SYNONYMS bHLHe73; PASD2; PAS domain-containing protein 2; Member of PAS protein 2; MOP2; Hypoxia-inducible factor 2-alpha; HLF; HIF2A; HIF2-alpha; HIF-2-alpha; HIF-1-alpha-like factor; Endothelial PAS domain-containing protein 1; EPAS-1; Class E basic helix-loop-helix protein 73; Basic-helix-loop-helix-PAS protein MOP2 T21123 FUNCTION Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation requires recruitment of transcriptional coactivators such as CREBBP and probably EP300. Interaction with redox regulatory protein APEX seems to activate CTAD. Transcription factor involved in the induction of oxygen regulated genes. T21123 PDBSTRUC 6D0C; 6D0B; 6D09; 6CZW; 6BVB T21123 SEQUENCE MTADKEKKRSSSERRKEKSRDAARCRRSKETEVFYELAHELPLPHSVSSHLDKASIMRLAISFLRTHKLLSSVCSENESEAEADQQMDNLYLKALEGFIAVVTQDGDMIFLSENISKFMGLTQVELTGHSIFDFTHPCDHEEIRENLSLKNGSGFGKKSKDMSTERDFFMRMKCTVTNRGRTVNLKSATWKVLHCTGQVKVYNNCPPHNSLCGYKEPLLSCLIIMCEPIQHPSHMDIPLDSKTFLSRHSMDMKFTYCDDRITELIGYHPEELLGRSAYEFYHALDSENMTKSHQNLCTKGQVVSGQYRMLAKHGGYVWLETQGTVIYNPRNLQPQCIMCVNYVLSEIEKNDVVFSMDQTESLFKPHLMAMNSIFDSSGKGAVSEKSNFLFTKLKEEPEELAQLAPTPGDAIISLDFGNQNFEESSAYGKAILPPSQPWATELRSHSTQSEAGSLPAFTVPQAAAPGSTTPSATSSSSSCSTPNSPEDYYTSLDNDLKIEVIEKLFAMDTEAKDQCSTQTDFNELDLETLAPYIPMDGEDFQLSPICPEERLLAENPQSTPQHCFSAMTNIFQPLAPVAPHSPFLLDKFQQQLESKKTEPEHRPMSSIFFDAGSKASLPPCCGQASTPLSSMGGRSNTQWPPDPPLHFGPTKWAVGDQRTEFLGAAPLGPPVSPPHVSTFKTRSAKGFGARGPDVLSPAMVALSNKLKLKRQLEYEEQAFQDLSGGDPPGGSTSHLMWKRMKNLRGGSCPLMPDKPLSANVPNDKFTQNPMRGLGHPLRHLPLPQPPSAISPGENSKSRFPPQCYATQYQDYSLSSAHKVSGMASRLLGPSFESYLLPELTRYDCEVNVPVLGSSTLLQGGDLLRALDQAT T21123 DRUGINFO D0NU8J Belzutifan Approved T21123 DRUGINFO D0C9PZ PT2385 Phase 2 T10988 TARGETID T10988 T10988 UNIPROID ILRL2_HUMAN T10988 TARGNAME IL-1 receptor-like 2 (IL1RL2) T10988 GENENAME IL1RL2 T10988 TARGTYPE Successful T10988 SYNONYMS Interleukin-1 receptor-related protein 2; Interleukin-1 receptor-like 2; IL1RRP2; IL1R-rp2; IL-36R; IL-36 receptor; IL-1Rrp2 T10988 FUNCTION After binding to interleukin-36 associates with the coreceptor IL1RAP to form the interleukin-36 receptor complex which mediates interleukin-36-dependent activation of NF-kappa-B, MAPK and other pathways. The IL-36 signaling system is thought to be present in epithelial barriers and to take part in local inflammatory response; it is similar to the IL-1 system. Seems to be involved in skin inflammatory response by induction of the IL-23/IL-17/IL-22 pathway. Receptor for interleukin-36 (IL36A, IL36B and IL36G). T10988 BIOCLASS Cytokine receptor T10988 SEQUENCE MWSLLLCGLSIALPLSVTADGCKDIFMKNEILSASQPFAFNCTFPPITSGEVSVTWYKNSSKIPVSKIIQSRIHQDETWILFLPMEWGDSGVYQCVIKGRDSCHRIHVNLTVFEKHWCDTSIGGLPNLSDEYKQILHLGKDDSLTCHLHFPKSCVLGPIKWYKDCNEIKGERFTVLETRLLVSNVSAEDRGNYACQAILTHSGKQYEVLNGITVSITERAGYGGSVPKIIYPKNHSIEVQLGTTLIVDCNVTDTKDNTNLRCWRVNNTLVDDYYDESKRIREGVETHVSFREHNLYTVNITFLEVKMEDYGLPFMCHAGVSTAYIILQLPAPDFRAYLIGGLIALVAVAVSVVYIYNIFKIDIVLWYRSAFHSTETIVDGKLYDAYVLYPKPHKESQRHAVDALVLNILPEVLERQCGYKLFIFGRDEFPGQAVANVIDENVKLCRRLIVIVVPESLGFGLLKNLSEEQIAVYSALIQDGMKVILIELEKIEDYTVMPESIQYIKQKHGAIRWHGDFTEQSQCMKTKFWKTVRYHMPPRRCRPFPPVQLLQHTPCYRTAGPELGSRRKKCTLTTG T10988 DRUGINFO D0W9YW Spesolimab Approved T10988 DRUGINFO D1I0LQ Nemvaleukin alfa Phase 3 T10988 DRUGINFO DZ49IJ Imsidolimab Phase 3 T53139 TARGETID T53139 T53139 FORMERID TTDNR00642 T53139 UNIPROID ANGL3_HUMAN T53139 TARGNAME Angiopoietin-related protein 3 (ANGPTL3) T53139 GENENAME ANGPTL3 T53139 TARGTYPE Successful T53139 SYNONYMS UNQ153/PRO179; Angiopoietin-like protein 3; Angiopoietin-5; ANGPT5; ANG-5 T53139 FUNCTION Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1. Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids. Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol. Suppresses LPL specifically in oxidative tissues which is required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT (By similarity). Contributes to lower plasma levels of low density lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway implicating APOE and LDLR. May stimulate hypothalamic LPL activity (By similarity). T53139 PDBSTRUC 6EUA T53139 BIOCLASS Fibrinogen protein T53139 SEQUENCE MFTIKLLLFIVPLVISSRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGLLQLGHGLKDFVHKTKGQINDIFQKLNIFDQSFYDLSLQTSEIKEEEKELRRTTYKLQVKNEEVKNMSLELNSKLESLLEEKILLQQKVKYLEEQLTNLIQNQPETPEHPEVTSLKTFVEKQDNSIKDLLQTVEDQYKQLNQQHSQIKEIENQLRRTSIQEPTEISLSSKPRAPRTTPFLQLNEIRNVKHDGIPAECTTIYNRGEHTSGMYAIRPSNSQVFHVYCDVISGSPWTLIQHRIDGSQNFNETWENYKYGFGRLDGEFWLGLEKIYSIVKQSNYVLRIELEDWKDNKHYIEYSFYLGNHETNYTLHLVAITGNVPNAIPENKDLVFSTWDHKAKGHFNCPEGYSGGWWWHDECGENNLNGKYNKPRAKSKPERRRGLSWKSQNGRLYSIKSTKMLIHPTDSESFE T53139 DRUGINFO D03WOG Evinacumab Approved T53139 DRUGINFO D0H3ST AKCEA-ANGPTL3-LRX Phase 2 T53139 DRUGINFO D49KHP LNA043 Phase 2 T23343 TARGETID T23343 T23343 FORMERID TTDI02212 T23343 UNIPROID POL_HV1B1 T23343 TARGNAME Human immunodeficiency virus Capsid p24 (HIV p24) T23343 GENENAME HIV p24 T23343 TARGTYPE Successful T23343 SYNONYMS CA T23343 FUNCTION Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre- integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This processis mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration. T23343 PDBSTRUC 6OE3; 6HAK; 6ELI; 6DUH; 6DUG T23343 SEQUENCE PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVL T23343 DRUGINFO D24GYL Lenacapavir Approved T23343 DRUGINFO D0F3GL Vacc-4x Phase 2 T23343 DRUGINFO D05GBH F4co vaccine Phase 2 T23343 DRUGINFO D8ID3Y VH4004280 Phase 1 T23343 DRUGINFO DB2VY6 VH4011499 Phase 1 T00972 TARGETID T00972 T00972 FORMERID TTDI01924 T00972 UNIPROID ENV_HV1H2 T00972 TARGNAME Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) T00972 GENENAME HIV gp120 T00972 TARGTYPE Successful T00972 SYNONYMS Env polyprotein gp120 (33-511) T00972 FUNCTION Transmembrane protein gp41: Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin- dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm. T00972 PDBSTRUC 6DLN; 6DE7; 6BXQ; 6BXP; 6B9K T00972 SEQUENCE KLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR T00972 DRUGINFO D00ZCT Fostemsavir Approved T00972 DRUGINFO D06BGS AIDSVAX Phase 3 T00972 DRUGINFO D01NGH Multi-envelope HIV vaccine Phase 1 T00972 DRUGINFO D09EVZ BMS-488043 Discontinued in Phase 2 T00972 DRUGINFO D0ZR3N Pro 542 Discontinued in Phase 2 T00972 DRUGINFO D04MGI PF-821385 Preclinical T00972 DRUGINFO D0U6NR CD4 red blood cell electroinsertion Investigative T61339 TARGETID T61339 T61339 FORMERID TTDR00001 T61339 UNIPROID LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN T61339 TARGNAME Alpha-glucosidase (GLA) T61339 GENENAME GAA; GANAB; GANC T61339 TARGTYPE Successful T61339 SYNONYMS Maltase-glucoamylase; Maltase; Glucosidosucrase; Glucosidoinvertase; Glucoinvertase; Alpha-glucoside hydrolase; Alpha-glucopyranosidase; Alpha-D-glucoside glucohydrolase; Alpha-D-glucosidase; Alpha-1;4-glucosidase T61339 FUNCTION Breaks down starch and disaccharides to glucose. T61339 SEQUENCE MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC T61339 DRUGINFO D67KYA Cipaglucosidase alfa Approved T61339 DRUGINFO DW7EN6 Cipaglucosidase alfa Approved in EU T61339 DRUGINFO D03WAU Anamorelin Phase 3 T61339 DRUGINFO D0S5LT Deoxynojirimycin Phase 3 T61339 DRUGINFO D04RYY Maltose Phase 1/2 T61339 DRUGINFO DFV71O AAV2/8-LSPhGAA Phase 1 T61339 DRUGINFO D0IT1M 4,6-Dideoxyglucose Investigative T61339 DRUGINFO D0P6IA Tendamistat Investigative T61339 DRUGINFO D0E0VN 6-Deoxy-Alpha-D-Glucose Investigative T61339 DRUGINFO D08SMN POP-1 Investigative T61339 DRUGINFO D0JR9V JBP-1 Investigative T61339 DRUGINFO D07ONX Beta-D-Glucose Investigative T61339 DRUGINFO D0H1GU Double Oxidized Cysteine Investigative T61339 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T94718 TARGETID T94718 T94718 FORMERID TTDNC00414 T94718 UNIPROID LAG3_HUMAN T94718 TARGNAME Lymphocyte activation gene 3 protein (LAG3) T94718 GENENAME LAG3 T94718 TARGTYPE Successful T94718 SYNONYMS Protein FDC; LAG-3; FDC; CD223 T94718 FUNCTION Delivers inhibitory signals upon binding to ligands, such as FGL1. FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function. Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1. Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells. Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function. Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation. Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear. Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells. T94718 BIOCLASS Immunoglobulin T94718 SEQUENCE MWEAQFLGLLFLQPLWVAPVKPLQPGAEVPVVWAQEGAPAQLPCSPTIPLQDLSLLRRAGVTWQHQPDSGPPAAAPGHPLAPGPHPAAPSSWGPRPRRYTVLSVGPGGLRSGRLPLQPRVQLDERGRQRGDFSLWLRPARRADAGEYRAAVHLRDRALSCRLRLRLGQASMTASPPGSLRASDWVILNCSFSRPDRPASVHWFRNRGQGRVPVRESPHHHLAESFLFLPQVSPMDSGPWGCILTYRDGFNVSIMYNLTVLGLEPPTPLTVYAGAGSRVGLPCRLPAGVGTRSFLTAKWTPPGGGPDLLVTGDNGDFTLRLEDVSQAQAGTYTCHIHLQEQQLNATVTLAIITVTPKSFGSPGSLGKLLCEVTPVSGQERFVWSSLDTPSQRSFSGPWLEAQEAQLLSQPWQCQLYQGERLLGAAVYFTELSSPGAQRSGRAPGALPAGHLLLFLILGVLSLLLLVTGAFGFHLWRRQWRPRRFSALEQGIHPPQAQSKIEELEQEPEPEPEPEPEPEPEPEPEQL T94718 DRUGINFO D0A3WJ Relatlimab Approved T94718 DRUGINFO D0T7OI Anti-LAG3 Phase 2 T94718 DRUGINFO D03ZSA BMS-986016 Phase 1/2 T94718 DRUGINFO D0P9MW IMP-321 Phase 1/2 T94718 DRUGINFO DS6MP8 Favezelimab Phase 1/2 T94718 DRUGINFO D02IYC IMP-701 Phase 1 T94718 DRUGINFO D0ZX2L GSK2831781 Phase 1 T94718 DRUGINFO D4KTA9 INCAGN2385 Phase 1 T94718 DRUGINFO D4L3IZ Sym022 Phase 1 T94718 DRUGINFO D7TV5I MK-4280 Phase 1 T94718 DRUGINFO DF5PB0 A289 Phase 1 T94718 DRUGINFO DL07ZP GSK4074386 Phase 1 T94718 DRUGINFO D0BOM7 XmAb22841 Phase 1 T94718 DRUGINFO D0XO9F FS118 Phase 1 T94718 DRUGINFO D4CGN3 RG6139 Phase 1 T94718 DRUGINFO DMEQ73 ADPT01 Phase 1 T94718 DRUGINFO D05ZLH IMP-731 Investigative T94718 DRUGINFO D0DB2F Concatameric LAG3Ig Investigative T66693 TARGETID T66693 T66693 FORMERID TTDR00934 T66693 UNIPROID TNR17_HUMAN T66693 TARGNAME B-cell maturation protein (TNFRSF17) T66693 GENENAME TNFRSF17 T66693 TARGTYPE Successful T66693 SYNONYMS Tumor necrosis factor receptor superfamily member 17; CD269; BCMA; BCM T66693 FUNCTION Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. T66693 PDBSTRUC 6J7W; 4ZFO; 2KN1; 1XU2; 1OQD T66693 SEQUENCE MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAILWTCLGLSLIISLAVFVLMFLLRKINSEPLKDEFKNTGSGLLGMANIDLEKSRTGDEIILPRGLEYTVEECTCEDCIKSKPKVDSDHCFPLPAMEEGATILVTTKTNDYCKSLPAALSATEIEKSISAR T66693 DRUGINFO D03AFF Teclistamab Approved T66693 DRUGINFO D03NPI Idecabtagene vicleucel Approved T66693 DRUGINFO D52NZX Belantamab mafodotin Approved T66693 DRUGINFO D3KO5Y Elranatamab Approved T66693 DRUGINFO DXV06E Ciltacabtagene autoleucel Phase 3 T66693 DRUGINFO D07CUR Bb2121 Phase 2 T66693 DRUGINFO D0K1AK LCAR-B38M CAR-T Cell Phase 2 T66693 DRUGINFO D0Z6AR Descartes-08 Phase 2 T66693 DRUGINFO DN28SH Descartes-11 Phase 2 T66693 DRUGINFO D01CUC BCMA CAR T cells Phase 1/2 T66693 DRUGINFO D02JNC BCMA CAR-T Phase 1/2 T66693 DRUGINFO D04PIU CART-BCMA cells Phase 1/2 T66693 DRUGINFO D07PJS JNJ-68284528 Phase 1/2 T66693 DRUGINFO D07QIQ Anti-BCMA-CAR-transduced T cells Phase 1/2 T66693 DRUGINFO D0D4ZN CAR-T cells targeting BCMA Phase 1/2 T66693 DRUGINFO D0EQ6D JCARH125 Phase 1/2 T66693 DRUGINFO D0MK7H Anti-BCMA CAR-T cells Phase 1/2 T66693 DRUGINFO D7LU8R PBCAR269A Phase 1/2 T66693 DRUGINFO D0AC9S CART-19/BCMA Phase 1/2 T66693 DRUGINFO D0B8UW AUTO2 Phase 1/2 T66693 DRUGINFO D0G0PI CD38 and BCMA CAR-T Cells Phase 1/2 T66693 DRUGINFO DR7Q5N REGN5458 Phase 1/2 T66693 DRUGINFO DY9G1D REGN5459 Phase 1/2 T66693 DRUGINFO D00OXP Bb21217 Phase 1 T66693 DRUGINFO D01YZF CART-BCMA Phase 1 T66693 DRUGINFO D05XNF IM21 CART Phase 1 T66693 DRUGINFO D07HJS Anti-BCMA CAR-T cells Phase 1 T66693 DRUGINFO D0B2WU CAR-T cells targeting BCMA Phase 1 T66693 DRUGINFO D0C8QA KITE-585 Phase 1 T66693 DRUGINFO D0F0VW Anti-BCMA CAR-T cells Phase 1 T66693 DRUGINFO D0I1PF LCAR-B4822M CAR-T Cell Phase 1 T66693 DRUGINFO D0J7OU C-CAR088 Phase 1 T66693 DRUGINFO D0MS2T BCMA-specific CAR-expressing T Lymphocytes Phase 1 T66693 DRUGINFO D0NG3T BCMA CAR-T Cells Phase 1 T66693 DRUGINFO D0NK6K P-BCMA-101 CAR-T cells Phase 1 T66693 DRUGINFO D0RA7L Anti-BCMA CART Cells Phase 1 T66693 DRUGINFO D0RD0D BCMA CART Phase 1 T66693 DRUGINFO D0T9CE BCMA nanobody CAR-T cells Phase 1 T66693 DRUGINFO D0U2PU Anti-BCMA CAR T cells Phase 1 T66693 DRUGINFO D0W1GP Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 Phase 1 T66693 DRUGINFO D0W7AB Anti-BCMA CAR T cells Phase 1 T66693 DRUGINFO D12DYT HPN217 Phase 1 T66693 DRUGINFO D1WOX4 CT053 Phase 1 T66693 DRUGINFO D3T7NY CART-ddBCMA Phase 1 T66693 DRUGINFO D4QZ3O SEA-BCMA Phase 1 T66693 DRUGINFO D5YN8U ALLO-715 Phase 1 T66693 DRUGINFO D67ZDJ PHE885 Phase 1 T66693 DRUGINFO DE49RW CTX120 Phase 1 T66693 DRUGINFO DG80IS MEDI2228 Phase 1 T66693 DRUGINFO DH5BX2 CC-99712 Phase 1 T66693 DRUGINFO DN68MW P-PSMA-101 Phase 1 T66693 DRUGINFO DOQ13X CC-93269 Phase 1 T66693 DRUGINFO DS86KN RG6538 Phase 1 T66693 DRUGINFO DUZ0F7 AMG 420 Phase 1 T66693 DRUGINFO DX6J8M CC-98633 Phase 1 T66693 DRUGINFO D0T8RV BCMA CART and huCART19 Phase 1 T66693 DRUGINFO D0U7WY Anti-CD19/BCMA CAR-T cells Phase 1 T66693 DRUGINFO D81YIK WVT078 Phase 1 T66693 DRUGINFO DC3Y7O RG6296 Phase 1 T66693 DRUGINFO DF43EH AMG 701 Phase 1 T66693 DRUGINFO DTR05Z BCMA-CD19 cCAR Phase 1 T66693 DRUGINFO DW1H9O TNB-383B Phase 1 T66693 DRUGINFO DX1LD3 BCMA-CS1 cCAR Phase 1 T66693 DRUGINFO D09ZGK BCMA-CART Clinical trial T66693 DRUGINFO D0LP1L CAR-T cells targeting BCMA Clinical trial T66693 DRUGINFO D0N8NT BCMA-UCART Clinical trial T66693 DRUGINFO D0PF1A CAR-BCMA T cell Clinical trial T66693 DRUGINFO D01SNU P-BCMA-ALL01 Preclinical T71536 TARGETID T71536 T71536 FORMERID TTDI01205 T71536 TARGNAME Human Deoxyribonucleic acid minor groove (hDNA min) T71536 TARGTYPE Successful T71536 DRUGINFO D0V6OA Lurbinectedin Approved T71536 DRUGINFO D0OY5G Brostallicin Phase 2 T71536 DRUGINFO D01YRT Di-imidazole lexitropsin Investigative T71536 DRUGINFO D05ITH Duocarmycin Investigative T71536 DRUGINFO D05ZVR Netropsin Investigative T71536 DRUGINFO D0BS6Q Distamycin A Investigative T16538 TARGETID T16538 T16538 UNIPROID EGFR_HUMAN T16538 TARGNAME EGFR T790M mutant (EGFR T790M) T16538 GENENAME EGFR T16538 TARGTYPE Successful T16538 SYNONYMS Receptor tyrosine-protein kinase erbB-1 T790M mutant; Proto-oncogene c-ErbB-1 T790M mutant; HER1 T790M mutant; Epidermal growth factor receptor T790M mutant; ERBB1 T790M mutant; ERBB T790M mutant T16538 FUNCTION Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance. T16538 PDBSTRUC 6D8E; 6B3S; 6ARU; 5ZWJ; 5YU9 T16538 BIOCLASS Kinase T16538 ECNUMBER EC 2.7.10.1 T16538 SEQUENCE MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA T16538 DRUGINFO D0O8GK Osimertinib Approved T16538 DRUGINFO D01DBB PMID27774824-Compound-Figure9Example2down Patented T66011 TARGETID T66011 T66011 FORMERID TTDI02354 T66011 UNIPROID CFAB_HUMAN T66011 TARGNAME Complement factor B (CFB) T66011 GENENAME CFB T66011 TARGTYPE Successful T66011 SYNONYMS Properdin factor B; PBF2; Glycinerich beta glycoprotein; Glycine-rich beta glycoprotein; GBG; Complement factor B Bb fragment; C3/C5 convertase; BFD; BF T66011 FUNCTION Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes. T66011 PDBSTRUC 6RAV; 6QSX; 6QSW; 5M6W; 3HS0 T66011 BIOCLASS Peptidase T66011 ECNUMBER EC 3.4.21.47 T66011 SEQUENCE MGSNLSPQLCLMPFILGLLSGGVTTTPWSLARPQGSCSLEGVEIKGGSFRLLQEGQALEYVCPSGFYPYPVQTRTCRSTGSWSTLKTQDQKTVRKAECRAIHCPRPHDFENGEYWPRSPYYNVSDEISFHCYDGYTLRGSANRTCQVNGRWSGQTAICDNGAGYCSNPGIPIGTRKVGSQYRLEDSVTYHCSRGLTLRGSQRRTCQEGGSWSGTEPSCQDSFMYDTPQEVAEAFLSSLTETIEGVDAEDGHGPGEQQKRKIVLDPSGSMNIYLVLDGSDSIGASNFTGAKKCLVNLIEKVASYGVKPRYGLVTYATYPKIWVKVSEADSSNADWVTKQLNEINYEDHKLKSGTNTKKALQAVYSMMSWPDDVPPEGWNRTRHVIILMTDGLHNMGGDPITVIDEIRDLLYIGKDRKNPREDYLDVYVFGVGPLVNQVNINALASKKDNEQHVFKVKDMENLEDVFYQMIDESQSLSLCGMVWEHRKGTDYHKQPWQAKISVIRPSKGHESCMGAVVSEYFVLTAAHCFTVDDKEHSIKVSVGGEKRDLEIEVVLFHPNYNINGKKEAGIPEFYDYDVALIKLKNKLKYGQTIRPICLPCTEGTTRALRLPPTTTCQQQKEELLPAQDIKALFVSEEEKKLTRKEVYIKNGDKKGSCERDAQYAPGYDKVKDISEVVTPRFLCTGGVSPYADPNTCRGDSGGPLIVHKRSRFIQVGVISWGVVDVCKNQKRQKQVPAHARDFHINLFQVLPWLKEKLQDEDLGFL T66011 DRUGINFO DJ48HT Iptacopan Approved T66011 DRUGINFO D7PVH4 LPN023 Phase 2 T66011 DRUGINFO DZ7Q8I RG6299 Phase 2 T66011 DRUGINFO DJ0P6Z SAR443809 Phase 1 T66011 DRUGINFO D0Q0OP CAB-2 Discontinued in Phase 1 T66011 DRUGINFO D01ODC TA-106 Investigative T66011 DRUGINFO D09JGO PMID19743866C51 Investigative T66011 DRUGINFO D09PKZ NM-9308 Investigative T52189 TARGETID T52189 T52189 FORMERID TTDR01004 T52189 UNIPROID ACLY_HUMAN T52189 TARGNAME ATP-citrate synthase (ACLY) T52189 GENENAME ACLY T52189 TARGTYPE Successful T52189 SYNONYMS Citrate cleavage enzyme; ATP-citrate (pro-S-)-lyase; ACL T52189 FUNCTION ATP-citrate synthase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Has a central role in de novo lipid synthesis. In nervous tissue it may be involved in the biosynthesis of acetylcholine. T52189 PDBSTRUC 6QFB; 6O0H; 6HXM; 6HXL; 6HXK T52189 BIOCLASS Acyltransferase T52189 ECNUMBER EC 2.3.3.8 T52189 SEQUENCE MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVPHSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYICKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASVVYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSIANFTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIHVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESRADEVAPAKKAKPAMPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSRDEPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLRSAYDSTMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKIGNTGGMLDNILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPGSTFMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMFSSEVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVIVPAQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEEMGIGGVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTSGLLTIGDRFGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNPDMRVQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCGSFTREEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHMSM T52189 DRUGINFO D0D9NY Bempedoic acid Approved T52189 DRUGINFO D09AXB SB-201076 Investigative T52189 DRUGINFO D0IC1N (-)-hydroxycitrate Investigative T72545 TARGETID T72545 T72545 FORMERID TTDR01169 T72545 UNIPROID PARC_ECOLI T72545 TARGNAME Bacterial DNA topoisomerase 4A (Bact parC) T72545 GENENAME Bact parC T72545 TARGTYPE Successful T72545 SYNONYMS parC; Topoisomerase IV subunit A of Escherichia coli T72545 FUNCTION Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule. MukB stimulates the relaxation activity of topoisomeraseIV and also has a modest effect on decatenation. T72545 PDBSTRUC 4MN4; 1ZVU; 1ZVT T72545 BIOCLASS Topoisomerase GyrA ParC T72545 ECNUMBER EC 5.6.2.3 T72545 SEQUENCE MSDMAERLALHEFTENAYLNYSMYVIMDRALPFIGDGLKPVQRRIVYAMSELGLNASAKFKKSARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQGNWGAPDDPKSFAAMRYTESRLSKYSELLLSELGQGTADWVPNFDGTLQEPKMLPARLPNILLNGTTGIAVGMATDIPPHNLREVAQAAIALIDQPKTTLDQLLDIVQGPDYPTEAEIITSRAEIRKIYENGRGSVRMRAVWKKEDGAVVISALPHQVSGARVLEQIAAQMRNKKLPMVDDLRDESDHENPTRLVIVPRSNRVDMDQVMNHLFATTDLEKSYRINLNMIGLDGRPAVKNLLEILSEWLVFRRDTVRRRLNYRLEKVLKRLHILEGLLVAFLNIDEVIEIIRNEDEPKPALMSRFGLTETQAEAILELKLRHLAKLEEMKIRGEQSELEKERDQLQGILASERKMNNLLKKELQADAQAYGDDRRSPLQEREEAKAMSEHDMLPSEPVTIVLSQMGWVRSAKGHDIDAPGLNYKAGDSFKAAVKGKSNQPVVFVDSTGRSYAIDPITLPSARGQGEPLTGKLTLPPGATVDHMLMESDDQKLLMASDAGYGFVCTFNDLVARNRAGKALITLPENAHVMPPVVIEDASDMLLAITQAGRMLMFPVSDLPQLSKGKGNKIINIPSAEAARGEDGLAQLYVLPPQSTLTIHVGKRKIKLRPEELQKVTGERGRRGTLMRGLQRIDRVEIDSPRRASSGDSEE T72545 DRUGINFO DR36YB Prulifloxacin Approved T72545 DRUGINFO D05STQ Pazufloxacin Phase 3 T72545 DRUGINFO D2FCM4 VB 1953 Phase 2 T72545 DRUGINFO D39VXL JNJ-32729463 Phase 2 T72545 DRUGINFO D4M8RS TNP-2092 Phase 2 T72545 DRUGINFO D6DT3X Sitafloxacin Phase 2 T72545 DRUGINFO D04QJK A-62824 Investigative T06020 TARGETID T06020 T06020 FORMERID TTDR00482 T06020 UNIPROID FCGRN_HUMAN T06020 TARGNAME Neonatal Fc receptor (FCGRT) T06020 GENENAME FCGRT T06020 TARGTYPE Successful T06020 SYNONYMS Neonatal FcR; MHC class I family-like Fc receptor; IgG Fc fragment receptor transporter, alpha chain; FcRn; FCGRT T06020 FUNCTION Binds to the Fc region of monomericimmunoglobulins gamma. Mediates the uptake of IgG from milk. Possible role in transfer of immunoglobulin G from mother to fetus. T06020 PDBSTRUC 6ILM; 6FGB; 6C99; 6C98; 6C97 T06020 BIOCLASS Immunoglobulin T06020 SEQUENCE MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA T06020 DRUGINFO D0P0LD Efgartigimod alfa Approved T06020 DRUGINFO DMWA10 Batoclimab Phase 3 T06020 DRUGINFO DR5V8I Nipocalimab? Phase 3 T06020 DRUGINFO DZA98D ARGX-113 Phase 3 T06020 DRUGINFO D0QR7C SYN-1327 Investigative T99989 TARGETID T99989 T99989 FORMERID TTDI03081 T99989 UNIPROID KC1E_HUMAN T99989 TARGNAME Casein kinase I epsilon (CSNK1E) T99989 GENENAME CSNK1E T99989 TARGTYPE Successful T99989 SYNONYMS Casein kinase I isoform epsilon; CKIe; CKI-epsilon T99989 FUNCTION Can phosphorylate a large number of proteins. Participates in Wnt signaling. Phosphorylates DVL1 and DVL2. Central component of the circadian clock. In balance with PP1, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. Controls PER1 and PER2 nuclear transport and degradation. Inhibits cytokine-induced granuloytic differentiation. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. T99989 PDBSTRUC 4HOK; 4HNI T99989 BIOCLASS Kinase T99989 ECNUMBER EC 2.7.11.1 T99989 SEQUENCE MELRVGNKYRLGRKIGSGSFGDIYLGANIASGEEVAIKLECVKTKHPQLHIESKFYKMMQGGVGIPSIKWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFSTYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLKFGAARNPEDVDRERREHEREERMGQLRGSATRALPPGPPTGATANRLRSAAEPVASTPASRIQPAGNTSPRAISRVDRERKVSMRLHRGAPANVSSSDLTGRQEVSRIPASQTSVPFDHLGK T99989 DRUGINFO D0O8SJ Umbralisib Approved T99989 DRUGINFO D06QYR PF-4800567 Preclinical T99989 DRUGINFO DZK7E0 PF-670462 Preclinical T99989 DRUGINFO D0UN8H IC261 Preclinical T53242 TARGETID T53242 T53242 FORMERID TTDI01357 T53242 UNIPROID CMAS1_MYCTU; CMAS2_MYCTU; CMAS3_MYCTU T53242 TARGNAME Mycobacterium Mycolic acid synthase (MycB cma) T53242 GENENAME MycB cmaA1; MycB cmaA2; MycB pcaA T53242 TARGTYPE Successful T53242 SYNONYMS cma; SAM-MT; S-adenosylmethionine-dependent methyltransferase; Mycolic acid methyltransferase; MA-MT; Cyclopropane-fatty-acyl-phospholipid synthase; Cyclopropane mycolic acid synthase; Cyclopropane fatty acid synthase; CMAS; CFA synthase; AdoMet-MT T53242 FUNCTION Catalyzes the conversion of a double bond to a cyclopropane ring at the distal position of an alpha mycolic acid via the transfer of a methylene group from S-adenosyl-L-methionine. Cyclopropanated mycolic acids are key factors participating in cell envelope permeability, host immunomodulation and persistence. T53242 SEQUENCE MPDELKPHFANVQAHYDLSDDFFRLFLDPTQTYSCAYFERDDMTLQEAQIAKIDLALGKLGLQPGMTLLDVGCGWGATMMRAVEKYDVNVVGLTLSKNQANHVQQLVANSENLRSKRVLLAGWEQFDEPVDRIVSIGAFEHFGHERYDAFFSLAHRLLPADGVMLLHTITGLHPKEIHERGLPMSFTFARFLKFIVTEIFPGGRLPSIPMVQECASANGFTVTRVQSLQPHYAKTLDLWSAALQANKGQAIALQSEEVYERYMKYLTGCAEMFRIGYIDVNQFTCQK T53242 DRUGINFO D02AYL Pretomanid Approved T78111 TARGETID T78111 T78111 FORMERID TTDS00303 T78111 TARGNAME Nicotinic acetylcholine receptor (nAChR) T78111 TARGTYPE Successful T78111 SYNONYMS nAChR; Nicotinergic acetylcholine receptor T78111 FUNCTION After binding acetylcholine, the AChRresponds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. T78111 BIOCLASS Ion transport T78111 DRUGINFO D0AA0L Pancuronium Approved T78111 DRUGINFO D0Q1PR Atracurium Approved T78111 DRUGINFO D0T8GD Nicotine Approved T78111 DRUGINFO D0TY5N Cotinine Approved T78111 DRUGINFO D0V8HA Mecamylamine Approved T78111 DRUGINFO D08XPW CYTISINE Phase 3 T78111 DRUGINFO D00QKS BMS-954561 Phase 2 T78111 DRUGINFO D08NYZ ASM-024 Phase 2 T78111 DRUGINFO D0MC2S NIC-002 Phase 2 T78111 DRUGINFO D0X8HP TRIDMAC Phase 2 T78111 DRUGINFO D0Y6OE A-85380 Phase 2 T78111 DRUGINFO D03QWO Dexefaroxan Phase 2 T78111 DRUGINFO D03JJY GANTACURIUM CHLORIDE Phase 1/2 T78111 DRUGINFO D0E7MA ATG002 Phase 1/2 T78111 DRUGINFO D0UI4L ND-0801 Phase 1/2 T78111 DRUGINFO D05FVK RPI-78M Phase 1 T78111 DRUGINFO D0K3JQ RPI-MN Phase 1 T78111 DRUGINFO D06TVG Inaperisone Discontinued in Preregistration T78111 DRUGINFO D03UID RJR-2403 Discontinued in Phase 2 T78111 DRUGINFO D0C2HR ORG-9273 Discontinued in Phase 2 T78111 DRUGINFO D00ECO SIB-1553A Discontinued in Phase 2 T78111 DRUGINFO D04HYP ABT-594 Discontinued in Phase 2 T78111 DRUGINFO D09ADT ABT-418 Discontinued in Phase 2 T78111 DRUGINFO D08VUJ ABT-202 Discontinued in Phase 1 T78111 DRUGINFO D0N1DQ ANQ-9040 Discontinued in Phase 1 T78111 DRUGINFO D03DMI SIB-1663 Terminated T78111 DRUGINFO D04JNR SIB-1765F Terminated T78111 DRUGINFO D09GRB NNC-90-0270 Terminated T78111 DRUGINFO D0A4RM DBO-83 Terminated T78111 DRUGINFO D0N5UA Dianicline+rimonabant Terminated T78111 DRUGINFO D0O5EZ Epibatidine Investigative T78111 DRUGINFO D0Q5AD PROTOSTEMODIOL Investigative T78111 DRUGINFO D0YN5P 8-aminoquinolines Investigative T11754 TARGETID T11754 T11754 FORMERID TTDS00177 T11754 TARGNAME Fatty acid amide hydrolase (FAAH) T11754 TARGTYPE Successful T11754 SYNONYMS Oleamidehydrolase; Anandamide amidohydrolase T11754 FUNCTION Degradesbioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates. T11754 DRUGINFO D00MYT Thiopental Approved T11754 DRUGINFO D0A3HB Propofol Approved T11754 DRUGINFO D02GPG JNJ-42165279 Phase 2 T11754 DRUGINFO D03DSX SSR411298 Phase 2 T11754 DRUGINFO D0FH5N IW-6118 Phase 2 T11754 DRUGINFO D0JT5I PF-04457845 Phase 2 T11754 DRUGINFO D0CR4Z IPI-940 Phase 1 T11754 DRUGINFO D00PFD Benzyl pyrrolyloxoacetamide derivative 1 Patented T11754 DRUGINFO D00RKV Carbamate derivative 8 Patented T11754 DRUGINFO D00ZGG Azole derivative 2 Patented T11754 DRUGINFO D02JER Tetra-substituted urea derivative 2 Patented T11754 DRUGINFO D02LJQ Boronic acid derivative 1 Patented T11754 DRUGINFO D02ZPG Aryl urea derivative 1 Patented T11754 DRUGINFO D03MCC Tetra-hydro-naphthalene derivative 1 Patented T11754 DRUGINFO D04USU Heteroaryl-substituted urea derivative 2 Patented T11754 DRUGINFO D04VYE Benzyl pyrrolyloxoacetamide derivative 2 Patented T11754 DRUGINFO D05FQX N-alkyl-4-oxazolecar boxamide derivative 1 Patented T11754 DRUGINFO D05HJF Boronic acid derivative 5 Patented T11754 DRUGINFO D05IZN Azole derivative 4 Patented T11754 DRUGINFO D05KXF Tetra-hydro-naphthyridine derivative 1 Patented T11754 DRUGINFO D05LBM Azole derivative 5 Patented T11754 DRUGINFO D05MKN Azetidine urea derivative 3 Patented T11754 DRUGINFO D05RQF Benzoxazole derivative 1 Patented T11754 DRUGINFO D07JMG Boronic acid derivative 4 Patented T11754 DRUGINFO D07MIY Aryl urea derivative 3 Patented T11754 DRUGINFO D07VNW Enol carbamate derivative 1 Patented T11754 DRUGINFO D08JES Piperazine urea derivative 1 Patented T11754 DRUGINFO D09AAB Imidazolyl urea derivative 1 Patented T11754 DRUGINFO D09SWG Azole derivative 1 Patented T11754 DRUGINFO D09VEY Spirocyclic diamine urea derivative 2 Patented T11754 DRUGINFO D0BN7S Azetidine urea derivative 1 Patented T11754 DRUGINFO D0DD7K Aryl urea derivative 5 Patented T11754 DRUGINFO D0GI7I Spirocyclic diamine urea derivative 1 Patented T11754 DRUGINFO D0H8LZ Boronic acid derivative 6 Patented T11754 DRUGINFO D0HZ7J N-alkyl-4-oxazolecar boxamide derivative 2 Patented T11754 DRUGINFO D0IK9V Ketoheterocycle derivative 3 Patented T11754 DRUGINFO D0J1KT Azetidine urea derivative 2 Patented T11754 DRUGINFO D0K2WP Aryl urea derivative 2 Patented T11754 DRUGINFO D0KE8U Carbamate derivative 3 Patented T11754 DRUGINFO D0LB8Y Heteroaryl-substituted urea derivative 1 Patented T11754 DRUGINFO D0LR7Z Carbamate derivative 1 Patented T11754 DRUGINFO D0LZ8I Tetra-hydro-naphthalene derivative 3 Patented T11754 DRUGINFO D0OI8P Isoxazoline derivative 4 Patented T11754 DRUGINFO D0P2AB Azole derivative 3 Patented T11754 DRUGINFO D0P3MU Boronic acid derivative 2 Patented T11754 DRUGINFO D0PU2A Boronic acid derivative 3 Patented T11754 DRUGINFO D0Q6GP Isoxazoline derivative 2 Patented T11754 DRUGINFO D0R3JK Isoxazoline derivative 1 Patented T11754 DRUGINFO D0RZ5O Tetrazolyl urea derivative 1 Patented T11754 DRUGINFO D0U0QQ Tetra-substituted urea derivative 1 Patented T11754 DRUGINFO D0UD4X Ketoheterocycle derivative 1 Patented T11754 DRUGINFO D0V1VT Tetra-hydro-naphthalene derivative 2 Patented T11754 DRUGINFO D0W9GL Carbamate derivative 7 Patented T11754 DRUGINFO D0WJ0T Ketoheterocycle derivative 2 Patented T11754 DRUGINFO D0X7MV Pyrrolidinyl urea derivative 1 Patented T11754 DRUGINFO D0X8VL Isoxazoline derivative 3 Patented T11754 DRUGINFO D0XQ4B Aryl urea derivative 4 Patented T11754 DRUGINFO D0Z5MJ Ketoheterocycle derivative 4 Patented T11754 DRUGINFO D00IPI Carbamide derivative 24 Patented T11754 DRUGINFO D01THA Ethylaminopyrimidine derivative 1 Patented T11754 DRUGINFO D02ZUW Carbamide derivative 26 Patented T11754 DRUGINFO D05DBG Carbamate derivative 16 Patented T11754 DRUGINFO D08SMT Carbamate derivative 17 Patented T11754 DRUGINFO D09RGE Carbamide derivative 25 Patented T11754 DRUGINFO D0B7CW PMID26413912-Compound-84 Patented T11754 DRUGINFO D0IA7Z Carbamide derivative 1 Patented T11754 DRUGINFO D0L6XG Carbamate derivative 9 Patented T11754 DRUGINFO D0M1ND Pyrimidinyl ethylenediamine derivative 1 Patented T11754 DRUGINFO D0S2JF Pyrazole derivative 83 Patented T11754 DRUGINFO D0V7PO PMID29053063-Compound-14 Patented T11754 DRUGINFO D0Y7LM Carbamate derivative 10 Patented T11754 DRUGINFO D0YM0G Pyrazole derivative 84 Patented T11754 DRUGINFO D0GT0I PMID29053063-Compound-11d Patented T11754 DRUGINFO D0J6TA Piperazine carbamic compound 1 Patented T11754 DRUGINFO D0LC5Y Piperazine carbamic compound 2 Patented T11754 DRUGINFO D0LL0X Pyrazole derivative 82 Patented T11754 DRUGINFO D0O9DS Pyrazole derivative 81 Patented T11754 DRUGINFO D0TL1G PMID29053063-Compound-15 Patented T11754 DRUGINFO D0X9GC Pyrazole derivative 80 Patented T11754 DRUGINFO D00CKY 7-Phenyl-1-(1,3,4-thiadiazol-2-yl)-heptan-1-one Investigative T11754 DRUGINFO D00FOZ Propan-2-one O-3-butoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D00NXA Benzofuran-2-ylboronic acid Investigative T11754 DRUGINFO D00UBR Cyclohexylmethylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D00ULT 1,1,1-Trifluoro-undecan-2-one Investigative T11754 DRUGINFO D00VVB Propan-2-one O-4-(heptyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D00ZMY 2-Cyclohexylacetic acidbiphenyl-3-yl ester Investigative T11754 DRUGINFO D01BGK 1-(4-methoxyoxazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D01DIT N-(2-hydroxyethyl)linoleoylamide Investigative T11754 DRUGINFO D01FLQ 2-methoxyphenylboronic acid Investigative T11754 DRUGINFO D01HBS Cyclohexylcarbamic acidbiphenyl-3-yl ester Investigative T11754 DRUGINFO D01HCR Benzaldehyde O-4-(octyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D01IGL (+/-)-3-allyl-1-pent-4-enoylazetidin-2-one Investigative T11754 DRUGINFO D01JCJ 1-(oxazolo[4,5-b]pyridin-2-yl)octan-1-one Investigative T11754 DRUGINFO D01NWS 3-(biphenyl-4-yl)-1-(oxazol-2-yl)propan-1-one Investigative T11754 DRUGINFO D01UVD N-(2-iodoethyl)linoleoylamide Investigative T11754 DRUGINFO D01YWD 4-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate Investigative T11754 DRUGINFO D01ZUN 3,3-di(pent-4-enyl)azetidin-2-one Investigative T11754 DRUGINFO D02AIH 1-(5-(pyridin-2-yl)oxazol-2-yl)pentan-1-one Investigative T11754 DRUGINFO D02BZV BMS-1 Investigative T11754 DRUGINFO D02DKM Propan-2-one O-4-(hexyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D02ENI (Z)-1-(benzo[d]oxazol-2-yl)octadec-9-en-1-one Investigative T11754 DRUGINFO D02IQP 1-(oxazolo[4,5-b]pyridin-2-yl)pentan-1-one Investigative T11754 DRUGINFO D02JRK Phenyl 1-(4-butoxyphenyl)propylcarbamate Investigative T11754 DRUGINFO D02JVI 1-Benzooxazol-2-yl-6-phenyl-hexan-1-one Investigative T11754 DRUGINFO D02XGS 2-fluorophenyl 4-(hexyloxy)phenylcarbamate Investigative T11754 DRUGINFO D03AYF 3-chlorophenyl 4-butoxybenzylcarbamate Investigative T11754 DRUGINFO D03DFG 1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one Investigative T11754 DRUGINFO D03DXV 4-(1,2,3-thiadiazol-4-yl)phenyl butylcarbamate Investigative T11754 DRUGINFO D03EYI Phenylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D03JFC 3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate Investigative T11754 DRUGINFO D03NTQ 7-Phenyl-1-(pyridazin-3-yl)-heptan-1-one Investigative T11754 DRUGINFO D03NUC Cyclopentylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D03OGD Methyl 2-(7-phenylheptanoyl)oxazole-4-carboxylate Investigative T11754 DRUGINFO D03SNN 2-fluorophenyl 4-butoxyphenylcarbamate Investigative T11754 DRUGINFO D03SUI Pyridin-3-yl 4-butoxybenzylcarbamate Investigative T11754 DRUGINFO D03XIY 7-Phenyl-1-(thiazol-2-yl)-heptan-1-one Investigative T11754 DRUGINFO D03YHF Propan-2-one O-4-butoxybenzylcarbamoyl oxime Investigative T11754 DRUGINFO D03YUT 2-chloro-1-(5-(pyridin-2-yl)oxazol-2-yl)ethanone Investigative T11754 DRUGINFO D04AUL Propan-2-one O-4-(decyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D04BIH 4-Phenylbutylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D04FFS Benzaldehyde O-4-(pentyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D04GAX 3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate Investigative T11754 DRUGINFO D04JWW 1-(4-iodooxazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D04JYW (+/-)-oxiran-2-ylmethyl (9Z)-hexadec-9-enoate Investigative T11754 DRUGINFO D04OMK Nicotinaldehyde O-4-butoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D04PMA 1,1,1-Trifluoro-tridecan-2-one Investigative T11754 DRUGINFO D05FZP 3-(ethoxycarbonyl)phenylboronic acid Investigative T11754 DRUGINFO D05GPK Biphenyl-3-ylboronic acid Investigative T11754 DRUGINFO D05HIG 6-Phenylhexylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D05ICC 2-fluorophenyl 4-butoxybenzylcarbamate Investigative T11754 DRUGINFO D05MBJ 1-(4-acetyloxazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D06BGU (+/-)-3-(but-3-enyl)-1-pent-4-enoylazetidin-2-one Investigative T11754 DRUGINFO D06JBN 2-arachidonoylglycerol Investigative T11754 DRUGINFO D06MNW 1-(oxazol-2-yl)octadec-9-en-1-one Investigative T11754 DRUGINFO D06QER Benzaldehyde O-4-(nonyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D06VSA Methyl 2-(7-phenylheptanoyl)oxazole-5-carboxylate Investigative T11754 DRUGINFO D07BGB Propan-2-one O-4-propoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D07CER 1-Biphenyl-4-ylmethylmaleimide Investigative T11754 DRUGINFO D07GOA OL-92 Investigative T11754 DRUGINFO D07LQX 2-fluorophenyl 4-(undecyloxy)phenylcarbamate Investigative T11754 DRUGINFO D07MQJ (Z)-1-(4-phenyloxazol-2-yl)octadec-9-en-1-one Investigative T11754 DRUGINFO D07MSJ 1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-yn-1-one Investigative T11754 DRUGINFO D07PAF PHENMEDIPHAM Investigative T11754 DRUGINFO D07PLS 2-fluorophenyl 4-(heptyloxy)phenylcarbamate Investigative T11754 DRUGINFO D07QOG 2-(7-phenylheptanoyl)oxazole-4-carbaldehyde Investigative T11754 DRUGINFO D07RDB 2,4-difluorophenyl 4-butoxybenzylcarbamate Investigative T11754 DRUGINFO D07XWB 4-(thiazol-2-yl)phenyl butylcarbamate Investigative T11754 DRUGINFO D08ILW Cyclohexyl biphenyl-4-ylcarbamate Investigative T11754 DRUGINFO D08KJN Phenethylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D08TFH Indan-2-ylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D08UST (Z)-2,2-Dimethyl-1-oxazol-2-yl-octadec-9-en-1-one Investigative T11754 DRUGINFO D09CIX 8-Phenyloctylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D09GVB OL-135 Investigative T11754 DRUGINFO D09NFX Nicotinaldehyde O-4-propoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D09YVZ Benzaldehyde O-4-(heptyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D0A2SK (Z)-1-(pyridazin-3-yl)octadec-9-en-1-one Investigative T11754 DRUGINFO D0A5OS Phenyl-1,4-bismaleimide Investigative T11754 DRUGINFO D0A6RL Benzylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0AR1Y 1,4-bis(malimido)xylene Investigative T11754 DRUGINFO D0AV1T N-(2-iodethyl)arachidonylamide Investigative T11754 DRUGINFO D0AW4G 4-cyanophenylboronic acid Investigative T11754 DRUGINFO D0B0IO Nicotinaldehyde O-4-ethoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D0B0KP 1-Oxazolo[4,5-b]pyridin-2-yl-octadec-9-yn-1-one Investigative T11754 DRUGINFO D0B1BQ 1,1,1-Trifluoro-nonadecan-2-one Investigative T11754 DRUGINFO D0B4GP Propan-2-one O-4-(nonyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D0C3JV 1,8-bis-maleimidodiethyleneglycol Investigative T11754 DRUGINFO D0C6HH 6-fluoropyridin-3-ylboronic acid Investigative T11754 DRUGINFO D0C9FO 2-(7-phenylheptanoyl)oxazole-5-carboxylic acid Investigative T11754 DRUGINFO D0CH0K 1-(5-(pyridin-2-yl)oxazol-2-yl)octadec-9-en-1-one Investigative T11754 DRUGINFO D0D0FX 1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one Investigative T11754 DRUGINFO D0D0NG 4-(cyclohexylmethylcarbamoyloxy)benzoic acid Investigative T11754 DRUGINFO D0D4IJ N-Hexylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0D6TB 1-(oxazol-2-yl)-4-(piperidin-4-yl)butan-1-one Investigative T11754 DRUGINFO D0D7HU 7-Phenyl-1-(2H-tetrazol-5-yl)-heptan-1-one Investigative T11754 DRUGINFO D0D7MP (+/-)-oxiran-2-ylmethyl (9Z)-octadec-9-enoate Investigative T11754 DRUGINFO D0D8OR 3-cyanophenylboronic acid Investigative T11754 DRUGINFO D0D9GS 1-(1,2,4-Oxadiazol-3-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D0E0JC 7-phenyl-1-(5-phenyloxazol-2-yl)heptan-1-one Investigative T11754 DRUGINFO D0E1YQ 2-(7-phenylheptanoyl)oxazole-4-carboxamide Investigative T11754 DRUGINFO D0E2BI 2-fluorophenyl 4'-ethylbiphenyl-4-ylcarbamate Investigative T11754 DRUGINFO D0E9UX PF3845 Investigative T11754 DRUGINFO D0F1BD 1-Biphenyl-4-ylmaleimide Investigative T11754 DRUGINFO D0F1UD 4-nonylphenylboronic acid Investigative T11754 DRUGINFO D0F7OX Benzaldehyde O-4-methoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D0F9LO 1-(4-chlorooxazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D0G2CY (+/-)-3-allylazetidin-2-one Investigative T11754 DRUGINFO D0GM1P Phenyl 4-(hexyloxy)phenylcarbamate Investigative T11754 DRUGINFO D0H5RS 1-(oxazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D0H5WN Isopropylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0H6FG Methoxy arachidonyl fluorophosphonate Investigative T11754 DRUGINFO D0H6OO HTS-00798 Investigative T11754 DRUGINFO D0HP2H 2-fluorophenyl 4-(decyloxy)phenylcarbamate Investigative T11754 DRUGINFO D0I0MR (Z)-1,1,1-Trifluoro-nonadec-10-en-2-one Investigative T11754 DRUGINFO D0I1WN 1,10-(methylenedi-4,1-phenylene)bismaleimide Investigative T11754 DRUGINFO D0I3XN 4-nitrophenylboronic acid Investigative T11754 DRUGINFO D0I8BO 1-(5-(furan-2-yl)oxazol-2-yl)octadec-9-en-1-one Investigative T11754 DRUGINFO D0I9MF Benzaldehyde O-4-ethoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D0IV9K 3-(trifluoromethyl)phenyl 4-butoxybenzylcarbamate Investigative T11754 DRUGINFO D0J3CJ 2-fluorophenyl 4-(octyloxy)phenylcarbamate Investigative T11754 DRUGINFO D0J7FJ 1-(5-fluorooxazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D0J8VU 4-(1,2,3-thiadiazol-4-yl)phenyl hexylcarbamate Investigative T11754 DRUGINFO D0JL3O NICARBAZIN Investigative T11754 DRUGINFO D0K0JP Phenyl 4-(octyloxy)phenylcarbamate Investigative T11754 DRUGINFO D0K0OR 1-(5-(pyridin-2-yl)oxazol-2-yl)octan-1-one Investigative T11754 DRUGINFO D0K0YF 4-fluorophenylboronic acid Investigative T11754 DRUGINFO D0K5EI Naphthalen-2-yl cyclohexylcarbamate Investigative T11754 DRUGINFO D0K6MH 2-(7-phenylheptanoyl)oxazole-4-carbonitrile Investigative T11754 DRUGINFO D0K9HO N-arachidonylmaleimide Investigative T11754 DRUGINFO D0KI3F 1-(4-bromooxazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D0KQ6L Phenyl 4-(dodecyloxy)phenylcarbamate Investigative T11754 DRUGINFO D0L1YC 1-DODECANOL Investigative T11754 DRUGINFO D0L2LQ Allylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0L6VM 2-fluorophenyl 4-(dodecyloxy)phenylcarbamate Investigative T11754 DRUGINFO D0L7AW Benzaldehyde O-4-(decyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D0L7TW Phenyl 4-(heptyloxy)phenylcarbamate Investigative T11754 DRUGINFO D0M7KD Cyclobutylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0M7SQ 1,1,1-Trifluoro-9-phenyl-nonan-2-one Investigative T11754 DRUGINFO D0M8AR 1-(5-phenyloxazol-2-yl)octadec-9-en-1-one Investigative T11754 DRUGINFO D0MR1Z Benzaldehyde O-4-butoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D0N8RT Cyclopentyl(5-(pyridin-2-yl)oxazol-2-yl)methanone Investigative T11754 DRUGINFO D0NH1E Org-231295 Investigative T11754 DRUGINFO D0O1UQ 4-(trifluoromethyl)phenylboronic acid Investigative T11754 DRUGINFO D0OD3U 3-(trifluoromethyl)phenylboronic acid Investigative T11754 DRUGINFO D0OJ7E 3'-carbamoylbiphenyl-3-yl 6-phenylhexylcarbamate Investigative T11754 DRUGINFO D0P9ZZ Phenyl 4-(undecyloxy)phenylcarbamate Investigative T11754 DRUGINFO D0PJ3R (Z)-2-Methyl-1-oxazol-2-yl-octadec-9-en-1-one Investigative T11754 DRUGINFO D0PN9S 7-phenyl-1-(4-phenyloxazol-2-yl)heptan-1-one Investigative T11754 DRUGINFO D0Q2CR 1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D0Q9JN 1-(5-methyloxazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D0R5RW 4-Nitrophenyl 4-Benzylpiperazine-1-carboxylate Investigative T11754 DRUGINFO D0R8JR Propan-2-one O-4-butoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D0S6FJ Benzaldehyde O-4-(hexyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D0TN0A 1-Oxazolo[4,5-b]pyridin-2-yl-6-phenyl-hexan-1-one Investigative T11754 DRUGINFO D0TP1H 2-(7-phenylheptanoyl)oxazole-4-carboxylic acid Investigative T11754 DRUGINFO D0TV9X Propan-2-one O-4-(octyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D0U1WH N-Butylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0U3YC LY-2318912 Investigative T11754 DRUGINFO D0U7RS 2-fluorophenylboronic acid Investigative T11754 DRUGINFO D0U8YV 1-(1,2,4-Oxadiazol-5-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D0V8WE 4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate Investigative T11754 DRUGINFO D0VN9U Phenyl 4-(decyloxy)phenylcarbamate Investigative T11754 DRUGINFO D0VQ3O 1-(oxazol-2-yl)-3-(4-phenoxyphenyl)propan-1-one Investigative T11754 DRUGINFO D0W0SE PF750 Investigative T11754 DRUGINFO D0W0XK (+/-)-3-(pent-4-enyl)azetidin-2-one Investigative T11754 DRUGINFO D0W1OX Biphenyl-3-ylcarbamic acid cyclohexyl ester Investigative T11754 DRUGINFO D0W5WG JNJ-1661010 Investigative T11754 DRUGINFO D0W7NY 2-(7-phenylheptanoyl)oxazole-5-carbonitrile Investigative T11754 DRUGINFO D0W7XR LY-2183240 Investigative T11754 DRUGINFO D0W9JC 1-(5-(pyridin-2-yl)oxazol-2-yl)dodecan-1-one Investigative T11754 DRUGINFO D0WW5X N-Octylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0X6WV 1-(4-methyloxazol-2-yl)-7-phenylheptan-1-one Investigative T11754 DRUGINFO D0X7HP 2-fluorophenyl 4-phenoxyphenylcarbamate Investigative T11754 DRUGINFO D0X8ZO 1-(oxazolo[4,5-b]pyridin-2-yl)dodecan-1-one Investigative T11754 DRUGINFO D0XH1F 4-fluorophenyl 4-butoxybenzylcarbamate Investigative T11754 DRUGINFO D0Y2UR Methylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0Y5MR 2-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate Investigative T11754 DRUGINFO D0YU4D Propan-2-one O-4-(pentyloxy)phenylcarbamoyl oxime Investigative T11754 DRUGINFO D0Z0LX 4-methoxyphenyl 1-(4-butoxyphenyl)propylcarbamate Investigative T11754 DRUGINFO D0Z0QC Propan-2-one O-4-ethoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D0Z1ID Furan-2-ylmethylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0Z4RZ Adamant-1-ylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0Z5QM Benzaldehyde O-4-propoxyphenylcarbamoyl oxime Investigative T11754 DRUGINFO D0Z6BZ Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester Investigative T11754 DRUGINFO D0ZD6Z 3-methoxyphenylboronic acid Investigative T11754 DRUGINFO D00IAK 1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one Investigative T11754 DRUGINFO D00QUN Isopropyl 4-nitrophenyl dodecylphosphonate Investigative T11754 DRUGINFO D00VKB 3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one Investigative T11754 DRUGINFO D01NDE 2,2-dimethyl-3-methyleneheptadecane Investigative T11754 DRUGINFO D02SDT 3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one Investigative T11754 DRUGINFO D03ZBS 4-cyanophenyl ethyl dodecylphosphonate Investigative T11754 DRUGINFO D04BWH Benzo[b]thiophen-2-ylboronic acid Investigative T11754 DRUGINFO D04UEN 1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one Investigative T11754 DRUGINFO D04YUA Octane-1-sulfonyl fluoride Investigative T11754 DRUGINFO D08YHD 1,1,1-Trifluoro-7-phenylheptan-2-one Investigative T11754 DRUGINFO D09YUL bromoenol lactone Investigative T11754 DRUGINFO D0B4GJ 3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one Investigative T11754 DRUGINFO D0E5CF 3-(decylthio)-1,1,1-trifluoropropan-2-one Investigative T11754 DRUGINFO D0FD8G 2-(biphenyl-4-yl)vinylboronic acid Investigative T11754 DRUGINFO D0I7FF 1,1,1-trifluorododecan-2-one Investigative T11754 DRUGINFO D0J8TY ARACHIDONYL TRIFLUOROMETHYLKETONE Investigative T11754 DRUGINFO D0K6GY Ethyl octylfluorophosphonate Investigative T11754 DRUGINFO D0N1CK 1,1,1-Trifluoro-8-phenyl-octan-2-one Investigative T11754 DRUGINFO D0Q3GH 1,1,1-trifluoro-3-(octylthio)propan-2-one Investigative T11754 DRUGINFO D0T4HB Methyl icosylphosphonofluoridate Investigative T11754 DRUGINFO D0U0CV Dodecane-1-sulfonyl fluoride Investigative T11754 DRUGINFO D0W4VM AR-C70484XX Investigative T11754 DRUGINFO D0Y0FN 3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one Investigative T11754 DRUGINFO D0Y2BD 1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one Investigative T11754 DRUGINFO D0Z7WK 1,1,1-trifluoro-3-(hexylthio)propan-2-one Investigative T11754 DRUGINFO D02GOH AM-404 Investigative T11754 DRUGINFO D06ORV Phenethylboronic acid Investigative T11754 DRUGINFO D0HQ4M Isopropyl dodecylfluorophosphonate Investigative T11754 DRUGINFO D0L1UA N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide Investigative T11754 DRUGINFO D0PC5A VER-156084 Investigative T11754 DRUGINFO D0W6PT Chlorphrifos oxon Investigative T11754 DRUGINFO D09OSN Biphenyl-4-ylboronic acid Investigative T11754 DRUGINFO D0A4HS 4-methoxyphenylboronic acid Investigative T11754 DRUGINFO D08XQI PARAOXON Investigative T11754 DRUGINFO D0EJ9B Phenyl Boronic acid Investigative T54128 TARGETID T54128 T54128 FORMERID TTDS00121 T54128 TARGNAME Glutamate receptor AMPA (GRIA) T54128 TARGTYPE Successful T54128 SYNONYMS Glutamate receptor ionotropic, AMPA; Glutamate receptor; AMPA selective glutamate receptor; AMPA receptor T54128 BIOCLASS Chloride channel T54128 DRUGINFO D02EZM Fospropofol disodium Approved T54128 DRUGINFO D03WAJ Heptabarbital Approved T54128 DRUGINFO D05TMQ Aprobarbital Approved T54128 DRUGINFO D0AO9S Enflurane Approved T54128 DRUGINFO D0D8VE Halothane Approved T54128 DRUGINFO D0DP6L Isoflurane Approved T54128 DRUGINFO D0E3FD Bromazepam Approved T54128 DRUGINFO D0GC2M Acamprosate Approved T54128 DRUGINFO D0H4GN Desflurane Approved T54128 DRUGINFO D0Q5IN Lindane Approved T54128 DRUGINFO D0W6ZF Sevoflurane Approved T54128 DRUGINFO D0ZB7K Zopiclone Approved T54128 DRUGINFO D03KEK Artemisinin SP Approved T54128 DRUGINFO D0SP3D Dihydroergotoxine Approved T54128 DRUGINFO D0WB9V Barbiturate Approved T54128 DRUGINFO D0U3ED E-2007 Approved T54128 DRUGINFO D07WHN FASORACETAM Phase 3 T54128 DRUGINFO D03DHQ CX-516 Phase 2/3 T54128 DRUGINFO D0MM3A BIIB104 Phase 2a T54128 DRUGINFO D01MHI Coluracetam Phase 2 T54128 DRUGINFO D01WBD Mibampator Phase 2 T54128 DRUGINFO D02RVN Selurampanel Phase 2 T54128 DRUGINFO D05PZN TRO-19622 Phase 2 T54128 DRUGINFO D08BEO Talampanel Phase 2 T54128 DRUGINFO D0FR7E CX1789 Phase 2 T54128 DRUGINFO D0G3AR CX-717 Phase 2 T54128 DRUGINFO D0G8UY PF-04958242 Phase 2 T54128 DRUGINFO D0HO2T AZD7325 Phase 2 T54128 DRUGINFO D0J8DD TAK-653 Phase 2 T54128 DRUGINFO D0R6JV CX-1739 Phase 2 T54128 DRUGINFO D00VNH ZK-200775 Phase 1 T54128 DRUGINFO D0D3XM TAK-137 Phase 1 T54128 DRUGINFO D0IV7Z AZD-8418 Phase 1 T54128 DRUGINFO D02VKC NBQX Phase 1 T54128 DRUGINFO D01NAM ELB-139 Discontinued in Phase 2 T54128 DRUGINFO D0B4EV IPENOXAZONE Discontinued in Phase 2 T54128 DRUGINFO D0M0HJ S-18986 Discontinued in Phase 2 T54128 DRUGINFO D0P1QW Becampanel Discontinued in Phase 2 T54128 DRUGINFO D02TTF YM-90K Discontinued in Phase 2 T54128 DRUGINFO D04LEK GSK729327 Discontinued in Phase 1 T54128 DRUGINFO D0P1YH S-1746 Discontinued in Phase 1 T54128 DRUGINFO D04RAT BIIR-777 Preclinical T54128 DRUGINFO D06DFU TP-023 Preclinical T54128 DRUGINFO D0V9YW GYKI-47261 Preclinical T54128 DRUGINFO D0XM3S CX-1501 Preclinical T54128 DRUGINFO D0YH9A TPT-43 Preclinical T54128 DRUGINFO D02QZL PNQX Terminated T54128 DRUGINFO D06WHL NS-257 Terminated T54128 DRUGINFO D0B4AB ACEA-2085 Terminated T54128 DRUGINFO D0EP5O NS-377 Terminated T54128 DRUGINFO D0A9VO GYKI-52466 Terminated T54128 DRUGINFO D0M7MW GYKI-53655 Terminated T54128 DRUGINFO D0S0VZ IDRA-21 Terminated T54128 DRUGINFO D0Z9CC Zonampanel Terminated T54128 DRUGINFO D0AZ5V L-698544 Terminated T54128 DRUGINFO D00XNY 4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridin-3-ol Investigative T54128 DRUGINFO D08RAZ N-methylbicuculline Investigative T54128 DRUGINFO D0C5WK LY-392098 Investigative T54128 DRUGINFO D0E4GJ LY-314657 Investigative T54128 DRUGINFO D00LBX Bicuculline Investigative T54128 DRUGINFO D04SMQ (S)-WILLARDIINE Investigative T54128 DRUGINFO D08SYX Piriqualone Investigative T54128 DRUGINFO D0AA9A N-(4-hydroxyphenylpropanyl)-spermine Investigative T54128 DRUGINFO D0J1PG 2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX) Investigative T54128 DRUGINFO D0T5SU (S)-AMPA Investigative T54128 DRUGINFO D0Z8IJ Muscimol Investigative T54128 DRUGINFO D03PGF RPR-118723 Investigative T54128 DRUGINFO D05VVC 7-chloro-3-hydroxyquinazoline-2,4-dione Investigative T54128 DRUGINFO D0E5UQ [3H]CNQX Investigative T54128 DRUGINFO D05KQC DNQX Investigative T54128 DRUGINFO D04PFN [3H]kainate Investigative T20710 TARGETID T20710 T20710 FORMERID TTDS00139 T20710 TARGNAME Interleukin 2 receptor (IL2R) T20710 TARGTYPE Successful T20710 SYNONYMS p64; gammaC; Interleukin2 receptor subunit gamma; Interleukin-2 receptor subunit gamma; IL2R subunit gamma; IL2 receptor subunit gamma; IL-2RG; IL-2R subunit gamma; IL-2R; IL-2 receptor subunit gamma; Cytokine receptor common subunit gamma; CD132 T20710 FUNCTION Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. Common subunit for the receptors for a variety of interleukins. T20710 BIOCLASS Cytokine receptor T20710 DRUGINFO D0J3RY Denileukin diftitox Approved T20710 DRUGINFO DQGF20 ALKS 4230 Phase 2 T20710 DRUGINFO D09JHT Ro26-4550 Investigative T29303 TARGETID T29303 T29303 FORMERID TTDS00155 T29303 TARGNAME Sodium channel unspecific (NaC) T29303 TARGTYPE Successful T29303 FUNCTION Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. T29303 DRUGINFO D04MSM Carbamazepine Approved T29303 DRUGINFO D06ORU Butacaine Approved T29303 DRUGINFO D07ONP Phenacemide Approved T29303 DRUGINFO D09QUQ Levobupivacaine Approved T29303 DRUGINFO D09ZIS Zonisamide Approved T29303 DRUGINFO D0E4DW Phenytoin Approved T29303 DRUGINFO D0H2SY Oxybuprocaine Approved T29303 DRUGINFO D0H7AV Pilsicainide Approved T29303 DRUGINFO D0K8MP Permethrin Approved T29303 DRUGINFO D0L0MK Pachycarpine Approved T29303 DRUGINFO D0MD2L Rufinamide Approved T29303 DRUGINFO D0Q8ZX Benzocaine Approved T29303 DRUGINFO D0T7WL Pirmenol Approved T29303 DRUGINFO D0WO8W Mepivacaine Approved T29303 DRUGINFO D04QZD Eslicarbazepine Approved T29303 DRUGINFO D0C7ET Tetrodotoxin Approved T29303 DRUGINFO D0L7VL LIDOFLAZINE Approved T29303 DRUGINFO D0N3ZJ LOMERIZINE Approved T29303 DRUGINFO D0S0FZ Carisbamate Phase 3 T29303 DRUGINFO D00GEG Ralfinamide Phase 3 T29303 DRUGINFO D00EJP GSK2339345 Phase 2 T29303 DRUGINFO D04XZE NS-7 Phase 2 T29303 DRUGINFO D05OTL NW-3509 Phase 2 T29303 DRUGINFO D0E8DK COL-1077 Phase 2 T29303 DRUGINFO D0K4MU Crobenetine Phase 2 T29303 DRUGINFO D05OTZ SMP-986 Phase 2 T29303 DRUGINFO D0I8QS BN82451 Phase 2 T29303 DRUGINFO D02SVQ HBI-3000 Phase 2 T29303 DRUGINFO D0B7CH Phenylbutyrate Phase 2 T29303 DRUGINFO D0N1TH ATI-2042 Phase 2 T29303 DRUGINFO D0Q7JC P-552-02 Phase 1/2 T29303 DRUGINFO D0I6AU BDD-10103 Phase 1 T29303 DRUGINFO D0P5CM AZD-3161 Phase 1 T29303 DRUGINFO D03JRO ADCI Phase 1 T29303 DRUGINFO D08LDS LUBELUZOLE Discontinued in Preregistration T29303 DRUGINFO D04DZD Bidisomide Discontinued in Phase 3 T29303 DRUGINFO D08NLQ Licarbazepine Discontinued in Phase 3 T29303 DRUGINFO D01EBJ 4991W93 Discontinued in Phase 2 T29303 DRUGINFO D02GMT Org-7797 Discontinued in Phase 2 T29303 DRUGINFO D04VIP 4030W92 Discontinued in Phase 2 T29303 DRUGINFO D08XQA RSD-921 Discontinued in Phase 2 T29303 DRUGINFO D0A9CY Pentisomide Discontinued in Phase 2 T29303 DRUGINFO D0D3BO SOLPECAINOL HYDROCHLORIDE Discontinued in Phase 2 T29303 DRUGINFO D0R3WG SILPERISONE HYDROCHLORIDE Discontinued in Phase 2 T29303 DRUGINFO D0V9OL 534U87 Discontinued in Phase 2 T29303 DRUGINFO D0W9PG Pyrazinoylguanidine Discontinued in Phase 2 T29303 DRUGINFO D0B7HX Levosemotiadil Discontinued in Phase 2 T29303 DRUGINFO D0EC2K SIPATRIGINE Discontinued in Phase 2 T29303 DRUGINFO D06WSQ AWD-140-190 Discontinued in Phase 1 T29303 DRUGINFO D07IIX AMELTOLIDE Discontinued in Phase 1 T29303 DRUGINFO D0B4ZQ SL-90.0571 Discontinued in Phase 1 T29303 DRUGINFO D0JJ1B Artilide Discontinued in Phase 1 T29303 DRUGINFO D00KWA Recainam Terminated T29303 DRUGINFO D00LYW BW-1003C87 Terminated T29303 DRUGINFO D01NBX RS-2135 Terminated T29303 DRUGINFO D05VXQ SRSC-355 Terminated T29303 DRUGINFO D09VHA BDF-9148 Terminated T29303 DRUGINFO D0B7HJ U-54494A Terminated T29303 DRUGINFO D0B8QA RP-66055 Terminated T29303 DRUGINFO D0EF9I A-76895 Terminated T29303 DRUGINFO D0K0KP GE-68 Terminated T29303 DRUGINFO D0NF7S R-59494 Terminated T29303 DRUGINFO D0T7XN E-2070 Terminated T29303 DRUGINFO D0V1HK Berlafenone Terminated T29303 DRUGINFO D0V1NI AM-66 Terminated T29303 DRUGINFO D0X6MO Ralitoline Terminated T29303 DRUGINFO D05ZGW DPI-201-106 Terminated T29303 DRUGINFO D02NLI PD-85639 Terminated T29303 DRUGINFO D0OW2O U-92032 Terminated T29303 DRUGINFO D0P8TL Saxitoxin Investigative T29303 DRUGINFO D05XEF 5-Hexyl-5-phenyl-imidazolidine-2,4-dione Investigative T29303 DRUGINFO D08KBV 4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole Investigative T29303 DRUGINFO D08RNW 2-Hydroxy-2-phenyl-nonanoic acid amide Investigative T29303 DRUGINFO D08VUM 2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole Investigative T29303 DRUGINFO D08WQO 2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole Investigative T29303 DRUGINFO D0B8GI 5-Heptyl-5-phenyl-imidazolidine-2,4-dione Investigative T29303 DRUGINFO D0FL7O 4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole Investigative T29303 DRUGINFO D0K1UR 4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole Investigative T29303 DRUGINFO D0K8DH 4-Biphenyl-4-yl-2-hexyl-1H-imidazole Investigative T29303 DRUGINFO D0L5UC 5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione Investigative T29303 DRUGINFO D0Q7GZ 5-Nonyl-5-phenyl-imidazolidine-2,4-dione Investigative T29303 DRUGINFO D0S7ZU 4-Biphenyl-4-yl-2-methyl-1H-imidazole Investigative T29303 DRUGINFO D0B9UU BW-202W92 Investigative T29303 DRUGINFO D0WU9R L-741742 Investigative T68536 TARGETID T68536 T68536 FORMERID TTDS00308 T68536 TARGNAME Tubulin beta (TUBB) T68536 TARGTYPE Successful T68536 SYNONYMS Major cysteine proteinase; Cysteine proteinase cruzipain; Cruzaine; Congopain; Beta-tubulin T68536 FUNCTION Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. T68536 BIOCLASS Tubulin family T68536 DRUGINFO D00KVO Albendazole Approved T68536 DRUGINFO D04RLY Vindesine Approved T68536 DRUGINFO D09QVV Vincristine Approved T68536 DRUGINFO D0J1MI Mebendazole Approved T68536 DRUGINFO D0C4RB Taxol Approved T68536 DRUGINFO D0ZE1O Plinabulin Phase 3 T68536 DRUGINFO D08NAD Batabulin Phase 2/3 T68536 DRUGINFO D01AZP BNC-105 Phase 2 T68536 DRUGINFO D01JNE Lexibulin Phase 2 T68536 DRUGINFO D04AMD ZD-6126 Phase 2 T68536 DRUGINFO D07QFU T-607 Phase 2 T68536 DRUGINFO D09BOH Verubulin Phase 2 T68536 DRUGINFO D09EHO ABT-751 Phase 2 T68536 DRUGINFO D0PF3J DOLASTATIN-10 Phase 2 T68536 DRUGINFO D04EON BAL-101553 Phase 1/2 T68536 DRUGINFO D01RRF STA-5312 Phase 1 T68536 DRUGINFO D03RMN 1069C Phase 1 T68536 DRUGINFO D03XCR Simotaxel Phase 1 T68536 DRUGINFO D05KNG ALB-109564(a) Phase 1 T68536 DRUGINFO D07JAI NSC-639829 Phase 1 T68536 DRUGINFO D08OVG CKD-516 Phase 1 T68536 DRUGINFO D0J4MY Tasidotin hydrochloride Phase 1 T68536 DRUGINFO D0K5CJ DAVLB-HYDRAZIDE Phase 1 T68536 DRUGINFO D0P4KU ABI-011 Phase 1 T68536 DRUGINFO D09TXG CEMADOTIN HYDROCHLORIDE Discontinued in Phase 2 T68536 DRUGINFO D0KX9Z S-12363 Discontinued in Phase 2 T68536 DRUGINFO D0N4OZ Epothilone D Discontinued in Phase 2 T68536 DRUGINFO D01HBE RHIZOXIN Discontinued in Phase 2 T68536 DRUGINFO D0X1BJ Denibulin Discontinued in Phase 1 T68536 DRUGINFO D03TJN KOS-1803 Preclinical T68536 DRUGINFO D00ZBQ TL-1892 Investigative T68536 DRUGINFO D04EPS ON-24160 Investigative T68536 DRUGINFO D04RKH APH-0911 Investigative T68536 DRUGINFO D06QRY IDN-5390 Investigative T68536 DRUGINFO D07XBZ ARC-200 Investigative T68536 DRUGINFO D09EQZ XN-0502 Investigative T68536 DRUGINFO D0XA1B RTA-301 Investigative T68536 DRUGINFO D00BEM 2-m-Tolyl-1H-[1,8]naphthyridin-4-one Investigative T68536 DRUGINFO D00CPM 2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde Investigative T68536 DRUGINFO D00GCN 2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one Investigative T68536 DRUGINFO D02BXC GNF-PF-117 Investigative T68536 DRUGINFO D02XKD 3-bromo-4,4',5-trimethoxy-(Z)-stilbene Investigative T68536 DRUGINFO D03CYV 6-ile-ustiloxin Investigative T68536 DRUGINFO D03NTD 3,4',5-trimethoxy-(Z)-stilbene Investigative T68536 DRUGINFO D04XJT 2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol Investigative T68536 DRUGINFO D05HFW CENTAUREIDIN Investigative T68536 DRUGINFO D05MPS MYOSEVERIN Investigative T68536 DRUGINFO D06JNW NSC-106970 Investigative T68536 DRUGINFO D07UWD Ustiloxin D Investigative T68536 DRUGINFO D07XJB PHENSTATIN Investigative T68536 DRUGINFO D08BLV Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate Investigative T68536 DRUGINFO D08CQQ NSC-679036 Investigative T68536 DRUGINFO D09HKD 2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one Investigative T68536 DRUGINFO D09IEG 6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one Investigative T68536 DRUGINFO D0B1CM 2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol Investigative T68536 DRUGINFO D0B6OH COMBETASTATIN Investigative T68536 DRUGINFO D0C6EW Ustiloxin F Investigative T68536 DRUGINFO D0K1MS 2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol Investigative T68536 DRUGINFO D0K4TV 5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one Investigative T68536 DRUGINFO D0K5CK 5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one Investigative T68536 DRUGINFO D0LH3S 3,4,4',5-tetramethoxy-(Z)-stilbene Investigative T68536 DRUGINFO D0M4ZQ 2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one Investigative T68536 DRUGINFO D0OW6Q 2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene Investigative T68536 DRUGINFO D0PT2D MR-22388 Investigative T68536 DRUGINFO D0QP5D NSC-664171 Investigative T68536 DRUGINFO D0S6FK USTILOXIN A Investigative T68536 DRUGINFO D0U7EG 7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one Investigative T68536 DRUGINFO D0VH8A N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide Investigative T68536 DRUGINFO D0VI1H COLCHINOL Investigative T68536 DRUGINFO D0W5RQ 2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene Investigative T68536 DRUGINFO D0X9OV 2-amino-3,4',5-trimethoxy-(Z)-stillbene Investigative T68536 DRUGINFO D0Y8UP 2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one Investigative T68536 DRUGINFO D0Z3KA Thiocolchicine Investigative T56367 TARGETID T56367 T56367 FORMERID TTDS00167 T56367 TARGNAME Phosphodiesterase 1 (PDE1) T56367 TARGTYPE Successful T56367 SYNONYMS PDE-I; Cam-PDE 1 T56367 FUNCTION Has a higher affinity for cgmp than for camp. T56367 BIOCLASS Phosphoric diester hydrolase T56367 DRUGINFO D06BCB Vinpocetine Approved T56367 DRUGINFO D00XVL ITI-214 Phase 1/2 T56367 DRUGINFO D0E1SQ BIBW-22 Terminated T56367 DRUGINFO D00YPW ZAPRINAST Terminated T56367 DRUGINFO D0RC4F BUFROLIN Investigative T56367 DRUGINFO D0P7JE S,S-(2-Hydroxyethyl)Thiocysteine Investigative T56367 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T43189 TARGETID T43189 T43189 FORMERID TTDS00271 T43189 TARGNAME Tubulin (TUB) T43189 TARGTYPE Successful T43189 SYNONYMS Human tubulin T43189 FUNCTION Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. TUBB3 plays a critical role in proper axon guidance and mantainance. T43189 DRUGINFO D01HTL Vinorelbine Approved T43189 DRUGINFO D02HSB Cabazitaxel Approved T43189 DRUGINFO D09DHY Colchicine Approved T43189 DRUGINFO D0KK2E Eribulin Approved T43189 DRUGINFO D0O5WP Docetaxel Approved T43189 DRUGINFO D0W2EK Ixabepilone Approved T43189 DRUGINFO D07WPE Epothilon Phase 3 T43189 DRUGINFO D00AYA BMS-188797 Phase 2 T43189 DRUGINFO D04NXL Indibulin Phase 2 T43189 DRUGINFO D04TLJ Soblidotin Phase 2 T43189 DRUGINFO D07LAP BMS-184476 Phase 2 T43189 DRUGINFO D0DI8J BMS-275183 Phase 2 T43189 DRUGINFO D0J8WE CRYPTOPHYCIN 52 Phase 2 T43189 DRUGINFO D0JI8B Milataxel Phase 2 T43189 DRUGINFO D0PF3J DOLASTATIN-10 Phase 2 T43189 DRUGINFO D04EON BAL-101553 Phase 1/2 T43189 DRUGINFO D00FMK SDZ-LAV-694 Phase 1 T43189 DRUGINFO D05HBZ E 7974 Phase 1 T43189 DRUGINFO D0CV7Z Epothilone B Discontinued in Phase 3 T43189 DRUGINFO D0J0RV Larotaxel Discontinued in Phase 3 T43189 DRUGINFO D09PKU ERBULOZOLE Discontinued in Phase 2 T43189 DRUGINFO D0LI3C Cryptophycin Discontinued in Phase 2 T43189 DRUGINFO D0Q1IH ATX-201 Discontinued in Phase 2 T43189 DRUGINFO D01HBE RHIZOXIN Discontinued in Phase 2 T43189 DRUGINFO D09FZI TALTOBULIN Discontinued in Phase 1 T43189 DRUGINFO D0FD2I Discodermolide Discontinued in Phase 1 T43189 DRUGINFO D0V9ZL FCE-28161 Discontinued in Phase 1 T43189 DRUGINFO D0X5LG ABJ-879 Discontinued in Phase 1 T43189 DRUGINFO D0Y4BO ABI-013 Preclinical T43189 DRUGINFO D0GO7W 21-AMINOEPOTHILONE B Terminated T43189 DRUGINFO D02FNJ AL-309 Investigative T43189 DRUGINFO D09ZSA WR85915 Investigative T43189 DRUGINFO D0O5SC Eleutherobin Investigative T43189 DRUGINFO D0Z2FX AL-209 Investigative T43189 DRUGINFO D0Z9TO Sarcodictyin A Investigative T43189 DRUGINFO D00BEM 2-m-Tolyl-1H-[1,8]naphthyridin-4-one Investigative T43189 DRUGINFO D00CPM 2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde Investigative T43189 DRUGINFO D00GCN 2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one Investigative T43189 DRUGINFO D02BXC GNF-PF-117 Investigative T43189 DRUGINFO D04XJT 2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol Investigative T43189 DRUGINFO D05HFW CENTAUREIDIN Investigative T43189 DRUGINFO D05MPS MYOSEVERIN Investigative T43189 DRUGINFO D06JNW NSC-106970 Investigative T43189 DRUGINFO D07XJB PHENSTATIN Investigative T43189 DRUGINFO D08BLV Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate Investigative T43189 DRUGINFO D08CQQ NSC-679036 Investigative T43189 DRUGINFO D09HKD 2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one Investigative T43189 DRUGINFO D09IEG 6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one Investigative T43189 DRUGINFO D0B1CM 2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol Investigative T43189 DRUGINFO D0B6OH COMBETASTATIN Investigative T43189 DRUGINFO D0K1MS 2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol Investigative T43189 DRUGINFO D0K4TV 5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one Investigative T43189 DRUGINFO D0K5CK 5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one Investigative T43189 DRUGINFO D0M4ZQ 2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one Investigative T43189 DRUGINFO D0PT2D MR-22388 Investigative T43189 DRUGINFO D0QP5D NSC-664171 Investigative T43189 DRUGINFO D0U7EG 7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one Investigative T43189 DRUGINFO D0VI1H COLCHINOL Investigative T43189 DRUGINFO D0Y8UP 2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one Investigative T43189 DRUGINFO D0Z3KA Thiocolchicine Investigative T75984 TARGETID T75984 T75984 FORMERID TTDI01743 T75984 TARGNAME 5-HT 2 receptor (5HT2R) T75984 TARGTYPE Successful T75984 SYNONYMS Serotonin receptor 2; 5-hydroxytryptamine receptor 2; 5-HT2 receptor T75984 FUNCTION G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5- dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction. T75984 BIOCLASS GPCR rhodopsin T75984 DRUGINFO D01KHH Cyclobenzaprine Approved T75984 DRUGINFO D08VRO Ketanserin Approved T75984 DRUGINFO D0F6GV Perospirone Approved T75984 DRUGINFO D0R6RO Mianserin Approved T75984 DRUGINFO D05UAV Bis(olanzapine) pamoate monohydrate Phase 3 T75984 DRUGINFO D06FQS TGOF02N Phase 2 T75984 DRUGINFO D06BUA Nexopamil Phase 2 T75984 DRUGINFO D0S8DU TGWOOAA Phase 2 T75984 DRUGINFO D0MT8G FKB01MD Phase 2 T75984 DRUGINFO D0G7BR AMAP-102 Phase 1 T75984 DRUGINFO D0M1RM Heterocyclic-tetracyclic tetrahydrofuran derivative 1 Patented T75984 DRUGINFO D0K8NW Ritanserin Discontinued in Phase 3 T75984 DRUGINFO D00EBH ICI-170809 Discontinued in Phase 2 T75984 DRUGINFO D0A6YN SUN-C5174 Discontinued in Phase 2 T75984 DRUGINFO D0W2PK Beloxepin Discontinued in Phase 1 T75984 DRUGINFO D0C1CU SUN-9221 Discontinued in Phase 1 T75984 DRUGINFO D04PGO MDL-28133A Terminated T75984 DRUGINFO D05NTY NPC-18166 Terminated T75984 DRUGINFO D05SSJ Dotarizine Terminated T75984 DRUGINFO D05KRC Emopamil Terminated T75984 DRUGINFO D0Q6EN AHR-16303B Terminated T75984 DRUGINFO D0P3IZ E-2040 Terminated T75984 DRUGINFO D04EYR Metrenperone Investigative T84160 TARGETID T84160 T84160 FORMERID TTDS00106 T84160 TARGNAME 5-HT 3 receptor (5HT3R) T84160 TARGTYPE Successful T84160 SYNONYMS 5-hydroxytryptamine receptor type 3; 5-hydroxytryptamine receptor 3; 5-HT3R; 5-HT3 receptor; 5-HT-3 T84160 FUNCTION This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel. T84160 BIOCLASS GPCR rhodopsin T84160 DRUGINFO D00SVU Y-25130 Approved T84160 DRUGINFO D0J5KF Granisetron Approved T84160 DRUGINFO D0K7WK Ondansetron Approved T84160 DRUGINFO D0RA9E Ramosetron Approved T84160 DRUGINFO D00IJQ Zatosetron maleate Phase 3 T84160 DRUGINFO D00RJE Pancopride Phase 3 T84160 DRUGINFO D06QZL Lerisetron Phase 3 T84160 DRUGINFO D04MKJ Renzapride Phase 3 T84160 DRUGINFO D07AHC LITOXETINE Phase 3 T84160 DRUGINFO D04EFK DDP-225 Phase 2 T84160 DRUGINFO D08KTO AD04 Phase 2 T84160 DRUGINFO D0E2JN KB-6806 Phase 2 T84160 DRUGINFO D0N5KS Pumosetrag Phase 2 T84160 DRUGINFO D0Q8MI Lintopride Phase 2 T84160 DRUGINFO D01RVA ADR-851 Phase 1 T84160 DRUGINFO D02NIP ITASETRON Phase 1 T84160 DRUGINFO D0OU3Q TAK-058 Phase 1 T84160 DRUGINFO DO2P5G CVN058 Phase 1 T84160 DRUGINFO D01CDE BIMU-1 Phase 1 T84160 DRUGINFO D01XUE Tedatioxetine Phase 1 T84160 DRUGINFO D0D5ZX RG-12915 Discontinued in Phase 3 T84160 DRUGINFO D07QAA BRL-46470 Discontinued in Phase 2 T84160 DRUGINFO D0SB6K DAT-582 Discontinued in Phase 2 T84160 DRUGINFO D0T1MP Lurosetron Discontinued in Phase 2 T84160 DRUGINFO D0ZX7I SR-57227 Discontinued in Phase 2 T84160 DRUGINFO D04DMQ Fabesetron Discontinued in Phase 2 T84160 DRUGINFO D0Y0SY E-3620 Discontinued in Phase 2 T84160 DRUGINFO D03CFR SEP-226332 Discontinued in Phase 1 T84160 DRUGINFO D0S7VZ WAY-100289 Discontinued in Phase 1 T84160 DRUGINFO D0YT6Z Mirisetron maleate Discontinued in Phase 1 T84160 DRUGINFO D01JHN CR-3124 Terminated T84160 DRUGINFO D0C5DM SC-52150 Terminated T84160 DRUGINFO D0I8RY SDZ-ICM-567 Terminated T84160 DRUGINFO D0L3OE SRSS-021 Terminated T84160 DRUGINFO D0M7VW GR-65630 Terminated T84160 DRUGINFO D0Y5QO GK-128 Terminated T84160 DRUGINFO D0V1SD BP4.879a Terminated T84160 DRUGINFO D04NLG BRL 43694A Investigative T84160 DRUGINFO D0S0XK S-21007 Investigative T84160 DRUGINFO D00JKB SC-54750 Investigative T84160 DRUGINFO D03TPY SC-52491 Investigative T84160 DRUGINFO D0AJ3C (R)-zacopride Investigative T84160 DRUGINFO D0I3XA Ciproxifan Investigative T81183 TARGETID T81183 T81183 FORMERID TTDS00027 T81183 TARGNAME Adrenergic receptor Alpha-1 (ADRA1) T81183 TARGTYPE Successful T81183 SYNONYMS Alpha1-adrenoceptor; Alpha(1)-adrenoceptor T81183 BIOCLASS GPCR rhodopsin T81183 DRUGINFO D01TSI Ergotamine Approved T81183 DRUGINFO D02XJY Midodrine Approved T81183 DRUGINFO D0A8XN Labetalol Approved T81183 DRUGINFO D0W9LX Carvedilol Approved T81183 DRUGINFO D0WV3U Prazosin Approved T81183 DRUGINFO D0K0VO Urapidil Approved T81183 DRUGINFO D09JXM Phenylpropanolamine Withdrawn from market T81183 DRUGINFO D00LBD Metazosin Discontinued in Phase 3 T81183 DRUGINFO D07ODD DC-015 Terminated T39078 TARGETID T39078 T39078 FORMERID TTDS00145 T39078 TARGNAME Calcium-activated potassium channel (KCN) T39078 TARGTYPE Successful T39078 SYNONYMS Ca-activated K channel T39078 FUNCTION Forms a voltage-independent potassium channel that is activated by intracellular calcium. activation is followed by membrane hyperpolarization which promotes calcium influx. The channel is blocked by clotrimazole and charybdotoxin. T39078 DRUGINFO D08ZEB Chlorzoxazone Approved T39078 DRUGINFO D0U5OB Charybdotoxin Approved T39078 DRUGINFO D00BUR ICA-17043 Phase 2 T39078 DRUGINFO D02CZC 4-fluorophenyl-2,2-diphenylacetamide Investigative T39078 DRUGINFO D02LML N-methyl-2,2,2-triphenylacetamide Investigative T39078 DRUGINFO D03FAG TRIPHENYLMETHANAMINE Investigative T39078 DRUGINFO D05MDB N,N-dimethyl-2,2,2-triphenylacetamide Investigative T39078 DRUGINFO D06XXG (2-fluorophenyl)-(4-fluorophenyl)phenylacetamide Investigative T39078 DRUGINFO D06ZNX 2,2,2-tris-(3-fluorophenyl)-acetamide Investigative T39078 DRUGINFO D07EYJ 2-fluorophenyl-2,2-diphenylacetamide Investigative T39078 DRUGINFO D09LVX Bis(4-fluorophenyl)-2-fluorophenylacetamide Investigative T39078 DRUGINFO D09TSB N-ethyl-2,2,2-triphenylacetamide Investigative T39078 DRUGINFO D0A4LH 5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one Investigative T39078 DRUGINFO D0F7DQ Triphenylacetic acid methyl ester Investigative T39078 DRUGINFO D0HR0O 2,2,2-tris-(4-fluorophenyl)-acetamide Investigative T39078 DRUGINFO D0I5YS 2-(2-chlorophenyl)-2,2-diphenylethanamide Investigative T39078 DRUGINFO D0K1QB 2-(2,4-difluorophenyl)-2,2-diphenylacetamide Investigative T39078 DRUGINFO D0N2BP 2,2-bis-(3-fluorophenyl)-2-phenylacetamide Investigative T39078 DRUGINFO D0T5IP 2-trityl-4,5-dihydrooxazole Investigative T39078 DRUGINFO D0UF2B 2-(3,4-Difluorophenyl)-2,2-diphenylacetamide Investigative T39078 DRUGINFO D0V7RI 2,2-bis-(2-fluorophenyl)-2-phenylacetamide Investigative T39078 DRUGINFO D05RLR 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Investigative T39078 DRUGINFO D0R9CF 4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one Investigative T47941 TARGETID T47941 T47941 FORMERID TTDC00170 T47941 TARGNAME Phosphodiesterase 4 (PDE4) T47941 TARGTYPE Successful T47941 SYNONYMS PDE-4 T47941 FUNCTION Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes||Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents T47941 BIOCLASS Phosphoric diester hydrolase T47941 DRUGINFO D08NWF crisaborole Approved T47941 DRUGINFO D0R4UW Roflumilast Approved T47941 DRUGINFO D03QJL Ibudilast Approved T47941 DRUGINFO D0B0SH Oxtriphylline Approved T47941 DRUGINFO D07ESC Apremilast Approved T47941 DRUGINFO D0T0NG Arofylline Phase 3 T47941 DRUGINFO DST04F ARQ-151 Phase 3 T47941 DRUGINFO D09USN IC-485 Phase 2 T47941 DRUGINFO D0M5BS ONO-6126 Phase 2 T47941 DRUGINFO D0TT4H E6005 Phase 2 T47941 DRUGINFO D0U9WS LEO-32731 Phase 2 T47941 DRUGINFO D5ON9Z ASP9831 Phase 2 T47941 DRUGINFO D81WBS PF-07038124 Phase 2 T47941 DRUGINFO DH82BG ARQ-154 Phase 2 T47941 DRUGINFO D0I8FV SUN13834 Phase 2 T47941 DRUGINFO DRG3B4 TAK-648 Phase 1 T47941 DRUGINFO D02EMR Cilomilast Discontinued in Phase 3 T47941 DRUGINFO D0F3BY GW842470X Discontinued in Phase 2 T47941 DRUGINFO D07FHZ Ro 20-1724 Terminated T47941 DRUGINFO D03FJS S-(-)-enantiomer of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) Investigative T47941 DRUGINFO D0KM1H Iso-caffeine Investigative T47941 DRUGINFO D0M5DY SDZ-PDI-747 Investigative T47941 DRUGINFO D0U0EX CT-5357 Investigative T47941 DRUGINFO D01RUN (R)-Rolipram Investigative T47941 DRUGINFO D02FZD (S)-Rolipram Investigative T43920 TARGETID T43920 T43920 FORMERID TTDS00304 T43920 TARGNAME Carbonic anhydrase (CA) T43920 TARGTYPE Successful T43920 SYNONYMS Carbonate dehydratase T43920 DRUGINFO D0J8ZA Quinethazone Approved T43920 DRUGINFO D0K1QD Sulfamylon Approved T43920 DRUGINFO D07HBX Salicyclic acid Approved T43920 DRUGINFO D0VA4Y Phentermine+topiramate Phase 3 T43920 DRUGINFO D0A8JP PARABEN Phase 3 T43920 DRUGINFO D07SDQ Curcumin Phase 3 T43920 DRUGINFO D0L6HN PHENOL Phase 2/3 T43920 DRUGINFO D0Y6OA Coumate Phase 2 T43920 DRUGINFO D0V0UK SULFAMIDE Phase 1 T43920 DRUGINFO D02VIR PMID30074415-Compound-21 Patented T43920 DRUGINFO D07DGA Imatinib and nilotinib derivative 2 Patented T43920 DRUGINFO D0CE8B PMID30074415-Compound-19 Patented T43920 DRUGINFO D0F8XZ PMID30074415-Compound-20 Patented T43920 DRUGINFO D0OE4F Imatinib and nilotinib derivative 1 Patented T43920 DRUGINFO D03SLR FERULIC ACID Patented T43920 DRUGINFO D06ABW CLIOQUINOL Withdrawn from market T43920 DRUGINFO D0LD9S SPERMINE Terminated T43920 DRUGINFO D01BUB 2,5-difluorophenol Investigative T43920 DRUGINFO D07MQB 4-amino-3-fluoro-5-iodobenzenesulfonamide Investigative T43920 DRUGINFO D0Q1EI 4-amino-3,5-dibromobenzenesulfonamide Investigative T43920 DRUGINFO D0Q2XB 3,5-difluorophenol Investigative T43920 DRUGINFO D0W2XO Sodium maleate Investigative T43920 DRUGINFO D05PRS 4-Thiocyanato-benzenesulfonamide Investigative T43920 DRUGINFO D06LVE 4-Nitro-benzenesulfonamide Investigative T43920 DRUGINFO D07MTM 4-AMINOPHENOL Investigative T43920 DRUGINFO D07ZHE 3-Nitro-benzenesulfonamide Investigative T43920 DRUGINFO D0L8ZG P-tolylboronic acid Investigative T43920 DRUGINFO D0M6RM Phenylarsonic acid Investigative T43920 DRUGINFO D0SV6C PRONTOCIL Investigative T43920 DRUGINFO D00GVA 4-(2-Pyridin-4-ylacetamido)benzenesulfonamide Investigative T43920 DRUGINFO D01ISX 4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide Investigative T43920 DRUGINFO D05NFU 4-butylphenylboronic acid Investigative T43920 DRUGINFO D06XNT 4-(2-Phenylacetamidomethyl)benzenesulfonamide Investigative T43920 DRUGINFO D07CYN 2-amino-2,3-dihydro-1H-indene-5-sulfonamide Investigative T43920 DRUGINFO D09CSP 3-(4-sulfamoylphenyl)propanoic acid Investigative T43920 DRUGINFO D09LWR 4-(2-Phenylacetamidoethyl)benzenesulfonamide Investigative T43920 DRUGINFO D09TES 2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid Investigative T43920 DRUGINFO D0A3JR 4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide Investigative T43920 DRUGINFO D0C8ZY Beta-naphthylboronic acid Investigative T43920 DRUGINFO D0D2JA 4-phenoxyphenylboronic acid Investigative T43920 DRUGINFO D0N7WP 4-(2-Pyridin-2-ylacetamido)benzenesulfonamide Investigative T43920 DRUGINFO D0O0UE 4-(2-Phenylacetamido)benzenesulfonamide Investigative T43920 DRUGINFO D0O9VU 4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide Investigative T43920 DRUGINFO D0T0YI 4-nitrophenyl phosphate Investigative T43920 DRUGINFO D0W9VC 4-[2-(2-Thienyl)acetamido]benzenesulfonamide Investigative T43920 DRUGINFO D0XL5K Benzothiazole-2-sulfonic acid amide Investigative T43920 DRUGINFO D0Z1CL 4-bromophenylboronic acid Investigative T43920 DRUGINFO D0Z5GE 4-(2-Phenylacetamido)-3-bromobenzenesulfonamide Investigative T43920 DRUGINFO D00IUB 4-CYANOPHENOL Investigative T43920 DRUGINFO D01JTI 3-bromophenyl-difluoromethanesulfonamide Investigative T43920 DRUGINFO D04JIN (2-bromophenyl)difluoromethanesulfonamide Investigative T43920 DRUGINFO D04PSK N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide Investigative T43920 DRUGINFO D05QUG 7-phenethoxy-2H-chromen-2-one Investigative T43920 DRUGINFO D05VSK ETHOXYCOUMARIN Investigative T43920 DRUGINFO D06GPL 4-methylphenyl-difluoromethanesulfonamide Investigative T43920 DRUGINFO D06JVR N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T43920 DRUGINFO D07QJJ CATECHOL Investigative T43920 DRUGINFO D07SIA PHENYLMETHANESULFONAMIDE Investigative T43920 DRUGINFO D09OSN Biphenyl-4-ylboronic acid Investigative T43920 DRUGINFO D09UQM 1-(3,4-dichlorophenyl)-3-hydroxyurea Investigative T43920 DRUGINFO D0A4HS 4-methoxyphenylboronic acid Investigative T43920 DRUGINFO D0E3VJ N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide Investigative T43920 DRUGINFO D0I5YQ 4-nitrophenyl-difluoromethanesulfonamide Investigative T43920 DRUGINFO D0IU3X (4-bromophenyl)difluoromethanesulfonamide Investigative T43920 DRUGINFO D0S4NO N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T43920 DRUGINFO D0T2VH N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide Investigative T43920 DRUGINFO D0UN0E PHENYLDIFLUOROMETHANESULFONAMIDE Investigative T43920 DRUGINFO D0Z6TM 4-azidobenzenesulfonamide Investigative T43920 DRUGINFO D00RNZ 7-(benzyloxy)-2H-chromen-2-one Investigative T43920 DRUGINFO D02DBP RESORCINOL Investigative T43920 DRUGINFO D03VDJ SULFAMATE Investigative T43920 DRUGINFO D06DYP 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T43920 DRUGINFO D09WVV N1-(2-aminoethyl)ethane-1,2-diamine Investigative T43920 DRUGINFO D0A0YX SACCHARIN Investigative T43920 DRUGINFO D0C4QB 2-Amino-indan-5-sulfonic acid Investigative T43920 DRUGINFO D0G0FJ 2-hydrazinylbenzenesulfonamide Investigative T43920 DRUGINFO D0LC0F 2,3-dihydro-1H-indene-5-sulfonamide Investigative T43920 DRUGINFO D0LU4S 7-butoxy-2H-chromen-2-one Investigative T43920 DRUGINFO D0OT5L 7-propoxy-2H-chromen-2-one Investigative T43920 DRUGINFO D0RB0D 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid Investigative T43920 DRUGINFO D0TY8X 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide Investigative T43920 DRUGINFO D0X6IE 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide Investigative T43920 DRUGINFO D0Z1HY 4-amino-6-chlorobenzene-1,3-disulfonamide Investigative T43920 DRUGINFO D0ZC3W P-toluenesulfonamide Investigative T43920 DRUGINFO D00XJA 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T43920 DRUGINFO D04VLI 4-(2-Hydroxy-ethyl)-benzenesulfonamide Investigative T43920 DRUGINFO D07TAJ Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate Investigative T43920 DRUGINFO D08XQI PARAOXON Investigative T43920 DRUGINFO D0D6UR 2-oxo-2H-thiochromene-3-carboxylic acid Investigative T43920 DRUGINFO D0EJ9B Phenyl Boronic acid Investigative T43920 DRUGINFO D0H3NS 2-oxo-2H-chromene-3-carboxylic acid Investigative T43920 DRUGINFO D0J2AE 3-Amino-benzenesulfonamide Investigative T43920 DRUGINFO D0OI1H 2-Amino-benzenesulfonamide Investigative T43920 DRUGINFO D0X5HL N1-(naphthalen-1-yl)ethane-1,2-diamine Investigative T43920 DRUGINFO D04NSN 4-(2-AMINOETHYL)BENZENESULFONAMIDE Investigative T43920 DRUGINFO D05XZM 4-(hydroxymethyl)benzenesulfonamide Investigative T43920 DRUGINFO D09JPC Hexane-1,6-diamine Investigative T43920 DRUGINFO D09PWX Carzenide Investigative T43920 DRUGINFO D0G3BI 6-methyl-2-oxo-2H-chromene-3-carboxylic acid Investigative T43920 DRUGINFO D0L5TZ 6-(hydroxymethyl)-2H-chromen-2-one Investigative T43920 DRUGINFO D0Q2LL 6-Hydroxy-benzothiazole-2-sulfonic acid amide Investigative T43920 DRUGINFO D0U4BB HERNIARIN Investigative T43920 DRUGINFO D00YEF Decane-1,10-diyl disulfamate Investigative T43920 DRUGINFO D01STY 4-Amino-3-iodo-benzenesulfonamide Investigative T43920 DRUGINFO D02QGI Pentane-1,5-diamine Investigative T43920 DRUGINFO D03ZMQ COUMARIN Investigative T43920 DRUGINFO D04CVC 4-Amino-3-fluoro-benzenesulfonamide Investigative T43920 DRUGINFO D05TLB Octyl sulfamate Investigative T43920 DRUGINFO D09WSJ Decyl sulfamate Investigative T43920 DRUGINFO D0AU0M P-Coumaric Acid Investigative T43920 DRUGINFO D0D4OV Octane-1,8-diyl disulfamate Investigative T43920 DRUGINFO D0E8CC BENZOLAMIDE Investigative T43920 DRUGINFO D0M3PO 2,4-Disulfamyltrifluoromethylaniline Investigative T43920 DRUGINFO D0N1AW 6-(aminomethyl)-2H-chromen-2-one Investigative T43920 DRUGINFO D0NN3Q 4-Hydrazino-benzenesulfonamide Investigative T43920 DRUGINFO D0P6AM 4-Amino-3-bromo-benzenesulfonamide Investigative T43920 DRUGINFO D0Q7DJ Syringic Acid Investigative T43920 DRUGINFO D0VD7H CL-5343 Investigative T43920 DRUGINFO D0YU8J 4-Amino-3-chloro-benzenesulfonamide Investigative T43920 DRUGINFO D0V7AA CATECHIN Investigative T43920 DRUGINFO D0Y3TZ GALLICACID Investigative T43920 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T43920 DRUGINFO D0A1CM ELLAGIC ACID Investigative T52624 TARGETID T52624 T52624 FORMERID TTDS00261 T52624 TARGNAME Platelet-derived growth factor receptor (PDGFR) T52624 TARGTYPE Successful T52624 SYNONYMS Platelet-derived growth factor receptor tyrosine kinase; PDGFR kinase; PDGF-R T52624 DRUGINFO D0U5SC CT-102 Approved T52624 DRUGINFO D0F0ZY Pazopanib HCl Approved T52624 DRUGINFO D09HNV Intedanib Approved T52624 DRUGINFO D0AZ3C Imatinib Approved T52624 DRUGINFO D0U2CV Trapidil Phase 4 T52624 DRUGINFO D07OZR TKI258 Phase 3 T52624 DRUGINFO D0A1AQ Rosiglitazone + metformin Phase 3 T52624 DRUGINFO D8AG3S Vorolanib Phase 2 T52624 DRUGINFO D07NOI BAY-57-9352 Phase 2 T52624 DRUGINFO D0L2ZY X-82 Phase 2 T52624 DRUGINFO D0S6IA PMID25623274-Compound-WO2014132220C2 Patented T52624 DRUGINFO D0Z4QJ PMID25623274-Compound-WO2014132220C1 Patented T52624 DRUGINFO D00DQX Motesanib Discontinued in Phase 3 T52624 DRUGINFO D01EFO CGP-53716 Terminated T52624 DRUGINFO D08NYO PDGF gene therapy Investigative T57361 TARGETID T57361 T57361 FORMERID TTDR00005 T57361 TARGNAME Kallikrein-related peptidase (KLK) T57361 TARGTYPE Successful T57361 SYNONYMS Human kallikrein T57361 BIOCLASS Peptidase T57361 DRUGINFO D0V9ZG Cetraxate Approved T57361 DRUGINFO D0P5AE Ecallantide Approved T57361 DRUGINFO D0SH3I Bortezomib Approved T57361 DRUGINFO D0ND3F LM-030 Phase 2 T57361 DRUGINFO D02YUQ Benzyl amine derivative 1 Patented T57361 DRUGINFO D0JO6Z Benzyl amine derivative 2 Patented T57361 DRUGINFO D0QH9W Heteroaryl-carboxamide derivative 11 Patented T57361 DRUGINFO D02MGJ Benzoxazinone derivative 2 Patented T65755 TARGETID T65755 T65755 FORMERID TTDC00297 T65755 TARGNAME Histone deacetylase (HDAC) T65755 TARGTYPE Successful T65755 SYNONYMS Human histone deacetylase T65755 FUNCTION Responsible for the deacetylation of lysine residues on the n-terminal part of the core histones (H2a, H2b, H3 and H4). Histone deacetylation givesa tag for epigenetic repression and plays an important role in transcriptional regulation. T65755 DRUGINFO D0P2GK Sodium phenylbutyrate Approved T65755 DRUGINFO D0Y3KG Valproate Approved T65755 DRUGINFO D00SQN HBI-8000 Registered T65755 DRUGINFO D0D2TZ CMS-024-02 Phase 3 T65755 DRUGINFO D0L2UQ Pracinostat Phase 3 T65755 DRUGINFO D0V0SL Abexinostat Phase 3 T65755 DRUGINFO D0B3FV NVP-LAQ824 Phase 3 T65755 DRUGINFO D0M8FD SNDX-275 Phase 3 T65755 DRUGINFO D0GH3Q ITF2357 Phase 3 T65755 DRUGINFO D00GIR DAC-060 Phase 2 T65755 DRUGINFO D00NBJ Remetinostat Phase 2 T65755 DRUGINFO D05KED Rocilinostat Phase 2 T65755 DRUGINFO D09XIZ JNJ-26481585 Phase 2 T65755 DRUGINFO D0N6AC SHAPE Phase 2 T65755 DRUGINFO D0XT6W PDX-101 Phase 2 T65755 DRUGINFO D00FHR MGCD-0103 Phase 2 T65755 DRUGINFO D08VAR APH-0812 Phase 2 T65755 DRUGINFO D09RYU Tractinostat Phase 1/2 T65755 DRUGINFO D0Q1SQ EDO-S101 Phase 1/2 T65755 DRUGINFO D39TVC Tinostamustine Phase 1/2 T65755 DRUGINFO D0E6UZ CUDC-907 Phase 1/2 T65755 DRUGINFO D04ERQ CXD-101 Phase 1 T65755 DRUGINFO D04KMQ GSK3117391 Phase 1 T65755 DRUGINFO D07JBE CG-200745 Phase 1 T65755 DRUGINFO D0O3XS GSK311739 Phase 1 T65755 DRUGINFO D0Q1GL CT-200 Phase 1 T65755 DRUGINFO DZL3F8 VTR-297 Phase 1 T65755 DRUGINFO DZU72C OKI 179 Phase 1 T65755 DRUGINFO D00SSZ OBP-801 Phase 1 T65755 DRUGINFO D01JPM PMID28092474-Compound-33 Patented T65755 DRUGINFO D01LDP Ampicidin analog 2 Patented T65755 DRUGINFO D0H2UJ Ampicidin analog 1 Patented T65755 DRUGINFO D0RF1Z PMID29671355-Compound-69 Patented T65755 DRUGINFO D0SO8W PMID28092474-Compound-32 Patented T65755 DRUGINFO D0T7RJ PMID28092474-Compound-34 Patented T65755 DRUGINFO D0TT4A PMID29671355-Compound-53 Patented T65755 DRUGINFO D01KCA PMID27376512-Compound-PG-11047 Patented T65755 DRUGINFO D02KWX Indole-based analog 11 Patented T65755 DRUGINFO D06QPW Aniline derivative 1 Patented T65755 DRUGINFO D08FOG PMID27376512-Compound-PG-11048 Patented T65755 DRUGINFO D0M5DX Oxazolyl methylthiothiazole derivative 1 Patented T65755 DRUGINFO D0G8NP CS-00028 Preclinical T65755 DRUGINFO D0RO0T MKC-1313 Terminated T65755 DRUGINFO D08PMD N-(5-Hydroxycarbamoyl-pentyl)-benzamide Investigative T65755 DRUGINFO D08VPK Suberic bishydroxamic acid Investigative T65755 DRUGINFO D0K7QR ST-5732 Investigative T65755 DRUGINFO D0LK8U CG-1521 Investigative T65755 DRUGINFO D0ME6Y N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide Investigative T65755 DRUGINFO D0NF6F Trichostatin A Investigative T65755 DRUGINFO D0P1HZ CHAP1 Investigative T65755 DRUGINFO D0PQ5T Azelaic bishydroxamic acid Investigative T65755 DRUGINFO D0T3PR Trifluoromethylketone Investigative T65755 DRUGINFO D0W1PV Apicidin Investigative T65755 DRUGINFO D0X1CB Trapoxin Investigative T65755 DRUGINFO D0Y2DW CHAP31 Investigative T65755 DRUGINFO D00HFS N-Hydroxy-N'-(4-methylphenyl)octanediamide Investigative T65755 DRUGINFO D01AMS N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T65755 DRUGINFO D01ZMJ N-(2-Ethylphenyl)-N'-hydroxyoctanediamide Investigative T65755 DRUGINFO D03BQS N-hydroxy-9,10-dihydroanthracene-9-carboxamide Investigative T65755 DRUGINFO D03QOD N-hydroxy-2,2-diphenylacetamide Investigative T65755 DRUGINFO D05GRZ N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T65755 DRUGINFO D06IMY N-hydroxy-9H-xanthene-9-carboxamide Investigative T65755 DRUGINFO D08ICY N-(4-Ethylphenyl)-N'-hydroxyoctanediamide Investigative T65755 DRUGINFO D08TIJ N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T65755 DRUGINFO D0A4HF 2,2-bis(3-fluorophenyl)-N-hydroxyacetamide Investigative T65755 DRUGINFO D0B8RC N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T65755 DRUGINFO D0FN5D 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide Investigative T65755 DRUGINFO D0H7QA N-Hydroxy-N'-(3-methylphenyl)octanediamide Investigative T65755 DRUGINFO D0I4RK N-hydroxy-2,2-diphenylpropanamide Investigative T65755 DRUGINFO D0J3CY N-(3-Ethylphenyl)-N'-hydroxyoctanediamide Investigative T65755 DRUGINFO D0L5KP N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T65755 DRUGINFO D0L6YF N-Hydroxy-N'-(4-methoxyphenyl)octanediamide Investigative T65755 DRUGINFO D0PK9V 2,2-bis(4-chlorophenyl)-N-hydroxyacetamide Investigative T65755 DRUGINFO D0Q2CC N-Hydroxy-N'-(2-methylphenyl)octanediamide Investigative T65755 DRUGINFO D0SQ1F N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative T65755 DRUGINFO D04DOL N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide Investigative T65755 DRUGINFO D04UVL N-(2-aminophenyl)nicotinamide Investigative T65755 DRUGINFO D0M9LJ N-(4-aminobiphenyl-3-yl)nicotinamide Investigative T65755 DRUGINFO D0Q2GM N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide Investigative T65755 DRUGINFO D0YO6M N-(2-aminophenyl)-4-methoxybenzamide Investigative T65755 DRUGINFO D02NWS 4-Phenylbutyrohydroxamic acid Investigative T65755 DRUGINFO D0S0WK 8-Oxo-8-phenyl-octanoic acid hydroxyamide Investigative T65755 DRUGINFO D01YBR ST-3050 Investigative T65755 DRUGINFO D07YZZ Octanedioic acid bis-hydroxyamide Investigative T65755 DRUGINFO D0N9AK ST-2986 Investigative T65755 DRUGINFO D00KFF 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative T65755 DRUGINFO D00SEE 7-Mercapto-heptanoic acid phenylamide Investigative T65755 DRUGINFO D00ZSD 6-benzenesulfinylhexanoic acid hydroxamide Investigative T65755 DRUGINFO D01MFV N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative T65755 DRUGINFO D01XWZ 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative T65755 DRUGINFO D01XXN N-Hydroxy-4-phenylacetylamino-benzamide Investigative T65755 DRUGINFO D02MQM 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative T65755 DRUGINFO D02UTC N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative T65755 DRUGINFO D02WZK 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T65755 DRUGINFO D04GGW Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative T65755 DRUGINFO D04HSS N-(6-Mercapto-hexyl)-benzamide Investigative T65755 DRUGINFO D04NSP 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T65755 DRUGINFO D04ZDI N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative T65755 DRUGINFO D05AHZ 6-benzenesulfonylhexanoic acid hydroxamide Investigative T65755 DRUGINFO D05FEJ 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative T65755 DRUGINFO D05GVY Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative T65755 DRUGINFO D05LLX 4-Butyrylamino-N-hydroxy-benzamide Investigative T65755 DRUGINFO D05VFP 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T65755 DRUGINFO D05XAN 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative T65755 DRUGINFO D06IQB 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative T65755 DRUGINFO D06VBN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative T65755 DRUGINFO D06XNP 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative T65755 DRUGINFO D07FJU 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative T65755 DRUGINFO D09YBN 6-Phenoxy-hexane-1-thiol Investigative T65755 DRUGINFO D09ZNU 4-Benzoylamino-N-hydroxy-benzamide Investigative T65755 DRUGINFO D0A5LS 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T65755 DRUGINFO D0AX7B 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative T65755 DRUGINFO D0B2ZJ 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T65755 DRUGINFO D0B3ZM 6-Mercapto-hexanoic acid phenylamide Investigative T65755 DRUGINFO D0C0VP Cyclostellettamine derivative Investigative T65755 DRUGINFO D0C2KD N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative T65755 DRUGINFO D0D2KE 5-Mercapto-pentanoic acid phenylamide Investigative T65755 DRUGINFO D0E8KR Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative T65755 DRUGINFO D0F0KS N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative T65755 DRUGINFO D0H1FZ 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative T65755 DRUGINFO D0KE3I (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative T65755 DRUGINFO D0QO0L N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative T65755 DRUGINFO D0R4BS N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative T65755 DRUGINFO D0R5VG N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative T65755 DRUGINFO D0RU1X 8-Oxo-8-phenyl-octanoic acid Investigative T65755 DRUGINFO D0S7WQ N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative T65755 DRUGINFO D0S9JF 6-phenylsulfanylhexanoic acid hydroxamide Investigative T65755 DRUGINFO D0T0SK ST-2987 Investigative T65755 DRUGINFO D0T4IY 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative T65755 DRUGINFO D0V2ZO 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative T65755 DRUGINFO D0XZ9Q 8-Mercapto-octanoic acid phenylamide Investigative T65755 DRUGINFO D0YY9M N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative T65755 DRUGINFO D0Z3BM 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative T65755 DRUGINFO D0Z5KX 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative T65755 DRUGINFO D0Z7YS N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative T65755 DRUGINFO D0N0TS PSAMMAPLIN A Investigative T92308 TARGETID T92308 T92308 FORMERID TTDS00312 T92308 TARGNAME DNA [cytosine-5]-methyltransferase (DNMT) T92308 TARGTYPE Successful T92308 SYNONYMS DNA MTase T92308 FUNCTION This methylase recognizes the double-stranded sequence ccwgg, causes specific methylation on c-2 on both strands. T92308 DRUGINFO D09FAZ Azacitidine Approved T92308 DRUGINFO D0NH3R ASTX727 Phase 3 T92308 DRUGINFO D0A2BO S-110 Phase 3 T92308 DRUGINFO D07SDQ Curcumin Phase 3 T92308 DRUGINFO D04LBL PMID27376512-Compound-MTC-434 Patented T92308 DRUGINFO D05NMG PMID27376512-Compound-CROs Patented T92308 DRUGINFO D01KCA PMID27376512-Compound-PG-11047 Patented T92308 DRUGINFO D08FOG PMID27376512-Compound-PG-11048 Patented T92308 DRUGINFO D01VNN NSC-622444 Investigative T92308 DRUGINFO D03PWU NSC-138419 Investigative T92308 DRUGINFO D06RGX NSC-319745 Investigative T92308 DRUGINFO D06VVV NSC-348926 Investigative T92308 DRUGINFO D07VWC NSC-401077 Investigative T92308 DRUGINFO D08TGQ S-tubercidinylhomocysteine Investigative T92308 DRUGINFO D0A2ZH NSC-106084 Investigative T92308 DRUGINFO D0C4NA NSC-154957 Investigative T92308 DRUGINFO D0FN7C NSC-54162 Investigative T92308 DRUGINFO D0G9NS NSC-57893 Investigative T92308 DRUGINFO D0H1YK NSC-56071 Investigative T92308 DRUGINFO D0I5JP NSC-137546 Investigative T92308 DRUGINFO D0LS2U NSC-623548 Investigative T92308 DRUGINFO D0MP7N NSC-345763 Investigative T92308 DRUGINFO D0W5SZ NSC-158324 Investigative T92308 DRUGINFO D09CLP (L-)-S-adenosyl-L-homocysteine Investigative T92308 DRUGINFO D0J5VK NSC-622445 Investigative T85605 TARGETID T85605 T85605 FORMERID TTDS00097 T85605 TARGNAME 5-HT receptor (5HTR) T85605 TARGTYPE Successful T85605 SYNONYMS 5-Hydroxytryptamine receptor T85605 BIOCLASS GPCR rhodopsin T85605 DRUGINFO D06OSM Tandospirone Approved T85605 DRUGINFO D06XZR Pizotyline Approved T85605 DRUGINFO D07YWY Nafronyl Approved T85605 DRUGINFO D0B3UJ Paliperidone Approved T85605 DRUGINFO D0RA9E Ramosetron Approved T85605 DRUGINFO D0UA0I Metergolin Approved T85605 DRUGINFO D09WNK Fenfluramine Phase 3 T85605 DRUGINFO D0Q0EF ITI-007 Phase 3 T85605 DRUGINFO D0H4GU EPX-200 Phase 2 T85605 DRUGINFO D0X4PP EPX-300 Phase 2 T85605 DRUGINFO D0A8QM Lu-AA34893 Phase 2 T85605 DRUGINFO DS31JZ SEP--4199 Phase 2 T85605 DRUGINFO D0Z4FE MIN-117 Phase 2 T85605 DRUGINFO D00BND BF-1 Phase 1 T85605 DRUGINFO D07YKQ EPX-100 Phase 1 T85605 DRUGINFO D0Y8RS DSP-6745 Phase 1 T85605 DRUGINFO D0K8NW Ritanserin Discontinued in Phase 3 T85605 DRUGINFO D01DRL RGH-2721 Terminated T85605 DRUGINFO D00TRL REV-598 Terminated T85605 DRUGINFO D09XYA SB 203106 Investigative T85605 DRUGINFO D0F0UA MCI Investigative T85605 DRUGINFO D0R1RK EpiCept Investigative T25663 TARGETID T25663 T25663 FORMERID TTDS00185 T25663 TARGNAME Adenosine receptor (ADOR) T25663 TARGTYPE Successful T25663 SYNONYMS P1 receptor T25663 BIOCLASS GPCR rhodopsin T25663 DRUGINFO D0F8RA Theophylline Approved T25663 DRUGINFO D0LJ4E NIR178 Phase 2 T25663 DRUGINFO D0UF2N DIADENOSINE TETRAPHOSPHATE Phase 2 T25663 DRUGINFO D0F7XN M-216765 Terminated T25663 DRUGINFO D09QLB 8-sulfophenyl theophylline Investigative T25663 DRUGINFO D0X7AZ SPT Investigative T25663 DRUGINFO D0K0OT GNF-PF-2224 Investigative T31424 TARGETID T31424 T31424 FORMERID TTDS00031 T31424 TARGNAME Adrenergic receptor Alpha-2 (ADRA2) T31424 TARGTYPE Successful T31424 SYNONYMS Alpha-2 adrenergic receptor; Alpha(2)-adrenoceptor T31424 BIOCLASS GPCR rhodopsin T31424 DRUGINFO D00UYE Meperidine Approved T31424 DRUGINFO D01MDT Tizanidine Approved T31424 DRUGINFO D04YZL Sodium chloride Approved T31424 DRUGINFO D09EBS Oxymetazoline Approved T31424 DRUGINFO D0F7NZ Guanidine Hydrochloride Approved T31424 DRUGINFO D0H4JM Yohimbine Approved T31424 DRUGINFO D0L4HY Guanabenz Approved T31424 DRUGINFO D0MT0M Apraclonidine Approved T31424 DRUGINFO D0U3DU Dexmedetomidine Approved T31424 DRUGINFO D0V2GH Nicergoline Approved T31424 DRUGINFO D0Y6KO Methyldopate Hydrochloride Approved T31424 DRUGINFO D03SKR Clonidine Approved T31424 DRUGINFO D0AE3X Brimonidine Approved T31424 DRUGINFO D0K0MW Lofexidine Approved T31424 DRUGINFO D07ILQ Guanfacine extended release Approved T31424 DRUGINFO D05LGX Fipamezole Phase 2 T31424 DRUGINFO D0U1NA Fadolmidine Phase 2 T31424 DRUGINFO D0V1RX Mivazerol Discontinued in Phase 3 T31424 DRUGINFO D05OVC Atipamezole Discontinued in Phase 2 T31424 DRUGINFO D0N8UU ADX415 Terminated T31424 DRUGINFO D00ARM Brominide tartrate Investigative T31424 DRUGINFO D0Z7EA [3H]rauwolscine Investigative T87467 TARGETID T87467 T87467 FORMERID TTDS00489 T87467 TARGNAME Folate receptor (FOLR) T87467 TARGTYPE Successful T87467 SYNONYMS FR; FOLR T87467 FUNCTION Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells. Isoform short does not bind folate. T87467 BIOCLASS Folate receptor T87467 DRUGINFO D0H2QO Tetrahydrofolic acid Approved T87467 DRUGINFO D0Z0DW Folic Acid Approved T71398 TARGETID T71398 T71398 FORMERID TTDS00443 T71398 TARGNAME Guanylate cyclase (GC) T71398 TARGTYPE Successful T71398 SYNONYMS Guanylyl Cyclase T71398 BIOCLASS Phosphorus-oxygen lyase T71398 DRUGINFO D06IZM Erythrityl Tetranitrate Approved T71398 DRUGINFO D0I1SK Isosorbide Dinitrate Approved T71398 DRUGINFO D0YS7D Isosorbide Mononitrate Approved T71398 DRUGINFO D09NYS Methylene blue Approved T71398 DRUGINFO D0A5FM Nitric Oxide Approved T71398 DRUGINFO D0O2AG Pirsidomine Phase 2 T71398 DRUGINFO D2SPH4 IW-1701 Phase 2 T45598 TARGETID T45598 T45598 FORMERID TTDI01799 T45598 TARGNAME Interferon alpha (IFNA) T45598 TARGTYPE Successful T45598 SYNONYMS IFN-A T45598 FUNCTION Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. T45598 DRUGINFO D07CMM Interferon alfa-n3 Approved T45598 DRUGINFO D0L7QB Alfaferone Approved T45598 DRUGINFO DA74SC P1101 Phase 3 T45598 DRUGINFO D00QGV Human interferon alpha oral Phase 2 T45598 DRUGINFO D02JDN IFN-alpha Phase 2 T45598 DRUGINFO D0H5ES Rontalizumab Phase 2 T45598 DRUGINFO D0U7SU Interferon-alpha lozenge Phase 2 T45598 DRUGINFO D0V0HU IFN alpha kinoid Phase 1/2 T45598 DRUGINFO D03BLG AGS-009 Phase 1 T45598 DRUGINFO D03QWG Ad-IFN-alpha Phase 1 T45598 DRUGINFO D1A8NU NG-641 Phase 1 T45598 DRUGINFO D05TGV PEG-Infergen Discontinued in Phase 2 T45598 DRUGINFO D0I8NM Gene therapy, IFN-alpha Terminated T45598 DRUGINFO D0Q5MU R-7025 Terminated T33754 TARGETID T33754 T33754 FORMERID TTDS00200 T33754 TARGNAME Phosphodiesterase 3 (PDE3) T33754 TARGTYPE Successful T33754 SYNONYMS Phosphodiesterase III; PDE3; Cyclic GMP inhibited phosphodiesterase; Cyclic AMP phosphodiesterase III; CGI-PDE; CAMP phosphodiesterase III T33754 BIOCLASS Phosphoric diester hydrolase T33754 DRUGINFO D03ZBN Olprinone Approved T33754 DRUGINFO D0R6TI Inamrinone Lactate Approved T33754 DRUGINFO D0Y9ZE Milrinone Approved T33754 DRUGINFO D03QJL Ibudilast Approved T33754 DRUGINFO D03VPC Cilostazol Approved T33754 DRUGINFO D0B0SH Oxtriphylline Approved T33754 DRUGINFO D0E0SW Enoximone Approved T33754 DRUGINFO D08VHG RPL-554 Phase 2 T33754 DRUGINFO D09PLF Org-30029 Phase 2 T33754 DRUGINFO D0S4SX K-134 Phase 2 T33754 DRUGINFO D0Q7UG Tipelukast Phase 2 T33754 DRUGINFO DB82TO Tofisopam Phase 2 T33754 DRUGINFO D02ADC SDZ-MKS-492 Phase 1 T33754 DRUGINFO D0F7NT 349U85.HCL Phase 1 T33754 DRUGINFO D05YAS Tolafentrine Discontinued in Phase 2 T33754 DRUGINFO D06PQR OPC-8490 Discontinued in Phase 2 T33754 DRUGINFO D0LC2B NSP-805 Discontinued in Phase 2 T33754 DRUGINFO D0S8DB Org-9731 Discontinued in Phase 2 T33754 DRUGINFO D0V7IS Pumafentrine Discontinued in Phase 2 T33754 DRUGINFO D0J4WW NIP-520 Discontinued in Phase 1 T33754 DRUGINFO D0W0TH R 80122 Discontinued in Phase 1 T33754 DRUGINFO D0F0CS ZARDAVERINE Terminated T33754 DRUGINFO D0J5UC SDZ-ISQ-844 Terminated T33754 DRUGINFO D0N6OE Benafentrine dimaleate Terminated T33754 DRUGINFO D0PB6P Org-9935 Terminated T33754 DRUGINFO D0Q7VI Siguazodan Terminated T33754 DRUGINFO D0Z4VA UD-CG-212 Terminated T33754 DRUGINFO D0J0CB Cilostamide Investigative T23761 TARGETID T23761 T23761 FORMERID TTDS00517 T23761 TARGNAME Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) T23761 TARGTYPE Successful T23761 SYNONYMS SERCA pump; SERCA; Calcium-transporting ATPase; Calcium pump; Ca2+-ATPase; Ca(2+)-ATPase; ATP4 T23761 BIOCLASS Acid anhydrides hydrolase T23761 DRUGINFO D00ZTD OZ277 Approved T23761 DRUGINFO D0D4JO Artesunate Approved T23761 DRUGINFO D0E0KQ Pyronaridine Approved T23761 DRUGINFO D0N6FH Dihydroartemisinin Approved T23761 DRUGINFO D0P0SZ Piperaquine Approved T23761 DRUGINFO D03KEK Artemisinin SP Approved T23761 DRUGINFO D0S3WH Artemisinin Approved T23761 DRUGINFO D08NCO Vanadate Phase 3 T23761 DRUGINFO D02KGR THAPSIGARGIN Preclinical T23761 DRUGINFO D0K6HL Cyclopiazonic acid Investigative T82266 TARGETID T82266 T82266 FORMERID TTDS00160 T82266 TARGNAME Voltage-gated L-type calcium channel (L-CaC) T82266 TARGTYPE Successful T82266 SYNONYMS L-type voltage-dependent Ca(2+) channel; L-type Ca2+ channel; L-type Ca(2+) channel T82266 BIOCLASS Voltage-gated ion channel T82266 DRUGINFO D04OSE Nifedipine Approved T82266 DRUGINFO D0K8CI Otilonium bromide Approved T82266 DRUGINFO D03KOZ Epalrestat Approved T82266 DRUGINFO D09ELP Clevidipine butyrate Approved T82266 DRUGINFO D0I2WV Levamlodipine Phase 4 T82266 DRUGINFO D0J1NQ Pinaverium bromide Phase 3 T82266 DRUGINFO D0N3SR Cilnidipine Phase 3 T82266 DRUGINFO D08UQS MEM-1003 Phase 2a T82266 DRUGINFO D0K4QT BAY-Y-5959 Phase 2 T82266 DRUGINFO D00ERV Gallopamil Phase 2 T82266 DRUGINFO D0X9VP Furnidipine Discontinued in Phase 3 T82266 DRUGINFO D01RAD Bay K 8644 Investigative T82266 DRUGINFO D02LIY Euro-Celtique 2 Investigative T82266 DRUGINFO D03IVC S 202 791 Investigative T82266 DRUGINFO D05BLQ Neuromed 2 Investigative T82266 DRUGINFO D06PJK Euro-Celtique 3 Investigative T82266 DRUGINFO D07APX Neuromed 5 Investigative T82266 DRUGINFO D08UEJ Ajinomoto 2 Investigative T82266 DRUGINFO D08ZSQ Parke-Davis 1 Investigative T82266 DRUGINFO D09TRN Dihydropyridines Investigative T82266 DRUGINFO D0A6MS Parke-Davis 9 Investigative T82266 DRUGINFO D0M3ON Euro-Celtique 4 Investigative T82266 DRUGINFO D0PE8P PD173212 Investigative T82266 DRUGINFO D0Q8TX Ajinomoto 1 Investigative T82266 DRUGINFO D0S6YO Ajinomoto 3 Investigative T82266 DRUGINFO D0T3CB Ono 1 Investigative T82266 DRUGINFO D0UB0T PD176078 Investigative T82266 DRUGINFO D0V8ZD SQ32,910 Investigative T82266 DRUGINFO D0V9MO Ono 3 Investigative T82266 DRUGINFO D0Y9OS Euro-Celtique 1 Investigative T82266 DRUGINFO D03UJT [3H](-)devapamil Investigative T23003 TARGETID T23003 T23003 FORMERID TTDI01775 T23003 TARGNAME MAPK/ERK kinase kinase (MAP3K) T23003 TARGTYPE Successful T23003 FUNCTION Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leadingto their activation and further transduction of the signal within the MAPK/ERK cascade. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator- activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis. T23003 BIOCLASS Kinase T23003 DRUGINFO D04XVN Trametinib Approved T23003 DRUGINFO D0C4LF ARRY-162 Approved T23003 DRUGINFO D03SKL BAY 86-9766 Phase 3 T23003 DRUGINFO D0T5DP Selumetinib Phase 3 T23003 DRUGINFO D01CNB E6201 Phase 2 T23003 DRUGINFO D03CHM MSC1936369B Phase 2 T23003 DRUGINFO D0K0YC PD-0325901 Phase 2 T23003 DRUGINFO D0M6BD RO-5126766 Phase 2 T23003 DRUGINFO D0O4QS WX-554 Phase 1/2 T23003 DRUGINFO D05NLD ARRY-300 Phase 1 T23003 DRUGINFO D0I3RD TAK-733 Phase 1 T23003 DRUGINFO D08DCP BI-847325 Phase 1 T23003 DRUGINFO D06EFW RG7304 Phase 1 T23003 DRUGINFO D09GHB RO-4987655 Discontinued in Phase 1 T23003 DRUGINFO D0P0HI AZD8330 Discontinued in Phase 1 T23003 DRUGINFO D0ZG1Y RG-7167 Discontinued in Phase 1 T23003 DRUGINFO D04WPA SL-327 Investigative T23003 DRUGINFO D0HR5Q CIP-137401 Investigative T23003 DRUGINFO D0K3ES MEK inhibitor I Investigative T23003 DRUGINFO D0M7IG RO-4920506 Investigative T23003 DRUGINFO D0TY0P G-573 Investigative T23003 DRUGINFO D0V0QJ NSC-686549 Investigative T96721 TARGETID T96721 T96721 FORMERID TTDS00339 T96721 UNIPROID VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN T96721 TARGNAME Vascular endothelial growth factor (VEGF) T96721 TARGTYPE Successful T96721 SYNONYMS Vascular endothelial cell growth factor T96721 BIOCLASS Growth factor T96721 DRUGINFO D5DO9L Brolucizumab Approved T96721 DRUGINFO D02MUA PF-06439535 Phase 3 T96721 DRUGINFO D2KVG4 TRS003 Phase 3 T96721 DRUGINFO D4Z5CU M710 Phase 3 T96721 DRUGINFO D7GYE9 SB15 Phase 3 T96721 DRUGINFO D8F6PB FKB238 Phase 3 T96721 DRUGINFO DO7QK1 KSI-301 Phase 3 T96721 DRUGINFO DYH3Q6 MYL-1402O Phase 3 T96721 DRUGINFO D07PVB Squalamine Phase 3 T96721 DRUGINFO D0B1VZ ALG-1001 Phase 2 T96721 DRUGINFO D0GP9Q TG100801 Phase 2 T96721 DRUGINFO D0X3QR AVA-101 Phase 2 T96721 DRUGINFO DMEV15 Dilpacimab Phase 2 T96721 DRUGINFO D09HFJ NM-3 Phase 1 T96721 DRUGINFO D0U6XE PAN-90806 Phase 1 T96721 DRUGINFO D0V7QO BI-836880 Phase 1 T96721 DRUGINFO D0PP6A ABT-165 Phase 1 T96721 DRUGINFO D57NHD Zifibancimig Phase 1 T96721 DRUGINFO D62LKT BI 836880 Phase 1 T96721 DRUGINFO DIPY14 NOV1501 Phase 1 T96721 DRUGINFO D0N1RE BIBF100 Investigative T11822 TARGETID T11822 T11822 FORMERID TTDS00072 T11822 TARGNAME Retinoic acid receptor (RAR) T11822 TARGTYPE Successful T11822 SYNONYMS Retinoic acid receptor T11822 DRUGINFO D00DKK Isotretinoin Approved T11822 DRUGINFO D0JC9N Adapalene Approved T11822 DRUGINFO D02DGU Tretinoin Approved T11822 DRUGINFO D0S7WX Vitamin A Approved T11822 DRUGINFO D05TOJ Peretinoin Phase 3 T11822 DRUGINFO D07PTH 13-cis-retinoic acid Phase 3 T11822 DRUGINFO D08JAC Fenretinide Phase 3 T11822 DRUGINFO D0D0QQ Velac Gel Phase 3 T11822 DRUGINFO D0I9HG Amsilarotene Phase 2 T11822 DRUGINFO D04DAL LAS-41001 Discontinued in Preregistration T11822 DRUGINFO D0T0LE IRX-4310 Discontinued in Phase 3 T11822 DRUGINFO D08GRF LG-1550 Discontinued in Phase 2 T11822 DRUGINFO D0W9JH BMY-30123 Discontinued in Phase 2 T11822 DRUGINFO D0Y8IF MX-781 Terminated T43415 TARGETID T43415 T43415 FORMERID TTDC00316 T43415 TARGNAME Tyrosine-protein kinase (PTK) T43415 TARGTYPE Successful T43415 SYNONYMS Protein-tyrosine kinase; PTK T43415 DRUGINFO D0Y7IC Baricitinib Approved T43415 DRUGINFO D0MW0N Masitinib Phase 3 T43415 DRUGINFO D06EIC ASP-015K Phase 3 T43415 DRUGINFO D05UGH LEO 124249 Phase 2 T43415 DRUGINFO D0CG0K ATI-502 Phase 2 T43415 DRUGINFO D06WRF KD019 Phase 2 T43415 DRUGINFO D0Z1QR TD-1473 Phase 1 T43415 DRUGINFO D04XNL Ruxolitinib derivative 1 Patented T43415 DRUGINFO D05PDI Tetra-cyclic compound 1 Patented T43415 DRUGINFO D0D8MK PMID27774822-Compound-Figure10CompoundA Patented T43415 DRUGINFO D0GH8D PMID27774822-Compound-Figure10Example1 Patented T43415 DRUGINFO D07PTU Imidazo[4,5-c]pyridine derivative 1 Patented T43415 DRUGINFO D09ALF Aminotriazolopyridine derivative 1 Patented T43415 DRUGINFO D0VJ1R Imidazo[4,5-c]pyridine derivative 2 Patented T43415 DRUGINFO D0YR8S PMID27774824-Compound-Figure11Example1up Patented T43415 DRUGINFO D0D5CJ SDZ-LAP-977 Discontinued in Phase 2 T43415 DRUGINFO D06BUI PN-355 Discontinued in Phase 1 T43415 DRUGINFO D06KJG CLX-0301 Terminated T43415 DRUGINFO D0HV6O AP-23588 Terminated T69494 TARGETID T69494 T69494 FORMERID TTDS00135 T69494 TARGNAME N-methyl-D-aspartate receptor (NMDAR) T69494 TARGTYPE Successful T69494 SYNONYMS NMDA-R T69494 DRUGINFO D00ENY L-Glutamic Acid Approved T69494 DRUGINFO D01JEU Memantine Approved T69494 DRUGINFO D02LDN Magnesium Sulfate Approved T69494 DRUGINFO D05KON Felbamate Approved T69494 DRUGINFO D0B8QB Magnesium Approved T69494 DRUGINFO D0D9FV Orphenadrine Approved T69494 DRUGINFO D0O8DI Nitrous oxide Approved T69494 DRUGINFO D0T5UL Benzphetamine Approved T69494 DRUGINFO D0UM7O Ketamine Approved T69494 DRUGINFO D06XWB Huperzine A Approved T69494 DRUGINFO D0T3HY Levorphanol Approved T69494 DRUGINFO D02WFK Cycloserine Approved T69494 DRUGINFO D01YVZ GLYX-13 Phase 3 T69494 DRUGINFO D05JET Remacemide Phase 3 T69494 DRUGINFO D0F1UZ Amitriptyline+ketamine Phase 3 T69494 DRUGINFO D0QNS3 REL-1017 Phase 3 T69494 DRUGINFO D0TP5H Esketamine Phase 3 T69494 DRUGINFO D0Y9RO Dexanabinol Phase 3 T69494 DRUGINFO D3PD8C AXS-05 Phase 3 T69494 DRUGINFO D0M9EV NBTX-001 Phase 2/3 T69494 DRUGINFO D00YLM TRAXOPRODIL MESYLATE Phase 2 T69494 DRUGINFO D01KMR Neramexane Phase 2 T69494 DRUGINFO D03RHZ MDL-27192 Phase 2 T69494 DRUGINFO D03ZLR Apimostinel Phase 2 T69494 DRUGINFO D09BEG CNS-5161 Phase 2 T69494 DRUGINFO D0T9DN Dimiracetam Phase 2 T69494 DRUGINFO D0U0AY AV-101 Phase 2 T69494 DRUGINFO D0U2TZ NYX-2925 Phase 2 T69494 DRUGINFO D12THW AGN-241751 Phase 2 T69494 DRUGINFO D3IK7O NYX-783 Phase 2 T69494 DRUGINFO DB18SE SAGE-718 Phase 2 T69494 DRUGINFO DB8V4Z NYX-458 Phase 2 T69494 DRUGINFO DI54FM SAGE‐718 Phase 2 T69494 DRUGINFO DLG95A NYX-2925 Phase 2 T69494 DRUGINFO DNI61P CP101 Phase 2 T69494 DRUGINFO D0J8RR Dextromethorphan+quinidine Phase 2 T69494 DRUGINFO D04RCT CHF-3381 Phase 2 T69494 DRUGINFO D06YUM AZD6423 Phase 1 T69494 DRUGINFO D0AY8D NBXT-001+Nobilis inhalation device Phase 1 T69494 DRUGINFO D0F9AO BHV-5000 Phase 1 T69494 DRUGINFO D0L1UH ASP-0777 Phase 1 T69494 DRUGINFO D03JRO ADCI Phase 1 T69494 DRUGINFO D0H1FV Selfotel Discontinued in Phase 3 T69494 DRUGINFO D0HK7R Midafotel Discontinued in Phase 3 T69494 DRUGINFO D0G2GT SGS-111 Discontinued in Phase 2 T69494 DRUGINFO D0N4YX EAA-090 Discontinued in Phase 2 T69494 DRUGINFO D0OK9X AZD6765 Discontinued in Phase 2 T69494 DRUGINFO D06DLQ CGP-37849 Discontinued in Phase 1 T69494 DRUGINFO D0MF9H Delucemine Discontinued in Phase 1 T69494 DRUGINFO D0P1YH S-1746 Discontinued in Phase 1 T69494 DRUGINFO D04BXJ ED-1812 Preclinical T69494 DRUGINFO D04MMJ ADX-2 series Preclinical T69494 DRUGINFO D09HDV AD-529 Preclinical T69494 DRUGINFO D00MFY GPI-3000 Terminated T69494 DRUGINFO D02OTH FR-115427 Terminated T69494 DRUGINFO D03HDP ACEA-1416 Terminated T69494 DRUGINFO D03RZU CNS-5788 Terminated T69494 DRUGINFO D04LIR PD-159913 Terminated T69494 DRUGINFO D07GLX CNS-1531 Terminated T69494 DRUGINFO D09OTF ACEA-1031 Terminated T69494 DRUGINFO D0KJ4U ACEA-1011 Terminated T69494 DRUGINFO D0N5YX PD-158473 Terminated T69494 DRUGINFO D0O4JH ACEA-1328 Terminated T69494 DRUGINFO D0Q3SP NPS-1392 Terminated T69494 DRUGINFO D0X6PG LY-274614 Terminated T69494 DRUGINFO D02NVF M-241247 Terminated T69494 DRUGINFO D0S0VZ IDRA-21 Terminated T69494 DRUGINFO D0AZ5V L-698544 Terminated T69494 DRUGINFO D03UNN L-689560 Terminated T69494 DRUGINFO D01HTH Aptiganel HCl Investigative T69494 DRUGINFO D0T6NS ACPC Investigative T99031 TARGETID T99031 T99031 FORMERID TTDC00164 T99031 TARGNAME ERK activator kinase (MEK) T99031 TARGTYPE Successful T99031 SYNONYMS MEK; MAPKK; MAP kinase kinase T99031 DRUGINFO D0C4LF ARRY-162 Approved T99031 DRUGINFO DHM3X5 NFX-179 Phase 2 T99031 DRUGINFO DJ8TN2 HL-085 Phase 1/2 T99031 DRUGINFO D0R3VK GDC-0623 Phase 1 T99031 DRUGINFO DL5UR0 BI 3011441 Phase 1 T99031 DRUGINFO D06EFW RG7304 Phase 1 T99031 DRUGINFO D01GWS Pyridinone compound 1 Patented T99031 DRUGINFO D03WFE Quinazolines and azaquinazoline derivative 1 Patented T99031 DRUGINFO D05VVZ PMID28594589-Compound-TABLE3C2 Patented T99031 DRUGINFO D0A8KL Benzoheterocyclic compound 1 Patented T99031 DRUGINFO D0DB3L Benzoimidazole derivative 1 Patented T99031 DRUGINFO D0J7DA PMID28594589-Compound-TABLE3C12 Patented T99031 DRUGINFO D0K6HD Azetidine derivative 2 Patented T99031 DRUGINFO D0KV2U P-toluenesulfonate derivative 1 Patented T99031 DRUGINFO D0OR2V N-(arylamino)sulfonamide derivative 1 Patented T99031 DRUGINFO D0PK6X Pyridopyrimidine derivative 1 Patented T99031 DRUGINFO D0R8DW Benzoimidazole derivative 2 Patented T99031 DRUGINFO D0UU5N PMID28594589-Compound-TABLE3C14 Patented T99031 DRUGINFO D0V3MX PMID28594589-Compound-TABLE3C1 Patented T15117 TARGETID T15117 T15117 FORMERID TTDNS00566 T15117 TARGNAME Adrenergic receptor (ADR) T15117 TARGTYPE Successful T15117 SYNONYMS Adrenoceptor T15117 BIOCLASS GPCR rhodopsin T15117 DRUGINFO D05ZSB Ovine corticotropin-releasing hormone Approved T15117 DRUGINFO D06REO Befunolol hci Approved T15117 DRUGINFO D07QLG Oxilofrine Approved T15117 DRUGINFO D0AY7K Celiprolol hcl Approved T15117 DRUGINFO D0Q2WS Terbutyline Approved T15117 DRUGINFO D0U3CR Guanadrel Sulfate Approved T15117 DRUGINFO D01FDL Dabelotine Phase 3 T15117 DRUGINFO D0MY3C AR08 Phase 2 T15117 DRUGINFO D0E7FT PMID30124346-Compound-60TABLE5 Patented T15117 DRUGINFO D01MXV Etilefrine Withdrawn from market T15117 DRUGINFO D01DQR AIR-Epinephrine Discontinued in Phase 1 T34743 TARGETID T34743 T34743 FORMERID TTDS00213 T34743 TARGNAME Bacterial Penicillin binding protein (Bact PBP) T34743 TARGTYPE Successful T34743 FUNCTION Cell wall formation. T34743 DRUGINFO D00HWO Cyclacillin Approved T34743 DRUGINFO D00XHD Balofloxacin Approved T34743 DRUGINFO D01BQC Cefonicid Approved T34743 DRUGINFO D01DSP Cephapirin Approved T34743 DRUGINFO D01ZEC Cefacetrile Approved T34743 DRUGINFO D02IIE Penicillin V Potassium Approved T34743 DRUGINFO D02MZY Cefpiramide Approved T34743 DRUGINFO D02TBI Carbenicillin Approved T34743 DRUGINFO D02VFC Cefoxitin Approved T34743 DRUGINFO D04CFW Bacampicillin Approved T34743 DRUGINFO D04KAQ Pivampicillin Approved T34743 DRUGINFO D04KTZ Cloxacillin Approved T34743 DRUGINFO D04ZAH Piperacillin Approved T34743 DRUGINFO D05JDR Ceftibuten Approved T34743 DRUGINFO D06KKS Cefradine Approved T34743 DRUGINFO D06OUL Ceforanide Approved T34743 DRUGINFO D06OVY Cefixime Approved T34743 DRUGINFO D06TQZ Meticillin Approved T34743 DRUGINFO D06YHL Cefamandole Approved T34743 DRUGINFO D07ACT Ceftriaxone Approved T34743 DRUGINFO D07WZH Cephaloglycin Approved T34743 DRUGINFO D08HDY Pivmecillinam Approved T34743 DRUGINFO D08USU Ticarcillin Approved T34743 DRUGINFO D09CPR Penicillin V Approved T34743 DRUGINFO D09KDN Cefazolin Approved T34743 DRUGINFO D0A0JH Nafcillin Approved T34743 DRUGINFO D0A5LH Penicillin G Procaine Approved T34743 DRUGINFO D0AP9T Cefotetan Approved T34743 DRUGINFO D0C2YB Cefoperazone Approved T34743 DRUGINFO D0DT5E Cephalothin Sodium Approved T34743 DRUGINFO D0E3RW Cefditoren Approved T34743 DRUGINFO D0E9WL Loracarbef Approved T34743 DRUGINFO D0K5OT Penicillin G Sodium Approved T34743 DRUGINFO D0MB8I Oxacillin Approved T34743 DRUGINFO D0O5FY Meropenem Approved T34743 DRUGINFO D0PA2N Azlocillin Approved T34743 DRUGINFO D0PH5Z Ceftazidime Approved T34743 DRUGINFO D0PN1F Carbenicillin Indanyl Sodium Approved T34743 DRUGINFO D0PW7C Cefaclor Approved T34743 DRUGINFO D0Q1MS Ertapenem Approved T34743 DRUGINFO D0Q2AT Flucloxacillin Approved T34743 DRUGINFO D0R1BD Penicillin Approved T34743 DRUGINFO D0R2KJ Dicloxacillin Approved T34743 DRUGINFO D0U4YG Penicillin G Benzathine Approved T34743 DRUGINFO D0W6CA Cefpodoxime Approved T34743 DRUGINFO D0W7RJ Hetacillin Approved T34743 DRUGINFO D0WS1X Cefdinir Approved T34743 DRUGINFO D0X9ZC Cefadroxil Approved T34743 DRUGINFO D0Y2IE Cefuroxime Approved T34743 DRUGINFO D0Y7BD Ceftizoxime Approved T34743 DRUGINFO D0YA9Z Ampicillin Approved T34743 DRUGINFO D0YX4S Cefprozil Approved T34743 DRUGINFO D0Z5EM Cephalexin Approved T34743 DRUGINFO D4LOR2 Tebipenem pivoxil Approved T34743 DRUGINFO D0R5RR Clofarabine Approved T34743 DRUGINFO D0O1WX Ciprofloxacin XR Approved T34743 DRUGINFO D03IUD Ceftolozane sulfate Phase 4 T34743 DRUGINFO D08KYQ Sulopenem Phase 3 T34743 DRUGINFO D0CI9T Ceftobiprole Phase 3 T34743 DRUGINFO D0Z1BQ Cefluprenam Phase 3 T34743 DRUGINFO D4H2CP Ceftobiprole medocaril Phase 3 T34743 DRUGINFO D0A5SR Lenapenem hydrochloride hydrate Phase 2 T34743 DRUGINFO DQ18VG BOS-228 Phase 2 T34743 DRUGINFO D07PRC BAL-30072 Phase 1 T34743 DRUGINFO D0H9RD DZ-2640 Phase 1 T34743 DRUGINFO D04KHH CEFCANEL DALOXATE HYDROCHLORIDE Discontinued in Phase 3 T34743 DRUGINFO D0K1QO CEFETECOL Discontinued in Phase 3 T34743 DRUGINFO D0S4LL Sanfetrinem Discontinued in Phase 3 T34743 DRUGINFO D03REC KP-736 Discontinued in Phase 2 T34743 DRUGINFO D07XDS Tomopenem Discontinued in Phase 2 T34743 DRUGINFO D0Q1HG PA-1806 Discontinued in Phase 2 T34743 DRUGINFO D00ROV FK-041 Discontinued in Phase 1 T34743 DRUGINFO D04KXF CEFTRAZONAL BOPENTIL Discontinued in Phase 1 T34743 DRUGINFO D04MDJ Cefdaloxime pentexil tosilate Discontinued in Phase 1 T34743 DRUGINFO D09ANC MC-02,479 Discontinued in Phase 1 T34743 DRUGINFO D0B6SO BRL-44154 Discontinued in Phase 1 T34743 DRUGINFO D0YJ9T DU-6681 Discontinued in Phase 1 T34743 DRUGINFO D0ZA2L ER-35786 Discontinued in Phase 1 T34743 DRUGINFO D00ZZH BK-218 Terminated T34743 DRUGINFO D02SAE Sanfetrinem cilexetil Investigative T34743 DRUGINFO D0I3BL Naphthyridinomycin Investigative T34743 DRUGINFO D0Q7GG Anthramycin Investigative T34743 DRUGINFO D0SK5C RO 244383 Investigative T34743 DRUGINFO D0Y5KQ Cis-[PtCl(NH3)2(N7-acyclovir)]+ Investigative T45993 TARGETID T45993 T45993 FORMERID TTDS00163 T45993 TARGNAME Calcium channel unspecific (CaC) T45993 TARGTYPE Successful T45993 DRUGINFO D0S5CU Nisoldipine Approved T45993 DRUGINFO D0T0KA Nicardipine Approved T45993 DRUGINFO D0WN0U Felodipine Approved T45993 DRUGINFO D0XN1F Nimodipine Approved T45993 DRUGINFO D0Y4JJ Bepridil Approved T45993 DRUGINFO D0Z7KE Isradipine Approved T45993 DRUGINFO D09ELP Clevidipine butyrate Approved T45993 DRUGINFO D06RBJ DIPROTEVERINE HYDROCHLORIDE Phase 3 T45993 DRUGINFO D01MPE S-2150 Phase 2 T45993 DRUGINFO D0N1CH Arverapamil Phase 2 T45993 DRUGINFO D06BUA Nexopamil Phase 2 T45993 DRUGINFO D02SVQ HBI-3000 Phase 2 T45993 DRUGINFO D0N1TH ATI-2042 Phase 2 T45993 DRUGINFO D04MGD Elpetrigine Phase 1 T45993 DRUGINFO D06EDP DSP-0565 Phase 1 T45993 DRUGINFO D0G4ES Tetrandrine Phase 1 T45993 DRUGINFO D0W3JH CM2489 Phase 1 T45993 DRUGINFO D0P9KA YM-16151-4 Phase 1 T45993 DRUGINFO D00KOV Monatepil maleate Discontinued in Preregistration T45993 DRUGINFO D06LDC Palonidipine hydrochloride Discontinued in Preregistration T45993 DRUGINFO D07EGW AE-0047 Discontinued in Preregistration T45993 DRUGINFO D0KT8U Semotiadil Discontinued in Preregistration T45993 DRUGINFO D09ESW Anipamil Discontinued in Phase 3 T45993 DRUGINFO D0G2XN S-12968 Discontinued in Phase 3 T45993 DRUGINFO D0HQ3A ELGODIPINE HYDROCHLORIDE Discontinued in Phase 3 T45993 DRUGINFO D00ECB CD-349 Discontinued in Phase 2 T45993 DRUGINFO D07FNG AM336 Discontinued in Phase 2 T45993 DRUGINFO D0A4OT TAMOLARIZINE HYDROCHLORIDE Discontinued in Phase 2 T45993 DRUGINFO D0B3IC Dopropidil Discontinued in Phase 2 T45993 DRUGINFO D0G0LH S-312-d Discontinued in Phase 2 T45993 DRUGINFO D0LK8O Lifarizine Discontinued in Phase 2 T45993 DRUGINFO D0TX8Z FLOSATIDIL Discontinued in Phase 2 T45993 DRUGINFO D08WSW BRL-32872A Discontinued in Phase 2 T45993 DRUGINFO D0B7HX Levosemotiadil Discontinued in Phase 2 T45993 DRUGINFO D00UCW CEREBROCRAST Discontinued in Phase 1 T45993 DRUGINFO D06HCD SM-6586 Discontinued in Phase 1 T45993 DRUGINFO D06JWO KT-362 Discontinued in Phase 1 T45993 DRUGINFO D07JHJ IGANIDIPINE HYDROCHLORIDE Discontinued in Phase 1 T45993 DRUGINFO D07NTN CERM-11956 Discontinued in Phase 1 T45993 DRUGINFO D08AFD NP-252 Discontinued in Phase 1 T45993 DRUGINFO D0A8ZD SR-33805 Discontinued in Phase 1 T45993 DRUGINFO D06KYU Rycals Preclinical T45993 DRUGINFO D00ICM Naltiazem hydrochloride Terminated T45993 DRUGINFO D00ZWG NS-638 Terminated T45993 DRUGINFO D03SDH Siratiazem Terminated T45993 DRUGINFO D03ZPY SQ-33351 Terminated T45993 DRUGINFO D04LRU AHR-16462B Terminated T45993 DRUGINFO D04MFY AJ-3941 Terminated T45993 DRUGINFO D06BBZ ZM-224832 Terminated T45993 DRUGINFO D07AGR SB-206284A Terminated T45993 DRUGINFO D07SDE Pranidipine Terminated T45993 DRUGINFO D08LLR UK-51656 Terminated T45993 DRUGINFO D08ZAX RS-93522 Terminated T45993 DRUGINFO D08ZZO NS-696 Terminated T45993 DRUGINFO D0B9TX Darodipine Terminated T45993 DRUGINFO D0BX1S CD-832 Terminated T45993 DRUGINFO D0DI3E DHP-218 Terminated T45993 DRUGINFO D0DM5A SIM-6080 Terminated T45993 DRUGINFO D0E6VL RWJ-22108 Terminated T45993 DRUGINFO D0F6GR Clentiazem Terminated T45993 DRUGINFO D0F9KI LAS-30538 Terminated T45993 DRUGINFO D0FF7A Z-6568 Terminated T45993 DRUGINFO D0G7HO NS-649 Terminated T45993 DRUGINFO D0HQ1W SKF-96365 Terminated T45993 DRUGINFO D0KE1V SDZ-249482 Terminated T45993 DRUGINFO D0NH6F VUF-8929 Terminated T45993 DRUGINFO D0R3SI NNC-09-0026 Terminated T45993 DRUGINFO D0UU3J RWJ-37868 Terminated T45993 DRUGINFO D0W6MA E-2050 Terminated T45993 DRUGINFO D05KRC Emopamil Terminated T45993 DRUGINFO D06VXY SB-237376 Terminated T45993 DRUGINFO D0Q6EN AHR-16303B Terminated T45993 DRUGINFO D01BMA BELFOSDIL Investigative T45993 DRUGINFO D01QSU leualacin Investigative T45993 DRUGINFO D0G0EA AGN-190744 Investigative T45993 DRUGINFO D0I0MJ CD-832.HCL Investigative T45993 DRUGINFO D0LN9P TELUDIPINE HYDROCHLORIDE Investigative T45993 DRUGINFO D0V6YT SR-33805A Investigative T99727 TARGETID T99727 T99727 FORMERID TTDI02003 T99727 TARGNAME Hyperpolarization cyclic nucleotide-gated channel (HCN) T99727 TARGTYPE Successful T99727 FUNCTION Hyperpolarization-activated ion channel exhibiting weak selectivity for potassium over sodium ions. Contributes to the native pacemaker currents in heart (If) and in neurons (Ih). May mediate responses to sour stimuli. T99727 BIOCLASS Voltage-gated ion channel T99727 DRUGINFO D0S9QA Ivabradine Approved T99727 DRUGINFO D03YJC SKL-NP Phase 2 T99727 DRUGINFO D06TKE ZD-7288 Phase 2 T99727 DRUGINFO D0PO0B Cilobradine Phase 1 T28925 TARGETID T28925 T28925 FORMERID TTDI01771 T28925 TARGNAME Inosine-5'-monophosphate dehydrogenase (IMPDH) T28925 TARGTYPE Successful T28925 BIOCLASS Short-chain dehydrogenases reductase T28925 DRUGINFO D02ZXM Thioguanine Approved T28925 DRUGINFO D06MRY Enteric-coated mycophenolate sodium Approved T28925 DRUGINFO D05QIS VX-944 Phase 2 T28925 DRUGINFO D00CGU IMS Discontinued in Phase 1 T28925 DRUGINFO D0V7XC R-1518 Discontinued in Phase 1 T28925 DRUGINFO D04WCO EPB-415 Investigative T16422 TARGETID T16422 T16422 FORMERID TTDS00255 T16422 TARGNAME Multidrug resistance protein (MDR) T16422 TARGTYPE Successful T16422 SYNONYMS P-glycoprotein T16422 BIOCLASS ABC transporter T16422 DRUGINFO D02DKD Benzquinamide Approved T16422 DRUGINFO D07SDQ Curcumin Phase 3 T16422 DRUGINFO D09ALR MM36 Phase 2 T16422 DRUGINFO D0YX7E Ortataxel Phase 2 T16422 DRUGINFO D09TGX Valspodar Discontinued in Phase 3 T16422 DRUGINFO D03OPW WK-X-34 Investigative T16422 DRUGINFO D0I8ON KP772 Investigative T16422 DRUGINFO D0P2OZ Chemosensitizers Investigative T09130 TARGETID T09130 T09130 FORMERID TTDI01749 T09130 TARGNAME Muscarinic acetylcholine receptor (CHRM) T09130 TARGTYPE Successful T09130 FUNCTION The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through theaction of G proteins. Primary transducing effect is Pi turnover. T09130 DRUGINFO D09ZOQ Incruse Ellipta Approved T09130 DRUGINFO D0B7YT Scopolamine Approved T09130 DRUGINFO D0K1ST Revefenacin Approved T09130 DRUGINFO D0Q9HF Acetylcholine Approved T09130 DRUGINFO D0R1DH Oxybutynin hydrochloride Approved T09130 DRUGINFO D0Z9PX Isopropamide iodide Approved T09130 DRUGINFO D0P1WA Tiotropium Approved T09130 DRUGINFO D0Q1BT Clidinium Approved T09130 DRUGINFO D0Y5AM Darifenacin Approved T09130 DRUGINFO D0M6VK Methylscopolamine Approved T09130 DRUGINFO D04RNN SUN-101 Phase 3 T09130 DRUGINFO D09FQW THVD-201 Phase 3 T09130 DRUGINFO D04XVE QAX-028 Phase 2 T09130 DRUGINFO D05GNW AZD-9164 Phase 2 T09130 DRUGINFO D08WSG AZD-8683 Phase 2 T09130 DRUGINFO D0KX9B EP-101 Phase 2 T09130 DRUGINFO D0XQ6V APD-515 Phase 2 T09130 DRUGINFO D05OTZ SMP-986 Phase 2 T09130 DRUGINFO D0L9CD AZD-2115 Phase 2 T09130 DRUGINFO D09ZRB PUR0200 Phase 1 T09130 DRUGINFO D0FX4J Telenzepine Discontinued in Preregistration T09130 DRUGINFO D0UX0T Milameline Discontinued in Phase 3 T09130 DRUGINFO D07RUV Terflavoxate Discontinued in Phase 2 T09130 DRUGINFO D02VHE A-72055 Terminated T09130 DRUGINFO D0X3KX U-80816 Terminated T09130 DRUGINFO D00CUZ [3H]pirenzepine Investigative T09130 DRUGINFO D02DPM [3H]dimethyl-W84 Investigative T09130 DRUGINFO D02KZD ML375 Investigative T09130 DRUGINFO D02QQD VU0010010 Investigative T09130 DRUGINFO D03RMI LY2033298 Investigative T09130 DRUGINFO D03XVJ C7/3-phth Investigative T09130 DRUGINFO D04ZSZ DS-AH-14 Investigative T09130 DRUGINFO D09KDI THRX160209 Investigative T09130 DRUGINFO D0A6ZC [11C]butylthio-TZTP Investigative T09130 DRUGINFO D0BM7O Duo3 Investigative T09130 DRUGINFO D0C2DM LY593093 Investigative T09130 DRUGINFO D0F3AN LY2119620 Investigative T09130 DRUGINFO D0FX4W iperoxo Investigative T09130 DRUGINFO D0G8IA Cy3B-telenzepine Investigative T09130 DRUGINFO D0I1EE Alexa-488-telenzepine Investigative T09130 DRUGINFO D0K3HY VU0152100 Investigative T09130 DRUGINFO D0K5ME levetimide Investigative T09130 DRUGINFO D0L5AG VU0029767 Investigative T09130 DRUGINFO D0L5OU [11C]xanomeline Investigative T09130 DRUGINFO D0M0VI BODIPY-pirenzepine Investigative T09130 DRUGINFO D0O0OP [18F](R,R)-quinuclidinyl-4-fluoromethyl-benzilate Investigative T09130 DRUGINFO D0O6BD VU0090157 Investigative T09130 DRUGINFO D0O9KA W-84 Investigative T09130 DRUGINFO D0OY7A RBx-343E48F0 Investigative T09130 DRUGINFO D0Q2VN [3H]4NMPB Investigative T09130 DRUGINFO D0V0OM [18F]FP-TZTP Investigative T09130 DRUGINFO D0WV0Q ML169 Investigative T09130 DRUGINFO D0Y1VB VU0152099 Investigative T09130 DRUGINFO D0Y7RV benzoquinazolinone 12 Investigative T09130 DRUGINFO D0Y9SE KT 5823 Investigative T09130 DRUGINFO D0Z6VT ML380 Investigative T09130 DRUGINFO D0Z9KR WDuo3 Investigative T09130 DRUGINFO D00NRJ silahexocyclium Investigative T09130 DRUGINFO D00WNA ML381 Investigative T09130 DRUGINFO D02BOW McN-A-343 Investigative T09130 DRUGINFO D02IIN WIN 62,577 Investigative T09130 DRUGINFO D02MJE NNC 11-1314 Investigative T09130 DRUGINFO D02UNX VU0255035 Investigative T09130 DRUGINFO D02VGM [3H]QNB Investigative T09130 DRUGINFO D03DMR lithocholylcholine Investigative T09130 DRUGINFO D03LSH UH-AH 37 Investigative T09130 DRUGINFO D05PSD WIN 51,708 Investigative T09130 DRUGINFO D05WXF thiochrome Investigative T09130 DRUGINFO D07CAB NNC 11-1585 Investigative T09130 DRUGINFO D07GPQ tripitramine Investigative T09130 DRUGINFO D07LDP hexahydrosiladifenidol Investigative T09130 DRUGINFO D07OAK Go7874 Investigative T09130 DRUGINFO D08BGK N-chloromethyl-brucine Investigative T09130 DRUGINFO D08KNP N-benzyl brucine Investigative T09130 DRUGINFO D08XBQ NNC 11-1607 Investigative T09130 DRUGINFO D0G4CG [3H]oxotremorine-M Investigative T09130 DRUGINFO D0H2UT brucine Investigative T09130 DRUGINFO D0I9AL guanylpirenzepine Investigative T09130 DRUGINFO D0I9LU arecaidine propargyl ester Investigative T09130 DRUGINFO D0K3VR p-F-HHSiD Investigative T09130 DRUGINFO D0PL0Y furtrethonium Investigative T09130 DRUGINFO D0S4DT vinburnine Investigative T09130 DRUGINFO D0T6ID pentylthio-TZTP Investigative T09130 DRUGINFO D0W8XI hexahydrodifenidol Investigative T09130 DRUGINFO D0WO3A methylfurmethide Investigative T09130 DRUGINFO D0HP1O AF-DX-384 Investigative T23547 TARGETID T23547 T23547 FORMERID TTDS00125 T23547 TARGNAME Opioid receptor (OPR) T23547 TARGTYPE Successful T23547 SYNONYMS Opioid receptor T23547 DRUGINFO D02NSF Oxymorphone Approved T23547 DRUGINFO D04BCW Ketobemidone Approved T23547 DRUGINFO D05VIL Nalmefene Approved T23547 DRUGINFO D09OJQ Methadone Approved T23547 DRUGINFO D0D4PB Dextropropoxyphene Approved T23547 DRUGINFO D0D8DD Sufentanil Approved T23547 DRUGINFO D0PG8O Naltrexone Approved T23547 DRUGINFO D0U9MR Tilidine Approved T23547 DRUGINFO D0W6DG Pentazocine Approved T23547 DRUGINFO D0T3HY Levorphanol Approved T23547 DRUGINFO D0T6RC Dihydrocodeine Phase 4 T23547 DRUGINFO D03YZJ ALO-02 Phase 3 T23547 DRUGINFO D01TMQ Bupropion+naltrexone Phase 3 T23547 DRUGINFO D0K8NR AMG 386 Phase 3 T23547 DRUGINFO D03GVG NP-2 Phase 2 T23547 DRUGINFO D04GLJ OCFENTANIL Phase 2 T23547 DRUGINFO D0D8XG AeroLEF Phase 2 T23547 DRUGINFO D0K2OV Oxytrex Phase 2 T23547 DRUGINFO D0Q3PD S-297995 Phase 2 T23547 DRUGINFO D0R0EF AZD-7268 Phase 2 T23547 DRUGINFO D0RK8U JKB-122 Phase 2 T23547 DRUGINFO D0S6SQ Odelepran Phase 2 T23547 DRUGINFO D0D7MJ CNSB-001 Phase 2 T23547 DRUGINFO D0C8KY SYN-1001 Phase 1 T23547 DRUGINFO D0YN4Y PTI-202 Phase 1 T23547 DRUGINFO D08LIF Propiram fumarate Discontinued in Phase 3 T23547 DRUGINFO D01YLF PTI-701 Discontinued in Phase 2 T23547 DRUGINFO D03KJV Ultramorph Discontinued in Phase 2 T23547 DRUGINFO D0RW4F CereCRIB Discontinued in Phase 2 T23547 DRUGINFO D02JNX OxycoDex Discontinued in Phase 2 T23547 DRUGINFO D06MXY BL-1827 Discontinued in Phase 1 T23547 DRUGINFO D0P6LP CB-01-16 Preclinical T23547 DRUGINFO D07ULK OX-23 Terminated T23547 DRUGINFO D09ENA Org-30035 Terminated T23547 DRUGINFO D0H1TA EK-399 Terminated T23547 DRUGINFO D0Y8GL APF-580 Terminated T23547 DRUGINFO D0H2NH BRIFENTANIL Investigative T23547 DRUGINFO D0L1VT Cyprodine Investigative T31946 TARGETID T31946 T31946 FORMERID TTDR00073 T31946 TARGNAME Vascular endothelial growth factor receptor (VEGFR) T31946 TARGTYPE Successful T31946 BIOCLASS Kinase T31946 DRUGINFO D03JTG Fruquintinib Approved T31946 DRUGINFO D09HNV Intedanib Approved T31946 DRUGINFO D0O9XO KH-902 Phase 3 T31946 DRUGINFO D58JRA ABP 938 Phase 3 T31946 DRUGINFO D05PWX Sulfatinib Phase 3 T31946 DRUGINFO D04OTY BFH-772 Phase 2 T31946 DRUGINFO D0K4CD ASP-8477 Phase 2 T31946 DRUGINFO D8AG3S Vorolanib Phase 2 T31946 DRUGINFO D07NOI BAY-57-9352 Phase 2 T31946 DRUGINFO D0L2ZY X-82 Phase 2 T31946 DRUGINFO D00NSD XL-820 Phase 2 T31946 DRUGINFO D03CGQ AG-013958 Phase 1/2 T31946 DRUGINFO DRF94Z AIV001 Phase 1/2 T31946 DRUGINFO D1TNJ2 XL092 Phase 1 T31946 DRUGINFO D0P0QG HuMV833 Discontinued in Phase 1 T31946 DRUGINFO D08OUU Genevx Terminated T31946 DRUGINFO D0L5YF ZD-4190 Terminated T31946 DRUGINFO D09ZAV RG-8803 Terminated T31946 DRUGINFO D0Y1YX AZD-9935 Terminated T30374 TARGETID T30374 T30374 FORMERID TTDS00023 T30374 TARGNAME Gamma-aminobutyric acid uptake (GABAU) T30374 TARGTYPE Successful T30374 SYNONYMS GABA uptake T30374 DRUGINFO D0ED7U Tiagabine Approved T30374 DRUGINFO D0H5YE NNC 05-2045 Terminated T30374 DRUGINFO D06YXT NNC 711 Investigative T30374 DRUGINFO D0E5ON Cis-4-hydroxynipecotic acid Investigative T30374 DRUGINFO D0M4FW THPO Investigative T30374 DRUGINFO D0D2EF (R)-nipecotic acid Investigative T30374 DRUGINFO D0V7RG 4-substituted 2,4-dioxobutanoic acids Investigative T34867 TARGETID T34867 T34867 TARGNAME Poly [ADP-ribose] polymerase (PARP) T34867 TARGTYPE Successful T34867 SYNONYMS Poly-ADP-ribose polymerase T34867 DRUGINFO D01SHZ Rucaparib Approved T34867 DRUGINFO D0GV8J Talazoparib Approved T34867 DRUGINFO D0J9HW Olaparib Approved T34867 DRUGINFO D00BMF MK-4827 Phase 3 T34867 DRUGINFO D0IK5F BSI-201 Phase 3 T34867 DRUGINFO D0NA8B Rubraca rucaparib Phase 3 T34867 DRUGINFO D0Q7UD ABT-888 Phase 3 T34867 DRUGINFO D0ZY3E INO-1001 Phase 3 T34867 DRUGINFO D06DHB E7016 Phase 2 T34867 DRUGINFO DC23ER AZD9574 Phase 2 T34867 DRUGINFO D08LRV BGP-15 Phase 2 T34867 DRUGINFO D0D9IQ BGB-290 Phase 2 T34867 DRUGINFO D0SZ9R 2X-121 Phase 2 T34867 DRUGINFO D0Q9IK CEP-9722 Phase 1/2 T34867 DRUGINFO D0HH0G ABT-767 Phase 1 T34867 DRUGINFO D0YU1L MP-124 Phase 1 T34867 DRUGINFO D00JAH PMID27841036-Compound-24 Patented T34867 DRUGINFO D01PSK PMID27841036-Compound-23 Patented T34867 DRUGINFO D06UXE PMID27841036-Compound-V Patented T34867 DRUGINFO D06VZX PMID27841036-Compound-38 Patented T34867 DRUGINFO D09OSS Dihydropyrido phthalazinone derivative 4 Patented T34867 DRUGINFO D0A9HR Phthalazine derivative 1 Patented T34867 DRUGINFO D0AE5G Phthalazine derivative 2 Patented T34867 DRUGINFO D0C7HZ PMID27841036-Compound-XI Patented T34867 DRUGINFO D0IL3B PMID27841036-Compound-XVII Patented T34867 DRUGINFO D0IL3C Tetra/penta-cyclic pyridophthalazinone derivative 1 Patented T34867 DRUGINFO D0JA4K PMID27841036-Compound-36 Patented T34867 DRUGINFO D0JY0L 7-azaindole derivative 9 Patented T34867 DRUGINFO D0SS2O Dihydrodiazepinocarbazolone derivative 2 Patented T34867 DRUGINFO D0W8EC Dihydropyrido phthalazinone derivative 3 Patented T34867 DRUGINFO D0YA6M Aza-phenalene-3-ketone derivative 1 Patented T34867 DRUGINFO D0U2WO ONO-2231 Discontinued in Phase 1 T62151 TARGETID T62151 T62151 TARGNAME Monoamine oxidase (MAO) T62151 TARGTYPE Successful T62151 SYNONYMS Human monoamine oxidase T62151 DRUGINFO D02IQY Ergoloid mesylate Approved T62151 DRUGINFO D01ZSO Moclobemide Approved T62151 DRUGINFO D09NYS Methylene blue Approved T62151 DRUGINFO D09QDP Clorgyline Approved T62151 DRUGINFO D0P9AC Phenelzine Approved T62151 DRUGINFO D0R0UJ Pargyline Approved T62151 DRUGINFO D0H0HJ Tranylcypromine Approved T62151 DRUGINFO D0S2UG Selegiline Approved T62151 DRUGINFO D0S7KA (-)-deprenyl Patented T62151 DRUGINFO D02CIX Cyclopropylamine derivative 11 Patented T62151 DRUGINFO D03MPD PMID27019002-Compound-20a Patented T62151 DRUGINFO D04PWX Cyclopropylamine derivative 9 Patented T62151 DRUGINFO D06QRW Lazabemide Patented T62151 DRUGINFO D07DIJ Cyclopropylamine derivative 13 Patented T62151 DRUGINFO D0R2YA Cyclopropylamine derivative 12 Patented T62151 DRUGINFO D0W9VF Cyclopropylamine derivative 10 Patented T62151 DRUGINFO D0WT1Z PMID27019002-Compound-17 Patented T62151 DRUGINFO D0XH9M N-(2-phenylcyclopropyl) amino acid derivative 2 Patented T84726 TARGETID T84726 T84726 TARGNAME Rho-associated protein kinase (ROCK) T84726 TARGTYPE Successful T84726 SYNONYMS Rho-associated, coiled-coil-containing protein kinase; Rho associated protein kinase T84726 DRUGINFO D0B5LF Ximelegatran Approved T84726 DRUGINFO D04WYX Netarsudil Approved T84726 DRUGINFO D0BN7W Roclatan Phase 3 T84726 DRUGINFO D07EJY AR-12286 Phase 2 T84726 DRUGINFO D08MPA AMA-76 Phase 2 T84726 DRUGINFO D0AD4H Cethrin Phase 1/2 T84726 DRUGINFO D0U9LT Y-39983 Phase 1/2 T84726 DRUGINFO D09IYM AT13148 Phase 1 T84726 DRUGINFO D0X6DC STM 434 Phase 1 T84726 DRUGINFO D05OEZ Hexahydro azepinone derivative 1 Patented T84726 DRUGINFO D0FX7I Isoquinoline sulfonyl derivative 2 Patented T84726 DRUGINFO D0IF5M Isoquinoline derivative 4 Patented T84726 DRUGINFO D0N0YE Isoquinoline sulfonamide derivative 2 Patented T84726 DRUGINFO D0OS9O Isoquinoline sulfonamide derivative 1 Patented T84726 DRUGINFO D0P6GJ Isoquinoline sulfonyl derivative 3 Patented T84726 DRUGINFO D0QF4V Isoquinoline derivative 5 Patented T84726 DRUGINFO D0VX0H Isoquinoline sulfonyl derivative 1 Patented T95139 TARGETID T95139 T95139 FORMERID TTDR00070 T95139 TARGNAME Cysteine protease (CYP) T95139 TARGTYPE Successful T95139 DRUGINFO D06HCP MELARSOPROL Approved T95139 DRUGINFO D0D0JU S-hexyl hexane-1-sulfinothioate Investigative T95139 DRUGINFO D0S4EI S-benzyl phenylmethanesulfinothioate Investigative T95139 DRUGINFO D0T0IR S-isopentyl 3-methylbutane-1-sulfinothioate Investigative T95139 DRUGINFO D0V7LZ S-propyl propane-1-sulfinothioate Investigative T95139 DRUGINFO D0X9YD ALLICIN Investigative T95139 DRUGINFO D08TMM K-777 Investigative T95139 DRUGINFO D0M7AU N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi) Investigative T71484 TARGETID T71484 T71484 FORMERID TTDS00300 T71484 TARGNAME Fungal Microtubule (Fung MicroTU) T71484 TARGTYPE Successful T71484 SYNONYMS Keratin T71484 DRUGINFO D0C1SF Griseofulvin Approved T64382 TARGETID T64382 T64382 FORMERID TTDS00018 T64382 TARGNAME Gamma-aminobutyric acid receptor (GAR) T64382 TARGTYPE Successful T64382 DRUGINFO D01XLM Piperazine Approved T64382 DRUGINFO D0CP4E Clonazepam Approved T64382 DRUGINFO D0D9FW DP-VPA Approved T64382 DRUGINFO D0Y7RW Phenobarbital Approved T64382 DRUGINFO D01XOD Alpidem Approved T64382 DRUGINFO D05AWP Moxidectin Approved T64382 DRUGINFO D00VZZ Allopregnanolone approved T64382 DRUGINFO D0IG4I THIOCOLCHICOSIDE Approved T64382 DRUGINFO D0H5HO ANDROSTERONE Phase 3 T64382 DRUGINFO D0VA4Y Phentermine+topiramate Phase 3 T64382 DRUGINFO D07ZCK ZK-93423 Phase 3 T64382 DRUGINFO D03YXI PIKAMILONE Phase 2 T64382 DRUGINFO D0U2DA BNC-210 Phase 2 T64382 DRUGINFO D07TXJ Dextofisopam Phase 2 T64382 DRUGINFO D0L6OA BL-1020 Phase 2 T64382 DRUGINFO D0B7CH Phenylbutyrate Phase 2 T64382 DRUGINFO D0C9XA GSK683699 Phase 2 T64382 DRUGINFO D0B8YZ ELTANOLONE Discontinued in Phase 3 T64382 DRUGINFO D01BBR Dezinamide Discontinued in Phase 2 T64382 DRUGINFO D0U0TD Gedocarnil Discontinued in Phase 1 T64382 DRUGINFO D05EVI U-78875 Discontinued in Phase 1 T64382 DRUGINFO D05CTS C-202 Terminated T64382 DRUGINFO D08BCU U-90042 Terminated T64382 DRUGINFO D0P6CN XR-368 Terminated T64382 DRUGINFO D01BCQ Divaplon Terminated T64382 DRUGINFO D06BFP CGS-17867A Terminated T64382 DRUGINFO D0V4GI CGS-9896 Terminated T64382 DRUGINFO D00EPL Pitrazepine Investigative T64382 DRUGINFO D00PUF 4-Amino-3-hydroxy-butyric acid Investigative T64382 DRUGINFO D01XXZ 6-Ethyl-2-phenyl-chromen-4-one Investigative T64382 DRUGINFO D02IQH 7-Diazonium-naphthalene-1-sulfonic acid anion Investigative T64382 DRUGINFO D02YGZ 5-tert-Butyl-2-(4-fluoro-phenyl)-[1,3]dithiane Investigative T64382 DRUGINFO D04HZW 8-Diazonium-naphthalene-1-sulfonic acid anion Investigative T64382 DRUGINFO D04XOT 2-(3-Hydroxy-phenyl)-6-methyl-chromen-4-one Investigative T64382 DRUGINFO D06PWM Acetic acid 2,6-diisopropyl-phenyl ester Investigative T64382 DRUGINFO D06PZU 2-(2-Amino-phenyl)-6-methyl-chromen-4-one Investigative T64382 DRUGINFO D06UBH ALFAXALONE Investigative T64382 DRUGINFO D07RRZ 2,6-Diisopropyl-4-nitro-phenol Investigative T64382 DRUGINFO D08IEE 3-Hydroxy-piperidine-4-carboxylic acid Investigative T64382 DRUGINFO D08QCQ 4-(5-tert-Butyl-[1,3]dithian-2-yl)-benzonitrile Investigative T64382 DRUGINFO D09CKP 3,3-Dimethyl-dihydro-furan-2-one Investigative T64382 DRUGINFO D09EVY 4-Methyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T64382 DRUGINFO D09MWG ETIOCHOLANOLONE Investigative T64382 DRUGINFO D09RPY Benzoic acid 2,6-diisopropyl-phenyl ester Investigative T64382 DRUGINFO D0E1DB 5-Aminomethyl-4,5-dihydro-isoxazol-3-ol Investigative T64382 DRUGINFO D0E5WS 6-Methyl-2-p-tolyl-chromen-4-one Investigative T64382 DRUGINFO D0E6TO 2-(3-Butoxy-phenyl)-6-methyl-chromen-4-one Investigative T64382 DRUGINFO D0E8IH 2-(2-Methoxy-phenyl)-6-methyl-chromen-4-one Investigative T64382 DRUGINFO D0EQ8X 2-Phenyl-6-propyl-chromen-4-one Investigative T64382 DRUGINFO D0ER1D 2-(3-Methoxy-phenyl)-6-methyl-chromen-4-one Investigative T64382 DRUGINFO D0F8QJ WEDELOLACTONE Investigative T64382 DRUGINFO D0G8XR 4-Iodo-2,6-diisopropyl-phenol Investigative T64382 DRUGINFO D0GG7Z AFLATREME Investigative T64382 DRUGINFO D0H1VB 5-tert-Butyl-2-(4-ethynyl-phenyl)-[1,3]dithiane Investigative T64382 DRUGINFO D0IM4E 2-(3-Amino-phenyl)-6-methyl-chromen-4-one Investigative T64382 DRUGINFO D0J5TL 4-Ethyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T64382 DRUGINFO D0L1BW SR95531 Investigative T64382 DRUGINFO D0L4AR 2-(4-Amino-phenyl)-6-methyl-chromen-4-one Investigative T64382 DRUGINFO D0L8CX 4-Bromo-2,6-diisopropyl-phenol Investigative T64382 DRUGINFO D0NW7F 2-(3-Bromo-phenyl)-6-methyl-chromen-4-one Investigative T64382 DRUGINFO D0O1OZ BRL-54504AX Investigative T64382 DRUGINFO D0O4IM (R)-4-amino-2-methylbutanoic acid Investigative T64382 DRUGINFO D0P3CX 6-Methyl-2-phenyl-chromen-4-one Investigative T64382 DRUGINFO D0R7QZ 2-(2-Hydroxy-phenyl)-6-methyl-chromen-4-one Investigative T64382 DRUGINFO D0U1PE 6-Isopropyl-2-phenyl-chromen-4-one Investigative T64382 DRUGINFO D0U2XR 4-Hydroxy-3,5-diisopropyl-benzaldehyde Investigative T64382 DRUGINFO D0U6FH 4-Chloro-2,6-diisopropyl-phenol Investigative T64382 DRUGINFO D0VG9P 4-Dimethylamino-2,6-diisopropyl-phenol Investigative T64382 DRUGINFO D0Y5KJ 6-Methyl-2-pyridin-3-yl-chromen-4-one Investigative T64382 DRUGINFO D0Y6MY Toluene-1-diazonium-3-sulfonic acid anion Investigative T64382 DRUGINFO D00ASA 2-(3-Chloro-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D00LBX Bicuculline Investigative T64382 DRUGINFO D02ANG (2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid Investigative T64382 DRUGINFO D02CHG 6-Chloro-2-phenyl-chromen-4-one Investigative T64382 DRUGINFO D02HEK 1-(9H-beta-Carbolin-3-yl)-ethanone Investigative T64382 DRUGINFO D02HRB RWJ-16979 Investigative T64382 DRUGINFO D02LLU 2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one Investigative T64382 DRUGINFO D02ONZ 6-Bromo-2-(4-nitro-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D03EQH RIPAZEPAM Investigative T64382 DRUGINFO D03NWH 2-(3-Bromo-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D04JTK (6-Benzylamino-9H-beta-carbolin-3-yl)-methanol Investigative T64382 DRUGINFO D04JUH NSC-73613 Investigative T64382 DRUGINFO D04UUT 2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one Investigative T64382 DRUGINFO D04WIA 2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one Investigative T64382 DRUGINFO D04YHZ 3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium Investigative T64382 DRUGINFO D05AEG N-(9H-beta-Carbolin-3-yl)-acetamide Investigative T64382 DRUGINFO D05LXP 7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene Investigative T64382 DRUGINFO D05WZL ((E)-3-Amino-propenyl)-methyl-phosphinic acid Investigative T64382 DRUGINFO D05YQE 3-(2,2-Dimethyl-propoxy)-9H-beta-carboline Investigative T64382 DRUGINFO D06BNI (9H-beta-Carbolin-3-yl)-methanol Investigative T64382 DRUGINFO D06DTT RO-054520 Investigative T64382 DRUGINFO D06JBP Benzyl-(9H-beta-carbolin-6-yl)-amine Investigative T64382 DRUGINFO D07CUW 6-Bromo-2-(3-nitro-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D07LCC 4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline Investigative T64382 DRUGINFO D07MRF 3-Nitro-9H-beta-carboline Investigative T64382 DRUGINFO D08LJJ 6-Bromo-2-(2-nitro-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D09NNI 3-Methoxy-9H-beta-carboline Investigative T64382 DRUGINFO D09PKJ 2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline Investigative T64382 DRUGINFO D0A4UQ 6-Bromo-2-(3-bromo-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D0A6AX (9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester Investigative T64382 DRUGINFO D0AU7Y 2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one Investigative T64382 DRUGINFO D0C5XB NSC-93394 Investigative T64382 DRUGINFO D0C8CR 9H-beta-Carbolin-6-ylamine Investigative T64382 DRUGINFO D0D2NV Pyrrolidin-3-yl-acetic acid Investigative T64382 DRUGINFO D0F8AP 9H-beta-Carbolin-3-ol Investigative T64382 DRUGINFO D0K6WD (9H-beta-Carbolin-3-yl)-ethyl-amine Investigative T64382 DRUGINFO D0N4EZ 3-ammoniopropane-1-sulfinate Investigative T64382 DRUGINFO D0N9DG 3-Isopropoxy-9H-beta-carboline Investigative T64382 DRUGINFO D0O4MK 3-Chloro-9H-beta-carboline Investigative T64382 DRUGINFO D0P2DB 7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene Investigative T64382 DRUGINFO D0Q6CJ 2-(3-Bromo-phenyl)-6-nitro-chromen-4-one Investigative T64382 DRUGINFO D0R2ES 2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline Investigative T64382 DRUGINFO D0R2HJ Isoquinoline-3-carboxylic acid methyl ester Investigative T64382 DRUGINFO D0R6FJ NORHARMANE Investigative T64382 DRUGINFO D0S4RQ 3-sec-Butoxy-9H-beta-carboline Investigative T64382 DRUGINFO D0S6GS 6-Bromo-2-phenyl-chromen-4-one Investigative T64382 DRUGINFO D0T4ZI 6-Chloro-2-(3-nitro-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D0V4AR 2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline Investigative T64382 DRUGINFO D0W3FQ 6-Nitro-2-phenyl-chromen-4-one Investigative T64382 DRUGINFO D0W7ND 2-Phenyl-3H-imidazo[4,5-c]quinoline Investigative T64382 DRUGINFO D0W9WW 6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D0X2CC 1-(9H-beta-Carbolin-3-yl)-butan-1-one Investigative T64382 DRUGINFO D0Z8IJ Muscimol Investigative T64382 DRUGINFO D0ZJ5V N-(9H-beta-Carbolin-3-yl)-formamide Investigative T64382 DRUGINFO D00OAN 9H-beta-Carboline-3-carboxylic acid propyl ester Investigative T64382 DRUGINFO D00SXO 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one Investigative T64382 DRUGINFO D01BVR 5-(4-piperidyl)-4-propylisothiazol-3-ol Investigative T64382 DRUGINFO D06QOX 1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one Investigative T64382 DRUGINFO D06ZOM 3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one Investigative T64382 DRUGINFO D07BIF [3H]CGP27492 Investigative T64382 DRUGINFO D09AVL 4-benzyl-5-(4-piperidyl)isothiazol-3-ol Investigative T64382 DRUGINFO D09TTI 2,4-Diamino-butyric acid(GABA) Investigative T64382 DRUGINFO D0D6IU 2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide Investigative T64382 DRUGINFO D0J9SS 6-Nitro-2-(3-nitro-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D0JV5L 4-Methyl-5-(4-piperidyl)isothiazol-3-ol Investigative T64382 DRUGINFO D0KS2X CGS-9895 Investigative T64382 DRUGINFO D0P3FZ 5-(piperidin-4-yl)isothiazol-3-ol Investigative T64382 DRUGINFO D0S9YE (beta-CCE)9H-beta-Carboline-3-carboxylic acid Investigative T64382 DRUGINFO D0V2LK 6-Nitro-2-(4-nitro-phenyl)-chromen-4-one Investigative T64382 DRUGINFO D00CQR 6-Methyl-2-oxa-spiro[4.4]nonan-1-one Investigative T64382 DRUGINFO D00VWR 3,3-Diethyl-dihydro-furan-2-one Investigative T64382 DRUGINFO D00WON 3-Ethyl-3-methyl-dihydro-furan-2-one Investigative T64382 DRUGINFO D01OZS 3,3-Diisopropyl-dihydro-furan-2-one Investigative T64382 DRUGINFO D01PPZ Ridine-5-carboxylic acid ethyl ester Investigative T64382 DRUGINFO D01UZT 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole Investigative T64382 DRUGINFO D02FXS 3-carboxy-6-ethyl-4-quinolone Investigative T64382 DRUGINFO D02RUV 3-Isopropyl-3-methyl-dihydro-furan-2-one Investigative T64382 DRUGINFO D02XXK (9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine Investigative T64382 DRUGINFO D03CKN 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone Investigative T64382 DRUGINFO D03EOK N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide Investigative T64382 DRUGINFO D03FBS 6-ethyl-3-propoxycarbonyl-4-quinolone Investigative T64382 DRUGINFO D03OEN N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide Investigative T64382 DRUGINFO D03OQG 1-Methyl-5-oxa-spiro[2.4]heptan-4-one Investigative T64382 DRUGINFO D03YLX 3-Methyl-9H-beta-carboline Investigative T64382 DRUGINFO D04EOV 3-ethoxycarbonyl-6-propyl-4-quinolone Investigative T64382 DRUGINFO D05OOA 6-ethyl-3-pentoxycarbonyl-4-quinolone Investigative T64382 DRUGINFO D05SVA 5-(piperidin-4-yl)isoxazol-3-ol Investigative T64382 DRUGINFO D05TVT 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone Investigative T64382 DRUGINFO D06EUJ 3-butoxycarbonyl-4-quinolone Investigative T64382 DRUGINFO D06GAI 1-(4-chlorophenyl)-4-phenyl-1H-imidazole Investigative T64382 DRUGINFO D06OSB 6-ethyl-3-i-propoxycarbonyl-4-quinolone Investigative T64382 DRUGINFO D07OON 3-Ethyl-3-isopropyl-dihydro-furan-2-one Investigative T64382 DRUGINFO D07QGN CGS-13767 Investigative T64382 DRUGINFO D08AID 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone Investigative T64382 DRUGINFO D08HGK N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide Investigative T64382 DRUGINFO D09AYK 3-ethoxycarbonyl-4-quinolone Investigative T64382 DRUGINFO D09CQO 2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline Investigative T64382 DRUGINFO D09RWW 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone Investigative T64382 DRUGINFO D0AR4P 2-(9-Benzyl-9H-purin-6-ylamino)-ethanol Investigative T64382 DRUGINFO D0B4CQ 6-benzyl-3-propylaminocarbonyl-4-quinolone Investigative T64382 DRUGINFO D0B4WR 2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline Investigative T64382 DRUGINFO D0CR6M 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone Investigative T64382 DRUGINFO D0D2PJ GNF-PF-4421 Investigative T64382 DRUGINFO D0ER0L 4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T64382 DRUGINFO D0FQ2N 3-Isothiocyanato-9H-beta-carboline Investigative T64382 DRUGINFO D0FR4S 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol Investigative T64382 DRUGINFO D0G6IG 3-butoxycarbonyl-6-ethyl-4-quinolone Investigative T64382 DRUGINFO D0H0DP 3-amino-3-demethoxythiocolchicine Investigative T64382 DRUGINFO D0H0NE 6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one Investigative T64382 DRUGINFO D0I4HT 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol Investigative T64382 DRUGINFO D0J0CA BETA-CCM Investigative T64382 DRUGINFO D0J9VP 3-tert-Butyl-3-ethyl-dihydro-furan-2-one Investigative T64382 DRUGINFO D0K2CZ 1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one Investigative T64382 DRUGINFO D0KS3X U-89267 Investigative T64382 DRUGINFO D0L2KB RO-145974 Investigative T64382 DRUGINFO D0M0ZX 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone Investigative T64382 DRUGINFO D0M2AY 6-ethyl-3-propylaminocarbonyl-4-quinolone Investigative T64382 DRUGINFO D0O9SG 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one Investigative T64382 DRUGINFO D0Q8UV RO-145975 Investigative T64382 DRUGINFO D0R1IL 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol Investigative T64382 DRUGINFO D0S6ME 6-benzyl-3-propoxycarbonyl-4-quinolone Investigative T64382 DRUGINFO D0TJ2L RO-147437 Investigative T64382 DRUGINFO D0U9ET 6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one Investigative T64382 DRUGINFO D0UQ6J RO-194603 Investigative T64382 DRUGINFO D0W5IP GNF-PF-3645 Investigative T64382 DRUGINFO D0WC5L 3-butylaminocarbonyl-6-ethyl-4-quinolone Investigative T64382 DRUGINFO D0X4OW 2-Oxa-spiro[4.4]nonan-1-one Investigative T64382 DRUGINFO D0YS9E 4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol Investigative T64382 DRUGINFO D01UAS 6-bromo-3-ethoxycarbonyl-4-quinolone Investigative T64382 DRUGINFO D02CZO 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone Investigative T64382 DRUGINFO D03LMR 6-benzyl-3-ethoxycarbonyl-4-quinolone Investigative T64382 DRUGINFO D0H4GQ RY-066 Investigative T64382 DRUGINFO D0RF2M NIPECOTIC ACID Investigative T64382 DRUGINFO D01CUR 3-Ethoxy-9H-beta-carboline Investigative T64382 DRUGINFO D01RLF 9H-beta-Carboline-3-carboxylic acid ethyl ester Investigative T64382 DRUGINFO D03PPZ Beta-Carboline-3-carboxylic acid t-butyl ester Investigative T64382 DRUGINFO D04RVA 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine Investigative T64382 DRUGINFO D06WMM 3-Butoxy-9H-beta-carboline Investigative T64382 DRUGINFO D06XGL 3-demethoxy-3-D-xylopyranosylaminothiocolchicine Investigative T64382 DRUGINFO D08BOP 3-Propoxy-9H-beta-carboline Investigative T64382 DRUGINFO D08BXK 3-(3-Methyl-butoxy)-9H-beta-carboline Investigative T64382 DRUGINFO D08YLW 3-demethoxy-3-L-fucopyranosylaminothiocolchicine Investigative T64382 DRUGINFO D09MHS 3-demethoxy-3D-glucopyranosylaminothiocolchicine Investigative T64382 DRUGINFO D09MYJ 3-Isobutoxy-9H-beta-carboline Investigative T64382 DRUGINFO D0C6WO Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate Investigative T64382 DRUGINFO D0D4MM Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate Investigative T64382 DRUGINFO D0E7PY Ro-4938581 Investigative T64382 DRUGINFO D0LP2K 3-demethoxy-3-D-mannopyranosylaminothiocolchicine Investigative T64382 DRUGINFO D0O9MG L-655708 Investigative T64382 DRUGINFO D0P3BU 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole Investigative T64382 DRUGINFO D0R5OU 3-(benzyloxy)-9H-pyrido[3,4-b]indole Investigative T64382 DRUGINFO D01IHM CI-218872 Investigative T64382 DRUGINFO D07NKO 5-[(1R)-1-ammonioethyl]isoxazol-3-olate Investigative T64382 DRUGINFO D09ACO (2E,4S)-4-ammoniopent-2-enoate Investigative T64382 DRUGINFO D0A8EU (4R)-4-ammoniopentanoate Investigative T64382 DRUGINFO D0N0ZK (4S)-4-ammoniopentanoate Investigative T64382 DRUGINFO D0S0RK flavone Investigative T64382 DRUGINFO D0S5PS 5-[(1S)-1-ammonioethyl]isoxazol-3-olate Investigative T64382 DRUGINFO D00WHO Ro-15-3505 Investigative T64382 DRUGINFO D0AC2H isonipecotic acid Investigative T64382 DRUGINFO D0M4CP [3H]Ro154513 Investigative T64382 DRUGINFO D0M9RM [3H]CGS8216 Investigative T64382 DRUGINFO D06HRX AMENTOFLAVONE Investigative T48940 TARGETID T48940 T48940 TARGNAME HIF-prolyl hydroxylase (HPH) T48940 TARGTYPE Successful T48940 DRUGINFO D07GRH Ciclopirox Approved T48940 DRUGINFO D07KEH AKB-6548 Phase 3 T48940 DRUGINFO D0B8WU JTZ-951 Phase 3 T48940 DRUGINFO D32XRQ BAY 853934 Phase 3 T48940 DRUGINFO D0N6CS FG-2216 Phase 2 T48940 DRUGINFO D0E6VR DS-1093 Phase 1 T48940 DRUGINFO DE8OJ0 ZYAN1 Phase 1 T48940 DRUGINFO D6VLX2 JNJ-42905343 Preclinical T81905 TARGETID T81905 T81905 FORMERID TTDS00085 T81905 TARGNAME Histamine receptor (HR) T81905 TARGTYPE Successful T81905 BIOCLASS GPCR rhodopsin T81905 DRUGINFO D0EN0G Histamine Phosphate Approved T81905 DRUGINFO D0O6KE Repirinast Approved T81905 DRUGINFO D0L2JM Levomequitazine Phase 3 T81905 DRUGINFO D00EGN ETX-9101 Phase 2 T81905 DRUGINFO D01KNY LCB-2183 Phase 2 T81905 DRUGINFO D02JZJ ETS-6218 Phase 2 T81905 DRUGINFO D09ZMV Votucalis Phase 2 T81905 DRUGINFO D0L8ZX OX-NLA Discontinued in Phase 3 T81905 DRUGINFO D0R6RM CP-118 Discontinued in Phase 2 T81905 DRUGINFO D0X9PW Tesmilifene Discontinued in Phase 2 T81905 DRUGINFO D0H6VG KF-15766 Terminated T81905 DRUGINFO D00TRL REV-598 Terminated T93662 TARGETID T93662 T93662 FORMERID TTDI02275 T93662 TARGNAME Hyaluronidase (HYAL) T93662 TARGTYPE Successful T93662 BIOCLASS Glycosylase T93662 DRUGINFO D00JRA Asenapine Approved T93662 DRUGINFO D0IP9E Hyqvia Approved T93662 DRUGINFO D05INV PEGPH20 Phase 2 T93662 DRUGINFO D0L5IA PEGylated hyaluronidase (human recombinant) Phase 1/2 T99905 TARGETID T99905 T99905 FORMERID TTDI01883 T99905 TARGNAME Immunoglobulin G (IgG) T99905 TARGTYPE Successful T99905 BIOCLASS Immunoglobulin T67952 TARGETID T67952 T67952 FORMERID TTDR00174 T67952 TARGNAME Potassium channel unspecific (KC) T67952 TARGTYPE Successful T67952 DRUGINFO D02KMO Pinacidil Approved T67952 DRUGINFO D02MLW Ibutilide Approved T67952 DRUGINFO D06PSS Nateglinide Approved T67952 DRUGINFO D07WEP Diazoxide Approved T67952 DRUGINFO D08YIN Dalfampridine Approved T67952 DRUGINFO D0HE0Y Amifampridine Approved T67952 DRUGINFO D0L5WM Amiodarone Approved T67952 DRUGINFO D0NW3X Dofetilide Approved T67952 DRUGINFO D0Y2CJ Minoxidil Approved T67952 DRUGINFO D05CPV Dronedarone Approved T67952 DRUGINFO D08PGC Andolast Phase 3 T67952 DRUGINFO D0J6II Azimilide Phase 3 T67952 DRUGINFO D01ISE Bimakalim Phase 2 T67952 DRUGINFO D03OGQ AZD-7009 Phase 2 T67952 DRUGINFO D05RZW YM-934 Phase 2 T67952 DRUGINFO D09KYR RP-49356 Phase 2 T67952 DRUGINFO D0MT1Q K-201 Phase 2 T67952 DRUGINFO D0Q5BU MSH-1001 Phase 2 T67952 DRUGINFO D02SVQ HBI-3000 Phase 2 T67952 DRUGINFO D0N1TH ATI-2042 Phase 2 T67952 DRUGINFO D07LWK AVE0118 Phase 1 T67952 DRUGINFO D08LLM NS-8 Phase 1 T67952 DRUGINFO D09BZY Nibentan Phase 1 T67952 DRUGINFO D0GU4Z CLP-1004 Phase 1 T67952 DRUGINFO D0J0RG UK-66914 Phase 1 T67952 DRUGINFO D0S1BN Iptakalim Phase 1 T67952 DRUGINFO D08DKA Levcromakalim Discontinued in Preregistration T67952 DRUGINFO D03LQQ Alinidine Discontinued in Phase 3 T67952 DRUGINFO D0S6QR BMS-204352 Discontinued in Phase 3 T67952 DRUGINFO D0Z0CH Almokalant Discontinued in Phase 3 T67952 DRUGINFO D04BQR Acecainide Discontinued in Phase 3 T67952 DRUGINFO D00LWF P-1075 Discontinued in Phase 2 T67952 DRUGINFO D03NDI KCO-912 Discontinued in Phase 2 T67952 DRUGINFO D06QHT Risotilide Discontinued in Phase 2 T67952 DRUGINFO D08HFA Y-27152 Discontinued in Phase 2 T67952 DRUGINFO D08PIJ JTV-506 Discontinued in Phase 2 T67952 DRUGINFO D08WCU BMS-180448 Discontinued in Phase 2 T67952 DRUGINFO D0E2PX E-4031 Discontinued in Phase 2 T67952 DRUGINFO D0GT4N BRL-55834 Discontinued in Phase 2 T67952 DRUGINFO D0I3BB KW-7158 Discontinued in Phase 2 T67952 DRUGINFO D0NF0Q ZD-0947 Discontinued in Phase 2 T67952 DRUGINFO D0X7HV ZD-6169 Discontinued in Phase 2 T67952 DRUGINFO D0ZF1D Ambasilide Discontinued in Phase 2 T67952 DRUGINFO D08WSW BRL-32872A Discontinued in Phase 2 T67952 DRUGINFO D00LCT Symakalim Discontinued in Phase 1 T67952 DRUGINFO D01KHX Rilmakalim Discontinued in Phase 1 T67952 DRUGINFO D0B6ER Ro-31-6930 Discontinued in Phase 1 T67952 DRUGINFO D0LG4V SR-47063 Discontinued in Phase 1 T67952 DRUGINFO D0N0KR Emakalim Discontinued in Phase 1 T67952 DRUGINFO D0O1UC NTC-801 Discontinued in Phase 1 T67952 DRUGINFO D0U8IJ SDZ-PCO-400 Discontinued in Phase 1 T67952 DRUGINFO D0V8RY KR-30450 Discontinued in Phase 1 T67952 DRUGINFO D01BQJ TCV-295 Terminated T67952 DRUGINFO D01SEO ICI-181037 Terminated T67952 DRUGINFO D03BVH AWD-23-111 Terminated T67952 DRUGINFO D03WUH YM-099 Terminated T67952 DRUGINFO D04WWG S-1389 Terminated T67952 DRUGINFO D06IVH Org-20781 Terminated T67952 DRUGINFO D06MLZ WAY-123223 Terminated T67952 DRUGINFO D07JOS NS-004 Terminated T67952 DRUGINFO D09BWC E-4080 Terminated T67952 DRUGINFO D0B7ND UR-8225 Terminated T67952 DRUGINFO D0C8DC Ki-1769 Terminated T67952 DRUGINFO D0E6OA TERIKALANT Terminated T67952 DRUGINFO D0OY1V NS-1608 Terminated T67952 DRUGINFO D0Q7WW UR-8328 Terminated T67952 DRUGINFO D0R7UK UR-8308 Terminated T67952 DRUGINFO D0TB1X AL-0671 Terminated T67952 DRUGINFO D0U5GI RP-66784 Terminated T67952 DRUGINFO D0V4UR NS-1546 Terminated T67952 DRUGINFO D0X9FO KC-399 Terminated T67952 DRUGINFO D06VXY SB-237376 Terminated T67952 DRUGINFO D00MIG MJ-451 Investigative T67952 DRUGINFO D01UUW Trecetilide fumarate Investigative T67952 DRUGINFO D03EBZ HMR1883 Investigative T67952 DRUGINFO D05GPX Y-26763 Investigative T67952 DRUGINFO D07SYP L 691121 Investigative T67952 DRUGINFO D0J0KR RP-66471 Investigative T67952 DRUGINFO D0UZ5N WAY-125971 Investigative T67952 DRUGINFO D0XL9W CGS-7181 Investigative T20297 TARGETID T20297 T20297 FORMERID TTDR01271 T20297 TARGNAME Serine protease unspecific (SP) T20297 TARGTYPE Successful T20297 DRUGINFO D05PHH Gabexate Approved T20297 DRUGINFO D08XYX Aprotinin Approved T20297 DRUGINFO D07XHO Nafamostat Approved T20297 DRUGINFO D05QHL Sivelestat sodium hydrate Phase 4 T20297 DRUGINFO D0O2XW VT-111a Phase 2 T20297 DRUGINFO D0Y6SQ Camostat Phase 2 T20297 DRUGINFO D0N7WR Sepimostat mesylate Discontinued in Phase 3 T20297 DRUGINFO D0V9ME VT-111 Preclinical T20297 DRUGINFO D0B6QO NPI-1999 Terminated T20297 DRUGINFO D0C0EX SDZ-MTH-958 Terminated T60345 TARGETID T60345 T60345 TARGNAME T-cell surface glycoprotein CD3 (CD3) T60345 TARGTYPE Successful T60345 SYNONYMS Cluster of differentiation 3 T60345 DRUGINFO D0VH4V Teplizumab Approved T60345 DRUGINFO D0K4RK Blinatumomab Approved T60345 DRUGINFO D2HDB8 Mosunetuzumab Approved T60345 DRUGINFO D3KO5Y Elranatamab Approved T60345 DRUGINFO DB4M9J Epcoritamab Approved T60345 DRUGINFO DKF7G0 Glofitamab Approved T60345 DRUGINFO DXR1A6 Talquetamab Approved T60345 DRUGINFO D0O2VZ Otelixizumab Phase 2 T60345 DRUGINFO DDIO36 Odronextamab Phase 2 T60345 DRUGINFO DHN9I5 TAK-280 Phase 2 T60345 DRUGINFO DI57MF Nivatrotamab Phase 2 T60345 DRUGINFO DLM8G6 Plamotamab Phase 2 T60345 DRUGINFO DRH03S Tarlatamab Phase 2 T60345 DRUGINFO D0LA9K REGN4018 Phase 1/2 T60345 DRUGINFO D5MV0R Acapatamab Phase 1/2 T60345 DRUGINFO D6L5YT REGN4336 Phase 1/2 T60345 DRUGINFO D9OMQ3 GEN3013 Phase 1/2 T60345 DRUGINFO DE0L6O ISB 1342 Phase 1/2 T60345 DRUGINFO DL1FG3 SAR440234 Phase 1/2 T60345 DRUGINFO DNC79U ISB 1302 Phase 1/2 T60345 DRUGINFO DR7Q5N REGN5458 Phase 1/2 T60345 DRUGINFO DY9G1D REGN5459 Phase 1/2 T60345 DRUGINFO D7QHV6 ABBV-184 Phase 1 T60345 DRUGINFO D00JDL MGD006 Phase 1 T60345 DRUGINFO D0DBS7 GBR1302 Phase 1 T60345 DRUGINFO D0NQ1S JNJ-78278343 Phase 1 T60345 DRUGINFO D0TW3L CD20Bi aATC Phase 1 T60345 DRUGINFO D2GY5C APVO436 Phase 1 T60345 DRUGINFO D2Q3VY Tepoditamab Phase 1 T60345 DRUGINFO D3FYE1 M802 Phase 1 T60345 DRUGINFO D6RT9L RG6234 Phase 1 T60345 DRUGINFO D73FNL CX-904 Phase 1 T60345 DRUGINFO D7FPZ4 A-337 Phase 1 T60345 DRUGINFO D7IA0N AMG 757 Phase 1 T60345 DRUGINFO D7LN0E TNB-486 Phase 1 T60345 DRUGINFO D7WMF3 PF-07260437 Phase 1 T60345 DRUGINFO D81YIK WVT078 Phase 1 T60345 DRUGINFO D8AOC1 AMG 330 Phase 1 T60345 DRUGINFO D91CMX AMG 427 Phase 1 T60345 DRUGINFO D9TG4H JNJ-63709178 Phase 1 T60345 DRUGINFO DEDP81 AMG 910 Phase 1 T60345 DRUGINFO DEP3Z8 AMG 199 Phase 1 T60345 DRUGINFO DF43EH AMG 701 Phase 1 T60345 DRUGINFO DF8X5N RG6156 Phase 1 T60345 DRUGINFO DH7ZV4 JNJ-75348780 Phase 1 T60345 DRUGINFO DHWF68 RG6007 Phase 1 T60345 DRUGINFO DK87UQ PF-07062119 Phase 1 T60345 DRUGINFO DKX1U6 AMG 340 Phase 1 T60345 DRUGINFO DLY65X AMG 424 Phase 1 T60345 DRUGINFO DN91RC IGM-2323 Phase 1 T60345 DRUGINFO DNS2P1 AMG 673 Phase 1 T60345 DRUGINFO DOJ6E8 AMG 596 Phase 1 T60345 DRUGINFO DOY4E6 AMG 160 Phase 1 T60345 DRUGINFO DQ15HJ GEN1044 Phase 1 T60345 DRUGINFO DQD1T2 GEM333 Phase 1 T60345 DRUGINFO DRI97M MGD014 Phase 1 T60345 DRUGINFO DTQL30 ASP2138 Phase 1 T60345 DRUGINFO DVOB28 AFM11 Phase 1 T60345 DRUGINFO DW1H9O TNB-383B Phase 1 T60345 DRUGINFO DY4X5W CCW702 Phase 1 T60345 DRUGINFO D2L9MD RG6524 Phase 1 T60345 DRUGINFO DBP9Q5 SAR442257 Phase 1 T60345 DRUGINFO DL6F3E SAR443216 Phase 1 T60345 DRUGINFO DCUQ32 Runimotamab Phase 1 T60345 DRUGINFO DCUQ32 Runimotamab Phase 1 T60345 DRUGINFO DNUS02 IM1240 Preclinical T04394 TARGETID T04394 T04394 FORMERID TTDR00370 T04394 TARGNAME Vasopressin receptor (VR) T04394 TARGTYPE Successful T04394 SYNONYMS Human vasopressin receptor T04394 DRUGINFO D0U7SH Desmopressin Approved T04394 DRUGINFO D00XVE BR6819 Phase 1 T04394 DRUGINFO D0N6ZP SKF-105494 Phase 1 T04394 DRUGINFO D0U7NG BAY 86-8050 Phase 1 T04394 DRUGINFO D06QJE F-992 Terminated T29999 TARGETID T29999 T29999 FORMERID TTDR00176 T29999 TARGNAME Vasopressin V1 receptor (V1R) T29999 TARGTYPE Successful T29999 SYNONYMS Vasopressin receptor 1; ADH V1 receptor T29999 DRUGINFO D09PZZ Lypressin Approved T29999 DRUGINFO D03GET Menadione Approved T29999 DRUGINFO D0F4NS Mozavaptan Approved T29999 DRUGINFO D08ORO OPC-21268 Discontinued in Phase 2 T62945 TARGETID T62945 T62945 FORMERID TTDI01618 T62945 TARGNAME Voltage-gated calcium channel (Cav) T62945 TARGTYPE Successful T62945 BIOCLASS Voltage-gated ion channel T62945 DRUGINFO D0X0WU Tolperisone Approved T62945 DRUGINFO D0P8TS Eperisone Phase 3 T62945 DRUGINFO D07HYR GCC-1290K Phase 1 T72065 TARGETID T72065 T72065 FORMERID TTDI01857 T72065 TARGNAME Voltage-gated sodium channel (Nav) T72065 TARGTYPE Successful T72065 BIOCLASS Voltage-gated ion channel T72065 DRUGINFO D01PJR Tocainide Approved T72065 DRUGINFO D03DAP Flecainide Approved T72065 DRUGINFO D0J2KV Propafenone Approved T72065 DRUGINFO D0U5SI Procainamide Approved T72065 DRUGINFO DU8CF6 Cenobamate Approved T72065 DRUGINFO D04QZD Eslicarbazepine Approved T72065 DRUGINFO D05OFX Lacosamide Approved T72065 DRUGINFO D0C7ET Tetrodotoxin Approved T72065 DRUGINFO DDKF39 Evenamide Phase 2 T72065 DRUGINFO D06HYG Barucainide Terminated T30520 TARGETID T30520 T30520 FORMERID TTDS00227 T30520 TARGNAME Bacterial RNA polymerase switch region (Bact RNAP-SR) T30520 TARGTYPE Successful T30520 DRUGINFO D06LNW Fidaxomicin Approved T30520 DRUGINFO D0G3DL Rifampin Approved T30520 DRUGINFO D0XW9L Rifalazil Phase 3 T32387 TARGETID T32387 T32387 FORMERID TTDNS00610 T32387 TARGNAME Endothelium of blood vessels (Endothelium) T32387 TARGTYPE Successful T32387 SYNONYMS Endothelium of blood vessels T32387 DRUGINFO D05ZPL Polidocanol Approved T83051 TARGETID T83051 T83051 FORMERID TTDI01623 T83051 TARGNAME Bacterial Ribosome (Bact RIBS) T83051 TARGTYPE Successful T83051 DRUGINFO D0LZ7E TP-434 Approved T83051 DRUGINFO DEN52G OTB-658 Preclinical T44351 TARGETID T44351 T44351 FORMERID TTDR00168 T44351 TARGNAME Cannabinoid receptor (CB) T44351 TARGTYPE Successful T44351 DRUGINFO D0O1UZ Cannabidiol Approved T44351 DRUGINFO D00OZC THX-TS01 Phase 3 T57585 TARGETID T57585 T57585 FORMERID TTDI01571 T57585 TARGNAME Chloride channel unspecific (ClC) T57585 TARGTYPE Successful T57585 DRUGINFO D01LWO TM-601 Phase 2 T57585 DRUGINFO D0H8XB Lancovutide Phase 2 T57585 DRUGINFO D0K9WP 131I-TM-601 Phase 2 T57585 DRUGINFO D0I8KA BLZ-100 Phase 1/2 T57585 DRUGINFO D00NWT GR-213487 Discontinued in Phase 2 T57585 DRUGINFO D09BLW TgAAV-CFTR Discontinued in Phase 2 T57585 DRUGINFO D0Y4ZS Endovion Terminated T18632 TARGETID T18632 T18632 FORMERID TTDR01239 T18632 TARGNAME Cholinergic receptor unspecific (CHR) T18632 TARGTYPE Successful T18632 DRUGINFO D08ALK Cisatracurium Approved T18632 DRUGINFO D0VK9O Sofpironium bromide Phase 3 T68934 TARGETID T68934 T68934 FORMERID TTDS00434 T68934 TARGNAME Collagen (CO) T68934 TARGTYPE Successful T68934 DRUGINFO D0Y4KE Collagenase Approved T68934 DRUGINFO D07AHW Vitamin C Approved T68934 DRUGINFO D08WZQ MRG-201 Phase 2 T68934 DRUGINFO D00HAM Clostridial collagenase Investigative T67977 TARGETID T67977 T67977 FORMERID TTDNC00352 T67977 TARGNAME Cytochrome P450 3A (CYP3A) T67977 TARGTYPE Successful T67977 DRUGINFO D02VJP Cobicistat Approved T67977 DRUGINFO D0V4ZN Cobicistat/darunavir Approved T39147 TARGETID T39147 T39147 TARGNAME Cytomegalovirus Terminase (CMV TRM) T39147 TARGTYPE Successful T39147 DRUGINFO D0G8PA MK-8228 Approved T39147 DRUGINFO D0GH9Z GW-275175 Terminated T17003 TARGETID T17003 T17003 FORMERID TTDS00225 T17003 TARGNAME DNA-directed RNA polymerase (RNAP) T17003 TARGTYPE Successful T17003 DRUGINFO D05CHI Rifabutin Approved T17003 DRUGINFO D0G9IU Rifapentine Approved T17003 DRUGINFO D0AJ5E Rifaximin DR Phase 3 T34772 TARGETID T34772 T34772 FORMERID TTDI01701 T34772 TARGNAME Endopeptidase (ENP) T34772 TARGTYPE Successful T34772 DRUGINFO D0JY3V Racecadotril Approved T10362 TARGETID T10362 T10362 FORMERID TTDI01629 T10362 TARGNAME Enzyme unspecific (Enz) T10362 TARGTYPE Successful T10362 DRUGINFO D02HFD Glutathione Approved T10362 DRUGINFO D0U6BJ Desoxyribonuclease Approved T10362 DRUGINFO D01VWD HTI-101 Phase 2 T10362 DRUGINFO D0UA9J VT-1129 Phase 2 T10362 DRUGINFO D06PZO ASC-101 Phase 1/2 T10362 DRUGINFO D0KG1U BXCL702 Phase 1 T10362 DRUGINFO D00YEO NZ-1002 Terminated T10362 DRUGINFO D03XHD A-11259 Terminated T10362 DRUGINFO D09PTL SRI-3072 Terminated T10362 DRUGINFO D0T2OT GW-278884 Terminated T10362 DRUGINFO D0W2DV BM-13677 Terminated T10362 DRUGINFO D0Y6HY A-364 Terminated T10362 DRUGINFO D0Z0RU APC-6336 Terminated T10362 DRUGINFO D09LTO A-76341 Investigative T87975 TARGETID T87975 T87975 TARGNAME Fungal Proton pump (FPPCM) T87975 TARGTYPE Successful T87975 DRUGINFO D0C8FX Pyrithione Zinc Approved T21447 TARGETID T21447 T21447 FORMERID TTDNS00559 T21447 TARGNAME Glutamine receptor (GluR) T21447 TARGTYPE Successful T21447 DRUGINFO D07WXE L-alanyl-l-glutamine Approved T30014 TARGETID T30014 T30014 FORMERID TTDI01900 T30014 TARGNAME Immunoglobulin unspecific (Ig) T30014 TARGTYPE Successful T30014 DRUGINFO D01PQM Vaccinia immune globulin Approved T83717 TARGETID T83717 T83717 FORMERID TTDS00349 T83717 TARGNAME Neuronal acetylcholine receptor alpha (NACHRA) T83717 TARGTYPE Successful T83717 DRUGINFO D0Y7TO Doxacurium Approved T06438 TARGETID T06438 T06438 FORMERID TTDI01899 T06438 TARGNAME Oxidoreductase unspecific (OR) T06438 TARGTYPE Successful T06438 DRUGINFO D00KRE Olsalazine Approved T06438 DRUGINFO D05TPI EPICATECHIN Phase 1/2 T47077 TARGETID T47077 T47077 FORMERID TTDI01591 T47077 TARGNAME Prostaglandin receptor (PTGR) T47077 TARGTYPE Successful T47077 DRUGINFO D09SRR Unoprostone Approved T47077 DRUGINFO D0Q2XF Bimatoprost Approved T47077 DRUGINFO D04LBC Iclaprim Phase 3 T47077 DRUGINFO D0Y5JZ JB991 Phase 2 T47077 DRUGINFO D06YXD Taprostene Discontinued in Phase 3 T47077 DRUGINFO D0I7LB ZD-4953 Discontinued in Phase 2 T47077 DRUGINFO D0SX3X TEI-6122 Discontinued in Phase 2 T47077 DRUGINFO D01AJM YP-009 Terminated T47077 DRUGINFO D0L8TL YP-008 Terminated T47077 DRUGINFO D0M7TT IP-1200 Investigative T01840 TARGETID T01840 T01840 FORMERID TTDNC00449 T01840 TARGNAME Protease unspecific (PRO) T01840 TARGTYPE Successful T01840 DRUGINFO D0V3SB Prolastin Approved T01840 DRUGINFO D02ALZ ONO-3307 Phase 2 T01840 DRUGINFO D0J6ZA SRD-441 Phase 2 T01840 DRUGINFO D0E4GE AZD-2551 Phase 1 T01840 DRUGINFO D01CAJ AZD-3342 Discontinued in Phase 1 T01840 DRUGINFO D02WQZ Aprosulate sodium Discontinued in Phase 1 T01840 DRUGINFO D02ERH EP-2060 Terminated T01840 DRUGINFO D04RDT CEP-431 Terminated T01840 DRUGINFO D04YNI WY-48989 Terminated T01840 DRUGINFO D05OVR ALP-242 Terminated T69707 TARGETID T69707 T69707 FORMERID TTDNC00646 T69707 TARGNAME Proteasome (PS) T69707 TARGTYPE Successful T69707 DRUGINFO D00UVA Carfilzomib Approved T69707 DRUGINFO D01MML MLN9708 Approved T69707 DRUGINFO D0SH3I Bortezomib Approved T69707 DRUGINFO D0N0RN Marizomib Phase 3 T69707 DRUGINFO D02BLD Oprozomib Phase 2 T69707 DRUGINFO D0VO0T Delanzomib Phase 2 T69707 DRUGINFO DM8RI3 GSK3494245 Phase 1 T69707 DRUGINFO D00QIK PS-519 Terminated T69707 DRUGINFO D06FFP MG-101 Investigative T78937 TARGETID T78937 T78937 FORMERID TTDNS00539 T78937 TARGNAME Ribosome A (hRA) T78937 TARGTYPE Successful T78937 DRUGINFO D07JPC Arbekacin Approved T78937 DRUGINFO D0M4XY Omacetaxine mepesuccinate Approved T89883 TARGETID T89883 T89883 TARGNAME Ryanodine receptor (RYR) T89883 TARGTYPE Successful T89883 DRUGINFO D0I8DD Dantrolene Approved T89883 DRUGINFO D0U1OO ARM210 Phase 1 T12427 TARGETID T12427 T12427 FORMERID TTDNS00570 T12427 TARGNAME Sodium pump (NaP) T12427 TARGTYPE Successful T12427 DRUGINFO D0L4SD Alpha-acetyldigoxin Approved T12427 DRUGINFO D0M9QK Beta-acetyldigoxin Approved T26240 TARGETID T26240 T26240 FORMERID TTDS00459 T26240 TARGNAME Estramustine binding protein (EMBP) T26240 TARGTYPE Successful T26240 DRUGINFO D03SRY Estramustine Approved T52007 TARGETID T52007 T52007 FORMERID TTDS00457 T52007 TARGNAME Peripheral carotid chemoreceptor (PCC) T52007 TARGTYPE Successful T52007 DRUGINFO D0M7BT Doxapram Approved T06042 TARGETID T06042 T06042 FORMERID TTDI01903 T06042 TARGNAME Sinus node I(f) channel (SA node IfC) T06042 TARGTYPE Successful T06042 DRUGINFO D0S9QA Ivabradine Approved T95212 TARGETID T95212 T95212 FORMERID TTDI01158 T95212 TARGNAME Streptococcus Diphtheria protein (Stre DIPP) T95212 TARGTYPE Successful T95212 DRUGINFO D0M1PR Prevnar Approved T95212 DRUGINFO D0I2MA IO-21 Discontinued in Phase 2 T75041 TARGETID T75041 T75041 FORMERID TTDS00458 T75041 TARGNAME Tumor-associated glycoprotein 72 (TAG-72) T75041 TARGTYPE Successful T75041 DRUGINFO D0V6RC Satumomab Pendetide Approved T74654 TARGETID T74654 T74654 FORMERID TTDS00527 T74654 TARGNAME Adrenergic neuron (AD neuro) T74654 TARGTYPE Successful T74654 DRUGINFO D0MP5H Debrisoquin Approved T74654 DRUGINFO D0N3PE Guanethidine Approved T82349 TARGETID T82349 T82349 TARGNAME Bacterial Cell membrane (Bact CM) T82349 TARGTYPE Successful T82349 DRUGINFO D0B6GW Diphtheria-tetanus vaccine Approved T82349 DRUGINFO D0F6EO Amoxicillin Approved T82349 DRUGINFO D0K6MW Teicoplanin Approved T82349 DRUGINFO D0S3NU Delamanid Approved T82349 DRUGINFO D03RCV D2A21 Phase 3 T82349 DRUGINFO D06XMW DPK-060 Phase 2 T82349 DRUGINFO D08CQY Brilacidin Phase 2 T82349 DRUGINFO D0J5ED LTX-109 Phase 2 T82349 DRUGINFO D0G6HI Friulimicin Phase 1 T82349 DRUGINFO D0O7RY IDR-1018 Phase 1 T82349 DRUGINFO D0PK3W Lotilibcin Phase 1 T82349 DRUGINFO D02QWJ EREMOMYCIN Discontinued in Phase 2 T82349 DRUGINFO D0L8EQ CB-182804 Discontinued in Phase 1 T82349 DRUGINFO D0BW9R BMS-181184 Terminated T82349 DRUGINFO D0F6ZS Ro-25-6833 Terminated T87119 TARGETID T87119 T87119 FORMERID TTDS00463 T87119 TARGNAME Fungal Cell membrane (Fung CM) T87119 TARGTYPE Successful T87119 DRUGINFO D02FEM Natamycin Approved T87119 DRUGINFO D06ZAY Haloprogin Approved T03006 TARGETID T03006 T03006 FORMERID TTDI01879 T03006 TARGNAME Acetylcholine release (Ach rele) T03006 TARGTYPE Successful T03006 DRUGINFO D0H3AB Incobotulinum toxin A Approved T03006 DRUGINFO D0M7IH Abobotulinum toxin A Approved T03006 DRUGINFO D01DPD KW-6055 Discontinued in Phase 1 T03006 DRUGINFO D0K7TX HOE-065 Discontinued in Phase 1 T29064 TARGETID T29064 T29064 FORMERID TTDI01890 T29064 TARGNAME Angiogenesis/myeloma cell growth (AMCG) T29064 TARGTYPE Successful T29064 DRUGINFO D0A3ZU Pomalidomide Approved T95339 TARGETID T95339 T95339 FORMERID TTDI01182 T95339 TARGNAME Beta-hematin formation (BHF) T95339 TARGTYPE Successful T95339 DRUGINFO D0Y5ZA Arteether Approved T95339 DRUGINFO D06OZW Artemisone Phase 2/3 T60810 TARGETID T60810 T60810 FORMERID TTDI01189 T60810 TARGNAME Cell mediated immunity response (CMIR) T60810 TARGTYPE Successful T60810 DRUGINFO D02QQT Quattvaxem Approved T60810 DRUGINFO D04SOA H1N1 pandemic influenza A vaccine Approved T60810 DRUGINFO D09AWJ H5N1 influenza vaccine Approved T60810 DRUGINFO D0BI1C Live attenuated influenza vaccine Approved T60810 DRUGINFO D0D6NQ HEV-239 Approved T60810 DRUGINFO D0F0ID Polyoxidonium Approved T60810 DRUGINFO D0F0RR GSK2592984A Approved T60810 DRUGINFO D0O4RQ Focetria A(H1N1) Approved T60810 DRUGINFO D0TL1L Fendrix Approved T60810 DRUGINFO D0Y6NL Arepanrix Approved T60810 DRUGINFO D0Z4BH Celtura Approved T60810 DRUGINFO D03FFA HB-AS02V Phase 3 T60810 DRUGINFO D04SNL Grippol Plus Phase 3 T60810 DRUGINFO D05ZAI Grippol TC Phase 3 T60810 DRUGINFO D0HE7I H1N1 influenza vaccine Phase 3 T60810 DRUGINFO D0QO0D H5N1 influenza vaccine Phase 3 T60810 DRUGINFO D06OFZ LEISH-F1 Phase 2 T60810 DRUGINFO D0Q1XV HBV vaccine Phase 2 T60810 DRUGINFO D0Y5VR H5N1 influenza vaccine Phase 2 T60810 DRUGINFO D0PY7Z Aflunov Phase 1/2 T60810 DRUGINFO D00HHU AFO-18 Phase 1 T60810 DRUGINFO D0O1WR GMZ-2 Phase 1 T60810 DRUGINFO D0R2KO CAF-01 Phase 1 T60810 DRUGINFO D06IQE H1N1 influenza vaccine Discontinued in Phase 3 T60810 DRUGINFO D0V2GZ BioVant Investigative T21112 TARGETID T21112 T21112 TARGNAME DNA replication (DNA repli) T21112 TARGTYPE Successful T21112 DRUGINFO D0JO3U Elliptinium acetate Approved T21112 DRUGINFO D0V8QT Chlorambucil Approved T21112 DRUGINFO D01XWG Daunorubicin Approved T21112 DRUGINFO D0X1HE Ozenoxacin Approved T21112 DRUGINFO D0KE1F DFP-10917 Phase 3 T30418 TARGETID T30418 T30418 FORMERID TTDI01179 T30418 TARGNAME DNA synthesis (DNA synth) T30418 TARGTYPE Successful T30418 DRUGINFO D0B8UJ Nelarabine Approved T30418 DRUGINFO D0M1IN acelarin Phase 3 T30418 DRUGINFO D0L9IA Glufosfamide Phase 3 T30418 DRUGINFO D0U1KE FF-10502-01 Phase 1 T30418 DRUGINFO D0WM3D TAR-200 Phase 1 T30418 DRUGINFO D0T2EP CLOTURIN Discontinued in Phase 2 T30418 DRUGINFO D05PTG EPD-clofarabine Terminated T69189 TARGETID T69189 T69189 FORMERID TTDI01547 T69189 TARGNAME Hedgehog signaling pathway (HS pathway) T69189 TARGTYPE Successful T69189 DRUGINFO D0V4IB Itraconazole Approved T69189 DRUGINFO D0S5LO PF-04449913 Approved T69189 DRUGINFO D0GD4Q Patidegib Phase 2 T69189 DRUGINFO D6A7KB ENV-101 Phase 2 T90848 TARGETID T90848 T90848 TARGNAME HGF/Met signaling pathway (HGF/Met pathway) T90848 TARGTYPE Successful T90848 DRUGINFO D03ZBT Crizotinib Approved T90848 DRUGINFO DDBY18 Fosgonimeton Phase 2/3 T90848 DRUGINFO D07QNH SAIT301 Investigative T71556 TARGETID T71556 T71556 FORMERID TTDI01858 T71556 TARGNAME Lymphoid cell adhesion molecule expression (LCDME) T71556 TARGTYPE Successful T71556 DRUGINFO D00OGX Anapsos Approved T66030 TARGETID T66030 T66030 FORMERID TTDI01862 T66030 TARGNAME Natural killer cell activation (NKA) T66030 TARGTYPE Successful T66030 DRUGINFO D0X4BZ Virulizin Approved T95498 TARGETID T95498 T95498 FORMERID TTDI01894 T95498 TARGNAME NFE2-related factor 2 pathway (Nrf2 pathway) T95498 TARGTYPE Successful T95498 DRUGINFO D0A7MY TECFIDERA Approved T90695 TARGETID T90695 T90695 TARGNAME PI3K/AKT/mTOR pathway (PAm pathway) T90695 TARGTYPE Successful T90695 DRUGINFO D03LJR Sirolimus Approved T90695 DRUGINFO D02ESL ON-01210.Na Phase 1 T90695 DRUGINFO D0D6EW Glypromate Discontinued in Phase 2 T65868 TARGETID T65868 T65868 FORMERID TTDNS00584 T65868 TARGNAME RNA synthesis (hRNA synth) T65868 TARGTYPE Successful T65868 DRUGINFO D06EPF Plicamycin Approved T42748 TARGETID T42748 T42748 FORMERID TTDI01832 T42748 TARGNAME Serotoninnorepinephrinedopamine reuptake (SNDR) T42748 TARGTYPE Successful T42748 DRUGINFO D01VJN Olanzapine/fluoxetine combination Approved T42748 DRUGINFO D0W6KM Dasotraline Approved T42748 DRUGINFO DSIW85 OPC-64005 Phase 2 T42748 DRUGINFO D05XEA RP5063 Phase 2 T42748 DRUGINFO D15BZU Brilaroxazine Phase 1 T73760 TARGETID T73760 T73760 FORMERID TTDI01856 T73760 TARGNAME T(H2) cytokine production (TH2 produ) T73760 TARGTYPE Successful T73760 DRUGINFO D0P8MI Suplatast tosilate Approved T84665 TARGETID T84665 T84665 FORMERID TTDI01853 T84665 TARGNAME Tromboxane A2 synthesis (TA2 synth) T84665 TARGTYPE Successful T84665 DRUGINFO D0F5ZM Imidazole salicylate Approved T17687 TARGETID T17687 T17687 FORMERID TTDR00314 T17687 TARGNAME Fibroblast growth factor receptor (FGFR) T17687 TARGTYPE Successful T17687 SYNONYMS FGF receptor T17687 DRUGINFO D01ZLU Futibatinib Approved T17687 DRUGINFO D03LWG Infigratinib Approved T17687 DRUGINFO D0NW0T Erdafitinib Approved T17687 DRUGINFO D0B0AX HIF-1alpha Phase 4 T17687 DRUGINFO D07PQJ ARQ-087 Phase 3 T17687 DRUGINFO D0NU0U AZD4547 Phase 2/3 T17687 DRUGINFO D0E8PR BAY1163877 Phase 2 T17687 DRUGINFO DZM65T ICP-192 Phase 2 T17687 DRUGINFO D0XT0W Debio 1347 Phase 2 T17687 DRUGINFO D0H9FR PRN1371 Phase 1 T17687 DRUGINFO D06SKN SU5403 Investigative T17687 DRUGINFO D0HE0E SU4984 Investigative T17687 DRUGINFO D0O5CL ARO 087 Investigative T17687 DRUGINFO D0VF6E PD173074 Investigative T49049 TARGETID T49049 T49049 FORMERID TTDR00940 T49049 TARGNAME Immunoglobulin Fc receptor (FCR) T49049 TARGTYPE Successful T49049 BIOCLASS Immunoglobulin T49049 DRUGINFO D01TWG Rozanolixizumab Approved T49049 DRUGINFO DS69NO Nipocalimab Phase 3 T49049 DRUGINFO D0R3KS DX-2500 Investigative T80942 TARGETID T80942 T80942 FORMERID TTDI01565 T80942 TARGNAME Matrix metalloproteinase (MMP) T80942 TARGTYPE Successful T80942 SYNONYMS Matrix metalloproteinase T80942 DRUGINFO D5IS6V Abametapir Approved T80942 DRUGINFO D0N4IV S-3304 Phase 1/2 T80942 DRUGINFO D0I8KA BLZ-100 Phase 1/2 T80942 DRUGINFO D00UCC ABT-518 Discontinued in Phase 1 T80942 DRUGINFO D01JOA D-1927 Discontinued in Phase 1 T80942 DRUGINFO D08NES S-3536 Discontinued in Phase 1 T80942 DRUGINFO D0RJ2P BB-2983 Discontinued in Phase 1 T80942 DRUGINFO D0W8QH ONO-4817 Discontinued in Phase 1 T80942 DRUGINFO D0EF9B DFD-11 Application submitted T80942 DRUGINFO D06NOU D-9120 Terminated T80942 DRUGINFO D09TRM D-5410 Terminated T80942 DRUGINFO D0G2CL AG-2024 Terminated T80942 DRUGINFO D0GA3M BE-16627B Terminated T80942 DRUGINFO D0H5CD GI-129471 Terminated T80942 DRUGINFO D0L0CL CP-471358 Terminated T80942 DRUGINFO D0L4GF AG-3296 Terminated T80942 DRUGINFO D0V0RW BB-1433 Terminated T80942 DRUGINFO D05QAA PNU-248686A Investigative T97617 TARGETID T97617 T97617 TARGNAME Sphingosine-1 phosphate receptor (S1PR) T97617 TARGTYPE Successful T97617 BIOCLASS GPCR rhodopsin T97617 DRUGINFO D07FKQ Siponimod Approved T97617 DRUGINFO D0WB0R KPP203 Phase 2 T89950 TARGETID T89950 T89950 TARGNAME Calcitonin gene-related peptide (CALC) T89950 TARGTYPE Successful T89950 DRUGINFO D0H6QD Eptinezumab Approved T89950 DRUGINFO DM6KV2 TEV-48125 Phase 3 T89950 DRUGINFO D0Z1OT ALD-403 Phase 2 T89950 DRUGINFO D04JAT PF-4427429 Phase 1 T89950 DRUGINFO D01SPI CGRP Discontinued in Phase 2 T84457 TARGETID T84457 T84457 TARGNAME GABA(A) receptor (GABAR) T84457 TARGTYPE Successful T84457 DRUGINFO D0X0CH Ganaxolone Approved T84457 DRUGINFO D0J1ZH PH94B NS Phase 3 T84457 DRUGINFO DKI03V OV101 Phase 3 T84457 DRUGINFO DCA5M2 Padsevonil Phase 2/3 T84457 DRUGINFO D0EV9B BTD-001 Phase 2 T84457 DRUGINFO D4A2DQ SAGE-324 Phase 2 T84457 DRUGINFO DUAO82 Evt201 Phase 2 T88637 TARGETID T88637 T88637 TARGNAME Myosin (MYO) T88637 TARGTYPE Successful T88637 DRUGINFO D0D1ZF Mavacamten Approved T88637 DRUGINFO DT52FI MYK-491 Phase 2 T27021 TARGETID T27021 T27021 FORMERID TTDI01578 T27021 TARGNAME Transferase unspecific (TF) T27021 TARGTYPE Successful T27021 DRUGINFO D0U3YU Ademetionine Approved T27021 DRUGINFO D0B2WQ Lomeguatrib Discontinued in Phase 2 T27021 DRUGINFO D0V2ZJ BCX-25 Terminated T13712 TARGETID T13712 T13712 FORMERID TTDI01206 T13712 TARGNAME Cholesterol synthesis (Chole synth) T13712 TARGTYPE Successful T13712 DRUGINFO D0D9NY Bempedoic acid Approved T81774 TARGETID T81774 T81774 FORMERID TTDI01211 T81774 TARGNAME Tubulin polymerization (TubP) T81774 TARGTYPE Successful T81774 DRUGINFO D02LJW Tirbanibulin Approved T81774 DRUGINFO D05BGY PM184 Phase 2 T86671 TARGETID T86671 T86671 FORMERID TTDI01806 T86671 TARGNAME Orexin receptor (HCRTR) T86671 TARGTYPE Successful T86671 SYNONYMS Hypocretin receptor T86671 FUNCTION Moderately selective excitatory receptor for orexin-A and, with a lower affinity, for orexin-B neuropeptide. Seems to be exclusively coupled to the G(q) subclass of heteromeric G proteins, which activates the phospholipase C mediated signaling cascade. T86671 DRUGINFO DFN1D5 Daridorexant Approved T86671 DRUGINFO D0ZO9C 1,2-diamino cyclopentane-based derivative 28 Patented T05876 TARGETID T05876 T05876 UNIPROID VGP_EBOZM T05876 TARGNAME Ebola virus Envelope glycoprotein (EV GP) T05876 GENENAME EV GP T05876 TARGTYPE Successful T05876 SYNONYMS GP1,2; GP T05876 FUNCTION Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, downregulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity) (Probable). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes. Downregulates as well the function of host natural killer cells. Counteracts the antiviral effect of host BST2/tetherin that restricts release of progeny virions from infected cells. However, cooperates with VP40 and host BST2 to activate canonical NF-kappa-B pathway in a manner dependent on neddylation. T05876 SEQUENCE MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVGLNLEGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRGFPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHPLREPVNATEDPSSGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLESRFTPQFLLQLNETIYTSGKRSNTTGKLIWKVNPEIDTTIGEWAFWETKKNLTRKIRSEELSFTVVSNGAKNISGQSPARTSSDPGTNTTTEDHKIMASENSSAMVQVHSQGREAAVSHLTTLATISTSPQSLTTKPGPDNSTHNTPVYKLDISEATQVEQHHRRTDNDSTASDTPSATTAAGPPKAENTNTSKSTDFLDPATTTSPQNHSETAGNNNTHHQDTGEESASSGKLGLITNTIAGVAGLITGGRRTRREAIVNAQPKCNPNLHYWTTQDEGAAIGLAWIPYFGPAAEGIYIEGLMHNQDGLICGLRQLANETTQALQLFLRATTELRTFSILNRKAIDFLLQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQGDNDNWWTGWRQWIPAGIGVTGVIIAVIALFCICKFVF T05876 DRUGINFO DRM1X5 Ansuvimab Approved T05876 DRUGINFO D1U3EG MAb114 Phase 2/3 T07341 TARGETID T07341 T07341 TARGNAME Dabigatran (Dabi) T07341 TARGTYPE Successful T07341 DRUGINFO D0B9FW Idarucizumab Approved T17629 TARGETID T17629 T17629 UNIPROID TACD2_HUMAN T17629 TARGNAME Tumor associated calcium signal transducer 2 (TACSTD2) T17629 GENENAME TACSTD2 T17629 TARGTYPE Successful T17629 SYNONYMS Cell surface glycoprotein Trop-2; Membrane component chromosome 1 surface marker 1; Pancreatic carcinoma marker protein GA733-1 T17629 FUNCTION May function as a growth factor receptor. T17629 SEQUENCE MARGPGLAPPPLRLPLLLLVLAAVTGHTAAQDNCTCPTNKMTVCSPDGPGGRCQCRALGSGMAVDCSTLTSKCLLLKARMSAPKNARTLVRPSEHALVDNDGLYDPDCDPEGRFKARQCNQTSVCWCVNSVGVRRTDKGDLSLRCDELVRTHHILIDLRHRPTAGAFNHSDLDAELRRLFRERYRLHPKFVAAVHYEQPTIQIELRQNTSQKAAGDVDIGDAAYYFERDIKGESLFQGRGGLDLRVRGEPLQVERTLIYYLDEIPPKFSMKRLTAGLIAVIVVVVVALVAGMAVLVITNRRKSGKYKKVEIKELGELRKEPSL T17629 DRUGINFO D8LAE2 Sacituzumab govitecan Approved T17629 DRUGINFO DOS62C SKB264 Phase 1/2 T17629 DRUGINFO DKHL40 YH012 Investigative T20563 TARGETID T20563 T20563 UNIPROID EGFR_HUMAN T20563 TARGNAME EGFR Exon20ins mutant (EGFR Exon20ins) T20563 GENENAME EGFR T20563 TARGTYPE Successful T20563 BIOCLASS Kinase T20563 SEQUENCE MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA T20563 DRUGINFO DI4HA7 Mobocertinib Approved T20563 DRUGINFO DM8Y2N DZD9008 Phase 1/2 T23519 TARGETID T23519 T23519 UNIPROID GPC5D_HUMAN T23519 TARGNAME G-protein coupled receptor C 5D (GPRC5D) T23519 GENENAME GPRC5D T23519 TARGTYPE Successful T23519 FUNCTION extracellular exosome, intracellular membrane-bounded organelle, plasma membrane, receptor complex, protein kinase activator activity T23519 SEQUENCE MYKDCIESTGDYFLLCDAEGPWGIILESLAILGIVVTILLLLAFLFLMRKIQDCSQWNVLPTQLLFLLSVLGLFGLAFAFIIELNQQTAPVRYFLFGVLFALCFSCLLAHASNLVKLVRGCVSFSWTTILCIAIGCSLLQIIIATEYVTLIMTRGMMFVNMTPCQLNVDFVVLLVYVLFLMALTFFVSKATFCGPCENWKQHGRLIFITVLFSIIIWVVWISMLLRGNPQFQRQPQWDDPVVCIALVTNAWVFLLLYIVPELCILYRSCRQECPLQGNACPVTAYQHSFQVENQELSRARDSDGAEEDVALTSYGTPIQPQTVDPTQECFIPQAKLSPQQDAGGV T23519 DRUGINFO DXR1A6 Talquetamab Approved T23519 DRUGINFO DV9M0Y GPRC5D CAR-T cell therapy Phase 1 T23519 DRUGINFO D6RT9L RG6234 Phase 1 T32790 TARGETID T32790 T32790 UNIPROID LDHA_HUMAN T32790 TARGNAME LDHA messenger RNA (LDHA mRNA) T32790 GENENAME LDHA T32790 TARGTYPE Successful T32790 SYNONYMS LDH-A; Cell proliferation-inducing gene 19 protein; LDH muscle subunit; LDH-M; Renal carcinoma antigen NY-REN-59 T32790 BIOCLASS mRNA target T32790 ECNUMBER EC 1.1.1.27 T32790 SEQUENCE MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF T32790 DRUGINFO DZ8DF0 Nedosiran Approved T59480 TARGETID T59480 T59480 UNIPROID RASK_HUMAN T59480 TARGNAME KRAS G12C mutant (KRAS G12C) T59480 GENENAME KRAS T59480 TARGTYPE Successful T59480 SEQUENCE MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM T59480 DRUGINFO D0R7LD Sotorasib Approved T59480 DRUGINFO DUQV41 Adagrasib Approved T59480 DRUGINFO D37IQM JDQ443 Phase 3 T59480 DRUGINFO DEXM29 LY3499446 Phase 1/2 T59480 DRUGINFO DDZ6B0 RG6330 Phase 1 T59480 DRUGINFO DZY4R2 JNJ-74699157 Phase 1 T86041 TARGETID T86041 T86041 UNIPROID HEM1_HUMAN T86041 TARGNAME ALAS1 messenger RNA (ALAS1 mRNA) T86041 GENENAME ALAS1 T86041 TARGTYPE Successful T86041 SYNONYMS ALAS-H; 5-aminolevulinic acid synthase 1; Delta-ALA synthase 1; Delta-aminolevulinate synthase 1 T86041 BIOCLASS mRNA target T86041 ECNUMBER EC 2.3.1.37 T86041 SEQUENCE MESVVRRCPFLSRVPQAFLQKAGKSLLFYAQNCPKMMEVGAKPAPRALSTAAVHYQQIKETPPASEKDKTAKAKVQQTPDGSQQSPDGTQLPSGHPLPATSQGTASKCPFLAAQMNQRGSSVFCKASLELQEDVQEMNAVRKEVAETSAGPSVVSVKTDGGDPSGLLKNFQDIMQKQRPERVSHLLQDNLPKSVSTFQYDRFFEKKIDEKKNDHTYRVFKTVNRRAHIFPMADDYSDSLITKKQVSVWCSNDYLGMSRHPRVCGAVMDTLKQHGAGAGGTRNISGTSKFHVDLERELADLHGKDAALLFSSCFVANDSTLFTLAKMMPGCEIYSDSGNHASMIQGIRNSRVPKYIFRHNDVSHLRELLQRSDPSVPKIVAFETVHSMDGAVCPLEELCDVAHEFGAITFVDEVHAVGLYGARGGGIGDRDGVMPKMDIISGTLGKAFGCVGGYIASTSSLIDTVRSYAAGFIFTTSLPPMLLAGALESVRILKSAEGRVLRRQHQRNVKLMRQMLMDAGLPVVHCPSHIIPVRVADAAKNTEVCDELMSRHNIYVQAINYPTVPRGEELLRIAPTPHHTPQMMNYFLENLLVTWKQVGLELKPHSSAECNFCRRPLHFEVMSEREKSYFSGLSKLVSAQA T86041 DRUGINFO DF36DY Givosiran Approved T63155 TARGETID T63155 T63155 UNIPROID KPYR_HUMAN T63155 TARGNAME Pyruvate kinase PKLR (PKLR) T63155 GENENAME PKLR T63155 TARGTYPE Successful T63155 SYNONYMS Pyruvate kinase 1; Pyruvate kinase isozymes L/R; R-type/L-type pyruvate kinase; Red cell/liver pyruvate kinase T63155 FUNCTION Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis. {ECO:0000269|PubMed:11960989}. T63155 PDBSTRUC 2VGB;2VGF;2VGG;2VGI;4IMA;4IP7;5SC8;5SC9;5SCA;5SCB;5SCC;5SCD;5SCE;5SCF;5SCG;5SCH;5SCI;5SCJ;5SCK;5SCL;5SDT;6NN4;6NN5;6NN7;6NN8;7FRV;7FRW;7FRX;7FRY;7FRZ;7FS0;7FS1;7FS2;7FS3;7FS4;7FS5;7FS6;7FS7;7FS8;7FS9;7FSA;7FSB;7FSC;7FSD;7QDN;7QZU T63155 BIOCLASS Kinase T63155 ECNUMBER EC 2.7.1.40 T63155 SEQUENCE MSIQENISSLQLRSWVSKSQRDLAKSILIGAPGGPAGYLRRASVAQLTQELGTAFFQQQQLPAAMADTFLEHLCLLDIDSEPVAARSTSIIATIGPASRSVERLKEMIKAGMNIARLNFSHGSHEYHAESIANVREAVESFAGSPLSYRPVAIALDTKGPEIRTGILQGGPESEVELVKGSQVLVTVDPAFRTRGNANTVWVDYPNIVRVVPVGGRIYIDDGLISLVVQKIGPEGLVTQVENGGVLGSRKGVNLPGAQVDLPGLSEQDVRDLRFGVEHGVDIVFASFVRKASDVAAVRAALGPEGHGIKIISKIENHEGVKRFDEILEVSDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNLAGKPVVCATQMLESMITKPRPTRAETSDVANAVLDGADCIMLSGETAKGNFPVEAVKMQHAIAREAEAAVYHRQLFEELRRAAPLSRDPTEVTAIGAVEAAFKCCAAAIIVLTTTGRSAQLLSRYRPRAAVIAVTRSAQAARQVHLCRGVFPLLYREPPEAIWADDVDRRVQFGIESGKLRGFLRVGDLVIVVTGWRPGSGYTNIMRVLSIS T63155 DRUGINFO D0C8AP Mitapivat Approved T63155 DRUGINFO D0YX3D Olipudase alfa Approved T63155 DRUGINFO D6DO9A RP-L301 Phase 1 T63156 TARGETID T63156 T63156 UNIPROID MA2B1_HUMAN T63156 TARGNAME Lysosomal alpha-mannosidase (MAN2B1) T63156 GENENAME MAN2B1 T63156 TARGTYPE Successful T63156 SYNONYMS Laman; Lysosomal acid alpha-mannosidase; Mannosidase alpha class 2B member 1; Mannosidase alpha-B T63156 FUNCTION Necessary for the catabolism of N-linked carbohydrates released during glycoprotein turnover. Cleaves all known types of alpha-mannosidic linkages. T63156 BIOCLASS Glycosyl hydrolase T63156 ECNUMBER EC 3.2.1.24 T63156 SEQUENCE MGAYARASGVCARGCLDSAGPWTMSRALRPPLPPLCFFLLLLAAAGARAGGYETCPTVQPNMLNVHLLPHTHDDVGWLKTVDQYFYGIKNDIQHAGVQYILDSVISALLADPTRRFIYVEIAFFSRWWHQQTNATQEVVRDLVRQGRLEFANGGWVMNDEAATHYGAIVDQMTLGLRFLEDTFGNDGRPRVAWHIDPFGHSREQASLFAQMGFDGFFFGRLDYQDKWVRMQKLEMEQVWRASTSLKPPTADLFTGVLPNGYNPPRNLCWDVLCVDQPLVEDPRSPEYNAKELVDYFLNVATAQGRYYRTNHTVMTMGSDFQYENANMWFKNLDKLIRLVNAQQAKGSSVHVLYSTPACYLWELNKANLTWSVKHDDFFPYADGPHQFWTGYFSSRPALKRYERLSYNFLQVCNQLEALVGLAANVGPYGSGDSAPLNEAMAVLQHHDAVSGTSRQHVANDYARQLAAGWGPCEVLLSNALARLRGFKDHFTFCQQLNISICPLSQTAARFQVIVYNPLGRKVNWMVRLPVSEGVFVVKDPNGRTVPSDVVIFPSSDSQAHPPELLFSASLPALGFSTYSVAQVPRWKPQARAPQPIPRRSWSPALTIENEHIRATFDPDTGLLMEIMNMNQQLLLPVRQTFFWYNASIGDNESDQASGAYIFRPNQQKPLPVSRWAQIHLVKTPLVQEVHQNFSAWCSQVVRLYPGQRHLELEWSVGPIPVGDTWGKEVISRFDTPLETKGRFYTDSNGREILERRRDYRPTWKLNQTEPVAGNYYPVNTRIYITDGNMQLTVLTDRSQGGSSLRDGSLELMVHRRLLKDDGRGVSEPLMENGSGAWVRGRHLVLLDTAQAAAAGHRLLAEQEVLAPQVVLAPGGGAAYNLGAPPRTQFSGLRRDLPPSVHLLTLASWGPEMVLLRLEHQFAVGEDSGRNLSAPVTLNLRDLFSTFTITRLQETTLVANQLREAASRLKWTTNTGPTPHQTPYQLDPANITLEPMEIRTFLASVQWKEVDG T63156 DRUGINFO D96DLV Velmanase alfa Approved T63158 TARGETID T63158 T63158 UNIPROID ASM_HUMAN T63158 TARGNAME Sphingomyelin phosphodiesterase (SMPD1) T63158 GENENAME SMPD1 T63158 TARGTYPE Successful T63158 SYNONYMS Acid sphingomyelinase; aSMase T63158 FUNCTION Converts sphingomyelin to ceramide (PubMed:1840600, PubMed:18815062, PubMed:27659707, PubMed:25920558, PubMed:25339683, PubMed:33163980, PubMed:12563314). Exists as two enzymatic forms that arise from alternative trafficking of a single protein precursor, one that is targeted to the endolysosomal compartment, whereas the other is released extracellularly (PubMed:21098024, PubMed:9660788, PubMed:20807762). However, in response to various forms of stress, lysosomal exocytosis may represent a major source of the secretory form (PubMed:20530211, PubMed:12563314, PubMed:20807762, PubMed:9393854, PubMed:22573858). {ECO:0000269|PubMed:12563314, ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:20530211, ECO:0000269|PubMed:20807762, ECO:0000269|PubMed:21098024, ECO:0000269|PubMed:22573858, ECO:0000269|PubMed:25339683, ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:33163980, ECO:0000269|PubMed:9393854, ECO:0000269|PubMed:9660788, ECO:0000305}.; In the lysosomes, converts sphingomyelin to ceramide (PubMed:20807762, PubMed:21098024). Plays an important role in the export of cholesterol from the intraendolysosomal membranes (PubMed:25339683). Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol (PubMed:25339683). Modulates stress-induced apoptosis through the production of ceramide (PubMed:8706124). {ECO:0000269|PubMed:20807762, ECO:0000269|PubMed:21098024, ECO:0000269|PubMed:25339683, ECO:0000269|PubMed:8706124}.; When secreted, modulates cell signaling with its ability to reorganize the plasma membrane by converting sphingomyelin to ceramide (PubMed:12563314, PubMed:20807762, PubMed:17303575). Secreted form is increased in response to stress and inflammatory mediators such as IL1B, IFNG or TNF as well as upon infection with bacteria and viruses (PubMed:12563314, PubMed:20807762, PubMed:9393854). Produces the release of ceramide in the outer leaflet of the plasma membrane playing a central role in host defense (PubMed:12563314, PubMed:20807762, PubMed:9393854). Ceramide reorganizes these rafts into larger signaling platforms that are required to internalize P. aeruginosa, induce apoptosis and regulate the cytokine response in infected cells (PubMed:12563314). In wounded cells, the lysosomal form is released extracellularly in the presence of Ca(2+) and promotes endocytosis and plasma membrane repair (PubMed:20530211). {ECO:0000269|PubMed:12563314, ECO:0000269|PubMed:17303575, ECO:0000269|PubMed:20530211, ECO:0000269|PubMed:20807762, ECO:0000269|PubMed:9393854}.; [Sphingomyelin phosphodiesterase, processed form]: This form is generated following cleavage by CASP7 in the extracellular milieu in response to bacterial infection (PubMed:21157428). It shows increased ability to convert sphingomyelin to ceramide and promotes plasma membrane repair (By similarity). Plasma membrane repair by ceramide counteracts the action of gasdermin-D (GSDMD) perforin (PRF1) pores that are formed in response to bacterial infection (By similarity). {ECO:0000250|UniProtKB:Q04519, ECO:0000269|PubMed:21157428}.; (Microbial infection) Secretion is activated by bacteria such as P. aeruginos, N. gonorrhoeae and others, this activation results in the release of ceramide in the outer leaflet of the plasma membrane which facilitates the infection. {ECO:0000269|PubMed:12563314, ECO:0000269|PubMed:9393854, ECO:0000305|PubMed:31155842}.; (Microbial infection) Secretion is activated by human coronaviruses SARS-CoV and SARS-CoV-2 as well as Zaire ebolavirus, this activation results in the release of ceramide in the outer leaflet of the plasma membrane which facilitates the infection. {ECO:0000269|PubMed:22573858, ECO:0000269|PubMed:33163980}.; [Isoform 2]: Lacks residues that bind the cofactor Zn(2+) and has no enzyme activity. {ECO:0000269|PubMed:1840600, ECO:0000305}.; [Isoform 3]: Lacks residues that bind the cofactor Zn(2+) and has no enzyme activity. {ECO:0000269|PubMed:1840600, ECO:0000305}. T63158 PDBSTRUC 5I81;5I85;5I8R;5JG8 T63158 ECNUMBER EC 3.1.4.12; EC 3.1.4.3 T63158 SEQUENCE MPRYGASLRQSCPRSGREQGQDGTAGAPGLLWMGLVLALALALALALALSDSRVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVSRILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASRPGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGNHESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEALRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTDPAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAVAFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYILNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVYRMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQLSARADSPALCRHLMPDGSLPEAQSLWPRPLFC T63158 DRUGINFO D0YX3D Olipudase alfa Approved T25258 TARGETID T25258 T25258 FORMERID TTDR00007 T25258 UNIPROID MDR1_HUMAN T25258 TARGNAME Multidrug resistance protein 1 (ABCB1) T25258 GENENAME ABCB1 T25258 TARGTYPE Clinical trial T25258 SYNONYMS PGY1; P-glycoprotein 1; P-gp; Pgp; MDR1; CD243 antigen; CD243; ATP-binding cassette sub-family B member 1 T25258 FUNCTION Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells. T25258 PDBSTRUC 6QEX; 6FN4; 6FN1; 6C0V T25258 BIOCLASS ABC transporter T25258 ECNUMBER EC 7.6.2.2 T25258 SEQUENCE MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAIIHGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSGIGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVSKINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFTDKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIGAAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLFATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAGFDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRSSLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAIINGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKAGEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNIANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEAIENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFGAYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDSYSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVVQLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVVSQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLDEATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQLLAQKGIYFSMVSVQAGTKRQ T25258 DRUGINFO D09LSY EDP-322 Phase 1 T25258 DRUGINFO D0GS2W W-198 Phase 1 T25258 DRUGINFO D06XVF CBT-1 Discontinued in Phase 3 T25258 DRUGINFO D06DCL LY335979 Discontinued in Phase 3 T25258 DRUGINFO D02VJY Biricodar Discontinued in Phase 2 T25258 DRUGINFO D04RLX Tariquidar Discontinued in Phase 2 T25258 DRUGINFO D0CO2M S-9788 Discontinued in Phase 2 T25258 DRUGINFO D01GDH XR-9051 Discontinued in Phase 1 T25258 DRUGINFO D09FGX Elacridar Discontinued in Phase 1 T25258 DRUGINFO D0SR4G ONT-093 Discontinued in Phase 1 T25258 DRUGINFO D05XGZ 6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol Investigative T25258 DRUGINFO D03PLP [1,1':2',1'']-terphenyl-4,3'',5''-triol Investigative T25258 DRUGINFO D04GYT XR-9456 Investigative T25258 DRUGINFO D09HIM XR-9504 Investigative T25258 DRUGINFO D0A4TF XR-9544 Investigative T25258 DRUGINFO D0AW4W 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl Investigative T25258 DRUGINFO D0S8CE XR-9577 Investigative T25258 DRUGINFO D0O9NE TRISMETHOXYRESVERATROL Investigative T22274 TARGETID T22274 T22274 FORMERID TTDNC00542 T22274 UNIPROID HDAC6_HUMAN T22274 TARGNAME Histone deacetylase 6 (HDAC6) T22274 GENENAME HDAC6 T22274 TARGTYPE Clinical trial T22274 SYNONYMS KIAA0901; JM21; HD6 T22274 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). T22274 PDBSTRUC 6CEF; 6CEE; 6CED; 6CEC; 6CEA T22274 BIOCLASS Carbon-nitrogen hydrolase T22274 ECNUMBER EC 3.5.1.98 T22274 SEQUENCE MTSTGQDSTTTRQRRSRQNPQSPPQDSSVTSKRNIKKGAVPRSIPNLAEVKKKGKMKKLGQAMEEDLIVGLQGMDLNLEAEALAGTGLVLDEQLNEFHCLWDDSFPEGPERLHAIKEQLIQEGLLDRCVSFQARFAEKEELMLVHSLEYIDLMETTQYMNEGELRVLADTYDSVYLHPNSYSCACLASGSVLRLVDAVLGAEIRNGMAIIRPPGHHAQHSLMDGYCMFNHVAVAARYAQQKHRIRRVLIVDWDVHHGQGTQFTFDQDPSVLYFSIHRYEQGRFWPHLKASNWSTTGFGQGQGYTINVPWNQVGMRDADYIAAFLHVLLPVALEFQPQLVLVAAGFDALQGDPKGEMAATPAGFAQLTHLLMGLAGGKLILSLEGGYNLRALAEGVSASLHTLLGDPCPMLESPGAPCRSAQASVSCALEALEPFWEVLVRSTETVERDNMEEDNVEESEEEGPWEPPVLPILTWPVLQSRTGLVYDQNMMNHCNLWDSHHPEVPQRILRIMCRLEELGLAGRCLTLTPRPATEAELLTCHSAEYVGHLRATEKMKTRELHRESSNFDSIYICPSTFACAQLATGAACRLVEAVLSGEVLNGAAVVRPPGHHAEQDAACGFCFFNSVAVAARHAQTISGHALRILIVDWDVHHGNGTQHMFEDDPSVLYVSLHRYDHGTFFPMGDEGASSQIGRAAGTGFTVNVAWNGPRMGDADYLAAWHRLVLPIAYEFNPELVLVSAGFDAARGDPLGGCQVSPEGYAHLTHLLMGLASGRIILILEGGYNLTSISESMAACTRSLLGDPPPLLTLPRPPLSGALASITETIQVHRRYWRSLRVMKVEDREGPSSSKLVTKKAPQPAKPRLAERMTTREKKVLEAGMGKVTSASFGEESTPGQTNSETAVVALTQDQPSEAATGGATLAQTISEAAIGGAMLGQTTSEEAVGGATPDQTTSEETVGGAILDQTTSEDAVGGATLGQTTSEEAVGGATLAQTTSEAAMEGATLDQTTSEEAPGGTELIQTPLASSTDHQTPPTSPVQGTTPQISPSTLIGSLRTLELGSESQGASESQAPGEENLLGEAAGGQDMADSMLMQGSRGLTDQAIFYAVTPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTIQENWVCLSCYQVYCGRYINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAYVHHQALLDVKNIAHQNKFGEDMPHPH T22274 DRUGINFO D01WKZ Citarinostat Phase 1 T22274 DRUGINFO D0O6SA KA2507 Phase 1 T22274 DRUGINFO D05OKZ Sulfonamide derivative 16 Patented T22274 DRUGINFO D0H5GP PMID29671355-Compound-15 Patented T22274 DRUGINFO D0N6WW PMID29671355-Compound-14 Patented T22274 DRUGINFO D0TO3O PMID29671355-Compound-16 Patented T22274 DRUGINFO D00ACL PMID28092474-Compound-33d Patented T22274 DRUGINFO D00GLJ PMID28092474-Compound-32u Patented T22274 DRUGINFO D00LLN PMID28092474-Compound-33a Patented T22274 DRUGINFO D00XWZ PMID28092474-Compound-32a Patented T22274 DRUGINFO D01LCZ PMID28092474-Compound-32j Patented T22274 DRUGINFO D02YDG PMID28092474-Compound-32z Patented T22274 DRUGINFO D03EUD PMID28092474-Compound-32g Patented T22274 DRUGINFO D04AMI PMID28092474-Compound-34c Patented T22274 DRUGINFO D04KQU PMID28092474-Compound-32x Patented T22274 DRUGINFO D04MVN PMID28092474-Compound-33b Patented T22274 DRUGINFO D04VQE PMID28092474-Compound-32b Patented T22274 DRUGINFO D06IIL PMID28092474-Compound-32o Patented T22274 DRUGINFO D08GBR PMID28092474-Compound-33g Patented T22274 DRUGINFO D08GQL PMID28092474-Compound-33j Patented T22274 DRUGINFO D08SNJ PMID28092474-Compound-33p Patented T22274 DRUGINFO D08XLK PMID28092474-Compound-33m Patented T22274 DRUGINFO D08ZJZ PMID28092474-Compound-32v Patented T22274 DRUGINFO D09PVH PMID29671355-Compound-24 Patented T22274 DRUGINFO D0BY1R PMID28092474-Compound-34b Patented T22274 DRUGINFO D0CH4M PMID28092474-Compound-33e Patented T22274 DRUGINFO D0CX1Y PMID28092474-Compound-32t Patented T22274 DRUGINFO D0DH7R PMID28092474-Compound-32c Patented T22274 DRUGINFO D0E5CO PMID28092474-Compound-33i Patented T22274 DRUGINFO D0ET4U PMID28092474-Compound-32r Patented T22274 DRUGINFO D0EU5A PMID28092474-Compound-32h Patented T22274 DRUGINFO D0F3TB PMID29671355-Compound-65a Patented T22274 DRUGINFO D0HM6Y PMID28092474-Compound-32y Patented T22274 DRUGINFO D0JN0A PMID28092474-Compound-33h Patented T22274 DRUGINFO D0JR9L PMID29671355-Compound-38a Patented T22274 DRUGINFO D0K2UF PMID28092474-Compound-33f Patented T22274 DRUGINFO D0KA3X Diaryl amine derivative 3 Patented T22274 DRUGINFO D0L3CU PMID28092474-Compound-33c Patented T22274 DRUGINFO D0L7HG PMID29671355-Compound-39 Patented T22274 DRUGINFO D0LV6K PMID29671355-Compound-19 Patented T22274 DRUGINFO D0M7XL PMID28092474-Compound-32e Patented T22274 DRUGINFO D0MQ2D PMID28092474-Compound-32m Patented T22274 DRUGINFO D0MR7U PMID28092474-Compound-32p Patented T22274 DRUGINFO D0N1RX PMID28092474-Compound-32d Patented T22274 DRUGINFO D0N2FN PMID29671355-Compound-74 Patented T22274 DRUGINFO D0O6SJ PMID28092474-Compound-32n Patented T22274 DRUGINFO D0Q9XK PMID28092474-Compound-33k Patented T22274 DRUGINFO D0QF0Y PMID28092474-Compound-32k Patented T22274 DRUGINFO D0QN8W PMID28092474-Compound-34a Patented T22274 DRUGINFO D0QX3G PMID29671355-Compound-22 Patented T22274 DRUGINFO D0R3RJ PMID29671355-Compound-26 Patented T22274 DRUGINFO D0RD7T PMID28092474-Compound-33o Patented T22274 DRUGINFO D0S3ZB PMID28092474-Compound-32f Patented T22274 DRUGINFO D0S7NE Diaryl amine derivative 2 Patented T22274 DRUGINFO D0SF8N PMID28092474-Compound-33l Patented T22274 DRUGINFO D0SK9K PMID28092474-Compound-32i Patented T22274 DRUGINFO D0TH3L PMID28092474-Compound-32q Patented T22274 DRUGINFO D0TN6E PMID29671355-Compound-18 Patented T22274 DRUGINFO D0V5IQ PMID29671355-Compound-27 Patented T22274 DRUGINFO D0W1AX PMID28092474-Compound-32l Patented T22274 DRUGINFO D0XN2W Diaryl amine derivative 4 Patented T22274 DRUGINFO D0YC2M PMID28092474-Compound-32s Patented T22274 DRUGINFO D0YD7B PMID29671355-Compound-38b Patented T22274 DRUGINFO D0Z7QI PMID29671355-Compound-28 Patented T22274 DRUGINFO D0T7OQ PMID29671355-Compound-73 Patented T22274 DRUGINFO D0ZG5X PMID29671355-Compound-13 Patented T22274 DRUGINFO D0EH2K PMID29671355-Compound-11 Patented T22274 DRUGINFO D0Q1QY PMID29671355-Compound-9 Patented T22274 DRUGINFO D0LN1T PMID29671355-Compound-8 Patented T22274 DRUGINFO D0JB4S PMID29671355-Compound-61 Patented T22274 DRUGINFO D00HXJ PMID29671355-Compound-23 Patented T22274 DRUGINFO D0N2DK PMID29671355-Compound-44 Patented T22274 DRUGINFO D0CH8Q PMID29671355-Compound-56 Patented T22274 DRUGINFO D0M0RE PMID29671355-Compound-67 Patented T22274 DRUGINFO D0DI9S PMID29671355-Compound-31 Patented T22274 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T22274 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T22274 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T22274 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T22274 DRUGINFO D00JIX IKH-25 Investigative T22274 DRUGINFO D01DOV (S)-2-Amino-N-cyclopentyl-7-mercaptoheptanamide Investigative T22274 DRUGINFO D04KQF Tubacin Investigative T22274 DRUGINFO D05OVV ST-2741 Investigative T22274 DRUGINFO D0G3ZH N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide Investigative T22274 DRUGINFO D0G6DH PMID19111466C7d Investigative T22274 DRUGINFO D0L0LR UCL-67022 Investigative T22274 DRUGINFO D0MC9C PMID20947351C16 Investigative T22274 DRUGINFO D0Q4AV N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide Investigative T22274 DRUGINFO D0Q4EG NQN-1 Investigative T22274 DRUGINFO D0R8JK N-phenyl-6-(sulfamoylamino)hexanamide Investigative T22274 DRUGINFO D0T8AJ N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide Investigative T22274 DRUGINFO D0X4VO N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide Investigative T22274 DRUGINFO D0XU0G N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide Investigative T22274 DRUGINFO D06FAK 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide Investigative T22274 DRUGINFO D08XMS N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide Investigative T22274 DRUGINFO D0L7HP NILTUBACIN Investigative T22274 DRUGINFO D0Q5DI nexturastat A Investigative T22274 DRUGINFO D0YP4F N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide Investigative T22274 DRUGINFO D00VXM droxinostat Investigative T22274 DRUGINFO D00XTC Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) Investigative T22274 DRUGINFO D02HVH 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide Investigative T22274 DRUGINFO D02NAF Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) Investigative T22274 DRUGINFO D02NVY Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) Investigative T22274 DRUGINFO D03PRG Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) Investigative T22274 DRUGINFO D04CDZ Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) Investigative T22274 DRUGINFO D04DOL N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide Investigative T22274 DRUGINFO D09RKA santacruzamate A Investigative T22274 DRUGINFO D0E8UH Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) Investigative T22274 DRUGINFO D0G1EX Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) Investigative T22274 DRUGINFO D0N5RV Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) Investigative T22274 DRUGINFO D0R3XO Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) Investigative T22274 DRUGINFO D0U0EZ Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) Investigative T22274 DRUGINFO D0X4QC Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) Investigative T22274 DRUGINFO D0Z6HR Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) Investigative T22274 DRUGINFO D0Z6MI Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) Investigative T22274 DRUGINFO D02NWS 4-Phenylbutyrohydroxamic acid Investigative T22274 DRUGINFO D0S0WK 8-Oxo-8-phenyl-octanoic acid hydroxyamide Investigative T22274 DRUGINFO D01YBR ST-3050 Investigative T22274 DRUGINFO D07YZZ Octanedioic acid bis-hydroxyamide Investigative T22274 DRUGINFO D0N9AK ST-2986 Investigative T22274 DRUGINFO D00KFF 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative T22274 DRUGINFO D00SEE 7-Mercapto-heptanoic acid phenylamide Investigative T22274 DRUGINFO D00ZSD 6-benzenesulfinylhexanoic acid hydroxamide Investigative T22274 DRUGINFO D01MFV N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative T22274 DRUGINFO D01XWZ 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative T22274 DRUGINFO D01XXN N-Hydroxy-4-phenylacetylamino-benzamide Investigative T22274 DRUGINFO D02MQM 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative T22274 DRUGINFO D02UTC N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative T22274 DRUGINFO D02WZK 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T22274 DRUGINFO D04GGW Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative T22274 DRUGINFO D04HSS N-(6-Mercapto-hexyl)-benzamide Investigative T22274 DRUGINFO D04NSP 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T22274 DRUGINFO D04ZDI N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative T22274 DRUGINFO D05AHZ 6-benzenesulfonylhexanoic acid hydroxamide Investigative T22274 DRUGINFO D05FEJ 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative T22274 DRUGINFO D05GVY Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative T22274 DRUGINFO D05LLX 4-Butyrylamino-N-hydroxy-benzamide Investigative T22274 DRUGINFO D05VFP 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T22274 DRUGINFO D05XAN 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative T22274 DRUGINFO D06IQB 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative T22274 DRUGINFO D06VBN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative T22274 DRUGINFO D06XNP 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative T22274 DRUGINFO D07FJU 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative T22274 DRUGINFO D09YBN 6-Phenoxy-hexane-1-thiol Investigative T22274 DRUGINFO D09ZNU 4-Benzoylamino-N-hydroxy-benzamide Investigative T22274 DRUGINFO D0A5LS 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T22274 DRUGINFO D0AX7B 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative T22274 DRUGINFO D0B2ZJ 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T22274 DRUGINFO D0B3ZM 6-Mercapto-hexanoic acid phenylamide Investigative T22274 DRUGINFO D0C0VP Cyclostellettamine derivative Investigative T22274 DRUGINFO D0C2KD N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative T22274 DRUGINFO D0D2KE 5-Mercapto-pentanoic acid phenylamide Investigative T22274 DRUGINFO D0E8KR Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative T22274 DRUGINFO D0F0KS N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative T22274 DRUGINFO D0H1FZ 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative T22274 DRUGINFO D0KE3I (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative T22274 DRUGINFO D0QO0L N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative T22274 DRUGINFO D0R4BS N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative T22274 DRUGINFO D0R5VG N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative T22274 DRUGINFO D0RU1X 8-Oxo-8-phenyl-octanoic acid Investigative T22274 DRUGINFO D0S7WQ N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative T22274 DRUGINFO D0S9JF 6-phenylsulfanylhexanoic acid hydroxamide Investigative T22274 DRUGINFO D0T0SK ST-2987 Investigative T22274 DRUGINFO D0T4IY 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative T22274 DRUGINFO D0V2ZO 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative T22274 DRUGINFO D0XZ9Q 8-Mercapto-octanoic acid phenylamide Investigative T22274 DRUGINFO D0YY9M N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative T22274 DRUGINFO D0Z3BM 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative T22274 DRUGINFO D0Z5KX 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative T22274 DRUGINFO D0Z7YS N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative T22274 DRUGINFO D0N0TS PSAMMAPLIN A Investigative T86052 TARGETID T86052 T86052 FORMERID TTDC00195 T86052 UNIPROID TERT_HUMAN T86052 TARGNAME Telomerase reverse transcriptase (TERT) T86052 GENENAME TERT T86052 TARGTYPE Clinical trial T86052 SYNONYMS Telomerase-associated protein 2; Telomerase catalytic subunit; TRT; TP2; TCS1; HEST2; EST2 T86052 FUNCTION Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis. T86052 PDBSTRUC 5UGW; 5MER; 5MEQ; 5MEP; 5MEO T86052 BIOCLASS Kinase T86052 ECNUMBER EC 2.7.7.49 T86052 SEQUENCE MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD T86052 DRUGINFO D0W8WB Berberine Phase 4 T86052 DRUGINFO D0N0QC GV1001 Phase 3 T86052 DRUGINFO D04XEQ Imetelstat Phase 2/3 T86052 DRUGINFO DK5VM1 VM1500A Phase 2/3 T86052 DRUGINFO D09NFW Dendritic cell vaccine Phase 2 T86052 DRUGINFO D0I6RI GRNVAC1 Phase 2 T86052 DRUGINFO D0I8BH Vx-001 Phase 2 T86052 DRUGINFO D0NT1S CB-10-01 Phase 2 T86052 DRUGINFO D07JRL Epithalon Phase 1/2 T86052 DRUGINFO D0D8ZK OBP-301 Phase 1/2 T86052 DRUGINFO D03BKV KML-001 Phase 1 T86052 DRUGINFO D04HDZ GRN163 Phase 1 T86052 DRUGINFO D04VVD TeloB-Vax Phase 1 T86052 DRUGINFO D0RH3S DC/I540/KLH vaccine Phase 1 T86052 DRUGINFO DI9X5U AAV-hTERT Phase 1 T86052 DRUGINFO DI9X5U AAV-hTERT Phase 1 T86052 DRUGINFO D01GEO Telomestatin Investigative T86052 DRUGINFO D08UZL TMPyP4 Investigative T86052 DRUGINFO D0E6BA 2,3,7-trichloro-5-nitroquinoxaline (TNQX) Investigative T86052 DRUGINFO D0XI2Z PPA Investigative T37848 TARGETID T37848 T37848 FORMERID TTDS00418 T37848 UNIPROID CP3A4_HUMAN T37848 TARGNAME Albendazole monooxygenase (CYP3A4) T37848 GENENAME CYP3A4 T37848 TARGTYPE Clinical trial T37848 SYNONYMS Taurochenodeoxycholate 6-alpha-hydroxylase; Quinine 3-monooxygenase; P450-PCN1; Nifedipine oxidase; NF-25; HLp; Cytochrome P450-PCN1; Cytochrome P450 NF-25; Cytochrome P450 HLp; Cytochrome P450 3A4; Cytochrome P450 3A3; CYPIIIA4; CYPIIIA3; CYP3A3; Albendazole sulfoxidase; Albendazole monooxygenase (sulfoxide-forming); 1,8-cineole 2-exo-monooxygenase T37848 FUNCTION In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e. g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide. Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole. Cytochromes P450 are a group of heme-thiolate monooxygenases. T37848 PDBSTRUC 6BDM; 6BDK; 6BDI; 6BDH; 6BD8 T37848 BIOCLASS Paired donor oxygen oxidoreductase T37848 ECNUMBER EC 1.14.14.- T37848 SEQUENCE MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA T37848 DRUGINFO D07SDQ Curcumin Phase 3 T37848 DRUGINFO D0G2XE PMX-53 Phase 2 T37848 DRUGINFO D00GOQ Alpha-methylcubebin Investigative T37848 DRUGINFO D00RGP MEDIORESINOL Investigative T37848 DRUGINFO D01FBL (-)-yatein Investigative T37848 DRUGINFO D02EAP 3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine Investigative T37848 DRUGINFO D02HSP (-)-cubebinin Investigative T37848 DRUGINFO D02SGJ PALMATINE Investigative T37848 DRUGINFO D02TKC 1,2-Diacetoxylycorine Investigative T37848 DRUGINFO D03DMA Geranylcoumarin Investigative T37848 DRUGINFO D05KIF (-)-cubebininolide Investigative T37848 DRUGINFO D06MLU (-)-dihydroclusin Investigative T37848 DRUGINFO D06TRS 3-(3-methylthiophen-2-yl)pyridine Investigative T37848 DRUGINFO D08BOH (-)-thujaplicatintrimethyl ether Investigative T37848 DRUGINFO D08FZC DIETHOXYFLOURESCEIN Investigative T37848 DRUGINFO D08TSE 1-Acetoxy-2-tert-butyldimethylsilyl-oxylycorine Investigative T37848 DRUGINFO D09REF 1-Acetoxylycorine Investigative T37848 DRUGINFO D09VMS (-)-clusin Investigative T37848 DRUGINFO D0A1SJ ETHOXYCLUSIN Investigative T37848 DRUGINFO D0B2ZB (8R,8'R)-4-hydroxycubebinone Investigative T37848 DRUGINFO D0C7JC 5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime Investigative T37848 DRUGINFO D0D5YP BERGAPTOL Investigative T37848 DRUGINFO D0E2GV 2-tert-Butyldimethylsilyloxylycorine Investigative T37848 DRUGINFO D0F5AQ 5-(2-phenethylpiperazin-1-yl)-1H-indazole Investigative T37848 DRUGINFO D0G9YL GSK-8062 Investigative T37848 DRUGINFO D0IB3K TILIROSIDE Investigative T37848 DRUGINFO D0J1IE 3-(5-((methylthio)methyl)furan-2-yl)pyridine Investigative T37848 DRUGINFO D0K4LS Go-Y026 Investigative T37848 DRUGINFO D0NC3P (-)-cubebin Investigative T37848 DRUGINFO D0O1HH 3-(pyridin-3-yl)prop-2-yn-1-amine Investigative T37848 DRUGINFO D0Q7QU Alpha-Hydroxy-Midazolam Investigative T37848 DRUGINFO D0S0QN 2,5-bis(4-hydroxybenzylidene)cyclopentanone Investigative T37848 DRUGINFO D0T4AC (8R,8'R,9'S)-5-methoxyclusin Investigative T37848 DRUGINFO D0V0NM JATRORRHIZINE Investigative T37848 DRUGINFO D0VD5O 2-fluoro-5-(3-methylthiophen-2-yl)pyridine Investigative T37848 DRUGINFO D0X3CF HINOKININ Investigative T37848 DRUGINFO D00PYW 4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine Investigative T37848 DRUGINFO D00TOF DIHYDROCUBEBIN Investigative T37848 DRUGINFO D00YNA 3,3-(1,3-Thiazole-2,5-diyl)diphenol Investigative T37848 DRUGINFO D01ARE Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine Investigative T37848 DRUGINFO D02DTR 3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine Investigative T37848 DRUGINFO D03KXT 4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine Investigative T37848 DRUGINFO D06CWR 4-(6-Methoxynaphthalen-2-yl)isoquinoline Investigative T37848 DRUGINFO D06JYY 3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine Investigative T37848 DRUGINFO D07ANY 1H-1,2,3-benzotriazol-1-amine Investigative T37848 DRUGINFO D07JOZ 1,1':4',1''-terphenyl-3,3''-diol Investigative T37848 DRUGINFO D07VHB 1-(4-Butoxy-phenyl)-1H-imidazole Investigative T37848 DRUGINFO D07WLT 6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one Investigative T37848 DRUGINFO D08IDC 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine Investigative T37848 DRUGINFO D0B0LC 2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine Investigative T37848 DRUGINFO D0G6BJ 1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX) Investigative T37848 DRUGINFO D0J4CB 1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX) Investigative T37848 DRUGINFO D0K3EW 6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX) Investigative T37848 DRUGINFO D0NM0P 3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol Investigative T37848 DRUGINFO D0U7BJ 2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine Investigative T37848 DRUGINFO D0YP4A (5-pyridin-3-yl-furan-2-yl)methanethiol Investigative T37848 DRUGINFO D01RZP 4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol Investigative T37848 DRUGINFO D0M0KX 2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol Investigative T37848 DRUGINFO D0Y2RL 4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol Investigative T37848 DRUGINFO D01JXM 2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole Investigative T37848 DRUGINFO D09HBZ ML-3375 Investigative T37848 DRUGINFO D0W4FF ML-3403 Investigative T37848 DRUGINFO D08DSJ ML-3163 Investigative T37848 DRUGINFO D0P8PK 6-(3-Hydroxy-phenyl)-naphthalen-2-ol Investigative T37848 DRUGINFO D0M4SY BMS-536924 Investigative T37848 DRUGINFO D0UU1I Heme Investigative T54156 TARGETID T54156 T54156 FORMERID TTDC00076 T54156 UNIPROID MMP9_HUMAN T54156 TARGNAME Matrix metalloproteinase-9 (MMP-9) T54156 GENENAME MMP9 T54156 TARGTYPE Clinical trial T54156 SYNONYMS Matrix metalloproteinase 9; GELB; CLG4B; 92 kDa type IV collagenase; 92 kDa gelatinase T54156 FUNCTION Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide. May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. T54156 PDBSTRUC 6ESM; 5UE4; 5UE3; 5TH9; 5TH6 T54156 BIOCLASS Peptidase T54156 ECNUMBER EC 3.4.24.35 T54156 SEQUENCE MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTQDGNADGKPCQFPFIFQGQSYSACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFPFTFLGKEYSTCTSEGRGDGRLWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYRFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSERPTAGPTGPPSAGPTGPPTAGPSTATTVPLSPVDDACNVNIFDAIAEIGNQLYLFKDGKYWRFSEGRGSRPQGPFLIADKWPALPRKLDSVFEERLSKKLFFFSGRQVWVYTGASVLGPRRLDKLGLGADVAQVTGALRSGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLDTHDVFQYREKAYFCQDRFYWRVSSRSELNQVDQVGYVTYDILQCPED T54156 DRUGINFO D04PWT DP-b99 Phase 3 T54156 DRUGINFO D0WL0Q GS-5745 Phase 3 T54156 DRUGINFO D0Z6SP Andecaliximab Phase 3 T54156 DRUGINFO D07SDQ Curcumin Phase 3 T54156 DRUGINFO D0I8KA BLZ-100 Phase 1/2 T54156 DRUGINFO D0T4BL Neovastat Phase 1 T54156 DRUGINFO D0LP0D PMID29130358-Compound-Figure17(13) Patented T54156 DRUGINFO D00ZZJ PMID29130358-Compound-Figure17(12) Patented T54156 DRUGINFO D09ATD PMID29130358-Compound-Figure17(10) Patented T54156 DRUGINFO D0DB0Z PMID29130358-Compound-SB-3CT Patented T54156 DRUGINFO D0L6HL PMID29130358-Compound-Figure17(11) Patented T54156 DRUGINFO D0Q4QB PMID29130358-Compound-Figure13(4) Patented T54156 DRUGINFO D0W7HO PMID29130358-Compound-LonimacranthoideVII Patented T54156 DRUGINFO D0X6GG PMID29130358-Compound-Figure18(14a) Patented T54156 DRUGINFO D05WTZ Galarubicin Discontinued in Phase 2 T54156 DRUGINFO D03BOZ RS-130830 Discontinued in Phase 2 T54156 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T54156 DRUGINFO D05VEP DX-2802 Preclinical T54156 DRUGINFO D0O7DU CT-1746 Terminated T54156 DRUGINFO D02GYD CDP-845 Terminated T54156 DRUGINFO D0E5GY RO-319790 Terminated T54156 DRUGINFO D0Y1XT SC-44463 Terminated T54156 DRUGINFO D00CWH 2-Amino-N,3,3-Trimethylbutanamide Investigative T54156 DRUGINFO D03WJG PMID15055993C1a Investigative T54156 DRUGINFO D03ZDZ Carboxylated glucosamine Investigative T54156 DRUGINFO D04PAW Methotrexate gamma-L-phenylalaninehydroxamic acid Investigative T54156 DRUGINFO D09GIL 5-Methyl-5-phenyl-pyrimidine-2,4,6-trione Investigative T54156 DRUGINFO D0Q4TA ARP100 Investigative T54156 DRUGINFO D0Z4LO Ro 28-2653 Investigative T54156 DRUGINFO D01HKU Methotrexate gamma-L-proline-hydroxamic acid Investigative T54156 DRUGINFO D07DRT PMID23631440C29e Investigative T54156 DRUGINFO D07LTB 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione Investigative T54156 DRUGINFO D0B0UI Methotrexate gamma-hydroxamic acid Investigative T54156 DRUGINFO D0E5MB 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid Investigative T54156 DRUGINFO D0K4TI 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione Investigative T54156 DRUGINFO D0Q9LC 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione Investigative T54156 DRUGINFO D0U7CD Roche 28-2653 Investigative T54156 DRUGINFO D00RNA N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide Investigative T54156 DRUGINFO D03SNK 2-(biphenyl-4-ylsulfonamido)pentanedioic acid Investigative T54156 DRUGINFO D07SPC N-hydroxy-2,3-bis(phenylsulfonamido)propanamide Investigative T54156 DRUGINFO D08ICI N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) Investigative T54156 DRUGINFO D0A5MV 3-(4-Phenylethynylbenzoyl)nonanoic acid Investigative T54156 DRUGINFO D0P8EY Folate gamma-hydroxamic acid Investigative T54156 DRUGINFO D0V9GS 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid Investigative T54156 DRUGINFO D0Y7NV 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione Investigative T54156 DRUGINFO D0G3YZ (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid Investigative T54156 DRUGINFO D0L4EO 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid Investigative T54156 DRUGINFO D0NP8A UK-356618 Investigative T54156 DRUGINFO D0XL8K Ro-37-9790 Investigative T54156 DRUGINFO D05THD 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide Investigative T54156 DRUGINFO D07GEL SL422 Investigative T54156 DRUGINFO D07MJD [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid Investigative T54156 DRUGINFO D0S9OL N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide Investigative T54156 DRUGINFO D03AMR SR-973 Investigative T54156 DRUGINFO D0W2UK IK-862 Investigative T54156 DRUGINFO D0A4TC MMI270 Investigative T08856 TARGETID T08856 T08856 FORMERID TTDR01266 T08856 UNIPROID MMP8_HUMAN T08856 TARGNAME Matrix metalloproteinase-8 (MMP-8) T08856 GENENAME MMP8 T08856 TARGTYPE Clinical trial T08856 SYNONYMS PMNL-CL; PMNL collagenase; Neutrophil collagenase; CLG1 T08856 FUNCTION Can degrade fibrillar type I, II, and III collagens. T08856 PDBSTRUC 5H8X; 4QKZ; 3TT4; 3DPF; 3DPE T08856 BIOCLASS Peptidase T08856 ECNUMBER EC 3.4.24.34 T08856 SEQUENCE MFSLKTLPFLLLLHVQISKAFPVSSKEKNTKTVQDYLEKFYQLPSNQYQSTRKNGTNVIVEKLKEMQRFFGLNVTGKPNEETLDMMKKPRCGVPDSGGFMLTPGNPKWERTNLTYRIRNYTPQLSEAEVERAIKDAFELWSVASPLIFTRISQGEADINIAFYQRDHGDNSPFDGPNGILAHAFQPGQGIGGDAHFDAEETWTNTSANYNLFLVAAHEFGHSLGLAHSSDPGALMYPNYAFRETSNYSLPQDDIDGIQAIYGLSSNPIQPTGPSTPKPCDPSLTFDAITTLRGEILFFKDRYFWRRHPQLQRVEMNFISLFWPSLPTGIQAAYEDFDRDLIFLFKGNQYWALSGYDILQGYPKDISNYGFPSSVQAIDAAVFYRSKTYFFVNDQFWRYDNQRQFMEPGYPKSISGAFPGIESKVDAVFQQEHFFHVFSGPRYYAFDLIAQRVTRVARGNKWLNCRYG T08856 DRUGINFO D0MW3H CIPEMASTAT Phase 3 T08856 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T08856 DRUGINFO D05VNG BB-1101 Terminated T08856 DRUGINFO D0Y1XT SC-44463 Terminated T08856 DRUGINFO D0H2CS Glycinamid Investigative T08856 DRUGINFO D0L2AW 1-Hydroxyamine-2-Isobutylmalonic Acid Investigative T08856 DRUGINFO D0MM6L 2-HYDROXYCARBAMOYL-4-METHYL-PENTANOIC ACID Investigative T08856 DRUGINFO D0SS8M 3-AMINO-AZACYCLOTRIDECAN-2-ONE Investigative T08856 DRUGINFO D00KSS 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol Investigative T08856 DRUGINFO D0R2BO METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID Investigative T08856 DRUGINFO D0W3UL 2-Thiomethyl-3-Phenylpropanoic Acid Investigative T08856 DRUGINFO D03SNK 2-(biphenyl-4-ylsulfonamido)pentanedioic acid Investigative T08856 DRUGINFO D0D7UA 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol Investigative T08856 DRUGINFO D0K3RC 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol Investigative T08856 DRUGINFO D0N0FX 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol Investigative T08856 DRUGINFO D0V9GS 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid Investigative T08856 DRUGINFO D0XL8K Ro-37-9790 Investigative T08856 DRUGINFO D05THD 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide Investigative T08856 DRUGINFO D07GEL SL422 Investigative T08856 DRUGINFO D07MJD [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid Investigative T08856 DRUGINFO D0S9OL N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide Investigative T08856 DRUGINFO D0W2UK IK-862 Investigative T08856 DRUGINFO D0A4TC MMI270 Investigative T34296 TARGETID T34296 T34296 FORMERID TTDC00150 T34296 UNIPROID MMP13_HUMAN T34296 TARGNAME Matrix metalloproteinase-13 (MMP-13) T34296 GENENAME MMP13 T34296 TARGTYPE Clinical trial T34296 SYNONYMS Matrix metalloproteinase 13; Collagenase-3; Collagenase 3 T34296 FUNCTION Cleaves triple helical collagens, including type I, type II and type III collagen, but has the highest activity with soluble type II collagen. Can also degrade collagen type IV, type XIV and type X. May also function by activating or degrading key regulatory proteins, such as TGFB1 and CTGF. Plays a role in wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. Required for normal embryonic bone development and ossification. Plays a role in the healing of bone fractures via endochondral ossification. Plays a role in wound healing, probably by a mechanism that involves proteolytic activation of TGFB1 and degradation of CTGF. Plays a role in keratinocyte migration during wound healing. May play a role in cell migration and in tumor cell invasion. Plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN. T34296 PDBSTRUC 830C; 5UWN; 5UWM; 5UWL; 5UWK T34296 BIOCLASS Peptidase T34296 ECNUMBER EC 3.4.24.- T34296 SEQUENCE MHPGVLAAFLFLSWTHCRALPLPSGGDEDDLSEEDLQFAERYLRSYYHPTNLAGILKENAASSMTERLREMQSFFGLEVTGKLDDNTLDVMKKPRCGVPDVGEYNVFPRTLKWSKMNLTYRIVNYTPDMTHSEVEKAFKKAFKVWSDVTPLNFTRLHDGIADIMISFGIKEHGDFYPFDGPSGLLAHAFPPGPNYGGDAHFDDDETWTSSSKGYNLFLVAAHEFGHSLGLDHSKDPGALMFPIYTYTGKSHFMLPDDDVQGIQSLYGPGDEDPNPKHPKTPDKCDPSLSLDAITSLRGETMIFKDRFFWRLHPQQVDAELFLTKSFWPELPNRIDAAYEHPSHDLIFIFRGRKFWALNGYDILEGYPKKISELGLPKEVKKISAAVHFEDTGKTLLFSGNQVWRYDDTNHIMDKDYPRLIEEDFPGIGDKVDAVYEKNGYIYFFNGPIQFEYSIWSNRIVRVMPANSILWC T34296 DRUGINFO D07SDQ Curcumin Phase 3 T34296 DRUGINFO D0HG5M Apratastat Phase 2 T34296 DRUGINFO D0A4RF PMID17935984C1 Clinical trial T34296 DRUGINFO D0A9ZW PMID29130358-Compound-Figure16(9b) Patented T34296 DRUGINFO D0LS4Y PMID29130358-Compound-Figure16(9a) Patented T34296 DRUGINFO D0O8RQ PMID29130358-Compound-Figure18(14) Patented T34296 DRUGINFO D0S3PN PMID29130358-Compound-Figure16(9c) Patented T34296 DRUGINFO D0X6GG PMID29130358-Compound-Figure18(14a) Patented T34296 DRUGINFO D03BOZ RS-130830 Discontinued in Phase 2 T34296 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T34296 DRUGINFO D02PKO 3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol Investigative T34296 DRUGINFO D03FEI 1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol Investigative T34296 DRUGINFO D04GOO N1,N3-bis(3-methoxybenzyl)isophthalamide Investigative T34296 DRUGINFO D04VPH PMID22017539C15 Investigative T34296 DRUGINFO D05DBJ 2-(4-methoxybenzylthio)-6-methylpyrimidin-4-ol Investigative T34296 DRUGINFO D05PZV 4-(2,2'-bithiophen-5-ylmethyleneamino)phenol Investigative T34296 DRUGINFO D09GLA WAY-151693 Investigative T34296 DRUGINFO D0D6LF PD-156 Investigative T34296 DRUGINFO D0E9JR Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate Investigative T34296 DRUGINFO D0I0WP 4-(methyl(4-phenylthiazol-2-yl)amino)phenol Investigative T34296 DRUGINFO D0LL8I WAY170523 Investigative T34296 DRUGINFO D0R5MR N4,N6-dibenzylpyrimidine-4,6-dicarboxamide Investigative T34296 DRUGINFO D0Z7EF CL82198 Investigative T34296 DRUGINFO D00KSS 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol Investigative T34296 DRUGINFO D01OCR 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol Investigative T34296 DRUGINFO D05HOS Hydroxyaminovaline Investigative T34296 DRUGINFO D07OME 1-Methyloxy-4-Sulfone-Benzene Investigative T34296 DRUGINFO D09XUQ 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol Investigative T34296 DRUGINFO D0JM0Z 3-Methylpyridine Investigative T34296 DRUGINFO D0K0YX 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid Investigative T34296 DRUGINFO D0LM2K 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid Investigative T34296 DRUGINFO D0XE4B 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol Investigative T34296 DRUGINFO D03SNK 2-(biphenyl-4-ylsulfonamido)pentanedioic acid Investigative T34296 DRUGINFO D0D7UA 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol Investigative T34296 DRUGINFO D0K3RC 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol Investigative T34296 DRUGINFO D0N0FX 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol Investigative T34296 DRUGINFO D0V9GS 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid Investigative T34296 DRUGINFO D08ELY 3-Benzenesulfonyl-heptanoic acid hydroxyamide Investigative T34296 DRUGINFO D0G3YZ (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid Investigative T34296 DRUGINFO D0N6CD 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide Investigative T34296 DRUGINFO D0H2PA PKF-242-484 Investigative T34296 DRUGINFO D0NP8A UK-356618 Investigative T34296 DRUGINFO D0XL8K Ro-37-9790 Investigative T34296 DRUGINFO D05THD 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide Investigative T34296 DRUGINFO D07GEL SL422 Investigative T34296 DRUGINFO D07MJD [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid Investigative T34296 DRUGINFO D0S9OL N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide Investigative T34296 DRUGINFO D03AMR SR-973 Investigative T34296 DRUGINFO D0W2UK IK-862 Investigative T34296 DRUGINFO D0A4TC MMI270 Investigative T70977 TARGETID T70977 T70977 FORMERID TTDC00162 T70977 UNIPROID GSK3B_HUMAN T70977 TARGNAME Glycogen synthase kinase-3 beta (GSK-3B) T70977 GENENAME GSK3B T70977 TARGTYPE Clinical trial T70977 SYNONYMS Serine/threonine-protein kinase GSK3B; GSK-3 beta T70977 FUNCTION Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity. Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity. Phosphorylates ZC3HAV1 which enhances its antiviral activity. Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination and proteasomal degradation. Phosphorylates SFPQ at 'Thr-687' upon T-cell activation. Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59' and stabilizes it by protecting it from proteasomal degradation. Regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2. Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal degradation. Phosphorylates ARNTL/BMAL1 at 'Ser-17' and 'Ser-21' and primes it for ubiquitination and proteasomal degradation. Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively regulates its activity. Phosphorylates MYCN in neuroblastoma cells which may promote its degradation. Regulates the circadian rhythmicity of hippocampal long-term potentiation and ARNTL/BMLA1 and PER2 expression. Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, leading to activate KAT5/TIP60 acetyltransferase activity and promote acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer. Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. T70977 PDBSTRUC 6NPZ; 6H0U; 6GN1; 6GJO; 6BUU T70977 BIOCLASS Kinase T70977 ECNUMBER EC 2.7.11.26 T70977 SEQUENCE MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST T70977 DRUGINFO D0BS5E AMO-02 Phase 2/3 T70977 DRUGINFO D0UT7X Tideglusib Phase 2 T70977 DRUGINFO D4USX5 9-ING-41 Phase 2 T70977 DRUGINFO D0Z1DH LY2090314 Phase 2 T70977 DRUGINFO D5MF8Y Lithium Phase 2 T70977 DRUGINFO D0D1UQ Neu-120 Phase 1/2 T70977 DRUGINFO D06KNK TDZD-8 Patented T70977 DRUGINFO D0A3MV AR-A014418 Patented T70977 DRUGINFO D0F7DS PMID26161698-Compound-18 Patented T70977 DRUGINFO D0YK9D CHIR-99021 Patented T70977 DRUGINFO D00PWQ KENPAULLONE Patented T70977 DRUGINFO D0MC0O AZD-1080 Discontinued in Phase 1 T70977 DRUGINFO D07YNH SAN-61 Terminated T70977 DRUGINFO D0R5ZR RO-320432 Terminated T70977 DRUGINFO D00AAN 8-O-(4-chlorobenzenesulfonyl)manzamine F Investigative T70977 DRUGINFO D00HUP N,8-diphenyl-9H-purin-6-amine Investigative T70977 DRUGINFO D00XUF N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide Investigative T70977 DRUGINFO D01IPF N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D01MEP GSK-3beta inhibitor II Investigative T70977 DRUGINFO D01OJG 3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione Investigative T70977 DRUGINFO D01RKI 8-O-(4-bromobenzenesulfonyl)manzamine F Investigative T70977 DRUGINFO D02OPH I-5 Investigative T70977 DRUGINFO D02ZIY GSK-3beta inhibitor XI Investigative T70977 DRUGINFO D03GQF Manzamine E Investigative T70977 DRUGINFO D03OED N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D04ACJ N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D04VBD N-(6-bromo-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D05GIC Manzamine Y Investigative T70977 DRUGINFO D05SXF IM-12 Investigative T70977 DRUGINFO D06YMZ N-(6-phenethyl-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D07IVD N-(6-benzyl-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D07MZD (2'Z,3'E)-7-Azaindirubin-3'-oxime Investigative T70977 DRUGINFO D07PTD N-(6-phenyl-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D09AEV Neo-kauluamine Investigative T70977 DRUGINFO D09BQY (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D09ITI 8-OH-MANZAMINE A Investigative T70977 DRUGINFO D09RYG 6-deoxymanzamine X Investigative T70977 DRUGINFO D0A9MY N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D0C9OT N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D0D5ZL PAULLONE Investigative T70977 DRUGINFO D0E2XM 12,13-DEHYDRO-8-O-ACETYLMANZAMINE A Investigative T70977 DRUGINFO D0E6GC N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D0F5EI 4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine Investigative T70977 DRUGINFO D0I3US 9-N-METHYL-8-METHOXY-MANZAMINE A Investigative T70977 DRUGINFO D0IL0G N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D0M3SC N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D0NL1F 12,13-DEHYDROMANZAMINE A Investigative T70977 DRUGINFO D0Q3KS CT-98024 Investigative T70977 DRUGINFO D0R5EF N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D0R6TL N-(6-chloro-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D0R7QL 9-N-ETHYL-8-ETHOXY-MANZAMINE A Investigative T70977 DRUGINFO D0S3RP N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D0T1CE N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D0T8CQ CP-70949 Investigative T70977 DRUGINFO D0V6HG 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile Investigative T70977 DRUGINFO D0WN1N DM-204 Investigative T70977 DRUGINFO D0X4CO CHIR-98023 Investigative T70977 DRUGINFO D0X4KR 8-O-(4-toluenesulfonyl)manzamine A Investigative T70977 DRUGINFO D0YM4A N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide Investigative T70977 DRUGINFO D04ZWF CHIR-98014 Investigative T70977 DRUGINFO D05NKG alsterpaullone 2-cyanoethyl Investigative T70977 DRUGINFO D0B3ZB indirubin deriv. 8a Investigative T70977 DRUGINFO D0K1DR LEUCETTAMINE B Investigative T70977 DRUGINFO D0N4WB SB-415286 Investigative T70977 DRUGINFO D0Q4QF MANZAMINE A Investigative T70977 DRUGINFO D02DLC PYRAZOLOPYRIDAZINE 1 Investigative T70977 DRUGINFO D0J4ON RGB-286147 Investigative T70977 DRUGINFO D0O0VP PYRAZOLOPYRIDAZINE 2 Investigative T70977 DRUGINFO D0Q7TO K00244 Investigative T70977 DRUGINFO D0R5FH Quinoxaline1 Investigative T70977 DRUGINFO D0T8KR TWS-119 Investigative T70977 DRUGINFO D04QCF AS-601245 Investigative T70977 DRUGINFO D0DR8N AZAKENPAULLONE Investigative T70977 DRUGINFO D0TF9P Thieno analogue of kenpaullone Investigative T70977 DRUGINFO D06WJA L-779450 Investigative T70977 DRUGINFO D0Y5RO NU-6102 Investigative T70977 DRUGINFO D02QAZ PF-228 Investigative T70977 DRUGINFO D0IX7Y BX-912 Investigative T70977 DRUGINFO D0RG0Z BX-795 Investigative T70977 DRUGINFO D0T8NU PMID19115845C89S Investigative T70977 DRUGINFO D0GB4V STAUROSPORINONE Investigative T70977 DRUGINFO D0M5FF Ro31-8220 Investigative T70977 DRUGINFO D00ICA AMP-PNP Investigative T70977 DRUGINFO D0A1CM ELLAGIC ACID Investigative T70977 DRUGINFO D0B9BU CI-1040 Investigative T70977 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T70977 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T70977 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T82393 TARGETID T82393 T82393 FORMERID TTDR00847 T82393 UNIPROID ADA17_HUMAN T82393 TARGNAME TNF alpha converting enzyme (ADAM17) T82393 GENENAME ADAM17 T82393 TARGTYPE Clinical trial T82393 SYNONYMS TNFalpha converting enzyme; TNF-alpha-converting enzyme; TNF-alpha converting enzyme; TNF-alpha convertase; TACE; Snake venom-like protease; Disintegrin and metalloproteinase domain-containing protein 17; CSVP; CD156b antigen; CD156b; ADAM 17; A disintegrin and metalloproteinase domain 17 T82393 FUNCTION Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Plays a role in the proteolytic processing of ACE2. Plays a role in hemostasis through shedding of GP1BA, the platelet glycoprotein Ib alpha chain. Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3. Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. T82393 PDBSTRUC 3O64; 3LGP; 3LEA; 3LE9; 3L0V T82393 BIOCLASS Peptidase T82393 ECNUMBER EC 3.4.24.86 T82393 SEQUENCE MRQSLLFLTSVVPFVLAPRPPDDPGFGPHQRLEKLDSLLSDYDILSLSNIQQHSVRKRDLQTSTHVETLLTFSALKRHFKLYLTSSTERFSQNFKVVVVDGKNESEYTVKWQDFFTGHVVGEPDSRVLAHIRDDDVIIRINTDGAEYNIEPLWRFVNDTKDKRMLVYKSEDIKNVSRLQSPKVCGYLKVDNEELLPKGLVDREPPEELVHRVKRRADPDPMKNTCKLLVVADHRFYRYMGRGEESTTTNYLIELIDRVDDIYRNTSWDNAGFKGYGIQIEQIRILKSPQEVKPGEKHYNMAKSYPNEEKDAWDVKMLLEQFSFDIAEEASKVCLAHLFTYQDFDMGTLGLAYVGSPRANSHGGVCPKAYYSPVGKKNIYLNSGLTSTKNYGKTILTKEADLVTTHELGHNFGAEHDPDGLAECAPNEDQGGKYVMYPIAVSGDHENNKMFSNCSKQSIYKTIESKAQECFQERSNKVCGNSRVDEGEECDPGIMYLNNDTCCNSDCTLKEGVQCSDRNSPCCKNCQFETAQKKCQEAINATCKGVSYCTGNSSECPPPGNAEDDTVCLDLGKCKDGKCIPFCEREQQLESCACNETDNSCKVCCRDLSGRCVPYVDAEQKNLFLRKGKPCTVGFCDMNGKCEKRVQDVIERFWDFIDQLSINTFGKFLADNIVGSVLVFSLIFWIPFSILVHCVDKKLDKQYESLSLFHPSNVEMLSSMDSASVRIIKPFPAPQTPGRLQPAPVIPSAPAAPKLDHQRMDTIQEDPSTDSHMDEDGFEKDPFPNSSTAAKSFEDLTDHPVTRSEKAASFKLQRQNRVDSKETEC T82393 DRUGINFO D0HG5M Apratastat Phase 2 T82393 DRUGINFO D02CZF Aderbasib Phase 1/2 T82393 DRUGINFO D03ESO GW-3333 Preclinical T82393 DRUGINFO D01DVX DPC-333 Terminated T82393 DRUGINFO D04WWO IM-491 Investigative T82393 DRUGINFO D08VFY Batimistat Investigative T82393 DRUGINFO D0DD7N CH4474 Investigative T82393 DRUGINFO D02UYR PKF-241-466 Investigative T82393 DRUGINFO D09ZOA 2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide Investigative T82393 DRUGINFO D0NV9C 2-(4-bromophenylsulfonamido)-N-hydroxyacetamide Investigative T82393 DRUGINFO D0XK7G N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide Investigative T82393 DRUGINFO D00RNA N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide Investigative T82393 DRUGINFO D08ICI N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) Investigative T82393 DRUGINFO D0H2PA PKF-242-484 Investigative T82393 DRUGINFO D07GEL SL422 Investigative T82393 DRUGINFO D03AMR SR-973 Investigative T82393 DRUGINFO D0W2UK IK-862 Investigative T35940 TARGETID T35940 T35940 FORMERID TTDR00148 T35940 UNIPROID MP2K1_HUMAN T35940 TARGNAME ERK activator kinase 1 (MEK1) T35940 GENENAME MAP2K1 T35940 TARGTYPE Clinical trial T35940 SYNONYMS PRKMK1; Mitogen-activated protein kinase kinase 1; MKK1; MEK 1; MAPKK 1; MAPK/ERKkinase 1; MAPK/ERK kinase 1; MAP kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1 T35940 FUNCTION Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis. Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. T35940 PDBSTRUC 5YT3; 5HZE; 5EYM; 5BX0; 4U81 T35940 BIOCLASS Kinase T35940 ECNUMBER EC 2.7.12.2 T35940 SEQUENCE MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV T35940 DRUGINFO D0T5DP Selumetinib Phase 3 T35940 DRUGINFO D0XW4G Pyridic ketone derivative 1 Patented T35940 DRUGINFO D0LR2Y Diamidothiazole derivative 1 Patented T35940 DRUGINFO D02UQG RDEA-436 Discontinued in Phase 1 T35940 DRUGINFO D0I4NN 4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide Investigative T35940 DRUGINFO D0T0VC 5-phenylamino-4-cyano-3-hydroxy-isothiazole Investigative T35940 DRUGINFO D0TF0V ALDISIN Investigative T35940 DRUGINFO D00JMT REVERSINE Investigative T35940 DRUGINFO D08BMM OROIDIN Investigative T35940 DRUGINFO D9ILC1 PD98059 Investigative T35940 DRUGINFO D01WAI DEBROMOHYMENIALDISINE Investigative T35940 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T64567 TARGETID T64567 T64567 FORMERID TTDR00211 T64567 UNIPROID CAH9_HUMAN T64567 TARGNAME Carbonic anhydrase IX (CA-IX) T64567 GENENAME CA9 T64567 TARGTYPE Clinical trial T64567 SYNONYMS Renal cell carcinoma-associated antigen G250; RCC-associated antigen G250; PMW1; P54/58N; Membrane antigen MN; MN; G250 antigen (MN/CA IX/G250); G250; Carbonic anhydrase 9; Carbonate dehydratase IX; CAIX T64567 FUNCTION Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervical neoplasia. Reversible hydration of carbon dioxide. T64567 PDBSTRUC 6G9U; 6G98; 6FE2; 6FE1; 6FE0 T64567 BIOCLASS Alpha-carbonic anhydrase T64567 ECNUMBER EC 4.2.1.1 T64567 SEQUENCE MAPLCPSPWLPLLIPAPAPGLTVQLLLSLLLLVPVHPQRLPRMQEDSPLGGGSSGEDDPLGEEDLPSEEDSPREEDPPGEEDLPGEEDLPGEEDLPEVKPKSEEEGSLKLEDLPTVEAPGDPQEPQNNAHRDKEGDDQSHWRYGGDPPWPRVSPACAGRFQSPVDIRPQLAAFCPALRPLELLGFQLPPLPELRLRNNGHSVQLTLPPGLEMALGPGREYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHVVHLSTAFARVDEALGRPGGLAVLAAFLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLDISALLPSDFSRYFQYEGSLTTPPCAQGVIWTVFNQTVMLSAKQLHTLSDTLWGPGDSRLQLNFRATQPLNGRVIEASFPAGVDSSPRAAEPVQLNSCLAAGDILALVFGLLFAVTSVAFLVQMRRQHRRGTKGGVSYRPAEVAETGA T64567 DRUGINFO D0A8JP PARABEN Phase 3 T64567 DRUGINFO D07SDQ Curcumin Phase 3 T64567 DRUGINFO D0L6HN PHENOL Phase 2/3 T64567 DRUGINFO D04IIU INDISULAM Phase 2 T64567 DRUGINFO D0BH7Z Girentuximab I-124 Phase 2 T64567 DRUGINFO D0Y6OA Coumate Phase 2 T64567 DRUGINFO D03PQW BAY 79-4620 Phase 1 T64567 DRUGINFO D05CVC 90Y-cG250 Phase 1 T64567 DRUGINFO D0V0UK SULFAMIDE Phase 1 T64567 DRUGINFO D01YQE PMID30074415-Compound-GS3 Patented T64567 DRUGINFO D06LLY Sulfonamide-thiadiazole derivative 2 Patented T64567 DRUGINFO D08RPE Sulfonamide derivative 12 Patented T64567 DRUGINFO D0UK9U PMID30074415-Compound-12 Patented T64567 DRUGINFO D0W9VU Sulfonamide-thiadiazole derivative 1 Patented T64567 DRUGINFO D03SLR FERULIC ACID Patented T64567 DRUGINFO D01BUS CA9-ADC Discontinued in Phase 1 T64567 DRUGINFO D0LD9S SPERMINE Terminated T64567 DRUGINFO D00TRF 2-(benzyloxyamino)-N-hydroxyacetamide Investigative T64567 DRUGINFO D01CXM 6-Acetyl-7-ethoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D01FOK 7-ethoxy-8-propionyl-2H-chromen-2-one Investigative T64567 DRUGINFO D02MAK 6-Acetyl-7-hydroxy-2H-chromen-2-one Investigative T64567 DRUGINFO D03LHJ 8-acetyl-7-propoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D05VUA 6-acetyl-7-methoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D06WZG 8-acetyl-7-ethoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D07VXX 2-(benzyloxyamino)-N-hydroxy-3-methylpentanamide Investigative T64567 DRUGINFO D08JNO 8-acetyl-7-butoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D09JAR BICARBONATE Investigative T64567 DRUGINFO D0BM2T (4-sulfamoylphenylethylthioureido)fluorescein Investigative T64567 DRUGINFO D0EH0S 7-hydroxy-8-propionyl-2H-chromen-2-one Investigative T64567 DRUGINFO D0EY2F 7-hydroxy-6-propionyl-2H-chromen-2-one Investigative T64567 DRUGINFO D0F7KC 8-acetyl-7-methoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D0J7KJ 6-acetyl-7-propoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D0K1FG 8-Acetyl-7-hydroxy-2H-chromen-2-one Investigative T64567 DRUGINFO D0O6ZD 8-acetyl-7-(benzyloxy)-2H-chromen-2-one Investigative T64567 DRUGINFO D0T9BB 7-methoxy-8-propionyl-2H-chromen-2-one Investigative T64567 DRUGINFO D0V0FY 8-Propionyl-7-propoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D00RDE 4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide Investigative T64567 DRUGINFO D02JEZ 7-hydroxycoumarin Investigative T64567 DRUGINFO D02KDH 2-(N''-Acetyl-hydrazino)-benzenesulfonamide Investigative T64567 DRUGINFO D06KTD 2-Hydrazinocarbonyl-benzenesulfonamide Investigative T64567 DRUGINFO D07CQI 2-Sulfamoyl-benzoic acid methyl ester Investigative T64567 DRUGINFO D07UCQ Sodium phenylaminomethanesulfonate Investigative T64567 DRUGINFO D0C6ED 1,4-phenylene disulfamate Investigative T64567 DRUGINFO D0F7SO Quinoline-8-sulfonamide Investigative T64567 DRUGINFO D0M9IQ Sodium N-methylphenylaminomethanesulfonate Investigative T64567 DRUGINFO D0N5KX Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester Investigative T64567 DRUGINFO D0Y1XM 2-(benzyloxyamino)-N-hydroxyhexanamide Investigative T64567 DRUGINFO D00FGB 2-acetamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D00XIB 1-acetamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D01EEM 2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide Investigative T64567 DRUGINFO D01UDU 3-Chloro-4-hydrazino-benzenesulfonamide Investigative T64567 DRUGINFO D01YHK 3-Fluoro-4-hydrazino-benzenesulfonamide Investigative T64567 DRUGINFO D03DAM 2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide Investigative T64567 DRUGINFO D04BKU Sulfamic acid 4-sulfamoyloxy-butyl ester Investigative T64567 DRUGINFO D04HRS 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide Investigative T64567 DRUGINFO D04POB ACETYLSULFANILAMIDE Investigative T64567 DRUGINFO D05BMD 2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide Investigative T64567 DRUGINFO D05FNN Sulfamic acid 7-sulfamoyloxy-heptyl ester Investigative T64567 DRUGINFO D05QEK Aminobenzolamide derivative Investigative T64567 DRUGINFO D06NDR 2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide Investigative T64567 DRUGINFO D07CBA Sulfamic acid 16-sulfamoyloxy-hexadecyl ester Investigative T64567 DRUGINFO D07IHP Sulfamic acid 3-sulfamoyloxy-phenyl ester Investigative T64567 DRUGINFO D07LYW 2-valproylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D07PNA 2-nonylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D07YSQ N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide Investigative T64567 DRUGINFO D07ZXR Sulfamic acid 12-sulfamoyloxy-dodecyl ester Investigative T64567 DRUGINFO D08AOA 2-ethylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D09JHA Azide Investigative T64567 DRUGINFO D0B4IN NSC-654077 Investigative T64567 DRUGINFO D0BD0K 3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide Investigative T64567 DRUGINFO D0C7WG 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide Investigative T64567 DRUGINFO D0D0BO 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide Investigative T64567 DRUGINFO D0DY9U 3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide Investigative T64567 DRUGINFO D0G0OP 2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide Investigative T64567 DRUGINFO D0G9NE 1-cyclohexylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D0H4CF 3-((4-aminophenyl)diazenyl)benzenesulfonamide Investigative T64567 DRUGINFO D0HN0R 2-cyclohexylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D0J1PZ N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide Investigative T64567 DRUGINFO D0J3SP 2-pentafluorophenylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D0KZ2D 1-valproylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D0L4FM PHENYLSULFAMATE Investigative T64567 DRUGINFO D0LJ5P 4-ethynyl benzene sulfonamide Investigative T64567 DRUGINFO D0O4KL 1-pentafluorophenylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D0O8WV 2-propylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D0Q0EK 4-Hydrazinocarbonyl-benzenesulfonamide Investigative T64567 DRUGINFO D0SF3B 2-butylamido-5-sulfonamidoindane Investigative T64567 DRUGINFO D0T2YZ N-(4-Sulfamoyl-phenyl)-isobutyramide Investigative T64567 DRUGINFO D0T6ZX HYDROSULFIDE Investigative T64567 DRUGINFO D0X0PO Sulfamic acid 6-sulfamoyloxy-hexyl ester Investigative T64567 DRUGINFO D0X1MY 5-Amino-[1,3,4]thiadiazole-2-thiol Investigative T64567 DRUGINFO D0X9LJ 4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide Investigative T64567 DRUGINFO D00IKQ 4-Methoxy-3-pyridinesulfonamide Investigative T64567 DRUGINFO D00NUK 4-Methanesulfonylamino-benzenesulfonamide Investigative T64567 DRUGINFO D01JTI 3-bromophenyl-difluoromethanesulfonamide Investigative T64567 DRUGINFO D02NQK 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide Investigative T64567 DRUGINFO D04JIN (2-bromophenyl)difluoromethanesulfonamide Investigative T64567 DRUGINFO D04SNH 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide Investigative T64567 DRUGINFO D05EBZ 4-(4-Cyanophenoxy)-3-pyridinesulfonamide Investigative T64567 DRUGINFO D05QUG 7-phenethoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D05RAB 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide Investigative T64567 DRUGINFO D05VSK ETHOXYCOUMARIN Investigative T64567 DRUGINFO D06GPL 4-methylphenyl-difluoromethanesulfonamide Investigative T64567 DRUGINFO D06ZMH 3-(3-Phenyl-ureido)-benzenesulfonamide Investigative T64567 DRUGINFO D07SIA PHENYLMETHANESULFONAMIDE Investigative T64567 DRUGINFO D08JCC 4-(4-Fluorophenoxy)-3-pyridinesulfonamide Investigative T64567 DRUGINFO D09CXX N-hydroxysulfamide Investigative T64567 DRUGINFO D09LUD 4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide Investigative T64567 DRUGINFO D09UQM 1-(3,4-dichlorophenyl)-3-hydroxyurea Investigative T64567 DRUGINFO D0I5YQ 4-nitrophenyl-difluoromethanesulfonamide Investigative T64567 DRUGINFO D0IU3X (4-bromophenyl)difluoromethanesulfonamide Investigative T64567 DRUGINFO D0K3LN N-(4-Sulfamoyl-phenyl)-butyramide Investigative T64567 DRUGINFO D0KB6T N-(4-Sulfamoyl-phenyl)-benzamide Investigative T64567 DRUGINFO D0M4EV N-(4-cyanophenyl)sulfamide Investigative T64567 DRUGINFO D0N8LR N-(4-Sulfamoyl-phenyl)-propionamide Investigative T64567 DRUGINFO D0PA5L N-(pentafluorophenyl)sulfamide Investigative T64567 DRUGINFO D0Q0XO Pentanoic acid (4-sulfamoyl-phenyl)-amide Investigative T64567 DRUGINFO D0RK7J 2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide Investigative T64567 DRUGINFO D0UN0E PHENYLDIFLUOROMETHANESULFONAMIDE Investigative T64567 DRUGINFO D0YD9F 4-Benzenesulfonylamino-benzenesulfonamide Investigative T64567 DRUGINFO D0Z6TM 4-azidobenzenesulfonamide Investigative T64567 DRUGINFO D00IAE Prop-2-ynyl 4-sulfamoylbenzoate Investigative T64567 DRUGINFO D00RNZ 7-(benzyloxy)-2H-chromen-2-one Investigative T64567 DRUGINFO D01OTW 4-(Cyanomethylthio)pyridine-3-sulfonamide Investigative T64567 DRUGINFO D01XFH N-propynyl amidebenzenesulphonide Investigative T64567 DRUGINFO D02BMV 4-(2-Propynylthio)pyridine-3-sulfonamide Investigative T64567 DRUGINFO D03KRB 4,4'-thiodipyridine-3-sulfonamide Investigative T64567 DRUGINFO D03VDJ SULFAMATE Investigative T64567 DRUGINFO D04VSP 4-Ethoxy-3-pyridinesulfonamide Investigative T64567 DRUGINFO D05ETN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide Investigative T64567 DRUGINFO D05JAJ 4-(Quinolinoxy)-3-pyridinesulfonamide Investigative T64567 DRUGINFO D06DYP 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T64567 DRUGINFO D06IOI 4-Benzythiopyridine-3-sulfonamide Investigative T64567 DRUGINFO D09TKG 4-(Allylamino)-3-pyridinesulfonamide Investigative T64567 DRUGINFO D09WVV N1-(2-aminoethyl)ethane-1,2-diamine Investigative T64567 DRUGINFO D0A0YX SACCHARIN Investigative T64567 DRUGINFO D0G0FJ 2-hydrazinylbenzenesulfonamide Investigative T64567 DRUGINFO D0J7GU 4-Methylthiopyridine-3-sulfonamide Investigative T64567 DRUGINFO D0LU4S 7-butoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D0OT5L 7-propoxy-2H-chromen-2-one Investigative T64567 DRUGINFO D0Q5VB 4-(Methylhydrazino)-3-pyridinesulfonamide Investigative T64567 DRUGINFO D0R4KQ 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide Investigative T64567 DRUGINFO D0RB0D 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid Investigative T64567 DRUGINFO D0TY8X 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide Investigative T64567 DRUGINFO D0UM1I 4-Hydrazino-3-pyridinesulfonamide Investigative T64567 DRUGINFO D0V5OW 4-(Carbamolymethylthio)pyridine-3-sulfonamide Investigative T64567 DRUGINFO D0X6IE 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide Investigative T64567 DRUGINFO D0Z1HY 4-amino-6-chlorobenzene-1,3-disulfonamide Investigative T64567 DRUGINFO D0ZC3W P-toluenesulfonamide Investigative T64567 DRUGINFO D00XJA 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid Investigative T64567 DRUGINFO D04VLI 4-(2-Hydroxy-ethyl)-benzenesulfonamide Investigative T64567 DRUGINFO D07TAJ Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate Investigative T64567 DRUGINFO D0D6UR 2-oxo-2H-thiochromene-3-carboxylic acid Investigative T64567 DRUGINFO D0H3NS 2-oxo-2H-chromene-3-carboxylic acid Investigative T64567 DRUGINFO D0J2AE 3-Amino-benzenesulfonamide Investigative T64567 DRUGINFO D0OI1H 2-Amino-benzenesulfonamide Investigative T64567 DRUGINFO D0X5HL N1-(naphthalen-1-yl)ethane-1,2-diamine Investigative T64567 DRUGINFO D04NSN 4-(2-AMINOETHYL)BENZENESULFONAMIDE Investigative T64567 DRUGINFO D05XZM 4-(hydroxymethyl)benzenesulfonamide Investigative T64567 DRUGINFO D09JPC Hexane-1,6-diamine Investigative T64567 DRUGINFO D09PWX Carzenide Investigative T64567 DRUGINFO D0G3BI 6-methyl-2-oxo-2H-chromene-3-carboxylic acid Investigative T64567 DRUGINFO D0L5TZ 6-(hydroxymethyl)-2H-chromen-2-one Investigative T64567 DRUGINFO D0Q2LL 6-Hydroxy-benzothiazole-2-sulfonic acid amide Investigative T64567 DRUGINFO D0U4BB HERNIARIN Investigative T64567 DRUGINFO D00YEF Decane-1,10-diyl disulfamate Investigative T64567 DRUGINFO D01STY 4-Amino-3-iodo-benzenesulfonamide Investigative T64567 DRUGINFO D02QGI Pentane-1,5-diamine Investigative T64567 DRUGINFO D03ZMQ COUMARIN Investigative T64567 DRUGINFO D04CVC 4-Amino-3-fluoro-benzenesulfonamide Investigative T64567 DRUGINFO D05TLB Octyl sulfamate Investigative T64567 DRUGINFO D09WSJ Decyl sulfamate Investigative T64567 DRUGINFO D0AU0M P-Coumaric Acid Investigative T64567 DRUGINFO D0D4OV Octane-1,8-diyl disulfamate Investigative T64567 DRUGINFO D0E8CC BENZOLAMIDE Investigative T64567 DRUGINFO D0M3PO 2,4-Disulfamyltrifluoromethylaniline Investigative T64567 DRUGINFO D0N1AW 6-(aminomethyl)-2H-chromen-2-one Investigative T64567 DRUGINFO D0NN3Q 4-Hydrazino-benzenesulfonamide Investigative T64567 DRUGINFO D0P6AM 4-Amino-3-bromo-benzenesulfonamide Investigative T64567 DRUGINFO D0Q7DJ Syringic Acid Investigative T64567 DRUGINFO D0VD7H CL-5343 Investigative T64567 DRUGINFO D0YU8J 4-Amino-3-chloro-benzenesulfonamide Investigative T64567 DRUGINFO D0V7AA CATECHIN Investigative T64567 DRUGINFO D0Y3TZ GALLICACID Investigative T64567 DRUGINFO D0A4TC MMI270 Investigative T64567 DRUGINFO D0A1CM ELLAGIC ACID Investigative T51191 TARGETID T51191 T51191 FORMERID TTDR01156 T51191 UNIPROID HDAC2_HUMAN T51191 TARGNAME Histone deacetylase 2 (HDAC2) T51191 GENENAME HDAC2 T51191 TARGTYPE Clinical trial T51191 SYNONYMS HD2 T51191 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. Interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, CAF1. Deacetylates TSHZ3 and regulates its transcriptional repressor activity. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. May be involved in the transcriptional repression of circadian target genes, such as PER1, mediated by CRY1 through histone deacetylation. Involved in MTA1-mediated transcriptional corepression of TFF1 and CDKN1A. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). T51191 PDBSTRUC 6G3O; 5IX0; 5IWG; 4LY1; 4LXZ T51191 BIOCLASS Carbon-nitrogen hydrolase T51191 ECNUMBER EC 3.5.1.98 T51191 SEQUENCE MAYSQGGGKKKVCYYYDGDIGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKATAEEMTKYHSDEYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVAGAVKLNRQQTDMAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNFPMRDGIDDESYGQIFKPIISKVMEMYQPSAVVLQCGADSLSGDRLGCFNLTVKGHAKCVEVVKTFNLPLLMLGGGGYTIRNVARCWTYETAVALDCEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTPEYMEKIKQRLFENLRMLPHAPGVQMQAIPEDAVHEDSGDEDGEDPDKRISIRASDKRIACDEEFSDSEDEGEGGRRNVADHKKGAKKARIEEDKKETEDKKTDVKEEDKSKDNSGEKTDTKGTKSEQLSNP T51191 DRUGINFO D06TKI CHR-3996 Phase 1/2 T51191 DRUGINFO D0N2FN PMID29671355-Compound-74 Patented T51191 DRUGINFO D0C9NX PMID29671355-Compound-59 Patented T51191 DRUGINFO D0OU0J PMID29671355-Compound-55 Patented T51191 DRUGINFO D0EH2K PMID29671355-Compound-11 Patented T51191 DRUGINFO D0Q1QY PMID29671355-Compound-9 Patented T51191 DRUGINFO D0LN1T PMID29671355-Compound-8 Patented T51191 DRUGINFO D0JB4S PMID29671355-Compound-61 Patented T51191 DRUGINFO D00HXJ PMID29671355-Compound-23 Patented T51191 DRUGINFO D0N2DK PMID29671355-Compound-44 Patented T51191 DRUGINFO D0CH8Q PMID29671355-Compound-56 Patented T51191 DRUGINFO D0M0RE PMID29671355-Compound-67 Patented T51191 DRUGINFO D0DI9S PMID29671355-Compound-31 Patented T51191 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T51191 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T51191 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T51191 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T51191 DRUGINFO D01AVS N8-hydroxy-2-methoxy-N1-phenyloctanediamide Investigative T51191 DRUGINFO D01TSM N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D02TQA N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide Investigative T51191 DRUGINFO D03TNE N7-hydroxy-2-methoxy-N1-phenylheptanediamide Investigative T51191 DRUGINFO D03TQD N7-hydroxy-N1-phenyl-2-propoxyheptanediamide Investigative T51191 DRUGINFO D05RWU N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D06IWR N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D06YYY KAR-1880 Investigative T51191 DRUGINFO D07BMT N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide Investigative T51191 DRUGINFO D07WSB N-(4-amino-3'-methylbiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D08USK N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D08YLO N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D09SVH N8,2-dihydroxy-N1-phenyloctanediamide Investigative T51191 DRUGINFO D0A4KW N-(2-amino-5-(furan-3-yl)phenyl)benzamide Investigative T51191 DRUGINFO D0AK8Q N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide Investigative T51191 DRUGINFO D0D2US 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide Investigative T51191 DRUGINFO D0FI2F 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide Investigative T51191 DRUGINFO D0H4SC N-(4-amino-4'-bromobiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D0I2KC N-(2-amino-5-(furan-2-yl)phenyl)benzamide Investigative T51191 DRUGINFO D0K3MR 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide Investigative T51191 DRUGINFO D0MD7H N-(4-aminobiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D0Q4LX N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide Investigative T51191 DRUGINFO D0U8FC N-(2-aminophenyl)benzamide Investigative T51191 DRUGINFO D0W2PX N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D0W9BH N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide Investigative T51191 DRUGINFO D0Y4SD N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide Investigative T51191 DRUGINFO D01FYB N-(2-aminophenyl)quinoxaline-6-carboxamide Investigative T51191 DRUGINFO D01RJY 7-Biphenyl-4-yl-heptanoic acid hydroxyamide Investigative T51191 DRUGINFO D03XXI 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid Investigative T51191 DRUGINFO D04ETX 1,1,1-Trifluoro-8-phenoxy-octan-2-one Investigative T51191 DRUGINFO D04LLD 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide Investigative T51191 DRUGINFO D05ZGM 7-Phenoxy-heptanoic acid hydroxyamide Investigative T51191 DRUGINFO D06BKA 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one Investigative T51191 DRUGINFO D0E0TA N-(4-hydroxybiphenyl-3-yl)benzamide Investigative T51191 DRUGINFO D0H9DS 8-Phenyl-octanoic acid hydroxyamide Investigative T51191 DRUGINFO D0NL6C 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one Investigative T51191 DRUGINFO D04UVL N-(2-aminophenyl)nicotinamide Investigative T51191 DRUGINFO D09RKA santacruzamate A Investigative T51191 DRUGINFO D0M9LJ N-(4-aminobiphenyl-3-yl)nicotinamide Investigative T51191 DRUGINFO D0Q2GM N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide Investigative T51191 DRUGINFO D0YO6M N-(2-aminophenyl)-4-methoxybenzamide Investigative T51191 DRUGINFO D02NWS 4-Phenylbutyrohydroxamic acid Investigative T51191 DRUGINFO D0S0WK 8-Oxo-8-phenyl-octanoic acid hydroxyamide Investigative T51191 DRUGINFO D07YZZ Octanedioic acid bis-hydroxyamide Investigative T51191 DRUGINFO D0N9AK ST-2986 Investigative T51191 DRUGINFO D00KFF 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative T51191 DRUGINFO D00SEE 7-Mercapto-heptanoic acid phenylamide Investigative T51191 DRUGINFO D00ZSD 6-benzenesulfinylhexanoic acid hydroxamide Investigative T51191 DRUGINFO D01MFV N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative T51191 DRUGINFO D01XWZ 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative T51191 DRUGINFO D01XXN N-Hydroxy-4-phenylacetylamino-benzamide Investigative T51191 DRUGINFO D02MQM 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative T51191 DRUGINFO D02UTC N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative T51191 DRUGINFO D02WZK 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T51191 DRUGINFO D04GGW Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative T51191 DRUGINFO D04HSS N-(6-Mercapto-hexyl)-benzamide Investigative T51191 DRUGINFO D04NSP 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T51191 DRUGINFO D04ZDI N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative T51191 DRUGINFO D05AHZ 6-benzenesulfonylhexanoic acid hydroxamide Investigative T51191 DRUGINFO D05FEJ 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative T51191 DRUGINFO D05GVY Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative T51191 DRUGINFO D05LLX 4-Butyrylamino-N-hydroxy-benzamide Investigative T51191 DRUGINFO D05VFP 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T51191 DRUGINFO D05XAN 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative T51191 DRUGINFO D06IQB 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative T51191 DRUGINFO D06VBN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative T51191 DRUGINFO D06XNP 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative T51191 DRUGINFO D07FJU 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative T51191 DRUGINFO D09YBN 6-Phenoxy-hexane-1-thiol Investigative T51191 DRUGINFO D09ZNU 4-Benzoylamino-N-hydroxy-benzamide Investigative T51191 DRUGINFO D0A5LS 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T51191 DRUGINFO D0AX7B 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative T51191 DRUGINFO D0B2ZJ 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T51191 DRUGINFO D0B3ZM 6-Mercapto-hexanoic acid phenylamide Investigative T51191 DRUGINFO D0C0VP Cyclostellettamine derivative Investigative T51191 DRUGINFO D0C2KD N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative T51191 DRUGINFO D0D2KE 5-Mercapto-pentanoic acid phenylamide Investigative T51191 DRUGINFO D0E8KR Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative T51191 DRUGINFO D0F0KS N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative T51191 DRUGINFO D0H1FZ 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative T51191 DRUGINFO D0KE3I (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative T51191 DRUGINFO D0QO0L N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative T51191 DRUGINFO D0R4BS N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative T51191 DRUGINFO D0R5VG N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative T51191 DRUGINFO D0RU1X 8-Oxo-8-phenyl-octanoic acid Investigative T51191 DRUGINFO D0S7WQ N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative T51191 DRUGINFO D0S9JF 6-phenylsulfanylhexanoic acid hydroxamide Investigative T51191 DRUGINFO D0T0SK ST-2987 Investigative T51191 DRUGINFO D0T4IY 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative T51191 DRUGINFO D0V2ZO 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative T51191 DRUGINFO D0XZ9Q 8-Mercapto-octanoic acid phenylamide Investigative T51191 DRUGINFO D0YY9M N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative T51191 DRUGINFO D0Z3BM 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative T51191 DRUGINFO D0Z5KX 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative T51191 DRUGINFO D0Z7YS N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative T51191 DRUGINFO D0N0TS PSAMMAPLIN A Investigative T02562 TARGETID T02562 T02562 FORMERID TTDR00630 T02562 UNIPROID PTGES_HUMAN T02562 TARGNAME Prostaglandin E synthase (PTGES) T02562 GENENAME PTGES T02562 TARGTYPE Clinical trial T02562 SYNONYMS p53-induced gene 12 protein; PIG12; PGES; PGE synthase; P53-induced apoptosis protein 12; Microsomal prostaglandin E synthase 1; Microsomal glutathione S-transferase 1-like 1; MPGES1; MPGES-1; MGST1L1; MGST1-L1 T02562 FUNCTION Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). T02562 PDBSTRUC 5TL9; 5T37; 5T36; 5K0I; 5BQI T02562 BIOCLASS Intramolecular oxidoreductase T02562 ECNUMBER EC 5.3.99.3 T02562 SEQUENCE MPAHSLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL T02562 DRUGINFO D00MBY AAD-2004 Phase 1 T02562 DRUGINFO D00PHK Carboxylic acid derivative 1 Patented T02562 DRUGINFO D00XFM Phthalazinone derivative 1 Patented T02562 DRUGINFO D02DXA Benzamide derivative 18 Patented T02562 DRUGINFO D07WOT Betais-sulfonylamino derivative 1 Patented T02562 DRUGINFO D07YPE Benzimidazole derivative 13 Patented T02562 DRUGINFO D0AH1A Benzamide derivative 16 Patented T02562 DRUGINFO D0BR7G Imidazopyridine derivative 5 Patented T02562 DRUGINFO D0C3ZN Imidazopyridine derivative 6 Patented T02562 DRUGINFO D0EB9M PMID28627961-Compound-22 Patented T02562 DRUGINFO D0F8KE Imidazole benzamide derivative 1 Patented T02562 DRUGINFO D0FX6I Benzamide derivative 15 Patented T02562 DRUGINFO D0HH5B Benzimidazole derivative 15 Patented T02562 DRUGINFO D0I1GO PMID28627961-Compound-32 Patented T02562 DRUGINFO D0I5DE Benzimidazole derivative 14 Patented T02562 DRUGINFO D0JH7Q PMID28627961-Compound-33 Patented T02562 DRUGINFO D0KY1Y Benzimidazole derivative 16 Patented T02562 DRUGINFO D0LY6S PMID28627961-Compound-31 Patented T02562 DRUGINFO D0N2DJ Benzimidazole derivative 11 Patented T02562 DRUGINFO D0O2DY PMID28627961-Compound-41 Patented T02562 DRUGINFO D0OE9W Alpha-substituted pirinixic acid and pirinixic acid ester derivative 1 Patented T02562 DRUGINFO D0RM0U Boswellia acid derivative 1 Patented T02562 DRUGINFO D0S2UD PMID28627961-Compound-30 Patented T02562 DRUGINFO D0T1UU Benzimidazole derivative 17 Patented T02562 DRUGINFO D0U9LS Polycyclic compound 1 Patented T02562 DRUGINFO D0UJ5D Imidazopyridine derivative 7 Patented T02562 DRUGINFO D0V4FE Piperidine carboxamide derivative 1 Patented T02562 DRUGINFO D0WG5P PMID28627961-Compound-44 Patented T02562 DRUGINFO D0WR0Q Pyrimidine derivative 2 Patented T02562 DRUGINFO D0XM9M Methyl-piperidine compound 1 Patented T02562 DRUGINFO D0YO3X Benzamide derivative 14 Patented T02562 DRUGINFO D0ZT9I Benzimidazole derivative 12 Patented T02562 DRUGINFO D0I9JH L-655240 Terminated T62449 TARGETID T62449 T62449 FORMERID TTDC00005 T62449 UNIPROID CHK1_HUMAN T62449 TARGNAME Checkpoint kinase-1 (CHK1) T62449 GENENAME CHEK1 T62449 TARGTYPE Clinical trial T62449 SYNONYMS Serine/threonine-protein kinase Chk1; Chk1; Cell cycle checkpoint kinase; CHK1 checkpoint homolog T62449 FUNCTION May also negatively regulate cell cycle progression during unperturbed cell cycles. This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome. Recognizes the substrate consensus sequence [R-X-X-S/T]. Binds to and phosphorylates CDC25A, CDC25B and CDC25C. Phosphorylation of CDC25A at 'Ser-178' and 'Thr-507' and phosphorylation of CDC25C at 'Ser-216' creates binding sites for 14-3-3 proteins which inhibit CDC25A and CDC25C. Phosphorylation of CDC25A at 'Ser-76', 'Ser-124', 'Ser-178', 'Ser-279' and 'Ser-293' promotes proteolysis of CDC25A. Phosphorylation of CDC25A at 'Ser-76' primes the protein for subsequent phosphorylation at 'Ser-79', 'Ser-82' and 'Ser-88' by NEK11, which is required for polyubiquitination and degradation of CDCD25A. Inhibition of CDC25 leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. Also phosphorylates NEK6. Binds to and phosphorylates RAD51 at 'Thr-309', which promotes the release of RAD51 from BRCA2 and enhances the association of RAD51 with chromatin, thereby promoting DNA repair by homologous recombination. Phosphorylates multiple sites within the C-terminus of TP53, which promotes activation of TP53 by acetylation and promotes cell cycle arrest and suppression of cellular proliferation. Also promotes repair of DNA cross-links through phosphorylation of FANCE. Binds to and phosphorylates TLK1 at 'Ser-743', which prevents the TLK1-dependent phosphorylation of the chromatin assembly factor ASF1A. This may enhance chromatin assembly both in the presence or absence of DNA damage. May also play a role in replication fork maintenance through regulation of PCNA. May regulate the transcription of genes that regulate cell-cycle progression through the phosphorylation of histones. Phosphorylates histone H3. 1 (to form H3T11ph), which leads to epigenetic inhibition of a subset of genes. May also phosphorylate RB1 to promote its interaction with the E2F family of transcription factors and subsequent cell cycle arrest. Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA. T62449 PDBSTRUC 6FCK; 6FCF; 6FC8; 5WI2; 5OQ8 T62449 BIOCLASS Kinase T62449 ECNUMBER EC 2.7.11.1 T62449 SEQUENCE MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICINKMLNHENVVKFYGHRREGNIQYLFLEYCSGGELFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPENLLLDERDNLKISDFGLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGFSKHIQSNLDFSPVNSASSEENVKYSSSQPEPRTGLSLWDTSPSYIDKLVQGISFSQPTCPDHMLLNSQLLGTPGSSQNPWQRLVKRMTRFFTKLDADKSYQCLKETCEKLGYQWKKSCMNQVTISTTDRRNNKLIFKVNLLEMDDKILVDFRLSKGDGLEFKRHFLKIKGKLIDIVSSQKIWLPAT T62449 DRUGINFO D00NZL LY2603618 Phase 2 T62449 DRUGINFO D05FWH SCH-900776 Phase 2 T62449 DRUGINFO D08UUL LY2606368 Phase 2 T62449 DRUGINFO D0Z9VY UCN-01 Phase 2 T62449 DRUGINFO DXJ4B7 LY2880070 Phase 1/2 T62449 DRUGINFO D00UQW RG7741 Phase 1 T62449 DRUGINFO D01ZUV GDC-0425 Phase 1 T62449 DRUGINFO D0PM7Q AZD7762 Phase 1 T62449 DRUGINFO D4MW3O MK-8776 Phase 1 T62449 DRUGINFO D0LR2Y Diamidothiazole derivative 1 Patented T62449 DRUGINFO D0O3KA RG7602 Discontinued in Phase 1 T62449 DRUGINFO D0U9IQ PF-477736 Discontinued in Phase 1 T62449 DRUGINFO D05UGJ XL844 Discontinued in Phase 1 T62449 DRUGINFO D00KDF SB 218078 Investigative T62449 DRUGINFO D01HUO BIS-IMIDE A Investigative T62449 DRUGINFO D03CQN Chk1-A Investigative T62449 DRUGINFO D06EZQ GRANULATIMIDE Investigative T62449 DRUGINFO D08OPW ARRY-575 Investigative T62449 DRUGINFO D08XCD 2-(cyclohexylamino)benzoic acid Investigative T62449 DRUGINFO D09YHQ 9-chlorobenzo[h]isoquinolin-1(2H)-one Investigative T62449 DRUGINFO D09YVU 6-(3-aminopropyl)benzo[h]isoquinolin-1(2H)-one Investigative T62449 DRUGINFO D0D6DH A-432411 Investigative T62449 DRUGINFO D0FO2K N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE Investigative T62449 DRUGINFO D0OC6H S-024 Investigative T62449 DRUGINFO D0S3TJ 6-MORPHOLIN-4-YL-9H-PURINE Investigative T62449 DRUGINFO D0Z2CN Isogranulatimide Investigative T62449 DRUGINFO D3U1LH V158411 Investigative T62449 DRUGINFO DYS56C SB218078 Investigative T62449 DRUGINFO D0M9OF 3-(1H-Indol-2-yl)-1H-quinolin-2-one Investigative T62449 DRUGINFO D0P4DG S-070 Investigative T62449 DRUGINFO D0Y3PH 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Investigative T62449 DRUGINFO D00ERW PMID17935989C25 Investigative T62449 DRUGINFO D0ME9B PMID20855207C25 Investigative T62449 DRUGINFO D0Z8PT CCT244747 Investigative T62449 DRUGINFO D01WAI DEBROMOHYMENIALDISINE Investigative T62449 DRUGINFO D0XC6G 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole Investigative T62449 DRUGINFO D0Y5RO NU-6102 Investigative T62449 DRUGINFO D01YWE PMID19364658C33 Investigative T62449 DRUGINFO D0IX7Y BX-912 Investigative T62449 DRUGINFO D0RG0Z BX-795 Investigative T62449 DRUGINFO D0N6ES KN-62 Investigative T62449 DRUGINFO D0B9BU CI-1040 Investigative T62449 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T62449 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T62449 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T62449 DRUGINFO D0L8HO RO-316233 Investigative T78429 TARGETID T78429 T78429 FORMERID TTDR01206 T78429 UNIPROID IKKB_HUMAN T78429 TARGNAME Inhibitor of nuclear factor kappa-B kinase beta (IKKB) T78429 GENENAME IKBKB T78429 TARGTYPE Clinical trial T78429 SYNONYMS Nuclear factor NF-kappa-B inhibitor kinase beta; NFKBIKB; Inhibitor of nuclear factor kappa-B kinase subunit beta; IkBKB; IKKB; IKK2; IKK-beta; IKK-B; I-kappa-B-kinase beta; I-kappa-B kinase 2 T78429 FUNCTION Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation. Phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs. Phosphorylates FOXO3, mediating the TNF-dependent inactivation of this pro-apoptotic transcription factor. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation. T78429 PDBSTRUC 4KIK; 4E3C; 3BRV; 3BRT T78429 BIOCLASS Kinase T78429 ECNUMBER EC 2.7.11.10 T78429 SEQUENCE MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCLEIQIMRRLTHPNVVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREGAILTLLSDIASALRYLHENRIIHRDLKPENIVLQQGEQRLIHKIIDLGYAKELDQGSLCTSFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPNWQPVQWHSKVRQKSEVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPTYGPNGCFKALDDILNLKLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELLQEAGLALIPDKPATQCISDGKLNEGHTLDMDLVFLFDNSKITYETQISPRPQPESVSCILQEPKRNLAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNNSCLSKMKNSMASMSQQLKAKLDFFKTSIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKIACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS T78429 DRUGINFO D07VIK Arsenic trioxide Approved T78429 DRUGINFO D0AE3U SAR-113945 Phase 2 T78429 DRUGINFO D0V3CK IMD-1041 Phase 2 T78429 DRUGINFO D0M4KE Parthenolide Phase 2 T78429 DRUGINFO D0Z5DM IMD-0354 Phase 1 T78429 DRUGINFO D06ZYC MLN0415 Discontinued in Phase 1 T78429 DRUGINFO D00XDG 5-amino-2-phenyl-oxazole-4-carboxylic acid amide Investigative T78429 DRUGINFO D01FPX 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide Investigative T78429 DRUGINFO D03PVS 3-amino-benzo[b]thiophene-2-carboxylic acid amide Investigative T78429 DRUGINFO D06CBR 2-amino-5-phenylthiophene-3-carboxamide Investigative T78429 DRUGINFO D08VQM 3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide Investigative T78429 DRUGINFO D09PLJ 6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine Investigative T78429 DRUGINFO D0N1UB 2-amino-quinoline-3-carboxylic acid amide Investigative T78429 DRUGINFO D0T6VA SC-514 Investigative T78429 DRUGINFO D0UP6G 4-amino-biphenyl-3-carboxylic acid amide Investigative T78429 DRUGINFO D0E3TC Staurosporine Investigative T78429 DRUGINFO D01OBJ 5-Bromo-6-methoxy-9H-beta-carboline Investigative T78429 DRUGINFO D02QAZ PF-228 Investigative T87675 TARGETID T87675 T87675 FORMERID TTDC00006 T87675 UNIPROID AURKA_HUMAN T87675 TARGNAME Aurora kinase A (AURKA) T87675 GENENAME AURKA T87675 TARGTYPE Clinical trial T87675 SYNONYMS hARK1; Serine/threonine-protein kinase aurora-A; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase 15; Serine/threonine kinase 15; STK6; STK15; IAK1; Breast tumor-amplified kinase; BTAK; Aurora/IPL1-related kinase 1; Aurora-related kinase 1; Aurora-A; Aurora 2; AYK1; AURA; ARK1; ARK-1; AIRK1; AIK T87675 FUNCTION Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for normal spindle positioning during mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex during metaphase. Required for initial activation of CDK1 at centrosomes. Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. Regulates KIF2A tubulin depolymerase activity. Required for normal axon formation. Plays a role in microtubule remodeling during neurite extension. Important for microtubule formation and/or stabilization. Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and stabilizing p53/TP53. Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity. Necessary for proper cilia disassembly prior to mitosis. Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression. T87675 PDBSTRUC 6R4D; 6R4C; 6R4B; 6R4A; 6R49 T87675 BIOCLASS Kinase T87675 ECNUMBER EC 2.7.11.1 T87675 SEQUENCE MDRSKENCISGPVKATAPVGGPKRVLVTQQFPCQNPLPVNSGQAQRVLCPSNSSQRVPLQAQKLVSSHKPVQNQKQKQLQATSVPHPVSRPLNNTQKSKQPLPSAPENNPEEELASKQKNEESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS T87675 DRUGINFO D0S4JK MLN8237 Phase 3 T87675 DRUGINFO D05PZB AT9283 Phase 3 T87675 DRUGINFO D0A1AQ Rosiglitazone + metformin Phase 3 T87675 DRUGINFO D0S7HM ENMD-2076 Phase 2 T87675 DRUGINFO D02XNW VX-680 Phase 2 T87675 DRUGINFO D08HOM ABT-348 Phase 2 T87675 DRUGINFO D02RJY PHA-739358 Phase 2 T87675 DRUGINFO D3QEZ2 LY3295668 Phase 1/2 T87675 DRUGINFO D0A5MC MLN8054 Phase 1 T87675 DRUGINFO D0L3RO TAS-119 Phase 1 T87675 DRUGINFO D6FX2G VIC-1911 Phase 1 T87675 DRUGINFO D0E5XA R763 Phase 1 T87675 DRUGINFO D0J6AB MK-5108 Phase 1 T87675 DRUGINFO D05LKZ HPP-607 Phase 1 T87675 DRUGINFO D0CY1B CYC116 Phase 1 T87675 DRUGINFO D0EJ3B AMG 900 Phase 1 T87675 DRUGINFO D0OA5G SNS-314 Phase 1 T87675 DRUGINFO D0H7AC PF-03814735 Discontinued in Phase 1 T87675 DRUGINFO D04YQF 2-(1H-pyrazol-3-yl)-1H-benzimidazole Investigative T87675 DRUGINFO D0QC0W ZM-447439 Investigative T87675 DRUGINFO D04MYT 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine Investigative T87675 DRUGINFO D00TKJ 7-fluoroindirubin-3-oxime Investigative T87675 DRUGINFO D06AGN Indirubin-3-acetoxime Investigative T87675 DRUGINFO D0V6LP Indirubin-3-methoxime Investigative T87675 DRUGINFO D06OAH 6-bromoindirubin-3-oxime Investigative T87675 DRUGINFO D05BHG Phosphonothreonine Investigative T87675 DRUGINFO D0Y0ES Indirubin-3'-monoxime Investigative T78198 TARGETID T78198 T78198 FORMERID TTDC00091 T78198 UNIPROID PNPH_HUMAN T78198 TARGNAME Purine nucleoside phosphorylase (PNP) T78198 GENENAME PNP T78198 TARGTYPE Clinical trial T78198 SYNONYMS PNP; Inosine phosphorylase T78198 FUNCTION The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta- (deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. T78198 PDBSTRUC 5UGF; 5ETJ; 4GKA; 4ECE; 4EB8 T78198 BIOCLASS Pentosyltransferase T78198 ECNUMBER EC 2.4.2.1 T78198 SEQUENCE MENGYTYEDYKNTAEWLLSHTKHRPQVAIICGSGLGGLTDKLTQAQIFDYGEIPNFPRSTVPGHAGRLVFGFLNGRACVMMQGRFHMYEGYPLWKVTFPVRVFHLLGVDTLVVTNAAGGLNPKFEVGDIMLIRDHINLPGFSGQNPLRGPNDERFGDRFPAMSDAYDRTMRQRALSTWKQMGEQRELQEGTYVMVAGPSFETVAECRVLQKLGADAVGMSTVPEVIVARHCGLRVFGFSLITNKVIMDYESLEKANHEEVLAAGKQAAQKLEQFVSILMASIPLPDKAS T78198 DRUGINFO D02ZKR BCX-3408 Phase 2 T78198 DRUGINFO D04XYL 2'3'-Dideoxyinosine Phase 2 T78198 DRUGINFO D02ZUO Forodesine Phase 1/2 T78198 DRUGINFO D08OBT Peldesine Phase 1 T78198 DRUGINFO D0H1OL Guanosine Phase 1 T78198 DRUGINFO D05UPB CI-972 Discontinued in Phase 1 T78198 DRUGINFO D01NTY 8-Iodo-Guanine Investigative T78198 DRUGINFO D01OHV 8-Azaguanine Investigative T78198 DRUGINFO D03HVE Hypoxanthine Investigative T78198 DRUGINFO D04JOV MT-Immucillin-H Investigative T78198 DRUGINFO D04LUI Ribose-1-Phosphate Investigative T78198 DRUGINFO D06KVV 2-Hydroxymethyl-Pyrrolidine-3,4-Diol Investigative T78198 DRUGINFO D07BGQ (+/-)-5'-deoxy-4'-fluoro-5'-methylthio-DADMe-ImmH Investigative T78198 DRUGINFO D07BNM 9-(5,5-Difluoro-5-Phosphonopentyl)Guanine Investigative T78198 DRUGINFO D07VEW DADMe-ImmG Investigative T78198 DRUGINFO D08TGC GUANOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE Investigative T78198 DRUGINFO D0A9WP Immucillin-G Investigative T78198 DRUGINFO D0BP5T Aza-C-nucleosides Investigative T78198 DRUGINFO D0D7PF 3-((2-Pyrrolidine-1-yl)-ethyl)uracil Investigative T78198 DRUGINFO D0E6BI 5'-Methylthio-ImmH Investigative T78198 DRUGINFO D0F7DM 9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE Investigative T78198 DRUGINFO D0FI2L 8-aminoguanosine Investigative T78198 DRUGINFO D0I8JJ 9-Deazainosine Investigative T78198 DRUGINFO D0J0HK 3-Deoxyguanosine Investigative T78198 DRUGINFO D0N2AA 8-aza-DADMe-ImmH Investigative T78198 DRUGINFO D0N2LE GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE Investigative T78198 DRUGINFO D0N5BA 9-Deazahypoxanthine Investigative T78198 DRUGINFO D0R5RF 5'-phenylthio-ImmH Investigative T78198 DRUGINFO D0R6UA 8-AMINOGUANINE Investigative T78198 DRUGINFO D0SO9G 5'-methylthio-immucillin-H Investigative T78198 DRUGINFO D0T7LB 5'-deoxy-4'-hydroxy-5'-methylthio-DADMe-ImmH Investigative T78198 DRUGINFO D0Z3OD 8-amino-9-benzylguanine Investigative T78198 DRUGINFO D02COM 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30) Investigative T23471 TARGETID T23471 T23471 FORMERID TTDC00199 T23471 UNIPROID PERM_HUMAN T23471 TARGNAME Myeloperoxidase (MPO) T23471 GENENAME MPO T23471 TARGTYPE Clinical trial T23471 SYNONYMS MPO T23471 FUNCTION Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acidin physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity. T23471 PDBSTRUC 6BMT; 6AZP; 5UZU; 5MFA; 5FIW T23471 BIOCLASS Peroxidases T23471 ECNUMBER EC 1.11.2.2 T23471 SEQUENCE MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTSLVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLHVALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMCNNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTDQLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPNDPRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQLGLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLLREHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYRSYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLEGGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYNAWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPLLACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMSNSYPRDFVNCSTLPALNLASWREAS T23471 DRUGINFO D0XD5A E-101 Phase 3 T23471 DRUGINFO D87IQS Mitiperstat Phase 2/3 T23471 DRUGINFO D08TRG AZD-3241 Phase 2 T23471 DRUGINFO D07SBP AZD4831 Phase 1 T23471 DRUGINFO D0Y3LJ AZD5904 Discontinued in Phase 1 T23471 DRUGINFO D01ZZG INV-311 Investigative T23471 DRUGINFO D05OZR 4-aminobenzoic acid hydrazide Investigative T49898 TARGETID T49898 T49898 FORMERID TTDC00166 T49898 UNIPROID CDK1_HUMAN T49898 TARGNAME Cyclin-dependent kinase 1 (CDK1) T49898 GENENAME CDK1 T49898 TARGTYPE Clinical trial T49898 SYNONYMS P34CDC2; P34 protein kinase; CDKN1; CDC28A; CDC2 T49898 FUNCTION Required in higher cells for entry into S-phase and mitosis. Phosphorylates PARVA/actopaxin, APC, AMPH, APC, BARD1, Bcl-xL/BCL2L1, BRCA2, CALD1, CASP8, CDC7, CDC20, CDC25A, CDC25C, CC2D1A, CENPA, CSNK2 proteins/CKII, FZR1/CDH1, CDK7, CEBPB, CHAMP1, DMD/dystrophin, EEF1 proteins/EF-1, EZH2, KIF11/EG5, EGFR, FANCG, FOS, GFAP, GOLGA2/GM130, GRASP1, UBE2A/hHR6A, HIST1H1 proteins/histone H1, HMGA1, HIVEP3/KRC, LMNA, LMNB, LMNC, LBR, LATS1, MAP1B, MAP4, MARCKS, MCM2, MCM4, MKLP1, MYB, NEFH, NFIC, NPC/nuclear pore complex, PITPNM1/NIR2, NPM1, NCL, NUCKS1, NPM1/numatrin, ORC1, PRKAR2A, EEF1E1/p18, EIF3F/p47, p53/TP53, NONO/p54NRB, PAPOLA, PLEC/plectin, RB1, UL40/R2, RAB4A, RAP1GAP, RCC1, RPS6KB1/S6K1, KHDRBS1/SAM68, ESPL1, SKI, BIRC5/survivin, STIP1, TEX14, beta-tubulins, MAPT/TAU, NEDD1, VIM/vimentin, TK1, FOXO1, RUNX1/AML1, SAMHD1, SIRT2 and RUNX2. CDK1/CDC2-cyclin-B controls pronuclear union in interphase fertilized eggs. Essential for early stages of embryonic development. During G2 and early mitosis, CDC25A/B/C-mediated dephosphorylation activates CDK1/cyclin complexes which phosphorylate several substrates that trigger at least centrosome separation, Golgi dynamics, nuclear envelope breakdown and chromosome condensation. Once chromosomes are condensed and aligned at the metaphase plate, CDK1 activity is switched off by WEE1- and PKMYT1-mediated phosphorylation to allow sister chromatid separation, chromosome decondensation, reformation of the nuclear envelope and cytokinesis. Inactivated by PKR/EIF2AK2- and WEE1-mediated phosphorylation upon DNA damage to stop cell cycle and genome replication at the G2 checkpoint thus facilitating DNA repair. Reactivated after successful DNA repair through WIP1-dependent signaling leading to CDC25A/B/C-mediated dephosphorylation and restoring cell cycle progression. In proliferating cells, CDK1-mediated FOXO1 phosphorylation at the G2-M phase represses FOXO1 interaction with 14-3-3 proteins and thereby promotes FOXO1 nuclear accumulation and transcription factor activity, leading to cell death of postmitotic neurons. The phosphorylation of beta-tubulins regulates microtubule dynamics during mitosis. NEDD1 phosphorylation promotes PLK1-mediated NEDD1 phosphorylation and subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. In addition, CC2D1A phosphorylation regulates CC2D1A spindle pole localization and association with SCC1/RAD21 and centriole cohesion during mitosis. The phosphorylation of Bcl-xL/BCL2L1 after prolongated G2 arrest upon DNA damage triggers apoptosis. In contrast, CASP8 phosphorylation during mitosis prevents its activation by proteolysis and subsequent apoptosis. This phosphorylation occurs in cancer cell lines, as well as in primary breast tissues and lymphocytes. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. CALD1 phosphorylation promotes Schwann cell migration during peripheral nerve regeneration. CDK1-cyclin-B complex phosphorylates NCKAP5L and mediates its dissociation from centrosomes during mitosis. Regulates the amplitude of the cyclic expression of the core clock gene ARNTL/BMAL1 by phosphorylating its transcriptional repressor NR1D1, and this phosphorylation is necessary for SCF(FBXW7)-mediated ubiquitination and proteasomal degradation of NR1D1. Plays a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle as well as mitotic onset; promotes G2-M transition, and regulates G1 progress and G1-S transition via association with multiple interphase cyclins. T49898 PDBSTRUC 6GU7; 6GU6; 6GU4; 6GU3; 6GU2 T49898 BIOCLASS Kinase T49898 ECNUMBER EC 2.7.11.22 T49898 SEQUENCE MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRHPNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKM T49898 DRUGINFO D0W8IY P-276 Phase 2 T49898 DRUGINFO D01UMT Ro 31-7453 Phase 2 T49898 DRUGINFO D05IRT P276-00 Phase 2 T49898 DRUGINFO D05ADP R-roscovitine Phase 2 T49898 DRUGINFO D0IX4B AG-024322 Phase 1 T49898 DRUGINFO D0P1CV PHA-793887 Phase 1 T49898 DRUGINFO D03DKV RGB-286638 Phase 1 T49898 DRUGINFO D04AKA Pyrrolo[2,3-d]pyrimidine derivative 10 Patented T49898 DRUGINFO D08KKC Pyrrolo[2,3-d]pyrimidine derivative 9 Patented T49898 DRUGINFO D08WJG Naphthyridine and isoquinoline derivative 1 Patented T49898 DRUGINFO D01CJE 4-(thiazol-5-yl)-pyrimidine derivative 2 Patented T49898 DRUGINFO D0LX6X Indole-based analog 13 Patented T49898 DRUGINFO D0NB7Y Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 Patented T49898 DRUGINFO D0W4MN Isoquinoline 1,3-dione derivative 1 Patented T49898 DRUGINFO D0YK9D CHIR-99021 Patented T49898 DRUGINFO D07DUX Roscovitine derivative 1 Patented T49898 DRUGINFO D0NY7M Tricyclic benzimidazole derivative 1 Patented T49898 DRUGINFO D00PWQ KENPAULLONE Patented T49898 DRUGINFO D0H4HD PMID25991433-Compound-A1 Patented T49898 DRUGINFO D0M5DX Oxazolyl methylthiothiazole derivative 1 Patented T49898 DRUGINFO D0D3PX SCH 727965 Discontinued in Phase 3 T49898 DRUGINFO D0NV9O BAY 10-00394 Discontinued in Phase 2 T49898 DRUGINFO D04FHB R547 Discontinued in Phase 1 T49898 DRUGINFO D00VBT ZK 304709 Discontinued in Phase 1 T49898 DRUGINFO D02MNY ON-01135 Preclinical T49898 DRUGINFO D0WS1V L-751250 Preclinical T49898 DRUGINFO D0U2TQ CGP-60474 Terminated T49898 DRUGINFO D00BPA Olomoucine Terminated T49898 DRUGINFO D03XGJ (2,6-Diamino-pyridin-3-yl)-phenyl-methanone Investigative T49898 DRUGINFO D03YVL Cdk1 inhibitor Investigative T49898 DRUGINFO D0D2FC CGP74514A Investigative T49898 DRUGINFO D0DM5S IN1535 Investigative T49898 DRUGINFO D04NGS JNJ-7706621 Investigative T49898 DRUGINFO D05NKG alsterpaullone 2-cyanoethyl Investigative T49898 DRUGINFO D05SZH BMS-265246 Investigative T49898 DRUGINFO D06BVH 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile Investigative T49898 DRUGINFO D07HRP 3,4-bis(indol-3-yl)maleimide derivative Investigative T49898 DRUGINFO D08JML Microxine Investigative T49898 DRUGINFO D0E9DI 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile Investigative T49898 DRUGINFO D0L5GS 4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine Investigative T49898 DRUGINFO D0P2WA CVT-313 Investigative T49898 DRUGINFO D0Y7QZ 4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine Investigative T49898 DRUGINFO D07OAT Purvalanol A Investigative T49898 DRUGINFO D07OCA Cdk1/2 inhibitor III Investigative T49898 DRUGINFO D0D5HQ K00024 Investigative T49898 DRUGINFO D0F0AX 10Z-Hymenialdisine Investigative T49898 DRUGINFO D0G2GA aminopurvalanol A Investigative T49898 DRUGINFO D0H3EV 9-Nitropaullone Investigative T49898 DRUGINFO D0L3FK SU9516 Investigative T49898 DRUGINFO D0R5FH Quinoxaline1 Investigative T49898 DRUGINFO D0DR8N AZAKENPAULLONE Investigative T49898 DRUGINFO D0P6JS PMID18986805C9b Investigative T49898 DRUGINFO D0TF9P Thieno analogue of kenpaullone Investigative T49898 DRUGINFO D0G2CT Indirubin-5-sulfonate Investigative T49898 DRUGINFO D02QAZ PF-228 Investigative T49898 DRUGINFO D02XHC aloisine A Investigative T49898 DRUGINFO D04WFN NU6140 Investigative T49898 DRUGINFO D0T8NU PMID19115845C89S Investigative T49898 DRUGINFO D0Y0ES Indirubin-3'-monoxime Investigative T49898 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T49898 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T49898 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T49898 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T49898 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T49898 DRUGINFO D0L8HO RO-316233 Investigative T67102 TARGETID T67102 T67102 FORMERID TTDR00447 T67102 UNIPROID CATD_HUMAN T67102 TARGNAME Cathepsin D (CTSD) T67102 GENENAME CTSD T67102 TARGTYPE Clinical trial T67102 SYNONYMS CPSD; CD T67102 FUNCTION Plays a role in APP processing following cleavage and activation by ADAM30 which leads to APP degradation. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease. Acid protease active in intracellular protein breakdown. T67102 PDBSTRUC 4OD9; 4OC6; 4OBZ; 1LYW; 1LYB T67102 BIOCLASS Peptidase T67102 ECNUMBER EC 3.4.23.5 T67102 SEQUENCE MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVPAVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIHHKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFGEATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQPGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSLMVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQAGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL T67102 DRUGINFO D0FE7H PMID10498202C1 Clinical trial T67102 DRUGINFO D04TSV CI-992 Terminated T67102 DRUGINFO D07DYJ N-Aminoethylmorpholine Investigative T67102 DRUGINFO D0W5NB 1h-Benoximidazole-2-Carboxylic Acid Investigative T67102 DRUGINFO D02LCH GRL-7234 Investigative T67102 DRUGINFO D0CU4Q S-Methylcysteine Investigative T67102 DRUGINFO D0H3EJ Carbocyclic Peptidomimetic Investigative T67102 DRUGINFO D0S3BO KNI-10006 Investigative T67102 DRUGINFO D0P6RT PMID8410973C3 Investigative T67102 DRUGINFO D0Y5IQ Grassystatin a Investigative T67102 DRUGINFO D07LUR Alpha-D-Mannose Investigative T75570 TARGETID T75570 T75570 FORMERID TTDS00408 T75570 UNIPROID YES_HUMAN T75570 TARGNAME Yes tyrosine kinase (YES) T75570 GENENAME YES1 T75570 TARGTYPE Clinical trial T75570 SYNONYMS p61-Yes; Yes p59-Fyn; Yes Protooncogene Syn; Tyrosine-protein kinase Yes; Proto-oncogene c-Yes T75570 FUNCTION Stimulation by receptor tyrosine kinases (RTKs) including EGRF, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signaling pathway and mediates AKT-mediated cell migration. Plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. Also involved in G2/M progression and cytokinesis. Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. T75570 PDBSTRUC 2HDA T75570 BIOCLASS Kinase T75570 ECNUMBER EC 2.7.10.2 T75570 SEQUENCE MGCIKSKENKSPAIKYRPENTPEPVSTSVSHYGAEPTTVSPCPSSSAKGTAVNFSSLSMTPFGGSSGVTPFGGASSSFSVVPSSYPAGLTGGVTIFVALYDYEARTTEDLSFKKGERFQIINNTEGDWWEARSIATGKNGYIPSNYVAPADSIQAEEWYFGKMGRKDAERLLLNPGNQRGIFLVRESETTKGAYSLSIRDWDEIRGDNVKHYKIRKLDNGGYYITTRAQFDTLQKLVKHYTEHADGLCHKLTTVCPTVKPQTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWMGTWNGTTKVAIKTLKPGTMMPEAFLQEAQIMKKLRHDKLVPLYAVVSEEPIYIVTEFMSKGSLLDFLKEGDGKYLKLPQLVDMAAQIADGMAYIERMNYIHRDLRAANILVGENLVCKIADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILQTELVTKGRVPYPGMVNREVLEQVERGYRMPCPQGCPESLHELMNLCWKKDPDERPTFEYIQSFLEDYFTATEPQYQPGENL T75570 DRUGINFO D0U3XL JNJ-26483327 Phase 1 T75570 DRUGINFO D0H1OK TG-100435 Investigative T40332 TARGETID T40332 T40332 FORMERID TTDS00448 T40332 UNIPROID ELNE_HUMAN T40332 TARGNAME Neutrophil elastase (NE) T40332 GENENAME ELANE T40332 TARGTYPE Clinical trial T40332 SYNONYMS PMN elastase; Medullasin; Human leukocyte elastase; HLE; Elastase-2; ELA2; Bone marrow serine protease T40332 FUNCTION Inhibits C5a-dependent neutrophil enzyme release and chemotaxis. Modifies the functions of natural killer cells, monocytes and granulocytes. T40332 PDBSTRUC 6F5M; 5ABW; 5A8Z; 5A8Y; 5A8X T40332 BIOCLASS Peptidase T40332 ECNUMBER EC 3.4.21.37 T40332 SEQUENCE MTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQRSEDNPCPHPRDPDPASRTH T40332 DRUGINFO D05QHL Sivelestat sodium hydrate Phase 4 T40332 DRUGINFO D0FT4R Sivelestat Phase 3 T40332 DRUGINFO D0U2BH Epigallocatechin gallate Phase 3 T40332 DRUGINFO D02PHE AZD9668 Phase 2 T40332 DRUGINFO D08PBB L-694,458 Phase 2 T40332 DRUGINFO D0A0SI BAY 85-8501 Phase 2 T40332 DRUGINFO D0M0PY DX-890 Phase 2 T40332 DRUGINFO D05BPC Tiprelestat Phase 2 T40332 DRUGINFO D01OGV POL-6014 Phase 1 T40332 DRUGINFO D0U0AU AZD-9819 Phase 1 T40332 DRUGINFO D8PO7Y BI 1323495 Phase 1 T40332 DRUGINFO D00CDI Peptide analog 67 Patented T40332 DRUGINFO D00WHH 4-pyridone derivative 2 Patented T40332 DRUGINFO D00YXL 2-pyrazinone derivative 1 Patented T40332 DRUGINFO D02IXA Uracil derivative 1 Patented T40332 DRUGINFO D02UCA Pyrimidine derivative 34 Patented T40332 DRUGINFO D06TAS 2-pyrazinone derivative 2 Patented T40332 DRUGINFO D07RRV Tetra-hydro-triazolopyrimidine derivative 2 Patented T40332 DRUGINFO D08HBW Peptide analog 64 Patented T40332 DRUGINFO D09EPZ 4-pyridone derivative 1 Patented T40332 DRUGINFO D09VDQ Pyrimidinone derivative 4 Patented T40332 DRUGINFO D0A6AJ Peptide analog 65 Patented T40332 DRUGINFO D0B5QU 2-pyrazinone derivative 5 Patented T40332 DRUGINFO D0EE5S 2-pyrazinone derivative 7 Patented T40332 DRUGINFO D0HU0O Tetra-hydro-pyrrolopyrimidinedione derivative 1 Patented T40332 DRUGINFO D0L9AS Peptide analog 66 Patented T40332 DRUGINFO D0M3EA 2-pyrazinone derivative 6 Patented T40332 DRUGINFO D0M3NR Peptide analog 68 Patented T40332 DRUGINFO D0NS8V Dihydropyrimidinone derivative 2 Patented T40332 DRUGINFO D0R2TH 2-pyrazinone derivative 3 Patented T40332 DRUGINFO D0S9NB 2-pyrazinone derivative 4 Patented T40332 DRUGINFO D0TP0X Peptide analog 63 Patented T40332 DRUGINFO D0VU3I Hypersulfated disaccharide compound 1 Patented T40332 DRUGINFO D0W3EJ Peptide analog 69 Patented T40332 DRUGINFO D0W6PE Dihydropyrimidinone derivative 1 Patented T40332 DRUGINFO D00TCL Peptide analog 59 Patented T40332 DRUGINFO D09ZUJ Peptide analog 61 Patented T40332 DRUGINFO D0IL0Y Peptide analog 55 Patented T40332 DRUGINFO D0K2RX Peptide analog 60 Patented T40332 DRUGINFO D0M6WD Peptide analog 70 Patented T40332 DRUGINFO D0O8MI Peptide analog 56 Patented T40332 DRUGINFO D0R7UI Peptide analog 57 Patented T40332 DRUGINFO D0ZA3S Peptide analog 58 Patented T40332 DRUGINFO D0ZW9O Peptide analog 62 Patented T40332 DRUGINFO D0R9ON MR-889 Discontinued in Phase 3 T40332 DRUGINFO D08ZCW ZD-8321 Discontinued in Phase 2 T40332 DRUGINFO D0P4IK FK-706 Discontinued in Phase 2 T40332 DRUGINFO D0T5GT CE-1037 Discontinued in Phase 2 T40332 DRUGINFO D0B9EH Dermolastin Discontinued in Phase 2 T40332 DRUGINFO D06DET AE-3763 Discontinued in Phase 1 T40332 DRUGINFO D0Q9UO GW-311616 Discontinued in Phase 1 T40332 DRUGINFO D0WY9H ZD-0892 Discontinued in Phase 1 T40332 DRUGINFO D0X7WK AZD-6553 Discontinued in Phase 1 T40332 DRUGINFO D05QMG FR167653 Discontinued in Phase 1 T40332 DRUGINFO D02YSI FR-901277 Terminated T40332 DRUGINFO D03GII SR-26831 Terminated T40332 DRUGINFO D0I0FM FR-901451 Terminated T40332 DRUGINFO D0O6GN Mdl 101,146 Terminated T40332 DRUGINFO D00QBV DD7 Investigative T40332 DRUGINFO D00TYW 6-Heptyl-4-hydroxy-3-octanoyl-pyran-2-one Investigative T40332 DRUGINFO D01NJE ED45 Investigative T40332 DRUGINFO D01UNT ICI 200,880 Investigative T40332 DRUGINFO D02NRY (4-bromo-1H-pyrazol-1-yl)(o-tolyl)methanone Investigative T40332 DRUGINFO D03BNM Cbz-Val-Pro-Val-(2-benzoxazole) Investigative T40332 DRUGINFO D03MNO L-658,758 Investigative T40332 DRUGINFO D03STO 1-benzyl-3,3-diethylazetidine-2,4-dione Investigative T40332 DRUGINFO D04KAS Ac-Ala-Pro-Val-(2-benzoxazole) Investigative T40332 DRUGINFO D04ODG 3-Ethyl-3-isobutyl-1-phenylazetidine-2,4-dione Investigative T40332 DRUGINFO D04SPO E-6-O-p-methoxycinnamoyl scandoside methyl ester Investigative T40332 DRUGINFO D05CWG TEI-8362 Investigative T40332 DRUGINFO D06JMS 3-Benzyl-3-methyl-1-phenylazetidine-2,4-dione Investigative T40332 DRUGINFO D07DOW (1H-pyrazol-1-yl)(o-tolyl)methanone Investigative T40332 DRUGINFO D07HLC 1-benzyl-3,3-dimethylazetidine-2,4-dione Investigative T40332 DRUGINFO D08RPN (4-bromo-1H-pyrazol-1-yl)(m-tolyl)methanone Investigative T40332 DRUGINFO D0A5ZF 3,3-Diethyl-1-(pyridin-3-yl)azetidine-2,4-dione Investigative T40332 DRUGINFO D0B4WZ 3-Benzyl-3-ethyl-1-phenylazetidine-2,4-dione Investigative T40332 DRUGINFO D0B5VN ICI 200,355 Investigative T40332 DRUGINFO D0D6ZB AX-9657 Investigative T40332 DRUGINFO D0E0EQ 2-methylbut-3-yn-2-yl 4-methoxybenzoate Investigative T40332 DRUGINFO D0F3CA 3,4-dichloroisocoumarin Investigative T40332 DRUGINFO D0G1SN ED1 Investigative T40332 DRUGINFO D0H8EO 3,3-diethyl-1-phenylazetidine-2,4-dione Investigative T40332 DRUGINFO D0I1AC (4-chloro-1H-pyrazol-1-yl)(o-tolyl)methanone Investigative T40332 DRUGINFO D0J1LX Bornyl (3,4,5-trihydroxy)-cinnamate Investigative T40332 DRUGINFO D0K2MT ADC-7828 Investigative T40332 DRUGINFO D0L8DL WIN-63395 Investigative T40332 DRUGINFO D0MQ8A 3-butyl-3-ethyl-1-phenylazetidine-2,4-dione Investigative T40332 DRUGINFO D0N9DP 4-Hydroxy-3-nonanoyl-6-octyl-pyran-2-one Investigative T40332 DRUGINFO D0O8PM N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide Investigative T40332 DRUGINFO D0PQ8B 3-Decanoyl-4-hydroxy-6-nonyl-pyran-2-one Investigative T40332 DRUGINFO D0Z7LS 3,3-Diethyl-1-o-tolylazetidine-2,4-dione Investigative T40332 DRUGINFO D02AKP 4-methoxy-N'-(2-phenylacetyl)benzohydrazide Investigative T40332 DRUGINFO D06GTS PMID24556381C10l Investigative T40332 DRUGINFO D0T9WZ PMID24556381C10f Investigative T40332 DRUGINFO D0VP6M 1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione Investigative T40332 DRUGINFO D00WFQ (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone Investigative T40332 DRUGINFO D02PAU ZK-814048 Investigative T40332 DRUGINFO D06LPR (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone Investigative T40332 DRUGINFO D08WQJ (3-nitro-1H-pyrazol-1-yl)(phenyl)methanone Investigative T40332 DRUGINFO D0C1NP PMID22595175C4g Investigative T40332 DRUGINFO D05ZIP (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative T40332 DRUGINFO D08OCS (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative T40332 DRUGINFO D0IU5E 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide Investigative T40332 DRUGINFO D0X1OY (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone Investigative T40332 DRUGINFO D0G6XS Fucose Investigative T86385 TARGETID T86385 T86385 FORMERID TTDC00019 T86385 UNIPROID CATG_HUMAN T86385 TARGNAME Cathepsin G (CTSG) T86385 GENENAME CTSG T86385 TARGTYPE Clinical trial T86385 SYNONYMS CG T86385 FUNCTION Cleaves complement C3. Has antibacterial activity against the Gram-negative bacterium P. aeruginosa, antibacterial activity is inhibited by LPS from P. aeruginosa, Z-Gly-Leu-Phe-CH2Cl and phenylmethylsulfonyl fluoride. Serine protease with trypsin- and chymotrypsin-like specificity. T86385 PDBSTRUC 1T32; 1KYN; 1CGH; 1AU8 T86385 BIOCLASS Peptidase T86385 ECNUMBER EC 3.4.21.20 T86385 SEQUENCE MQPLLLLLAFLLPTGAEAGEIIGGRESRPHSRPYMAYLQIQSPAGQSRCGGFLVREDFVLTAAHCWGSNINVTLGAHNIQRRENTQQHITARRAIRHPQYNQRTIQNDIMLLQLSRRVRRNRNVNPVALPRAQEGLRPGTLCTVAGWGRVSMRRGTDTLREVQLRVQRDRQCLRIFGSYDPRRQICVGDRRERKAAFKGDSGGPLLCNNVAHGIVSYGKSSGVPPEVFTRVSSFLPWIRTTMRSFKLLDQMETPL T86385 DRUGINFO D01YIO JNJ-10311795 Phase 2 T86385 DRUGINFO D00TCL Peptide analog 59 Patented T86385 DRUGINFO D09ZUJ Peptide analog 61 Patented T86385 DRUGINFO D0IL0Y Peptide analog 55 Patented T86385 DRUGINFO D0K2RX Peptide analog 60 Patented T86385 DRUGINFO D0M6WD Peptide analog 70 Patented T86385 DRUGINFO D0O8MI Peptide analog 56 Patented T86385 DRUGINFO D0R7UI Peptide analog 57 Patented T86385 DRUGINFO D0ZA3S Peptide analog 58 Patented T86385 DRUGINFO D0ZW9O Peptide analog 62 Patented T86385 DRUGINFO D0NJ1A Aloxistatin Discontinued in Phase 3 T86385 DRUGINFO D0B9EH Dermolastin Discontinued in Phase 2 T86385 DRUGINFO D05EGR Bis-Napthyl Beta-Ketophosphonic Acid Investigative T86385 DRUGINFO D0F2YC 1,3-Dibenzyl-[1,3]diazetidine-2,4-dione Investigative T86385 DRUGINFO D0C1NP PMID22595175C4g Investigative T43115 TARGETID T43115 T43115 FORMERID TTDR00611 T43115 UNIPROID PTPRC_HUMAN T43115 TARGNAME Leukocyte common antigen (PTPRC) T43115 GENENAME PTPRC T43115 TARGTYPE Clinical trial T43115 SYNONYMS T200; Receptor-type tyrosine-protein phosphatase C; L-CA; CD45 antigen; CD45 T43115 FUNCTION Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity. Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. T43115 PDBSTRUC 5FN7; 5FN6; 5FMV; 1YGU; 1YGR T43115 BIOCLASS Phosphoric monoester hydrolase T43115 ECNUMBER EC 3.1.3.48 T43115 SEQUENCE MTMYLWLKLLAFGFAFLDTEVFVTGQSPTPSPTGLTTAKMPSVPLSSDPLPTHTTAFSPASTFERENDFSETTTSLSPDNTSTQVSPDSLDNASAFNTTGVSSVQTPHLPTHADSQTPSAGTDTQTFSGSAANAKLNPTPGSNAISDVPGERSTASTFPTDPVSPLTTTLSLAHHSSAALPARTSNTTITANTSDAYLNASETTTLSPSGSAVISTTTIATTPSKPTCDEKYANITVDYLYNKETKLFTAKLNVNENVECGNNTCTNNEVHNLTECKNASVSISHNSCTAPDKTLILDVPPGVEKFQLHDCTQVEKADTTICLKWKNIETFTCDTQNITYRFQCGNMIFDNKEIKLENLEPEHEYKCDSEILYNNHKFTNASKIIKTDFGSPGEPQIIFCRSEAAHQGVITWNPPQRSFHNFTLCYIKETEKDCLNLDKNLIKYDLQNLKPYTKYVLSLHAYIIAKVQRNGSAAMCHFTTKSAPPSQVWNMTVSMTSDNSMHVKCRPPRDRNGPHERYHLEVEAGNTLVRNESHKNCDFRVKDLQYSTDYTFKAYFHNGDYPGEPFILHHSTSYNSKALIAFLAFLIIVTSIALLVVLYKIYDLHKKRSCNLDEQQELVERDDEKQLMNVEPIHADILLETYKRKIADEGRLFLAEFQSIPRVFSKFPIKEARKPFNQNKNRYVDILPYDYNRVELSEINGDAGSNYINASYIDGFKEPRKYIAAQGPRDETVDDFWRMIWEQKATVIVMVTRCEEGNRNKCAEYWPSMEEGTRAFGDVVVKINQHKRCPDYIIQKLNIVNKKEKATGREVTHIQFTSWPDHGVPEDPHLLLKLRRRVNAFSNFFSGPIVVHCSAGVGRTGTYIGIDAMLEGLEAENKVDVYGYVVKLRRQRCLMVQVEAQYILIHQALVEYNQFGETEVNLSELHPYLHNMKKRDPPSEPSPLEAEFQRLPSYRSWRTQHIGNQEENKSKNRNSNVIPYDYNRVPLKHELEMSKESEHDSDESSDDDSDSEEPSKYINASFIMSYWKPEVMIAAQGPLKETIGDFWQMIFQRKVKVIVMLTELKHGDQEICAQYWGEGKQTYGDIEVDLKDTDKSSTYTLRVFELRHSKRKDSRTVYQYQYTNWSVEQLPAEPKELISMIQVVKQKLPQKNSSEGNKHHKSTPLLIHCRDGSQQTGIFCALLNLLESAETEEVVDIFQVVKALRKARPGMVSTFEQYQFLYDVIASTYPAQNGQVKKNNHQEDKIEFDNEVDKVKQDANCVNPLGAPEKLPEAKEQAEGSEPTSGTEGPEHSVNGPASPALNQGS T43115 DRUGINFO D08BBL Iomab-B Phase 3 T43115 DRUGINFO DC8EN0 131I-labelled aCD45 Phase 3 T43115 DRUGINFO D0G5OE [131I]-BC8 Phase 2 T43115 DRUGINFO D06MMU LM-CD45 Phase 1 T43115 DRUGINFO D0I0ZO Anti-CD45 mabs Phase 1 T43115 DRUGINFO DZ7OC3 Iomab-ACT Phase 1 T43115 DRUGINFO D0V4FP OX-30 Terminated T43115 DRUGINFO D0N7VL Asp-BrPmp-Leu Investigative T36059 TARGETID T36059 T36059 FORMERID TTDS00189 T36059 UNIPROID AA3R_HUMAN T36059 TARGNAME Adenosine A3 receptor (ADORA3) T36059 GENENAME ADORA3 T36059 TARGTYPE Clinical trial T36059 SYNONYMS Adenosine receptor A3A; Adenosine receptor A3; Adenosine 3 receptor; A3AR; A3 Adenosine receptor T36059 FUNCTION The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Isoform 2: Receptor for adenosine. T36059 PDBSTRUC 1R7N; 1OEA T36059 BIOCLASS GPCR rhodopsin T36059 SEQUENCE MPNNSTALSLANVTYITMEIFIGLCAIVGNVLVICVVKLNPSLQTTTFYFIVSLALADIAVGVLVMPLAIVVSLGITIHFYSCLFMTCLLLIFTHASIMSLLAIAVDRYLRVKLTVRYKRVTTHRRIWLALGLCWLVSFLVGLTPMFGWNMKLTSEYHRNVTFLSCQFVSVMRMDYMVYFSFLTWIFIPLVVMCAIYLDIFYIIRNKLSLNLSNSKETGAFYGREFKTAKSLFLVLFLFALSWLPLSIINCIIYFNGEVPQLVLYMGILLSHANSMMNPIVYAYKIKKFKETYLLILKACVVCHPSDSLDTSIEKNSE T36059 DRUGINFO D0Y6ZK IB-MECA Phase 3 T36059 DRUGINFO D0U0KR CF102 Phase 2 T36059 DRUGINFO D0LI1C NITD609 Phase 2 T36059 DRUGINFO D00SUK Tonapofylline Phase 2 T36059 DRUGINFO D7FJX0 AST-004 Phase 1 T36059 DRUGINFO D02YQO SCH-442416 Phase 1 T36059 DRUGINFO D0V3GT BEMESETRON Discontinued in Phase 3 T36059 DRUGINFO D06PXT CF602 Preclinical T36059 DRUGINFO D0I5VA CF502 Preclinical T36059 DRUGINFO D0HE1P BAY 60-6583 Preclinical T36059 DRUGINFO D0NQ5I METRIFUDIL Terminated T36059 DRUGINFO D02KLW DIZOCILPINE Terminated T36059 DRUGINFO D0E4WF METHYLTHIOADENOSINE Terminated T36059 DRUGINFO D00CVD MRS1067 Investigative T36059 DRUGINFO D00HVX [1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one Investigative T36059 DRUGINFO D00YXE 2-(5-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T36059 DRUGINFO D01DPF MRS1505 Investigative T36059 DRUGINFO D01NTI N*2*-Benzyl-N*6*-cyclohexyl-9H-purine-2,6-diamine Investigative T36059 DRUGINFO D02OMP I-ABA Investigative T36059 DRUGINFO D02ZZQ 8-Hydroxy-5,7,9-trimethyl-delta-carboline Investigative T36059 DRUGINFO D04SDD N6-(3-Iodobenzyl)-2'-O-methyladenosine Investigative T36059 DRUGINFO D04UCF MRE 3010F20 Investigative T36059 DRUGINFO D04VYZ 2-(3''-(benzotriazole-1''-yl)ethyloxy)adenosine Investigative T36059 DRUGINFO D05CEJ N-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide Investigative T36059 DRUGINFO D05NEM 1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea Investigative T36059 DRUGINFO D05TMJ 1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea Investigative T36059 DRUGINFO D05XKT 1,2-dihydro-2-oxoquinazoline-4-carboxyanilide Investigative T36059 DRUGINFO D06FNT VUF-8504 Investigative T36059 DRUGINFO D06MWU LUF-5833 Investigative T36059 DRUGINFO D06NRZ CIRSIMARITIN Investigative T36059 DRUGINFO D06QID 2,6-bis(4-chlorophenyl)-9H-purine Investigative T36059 DRUGINFO D06TXS 1-phenyl-3-(quinazolin-4-yl)urea Investigative T36059 DRUGINFO D06ZLJ MRS1476 Investigative T36059 DRUGINFO D07IYH NSC-407228 Investigative T36059 DRUGINFO D07ZQB MPC-MECA Investigative T36059 DRUGINFO D08FSF 1-Allyl-3,7-dihydro-purine-2,6-dione Investigative T36059 DRUGINFO D08NQA MRS5698 Investigative T36059 DRUGINFO D08TSA MRS1177 Investigative T36059 DRUGINFO D09JKT 2-acetylaminoquinazoline-4-carboxyanilide Investigative T36059 DRUGINFO D09SUZ 2-aminoquinazoline-4-carboxyanilide Investigative T36059 DRUGINFO D0A0GA 2,6-bis(4-methoxyphenyl)-9H-purine Investigative T36059 DRUGINFO D0A2WH 1-Butyl-3,7-dihydro-purine-2,6-dione Investigative T36059 DRUGINFO D0AT5L [125I]AB-MECA Investigative T36059 DRUGINFO D0B2NE 2-phenylethylyl-adenosine derivative Investigative T36059 DRUGINFO D0C8FY MRS1097 Investigative T36059 DRUGINFO D0D4NS 2-(1H-imidazo[4,5-c]pyridin-2-yl)quinoxaline Investigative T36059 DRUGINFO D0E5QE 8-Hydroxy-7,9-dimethyl-delta-carboline Investigative T36059 DRUGINFO D0F4EN 2-Phenyl-2H-pyrazolo[4,3-c]quinoline Investigative T36059 DRUGINFO D0G4WF 5,6,7-Trimethyl-2-p-tolyl-chromen-4-one Investigative T36059 DRUGINFO D0GC7S 1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea Investigative T36059 DRUGINFO D0GR6H 2-benzoylaminoquinazoline-4-carboxyanilide Investigative T36059 DRUGINFO D0H4RE 1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea Investigative T36059 DRUGINFO D0H9EY 2'-Me-CCPA Investigative T36059 DRUGINFO D0I8GD MRS1186 Investigative T36059 DRUGINFO D0IJ2X 1-Prop-2-ynyl-3,7-dihydro-purine-2,6-dione Investigative T36059 DRUGINFO D0J0UT 9H-purine derivative Investigative T36059 DRUGINFO D0J9FK [3H]PSB-11 Investigative T36059 DRUGINFO D0K5WC 6-Hydroxy-5,7-dimethyl-beta-carboline Investigative T36059 DRUGINFO D0K8ZW 1-Cyclopentyl-3,7-dihydro-purine-2,6-dione Investigative T36059 DRUGINFO D0NF3E 2-(4-nitro-1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T36059 DRUGINFO D0O2AV MRS1486 Investigative T36059 DRUGINFO D0RI4S 2-benzyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one Investigative T36059 DRUGINFO D0U2EF ACN-1052 Investigative T36059 DRUGINFO D0U6NZ [125I]APNEA Investigative T36059 DRUGINFO D0V1TS 1-Benzyl-1H-1,3,4b,9-tetraaza-fluorene-2,4-dione Investigative T36059 DRUGINFO D0V2NH 1-Phenethyl-3,7-dihydro-purine-2,6-dione Investigative T36059 DRUGINFO D0V7TA 2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one Investigative T36059 DRUGINFO D0Y8EU MRS-1220 Investigative T36059 DRUGINFO D0Z2CL 2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide Investigative T36059 DRUGINFO D0ZF8N 4-Methoxy-2-phenyl-2H-pyrazolo[4,3-c]quinoline Investigative T36059 DRUGINFO D00JMT REVERSINE Investigative T36059 DRUGINFO D01WXR N-(4,5-diphenylpyrimidin-2-yl)acetamide Investigative T36059 DRUGINFO D02HHW CP608,039 Investigative T36059 DRUGINFO D02HZJ N-(2,6-diphenylpyrimidin-4-yl)benzamide Investigative T36059 DRUGINFO D02WTN Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide Investigative T36059 DRUGINFO D04PLH VUF-8507 Investigative T36059 DRUGINFO D06UXW METHOCTRAMINE Investigative T36059 DRUGINFO D07FGB 2,6-bis(4-tolyl)-9H-purine Investigative T36059 DRUGINFO D07HVJ 2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine Investigative T36059 DRUGINFO D08AJS 3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one Investigative T36059 DRUGINFO D09NEP MRS1088 Investigative T36059 DRUGINFO D0A5KG 2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine Investigative T36059 DRUGINFO D0B9CC 3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione Investigative T36059 DRUGINFO D0D9YL 1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione Investigative T36059 DRUGINFO D0MH4R visnagin Investigative T36059 DRUGINFO D0N1PT 2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T36059 DRUGINFO D0N2DP N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine Investigative T36059 DRUGINFO D0O8QS 4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide Investigative T36059 DRUGINFO D0P1JJ 6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D0P5ZE Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine Investigative T36059 DRUGINFO D0PM5R AB-MECA Investigative T36059 DRUGINFO D0Q5HW N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine Investigative T36059 DRUGINFO D0R4LZ 2-(4-methoxyphenyl)-6-phenyl-9H-purine Investigative T36059 DRUGINFO D0X3PD I-ABOPX Investigative T36059 DRUGINFO D0Y8SB L-249313 Investigative T36059 DRUGINFO D0YR1V 5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine Investigative T36059 DRUGINFO D0Z3IZ N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine Investigative T36059 DRUGINFO D00ASZ 2-(3''-pyrrolylethyloxy)adenosine Investigative T36059 DRUGINFO D00GQI N-(2,6-diphenylpyrimidin-4-yl)isobutyramide Investigative T36059 DRUGINFO D00IOF PSB36 Investigative T36059 DRUGINFO D00NFW 2,6-diphenyl-8-ethyl-1-deazapurine Investigative T36059 DRUGINFO D01AAI VUF5574 Investigative T36059 DRUGINFO D01NHH 2,6-diphenyl-8-tButyl-1-deazapurine Investigative T36059 DRUGINFO D01PGY 2-(hex-1-ynyl)-N6-methoxyadenosine Investigative T36059 DRUGINFO D01QBK 8-Bromo-9-cyclohexyl-9H-adenine Investigative T36059 DRUGINFO D01VEU 9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine Investigative T36059 DRUGINFO D01VXC N-(4,6-diphenylpyrimidin-2-yl)propionamide Investigative T36059 DRUGINFO D01VXP 2-ethynyl-N6-methoxyadenosine Investigative T36059 DRUGINFO D02EAO N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine Investigative T36059 DRUGINFO D02FLH 2,6-dphenyl-8-propyl-1-deazapurine Investigative T36059 DRUGINFO D02HYT N-(2,6-diphenylpyrimidin-4-yl)propionamide Investigative T36059 DRUGINFO D02JCM N(6)-cyclohexyladenosine Investigative T36059 DRUGINFO D02JMR 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D02SKN MRS1041 Investigative T36059 DRUGINFO D02VQK LUF-5433 Investigative T36059 DRUGINFO D03FVK N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine Investigative T36059 DRUGINFO D03HBG 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D03POP N6-methoxy-2-phenylethynyladenosine Investigative T36059 DRUGINFO D04TTP 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol Investigative T36059 DRUGINFO D05QNV ATL802 Investigative T36059 DRUGINFO D06KMJ MRS5151 Investigative T36059 DRUGINFO D06RCT 2-(3''-indolylethyloxy)adenosine Investigative T36059 DRUGINFO D07IPZ 2-(4-hydroxypent-1-yl)-N6-methoxyadenosine Investigative T36059 DRUGINFO D07PPM PSB-10 Investigative T36059 DRUGINFO D07VCN 4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one Investigative T36059 DRUGINFO D08BCH TCPA Investigative T36059 DRUGINFO D08EBT [3H]HEMADO Investigative T36059 DRUGINFO D08EZI N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide Investigative T36059 DRUGINFO D08HBH N-(2,6-diphenylpyrimidin-4-yl)butyramide Investigative T36059 DRUGINFO D08JUQ 2-tolyl-6-phenyl-9H-purine Investigative T36059 DRUGINFO D08JYX 2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine Investigative T36059 DRUGINFO D08LZN Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine Investigative T36059 DRUGINFO D09IRV LUF-5957 Investigative T36059 DRUGINFO D09RKX PSB-11 Investigative T36059 DRUGINFO D09VOP 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D09VRX 2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T36059 DRUGINFO D0A6IO MRE 3008F20 Investigative T36059 DRUGINFO D0B0QW N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine Investigative T36059 DRUGINFO D0B3NZ N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide Investigative T36059 DRUGINFO D0B3UE 9-Cyclopentyl-9H-adenine Investigative T36059 DRUGINFO D0B7OW sakuranetin Investigative T36059 DRUGINFO D0B8DR MRS1093 Investigative T36059 DRUGINFO D0B8RQ LUF-5767 Investigative T36059 DRUGINFO D0C2UJ 2-chloroadenosine Investigative T36059 DRUGINFO D0E4LB 2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine Investigative T36059 DRUGINFO D0E7YE 2,6,8-triphenyl-9H-purine Investigative T36059 DRUGINFO D0E9QX (S)-PIA Investigative T36059 DRUGINFO D0G5ZF N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine Investigative T36059 DRUGINFO D0G6BI 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D0G6VT 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D0H9BP xanthine amine congener Investigative T36059 DRUGINFO D0I1EP MRS928 Investigative T36059 DRUGINFO D0I1IW 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D0I2EQ 2,6-diphenyl-8-methyl-1-deazapurine Investigative T36059 DRUGINFO D0I3HE KF26777 Investigative T36059 DRUGINFO D0I6XA (2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol Investigative T36059 DRUGINFO D0I7HL 2-phenylpropoxyadenosine Investigative T36059 DRUGINFO D0J1BA MRS1191 Investigative T36059 DRUGINFO D0KJ3H 2-(2''-indolylethyloxy)adenosine Investigative T36059 DRUGINFO D0KT3L 2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine Investigative T36059 DRUGINFO D0L0VU MRE 2029F20 Investigative T36059 DRUGINFO D0L2MN 2-(4-chlorophenyl)-6-phenyl-9H-purine Investigative T36059 DRUGINFO D0L6YI 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D0LD0X 1-Propyl-3,7-dihydro-purine-2,6-dione Investigative T36059 DRUGINFO D0LP5V LUF-5956 Investigative T36059 DRUGINFO D0N1QO N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine Investigative T36059 DRUGINFO D0N1QP 2,6-diphenyl-1-deazapurine Investigative T36059 DRUGINFO D0OX0V 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline Investigative T36059 DRUGINFO D0P0BV 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D0P7CS LUF-5417 Investigative T36059 DRUGINFO D0PU6F 2-(1H-benzo[d]imidazol-2-yl)quinoxaline Investigative T36059 DRUGINFO D0Q1RD 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D0Q3LM N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine Investigative T36059 DRUGINFO D0Q5CS 6-guanidino-2-(3''-indolylethyloxy)adenosine Investigative T36059 DRUGINFO D0QN4U 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine Investigative T36059 DRUGINFO D0RZ2M 2,6-diphenyl-9H-purine Investigative T36059 DRUGINFO D0T7GG LUF-5816 Investigative T36059 DRUGINFO D0TC7N PENECA Investigative T36059 DRUGINFO D0V9OO (R,S)-PHPNECA Investigative T36059 DRUGINFO D0W3MT 8-propyl-2,6-diphenyl-9H-purine Investigative T36059 DRUGINFO D0WI4D LUF-5962 Investigative T36059 DRUGINFO D0XC9U MRS1042 Investigative T36059 DRUGINFO D0Y5WQ PSB603 Investigative T36059 DRUGINFO D0Y6HQ N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine Investigative T36059 DRUGINFO D0Y7HG Galangin Investigative T36059 DRUGINFO D0Z1WY 2-chloro-2'-C-methyl-tecadenoson Investigative T36059 DRUGINFO D0Z3XC N-(2,6-diphenylpyrimidin-4-yl)acetamide Investigative T36059 DRUGINFO D0ZL2A MRS1523 Investigative T36059 DRUGINFO D0ZW9L 5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol Investigative T36059 DRUGINFO D00GNW 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine Investigative T36059 DRUGINFO D00JWA N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide Investigative T36059 DRUGINFO D02PBY 3-noradamantyl-1,3-dipropylxanthine Investigative T36059 DRUGINFO D04LZN 8-Bromo-9-cyclobutyl-9H-adenine Investigative T36059 DRUGINFO D05KEF LUF-5978 Investigative T36059 DRUGINFO D06KYP 8-Bromo-9-isopropyl-9H-adenine Investigative T36059 DRUGINFO D0AI8F 8-Bromo-9-cyclopentyl-9H-adenine Investigative T36059 DRUGINFO D0B0TX 8-bromo-9-isobutyl-9H-purin-6-amine Investigative T36059 DRUGINFO D0CX7N 8-Bromo-9-(3-hydroxypropyl)-9H-adenine Investigative T36059 DRUGINFO D0IG5E 2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine Investigative T36059 DRUGINFO D0JJ6T N6-((+/-)-endo-norborn-2-yl)adenosine Investigative T36059 DRUGINFO D0K5NZ MESULERGINE Investigative T36059 DRUGINFO D0K6ZA [3H]OSIP339391 Investigative T36059 DRUGINFO D0K8ZZ [3H]NECA Investigative T36059 DRUGINFO D0M3CG R-N6-(phenylisopropyl)adenosine Investigative T36059 DRUGINFO D0NO5E Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate Investigative T36059 DRUGINFO D0O4KI 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine Investigative T36059 DRUGINFO D0O7DA (+)-BUTACLAMOL Investigative T36059 DRUGINFO D0R1XY [3H]CCPA Investigative T36059 DRUGINFO D0TU7I (E)-8-(3-chlorostyryl)-caffeine Investigative T36059 DRUGINFO D0V8MD 8-PHENYL THEOPHYLLINE Investigative T36059 DRUGINFO D0W1PF LUF-5980 Investigative T36059 DRUGINFO D0Y9WZ SB-298 Investigative T36059 DRUGINFO D0Z8NC LUF-5981 Investigative T36059 DRUGINFO D0Z8VU 8-Bromo-9-(sec-butyl)-9H-adenine Investigative T36059 DRUGINFO D0K0OT GNF-PF-2224 Investigative T36059 DRUGINFO D0RF2M NIPECOTIC ACID Investigative T36059 DRUGINFO D03RFA N6-CYCLOPENTYLADENOSINE Investigative T36059 DRUGINFO D0S0RK flavone Investigative T36059 DRUGINFO D04PFN [3H]kainate Investigative T36059 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T36059 DRUGINFO D0F6CD SEROTONIN Investigative T36059 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T94085 TARGETID T94085 T94085 FORMERID TTDS00073 T94085 UNIPROID RARA_HUMAN T94085 TARGNAME Retinoic acid receptor alpha (RARA) T94085 GENENAME RARA T94085 TARGTYPE Clinical trial T94085 SYNONYMS RAR-alpha; RAR alpha; Nuclear receptor subfamily 1 group B member 1; NR1B1 T94085 FUNCTION Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function. Receptor for retinoic acid. T94085 PDBSTRUC 5K13; 4DQM; 3KMZ; 3KMR; 3A9E T94085 BIOCLASS Nuclear hormone receptor T94085 SEQUENCE MASNSSSCPTPGGGHLNGYPVPPYAFFFPPMLGGLSPPGALTTLQHQLPVSGYSTPSPATIETQSSSSEEIVPSPPSPPPLPRIYKPCFVCQDKSSGYHYGVSACEGCKGFFRRSIQKNMVYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKESVRNDRNKKKKEVPKPECSESYTLTPEVGELIEKVRKAHQETFPALCQLGKYTTNNSSEQRVSLDIDLWDKFSELSTKCIIKTVEFAKQLPGFTTLTIADQITLLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFANQLLPLEMDDAETGLLSAICLICGDRQDLEQPDRVDMLQEPLLEALKVYVRKRRPSRPHMFPKMLMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGLDTLSGQPGGGGRDGGGLAPPPGSCSPSLSPSSNRSSPATHSP T94085 DRUGINFO D02GTY Tamibarotene Phase 3 T94085 DRUGINFO D0HY3D SY-1425 Phase 1 T94085 DRUGINFO D0T3DO IRX-5183 Phase 1 T94085 DRUGINFO D02FAA PMID27336223-Compound-4 Patented T94085 DRUGINFO D0AW3F PMID27336223-Compound-5 Patented T94085 DRUGINFO D0YO4D LG100268 Discontinued in Phase 1 T94085 DRUGINFO D02OAI AGN193836 Investigative T94085 DRUGINFO D03DEJ BMS614 Investigative T94085 DRUGINFO D07TPL Ro-40-0655 Investigative T94085 DRUGINFO D07YTL BMS753 Investigative T94085 DRUGINFO D0JQ1D Ro 41-5253 Investigative T94085 DRUGINFO D0RD0R Ro 40-6055 Investigative T94085 DRUGINFO D0F8CC CD666 Investigative T94085 DRUGINFO D0Q0IR AGN193109 Investigative T44011 TARGETID T44011 T44011 FORMERID TTDR00587 T44011 UNIPROID DHB1_HUMAN T44011 TARGNAME Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) T44011 GENENAME HSD17B1 T44011 TARGTYPE Clinical trial T44011 SYNONYMS Short chain dehydrogenase/reductase family 28C member 1; SDR28C1; Placental 17-beta-hydroxysteroid dehydrogenase; Estradiol 17-beta-dehydrogenase 1; EDHB17; EDH17B2; EDH17B1; E2DH; E17KSR; 20-alpha-HSD; 20 alpha-hydroxysteroid dehydrogenase; 17-beta-Hydroxysteroid dehydrogenase type 1; 17-beta-HSD 1 T44011 FUNCTION Has 20-alpha-HSD activity. Uses preferentially NADH. Favors the reduction of estrogens and androgens. T44011 PDBSTRUC 6MNE; 6MNC; 6DTP; 6CGE; 6CGC T44011 BIOCLASS CH-OH donor oxidoreductase T44011 ECNUMBER EC 1.1.1.62 T44011 SEQUENCE MARTVVLITGCSSGIGLHLAVRLASDPSQSFKVYATLRDLKTQGRLWEAARALACPPGSLETLQLDVRDSKSVAAARERVTEGRVDVLVCNAGLGLLGPLEALGEDAVASVLDVNVVGTVRMLQAFLPDMKRRGSGRVLVTGSVGGLMGLPFNDVYCASKFALEGLCESLAVLLLPFGVHLSLIECGPVHTAFMEKVLGSPEEVLDRTDIHTFHRFYQYLAHSKQVFREAAQNPEEVAEVFLTALRAPKPTLRYFTTERFLPLLRMRLDDPSGSNYVTAMHREVFGDVPAKAEAGAEAGGGAGPGAEDEAGRGAVGDPELGDPPAAPQ T44011 DRUGINFO D02ABO NARINGENIN Phase 1 T44011 DRUGINFO D00PUR 3'-(1-Benzothien-2-yl)biphenyl-3-ol Investigative T44011 DRUGINFO D00SLE 3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol Investigative T44011 DRUGINFO D01AVM Ethyl estrone-16-methylcarboxylate Investigative T44011 DRUGINFO D01ERB 16-(pyridin-4-yl)methylene-estradiol Investigative T44011 DRUGINFO D01JVG 3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol Investigative T44011 DRUGINFO D01OCZ 16-isobutylidene-estrone Investigative T44011 DRUGINFO D01SGP N-methyl estrone-16-methyl carboxamide Investigative T44011 DRUGINFO D01ZCG 3-[5-(4-hydroxyphenyl)-2-thienyl]phenol Investigative T44011 DRUGINFO D02BEJ 3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol Investigative T44011 DRUGINFO D02DYZ N-(pyridin-4-ylmethyl) estradiol-16-carboxamide Investigative T44011 DRUGINFO D02JRB 6-oxo-16-formyl-estrone Investigative T44011 DRUGINFO D02MQT 16-(4-dimethylamino-benzylidene)-estrone Investigative T44011 DRUGINFO D02MZN N-N-diethyl estradiol-16-methyl carboxamide Investigative T44011 DRUGINFO D02QLY 2-Hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide Investigative T44011 DRUGINFO D02UUR 3-[3-(4-hydroxyphenyl)isoxazol-5-yl]phenol Investigative T44011 DRUGINFO D02XZO 16-(pyridin-2-yl)methylene-estradiol Investigative T44011 DRUGINFO D03BZT 6-oxo-estrone Investigative T44011 DRUGINFO D03XHF 2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol Investigative T44011 DRUGINFO D03XMR N-methyl-N-ethyl estrone-16-methyl carboxamide Investigative T44011 DRUGINFO D04CQM N-(1'-Phenyl-ethyl) estradiol-16-carboxamide Investigative T44011 DRUGINFO D04EPO 7-Hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile Investigative T44011 DRUGINFO D05AIT 3-[6-(5-Chloro-2-thienyl)pyridin-2-yl]phenol Investigative T44011 DRUGINFO D06AYL N-(pyridin-3-ylmethyl) estradiol-16-carboxamide Investigative T44011 DRUGINFO D06CED 3'-(5-Chloro-2-thienyl)biphenyl-3-ol Investigative T44011 DRUGINFO D06FPP 16-(pyridin-4-yl)methyl-estradiol Investigative T44011 DRUGINFO D06NDT 3-(3-hydroxyphenyl)quinolin-7-ol Investigative T44011 DRUGINFO D06ZNI 16-(2',2'-Dimethyl)-propylidene-estradiol Investigative T44011 DRUGINFO D07VXQ 3,3'-Pyridine-2,5-diyldiphenol Investigative T44011 DRUGINFO D08CXO N-isopropyl estradiol-16-carboxamide Investigative T44011 DRUGINFO D08EHR 16-(pyridin-3-yl)methylene-estradiol Investigative T44011 DRUGINFO D08NFA N-(4'-methyl-piperazinyl) estradiol-16-carboxamide Investigative T44011 DRUGINFO D08OKP 4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol Investigative T44011 DRUGINFO D08OQX 3,3'-Thiene-2,4-diyldiphenol Investigative T44011 DRUGINFO D08PDK 1-Bromo-6-(3-hydroxyphenyl)-2-naphthol Investigative T44011 DRUGINFO D09GQE 3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol Investigative T44011 DRUGINFO D0A0CG 16-(thiophen-2-yl)methylene-estrone Investigative T44011 DRUGINFO D0A2GN 3-[5-(3-Fluorophenyl)-2-thienyl]phenol Investigative T44011 DRUGINFO D0A4XA 3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol Investigative T44011 DRUGINFO D0A5CD N,N-diethyl estrone-16-methyl carboxamide Investigative T44011 DRUGINFO D0A7PU 3-[4-(5-Chloro-2-thienyl)pyridin-2-yl]phenol Investigative T44011 DRUGINFO D0B6SA N-isopropyl estradiol-16-methyl carboxamide Investigative T44011 DRUGINFO D0B6SF 3,3'-(3-Phenylthiene-2,5-diyl)diphenol Investigative T44011 DRUGINFO D0B9HX 16-beta-ethoxymethyl-estrone Investigative T44011 DRUGINFO D0BF3Y 4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol Investigative T44011 DRUGINFO D0C9KZ 1,1':4',1''-terphenyl-3,4''-diol Investigative T44011 DRUGINFO D0D1KA 3-Hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile Investigative T44011 DRUGINFO D0DC3E 3,3'-pyrazine-2,5-diyldiphenol Investigative T44011 DRUGINFO D0EK5U 16beta-cyano-estradiol Investigative T44011 DRUGINFO D0EL1Y 3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol Investigative T44011 DRUGINFO D0F0EI 3-(6-hydroxy-2-naphthyl)benzoic acid Investigative T44011 DRUGINFO D0F6ZH 3-(2-naphthyl)phenol Investigative T44011 DRUGINFO D0G1DN 3-(5-phenyl-2-thienyl)phenol Investigative T44011 DRUGINFO D0G4KT 16-isobutylidene-estradiol Investigative T44011 DRUGINFO D0G5CP 4'-(6-Methoxypyridin-3-yl)biphenyl-3-ol Investigative T44011 DRUGINFO D0G7PB N-methyl-N-ethyl estradiol-16-carboxamide Investigative T44011 DRUGINFO D0HR7O 16-(4-dimethylamino-benzylidene)-estradiol Investigative T44011 DRUGINFO D0I0KV 16-(2',2'-Dimethyl)-propylidene-estrone Investigative T44011 DRUGINFO D0I5YT 3,4'-(thiophene-2,4-diyl)diphenol Investigative T44011 DRUGINFO D0IZ4Z 3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol Investigative T44011 DRUGINFO D0J8LU 4-Methyl-1,1':4',1''-terphenyl-3,4''-diol Investigative T44011 DRUGINFO D0JI0Q N-methyl estradiol-16-methyl carboxamide Investigative T44011 DRUGINFO D0K6MM N-(furan-2-ylmethyl)estradiol-16-carboxamide Investigative T44011 DRUGINFO D0K8VL N-(furan-2-ylmethyl)-estrone-16-methyl carboxamide Investigative T44011 DRUGINFO D0KG1D 2-(3-hydroxyphenyl)quinolin-6-ol Investigative T44011 DRUGINFO D0M3RQ 5-(6-hydroxy-2-naphthyl)pyridin-3-ol Investigative T44011 DRUGINFO D0M4SL N-isopropyl estrone-16-methyl carboxamide Investigative T44011 DRUGINFO D0N1LT 16-(pyridin-3-yl)methyl-estradiol Investigative T44011 DRUGINFO D0P6JE 3,3'-(3-Methylthiene-2,5-diyl]diphenol Investigative T44011 DRUGINFO D0Q3AN 2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol Investigative T44011 DRUGINFO D0Q6AD 4'-(5-Chloro-2-thienyl)biphenyl-3-ol Investigative T44011 DRUGINFO D0Q9CI N-methoxyethyl estrone-16-methyl carboxamide Investigative T44011 DRUGINFO D0QX5D 3-[2-(5-Chloro-2-thienyl)pyridin-4-yl]phenol Investigative T44011 DRUGINFO D0R3HP 3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol Investigative T44011 DRUGINFO D0R5WV 3,3'-(1,2,4-Thiadiazol-2,5-diyl)diphenol Investigative T44011 DRUGINFO D0R6DT Equilin Investigative T44011 DRUGINFO D0S2BW Methyl estradiol-16-beta-carboxylate Investigative T44011 DRUGINFO D0T6WL 3,3'-(1,3-Thiazol-2,4-diyl)diphenol Investigative T44011 DRUGINFO D0TA0J 3,3'-thiene-2,5-diyldiphenol Investigative T44011 DRUGINFO D0U7DJ 16-(4-cyano-benzylidene)-estradiol Investigative T44011 DRUGINFO D0UR6C 3-[5-(4-Fluorophenyl)-2-thienyl]phenol Investigative T44011 DRUGINFO D0V2QH 6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol Investigative T44011 DRUGINFO D0V4BE N-ethyl estrone-16-methyl carboxamide Investigative T44011 DRUGINFO D0V5JV N-ethyl estradiol-16-methyl carboxamide Investigative T44011 DRUGINFO D0W5CR EM-1745 Investigative T44011 DRUGINFO D0WM4K 16-(pyridin-2-yl)methyl-estradiol Investigative T44011 DRUGINFO D0Z1AT 16-beta-hydroxymethyl-estradiol Investigative T44011 DRUGINFO D0Z1MJ 3,3',3''-Thiene-2,3,5-triyltriphenol Investigative T44011 DRUGINFO D00YNA 3,3-(1,3-Thiazole-2,5-diyl)diphenol Investigative T44011 DRUGINFO D07JOZ 1,1':4',1''-terphenyl-3,3''-diol Investigative T44011 DRUGINFO D0NM0P 3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol Investigative T44011 DRUGINFO D0T5MO 5alpha-Androstan-3,17-Dione Investigative T44011 DRUGINFO D01IAT 7-(3-Hydroxy-phenyl)-naphthalen-2-ol Investigative T44011 DRUGINFO D01KKU NSC-94258 Investigative T44011 DRUGINFO D01RZP 4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol Investigative T44011 DRUGINFO D0H8PI 6-(4-Hydroxy-phenyl)-naphthalen-1-ol Investigative T44011 DRUGINFO D0M0KX 2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol Investigative T44011 DRUGINFO D0Y2RL 4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol Investigative T44011 DRUGINFO D0M8RO 4-ANDROSTENE-3-17-DIONE Investigative T44011 DRUGINFO D0P8PK 6-(3-Hydroxy-phenyl)-naphthalen-2-ol Investigative T44011 DRUGINFO D00RIX APIGENIN Investigative T44011 DRUGINFO D0G3TK KAEMPFEROL Investigative T44011 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T44011 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T19160 TARGETID T19160 T19160 FORMERID TTDC00025 T19160 UNIPROID PA2GA_HUMAN T19160 TARGNAME Group IIA phospholipase A2 (GIIA sPLA2) T19160 GENENAME PLA2G2A T19160 TARGTYPE Clinical trial T19160 SYNONYMS RASF-A; Phospholipase A2, membrane associated; Phosphatidylcholine 2-acylhydrolase 2A; PLA2L; PLA2B; Non-pancreatic secretory phospholipase A2; NPS-PLA2; GIIC sPLA2 T19160 FUNCTION Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Thought to participate in the regulation of phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Independent of its catalytic activity, acts as a ligand for integrins. Binds to and activates integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1. Binds to a site (site 2) which is distinct from the classical ligand-binding site (site 1) and induces integrin conformational changes and enhanced ligand binding to site 1. Induces cell proliferation in an integrin-dependent manner. T19160 PDBSTRUC 5G3N; 3U8I; 3U8H; 3U8D; 3U8B T19160 BIOCLASS Carboxylic ester hydrolase T19160 ECNUMBER EC 3.1.1.4 T19160 SEQUENCE MKTLLLLAVIMIFGLLQAHGNLVNFHRMIKLTTGKEAALSYGFYGCHCGVGGRGSPKDATDRCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQLCECDKAAATCFARNKTTYNKKYQYYSNKHCRGSTPRC T19160 DRUGINFO D0LB0X KH064 Clinical trial T19160 DRUGINFO D04TKG LUFFARIELLOLIDE Investigative T19160 DRUGINFO D0J2EE DIDODECANOYLPHLOROGLUCINOL Investigative T19160 DRUGINFO D0O6SI 1,4-Butanediol Investigative T19160 DRUGINFO D0Y0OA Ochnaflavone Investigative T19160 DRUGINFO D02AYI 2-(4-phenoxyphenoxy)ethanamine Investigative T19160 DRUGINFO D02IVU CACOSPONGIONOLIDE Investigative T19160 DRUGINFO D03AHJ Elaidoylamide Investigative T19160 DRUGINFO D03BAB Cacospongionolide E Investigative T19160 DRUGINFO D06YGT N-Tridecanoic Acid Investigative T19160 DRUGINFO D0B9VV CACOSPONGIONOLIDE B Investigative T19160 DRUGINFO D0T3CM BOLINAQUINONE Investigative T19160 DRUGINFO D0U9HN DYSIDINE Investigative T19160 DRUGINFO D0W7LK 2-Propanol, Isopropanol Investigative T19160 DRUGINFO D0N0UC Lauric Acid Investigative T19160 DRUGINFO D02UVH B-Octylglucoside Investigative T67272 TARGETID T67272 T67272 FORMERID TTDR00784 T67272 UNIPROID AMPN_HUMAN T67272 TARGNAME Aminopeptidase N (ANPEP) T67272 GENENAME ANPEP T67272 TARGTYPE Clinical trial T67272 SYNONYMS Myeloid plasma membrane glycoprotein CD13; Microsomal aminopeptidase; HAPN; Gp150; Aminopeptidase M; Alanyl aminopeptidase; ANPEP T67272 FUNCTION Broad specificity aminopeptidase. Plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. May play a critical role in the pathogenesis of cholesterol gallstone disease. May be involved in the metabolism of regulatory peptides of diverse cell types, responsible for the processing of peptide hormones, such as angiotensin III and IV, neuropeptides, and chemokines. Found to cleave antigen peptides bound to major histocompatibility complex class II molecules of presenting cells and to degrade neurotransmitters at synaptic junctions. Is also implicated as a regulator of IL-8 bioavailability in the endometrium, and therefore may contribute to the regulation of angiogenesis. Is used as a marker for acute myeloid leukemia and plays a role in tumor invasion. In case of human coronavirus 229E (HCoV-229E) infection, serves as receptor for HCoV-229E spike glycoprotein. Mediates as well human cytomegalovirus (HCMV) infection. T67272 PDBSTRUC 6ATK; 5LHD; 4FYT; 4FYS; 4FYR T67272 BIOCLASS Peptidase T67272 ECNUMBER EC 3.4.11.2 T67272 SEQUENCE MAKGFYISKSLGILGILLGVAAVCTIIALSVVYSQEKNKNANSSPVASTTPSASATTNPASATTLDQSKAWNRYRLPNTLKPDSYRVTLRPYLTPNDRGLYVFKGSSTVRFTCKEATDVIIIHSKKLNYTLSQGHRVVLRGVGGSQPPDIDKTELVEPTEYLVVHLKGSLVKDSQYEMDSEFEGELADDLAGFYRSEYMEGNVRKVVATTQMQAADARKSFPCFDEPAMKAEFNITLIHPKDLTALSNMLPKGPSTPLPEDPNWNVTEFHTTPKMSTYLLAFIVSEFDYVEKQASNGVLIRIWARPSAIAAGHGDYALNVTGPILNFFAGHYDTPYPLPKSDQIGLPDFNAGAMENWGLVTYRENSLLFDPLSSSSSNKERVVTVIAHELAHQWFGNLVTIEWWNDLWLNEGFASYVEYLGADYAEPTWNLKDLMVLNDVYRVMAVDALASSHPLSTPASEINTPAQISELFDAISYSKGASVLRMLSSFLSEDVFKQGLASYLHTFAYQNTIYLNLWDHLQEAVNNRSIQLPTTVRDIMNRWTLQMGFPVITVDTSTGTLSQEHFLLDPDSNVTRPSEFNYVWIVPITSIRDGRQQQDYWLIDVRAQNDLFSTSGNEWVLLNLNVTGYYRVNYDEENWRKIQTQLQRDHSAIPVINRAQIINDAFNLASAHKVPVTLALNNTLFLIEERQYMPWEAALSSLSYFKLMFDRSEVYGPMKNYLKKQVTPLFIHFRNNTNNWREIPENLMDQYSEVNAISTACSNGVPECEEMVSGLFKQWMENPNNNPIHPNLRSTVYCNAIAQGGEEEWDFAWEQFRNATLVNEADKLRAALACSKELWILNRYLSYTLNPDLIRKQDATSTIISITNNVIGQGLVWDFVQSNWKKLFNDYGGGSFSFSNLIQAVTRRFSTEYELQQLEQFKKDNEETGFGSGTRALEQALEKTKANIKWVKENKEVVLQWFTENSK T67272 DRUGINFO D0E3HY IP10 C8 Phase 2 T67272 DRUGINFO D00KIV (1-Amino-3-phenyl-propyl)-phosphinic acid Investigative T67272 DRUGINFO D00SLJ N1-(3,3-diphenylpropyl)-N3-hydroxymalonamide Investigative T67272 DRUGINFO D01LFP N1-(4-chlorobenzyl)-2-benzyl-N3-hydroxymalonamide Investigative T67272 DRUGINFO D02EFK N1,2-dibenzyl-N3-hydroxy-N1-phenethylmalonamide Investigative T67272 DRUGINFO D03JAL 1-aminohexylphosphonic acid Investigative T67272 DRUGINFO D04KOZ (S)-2-Amino-3-phenyl-propane-1-thiol Investigative T67272 DRUGINFO D04MKQ (Amino-phenyl-methyl)-phosphinic acid Investigative T67272 DRUGINFO D04XBZ 1-aminohexylphosphonic acid monophenyl ester Investigative T67272 DRUGINFO D05EPO 1-aminobutylphosphonic acid Investigative T67272 DRUGINFO D06AFP N-Hydroxy-2-(naphthalen-2-ylsulfanyl)-acetamide Investigative T67272 DRUGINFO D06RLF (1-Amino-ethyl)-phosphinic acid Investigative T67272 DRUGINFO D06TVS N1-benzyl-N3-hydroxy-2-isobutylmalonamide Investigative T67272 DRUGINFO D06VON (S)-2-Amino-2-phenyl-ethanethiol Investigative T67272 DRUGINFO D0D8FZ 2-benzyl-N1-hydroxy-N3-phenethylmalonamide Investigative T67272 DRUGINFO D0DS7F (S)-2-Amino-4-phenyl-butane-1-thiol Investigative T67272 DRUGINFO D0EG8X (1-Amino-3-methylsulfanyl-propyl)-phosphinic acid Investigative T67272 DRUGINFO D0F2HJ 2-Cinnamamido-N1-hydroxy-N4-pentylsuccinamide Investigative T67272 DRUGINFO D0GB8I N1-hydroxy-2-isobutyl-N3-phenethylmalonamide Investigative T67272 DRUGINFO D0GI9S (S)-2-Amino-4-methylsulfanyl-butane-1-thiol Investigative T67272 DRUGINFO D0H5BG PMID23428964CI3 Investigative T67272 DRUGINFO D0J0WJ N4-Butyl-2-cinnamamido-N1-hydroxysuccinamide Investigative T67272 DRUGINFO D0J9TD N-biphenyl-3-ylmethyl-N'-hydroxy-malonamide Investigative T67272 DRUGINFO D0K9XV N1-(4-fluorobenzyl)-2-benzyl-N3-hydroxymalonamide Investigative T67272 DRUGINFO D0L3PY Angiotensin IV Investigative T67272 DRUGINFO D0N3UO (1-Amino-3-methyl-butyl)-phosphinic acid Investigative T67272 DRUGINFO D0NL7J N1-(4-chlorobenzyl)-2-amino-N3-hydroxymalonamide Investigative T67272 DRUGINFO D0P9YU (1-Amino-2-phenyl-ethyl)-phosphinic acid Investigative T67272 DRUGINFO D0Q0EY (S)-2-Amino-4-methyl-pentane-1-thiol Investigative T67272 DRUGINFO D0R9AA (S)-2-Amino-propane-1-thiol Investigative T67272 DRUGINFO D0RH4S 1-aminopentylphosphonic acid monophenyl ester Investigative T67272 DRUGINFO D0UI1P 2-Cinnamamido-N4-hexyl-N1-hydroxysuccinamide Investigative T67272 DRUGINFO D0UT7Y N1-(3-phenoxybenzyl)-N3-hydroxymalonamide Investigative T67272 DRUGINFO D0YA8C 2-benzyl-N1-hydroxy-N3-(3-phenylpropyl)malonamide Investigative T67272 DRUGINFO D0YO0R 2-benzyl-N1-hydroxy-N3-(4-phenylbutyl)malonamide Investigative T67272 DRUGINFO D0Z2JN N1,2-dibenzyl-N3-hydroxymalonamide Investigative T67272 DRUGINFO D0Z4AC 2-amino-N1-benzyl-N3-hydroxymalonamide Investigative T67272 DRUGINFO D0Z4NU 2-Cinnamamido-N1-hydroxy-N4-octylsuccinamide Investigative T67272 DRUGINFO D04QJY KELATORPHAN Investigative T67272 DRUGINFO D0U8IF [(125)I] RB129 Investigative T52389 TARGETID T52389 T52389 FORMERID TTDC00200 T52389 UNIPROID NQO1_HUMAN T52389 TARGNAME Quinone reductase 1 (NQO1) T52389 GENENAME NQO1 T52389 TARGTYPE Clinical trial T52389 SYNONYMS Qui reductase 1; QR1; Phylloquinone reductase; Phylloqui reductase; NMOR1; NAD(P)H:quinone oxidoreductase 1; NAD(P)H dehydrogenase [quinone] 1; Menadione reductase; DTD; DT-diaphorase 1; DT-diaphorase; DIA4; Azoreductase T52389 FUNCTION The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis. T52389 PDBSTRUC 6FY4; 5FUQ; 5EAI; 5EA2; 5A4K T52389 BIOCLASS NADH/NADPH oxidoreductase T52389 ECNUMBER EC 1.6.5.2 T52389 SEQUENCE MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKLKDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFCGFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK T52389 DRUGINFO D0DR0P ARQ 761 Phase 2 T52389 DRUGINFO D0MM6A Coenzyme Q10 analog Phase 2 T52389 DRUGINFO D0RI4I BioE-743 Phase 2 T52389 DRUGINFO D00SRM NSC-354279 Investigative T52389 DRUGINFO D01WPJ Duroquinone Investigative T52389 DRUGINFO D02ONP Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate Investigative T52389 DRUGINFO D03CDH 3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one Investigative T52389 DRUGINFO D05GWI NSC-106547 Investigative T52389 DRUGINFO D06BHJ 3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one Investigative T52389 DRUGINFO D07DGS NSC-2113 Investigative T52389 DRUGINFO D07JNQ NSC-73410 Investigative T52389 DRUGINFO D07MGN NSC-224124 Investigative T52389 DRUGINFO D08XJX 3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one Investigative T52389 DRUGINFO D09CYJ 4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one Investigative T52389 DRUGINFO D09FMZ 3-Benzyl-4-hydroxy-2H-chromen-2-one Investigative T52389 DRUGINFO D09ITX 2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one Investigative T52389 DRUGINFO D0A5TD NSC-621351 Investigative T52389 DRUGINFO D0AN7U NSC-316158 Investigative T52389 DRUGINFO D0B4GV 4-amino-2H-chromen-2-one Investigative T52389 DRUGINFO D0E2LU NSC-275420 Investigative T52389 DRUGINFO D0GE8S ES-936 Investigative T52389 DRUGINFO D0H1BY Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone] Investigative T52389 DRUGINFO D0H4YP 4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one Investigative T52389 DRUGINFO D0L3VV NSC-339583 Investigative T52389 DRUGINFO D0O8YZ NSC-65069 Investigative T52389 DRUGINFO D0T4RW NSC-645827 Investigative T52389 DRUGINFO D0VB8K NSC-339580 Investigative T52389 DRUGINFO D0E0DQ NSC-645808 Investigative T52389 DRUGINFO D0J3RB NSC-106080 Investigative T52389 DRUGINFO D0M0WT NSC-99528 Investigative T52389 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T24587 TARGETID T24587 T24587 FORMERID TTDR00624 T24587 UNIPROID MGMT_HUMAN T24587 TARGNAME O-6-methylguanine-DNA-alkyltransferase (MGMT) T24587 GENENAME MGMT T24587 TARGTYPE Clinical trial T24587 SYNONYMS Methylated-DNA--protein-cysteine methyltransferase; Human O(6)-alkylguanine-DNA alkyltransferase; 6-O-methylguanine-DNA methyltransferase T24587 FUNCTION Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated. Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. T24587 PDBSTRUC 1YFH; 1T39; 1T38; 1QNT; 1EH8 T24587 BIOCLASS Methyltransferase T24587 ECNUMBER EC 2.1.1.63 T24587 SEQUENCE MDKDCEMKRTTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLMQCTAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYQQLAALAGNPKAARAVGGAMRGNPVPILIPCHRVVCSSGAVGNYSGGLAVKEWLLAHEGHRLGKPGLGGSSGLAGAWLKGAGATSGSPPAGRN T24587 DRUGINFO D0S0HA O6-Benzylguanine alkylade Phase 3 T24587 DRUGINFO D04RNU 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine Investigative T24587 DRUGINFO D07BTU 6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine Investigative T24587 DRUGINFO D0B5BG 6-Benzyloxy-9H-purin-2-ylamine Investigative T24587 DRUGINFO D0S0JL Benzylcysteine Investigative T24587 DRUGINFO D0Z8EI 6-Allyloxy-9H-purin-2-ylamine Investigative T24587 DRUGINFO D0CU4Q S-Methylcysteine Investigative T10735 TARGETID T10735 T10735 FORMERID TTDC00027 T10735 UNIPROID DCHS_HUMAN T10735 TARGNAME Histidine decarboxylase (HDC) T10735 GENENAME HDC T10735 TARGTYPE Clinical trial T10735 SYNONYMS Human histidine decarboxylase T10735 FUNCTION Catalyzes the biosynthesis of histamine from histidine. T10735 PDBSTRUC 4E1O T10735 BIOCLASS Carbon-carbon lyase T10735 ECNUMBER EC 4.1.1.22 T10735 SEQUENCE MMEPEEYRERGREMVDYICQYLSTVRERRVTPDVQPGYLRAQLPESAPEDPDSWDSIFGDIERIIMPGVVHWQSPHMHAYYPALTSWPSLLGDMLADAINCLGFTWASSPACTELEMNVMDWLAKMLGLPEHFLHHHPSSQGGGVLQSTVSESTLIALLAARKNKILEMKTSEPDADESCLNARLVAYASDQAHSSVEKAGLISLVKMKFLPVDDNFSLRGEALQKAIEEDKQRGLVPVFVCATLGTTGVCAFDCLSELGPICAREGLWLHIDAAYAGTAFLCPEFRGFLKGIEYADSFTFNPSKWMMVHFDCTGFWVKDKYKLQQTFSVNPIYLRHANSGVATDFMHWQIPLSRRFRSVKLWFVIRSFGVKNLQAHVRHGTEMAKYFESLVRNDPSFEIPAKRHLGLVVFRLKGPNCLTENVLKEIAKAGRLFLIPATIQDKLIIRFTVTSQFTTRDDILRDWNLIRDAATLILSQHCTSQPSPRVGNLISQIRGARAWACGTSLQSVSGAGDDPVQARKIIKQPQRVGAGPMKRENGLHLETLLDPVDDCFSEEAPDATKHKLSSFLFSYLSVQTKKKTVRSLSCNSVPVSAQKPLPTEASVKNGGSSRVRIFSRFPEDMMMLKKSAFKKLIKFYSVPSFPECSSQCGLQLPCCPLQAMV T10735 DRUGINFO D07EEN Lixivaptan Phase 3 T10735 DRUGINFO D0U5BF ALPHA-FMH Phase 1 T10735 DRUGINFO D05BKG AMA Investigative T10735 DRUGINFO D06KMO Brocresine Investigative T01908 TARGETID T01908 T01908 FORMERID TTDC00028 T01908 UNIPROID KLK2_HUMAN T01908 TARGNAME Tissue kallikrein (KLK2) T01908 GENENAME KLK2 T01908 TARGTYPE Clinical trial T01908 SYNONYMS hGK-1; Tissue kallikrein-2; Kallikrein-2; Glandular kallikrein-1 T01908 FUNCTION Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin. T01908 PDBSTRUC 4NFF; 4NFE T01908 BIOCLASS Peptidase T01908 ECNUMBER EC 3.4.21.35 T01908 SEQUENCE MWDLVLSIALSVGCTGAVPLIQSRIVGGWECEKHSQPWQVAVYSHGWAHCGGVLVHPQWVLTAAHCLKKNSQVWLGRHNLFEPEDTGQRVPVSHSFPHPLYNMSLLKHQSLRPDEDSSHDLMLLRLSEPAKITDVVKVLGLPTQEPALGTTCYASGWGSIEPEEFLRPRSLQCVSLHLLSNDMCARAYSEKVTEFMLCAGLWTGGKDTCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKVVHYRKWIKDTIAANP T01908 DRUGINFO D0V4HO Avoralstat Phase 2/3 T01908 DRUGINFO DK6P5A VDA-1102 Phase 2 T01908 DRUGINFO D4NGM6 JNJ-75229414 Phase 1 T01908 DRUGINFO D4TI9A JNJ-69086420 Phase 1 T01908 DRUGINFO D0NQ1S JNJ-78278343 Phase 1 T01908 DRUGINFO D0B9EH Dermolastin Discontinued in Phase 2 T01908 DRUGINFO D03OMK DM-107 Investigative T01908 DRUGINFO D05FYR hK2p01 derivative KLK2 inhibitor Investigative T65116 TARGETID T65116 T65116 FORMERID TTDR01229 T65116 UNIPROID 5NTD_HUMAN T65116 TARGNAME Ecto-5'-nucleotidase (CD73) T65116 GENENAME NT5E T65116 TARGTYPE Clinical trial T65116 SYNONYMS NT5; CD73 antigen; 5'-nucleotidase; 5'-NT T65116 FUNCTION Exhibits AMP-, NAD-, and NMN-nucleosidase activities. Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. T65116 PDBSTRUC 4H2I; 4H2G; 4H2F; 4H2B; 4H1Y T65116 BIOCLASS Phosphoric monoester hydrolase T65116 ECNUMBER EC 3.1.3.5 T65116 SEQUENCE MCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSKCVNASRCMGGVARLFTKVQQIRRAEPNVLLLDAGDQYQGTIWFTVYKGAEVAHFMNALRYDAMALGNHEFDNGVEGLIEPLLKEAKFPILSANIKAKGPLASQISGLYLPYKVLPVGDEVVGIVGYTSKETPFLSNPGTNLVFEDEITALQPEVDKLKTLNVNKIIALGHSGFEMDKLIAQKVRGVDVVVGGHSNTFLYTGNPPSKEVPAGKYPFIVTSDDGRKVPVVQAYAFGKYLGYLKIEFDERGNVISSHGNPILLNSSIPEDPSIKADINKWRIKLDNYSTQELGKTIVYLDGSSQSCRFRECNMGNLICDAMINNNLRHTDEMFWNHVSMCILNGGGIRSPIDERNNGTITWENLAAVLPFGGTFDLVQLKGSTLKKAFEHSVHRYGQSTGEFLQVGGIHVVYDLSRKPGDRVVKLDVLCTKCRVPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDELLRHDSGDQDINVVSTYISKMKVIYPAVEGRIKFSTGSHCHGSFSLIFLSLWAVIFVLYQ T65116 DRUGINFO DFYL50 TJ004309 Phase 2 T65116 DRUGINFO D02GRR Oleclumab Phase 1 T65116 DRUGINFO D7CE6N AB680 Phase 1 T65116 DRUGINFO D9IQ6N TJ4309 Phase 1 T65116 DRUGINFO DKL13E CPI-006 Phase 1 T65116 DRUGINFO DN65GW LY3475070 Phase 1 T65116 DRUGINFO DP6GC3 NZV930 Phase 1 T65116 DRUGINFO DG6V7E GS-1423 Phase 1 T65116 DRUGINFO D00BQR PMID28870136-Compound-57 Patented T65116 DRUGINFO D01ADE PMID28870136-Compound-46 Patented T65116 DRUGINFO D01NBW PMID28870136-Compound-53 Patented T65116 DRUGINFO D01OIQ PMID28870136-Compound-45 Patented T65116 DRUGINFO D02DLG PMID28870136-Compound-38 Patented T65116 DRUGINFO D03VLV PMID28870136-Compound-36 Patented T65116 DRUGINFO D03XTA PMID28870136-Compound-49 Patented T65116 DRUGINFO D04GYR PMID28870136-Compound-61 Patented T65116 DRUGINFO D04TGG PMID28870136-Compound-68 Patented T65116 DRUGINFO D06YAB PMID28870136-Compound-51 Patented T65116 DRUGINFO D07DGB PMID28870136-Compound-55 Patented T65116 DRUGINFO D08LPX PMID28870136-Compound-69 Patented T65116 DRUGINFO D08ZDR PMID28870136-Compound-67 Patented T65116 DRUGINFO D09QNH PMID28870136-Compound-50 Patented T65116 DRUGINFO D09XUJ PMID28870136-Compound-59 Patented T65116 DRUGINFO D0AF4A PMID28870136-Compound-40 Patented T65116 DRUGINFO D0C2UP PMID28870136-Compound-42 Patented T65116 DRUGINFO D0C7ON PMID28870136-Compound-43 Patented T65116 DRUGINFO D0CH7Z PMID28870136-Compound-44 Patented T65116 DRUGINFO D0DF2M PMID28870136-Compound-48 Patented T65116 DRUGINFO D0FK2Q PMID28870136-Compound-47 Patented T65116 DRUGINFO D0H9IX PMID28870136-Compound-52 Patented T65116 DRUGINFO D0JF6W PMID28870136-Compound-65 Patented T65116 DRUGINFO D0KS3G PMID29166791-Compound-AMPCP Patented T65116 DRUGINFO D0LB7I PMID28870136-Compound-64 Patented T65116 DRUGINFO D0MA9U PMID28870136-Compound-60 Patented T65116 DRUGINFO D0QL7B PMID28870136-Compound-41 Patented T65116 DRUGINFO D0SK3R PMID28870136-Compound-39 Patented T65116 DRUGINFO D0U2YE PMID28870136-Compound-56 Patented T65116 DRUGINFO D0V5NK PMID28870136-Compound-54 Patented T65116 DRUGINFO D0V7OE PMID28870136-Compound-58 Patented T65116 DRUGINFO D0X1MK PMID28870136-Compound-37 Patented T65116 DRUGINFO D0Y2QO PMID28870136-Compound-62 Patented T65116 DRUGINFO D0Y9TP PMID28870136-Compound-63 Patented T65116 DRUGINFO D08DXA Acid blue 25 Investigative T65116 DRUGINFO D0DZ1K PSB-0952 Investigative T65116 DRUGINFO D0O9GJ alphabeta-methyleneADP Investigative T65116 DRUGINFO D06GQY PSB-0963 Investigative T65116 DRUGINFO D0B0ZQ RB 2 Investigative T94479 TARGETID T94479 T94479 FORMERID TTDC00145 T94479 UNIPROID KS6B1_HUMAN T94479 TARGNAME Ribosomal protein S6 kinase beta-1 (S6K1) T94479 GENENAME RPS6KB1 T94479 TARGTYPE Clinical trial T94479 SYNONYMS p70-S6K 1; p70 ribosomal S6 kinase alpha; p70 S6KA; p70 S6K-alpha; p70 S6 kinase alpha; Serine/threonine-protein kinase 14A; STK14A; S6K-beta-1; S6K; Ribosomal protein S6 kinase I; P70S6K1; P70-S6K; 70 kDa ribosomal protein S6 kinase 1 T94479 FUNCTION Regulates protein synthesis through phosphorylation of EIF4B, RPS6 and EEF2K, and contributes to cell survival by repressing the pro-apoptotic function of BAD. Under conditions of nutrient depletion, the inactive form associates with the EIF3 translation initiation complex. Upon mitogenic stimulation, phosphorylation by the mammalian target of rapamycin complex 1 (mTORC1) leads to dissociation from the EIF3 complex and activation. The active form then phosphorylates and activates several substrates in the pre-initiation complex, including the EIF2B complex and the cap-binding complex component EIF4B. Also controls translation initiation by phosphorylating a negative regulator of EIF4A, PDCD4, targeting it for ubiquitination and subsequent proteolysis. Promotes initiation of the pioneer round of protein synthesis by phosphorylating POLDIP3/SKAR. In response to IGF1, activates translation elongation by phosphorylating EEF2 kinase (EEF2K), which leads to its inhibition and thus activation of EEF2. Also plays a role in feedback regulation of mTORC2 by mTORC1 by phosphorylating RICTOR, resulting in the inhibition of mTORC2 and AKT1 signaling. Mediates cell survival by phosphorylating the pro-apoptotic protein BAD and suppressing its pro-apoptotic function. Phosphorylates mitochondrial URI1 leading to dissociation of a URI1-PPP1CC complex. The free mitochondrial PPP1CC can then dephosphorylate RPS6KB1 at Thr-412, which is proposed to be a negative feedback mechanism for the RPS6KB1 anti-apoptotic function. Mediates TNF-alpha-induced insulin resistance by phosphorylating IRS1 at multiple serine residues, resulting in accelerated degradation of IRS1. In cells lacking functional TSC1-2 complex, constitutively phosphorylates and inhibits GSK3B. May be involved in cytoskeletal rearrangement through binding to neurabin. Phosphorylates and activates the pyrimidine biosynthesis enzyme CAD, downstream of MTOR. Following activation by mTORC1, phosphorylates EPRS and thereby plays a key role in fatty acid uptake by adipocytes and also most probably in interferon-gamma-induced translation inhibition. Serine/threonine-protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression. T94479 PDBSTRUC 5WBK; 5WBH; 4RLP; 4RLO; 4L46 T94479 BIOCLASS Kinase T94479 ECNUMBER EC 2.7.11.1 T94479 SEQUENCE MRRRRRRDGFYPAPDFRDREAEDMAGVFDIDLDQPEDAGSEDELEEGGQLNESMDHGGVGPYELGMEHCEKFEISETSVNRGPEKIRPECFELLRVLGKGGYGKVFQVRKVTGANTGKIFAMKVLKKAMIVRNAKDTAHTKAERNILEEVKHPFIVDLIYAFQTGGKLYLILEYLSGGELFMQLEREGIFMEDTACFYLAEISMALGHLHQKGIIYRDLKPENIMLNHQGHVKLTDFGLCKESIHDGTVTHTFCGTIEYMAPEILMRSGHNRAVDWWSLGALMYDMLTGAPPFTGENRKKTIDKILKCKLNLPPYLTQEARDLLKKLLKRNAASRLGAGPGDAGEVQAHPFFRHINWEELLARKVEPPFKPLLQSEEDVSQFDSKFTRQTPVDSPDDSTLSESANQVFLGFTYVAPSVLESVKEKFSFEPKIRSPRRFIGSPRTPVSPVKFSPGDFWGRGASASTANPQTPVEYPMETSGIEQMDVTMSGEASAPLPIRQPNSGPYKKQAFPMISKRPEHLRMNL T94479 DRUGINFO D6KWF3 NNI‐362 Phase 1 T94479 DRUGINFO D06HYF M2698 Phase 1 T94479 DRUGINFO D0Y4LI PF-4708671 Clinical trial T94479 DRUGINFO D02ABC PMID27410995-Compound-Figure3c Patented T94479 DRUGINFO D0BN4A Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1 Patented T94479 DRUGINFO D0N4WB SB-415286 Investigative T94479 DRUGINFO D0I1FJ SB-747651A Investigative T94479 DRUGINFO D0R6OM ACTB-1003 Investigative T94479 DRUGINFO D0L2WP PMID20005102C1 Investigative T94479 DRUGINFO D0G2VC KT-5720 Investigative T94479 DRUGINFO D0GB4V STAUROSPORINONE Investigative T94479 DRUGINFO D0M5FF Ro31-8220 Investigative T94479 DRUGINFO D0N6ES KN-62 Investigative T94479 DRUGINFO D0B9BU CI-1040 Investigative T94479 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T94479 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T94479 DRUGINFO D0L8HO RO-316233 Investigative T05114 TARGETID T05114 T05114 FORMERID TTDR00197 T05114 UNIPROID CMA1_HUMAN T05114 TARGNAME Chymase (CYM) T05114 GENENAME CMA1 T05114 TARGTYPE Clinical trial T05114 SYNONYMS Mast cell protease I; CYH; Alpha-chymase T05114 FUNCTION Major secreted protease of mast cells with suspected roles in vasoactive peptide generation, extracellular matrix degradation, and regulation of gland secretion. T05114 PDBSTRUC 5YJP; 5YJM; 4KP0; 4K69; 4K60 T05114 BIOCLASS Peptidase T05114 ECNUMBER EC 3.4.21.39 T05114 SEQUENCE MLLLPLPLLLFLLCSRAEAGEIIGGTECKPHSRPYMAYLEIVTSNGPSKFCGGFLIRRNFVLTAAHCAGRSITVTLGAHNITEEEDTWQKLEVIKQFRHPKYNTSTLHHDIMLLKLKEKASLTLAVGTLPFPSQFNFVPPGRMCRVAGWGRTGVLKPGSDTLQEVKLRLMDPQACSHFRDFDHNLQLCVGNPRKTKSAFKGDSGGPLLCAGVAQGIVSYGRSDAKPPAVFTRISHYRPWINQILQAN T05114 DRUGINFO D0B1OH ASB17061 Phase 2 T05114 DRUGINFO D0M0YB BAY 11-42524 Phase 2 T05114 DRUGINFO DGD72N BAY 1142524 Phase 2 T05114 DRUGINFO D01YIO JNJ-10311795 Phase 2 T05114 DRUGINFO D0I8FV SUN13834 Phase 2 T05114 DRUGINFO D05QCE KM-01221 Investigative T05114 DRUGINFO D08QZD Y-40613 Investigative T05114 DRUGINFO D0C8UF Rac-2q Investigative T05114 DRUGINFO D0F3CS Phenylalanylmethane Investigative T05114 DRUGINFO D0H3SL NK3201 Investigative T05114 DRUGINFO D0J3SW BCEAB Investigative T05114 DRUGINFO D0L0QR CHYMOSTATIN Investigative T05114 DRUGINFO D0S1HT SUN-C8257 Investigative T05114 DRUGINFO D0PA1G Benzylsulfinic Acid Investigative T05114 DRUGINFO D07KZA 2-(N-Morpholino)-Ethanesulfonic Acid Investigative T11487 TARGETID T11487 T11487 FORMERID TTDC00313 T11487 UNIPROID THIL_HUMAN T11487 TARGNAME Acetoacetyl-CoA thiolase (ACAT1) T11487 GENENAME ACAT1 T11487 TARGTYPE Clinical trial T11487 SYNONYMS T2; MAT; Acetyl-CoA acetyltransferase, mitochondrial T11487 FUNCTION Plays a major role in ketone body metabolism. T11487 PDBSTRUC 2IBY; 2IBW; 2IBU; 2IB9; 2IB8 T11487 BIOCLASS Acyltransferase T11487 ECNUMBER EC 2.3.1.9 T11487 SEQUENCE MAVLAALLRSGARSRSPLLRRLVQEIRYVERSYVSKPTLKEVVIVSATRTPIGSFLGSLSLLPATKLGSIAIQGAIEKAGIPKEEVKEAYMGNVLQGGEGQAPTRQAVLGAGLPISTPCTTINKVCASGMKAIMMASQSLMCGHQDVMVAGGMESMSNVPYVMNRGSTPYGGVKLEDLIVKDGLTDVYNKIHMGSCAENTAKKLNIARNEQDAYAINSYTRSKAAWEAGKFGNEVIPVTVTVKGQPDVVVKEDEEYKRVDFSKVPKLKTVFQKENGTVTAANASTLNDGAAALVLMTADAAKRLNVTPLARIVAFADAAVEPIDFPIAPVYAASMVLKDVGLKKEDIAMWEVNEAFSLVVLANIKMLEIDPQKVNINGGAVSLGHPIGMSGARIVGHLTHALKQGEYGLASICNGGGGASAMLIQKL T11487 DRUGINFO D0LM4U ATR-01 Phase 1 T11487 DRUGINFO D04TSP PMID25470667-Compound-K-604 Patented T11487 DRUGINFO D00CCI Benoxaprofen Withdrawn from market T11487 DRUGINFO D00EYY PMID16242323C18a Investigative T11487 DRUGINFO D00MJG PMID16242323C16 Investigative T11487 DRUGINFO D01UWZ PMID16242323C22c Investigative T11487 DRUGINFO D04SPQ PMID16242323C26a Investigative T11487 DRUGINFO D07LER Nonanoic acid biphenyl-2-ylamide Investigative T11487 DRUGINFO D0A7YE Octanoic acid biphenyl-2-ylamide Investigative T11487 DRUGINFO D0IY3E PMID16242323C22d Investigative T11487 DRUGINFO D0K6SD PMID16242323C15a Investigative T11487 DRUGINFO D0KS1Z PMID16242323C26c Investigative T11487 DRUGINFO D0M8SY PMID16242323C18b Investigative T11487 DRUGINFO D0RG1F PMID16242323C26b Investigative T11487 DRUGINFO D0T9RD (Z)-2,6-diisopropyl-N-phenyloctadec-9-enamide Investigative T11487 DRUGINFO D0W5HL PMID16242323C15b Investigative T70176 TARGETID T70176 T70176 FORMERID TTDC00088 T70176 UNIPROID CDK2_HUMAN T70176 TARGNAME Cyclin-dependent kinase 2 (CDK2) T70176 GENENAME CDK2 T70176 TARGTYPE Clinical trial T70176 SYNONYMS Sin3 associated polypeptide; SIN3-associated protein; P33 protein kinase; Cell division protein kinase 2; CDKN2 T70176 FUNCTION Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1. Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization. Phosphorylates FOXP3 and negatively regulates its transcriptional activity and protein stability. Phosphorylates CDK2AP2. Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. T70176 PDBSTRUC 6Q4K; 6Q4J; 6Q4I; 6Q4H; 6Q4G T70176 BIOCLASS Kinase T70176 ECNUMBER EC 2.7.11.22 T70176 SEQUENCE MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL T70176 DRUGINFO D0Q9UX PHA848125 Phase 2 T70176 DRUGINFO D01UMT Ro 31-7453 Phase 2 T70176 DRUGINFO D05ADP R-roscovitine Phase 2 T70176 DRUGINFO D0P0KN TG02 Phase 1/2 T70176 DRUGINFO D70HZT NUV-422 Phase 1/2 T70176 DRUGINFO D06WHY AZD-5438 Phase 1 T70176 DRUGINFO D07DTV AT7519 Phase 1 T70176 DRUGINFO D5TH2B PF-07104091 Phase 1 T70176 DRUGINFO D0PL7P CYC065 Phase 1 T70176 DRUGINFO D0IX4B AG-024322 Phase 1 T70176 DRUGINFO D0P1CV PHA-793887 Phase 1 T70176 DRUGINFO D0S5RC SNS-032 Phase 1 T70176 DRUGINFO DYH94Z RGT-419B Phase 1 T70176 DRUGINFO DKCU40 FN-1501 Phase 1 T70176 DRUGINFO D03DKV RGB-286638 Phase 1 T70176 DRUGINFO D09ISI Fluorinated compound 1 Patented T70176 DRUGINFO D0JU4Z 4-amino-3,5-di-substituted-thiazole derivative 1 Patented T70176 DRUGINFO D02KWX Indole-based analog 11 Patented T70176 DRUGINFO D03EYT N-(pyridin-2-yl)pyridine methylsulfone derivative 1 Patented T70176 DRUGINFO D03HED Palbociclib/ribociclib analog 1 Patented T70176 DRUGINFO D05UJQ Alkyl sulfone derivative 1 Patented T70176 DRUGINFO D06QPW Aniline derivative 1 Patented T70176 DRUGINFO D07QIP 4-(thiazol-5-yl)-pyrimidine derivative 1 Patented T70176 DRUGINFO D0AY5G N-phenyl-pyrimidin-4-amine derivative 1 Patented T70176 DRUGINFO D0GQ7L PMID26161698-Compound-25 Patented T70176 DRUGINFO D0P4NP Diaryl amine derivative 1 Patented T70176 DRUGINFO D0P9WR Flavopiridol analog 1 Patented T70176 DRUGINFO D0QR1Z Isosteric imidazolyl pyrimidine derivative 1 Patented T70176 DRUGINFO D0QS2B N-(pyridin-2-yl)pyrimidin-4-amine derivative 2 Patented T70176 DRUGINFO D0T6CM Pyrazolo-triazine derivative 2 Patented T70176 DRUGINFO D0UU0V 1,5-di-substituted pyridine derivative 1 Patented T70176 DRUGINFO D0V7RP 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1 Patented T70176 DRUGINFO D08KKC Pyrrolo[2,3-d]pyrimidine derivative 9 Patented T70176 DRUGINFO D08WJG Naphthyridine and isoquinoline derivative 1 Patented T70176 DRUGINFO D0LK4L Nitrogen mustard derivative 1 Patented T70176 DRUGINFO D01CJE 4-(thiazol-5-yl)-pyrimidine derivative 2 Patented T70176 DRUGINFO D0LR2Y Diamidothiazole derivative 1 Patented T70176 DRUGINFO D0LX6X Indole-based analog 13 Patented T70176 DRUGINFO D0NB7Y Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 Patented T70176 DRUGINFO D0W4MN Isoquinoline 1,3-dione derivative 1 Patented T70176 DRUGINFO D07DUX Roscovitine derivative 1 Patented T70176 DRUGINFO D0H4HD PMID25991433-Compound-A1 Patented T70176 DRUGINFO D0M5DX Oxazolyl methylthiothiazole derivative 1 Patented T70176 DRUGINFO D0D3PX SCH 727965 Discontinued in Phase 3 T70176 DRUGINFO D0NV9O BAY 10-00394 Discontinued in Phase 2 T70176 DRUGINFO D04FHB R547 Discontinued in Phase 1 T70176 DRUGINFO D00VBT ZK 304709 Discontinued in Phase 1 T70176 DRUGINFO D07ZJC INOC-005 Preclinical T70176 DRUGINFO D0WS1V L-751250 Preclinical T70176 DRUGINFO D00BPA Olomoucine Terminated T70176 DRUGINFO D0Z0KD PD-0183812 Terminated T70176 DRUGINFO D01LPG 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide Investigative T70176 DRUGINFO D03BZV PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE Investigative T70176 DRUGINFO D06FIQ 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE Investigative T70176 DRUGINFO D07ADR BOHEMINE Investigative T70176 DRUGINFO D07ODE N-phenyl-1H-pyrazole-3-carboxamide Investigative T70176 DRUGINFO D07SGT 5-hydroxynaphthalene-1-sulfonamide Investigative T70176 DRUGINFO D0D3HB N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide Investigative T70176 DRUGINFO D0I1SZ N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE Investigative T70176 DRUGINFO D0I9VN 1-Amino-6-Cyclohex-3-Enylmethyloxypurine Investigative T70176 DRUGINFO D0M5PI Benzyl-(9-isopropyl-9H-purin-6-yl)-amine Investigative T70176 DRUGINFO D0MK6D N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide Investigative T70176 DRUGINFO D0P7RO TRIAZOLOPYRIMIDINE Investigative T70176 DRUGINFO D0QI7H 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE Investigative T70176 DRUGINFO D0T4SJ SCH-546909 Investigative T70176 DRUGINFO D0T5AH PHA-690509 Investigative T70176 DRUGINFO D0U0GE 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine Investigative T70176 DRUGINFO D0V1NK VER-54505 Investigative T70176 DRUGINFO D0W0PF 2-Amino-6-Chloropyrazine Investigative T70176 DRUGINFO D0Y6DX 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine Investigative T70176 DRUGINFO D01FJB 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine Investigative T70176 DRUGINFO D01PSU (2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime Investigative T70176 DRUGINFO D02ZYA 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine Investigative T70176 DRUGINFO D03KLM (2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime Investigative T70176 DRUGINFO D03XKK 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine Investigative T70176 DRUGINFO D04AGE (2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime Investigative T70176 DRUGINFO D04NGS JNJ-7706621 Investigative T70176 DRUGINFO D04RBG GW-8510 Investigative T70176 DRUGINFO D05SZH BMS-265246 Investigative T70176 DRUGINFO D06GLV (2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime Investigative T70176 DRUGINFO D06XIW (2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime Investigative T70176 DRUGINFO D07AEC RESCOVITINE Investigative T70176 DRUGINFO D07HPE Cdk4 inhibitor III Investigative T70176 DRUGINFO D07JHG 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine Investigative T70176 DRUGINFO D0B1LM (2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime Investigative T70176 DRUGINFO D0F3OM 2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol Investigative T70176 DRUGINFO D0GP3R 5-nitroindirubin-3'-oxime Investigative T70176 DRUGINFO D0H0EN (2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime Investigative T70176 DRUGINFO D0I6AE (2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime Investigative T70176 DRUGINFO D0J3RS (2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime Investigative T70176 DRUGINFO D0JR0G (2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime Investigative T70176 DRUGINFO D0KH5T 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline Investigative T70176 DRUGINFO D0L5PI (2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime Investigative T70176 DRUGINFO D0M4XD (2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime Investigative T70176 DRUGINFO D0MS4R Oxindole 95 Investigative T70176 DRUGINFO D0P2WA CVT-313 Investigative T70176 DRUGINFO D0R1FT 6-O-Cyclohexylmethyl Guanine Investigative T70176 DRUGINFO D0U8YN NU-6027 Investigative T70176 DRUGINFO D0VD8B NSC-625987 Investigative T70176 DRUGINFO D0W2FM (2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime Investigative T70176 DRUGINFO D0YZ9Y (2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime Investigative T70176 DRUGINFO D00SEC aloisine Investigative T70176 DRUGINFO D01PEF MERIOLIN 8 Investigative T70176 DRUGINFO D02DLC PYRAZOLOPYRIDAZINE 1 Investigative T70176 DRUGINFO D07OAT Purvalanol A Investigative T70176 DRUGINFO D07OCA Cdk1/2 inhibitor III Investigative T70176 DRUGINFO D08KSQ MERIOLIN 1 Investigative T70176 DRUGINFO D0B9YR MERIOLIN 4 Investigative T70176 DRUGINFO D0CC0B Lysine Nz-Carboxylic Acid Investigative T70176 DRUGINFO D0D0ZQ MERIOLIN 6 Investigative T70176 DRUGINFO D0D5HQ K00024 Investigative T70176 DRUGINFO D0F0AX 10Z-Hymenialdisine Investigative T70176 DRUGINFO D0G2GA aminopurvalanol A Investigative T70176 DRUGINFO D0H3EV 9-Nitropaullone Investigative T70176 DRUGINFO D0H6CQ MERIOLIN 5 Investigative T70176 DRUGINFO D0L3FK SU9516 Investigative T70176 DRUGINFO D0O0VP PYRAZOLOPYRIDAZINE 2 Investigative T70176 DRUGINFO D0S8VE MERIOLIN 3 Investigative T70176 DRUGINFO D0U1WL MERIOLIN 2 Investigative T70176 DRUGINFO D0P6JS PMID18986805C9b Investigative T70176 DRUGINFO D0W0BL 3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol Investigative T70176 DRUGINFO D0G2CT Indirubin-5-sulfonate Investigative T70176 DRUGINFO D0S7IE N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide Investigative T70176 DRUGINFO D0Y5RO NU-6102 Investigative T70176 DRUGINFO D02QAZ PF-228 Investigative T70176 DRUGINFO D02XHC aloisine A Investigative T70176 DRUGINFO D04WFN NU6140 Investigative T70176 DRUGINFO D0IX7Y BX-912 Investigative T70176 DRUGINFO D0RG0Z BX-795 Investigative T70176 DRUGINFO D0T8NU PMID19115845C89S Investigative T70176 DRUGINFO D0Y0ES Indirubin-3'-monoxime Investigative T70176 DRUGINFO D0H1GU Double Oxidized Cysteine Investigative T70176 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T70176 DRUGINFO D0M4SY BMS-536924 Investigative T70176 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T70176 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T70176 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T70176 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T90553 TARGETID T90553 T90553 FORMERID TTDC00281 T90553 UNIPROID MARK3_HUMAN T90553 TARGNAME Microtubule affinity regulating kinase 3 (MARK3) T90553 GENENAME MARK3 T90553 TARGTYPE Clinical trial T90553 SYNONYMS cTAK1; Serine/threonine-protein kinase p78; Ser/Thr protein kinase PAR-1; Protein kinase STK10); Protein kinase STK10; Par-1a; MAP/microtubule affinity-regulating kinase 3; EMK2; EMK-2; ELKL motif kinase 2; Cdc25C-associated protein kinase 1; C-TAK1 T90553 FUNCTION Involved in the specific phosphorylation of microtubule-associated proteins for MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TAU. Phosphorylates CDC25C on 'Ser-216'. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus. Negatively regulates the Hippo signaling pathway and antagonizes the phosphorylation of LATS1. Cooperates with DLG5 to inhibit the kinase activity of STK3/MST2 toward LATS1. Serine/threonine-protein kinase. T90553 PDBSTRUC 3FE3; 2QNJ T90553 BIOCLASS Kinase T90553 ECNUMBER EC 2.7.11.1 T90553 SEQUENCE MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKTQLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLKAENLLLDADMNIKIADFGFSNEFTVGGKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENLLKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYLLLGRKSSELDASDSSSSSNLSLAKVRPSSDLNNSTGQSPHHKVQRSVSSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISSRKSSGSAVGGKGIAPASPMLGNASNPNKADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTHSISSAATPDRIRFPRGTASRSTFHGQPRERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRRNMSFRFIKRLPTEYERNGRYEGSSRNVSAEQKDENKEAKPRSLRFTWSMKTTSSMDPGDMMREIRKVLDANNCDYEQRERFLLFCVHGDGHAENLVQWEMEVCKLPRLSLNGVRFKRISGTSIAFKNIASKIANELKL T90553 DRUGINFO D02NNN CBP-501 Phase 1/2 T90553 DRUGINFO D03BJF PMID23099093C17d Investigative T58970 TARGETID T58970 T58970 FORMERID TTDR00372 T58970 UNIPROID MK01_HUMAN T58970 TARGNAME Extracellular signal-regulated kinase 2 (ERK2) T58970 GENENAME MAPK1 T58970 TARGTYPE Clinical trial T58970 SYNONYMS PRKM2; PRKM1; P42-MAPK; P42 Mitogen-activated protein kinase; Mitogen-activated protein kinase 2; Mitogen-activated protein kinase 1; MAPK 2; MAPK 1; MAP kinase isoform p42; MAP kinase 2; MAP kinase 1; ERT1; ERK-2 T58970 FUNCTION MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Mediates phosphorylation of TPR in respons to EGF stimulation. May play a role in the spindle assembly checkpoint. Phosphorylates PML and promotes its interaction with PIN1, leading to PML degradation. Phosphorylates CDK2AP2. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. T58970 PDBSTRUC 6QAW; 6QAQ; 6QAL; 6QAG; 6Q7K T58970 BIOCLASS Kinase T58970 ECNUMBER EC 2.7.11.24 T58970 SEQUENCE MAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS T58970 DRUGINFO D01IED BVD-523 Phase 2 T58970 DRUGINFO D1KIY9 HH2710 Phase 1/2 T58970 DRUGINFO DM1FD5 ASTX029 Phase 1/2 T58970 DRUGINFO D0TN3Q LY3214996 Phase 1 T58970 DRUGINFO D08KNG VAN-10-4-eluting stent Phase 1 T58970 DRUGINFO D0Q4IX GDC-0994 Phase 1 T58970 DRUGINFO DBU16T JSI-1187 Phase 1 T58970 DRUGINFO D0YK9D CHIR-99021 Patented T58970 DRUGINFO DOJ6D9 COR-D Preclinical T58970 DRUGINFO D09ICC SB220025 Terminated T58970 DRUGINFO D07NEE AEZS-131 Investigative T58970 DRUGINFO D08XVZ SCH772984 Investigative T58970 DRUGINFO D0C5AD ERK inhibitor III Investigative T58970 DRUGINFO D0Q1AC (4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine Investigative T58970 DRUGINFO D0ZG4G FR-180204 Investigative T58970 DRUGINFO D01WAI DEBROMOHYMENIALDISINE Investigative T58970 DRUGINFO D05BHG Phosphonothreonine Investigative T58970 DRUGINFO D0G2VC KT-5720 Investigative T58970 DRUGINFO D0M5FF Ro31-8220 Investigative T58970 DRUGINFO D09XIL Ro-4396686 Investigative T58970 DRUGINFO D0M4SY BMS-536924 Investigative T58970 DRUGINFO D0N6ES KN-62 Investigative T58970 DRUGINFO D0B9BU CI-1040 Investigative T58970 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T58970 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T58970 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T58970 DRUGINFO D0L8HO RO-316233 Investigative T65200 TARGETID T65200 T65200 FORMERID TTDC00070 T65200 UNIPROID DHI1_HUMAN T65200 TARGNAME Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) T65200 GENENAME HSD11B1 T65200 TARGTYPE Clinical trial T65200 SYNONYMS HSD11B1; 11beta-HSD1A; 11HSD1; 11-beta-hydroxysteroid dehydrogenase 1; 11-beta-HSD1; 11-DH; 11 beta-hydroxysteroid dehydrogenase type 1 T65200 FUNCTION Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7- ketocholesterol to 7-beta-hydroxycholesterol. T65200 PDBSTRUC 5QII; 5PGY; 5PGX; 5PGW; 5PGV T65200 BIOCLASS Short-chain dehydrogenases reductase T65200 ECNUMBER EC 1.1.1.146 T65200 SEQUENCE MAFMKKYLLPILGLFMAYYYYSANEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHVVVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHITNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVAAYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEECALEIIKGGALRQEEVYYDSSLWTTLLIRNPCRKILEFLYSTSYNMDRFINK T65200 DRUGINFO D02ENG BVT.2733 Phase 3 T65200 DRUGINFO D0T8QB GLYCYRRHIZIN Phase 3 T65200 DRUGINFO D05XLO INCB13739 Phase 2a T65200 DRUGINFO D01THN JTT-654 Phase 2 T65200 DRUGINFO D09DIB RG-4929 Phase 2 T65200 DRUGINFO D0L4US BMS-770767 Phase 2 T65200 DRUGINFO D0OE5S UE-2343 Phase 2 T65200 DRUGINFO D0R8IU AZD-4017 Phase 2 T65200 DRUGINFO D07LUJ URSOLIC ACID Phase 2 T65200 DRUGINFO DJMK69 Xanamem Phase 1/2 T65200 DRUGINFO D08VSQ BMS-816336 Phase 1 T65200 DRUGINFO D0B5HF BI-135585 Phase 1 T65200 DRUGINFO D0O1ZI AZD8329 Phase 1 T65200 DRUGINFO D01MYN LY-2523199 Discontinued in Phase 2 T65200 DRUGINFO D07EBU AMG-221 Discontinued in Phase 1 T65200 DRUGINFO D07FHW PF-915275 Discontinued in Phase 1 T65200 DRUGINFO D0U1BU HPP-851 Preclinical T65200 DRUGINFO D0E0GW BVT-3498 Terminated T65200 DRUGINFO D00DDJ Adamantan-1-yl-piperazin-1-yl-methanone Investigative T65200 DRUGINFO D00PSW MERCK-544 Investigative T65200 DRUGINFO D00QOL 3-benzyl-1-cyclohexylpyrrolidin-2-one Investigative T65200 DRUGINFO D01CAC (4-methoxyphenyl)(4-phenylazepan-1-yl)methanone Investigative T65200 DRUGINFO D01EBV 3-epicorosolic acid methyl ester Investigative T65200 DRUGINFO D02KXX 1-(4-chlorophenyl)-2-(phenylsulfonyl)ethanone Investigative T65200 DRUGINFO D02WUU 2-(phenylsulfonyl)-1-p-tolylethanone Investigative T65200 DRUGINFO D03JWH 2-(o-toluidino)-5-ethylthiazol-4(5H)-one Investigative T65200 DRUGINFO D03KRW 1-(4-methoxyphenylsulfonyl)-4-phenylazepan-4-ol Investigative T65200 DRUGINFO D03PVF 2-(4-tosylpiperazin-1-yl)nicotinonitrile Investigative T65200 DRUGINFO D03QYZ PF-877423 Investigative T65200 DRUGINFO D04KAZ 1-phenyl-3-(phenylsulfonyl)propan-1-one Investigative T65200 DRUGINFO D04LGV 1-(4-ethylphenylsulfonyl)-4-phenylazepan-4-ol Investigative T65200 DRUGINFO D04WVV FIG 1 Investigative T65200 DRUGINFO D04ZEP A-849531 Investigative T65200 DRUGINFO D05ADD 1-(4-fluorophenyl)-3-(phenylsulfonyl)propan-1-one Investigative T65200 DRUGINFO D05NSB Adamantan-2-yl-piperidin-1-yl-methanone Investigative T65200 DRUGINFO D06CPL 1-phenyl-4-(1-phenyl-1H-tetrazol-5-yl)butan-2-one Investigative T65200 DRUGINFO D06GVN Tormentic acid methyl ester Investigative T65200 DRUGINFO D06RKS 1-(phenylsulfonyl)butan-2-one Investigative T65200 DRUGINFO D06UPR 1-(4-nitrophenyl)-2-(phenylsulfonyl)ethanone Investigative T65200 DRUGINFO D07IRZ 1,1-diphenyl-3-(phenylsulfonyl)propan-2-one Investigative T65200 DRUGINFO D08EDV N-benzyl-N-(phenylsulfonyl)benzamide Investigative T65200 DRUGINFO D09KDS Adamantan-1-yl-(4-ethyl-piperazin-1-yl)-methanone Investigative T65200 DRUGINFO D09VPP 11-keto-ursolic acid Investigative T65200 DRUGINFO D0A4ZR 2-(cyclooctylamino)-5,5-diethyloxazol-4(5H)-one Investigative T65200 DRUGINFO D0A5JU Piperidine-1-carboxylic acid adamantan-2-yl ester Investigative T65200 DRUGINFO D0B6HE SKI-2852 Investigative T65200 DRUGINFO D0BN7E 5-isopropyl-2-(phenylamino)thiazol-4(5H)-one Investigative T65200 DRUGINFO D0D3NV Adamantan-1-yl-piperidin-1-yl-methanone Investigative T65200 DRUGINFO D0D3PY 1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)ethanone Investigative T65200 DRUGINFO D0DS7W 1-(3-chloropyridin-2-yl)-4-tosylpiperazine Investigative T65200 DRUGINFO D0E3ST 1-(4-ethylpiperazin-1-yl)-2-phenylethanone Investigative T65200 DRUGINFO D0EU9W 1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone Investigative T65200 DRUGINFO D0F9RO Corosolic acid Investigative T65200 DRUGINFO D0I5ND CNX-010 Investigative T65200 DRUGINFO D0J3DW Piperidine-1-carboxylic acid adamantan-2-ylamide Investigative T65200 DRUGINFO D0J5RQ 3-acetyl-11-keto-ursolic acid Investigative T65200 DRUGINFO D0J6IE 2-(2-chlorophenylamino)-5-methylthiazol-4(5H)-one Investigative T65200 DRUGINFO D0KG3M 1-(4-chlorophenylsulfonyl)-4-phenylazepan-4-ol Investigative T65200 DRUGINFO D0L4VR Carbenoxolone Investigative T65200 DRUGINFO D0L5KQ 2-(benzylamino)-5,5-diethyloxazol-4(5H)-one Investigative T65200 DRUGINFO D0M3XF 1-(4-tert-butylphenylsulfonyl)-4-methoxyazepane Investigative T65200 DRUGINFO D0M4PP 1-(4-methoxyphenyl)-2-(phenylsulfonyl)ethanone Investigative T65200 DRUGINFO D0O8RL EQ-1280 Investigative T65200 DRUGINFO D0P7RN 1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone Investigative T65200 DRUGINFO D0Q2MI 1-(3,5-dimethylphenyl)-2-(phenylsulfonyl)ethanone Investigative T65200 DRUGINFO D0Q2TF 1-(4-tert-butylphenylsulfonyl)azepan-4-ol Investigative T65200 DRUGINFO D0R4DK 1-(1-phenyl-1H-tetrazol-5-ylthio)propan-2-one Investigative T65200 DRUGINFO D0T3FW 1-(2-adamantyl)-3-benzylpyrrolidin-2-one Investigative T65200 DRUGINFO D0T9NX 1-(3-methylpyridin-2-yl)-4-tosylpiperazine Investigative T65200 DRUGINFO D0TF9R 2-(o-toluidino)-5-isopropylthiazol-4(5H)-one Investigative T65200 DRUGINFO D0UJ2C 2-(phenylsulfonyl)-1-(thiophen-3-yl)ethanone Investigative T65200 DRUGINFO D0UQ6U Abietic acid Investigative T65200 DRUGINFO D0V5TC 1-(3-nitropyridin-2-yl)-4-tosylpiperazine Investigative T65200 DRUGINFO D0VC2M Adamantan-1-yl-pyrrolidin-1-yl-methanone Investigative T65200 DRUGINFO D0W9WG 5,5-diethyl-2-(phenethylamino)oxazol-4(5H)-one Investigative T65200 DRUGINFO D0Y9XK 1-phenyl-2-(1-phenyl-1H-tetrazol-5-yloxy)ethanone Investigative T65200 DRUGINFO D0ZG3Q 2-(adamantan-1-ylamino)-5,5-diethyl-oxazol-4-one Investigative T65200 DRUGINFO D02XEX 3-acetyl-11-keto-beta-boswellic acid Investigative T65200 DRUGINFO D09VYW 11-keto-beta-boswellicacid Investigative T65200 DRUGINFO D0B4VE Flavanone Investigative T65200 DRUGINFO D03TNT (11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE Investigative T65200 DRUGINFO D0U8IF [(125)I] RB129 Investigative T65200 DRUGINFO D07KZA 2-(N-Morpholino)-Ethanesulfonic Acid Investigative T65200 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T06046 TARGETID T06046 T06046 FORMERID TTDC00097 T06046 UNIPROID NOS3_HUMAN T06046 TARGNAME Nitric-oxide synthase endothelial (NOS3) T06046 GENENAME NOS3 T06046 TARGTYPE Clinical trial T06046 SYNONYMS Nitric oxide synthase, endothelial; NOSIII; NOS,type III; NOS type III; Endothelial nitric oxide synthase; Endothelial NOS; ENOS; EC-NOS; Constitutive NOS; CNOS T06046 FUNCTION NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. T06046 PDBSTRUC 6CIF; 6CIE; 6AV7; 6AV6; 5XOF T06046 BIOCLASS Paired donor oxygen oxidoreductase T06046 ECNUMBER EC 1.14.13.39 T06046 SEQUENCE MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLTQPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDDPPELFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATILVRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNSP T06046 DRUGINFO D06OQI Tilarginine acetate Phase 3 T06046 DRUGINFO D0D3AI L-NAME Phase 2 T06046 DRUGINFO D0J7EH ACCLAIM Phase 2 T06046 DRUGINFO D0N2JI VAS-203 Phase 2 T06046 DRUGINFO D0X1RQ MTR105 Phase 2 T06046 DRUGINFO D0H3GK Autologous cell based gene therapy Phase 1 T06046 DRUGINFO D0Y7VJ L-NIL Terminated T06046 DRUGINFO D01FMS AP-Cav Investigative T06046 DRUGINFO D02RNH Se-Ethyl-Isoselenourea Investigative T06046 DRUGINFO D03EBE 6s-5,6,7,8-Tetrahydrobiopterin Investigative T06046 DRUGINFO D03RGI 1,2,4-Triazole-Carboxamidine Investigative T06046 DRUGINFO D06PFL 4-Methyl-3,6-dihydro-1H-pyridin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D08DNK N-(Chlorophenyl)-N'-Hydroxyguanidine Investigative T06046 DRUGINFO D0DI7W 4-Methyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D0F8VS L-Homoarginine Investigative T06046 DRUGINFO D0FK0A 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine Investigative T06046 DRUGINFO D0J1LO S-Isopropyl-Isothiourea Investigative T06046 DRUGINFO D0N5LD 7-Nitroindazole-2-Carboxamidine Investigative T06046 DRUGINFO D0P6IL 5,6-Cyclic-Tetrahydropteridine Investigative T06046 DRUGINFO D0V9FZ L-2-Amino-4-(Guanidinooxy)Butyric Acid Investigative T06046 DRUGINFO D0Y8DZ 4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D0Z3JI N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane Investigative T06046 DRUGINFO D00TDJ 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea Investigative T06046 DRUGINFO D01TDG S-Ethyl-N-Phenyl-Isothiourea Investigative T06046 DRUGINFO D02DQQ N,N-dimethylarginine Investigative T06046 DRUGINFO D06YEV Hydroxydimethylarsine Oxide Investigative T06046 DRUGINFO D0D2WC 5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D0GC1Y Nitroarginine Investigative T06046 DRUGINFO D0I7VD Ethylisothiourea Investigative T06046 DRUGINFO D0VB2W 5-Nitroindazole Investigative T06046 DRUGINFO D0X2XQ 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea Investigative T06046 DRUGINFO D0Y0FS 6-Nitroindazole Investigative T06046 DRUGINFO D00EVC 6-isobutyl-4-methylpyridin-2-amine Investigative T06046 DRUGINFO D01EHS 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T06046 DRUGINFO D01ILO 2-Aminothiazoline Investigative T06046 DRUGINFO D01XOR (5-Imino-[1,4]thiazepan-3-yl)-methanol Investigative T06046 DRUGINFO D02ELA L-NIO Investigative T06046 DRUGINFO D02EOF 4-Ethyl-pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D02TMX 4-methyl-6-propylpyridin-2-amine Investigative T06046 DRUGINFO D02TYS [1,4]Thiazepan-(3E)-ylideneamine Investigative T06046 DRUGINFO D03CAJ 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine Investigative T06046 DRUGINFO D03EHB 3-Bromo-1H-indazole-7-carbonitrile Investigative T06046 DRUGINFO D03FJM 2-Amino-5-(N-nitro-guanidino)-pentanoic acid Investigative T06046 DRUGINFO D03JXX 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D03WOZ 7-nitro-1H-indazole Investigative T06046 DRUGINFO D04JZV (6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin Investigative T06046 DRUGINFO D04PBI N5-(1-iminopropyl)-L-ornithine Investigative T06046 DRUGINFO D06VYU (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T06046 DRUGINFO D07VFC 6-(2-Fluoropropyl)-4-methylpyridin-2-amine Investigative T06046 DRUGINFO D08ALG Azepan-(2Z)-ylideneamine Investigative T06046 DRUGINFO D08FXW 6-(3-Fluoropropyl)-4-methylpyridin-2-amine Investigative T06046 DRUGINFO D08TGY S-(Dimethylarsenic)Cysteine Investigative T06046 DRUGINFO D08WEI 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T06046 DRUGINFO D09NRX 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T06046 DRUGINFO D0AO5D 1400W Investigative T06046 DRUGINFO D0C1OB Pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D0D0TO Piperidin-(2E)-ylideneamine Investigative T06046 DRUGINFO D0D7PK 4-Methyl-piperidin-(2E)-ylideneamine Investigative T06046 DRUGINFO D0D9LT 5-Methyl-pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D0DD9E N-omega-allyl-L-arginine Investigative T06046 DRUGINFO D0E0QG THIOCITRULLINE Investigative T06046 DRUGINFO D0G4ZL 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D0GL9I N-Omega-Hydroxy-L-Arginine Investigative T06046 DRUGINFO D0GX7G N5-(1-iminobutyl)-L-ornithine Investigative T06046 DRUGINFO D0I3ZP [1,4]Oxazepan-(3E)-ylideneamine Investigative T06046 DRUGINFO D0J7NS 4-Methyl-pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D0K4YY (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine Investigative T06046 DRUGINFO D0L4RU N-omega-propargyl-L-arginine Investigative T06046 DRUGINFO D0L5KY N5-(1-iminobut-3-enyl)-L-ornithine Investigative T06046 DRUGINFO D0LE6N Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine Investigative T06046 DRUGINFO D0M4BM [1,3]Oxazinan-(2E)-ylideneamine Investigative T06046 DRUGINFO D0N3HU [1,4]Thiazepan-(5E)-ylideneamine Investigative T06046 DRUGINFO D0N8EU (S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid Investigative T06046 DRUGINFO D0O3XZ 2-amino-4-methylpyridine Investigative T06046 DRUGINFO D0O9II [1,3]Thiazinan-(2E)-ylideneamine Investigative T06046 DRUGINFO D0R9KX (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine Investigative T06046 DRUGINFO D0SB5H 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T06046 DRUGINFO D0T3QN (S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid Investigative T06046 DRUGINFO D0V5HI N-(5-Amino-6-oxo-heptyl)-acetamidine Investigative T06046 DRUGINFO D0X5QJ 3-bromo-7-nitro-1H-indazole Investigative T06046 DRUGINFO D0X6MB 3-Methyl-pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D0X6QY 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D0XJ1C 5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T06046 DRUGINFO D09TVP Cacodylate Ion Investigative T06046 DRUGINFO D0W7LK 2-Propanol, Isopropanol Investigative T06046 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T06046 DRUGINFO D0UU1I Heme Investigative T06046 DRUGINFO D0F2ME Acetate Ion Investigative T16117 TARGETID T16117 T16117 FORMERID TTDC00063 T16117 UNIPROID NOS1_HUMAN T16117 TARGNAME Nitric-oxide synthase brain (NOS1) T16117 GENENAME NOS1 T16117 TARGTYPE Clinical trial T16117 SYNONYMS Peptidyl-cysteine S-nitrosylase NOS1; Nitric oxide synthase, brain; Neuronal NOS; NOS, type I; NOS type I; NNOS; NC-NOS; N-NOS; BNOS T16117 FUNCTION In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. Probably has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such SRR. Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. T16117 PDBSTRUC 6NHC; 6NHB; 6NGI; 6NGH; 6NGF T16117 BIOCLASS Paired donor oxygen oxidoreductase T16117 ECNUMBER EC 1.14.13.39 T16117 SEQUENCE MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQAGDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTIRVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAPRPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQVDRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANNSLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFVRLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGVISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEYEEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIVSYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS T16117 DRUGINFO D0W9IT NXN-462 Phase 2 T16117 DRUGINFO D0O2XJ NXN-188 Phase 2 T16117 DRUGINFO D0Y7VJ L-NIL Terminated T16117 DRUGINFO D01KAH 1-[(3-Methoxybenzyl)amino]ethaniminium chloride Investigative T16117 DRUGINFO D01RGM S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea Investigative T16117 DRUGINFO D02OAB 5-bromo-1H-indazole Investigative T16117 DRUGINFO D03UTI 4-iodo-1H-indazole Investigative T16117 DRUGINFO D04EIE N5-(1-iminopent-3-enyl)-L-ornithine Investigative T16117 DRUGINFO D04KUP 6-bromo-1H-indazole Investigative T16117 DRUGINFO D04QFO Hexahydro-cyclopenta[b]pyrrol-(2Z)-ylideneamine Investigative T16117 DRUGINFO D05BGM Eusynstyelamide C Investigative T16117 DRUGINFO D06BCG EUSYNSTYELAMIDE B Investigative T16117 DRUGINFO D07GEN 4-chloro-1H-indazole Investigative T16117 DRUGINFO D07LMI 1-Benzyl-2-methyl-1H-imidazole Investigative T16117 DRUGINFO D07OVY 5-iodo-1H-indazole Investigative T16117 DRUGINFO D07PYV 2-aminopyridine Investigative T16117 DRUGINFO D08JSR Tetrahydro-pyrimidin-2-ylideneamine Investigative T16117 DRUGINFO D08WHV 5-N-Allyl-Arginine Investigative T16117 DRUGINFO D09BPC N5-(1-Imino-3-Butenyl)-L-Ornithine Investigative T16117 DRUGINFO D0A6RU 7-chloro-1H-indazole Investigative T16117 DRUGINFO D0D4US 4-bromo-1H-indazole Investigative T16117 DRUGINFO D0IX0N N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine Investigative T16117 DRUGINFO D0LL3D 7-bromo-1H-indazole Investigative T16117 DRUGINFO D0P5OF 7-Methoxy-1H-indazole Investigative T16117 DRUGINFO D0Q7NZ 1-(Benzhydrylamino)ethaniminium bromide Investigative T16117 DRUGINFO D0Q7VU N-Butyl-N'-Hydroxyguanidine Investigative T16117 DRUGINFO D0Q8EX N-Isopropyl-N'-Hydroxyguanidine Investigative T16117 DRUGINFO D0T9ZQ 5-chloro-1H-indazole Investigative T16117 DRUGINFO D0VN7G Hexahydro-pyrrolizin-(3E)-ylideneamine Investigative T16117 DRUGINFO D0W0OJ 6-chloro-1H-indazole Investigative T16117 DRUGINFO D0W9UV 2-amino-4,6-dimethylpyridine Investigative T16117 DRUGINFO D0Z3ZZ (+/-)-2-Methyl-1-(1-phenylethyl)-1H-imidazole Investigative T16117 DRUGINFO D00KOE 4-Isopropyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D00TDJ 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea Investigative T16117 DRUGINFO D01DFX 4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine Investigative T16117 DRUGINFO D01MEA 3-Butyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D01TDG S-Ethyl-N-Phenyl-Isothiourea Investigative T16117 DRUGINFO D01YNT ((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine Investigative T16117 DRUGINFO D02FHX 4-Ethyl-oxazolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D02MFQ Azonan-(2Z)-ylideneamine Investigative T16117 DRUGINFO D03ODQ [1,4]Oxazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D03QMU 7-Butyl-azepan-(2Z)-ylideneamine Investigative T16117 DRUGINFO D03QSQ 5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D03YZT 5-Ethyl-oxazolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D05APC 4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D05LPK 5-Methyl-oxazolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D05VAB AR-C102222 Investigative T16117 DRUGINFO D05ZYA 5-Bromomethyl-oxazolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D06EXH (4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D07INO Octahydro-isoindol-(1Z)-ylideneamine Investigative T16117 DRUGINFO D07MFH 3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane Investigative T16117 DRUGINFO D07OQX 4-Butyl-thiazolidin-(2E)-ylideneamine Investigative T16117 DRUGINFO D08CMQ 3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D08DQZ 4-Methyl-oxazolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D08PZX (R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D08UWE (4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D09BKV 3-Propyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D0C3CS 4,5,6,7-tetrafluoro-3-methyl-1H-indazole Investigative T16117 DRUGINFO D0D2WC 5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0GC1Y Nitroarginine Investigative T16117 DRUGINFO D0IR4Y 2-(2-Amino-ethyl)-7-imino-azepane Investigative T16117 DRUGINFO D0J2RI 4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0K1CM Azocan-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0K4SV 3,4-Dihydro-1H-quinolin-(2E)-ylideneamine Investigative T16117 DRUGINFO D0LB9U 3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine Investigative T16117 DRUGINFO D0O2KO N-Omega-Propyl-L-Arginine Investigative T16117 DRUGINFO D0OW8M AR-C133057XX Investigative T16117 DRUGINFO D0UP8X (4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0X2XQ 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea Investigative T16117 DRUGINFO D00EVC 6-isobutyl-4-methylpyridin-2-amine Investigative T16117 DRUGINFO D01EHS 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D01ILO 2-Aminothiazoline Investigative T16117 DRUGINFO D01XOR (5-Imino-[1,4]thiazepan-3-yl)-methanol Investigative T16117 DRUGINFO D02ELA L-NIO Investigative T16117 DRUGINFO D02EOF 4-Ethyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D02TMX 4-methyl-6-propylpyridin-2-amine Investigative T16117 DRUGINFO D02TYS [1,4]Thiazepan-(3E)-ylideneamine Investigative T16117 DRUGINFO D03CAJ 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine Investigative T16117 DRUGINFO D03EHB 3-Bromo-1H-indazole-7-carbonitrile Investigative T16117 DRUGINFO D03FJM 2-Amino-5-(N-nitro-guanidino)-pentanoic acid Investigative T16117 DRUGINFO D03JXX 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D03WOZ 7-nitro-1H-indazole Investigative T16117 DRUGINFO D04JZV (6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin Investigative T16117 DRUGINFO D04PBI N5-(1-iminopropyl)-L-ornithine Investigative T16117 DRUGINFO D06VYU (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D07VFC 6-(2-Fluoropropyl)-4-methylpyridin-2-amine Investigative T16117 DRUGINFO D08ALG Azepan-(2Z)-ylideneamine Investigative T16117 DRUGINFO D08FXW 6-(3-Fluoropropyl)-4-methylpyridin-2-amine Investigative T16117 DRUGINFO D08WEI 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D09NRX 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D0AO5D 1400W Investigative T16117 DRUGINFO D0C1OB Pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0D0TO Piperidin-(2E)-ylideneamine Investigative T16117 DRUGINFO D0D7PK 4-Methyl-piperidin-(2E)-ylideneamine Investigative T16117 DRUGINFO D0D9LT 5-Methyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0DD9E N-omega-allyl-L-arginine Investigative T16117 DRUGINFO D0E0QG THIOCITRULLINE Investigative T16117 DRUGINFO D0G4ZL 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0GL9I N-Omega-Hydroxy-L-Arginine Investigative T16117 DRUGINFO D0GX7G N5-(1-iminobutyl)-L-ornithine Investigative T16117 DRUGINFO D0I3ZP [1,4]Oxazepan-(3E)-ylideneamine Investigative T16117 DRUGINFO D0J7NS 4-Methyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0K4YY (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine Investigative T16117 DRUGINFO D0L4RU N-omega-propargyl-L-arginine Investigative T16117 DRUGINFO D0L5KY N5-(1-iminobut-3-enyl)-L-ornithine Investigative T16117 DRUGINFO D0LE6N Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine Investigative T16117 DRUGINFO D0M4BM [1,3]Oxazinan-(2E)-ylideneamine Investigative T16117 DRUGINFO D0N3HU [1,4]Thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D0N8EU (S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid Investigative T16117 DRUGINFO D0O3XZ 2-amino-4-methylpyridine Investigative T16117 DRUGINFO D0O9II [1,3]Thiazinan-(2E)-ylideneamine Investigative T16117 DRUGINFO D0R9KX (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine Investigative T16117 DRUGINFO D0SB5H 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T16117 DRUGINFO D0T3QN (S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid Investigative T16117 DRUGINFO D0V5HI N-(5-Amino-6-oxo-heptyl)-acetamidine Investigative T16117 DRUGINFO D0X5QJ 3-bromo-7-nitro-1H-indazole Investigative T16117 DRUGINFO D0X6MB 3-Methyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0X6QY 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D0XJ1C 5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T16117 DRUGINFO D06EWG Formic Acid Investigative T16117 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T16117 DRUGINFO D0UU1I Heme Investigative T16117 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T16117 DRUGINFO D0F2ME Acetate Ion Investigative T16117 DRUGINFO D07LUR Alpha-D-Mannose Investigative T69991 TARGETID T69991 T69991 FORMERID TTDC00256 T69991 UNIPROID WEE1_HUMAN T69991 TARGNAME Wee1-like protein kinase (WEE1) T69991 GENENAME WEE1 T69991 TARGTYPE Clinical trial T69991 SYNONYMS Wee1A kinase; WEE1hu T69991 FUNCTION Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation. Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. T69991 PDBSTRUC 5VDA; 5VD9; 5VD8; 5VD7; 5VD5 T69991 BIOCLASS Kinase T69991 ECNUMBER EC 2.7.10.2 T69991 SEQUENCE MSFLSRQQPPPPRRAGAACTLRQKLIFSPCSDCEEEEEEEEEEGSGHSTGEDSAFQEPDSPLPPARSPTEPGPERRRSPGPAPGSPGELEEDLLLPGACPGADEAGGGAEGDSWEEEGFGSSSPVKSPAAPYFLGSSFSPVRCGGPGDASPRGCGARRAGEGRRSPRPDHPGTPPHKTFRKLRLFDTPHTPKSLLSKARGIDSSSVKLRGSSLFMDTEKSGKREFDVRQTPQVNINPFTPDSLLLHSSGQCRRRKRTYWNDSCGEDMEASDYELEDETRPAKRITITESNMKSRYTTEFHELEKIGSGEFGSVFKCVKRLDGCIYAIKRSKKPLAGSVDEQNALREVYAHAVLGQHSHVVRYFSAWAEDDHMLIQNEYCNGGSLADAISENYRIMSYFKEAELKDLLLQVGRGLRYIHSMSLVHMDIKPSNIFISRTSIPNAASEEGDEDDWASNKVMFKIGDLGHVTRISSPQVEEGDSRFLANEVLQENYTHLPKADIFALALTVVCAAGAEPLPRNGDQWHEIRQGRLPRIPQVLSQEFTELLKVMIHPDPERRPSAMALVKHSVLLSASRKSAEQLRIELNAEKFKNSLLQKELKKAQMAKAAAEERALFTDRMATRSTTQSNRTSRLIGKKMNRSVSLTIY T69991 DRUGINFO D02KKA MK-1775 Phase 2 T69991 DRUGINFO DRQN21 ZN-c3 Phase 2 T69991 DRUGINFO D0Y3PH 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Investigative T28330 TARGETID T28330 T28330 FORMERID TTDC00082 T28330 UNIPROID CCKAR_HUMAN T28330 TARGNAME Cholecystokinin receptor type A (CCKAR) T28330 GENENAME CCKAR T28330 TARGTYPE Clinical trial T28330 SYNONYMS CCKAR; CCK-AR; CCK-A receptor T28330 FUNCTION Receptor forcholecystokinin. Mediates pancreatic growth and enzyme secretion, smooth muscle contraction of the gall bladder and stomach. Has a 1000-fold higher affinity for CCK rather than for gastrin. It modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. T28330 PDBSTRUC 1PB2; 1HZN; 1D6G T28330 BIOCLASS GPCR rhodopsin T28330 SEQUENCE MDVVDSLLVNGSNITPPCELGLENETLFCLDQPRPSKEWQPAVQILLYSLIFLLSVLGNTLVITVLIRNKRMRTVTNIFLLSLAVSDLMLCLFCMPFNLIPNLLKDFIFGSAVCKTTTYFMGTSVSVSTFNLVAISLERYGAICKPLQSRVWQTKSHALKVIAATWCLSFTIMTPYPIYSNLVPFTKNNNQTANMCRFLLPNDVMQQSWHTFLLLILFLIPGIVMMVAYGLISLELYQGIKFEASQKKSAKERKPSTTSSGKYEDSDGCYLQKTRPPRKLELRQLSTGSSSRANRIRSNSSAANLMAKKRVIRMLIVIVVLFFLCWMPIFSANAWRAYDTASAERRLSGTPISFILLLSYTSSCVNPIIYCFMNKRFRLGFMATFPCCPNPGPPGARGEVGEEEEGGTTGASLSRFSYSHMSASVPPQ T28330 DRUGINFO D04HQT proglumide Phase 2 T28330 DRUGINFO D0TL7L Dexloxiglumide Phase 2 T28330 DRUGINFO D01ZXW Lintitript Discontinued in Phase 2 T28330 DRUGINFO D03XDX Tarazepide Discontinued in Phase 2 T28330 DRUGINFO D0F6CT GI 181771 Discontinued in Phase 2 T28330 DRUGINFO D0RL4M Pranazepide Discontinued in Phase 2 T28330 DRUGINFO D0W9ZY CE-326597 Discontinued in Phase 2 T28330 DRUGINFO D03JIH SSR-125180 Discontinued in Phase 1 T28330 DRUGINFO D05HSI T-0632 Discontinued in Phase 1 T28330 DRUGINFO D0T3EV SR-146131 Discontinued in Phase 1 T28330 DRUGINFO D0T7CM UCL-2000; butabindide Discontinued in Phase 1 T28330 DRUGINFO D02PSZ A-74498 Preclinical T28330 DRUGINFO D08GNX FPL-14294 Preclinical T28330 DRUGINFO D09IJP A-71378 Preclinical T28330 DRUGINFO D0A1VL AR-R-1589 Preclinical T28330 DRUGINFO D06DPS PD-170292 Preclinical T28330 DRUGINFO D0W4OZ GG-8573 Preclinical T28330 DRUGINFO D05LCX A-70276 Terminated T28330 DRUGINFO D06UXL GI-248573 Terminated T28330 DRUGINFO D0C8ZD A-71623 Terminated T28330 DRUGINFO D0K5UH CR-1795 Terminated T28330 DRUGINFO D0R3OR SR-27950 Terminated T28330 DRUGINFO D0Y7WL Lorglumide Terminated T28330 DRUGINFO D01ZDR FR-208419 Terminated T28330 DRUGINFO D05HGU IQM-95333 Terminated T28330 DRUGINFO D0I3BT PD-135666 Terminated T28330 DRUGINFO D0W8TS SNF-9007 Terminated T28330 DRUGINFO D00ODL IQM-97423 Investigative T28330 DRUGINFO D00OFV Asperlicin Investigative T28330 DRUGINFO D00UKA Boc-D-Glu-Tyr(SO3H)-Nle-D-Nle-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D01FHK Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D03EHS Boc-D-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D03GPH 1-(4-Chloro-phenyl)-3-(3-pentyl-oct-2-enyl)-urea Investigative T28330 DRUGINFO D03MOQ 1-(4-Chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea Investigative T28330 DRUGINFO D03ZWL L-740093 Investigative T28330 DRUGINFO D05QBF Devazepide Investigative T28330 DRUGINFO D05RRZ Glaxo-11p Investigative T28330 DRUGINFO D05YZC [3H]devazepide Investigative T28330 DRUGINFO D06CIH VL-1499 Investigative T28330 DRUGINFO D06FIK JNJ-17156516 Investigative T28330 DRUGINFO D06KWA VL-0699 Investigative T28330 DRUGINFO D09PNV KSG-504 Investigative T28330 DRUGINFO D0D2UA 2-NAP Investigative T28330 DRUGINFO D0EZ2W CR-2345 Investigative T28330 DRUGINFO D0F0MN Boc-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D0F1VP VL-2799 Investigative T28330 DRUGINFO D0GC9B JMV180 Investigative T28330 DRUGINFO D0H9AX L-736380 Investigative T28330 DRUGINFO D0N4QT L-708474 Investigative T28330 DRUGINFO D0O5OM VL-0395 Investigative T28330 DRUGINFO D0O8HW FR-175985 Investigative T28330 DRUGINFO D0P9OL Boc-cyclo-(Glu-Tyr-Nle-D-Lys)-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D0S4CE VL-0494 Investigative T28330 DRUGINFO D0SY6T 1-(3,3-Diphenyl-allyl)-3-m-tolyl-urea Investigative T28330 DRUGINFO D0VA0J 3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide Investigative T28330 DRUGINFO D0Z6UK SC-50998 Investigative T28330 DRUGINFO D00FLQ PD-140547 Investigative T28330 DRUGINFO D02MIN PD-138915 Investigative T28330 DRUGINFO D02ZML GW-5823 Investigative T28330 DRUGINFO D04VOM PD-136621 Investigative T28330 DRUGINFO D05OUQ CCK-33 Investigative T28330 DRUGINFO D05XXE Tetragastrin Investigative T28330 DRUGINFO D08EYZ PD-140548 Investigative T28330 DRUGINFO D0C2KS CI-1015 Investigative T28330 DRUGINFO D0CE9U Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe Investigative T28330 DRUGINFO D0D2ZM PD-135158 Investigative T28330 DRUGINFO D0E4JX PD-137337 Investigative T28330 DRUGINFO D0ES2U TP-680 Investigative T28330 DRUGINFO D0G1CK PD-140723 Investigative T28330 DRUGINFO D0G7RE PD-137342 Investigative T28330 DRUGINFO D0I8AF CCK-8 Investigative T28330 DRUGINFO D0L9OU PD-138916 Investigative T28330 DRUGINFO D0M6ZF Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2 Investigative T28330 DRUGINFO D0O0IZ PD-135118 Investigative T28330 DRUGINFO D0I9PH H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H Investigative T28330 DRUGINFO D0O7PT Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] Investigative T28330 DRUGINFO D01AQC Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D03EPA Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D06BRA Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D07ICW Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D07LQQ Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D09EMR Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D0E2OG Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D0J7GJ H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H Investigative T28330 DRUGINFO D0N6DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc Investigative T28330 DRUGINFO D0QP2S Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc Investigative T28330 DRUGINFO D0R4GI Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D0TR0U Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D0U6OA Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 Investigative T28330 DRUGINFO D0V9DY H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H Investigative T02703 TARGETID T02703 T02703 FORMERID TTDS00337 T02703 UNIPROID NOS2_HUMAN T02703 TARGNAME Nitric-oxide synthase inducible (NOS2) T02703 GENENAME NOS2 T02703 TARGTYPE Clinical trial T02703 SYNONYMS iNOS; Peptidyl-cysteine S-nitrosylase NOS2; Nitric oxide synthase, inducible; NOS2A; NOS type II; Inducible NOS; Inducible NO synthase; Hepatocyte NOS; HEP-NOS T02703 FUNCTION Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM. Involved in inflammation, enhances the synthesis of proinflammatory mediators such as IL6 and IL8. T02703 PDBSTRUC 5XN3; 5TP6; 4NOS; 4CX7; 3HR4 T02703 BIOCLASS Paired donor oxygen oxidoreductase T02703 ECNUMBER EC 1.14.13.39 T02703 SEQUENCE MACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSPVTQDDLQYHNLSKQQNESPQPLVETGKKSPESLVKLDATPLSSPRHVRIKNWGSGMTFQDTLHHKAKGILTCRSKSCLGSIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETTGTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTNNGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWKPKYGRFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVGGLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINIAVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGGCPADWIWLVPPMSGSITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRKTMASRVRVTILFATETGKSEALAWDLGALFSCAFNPKVVCMDKYRLSCLEEERLLLVVTSTFGNGDCPGNGEKLKKSLFMLKELNNKFRYAVFGLGSSMYPRFCAFAHDIDQKLSHLGASQLTPMGEGDELSGQEDAFRSWAVQTFKAACETFDVRGKQHIQIPKLYTSNVTWDPHHYRLVQDSQPLDLSKALSSMHAKNVFTMRLKSRQNLQSPTSSRATILVELSCEDGQGLNYLPGEHLGVCPGNQPALVQGILERVVDGPTPHQTVRLEALDESGSYWVSDKRLPPCSLSQALTYFLDITTPPTQLLLQKLAQVATEEPERQRLEALCQPSEYSKWKFTNSPTFLEVLEEFPSLRVSAGFLLSQLPILKPRFYSISSSRDHTPTEIHLTVAVVTYHTRDGQGPLHHGVCSTWLNSLKPQDPVPCFVRNASGFHLPEDPSHPCILIGPGTGIAPFRSFWQQRLHDSQHKGVRGGRMTLVFGCRRPDEDHIYQEEMLEMAQKGVLHAVHTAYSRLPGKPKVYVQDILRQQLASEVLRVLHKEPGHLYVCGDVRMARDVAHTLKQLVAAKLKLNEEQVEDYFFQLKSQKRYHEDIFGAVFPYEAKKDRVAVQPSSLEMSAL T02703 DRUGINFO D02MBN SD-6010 Phase 3 T02703 DRUGINFO D0T4GZ MPL-S Phase 3 T02703 DRUGINFO D07SDQ Curcumin Phase 3 T02703 DRUGINFO D0J3BY Pimagedine HCl Phase 2/3 T02703 DRUGINFO D05QJT GW274150 Phase 2 T02703 DRUGINFO D07NCV BXT-51072 Phase 2 T02703 DRUGINFO D09ZKS HP-228 Phase 2 T02703 DRUGINFO D0I8ZM CR-3294 Phase 2 T02703 DRUGINFO D0MJ2H KD-7040 Phase 2 T02703 DRUGINFO D06HBT LT-1951 Phase 1/2 T02703 DRUGINFO D0V0NL Aminoguanidine Phase 1 T02703 DRUGINFO D0KM3P NOStentin Discontinued in Phase 1 T02703 DRUGINFO D0R5XK ONO-1714 Discontinued in Phase 1 T02703 DRUGINFO D0Y7VJ L-NIL Terminated T02703 DRUGINFO D00GYE 6-(4-Fluorobutyl)-4-methylpyridin-2-amine Investigative T02703 DRUGINFO D00PEC PIBTU Investigative T02703 DRUGINFO D01EBY L-Thiocitrulline Investigative T02703 DRUGINFO D01TDC 6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine Investigative T02703 DRUGINFO D02ZGN 1-(6-Amino-4-methylpyridin-2-yl)propan-2-ol Investigative T02703 DRUGINFO D03HCR (4S,5S)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D03MJJ Thiocoumarin Investigative T02703 DRUGINFO D03YRO (4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D05PZA N-benzylacetimidamide hydrobromide Investigative T02703 DRUGINFO D05SCE CDDO Investigative T02703 DRUGINFO D06JZQ 4-Methyl-6-(2-methylprop-1-enyl)pyridin-2-amine Investigative T02703 DRUGINFO D07BLJ [1,5]Thiazocan-(4E)-ylideneamine Investigative T02703 DRUGINFO D07FVL Oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D08ISP 5-Methyl-4-propyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D09OWC SKLB-010 Investigative T02703 DRUGINFO D0D3CJ BYK-191023 Investigative T02703 DRUGINFO D0H4DU KD-7332 Investigative T02703 DRUGINFO D0JZ3S 4r-Fluoro-N6-Ethanimidoyl-L-Lysine Investigative T02703 DRUGINFO D0L9SL 3-Butyl-[1,4]oxazepan-(5Z)-ylideneamine Investigative T02703 DRUGINFO D0S7MJ (S)-N-(1-phenylethyl)acetimidamide hydrobromide Investigative T02703 DRUGINFO D0U8OA (E)-4-Methyl-6-(prop-1-enyl)pyridin-2-amine Investigative T02703 DRUGINFO D0U8TM 4,5,6,7-tetrafluoro-3-perfluorophenyl-1H-indazole Investigative T02703 DRUGINFO D0W5UJ (S)-2-Amino-6-[(E)-ethylimino]-hexanoic acid Investigative T02703 DRUGINFO D0W6VA 4-(1H-IMIDAZOL-1-YL)PHENOL Investigative T02703 DRUGINFO D0Y2AO Aminothiazoline Investigative T02703 DRUGINFO D00KOE 4-Isopropyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D01DFX 4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine Investigative T02703 DRUGINFO D01MEA 3-Butyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D01YNT ((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine Investigative T02703 DRUGINFO D02DQQ N,N-dimethylarginine Investigative T02703 DRUGINFO D02FHX 4-Ethyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D02MFQ Azonan-(2Z)-ylideneamine Investigative T02703 DRUGINFO D03ODQ [1,4]Oxazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D03QMU 7-Butyl-azepan-(2Z)-ylideneamine Investigative T02703 DRUGINFO D03QSQ 5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D03YZT 5-Ethyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D05APC 4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D05LPK 5-Methyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D05VAB AR-C102222 Investigative T02703 DRUGINFO D05ZYA 5-Bromomethyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D06EXH (4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D07INO Octahydro-isoindol-(1Z)-ylideneamine Investigative T02703 DRUGINFO D07MFH 3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane Investigative T02703 DRUGINFO D07OQX 4-Butyl-thiazolidin-(2E)-ylideneamine Investigative T02703 DRUGINFO D08CMQ 3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D08DQZ 4-Methyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D08PZX (R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D08UWE (4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D09BKV 3-Propyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D0C3CS 4,5,6,7-tetrafluoro-3-methyl-1H-indazole Investigative T02703 DRUGINFO D0I7VD Ethylisothiourea Investigative T02703 DRUGINFO D0IR4Y 2-(2-Amino-ethyl)-7-imino-azepane Investigative T02703 DRUGINFO D0J2RI 4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0K1CM Azocan-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0K4SV 3,4-Dihydro-1H-quinolin-(2E)-ylideneamine Investigative T02703 DRUGINFO D0LB9U 3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine Investigative T02703 DRUGINFO D0O2KO N-Omega-Propyl-L-Arginine Investigative T02703 DRUGINFO D0OW8M AR-C133057XX Investigative T02703 DRUGINFO D0UP8X (4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0VB2W 5-Nitroindazole Investigative T02703 DRUGINFO D0Y0FS 6-Nitroindazole Investigative T02703 DRUGINFO D00EVC 6-isobutyl-4-methylpyridin-2-amine Investigative T02703 DRUGINFO D01EHS 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D01ILO 2-Aminothiazoline Investigative T02703 DRUGINFO D01XOR (5-Imino-[1,4]thiazepan-3-yl)-methanol Investigative T02703 DRUGINFO D02ELA L-NIO Investigative T02703 DRUGINFO D02EOF 4-Ethyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D02TMX 4-methyl-6-propylpyridin-2-amine Investigative T02703 DRUGINFO D02TYS [1,4]Thiazepan-(3E)-ylideneamine Investigative T02703 DRUGINFO D03CAJ 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine Investigative T02703 DRUGINFO D03EHB 3-Bromo-1H-indazole-7-carbonitrile Investigative T02703 DRUGINFO D03FJM 2-Amino-5-(N-nitro-guanidino)-pentanoic acid Investigative T02703 DRUGINFO D03JXX 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D03WOZ 7-nitro-1H-indazole Investigative T02703 DRUGINFO D04JZV (6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin Investigative T02703 DRUGINFO D04JZY Resveratrol Potassium4,-Sulfate Investigative T02703 DRUGINFO D04PBI N5-(1-iminopropyl)-L-ornithine Investigative T02703 DRUGINFO D06VYU (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D07VFC 6-(2-Fluoropropyl)-4-methylpyridin-2-amine Investigative T02703 DRUGINFO D08ALG Azepan-(2Z)-ylideneamine Investigative T02703 DRUGINFO D08FXW 6-(3-Fluoropropyl)-4-methylpyridin-2-amine Investigative T02703 DRUGINFO D08WEI 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D09NRX 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D0AO5D 1400W Investigative T02703 DRUGINFO D0C1OB Pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0D0TO Piperidin-(2E)-ylideneamine Investigative T02703 DRUGINFO D0D7PK 4-Methyl-piperidin-(2E)-ylideneamine Investigative T02703 DRUGINFO D0D9LT 5-Methyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0DD9E N-omega-allyl-L-arginine Investigative T02703 DRUGINFO D0E0QG THIOCITRULLINE Investigative T02703 DRUGINFO D0F3XT 7,8-dihydrobiopterin Investigative T02703 DRUGINFO D0G4ZL 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0GL9I N-Omega-Hydroxy-L-Arginine Investigative T02703 DRUGINFO D0GX7G N5-(1-iminobutyl)-L-ornithine Investigative T02703 DRUGINFO D0I3ZP [1,4]Oxazepan-(3E)-ylideneamine Investigative T02703 DRUGINFO D0J7NS 4-Methyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0K4YY (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine Investigative T02703 DRUGINFO D0L4RU N-omega-propargyl-L-arginine Investigative T02703 DRUGINFO D0L5KY N5-(1-iminobut-3-enyl)-L-ornithine Investigative T02703 DRUGINFO D0LE6N Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine Investigative T02703 DRUGINFO D0M4BM [1,3]Oxazinan-(2E)-ylideneamine Investigative T02703 DRUGINFO D0N3HU [1,4]Thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D0N8EU (S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid Investigative T02703 DRUGINFO D0O3XZ 2-amino-4-methylpyridine Investigative T02703 DRUGINFO D0O9II [1,3]Thiazinan-(2E)-ylideneamine Investigative T02703 DRUGINFO D0R9KX (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine Investigative T02703 DRUGINFO D0SB5H 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine Investigative T02703 DRUGINFO D0T3QN (S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid Investigative T02703 DRUGINFO D0V5HI N-(5-Amino-6-oxo-heptyl)-acetamidine Investigative T02703 DRUGINFO D0X5QJ 3-bromo-7-nitro-1H-indazole Investigative T02703 DRUGINFO D0X6MB 3-Methyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0X6QY 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0XJ1C 5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine Investigative T02703 DRUGINFO D0UU1I Heme Investigative T02703 DRUGINFO D02UVH B-Octylglucoside Investigative T87166 TARGETID T87166 T87166 FORMERID TTDC00141 T87166 UNIPROID HXK4_HUMAN T87166 TARGNAME Glucokinase (GCK) T87166 GENENAME GCK T87166 TARGTYPE Clinical trial T87166 SYNONYMS Hexokinase type IV; Hexokinase D; HK4; HK IV T87166 FUNCTION Catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. Glucokinase has a high Km for glucose, and so it is effective only when glucose is abundant. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting asan insulin-sensitive determinant of hepatic glucose usage. T87166 PDBSTRUC 5V4X; 5V4W; 4RCH; 4NO7; 4MLH T87166 BIOCLASS Kinase T87166 ECNUMBER EC 2.7.1.2 T87166 SEQUENCE MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ T87166 DRUGINFO D01CGV LY-2599506 Phase 2 T87166 DRUGINFO D07JHK AMG 151 Phase 2 T87166 DRUGINFO D0C6MS PF-04991532 Phase 2 T87166 DRUGINFO D0D7VO GK1-399 Phase 2 T87166 DRUGINFO D0E1WH LY-2608204 Phase 2 T87166 DRUGINFO D0M5PH PF-04937319 Phase 2 T87166 DRUGINFO D0O8BS AZD1656 Phase 2 T87166 DRUGINFO DG68CL TTP399 Phase 2 T87166 DRUGINFO D00AYW HMS5552 Phase 1 T87166 DRUGINFO D02AVC BMS-820132 Phase 1 T87166 DRUGINFO D03MDW DS-7309 Phase 1 T87166 DRUGINFO D05LOV ADV-1002401 Phase 1 T87166 DRUGINFO D0G0ZE TTP-547 Phase 1 T87166 DRUGINFO D0L5FB TAK-329 Phase 1 T87166 DRUGINFO D0M0UU ZYGK-1 Phase 1 T87166 DRUGINFO D0O9OC AZD5658 Phase 1 T87166 DRUGINFO D08BVM TTP-355 Discontinued in Phase 2 T87166 DRUGINFO D08RGA AZD6370 Discontinued in Phase 2 T87166 DRUGINFO D0SN2Q AZD-6714 Discontinued in Phase 1 T87166 DRUGINFO D04JPQ PSN-101 Investigative T87166 DRUGINFO D04MLE GKA-23 Investigative T87166 DRUGINFO D04QGH Piragliatin Investigative T87166 DRUGINFO D0P0PP GKA1 Investigative T87166 DRUGINFO D0Q3OM SKL-19014 Investigative T87166 DRUGINFO D07ONX Beta-D-Glucose Investigative T55709 TARGETID T55709 T55709 FORMERID TTDR00805 T55709 UNIPROID CHKA_HUMAN T55709 TARGNAME Choline kinase (CHKA) T55709 GENENAME CHKA T55709 TARGTYPE Clinical trial T55709 SYNONYMS ChoK; CHKA; CHETK-alpha T55709 FUNCTION Has a key role in phospholipid biosynthesis and may contribute to tumor cell growth. Catalyzes the first step in phosphatidylcholine biosynthesis. Contributes to phosphatidylethanolamine biosynthesis. Phosphorylates choline and ethanolamine. Has higher activity with choline. T55709 PDBSTRUC 5W6O; 5FUT; 5FTG; 5EQY; 5EQP T55709 BIOCLASS Kinase T55709 ECNUMBER EC 2.7.1.32 T55709 SEQUENCE MKTKFCTGGEAEPSPLGLLLSCGSGSAAPAPGVGQQRDAASDLESKQLGGQQPPLALPPPPPLPLPLPLPQPPPPQPPADEQPEPRTRRRAYLWCKEFLPGAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYGAILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGIFPQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWLFGTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSPVVFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCEWMYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKSIIKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYFHQKRKLGV T55709 DRUGINFO D0G2XR TCD-717 Phase 1 T89055 TARGETID T89055 T89055 FORMERID TTDNC00613 T89055 UNIPROID MP2K2_HUMAN T89055 TARGNAME ERK activator kinase 2 (MEK2) T89055 GENENAME MAP2K2 T89055 TARGTYPE Clinical trial T89055 SYNONYMS PRKMK2; MKK2; MEK 2; MAPKK 2; MAPK/ERK kinase 2; MAP kinase kinase 2; Dual specificity mitogenactivated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 2 T89055 FUNCTION Activates the ERK1 and ERK2 MAP kinases. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. T89055 PDBSTRUC 4H3Q; 1S9I T89055 BIOCLASS Kinase T89055 ECNUMBER EC 2.7.12.2 T89055 SEQUENCE MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV T89055 DRUGINFO D0T5DP Selumetinib Phase 3 T89055 DRUGINFO D0XW4G Pyridic ketone derivative 1 Patented T89055 DRUGINFO D02UQG RDEA-436 Discontinued in Phase 1 T89055 DRUGINFO D9ILC1 PD98059 Investigative T53389 TARGETID T53389 T53389 FORMERID TTDR00998 T53389 UNIPROID TGFR1_HUMAN T53389 TARGNAME TGF-beta receptor type I (TGFBR1) T53389 GENENAME TGFBR1 T53389 TARGTYPE Clinical trial T53389 SYNONYMS Type I TGFbeta receptor kinase; Transforming growth factor-beta receptor type I; TbetaRI; TbetaR-I; TGFR-1; TGF-beta type I receptor; TGF-beta receptor type-1; Serine/threonine-protein kinase receptor R4; SKR4; Activin receptor-like kinase 5; Activin A receptor type II-like protein kinase of 53kD; ALK5; ALK-5 T53389 FUNCTION Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation. Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. T53389 PDBSTRUC 6B8Y; 5USQ; 5QIM; 5QIL; 5QIK T53389 BIOCLASS Kinase T53389 ECNUMBER EC 2.7.11.30 T53389 SEQUENCE MEAAVAAPRPRLLLLVLAAAAAAAAALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVELAAVIAGPVCFVCISLMLMVYICHNRTVIHHRVPNEEDPSLDRPFISEGTTLKDLIYDMTTSGSGSGLPLLVQRTIARTIVLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM T53389 DRUGINFO D06TFI LY2157299 Phase 2/3 T53389 DRUGINFO D0MR0B TEW-7197 Phase 2 T53389 DRUGINFO D06FAA Metelimumab Phase 1/2 T53389 DRUGINFO D02USG P-2745 Phase 1 T53389 DRUGINFO D06BGZ LY3200882 Phase 1 T53389 DRUGINFO DQ5Y6Z PF-06952229 Phase 1 T53389 DRUGINFO DNI28K TP-0184 Phase 1 T53389 DRUGINFO D0C7WP SB-431542 Preclinical T53389 DRUGINFO D0I4LB SM-16 Terminated T53389 DRUGINFO D0ID0R LF-984 Terminated T53389 DRUGINFO D00ZFC WilVent Investigative T53389 DRUGINFO D03ANS SB-525334 Investigative T53389 DRUGINFO D05BMP 5''-Quinolin-4-yl-[2,4'']bithiazolyl-2''-ylamine Investigative T53389 DRUGINFO D07ZMW 4-Pyridin-2-yl-5-quinolin-2-yl-thiazol-2-ylamine Investigative T53389 DRUGINFO D0H5CE 4-Pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine Investigative T53389 DRUGINFO D0I4VX DRP-049 Investigative T53389 DRUGINFO D0J6JC PTL-101 Investigative T53389 DRUGINFO D0Q5UH SB-505124 Investigative T53389 DRUGINFO D0QJ4Y TGF-beta Shield Investigative T53389 DRUGINFO D0S5TT ACE-435 Investigative T53389 DRUGINFO D0V3OJ 2-phenyl-N-(pyridin-4-yl)quinazolin-4-amine Investigative T53389 DRUGINFO D0V8AC SD-208 Investigative T53389 DRUGINFO D0XB4P HTS-466284 Investigative T53389 DRUGINFO D0XL7C 4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine Investigative T53389 DRUGINFO D06KKN LY2109761 Investigative T53389 DRUGINFO D0K6YK IN-1130 Investigative T53389 DRUGINFO D06BDC PMID16539403C15b Investigative T53389 DRUGINFO D0C3AD GW-788388 Investigative T53389 DRUGINFO D0H6ZP IN-1166 Investigative T53389 DRUGINFO D06CMG LDN-214117 Investigative T53389 DRUGINFO D05NEC PMID23639540C13r Investigative T53389 DRUGINFO D0F2MP PMID23639540C13d Investigative T03500 TARGETID T03500 T03500 FORMERID TTDC00157 T03500 UNIPROID MMP12_HUMAN T03500 TARGNAME Matrix metalloproteinase-12 (MMP-12) T03500 GENENAME MMP12 T03500 TARGTYPE Clinical trial T03500 SYNONYMS Macrophage metalloelastase; Macrophage elastase; MME; ME; HME T03500 FUNCTION Has significant elastolytic activity. Can accept large and small amino acids at the P1' site, but has a preference for leucine. Aromatic or hydrophobic residues are preferred at the P1 site, with small hydrophobic residues (preferably alanine) occupying P3. May be involved in tissue injury and remodeling. T03500 PDBSTRUC 6EOX; 6ENM; 6ELA; 6EKN; 5N5K T03500 BIOCLASS Peptidase T03500 ECNUMBER EC 3.4.24.65 T03500 SEQUENCE MKFLLILLLQATASGALPLNSSTSLEKNNVLFGERYLEKFYGLEINKLPVTKMKYSGNLMKEKIQEMQHFLGLKVTGQLDTSTLEMMHAPRCGVPDVHHFREMPGGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDFHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYGDPKENQRLPNPDNSEPALCDPNLSFDAVTTVGNKIFFFKDRFFWLKVSERPKTSVNLISSLWPTLPSGIEAAYEIEARNQVFLFKDDKYWLISNLRPEPNYPKSIHSFGFPNFVKKIDAAVFNPRFYRTYFFVDNQYWRYDERRQMMDPGYPKLITKNFQGIGPKIDAVFYSKNKYYYFFQGSNQFEYDFLLQRITKTLKSNSWFGC T03500 DRUGINFO D0F470 FP-025 Phase 1 T03500 DRUGINFO D0T4BL Neovastat Phase 1 T03500 DRUGINFO D00ZZJ PMID29130358-Compound-Figure17(12) Patented T03500 DRUGINFO D09ATD PMID29130358-Compound-Figure17(10) Patented T03500 DRUGINFO D0L6HL PMID29130358-Compound-Figure17(11) Patented T03500 DRUGINFO D0E5YG AZD1236 Discontinued in Phase 2 T03500 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T03500 DRUGINFO D06CZS V85546 Discontinued in Phase 1 T03500 DRUGINFO D00NPE MMP-408 Investigative T03500 DRUGINFO D02ECA PF-00356231 Investigative T03500 DRUGINFO D03QXD RXP-470 Investigative T03500 DRUGINFO D04UBY 5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid Investigative T03500 DRUGINFO D05OZZ N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide Investigative T03500 DRUGINFO D06MGJ N-(biphenyl-4-ylsulfonyl)-D-leucine Investigative T03500 DRUGINFO D07KZL PMID24900526C5 Investigative T03500 DRUGINFO D07NDK WAY-644 Investigative T03500 DRUGINFO D09MLQ PMID22153340C20 Investigative T03500 DRUGINFO D0A0FY N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide Investigative T03500 DRUGINFO D0B3UN RXP470.1 Investigative T03500 DRUGINFO D0C1EQ 2-(2-(biphenyl-4-yl)ethylthio)acetic acid Investigative T03500 DRUGINFO D0F4UT 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid Investigative T03500 DRUGINFO D0K4ZP N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine Investigative T03500 DRUGINFO D0L6ND AGELADINE A Investigative T03500 DRUGINFO D0LB0N 5-(biphenyl-4-yl)-3-oxopentanoic acid Investigative T03500 DRUGINFO D0M2RC N-[(4-methoxyphenyl)sulfonyl]-D-alanine Investigative T03500 DRUGINFO D0TL3N 5-(biphenyl-4-yl)-3-methoxypentanoic acid Investigative T03500 DRUGINFO D0W9TD N-oxo-2-(phenylsulfonylamino)ethanamide Investigative T03500 DRUGINFO D0Y0BZ PUP-1 Investigative T03500 DRUGINFO D0Y4GL CP-271485 Investigative T03500 DRUGINFO D0YN1A PMID24900526C1 Investigative T03500 DRUGINFO D05JPV 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid Investigative T03500 DRUGINFO D0K0YX 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid Investigative T03500 DRUGINFO D0LM2K 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid Investigative T03500 DRUGINFO D0A5MV 3-(4-Phenylethynylbenzoyl)nonanoic acid Investigative T03500 DRUGINFO D08ELY 3-Benzenesulfonyl-heptanoic acid hydroxyamide Investigative T03500 DRUGINFO D0G3YZ (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid Investigative T03500 DRUGINFO D0L4EO 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid Investigative T03500 DRUGINFO D0N6CD 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide Investigative T03500 DRUGINFO D05THD 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide Investigative T03500 DRUGINFO D07MJD [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid Investigative T03500 DRUGINFO D0S9OL N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide Investigative T03500 DRUGINFO D0F2ME Acetate Ion Investigative T11388 TARGETID T11388 T11388 FORMERID TTDC00068 T11388 UNIPROID CATK_HUMAN T11388 TARGNAME Cathepsin K (CTSK) T11388 GENENAME CTSK T11388 TARGTYPE Clinical trial T11388 SYNONYMS Cathepsin X; Cathepsin O2; Cathepsin O; CTSO2; CTSO T11388 FUNCTION Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. T11388 PDBSTRUC 7PCK; 6QBS; 6ASH; 5Z5O; 5TUN T11388 BIOCLASS Peptidase T11388 ECNUMBER EC 3.4.22.38 T11388 SEQUENCE MWGLKVLLLPVVSFALYPEEILDTHWELWKKTHRKQYNNKVDEISRRLIWEKNLKYISIHNLEASLGVHTYELAMNHLGDMTSEEVVQKMTGLKVPLSHSRSNDTLYIPEWEGRAPDSVDYRKKGYVTPVKNQGQCGSCWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM T11388 DRUGINFO D0J6AU Odanacatib Phase 3 T11388 DRUGINFO D07BIK VEL-0230 Phase 1 T11388 DRUGINFO D08KIB SAR-114137 Phase 1 T11388 DRUGINFO D00KGL PMID27998201-Compound-8 Patented T11388 DRUGINFO D0BR6D PMID27998201-Compound-10 Patented T11388 DRUGINFO D0MR9V PMID27998201-Compound-15 Patented T11388 DRUGINFO D0QM0D Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 Patented T11388 DRUGINFO D04VGR PMID27998201-Compound-9 Patented T11388 DRUGINFO D06LLT PMID25399719-Compound-17 Patented T11388 DRUGINFO D05OIU PMID27998201-Compound-5 Patented T11388 DRUGINFO D06XCD PMID27998201-Compound-12 Patented T11388 DRUGINFO D00ZUU ONO-5334 Discontinued in Phase 2 T11388 DRUGINFO D01LNG Balicatib Discontinued in Phase 2 T11388 DRUGINFO D0T5PH Relacatib Discontinued in Phase 2 T11388 DRUGINFO D0J5FU MIV-701 Discontinued in Phase 1 T11388 DRUGINFO D0FJ3P GW-2592X Preclinical T11388 DRUGINFO D0Z0PR L-006235-1 Preclinical T11388 DRUGINFO D00FGA Pyrrolidine-1-carbonitrile Investigative T11388 DRUGINFO D00QIA (S)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate Investigative T11388 DRUGINFO D00TRY Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate Investigative T11388 DRUGINFO D02QOT 3-Amino-5-Phenylpentane Investigative T11388 DRUGINFO D02TNR N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide Investigative T11388 DRUGINFO D04HBH AM-3701 Investigative T11388 DRUGINFO D04QHB 2-cyclohexylamino-pyrimidine-4-carbonitrile Investigative T11388 DRUGINFO D06AZJ 4-cyclohexylamino-pyrimidine-2-carbonitrile Investigative T11388 DRUGINFO D0A8PI Boc-Agly-Val-Agly-OEt Investigative T11388 DRUGINFO D0B2FE 4-phenyl-6-propylpyrimidine-2-carbonitrile Investigative T11388 DRUGINFO D0FC7L 2-cyclohexylamino-pyridine-2-carbonitrile Investigative T11388 DRUGINFO D0H8CC Tert-butyl (2S)-1-cyanopyrrolidine-2-carboxylate Investigative T11388 DRUGINFO D0MM4X MIV-710 Investigative T11388 DRUGINFO D0P5BY N-(cyanomethyl)cyclohex-1-ene-1-carboxamide Investigative T11388 DRUGINFO D0V1UZ BF/PC-21 Investigative T11388 DRUGINFO D0W0BK TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE Investigative T11388 DRUGINFO D0Y5LX 4-cyclohexyl-6-propylpyrimidine-2-carbonitrile Investigative T11388 DRUGINFO D00NVC Z-Ala-Leu-Nal-Agly-Ile-Val-OMe Investigative T11388 DRUGINFO D01BIZ Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2 Investigative T11388 DRUGINFO D01JGB 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile Investigative T11388 DRUGINFO D01TFO Z-Ala-Leu-lle-Agly-Ile-Val-OMe Investigative T11388 DRUGINFO D03ETT Z-Ala-Leu-His-Agly-Ile-Val-OMe Investigative T11388 DRUGINFO D03FJH Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2 Investigative T11388 DRUGINFO D03VHO Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe Investigative T11388 DRUGINFO D04BGT 4-propyl-6-m-tolylpyrimidine-2-carbonitrile Investigative T11388 DRUGINFO D05WZF P2,P3 Ketoamide derivative Investigative T11388 DRUGINFO D06QJT Z-leu-Val-Agly-Val-OBzl Investigative T11388 DRUGINFO D07JLV Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl Investigative T11388 DRUGINFO D07RDV Z-Ala-Leu-Phe-Agly-Ile-Val-OMe Investigative T11388 DRUGINFO D0A7ER N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile Investigative T11388 DRUGINFO D0G2QG PMID16290936C1b Investigative T11388 DRUGINFO D0H8TE Z-Arg-Leu-Val-Agly-Ala-Gly-NH2 Investigative T11388 DRUGINFO D0N7BP Z-Arg-Leu-Val-Agly-Val-Ala-NH2 Investigative T11388 DRUGINFO D0Q4YY Z-Arg-Leu-Val-Agly-Ileu-Val-OMe Investigative T11388 DRUGINFO D0T7QF (S)-tert-butyl 1-oxohexan-2-ylcarbamate Investigative T11388 DRUGINFO D0U4TY 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile Investigative T11388 DRUGINFO D01YNC N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile Investigative T11388 DRUGINFO D06VIP N-(tert-butoxycarbonyl)-valyl-glycine-nitrile Investigative T11388 DRUGINFO D07FLB N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile Investigative T11388 DRUGINFO D07RSA N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile Investigative T11388 DRUGINFO D09AHN N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile Investigative T11388 DRUGINFO D0A8OV N-acetyl-phenylalanyl-glycine-nitrile Investigative T11388 DRUGINFO D0G8OD N-(benzyloxycarbonyl)-leucyl-glycine-nitrile Investigative T11388 DRUGINFO D0JN8Q N-benzoyl-phenylalanyl-glycine-nitrile Investigative T11388 DRUGINFO D0U0XG N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile Investigative T11388 DRUGINFO D0VE0F (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate Investigative T11388 DRUGINFO D0D0LD L-873724 Investigative T11388 DRUGINFO D0L9VP GNF-PF-5434 Investigative T40097 TARGETID T40097 T40097 FORMERID TTDC00102 T40097 UNIPROID MK08_HUMAN T40097 TARGNAME Stress-activated protein kinase JNK1 (JNK1) T40097 GENENAME MAPK8 T40097 TARGTYPE Clinical trial T40097 SYNONYMS Stress-activated protein kinase 1c; SAPK1c; PRKM8; Mitogen-activated protein kinase 8; MAPK 8; MAP kinase 8; JNK-46; C-Jun N-terminal kinase 1 T40097 FUNCTION Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK8/JNK1. In turn, MAPK8/JNK1 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1 transcriptional activity. Phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Contributes to the survival of erythroid cells by phosphorylating the antagonist of cell death BAD upon EPO stimulation. Mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy. Phosphorylates STMN2 and hence regulates microtubule dynamics, controlling neurite elongation in cortical neurons. In the developing brain, through its cytoplasmic activity on STMN2, negatively regulates the rate of exit from multipolar stage and of radial migration from the ventricular zone. Phosphorylates several other substrates including heat shock factor protein 4 (HSF4), the deacetylase SIRT1, ELK1, or the E3 ligase ITCH. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock. Phosphorylates the heat shock transcription factor HSF1, suppressing HSF1-induced transcriptional activity. Phosphorylates POU5F1, which results in the inhibition of POU5F1's transcriptional activity and enhances its proteosomal degradation. Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. T40097 PDBSTRUC 6F5E; 5LW1; 4YR8; 4UX9; 4QTD T40097 BIOCLASS Kinase T40097 ECNUMBER EC 2.7.11.24 T40097 SEQUENCE MSRSKRDNNFYSVEIGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSKMLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEVMDLEERTKNGVIRGQPSPLGAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR T40097 DRUGINFO D08SIT NKP-1339 Phase 1 T40097 DRUGINFO D00JGN PMID25991433-Compound-H3 Patented T40097 DRUGINFO D01GSU PMID25991433-Compound-H2 Patented T40097 DRUGINFO D06WAW PMID25991433-Compound-E5 Patented T40097 DRUGINFO D09QKG PMID25991433-Compound-E1 Patented T40097 DRUGINFO D0EA5P PMID25991433-Compound-G4 Patented T40097 DRUGINFO D0EA6L PMID25991433-Compound-K2 Patented T40097 DRUGINFO D0I3NS PMID25991433-Compound-G2 Patented T40097 DRUGINFO D0J8DR PMID25991433-Compound-G1 Patented T40097 DRUGINFO D0MW7D PMID25991433-Compound-Eb Patented T40097 DRUGINFO D0TK0L PMID25991433-Compound-E2 Patented T40097 DRUGINFO D0V0WT PMID25991433-Compound-G5 Patented T40097 DRUGINFO D0XB1S PMID25991433-Compound-H1 Patented T40097 DRUGINFO D0XH9K PMID25991433-Compound-E4 Patented T40097 DRUGINFO D0Y4HR PMID25991433-Compound-E3 Patented T40097 DRUGINFO D0Y7QW PMID25991433-Compound-K1 Patented T40097 DRUGINFO D03HEK PMID25991433-Compound-A10 Patented T40097 DRUGINFO D04JUD PMID25991433-Compound-A6 Patented T40097 DRUGINFO D07JQX PMID25991433-Compound-D2 Patented T40097 DRUGINFO D08JIS PMID25991433-Compound-N3 Patented T40097 DRUGINFO D09YEH PMID25991433-Compound-A11 Patented T40097 DRUGINFO D0AM2B PMID25991433-Compound-A8 Patented T40097 DRUGINFO D0B4IH PMID25991433-Compound-D1 Patented T40097 DRUGINFO D0ID4H PMID25991433-Compound-N1 Patented T40097 DRUGINFO D0RV2Z PMID25991433-Compound-A2 Patented T40097 DRUGINFO D0S1OV PMID25991433-Compound-A7 Patented T40097 DRUGINFO D0S3AP PMID25991433-Compound-A9 Patented T40097 DRUGINFO D0V1CB PMID25991433-Compound-A5 Patented T40097 DRUGINFO D0VE3Y PMID25991433-Compound-A3 Patented T40097 DRUGINFO D05SJB 7-azaindole derivative 1 Patented T40097 DRUGINFO D07KMK 7-azaindole derivative 5 Patented T40097 DRUGINFO D08DNZ PMID25991433-Compound-P6 Patented T40097 DRUGINFO D08JOC PMID25991433-Compound-J3 Patented T40097 DRUGINFO D0L2MS PMID25991433-Compound-P1 Patented T40097 DRUGINFO D0Q4WA PMID25991433-Compound-O3 Patented T40097 DRUGINFO D0Q8CR PMID25991433-Compound-L1 Patented T40097 DRUGINFO D0RQ8Q PMID25991433-Compound-J2 Patented T40097 DRUGINFO D0T6IZ 7-azaindole derivative 3 Patented T40097 DRUGINFO D0VR1O 7-azaindole derivative 2 Patented T40097 DRUGINFO D0W8BL PMID25991433-Compound-P5 Patented T40097 DRUGINFO D0X2SG PMID25991433-Compound-P4 Patented T40097 DRUGINFO D0ZU8L PMID25991433-Compound-J5 Patented T40097 DRUGINFO D06JRV PMID25991433-Compound-F2 Patented T40097 DRUGINFO D0H4HD PMID25991433-Compound-A1 Patented T40097 DRUGINFO DOJ6D9 COR-D Preclinical T40097 DRUGINFO D01HCO 2-(2-propoxypyrimidin-4-ylamino)benzoic acid Investigative T40097 DRUGINFO D03UUO 2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid Investigative T40097 DRUGINFO D07HNL 2-(2-phenoxypyrimidin-4-ylamino)benzoic acid Investigative T40097 DRUGINFO D08IOV 2-(2-butoxypyrimidin-4-ylamino)benzoic acid Investigative T40097 DRUGINFO D08UVX 2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide Investigative T40097 DRUGINFO D0E8KF N-(6-ethoxypyridin-2-yl)acetamide Investigative T40097 DRUGINFO D0KB8D 2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid Investigative T40097 DRUGINFO D0SV1F 2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid Investigative T40097 DRUGINFO D0Y5BR Phylomers Investigative T40097 DRUGINFO D0F5BY N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide Investigative T40097 DRUGINFO D00HVA Aminopyridine deriv. 2 Investigative T40097 DRUGINFO D0Q3NG N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide Investigative T40097 DRUGINFO D0VJ2S JNK-IN-8 Investigative T40097 DRUGINFO D04QCF AS-601245 Investigative T40097 DRUGINFO D02PVB 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One Investigative T40097 DRUGINFO D0GT8N NM-PP1 Investigative T40097 DRUGINFO D0S7IE N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide Investigative T40097 DRUGINFO D0G2VC KT-5720 Investigative T40097 DRUGINFO D0GB4V STAUROSPORINONE Investigative T40097 DRUGINFO D0M5FF Ro31-8220 Investigative T40097 DRUGINFO D0N6ES KN-62 Investigative T40097 DRUGINFO D0B9BU CI-1040 Investigative T40097 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T40097 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T40097 DRUGINFO D0L8HO RO-316233 Investigative T86161 TARGETID T86161 T86161 FORMERID TTDR00015 T86161 UNIPROID PPCE_HUMAN T86161 TARGNAME Prolyl endopeptidase (PREP) T86161 GENENAME PREP T86161 TARGTYPE Clinical trial T86161 SYNONYMS Post-proline cleaving enzyme; PREP; PE T86161 FUNCTION Cleaves peptide bonds on the C-terminal side of prolyl residues within peptides that are up to approximately 30 amino acids long. T86161 PDBSTRUC 3DDU T86161 BIOCLASS Peptidase T86161 ECNUMBER EC 3.4.21.26 T86161 SEQUENCE MLSLQYPDVYRDETAVQDYHGHKICDPYAWLEDPDSEQTKAFVEAQNKITVPFLEQCPIRGLYKERMTELYDYPKYSCHFKKGKRYFYFYNTGLQNQRVLYVQDSLEGEARVFLDPNILSDDGTVALRGYAFSEDGEYFAYGLSASGSDWVTIKFMKVDGAKELPDVLERVKFSCMAWTHDGKGMFYNSYPQQDGKSDGTETSTNLHQKLYYHVLGTDQSEDILCAEFPDEPKWMGGAELSDDGRYVLLSIREGCDPVNRLWYCDLQQESSGIAGILKWVKLIDNFEGEYDYVTNEGTVFTFKTNRQSPNYRVINIDFRDPEESKWKVLVPEHEKDVLEWIACVRSNFLVLCYLHDVKNILQLHDLTTGALLKTFPLDVGSIVGYSGQKKDTEIFYQFTSFLSPGIIYHCDLTKEELEPRVFREVTVKGIDASDYQTVQIFYPSKDGTKIPMFIVHKKGIKLDGSHPAFLYGYGGFNISITPNYSVSRLIFVRHMGGILAVANIRGGGEYGETWHKGGILANKQNCFDDFQCAAEYLIKEGYTSPKRLTINGGSNGGLLVAACANQRPDLFGCVIAQVGVMDMLKFHKYTIGHAWTTDYGCSDSKQHFEWLVKYSPLHNVKLPEADDIQYPSMLLLTADHDDRVVPLHSLKFIATLQYIVGRSRKQSNPLLIHVDTKAGHGAGKPTAKVIEEVSDMFAFIARCLNVDWIP T86161 DRUGINFO D00WBN ALV-003 Phase 2 T86161 DRUGINFO D0F5JR ONO-1603 Phase 2 T86161 DRUGINFO D00YEV BAICALEIN Phase 2 T86161 DRUGINFO D09RJN S-17092-1 Phase 1 T86161 DRUGINFO D01XGX JTP-4819 Discontinued in Phase 2 T86161 DRUGINFO D08RUX Z-321 Discontinued in Phase 1 T86161 DRUGINFO D08PUW BAICALIN Terminated T86161 DRUGINFO D0M8AS Y-29794 Terminated T86161 DRUGINFO D01WXB Monothioglycerol Investigative T86161 DRUGINFO D06FNK Z-Pro-Prolinal Investigative T86161 DRUGINFO D0M9VP 1-Hydroxy-1-Thio-Glycerol Investigative T86161 DRUGINFO D0N2UF ARI-3531 Investigative T86161 DRUGINFO D0H1GU Double Oxidized Cysteine Investigative T65019 TARGETID T65019 T65019 FORMERID TTDC00042 T65019 UNIPROID MMP14_HUMAN T65019 TARGNAME Matrix metalloproteinase-14 (MMP-14) T65019 GENENAME MMP14 T65019 TARGTYPE Clinical trial T65019 SYNONYMS Membrane-type-1 matrix metalloproteinase; Membrane-type matrix metalloproteinase 1; MTMMP1; MT1MMP; MT1-MMP; MT-MMP 1; MMP-X1 T65019 FUNCTION Activates progelatinase A. Essential for pericellular collagenolysis and modeling of skeletal and extraskeletal connective tissues during development. May be involved in actin cytoskeleton reorganization by cleaving PTK7. Acts as a positive regulator of cell growth and migration via activation of MMP15. Involved in the formation of the fibrovascular tissues in association with pro-MMP2. Cleaves ADGRB1 to release vasculostatin-40 which inhibits angiogenesis. Endopeptidase that degrades various components of the extracellular matrix such as collagen. T65019 PDBSTRUC 6CM1; 6CLZ; 5H0U; 4QXU; 4P3D T65019 BIOCLASS Peptidase T65019 ECNUMBER EC 3.4.24.80 T65019 SEQUENCE MSPAPRPPRCLLLPLLTLGTALASLGSAQSSSFSPEAWLQQYGYLPPGDLRTHTQRSPQSLSAAIAAMQKFYGLQVTGKADADTMKAMRRPRCGVPDKFGAEIKANVRRKRYAIQGLKWQHNEITFCIQNYTPKVGEYATYEAIRKAFRVWESATPLRFREVPYAYIREGHEKQADIMIFFAEGFHGDSTPFDGEGGFLAHAYFPGPNIGGDTHFDSAEPWTVRNEDLNGNDIFLVAVHELGHALGLEHSSDPSAIMAPFYQWMDTENFVLPDDDRRGIQQLYGGESGFPTKMPPQPRTTSRPSVPDKPKNPTYGPNICDGNFDTVAMLRGEMFVFKERWFWRVRNNQVMDGYPMPIGQFWRGLPASINTAYERKDGKFVFFKGDKHWVFDEASLEPGYPKHIKELGRGLPTDKIDAALFWMPNGKTYFFRGNKYYRFNEELRAVDSEYPKNIKVWEGIPESPRGSFMGSDEVFTYFYKGNKYWKFNNQKLKVEPGYPKSALRDWMGCPSGGRPDEGTEEETEVIIIEVDEEGGGAVSAAAVVLPVLLLLLVLAVGLAVFFFRRHGTPRRLLYCQRSLLDKV T65019 DRUGINFO D0U2BH Epigallocatechin gallate Phase 3 T65019 DRUGINFO DE2Z7V BT1718 Phase 1/2a T65019 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T65019 DRUGINFO D03XBB DX-2400 Investigative T65019 DRUGINFO D07DRT PMID23631440C29e Investigative T65019 DRUGINFO D09ZOA 2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide Investigative T65019 DRUGINFO D0NV9C 2-(4-bromophenylsulfonamido)-N-hydroxyacetamide Investigative T65019 DRUGINFO D0XK7G N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide Investigative T65019 DRUGINFO D0NP8A UK-356618 Investigative T65019 DRUGINFO D05THD 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide Investigative T65019 DRUGINFO D07MJD [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid Investigative T65019 DRUGINFO D0S9OL N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide Investigative T65019 DRUGINFO D03AMR SR-973 Investigative T65019 DRUGINFO D0W2UK IK-862 Investigative T65019 DRUGINFO D0A4TC MMI270 Investigative T44458 TARGETID T44458 T44458 FORMERID TTDC00095 T44458 UNIPROID CDK9_HUMAN T44458 TARGNAME Cyclin-dependent kinase 9 (CDK9) T44458 GENENAME CDK9 T44458 TARGTYPE Clinical trial T44458 SYNONYMS Tat-associated kinase complex catalytic subunit; TAK; Similar to cyclin-dependent kinase 9; Serine/threonine-protein kinase PITALRE; Cyclin-dependent protein kinase Cdk9; Cell division protein kinase 9; Cell division cycle 2-like protein kinase 4; CDC2L4; CDC2-related kinase; C-2K T44458 FUNCTION Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP. This complex is inactive when in the 7SK snRNP complex form. Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR, and the negative elongation factors DSIF and NELF. Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e. g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis. P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export. Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing. The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro. Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage. In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6. Promotes cardiac myocyte enlargement. RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription. AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect. The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation. Protein kinase involved in the regulation of transcription. T44458 PDBSTRUC 6GZH; 6CYT; 5L1Z; 4OR5; 4OGR T44458 BIOCLASS Kinase T44458 ECNUMBER EC 2.7.11.22 T44458 SEQUENCE MAKQYDSVECPFCDEVSKYEKLAKIGQGTFGEVFKARHRKTGQKVALKKVLMENEKEGFPITALREIKILQLLKHENVVNLIEICRTKASPYNRCKGSIYLVFDFCEHDLAGLLSNVLVKFTLSEIKRVMQMLLNGLYYIHRNKILHRDMKAANVLITRDGVLKLADFGLARAFSLAKNSQPNRYTNRVVTLWYRPPELLLGERDYGPPIDLWGAGCIMAEMWTRSPIMQGNTEQHQLALISQLCGSITPEVWPNVDNYELYEKLELVKGQKRKVKDRLKAYVRDPYALDLIDKLLVLDPAQRIDSDDALNHDFFWSDPMPSDLKGMLSTHLTSMFEYLAPPRRKGSQITQQSTNQSRNPATTNQTEFERVF T44458 DRUGINFO D05IRT P276-00 Phase 2 T44458 DRUGINFO D0LF1U Flavopiridol Phase 2 T44458 DRUGINFO D07KBM AZD4573 Phase 1 T44458 DRUGINFO D2GJ4P TP-1287 Phase 1 T44458 DRUGINFO D2YGA4 AZD7503 Phase 1 T44458 DRUGINFO D34RXC VIP-152 Phase 1 T44458 DRUGINFO D0PL7P CYC065 Phase 1 T44458 DRUGINFO D0S5RC SNS-032 Phase 1 T44458 DRUGINFO D5VMP4 BTX-A51 Phase 1 T44458 DRUGINFO D03DKV RGB-286638 Phase 1 T44458 DRUGINFO D00DDX N-(pyridin-2-yl)pyrimidin-4-amine derivative 1 Patented T44458 DRUGINFO D03YMA Aryl pyrimidine derivative 1 Patented T44458 DRUGINFO D07VPQ Pyrazinylpyridine derivative 1 Patented T44458 DRUGINFO D08DWG Phenylpyridine derivative 1 Patented T44458 DRUGINFO D09PGP Phenylpyridine derivative 2 Patented T44458 DRUGINFO D0FR3Z Aminoarylpyridine derivative 1 Patented T44458 DRUGINFO D0SV2E PMID26161698-Compound-32 Patented T44458 DRUGINFO D0TH7T Bipyridine derivative 1 Patented T44458 DRUGINFO D00BFF Benzothiazine derivative 1 Patented T44458 DRUGINFO D03EYT N-(pyridin-2-yl)pyridine methylsulfone derivative 1 Patented T44458 DRUGINFO D05UJQ Alkyl sulfone derivative 1 Patented T44458 DRUGINFO D07QIP 4-(thiazol-5-yl)-pyrimidine derivative 1 Patented T44458 DRUGINFO D0AY5G N-phenyl-pyrimidin-4-amine derivative 1 Patented T44458 DRUGINFO D0GQ7L PMID26161698-Compound-25 Patented T44458 DRUGINFO D0P4NP Diaryl amine derivative 1 Patented T44458 DRUGINFO D0P9WR Flavopiridol analog 1 Patented T44458 DRUGINFO D0QS2B N-(pyridin-2-yl)pyrimidin-4-amine derivative 2 Patented T44458 DRUGINFO D0UU0V 1,5-di-substituted pyridine derivative 1 Patented T44458 DRUGINFO D0V7RP 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1 Patented T44458 DRUGINFO D0LK4L Nitrogen mustard derivative 1 Patented T44458 DRUGINFO D01CJE 4-(thiazol-5-yl)-pyrimidine derivative 2 Patented T44458 DRUGINFO D0LX6X Indole-based analog 13 Patented T44458 DRUGINFO D0NB7Y Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 Patented T44458 DRUGINFO D07DUX Roscovitine derivative 1 Patented T44458 DRUGINFO D0NY7M Tricyclic benzimidazole derivative 1 Patented T44458 DRUGINFO D0M5DX Oxazolyl methylthiothiazole derivative 1 Patented T44458 DRUGINFO D0D3PX SCH 727965 Discontinued in Phase 3 T44458 DRUGINFO D0NV9O BAY 10-00394 Discontinued in Phase 2 T44458 DRUGINFO D00VBT ZK 304709 Discontinued in Phase 1 T44458 DRUGINFO D0D5CQ NVP-2 Preclinical T44458 DRUGINFO D04UNQ 4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine Investigative T44458 DRUGINFO D0CI3C Deschloroflavopiridol Investigative T44458 DRUGINFO D0E3FK MERIOLIN 7 Investigative T44458 DRUGINFO D01PEF MERIOLIN 8 Investigative T44458 DRUGINFO D08HFG PMID20873740C18 Investigative T44458 DRUGINFO D08KSQ MERIOLIN 1 Investigative T44458 DRUGINFO D0B9YR MERIOLIN 4 Investigative T44458 DRUGINFO D0D0ZQ MERIOLIN 6 Investigative T44458 DRUGINFO D0H6CQ MERIOLIN 5 Investigative T44458 DRUGINFO D0S8VE MERIOLIN 3 Investigative T44458 DRUGINFO D0U1WL MERIOLIN 2 Investigative T44458 DRUGINFO D0W0BL 3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol Investigative T44458 DRUGINFO D0T8NU PMID19115845C89S Investigative T44458 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T40694 TARGETID T40694 T40694 FORMERID TTDC00160 T40694 UNIPROID PLK1_HUMAN T40694 TARGNAME Polo-like kinase 1 (PLK1) T40694 GENENAME PLK1 T40694 TARGTYPE Clinical trial T40694 SYNONYMS Serine/threonine-protein kinase PLK1; Serine/threonine-protein kinase 13; Serine-threonine protein kinase 13; STPK13; Plk1; PLK-1; PLK; Mitoticserine-threonine kinase polo-like kinase 1 T40694 FUNCTION Polo-like kinase proteins acts by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates BORA, BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1, KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, KIZ, PPP1R12A/MYPT1, PRC1, RACGAP1/CYK4, SGO1, STAG2/SA2, TEX14, TOPORS, p73/TP73, TPT1, WEE1 and HNRNPU. Plays a key role in centrosome functions and the assembly of bipolar spindles by phosphorylating KIZ, NEDD1 and NINL. NEDD1 phosphorylation promotes subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. Phosphorylation of NINL component of the centrosome leads to NINL dissociation from other centrosomal proteins. Involved in mitosis exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2, CENPU, PRC1 and RACGAP1. Recruited at the central spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own docking sites on PRC1 and KIF20A/MKLP2 by mediating phosphorylation of sites subsequently recognized by the POLO box domains. Phosphorylates RACGAP1, thereby creating a docking site for the Rho GTP exchange factor ECT2 that is essential for the cleavage furrow formation. Promotes the central spindle recruitment of ECT2. Plays a central role in G2/M transition of mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, CENPU, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1. Part of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the positive regulator CDC25C and inhibiting the negative regulators WEE1 and PKMYT1/MYT1. Also acts by mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in prophase. Phosphorylates FOXM1, a key mitotic transcription regulator, leading to enhance FOXM1 transcriptional activity. Involved in kinetochore functions and sister chromatid cohesion by phosphorylating BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2. PLK1 is high on non-attached kinetochores suggesting a role of PLK1 in kinetochore attachment or in spindle assembly checkpoint (SAC) regulation. Required for kinetochore localization of BUB1B. Regulates the dissociation of cohesin from chromosomes by phosphorylating cohesin subunits such as STAG2/SA2. Phosphorylates SGO1: required for spindle pole localization of isoform 3 of SGO1 and plays a role in regulating its centriole cohesion function. Mediates phosphorylation of FBXO5/EMI1, a negative regulator of the APC/C complex during prophase, leading to FBXO5/EMI1 ubiquitination and degradation by the proteasome. Acts as a negative regulator of p53 family members: phosphorylates TOPORS, leading to inhibit the sumoylation of p53/TP53 and simultaneously enhance the ubiquitination and subsequent degradation of p53/TP53. Phosphorylates the transactivation domain of the transcription factor p73/TP73, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the degradation of BORA. Contributes to the regulation of AURKA function. Also required for recovery after DNA damage checkpoint and entry into mitosis. Phosphorylates MISP, leading to stabilization of cortical and astral microtubule attachments required for proper spindle positioning. Together with MEIKIN, acts as a regulator of kinetochore function during meiosis I: required both for mono-orientation of kinetochores on sister chromosomes and protection of centromeric cohesin from separase-mediated cleavage. Phosphorylates CEP68 and is required for its degradation. Regulates nuclear envelope breakdown during prophase by phosphorylating DCTN1 resulting in its localization in the nuclear envelope. Phosphorylates the heat shock transcription factor HSF1, promoting HSF1 nuclear translocation upon heat shock. Phosphorylates HSF1 also in the early mitotic period; this phosphorylation regulates HSF1 localization to the spindle pole, the recruitment of the SCF(BTRC) ubiquitin ligase complex induicing HSF1 degradation, and hence mitotic progression. Regulates mitotic progression by phosphorylating RIOK2. Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis. T40694 PDBSTRUC 6AX4; 5TA8; 5TA6; 5NN2; 5NN1 T40694 BIOCLASS Kinase T40694 ECNUMBER EC 2.7.11.21 T40694 SEQUENCE MSAAVTAGKLARAPADPGKAGVPGVAAPGAPAAAPPAKEIPEVLVDPRSRRRYVRGRFLGKGGFAKCFEISDADTKEVFAGKIVPKSLLLKPHQREKMSMEISIHRSLAHQHVVGFHGFFEDNDFVFVVLELCRRRSLLELHKRRKALTEPEARYYLRQIVLGCQYLHRNRVIHRDLKLGNLFLNEDLEVKIGDFGLATKVEYDGERKKTLCGTPNYIAPEVLSKKGHSFEVDVWSIGCIMYTLLVGKPPFETSCLKETYLRIKKNEYSIPKHINPVAASLIQKMLQTDPTARPTINELLNDEFFTSGYIPARLPITCLTIPPRFSIAPSSLDPSNRKPLTVLNKGLENPLPERPREKEEPVVRETGEVVDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS T40694 DRUGINFO D00BYM Volasertib Phase 3 T40694 DRUGINFO D0KF9Q Rigosertib Phase 3 T40694 DRUGINFO D03HUX PCM-075 Phase 2 T40694 DRUGINFO D0O0LQ BI 2536 Phase 2 T40694 DRUGINFO D05RGV MK-1496 Phase 1 T40694 DRUGINFO D08RMJ GSK461364 Phase 1 T40694 DRUGINFO D09JGK TAK-960 Phase 1 T40694 DRUGINFO DK26FL CYC140 Phase 1 T40694 DRUGINFO D0F3GC Dihydropyrido pyrazinone compound 3 Patented T40694 DRUGINFO D0S0HQ Dihydropyrido pyrazinone compound 2 Patented T40694 DRUGINFO D0R7ID HMN-214 Discontinued in Phase 1 T40694 DRUGINFO D05ZCQ DAP-81 Preclinical T40694 DRUGINFO D07RMX ZK-thiazolidinone Preclinical T40694 DRUGINFO D0WZ4J CYC-800 Preclinical T40694 DRUGINFO D01HHH CHR-4125 Investigative T40694 DRUGINFO D03BQD NMS-1 Investigative T40694 DRUGINFO D05QMQ MLN-0905 Investigative T40694 DRUGINFO D05WDM Ro5203280 Investigative T40694 DRUGINFO D09ZKY GW853606 Investigative T40694 DRUGINFO D0H8WY PMID19097784C2 Investigative T40694 DRUGINFO D0X5ZH LC-445 Investigative T40694 DRUGINFO D0X1RH GSK579289A Investigative T49507 TARGETID T49507 T49507 FORMERID TTDC00045 T49507 UNIPROID EPHB4_HUMAN T49507 TARGNAME Ephrin type-B receptor 4 (EPHB4) T49507 GENENAME EPHB4 T49507 TARGTYPE Clinical trial T49507 SYNONYMS Tyrosine-protein kinase TYRO11; TYRO11; MYK1; Hepatoma transmembrane kinase; HTK T49507 FUNCTION Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cognate ligand/functional ligand EFNB2 it is involved in the regulation of cell adhesion and migration, and plays a central role in heart morphogenesis, angiogenesis and blood vessel remodeling and permeability. EPHB4-mediated forward signaling controls cellular repulsion and segregation from EFNB2-expressing cells. T49507 PDBSTRUC 6FNM; 6FNL; 6FNK; 6FNJ; 6FNI T49507 BIOCLASS Kinase T49507 ECNUMBER EC 2.7.10.1 T49507 SEQUENCE MELRVLLCWASLAAALEETLLNTKLETADLKWVTFPQVDGQWEELSGLDEEQHSVRTYEVCDVQRAPGQAHWLRTGWVPRRGAVHVYATLRFTMLECLSLPRAGRSCKETFTVFYYESDADTATALTPAWMENPYIKVDTVAAEHLTRKRPGAEATGKVNVKTLRLGPLSKAGFYLAFQDQGACMALLSLHLFYKKCAQLTVNLTRFPETVPRELVVPVAGSCVVDAVPAPGPSPSLYCREDGQWAEQPVTGCSCAPGFEAAEGNTKCRACAQGTFKPLSGEGSCQPCPANSHSNTIGSAVCQCRVGYFRARTDPRGAPCTTPPSAPRSVVSRLNGSSLHLEWSAPLESGGREDLTYALRCRECRPGGSCAPCGGDLTFDPGPRDLVEPWVVVRGLRPDFTYTFEVTALNGVSSLATGPVPFEPVNVTTDREVPPAVSDIRVTRSSPSSLSLAWAVPRAPSGAVLDYEVKYHEKGAEGPSSVRFLKTSENRAELRGLKRGASYLVQVRARSEAGYGPFGQEHHSQTQLDESEGWREQLALIAGTAVVGVVLVLVVIVVAVLCLRKQSNGREAEYSDKHGQYLIGHGTKVYIDPFTYEDPNEAVREFAKEIDVSYVKIEEVIGAGEFGEVCRGRLKAPGKKESCVAIKTLKGGYTERQRREFLSEASIMGQFEHPNIIRLEGVVTNSMPVMILTEFMENGALDSFLRLNDGQFTVIQLVGMLRGIASGMRYLAEMSYVHRDLAARNILVNSNLVCKVSDFGLSRFLEENSSDPTYTSSLGGKIPIRWTAPEAIAFRKFTSASDAWSYGIVMWEVMSFGERPYWDMSNQDVINAIEQDYRLPPPPDCPTSLHQLMLDCWQKDRNARPRFPQVVSALDKMIRNPASLKIVARENGGASHPLLDQRQPHYSAFGSVGEWLRAIKMGRYEESFAAAGFGSFELVSQISAEDLLRIGVTLAGHQKKILASVQHMKSQAKPGTPGGTGGPAPQY T49507 DRUGINFO D06WRF KD019 Phase 2 T49507 DRUGINFO D0Q6GK EphB4-131 Investigative T49507 DRUGINFO D0H1OK TG-100435 Investigative T49507 DRUGINFO D05FXD PMID19788238C66 Investigative T49507 DRUGINFO D0X8BU PMID23489211C20 Investigative T91661 TARGETID T91661 T91661 FORMERID TTDR00529 T91661 UNIPROID ADK_HUMAN T91661 TARGNAME Adenosine kinase (ADK) T91661 GENENAME ADK T91661 TARGTYPE Clinical trial T91661 SYNONYMS Adenosine 5'-phosphotransferase; AK T91661 FUNCTION Serves as a potential regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides. ATP dependent phosphorylation of adenosine and other related nucleoside analogs to monophosphate derivatives. T91661 PDBSTRUC 4O1L; 2I6B; 2I6A; 1BX4 T91661 BIOCLASS Kinase T91661 ECNUMBER EC 2.7.1.20 T91661 SEQUENCE MAAAEEEPKPKKLKVEAPQALRENILFGMGNPLLDISAVVDKDFLDKYSLKPNDQILAEDKHKELFDELVKKFKVEYHAGGSTQNSIKVAQWMIQQPHKAATFFGCIGIDKFGEILKRKAAEAHVDAHYYEQNEQPTGTCAACITGDNRSLIANLAAANCYKKEKHLDLEKNWMLVEKARVCYIAGFFLTVSPESVLKVAHHASENNRIFTLNLSAPFISQFYKESLMKVMPYVDILFGNETEAATFAREQGFETKDIKEIAKKTQALPKMNSKRQRIVIFTQGRDDTIMATESEVTAFAVLDQDQKEIIDTNGAGDAFVGGFLSQLVSDKPLTECIRAGHYAASIIIRRTGCTFPEKPDFH T91661 DRUGINFO D01GVC GP-3269 Phase 1 T91661 DRUGINFO D08LUT ABT-702 Terminated T91661 DRUGINFO D0JI1J GP-683 Terminated T91661 DRUGINFO D0S9XV A-134974 Terminated T91661 DRUGINFO D00RDY 5'-iodotubercidin Investigative T91661 DRUGINFO D00WHC MB-03966 Investigative T91661 DRUGINFO D03SHX 5-iodo,5'-deoxytubercidin Investigative T91661 DRUGINFO D0K1YY 6-Benzylthioinosine Investigative T91661 DRUGINFO D0S2FW Iodotubercidin Investigative T91661 DRUGINFO D07OAC GP515 Investigative T63816 TARGETID T63816 T63816 FORMERID TTDC00159 T63816 UNIPROID HDAC4_HUMAN T63816 TARGNAME Histone deacetylase 4 (HDAC4) T63816 GENENAME HDAC4 T63816 TARGTYPE Clinical trial T63816 SYNONYMS KIAA0288; HD4 T63816 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation via its interaction with the myocyte enhancer factors such as MEF2A, MEF2C and MEF2D. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Deacetylates HSPA1A and HSPA1B at 'Lys-77' leading to their preferential binding to co-chaperone STUB1. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). T63816 PDBSTRUC 6FYZ; 5ZOP; 5ZOO; 5A2S; 4CBY T63816 BIOCLASS Carbon-nitrogen hydrolase T63816 ECNUMBER EC 3.5.1.98 T63816 SEQUENCE MSSQSHPDGLSGRDQPVELLNPARVNHMPSTVDVATALPLQVAPSAVPMDLRLDHQFSLPVAEPALREQQLQQELLALKQKQQIQRQILIAEFQRQHEQLSRQHEAQLHEHIKQQQEMLAMKHQQELLEHQRKLERHRQEQELEKQHREQKLQQLKNKEKGKESAVASTEVKMKLQEFVLNKKKALAHRNLNHCISSDPRYWYGKTQHSSLDQSSPPQSGVSTSYNHPVLGMYDAKDDFPLRKTASEPNLKLRSRLKQKVAERRSSPLLRRKDGPVVTALKKRPLDVTDSACSSAPGSGPSSPNNSSGSVSAENGIAPAVPSIPAETSLAHRLVAREGSAAPLPLYTSPSLPNITLGLPATGPSAGTAGQQDAERLTLPALQQRLSLFPGTHLTPYLSTSPLERDGGAAHSPLLQHMVLLEQPPAQAPLVTGLGALPLHAQSLVGADRVSPSIHKLRQHRPLGRTQSAPLPQNAQALQHLVIQQQHQQFLEKHKQQFQQQQLQMNKIIPKPSEPARQPESHPEETEEELREHQALLDEPYLDRLPGQKEAHAQAGVQVKQEPIESDEEEAEPPREVEPGQRQPSEQELLFRQQALLLEQQRIHQLRNYQASMEAAGIPVSFGGHRPLSRAQSSPASATFPVSVQEPPTKPRFTTGLVYDTLMLKHQCTCGSSSSHPEHAGRIQSIWSRLQETGLRGKCECIRGRKATLEELQTVHSEAHTLLYGTNPLNRQKLDSKKLLGSLASVFVRLPCGGVGVDSDTIWNEVHSAGAARLAVGCVVELVFKVATGELKNGFAVVRPPGHHAEESTPMGFCYFNSVAVAAKLLQQRLSVSKILIVDWDVHHGNGTQQAFYSDPSVLYMSLHRYDDGNFFPGSGAPDEVGTGPGVGFNVNMAFTGGLDPPMGDAEYLAAFRTVVMPIASEFAPDVVLVSSGFDAVEGHPTPLGGYNLSARCFGYLTKQLMGLAGGRIVLALEGGHDLTAICDASEACVSALLGNELDPLPEKVLQQRPNANAVRSMEKVMEIHSKYWRCLQRTTSTAGRSLIEAQTCENEEAETVTAMASLSVGVKPAEKRPDEEPMEEEPPL T63816 DRUGINFO D02YLT PMID29671355-Compound-52 Patented T63816 DRUGINFO D03KOH PMID29671355-Compound-72a Patented T63816 DRUGINFO D07KQB PMID29671355-Compound-47c Patented T63816 DRUGINFO D08CYC PMID29671355-Compound-70 Patented T63816 DRUGINFO D0BV4M PMID29671355-Compound-71b Patented T63816 DRUGINFO D0E7TU PMID29671355-Compound-72b Patented T63816 DRUGINFO D0L1NO PMID29671355-Compound-47a Patented T63816 DRUGINFO D0M7GG PMID29671355-Compound-50 Patented T63816 DRUGINFO D0NG9V PMID29671355-Compound-47b Patented T63816 DRUGINFO D0O1LX PMID29671355-Compound-71a Patented T63816 DRUGINFO D0SP7T PMID29671355-Compound-47d Patented T63816 DRUGINFO D0UE9B PMID29671355-Compound-12 Patented T63816 DRUGINFO D0GD6R PMID29671355-Compound-68b Patented T63816 DRUGINFO D0YN2T PMID29671355-Compound-45a Patented T63816 DRUGINFO D0JB4S PMID29671355-Compound-61 Patented T63816 DRUGINFO D00HXJ PMID29671355-Compound-23 Patented T63816 DRUGINFO D0CH8Q PMID29671355-Compound-56 Patented T63816 DRUGINFO D0M0RE PMID29671355-Compound-67 Patented T63816 DRUGINFO D0DI9S PMID29671355-Compound-31 Patented T63816 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T63816 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T63816 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T63816 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T63816 DRUGINFO D03BQS N-hydroxy-9,10-dihydroanthracene-9-carboxamide Investigative T63816 DRUGINFO D03QOD N-hydroxy-2,2-diphenylacetamide Investigative T63816 DRUGINFO D06IMY N-hydroxy-9H-xanthene-9-carboxamide Investigative T63816 DRUGINFO D0A4HF 2,2-bis(3-fluorophenyl)-N-hydroxyacetamide Investigative T63816 DRUGINFO D0E9DD AZUMAMIDE E Investigative T63816 DRUGINFO D0FN5D 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide Investigative T63816 DRUGINFO D0I4RK N-hydroxy-2,2-diphenylpropanamide Investigative T63816 DRUGINFO D0M1ZI AZUMAMIDE B Investigative T63816 DRUGINFO D0PK9V 2,2-bis(4-chlorophenyl)-N-hydroxyacetamide Investigative T63816 DRUGINFO D0Q9PO AZUMAMIDE C Investigative T63816 DRUGINFO D0Z8PX LARGAZOLE Investigative T63816 DRUGINFO D00XTC Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) Investigative T63816 DRUGINFO D02HVH 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide Investigative T63816 DRUGINFO D02NAF Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) Investigative T63816 DRUGINFO D02NVY Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) Investigative T63816 DRUGINFO D03PRG Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) Investigative T63816 DRUGINFO D04CDZ Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) Investigative T63816 DRUGINFO D09RKA santacruzamate A Investigative T63816 DRUGINFO D0E8UH Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) Investigative T63816 DRUGINFO D0G1EX Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) Investigative T63816 DRUGINFO D0N5RV Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) Investigative T63816 DRUGINFO D0R3XO Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) Investigative T63816 DRUGINFO D0U0EZ Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) Investigative T63816 DRUGINFO D0X4QC Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) Investigative T63816 DRUGINFO D0Z6HR Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) Investigative T63816 DRUGINFO D0Z6MI Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) Investigative T63816 DRUGINFO D0R7JA TMP269 Investigative T63816 DRUGINFO D0S0WK 8-Oxo-8-phenyl-octanoic acid hydroxyamide Investigative T63816 DRUGINFO D01YBR ST-3050 Investigative T63816 DRUGINFO D07YZZ Octanedioic acid bis-hydroxyamide Investigative T63816 DRUGINFO D00KFF 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative T63816 DRUGINFO D00SEE 7-Mercapto-heptanoic acid phenylamide Investigative T63816 DRUGINFO D00ZSD 6-benzenesulfinylhexanoic acid hydroxamide Investigative T63816 DRUGINFO D01MFV N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative T63816 DRUGINFO D01XWZ 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative T63816 DRUGINFO D01XXN N-Hydroxy-4-phenylacetylamino-benzamide Investigative T63816 DRUGINFO D02MQM 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative T63816 DRUGINFO D02UTC N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative T63816 DRUGINFO D02WZK 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T63816 DRUGINFO D04GGW Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative T63816 DRUGINFO D04HSS N-(6-Mercapto-hexyl)-benzamide Investigative T63816 DRUGINFO D04NSP 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T63816 DRUGINFO D04ZDI N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative T63816 DRUGINFO D05AHZ 6-benzenesulfonylhexanoic acid hydroxamide Investigative T63816 DRUGINFO D05FEJ 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative T63816 DRUGINFO D05GVY Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative T63816 DRUGINFO D05LLX 4-Butyrylamino-N-hydroxy-benzamide Investigative T63816 DRUGINFO D05VFP 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T63816 DRUGINFO D05XAN 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative T63816 DRUGINFO D06IQB 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative T63816 DRUGINFO D06VBN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative T63816 DRUGINFO D06XNP 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative T63816 DRUGINFO D07FJU 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative T63816 DRUGINFO D09YBN 6-Phenoxy-hexane-1-thiol Investigative T63816 DRUGINFO D09ZNU 4-Benzoylamino-N-hydroxy-benzamide Investigative T63816 DRUGINFO D0A5LS 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T63816 DRUGINFO D0AX7B 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative T63816 DRUGINFO D0B2ZJ 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T63816 DRUGINFO D0B3ZM 6-Mercapto-hexanoic acid phenylamide Investigative T63816 DRUGINFO D0C0VP Cyclostellettamine derivative Investigative T63816 DRUGINFO D0C2KD N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative T63816 DRUGINFO D0D2KE 5-Mercapto-pentanoic acid phenylamide Investigative T63816 DRUGINFO D0E8KR Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative T63816 DRUGINFO D0F0KS N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative T63816 DRUGINFO D0H1FZ 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative T63816 DRUGINFO D0KE3I (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative T63816 DRUGINFO D0QO0L N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative T63816 DRUGINFO D0R4BS N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative T63816 DRUGINFO D0R5VG N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative T63816 DRUGINFO D0RU1X 8-Oxo-8-phenyl-octanoic acid Investigative T63816 DRUGINFO D0S7WQ N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative T63816 DRUGINFO D0S9JF 6-phenylsulfanylhexanoic acid hydroxamide Investigative T63816 DRUGINFO D0T0SK ST-2987 Investigative T63816 DRUGINFO D0T4IY 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative T63816 DRUGINFO D0V2ZO 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative T63816 DRUGINFO D0XZ9Q 8-Mercapto-octanoic acid phenylamide Investigative T63816 DRUGINFO D0YY9M N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative T63816 DRUGINFO D0Z3BM 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative T63816 DRUGINFO D0Z5KX 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative T63816 DRUGINFO D0Z7YS N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative T63816 DRUGINFO D0N0TS PSAMMAPLIN A Investigative T51565 TARGETID T51565 T51565 FORMERID TTDR00257 T51565 UNIPROID CSK21_HUMAN T51565 TARGNAME Casein kinase II alpha (CSNK2A1) T51565 GENENAME CSNK2A1 T51565 TARGTYPE Clinical trial T51565 SYNONYMS Protein kinase CK2; Casein kinase II subunit alpha; CK2A1; CK II alpha; CK II T51565 FUNCTION Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV. Phosphorylates PML at 'Ser-565' and primes it for ubiquitin-mediated degradation. Plays an important role in the circadian clock function by phosphorylating ARNTL/BMAL1 at 'Ser-90' which is pivotal for its interaction with CLOCK and which controls CLOCK nuclear entry. Phosphorylates CCAR2 at 'Thr-454' in gastric carcinoma tissue. Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. T51565 PDBSTRUC 6Q4Q; 6Q38; 6HME; 6HBN; 6GMD T51565 BIOCLASS Kinase T51565 ECNUMBER EC 2.7.11.1 T51565 SEQUENCE MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMSGISSVPTPSPLGPLAGSPVIAAANPLGMPVPAAAGAQQ T51565 DRUGINFO D09JEJ CX-4945 Phase 2 T51565 DRUGINFO D0U7OU EMODIN Terminated T51565 DRUGINFO D0R2TM BALANOL Terminated T51565 DRUGINFO D04BNM 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole Investigative T51565 DRUGINFO D06SEA CX-7000 Investigative T51565 DRUGINFO D09ZNV CGP-029482 Investigative T51565 DRUGINFO D0CP3M 4,5,6,7-tetrabromo-1H-benzimidazole Investigative T51565 DRUGINFO D0CR9I CX-5011 Investigative T51565 DRUGINFO D0V5HG 7,8-dichloroquinoline-4-one-3-carboxylic acid Investigative T51565 DRUGINFO D0Y8CU 5,6,8-trichloroquinoline-4-one-3-carboxylic acid Investigative T51565 DRUGINFO D0K6BI PMID22115617C2c Investigative T51565 DRUGINFO D07MMG AdoC(Dpr)2AlaArg6 Investigative T51565 DRUGINFO D04TPA PMID24900749C1a Investigative T51565 DRUGINFO D00RIX APIGENIN Investigative T51565 DRUGINFO D0A1CM ELLAGIC ACID Investigative T51565 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T51565 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T19760 TARGETID T19760 T19760 FORMERID TTDR00339 T19760 UNIPROID M3K9_HUMAN T19760 TARGNAME Mixed lineage kinase 1 (MAP3K9) T19760 GENENAME MAP3K9 T19760 TARGTYPE Clinical trial T19760 SYNONYMS PRKE1; Mitogen-activated protein kinase kinase kinase 9; MLK1 T19760 FUNCTION Plays an important role in the cascades of cellular responses evoked by changes in the environment. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade through the phosphorylation of MAP2K4/MKK4 and MAP2K7/MKK7 which in turn activate the JNKs. The MKK/JNK signaling pathway regulates stress response via activator protein-1 (JUN) and GATA4 transcription factors. Plays also a role in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. T19760 PDBSTRUC 4UY9; 3DTC T19760 BIOCLASS Kinase T19760 ECNUMBER EC 2.7.11.25 T19760 SEQUENCE MEPSRALLGCLASAAAAAPPGEDGAGAGAEEEEEEEEEAAAAVGPGELGCDAPLPYWTAVFEYEAAGEDELTLRLGDVVEVLSKDSQVSGDEGWWTGQLNQRVGIFPSNYVTPRSAFSSRCQPGGEDPSCYPPIQLLEIDFAELTLEEIIGIGGFGKVYRAFWIGDEVAVKAARHDPDEDISQTIENVRQEAKLFAMLKHPNIIALRGVCLKEPNLCLVMEFARGGPLNRVLSGKRIPPDILVNWAVQIARGMNYLHDEAIVPIIHRDLKSSNILILQKVENGDLSNKILKITDFGLAREWHRTTKMSAAGTYAWMAPEVIRASMFSKGSDVWSYGVLLWELLTGEVPFRGIDGLAVAYGVAMNKLALPIPSTCPEPFAKLMEDCWNPDPHSRPSFTNILDQLTTIEESGFFEMPKDSFHCLQDNWKHEIQEMFDQLRAKEKELRTWEEELTRAALQQKNQEELLRRREQELAEREIDILERELNIIIHQLCQEKPRVKKRKGKFRKSRLKLKDGNRISLPSDFQHKFTVQASPTMDKRKSLINSRSSPPASPTIIPRLRAIQLTPGESSKTWGRSSVVPKEEGEEEEKRAPKKKGRTWGPGTLGQKELASGDEGSPQRREKANGLSTPSESPHFHLGLKSLVDGYKQWSSSAPNLVKGPRSSPALPGFTSLMEMEDEDSEGPGSGESRLQHSPSQSYLCIPFPRGEDGDGPSSDGIHEEPTPVNSATSTPQLTPTNSLKRGGAHHRRCEVALLGCGAVLAATGLGFDLLEAGKCQLLPLEEPEPPAREEKKRREGLFQRSSRPRRSTSPPSRKLFKKEEPMLLLGDPSASLTLLSLSSISECNSTRSLLRSDSDEIVVYEMPVSPVEAPPLSPCTHNPLVNVRVERFKRDPNQSLTPTHVTLTTPSQPSSHRRTPSDGALKPETLLASRSPSSNGLSPSPGAGMLKTPSPSRDPGEFPRLPDPNVVFPPTPRRWNTQQDSTLERPKTLEFLPRPRPSANRQRLDPWWFVSPSHARSTSPANSSSTETPSNLDSCFASSSSTVEERPGLPALLPFQAGPLPPTERTLLDLDAEGQSQDSTVPLCRAELNTHRPAPYEIQQEFWS T19760 DRUGINFO D03QLG CEP1347 Phase 2/3 T19760 DRUGINFO D07IHM CEP-6331 Investigative T19760 DRUGINFO D09QBA CEP-5104 Investigative T19760 DRUGINFO D07ADX URMC-099 Investigative T00176 TARGETID T00176 T00176 FORMERID TTDC00206 T00176 UNIPROID MDM2_HUMAN T00176 TARGNAME Ubiquitin-protein ligase E3 Mdm2 (MDM2) T00176 GENENAME MDM2 T00176 TARGTYPE Clinical trial T00176 SYNONYMS RING-type E3 ubiquitin transferase Mdm2; P53-binding protein Mdm2; Oncoprotein Mdm2; MDM2 protein; Hdm2; E3 ubiquitin-protein ligase Mdm2; Double minute 2 protein T00176 FUNCTION Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation. Ubiquitinates DCX, leading to DCX degradation and reduction of the dendritic spine density of olfactory bulb granule cells. Ubiquitinates DLG4, leading to proteasomal degradation of DLG4 which is required for AMPA receptor endocytosis. E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. T00176 PDBSTRUC 6Q9O; 6Q9L; 6Q9H; 6Q96; 6IM9 T00176 BIOCLASS Acyltransferase T00176 ECNUMBER EC 2.3.2.27 T00176 SEQUENCE MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFP T00176 DRUGINFO D0OC4O RG7388 Phase 3 T00176 DRUGINFO D0C1WR AMG 232 Phase 2 T00176 DRUGINFO D04SXL APG-115 Phase 2 T00176 DRUGINFO D07UKT ALRN-6924 Phase 2 T00176 DRUGINFO DE7N6F ASTX295 Phase 1/2 T00176 DRUGINFO D08JSQ DS-3032 Phase 1 T00176 DRUGINFO D08TNG RG7775 Phase 1 T00176 DRUGINFO D0B3GF JNJ-26854165 Phase 1 T00176 DRUGINFO DW3AX4 BI 907828 Phase 1 T00176 DRUGINFO D01KTG HDM201 Phase 1 T00176 DRUGINFO DNY16U MI-219 Investigative T92144 TARGETID T92144 T92144 FORMERID TTDC00161 T92144 UNIPROID TIE2_HUMAN T92144 TARGNAME Angiopoietin 1 receptor (TEK) T92144 GENENAME TEK T92144 TARGTYPE Clinical trial T92144 SYNONYMS hTIE2; VMCM1; VMCM; Tyrosine-protein kinase receptor TIE-2; Tyrosine-protein kinase receptor TEK; Tyrosine kinase with Ig and EGF homology domains-2; Tunica interna endothelial cell kinase; TIE2; P140 TEK; Endothelial tyrosine kinase; Endothelial Cell-Specific Receptor TIE-2; CD202b antigen; CD202b T92144 FUNCTION Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1. Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. T92144 PDBSTRUC 6MWE; 5UTK; 5MYB; 5MYA; 4X3J T92144 BIOCLASS Kinase T92144 ECNUMBER EC 2.7.10.1 T92144 SEQUENCE MDSLASLVLCGVSLLLSGTVEGAMDLILINSLPLVSDAETSLTCIASGWRPHEPITIGRDFEALMNQHQDPLEVTQDVTREWAKKVVWKREKASKINGAYFCEGRVRGEAIRIRTMKMRQQASFLPATLTMTVDKGDNVNISFKKVLIKEEDAVIYKNGSFIHSVPRHEVPDILEVHLPHAQPQDAGVYSARYIGGNLFTSAFTRLIVRRCEAQKWGPECNHLCTACMNNGVCHEDTGECICPPGFMGRTCEKACELHTFGRTCKERCSGQEGCKSYVFCLPDPYGCSCATGWKGLQCNEACHPGFYGPDCKLRCSCNNGEMCDRFQGCLCSPGWQGLQCEREGIQRMTPKIVDLPDHIEVNSGKFNPICKASGWPLPTNEEMTLVKPDGTVLHPKDFNHTDHFSVAIFTIHRILPPDSGVWVCSVNTVAGMVEKPFNISVKVLPKPLNAPNVIDTGHNFAVINISSEPYFGDGPIKSKKLLYKPVNHYEAWQHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTASIGLPPPRGLNLLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSVLLNNLHPREQYVVRARVNTKAQGEWSEDLTAWTLSDILPPQPENIKISNITHSSAVISWTILDGYSISSITIRYKVQGKNEDQHVDVKIKNATITQYQLKGLEPETAYQVDIFAENNIGSSNPAFSHELVTLPESQAPADLGGGKMLLIAILGSAGMTCLTVLLAFLIILQLKRANVQRRMAQAFQNVREEPAVQFNSGTLALNRKVKNNPDPTIYPVLDWNDIKFQDVIGEGNFGQVLKARIKKDGLRMDAAIKRMKEYASKDDHRDFAGELEVLCKLGHHPNIINLLGACEHRGYLYLAIEYAPHGNLLDFLRKSRVLETDPAFAIANSTASTLSSQQLLHFAADVARGMDYLSQKQFIHRDLAARNILVGENYVAKIADFGLSRGQEVYVKKTMGRLPVRWMAIESLNYSVYTTNSDVWSYGVLLWEIVSLGGTPYCGMTCAELYEKLPQGYRLEKPLNCDDEVYDLMRQCWREKPYERPSFAQILVSLNRMLEERKTYVNTTLYEKFTYAGIDCSAEEAA T92144 DRUGINFO D08VIS AKB-9778 Phase 2 T92144 DRUGINFO D0E0NM DCC-2036 Phase 1/2 T92144 DRUGINFO D0FD6D CEP-11981 Phase 1 T92144 DRUGINFO D0FA6S Altiratinib Phase 1 T92144 DRUGINFO D0ML0L ARRY-614 Discontinued in Phase 1 T92144 DRUGINFO D0K5QY AP-101 Investigative T92144 DRUGINFO D1JS9X ABTAA Investigative T92144 DRUGINFO D07AIB (4-Phenoxy-phenyl)-quinazolin-4-yl-amine Investigative T92144 DRUGINFO D0BS6R A-420983 Investigative T92144 DRUGINFO D02BXJ PMID21561767C8h Investigative T92144 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T92144 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T92144 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T92144 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T23995 TARGETID T23995 T23995 FORMERID TTDC00178 T23995 UNIPROID KPCT_HUMAN T23995 TARGNAME Protein kinase C theta (PRKCQ) T23995 GENENAME PRKCQ T23995 TARGTYPE Clinical trial T23995 SYNONYMS Protein kinase C theta type; PRKCT; NPKC-theta T23995 FUNCTION In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates in the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response. Upon TCR stimulation, mediates T-cell protective survival signal by phosphorylating BAD, thus protecting T-cells from BAD-induced apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF-kappa-B and JUN pathways. In platelets, regulates signal transduction downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, playing a positive role in 'outside-in' signaling and granule secretion signal transduction. May relay signals from the activated ITGA2B receptor by regulating the uncoupling of WASP and WIPF1, thereby permitting the regulation of actin filament nucleation and branching activity of the Arp2/3 complex. May mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1, which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at 'Ser-504' and 'Ser-532' and negatively regulates its ability to phosphorylate PKB/AKT1. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. T23995 PDBSTRUC 5F9E; 4RA5; 4Q9Z; 2JED; 2ENZ T23995 BIOCLASS Kinase T23995 ECNUMBER EC 2.7.11.13 T23995 SEQUENCE MSPFLRIGLSNFDCGSCQSCQGEAVNPYCAVLVKEYVESENGQMYIQKKPTMYPPWDSTFDAHINKGRVMQIIVKGKNVDLISETTVELYSLAERCRKNNGKTEIWLELKPQGRMLMNARYFLEMSDTKDMNEFETEGFFALHQRRGAIKQAKVHHVKCHEFTATFFPQPTFCSVCHEFVWGLNKQGYQCRQCNAAIHKKCIDKVIAKCTGSAINSRETMFHKERFKIDMPHRFKVYNYKSPTFCEHCGTLLWGLARQGLKCDACGMNVHHRCQTKVANLCGINQKLMAEALAMIESTQQARCLRDTEQIFREGPVEIGLPCSIKNEARPPCLPTPGKREPQGISWESPLDEVDKMCHLPEPELNKERPSLQIKLKIEDFILHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDDDVECTMVEKRVLSLAWEHPFLTHMFCTFQTKENLFFVMEYLNGGDLMYHIQSCHKFDLSRATFYAAEIILGLQFLHSKGIVYRDLKLDNILLDKDGHIKIADFGMCKENMLGDAKTNTFCGTPDYIAPEILLGQKYNHSVDWWSFGVLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPRWLEKEAKDLLVKLFVREPEKRLGVRGDIRQHPLFREINWEELERKEIDPPFRPKVKSPFDCSNFDKEFLNEKPRLSFADRALINSMDQNMFRNFSFMNPGMERLIS T23995 DRUGINFO D0F5HB Sotrastaurin acetate Phase 2 T23995 DRUGINFO D0J7CE CDE-6960 Terminated T23995 DRUGINFO D0X0HN LY-317644 Terminated T23995 DRUGINFO D0R5ZR RO-320432 Terminated T23995 DRUGINFO D05BHG Phosphonothreonine Investigative T23995 DRUGINFO D00TWA [2,2':5',2'']Terthiophen-4-yl-methanol Investigative T23995 DRUGINFO D02PUV 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol Investigative T23995 DRUGINFO D02QME 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile Investigative T23995 DRUGINFO D05LRV [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde Investigative T23995 DRUGINFO D09TSC Ro-32-0557 Investigative T23995 DRUGINFO D09XIE 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile Investigative T23995 DRUGINFO D0A8MN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile Investigative T23995 DRUGINFO D0D3MR [2,2':5',2'']Terthiophene-4-carbaldehyde Investigative T23995 DRUGINFO D0Q3GQ 4-cycloheptyliden(4-hydroxyphenyl)methylphenol Investigative T23995 DRUGINFO D0S9UK 2,3,3-Triphenyl-acrylonitrile Investigative T23995 DRUGINFO D0T0UH 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile Investigative T23995 DRUGINFO D0V9SW 4-cyclohexyliden(4-hydroxyphenyl)methylphenol Investigative T23995 DRUGINFO D07PZQ L-serine-O-phosphate Investigative T23995 DRUGINFO D06ZCX LY-326449 Investigative T23995 DRUGINFO D0L8HO RO-316233 Investigative T44861 TARGETID T44861 T44861 FORMERID TTDNC00553 T44861 UNIPROID KPCD_HUMAN T44861 TARGNAME Protein kinase C delta (PRKCD) T44861 GENENAME PRKCD T44861 TARGTYPE Clinical trial T44861 SYNONYMS nPKC-delta; Tyrosine-protein kinase PRKCD; SDK1; Protein kinase C delta type catalytic subunit; Protein kinase C delta type; PKC-delta T44861 FUNCTION Negatively regulates B cell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and apoptosis. In response to oxidative stress, interact with and activate CHUK/IKKA in the nucleus, causing the phosphorylation of p53/TP53. In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53/TP53. In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2/M DNA damage checkpoint activation. Can protect glioma cells from the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1. Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by direct phosphorylation and activation of NCF1 or indirectly through MAPK1/3 (ERK1/2) signaling pathways. May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA. In collagen-induced platelet aggregation, acts a negative regulator of filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation. Downstream of PAR1, PAR4 and CD36/GP4 receptors, regulates differentially platelet dense granule secretion; acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion. Phosphorylates ELAVL1 in response to angiotensin-2 treatment. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses. T44861 PDBSTRUC 2YUU; 1YRK T44861 BIOCLASS Kinase T44861 ECNUMBER EC 2.7.11.13 T44861 SEQUENCE MAPFLRIAFNSYELGSLQAEDEANQPFCAVKMKEALSTERGKTLVQKKPTMYPEWKSTFDAHIYEGRVIQIVLMRAAEEPVSEVTVGVSVLAERCKKNNGKAEFWLDLQPQAKVLMSVQYFLEDVDCKQSMRSEDEAKFPTMNRRGAIKQAKIHYIKNHEFIATFFGQPTFCSVCKDFVWGLNKQGYKCRQCNAAIHKKCIDKIIGRCTGTAANSRDTIFQKERFNIDMPHRFKVHNYMSPTFCDHCGSLLWGLVKQGLKCEDCGMNVHHKCREKVANLCGINQKLLAEALNQVTQRASRRSDSASSEPVGIYQGFEKKTGVAGEDMQDNSGTYGKIWEGSSKCNINNFIFHKVLGKGSFGKVLLGELKGRGEYFAIKALKKDVVLIDDDVECTMVEKRVLTLAAENPFLTHLICTFQTKDHLFFVMEFLNGGDLMYHIQDKGRFELYRATFYAAEIMCGLQFLHSKGIIYRDLKLDNVLLDRDGHIKIADFGMCKENIFGESRASTFCGTPDYIAPEILQGLKYTFSVDWWSFGVLLYEMLIGQSPFHGDDEDELFESIRVDTPHYPRWITKESKDILEKLFEREPTKRLGVTGNIKIHPFFKTINWTLLEKRRLEPPFRPKVKSPRDYSNFDQEFLNEKARLSYSDKNLIDSMDQSAFAGFSFVNPKFEHLLED T44861 DRUGINFO D0O6HP KAI-9803 Phase 1/2 T44861 DRUGINFO D04VPV AD 198 Terminated T44861 DRUGINFO D0X0HN LY-317644 Terminated T44861 DRUGINFO D0R5ZR RO-320432 Terminated T44861 DRUGINFO D02KPV Phorbol 12,13-butyrate Investigative T44861 DRUGINFO D0G3BJ Ingenol-3-bezoate Investigative T44861 DRUGINFO D0J1SA 13-Acetylphorbol Investigative T44861 DRUGINFO D0K5ZY INDOLACTUM Investigative T44861 DRUGINFO D0M3UR THYMELEATOXIN Investigative T44861 DRUGINFO D00TWA [2,2':5',2'']Terthiophen-4-yl-methanol Investigative T44861 DRUGINFO D02PUV 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol Investigative T44861 DRUGINFO D02QME 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile Investigative T44861 DRUGINFO D05LRV [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde Investigative T44861 DRUGINFO D09TSC Ro-32-0557 Investigative T44861 DRUGINFO D09XIE 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile Investigative T44861 DRUGINFO D0A8MN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile Investigative T44861 DRUGINFO D0D3MR [2,2':5',2'']Terthiophene-4-carbaldehyde Investigative T44861 DRUGINFO D0Q3GQ 4-cycloheptyliden(4-hydroxyphenyl)methylphenol Investigative T44861 DRUGINFO D0S9UK 2,3,3-Triphenyl-acrylonitrile Investigative T44861 DRUGINFO D0T0UH 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile Investigative T44861 DRUGINFO D0V9SW 4-cyclohexyliden(4-hydroxyphenyl)methylphenol Investigative T44861 DRUGINFO D04JNZ PROSTRATIN Investigative T44861 DRUGINFO D06ZCX LY-326449 Investigative T44861 DRUGINFO D0L8HO RO-316233 Investigative T10265 TARGETID T10265 T10265 FORMERID TTDR00466 T10265 UNIPROID PDE4B_HUMAN T10265 TARGNAME Phosphodiesterase 4B (PDE4B) T10265 GENENAME PDE4B T10265 TARGTYPE Clinical trial T10265 SYNONYMS cAMP-specific 3',5'-cyclic phosphodiesterase 4B; Type 4B cAMP phosphodiesterase; Type 4 cyclic adenosine monophosphate phosphodiesterase (type 4 PDE); PDE32; DPDE4 T10265 FUNCTION May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents. Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. T10265 PDBSTRUC 6BOJ; 5OHJ; 5LAQ; 5K6J; 4X0F T10265 BIOCLASS Phosphoric diester hydrolase T10265 ECNUMBER EC 3.1.4.53 T10265 SEQUENCE MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNLQLPPLSQRQSERARTPEGDGISRPTTLPLTTLPSIAITTVSQECFDVENGPSPGRSPLDPQASSSAGLVLHATFPGHSQRRESFLYRSDSDYDLSPKAMSRNSSLPSEQHGDDLIVTPFAQVLASLRSVRNNFTILTNLHGTSNKRSPAASQPPVSRVNPQEESYQKLAMETLEELDWCLDQLETIQTYRSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKKKQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGLNIFNVAGYSHNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYHSDVAYHNSLHAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTKKQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYTDRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRNWYQSMIPQSPSPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGEGHSYFSSTKTLCVIDPENRDSLGETDIDIATEDKSPVDT T10265 DRUGINFO D02EOZ BI 1015550 Phase 3 T10265 DRUGINFO D01XHG DENBUFYLLINE Phase 3 T10265 DRUGINFO D06VFP SOTB07 Phase 3 T10265 DRUGINFO D00JED AN-2898 Phase 2 T10265 DRUGINFO D01XFZ GPD-1116 Phase 2 T10265 DRUGINFO D02POH TA-7906 Phase 2 T10265 DRUGINFO D07OCV HT-0712 Phase 2 T10265 DRUGINFO D09TFB TOFIMILAST Phase 2 T10265 DRUGINFO D0F4TV AWD-12-281 Phase 2 T10265 DRUGINFO D0F5IY LIRIMILAST Phase 2 T10265 DRUGINFO D0L8KJ Oglemilast Phase 2 T10265 DRUGINFO D0M7CB MK-0873 Phase 2 T10265 DRUGINFO D0RJ1W OX-914 Phase 2 T10265 DRUGINFO D0U2DH CC-1088 Phase 2 T10265 DRUGINFO D0X0PW Revamilast Phase 2 T10265 DRUGINFO D0Z2FB Piclamilast Phase 2 T10265 DRUGINFO D01WZL AVE-8112 Phase 1 T10265 DRUGINFO D03CWX MEM-1414 Phase 1 T10265 DRUGINFO D0K9DI GSK-356278 Phase 1 T10265 DRUGINFO D0O8JW Ronomilast Phase 1 T10265 DRUGINFO D0H9KW Filaminast Discontinued in Phase 2 T10265 DRUGINFO D00DBE CI-1018 Discontinued in Phase 2 T10265 DRUGINFO D03ZVD KW-4490 Discontinued in Phase 2 T10265 DRUGINFO D08SNX V-11294A Discontinued in Phase 2 T10265 DRUGINFO D0I0GM Daxalipram Discontinued in Phase 2 T10265 DRUGINFO D0UG4T CDP840 Discontinued in Phase 2 T10265 DRUGINFO D0V2CN LAS-37779 Discontinued in Phase 2 T10265 DRUGINFO D01FXD SCH-351591 Discontinued in Phase 1 T10265 DRUGINFO D0C7JT YM-976 Discontinued in Phase 1 T10265 DRUGINFO D0K1OA D-4418 Discontinued in Phase 1 T10265 DRUGINFO D01OUA TJN-598 Terminated T10265 DRUGINFO D01QUF GW-3600 Terminated T10265 DRUGINFO D07UHY NIK-616 Terminated T10265 DRUGINFO D0F7TV Torbafylline Terminated T10265 DRUGINFO D0R1QJ D-22888 Terminated T10265 DRUGINFO D06PUS 3-(2-Bromophenyl)-2-thioxo-(1H )-quinazolin-4-one Investigative T10265 DRUGINFO D0R5ZH 8-Bromo-Adenosine-5'-Monophosphate Investigative T10265 DRUGINFO D02NKD 8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine Investigative T10265 DRUGINFO D02NWF Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine Investigative T10265 DRUGINFO D09AUL Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine Investigative T10265 DRUGINFO D0DL6J CI-1044 Investigative T10265 DRUGINFO D0O3BL RS-14491 Investigative T10265 DRUGINFO D0V5BX NITRAQUAZONE Investigative T10265 DRUGINFO D01RUN (R)-Rolipram Investigative T10265 DRUGINFO D01TOR Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine Investigative T10265 DRUGINFO D02FZD (S)-Rolipram Investigative T10265 DRUGINFO D04BMR AL-59640 Investigative T10265 DRUGINFO D04JNC ZL-N-91 Investigative T10265 DRUGINFO D05YEL CH-3697 Investigative T10265 DRUGINFO D0E5VP KF-66490 Investigative T10265 DRUGINFO D0J7GF Benzyl-(2-phenyl-quinazolin-4-yl)-amine Investigative T10265 DRUGINFO D0JD4C L-454560 Investigative T10265 DRUGINFO D0K9PS CHF-5480 Investigative T10265 DRUGINFO D0N7HS ASP-3258 Investigative T10265 DRUGINFO D0S1HX TAS-203 Investigative T10265 DRUGINFO D0S6MA OCID-2987 Investigative T10265 DRUGINFO D0U4SS CD-160130 Investigative T10265 DRUGINFO D0U8YQ Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine Investigative T10265 DRUGINFO D0W7WV L-869298 Investigative T10265 DRUGINFO D00QCL SOPHOFLAVESCENOL Investigative T10265 DRUGINFO D02ZPV UCB-101333-3 Investigative T10265 DRUGINFO D0P2HX RS-25344 Investigative T10265 DRUGINFO D0T5PO ROLIPRAM Investigative T10265 DRUGINFO D0W4ZU KURARINOL Investigative T10265 DRUGINFO D06GUJ KURAIDIN Investigative T10265 DRUGINFO D0P7JE S,S-(2-Hydroxyethyl)Thiocysteine Investigative T10265 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T69912 TARGETID T69912 T69912 FORMERID TTDC00116 T69912 UNIPROID PAFA_HUMAN T69912 TARGNAME Platelet-activating factor acetylhydrolase (PLA2G7) T69912 GENENAME PLA2G7 T69912 TARGTYPE Clinical trial T69912 SYNONYMS gVIIA-PLA2; PAFAH; PAF acetylhydrolase; PAF 2-acylhydrolase; Lipoprotein-associated phospholipase A2; LDL-associated phospholipase A2; LDL-PLA(2); Group-VIIA phospholipase A2; 2-acetyl-1-alkylglycerophosphocholine esterase; 1-alkyl-2-acetylglycerophosphocholine esterase T69912 FUNCTION Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. T69912 PDBSTRUC 5YEA; 5YE9; 5YE8; 5YE7; 5LZ9 T69912 BIOCLASS Carboxylic ester hydrolase T69912 ECNUMBER EC 3.1.1.47 T69912 SEQUENCE MVPPKLHVLFCLCGCLAVVYPFDWQYINPVAHMKSSAWVNKIQVLMAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHIMLQNSSGIEKYN T69912 DRUGINFO D0E6KN GSK2647544 Phase 1 T69912 DRUGINFO D05GZD Rilapladib Phase 1 T69912 DRUGINFO D0N8BA Bicyclic pyrimidine derivative 2 Patented T69912 DRUGINFO D00CKV Indolizine derivative 1 Patented T69912 DRUGINFO D0AK5G RPAF-AH Discontinued in Phase 3 T69912 DRUGINFO D0CA3J GSK568859 Discontinued in Phase 1 T69912 DRUGINFO D0MC3R Goxalapladib Discontinued in Phase 1 T69912 DRUGINFO D0A1SO Benzaldehyde O-benzoyloxime Investigative T69912 DRUGINFO D0D7AS (E)-(thiophen-2-ylmethylidene)amino benzoate Investigative T69912 DRUGINFO D0JI8S 3,4-difluorobenzaldehyde O-benzoyloxime Investigative T69912 DRUGINFO D0WW7A SB-381320 Investigative T69912 DRUGINFO D0X6UV 4-fluorobenzaldehyde O-benzoyloxime Investigative T69912 DRUGINFO D0Y8RM (1r)-1,2,2-trimethylpropyl (r)-methylphosphinate Investigative T55729 TARGETID T55729 T55729 FORMERID TTDR00352 T55729 UNIPROID MK11_HUMAN T55729 TARGNAME Stress-activated protein kinase 2b (p38 beta) T55729 GENENAME MAPK11 T55729 TARGTYPE Clinical trial T55729 SYNONYMS Stress-activated protein kinase-2; SAPK2b; SAPK2; PRKM11; P38b; P38-2; P38 Mitogen-activated protein kinase beta; Mitogen-activated protein kinase p38 beta; Mitogen-activated protein kinase 11; MAPK 11; MAP kinase p38 beta; MAP kinase 11 T55729 FUNCTION MAPK11 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. MAPK11 functions are mostly redundant with those of MAPK14. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Additional examples of p38 MAPK substrates are the FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. T55729 PDBSTRUC 3GP0; 3GC9; 3GC8 T55729 BIOCLASS Kinase T55729 ECNUMBER EC 2.7.11.24 T55729 SEQUENCE MSGPRAGFYRQELNKTVWEVPQRLQGLRPVGSGAYGSVCSAYDARLRQKVAVKKLSRPFQSLIHARRTYRELRLLKHLKHENVIGLLDVFTPATSIEDFSEVYLVTTLMGADLNNIVKCQALSDEHVQFLVYQLLRGLKYIHSAGIIHRDLKPSNVAVNEDCELRILDFGLARQADEEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLQGKALFPGSDYIDQLKRIMEVVGTPSPEVLAKISSEHARTYIQSLPPMPQKDLSSIFRGANPLAIDLLGRMLVLDSDQRVSAAEALAHAYFSQYHDPEDEPEAEPYDESVEAKERTLEEWKELTYQEVLSFKPPEPPKPPGSLEIEQ T55729 DRUGINFO D02NNV VX-745 Phase 2 T55729 DRUGINFO D0W0AM SB 235699 Discontinued in Phase 1 T55729 DRUGINFO D06NUL RWJ-68354 Investigative T55729 DRUGINFO D09HBZ ML-3375 Investigative T55729 DRUGINFO D0W4FF ML-3403 Investigative T55729 DRUGINFO D06WJA L-779450 Investigative T55729 DRUGINFO D08DSJ ML-3163 Investigative T55729 DRUGINFO D0G2VC KT-5720 Investigative T55729 DRUGINFO D0GB4V STAUROSPORINONE Investigative T55729 DRUGINFO D0M5FF Ro31-8220 Investigative T55729 DRUGINFO D0N6ES KN-62 Investigative T55729 DRUGINFO D0B9BU CI-1040 Investigative T55729 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T55729 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T55729 DRUGINFO D0L8HO RO-316233 Investigative T12119 TARGETID T12119 T12119 FORMERID TTDS00503 T12119 UNIPROID SCN9A_HUMAN T12119 TARGNAME Voltage-gated sodium channel alpha Nav1.7 (SCN9A) T12119 GENENAME SCN9A T12119 TARGTYPE Clinical trial T12119 SYNONYMS hNE-Na; Voltage-gated sodium channel subunit alpha Nav1.7; Sodium channel proteintype IX subunit alpha; Sodium channel proteintype 9 subunit alpha; Sodium channel protein type IX subunit alpha; Sodium channel protein type 9 subunit alpha; Peripheral sodium channel 1; PN1; Neuroendocrine sodium channel; NENA T12119 FUNCTION Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-sensitive Na(+) channel isoform. Plays a role in pain mechanisms, especially in the development of inflammatory pain. Mediates the voltage-dependent sodium ion permeability of excitable membranes. T12119 PDBSTRUC 6NT4; 6NT3; 6N4R; 6N4Q; 6J8J T12119 BIOCLASS Voltage-gated ion channel T12119 SEQUENCE MAMLPPPGPQSFVHFTKQSLALIEQRIAERKSKEPKEEKKDDDEEAPKPSSDLEAGKQLPFIYGDIPPGMVSEPLEDLDPYYADKKTFIVLNKGKTIFRFNATPALYMLSPFSPLRRISIKILVHSLFSMLIMCTILTNCIFMTMNNPPDWTKNVEYTFTGIYTFESLVKILARGFCVGEFTFLRDPWNWLDFVVIVFAYLTEFVNLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLKHKCFRNSLENNETLESIMNTLESEEDFRKYFYYLEGSKDALLCGFSTDSGQCPEGYTCVKIGRNPDYGYTSFDTFSWAFLALFRLMTQDYWENLYQQTLRAAGKTYMIFFVVVIFLGSFYLINLILAVVAMAYEEQNQANIEEAKQKELEFQQMLDRLKKEQEEAEAIAAAAAEYTSIRRSRIMGLSESSSETSKLSSKSAKERRNRRKKKNQKKLSSGEEKGDAEKLSKSESEDSIRRKSFHLGVEGHRRAHEKRLSTPNQSPLSIRGSLFSARRSSRTSLFSFKGRGRDIGSETEFADDEHSIFGDNESRRGSLFVPHRPQERRSSNISQASRSPPMLPVNGKMHSAVDCNGVVSLVDGRSALMLPNGQLLPEVIIDKATSDDSGTTNQIHKKRRCSSYLLSEDMLNDPNLRQRAMSRASILTNTVEELEESRQKCPPWWYRFAHKFLIWNCSPYWIKFKKCIYFIVMDPFVDLAITICIVLNTLFMAMEHHPMTEEFKNVLAIGNLVFTGIFAAEMVLKLIAMDPYEYFQVGWNIFDSLIVTLSLVELFLADVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKINDDCTLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLIVYMMVMVIGNLVVLNLFLALLLSSFSSDNLTAIEEDPDANNLQIAVTRIKKGINYVKQTLREFILKAFSKKPKISREIRQAEDLNTKKENYISNHTLAEMSKGHNFLKEKDKISGFGSSVDKHLMEDSDGQSFIHNPSLTVTVPIAPGESDLENMNAEELSSDSDSEYSKVRLNRSSSSECSTVDNPLPGEGEEAEAEPMNSDEPEACFTDGCVWRFSCCQVNIESGKGKIWWNIRKTCYKIVEHSWFESFIVLMILLSSGALAFEDIYIERKKTIKIILEYADKIFTYIFILEMLLKWIAYGYKTYFTNAWCWLDFLIVDVSLVTLVANTLGYSDLGPIKSLRTLRALRPLRALSRFEGMRVVVNALIGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYECINTTDGSRFPASQVPNRSECFALMNVSQNVRWKNLKVNFDNVGLGYLSLLQVATFKGWTIIMYAAVDSVNVDKQPKYEYSLYMYIYFVVFIIFGSFFTLNLFIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKIQGCIFDLVTNQAFDISIMVLICLNMVTMMVEKEGQSQHMTEVLYWINVVFIILFTGECVLKLISLRHYYFTVGWNIFDFVVVIISIVGMFLADLIETYFVSPTLFRVIRLARIGRILRLVKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKKEDGINDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSKPPDCDPKKVHPGSSVEGDCGNPSVGIFYFVSYIIISFLVVVNMYIAVILENFSVATEESTEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALDPPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDSLRSQMEERFMSANPSKVSYEPITTTLKRKQEDVSATVIQRAYRRYRLRQNVKNISSIYIKDGDRDDDLLNKKDMAFDNVNENSSPEKTDATSSTTSPPSYDSVTKPDKEKYEQDRTEKEDKGKDSKESKK T12119 DRUGINFO D04PER XEN-402 Phase 2 T12119 DRUGINFO D0O7QA PF-05089771 Phase 2 T12119 DRUGINFO D0OX9F BIIB074 Phase 2 T12119 DRUGINFO D00FSB BIIB095 Phase 1 T12119 DRUGINFO D01FZZ GDC0310 Phase 1 T12119 DRUGINFO D09INX DSP-3905 Phase 1 T12119 DRUGINFO D0BT0Z PF-05241328 Phase 1 T12119 DRUGINFO D0G0ER DWJ-208 Phase 1 T12119 DRUGINFO D0PB0U RG7893 Phase 1 T12119 DRUGINFO D0SD3E PF-05186462 Phase 1 T12119 DRUGINFO D0XO1O CC8464 Phase 1 T12119 DRUGINFO D0VE7B DSP-2230 Phase 1 T12119 DRUGINFO D01RJL Cyclopropyl-spiro piperidine derivative 4 Patented T12119 DRUGINFO D02GCY Cyclopropyl-spiro piperidine derivative 3 Patented T12119 DRUGINFO D06QWY Benzene sulfonamide derivative 9 Patented T12119 DRUGINFO D07NQG Methylsulfonylbenzamide derivative 2 Patented T12119 DRUGINFO D0D8NX Cyclopropyl-spiro piperidine derivative 1 Patented T12119 DRUGINFO D0E9ZW Tarizine derivative 1 Patented T12119 DRUGINFO D0I0MT Aryl carboxamide derivative 4 Patented T12119 DRUGINFO D0OX5S Cyclopropyl-spiro piperidine derivative 2 Patented T12119 DRUGINFO D0TA8W Benzene sulfonamide derivative 11 Patented T12119 DRUGINFO D0VY1Y Benzene sulfonamide derivative 12 Patented T12119 DRUGINFO D0W6ZS Pyrrolo-benzo-diazine derivative 1 Patented T12119 DRUGINFO D0XJ0B Enzoxazolinone sulfonamide derivative 1 Patented T12119 DRUGINFO D0Y7MC Benzene sulfonamide derivative 15 Patented T12119 DRUGINFO D03GPV Pyrimidine derivative 1 Patented T12119 DRUGINFO D06VYB Pyrrolo-pyridinone derivative 6 Patented T12119 DRUGINFO D09YJV Pyrrolo-pyridinone derivative 5 Patented T12119 DRUGINFO D0UL0K Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 Patented T12119 DRUGINFO D0M8WO Aryl carboxamide derivative 1 Patented T12119 DRUGINFO D0OP5F Aryl carboxamide derivative 2 Patented T12119 DRUGINFO D08FZT Corus 1030 Discontinued in Phase 2 T12119 DRUGINFO D0EC2K SIPATRIGINE Discontinued in Phase 2 T12119 DRUGINFO D07EQF V-102862 Discontinued in Phase 1 T12119 DRUGINFO D00TGC N-Me-aminopyrimidinone 9 Investigative T12119 DRUGINFO D02HMZ 4-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole Investigative T12119 DRUGINFO D02PZJ 4-(2'-(trifluoromethoxy)biphenyl-3-yl)oxazole Investigative T12119 DRUGINFO D0F5MZ 4-(2'-(trifluoromethyl)biphenyl-3-yl)oxazole Investigative T12119 DRUGINFO D0M1OU XEN-907 Investigative T12119 DRUGINFO D0R8KA pyrrolopyrimidine 48 Investigative T12119 DRUGINFO D0G9WE batrachotoxin Investigative T12119 DRUGINFO D0S4MN veratridine Investigative T65864 TARGETID T65864 T65864 FORMERID TTDC00201 T65864 UNIPROID MK14_HUMAN T65864 TARGNAME Stress-activated protein kinase 2a (p38 alpha) T65864 GENENAME MAPK14 T65864 TARGTYPE Clinical trial T65864 SYNONYMS SAPK2A; P38 mitogen activatedprotein kinase; P38 Mitogen-activatedprotein kinase alpha; Mitogen-activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; MXI2; MAX-interacting protein 2; MAPK 14; MAP kinase p38alpha; MAP kinase p38 alpha; MAP kinase MXI2; MAP kinase 14; Cytokine suppressive anti-inflammatory drug-binding protein; Cytokine suppressive anti-inflammatory drug binding protein; CSPB1; CSBP2; CSBP1; CSBP; CSAID-binding protein; CSAID binding protein; CRK1 T65864 FUNCTION MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. MAPK14 interacts also with casein kinase II, leading to its activation through autophosphorylation and further phosphorylation of TP53/p53. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin ligase SIAH2, regulating its activity towards EGLN3. MAPK14 may also inhibit the lysosomal degradation pathway of autophagy by interfering with the intracellular trafficking of the transmembrane protein ATG9. Another function of MAPK14 is to regulate the endocytosis of membrane receptors by different mechanisms that impinge on the small GTPase RAB5A. In addition, clathrin-mediated EGFR internalization induced by inflammatory cytokines and UV irradiation depends on MAPK14-mediated phosphorylation of EGFR itself as well as of RAB5A effectors. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required for binding to 14-3-3 proteins and leads to initiation of a G2 delay after ultraviolet radiation. Phosphorylates TIAR following DNA damage, releasing TIAR from GADD45A mRNA and preventing mRNA degradation. The p38 MAPKs may also have kinase-independent roles, which are thought to be due to the binding to targets in the absence of phosphorylation. Protein O-Glc-N-acylation catalyzed by the OGT is regulated by MAPK14, and, although OGT does not seem to be phosphorylated by MAPK14, their interaction increases upon MAPK14 activation induced by glucose deprivation. This interaction may regulate OGT activity by recruiting it to specific targets such as neurofilament H, stimulating its O-Glc-N-acylation. Required in mid-fetal development for the growth of embryo-derived blood vessels in the labyrinth layer of the placenta. Also plays an essential role in developmental and stress-induced erythropoiesis, through regulation of EPO gene expression. Isoform MXI2 activation is stimulated by mitogens and oxidative stress and only poorly phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early onset of apoptosis. Phosphorylates S100A9 at 'Thr-113'. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. T65864 PDBSTRUC 6M9L; 6M95; 6HWV; 6HWU; 6HWT T65864 BIOCLASS Kinase T65864 ECNUMBER EC 2.7.11.24 T65864 SEQUENCE MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES T65864 DRUGINFO D0C7AA Ozagrel Phase 4 T65864 DRUGINFO D0C8DD Losmapimod Phase 3 T65864 DRUGINFO D0D9AH VX-702 Phase 2a T65864 DRUGINFO D0K0JQ Dilmapimod Phase 2 T65864 DRUGINFO D02NNV VX-745 Phase 2 T65864 DRUGINFO D03JFK PMID25991433-Compound-O2 Patented T65864 DRUGINFO D08OJQ PMID25991433-Compound-L2 Patented T65864 DRUGINFO D0G7LB PMID25991433-Compound-L3 Patented T65864 DRUGINFO D0Q8CR PMID25991433-Compound-L1 Patented T65864 DRUGINFO D06JRV PMID25991433-Compound-F2 Patented T65864 DRUGINFO D0H4HD PMID25991433-Compound-A1 Patented T65864 DRUGINFO D04WCI PAMAPIMOD Discontinued in Phase 2 T65864 DRUGINFO D04YHW R-1487 Discontinued in Phase 1 T65864 DRUGINFO D05QMG FR167653 Discontinued in Phase 1 T65864 DRUGINFO D0A9KI SB-242235 Discontinued in Phase 1 T65864 DRUGINFO D0W0AM SB 235699 Discontinued in Phase 1 T65864 DRUGINFO D0O7BW SC-102 Terminated T65864 DRUGINFO D09ICC SB220025 Terminated T65864 DRUGINFO D0F8DL SB 203580 Terminated T65864 DRUGINFO D00ODN 9-Benzyl-6-phenylsulfanyl-9H-purine Investigative T65864 DRUGINFO D00PPB N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide Investigative T65864 DRUGINFO D00YRF UCB-1277763 Investigative T65864 DRUGINFO D01CRK Small molecule 34 Investigative T65864 DRUGINFO D02NKV SB-218655 Investigative T65864 DRUGINFO D03XYK 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine Investigative T65864 DRUGINFO D04CRB 6-Phenylsulfanyl-9H-purine Investigative T65864 DRUGINFO D04HWF Talmapimod Investigative T65864 DRUGINFO D07TTR N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide Investigative T65864 DRUGINFO D08BIP Dihydro-quinolinone Investigative T65864 DRUGINFO D08WFC (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone Investigative T65864 DRUGINFO D09GQO 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE Investigative T65864 DRUGINFO D09OKU PMID22521646C12 Investigative T65864 DRUGINFO D09XVY N-(4-methyl-benzyl)-4-phenoxy-benzamide Investigative T65864 DRUGINFO D09ZZI 2-Chlorophenol Investigative T65864 DRUGINFO D0DK2X GSK-280 Investigative T65864 DRUGINFO D0E4LU SB-216995 Investigative T65864 DRUGINFO D0H8RU N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide Investigative T65864 DRUGINFO D0L1NU PHA-666859 Investigative T65864 DRUGINFO D0L3DF 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine Investigative T65864 DRUGINFO D0M2OL SB-227931 Investigative T65864 DRUGINFO D0N9HX N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide Investigative T65864 DRUGINFO D0Q8HM 6-(4-Fluoro-phenylsulfanyl)-9H-purine Investigative T65864 DRUGINFO D0QS9T 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE Investigative T65864 DRUGINFO D0S4BP DP-802 Investigative T65864 DRUGINFO D0S6GE Ro-3201195 Investigative T65864 DRUGINFO D0S9SX 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine Investigative T65864 DRUGINFO D0X5CM Triazolopyridine Investigative T65864 DRUGINFO D09DRF 3-(Benzyloxy)Pyridin-2-Amine Investigative T65864 DRUGINFO D0BH7S 6-Benzylsulfanyl-9H-purine Investigative T65864 DRUGINFO D0H2PE Phenyl-(3-phenyl-1H-indazol-6-yl)-amine Investigative T65864 DRUGINFO D0K6YK IN-1130 Investigative T65864 DRUGINFO D0M3CT 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine Investigative T65864 DRUGINFO D0ZH1U Tyrphostin ag-1478 Investigative T65864 DRUGINFO D06NUL RWJ-68354 Investigative T65864 DRUGINFO D0C3AD GW-788388 Investigative T65864 DRUGINFO D0H6ZP IN-1166 Investigative T65864 DRUGINFO D0VC0I Oxindole 94 Investigative T65864 DRUGINFO D00NWF ZM-336372 Investigative T65864 DRUGINFO D09HBZ ML-3375 Investigative T65864 DRUGINFO D09HXU 6-o-tolylquinazolin-2-amine Investigative T65864 DRUGINFO D0W4FF ML-3403 Investigative T65864 DRUGINFO D06WJA L-779450 Investigative T65864 DRUGINFO D08DSJ ML-3163 Investigative T65864 DRUGINFO D0G2VC KT-5720 Investigative T65864 DRUGINFO D0GW4Q PD-0173956 Investigative T65864 DRUGINFO D0P3JW PD-0166326 Investigative T65864 DRUGINFO D0GB4V STAUROSPORINONE Investigative T65864 DRUGINFO D0M5FF Ro31-8220 Investigative T65864 DRUGINFO D0N6ES KN-62 Investigative T65864 DRUGINFO D0B9BU CI-1040 Investigative T65864 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T65864 DRUGINFO D02UVH B-Octylglucoside Investigative T65864 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T65864 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T65864 DRUGINFO D0L8HO RO-316233 Investigative T14731 TARGETID T14731 T14731 FORMERID TTDC00052 T14731 UNIPROID SIR1_HUMAN T14731 TARGNAME NAD-dependent deacetylase sirtuin-1 (SIRT1) T14731 GENENAME SIRT1 T14731 TARGTYPE Clinical trial T14731 SYNONYMS hSIRT1; hSIR2; SIR2L1; SIR2-like protein 1; Regulatory protein SIR2 homolog 1; NAD-dependent protein deacetylase sirtuin-1 T14731 FUNCTION Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. Deacetylates a broad range of transcription factors and coregulators, thereby regulating target gene expression positively and negatively. Serves as a sensor of the cytosolic ratio of NAD(+)/NADH which is altered by glucose deprivation and metabolic changes associated with caloric restriction. Is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. Deacetylates 'Lys-266' of SUV39H1, leading to its activation. Inhibits skeletal muscle differentiation by deacetylating PCAF and MYOD1. Deacetylates H2A and 'Lys-26' of HIST1H1E. Deacetylates 'Lys-16' of histone H4 (in vitro). Involved in NR0B2/SHP corepression function through chromatin remodeling: Recruited to LRH1 target gene promoters by NR0B2/SHP thereby stimulating histone H3 and H4 deacetylation leading to transcriptional repression. Proposed to contribute to genomic integrity via positive regulation of telomere length; however, reports on localization to pericentromeric heterochromatin are conflicting. Proposed to play a role in constitutive heterochromatin (CH) formation and/or maintenance through regulation of the available pool of nuclear SUV39H1. Upon oxidative/metabolic stress decreases SUV39H1 degradation by inhibiting SUV39H1 polyubiquitination by MDM2. This increase in SUV39H1 levels enhances SUV39H1 turnover in CH, which in turn seems to accelerate renewal of the heterochromatin which correlates with greater genomic integrity during stress response. Deacetylates 'Lys-382' of p53/TP53 and impairs its ability to induce transcription-dependent proapoptotic program and modulate cell senescence. Deacetylates TAF1B and thereby represses rDNA transcription by the RNA polymerase I. Deacetylates MYC, promotes the association of MYC with MAX and decreases MYC stability leading to compromised transformational capability. Deacetylates FOXO3 in response to oxidative stress thereby increasing its ability to induce cell cycle arrest and resistance to oxidative stress but inhibiting FOXO3-mediated induction of apoptosis transcriptional activity; also leading to FOXO3 ubiquitination and protesomal degradation. Appears to have a similar effect on MLLT7/FOXO4 in regulation of transcriptional activity and apoptosis. Deacetylates DNMT1; thereby impairs DNMT1 methyltransferase-independent transcription repressor activity, modulates DNMT1 cell cycle regulatory function and DNMT1-mediated gene silencing. Deacetylates RELA/NF-kappa-B p65 thereby inhibiting its transactivating potential and augments apoptosis in response to TNF-alpha. Deacetylates HIF1A, KAT5/TIP60, RB1 and HIC1. Deacetylates FOXO1 resulting in its nuclear retention and enhancement of its transcriptional activity leading to increased gluconeogenesis in liver. Inhibits E2F1 transcriptional activity and apoptotic function, possibly by deacetylation. Involved in HES1- and HEY2-mediated transcriptional repression. In cooperation with MYCN seems to be involved in transcriptional repression of DUSP6/MAPK3 leading to MYCN stabilization by phosphorylation at 'Ser-62'. Deacetylates MEF2D. Required for antagonist-mediated transcription suppression of AR-dependent genes which may be linked to local deacetylation of histone H3. Represses HNF1A-mediated transcription. Required for the repression of ESRRG by CREBZF. Deacetylates NR1H3 and NR1H2 and deacetylation of NR1H3 at 'Lys-434' positively regulates transcription of NR1H3:RXR target genes, promotes NR1H3 proteosomal degradation and results in cholesterol efflux; a promoter clearing mechanism after reach round of transcription is proposed. Involved in lipid metabolism. Implicated in regulation of adipogenesis and fat mobilization in white adipocytes by repression of PPARG which probably involves association with NCOR1 and SMRT/NCOR2. Deacetylates p300/EP300 and PRMT1. Deacetylates ACSS2 leading to its activation, and HMGCS1 deacetylation. Involved in liver and muscle metabolism. Through deacteylation and activation of PPARGC1A is required to activate fatty acid oxidation in skeletel muscle under low-glucose conditions and is involved in glucose homeostasis. Involved in regulation of PPARA and fatty acid beta-oxidation in liver. Involved in positive regulation of insulin secretion in pancreatic beta cells in response to glucose; the function seems to imply transcriptional repression of UCP2. Proposed to deacetylate IRS2 thereby facilitating its insulin-induced tyrosine phosphorylation. Deacetylates SREBF1 isoform SREBP-1C thereby decreasing its stability and transactivation in lipogenic gene expression. Involved in DNA damage response by repressing genes which are involved in DNA repair, such as XPC and TP73, deacetylating XRCC6/Ku70, and faciliting recruitment of additional factors to sites of damaged DNA, such as SIRT1-deacetylated NBN can recruit ATM to initiate DNA repair and SIRT1-deacetylated XPA interacts with RPA2. Also involved in DNA repair of DNA double-strand breaks by homologous recombination and specifically single-strand annealing independently of XRCC6/Ku70 and NBN. Transcriptional suppression of XPC probably involves an E2F4:RBL2 suppressor complex and protein kinase B (AKT) signaling. Transcriptional suppression of TP73 probably involves E2F4 and PCAF. Deacetylates WRN thereby regulating its helicase and exonuclease activities and regulates WRN nuclear translocation in response to DNA damage. Deacetylates APEX1 at 'Lys-6' and 'Lys-7' and stimulates cellular AP endonuclease activity by promoting the association of APEX1 to XRCC1. Increases p53/TP53-mediated transcription-independent apoptosis by blocking nuclear translocation of cytoplasmic p53/TP53 and probably redirecting it to mitochondria. Deacetylates XRCC6/Ku70 at 'Lys-539' and 'Lys-542' causing it to sequester BAX away from mitochondria thereby inhibiting stress-induced apoptosis. Is involved in autophagy, presumably by deacetylating ATG5, ATG7 and MAP1LC3B/ATG8. Deacetylates AKT1 which leads to enhanced binding of AKT1 and PDK1 to PIP3 and promotes their activation. Proposed to play role in regulation of STK11/LBK1-dependent AMPK signaling pathways implicated in cellular senescence which seems to involve the regulation of the acetylation status of STK11/LBK1. Can deacetylate STK11/LBK1 and thereby increase its activity, cytoplasmic localization and association with STRAD; however, the relevance of such activity in normal cells is unclear. In endothelial cells is shown to inhibit STK11/LBK1 activity and to promote its degradation. Deacetylates SMAD7 at 'Lys-64' and 'Lys-70' thereby promoting its degradation. Deacetylates CIITA and augments its MHC class II transactivation and contributes to its stability. Deacteylates MECOM/EVI1. Deacetylates PML at 'Lys-487' and this deacetylation promotes PML control of PER2 nuclear localization. During the neurogenic transition, repress selective NOTCH1-target genes through histone deacetylation in a BCL6-dependent manner and leading to neuronal differentiation. Regulates the circadian expression of several core clock genes, including ARNTL/BMAL1, RORC, PER2 and CRY1 and plays a critical role in maintaining a controlled rhythmicity in histone acetylation, thereby contributing to circadian chromatin remodeling. Deacetylates ARNTL/BMAL1 and histones at the circadian gene promoters in order to facilitate repression by inhibitory components of the circadian oscillator. Deacetylates PER2, facilitating its ubiquitination and degradation by the proteosome. Protects cardiomyocytes against palmitate-induced apoptosis. Deacetylates XBP1 isoform 2; deacetylation decreases protein stability of XBP1 isoform 2 and inhibits its transcriptional activity. Deacetylates PCK1 and directs its activity toward phosphoenolpyruvate production promoting gluconeogenesis. Involved in the CCAR2-mediated regulation of PCK1 and NR1D1. Deacetylates CTNB1 at 'Lys-49'. In POMC (pro-opiomelanocortin) neurons, required for leptin-induced activation of PI3K signaling. NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metobolism, apoptosis and autophagy. T14731 PDBSTRUC 5BTR; 4ZZJ; 4ZZI; 4ZZH; 4KXQ T14731 BIOCLASS Carbon-nitrogen hydrolase T14731 ECNUMBER EC 3.5.1.- T14731 SEQUENCE MADEAALALQPGGSPSAAGADREAASSPAGEPLRKRPRRDGPGLERSPGEPGGAAPEREVPAAARGCPGAAAAALWREAEAEAAAAGGEQEAQATAAAGEGDNGPGLQGPSREPPLADNLYDEDDDDEGEEEEEAAAAAIGYRDNLLFGDEIITNGFHSCESDEEDRASHASSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLEDEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS T14731 DRUGINFO D0U3EP Resveratrol Phase 3 T14731 DRUGINFO D04JNI GSK2245840 Phase 2 T14731 DRUGINFO D0E3LP SEN-196 Phase 2 T14731 DRUGINFO D0TU7V MB-12066 Phase 2 T14731 DRUGINFO D0O3EP SRT2379 Phase 1 T14731 DRUGINFO D0X3TI SRT3025 Phase 1 T14731 DRUGINFO D02QKC PMID25435179-Compound-WO2012106509Salermide Patented T14731 DRUGINFO D04JZE CAMBINOL Patented T14731 DRUGINFO D06IHB PMID25435179-Compound-WO2012106509CAY10602 Patented T14731 DRUGINFO D0PE8E PMID25435179-Compound-WO2012106509Tenovin-6 Patented T14731 DRUGINFO D0R3EL GSK184072 Discontinued in Phase 2 T14731 DRUGINFO D00LYI Meta-sirtinol Investigative T14731 DRUGINFO D02AYX 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione Investigative T14731 DRUGINFO D02EWM (R)-sirtinol Investigative T14731 DRUGINFO D03EGA SRT1720 Investigative T14731 DRUGINFO D05UDU YK-3237 Investigative T14731 DRUGINFO D09SUO splitomicin Investigative T14731 DRUGINFO D0E1QP 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide Investigative T14731 DRUGINFO D0F1KR (S)-sirtinol Investigative T14731 DRUGINFO D0UO1E Para-sirtinol Investigative T14731 DRUGINFO D0M5FF Ro31-8220 Investigative T14731 DRUGINFO D0L8HO RO-316233 Investigative T46781 TARGETID T46781 T46781 FORMERID TTDC00139 T46781 UNIPROID AURKB_HUMAN T46781 TARGNAME Aurora kinase B (AURKB) T46781 GENENAME AURKB T46781 TARGTYPE Clinical trial T46781 SYNONYMS Serine/threonine-protein kinase aurora-B; Serine/threonine-protein kinase 5; Serine/threonine-protein kinase 12; Serine/threonine protein kinase 12; STK5; STK12; Aurora/IPL1-related kinase 2; Aurora-related kinase 2; Aurora-B; Aurora-2 kinase; Aurora-2; Aurora- and Ipl1-like midbody-associated protein 1; Aurora 1; ARK2; ARK-2; AIRK2; AIM1; AIM-1; AIK2 T46781 FUNCTION The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. Required for central/midzone spindle assembly and cleavage furrow formation. Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: phosphorylates CHMP4C, leading to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP. Phosphorylation of INCENP leads to increased AURKB activity. Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, HASPIN, and histone H3. A positive feedback loop involving HASPIN and AURKB contributes to localization of CPC to centromeres. Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis (H3S10ph and H3S28ph, respectively). A positive feedback between HASPIN and AURKB contributes to CPC localization. AURKB is also required for kinetochore localization of BUB1 and SGO1. Phosphorylation of p53/TP53 negatively regulates its transcriptional activity. Key regulator of active promoters in resting B- and T-lymphocytes: acts by mediating phosphorylation of H3S28ph at active promoters in resting B-cells, inhibiting RNF2/RING1B-mediated ubiquitination of histone H2A and enhancing binding and activity of the USP16 deubiquitinase at transcribed genes. Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. T46781 PDBSTRUC 4AF3 T46781 BIOCLASS Kinase T46781 ECNUMBER EC 2.7.11.1 T46781 SEQUENCE MAQKENSYPWPYGRQTAPSGLSTLPQRVLRKEPVTPSALVLMSRSNVQPTAAPGQKVMENSSGTPDILTRHFTIDDFEIGRPLGKGKFGNVYLAREKKSHFIVALKVLFKSQIEKEGVEHQLRREIEIQAHLHHPNILRLYNYFYDRRRIYLILEYAPRGELYKELQKSCTFDEQRTATIMEELADALMYCHGKKVIHRDIKPENLLLGLKGELKIADFGWSVHAPSLRRKTMCGTLDYLPPEMIEGRMHNEKVDLWCIGVLCYELLVGNPPFESASHNETYRRIVKVDLKFPASVPMGAQDLISKLLRHNPSERLPLAQVSAHPWVRANSRRVLPPSALQSVA T46781 DRUGINFO D05PZB AT9283 Phase 3 T46781 DRUGINFO D0A1AQ Rosiglitazone + metformin Phase 3 T46781 DRUGINFO D02XNW VX-680 Phase 2 T46781 DRUGINFO D08HOM ABT-348 Phase 2 T46781 DRUGINFO D02RJY PHA-739358 Phase 2 T46781 DRUGINFO D08HFW TAK-901 Phase 1 T46781 DRUGINFO D09KRU BI-831266 Phase 1 T46781 DRUGINFO D0P5IZ BI-811283 Phase 1 T46781 DRUGINFO D0Q7RE AZD-1152-HQPA Phase 1 T46781 DRUGINFO D08DCP BI-847325 Phase 1 T46781 DRUGINFO D0E5XA R763 Phase 1 T46781 DRUGINFO D0IQ0Z GSK1070916 Phase 1 T46781 DRUGINFO D0J6AB MK-5108 Phase 1 T46781 DRUGINFO D0P0HU GSK1070916A Phase 1 T46781 DRUGINFO D05LKZ HPP-607 Phase 1 T46781 DRUGINFO D0CY1B CYC116 Phase 1 T46781 DRUGINFO D0EJ3B AMG 900 Phase 1 T46781 DRUGINFO D0OA5G SNS-314 Phase 1 T46781 DRUGINFO D0H7AC PF-03814735 Discontinued in Phase 1 T46781 DRUGINFO D14NDZ Deguelin Investigative T98896 TARGETID T98896 T98896 FORMERID TTDR00697 T98896 UNIPROID ATS5_HUMAN T98896 TARGNAME Aggrecanase (ADAMTS5) T98896 GENENAME ADAMTS5 T98896 TARGTYPE Clinical trial T98896 SYNONYMS Aggrecanase-2; ADMP-2; ADAMTS5; ADAMTS-5; ADAM-TS5; ADAM-TS 5; ADAM-TS 11; A disintegrin and metalloproteinase with thrombospondinmotifs 5 T98896 FUNCTION Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. May play a role in proteolytic processing mostly during the peri-implantation period. T98896 PDBSTRUC 3LJT; 3HYG; 3HY9; 3HY7; 3B8Z T98896 BIOCLASS Peptidase T98896 ECNUMBER EC 3.4.24.- T98896 SEQUENCE MLLGWASLLLCAFRLPLAAVGPAATPAQDKAGQPPTAAAAAQPRRRQGEEVQERAEPPGHPHPLAQRRRSKGLVQNIDQLYSGGGKVGYLVYAGGRRFLLDLERDGSVGIAGFVPAGGGTSAPWRHRSHCFYRGTVDGSPRSLAVFDLCGGLDGFFAVKHARYTLKPLLRGPWAEEEKGRVYGDGSARILHVYTREGFSFEALPPRASCETPASTPEAHEHAPAHSNPSGRAALASQLLDQSALSPAGGSGPQTWWRRRRRSISRARQVELLLVADASMARLYGRGLQHYLLTLASIANRLYSHASIENHIRLAVVKVVVLGDKDKSLEVSKNAATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTVAHEIGHLLGLSHDDSKFCEETFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDLPRKQILGPEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRICLQGKCVDKTKKKYYSTSSHGNWGSWGSWGQCSRSCGGGVQFAYRHCNNPAPRNNGRYCTGKRAIYRSCSLMPCPPNGKSFRHEQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRLYSNSVCVRGKCVRTGCDGIIGSKLQYDKCGVCGGDNSSCTKIVGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYLALKKKNGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKPLDVRYSFFVPKKSTPKVNSVTSHGSNKVGSHTSQPQWVTGPWLACSRTCDTGWHTRTVQCQDGNRKLAKGCPLSQRPSAFKQCLLKKC T98896 DRUGINFO D0C5NP AGG-523 Phase 1 T98896 DRUGINFO D0Y1XT SC-44463 Terminated T98896 DRUGINFO D0FD9M PMID21536437C15c Investigative T98896 DRUGINFO D0MI1N CR-5259 Investigative T97592 TARGETID T97592 T97592 FORMERID TTDC00059 T97592 UNIPROID AURKC_HUMAN T97592 TARGNAME Aurora kinase C (AURKC) T97592 GENENAME AURKC T97592 TARGTYPE Clinical trial T97592 SYNONYMS Serine/threonine-protein kinase aurora-C; STK13; Aurora/Ipl1/Eg2 protein 2; Aurora/Ipl1-related kinase 3; Aurora-related kinase 3; Aurora-C; Aurora 3; ARK3; ARK-3; AIRK3; AIK3; AIE2 T97592 FUNCTION The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Plays also a role in meiosis and more particularly in spermatogenesis. Has redundant cellular functions with AURKB and can rescue an AURKB knockdown. Like AURKB, AURKC phosphorylates histone H3 at 'Ser-10' and 'Ser-28'. AURKC phosphorylates the CPC complex subunits BIRC5/survivin and INCENP leading to increased AURKC activity. Phosphorylates TACC1, another protein involved in cell division, at 'Ser-228'. Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. T97592 PDBSTRUC 6GR9; 6GR8 T97592 BIOCLASS Kinase T97592 ECNUMBER EC 2.7.11.1 T97592 SEQUENCE MSSPRAVVQLGKAQPAGEELATANQTAQQPSSPAMRRLTVDDFEIGRPLGKGKFGNVYLARLKESHFIVALKVLFKSQIEKEGLEHQLRREIEIQAHLQHPNILRLYNYFHDARRVYLILEYAPRGELYKELQKSEKLDEQRTATIIEELADALTYCHDKKVIHRDIKPENLLLGFRGEVKIADFGWSVHTPSLRRKTMCGTLDYLPPEMIEGRTYDEKVDLWCIGVLCYELLVGYPPFESASHSETYRRILKVDVRFPLSMPLGARDLISRLLRYQPLERLPLAQILKHPWVQAHSRRVLPPCAQMAS T97592 DRUGINFO D08HOM ABT-348 Phase 2 T97592 DRUGINFO D02RJY PHA-739358 Phase 2 T97592 DRUGINFO D0IQ0Z GSK1070916 Phase 1 T97592 DRUGINFO D0P0HU GSK1070916A Phase 1 T97592 DRUGINFO D05LKZ HPP-607 Phase 1 T97592 DRUGINFO D0EJ3B AMG 900 Phase 1 T97592 DRUGINFO D0OA5G SNS-314 Phase 1 T97592 DRUGINFO D0M0KB MK-6592 Discontinued in Phase 1 T97592 DRUGINFO D00UTU 7-bromoindirubin-3-acetoxime Investigative T97592 DRUGINFO D06XLC BMS-739562 Investigative T97592 DRUGINFO D08VMW MP-529 Investigative T97592 DRUGINFO D09VAB BPR1K-0224 Investigative T97592 DRUGINFO D0Q3EW 2np8 Investigative T97592 DRUGINFO D06LJL PMID16451062C46 Investigative T97592 DRUGINFO D0I1IK 7-fluoroindirubin-3-acetoxime Investigative T97592 DRUGINFO D0K6VW 7-iodoindirubin-3-oxime Investigative T97592 DRUGINFO D0K8YI 7-chloroindirubin-3-oxime Investigative T97592 DRUGINFO D0L1GF 7-bromoindirubin-3-oxime Investigative T97592 DRUGINFO D0U8VY quinazoline deriv. 1 Investigative T97592 DRUGINFO D0Y8DT Glycyl-H 1152 Investigative T97592 DRUGINFO D00TKJ 7-fluoroindirubin-3-oxime Investigative T97592 DRUGINFO D06AGN Indirubin-3-acetoxime Investigative T97592 DRUGINFO D0ME9B PMID20855207C25 Investigative T97592 DRUGINFO D0Q7TO K00244 Investigative T97592 DRUGINFO D0V6LP Indirubin-3-methoxime Investigative T97592 DRUGINFO D06OAH 6-bromoindirubin-3-oxime Investigative T97592 DRUGINFO D0CE3R SU 6656 Investigative T97592 DRUGINFO D0Y0ES Indirubin-3'-monoxime Investigative T96788 TARGETID T96788 T96788 FORMERID TTDR01361 T96788 UNIPROID ERBB2_HUMAN T96788 TARGNAME ERBB2 messenger RNA (HER2 mRNA) T96788 GENENAME ERBB2 T96788 TARGTYPE Clinical trial T96788 SYNONYMS Tyrosine kinase-type cell surface receptor HER2 (mRNA); Tyrosine kinase receptor ErbB2 (mRNA); Receptor tyrosine-protein kinase erbB-2 (mRNA); Proto-oncogene c-ErbB-2 (mRNA); Proto-oncogene Neu (mRNA); P185erbB2 (mRNA); NGL (mRNA); NEU proto-oncogene (mRNA); NEU (mRNA); Metastatic lymph node gene 19 protein (mRNA); MLN19 (mRNA); MLN 19 (mRNA); HER2/neu (mRNA); HER2 (erbB2/neu) (mRNA); HER-2 (mRNA); Erb2 (mRNA); Epidermal growth factor receptor 2 (mRNA); CD340 (mRNA); C-erbB-2 oncoprotein (mRNA); C-erbB-2 (mRNA) T96788 FUNCTION Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. T96788 PDBSTRUC 6OGE; 6J71; 6BGT; 6ATT; 5TQS T96788 BIOCLASS mRNA target T96788 ECNUMBER EC 2.7.10.1 T96788 SEQUENCE MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV T96788 DRUGINFO D0Q9CY HKI-272 Phase 3 T96788 DRUGINFO D0R6UV BMS-690514 Phase 2 T96788 DRUGINFO D01OKF 4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide Investigative T96788 DRUGINFO D06JEJ ISIS 9002 Investigative T96788 DRUGINFO D06VFH ISIS 12883 Investigative T96788 DRUGINFO D09HJE ISIS 12884 Investigative T96788 DRUGINFO D09RFE 4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole Investigative T96788 DRUGINFO D0AA2X PNT-500 Investigative T96788 DRUGINFO D0B7ZB 4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole Investigative T96788 DRUGINFO D0C0EE ISIS 9005 Investigative T96788 DRUGINFO D0C2SF 4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole Investigative T96788 DRUGINFO D0EE7R ISIS 9003 Investigative T96788 DRUGINFO D0H2DD 4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole Investigative T96788 DRUGINFO D0S3AR ISIS 12882 Investigative T96788 DRUGINFO D01VFR PD-168393 Investigative T96788 DRUGINFO D01WYI N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide Investigative T96788 DRUGINFO D02ARA (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine Investigative T96788 DRUGINFO D0Q3GG AG-213 Investigative T96788 DRUGINFO D0X4OU 4557W Investigative T96788 DRUGINFO D00TZD CL-387785 Investigative T96788 DRUGINFO D05FFT HDS-029 Investigative T96788 DRUGINFO D0H6OS Geldanamycin-estradiol hybrid Investigative T96788 DRUGINFO D06BJG PMID24915291C38 Investigative T96788 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T96788 DRUGINFO D0M4SY BMS-536924 Investigative T96788 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T96788 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T96788 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T90648 TARGETID T90648 T90648 FORMERID TTDR01373 T90648 UNIPROID BRAF_HUMAN T90648 TARGNAME B-Raf messenger RNA (BRAF mRNA) T90648 GENENAME BRAF T90648 TARGTYPE Clinical trial T90648 SYNONYMS V-Raf murine sarcoma viral oncogene homolog B1 (mRNA); Serine/threonine-protein kinase B-raf (mRNA); RAFB1 (mRNA); Proto-oncogene B-Raf (mRNA); P94 (mRNA); BRAF1 (mRNA); BRAF(V599E) (mRNA); BRAF serine/threonine kinase (mRNA); B-raf protein (mRNA); B-Raf (mRNA) T90648 FUNCTION May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway. Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. T90648 PDBSTRUC 6CAD; 6B8U; 5VYK; 5VR3; 5VAM T90648 BIOCLASS mRNA target T90648 ECNUMBER EC 2.7.11.1 T90648 SEQUENCE MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH T90648 DRUGINFO D07IEU MLN2480 Phase 2 T90648 DRUGINFO D02DXC SPN-803 Phase 1 T90648 DRUGINFO D0F5JZ PLX-4720 Phase 1 T90648 DRUGINFO D06EFW RG7304 Phase 1 T90648 DRUGINFO D01DDB 2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine Investigative T90648 DRUGINFO D07LZP ISIS 13741 Investigative T90648 DRUGINFO D07TDZ ISIS 14144 Investigative T90648 DRUGINFO D07UFK PMID26061392C2 Investigative T90648 DRUGINFO D09AIJ ISIS 13740 Investigative T90648 DRUGINFO D0C5BL ISIS 13730 Investigative T90648 DRUGINFO D0O9XE ISIS 13743 Investigative T90648 DRUGINFO D0OR5S 2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine Investigative T90648 DRUGINFO D0P5VF Pyrazolo[1,5-a]pyrimidine-3-carboxylate Investigative T90648 DRUGINFO D0X7MU ISIS 13727 Investigative T90648 DRUGINFO D06YMT PLX-ORI3 Investigative T90648 DRUGINFO D00NWF ZM-336372 Investigative T90648 DRUGINFO D06WJA L-779450 Investigative T77764 TARGETID T77764 T77764 FORMERID TTDR01420 T77764 UNIPROID AURKB_HUMAN T77764 TARGNAME Aurora B messenger RNA (AURKB mRNA) T77764 GENENAME AURKB T77764 TARGTYPE Clinical trial T77764 SYNONYMS Serine/threonine-protein kinase aurora-B (mRNA); Serine/threonine-protein kinase 5 (mRNA); Serine/threonine-protein kinase 12 (mRNA); Serine/threonine protein kinase 12 (mRNA); STK5 (mRNA); STK12 (mRNA); Aurora/IPL1-related kinase 2 (mRNA); Aurora-related kinase 2 (mRNA); Aurora-B (mRNA); Aurora-2 kinase (mRNA); Aurora-2 (mRNA); Aurora- and Ipl1-like midbody-associated protein 1 (mRNA); Aurora 1 (mRNA); ARK2 (mRNA); ARK-2 (mRNA); AIRK2 (mRNA); AIM1 (mRNA); AIM-1 (mRNA); AIK2 (mRNA) T77764 FUNCTION The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. Required for central/midzone spindle assembly and cleavage furrow formation. Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: phosphorylates CHMP4C, leading to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP. Phosphorylation of INCENP leads to increased AURKB activity. Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, HASPIN, and histone H3. A positive feedback loop involving HASPIN and AURKB contributes to localization of CPC to centromeres. Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis (H3S10ph and H3S28ph, respectively). A positive feedback between HASPIN and AURKB contributes to CPC localization. AURKB is also required for kinetochore localization of BUB1 and SGO1. Phosphorylation of p53/TP53 negatively regulates its transcriptional activity. Key regulator of active promoters in resting B- and T-lymphocytes: acts by mediating phosphorylation of H3S28ph at active promoters in resting B-cells, inhibiting RNF2/RING1B-mediated ubiquitination of histone H2A and enhancing binding and activity of the USP16 deubiquitinase at transcribed genes. Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. T77764 PDBSTRUC 4AF3 T77764 BIOCLASS mRNA target T77764 ECNUMBER EC 2.7.11.1 T77764 SEQUENCE MAQKENSYPWPYGRQTAPSGLSTLPQRVLRKEPVTPSALVLMSRSNVQPTAAPGQKVMENSSGTPDILTRHFTIDDFEIGRPLGKGKFGNVYLAREKKSHFIVALKVLFKSQIEKEGVEHQLRREIEIQAHLHHPNILRLYNYFYDRRRIYLILEYAPRGELYKELQKSCTFDEQRTATIMEELADALMYCHGKKVIHRDIKPENLLLGLKGELKIADFGWSVHAPSLRRKTMCGTLDYLPPEMIEGRMHNEKVDLWCIGVLCYELLVGNPPFESASHNETYRRIVKVDLKFPASVPMGAQDLISKLLRHNPSERLPLAQVSAHPWVRANSRRVLPPSALQSVA T77764 DRUGINFO D02RJY PHA-739358 Phase 2 T77764 DRUGINFO D05WSM HESPERADIN Investigative T77764 DRUGINFO D07PVS ISIS 173848 Investigative T77764 DRUGINFO D0K1JI ISIS 173813 Investigative T77764 DRUGINFO D0PI2A ISIS 173831 Investigative T77764 DRUGINFO D0Y5UO ISIS 173840 Investigative T77764 DRUGINFO D04MYT 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine Investigative T77764 DRUGINFO D06LJL PMID16451062C46 Investigative T77764 DRUGINFO D0I1IK 7-fluoroindirubin-3-acetoxime Investigative T77764 DRUGINFO D0K6VW 7-iodoindirubin-3-oxime Investigative T77764 DRUGINFO D0K8YI 7-chloroindirubin-3-oxime Investigative T77764 DRUGINFO D0L1GF 7-bromoindirubin-3-oxime Investigative T77764 DRUGINFO D0U8VY quinazoline deriv. 1 Investigative T77764 DRUGINFO D00TKJ 7-fluoroindirubin-3-oxime Investigative T77764 DRUGINFO D01TDV PMID21742770C1 Investigative T77764 DRUGINFO D06AGN Indirubin-3-acetoxime Investigative T77764 DRUGINFO D0A7FQ CGP-57380 Investigative T77764 DRUGINFO D0ME9B PMID20855207C25 Investigative T77764 DRUGINFO D0V6LP Indirubin-3-methoxime Investigative T77764 DRUGINFO D06OAH 6-bromoindirubin-3-oxime Investigative T77764 DRUGINFO D0CE3R SU 6656 Investigative T77764 DRUGINFO D0Y0ES Indirubin-3'-monoxime Investigative T64682 TARGETID T64682 T64682 FORMERID TTDR01250 T64682 UNIPROID SGK1_HUMAN T64682 TARGNAME Serine/threonine-protein kinase Sgk1 (SGK1) T64682 GENENAME SGK1 T64682 TARGTYPE Clinical trial T64682 SYNONYMS Serum/glucocorticoid-regulated kinase 1; SGK1 T64682 FUNCTION Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarization and memory consolidation. Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na(+)/dicarboxylate cotransporter: SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Stimulates sodium transport into epithelial cells by enhancing the stability and expression of SCNN1A/ENAC. This is achieved by phosphorylating the NEDD4L ubiquitin E3 ligase, promoting its interaction with 14-3-3 proteins, thereby preventing it from binding to SCNN1A/ENAC and targeting it for degradation. Regulates store-operated Ca(+2) entry (SOCE) by stimulating ORAI1 and STIM1. Regulates KCNJ1/ROMK1 directly via its phosphorylation or indirectly via increased interaction with SLC9A3R2/NHERF2. Phosphorylates MDM2 and activates MDM2-dependent ubiquitination of p53/TP53. Phosphorylates MAPT/TAU and mediates microtubule depolymerization and neurite formation in hippocampal neurons. Phosphorylates SLC2A4/GLUT4 and up-regulates its activity. Phosphorylates APBB1/FE65 and promotes its localization to the nucleus. Phosphorylates MAPK1/ERK2 and activates it by enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. Phosphorylates FBXW7 and plays an inhibitory role in the NOTCH1 signaling. Phosphorylates FOXO1 resulting in its relocalization from the nucleus to the cytoplasm. Phosphorylates FOXO3, promoting its exit from the nucleus and interference with FOXO3-dependent transcription. Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits their activity. Phosphorylates SLC9A3/NHE3 in response to dexamethasone, resulting in its activation and increased localization at the cell membrane. Phosphorylates CREB1. Necessary for vascular remodeling during angiogenesis. Sustained high levels and activity may contribute to conditions such as hypertension and diabetic nephropathy. Isoform 2 exhibited a greater effect on cell plasma membrane expression of SCNN1A/ENAC and Na(+) transport than isoform 1. Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. T64682 PDBSTRUC 3HDN; 3HDM; 2R5T T64682 BIOCLASS Kinase T64682 ECNUMBER EC 2.7.11.1 T64682 SEQUENCE MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLGFSYAPPTDSFL T64682 DRUGINFO D0F3FC GSK-650394 Investigative T64682 DRUGINFO D0A7FQ CGP-57380 Investigative T64682 DRUGINFO D0N6ES KN-62 Investigative T64682 DRUGINFO D0B9BU CI-1040 Investigative T64682 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T64682 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T64682 DRUGINFO D0L8HO RO-316233 Investigative T81443 TARGETID T81443 T81443 FORMERID TTDC00209 T81443 UNIPROID TLR4_HUMAN T81443 TARGNAME Toll-like receptor 4 (TLR4) T81443 GENENAME TLR4 T81443 TARGTYPE Clinical trial T81443 SYNONYMS TLR-4; HToll; CD284 T81443 FUNCTION Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+). Responses triggered by Ni(2+) require non-conserved histidines and are, therefore, species-specific. Both M. tuberculosis HSP70 (dnaK) and HSP65 (groEL-2) act via this protein to stimulate NF-kappa-B expression. In complex with TLR6, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-). Stimulation of monocytes in vitro with M. tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via TLR2, but also partially via this receptor. Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). T81443 PDBSTRUC 5NAO; 5NAM; 4G8A; 3ULA; 3UL9 T81443 BIOCLASS Toll-like receptor T81443 SEQUENCE MMSASRLAGTLIPAMAFLSCVRPESWEPCVEVVPNITYQCMELNFYKIPDNLPFSTKNLDLSFNPLRHLGSYSFFSFPELQVLDLSRCEIQTIEDGAYQSLSHLSTLILTGNPIQSLALGAFSGLSSLQKLVAVETNLASLENFPIGHLKTLKELNVAHNLIQSFKLPEYFSNLTNLEHLDLSSNKIQSIYCTDLRVLHQMPLLNLSLDLSLNPMNFIQPGAFKEIRLHKLTLRNNFDSLNVMKTCIQGLAGLEVHRLVLGEFRNEGNLEKFDKSALEGLCNLTIEEFRLAYLDYYLDDIIDLFNCLTNVSSFSLVSVTIERVKDFSYNFGWQHLELVNCKFGQFPTLKLKSLKRLTFTSNKGGNAFSEVDLPSLEFLDLSRNGLSFKGCCSQSDFGTTSLKYLDLSFNGVITMSSNFLGLEQLEHLDFQHSNLKQMSEFSVFLSLRNLIYLDISHTHTRVAFNGIFNGLSSLEVLKMAGNSFQENFLPDIFTELRNLTFLDLSQCQLEQLSPTAFNSLSSLQVLNMSHNNFFSLDTFPYKCLNSLQVLDYSLNHIMTSKKQELQHFPSSLAFLNLTQNDFACTCEHQSFLQWIKDQRQLLVEVERMECATPSDKQGMPVLSLNITCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI T81443 DRUGINFO D08KNK MPL-containing Pollinex allergy desensitization vaccine Preregistration T81443 DRUGINFO D0E4GG Resatorvid Phase 3 T81443 DRUGINFO D0SJ8Q ERITORAN Phase 3 T81443 DRUGINFO D0V0JR Cadi-05 Phase 3 T81443 DRUGINFO D0MD5M G100 Phase 2 T81443 DRUGINFO D04MZP NI-0101 Phase 1 T81443 DRUGINFO D0MM4H GSK1795091 Phase 1 T81443 DRUGINFO D0O2MO CRX-675 Phase 1 T81443 DRUGINFO D09POQ OM-174 Phase 1 T81443 DRUGINFO D09LZA CS-4771 Discontinued in Phase 1 T81443 DRUGINFO D06TTS LZ-8 Terminated T81443 DRUGINFO D00GLW OM-294-DP Investigative T81443 DRUGINFO D02SGT OM-197-MP-AC Investigative T81443 DRUGINFO D06MKE CRX-526 Investigative T81443 DRUGINFO D0J0GM 6-(2-aminophenoxy)benzo[d]isothiazol-3-amine Investigative T81443 DRUGINFO D0NB4V Fibronectin extra domain A Investigative T81443 DRUGINFO D0Q7RV AS04 Investigative T81443 DRUGINFO D0A0GD 3-Hydroxy-Myristic Acid Investigative T81443 DRUGINFO D04PFD TriMixDC Investigative T81443 DRUGINFO D0N0UC Lauric Acid Investigative T81443 DRUGINFO D08OBF MYRISTIC ACID Investigative T77645 TARGETID T77645 T77645 FORMERID TTDC00267 T77645 UNIPROID TR10A_HUMAN T77645 TARGNAME TRAIL receptor 1 (TRAIL-R1) T77645 GENENAME TNFRSF10A T77645 TARGTYPE Clinical trial T77645 SYNONYMS Tumor necrosis factor receptor superfamily member 10A; TRAILR1; TNF-related apoptosis-inducing ligand receptor 1; Death receptor 4; DR4; CD261; APO2 T77645 FUNCTION The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Receptor for the cytotoxic ligand TNFSF10/TRAIL. T77645 PDBSTRUC 5CIR T77645 BIOCLASS Cytokine receptor T77645 SEQUENCE MAPPPARVHLGAFLAVTPNPGSAASGTEAAAATPSKVWGSSAGRIEPRGGGRGALPTSMGQHGPSARARAGRAPGPRPAREASPRLRVHKTFKFVVVGVLLQVVPSSAATIKLHDQSIGTQQWEHSPLGELCPPGSHRSEHPGACNRCTEGVGYTNASNNLFACLPCTACKSDEEERSPCTTTRNTACQCKPGTFRNDNSAEMCRKCSRGCPRGMVKVKDCTPWSDIECVHKESGNGHNIWVILVVTLVVPLLLVAVLIVCCCIGSGCGGDPKCMDRVCFWRLGLLRGPGAEDNAHNEILSNADSLSTFVSEQQMESQEPADLTGVTVQSPGEAQCLLGPAEAEGSQRRRLLVPANGADPTETLMLFFDKFANIVPFDSWDQLMRQLDLTKNEIDVVRAGTAGPGDALYAMLMKWVNKTGRNASIHTLLDALERMEERHAREKIQDLLVDSGKFIYLEDGTGSAVSLE T77645 DRUGINFO D0KG5D Mapatumumab Phase 2 T77645 DRUGINFO D08JRT RhApo2L/TRAIL Discontinued in Phase 1/2 T77645 DRUGINFO D0X3PN DR-5/DR-4 cross reactive mabs Investigative T77400 TARGETID T77400 T77400 FORMERID TTDR00256 T77400 UNIPROID PDE2A_HUMAN T77400 TARGNAME Phosphodiesterase 2A (PDE2A) T77400 GENENAME PDE2A T77400 TARGTYPE Clinical trial T77400 SYNONYMS cGMP-dependent 3',5'-cyclic phosphodiesterase; PDE-II; Cyclic-GMP phosphodiesterase; Cyclic GMP-stimulated phosphodiesterase; Cyclic GMP stimulated phosphodiesterase; CGSPDE; CGS-PDE T77400 FUNCTION Plays an important role in growth and invasion of malignant melanoma cells (e. g. pseudomyxoma peritonei (PMP) cell line). Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. T77400 PDBSTRUC 6CYD; 6CYC; 6CYB; 6C7J; 6C7I T77400 BIOCLASS Phosphoric diester hydrolase T77400 ECNUMBER EC 3.1.4.17 T77400 SEQUENCE MGQACGHSILCRSQQYPAARPAEPRGQQVFLKPDEPPPPPQPCADSLQDALLSLGSVIDISGLQRAVKEALSAVLPRVETVYTYLLDGESQLVCEDPPHELPQEGKVREAIISQKRLGCNGLGFSDLPGKPLARLVAPLAPDTQVLVMPLADKEAGAVAAVILVHCGQLSDNEEWSLQAVEKHTLVALRRVQVLQQRGPREAPRAVQNPPEGTAEDQKGGAAYTDRDRKILQLCGELYDLDASSLQLKVLQYLQQETRASRCCLLLVSEDNLQLSCKVIGDKVLGEEVSFPLTGCLGQVVEDKKSIQLKDLTSEDVQQLQSMLGCELQAMLCVPVISRATDQVVALACAFNKLEGDLFTDEDEHVIQHCFHYTSTVLTSTLAFQKEQKLKCECQALLQVAKNLFTHLDDVSVLLQEIITEARNLSNAEICSVFLLDQNELVAKVFDGGVVDDESYEIRIPADQGIAGHVATTGQILNIPDAYAHPLFYRGVDDSTGFRTRNILCFPIKNENQEVIGVAELVNKINGPWFSKFDEDLATAFSIYCGISIAHSLLYKKVNEAQYRSHLANEMMMYHMKVSDDEYTKLLHDGIQPVAAIDSNFASFTYTPRSLPEDDTSMAILSMLQDMNFINNYKIDCPTLARFCLMVKKGYRDPPYHNWMHAFSVSHFCYLLYKNLELTNYLEDIEIFALFISCMCHDLDHRGTNNSFQVASKSVLAALYSSEGSVMERHHFAQAIAILNTHGCNIFDHFSRKDYQRMLDLMRDIILATDLAHHLRIFKDLQKMAEVGYDRNNKQHHRLLLCLLMTSCDLSDQTKGWKTTRKIAELIYKEFFSQGDLEKAMGNRPMEMMDREKAYIPELQISFMEHIAMPIYKLLQDLFPKAAELYERVASNREHWTKVSHKFTIRGLPSNNSLDFLDEEYEVPDLDGTRAPINGCCSLDAE T77400 DRUGINFO D0M7OU CP-461 Phase 2 T77400 DRUGINFO DB82TO Tofisopam Phase 2 T77400 DRUGINFO D0I2VT ND7001 Phase 1 T77400 DRUGINFO D00ONN Imidazo triazine derivative 1 Patented T77400 DRUGINFO D01IRA Pyrazolo[3,4-d]pyrimidine derivative 3 Patented T77400 DRUGINFO D05UNO Imidazo triazine derivative 4 Patented T77400 DRUGINFO D07OOA Pyrazolo[3,4-d]pyrimidine derivative 2 Patented T77400 DRUGINFO D07YWQ Pyrazolo[3,4-d]pyrimidine derivative 1 Patented T77400 DRUGINFO D08CEK Imidazo triazine derivative 5 Patented T77400 DRUGINFO D09PMC PMID27321640-Compound-75 Patented T77400 DRUGINFO D0A5YE PMID27321640-Compound-74 Patented T77400 DRUGINFO D0AK5Y Oxindole derivative 1 Patented T77400 DRUGINFO D0ET2A Imidazo triazine derivative 3 Patented T77400 DRUGINFO D0H4LG 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 1 Patented T77400 DRUGINFO D0HC5P 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 3 Patented T77400 DRUGINFO D0K3QR Purin-6-one derivative 1 Patented T77400 DRUGINFO D0KN9S PMID27321640-Compound-76 Patented T77400 DRUGINFO D0KZ5Q Imidazo triazine derivative 2 Patented T77400 DRUGINFO D0L0MI Imidazotriazinone derivative 1 Patented T77400 DRUGINFO D0MA2R Triazolo-phthalazine derivative 1 Patented T77400 DRUGINFO D0OC1S Pyrido[2,3-d]pyrimidine-2,4-diamine derivative 1 Patented T77400 DRUGINFO D0T8MJ 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 2 Patented T77400 DRUGINFO D0TK5G Benzodiazepine derivative 2 Patented T77400 DRUGINFO D0UR7K 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 1 Patented T77400 DRUGINFO D0V6LW Pyrazolo[3,4-d]pyrimidine derivative 4 Patented T77400 DRUGINFO D0XJ4J 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 2 Patented T77400 DRUGINFO D00YOY Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 Patented T77400 DRUGINFO D01ITP Triazolo-pyridine derivative 5 Patented T77400 DRUGINFO D02PFP PMID27321640-Compound-58 Patented T77400 DRUGINFO D05VBJ Triazolo-pyridine derivative 4 Patented T77400 DRUGINFO D07EUB Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3 Patented T77400 DRUGINFO D07NRP Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4 Patented T77400 DRUGINFO D07ZTT Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5 Patented T77400 DRUGINFO D09BDD 1,2,4-triazole [4,3-a]quinoxaline derivative 1 Patented T77400 DRUGINFO D09RWM PMID27321640-Compound-59 Patented T77400 DRUGINFO D0A8EV Triazolo-pyridine derivative 6 Patented T77400 DRUGINFO D0D0QT Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2 Patented T77400 DRUGINFO D0D4YR Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1 Patented T77400 DRUGINFO D0FV3G 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 Patented T77400 DRUGINFO D0I5UY Imidazo[5,1-c][1,2,4]benzotriazine derivative 2 Patented T77400 DRUGINFO D0J6KS 1,2,4-triazole [4,3-a]quinoxaline derivative 3 Patented T77400 DRUGINFO D0J8YF Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8 Patented T77400 DRUGINFO D0JJ8K Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7 Patented T77400 DRUGINFO D0L6AM Imidazo[5,1-c][1,2,4]benzotriazine derivative 4 Patented T77400 DRUGINFO D0LI6Z 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3 Patented T77400 DRUGINFO D0MK7X Imidazo[5,1-c][1,2,4]benzotriazine derivative 3 Patented T77400 DRUGINFO D0PP8O Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6 Patented T77400 DRUGINFO D0QE7X 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4 Patented T77400 DRUGINFO D0QI8G Imidazo[5,1-c][1,2,4]benzotriazine derivative 1 Patented T77400 DRUGINFO D0RI3W 1,2,4-triazole [4,3-a]quinoxaline derivative 2 Patented T77400 DRUGINFO D0SV1I Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3 Patented T77400 DRUGINFO D0U3KV Triazolo-pyridine derivative 2 Patented T77400 DRUGINFO D0X2UO 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5 Patented T77400 DRUGINFO D0Z4IA Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1 Patented T77400 DRUGINFO D0Z8VY Triazolo-pyridine derivative 3 Patented T77400 DRUGINFO D01LSP Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 Patented T77400 DRUGINFO D0T8WU Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 Patented T77400 DRUGINFO D09UMA IMAZODAN Terminated T77400 DRUGINFO D0V9MI BAY-60-7550 Investigative T77400 DRUGINFO D05ZHQ EHNA Investigative T77400 DRUGINFO D09LAQ Cyclic Guanosine Monophosphate Investigative T77400 DRUGINFO D0W3RR 2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one Investigative T77400 DRUGINFO D01TOR Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine Investigative T77400 DRUGINFO D0I6XA (2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol Investigative T77400 DRUGINFO D0U8YQ Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine Investigative T77400 DRUGINFO D0R6MT isobutylmethylxanthine Investigative T31902 TARGETID T31902 T31902 FORMERID TTDI02327 T31902 UNIPROID ADA10_HUMAN T31902 TARGNAME Mammalian disintegrin-metalloprotease (ADAM10) T31902 GENENAME ADAM10 T31902 TARGTYPE Clinical trial T31902 SYNONYMS Mammalian disintegrinmetalloprotease; MADM; Kuzbanian protein homolog; KUZ; Disintegrin and metalloproteinase domaincontaining protein 10; Disintegrin and metalloproteinase domain-containing protein 10; CDw156; CD156c; ADAM 10 T31902 FUNCTION Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth-like factor, ephrin-A2, CD44, CDH2 and for constitutive and regulated alpha-secretase cleavage of amyloid precursor protein (APP). Contributes to the normal cleavage of the cellular prion protein. Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity. Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis. Responsible for the FasL ectodomain shedding and for the generation of the remnant ADAM10-processed FasL (FasL APL) transmembrane form. Also cleaves the ectodomain of the integral membrane proteins CORIN and ITM2B. Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3. May regulate the EFNA5-EPHA3 signaling. Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-|-Val-77' to its mature soluble form. T31902 PDBSTRUC 6BE6; 6BDZ; 1M1I T31902 BIOCLASS Peptidase T31902 ECNUMBER EC 3.4.24.81 T31902 SEQUENCE MVLLRVLILLLSWAAGMGGQYGNPLNKYIRHYEGLSYNVDSLHQKHQRAKRAVSHEDQFLRLDFHAHGRHFNLRMKRDTSLFSDEFKVETSNKVLDYDTSHIYTGHIYGEEGSFSHGSVIDGRFEGFIQTRGGTFYVEPAERYIKDRTLPFHSVIYHEDDINYPHKYGPQGGCADHSVFERMRKYQMTGVEEVTQIPQEEHAANGPELLRKKRTTSAEKNTCQLYIQTDHLFFKYYGTREAVIAQISSHVKAIDTIYQTTDFSGIRNISFMVKRIRINTTADEKDPTNPFRFPNIGVEKFLELNSEQNHDDYCLAYVFTDRDFDDGVLGLAWVGAPSGSSGGICEKSKLYSDGKKKSLNTGIITVQNYGSHVPPKVSHITFAHEVGHNFGSPHDSGTECTPGESKNLGQKENGNYIMYARATSGDKLNNNKFSLCSIRNISQVLEKKRNNCFVESGQPICGNGMVEQGEECDCGYSDQCKDECCFDANQPEGRKCKLKPGKQCSPSQGPCCTAQCAFKSKSEKCRDDSDCAREGICNGFTALCPASDPKPNFTDCNRHTQVCINGQCAGSICEKYGLEECTCASSDGKDDKELCHVCCMKKMDPSTCASTGSVQWSRHFSGRTITLQPGSPCNDFRGYCDVFMRCRLVDADGPLARLKKAIFSPELYENIAEWIVAHWWAVLLMGIALIMLMAGFIKICSVHTPSSNPKLPPPKPLPGTLKRRRPPQPIQQPQRQRPRESYQMGHMRR T31902 DRUGINFO D02CZF Aderbasib Phase 1/2 T31902 DRUGINFO D06EHW IAI-100 Investigative T70067 TARGETID T70067 T70067 FORMERID TTDC00266 T70067 UNIPROID TR10B_HUMAN T70067 TARGNAME TRAIL receptor 2 (TRAIL-R2) T70067 GENENAME TNFRSF10B T70067 TARGTYPE Clinical trial T70067 SYNONYMS ZTNFR9; UNQ160/PRO186; Tumor necrosis factor receptor superfamily member 10B; TRICK2; TRAILR2; TNF-related apoptosis-inducing ligand receptor 2; KILLER; Death receptor 5; DR5; CD262 T70067 FUNCTION The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis. Receptor for the cytotoxic ligand TNFSF10/TRAIL. T70067 PDBSTRUC 6NHY; 6NHW; 4OD2; 4N90; 4I9X T70067 BIOCLASS Cytokine receptor T70067 SEQUENCE MEQRGQNAPAASGARKRHGPGPREARGARPGPRVPKTLVLVVAAVLLLVSAESALITQQDLAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDCISCKYGQDYSTHWNDLLFCLRCTRCDSGEVELSPCTTTRNTVCQCEEGTFREEDSPEMCRKCRTGCPRGMVKVGDCTPWSDIECVHKESGTKHSGEVPAVEETVTSSPGTPASPCSLSGIIIGVTVAAVVLIVAVFVCKSLLWKKVLPYLKGICSGGGGDPERVDRSSQRPGAEDNVLNEIVSILQPTQVPEQEMEVQEPAEPTGVNMLSPGESEHLLEPAEAERSQRRRLLVPANEGDPTETLRQCFDDFADLVPFDSWEPLMRKLGLMDNEIKVAKAEAAGHRDTLYTMLIKWVNKTGRDASVHTLLDALETLGERLAKQKIEDHLLSSGKFMYLEGNADSAMS T70067 DRUGINFO D0MW7S Lexatumumab Phase 2 T70067 DRUGINFO D00WME Conatumumab Phase 2 T70067 DRUGINFO D0LW4A Anti-DR5 cells Phase 1/2 T70067 DRUGINFO D48UEV IGM-8444 Phase 1 T70067 DRUGINFO D56ERU INBRX-109 Phase 1 T70067 DRUGINFO D9Y8ZU BI 905711 Phase 1 T70067 DRUGINFO DH17JI DS-8273 Phase 1 T70067 DRUGINFO DVX4P3 GEN1029 Phase 1 T70067 DRUGINFO D08JRT RhApo2L/TRAIL Discontinued in Phase 1/2 T70067 DRUGINFO D05CHR LBY-135 Discontinued in Phase 1 T70067 DRUGINFO D06JBA HGS-TR2J Discontinued in Phase 1 T70067 DRUGINFO D04UYY AD5-10 Investigative T70067 DRUGINFO D0X3PN DR-5/DR-4 cross reactive mabs Investigative T25608 TARGETID T25608 T25608 FORMERID TTDNC00653 T25608 UNIPROID FFAR1_HUMAN T25608 TARGNAME Free fatty acid receptor 1 (GPR40) T25608 GENENAME FFAR1 T25608 TARGTYPE Clinical trial T25608 SYNONYMS Gprotein coupled receptor 40; FFAR1 T25608 FUNCTION G-protein coupled receptor for medium and long chain saturated and unsaturated fatty acids that plays an important role in glucose homeostasis. Fatty acid binding increases glucose- stimulated insulin secretion, and may also enhance the secretion of glucagon-like peptide 1 (GLP-1). May also play a role in bone homeostasis; receptor signaling activates pathways that inhibit osteoclast differentiation. Ligand binding leads to a conformation change that triggers signaling via G-proteins that activate phospholipase C, leading to an increase of the intracellular calcium concentration. Seems to act through a G(q) and G(i)-mediated pathway. T25608 PDBSTRUC 5TZY; 5TZR; 5KW2; 4PHU T25608 BIOCLASS GPCR rhodopsin T25608 SEQUENCE MDLPPQLSFGLYVAAFALGFPLNVLAIRGATAHARLRLTPSLVYALNLGCSDLLLTVSLPLKAVEALASGAWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAFPLGYQAFRRPCYSWGVCAAIWALVLCHLGLVFGLEAPGGWLDHSNTSLGINTPVNGSPVCLEAWDPASAGPARFSLSLLLFFLPLAITAFCYVGCLRALARSGLTHRRKLRAAWVAGGALLTLLLCVGPYNASNVASFLYPNLGGSWRKLGLITGAWSVVLNPLVTGYLGRGPGLKTVCAARTQGGKSQK T25608 DRUGINFO D0M0WV Fasiglifam hemihydrate Phase 3 T25608 DRUGINFO D0V1WQ TAK-875 Phase 3 T25608 DRUGINFO D01CEG P-1736 Phase 2 T25608 DRUGINFO D0U8QB JTT-851 Phase 2 T25608 DRUGINFO DT56YX PBI-4050 Phase 2 T25608 DRUGINFO D0EO2C LY-2881835 Phase 1 T25608 DRUGINFO D0FP9N P11187 Phase 1 T25608 DRUGINFO D6CZ0T CPL207-280CA Phase 1 T25608 DRUGINFO DMDS20 LY2922470 Phase 1 T25608 DRUGINFO DZLM72 SHR0534 Phase 1 T25608 DRUGINFO D4M0GR CNX-011-67 Preclinical T25608 DRUGINFO DDV09U DS-1558 Preclinical T25608 DRUGINFO DRN30U BMS-986118 Preclinical T25608 DRUGINFO D01CCG TUG-424 Investigative T25608 DRUGINFO D03VMX GW1100 Investigative T25608 DRUGINFO D08LVH medica 16 Investigative T25608 DRUGINFO D08MLH TUG-469 Investigative T25608 DRUGINFO D0O5UF CNX-011 Investigative T25608 DRUGINFO D0Q7BG AMG-837 Investigative T25608 DRUGINFO D0S0QY TUG-770 Investigative T25608 DRUGINFO D0UH9E PMID18477808CB Investigative T25608 DRUGINFO D08ZYC GW9508 Investigative T25608 DRUGINFO D0C5SV alpha-linolenic acid Investigative T02677 TARGETID T02677 T02677 FORMERID TTDC00273 T02677 UNIPROID BIRC5_HUMAN T02677 TARGNAME Apoptosis inhibitor survivin (BIRC5) T02677 GENENAME BIRC5 T02677 TARGTYPE Clinical trial T02677 SYNONYMS Survivin; IAP4; Baculoviral IAP repeat-containing protein 5; Apoptosis inhibitor 4; API4 T02677 FUNCTION Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. The acetylated form represses STAT3 transactivation of target gene promoters. May play a role in neoplasia. Inhibitor of CASP3 and CASP7. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform. Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. T02677 PDBSTRUC 4A0N; 4A0J; 4A0I; 3UIK; 3UIJ T02677 BIOCLASS Acyltransferase T02677 SEQUENCE MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLAQCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD T02677 DRUGINFO D07TMR ISIS 23722 Phase 3 T02677 DRUGINFO D0KQ8W SurVaxM Phase 2 T02677 DRUGINFO D02DVK CV-9201 Phase 1/2 T02677 DRUGINFO D01GQD EZN-3042 Phase 1 T67894 TARGETID T67894 T67894 FORMERID TTDC00007 T67894 UNIPROID TLR3_HUMAN T67894 TARGNAME Toll-like receptor 3 (TLR3) T67894 GENENAME TLR3 T67894 TARGTYPE Clinical trial T67894 SYNONYMS CD283 T67894 FUNCTION Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. Acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. T67894 PDBSTRUC 5GS0; 3ULV; 3ULU; 2MKA; 2MK9 T67894 BIOCLASS Toll-like receptor T67894 SEQUENCE MRQTLPCIYFWGGLLPFGMLCASSTTKCTVSHEVADCSHLKLTQVPDDLPTNITVLNLTHNQLRRLPAANFTRYSQLTSLDVGFNTISKLEPELCQKLPMLKVLNLQHNELSQLSDKTFAFCTNLTELHLMSNSIQKIKNNPFVKQKNLITLDLSHNGLSSTKLGTQVQLENLQELLLSNNKIQALKSEELDIFANSSLKKLELSSNQIKEFSPGCFHAIGRLFGLFLNNVQLGPSLTEKLCLELANTSIRNLSLSNSQLSTTSNTTFLGLKWTNLTMLDLSYNNLNVVGNDSFAWLPQLEYFFLEYNNIQHLFSHSLHGLFNVRYLNLKRSFTKQSISLASLPKIDDFSFQWLKCLEHLNMEDNDIPGIKSNMFTGLINLKYLSLSNSFTSLRTLTNETFVSLAHSPLHILNLTKNKISKIESDAFSWLGHLEVLDLGLNEIGQELTGQEWRGLENIFEIYLSYNKYLQLTRNSFALVPSLQRLMLRRVALKNVDSSPSPFQPLRNLTILDLSNNNIANINDDMLEGLEKLEILDLQHNNLARLWKHANPGGPIYFLKGLSHLHILNLESNGFDEIPVEVFKDLFELKIIDLGLNNLNTLPASVFNNQVSLKSLNLQKNLITSVEKKVFGPAFRNLTELDMRFNPFDCTCESIAWFVNWINETHTNIPELSSHYLCNTPPHYHGFPVRLFDTSSCKDSAPFELFFMINTSILLIFIFIVLLIHFEGWRISFYWNVSVHRVLGFKEIDRQTEQFEYAAYIIHAYKDKDWVWEHFSSMEKEDQSLKFCLEERDFEAGVFELEAIVNSIKRSRKIIFVITHHLLKDPLCKRFKVHHAVQQAIEQNLDSIILVFLEEIPDYKLNHALCLRRGMFKSHCILNWPVQKERIGAFRHKLQVALGSKNSVH T67894 DRUGINFO D08JIP Rintatolimod Phase 3 T67894 DRUGINFO D0V8AG Poly-ICLC Phase 2 T67894 DRUGINFO D09LPI BCG65-E7 Discontinued in Phase 3 T67894 DRUGINFO D07THJ IPH-3102 Terminated T67894 DRUGINFO D0B6MQ polyIC Investigative T67894 DRUGINFO D0J7CD Poly IC-poly arginine Investigative T67894 DRUGINFO D0L8EO Anti-TLR3 mabs Investigative T67894 DRUGINFO D0O0BR Poly-ICR Investigative T54132 TARGETID T54132 T54132 FORMERID TTDC00128 T54132 UNIPROID KCNQ3_HUMAN T54132 TARGNAME Voltage-gated potassium channel Kv7.3 (KCNQ3) T54132 GENENAME KCNQ3 T54132 TARGTYPE Clinical trial T54132 SYNONYMS Voltage-gated potassium channel subunit Kv7.3; Potassium channel alpha subunit KvLQT3; Potassium channel KQT-like 3; KQT-like 3; KCNQ3; K+ channel KCNQ3 T54132 FUNCTION Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. T54132 PDBSTRUC 5J03 T54132 BIOCLASS Voltage-gated ion channel T54132 SEQUENCE MGLKARRAAGAAGGGGDGGGGGGGAANPAGGDAAAAGDEERKVGLAPGDVEQVTLALGAGADKDGTLLLEGGGRDEGQRRTPQGIGLLAKTPLSRPVKRNNAKYRRIQTLIYDALERPRGWALLYHALVFLIVLGCLILAVLTTFKEYETVSGDWLLLLETFAIFIFGAEFALRIWAAGCCCRYKGWRGRLKFARKPLCMLDIFVLIASVPVVAVGNQGNVLATSLRSLRFLQILRMLRMDRRGGTWKLLGSAICAHSKELITAWYIGFLTLILSSFLVYLVEKDVPEVDAQGEEMKEEFETYADALWWGLITLATIGYGDKTPKTWEGRLIAATFSLIGVSFFALPAGILGSGLALKVQEQHRQKHFEKRRKPAAELIQAAWRYYATNPNRIDLVATWRFYESVVSFPFFRKEQLEAASSQKLGLLDRVRLSNPRGSNTKGKLFTPLNVDAIEESPSKEPKPVGLNNKERFRTAFRMKAYAFWQSSEDAGTGDPMAEDRGYGNDFPIEDMIPTLKAAIRAVRILQFRLYKKKFKETLRPYDVKDVIEQYSAGHLDMLSRIKYLQTRIDMIFTPGPPSTPKHKKSQKGSAFTFPSQQSPRNEPYVARPSTSEIEDQSMMGKFVKVERQVQDMGKKLDFLVDMHMQHMERLQVQVTEYYPTKGTSSPAEAEKKEDNRYSDLKTIICNYSETGPPEPPYSFHQVTIDKVSPYGFFAHDPVNLPRGGPSSGKVQATPPSSATTYVERPTVLPILTLLDSRVSCHSQADLQGPYSDRISPRQRRSITRDSDTPLSLMSVNHEELERSPSGFSISQDRDDYVFGPNGGSSWMREKRYLAEGETDTDTDPFTPSGSMPLSSTGDGISDSVWTPSNKPI T54132 DRUGINFO D0X7GL Retigabine Approved T54132 DRUGINFO D08YHS Linopirdine Phase 3 T54132 DRUGINFO D08OJF ICA-105665 Phase 2 T54132 DRUGINFO D0WW3O XEN1101 Phase 1 T54132 DRUGINFO D0E2FZ ICA-69673 Preclinical T54132 DRUGINFO D08RJC PD-32577 Investigative T54132 DRUGINFO D06PZZ [14C]TEA Investigative T16739 TARGETID T16739 T16739 FORMERID TTDI02104 T16739 UNIPROID KDM1A_HUMAN T16739 TARGNAME Lysine-specific histone demethylase 1 (LSD) T16739 GENENAME KDM1A T16739 TARGTYPE Clinical trial T16739 SYNONYMS Lysine-specific histone demethylase 1A; LSD1; KIAA0601; KDM1; Flavin-containing amine oxidase domain-containing protein 2; BRAF35-HDAC complex protein BHC110; AOF2 T16739 FUNCTION Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. Acts as a corepressor by mediating demethylation of H3K4me, a specific tag for epigenetic transcriptional activation. Demethylates both mono- (H3K4me1) and di-methylated (H3K4me2) H3K4me. May play a role in the repression of neuronal genes. Alone, it is unable to demethylate H3K4me on nucleosomes and requires the presence of RCOR1/CoREST to achieve such activity. Also acts as a coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and mediating demethylation of H3K9me, a specific tag for epigenetic transcriptional repression. The presence of PRKCB in ANDR-containing complexes, which mediates phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag that prevents demethylation H3K4me, prevents H3K4me demethylase activity of KDM1A. Demethylates di-methylated 'Lys-370' of p53/TP53 which prevents interaction of p53/TP53 with TP53BP1 and represses p53/TP53-mediated transcriptional activation. Demethylates and stabilizes the DNA methylase DNMT1. Required for gastrulation during embryogenesis. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. Effector of SNAI1-mediated transcription repression of E-cadherin/CDH1, CDN7 and KRT8. Required for the maintenance of the silenced state of the SNAI1 target genes E-cadherin/CDH1 and CDN7. T16739 PDBSTRUC 6NQU; 6NQM; 5YJB; 5X60; 5LHI T16739 BIOCLASS CH-NH(2) donor oxidoreductase T16739 ECNUMBER EC 1.-.-.- T16739 SEQUENCE MLSGKKAAAAAAAAAAAATGTEAGPGTAGGSENGSEVAAQPAGLSGPAEVGPGAVGERTPRKKEPPRASPPGGLAEPPGSAGPQAGPTVVPGSATPMETGIAETPEGRRTSRRKRAKVEYREMDESLANLSEDEYYSEEERNAKAEKEKKLPPPPPQAPPEEENESEPEEPSGVEGAAFQSRLPHDRMTSQEAACFPDIISGPQQTQKVFLFIRNRTLQLWLDNPKIQLTFEATLQQLEAPYNSDTVLVHRVHSYLERHGLINFGIYKRIKPLPTKKTGKVIIIGSGVSGLAAARQLQSFGMDVTLLEARDRVGGRVATFRKGNYVADLGAMVVTGLGGNPMAVVSKQVNMELAKIKQKCPLYEANGQAVPKEKDEMVEQEFNRLLEATSYLSHQLDFNVLNNKPVSLGQALEVVIQLQEKHVKDEQIEHWKKIVKTQEELKELLNKMVNLKEKIKELHQQYKEASEVKPPRDITAEFLVKSKHRDLTALCKEYDELAETQGKLEEKLQELEANPPSDVYLSSRDRQILDWHFANLEFANATPLSTLSLKHWDQDDDFEFTGSHLTVRNGYSCVPVALAEGLDIKLNTAVRQVRYTASGCEVIAVNTRSTSQTFIYKCDAVLCTLPLGVLKQQPPAVQFVPPLPEWKTSAVQRMGFGNLNKVVLCFDRVFWDPSVNLFGHVGSTTASRGELFLFWNLYKAPILLALVAGEAAGIMENISDDVIVGRCLAILKGIFGSSAVPQPKETVVSRWRADPWARGSYSYVAAGSSGNDYDLMAQPITPGPSIPGAPQPIPRLFFAGEHTIRNYPATVHGALLSGLREAGRIADQFLGAMYTLPRQATPGVPAQQSPSM T16739 DRUGINFO D03EOZ IMG-7289 Phase 2 T16739 DRUGINFO D5NAL9 Vafidemstat Phase 2 T16739 DRUGINFO DB5UA2 CC-90011 Phase 2 T16739 DRUGINFO DL50ZE ORY-2001 Phase 2 T16739 DRUGINFO D0R7CD INCB59872 Phase 1/2 T16739 DRUGINFO D04GNG CC-90011 Phase 1 T16739 DRUGINFO D0I4ZN GSK2879552 Phase 1 T16739 DRUGINFO DCWT40 Seclidemstat Phase 1 T16739 DRUGINFO DI17KH TAS-1440 Phase 1 T16739 DRUGINFO D02YGX PMID27019002-Compound-16 Patented T16739 DRUGINFO D05FVW PMID27019002-Compound-41 Patented T16739 DRUGINFO D05HBM Benzenamine derivative 2 Patented T16739 DRUGINFO D06XEU PMID27019002-Compound-28a Patented T16739 DRUGINFO D07IAO Aryl cyclopropylamine derivative 5 Patented T16739 DRUGINFO D07LKA Pyrimidine derivative 17 Patented T16739 DRUGINFO D08FVR PMID27019002-Compound-31b Patented T16739 DRUGINFO D08WMK Benzenamine derivative 3 Patented T16739 DRUGINFO D0B6GK Cyclopropylamine derivative 1 Patented T16739 DRUGINFO D0BE4Z N6-cyclopropyllydine derivative 1 Patented T16739 DRUGINFO D0BG7B Tarnylcypromine derivative 1 Patented T16739 DRUGINFO D0C0PK Cyclopropylamine derivative 7 Patented T16739 DRUGINFO D0C1TH Aryl cyclopropylamine derivative 4 Patented T16739 DRUGINFO D0D9CK PMID27019002-Compound-45 Patented T16739 DRUGINFO D0DD4I PMID27019002-Compound-13 Patented T16739 DRUGINFO D0DL5J PMID27019002-Compound-49 Patented T16739 DRUGINFO D0F1CT Cyclopropylamine derivative 4 Patented T16739 DRUGINFO D0GA7D PMID27019002-Compound-42b Patented T16739 DRUGINFO D0I9QC PMID27019002-Compound-31a Patented T16739 DRUGINFO D0J1HQ PMID27019002-Compound-43c Patented T16739 DRUGINFO D0JE6I Aryl cyclopropylamine derivative 3 Patented T16739 DRUGINFO D0KR0I Benzenamine derivative 4 Patented T16739 DRUGINFO D0KZ5T Cyclopropylamine derivative 6 Patented T16739 DRUGINFO D0L0DT Pyrimidine derivative 16 Patented T16739 DRUGINFO D0L4OH PMID27019002-Compound-28 Patented T16739 DRUGINFO D0LK8A Heteroaryl-cyclopropylamine derivative 2 Patented T16739 DRUGINFO D0LR6D Cyclopropylamine derivative 5 Patented T16739 DRUGINFO D0MO5Y PMID27019002-Compound-43b Patented T16739 DRUGINFO D0N2QZ Pyrimidine derivative 18 Patented T16739 DRUGINFO D0NJ6B Cyclopropylamine derivative 3 Patented T16739 DRUGINFO D0O2WW PMID27019002-Compound-20b Patented T16739 DRUGINFO D0P4NF PMID27019002-Compound-50 Patented T16739 DRUGINFO D0R7RY Cyclopropylamine derivative 8 Patented T16739 DRUGINFO D0RC0G PMID27019002-Compound-43a Patented T16739 DRUGINFO D0U1DY Benzenamine derivative 1 Patented T16739 DRUGINFO D0U4DT PMID27019002-Compound-7 Patented T16739 DRUGINFO D0UG5Q PMID27019002-Compound-42a Patented T16739 DRUGINFO D0VB7F PMID27019002-Compound-37a Patented T16739 DRUGINFO D0W8XM PMID27019002-Compound-44 Patented T16739 DRUGINFO D0YI0V PMID27019002-Compound-21a Patented T16739 DRUGINFO D0YX4R PMID27019002-Compound-37b Patented T16739 DRUGINFO D01CIK Heteroaryl-cyclopropylamine derivative 4 Patented T16739 DRUGINFO D02CIX Cyclopropylamine derivative 11 Patented T16739 DRUGINFO D02WXS PMID25399762-Compound-Table 6-11 Patented T16739 DRUGINFO D03MPD PMID27019002-Compound-20a Patented T16739 DRUGINFO D04PWX Cyclopropylamine derivative 9 Patented T16739 DRUGINFO D06KBT PMID25399762-Compound-Table 6-13 Patented T16739 DRUGINFO D06VMN Heteroaryl-cyclopropylamine derivative 3 Patented T16739 DRUGINFO D07DIJ Cyclopropylamine derivative 13 Patented T16739 DRUGINFO D07MQD PMID27019002-Compound-21b Patented T16739 DRUGINFO D09OMM PMID27019002-Compound-48 Patented T16739 DRUGINFO D0AI6J PMID25399762-Compound-Table 6-10 Patented T16739 DRUGINFO D0E7SF PMID25399762-Compound-Table 6-12 Patented T16739 DRUGINFO D0IO2A PMID25399762-Compound-Table 6-9 Patented T16739 DRUGINFO D0PM2S PMID25399762-Compound-Table 6-14 Patented T16739 DRUGINFO D0Q1EG PMID25399762-Compound-Table 6-15 Patented T16739 DRUGINFO D0R2YA Cyclopropylamine derivative 12 Patented T16739 DRUGINFO D0UE4K PMID27019002-Compound-21c Patented T16739 DRUGINFO D0W9VF Cyclopropylamine derivative 10 Patented T16739 DRUGINFO D0WO5W PMID27019002-Compound-47 Patented T16739 DRUGINFO D0WT1Z PMID27019002-Compound-17 Patented T16739 DRUGINFO D0XH9M N-(2-phenylcyclopropyl) amino acid derivative 2 Patented T16739 DRUGINFO D0Z7HE PMID27019002-Compound-46 Patented T16739 DRUGINFO D04OEV Cyclic peptide derivative 1 Patented T16739 DRUGINFO D07NTA Heteroaryl-cyclopropylamine derivative 1 Patented T16739 DRUGINFO D08IOP N-(2-phenylcyclopropyl) amino acid derivative 3 Patented T16739 DRUGINFO D0UL9U N-(2-phenylcyclopropyl) amino acid derivative 1 Patented T16739 DRUGINFO D04OHC Tarnylcypromine derivative 2 Patented T16739 DRUGINFO D0O7IH Tarnylcypromine derivative 3 Patented T16739 DRUGINFO D0C8SX OG-L002 Investigative T16739 DRUGINFO D0EV7U GSK-LSD1 Investigative T16739 DRUGINFO D0L6TQ NCL-1 Investigative T17852 TARGETID T17852 T17852 FORMERID TTDI02148 T17852 UNIPROID PDE9A_HUMAN T17852 TARGNAME Phosphodiesterase 9 (PDE9) T17852 GENENAME PDE9A T17852 TARGTYPE Clinical trial T17852 SYNONYMS High affinity cGMPspecific 3',5'cyclic phosphodiesterase 9A; High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A T17852 FUNCTION Highly specific: compared to other members of the cyclic nucleotide phosphodiesterase family, has the highest affinity and selectivity for cGMP. Specifically regulates natriuretic-peptide-dependent cGMP signaling in heart, acting as a regulator of cardiac hypertrophy in myocytes and muscle. Does not regulate nitric oxide-dependent cGMP in heart. Additional experiments are required to confirm whether its ability to hydrolyze natriuretic-peptide-dependent cGMP is specific to heart or is a general feature of the protein. In brain, involved in cognitive function, such as learning and long-term memory. Specifically hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes. T17852 PDBSTRUC 6A3N; 4Y8C; 4Y87; 4Y86; 4GH6 T17852 BIOCLASS Phosphoric diester hydrolase T17852 ECNUMBER EC 3.1.4.35 T17852 SEQUENCE MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCIATGLPRNTTISLLTTDDAMVSIDPTMPANSERTPYKVRPVAIKQLSAGVEDKRTTSRGQSAERPLRDRRVVGLEQPRREGAFESGQVEPRPREPQGCYQEGQRIPPEREELIQSVLAQVAEQFSRAFKINELKAEVANHLAVLEKRVELEGLKVVEIEKCKSDIKKMREELAARSSRTNCPCKYSFLDNHKKLTPRRDVPTYPKYLLSPETIEALRKPTFDVWLWEPNEMLSCLEHMYHDLGLVRDFSINPVTLRRWLFCVHDNYRNNPFHNFRHCFCVAQMMYSMVWLCSLQEKFSQTDILILMTAAICHDLDHPGYNNTYQINARTELAVRYNDISPLENHHCAVAFQILAEPECNIFSNIPPDGFKQIRQGMITLILATDMARHAEIMDSFKEKMENFDYSNEEHMTLLKMILIKCCDISNEVRPMEVAEPWVDCLLEEYFMQSDREKSEGLPVAPFMDRDKVTKATAQIGFIKFVLIPMFETVTKLFPMVEEIMLQPLWESRDRYEELKRIDDAMKELQKKTDSLTSGATEKSRERSRDVKNSEGDCA T17852 DRUGINFO D0A9IY PF-4447943 Phase 2 T17852 DRUGINFO D0BT7R ASP-4901 Phase 2 T17852 DRUGINFO D0S0FD E2027 Phase 2 T17852 DRUGINFO D0W7UN BI-409306 Phase 2 T17852 DRUGINFO D1Z0IM IMR-687 Phase 2 T17852 DRUGINFO DNGT70 CRD-740 Phase 2 T17852 DRUGINFO DSN1B6 TT-00920 Phase 1 T17852 DRUGINFO D06NIT PF-4181366 Investigative T17852 DRUGINFO D02VHD SCH51866 Investigative T01575 TARGETID T01575 T01575 FORMERID TTDI02173 T01575 UNIPROID SGPL1_HUMAN T01575 TARGNAME Sphingosine-1-phosphate lyase 1 (SGPL1) T01575 GENENAME SGPL1 T01575 TARGTYPE Clinical trial T01575 SYNONYMS hSPL; Sphingosine-1-phosphate aldolase; SPL 1; SP-lyase 1; S1PL; KIAA1252 T01575 FUNCTION Elevates stress-induced ceramide production and apoptosis. Required for global lipid homeostasis in liver and cholesterol homeostasis in fibroblasts. Involved in the regulation of pro-inflammatory response and neutrophil trafficking. Modulates neuronal autophagy via phosphoethanolamine production which regulates accumulation of aggregate-prone proteins such as APP. Seems to play a role in establishing neuronal contact sites and axonal maintenance. Cleaves phosphorylated sphingoid bases (PSBs), such as sphingosine-1-phosphate, into fatty aldehydes and phosphoethanolamine. T01575 PDBSTRUC 4Q6R T01575 BIOCLASS Carbon-carbon lyase T01575 ECNUMBER EC 4.1.2.27 T01575 SEQUENCE MPSTDLLMLKAFEPYLEILEVYSTKAKNYVNGHCTKYEPWQLIAWSVVWTLLIVWGYEFVFQPESLWSRFKKKCFKLTRKMPIIGRKIQDKLNKTKDDISKNMSFLKVDKEYVKALPSQGLSSSAVLEKLKEYSSMDAFWQEGRASGTVYSGEEKLTELLVKAYGDFAWSNPLHPDIFPGLRKIEAEIVRIACSLFNGGPDSCGCVTSGGTESILMACKAYRDLAFEKGIKTPEIVAPQSAHAAFNKAASYFGMKIVRVPLTKMMEVDVRAMRRAISRNTAMLVCSTPQFPHGVIDPVPEVAKLAVKYKIPLHVDACLGGFLIVFMEKAGYPLEHPFDFRVKGVTSISADTHKYGYAPKGSSLVLYSDKKYRNYQFFVDTDWQGGIYASPTIAGSRPGGISAACWAALMHFGENGYVEATKQIIKTARFLKSELENIKGIFVFGNPQLSVIALGSRDFDIYRLSNLMTAKGWNLNQLQFPPSIHFCITLLHARKRVAIQFLKDIRESVTQIMKNPKAKTTGMGAIYGMAQTTVDRNMVAELSSVFLDSLYSTDTVTQGSQMNGSPKPH T01575 DRUGINFO D09ZWH LX2931 Phase 2 T01575 DRUGINFO D01FLN LX-2932 Terminated T01575 DRUGINFO D0S5OU PMID24809814C31 Investigative T28713 TARGETID T28713 T28713 FORMERID TTDC00010 T28713 UNIPROID CHK2_HUMAN T28713 TARGNAME Serine/threonine-protein kinase Chk2 (RAD53) T28713 GENENAME CHEK2 T28713 TARGTYPE Clinical trial T28713 SYNONYMS hCds1; Hucds1; Checkpoint kinase 2; Cds1 homolog; Cds1; CHK2 checkpoint homolog; CHK2 T28713 FUNCTION May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells. Promotes the CCAR2-SIRT1 association and is required for CCAR2-mediated SIRT1 inhibition. Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. T28713 PDBSTRUC 4BDK; 4BDJ; 4BDI; 4BDH; 4BDG T28713 BIOCLASS Kinase T28713 ECNUMBER EC 2.7.11.1 T28713 SEQUENCE MSRESDVEAQQSHGSSACSQPHGSVTQSQGSSSQSQGISSSSTSTMPNSSQSSHSSSGTLSSLETVSTQELYSIPEDQEPEDQEPEEPTPAPWARLWALQDGFANLECVNDNYWFGRDKSCEYCFDEPLLKRTDKYRTYSKKHFRIFREVGPKNSYIAYIEDHSGNGTFVNTELVGKGKRRPLNNNSEIALSLSRNKVFVFFDLTVDDQSVYPKALRDEYIMSKTLGSGACGEVKLAFERKTCKKVAIKIISKRKFAIGSAREADPALNVETEIEILKKLNHPCIIKIKNFFDAEDYYIVLELMEGGELFDKVVGNKRLKEATCKLYFYQMLLAVQYLHENGIIHRDLKPENVLLSSQEEDCLIKITDFGHSKILGETSLMRTLCGTPTYLAPEVLVSVGTAGYNRAVDCWSLGVILFICLSGYPPFSEHRTQVSLKDQITSGKYNFIPEVWAEVSEKALDLVKKLLVVDPKARFTTEEALRHPWLQDEDMKRKFQDLLSEENESTALPQVLAQPSTSRKRPREGEAEGAETTKRPAVCAAVL T28713 DRUGINFO D00EPT E7850 Phase 2 T28713 DRUGINFO D0O6TG PMID27410995-Compound-Figure3j Patented T28713 DRUGINFO D05UGJ XL844 Discontinued in Phase 1 T28713 DRUGINFO D00MLE 2-(4-Phenoxy-phenyl)-1H-benzoimidazol-5-ylamine Investigative T28713 DRUGINFO D02HWR PV-1019 Investigative T28713 DRUGINFO D0D3AS 5-Nitro-2-(4-phenoxy-phenyl)-1H-benzoimidazole Investigative T28713 DRUGINFO D0DH1H CCT-241533 Investigative T28713 DRUGINFO D0EM1C Chk2 inhibitor II Investigative T28713 DRUGINFO D01WAI DEBROMOHYMENIALDISINE Investigative T28713 DRUGINFO D09AID PMID22564207C25b Investigative T22977 TARGETID T22977 T22977 FORMERID TTDR00265 T22977 UNIPROID SODC_HUMAN T22977 TARGNAME Superoxide dismutase Cu-Zn (SOD Cu-Zn) T22977 GENENAME SOD1 T22977 TARGTYPE Clinical trial T22977 SYNONYMS hSod1; Superoxide dismutase [Cu-Zn]; Superoxide dismutase 1; Superoxide dismutase T22977 FUNCTION Destroys radicals which are normally produced within the cells and which are toxic to biological systems. T22977 PDBSTRUC 6FP6; 6FON; 6FOL; 6FOI; 6FLH T22977 BIOCLASS Superoxide dismutase/reductase T22977 ECNUMBER EC 1.15.1.1 T22977 SEQUENCE MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ T22977 DRUGINFO D06WPM Coprexa Phase 3 T22977 DRUGINFO D04GZS Tempol Phase 2 T22977 DRUGINFO D05RTV Superoxide dismutase Phase 2 T22977 DRUGINFO D09IUR Midismase Phase 2 T22977 DRUGINFO D0D9NZ Methoxyestradiol Phase 2 T22977 DRUGINFO D0T8MA ATN-224 Phase 2 T22977 DRUGINFO D0U6PJ PC-SOD Phase 2 T22977 DRUGINFO D0HE9J APN-201 Phase 1/2 T22977 DRUGINFO D06VAQ EUK-189 Phase 1 T22977 DRUGINFO D0G1EH AEOL-10150 Preclinical T22977 DRUGINFO D0N4SU Pegorgotein Terminated T22977 DRUGINFO D0U0PV M-40401 Terminated T22977 DRUGINFO D0U1FZ EUK-207 Terminated T22977 DRUGINFO D02TFB EC-SOD Investigative T22977 DRUGINFO D05SCQ TDI-0079 Investigative T22977 DRUGINFO D0BT4P TDI-0060 Investigative T22977 DRUGINFO D0LE6M VLTS-582 Investigative T22977 DRUGINFO D0W7DP TDI-0107 Investigative T22977 DRUGINFO D0F2ME Acetate Ion Investigative T91696 TARGETID T91696 T91696 FORMERID TTDC00012 T91696 UNIPROID FINC_HUMAN T91696 TARGNAME Fibronectin (FN1) T91696 GENENAME FN1 T91696 TARGTYPE Clinical trial T91696 SYNONYMS FN; Cold-insoluble globulin; CIG T91696 FUNCTION Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization. Participates in the regulation of type I collagen deposition by osteoblasts. T91696 PDBSTRUC 6HNF; 5N48; 5N47; 5M0A; 5J7C T91696 BIOCLASS Fibronectin protein T91696 SEQUENCE MLRGPGPGLLLLAVQCLGTAVPSTGASKSKRQAQQMVQPQSPVAVSQSKPGCYDNGKHYQINQQWERTYLGNALVCTCYGGSRGFNCESKPEAEETCFDKYTGNTYRVGDTYERPKDSMIWDCTCIGAGRGRISCTIANRCHEGGQSYKIGDTWRRPHETGGYMLECVCLGNGKGEWTCKPIAEKCFDHAAGTSYVVGETWEKPYQGWMMVDCTCLGEGSGRITCTSRNRCNDQDTRTSYRIGDTWSKKDNRGNLLQCICTGNGRGEWKCERHTSVQTTSSGSGPFTDVRAAVYQPQPHPQPPPYGHCVTDSGVVYSVGMQWLKTQGNKQMLCTCLGNGVSCQETAVTQTYGGNSNGEPCVLPFTYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQKYSFCTDHTVLVQTRGGNSNGALCHFPFLYNNHNYTDCTSEGRRDNMKWCGTTQNYDADQKFGFCPMAAHEEICTTNEGVMYRIGDQWDKQHDMGHMMRCTCVGNGRGEWTCIAYSQLRDQCIVDDITYNVNDTFHKRHEEGHMLNCTCFGQGRGRWKCDPVDQCQDSETGTFYQIGDSWEKYVHGVRYQCYCYGRGIGEWHCQPLQTYPSSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTPVTSNTVTGETTPFSPLVATSESVTEITASSFVVSWVSASDTVSGFRVEYELSEEGDEPQYLDLPSTATSVNIPDLLPGRKYIVNVYQISEDGEQSLILSTSQTTAPDAPPDTTVDQVDDTSIVVRWSRPQAPITGYRIVYSPSVEGSSTELNLPETANSVTLSDLQPGVQYNITIYAVEENQESTPVVIQQETTGTPRSDTVPSPRDLQFVEVTDVKVTIMWTPPESAVTGYRVDVIPVNLPGEHGQRLPISRNTFAEVTGLSPGVTYYFKVFAVSHGRESKPLTAQQTTKLDAPTNLQFVNETDSTVLVRWTPPRAQITGYRLTVGLTRRGQPRQYNVGPSVSKYPLRNLQPASEYTVSLVAIKGNQESPKATGVFTTLQPGSSIPPYNTEVTETTIVITWTPAPRIGFKLGVRPSQGGEAPREVTSDSGSIVVSGLTPGVEYVYTIQVLRDGQERDAPIVNKVVTPLSPPTNLHLEANPDTGVLTVSWERSTTPDITGYRITTTPTNGQQGNSLEEVVHADQSSCTFDNLSPGLEYNVSVYTVKDDKESVPISDTIIPEVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRITVVAAGEGIPIFEDFVDSSVGYYTVTGLEPGIDYDISVITLINGGESAPTTLTQQTAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKNEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTGLDSPTGIDFSDITANSFTVHWIAPRATITGYRIRHHPEHFSGRPREDRVPHSRNSITLTNLTPGTEYVVSIVALNGREESPLLIGQQSTVSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRTEIDKPSQMQVTDVQDNSISVKWLPSSSPVTGYRVTTTPKNGPGPTKTKTAGPDQTEMTIEGLQPTVEYVVSVYAQNPSGESQPLVQTAVTNIDRPKGLAFTDVDVDSIKIAWESPQGQVSRYRVTYSSPEDGIHELFPAPDGEEDTAELQGLRPGSEYTVSVVALHDDMESQPLIGTQSTAIPAPTDLKFTQVTPTSLSAQWTPPNVQLTGYRVRVTPKEKTGPMKEINLAPDSSSVVVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVSPPRRARVTDATETTITISWRTKTETITGFQVDAVPANGQTPIQRTIKPDVRSYTITGLQPGTDYKIYLYTLNDNARSSPVVIDASTAIDAPSNLRFLATTPNSLLVSWQPPRARITGYIIKYEKPGSPPREVVPRPRPGVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKKTDELPQLVTLPHPNLHGPEILDVPSTVQKTPFVTHPGYDTGNGIQLPGTSGQQPSVGQQMIFEEHGFRRTTPPTTATPIRHRPRPYPPNVGEEIQIGHIPREDVDYHLYPHGPGLNPNASTGQEALSQTTISWAPFQDTSEYIISCHPVGTDEEPLQFRVPGTSTSATLTGLTRGATYNVIVEALKDQQRHKVREEVVTVGNSVNEGLNQPTDDSCFDPYTVSHYAVGDEWERMSESGFKLLCQCLGFGSGHFRCDSSRWCHDNGVNYKIGEKWDRQGENGQMMSCTCLGNGKGEFKCDPHEATCYDDGKTYHVGEQWQKEYLGAICSCTCFGGQRGWRCDNCRRPGGEPSPEGTTGQSYNQYSQRYHQRTNTNVNCPIECFMPLDVQADREDSRE T91696 DRUGINFO D0Y7XG Ocriplasmin Approved T91696 DRUGINFO D0GZ3A L19-TNF-alpha Phase 2 T39321 TARGETID T39321 T39321 FORMERID TTDR00995 T39321 UNIPROID G3P_HUMAN T39321 TARGNAME Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) T39321 GENENAME GAPDH T39321 TARGTYPE Clinical trial T39321 SYNONYMS Peptidyl-cysteine S-nitrosylase GAPDH; OK/SW-cl.12; GAPD; D-glyceraldehyde-3-phosphate dehydrogenase; CDABP0047 T39321 FUNCTION Participates in nuclear events including transcription, RNA transport, DNA replication and apoptosis. Nuclear functions are probably due to the nitrosylase activity that mediates cysteine S-nitrosylation of nuclear target proteins such as SIRT1, HDAC2 and PRKDC. Modulates the organization and assembly of the cytoskeleton. Facilitates the CHP1-dependent microtubule and membrane associations through its ability to stimulate the binding of CHP1 to microtubules. Glyceraldehyde-3-phosphate dehydrogenase is a key enzyme in glycolysis that catalyzes the first step of the pathway by converting D-glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-glyceroyl phosphate. Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes. Upon interferon-gamma treatment assembles into the GAIT complex which binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and suppresses their translation. Has both glyceraldehyde-3-phosphate dehydrogenase and nitrosylase activities, thereby playing a role in glycolysis and nuclear functions, respectively. T39321 PDBSTRUC 6ADE; 4WNI; 4WNC; 3GPD; 2FEH T39321 BIOCLASS Aldehyde/oxo donor oxidoreductase T39321 ECNUMBER EC 1.2.1.12 T39321 SEQUENCE MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVYMFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWYDNEFGYSNRVVDLMAHMASKE T39321 DRUGINFO D06KSV Omigapil Phase 2 T39321 DRUGINFO D0K6UK Saframycin A Investigative T15739 TARGETID T15739 T15739 FORMERID TTDC00118 T15739 UNIPROID P53_HUMAN T15739 TARGNAME Cellular tumor antigen p53 (TP53) T15739 GENENAME TP53 T15739 TARGTYPE Clinical trial T15739 SYNONYMS Tumor suppressor p53; Phosphoprotein p53; P53; Antigen NY-CO-13 T15739 FUNCTION Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2. Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. T15739 PDBSTRUC 6GGF; 6GGE; 6GGD; 6GGC; 6GGB T15739 SEQUENCE MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD T15739 DRUGINFO D04FYL Contusugene ladenovec Phase 3 T15739 DRUGINFO D0D5ZU QPI-1002 Phase 3 T15739 DRUGINFO DY4OZ6 Thymoquinone Phase 2/3 T15739 DRUGINFO D02EOH SGT-53 Phase 2 T15739 DRUGINFO D03XTY APR-246 Phase 2 T15739 DRUGINFO D0CO9B Ad-p53 Phase 2 T15739 DRUGINFO D0K7DV Kevetrin Phase 2 T15739 DRUGINFO D0V2SP INGN-225 Phase 2 T15739 DRUGINFO D0V5JH ALT-801 Phase 2 T15739 DRUGINFO D04SXL APG-115 Phase 2 T15739 DRUGINFO D0KK4N ISA-P53-01 Phase 1/2 T15739 DRUGINFO D03YSQ SAR-405838 Phase 1 T15739 DRUGINFO D05CPS Dendritic cell vaccine Phase 1 T15739 DRUGINFO D0G7YS ONYX-015 Phase 1 T15739 DRUGINFO D0G8CU COTI-2 Phase 1 T15739 DRUGINFO D0Q7AG CGM097 Phase 1 T15739 DRUGINFO D01KTG HDM201 Phase 1 T15739 DRUGINFO D05AHK INGN-234 Discontinued in Phase 2 T15739 DRUGINFO D02NYK Pifithrin-alpha Terminated T15739 DRUGINFO D0LG1K TAR-1 Terminated T15739 DRUGINFO D08PLU 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Investigative T15739 DRUGINFO D01QKK NUTLIN-3 Investigative T15739 DRUGINFO D0F1SN NU-8231 Investigative T44282 TARGETID T44282 T44282 FORMERID TTDR01185 T44282 UNIPROID ALDH2_HUMAN T44282 TARGNAME Mitochondrial aldehyde dehydrogenase (ALDH2) T44282 GENENAME ALDH2 T44282 TARGTYPE Clinical trial T44282 SYNONYMS Aldehyde dehydrogenase, mitochondrial; ALDM; ALDHI; ALDH-E2; ALDH class 2 T44282 FUNCTION Second enzyme of the major oxidative pathway of alcohol metabolism. Catalyzes the chemical transformation from acetaldehyde to acetic acid. Additionally, functions as a protector against oxidative stress. T44282 PDBSTRUC 5L13; 4KWG; 4KWF; 4FR8; 4FQF T44282 BIOCLASS Aldehyde/oxo donor oxidoreductase T44282 ECNUMBER EC 1.2.1.3 T44282 SEQUENCE MLRAAARFGPRLGRRLLSAAATQAVPAPNQQPEVFCNQIFINNEWHDAVSRKTFPTVNPSTGEVICQVAEGDKEDVDKAVKAARAAFQLGSPWRRMDASHRGRLLNRLADLIERDRTYLAALETLDNGKPYVISYLVDLDMVLKCLRYYAGWADKYHGKTIPIDGDFFSYTRHEPVGVCGQIIPWNFPLLMQAWKLGPALATGNVVVMKVAEQTPLTALYVANLIKEAGFPPGVVNIVPGFGPTAGAAIASHEDVDKVAFTGSTEIGRVIQVAAGSSNLKRVTLELGGKSPNIIMSDADMDWAVEQAHFALFFNQGQCCCAGSRTFVQEDIYDEFVERSVARAKSRVVGNPFDSKTEQGPQVDETQFKKILGYINTGKQEGAKLLCGGGIAADRGYFIQPTVFGDVQDGMTIAKEEIFGPVMQILKFKTIEEVVGRANNSTYGLAAAVFTKDLDKANYLSQALQAGTVWVNCYDVFGAQSPFGGYKMSGSGRELGEYGLQAYTEVKTVTVKVPQKNS T44282 DRUGINFO D0D8SN ALD-401 Phase 2 T44282 DRUGINFO D00IXN GS-6637 Phase 1 T44282 DRUGINFO D09PSY ANS-6637 Phase 1 T44282 DRUGINFO D0BI7J FP-045 Phase 1 T44282 DRUGINFO D01WGJ Daidzin Terminated T44282 DRUGINFO D08MTZ ISOFORMONENTIN Investigative T44282 DRUGINFO D0A9RM prunetin Investigative T44282 DRUGINFO D0W4WP CVT-10216 Investigative T44282 DRUGINFO D09CSB crotylaldehyde Investigative T44282 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T15556 TARGETID T15556 T15556 FORMERID TTDR00556 T15556 UNIPROID PAI1_HUMAN T15556 TARGNAME Endothelial plasminogen activator inhibitor (SERPINE1) T15556 GENENAME SERPINE1 T15556 TARGTYPE Clinical trial T15556 SYNONYMS Serpin E1; Plasminogen activator inhibitor type 1; Plasminogen activator inhibitor 1; PLANH1; PAI1; PAI-1 T15556 FUNCTION Inhibits TMPRSS7. Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots. As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading. Acts as a regulator of cell migration, independently of its role as protease inhibitor. It is required for stimulation of keratinocyte migration during cutaneous injury repair. It is involved in cellular and replicative senescence. Plays a role in alveolar type 2 cells senescence in the lung. Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis. Serine protease inhibitor. T15556 PDBSTRUC 9PAI; 6I8S; 5ZLZ; 5BRR; 4IC0 T15556 BIOCLASS Serpin protein T15556 SEQUENCE MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP T15556 DRUGINFO D05ZDJ THR-18 Phase 2 T15556 DRUGINFO D0XJ6C DIAPLASININ Phase 1 T15556 DRUGINFO D0YK7C XR-5118 Terminated T15556 DRUGINFO D05GSZ AR-HO29953XX Investigative T15556 DRUGINFO D05VKW Sideroxylonal C Investigative T15556 DRUGINFO D0U4LV SIDEROXYLONAL B Investigative T15556 DRUGINFO D0WX7S SIDEROXYLONAL A Investigative T01851 TARGETID T01851 T01851 FORMERID TTDC00148 T01851 UNIPROID ITB1_HUMAN T01851 TARGNAME Integrin beta-1 (ITGB1) T01851 GENENAME ITGB1 T01851 TARGTYPE Clinical trial T01851 SYNONYMS VLA-4 subunit beta; MSK12; MDF2; Integrin VLA-4 beta subunit; Glycoprotein IIa; GPIIA; Fibronectin receptor subunit beta; Fibronectin receptor beta subunit; FNRB; CD29 antigen; CD29; Beta(1) integrin T01851 FUNCTION Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha-10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for fibronectin. Alpha-4/beta-1 recognizes one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. Integrin alpha-5/beta-1 is a receptor for fibrinogen. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-6/beta-1 (ITGA6:ITGB1) is present in oocytes and is involved in sperm-egg fusion. Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin, thrombospondin and CSPG4. Alpha-3/beta-1 may mediate with LGALS3 the stimulation by CSPG4 of endothelial cells migration. Integrin alpha-V/beta-1 is a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform 2 interferes with isoform 1 resulting in a dominant negative effect on cell adhesion and migration (in vitro). When associated with alpha-7/beta-1 integrin, regulates cell adhesion and laminin matrix deposition. Involved in promoting endothelial cell motility and angiogenesis. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process and the formation of mineralized bone nodules. May be involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. Together with KRT1 and RACK1, serves as a platform for SRC activation or inactivation. Plays a mechanistic adhesive role during telophase, required for the successful completion of cytokinesis. Integrin alpha-3/beta-1 provides a docking site for FAP (seprase) at invadopodia plasma membranes in a collagen-dependent manner and hence may participate in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGA4:ITGB1 and ITGA5:ITGB1 bind to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. ITGA5:ITGB1 is a receptor for IL1B and binding is essential for IL1B signaling. Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-1 and alpha-11/beta-1 are receptors for collagen. T01851 PDBSTRUC 4WK4; 4WK2; 4WK0; 4WJK; 4DX9 T01851 BIOCLASS Integrin T01851 SEQUENCE MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGK T01851 DRUGINFO D0H4GT 131I-radretumab Phase 1/2 T01851 DRUGINFO DB8MR6 OS2966 Phase 1 T01851 DRUGINFO D0ZT4J JSM 6427 Phase 1 T01851 DRUGINFO D09XED MK-0668 Investigative T01851 DRUGINFO D0R3CY SB-265123 Investigative T01851 DRUGINFO D0B4JU C(-GRGDfL-) Investigative T40276 TARGETID T40276 T40276 FORMERID TTDC00163 T40276 UNIPROID KPCB_HUMAN T40276 TARGNAME Protein kinase C beta (PRKCB) T40276 GENENAME PRKCB T40276 TARGTYPE Clinical trial T40276 SYNONYMS Protein kinase C beta type; PRKCB1; PKCB; PKC-beta; PKC-B T40276 FUNCTION Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signaling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localization and in turn inhibition of BTK activity. Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts as a coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and specifically mediating phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional activation that prevents demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A. In insulin signaling, may function downstream of IRS1 in muscle cells and mediate insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling cascade. May participate in the regulation of glucose transport in adipocytes by negatively modulating the insulin-stimulated translocation of the glucose transporter SLC2A4/GLUT4. Under high glucose in pancreatic beta-cells, is probably involved in the inhibition of the insulin gene transcription, via regulation of MYC expression. In endothelial cells, activation of PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by insulin, which causes endothelial dysfunction. Also involved in triglyceride homeostasis. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation. T40276 PDBSTRUC 2I0E T40276 BIOCLASS Kinase T40276 ECNUMBER EC 2.7.11.13 T40276 SEQUENCE MADPAAGPPPSEGEESTVRFARKGALRQKNVHEVKNHKFTARFFKQPTFCSHCTDFIWGFGKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPASDDPRSKHKFKIHTYSSPTFCDHCGSLLYGLIHQGMKCDTCMMNVHKRCVMNVPSLCGTDHTERRGRIYIQAHIDRDVLIVLVRDAKNLVPMDPNGLSDPYVKLKLIPDPKSESKQKTKTIKCSLNPEWNETFRFQLKESDKDRRLSVEIWDWDLTSRNDFMGSLSFGISELQKASVDGWFKLLSQEEGEYFNVPVPPEGSEANEELRQKFERAKISQGTKVPEEKTTNTVSKFDNNGNRDRMKLTDFNFLMVLGKGSFGKVMLSERKGTDELYAVKILKKDVVIQDDDVECTMVEKRVLALPGKPPFLTQLHSCFQTMDRLYFVMEYVNGGDLMYHIQQVGRFKEPHAVFYAAEIAIGLFFLQSKGIIYRDLKLDNVMLDSEGHIKIADFGMCKENIWDGVTTKTFCGTPDYIAPEIIAYQPYGKSVDWWAFGVLLYEMLAGQAPFEGEDEDELFQSIMEHNVAYPKSMSKEAVAICKGLMTKHPGKRLGCGPEGERDIKEHAFFRYIDWEKLERKEIQPPYKPKARDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSYTNPEFVINV T40276 DRUGINFO D0MV4W RUBOXISTAURIN HYDROCHLORIDE Phase 3 T40276 DRUGINFO D0I6VU Enzastaurin Phase 3 T40276 DRUGINFO D0W3LI LY333531 Phase 2 T40276 DRUGINFO D0F5HB Sotrastaurin acetate Phase 2 T40276 DRUGINFO D98VPM MS-553 Phase 1 T40276 DRUGINFO D0E8UV Linetastine Discontinued in Phase 2 T40276 DRUGINFO D0X0HN LY-317644 Terminated T40276 DRUGINFO D0R5ZR RO-320432 Terminated T40276 DRUGINFO D0R2TM BALANOL Terminated T40276 DRUGINFO D04TBJ O-Phosphoethanolamine Investigative T40276 DRUGINFO D0H7DQ K00248 Investigative T40276 DRUGINFO D0B1SO TANNIN Investigative T40276 DRUGINFO D0Q3XB PUNICAFOLIN Investigative T40276 DRUGINFO D0X2DH 3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione Investigative T40276 DRUGINFO D04OHM 4-cyclopentyliden(4-hydroxyphenyl)methylphenol Investigative T40276 DRUGINFO D0L1YA (-)-Cercosporamide Investigative T40276 DRUGINFO D06TLL Go 6983 Investigative T40276 DRUGINFO D00TWA [2,2':5',2'']Terthiophen-4-yl-methanol Investigative T40276 DRUGINFO D02PUV 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol Investigative T40276 DRUGINFO D02QME 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile Investigative T40276 DRUGINFO D05LRV [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde Investigative T40276 DRUGINFO D09TSC Ro-32-0557 Investigative T40276 DRUGINFO D09XIE 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile Investigative T40276 DRUGINFO D0A8MN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile Investigative T40276 DRUGINFO D0D3MR [2,2':5',2'']Terthiophene-4-carbaldehyde Investigative T40276 DRUGINFO D0Q3GQ 4-cycloheptyliden(4-hydroxyphenyl)methylphenol Investigative T40276 DRUGINFO D0S9UK 2,3,3-Triphenyl-acrylonitrile Investigative T40276 DRUGINFO D0T0UH 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile Investigative T40276 DRUGINFO D0V9SW 4-cyclohexyliden(4-hydroxyphenyl)methylphenol Investigative T40276 DRUGINFO D04JNZ PROSTRATIN Investigative T40276 DRUGINFO D06ZCX LY-326449 Investigative T40276 DRUGINFO D0L8HO RO-316233 Investigative T67103 TARGETID T67103 T67103 FORMERID TTDR00473 T67103 UNIPROID ITAV_HUMAN T67103 TARGNAME Integrin alpha-V (ITGAV) T67103 GENENAME ITGAV T67103 TARGTYPE Clinical trial T67103 SYNONYMS Vitronectin receptor subunit alpha; Vitronectin receptor alpha subunit; Vitronectin receptor; VTNR; VNRA; MSK8; CD51 antigen; CD51 T67103 FUNCTION The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling. ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling. ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling. ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling. ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling. ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation. T67103 PDBSTRUC 6DJP; 6AVU; 6AVR; 6AVQ; 5NEU T67103 BIOCLASS Integrin T67103 SEQUENCE MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET T67103 DRUGINFO D0F9QH Abituzumab Phase 2 T67103 DRUGINFO D07HKV IMGN-388 Phase 1 T67103 DRUGINFO D0LT1S SB-223245 Terminated T67103 DRUGINFO D06LUT G(D-Pen)-G-H-R-G-D-L-R-C-A Investigative T67103 DRUGINFO D06WNY NAVPNLRGDLQVLAQKVART Investigative T67103 DRUGINFO D07SFV C[RGDf-(3S)-Carboxymorpholine] Investigative T67103 DRUGINFO D0F7SE C[RGDf-(3R)-Carboxymorpholine] Investigative T67103 DRUGINFO D00YBU C(RGDfF) Investigative T67103 DRUGINFO D01AXA Ac-Asp-Arg-Leu-Asp-Ser-OH Investigative T67103 DRUGINFO D01BZH C[-Arg-Gly-Asp-Acpca21-] Investigative T67103 DRUGINFO D01MGI C-[-Arg-Gly-Asp-Acpca32-] Investigative T67103 DRUGINFO D03KLT Cyclo-[-Arg-Gly-Asp-Amp22-] Investigative T67103 DRUGINFO D03YLY Cyclo-[-Arg-Gly-Asp-Amp21-] Investigative T67103 DRUGINFO D04MCL Cypate-[(RGD)2-NH2]2 Investigative T67103 DRUGINFO D04WVG C[-Arg-Gly-Asp-Acpca35-] Investigative T67103 DRUGINFO D05EWB C[RGDf-(S)-alpha-TfmV] Investigative T67103 DRUGINFO D05GXK Cyclo-[-Arg-Gly-Asp-Amp26-] Investigative T67103 DRUGINFO D05MJG E[c(RGDyK)]2 Investigative T67103 DRUGINFO D05VEC C-[-Arg-Gly-Asp-Acpca30-] Investigative T67103 DRUGINFO D06JLN C[-Arg-Gly-Asp-Acpca36-] Investigative T67103 DRUGINFO D06LKH Gly-Arg-Gly-Asp-Ser Investigative T67103 DRUGINFO D07QJD Cyclo-[-Arg-Gly-Asp-Amp25-] Investigative T67103 DRUGINFO D07UOF C(RGDfMeF) Investigative T67103 DRUGINFO D08CFM C[RGDf-(R)-alpha-TfmV] Investigative T67103 DRUGINFO D08DSG C(Arg-Gly-Asp-D-Phe-Val) Investigative T67103 DRUGINFO D09PLA C-[-Arg-Gly-Asp-Acpca31-] Investigative T67103 DRUGINFO D0D4QZ RGDechi Investigative T67103 DRUGINFO D0G8JI Cyclo(RGDfV) (control) Investigative T67103 DRUGINFO D0H4EK C[RGDf-(R)-N-Me-alpha-TfmF] Investigative T67103 DRUGINFO D0H4MB ISONIPECOTAMIDE Investigative T67103 DRUGINFO D0I5BY C[RGDf-(S)-alpha-TfmF] Investigative T67103 DRUGINFO D0ID6U CYCLORGDFV Investigative T67103 DRUGINFO D0J6SP Cyclo-[-Arg-Gly-Asp-Amp28-] Investigative T67103 DRUGINFO D0K5DM E[c(RGDyK)]2-PTX conjugate Investigative T67103 DRUGINFO D0L2PQ Cypate-[(RGD)3-NH2]1 Investigative T67103 DRUGINFO D0LF7W C[-Arg-Gly-Asp-Acpca19-] Investigative T67103 DRUGINFO D0LV6B Gly-Arg-Gly-Asp-Ser-Pro-Lys Investigative T67103 DRUGINFO D0M0BN C[RGDf-(R)-alpha-TfmF] Investigative T67103 DRUGINFO D0M6NQ C[RGDf-(S)-N-Me-alpha-TfmF] Investigative T67103 DRUGINFO D0N9NA Cypate-[(RGD)4-NH2]2 Investigative T67103 DRUGINFO D0O6DN C[-Arg-Gly-Asp-Acpca34-] Investigative T67103 DRUGINFO D0O9FL Cyclo-[-Arg-Gly-Asp-Amp24-] Investigative T67103 DRUGINFO D0P4RB Cypate-[(RGD)2-NH2]1 Investigative T67103 DRUGINFO D0R9AD N-(3,5-dichlorophenyl)imidodicarbonimidic diamide Investigative T67103 DRUGINFO D0R9GW C[-Arg-Gly-Asp-Acpca22-] Investigative T67103 DRUGINFO D0R9SJ ST-1646 Investigative T67103 DRUGINFO D0T1II Cyclo[RGDfK(cypate)] Investigative T67103 DRUGINFO D0U0VF Cyclo-[-Arg-Gly-Asp-Amp27-] Investigative T67103 DRUGINFO D0U2NV C[RGD-(R)-alpha-TfmfV] Investigative T67103 DRUGINFO D0UE7H C-[-Arg-Gly-Asp-Acpca33-] Investigative T67103 DRUGINFO D0UO0Y Cypate-[(RGD)3-NH2]2 Investigative T67103 DRUGINFO D0V0JC C[RGD-(S)-alpha-TfmfV] Investigative T67103 DRUGINFO D0W6CJ C[-Arg-Gly-Asp-Acpca20-] Investigative T67103 DRUGINFO D0WK2F C[RGDf-(S,R)-alpha-Dfm-F] Investigative T67103 DRUGINFO D0X4EE AcDRGDS Investigative T67103 DRUGINFO D0Y8UD Cypate-[(RGD)4-NH2]1 Investigative T67103 DRUGINFO D0Z6WZ Cyclo-[-Arg-Gly-Asp-Amp23-] Investigative T67103 DRUGINFO D0R3CY SB-265123 Investigative T67103 DRUGINFO D0B4JU C(-GRGDfL-) Investigative T93509 TARGETID T93509 T93509 FORMERID TTDC00017 T93509 UNIPROID CALCA_HUMAN T93509 TARGNAME Calcitonin gene-related peptide 1 (CALCA) T93509 GENENAME CALCA T93509 TARGTYPE Clinical trial T93509 SYNONYMS Calcitonin gene-related peptide I; CGRP-I; CALCA; CALC1; Alpha-type CGRP T93509 FUNCTION CGRP induces vasodilation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role. It also elevates platelet cAMP. T93509 PDBSTRUC 6E3Y; 1LS7 T93509 BIOCLASS Cytotoxic amylin family T93509 SEQUENCE MGFQKFSPFLALSILVLLQAGSLHAAPFRSALESSPADPATLSEDEARLLLAALVQDYVQMKASELEQEQEREGSRIIAQKRACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAFGRRRRDLQA T93509 DRUGINFO D04BUH Cizolirtine Phase 2 T93509 DRUGINFO D02YXI Ac-WVTH[hArg]LAGLLS[hArg]SGGVVRKNFVPTDVGPFAF-NH2 Investigative T93509 DRUGINFO D03VFP Ac-WVEHRLKGELSRKGGVV[hArg]KNFVPTDVGPFAF-NH2 Investigative T93509 DRUGINFO D05LMD VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2 Investigative T93509 DRUGINFO D06JYM Ac-WVTHQLAGLLSQSGGVVRKNFVPTDVGPFAF-NH2 Investigative T93509 DRUGINFO D08WZV Ac-VTHRLAGLLSRSGGVVKNNFVPTDVGPFAF-NH2 Investigative T93509 DRUGINFO D09EJG Ac-WVTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2 Investigative T93509 DRUGINFO D09WRS Ac-WVTH[Cit]LAGLLSRSGGVVRKNFVPTDVGPFAF-NH2 Investigative T93509 DRUGINFO D0G7CO Ac-WVTHRLAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2 Investigative T93509 DRUGINFO D0I2HH Ac-WVTH[Cit]LAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2 Investigative T93509 DRUGINFO D0I2PK Ac-VTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2 Investigative T93509 DRUGINFO D0U4BO WVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2 Investigative T93509 DRUGINFO D0I2KW FV-Aib-TDVGPFAF Investigative T36935 TARGETID T36935 T36935 FORMERID TTDR00503 T36935 UNIPROID KLK3_HUMAN T36935 TARGNAME Prostate specific antigen (KLK3) T36935 GENENAME KLK3 T36935 TARGTYPE Clinical trial T36935 SYNONYMS Seminin; Semenogelase; Prostate-specific antigen; PSA; P-30 antigen; Kallikrein-3; Gamma-seminoprotein; APS T36935 FUNCTION Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum. T36935 PDBSTRUC 3QUM; 2ZCL; 2ZCK; 2ZCH; 2PSA T36935 BIOCLASS Peptidase T36935 ECNUMBER EC 3.4.21.77 T36935 SEQUENCE MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYRKWIKDTIVANP T36935 DRUGINFO D08KGY PRX-302 Phase 3 T36935 DRUGINFO D0A3FZ Rilimogene galvacirepvec Phase 3 T36935 DRUGINFO D0G2MR ProstaVac Phase 3 T36935 DRUGINFO D0U3RV Motexafin lutetium Phase 3 T36935 DRUGINFO D09SCP ADXS-PSA Phase 1/2 T36935 DRUGINFO D08GFN MVA-BN Breast Phase 1 T36935 DRUGINFO D04BPQ PMID23692593C20 Investigative T36935 DRUGINFO D07NCC VTT-201 Investigative T36935 DRUGINFO D0BK3Z ProstaRex Investigative T36935 DRUGINFO D0Z3AB Anti-PSA mabs Investigative T41141 TARGETID T41141 T41141 FORMERID TTDR01031 T41141 UNIPROID CATL1_HUMAN T41141 TARGNAME Cathepsin L (CTSL) T41141 GENENAME CTSL T41141 TARGTYPE Clinical trial T41141 SYNONYMS Major excreted protein; MEP; Cathepsin L1; CTSL1 T41141 FUNCTION Important for the overall degradation of proteins in lysosomes. T41141 PDBSTRUC 6F06; 6EZX; 6EZP; 5MQY; 5MAJ T41141 BIOCLASS Peptidase T41141 ECNUMBER EC 3.4.22.15 T41141 SEQUENCE MNPTLILAAFCLGIASATLTFDHSLEAQWTKWKAMHNRLYGMNEEGWRRAVWEKNMKMIELHNQEYREGKHSFTMAMNAFGDMTSEEFRQVMNGFQNRKPRKGKVFQEPLFYEAPRSVDWREKGYVTPVKNQGQCGSCWAFSATGALEGQMFRKTGRLISLSEQNLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPKYSVANDTGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVKNSWGEEWGMGGYVKMAKDRRNHCGIASAASYPTV T41141 DRUGINFO D0X6QL KGP94 Clinical trial T41141 DRUGINFO D0J0WG PMID27998201-Compound-1 Patented T41141 DRUGINFO D0ZN3M PMID27998201-Compound-19 Patented T41141 DRUGINFO D01MKD Phenylalanine derivative 1 Patented T41141 DRUGINFO D0JD5W PMID27998201-Compound-7 Patented T41141 DRUGINFO D0X1AF PMID27998201-Compound-6 Patented T41141 DRUGINFO D06XTA PMID27998201-Compound-17 Patented T41141 DRUGINFO D04VGR PMID27998201-Compound-9 Patented T41141 DRUGINFO D06LLT PMID25399719-Compound-17 Patented T41141 DRUGINFO D05OIU PMID27998201-Compound-5 Patented T41141 DRUGINFO D06XCD PMID27998201-Compound-12 Patented T41141 DRUGINFO DW24LQ CLIK-148 Preclinical T41141 DRUGINFO DYU3I8 CLIK-181 Preclinical T41141 DRUGINFO DCZ16N SD1002 Preclinical T41141 DRUGINFO DM69TL Z-Phe-Ala-diazomethylketone Preclinical T41141 DRUGINFO DSM03D SD1003 Preclinical T41141 DRUGINFO D0Z0PR L-006235-1 Preclinical T41141 DRUGINFO D00VAN [(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone Investigative T41141 DRUGINFO D01CSE Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone Investigative T41141 DRUGINFO D01YTS CAA0225 Investigative T41141 DRUGINFO D02RWL BIPHENYL-4-YL-ACETALDEHYDE Investigative T41141 DRUGINFO D08TWJ Peptide alpha-keto-beta-aldehyde-based inhibitors Investigative T41141 DRUGINFO D09NBP (3-Bromobenzoylpyridine)thiosemicarbazone Investigative T41141 DRUGINFO D0B4JS 1-(1,3-diphenylpropylidene)thiosemicarbazide Investigative T41141 DRUGINFO D0J7OM 6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile Investigative T41141 DRUGINFO D0LL1F [2-Phenylacetophenone]thiosemicarbazone Investigative T41141 DRUGINFO D0M3AP Bis(3-Fluorophenyl)-ketone]thiosemicarbazone Investigative T41141 DRUGINFO D0MD6D 9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile Investigative T41141 DRUGINFO D03JYN 1-(phenyl(p-tolyl)methylene)thiosemicarbazide Investigative T41141 DRUGINFO D04DFX Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone Investigative T41141 DRUGINFO D0B2JC [(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone Investigative T41141 DRUGINFO D0JF8D N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile Investigative T41141 DRUGINFO D0T7QF (S)-tert-butyl 1-oxohexan-2-ylcarbamate Investigative T41141 DRUGINFO D01YNC N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile Investigative T41141 DRUGINFO D06VIP N-(tert-butoxycarbonyl)-valyl-glycine-nitrile Investigative T41141 DRUGINFO D07FLB N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile Investigative T41141 DRUGINFO D07RSA N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile Investigative T41141 DRUGINFO D09AHN N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile Investigative T41141 DRUGINFO D0A8OV N-acetyl-phenylalanyl-glycine-nitrile Investigative T41141 DRUGINFO D0G8OD N-(benzyloxycarbonyl)-leucyl-glycine-nitrile Investigative T41141 DRUGINFO D0JN8Q N-benzoyl-phenylalanyl-glycine-nitrile Investigative T41141 DRUGINFO D0U0XG N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile Investigative T41141 DRUGINFO D0VE0F (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate Investigative T41141 DRUGINFO D05AMX Cysteinesulfonic Acid Investigative T41141 DRUGINFO D0D0LD L-873724 Investigative T68163 TARGETID T68163 T68163 FORMERID TTDI02273 T68163 UNIPROID LYN_HUMAN T68163 TARGNAME Tyrosine-protein kinase Lyn (JTK8) T68163 GENENAME LYN T68163 TARGTYPE Clinical trial T68163 SYNONYMS p56Lyn; p53Lyn; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; Lck/Yes-related novel protein tyrosine kinase T68163 FUNCTION Functions primarily as negative regulator, but can also function as activator, depending on the context. Required for the initiation of the B-cell response, but also for its down-regulation and termination. Plays an important role in the regulation of B-cell differentiation, proliferation, survival and apoptosis, and is important for immune self-tolerance. Acts downstream of several immune receptors, including the B-cell receptor, CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4. Plays a role in the inflammatory response to bacterial lipopolysaccharide. Mediates the responses to cytokines and growth factors in hematopoietic progenitors, platelets, erythrocytes, and in mature myeloid cells, such as dendritic cells, neutrophils and eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an important role in integrin signaling. Regulates cell proliferation, survival, differentiation, migration, adhesion, degranulation, and cytokine release. Down-regulates signaling pathways by phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIM), that then serve as binding sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1, that modulate signaling by dephosphorylation of kinases and their substrates. Phosphorylates LIME1 in response to CD22 activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A, CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B, SYK and TEC. Promotes phosphorylation of SIRPA, PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates phosphorylation of the BCR-ABL fusion protein. Required for rapid phosphorylation of FER in response to FCER1 activation. Mediates KIT phosphorylation. Acts as an effector of EPOR (erythropoietin receptor) in controlling KIT expression and may play a role in erythroid differentiation during the switch between proliferation and maturation. Depending on the context, activates or inhibits several signaling cascades. Regulates phosphatidylinositol 3-kinase activity and AKT1 activation. Regulates activation of the MAP kinase signaling cascade, including activation of MAP2K1/MEK1, MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates activation of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-72'. Kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation. Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. T68163 PDBSTRUC 6NMW; 5XY1; 3A4O; 1WA7; 1W1F T68163 BIOCLASS Kinase T68163 ECNUMBER EC 2.7.10.2 T68163 SEQUENCE MGCIKSKGKDSLSDDGVDLKTQPVRNTERTIYVRDPTSNKQQRPVPESQLLPGQRFQTKDPEEQGDIVVALYPYDGIHPDDLSFKKGEKMKVLEEHGEWWKAKSLLTKKEGFIPSNYVAKLNTLETEEWFFKDITRKDAERQLLAPGNSAGAFLIRESETLKGSFSLSVRDFDPVHGDVIKHYKIRSLDNGGYYISPRITFPCISDMIKHYQKQADGLCRRLEKACISPKPQKPWDKDAWEIPRESIKLVKRLGAGQFGEVWMGYYNNSTKVAVKTLKPGTMSVQAFLEEANLMKTLQHDKLVRLYAVVTREEPIYIITEYMAKGSLLDFLKSDEGGKVLLPKLIDFSAQIAEGMAYIERKNYIHRDLRAANVLVSESLMCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGCFTIKSDVWSFGILLYEIVTYGKIPYPGRTNADVMTALSQGYRMPRVENCPDELYDIMKMCWKEKAEERPTFDYLQSVLDDFYTATEGQYQQQP T68163 DRUGINFO D0G0VV Bafetinib Phase 2 T68163 DRUGINFO D0U3XL JNJ-26483327 Phase 1 T68163 DRUGINFO D0JZ2B Alkynyl-substituted pyrimidinyl-pyrrole derivative 1 Patented T68163 DRUGINFO D04TLI PMID17600705C23 Investigative T68163 DRUGINFO D0X7IC NG-25 Investigative T05409 TARGETID T05409 T05409 FORMERID TTDS00449 T05409 UNIPROID NEP_HUMAN T05409 TARGNAME Neutral endopeptidase (MME) T05409 GENENAME MME T05409 TARGTYPE Clinical trial T05409 SYNONYMS Skin fibroblast elastase; SFE; Neutral endopeptidase 24.11; Neprilysin; NEP protein; Enkephalinase; EPN; Common acute lymphocytic leukemia antigen; CD10; CALLA; Atriopeptidase T05409 FUNCTION Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond. Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9. Involved in the degradation of atrial natriuretic factor (ANF). Displays UV-inducible elastase activity toward skin preelastic and elastic fibers. Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids. T05409 PDBSTRUC 6GID; 5JMY; 4CTH; 2YB9; 2QPJ T05409 BIOCLASS Peptidase T05409 ECNUMBER EC 3.4.24.11 T05409 SEQUENCE MGKSESQMDITDINTPKPKKKQRWTPLEISLSVLVLLLTIIAVTMIALYATYDDGICKSSDCIKSAARLIQNMDATTEPCTDFFKYACGGWLKRNVIPETSSRYGNFDILRDELEVVLKDVLQEPKTEDIVAVQKAKALYRSCINESAIDSRGGEPLLKLLPDIYGWPVATENWEQKYGASWTAEKAIAQLNSKYGKKVLINLFVGTDDKNSVNHVIHIDQPRLGLPSRDYYECTGIYKEACTAYVDFMISVARLIRQEERLPIDENQLALEMNKVMELEKEIANATAKPEDRNDPMLLYNKMTLAQIQNNFSLEINGKPFSWLNFTNEIMSTVNISITNEEDVVVYAPEYLTKLKPILTKYSARDLQNLMSWRFIMDLVSSLSRTYKESRNAFRKALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKRAEEKALAIKERIGYPDDIVSNDNKLNNEYLELNYKEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAAVVNAFYSSGRNQIVFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSASNFKEQSQCMVYQYGNFSWDLAGGQHLNGINTLGENIADNGGLGQAYRAYQNYIKKNGEEKLLPGLDLNHKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSPGNFRIIGTLQNSAEFSEAFHCRKNSYMNPEKKCRVW T05409 DRUGINFO D0LJ8C LCZ696 Approved T05409 DRUGINFO D0WF7K Candoxatril Phase 3 T05409 DRUGINFO D09JES Sampatrilat Phase 2 T05409 DRUGINFO D01HDP SLV 306 Phase 2 T05409 DRUGINFO D03CPM SLV-334 Phase 2 T05409 DRUGINFO D0N1SH VX-15 Phase 2 T05409 DRUGINFO D00ERV Gallopamil Phase 2 T05409 DRUGINFO D02HUY Debio 0827 Phase 1 T05409 DRUGINFO D04SKM CART-10 cells Phase 1 T05409 DRUGINFO D06WTQ TD-0714 Phase 1 T05409 DRUGINFO D08HKK CD10-CART Phase 1 T05409 DRUGINFO D0WY3J Pfizer 4 Phase 1 T05409 DRUGINFO D00CLC SLV-338 Phase 1 T05409 DRUGINFO D0C1AY GW-796406 Phase 1 T05409 DRUGINFO D0K6SM Ilepatril Discontinued in Phase 2/3 T05409 DRUGINFO D01IPI Gemopatrilat Discontinued in Phase 2 T05409 DRUGINFO D02HBW SCH-32615 Discontinued in Phase 2 T05409 DRUGINFO D09PYD CGS-25462 Discontinued in Phase 2 T05409 DRUGINFO D0H1GF Sch-34826 Discontinued in Phase 2 T05409 DRUGINFO D0L2IQ Fasidotril Discontinued in Phase 2 T05409 DRUGINFO D0M0RN SCH-42495 Discontinued in Phase 2 T05409 DRUGINFO D0N5HN M-100240 Discontinued in Phase 2 T05409 DRUGINFO D04LAQ Candoxatrilat Discontinued in Phase 1 T05409 DRUGINFO D02DLE CGS-26303 Terminated T05409 DRUGINFO D06WBA SQ-28603 Terminated T05409 DRUGINFO D0DS4P CGS-26393 Terminated T05409 DRUGINFO D04MBS BMS-182657 Terminated T05409 DRUGINFO D05UQD Omapatrilat Terminated T05409 DRUGINFO D0F9BX GW-660511 Terminated T05409 DRUGINFO D0I5QZ SQ-26332 Terminated T05409 DRUGINFO D0KR3X CGS-30440 Terminated T05409 DRUGINFO D0K9YR SCH-54470 Terminated T05409 DRUGINFO D02NQB LBQ657 Investigative T05409 DRUGINFO D0DY1C 9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid Investigative T05409 DRUGINFO D0K1MA CGS-314447 Investigative T05409 DRUGINFO D0PB5Q Thiorphan Investigative T05409 DRUGINFO D04DHD fasidotrilat Investigative T05409 DRUGINFO D09GXF RB-105 Investigative T05409 DRUGINFO D09NAJ Phosphoramidon Investigative T05409 DRUGINFO D09SZG [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala Investigative T05409 DRUGINFO D0N4RO PMID18078750C1b Investigative T29879 TARGETID T29879 T29879 FORMERID TTDC00020 T29879 UNIPROID ITA5_HUMAN T29879 TARGNAME Integrin alpha-5 (ITGA5) T29879 GENENAME ITGA5 T29879 TARGTYPE Clinical trial T29879 SYNONYMS VLA-5; Integrin alpha-F; Integrin alpha-5 light chain; Integrin alpha-5 heavy chain; Fibronectin receptor subunit alpha; FNRA; CD49e antigen; CD49e; CD49 antigen-like family member E T29879 FUNCTION It recognizes the sequence R-G-D in its ligands. ITGA5:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. ITGA5:ITGB1 is a receptor for IL1B and binding is essential for IL1B signaling. Integrin alpha-5/beta-1 (ITGA5:ITGB1) is a receptor for fibronectin and fibrinogen. T29879 PDBSTRUC 4WK4; 4WK2; 4WK0; 4WJK; 3VI4 T29879 BIOCLASS Integrin T29879 SEQUENCE MGSRTPESPLHAVQLRWGPRRRPPLLPLLLLLLPPPPRVGGFNLDAEAPAVLSGPPGSFFGFSVEFYRPGTDGVSVLVGAPKANTSQPGVLQGGAVYLCPWGASPTQCTPIEFDSKGSRLLESSLSSSEGEEPVEYKSLQWFGATVRAHGSSILACAPLYSWRTEKEPLSDPVGTCYLSTDNFTRILEYAPCRSDFSWAAGQGYCQGGFSAEFTKTGRVVLGGPGSYFWQGQILSATQEQIAESYYPEYLINLVQGQLQTRQASSIYDDSYLGYSVAVGEFSGDDTEDFVAGVPKGNLTYGYVTILNGSDIRSLYNFSGEQMASYFGYAVAATDVNGDGLDDLLVGAPLLMDRTPDGRPQEVGRVYVYLQHPAGIEPTPTLTLTGHDEFGRFGSSLTPLGDLDQDGYNDVAIGAPFGGETQQGVVFVFPGGPGGLGSKPSQVLQPLWAASHTPDFFGSALRGGRDLDGNGYPDLIVGSFGVDKAVVYRGRPIVSASASLTIFPAMFNPEERSCSLEGNPVACINLSFCLNASGKHVADSIGFTVELQLDWQKQKGGVRRALFLASRQATLTQTLLIQNGAREDCREMKIYLRNESEFRDKLSPIHIALNFSLDPQAPVDSHGLRPALHYQSKSRIEDKAQILLDCGEDNICVPDLQLEVFGEQNHVYLGDKNALNLTFHAQNVGEGGAYEAELRVTAPPEAEYSGLVRHPGNFSSLSCDYFAVNQSRLLVCDLGNPMKAGASLWGGLRFTVPHLRDTKKTIQFDFQILSKNLNNSQSDVVSFRLSVEAQAQVTLNGVSKPEAVLFPVSDWHPRDQPQKEEDLGPAVHHVYELINQGPSSISQGVLELSCPQALEGQQLLYVTRVTGLNCTTNHPINPKGLELDPEGSLHHQQKREAPSRSSASSGPQILKCPEAECFRLRCELGPLHQQESQSLQLHFRVWAKTFLQREHQPFSLQCEAVYKALKMPYRILPRQLPQKERQVATAVQWTKAEGSYGVPLWIIILAILFGLLLLGLLIYILYKLGFFKRSLPYGTAMEKAQLKPPATSDA T29879 DRUGINFO D0ZT4J JSM 6427 Phase 1 T29879 DRUGINFO D0F9QP GW-559090 Discontinued in Phase 2 T29879 DRUGINFO D01VSK TR-14531 Discontinued in Phase 1 T29879 DRUGINFO D03EIC ZD-7349 Discontinued in Phase 1 T29879 DRUGINFO D0I5PM DW-908e Discontinued in Phase 1 T29879 DRUGINFO D0B4JU C(-GRGDfL-) Investigative T21669 TARGETID T21669 T21669 FORMERID TTDI02088 T21669 UNIPROID GSTP1_HUMAN T21669 TARGNAME Glutathione S-transferase P (GSTP1) T21669 GENENAME GSTP1 T21669 TARGTYPE Clinical trial T21669 SYNONYMS GSTP11; GSTP1-1; GST3; GST classpi; GST class-pi; FAEES3 T21669 FUNCTION Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration. Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. T21669 PDBSTRUC 9GSS; 8GSS; 7GSS; 6GSS; 6AP9 T21669 BIOCLASS Alkyl aryl transferase T21669 ECNUMBER EC 2.5.1.18 T21669 SEQUENCE MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ T21669 DRUGINFO D0A9SA Canfosfamide Phase 3 T21669 DRUGINFO D0F5VD Ezatiostat Phase 2 T25703 TARGETID T25703 T25703 FORMERID TTDC00134 T25703 UNIPROID HMOX1_HUMAN T25703 TARGNAME Heme oxygenase 1 (HMOX1) T25703 GENENAME HMOX1 T25703 TARGTYPE Clinical trial T25703 SYNONYMS HO1; HO-1; HO T25703 FUNCTION Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Exhibits cytoprotective effects since excess of free heme sensitizes cells to undergo apoptosis. T25703 PDBSTRUC 6EHA; 5BTQ; 4WD4; 3TGM; 3K4F T25703 BIOCLASS Paired donor oxygen oxidoreductase T25703 ECNUMBER EC 1.14.14.18 T25703 SEQUENCE MERPQPDSMPQDLSEALKEATKEVHTQAENAEFMRNFQKGQVTRDGFKLVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYLGDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQSPSRAPGLRQRASNKVQDSAPVETPRGKPPLNTRSQAPLLRWVLTLSFLVATVAVGLYAM T25703 DRUGINFO D02JAY Stannsoporfin Phase 2 T25703 DRUGINFO D02AVZ 2-Phenylheme Investigative T25703 DRUGINFO D06SCF Biliverdine Ix Alpha Investigative T25703 DRUGINFO D06UNX Verdoheme Investigative T25703 DRUGINFO D0HX0D Tin protoporphyrin Investigative T25703 DRUGINFO D0K1NM 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone Investigative T25703 DRUGINFO D0S8UN 12-Phenylheme Investigative T25703 DRUGINFO D0W7LK 2-Propanol, Isopropanol Investigative T25703 DRUGINFO D06EWG Formic Acid Investigative T25703 DRUGINFO D0UU1I Heme Investigative T77594 TARGETID T77594 T77594 FORMERID TTDI02087 T77594 UNIPROID BIP_HUMAN T77594 TARGNAME Endoplasmic reticulum chaperone BiP (HSPA5) T77594 GENENAME HSPA5 T77594 TARGTYPE Clinical trial T77594 SYNONYMS Immunoglobulin heavy chainbinding protein; Immunoglobulin heavy chain-binding protein; Heat shock protein family A member 5; Heat shock protein 70 family protein 5; Heat shock 70 kDa protein 5; HSP70 family protein 5; GRP78; GRP-78; Endoplasmic reticulum lumenal Ca(2+)binding protein grp78; Binding-immunoglobulin protein; BiP; 78 kDa glucose-regulated protein T77594 FUNCTION Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10/ERdj5, probably to facilitate the release of DNAJC10/ERdj5 from its substrate. Acts as a key repressor of the ERN1/IRE1-mediated unfolded protein response (UPR). In the unstressed endoplasmic reticulum, recruited by DNAJB9/ERdj4 to the luminal region of ERN1/IRE1, leading to disrupt the dimerization of ERN1/IRE1, thereby inactivating ERN1/IRE1. Accumulation of misfolded protein in the endoplasmic reticulum causes release of HSPA5/BiP from ERN1/IRE1, allowing homodimerization and subsequent activation of ERN1/IRE1. Plays an auxiliary role in post-translational transport of small presecretory proteins across endoplasmic reticulum (ER). May function as an allosteric modulator for SEC61 channel-forming translocon complex, likely cooperating with SEC62 to enable the productive insertion of these precursors into SEC61 channel. Appears to specifically regulate translocation of precursors having inhibitory residues in their mature region that weaken channel gating. Endoplasmic reticulum chaperone that plays a key role in protein folding and quality control in the endoplasmic reticulum lumen. T77594 PDBSTRUC 6DFO; 6DFM; 6CZ1; 6ASY; 5F2R T77594 BIOCLASS Acid anhydride hydrolase T77594 ECNUMBER EC 3.6.4.10 T77594 SEQUENCE MKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTAEKDEL T77594 DRUGINFO D06PZC SAM-6 Phase 1 T77594 DRUGINFO D0Q4LG IT-139 Phase 1 T77594 DRUGINFO D08SIT NKP-1339 Phase 1 T50594 TARGETID T50594 T50594 FORMERID TTDNC00498 T50594 UNIPROID PIM1_HUMAN T50594 TARGNAME Serine/threonine-protein kinase pim-1 (PIM1) T50594 GENENAME PIM1 T50594 TARGTYPE Clinical trial T50594 SYNONYMS Pim-1 proto-oncogene, serine/threonine kinase; PIM T50594 FUNCTION Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis. Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. T50594 PDBSTRUC 6QXK; 6NO9; 6MT0; 6BSK; 6AYD T50594 BIOCLASS Kinase T50594 ECNUMBER EC 2.7.11.1 T50594 SEQUENCE MLLSKINSLAHLRAAPCNDLHATKLAPGKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK T50594 DRUGINFO D0X8ID SEL-24 Phase 1/2 T50594 DRUGINFO D00YDN CXR-1002 Phase 1 T50594 DRUGINFO D00BFF Benzothiazine derivative 1 Patented T50594 DRUGINFO D0Q1HF NCGC00167772-01 Investigative T50594 DRUGINFO DAJ3D2 SMI-4a Investigative T50594 DRUGINFO D06HVH PMID22136433C20 Investigative T50594 DRUGINFO D06UKS PMID21982499C14k Investigative T50594 DRUGINFO D04IMY leucettine L41 Investigative T15334 TARGETID T15334 T15334 FORMERID TTDC00124 T15334 UNIPROID CETP_HUMAN T15334 TARGNAME Cholesteryl ester transfer protein (CETP) T15334 GENENAME CETP T15334 TARGTYPE Clinical trial T15334 SYNONYMS Lipid transfer protein I; Cholesterol ester transfer protein T15334 FUNCTION Allows the net movement of cholesteryl ester from high density lipoproteins/HDL to triglyceride-rich very low density lipoproteins/VLDL, and the equimolar transport of triglyceride from VLDL to HDL. Regulates the reverse cholesterol transport, by which excess cholesterol is removed from peripheral tissues and returned to the liver for elimination. Involved in the transfer of neutral lipids, including cholesteryl ester and triglyceride, among lipoprotein particles. T15334 PDBSTRUC 4F2A; 4EWS; 2OBD T15334 BIOCLASS Bactericidal permeability increasing protein T15334 SEQUENCE MLAATVLTLALLGNAHACSKGTSHEAGIVCRITKPALLVLNHETAKVIQTAFQRASYPDITGEKAMMLLGQVKYGLHNIQISHLSIASSQVELVEAKSIDVSIQNVSVVFKGTLKYGYTTAWWLGIDQSIDFEIDSAIDLQINTQLTCDSGRVRTDAPDCYLSFHKLLLHLQGEREPGWIKQLFTNFISFTLKLVLKGQICKEINVISNIMADFVQTRAASILSDGDIGVDISLTGDPVITASYLESHHKGHFIYKNVSEDLPLPTFSPTLLGDSRMLYFWFSERVFHSLAKVAFQDGRLMLSLMGDEFKAVLETWGFNTNQEIFQEVVGGFPSQAQVTVHCLKMPKISCQNKGVVVNSSVMVKFLFPRPDQQHSVAYTFEEDIVTTVQASYSKKKLFLSLLDFQITPKTVSNLTESSSESVQSFLQSMITAVGIPEVMSRLEVVFTALMNSKGVSLFDIINPEIITRDGFLLLQMDFGFPEHLLVDFLQSLS T15334 DRUGINFO D02XXN Evacetrapib Phase 3 T15334 DRUGINFO D05SSC Dalcetrapib Phase 3 T15334 DRUGINFO D07HLS Anacetrapib Phase 3 T15334 DRUGINFO D04ZBU JTT-302 Phase 2 T15334 DRUGINFO D07UJA DRL-17822 Phase 2 T15334 DRUGINFO D0G7MM TA-8995 Phase 2 T15334 DRUGINFO D00JQE BAY-60-5521 Phase 1 T15334 DRUGINFO D07GDN Torcetrapib Discontinued in Phase 2 T15334 DRUGINFO D0J4KC CETi-1 Discontinued in Phase 2 T15334 DRUGINFO D03MAD CP-800569 Discontinued in Phase 1 T15334 DRUGINFO D0B0UN R7232 Discontinued in Phase 1 T15334 DRUGINFO D0F8XI DS-1442 Discontinued in Phase 1 T15334 DRUGINFO D0K3GU PF-3185043 Discontinued in Phase 1 T15334 DRUGINFO D05QXT BAY-38-1315 Preclinical T15334 DRUGINFO D04VCE TETRAHYDROQUINOLINE A Investigative T15334 DRUGINFO D04WPM SC-795 Investigative T15334 DRUGINFO D05TQP NSC-89508 Investigative T15334 DRUGINFO D0C9FK TETRAHYDROQUINOLINE B Investigative T15334 DRUGINFO D0M1TF NSC-40331 Investigative T11309 TARGETID T11309 T11309 FORMERID TTDR00451 T11309 UNIPROID CCL2_HUMAN T11309 TARGNAME Monocyte chemotactic and activating factor (CCL2) T11309 GENENAME CCL2 T11309 TARGTYPE Clinical trial T11309 SYNONYMS Small-inducible cytokine A2; SCYA2; Monocyte secretory protein JE; Monocyte chemotactic protein 1; Monocyte chemoattractant protein-1; Monocyte Chemoattractant Protein 1; MCP1; MCP-1; MCAF; HC11; C-C motif chemokine 2 T11309 FUNCTION Signals through binding and activation of CCR2 and induces a strong chemotactic response and mobilization of intracellular calcium ions. Exhibits a chemotactic activity for monocytes and basophils but not neutrophils or eosinophils. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. Acts as a ligand for C-C chemokine receptor CCR2. T11309 PDBSTRUC 4ZK9; 4R8I; 4DN4; 3IFD; 2NZ1 T11309 BIOCLASS Cytokine: CC chemokine T11309 SEQUENCE MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT T11309 DRUGINFO D0XM4G Bindarit Phase 3 T11309 DRUGINFO D06WUK Carlumab Phase 2 T11309 DRUGINFO D09LKU NOX-E36 Phase 2 T11309 DRUGINFO D07HZP CNTO888 Phase 1 T11309 DRUGINFO D04MYO ABN-912 Discontinued in Phase 1 T11309 DRUGINFO D0V9ND MCP-1 Preclinical T11309 DRUGINFO D0X4SI RS-504393 Preclinical T39977 TARGETID T39977 T39977 FORMERID TTDC00103 T39977 UNIPROID MIF_HUMAN T39977 TARGNAME Macrophage migration inhibitory factor (MIF) T39977 GENENAME MIF T39977 TARGTYPE Clinical trial T39977 SYNONYMS Phenylpyruvate tautomerase; MMIF; L-dopachrome tautomerase; L-dopachrome isomerase; Glycosylation-inhibiting factor; GLIF; GIF T39977 FUNCTION Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity. Pro-inflammatory cytokine. T39977 PDBSTRUC 6FVH; 6FVE; 6CBH; 6CBG; 6CBF T39977 BIOCLASS Intramolecular oxidoreductase T39977 ECNUMBER EC 5.3.2.1 T39977 SEQUENCE MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA T39977 DRUGINFO D0O7IZ Anti-MIF antibodies Phase 4 T39977 DRUGINFO D0V9EN 3,4-Dihydroxycinnamic Acid Phase 4 T39977 DRUGINFO D04KKT ISO-1 Phase 1 T39977 DRUGINFO D0F3II COR100140 Preclinical T39977 DRUGINFO D00YTS AVP-13546 Investigative T39977 DRUGINFO D01SWJ AVP-13748 Investigative T39977 DRUGINFO D0NN3G 4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME Investigative T39977 DRUGINFO D0W1JY NAPQI Investigative T39977 DRUGINFO D0A6HS 6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE Investigative T39977 DRUGINFO D0G6RI 4-hydroxyphenylpyruvic acid Investigative T83797 TARGETID T83797 T83797 FORMERID TTDC00194 T83797 UNIPROID HGF_HUMAN T83797 TARGNAME Hepatocyte growth factor (HGF) T83797 GENENAME HGF T83797 TARGTYPE Clinical trial T83797 SYNONYMS Scatter factor; SF; Hepatopoietin-A; Hepatopoeitin A; HPTA T83797 FUNCTION Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. T83797 PDBSTRUC 5CT3; 5CT2; 5CT1; 5CSQ; 5CS9 T83797 BIOCLASS Peptidase T83797 SEQUENCE MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCADNTMNDTDVPLETTECIQGQGEGYRGTVNTIWNGIPCQRWDSQYPHEHDMTPENFKCKDLRENYCRNPDGSESPWCFTTDPNIRVGYCSQIPNCDMSHGQDCYRGNGKNYMGNLSQTRSGLTCSMWDKNMEDLHRHIFWEPDASKLNENYCRNPDDDAHGPWCYTGNPLIPWDYCPISRCEGDTTPTIVNLDHPVISCAKTKQLRVVNGIPTRTNIGWMVSLRYRNKHICGGSLIKESWVLTARQCFPSRDLKDYEAWLGIHDVHGRGDEKCKQVLNVSQLVYGPEGSDLVLMKLARPAVLDDFVSTIDLPNYGCTIPEKTSCSVYGWGYTGLINYDGLLRVAHLYIMGNEKCSQHHRGKVTLNESEICAGAEKIGSGPCEGDYGGPLVCEQHKMRMVLGVIVPGRGCAIPNRPGIFVRVAYYAKWIHKIILTYKVPQS T83797 DRUGINFO D0D4OS VM-202 Phase 3 T83797 DRUGINFO D5E2KR ANG-3777 Phase 3 T83797 DRUGINFO D9CI7V Donaperminogene seltoplasmid Phase 3 T83797 DRUGINFO D03UBW Ficlatuzumab Phase 2 T83797 DRUGINFO DNHW41 Collategene Phase 2 T83797 DRUGINFO D0ME7Q MP0250 Phase 1/2 T83797 DRUGINFO D0H9HT TAK-701 Phase 1 T83797 DRUGINFO D0P4KU ABI-011 Phase 1 T83797 DRUGINFO D07AOO Rilotumumab Discontinued in Phase 2 T83797 DRUGINFO D06VYT O2-Sulfo-Glucuronic Acid Investigative T83797 DRUGINFO D0B0SV N,O6-Disulfo-Glucosamine Investigative T19579 TARGETID T19579 T19579 FORMERID TTDC00026 T19579 UNIPROID IL2RB_HUMAN T19579 TARGNAME Interleukin 2 receptor beta (IL2RB) T19579 GENENAME IL2RB T19579 TARGTYPE Clinical trial T19579 SYNONYMS P70-75; Interleukin-2 receptor subunit beta; Interleukin-15 receptor subunit beta; IL15RB; IL-2RB; IL-2R subunit beta; IL-2 receptor subunit beta; IL-2 receptor; High affinity IL-2 receptor subunit beta; CD122 T19579 FUNCTION Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. T19579 PDBSTRUC 6E8K; 5M5E; 4GS7; 3QAZ; 2ERJ T19579 BIOCLASS Cytokine receptor T19579 SEQUENCE MAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEEAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDTIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVPDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQELQGQDPTHLV T19579 DRUGINFO D02QQE NKTR 214 Phase 3 T19579 DRUGINFO D5ISZ1 NKTR-214 Phase 3 T19579 DRUGINFO D05YFL AFTVac Phase 2 T19579 DRUGINFO D0U0RJ Leukocyte interleukin Phase 1 T19579 DRUGINFO D06KWH DAB-486-IL-2 Investigative T72335 TARGETID T72335 T72335 FORMERID TTDR01027 T72335 UNIPROID LEF_BACAN T72335 TARGNAME Bacterial Lethal factor (Bact lef) T72335 GENENAME Bact lef T72335 TARGTYPE Clinical trial T72335 SYNONYMS lef; Anthrax lethal toxin endopeptidase component; Anthrax lethal factor; ALF T72335 FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. LF is the lethal factor that, when associated with PA, causes death. LF is not toxic by itself. It is a protease that cleaves the N-terminal of most dual specificity mitogen-activated protein kinase kinases (MAPKKs or MAP2Ks) (except for MAP2K5). Cleavage invariably occurs within the N-terminal proline-rich region preceding the kinase domain, thus disrupting a sequence involved in directing specific protein-protein interactions necessary for the assembly of signaling complexes. There may be other cytosolic targets of LF involved in cytotoxicity. The proteasome may mediate a toxic process initiated by LF in the cell cytosol involving degradation of unidentified molecules that are essential for macrophage homeostasis. This is an early step in LeTx intoxication, but it is downstream of the cleavage by LF of MEK1 or other putative substrates. T72335 PDBSTRUC 5D1U; 5D1T; 5D1S; 4XM8; 4XM7 T72335 BIOCLASS Peptidase T72335 ECNUMBER EC 3.4.24.83 T72335 SEQUENCE MNIKKEFIKVISMSCLVTAITLSGPVFIPLVQGAGGHGDVGMHVKEKEKNKDENKRKDEERNKTQEEHLKEIMKHIVKIEVKGEEAVKKEAAEKLLEKVPSDVLEMYKAIGGKIYIVDGDITKHISLEALSEDKKKIKDIYGKDALLHEHYVYAKEGYEPVLVIQSSEDYVENTEKALNVYYEIGKILSRDILSKINQPYQKFLDVLNTIKNASDSDGQDLLFTNQLKEHPTDFSVEFLEQNSNEVQEVFAKAFAYYIEPQHRDVLQLYAPEAFNYMDKFNEQEINLSLEELKDQRMLARYEKWEKIKQHYQHWSDSLSEEGRGLLKKLQIPIEPKKDDIIHSLSQEEKELLKRIQIDSSDFLSTEEKEFLKKLQIDIRDSLSEEEKELLNRIQVDSSNPLSEKEKEFLKKLKLDIQPYDINQRLQDTGGLIDSPSINLDVRKQYKRDIQNIDALLHQSIGSTLYNKIYLYENMNINNLTATLGADLVDSTDNTKINRGIFNEFKKNFKYSISSNYMIVDINERPALDNERLKWRIQLSPDTRAGYLENGKLILQRNIGLEIKDVQIIKQSEKEYIRIDAKVVPKSKIDTKIQEAQLNINQEWNKALGLPKYTKLITFNVHNRYASNIVESAYLILNEWKNNIQSDLIKKVTNYLVDGNGRFVFTDITLPNIAEQYTHQDEIYEQVHSKGLYVPESRSILLHGPSKGVELRNDSEGFIHEFGHAVDDYAGYLLDKNQSDLVTNSKKFIDIFKEEGSNLTSYGRTNEAEFFAEAFRLMHSTDHAERLKVQKNAPKTFQFINDQIKFIINS T72335 DRUGINFO D09SZY IQ-DAA Phase 1 T72335 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T72335 DRUGINFO D01MBG N-(Sulfanylacetyl)Tyrosylprolylmethioninamide Investigative T72335 DRUGINFO D01QWL N-(3,4-dihydroxybenzyl)oleamide Investigative T72335 DRUGINFO D03QAN N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea Investigative T72335 DRUGINFO D0EL3A N-hydroxy-4-(oleamidomethyl)benzamide Investigative T72335 DRUGINFO D0M2KQ N-(3,4,5-trihydroxyphenethyl)oleamide Investigative T72335 DRUGINFO D0M4IF N-oleoyl-dopamine Investigative T72335 DRUGINFO D0MV0W GNF-PF-600 Investigative T72335 DRUGINFO D0SU7B N-hydroxy-4-(2-oleamidoethyl)benzamide Investigative T72335 DRUGINFO D0X1JG 3-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid Investigative T72335 DRUGINFO D0J5VK NSC-622445 Investigative T72335 DRUGINFO D0A4TC MMI270 Investigative T72335 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T00938 TARGETID T00938 T00938 FORMERID TTDI02203 T00938 UNIPROID TYRP1_HUMAN T00938 TARGNAME Melanoma antigen gp75 (TYRP1) T00938 GENENAME TYRP1 T00938 TARGTYPE Clinical trial T00938 SYNONYMS Tyrosinaserelated protein 1; TYRP1; TRP; Glycoprotein 75; Catalase B; 5,6dihydroxyindole2carboxylic acid oxidase T00938 FUNCTION Oxidation of 5,6-dihydroxyindole-2-carboxylic acid (DHICA)into indole-5,6-quinone-2-carboxylic acid. May regulate or influence the type of melanin synthesized. T00938 PDBSTRUC 5M8T; 5M8S; 5M8R; 5M8Q; 5M8P T00938 BIOCLASS Tyrosinase T00938 ECNUMBER EC 1.14.18.- T00938 SEQUENCE MSAPKLLSLGCIFFPLLLFQQARAQFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPSREFSVPEIIAIAVVGALLLVALIFGTASYLIRARRSMDEANQPLLTDQYQCYAEEYEKLQNPNQSVV T00938 DRUGINFO D0TI3R FLX-787 Phase 2 T00938 DRUGINFO D05WQT Flanvotumab Phase 1 T04902 TARGETID T04902 T04902 FORMERID TTDR00505 T04902 UNIPROID CAN2_HUMAN T04902 TARGNAME Calpain-2 (CAPN2) T04902 GENENAME CAPN2 T04902 TARGTYPE Clinical trial T04902 SYNONYMS Millimolar-calpain; M-calpain; Calpain-2 large subunit; Calpain-2 catalytic subunit; Calpain large polypeptide L2; Calpain M-type; Calcium-activated neutral proteinase 2; Calcium-activated neutral proteinase; CANPL2; CANP 2; CANP T04902 FUNCTION Proteolytically cleaves MYOC at 'Arg-226'. Proteolytically cleaves CPEB3 following neuronal stimulation which abolishes CPEB3 translational repressor activity, leading to translation of CPEB3 target mRNAs. Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction. T04902 BIOCLASS Peptidase T04902 ECNUMBER EC 3.4.22.53 T04902 SEQUENCE MAGIAAKLAKDREAAEGLGSHDRAIKYLNQDYEALRNECLEAGTLFQDPSFPAIPSALGFKELGPYSSKTRGIEWKRPTEICADPQFIIGGATRTDICQGALGDCWLLAAIASLTLNEEILARVVPLNQSFQENYAGIFHFQFWQYGEWVEVVVDDRLPTKDGELLFVHSAEGSEFWSALLEKAYAKINGCYEALSGGATTEGFEDFTGGIAEWYELKKPPPNLFKIIQKALQKGSLLGCSIDITSAADSEAITFQKLVKGHAYSVTGAEEVESNGSLQKLIRIRNPWGEVEWTGRWNDNCPSWNTIDPEERERLTRRHEDGEFWMSFSDFLRHYSRLEICNLTPDTLTSDTYKKWKLTKMDGNWRRGSTAGGCRNYPNTFWMNPQYLIKLEEEDEDEEDGESGCTFLVGLIQKHRRRQRKMGEDMHTIGFGIYEVPEELSGQTNIHLSKNFFLTNRARERSDTFINLREVLNRFKLPPGEYILVPSTFEPNKDGDFCIRVFSEKKADYQAVDDEIEANLEEFDISEDDIDDGFRRLFAQLAGEDAEISAFELQTILRRVLAKRQDIKSDGFSIETCKIMVDMLDSDGSGKLGLKEFYILWTKIQKYQKIYREIDVDRSGTMNSYEMRKALEEAGFKMPCQLHQVIVARFADDQLIIDFDNFVRCLVRLETLFKIFKQLDPENTGTIELDLISWLCFSVL T04902 DRUGINFO D03NLQ ABT-957 Phase 1 T04902 DRUGINFO D03ZOR Epoxysuccinate derivative 9 Patented T04902 DRUGINFO D05LZV Epoxysuccinate derivative 4 Patented T04902 DRUGINFO D06JCF Carboxamide derivative 7 Patented T04902 DRUGINFO D08CGI Epoxysuccinate derivative 7 Patented T04902 DRUGINFO D09CGG Carboxamide derivative 10 Patented T04902 DRUGINFO D0C4YX Carboxamide derivative 11 Patented T04902 DRUGINFO D0CO2G Carboxamide derivative 8 Patented T04902 DRUGINFO D0FG4C Epoxysuccinate derivative 10 Patented T04902 DRUGINFO D0H0LO Carboxamide derivative 6 Patented T04902 DRUGINFO D0HZ1Z Epoxysuccinate derivative 2 Patented T04902 DRUGINFO D0IO8Y Epoxysuccinate derivative 8 Patented T04902 DRUGINFO D0KA3L Epoxysuccinate derivative 6 Patented T04902 DRUGINFO D0L3RN Epoxysuccinate derivative 5 Patented T04902 DRUGINFO D0OI2F Epoxysuccinate derivative 1 Patented T04902 DRUGINFO D0U2JU 5-azolone derivative 1 Patented T04902 DRUGINFO D0WS4U Epoxysuccinate derivative 3 Patented T04902 DRUGINFO D0X9DL Carboxamide derivative 9 Patented T04902 DRUGINFO D0XC2D Carboxamide derivative 5 Patented T04902 DRUGINFO D06LLT PMID25399719-Compound-17 Patented T04902 DRUGINFO D0QQ1J BITHIONOL Withdrawn from market T04902 DRUGINFO D0NJ1A Aloxistatin Discontinued in Phase 3 T04902 DRUGINFO D00QHT AK-295 Terminated T04902 DRUGINFO D06VTU SJA-6017 Terminated T04902 DRUGINFO D0G5ZE MDL-28170 Terminated T04902 DRUGINFO D00JPH N-(1-Benzyl-2-oxo-ethyl)-benzamide Investigative T04902 DRUGINFO D01HUQ 3-(1H-Pyrrol-3-yl)-propionamide Investigative T04902 DRUGINFO D03GAN A-558693 Investigative T04902 DRUGINFO D03UYO PMID8831774C19 Investigative T04902 DRUGINFO D07ZYE PMID20690647C4b Investigative T04902 DRUGINFO D08TCW Calpastatin Investigative T04902 DRUGINFO D0G0HK GNF-PF-4453 Investigative T04902 DRUGINFO D0L2AO DIHYDROXANTHOHUMOL Investigative T04902 DRUGINFO D0N6QM (1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester Investigative T04902 DRUGINFO D0S9XO mercaptoacrylate inhibitor of calpain 1 Investigative T04902 DRUGINFO D0T4FT PMID20690647C5a Investigative T04902 DRUGINFO D0W9ZV AW-00430 Investigative T82543 TARGETID T82543 T82543 FORMERID TTDC00301 T82543 UNIPROID ACHB2_HUMAN T82543 TARGNAME Neuronal acetylcholine receptor beta-2 (CHRNB2) T82543 GENENAME CHRNB2 T82543 TARGTYPE Clinical trial T82543 SYNONYMS Nicotinic acetylcholine receptor beta2; Nicotinic acetylcholine receptor beta 2-subunit protein; CHRNB2; Beta-2 nAChR; Alpha-4/beta-2 nicotinic receptor T82543 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions. T82543 PDBSTRUC 6CNK; 6CNJ; 5KXI; 2LM2; 2KSR T82543 BIOCLASS Neurotransmitter receptor T82543 SEQUENCE MARRCGPVALLLGFGLLRLCSGVWGTDTEERLVEHLLDPSRYNKLIRPATNGSELVTVQLMVSLAQLISVHEREQIMTTNVWLTQEWEDYRLTWKPEEFDNMKKVRLPSKHIWLPDVVLYNNADGMYEVSFYSNAVVSYDGSIFWLPPAIYKSACKIEVKHFPFDQQNCTMKFRSWTYDRTEIDLVLKSEVASLDDFTPSGEWDIVALPGRRNENPDDSTYVDITYDFIIRRKPLFYTINLIIPCVLITSLAILVFYLPSDCGEKMTLCISVLLALTVFLLLISKIVPPTSLDVPLVGKYLMFTMVLVTFSIVTSVCVLNVHHRSPTTHTMAPWVKVVFLEKLPALLFMQQPRHHCARQRLRLRRRQREREGAGALFFREAPGADSCTCFVNRASVQGLAGAFGAEPAPVAGPGRSGEPCGCGLREAVDGVRFIADHMRSEDDDQSVSEDWKYVAMVIDRLFLWIFVFVCVFGTIGMFLQPLFQNYTTTTFLHSDHSAPSSK T82543 DRUGINFO D08XPW CYTISINE Phase 3 T82543 DRUGINFO D0D7YW TC-5214 Phase 2 T82543 DRUGINFO D07WJU SUVN-911 Phase 1 T82543 DRUGINFO D04HYP ABT-594 Discontinued in Phase 2 T82543 DRUGINFO D09ADT ABT-418 Discontinued in Phase 2 T82543 DRUGINFO D0F7FX AZD-9684 Discontinued in Phase 2 T82543 DRUGINFO D0C9KD HOMOEPIBATIDINE Terminated T82543 DRUGINFO D01OMG NS9283 Investigative T82543 DRUGINFO D02BPT [3H]nicotine Investigative T82543 DRUGINFO D0V0AW TC-2559 Investigative T82543 DRUGINFO D02LWF GCCSHPACAGNNQHIC* Investigative T82543 DRUGINFO D03FEV N-methyl-2-(pyridin-3-yloxy)ethanamine Investigative T82543 DRUGINFO D03SYO N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine Investigative T82543 DRUGINFO D04HQP N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine Investigative T82543 DRUGINFO D06KYM N-methyl-N-(pyridin-3-ylmethyl)ethanamine Investigative T82543 DRUGINFO D0A7HM N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine Investigative T82543 DRUGINFO D0P9ED CMI-489 Investigative T82543 DRUGINFO D0R8YJ N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine Investigative T82543 DRUGINFO D0U2HZ 6'-methylepibatidine Investigative T82543 DRUGINFO D0UX5M N,N-dimethyl(pyridin-3-yl)methanamine Investigative T82543 DRUGINFO D0V2KB Predicentrine methiodide Investigative T82543 DRUGINFO D0V7HJ 3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine Investigative T82543 DRUGINFO D04MIG LY2087101 Investigative T82543 DRUGINFO D0D4LF NS1738 Investigative T82543 DRUGINFO D0DA1E A-867744 Investigative T82543 DRUGINFO D0UH8F GCCSNPVCHLEHSNLC* Investigative T82543 DRUGINFO D0Y3DW [3H]cytisine Investigative T82543 DRUGINFO D0LH4L BOLDINE Investigative T82543 DRUGINFO D0R4RN [125I]epibatidine Investigative T82543 DRUGINFO D00QCP (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol Investigative T82543 DRUGINFO D03YQY (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol Investigative T82543 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T16347 TARGETID T16347 T16347 FORMERID TTDI01934 T16347 UNIPROID PTN1_HUMAN T16347 TARGNAME Protein-tyrosine phosphatase 1B (PTP1B) T16347 GENENAME PTPN1 T16347 TARGTYPE Clinical trial T16347 SYNONYMS Tyrosine-protein phosphatase non-receptor type 1; PTP-1B T16347 FUNCTION Mediates dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase activity of EIF2AK3/PERK. May play an important role in CKII- and p60c-src-induced signal transduction cascades. May regulate the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET. Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response. T16347 PDBSTRUC 6CWV; 6CWU; 6BAI; 6B95; 6B90 T16347 BIOCLASS Phosphoric monoester hydrolase T16347 ECNUMBER EC 3.1.3.48 T16347 SEQUENCE MEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEPPPEHIPPPPRPPKRILEPHNGKCREFFPNHQWVKEETQEDKDCPIKEEKGSPLNAAPYGIESMSQDTEVRSRVVGGSLRGAQAASPAKGEPSLPEKDEDHALSYWKPFLVNMCVATVLTAGAYLCYRFLFNSNT T16347 DRUGINFO D0LI5N IONIS-PTP1BRX Phase 2 T16347 DRUGINFO D00QUZ TTP-814 Phase 1/2 T16347 DRUGINFO D0O3QW Trodusquemine Phase 1 T16347 DRUGINFO D0Y4MJ KQ-791 Phase 1 T16347 DRUGINFO D0DN1I JTT-551 Terminated T82028 TARGETID T82028 T82028 FORMERID TTDR00347 T82028 UNIPROID SL9A1_HUMAN T82028 TARGNAME Sodium/hydrogen exchanger 1 (SLC9A1) T82028 GENENAME SLC9A1 T82028 TARGTYPE Clinical trial T82028 SYNONYMS Solute carrier family 9 member 1; Na+/H+ antiporter, amiloride-sensitive; Na(+)Sodium/hydrogen exchanger 1/H(+) exchanger 1; Na(+)/H(+) exchanger 1; Na(+)/H(+) antiporter, amiloride-sensitive; NHE1; NHE-1; Myocardial Na+/H+ exchanger; APNH1; APNH T82028 FUNCTION Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction. Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. T82028 PDBSTRUC 6BJF; 2YGG; 2MDF; 2L0E; 2KBV T82028 BIOCLASS Monovalent cation:proton antiporter-1 T82028 SEQUENCE MVLRSGICGLSPHRIFPSLLVVVALVGLLPVLRSHGLQLSPTASTIRSSEPPRERSIGDVTTAPPEVTPESRPVNHSVTDHGMKPRKAFPVLGIDYTHVRTPFEISLWILLACLMKIGFHVIPTISSIVPESCLLIVVGLLVGGLIKGVGETPPFLQSDVFFLFLLPPIILDAGYFLPLRQFTENLGTILIFAVVGTLWNAFFLGGLMYAVCLVGGEQINNIGLLDNLLFGSIISAVDPVAVLAVFEEIHINELLHILVFGESLLNDAVTVVLYHLFEEFANYEHVGIVDIFLGFLSFFVVALGGVLVGVVYGVIAAFTSRFTSHIRVIEPLFVFLYSYMAYLSAELFHLSGIMALIASGVVMRPYVEANISHKSHTTIKYFLKMWSSVSETLIFIFLGVSTVAGSHHWNWTFVISTLLFCLIARVLGVLGLTWFINKFRIVKLTPKDQFIIAYGGLRGAIAFSLGYLLDKKHFPMCDLFLTAIITVIFFTVFVQGMTIRPLVDLLAVKKKQETKRSINEEIHTQFLDHLLTGIEDICGHYGHHHWKDKLNRFNKKYVKKCLIAGERSKEPQLIAFYHKMEMKQAIELVESGGMGKIPSAVSTVSMQNIHPKSLPSERILPALSKDKEEEIRKILRNNLQKTRQRLRSYNRHTLVADPYEEAWNQMLLRRQKARQLEQKINNYLTVPAHKLDSPTMSRARIGSDPLAYEPKEDLPVITIDPASPQSPESVDLVNEELKGKVLGLSRDPAKVAEEDEDDDGGIMMRSKETSSPGTDDVFTPAPSDSPSSQRIQRCLSDPGPHPEPGEGEPFFPKGQ T82028 DRUGINFO D0C8PI Zoniporide hydrochloride Phase 3 T82028 DRUGINFO D0N8QQ CARIPORIDE Discontinued in Phase 2 T82028 DRUGINFO D0V9RU ENIPORIDE Discontinued in Phase 2 T82028 DRUGINFO D0K2CV HOE-694 Terminated T82028 DRUGINFO D01RDB N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine Investigative T82028 DRUGINFO D01ZIP N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine Investigative T82028 DRUGINFO D06AKW N-(5-m-Tolyl-furan-2-carbonyl)-guanidine Investigative T82028 DRUGINFO D07WXS Homoserine Lactone Investigative T82028 DRUGINFO D08BDI N-(5-o-Tolyl-furan-2-carbonyl)-guanidine Investigative T82028 DRUGINFO D09ZSK N-(5-Phenyl-furan-2-carbonyl)-guanidine Investigative T82028 DRUGINFO D0D3OX N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine Investigative T82028 DRUGINFO D0NS9C BIIB-513 Investigative T82028 DRUGINFO D0V5NZ 5'-(N-ethyl-N-isopropyl)amiloride Investigative T82028 DRUGINFO D0Y4CC N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine Investigative T82028 DRUGINFO D03AGV N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine Investigative T82028 DRUGINFO D04OTF N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine Investigative T82028 DRUGINFO D04UMY N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine Investigative T82028 DRUGINFO D05CQR N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine Investigative T82028 DRUGINFO D07DUW N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine Investigative T82028 DRUGINFO D0T1OG N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine Investigative T96627 TARGETID T96627 T96627 FORMERID TTDC00225 T96627 UNIPROID CXCL2_HUMAN T96627 TARGNAME C-X-C motif chemokine 2 (CXCL2) T96627 GENENAME CXCL2 T96627 TARGTYPE Clinical trial T96627 SYNONYMS SCYB2; Macrophage inflammatory protein 2-alpha; MIP2A; MIP2-alpha; Growth-regulated protein beta; Growth regulatedprotein beta; Gro-beta; GROB; GRO2 T96627 FUNCTION Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. GRO-beta(5-73) shows a highly enhanced hematopoietic activity. Produced by activated monocytes and neutrophils and expressed at sites of inflammation. T96627 PDBSTRUC 5OB5; 1QNK T96627 BIOCLASS Cytokine: CXC chemokine T96627 SEQUENCE MARATLSAAPSNPRLLRVALLLLLLVAASRRAAGAPLATELRCQCLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNGQKACLNPASPMVKKIIEKMLKNGKSN T96627 DRUGINFO D09INF Laquinamod Phase 3 T86350 TARGETID T86350 T86350 FORMERID TTDR01265 T86350 UNIPROID ERBB3_HUMAN T86350 TARGNAME Erbb3 tyrosine kinase receptor (Erbb-3) T86350 GENENAME ERBB3 T86350 TARGTYPE Clinical trial T86350 SYNONYMS Tyrosine kinase-type cell surface receptor HER3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; HER3; C-erbB3; C-erbB-3 protein T86350 FUNCTION Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase. May also be activated by CSPG5. Involved in the regulation of myeloid cell differentiation. Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. T86350 PDBSTRUC 5O7P; 5O4O; 5CUS; 4RIY; 4RIX T86350 BIOCLASS Kinase T86350 ECNUMBER EC 2.7.10.1 T86350 SEQUENCE MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGAEPYAGLRLAEVPDLLEKGERLAQPQICTIDVYMVMVKCWMIDENIRPTFKELANEFTRMARDPPRYLVIKRESGPGIAPGPEPHGLTNKKLEEVELEPELDLDLDLEAEEDNLATTTLGSALSLPVGTLNRPRGSQSLLSPSSGYMPMNQGNLGESCQESAVSGSSERCPRPVSLHPMPRGCLASESSEGHVTGSEAELQEKVSMCRSRSRSRSPRPRGDSAYHSQRHSLLTPVTPLSPPGLEEEDVNGYVMPDTHLKGTPSSREGTLSSVGLSSVLGTEEEDEDEEYEYMNRRRRHSPPHPPRPSSLEELGYEYMDVGSDLSASLGSTQSCPLHPVPIMPTAGTTPDEDYEYMNRQRDGGGPGGDYAAMGACPASEQGYEEMRAFQGPGHQAPHVHYARLKTLRSLEATDSAFDNPDYWHSRLFPKANAQRT T86350 DRUGINFO D06DOJ Seribantumab Phase 2 T86350 DRUGINFO D06FUE CDX-3379 Phase 2 T86350 DRUGINFO D06SBL MM-121 Phase 2 T86350 DRUGINFO D08GIM Elisidepsin Phase 2 T86350 DRUGINFO D09BZJ MEHD-7945A Phase 2 T86350 DRUGINFO D1J4CI Zenocutuzumab Phase 2 T86350 DRUGINFO D00BUO MM-141 Phase 2 T86350 DRUGINFO D05ECA LJM716 Phase 1/2 T86350 DRUGINFO D0T8CE AMG888/U3-1287 Phase 1/2 T86350 DRUGINFO D6SL3N Zenocutuzomab Phase 1/2 T86350 DRUGINFO D0FF2G Sym013 Phase 1/2 T86350 DRUGINFO D00EQY KTN3379 Phase 1 T86350 DRUGINFO D04RHJ RG7116 Phase 1 T86350 DRUGINFO D0D4UT GSK2849330 Phase 1 T86350 DRUGINFO D0I4QA Drug 2849330 Phase 1 T86350 DRUGINFO D0N2QW Patritumab Phase 1 T86350 DRUGINFO D0UK7B REGN1400 Phase 1 T86350 DRUGINFO D0Y5ED AV-203 Phase 1 T86350 DRUGINFO D01NAP MM-151 Phase 1 T86350 DRUGINFO D0JW2O Anti-HER3/EGFR DAF Phase 1 T86350 DRUGINFO D0UL7L Recombinant human Erbb3 fragment therapeutic tumor vaccine Phase 1 T86350 DRUGINFO D6JM8Z SI-B001 Phase 1 T86350 DRUGINFO D0F1OG Soluble ErbB3 theragnostics Investigative T86350 DRUGINFO D0T4ZW MP-RM-1 Investigative T86350 DRUGINFO D0Q8GX SYM-011 Investigative T15882 TARGETID T15882 T15882 FORMERID TTDI02312 T15882 UNIPROID PRTN3_HUMAN T15882 TARGNAME Leukocyte proteinase-3 (PRTN3) T15882 GENENAME PRTN3 T15882 TARGTYPE Clinical trial T15882 SYNONYMS Wegener autoantigen; PR3; PR-3; P29; Neutrophil proteinase 4; NP4; NP-4; Myeloblastin; MBN; Leukocyte proteinase 3; CANCA antigen; C-ANCA antigen; AGP7 T15882 FUNCTION By cleaving and activating receptor F2RL1/PAR-2, enhances endothelial cell barrier function and thus vascular integrity during neutrophil transendothelial migration. May play a role in neutrophil transendothelial migration, probably when associated with CD177. Serine protease that degrades elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV (in vitro). T15882 PDBSTRUC 1FUJ T15882 BIOCLASS Peptidase T15882 ECNUMBER EC 3.4.21.76 T15882 SEQUENCE MAHRPPSPALASVLLALLLSGAARAAEIVGGHEAQPHSRPYMASLQMRGNPGSHFCGGTLIHPSFVLTAAHCLRDIPQRLVNVVLGAHNVRTQEPTQQHFSVAQVFLNNYDAENKLNDVLLIQLSSPANLSASVATVQLPQQDQPVPHGTQCLAMGWGRVGAHDPPAQVLQELNVTVVTFFCRPHNICTFVPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRVEAKGRP T15882 DRUGINFO D05BPC Tiprelestat Phase 2 T15882 DRUGINFO D0O8AY Combined PR1/WT1 vaccine Phase 2 T15882 DRUGINFO D0C1NP PMID22595175C4g Investigative T78356 TARGETID T78356 T78356 FORMERID TTDC00086 T78356 UNIPROID THAS_HUMAN T78356 TARGNAME Thromboxane-A synthase (TBXAS1) T78356 GENENAME TBXAS1 T78356 TARGTYPE Clinical trial T78356 SYNONYMS Thromboxane A2 synthase; TXS; TXA synthase; Cytochrome P450 5A1; CYP5A1; CYP5 T78356 FUNCTION endoplasmic reticulum membrane, 12-hydroxyheptadecatrienoic acid synthase activity, thromboxane-A synthase activity, cyclooxygenase pathway, icosanoid metabolic process. T78356 BIOCLASS Intramolecular oxidoreductase T78356 ECNUMBER EC 5.3.99.5 T78356 SEQUENCE MEALGFLKLEVNGPMVTVALSVALLALLKWYSTSAFSRLEKLGLRHPKPSPFIGNLTFFRQGFWESQMELRKLYGPLCGYYLGRRMFIVISEPDMIKQVLVENFSNFTNRMASGLEFKSVADSVLFLRDKRWEEVRGALMSAFSPEKLNEMVPLISQACDLLLAHLKRYAESGDAFDIQRCYCNYTTDVVASVAFGTPVDSWQAPEDPFVKHCKRFFEFCIPRPILVLLLSFPSIMVPLARILPNKNRDELNGFFNKLIRNVIALRDQQAAEERRRDFLQMVLDARHSASPMGVQDFDIVRDVFSSTGCKPNPSRQHQPSPMARPLTVDEIVGQAFIFLIAGYEIITNTLSFATYLLATNPDCQEKLLREVDVFKEKHMAPEFCSLEEGLPYLDMVIAETLRMYPPAFRFTREAAQDCEVLGQRIPAGAVLEMAVGALHHDPEHWPSPETFNPERFTAEARQQHRPFTYLPFGAGPRSCLGVRLGLLEVKLTLLHVLHKFRFQACPETQVPLQLESKSALGPKNGVYIKIVSR T78356 DRUGINFO D0T8LY PYRIDINE Phase 4 T78356 DRUGINFO D06LFV NM-702 Phase 3 T78356 DRUGINFO D08PKI EV-077 Phase 2 T78356 DRUGINFO D0K9UK E-6700 Phase 2 T78356 DRUGINFO D0WH9U FK-070 Phase 2 T78356 DRUGINFO D07YEK NV-52 Phase 1 T78356 DRUGINFO D0RU7T G-619 Phase 1 T78356 DRUGINFO D0L0MO Satigrel Discontinued in Preregistration T78356 DRUGINFO D05DON MILACAINIDE TARTRATE Discontinued in Phase 2 T78356 DRUGINFO D0K4UW Imitrodast Discontinued in Phase 2 T78356 DRUGINFO D0V7GC Rolafagrel Discontinued in Phase 2 T78356 DRUGINFO D0G5DK ONO-1301 Preclinical T78356 DRUGINFO D04EEU Dazoxiben Terminated T78356 DRUGINFO D09QRO CGS-13080 Terminated T78356 DRUGINFO D01JWT 2-(10-Imidazol-1-yl-decyl)-isoindole-1,3-dione Investigative T78356 DRUGINFO D01NZS 2-(6-Imidazol-1-yl-hexyl)-isoindole-1,3-dione Investigative T78356 DRUGINFO D01QOU ONO-1581 Investigative T78356 DRUGINFO D05KVN 2-(8-Imidazol-1-yl-octyl)-isoindole-1,3-dione Investigative T78356 DRUGINFO D09IQS 4-Methyl-pyridine Investigative T78356 DRUGINFO D0F0KV CV-6504.HCL Investigative T78356 DRUGINFO D0K2SE 5-Imidazol-1-yl-5,6,7,8-tetrahydro-quinoline Investigative T78356 DRUGINFO D08PKR 6-Imidazol-1-yl-isoquinoline Investigative T78356 DRUGINFO D04ZGF 5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline Investigative T68290 TARGETID T68290 T68290 FORMERID TTDC00067 T68290 UNIPROID CATS_HUMAN T68290 TARGNAME Cathepsin S (CTSS) T68290 GENENAME CTSS T68290 TARGTYPE Clinical trial T68290 SYNONYMS Cysteine protease cathepsin S T68290 FUNCTION Key protease responsible for the removal of the invariant chain from MHC class II molecules. The bond-specificity of this proteinase is in part similar to the specificities of cathepsin L. Thiol protease. T68290 PDBSTRUC 5QCJ; 5QCI; 5QCH; 5QCG; 5QCF T68290 BIOCLASS Peptidase T68290 ECNUMBER EC 3.4.22.27 T68290 SEQUENCE MKRLVCVLLVCSSAVAQLHKDPTLDHHWHLWKKTYGKQYKEKNEEAVRRLIWEKNLKFVMLHNLEHSMGMHSYDLGMNHLGDMTSEEVMSLMSSLRVPSQWQRNITYKSNPNRILPDSVDWREKGCVTEVKYQGSCGACWAFSAVGALEAQLKLKTGKLVSLSAQNLVDCSTEKYGNKGCNGGFMTTAFQYIIDNKGIDSDASYPYKAMDQKCQYDSKYRAATCSKYTELPYGREDVLKEAVANKGPVSVGVDARHPSFFLYRSGVYYEPSCTQNVNHGVLVVGYGDLNGKEYWLVKNSWGHNFGEEGYIRMARNKGNHCGIASFPSYPEI T68290 DRUGINFO D0DQ2D RG7625 Phase 2 T68290 DRUGINFO D01REJ VBY- 891 Phase 1 T68290 DRUGINFO D07ODC VBY- 036 Phase 1 T68290 DRUGINFO D07UKF VBY-129 Phase 1 T68290 DRUGINFO D08KIB SAR-114137 Phase 1 T68290 DRUGINFO D01MKD Phenylalanine derivative 1 Patented T68290 DRUGINFO D0JD5W PMID27998201-Compound-7 Patented T68290 DRUGINFO D0MR9V PMID27998201-Compound-15 Patented T68290 DRUGINFO D0QM0D Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 Patented T68290 DRUGINFO D0X1AF PMID27998201-Compound-6 Patented T68290 DRUGINFO D06XTA PMID27998201-Compound-17 Patented T68290 DRUGINFO D04VGR PMID27998201-Compound-9 Patented T68290 DRUGINFO D06LLT PMID25399719-Compound-17 Patented T68290 DRUGINFO D05OIU PMID27998201-Compound-5 Patented T68290 DRUGINFO D06XCD PMID27998201-Compound-12 Patented T68290 DRUGINFO D0D3KG RG-7236 Discontinued in Phase 1 T68290 DRUGINFO DC9J1Y RO5461111 Preclinical T68290 DRUGINFO D0Z0PR L-006235-1 Preclinical T68290 DRUGINFO D0K0IW CRA-028129 Terminated T68290 DRUGINFO D01IFO 6-(3-(trifluoromethyl)phenyl)picolinonitrile Investigative T68290 DRUGINFO D01NCW Cbz-Ile-Phe-Ala-LeuVSMe Investigative T68290 DRUGINFO D02FPU N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide Investigative T68290 DRUGINFO D05MDE Cbz-Ile-Pro-Ala-LeuVSMe Investigative T68290 DRUGINFO D07SOQ N-(2-naphthylsulfonyl)-glycyl-glycine-nitrile Investigative T68290 DRUGINFO D08WDP AM-3840 Investigative T68290 DRUGINFO D09GZQ Ac-hPhe-Leu-Gly-LeuVSMe Investigative T68290 DRUGINFO D09IMK Cbz-Ile-t-ButylGln-Ala-LeuVSMe Investigative T68290 DRUGINFO D0B3US Cbz-Ile-MetO2-Ala-LeuVSMe Investigative T68290 DRUGINFO D0G3PK Fsn-0503 Investigative T68290 DRUGINFO D0J0HV VBY- 285 Investigative T68290 DRUGINFO D0K0KT Cbz-Glu(OtBu)-Ala-LeuVSMe Investigative T68290 DRUGINFO D0M8WX 2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL Investigative T68290 DRUGINFO D0P5RJ BF/PC-18 Investigative T68290 DRUGINFO D0RL4S Cbz-Ile-hPhe-Ala-LeuVSMe Investigative T68290 DRUGINFO D0V5LJ JNJ-10329670 Investigative T68290 DRUGINFO D0Y8LO Clik60 Investigative T68290 DRUGINFO D01JGB 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile Investigative T68290 DRUGINFO D04BGT 4-propyl-6-m-tolylpyrimidine-2-carbonitrile Investigative T68290 DRUGINFO D05VEV Ac-hPhe-Leu-Ala-LeuVSMe Investigative T68290 DRUGINFO D05WZF P2,P3 Ketoamide derivative Investigative T68290 DRUGINFO D06NEB Ac-hPhe-Leu-Phe-LeuVSMe Investigative T68290 DRUGINFO D06WQP PMID22686657C(R)-26 Investigative T68290 DRUGINFO D0A7ER N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile Investigative T68290 DRUGINFO D0I0MU Cbz-Ile-Leu-Ala-LeuVSMe Investigative T68290 DRUGINFO D0JF8D N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile Investigative T68290 DRUGINFO D0QY3R Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe Investigative T68290 DRUGINFO D0U4TY 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile Investigative T68290 DRUGINFO D01YNC N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile Investigative T68290 DRUGINFO D06VIP N-(tert-butoxycarbonyl)-valyl-glycine-nitrile Investigative T68290 DRUGINFO D07FLB N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile Investigative T68290 DRUGINFO D07RSA N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile Investigative T68290 DRUGINFO D09AHN N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile Investigative T68290 DRUGINFO D0A8OV N-acetyl-phenylalanyl-glycine-nitrile Investigative T68290 DRUGINFO D0G8OD N-(benzyloxycarbonyl)-leucyl-glycine-nitrile Investigative T68290 DRUGINFO D0JN8Q N-benzoyl-phenylalanyl-glycine-nitrile Investigative T68290 DRUGINFO D0U0XG N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile Investigative T68290 DRUGINFO D09FGQ E-64 Investigative T68290 DRUGINFO D0D0LD L-873724 Investigative T68290 DRUGINFO D0L9VP GNF-PF-5434 Investigative T68290 DRUGINFO D0G6XS Fucose Investigative T45758 TARGETID T45758 T45758 FORMERID TTDC00188 T45758 UNIPROID TNR5_HUMAN T45758 TARGNAME CD40L receptor (CD40) T45758 GENENAME CD40 T45758 TARGTYPE Clinical trial T45758 SYNONYMS Tumor necrosis factor receptor superfamily member 5; TNFRSF5; CDw40; Bp50; B-cell surfaceantigen CD40; B-cell surface antigen CD40 T45758 FUNCTION Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion. Receptor for TNFSF5/CD40LG. T45758 PDBSTRUC 6FAX; 5IHL; 5DMJ; 5DMI; 3QD6 T45758 BIOCLASS Cytokine receptor T45758 SEQUENCE MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ T45758 DRUGINFO D01ZLK APX005M Phase 2 T45758 DRUGINFO D0G3TJ ASKP-1240 Phase 2 T45758 DRUGINFO D0SD6V CFZ533 Phase 2 T45758 DRUGINFO D3NSU0 KPL-404 Phase 2 T45758 DRUGINFO D4B9KS Iscalimab Phase 2 T45758 DRUGINFO D6WO5I Frexalimab Phase 2 T45758 DRUGINFO DPDI65 Dazodalibep Phase 2 T45758 DRUGINFO DQ5YL2 AT-1501 Phase 2 T45758 DRUGINFO D0C8NG BI 655064 Phase 2 T45758 DRUGINFO D01NZH ABBV-323 Phase 1 T45758 DRUGINFO D91DAH RG6189 Phase 1 T45758 DRUGINFO DE0TD1 CP-870,893 Phase 1 T45758 DRUGINFO DKM7S3 CDX-1140 Phase 1 T45758 DRUGINFO DNMF63 YH003 Phase 1 T45758 DRUGINFO DTM8B0 NG-350A Phase 1 T45758 DRUGINFO DKUF26 SL-172154 Phase 1 T45758 DRUGINFO DN28KM GEN1042 Phase 1 T45758 DRUGINFO D0L4BR HuCD40L Terminated T45758 DRUGINFO D0Y3XB RhuCD40L Terminated T45758 DRUGINFO D0A9BO PG-120 Investigative T45758 DRUGINFO D0Q5GS CD154 Investigative T45758 DRUGINFO D0SO4M Human CD40 agonist ligand Investigative T45758 DRUGINFO D0V3HC Anti-CD40-XTEN Investigative T45758 DRUGINFO DH0JW9 YH008 Investigative T88304 TARGETID T88304 T88304 FORMERID TTDNC00597 T88304 UNIPROID DNMT1_HUMAN T88304 TARGNAME DNA [cytosine-5]-methyltransferase 1 (DNMT1) T88304 GENENAME DNMT1 T88304 TARGTYPE Clinical trial T88304 SYNONYMS MCMT; M.HsaI; Dnmt1; DNMT; DNA methyltransferase HsaI; DNA MTase HsaI; DNA (cytosine5)methyltransferase 1; DNA (cytosine-5)-methyltransferase 1; CXXCtype zinc finger protein 9; CXXC9; CXXC-type zinc finger protein 9; AIM T88304 FUNCTION Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is essential for epigenetic inheritance. Associates with chromatin during G2 and M phases to maintain DNA methylation independently of replication. It is responsible for maintaining methylation patterns established in development. DNA methylation is coordinated with methylation of histones. Mediates transcriptional repression by direct binding to HDAC2. In association with DNMT3B and via the recruitment of CTCFL/BORIS, involved in activation of BAG1 gene expression by modulating dimethylation of promoter histone H3 at H3K4 and H3K9. Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells. Also required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs). Associates at promoter regions of tumor suppressor genes (TSGs) leading to their gene silencing. Promotes tumor growth. Methylates CpG residues. T88304 PDBSTRUC 5YDR; 5WVO; 4Z97; 4Z96; 4YOC T88304 BIOCLASS Methyltransferase T88304 ECNUMBER EC 2.1.1.37 T88304 SEQUENCE MPARTAPARVPTLAVPAISLPDDVRRRLKDLERDSLTEKECVKEKLNLLHEFLQTEIKNQLCDLETKLRKEELSEEGYLAKVKSLLNKDLSLENGAHAYNREVNGRLENGNQARSEARRVGMADANSPPKPLSKPRTPRRSKSDGEAKPEPSPSPRITRKSTRQTTITSHFAKGPAKRKPQEESERAKSDESIKEEDKDQDEKRRRVTSRERVARPLPAEEPERAKSGTRTEKEEERDEKEEKRLRSQTKEPTPKQKLKEEPDREARAGVQADEDEDGDEKDEKKHRSQPKDLAAKRRPEEKEPEKVNPQISDEKDEDEKEEKRRKTTPKEPTEKKMARAKTVMNSKTHPPKCIQCGQYLDDPDLKYGQHPPDAVDEPQMLTNEKLSIFDANESGFESYEALPQHKLTCFSVYCKHGHLCPIDTGLIEKNIELFFSGSAKPIYDDDPSLEGGVNGKNLGPINEWWITGFDGGEKALIGFSTSFAEYILMDPSPEYAPIFGLMQEKIYISKIVVEFLQSNSDSTYEDLINKIETTVPPSGLNLNRFTEDSLLRHAQFVVEQVESYDEAGDSDEQPIFLTPCMRDLIKLAGVTLGQRRAQARRQTIRHSTREKDRGPTKATTTKLVYQIFDTFFAEQIEKDDREDKENAFKRRRCGVCEVCQQPECGKCKACKDMVKFGGSGRSKQACQERRCPNMAMKEADDDEEVDDNIPEMPSPKKMHQGKKKKQNKNRISWVGEAVKTDGKKSYYKKVCIDAETLEVGDCVSVIPDDSSKPLYLARVTALWEDSSNGQMFHAHWFCAGTDTVLGATSDPLELFLVDECEDMQLSYIHSKVKVIYKAPSENWAMEGGMDPESLLEGDDGKTYFYQLWYDQDYARFESPPKTQPTEDNKFKFCVSCARLAEMRQKEIPRVLEQLEDLDSRVLYYSATKNGILYRVGDGVYLPPEAFTFNIKLSSPVKRPRKEPVDEDLYPEHYRKYSDYIKGSNLDAPEPYRIGRIKEIFCPKKSNGRPNETDIKIRVNKFYRPENTHKSTPASYHADINLLYWSDEEAVVDFKAVQGRCTVEYGEDLPECVQVYSMGGPNRFYFLEAYNAKSKSFEDPPNHARSPGNKGKGKGKGKGKPKSQACEPSEPEIEIKLPKLRTLDVFSGCGGLSEGFHQAGISDTLWAIEMWDPAAQAFRLNNPGSTVFTEDCNILLKLVMAGETTNSRGQRLPQKGDVEMLCGGPPCQGFSGMNRFNSRTYSKFKNSLVVSFLSYCDYYRPRFFLLENVRNFVSFKRSMVLKLTLRCLVRMGYQCTFGVLQAGQYGVAQTRRRAIILAAAPGEKLPLFPEPLHVFAPRACQLSVVVDDKKFVSNITRLSSGPFRTITVRDTMSDLPEVRNGASALEISYNGEPQSWFQRQLRGAQYQPILRDHICKDMSALVAARMRHIPLAPGSDWRDLPNIEVRLSDGTMARKLRYTHHDRKNGRSSSGALRGVCSCVEAGKACDPAARQFNTLIPWCLPHTGNRHNHWAGLYGRLEWDGFFSTTVTNPEPMGKQGRVLHPEQHRVVSVRECARSQGFPDTYRLFGNILDKHRQVGNAVPPPLAKAIGLEIKLCMLAKARESASAKIKEEEAAKD T88304 DRUGINFO D0Q5KZ SGI110 Phase 3 T88304 DRUGINFO D0VZ4N Guadecitabine Phase 3 T88304 DRUGINFO D09NTC CC-486 Phase 3 T88304 DRUGINFO D0A2BO S-110 Phase 3 T88304 DRUGINFO D04FDN Palifosfamide Phase 2 T88304 DRUGINFO D0L7WS RX-3117 Phase 2 T88304 DRUGINFO D0T3AW Antroquinonol Phase 2 T88304 DRUGINFO D5QR2M GSK4172239 Phase 1 T88304 DRUGINFO D01CGQ PMID27376512-Compound-miR-155-5p Patented T88304 DRUGINFO D04JIH PMID27376512-Compound-Table1Example11 Patented T88304 DRUGINFO D05DSL PMID27376512-Compound-Table1Example16 Patented T88304 DRUGINFO D09FMS PMID27376512-Compound-Table1Example5 Patented T88304 DRUGINFO D0E7OA PMID27376512-Compound-asCEBP-2HPE Patented T88304 DRUGINFO D0G6ON PMID27376512-Compound-asCEBP-1 Patented T88304 DRUGINFO D0K4YF PMID27376512-Compound-Table1Example4 Patented T88304 DRUGINFO D0KE4E PMID27376512-Compound-asCEBP-2 Patented T88304 DRUGINFO D0LK4R PMID27376512-Compound-asCEBP-1HPE Patented T88304 DRUGINFO D0RT6C PMID27376512-Compound-Table1Example8 Patented T88304 DRUGINFO D0U5CK PMID27376512-Compound-MTC-433 Patented T88304 DRUGINFO D0YK6K PMID27376512-Compound-Table1Example30 Patented T88304 DRUGINFO D02WRM PMID27376512-Compound-MTC-424 Patented T88304 DRUGINFO D0HA0J PMID27376512-Compound-MTC-427 Patented T88304 DRUGINFO D0QY0N PMID27376512-Compound-MTC-422 Patented T88304 DRUGINFO D0W9VZ PMID27376512-Compound-MTC-423 Patented T88304 DRUGINFO D03DTQ PMX-700 Investigative T88304 DRUGINFO D0JV8Q XB-05 Investigative T88304 DRUGINFO D0OT1S CP-4200 Investigative T23347 TARGETID T23347 T23347 FORMERID TTDC00234 T23347 UNIPROID IL1R2_HUMAN T23347 TARGNAME Interleukin 1 receptor type 2 (IL1R2) T23347 GENENAME IL1R2 T23347 TARGTYPE Clinical trial T23347 SYNONYMS Interleukin-1 receptor type II; Interleukin-1 receptor type 2; Interleukin-1 receptor beta; Interleukin 1 receptor type II; IL1RB; IL-1RT2; IL-1RT-2; IL-1R-beta; IL-1R-2; IL-1 type II receptor; CDw121b; CD121b; CD121 antigen-like family member B; Antigen CDw121b T23347 FUNCTION Reduces IL1B activities. Serves as a decoy receptor by competetive binding to IL1B and preventing its binding to IL1R1. Also modulates cellular response through non-signaling association with IL1RAP after binding to IL1B. IL1R2 (membrane and secreted forms) preferentially binds IL1B and poorly IL1A and IL1RN. The secreted IL1R2 recruits secreted IL1RAP with high affinity; this complex formation may be the dominant mechanism for neutralization of IL1B by secreted/soluble receptors. Non-signaling receptor for IL1A, IL1B and IL1RN. T23347 PDBSTRUC 3O4O T23347 BIOCLASS Cytokine receptor T23347 SEQUENCE MLRLYVLVMGVSAFTLQPAAHTGAARSCRFRGRHYKREFRLEGEPVALRCPQVPYWLWASVSPRINLTWHKNDSARTVPGEEETRMWAQDGALWLLPALQEDSGTYVCTTRNASYCDKMSIELRVFENTDAFLPFISYPQILTLSTSGVLVCPDLSEFTRDKTDVKIQWYKDSLLLDKDNEKFLSVRGTTHLLVHDVALEDAGYYRCVLTFAHEGQQYNITRSIELRIKKKKEETIPVIISPLKTISASLGSRLTIPCKVFLGTGTPLTTMLWWTANDTHIESAYPGGRVTEGPRQEYSENNENYIEVPLIFDPVTREDLHMDFKCVVHNTLSFQTLRTTVKEASSTFSWGIVLAPLSLAFLVLGGIWMHRRCKHRTGKADGLTVLWPHHQDFQSYPK T23347 DRUGINFO D03FVR GSK-1827771 Phase 1 T23347 DRUGINFO D0W7VG AMG 108 Discontinued in Phase 2 T23347 DRUGINFO D0S7VN MRL-953 Terminated T23347 DRUGINFO D04SVB FR-133605 Terminated T35194 TARGETID T35194 T35194 FORMERID TTDR00085 T35194 UNIPROID DUS1_HUMAN T35194 TARGNAME Dual specificity protein phosphatase 1 (DUSP1) T35194 GENENAME DUSP1 T35194 TARGTYPE Clinical trial T35194 SYNONYMS VH1; Protein-tyrosine phosphatase CL100; PTPN10; Mitogen-activated protein kinase phosphatase 1; MKP1; MKP-1; MAP kinase phosphatase-1; MAP kinase phosphatase 1; Dual specificity protein phosphatase hVH1; CL100 T35194 FUNCTION Dual specificity phosphatase that dephosphorylates MAP kinase MAPK1/ERK2 on both 'Thr-183' and 'Tyr-185', regulating its activity during the meiotic cell cycle. T35194 PDBSTRUC 6D67; 6D66; 6D65; 6APX T35194 BIOCLASS Phosphoric monoester hydrolase T35194 ECNUMBER EC 3.1.3.16 T35194 SEQUENCE MVMEVGTLDAGGLRALLGERAAQCLLLDCRSFFAFNAGHIAGSVNVRFSTIVRRRAKGAMGLEHIVPNAELRGRLLAGAYHAVVLLDERSAALDGAKRDGTLALAAGALCREARAAQVFFLKGGYEAFSASCPELCSKQSTPMGLSLPLSTSVPDSAESGCSSCSTPLYDQGGPVEILPFLYLGSAYHASRKDMLDALGITALINVSANCPNHFEGHYQYKSIPVEDNHKADISSWFNEAIDFIDSIKNAGGRVFVHCQAGISRSATICLAYLMRTNRVKLDEAFEFVKQRRSIISPNFSFMGQLLQFESQVLAPHCSAEAGSPAMAVLDRGTSTTTVFNFPVSIPVHSTNSALSYLQSPITTSPSC T35194 DRUGINFO D0C0NH Avastin+/-Tarceva Phase 3 T35194 DRUGINFO D01SLG Okadaic acid Investigative T35194 DRUGINFO D07FFL ADOCIAQUINONE B Investigative T35194 DRUGINFO D07REK 4-ethoxynaphthalene-1,2-dione Investigative T73756 TARGETID T73756 T73756 FORMERID TTDR01133 T73756 UNIPROID EPHB2_HUMAN T73756 TARGNAME Ephrin type-B receptor 2 (EPHB2) T73756 GENENAME EPHB2 T73756 TARGTYPE Clinical trial T73756 SYNONYMS hEK5; Tyrosine-protein kinase receptor EPH-3; Tyrosine-protein kinase TYRO5; TYRO5; Renal carcinoma antigen NY-REN-47; Receptor protein-tyrosine kinase HEK5; EphB2 receptor tyrosine kinase; EphB2; EPTH3; EPHT3; EPH-like kinase 5; EPH tyrosine kinase 3; ELK-related tyrosine kinase; EK5; Developmentally-regulated Eph-related tyrosine kinase; DRT T73756 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. In addition to axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor. Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T73756 PDBSTRUC 3ZFM; 2QBX; 1F0M; 1B4F T73756 BIOCLASS Kinase T73756 ECNUMBER EC 2.7.10.1 T73756 SEQUENCE MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYDENMNTIRTYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSIPSVPGSCKETFNLYYYEADFDSATKTFPNWMENPWVKVDTIAADESFSQVDLGGRVMKINTEVRSFGPVSRSGFYLAFQDYGGCMSLIAVRVFYRKCPRIIQNGAIFQETLSGAESTSLVAARGSCIANAEEVDVPIKLYCNGDGEWLVPIGRCMCKAGFEAVENGTVCRGCPSGTFKANQGDEACTHCPINSRTTSEGATNCVCRNGYYRADLDPLDMPCTTIPSAPQAVISSVNETSLMLEWTPPRDSGGREDLVYNIICKSCGSGRGACTRCGDNVQYAPRQLGLTEPRIYISDLLAHTQYTFEIQAVNGVTDQSPFSPQFASVNITTNQAAPSAVSIMHQVSRTVDSITLSWSQPDQPNGVILDYELQYYEKELSEYNATAIKSPTNTVTVQGLKAGAIYVFQVRARTVAGYGRYSGKMYFQTMTEAEYQTSIQEKLPLIIGSSAAGLVFLIAVVVIAIVCNRRGFERADSEYTDKLQHYTSGHMTPGMKIYIDPFTYEDPNEAVREFAKEIDISCVKIEQVIGAGEFGEVCSGHLKLPGKREIFVAIKTLKSGYTEKQRRDFLSEASIMGQFDHPNVIHLEGVVTKSTPVMIITEFMENGSLDSFLRQNDGQFTVIQLVGMLRGIAAGMKYLADMNYVHRDLAARNILVNSNLVCKVSDFGLSRFLEDDTSDPTYTSALGGKIPIRWTAPEAIQYRKFTSASDVWSYGIVMWEVMSYGERPYWDMTNQDVINAIEQDYRLPPPMDCPSALHQLMLDCWQKDRNHRPKFGQIVNTLDKMIRNPNSLKAMAPLSSGINLPLLDRTIPDYTSFNTVDEWLEAIKMGQYKESFANAGFTSFDVVSQMMMEDILRVGVTLAGHQKKILNSIQVMRAQMNQIQSVEGQPLARRPRATGRTKRCQPRDVTKKTCNSNDGKKKGMGKKKTDPGRGREIQGIFFKEDSHKESNDCSCGG T73756 DRUGINFO DXWP72 SEphB4-HSA Phase 2 T73756 DRUGINFO D01IED BVD-523 Phase 2 T73756 DRUGINFO D0A1DG KO-947 Phase 1 T73756 DRUGINFO D0L1GD MK-8353 Phase 1 T73756 DRUGINFO D0H3IS SNEWIQPRLPQH Investigative T73756 DRUGINFO D05FXD PMID19788238C66 Investigative T73756 DRUGINFO D00ICA AMP-PNP Investigative T73756 DRUGINFO D0X8BU PMID23489211C20 Investigative T98269 TARGETID T98269 T98269 FORMERID TTDR00434 T98269 UNIPROID CASP1_HUMAN T98269 TARGNAME Caspase-1 (CASP1) T98269 GENENAME CASP1 T98269 TARGTYPE Clinical trial T98269 SYNONYMS P45; Interleukin-1 beta-converting enzyme; Interleukin-1 beta converting enzyme; Interleukin-1 beta convertase; IL1BCE; IL1BC; IL-1BC; IL-1 beta-converting enzyme; IL-1 beta converting enzyme; ICE; CASP-1 T98269 FUNCTION Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis. Upon inflammasome activation, during DNA virus infection but not RNA virus challenge, controls antiviral immunity through the cleavage of CGAS, rendering it inactive. Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. T98269 BIOCLASS Peptidase T98269 ECNUMBER EC 3.4.22.36 T98269 SEQUENCE MADKVLKEKRKLFIRSMGEGTINGLLDELLQTRVLNKEEMEKVKRENATVMDKTRALIDSVIPKGAQACQICITYICEEDSYLAGTLGLSADQTSGNYLNMQDSQGVLSSFPAPQAVQDNPAMPTSSGSEGNVKLCSLEEAQRIWKQKSAEIYPIMDKSSRTRLALIICNEEFDSIPRRTGAEVDITGMTMLLQNLGYSVDVKKNLTASDMTTELEAFAHRPEHKTSDSTFLVFMSHGIREGICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRGDSPGVVWFKDSVGVSGNLSLPTTEEFEDDAIKKAHIEKDFIAFCSSTPDNVSWRHPTMGSVFIGRLIEHMQEYACSCDVEEIFRKVRFSFEQPDGRAQMPTTERVTLTRCFYLFPGH T98269 DRUGINFO D0HK3N Belnacasan Phase 2 T98269 DRUGINFO D0U6WQ PRALNACASAN Phase 2 T98269 DRUGINFO D0Z2JF Nivocasan Phase 2 T98269 DRUGINFO D0WP2R AC-201 Phase 2 T98269 DRUGINFO D04KIH Ac-YVAD-FMK Patented T98269 DRUGINFO D07AVV Ac-YVAD-cmk Patented T98269 DRUGINFO D0A3HF VE-16084 Terminated T98269 DRUGINFO D0F9FA L-709049 Terminated T98269 DRUGINFO D0K1CL SDZ-224-015 Terminated T98269 DRUGINFO D0B3WF YVAD Investigative T98269 DRUGINFO D0P3XJ Z-YVAD-CHO Investigative T98269 DRUGINFO D0X8XO Z-VAD-CHO Investigative T98269 DRUGINFO D0YX4V Z-YVAD-FMK Investigative T98269 DRUGINFO D00YNW M826 Investigative T46365 TARGETID T46365 T46365 FORMERID TTDR00116 T46365 UNIPROID MPIP2_HUMAN T46365 TARGNAME M-phase inducer phosphatase 2 (MPIP2) T46365 GENENAME CDC25B T46365 TARGTYPE Clinical trial T46365 SYNONYMS Dual specificity phosphatase Cdc25B; Cdc25B phosphatase; CDC25HU2 T46365 FUNCTION Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Directly dephosphorylates CDK1 and stimulates its kinase activity. The three isoforms seem to have a different level of activity. Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. T46365 PDBSTRUC 4WH9; 4WH7; 3FQU; 3FQT; 2UZQ T46365 BIOCLASS Phosphoric monoester hydrolase T46365 ECNUMBER EC 3.1.3.48 T46365 SEQUENCE MEVPQPEPAPGSALSPAGVCGGAQRPGHLPGLLLGSHGLLGSPVRAAASSPVTTLTQTMHDLAGLGSETPKSQVGTLLFRSRSRLTHLSLSRRASESSLSSESSESSDAGLCMDSPSPMDPHMAEQTFEQAIQAASRIIRNEQFAIRRFQSMPVRLLGHSPVLRNITNSQAPDGRRKSEAGSGAASSSGEDKENDGFVFKMPWKPTHPSSTHALAEWASRREAFAQRPSSAPDLMCLSPDRKMEVEELSPLALGRFSLTPAEGDTEEDDGFVDILESDLKDDDAVPPGMESLISAPLVKTLEKEEEKDLVMYSKCQRLFRSPSMPCSVIRPILKRLERPQDRDTPVQNKRRRSVTPPEEQQEAEEPKARVLRSKSLCHDEIENLLDSDHRELIGDYSKAFLLQTVDGKHQDLKYISPETMVALLTGKFSNIVDKFVIVDCRYPYEYEGGHIKTAVNLPLERDAESFLLKSPIAPCSLDKRVILIFHCEFSSERGPRMCRFIRERDRAVNDYPSLYYPEMYILKGGYKEFFPQHPNFCEPQDYRPMNHEAFKDELKTFRLKTRSWAGERSRRELCSRLQDQ T46365 DRUGINFO D0C0NH Avastin+/-Tarceva Phase 3 T46365 DRUGINFO D06REJ MX-7065 Terminated T46365 DRUGINFO D02UHP 6,7-dibromoquinoline-5,8-dione Investigative T46365 DRUGINFO D0L5LN ANTHRAQUINONE Investigative T46365 DRUGINFO D0SI7S 5,6,7,8-tetrahydroanthracene-1,4-dione Investigative T46365 DRUGINFO D07FFL ADOCIAQUINONE B Investigative T46365 DRUGINFO D07JRA 3-isopropyl-4-phenylnaphthalene-1,2-dione Investigative T46365 DRUGINFO D07REK 4-ethoxynaphthalene-1,2-dione Investigative T46365 DRUGINFO D09CZV Methyl Mercury Ion Investigative T46365 DRUGINFO D0J1KH NSC-95397 Investigative T46365 DRUGINFO D0X5WD 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione Investigative T46365 DRUGINFO D08GWQ 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione Investigative T46365 DRUGINFO D0N7YT 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione Investigative T46365 DRUGINFO D05AMX Cysteinesulfonic Acid Investigative T46365 DRUGINFO D0V6UC Cysteine Sulfenic Acid Investigative T46365 DRUGINFO D0H1GU Double Oxidized Cysteine Investigative T46365 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T28226 TARGETID T28226 T28226 FORMERID TTDR00115 T28226 UNIPROID GCH1_HUMAN T28226 TARGNAME GTP cyclohydrolase-I (GCH1) T28226 GENENAME GCH1 T28226 TARGTYPE Clinical trial T28226 SYNONYMS Guanosine triphosphate cyclohydrolase I; GTP-CH-I; GTP cyclohydrolase I; GTP cyclohydrolase 1; GCH; DYT5 T28226 FUNCTION May be involved in dopamine synthesis. May modify pain sensitivity and persistence. Isoform GCH-1 is the functional enzyme, the potential function of the enzymatically inactive isoforms remains unknown. Positively regulates nitric oxide synthesis in umbilical vein endothelial cells (HUVECs). T28226 PDBSTRUC 1FB1 T28226 BIOCLASS Carbon-nitrogen hydrolase T28226 ECNUMBER EC 3.5.4.16 T28226 SEQUENCE MEKGPVRAPAEKPRGARCSNGFPERDPPRPGPSRPAEKPPRPEAKSAQPADGWKGERPRSEEDNELNLPNLAAAYSSILSSLGENPQRQGLLKTPWRAASAMQFFTKGYQETISDVLNDAIFDEDHDEMVIVKDIDMFSMCEHHLVPFVGKVHIGYLPNKQVLGLSKLARIVEIYSRRLQVQERLTKQIAVAITEALRPAGVGVVVEATHMCMVMRGVQKMNSKTVTSTMLGVFREDPKTREEFLTLIRS T28226 DRUGINFO D08NKJ Guanine Phase 3 T28226 DRUGINFO D05ICS ProSavin Phase 1/2 T28226 DRUGINFO D72UDH OXB-102 Phase 1/2 T28226 DRUGINFO D07FSW 8-hydroxyguanine Investigative T28226 DRUGINFO D0EQ4T Guanosine-5'-Triphosphate Investigative T28226 DRUGINFO D0W7LK 2-Propanol, Isopropanol Investigative T73724 TARGETID T73724 T73724 FORMERID TTDR00164 T73724 UNIPROID ACHB4_HUMAN T73724 TARGNAME Neuronal acetylcholine receptor beta-4 (CHRNB4) T73724 GENENAME CHRNB4 T73724 TARGTYPE Clinical trial T73724 SYNONYMS CHRNB4; Beta-4 nAChR T73724 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. T73724 PDBSTRUC 2ASG T73724 BIOCLASS Neurotransmitter receptor T73724 SEQUENCE MRRAPSLVLFFLVALCGRGNCRVANAEEKLMDDLLNKTRYNNLIRPATSSSQLISIKLQLSLAQLISVNEREQIMTTNVWLKQEWTDYRLTWNSSRYEGVNILRIPAKRIWLPDIVLYNNADGTYEVSVYTNLIVRSNGSVLWLPPAIYKSACKIEVKYFPFDQQNCTLKFRSWTYDHTEIDMVLMTPTASMDDFTPSGEWDIVALPGRRTVNPQDPSYVDVTYDFIIKRKPLFYTINLIIPCVLTTLLAILVFYLPSDCGEKMTLCISVLLALTFFLLLISKIVPPTSLDVPLIGKYLMFTMVLVTFSIVTSVCVLNVHHRSPSTHTMAPWVKRCFLHKLPTFLFMKRPGPDSSPARAFPPSKSCVTKPEATATSTSPSNFYGNSMYFVNPASAASKSPAGSTPVAIPRDFWLRSSGRFRQDVQEALEGVSFIAQHMKNDDEDQSVVEDWKYVAMVVDRLFLWVFMFVCVLGTVGLFLPPLFQTHAASEGPYAAQRD T73724 DRUGINFO D08XPW CYTISINE Phase 3 T73724 DRUGINFO D00ECO SIB-1553A Discontinued in Phase 2 T73724 DRUGINFO D0C9KD HOMOEPIBATIDINE Terminated T73724 DRUGINFO D00YDR 18-Methylaminocoronaridine Investigative T73724 DRUGINFO D02FCS 15-nor-18-Methoxycornaridine Investigative T73724 DRUGINFO D06CDG 2-Acetylaminoethyl 18-methoxycoronaridinate Investigative T73724 DRUGINFO D0B6PX N,N-Dimethylaminoethyl 18-methoxycoronaridinate Investigative T73724 DRUGINFO D0F7XJ 2-Methoxyethyl 18-methoxycoronaridinate Investigative T73724 DRUGINFO D0T2YP 2-Hydroxyethyl 18-methoxycoronaridinate Investigative T73724 DRUGINFO D0U0LH 18-Dimethylaminocoronaridine Investigative T73724 DRUGINFO D0VA5V 18-methoxycoronaridinate 2-Hydroxyethylamide Investigative T73724 DRUGINFO D0WQ9A 18-methoxycoronaridinate 2-methoxyethylamide Investigative T73724 DRUGINFO D0UH8F GCCSNPVCHLEHSNLC* Investigative T73724 DRUGINFO D00QCP (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol Investigative T73724 DRUGINFO D03YQY (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol Investigative T86364 TARGETID T86364 T86364 FORMERID TTDC00204 T86364 UNIPROID VIPR1_HUMAN T86364 TARGNAME Vasoactive intestinal polypeptide receptor 1 (VIPR1) T86364 GENENAME VIPR1 T86364 TARGTYPE Clinical trial T86364 SYNONYMS Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor-1; Vasoactive intestinal peptide receptor 1; VPAC1; VPAC-1; VIPR1; VIP-R-1; Pituitary adenylate cyclase activating polypeptide type II receptor; PACAP-R-2; PACAP type II receptor T86364 FUNCTION This is a receptor for vip. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The affinity is vip = pacap-27 > pacap-38. T86364 PDBSTRUC 5IB5; 5IB4; 5IB3; 5IB2; 5IB1 T86364 BIOCLASS GPCR secretin T86364 SEQUENCE MRPPSPLPARWLCVLAGALAWALGPAGGQAARLQEECDYVQMIEVQHKQCLEEAQLENETIGCSKMWDNLTCWPATPRGQVVVLACPLIFKLFSSIQGRNVSRSCTDEGWTHLEPGPYPIACGLDDKAASLDEQQTMFYGSVKTGYTIGYGLSLATLLVATAILSLFRKLHCTRNYIHMHLFISFILRAAAVFIKDLALFDSGESDQCSEGSVGCKAAMVFFQYCVMANFFWLLVEGLYLYTLLAVSFFSERKYFWGYILIGWGVPSTFTMVWTIARIHFEDYGCWDTINSSLWWIIKGPILTSILVNFILFICIIRILLQKLRPPDIRKSDSSPYSRLARSTLLLIPLFGVHYIMFAFFPDNFKPEVKMVFELVVGSFQGFVVAILYCFLNGEVQAELRRKWRRWHLQGVLGWNPKYRHPSGGSNGATCSTQVSMLTRVSPGARRSSSFQAEVSLV T86364 DRUGINFO D0T4TN Vasoactive intestinal peptide Phase 2 T86364 DRUGINFO D0B2MN helodermin Investigative T86364 DRUGINFO D0MC5J PACAP-27 Investigative T16016 TARGETID T16016 T16016 FORMERID TTDC00215 T16016 UNIPROID CCR1_HUMAN T16016 TARGNAME C-C chemokine receptor type 1 (CCR1) T16016 GENENAME CCR1 T16016 TARGTYPE Clinical trial T16016 SYNONYMS SCYAR1; RANTES-R; Macrophage inflammatory protein-1 alpha receptor; Macrophage inflammatory protein 1-alpha receptor; MIP-1alpha-R; LD78 receptor; HM145; Chemokine receptor CCR1; CMKR1; CMKBR1; CD191; CCR-1; CC-CKR-1; C-C CKR-1 T16016 FUNCTION Binds to MIP-1-alpha, MIP-1-delta, RANTES, and MCP-3 and, less efficiently, to MIP-1-beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. Responsible for affecting stem cell proliferation. Receptor for a C-C type chemokine. T16016 PDBSTRUC 1Y5D T16016 BIOCLASS GPCR rhodopsin T16016 SEQUENCE METPNTTEDYDTTTEFDYGDATPCQKVNERAFGAQLLPPLYSLVFVIGLVGNILVVLVLVQYKRLKNMTSIYLLNLAISDLLFLFTLPFWIDYKLKDDWVFGDAMCKILSGFYYTGLYSEIFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIIIWALAILASMPGLYFSKTQWEFTHHTCSLHFPHESLREWKLFQALKLNLFGLVLPLLVMIICYTGIIKILLRRPNEKKSKAVRLIFVIMIIFFLFWTPYNLTILISVFQDFLFTHECEQSRHLDLAVQVTEVIAYTHCCVNPVIYAFVGERFRKYLRQLFHRRVAVHLVKWLPFLSVDRLERVSSTSPSTGEHELSAGF T16016 DRUGINFO D05VTN CCX-354 Phase 2 T16016 DRUGINFO D0UX2V BMS-817399 Phase 2 T16016 DRUGINFO D0Q2BB AVE1701 Phase 1 T16016 DRUGINFO D00PFW AZD4818 Discontinued in Phase 2 T16016 DRUGINFO D0KF6X MLN3897 Discontinued in Phase 2 T16016 DRUGINFO D00FOE COSALANE Terminated T16016 DRUGINFO D05XZF BX 471 Investigative T16016 DRUGINFO D0X9MZ Cosalane derivative Investigative T16016 DRUGINFO D0F9QT A-987306 Investigative T35734 TARGETID T35734 T35734 FORMERID TTDR01203 T35734 UNIPROID HYES_HUMAN T35734 TARGNAME Soluble epoxide hydrolase (EPHX2) T35734 GENENAME EPHX2 T35734 TARGTYPE Clinical trial T35734 SYNONYMS Bifunctional epoxide hydrolase 2 T35734 FUNCTION Bifunctional enzyme. The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides. Plays a role in xenobiotic metabolism by degrading potentially toxic epoxides (By similarity). Also determines steady-state levels of physiological mediators. The N-terminal domain has lipid phosphatase activity, with the highest activity towards threo-9,10-phosphonooxy-hydroxy-octadecanoic acid, followed by erythro-9,10-phosphonooxy-hydroxy-octadecanoic acid, 12-phosphonooxy-octadec-9Z-enoic acid and 12-phosphonooxy-octadec-9E-enoic acid. T35734 PDBSTRUC 6AUM; 5MWA; 5FP0; 5AM5; 5AM4 T35734 BIOCLASS Ether bond hydrolase T35734 SEQUENCE MTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARNPPVVSKM T35734 DRUGINFO D0KL3U AR9281 Phase 2 T35734 DRUGINFO D0A8KQ GSK2256294 Phase 1 T35734 DRUGINFO D00CHD 13-n-Heptanamidotridec-8(Z)-enoic acid Investigative T35734 DRUGINFO D00HAZ N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine Investigative T35734 DRUGINFO D00RST 1-adamantan-1-yl-3-(6-propyloxyhexyl)urea Investigative T35734 DRUGINFO D00VZE N-adamantyl-N'-cyclohexylurea Investigative T35734 DRUGINFO D01CGC 13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid Investigative T35734 DRUGINFO D01DZF N-(3,3-Diphenyl-propyl)-isonicotinamide Investigative T35734 DRUGINFO D01JJV 1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea Investigative T35734 DRUGINFO D01NFH 1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea Investigative T35734 DRUGINFO D01OZF 1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea Investigative T35734 DRUGINFO D02ATA 9-(3-n-Pentylureido)non-4-ynoic acid Investigative T35734 DRUGINFO D02CKF 13-(3-n-Pentylureido)tridec-8-ynoic acid Investigative T35734 DRUGINFO D02UJV 1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea Investigative T35734 DRUGINFO D02YEE N-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide Investigative T35734 DRUGINFO D03CSL 13-(n-Pentylcarbamoyloxy)tridec-8(Z)-enoic acid Investigative T35734 DRUGINFO D03IVU Methyl 14-(3-n-butylureido)tetradec-8(Z)-enoate Investigative T35734 DRUGINFO D04ARH 1-Octyl-3-(1-propionylpiperidin-4-yl)urea Investigative T35734 DRUGINFO D04NJC 1-Adamantan-1-yl-3-(4-methoxy-phenyl)-urea Investigative T35734 DRUGINFO D04PNC 2-Cyclohexyl-N-phenethyl-acetamide Investigative T35734 DRUGINFO D05IKY 14-(n-Hexylamino)-14-oxotetradec-8(Z)-enoic acid Investigative T35734 DRUGINFO D05MAT 1-adamantan-1-yl-3-(3-hydroxypropyl)urea Investigative T35734 DRUGINFO D05MTA 1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea Investigative T35734 DRUGINFO D05NZH Methyl 4-(3-cyclohexylureido)butanoate Investigative T35734 DRUGINFO D06DZO Dodecanoic acid adamantan-1-ylamide Investigative T35734 DRUGINFO D06OFY [4-(3-Adamantan-1-yl-ureido)-phenyl]-acetic acid Investigative T35734 DRUGINFO D06RJQ 1-(3-Chloro-phenyl)-3-(4-hydroxy-decyl)-urea Investigative T35734 DRUGINFO D07BJC 13-n-Heptanamidotridec-5-ynoic acid Investigative T35734 DRUGINFO D07BQN N-(3,3-Diphenyl-propyl)-2-pyridine-3-ylacetamide Investigative T35734 DRUGINFO D07HSQ 1-adamantan-1-yl-3-((R)-1-phenyl-ethyl)-urea Investigative T35734 DRUGINFO D07HWV 13-(5-n-Pentylfuran-2-yl)tridec-8(Z)-enoic acid Investigative T35734 DRUGINFO D07MHZ N-Cyclohexyl-N'-(Propyl)Phenyl Urea Investigative T35734 DRUGINFO D07QNN N-Cyclohexyl-2-phenyl-acetamide Investigative T35734 DRUGINFO D07TOI 1-adamantan-1-yl-3-(4-pentyloxybutyl)urea Investigative T35734 DRUGINFO D07UIO 13-(3-n-Pentylureido)tridec-8(E)-enoic acid Investigative T35734 DRUGINFO D08AKP 13-(N-Isopropylheptanamido)tridec-8(Z)-enoic acid Investigative T35734 DRUGINFO D08AZT 1-Adamantan-1-yl-3-(2-hydroxy-phenyl)-urea Investigative T35734 DRUGINFO D08HUX N-(3,3-diphenyl-propyl)-nicotinamide Investigative T35734 DRUGINFO D08IBD N-(3-Chloro-phenyl)-2-cyclohexyl-acetamide Investigative T35734 DRUGINFO D08RFH Cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea Investigative T35734 DRUGINFO D08RPW 1-Cyclohexyl-3-phenethyl-urea Investigative T35734 DRUGINFO D08TWI 12-(3-n-Hexylureido)dodec-8(Z)-enoic acid Investigative T35734 DRUGINFO D08USX N-(4,4-Diphenyl-butyl)-nicotinamide Investigative T35734 DRUGINFO D08WHU 4-(3-Adamantan-1-yl-ureido)-benzoic acid Investigative T35734 DRUGINFO D08XYV 9-(3-n-Pentylureido)non-4(Z)-enoic acid Investigative T35734 DRUGINFO D08YJF 2-Cyclohexyl-N-phenyl-acetamide Investigative T35734 DRUGINFO D09DPC 1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea Investigative T35734 DRUGINFO D09FEC 1-Cyclohexyl-3-(4-methoxy-phenyl)-urea Investigative T35734 DRUGINFO D09VSL 1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea Investigative T35734 DRUGINFO D09WQW 6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID Investigative T35734 DRUGINFO D0A4VS 1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea Investigative T35734 DRUGINFO D0AT6Z 16-(3-Ethylureido)hexadec-11(Z)-enoic acid Investigative T35734 DRUGINFO D0B0ES 1-(3-Chloro-phenyl)-3-cyclohexyl-urea Investigative T35734 DRUGINFO D0B0MU 12-(3-n-Pentylureidooxy)dodec-8(Z)-enoic acid Investigative T35734 DRUGINFO D0B3GP 6-amino-N-(2,4-dichlorobenzyl)nicotinamide Investigative T35734 DRUGINFO D0B4CV N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE Investigative T35734 DRUGINFO D0BI0Z 4,4-Diphenyl-N-(pyridin-3-yl)-butyramide Investigative T35734 DRUGINFO D0C1EP N-(biphenyl-3-yl)benzo[d]isoxazol-3-amine Investigative T35734 DRUGINFO D0C5GW 1-Cyclohexyl-3-phenyl-urea Investigative T35734 DRUGINFO D0C8HN 13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid Investigative T35734 DRUGINFO D0D0KT N-(3-Phenyl-propyl)-nicotinamide Investigative T35734 DRUGINFO D0D3GF 1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea Investigative T35734 DRUGINFO D0D7ID N-Cyclohexyl-N'-Decylurea Investigative T35734 DRUGINFO D0F3PF 1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea Investigative T35734 DRUGINFO D0F3VZ 1-Cycloheptyl-3-(1-propionylpiperidin-4-yl)urea Investigative T35734 DRUGINFO D0F5XQ 1-adamantan-1-yl-3-(4-hydroxybutyl)urea Investigative T35734 DRUGINFO D0G8HM N-Cyclohexyl-N'-(4-Iodophenyl)Urea Investigative T35734 DRUGINFO D0I0YE N-[3,3-Bis-(4-fluorophenyl)-propyl]-benzamide Investigative T35734 DRUGINFO D0I4KB 1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea Investigative T35734 DRUGINFO D0IC8U 1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea Investigative T35734 DRUGINFO D0IM1Q N-(biphenyl-4-yl)benzo[d]isoxazol-3-amine Investigative T35734 DRUGINFO D0J0YB 1-adamantan-1-yl-3-(2-hydroxyethyl)urea Investigative T35734 DRUGINFO D0J5KK 1-adamantan-1-yl-3-piperidin-4-yl-urea Investigative T35734 DRUGINFO D0J7FK Methyl 6-(3-cyclohexylureido)hexanoate Investigative T35734 DRUGINFO D0K6GX N-Cyclohexyl-4-phenyl-butyramide Investigative T35734 DRUGINFO D0K6IW N-[3,3-Bis-(4-fluorophenyl)-propyl]-nicotinamide Investigative T35734 DRUGINFO D0K6OL 2-Cyclohexyl-N-(4-methoxy-phenyl)-acetamide Investigative T35734 DRUGINFO D0M0KA 1-adamantan-1-yl-3-(5-butoxypentyl)urea Investigative T35734 DRUGINFO D0N1SE 1-(1-Propionylpiperidin-4-yl)-3-m-tolylurea Investigative T35734 DRUGINFO D0P3WB 6-amino-N-(3,3-diphenylpropyl)nicotinamide Investigative T35734 DRUGINFO D0P8MM 1-(1-Propionylpiperidin-4-yl)-3-o-tolylurea Investigative T35734 DRUGINFO D0Q8NE 1-Adamantan-1-yl-3-(4-hydroxy-phenyl)-urea Investigative T35734 DRUGINFO D0R1YP Trans,trans-1,3-bis-(4-hydroxycyclohexyl)urea Investigative T35734 DRUGINFO D0R6CW 1-Phenyl-3-(1-propionylpiperidin-4-yl)urea Investigative T35734 DRUGINFO D0RK4K 3-(3-Adamantan-1-yl-ureido)-benzoic acid Investigative T35734 DRUGINFO D0RX9W N,N'-dicyclohexyl-urea Investigative T35734 DRUGINFO D0S0SH 12-(3-Adamantan-1-yl-ureido)-dodeca noic acid Investigative T35734 DRUGINFO D0S3KS N-Cyclohexyl-2-(4-methoxy-phenyl)-acetamide Investigative T35734 DRUGINFO D0T9ZN 1-Adamantan-1-yl-3-(4-hydroxy-decyl)-urea Investigative T35734 DRUGINFO D0TS7G 4-(3-cyclohexylureido)butanoic acid Investigative T35734 DRUGINFO D0U0WU 13-(3-Pentyluredo)tridec-8(Z)-enoic acid Investigative T35734 DRUGINFO D0U4KM 1-(1-Adamantyl)-3-(1-propionylpiperidin-4-yl)urea Investigative T35734 DRUGINFO D0U6TM 2-Adamantan-1-yl-N-decyl-acetamide Investigative T35734 DRUGINFO D0UJ9V 1-adamantan-1-yl-3-(5-hydroxypentyl)urea Investigative T35734 DRUGINFO D0V8EQ 1-Adamantan-1-yl-3-(3-methoxy-phenyl)-urea Investigative T35734 DRUGINFO D0VW6Y 1-adamantan-1-yl-3-(3-hexyloxypropyl)urea Investigative T35734 DRUGINFO D0X0ZD EXRD-4605 Investigative T35734 DRUGINFO D0X1EG 13-(3-n-Pentylureido)tridec-5(Z)-enoic acid Investigative T35734 DRUGINFO D0X6ZY Cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea Investigative T35734 DRUGINFO D0X7IM 1,3-DIPHENYLUREA Investigative T35734 DRUGINFO D0XG0G 1-Adamantan-1-yl-3-decyl-urea Investigative T35734 DRUGINFO D0XS3W 1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea Investigative T35734 DRUGINFO D0YS1G 1-adamantan-1-yl-3-(2-heptyloxyethyl)urea Investigative T35734 DRUGINFO D0Z0XL N-(naphthalen-2-yl)benzo[d]isoxazol-3-amine Investigative T35734 DRUGINFO D0Z6SS 1-Adamantan-1-yl-3-phenyl-urea Investigative T35734 DRUGINFO D0Z8RL 1-adamantan-1-yl-3-(6-hydroxyhexyl)urea Investigative T18876 TARGETID T18876 T18876 FORMERID TTDC00151 T18876 UNIPROID PE2R4_HUMAN T18876 TARGNAME Prostaglandin E2 receptor EP4 (PTGER4) T18876 GENENAME PTGER4 T18876 TARGTYPE Clinical trial T18876 SYNONYMS Prostanoid EP4 receptor; Prostaglandin E2 receptor EP4 subtype; PTGER2; PGE2 receptor EP4 subtype; PGE receptor EP4 subtype T18876 FUNCTION Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. T18876 PDBSTRUC 5YWY; 5YHL T18876 BIOCLASS GPCR rhodopsin T18876 SEQUENCE MSTPGVNSSASLSPDRLNSPVTIPAVMFIFGVVGNLVAIVVLCKSRKEQKETTFYTLVCGLAVTDLLGTLLVSPVTIATYMKGQWPGGQPLCEYSTFILLFFSLSGLSIICAMSVERYLAINHAYFYSHYVDKRLAGLTLFAVYASNVLFCALPNMGLGSSRLQYPDTWCFIDWTTNVTAHAAYSYMYAGFSSFLILATVLCNVLVCGALLRMHRQFMRRTSLGTEQHHAAAAASVASRGHPAASPALPRLSDFRRRRSFRRIAGAEIQMVILLIATSLVVLICSIPLVVRVFVNQLYQPSLEREVSKNPDLQAIRIASVNPILDPWIYILLRKTVLSKAIEKIKCLFCRIGGSRRERSGQHCSDSQRTSSAMSGHSRSFISRELKEISSTSQTLLPDLSLPDLSENGLGGRNLLPGVPGMGLAQEDTTSLRTLRISETSDSSQGQDSESVLLVDEAGGSGRAGPAPKGSSLQVTFPSETLNLSEKCI T18876 DRUGINFO D00IQH RQ-00000007 (oral) Phase 2 T18876 DRUGINFO D03YAS ONO-AE1-437 Phase 2 T18876 DRUGINFO D0HJ5H BGC-20-1531 Phase 2 T18876 DRUGINFO D0U7WF 16,16-dimethyl-PGE2 Phase 2 T18876 DRUGINFO D1KES8 IK-007 Phase 1/2 T18876 DRUGINFO D01SHJ E7046 Phase 1 T18876 DRUGINFO D02STG ONO-4232 Phase 1 T18876 DRUGINFO D03UHV ONO-4578 Phase 1 T18876 DRUGINFO D1G4EK AN0025 Phase 1 T18876 DRUGINFO D54FYW TPST-1495 Phase 1 T18876 DRUGINFO D00HTY PGF2alpha Clinical trial T18876 DRUGINFO D0W2OT BUTAPROST Patented T18876 DRUGINFO D0O4XW ONO-4819 Discontinued in Phase 2 T18876 DRUGINFO D01HCL 13,14-dihydro-PGE1 Investigative T18876 DRUGINFO D01WXZ 11-deoxy-PGE2 Investigative T18876 DRUGINFO D02MXT MK-2894 Investigative T18876 DRUGINFO D03URI GW 627368 Investigative T18876 DRUGINFO D07JMB 8-aza-11-deoxyprostaglandin E1 Investigative T18876 DRUGINFO D07UXB 1-OH-PGE1 Investigative T18876 DRUGINFO D08CEW L902688 Investigative T18876 DRUGINFO D09TPW PF-04475270 Investigative T18876 DRUGINFO D0D8DA KAG-308 Investigative T18876 DRUGINFO D0F4QJ CR-5790 Investigative T18876 DRUGINFO D0H5TU RQ-00000008 Investigative T18876 DRUGINFO D0N1TQ ER819762 Investigative T18876 DRUGINFO D0S2LO TCS 2510 Investigative T18876 DRUGINFO D0Y6FA CP734432 Investigative T18876 DRUGINFO D05MXO 19(R)-OH-PGE2 Investigative T18876 DRUGINFO D07WQV AH23848 Investigative T18876 DRUGINFO D08KPK ONO-AE3-240 Investigative T18876 DRUGINFO D0AK4K ONO-AE3-208 Investigative T18876 DRUGINFO D0I0UI ONO-AE2-227 Investigative T18876 DRUGINFO D02LXJ 3-(2-cinnamylphenyl)acrylic acid Investigative T18876 DRUGINFO D02SAD 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid Investigative T18876 DRUGINFO D06VZS ONO-AE1-329 Investigative T18876 DRUGINFO D0G5MT 11-deoxy-PGE1 Investigative T18876 DRUGINFO D0TA0L FR-181157 Investigative T18876 DRUGINFO D0W4GQ 3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid Investigative T18876 DRUGINFO D0Z3XJ 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid Investigative T18876 DRUGINFO D05SFA cicaprost Investigative T18876 DRUGINFO D08MNO butaprost (free acid form) Investigative T18876 DRUGINFO D0BN1U M&B 28767 Investigative T18876 DRUGINFO D06KBO PGD2 Investigative T18876 DRUGINFO D0W7RI carbacyclin Investigative T18876 DRUGINFO D03PLH U46619 Investigative T02546 TARGETID T02546 T02546 FORMERID TTDS00416 T02546 UNIPROID SCN4A_HUMAN T02546 TARGNAME Voltage-gated sodium channel alpha Nav1.4 (SCN4A) T02546 GENENAME SCN4A T02546 TARGTYPE Clinical trial T02546 SYNONYMS Voltage-gated sodium channel subunit alpha Nav1.4; Sodium channel protein type IV subunit alpha; Sodium channel protein skeletal muscle subunit alpha; SkM1; SCN4A T02546 FUNCTION This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. This sodium channel may be present in both denervated and innervated skeletal muscle. T02546 PDBSTRUC 6MC9; 6MBA; 6AGF T02546 BIOCLASS Voltage-gated ion channel T02546 SEQUENCE MARPSLCTLVPLGPECLRPFTRESLAAIEQRAVEEEARLQRNKQMEIEEPERKPRSDLEAGKNLPMIYGDPPPEVIGIPLEDLDPYYSNKKTFIVLNKGKAIFRFSATPALYLLSPFSVVRRGAIKVLIHALFSMFIMITILTNCVFMTMSDPPPWSKNVEYTFTGIYTFESLIKILARGFCVDDFTFLRDPWNWLDFSVIMMAYLTEFVDLGNISALRTFRVLRALKTITVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALVGLQLFMGNLRQKCVRWPPPFNDTNTTWYSNDTWYGNDTWYGNEMWYGNDSWYANDTWNSHASWATNDTFDWDAYISDEGNFYFLEGSNDALLCGNSSDAGHCPEGYECIKTGRNPNYGYTSYDTFSWAFLALFRLMTQDYWENLFQLTLRAAGKTYMIFFVVIIFLGSFYLINLILAVVAMAYAEQNEATLAEDKEKEEEFQQMLEKFKKHQEELEKAKAAQALEGGEADGDPAHGKDCNGSLDTSQGEKGAPRQSSSGDSGISDAMEELEEAHQKCPPWWYKCAHKVLIWNCCAPWLKFKNIIHLIVMDPFVDLGITICIVLNTLFMAMEHYPMTEHFDNVLTVGNLVFTGIFTAEMVLKLIAMDPYEYFQQGWNIFDSIIVTLSLVELGLANVQGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKIALDCNLPRWHMHDFFHSFLIVFRILCGEWIETMWDCMEVAGQAMCLTVFLMVMVIGNLVVLNLFLALLLSSFSADSLAASDEDGEMNNLQIAIGRIKLGIGFAKAFLLGLLHGKILSPKDIMLSLGEADGAGEAGEAGETAPEDEKKEPPEEDLKKDNHILNHMGLADGPPSSLELDHLNFINNPYLTIQVPIASEESDLEMPTEEETDTFSEPEDSKKPPQPLYDGNSSVCSTADYKPPEEDPEEQAEENPEGEQPEECFTEACVQRWPCLYVDISQGRGKKWWTLRRACFKIVEHNWFETFIVFMILLSSGALAFEDIYIEQRRVIRTILEYADKVFTYIFIMEMLLKWVAYGFKVYFTNAWCWLDFLIVDVSIISLVANWLGYSELGPIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYYCINTTTSERFDISEVNNKSECESLMHTGQVRWLNVKVNYDNVGLGYLSLLQVATFKGWMDIMYAAVDSREKEEQPQYEVNLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKLGGKDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPQNKIQGMVYDLVTKQAFDITIMILICLNMVTMMVETDNQSQLKVDILYNINMIFIIIFTGECVLKMLALRQYYFTVGWNIFDFVVVILSIVGLALSDLIQKYFVSPTLFRVIRLARIGRVLRLIRGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMSNFAYVKKESGIDDMFNFETFGNSIICLFEITTSAGWDGLLNPILNSGPPDCDPNLENPGTSVKGDCGNPSIGICFFCSYIIISFLIVVNMYIAIILENFNVATEESSEPLGEDDFEMFYETWEKFDPDATQFIAYSRLSDFVDTLQEPLRIAKPNKIKLITLDLPMVPGDKIHCLDILFALTKEVLGDSGEMDALKQTMEEKFMAANPSKVSYEPITTTLKRKHEEVCAIKIQRAYRRHLLQRSMKQASYMYRHSHDGSGDDAPEKEGLLANTMSKMYGHENGNSSSPSPEEKGEAGDAGPTMGLMPISPSDTAWPPAPPPGQTVRPGVKESLV T02546 DRUGINFO D0O9VW Lanperisone Phase 3 T02546 DRUGINFO D0EC2K SIPATRIGINE Discontinued in Phase 2 T02546 DRUGINFO D07EQF V-102862 Discontinued in Phase 1 T02546 DRUGINFO D01YPT CCNCSSKWCRAHSRCC Investigative T02546 DRUGINFO D05PRQ CCACSSKWCRDHSRCC Investigative T02546 DRUGINFO D06KAD CCNCASKWCRDHSRCC Investigative T02546 DRUGINFO D0H5QU ZNCCNCSSKWCRDHSRCC Investigative T02546 DRUGINFO D0KH1D 3-[4-(4-Fluoro-phenoxy)-phenyl]-1H-pyrazole Investigative T02546 DRUGINFO D0M5VF 3-(4-Phenoxy-phenyl)-1H-pyrazole Investigative T02546 DRUGINFO D0RO2K CCNCSSKWCRDHARCC Investigative T02546 DRUGINFO D0W5HA XEP-018 Investigative T02546 DRUGINFO D0Y4AU CCNCSAKWCRDHSRCC Investigative T02546 DRUGINFO D0YA8J grayanotoxin III Investigative T02546 DRUGINFO D0Z5LN ZRCCNCSSKWCRDHSRCC Investigative T02546 DRUGINFO D0N0KO CCNCSSKWCRDHSRCC Investigative T02546 DRUGINFO D0B9UU BW-202W92 Investigative T02546 DRUGINFO D0G9WE batrachotoxin Investigative T02546 DRUGINFO D0S4MN veratridine Investigative T40785 TARGETID T40785 T40785 FORMERID TTDS00299 T40785 UNIPROID FKS1_YEAST T40785 TARGNAME Fungal Papulacandin B resistance protein 1 (Fung FKS1) T40785 GENENAME Fung FKS1 T40785 TARGTYPE Clinical trial T40785 SYNONYMS UDP-glucose-1,3-beta-D-glucan glucosyltransferase; Papulacandin B sensitivity protein 1 of Saccharomyces cerevisiae; Glucan synthase; FKS1 protein of Saccharomyces cerevisiae; FKS1; CWN53 protein of Saccharomyces cerevisiae; CND1 protein of Saccharomyces cerevisiae; Beta-1,3-glucan synthetase; Beta-1,3-glucan synthase; 1,3-beta-D-glucan-UDP glucosyltransferase of Saccharomyces cerevisiae; (1,3)-beta-D-glucan synthase T40785 FUNCTION Alternate catalytic subunit of the 1,3-beta-glucan synthase (GS). Synthesizes 1,3-beta-glucan, a major structural component of the yeast cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling. T40785 BIOCLASS Hexosyltransferase T40785 ECNUMBER EC 2.4.1.34 T40785 SEQUENCE MNTDQQPYQGQTDYTQGPGNGQSQEQDYDQYGQPLYPSQADGYYDPNVAAGTEADMYGQQPPNESYDQDYTNGEYYGQPPNMAAQDGENFSDFSSYGPPGTPGYDSYGGQYTASQMSYGEPNSSGTSTPIYGNYDPNAIAMALPNEPYPAWTADSQSPVSIEQIEDIFIDLTNRLGFQRDSMRNMFDHFMVLLDSRSSRMSPDQALLSLHADYIGGDTANYKKWYFAAQLDMDDEIGFRNMSLGKLSRKARKAKKKNKKAMEEANPEDTEETLNKIEGDNSLEAADFRWKAKMNQLSPLERVRHIALYLLCWGEANQVRFTAECLCFIYKCALDYLDSPLCQQRQEPMPEGDFLNRVITPIYHFIRNQVYEIVDGRFVKRERDHNKIVGYDDLNQLFWYPEGIAKIVLEDGTKLIELPLEERYLRLGDVVWDDVFFKTYKETRTWLHLVTNFNRIWVMHISIFWMYFAYNSPTFYTHNYQQLVDNQPLAAYKWASCALGGTVASLIQIVATLCEWSFVPRKWAGAQHLSRRFWFLCIIFGINLGPIIFVFAYDKDTVYSTAAHVVAAVMFFVAVATIIFFSIMPLGGLFTSYMKKSTRRYVASQTFTAAFAPLHGLDRWMSYLVWVTVFAAKYSESYYFLVLSLRDPIRILSTTAMRCTGEYWWGAVLCKVQPKIVLGLVIATDFILFFLDTYLWYIIVNTIFSVGKSFYLGISILTPWRNIFTRLPKRIYSKILATTDMEIKYKPKVLISQVWNAIIISMYREHLLAIDHVQKLLYHQVPSEIEGKRTLRAPTFFVSQDDNNFETEFFPRDSEAERRISFFAQSLSTPIPEPLPVDNMPTFTVLTPHYAERILLSLREIIREDDQFSRVTLLEYLKQLHPVEWECFVKDTKILAEETAAYEGNENEAEKEDALKSQIDDLPFYCIGFKSAAPEYTLRTRIWASLRSQTLYRTISGFMNYSRAIKLLYRVENPEIVQMFGGNAEGLERELEKMARRKFKFLVSMQRLAKFKPHELENAEFLLRAYPDLQIAYLDEEPPLTEGEEPRIYSALIDGHCEILDNGRRRPKFRVQLSGNPILGDGKSDNQNHALIFYRGEYIQLIDANQDNYLEECLKIRSVLAEFEELNVEQVNPYAPGLRYEEQTTNHPVAIVGAREYIFSENSGVLGDVAAGKEQTFGTLFARTLSQIGGKLHYGHPDFINATFMTTRGGVSKAQKGLHLNEDIYAGMNAMLRGGRIKHCEYYQCGKGRDLGFGTILNFTTKIGAGMGEQMLSREYYYLGTQLPVDRFLTFYYAHPGFHLNNLFIQLSLQMFMLTLVNLSSLAHESIMCIYDRNKPKTDVLVPIGCYNFQPAVDWVRRYTLSIFIVFWIAFVPIVVQELIERGLWKATQRFFCHLLSLSPMFEVFAGQIYSSALLSDLAIGGARYISTGRGFATSRIPFSILYSRFAGSAIYMGARSMLMLLFGTVAHWQAPLLWFWASLSSLIFAPFVFNPHQFAWEDFFLDYRDYIRWLSRGNNQYHRNSWIGYVRMSRARITGFKRKLVGDESEKAAGDASRAHRTNLIMAEIIPCAIYAAGCFIAFTFINAQTGVKTTDDDRVNSVLRIIICTLAPIAVNLGVLFFCMGMSCCSGPLFGMCCKKTGSVMAGIAHGVAVIVHIAFFIVMWVLESFNFVRMLIGVVTCIQCQRLIFHCMTALMLTREFKNDHANTAFWTGKWYGKGMGYMAWTQPSRELTAKVIELSEFAADFVLGHVILICQLPLIIIPKIDKFHSIMLFWLKPSRQIRPPIYSLKQTRLRKRMVKKYCSLYFLVLAIFAGCIIGPAVASAKIHKHIGDSLDGVVHNLFQPINTTNNDTGSQMSTYQSHYYTHTPSLKTWSTIK T40785 DRUGINFO D0O2NQ Eraxis/Vfend Phase 3 T40785 DRUGINFO D0V6VL Cilofungin Terminated T40785 DRUGINFO D09DNJ L-692289 Investigative T40785 DRUGINFO D0C9KY Pyridobenzimidazole Investigative T40785 DRUGINFO D0E4OS ACULEACIN A Investigative T32240 TARGETID T32240 T32240 FORMERID TTDC00251 T32240 UNIPROID IL15_HUMAN T32240 TARGNAME Interleukin-15 (IL15) T32240 GENENAME IL15 T32240 TARGTYPE Clinical trial T32240 SYNONYMS IL-15 T32240 FUNCTION Stimulation by IL15 requires interaction of IL15 with components of the IL2 receptor, including IL2RB and probably IL2RG but not IL2RA. In neutrophils, stimulates phagocytosis probably by signaling through the IL15 receptor, composed of the subunits IL15RA, IL2RB and IL2RG, which results in kinase SYK activation. Cytokine that stimulates the proliferation of T-lymphocytes. T32240 PDBSTRUC 4GS7; 2Z3R; 2Z3Q; 2XQB T32240 BIOCLASS Cytokine: interleukin T32240 SEQUENCE MRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS T32240 DRUGINFO D0A5EN AMG-714 Phase 2 T32240 DRUGINFO D53YZV SAR445877 Phase 2 T32240 DRUGINFO DE09IO BNZ-1 Phase 2 T32240 DRUGINFO DO6T4G PF-07209960 Phase 1 T32240 DRUGINFO DT7I5A N-803 Phase 1 T52921 TARGETID T52921 T52921 FORMERID TTDR01247 T52921 UNIPROID OPRX_HUMAN T52921 TARGNAME Nociceptin receptor (OPRL1) T52921 GENENAME OPRL1 T52921 TARGTYPE Clinical trial T52921 SYNONYMS Orphanin FQ receptor; Opioid-receptor-like 1; Opioid receptor like-1 receptor; Opioid receptor 4; ORL-1 receptor; ORL-1; OPRL1; OP(4); Kappa-type 3 opioid receptor; KOR-3 T52921 FUNCTION G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin. T52921 PDBSTRUC 5DHH; 5DHG; 4EA3 T52921 BIOCLASS GPCR rhodopsin T52921 SEQUENCE MEPLFPAPFWEVIYGSHLQGNLSLLSPNHSLLPPHLLLNASHGAFLPLGLKVTIVGLYLAVCVGGLLGNCLVMYVILRHTKMKTATNIYIFNLALADTLVLLTLPFQGTDILLGFWPFGNALCKTVIAIDYYNMFTSTFTLTAMSVDRYVAICHPIRALDVRTSSKAQAVNVAIWALASVVGVPVAIMGSAQVEDEEIECLVEIPTPQDYWGPVFAICIFLFSFIVPVLVISVCYSLMIRRLRGVRLLSGSREKDRNLRRITRLVLVVVAVFVGCWTPVQVFVLAQGLGVQPSSETAVAILRFCTALGYVNSCLNPILYAFLDENFKACFRKFCCASALRRDVQVSDRVRSIAKDVALACKTSETVPRPA T52921 DRUGINFO D08FSD SER-100 Phase 2 T52921 DRUGINFO D0IA9E BTRX-246040 Phase 2 T52921 DRUGINFO D0Z9GM LY-2940094 Phase 2 T52921 DRUGINFO D0G2XE PMX-53 Phase 2 T52921 DRUGINFO D0W4YO NOCICEPTIN Phase 1 T52921 DRUGINFO D08SNL JTC-801 Discontinued in Phase 2 T52921 DRUGINFO D00ACC ND1251 Discontinued in Phase 1 T52921 DRUGINFO D0M1YN ATI-17000 Preclinical T52921 DRUGINFO D00BIE Cyclo-[Asp6,Lys10]N/OFQ(1-13)NH2 Investigative T52921 DRUGINFO D00FLZ CFGGFTGARKCARK Investigative T52921 DRUGINFO D00HYL F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-CONH2 Investigative T52921 DRUGINFO D00LVW Ada-RYYRIK-NH2 Investigative T52921 DRUGINFO D01CFO IsoVa-RYYRIK-NH2 Investigative T52921 DRUGINFO D01LZL FGGFTGCRKSCRK Investigative T52921 DRUGINFO D02IMK FGGFTGARKSARKRKRK Investigative T52921 DRUGINFO D02IWH F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-COOH Investigative T52921 DRUGINFO D02LMJ FGGFTGARKCARKC Investigative T52921 DRUGINFO D02NSY Banyu Compound-24 Investigative T52921 DRUGINFO D02WBU 2,2-diMeBut-RYYRIK-NH2 Investigative T52921 DRUGINFO D02WKZ F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-CONH2 Investigative T52921 DRUGINFO D03BVN 2-MePen-RYYRIK-NH2 Investigative T52921 DRUGINFO D04PUK 1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol Investigative T52921 DRUGINFO D04WRO H-RYYRIK-NH2 Investigative T52921 DRUGINFO D05EUV FGGFTGARKSARKRRNQ Investigative T52921 DRUGINFO D05GXA F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-COOH Investigative T52921 DRUGINFO D05MUA NOX 2149 Investigative T52921 DRUGINFO D05NHR FGGFTGARKSARKKRNQ Investigative T52921 DRUGINFO D05NIE 4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol Investigative T52921 DRUGINFO D05PJJ NOX 2137a/b Investigative T52921 DRUGINFO D05YMD MeBut-RYYRIK-NH2 Investigative T52921 DRUGINFO D06RSR Bz--RYYRIK-NH2 Investigative T52921 DRUGINFO D06ZTU FGGFTGARKSARKLLNQ Investigative T52921 DRUGINFO D07HWJ FGGFTGARKSARKRKNQ Investigative T52921 DRUGINFO D07HZU FGGFTGARKSARKLVNQ Investigative T52921 DRUGINFO D07KNS FGGFTGARKSARKLKNQ Investigative T52921 DRUGINFO D07TKE 4-phenyl-1-(3-phenylpropyl)piperidin-4-ol Investigative T52921 DRUGINFO D07WQG FGGFTGARKSARKLADE Investigative T52921 DRUGINFO D07ZFH FGGFTRKRKSARKLANQ Investigative T52921 DRUGINFO D08BAW Bu-RYYRIK-NH2 Investigative T52921 DRUGINFO D08NDP Cyclo[Cys7,Cys10]N/OFQ(1-13)NH2 Investigative T52921 DRUGINFO D08RIW F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-CONH2 Investigative T52921 DRUGINFO D08ZDP 1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol Investigative T52921 DRUGINFO D08ZIR FGGFTGARKSARKLFNQ Investigative T52921 DRUGINFO D08ZJR FGGFTGARKSARKWKNQ Investigative T52921 DRUGINFO D09POP FGGFTGARKRKRKLANQ Investigative T52921 DRUGINFO D09SUP peptide III-BTD Investigative T52921 DRUGINFO D09XZM FGGFTCARKCARK Investigative T52921 DRUGINFO D09ZTU FGGFTGARKSARKWRNQ Investigative T52921 DRUGINFO D0A8NZ Cyclo[DAsp7,Lys10]N/OFQ(1-13)NH2 Investigative T52921 DRUGINFO D0A8ZS EtBut-RYYRIK-NH2 Investigative T52921 DRUGINFO D0A9VZ F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-COOH Investigative T52921 DRUGINFO D0AC0A SB-612111 Investigative T52921 DRUGINFO D0BH3Y FGGFTGARKSARKLRNQ Investigative T52921 DRUGINFO D0C1US FGGFTGARKSARKLWNQ Investigative T52921 DRUGINFO D0C9QV F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-COOH Investigative T52921 DRUGINFO D0CV7C CFGGFTCARKSARK Investigative T52921 DRUGINFO D0H7NY FGGFTGARKSARKAANQ Investigative T52921 DRUGINFO D0HK7B FGGFTGARKSARKYANQ Investigative T52921 DRUGINFO D0HN2M UFP-112 Investigative T52921 DRUGINFO D0I3KG FGGFTGARKSARKKWNQ Investigative T52921 DRUGINFO D0J2RW FGGFTGCRKSARKC Investigative T52921 DRUGINFO D0J7DN F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-CONH2 Investigative T52921 DRUGINFO D0K0CJ F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-COOH Investigative T52921 DRUGINFO D0K2NY Va-RYYRIK-NH2 Investigative T52921 DRUGINFO D0K4XA F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-COOH Investigative T52921 DRUGINFO D0L1BS PF-454583 Investigative T52921 DRUGINFO D0L3JC FGGFTGARKSARKRANQ Investigative T52921 DRUGINFO D0L5BC FGGFTGARKSARKFANQ Investigative T52921 DRUGINFO D0L8YY SR-14136 Investigative T52921 DRUGINFO D0M7TP Piv-RYYRIK-NH2 Investigative T52921 DRUGINFO D0N7ZF FGGFTGARKSARKWANQ Investigative T52921 DRUGINFO D0O3SJ FGGFTGARKSARKLYNQ Investigative T52921 DRUGINFO D0O6NZ F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-CONH2 Investigative T52921 DRUGINFO D0PN2C IsoBu-RYYRIK-NH2 Investigative T52921 DRUGINFO D0PR2Q Pr-RYYRIK-NH2 Investigative T52921 DRUGINFO D0Q2PO [Asp6,Lys10]N/OFQ(1-13)NH2 Investigative T52921 DRUGINFO D0R6GK F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-CONH2 Investigative T52921 DRUGINFO D0R7FI 4-phenyl-1-(1-phenylpropan-2-yl)piperidin-4-ol Investigative T52921 DRUGINFO D0R7IM UFP-101 Investigative T52921 DRUGINFO D0RS4B FGGFTGARKSARKVANQ Investigative T52921 DRUGINFO D0SE9S SCH-221510 Investigative T52921 DRUGINFO D0SG5A FGGFTGARKSARKRWNQ Investigative T52921 DRUGINFO D0SN6V T-BuAc-RYYRIK-NH2 Investigative T52921 DRUGINFO D0T0GL For-RYYRIK-NH2 Investigative T52921 DRUGINFO D0TJ7R 1-benzyl-4-phenylpiperidin-4-ol Investigative T52921 DRUGINFO D0U6FM Hex-RYYRIK-NH2 Investigative T52921 DRUGINFO D0U9QL [Nphe(1)]-nociceptin (1-13)-NH(2) Investigative T52921 DRUGINFO D0V6HE FGGFTGARKSARKLARK Investigative T52921 DRUGINFO D0VH3M Cyclo[Cys6,Cys10]N/OFQ(1-13)NH2 Investigative T52921 DRUGINFO D0W7CF Ac-RYYRIK-NH2 Investigative T52921 DRUGINFO D0X2MZ Syn-1020 Investigative T52921 DRUGINFO D0Y0IE FGGFTGARKSARKL Investigative T52921 DRUGINFO D0Y2MR F-G-G-F-T-G-Aib-R-K-S-Aib-R-K-L-A-N-Q-CONH2 Investigative T52921 DRUGINFO D0Y4EW N/OFQ-(1-13)-NH2 Investigative T52921 DRUGINFO D0Y5AT FGGFTGARKSARKKKNQ Investigative T52921 DRUGINFO D0Y5MF BND-001 Investigative T52921 DRUGINFO D0YM8F [D-Asp7,Lys10]N/OFQ(1-13)NH2 Investigative T52921 DRUGINFO D0Z3HM FGGFTGARKSARKKANQ Investigative T52921 DRUGINFO D02TPK Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG Investigative T52921 DRUGINFO D09CTG Ac-RYYRIK-K-(NH2)-YRFB Investigative T52921 DRUGINFO D09KBQ FLUPERAMIDE Investigative T52921 DRUGINFO D0E3RQ Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG Investigative T52921 DRUGINFO D0F8AX 1-benzhydryl-4-cyclopropylpiperidin-4-ol Investigative T52921 DRUGINFO D0Y2MT Ac-RYYRIK-K-(NH2)-YAFGYPS Investigative T52921 DRUGINFO D00XZH 1-benzhydryl-4-isopropylpiperidin-4-ol Investigative T52921 DRUGINFO D01MUV 1-benzhydryl-4-tert-butylpiperidin-4-ol Investigative T52921 DRUGINFO D05RII 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole Investigative T52921 DRUGINFO D06PVO 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol Investigative T52921 DRUGINFO D07FCB 4-phenyl-1-(1-phenylethyl)piperidin-4-ol Investigative T52921 DRUGINFO D0D9BB 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol Investigative T52921 DRUGINFO D0IL9H 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol Investigative T52921 DRUGINFO D0S2OA 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine Investigative T52921 DRUGINFO D0Y7KE 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol Investigative T52921 DRUGINFO D00YCW 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol Investigative T52921 DRUGINFO D01WMU 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol Investigative T52921 DRUGINFO D03PTV 1-benzhydryl-4-ethoxy-4-phenylpiperidine Investigative T52921 DRUGINFO D03UJW 1-benzhydryl-4-butylpiperidin-4-ol Investigative T52921 DRUGINFO D04ZQX 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol Investigative T52921 DRUGINFO D06MQG 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol Investigative T52921 DRUGINFO D06PHT 1-benzhydryl-4-phenylpiperidin-4-ol Investigative T52921 DRUGINFO D07CIU 1-benzhydryl-4-p-tolylpiperidin-4-ol Investigative T52921 DRUGINFO D07NMH 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol Investigative T52921 DRUGINFO D08DVV 1-benzhydryl-4-hexylpiperidin-4-ol Investigative T52921 DRUGINFO D08QBU 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol Investigative T52921 DRUGINFO D08TFY 1-benzhydryl-4-cyclohexylpiperidin-4-ol Investigative T52921 DRUGINFO D09BYD 1-benzhydryl-4-o-tolylpiperidin-4-ol Investigative T52921 DRUGINFO D09FJY 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol Investigative T52921 DRUGINFO D09LRO 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol Investigative T52921 DRUGINFO D09VRT 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol Investigative T52921 DRUGINFO D0D0UP 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol Investigative T52921 DRUGINFO D0G4FA 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol Investigative T52921 DRUGINFO D0G7DF 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol Investigative T52921 DRUGINFO D0J5JO 1-benzhydryl-4-m-tolylpiperidin-4-ol Investigative T52921 DRUGINFO D0JH5D 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol Investigative T52921 DRUGINFO D0O7JV 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol Investigative T52921 DRUGINFO D0P3FP 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol Investigative T52921 DRUGINFO D0Q9TQ 1-benzhydryl-4-methoxy-4-phenylpiperidine Investigative T52921 DRUGINFO D0QH4A 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol Investigative T52921 DRUGINFO D0T4ZY 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol Investigative T52921 DRUGINFO D0T9KE 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol Investigative T52921 DRUGINFO D0W3VT 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol Investigative T52921 DRUGINFO D0X4SX 1-benzhydryl-4-phenyl-4-propoxypiperidine Investigative T52921 DRUGINFO D0XX1Y 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol Investigative T52921 DRUGINFO D0Y5LJ 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol Investigative T52921 DRUGINFO D0ZE2W 1-benzhydryl-4-benzylpiperidin-4-ol Investigative T93515 TARGETID T93515 T93515 FORMERID TTDC00179 T93515 UNIPROID P2RY2_HUMAN T93515 TARGNAME P2Y purinoceptor 2 (P2RY2) T93515 GENENAME P2RY2 T93515 TARGTYPE Clinical trial T93515 SYNONYMS P2Y2; P2U1; P2U receptor; P2U purinoceptor 1; P2U nucleotide receptor; P2RY2; Adenosine P2Y2 receptor T93515 FUNCTION Receptor for ATP and UTP coupled to G-proteins thatactivate a phosphatidylinositol-calcium second messenger system. The affinity range is UTP = ATP > ATP-gamma-S >> 2-methylthio-ATP = ADP. T93515 PDBSTRUC 1Z8E T93515 BIOCLASS GPCR rhodopsin T93515 SEQUENCE MAADLGPWNDTINGTWDGDELGYRCRFNEDFKYVLLPVSYGVVCVPGLCLNAVALYIFLCRLKTWNASTTYMFHLAVSDALYAASLPLLVYYYARGDHWPFSTVLCKLVRFLFYTNLYCSILFLTCISVHRCLGVLRPLRSLRWGRARYARRVAGAVWVLVLACQAPVLYFVTTSARGGRVTCHDTSAPELFSRFVAYSSVMLGLLFAVPFAVILVCYVLMARRLLKPAYGTSGGLPRAKRKSVRTIAVVLAVFALCFLPFHVTRTLYYSFRSLDLSCHTLNAINMAYKVTRPLASANSCLDPVLYFLAGQRLVRFARDAKPPTGPSPATPARRRLGLRRSDRTDMQRIEDVLGSSEDSRRTESTPAGSENTKDIRL T93515 DRUGINFO D0S6AE Diquafosol Phase 3 T93515 DRUGINFO D07QQP INS-37217 Phase 2 T93515 DRUGINFO D0Z7FU INS 316 Discontinued in Phase 3 T93515 DRUGINFO D04IWB 2-thioUTP Investigative T93515 DRUGINFO D06DBA SB-416 Investigative T93515 DRUGINFO D09CLX MDT-006 Investigative T93515 DRUGINFO D09SFJ AR-C126313 Investigative T93515 DRUGINFO D0GF4I 4-thio-UTP Investigative T93515 DRUGINFO D0P4GP PSB1114 Investigative T93515 DRUGINFO D0Q1HE MRS2698 Investigative T93515 DRUGINFO D0UC4G PSB-716 Investigative T93515 DRUGINFO D0Y3WN MRS2768 Investigative T93515 DRUGINFO D0Z4GJ AR-C118925XX Investigative T93515 DRUGINFO D02OAJ UTPgammaS Investigative T93515 DRUGINFO D08DXA Acid blue 25 Investigative T93515 DRUGINFO D0P7RI 5BrUTP Investigative T93515 DRUGINFO D06GQY PSB-0963 Investigative T93515 DRUGINFO D0B0ZQ RB 2 Investigative T99347 TARGETID T99347 T99347 FORMERID TTDC00100 T99347 UNIPROID GRM5_HUMAN T99347 TARGNAME Metabotropic glutamate receptor 5 (mGluR5) T99347 GENENAME GRM5 T99347 TARGTYPE Clinical trial T99347 SYNONYMS MGLUR5; GPRC1E T99347 FUNCTION G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-calcium second messenger system and generates a calcium-activated chloride current. Plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity. T99347 PDBSTRUC 6N52; 6N51; 6N50; 6N4Y; 6N4X T99347 BIOCLASS GPCR glutamate T99347 SEQUENCE MVLLLILSVLLLKEDVRGSAQSSERRVVAHMPGDIIIGALFSVHHQPTVDKVHERKCGAVREQYGIQRVEAMLHTLERINSDPTLLPNITLGCEIRDSCWHSAVALEQSIEFIRDSLISSEEEEGLVRCVDGSSSSFRSKKPIVGVIGPGSSSVAIQVQNLLQLFNIPQIAYSATSMDLSDKTLFKYFMRVVPSDAQQARAMVDIVKRYNWTYVSAVHTEGNYGESGMEAFKDMSAKEGICIAHSYKIYSNAGEQSFDKLLKKLTSHLPKARVVACFCEGMTVRGLLMAMRRLGLAGEFLLLGSDGWADRYDVTDGYQREAVGGITIKLQSPDVKWFDDYYLKLRPETNHRNPWFQEFWQHRFQCRLEGFPQENSKYNKTCNSSLTLKTHHVQDSKMGFVINAIYSMAYGLHNMQMSLCPGYAGLCDAMKPIDGRKLLESLMKTNFTGVSGDTILFDENGDSPGRYEIMNFKEMGKDYFDYINVGSWDNGELKMDDDEVWSKKSNIIRSVCSEPCEKGQIKVIRKGEVSCCWTCTPCKENEYVFDEYTCKACQLGSWPTDDLTGCDLIPVQYLRWGDPEPIAAVVFACLGLLATLFVTVVFIIYRDTPVVKSSSRELCYIILAGICLGYLCTFCLIAKPKQIYCYLQRIGIGLSPAMSYSALVTKTNRIARILAGSKKKICTKKPRFMSACAQLVIAFILICIQLGIIVALFIMEPPDIMHDYPSIREVYLICNTTNLGVVTPLGYNGLLILSCTFYAFKTRNVPANFNEAKYIAFTMYTTCIIWLAFVPIYFGSNYKIITMCFSVSLSATVALGCMFVPKVYIILAKPERNVRSAFTTSTVVRMHVGDGKSSSAASRSSSLVNLWKRRGSSGETLRYKDRRLAQHKSEIECFTPKGSMGNGGRATMSSSNGKSVTWAQNEKSSRGQHLWQRLSIHINKKENPNQTAVIKPFPKSTESRGLGAGAGAGGSAGGVGATGGAGCAGAGPGGPESPDAGPKALYDVAEAEEHFPAPARPRSPSPISTLSHRAGSASRTDDDVPSLHSEPVARSSSSQGSLMEQISSVVTRFTANISELNSMMLSTAAPSPGVGAPLCSSYLIPKEIQLPTTMTTFAEIQPLPAIEVTGGAQPAAGAQAAGDAARESPAAGPEAAAAKPDLEELVALTPPSPFRDSVDSGSTTPNSPVSESALCIPSSPKYDTLIIRDYTQSSSSL T99347 DRUGINFO D0G5PF AFQ056 Phase 2/3 T99347 DRUGINFO D0I5TL ADX-48621 Phase 2/3 T99347 DRUGINFO D04QKU RG-7090 Phase 2 T99347 DRUGINFO D09YDQ STX-107 Phase 2 T99347 DRUGINFO D0P4WO ADX10059 Phase 2 T99347 DRUGINFO D0L1YM McN3377 Phase 1/2 T99347 DRUGINFO D09PYZ MK-3328 Phase 1 T99347 DRUGINFO D0I0JG [3H]fenobam Phase 1 T99347 DRUGINFO D0L2GX RG7342 Phase 1 T99347 DRUGINFO D34YLZ BMS-984923 Phase 1 T99347 DRUGINFO DB7V3D BMS‐984923 Phase 1 T99347 DRUGINFO D01AFN Pyrrolidine derivative 3 Patented T99347 DRUGINFO D01BSX Ethynyl compound 7 Patented T99347 DRUGINFO D03ZXG Imidazopyridine and triazolopyridine compound 1 Patented T99347 DRUGINFO D04IGZ Pyrrolidine derivative 4 Patented T99347 DRUGINFO D05RUG Ethynyl compound 6 Patented T99347 DRUGINFO D05VWD Ethynyl compound 5 Patented T99347 DRUGINFO D06FVQ Bicarboxylic and tricarboxylic ethynyl derivative 3 Patented T99347 DRUGINFO D06JFS Pyrazolopyrimidine derivative 2 Patented T99347 DRUGINFO D07EFT Ethynyl compound 3 Patented T99347 DRUGINFO D07JTE Tetra-hydro-pyrazolopyrazine derivative 1 Patented T99347 DRUGINFO D07KER Tetra-hydro-pyrazolopyrazine derivative 3 Patented T99347 DRUGINFO D08DMM Imidazopyridine and triazolopyridine compound 3 Patented T99347 DRUGINFO D09CAM Central azetidine derivative 1 Patented T99347 DRUGINFO D09QQS Diazepinone derivative 1 Patented T99347 DRUGINFO D09UVF Bicarboxylic and tricarboxylic ethynyl derivative 2 Patented T99347 DRUGINFO D09VNK Heterocyclic derivative 2 Patented T99347 DRUGINFO D0A7NX Pyrazolopyrimidine derivative 6 Patented T99347 DRUGINFO D0AK4X Tetra-hydro-oxazolopyridine derivative 5 Patented T99347 DRUGINFO D0AZ6X Pyridine derivative 16 Patented T99347 DRUGINFO D0B3CG Pyrazolopyrimidine derivative 4 Patented T99347 DRUGINFO D0B4IU Heterocyclic derivative 1 Patented T99347 DRUGINFO D0BS0K Tetra-hydro-pyrazolopyrazine derivative 5 Patented T99347 DRUGINFO D0CI3E Bicyclic heteroaryl carboxamide analog 1 Patented T99347 DRUGINFO D0CI9L Pyridine derivative 13 Patented T99347 DRUGINFO D0D3GL Tetra-hydro-pyrazolopyrazine derivative 2 Patented T99347 DRUGINFO D0DL7P Diazepinone derivative 4 Patented T99347 DRUGINFO D0DR0S Pyridine derivative 15 Patented T99347 DRUGINFO D0DZ0M Pyrrolidine derivative 1 Patented T99347 DRUGINFO D0FS2X PMID28067079-Compound-98 Patented T99347 DRUGINFO D0GS6T 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 1 Patented T99347 DRUGINFO D0HG1W 2-(substituted ethynyl)quinoline derivative 4 Patented T99347 DRUGINFO D0IK9N Ethynyl compound 1 Patented T99347 DRUGINFO D0J4QE Diazepinone derivative 5 Patented T99347 DRUGINFO D0K4LQ Pyrazolopyrimidine derivative 3 Patented T99347 DRUGINFO D0KG5I N-alkylamide derivative 1 Patented T99347 DRUGINFO D0L7YW Pyridine derivative 12 Patented T99347 DRUGINFO D0LI2I Imidazopyridine and triazolopyridine compound 4 Patented T99347 DRUGINFO D0LU9X Tetra-hydro-oxazolopyridine derivative 3 Patented T99347 DRUGINFO D0M3VE Pyrazolopyrimidine derivative 5 Patented T99347 DRUGINFO D0M4KF PMID28067079-Compound-97 Patented T99347 DRUGINFO D0M8IR Heterocyclic derivative 3 Patented T99347 DRUGINFO D0MB0V 2-(substituted ethynyl)quinoline derivative 2 Patented T99347 DRUGINFO D0MI7K Bicarboxylic and tricarboxylic ethynyl derivative 1 Patented T99347 DRUGINFO D0MM8M Diazepinone derivative 2 Patented T99347 DRUGINFO D0N6HP Bicyclic heteroaryl carboxamide analog 3 Patented T99347 DRUGINFO D0NJ9E Imidazopyridine and triazolopyridine compound 2 Patented T99347 DRUGINFO D0O4KM Ethynyl compound 4 Patented T99347 DRUGINFO D0OH5L N-alkylamide derivative 2 Patented T99347 DRUGINFO D0PJ8X 2-(substituted ethynyl)quinoline derivative 1 Patented T99347 DRUGINFO D0Q1WV Pyrrolidine derivative 5 Patented T99347 DRUGINFO D0Q4ST Diazepinone derivative 3 Patented T99347 DRUGINFO D0QE8S Bicyclic heteroaryl carboxamide analog 2 Patented T99347 DRUGINFO D0QM1D Central azetidine derivative 2 Patented T99347 DRUGINFO D0RG9J Pyrrolidine derivative 2 Patented T99347 DRUGINFO D0RU0W Tetra-hydro-oxazolopyridine derivative 4 Patented T99347 DRUGINFO D0SZ5A Pyrazolopyrimidine derivative 1 Patented T99347 DRUGINFO D0T9IR 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 3 Patented T99347 DRUGINFO D0UX1S PMID28067079-Compound-95 Patented T99347 DRUGINFO D0V2VM Pyridine derivative 17 Patented T99347 DRUGINFO D0V3SA Pyridine derivative 14 Patented T99347 DRUGINFO D0V5GR Tetra-hydro-pyrazolopyrazine derivative 4 Patented T99347 DRUGINFO D0VI3F Imidazo[1,2-a]pyridine derivative 1 Patented T99347 DRUGINFO D0VM5Z Ethynyl compound 2 Patented T99347 DRUGINFO D0XB2W 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 2 Patented T99347 DRUGINFO D0XQ4T 2-(substituted ethynyl)quinoline derivative 3 Patented T99347 DRUGINFO D0XX9N Tetra-hydro-oxazolopyridine derivative 6 Patented T99347 DRUGINFO D0DL1O Tetra-hydro-oxazolopyridine derivative 2 Patented T99347 DRUGINFO D0GQ2Z Tetra-hydro-oxazolopyridine derivative 1 Patented T99347 DRUGINFO D06UDV AZD2516 Discontinued in Phase 2 T99347 DRUGINFO D09GPB AZD2066 Discontinued in Phase 2 T99347 DRUGINFO D04XMJ LY525327 Terminated T99347 DRUGINFO D08XOT LY467711 Terminated T99347 DRUGINFO D00EPM VU0463841 Investigative T99347 DRUGINFO D00HIH LSN2814617 Investigative T99347 DRUGINFO D00JUO PMID21757343C30 Investigative T99347 DRUGINFO D00SAB 7-m-tolyl-1,6-naphthyridine Investigative T99347 DRUGINFO D01AJZ 3-(4-Pyridin-2-yl-imidazol-1-yl)-benzonitrile Investigative T99347 DRUGINFO D01ALS 2-methyl-4-(2-thienylethynyl)thiazole Investigative T99347 DRUGINFO D01AMV 3-(6-fluoroquinazolin-4-ylamino)benzonitrile Investigative T99347 DRUGINFO D01DPN 3-[(5-ethyl-2-methyl-4-thiazolyl)ethynyl]pyridine Investigative T99347 DRUGINFO D01ECL 2-(2-Methyl-thiazol-4-ylethynyl)-pyridine Investigative T99347 DRUGINFO D01FGW 6-bromo-N-(3-bromophenyl)quinazolin-4-amine Investigative T99347 DRUGINFO D01FTP 2-methyl-7-m-tolylquinoline Investigative T99347 DRUGINFO D01MAN 2-Benzoxy-5-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D01PTE 2-benzyloxy-7,8-dihydro-6H-quinolin-5-one Investigative T99347 DRUGINFO D01SYO 4-(2-Methyl-thiazol-4-ylethynyl)-pyridine Investigative T99347 DRUGINFO D01TQD VU0424465 Investigative T99347 DRUGINFO D01UUH 4-(3-pyridylethynyl)-2-thiazolylamine Investigative T99347 DRUGINFO D01VOJ RTI-4229-982 Investigative T99347 DRUGINFO D01XMK 2-(3-(2-methylquinolin-7-yl)phenyl)acetonitrile Investigative T99347 DRUGINFO D02BFK 4-(3-chlorophenylethynyl)-2-methylthiazole Investigative T99347 DRUGINFO D02BNC 3-(1,8-naphthyridin-2-yl)benzonitrile Investigative T99347 DRUGINFO D02CKM N-(3-chlorophenyl)-3-cyano-5-fluorobenzamide Investigative T99347 DRUGINFO D02DOP 3-(1-Pyridin-2-yl-1H-pyrazol-3-yl)-benzonitrile Investigative T99347 DRUGINFO D02GLY Br-5MPEPy Investigative T99347 DRUGINFO D02KHF 2-Cyclohexylethynyl-pyridine Investigative T99347 DRUGINFO D02MOV 6-bromo-N-(3-fluorophenyl)quinazolin-4-amine Investigative T99347 DRUGINFO D02NHZ 7-(4-methoxyphenyl)-2-methylquinoline Investigative T99347 DRUGINFO D02OHW 2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine Investigative T99347 DRUGINFO D02QEP VU0361747 Investigative T99347 DRUGINFO D02QML 1-(3-(2-methylquinolin-7-yl)phenyl)ethanone Investigative T99347 DRUGINFO D02QTE ACDPP Investigative T99347 DRUGINFO D02RZH 3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide Investigative T99347 DRUGINFO D02SSD 7-(2-methoxyphenyl)-2-methylquinoline Investigative T99347 DRUGINFO D02VFF VU0357121 Investigative T99347 DRUGINFO D02XFR 3-chloro-N-(4-methylthiazol-2-yl)benzamide Investigative T99347 DRUGINFO D03CCP 2-ethynyl-4-(3-fluorophenylethynyl)thiazole Investigative T99347 DRUGINFO D03FOM 2-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D03LCM 3-chloro-N-(6-chloropyridin-2-yl)benzamide Investigative T99347 DRUGINFO D03NIO 5-[(2-methyl-4-thiazolyl)ethynyl]pyrimidine Investigative T99347 DRUGINFO D03NYF 4-Biphenyl-4-ylethynyl-2-methyl-thiazole Investigative T99347 DRUGINFO D03OLR PMID23374867C24 Investigative T99347 DRUGINFO D03QRG 3-(3-methylphenylethynyl)-5-methyl[1,2,4]triazine Investigative T99347 DRUGINFO D03TRO GRN-529 Investigative T99347 DRUGINFO D03UZZ 3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide Investigative T99347 DRUGINFO D03XHE alloswitch-1 Investigative T99347 DRUGINFO D04BES 2-(4-(3-chlorophenyl)but-1-ynyl)-6-methylpyridine Investigative T99347 DRUGINFO D04GPT N-(3-acetamidophenyl)-3-chlorobenzamide Investigative T99347 DRUGINFO D04IKS 7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine Investigative T99347 DRUGINFO D04ILS 2-(3-chlorobenzyloxy)-6-chloroisonicotinonitrile Investigative T99347 DRUGINFO D04PBZ 4-(3-methoxyphenylethynyl)-2-methylthiazole Investigative T99347 DRUGINFO D04RVW 2-Phenyl-5-(2-methylthiazol-4ylethynyl)pyridine Investigative T99347 DRUGINFO D04UDE 7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline Investigative T99347 DRUGINFO D04WGR 5-(2-methylquinolin-7-yl)isophthalonitrile Investigative T99347 DRUGINFO D04YTO 6-fluoro-N-m-tolylquinazolin-4-amine Investigative T99347 DRUGINFO D04YXB 2-phenyl-1,8-naphthyridine Investigative T99347 DRUGINFO D05AJJ VU0240382 Investigative T99347 DRUGINFO D05BPM 3-cyano-5-fluoro-N-m-tolylbenzamide Investigative T99347 DRUGINFO D05DDU 3-(2-methylquinolin-7-yl)phenol Investigative T99347 DRUGINFO D05FCO 2-Cyclopent-1-enylethynyl-pyridine Investigative T99347 DRUGINFO D05FEO LSN2463359 Investigative T99347 DRUGINFO D05HUS 7-(3-fluorophenyl)-2-methylquinoline Investigative T99347 DRUGINFO D05TFE SIB-1757 Investigative T99347 DRUGINFO D05XNS N-(6-methylpyridin-2-yl)biphenyl-3-carboxamide Investigative T99347 DRUGINFO D06KVX 4-(2-methoxyphenylethynyl)-2-methylthiazole Investigative T99347 DRUGINFO D06OMD 7-(4-methoxypyrimidin-2-yl)-2-methylquinoline Investigative T99347 DRUGINFO D06PTC 2-methyl-6-(5-phenylpent-1-ynyl)pyridine Investigative T99347 DRUGINFO D06SFA 3-(3,4-dimethylphenyl)-1,5-naphthyridine Investigative T99347 DRUGINFO D06SXN 3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D06TCX 4-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide Investigative T99347 DRUGINFO D06TMM PTeB Investigative T99347 DRUGINFO D06XFS 2-methyl-7-(pyridin-3-yl)quinoline Investigative T99347 DRUGINFO D06YKH 2-bromo-4-(3-fluorophenylethynyl)thiazole Investigative T99347 DRUGINFO D06ZBT 3-bromo-5-[(2-methyl-4-thiazolyl)ethynyl]pyridine Investigative T99347 DRUGINFO D06ZSX 3-chloro-N-(3-isobutyramidophenyl)benzamide Investigative T99347 DRUGINFO D07FVZ CPPHA Investigative T99347 DRUGINFO D07FXC 2-(3-(3-methoxyphenoxy)prop-1-ynyl)pyridine Investigative T99347 DRUGINFO D07JLC 3-iodo-N-(6-methylpyridin-2-yl)benzamide Investigative T99347 DRUGINFO D07KEV 5PAM523 Investigative T99347 DRUGINFO D07LMB PMID20809633C29b Investigative T99347 DRUGINFO D07QJQ 2-Methyl-4-phenylethynyl-thiazole Investigative T99347 DRUGINFO D07RRA 2-[(2-methyl-4-thiazolyl)ethynyl]pyrazine Investigative T99347 DRUGINFO D07XZP N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide Investigative T99347 DRUGINFO D08ADI 3-(3-(3-chlorobenzyloxy)-5-methylphenyl)pyridine Investigative T99347 DRUGINFO D08FDI 3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)-benzonitrile Investigative T99347 DRUGINFO D08FEV 3-[(2-methyl-4-thiazolyl)ethynyl]benzamide Investigative T99347 DRUGINFO D08KYB 2-(3,5-dimethoxyphenyl)-1,8-naphthyridine Investigative T99347 DRUGINFO D08NJT 3-bromo-5-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D08NOP 2-methyl-7-m-tolyl-1,6-naphthyridine Investigative T99347 DRUGINFO D08NQW CHPG Investigative T99347 DRUGINFO D08PDF 5-(phenylethynyl)pyrimidine Investigative T99347 DRUGINFO D08RLS 2-m-tolyl-1,8-naphthyridine Investigative T99347 DRUGINFO D08SSG 3-[(2,5-dimethyl-4-thiazolyl)ethynyl]pyridine Investigative T99347 DRUGINFO D08SYN 3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide Investigative T99347 DRUGINFO D08USC 7-bromo-N-(3-bromophenyl)isoquinolin-1-amine Investigative T99347 DRUGINFO D09GMG 3-methoxy-N-(6-methylpyridin-2-yl)benzamide Investigative T99347 DRUGINFO D09GYH 3-methyl-5-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D09HRX VU-1545 Investigative T99347 DRUGINFO D09JHM N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine Investigative T99347 DRUGINFO D09JXO 2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine Investigative T99347 DRUGINFO D09LDM 2-methyl-4-(m-tolylethynyl)thiazole Investigative T99347 DRUGINFO D09PCZ PMID16439120C20 Investigative T99347 DRUGINFO D09QUN VU0404251 Investigative T99347 DRUGINFO D09RNK 5-Biphenyl-4-ylethynyl-pyrimidine Investigative T99347 DRUGINFO D09RPR SP203 Investigative T99347 DRUGINFO D09VPJ 2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine Investigative T99347 DRUGINFO D09WPX VU0366058 Investigative T99347 DRUGINFO D0A0LE 3-(2-methylbenzo[d]thiazol-5-yl)benzonitrile Investigative T99347 DRUGINFO D0A1WQ VU0364289 Investigative T99347 DRUGINFO D0A2LP 2-methyl-7-m-tolyl-1,8-naphthyridine Investigative T99347 DRUGINFO D0A5QP N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide Investigative T99347 DRUGINFO D0A8QA 2-Chloro-5-(2-methylquinolin-7-yl)nicotinonitrile Investigative T99347 DRUGINFO D0AG1Q PMID15686941C13 Investigative T99347 DRUGINFO D0B2GK PMID17723296C18 Investigative T99347 DRUGINFO D0B2LP PMID15482908C8 Investigative T99347 DRUGINFO D0B5OK 6-phenylethynyl-nicotinic acid methyl ester Investigative T99347 DRUGINFO D0B9SS 7-(3-methoxyphenyl)-2-methylquinoline Investigative T99347 DRUGINFO D0BO6C N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide Investigative T99347 DRUGINFO D0BU5N 3-chloro-5-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D0C0FH 2-Cyclohex-1-enylethynyl-pyridine Investigative T99347 DRUGINFO D0C4OV PMID14697765C16a Investigative T99347 DRUGINFO D0C6BY PMID23434029C41 Investigative T99347 DRUGINFO D0C6JG 2-methyl-6-(3-(phenylthio)prop-1-ynyl)pyridine Investigative T99347 DRUGINFO D0C7TX 3-cyano-N-(6-methylpyridin-2-yl)benzamide Investigative T99347 DRUGINFO D0C9FH N-[4-(3-pyridylethynyl)-2-thiazolyl]acetamide Investigative T99347 DRUGINFO D0CQ6I 3-[(2-methyl-4-thiazolyl)ethynyl]-5-vinylpyridine Investigative T99347 DRUGINFO D0CT7P 2-(pyridin-2-yl)-4-(m-tolylthio)pyrimidine Investigative T99347 DRUGINFO D0D1GI 3-(1-Pyridin-2-yl-1H-pyrrol-3-yl)-benzonitrile Investigative T99347 DRUGINFO D0D2FB 2-(3-(benzyloxy)phenyl)isoindoline-1,3-dione Investigative T99347 DRUGINFO D0D3FF 2-(phenylethynyl)pyrimidine Investigative T99347 DRUGINFO D0D4AE N-(3-(3-cyanobenzamido)phenyl)-2-methoxybenzamide Investigative T99347 DRUGINFO D0D4HG 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide Investigative T99347 DRUGINFO D0D7DC 2-chloro-N-(3-(3-chlorobenzamido)phenyl)benzamide Investigative T99347 DRUGINFO D0DX6U PMID19931453C16m Investigative T99347 DRUGINFO D0E3WH 2-methyl-6-(3-(p-tolyloxy)prop-1-ynyl)pyridine Investigative T99347 DRUGINFO D0E8DM 3-(4-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile Investigative T99347 DRUGINFO D0E8IJ 3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D0EB9H 3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D0EK6F 5-methyl-3-phenylethynyl[1,2,4]triazine Investigative T99347 DRUGINFO D0ET4S BOMA Investigative T99347 DRUGINFO D0EX7S 3-cyano-N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide Investigative T99347 DRUGINFO D0F2KL 3-[(6-Methylpyridin-2-yl)ethynyl]benzonitrile Investigative T99347 DRUGINFO D0F6EJ PMID21927650C18 Investigative T99347 DRUGINFO D0F6YB 3-cyano-5-fluoro-N-phenylbenzamide Investigative T99347 DRUGINFO D0F9QY 3,3'-difluorobenzaldazine Investigative T99347 DRUGINFO D0FK3W 2-(3-bromophenyl)pyrido[2,3-d]pyrimidine Investigative T99347 DRUGINFO D0G0OV 2-phenylethynyl-5,6,7,8-tetrahydro-quinoline Investigative T99347 DRUGINFO D0G0WC 2-(3-bromophenyl)-7-methyl-1,8-naphthyridine Investigative T99347 DRUGINFO D0GA4M 3-(1-Pyridin-2-yl-1H-pyrazol-4-yl)-benzonitrile Investigative T99347 DRUGINFO D0H3DT (3-(2-methylquinolin-7-yl)phenyl)methanol Investigative T99347 DRUGINFO D0H3LE 7-methyl-2-phenylpyrido[2,3-d]pyrimidine Investigative T99347 DRUGINFO D0I1TB 5-(2-Methylquinolin-7-yl)-2-phenylnicotinonitrile Investigative T99347 DRUGINFO D0I2JX 3-isobutoxy-5-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D0I6KU 5-(2-m-tolylethynyl)pyrimidine Investigative T99347 DRUGINFO D0I9NE 4-(2-(3-fluorophenyl)ethynyl)-2-methylthiazole Investigative T99347 DRUGINFO D0J3NX N-cyclopentyl-6-(2-phenylethynyl)nicotinamide Investigative T99347 DRUGINFO D0J4HH 3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile Investigative T99347 DRUGINFO D0JG2W 4-(4-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine Investigative T99347 DRUGINFO D0JH2D 2-methyl-6-(4-phenylbut-1-ynyl)pyridine Investigative T99347 DRUGINFO D0K0ZK ADX-63365 Investigative T99347 DRUGINFO D0K7KM 3-Phenyl-1-(2-methylthiazol-4-ylethynyl)benzene Investigative T99347 DRUGINFO D0L0KO 6-bromo-N-m-tolylquinazolin-4-amine Investigative T99347 DRUGINFO D0L1PQ 3-(3-Pyridin-2-yl-pyrrol-1-yl)-benzonitrile Investigative T99347 DRUGINFO D0L2KN 2-methyl-4-(3-thienylethynyl)thiazole Investigative T99347 DRUGINFO D0L5FW [3H]methoxy-PEPy Investigative T99347 DRUGINFO D0L6PL 3-biphenyl-4-ylethynyl-5-methyl-[1,2,4]triazine Investigative T99347 DRUGINFO D0L9FD PMID21295468C47 Investigative T99347 DRUGINFO D0LO8S 3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile Investigative T99347 DRUGINFO D0LP7W GSK-2210875 Investigative T99347 DRUGINFO D0M0LC 5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine Investigative T99347 DRUGINFO D0M1EI 5-(2-Methylquinolin-7-yl)-2-phenylbenzonitrile Investigative T99347 DRUGINFO D0M2YQ PMID15482906C10 Investigative T99347 DRUGINFO D0N2TP 2-(m-tolylethynyl)pyrimidine Investigative T99347 DRUGINFO D0N5LF 3-(1,5-naphthyridin-3-yl)benzonitrile Investigative T99347 DRUGINFO D0N6FJ 5-(2-(3,5-difluorophenyl)ethynyl)pyrimidine Investigative T99347 DRUGINFO D0NB2G PMID16439120C26 Investigative T99347 DRUGINFO D0NS9H 2-methyl-6-(4-phenylpent-1-ynyl)pyridine Investigative T99347 DRUGINFO D0O4QX 2-ethoxy-5-(m-tolylethynyl)pyrimidine Investigative T99347 DRUGINFO D0ON2A 5-(2-methylquinolin-7-yl)nicotinonitrile Investigative T99347 DRUGINFO D0P0QI VU0285683 Investigative T99347 DRUGINFO D0P0RY 3-[(2-methyl-4-thiazolyl)ethynyl]benzonitrile Investigative T99347 DRUGINFO D0P2DV 4-(2-(4-fluorophenyl)ethynyl)-2-methylthiazole Investigative T99347 DRUGINFO D0P2IJ CPPZ Investigative T99347 DRUGINFO D0P4TX [14C]MTEP Investigative T99347 DRUGINFO D0PI5D 7-methyl-2-m-tolylpyrido[2,3-d]pyrimidine Investigative T99347 DRUGINFO D0PU1R 2-methyl-7-phenyl-1,8-naphthyridine Investigative T99347 DRUGINFO D0Q3DI 3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile Investigative T99347 DRUGINFO D0Q6EE 3-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D0Q6VH SIB-1893 Investigative T99347 DRUGINFO D0Q9CM 4-(3-bromophenoxy)-6-chloroquinazoline Investigative T99347 DRUGINFO D0QE0D 5-((6-Methylpyridin-2-yl)ethynyl)nicotinonitrile Investigative T99347 DRUGINFO D0QE3C 2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one Investigative T99347 DRUGINFO D0R0JE 3-(3-bromophenylethynyl)-5-methyl[1,2,4]triazine Investigative T99347 DRUGINFO D0R0PU 7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine Investigative T99347 DRUGINFO D0R0UZ 3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile Investigative T99347 DRUGINFO D0R2CF 7-(3,5-dimethoxyphenyl)-1,6-naphthyridine Investigative T99347 DRUGINFO D0R2OX 5-MPEP Investigative T99347 DRUGINFO D0R7VW 4-(3-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine Investigative T99347 DRUGINFO D0RI6U 3-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide Investigative T99347 DRUGINFO D0RJ5B 4-(3-bromophenylthio)-2-(pyridin-2-yl)pyrimidine Investigative T99347 DRUGINFO D0S1CS 3-fluoro-5-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D0S1DD 3-chloro-N-(6-methylpyridin-2-yl)benzamide Investigative T99347 DRUGINFO D0S7SE [3H]methoxymethyl-MTEP Investigative T99347 DRUGINFO D0SE2D 6-(4-chlorophenylamino)-N,N-diethylnicotinamide Investigative T99347 DRUGINFO D0SE9M PMID23434029C53 Investigative T99347 DRUGINFO D0ST3S 4-(3-fluorophenylethynyl)-2-thiazolylamine Investigative T99347 DRUGINFO D0T2DC 3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide Investigative T99347 DRUGINFO D0T4QX CTEP Investigative T99347 DRUGINFO D0T4YQ VU0092273 Investigative T99347 DRUGINFO D0T7BZ 7-(3-(methoxymethyl)phenyl)-2-methylquinoline Investigative T99347 DRUGINFO D0T7SA 4-Biphenyl-2-ylethynyl-2-methyl-thiazole Investigative T99347 DRUGINFO D0TW0I (E)-3-[2-(2-methyl-4-thiazolyl)vinyl]pyridine Investigative T99347 DRUGINFO D0U0UB 2-Methyl-4-o-tolylethynyl-thiazole Investigative T99347 DRUGINFO D0U2GG 5-(3-chlorophenylethynyl)-5-methyl[1,2,4]triazine Investigative T99347 DRUGINFO D0U7IO N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine Investigative T99347 DRUGINFO D0UN6P N-(3-chlorophenyl)-6-nitroquinazolin-4-amine Investigative T99347 DRUGINFO D0UO6Q 2-methyl-7-phenylquinoline Investigative T99347 DRUGINFO D0V4RO 3-(3-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile Investigative T99347 DRUGINFO D0V4TK N-(6-methylpyridin-2-yl)-6-phenylnicotinamide Investigative T99347 DRUGINFO D0V6TM PMID14697765C11a Investigative T99347 DRUGINFO D0V7KU 2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine Investigative T99347 DRUGINFO D0V7TC 5-(2-(3-chlorophenyl)ethynyl)pyrimidine Investigative T99347 DRUGINFO D0W1SX 3-bromo-N-(6-methylpyridin-2-yl)benzamide Investigative T99347 DRUGINFO D0W5JE 4-(3,5-difluorophenylethynyl)-2-methylthiazole Investigative T99347 DRUGINFO D0W6AC PMID23357634C24d Investigative T99347 DRUGINFO D0WJ8I 3-[(2-methyl-4-thiazolyl)ethynyl]phenol Investigative T99347 DRUGINFO D0X3TO PMID20598884C8 Investigative T99347 DRUGINFO D0X4UN 3-methyl-N-(6-methylpyridin-2-yl)benzamide Investigative T99347 DRUGINFO D0X5SZ PMID17189691C42 Investigative T99347 DRUGINFO D0X6EI PMID17936624C36 Investigative T99347 DRUGINFO D0X8VQ 3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile Investigative T99347 DRUGINFO D0XN4W 2-(3,4-dimethylphenyl)-1,8-naphthyridine Investigative T99347 DRUGINFO D0XT4J 7-(3-chlorophenyl)-2-methylquinoline Investigative T99347 DRUGINFO D0Y2GE 3-cyano-5-fluoro-N-(pyridin-2-yl)benzamide Investigative T99347 DRUGINFO D0Y3PV 2-phenylethynyl-5,6,7,8-tetrahydro-quinolin-5-ol Investigative T99347 DRUGINFO D0Y3UT N-(6-methylpyridin-2-yl)-5-phenylpicolinamide Investigative T99347 DRUGINFO D0Y3VE 3-m-tolyl-1,5-naphthyridine Investigative T99347 DRUGINFO D0YZ8G 5-Chloro-2-(2-methylquinolin-7-yl)benzonitrile Investigative T99347 DRUGINFO D0Z0JF M-5MPEP Investigative T99347 DRUGINFO D0Z0JU (3-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amine Investigative T99347 DRUGINFO D0Z0LV VU0360172 Investigative T99347 DRUGINFO D0Z0ZP 5-(2-(2,5-dimethylphenyl)ethynyl)pyrimidine Investigative T99347 DRUGINFO D0Z1OC 3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide Investigative T99347 DRUGINFO D0Z1PY 4-(2-fluorophenylethynyl)-2-methylthiazole Investigative T99347 DRUGINFO D0Z4KU 7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline Investigative T99347 DRUGINFO D0Z9QZ 2-Methyl-4-p-tolylethynyl-thiazole Investigative T99347 DRUGINFO D0ZY8G NCFP Investigative T99347 DRUGINFO D01IUB [3H]resolvin E1 Investigative T99347 DRUGINFO D01YEN ibotenate Investigative T99347 DRUGINFO D02FMR 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine Investigative T99347 DRUGINFO D03VAO N-(3-bromophenyl)-6-fluoroquinazolin-4-amine Investigative T99347 DRUGINFO D04ODF LY-3390334 Investigative T99347 DRUGINFO D0B5RX (E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone Investigative T99347 DRUGINFO D0E7LU 3,5-DHPG Investigative T99347 DRUGINFO D0J5SK 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine Investigative T99347 DRUGINFO D0L3RY 3-methoxy-N-(4-methylthiazol-2-yl)benzamide Investigative T99347 DRUGINFO D0OH2P (S)-(+)-CBPG Investigative T99347 DRUGINFO D0P3XO (S)-4CPG Investigative T99347 DRUGINFO D0R6ZS N-(3-bromophenyl)-6-chloroquinazolin-4-amine Investigative T99347 DRUGINFO D0U5YT (S)-3HPG Investigative T99347 DRUGINFO D0IO8J 2-methyl-6-(phenylethynyl)pyridine Investigative T99347 DRUGINFO D0S6DK (S)-4C3HPG Investigative T99347 DRUGINFO D0J8OW (+)-MCPG Investigative T99347 DRUGINFO D04DKM (1S,3R)-ACPD Investigative T99347 DRUGINFO D06DUE [3H]quisqualate Investigative T99347 DRUGINFO D0Z7CZ L-CCG-I Investigative T89988 TARGETID T89988 T89988 FORMERID TTDC00122 T89988 UNIPROID CCR2_HUMAN T89988 TARGNAME C-C chemokine receptor type 2 (CCR2) T89988 GENENAME CCR2 T89988 TARGTYPE Clinical trial T89988 SYNONYMS Monocyte chemoattractant protein 1 receptor; MCP-1-R; Chemokine receptor CCR2B; CMKBR2; CD192; CCR-2; CC-CKR-2; C-C CKR-2 T89988 FUNCTION Its binding with CCL2 on monocytes and macrophages mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion. Also acts as a receptor for the beta-defensin DEFB106A/DEFB106B. Regulates the expression of T-cell inflammatory cytokines and T-cell differentiation, promoting the differentiation of T-cells into T-helper 17 cells (Th17) during inflammation. Faciltates the export of mature thymocytes by enhancing directional movement of thymocytes to sphingosine-1-phosphate stimulation and up-regulation of S1P1R expression; signals through the JAK-STAT pathway to regulate FOXO1 activity leading to an increased expression of S1P1R. Plays an important role in mediating peripheral nerve injury-induced neuropathic pain. Increases NMDA-mediated synaptic transmission in both dopamine D1 and D2 receptor-containing neurons, which may be caused by MAPK/ERK-dependent phosphorylation of GRIN2B/NMDAR2B. Mediates the recruitment of macrophages and monocytes to the injury site following brain injury. Key functional receptor for CCL2 but can also bind CCL7 and CCL12. T89988 PDBSTRUC 5T1A; 2MLQ; 2MLO; 1KP1; 1KAD T89988 BIOCLASS GPCR rhodopsin T89988 SEQUENCE MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYSLVFIFGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLFLITLPLWAHSAANEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVFALKARTVTFGVVTSVITWLVAVFASVPGIIFTKCQKEDSVYVCGPYFPRGWNNFHTIMRNILGLVLPLLIMVICYSGILKTLLRCRNEKKRHRAVRVIFTIMIVYFLFWTPYNIVILLNTFQEFFGLSNCESTSQLDQATQVTETLGMTHCCINPIIYAFVGEKFRSLFHIALGCRIAPLQKPVCGGPGVRPGKNVKVTTQGLLDGRGKGKSIGRAPEASLQDKEGA T89988 DRUGINFO D06IME CCX-140 Phase 2 T89988 DRUGINFO D0E5NY AZD-2423 Phase 2 T89988 DRUGINFO D0Q3PB CCX872 Phase 2 T89988 DRUGINFO D0TG9Q MK-0812 Phase 2 T89988 DRUGINFO D06KCU MLN1202 Phase 2 T89988 DRUGINFO D0B1SG BMS-813160 Phase 2 T89988 DRUGINFO D0YQ7U Cenicriviroc Phase 2 T89988 DRUGINFO D0DT2S TAK-202 Phase 1 T89988 DRUGINFO D0U7PM OPL-CCL2-LPM Phase 1 T89988 DRUGINFO D0VR7F CNTX-6970 Phase 1 T89988 DRUGINFO D0V0NL Aminoguanidine Phase 1 T89988 DRUGINFO D07VXT INCB8696 Discontinued in Phase 1 T89988 DRUGINFO D0MT0A CCX915 Discontinued in Phase 1 T89988 DRUGINFO D0V9ND MCP-1 Preclinical T89988 DRUGINFO D0X4SI RS-504393 Preclinical T89988 DRUGINFO D07KIJ INCB3344 Terminated T89988 DRUGINFO D0I9YI AZD-6942 Terminated T89988 DRUGINFO D0Q2JS SB-282241 Terminated T89988 DRUGINFO D00JXV INCB-10820 Investigative T89988 DRUGINFO D00VYD RS-136270 Investigative T89988 DRUGINFO D01KYM (S)-3-(2',2'-Dimethyl-propionyl)amino-caprolactam Investigative T89988 DRUGINFO D02XNT BMS-A Investigative T89988 DRUGINFO D07RPC RAP-103 Investigative T89988 DRUGINFO D0C5XF GSK-1344386B Investigative T89988 DRUGINFO D0G1JJ (S)-3-(1'-Adamantanecarbonyl)amino-caprolactam Investigative T89988 DRUGINFO D0H5WL NSC-651016 Investigative T89988 DRUGINFO D0J9QK (R)-3-(1'-Adamantanecarbonyl)amino-caprolactam Investigative T89988 DRUGINFO D0M8CJ RS-102895 Investigative T89988 DRUGINFO D0RM7J Teijin-lead_cmp_5 Investigative T89988 DRUGINFO D0W9OW RAP-310 Investigative T89988 DRUGINFO D09PZD viral macrophage inflammatory protein-II Investigative T05031 TARGETID T05031 T05031 FORMERID TTDI02297 T05031 UNIPROID PK3CB_HUMAN T05031 TARGNAME PI3-kinase beta (PIK3CB) T05031 GENENAME PIK3CB T05031 TARGTYPE Clinical trial T05031 SYNONYMS p110beta; PtdIns3kinase subunit p110beta; PtdIns3kinase subunit beta; PtdIns-3-kinase subunit p110-beta; PtdIns-3-kinase subunit beta; Phosphatidylinositol 4,5bisphosphate 3kinase catalytic subunitbeta isoform; Phosphatidylinositol 4,5bisphosphate 3kinase 110 kDa catalyticsubunit beta; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; PIK3C1; PI3kinase subunit beta; PI3Kbeta; PI3K-beta; PI3-kinase subunit beta T05031 FUNCTION Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors. T05031 BIOCLASS Kinase T05031 ECNUMBER EC 2.7.1.153 T05031 SEQUENCE MCFSFIMPPAMADILDIWAVDSQIASDGSIPVDFLLPTGIYIQLEVPREATISYIKQMLWKQVHNYPMFNLLMDIDSYMFACVNQTAVYEELEDETRRLCDVRPFLPVLKLVTRSCDPGEKLDSKIGVLIGKGLHEFDSLKDPEVNEFRRKMRKFSEEKILSLVGLSWMDWLKQTYPPEHEPSIPENLEDKLYGGKLIVAVHFENCQDVFSFQVSPNMNPIKVNELAIQKRLTIHGKEDEVSPYDYVLQVSGRVEYVFGDHPLIQFQYIRNCVMNRALPHFILVECCKIKKMYEQEMIAIEAAINRNSSNLPLPLPPKKTRIISHVWENNNPFQIVLVKGNKLNTEETVKVHVRAGLFHGTELLCKTIVSSEVSGKNDHIWNEPLEFDINICDLPRMARLCFAVYAVLDKVKTKKSTKTINPSKYQTIRKAGKVHYPVAWVNTMVFDFKGQLRTGDIILHSWSSFPDELEEMLNPMGTVQTNPYTENATALHVKFPENKKQPYYYPPFDKIIEKAAEIASSDSANVSSRGGKKFLPVLKEILDRDPLSQLCENEMDLIWTLRQDCREIFPQSLPKLLLSIKWNKLEDVAQLQALLQIWPKLPPREALELLDFNYPDQYVREYAVGCLRQMSDEELSQYLLQLVQVLKYEPFLDCALSRFLLERALGNRRIGQFLFWHLRSEVHIPAVSVQFGVILEAYCRGSVGHMKVLSKQVEALNKLKTLNSLIKLNAVKLNRAKGKEAMHTCLKQSAYREALSDLQSPLNPCVILSELYVEKCKYMDSKMKPLWLVYNNKVFGEDSVGVIFKNGDDLRQDMLTLQMLRLMDLLWKEAGLDLRMLPYGCLATGDRSGLIEVVSTSETIADIQLNSSNVAAAAAFNKDALLNWLKEYNSGDDLDRAIEEFTLSCAGYCVASYVLGIGDRHSDNIMVKKTGQLFHIDFGHILGNFKSKFGIKRERVPFILTYDFIHVIQQGKTGNTEKFGRFRQCCEDAYLILRRHGNLFITLFALMLTAGLPELTSVKDIQYLKDSLALGKSEEEALKQFKQKFDEALRESWTTKVNWMAHTVRKDYRS T05031 DRUGINFO D01QSO Buparlisib Phase 3 T05031 DRUGINFO D0TU7B PQR309 Phase 2 T05031 DRUGINFO D05CBJ PA-799 Phase 1/2 T05031 DRUGINFO D0G3MN GSK2636771 Phase 1 T05031 DRUGINFO D0KJ2J BAY 1082439 Phase 1 T05031 DRUGINFO D03BHZ AZD8186 Phase 1 T05031 DRUGINFO D0D0QA AZD6482 Terminated T05031 DRUGINFO D01SSI PI-3065 Investigative T05031 DRUGINFO D06DNH TGX-221 Investigative T05031 DRUGINFO D00HSJ PIK-75 Investigative T05031 DRUGINFO D0R0TW KU-0060648 Investigative T05031 DRUGINFO D03EHM PP121 Investigative T57943 TARGETID T57943 T57943 FORMERID TTDR00440 T57943 UNIPROID CASP3_HUMAN T57943 TARGNAME Caspase-3 (CASP3) T57943 GENENAME CASP3 T57943 TARGTYPE Clinical trial T57943 SYNONYMS Yama protein; SREBP cleavage activity 1; SCA-1; Protein Yama; Cysteine protease CPP32; Caspase 3; CPP32; CPP-32; CASP-3; Apopain T57943 FUNCTION At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. Cleaves and activates caspase-6, -7 and -9. Involved in the cleavage of huntingtin. Triggers cell adhesion in sympathetic neurons through RET cleavage. Involved in the activation cascade of caspases responsible for apoptosis execution. T57943 BIOCLASS Peptidase T57943 ECNUMBER EC 3.4.22.56 T57943 SEQUENCE MENTENSVDSKSIKNLEPKIIHGSESMDSGISLDNSYKMDYPEMGLCIIINNKNFHKSTGMTSRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIVELMRDVSKEDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSGVDDDMACHKIPVEADFLYAYSTAPGYYSWRNSKDGSWFIQSLCAMLKQYADKLEFMHILTRVNRKVATEFESFSFDATFHAKKQIPCIVSMLTKELYFYH T57943 DRUGINFO D01YIF PAC1 Phase 1 T57943 DRUGINFO D01XMM 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione Investigative T57943 DRUGINFO D02DOK SJ-8002 Investigative T57943 DRUGINFO D03JDL AZ10417808 Investigative T57943 DRUGINFO D05GGE 2-phenethylisoquinoline-1,3,4-trione Investigative T57943 DRUGINFO D09AED 2-benzylisoquinoline-1,3,4-trione Investigative T57943 DRUGINFO D09GKA 2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione Investigative T57943 DRUGINFO D0B6VI 5-(azetidin-1-ylsulfonyl)indoline-2,3-dione Investigative T57943 DRUGINFO D0B8HU 2-allylisoquinoline-1,3,4-trione Investigative T57943 DRUGINFO D0D4RW 5-(azepan-1-ylsulfonyl)indoline-2,3-dione Investigative T57943 DRUGINFO D0FZ7W 2-methylisoquinoline-1,3,4-trione Investigative T57943 DRUGINFO D0L3PO 2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione Investigative T57943 DRUGINFO D0N5MU 5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione Investigative T57943 DRUGINFO D0P0XF Ac-Asp-Glu-Val-Asp-CHO Investigative T57943 DRUGINFO D0T5GV PETCM Investigative T57943 DRUGINFO D0L9AX Ac-DEVD-CHO Investigative T57943 DRUGINFO D0Y2TI Glionitrin A Investigative T57943 DRUGINFO D0V6DX Isoquinoline-1,3,4(2H)-trione Investigative T57943 DRUGINFO D00YNW M826 Investigative T96760 TARGETID T96760 T96760 FORMERID TTDI02078 T96760 UNIPROID GDF5_HUMAN T96760 TARGNAME Growth/differentiation factor 5 (GDF-5) T96760 GENENAME GDF5 T96760 TARGTYPE Clinical trial T96760 SYNONYMS Radotermin; Lipopolysaccharide-associated protein 4; LPS-associated protein 4; LAP-4; Cartilagederived morphogenetic protein 1; Cartilage-derived morphogenetic protein 1; CDMP1; CDMP-1; Bone morphogenetic protein 14; BMP14; BMP-14 T96760 FUNCTION During cartilage development regulates differentiation of chondrogenic tissue through two pathways. Firstly, positively regulates differentiation of chondrogenic tissue through its binding of high affinity with BMPR1B and of less affinity with BMPR1A, leading to induction of SMAD1-SMAD5-SMAD8 complex phosphorylation and then SMAD protein signaling transduction. Secondly, negatively regulates chondrogenic differentiation through its interaction with NOG. Required to prevent excessive muscle loss upon denervation. This function requires SMAD4 and is mediated by phosphorylated SMAD1/5/8. Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Growth factor involved in bone and cartilage formation. T96760 PDBSTRUC 5HK5; 3QB4; 3EVS; 2BHK; 1WAQ T96760 BIOCLASS Growth factor T96760 SEQUENCE MRLPKLLTFLLWYLAWLDLEFICTVLGAPDLGQRPQGTRPGLAKAEAKERPPLARNVFRPGGHSYGGGATNANARAKGGTGQTGGLTQPKKDEPKKLPPRPGGPEPKPGHPPQTRQATARTVTPKGQLPGGKAPPKAGSVPSSFLLKKAREPGPPREPKEPFRPPPITPHEYMLSLYRTLSDADRKGGNSSVKLEAGLANTITSFIDKGQDDRGPVVRKQRYVFDISALEKDGLLGAELRILRKKPSDTAKPAAPGGGRAAQLKLSSCPSGRQPASLLDVRSVPGLDGSGWEVFDIWKLFRNFKNSAQLCLELEAWERGRAVDLRGLGFDRAARQVHEKALFLVFGRTKKRDLFFNEIKARSGQDDKTVYEYLFSQRRKRRAPLATRQGKRPSKNLKARCSRKALHVNFKDMGWDDWIIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISILFIDSANNVVYKQYEDMVVESCGCR T96760 DRUGINFO D0V4IQ RhGDF-5 Phase 2 T85467 TARGETID T85467 T85467 FORMERID TTDC00037 T85467 UNIPROID PE2R3_HUMAN T85467 TARGNAME Prostaglandin E2 receptor EP3 (PTGER3) T85467 GENENAME PTGER3 T85467 TARGTYPE Clinical trial T85467 SYNONYMS Prostanoid EP3 receptor; Prostaglandin E2 receptor EP3 subtype; PGE2-R; PGE2 receptor EP3 subtype; PGE receptor, EP3 subtype; PGE receptor EP3 subtype T85467 FUNCTION The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G(i) proteins, and to an elevation of intracellular calcium. Required for normal development of fever in response to pyrinogens, including IL1B, prostaglandin E2 and bacterial lipopolysaccharide (LPS). Required for normal potentiation of platelet aggregation by prostaglandin E2, and thus plays a role in the regulation of blood coagulation. Required for increased HCO3(-) secretion in the duodenum in response to mucosal acidification, and thereby contributes to the protection of the mucosa against acid-induced ulceration. Not required for normal kidney function, normal urine volume and osmolality. Receptor for prostaglandin E2 (PGE2). T85467 PDBSTRUC 6M9T; 6AK3 T85467 BIOCLASS GPCR rhodopsin T85467 SEQUENCE MKETRGYGGDAPFCTRLNHSYTGMWAPERSAEARGNLTRPPGSGEDCGSVSVAFPITMLLTGFVGNALAMLLVSRSYRRRESKRKKSFLLCIGWLALTDLVGQLLTTPVVIVVYLSKQRWEHIDPSGRLCTFFGLTMTVFGLSSLFIASAMAVERALAIRAPHWYASHMKTRATRAVLLGVWLAVLAFALLPVLGVGQYTVQWPGTWCFISTGRGGNGTSSSHNWGNLFFASAFAFLGLLALTVTFSCNLATIKALVSRCRAKATASQSSAQWGRITTETAIQLMGIMCVLSVCWSPLLIMMLKMIFNQTSVEHCKTHTEKQKECNFFLIAVRLASLNQILDPWVYLLLRKILLRKFCQIRYHTNNYASSSTSLPCQCSSTLMWSDHLER T85467 DRUGINFO D0V5QH ONO-9054 Phase 2 T85467 DRUGINFO D0U7WF 16,16-dimethyl-PGE2 Phase 2 T85467 DRUGINFO D00HTY PGF2alpha Clinical trial T85467 DRUGINFO D0W2OT BUTAPROST Patented T85467 DRUGINFO D08QHS DG041 Discontinued in Phase 2 T85467 DRUGINFO D07RVP GR-63799X Discontinued in Phase 1 T85467 DRUGINFO D07TWQ ONO-AE5-599 Investigative T85467 DRUGINFO D07UDT L-798,106 Investigative T85467 DRUGINFO D0K4VN Molecule 21 Investigative T85467 DRUGINFO D0L8DV SC46275 Investigative T85467 DRUGINFO D0VR8J ONO-AP-324 Investigative T85467 DRUGINFO D0X6DO L-826266 Investigative T85467 DRUGINFO D00GTU STA2 Investigative T85467 DRUGINFO D08KPK ONO-AE3-240 Investigative T85467 DRUGINFO D0AK4K ONO-AE3-208 Investigative T85467 DRUGINFO D0CW4T ONO-AE-248 Investigative T85467 DRUGINFO D0I0UI ONO-AE2-227 Investigative T85467 DRUGINFO D0T2GA ONO-8713 Investigative T85467 DRUGINFO D02LXJ 3-(2-cinnamylphenyl)acrylic acid Investigative T85467 DRUGINFO D02SAD 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid Investigative T85467 DRUGINFO D02YIJ isocarbacyclin Investigative T85467 DRUGINFO D05TNX fluprostenol Investigative T85467 DRUGINFO D06VZS ONO-AE1-329 Investigative T85467 DRUGINFO D0G5MT 11-deoxy-PGE1 Investigative T85467 DRUGINFO D0TA0L FR-181157 Investigative T85467 DRUGINFO D0W4GQ 3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid Investigative T85467 DRUGINFO D0X2MQ 17-phenyl-omega-trinor-PGE2 Investigative T85467 DRUGINFO D0X5MA I-BOP Investigative T85467 DRUGINFO D0Z3XJ 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid Investigative T85467 DRUGINFO D0J9PG AH6809 Investigative T85467 DRUGINFO D05SFA cicaprost Investigative T85467 DRUGINFO D0O9ES cloprostenol Investigative T85467 DRUGINFO D08MNO butaprost (free acid form) Investigative T85467 DRUGINFO D0BN1U M&B 28767 Investigative T85467 DRUGINFO D06KBO PGD2 Investigative T85467 DRUGINFO D0W7RI carbacyclin Investigative T85467 DRUGINFO D03PLH U46619 Investigative T54582 TARGETID T54582 T54582 FORMERID TTDI02132 T54582 UNIPROID NAMPT_HUMAN T54582 TARGNAME Nicotinamide phosphoribosyltransferase (NAMPT) T54582 GENENAME NAMPT T54582 TARGTYPE Clinical trial T54582 SYNONYMS Visfatin; PreBcell colonyenhancing factor 1; PreB cellenhancing factor; Pre-B-cell colony-enhancing factor 1; Pre-B cell-enhancing factor; PBEF1; PBEF; Nampt; NAmPRTase T54582 FUNCTION It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependent SIRT1-mediated suppression. Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. T54582 PDBSTRUC 6B76; 6B75; 6AZJ; 6ATB; 6.00E+68 T54582 BIOCLASS Glycosyltransferases T54582 ECNUMBER EC 2.4.2.12 T54582 SEQUENCE MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYEETVFYGLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIKAVPEGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDPVPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINTLQEIVEGMKQKMWSIENIAFGSGGGLLQKLTRDLLNCSFKCSYVVTNGLGINVFKDPVADPNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNAQLNIELEAAHH T54582 DRUGINFO D0H9SX Daporinad Phase 2 T54582 DRUGINFO D0Y1NC CHS-828 Phase 1/2 T54582 DRUGINFO D0V7YA GMX1777 Phase 1 T54582 DRUGINFO DN6MT7 OT-82 Phase 1 T78692 TARGETID T78692 T78692 FORMERID TTDS00150 T78692 UNIPROID KCNJ5_HUMAN T78692 TARGNAME Inward rectifier potassium channel Kir3.4 (KCNJ5) T78692 GENENAME KCNJ5 T78692 TARGTYPE Clinical trial T78692 SYNONYMS Potassium channel, inwardly rectifying, subfamily J, member 5; KCNJ5; KATP-1; KATP channel; Inward rectifier K+ channel Kir3.4; Heart KATP channel; GIRK4; Cardiac inward rectifier; CIR T78692 FUNCTION This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium. T78692 BIOCLASS Inward rectifier potassium channel T78692 SEQUENCE MAGDSRNAMNQDMEIGVTPWDPKKIPKQARDYVPIATDRTRLLAEGKKPRQRYMEKSGKCNVHHGNVQETYRYLSDLFTTLVDLKWRFNLLVFTMVYTVTWLFFGFIWWLIAYIRGDLDHVGDQEWIPCVENLSGFVSAFLFSIETETTIGYGFRVITEKCPEGIILLLVQAILGSIVNAFMVGCMFVKISQPKKRAETLMFSNNAVISMRDEKLCLMFRVGDLRNSHIVEASIRAKLIKSRQTKEGEFIPLNQTDINVGFDTGDDRLFLVSPLIISHEINQKSPFWEMSQAQLHQEEFEVVVILEGMVEATGMTCQARSSYMDTEVLWGHRFTPVLTLEKGFYEVDYNTFHDTYETNTPSCCAKELAEMKREGRLLQYLPSPPLLGGCAEAGLDAEAEQNEEDEPKGLGGSREARGSV T78692 DRUGINFO D09DHT phorbol 12-myristate 13-acetate Phase 2 T78692 DRUGINFO D07ZAJ PIP2 Investigative T93105 TARGETID T93105 T93105 FORMERID TTDR00444 T93105 UNIPROID PSN1_HUMAN T93105 TARGNAME Presenilin 1 (PSEN1) T93105 GENENAME PSEN1 T93105 TARGTYPE Clinical trial T93105 SYNONYMS S182 protein; Protein S182; Presenilin-1; PSNL1; PS1; PS-1; AD3 T93105 FUNCTION Requires the presence of the other members of the gamma-secretase complex for protease activity. Plays a role in Notch and Wnt signaling cascades and regulation of downstream processes via its role in processing key regulatory proteins, and by regulating cytosolic CTNNB1 levels. Stimulates cell-cell adhesion via its interaction with CDH1; this stabilizes the complexes between CDH1 (E-cadherin) and its interaction partners CTNNB1 (beta-catenin), CTNND1 and JUP (gamma-catenin). Under conditions of apoptosis or calcium influx, cleaves CDH1. This promotes the disassembly of the complexes between CDH1 and CTNND1, JUP and CTNNB1, increases the pool of cytoplasmic CTNNB1, and thereby negatively regulates Wnt signaling. Required for normal embryonic brain and skeleton development, and for normal angiogenesis. Mediates the proteolytic cleavage of EphB2/CTF1 into EphB2/CTF2. The holoprotein functions as a calcium-leak channel that allows the passive movement of calcium from endoplasmic reticulum to cytosol and is therefore involved in calcium homeostasis. Involved in the regulation of neurite outgrowth. Is a regulator of presynaptic facilitation, spike transmission and synaptic vesicles replenishment in a process that depends on gamma-secretase activity. It acts through the control of SYT7 presynaptic expression. Catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein). T93105 PDBSTRUC 6IYC; 6IDF; 5FN5; 5FN4; 5FN3 T93105 BIOCLASS Peptidase T93105 ECNUMBER EC 3.4.23.- T93105 SEQUENCE MTELPAPLSYFQNAQMSEDNHLSNTVRSQNDNRERQEHNDRRSLGHPEPLSNGRPQGNSRQVVEQDEEEDEELTLKYGAKHVIMLFVPVTLCMVVVVATIKSVSFYTRKDGQLIYTPFTEDTETVGQRALHSILNAAIMISVIVVMTILLVVLYKYRCYKVIHAWLIISSLLLLFFFSFIYLGEVFKTYNVAVDYITVALLIWNFGVVGMISIHWKGPLRLQQAYLIMISALMALVFIKYLPEWTAWLILAVISVYDLVAVLCPKGPLRMLVETAQERNETLFPALIYSSTMVWLVNMAEGDPEAQRRVSKNSKYNAESTERESQDTVAENDDGGFSEEWEAQRDSHLGPHRSTPESRAAVQELSSSILAGEDPEERGVKLGLGDFIFYSVLVGKASATASGDWNTTIACFVAILIGLCLTLLLLAIFKKALPALPISITFGLVFYFATDYLVQPFMDQLAFHQFYI T93105 DRUGINFO D0G2IC (S)-FLURBIPROFEN Preregistration T93105 DRUGINFO D05FGR R-flurbiprofen Phase 2 T93105 DRUGINFO D0K8LN 1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene Investigative T93105 DRUGINFO D00DFR (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone Investigative T93105 DRUGINFO D04TWU (5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone Investigative T93105 DRUGINFO D06TPT Drug 311951 Investigative T93105 DRUGINFO D09HAD Drug 311383 Investigative T93105 DRUGINFO D0I8BA 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one Investigative T93105 DRUGINFO D0M2LV (2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone Investigative T93105 DRUGINFO D0V7YM Drug 311952 Investigative T93105 DRUGINFO D0XQ2T Drug 311440 Investigative T16691 TARGETID T16691 T16691 FORMERID TTDC00185 T16691 UNIPROID 5HT6R_HUMAN T16691 TARGNAME 5-HT 6 receptor (HTR6) T16691 GENENAME HTR6 T16691 TARGTYPE Clinical trial T16691 SYNONYMS Serotonin receptor 6; 5-hydroxytryptamine receptor 6; 5-HT6 receptor; 5-HT6; 5-HT-6 T16691 FUNCTION The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs. Controls pyramidal neurons migration during corticogenesis, through the regulation of CDK5 activity. Is an activator of TOR signaling. This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. T16691 BIOCLASS GPCR rhodopsin T16691 SEQUENCE MVPEPGPTANSTPAWGAGPPSAPGGSGWVAAALCVVIALTAAANSLLIALICTQPALRNTSNFFLVSLFTSDLMVGLVVMPPAMLNALYGRWVLARGLCLLWTAFDVMCCSASILNLCLISLDRYLLILSPLRYKLRMTPLRALALVLGAWSLAALASFLPLLLGWHELGHARPPVPGQCRLLASLPFVLVASGLTFFLPSGAICFTYCRILLAARKQAVQVASLTTGMASQASETLQVPRTPRPGVESADSRRLATKHSRKALKASLTLGILLGMFFVTWLPFFVANIVQAVCDCISPGLFDVLTWLGYCNSTMNPIIYPLFMRDFKRALGRFLPCPRCPRERQASLASPSLRTSHSGPRPGLSLQQVLPLPLPPDSDSDSDAGSGGSSGLRLTAQLLLPGEATQDPPLPTRAAAAVNFFNIDPAEPELRPHPLGIPTN T16691 DRUGINFO D09IRN LU AE58054 Phase 3 T16691 DRUGINFO D0R9HI SB-742457 Phase 3 T16691 DRUGINFO D0WH4L AVN 211 Phase 2/3 T16691 DRUGINFO D01NDF AVN 101 Phase 2 T16691 DRUGINFO D07RQR SYN-120 Phase 2 T16691 DRUGINFO D0G1YA PF-05212377 Phase 2 T16691 DRUGINFO D0L8IO AVN 322 Phase 2 T16691 DRUGINFO D0V4ZQ SAM-531 Phase 2 T16691 DRUGINFO D0Z0GX SUVN-502 Phase 2 T16691 DRUGINFO D9I3WE SYN120 Phase 2 T16691 DRUGINFO D02KLD BVT-74316 Phase 1 T16691 DRUGINFO D03ZPX PRX-07034 Phase 1 T16691 DRUGINFO D08PIK 11C-GSK-215083 Phase 1 T16691 DRUGINFO D0X9HF ABT-354 Phase 1 T16691 DRUGINFO DWD06K AVN-322 Phase 1 T16691 DRUGINFO D09BCJ PMID30124346-Compound-34TABLE4 Patented T16691 DRUGINFO D0F4NB PMID30124346-Compound-13TABLE4 Patented T16691 DRUGINFO D0J7EP AVN 397 Discontinued in Phase 2 T16691 DRUGINFO D04VTV SYN-114 Discontinued in Phase 1 T16691 DRUGINFO D06ZVC WAY-181187 Discontinued in Phase 1 T16691 DRUGINFO D00DZY 4-(2-benzenesulfonylphenyl)piperazine Investigative T16691 DRUGINFO D00OCC 4-(3-benzenesulfonylphenyl)piperazine Investigative T16691 DRUGINFO D00PBI SUVN-501 Investigative T16691 DRUGINFO D01DCE 4-(Indan-1-ylsulfanyl)-phenylamine Investigative T16691 DRUGINFO D01TYJ 4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine Investigative T16691 DRUGINFO D01ZMO 4-(3H-Inden-1-ylmethyl)-phenylamine Investigative T16691 DRUGINFO D02JFD SB399885 Investigative T16691 DRUGINFO D02LFU 1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole Investigative T16691 DRUGINFO D02SBM 6-(piperazin-1-yl)-3-tosyl-1H-indazole Investigative T16691 DRUGINFO D02VHJ 2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine Investigative T16691 DRUGINFO D05DAF N-(3-aminophenyl)benzenesulfonamide Investigative T16691 DRUGINFO D05HJP 4-Inden-(1E)-ylidenemethyl-phenylamine Investigative T16691 DRUGINFO D05JPG [2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine Investigative T16691 DRUGINFO D05SAP N-(3-(aminomethyl)phenyl)benzenesulfonamide Investigative T16691 DRUGINFO D05XGR SB-214111 Investigative T16691 DRUGINFO D06FXO 3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole Investigative T16691 DRUGINFO D06PXY alpha-ergocryptine Investigative T16691 DRUGINFO D06QVB 4-(Naphthalene-1-sulfonyl)-phenylamine Investigative T16691 DRUGINFO D07DCN 4-(3-benzenesulfonamidophenyl)piperazine Investigative T16691 DRUGINFO D07LIE 2-(3-benzenesulfonyl)phenyl-1-aminoethane Investigative T16691 DRUGINFO D08SMK 2-(1-tosyl-1H-indol-3-yl)ethanamine Investigative T16691 DRUGINFO D09CHX AMR-SIX-1 Investigative T16691 DRUGINFO D09LVG 4-(1H-Inden-1-ylmethyl)-phenylamine Investigative T16691 DRUGINFO D09RXU 2-Benzyl-4-piperazin-1-yl-1H-benzimidazole Investigative T16691 DRUGINFO D09VSK 4-(1H-Indol-3-ylmethyl)-phenylamine Investigative T16691 DRUGINFO D0C4AE 3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole Investigative T16691 DRUGINFO D0C8UV 4-(4-benzenesulfonylphenyl)piperazine Investigative T16691 DRUGINFO D0CY6E 2-(4-(benzenesulfonyl)phenyl)-1-aminoethane Investigative T16691 DRUGINFO D0D2XH 4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine Investigative T16691 DRUGINFO D0D6FC N-(4-(2-aminoethyl)phenyl)benzenesulfonamide Investigative T16691 DRUGINFO D0DE8K lergotrile Investigative T16691 DRUGINFO D0E0DR N-(3-(2-aminoethyl)phenyl)benzenesulfonamide Investigative T16691 DRUGINFO D0F6GP 5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole Investigative T16691 DRUGINFO D0FV7K 4-((1H-indol-1-yl)methyl)benzenamine Investigative T16691 DRUGINFO D0G6NV 4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine Investigative T16691 DRUGINFO D0G7QT EMD-386088 Investigative T16691 DRUGINFO D0H0IZ N-phenyl-3-(2-aminoethyl)benzenesulfonamide Investigative T16691 DRUGINFO D0H5EP 1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole Investigative T16691 DRUGINFO D0H7PC SB-357134 Investigative T16691 DRUGINFO D0J7EM 1-phenylthio-N,N-dimethyltryptamine Investigative T16691 DRUGINFO D0J9MP N-(3-(3-aminopropyl)phenyl)benzenesulfonamide Investigative T16691 DRUGINFO D0JT3M [2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine Investigative T16691 DRUGINFO D0K8PH SUVN-504 Investigative T16691 DRUGINFO D0KD8D [2-(3-Benzyl-3H-indol-1-yl)-ethyl]-dimethyl-amine Investigative T16691 DRUGINFO D0L7PA SB 258585 Investigative T16691 DRUGINFO D0LA4I 4-(Indane-1-sulfonyl)-phenylamine Investigative T16691 DRUGINFO D0N7NK E6801 Investigative T16691 DRUGINFO D0N8AO 4-(4-benzenesulfonamidophenyl)piperazine Investigative T16691 DRUGINFO D0O3GQ 2-(3-phenylthio)phenyl)-1-aminoethane Investigative T16691 DRUGINFO D0P8JA Ro-04-6790 Investigative T16691 DRUGINFO D0PQ1U 2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine Investigative T16691 DRUGINFO D0Q7AF E-6837 Investigative T16691 DRUGINFO D0R7VT 4-(1H-indol-1-ylsulfonyl)benzenamine Investigative T16691 DRUGINFO D0S3UH SUVN-507 Investigative T16691 DRUGINFO D0S4XR 1-(3-(benzyloxy)-2-methylphenyl)piperazine Investigative T16691 DRUGINFO D0SJ6E N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine Investigative T16691 DRUGINFO D0T7VZ 2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine Investigative T16691 DRUGINFO D0TG0I 1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole Investigative T16691 DRUGINFO D0TX8W 4-(piperazin-1-yl)-1H-indole Investigative T16691 DRUGINFO D0UB6O [125I]SB-258585 Investigative T16691 DRUGINFO D0V2PB [3H]Ro 63-0563 Investigative T16691 DRUGINFO D0V5AN 6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole Investigative T16691 DRUGINFO D0VI0S 4-(piperazin-1-yl)-3-tosyl-1H-indazole Investigative T16691 DRUGINFO D0W2HW N,N-diethyl-2-(1H-indol-3-yl)ethanamine Investigative T16691 DRUGINFO D0W2QN 2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole Investigative T16691 DRUGINFO D0X1IU 4-Indan-1-ylmethyl-phenylamine Investigative T16691 DRUGINFO D0XJ6D 4-(3-Methyl-indole-1-sulfonyl)-phenylamine Investigative T16691 DRUGINFO D0Y1LJ 2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine Investigative T16691 DRUGINFO D0Y4WH 3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole Investigative T16691 DRUGINFO D0ZC9Q [2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine Investigative T16691 DRUGINFO D00VRV 2-bromo-LSD Investigative T16691 DRUGINFO D02YSX DIMEBOLIN Investigative T16691 DRUGINFO D09ULA OPC 4392 Investigative T16691 DRUGINFO D0F8TG fluperlapine Investigative T16691 DRUGINFO D0J0KG DM-1451 Investigative T16691 DRUGINFO D0T4PS LY 165,163 Investigative T16691 DRUGINFO D03DLZ 2-(1H-indol-3-yl)-N,N-dimethylethanamine Investigative T16691 DRUGINFO D04AQE 5-METHOXYTRYPTAMINE Investigative T16691 DRUGINFO D0X6MT METHIOTHEPIN Investigative T16691 DRUGINFO D07HQZ [3H]LSD Investigative T16691 DRUGINFO D0C5XQ 5-MEO-DMT Investigative T16691 DRUGINFO D08PJK [3H]5-CT Investigative T16691 DRUGINFO D0OG0R WAY-208466 Investigative T16691 DRUGINFO D0P1XQ SEL-73 Investigative T16691 DRUGINFO D0SP2J bufotenine Investigative T16691 DRUGINFO D0CK9K EDMT Investigative T16691 DRUGINFO D0V3XU CHLOROPHENYLPIPERAZINE Investigative T16691 DRUGINFO D06VPR WAY-466 Investigative T16691 DRUGINFO D08BCF QUIPAZINE Investigative T16691 DRUGINFO D0C5GF MPDT Investigative T16691 DRUGINFO D0D3YN OCTOCLOTHEPIN Investigative T16691 DRUGINFO D0J6JT m-chlorophenylpiperazine Investigative T16691 DRUGINFO D0LG8A 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine Investigative T16691 DRUGINFO D0V4RP 1-(2-Methoxy-phenyl)-piperazine Investigative T16691 DRUGINFO D00CRA 2-methyl-5-HT Investigative T16691 DRUGINFO D05EQG [3H]spiperone Investigative T16691 DRUGINFO D08VGJ 5,6-dichloro-3,4-dihydroquinazolin-2-amine Investigative T16691 DRUGINFO D09OYA alpha-methyl-5-HT Investigative T16691 DRUGINFO D03TDN 1-naphthylpiperazine Investigative T16691 DRUGINFO D04TVG BRL-15572 Investigative T16691 DRUGINFO D07LRJ SB-271046 Investigative T16691 DRUGINFO D02UWB 5-CT Investigative T16691 DRUGINFO D0V5HV TFMPP Investigative T16691 DRUGINFO D0F6CD SEROTONIN Investigative T16691 DRUGINFO D0L5MW (+/-)-nantenine Investigative T75596 TARGETID T75596 T75596 FORMERID TTDR00721 T75596 UNIPROID MAP2_HUMAN T75596 TARGNAME Methionine aminopeptidase 2 (METAP2) T75596 GENENAME METAP2 T75596 TARGTYPE Clinical trial T75596 SYNONYMS Peptidase M 2; P67eIF2; P67; MetAP 2; METAP2; Initiation factor 2 associated 67 kDa glycoprotein; (MetAP)-2 T75596 FUNCTION Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). T75596 PDBSTRUC 6QEJ; 6QEI; 6QEH; 6QEG; 6QEF T75596 BIOCLASS Peptidase T75596 ECNUMBER EC 3.4.11.18 T75596 SEQUENCE MAGVEEVAASGSHLNGDLDPDDREEGAASTAEEAAKKKRRKKKKSKGPSAAGEQEPDKESGASVDEVARQLERSALEDKERDEDDEDGDGDGDGATGKKKKKKKKKRGPKVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY T75596 DRUGINFO D0E4VQ Beloranib Phase 3 T75596 DRUGINFO D0N0KW D-Methionine Phase 3 T75596 DRUGINFO DA3GL5 ZGN-1061 Phase 2 T75596 DRUGINFO D02SHI M8891 Phase 1 T75596 DRUGINFO D07DWC SDX-7320 Phase 1 T75596 DRUGINFO D0KR1N PPI-2458 Phase 1 T75596 DRUGINFO D09OAQ TNP-470 Discontinued in Phase 2 T75596 DRUGINFO D00MUJ 2-(phenylsulfonamido)-5-propylbenzoic acid Investigative T75596 DRUGINFO D02ADV 5-p-Tolyl-1H-[1,2,3]triazole Investigative T75596 DRUGINFO D02APY A-357300 Investigative T75596 DRUGINFO D04MIY 5-chloro-2-(pyridin-2-yl)-1H-benzo[d]imidazole Investigative T75596 DRUGINFO D04SLM Ovalicin Investigative T75596 DRUGINFO D05DCQ 3-anilino-5-benzylthio-1,2,4-triazole Investigative T75596 DRUGINFO D05YKW 3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium Investigative T75596 DRUGINFO D07CWJ 5-methyl-2-(phenylsulfonamido)benzoic acid Investigative T75596 DRUGINFO D07PXR 5-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazole Investigative T75596 DRUGINFO D08AXA 2-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine Investigative T75596 DRUGINFO D08CFL Fumagillin Investigative T75596 DRUGINFO D09KTF 5-butyl-2-(phenylsulfonamido)benzoic acid Investigative T75596 DRUGINFO D0B1LR 2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine Investigative T75596 DRUGINFO D0C0UB 5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole Investigative T75596 DRUGINFO D0FO2B OXYQUINOLINE Investigative T75596 DRUGINFO D0I6RL 2-(phenylsulfonamido)-1-naphthoic acid Investigative T75596 DRUGINFO D0K5UM 3,5-dimethyl-2-(phenylsulfonamido)benzoic acid Investigative T75596 DRUGINFO D0K7PS 5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid Investigative T75596 DRUGINFO D0L4YF 2-(pyridin-2-yl)-1H-benzo[d]imidazole Investigative T75596 DRUGINFO D0L6ZY 2-(pyridin-2-yl)-1H-benzo[d]imidazol-5-amine Investigative T75596 DRUGINFO D0MT5K XMT-1191 Investigative T75596 DRUGINFO D0R4KE 2-(4-fluorophenylsulfonamido)-1-naphthoic acid Investigative T75596 DRUGINFO D0S5GM 5-ethyl-2-(phenylsulfonamido)benzoic acid Investigative T75596 DRUGINFO D0Q7LD 2-Methyl-2-Propanol Investigative T58449 TARGETID T58449 T58449 FORMERID TTDC00094 T58449 UNIPROID CDK7_HUMAN T58449 TARGNAME Cyclin-dependent kinase 7 (CDK7) T58449 GENENAME CDK7 T58449 TARGTYPE Clinical trial T58449 SYNONYMS TFIIH basal transcription factor complex kinase subunit; Serine/threonine-protein kinase 1; P39 Mo15; MO15; Cell division protein kinase 7; CDKN7; CDK-activating kinase 1; CDK-activating kinase; CAK1; CAK; 39 kDa protein kinase T58449 FUNCTION Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition. Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. T58449 PDBSTRUC 2HIC; 1UA2; 1PA8; 1LG3 T58449 BIOCLASS Kinase T58449 ECNUMBER EC 2.7.11.22 T58449 SEQUENCE MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTNQIVAIKKIKLGHRSEAKDGINRTALREIKLLQELSHPNIIGLLDAFGHKSNISLVFDFMETDLEVIIKDNSLVLTPSHIKAYMLMTLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRAPELLFGARMYGVGVDMWAVGCILAELLLRVPFLPGDSDLDQLTRIFETLGTPTEEQWPDMCSLPDYVTFKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQALKMKYFSNRPGPTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF T58449 DRUGINFO D05ADP R-roscovitine Phase 2 T58449 DRUGINFO DV74BT Samuraciclib Phase 1/2 T58449 DRUGINFO D09OHR SY-1365 Phase 1 T58449 DRUGINFO D0VIG4 LY3405105 Phase 1 T58449 DRUGINFO DJ9WC4 SY-5609 Phase 1 T58449 DRUGINFO D0S5RC SNS-032 Phase 1 T58449 DRUGINFO D5VMP4 BTX-A51 Phase 1 T58449 DRUGINFO D0G2SI Pyrazolo-triazine derivative 1 Patented T58449 DRUGINFO D0NA4O PMID26161698-Compound-34 Patented T58449 DRUGINFO D0T6CM Pyrazolo-triazine derivative 2 Patented T58449 DRUGINFO D07DUX Roscovitine derivative 1 Patented T58449 DRUGINFO D0NY7M Tricyclic benzimidazole derivative 1 Patented T58449 DRUGINFO D0M5DX Oxazolyl methylthiothiazole derivative 1 Patented T58449 DRUGINFO D04FHB R547 Discontinued in Phase 1 T58449 DRUGINFO D00VBT ZK 304709 Discontinued in Phase 1 T58449 DRUGINFO D0LO5B THZ1 Investigative T58449 DRUGINFO D06WUE 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide Investigative T58449 DRUGINFO D0J4ON RGB-286147 Investigative T58449 DRUGINFO D02QAZ PF-228 Investigative T58449 DRUGINFO D04WFN NU6140 Investigative T58449 DRUGINFO D05BHG Phosphonothreonine Investigative T28484 TARGETID T28484 T28484 FORMERID TTDC00143 T28484 UNIPROID KIF11_HUMAN T28484 TARGNAME Kinesin-like protein KIF11 (KIF11) T28484 GENENAME KIF11 T28484 TARGTYPE Clinical trial T28484 SYNONYMS Thyroid receptor interacting protein 5; TRIP5; Kinesin-related motor protein Eg5; Kinesin-like spindle protein HKSP; Kinesin-like protein 1; KIF11; Eg5 T28484 FUNCTION Motor protein required for establishing a bipolar spindle. Blocking of KIF11 prevents centrosome migration and arrest cells in mitosis with monoastral microtubule arrays. T28484 PDBSTRUC 6G6Z; 6G6Y; 5ZO9; 5ZO8; 5ZO7 T28484 BIOCLASS Kinesin-like protein family T28484 SEQUENCE MASQPNSSAKKKEEKGKNIQVVVRCRPFNLAERKASAHSIVECDPVRKEVSVRTGGLADKSSRKTYTFDMVFGASTKQIDVYRSVVCPILDEVIMGYNCTIFAYGQTGTGKTFTMEGERSPNEEYTWEEDPLAGIIPRTLHQIFEKLTDNGTEFSVKVSLLEIYNEELFDLLNPSSDVSERLQMFDDPRNKRGVIIKGLEEITVHNKDEVYQILEKGAAKRTTAATLMNAYSSRSHSVFSVTIHMKETTIDGEELVKIGKLNLVDLAGSENIGRSGAVDKRAREAGNINQSLLTLGRVITALVERTPHVPYRESKLTRILQDSLGGRTRTSIIATISPASLNLEETLSTLEYAHRAKNILNKPEVNQKLTKKALIKEYTEEIERLKRDLAAAREKNGVYISEENFRVMSGKLTVQEEQIVELIEKIGAVEEELNRVTELFMDNKNELDQCKSDLQNKTQELETTQKHLQETKLQLVKEEYITSALESTEEKLHDAASKLLNTVEETTKDVSGLHSKLDRKKAVDQHNAEAQDIFGKNLNSLFNNMEELIKDGSSKQKAMLEVHKTLFGNLLSSSVSALDTITTVALGSLTSIPENVSTHVSQIFNMILKEQSLAAESKTVLQELINVLKTDLLSSLEMILSPTVVSILKINSQLKHIFKTSLTVADKIEDQKKELDGFLSILCNNLHELQENTICSLVESQKQCGNLTEDLKTIKQTHSQELCKLMNLWTERFCALEEKCENIQKPLSSVQENIQQKSKDIVNKMTFHSQKFCADSDGFSQELRNFNQEGTKLVEESVKHSDKLNGNLEKISQETEQRCESLNTRTVYFSEQWVSSLNEREQELHNLLEVVSQCCEASSSDITEKSDGRKAAHEKQHNIFLDQMTIDEDKLIAQNLELNETIKIGLTKLNCFLEQDLKLDIPTGTTPQRKSYLYPSTLVRTEPREHLLDQLKRKQPELLMMLNCSENNKEETIPDVDVEEAVLGQYTEEPLSQEPSVDAGVDCSSIGGVPFFQHKKSHGKDKENRGINTLERSKVEETTEHLVTKSRLPLRAQINL T28484 DRUGINFO D02AAO AZD-4877 Phase 2 T28484 DRUGINFO D04VWJ ARRY-520 Phase 2 T28484 DRUGINFO D0PW4N Ispinesib Phase 2 T28484 DRUGINFO D0U4EU SB-743921 Phase 2 T28484 DRUGINFO D0W9SL LY2523355 Phase 2 T28484 DRUGINFO D07BKR ARQ 621 Phase 1 T28484 DRUGINFO D08OPX 4SC-205 Phase 1 T28484 DRUGINFO D0V2YJ MK-0731 Phase 1 T28484 DRUGINFO D0ZK2G Monastrol Investigative T70490 TARGETID T70490 T70490 FORMERID TTDR00571 T70490 UNIPROID CATC_HUMAN T70490 TARGNAME Dipeptidyl peptidase I (CTSC) T70490 GENENAME CTSC T70490 TARGTYPE Clinical trial T70490 SYNONYMS Dipeptidyl transferase; Dipeptidyl peptidase 1; DPPI; DPP-I; Cysteine protease dipeptidyl peptidase I; Cathepsin J; Cathepsin C; CPPI T70490 FUNCTION Has dipeptidylpeptidase activity. Active against a broad range of dipeptide substrates composed of both polar and hydrophobic amino acids. Proline cannot occupy the P1 position and arginine cannot occupy the P2 position of the substrate. Can act as both an exopeptidase and endopeptidase. Activates serine proteases such as elastase, cathepsin G and granzymes A and B. Can also activate neuraminidase and factor XIII. Thiol protease. T70490 PDBSTRUC 4OEM; 4OEL; 4CDF; 4CDE; 4CDD T70490 BIOCLASS Peptidase T70490 ECNUMBER EC 3.4.14.1 T70490 SEQUENCE MGAGPSLLLAALLLLLSGDGAVRCDTPANCTYLDLLGTWVFQVGSSGSQRDVNCSVMGPQEKKVVVYLQKLDTAYDDLGNSGHFTIIYNQGFEIVLNDYKWFAFFKYKEEGSKVTTYCNETMTGWVHDVLGRNWACFTGKKVGTASENVYVNIAHLKNSQEKYSNRLYKYDHNFVKAINAIQKSWTATTYMEYETLTLGDMIRRSGGHSRKIPRPKPAPLTAEIQQKILHLPTSWDWRNVHGINFVSPVRNQASCGSCYSFASMGMLEARIRILTNNSQTPILSPQEVVSCSQYAQGCEGGFPYLIAGKYAQDFGLVEEACFPYTGTDSPCKMKEDCFRYYSSEYHYVGGFYGGCNEALMKLELVHHGPMAVAFEVYDDFLHYKKGIYHHTGLRDPFNPFELTNHAVLLVGYGTDSASGMDYWIVKNSWGTGWGENGYFRIRRGTDECAIESIAVAATPIPKL T70490 DRUGINFO D5H9TE BI 1291583 Phase 2 T70490 DRUGINFO D0V4XG GSK2793660 Phase 1 T70490 DRUGINFO D0IV5D PMID3941405C3d Investigative T70490 DRUGINFO D0U4TA (S)-2-amino-N-(1-cyano-2-phenylethyl)acetamide Investigative T70490 DRUGINFO D0L9VP GNF-PF-5434 Investigative T12646 TARGETID T12646 T12646 FORMERID TTDI02187 T12646 UNIPROID TERA_HUMAN T12646 TARGNAME Valosin-containing protein p97 (VCP) T12646 GENENAME VCP T12646 TARGTYPE Clinical trial T12646 SYNONYMS Valosin-containing protein; Transitional endoplasmic reticulum ATPase; TER ATPase; 15S Mg(2+)-ATPase p97 subunit T12646 FUNCTION Involved in the formation of the transitional endoplasmic reticulum (tER). The transfer of membranes from the endoplasmic reticulum to the Golgi apparatus occurs via 50-70 nm transition vesicles which derive from part-rough, part-smooth transitional elements of the endoplasmic reticulum (tER). Vesicle budding from the tER is an ATP-dependent process. The ternary complex containing UFD1, VCP and NPLOC4 binds ubiquitinated proteins and is necessary for the export of misfolded proteins from the ER to the cytoplasm, where they are degraded by the proteasome. The NPLOC4-UFD1-VCP complex regulates spindle disassembly at the end of mitosis and is necessary for the formation of a closed nuclear envelope. Regulates E3 ubiquitin-protein ligase activity of RNF19A. Component of the VCP/p97-AMFR/gp78 complex that participates in the final step of the sterol-mediated ubiquitination and endoplasmic reticulum-associated degradation (ERAD) of HMGCR. Involved in endoplasmic reticulum stress-induced pre-emptive quality control, a mechanism that selectively attenuates the translocation of newly synthesized proteins into the endoplasmic reticulum and reroutes them to the cytosol for proteasomal degradation. Plays a role in the regulation of stress granules (SGs) clearance process upon arsenite-induced response. Also involved in DNA damage response: recruited to double-strand breaks (DSBs) sites in a RNF8- and RNF168-dependent manner and promotes the recruitment of TP53BP1 at DNA damage sites. Recruited to stalled replication forks by SPRTN: may act by mediating extraction of DNA polymerase eta (POLH) to prevent excessive translesion DNA synthesis and limit the incidence of mutations induced by DNA damage. Required for cytoplasmic retrotranslocation of stressed/damaged mitochondrial outer-membrane proteins and their subsequent proteasomal degradation. Essential for the maturation of ubiquitin-containing autophagosomes and the clearance of ubiquitinated protein by autophagy. Acts as a negative regulator of type I interferon production by interacting with DDX58/RIG-I: interaction takes place when DDX58/RIG-I is ubiquitinated via 'Lys-63'-linked ubiquitin on its CARD domains, leading to recruit RNF125 and promote ubiquitination and degradation of DDX58/RIG-I. May play a role in the ubiquitin-dependent sorting of membrane proteins to lysosomes where they undergo degradation. May more particularly play a role in caveolins sorting in cells. By controlling the steady-state expression of the IGF1R receptor, indirectly regulates the insulin-like growth factor receptor signaling pathway. Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis. T12646 PDBSTRUC 6MCK; 6G30; 6G2Z; 6G2Y; 6G2X T12646 BIOCLASS Acid anhydride hydrolase T12646 ECNUMBER EC 3.6.4.6 T12646 SEQUENCE MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG T12646 DRUGINFO D08OOJ CB-5083 Phase 1 T12646 DRUGINFO DFC0V4 CB-5339 Phase 1 T15610 TARGETID T15610 T15610 FORMERID TTDC00249 T15610 UNIPROID PSA_HUMAN T15610 TARGNAME Puromycin-sensitive aminopeptidase (NPEPPS) T15610 GENENAME NPEPPS T15610 TARGTYPE Clinical trial T15610 SYNONYMS NPEPPS T15610 FUNCTION Aminopeptidase with broad substrate specificity for several peptides. Involved in proteolytic events essential for cell growth and viability. May act as regulator of neuropeptide activity. Plays a role in the antigen-processing pathway for MHC class I molecules. Involved in the N-terminal trimming of cytotoxic T-cell epitope precursors. Digests the poly-Q peptides found in many cellular proteins. Digests tau from normal brain moreefficiently than tau from Alzheimer disease brain. T15610 BIOCLASS Peptidase T15610 ECNUMBER EC 3.4.11.14 T15610 SEQUENCE MWLAAAAPSLARRLLFLGPPPPPLLLLVFSRSSRRRLHSLGLAAMPEKRPFERLPADVSPINYSLCLKPDLLDFTFEGKLEAAAQVRQATNQIVMNCADIDIITASYAPEGDEEIHATGFNYQNEDEKVTLSFPSTLQTGTGTLKIDFVGELNDKMKGFYRSKYTTPSGEVRYAAVTQFEATDARRAFPCWDEPAIKATFDISLVVPKDRVALSNMNVIDRKPYPDDENLVEVKFARTPVMSTYLVAFVVGEYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNVPYPLPKIDLIAIADFAAGAMENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGFASWIEYLCVDHCFPEYDIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDKDFKKGMNMYLTKFQQKNAATEDLWESLENASGKPIAAVMNTWTKQMGFPLIYVEAEQVEDDRLLRLSQKKFCAGGSYVGEDCPQWMVPITISTSEDPNQAKLKILMDKPEMNVVLKNVKPDQWVKLNLGTVGFYRTQYSSAMLESLLPGIRDLSLPPVDRLGLQNDLFSLARAGIISTVEVLKVMEAFVNEPNYTVWSDLSCNLGILSTLLSHTDFYEEIQEFVKDVFSPIGERLGWDPKPGEGHLDALLRGLVLGKLGKAGHKATLEEARRRFKDHVEGKQILSADLRSPVYLTVLKHGDGTTLDIMLKLHKQADMQEEKNRIERVLGATLLPDLIQKVLTFALSEEVRPQDTVSVIGGVAGGSKHGRKAAWKFIKDNWEELYNRYQGGFLISRLIKLSVEGFAVDKMAGEVKAFFESHPAPSAERTIQQCCENILLNAAWLKRDAESIHQYLLQRKASPPTV T15610 DRUGINFO D0F2JS CHR-2797 Phase 2 T15610 DRUGINFO D0J0IY ANTAQ Investigative T14143 TARGETID T14143 T14143 FORMERID TTDC00272 T14143 UNIPROID TGFB2_HUMAN T14143 TARGNAME Transforming growth factor beta 2 (TGFB2) T14143 GENENAME TGFB2 T14143 TARGTYPE Clinical trial T14143 SYNONYMS Transforming growth factor beta-2 proprotein; TGF-beta 2; Polyergin; Glioblastoma-derived T-cell suppressor factor; G-TSF; Cetermin; BSC-1 cell growth inhibitor T14143 FUNCTION Transforming growth factor beta-2 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. T14143 PDBSTRUC 5TY4; 5TX4; 4KXZ; 2TGI; 1TFG T14143 BIOCLASS Growth factor T14143 SEQUENCE MHYCVLSAFLILHLVTVALSLSTCSTLDMDQFMRKRIEAIRGQILSKLKLTSPPEDYPEPEEVPPEVISIYNSTRDLLQEKASRRAAACERERSDEEYYAKEVYKIDMPPFFPSENAIPPTFYRPYFRIVRFDVSAMEKNASNLVKAEFRVFRLQNPKARVPEQRIELYQILKSKDLTSPTQRYIDSKVVKTRAEGEWLSFDVTDAVHEWLHHKDRNLGFKISLHCPCCTFVPSNNYIIPNKSEELEARFAGIDGTSTYTSGDQKTIKSTRKKNSGKTPHLLLMLLPSYRLESQQTNRRKKRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQHSRVLSLYNTINPEASASPCCVSQDLEPLTILYYIGKTPKIEQLSNMIVKSCKCS T14143 DRUGINFO D08KSU AP12009 Phase 3 T14143 DRUGINFO D0PR9I Lerdelimumab Investigative T81735 TARGETID T81735 T81735 FORMERID TTDR01142 T81735 UNIPROID PRKDC_HUMAN T81735 TARGNAME DNA-dependent protein kinase catalytic (PRKDC) T81735 GENENAME PRKDC T81735 TARGTYPE Clinical trial T81735 SYNONYMS p460; HYRC1; HYRC; DNPK1; DNA-dependent protein kinase catalytic subunit; DNA-PKcs; DNA-PK catalytic subunit T81735 FUNCTION Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its catalytic properties. Promotes processing of hairpin DNA structures in V(D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step. Required to protect and align broken ends of DNA. May also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion. Also involved in modulation of transcription. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby regulating DNA damage response mechanism. Phosphorylates DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, FH, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2. Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA. Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D. Contributes to the determination of the circadian period length by antagonizing phosphorylation of CRY1 'Ser-588' and increasing CRY1 protein stability, most likely through an indirect mechanism (By similarity). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway. T81735 PDBSTRUC 5Y3R; 5W1R; 5LUQ T81735 BIOCLASS Kinase T81735 ECNUMBER EC 2.7.11.1 T81735 SEQUENCE MAGSGAGVRCSLLRLQETLSAADRCGAALAGHQLIRGLGQECVLSSSPAVLALQTSLVFSRDFGLLVFVRKSLNSIEFRECREEILKFLCIFLEKMGQKIAPYSVEIKNTCTSVYTKDRAAKCKIPALDLLIKLLQTFRSSRLMDEFKIGELFSKFYGELALKKKIPDTVLEKVYELLGLLGEVHPSEMINNAENLFRAFLGELKTQMTSAVREPKLPVLAGCLKGLSSLLCNFTKSMEEDPQTSREIFNFVLKAIRPQIDLKRYAVPSAGLRLFALHASQFSTCLLDNYVSLFEVLLKWCAHTNVELKKAALSALESFLKQVSNMVAKNAEMHKNKLQYFMEQFYGIIRNVDSNNKELSIAIRGYGLFAGPCKVINAKDVDFMYVELIQRCKQMFLTQTDTGDDRVYQMPSFLQSVASVLLYLDTVPEVYTPVLEHLVVMQIDSFPQYSPKMQLVCCRAIVKVFLALAAKGPVLRNCISTVVHQGLIRICSKPVVLPKGPESESEDHRASGEVRTGKWKVPTYKDYVDLFRHLLSSDQMMDSILADEAFFSVNSSSESLNHLLYDEFVKSVLKIVEKLDLTLEIQTVGEQENGDEAPGVWMIPTSDPAANLHPAKPKDFSAFINLVEFCREILPEKQAEFFEPWVYSFSYELILQSTRLPLISGFYKLLSITVRNAKKIKYFEGVSPKSLKHSPEDPEKYSCFALFVKFGKEVAVKMKQYKDELLASCLTFLLSLPHNIIELDVRAYVPALQMAFKLGLSYTPLAEVGLNALEEWSIYIDRHVMQPYYKDILPCLDGYLKTSALSDETKNNWEVSALSRAAQKGFNKVVLKHLKKTKNLSSNEAISLEEIRIRVVQMLGSLGGQINKNLLTVTSSDEMMKSYVAWDREKRLSFAVPFREMKPVIFLDVFLPRVTELALTASDRQTKVAACELLHSMVMFMLGKATQMPEGGQGAPPMYQLYKRTFPVLLRLACDVDQVTRQLYEPLVMQLIHWFTNNKKFESQDTVALLEAILDGIVDPVDSTLRDFCGRCIREFLKWSIKQITPQQQEKSPVNTKSLFKRLYSLALHPNAFKRLGASLAFNNIYREFREEESLVEQFVFEALVIYMESLALAHADEKSLGTIQQCCDAIDHLCRIIEKKHVSLNKAKKRRLPRGFPPSASLCLLDLVKWLLAHCGRPQTECRHKSIELFYKFVPLLPGNRSPNLWLKDVLKEEGVSFLINTFEGGGCGQPSGILAQPTLLYLRGPFSLQATLCWLDLLLAALECYNTFIGERTVGALQVLGTEAQSSLLKAVAFFLESIAMHDIIAAEKCFGTGAAGNRTSPQEGERYNYSKCTVVVRIMEFTTTLLNTSPEGWKLLKKDLCNTHLMRVLVQTLCEPASIGFNIGDVQVMAHLPDVCVNLMKALKMSPYKDILETHLREKITAQSIEELCAVNLYGPDAQVDRSRLAAVVSACKQLHRAGLLHNILPSQSTDLHHSVGTELLSLVYKGIAPGDERQCLPSLDLSCKQLASGLLELAFAFGGLCERLVSLLLNPAVLSTASLGSSQGSVIHFSHGEYFYSLFSETINTELLKNLDLAVLELMQSSVDNTKMVSAVLNGMLDQSFRERANQKHQGLKLATTILQHWKKCDSWWAKDSPLETKMAVLALLAKILQIDSSVSFNTSHGSFPEVFTTYISLLADTKLDLHLKGQAVTLLPFFTSLTGGSLEELRRVLEQLIVAHFPMQSREFPPGTPRFNNYVDCMKKFLDALELSQSPMLLELMTEVLCREQQHVMEELFQSSFRRIARRGSCVTQVGLLESVYEMFRKDDPRLSFTRQSFVDRSLLTLLWHCSLDALREFFSTIVVDAIDVLKSRFTKLNESTFDTQITKKMGYYKILDVMYSRLPKDDVHAKESKINQVFHGSCITEGNELTKTLIKLCYDAFTENMAGENQLLERRRLYHCAAYNCAISVICCVFNELKFYQGFLFSEKPEKNLLIFENLIDLKRRYNFPVEVEVPMERKKKYIEIRKEAREAANGDSDGPSYMSSLSYLADSTLSEEMSQFDFSTGVQSYSYSSQDPRPATGRFRRREQRDPTVHDDVLELEMDELNRHECMAPLTALVKHMHRSLGPPQGEEDSVPRDLPSWMKFLHGKLGNPIVPLNIRLFLAKLVINTEEVFRPYAKHWLSPLLQLAASENNGGEGIHYMVVEIVATILSWTGLATPTGVPKDEVLANRLLNFLMKHVFHPKRAVFRHNLEIIKTLVECWKDCLSIPYRLIFEKFSGKDPNSKDNSVGIQLLGIVMANDLPPYDPQCGIQSSEYFQALVNNMSFVRYKEVYAAAAEVLGLILRYVMERKNILEESLCELVAKQLKQHQNTMEDKFIVCLNKVTKSFPPLADRFMNAVFFLLPKFHGVLKTLCLEVVLCRVEGMTELYFQLKSKDFVQVMRHRDDERQKVCLDIIYKMMPKLKPVELRELLNPVVEFVSHPSTTCREQMYNILMWIHDNYRDPESETDNDSQEIFKLAKDVLIQGLIDENPGLQLIIRNFWSHETRLPSNTLDRLLALNSLYSPKIEVHFLSLATNFLLEMTSMSPDYPNPMFEHPLSECEFQEYTIDSDWRFRSTVLTPMFVETQASQGTLQTRTQEGSLSARWPVAGQIRATQQQHDFTLTQTADGRSSFDWLTGSSTDPLVDHTSPSSDSLLFAHKRSERLQRAPLKSVGPDFGKKRLGLPGDEVDNKVKGAAGRTDLLRLRRRFMRDQEKLSLMYARKGVAEQKREKEIKSELKMKQDAQVVLYRSYRHGDLPDIQIKHSSLITPLQAVAQRDPIIAKQLFSSLFSGILKEMDKFKTLSEKNNITQKLLQDFNRFLNTTFSFFPPFVSCIQDISCQHAALLSLDPAAVSAGCLASLQQPVGIRLLEEALLRLLPAELPAKRVRGKARLPPDVLRWVELAKLYRSIGEYDVLRGIFTSEIGTKQITQSALLAEARSDYSEAAKQYDEALNKQDWVDGEPTEAEKDFWELASLDCYNHLAEWKSLEYCSTASIDSENPPDLNKIWSEPFYQETYLPYMIRSKLKLLLQGEADQSLLTFIDKAMHGELQKAILELHYSQELSLLYLLQDDVDRAKYYIQNGIQSFMQNYSSIDVLLHQSRLTKLQSVQALTEIQEFISFISKQGNLSSQVPLKRLLNTWTNRYPDAKMDPMNIWDDIITNRCFFLSKIEEKLTPLPEDNSMNVDQDGDPSDRMEVQEQEEDISSLIRSCKFSMKMKMIDSARKQNNFSLAMKLLKELHKESKTRDDWLVSWVQSYCRLSHCRSRSQGCSEQVLTVLKTVSLLDENNVSSYLSKNILAFRDQNILLGTTYRIIANALSSEPACLAEIEEDKARRILELSGSSSEDSEKVIAGLYQRAFQHLSEAVQAAEEEAQPPSWSCGPAAGVIDAYMTLADFCDQQLRKEEENASVIDSAELQAYPALVVEKMLKALKLNSNEARLKFPRLLQIIERYPEETLSLMTKEISSVPCWQFISWISHMVALLDKDQAVAVQHSVEEITDNYPQAIVYPFIISSESYSFKDTSTGHKNKEFVARIKSKLDQGGVIQDFINALDQLSNPELLFKDWSNDVRAELAKTPVNKKNIEKMYERMYAALGDPKAPGLGAFRRKFIQTFGKEFDKHFGKGGSKLLRMKLSDFNDITNMLLLKMNKDSKPPGNLKECSPWMSDFKVEFLRNELEIPGQYDGRGKPLPEYHVRIAGFDERVTVMASLRRPKRIIIRGHDEREHPFLVKGGEDLRQDQRVEQLFQVMNGILAQDSACSQRALQLRTYSVVPMTSRLGLIEWLENTVTLKDLLLNTMSQEEKAAYLSDPRAPPCEYKDWLTKMSGKHDVGAYMLMYKGANRTETVTSFRKRESKVPADLLKRAFVRMSTSPEAFLALRSHFASSHALICISHWILGIGDRHLNNFMVAMETGGVIGIDFGHAFGSATQFLPVPELMPFRLTRQFINLMLPMKETGLMYSIMVHALRAFRSDPGLLTNTMDVFVKEPSFDWKNFEQKMLKKGGSWIQEINVAEKNWYPRQKICYAKRKLAGANPAVITCDELLLGHEKAPAFRDYVAVARGSKDHNIRAQEPESGLSEETQVKCLMDQATDPNILGRTWEGWEPWM T81735 DRUGINFO D0H3UR M3814 Phase 1/2 T81735 DRUGINFO DPNT63 AZD7648 Phase 1/2 T81735 DRUGINFO D02IKF M9831 Phase 1 T81735 DRUGINFO D00HXZ 2-morpholino-6-(thianthren-1-yl)-4H-chromen-4-one Investigative T81735 DRUGINFO D00IRL 2-(4-methoxyphenyl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D00MCG 2-(1H-indol-5-yl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D00MXW 8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D00TUH 8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D01MXN 8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D01SXB 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzaldehyde Investigative T81735 DRUGINFO D01ZMP 2-morpholino-6-(thiophen-2-yl)-4H-pyran-4-one Investigative T81735 DRUGINFO D02DDM 2-(2-methoxyphenyl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D02IDN 2-(4-Amino-phenyl)-benzo[h]chromen-4-one Investigative T81735 DRUGINFO D02MPG 2-(4-chlorophenyl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D02PBS 7-benzoyloxy-2-(morpholin-4-yl)-chromen-4-one Investigative T81735 DRUGINFO D02SMG 2-(furan-2-yl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D02TCZ 2-Thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one Investigative T81735 DRUGINFO D03DGP 6-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D03DJC 2-(2-aminophenyl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D03FTE 2-dibenzofuran-4-yl-6-morpholin-4-yl-pyran-4-one Investigative T81735 DRUGINFO D03IQX 2-(2-Fluoro-phenyl)-benzo[h]chromen-4-one Investigative T81735 DRUGINFO D03MDA 2-morpholin-4-yl-6-phenyl-4H-thiopyran-4-one Investigative T81735 DRUGINFO D03QQH AMA37 Investigative T81735 DRUGINFO D03TQO 6-(3-hydroxyphenyl)-2-morpholino-4H-chromen-4-one Investigative T81735 DRUGINFO D04DQF 2-(3-acetylphenyl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D04ECT 4-Thiomorpholin-4-yl-benzo[g]chromen-2-one Investigative T81735 DRUGINFO D04JGZ 2-morpholin-4-yl-8-styrylchromen-4-one Investigative T81735 DRUGINFO D04NVK ShRNA molecule silencing DNAPK radiosensitizer Investigative T81735 DRUGINFO D04RAW 2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one Investigative T81735 DRUGINFO D04SCD 6-Chloro-4-morpholin-4-yl-chromen-2-one Investigative T81735 DRUGINFO D04XFN 7-phenyloxyethoxy-2-morpholin-4-yl-chromen-4-one Investigative T81735 DRUGINFO D05SBJ 1-Morpholin-4-yl-benzo[f]chromen-3-one Investigative T81735 DRUGINFO D05SGV 3-morpholino-1H-benzo[f]chromen-1-one Investigative T81735 DRUGINFO D05USL KU-55933 Investigative T81735 DRUGINFO D06BDY 6-Methoxy-4-morpholin-4-yl-chromen-2-one Investigative T81735 DRUGINFO D06DAY 8-furan-2-yl-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D06GNE IC86621 Investigative T81735 DRUGINFO D06TGR 8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D06WCT 7-phenylethoxy-2-morpholin-4-yl-chromen-4-one Investigative T81735 DRUGINFO D07AXO 8-Methoxy-4-morpholin-4-yl-chromen-2-one Investigative T81735 DRUGINFO D07NSR 4-Morpholin-4-yl-benzo[g]chromen-2-one Investigative T81735 DRUGINFO D08BRZ 2-(4-fluorophenyl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D08WQW 2-biphenyl-4-yl-6-morpholin-4-yl-pyran-4-one Investigative T81735 DRUGINFO D09TJK 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile Investigative T81735 DRUGINFO D09YAL 6-tert-Butyl-2-morpholin-4-yl-4H-thiopyran-4-one Investigative T81735 DRUGINFO D0AG8B 2-thiomorpholino-4H-benzo[h]chromen-4-one Investigative T81735 DRUGINFO D0B0QS 2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one Investigative T81735 DRUGINFO D0B4CJ 2-Morpholin-4-yl-6-phenyl-chromen-4-one Investigative T81735 DRUGINFO D0B9EZ 2-(piperidin-1-yl)-4H-benzo[h]chromen-4-one Investigative T81735 DRUGINFO D0C3SJ 6-isopropyl-2-morpholin-4-yl-4H-thiopyran-4-one Investigative T81735 DRUGINFO D0C8MK 2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one Investigative T81735 DRUGINFO D0D9RN 7-hydroxy-2-(morpholin-4-yl)chromen-4-one Investigative T81735 DRUGINFO D0F5BD 2-morpholinobenzo[h]quinolin-4(1H)-one Investigative T81735 DRUGINFO D0F6ZC 8-Methyl-2-morpholin-4-yl-chromen-4-one Investigative T81735 DRUGINFO D0F7ZK 2-morpholino-6-styryl-4H-pyran-4-one Investigative T81735 DRUGINFO D0G4RG 4-Morpholin-4-yl-benzo[h]chromen-2-one Investigative T81735 DRUGINFO D0H2BL 7-benzyloxy-2-(morpholin-4-yl)-chromen-4-one Investigative T81735 DRUGINFO D0H9DB 8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D0I1LR 2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one Investigative T81735 DRUGINFO D0I3IO 6-(4-fluorostyryl)-2-morpholino-4H-chromen-4-one Investigative T81735 DRUGINFO D0J7BH 4-Morpholin-4-yl-chromen-2-one Investigative T81735 DRUGINFO D0JB6H 6-Methyl-4-morpholin-4-yl-chromen-2-one Investigative T81735 DRUGINFO D0JH9J 6-biphenyl-2-yl-2-morpholin-4-yl-chromen-4-one Investigative T81735 DRUGINFO D0K3VK 4-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile Investigative T81735 DRUGINFO D0K5VE 6-(4-chlorophenyl)-4-morpholino-2H-pyran-2-one Investigative T81735 DRUGINFO D0K7LZ 8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D0KG0Z 2-(3-Fluoro-phenyl)-benzo[h]chromen-4-one Investigative T81735 DRUGINFO D0KH8S 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzoic acid Investigative T81735 DRUGINFO D0L3TX 4-Piperidin-1-yl-chromen-2-one Investigative T81735 DRUGINFO D0LC5C 6-(4-chlorophenyl)-2-morpholin-4-ylpyridin-4-ol Investigative T81735 DRUGINFO D0M3RY 4-morpholino-6-phenyl-2H-pyran-2-one Investigative T81735 DRUGINFO D0N2LW 8-Phenyl-2-thiomorpholin-4-yl-chromen-4-one Investigative T81735 DRUGINFO D0N2XO 2-(3-methoxyphenyl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D0O3VF 2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one Investigative T81735 DRUGINFO D0O4KC 7-Methoxy-4-morpholin-4-yl-chromen-2-one Investigative T81735 DRUGINFO D0O5BC 2-(benzofuran-2-yl)-6-morpholino-4H-pyran-4-one Investigative T81735 DRUGINFO D0O9OB 7-propoxy-2-(morpholin-4-yl)-chromen-4-one Investigative T81735 DRUGINFO D0P4MU 7-ethyloxyethoxy-2-morpholin-4-yl-chromen-4-one Investigative T81735 DRUGINFO D0PO9X 2-morpholino-6-(naphthalen-1-yl)-4H-pyran-4-one Investigative T81735 DRUGINFO D0Q4GJ 2-Pyridin-3-yl-benzo[h]chromen-4-one Investigative T81735 DRUGINFO D0Q5FJ 8-Phenyl-2-piperidin-1-yl-chromen-4-one Investigative T81735 DRUGINFO D0QB9L 2-morpholino-6-(naphthalen-2-yl)-4H-pyran-4-one Investigative T81735 DRUGINFO D0R1BG 8-Methoxy-2-morpholin-4-yl-chromen-4-one Investigative T81735 DRUGINFO D0R7HM 2-morpholino-6-phenyl-4H-pyran-4-one Investigative T81735 DRUGINFO D0S5SG 2-morpholino-6-(thiophen-3-yl)-4H-pyran-4-one Investigative T81735 DRUGINFO D0S7NM 8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D0U4JL 6-(4-hydroxyphenyl)-2-morpholino-4H-chromen-4-one Investigative T81735 DRUGINFO D0U7WU 2-morpholino-4H-benzo[g]chromen-4-one Investigative T81735 DRUGINFO D0U9ZW 8-Methyl-4-morpholin-4-yl-chromen-2-one Investigative T81735 DRUGINFO D0V0SD 2-Morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one Investigative T81735 DRUGINFO D0V3XZ 8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one Investigative T81735 DRUGINFO D0V8VY 2-Pyrrolidin-1-yl-benzo[h]chromen-4-one Investigative T81735 DRUGINFO D0W3QB 2-Morpholin-4-yl-benzo[h]chromene-4-thione Investigative T81735 DRUGINFO D0XL6P 2-morpholino-6-(naphthalen-1-yl)-4H-chromen-4-one Investigative T81735 DRUGINFO D0Y3OO NU-7432 Investigative T81735 DRUGINFO D0Y7WU 6-(4-methoxyphenyl)-4-morpholino-2H-pyran-2-one Investigative T81735 DRUGINFO D0Z3CC 2-morpholino-6-(quinolin-8-yl)-4H-pyran-4-one Investigative T81735 DRUGINFO D0ZQ8Z 7-Methoxy-2-morpholin-4-yl-chromen-4-one Investigative T81735 DRUGINFO D0I7GE ALPHA-NAPHTHOFLAVONE Investigative T81735 DRUGINFO D0T0BY 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one Investigative T81735 DRUGINFO D0X7TB 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one Investigative T81735 DRUGINFO D00HSJ PIK-75 Investigative T81735 DRUGINFO D0R0TW KU-0060648 Investigative T81735 DRUGINFO D07APP LY-292223 Investigative T81735 DRUGINFO D0W1ST Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate Investigative T81735 DRUGINFO D03EHM PP121 Investigative T43721 TARGETID T43721 T43721 FORMERID TTDR01269 T43721 UNIPROID DHI2_HUMAN T43721 TARGNAME Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) T43721 GENENAME HSD11B2 T43721 TARGTYPE Clinical trial T43721 SYNONYMS NAD-dependent 11-beta-hydroxysteroid dehydrogenase; HSD11B2; 11-beta-hydroxysteroid dehydrogenase type 2; 11-beta-HSD2; 11-DH2; 11 beta-hydroxysteroid dehydrogenase type 2; 11 beta-HSD2 T43721 FUNCTION Catalyzes the conversion of cortisol to the inactive metabolite cortisone. modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids. T43721 BIOCLASS Short-chain dehydrogenases reductase T43721 ECNUMBER EC 1.1.1.- T43721 SEQUENCE MERWPWPSGGAWLLVAARALLQLLRSDLRLGRPLLAALALLAALDWLCQRLLPPPAALAVLAAAGWIALSRLARPQRLPVATRAVLITGCDSGFGKETAKKLDSMGFTVLATVLELNSPGAIELRTCCSPRLRLLQMDLTKPGDISRVLEFTKAHTTSTGLWGLVNNAGHNEVVADAELSPVATFRSCMEVNFFGALELTKGLLPLLRSSRGRIVTVGSPAGDMPYPCLGAYGTSKAAVALLMDTFSCELLPWGVKVSIIQPGCFKTESVRNVGQWEKRKQLLLANLPQELLQAYGKDYIEHLHGQFLHSLRLAMSDLTPVVDAITDALLAARPRRRYYPGQGLGLMYFIHYYLPEGLRRRFLQAFFISHCLPRALQPGQPGTTPPQDAAQDPNLSPGPSPAVAR T43721 DRUGINFO D04ZNL RG-7234 Phase 2 T43721 DRUGINFO D03NPA Ganoderic acid A Investigative T43721 DRUGINFO D02XEX 3-acetyl-11-keto-beta-boswellic acid Investigative T43721 DRUGINFO D09VYW 11-keto-beta-boswellicacid Investigative T43721 DRUGINFO D0U8IF [(125)I] RB129 Investigative T36557 TARGETID T36557 T36557 FORMERID TTDC00069 T36557 UNIPROID PPARD_HUMAN T36557 TARGNAME Peroxisome proliferator-activated receptor delta (PPARD) T36557 GENENAME PPARD T36557 TARGTYPE Clinical trial T36557 SYNONYMS Peroxisomeproliferator-activated receptor beta; Peroxisomeproliferator activated receptor beta/delta; Peroxisome proliferator-activated receptor beta; PPARdelta; PPARB; PPAR-delta; PPAR-beta; Nuclear receptor subfamily 1 group C member 2; Nuclear hormone receptor 1; NUCI; NUC1; NR1C2 T36557 FUNCTION Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene. Decreases expression of NPC1L1 once activated by a ligand. Ligand-activated transcription factor. T36557 PDBSTRUC 5ZXI; 5Y7X; 5XMX; 5U46; 5U45 T36557 BIOCLASS Nuclear hormone receptor T36557 SEQUENCE MEQPQEEAPEVREEEEKEEVAEAEGAPELNGGPQHALPSSSYTDLSRSSSPPSLLDQLQMGCDGASCGSLNMECRVCGDKASGFHYGVHACEGCKGFFRRTIRMKLEYEKCERSCKIQKKNRNKCQYCRFQKCLALGMSHNAIRFGRMPEAEKRKLVAGLTANEGSQYNPQVADLKAFSKHIYNAYLKNFNMTKKKARSILTGKASHTAPFVIHDIETLWQAEKGLVWKQLVNGLPPYKEISVHVFYRCQCTTVETVRELTEFAKSIPSFSSLFLNDQVTLLKYGVHEAIFAMLASIVNKDGLLVANGSGFVTREFLRSLRKPFSDIIEPKFEFAVKFNALELDDSDLALFIAAIILCGDRPGLMNVPRVEAIQDTILRALEFHLQANHPDAQYLFPKLLQKMADLRQLVTEHAQMMQRIKKTETETSLHPLLQEIYKDMY T36557 DRUGINFO D0LW1Y GFT-505 Phase 3 T36557 DRUGINFO D03OSG MBX-8025 Phase 2/3 T36557 DRUGINFO D53BEH T3D‐959 Phase 2 T36557 DRUGINFO D0ZT8A T3D-959 Phase 1/2 T36557 DRUGINFO D01PVV KD3010 Phase 1 T36557 DRUGINFO D04NJS SAR351034 Phase 1 T36557 DRUGINFO D06KPR CER-002 Phase 1 T36557 DRUGINFO D0V0JN PMID25416646-Compound-Figure5-C Patented T36557 DRUGINFO D05HDX GW-501516 Discontinued in Phase 4 T36557 DRUGINFO D01JGG Sodelglitazar Discontinued in Phase 2 T36557 DRUGINFO D09OHP Indeglitazar Discontinued in Phase 2 T36557 DRUGINFO D0S6KX GSK-677954 Discontinued in Phase 2 T36557 DRUGINFO D06GFG KD-3020 Preclinical T36557 DRUGINFO D0V0TT CS-204 Terminated T36557 DRUGINFO D06VBQ GSK-0660 Investigative T36557 DRUGINFO D07USR SAVX-1 Investigative T36557 DRUGINFO D0K1TQ GW0742X Investigative T36557 DRUGINFO D0NM0G GSK-3787 Investigative T36557 DRUGINFO D0V6DE (11E)-OCTADEC-11-ENOIC ACID Investigative T36557 DRUGINFO D0XR8Q GW2433 Investigative T36557 DRUGINFO D0YK9T L-165041 Investigative T36557 DRUGINFO D06IBV Heptyl-Beta-D-Glucopyranoside Investigative T36557 DRUGINFO D01ARG DB-900 Investigative T36557 DRUGINFO D09JII L-796449 Investigative T36557 DRUGINFO D0F0MP L-165461 Investigative T36557 DRUGINFO D08QXD L-783483 Investigative T88285 TARGETID T88285 T88285 FORMERID TTDR01246 T88285 UNIPROID LGUL_HUMAN T88285 TARGNAME Lactoylglutathione lyase (GLO1) T88285 GENENAME GLO1 T88285 TARGTYPE Clinical trial T88285 SYNONYMS S-D-lactoylglutathione methylglyoxal lyase; Methylglyoxalase; Ketone-aldehyde mutase; Glyoxalase I; GlxI; Glx I; GLO1; Aldoketomutase T88285 FUNCTION Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. Involved in the regulation of TNF-induced transcriptional activity of NF- kappa-B. Required for normal osteoclastogenesis. T88285 PDBSTRUC 3W0U; 3W0T; 3VW9; 1QIP; 1QIN T88285 BIOCLASS Carbon-sulfur lyases T88285 ECNUMBER EC 4.4.1.5 T88285 SEQUENCE MAEPQPPSGGLTDEAALSCCSDADPSTKDFLLQQTMLRVKDPKKSLDFYTRVLGMTLIQKCDFPIMKFSLYFLAYEDKNDIPKEKDEKIAWALSRKATLELTHNWGTEDDETQSYHNGNSDPRGFGHIGIAVPDVYSACKRFEELGVKFVKKPDDGKMKGLAFIQDPDGYWIEILNPNKMATLM T88285 DRUGINFO D00YEV BAICALEIN Phase 2 T88285 DRUGINFO D02ABO NARINGENIN Phase 1 T88285 DRUGINFO D00XKH S-(N-butyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D01UKL S-(N-heptyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D03OXL S-(N-propyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D08DOY S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione Investigative T88285 DRUGINFO D0E3VR S-(N-pentyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D0FX3J S-(N-methyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D0I2AG S-(N-4bromophenyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D0I6JQ S-(N-4chlorophenyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D0I8PQ S-(N-ethyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D0K2UP S-Benzyl-Glutathione Investigative T88285 DRUGINFO D0O3DI PELARGONIDIN CHLORIDE Investigative T88285 DRUGINFO D0R3IN S-p-bromobenzyl glutatione Investigative T88285 DRUGINFO D0V3PG CYANIDIN Investigative T88285 DRUGINFO D0X7OS S-P-Nitrobenzyloxycarbonylglutathione Investigative T88285 DRUGINFO D0YI5C S-(N-hexyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D0Z9WS S-(N-phenyl-N-hydroxycarbamoyl)glutathione Investigative T88285 DRUGINFO D0G3TK KAEMPFEROL Investigative T88285 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T01973 TARGETID T01973 T01973 FORMERID TTDNC00418 T01973 UNIPROID RON_HUMAN T01973 TARGNAME Macrophage-stimulating protein receptor (RON) T01973 GENENAME MST1R T01973 TARGTYPE Clinical trial T01973 SYNONYMS p185Ron; Proteintyrosine kinase 8; Macrophagestimulating protein receptor beta chain; Macrophagestimulating protein receptor; MST1R; MSP receptor; CDw136; CD136 T01973 FUNCTION Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Plays also a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand. T01973 PDBSTRUC 4QT8; 4FWW; 3PLS T01973 BIOCLASS Kinase T01973 ECNUMBER EC 2.7.10.1 T01973 SEQUENCE MELLPPLPQSFLLLLLLPAKPAAGEDWQCPRTPYAASRDFDVKYVVPSFSAGGLVQAMVTYEGDRNESAVFVAIRNRLHVLGPDLKSVQSLATGPAGDPGCQTCAACGPGPHGPPGDTDTKVLVLDPALPALVSCGSSLQGRCFLHDLEPQGTAVHLAAPACLFSAHHNRPDDCPDCVASPLGTRVTVVEQGQASYFYVASSLDAAVAASFSPRSVSIRRLKADASGFAPGFVALSVLPKHLVSYSIEYVHSFHTGAFVYFLTVQPASVTDDPSALHTRLARLSATEPELGDYRELVLDCRFAPKRRRRGAPEGGQPYPVLRVAHSAPVGAQLATELSIAEGQEVLFGVFVTGKDGGPGVGPNSVVCAFPIDLLDTLIDEGVERCCESPVHPGLRRGLDFFQSPSFCPNPPGLEALSPNTSCRHFPLLVSSSFSRVDLFNGLLGPVQVTALYVTRLDNVTVAHMGTMDGRILQVELVRSLNYLLYVSNFSLGDSGQPVQRDVSRLGDHLLFASGDQVFQVPIQGPGCRHFLTCGRCLRAWHFMGCGWCGNMCGQQKECPGSWQQDHCPPKLTEFHPHSGPLRGSTRLTLCGSNFYLHPSGLVPEGTHQVTVGQSPCRPLPKDSSKLRPVPRKDFVEEFECELEPLGTQAVGPTNVSLTVTNMPPGKHFRVDGTSVLRGFSFMEPVLIAVQPLFGPRAGGTCLTLEGQSLSVGTSRAVLVNGTECLLARVSEGQLLCATPPGATVASVPLSLQVGGAQVPGSWTFQYREDPVVLSISPNCGYINSHITICGQHLTSAWHLVLSFHDGLRAVESRCERQLPEQQLCRLPEYVVRDPQGWVAGNLSARGDGAAGFTLPGFRFLPPPHPPSANLVPLKPEEHAIKFEYIGLGAVADCVGINVTVGGESCQHEFRGDMVVCPLPPSLQLGQDGAPLQVCVDGECHILGRVVRPGPDGVPQSTLLGILLPLLLLVAALATALVFSYWWRRKQLVLPPNLNDLASLDQTAGATPLPILYSGSDYRSGLALPAIDGLDSTTCVHGASFSDSEDESCVPLLRKESIQLRDLDSALLAEVKDVLIPHERVVTHSDRVIGKGHFGVVYHGEYIDQAQNRIQCAIKSLSRITEMQQVEAFLREGLLMRGLNHPNVLALIGIMLPPEGLPHVLLPYMCHGDLLQFIRSPQRNPTVKDLISFGLQVARGMEYLAEQKFVHRDLAARNCMLDESFTVKVADFGLARDILDREYYSVQQHRHARLPVKWMALESLQTYRFTTKSDVWSFGVLLWELLTRGAPPYRHIDPFDLTHFLAQGRRLPQPEYCPDSLYQVMQQCWEADPAVRPTFRVLVGEVEQIVSALLGDHYVQLPATYMNLGPSTSHEMNVRPEQPQFSPMPGNVRRPRPLSEPPRPT T01973 DRUGINFO D00DRL MK-2461 Phase 1/2 T01973 DRUGINFO D07PWY Anti-RON receptor mabs Investigative T01973 DRUGINFO D0BG2L ABC-7 Investigative T15068 TARGETID T15068 T15068 FORMERID TTDR00669 T15068 UNIPROID FAK1_HUMAN T15068 TARGNAME Focal adhesion kinase 1 (FAK) T15068 GENENAME PTK2 T15068 TARGTYPE Clinical trial T15068 SYNONYMS pp125FAK; p125FAK; Protein-tyrosine kinase 2; Protein phosphatase 1 regulatory subunit 71; PPP1R71; Focal adhesion kinase-related nonkinase; FRNK; FAK1; FADK 1; FADK T15068 FUNCTION Required for early embryonic development and placenta development. Required for embryonic angiogenesis, normal cardiomyocyte migration and proliferation, and normal heart development. Regulates axon growth and neuronal cell migration, axon branching and synapse formation; required for normal development of the nervous system. Plays a role in osteogenesis and differentiation of osteoblasts. Functions in integrin signal transduction, but also in signaling downstream of numerous growth factor receptors, G-protein coupled receptors (GPCR), EPHA2, netrin receptors and LDL receptors. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascade. Promotes activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling cascade. Promotes localized and transient activation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), and thereby modulates the activity of Rho family GTPases. Signaling via CAS family members mediates activation of RAC1. Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ACTN1, ARHGEF7, GRB7, RET and WASL. Promotes phosphorylation of PXN and STAT1; most likely PXN and STAT1 are phosphorylated by a SRC family kinase that is recruited to autophosphorylated PTK2/FAK1, rather than by PTK2/FAK1 itself. Promotes phosphorylation of BCAR1; GIT2 and SHC1; this requires both SRC and PTK2/FAK1. Promotes phosphorylation of BMX and PIK3R1. Isoform 6 (FRNK) does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation and signaling. Its enhanced expression can attenuate the nuclear accumulation of LPXN and limit its ability to enhance serum response factor (SRF)-dependent gene transcription. Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. T15068 PDBSTRUC 6I8Z; 4Q9S; 4NY0; 4KAO; 4KAB T15068 BIOCLASS Kinase T15068 ECNUMBER EC 2.7.10.2 T15068 SEQUENCE MAAAYLDPNLNHTPNSSTKTHLGTGMERSPGAMERVLKVFHYFESNSEPTTWASIIRHGDATDVRGIIQKIVDSHKVKHVACYGFRLSHLRSEEVHWLHVDMGVSSVREKYELAHPPEEWKYELRIRYLPKGFLNQFTEDKPTLNFFYQQVKSDYMLEIADQVDQEIALKLGCLEIRRSYWEMRGNALEKKSNYEVLEKDVGLKRFFPKSLLDSVKAKTLRKLIQQTFRQFANLNREESILKFFEILSPVYRFDKECFKCALGSSWIISVELAIGPEEGISYLTDKGCNPTHLADFTQVQTIQYSNSEDKDRKGMLQLKIAGAPEPLTVTAPSLTIAENMADLIDGYCRLVNGTSQSFIIRPQKEGERALPSIPKLANSEKQGMRTHAVSVSETDDYAEIIDEEDTYTMPSTRDYEIQRERIELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKLIGVITENPVWIIMELCTLGELRSFLQVRKYSLDLASLILYAYQLSTALAYLESKRFVHRDIAARNVLVSSNDCVKLGDFGLSRYMEDSTYYKASKGKLPIKWMAPESINFRRFTSASDVWMFGVCMWEILMHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTILEEEKAQQEERMRMESRRQATVSWDSGGSDEAPPKPSRPGYPSPRSSEGFYPSPQHMVQTNHYQVSGYPGSHGITAMAGSIYPGQASLLDQTDSWNHRPQEIAMWQPNVEDSTVLDLRGIGQVLPTHLMEERLIRQQQEMEEDQRWLEKEERFLKPDVRLSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPKKPPRPGAPGHLGSLASLSSPADSYNEGVKLQPQEISPPPTANLDRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGLALRTLLATVDETIPLLPASTHREIEMAQKLLNSDLGELINKMKLAQQYVMTSLQQEYKKQMLTAAHALAVDAKNLLDVIDQARLKMLGQTRPH T15068 DRUGINFO D0Y1UO VS-6063 Phase 2 T15068 DRUGINFO D00KNI BI-853520 Phase 1 T15068 DRUGINFO D01SJT PF-562271 Phase 1 T15068 DRUGINFO D0A6VD VS-4718 Phase 1 T15068 DRUGINFO D0B9MR GSK-2256098 Phase 1 T15068 DRUGINFO D0N6NM CEP-37440 Phase 1 T15068 DRUGINFO D1EW3O IN10018 Phase 1 T15068 DRUGINFO D07XYI 1,2,4-triazolo[1,5a]pyridine derivative 1 Patented T15068 DRUGINFO D0AY0F PMID23414845C30 Investigative T15068 DRUGINFO D02QAZ PF-228 Investigative T15068 DRUGINFO D0M4SY BMS-536924 Investigative T13057 TARGETID T13057 T13057 FORMERID TTDR01263 T13057 UNIPROID PTN11_HUMAN T13057 TARGNAME Protein-tyrosine phosphatase SHP-2 (PTPN11) T13057 GENENAME PTPN11 T13057 TARGTYPE Clinical trial T13057 SYNONYMS Tyrosine-protein phosphatase non-receptor type 11; SHPTP2; SHP2; SHP-2; SH-PTP3; SH-PTP2; Protein-tyrosine phosphatase SHP2; Protein-tyrosine phosphatase 2C; Protein-tyrosine phosphatase 1D; PTP2C; PTP-2C; PTP-1D T13057 FUNCTION Positively regulates MAPK signal transduction pathway. Dephosphorylates GAB1, ARHGAP35 and EGFR. Dephosphorylates ROCK2 at 'Tyr-722' resulting in stimulatation of its RhoA binding activity. Dephosphorylates CDC73. Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. T13057 PDBSTRUC 6MDD; 6MDC; 6MDB; 6MDA; 6MD9 T13057 BIOCLASS Phosphoric monoester hydrolase T13057 ECNUMBER EC 3.1.3.48 T13057 SEQUENCE MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR T13057 DRUGINFO D1LEU5 JAB-3312 Phase 1/2 T13057 DRUGINFO D08IID TNO155 Phase 1 T13057 DRUGINFO D0AF1I PF-07284892 Phase 1 T13057 DRUGINFO D2CL0D RG6433 Phase 1 T13057 DRUGINFO DM16HS JAB-3068 Phase 1 T13057 DRUGINFO DN7M4T BBP-398 Phase 1 T13057 DRUGINFO DQ8F7A A380 Phase 1 T13057 DRUGINFO DS9R3G SAR442720 Phase 1 T13057 DRUGINFO DYQZ38 RLY-1971 Phase 1 T13057 DRUGINFO D00MFW NSC-87877 Patented T13057 DRUGINFO D0P7KP Dodecane-Trimethylamine Investigative T31956 TARGETID T31956 T31956 FORMERID TTDR00531 T31956 UNIPROID AMPE_HUMAN T31956 TARGNAME Glutamyl aminopeptidase (ENPEP) T31956 GENENAME ENPEP T31956 TARGTYPE Clinical trial T31956 SYNONYMS ENPEP; EAP; Differentiation antigen gp160; Aminopeptidase A; APA T31956 FUNCTION Appears to have a role in the catabolicpathway of the renin-angiotensin system. Probably plays a role in regulating growth and differentiation of early B-lineage cells. T31956 PDBSTRUC 4KXD; 4KXC; 4KXB; 4KXA; 4KX9 T31956 BIOCLASS Peptidase T31956 ECNUMBER EC 3.4.11.7 T31956 SEQUENCE MNFAEREGSKRYCIQTKHVAILCAVVVGVGLIVGLAVGLTRSCDSSGDGGPGTAPAPSHLPSSTASPSGPPAQDQDICPASEDESGQWKNFRLPDFVNPVHYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHLRETRITRLPELKRPSGDQVQVRRCFEYKKQEYVVVEAEEELTPSSGDGLYLLTMEFAGWLNGSLVGFYRTTYTENGQVKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYGALSNMPVAKEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAEYAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYDPKESASSNQQRVATVVAHELVHQWFGNIVTMDWWEDLWLNEGFASFFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYSKGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEASRLPVKEVMDTWTRQMGYPVLNVNGVKNITQKRFLLDPRANPSQPPSDLGYTWNIPVKWTEDNITSSVLFNRSEKEGITLNSSNPSGNAFLKINPDHIGFYRVNYEVATWDSIATALSLNHKTFSSADRASLIDDAFALARAQLLDYKVALNLTKYLKREENFLPWQRVISAVTYIISMFEDDKELYPMIEEYFQGQVKPIADSLGWNDAGDHVTKLLRSSVLGFACKMGDREALNNASSLFEQWLNGTVSLPVNLRLLVYRYGMQNSGNEISWNYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLKDTNLIKTQDVFTVIRYISYNSYGKNMAWNWIQLNWDYLVNRYTLNNRNLGRIVTIAEPFNTELQLWQMESFFAKYPQAGAGEKPREQVLETVKNNIEWLKQHRNTIREWFFNLLESG T31956 DRUGINFO D0C1JV QGC-001 Phase 2 T31956 DRUGINFO D0B9ZE PMID10602705C40 Investigative T31956 DRUGINFO D0IW6G EC33 Investigative T31956 DRUGINFO D04QJY KELATORPHAN Investigative T56510 TARGETID T56510 T56510 FORMERID TTDC00168 T56510 UNIPROID B2CL1_HUMAN T56510 TARGNAME Apoptosis regulator Bcl-xL (BCL-xL) T56510 GENENAME BCL2L1 T56510 TARGTYPE Clinical trial T56510 SYNONYMS Bcl2like protein 1; Bcl2L1; Bcl2-L-1; Bcl-XL; Bcl-2-like protein 1; BCLX; BCL2L; Apoptosis regulator Bcl-X T56510 FUNCTION Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis. Potent inhibitor of cell death. T56510 PDBSTRUC 6IJQ; 6F46; 6DCO; 6DCN; 6BF2 T56510 BIOCLASS B-cell lymphoma Bcl-2 T56510 SEQUENCE MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK T56510 DRUGINFO D06ETI ABT-263 Phase 3 T56510 DRUGINFO D02OZK Obatoclax Phase 2 T56510 DRUGINFO D4WN2M APG-1252 Phase 1/2 T56510 DRUGINFO DQ1P6X AZD0466 Phase 1/2 T56510 DRUGINFO D09XWR PMID27744724-Compound-26 Patented T56510 DRUGINFO D0F9QC PMID27744724-Compound-27 Patented T56510 DRUGINFO D0C2DV Indole-based analog 2 Patented T56510 DRUGINFO D0IS8R PMID27744724-Compound-10 Patented T56510 DRUGINFO D0J9FN PMID27744724-Compound-21 Patented T56510 DRUGINFO D0MZ7I Indole-based analog 3 Patented T56510 DRUGINFO D0TU3N PMID27744724-Compound-18 Patented T56510 DRUGINFO D04IPX WEHI-0103122 Investigative T56510 DRUGINFO D09FWK E-003 Investigative T56510 DRUGINFO D0T3VP 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID Investigative T56510 DRUGINFO D2SJZ9 EAPB0203 Investigative T14912 TARGETID T14912 T14912 FORMERID TTDC00048 T14912 UNIPROID MCL1_HUMAN T14912 TARGNAME Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) T14912 GENENAME MCL1 T14912 TARGTYPE Clinical trial T14912 SYNONYMS mcl1/EAT; Bcl2-L-3; Bcl-2-related protein EAT/mcl1; Bcl-2-like protein 3; BCL2L3 T14912 FUNCTION Mediates its effects by interactions with a number of other regulators of apoptosis. Isoform 1 inhibits apoptosis. Isoform 2 promotes apoptosis. Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. T14912 PDBSTRUC 6OVC; 6OQN; 6OQD; 6OQC; 6OQB T14912 BIOCLASS B-cell lymphoma Bcl-2 T14912 SEQUENCE MFGLKRNAVIGLNLYCGGAGLGAGSGGATRPGGRLLATEKEASARREIGGGEAGAVIGGSAGASPPSTLTPDSRRVARPPPIGAEVPDVTATPARLLFFAPTRRAAPLEEMEAPAADAIMSPEEELDGYEPEPLGKRPAVLPLLELVGESGNNTSTDGSLPSTPPPAEEEEDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGGIRNVLLAFAGVAGVGAGLAYLIR T14912 DRUGINFO D02OZK Obatoclax Phase 2 T14912 DRUGINFO D06XCP AZD5991 Phase 1 T14912 DRUGINFO D0I5DP AMG 176 Phase 1 T14912 DRUGINFO D50CXM PRT1419 Phase 1 T14912 DRUGINFO D63QIY ABBV-467 Phase 1 T14912 DRUGINFO D7LC8N MIK665 Phase 1 T14912 DRUGINFO DBI81F AMG 397 Phase 1 T14912 DRUGINFO D00BEJ PMID27744724-Compound-19 Patented T14912 DRUGINFO D03FZI Biphenyl carboxylic acid derivative 1 Patented T14912 DRUGINFO D09SGU Biphenyl carboxylic acid derivative 2 Patented T14912 DRUGINFO D0DG0F PMID27744724-Compound-Fomula2 Patented T14912 DRUGINFO D0F8LE Indole-based analog 1 Patented T14912 DRUGINFO D0H3NO PMID27744724-Compound-4 Patented T14912 DRUGINFO D0I9PC PMID27744724-Compound-13 Patented T14912 DRUGINFO D0IV8T PMID27744724-Compound-5 Patented T14912 DRUGINFO D0JA5B PMID27744724-Compound-3 Patented T14912 DRUGINFO D0JZ4W PMID27744724-Compound-29 Patented T14912 DRUGINFO D0LO7X PMID27744724-Compound-23 Patented T14912 DRUGINFO D0M6MP PMID27744724-Compound-28 Patented T14912 DRUGINFO D0NT2S PMID27744724-Compound-20 Patented T14912 DRUGINFO D0QE9E PMID27744724-Compound-22 Patented T14912 DRUGINFO D0RJ1U PMID27744724-Compound-6 Patented T14912 DRUGINFO D09XWR PMID27744724-Compound-26 Patented T14912 DRUGINFO D0F9QC PMID27744724-Compound-27 Patented T14912 DRUGINFO D0C2DV Indole-based analog 2 Patented T14912 DRUGINFO D0IS8R PMID27744724-Compound-10 Patented T14912 DRUGINFO D0J9FN PMID27744724-Compound-21 Patented T14912 DRUGINFO D0MZ7I Indole-based analog 3 Patented T14912 DRUGINFO D0TU3N PMID27744724-Compound-18 Patented T14912 DRUGINFO D0QQ1J BITHIONOL Withdrawn from market T14912 DRUGINFO D00MEV Sch-45752 Terminated T14912 DRUGINFO D0G3SZ ALTENUSIN Investigative T14912 DRUGINFO D0G5LZ GNF-PF-1591 Investigative T14912 DRUGINFO D0GN5Z SULFURETIN Investigative T14912 DRUGINFO D0H7BH GNF-PF-3955 Investigative T14912 DRUGINFO D0U4QZ EU-517 Investigative T14912 DRUGINFO D05PTT ROSMARINIC ACID Investigative T14912 DRUGINFO D0IK4V GNF-PF-5134 Investigative T14912 DRUGINFO D0WN7V NSC-180246 Investigative T14912 DRUGINFO D0XU4Y NSC-66209 Investigative T14912 DRUGINFO D00LHS TW-37 Investigative T14912 DRUGINFO D0S6IW QEDIIRNIARHLAQVGDSMDR Investigative T14912 DRUGINFO D0NJ4H MORIN Investigative T14912 DRUGINFO D06HRX AMENTOFLAVONE Investigative T55781 TARGETID T55781 T55781 FORMERID TTDI00012 T55781 UNIPROID MERTK_HUMAN T55781 TARGNAME Tyrosine-protein kinase Mer (MERTK) T55781 GENENAME MERTK T55781 TARGTYPE Clinical trial T55781 SYNONYMS Receptor tyrosine kinase MerTK; Proto-oncogene c-Mer T55781 FUNCTION Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). Ligand binding at the cell surface induces autophosphorylation of MERTK on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6. T55781 PDBSTRUC 5U6C; 5TD2; 5TC0; 5K0X; 5K0K T55781 BIOCLASS Kinase T55781 ECNUMBER EC 2.7.10.1 T55781 SEQUENCE MGPAPLPLLLGLFLPALWRRAITEAREEAKPYPLFPGPFPGSLQTDHTPLLSLPHASGYQPALMFSPTQPGRPHTGNVAIPQVTSVESKPLPPLAFKHTVGHIILSEHKGVKFNCSISVPNIYQDTTISWWKDGKELLGAHHAITQFYPDDEVTAIIASFSITSVQRSDNGSYICKMKINNEEIVSDPIYIEVQGLPHFTKQPESMNVTRNTAFNLTCQAVGPPEPVNIFWVQNSSRVNEQPEKSPSVLTVPGLTEMAVFSCEAHNDKGLTVSKGVQINIKAIPSPPTEVSIRNSTAHSILISWVPGFDGYSPFRNCSIQVKEADPLSNGSVMIFNTSALPHLYQIKQLQALANYSIGVSCMNEIGWSAVSPWILASTTEGAPSVAPLNVTVFLNESSDNVDIRWMKPPTKQQDGELVGYRISHVWQSAGISKELLEEVGQNGSRARISVQVHNATCTVRIAAVTRGGVGPFSDPVKIFIPAHGWVDYAPSSTPAPGNADPVLIIFGCFCGFILIGLILYISLAIRKRVQETKFGNAFTEEDSELVVNYIAKKSFCRRAIELTLHSLGVSEELQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEMSSQGIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPLDRPTFSVLRLQLEKLLESLPDVRNQADVIYVNTQLLESSEGLAQGSTLAPLDLNIDPDSIIASCTPRAAISVVTAEVHDSKPHEGRYILNGGSEEWEDLTSAPSAAVTAEKNSVLPGERLVRNGVSWSHSSMLPLGSSLPDELLFADDSSEGSEVLM T55781 DRUGINFO DA1MG8 ONO-7475 Phase 1/2 T55781 DRUGINFO D00DRL MK-2461 Phase 1/2 T55781 DRUGINFO D0VH4T ONO-7475 Phase 1 T55781 DRUGINFO D10LNV MRX-2843 Phase 1 T55781 DRUGINFO DP4KH3 PF-07265807 Phase 1 T55781 DRUGINFO DQX83Z INCB81776 Phase 1 T55781 DRUGINFO D7HZ3T RXDX-106 Phase 1 T55781 DRUGINFO DCJX65 UNC2025 Investigative T55781 DRUGINFO DI81LW UNC569 Investigative T55781 DRUGINFO D0N3XP G749 Investigative T55781 DRUGINFO D09TFN LDC1267 Investigative T53764 TARGETID T53764 T53764 FORMERID TTDR01154 T53764 UNIPROID SEPR_HUMAN T53764 TARGNAME Prolyl endopeptidase FAP (FAP) T53764 GENENAME FAP T53764 TARGTYPE Clinical trial T53764 SYNONYMS Integral membrane serine protease; Fibroblast activation protein alpha; FAP; Antiplasmin-cleaving enzyme; APCE; 170-kDa melanoma membrane-bound gelatinase T53764 FUNCTION Cell surface glycoprotein serine protease that participatesin extracellular matrix degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. Both plasma membrane and soluble formsexhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences, on substrate such as alpha-2-antiplasmin SERPINF2 and SPRY2 (PubMed:14751930, PubMed:16223769, PubMed:16480718, PubMed:16410248, PubMed:17381073, PubMed:18095711, PubMed:21288888, PubMed:24371721). Degrade also gelatin, heat-denatured type I collagen, but not native collagen type I and IV, vibronectin, tenascin, laminin, fibronectin, fibrin or casein (PubMed:9065413, PubMed:2172980, PubMed:7923219, PubMed:10347120, PubMed:10455171, PubMed:12376466, PubMed:16223769, PubMed:16651416, PubMed:18095711). Have also dipeptidyl peptidase activity, exhibiting the ability to hydrolyze the prolyl bond two residues from the N-terminus of synthetic dipeptide substrates provided that the penultimate residue is proline, with a preference for Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro and Pro-Pro (PubMed:10347120, PubMed:10593948, PubMed:16175601, PubMed:16223769, PubMed:16651416, PubMed:16410248, PubMed:17381073, PubMed:21314817, PubMed:24371721, PubMed:24717288). Natural neuropeptide hormones for dipeptidyl peptidase are the neuropeptide Y (NPY), peptide YY (PYY), substance P (TAC1) and brain natriuretic peptide 32 (NPPB) (PubMed:21314817). The plasma membrane form, in association with either DPP4, PLAUR or integrins, is involved in the pericellular proteolysis of the extracellular matrix (ECM), and hence promotes cell adhesion, migration and invasion through the ECM. Plays a role in tissue remodeling during development and wound healing. Participates in the cell invasiveness towards the ECM in malignant melanoma cancers. Enhances tumor growth progression by increasing angiogenesis, collagen fiber degradation and apoptosis and by reducing antitumor response of the immune system. Promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. Acts as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner. T53764 PDBSTRUC 1Z68 T53764 BIOCLASS Peptidase T53764 ECNUMBER EC 3.4.21.26 T53764 SEQUENCE MKTWVKIVFGVATSAVLALLVMCIVLRPSRVHNSEENTMRALTLKDILNGTFSYKTFFPNWISGQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNASNYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLSNGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYLKQRPGDPPFQITFNGRENKIFNGIPDWVYEEEMLATKYALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYPRTINIPYPKAGAKNPVVRIFIIDTTYPAYVGPQEVPVPAMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVLSICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVSTPVFSYDAISYYKIFSDKDGYKHIHYIKDTVENAIQITSGKWEAINIFRVTQDSLFYSSNEFEEYPGRRNIYRISIGSYPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVCYGPGIPISTLHDGRTDQEIKILEENKELENALKNIQLPKEEIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVYGGPCSQSVRSVFAVNWISYLASKEGMVIALVDGRGTAFQGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFIDEKRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVSSWEYYASVYTERFMGLPTKDDNLEHYKNSTVMARAEYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQVDFQAMWYSDQNHGLSGLSTNHLYTHMTHFLKQCFSLSD T53764 DRUGINFO D0FQ2U Talabostat Phase 3 T53764 DRUGINFO D0N7LA BIBH 1 Phase 2 T53764 DRUGINFO DVX3H0 Sibrotuzumab Phase 2 T53764 DRUGINFO D0V7GS RG7461 Phase 1 T53764 DRUGINFO DN2F9A AMG 506 Phase 1 T53764 DRUGINFO D1A8NU NG-641 Phase 1 T53764 DRUGINFO DO7HS1 FAP5-DM1 Preclinical T53764 DRUGINFO D7K0GP PT630 Preclinical T53764 DRUGINFO D01HTS MIP-1231 Investigative T53764 DRUGINFO D0A9WW FE-999040 Investigative T53764 DRUGINFO D0M9SD VA-119930 Investigative T53764 DRUGINFO D03DNV ARI-3099 Investigative T97196 TARGETID T97196 T97196 FORMERID TTDI03045 T97196 UNIPROID ATM_HUMAN T97196 TARGNAME ATM serine/threonine kinase (ATM) T97196 GENENAME ATM T97196 TARGTYPE Clinical trial T97196 SYNONYMS Serine-protein kinase ATM; Ataxia telangiectasia mutated; A-T mutated T97196 FUNCTION Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. May function as a tumor suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9, UBQLN4 and DCLRE1C. May play a role in vesicle and/or protein transport. Could play a role in T-cell development, gonad and neurological function. Plays a role in replication-dependent histone mRNA degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in response to genotoxic stress prevents its MDM2-mediated ubiquitination and subsequent proteasome degradation. Phosphorylates ATF2 which stimulates its function in DNA damage response. T97196 PDBSTRUC 6HKA; 5NP1; 5NP0 T97196 BIOCLASS Kinase T97196 ECNUMBER EC 2.7.11.1 T97196 SEQUENCE MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV T97196 DRUGINFO D0L6XO AZD1390 Phase 1 T97196 DRUGINFO D0NW8C M3541 Phase 1 T97196 DRUGINFO D0XD4I AZD0156 Phase 1 T97196 DRUGINFO D02NUT KU-60019 Clinical trial T97196 DRUGINFO D00PXO CGK733 Investigative T16308 TARGETID T16308 T16308 FORMERID TTDR00355 T16308 UNIPROID PIN1_HUMAN T16308 TARGNAME Rotamase Pin1 (PIN1) T16308 GENENAME PIN1 T16308 TARGTYPE Clinical trial T16308 SYNONYMS Prolyl isomerase Pin1; Peptidyl-prolyl cis-trans isomerase Pin1; Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1; Peptidyl prolyl cis/trans isomerase Pin1; PPIase Pin1 T16308 FUNCTION By inducing conformational changes in a subset of phosphorylated proteins, acts as a molecular switch in multiple cellular processes (, Ref. 21). Displays a preference for acidic residues located N-terminally to the proline bond to be isomerized. Regulates mitosis presumably by interacting with NIMA and attenuating its mitosis-promoting activity. Down-regulates kinase activity of BTK. Can transactivate multiple oncogenes and induce centrosome amplification, chromosome instability and cell transformation. Required for the efficient dephosphorylation and recycling of RAF1 after mitogen activation. Binds and targets PML and BCL6 for degradation in a phosphorylation-dependent manner. Acts as a regulator of JNK cascade by binding to phosphorylated FBXW7, disrupting FBXW7 dimerization and promoting FBXW7 autoubiquitination and degradation: degradation of FBXW7 leads to subsequent stabilization of JUN. May facilitate the ubiquitination and proteasomal degradation of RBBP8/CtIP through CUL3/KLHL15 E3 ubiquitin-protein ligase complex, hence favors DNA double-strand repair through error-prone non-homologous end joining (NHEJ) over error-free, RBBP8-mediated homologous recombination (HR). Peptidyl-prolyl cis/trans isomerase (PPIase) that binds to and isomerizes specific phosphorylated Ser/Thr-Pro (pSer/Thr-Pro) motifs. T16308 PDBSTRUC 6DUN; 5VTK; 5VTJ; 5VTI; 5UY9 T16308 BIOCLASS Cis-trans-isomerase T16308 ECNUMBER EC 5.2.1.8 T16308 SEQUENCE MADEEKLPPGWEKRMSRSSGRVYYFNHITNASQWERPSGNSSSGGKNGQGEPARVRCSHLLVKHSQSRRPSSWRQEKITRTKEEALELINGYIQKIKSGEEDFESLASQFSDCSSAKARGDLGAFSRGQMQKPFEDASFALRTGEMSGPVFTDSGIHIILRTE T16308 DRUGINFO D0C0NH Avastin+/-Tarceva Phase 3 T16308 DRUGINFO D08MJE (R,)-2-(2-naphthamido)-5-phenylpent-4-enoic acid Investigative T16308 DRUGINFO D08TZA (R)-2-(2-naphthamido)-3-p-tolylpropanoic acid Investigative T16308 DRUGINFO D0E2AC 3,6,9,12,15,18-HEXAOXAICOSANE Investigative T16308 DRUGINFO D0M9FC (R)-3-(2-naphthamido)-4-m-tolylbutanoic acid Investigative T16308 DRUGINFO D0N9NS (R)-2-(2-naphthamido)-3-m-tolylpropanoic acid Investigative T16308 DRUGINFO D0Q9YG (R)-2-(2-naphthamido)-5-phenylpent-4-ynoic acid Investigative T16308 DRUGINFO D0W4CN Ac-Phe-D-Thr(PO3H2)-Pip-Nal-Gln-NH2 Investigative T16308 DRUGINFO D0W8MX Ac-Phe-Thr(PO3H2)-Pip-Nal-Gln-NH2 Investigative T16308 DRUGINFO D0Y7PY Ac-Bth-Thr(PO3H2)-Pip-Nal-Gln-NH2 Investigative T16308 DRUGINFO D0N0YX Beta-(2-Naphthyl)-Alanine Investigative T06671 TARGETID T06671 T06671 FORMERID TTDC00221 T06671 UNIPROID IL18_HUMAN T06671 TARGNAME Interleukin-18 (IL18) T06671 GENENAME IL18 T06671 TARGTYPE Clinical trial T06671 SYNONYMS Interleukin-1 gamma; Interferon-gamma inducing factor; Interferon gamma-inducing factor; Iboctadekin; IL1F4; IL-18; IL-1 gamma; IGIF; IFN-gamma-inducing factor T06671 FUNCTION Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells. A proinflammatory cytokine primarily involved in polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses. T06671 PDBSTRUC 4XFU; 4XFT; 4XFS; 4R6U; 4HJJ T06671 BIOCLASS Cytokine: interleukin T06671 SEQUENCE MAAEPVEDNCINFVAMKFIDNTLYFIAEDDENLESDYFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRTIFIISMYKDSQPRGMAVTISVKCEKISTLSCENKIISFKEMNPPDNIKDTKSDIIFFQRSVPGHDNKMQFESSSYEGYFLACEKERDLFKLILKKEDELGDRSIMFTVQNED T06671 DRUGINFO DF6UP7 Tadekinig alfa Phase 3 T06671 DRUGINFO D06XDS GSK-1070806 Phase 2 T06671 DRUGINFO D05UCW MEDI-2338 Phase 1 T06671 DRUGINFO D0A8HN Iboctadekin Phase 1 T06671 DRUGINFO D0F3PU Iboctadekin + Doxil Phase 1 T06671 DRUGINFO D0J2VB Iboctadekin + rituximab Phase 1 T06671 DRUGINFO D0I1BQ IL-18BP Discontinued in Phase 1 T62820 TARGETID T62820 T62820 FORMERID TTDR00321 T62820 UNIPROID GRM2_HUMAN T62820 TARGNAME Metabotropic glutamate receptor 2 (mGluR2) T62820 GENENAME GRM2 T62820 TARGTYPE Clinical trial T62820 SYNONYMS mGLUR2; Group II metabotropic glutamate receptor; Glutamate receptor mGLU2; GPRC1B T62820 FUNCTION Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization. G-protein coupled receptor for glutamate. T62820 PDBSTRUC 5KZQ; 5KZN; 5CNJ; 5CNI; 4XAS T62820 BIOCLASS GPCR glutamate T62820 SEQUENCE MGSLLALLALLLLWGAVAEGPAKKVLTLEGDLVLGGLFPVHQKGGPAEDCGPVNEHRGIQRLEAMLFALDRINRDPHLLPGVRLGAHILDSCSKDTHALEQALDFVRASLSRGADGSRHICPDGSYATHGDAPTAITGVIGGSYSDVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFFQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFELEARARNICVATSEKVGRAMSRAAFEGVVRALLQKPSARVAVLFTRSEDARELLAASQRLNASFTWVASDGWGALESVVAGSEGAAEGAITIELASYPISDFASYFQSLDPWNNSRNPWFREFWEQRFRCSFRQRDCAAHSLRAVPFEQESKIMFVVNAVYAMAHALHNMHRALCPNTTRLCDAMRPVNGRRLYKDFVLNVKFDAPFRPADTHNEVRFDRFGDGIGRYNIFTYLRAGSGRYRYQKVGYWAEGLTLDTSLIPWASPSAGPLPASRCSEPCLQNEVKSVQPGEVCCWLCIPCQPYEYRLDEFTCADCGLGYWPNASLTGCFELPQEYIRWGDAWAVGPVTIACLGALATLFVLGVFVRHNATPVVKASGRELCYILLGGVFLCYCMTFIFIAKPSTAVCTLRRLGLGTAFSVCYSALLTKTNRIARIFGGAREGAQRPRFISPASQVAICLALISGQLLIVVAWLVVEAPGTGKETAPERREVVTLRCNHRDASMLGSLAYNVLLIALCTLYAFKTRKCPENFNEAKFIGFTMYTTCIIWLAFLPIFYVTSSDYRVQTTTMCVSVSLSGSVVLGCLFAPKLHIILFQPQKNVVSHRAPTSRFGSAAARASSSLGQGSGSQFVPTVCNGREVVDSTTSSL T62820 DRUGINFO D8GJ1E JNJ-64281802 Phase 2 T62820 DRUGINFO D08OTE RO-4995819 Phase 2 T62820 DRUGINFO D0N5CW Oleoyl-estrone Phase 2 T62820 DRUGINFO DSK7I5 MP-101 Phase 2 T62820 DRUGINFO D02XLI LY-2979165 Phase 1 T62820 DRUGINFO D07GVM JNJ-42491293 Phase 1 T62820 DRUGINFO D0TS8E ADX71149 Phase 1 T62820 DRUGINFO D09WZU BCI-838 Phase 1 T62820 DRUGINFO D0P0ZY Pomaglumetad Phase 1 T62820 DRUGINFO D0T3DG BCI-632 Phase 1 T62820 DRUGINFO D01EVT Ethinyl-pyrazole derivative 1 Patented T62820 DRUGINFO D02RRE Pyrazole derivative 78 Patented T62820 DRUGINFO D03KYL Quinoline derivative 4 Patented T62820 DRUGINFO D03PRA Heteroaryl-pyrazole derivative 2 Patented T62820 DRUGINFO D04LRT Quinoline derivative 9 Patented T62820 DRUGINFO D04VAE PMID25435285-Compound-26 Patented T62820 DRUGINFO D05CBS PMID25435285-Compound-37 Patented T62820 DRUGINFO D06NZY PMID25435285-Compound-44 Patented T62820 DRUGINFO D08JPW N-substituted pyrazole derivative 1 Patented T62820 DRUGINFO D08PHH PMID25435285-Compound-45 Patented T62820 DRUGINFO D09JZA Quinoline derivative 8 Patented T62820 DRUGINFO D09NRH Quinoline derivative 5 Patented T62820 DRUGINFO D09OQZ PMID25435285-Compound-49 Patented T62820 DRUGINFO D09WXH PMID25435285-Compound-25 Patented T62820 DRUGINFO D0B6DN Ethinyl-pyrazole derivative 3 Patented T62820 DRUGINFO D0BP6R Ethinyl-pyrazole derivative 2 Patented T62820 DRUGINFO D0C2ZJ Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 3 Patented T62820 DRUGINFO D0CZ6T Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 2 Patented T62820 DRUGINFO D0E5QO Quinoline derivative 7 Patented T62820 DRUGINFO D0H2BU PMID25435285-Compound-53 Patented T62820 DRUGINFO D0H2LD PMID25435285-Compound-43 Patented T62820 DRUGINFO D0HD8F Pyrazole derivative 76 Patented T62820 DRUGINFO D0I6LO PMID25435285-Compound-47 Patented T62820 DRUGINFO D0IL4Z PMID25435285-Compound-38 Patented T62820 DRUGINFO D0IY8T PMID25435285-Compound-46 Patented T62820 DRUGINFO D0K0ZX Heteroaryl-pyrazole derivative 3 Patented T62820 DRUGINFO D0K1RU Quinoline derivative 3 Patented T62820 DRUGINFO D0KZ6Q PMID25435285-Compound-40 Patented T62820 DRUGINFO D0LI2E Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 1 Patented T62820 DRUGINFO D0N0FA PMID25435285-Compound-51 Patented T62820 DRUGINFO D0N1CC PMID25435285-Compound-42 Patented T62820 DRUGINFO D0N9IA Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 4 Patented T62820 DRUGINFO D0NE0W Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 6 Patented T62820 DRUGINFO D0O6QC Heteroaryl-pyrazole derivative 1 Patented T62820 DRUGINFO D0O9TL PMID25435285-Compound-52 Patented T62820 DRUGINFO D0OT4O Quinoline derivative 6 Patented T62820 DRUGINFO D0P7DA PMID25435285-Compound-10 Patented T62820 DRUGINFO D0Q2FC Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 5 Patented T62820 DRUGINFO D0QM1R Pyrazole derivative 77 Patented T62820 DRUGINFO D0RX0M PMID25435285-Compound-39 Patented T62820 DRUGINFO D0S5SK Pyrazole derivative 79 Patented T62820 DRUGINFO D0V0BC N-substituted pyrazole derivative 2 Patented T62820 DRUGINFO D0WP5S N-substituted pyrazole derivative 3 Patented T62820 DRUGINFO D0Y5DN PMID25435285-Compound-41 Patented T62820 DRUGINFO D0YZ7D PMID25435285-Compound-50 Patented T62820 DRUGINFO D01VZE PMID25435285-Compound-16 Patented T62820 DRUGINFO D0D4OW PMID25435285-Compound-15 Patented T62820 DRUGINFO D0KV7D PMID25435285-Compound-20 Patented T62820 DRUGINFO D0SF1E PMID25435285-Compound-22 Patented T62820 DRUGINFO D0P4BQ LY-544344 Discontinued in Phase 3 T62820 DRUGINFO D08JNE RG1578 Discontinued in Phase 2 T62820 DRUGINFO D09RON LY-2300559 Discontinued in Phase 2 T62820 DRUGINFO D0U5CS LY354740 Discontinued in Phase 2 T62820 DRUGINFO D0Y3RY R-1578 Discontinued in Phase 2 T62820 DRUGINFO D07WSR TS-032 Discontinued in Phase 1 T62820 DRUGINFO D00HKQ PMID22364337C48 Investigative T62820 DRUGINFO D01EAQ [3H]2,2,2-TEMPS Investigative T62820 DRUGINFO D01ETL 3-MPPTS Investigative T62820 DRUGINFO D02DEF JNJ-42153605 Investigative T62820 DRUGINFO D02HNQ PMID21155570C14 Investigative T62820 DRUGINFO D03IES cyPPTS Investigative T62820 DRUGINFO D04GWD [3H]JNJ-40068782 Investigative T62820 DRUGINFO D06SDD MGS0028 Investigative T62820 DRUGINFO D07MHL biphenylindanone A Investigative T62820 DRUGINFO D07TBD DT-2228 Investigative T62820 DRUGINFO D08BXD 4-MPPTS Investigative T62820 DRUGINFO D08JKW PMID20409708C34 Investigative T62820 DRUGINFO D08LEB RO5488608 Investigative T62820 DRUGINFO D08OCG PTBE Investigative T62820 DRUGINFO D09RZQ CBiPES Investigative T62820 DRUGINFO D09UBS Ro64-5229 Investigative T62820 DRUGINFO D0EK6P (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate Investigative T62820 DRUGINFO D0ES5X 4-APPES Investigative T62820 DRUGINFO D0I6WA THIIC Investigative T62820 DRUGINFO D0J2WN PCCG-4 Investigative T62820 DRUGINFO D0N6HV RO4988546 Investigative T62820 DRUGINFO D0SL4Q GSK1331268 Investigative T62820 DRUGINFO D0Y1WV DCG IV Investigative T62820 DRUGINFO D01WKR eGlu Investigative T62820 DRUGINFO D06PAK LY-389795 Investigative T62820 DRUGINFO D06UJA MNI-136 Investigative T62820 DRUGINFO D07GRG LY-379268 Investigative T62820 DRUGINFO D09YEQ Ro4491533 Investigative T62820 DRUGINFO D0C3JX MNI-137 Investigative T62820 DRUGINFO D0H3FH MNI-135 Investigative T62820 DRUGINFO D0S6DK (S)-4C3HPG Investigative T62820 DRUGINFO D0N9UZ [3H]LY341495 Investigative T62820 DRUGINFO D0O8AK alpha-methylserine-O-phosphate Investigative T62820 DRUGINFO D0J8OW (+)-MCPG Investigative T62820 DRUGINFO D04DKM (1S,3R)-ACPD Investigative T62820 DRUGINFO D06DUE [3H]quisqualate Investigative T62820 DRUGINFO D0Z7CZ L-CCG-I Investigative T02719 TARGETID T02719 T02719 FORMERID TTDC00126 T02719 UNIPROID GRM3_HUMAN T02719 TARGNAME Metabotropic glutamate receptor 3 (mGluR3) T02719 GENENAME GRM3 T02719 TARGTYPE Clinical trial T02719 SYNONYMS mGLUR3; Group III metabotropic glutamate receptor; GPRC1C T02719 FUNCTION Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for glutamate. T02719 PDBSTRUC 6B7H; 5CNM; 5CNK; 4XAR; 3SM9 T02719 BIOCLASS GPCR glutamate T02719 SEQUENCE MKMLTRLQVLTLALFSKGFLLSLGDHNFLRREIKIEGDLVLGGLFPINEKGTGTEECGRINEDRGIQRLEAMLFAIDEINKDDYLLPGVKLGVHILDTCSRDTYALEQSLEFVRASLTKVDEAEYMCPDGSYAIQENIPLLIAGVIGGSYSSVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFYQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFEQEARLRNICIATAEKVGRSNIRKSYDSVIRELLQKPNARVVVLFMRSDDSRELIAAASRANASFTWVASDGWGAQESIIKGSEHVAYGAITLELASQPVRQFDRYFQSLNPYNNHRNPWFRDFWEQKFQCSLQNKRNHRRVCDKHLAIDSSNYEQESKIMFVVNAVYAMAHALHKMQRTLCPNTTKLCDAMKILDGKKLYKDYLLKINFTAPFNPNKDADSIVKFDTFGDGMGRYNVFNFQNVGGKYSYLKVGHWAETLSLDVNSIHWSRNSVPTSQCSDPCAPNEMKNMQPGDVCCWICIPCEPYEYLADEFTCMDCGSGQWPTADLTGCYDLPEDYIRWEDAWAIGPVTIACLGFMCTCMVVTVFIKHNNTPLVKASGRELCYILLFGVGLSYCMTFFFIAKPSPVICALRRLGLGSSFAICYSALLTKTNCIARIFDGVKNGAQRPKFISPSSQVFICLGLILVQIVMVSVWLILEAPGTRRYTLAEKRETVILKCNVKDSSMLISLTYDVILVILCTVYAFKTRKCPENFNEAKFIGFTMYTTCIIWLAFLPIFYVTSSDYRVQTTTMCISVSLSGFVVLGCLFAPKVHIILFQPQKNVVTHRLHLNRFSVSGTGTTYSQSSASTYVPTVCNGREVLDSTTSSL T02719 DRUGINFO D0B6RA LY404039 Phase 3 T02719 DRUGINFO D08OTE RO-4995819 Phase 2 T02719 DRUGINFO D0N5CW Oleoyl-estrone Phase 2 T02719 DRUGINFO DSK7I5 MP-101 Phase 2 T02719 DRUGINFO D09WZU BCI-838 Phase 1 T02719 DRUGINFO D0P0ZY Pomaglumetad Phase 1 T02719 DRUGINFO D0T3DG BCI-632 Phase 1 T02719 DRUGINFO D01VZE PMID25435285-Compound-16 Patented T02719 DRUGINFO D0D4OW PMID25435285-Compound-15 Patented T02719 DRUGINFO D0KV7D PMID25435285-Compound-20 Patented T02719 DRUGINFO D0SF1E PMID25435285-Compound-22 Patented T02719 DRUGINFO D0P4BQ LY-544344 Discontinued in Phase 3 T02719 DRUGINFO D0U5CS LY354740 Discontinued in Phase 2 T02719 DRUGINFO D0Y3RY R-1578 Discontinued in Phase 2 T02719 DRUGINFO D02FCY NAAG Investigative T02719 DRUGINFO D0R0IB VU0463597 Investigative T02719 DRUGINFO D01WKR eGlu Investigative T02719 DRUGINFO D06PAK LY-389795 Investigative T02719 DRUGINFO D06UJA MNI-136 Investigative T02719 DRUGINFO D07GRG LY-379268 Investigative T02719 DRUGINFO D09YEQ Ro4491533 Investigative T02719 DRUGINFO D0C3JX MNI-137 Investigative T02719 DRUGINFO D0H3FH MNI-135 Investigative T02719 DRUGINFO D0N9UZ [3H]LY341495 Investigative T02719 DRUGINFO D0J8OW (+)-MCPG Investigative T02719 DRUGINFO D04DKM (1S,3R)-ACPD Investigative T02719 DRUGINFO D06DUE [3H]quisqualate Investigative T02719 DRUGINFO D0Z7CZ L-CCG-I Investigative T44141 TARGETID T44141 T44141 FORMERID TTDC00247 T44141 UNIPROID ANGP1_HUMAN T44141 TARGNAME Angiopoietin-1 (ANGPT1) T44141 GENENAME ANGPT1 T44141 TARGTYPE Clinical trial T44141 SYNONYMS Angiopoietin1; ANGPT1; ANG1; ANG-1 T44141 FUNCTION Binds and activates TEK/TIE2 receptor by inducing its dimerization and tyrosine phosphorylation. Plays an important role in the regulation of angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Required for normal angiogenesis and heart development during embryogenesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. Mediates blood vessel maturation/stability. Implicated in endothelial developmental processes laterand distinct from that of VEGF. Appears to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme. T44141 PDBSTRUC 4K0V; 4JYO; 4EPU T44141 BIOCLASS Fibrinogen protein T44141 SEQUENCE MTVFLSFAFLAAILTHIGCSNQRRSPENSGRRYNRIQHGQCAYTFILPEHDGNCRESTTDQYNTNALQRDAPHVEPDFSSQKLQHLEHVMENYTQWLQKLENYIVENMKSEMAQIQQNAVQNHTATMLEIGTSLLSQTAEQTRKLTDVETQVLNQTSRLEIQLLENSLSTYKLEKQLLQQTNEILKIHEKNSLLEHKILEMEGKHKEELDTLKEEKENLQGLVTRQTYIIQELEKQLNRATTNNSVLQKQQLELMDTVHNLVNLCTKEGVLLKGGKREEEKPFRDCADVYQAGFNKSGIYTIYINNMPEPKKVFCNMDVNGGGWTVIQHREDGSLDFQRGWKEYKMGFGNPSGEYWLGNEFIFAITSQRQYMLRIELMDWEGNRAYSQYDRFHIGNEKQNYRLYLKGHTGTAGKQSSLILHGADFSTKDADNDNCMCKCALMLTGGWWFDACGPSNLNGMFYTAGQNHGKLNGIKWHYFKGPSYSLRSTTMMIRPLDF T44141 DRUGINFO D9NL3R Trebananib Phase 3 T44141 DRUGINFO D0K8NR AMG 386 Phase 3 T44141 DRUGINFO D08UHV AMG 780 Phase 1 T92521 TARGETID T92521 T92521 FORMERID TTDR00242 T92521 UNIPROID CP1B1_HUMAN T92521 TARGNAME Cytochrome P450 1B1 (CYP1B1) T92521 GENENAME CYP1B1 T92521 TARGTYPE Clinical trial T92521 SYNONYMS CYPIB1 T92521 FUNCTION In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compounds to their activated forms, including polycyclic aromatic hydrocarbons. Promotes angiogenesis by removing cellular oxygenation products, thereby decreasing oxidative stress, release of antiangiogenic factor THBS2, then allowing endothelial cells migration, cell adhesion and capillary morphogenesis. These changes are concommitant with the endothelial nitric oxide synthase activity and nitric oxide synthesis. Plays an important role in the regulation of perivascular cell proliferation, migration, and survival through modulation of the intracellular oxidative state and NF-kappa-B expression and/or activity, during angiogenesis. Contributes to oxidative homeostasis and ultrastructural organization and function of trabecular meshwork tissue through modulation of POSTN expression. Cytochromes P450 are a group of heme-thiolate monooxygenases. T92521 PDBSTRUC 6IQ5; 3PM0 T92521 BIOCLASS Paired donor oxygen oxidoreductase T92521 ECNUMBER EC 1.14.14.- T92521 SEQUENCE MGTSLSPNDPWPLNPLSIQQTTLLLLLSVLATVHVGQRLLRQRRRQLRSAPPGPFAWPLIGNAAAVGQAAHLSFARLARRYGDVFQIRLGSCPIVVLNGERAIHQALVQQGSAFADRPAFASFRVVSGGRSMAFGHYSEHWKVQRRAAHSMMRNFFTRQPRSRQVLEGHVLSEARELVALLVRGSADGAFLDPRPLTVVAVANVMSAVCFGCRYSHDDPEFRELLSHNEEFGRTVGAGSLVDVMPWLQYFPNPVRTVFREFEQLNRNFSNFILDKFLRHCESLRPGAAPRDMMDAFILSAEKKAAGDSHGGGARLDLENVPATITDIFGASQDTLSTALQWLLLLFTRYPDVQTRVQAELDQVVGRDRLPCMGDQPNLPYVLAFLYEAMRFSSFVPVTIPHATTANTSVLGYHIPKDTVVFVNQWSVNHDPLKWPNPENFDPARFLDKDGLINKDLTSRVMIFSVGKRRCIGEELSKMQLFLFISILAHQCDFRANPNEPAKMNFSYGLTIKPKSFKVNVTLRESMELLDSAVQNLQAKETCQ T92521 DRUGINFO D0G5CS PINOCEMBRIN Phase 2 T92521 DRUGINFO D02ABO NARINGENIN Phase 1 T92521 DRUGINFO D00RFY DIOSMETIN Investigative T92521 DRUGINFO D01FJE ISOSAKUTANETIN Investigative T92521 DRUGINFO D04DYO KAEMPFERIDE Investigative T92521 DRUGINFO D06PZE TAMARIXETIN Investigative T92521 DRUGINFO D06VXW 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan Investigative T92521 DRUGINFO D08AIJ ERIODICTYOL Investigative T92521 DRUGINFO D0CR8V HOMOERIODICTYOL Investigative T92521 DRUGINFO D0J9OG N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide Investigative T92521 DRUGINFO D0T9IK 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine Investigative T92521 DRUGINFO D0Z1AL 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene Investigative T92521 DRUGINFO D01FGM CHRYSOERIOL Investigative T92521 DRUGINFO D07YDN ISORHAMNETIN Investigative T92521 DRUGINFO D0NS1S ACACETIN Investigative T92521 DRUGINFO D0O9NE TRISMETHOXYRESVERATROL Investigative T92521 DRUGINFO D0Y7HG Galangin Investigative T92521 DRUGINFO D01UYI Chrysin Investigative T92521 DRUGINFO D00RIX APIGENIN Investigative T92521 DRUGINFO D0G3TK KAEMPFEROL Investigative T87686 TARGETID T87686 T87686 FORMERID TTDNC00492 T87686 UNIPROID DOT1L_HUMAN T87686 TARGNAME Histone-lysine N-methyltransferase (HLNM) T87686 GENENAME DOT1L T87686 TARGTYPE Clinical trial T87686 SYNONYMS Lysine N-methyltransferase 4; KMT4; KIAA1814; Histone-lysine N-methyltransferase, H3 lysine-79 specific; Histone H3-K79 methyltransferase; H3-K79-HMTase; DOT1-like protein T87686 FUNCTION Histone methyltransferase. Methylates 'Lys-79' of histone H3. Nucleosomes are preferred as substrate compared to free histones. Binds to DNA. T87686 PDBSTRUC 6O96; 6NQA; 6NOG; 6NN6; 6NJ9 T87686 BIOCLASS Methyltransferase T87686 ECNUMBER EC 2.1.1.43 T87686 SEQUENCE MGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPKLREEQEAARRRQQRESKSNAATPTKGPEGKVAGPADAPMDSGAEEEKAGAATVKKPSPSKARKKKLNKKGRKMAGRKRGRPKKMNTANPERKPKKNQTALDALHAQTVSQTAASSPQDAYRSPHSPFYQLPPSVQRHSPNPLLVAPTPPALQKLLESFKIQYLQFLAYTKTPQYKASLQELLGQEKEKNAQLLGAAQQLLSHCQAQKEEIRRLFQQKLDELGVKALTYNDLIQAQKEISAHNQQLREQSEQLEQDNRALRGQSLQLLKARCEELQLDWATLSLEKLLKEKQALKSQISEKQRHCLELQISIVELEKSQRQQELLQLKSCVPPDDALSLHLRGKGALGRELEPDASRLHLELDCTKFSLPHLSSMSPELSMNGQAAGYELCGVLSRPSSKQNTPQYLASPLDQEVVPCTPSHVGRPRLEKLSGLAAPDYTRLSPAKIVLRRHLSQDHTVPGRPAASELHSRAEHTKENGLPYQSPSVPGSMKLSPQDPRPLSPGALQLAGEKSSEKGLRERAYGSSGELITSLPISIPLSTVQPNKLPVSIPLASVVLPSRAERARSTPSPVLQPRDPSSTLEKQIGANAHGAGSRSLALAPAGFSYAGSVAISGALAGSPASLTPGAEPATLDESSSSGSLFATVGSRSSTPQHPLLLAQPRNSLPASPAHQLSSSPRLGGAAQGPLPEASKGDLPSDSGFSDPESEAKRRIVFTITTGAGSAKQSPSSKHSPLTASARGDCVPSHGQDSRRRGRRKRASAGTPSLSAGVSPKRRALPSVAGLFTQPSGSPLNLNSMVSNINQPLEITAISSPETSLKSSPVPYQDHDQPPVLKKERPLSQTNGAHYSPLTSDEEPGSEDEPSSARIERKIATISLESKSPPKTLENGGGLAGRKPAPAGEPVNSSKWKSTFSPISDIGLAKSADSPLQASSALSQNSLFTFRPALEEPSADAKLAAHPRKGFPGSLSGADGLSPGTNPANGCTFGGGLAADLSLHSFSDGASLPHKGPEAAGLSSPLSFPSQRGKEGSDANPFLSKRQLDGLAGLKGEGSRGKEAGEGGLPLCGPTDKTPLLSGKAAKARDREVDLKNGHNLFISAAAVPPGSLLSGPGLAPAASSAGGAASSAQTHRSFLGPFPPGPQFALGPMSLQANLGSVAGSSVLQSLFSSVPAAAGLVHVSSAATRLTNSHAMGSFSGVAGGTVGGN T87686 DRUGINFO D0C6GK EPZ-5676 Phase 1/2 T87686 DRUGINFO D09ENZ EPZ-004777 Investigative T87686 DRUGINFO D0L0DC bromo-deaza-SAH Investigative T87686 DRUGINFO D0S9SJ SGC0946 Investigative T92640 TARGETID T92640 T92640 FORMERID TTDR00580 T92640 UNIPROID LPAR1_HUMAN T92640 TARGNAME Lysophosphatidic acid receptor 1 (LPAR1) T92640 GENENAME LPAR1 T92640 TARGTYPE Clinical trial T92640 SYNONYMS Lysophosphatidic acid receptor Edg-2; LPA1; LPA-1; LPA receptor 1; EDG2; EDG 2 receptor T92640 FUNCTION Plays a role in the reorganization of the actin cytoskeleton, cell migration, differentiation and proliferation, and thereby contributes to the responses to tissue damage and infectious agents. Activates downstream signaling cascades via the G(i)/G(o), G(12)/G(13), and G(q) families of heteromeric G proteins. Signaling inhibits adenylyl cyclase activity and decreases cellular cAMP levels. Signaling triggers an increase of cytoplasmic Ca(2+) levels. Activates RALA; this leads to the activation of phospholipase C (PLC) and the formation of inositol 1,4,5-trisphosphate. Signaling mediates activation of down-stream MAP kinases. Contributes to the regulation of cell shape. Promotes Rho-dependent reorganization of the actin cytoskeleton in neuronal cells and neurite retraction. Promotes the activation of Rho and the formation of actin stress fibers. Promotes formation of lamellipodia at the leading edge of migrating cells via activation of RAC1. Through its function as lysophosphatidic acid receptor, plays a role in chemotaxis and cell migration, including responses to injury and wounding. Plays a role in triggering inflammation in response to bacterial lipopolysaccharide (LPS) via its interaction with CD14. Promotes cell proliferation in response to lysophosphatidic acid. Required for normal skeleton development. May play a role in osteoblast differentiation. Required for normal brain development. Required for normal proliferation, survival and maturation of newly formed neurons in the adult dentate gyrus. Plays a role in pain perception and in the initiation of neuropathic pain. Receptor for lysophosphatidic acid (LPA). T92640 PDBSTRUC 4Z36; 4Z35; 4Z34 T92640 BIOCLASS GPCR rhodopsin T92640 SEQUENCE MAAISTSIPVISQPQFTAMNEPQCFYNESIAFFYNRSGKHLATEWNTVSKLVMGLGITVCIFIMLANLLVMVAIYVNRRFHFPIYYLMANLAAADFFAGLAYFYLMFNTGPNTRRLTVSTWLLRQGLIDTSLTASVANLLAIAIERHITVFRMQLHTRMSNRRVVVVIVVIWTMAIVMGAIPSVGWNCICDIENCSNMAPLYSDSYLVFWAIFNLVTFVVMVVLYAHIFGYVRQRTMRMSRHSSGPRRNRDTMMSLLKTVVIVLGAFIICWTPGLVLLLLDVCCPQCDVLAYEKFFLLLAEFNSAMNPIIYSYRDKEMSATFRQILCCQRSENPTGPTEGSDRSASSLNHTILAGVHSNDHSVV T92640 DRUGINFO D0D6ZW BMS-986020 Phase 2 T92640 DRUGINFO DB53RG BMS-986278 Phase 2 T92640 DRUGINFO D07WCT SAR-100842 Phase 2 T92640 DRUGINFO DCW89Z BMS-986337 Phase 1 T92640 DRUGINFO D06XGC BMS-986202 Preclinical T92640 DRUGINFO D02RYR Phosphoric acid monodec-9-enyl ester Investigative T92640 DRUGINFO D03HLU Phosphoric acid mono-((E)-dec-4-enyl) ester Investigative T92640 DRUGINFO D04BLL Phosphoric acid mono-((E)-tetradec-11-enyl) ester Investigative T92640 DRUGINFO D04CJG Phosphoric acid monotetradecyl ester Investigative T92640 DRUGINFO D06YTN Decyl-phosphonic acid Investigative T92640 DRUGINFO D07WLV Phosphoric acid mono-((E)-dodec-9-enyl) ester Investigative T92640 DRUGINFO D07YUV Phosphoric acid mono-((E)-tetradec-9-enyl) ester Investigative T92640 DRUGINFO D0BP3E (1,1-Difluoro-pentadecyl)-phosphonic acid Investigative T92640 DRUGINFO D0F2SQ Thiophosphoric acid dec-9-enyl ester Investigative T92640 DRUGINFO D0J2WC ONO-9780307 Investigative T92640 DRUGINFO D0N3YN ONO-3080573 Investigative T92640 DRUGINFO D0N4AG Thiophosphoric acid (E)-tetradec-9-enyl ester Investigative T92640 DRUGINFO D0OF2J anti-BrP-LPA Investigative T92640 DRUGINFO D0P7GR Tetradecyl-phosphonic acid Investigative T92640 DRUGINFO D0S8MS ONO-9910539 Investigative T92640 DRUGINFO D0U5US Dodecyl-phosphonic acid Investigative T92640 DRUGINFO D0X7MB syn-BrP-LPA Investigative T92640 DRUGINFO D0XJ9P Phosphoric acid monododecyl ester Investigative T92640 DRUGINFO D0XY0Z Thiophosphoric acid (E)-dodec-9-enyl ester Investigative T92640 DRUGINFO D0Z2QV Thiophosphoric acid decyl ester Investigative T92640 DRUGINFO D06IXI BrP-LPA Investigative T92640 DRUGINFO D0S6CW VPC32183 Investigative T92640 DRUGINFO D0X0OP alkyl OMPT Investigative T92640 DRUGINFO D0Z6DG T13 Investigative T92640 DRUGINFO D04KQT dodecyl-thiophosphate Investigative T92640 DRUGINFO D0K3GQ oleoyl-thiophosphate Investigative T92640 DRUGINFO D0PI4H VPC12249 Investigative T92640 DRUGINFO D0R8LB NAEPA Investigative T92640 DRUGINFO D02LXI Ki16425 Investigative T92640 DRUGINFO D0G6XT dioctanoylglycerol pyrophosphate Investigative T92640 DRUGINFO D0R2VH 2-oleoyl-LPA Investigative T92640 DRUGINFO D0X0UR LPA Investigative T46871 TARGETID T46871 T46871 FORMERID TTDI02174 T46871 UNIPROID SHIP1_HUMAN T46871 TARGNAME SH2 domain inositol 5'-phosphatase 1 (INPP5D) T46871 GENENAME INPP5D T46871 TARGTYPE Clinical trial T46871 SYNONYMS p150Ship; hp51CN; SIP145; SIP-145; SHIP1; SHIP-1; SHIP; SH2 domaincontaining inositol phosphatase 1; SH2 domaincontaining inositol 5'phosphatase 1; SH2 domain-containing inositol phosphatase 1; SH2 domain-containing inositol 5'-phosphatase 1; Phosphatidylinositol 3,4,5trisphosphate 5phosphatase 1; Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1; Inositol polyphosphate5phosphatase of 145 kDa; Inositol polyphosphate-5-phosphatase of 145 kDa T46871 FUNCTION Acts as a negative regulator of B-cell antigen receptor signaling. Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Acts as a negative regulator of myeloid cell proliferation/survival and chemotaxis, mast cell degranulation, immune cells homeostasis, integrin alpha-IIb/beta-3 signaling in platelets and JNK signaling in B-cells. Regulates proliferation of osteoclast precursors, macrophage programming, phagocytosis and activation and is required for endotoxin tolerance. Involved in the control of cell-cell junctions, CD32a signaling in neutrophils and modulation of EGF-induced phospholipase C activity. Key regulator of neutrophil migration, by governing the formation of the leading edge and polarization required for chemotaxis. Modulates FCGR3/CD16-mediated cytotoxicity in NK cells. Mediates the activin/TGF-beta-induced apoptosis through its Smad-dependent expression. May also hydrolyze PtdIns(1,3,4,5)P4, and could thus affect the levels of the higher inositol polyphosphates like InsP6. Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways. T46871 PDBSTRUC 6IBD; 2YSX T46871 BIOCLASS Phosphoric monoester hydrolase T46871 ECNUMBER EC 3.1.3.86 T46871 SEQUENCE MVPCWNHGNITRSKAEELLSRTGKDGSFLVRASESISRAYALCVLYRNCVYTYRILPNEDDKFTVQASEGVSMRFFTKLDQLIEFYKKENMGLVTHLQYPVPLEEEDTGDDPEEDTVESVVSPPELPPRNIPLTASSCEAKEVPFSNENPRATETSRPSLSETLFQRLQSMDTSGLPEEHLKAIQDYLSTQLAQDSEFVKTGSSSLPHLKKLTTLLCKELYGEVIRTLPSLESLQRLFDQQLSPGLRPRPQVPGEANPINMVSKLSQLTSLLSSIEDKVKALLHEGPESPHRPSLIPPVTFEVKAESLGIPQKMQLKVDVESGKLIIKKSKDGSEDKFYSHKKILQLIKSQKFLNKLVILVETEKEKILRKEYVFADSKKREGFCQLLQQMKNKHSEQPEPDMITIFIGTWNMGNAPPPKKITSWFLSKGQGKTRDDSADYIPHDIYVIGTQEDPLSEKEWLEILKHSLQEITSVTFKTVAIHTLWNIRIVVLAKPEHENRISHICTDNVKTGIANTLGNKGAVGVSFMFNGTSLGFVNSHLTSGSEKKLRRNQNYMNILRFLALGDKKLSPFNITHRFTHLFWFGDLNYRVDLPTWEAETIIQKIKQQQYADLLSHDQLLTERREQKVFLHFEEEEITFAPTYRFERLTRDKYAYTKQKATGMKYNLPSWCDRVLWKSYPLVHVVCQSYGSTSDIMTSDHSPVFATFEAGVTSQFVSKNGPGTVDSQGQIEFLRCYATLKTKSQTKFYLEFHSSCLESFVKSQEGENEEGSEGELVVKFGETLPKLKPIISDPEYLLDQHILISIKSSDSDESYGEGCIALRLEATETQLPIYTPLTHHGELTGHFQGEIKLQTSQGKTREKLYDFVKTERDESSGPKTLKSLTSHDPMKQWEVTSRAPPCSGSSITEIINPNYMGVGPFGPPMPLHVKQTLSPDQQPTAWSYDQPPKDSPLGPCRGESPPTPPGQPPISPKKFLPSTANRGLPPRTQESRPSDLGKNAGDTLPQEDLPLTKPEMFENPLYGSLSSFPKPAPRKDQESPKMPRKEPPPCPEPGILSPSIVLTKAQEADRGEGPGKQVPAPRLRSFTCSSSAEGRAAGGDKSQGKPKTPVSSQAPVPAKRPIKPSRSEINQQTPPTPTPRPPLPVKSPAVLHLQHSKGRDYRDNTELPHHGKHRPEEGPPGPLGRTAMQ T46871 DRUGINFO D02HDG AQX-1125 Phase 2 T03755 TARGETID T03755 T03755 FORMERID TTDC00244 T03755 UNIPROID B2CL2_HUMAN T03755 TARGNAME Apoptosis regulator Bcl-W (BCL-W) T03755 GENENAME BCL2L2 T03755 TARGTYPE Clinical trial T03755 SYNONYMS KIAA0271; Bcl2-L-2; Bcl-2-like protein 2; BCLW T03755 FUNCTION Blocks dexamethasone-induced apoptosis. Mediates survival of postmitotic Sertoli cells by suppressing death-promoting activity of BAX. Promotes cell survival. T03755 PDBSTRUC 4CIM; 2Y6W; 1ZY3; 1O0L; 1MK3 T03755 BIOCLASS B-cell lymphoma Bcl-2 T03755 SEQUENCE MATPASAPDTRALVADFVGYKLRQKGYVCGAGPGEGPAADPLHQAMRAAGDEFETRFRRTFSDLAAQLHVTPGSAQQRFTQVSDELFQGGPNWGRLVAFFVFGAALCAESVNKEMEPLVGQVQEWMVAYLETQLADWIHSSGGWAEFTALYGDGALEEARRLREGNWASVRTVLTGAVALGALVTVGAFFASK T03755 DRUGINFO D06ETI ABT-263 Phase 3 T03755 DRUGINFO D0TU3N PMID27744724-Compound-18 Patented T98022 TARGETID T98022 T98022 FORMERID TTDC00053 T98022 UNIPROID CBPB2_HUMAN T98022 TARGNAME Carboxypeptidase B2 (CPB2) T98022 GENENAME CPB2 T98022 TARGTYPE Clinical trial T98022 SYNONYMS Thrombin-activable fibrinolysis inhibitor; TAFI; Plasma carboxypeptidase B; Carboxypeptidase U; CPU; CPB2 T98022 FUNCTION Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down- regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin. T98022 PDBSTRUC 5HVH; 5HVG; 5HVF; 4P10; 3LMS T98022 BIOCLASS Peptidase T98022 ECNUMBER EC 3.4.17.20 T98022 SEQUENCE MKLCSLAVLVPIVLFCEQHVFAFQSGQVLAALPRTSRQVQVLQNLTTTYEIVLWQPVTADLIVKKKQVHFFVNASDVDNVKAHLNVSGIPCSVLLADVEDLIQQQISNDTVSPRASASYYEQYHSLNEIYSWIEFITERHPDMLTKIHIGSSFEKYPLYVLKVSGKEQAAKNAIWIDCGIHAREWISPAFCLWFIGHITQFYGIIGQYTNLLRLVDFYVMPVVNVDGYDYSWKKNRMWRKNRSFYANNHCIGTDLNRNFASKHWCEEGASSSSCSETYCGLYPESEPEVKAVASFLRRNINQIKAYISMHSYSQHIVFPYSYTRSKSKDHEELSLVASEAVRAIEKISKNTRYTHGHGSETLYLAPGGGDDWIYDLGIKYSFTIELRDTGTYGFLLPERYIKPTCREAFAAVSKIAWHVIRNV T98022 DRUGINFO D01NXX SAR-126119 Phase 1 T98022 DRUGINFO D05WSP UK-396082 Phase 1 T98022 DRUGINFO D06RHC DS-1040 Phase 1 T98022 DRUGINFO D0V6JF SAR-104772 Phase 1 T98022 DRUGINFO D0F7FX AZD-9684 Discontinued in Phase 2 T98022 DRUGINFO D00DXB 3-mercapto-2-(piperidin-3-yl)propanoic acid Investigative T98022 DRUGINFO D00GOD 6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid Investigative T98022 DRUGINFO D06TJC 3-mercapto-2-(piperidin-4-yl)propanoic acid Investigative T98022 DRUGINFO D07RXJ 2-(4-benzoylpiperidine-1-carbonyl)benzoic acid Investigative T98022 DRUGINFO D08SBS DL-guanidinoethylmercaptosuccinic acid Investigative T98022 DRUGINFO D0D2MV 2-(3-guanidinophenyl)-3-mercaptopropanoic acid Investigative T98022 DRUGINFO D0JD9E SQ-24798 Investigative T98022 DRUGINFO D0R2PW 2-(3-aminophenyl)-3-mercaptopropanoic acid Investigative T98022 DRUGINFO D0R3KN MN-462 Investigative T98022 DRUGINFO D0R7PE (+/-)-5-amino-2-(mercaptomethyl)pentanoic acid Investigative T98022 DRUGINFO D06LNX DL-benzylsuccinic acid Investigative T98022 DRUGINFO D0O3QJ PMID19954973C4 Investigative T98022 DRUGINFO D0XA0N PMID14640538C3 Investigative T27889 TARGETID T27889 T27889 FORMERID TTDNC00602 T27889 UNIPROID ACE2_HUMAN T27889 TARGNAME Angiotensin-converting enzyme 2 (ACE2) T27889 GENENAME ACE2 T27889 TARGTYPE Clinical trial T27889 SYNONYMS Processed angiotensinconverting enzyme 2; Metalloprotease MPROT15; Angiotensinconverting enzyme homolog; Angiotensinconverting enzyme 2; ACErelated carboxypeptidase; ACEH; ACE2 T27889 FUNCTION Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin- 13 and dynorphin-13 with high efficiency. May be an important regulator of heart function. In case of human coronaviruses SARS and HCoV-NL63 infections, serve as functional receptor for the spike glycoprotein of both coronaviruses. T27889 PDBSTRUC 6CS2; 6ACK; 6ACJ; 6ACG; 3SCL T27889 BIOCLASS Peptidase T27889 ECNUMBER EC 3.4.17.23 T27889 SEQUENCE MSSSSWLLLSLVAVTAAQSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHDETYCDPASLFHVSNDYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPWTLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYADQSIKVRISLKSALGDKAYEWNDNEMYLFRSSVAYAMRQYFLKVKNQMILFGEEDVRVANLKPRISFNFFVTAPKNVSDIIPRTEVEKAIRMSRSRINDAFRLNDNSLEFLGIQPTLGPPNQPPVSIWLIVFGVVMGVIVVGIVILIFTGIRDRKKKNKARSGENPYASIDISKGENNPGFQNTDDVQTSF T27889 DRUGINFO D0ET2T GSK2586881 Phase 2 T27889 DRUGINFO D08EYQ ORE-1001 Phase 1/2 T27889 DRUGINFO D0NQ0B XNT Investigative T27889 DRUGINFO D0P0MP PMID18324760C28 Investigative T26500 TARGETID T26500 T26500 FORMERID TTDR01193 T26500 UNIPROID HRH4_HUMAN T26500 TARGNAME Histamine H4 receptor (H4R) T26500 GENENAME HRH4 T26500 TARGTYPE Clinical trial T26500 SYNONYMS SP9144; Pfi-013; HH4R; H4 receptor; GPRv53; GPCR105; G protein-coupled receptor 105; AXOR35 T26500 FUNCTION Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist). The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. T26500 BIOCLASS GPCR rhodopsin T26500 SEQUENCE MPDTNSTINLSLSTRVTLAFFMSLVAFAIMLGNALVILAFVVDKNLRHRSSYFFLNLAISDFFVGVISIPLYIPHTLFEWDFGKEICVFWLTTDYLLCTASVYNIVLISYDRYLSVSNAVSYRTQHTGVLKIVTLMVAVWVLAFLVNGPMILVSESWKDEGSECEPGFFSEWYILAITSFLEFVIPVILVAYFNMNIYWSLWKRDHLSRCQSHPGLTAVSSNICGHSFRGRLSSRRSLSASTEVPASFHSERQRRKSSLMFSSRTKMNSNTIASKMGSFSQSDSVALHQREHVELLRARRLAKSLAILLGVFAVCWAPYSLFTIVLSFYSSATGPKSVWYRIAFWLQWFNSFVNPLLYPLCHKRFQKAFLKIFCIKKQPLPSQHSRSVSS T26500 DRUGINFO D02DTQ PF-3893787 Phase 2 T26500 DRUGINFO D04VBF JNJ-38518168 Phase 2 T26500 DRUGINFO D05GYL UR-63325 Phase 2 T26500 DRUGINFO D05FYA Thioperamide Terminated T26500 DRUGINFO D00XJR JNJ-10191584 Investigative T26500 DRUGINFO D02SQF 4-methylhistamine Investigative T26500 DRUGINFO D04EDO improgan Investigative T26500 DRUGINFO D05OIF N-ethylhistamine Investigative T26500 DRUGINFO D08BLM 9-benzyl-6-(4-methylpiperazin-1-yl)-9H-purine Investigative T26500 DRUGINFO D08DOG A-846714 Investigative T26500 DRUGINFO D09HUF UR-60427 Investigative T26500 DRUGINFO D09UVB HTMT Investigative T26500 DRUGINFO D0E9SR [3H]JNJ 7777120 Investigative T26500 DRUGINFO D0G3RZ 6-(4-Methylpiperazin-1-yl)-9H-purin-2-amine Investigative T26500 DRUGINFO D0IF3N N,N-dimethylhistamine Investigative T26500 DRUGINFO D0MP8E VUF 8430 Investigative T26500 DRUGINFO D0P8DW A-943931 Investigative T26500 DRUGINFO D0QT2F 6-(4-methylpiperazin-1-yl)-9Hpurine Investigative T26500 DRUGINFO D0TC5E 2-methylhistamine Investigative T26500 DRUGINFO D0UK0F 6-(4-Methylpiperazin-1-yl)pyrimidine-2,4-diamine Investigative T26500 DRUGINFO D02RAN Imetit Investigative T26500 DRUGINFO D03ECU [125I]iodophenpropit Investigative T26500 DRUGINFO D03SAM (R)-alpha-methylhistamine Investigative T26500 DRUGINFO D08ECP N-[3H]alpha-methylhistamine Investigative T26500 DRUGINFO D0A4XL N-[3H]methylhistamine Investigative T26500 DRUGINFO D0C8IB (R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate Investigative T26500 DRUGINFO D0G6AQ 2-(3-bromophenyl)histamine Investigative T26500 DRUGINFO D0H2KD (1H-indol-2-yl)(piperazin-1-yl)methanone Investigative T26500 DRUGINFO D0Q8BS (S)-alpha-methylhistamine Investigative T26500 DRUGINFO D0T6SC N-methylhistamine Investigative T26500 DRUGINFO D0T8OD Clobenpropit Investigative T26500 DRUGINFO D06RNM burimamide Investigative T26500 DRUGINFO D01JXM 2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole Investigative T26500 DRUGINFO D0B4SF impromidine Investigative T30563 TARGETID T30563 T30563 FORMERID TTDR00545 T30563 UNIPROID LT4R2_HUMAN T30563 TARGNAME Leukotriene B4 receptor 2 (LTB4R2) T30563 GENENAME LTB4R2 T30563 TARGTYPE Clinical trial T30563 SYNONYMS Seven transmembrane receptor BLTR2; Leukotriene B4 receptor BLT2; Leukotriene B(4) receptor BLT2; LTB4-R2; LTB4-R 2; LTB4 receptor JULF2; BLTR2; BLT2R T30563 FUNCTION Mediates chemotaxis of granulocytes and macrophages. The response is mediated via G-proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinities for the leukotrienes is LTB4 > 12-epi-LTB4 > LTB5 > LTB3. Low-affinity receptor for leukotrienes including leukotriene B4. T30563 BIOCLASS GPCR rhodopsin T30563 SEQUENCE MSVCYRPPGNETLLSWKTSRATGTAFLLLAALLGLPGNGFVVWSLAGWRPARGRPLAATLVLHLALADGAVLLLTPLFVAFLTRQAWPLGQAGCKAVYYVCALSMYASVLLTGLLSLQRCLAVTRPFLAPRLRSPALARRLLLAVWLAALLLAVPAAVYRHLWRDRVCQLCHPSPVHAAAHLSLETLTAFVLPFGLMLGCYSVTLARLRGARWGSGRHGARVGRLVSAIVLAFGLLWAPYHAVNLLQAVAALAPPEGALAKLGGAGQAARAGTTALAFFSSSVNPVLYVFTAGDLLPRAGPRFLTRLFEGSGEARGGGRSREGTMELRTTPQLKVVGQGRGNGDPGGGMEKDGPEWDL T30563 DRUGINFO D0O4NR LTB4 Phase 2 T30563 DRUGINFO D0S0WN Biomed 101 Phase 1 T30563 DRUGINFO D0Z0OT ONO-4057 Discontinued in Phase 2 T30563 DRUGINFO D0C0EO CP-105696 Discontinued in Phase 1 T30563 DRUGINFO D01XMO LY-292728 Terminated T30563 DRUGINFO D0Y2IH LY-255283 Terminated T30563 DRUGINFO D01CRJ ZK-158252 Investigative T30563 DRUGINFO D07BYG [3H]LTB4 Investigative T30563 DRUGINFO D0F7XM 12-epi LTB4 Investigative T30563 DRUGINFO D0I4FF 20-hydroxy-LTB4 Investigative T30563 DRUGINFO D0S0DT CAY10583 Investigative T30563 DRUGINFO D0SK3A BIIL 260 Investigative T30563 DRUGINFO D0SM3V 12-hydroxyheptadecatrienoic acid Investigative T30563 DRUGINFO D0V3ZG RO5101576 Investigative T30563 DRUGINFO D0Y2XY 12R-HETE Investigative T30563 DRUGINFO D05HNB LY-282210 Investigative T30563 DRUGINFO D06IGT (3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol Investigative T30563 DRUGINFO D0Z5QA 12S-HETE Investigative T86014 TARGETID T86014 T86014 FORMERID TTDI02179 T86014 UNIPROID SPHK1_HUMAN T86014 TARGNAME Sphingosine kinase 1 (SPHK1) T86014 GENENAME SPHK1 T86014 TARGTYPE Clinical trial T86014 SYNONYMS SPK 1; SPK; SPHK1; SK 1; Acetyltransferase SPHK1 T86014 FUNCTION Acts on D-erythro-sphingosine and to a lesser extent sphinganine, but not other lipids, such as D,L-threo-dihydrosphingosine, N,N-dimethylsphingosine, diacylglycerol, ceramide, or phosphatidylinositol. In contrast to proapoptotic SPHK2, has a negative effect on intracellular ceramide levels, enhances cell growth and inhibits apoptosis. Involved in the regulation of inflammatory response and neuroinflammation. Via the product sphingosine 1-phosphate, stimulates TRAF2 E3 ubiquitin ligase activity, and promotes activation of NF-kappa-B in response to TNF signaling leading to IL17 secretion. In response to TNF and in parallel to NF-kappa-B activation, negatively regulates RANTES inducion through p38 MAPK signaling pathway. Involved in endocytic membrane trafficking induced by sphingosine, recruited to dilate endosomes, also plays a role on later stages of endosomal maturation and membrane fusion independently of its kinase activity. In Purkinje cells, seems to be also involved in the regulation of autophagosome-lysosome fusion upon VEGFA. Catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (SPP), a lipid mediator with both intra- and extracellular functions. T86014 PDBSTRUC 4V24; 4L02; 3VZD; 3VZC; 3VZB T86014 BIOCLASS Kinase T86014 ECNUMBER EC 2.7.1.91 T86014 SEQUENCE MDPAGGPRGVLPRPCRVLVLLNPRGGKGKALQLFRSHVQPLLAEAEISFTLMLTERRNHARELVRSEELGRWDALVVMSGDGLMHEVVNGLMERPDWETAIQKPLCSLPAGSGNALAASLNHYAGYEQVTNEDLLTNCTLLLCRRLLSPMNLLSLHTASGLRLFSVLSLAWGFIADVDLESEKYRRLGEMRFTLGTFLRLAALRTYRGRLAYLPVGRVGSKTPASPVVVQQGPVDAHLVPLEEPVPSHWTVVPDEDFVLVLALLHSHLGSEMFAAPMGRCAAGVMHLFYVRAGVSRAMLLRLFLAMEKGRHMEYECPYLVYVPVVAFRLEPKDGKGVFAVDGELMVSEAVQGQVHPNYFWMVSGCVEPPPSWKPQQMPPPEEPL T86014 DRUGINFO D03YOS Phenoxodiol Phase 1/2 T86014 DRUGINFO D0HI1K GSK618334 Phase 1 T86014 DRUGINFO D02DLL PMID27539678-Compound-6 Patented T86014 DRUGINFO D04VDD Methylbenzenesulfonamide derivative 1 Patented T86014 DRUGINFO D07QBL PMID27539678-Compound-12 Patented T86014 DRUGINFO D0DG7E PMID27539678-Compound-10 Patented T86014 DRUGINFO D0G2TX PMID27539678-Compound-16 Patented T86014 DRUGINFO D0H1BQ PMID27539678-Compound-14 Patented T86014 DRUGINFO D0HM6Q PMID27539678-Compound-13 Patented T86014 DRUGINFO D0QT5B PMID27539678-Compound-11 Patented T86014 DRUGINFO D0RE9W PMID27539678-Compound-7 Patented T86014 DRUGINFO D0TR9T PMID27539678-Compound-17 Patented T86014 DRUGINFO D0VB2X PMID27539678-Compound-9 Patented T86014 DRUGINFO D02YQJ B-5354a Terminated T86014 DRUGINFO D0O0JH F-12509A Terminated T86014 DRUGINFO D00YNY VPC-94075 Investigative T86014 DRUGINFO D05SLY SK1-I Investigative T86014 DRUGINFO D08SND PF-543 Investigative T07279 TARGETID T07279 T07279 FORMERID TTDNR00746 T07279 UNIPROID PIM2_HUMAN T07279 TARGNAME Serine/threonine-protein kinase pim-2 (PIM2) T07279 GENENAME PIM2 T07279 TARGTYPE Clinical trial T07279 SYNONYMS Pim-2h; PIM2 T07279 FUNCTION Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilization of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti- apoptotic protein Bcl-X(L)/BCL2L1. Promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade; this process requires phosphorylation of MAP3K8/COT. Isoform 1 is less active in this respect. Promotes growth factor-independent proliferation by phosphorylation of cell cycle factors such as CDKN1A and CDKN1B. Involved in the positive regulation of chondrocyte survival and autophagy in the epiphyseal growth plate. T07279 PDBSTRUC 4X7Q; 2IWI T07279 BIOCLASS Kinase T07279 ECNUMBER EC 2.7.11.1 T07279 SEQUENCE MLTKPLQGPPAPPGTPTPPPGGKDREAFEAEYRLGPLLGKGGFGTVFAGHRLTDRLQVAIKVIPRNRVLGWSPLSDSVTCPLEVALLWKVGAGGGHPGVIRLLDWFETQEGFMLVLERPLPAQDLFDYITEKGPLGEGPSRCFFGQVVAAIQHCHSRGVVHRDIKDENILIDLRRGCAKLIDFGSGALLHDEPYTDFDGTRVYSPPEWISRHQYHALPATVWSLGILLYDMVCGDIPFERDQEILEAELHFPAHVSPDCCALIRRCLAPKPSSRPSLEEILLDPWMQTPAEDVPLNPSKGGPAPLAWSLLP T07279 DRUGINFO D07EHV LGH-447 Phase 1/2 T07279 DRUGINFO D00IFR AZD1208 Phase 1 T07279 DRUGINFO D0V9MV IDDBCP226234 Investigative T07279 DRUGINFO D06UKS PMID21982499C14k Investigative T65501 TARGETID T65501 T65501 FORMERID TTDR01100 T65501 UNIPROID DNM3B_HUMAN T65501 TARGNAME DNA [cytosine-5]-methyltransferase 3B (DNMT3B) T65501 GENENAME DNMT3B T65501 TARGTYPE Clinical trial T65501 SYNONYMS M.HsaIIIB; Dnmt3b; DNA methyltransferase HsaIIIB; DNA methyltransferase 3B; DNA MTase HsaIIIB; DNA (cytosine-5)-methyltransferase 3B T65501 FUNCTION DNA methylation is coordinated with methylation of histones. May preferentially methylates nucleosomal DNA within the nucleosome core region. May function as transcriptional co-repressor by associating with CBX4 and independently of DNA methylation. Seems to be involved in gene silencing. In association with DNMT1 and via the recruitment of CTCFL/BORIS, involved in activation of BAG1 gene expression by modulating dimethylation of promoter histone H3 at H3K4 and H3K9. Isoforms 4 and 5 are probably not functional due to the deletion of two conserved methyltransferase motifs. Function as transcriptional corepressor by associating with ZHX1. Required for DUX4 silencing in somatic cells. Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development. T65501 PDBSTRUC 5NVO; 5NV7; 5NV2; 5NV0; 5NRV T65501 BIOCLASS Methyltransferase T65501 ECNUMBER EC 2.1.1.37 T65501 SEQUENCE MKGDTRHLNGEEDAGGREDSILVNGACSDQSSDSPPILEAIRTPEIRGRRSSSRLSKREVSSLLSYTQDLTGDGDGEDGDGSDTPVMPKLFRETRTRSESPAVRTRNNNSVSSRERHRPSPRSTRGRQGRNHVDESPVEFPATRSLRRRATASAGTPWPSPPSSYLTIDLTDDTEDTHGTPQSSSTPYARLAQDSQQGGMESPQVEADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQPVVNKSKVRRAGSRKLESRKYENKTRRRTADDSATSDYCPAPKRLKTNCYNNGKDRGDEDQSREQMASDVANNKSSLEDGCLSCGRKNPVSFHPLFEGGLCQTCRDRFLELFYMYDDDGYQSYCTVCCEGRELLLCSNTSCCRCFCVECLEVLVGTGTAAEAKLQEPWSCYMCLPQRCHGVLRRRKDWNVRLQAFFTSDTGLEYEAPKLYPAIPAARRRPIRVLSLFDGIATGYLVLKELGIKVGKYVASEVCEESIAVGTVKHEGNIKYVNDVRNITKKNIEEWGPFDLVIGGSPCNDLSNVNPARKGLYEGTGRLFFEFYHLLNYSRPKEGDDRPFFWMFENVVAMKVGDKRDISRFLECNPVMIDAIKVSAAHRARYFWGNLPGMNRPVIASKNDKLELQDCLEYNRIAKLKKVQTITTKSNSIKQGKNQLFPVVMNGKEDVLWCTELERIFGFPVHYTDVSNMGRGARQKLLGRSWSVPVIRHLFAPLKDYFACE T65501 DRUGINFO D07SDQ Curcumin Phase 3 T65501 DRUGINFO D02WRM PMID27376512-Compound-MTC-424 Patented T65501 DRUGINFO D0HA0J PMID27376512-Compound-MTC-427 Patented T65501 DRUGINFO D0QY0N PMID27376512-Compound-MTC-422 Patented T65501 DRUGINFO D0W9VZ PMID27376512-Compound-MTC-423 Patented T65501 DRUGINFO D01VNN NSC-622444 Investigative T65501 DRUGINFO D03PWU NSC-138419 Investigative T65501 DRUGINFO D06RGX NSC-319745 Investigative T65501 DRUGINFO D06VVV NSC-348926 Investigative T65501 DRUGINFO D07VWC NSC-401077 Investigative T65501 DRUGINFO D08TGQ S-tubercidinylhomocysteine Investigative T65501 DRUGINFO D0A2ZH NSC-106084 Investigative T65501 DRUGINFO D0C4NA NSC-154957 Investigative T65501 DRUGINFO D0FN7C NSC-54162 Investigative T65501 DRUGINFO D0G9NS NSC-57893 Investigative T65501 DRUGINFO D0H1YK NSC-56071 Investigative T65501 DRUGINFO D0I5JP NSC-137546 Investigative T65501 DRUGINFO D0LS2U NSC-623548 Investigative T65501 DRUGINFO D0MP7N NSC-345763 Investigative T65501 DRUGINFO D0W5SZ NSC-158324 Investigative T65501 DRUGINFO D09CLP (L-)-S-adenosyl-L-homocysteine Investigative T65501 DRUGINFO D0J5VK NSC-622445 Investigative T84133 TARGETID T84133 T84133 FORMERID TTDNC00456 T84133 UNIPROID PDE10_HUMAN T84133 TARGNAME Phosphodiesterase 10A (PDE10) T84133 GENENAME PDE10A T84133 TARGTYPE Clinical trial T84133 SYNONYMS cAMP and cAMPinhibited cGMP 3',5'cyclic phosphodiesterase 10A; cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A T84133 FUNCTION Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate. May play a critical role in regulating cAMP and cGMP levels in the striatum, a region of the brain that contributes to the control of movement and cognition. Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. T84133 PDBSTRUC 6MSC; 6MSA; 6IJI; 6IJH; 5ZNL T84133 BIOCLASS Phosphoric diester hydrolase T84133 ECNUMBER EC 3.1.4.17 T84133 SEQUENCE MRIEERKSQHLTGLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKNNKSEDESAPKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATKADGFALYFLGECNNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDILGDERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHKNKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHRIRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED T84133 DRUGINFO D09UZL TAK-063 Phase 2 T84133 DRUGINFO D0OH2W PF-02545920 Phase 2 T84133 DRUGINFO D0U3QK OMS824 Phase 2 T84133 DRUGINFO DC29HL Lu AF11167 Phase 2 T84133 DRUGINFO DB82TO Tofisopam Phase 2 T84133 DRUGINFO D09GPI FRM-6308 Phase 1b T84133 DRUGINFO D0LB6D RG7203 Phase 1 T84133 DRUGINFO D0X0PP AMG 579 Phase 1 T84133 DRUGINFO DJ0P6A PBF-999 Phase 1 T84133 DRUGINFO D00YOY Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 Patented T84133 DRUGINFO D01ITP Triazolo-pyridine derivative 5 Patented T84133 DRUGINFO D02PFP PMID27321640-Compound-58 Patented T84133 DRUGINFO D05VBJ Triazolo-pyridine derivative 4 Patented T84133 DRUGINFO D07EUB Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3 Patented T84133 DRUGINFO D07NRP Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4 Patented T84133 DRUGINFO D07ZTT Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5 Patented T84133 DRUGINFO D09BDD 1,2,4-triazole [4,3-a]quinoxaline derivative 1 Patented T84133 DRUGINFO D09RWM PMID27321640-Compound-59 Patented T84133 DRUGINFO D0A8EV Triazolo-pyridine derivative 6 Patented T84133 DRUGINFO D0D0QT Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2 Patented T84133 DRUGINFO D0D4YR Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1 Patented T84133 DRUGINFO D0FV3G 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 Patented T84133 DRUGINFO D0I5UY Imidazo[5,1-c][1,2,4]benzotriazine derivative 2 Patented T84133 DRUGINFO D0J6KS 1,2,4-triazole [4,3-a]quinoxaline derivative 3 Patented T84133 DRUGINFO D0J8YF Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8 Patented T84133 DRUGINFO D0JJ8K Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7 Patented T84133 DRUGINFO D0L6AM Imidazo[5,1-c][1,2,4]benzotriazine derivative 4 Patented T84133 DRUGINFO D0LI6Z 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3 Patented T84133 DRUGINFO D0MK7X Imidazo[5,1-c][1,2,4]benzotriazine derivative 3 Patented T84133 DRUGINFO D0PP8O Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6 Patented T84133 DRUGINFO D0QE7X 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4 Patented T84133 DRUGINFO D0QI8G Imidazo[5,1-c][1,2,4]benzotriazine derivative 1 Patented T84133 DRUGINFO D0RI3W 1,2,4-triazole [4,3-a]quinoxaline derivative 2 Patented T84133 DRUGINFO D0SV1I Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3 Patented T84133 DRUGINFO D0U3KV Triazolo-pyridine derivative 2 Patented T84133 DRUGINFO D0X2UO 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5 Patented T84133 DRUGINFO D0Z4IA Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1 Patented T84133 DRUGINFO D0Z8VY Triazolo-pyridine derivative 3 Patented T84133 DRUGINFO D01LSP Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 Patented T84133 DRUGINFO D0T8WU Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 Patented T61722 TARGETID T61722 T61722 FORMERID TTDC00237 T61722 UNIPROID PD2R2_HUMAN T61722 TARGNAME Prostaglandin D2 receptor 2 (PTGDR2) T61722 GENENAME PTGDR2 T61722 TARGTYPE Clinical trial T61722 SYNONYMS PTGDR2; Chemoattractant receptor-homologous molecule expressed on Th2 cells; CD294 T61722 FUNCTION Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin- sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, ADRBK1/GRK2, GPRK5/GRK5 and GRK6. Receptoractivation is responsible, at least in part, in immune regulation and allergic/inflammation responses. T61722 PDBSTRUC 6D27; 6D26 T61722 BIOCLASS GPCR rhodopsin T61722 SEQUENCE MSANATLKPLCPILEQMSRLQSHSNTSIRYIDHAAVLLHGLASLLGLVENGVILFVVGCRMRQTVVTTWVLHLALSDLLASASLPFFTYFLAVGHSWELGTTFCKLHSSIFFLNMFASGFLLSAISLDRCLQVVRPVWAQNHRTVAAAHKVCLVLWALAVLNTVPYFVFRDTISRLDGRIMCYYNVLLLNPGPDRDATCNSRQVALAVSKFLLAFLVPLAIIASSHAAVSLRLQHRGRRRPGRFVRLVAAVVAAFALCWGPYHVFSLLEARAHANPGLRPLVWRGLPFVTSLAFFNSVANPVLYVLTCPDMLRKLRRSLRTVLESVLVDDSELGGAGSSRRRRTSSTARSASPLALCSRPEEPRGPARLLGWLLGSCAASPQTGPLNRALSSTSS T61722 DRUGINFO D0WL5V LAROPIPRANT Phase 4 T61722 DRUGINFO DH7F9S Fevipiprant Phase 3 T61722 DRUGINFO D0SP5V Setipiprant Phase 3 T61722 DRUGINFO D0GC5H Ramatroban Phase 2/3 T61722 DRUGINFO D02JND ADC-3680 Phase 2 T61722 DRUGINFO D05STL ARRY-502 Phase 2 T61722 DRUGINFO D0K1EG QAV-680 Phase 2 T61722 DRUGINFO D0RL4X AP-761 Phase 2 T61722 DRUGINFO D0T4SG AZD1981 Phase 2 T61722 DRUGINFO D0X7EG OC-000459 Phase 2 T61722 DRUGINFO DKP0T7 GB001 Phase 2 T61722 DRUGINFO DVT3F8 BBI-5000 Phase 2 T61722 DRUGINFO D0YB2Y AMG 853 Phase 2 T61722 DRUGINFO D06ESU AM-461 Phase 1 T61722 DRUGINFO D0I3TU MK-7246 Phase 1 T61722 DRUGINFO D0U1HN AM-211 Phase 1 T61722 DRUGINFO D00HTY PGF2alpha Clinical trial T61722 DRUGINFO D01NGT RG-7185 Discontinued in Phase 1 T61722 DRUGINFO D01RVS AZD5985 Discontinued in Phase 1 T61722 DRUGINFO D06XSG AZD8075 Discontinued in Phase 1 T61722 DRUGINFO D00GHK 13,14-dihydro-15-keto-PGD2 Investigative T61722 DRUGINFO D00GUE 2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid Investigative T61722 DRUGINFO D01AFV 2-(4-bromo-2-cyclohexylphenoxy)acetic acid Investigative T61722 DRUGINFO D03ZPH 15-deoxy-Delta12,14-PGD2 Investigative T61722 DRUGINFO D05GWV 2-(4-cyano-2-cyclohexylphenoxy)acetic acid Investigative T61722 DRUGINFO D05HPB 2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid Investigative T61722 DRUGINFO D07GCA 2-(4-chloro-2-cycloheptylphenoxy)acetic acid Investigative T61722 DRUGINFO D08CLB 2-(2-cyclohexylphenoxy)acetic acid Investigative T61722 DRUGINFO D08KZJ CAY 10471 Investigative T61722 DRUGINFO D09ZSV 2-(4-bromo-2-formylphenoxy)acetic acid Investigative T61722 DRUGINFO D0A0UL 15(S)-15-methyl-PGD2 Investigative T61722 DRUGINFO D0C0FU Methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate Investigative T61722 DRUGINFO D0CS4I 15(R)-15-methyl-PGD2 Investigative T61722 DRUGINFO D0E0HT 2-(2-allyl-4-chlorophenoxy)acetic acid Investigative T61722 DRUGINFO D0E3WT 2-(2,4-diphenylthiazol-5-yl)acetic acid Investigative T61722 DRUGINFO D0H2SL 2-(4-bromo-2-tert-butylphenoxy)acetic acid Investigative T61722 DRUGINFO D0HK3U AM-156 Investigative T61722 DRUGINFO D0I8MN 2-(4-chloro-2-cyclopentylphenoxy)acetic acid Investigative T61722 DRUGINFO D0J2PW 2-(2-formylphenoxy)acetic acid Investigative T61722 DRUGINFO D0J5OX 3-(4-chloro-2-cyclohexylphenoxy)propanoic acid Investigative T61722 DRUGINFO D0M2DJ 2-(2-acetyl-4-bromophenoxy)acetic acid Investigative T61722 DRUGINFO D0Q0GY IW-1221 Investigative T61722 DRUGINFO D0QE3V L-888607 Investigative T61722 DRUGINFO D0QH5C 2-(4-chloro-2-cyclohexylphenoxy)acetic acid Investigative T61722 DRUGINFO D0R1KE 2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid Investigative T61722 DRUGINFO D0S0BK 2-(2-cyclohexyl-4-methylphenoxy)acetic acid Investigative T61722 DRUGINFO D0U3LA 2-(2-benzoyl-4-bromophenoxy)acetic acid Investigative T61722 DRUGINFO D0U3YW ADC-9971 Investigative T61722 DRUGINFO D0U5PC 4-(4-chloro-2-cyclohexylphenoxy)butanoic acid Investigative T61722 DRUGINFO D0V4PZ PGD3 Investigative T61722 DRUGINFO D0X4NG 13,14-dihydro-15-keto-PGF2alpha Investigative T61722 DRUGINFO D0Y4UG 2-(2-cyclohexyl-4-fluorophenoxy)acetic acid Investigative T61722 DRUGINFO D01RQK 15-deoxy-Delta12,14-PGJ2 Investigative T61722 DRUGINFO D0MS3D Delta12-PGJ2 Investigative T61722 DRUGINFO D0WV5J L-888,291 Investigative T61722 DRUGINFO D0Y6OX PGJ2 Investigative T61722 DRUGINFO D06KBO PGD2 Investigative T61722 DRUGINFO D03PLH U46619 Investigative T92463 TARGETID T92463 T92463 FORMERID TTDR01346 T92463 UNIPROID RIPK2_HUMAN T92463 TARGNAME RIP2 messenger RNA (RIP2 mRNA) T92463 GENENAME RIPK2 T92463 TARGTYPE Clinical trial T92463 SYNONYMS UNQ277/PRO314/PRO34092 (mRNA); Tyrosine-protein kinase RIPK2 (mRNA); Receptor-interacting serine/threonine-protein kinase 2 (mRNA); Receptor-interacting protein 2 (mRNA); RIP2 (mRNA); RIP-like-interacting CLARP kinase (mRNA); RIP-2 (mRNA); RICK (mRNA); CARDIAK (mRNA); CARD-containing interleukin-1 beta-converting enzyme-associated kinase (mRNA); CARD-containing IL-1 beta ICE-kinase (mRNA) T92463 FUNCTION Upon stimulation by bacterial peptidoglycans, NOD1 and NOD2 are activated, oligomerize and recruit RIPK2 through CARD-CARD domains. Contributes to the tyrosine phosphorylation of the guanine exchange factor ARHGEF2 through Src tyrosine kinase leading to NF-kappaB activation by NOD2. Once recruited, RIPK2 autophosphorylates and undergoes 'Lys-63'-linked polyubiquitination by E3 ubiquitin ligases XIAP, BIRC2 and BIRC3. The polyubiquitinated protein mediates the recruitment of MAP3K7/TAK1 to IKBKG/NEMO and induces 'Lys-63'-linked polyubiquitination of IKBKG/NEMO and subsequent activation of IKBKB/IKKB. In turn, NF-kappa-B is released from NF-kappa-B inhibitors and translocates into the nucleus where it activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Plays also a role during engagement of the T-cell receptor (TCR) in promoting BCL10 phosphorylation and subsequent NF-kappa-B activation. Serine/threonine/tyrosine kinase that plays an essential role in modulation of innate and adaptive immune responses. T92463 PDBSTRUC 6HMX; 6GGS; 6GFJ; 6FU5; 6ES0 T92463 BIOCLASS mRNA target T92463 ECNUMBER EC 2.7.11.1 T92463 SEQUENCE MNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLKKTKLQSVSSAIHLCDKKKMELSLNIPVNHGPQEESCGSSQLHENSGSPETSRSLPAPQDNDFLSRKAQDCYFMKLHHCPGNHSWDSTISGSQRAAFCDHKTTPCSSAIINPLSTAGNSERLQPGIAQQWIQSKREDIVNQMTEACLNQSLDALLSRDLIMKEDYELVSTKPTRTSKVRQLLDTTDIQGEEFAKVIVQKLKDNKQMGLQPYPEILVVSRSPSLNLLQNKSM T92463 DRUGINFO D06CIJ ISIS-CRP Phase 1 T92463 DRUGINFO D02AOC ISIS 104258 Investigative T92463 DRUGINFO D05EHP ISIS 104254 Investigative T92463 DRUGINFO D07RJW ISIS 104211 Investigative T92463 DRUGINFO D0F8WV ISIS 104257 Investigative T92463 DRUGINFO D0J1DV ISIS 104256 Investigative T92463 DRUGINFO D0PE2Y ISIS 104255 Investigative T92463 DRUGINFO D0Q0IN ISIS 104253 Investigative T92463 DRUGINFO D0U2QT Src kinase inhibitor I Investigative T92463 DRUGINFO D0GT8N NM-PP1 Investigative T10482 TARGETID T10482 T10482 FORMERID TTDI02677 T10482 UNIPROID FA12_HUMAN T10482 TARGNAME Factor XII messenger RNA (FA12 mRNA) T10482 GENENAME F12 T10482 TARGTYPE Clinical trial T10482 SYNONYMS Hageman factor (mRNA); HAF (mRNA); Coagulation factor XII (mRNA) T10482 FUNCTION Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa. Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. T10482 PDBSTRUC 6B77; 6B74; 4XE4; 4XDE; 4BDX T10482 BIOCLASS mRNA target T10482 ECNUMBER EC 3.4.21.38 T10482 SEQUENCE MRALLLLGFLLVSLESTLSIPPWEAPKEHKYKAEEHTVVLTVTGEPCHFPFQYHRQLYHKCTHKGRPGPQPWCATTPNFDQDQRWGYCLEPKKVKDHCSKHSPCQKGGTCVNMPSGPHCLCPQHLTGNHCQKEKCFEPQLLRFFHKNEIWYRTEQAAVARCQCKGPDAHCQRLASQACRTNPCLHGGRCLEVEGHRLCHCPVGYTGAFCDVDTKASCYDGRGLSYRGLARTTLSGAPCQPWASEATYRNVTAEQARNWGLGGHAFCRNPDNDIRPWCFVLNRDRLSWEYCDLAQCQTPTQAAPPTPVSPRLHVPLMPAQPAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTRNGPLSCGQRLRKSLSSMTRVVGGLVALRGAHPYIAALYWGHSFCAGSLIAPCWVLTAAHCLQDRPAPEDLTVVLGQERRNHSCEPCQTLAVRSYRLHEAFSPVSYQHDLALLRLQEDADGSCALLSPYVQPVCLPSGAARPSETTLCQVAGWGHQFEGAEEYASFLQEAQVPFLSLERCSAPDVHGSSILPGMLCAGFLEGGTDACQGDSGGPLVCEDQAAERRLTLQGIISWGSGCGDRNKPGVYTDVAYYLAWIREHTVS T10482 DRUGINFO D0R7EA methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate Clinical trial T15803 TARGETID T15803 T15803 FORMERID TTDC00330 T15803 UNIPROID FA11_HUMAN T15803 TARGNAME Factor XI messenger RNA (F11 mRNA) T15803 GENENAME F11 T15803 TARGTYPE Clinical trial T15803 SYNONYMS Plasma thromboplastin antecedent (mRNA); PTA (mRNA); FXI (mRNA); Coagulation factor XI (mRNA) T15803 FUNCTION Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. T15803 PDBSTRUC 6R8X; 6I58; 6C0S; 6AOD; 5WB6 T15803 BIOCLASS mRNA target T15803 ECNUMBER EC 3.4.21.27 T15803 SEQUENCE MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV T15803 DRUGINFO D0KY7S ISIS-FXI Phase 2 T15803 DRUGINFO DB6XD8 BMS-986177 Phase 2 T15803 DRUGINFO DD2C5E IONIS-416858 Phase 2 T15803 DRUGINFO D05TKW alpha-ketothiazole analogue 36 Clinical trial T15803 DRUGINFO D0F7ZH FXI-AS1 Investigative T46521 TARGETID T46521 T46521 FORMERID TTDC00332 T46521 UNIPROID ANDR_HUMAN T46521 TARGNAME Androgen receptor messenger RNA (AR mRNA) T46521 GENENAME AR T46521 TARGTYPE Clinical trial T46521 SYNONYMS Testosterone receptor (mRNA); Nuclear receptor subfamily 3 group C member 4 (mRNA); NR3C4 (mRNA); Dihydrotestosterone receptor (mRNA); DHTR (mRNA); Androgen receptor (mRNA) T46521 FUNCTION Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation. Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. T46521 PDBSTRUC 5VO4; 5V8Q; 5T8J; 5T8E; 5JJM T46521 BIOCLASS mRNA target T46521 SEQUENCE MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ T46521 DRUGINFO D04DJN Dihydrotestosterone Phase 4 T46521 DRUGINFO D0L3HU BAY 86-5044 Phase 2 T46521 DRUGINFO D0SD9Z TRC-253 Phase 1/2 T46521 DRUGINFO D3BZ0H IONIS-AR-2.5Rx Phase 1/2 T46521 DRUGINFO D03POY ISIS-AR Phase 1 T46521 DRUGINFO D09RND EZN-4176 Phase 1 T46521 DRUGINFO D0O4QB EUGENOL Patented T46521 DRUGINFO D0L5KF RU-58841 Discontinued in Phase 1 T46521 DRUGINFO D00BLY 4-(isopropylthio)-2-methoxybenzonitrile Investigative T46521 DRUGINFO D00CDF andarine Investigative T46521 DRUGINFO D01THF 4-(mesitylthio)-2-methoxybenzonitrile Investigative T46521 DRUGINFO D02CXU 3-methoxy-4-(m-tolyloxy)benzonitrile Investigative T46521 DRUGINFO D02ZEE 2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile Investigative T46521 DRUGINFO D03MQA 4-(cyclopropylmethylthio)-2-methoxybenzonitrile Investigative T46521 DRUGINFO D03VQC 4-(isopentylthio)-2-methoxybenzonitrile Investigative T46521 DRUGINFO D03WHD 6-amino-4-trifluoromethylquinolin-2(1H)-one Investigative T46521 DRUGINFO D04KPW 2-methoxy-4-(m-tolyloxy)benzonitrile Investigative T46521 DRUGINFO D04PLB 2-chloro-4-(o-tolyloxy)benzonitrile Investigative T46521 DRUGINFO D04QAT 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D04USO 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D05FPU 4-(butylthio)-2-methoxybenzonitrile Investigative T46521 DRUGINFO D06JPP LG-121071 Investigative T46521 DRUGINFO D06PRV 3-chloro-4-(o-tolylthio)benzonitrile Investigative T46521 DRUGINFO D06WNK 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile Investigative T46521 DRUGINFO D06YKU NSC-26745 Investigative T46521 DRUGINFO D06ZZM 3-chloro-4-(o-tolyloxy)benzonitrile Investigative T46521 DRUGINFO D07GCR 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D07QFN 3-methoxy-4-(p-tolyloxy)benzonitrile Investigative T46521 DRUGINFO D07TVI PF-0998425 Investigative T46521 DRUGINFO D08DHC 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D08FZN 6-N-propyl -4-trifluoromethylquinolin-2(1H)-one Investigative T46521 DRUGINFO D08FZR 2-methoxy-4-(2-methoxyphenylthio)benzonitrile Investigative T46521 DRUGINFO D08RCS 2-methoxy-4-(propylthio)benzonitrile Investigative T46521 DRUGINFO D09SJY 2-methoxy-4-(o-tolyloxy)benzonitrile Investigative T46521 DRUGINFO D0B2JG 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D0BU5X 4-(cyclobutylmethylthio)-2-methoxybenzonitrile Investigative T46521 DRUGINFO D0F5JY BMS-564929 Investigative T46521 DRUGINFO D0FI1I 3-methoxy-4-(o-tolyloxy)benzonitrile Investigative T46521 DRUGINFO D0G0XB 3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile Investigative T46521 DRUGINFO D0G3IT RU-56187 Investigative T46521 DRUGINFO D0I5YU 4-(propylthio)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D0L7OC 4-(butylthio)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D0M0RS LGD-2226 Investigative T46521 DRUGINFO D0O0ZC 6-Hydroxyflavanone Investigative T46521 DRUGINFO D0P0ZQ 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D0T7LR 2-methoxy-4-(p-tolyloxy)benzonitrile Investigative T46521 DRUGINFO D0U9IR 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D0V3UU YM-175735 Investigative T46521 DRUGINFO D0V5HF 5-Methoxyflavone Investigative T46521 DRUGINFO D0VE6A 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile Investigative T46521 DRUGINFO D02RQP bisphenol A Investigative T46521 DRUGINFO D06BLF 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane Investigative T46521 DRUGINFO D06VZE [3H]mibolerone Investigative T46521 DRUGINFO D07KWO RU-43044 Investigative T46521 DRUGINFO D01ETZ [3H]methyltrienolone Investigative T46521 DRUGINFO D09OKK LG-120838 Investigative T46521 DRUGINFO D0G5OV WAY-255348 Investigative T46521 DRUGINFO D0XS0R Epierenone Investigative T46521 DRUGINFO D08KQM LGD-5552 Investigative T46521 DRUGINFO D0GR5L AL-43 Investigative T46521 DRUGINFO D0J7XZ CP-409069 Investigative T46521 DRUGINFO D0L5IC CP-394531 Investigative T46521 DRUGINFO D0S0RK flavone Investigative T46521 DRUGINFO D00RIX APIGENIN Investigative T46521 DRUGINFO D0G3TK KAEMPFEROL Investigative T41515 TARGETID T41515 T41515 FORMERID TTDR01438 T41515 UNIPROID FGFR4_HUMAN T41515 TARGNAME FGFR4 messenger RNA (FGFR4 mRNA) T41515 GENENAME FGFR4 T41515 TARGTYPE Clinical trial T41515 SYNONYMS TKF (mRNA); JTK2 (mRNA); FGFR-4 (mRNA); CD334 (mRNA) T41515 FUNCTION Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. T41515 PDBSTRUC 6JPJ; 5XFJ; 5XFF; 5NWZ; 5NUD T41515 BIOCLASS mRNA target T41515 ECNUMBER EC 2.7.10.1 T41515 SEQUENCE MRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRAERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDSLTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTPTIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLDVLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFPYVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLARQFSLESGSSGKSSSSLVRGVRLSSSGPALLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQVVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVCTQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGMQYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEALFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYGLMRECWHAAPSQRPTFKQLVEALDKVLLAVSEEYLDLRLTFGPYSPSGGDASSTCSSSDSVFSHDPLPLGSSSFPFGSGVQT T41515 DRUGINFO D0SL8T ISIS-FGFR4 Phase 2 T41515 DRUGINFO D08EQD FGF401 Phase 1/2 T41515 DRUGINFO D0D6XT H3B-6527 Phase 1 T41515 DRUGINFO D0XZ1D BLU-554 Phase 1 T41515 DRUGINFO D0Z0KD PD-0183812 Terminated T41515 DRUGINFO D09XIL Ro-4396686 Investigative T37952 TARGETID T37952 T37952 FORMERID TTDI02237 T37952 UNIPROID KSYK_HUMAN T37952 TARGNAME SYK messenger RNA (SYK mRNA) T37952 GENENAME SYK T37952 TARGTYPE Clinical trial T37952 SYNONYMS p72-Syk (mRNA); Spleen tyrosine kinase (mRNA) T37952 FUNCTION Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK. Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition. Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR plays also a role in T-cell receptor signaling. Plays also a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF-kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade. Required for the stimulation of neutrophil phagocytosis by IL15. Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Involved in interleukin-3/IL3-mediated signaling pathway in basophils. Also functions downstream of receptors mediating cell adhesion. Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG-mediated recruitment of leukocytes to inflammatory loci. Plays also a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen. Together with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response. Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). T37952 PDBSTRUC 6HM7; 6HM6; 5Y5U; 5Y5T; 5TT7 T37952 BIOCLASS mRNA target T37952 ECNUMBER EC 2.7.10.2 T37952 SEQUENCE MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRKAHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPFEDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQIVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQLVEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPATWSAGGIISRIKSYSFPKPGHRKSSPAQGNRQESTVSFNPYEPELAPWAADKGPQREALPMDTEVYESPYADPEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN T37952 DRUGINFO D0TG4S ASN002 Phase 2 T87875 TARGETID T87875 T87875 FORMERID TTDC00286 T87875 UNIPROID GLR_HUMAN T87875 TARGNAME Glucagon receptor messenger RNA (GCGR mRNA) T87875 GENENAME GCGR T87875 TARGTYPE Clinical trial T87875 SYNONYMS Glucagon receptor (mRNA); GLR (mRNA); GL-R (mRNA) T87875 FUNCTION Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system. G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. T87875 PDBSTRUC 5XEZ; 5EE7; 4LF3; 4L6R; 4ERS T87875 BIOCLASS mRNA target T87875 SEQUENCE MPPCQPQRPLLLLLLLLACQPQVPSAQVMDFLFEKWKLYGDQCHHNLSLLPPPTELVCNRTFDKYSCWPDTPANTTANISCPWYLPWHHKVQHRFVFKRCGPDGQWVRGPRGQPWRDASQCQMDGEEIEVQKEVAKMYSSFQVMYTVGYSLSLGALLLALAILGGLSKLHCTRNAIHANLFASFVLKASSVLVIDGLLRTRYSQKIGDDLSVSTWLSDGAVAGCRVAAVFMQYGIVANYCWLLVEGLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVVPWAVVKCLFENVQCWTSNDNMGFWWILRFPVFLAILINFFIFVRIVQLLVAKLRARQMHHTDYKFRLAKSTLTLIPLLGVHEVVFAFVTDEHAQGTLRSAKLFFDLFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRWRLGKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGGSQDSSAETPLAGGLPRLAESPF T87875 DRUGINFO D04WIF ISIS-GCGR Phase 2 T87875 DRUGINFO DW7XC5 IONIS-GCGR-Rx Phase 2 T87875 DRUGINFO D05LTJ ISIS 325568 Phase 1 T81892 TARGETID T81892 T81892 FORMERID TTDC00280 T81892 UNIPROID XIAP_HUMAN T81892 TARGNAME XIAP messenger RNA (XIAP mRNA) T81892 GENENAME XIAP T81892 TARGTYPE Clinical trial T81892 SYNONYMS hILP (mRNA); hIAP3 (mRNA); hIAP-3 (mRNA); Xlinked IAP (mRNA); X-linked IAP (mRNA); RING-type E3 ubiquitin transferase XIAP (mRNA); Inhibitor of apoptosis protein 3 (mRNA); ILP (mRNA); IAPlike protein (mRNA); IAP3 (mRNA); IAP-like protein (mRNA); IAP-3 (mRNA); E3 ubiquitinprotein ligase XIAP (mRNA); E3 ubiquitin-protein ligase XIAP (mRNA); Baculoviral IAP repeatcontaining protein 4 (mRNA); Baculoviral IAP repeat-containing protein 4 (mRNA); BIRC4 (mRNA); API3 (mRNA) T81892 FUNCTION Acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. Inactivates CASP9 by keeping it in a monomeric, inactive state. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, CASP3, CASP7, CASP8, CASP9, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS and BIRC5/survivin. Ubiquitinion of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation. Ubiquitinion of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation. Plays a role in copper homeostasis by ubiquitinationg COMMD1 and promoting its proteasomal degradation. Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. Acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES. Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. T81892 PDBSTRUC 6QCI; 6EY2; 5OQW; 5O6T; 5M6M T81892 BIOCLASS mRNA target T81892 ECNUMBER EC 2.3.2.27 T81892 SEQUENCE MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDTVRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENYLGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLTPRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSESDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTPSLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKDSMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDKCPMCYTVITFKQKIFMS T81892 DRUGINFO D01NUR ASTX660 Phase 2 T81892 DRUGINFO D0C1JP AEG35156 Phase 1/2 T81892 DRUGINFO D05HSW EMBELIN Terminated T81892 DRUGINFO D09BKS ARPFAQK-FAM Investigative T81892 DRUGINFO D0E7NV AVPIAQKSEK-FAM Investigative T81892 DRUGINFO D03KZH SM-337 Investigative T81892 DRUGINFO D0BW7P SM-131 Investigative T81892 DRUGINFO D0O4UQ BV-6 Investigative T81892 DRUGINFO D0Q7TL SM-122 Investigative T81892 DRUGINFO D0VK7M AZD5582 Investigative T81358 TARGETID T81358 T81358 FORMERID TTDI02039 T81358 UNIPROID CDC7_HUMAN T81358 TARGNAME CDC7-related kinase (CDC7) T81358 GENENAME CDC7 T81358 TARGTYPE Clinical trial T81358 SYNONYMS huCdc7; HsCdc7; Cell division cycle 7related protein kinase; Cell division cycle 7-related protein kinase; CDC7related kinase; CDC7L1 T81358 FUNCTION Can phosphorylates MCM2 and MCM3. Seems to phosphorylate critical substrates that regulate the G1/S phase transition and/or DNA replication. T81358 PDBSTRUC 5UWR; 5UWQ; 4F9C; 4F9B; 4F9A T81358 BIOCLASS Kinase T81358 ECNUMBER EC 2.7.11.1 T81358 SEQUENCE MEASLGIQMDEPMAFSPQRDRFQAEGSLKKNEQNFKLAGVKKDIEKLYEAVPQLSNVFKIEDKIGEGTFSSVYLATAQLQVGPEEKIALKHLIPTSHPIRIAAELQCLTVAGGQDNVMGVKYCFRKNDHVVIAMPYLEHESFLDILNSLSFQEVREYMLNLFKALKRIHQFGIVHRDVKPSNFLYNRRLKKYALVDFGLAQGTHDTKIELLKFVQSEAQQERCSQNKSHIITGNKIPLSGPVPKELDQQSTTKASVKRPYTNAQIQIKQGKDGKEGSVGLSVQRSVFGERNFNIHSSISHESPAVKLMKQSKTVDVLSRKLATKKKAISTKVMNSAVMRKTASSCPASLTCDCYATDKVCSICLSRRQQVAPRAGTPGFRAPEVLTKCPNQTTAIDMWSAGVIFLSLLSGRYPFYKASDDLTALAQIMTIRGSRETIQAAKTFGKSILCSKEVPAQDLRKLCERLRGMDSSTPKLTSDIQGHASHQPAISEKTDHKASCLVQTPPGQYSGNSFKKGDSNSCEHCFDEYNTNLEGWNEVPDEAYDLLDKLLDLNPASRITAEEALLHPFFKDMSL T81358 DRUGINFO D03ISJ BMS-863233 Phase 1/2 T81358 DRUGINFO D0LL4Y TAK-931 Phase 1 T81358 DRUGINFO D0G6QW PMID26161698-Compound-44 Patented T81358 DRUGINFO D03DZO PHA-767491 Investigative T81358 DRUGINFO D0N3LC PMID24793884C77 Investigative T81358 DRUGINFO D08HFG PMID20873740C18 Investigative T81358 DRUGINFO D0RJ8J PMID24793884C74 Investigative T81358 DRUGINFO D0T8NU PMID19115845C89S Investigative T87749 TARGETID T87749 T87749 FORMERID TTDR00823 T87749 UNIPROID GDF8_HUMAN T87749 TARGNAME Growth/differentiation factor 8 (GDF-8) T87749 GENENAME MSTN T87749 TARGTYPE Clinical trial T87749 SYNONYMS GDF8 T87749 FUNCTION Acts specifically as a negative regulator of skeletal muscle growth. T87749 PDBSTRUC 5NXS; 5NTU; 5F3H; 5F3B T87749 BIOCLASS Growth factor T87749 SEQUENCE MQKLQLCVYIYLFMLIVAGPVDLNENSEQKENVEKEGLCNACTWRQNTKSSRIEAIKIQILSKLRLETAPNISKDVIRQLLPKAPPLRELIDQYDVQRDDSSDGSLEDDDYHATTETIITMPTESDFLMQVDGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVETPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGEDGLNPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPINMLYFNGKEQIIYGKIPAMVVDRCGCS T87749 DRUGINFO D00TUR LY2495655 Phase 2 T87749 DRUGINFO D00UFZ AMG 745 Phase 2 T87749 DRUGINFO D05KKP PF-06252616 Phase 2 T87749 DRUGINFO D09GIA SAR391786 Phase 2 T87749 DRUGINFO D0OK1N Domagrozumab Phase 2 T87749 DRUGINFO D0T6EE ACE-031 Phase 2 T87749 DRUGINFO D0C6IQ Stamulumab Phase 1/2 T51407 TARGETID T51407 T51407 FORMERID TTDNR00671 T51407 UNIPROID XPO1_HUMAN T51407 TARGNAME Exportin-1 (XPO1) T51407 GENENAME XPO1 T51407 TARGTYPE Clinical trial T51407 SYNONYMS Exp1; Chromosome region maintenance 1 protein homolog; CRM1 T51407 FUNCTION In the nucleus, in association with RANBP3, binds cooperatively to the NES on its target protein and to the GTPase RAN in its active GTP-bound form (Ran-GTP). Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the cargo from the export receptor. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Involved in U3 snoRNA transport from Cajal bodies to nucleoli. Binds to late precursor U3 snoRNA bearing a TMG cap. Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs. T51407 PDBSTRUC 5DIS; 4BSN; 4BSM; 3GB8; 2L1L T51407 BIOCLASS Eukaryotic nuclear pore complex T51407 SEQUENCE MPAIMTMLADHAARQLLDFSQKLDINLLDNVVNCLYHGEGAQQRMAQEVLTHLKEHPDAWTRVDTILEFSQNMNTKYYGLQILENVIKTRWKILPRNQCEGIKKYVVGLIIKTSSDPTCVEKEKVYIGKLNMILVQILKQEWPKHWPTFISDIVGASRTSESLCQNNMVILKLLSEEVFDFSSGQITQVKSKHLKDSMCNEFSQIFQLCQFVMENSQNAPLVHATLETLLRFLNWIPLGYIFETKLISTLIYKFLNVPMFRNVSLKCLTEIAGVSVSQYEEQFVTLFTLTMMQLKQMLPLNTNIRLAYSNGKDDEQNFIQNLSLFLCTFLKEHDQLIEKRLNLRETLMEALHYMLLVSEVEETEIFKICLEYWNHLAAELYRESPFSTSASPLLSGSQHFDVPPRRQLYLPMLFKVRLLMVSRMAKPEEVLVVENDQGEVVREFMKDTDSINLYKNMRETLVYLTHLDYVDTERIMTEKLHNQVNGTEWSWKNLNTLCWAIGSISGAMHEEDEKRFLVTVIKDLLGLCEQKRGKDNKAIIASNIMYIVGQYPRFLRAHWKFLKTVVNKLFEFMHETHDGVQDMACDTFIKIAQKCRRHFVQVQVGEVMPFIDEILNNINTIICDLQPQQVHTFYEAVGYMIGAQTDQTVQEHLIEKYMLLPNQVWDSIIQQATKNVDILKDPETVKQLGSILKTNVRACKAVGHPFVIQLGRIYLDMLNVYKCLSENISAAIQANGEMVTKQPLIRSMRTVKRETLKLISGWVSRSNDPQMVAENFVPPLLDAVLIDYQRNVPAAREPEVLSTMAIIVNKLGGHITAEIPQIFDAVFECTLNMINKDFEEYPEHRTNFFLLLQAVNSHCFPAFLAIPPTQFKLVLDSIIWAFKHTMRNVADTGLQILFTLLQNVAQEEAAAQSFYQTYFCDILQHIFSVVTDTSHTAGLTMHASILAYMFNLVEEGKISTSLNPGNPVNNQIFLQEYVANLLKSAFPHLQDAQVKLFVTGLFSLNQDIPAFKEHLRDFLVQIKEFAGEDTSDLFLEEREIALRQADEEKHKRQMSVPGIFNPHEIPEEMCD T51407 DRUGINFO D00LNW Selinexor Phase 3 T51407 DRUGINFO D0VI7R Selinexor oral Phase 2 T51407 DRUGINFO D0JF6C Eltanexor oral Phase 1/2 T51407 DRUGINFO D0SP6A SL-801 Phase 1 T51407 DRUGINFO D0Z8EJ KOS-1815 Preclinical T51407 DRUGINFO D2U4RX S109 Investigative T51407 DRUGINFO D3GD1L Octahydrocurcumin Investigative T05090 TARGETID T05090 T05090 FORMERID TTDI01956 T05090 UNIPROID HDAC3_HUMAN T05090 TARGNAME Histone deacetylase 3 (HDAC3) T05090 GENENAME HDAC3 T05090 TARGTYPE Clinical trial T05090 SYNONYMS SMAP45; RPD32; RPD3-2; HD3 T05090 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Participates in the BCL6 transcriptional repressor activity by deacetylating the H3 'Lys-27' (H3K27) on enhancer elements, antagonizing EP300 acetyltransferase activity and repressing proximal gene expression. Probably participates in the regulation of transcription through its binding to the zinc-finger transcription factor YY1; increases YY1 repression activity. Required to repress transcription of the POU1F1 transcription factor. Acts as a molecular chaperone for shuttling phosphorylated NR2C1 to PML bodies for sumoylation. Contributes, together with XBP1 isoform 1, to the activation of NFE2L2-mediated HMOX1 transcription factor gene expression in a PI(3)K/mTORC2/Akt-dependent signaling pathway leading to endothelial cell (EC) survival under disturbed flow/oxidative stress. Regulates both the transcriptional activation and repression phases of the circadian clock in a deacetylase activity-independent manner. During the activation phase, promotes the accumulation of ubiquitinated ARNTL/BMAL1 at the E-boxes and during the repression phase, blocks FBXL3-mediated CRY1/2 ubiquitination and promotes the interaction of CRY1 and ARNTL/BMAL1. The NCOR1-HDAC3 complex regulates the circadian expression of the core clock gene ARTNL/BMAL1 and the genes involved in lipid metabolism in the liver. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4), and some other non-histone substrates. T05090 PDBSTRUC 4A69 T05090 BIOCLASS Carbon-nitrogen hydrolase T05090 ECNUMBER EC 3.5.1.98 T05090 SEQUENCE MAKTVAYFYDPDVGNFHYGAGHPMKPHRLALTHSLVLHYGLYKKMIVFKPYQASQHDMCRFHSEDYIDFLQRVSPTNMQGFTKSLNAFNVGDDCPVFPGLFEFCSRYTGASLQGATQLNNKICDIAINWAGGLHHAKKFEASGFCYVNDIVIGILELLKYHPRVLYIDIDIHHGDGVQEAFYLTDRVMTVSFHKYGNYFFPGTGDMYEVGAESGRYYCLNVPLRDGIDDQSYKHLFQPVINQVVDFYQPTCIVLQCGADSLGCDRLGCFNLSIRGHGECVEYVKSFNIPLLVLGGGGYTVRNVARCWTYETSLLVEEAISEELPYSEYFEYFAPDFTLHPDVSTRIENQNSRQYLDQIRQTIFENLKMLNHAPSVQIHDVPADLLTYDRTDEADAEERGPEENYSRPEAPNEFYDGDHDNDKESDVEI T05090 DRUGINFO D06TKI CHR-3996 Phase 1/2 T05090 DRUGINFO D0UD9R PMID29671355-Compound-57 Patented T05090 DRUGINFO D0XN2W Diaryl amine derivative 4 Patented T05090 DRUGINFO D0C9NX PMID29671355-Compound-59 Patented T05090 DRUGINFO D0OU0J PMID29671355-Compound-55 Patented T05090 DRUGINFO D0EH2K PMID29671355-Compound-11 Patented T05090 DRUGINFO D0Q1QY PMID29671355-Compound-9 Patented T05090 DRUGINFO D0LN1T PMID29671355-Compound-8 Patented T05090 DRUGINFO D0JB4S PMID29671355-Compound-61 Patented T05090 DRUGINFO D0N2DK PMID29671355-Compound-44 Patented T05090 DRUGINFO D0CH8Q PMID29671355-Compound-56 Patented T05090 DRUGINFO D0M0RE PMID29671355-Compound-67 Patented T05090 DRUGINFO D0DI9S PMID29671355-Compound-31 Patented T05090 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T05090 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T05090 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T05090 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T05090 DRUGINFO D00HXX RGFP966 Investigative T05090 DRUGINFO D00VXM droxinostat Investigative T20891 TARGETID T20891 T20891 FORMERID TTDR00273 T20891 UNIPROID PDPK1_HUMAN T20891 TARGNAME Phosphoinositide dependent protein kinase-1 (PDPK1) T20891 GENENAME PDPK1 T20891 TARGTYPE Clinical trial T20891 SYNONYMS PDK1; HPDK1; 3-phosphoinositide-dependent protein kinase 1; 3-Phosphoinositide-dependent kinase-1; 3'-phosphoinositide dependent kinase 1 T20891 FUNCTION Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated kinase-1 (PAK1), protein kinase PKN (PKN1 and PKN2). Plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. Negatively regulates the TGF-beta-induced signaling by: modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta. Activates PPARG transcriptional activity and promotes adipocyte differentiation. Activates the NF-kappa-B pathway via phosphorylation of IKKB. The tyrosine phosphorylated form is crucial for the regulation of focal adhesions by angiotensin II. Controls proliferation, survival, and growth of developing pancreatic cells. Participates in the regulation of Ca(2+) entry and Ca(2+)-activated K(+) channels of mast cells. Essential for the motility of vascular endothelial cells (ECs) and is involved in the regulation of their chemotaxis. Plays a critical role in cardiac homeostasis by serving as a dual effector for cell survival and beta-adrenergic response. Plays an important role during thymocyte development by regulating the expression of key nutrient receptors on the surface of pre-T cells and mediating Notch-induced cell growth and proliferative responses. Provides negative feedback inhibition to toll-like receptor-mediated NF-kappa-B activation in macrophages. Isoform 3 is catalytically inactive. Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. T20891 PDBSTRUC 5MRD; 5LVP; 5LVO; 5LVN; 5LVM T20891 BIOCLASS Kinase T20891 ECNUMBER EC 2.7.11.1 T20891 SEQUENCE MARTTSQLYDAVPIQSSVVLCSCPSPSMVRTQTESSTPPGIPGGSRQGPAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLTAYLPAMSEDDEDCYGNYDNLLSQFGCMQVSSSSSSHSLSASDTGLPQRSGSNIEQYIHDLDSNSFELDLQFSEDEKRLLLEKQAGGNPWHQFVENNLILKMGPVDKRKGLFARRRQLLLTEGPHLYYVDPVNKVLKGEIPWSQELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQEVWRQRYQSHPDAAVQ T20891 DRUGINFO D0C9JJ AR-12 Phase 1 T20891 DRUGINFO D09BXJ PF-5177624 Investigative T20891 DRUGINFO D0EU1R GSK-2334470 Investigative T20891 DRUGINFO D0M9QJ PHT-427 Investigative T20891 DRUGINFO D0IX7Y BX-912 Investigative T20891 DRUGINFO D0RG0Z BX-795 Investigative T20891 DRUGINFO D0L2WP PMID20005102C1 Investigative T20891 DRUGINFO D07PZQ L-serine-O-phosphate Investigative T84634 TARGETID T84634 T84634 FORMERID TTDC00232 T84634 UNIPROID CP26A_HUMAN T84634 TARGNAME Cytochrome P450 26 (CYP26A1) T84634 GENENAME CYP26A1 T84634 TARGTYPE Clinical trial T84634 SYNONYMS Retinoic acid-metabolizing cytochrome; Retinoic acid inducible enzyme; Retinoic acid 4-hydroxylase; P450RAI; P450 retinoic acid-inactivating 1; HP450RAI; Cytochrome P450RAI; CYP26A1 T84634 FUNCTION Plays a key role in retinoic acid metabolism. Acts on retinoids, including all-trans-retinoic acid (RA) and its stereoisomer 9-cis-RA. Capable of both 4-hydroxylation and 18- hydroxylation. Responsible for generation of several hydroxylated forms of RA, including 4-OH-RA, 4-oxo-RA and 18-OH-RA. T84634 BIOCLASS Paired donor oxygen oxidoreductase T84634 ECNUMBER EC 1.14.13.- T84634 SEQUENCE MGLPALLASALCTFVLPLLLFLAAIKLWDLYCVSGRDRSCALPLPPGTMGFPFFGETLQMVLQRRKFLQMKRRKYGFIYKTHLFGRPTVRVMGADNVRRILLGEHRLVSVHWPASVRTILGSGCLSNLHDSSHKQRKKVIMRAFSREALECYVPVITEEVGSSLEQWLSCGERGLLVYPEVKRLMFRIAMRILLGCEPQLAGDGDSEQQLVEAFEEMTRNLFSLPIDVPFSGLYRGMKARNLIHARIEQNIRAKICGLRASEAGQGCKDALQLLIEHSWERGERLDMQALKQSSTELLFGGHETTASAATSLITYLGLYPHVLQKVREELKSKGLLCKSNQDNKLDMEILEQLKYIGCVIKETLRLNPPVPGGFRVALKTFELNGYQIPKGWNVIYSICDTHDVAEIFTNKEEFNPDRFMLPHPEDASRFSFIPFGGGLRSCVGKEFAKILLKIFTVELARHCDWQLLNGPPTMKTSPTVYPVDNLPARFTHFHGEI T84634 DRUGINFO D08UGX LIAROZOLE Phase 2/3 T84634 DRUGINFO D0AA6Z Rambazole Phase 2 T84634 DRUGINFO D07VYX 4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate Investigative T84634 DRUGINFO D0F8JO 4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid Investigative T62306 TARGETID T62306 T62306 FORMERID TTDC00155 T62306 UNIPROID MTLR_HUMAN T62306 TARGNAME Motilin receptor (MLNR) T62306 GENENAME MLNR T62306 TARGTYPE Clinical trial T62306 SYNONYMS MLNR; Gprotein coupled receptor 38 T62306 FUNCTION Receptor for motilin. T62306 BIOCLASS GPCR rhodopsin T62306 SEQUENCE MGSPWNGSDGPEGAREPPWPALPPCDERRCSPFPLGALVPVTAVCLCLFVVGVSGNVVTVMLIGRYRDMRTTTNLYLGSMAVSDLLILLGLPFDLYRLWRSRPWVFGPLLCRLSLYVGEGCTYATLLHMTALSVERYLAICRPLRARVLVTRRRVRALIAVLWAVALLSAGPFLFLVGVEQDPGISVVPGLNGTARIASSPLASSPPLWLSRAPPPSPPSGPETAEAAALFSRECRPSPAQLGALRVMLWVTTAYFFLPFLCLSILYGLIGRELWSSRRPLRGPAASGRERGHRQTVRVLLVVVLAFIICWLPFHVGRIIYINTEDSRMMYFSQYFNIVALQLFYLSASINPILYNLISKKYRAAAFKLLLARKSRPRGFHRSRDTAGEVAGDTGGDTVGYTETSANVKTMG T62306 DRUGINFO D05SGO MOTILIN Phase 4 T62306 DRUGINFO D05UYQ Camicinal Phase 2 T62306 DRUGINFO D0XH0K Mitemcinal fumarate Phase 2 T62306 DRUGINFO D04UPW RWJ-68023 Phase 1 T62306 DRUGINFO D08WBJ KOS-2187 Phase 1 T62306 DRUGINFO D0T5FU DS-3801 Phase 1 T62306 DRUGINFO D0U9HM GSK-1322888 Phase 1 T62306 DRUGINFO D04JFT KW-5139 Discontinued in Phase 2 T62306 DRUGINFO D07SCN KC-11458 Discontinued in Phase 2 T62306 DRUGINFO D0ZY9U SLV-305 Discontinued in Phase 2 T62306 DRUGINFO D0E3BJ SLV-311 Discontinued in Phase 1 T62306 DRUGINFO D04LDK TZP-202 Preclinical T62306 DRUGINFO D0U9OJ GSK-326416 Preclinical T62306 DRUGINFO D02IUX MA-2029 Investigative T62306 DRUGINFO D03FQP ME4 Investigative T62306 DRUGINFO D03OCS ME36 Investigative T62306 DRUGINFO D06ZDF ME67 Investigative T62306 DRUGINFO D0D7LP RQ-00201894 Investigative T62306 DRUGINFO D0F5QL GM-109 Investigative T62306 DRUGINFO D0J2VQ EM-523 Investigative T62306 DRUGINFO D0M6OV KOS1326 Investigative T62306 DRUGINFO D0Q9IU [Leu13]motilin (human) Investigative T62306 DRUGINFO D0W6AQ TZP-201 Investigative T62306 DRUGINFO D0Z7FY CEM-301 Investigative T73482 TARGETID T73482 T73482 FORMERID TTDC00153 T73482 UNIPROID OX1R_HUMAN T73482 TARGNAME Orexin receptor type 1 (HCRTR1) T73482 GENENAME HCRTR1 T73482 TARGTYPE Clinical trial T73482 SYNONYMS Ox1r; Ox1-R; Ox-1-R; Orexin-1 receptor; Hypocretin receptor type 1; HFGAN72 receptor; 7-transmembrane G-protein coupledneuropeptide receptor T73482 FUNCTION Triggers an increase in cytoplasmic Ca(2+) levels in response to orexin-A binding. Moderately selective excitatory receptor for orexin-A and, with a lower affinity, for orexin-B neuropeptide. T73482 PDBSTRUC 4ZJC; 4ZJ8 T73482 BIOCLASS GPCR rhodopsin T73482 SEQUENCE MEPSATPGAQMGVPPGSREPSPVPPDYEDEFLRYLWRDYLYPKQYEWVLIAAYVAVFVVALVGNTLVCLAVWRNHHMRTVTNYFIVNLSLADVLVTAICLPASLLVDITESWLFGHALCKVIPYLQAVSVSVAVLTLSFIALDRWYAICHPLLFKSTARRARGSILGIWAVSLAIMVPQAAVMECSSVLPELANRTRLFSVCDERWADDLYPKIYHSCFFIVTYLAPLGLMAMAYFQIFRKLWGRQIPGTTSALVRNWKRPSDQLGDLEQGLSGEPQPRARAFLAEVKQMRARRKTAKMLMVVLLVFALCYLPISVLNVLKRVFGMFRQASDREAVYACFTFSHWLVYANSAANPIIYNFLSGKFREQFKAAFSCCLPGLGPCGSLKAPSPRSSASHKSLSLQSRCSISKISEHVVLTSVTTVLP T73482 DRUGINFO D06CKX SB-649868 Phase 2 T73482 DRUGINFO D0WZC1 JNJ-61393215 Phase 2 T73482 DRUGINFO D0YK9O AZD4041 Phase 1 T73482 DRUGINFO D00VEM 1,2-diamino cyclopentane-based derivative 25 Patented T73482 DRUGINFO D01NWU 1,2-diamino cyclopentane-based derivative 5 Patented T73482 DRUGINFO D02CCF 1,2-diamino cyclopentane-based derivative 20 Patented T73482 DRUGINFO D02LWJ 1,2-diamino cyclopentane-based derivative 15 Patented T73482 DRUGINFO D03JAZ 1,2-diamino cyclopentane-based derivative 13 Patented T73482 DRUGINFO D04DCO 1,2-diamino cyclopentane-based derivative 9 Patented T73482 DRUGINFO D04JLF 1,2-diamino cyclopentane-based derivative 8 Patented T73482 DRUGINFO D05PMY 1,2-diamino cyclopentane-based derivative 26 Patented T73482 DRUGINFO D05QWJ 1,2-diamino cyclopentane-based derivative 2 Patented T73482 DRUGINFO D05WDQ 1,2-diamino cyclopentane-based derivative 12 Patented T73482 DRUGINFO D06NRQ 1,2-diamino cyclopentane-based derivative 18 Patented T73482 DRUGINFO D06OTA 1,2-diamino cyclopentane-based derivative 29 Patented T73482 DRUGINFO D08KYM 1,2-diamino cyclopentane-based derivative 22 Patented T73482 DRUGINFO D08ZRN 1,2-diamino cyclopentane-based derivative 27 Patented T73482 DRUGINFO D09XLY 1,2-diamino cyclopentane-based derivative 31 Patented T73482 DRUGINFO D0AL3I 1,2-diamino cyclopentane-based derivative 16 Patented T73482 DRUGINFO D0C6GE 1,2-diamino cyclopentane-based derivative 21 Patented T73482 DRUGINFO D0CG0D 1,2-diamino cyclopentane-based derivative 33 Patented T73482 DRUGINFO D0DO4J 1,2-diamino cyclopentane-based derivative 11 Patented T73482 DRUGINFO D0EG3N 1,2-diamino cyclopentane-based derivative 34 Patented T73482 DRUGINFO D0FI1W 1,2-diamino cyclopentane-based derivative 10 Patented T73482 DRUGINFO D0J4YW 1,2-diamino cyclopentane-based derivative 24 Patented T73482 DRUGINFO D0L0YA 1,2-diamino cyclopentane-based derivative 19 Patented T73482 DRUGINFO D0NX4W 1,2-diamino cyclopentane-based derivative 14 Patented T73482 DRUGINFO D0P8AX 1,2-diamino cyclopentane-based derivative 23 Patented T73482 DRUGINFO D0S4UG 1,2-diamino cyclopentane-based derivative 32 Patented T73482 DRUGINFO D0U7VC 1,2-diamino cyclopentane-based derivative 7 Patented T73482 DRUGINFO D0U9WX 1,2-diamino cyclopentane-based derivative 30 Patented T73482 DRUGINFO D0VE3H 1,2-diamino cyclopentane-based derivative 17 Patented T73482 DRUGINFO D0VR1K 1,2-diamino cyclopentane-based derivative 3 Patented T73482 DRUGINFO D0WX1B 1,2-diamino cyclopentane-based derivative 1 Patented T73482 DRUGINFO D0YI3Z 1,2-diamino cyclopentane-based derivative 4 Patented T73482 DRUGINFO D0ZC1O 1,2-diamino cyclopentane-based derivative 6 Patented T73482 DRUGINFO D06BTF Almorexant Terminated T73482 DRUGINFO D0KP3K SB-410220 Investigative T73482 DRUGINFO D08MXD [3H]SB-674042 Investigative T73482 DRUGINFO D0J3PJ SB-408124 Investigative T73482 DRUGINFO D0MY0E orexin-B Investigative T73482 DRUGINFO D0R4BT PMID15261275C1 Investigative T73482 DRUGINFO D0UZ4J SB-334867 Investigative T82078 TARGETID T82078 T82078 FORMERID TTDR00813 T82078 UNIPROID TLR2_HUMAN T82078 TARGNAME Toll-like receptor 2 (TLR2) T82078 GENENAME TLR2 T82078 TARGTYPE Clinical trial T82078 SYNONYMS Toll/interleukin-1 receptor-like protein 4; TIL4; CD282 T82078 FUNCTION Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also activate immune cells and promote apoptosis in response to the lipid moiety of lipoproteins. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B. burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6. Stimulation of monocytes in vitro with M. tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via this receptor, but also partially via TLR4. MAPK activation in response to bacterial peptidoglycan also occurs via this receptor. Acts as a receptor for M. tuberculosis lipoproteins LprA, LprG, LpqH and PstS1, some lipoproteins are dependent on other coreceptors (TLR1, CD14 and/or CD36); the lipoproteins act as agonists to modulate antigen presenting cell functions in response to the pathogen. M. tuberculosis HSP70 (dnaK) but not HSP65 (groEL-2) acts via this protein to stimulate NF-kappa-B expression. Recognizes M. tuberculosis major T-antigen EsxA (ESAT-6) which inhibits downstream MYD88-dependent signaling (shown in mouse). Forms activation clusters composed of several receptors depending on the ligand, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to triacylated lipopeptides. Required for normal uptake of M. tuberculosis, a process that is inhibited by M. tuberculosis LppM. Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. T82078 PDBSTRUC 6NIG; 2Z80; 2Z7X; 1O77; 1FYX T82078 BIOCLASS Toll-like receptor T82078 SEQUENCE MPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLSNNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWFKPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELEIDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFSELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDNDRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLKSLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDISKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLKELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCEFLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFLLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMVQELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFSHFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRAAIKS T82078 DRUGINFO D0V0JR Cadi-05 Phase 3 T82078 DRUGINFO D03ONZ MCS-18 Phase 2 T82078 DRUGINFO D0VI9P OPN-305 Phase 2 T82078 DRUGINFO D00UVU Lipoteichoic acid Phase 1/2 T82078 DRUGINFO D0K3SM MALP-2S Phase 1/2 T82078 DRUGINFO D09POQ OM-174 Phase 1 T82078 DRUGINFO D07CQJ F-50040 Discontinued in Phase 1 T82078 DRUGINFO D04UYT CBLB-612 Investigative T82078 DRUGINFO D08TGY S-(Dimethylarsenic)Cysteine Investigative T40556 TARGETID T40556 T40556 FORMERID TTDI02032 T40556 UNIPROID BRD4_HUMAN T40556 TARGNAME Bromodomain-containing protein 4 (BRD4) T40556 GENENAME BRD4 T40556 TARGTYPE Clinical trial T40556 SYNONYMS Protein HUNK1; HUNK1 T40556 FUNCTION Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P-TEFb complex and recruiting it to promoters. Also recruits P-TEFb complex to distal enhancers, so called anti-pause enhancers in collaboration with JMJD6. BRD4 and JMJD6 are required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P-TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II. Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II. According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo. In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B. Also acts as a regulator of p53/TP53-mediated transcription: following phosphorylation by CK2, recruited to p53/TP53 specific target promoters. T40556 PDBSTRUC 6Q3Z; 6Q3Y; 6MNL; 6MAU; 6HDQ T40556 BIOCLASS Bromodomain T40556 SEQUENCE MSAESGPGTRLRNLPVMGDGLETSQMSTTQAQAQPQPANAASTNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEETEIMIVQAKGRGRGRKETGTAKPGVSTVPNTTQASTPPQTQTPQPNPPPVQATPHPFPAVTPDLIVQTPVMTVVPPQPLQTPPPVPPQPQPPPAPAPQPVQSHPPIIAATPQPVKTKKGVKRKADTTTPTTIDPIHEPPSLPPEPKTTKLGQRRESSRPVKPPKKDVPDSQQHPAPEKSSKVSEQLKCCSGILKEMFAKKHAAYAWPFYKPVDVEALGLHDYCDIIKHPMDMSTIKSKLEAREYRDAQEFGADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDEPEEPVVAVSSPAVPPPTKVVAPPSSSDSSSDSSSDSDSSTDDSEEERAQRLAELQEQLKAVHEQLAALSQPQQNKPKKKEKDKKEKKKEKHKRKEEVEENKKSKAKEPPPKKTKKNNSSNSNVSKKEPAPMKSKPPPTYESEEEDKCKPMSYEEKRQLSLDINKLPGEKLGRVVHIIQSREPSLKNSNPDEIEIDFETLKPSTLRELERYVTSCLRKKRKPQAEKVDVIAGSSKMKGFSSSESESSSESSSSDSEDSETEMAPKSKKKGHPGREQKKHHHHHHQQMQQAPAPVPQQPPPPPQQPPPPPPPQQQQQPPPPPPPPSMPQQAAPAMKSSPPPFIATQVPVLEPQLPGSVFDPIGHFTQPILHLPQPELPPHLPQPPEHSTPPHLNQHAVVSPPALHNALPQQPSRPSNRAAALPPKPARPPAVSPALTQTPLLPQPPMAQPPQVLLEDEEPPAPPLTSMQMQLYLQQLQKVQPPTPLLPSVKVQSQPPPPLPPPPHPSVQQQLQQQPPPPPPPQPQPPPQQQHQPPPRPVHLQPMQFSTHIQQPPPPQGQQPPHPPPGQQPPPPQPAKPQQVIQHHHSPRHHKSDPYSTGHLREAPSPLMIHSPQMSQFQSLTHQSPPQQNVQPKKQELRAASVVQPQPLVVVKEEKIHSPIIRSEPFSPSLRPEPPKHPESIKAPVHLPQRPEMKPVDVGRPVIRPPEQNAPPPGAPDKDKQKQEPKTPVAPKKDLKIKNMGSWASLVQKHPTTPSSTAKSSSDSFEQFRRAAREKEEREKALKAQAEHAEKEKERLRQERMRSREDEDALEQARRAHEEARRRQEQQQQQRQEQQQQQQQQAAAVAAAATPQAQSSQPQSMLDQQRELARKREQERRRREAMAATIDMNFQSDLLSIFEENLF T40556 DRUGINFO D01LVE CPI-0610 Phase 3 T40556 DRUGINFO D07GHA PLX2853 Phase 1/2 T40556 DRUGINFO D0N7WW RVX-208 Phase 1/2 T40556 DRUGINFO D0P7FM INCB57643 Phase 1/2 T40556 DRUGINFO D02YNI OTX-015 Phase 1/2 T40556 DRUGINFO D0B5PK TEN010 Phase 1 T40556 DRUGINFO D0PH9I AZD5153 Phase 1 T40556 DRUGINFO D07OFM GSK525762 Phase 1 T40556 DRUGINFO D05ICT ABBV-744 Phase 1 T40556 DRUGINFO D0ZW4W (+)-JQ1 Phase 1 T40556 DRUGINFO D00MXR PMID26924192-Compound-23 Patented T40556 DRUGINFO D04HTM Aminocyclopentenone compound 1 Patented T40556 DRUGINFO D05LTB Pyrazole and thiophene derivative 4 Patented T40556 DRUGINFO D07CSE Benzothiazepine analog 12 Patented T40556 DRUGINFO D07IYX PMID26924192-Compound-20 Patented T40556 DRUGINFO D08BCK PMID26924192-Compound-24 Patented T40556 DRUGINFO D08JHQ Aminocyclopentenone compound 2 Patented T40556 DRUGINFO D09FVR Pyrrolo-pyrrolone derivative 3 Patented T40556 DRUGINFO D09QSH Aminocyclopentenone compound 5 Patented T40556 DRUGINFO D0AU3O Aminocyclopentenone compound 6 Patented T40556 DRUGINFO D0C9RQ PMID26924192-Compound-22 Patented T40556 DRUGINFO D0CB8D PMID26924192-Compound-31 Patented T40556 DRUGINFO D0EN4B Pyrazole and thiophene derivative 2 Patented T40556 DRUGINFO D0FN6F PMID26924192-Compound-25 Patented T40556 DRUGINFO D0HO8V Pyrrolo-pyrrolone derivative 4 Patented T40556 DRUGINFO D0J4QG Pyrazole and thiophene derivative 3 Patented T40556 DRUGINFO D0KF8C Aminocyclopentenone compound 3 Patented T40556 DRUGINFO D0N6JZ Aminocyclopentenone compound 4 Patented T40556 DRUGINFO D0PE1R Pyrrolo-pyrrolone derivative 2 Patented T40556 DRUGINFO D0S5ID Benzothiazepine analog 11 Patented T40556 DRUGINFO D0SQ0F Pyrazole and thiophene derivative 1 Patented T40556 DRUGINFO D0XM8B PMID26924192-Compound-21 Patented T40556 DRUGINFO D0XR9Y Pyrrolo-pyrrolone derivative 5 Patented T40556 DRUGINFO D0Y7YC Benzothiazepine analog 10 Patented T40556 DRUGINFO D0L7SK PMID26924192-Compound-30 Patented T40556 DRUGINFO D0SB3H PMID26924192-Compound-32 Patented T40556 DRUGINFO D0VB3P PMID26924192-Compound-33 Patented T40556 DRUGINFO D0YM3G Pyrrolo-pyrrolone derivative 1 Patented T40556 DRUGINFO D03NWT PMID26924192-Compound-104 Patented T40556 DRUGINFO D03RPJ PMID26924192-Compound-102 Patented T40556 DRUGINFO D05XXS PMID26924192-Compound-103 Patented T40556 DRUGINFO D0NN4U PMID26924192-Compound-105 Patented T40556 DRUGINFO D01DMN XD1 Investigative T40556 DRUGINFO D01EVE PMID25703523C7d Investigative T40556 DRUGINFO D01YSN isoxazole azepine compound 3 Investigative T40556 DRUGINFO D03LNF PFI-1 Investigative T40556 DRUGINFO D09HBR MS436 Investigative T40556 DRUGINFO D0C2JS CPI-203 Investigative T40556 DRUGINFO D0M5DB BzT-7 Investigative T40556 DRUGINFO D0O2RX PMID23517011C9 Investigative T40556 DRUGINFO D0T3YY MS417 Investigative T40556 DRUGINFO D03BTJ PMID25408830C3 Investigative T40556 DRUGINFO D09ZPM PMID25408830C1 Investigative T40556 DRUGINFO D0H3TC PMID21851057C4d Investigative T40556 DRUGINFO D0J6XI PMID25408830C2 Investigative T40556 DRUGINFO D03LIP GW841819X Investigative T40556 DRUGINFO D0C2XT PMID24000170C36 Investigative T40556 DRUGINFO D0Q2GK PMID24000170C38 Investigative T40556 DRUGINFO D0WU1S I-BET151 Investigative T40556 DRUGINFO D07FGY XD14 Investigative T56697 TARGETID T56697 T56697 FORMERID TTDNC00370 T56697 UNIPROID DKK1_HUMAN T56697 TARGNAME Dickkopf-related protein 1 (DKK1) T56697 GENENAME DKK1 T56697 TARGTYPE Clinical trial T56697 SYNONYMS hDkk1; hDkk-1; UNQ492/PRO1008; Dkk1; Dkk-1; Dickkopfrelated protein 1; Dickkopf1; Dickkopf-1 T56697 FUNCTION DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease. Inhibits the pro-apoptotic function of KREMEN1 in a Wnt-independent manner, and has anti-apoptotic activity. Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6. T56697 PDBSTRUC 5GJE; 5FWW; 3SOQ; 3S8V; 3S2K T56697 BIOCLASS Dickkopf protein T56697 SEQUENCE MMALGAAGATRVFVAMVAAALGGHPLLGVSATLNSVLNSNAIKNLPPPLGGAAGHPGSAVSAAPGILYPGGNKYQTIDNYQPYPCAEDEECGTDEYCASPTRGGDAGVQICLACRKRRKRCMRHAMCCPGNYCKNGICVSSDQNHFRGEIEETITESFGNDHSTLDGYSRRTTLSSKMYHTKGQEGSVCLRSSDCASGLCCARHFWSKICKPVLKEGQVCTKHRRKGSHGLEIFQRCYCGEGLSCRIQKDHHQASNSSRLHTCQRH T56697 DRUGINFO D62FLA BHQ880 Phase 2 T56697 DRUGINFO DMF73Z DKN-01 Phase 2 T56697 DRUGINFO D04OMR PF-04840082 Phase 1 T23797 TARGETID T23797 T23797 FORMERID TTDI02101 T23797 UNIPROID IL33_HUMAN T23797 TARGNAME Interleukin-33 (IL33) T23797 GENENAME IL33 T23797 TARGTYPE Clinical trial T23797 SYNONYMS Nuclear factor from high endothelial venules; NFHEV; NF-HEV; Interleukin1 family member 11; Interleukin-1 family member 11; IL1F11; IL-33; IL-1F11; C9orf26 T23797 FUNCTION Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an "alarmin", that amplifies immune responses during tissue injury. Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. T23797 PDBSTRUC 4KC3; 2KLL T23797 BIOCLASS Cytokine: interleukin T23797 SEQUENCE MKPKMKYSTNKISTAKWKNTASKALCFKLGKSQQKAKEVCPMYFMKLRSGLMIKKEACYFRRETTKRPSLKTGRKHKRHLVLAACQQQSTVECFAFGISGVQKYTRALHDSSITGISPITEYLASLSTYNDQSITFALEDESYEIYVEDLKKDEKKDKVLLSYYESQHPSNESGDGVDGKMLMVTLSPTKDFWLHANNKEHSVELHKCEKPLPDQAFFVLHNMHSNCVSFECKTDPGVFIGVKDNHLALIKVDSSENLCTENILFKLSET T23797 DRUGINFO D0YFN1 Tozorakimab Phase 3 T23797 DRUGINFO D8U1EX SAR440340 Phase 3 T23797 DRUGINFO DOTF14 MEDI3506 Phase 3 T23797 DRUGINFO DPT90B Itepekimab Phase 3 T23797 DRUGINFO D07GDR AMG 282 Phase 1 T23797 DRUGINFO D1LP4B PF-07264660 Phase 1 T29339 TARGETID T29339 T29339 FORMERID TTDI02051 T29339 UNIPROID DDX58_HUMAN T29339 TARGNAME Retinoic acid-inducible gene-1 (RIG-1) T29339 GENENAME DDX58 T29339 TARGTYPE Clinical trial T29339 SYNONYMS Retinoic acidinducible gene I protein; Retinoic acidinducible gene 1 protein; Retinoic acid-inducible gene I protein; Retinoic acid-inducible gene 1 protein; RLR1; RLR-1; RIGIlike receptor 1; RIGI; RIG1; RIG-I-like receptor 1; RIG-I; Probable ATPdependent RNA helicase DDX58; Probable ATP-dependent RNA helicase DDX58; DEAD box protein 58 T29339 FUNCTION Its ligands include: 5'-triphosphorylated ssRNA and dsRNA and short dsRNA (<1 kb in length). In addition to the 5'-triphosphate moiety, blunt-end base pairing at the 5'-end of the RNA is very essential. Overhangs at the non-triphosphorylated end of the dsRNA RNA have no major impact on its activity. A 3'overhang at the 5'triphosphate end decreases and any 5'overhang at the 5' triphosphate end abolishes its activity. Upon ligand binding it associates with mitochondria antiviral signaling protein (MAVS/IPS1) which activates the IKK-related kinases: TBK1 and IKBKE which phosphorylate interferon regulatory factors: IRF3 and IRF7 which in turn activate transcription of antiviral immunological genes, including interferons (IFNs); IFN-alpha and IFN-beta. Detects both positive and negative strand RNA viruses including members of the families Paramyxoviridae: Human respiratory syncytial virus and measles virus (MeV), Rhabdoviridae: vesicular stomatitis virus (VSV), Orthomyxoviridae: influenza A and B virus, Flaviviridae: Japanese encephalitis virus (JEV), hepatitis C virus (HCV), dengue virus (DENV) and west Nile virus (WNV). It also detects rotavirus and reovirus. Also involved in antiviral signaling in response to viruses containing a dsDNA genome such as Epstein-Barr virus (EBV). Detects dsRNA produced from non-self dsDNA by RNA polymerase III, such as Epstein-Barr virus-encoded RNAs (EBERs). May play important roles in granulocyte production and differentiation, bacterial phagocytosis and in the regulation of cell migration. Innate immune receptor which acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines. T29339 PDBSTRUC 6GPG; 5F9H; 5F9F; 5F98; 5E3H T29339 BIOCLASS Acid anhydride hydrolase T29339 ECNUMBER EC 3.6.4.13 T29339 SEQUENCE MTTEQRRSLQAFQDYIRKTLDPTYILSYMAPWFREEEVQYIQAEKNNKGPMEAATLFLKFLLELQEEGWFRGFLDALDHAGYSGLYEAIESWDFKKIEKLEEYRLLLKRLQPEFKTRIIPTDIISDLSECLINQECEEILQICSTKGMMAGAEKLVECLLRSDKENWPKTLKLALEKERNKFSELWIVEKGIKDVETEDLEDKMETSDIQIFYQEDPECQNLSENSCPPSEVSDTNLYSPFKPRNYQLELALPAMKGKNTIICAPTGCGKTFVSLLICEHHLKKFPQGQKGKVVFFANQIPVYEQQKSVFSKYFERHGYRVTGISGATAENVPVEQIVENNDIIILTPQILVNNLKKGTIPSLSIFTLMIFDECHNTSKQHPYNMIMFNYLDQKLGGSSGPLPQVIGLTASVGVGDAKNTDEALDYICKLCASLDASVIATVKHNLEELEQVVYKPQKFFRKVESRISDKFKYIIAQLMRDTESLAKRICKDLENLSQIQNREFGTQKYEQWIVTVQKACMVFQMPDKDEESRICKALFLYTSHLRKYNDALIISEHARMKDALDYLKDFFSNVRAAGFDEIEQDLTQRFEEKLQELESVSRDPSNENPKLEDLCFILQEEYHLNPETITILFVKTRALVDALKNWIEGNPKLSFLKPGILTGRGKTNQNTGMTLPAQKCILDAFKASGDHNILIATSVADEGIDIAQCNLVILYEYVGNVIKMIQTRGRGRARGSKCFLLTSNAGVIEKEQINMYKEKMMNDSILRLQTWDEAVFREKILHIQTHEKFIRDSQEKPKPVPDKENKKLLCRKCKALACYTADVRVIEECHYTVLGDAFKECFVSRPHPKPKQFSSFEKRAKIFCARQNCSHDWGIHVKYKTFEIPVIKIESFVVEDIATGVQTLYSKWKDFHFEKIPFDPAEMSK T29339 DRUGINFO D04HQC SB-9200 Phase 2 T29339 DRUGINFO DFO5W3 MK-4621 Phase 1 T29339 DRUGINFO DVU2H8 CV8102 Phase 1 T98293 TARGETID T98293 T98293 FORMERID TTDI02145 T98293 UNIPROID PAK4_HUMAN T98293 TARGNAME PAK-4 protein kinase (PAK4) T98293 GENENAME PAK4 T98293 TARGTYPE Clinical trial T98293 SYNONYMS p21-activated kinase 4; Serine/threonine-protein kinase PAK 4; PAK-4; KIAA1142 T98293 FUNCTION Activation by various effectors including growth factor receptors or active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Phosphorylates and inactivates the protein phosphatase SSH1, leading to increased inhibitory phosphorylation of the actin binding/depolymerizing factor cofilin. Decreased cofilin activity may lead to stabilization of actin filaments. Phosphorylates LIMK1, a kinase that also inhibits the activity of cofilin. Phosphorylates integrin beta5/ITGB5 and thus regulates cell motility. Phosphorylates ARHGEF2 and activates the downstream target RHOA that plays a role in the regulation of assembly of focal adhesions and actin stress fibers. Stimulates cell survival by phosphorylating the BCL2 antagonist of cell death BAD. Alternatively, inhibits apoptosis by preventing caspase-8 binding to death domain receptors in a kinase independent manner. Plays a role in cell-cycle progression by controlling levels of the cell-cycle regulatory protein CDKN1A and by phosphorylating RAN. Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, growth, proliferation or cell survival. T98293 PDBSTRUC 5ZJW; 5XVG; 5XVF; 5XVA; 5VEF T98293 BIOCLASS Kinase T98293 ECNUMBER EC 2.7.11.1 T98293 SEQUENCE MFGKRKKRVEISAPSNFEHRVHTGFDQHEQKFTGLPRQWQSLIEESARRPKPLVDPACITSIQPGAPKTIVRGSKGAKDGALTLLLDEFENMSVTRSNSLRRDSPPPPARARQENGMPEEPATTARGGPGKAGSRGRFAGHSEAGGGSGDRRRAGPEKRPKSSREGSGGPQESSRDKRPLSGPDVGTPQPAGLASGAKLAAGRPFNTYPRADTDHPSRGAQGEPHDVAPNGPSAGGLAIPQSSSSSSRPPTRARGAPSPGVLGPHASEPQLAPPACTPAAPAVPGPPGPRSPQREPQRVSHEQFRAALQLVVDPGDPRSYLDNFIKIGEGSTGIVCIATVRSSGKLVAVKKMDLRKQQRRELLFNEVVIMRDYQHENVVEMYNSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIAAVCLAVLQALSVLHAQGVIHRDIKSDSILLTHDGRVKLSDFGFCAQVSKEVPRRKSLVGTPYWMAPELISRLPYGPEVDIWSLGIMVIEMVDGEPPYFNEPPLKAMKMIRDNLPPRLKNLHKVSPSLKGFLDRLLVRDPAQRATAAELLKHPFLAKAGPPASIVPLMRQNRTR T98293 DRUGINFO D04ZQB KPT-9274 Phase 1 T98293 DRUGINFO D08MHM PF-3758309 Phase 1 T66383 TARGETID T66383 T66383 FORMERID TTDC00326 T66383 UNIPROID CFAD_HUMAN T66383 TARGNAME Complement factor D (CFD) T66383 GENENAME CFD T66383 TARGTYPE Clinical trial T66383 SYNONYMS Properdin factor D; PFD; DF; C3 convertase activator; Adipsin T66383 FUNCTION Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Its function is homologous to that of C1s in the classical pathway. T66383 PDBSTRUC 6QMT; 6QMR; 6FUT; 6FUJ; 6FUI T66383 BIOCLASS Peptidase T66383 ECNUMBER EC 3.4.21.46 T66383 SEQUENCE MHSWERLAVLVLLGAAACAAPPRGRILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLA T66383 DRUGINFO DJ43UK ALXN2040 Phase 3 T66383 DRUGINFO DM7Z6Y Lampalizumab Phase 3 T66383 DRUGINFO D0C9MA ACH-4471 Phase 2 T66383 DRUGINFO DZ9N5O BCX-9930 Phase 2 T66383 DRUGINFO D3LZ2F Vemircopan Phase 2 T66383 DRUGINFO D3LZ2F Vemircopan Phase 2 T66383 DRUGINFO D08ZDI Anti-Factor D Phase 1/2 T66383 DRUGINFO DKI1A8 ALXN2080 Phase 1 T66383 DRUGINFO D04MIN example 373 [WO2012093101] Investigative T66383 DRUGINFO D0P8LR HC3-1496 Investigative T35486 TARGETID T35486 T35486 FORMERID TTDI01767 T35486 UNIPROID RASN_HUMAN T35486 TARGNAME GTPase NRas (NRAS) T35486 GENENAME NRAS T35486 TARGTYPE Clinical trial T35486 SYNONYMS Transforming protein N-Ras; HRAS1 T35486 FUNCTION Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. T35486 PDBSTRUC 5UHV; 3CON; 2N9C T35486 BIOCLASS Small GTPase T35486 SEQUENCE MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNSKSFADINLYREQIKRVKDSDDVPMVLVGNKCDLPTRTVDTKQAHELAKSYGIPFIETSAKTRQGVEDAFYTLVREIRQYRMKKLNSSDDGTQGCMGLPCVVM T35486 DRUGINFO D01LFC Mutant ras vaccine Phase 2 T35486 DRUGINFO D0N4SF GI-4000 Phase 2 T35486 DRUGINFO D0VV6V Reovirus Phase 2 T35486 DRUGINFO D00KTV Salirasib Phase 2 T35486 DRUGINFO D0S2HO Perillyl alcohol Discontinued in Phase 2 T35486 DRUGINFO D01SVG KA-10X Investigative T35486 DRUGINFO D03ZWR APC-300 Investigative T85670 TARGETID T85670 T85670 FORMERID TTDI02219 T85670 UNIPROID NGF_HUMAN T85670 TARGNAME Nerve growth factor (NGF) T85670 GENENAME NGF T85670 TARGTYPE Clinical trial T85670 SYNONYMS NGFB; Beta-nerve growth factor; Beta-NGF T85670 FUNCTION Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades to regulate neuronal proliferation, differentiation and survival (Probable). The immature NGF precursor (proNGF) functions as ligand for the heterodimeric receptor formed by SORCS2 and NGFR, and activates cellular signaling cascades that lead to inactivation of RAC1 and/or RAC2, reorganization of the actin cytoskeleton and neuronal growth cone collapse. In contrast to mature NGF, the precursor form (proNGF) promotes neuronal apoptosis (in vitro) (By similarity). Inhibits metalloproteinase-dependent proteolysis of platelet glycoprotein VI. Binds lysophosphatidylinositol and lysophosphatidylserine between the two chains of the homodimer. The lipid-bound form promotes histamine relase from mast cells, contrary to the lipid-free form (By similarity). T85670 PDBSTRUC 5JZ7; 4ZBN; 4EDX; 4EDW; 2IFG T85670 BIOCLASS Growth factor T85670 SEQUENCE MSMLFYTLITAFLIGIQAEPHSESNVPAGHTIPQAHWTKLQHSLDTALRRARSAPAAAIAARVAGQTRNITVDPRLFKKRRLRSPRVLFSTQPPREAADTQDLDFEVGGAAPFNRTHRSKRSSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCRDPNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAVRRA T85670 DRUGINFO D00BVS Tanezumab Phase 3 T85670 DRUGINFO D0AD4Z Fasinumab Phase 3 T85670 DRUGINFO D0SB5K SAR164877 Phase 2/3 T85670 DRUGINFO D0MP1M CERE-110 Phase 2 T85670 DRUGINFO D0U9PV CXB-909 Phase 1/2 T85670 DRUGINFO D03APM ABT-110 Phase 1 T85670 DRUGINFO D0D0GH NsG-0202 Phase 1 T85670 DRUGINFO D0JA3Y MEDI-578 Phase 1 T85670 DRUGINFO D0A0MJ Nerve growth factor Terminated T16128 TARGETID T16128 T16128 FORMERID TTDI02076 T16128 UNIPROID GAST_HUMAN T16128 TARGNAME Gastrin (GAST) T16128 GENENAME GAST T16128 TARGTYPE Clinical trial T16128 SYNONYMS Gastrin6; GAST; G52; G34; G14 T16128 FUNCTION Gastrin stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete its digestive enzymes. It also stimulates smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine. T16128 PDBSTRUC 5WRJ T16128 BIOCLASS Gastrin cholecystokinin T16128 SEQUENCE MQRLCVYVLIFALALAAFSEASWKPRSQQPDAPLGTGANRDLELPWLEQQGPASHHRRQLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDFGRRSAEDEN T16128 DRUGINFO D0G8ZQ G17DT Phase 3 T85158 TARGETID T85158 T85158 FORMERID TTDC00327 T85158 UNIPROID TNFB_HUMAN T85158 TARGNAME Lymphotoxin-alpha (LTA) T85158 GENENAME LTA T85158 TARGTYPE Clinical trial T85158 SYNONYMS Tumor necrosis factor ligand superfamily member 1; TNFSF1; TNFB; TNF-beta; LT-alpha T85158 FUNCTION In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and is cytotoxic for a wide range of tumor cells in vitro and in vivo. Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. T85158 PDBSTRUC 4MXW; 4MXV; 1TNR T85158 BIOCLASS Cytokine: tumor necrosis factor T85158 SEQUENCE MTPPERLFLPRVCGTTLHLLLLGLLLVLLPGAQGLPGVGLTPSAAQTARQHPKMHLAHSTLKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAYSPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQLSTHTDGIPHLVLSPSTVFFGAFAL T85158 DRUGINFO D0L1OC Anti-LT alpha Phase 2 T16340 TARGETID T16340 T16340 FORMERID TTDI01935 T16340 UNIPROID IL1A_HUMAN T16340 TARGNAME Interleukin-1 alpha (IL1A) T16340 GENENAME IL1A T16340 TARGTYPE Clinical trial T16340 SYNONYMS IL1F1; IL-1 alpha; Hematopoietin-1 T16340 FUNCTION Produced by activated macrophages, IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. IL-1 proteins are involved in the inflammatory response, being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and collagenase from synovial cells. T16340 PDBSTRUC 5UC6; 2L5X; 2KKI; 2ILA; 1ITA T16340 BIOCLASS Cytokine: interleukin T16340 SEQUENCE MAKVPDMFEDLKNCYSENEEDSSSIDHLSLNQKSFYHVSYGPLHEGCMDQSVSLSISETSKTSKLTFKESMVVVATNGKVLKKRRLSLSQSITDDDLEAIANDSEEEIIKPRSAPFSFLSNVKYNFMRIIKYEFILNDALNQSIIRANDQYLTAAALHNLDEAVKFDMGAYKSSKDDAKITVILRISKTQLYVTAQDEDQPVLLKEMPEIPKTITGSETNLLFFWETHGTKNYFTSVAHPNLFIATKQDYWVCLAGGPPSITDFQILENQA T16340 DRUGINFO D09AYM MABp1 Phase 3 T16340 DRUGINFO D0YO4C Xilonix Phase 3 T16340 DRUGINFO DCL35B Bermekimab Phase 2 T16340 DRUGINFO DOVW19 Natrunix Phase 2 T16340 DRUGINFO D01WQQ ABT-981 Phase 2 T16340 DRUGINFO D0X2PQ IX207-887 Discontinued in Phase 2 T16340 DRUGINFO D03VFV IL1aQb Terminated T16340 DRUGINFO D0B4DB Interleukin-1-alpha - Amgen/Roche Investigative T56545 TARGETID T56545 T56545 FORMERID TTDI02020 T56545 UNIPROID APOA1_HUMAN T56545 TARGNAME Apolipoprotein A-I (APOA1) T56545 GENENAME APOA1 T56545 TARGTYPE Clinical trial T56545 SYNONYMS Truncated apolipoprotein AI; Apolipoprotein A1; ApoAI; ApoA-I; Apo-AI T56545 FUNCTION As part of the SPAP complex, activates spermatozoa motility. Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). T56545 PDBSTRUC 6CM1; 6CLZ; 6CCX; 6CCH; 6CC9 T56545 BIOCLASS Apolipoprotein T56545 SEQUENCE MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ T56545 DRUGINFO D03AKH CER-001 Phase 2 T56545 DRUGINFO D0L8VA CSL-112 Phase 2 T56545 DRUGINFO D04PPK CER-522 Phase 1 T56545 DRUGINFO D0L1ZK MDCO-216 Phase 1 T56545 DRUGINFO D0I5QL CRD-5 Discontinued in Phase 2 T56545 DRUGINFO D03FPA APP-018 Discontinued in Phase 1 T56545 DRUGINFO D02TLD AMT-050 Terminated T56545 DRUGINFO D05AON LSI-518P Terminated T37742 TARGETID T37742 T37742 FORMERID TTDR00446 T37742 UNIPROID SAMP_HUMAN T37742 TARGNAME Serum amyloid P-component (APCS) T37742 GENENAME APCS T37742 TARGTYPE Clinical trial T37742 SYNONYMS SAP; APCS; 9.5S alpha-1-glycoprotein T37742 FUNCTION Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. May also function as a calcium-dependent lectin. T37742 PDBSTRUC 4AYU; 4AVV; 4AVT; 4AVS; 3KQR T37742 BIOCLASS Pentraxin family T37742 SEQUENCE MNKPLLWISVLTSLLEAFAHTDLSGKVFVFPRESVTDHVNLITPLEKPLQNFTLCFRAYSDLSRAYSLFSYNTQGRDNELLVYKERVGEYSLYIGRHKVTSKVIEKFPAPVHICVSWESSSGIAEFWINGTPLVKKGLRQGYFVEAQPKIVLGQEQDSYGGKFDRSQSFVGEIGDLYMWDSVLPPENILSAYQGTPLPANILDWQALNYEIRGYVIIKPLVWV T37742 DRUGINFO D19RKX Zinpentraxin alfa Phase 3 T37742 DRUGINFO D05FBZ CPHPC Phase 1/2 T37742 DRUGINFO D07LBQ GSK2398852 Phase 1 T37742 DRUGINFO D0AY1I GSK-2315698 Phase 1 T30635 TARGETID T30635 T30635 FORMERID TTDR00498 T30635 UNIPROID CXL10_HUMAN T30635 TARGNAME C-X-C motif chemokine 10 (CXCL10) T30635 GENENAME CXCL10 T30635 TARGTYPE Clinical trial T30635 SYNONYMS Small-inducible cytokine B10; SCYB10; IP-10; INP10; Gamma-IP10; 10 kDa interferon gamma-induced protein T30635 FUNCTION Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects. Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites (By similarity). Mechanistically, binding of CXCL10 to the CXCR3 receptor activates G protein-mediated signaling and results in downstream activation of phospholipase C-dependent pathway, an increase in intracellular calcium production and actin reorganization. In turn, recruitment of activated Th1 lymphocytes occurs at sites of inflammation. Activation of the CXCL10/CXCR3 axis plays also an important role in neurons in response to brain injury for activating microglia, the resident macrophage population of the central nervous system, and directing them to the lesion site. This recruitment is an essential element for neuronal reorganization (By similarity). T30635 PDBSTRUC 1O80; 1O7Z; 1O7Y; 1LV9 T30635 BIOCLASS Cytokine: CXC chemokine T30635 SEQUENCE MNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP T30635 DRUGINFO D00YWL BMS-936557 Phase 2 T30635 DRUGINFO D03VNB NI-0801 Phase 2 T30635 DRUGINFO D0C1UF MDX-1100 Phase 2 T30635 DRUGINFO D0L7LH Anti-IP10 Phase 2 T30635 DRUGINFO D0VE3U JT02 Phase 2 T30635 DRUGINFO D1A8NU NG-641 Phase 1 T30635 DRUGINFO D0F6OK N-Methylleucine Investigative T67801 TARGETID T67801 T67801 FORMERID TTDR01148 T67801 UNIPROID TRFL_HUMAN T67801 TARGNAME Lactotransferrin (LTF) T67801 GENENAME LTF T67801 TARGTYPE Clinical trial T67801 SYNONYMS Talalactoferrin; Lactoferrin; LF; Growth-inhibiting protein 12; GIG12 T67801 FUNCTION Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. T67801 PDBSTRUC 2PMS; 2HD4; 2GMD; 2GMC; 2DP4 T67801 BIOCLASS Transferrin T67801 ECNUMBER EC 3.4.21.- T67801 SEQUENCE MKLVFLVLLFLGALGLCLAGRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERQPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVPGADKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKDKSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAARRARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTAGKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCVPNSNERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRKPVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK T67801 DRUGINFO D05UWI Parecoxib Phase 4 T67801 DRUGINFO D0IM6O Talactoferrin Phase 3 T67801 DRUGINFO D0D8EY HLF 1-11 Phase 1/2 T67801 DRUGINFO D0C0JT Nimesulide Terminated T67801 DRUGINFO D01XEY Alpha-D-Fucose Investigative T67801 DRUGINFO D03ZSY Nitrilotriacetic Acid Investigative T67801 DRUGINFO D0H6MC 3h-Indole-5,6-Diol Investigative T67801 DRUGINFO D0N0UC Lauric Acid Investigative T67801 DRUGINFO D0G6XS Fucose Investigative T67801 DRUGINFO D07LUR Alpha-D-Mannose Investigative T89873 TARGETID T89873 T89873 FORMERID TTDR01293 T89873 UNIPROID FRIH_HUMAN T89873 TARGNAME Ferritin (FTH1) T89873 GENENAME FTH1 T89873 TARGTYPE Clinical trial T89873 SYNONYMS PIG15; OK/SW-cl.84; Ferritin heavy chain; Ferritin H subunit; FTHL6; FTH; Cell proliferationinducing gene 15 protein; Cell proliferation-inducing gene 15 protein T89873 FUNCTION Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney. Stores iron in a soluble, non-toxic, readily available form. T89873 PDBSTRUC 6IPQ; 6IPP; 6IPO; 6IPC; 6H5I T89873 BIOCLASS Metal ion oxidoreductase T89873 ECNUMBER EC 1.16.3.1 T89873 SEQUENCE MTTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES T89873 DRUGINFO D0D8KU Ferritarg P Phase 1/2 T01597 TARGETID T01597 T01597 FORMERID TTDI02035 T01597 UNIPROID CATA_HUMAN T01597 TARGNAME Catalase (CAT) T01597 GENENAME CAT T01597 TARGTYPE Clinical trial T01597 SYNONYMS Human catalase T01597 FUNCTION Promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells and normal and transformed fibroblast cells. Occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide. T01597 PDBSTRUC 1QQW; 1F4J; 1DGH; 1DGG; 1DGF T01597 BIOCLASS Peroxide acceptor oxidoreductase T01597 ECNUMBER EC 1.11.1.6 T01597 SEQUENCE MADSRDPASDQMQHWKEQRAAQKADVLTTGAGNPVGDKLNVITVGPRGPLLVQDVVFTDEMAHFDRERIPERVVHAKGAGAFGYFEVTHDITKYSKAKVFEHIGKKTPIAVRFSTVAGESGSADTVRDPRGFAVKFYTEDGNWDLVGNNTPIFFIRDPILFPSFIHSQKRNPQTHLKDPDMVWDFWSLRPESLHQVSFLFSDRGIPDGHRHMNGYGSHTFKLVNANGEAVYCKFHYKTDQGIKNLSVEDAARLSQEDPDYGIRDLFNAIATGKYPSWTFYIQVMTFNQAETFPFNPFDLTKVWPHKDYPLIPVGKLVLNRNPVNYFAEVEQIAFDPSNMPPGIEASPDKMLQGRLFAYPDTHRHRLGPNYLHIPVNCPYRARVANYQRDGPMCMQDNQGGAPNYYPNSFGAPEQQPSALEHSIQYSGEVRRFNTANDDNVTQVRAFYVNVLNEEQRKRLCENIAGHLKDAQIFIQKKAVKNFTEVHPDYGSHIQALLDKYNAEKPKNAIHTFVQSGSHLAAREKANL T01597 DRUGINFO D06VAQ EUK-189 Phase 1 T23673 TARGETID T23673 T23673 FORMERID TTDI02287 T23673 UNIPROID RAF1_HUMAN T23673 TARGNAME Proto-oncogene c-RAF (c-RAF) T23673 GENENAME RAF1 T23673 TARGTYPE Clinical trial T23673 SYNONYMS cRaf; Raf-1; RAF proto-oncogene serine/threonine-protein kinase; RAF T23673 FUNCTION RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation. Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. T23673 PDBSTRUC 4IHL; 4IEA; 4G3X; 4G0N; 4FJ3 T23673 BIOCLASS Kinase T23673 ECNUMBER EC 2.7.11.1 T23673 SEQUENCE MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF T23673 DRUGINFO D01WKE Semapimod Phase 2 T23673 DRUGINFO DMYS25 BGB-3245 Phase 2 T23673 DRUGINFO D0VS9E GDC-5573 Phase 1 T23673 DRUGINFO DU98JH Belvarafenib Phase 1 T89147 TARGETID T89147 T89147 FORMERID TTDI02177 T89147 UNIPROID SODM_HUMAN T89147 TARGNAME Superoxide dismutase Mn (SOD Mn) T89147 GENENAME SOD2 T89147 TARGTYPE Clinical trial T89147 SYNONYMS Superoxide dismutase [Mn], mitochondrial T89147 FUNCTION Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems. T89147 PDBSTRUC 5VF9; 5T30; 5GXO; 3C3T; 3C3S T89147 BIOCLASS Superoxide dismutase/reductase T89147 ECNUMBER EC 1.15.1.1 T89147 SEQUENCE MLSRAVCGTSRQLAPVLGYLGSRQKHSLPDLPYDYGALEPHINAQIMQLHHSKHHAAYVNNLNVTEEKYQEALAKGDVTAQIALQPALKFNGGGHINHSIFWTNLSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYLQYKNVRPDYLKAIWNVINWENVTERYMACKK T89147 DRUGINFO D00OYQ Imisopasem manganese Phase 2 T05661 TARGETID T05661 T05661 FORMERID TTDI02111 T05661 UNIPROID LCAT_HUMAN T05661 TARGNAME Lecithin-cholesterol acyltransferase (LCAT) T05661 GENENAME LCAT T05661 TARGTYPE Clinical trial T05661 SYNONYMS Phospholipidcholesterolacyltransferase; Phospholipid-cholesterol acyltransferase; Phosphatidylcholinesterol acyltransferase; Phosphatidylcholine-sterol acyltransferase T05661 FUNCTION Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines. Also produced in the brain by primary astrocytes, and esterifies free cholesterol on nascent APOE-containing lipoproteins secreted from glia and influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the cholesterol transporter ABCA1, plays a key role in the maturation of glial-derived, nascent lipoproteins. Required for remodeling high-density lipoprotein particles into their spherical forms. Central enzyme in the extracellular metabolism of plasma lipoproteins. T05661 PDBSTRUC 6MVD; 5TXF; 5BV7; 4XX1; 4XWG T05661 BIOCLASS Acyltransferase T05661 ECNUMBER EC 2.3.1.43 T05661 SEQUENCE MGPPGSPWQWVTLLLGLLLPPAAPFWLLNVLFPPHTTPKAELSNHTRPVILVPGCLGNQLEAKLDKPDVVNWMCYRKTEDFFTIWLDLNMFLPLGVDCWIDNTRVVYNRSSGLVSNAPGVQIRVPGFGKTYSVEYLDSSKLAGYLHTLVQNLVNNGYVRDETVRAAPYDWRLEPGQQEEYYRKLAGLVEEMHAAYGKPVFLIGHSLGCLHLLYFLLRQPQAWKDRFIDGFISLGAPWGGSIKPMLVLASGDNQGIPIMSSIKLKEEQRITTTSPWMFPSRMAWPEDHVFISTPSFNYTGRDFQRFFADLHFEEGWYMWLQSRDLLAGLPAPGVEVYCLYGVGLPTPRTYIYDHGFPYTDPVGVLYEDGDDTVATRSTELCGLWQGRQPQPVHLLPLHGIQHLNMVFSNLTLEHINAILLGAYRQGPPASPTASPEPPPPE T05661 DRUGINFO D0T5YB MEDI6012 Phase 2 T18639 TARGETID T18639 T18639 FORMERID TTDR00925 T18639 UNIPROID FGF1_HUMAN T18639 TARGNAME Heparin-binding growth factor 1 (FGF1) T18639 GENENAME FGF1 T18639 TARGTYPE Clinical trial T18639 SYNONYMS HBGF-1; Fibroblast growth factor 1; FGFA; FGF-1; Endothelial cell growth factor; ECGF-beta; ECGF; Beta-endothelial cell growth factor; Acidic fibroblast growth factor; AFGF T18639 FUNCTION Functions as potent mitogen in vitro. Acts as a ligand for FGFR1 and integrins. Binds to FGFR1 in the presence of heparin leading to FGFR1 dimerization and activation via sequential autophosphorylation on tyrosine residues which act as docking sites for interacting proteins, leading to the activation of several signaling cascades. Binds to integrin ITGAV:ITGB3. Its binding to integrin, subsequent ternary complex formation with integrin and FGFR1, and the recruitment of PTPN11 to the complex are essential for FGF1 signaling. Induces the phosphorylation and activation of FGFR1, FRS2, MAPK3/ERK1, MAPK1/ERK2 and AKT1. Can induce angiogenesis. Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. T18639 PDBSTRUC 4YOL; 4XKI; 4QO3; 4QC4; 4QBV T18639 BIOCLASS Growth factor T18639 SEQUENCE MAEGEITTFTALTEKFNLPPGNYKKPKLLYCSNGGHFLRILPDGTVDGTRDRSDQHIQLQLSAESVGEVYIKSTETGQYLAMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAEKNWFVGLKKNGSCKRGPRTHYGQKAILFLPLPVSSD T18639 DRUGINFO D06ANS CVBT-141H Phase 2 T18639 DRUGINFO D01OSN Riferminogene pecaplasmid Discontinued in Phase 3 T18639 DRUGINFO D07WQA Naphthalene Trisulfonate Investigative T18639 DRUGINFO D0I7FI 5-AMINO-NAPHTALENE-2-MONOSULFONATE Investigative T18639 DRUGINFO D0P9RP Sucrose Octasulfate Investigative T18639 DRUGINFO D06VYT O2-Sulfo-Glucuronic Acid Investigative T18639 DRUGINFO D0B0SV N,O6-Disulfo-Glucosamine Investigative T18639 DRUGINFO D06EWG Formic Acid Investigative T38431 TARGETID T38431 T38431 FORMERID TTDR00790 T38431 UNIPROID S10A9_HUMAN T38431 TARGNAME Calgranulin B (S100A9) T38431 GENENAME S100A9 T38431 TARGTYPE Clinical trial T38431 SYNONYMS S100 calcium-binding protein A9; Protein S100-A9; P14; Myeloid-related protein 14; Migration inhibitory factor-related protein 14; MRP14; MRP-14; Leukocyte L1 complex heavy chain; Calprotectin L1H subunit; Calgranulin-B; CAGB T38431 FUNCTION It can induce neutrophil chemotaxis, adhesion, can increase the bactericidal activity of neutrophils by promoting phagocytosis via activation of SYK, PI3K/AKT, and ERK1/2 and can induce degranulation of neutrophils by a MAPK-dependent mechanism. Predominantly found as calprotectin (S100A8/A9) which has a wide plethora of intra- and extracellular functions. The intracellular functions include: facilitating leukocyte arachidonic acid trafficking and metabolism, modulation of the tubulin-dependent cytoskeleton during migration of phagocytes and activation of the neutrophilic NADPH-oxidase. Activates NADPH-oxidase by facilitating the enzyme complex assembly at the cell membrane, transferring arachidonic acid, an essential cofactor, to the enzyme complex and S100A8 contributes to the enzyme assembly by directly binding to NCF2/P67PHOX. The extracellular functions involve proinflammatory, antimicrobial, oxidant-scavenging and apoptosis-inducing activities. Its proinflammatory activity includes recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to pattern recognition receptors such as Toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (AGER). Binding to TLR4 and AGER activates the MAP-kinase and NF-kappa-B signaling pathways resulting in the amplification of the proinflammatory cascade. Has antimicrobial activity towards bacteria and fungi and exerts its antimicrobial activity probably via chelation of Zn(2+) which is essential for microbial growth. Can induce cell death via autophagy and apoptosis and this occurs through the cross-talk of mitochondria and lysosomes via reactive oxygen species (ROS) and the process involves BNIP3. Can regulate neutrophil number and apoptosis by an anti-apoptotic effect; regulates cell survival via ITGAM/ITGB and TLR4 and a signaling mechanism involving MEK-ERK. Its role as an oxidant scavenger has a protective role in preventing exaggerated tissue damage by scavenging oxidants. Can act as a potent amplifier of inflammation in autoimmunity as well as in cancer development and tumor spread. Has transnitrosylase activity; in oxidatively-modified low-densitity lipoprotein (LDL(ox))-induced S-nitrosylation of GAPDH on 'Cys-247' proposed to transfer the NO moiety from NOS2/iNOS to GAPDH via its own S-nitrosylated Cys-3. The iNOS-S100A8/A9 transnitrosylase complex is proposed to also direct selective inflammatory stimulus-dependent S-nitrosylation of multiple targets such as ANXA5, EZR, MSN and VIM by recognizing a [IL]-x-C-x-x-[DE] motif. S100A9 is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. T38431 PDBSTRUC 6DS2; 5W1F; 5I8N; 4XJK; 4GGF T38431 BIOCLASS S100 calcium-binding protein T38431 SEQUENCE MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRKDLQNFLKKENKNEKVIEHIMEDLDTNADKQLSFEEFIMLMARLTWASHEKMHEGDEGPGHHHKPGLGEGTP T38431 DRUGINFO D02JMU Tasquinimod Phase 3 T38431 DRUGINFO D0G5SU Paquinimod Phase 2 T16601 TARGETID T16601 T16601 FORMERID TTDR00681 T16601 UNIPROID CEAM5_HUMAN T16601 TARGNAME Carcinoembryonic antigen CEA (CD66e) T16601 GENENAME CEACAM5 T16601 TARGTYPE Clinical trial T16601 SYNONYMS Meconium antigen 100; Carcinoembryonic antigen-related cell adhesion molecule 5; CEA; CD66e antigen T16601 FUNCTION Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells. Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. T16601 PDBSTRUC 2VER; 2QST; 2QSQ; 1.00E+07 T16601 BIOCLASS Immunoglobulin T16601 SEQUENCE MESPSAPPHRWCIPWQRLLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLVHNLPQHLFGYSWYKGERVDGNRQIIGYVIGTQQATPGPAYSGREIIYPNASLLIQNIIQNDTGFYTLHVIKSDLVNEEATGQFRVYPELPKPSISSNNSKPVEDKDAVAFTCEPETQDATYLWWVNNQSLPVSPRLQLSNGNRTLTLFNVTRNDTASYKCETQNPVSARRSDSVILNVLYGPDAPTISPLNTSYRSGENLNLSCHAASNPPAQYSWFVNGTFQQSTQELFIPNITVNNSGSYTCQAHNSDTGLNRTTVTTITVYAEPPKPFITSNNSNPVEDEDAVALTCEPEIQNTTYLWWVNNQSLPVSPRLQLSNDNRTLTLLSVTRNDVGPYECGIQNKLSVDHSDPVILNVLYGPDDPTISPSYTYYRPGVNLSLSCHAASNPPAQYSWLIDGNIQQHTQELFISNITEKNSGLYTCQANNSASGHSRTTVKTITVSAELPKPSISSNNSKPVEDKDAVAFTCEPEAQNTTYLWWVNGQSLPVSPRLQLSNGNRTLTLFNVTRNDARAYVCGIQNSVSANRSDPVTLDVLYGPDTPIISPPDSSYLSGANLNLSCHSASNPSPQYSWRINGIPQQHTQVLFIAKITPNNNGTYACFVSNLATGRNNSIVKSITVSASGTSPGLSAGATVGIMIGVLVGVALI T16601 DRUGINFO D05TBQ SAR408701 Phase 3 T16601 DRUGINFO D2D6NJ Tusamitamab ravtansine Phase 3 T16601 DRUGINFO D02UKX CAP1-6D Phase 2 T16601 DRUGINFO D0A3JJ Pentacea Phase 2 T16601 DRUGINFO D0L7VC GI-6207 Phase 2 T16601 DRUGINFO D0O5XF CeaVac Phase 2 T16601 DRUGINFO D0XP4A Labetuzumab I-131 Phase 2 T16601 DRUGINFO D03QMY IDM-2101 Phase 2 T16601 DRUGINFO D05ENG AVX701 Phase 1/2 T16601 DRUGINFO D0H5MS CT84.66 Phase 1/2 T16601 DRUGINFO D0T5DC CAR-T cells targeting CEA Phase 1/2 T16601 DRUGINFO D1XI9E BDC-1001 Phase 1/2 T16601 DRUGINFO D00KDQ Anti-CEA CAR-T cells Phase 1 T16601 DRUGINFO D08UVN Anti-CEA CAR-T cells Phase 1 T16601 DRUGINFO D0L6HU CAR-T Cells targeting CEA Phase 1 T16601 DRUGINFO D0M3GK RG7813 Phase 1 T16601 DRUGINFO D0P9UX AMG 211 Phase 1 T16601 DRUGINFO D0S1QN Anti-CEA-CAR T Phase 1 T16601 DRUGINFO D0T5LQ 123-Iodine-labeled MFE-23 Phase 1 T16601 DRUGINFO D0U1WP MV-CEA Phase 1 T16601 DRUGINFO D0Z0EP CIGB-M3 Phase 1 T16601 DRUGINFO DR0M3F CEA CAR-T Phase 1 T16601 DRUGINFO D7K5XP NEO-201 Phase 1 T16601 DRUGINFO D0S0DU KSB-303 Discontinued in Phase 1/2 T16601 DRUGINFO D00SJN HLL1-Fab-A3B3 Investigative T16601 DRUGINFO D05GIO ICT-037 Investigative T67207 TARGETID T67207 T67207 FORMERID TTDI02068 T67207 UNIPROID FCER2_HUMAN T67207 TARGNAME Lymphocyte IgE receptor (CD23) T67207 GENENAME FCER2 T67207 TARGTYPE Clinical trial T67207 SYNONYMS Low affinity immunoglobulin epsilon Fc receptor soluble form; Low affinity immunoglobulin epsilon Fc receptor; Immunoglobulin Ebinding factor; FcepsilonRII; FCER2; Ctype lectin domain family 4 member J; CD23; BLAST2 T67207 FUNCTION Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21. Has essential roles in the regulation of IgE production and in the differentiation of B-cells (it is a B-cell-specific antigen). T67207 PDBSTRUC 5LGK; 4KI1; 4J6Q; 4J6P; 4J6N T67207 BIOCLASS Immunoglobulin T67207 SEQUENCE MEEGQYSEIEELPRRRCCRRGTQIVLLGLVTAALWAGLLTLLLLWHWDTTQSLKQLEERAARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADLSSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKGTKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESMGPDSRPDPDGRLPTPSAPLHS T67207 DRUGINFO D0M5JA Lumiliximab Phase 2 T49064 TARGETID T49064 T49064 FORMERID TTDS00429 T49064 UNIPROID LIPG_HUMAN T49064 TARGNAME Gastric triacylglycerol lipase (LIPF) T49064 GENENAME LIPF T49064 TARGTYPE Clinical trial T49064 SYNONYMS Gastric lipase; GL T49064 FUNCTION An acidic lipase secreted by the gastric chief cells in the fundic mucosa in the stomach. Makes up 30% of lipid hydrolysis occurring during digestion in the human adult, T49064 PDBSTRUC 1HLG T49064 BIOCLASS Carboxylic ester hydrolase T49064 ECNUMBER EC 3.1.1.3 T49064 SEQUENCE MWLLLTMASLISVLGTTHGLFGKLHPGSPEVTMNISQMITYWGYPNEEYEVVTEDGYILEVNRIPYGKKNSGNTGQRPVVFLQHGLLASATNWISNLPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMAKYDLPATIDFIVKKTGQKQLHYVGHSQGTTIGFIAFSTNPSLAKRIKTFYALAPVATVKYTKSLINKLRFVPQSLFKFIFGDKIFYPHNFFDQFLATEVCSREMLNLLCSNALFIICGFDSKNFNTSRLDVYLSHNPAGTSVQNMFHWTQAVKSGKFQAYDWGSPVQNRMHYDQSQPPYYNVTAMNVPIAVWNGGKDLLADPQDVGLLLPKLPNLIYHKEIPFYNHLDFIWAMDAPQEVYNDIVSMISEDKK T49064 DRUGINFO D04NRB Cetilistat Phase 3 T49064 DRUGINFO D09BWD Undecyl-Phosphinic Acid Butyl Ester Investigative T49064 DRUGINFO D02UVH B-Octylglucoside Investigative T67416 TARGETID T67416 T67416 FORMERID TTDI01994 T67416 UNIPROID SYEP_HUMAN T67416 TARGNAME Bifunctional aminoacyl-tRNA synthetase (EPRS) T67416 GENENAME EPRS T67416 TARGTYPE Clinical trial T67416 SYNONYMS QPRS; QARS; ProlinetRNA ligase; PIG32; GlutamatylprolyltRNA synthetase; Glutamatyl-prolyl-tRNA synthetase; GluRS; EPRS; Cell proliferationinducing gene 32 protein; Cell proliferation-inducing gene 32 protein; Bifunctional glutamate/prolinetRNA ligase; Bifunctional glutamate/proline--tRNA ligase; Bifunctional aminoacyltRNA synthetase T67416 FUNCTION The phosphorylation of EPRS, induced by interferon-gamma, dissociates the protein from the aminoacyl-tRNA synthetase multienzyme complex and recruits it to the GAIT complex that binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin), suppressing their translation. Interferon-gamma can therefore redirect, in specific cells, the EPRS function from protein synthesis to translation inhibition. Also functions as an effector of the mTORC1 signaling pathway by promoting, through SLC27A1, the uptake of long-chain fatty acid by adipocytes. Thereby, it also plays a role in fat metabolism and more indirectly influences lifespan. Multifunctional protein which is primarily part of the aminoacyl-tRNA synthetase multienzyme complex, also know as multisynthetase complex, that catalyzes the attachment of the cognate amino acid to the corresponding tRNA in a two-step reaction: the amino acid is first activated by ATP to form a covalent intermediate with AMP and is then transferred to the acceptor end of the cognate tRNA. T67416 PDBSTRUC 5Y6L; 5VAD; 5V58; 5BMU; 5A5H T67416 BIOCLASS Carbon-oxygen ligase T67416 SEQUENCE MATLSLTVNSGDPPLGALLAVEHVKDDVSISVEEGKENILHVSENVIFTDVNSILRYLARVATTAGLYGSNLMEHTEIDHWLEFSATKLSSCDSFTSTINELNHCLSLRTYLVGNSLSLADLCVWATLKGNAAWQEQLKQKKAPVHVKRWFGFLEAQQAFQSVGTKWDVSTTKARVAPEKKQDVGKFVELPGAEMGKVTVRFPPEASGYLHIGHAKAALLNQHYQVNFKGKLIMRFDDTNPEKEKEDFEKVILEDVAMLHIKPDQFTYTSDHFETIMKYAEKLIQEGKAYVDDTPAEQMKAEREQRIDSKHRKNPIEKNLQMWEEMKKGSQFGQSCCLRAKIDMSSNNGCMRDPTLYRCKIQPHPRTGNKYNVYPTYDFACPIVDSIEGVTHALRTTEYHDRDEQFYWIIEALGIRKPYIWEYSRLNLNNTVLSKRKLTWFVNEGLVDGWDDPRFPTVRGVLRRGMTVEGLKQFIAAQGSSRSVVNMEWDKIWAFNKKVIDPVAPRYVALLKKEVIPVNVPEAQEEMKEVAKHPKNPEVGLKPVWYSPKVFIEGADAETFSEGEMVTFINWGNLNITKIHKNADGKIISLDAKLNLENKDYKKTTKVTWLAETTHALPIPVICVTYEHLITKPVLGKDEDFKQYVNKNSKHEELMLGDPCLKDLKKGDIIQLQRRGFFICDQPYEPVSPYSCKEAPCVLIYIPDGHTKEMPTSGSKEKTKVEATKNETSAPFKERPTPSLNNNCTTSEDSLVLYNRVAVQGDVVRELKAKKAPKEDVDAAVKQLLSLKAEYKEKTGQEYKPGNPPAEIGQNISSNSSASILESKSLYDEVAAQGEVVRKLKAEKSPKAKINEAVECLLSLKAQYKEKTGKEYIPGQPPLSQSSDSSPTRNSEPAGLETPEAKVLFDKVASQGEVVRKLKTEKAPKDQVDIAVQELLQLKAQYKSLIGVEYKPVSATGAEDKDKKKKEKENKSEKQNKPQKQNDGQRKDPSKNQGGGLSSSGAGEGQGPKKQTRLGLEAKKEENLADWYSQVITKSEMIEYHDISGCYILRPWAYAIWEAIKDFFDAEIKKLGVENCYFPMFVSQSALEKEKTHVADFAPEVAWVTRSGKTELAEPIAIRPTSETVMYPAYAKWVQSHRDLPIKLNQWCNVVRWEFKHPQPFLRTREFLWQEGHSAFATMEEAAEEVLQILDLYAQVYEELLAIPVVKGRKTEKEKFAGGDYTTTIEAFISASGRAIQGGTSHHLGQNFSKMFEIVFEDPKIPGEKQFAYQNSWGLTTRTIGVMTMVHGDNMGLVLPPRVACVQVVIIPCGITNALSEEDKEALIAKCNDYRRRLLSVNIRVRADLRDNYSPGWKFNHWELKGVPIRLEVGPRDMKSCQFVAVRRDTGEKLTVAENEAETKLQAILEDIQVTLFTRASEDLKTHMVVANTMEDFQKILDSGKIVQIPFCGEIDCEDWIKKTTARDQDLEPGAPSMGAKSLCIPFKPLCELQPGAKCVCGKNPAKYYTLFGRSY T67416 DRUGINFO D0U3KP HT-100 Phase 2 T47466 TARGETID T47466 T47466 FORMERID TTDI02359 T47466 UNIPROID HEM3_HUMAN T47466 TARGNAME Porphobilinogen deaminase (HMBS) T47466 GENENAME HMBS T47466 TARGTYPE Clinical trial T47466 SYNONYMS Preuroporphyrinogen synthase; PBGD; Hydroxymethylbilane synthase; HMBS T47466 FUNCTION Tetrapolymerization of the monopyrrole PBG into the hydroxymethylbilane pre-uroporphyrinogen in several discrete steps. T47466 PDBSTRUC 5M7F; 5M6R; 3EQ1; 3ECR T47466 BIOCLASS Alkyl aryl transferase T47466 ECNUMBER EC 2.5.1.61 T47466 SEQUENCE MSGNGNAAATAEENSPKMRVIRVGTRKSQLARIQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSKIGEKSLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKRENPHDAVVFHPKFVGKTLETLPEKSVVGTSSLRRAAQLQRKFPHLEFRSIRGNLNTRLRKLDEQQEFSAIILATAGLQRMGWHNRVGQILHPEECMYAVGQGALGVEVRAKDQDILDLVGVLHDPETLLRCIAERAFLRHLEGGCSVPVAVHTAMKDGQLYLTGGVWSLDGSDSIQETMQATIHVPAQHEDGPEDDPQLVGITARNIPRGPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH T47466 DRUGINFO D0C9IS P-9808 Phase 2 T52671 TARGETID T52671 T52671 FORMERID TTDR00831 T52671 UNIPROID APOA_HUMAN T52671 TARGNAME Apolipoprotein(a) (LPA) T52671 GENENAME LPA T52671 TARGTYPE Clinical trial T52671 SYNONYMS Lp(a); Lipoprotein(a); LPA; Apo(a) T52671 FUNCTION Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330. T52671 PDBSTRUC 4KIV; 4BVW; 4BVV; 4BVD; 4BVC T52671 BIOCLASS Apolipoprotein T52671 ECNUMBER EC 3.4.21.- T52671 SEQUENCE MEHKEVVLLLLLFLKSAAPEQSHVVQDCYHGDGQSYRGTYSTTVTGRTCQAWSSMTPHQHNRTTENYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDPVAAPYCYTRDPSVRWEYCNLTQCSDAEGTAVAPPTITPIPSLEAPSEQAPTEQRPGVQECYHGNGQSYQGTYFITVTGRTCQAWSSMTPHSHSRTPAYYPNAGLIKNYCRNPDPVAAPWCYTTDPSVRWEYCNLTRCSDAEWTAFVPPNVILAPSLEAFFEQALTEETPGVQDCYYHYGQSYRGTYSTTVTGRTCQAWSSMTPHQHSRTPENYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCLVTESSVLATLTVVPDPSTEASSEEAPTEQSPGVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEISPWCYTMDPNVRWEYCNLTQCPVTESSVLATSTAVSEQAPTEQSPTVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCPVMESTLLTTPTVVPVPSTELPSEEAPTENSTGVQDCYRGDGQSYRGTLSTTITGRTCQSWSSMTPHWHRRIPLYYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTRCPVTESSVLTTPTVAPVPSTEAPSEQAPPEKSPVVQDCYHGDGRSYRGISSTTVTGRTCQSWSSMIPHWHQRTPENYPNAGLTENYCRNPDSGKQPWCYTTDPCVRWEYCNLTQCSETESGVLETPTVVPVPSMEAHSEAAPTEQTPVVRQCYHGNGQSYRGTFSTTVTGRTCQSWSSMTPHRHQRTPENYPNDGLTMNYCRNPDADTGPWCFTMDPSIRWEYCNLTRCSDTEGTVVAPPTVIQVPSLGPPSEQDCMFGNGKGYRGKKATTVTGTPCQEWAAQEPHRHSTFIPGTNKWAGLEKNYCRNPDGDINGPWCYTMNPRKLFDYCDIPLCASSSFDCGKPQVEPKKCPGSIVGGCVAHPHSWPWQVSLRTRFGKHFCGGTLISPEWVLTAAHCLKKSSRPSSYKVILGAHQEVNLESHVQEIEVSRLFLEPTQADIALLKLSRPAVITDKVMPACLPSPDYMVTARTECYITGWGETQGTFGTGLLKEAQLLVIENEVCNHYKYICAEHLARGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYARVSRFVTWIEGMMRNN T52671 DRUGINFO DTG28Y LY3473329 Phase 2 T52671 DRUGINFO D02XAC MG-1102 Phase 1 T94094 TARGETID T94094 T94094 FORMERID TTDR00064 T94094 UNIPROID DPOL_HCMVA T94094 TARGNAME Cytomegalovirus DNA polymerase (CMV UL54) T94094 GENENAME CMV UL54 T94094 TARGTYPE Clinical trial T94094 SYNONYMS UL54; DNA polymerase of Human herpesvirus 5 T94094 FUNCTION Replicates viral genomic DNA in the late phase of lytic infection, producing long concatemeric DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. T94094 PDBSTRUC 1YYP T94094 BIOCLASS DNA polymerase type-B family T94094 ECNUMBER EC 2.7.7.7 T94094 SEQUENCE MFFNPYLSGGVTGGAVAGGRRQRSQPGSAQGSGKRPPQKQFLQIVPRGVMFDGQTGLIKHKTGRLPLMFYREIKHLLSHDMVWPCPWRETLVGRVVGPIRFHTYDQTDAVLFFDSPENVSPRYRQHLVPSGNVLRFFGATEHGYSICVNVFGQRSYFYCEYSDTDRLREVIASVGELVPEPRTPYAVSVTPATKTSIYGYGTRPVPDLQCVSISNWTMARKIGEYLLEQGFPVYEVRVDPLTRLVIDRRITTFGWCSVNRYDWRQQGRASTCDIEVDCDVSDLVAVPDDSSWPRYRCLSFDIECMSGEGGFPCAEKSDDIVIQISCVCYETGGNTAVDQGIPNGNDGRGCTSEGVIFGHSGLHLFTIGTCGQVGPDVDVYEFPSEYELLLGFMLFFQRYAPAFVTGYNINSFDLKYILTRLEYLYKVDSQRFCKLPTAQGGRFFLHSPAVGFKRQYAAAFPSASHNNPASTAATKVYIAGSVVIDMYPVCMAKTNSPNYKLNTMAELYLRQRKDDLSYKDIPRCFVANAEGRAQVGRYCLQDAVLVRDLFNTINFHYEAGAIARLAKIPLRRVIFDGQQIRIYTSLLDECACRDFILPNHYSKGTTVPETNSVAVSPNAAIISTAAVPGDAGSVAAMFQMSPPLQSAPSSQDGVSPGSGSNSSSSVGVFSVGSGSSGGVGVSNDNHGAGGTAAVSYQGATVFEPEVGYYNDPVAVFDFASLYPSIIMAHNLCYSTLLVPGGEYPVDPADVYSVTLENGVTHRFVRASVRVSVLSELLNKWVSQRRAVRECMRECQDPVRRMLLDKEQMALKVTCNAFYGFTGVVNGMMPCLPIAASITRIGRDMLERTARFIKDNFSEPCFLHNFFNQEDYVVGTREGDSEESSALPEGLETSSGGSNERRVEARVIYGDTDSVFVRFRGLTPQALVARGPSLAHYVTACLFVEPVKLEFEKVFVSLMMICKKRYIGKVEGASGLSMKGVDLVRKTACEFVKGVTRDVLSLLFEDREVSEAAVRLSRLSLDEVKKYGVPRGFWRILRRLVQARDDLYLHRVRVEDLVLSSVLSKDISLYRQSNLPHIAVIKRLAARSEELPSVGDRVFYVLTAPGVRTAPQGSSDNGDSVTAGVVSRSDAIDGTDDDADGGGVEESNRRGGEPAKKRARKPPSAVCNYEVAEDPSYVREHGVPIHADKYFEQVLKAVTNVLSPVFPGGETARKDKFLHMVLPRRLHLEPAFLPYSVKAHECC T94094 DRUGINFO D0H1OL Guanosine Phase 1 T94094 DRUGINFO D04AWP Guanosine-5'-Monophosphate Investigative T74937 TARGETID T74937 T74937 FORMERID TTDI02054 T74937 UNIPROID DOPO_HUMAN T74937 TARGNAME Dopamine beta hydroxylase (DBH) T74937 GENENAME DBH T74937 TARGTYPE Clinical trial T74937 SYNONYMS Soluble dopamine betahydroxylase; Dopamine betamonooxygenase; Dopamine betahydroxylase; Dopamine beta-monooxygenase; Dopamine beta-hydroxylase T74937 FUNCTION Conversion of dopamine to noradrenaline. T74937 PDBSTRUC 4ZEL T74937 BIOCLASS Paired donor oxygen oxidoreductase T74937 ECNUMBER EC 1.14.17.1 T74937 SEQUENCE MPALSRWASLPGPSMREAAFMYSTAVAIFLVILVAALQGSAPRESPLPYHIPLDPEGSLELSWNVSYTQEAIHFQLLVRRLKAGVLFGMSDRGELENADLVVLWTDGDTAYFADAWSDQKGQIHLDPQQDYQLLQVQRTPEGLTLLFKRPFGTCDPKDYLIEDGTVHLVYGILEEPFRSLEAINGSGLQMGLQRVQLLKPNIPEPELPSDACTMEVQAPNIQIPSQETTYWCYIKELPKGFSRHHIIKYEPIVTKGNEALVHHMEVFQCAPEMDSVPHFSGPCDSKMKPDRLNYCRHVLAAWALGAKAFYYPEEAGLAFGGPGSSRYLRLEVHYHNPLVIEGRNDSSGIRLYYTAKLRRFNAGIMELGLVYTPVMAIPPRETAFILTGYCTDKCTQLALPPSGIHIFASQLHTHLTGRKVVTVLVRDGREWEIVNQDNHYSPHFQEIRMLKKVVSVHPGDVLITSCTYNTEDRELATVGGFGILEEMCVNYVHYYPQTQLELCKSAVDAGFLQKYFHLINRFNNEDVCTCPQASVSQQFTSVPWNSFNRDVLKALYSFAPISMHCNKSSAVRFQGEWNLQPLPKVISTLEEPTPQCPTSQGRSPAGPTVVSIGGGKG T74937 DRUGINFO D0H5HZ Etamicastat Phase 2 T74937 DRUGINFO D0N5YD Nepicastat oral Phase 2 T33990 TARGETID T33990 T33990 FORMERID TTDC00263 T33990 UNIPROID CSF1_HUMAN T33990 TARGNAME Macrophage colony-stimulating factor 1 (CSF1) T33990 GENENAME CSF1 T33990 TARGTYPE Clinical trial T33990 SYNONYMS Processed macrophagecolony-stimulating factor 1; MCSF; M-CSF; Lanimostim; CSF-1 T33990 FUNCTION Promotes the release of proinflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. Required for normal male and female fertility. Promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration. Plays a role in lipoprotein clearance. Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. T33990 PDBSTRUC 5LXF; 4WRM; 4WRL; 4FA8; 4ADF T33990 SEQUENCE MTAPGAAGRCPPTTWLGSLLLLVCLLASRSITEEVSEYCSHMIGSGHLQSLQRLIDSQMETSCQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLRLKSCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAECSSQDVVTKPDCNCLYPKAIPSSDPASVSPHQPLAPSMAPVAGLTWEDSEGTEGSSLLPGEQPLHTVDPGSAKQRPPRSTCQSFEPPETPVVKDSTIGGSPQPRPSVGAFNPGMEDILDSAMGTNWVPEEASGEASEIPVPQGTELSPSRPGGGSMQTEPARPSNFLSASSPLPASAKGQQPADVTGTALPRVGPVRPTGQDWNHTPQKTDHPSALLRDPPEPGSPRISSLRPQGLSNPSTLSAQPQLSRSHSSGSVLPLGELEGRRSTRDRRSPAEPEGGPASEGAARPLPRFNSVPLTDTGHERQSEGSFSPQLQESVFHLLVPSVILVLLAVGGLLFYRWRRRSHQEPQRADSPLEQPEGSPLTQDDRQVELPV T33990 DRUGINFO D06NQH RG7155 Phase 2 T33990 DRUGINFO D00MJI Emactuzumab Phase 1 T33990 DRUGINFO D0PL8D PLX73086 Phase 1 T33990 DRUGINFO D18QIB MSC110 Phase 1 T37154 TARGETID T37154 T37154 FORMERID TTDNC00448 T37154 UNIPROID PPGB_HUMAN T37154 TARGNAME Cathepsin A (CTSA) T37154 GENENAME CTSA T37154 TARGTYPE Clinical trial T37154 SYNONYMS Protective protein for betagalactosidase; Protective protein cathepsin A; PPCA; Lysosomal protective protein 20 kDa chain; Lysosomal protective protein; Carboxypeptidase L; Carboxypeptidase C; CTSA T37154 FUNCTION Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability and activity. This protein is also a carboxypeptidase and can deamidate tachykinins. T37154 PDBSTRUC 4MWT; 4MWS; 4CIB; 4CIA; 4CI9 T37154 BIOCLASS Peptidase T37154 ECNUMBER EC 3.4.16.5 T37154 SEQUENCE MIRAAPPPLFLLLLLLLLLVSWASRGEAAPDQDEIQRLPGLAKQPSFRQYSGYLKGSGSKHLHYWFVESQKDPENSPVVLWLNGGPGCSSLDGLLTEHGPFLVQPDGVTLEYNPYSWNLIANVLYLESPAGVGFSYSDDKFYATNDTEVAQSNFEALQDFFRLFPEYKNNKLFLTGESYAGIYIPTLAVLVMQDPSMNLQGLAVGNGLSSYEQNDNSLVYFAYYHGLLGNRLWSSLQTHCCSQNKCNFYDNKDLECVTNLQEVARIVGNSGLNIYNLYAPCAGGVPSHFRYEKDTVVVQDLGNIFTRLPLKRMWHQALLRSGDKVRMDPPCTNTTAASTYLNNPYVRKALNIPEQLPQWDMCNFLVNLQYRRLYRSMNSQYLKLLSSQKYQILLYNGDVDMACNFMGDEWFVDSLNQKMEVQRRPWLVKYGDSGEQIAGFVKEFSHIAFLTIKGAGHMVPTDKPLAAFTMFSRFLNKQPY T37154 DRUGINFO D01CIB SAR164653 Phase 1 T37154 DRUGINFO D01QJT example 166 (WO2014154727) Investigative T37154 DRUGINFO D0I9PF PMID22861813C8a Investigative T11283 TARGETID T11283 T11283 FORMERID TTDR00663 T11283 UNIPROID CH60_HUMAN T11283 TARGNAME Mitochondrial matrix protein P1 (HSPD1) T11283 GENENAME HSPD1 T11283 TARGTYPE Clinical trial T11283 SYNONYMS P60 lymphocyte protein; HuCHA60; Hsp60; Heat shock protein 60; HSP-60; Chaperonin 60; CPN60; 60 kDa heat shock protein, mitochondrial; 60 kDa chaperonin T11283 FUNCTION Together with Hsp10, facilitates the correct folding of imported proteins. May also prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under stress conditions in the mitochondrial matrix. The functional units of these chaperonins consist of heptameric rings of the large subunit Hsp60, which function as a back-to-back double ring. In a cyclic reaction, Hsp60 ring complexes bind one unfolded substrate protein per ring, followed by the binding of ATP and association with 2 heptameric rings of the co-chaperonin Hsp10. This leads to sequestration of the substrate protein in the inner cavity of Hsp60 where, for a certain period of time, it can fold undisturbed by other cell components. Synchronous hydrolysis of ATP in all Hsp60 subunits results in the dissociation of the chaperonin rings and the release of ADP and the folded substrate protein. Chaperonin implicated in mitochondrial protein import and macromolecular assembly. T11283 PDBSTRUC 4PJ1 T11283 BIOCLASS Chaperonin ATPase T11283 ECNUMBER EC 5.6.1.7 T11283 SEQUENCE MLRLPTVFRQMRPVSRVLAPHLTRAYAKDVKFGADARALMLQGVDLLADAVAVTMGPKGRTVIIEQSWGSPKVTKDGVTVAKSIDLKDKYKNIGAKLVQDVANNTNEEAGDGTTTATVLARSIAKEGFEKISKGANPVEIRRGVMLAVDAVIAELKKQSKPVTTPEEIAQVATISANGDKEIGNIISDAMKKVGRKGVITVKDGKTLNDELEIIEGMKFDRGYISPYFINTSKGQKCEFQDAYVLLSEKKISSIQSIVPALEIANAHRKPLVIIAEDVDGEALSTLVLNRLKVGLQVVAVKAPGFGDNRKNQLKDMAIATGGAVFGEEGLTLNLEDVQPHDLGKVGEVIVTKDDAMLLKGKGDKAQIEKRIQEIIEQLDVTTSEYEKEKLNERLAKLSDGVAVLKVGGTSDVEVNEKKDRVTDALNATRAAVEEGIVLGGGCALLRCIPALDSLTPANEDQKIGIEIIKRTLKIPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEKGIIDPTKVVRTALLDAAGVASLLTTAEVVVTEIPKEEKDPGMGAMGGMGGGMGGGMF T11283 DRUGINFO D0G6TL DiaPep-277 Phase 3 T17048 TARGETID T17048 T17048 FORMERID TTDI01972 T17048 UNIPROID TOP2A_HUMAN T17048 TARGNAME DNA topoisomerase II alpha (TOP2A) T17048 GENENAME TOP2A T17048 TARGTYPE Clinical trial T17048 SYNONYMS DNA topoisomerase II, alpha isozyme; DNA topoisomerase 2alpha; DNA topoisomerase 2-alpha T17048 FUNCTION Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation. Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. T17048 PDBSTRUC 5NNE; 5GWK; 4R1F; 4FM9; 1ZXN T17048 BIOCLASS Topoisomerase T17048 ECNUMBER EC 5.6.2.3 T17048 SEQUENCE MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDNMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKENMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF T17048 DRUGINFO D01ZMS PK1 Phase 2 T17048 DRUGINFO DE53JQ Camsirubicin Phase 2 T17048 DRUGINFO DCT2Q3 Annamycin Phase 1/2 T17048 DRUGINFO DGZ38L NK314 Investigative T12909 TARGETID T12909 T12909 FORMERID TTDI02053 T12909 UNIPROID DMD_HUMAN T12909 TARGNAME Dystrophin (DMD) T12909 GENENAME DMD T12909 TARGTYPE Clinical trial T12909 SYNONYMS Dystrophin T12909 FUNCTION Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission. T12909 PDBSTRUC 3UUN; 1EG4; 1EG3; 1DXX T12909 BIOCLASS Dystrophin protein T12909 SEQUENCE MLWWEEVEDCYEREDVQKKTFTKWVNAQFSKFGKQHIENLFSDLQDGRRLLDLLEGLTGQKLPKEKGSTRVHALNNVNKALRVLQNNNVDLVNIGSTDIVDGNHKLTLGLIWNIILHWQVKNVMKNIMAGLQQTNSEKILLSWVRQSTRNYPQVNVINFTTSWSDGLALNALIHSHRPDLFDWNSVVCQQSATQRLEHAFNIARYQLGIEKLLDPEDVDTTYPDKKSILMYITSLFQVLPQQVSIEAIQEVEMLPRPPKVTKEEHFQLHHQMHYSQQITVSLAQGYERTSSPKPRFKSYAYTQAAYVTTSDPTRSPFPSQHLEAPEDKSFGSSLMESEVNLDRYQTALEEVLSWLLSAEDTLQAQGEISNDVEVVKDQFHTHEGYMMDLTAHQGRVGNILQLGSKLIGTGKLSEDEETEVQEQMNLLNSRWECLRVASMEKQSNLHRVLMDLQNQKLKELNDWLTKTEERTRKMEEEPLGPDLEDLKRQVQQHKVLQEDLEQEQVRVNSLTHMVVVVDESSGDHATAALEEQLKVLGDRWANICRWTEDRWVLLQDILLKWQRLTEEQCLFSAWLSEKEDAVNKIHTTGFKDQNEMLSSLQKLAVLKADLEKKKQSMGKLYSLKQDLLSTLKNKSVTQKTEAWLDNFARCWDNLVQKLEKSTAQISQAVTTTQPSLTQTTVMETVTTVTTREQILVKHAQEELPPPPPQKKRQITVDSEIRKRLDVDITELHSWITRSEAVLQSPEFAIFRKEGNFSDLKEKVNAIEREKAEKFRKLQDASRSAQALVEQMVNEGVNADSIKQASEQLNSRWIEFCQLLSERLNWLEYQNNIIAFYNQLQQLEQMTTTAENWLKIQPTTPSEPTAIKSQLKICKDEVNRLSDLQPQIERLKIQSIALKEKGQGPMFLDADFVAFTNHFKQVFSDVQAREKELQTIFDTLPPMRYQETMSAIRTWVQQSETKLSIPQLSVTDYEIMEQRLGELQALQSSLQEQQSGLYYLSTTVKEMSKKAPSEISRKYQSEFEEIEGRWKKLSSQLVEHCQKLEEQMNKLRKIQNHIQTLKKWMAEVDVFLKEEWPALGDSEILKKQLKQCRLLVSDIQTIQPSLNSVNEGGQKIKNEAEPEFASRLETELKELNTQWDHMCQQVYARKEALKGGLEKTVSLQKDLSEMHEWMTQAEEEYLERDFEYKTPDELQKAVEEMKRAKEEAQQKEAKVKLLTESVNSVIAQAPPVAQEALKKELETLTTNYQWLCTRLNGKCKTLEEVWACWHELLSYLEKANKWLNEVEFKLKTTENIPGGAEEISEVLDSLENLMRHSEDNPNQIRILAQTLTDGGVMDELINEELETFNSRWRELHEEAVRRQKLLEQSIQSAQETEKSLHLIQESLTFIDKQLAAYIADKVDAAQMPQEAQKIQSDLTSHEISLEEMKKHNQGKEAAQRVLSQIDVAQKKLQDVSMKFRLFQKPANFEQRLQESKMILDEVKMHLPALETKSVEQEVVQSQLNHCVNLYKSLSEVKSEVEMVIKTGRQIVQKKQTENPKELDERVTALKLHYNELGAKVTERKQQLEKCLKLSRKMRKEMNVLTEWLAATDMELTKRSAVEGMPSNLDSEVAWGKATQKEIEKQKVHLKSITEVGEALKTVLGKKETLVEDKLSLLNSNWIAVTSRAEEWLNLLLEYQKHMETFDQNVDHITKWIIQADTLLDESEKKKPQQKEDVLKRLKAELNDIRPKVDSTRDQAANLMANRGDHCRKLVEPQISELNHRFAAISHRIKTGKASIPLKELEQFNSDIQKLLEPLEAEIQQGVNLKEEDFNKDMNEDNEGTVKELLQRGDNLQQRITDERKREEIKIKQQLLQTKHNALKDLRSQRRKKALEISHQWYQYKRQADDLLKCLDDIEKKLASLPEPRDERKIKEIDRELQKKKEELNAVRRQAEGLSEDGAAMAVEPTQIQLSKRWREIESKFAQFRRLNFAQIHTVREETMMVMTEDMPLEISYVPSTYLTEITHVSQALLEVEQLLNAPDLCAKDFEDLFKQEESLKNIKDSLQQSSGRIDIIHSKKTAALQSATPVERVKLQEALSQLDFQWEKVNKMYKDRQGRFDRSVEKWRRFHYDIKIFNQWLTEAEQFLRKTQIPENWEHAKYKWYLKELQDGIGQRQTVVRTLNATGEEIIQQSSKTDASILQEKLGSLNLRWQEVCKQLSDRKKRLEEQKNILSEFQRDLNEFVLWLEEADNIASIPLEPGKEQQLKEKLEQVKLLVEELPLRQGILKQLNETGGPVLVSAPISPEEQDKLENKLKQTNLQWIKVSRALPEKQGEIEAQIKDLGQLEKKLEDLEEQLNHLLLWLSPIRNQLEIYNQPNQEGPFDVKETEIAVQAKQPDVEEILSKGQHLYKEKPATQPVKRKLEDLSSEWKAVNRLLQELRAKQPDLAPGLTTIGASPTQTVTLVTQPVVTKETAISKLEMPSSLMLEVPALADFNRAWTELTDWLSLLDQVIKSQRVMVGDLEDINEMIIKQKATMQDLEQRRPQLEELITAAQNLKNKTSNQEARTIITDRIERIQNQWDEVQEHLQNRRQQLNEMLKDSTQWLEAKEEAEQVLGQARAKLESWKEGPYTVDAIQKKITETKQLAKDLRQWQTNVDVANDLALKLLRDYSADDTRKVHMITENINASWRSIHKRVSEREAALEETHRLLQQFPLDLEKFLAWLTEAETTANVLQDATRKERLLEDSKGVKELMKQWQDLQGEIEAHTDVYHNLDENSQKILRSLEGSDDAVLLQRRLDNMNFKWSELRKKSLNIRSHLEASSDQWKRLHLSLQELLVWLQLKDDELSRQAPIGGDFPAVQKQNDVHRAFKRELKTKEPVIMSTLETVRIFLTEQPLEGLEKLYQEPRELPPEERAQNVTRLLRKQAEEVNTEWEKLNLHSADWQRKIDETLERLQELQEATDELDLKLRQAEVIKGSWQPVGDLLIDSLQDHLEKVKALRGEIAPLKENVSHVNDLARQLTTLGIQLSPYNLSTLEDLNTRWKLLQVAVEDRVRQLHEAHRDFGPASQHFLSTSVQGPWERAISPNKVPYYINHETQTTCWDHPKMTELYQSLADLNNVRFSAYRTAMKLRRLQKALCLDLLSLSAACDALDQHNLKQNDQPMDILQIINCLTTIYDRLEQEHNNLVNVPLCVDMCLNWLLNVYDTGRTGRIRVLSFKTGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRLGLLLHDSIQIPRQLGEVASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLEPQSMVWLPVLHRVAAAETAKHQAKCNICKECPIIGFRYRSLKHFNYDICQSCFFSGRVAKGHKMHYPMVEYCTPTTSGEDVRDFAKVLKNKFRTKRYFAKHPRMGYLPVQTVLEGDNMETPVTLINFWPVDSAPASSPQLSHDDTHSRIEHYASRLAEMENSNGSYLNDSISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLESEERGELERILADLEEENRNLQAEYDRLKQQHEHKGLSPLPSPPEMMPTSPQSPRDAELIAEAKLLRQHKGRLEARMQILEDHNKQLESQLHRLRQLLEQPQAEAKVNGTTVSSPSTSLQRSDSSQPMLLRVVGSQTSDSMGEEDLLSPPQDTSTGLEEVMEQLNNSFPSSRGRNTPGKPMREDTM T12909 DRUGINFO D34VAB Fordadistrogene movaparvovec Phase 3 T12909 DRUGINFO D06SZU WVE-210201 Phase 2/3 T12909 DRUGINFO D9M8FK SRP-9001 Phase 2 T12909 DRUGINFO D05EHS MyoDys Phase 1 T12909 DRUGINFO D08DTD Biostrophin Phase 1 T35232 TARGETID T35232 T35232 FORMERID TTDNC00584 T35232 UNIPROID IL7_HUMAN T35232 TARGNAME Interleukin-7 (IL7) T35232 GENENAME IL7 T35232 TARGTYPE Clinical trial T35232 SYNONYMS Interleukin7; IL-7 T35232 FUNCTION It is important for proliferation during certain stages of B-cell maturation. Hematopoietic growth factor capable of stimulating the proliferation of lymphoid progenitors. T35232 PDBSTRUC 3DI3; 3DI2; 1IL7 T35232 BIOCLASS Cytokine: interleukin T35232 SEQUENCE MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLEENKSLKEQKKLNDLCFLKRLLQEIKTCWNKILMGTKEH T35232 DRUGINFO D00SYV GSK2618960 Phase 1 T35232 DRUGINFO DPI9N4 GSK3888130? Phase 1 T35232 DRUGINFO D1FUQ2 ASP9801 Phase 1 T54771 TARGETID T54771 T54771 FORMERID TTDC00260 T54771 UNIPROID SC5A1_HUMAN T54771 TARGNAME Sodium/glucose cotransporter 1 (SGLT1) T54771 GENENAME SLC5A1 T54771 TARGTYPE Clinical trial T54771 SYNONYMS Solute carrier family 5 member 1; Na(+)/glucose cotransporter 1; NAGT; High affinity sodium-glucose cotransporter T54771 FUNCTION Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules. Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1. T54771 BIOCLASS Solute:sodium symporter T54771 SEQUENCE MDSSTWSPKTTAVTRPVETHELIRNAADISIIVIYFVVVMAVGLWAMFSTNRGTVGGFFLAGRSMVWWPIGASLFASNIGSGHFVGLAGTGAASGIAIGGFEWNALVLVVVLGWLFVPIYIKAGVVTMPEYLRKRFGGQRIQVYLSLLSLLLYIFTKISADIFSGAIFINLALGLNLYLAIFLLLAITALYTITGGLAAVIYTDTLQTVIMLVGSLILTGFAFHEVGGYDAFMEKYMKAIPTIVSDGNTTFQEKCYTPRADSFHIFRDPLTGDLPWPGFIFGMSILTLWYWCTDQVIVQRCLSAKNMSHVKGGCILCGYLKLMPMFIMVMPGMISRILYTEKIACVVPSECEKYCGTKVGCTNIAYPTLVVELMPNGLRGLMLSVMLASLMSSLTSIFNSASTLFTMDIYAKVRKRASEKELMIAGRLFILVLIGISIAWVPIVQSAQSGQLFDYIQSITSYLGPPIAAVFLLAIFWKRVNEPGAFWGLILGLLIGISRMITEFAYGTGSCMEPSNCPTIICGVHYLYFAIILFAISFITIVVISLLTKPIPDVHLYRLCWSLRNSKEERIDLDAEEENIQEGPKETIEIETQVPEKKKGIFRRAYDLFCGLEQHGAPKMTEEEEKAMKMKMTDTSEKPLWRTVLNVNGIILVTVAVFCHAYFA T54771 DRUGINFO D0X2UI LIK-066 Phase 2 T54771 DRUGINFO D6KEW7 YG1699 Phase 2 T54771 DRUGINFO D09GLS GSK1614235 Phase 1 T54771 DRUGINFO D5T7QW LX2761 Phase 1 T54771 DRUGINFO D0D2WX 1614235 + 2330672 Phase 1 T54771 DRUGINFO D0X1YF T-1095 Discontinued in Phase 2 T54771 DRUGINFO D06GXT Acerogenin A Investigative T54771 DRUGINFO D06WAL Phlorizin Investigative T54771 DRUGINFO D0H6DA QCP Investigative T54771 DRUGINFO D0K6SV QSPac Investigative T54771 DRUGINFO D0Q2YH QCPac Investigative T54771 DRUGINFO D0V7CD QNEQCPQVSac Investigative T54771 DRUGINFO D00HFT 10-methoxy-N(1)-methylburnamine-17-O-veratrate Investigative T54771 DRUGINFO D01DIQ Alstiphyllanine F Investigative T54771 DRUGINFO D03VSQ Kushenol N Investigative T54771 DRUGINFO D05AZW Alstiphyllanine E Investigative T54771 DRUGINFO D0I2FC Burnamine-17-O-3',4',5'-trimethoxybenzoate Investigative T54771 DRUGINFO D0L8OJ Alstiphyllanine D Investigative T54771 DRUGINFO D0M8EH O-spiroketal glucoside Investigative T54771 DRUGINFO D0S1MI ACEROGENIN B Investigative T54771 DRUGINFO D0VE0Q Sophoraflavanone G Investigative T54771 DRUGINFO D0X1TN sergliflozin Investigative T54771 DRUGINFO D01PNM KURARINONE Investigative T54771 DRUGINFO D06GUJ KURAIDIN Investigative T60526 TARGETID T60526 T60526 FORMERID TTDR00722 T60526 UNIPROID LYAM1_HUMAN T60526 TARGNAME L-selectin (SELL) T60526 GENENAME SELL T60526 TARGTYPE Clinical trial T60526 SYNONYMS TQ1; SELL; Lymph node homing receptor; Leukocyte-endothelial cell adhesion molecule 1; Leukocyte surface antigen Leu-8; Leukocyte adhesion molecule-1; LECAM1; LAM-1; Gp90-MEL; CD62L T60526 FUNCTION Cell surface adhesion protein. Mediates the adherence of lymphocytes to endothelial cells of high endothelial venules in peripheral lymph nodes. Promotes initial tethering and rolling of leukocytes in endothelia. T60526 PDBSTRUC 5VC1; 3CFW; 2LGF; 1KJB T60526 SEQUENCE MIFPWKCQSTQRDLWNIFKLWGWTMLCCDFLAHHGTDCWTYHYSEKPMNWQRARRFCRDNYTDLVAIQNKAEIEYLEKTLPFSRSYYWIGIRKIGGIWTWVGTNKSLTEEAENWGDGEPNNKKNKEDCVEIYIKRNKDAGKWNDDACHKLKAALCYTASCQPWSCSGHGECVEIINNYTCNCDVGYYGPQCQFVIQCEPLEAPELGTMDCTHPLGNFSFSSQCAFSCSEGTNLTGIEETTCGPFGNWSSPEPTCQVIQCEPLSAPDLGIMNCSHPLASFSFTSACTFICSEGTELIGKKKTICESSGIWSNPSPICQKLDKSFSMIKEGDYNPLFIPVAVMVTAFSGLAFIIWLARRLKKGKKSKRSMNDPY T60526 DRUGINFO D0N4EO GMI-1070 Phase 3 T60526 DRUGINFO D00YEV BAICALEIN Phase 2 T60526 DRUGINFO D0Z0HS Hu Dreg 55 Terminated T60526 DRUGINFO D0R7MJ PURPUROGALLIN Terminated T60526 DRUGINFO D03HTZ LD201t1 Investigative T60526 DRUGINFO D0E9NT 2,3,4-trihydroxybenzoic acid Investigative T81311 TARGETID T81311 T81311 FORMERID TTDI01987 T81311 UNIPROID ENPL_HUMAN T81311 TARGNAME Endoplasmin (HSP90B1) T81311 GENENAME HSP90B1 T81311 TARGTYPE Clinical trial T81311 SYNONYMS gp96 homolog; Tumor rejection antigen 1; TRA1; Heat shock protein 90 kDa beta member 1; GRP94; GRP-94; 94 kDa glucoseregulated protein; 94 kDa glucose-regulated protein T81311 FUNCTION When associated with CNPY3, required for proper folding of Toll-like receptors. Functions in endoplasmic reticulum associated degradation (ERAD). Has ATPase activity. Molecular chaperone that functions in the processing and transport of secreted proteins. T81311 PDBSTRUC 4NH9 T81311 BIOCLASS Heat shock protein T81311 SEQUENCE MRALWVLGLCCVLLTFGSVRADDEVDVDGTVEEDLGKSREGSRTDDEVVQREEEAIQLDGLNASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISLTDENALSGNEELTVKIKCDKEKNLLHVTDTGVGMTREELVKNLGTIAKSGTSEFLNKMTEAQEDGQSTSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTITLVLKEEASDYLELDTIKNLVKKYSQFINFPIYVWSSKTETVEEPMEEEEAAKEEKEESDDEAAVEEEEEEKKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMAYIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITDDFHDMMPKYLNFVKGVVDSDDLPLNVSRETLQQHKLLKVIRKKLVRKTLDMIKKIADDKYNDTFWKEFGTNIKLGVIEDHSNRTRLAKLLRFQSSHHPTDITSLDQYVERMKEKQDKIYFMAGSSRKEAESSPFVERLLKKGYEVIYLTEPVDEYCIQALPEFDGKRFQNVAKEGVKFDESEKTKESREAVEKEFEPLLNWMKDKALKDKIEKAVVSQRLTESPCALVASQYGWSGNMERIMKAQAYQTGKDISTNYYASQKKTFEINPRHPLIRDMLRRIKEDEDDKTVLDLAVVLFETATLRSGYLLPDTKAYGDRIERMLRLSLNIDPDAKVEEEPEEEPEETAEDTTEDTEQDEDEEMDVGTDEEEETAKESTAEKDEL T81311 DRUGINFO D0F3EO HS-110 Phase 2 T33124 TARGETID T33124 T33124 FORMERID TTDI02364 T33124 UNIPROID OXDA_HUMAN T33124 TARGNAME D-amino acid oxidase (DAO) T33124 GENENAME DAO T33124 TARGTYPE Clinical trial T33124 SYNONYMS Daminoacid oxidase; DAMOX; DAAO T33124 FUNCTION Regulates the level of the neuromodulator D-serine in the brain. Has high activity towards D-DOPA and contributes to dopamine synthesis. Could act as a detoxifying agent which removes D-amino acids accumulated during aging. Acts on a variety of D-amino acids with a preference for those having small hydrophobic side chains followed by those bearing polar, aromatic, and basic groups. Does not act on acidic amino acids. T33124 PDBSTRUC 5ZJA; 5ZJ9; 4QFD; 4QFC; 3ZNQ T33124 BIOCLASS CH-NH(2) donor oxidoreductase T33124 ECNUMBER EC 1.4.3.3 T33124 SEQUENCE MRVVVIGAGVIGLSTALCIHERYHSVLQPLDIKVYADRFTPLTTTDVAAGLWQPYLSDPNNPQEADWSQQTFDYLLSHVHSPNAENLGLFLISGYNLFHEAIPDPSWKDTVLGFRKLTPRELDMFPDYGYGWFHTSLILEGKNYLQWLTERLTERGVKFFQRKVESFEEVAREGADVIVNCTGVWAGALQRDPLLQPGRGQIMKVDAPWMKHFILTHDPERGIYNSPYIIPGTQTVTLGGIFQLGNWSELNNIQDHNTIWEGCCRLEPTLKNARIIGERTGFRPVRPQIRLEREQLRTGPSNTEVIHNYGHGGYGLTIHWGCALEAAKLFGRILEEKKLSRMPPSHL T33124 DRUGINFO D03RXS TAK-831 Phase 2 T33124 DRUGINFO DT45OV TAK-831 Phase 2 T33124 DRUGINFO D0XW4W SEP-227900 Terminated T67079 TARGETID T67079 T67079 FORMERID TTDC00186 T67079 UNIPROID IL9_HUMAN T67079 TARGNAME Interleukin-9 (IL9) T67079 GENENAME IL9 T67079 TARGTYPE Clinical trial T67079 SYNONYMS T-cell growth factor P40; P40 cytokine; IL-9; Cytokine P40 T67079 FUNCTION Supports IL-2 independent and IL-4 independent growth of helper T-cells. T67079 BIOCLASS Cytokine: interleukin T67079 SEQUENCE MLLAMVLTSALLLCSVAGQGCPTLAGILDINFLINKMQEDPASKCHCSANVTSCLCLGIPSDNCTRPCFSERLSQMTNTTMQTRYPLIFSRVKKSVEVLKNNKCPYFSCEQPCNQTTAGNALTFLKSLLEIFQKEKMRGMRGKI T67079 DRUGINFO D0FI5C MEDI-528 Phase 2 T67079 DRUGINFO DE09IO BNZ-1 Phase 2 T70518 TARGETID T70518 T70518 FORMERID TTDI02232 T70518 UNIPROID CBR1_HUMAN T70518 TARGNAME S-nitrosoglutathione reductase (CBR1) T70518 GENENAME CBR1 T70518 TARGTYPE Clinical trial T70518 SYNONYMS ProstaglandinE(2) 9reductase; Prostaglandin 9ketoreductase; NADPHdependent carbonyl reductase 1; Carbonyl reductase [NADPH] 1; CBR1; 15hydroxyprostaglandin dehydrogenase [NADP(+)] T70518 FUNCTION NADPH-dependent reductase with broad substratespecificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione. T70518 PDBSTRUC 4Z3D; 3BHM; 3BHJ; 3BHI; 2PFG T70518 BIOCLASS Short-chain dehydrogenases reductase T70518 ECNUMBER EC 1.1.1.184 T70518 SEQUENCE MSSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFHQLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRDVCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTKKGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKATKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW T70518 DRUGINFO D09LPV N6022 Phase 2 T72835 TARGETID T72835 T72835 FORMERID TTDC00098 T72835 UNIPROID LYAM2_HUMAN T72835 TARGNAME E-selectin (SELE) T72835 GENENAME SELE T72835 TARGTYPE Clinical trial T72835 SYNONYMS Leukocyte-endothelial cell adhesion molecule 2; LECAM2; Endothelial leukocyte adhesion molecule 1; ELAM1; ELAM-1; CD62E antigen; CD62E; CD62 antigen-like family member E T72835 FUNCTION Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with SELPLG/PSGL1. May have a role in capillary morphogenesis. Cell-surface glycoprotein having a role in immunoadhesion. T72835 PDBSTRUC 6EYK; 6EYJ; 6EYI; 4CSY; 4C16 T72835 SEQUENCE MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKCEQIVNCTALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACNVVECDAVTNPANGFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNWDNEKPTCKAVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECTTQGQWTQQIPVCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQGFVLKGSKRLQCGPTGEWDNEKPTCEAVRCDAVHQPPKGLVRCAHSPIGEFTYKSSCAFSCEEGFELHGSTQLECTSQGQWTEEVPSCQVVKCSSLAVPGKINMSCSGEPVFGTVCKFACPEGWTLNGSAARTCGATGHWSGLLPTCEAPTESNIPLVAGLSAAGLSLLTLAPFLLWLRKCLRKAKKFVPASSCQSLESDGSYQKPSYIL T72835 DRUGINFO D03PWD GMI-1271 Phase 3 T72835 DRUGINFO D0N4EO GMI-1070 Phase 3 T72835 DRUGINFO D0B7LK CY-1503 Phase 2/3 T72835 DRUGINFO D02AUB Bimosiamose Phase 2a T72835 DRUGINFO D2SRG1 PF-07209326 Phase 1 T72835 DRUGINFO DBDW09 GMI-1359 Phase 1 T72835 DRUGINFO D0L3XV SMART anti-E/P selectin Discontinued in Phase 1 T72835 DRUGINFO D0RR4T GI-270384X Terminated T72835 DRUGINFO D08RYE Efomycine M Investigative T72835 DRUGINFO D0U7DO 1na Investigative T72835 DRUGINFO D08WQM O-Sialic Acid Investigative T72835 DRUGINFO D0G6XS Fucose Investigative T15377 TARGETID T15377 T15377 FORMERID TTDR00513 T15377 UNIPROID AT2A2_HUMAN T15377 TARGNAME Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2) T15377 GENENAME ATP2A2 T15377 TARGTYPE Clinical trial T15377 SYNONYMS SR Ca(2+)Sarcoplasmic/endoplasmic reticulum calcium ATPase 2-ATPase 2; SR Ca(2+)-ATPase 2; SR Ca(2+)-ATPase; SR Ca(2+) pump; SERCA2; Endoplasmic reticulum class 1/2 Ca(2+) ATPase; Cardiacsarcoplasmic reticulum calcium ATPase; CardiacCa2+ ATPase (SERCA2a); Calciumpump 2; Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform; Calcium pump 2; ATP2B T15377 FUNCTION Isoform 2 is involved in the regulation of the contraction/relaxation cycle. Acts as a regulator of TNFSF11-mediated Ca(2+) signaling pathways via its interaction with TMEM64 which is critical for the TNFSF11-induced CREB1 activation and mitochondrial ROS generation necessary for proper osteoclast generation. Association between TMEM64 and SERCA2 in the ER leads to cytosolic Ca (2+) spiking for activation of NFATC1 and production of mitochondrial ROS, thereby triggering Ca (2+) signaling cascades that promote osteoclast differentiation and activation. This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen. T15377 PDBSTRUC 6JJU; 5ZTF T15377 BIOCLASS Cation transporting ATPase T15377 ECNUMBER EC 7.2.2.10 T15377 SEQUENCE MENAHTKTVEEVLGHFGVNESTGLSLEQVKKLKERWGSNELPAEEGKTLLELVIEQFEDLLVRILLLAACISFVLAWFEEGEETITAFVEPFVILLILVANAIVGVWQERNAENAIEALKEYEPEMGKVYRQDRKSVQRIKAKDIVPGDIVEIAVGDKVPADIRLTSIKSTTLRVDQSILTGESVSVIKHTDPVPDPRAVNQDKKNMLFSGTNIAAGKAMGVVVATGVNTEIGKIRDEMVATEQERTPLQQKLDEFGEQLSKVISLICIAVWIINIGHFNDPVHGGSWIRGAIYYFKIAVALAVAAIPEGLPAVITTCLALGTRRMAKKNAIVRSLPSVETLGCTSVICSDKTGTLTTNQMSVCRMFILDRVEGDTCSLNEFTITGSTYAPIGEVHKDDKPVNCHQYDGLVELATICALCNDSALDYNEAKGVYEKVGEATETALTCLVEKMNVFDTELKGLSKIERANACNSVIKQLMKKEFTLEFSRDRKSMSVYCTPNKPSRTSMSKMFVKGAPEGVIDRCTHIRVGSTKVPMTSGVKQKIMSVIREWGSGSDTLRCLALATHDNPLRREEMHLEDSANFIKYETNLTFVGCVGMLDPPRIEVASSVKLCRQAGIRVIMITGDNKGTAVAICRRIGIFGQDEDVTSKAFTGREFDELNPSAQRDACLNARCFARVEPSHKSKIVEFLQSFDEITAMTGDGVNDAPALKKAEIGIAMGSGTAVAKTASEMVLADDNFSTIVAAVEEGRAIYNNMKQFIRYLISSNVGEVVCIFLTAALGFPEALIPVQLLWVNLVTDGLPATALGFNPPDLDIMNKPPRNPKEPLISGWLFFRYLAIGCYVGAATVGAAAWWFIAADGGPRVSFYQLSHFLQCKEDNPDFEGVDCAIFESPYPMTMALSVLVTIEMCNALNSLSENQSLLRMPPWENIWLVGSICLSMSLHFLILYVEPLPLIFQITPLNVTQWLMVLKISLPVILMDETLKFVARNYLEPGKECVQPATKSCSFSACTDGISWPFVLLIMPLVIWVYSTDTNFSDMFWS T15377 DRUGINFO D01NXF Mydicar Phase 2 T15377 DRUGINFO D00ERV Gallopamil Phase 2 T85025 TARGETID T85025 T85025 FORMERID TTDC00136 T85025 UNIPROID IL7RA_HUMAN T85025 TARGNAME Interleukin 7 receptor alpha (IL7R) T85025 GENENAME IL7R T85025 TARGTYPE Clinical trial T85025 SYNONYMS Interleukin-7 receptor subunit alpha; IL-7RA; IL-7R-alpha; IL-7R subunit alpha; IL-7R alpha chain; IL-7 receptor subunit alpha; CDw127; CD127 antigen; CD127 T85025 FUNCTION Acts as a receptor for thymic stromal lymphopoietin (TSLP). Receptor for interleukin-7. T85025 PDBSTRUC 5J11; 3UP1; 3DI3; 3DI2 T85025 BIOCLASS Cytokine receptor T85025 SEQUENCE MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ T85025 DRUGINFO D08GVP ADX-914 Phase 2 T85025 DRUGINFO D0P1CE CYT 99007 Phase 2 T85025 DRUGINFO D0Q7IX PF-06342674 Phase 1 T55293 TARGETID T55293 T55293 FORMERID TTDR00276 T55293 UNIPROID ITA2_HUMAN T55293 TARGNAME Integrin alpha-2 (ITGA2) T55293 GENENAME ITGA2 T55293 TARGTYPE Clinical trial T55293 SYNONYMS VLA-2 subunit alpha; VLA-2 alphachain; VLA-2; Platelet membrane glycoprotein Ia; Platelet glycoprotein Ia/IIa; Glycoprotein Ia-IIa; GPIa/IIa; GPIa; Collagen receptor; CD49b; CD49 antigen-like family member B; Adhesive platelet receptor alpha1 beta2 T55293 FUNCTION It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. It is responsible for adhesion of platelets and other cells to collagens, modulation of collagen and collagenase gene expression, force generation and organization of newly synthesized extracellular matrix. Integrin alpha-2/beta-1 is a receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-cadherin. T55293 PDBSTRUC 6NDH; 6NDG; 6NDF; 6NDE; 6NDD T55293 BIOCLASS Integrin T55293 SEQUENCE MGPERTGAAPLPLLLVLALSQGILNCCLAYNVGLPEAKIFSGPSSEQFGYAVQQFINPKGNWLLVGSPWSGFPENRMGDVYKCPVDLSTATCEKLNLQTSTSIPNVTEMKTNMSLGLILTRNMGTGGFLTCGPLWAQQCGNQYYTTGVCSDISPDFQLSASFSPATQPCPSLIDVVVVCDESNSIYPWDAVKNFLEKFVQGLDIGPTKTQVGLIQYANNPRVVFNLNTYKTKEEMIVATSQTSQYGGDLTNTFGAIQYARKYAYSAASGGRRSATKVMVVVTDGESHDGSMLKAVIDQCNHDNILRFGIAVLGYLNRNALDTKNLIKEIKAIASIPTERYFFNVSDEAALLEKAGTLGEQIFSIEGTVQGGDNFQMEMSQVGFSADYSSQNDILMLGAVGAFGWSGTIVQKTSHGHLIFPKQAFDQILQDRNHSSYLGYSVAAISTGESTHFVAGAPRANYTGQIVLYSVNENGNITVIQAHRGDQIGSYFGSVLCSVDVDKDTITDVLLVGAPMYMSDLKKEEGRVYLFTIKKGILGQHQFLEGPEGIENTRFGSAIAALSDINMDGFNDVIVGSPLENQNSGAVYIYNGHQGTIRTKYSQKILGSDGAFRSHLQYFGRSLDGYGDLNGDSITDVSIGAFGQVVQLWSQSIADVAIEASFTPEKITLVNKNAQIILKLCFSAKFRPTKQNNQVAIVYNITLDADGFSSRVTSRGLFKENNERCLQKNMVVNQAQSCPEHIIYIQEPSDVVNSLDLRVDISLENPGTSPALEAYSETAKVFSIPFHKDCGEDGLCISDLVLDVRQIPAAQEQPFIVSNQNKRLTFSVTLKNKRESAYNTGIVVDFSENLFFASFSLPVDGTEVTCQVAASQKSVACDVGYPALKREQQVTFTINFDFNLQNLQNQASLSFQALSESQEENKADNLVNLKIPLLYDAEIHLTRSTNINFYEISSDGNVPSIVHSFEDVGPKFIFSLKVTTGSVPVSMATVIIHIPQYTKEKNPLMYLTGVQTDKAGDISCNADINPLKIGQTSSSVSFKSENFRHTKELNCRTASCSNVTCWLKDVHMKGEYFVNVTTRIWNGTFASSTFQTVQLTAAAEINTYNPEIYVIEDNTVTIPLMIMKPDEKAEVPTGVIIGSIIAGILLLLALVAILWKLGFFKRKYEKMTKNPDEIDETTELSS T55293 DRUGINFO D02BQE E7820 Phase 2 T55293 DRUGINFO D08PYJ MAGGIEMYCIN Investigative T55293 DRUGINFO D01ZJF 3-(3-(carbamoyl)benzamido)propanoic acid Investigative T55293 DRUGINFO D0G7QJ 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid Investigative T55293 DRUGINFO D0TP8S 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid Investigative T78915 TARGETID T78915 T78915 FORMERID TTDI01969 T78915 UNIPROID TPH1_HUMAN T78915 TARGNAME Tryptophan 5-hydroxylase 1 (TPH1) T78915 GENENAME TPH1 T78915 TARGTYPE Clinical trial T78915 SYNONYMS Tryptophan 5-monooxygenase 1; TRPH; TPRH T78915 FUNCTION Responsible for addition of the -HO group (hydroxylation) to the 5 position to form the amino acid 5-hydroxytryptophan (5-HTP), which is the initial and rate-limiting step in the synthesis of the neurotransmitter serotonin. T78915 PDBSTRUC 5TPG; 5L01; 5J6D; 3HFB; 3HF8 T78915 BIOCLASS Paired donor oxygen oxidoreductase T78915 ECNUMBER EC 1.14.16.4 T78915 SEQUENCE MIEDNKENKDHSLERGRASLIFSLKNEVGGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIFHLLKSHTNVLSVNLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKDTKSITSAMNELQHDLDVVSDALAKVSRKPSI T78915 DRUGINFO D09OWK AGN-2979 Phase 2 T78915 DRUGINFO D0VS3W KAR5585 Phase 1 T78915 DRUGINFO D0U9QD 6-fluorotryptophan Investigative T78915 DRUGINFO D0F2GG fenclonine Investigative T78915 DRUGINFO D0IT5D alpha-propyldopacetamide Investigative T70101 TARGETID T70101 T70101 FORMERID TTDR00956 T70101 UNIPROID PYRG1_HUMAN T70101 TARGNAME CTP synthase (CTPS1) T70101 GENENAME CTPS1 T70101 TARGTYPE Clinical trial T70101 SYNONYMS Uridine triphosphate aminase; UTP:ammonia ligase (ADP-forming); UTP--ammonia ligase; Cytidine triphosphate synthetase; Cytidine 5'-triphosphate synthetase; CTPS1; CTP synthetase T70101 FUNCTION This enzyme is involved in the de novo synthesis of CTP, a precursor of DNA, RNA and phospholipids. Catalyzes the ATP- dependent amination of UTP to CTP with either L-glutamine or ammonia as a source of nitrogen. This enzyme and its product, CTP, play a crucial role in the proliferation of activated lymphocytes and therefore in immunity. T70101 PDBSTRUC 5U03; 2VO1 T70101 BIOCLASS Carbon-nitrogen ligase T70101 ECNUMBER EC 6.3.4.2 T70101 SEQUENCE MKYILVTGGVISGIGKGIIASSVGTILKSCGLHVTSIKIDPYINIDAGTFSPYEHGEVFVLDDGGEVDLDLGNYERFLDIRLTKDNNLTTGKIYQYVINKERKGDYLGKTVQVVPHITDAIQEWVMRQALIPVDEDGLEPQVCVIELGGTVGDIESMPFIEAFRQFQFKVKRENFCNIHVSLVPQPSSTGEQKTKPTQNSVRELRGLGLSPDLVVCRCSNPLDTSVKEKISMFCHVEPEQVICVHDVSSIYRVPLLLEEQGVVDYFLRRLDLPIERQPRKMLMKWKEMADRYDRLLETCSIALVGKYTKFSDSYASVIKALEHSALAINHKLEIKYIDSADLEPITSQEEPVRYHEAWQKLCSAHGVLVPGGFGVRGTEGKIQAIAWARNQKKPFLGVCLGMQLAVVEFSRNVLGWQDANSTEFDPTTSHPVVVDMPEHNPGQMGGTMRLGKRRTLFQTKNSVMRKLYGDADYLEERHRHRFEVNPVWKKCLEEQGLKFVGQDVEGERMEIVELEDHPFFVGVQYHPEFLSRPIKPSPPYFGLLLASVGRLSHYLQKGCRLSPRDTYSDRSGSSSPDSEITELKFPSINHD T70101 DRUGINFO D0VW0I Cyclopentenylcytosine Phase 1 T70101 DRUGINFO D02JUT Acivicin Discontinued in Phase 3 T70101 DRUGINFO D08XAW Cyclopentylcytosine Investigative T70101 DRUGINFO D0B3MG Carbodine Investigative T70101 DRUGINFO D0GK2Q Cylopentenyl cytosine Investigative T70101 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T70309 TARGETID T70309 T70309 FORMERID TTDR01182 T70309 UNIPROID S5A1_HUMAN T70309 TARGNAME Steroid 5-alpha-reductase 1 (SRD5A1) T70309 GENENAME SRD5A1 T70309 TARGTYPE Clinical trial T70309 SYNONYMS SRD5A1; SR type 1; 5-alpha reductase 1 T70309 FUNCTION Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5- alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology. T70309 BIOCLASS CH-CH donor oxidoreductase T70309 ECNUMBER EC 1.3.1.22 T70309 SEQUENCE MATATGVAEERLLAALAYLQCAVGCAVFARNRQTNSVYGRHALPSHRLRVPARAAWVVQELPSLALPLYQYASESAPRLRSAPNCILLAMFLVHYGHRCLIYPFLMRGGKPMPLLACTMAIMFCTCNGYLQSRYLSHCAVYADDWVTDPRFLIGFGLWLTGMLINIHSDHILRNLRKPGDTGYKIPRGGLFEYVTAANYFGEIMEWCGYALASWSVQGAAFAFFTFCFLSGRAKEHHEWYLRKFEEYPKFRKIIIPFLF T70309 DRUGINFO D01CJY FR-146687 Phase 2 T70309 DRUGINFO D0C1SI MK-386 Discontinued in Phase 2 T70309 DRUGINFO D0P9EL AS-601811 Discontinued in Phase 1 T70309 DRUGINFO D0Z9UB Bexlosteride Terminated T70309 DRUGINFO D00IFJ 1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one Investigative T70309 DRUGINFO D02ZRX 1-Methyl-5-phenyl-piperidin-2-one Investigative T70309 DRUGINFO D07KDB 4-Methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one Investigative T70309 DRUGINFO D08SPJ 3,4,5,6-Tetrahydrobenzo[c]quinolizin-3-(4aH)-one Investigative T70309 DRUGINFO D09KZA 1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one Investigative T70309 DRUGINFO D0H7NB 5-(4-Chloro-phenyl)-1-methyl-piperidine-2-thione Investigative T70309 DRUGINFO D0JH9F 5-(4-Chloro-phenyl)-1-methyl-piperidin-2-one Investigative T70309 DRUGINFO D0M7OP LY-266111 Investigative T70309 DRUGINFO D01AUS 4-[4-benzyloxy)benzoyl]benzoic acid Investigative T70309 DRUGINFO D04AED 4-[4-(benzhydryloxy)benzoyl]benzoic acid Investigative T70309 DRUGINFO D05XPT (3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid Investigative T70309 DRUGINFO D07BHS (3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid Investigative T70309 DRUGINFO D07BQG {4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid Investigative T70309 DRUGINFO D0Q4GH (E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid Investigative T70309 DRUGINFO D0VR9L 4,4'-dihydroxyoctafluoroazobenzene Investigative T70309 DRUGINFO D0W6HB 4-(4-phenoxybenzoyl)benzoic acid Investigative T70309 DRUGINFO D07OAC GP515 Investigative T70309 DRUGINFO D07ZNR 2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol Investigative T13017 TARGETID T13017 T13017 FORMERID TTDI02170 T13017 UNIPROID SDC1_HUMAN T13017 TARGNAME Syndecan-1 (SDC1) T13017 GENENAME SDC1 T13017 TARGTYPE Clinical trial T13017 SYNONYMS SYND1; SDC; CD138 T13017 FUNCTION Regulates exosome biogenesis in concert with SDCBP and PDCD6IP. Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. T13017 PDBSTRUC 6EJE; 4GVD; 4GVC T13017 BIOCLASS Peptide translocating syndecan T13017 SEQUENCE MRRAALWLWLCALALSLQPALPQIVATNLPPEDQDGSGDDSDNFSGSGAGALQDITLSQQTPSTWKDTQLLTAIPTSPEPTGLEATAASTSTLPAGEGPKEGEAVVLPEVEPGLTAREQEATPRPRETTQLPTTHLASTTTATTAQEPATSHPHRDMQPGHHETSTPAGPSQADLHTPHTEDGGPSATERAAEDGASSQLPAAEGSGEQDFTFETSGENTAVVAVEPDRRNQSPVDQGATGASQGLLDRKEVLGGVIAGGLVGLIFAVCLVGFMLYRMKKKDEGSYSLEEPKQANGGAYQKPTKQEEFYA T13017 DRUGINFO D04PUI BT-062 Phase 2 T13017 DRUGINFO D05CTQ CD138 CAR T cells Phase 1/2 T13017 DRUGINFO D0M3RI CART-138 cells Phase 1/2 T13017 DRUGINFO D0Y4MA CART-138 cells Phase 1/2 T13017 DRUGINFO D09ZDY CAR138 T Cells Phase 1 T13017 DRUGINFO D0T6NG CAR-T cells targeting CD138 Clinical trial T59056 TARGETID T59056 T59056 FORMERID TTDNC00572 T59056 UNIPROID C11B2_HUMAN T59056 TARGNAME Aldosterone synthase (CYP11B2) T59056 GENENAME CYP11B2 T59056 TARGTYPE Clinical trial T59056 SYNONYMS Steroid 18hydroxylase; Cytochrome P450C18; Cytochrome P450Aldo; Cytochrome P450 11B2, mitochondrial; CYPXIB2; CYP11B2; Aldosteronesynthesizing enzyme; ALDOS T59056 FUNCTION Preferentially catalyzes the conversion of 11- deoxycorticosterone to aldosterone via corticosterone and 18- hydroxycorticosterone. T59056 PDBSTRUC 4ZGX; 4FDH; 4DVQ T59056 BIOCLASS Paired donor oxygen oxidoreductase T59056 ECNUMBER EC 1.14.15.4 T59056 SEQUENCE MALRAKAEVCVAAPWLSLQRARALGTRAARAPRTVLPFEAMPQHPGNRWLRLLQIWREQGYEHLHLEMHQTFQELGPIFRYNLGGPRMVCVMLPEDVEKLQQVDSLHPCRMILEPWVAYRQHRGHKCGVFLLNGPEWRFNRLRLNPDVLSPKAVQRFLPMVDAVARDFSQALKKKVLQNARGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFMPRSLSRWISPKVWKEHFEAWDCIFQYGDNCIQKIYQELAFNRPQHYTGIVAELLLKAELSLEAIKANSMELTAGSVDTTAFPLLMTLFELARNPDVQQILRQESLAAAASISEHPQKATTELPLLRAALKETLRLYPVGLFLERVVSSDLVLQNYHIPAGTLVQVFLYSLGRNAALFPRPERYNPQRWLDIRGSGRNFHHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHFLVETLTQEDIKMVYSFILRPGTSPLLTFRAIN T59056 DRUGINFO D8FHG5 Baxdrostat Phase 2 T59056 DRUGINFO DKO16W MLS-101 Phase 2 T86552 TARGETID T86552 T86552 FORMERID TTDNC00502 T86552 UNIPROID TNR1A_HUMAN T86552 TARGNAME Tumor necrosis factor receptor type I (TNF-R1) T86552 GENENAME TNFRSF1A T86552 TARGTYPE Clinical trial T86552 SYNONYMS p60; p55; Tumor necrosis factor-binding protein 1; Tumor necrosis factor receptor superfamily member 1A; Tumor necrosis factor receptor 1; TNFR1; TNFR-I; TNFAR; TNF-RI; TBPI; CD120a T86552 FUNCTION The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase. Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. T86552 PDBSTRUC 1TNR; 1NCF; 1ICH; 1FT4; 1EXT T86552 BIOCLASS Cytokine receptor T86552 SEQUENCE MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDCPGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCFNCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPLVIFFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPVPSSTFTSSSTYTPGDCPNFAAPRREVAPPYQGADPILATALASDPIPNPLQKWEDSAHKPQSLDTDDPATLYAVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLGCLEDIEEALCGPAALPPAPSLLR T86552 DRUGINFO D0S4LV VB-111 Phase 3 T86552 DRUGINFO D07LMO Drug 2862277 Phase 2 T86552 DRUGINFO D08ENB GSK1995057 Phase 1 T86552 DRUGINFO D03HIG AVX-470 Phase 1 T86552 DRUGINFO D0R4OD Anti-IFN gamma Terminated T86552 DRUGINFO D03IMU TNFR1 NAM Investigative T86552 DRUGINFO D08TQK NM-9405 Investigative T86552 DRUGINFO D0B6WV TNFmab Investigative T86552 DRUGINFO D0G9XS ADS-0101 Investigative T86552 DRUGINFO D0P4WI Recombinant human TNF receptor Investigative T86552 DRUGINFO D0U4QQ TNFcept Investigative T86552 DRUGINFO D0W0BN NM-2014 Investigative T86552 DRUGINFO D0W7FG ALF-421 Investigative T86552 DRUGINFO D0X8SM Anti-TNF human mabs Investigative T29960 TARGETID T29960 T29960 FORMERID TTDR00688 T29960 UNIPROID WT1_HUMAN T29960 TARGNAME Wilms tumor protein (WT1) T29960 GENENAME WT1 T29960 TARGTYPE Clinical trial T29960 SYNONYMS Wilms' tumour 1 protein; WT33; WT1 protein T29960 FUNCTION Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'. Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors. Isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing. Isoform 1 has lower affinity for DNA, and can bind RNA. Transcription factor that plays an important role in cellular development and cell survival. T29960 PDBSTRUC 6BLW; 6B0R; 6B0Q; 6B0P; 6B0O T29960 BIOCLASS EGR C2H2-type zinc-finger T29960 SEQUENCE MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAPPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAGACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPSYGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTGSQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTEGQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCRWPSCQKKFARSDELVRHHNMHQRNMTKLQLAL T29960 DRUGINFO D00QXB WT1 peptide vaccine Phase 2 T29960 DRUGINFO D02MLO WT1-targeted autologous dendritic cell vaccine Phase 2 T29960 DRUGINFO D0RG8Z FPI-01 Phase 2 T29960 DRUGINFO D0O8AY Combined PR1/WT1 vaccine Phase 2 T29960 DRUGINFO D01MYJ WT-4869 Phase 1/2 T29960 DRUGINFO D02JEW GSK-2130579A Phase 1 T29960 DRUGINFO D0P2ZY INNO-305 Phase 1 T39677 TARGETID T39677 T39677 FORMERID TTDR00692 T39677 UNIPROID CEL_HUMAN T39677 TARGNAME Bile-salt-activated lipase (CEL) T39677 GENENAME CEL T39677 TARGTYPE Clinical trial T39677 SYNONYMS Pancreatic lysophospholipase; Pancreatic cholesterol esterase; Cholesterol esterase; Carboxyl ester lipase; CEL; Bile-salt-stimulated lipase; BSSL; BAL T39677 FUNCTION Catalyzes fat and vitamin absorption. Acts in concert with pancreatic lipase and colipase for the complete digestion of dietary triglycerides. T39677 PDBSTRUC 6H1A; 6H19; 6H18; 6H0V; 6H0T T39677 BIOCLASS Carboxylic ester hydrolase T39677 ECNUMBER EC 3.1.1.13 T39677 SEQUENCE MGRLQLVVLGLTCCWAVASAAKLGAVYTEGGFVEGVNKKLGLLGDSVDIFKGIPFAAPTKALENPQPHPGWQGTLKAKNFKKRCLQATITQDSTYGDEDCLYLNIWVPQGRKQVSRDLPVMIWIYGGAFLMGSGHGANFLNNYLYDGEEIATRGNVIVVTFNYRVGPLGFLSTGDANLPGNYGLRDQHMAIAWVKRNIAAFGGDPNNITLFGESAGGASVSLQTLSPYNKGLIRRAISQSGVALSPWVIQKNPLFWAKKVAEKVGCPVGDAARMAQCLKVTDPRALTLAYKVPLAGLEYPMLHYVGFVPVIDGDFIPADPINLYANAADIDYIAGTNNMDGHIFASIDMPAINKGNKKVTEEDFYKLVSEFTITKGLRGAKTTFDVYTESWAQDPSQENKKKTVVDFETDVLFLVPTEIALAQHRANAKSAKTYAYLFSHPSRMPVYPKWVGADHADDIQYVFGKPFATPTGYRPQDRTVSKAMIAYWTNFAKTGDPNMGDSAVPTHWEPYTTENSGYLEITKKMGSSSMKRSLRTNFLRYWTLTYLALPTVTDQEATPVPPTGDSEATPVPPTGDSETAPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDAGPPPVPPTGDSGAPPVPPTGDSGAPPVTPTGDSETAPVPPTGDSGAPPVPPTGDSEAAPVPPTDDSKEAQMPAVIRF T39677 DRUGINFO D04MZR Bucelipase alfa Phase 3 T39677 DRUGINFO D09NTG Taurocholic Acid Phase 1/2 T39677 DRUGINFO D0GH1C CVT-1 Terminated T39677 DRUGINFO D0D2RR TgBSSL Investigative T39677 DRUGINFO D06GTS PMID24556381C10l Investigative T39677 DRUGINFO D0T9WZ PMID24556381C10f Investigative T56308 TARGETID T56308 T56308 FORMERID TTDR00519 T56308 UNIPROID IL11_HUMAN T56308 TARGNAME Interleukin-11 (IL11) T56308 GENENAME IL11 T56308 TARGTYPE Clinical trial T56308 SYNONYMS Oprelvekin; IL-11; Adipogenesis inhibitory factor; AGIF T56308 FUNCTION Promotes the proliferation of hepatocytes in response to liver damage. Binding to its receptor formed by IL6ST and either IL11RA1 or IL11RA2 activates a signaling cascade that promotes cell proliferation. Signaling leads to the activation of intracellular protein kinases and the phosphorylation of STAT3. Cytokine that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. T56308 PDBSTRUC 4MHL T56308 BIOCLASS Cytokine: interleukin T56308 SEQUENCE MNCVCRLVLVVLSLWPDTAVAPGPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQLLMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL T56308 DRUGINFO D05XKW VM-501 Phase 3 T52790 TARGETID T52790 T52790 FORMERID TTDC00090 T52790 UNIPROID NK2R_HUMAN T52790 TARGNAME Substance-K receptor (TACR2) T52790 GENENAME TACR2 T52790 TARGTYPE Clinical trial T52790 SYNONYMS Tachykinin receptor 2; Tachykinin neurokinin 2 receptor; TACR2; SKR; Neurokinin A receptor; NK-2R; NK-2 receptor T52790 FUNCTION This is a receptor for the tachykinin neuropeptide substance K (neurokinin A). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance K > neuromedin-K > substance P. T52790 BIOCLASS GPCR rhodopsin T52790 SEQUENCE MGTCDIVTEANISSGPESNTTGITAFSMPSWQLALWATAYLALVLVAVTGNAIVIWIILAHRRMRTVTNYFIVNLALADLCMAAFNAAFNFVYASHNIWYFGRAFCYFQNLFPITAMFVSIYSMTAIAADRYMAIVHPFQPRLSAPSTKAVIAGIWLVALALASPQCFYSTVTMDQGATKCVVAWPEDSGGKTLLLYHLVVIALIYFLPLAVMFVAYSVIGLTLWRRAVPGHQAHGANLRHLQAMKKFVKTMVLVVLTFAICWLPYHLYFILGSFQEDIYCHKFIQQVYLALFWLAMSSTMYNPIIYCCLNHRFRSGFRLAFRCCPWVTPTKEDKLELTPTTSLSTRVNRCHTKETLFMAGDTAPSEATSGEAGRPQDGSGLWFGYGLLAPTKTHVEI T52790 DRUGINFO D0XS4X Ibodutant Phase 3 T52790 DRUGINFO D0AA6Z Rambazole Phase 2 T52790 DRUGINFO D0G2XE PMX-53 Phase 2 T52790 DRUGINFO D0S6JV Nepadutant Phase 1/2 T52790 DRUGINFO D05WJQ Saredutant Discontinued in Phase 3 T52790 DRUGINFO D02FIJ FK-224 Discontinued in Phase 2 T52790 DRUGINFO D0C9FF DNK-333 Discontinued in Phase 2 T52790 DRUGINFO D03ZKE CS-003 Discontinued in Phase 2 T52790 DRUGINFO D0Y4GJ AVE-5883 Discontinued in Phase 1/2 T52790 DRUGINFO D08WVA UK-224671 Discontinued in Phase 1 T52790 DRUGINFO D0E9EE SR 144190 Discontinued in Phase 1 T52790 DRUGINFO D02NMG SLV-332 Preclinical T52790 DRUGINFO D02YWV GR-159897 Terminated T52790 DRUGINFO D04RCG MEN-10627 Terminated T52790 DRUGINFO D09KLO AZD-5106 Terminated T52790 DRUGINFO D0IW0Y MEN-10207 Terminated T52790 DRUGINFO D0J3QU ZD-7944 Terminated T52790 DRUGINFO D0S1RT UK-290795 Terminated T52790 DRUGINFO D08ZBV L-732138 Terminated T52790 DRUGINFO D05DYX ZM 253270 Investigative T52790 DRUGINFO D07CVE R396 Investigative T52790 DRUGINFO D08SGF GR100679 Investigative T52790 DRUGINFO D0KX3C ZM-274773 Investigative T52790 DRUGINFO D0N1PH YM49598 Investigative T52790 DRUGINFO D0RR7X GR94800 Investigative T52790 DRUGINFO D0U4WP YM44781 Investigative T52790 DRUGINFO D0ZJ6Y YM44778 Investigative T52790 DRUGINFO D0Z6TG ZD-6021 Investigative T52790 DRUGINFO D00HAJ Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2 Investigative T52790 DRUGINFO D01NPA neurokinin A Investigative T52790 DRUGINFO D07JAN SCH 206272 Investigative T52790 DRUGINFO D0C7LY WAY-207024 Investigative T52790 DRUGINFO D0F9QT A-987306 Investigative T52790 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T76914 TARGETID T76914 T76914 FORMERID TTDR00903 T76914 UNIPROID KCNA3_HUMAN T76914 TARGNAME Voltage-gated potassium channel Kv1.3 (KCNA3) T76914 GENENAME KCNA3 T76914 TARGTYPE Clinical trial T76914 SYNONYMS Voltage-gated potassium channel subunit Kv1.3; Voltage-gated Kv1.3 K(+) channel; Voltage-gated K(+) channel Kv1.3; Potassium channel Kv1.3; KCNA3; HuKIII; HPCN3; HLK3; HGK5 T76914 FUNCTION Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient. T76914 PDBSTRUC 4BGC T76914 BIOCLASS Voltage-gated ion channel T76914 SEQUENCE MDERLSLLRSPPPPSARHRAHPPQRPASSGGAHTLVNHGYAEPAAGRELPPDMTVVPGDHLLEPEVADGGGAPPQGGCGGGGCDRYEPLPPSLPAAGEQDCCGERVVINISGLRFETQLKTLCQFPETLLGDPKRRMRYFDPLRNEYFFDRNRPSFDAILYYYQSGGRIRRPVNVPIDIFSEEIRFYQLGEEAMEKFREDEGFLREEERPLPRRDFQRQVWLLFEYPESSGPARGIAIVSVLVILISIVIFCLETLPEFRDEKDYPASTSQDSFEAAGNSTSGSRAGASSFSDPFFVVETLCIIWFSFELLVRFFACPSKATFSRNIMNLIDIVAIIPYFITLGTELAERQGNGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEADDPTSGFSSIPDAFWWAVVTMTTVGYGDMHPVTIGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEGEEQSQYMHVGSCQHLSSSAEELRKARSNSTLSKSEYMVIEEGGMNHSAFPQTPFKTGNSTATCTTNNNPNSCVNIKKIFTDV T76914 DRUGINFO D01XEO Debio-0824 Phase 1b/2a T76914 DRUGINFO D0OK4O Dalazatide Phase 1b/2a T76914 DRUGINFO D0G1VS UK-78282 Terminated T76914 DRUGINFO D04UVC 2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide Investigative T76914 DRUGINFO D05CDC correolide Investigative T76914 DRUGINFO D0CI6E Correloid Investigative T76914 DRUGINFO D0E9MC CP-339818 Investigative T76914 DRUGINFO D0H1EI 5-(4-Phenylbutoxy)psoralen Investigative T76914 DRUGINFO D0L0FC [1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine Investigative T76914 DRUGINFO D0S8CL 1-Benzyl-7-chloro-4-hexyloxy-quinolinium Investigative T76914 DRUGINFO D0R9CF 4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one Investigative T76914 DRUGINFO D06PZZ [14C]TEA Investigative T89918 TARGETID T89918 T89918 FORMERID TTDR01240 T89918 UNIPROID PUR2_HUMAN T89918 TARGNAME Glycinamide ribonucleotide formyltransferase (GART) T89918 GENENAME GART T89918 TARGTYPE Clinical trial T89918 SYNONYMS Trifunctional purine biosynthetic protein adenosine-3; PRGS; PGFT T89918 FUNCTION A trifunctional polypeptide. Has Phosphoribosylamineglycine ligase, Phosphoribosylglycinamide formyltransferase, AIR synthetase (FGAM cyclase) activity which is required for de novo purine biosynthesis. T89918 PDBSTRUC 5J9F; 4ZZ3; 4ZZ2; 4ZZ1; 4ZZ0 T89918 BIOCLASS Carbon-nitrogen ligase T89918 SEQUENCE MAARVLIIGSGGREHTLAWKLAQSHHVKQVLVAPGNAGTACSEKISNTAISISDHTALAQFCKEKKIEFVVVGPEAPLAAGIVGNLRSAGVQCFGPTAEAAQLESSKRFAKEFMDRHGIPTAQWKAFTKPEEACSFILSADFPALVVKASGLAAGKGVIVAKSKEEACKAVQEIMQEKAFGAAGETIVIEELLDGEEVSCLCFTDGKTVAPMPPAQDHKRLLEGDGGPNTGGMGAYCPAPQVSNDLLLKIKDTVLQRTVDGMQQEGTPYTGILYAGIMLTKNGPKVLEFNCRFGDPECQVILPLLKSDLYEVIQSTLDGLLCTSLPVWLENHTALTVVMASKGYPGDYTKGVEITGFPEAQALGLEVFHAGTALKNGKVVTHGGRVLAVTAIRENLISALEEAKKGLAAIKFEGAIYRKDVGFRAIAFLQQPRSLTYKESGVDIAAGNMLVKKIQPLAKATSRSGCKVDLGGFAGLFDLKAAGFKDPLLASGTDGVGTKLKIAQLCNKHDTIGQDLVAMCVNDILAQGAEPLFFLDYFSCGKLDLSVTEAVVAGIAKACGKAGCALLGGETAEMPDMYPPGEYDLAGFAVGAMERDQKLPHLERITEGDVVVGIASSGLHSNGFSLVRKIVAKSSLQYSSPAPDGCGDQTLGDLLLTPTRIYSHSLLPVLRSGHVKAFAHITGGGLLENIPRVLPEKLGVDLDAQTWRIPRVFSWLQQEGHLSEEEMARTFNCGVGAVLVVSKEQTEQILRDIQQHKEEAWVIGSVVARAEGSPRVKVKNLIESMQINGSVLKNGSLTNHFSFEKKKARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEE T89918 DRUGINFO D0J9IH PELITREXOL Phase 2 T89918 DRUGINFO D0IZ1A LY309887 Phase 1 T89918 DRUGINFO D00UUG 10-Formyl-5,8,10-Trideazafolic Acid Investigative T89918 DRUGINFO D07DGI Glycinamide Ribonucleotide Investigative T89918 DRUGINFO D0E0CV (10r)-10-Formyl-5,8,10-Trideazafolic Acid Investigative T89918 DRUGINFO D0F2WA 10-trifluoroacetyl-DDACTHF Investigative T89918 DRUGINFO D0R7LQ Dideazaacyclotetrahydrofolic acid Investigative T89918 DRUGINFO D0XU7N 10-CF3C(OH)2-DDACTHF Investigative T89918 DRUGINFO D0Z9QC Dideazafolate Investigative T09092 TARGETID T09092 T09092 FORMERID TTDR00138 T09092 UNIPROID IL10_HUMAN T09092 TARGNAME Interleukin-10 (IL10) T09092 GENENAME IL10 T09092 TARGTYPE Clinical trial T09092 SYNONYMS IL-10; Cytokine synthesis inhibitory factor; CSIF T09092 FUNCTION Mechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3. In turn, STAT3 translocates to the nucleus where it drives expression of anti-inflammatory mediators. Targets antigen-presenting cells (APCs) such as macrophages and monocytes and inhibits their release of pro-inflammatory cytokines including granulocyte-macrophage colony-stimulating factor /GM-CSF, granulocyte colony-stimulating factor/G-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8 and TNF-alpha. Interferes also with antigen presentation by reducing the expression of MHC-class II and co-stimulatory molecules, thereby inhibiting their ability to induce T cell activation. In addition, controls the inflammatory response of macrophages by reprogramming essential metabolic pathways including mTOR signaling. Major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. T09092 PDBSTRUC 2ILK; 2H24; 1Y6K; 1LK3; 1J7V T09092 BIOCLASS Cytokine: interleukin T09092 SEQUENCE MHSSALLCCLVLLTGVRASPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN T09092 DRUGINFO D03MYX AM0010 Phase 3 T09092 DRUGINFO D0O5ZB Ilodecakin Phase 2 T09092 DRUGINFO D0T4KG F-8-IL-10 fusion protein Phase 2 T09092 DRUGINFO DPC0T8 XT-150 Phase 2 T09092 DRUGINFO DL6EZ5 AG019 Phase 1/2 T09092 DRUGINFO D05TZJ Ankinara Investigative T90989 TARGETID T90989 T90989 FORMERID TTDNC00621 T90989 UNIPROID FGFR4_HUMAN T90989 TARGNAME Fibroblast growth factor receptor 4 (FGFR4) T90989 GENENAME FGFR4 T90989 TARGTYPE Clinical trial T90989 SYNONYMS TKF; JTK2; FGFR-4; CD334 T90989 FUNCTION Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. T90989 PDBSTRUC 6JPJ; 5XFJ; 5XFF; 5NWZ; 5NUD T90989 BIOCLASS Kinase T90989 ECNUMBER EC 2.7.10.1 T90989 SEQUENCE MRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRAERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDSLTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTPTIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLDVLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFPYVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLARQFSLESGSSGKSSSSLVRGVRLSSSGPALLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQVVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVCTQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGMQYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEALFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYGLMRECWHAAPSQRPTFKQLVEALDKVLLAVSEEYLDLRLTFGPYSPSGGDASSTCSSSDSVFSHDPLPLGSSSFPFGSGVQT T90989 DRUGINFO D0BE8H INCB62079 Phase 1/2 T90989 DRUGINFO D08HZN ABC-4 Investigative T90989 DRUGINFO D0R6OM ACTB-1003 Investigative T55860 TARGETID T55860 T55860 FORMERID TTDI02194 T55860 UNIPROID TNFL4_HUMAN T55860 TARGNAME TAX transcriptionally-activated glycoprotein 1 (OX40) T55860 GENENAME TNFSF4 T55860 TARGTYPE Clinical trial T55860 SYNONYMS Tumor necrosis factor ligand superfamily member 4; TNFSF4; OX40L; Glycoprotein Gp34; CD252 T55860 FUNCTION Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production. T55860 PDBSTRUC 2HEV T55860 BIOCLASS Cytokine: tumor necrosis factor T55860 SEQUENCE MERVQPLEENVGNAARPRFERNKLLLVASVIQGLGLLLCFTYICLHFSALQVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPLFQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLDDFHVNGGELILIHQNPGEFCVL T55860 DRUGINFO D0K8NR AMG 386 Phase 3 T55860 DRUGINFO D03UZP RG7888 Phase 2 T55860 DRUGINFO DN2OL8 Amlitelimab Phase 2 T55860 DRUGINFO D02UBC MEDI6383 Phase 1 T55860 DRUGINFO D70SHJ mRNA-2416 Phase 1 T55860 DRUGINFO D31CPE SAR442970 Phase 1 T55860 DRUGINFO DC5A9Q mRNA-2752 Phase 1 T12355 TARGETID T12355 T12355 FORMERID TTDR00397 T12355 UNIPROID CCND1_HUMAN T12355 TARGNAME G1/S-specific cyclin-D1 (CCND1) T12355 GENENAME CCND1 T12355 TARGTYPE Clinical trial T12355 SYNONYMS PRAD1 oncogene; PRAD1; Cyclin D1; BCL1; BCL-1 oncogene; BCL-1; B-cell lymphoma 1 protein T12355 FUNCTION Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner. Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. T12355 PDBSTRUC 5VZU; 2W9Z; 2W9F; 2W99; 2W96 T12355 SEQUENCE MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCVQKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSMVAAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQAQQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI T12355 DRUGINFO D06ETI ABT-263 Phase 3 T12355 DRUGINFO D0T0KT Briciclib Phase 1 T12355 DRUGINFO D02JEZ 7-hydroxycoumarin Investigative T12355 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T12355 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T12355 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T12355 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T12355 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T86399 TARGETID T86399 T86399 FORMERID TTDI02030 T86399 UNIPROID BRD2_HUMAN T86399 TARGNAME Bromodomain-containing protein 2 (BRD2) T86399 GENENAME BRD2 T86399 TARGTYPE Clinical trial T86399 SYNONYMS Really interesting new gene 3 protein; RING3; O27.1.1; KIAA9001 T86399 FUNCTION Binds hyperacetylated chromatin and plays a role in the regulation of transcription, probably by chromatin remodeling. Regulates transcription of the CCND1 gene. Plays a role in nucleosome assembly. May play a role in spermatogenesis or folliculogenesis. T86399 PDBSTRUC 6MOA; 6MO9; 6MO8; 6MO7; 6FFG T86399 BIOCLASS Bromodomain T86399 SEQUENCE MLQNVTPHNKLPGEGNAGLLGLGPEAAAPGKRIRKPSLLYEGFESPTMASVPALQLTPANPPPPEVSNPKKPGRVTNQLQYLHKVVMKALWKHQFAWPFRQPVDAVKLGLPDYHKIIKQPMDMGTIKRRLENNYYWAASECMQDFNTMFTNCYIYNKPTDDIVLMAQTLEKIFLQKVASMPQEEQELVVTIPKNSHKKGAKLAALQGSVTSAHQVPAVSSVSHTALYTPPPEIPTTVLNIPHPSVISSPLLKSLHSAGPPLLAVTAAPPAQPLAKKKGVKRKADTTTPTPTAILAPGSPASPPGSLEPKAARLPPMRRESGRPIKPPRKDLPDSQQQHQSSKKGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPDEPLEPGPLPVSTAMPPGLAKSSSESSSEESSSESSSEEEEEEDEEDEEEEESESSDSEEERAHRLAELQEQLRAVHEQLAALSQGPISKPKRKREKKEKKKKRKAEKHRGRAGADEDDKGPRAPRPPQPKKSKKASGSGGGSAALGPSGFGPSGGSGTKLPKKATKTAPPALPTGYDSEEEEESRPMSYDEKRQLSLDINKLPGEKLGRVVHIIQAREPSLRDSNPEEIEIDFETLKPSTLRELERYVLSCLRKKPRKPYTIKKPVGKTKEELALEKKRELEKRLQDVSGQLNSTKKPPKKANEKTESSSAQQVAVSRLSASSSSSDSSSSSSSSSSSDTSDSDSG T86399 DRUGINFO D02YNI OTX-015 Phase 1/2 T86399 DRUGINFO D05ICT ABBV-744 Phase 1 T86399 DRUGINFO D0AE6Y PMID26924192-Compound-106 Patented T86399 DRUGINFO D0YM3G Pyrrolo-pyrrolone derivative 1 Patented T86399 DRUGINFO D03NWT PMID26924192-Compound-104 Patented T86399 DRUGINFO D03RPJ PMID26924192-Compound-102 Patented T86399 DRUGINFO D05XXS PMID26924192-Compound-103 Patented T86399 DRUGINFO D0NN4U PMID26924192-Compound-105 Patented T86399 DRUGINFO D08SEK ET bromodomain inhibitor Investigative T86399 DRUGINFO D09QOB ME bromodomain inhibitor Investigative T86399 DRUGINFO D0T3AT BIC1 Investigative T86399 DRUGINFO D0H3TC PMID21851057C4d Investigative T86399 DRUGINFO D03LIP GW841819X Investigative T86399 DRUGINFO D0C2XT PMID24000170C36 Investigative T86399 DRUGINFO D0Q2GK PMID24000170C38 Investigative T86399 DRUGINFO D0WU1S I-BET151 Investigative T86399 DRUGINFO D07FGY XD14 Investigative T14592 TARGETID T14592 T14592 FORMERID TTDI02199 T14592 UNIPROID TNR6_HUMAN T14592 TARGNAME Apoptosis mediating surface antigen FAS (FAS) T14592 GENENAME FAS T14592 TARGTYPE Clinical trial T14592 SYNONYMS Tumor necrosis factor receptor superfamily member 6; TNFRSF6; FASLG receptor; FAS1; CD95; Apoptosis-mediating surface antigen FAS; Apo-1 antigen; APT1 T14592 FUNCTION The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). Receptor for TNFSF6/FASLG. T14592 PDBSTRUC 3TJE; 3THM; 3EZQ; 3EWT; 2NA7 T14592 BIOCLASS Cytokine receptor T14592 SEQUENCE MLGIWTLLPLVLTSVARLSSKSVNAQVTDINSKGLELRKTVTTVETQNLEGLHHDGQFCHKPCPPGERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRRCRLCDEGHGLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKCEHGIIKECTLTSNTKCKEEGSRSNLGWLCLLLLPIPLIVWVKRKEVQKTCRKHRKENQGSHESPTLNPETVAINLSDVDLSKYITTIAGVMTLSQVKGFVRKNGVNEAKIDEIKNDNVQDTAEQKVQLLRNWHQLHGKKEAYDTLIKDLKKANLCTLAEKIQTIILKDITSDSENSNFRNEIQSLV T14592 DRUGINFO D0S4LV VB-111 Phase 3 T14592 DRUGINFO D07PRH DE-098 Phase 2 T14592 DRUGINFO D0N4JI APG-101 Phase 2 T14592 DRUGINFO D0Q6SF APO-010 Phase 1 T14592 DRUGINFO D0N1DG F61F12 Investigative T14592 DRUGINFO D0QA7X APG-103 Investigative T14592 DRUGINFO DAQ31P 2-aminophenoxazine-3-one Investigative T89213 TARGETID T89213 T89213 FORMERID TTDC00193 T89213 UNIPROID NPY1R_HUMAN T89213 TARGNAME Neuropeptide Y receptor type 1 (NPY1R) T89213 GENENAME NPY1R T89213 TARGTYPE Clinical trial T89213 SYNONYMS Neuropeptide Y-Y1 receptor; Neuropeptide Y receptor Y1; Neuropeptide Y Y(1) receptor; NPY1R; NPY1-R T89213 FUNCTION Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is NPY > [Pro-34] PYY, PYY and [Leu-31, Pro-34] NPY > NPY (2-36) > [Ile-31, Gln-34] PP and PYY (3-36) > PP > NPY free acid. T89213 PDBSTRUC 5ZBQ; 2IIL; 2F1U T89213 BIOCLASS GPCR rhodopsin T89213 SEQUENCE MNSTLFSQVENHSVHSNFSEKNAQLLAFENDDCHLPLAMIFTLALAYGAVIILGVSGNLALIIIILKQKEMRNVTNILIVNLSFSDLLVAIMCLPFTFVYTLMDHWVFGEAMCKLNPFVQCVSITVSIFSLVLIAVERHQLIINPRGWRPNNRHAYVGIAVIWVLAVASSLPFLIYQVMTDEPFQNVTLDAYKDKYVCFDQFPSDSHRLSYTTLLLVLQYFGPLCFIFICYFKIYIRLKRRNNMMDKMRDNKYRSSETKRINIMLLSIVVAFAVCWLPLTIFNTVFDWNHQIIATCNHNLLFLLCHLTAMISTCVNPIFYGFLNKNFQRDLQFFFNFCDFRSRDDDYETIAMSTMHTDVSKTSLKQASPVAFKKINNNDDNEKI T89213 DRUGINFO D0I1KQ NEUROPEPTIDE-Y Phase 2 T89213 DRUGINFO D03GAY H-409/22 Discontinued in Phase 2 T89213 DRUGINFO D0Q3UL PD-160170 Preclinical T89213 DRUGINFO D0R2CI GI-264879A Preclinical T89213 DRUGINFO D04QXG SR 120819A Terminated T89213 DRUGINFO D0V2GT BIBP 3226 Terminated T89213 DRUGINFO D01MBR BMS-245782 Investigative T89213 DRUGINFO D06HXC NPY-1 antagonist Investigative T89213 DRUGINFO D08VVZ J-104870 Investigative T89213 DRUGINFO D0F1IS BMS-189323 Investigative T89213 DRUGINFO D0SD8Q BMS-193885 Investigative T89213 DRUGINFO D0U5TK BIBO3304 Investigative T89213 DRUGINFO D02MKP AcPYY(22-36) Investigative T89213 DRUGINFO D07BCH [Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T89213 DRUGINFO D07DJT LRHYLNLLTRQRY-NH2 Investigative T89213 DRUGINFO D08ROQ S-25585 Investigative T89213 DRUGINFO D0H8KI [125I]GR231118 Investigative T89213 DRUGINFO D0NY7A S-19528 Investigative T89213 DRUGINFO D0P9KP PYY(22-36) Investigative T89213 DRUGINFO D00OLA H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 Investigative T89213 DRUGINFO D07OOG Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T89213 DRUGINFO D08YWE Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T89213 DRUGINFO D0G4HT Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 Investigative T89213 DRUGINFO D0J9VA H-[Trp-Arg-Nva-Arg-Tyr]2-NH2 Investigative T89213 DRUGINFO D0V0HM Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T89213 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T83192 TARGETID T83192 T83192 FORMERID TTDR00032 T83192 UNIPROID CNTF_HUMAN T83192 TARGNAME Ciliary neurotrophic factor (CNTF) T83192 GENENAME CNTF T83192 TARGTYPE Clinical trial T83192 SYNONYMS CNTF T83192 FUNCTION CNTF is a survival factor for various neuronal cell types. Seems to prevent the degeneration of motor axons after axotomy. T83192 PDBSTRUC 1CNT T83192 BIOCLASS Ciliary neurotrophic factor T83192 SEQUENCE MAFTEHSPLTPHRRDLCSRSIWLARKIRSDLTALTESYVKHQGLNKNINLDSADGMPVASTDQWSELTEAERLQENLQAYRTFHVLLARLLEDQQVHFTPTEGDFHQAIHTLLLQVAAFAYQIEELMILLEYKIPRNEADGMPINVGDGGLFEKKLWGLKVLQELSQWTVRSIHDLRFISSHQTGIPARGSHYIANNKKM T83192 DRUGINFO D07GWZ NT-501 CNTF Phase 1/2 T61033 TARGETID T61033 T61033 FORMERID TTDC00257 T61033 UNIPROID CNTFR_HUMAN T61033 TARGNAME Ciliary neurotrophic factor receptor alpha (CNTFR) T61033 GENENAME CNTFR T61033 TARGTYPE Clinical trial T61033 SYNONYMS Ciliary neurotrophic factor receptor subunit alpha; CNTFR-alpha; CNTFR alpha; CNTF receptor subunit alpha T61033 FUNCTION The alpha subunit provides the receptor specificity. Binds to CNTF. T61033 PDBSTRUC 1UC6 T61033 BIOCLASS Cytokine receptor T61033 SEQUENCE MAAPVPWACCAVLAAAAAVVYAQRHSPQEAPHVQYERLGSDVTLPCGTANWDAAVTWRVNGTDLAPDLLNGSQLVLHGLELGHSGLYACFHRDSWHLRHQVLLHVGLPPREPVLSCRSNTYPKGFYCSWHLPTPTYIPNTFNVTVLHGSKIMVCEKDPALKNRCHIRYMHLFSTIKYKVSISVSNALGHNATAITFDEFTIVKPDPPENVVARPVPSNPRRLEVTWQTPSTWPDPESFPLKFFLRYRPLILDQWQHVELSDGTAHTITDAYAGKEYIIQVAAKDNEIGTWSDWSVAAHATPWTEEPRHLTTEAQAAETTTSTTSSLAPPPTTKICDPGELGSGGGPSAPFLVSVPITLALAAAAATASSLLI T61033 DRUGINFO D0A7WO NT-501 Phase 2/3 T61033 DRUGINFO D0C2HI PegCNTF Phase 1 T23276 TARGETID T23276 T23276 FORMERID TTDR00373 T23276 UNIPROID MK03_HUMAN T23276 TARGNAME Extracellular signal-regulated kinase 1 (ERK1) T23276 GENENAME MAPK3 T23276 TARGTYPE Clinical trial T23276 SYNONYMS PRKM3; P44-MAPK; P44-ERK1; P44 Mitogen-activated protein kinase; Mitogen-activated protein kinase 3; Microtubule-associated protein-2 kinase; Microtubule-associated protein 2 kinase; MAPK 3; MAP kinase isoform p44; MAP kinase 3; Insulin-stimulated MAP2 kinase; ERT2; ERK-1 T23276 FUNCTION MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. T23276 PDBSTRUC 6GES; 4QTB; 2ZOQ T23276 BIOCLASS Kinase T23276 ECNUMBER EC 2.7.11.24 T23276 SEQUENCE MAAAAAQGGGGGEPRRTEGVGPGVPGEVEMVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRASTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFAMELDDLPKERLKELIFQETARFQPGVLEAP T23276 DRUGINFO D01IED BVD-523 Phase 2 T23276 DRUGINFO D1KIY9 HH2710 Phase 1/2 T23276 DRUGINFO DM1FD5 ASTX029 Phase 1/2 T23276 DRUGINFO D0D2XQ ASN007 Phase 1 T23276 DRUGINFO D08KNG VAN-10-4-eluting stent Phase 1 T23276 DRUGINFO D0Q4IX GDC-0994 Phase 1 T23276 DRUGINFO DBU16T JSI-1187 Phase 1 T23276 DRUGINFO DOJ6D9 COR-D Preclinical T23276 DRUGINFO D02TYK 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine Investigative T13348 TARGETID T13348 T13348 FORMERID TTDR00967 T13348 UNIPROID APEX1_HUMAN T13348 TARGNAME AP endonuclease 1 (APEX1) T13348 GENENAME APEX1 T13348 TARGTYPE Clinical trial T13348 SYNONYMS Redox factor-1; REF1; REF-1; HAP1; DNA-(apurinic or apyrimidinic site) lyase; Apurinic-apyrimidinic endonuclease 1; APX; APEX nuclease; APEX; APEN; APE1; APE-1; APE T13348 FUNCTION Multifunctional protein that plays a central role in the cellular response to oxidative stress. The two major activities of APEX1 are DNA repair and redox regulation of transcriptional factors. Functions as a apurinic/apyrimidinic (AP) endodeoxyribonuclease in the DNA base excision repair (BER) pathway of DNA lesions induced by oxidative and alkylating agents. Initiates repair of AP sites in DNA by catalyzing hydrolytic incision of the phosphodiester backbone immediately adjacent to the damage, generating a single-strand break with 5'-deoxyribose phosphate and 3'-hydroxyl ends. Does also incise at AP sites in the DNA strand of DNA/RNA hybrids, single-stranded DNA regions of R-loop structures, and single-stranded RNA molecules. Has a 3'-5' exoribonuclease activity on mismatched deoxyribonucleotides at the 3' termini of nicked or gapped DNA molecules during short-patch BER. Possesses a DNA 3' phosphodiesterase activity capable of removing lesions (such as phosphoglycolate) blocking the 3' side of DNA strand breaks. May also play a role in the epigenetic regulation of gene expression by participating in DNA demethylation. Acts as a loading factor for POLB onto non-incised AP sites in DNA and stimulates the 5'-terminal deoxyribose 5'-phosphate (dRp) excision activity of POLB. Plays a role in the protection from granzymes-mediated cellular repair leading to cell death. Also involved in the DNA cleavage step of class switch recombination (CSR). On the other hand, APEX1 also exerts reversible nuclear redox activity to regulate DNA binding affinity and transcriptional activity of transcriptional factors by controlling the redox status of their DNA-binding domain, such as the FOS/JUN AP-1 complex after exposure to IR. Involved in calcium-dependent down-regulation of parathyroid hormone (PTH) expression by binding to negative calcium response elements (nCaREs). Together with HNRNPL or the dimer XRCC5/XRCC6, associates with nCaRE, acting as an activator of transcriptional repression. Stimulates the YBX1-mediated MDR1 promoter activity, when acetylated at Lys-6 and Lys-7, leading to drug resistance. Acts also as an endoribonuclease involved in the control of single-stranded RNA metabolism. Plays a role in regulating MYC mRNA turnover by preferentially cleaving in between UA and CA dinucleotides of the MYC coding region determinant (CRD). In association with NMD1, plays a role in the rRNA quality control process during cell cycle progression. Associates, together with YBX1, on the MDR1 promoter. Together with NPM1, associates with rRNA. Binds DNA and RNA. T13348 PDBSTRUC 6MKO; 6MKM; 6MKK; 6MK3; 6BOW T13348 BIOCLASS Alpha-carbonic anhydrase T13348 ECNUMBER EC 3.1.-.- T13348 SEQUENCE MPKRGKKGAVAEDGDELRTEPEAKKSKTAAKKNDKEAAGEGPALYEDPPDQKTSPSGKPATLKICSWNVDGLRAWIKKKGLDWVKEEAPDILCLQETKCSENKLPAELQELPGLSHQYWSAPSDKEGYSGVGLLSRQCPLKVSYGIGDEEHDQEGRVIVAEFDSFVLVTAYVPNAGRGLVRLEYRQRWDEAFRKFLKGLASRKPLVLCGDLNVAHEEIDLRNPKGNKKNAGFTPQERQGFGELLQAVPLADSFRHLYPNTPYAYTFWTYMMNARSKNVGWRLDYFLLSHSLLPALCDSKIRSKALGSDHCPITLYLAL T13348 DRUGINFO D9YG4P APX3330 Phase 2 T13348 DRUGINFO D0U8XW APX-3330 Phase 1 T13348 DRUGINFO D06BFH 5-fluoro-1H-indole-2-carboxylic acid Investigative T13348 DRUGINFO D07DZS 1,3-bis(1,3-benzothiazol-2-ylthio)acetone Investigative T13348 DRUGINFO D0A3SQ 3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile Investigative T57278 TARGETID T57278 T57278 FORMERID TTDR01214 T57278 UNIPROID EPHA2_HUMAN T57278 TARGNAME Ephrin type-A receptor 2 (EPHA2) T57278 GENENAME EPHA2 T57278 TARGTYPE Clinical trial T57278 SYNONYMS Tyrosine-protein kinase receptor ECK; Epithelial cell kinase; EphA2receptor; ECK T57278 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand-independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis. Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T57278 PDBSTRUC 6NKP; 6NK2; 6NK1; 6NK0; 6NJZ T57278 BIOCLASS Kinase T57278 ECNUMBER EC 2.7.10.1 T57278 SEQUENCE MELQAARACFALLWGCALAAAAAAQGKEVVLLDFAAAGGELGWLTHPYGKGWDLMQNIMNDMPIYMYSVCNVMSGDQDNWLRTNWVYRGEAERIFIELKFTVRDCNSFPGGASSCKETFNLYYAESDLDYGTNFQKRLFTKIDTIAPDEITVSSDFEARHVKLNVEERSVGPLTRKGFYLAFQDIGACVALLSVRVYYKKCPELLQGLAHFPETIAGSDAPSLATVAGTCVDHAVVPPGGEEPRMHCAVDGEWLVPIGQCLCQAGYEKVEDACQACSPGFFKFEASESPCLECPEHTLPSPEGATSCECEEGFFRAPQDPASMPCTRPPSAPHYLTAVGMGAKVELRWTPPQDSGGREDIVYSVTCEQCWPESGECGPCEASVRYSEPPHGLTRTSVTVSDLEPHMNYTFTVEARNGVSGLVTSRSFRTASVSINQTEPPKVRLEGRSTTSLSVSWSIPPPQQSRVWKYEVTYRKKGDSNSYNVRRTEGFSVTLDDLAPDTTYLVQVQALTQEGQGAGSKVHEFQTLSPEGSGNLAVIGGVAVGVVLLLVLAGVGFFIHRRRKNQRARQSPEDVYFSKSEQLKPLKTYVDPHTYEDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSGSEGVPFRTVSEWLESIKMQQYTEHFMAAGYTAIEKVVQMTNDDIKRIGVRLPGHQKRIAYSLLGLKDQVNTVGIPI T57278 DRUGINFO D05OHY CAR-T cells targeting EphA2 Phase 1/2 T57278 DRUGINFO DS5C0K BT5528 Phase 1/2 T57278 DRUGINFO D03YBJ DS-8895 Phase 1 T57278 DRUGINFO D0B8MS MEDI-547 Phase 1 T57278 DRUGINFO D0W8HP MEDI-543 Preclinical T57278 DRUGINFO D02BXJ PMID21561767C8h Investigative T57278 DRUGINFO D05FXD PMID19788238C66 Investigative T57278 DRUGINFO D00ICA AMP-PNP Investigative T57278 DRUGINFO D0X8BU PMID23489211C20 Investigative T28413 TARGETID T28413 T28413 FORMERID TTDI02061 T28413 UNIPROID EPHA3_HUMAN T28413 TARGNAME Ephrin type-A receptor 3 (EPHA3) T28413 GENENAME EPHA3 T28413 TARGTYPE Clinical trial T28413 SYNONYMS hEK4; Tyrosineprotein kinase receptor ETK1; Tyrosineprotein kinase TYRO4; Tyrosine-protein kinase receptor ETK1; Tyrosine-protein kinase TYRO4; TYRO4; Human embryo kinase; HEK; Ephrin typeA receptor 3; Ephlike tyrosine kinase 1; Eph-like tyrosine kinase 1; ETK1; ETK protein; EPHlike kinase 4; EPH-like kinase 4; EK4 T28413 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous for ephrin-A ligands it binds preferentially EFNA5. Upon activation by EFNA5 regulates cell-cell adhesion, cytoskeletal organization and cell migration. Plays a role in cardiac cells migration and differentiation and regulates the formation of the atrioventricular canal and septum during development probably through activation by EFNA1. Involved in the retinotectal mapping of neurons. May also control the segregation but not the guidance of motor and sensory axons during neuromuscular circuit development. Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T28413 PDBSTRUC 4TWO; 4TWN; 4P5Z; 4P5Q; 4P4C T28413 BIOCLASS Kinase T28413 ECNUMBER EC 2.7.10.1 T28413 SEQUENCE MDCQLSILLLLSCSVLDSFGELIPQPSNEVNLLDSKTIQGELGWISYPSHGWEEISGVDEHYTPIRTYQVCNVMDHSQNNWLRTNWVPRNSAQKIYVELKFTLRDCNSIPLVLGTCKETFNLYYMESDDDHGVKFREHQFTKIDTIAADESFTQMDLGDRILKLNTEIREVGPVNKKGFYLAFQDVGACVALVSVRVYFKKCPFTVKNLAMFPDTVPMDSQSLVEVRGSCVNNSKEEDPPRMYCSTEGEWLVPIGKCSCNAGYEERGFMCQACRPGFYKALDGNMKCAKCPPHSSTQEDGSMNCRCENNYFRADKDPPSMACTRPPSSPRNVISNINETSVILDWSWPLDTGGRKDVTFNIICKKCGWNIKQCEPCSPNVRFLPRQFGLTNTTVTVTDLLAHTNYTFEIDAVNGVSELSSPPRQFAAVSITTNQAAPSPVLTIKKDRTSRNSISLSWQEPEHPNGIILDYEVKYYEKQEQETSYTILRARGTNVTISSLKPDTIYVFQIRARTAAGYGTNSRKFEFETSPDSFSISGESSQVVMIAISAAVAIILLTVVIYVLIGRFCGYKSKHGADEKRLHFGNGHLKLPGLRTYVDPHTYEDPTQAVHEFAKELDATNISIDKVVGAGEFGEVCSGRLKLPSKKEISVAIKTLKVGYTEKQRRDFLGEASIMGQFDHPNIIRLEGVVTKSKPVMIVTEYMENGSLDSFLRKHDAQFTVIQLVGMLRGIASGMKYLSDMGYVHRDLAARNILINSNLVCKVSDFGLSRVLEDDPEAAYTTRGGKIPIRWTSPEAIAYRKFTSASDVWSYGIVLWEVMSYGERPYWEMSNQDVIKAVDEGYRLPPPMDCPAALYQLMLDCWQKDRNNRPKFEQIVSILDKLIRNPGSLKIITSAAARPSNLLLDQSNVDITTFRTTGDWLNGVWTAHCKEIFTGVEYSSCDTIAKISTDDMKKVGVTVVGPQKKIISSIKALETQSKNGPVPV T28413 DRUGINFO D08NZG Ifabotuzumab Phase 2 T28413 DRUGINFO D0FJ9W KB-004 Phase 1/2 T28413 DRUGINFO D02BXJ PMID21561767C8h Investigative T28413 DRUGINFO D05FXD PMID19788238C66 Investigative T28413 DRUGINFO D0X8BU PMID23489211C20 Investigative T14755 TARGETID T14755 T14755 FORMERID TTDR00284 T14755 UNIPROID CD40L_HUMAN T14755 TARGNAME TNF related activation protein (CD40LG) T14755 GENENAME CD40LG T14755 TARGTYPE Clinical trial T14755 SYNONYMS Tumor necrosis factor ligand superfamily member 5; TRAP; TNFSF5; TNF-related activation protein; T-cell antigen Gp39; T cell antigen Gp39; CD40L; CD40-L; CD40 ligand; CD154 antigen; CD154 T14755 FUNCTION Costimulates T-cell proliferation and cytokine production. Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation. Induces the activation of NF-kappa-B and kinases MAPK8 and PAK2 in T-cells. Induces tyrosine phosphorylation of isoform 3 of CD28. Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4. Involved in immunoglobulin class switching. Cytokine that binds to CD40/TNFRSF5. T14755 PDBSTRUC 6BRB; 3QD6; 3LKJ; 1I9R; 1ALY T14755 BIOCLASS Cytokine: tumor necrosis factor T14755 SEQUENCE MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL T14755 DRUGINFO D03BBU Lucatumumab Phase 2 T14755 DRUGINFO D05CFV Dapirolizumab pegol Phase 2 T14755 DRUGINFO D05KAC PG-102 Phase 2 T14755 DRUGINFO D0HD8X ISF35 Phase 2 T14755 DRUGINFO D05RRU IL-2/CD40L-expressing leukemia vaccine Phase 2 T14755 DRUGINFO D0C8NG BI 655064 Phase 2 T14755 DRUGINFO D02KAW CDP-7657 Phase 1 T14755 DRUGINFO D06HNO MEDI4920 Phase 1 T14755 DRUGINFO D07WTH UltraCD40L Phase 1 T14755 DRUGINFO D0L6SS BPX-101 Phase 1 T14755 DRUGINFO D0M4BB Chi Lob 7/4 Phase 1 T14755 DRUGINFO D0QD4A ABBV-428 Phase 1 T14755 DRUGINFO D0A2NH IDEC-131 Discontinued in Phase 1 T14755 DRUGINFO D0PU8Z Dacetuzumab Terminated T14755 DRUGINFO D0W5ZU Antova Terminated T14755 DRUGINFO D04PFD TriMixDC Investigative T99816 TARGETID T99816 T99816 FORMERID TTDC00230 T99816 UNIPROID GRPR_HUMAN T99816 TARGNAME Gastrin-releasing peptide receptor (GRPR) T99816 GENENAME GRPR T99816 TARGTYPE Clinical trial T99816 SYNONYMS GRPR; GRP-preferring bombesin receptor; GRP-R; Bombesin/gastrin-releasing peptide receptor T99816 FUNCTION Receptor for gastrin-releasing peptide (GRP). Signals via association with G proteins that activate a phosphatidylinositol-calcium second messenger system, resulting in Akt phosphorylation. Contributes to the regulation of food intake. Contributes to the perception of prurient stimuli and transmission of itch signals in the spinal cord that promote scratching behavior, but does not play a role in the perception of pain. Contributes primarily to nonhistaminergic itch sensation. Contributes to long-term fear memory, but not normal spatial memory. T99816 BIOCLASS GPCR rhodopsin T99816 SEQUENCE MALNDCFLLNLEVDHFMHCNISSHSADLPVNDDWSHPGILYVIPAVYGVIILIGLIGNITLIKIFCTVKSMRNVPNLFISSLALGDLLLLITCAPVDASRYLADRWLFGRIGCKLIPFIQLTSVGVSVFTLTALSADRYKAIVRPMDIQASHALMKICLKAAFIWIISMLLAIPEAVFSDLHPFHEESTNQTFISCAPYPHSNELHPKIHSMASFLVFYVIPLSIISVYYYFIAKNLIQSAYNLPVEGNIHVKKQIESRKRLAKTVLVFVGLFAFCWLPNHVIYLYRSYHYSEVDTSMLHFVTSICARLLAFTNSCVNPFALYLLSKSFRKQFNTQLLCCQPGLIIRSHSTGRSTTCMTSLKSTNPSVATFSLINGNICHERYV T99816 DRUGINFO D03CDK ASP-7147 Phase 2 T99816 DRUGINFO D0AC8W RC-3095 Phase 2 T99816 DRUGINFO DD25UM 177Lu-labelled NeoBOMB1 Phase 2 T99816 DRUGINFO D0ZVM5 177-Lu-NeoB Phase 1/2 T99816 DRUGINFO D02TMO 177Lu-AMBA Phase 1 T99816 DRUGINFO D0Q8DM BIM-26226 Discontinued in Phase 1 T99816 DRUGINFO D01VUY [N40,Pro1,Tyr4,Nle 14]BB Investigative T99816 DRUGINFO D03DSG Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2 Investigative T99816 DRUGINFO D06JUN [Tyr4]Bombesin Investigative T99816 DRUGINFO D07GGP JMV 1693 Investigative T99816 DRUGINFO D07OAR (CH3)CCO-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 Investigative T99816 DRUGINFO D07ZUI Ac-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 Investigative T99816 DRUGINFO D08LCD JMV 1803 Investigative T99816 DRUGINFO D0D2ET JMV 1813 Investigative T99816 DRUGINFO D0FY6N [N40,Pro1,Tyr4]BB Investigative T99816 DRUGINFO D0H6TE JMV 1802 Investigative T99816 DRUGINFO D0HN2U JMV 1535 Investigative T99816 DRUGINFO D0LC2O Ac-His-Trp-Ala-Val-Ala-His-Leu-Met-NH2 Investigative T99816 DRUGINFO D0MH6P [(N4-Bzdig)0,Nle14]BB(7-14) Investigative T99816 DRUGINFO D0N1XQ JMV 1719 Investigative T99816 DRUGINFO D0N9MH JMV 1799 Investigative T99816 DRUGINFO D0W1BY (D)Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2 Investigative T99816 DRUGINFO D0W2EP JMV 1801 Investigative T99816 DRUGINFO D59BZJ 177Lu-labelled RM2 Investigative T99816 DRUGINFO D01PWM kuwanon H Investigative T99816 DRUGINFO D02QOD bombesin Investigative T99816 DRUGINFO D07IAK PD 168368 Investigative T99816 DRUGINFO D08RQW MK-5046 Investigative T99816 DRUGINFO D09FOQ bantag-1 Investigative T99816 DRUGINFO D0E1EC ranatensin Investigative T99816 DRUGINFO D0I5CS PD 176252 Investigative T99816 DRUGINFO D0R8TG [(N4-Bzdig)0]BB(7-14) Investigative T99816 DRUGINFO D0S3XL neuromedin B Investigative T02728 TARGETID T02728 T02728 FORMERID TTDC00144 T02728 UNIPROID NTR1_HUMAN T02728 TARGNAME Neurotensin receptor type 1 (NTSR1) T02728 GENENAME NTSR1 T02728 TARGTYPE Clinical trial T02728 SYNONYMS NTSR1; NTRH; NTR1; NTR subtype 1; NT-R1; NT-R-1; High-affinity levocabastine-insensitive neurotensin receptor T02728 FUNCTION G-protein coupled receptor for the tridecapeptide neurotensin (NTS). Signaling is effected via G proteins that activate a phosphatidylinositol-calcium second messenger system. Signaling leads to the activation of downstream MAP kinases and protects cells against apoptosis. T02728 PDBSTRUC 2LYW T02728 BIOCLASS GPCR rhodopsin T02728 SEQUENCE MRLNSSAPGTPGTPAADPFQRAQAGLEEALLAPGFGNASGNASERVLAAPSSELDVNTDIYSKVLVTAVYLALFVVGTVGNTVTAFTLARKKSLQSLQSTVHYHLGSLALSDLLTLLLAMPVELYNFIWVHHPWAFGDAGCRGYYFLRDACTYATALNVASLSVERYLAICHPFKAKTLMSRSRTKKFISAIWLASALLAVPMLFTMGEQNRSADGQHAGGLVCTPTIHTATVKVVIQVNTFMSFIFPMVVISVLNTIIANKLTVMVRQAAEQGQVCTVGGEHSTFSMAIEPGRVQALRHGVRVLRAVVIAFVVCWLPYHVRRLMFCYISDEQWTPFLYDFYHYFYMVTNALFYVSSTINPILYNLVSANFRHIFLATLACLCPVWRRRRKRPAFSRKADSVSSNHTLSSNATRETLY T02728 DRUGINFO D0G0TS Meclinertant Phase 2/3 T02728 DRUGINFO D03XUQ ABS-212 Terminated T02728 DRUGINFO D08ZIH CGX-1160 Terminated T02728 DRUGINFO D02WCJ Neurotensin(8-13) Investigative T02728 DRUGINFO D04LEF JMV449 Investigative T02728 DRUGINFO D05HYV SR48527 Investigative T02728 DRUGINFO D06ECM HBN-2 Investigative T02728 DRUGINFO D0A3DE [3H]meclinertant Investigative T02728 DRUGINFO D0B4SQ H-Arg-Arg-Pro-Tyr-Ile-Aac-OH Investigative T02728 DRUGINFO D0H7EB H-Arg-Arg-Pro-Tyr-N-Me-Ile-Leu-OH Investigative T02728 DRUGINFO D0H8AI NEUROTENSIN Investigative T02728 DRUGINFO D0N4RF Demotensin 3 Investigative T02728 DRUGINFO D0OJ7S SR142948A Investigative T02728 DRUGINFO D0OT9G H-Arg-Arg-Pro-Tyr-Ile-N-Me-Leu-OH Investigative T02728 DRUGINFO D0P5VL Demotensin 1 Investigative T02728 DRUGINFO D0S9PC H-Arg-N-Me-Arg-Pro-Tyr-Ile-Leu-OH Investigative T02728 DRUGINFO D0V4HB Demotensin 2 Investigative T02728 DRUGINFO D0W2KG NT-69-L Investigative T02728 DRUGINFO D0W9II EISAI-1 Investigative T02728 DRUGINFO D0X3RW Demotensin 4 Investigative T02728 DRUGINFO D09RSL JMV458 Investigative T02728 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T97008 TARGETID T97008 T97008 UNIPROID METK2_HUMAN T97008 TARGNAME S-adenosylmethionine synthase type-2 (MAT2A) T97008 GENENAME MAT2A T97008 TARGTYPE Clinical trial T97008 SYNONYMS Methionine adenosyltransferase II; Methionine adenosyltransferase 2; MAT-II; MAT 2; AdoMet synthase 2 T97008 FUNCTION Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis of the triphosphate. T97008 PDBSTRUC 6G6R; 6FWB; 6FCD; 6FCB; 6FBP T97008 BIOCLASS AdoMet synthase family T97008 ECNUMBER EC 2.5.1.6 T97008 SEQUENCE MNGQLNGFHEAFIEEGTFLFTSESVGEGHPDKICDQISDAVLDAHLQQDPDAKVACETVAKTGMILLAGEITSRAAVDYQKVVREAVKHIGYDDSSKGFDYKTCNVLVALEQQSPDIAQGVHLDRNEEDIGAGDQGLMFGYATDETEECMPLTIVLAHKLNAKLAELRRNGTLPWLRPDSKTQVTVQYMQDRGAVLPIRVHTIVISVQHDEEVCLDEMRDALKEKVIKAVVPAKYLDEDTIYHLQPSGRFVIGGPQGDAGLTGRKIIVDTYGGWGAHGGGAFSGKDYTKVDRSAAYAARWVAKSLVKGGLCRRVLVQVSYAIGVSHPLSISIFHYGTSQKSERELLEIVKKNFDLRPGVIVRDLDLKKPIYQRTAAYGHFGRDSFPWEVPKKLKY T97008 DRUGINFO D0C2BP AG-270 Phase 1 T97008 DRUGINFO DN62IU AG-270 Phase 1 T62974 TARGETID T62974 T62974 FORMERID TTDC00034 T62974 UNIPROID SSR4_HUMAN T62974 TARGNAME Somatostatin receptor type 4 (SSTR4) T62974 GENENAME SSTR4 T62974 TARGTYPE Clinical trial T62974 SYNONYMS SSTR4; SS4R T62974 FUNCTION Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. It is functionally coupled not only to inhibition of adenylate cyclase, but also to activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade. Mediates antiproliferative action of somatostatin in tumor cells. T62974 BIOCLASS GPCR rhodopsin T62974 SEQUENCE MSAPSTLPPGGEEGLGTAWPSAANASSAPAEAEEAVAGPGDARAAGMVAIQCIYALVCLVGLVGNALVIFVILRYAKMKTATNIYLLNLAVADELFMLSVPFVASSAALRHWPFGSVLCRAVLSVDGLNMFTSVFCLTVLSVDRYVAVVHPLRAATYRRPSVAKLINLGVWLASLLVTLPIAIFADTRPARGGQAVACNLQWPHPAWSAVFVVYTFLLGFLLPVLAIGLCYLLIVGKMRAVALRAGWQQRRRSEKKITRLVLMVVVVFVLCWMPFYVVQLLNLFVTSLDATVNHVSLILSYANSCANPILYGFLSDNFRRFFQRVLCLRCCLLEGAGGAEEEPLDYYATALKSKGGAGCMCPPLPCQQEALQPEPGRKRIPLTRTTTF T62974 DRUGINFO D06JFI ODT-8 Phase 3 T62974 DRUGINFO DXE53Z LY3556050 Phase 2 T62974 DRUGINFO D0M5VV 177Lu-DOTATATE Phase 2 T62974 DRUGINFO D0U0CF CNTX-0290 Phase 1 T62974 DRUGINFO D05EKM FR-121196 Terminated T62974 DRUGINFO D04QBM L-803,087 Investigative T62974 DRUGINFO D05CEM NNC269100 Investigative T62974 DRUGINFO D06AVM beta3-tetrapeptide Investigative T62974 DRUGINFO D07FYX Pyz7-D-Trp8-SRIF Investigative T62974 DRUGINFO D0S0AK D-Trp8-SRIF-14 Investigative T62974 DRUGINFO D03DRL Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF Investigative T62974 DRUGINFO D09EIG Pyz6-D-Trp8-SRIF Investigative T62974 DRUGINFO D09LHN Des-AA1,2,5-[IAmp9,Tyr11]-SRIF Investigative T62974 DRUGINFO D0A1XX Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF Investigative T62974 DRUGINFO D0GN3M Ala11-SRIF-14-amide Investigative T62974 DRUGINFO D0H0DC Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF Investigative T62974 DRUGINFO D0K9TS Pyz11-D-Trp8-SRIF Investigative T62974 DRUGINFO D0R0OX Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF Investigative T62974 DRUGINFO D0WG0O Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF Investigative T62974 DRUGINFO D0Y1PT Ala6-SRIF-14-amide Investigative T62974 DRUGINFO D02NJV Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF Investigative T62974 DRUGINFO D0W0AF Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF Investigative T62974 DRUGINFO D02OJQ Des-AA1,2,5-[D-Trp8,Tyr11]SRIF Investigative T62974 DRUGINFO D04ORV Des-AA1,2,5,12,13-[D-Trp8]SRIF Investigative T62974 DRUGINFO D06WCI SRIF-28 Investigative T62974 DRUGINFO D06WYG 99mTc-MIP-1407 Investigative T62974 DRUGINFO D09DAC Des-AA1,2,4,12,13-[D-Trp8]SRIF Investigative T62974 DRUGINFO D0B5AZ Cytotoxin Peptide Conjugate Investigative T62974 DRUGINFO D0C5RH Des-AA1,2,4,13-[D-Trp8]SRIF Investigative T62974 DRUGINFO D0H4WH Des-AA5-[D-Trp8]SRIF Investigative T62974 DRUGINFO D0J5OY Des-AA1,2,4,5-[D-Trp8]SRIF Investigative T62974 DRUGINFO D0P3WF CGP 23996 Investigative T62974 DRUGINFO D0R7OD SRIF-14 Investigative T62974 DRUGINFO D0Z3LZ Des-AA1,2,4,5,13-[D-Trp8]-SRIF Investigative T62974 DRUGINFO D0T5RO SOMATOSTATIN Investigative T79027 TARGETID T79027 T79027 FORMERID TTDI02040 T79027 UNIPROID CDD_HUMAN T79027 TARGNAME Cytidine deaminase (CDA) T79027 GENENAME CDA T79027 TARGTYPE Clinical trial T79027 SYNONYMS Cytidine aminohydrolase; CDA T79027 FUNCTION This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis. T79027 PDBSTRUC 1MQ0 T79027 BIOCLASS Carbon-nitrogen hydrolase T79027 ECNUMBER EC 3.5.4.5 T79027 SEQUENCE MAQKRPACTLKPECVQQLLVCSQEAKKSAYCPYSHFPVGAALLTQEGRIFKGCNIENACYPLGICAERTAIQKAVSEGYKDFRAIAIASDMQDDFISPCGACRQVMREFGTNWPVYMTKPDGTYIVMTVQELLPSSFGPEDLQKTQ T79027 DRUGINFO D0I5OR Tetrahydrouridine Phase 2 T74977 TARGETID T74977 T74977 FORMERID TTDR01110 T74977 UNIPROID TTK_HUMAN T74977 TARGNAME Dual specificity protein kinase TTK (MPS1) T74977 GENENAME TTK T74977 TARGTYPE Clinical trial T74977 SYNONYMS Tyrosine threonine kinase; Phosphotyrosine picked threonine-protein kinase; PYT; MPS1L1 T74977 FUNCTION Probably associated with cell proliferation. Essential for chromosome alignment by enhancing AURKB activity (via direct CDCA8 phosphorylation) at the centromere, and for the mitotic checkpoint. Phosphorylates proteins on serine, threonine, and tyrosine. T74977 PDBSTRUC 6N6O; 6H3K; 6GVJ; 6B4W; 5O91 T74977 BIOCLASS Kinase T74977 ECNUMBER EC 2.7.12.1 T74977 SEQUENCE MESEDLSGRELTIDSIMNKVRDIKNKFKNEDLTDELSLNKISADTTDNSGTVNQIMMMANNPEDWLSLLLKLEKNSVPLSDALLNKLIGRYSQAIEALPPDKYGQNESFARIQVRFAELKAIQEPDDARDYFQMARANCKKFAFVHISFAQFELSQGNVKKSKQLLQKAVERGAVPLEMLEIALRNLNLQKKQLLSEEEKKNLSASTVLTAQESFSGSLGHLQNRNNSCDSRGQTTKARFLYGENMPPQDAEIGYRNSLRQTNKTKQSCPFGRVPVNLLNSPDCDVKTDDSVVPCFMKRQTSRSECRDLVVPGSKPSGNDSCELRNLKSVQNSHFKEPLVSDEKSSELIITDSITLKNKTESSLLAKLEETKEYQEPEVPESNQKQWQSKRKSECINQNPAASSNHWQIPELARKVNTEQKHTTFEQPVFSVSKQSPPISTSKWFDPKSICKTPSSNTLDDYMSCFRTPVVKNDFPPACQLSTPYGQPACFQQQQHQILATPLQNLQVLASSSANECISVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEEMKYVLGQLVGLNSPNSILKAAKTLYEHYSGGESHNSSSSKTFEKKRGKK T74977 DRUGINFO D0HY9S BOS172722 Phase 1 T74977 DRUGINFO D0J6RV BAY1161909 Phase 1 T74977 DRUGINFO D81YNE CFI-402257 Phase 1 T74977 DRUGINFO D06GGI Tricyclic isoxazoloquinazoline derivative 2 Patented T74977 DRUGINFO D0JC8E Tricyclic isoxazoloquinazoline derivative 4 Patented T74977 DRUGINFO D0WK2S Tricyclic isoxazoloquinazoline derivative 3 Patented T74977 DRUGINFO D0J5FK GNE-7915 Investigative T74977 DRUGINFO D02PVB 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One Investigative T79062 TARGETID T79062 T79062 FORMERID TTDR00157 T79062 UNIPROID 5HT7R_HUMAN T79062 TARGNAME 5-HT 7 receptor (HTR7) T79062 GENENAME HTR7 T79062 TARGTYPE Clinical trial T79062 SYNONYMS Serotonin receptor 7; 5HT7; 5-hydroxytryptamine receptor 7; 5-HT7 receptor; 5-HT7; 5-HT-X; 5-HT-7 T79062 FUNCTION The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. T79062 BIOCLASS GPCR rhodopsin T79062 SEQUENCE MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTWDAPPDNASGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLIVSLALADLSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPVRQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYTIYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVEECANLSRLLKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSCIPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD T79062 DRUGINFO D0T8KA JNJ-18038683 Phase 2 T79062 DRUGINFO DM04QU AVN-101 Phase 2 T79062 DRUGINFO D05XEA RP5063 Phase 2 T79062 DRUGINFO D06NOF ATI-9242 Phase 1 T79062 DRUGINFO D0E6KF Carbamide derivative 2 Patented T79062 DRUGINFO D0F0XC 4-oxadiazole derivative 1 Patented T79062 DRUGINFO D09BCJ PMID30124346-Compound-34TABLE4 Patented T79062 DRUGINFO D0F4NB PMID30124346-Compound-13TABLE4 Patented T79062 DRUGINFO D0YP7L SB-269970 Terminated T79062 DRUGINFO D00PEU pirenperone Investigative T79062 DRUGINFO D01KVG DR-4004 Investigative T79062 DRUGINFO D02HZG 2-(2-Bromophenoxy)-N,N-dimethylethanamine Investigative T79062 DRUGINFO D03NBX P-hydroxyphenethyl trans-ferulate Investigative T79062 DRUGINFO D03TSY E55888 Investigative T79062 DRUGINFO D04GBL 2-(1-o-tolyl-1H-pyrrol-3-yl)ethanamine Investigative T79062 DRUGINFO D07JRV 2-(Biphenyl-2-ylthio)-N,N-dimethylethanamine Investigative T79062 DRUGINFO D07JTZ UCM-5600 Investigative T79062 DRUGINFO D08CKM SB-258741 Investigative T79062 DRUGINFO D09ROW IMPERATORIN Investigative T79062 DRUGINFO D0B4LD (2-biphenyl-3-yl-ethyl)-dimethyl-amine Investigative T79062 DRUGINFO D0B9TN 2-(2-Bromophenylthio)-N,N-dimethylethanamine Investigative T79062 DRUGINFO D0BG5H SB 269970-A Investigative T79062 DRUGINFO D0HE4S Disulergine Investigative T79062 DRUGINFO D0K0HU N,N-dimethyl-2-(2'-methylbiphenyl-3-yl)ethanamine Investigative T79062 DRUGINFO D0LT5D (R)-8-phenyl-N,N-dipropylchroman-3-amine Investigative T79062 DRUGINFO D0U8RZ 2-[1-(2-Chloro-phenyl)-1H-pyrrol-2-yl]-ethylamine Investigative T79062 DRUGINFO D0X7SD 2-(Biphenyl-2-yloxy)-N,N-dimethylethanamine Investigative T79062 DRUGINFO D0X9YS AS-19 Investigative T79062 DRUGINFO D00VRV 2-bromo-LSD Investigative T79062 DRUGINFO D03AHJ Elaidoylamide Investigative T79062 DRUGINFO D09ULA OPC 4392 Investigative T79062 DRUGINFO D09WIL SB-656104 Investigative T79062 DRUGINFO D0F8TG fluperlapine Investigative T79062 DRUGINFO D0H9QG SB-258719 Investigative T79062 DRUGINFO D0I0ML 2-(2'-methyl-biphenyl-3-yl)-ethylamine Investigative T79062 DRUGINFO D0J0KG DM-1451 Investigative T79062 DRUGINFO D0M7AU N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi) Investigative T79062 DRUGINFO D0UI3L dihydroergocryptine Investigative T79062 DRUGINFO D00GSD LP-211 Investigative T79062 DRUGINFO D0X6MT METHIOTHEPIN Investigative T79062 DRUGINFO D03ZHB 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine Investigative T79062 DRUGINFO D07HQZ [3H]LSD Investigative T79062 DRUGINFO D0BW9V [125I]LSD Investigative T79062 DRUGINFO D0D3PZ dipropyl-5-CT Investigative T79062 DRUGINFO D0G7NW cyamemazine Investigative T79062 DRUGINFO D0K5NZ MESULERGINE Investigative T79062 DRUGINFO D0N8BJ [3H]5-HT Investigative T79062 DRUGINFO D0X4PH LP-44 Investigative T79062 DRUGINFO D0Z1OF LP-12 Investigative T79062 DRUGINFO D04TPO 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T79062 DRUGINFO D08PJK [3H]5-CT Investigative T79062 DRUGINFO D08UOX FALCARINDIOL Investigative T79062 DRUGINFO D0OG0R WAY-208466 Investigative T79062 DRUGINFO D0P1XQ SEL-73 Investigative T79062 DRUGINFO D0SP2J bufotenine Investigative T79062 DRUGINFO D0XX2U 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine Investigative T79062 DRUGINFO D0CK9K EDMT Investigative T79062 DRUGINFO D06VPR WAY-466 Investigative T79062 DRUGINFO D0C5GF MPDT Investigative T79062 DRUGINFO D0J6JT m-chlorophenylpiperazine Investigative T79062 DRUGINFO D0LG8A 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine Investigative T79062 DRUGINFO D0V4RP 1-(2-Methoxy-phenyl)-piperazine Investigative T79062 DRUGINFO D0Y9TL 5-chloro-3,4-dihydroquinazolin-2-amine Investigative T79062 DRUGINFO D05EQG [3H]spiperone Investigative T79062 DRUGINFO D08VGJ 5,6-dichloro-3,4-dihydroquinazolin-2-amine Investigative T79062 DRUGINFO D03TDN 1-naphthylpiperazine Investigative T79062 DRUGINFO D07LRJ SB-271046 Investigative T79062 DRUGINFO D02UWB 5-CT Investigative T79062 DRUGINFO D0V5HV TFMPP Investigative T79062 DRUGINFO D0F6CD SEROTONIN Investigative T79062 DRUGINFO D0L5MW (+/-)-nantenine Investigative T79062 DRUGINFO D0T2RY 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Investigative T35040 TARGETID T35040 T35040 FORMERID TTDNR00648 T35040 UNIPROID BASI_HUMAN T35040 TARGNAME Basigin (BSG) T35040 GENENAME BSG T35040 TARGTYPE Clinical trial T35040 SYNONYMS UNQ6505/PRO21383; Tumor cell-derived collagenase stimulatory factor; TCSF; OK blood group antigen; Leukocyte activation antigen M6; Extracellular matrix metalloproteinase inducer; EMMPRIN; 5F7 T35040 FUNCTION Plays pivotal roles in spermatogenesis, embryo implantation, neural network formation and tumor progression. Stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPS). Seems to be a receptor for oligomannosidic glycans. In vitro, promotes outgrowth of astrocytic processes. Plays an important role in targeting the monocarboxylate transporters SLC16A1, SLC16A3, SLC16A8, SLC16A11 and SLC16A12 to the plasma membrane. T35040 PDBSTRUC 5XF0; 5X0T; 4U0Q; 3QR2; 3QQN T35040 BIOCLASS Basigin protein T35040 SEQUENCE MAAALFVLLGFALLGTHGASGAAGFVQAPLSQQRWVGGSVELHCEAVGSPVPEIQWWFEGQGPNDTCSQLWDGARLDRVHIHATYHQHAASTISIDTLVEEDTGTYECRASNDPDRNHLTRAPRVKWVRAQAVVLVLEPGTVFTTVEDLGSKILLTCSLNDSATEVTGHRWLKGGVVLKEDALPGQKTEFKVDSDDQWGEYSCVFLPEPMGTANIQLHGPPRVKAVKSSEHINEGETAMLVCKSESVPPVTDWAWYKITDSEDKALMNGSESRFFVSSSQGRSELHIENLNMEADPGQYRCNGTSSKGSDQAIITLRVRSHLAALWPFLGIVAEVLVLVTIIFIYEKRRKPEDVLDDDDAGSAPLKSSGQHQNDKGKNVRQRNSS T35040 DRUGINFO D03RDQ Gavilimomab Phase 2/3 T35040 DRUGINFO D0E5BW [131I]-Metuximab Phase 2 T55260 TARGETID T55260 T55260 UNIPROID PPM1A_HUMAN T55260 TARGNAME Protein phosphatase 1A (PPM1A) T55260 GENENAME PPM1A T55260 TARGTYPE Clinical trial T55260 SYNONYMS Protein phosphatase IA; Protein phosphatase 2C isoform alpha; PP2C-alpha T55260 FUNCTION Enzyme with a broad specificity. Negatively regulates TGF-beta signaling through dephosphorylating SMAD2 and SMAD3, resulting in their dissociation from SMAD4, nuclear export of the SMADs and termination of the TGF-beta-mediated signaling. Dephosphorylates PRKAA1 and PRKAA2. Plays an important role in the termination of TNF-alpha-mediated NF-kappa-B activation through dephosphorylating and inactivating IKBKB/IKKB. T55260 PDBSTRUC 6B67; 4RAG; 4RAF; 4RA2; 3FXO T55260 BIOCLASS PP2C family T55260 ECNUMBER EC 3.1.3.16 T55260 SEQUENCE MGAFLDKPKMEKHNAQGQGNGLRYGLSSMQGWRVEMEDAHTAVIGLPSGLESWSFFAVYDGHAGSQVAKYCCEHLLDHITNNQDFKGSAGAPSVENVKNGIRTGFLEIDEHMRVMSEKKHGADRSGSTAVGVLISPQHTYFINCGDSRGLLCRNRKVHFFTQDHKPSNPLEKERIQNAGGSVMIQRVNGSLAVSRALGDFDYKCVHGKGPTEQLVSPEPEVHDIERSEEDDQFIILACDGIWDVMGNEELCDFVRSRLEVTDDLEKVCNEVVDTCLYKGSRDNMSVILICFPNAPKVSPEAVKKEAELDKYLECRVEEIIKKQGEGVPDLVHVMRTLASENIPSLPPGGELASKRNVIEAVYNRLNPYKNDDTDSTSTDDMW T55260 DRUGINFO D01HZQ VP-102 Phase 3 T50699 TARGETID T50699 T50699 FORMERID TTDI02198 T50699 UNIPROID TNR3_HUMAN T50699 TARGNAME Lymphotoxin beta receptor (LTBR) T50699 GENENAME LTBR T50699 TARGTYPE Clinical trial T50699 SYNONYMS Tumor necrosis factor receptor type III; Tumor necrosis factor receptor superfamily member 3; Tumor necrosis factor receptor 2-related protein; Tumor necrosis factor C receptor; TNFRSF3; TNFR3; TNFR-III; TNFCR; TNF-RIII; Lymphotoxin-beta receptor; D12S370 T50699 FUNCTION Promotes apoptosis via TRAF3 and TRAF5. May play a role in the development of lymphoid organs. Receptor for the heterotrimeric lymphotoxin containing LTA and LTB, and for TNFS14/LIGHT. T50699 PDBSTRUC 4MXW; 1RF3 T50699 BIOCLASS Cytokine receptor T50699 SEQUENCE MLLPWATSAPGLAWGPLVLGLFGLLAASQPQAVPPYASENQTCRDQEKEYYEPQHRICCSRCPPGTYVSAKCSRIRDTVCATCAENSYNEHWNYLTICQLCRPCDPVMGLEEIAPCTSKRKTQCRCQPGMFCAAWALECTHCELLSDCPPGTEAELKDEVGKGNNHCVPCKAGHFQNTSSPSARCQPHTRCENQGLVEAAPGTAQSDTTCKNPLEPLPPEMSGTMLMLAVLLPLAFFLLLATVFSCIWKSHPSLCRKLGSLLKRRPQGEGPNPVAGSWEPPKAHPYFPDLVQPLLPISGDVSPVSTGLPAAPVLEAGVPQQQSPLDLTREPQLEPGEQSQVAHGTNGIHVTGGSMTITGNIYIYNGPVLGGPPGPGDLPATPEPPYPIPEEGDPGPPGLSTPHQEDGKAWHLAETEHCGATPSNRGPRNQFITHD T50699 DRUGINFO D08XVR Baminercept Phase 2 T50699 DRUGINFO D09XRQ HCBE-11 Phase 1 T36959 TARGETID T36959 T36959 FORMERID TTDC00338 T36959 UNIPROID ACVL1_HUMAN T36959 TARGNAME Activin receptor-like kinase-1 (ACVRL1) T36959 GENENAME ACVRL1 T36959 TARGTYPE Clinical trial T36959 SYNONYMS Serine/threonine-protein kinase receptor R3; SKR3; Activin receptor-like kinase 1; ALK-1; ACVRLK1; ACVRL1 T36959 FUNCTION Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bindactivin as well. T36959 PDBSTRUC 4FAO; 3MY0; 2LCR T36959 BIOCLASS Kinase T36959 ECNUMBER EC 2.7.11.30 T36959 SEQUENCE MTLGSPRKGLLMLLMALVTQGDPVKPSRGPLVTCTCESPHCKGPTCRGAWCTVVLVREEGRHPQEHRGCGNLHRELCRGRPTEFVNHYCCDSHLCNHNVSLVLEATQPPSEQPGTDGQLALILGPVLALLALVALGVLGLWHVRRRQEKQRGLHSELGESSLILKASEQGDSMLGDLLDSDCTTGSGSGLPFLVQRTVARQVALVECVGKGRYGEVWRGLWHGESVAVKIFSSRDEQSWFRETEIYNTVLLRHDNILGFIASDMTSRNSSTQLWLITHYHEHGSLYDFLQRQTLEPHLALRLAVSAACGLAHLHVEIFGTQGKPAIAHRDFKSRNVLVKSNLQCCIADLGLAVMHSQGSDYLDIGNNPRVGTKRYMAPEVLDEQIRTDCFESYKWTDIWAFGLVLWEIARRTIVNGIVEDYRPPFYDVVPNDPSFEDMKKVVCVDQQTPTIPNRLAADPVLSGLAQMMRECWYPNPSARLTALRIKKTLQKISNSPEKPKVIQ T36959 DRUGINFO D08JBL PF-03446962 Phase 2 T36959 DRUGINFO D0RF7O ML347 Investigative T36959 DRUGINFO D06CMG LDN-214117 Investigative T36959 DRUGINFO D05NEC PMID23639540C13r Investigative T36959 DRUGINFO D0F2MP PMID23639540C13d Investigative T36959 DRUGINFO D0PP6Y PMID23639540C13a Investigative T49989 TARGETID T49989 T49989 FORMERID TTDI02190 T49989 UNIPROID TGFR2_HUMAN T49989 TARGNAME TGF-beta receptor type II (TGFBR2) T49989 GENENAME TGFBR2 T49989 TARGTYPE Clinical trial T49989 SYNONYMS Transforminggrowth factor-beta receptor type II; Transforming growth factor-beta receptor type II; TbetaR-II; TGFR-2; TGF-beta type II receptor; TGF-beta receptor type-2 T49989 FUNCTION Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. T49989 PDBSTRUC 5TY4; 5TX4; 5QIN; 5E8Y; 5E8V T49989 BIOCLASS Kinase T49989 ECNUMBER EC 2.7.11.30 T49989 SEQUENCE MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYCYRVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDISSTCANNINHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYMAPEVLESRMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVESMKDNVLRDRGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSGRSCSEEKIPEDGSLNTTK T49989 DRUGINFO D0P7KU TGF-BR2 mab Phase 1 T49989 DRUGINFO D06KKN LY2109761 Investigative T49989 DRUGINFO D06BDC PMID16539403C15b Investigative T49989 DRUGINFO D0F2MP PMID23639540C13d Investigative T49989 DRUGINFO D0PP6Y PMID23639540C13a Investigative T03644 TARGETID T03644 T03644 FORMERID TTDI02186 T03644 UNIPROID SYUA_HUMAN T03644 TARGNAME Synuclein alpha (SNCA) T03644 GENENAME SNCA T03644 TARGTYPE Clinical trial T03644 SYNONYMS PARK1; Non-A4 component of amyloid precursor; Non-A beta component of AD amyloid; NACP; Alpha-synuclein T03644 FUNCTION Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis. Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. This chaperone activity is important to sustain normal SNARE-complex assembly during aging. Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity. T03644 PDBSTRUC 6H6B; 6FLT; 6CU8; 6CU7; 6CT7 T03644 BIOCLASS Synuclein T03644 SEQUENCE MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA T03644 DRUGINFO D05AEE RG7935 Phase 2 T03644 DRUGINFO D0TU9W BIIB054 Phase 2 T03644 DRUGINFO D4N2JV PRX002 Phase 2 T03644 DRUGINFO DA85YQ TAK-341 Phase 2 T03644 DRUGINFO D01UYA MEDI1341 Phase 1 T03644 DRUGINFO D05VAE Posiphen R-phenserine Phase 1 T03644 DRUGINFO D7G1JR UCB7853 Phase 1 T03644 DRUGINFO DIW37N NPT200-11 Phase 1 T03644 DRUGINFO DS8V3L Anle138b Phase 1 T03644 DRUGINFO D10KTZ SAR446159 Phase 1 T06182 TARGETID T06182 T06182 FORMERID TTDI02208 T06182 UNIPROID VIPR2_HUMAN T06182 TARGNAME Helodermin-preferring VIP receptor (VIPR2) T06182 GENENAME VIPR2 T06182 TARGTYPE Clinical trial T06182 SYNONYMS Vasoactive intestinal polypeptide receptor 2; VPAC2; VIPR2; VIP-R-2; Pituitary adenylate cyclase-activating polypeptide typeIII receptor; PACAP-R3; PACAP-R-3; PACAP type III receptor T06182 FUNCTION This is a receptor for VIP as well as PACAP-38 and -27,the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C. T06182 PDBSTRUC 2X57 T06182 BIOCLASS GPCR secretin T06182 SEQUENCE MRTLLPPALLTCWLLAPVNSIHPECRFHLEIQEEETKCAELLRSQTEKHKACSGVWDNITCWRPANVGETVTVPCPKVFSNFYSKAGNISKNCTSDGWSETFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVSLMSLATGSIILCLFRKLHCTRNYIHLNLFLSFILRAISVLVKDDVLYSSSGTLHCPDQPSSWVGCKLSLVFLQYCIMANFFWLLVEGLYLHTLLVAMLPPRRCFLAYLLIGWGLPTVCIGAWTAARLYLEDTGCWDTNDHSVPWWVIRIPILISIIVNFVLFISIIRILLQKLTSPDVGGNDQSQYKRLAKSTLLLIPLFGVHYMVFAVFPISISSKYQILFELCLGSFQGLVVAVLYCFLNSEVQCELKRKWRSRCPTPSASRDYRVCGSSFSRNGSEGALQFHRGSRAQSFLQTETSVI T06182 DRUGINFO D0G9JQ PB1046 Phase 2 T06182 DRUGINFO D0S7UQ RG-7103 Phase 1 T06182 DRUGINFO D03BFX PB-1120 Investigative T06182 DRUGINFO D0B2MN helodermin Investigative T06182 DRUGINFO D0MC5J PACAP-27 Investigative T42854 TARGETID T42854 T42854 FORMERID TTDI02338 T42854 UNIPROID MAGA1_HUMAN T42854 TARGNAME Melanoma-associated antigen 1 (MAGEA1) T42854 GENENAME MAGEA1 T42854 TARGTYPE Clinical trial T42854 SYNONYMS Melanomaassociated antigen 1; MAGE1A; MAGE1 antigen; MAGE1; MAGE-1 antigen; Cancer/testis antigen 1.1; CT1.1; Antigen MZ2E; Antigen MZ2-E T42854 FUNCTION May inhibit notch intracellular domain (NICD) transactivation. May play a role in embryonal development and tumor transformation or aspects of tumor progression. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. May be involved in transcriptional regulation through interaction with SNW1 and recruiting histone deactelyase HDAC1. T42854 PDBSTRUC 3BO8; 1W72 T42854 BIOCLASS Melanoma associated antigen T42854 SEQUENCE MSLEQRSLHCKPEEALEAQQEALGLVCVQAATSSSSPLVLGTLEEVPTAGSTDPPQSPQGASAFPTTINFTRQRQPSEGSSSREEEGPSTSCILESLFRAVITKKVADLVGFLLLKYRAREPVTKAEMLESVIKNYKHCFPEIFGKASESLQLVFGIDVKEADPTGHSYVLVTCLGLSYDGLLGDNQIMPKTGFLIIVLVMIAMEGGHAPEEEIWEELSVMEVYDGREHSAYGEPRKLLTQDLVQEKYLEYRQVPDSDPARYEFLWGPRALAETSYVKVLEYVIKVSARVRFFFPSLREAALREEEEGV T42854 DRUGINFO D0NA4J CAR-T cells targeting MAGE-A1 Phase 1/2 T42854 DRUGINFO D0C1EO Melanoma vaccine (ALVAC) Discontinued in Phase 2 T92124 TARGETID T92124 T92124 FORMERID TTDC00219 T92124 UNIPROID TNR4_HUMAN T92124 TARGNAME OX40L receptor (CD134) T92124 GENENAME TNFRSF4 T92124 TARGTYPE Clinical trial T92124 SYNONYMS Tumor necrosis factor receptor superfamily member 4; TXGP1L; TAX transcriptionally-activated glycoprotein 1 receptor; CD134; ACT35 antigen T92124 FUNCTION Receptor for TNFSF4/OX40L/GP34. Is a costimulatory molecule implicated in long-term T-cell immunity. T92124 PDBSTRUC 2HEY; 2HEV; 1D0A T92124 SEQUENCE MCVGARRLGRGPCAALLLLGLGLSTVTGLHCVGDTYPSNDRCCHECRPGNGMVSRCSRSQNTVCRPCGPGFYNDVVSSKPCKPCTWCNLRSGSERKQLCTATQDTVCRCRAGTQPLDSYKPGVDCAPCPPGHFSPGDNQACKPWTNCTLAGKHTLQPASNSSDAICEDRDPPATQPQETQGPPARPITVQPTEAWPRTSQGPSTRPVEVPGGRAVAAILGLGLVLGLLGPLAILLALYLLRRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI T92124 DRUGINFO D03AKW Rocatinlimab Phase 3 T92124 DRUGINFO D03DUI GBR 830 Phase 2 T92124 DRUGINFO D0E5WX PF-04518600 Phase 2 T92124 DRUGINFO DVCN93 INCAGN01949 Phase 2 T92124 DRUGINFO D03SXI INCAGN1949 Phase 1/2 T92124 DRUGINFO D0YG4P Anti-OX40 mab Phase 1 T92124 DRUGINFO D0ZO5K MEDI0562 Phase 1 T92124 DRUGINFO DBZ87Q BGB-A445 Phase 1 T92124 DRUGINFO DF6BU4 YH002 Phase 1 T92124 DRUGINFO D0U0EC TRemelimumab + MEDI0562 Phase 1 T92124 DRUGINFO D9SL1N TAK-252 Phase 1 T92124 DRUGINFO DZ7EG5 YH006 Investigative T71928 TARGETID T71928 T71928 FORMERID TTDI02105 T71928 UNIPROID KI2L1_HUMAN T71928 TARGNAME MHC class I NK cell receptor 2DL1 (CD158A) T71928 GENENAME KIR2DL1 T71928 TARGTYPE Clinical trial T71928 SYNONYMS p58.1 MHC class-I-specific NK receptor; p58 natural killer cell receptor clones CL-42/47.11; p58 NK receptor CL-42/47.11; Natural killer-associated transcript 1; NKAT1; NKAT-1; Killer cell immunoglobulin-like receptor 2DL1; CD158A; CD158 antigen-like family member A T71928 FUNCTION Receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6. Inhibits the activity of NK cells thus preventing cell lysis. T71928 PDBSTRUC 1NKR; 1IM9 T71928 BIOCLASS Immunoglobulin T71928 SEQUENCE MSLLVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVMFEHFLLHREGMFNDTLRLIGEHHDGVSKANFSISRMTQDLAGTYRCYGSVTHSPYQVSAPSDPLDIVIIGLYEKPSLSAQPGPTVLAGENVTLSCSSRSSYDMYHLSREGEAHERRLPAGPKVNGTFQADFPLGPATHGGTYRCFGSFHDSPYEWSKSSDPLLVSVTGNPSNSWPSPTEPSSKTGNPRHLHILIGTSVVIILFILLFFLLHRWCSNKKNAAVMDQESAGNRTANSEDSDEQDPQEVTYTQLNHCVFTQRKITRPSQRPKTPPTDIIVYTELPNAESRSKVVSCP T71928 DRUGINFO D00RYU IPH-2102 Phase 2 T71928 DRUGINFO D08XPN mab 1-7F9 Phase 2 T71928 DRUGINFO D04IXD IPH-2101 Phase 2 T54902 TARGETID T54902 T54902 FORMERID TTDI02106 T54902 UNIPROID KI2L2_HUMAN T54902 TARGNAME MHC class I NK cell receptor 2DL2 (CD158b1) T54902 GENENAME KIR2DL2 T54902 TARGTYPE Clinical trial T54902 SYNONYMS p58 natural killer cell receptor clone CL-43; p58 NK receptor CL-43; Natural killer-associated transcript 6; NKAT6; NKAT-6; Killer cell immunoglobulin-like receptor 2DL2; CD158B1; CD158 antigen-like family member B1 T54902 FUNCTION Receptor on natural killer (NK) cells for HLA-Cw1, 3, 7, and 8 allotypes. Inhibits the activity of NK cells thus preventing cell lysis. T54902 PDBSTRUC 2DLI; 2DL2; 1EFX T54902 BIOCLASS Immunoglobulin T54902 SEQUENCE MSLMVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGRLVKSEETVILQCWSDVRFEHFLLHREGKFKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHECRFSAGPKVNGTFQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVIGNPSNSWPSPTEPSSKTGNPRHLHILIGTSVVIILFILLFFLLHRWCSNKKNAAVMDQESAGNRTANSEDSDEQDPQEVTYTQLNHCVFTQRKITRPSQRPKTPPTDIIVYAELPNAESRSKVVSCP T54902 DRUGINFO D00RYU IPH-2102 Phase 2 T54902 DRUGINFO D08XPN mab 1-7F9 Phase 2 T54902 DRUGINFO D04IXD IPH-2101 Phase 2 T53472 TARGETID T53472 T53472 FORMERID TTDI02107 T53472 UNIPROID KI2L3_HUMAN T53472 TARGNAME MHC class I NK cell receptor 2DL3 (CD158b2) T53472 GENENAME KIR2DL3 T53472 TARGTYPE Clinical trial T53472 SYNONYMS p58.2 MHC class-I-specific NK receptor; p58 natural killer cell receptor clone CL-6; p58 NK receptor CL-6; Natural killer-associated transcript 2; NKAT2b; NKAT2a; NKAT2; NKAT-2; Killer inhibitory receptor cl 2-3; Killer cell immunoglobulin-like receptor 2DL3; KIRCL23; KIR-023GB; CD158B2; CD158 antigen-like family member B2 T53472 FUNCTION Receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). Inhibits the activity of NK cells thus preventing cell lysis. T53472 PDBSTRUC 1B6U T53472 BIOCLASS Immunoglobulin T53472 SEQUENCE MSLMVVSMVCVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVRFQHFLLHREGKFKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHERRFSAGPKVNGTFQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVTGNPSNSWPSPTEPSSETGNPRHLHVLIGTSVVIILFILLLFFLLHRWCCNKKNAVVMDQEPAGNRTVNREDSDEQDPQEVTYAQLNHCVFTQRKITRPSQRPKTPPTDIIVYTELPNAEP T53472 DRUGINFO D00RYU IPH-2102 Phase 2 T53472 DRUGINFO D08XPN mab 1-7F9 Phase 2 T53472 DRUGINFO D04IXD IPH-2101 Phase 2 T58589 TARGETID T58589 T58589 FORMERID TTDR00405 T58589 UNIPROID BKRB1_HUMAN T58589 TARGNAME B1 bradykinin receptor (BDKRB1) T58589 GENENAME BDKRB1 T58589 TARGTYPE Clinical trial T58589 SYNONYMS BRADYB1; BK-1 receptor; B1R T58589 FUNCTION This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation. T58589 BIOCLASS GPCR rhodopsin T58589 SEQUENCE MASSWPPLELQSSNQSQLFPQNATACDNAPEAWDLLHRVLPTFIISICFFGLLGNLFVLLVFLLPRRQLNVAEIYLANLAASDLVFVLGLPFWAENIWNQFNWPFGALLCRVINGVIKANLFISIFLVVAISQDRYRVLVHPMASRRQQRRRQARVTCVLIWVVGGLLSIPTFLLRSIQAVPDLNITACILLLPHEAWHFARIVELNILGFLLPLAAIVFFNYHILASLRTREEVSRTRCGGRKDSKTTALILTLVVAFLVCWAPYHFFAFLEFLFQVQAVRGCFWEDFIDLGLQLANFFAFTNSSLNPVIYVFVGRLFRTKVWELYKQCTPKSLAPISSSHRKEIFQLFWRN T58589 DRUGINFO D03UVL SSR-240612 Phase 2 T58589 DRUGINFO D06BHG Safotibant Phase 2 T58589 DRUGINFO D0R9HE BI 113823 Phase 1 T58589 DRUGINFO D01FAA Ac-Lys-[Leu(8)]-des-Arg(9)-BK Investigative T58589 DRUGINFO D04KFR NVP-SAA164 Investigative T58589 DRUGINFO D05TZN Des-Arg10-Kallidin Investigative T58589 DRUGINFO D0V0LY Des-Arg10-Leu9-Kallidin Investigative T58589 DRUGINFO D00FAE H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638) Investigative T58589 DRUGINFO D02DGP H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669) Investigative T58589 DRUGINFO D04KWH Des-Arg(9)-[Leu(8)]-BK Investigative T58589 DRUGINFO D0C3KW H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645) Investigative T58589 DRUGINFO D0N2GM JMV1431 Investigative T72120 TARGETID T72120 T72120 FORMERID TTDI02205 T72120 UNIPROID UTRO_HUMAN T72120 TARGNAME Utrophin (UTRN) T72120 GENENAME UTRN T72120 TARGTYPE Clinical trial T72120 SYNONYMS Dystrophin-related protein 1; DRP1; DRP-1; DMDL T72120 FUNCTION May play a role in anchoring the cytoskeleton to the plasma membrane. T72120 PDBSTRUC 1QAG; 1BHD T72120 BIOCLASS Zinc-finger T72120 SEQUENCE MAKYGEHEASPDNGQNEFSDIIKSRSDEHNDVQKKTFTKWINARFSKSGKPPINDMFTDLKDGRKLLDLLEGLTGTSLPKERGSTRVHALNNVNRVLQVLHQNNVELVNIGGTDIVDGNHKLTLGLLWSIILHWQVKDVMKDVMSDLQQTNSEKILLSWVRQTTRPYSQVNVLNFTTSWTDGLAFNAVLHRHKPDLFSWDKVVKMSPIERLEHAFSKAQTYLGIEKLLDPEDVAVQLPDKKSIIMYLTSLFEVLPQQVTIDAIREVETLPRKYKKECEEEAINIQSTAPEEEHESPRAETPSTVTEVDMDLDSYQIALEEVLTWLLSAEDTFQEQDDISDDVEEVKDQFATHEAFMMELTAHQSSVGSVLQAGNQLITQGTLSDEEEFEIQEQMTLLNARWEALRVESMDRQSRLHDVLMELQKKQLQQLSAWLTLTEERIQKMETCPLDDDVKSLQKLLEEHKSLQSDLEAEQVKVNSLTHMVVIVDENSGESATAILEDQLQKLGERWTAVCRWTEERWNRLQEINILWQELLEEQCLLKAWLTEKEEALNKVQTSNFKDQKELSVSVRRLAILKEDMEMKRQTLDQLSEIGQDVGQLLDNSKASKKINSDSEELTQRWDSLVQRLEDSSNQVTQAVAKLGMSQIPQKDLLETVRVREQAITKKSKQELPPPPPPKKRQIHVDIEAKKKFDAISAELLNWILKWKTAIQTTEIKEYMKMQDTSEMKKKLKALEKEQRERIPRADELNQTGQILVEQMGKEGLPTEEIKNVLEKVSSEWKNVSQHLEDLERKIQLQEDINAYFKQLDELEKVIKTKEEWVKHTSISESSRQSLPSLKDSCQRELTNLLGLHPKIEMARASCSALMSQPSAPDFVQRGFDSFLGRYQAVQEAVEDRQQHLENELKGQPGHAYLETLKTLKDVLNDSENKAQVSLNVLNDLAKVEKALQEKKTLDEILENQKPALHKLAEETKALEKNVHPDVEKLYKQEFDDVQGKWNKLKVLVSKDLHLLEEIALTLRAFEADSTVIEKWMDGVKDFLMKQQAAQGDDAGLQRQLDQCSAFVNEIETIESSLKNMKEIETNLRSGPVAGIKTWVQTRLGDYQTQLEKLSKEIATQKSRLSESQEKAANLKKDLAEMQEWMTQAEEEYLERDFEYKSPEELESAVEEMKRAKEDVLQKEVRVKILKDNIKLLAAKVPSGGQELTSELNVVLENYQLLCNRIRGKCHTLEEVWSCWIELLHYLDLETTWLNTLEERMKSTEVLPEKTDAVNEALESLESVLRHPADNRTQIRELGQTLIDGGILDDIISEKLEAFNSRYEDLSHLAESKQISLEKQLQVLRETDQMLQVLQESLGELDKQLTTYLTDRIDAFQVPQEAQKIQAEISAHELTLEELRRNMRSQPLTSPESRTARGGSQMDVLQRKLREVSTKFQLFQKPANFEQRMLDCKRVLDGVKAELHVLDVKDVDPDVIQTHLDKCMKLYKTLSEVKLEVETVIKTGRHIVQKQQTDNPKGMDEQLTSLKVLYNDLGAQVTEGKQDLERASQLARKMKKEAASLSEWLSATETELVQKSTSEGLLGDLDTEISWAKNVLKDLEKRKADLNTITESSAALQNLIEGSEPILEERLCVLNAGWSRVRTWTEDWCNTLMNHQNQLEIFDGNVAHISTWLYQAEALLDEIEKKPTSKQEEIVKRLVSELDDANLQVENVRDQALILMNARGSSSRELVEPKLAELNRNFEKVSQHIKSAKLLIAQEPLYQCLVTTETFETGVPFSDLEKLENDIENMLKFVEKHLESSDEDEKMDEESAQIEEVLQRGEEMLHQPMEDNKKEKIRLQLLLLHTRYNKIKAIPIQQRKMGQLASGIRSSLLPTDYLVEINKILLCMDDVELSLNVPELNTAIYEDFSFQEDSLKNIKDQLDKLGEQIAVIHEKQPDVILEASGPEAIQIRDTLTQLNAKWDRINRMYSDRKGCFDRAMEEWRQFHCDLNDLTQWITEAEELLVDTCAPGGSLDLEKARIHQQELEVGISSHQPSFAALNRTGDGIVQKLSQADGSFLKEKLAGLNQRWDAIVAEVKDRQPRLKGESKQVMKYRHQLDEIICWLTKAEHAMQKRSTTELGENLQELRDLTQEMEVHAEKLKWLNRTELEMLSDKSLSLPERDKISESLRTVNMTWNKICREVPTTLKECIQEPSSVSQTRIAAHPNVQKVVLVSSASDIPVQSHRTSEISIPADLDKTITELADWLVLIDQMLKSNIVTVGDVEEINKTVSRMKITKADLEQRHPQLDYVFTLAQNLKNKASSSDMRTAITEKLERVKNQWDGTQHGVELRQQQLEDMIIDSLQWDDHREETEELMRKYEARLYILQQARRDPLTKQISDNQILLQELGPGDGIVMAFDNVLQKLLEEYGSDDTRNVKETTEYLKTSWINLKQSIADRQNALEAEWRTVQASRRDLENFLKWIQEAETTVNVLVDASHRENALQDSILARELKQQMQDIQAEIDAHNDIFKSIDGNRQKMVKALGNSEEATMLQHRLDDMNQRWNDLKAKSASIRAHLEASAEKWNRLLMSLEELIKWLNMKDEELKKQMPIGGDVPALQLQYDHCKALRRELKEKEYSVLNAVDQARVFLADQPIEAPEEPRRNLQSKTELTPEERAQKIAKAMRKQSSEVKEKWESLNAVTSNWQKQVDKALEKLRDLQGAMDDLDADMKEAESVRNGWKPVGDLLIDSLQDHIEKIMAFREEIAPINFKVKTVNDLSSQLSPLDLHPSLKMSRQLDDLNMRWKLLQVSVDDRLKQLQEAHRDFGPSSQHFLSTSVQLPWQRSISHNKVPYYINHQTQTTCWDHPKMTELFQSLADLNNVRFSAYRTAIKIRRLQKALCLDLLELSTTNEIFKQHKLNQNDQLLSVPDVINCLTTTYDGLEQMHKDLVNVPLCVDMCLNWLLNVYDTGRTGKIRVQSLKIGLMSLSKGLLEEKYRYLFKEVAGPTEMCDQRQLGLLLHDAIQIPRQLGEVAAFGGSNIEPSVRSCFQQNNNKPEISVKEFIDWMHLEPQSMVWLPVLHRVAAAETAKHQAKCNICKECPIVGFRYRSLKHFNYDVCQSCFFSGRTAKGHKLHYPMVEYCIPTTSGEDVRDFTKVLKNKFRSKKYFAKHPRLGYLPVQTVLEGDNLETPITLISMWPEHYDPSQSPQLFHDDTHSRIEQYATRLAQMERTNGSFLTDSSSTTGSVEDEHALIQQYCQTLGGESPVSQPQSPAQILKSVEREERGELERIIADLEEEQRNLQVEYEQLKDQHLRRGLPVGSPPESIISPHHTSEDSELIAEAKLLRQHKGRLEARMQILEDHNKQLESQLHRLRQLLEQPESDSRINGVSPWASPQHSALSYSLDPDASGPQFHQAAGEDLLAPPHDTSTDLTEVMEQIHSTFPSCCPNVPSRPQAM T72120 DRUGINFO D0Y7YD SMT-C1100 Phase 2 T14834 TARGETID T14834 T14834 FORMERID TTDR00443 T14834 UNIPROID PA24A_HUMAN T14834 TARGNAME Cytosolic phospholipase A2 (GIVA cPLA2) T14834 GENENAME PLA2G4A T14834 TARGTYPE Clinical trial T14834 SYNONYMS Phospholipase A2 group IVA; PLA2G4; CPLA2 T14834 FUNCTION Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response. Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. T14834 PDBSTRUC 1RLW; 1CJY; 1BCI T14834 BIOCLASS Carboxylic ester hydrolase T14834 SEQUENCE MSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRTRHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEVPFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEGLHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSHPDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIGETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYGTFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEELENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFNTREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDVKSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMNKLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYRAPGVPRETEEEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRRQNPSRCSVSLSNVEARRFFNKEFLSKPKA T14834 DRUGINFO D02XBN ZPL521 Phase 1/2 T14834 DRUGINFO D0E1WY EFIPLADIB Terminated T14834 DRUGINFO D00GQP AX-006 Investigative T14834 DRUGINFO D01GZV N-(4-Ethoxybutyl)-2-oxohexadecanamide Investigative T14834 DRUGINFO D02GTZ [3,4''']biflavone Investigative T14834 DRUGINFO D03DIV 1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one Investigative T14834 DRUGINFO D03FQJ 1,1,1,3-Tetrafluoro-7-phenylheptan-2-one Investigative T14834 DRUGINFO D03NYE 4-(2-oxohexadecanamido)butanoic acid Investigative T14834 DRUGINFO D05BTF Tert-Butyl 5-(2-oxohexadecanamido)pentanoate Investigative T14834 DRUGINFO D05GUD AX-048 Investigative T14834 DRUGINFO D05LWK [6,4''']biflavone Investigative T14834 DRUGINFO D05MUN 1,1,1,2,2-Pentafluoro-9-phenyl-nonan-3-one Investigative T14834 DRUGINFO D05TGU 1,1,1,3-Tetrafluoro-6-phenylhexan-2-one Investigative T14834 DRUGINFO D05TZP Tert-Butyl 3-(2-oxo-8-phenyloctanamido)propanoate Investigative T14834 DRUGINFO D06OXA Tert-Butyl 3-(2-oxohexadecanamido)propanoate Investigative T14834 DRUGINFO D06XFP 1,1,1-Trifluoro-6-(4-hexyloxy-phenyl)-hexan-2-one Investigative T14834 DRUGINFO D07QSM Methyl 2-(2-oxohexadecanamido)acetate Investigative T14834 DRUGINFO D07TCK Tert-Butyl 2-(2-oxohexadecanamido)acetate Investigative T14834 DRUGINFO D07VJT [6,3''']biflavone Investigative T14834 DRUGINFO D08SIJ 1,1,1-Trifluoro-4-(4-hexyloxy-phenyl)-butan-2-one Investigative T14834 DRUGINFO D09CVD 1,1,1,3-Tetrafluoro-heptadecan-2-one Investigative T14834 DRUGINFO D09ZUX 1,1,1,2,2,4-hexafluoro-7-phenylheptan-3-one Investigative T14834 DRUGINFO D0B2RW (S)-Ethyl 6-(2-oxohexadecanamido)decanoate Investigative T14834 DRUGINFO D0D2SE (Z)-1,1,1,2,2,3,3-heptafluorohenicos-12-en-4-one Investigative T14834 DRUGINFO D0F4WJ 6-(4-Decyloxy-phenyl)-1,1,1-trifluoro-hexan-2-one Investigative T14834 DRUGINFO D0F7IW 1,1,1-Trifluoro-5-(4-octylphenoxy)pentan-2-one Investigative T14834 DRUGINFO D0F9PM WAY-196025 Investigative T14834 DRUGINFO D0K0HD Ethyl 2-(2-oxohexadecanamido)acetate Investigative T14834 DRUGINFO D0K2PI (S)-Methyl 4-(2-oxohexadecanamido)octanoate Investigative T14834 DRUGINFO D0L6GV [4',4''']-biflavone Investigative T14834 DRUGINFO D0ND4N Allyl 4-(2-oxohexadecanamido)butanoate Investigative T14834 DRUGINFO D0P5UW ECOPLADIB Investigative T14834 DRUGINFO D0P9CN 1,1,1,2,2,3,3,5-octafluoro-8-phenyloctan-4-one Investigative T14834 DRUGINFO D0PP8T Methyl 2-(2-oxo-8-phenyloctanamido)acetate Investigative T14834 DRUGINFO D0Q1LD Ethyl 4-(2-oxohexadecanamido)benzoate Investigative T14834 DRUGINFO D0R3AA 1,1,1-trifluoroheptadecan-2-one Investigative T14834 DRUGINFO D0U1YU (S)-tert-Butyl 4-(2-oxohexadecanamido)pentanoate Investigative T14834 DRUGINFO D0U2GX 4-(4-Decyloxy-phenyl)-1,1,1-trifluoro-butan-2-one Investigative T14834 DRUGINFO D0U2QY 1,1,1,2,2-Pentafluoro-8-phenyl-octan-3-one Investigative T14834 DRUGINFO D0UV2N 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-ol Investigative T14834 DRUGINFO D0V6QA Methyl arachidonyl fluorophosphonate Investigative T14834 DRUGINFO D08YHD 1,1,1-Trifluoro-7-phenylheptan-2-one Investigative T14834 DRUGINFO D0J8TY ARACHIDONYL TRIFLUOROMETHYLKETONE Investigative T14834 DRUGINFO D0N1CK 1,1,1-Trifluoro-8-phenyl-octan-2-one Investigative T14834 DRUGINFO D0W4VM AR-C70484XX Investigative T14834 DRUGINFO D0Y2BD 1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one Investigative T70201 TARGETID T70201 T70201 FORMERID TTDI02081 T70201 UNIPROID GLIP1_HUMAN T70201 TARGNAME Glioma pathogenesis-related protein 1 (GLIPR1) T70201 GENENAME GLIPR1 T70201 TARGTYPE Clinical trial T70201 SYNONYMS RTVP1; Protein RTVP-1; GliPR 1; GLIPR T70201 FUNCTION Similarity to both the pathogenesis-related protein (PR) superfamily and the cysteine-rich secretory protein (CRISP) family T70201 PDBSTRUC 3Q2U; 3Q2R T70201 BIOCLASS Cysteine-rich secretory protein T70201 SEQUENCE MRVTLATIAWMVSFVSNYSHTANILPDIENEDFIKDCVRIHNKFRSEVKPTASDMLYMTWDPALAQIAKAWASNCQFSHNTRLKPPHKLHPNFTSLGENIWTGSVPIFSVSSAITNWYDEIQDYDFKTRICKKVCGHYTQVVWADSYKVGCAVQFCPKVSGFDALSNGAHFICNYGPGGNYPTWPYKRGATCSACPNNDKCLDNLCVNRQRDQVKRYYSVVYPGWPIYPRNRYTSLFLIVNSVILILSVIITILVQHKYPNLVLLD T70201 DRUGINFO D09RZH AdRTVP-1 Phase 1 T69685 TARGETID T69685 T69685 FORMERID TTDC00227 T69685 UNIPROID SC6A9_HUMAN T69685 TARGNAME Glycine transporter GlyT-1 (SLC6A9) T69685 GENENAME SLC6A9 T69685 TARGTYPE Clinical trial T69685 SYNONYMS Solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1; Glycine type-1 transporter; Glycine transporter type 1; GlyT1; GlyT-1 T69685 FUNCTION May play a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission. Terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. T69685 BIOCLASS Neurotransmitter:sodium symporter T69685 SEQUENCE MSGGDTRAAIARPRMAAAHGPVAPSSPEQVTLLPVQRSFFLPPFSGATPSTSLAESVLKVWHGAYNSGLLPQLMAQHSLAMAQNGAVPSEATKRDQNLKRGNWGNQIEFVLTSVGYAVGLGNVWRFPYLCYRNGGGAFMFPYFIMLIFCGIPLFFMELSFGQFASQGCLGVWRISPMFKGVGYGMMVVSTYIGIYYNVVICIAFYYFFSSMTHVLPWAYCNNPWNTHDCAGVLDASNLTNGSRPAALPSNLSHLLNHSLQRTSPSEEYWRLYVLKLSDDIGNFGEVRLPLLGCLGVSWLVVFLCLIRGVKSSGKVVYFTATFPYVVLTILFVRGVTLEGAFDGIMYYLTPQWDKILEAKVWGDAASQIFYSLGCAWGGLITMASYNKFHNNCYRDSVIISITNCATSVYAGFVIFSILGFMANHLGVDVSRVADHGPGLAFVAYPEALTLLPISPLWSLLFFFMLILLGLGTQFCLLETLVTAIVDEVGNEWILQKKTYVTLGVAVAGFLLGIPLTSQAGIYWLLLMDNYAASFSLVVISCIMCVAIMYIYGHRNYFQDIQMMLGFPPPLFFQICWRFVSPAIIFFILVFTVIQYQPITYNHYQYPGWAVAIGFLMALSSVLCIPLYAMFRLCRTDGDTLLQRLKNATKPSRDWGPALLEHRTGRYAPTIAPSPEDGFEVQPLHPDKAQIPIVGSNGSSRLQDSRI T69685 DRUGINFO D0B6IZ R1678 Phase 3 T69685 DRUGINFO D76PDV BI 425809 Phase 3 T69685 DRUGINFO DJOU19 Iclepertin Phase 3 T69685 DRUGINFO D04NIZ AMG 747 Phase 2 T69685 DRUGINFO D0LT0U ORG-25935 Phase 2 T69685 DRUGINFO D0O0BM PF-3463275 Phase 2 T69685 DRUGINFO D02XSL GlyT1 PET radiotracers Phase 1 T69685 DRUGINFO D05WWJ ALX-5407 Phase 1 T69685 DRUGINFO D0F4NP JNJ-17305600 Phase 1 T69685 DRUGINFO D0R8HY DCCCyB Phase 1 T69685 DRUGINFO D0Y3AZ MK-2637 Phase 1 T69685 DRUGINFO D00JEC PMID29338548-Compound-24 Patented T69685 DRUGINFO D01IJO PMID29338548-Compound-25 Patented T69685 DRUGINFO D02TZT PMID29338548-Compound-17 Patented T69685 DRUGINFO D03PQS PMID29338548-Compound-38 Patented T69685 DRUGINFO D06BUG PMID29338548-Compound-41 Patented T69685 DRUGINFO D06OSE PMID29338548-Compound-39 Patented T69685 DRUGINFO D07GSH PMID29338548-Compound-31 Patented T69685 DRUGINFO D08GXR PMID29338548-Compound-18 Patented T69685 DRUGINFO D08UQK PMID29338548-Compound-29 Patented T69685 DRUGINFO D0B5NJ PMID29338548-Compound-46 Patented T69685 DRUGINFO D0E2VI PMID29338548-Compound-36 Patented T69685 DRUGINFO D0EF0P PMID29338548-Compound-23 Patented T69685 DRUGINFO D0EV6V PMID29338548-Compound-15 Patented T69685 DRUGINFO D0FG2H PMID29338548-Compound-26 Patented T69685 DRUGINFO D0GX8J PMID29338548-Compound-34 Patented T69685 DRUGINFO D0H2KL PMID29338548-Compound-13 Patented T69685 DRUGINFO D0H5VO PMID29338548-Compound-27 Patented T69685 DRUGINFO D0H5WE PMID29338548-Compound-30 Patented T69685 DRUGINFO D0I7AJ PMID29338548-Compound-14 Patented T69685 DRUGINFO D0K6CM PMID29338548-Compound-16 Patented T69685 DRUGINFO D0M6PI PMID29338548-Compound-44 Patented T69685 DRUGINFO D0MT4C PMID29338548-Compound-48 Patented T69685 DRUGINFO D0S6BG PMID29338548-Compound-20 Patented T69685 DRUGINFO D0T1BE PMID29338548-Compound-33 Patented T69685 DRUGINFO D0T2QP PMID29338548-Compound-22 Patented T69685 DRUGINFO D0V5KY PMID29338548-Compound-45 Patented T69685 DRUGINFO D0W2YK PMID29338548-Compound-40 Patented T69685 DRUGINFO D0W7FS PMID29338548-Compound-21 Patented T69685 DRUGINFO D0WT3F PMID29338548-Compound-37 Patented T69685 DRUGINFO D0X1ZA PMID29338548-Compound-28 Patented T69685 DRUGINFO D0XG8H PMID29338548-Compound-49 Patented T69685 DRUGINFO D0XS1I PMID29338548-Compound-47 Patented T69685 DRUGINFO D0Y9FA PMID29338548-Compound-19 Patented T69685 DRUGINFO D0WY2L GSK1018921 Discontinued in Phase 1 T69685 DRUGINFO D06SBS SSR-504734 Preclinical T69685 DRUGINFO D07PNC Organon Preclinical T69685 DRUGINFO D0I6JG Organon-3 Preclinical T69685 DRUGINFO D0O5ZT Organon-2 Preclinical T69685 DRUGINFO D0U1HP Org-24461 Preclinical T69685 DRUGINFO D0Y9KR SSR-103800 Preclinical T69685 DRUGINFO D00CFU RO-4840700 Investigative T69685 DRUGINFO D07IYZ [3H](R)-NPTS Investigative T69685 DRUGINFO D07PKH GSK931145 Investigative T69685 DRUGINFO D08AYM [3H]NFPS Investigative T69685 DRUGINFO D09FDV [35S]ACPPB Investigative T69685 DRUGINFO D0GI5V [3H]N-methyl-SSR504734 Investigative T69685 DRUGINFO D0H7RV [3H]SB-733993 Investigative T69685 DRUGINFO D0I5ZO AS-1522489-00 Investigative T69685 DRUGINFO D0O8LR [3H]GSK931145 Investigative T69685 DRUGINFO D0U1CN LY2365109 Investigative T21307 TARGETID T21307 T21307 FORMERID TTDI02119 T21307 UNIPROID MAPK2_HUMAN T21307 TARGNAME MAPK-activated protein kinase 2 (MAPKAPK2) T21307 GENENAME MAPKAPK2 T21307 TARGTYPE Clinical trial T21307 SYNONYMS MK2; MK-2; MAPKactivated protein kinase 2; MAPKAPK-2; MAPKAP-K2; MAPKAP kinase 2; MAP kinaseactivated protein kinase 2; MAP kinase-activated protein kinase 2 T21307 FUNCTION Following stress, it is phosphorylated and activated by MAP kinase p38-alpha/MAPK14, leading to phosphorylation of substrates. Phosphorylates serine in the peptide sequence, Hyd-X-R-X(2)-S, where Hyd is a large hydrophobic residue. Phosphorylates ALOX5, CDC25B, CDC25C, CEP131, ELAVL1, HNRNPA0, HSP27/HSPB1, KRT18, KRT20, LIMK1, LSP1, PABPC1, PARN, PDE4A, RCSD1, RPS6KA3, TAB3 and TTP/ZFP36. Phosphorylates HSF1; leading to the interaction with HSP90 proteins and inhibiting HSF1 homotrimerization, DNA-binding and transactivation activities. Mediates phosphorylation of HSP27/HSPB1 in response to stress, leading to the dissociation of HSP27/HSPB1 from large small heat-shock protein (sHsps) oligomers and impairment of their chaperone activities and ability to protect against oxidative stress effectively. Involved in inflammatory response by regulating tumor necrosis factor (TNF) and IL6 production post-transcriptionally: acts by phosphorylating AU-rich elements (AREs)-binding proteins ELAVL1, HNRNPA0, PABPC1 and TTP/ZFP36, leading to the regulation of the stability and translation of TNF and IL6 mRNAs. Phosphorylation of TTP/ZFP36, a major post-transcriptional regulator of TNF, promotes its binding to 14-3-3 proteins and reduces its ARE mRNA affinity, leading to inhibition of dependent degradation of ARE-containing transcripts. Phosphorylates CEP131 in response to cellular stress induced by ultraviolet irradiation which promotes binding of CEP131 to 14-3-3 proteins and inhibits formation of novel centriolar satellites. Also involved in late G2/M checkpoint following DNA damage through a process of post-transcriptional mRNA stabilization: following DNA damage, relocalizes from nucleus to cytoplasm and phosphorylates HNRNPA0 and PARN, leading to stabilization of GADD45A mRNA. Involved in toll-like receptor signaling pathway (TLR) in dendritic cells: required for acute TLR-induced macropinocytosis by phosphorylating and activating RPS6KA3. Stress-activated serine/threonine-protein kinase involved in cytokine production, endocytosis, reorganization of the cytoskeleton, cell migration, cell cycle control, chromatin remodeling, DNA damage response and transcriptional regulation. T21307 PDBSTRUC 4TYH; 3WI6; 3R30; 3R2Y; 3R2B T21307 BIOCLASS Kinase T21307 ECNUMBER EC 2.7.11.1 T21307 SEQUENCE MLSNSQGQSPPVPFPAPAPPPQPPTPALPHPPAQPPPPPPQQFPQFHVKSGLQIKKNAIIDDYKVTSQVLGLGINGKVLQIFNKRTQEKFALKMLQDCPKARREVELHWRASQCPHIVRIVDVYENLYAGRKCLLIVMECLDGGELFSRIQDRGDQAFTEREASEIMKSIGEAIQYLHSINIAHRDVKPENLLYTSKRPNAILKLTDFGFAKETTSHNSLTTPCYTPYYVAPEVLGPEKYDKSCDMWSLGVIMYILLCGYPPFYSNHGLAISPGMKTRIRMGQYEFPNPEWSEVSEEVKMLIRNLLKTEPTQRMTITEFMNHPWIMQSTKVPQTPLHTSRVLKEDKERWEDVKEEMTSALATMRVDYEQIKIKKIEDASNPLLLKRRKKARALEAAALAH T21307 DRUGINFO DQ15ZM Zunsemetinib Phase 2 T21307 DRUGINFO D02NNN CBP-501 Phase 1/2 T21307 DRUGINFO D0S7NS MMI-0100 Phase 1 T21307 DRUGINFO D06QBJ PF-3644022 Investigative T21307 DRUGINFO D0O7UT CMPD1 Investigative T21307 DRUGINFO D0EW9J PMID17480064C16 Investigative T21307 DRUGINFO D01YWE PMID19364658C33 Investigative T10670 TARGETID T10670 T10670 FORMERID TTDC00040 T10670 UNIPROID NPY2R_HUMAN T10670 TARGNAME Neuropeptide Y receptor type 2 (NPY2R) T10670 GENENAME NPY2R T10670 TARGTYPE Clinical trial T10670 SYNONYMS Y2 receptor; NPY2R; NPY2-R; NPY-Y2 receptor T10670 FUNCTION Receptor for neuropeptide Y andpeptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PYY > NPY > PYY (3-36) > NPY (2-36) > [Ile-31, Gln-34] PP > [Leu- 31, Pro-34] NPY > PP, [Pro-34] PYY and NPY free acid. T10670 PDBSTRUC 2IK3 T10670 BIOCLASS GPCR rhodopsin T10670 SEQUENCE MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQVVLILAYCSIILLGVIGNSLVIHVVIKFKSMRTVTNFFIANLAVADLLVNTLCLPFTLTYTLMGEWKMGPVLCHLVPYAQGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLASPLAIFREYSLIEIIPDFEIVACTEKWPGEEKSIYGTVYSLSSLLILYVLPLGIISFSYTRIWSKLKNHVSPGAANDHYHQRRQKTTKMLVCVVVVFAVSWLPLHAFQLAVDIDSQVLDLKEYKLIFTVFHIIAMCSTFANPLLYGWMNSNYRKAFLSAFRCEQRLDAIHSEVSVTFKAKKNLEVRKNSGPNDSFTEATNV T10670 DRUGINFO D0I1KQ NEUROPEPTIDE-Y Phase 2 T10670 DRUGINFO D0S2LQ PYY3-36 Discontinued in Phase 2 T10670 DRUGINFO D07SWU TM30338 Discontinued in Phase 2 T10670 DRUGINFO D03WMK AC-162352 Discontinued in Phase 1 T10670 DRUGINFO D08MCT BMS-192548 Preclinical T10670 DRUGINFO DV7JX1 CIN-110 Preclinical T10670 DRUGINFO D02WBY JNJ-5207787 Investigative T10670 DRUGINFO D06ERA AcNPY(25-36) Investigative T10670 DRUGINFO D06GFZ BIIE0246 Investigative T10670 DRUGINFO D08ZRC AcPYY(25-36) Investigative T10670 DRUGINFO D0J1KG PD-4048 Investigative T10670 DRUGINFO D0Q2IU AcPYY(26-36) Investigative T10670 DRUGINFO D0RF9B PYY(25-36) Investigative T10670 DRUGINFO D0U1HE PEGylated PYY-3-36 Investigative T10670 DRUGINFO D02MKP AcPYY(22-36) Investigative T10670 DRUGINFO D07DJT LRHYLNLLTRQRY-NH2 Investigative T10670 DRUGINFO D0P9KP PYY(22-36) Investigative T10670 DRUGINFO D00OLA H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 Investigative T10670 DRUGINFO D07OOG Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T10670 DRUGINFO D08YWE Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T10670 DRUGINFO D0G4HT Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 Investigative T10670 DRUGINFO D0J9VA H-[Trp-Arg-Nva-Arg-Tyr]2-NH2 Investigative T10670 DRUGINFO D0V0HM Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T99204 TARGETID T99204 T99204 FORMERID TTDR00445 T99204 UNIPROID PSN2_HUMAN T99204 TARGNAME Presenilin 2 (PSEN2) T99204 GENENAME PSEN2 T99204 TARGTYPE Clinical trial T99204 SYNONYMS STM2; STM-2; Presenilin-2; PSNL2; PS-2; E5-1; AD5; AD4; AD3LP T99204 FUNCTION Requires the other members of the gamma-secretase complex to have a protease activity. May play a role in intracellular signaling and gene expression or in linking chromatin to the nuclear membrane. May function in the cytoplasmic partitioning of proteins. The holoprotein functions as a calcium-leak channel that allows the passive movement of calcium from endoplasmic reticulum to cytosol and is involved in calcium homeostasis. Is a regulator of mitochondrion-endoplasmic reticulum membrane tethering and modulates calcium ions shuttling between ER and mitochondria. Probable catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein). T99204 BIOCLASS Peptidase T99204 ECNUMBER EC 3.4.23.- T99204 SEQUENCE MLTFMASDSEEEVCDERTSLMSAESPTPRSCQEGRQGPEDGENTAQWRSQENEEDGEEDPDRYVCSGVPGRPPGLEEELTLKYGAKHVIMLFVPVTLCMIVVVATIKSVRFYTEKNGQLIYTPFTEDTPSVGQRLLNSVLNTLIMISVIVVMTIFLVVLYKYRCYKFIHGWLIMSSLMLLFLFTYIYLGEVLKTYNVAMDYPTLLLTVWNFGAVGMVCIHWKGPLVLQQAYLIMISALMALVFIKYLPEWSAWVILGAISVYDLVAVLCPKGPLRMLVETAQERNEPIFPALIYSSAMVWTVGMAKLDPSSQGALQLPYDPEMEEDSYDSFGEPSYPEVFEPPLTGYPGEELEEEEERGVKLGLGDFIFYSVLVGKAAATGSGDWNTTLACFVAILIGLCLTLLLLAVFKKALPALPISITFGLIFYFSTDNLVRPFMDTLASHQLYI T99204 DRUGINFO D0G2IC (S)-FLURBIPROFEN Preregistration T99204 DRUGINFO D05FGR R-flurbiprofen Phase 2 T99204 DRUGINFO D0K8LN 1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene Investigative T99204 DRUGINFO D00DFR (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone Investigative T99204 DRUGINFO D04TWU (5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone Investigative T99204 DRUGINFO D06TPT Drug 311951 Investigative T99204 DRUGINFO D09HAD Drug 311383 Investigative T99204 DRUGINFO D0I8BA 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one Investigative T99204 DRUGINFO D0M2LV (2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone Investigative T99204 DRUGINFO D0V7YM Drug 311952 Investigative T99204 DRUGINFO D0XQ2T Drug 311440 Investigative T27944 TARGETID T27944 T27944 FORMERID TTDC00043 T27944 UNIPROID NPY4R_HUMAN T27944 TARGNAME Neuropeptide Y receptor type 4 (NPY4R) T27944 GENENAME NPY4R T27944 TARGTYPE Clinical trial T27944 SYNONYMS Pancreatic polypeptide receptor 1; PPYR1; NPY4R; NPY4-R T27944 FUNCTION Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PP, PP (2-36) and [Ile-31, Gln-34] PP > [Pro-34] PYY > PYY and [Leu-31, Pro-34] NPY > NPY > PYY (3-36) and NPY (2-36) > PP (13- 36) > PP (31-36) > NPY free acid. T27944 PDBSTRUC 2IK5 T27944 BIOCLASS GPCR rhodopsin T27944 SEQUENCE MNTSHLLALLLPKSPQGENRSKPLGTPYNFSEHCQDSVDVMVFIVTSYSIETVVGVLGNLCLMCVTVRQKEKANVTNLLIANLAFSDFLMCLLCQPLTAVYTIMDYWIFGETLCKMSAFIQCMSVTVSILSLVLVALERHQLIINPTGWKPSISQAYLGIVLIWVIACVLSLPFLANSILENVFHKNHSKALEFLADKVVCTESWPLAHHRTIYTTFLLLFQYCLPLGFILVCYARIYRRLQRQGRVFHKGTYSLRAGHMKQVNVVLVVMVVAFAVLWLPLHVFNSLEDWHHEAIPICHGNLIFLVCHLLAMASTCVNPFIYGFLNTNFKKEIKALVLTCQQSAPLEESEHLPLSTVHTEVSKGSLRLSGRSNPI T27944 DRUGINFO D0B7QP TM30339 Discontinued in Phase 2 T27944 DRUGINFO D07SWU TM30338 Discontinued in Phase 2 T27944 DRUGINFO D0CE5S PD-4074 Investigative T27944 DRUGINFO D07BCH [Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T27944 DRUGINFO D0H8KI [125I]GR231118 Investigative T27944 DRUGINFO D00OLA H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 Investigative T27944 DRUGINFO D07OOG Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T27944 DRUGINFO D08YWE Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T27944 DRUGINFO D0G4HT Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 Investigative T27944 DRUGINFO D0J9VA H-[Trp-Arg-Nva-Arg-Tyr]2-NH2 Investigative T27944 DRUGINFO D0V0HM Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2 Investigative T46084 TARGETID T46084 T46084 FORMERID TTDI02193 T46084 UNIPROID TNF10_HUMAN T46084 TARGNAME TNF related apoptosis inducing ligand (TNFSF10) T46084 GENENAME TNFSF10 T46084 TARGTYPE Clinical trial T46084 SYNONYMS Tumor necrosis factor ligand superfamily member 10; TRAIL; TNF-related apoptosis-inducing ligand; Protein TRAIL; CD253; Apo-2L; Apo-2 ligand; APO2L T46084 FUNCTION Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG. T46084 PDBSTRUC 5CIR; 4N90; 1DU3; 1DG6; 1D4V T46084 BIOCLASS Cytokine: tumor necrosis factor T46084 SEQUENCE MAMMEVQGGPSLGQTCVLIVIFTVLLQSLCVAVTYVYFTNELKQMQDKYSKSGIACFLKEDDSYWDPNDEESMNSPCWQVKWQLRQLVRKMILRTSEETISTVQEKQQNISPLVRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG T46084 DRUGINFO D0K1LJ Ad5-TRAIL Phase 1 T46084 DRUGINFO D0V3ZX DA-3607 Phase 1 T46084 DRUGINFO DCD1M8 ABBV-621 Phase 1 T46084 DRUGINFO D0C0JT Nimesulide Terminated T97873 TARGETID T97873 T97873 FORMERID TTDNC00667 T97873 UNIPROID CCR9_HUMAN T97873 TARGNAME C-C chemokine receptor type 9 (CCR9) T97873 GENENAME CCR9 T97873 TARGTYPE Clinical trial T97873 SYNONYMS Gprotein coupled receptor 28; GPR96; GPR28; GPR-9-6; G-protein coupled receptor 28; CDw199; CCR-9; CCCKR9; CC-CKR-9; CC chemokine receptor type 9; CC CKR9; C-C CKR-9 T97873 FUNCTION Subsequently transduces a signal by increasing the intracellular calcium ions level. Receptor for chemokine SCYA25/TECK. T97873 PDBSTRUC 5LWE T97873 BIOCLASS GPCR rhodopsin T97873 SEQUENCE MTPTDFTSPIPNMADDYGSESTSSMEDYVNFNFTDFYCEKNNVRQFASHFLPPLYWLVFIVGALGNSLVILVYWYCTRVKTMTDMFLLNLAIADLLFLVTLPFWAIAAADQWKFQTFMCKVVNSMYKMNFYSCVLLIMCISVDRYIAIAQAMRAHTWREKRLLYSKMVCFTIWVLAAALCIPEILYSQIKEESGIAICTMVYPSDESTKLKSAVLTLKVILGFFLPFVVMACCYTIIIHTLIQAKKSSKHKALKVTITVLTVFVLSQFPYNCILLVQTIDAYAMFISNCAVSTNIDICFQVTQTIAFFHSCLNPVLYVFVGERFRRDLVKTLKNLGCISQAQWVSFTRREGSLKLSSMLLETTSGALSL T97873 DRUGINFO D0K3UQ Vercirnon Phase 3 T97873 DRUGINFO D00YXU CCX-025 Phase 1 T97873 DRUGINFO D03DHM CCX507 Phase 1 T97873 DRUGINFO D0Q4CX MLN-3126 Phase 1 T64645 TARGETID T64645 T64645 FORMERID TTDI02180 T64645 UNIPROID SPHM_HUMAN T64645 TARGNAME N-sulphoglucosamine sulphohydrolase (SGSH) T64645 GENENAME SGSH T64645 TARGTYPE Clinical trial T64645 SYNONYMS Sulphamidase; Sulfoglucosamine sulfamidase; HSS T64645 FUNCTION Catalyzes a step in lysosomal heparan sulfate degradation. T64645 PDBSTRUC 4MIV; 4MHX T64645 BIOCLASS Sulfur-nitrogen hydrolase T64645 ECNUMBER EC 3.10.1.1 T64645 SEQUENCE MSCPVPACCALLLVLGLCRARPRNALLLLADDGGFESGAYNNSAIATPHLDALARRSLLFRNAFTSVSSCSPSRASLLTGLPQHQNGMYGLHQDVHHFNSFDKVRSLPLLLSQAGVRTGIIGKKHVGPETVYPFDFAYTEENGSVLQVGRNITRIKLLVRKFLQTQDDRPFFLYVAFHDPHRCGHSQPQYGTFCEKFGNGESGMGRIPDWTPQAYDPLDVLVPYFVPNTPAARADLAAQYTTVGRMDQGVGLVLQELRDAGVLNDTLVIFTSDNGIPFPSGRTNLYWPGTAEPLLVSSPEHPKRWGQVSEAYVSLLDLTPTILDWFSIPYPSYAIFGSKTIHLTGRSLLPALEAEPLWATVFGSQSHHEVTMSYPMRSVQHRHFRLVHNLNFKMPFPIDQDFYVSPTFQDLLNRTTAGQPTGWYKDLRHYYYRARWELYDRSRDPHETQNLATDPRFAQLLEMLRDQLAKWQWETHDPWVCAPDGVLEEKLSPQCQPLHNEL T64645 DRUGINFO D5DAR1 LYS-SAF302 Phase 2/3 T64645 DRUGINFO D0Q5BK HGT-1410 Phase 2 T64645 DRUGINFO D3W5TL ABO-102 Phase 1/2 T64645 DRUGINFO DQ62VF SOBI003 Phase 1/2 T96685 TARGETID T96685 T96685 UNIPROID HXK2_HUMAN T96685 TARGNAME Hexokinase-2 (HK2) T96685 GENENAME HK2 T96685 TARGTYPE Clinical trial T96685 SYNONYMS Muscle form hexokinase; Hexokinase type II; HK II T96685 FUNCTION cytosol, membrane, mitochondrial outer membrane, fructokinase activity, glucokinase activity, hexokinase activity, mannokinase activity, apoptotic mitochondrial changes, canonical glycolysis, cellular glucose homeostasis. T96685 PDBSTRUC 5HG1; 5HFU; 5HEX; 2NZT T96685 BIOCLASS Hexokinase family T96685 ECNUMBER EC 2.7.1.1 T96685 SEQUENCE MIASHLLAYFFTELNHDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHPTAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPEDIMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKSSGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNACYMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMISGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLMRLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVYKKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHLQLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTNFRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLPLGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVNDTVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGCLDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLKTRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAGMAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGSGKGAALITAVACRIREAGQR T96685 DRUGINFO D06QBX VDA-1102 Phase 2 T35063 TARGETID T35063 T35063 FORMERID TTDNC00413 T35063 UNIPROID GEM_HUMAN T35063 TARGNAME RAS-like protein KIR (GEM) T35063 GENENAME GEM T35063 TARGTYPE Clinical trial T35063 SYNONYMS RASlike protein KIR; GTPbinding protein GEM; GTPbinding mitogeninduced Tcell protein T35063 FUNCTION Could be a regulatory protein, possibly participating in receptor-mediated signal transduction at the plasma membrane. Has guanine nucleotide-binding activity but undetectable intrinsic GTPase activity. T35063 PDBSTRUC 2HT6; 2G3Y; 2CJW T35063 BIOCLASS Small GTPase superfamily T35063 SEQUENCE MTLNNVTMRQGTVGMQPQQQRWSIPADGRHLMVQKEPHQYSHRNRHSATPEDHCRRSWSSDSTDSVISSESGNTYYRVVLIGEQGVGKSTLANIFAGVHDSMDSDCEVLGEDTYERTLMVDGESATIILLDMWENKGENEWLHDHCMQVGDAYLIVYSITDRASFEKASELRIQLRRARQTEDIPIILVGNKSDLVRCREVSVSEGRACAVVFDCKFIETSAAVQHNVKELFEGIVRQVRLRRDSKEKNERRLAYQKRKESMPRKARRFWGKIVAKNNKNMAFKLKSKSCHDLSVL T35063 DRUGINFO D0I7PU Lirilumab Phase 2 T13714 TARGETID T13714 T13714 FORMERID TTDR00421 T13714 UNIPROID NR1H2_HUMAN T13714 TARGNAME Oxysterols receptor LXR-beta (NR1H2) T13714 GENENAME NR1H2 T13714 TARGTYPE Clinical trial T13714 SYNONYMS Ubiquitously-expressed nuclear receptor; Nuclear receptor subfamily 1 group H member 2; Nuclear receptor NER; Nuclear orphan receptor LXR-beta; NER; Liver X receptor beta; LXRbeta; LXRB T13714 FUNCTION Binds preferentially to double-stranded oligonucleotide direct repeats having the consensus half-site sequence 5'-AGGTCA-3' and 4-nt spacing (DR-4). Regulates cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8; DLDLR and LRP8. Interplays functionally with RORA for the regulation of genes involved in liver metabolism. Plays an anti-inflammatory role during the hepatic acute phase response by acting as a corepressor: inhibits the hepatic acute phase response by preventing dissociation of the N-Cor corepressor complex. Nuclear receptor that exhibits a ligand-dependent transcriptional activation activity. T13714 PDBSTRUC 5KYJ; 5KYA; 5JY3; 5I4V; 5HJP T13714 BIOCLASS Nuclear hormone receptor T13714 SEQUENCE MSSPTTSSLDTPLPGNGPPQPGAPSSSPTVKEEGPEPWPGGPDPDVPGTDEASSACSTDWVIPDPEEEPERKRKKGPAPKMLGHELCRVCGDKASGFHYNVLSCEGCKGFFRRSVVRGGARRYACRGGGTCQMDAFMRRKCQQCRLRKCKEAGMREQCVLSEEQIRKKKIRKQQQESQSQSQSPVGPQGSSSSASGPGASPGGSEAGSQGSGEGEGVQLTAAQELMIQQLVAAQLQCNKRSFSDQPKVTPWPLGADPQSRDARQQRFAHFTELAIISVQEIVDFAKQVPGFLQLGREDQIALLKASTIEIMLLETARRYNHETECITFLKDFTYSKDDFHRAGLQVEFINPIFEFSRAMRRLGLDDAEYALLIAINIFSADRPNVQEPGRVEALQQPYVEALLSYTRIKRPQDQLRFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE T13714 DRUGINFO D01XMC VTB-38543 Phase 2 T13714 DRUGINFO D08LFT Benzenesulfonyl Investigative T13714 DRUGINFO D00DLU GSK-9772 Investigative T13714 DRUGINFO D00HVP Riccardin C Investigative T13714 DRUGINFO D01HDD 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione Investigative T13714 DRUGINFO D03YUL AZ12260493 Investigative T13714 DRUGINFO D06VRA 4,17-dehydroxyriccardin C Investigative T13714 DRUGINFO D08URT 24(S)-hydroxycholesterol Investigative T13714 DRUGINFO D09UND 12,17-dehydroxyriccardin C Investigative T13714 DRUGINFO D0A1WR SR9238 Investigative T13714 DRUGINFO D0C2CY WAY-254011 Investigative T13714 DRUGINFO D0C6QI acetyl-podocarpic dimer Investigative T13714 DRUGINFO D0HA0U 12-dehydroxyriccardin C Investigative T13714 DRUGINFO D0IZ9O 4-dehydroxyriccardin C Investigative T13714 DRUGINFO D0PL4F GW-3965 Investigative T13714 DRUGINFO D0Q2RP 24(S), 25-epoxycholesterol Investigative T13714 DRUGINFO D0R8LN N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide Investigative T13714 DRUGINFO D0Z3TJ GSK2033 Investigative T13714 DRUGINFO D0Z8LE 17-dehydroxyriccardin C Investigative T13714 DRUGINFO D0Z8RH 2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole Investigative T13714 DRUGINFO D01RNA desmosterol Investigative T13714 DRUGINFO D0H2YM 27-hydroxycholesterol Investigative T13714 DRUGINFO D0K4GK 22R-hydroxycholesterol Investigative T13714 DRUGINFO D08QXD L-783483 Investigative T13714 DRUGINFO D0V4RZ WAY-214950 Investigative T13714 DRUGINFO D0W7LK 2-Propanol, Isopropanol Investigative T93903 TARGETID T93903 T93903 FORMERID TTDR01006 T93903 UNIPROID CASP9_HUMAN T93903 TARGNAME Caspase-9 (CASP9) T93903 GENENAME CASP9 T93903 TARGTYPE Clinical trial T93903 SYNONYMS MCH6; ICE-like apoptotic protease 6; ICE-LAP6; CASP-9; Apoptotic protease-activating factor 3; Apoptotic protease activating factor 3; Apoptotic protease Mch-6; APAF-3 T93903 FUNCTION Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Promotes DNA damage-induced apoptosis in a ABL1/c-Abl-dependent manner. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP). Involved in the activation cascade of caspases responsible for apoptosis execution. T93903 PDBSTRUC 5WVE; 5WVC; 5JUY; 4RHW; 3YGS T93903 BIOCLASS Peptidase T93903 ECNUMBER EC 3.4.22.62 T93903 SEQUENCE MDEADRRLLRRCRLRLVEELQVDQLWDALLSRELFRPHMIEDIQRAGSGSRRDQARQLIIDLETRGSQALPLFISCLEDTGQDMLASFLRTNRQAAKLSKPTLENLTPVVLRPEIRKPEVLRPETPRPVDIGSGGFGDVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELAQQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTS T93903 DRUGINFO D0J3SU isatin sulfonamide 34 Clinical trial T93903 DRUGINFO D08BFI Z-LEHD-fmk Investigative T93903 DRUGINFO D0U1DU NVX-207 Investigative T93903 DRUGINFO D0Y2TI Glionitrin A Investigative T17140 TARGETID T17140 T17140 FORMERID TTDR00278 T17140 UNIPROID P2RX3_HUMAN T17140 TARGNAME P2X purinoceptor 3 (P2RX3) T17140 GENENAME P2RX3 T17140 TARGTYPE Clinical trial T17140 SYNONYMS P2X3 receptor; P2X3; P2RX3; ATP-gated ion channel P2X(3) T17140 FUNCTION Receptor for ATP that acts as a ligand-gated ionchannel. T17140 PDBSTRUC 5YVE; 5SVT; 5SVS; 5SVR; 5SVQ T17140 BIOCLASS ATP-gated P2X receptor cation channel T17140 SEQUENCE MNCISDFFTYETTKSVVVKSWTIGIINRVVQLLIISYFVGWVFLHEKAYQVRDTAIESSVVTKVKGSGLYANRVMDVSDYVTPPQGTSVFVIITKMIVTENQMQGFCPESEEKYRCVSDSQCGPERLPGGGILTGRCVNYSSVLRTCEIQGWCPTEVDTVETPIMMEAENFTIFIKNSIRFPLFNFEKGNLLPNLTARDMKTCRFHPDKDPFCPILRVGDVVKFAGQDFAKLARTGGVLGIKIGWVCDLDKAWDQCIPKYSFTRLDSVSEKSSVSPGYNFRFAKYYKMENGSEYRTLLKAFGIRFDVLVYGNAGKFNIIPTIISSVAAFTSVGVGTVLCDIILLNFLKGADQYKAKKFEEVNETTLKIAALTNPVYPSDQTTAEKQSTDSGAFSIGH T17140 DRUGINFO D0PL3N Gefapixant Phase 3 T17140 DRUGINFO D01VRQ BAY-1902607 Phase 2 T17140 DRUGINFO D3X1TS BAY 1902607 Phase 1/2 T17140 DRUGINFO D0K4RU AF-130 Phase 1 T17140 DRUGINFO D0NF1D BAY-1817080 Phase 1 T17140 DRUGINFO DF0PI8 BAY 1817080 Phase 1 T17140 DRUGINFO D02RXA LVAYPWT Investigative T17140 DRUGINFO D04TGU MK-3901 Investigative T17140 DRUGINFO D05RRF Cyclic LVVYPWT Investigative T17140 DRUGINFO D0B1KT AF353 Investigative T17140 DRUGINFO D0G8NI RO3 Investigative T17140 DRUGINFO D0M8HU LAVYPWT Investigative T17140 DRUGINFO D0TR4N LVVAPWT Investigative T17140 DRUGINFO D0Z0QD LVVYPWT Investigative T17140 DRUGINFO D0Z1DQ [3H]A317491 Investigative T17140 DRUGINFO D0Z6UE AVVYPWT Investigative T17140 DRUGINFO D01VVM TNP-ATP Investigative T17140 DRUGINFO D05BFC ISOPPADS Investigative T17140 DRUGINFO D06HDW BzATP Investigative T79031 TARGETID T79031 T79031 UNIPROID BACE1_HUMAN T79031 TARGNAME Beta-secretase 1 (BACE1) T79031 GENENAME BACE1 T79031 TARGTYPE Clinical trial T79031 SYNONYMS Membrane-associated aspartic protease 2; Memapsin-2; KIAA1149; Beta-site amyloid precursor protein cleaving enzyme 1; Beta-site APP cleaving enzyme 1; BACE; Aspartyl protease 2; Asp 2; ASP2 T79031 FUNCTION Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. Cleaves APP with much more catalytic efficiency than for the wild-type. Responsible for the proteolytic processing of the amyloid precursor protein (APP). T79031 PDBSTRUC 6FGY; 6EQM; 6EJ3; 6EJ2; 6DMI T79031 BIOCLASS Peptidase T79031 ECNUMBER EC 3.4.23.46 T79031 SEQUENCE MAQALPWLLLWMGAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRQQHDDFADDISLLK T79031 DRUGINFO D08MHD E-2609 Phase 3 T79031 DRUGINFO D0R4KK verubecestat Phase 3 T79031 DRUGINFO D0H4YD AMG520 Phase 2/3 T40491 TARGETID T40491 T40491 FORMERID TTDI00641 T40491 UNIPROID PP2AA_HUMAN T40491 TARGNAME Serine/threonine PP2A-alpha (PPP2CA) T40491 GENENAME PPP2CA T40491 TARGTYPE Clinical trial T40491 SYNONYMS Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform; Replication protein C; RP-C; PP2A-alpha T40491 FUNCTION PP2A can modulate the activity of phosphorylase B kinase casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. Cooperates with SGO2 to protect centromeric cohesin from separase-mediated cleavage in oocytes specifically during meiosis I. Can dephosphorylate SV40 large T antigen and p53/TP53. Activates RAF1 by dephosphorylating it at 'Ser-259'. PP2A is the major phosphatase for microtubule-associated proteins (MAPs). T40491 PDBSTRUC 5W0W; 4LAC; 4IYP; 4I5N; 4I5L T40491 BIOCLASS Phosphoric monoester hydrolase T40491 ECNUMBER EC 3.1.3.16 T40491 SEQUENCE MDEKVFTKELDQWIEQLNECKQLSESQVKSLCEKAKEILTKESNVQEVRCPVTVCGDVHGQFHDLMELFRIGGKSPDTNYLFMGDYVDRGYYSVETVTLLVALKVRYRERITILRGNHESRQITQVYGFYDECLRKYGNANVWKYFTDLFDYLPLTALVDGQIFCLHGGLSPSIDTLDHIRALDRLQEVPHEGPMCDLLWSDPDDRGGWGISPRGAGYTFGQDISETFNHANGLTLVSRAHQLVMEGYNWCHDRNVVTIFSAPNYCYRCGNQAAIMELDDTLKYSFLQFDPAPRRGEPHVTRRTPDYFL T40491 DRUGINFO D01HZQ VP-102 Phase 3 T40491 DRUGINFO D02RNR LB-100 Phase 2 T02228 TARGETID T02228 T02228 FORMERID TTDS00084 T02228 UNIPROID PARC_STRPN T02228 TARGNAME Streptococcus Topoisomerase IV A (Stre-coc parC) T02228 GENENAME Stre-coc parC T02228 TARGTYPE Clinical trial T02228 SYNONYMS parC of Streptococcus pneumoniae serotype 4; DNA topoisomerase IV of Streptococcus pneumoniae serotype 4 T02228 FUNCTION Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule. T02228 PDBSTRUC 4Z53; 4Z4Q; 4Z3O; 4KPF; 4KPE T02228 BIOCLASS Topoisomerase GyrA ParC T02228 ECNUMBER EC 5.6.2.3 T02228 SEQUENCE MSNIQNMSLEDIMGERFGRYSKYIIQDRALPDIRDGLKPVQRRILYSMNKDSNTFDKSYRKSAKSVGNIMGNFHPHGDSSIYDAMVRMSQNWKNREILVEMHGNNGSMDGDPPAAMRYTEARLSEIAGYLLQDIEKKTVPFAWNFDDTEKEPTVLPAAFPNLLVNGSTGISAGYATDIPPHNLAEVIDAAVYMIDHPTAKIDKLMEFLPGPDFPTGAIIQGRDEIKKAYETGKGRVVVRSKTEIEKLKGGKEQIVIIEIPYEINKANLVKKIDDVRVNNKVAGIAEVRDESDRDGLRIAIELKKDANTELVLNYLFKYTDLQINYNFNMVAIDNFTPRQVGIVPILSSYIAHRREVILARSRFDKEKAEKRLHIVEGLIRVISILDEVIALIRASENKADAKENLKVSYDFTEEQAEAIVTLQLYRLTNTDVVVLQEEEAELREKIAMLAAIIGDERTMYNLMKKELREVKKKFATPRLSSLEDTAKAIEIDTASLIAEEDTYVSVTKAGYIKRTSPRSFAASTLEEIGKRDDDRLIFVQSAKTTQHLLMFTSLGNVIYRPIHELADIRWKDIGEHLSQTITNFETNEEILYVEVLDQFDDATTYFAVTRLGQIKRVERKEFTPWRTYRSKSVKYAKLKDDTDQIVAVAPIKLDDVVLVSQNGYALRFNIEEVPVVGAKAAGVKAMNLKEDDVLQSGFICNTSSFYLLTQRGSLKRVSIEEILATSRAKRGLQVLRELKNKPHRVFLAGAVAEQGFVGDFFSTEVDVNDQTLLVQSNKGTIYESRLQDLNLSERTSNGSFISDTISDEEVFDAYLQEVVTEDK T02228 DRUGINFO D07DTM Cetraxal Otic Phase 3 T02228 DRUGINFO D0PC5N Premafloxacin Investigative T02228 DRUGINFO D0V6EY Pumiliotoxin 251D Investigative T04507 TARGETID T04507 T04507 FORMERID TTDR00806 T04507 UNIPROID DLG4_HUMAN T04507 TARGNAME Presynaptic density protein 95 (DLG4) T04507 GENENAME DLG4 T04507 TARGTYPE Clinical trial T04507 SYNONYMS Synapse-associated protein 90; SAP90; SAP-90; Postsynaptic density-95; Postsynaptic density protein 95; PSD95; PSD-95; Disks large homolog 4; Discs, large homolog 4 T04507 FUNCTION Required for synaptic plasticity associated with NMDA receptor signaling. Overexpression or depletion of DLG4 changes the ratio of excitatory to inhibitory synapses in hippocampal neurons. May reduce the amplitude of ASIC3 acid-evoked currents by retaining the channel intracellularly. May regulate the intracellular trafficking of ADR1B. Also regulates AMPA-type glutamate receptor (AMPAR) immobilization at postsynaptic density keeping the channels in an activated state in the presence of glutamate and preventing synaptic depression. Interacts with the cytoplasmic tail of NMDA receptor subunits and shaker-type potassium channels. T04507 PDBSTRUC 6QJN; 6QJL; 6QJK; 6QJJ; 6QJI T04507 BIOCLASS Ezrin/radixin/moesin-binding phosphoprotein 50 T04507 SEQUENCE MDCLCIVTTKKYRYQDEDTPPLEHSPAHLPNQANSPPVIVNTDTLEAPGYELQVNGTEGEMEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRLRVNDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIKLIKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAVNSVGLEDVMHEDAVAALKNTYDVVYLKVAKPSNAYLSDSYAPPDITTSYSQHLDNEISHSSYLGTDYPTAMTPTSPRRYSPVAKDLLGEEDIPREPRRIVIHRGSTGLGFNIVGGEDGEGIFISFILAGGPADLSGELRKGDQILSVNGVDLRNASHEQAAIALKNAGQTVTIIAQYKPEEYSRFEAKIHDLREQLMNSSLGSGTASLRSNPKRGFYIRALFDYDKTKDCGFLSQALSFRFGDVLHVIDASDEEWWQARRVHSDSETDDIGFIPSKRRVERREWSRLKAKDWGSSSGSQGREDSVLSYETVTQMEVHYARPIIILGPTKDRANDDLLSEFPDKFGSCVPHTTRPKREYEIDGRDYHFVSSREKMEKDIQAHKFIEAGQYNSHLYGTSVQSVREVAEQGKHCILDVSANAVRRLQAAHLHPIAIFIRPRSLENVLEINKRITEEQARKAFDRATKLEQEFTECFSAIVEGDSFEEIYHKVKRVIEDLSGPYIWVPARERL T04507 DRUGINFO D01JLO Tat-NR2B9c Phase 3 T04507 DRUGINFO D00SOE KSG-YEKLSSIESDV Investigative T04507 DRUGINFO D00YVJ N-(3,4-Difluorophenyl)propyl-ETAV Investigative T04507 DRUGINFO D03HYZ N-Propyl-ETAV Investigative T04507 DRUGINFO D03LMH N-Phenylethyl-ETAV Investigative T04507 DRUGINFO D04HQL N-Cyclohexylmethyl-ETAV Investigative T04507 DRUGINFO D06DWW FETAV Investigative T04507 DRUGINFO D07FJR N-Butyl-ETAV Investigative T04507 DRUGINFO D08DUM N-Methyl-ETAV Investigative T04507 DRUGINFO D08FDY YGRKKRRQRRR-KLSSIESDV Investigative T04507 DRUGINFO D09QIC N-Phenylpropyl-ETAV Investigative T04507 DRUGINFO D09WVP N-Benzyl-ETAV Investigative T04507 DRUGINFO D0EV3O N-Ethyl-ETAV Investigative T04507 DRUGINFO D0H4NR N-(3,4-Dichlorophenyl)propyl-ETAV Investigative T04507 DRUGINFO D0SU5M N-Cyclohexylethyl-ETAV Investigative T04507 DRUGINFO D0T2HN N-(Naphthalene-2-yl)ethyl-ETAV Investigative T04507 DRUGINFO D0UJ6V KSG-LDTKNYKQTSV Investigative T04507 DRUGINFO D04AWP Guanosine-5'-Monophosphate Investigative T04507 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T36806 TARGETID T36806 T36806 FORMERID TTDR00732 T36806 UNIPROID ARGI2_HUMAN T36806 TARGNAME Kidney-type arginase (ARG2) T36806 GENENAME ARG2 T36806 TARGTYPE Clinical trial T36806 SYNONYMS Non-hepatic arginase; Human penile arginase; Arginase II; ARG2 T36806 FUNCTION May play a role in the regulation of extra-urea cycle arginine metabolism and also in down-regulation of nitric oxide synthesis. Extrahepatic arginase functions to regulate L-arginine bioavailability to NO synthase. Since NO synthase is found in the penile corpus cavernosum smooth muscle, the clitoral corpus cavernosum and the vagina, arginase II plays a role in both male and female sexual arousal. It is therefore a potential target for the treatment of male and female sexual arousal disorders. T36806 PDBSTRUC 4IXV; 4IXU; 4IE3; 4IE2; 4I06 T36806 BIOCLASS Carbon-nitrogen hydrolase T36806 ECNUMBER EC 3.5.3.1 T36806 SEQUENCE MSLRGSLSRLLQTRVHSILKKSVHSVAVIGAPFSQGQKRKGVEHGPAAIREAGLMKRLSSLGCHLKDFGDLSFTPVPKDDLYNNLIVNPRSVGLANQELAEVVSRAVSDGYSCVTLGGDHSLAIGTISGHARHCPDLCVVWVDAHADINTPLTTSSGNLHGQPVSFLLRELQDKVPQLPGFSWIKPCISSASIVYIGLRDVDPPEHFILKNYDIQYFSMRDIDRLGIQKVMERTFDLLIGKRQRPIHLSFDIDAFDPTLAPATGTPVVGGLTYREGMYIAEEIHNTGLLSALDLVEVNPQLATSEEEAKTTANLAVDVIASSFGQTREGGHIVYDQLPTPSSPDESENQARVRI T36806 DRUGINFO D09ZIC N-hydroxy-nor-L-arginine Investigative T36806 DRUGINFO D0A8ZM S-(2-boronoethyl)-L-cysteine Investigative T22995 TARGETID T22995 T22995 FORMERID TTDI02090 T22995 UNIPROID HEPC_HUMAN T22995 TARGNAME Hepcidin (HAMP) T22995 GENENAME HAMP T22995 TARGTYPE Clinical trial T22995 SYNONYMS Putative liver tumor regressor; PLTR; Liverexpressed antimicrobial peptide 1; LEAP1; Hepcidin20; Hepc25; Hepc20; HAMP T22995 FUNCTION Has strong antimicrobial activity against E.coli ML35P N.cinereaand weaker against S.epidermidis, S.aureus and group b streptococcus bacteria. Active against the fungus C.albicans. No activity against P.aeruginosa (PubMed:11113131, PubMed:11034317). T22995 PDBSTRUC 4QAE; 3H0T; 2KEF; 1M4F; 1M4E T22995 BIOCLASS Hepcidin family T22995 SEQUENCE MALSSQIWAACLLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGARASWMPMFQRRRRRDTHFPICIFCCGCCHRSKCGMCCKT T22995 DRUGINFO D02CAF NOX-H94 Phase 2 T22995 DRUGINFO DQ3AM0 PTG-300 Phase 2 T22995 DRUGINFO DXM30Y LJPC-401 Phase 2 T22995 DRUGINFO D0V4YW Hepcidin mab Phase 1 T22995 DRUGINFO DAOT46 LY2787106 Phase 1 T22995 DRUGINFO DY7IP9 12B9m Preclinical T16769 TARGETID T16769 T16769 FORMERID TTDI02333 T16769 UNIPROID XIAP_HUMAN T16769 TARGNAME X-linked inhibitor of apoptosis protein (XIAP) T16769 GENENAME XIAP T16769 TARGTYPE Clinical trial T16769 SYNONYMS hILP; hIAP3; hIAP-3; Xlinked IAP; X-linked IAP; RING-type E3 ubiquitin transferase XIAP; Inhibitor of apoptosis protein 3; ILP; IAPlike protein; IAP3; IAP-like protein; IAP-3; E3 ubiquitinprotein ligase XIAP; E3 ubiquitin-protein ligase XIAP; Baculoviral IAP repeatcontaining protein 4; Baculoviral IAP repeat-containing protein 4; BIRC4; API3 T16769 FUNCTION Acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. Inactivates CASP9 by keeping it in a monomeric, inactive state. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, CASP3, CASP7, CASP8, CASP9, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS and BIRC5/survivin. Ubiquitinion of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation. Ubiquitinion of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation. Plays a role in copper homeostasis by ubiquitinationg COMMD1 and promoting its proteasomal degradation. Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. Acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES. Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. T16769 PDBSTRUC 6QCI; 6EY2; 5OQW; 5O6T; 5M6M T16769 BIOCLASS Acyltransferase T16769 ECNUMBER EC 2.3.2.27 T16769 SEQUENCE MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDTVRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENYLGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLTPRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSESDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTPSLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKDSMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDKCPMCYTVITFKQKIFMS T16769 DRUGINFO D03MXK AT-406 Phase 3 T16769 DRUGINFO D0E8NP Birinapant Phase 2 T16769 DRUGINFO D03YOS Phenoxodiol Phase 1/2 T16769 DRUGINFO D02AMG HGS-1029 Phase 1 T16769 DRUGINFO D07CLV GDC-0152 Phase 1 T16769 DRUGINFO D0NP8P APG-1387 Phase 1 T16769 DRUGINFO D00VXV PMID25980951-Compound-40 Patented T16769 DRUGINFO D01JEH PMID25980951-Compound-29 Patented T16769 DRUGINFO D03JHD PMID25980951-Compound-15 Patented T16769 DRUGINFO D03TQU PMID25980951-Compound-31 Patented T16769 DRUGINFO D08UPQ PMID25980951-Compound-30 Patented T16769 DRUGINFO D0EZ9G PMID25980951-Compound-14 Patented T16769 DRUGINFO D0G9CR PMID25980951-Compound-39 Patented T16769 DRUGINFO D0K2PK PMID25980951-Compound-33 Patented T16769 DRUGINFO D0NB0V PMID25980951-Compound-28 Patented T16769 DRUGINFO D0P9PZ PMID25980951-Compound-10 Patented T16769 DRUGINFO D0PF7S PMID25980951-Compound-11 Patented T16769 DRUGINFO D0Q1XF PMID25980951-Compound-32 Patented T16769 DRUGINFO D0S0XT PMID25980951-Compound-26 Patented T16769 DRUGINFO D0U5TX PMID25980951-Compound-13 Patented T16769 DRUGINFO D0UT1G PMID25980951-Compound-12 Patented T16769 DRUGINFO D0UU7G PMID25980951-Compound-45 Patented T16769 DRUGINFO D02UOD PMID25980951-Compound-3 Patented T16769 DRUGINFO D02ZHC PMID25980951-Compound-4 Patented T16769 DRUGINFO D03DQW PMID25980951-Compound-21 Patented T16769 DRUGINFO D03PTG PMID25980951-Compound-42 Patented T16769 DRUGINFO D03VPP PMID25980951-Compound-22 Patented T16769 DRUGINFO D07FRU PMID25980951-Compound-37 Patented T16769 DRUGINFO D0AC8H PMID25980951-Compound-36 Patented T16769 DRUGINFO D0CV9K PMID25980951-Compound-20 Patented T16769 DRUGINFO D0GF3P PMID25980951-Compound-38 Patented T16769 DRUGINFO D0ID3R PMID25980951-Compound-5 Patented T16769 DRUGINFO D0M3BY PMID25980951-Compound-41 Patented T16769 DRUGINFO D0MH4B PMID25980951-Compound-19 Patented T16769 DRUGINFO D0O8ZD PMID25980951-Compound-7 Patented T16769 DRUGINFO D09VAX PMID25980951-Compound-6 Patented T16769 DRUGINFO D0B6KC PMID25980951-Compound-27 Patented T16769 DRUGINFO D0HY5Q PMID25980951-Compound-43 Patented T16769 DRUGINFO D0R3YM PMID25980951-Compound-1 Patented T16769 DRUGINFO D0YN1X PMID25980951-Compound-44 Patented T24793 TARGETID T24793 T24793 FORMERID TTDR00620 T24793 UNIPROID CAC1D_HUMAN T24793 TARGNAME Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) T24793 GENENAME CACNA1D T24793 TARGTYPE Clinical trial T24793 SYNONYMS Voltage-gated calcium channel alpha subunit Cav1.3; Voltage-gated L-type Ca2+ channel alpha1D; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CACNA1D T24793 FUNCTION Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin- GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). T24793 PDBSTRUC 3LV3 T24793 BIOCLASS Voltage-gated ion channel T24793 SEQUENCE MMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTVLSWQAAIDAARQAKAAQTMSTSAPPPVGSLSQRKRQQYAKSKKQGNSSNSRPARALFCLSLNNPIRRACISIVEWKPFDIFILLAIFANCVALAIYIPFPEDDSNSTNHNLEKVEYAFLIIFTVETFLKIIAYGLLLHPNAYVRNGWNLLDFVIVIVGLFSVILEQLTKETEGGNHSSGKSGGFDVKALRAFRVLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFIGKMHKTCFFADSDIVAEEDPAPCAFSGNGRQCTANGTECRSGWVGPNGGITNFDNFAFAMLTVFQCITMEGWTDVLYWMNDAMGFELPWVYFVSLVIFGSFFVLNLVLGVLSGEFSKEREKAKARGDFQKLREKQQLEEDLKGYLDWITQAEDIDPENEEEGGEEGKRNTSMPTSETESVNTENVSGEGENRGCCGSLCQAISKSKLSRRWRRWNRFNRRRCRAAVKSVTFYWLVIVLVFLNTLTISSEHYNQPDWLTQIQDIANKVLLALFTCEMLVKMYSLGLQAYFVSLFNRFDCFVVCGGITETILVELEIMSPLGISVFRCVRLLRIFKVTRHWTSLSNLVASLLNSMKSIASLLLLLFLFIIIFSLLGMQLFGGKFNFDETQTKRSTFDNFPQALLTVFQILTGEDWNAVMYDGIMAYGGPSSSGMIVCIYFIILFICGNYILLNVFLAIAVDNLADAESLNTAQKEEAEEKERKKIARKESLENKKNNKPEVNQIANSDNKVTIDDYREEDEDKDPYPPCDVPVGEEEEEEEEDEPEVPAGPRPRRISELNMKEKIAPIPEGSAFFILSKTNPIRVGCHKLINHHIFTNLILVFIMLSSAALAAEDPIRSHSFRNTILGYFDYAFTAIFTVEILLKMTTFGAFLHKGAFCRNYFNLLDMLVVGVSLVSFGIQSSAISVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIMIVTTLLQFMFACIGVQLFKGKFYRCTDEAKSNPEECRGLFILYKDGDVDSPVVRERIWQNSDFNFDNVLSAMMALFTVSTFEGWPALLYKAIDSNGENIGPIYNHRVEISIFFIIYIIIVAFFMMNIFVGFVIVTFQEQGEKEYKNCELDKNQRQCVEYALKARPLRRYIPKNPYQYKFWYVVNSSPFEYMMFVLIMLNTLCLAMQHYEQSKMFNDAMDILNMVFTGVFTVEMVLKVIAFKPKGYFSDAWNTFDSLIVIGSIIDVALSEADPTESENVPVPTATPGNSEESNRISITFFRLFRVMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIAMLFFIYAVIGMQMFGKVAMRDNNQINRNNNFQTFPQAVLLLFRCATGEAWQEIMLACLPGKLCDPESDYNPGEEYTCGSNFAIVYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWSEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVAMNMPLNSDGTVMFNATLFALVRTALKIKTEGNLEQANEELRAVIKKIWKKTSMKLLDQVVPPAGDDEVTVGKFYATFLIQDYFRKFKKRKEQGLVGKYPAKNTTIALQAGLRTLHDIGPEIRRAISCDLQDDEPEETKREEEDDVFKRNGALLGNHVNHVNSDRRDSLQQTNTTHRPLHVQRPSIPPASDTEKPLFPPAGNSVCHNHHNHNSIGKQVPTSTNANLNNANMSKAAHGKRPSIGNLEHVSENGHHSSHKHDREPQRRSSVKRTRYYETYIRSDSGDEQLPTICREDPEIHGYFRDPHCLGEQEYFSSEECYEDDSSPTWSRQNYGYYSRYPGRNIDSERPRGYHHPQGFLEDDDSPVCYDSRRSPRRRLLPPTPASHRRSSFNFECLRRQSSQEEVPSSPIFPHRTALPLHLMQQQIMAVAGLDSSKAQKYSPSHSTRSWATPPATPPYRDWTPCYTPLIQVEQSEALDQVNGSLPSLHRSSWYTDEPDISYRTFTPASLTVPSSFRNKNSDKQRSADSLVEAVLISEGLGRYARDPKFVSATKHEIADACDLTIDEMESAASTLLNGNVRPRANGDVGPLSHRQDYELQDFGPGYSDEEPDPGRDEEDLADEMICITTL T24793 DRUGINFO D06GRK ARC029 Phase 3 T24793 DRUGINFO D0EC2K SIPATRIGINE Discontinued in Phase 2 T24793 DRUGINFO D00JMZ CGS-27830 Terminated T24793 DRUGINFO D0QQ7N TH-9229 Terminated T24793 DRUGINFO D06HRY SNAP-5089 Terminated T24793 DRUGINFO D07FEO N,N'-Di-acenaphthen-5-yl-guanidine Investigative T24793 DRUGINFO D0D6PC azidopine Investigative T24793 DRUGINFO D04UDT MEBUDIPINE Investigative T24793 DRUGINFO D0I9VY CV-4093 Investigative T24793 DRUGINFO D0S3YP [3H](+)-isradipine Investigative T24793 DRUGINFO D02RIH (-)-(S)-BayK8644 Investigative T24793 DRUGINFO D09YTH CPU-228 Investigative T24793 DRUGINFO D08RJC PD-32577 Investigative T91435 TARGETID T91435 T91435 UNIPROID ROR2_HUMAN T91435 TARGNAME Neurotrophic tyrosine kinase ROR2 (ROR2) T91435 GENENAME ROR2 T91435 TARGTYPE Clinical trial T91435 SYNONYMS receptor tyrosine kinase like orphan receptor 2; neurotrophic tyrosine kinase, receptor-related 2; Tyrosine-protein kinase transmembrane receptor ROR2; NTRKR2; BDB1; BDB T91435 FUNCTION It seems to be required for cartilage and growth plate development. Phosphorylates YWHAB, leading to induction of osteogenesis and bone formation. In contrast, has also been shown to have very little tyrosine kinase activity in vitro. May act as a receptor for wnt ligand WNT5A which may result in the inhibition of WNT3A-mediated signaling. Tyrosine-protein kinase receptor which may be involved in the early formation of the chondrocytes. T91435 PDBSTRUC 4GT4; 3ZZW T91435 BIOCLASS Kinase T91435 ECNUMBER EC 2.7.10.1 T91435 SEQUENCE MARGSALPRRPLLCIPAVWAAAALLLSVSRTSGEVEVLDPNDPLGPLDGQDGPIPTLKGYFLNFLEPVNNITIVQGQTAILHCKVAGNPPPNVRWLKNDAPVVQEPRRIIIRKTEYGSRLRIQDLDTTDTGYYQCVATNGMKTITATGVLFVRLGPTHSPNHNFQDDYHEDGFCQPYRGIACARFIGNRTIYVDSLQMQGEIENRITAAFTMIGTSTHLSDQCSQFAIPSFCHFVFPLCDARSRTPKPRELCRDECEVLESDLCRQEYTIARSNPLILMRLQLPKCEALPMPESPDAANCMRIGIPAERLGRYHQCYNGSGMDYRGTASTTKSGHQCQPWALQHPHSHHLSSTDFPELGGGHAYCRNPGGQMEGPWCFTQNKNVRMELCDVPSCSPRDSSKMGILYILVPSIAIPLVIACLFFLVCMCRNKQKASASTPQRRQLMASPSQDMEMPLINQHKQAKLKEISLSAVRFMEELGEDRFGKVYKGHLFGPAPGEQTQAVAIKTLKDKAEGPLREEFRHEAMLRARLQHPNVVCLLGVVTKDQPLSMIFSYCSHGDLHEFLVMRSPHSDVGSTDDDRTVKSALEPPDFVHLVAQIAAGMEYLSSHHVVHKDLATRNVLVYDKLNVKISDLGLFREVYAADYYKLLGNSLLPIRWMAPEAIMYGKFSIDSDIWSYGVVLWEVFSYGLQPYCGYSNQDVVEMIRNRQVLPCPDDCPAWVYALMIECWNEFPSRRPRFKDIHSRLRAWGNLSNYNSSAQTSGASNTTQTSSLSTSPVSNVSNARYVGPKQKAPPFPQPQFIPMKGQIRPMVPPPQLYVPVNGYQPVPAYGAYLPNFYPVQIPMQMAPQQVPPQMVPKPSSHHSGSGSTSTGYVTTAPSNTSMADRAALLSEGADDTQNAPEDGAQSTVQEAEEEEEGSVPETELLGDCDTLQVDEAQVQLEA T91435 DRUGINFO D82BZH Ozuriftamab vedotin Phase 2 T91435 DRUGINFO D0C2PH CCT301-59 (targeting ROR2) Phase 1/2 T91435 DRUGINFO D0RA9C CCT301-38 (targeting ROR2) Phase 1/2 T61581 TARGETID T61581 T61581 FORMERID TTDS00424 T61581 UNIPROID GCYB1_HUMAN T61581 TARGNAME Guanylate cyclase soluble beta-1 (GUCY1B1) T61581 GENENAME GUCY1B1 T61581 TARGTYPE Clinical trial T61581 SYNONYMS Soluble guanylate cyclase small subunit; Guanylate cyclase soluble subunit beta-3; Guanylate cyclase soluble subunit beta-1; GUCY1B3; GUCSB3; GUC1B3; GCS-beta-3; GCS-beta-1 T61581 FUNCTION Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP. T61581 PDBSTRUC 5MNW; 4NI2; 3UVJ; 2WZ1 T61581 BIOCLASS Phosphorus-oxygen lyase T61581 ECNUMBER EC 4.6.1.2 T61581 SEQUENCE MYGFVNHALELLVIRNYGPEVWEDIKKEAQLDEEGQFLVRIIYDDSKTYDLVAAASKVLNLNAGEILQMFGKMFFVFCQESGYDTILRVLGSNVREFLQNLDALHDHLATIYPGMRAPSFRCTDAEKGKGLILHYYSEREGLQDIVIGIIKTVAQQIHGTEIDMKVIQQRNEECDHTQFLIEEKESKEEDFYEDLDRFEENGTQESRISPYTFCKAFPFHIIFDRDLVVTQCGNAIYRVLPQLQPGNCSLLSVFSLVRPHIDISFHGILSHINTVFVLRSKEGLLDVEKLECEDELTGTEISCLRLKGQMIYLPEADSILFLCSPSVMNLDDLTRRGLYLSDIPLHDATRDLVLLGEQFREEYKLTQELEILTDRLQLTLRALEDEKKKTDTLLYSVLPPSVANELRHKRPVPAKRYDNVTILFSGIVGFNAFCSKHASGEGAMKIVNLLNDLYTRFDTLTDSRKNPFVYKVETVGDKYMTVSGLPEPCIHHARSICHLALDMMEIAGQVQVDGESVQITIGIHTGEVVTGVIGQRMPRYCLFGNTVNLTSRTETTGEKGKINVSEYTYRCLMSPENSDPQFHLEHRGPVSMKGKKEPMQVWFLSRKNTGTEETKQDDD T61581 DRUGINFO D08YVP Vericigiuat Phase 2 T61581 DRUGINFO D0ZT0G Cinaciguat Phase 2 T61581 DRUGINFO D00TLD RIG-200 Discontinued in Phase 1 T22128 TARGETID T22128 T22128 FORMERID TTDI02320 T22128 UNIPROID DCE2_HUMAN T22128 TARGNAME Glutamate decarboxylase 2 (GAD2) T22128 GENENAME GAD2 T22128 TARGTYPE Clinical trial T22128 SYNONYMS Glutamate decarboxylase 65 kDa isoform; GAD65; GAD2; 65 kDa glutamic acid decarboxylase T22128 FUNCTION Catalyzes the production of GABA. T22128 PDBSTRUC 2OKK; 1ES0 T22128 BIOCLASS Carbon-carbon lyase T22128 ECNUMBER EC 4.1.1.15 T22128 SEQUENCE MASPGSGFWSFGSEDGSGDSENPGTARAWCQVAQKFTGGIGNKLCALLYGDAEKPAESGGSQPPRAAARKAACACDQKPCSCSKVDVNYAFLHATDLLPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQEYNWELADQPQNLEEILMHCQTTLKYAIKTGHPRYFNQLSTGLDMVGLAADWLTSTANTNMFTYEIAPVFVLLEYVTLKKMREIIGWPGGSGDGIFSPGGAISNMYAMMIARFKMFPEVKEKGMAALPRLIAFTSEHSHFSLKKGAAALGIGTDSVILIKCDERGKMIPSDLERRILEAKQKGFVPFLVSATAGTTVYGAFDPLLAVADICKKYKIWMHVDAAWGGGLLMSRKHKWKLSGVERANSVTWNPHKMMGVPLQCSALLVREEGLMQNCNQMHASYLFQQDKHYDLSYDTGDKALQCGRHVDVFKLWLMWRAKGTTGFEAHVDKCLELAEYLYNIIKNREGYEMVFDGKPQHTNVCFWYIPPSLRTLEDNEERMSRLSKVAPVIKARMMEYGTTMVSYQPLGDKVNFFRMVISNPAATHQDIDFLIEEIERLGQDL T22128 DRUGINFO D01KNA Diamyd Phase 3 T22128 DRUGINFO D09OTM s-allylglycine Investigative T92458 TARGETID T92458 T92458 FORMERID TTDI02046 T92458 UNIPROID CP24A_HUMAN T92458 TARGNAME Cytochrome P450 24 (CYP24A1) T92458 GENENAME CYP24A1 T92458 TARGTYPE Clinical trial T92458 SYNONYMS Vitamin D(3) 24hydroxylase; Cytochrome P450CC24; CYP24A1; 24OHase; 1,25dihydroxyvitamin D(3) 24hydroxylase, mitochondrial T92458 FUNCTION Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25- hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can perform up to 6 rounds of hydroxylation of calcitriol leading to calcitroic acid. It also shows 23- hydroxylating activity leading to 1-alpha,25-dihydroxyvitamin D(3)-26,23-lactone as end product. T92458 BIOCLASS Paired donor oxygen oxidoreductase T92458 ECNUMBER EC 1.14.15.16 T92458 SEQUENCE MSSPISKSRSLAAFLQQLRSPRQPPRLVTSTAYTSPQPREVPVCPLTAGGETQNAAALPGPTSWPLLGSLLQILWKGGLKKQHDTLVEYHKKYGKIFRMKLGSFESVHLGSPCLLEALYRTESAYPQRLEIKPWKAYRDYRKEGYGLLILEGEDWQRVRSAFQKKLMKPGEVMKLDNKINEVLADFMGRIDELCDERGHVEDLYSELNKWSFESICLVLYEKRFGLLQKNAGDEAVNFIMAIKTMMSTFGRMMVTPVELHKSLNTKVWQDHTLAWDTIFKSVKACIDNRLEKYSQQPSADFLCDIYHQNRLSKKELYAAVTELQLAAVETTANSLMWILYNLSRNPQVQQKLLKEIQSVLPENQVPRAEDLRNMPYLKACLKESMRLTPSVPFTTRTLDKATVLGEYALPKGTVLMLNTQVLGSSEDNFEDSSQFRPERWLQEKEKINPFAHLPFGVGKRMCIGRRLAELQLHLALCWIVRKYDIQATDNEPVEMLHSGTLVPSRELPIAFCQR T92458 DRUGINFO D00DYK Lunacalcipol Phase 2 T91761 TARGETID T91761 T91761 FORMERID TTDR00858 T91761 UNIPROID ITK_HUMAN T91761 TARGNAME T-cell-specific kinase (ITK) T91761 GENENAME ITK T91761 TARGTYPE Clinical trial T91761 SYNONYMS Tyrosine kinase ITK; Inducible T cell kinase; EMT T91761 FUNCTION Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. Once activated, phosphorylates PLCG1, leading to the activation of this lipase and subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. Phosphorylates 2 essential adapter proteins: the linker for activation of T-cells/LAT protein and LCP2. Then, a large number of signaling molecules such as VAV1 are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Phosphorylates TBX21 at 'Tyr-530' and mediates its interaction with GATA3. Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. T91761 PDBSTRUC 4RFM; 4QD6; 4PQN; 4PPC; 4PPB T91761 BIOCLASS Kinase T91761 ECNUMBER EC 2.7.10.2 T91761 SEQUENCE MNNFILLEEQLIKKSQQKRRTSPSNFKVRFFVLTKASLAYFEDRHGKKRTLKGSIELSRIKCVEIVKSDISIPCHYKYPFQVVHDNYLLYVFAPDRESRQRWVLALKEETRNNNSLVPKYHPNFWMDGKWRCCSQLEKLATGCAQYDPTKNASKKPLPPTPEDNRRPLWEPEETVVIALYDYQTNDPQELALRRNEEYCLLDSSEIHWWRVQDRNGHEGYVPSSYLVEKSPNNLETYEWYNKSISRDKAEKLLLDTGKEGAFMVRDSRTAGTYTVSVFTKAVVSENNPCIKHYHIKETNDNPKRYYVAEKYVFDSIPLLINYHQHNGGGLVTRLRYPVCFGRQKAPVTAGLRYGKWVIDPSELTFVQEIGSGQFGLVHLGYWLNKDKVAIKTIREGAMSEEDFIEEAEVMMKLSHPKLVQLYGVCLEQAPICLVFEFMEHGCLSDYLRTQRGLFAAETLLGMCLDVCEGMAYLEEACVIHRDLAARNCLVGENQVIKVSDFGMTRFVLDDQYTSSTGTKFPVKWASPEVFSFSRYSSKSDVWSFGVLMWEVFSEGKIPYENRSNSEVVEDISTGFRLYKPRLASTHVYQIMNHCWKERPEDRPAFSRLLRQLAEIAESGL T91761 DRUGINFO D01EJJ JTE-051 Phase 2 T91761 DRUGINFO D1YZ5O CPI-818 Phase 1 T91761 DRUGINFO D02IET PMID27774824-Compound-Figure3Example7 Patented T91761 DRUGINFO D09PIS Pyrazolo[4,3-c]pyridine derivative 2 Patented T91761 DRUGINFO D04PEI BMS-509744 Investigative T91761 DRUGINFO D05RPN BMS-488516 Investigative T06031 TARGETID T06031 T06031 FORMERID TTDNC00348 T06031 UNIPROID M3K1_HUMAN T06031 TARGNAME MAPK/ERK kinase kinase 1 (MAP3K1) T06031 GENENAME MAP3K1 T06031 TARGTYPE Clinical trial T06031 SYNONYMS Mitogenactivated protein kinase kinase kinase 1; Mitogen-activated protein kinase kinase kinase 1; MEKK1; MEKK 1; MEKK; MEK kinase 1; MAPKKK1 T06031 FUNCTION Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4. May phosphorylate the MAPK8/JNK1 kinase. Activates CHUK and IKBKB, the central protein kinases of the NF-kappa-B pathway. Component of a protein kinase signal transduction cascade. T06031 BIOCLASS Kinase T06031 ECNUMBER EC 2.7.11.25 T06031 SEQUENCE MAAAAGNRASSSGFPGARATSPEAGGGGGALKASSAPAAAAGLLREAGSGGRERADWRRRQLRKVRSVELDQLPEQPLFLAASPPASSTSPSPEPADAAGSGTGFQPVAVPPPHGAASRGGAHLTESVAAPDSGASSPAAAEPGEKRAPAAEPSPAAAPAGREMENKETLKGLHKMDDRPEERMIREKLKATCMPAWKHEWLERRNRRGPVVVKPIPVKGDGSEMNHLAAESPGEVQASAASPASKGRRSPSPGNSPSGRTVKSESPGVRRKRVSPVPFQSGRITPPRRAPSPDGFSPYSPEETNRRVNKVMRARLYLLQQIGPNSFLIGGDSPDNKYRVFIGPQNCSCARGTFCIHLLFVMLRVFQLEPSDPMLWRKTLKNFEVESLFQKYHSRRSSRIKAPSRNTIQKFVSRMSNSHTLSSSSTSTSSSENSIKDEEEQMCPICLLGMLDEESLTVCEDGCRNKLHHHCMSIWAEECRRNREPLICPLCRSKWRSHDFYSHELSSPVDSPSSLRAAQQQTVQQQPLAGSRRNQESNFNLTHYGTQQIPPAYKDLAEPWIQVFGMELVGCLFSRNWNVREMALRRLSHDVSGALLLANGESTGNSGGSSGSSPSGGATSGSSQTSISGDVVEACCSVLSMVCADPVYKVYVAALKTLRAMLVYTPCHSLAERIKLQRLLQPVVDTILVKCADANSRTSQLSISTLLELCKGQAGELAVGREILKAGSIGIGGVDYVLNCILGNQTESNNWQELLGRLCLIDRLLLEFPAEFYPHIVSTDVSQAEPVEIRYKKLLSLLTFALQSIDNSHSMVGKLSRRIYLSSARMVTTVPHVFSKLLEMLSVSSSTHFTRMRRRLMAIADEVEIAEAIQLGVEDTLDGQQDSFLQASVPNNYLETTENSSPECTVHLEKTGKGLCATKLSASSEDISERLASISVGPSSSTTTTTTTTEQPKPMVQTKGRPHSQCLNSSPLSHHSQLMFPALSTPSSSTPSVPAGTATDVSKHRLQGFIPCRIPSASPQTQRKFSLQFHRNCPENKDSDKLSPVFTQSRPLPSSNIHRPKPSRPTPGNTSKQGDPSKNSMTLDLNSSSKCDDSFGCSSNSSNAVIPSDETVFTPVEEKCRLDVNTELNSSIEDLLEASMPSSDTTVTFKSEVAVLSPEKAENDDTYKDDVNHNQKCKEKMEAEEEEALAIAMAMSASQDALPIVPQLQVENGEDIIIIQQDTPETLPGHTKAKQPYREDTEWLKGQQIGLGAFSSCYQAQDVGTGTLMAVKQVTYVRNTSSEQEEVVEALREEIRMMSHLNHPNIIRMLGATCEKSNYNLFIEWMAGGSVAHLLSKYGAFKESVVINYTEQLLRGLSYLHENQIIHRDVKGANLLIDSTGQRLRIADFGAAARLASKGTGAGEFQGQLLGTIAFMAPEVLRGQQYGRSCDVWSVGCAIIEMACAKPPWNAEKHSNHLALIFKIASATTAPSIPSHLSPGLRDVALRCLELQPQDRPPSRELLKHPVFRTTW T06031 DRUGINFO D0C7LR LLZ16406 Investigative T06031 DRUGINFO D0C1OZ Ro092210 Investigative T06031 DRUGINFO D0GD8Y U0126 Investigative T06031 DRUGINFO D0B9BU CI-1040 Investigative T68782 TARGETID T68782 T68782 FORMERID TTDR00802 T68782 UNIPROID PD2R_HUMAN T68782 TARGNAME Prostaglandin D2 receptor (PTGDR) T68782 GENENAME PTGDR T68782 TARGTYPE Clinical trial T68782 SYNONYMS Prostanoid DP receptor; PGD2 receptor; PGD receptor T68782 FUNCTION The activity of this receptor is mainly mediated by G(s) proteins that stimulate adenylate cyclase, resulting in an elevation of intracellular cAMP. A mobilization of calcium is also observed, but without formation of inositol 1,4,5-trisphosphate. Receptor for prostaglandin D2 (PGD2). T68782 BIOCLASS GPCR rhodopsin T68782 SEQUENCE MKSPFYRCQNTTSVEKGNSAVMGGVLFSTGLLGNLLALGLLARSGLGWCSRRPLRPLPSVFYMLVCGLTVTDLLGKCLLSPVVLAAYAQNRSLRVLAPALDNSLCQAFAFFMSFFGLSSTLQLLAMALECWLSLGHPFFYRRHITLRLGALVAPVVSAFSLAFCALPFMGFGKFVQYCPGTWCFIQMVHEEGSLSVLGYSVLYSSLMALLVLATVLCNLGAMRNLYAMHRRLQRHPRSCTRDCAEPRADGREASPQPLEELDHLLLLALMTVLFTMCSLPVIYRAYYGAFKDVKEKNRTSEEAEDLRALRFLSVISIVDPWIFIIFRSPVFRIFFHKIFIRPLRYRSRCSNSTNMESSL T68782 DRUGINFO D0WL5V LAROPIPRANT Phase 4 T68782 DRUGINFO D06XDI QAW-039 Phase 3 T68782 DRUGINFO D0SP5V Setipiprant Phase 3 T68782 DRUGINFO D04NWU ONO-4053 Phase 2 T68782 DRUGINFO D06GNF TS-022 Phase 2 T68782 DRUGINFO D0B9DM S-555739 Phase 2 T68782 DRUGINFO D0N4ZX MK-1029 Phase 2 T68782 DRUGINFO D0YB2Y AMG 853 Phase 2 T68782 DRUGINFO D0AR7L SAR-389644 Phase 1 T68782 DRUGINFO D0NU6Y 192C86 Phase 1 T68782 DRUGINFO DGV5Z3 MK-1092 Phase 1 T68782 DRUGINFO D00HTY PGF2alpha Clinical trial T68782 DRUGINFO D03GYK Laropiprant+niacin Discontinued in Phase 3 T68782 DRUGINFO D0K0VH S-5751 Discontinued in Phase 2 T68782 DRUGINFO D05PQF ONO-4127 Discontinued in Phase 1 T68782 DRUGINFO D07OEY ZK-118182 Terminated T68782 DRUGINFO D01TRN ONO-AE3-237 Investigative T68782 DRUGINFO D02LQA TTH 03-001 Investigative T68782 DRUGINFO D03AGD BWA868C Investigative T68782 DRUGINFO D06HPV DIASTEREOMER 2 Investigative T68782 DRUGINFO D08DFY SQ-27986 Investigative T68782 DRUGINFO D0H5FY RS 93520 Investigative T68782 DRUGINFO D0R2KL L-644,698 Investigative T68782 DRUGINFO D0R9CC BW 245C Investigative T68782 DRUGINFO D00QTX ZK110841 Investigative T68782 DRUGINFO D01RQK 15-deoxy-Delta12,14-PGJ2 Investigative T68782 DRUGINFO D0MS3D Delta12-PGJ2 Investigative T68782 DRUGINFO D0WV5J L-888,291 Investigative T68782 DRUGINFO D0Y6OX PGJ2 Investigative T68782 DRUGINFO D0J9PG AH6809 Investigative T68782 DRUGINFO D0O9ES cloprostenol Investigative T68782 DRUGINFO D08MNO butaprost (free acid form) Investigative T68782 DRUGINFO D06KBO PGD2 Investigative T68782 DRUGINFO D0W7RI carbacyclin Investigative T68782 DRUGINFO D03PLH U46619 Investigative T11011 TARGETID T11011 T11011 FORMERID TTDC00074 T11011 UNIPROID CRFR2_HUMAN T11011 TARGNAME Corticotropin-releasing factor receptor 2 (CRHR2) T11011 GENENAME CRHR2 T11011 TARGTYPE Clinical trial T11011 SYNONYMS Corticotropin-releasinghormone receptor 2; CRHR2; CRH2 receptor; CRH-R 2; CRF2; CRF-R 2 T11011 FUNCTION This is a receptor for corticotropin releasing factor. Shows high-affinity crf binding. Also binds to urocortin i, ii and iii. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. T11011 PDBSTRUC 3N96; 3N95; 3N93 T11011 BIOCLASS GPCR secretin T11011 SEQUENCE MDAALLHSLLEANCSLALAEELLLDGWGPPLDPEGPYSYCNTTLDQIGTCWPRSAAGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDDKQRKYDLHYRIALVVNYLGHCVSVAALVAAFLLFLALRSIRCLRNVIHWNLITTFILRNVMWFLLQLVDHEVHESNEVWCRCITTIFNYFVVTNFFWMFVEGCYLHTAIVMTYSTERLRKCLFLFIGWCIPFPIIVAWAIGKLYYENEQCWFGKEPGDLVDYIYQGPIILVLLINFVFLFNIVRILMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNSFLQSFQGFFVSVFYCFFNGEVRSAVRKRWHRWQDHHSLRVPMARAMSIPTSPTRISFHSIKQTAAV T11011 DRUGINFO D0W2HG Urocortin 2 Phase 2 T11011 DRUGINFO DYSA16 RT-400 Phase 2 T11011 DRUGINFO D07QWW NBI-34041 Phase 1 T11011 DRUGINFO D01TGH PF-572778 Terminated T11011 DRUGINFO D07NWC SC-241 Terminated T11011 DRUGINFO D0L5RY astressin Investigative T22655 TARGETID T22655 T22655 FORMERID TTDC00248 T22655 UNIPROID MADCA_HUMAN T22655 TARGNAME Mucosal addressin cell adhesion molecule 1 (MADCAM1) T22655 GENENAME MADCAM1 T22655 TARGTYPE Clinical trial T22655 SYNONYMS hMAdCAM-1; MAdCAM-1; MADCAM1 T22655 FUNCTION Cell adhesion leukocyte receptor expressed by mucosal venules, helps to direct lymphocyte traffic into mucosal tissues including the Peyer patches and the intestinal lamina propria. It can bind both integrin alpha-4/beta-7 and L-selectin, regulating both the passage and retention of leukocytes. Isoform 2, lacking the mucin-like domain, may be specialized in supporting integrin alpha-4/beta-7-dependent adhesion strengthening, independent of L- selectin binding. T22655 PDBSTRUC 4HD9; 4HCR; 4HC1; 4HBQ; 1GSM T22655 SEQUENCE MDFGLALLLAGLLGLLLGQSLQVKPLQVEPPEPVVAVALGASRQLTCRLACADRGASVQWRGLDTSLGAVQSDTGRSVLTVRNASLSAAGTRVCVGSCGGRTFQHTVQLLVYAFPDQLTVSPAALVPGDPEVACTAHKVTPVDPNALSFSLLVGGQELEGAQALGPEVQEEEEEPQGDEDVLFRVTERWRLPPLGTPVPPALYCQATMRLPGLELSHRQAIPVLHSPTSPEPPDTTSPESPDTTSPESPDTTSQEPPDTTSPEPPDKTSPEPAPQQGSTHTPRSPGSTRTRRPEISQAGPTQGEVIPTGSSKPAGDQLPAALWTSSAVLGLLLLALPTYHLWKRCRHLAEDDTHPPASLRLLPQVSAWAGLRGTGQVGISPS T22655 DRUGINFO D02QWK SHP647 Phase 3 T22655 DRUGINFO D00QKI SCH-527123 Phase 2 T35173 TARGETID T35173 T35173 FORMERID TTDI02026 T35173 UNIPROID BIRC3_HUMAN T35173 TARGNAME Cellular inhibitor of apoptosis 2 (BIRC3) T35173 GENENAME BIRC3 T35173 TARGTYPE Clinical trial T35173 SYNONYMS hIAP1; hIAP-1; TNFR2TRAFsignaling complex protein 1; TNFR2-TRAF-signaling complex protein 1; RNF49; RING-type E3 ubiquitin transferase BIRC3; RING finger protein 49; MIHC; Inhibitor of apoptosis protein 1; IAP1; IAP homolog C; CIAP2; C-IAP2; Baculoviral IAP repeatcontaining protein3; Baculoviral IAP repeat-containing protein 3; Apoptosis inhibitor 2; API2 T35173 FUNCTION Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. T35173 PDBSTRUC 3M0D; 3M0A; 3EB6; 3EB5; 2UVL T35173 BIOCLASS Acyltransferase T35173 ECNUMBER EC 2.3.2.27 T35173 SEQUENCE MNIVENSIFLSNLMKSANTFELKYDLSCELYRMSTYSTFPAGVPVSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKRGDSPTEKHKKLYPSCRFVQSLNSVNNLEATSQPTFPSSVTNSTHSLLPGTENSGYFRGSYSNSPSNPVNSRANQDFSALMRSSYHCAMNNENARLLTFQTWPLTFLSPTDLAKAGFYYIGPGDRVACFACGGKLSNWEPKDNAMSEHLRHFPKCPFIENQLQDTSRYTVSNLSMQTHAARFKTFFNWPSSVLVNPEQLASAGFYYVGNSDDVKCFCCDGGLRCWESGDDPWVQHAKWFPRCEYLIRIKGQEFIRQVQASYPHLLEQLLSTSDSPGDENAESSIIHFEPGEDHSEDAIMMNTPVINAAVEMGFSRSLVKQTVQRKILATGENYRLVNDLVLDLLNAEDEIREEERERATEEKESNDLLLIRKNRMALFQHLTCVIPILDSLLTAGIINEQEHDVIKQKTQTSLQARELIDTILVKGNIAATVFRNSLQEAEAVLYEHLFVQQDIKYIPTEDVSDLPVEEQLRRLQEERTCKVCMDKEVSIVFIPCGHLVVCKDCAPSLRKCPICRSTIKGTVRTFLS T35173 DRUGINFO D03MXK AT-406 Phase 3 T35173 DRUGINFO D0B6KC PMID25980951-Compound-27 Patented T35173 DRUGINFO D0HY5Q PMID25980951-Compound-43 Patented T35173 DRUGINFO D0R3YM PMID25980951-Compound-1 Patented T35173 DRUGINFO D0YN1X PMID25980951-Compound-44 Patented T35173 DRUGINFO D0VK7M AZD5582 Investigative T84780 TARGETID T84780 T84780 FORMERID TTDI02025 T84780 UNIPROID BIRC2_HUMAN T84780 TARGNAME Cellular inhibitor of apoptosis 1 (BIRC2) T84780 GENENAME BIRC2 T84780 TARGTYPE Clinical trial T84780 SYNONYMS hIAP2; hIAP-2; TNFR2TRAFsignaling complex protein 2; TNFR2-TRAF-signaling complex protein 2; RNF48; RING-type E3 ubiquitin transferase BIRC2; RING finger protein 48; MIHB; Inhibitor of apoptosis protein 2; IAP2; IAP homolog B; CIAP1; C-IAP1; Baculoviral IAP repeatcontaining protein 2; Baculoviral IAP repeat-containing protein 2; API1 T84780 FUNCTION Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, TRAF2, DIABLO/SMAC, MAP3K14/NIK, MAP3K5/ASK1, IKBKG/NEMO, IKBKE and MXD1/MAD1. Can also function as an E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Can stimulate the transcriptional activity of E2F1. Plays a role in the modulation of the cell cycle. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling, and cell proliferation, as well as cell invasion and metastasis. T84780 PDBSTRUC 6HPR; 6EXW; 5M6N; 4MU7; 4MTI T84780 BIOCLASS Acyltransferase T84780 ECNUMBER EC 2.3.2.27 T84780 SEQUENCE MHKTASQRLFPGPSYQNIKSIMEDSTILSDWTNSNKQKMKYDFSCELYRMSTYSTFPAGVPVSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKLGDSPIQKHKQLYPSCSFIQNLVSASLGSTSKNTSPMRNSFAHSLSPTLEHSSLFSGSYSSLSPNPLNSRAVEDISSSRTNPYSYAMSTEEARFLTYHMWPLTFLSPSELARAGFYYIGPGDRVACFACGGKLSNWEPKDDAMSEHRRHFPNCPFLENSLETLRFSISNLSMQTHAARMRTFMYWPSSVPVQPEQLASAGFYYVGRNDDVKCFCCDGGLRCWESGDDPWVEHAKWFPRCEFLIRMKGQEFVDEIQGRYPHLLEQLLSTSDTTGEENADPPIIHFGPGESSSEDAVMMNTPVVKSALEMGFNRDLVKQTVQSKILTTGENYKTVNDIVSALLNAEDEKREEEKEKQAEEMASDDLSLIRKNRMALFQQLTCVLPILDNLLKANVINKQEHDIIKQKTQIPLQARELIDTILVKGNAAANIFKNCLKEIDSTLYKNLFVDKNMKYIPTEDVSGLSLEEQLRRLQEERTCKVCMDKEVSVVFIPCGHLVVCQECAPSLRKCPICRGIIKGTVRTFLS T84780 DRUGINFO D03MXK AT-406 Phase 3 T84780 DRUGINFO D0E8NP Birinapant Phase 2 T84780 DRUGINFO D05HBW PMID25980951-Compound-18 Patented T84780 DRUGINFO D08XOV PMID25980951-Compound-16 Patented T84780 DRUGINFO D0F4GT PMID25980951-Compound-17 Patented T84780 DRUGINFO D02UOD PMID25980951-Compound-3 Patented T84780 DRUGINFO D02ZHC PMID25980951-Compound-4 Patented T84780 DRUGINFO D03DQW PMID25980951-Compound-21 Patented T84780 DRUGINFO D03PTG PMID25980951-Compound-42 Patented T84780 DRUGINFO D03VPP PMID25980951-Compound-22 Patented T84780 DRUGINFO D07FRU PMID25980951-Compound-37 Patented T84780 DRUGINFO D0AC8H PMID25980951-Compound-36 Patented T84780 DRUGINFO D0CV9K PMID25980951-Compound-20 Patented T84780 DRUGINFO D0GF3P PMID25980951-Compound-38 Patented T84780 DRUGINFO D0ID3R PMID25980951-Compound-5 Patented T84780 DRUGINFO D0M3BY PMID25980951-Compound-41 Patented T84780 DRUGINFO D0MH4B PMID25980951-Compound-19 Patented T84780 DRUGINFO D0O8ZD PMID25980951-Compound-7 Patented T84780 DRUGINFO D09VAX PMID25980951-Compound-6 Patented T84780 DRUGINFO D0B6KC PMID25980951-Compound-27 Patented T84780 DRUGINFO D0HY5Q PMID25980951-Compound-43 Patented T84780 DRUGINFO D0R3YM PMID25980951-Compound-1 Patented T84780 DRUGINFO D0YN1X PMID25980951-Compound-44 Patented T84780 DRUGINFO D0O4UQ BV-6 Investigative T84780 DRUGINFO D2SJZ9 EAPB0203 Investigative T84780 DRUGINFO D0VK7M AZD5582 Investigative T97155 TARGETID T97155 T97155 FORMERID TTDI02023 T97155 UNIPROID ATR_HUMAN T97155 TARGNAME Serine/threonine-protein kinase ATR (FRP1) T97155 GENENAME ATR T97155 TARGTYPE Clinical trial T97155 SYNONYMS FRAP-related protein 1; Ataxia telangiectasia and Rad3-related protein T97155 FUNCTION Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates BRCA1, CHEK1, MCM2, RAD17, RPA2, SMC1 and p53/TP53, which collectively inhibit DNA replication and mitosis and promote DNA repair, recombination and apoptosis. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at sites of DNA damage, thereby regulating DNA damage response mechanism. Required for FANCD2 ubiquitination. Critical for maintenance of fragile site stability and efficient regulation of centrosome duplication. Serine/threonine protein kinase which activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor. T97155 PDBSTRUC 5YZ0 T97155 BIOCLASS Kinase T97155 ECNUMBER EC 2.7.11.1 T97155 SEQUENCE MGEHGLELASMIPALRELGSATPEEYNTVVQKPRQILCQFIDRILTDVNVVAVELVKKTDSQPTSVMLLDFIQHIMKSSPLMFVNVSGSHEAKGSCIEFSNWIITRLLRIAATPSCHLLHKKICEVICSLLFLFKSKSPAIFGVLTKELLQLFEDLVYLHRRNVMGHAVEWPVVMSRFLSQLDEHMGYLQSAPLQLMSMQNLEFIEVTLLMVLTRIIAIVFFRRQELLLWQIGCVLLEYGSPKIKSLAISFLTELFQLGGLPAQPASTFFSSFLELLKHLVEMDTDQLKLYEEPLSKLIKTLFPFEAEAYRNIEPVYLNMLLEKLCVMFEDGVLMRLKSDLLKAALCHLLQYFLKFVPAGYESALQVRKVYVRNICKALLDVLGIEVDAEYLLGPLYAALKMESMEIIEEIQCQTQQENLSSNSDGISPKRRRLSSSLNPSKRAPKQTEEIKHVDMNQKSILWSALKQKAESLQISLEYSGLKNPVIEMLEGIAVVLQLTALCTVHCSHQNMNCRTFKDCQHKSKKKPSVVITWMSLDFYTKVLKSCRSLLESVQKLDLEATIDKVVKIYDALIYMQVNSSFEDHILEDLCGMLSLPWIYSHSDDGCLKLTTFAANLLTLSCRISDSYSPQAQSRCVFLLTLFPRRIFLEWRTAVYNWALQSSHEVIRASCVSGFFILLQQQNSCNRVPKILIDKVKDDSDIVKKEFASILGQLVCTLHGMFYLTSSLTEPFSEHGHVDLFCRNLKATSQHECSSSQLKASVCKPFLFLLKKKIPSPVKLAFIDNLHHLCKHLDFREDETDVKAVLGTLLNLMEDPDKDVRVAFSGNIKHILESLDSEDGFIKELFVLRMKEAYTHAQISRNNELKDTLILTTGDIGRAAKGDLVPFALLHLLHCLLSKSASVSGAAYTEIRALVAAKSVKLQSFFSQYKKPICQFLVESLHSSQMTALPNTPCQNADVRKQDVAHQREMALNTLSEIANVFDFPDLNRFLTRTLQVLLPDLAAKASPAASALIRTLGKQLNVNRREILINNFKYIFSHLVCSCSKDELERALHYLKNETEIELGSLLRQDFQGLHNELLLRIGEHYQQVFNGLSILASFASSDDPYQGPRDIISPELMADYLQPKLLGILAFFNMQLLSSSVGIEDKKMALNSLMSLMKLMGPKHVSSVRVKMMTTLRTGLRFKDDFPELCCRAWDCFVRCLDHACLGSLLSHVIVALLPLIHIQPKETAAIFHYLIIENRDAVQDFLHEIYFLPDHPELKKIKAVLQEYRKETSESTDLQTTLQLSMKAIQHENVDVRIHALTSLKETLYKNQEKLIKYATDSETVEPIISQLVTVLLKGCQDANSQARLLCGECLGELGAIDPGRLDFSTTETQGKDFTFVTGVEDSSFAYGLLMELTRAYLAYADNSRAQDSAAYAIQELLSIYDCREMETNGPGHQLWRRFPEHVREILEPHLNTRYKSSQKSTDWSGVKKPIYLSKLGSNFAEWSASWAGYLITKVRHDLASKIFTCCSIMMKHDFKVTIYLLPHILVYVLLGCNQEDQQEVYAEIMAVLKHDDQHTINTQDIASDLCQLSTQTVFSMLDHLTQWARHKFQALKAEKCPHSKSNRNKVDSMVSTVDYEDYQSVTRFLDLIPQDTLAVASFRSKAYTRAVMHFESFITEKKQNIQEHLGFLQKLYAAMHEPDGVAGVSAIRKAEPSLKEQILEHESLGLLRDATACYDRAIQLEPDQIIHYHGVVKSMLGLGQLSTVITQVNGVHANRSEWTDELNTYRVEAAWKLSQWDLVENYLAADGKSTTWSVRLGQLLLSAKKRDITAFYDSLKLVRAEQIVPLSAASFERGSYQRGYEYIVRLHMLCELEHSIKPLFQHSPGDSSQEDSLNWVARLEMTQNSYRAKEPILALRRALLSLNKRPDYNEMVGECWLQSARVARKAGHHQTAYNALLNAGESRLAELYVERAKWLWSKGDVHQALIVLQKGVELCFPENETPPEGKNMLIHGRAMLLVGRFMEETANFESNAIMKKYKDVTACLPEWEDGHFYLAKYYDKLMPMVTDNKMEKQGDLIRYIVLHFGRSLQYGNQFIYQSMPRMLTLWLDYGTKAYEWEKAGRSDRVQMRNDLGKINKVITEHTNYLAPYQFLTAFSQLISRICHSHDEVFVVLMEIIAKVFLAYPQQAMWMMTAVSKSSYPMRVNRCKEILNKAIHMKKSLEKFVGDATRLTDKLLELCNKPVDGSSSTLSMSTHFKMLKKLVEEATFSEILIPLQSVMIPTLPSILGTHANHASHEPFPGHWAYIAGFDDMVEILASLQKPKKISLKGSDGKFYIMMCKPKDDLRKDCRLMEFNSLINKCLRKDAESRRRELHIRTYAVIPLNDECGIIEWVNNTAGLRPILTKLYKEKGVYMTGKELRQCMLPKSAALSEKLKVFREFLLPRHPPIFHEWFLRTFPDPTSWYSSRSAYCRSTAVMSMVGYILGLGDRHGENILFDSLTGECVHVDFNCLFNKGETFEVPEIVPFRLTHNMVNGMGPMGTEGLFRRACEVTMRLMRDQREPLMSVLKTFLHDPLVEWSKPVKGHSKAPLNETGEVVNEKAKTHVLDIEQRLQGVIKTRNRVTGLPLSIEGHVHYLIQEATDENLLCQMYLGWTPYM T97155 DRUGINFO D0H9DA AZD6738 Phase 2 T97155 DRUGINFO DAD65R RP-3500 Phase 1/2 T97155 DRUGINFO DDSW97 Camonsertib Phase 1/2 T97155 DRUGINFO D03BYM BAY1895344 Phase 1 T97155 DRUGINFO D06DMQ VX-970 Phase 1 T97155 DRUGINFO D0IE9L M4344 Phase 1 T97155 DRUGINFO D3OWG9 M1774 Phase 1 T97155 DRUGINFO D02TSN AZ20 Investigative T97155 DRUGINFO D0G0BJ VE-821 Investigative T97155 DRUGINFO D00PXO CGK733 Investigative T73694 TARGETID T73694 T73694 FORMERID TTDR00884 T73694 UNIPROID PTK6_HUMAN T73694 TARGNAME Tyrosine-protein kinase BRK (PTK6) T73694 GENENAME PTK6 T73694 TARGTYPE Clinical trial T73694 SYNONYMS Protein-tyrosine kinase 6; Breast tumor kinase; BRK T73694 FUNCTION Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth. Function seems to be context dependent and differ depending on cell type, as well as its intracellular localization. A number of potential nuclear and cytoplasmic substrates have been identified. These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B and a variety of signaling molecules: ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of proteins that are likely upstream of PTK6 in various signaling pathways, or for which PTK6 may play an adapter-like role. These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6 promotes cellular differentiation and apoptosis. In tumors PTK6 contributes to cancer progression by sensitizing cells to mitogenic signals and enhancing proliferation, anchorage-independent survival and migration/invasion. Association with EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 kinase. Contributes to migration and proliferation by contributing to EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes association with RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. Nuclear PTK6 may be important for regulating growth in normal epithelia, while cytoplasmic PTK6 might activate oncogenic signaling pathways. T73694 PDBSTRUC 6CZ4; 6CZ3; 6CZ2; 5H2U; 5DA3 T73694 BIOCLASS Kinase T73694 ECNUMBER EC 2.7.10.2 T73694 SEQUENCE MVSRDQAHLGPKYVGLWDFKSRTDEELSFRAGDVFHVARKEEQWWWATLLDEAGGAVAQGYVPHNYLAERETVESEPWFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKIWRRAGGRLHLNEAVSFLSLPELVNYHRAQSLSHGLRLAAPCRKHEPEPLPHWDDWERPREEFTLCRKLGSGYFGEVFEGLWKDRVQVAIKVISRDNLLHQQMLQSEIQAMKKLRHKHILALYAVVSVGDPVYIITELMAKGSLLELLRDSDEKVLPVSELLDIAWQVAEGMCYLESQNYIHRDLAARNILVGENTLCKVGDFGLARLIKEDVYLSHDHNIPYKWTAPEALSRGHYSTKSDVWSFGILLHEMFSRGQVPYPGMSNHEAFLRVDAGYRMPCPLECPPSVHKLMLTCWCRDPEQRPCFKALRERLSSFTSYENPT T73694 DRUGINFO D06CIJ ISIS-CRP Phase 1 T73694 DRUGINFO D0IZ8M PMID21855335C19a Investigative T40459 TARGETID T40459 T40459 FORMERID TTDR00677 T40459 UNIPROID I13R2_HUMAN T40459 TARGNAME Interleukin 13 receptor alpha-2 (IL13RA2) T40459 GENENAME IL13RA2 T40459 TARGTYPE Clinical trial T40459 SYNONYMS Interleukin-13-binding protein; Interleukin-13 receptor subunit alpha-2; Interleukin-13 binding protein; IL-13RA2; IL-13R-alpha-2; IL-13R subunit alpha-2; IL-13R alpha-2 chain; IL-13 receptor subunit alpha-2; CD213a2 T40459 FUNCTION Binds as a monomer with high affinity to interleukin-13 (IL13), but not to interleukin-4 (IL4). T40459 PDBSTRUC 3LB6 T40459 BIOCLASS Cytokine receptor T40459 SEQUENCE MAFVCLAIGCLYTFLISTTFGCTSSSDTEIKVNPPQDFEIVDPGYLGYLYLQWQPPLSLDHFKECTVEYELKYRNIGSETWKTIITKNLHYKDGFDLNKGIEAKIHTLLPWQCTNGSEVQSSWAETTYWISPQGIPETKVQDMDCVYYNWQYLLCSWKPGIGVLLDTNYNLFYWYEGLDHALQCVDYIKADGQNIGCRFPYLEASDYKDFYICVNGSSENKPIRSSYFTFQLQNIVKPLPPVYLTFTRESSCEIKLKWSIPLGPIPARCFDYEIEIREDDTTLVTATVENETYTLKTTNETRQLCFVVRSKVNIYCSDDGIWSEWSDKQCWEGEDLSKKTLLRFWLPFGFILILVIFVTGLLLRKPNTYPKMIPEFFCDT T40459 DRUGINFO D0M1RD ICT-107 Phase 3 T40459 DRUGINFO D0N3WN ABT-308 Phase 2 T40459 DRUGINFO D0YN9Y MB-101 Phase 1 T42048 TARGETID T42048 T42048 FORMERID TTDI02031 T42048 UNIPROID BRD3_HUMAN T42048 TARGNAME Bromodomain-containing protein 3 (BRD3) T42048 GENENAME BRD3 T42048 TARGTYPE Clinical trial T42048 SYNONYMS RING3like protein; RING3L; RING3-like protein; KIAA0043 T42048 FUNCTION Regulates transcription by promoting the binding of the transcription factor GATA1 to its targets. Chromatin reader that recognizes and binds hyperacetylated chromatin and plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors. T42048 PDBSTRUC 6I7A; 6I68; 6I5P; 6I41; 6BGH T42048 BIOCLASS Bromodomain T42048 SEQUENCE MSTATTVAPAGIPATPGPVNPPPPEVSNPSKPGRKTNQLQYMQNVVVKTLWKHQFAWPFYQPVDAIKLNLPDYHKIIKNPMDMGTIKKRLENNYYWSASECMQDFNTMFTNCYIYNKPTDDIVLMAQALEKIFLQKVAQMPQEEVELLPPAPKGKGRKPAAGAQSAGTQQVAAVSSVSPATPFQSVPPTVSQTPVIAATPVPTITANVTSVPVPPAAAPPPPATPIVPVVPPTPPVVKKKGVKRKADTTTPTTSAITASRSESPPPLSDPKQAKVVARRESGGRPIKPPKKDLEDGEVPQHAGKKGKLSEHLRYCDSILREMLSKKHAAYAWPFYKPVDAEALELHDYHDIIKHPMDLSTVKRKMDGREYPDAQGFAADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDEPVEAPALPAPAAPMVSKGAESSRSSEESSSDSGSSDSEEERATRLAELQEQLKAVHEQLAALSQAPVNKPKKKKEKKEKEKKKKDKEKEKEKHKVKAEEEKKAKVAPPAKQAQQKKAPAKKANSTTTAGRQLKKGGKQASASYDSEEEEEGLPMSYDEKRQLSLDINRLPGEKLGRVVHIIQSREPSLRDSNPDEIEIDFETLKPTTLRELERYVKSCLQKKQRKPFSASGKKQAAKSKEELAQEKKKELEKRLQDVSGQLSSSKKPARKEKPGSAPSGGPSRLSSSSSSESGSSSSSGSSSDSSDSE T42048 DRUGINFO D05ICT ABBV-744 Phase 1 T42048 DRUGINFO D0YM3G Pyrrolo-pyrrolone derivative 1 Patented T42048 DRUGINFO D03NWT PMID26924192-Compound-104 Patented T42048 DRUGINFO D03RPJ PMID26924192-Compound-102 Patented T42048 DRUGINFO D05XXS PMID26924192-Compound-103 Patented T42048 DRUGINFO D0NN4U PMID26924192-Compound-105 Patented T42048 DRUGINFO D03LIP GW841819X Investigative T42048 DRUGINFO D0C2XT PMID24000170C36 Investigative T42048 DRUGINFO D0Q2GK PMID24000170C38 Investigative T42048 DRUGINFO D0WU1S I-BET151 Investigative T42048 DRUGINFO D07FGY XD14 Investigative T90782 TARGETID T90782 T90782 FORMERID TTDR00731 T90782 UNIPROID P2RY6_HUMAN T90782 TARGNAME P2Y purinoceptor 6 (P2RY6) T90782 GENENAME P2RY6 T90782 TARGTYPE Clinical trial T90782 SYNONYMS P2Y6; P2RY6; Adenosine P2Y6 receptor T90782 FUNCTION Receptor for extracellular UDP > UTP > ATP. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. T90782 PDBSTRUC 2B6R T90782 BIOCLASS GPCR rhodopsin T90782 SEQUENCE MEWDNGTGQALGLPPTTCVYRENFKQLLLPPVYSAVLAAGLPLNICVITQICTSRRALTRTAVYTLNLALADLLYACSLPLLIYNYAQGDHWPFGDFACRLVRFLFYANLHGSILFLTCISFQRYLGICHPLAPWHKRGGRRAAWLVCVAVWLAVTTQCLPTAIFAATGIQRNRTVCYDLSPPALATHYMPYGMALTVIGFLLPFAALLACYCLLACRLCRQDGPAEPVAQERRGKAARMAVVVAAAFAISFLPFHITKTAYLAVRSTPGVPCTVLEAFAAAYKGTRPFASANSVLDPILFYFTQKKFRRRPHELLQKLTAKWQRQGR T90782 DRUGINFO D0D4HO GC021109 Phase 1 T90782 DRUGINFO D0Z7FU INS 316 Discontinued in Phase 3 T90782 DRUGINFO D03WBX MRS2782 Investigative T90782 DRUGINFO D03YRN MRS2578 Investigative T90782 DRUGINFO D08VPN UDP-beta-S Investigative T90782 DRUGINFO D09RGZ Up3U Investigative T90782 DRUGINFO D0C5FN Rp-5-OMe-UDPalphaB Investigative T90782 DRUGINFO D0J4MU MRS2957 Investigative T90782 DRUGINFO D0P6KN INS48823 Investigative T90782 DRUGINFO D0Q2OK MRS2693 Investigative T90782 DRUGINFO D0T4WF 3-phenacyl-UDP Investigative T90782 DRUGINFO D0V4FT MRS2567 Investigative T90782 DRUGINFO D0DZ1K PSB-0952 Investigative T90782 DRUGINFO D0P7RI 5BrUTP Investigative T90782 DRUGINFO D0B0ZQ RB 2 Investigative T90782 DRUGINFO D0U1OJ 2MeSATP Investigative T90782 DRUGINFO D05NWF adenosine diphosphate Investigative T07400 TARGETID T07400 T07400 FORMERID TTDR00745 T07400 UNIPROID RAGE_HUMAN T07400 TARGNAME Advanced glycosylation end product receptor (AGER) T07400 GENENAME AGER T07400 TARGTYPE Clinical trial T07400 SYNONYMS Receptor foradvanced glycosylation end products; RAGESEC; RAGE; AGER T07400 FUNCTION Mediates interactions of advanced glycosylation end products (age). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Receptor for amyloid beta peptide. T07400 PDBSTRUC 5D7F; 4YBH; 4XYN; 4P2Y; 4OI8 T07400 BIOCLASS Immunoglobulin T07400 SEQUENCE MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGVILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP T07400 DRUGINFO D02YPU Pyridoxamine Phase 3 T07400 DRUGINFO D0MW7B PF-4494700 Phase 3 T07400 DRUGINFO D07JLM Alagebrium chloride Phase 2/3 T07400 DRUGINFO D0PU9C TTP-448 Phase 2 T07400 DRUGINFO D0I0YS TTP-4000 Phase 1 T07400 DRUGINFO D07QVY DBT-066 Investigative T25317 TARGETID T25317 T25317 FORMERID TTDI02057 T25317 UNIPROID EBP_HUMAN T25317 TARGNAME Cholestenol delta-isomerase (EBP) T25317 GENENAME EBP T25317 TARGTYPE Clinical trial T25317 SYNONYMS Emopamilbinding protein; EBP; Delta(8)Delta(7) sterol isomerase; D8D7 sterol isomerase; 3betahydroxysteroidDelta(8),Delta(7)isomerase T25317 FUNCTION Catalyzes the conversion of Delta(8)-sterols to their corresponding Delta(7)-isomers. T25317 BIOCLASS Intramolecular oxidoreductases T25317 ECNUMBER EC 5.3.3.5 T25317 SEQUENCE MTTNAGPLHPYWPQHLRLDNFVPNDRPTWHILAGLFSVTGVLVVTTWLLSGRAAVVPLGTWRRLSLCWFAVCGFIHLVIEGWFVLYYEDLLGDQAFLSQLWKEYAKGDSRYILGDNFTVCMETITACLWGPLSLWVVIAFLRQHPLRFILQLVVSVGQIYGDVLYFLTEHRDGFQHGELGHPLYFWFYFVFMNALWLVLPGVLVLDAVKHLTHAQSTLDAKATKAKSKKN T25317 DRUGINFO D0D4JI SR-31747 Phase 2 T59626 TARGETID T59626 T59626 FORMERID TTDC00129 T59626 UNIPROID LT4R1_HUMAN T59626 TARGNAME Leukotriene B4 receptor 1 (LTB4R) T59626 GENENAME LTB4R T59626 TARGTYPE Clinical trial T59626 SYNONYMS P2Y7; P2Y purinoceptor 7; P2RY7; Leukotriene B(4) receptor BLT1; LTB4-R1; LTB4-R 1; LTB4-R; GPR16; G-protein coupled receptor 16; Chemoattractant receptor-like 1; CMKRL1; BLTR; BLT1; BLT T59626 FUNCTION The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. May be the cardiac P2Y receptor involved in the regulation of cardiac muscle contraction through modulation of L-type calcium currents. Is a receptor for leukotriene B4, a potent chemoattractant involved in inflammation and immune response. Receptor for extracellular ATP > UTP and ADP. T59626 BIOCLASS GPCR rhodopsin T59626 SEQUENCE MNTTSSAAPPSLGVEFISLLAIILLSVALAVGLPGNSFVVWSILKRMQKRSVTALMVLNLALADLAVLLTAPFFLHFLAQGTWSFGLAGCRLCHYVCGVSMYASVLLITAMSLDRSLAVARPFVSQKLRTKAMARRVLAGIWVLSFLLATPVLAYRTVVPWKTNMSLCFPRYPSEGHRAFHLIFEAVTGFLLPFLAVVASYSDIGRRLQARRFRRSRRTGRLVVLIILTFAAFWLPYHVVNLAEAGRALAGQAAGLGLVGKRLSLARNVLIALAFLSSSVNPVLYACAGGGLLRSAGVGFVAKLLEGTGSEASSTRRGGSLGQTARSGPAALEPGPSESLTASSPLKLNELN T59626 DRUGINFO D0QG2D Amelubant Phase 2 T59626 DRUGINFO D0O4NR LTB4 Phase 2 T59626 DRUGINFO D0S0WN Biomed 101 Phase 1 T59626 DRUGINFO D00GNK LY293111 Discontinued in Phase 2 T59626 DRUGINFO D0B6JV SB-201993 Discontinued in Phase 2 T59626 DRUGINFO D0KV4Z CI-949 Discontinued in Phase 2 T59626 DRUGINFO D0MM2K CP-195543 Discontinued in Phase 2 T59626 DRUGINFO D0N0PU LTB 019 Discontinued in Phase 2 T59626 DRUGINFO D0U9JL LY-223982 Discontinued in Phase 2 T59626 DRUGINFO D0C0EO CP-105696 Discontinued in Phase 1 T59626 DRUGINFO D0P9KL TAK-683 Discontinued in Phase 1 T59626 DRUGINFO D04AWZ SB-201146 Terminated T59626 DRUGINFO D04JJE RP-66153 Terminated T59626 DRUGINFO D05LYL SC-51146 Terminated T59626 DRUGINFO D09LQP RG-14893 Terminated T59626 DRUGINFO D0A5ZJ DW-1350 Terminated T59626 DRUGINFO D0G7SP SB-209247 Terminated T59626 DRUGINFO D0J3NJ RP-69698 Terminated T59626 DRUGINFO D0NK8D SC-53228 Terminated T59626 DRUGINFO D0OP7B LY-210073 Terminated T59626 DRUGINFO D0Z1TF Ro-25-4094 Terminated T59626 DRUGINFO D01XMO LY-292728 Terminated T59626 DRUGINFO D05BBQ RP-66364 Terminated T59626 DRUGINFO D0Y2IH LY-255283 Terminated T59626 DRUGINFO D00HYO Leucettamidine Investigative T59626 DRUGINFO D06IJI SC-52073 Investigative T59626 DRUGINFO D07EGC SC-50073 Investigative T59626 DRUGINFO D09QJS SC-53229 Investigative T59626 DRUGINFO D0C2GW SC-52569 Investigative T59626 DRUGINFO D0F4EL LEUCETTAMINE A Investigative T59626 DRUGINFO D0H6YL (LTB4-(Csa)4)2-Glu-H Conjugate Investigative T59626 DRUGINFO D0L8VT DTPA Conjugate Investigative T59626 DRUGINFO D0R9ED SC-50676 Investigative T59626 DRUGINFO D0T1IK HYNIC Analogue Investigative T59626 DRUGINFO D0ZB8S SC-50135 Investigative T59626 DRUGINFO D05HNB LY-282210 Investigative T59626 DRUGINFO D06IGT (3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol Investigative T97141 TARGETID T97141 T97141 FORMERID TTDR00794 T97141 UNIPROID MYLK_HUMAN T97141 TARGNAME Myosin light kinase (MYLK) T97141 GENENAME MYLK T97141 TARGTYPE Clinical trial T97141 SYNONYMS smMLCK; Telokin; Myosin light chain kinase, smooth muscle; MYLK1; MLCK210; MLCK1; MLCK; Kinase-related protein; KRP; Endothelial cell (EC) MLCK isoform; EC mlck; 210,000 molecular weight myosin light chain kinase T97141 FUNCTION Regulates actin-myosin interaction through a non-kinase activity. Phosphorylates PTK2B/PYK2 and myosin light-chains. Involved in the inflammatory response (e. g. apoptosis, vascular permeability, leukocyte diapedesis), cell motility and morphology, airway hyperreactivity and other activities relevant to asthma. Required for tonic airway smooth muscle contraction that is necessary for physiological and asthmatic airway resistance. Necessary for gastrointestinal motility. Implicated in the regulation of endothelial as well as vascular permeability, probably via the regulation of cytoskeletal rearrangements. In the nervous system it has been shown to control the growth initiation of astrocytic processes in culture and to participate in transmitter release at synapses formed between cultured sympathetic ganglion cells. Critical participant in signaling sequences that result in fibroblast apoptosis. Plays a role in the regulation of epithelial cell survival. Required for epithelial wound healing, especially during actomyosin ring contraction during purse-string wound closure. Mediates RhoA-dependent membrane blebbing. Triggers TRPC5 channel activity in a calcium-dependent signaling, by inducing its subcellular localization at the plasma membrane. Promotes cell migration (including tumor cells) and tumor metastasis. PTK2B/PYK2 activation by phosphorylation mediates ITGB2 activation and is thus essential to trigger neutrophil transmigration during acute lung injury (ALI). May regulate optic nerve head astrocyte migration. Probably involved in mitotic cytoskeletal regulation. Regulates tight junction probably by modulating ZO-1 exchange in the perijunctional actomyosin ring. Mediates burn-induced microvascular barrier injury; triggers endothelial contraction in the development of microvascular hyperpermeability by phosphorylating MLC. Essential for intestinal barrier dysfunction. Mediates Giardia spp. -mediated reduced epithelial barrier function during giardiasis intestinal infection via reorganization of cytoskeletal F-actin and tight junctional ZO-1. Necessary for hypotonicity-induced Ca(2+) entry and subsequent activation of volume-sensitive organic osmolyte/anion channels (VSOAC) in cervical cancer cells. Responsible for high proliferative ability of breast cancer cells through anti-apoptosis. Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contraction via phosphorylation of myosin light chains (MLC). T97141 PDBSTRUC 6C6M; 5JTH; 5JQA; 2YR3; 2K0F T97141 BIOCLASS Kinase T97141 ECNUMBER EC 2.7.11.18 T97141 SEQUENCE MGDVKLVASSHISKTSLSVDPSRVDSMPLTEAPAFILPPRNLCIKEGATAKFEGRVRGYPEPQVTWHRNGQPITSGGRFLLDCGIRGTFSLVIHAVHEEDRGKYTCEATNGSGARQVTVELTVEGSFAKQLGQPVVSKTLGDRFSAPAVETRPSIWGECPPKFATKLGRVVVKEGQMGRFSCKITGRPQPQVTWLKGNVPLQPSARVSVSEKNGMQVLEIHGVNQDDVGVYTCLVVNGSGKASMSAELSIQGLDSANRSFVRETKATNSDVRKEVTNVISKESKLDSLEAAAKSKNCSSPQRGGSPPWAANSQPQPPRESKLESCKDSPRTAPQTPVLQKTSSSITLQAARVQPEPRAPGLGVLSPSGEERKRPAPPRPATFPTRQPGLGSQDVVSKAANRRIPMEGQRDSAFPKFESKPQSQEVKENQTVKFRCEVSGIPKPEVAWFLEGTPVRRQEGSIEVYEDAGSHYLCLLKARTRDSGTYSCTASNAQGQLSCSWTLQVERLAVMEVAPSFSSVLKDCAVIEGQDFVLQCSVRGTPVPRITWLLNGQPIQYARSTCEAGVAELHIQDALPEDHGTYTCLAENALGQVSCSAWVTVHEKKSSRKSEYLLPVAPSKPTAPIFLQGLSDLKVMDGSQVTMTVQVSGNPPPEVIWLHNGNEIQESEDFHFEQRGTQHSLCIQEVFPEDTGTYTCEAWNSAGEVRTQAVLTVQEPHDGTQPWFISKPRSVTASLGQSVLISCAIAGDPFPTVHWLRDGKALCKDTGHFEVLQNEDVFTLVLKKVQPWHAGQYEILLKNRVGECSCQVSLMLQNSSARALPRGREPASCEDLCGGGVGADGGGSDRYGSLRPGWPARGQGWLEEEDGEDVRGVLKRRVETRQHTEEAIRQQEVEQLDFRDLLGKKVSTKTLSEDDLKEIPAEQMDFRANLQRQVKPKTVSEEERKVHSPQQVDFRSVLAKKGTSKTPVPEKVPPPKPATPDFRSVLGGKKKLPAENGSSSAETLNAKAVESSKPLSNAQPSGPLKPVGNAKPAETLKPMGNAKPAETLKPMGNAKPDENLKSASKEELKKDVKNDVNCKRGHAGTTDNEKRSESQGTAPAFKQKLQDVHVAEGKKLLLQCQVSSDPPATIIWTLNGKTLKTTKFIILSQEGSLCSVSIEKALPEDRGLYKCVAKNDAGQAECSCQVTVDDAPASENTKAPEMKSRRPKSSLPPVLGTESDATVKKKPAPKTPPKAAMPPQIIQFPEDQKVRAGESVELFGKVTGTQPITCTWMKFRKQIQESEHMKVENSENGSKLTILAARQEHCGCYTLLVENKLGSRQAQVNLTVVDKPDPPAGTPCASDIRSSSLTLSWYGSSYDGGSAVQSYSIEIWDSANKTWKELATCRSTSFNVQDLLPDHEYKFRVRAINVYGTSEPSQESELTTVGEKPEEPKDEVEVSDDDEKEPEVDYRTVTINTEQKVSDFYDIEERLGSGKFGQVFRLVEKKTRKVWAGKFFKAYSAKEKENIRQEISIMNCLHHPKLVQCVDAFEEKANIVMVLEIVSGGELFERIIDEDFELTERECIKYMRQISEGVEYIHKQGIVHLDLKPENIMCVNKTGTRIKLIDFGLARRLENAGSLKVLFGTPEFVAPEVINYEPIGYATDMWSIGVICYILVSGLSPFMGDNDNETLANVTSATWDFDDEAFDEISDDAKDFISNLLKKDMKNRLDCTQCLQHPWLMKDTKNMEAKKLSKDRMKKYMARRKWQKTGNAVRAIGRLSSMAMISGLSGRKSSTGSPTSPLNAEKLESEEDVSQAFLEAVAEEKPHVKPYFSKTIRDLEVVEGSAARFDCKIEGYPDPEVVWFKDDQSIRESRHFQIDYDEDGNCSLIISDVCGDDDAKYTCKAVNSLGEATCTAELIVETMEEGEGEGEEEEE T97141 DRUGINFO D0L8MO ME-3407 Phase 2 T97141 DRUGINFO D03CPB RKI-1447 Investigative T46245 TARGETID T46245 T46245 FORMERID TTDI02156 T46245 UNIPROID QPCT_HUMAN T46245 TARGNAME Glutaminyl cyclase (QPCT) T46245 GENENAME QPCT T46245 TARGTYPE Clinical trial T46245 SYNONYMS sQC; QPCT; QC; Glutamyl cyclase; GlutaminyltRNA cyclotransferase; Glutaminylpeptide cyclotransferase; EC T46245 FUNCTION Responsible for the biosynthesis of pyroglutamyl peptides. Has a bias against acidic and tryptophan residues adjacent to the N-terminal glutaminyl residue and a lack of importance of chain length after the second residue. Also catalyzes N-terminal pyroglutamate formation. In vitro, catalyzes pyroglutamate formation of N-terminally truncated form of APP amyloid-beta peptides [Glu-3]-beta-amyloid. May be involved in the N-terminal pyroglutamate formation of several amyloid-related plaque-forming peptides. T46245 PDBSTRUC 6GBX; 4YWY; 4YU9; 3SI0; 3PBE T46245 BIOCLASS Acyltransferase T46245 ECNUMBER EC 2.3.2.5 T46245 SEQUENCE MAGGRHRRVVGTLHLLLLVAALPWASRGVSPSASAWPEEKNYHQPAILNSSALRQIAEGTSISEMWQNDLQPLLIERYPGSPGSYAARQHIMQRIQRLQADWVLEIDTFLSQTPYGYRSFSNIISTLNPTAKRHLVLACHYDSKYFSHWNNRVFVGATDSAVPCAMMLELARALDKKLLSLKTVSDSKPDLSLQLIFFDGEEAFLHWSPQDSLYGSRHLAAKMASTPHPPGARGTSQLHGMDLLVLLDLIGAPNPTFPNFFPNSARWFERLQAIEHELHELGLLKDHSLEGRYFQNYSYGGVIQDDHIPFLRRGVPVLHLIPSPFPEVWHTMDDNEENLDESTIDNLNKILQVFVLEYLHL T46245 DRUGINFO D0UD4Y PQ-912 Phase 2 T46245 DRUGINFO D00JHN PBD150 Investigative T32972 TARGETID T32972 T32972 UNIPROID CP51A_HUMAN T32972 TARGNAME Lanosterol 14-alpha demethylase (CYP51A1) T32972 GENENAME CYP51A1 T32972 TARGTYPE Clinical trial T32972 SYNONYMS Cytochrome P450LI; Cytochrome P45014DM; Cytochrome P450-14DM; Cytochrome P450 51A1 T32972 FUNCTION Catalyzes C14-demethylation of lanosterol; it transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol. T32972 PDBSTRUC 4UHL; 4UHI; 3LD6; 3JUV; 3JUS T32972 BIOCLASS Cytochrome P450 family T32972 ECNUMBER EC 1.14.14.154 T32972 SEQUENCE MLLLGLLQAGGSVLGQAMEKVTGGNLLSMLLIACAFTLSLVYLIRLAAGHLVQLPAGVKSPPYIFSPIPFLGHAIAFGKSPIEFLENAYEKYGPVFSFTMVGKTFTYLLGSDAAALLFNSKNEDLNAEDVYSRLTTPVFGKGVAYDVPNPVFLEQKKMLKSGLNIAHFKQHVSIIEKETKEYFESWGESGEKNVFEALSELIILTASHCLHGKEIRSQLNEKVAQLYADLDGGFSHAAWLLPGWLPLPSFRRRDRAHREIKDIFYKAIQKRRQSQEKIDDILQTLLDATYKDGRPLTDDEVAGMLIGLLLAGQHTSSTTSAWMGFFLARDKTLQKKCYLEQKTVCGENLPPLTYDQLKDLNLLDRCIKETLRLRPPIMIMMRMARTPQTVAGYTIPPGHQVCVSPTVNQRLKDSWVERLDFNPDRYLQDNPASGEKFAYVPFGAGRHRCIGENFAYVQIKTIWSTMLRLYEFDLIDGYFPTVNYTTMIHTPENPVIRYKRRSK T32972 DRUGINFO D0UA9J VT-1129 Phase 2 T90985 TARGETID T90985 T90985 FORMERID TTDI02033 T90985 UNIPROID BRDT_HUMAN T90985 TARGNAME Bromodomain testis-specific protein (BRDT) T90985 GENENAME BRDT T90985 TARGTYPE Clinical trial T90985 SYNONYMS Cancer/testis antigen 9; CT9 T90985 FUNCTION Required in late pachytene spermatocytes: plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. In the post-meiotic phase of spermatogenesis, binds to hyperacetylated histones and participates in their general removal from DNA. Also recognizes and binds a subset of butyrylated histones: able to bind histone H4 butyrylated at 'Lys-8' (H4K8ac), while it is not able to bind H4 butyrylated at 'Lys-5' (H4K5ac). Also acts as a component of the splicing machinery in pachytene spermatocytes and round spermatids and participates in 3'-UTR truncation of specific mRNAs in post-meiotic spermatids. Required for chromocenter organization, a structure comprised of peri-centromeric heterochromatin. Testis-specific chromatin protein that specifically binds histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, respectively) and plays a key role in spermatogenesis. T90985 PDBSTRUC 5VBR; 5VBQ; 4KCX; 4FLP; 2RFJ T90985 BIOCLASS Bromodomain T90985 SEQUENCE MSLPSRQTAIIVNPPPPEYINTKKNGRLTNQLQYLQKVVLKDLWKHSFSWPFQRPVDAVKLQLPDYYTIIKNPMDLNTIKKRLENKYYAKASECIEDFNTMFSNCYLYNKPGDDIVLMAQALEKLFMQKLSQMPQEEQVVGVKERIKKGTQQNIAVSSAKEKSSPSATEKVFKQQEIPSVFPKTSISPLNVVQGASVNSSSQTAAQVTKGVKRKADTTTPATSAVKASSEFSPTFTEKSVALPPIKENMPKNVLPDSQQQYNVVKTVKVTEQLRHCSEILKEMLAKKHFSYAWPFYNPVDVNALGLHNYYDVVKNPMDLGTIKEKMDNQEYKDAYKFAADVRLMFMNCYKYNPPDHEVVTMARMLQDVFETHFSKIPIEPVESMPLCYIKTDITETTGRENTNEASSEGNSSDDSEDERVKRLAKLQEQLKAVHQQLQVLSQVPFRKLNKKKEKSKKEKKKEKVNNSNENPRKMCEQMRLKEKSKRNQPKKRKQQFIGLKSEDEDNAKPMNYDEKRQLSLNINKLPGDKLGRVVHIIQSREPSLSNSNPDEIEIDFETLKASTLRELEKYVSACLRKRPLKPPAKKIMMSKEELHSQKKQELEKRLLDVNNQLNSRKRQTKSDKTQPSKAVENVSRLSESSSSSSSSSESESSSSDLSSSDSSDSESEMFPKFTEVKPNDSPSKENVKKMKNECIPPEGRTGVTQIGYCVQDTTSANTTLVHQTTPSHVMPPNHHQLAFNYQELEHLQTVKNISPLQILPPSGDSEQLSNGITVMHPSGDSDTTMLESECQAPVQKDIKIKNADSWKSLGKPVKPSGVMKSSDELFNQFRKAAIEKEVKARTQELIRKHLEQNTKELKASQENQRDLGNGLTVESFSNKIQNKCSGEEQKEHQQSSEAQDKSKLWLLKDRDLARQKEQERRRREAMVGTIDMTLQSDIMTMFENNFD T90985 DRUGINFO D0ZW4W (+)-JQ1 Phase 1 T90985 DRUGINFO D03NWT PMID26924192-Compound-104 Patented T90985 DRUGINFO D03RPJ PMID26924192-Compound-102 Patented T90985 DRUGINFO D05XXS PMID26924192-Compound-103 Patented T90985 DRUGINFO D0NN4U PMID26924192-Compound-105 Patented T90985 DRUGINFO D07FGY XD14 Investigative T78381 TARGETID T78381 T78381 FORMERID TTDI02296 T78381 UNIPROID IFNL1_HUMAN T78381 TARGNAME Interleukin-29 (IL29) T78381 GENENAME IFNL1 T78381 TARGTYPE Clinical trial T78381 SYNONYMS ZCYTO21; Interleukin29; Interferon lambda1; Interferon lambda-1; IL-29; IFNlambda1; IFN-lambda-1; Cytokine Zcyto21 T78381 FUNCTION Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression. Cytokine with antiviral, antitumour and immunomodulatory activities. T78381 PDBSTRUC 3OG6; 3OG4 T78381 BIOCLASS Cytokine: interleukin T78381 SEQUENCE MAAAWTVVLVTLVLGLAVAGPVPTSKPTTTGKGCHIGRFKSLSPQELASFKKARDALEESLKLKNWSCSSPVFPGNWDLRLLQVRERPVALEAELALTLKVLEAAAGPALEDVLDQPLHTLHHILSQLQACIQPQPTAGPRPRGRLHHWLHRLQEAPKKESAGCLEASVTFNLFRLLTRDLKYVADGNLCLRTSTHPEST T78381 DRUGINFO D0T6IN Peginterferon lambda-1a Phase 3 T78381 DRUGINFO D0D1XW PEG-Interferon lambda (IL-29) Phase 1 T58496 TARGETID T58496 T58496 FORMERID TTDR01258 T58496 UNIPROID TRPV3_HUMAN T58496 TARGNAME Transient receptor potential cation channel V3 (TRPV3) T58496 GENENAME TRPV3 T58496 TARGTYPE Clinical trial T58496 SYNONYMS Vanilloid receptor-like 3; VRL-3; TrpV3 T58496 FUNCTION Putative receptor-activated non-selective calcium permeant cation channel. It is activated by innocuous (warm) temperatures and shows an increased response at noxious temperatures greater than 39 degrees Celsius. Activation exhibits an outward rectification. May associate with TRPV1 and may modulate its activity. Is a negative regulator of hair growth and cycling: TRPV3-coupled signaling suppresses keratinocyte proliferation in hair follicles and induces apoptosis and premature hair follicle regression (catagen). T58496 PDBSTRUC 6OT5; 6OT2; 6MHX; 6MHW; 6MHV T58496 BIOCLASS Transient receptor potential catioin channel T58496 SEQUENCE MKAHPKEMVPLMGKRVAAPSGNPAILPEKRPAEITPTKKSAHFFLEIEGFEPNPTVAKTSPPVFSKPMDSNIRQCISGNCDDMDSPQSPQDDVTETPSNPNSPSAQLAKEEQRRKKRRLKKRIFAAVSEGCVEELVELLVELQELCRRRHDEDVPDFLMHKLTASDTGKTCLMKALLNINPNTKEIVRILLAFAEENDILGRFINAEYTEEAYEGQTALNIAIERRQGDIAALLIAAGADVNAHAKGAFFNPKYQHEGFYFGETPLALAACTNQPEIVQLLMEHEQTDITSRDSRGNNILHALVTVAEDFKTQNDFVKRMYDMILLRSGNWELETTRNNDGLTPLQLAAKMGKAEILKYILSREIKEKRLRSLSRKFTDWAYGPVSSSLYDLTNVDTTTDNSVLEITVYNTNIDNRHEMLTLEPLHTLLHMKWKKFAKHMFFLSFCFYFFYNITLTLVSYYRPREEEAIPHPLALTHKMGWLQLLGRMFVLIWAMCISVKEGIAIFLLRPSDLQSILSDAWFHFVFFIQAVLVILSVFLYLFAYKEYLACLVLAMALGWANMLYYTRGFQSMGMYSVMIQKVILHDVLKFLFVYIVFLLGFGVALASLIEKCPKDNKDCSSYGSFSDAVLELFKLTIGLGDLNIQQNSKYPILFLFLLITYVILTFVLLLNMLIALMGETVENVSKESERIWRLQRARTILEFEKMLPEWLRSRFRMGELCKVAEDDFRLCLRINEVKWTEWKTHVSFLNEDPGPVRRTDFNKIQDSSRNNSKTTLNAFEEVEEFPETSV T58496 DRUGINFO D03SLK SAR292833 Phase 2 T58496 DRUGINFO D01BDJ diphenyltetrahydrofuran Investigative T58496 DRUGINFO D03EYA carveol Investigative T58496 DRUGINFO D07GOR dihydrocarveol Investigative T58496 DRUGINFO D0D8PZ tetrahydrocannabivarin Investigative T58496 DRUGINFO D0F0BB 6-tert-butyl-m-cresol Investigative T58496 DRUGINFO D0H0EP EDP-18 Investigative T58496 DRUGINFO D0JW1C incensole acetate Investigative T58496 DRUGINFO D0P8RH borneol Investigative T58496 DRUGINFO D00VWN citral Investigative T58496 DRUGINFO D05PYO aspirin-triggered resolvin D1 Investigative T58496 DRUGINFO D07JDC carvacrol Investigative T58496 DRUGINFO D0PJ3M cinnamaldehyde Investigative T58496 DRUGINFO D03TWR diphenylboronic anhydride Investigative T58496 DRUGINFO D00HCI 2-APB Investigative T86273 TARGETID T86273 T86273 FORMERID TTDR01440 T86273 UNIPROID GPBAR_HUMAN T86273 TARGNAME G-protein coupled bile acid receptor 1 (GPBAR1) T86273 GENENAME GPBAR1 T86273 TARGTYPE Clinical trial T86273 SYNONYMS hGPCR19; hBG37; TGR5; Membrane-type receptor for bile acids; M-BAR; G-protein coupled receptor GPCR19; BG37 T86273 FUNCTION Bile acid-binding induces its internalization, activation of extracellular signal-regulated kinase and intracellular cAMP production. May be involved in the suppression of macrophage functions by bile acids. Receptor for bile acid. T86273 BIOCLASS GPCR rhodopsin T86273 SEQUENCE MTPNSTGEVPSPIPKGALGLSLALASLIITANLLLALGIAWDRRLRSPPAGCFFLSLLLAGLLTGLALPTLPGLWNQSRRGYWSCLLVYLAPNFSFLSLLANLLLVHGERYMAVLRPLQPPGSIRLALLLTWAGPLLFASLPALGWNHWTPGANCSSQAIFPAPYLYLEVYGLLLPAVGAAAFLSVRVLATAHRQLQDICRLERAVCRDEPSALARALTWRQARAQAGAMLLFGLCWGPYVATLLLSVLAYEQRPPLGPGTLLSLLSLGSASAAAVPVAMGLGDQRYTAPWRAAAQRCLQGLWGRASRDSPGPSIAYHPSSQSSVDLDLN T86273 DRUGINFO D03BZN Sodium taurocholate Phase 1/2 T86273 DRUGINFO D08LIB PMID29649907-Compound-INT767 Patented T86273 DRUGINFO D0AA3P PMID29649907-Compound-8 Patented T86273 DRUGINFO D09ODU XL475 Preclinical T86273 DRUGINFO DNZ96J INT-767 Preclinical T86273 DRUGINFO D0B7AH INT-777 Investigative T86273 DRUGINFO D0MZ9Q Bile acid Investigative T03634 TARGETID T03634 T03634 FORMERID TTDNC00387 T03634 UNIPROID CBP_HUMAN T03634 TARGNAME CREB-binding protein (CREBBP) T03634 GENENAME CREBBP T03634 TARGTYPE Clinical trial T03634 SYNONYMS CREBbinding protein; CBP T03634 FUNCTION Acetylates non-histone proteins, like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers. Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER). Functions as a transcriptional coactivator for SMAD4 in the TGF-beta signaling pathway. Acetylates histones, giving a specific tag for transcriptional activation. T03634 PDBSTRUC 6FRF; 6FR0; 6FQU; 6FQT; 6FQO T03634 BIOCLASS Acyltransferase T03634 ECNUMBER EC 2.3.1.48 T03634 SEQUENCE MAENLLDGPPNPKRAKLSSPGFSANDSTDFGSLFDLENDLPDELIPNGGELGLLNSGNLVPDAASKHKQLSELLRGGSGSSINPGIGNVSASSPVQQGLGGQAQGQPNSANMASLSAMGKSPLSQGDSSAPSLPKQAASTSGPTPAASQALNPQAQKQVGLATSSPATSQTGPGICMNANFNQTHPGLLNSNSGHSLINQASQGQAQVMNGSLGAAGRGRGAGMPYPTPAMQGASSSVLAETLTQVSPQMTGHAGLNTAQAGGMAKMGITGNTSPFGQPFSQAGGQPMGATGVNPQLASKQSMVNSLPTFPTDIKNTSVTNVPNMSQMQTSVGIVPTQAIATGPTADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRACSLPHCRTMKNVLNHMTHCQAGKACQVAHCASSRQIISHWKNCTRHDCPVCLPLKNASDKRNQQTILGSPASGIQNTIGSVGTGQQNATSLSNPNPIDPSSMQRAYAALGLPYMNQPQTQLQPQVPGQQPAQPQTHQQMRTLNPLGNNPMNIPAGGITTDQQPPNLISESALPTSLGATNPLMNDGSNSGNIGTLSTIPTAAPPSSTGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKDRRMENLVAYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRLHKQGILGNQPALPAPGAQPPVIPQAQPVRPPNGPLSLPVNRMQVSQGMNSFNPMSLGNVQLPQAPMGPRAASPMNHSVQMNSMGSVPGMAISPSRMPQPPNMMGAHTNNMMAQAPAQSQFLPQNQFPSSSGAMSVGMGQPPAQTGVSQGQVPGAALPNPLNMLGPQASQLPCPPVTQSPLHPTPPPASTAAGMPSLQHTTPPGMTPPQPAAPTQPSTPVSSSGQTPTPTPGSVPSATQTQSTPTVQAAAQAQVTPQPQTPVQPPSVATPQSSQQQPTPVHAQPPGTPLSQAAASIDNRVPTPSSVASAETNSQQPGPDVPVLEMKTETQAEDTEPDPGESKGEPRSEMMEEDLQGASQVKEETDIAEQKSEPMEVDEKKPEVKVEVKEEEESSSNGTASQSTSPSQPRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLGYCCGRKYEFSPQTLCCYGKQLCTIPRDAAYYSYQNRYHFCEKCFTEIQGENVTLGDDPSQPQTTISKDQFEKKKNDTLDPEPFVDCKECGRKMHQICVLHYDIIWPSGFVCDNCLKKTGRPRKENKFSAKRLQTTRLGNHLEDRVNKFLRRQNHPEAGEVFVRVVASSDKTVEVKPGMKSRFVDSGEMSESFPYRTKALFAFEEIDGVDVCFFGMHVQEYGSDCPPPNTRRVYISYLDSIHFFRPRCLRTAVYHEILIGYLEYVKKLGYVTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAFAERIIHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKKEESTAASETTEGSQGDSKNAKKKNNKKTNKNKSSISRANKKKPSMPNVSNDLSQKLYATMEKHKEVFFVIHLHAGPVINTLPPIVDPDPLLSCDLMDGRDAFLTLARDKHWEFSSLRRSKWSTLCMLVELHTQGQDRFVYTCNECKHHVETRWHCTVCEDYDLCINCYNTKSHAHKMVKWGLGLDDEGSSQGEPQSKSPQESRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCKQLIALCCYHAKHCQENKCPVPFCLNIKHKLRQQQIQHRLQQAQLMRRRMATMNTRNVPQQSLPSPTSAPPGTPTQQPSTPQTPQPPAQPQPSPVSMSPAGFPSVARTQPPTTVSTGKPTSQVPAPPPPAQPPPAAVEAARQIEREAQQQQHLYRVNINNSMPPGRTGMGTPGSQMAPVSLNVPRPNQVSGPVMPSMPPGQWQQAPLPQQQPMPGLPRPVISMQAQAAVAGPRMPSVQPPRSISPSALQDLLRTLKSPSSPQQQQQVLNILKSNPQLMAAFIKQRTAKYVANQPGMQPQPGLQSQPGMQPQPGMHQQPSLQNLNAMQAGVPRPGVPPQQQAMGGLNPQGQALNIMNPGHNPNMASMNPQYREMLRRQLLQQQQQQQQQQQQQQQQQQGSAGMAGGMAGHGQFQQPQGPGGYPPAMQQQQRMQQHLPLQGSSMGQMAAQMGQLGQMGQPGLGADSTPNIQQALQQRILQQQQMKQQIGSPGQPNPMSPQQHMLSGQPQASHLPGQQIATSLSNQVRSPAPVQSPRPQSQPPHSSPSPRIQPQPSPHHVSPQTGSPHPGLAVTMASSIDQGHLGNPEQSAMLPQLNTPSRSALSSELSLVGDTTGDTLEKFVEGL T03634 DRUGINFO D0Q0ZY PRI-724 Phase 1/2 T03634 DRUGINFO D0DA5M C 82 Phase 1/2 T03634 DRUGINFO DIY4C2 CCS1477 Phase 1/2 T03634 DRUGINFO DT8IL6 FT-7051 Phase 1 T03634 DRUGINFO D0O9WQ Pyrrolo-pyrrolone derivative 6 Patented T03634 DRUGINFO D00DXI ischemin Investigative T03634 DRUGINFO D03XXT SGC-CBP30 Investigative T03634 DRUGINFO D0J3JI I-CBP112 Investigative T64074 TARGETID T64074 T64074 FORMERID TTDC00341 T64074 UNIPROID DCPS_HUMAN T64074 TARGNAME Scavenger decapping enzyme DcpS (DCPS) T64074 GENENAME DCPS T64074 TARGTYPE Clinical trial T64074 SYNONYMS Scavenger mRNA-decapping enzyme DcpS; Histidine triad protein member5; Hint-related 7meGMP-directed hydrolase; HINT-5; DCS-1; DCPS T64074 FUNCTION Decapping scavenger enzyme that catalyzes the cleavage of a residual cap structure following the degradation of mRNAs by the 3'->5' exosome-mediated mRNA decay pathway. Hydrolyzes cap analog structures like 7-methylguanosine nucleoside triphosphate (m7GpppG) with up to 10 nucleotide substrates (small capped oligoribonucleotides) and specifically releases 5'-phosphorylated RNA fragments and 7-methylguanosine monophosphate (m7GMP). Cleaves cap analog structures like tri-methyl guanosine nucleoside triphosphate (m3(2,2,7)GpppG) with very poor efficiency. Does not hydrolyze unmethylated cap analog (GpppG) and shows no decapping activity on intact m7GpppG-capped mRNA molecules longer than 25 nucleotides. Does not hydrolyze 7-methylguanosine diphosphate (m7GDP) to m7GMP (PubMed:22985415). May also play a role in the 5'->3 mRNA decay pathway; m7GDP, the downstream product released by the 5'->3' mRNA mediated decapping activity, may be also converted by DCPS to m7GMP (PubMed:14523240). Binds to m7GpppG and strongly to m7GDP. Plays a role in first intron splicing of pre- mRNAs. Inhibits activation-induced cell death. T64074 PDBSTRUC 5OSY; 4QEB; 4QDV; 4QDE; 3BLA T64074 BIOCLASS Acid anhydrides hydrolase T64074 ECNUMBER EC 3.6.1.59 T64074 SEQUENCE MADAAPQLGKRKRELDVEEAHAASTEEKEAGVGNGTCAPVRLPFSGFRLQKVLRESARDKIIFLHGKVNEASGDGDGEDAVVILEKTPFQVEQVAQLLTGSPELQLQFSNDIYSTYHLFPPRQLNDVKTTVVYPATEKHLQKYLRQDLRLIRETGDDYRNITLPHLESQSLSIQWVYNILDKKAEADRIVFENPDPSDGFVLIPDLKWNQQQLDDLYLIAICHRRGIRSLRDLTPEHLPLLRNILHQGQEAILQRYRMKGDHLRVYLHYLPSYYHLHVHFTALGFEAPGSGVERAHLLAEVIENLECDPRHYQQRTLTFALRADDPLLKLLQEAQQS T64074 DRUGINFO D0KV6C RG3039 Phase 1 T05643 TARGETID T05643 T05643 FORMERID TTDI02113 T05643 UNIPROID LIGO1_HUMAN T05643 TARGNAME Leucine-rich repeat neuronal protein 1 (LINGO1) T05643 GENENAME LINGO1 T05643 TARGTYPE Clinical trial T05643 SYNONYMS Leucinerich repeat neuronal protein 6A; Leucinerich repeat and immunoglobulinlike domaincontaining nogo receptorinteracting protein 1; Leucinerich repeat and immunoglobulin domaincontaining protein 1; LINGO1 T05643 FUNCTION Functional component of the Nogo receptor signaling complex (RTN4R/NGFR) in RhoA activation responsible for some inhibition of axonal regeneration by myelin-associated factors. Is also an important negative regulator of oligodentrocyte differentiation and axonal myelination. Acts in conjunction with RTN4 and RTN4R in regulating neuronal precursor cell motility during cortical development. {ECO:0000250}. T05643 PDBSTRUC 4OQT; 2ID5 T05643 BIOCLASS Immunoglobulin T05643 SEQUENCE MQVSKRMLAGGVRSMPSPLLACWQPILLLVLGSVLSGSATGCPPRCECSAQDRAVLCHRKRFVAVPEGIPTETRLLDLGKNRIKTLNQDEFASFPHLEELELNENIVSAVEPGAFNNLFNLRTLGLRSNRLKLIPLGVFTGLSNLTKLDISENKIVILLDYMFQDLYNLKSLEVGDNDLVYISHRAFSGLNSLEQLTLEKCNLTSIPTEALSHLHGLIVLRLRHLNINAIRDYSFKRLYRLKVLEISHWPYLDTMTPNCLYGLNLTSLSITHCNLTAVPYLAVRHLVYLRFLNLSYNPISTIEGSMLHELLRLQEIQLVGGQLAVVEPYAFRGLNYLRVLNVSGNQLTTLEESVFHSVGNLETLILDSNPLACDCRLLWVFRRRWRLNFNRQQPTCATPEFVQGKEFKDFPDVLLPNYFTCRRARIRDRKAQQVFVDEGHTVQFVCRADGDPPPAILWLSPRKHLVSAKSNGRLTVFPDGTLEVRYAQVQDNGTYLCIAANAGGNDSMPAHLHVRSYSPDWPHQPNKTFAFISNQPGEGEANSTRATVPFPFDIKTLIIATTMGFISFLGVVLFCLVLLFLWSRGKGNTKHNIEIEYVPRKSDAGISSADAPRKFNMKMI T05643 DRUGINFO D07DSN BIIB 033 Phase 2 T76093 TARGETID T76093 T76093 FORMERID TTDNC00420 T76093 UNIPROID HBEGF_HUMAN T76093 TARGNAME Proheparin-binding EGF-like growth factor (HBEGF) T76093 GENENAME HBEGF T76093 TARGTYPE Clinical trial T76093 SYNONYMS Proheparinbinding EGFlike growth factor; Heparinbinding EGFlike growth factor; Heparin-binding EGF-like growth factor; HEGFL; HB-EGF; Diphtheria toxin receptor; DTS; DTR; DT-R T76093 FUNCTION Required for normal cardiac valve formation and normal heart function. Promotes smooth muscle cell proliferation. May be involved in macrophage-mediated cellular proliferation. It is mitogenic for fibroblasts, but not endothelial cells. It is able to bind EGF receptor/EGFR with higher affinity than EGF itself and is a far more potent mitogen for smooth muscle cells than EGF. Also acts as a diphtheria toxin receptor. Growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. T76093 PDBSTRUC 2M8S; 1XDT T76093 BIOCLASS Growth factor T76093 SEQUENCE MKLLPSVVLKLFLAAVLSALVTGESLERLRRGLAAGTSNPDPPTVSTDQLLPLGGGRDRKVRDLQEADLDLLRVTLSSKPQALATPNKEEHGKRKKKGKGLGKKRDPCLRKYKDFCIHGECKYVKELRAPSCICHPGYHGERCHGLSLPVENRLYTYDHTTILAVVAVVLSSVCLLVIVGLLMFRYHRRGGYDVENEEKVKLGMTNSH T76093 DRUGINFO D06ZXF U3-1565 Phase 1 T76093 DRUGINFO D0S4KJ KHK-2866 Phase 1 T76093 DRUGINFO DM5PA2 ASP0598 Phase 1 T32973 TARGETID T32973 T32973 FORMERID TTDI02612 T32973 UNIPROID LGMN_HUMAN T32973 TARGNAME Legumain (LGMN) T32973 GENENAME LGMN T32973 TARGTYPE Clinical trial T32973 SYNONYMS Protease, cysteine 1; PRSC1; Asparaginyl endopeptidase T32973 FUNCTION Can also cleave aspartyl bonds slowly, especially under acidic conditions. Required for normal lysosomal protein degradation in renal proximal tubules. Required for normal degradation of internalized EGFR. Plays a role in the regulation of cell proliferation via its role in EGFR degradation. May be involved in the processing of proteins for MHC class II antigen presentation in the lysosomal/endosomal system. Has a strict specificity for hydrolysis of asparaginyl bonds. T32973 PDBSTRUC 5LUB; 5LUA; 5LU9; 5LU8; 4N6O T32973 BIOCLASS Peptidase T32973 ECNUMBER EC 3.4.22.34 T32973 SEQUENCE MVWKVAVFLSVALGIGAVPIDDPEDGGKHWVVIVAGSNGWYNYRHQADACHAYQIIHRNGIPDEQIVVMMYDDIAYSEDNPTPGIVINRPNGTDVYQGVPKDYTGEDVTPQNFLAVLRGDAEAVKGIGSGKVLKSGPQDHVFIYFTDHGSTGILVFPNEDLHVKDLNETIHYMYKHKMYRKMVFYIEACESGSMMNHLPDNINVYATTAANPRESSYACYYDEKRSTYLGDWYSVNWMEDSDVEDLTKETLHKQYHLVKSHTNTSHVMQYGNKTISTMKVMQFQGMKRKASSPVPLPPVTHLDLTPSPDVPLTIMKRKLMNTNDLEESRQLTEEIQRHLDARHLIEKSVRKIVSLLAASEAEVEQLLSERAPLTGHSCYPEALLHFRTHCFNWHSPTYEYALRHLYVLVNLCEKPYPLHRIKLSMDHVCLGHY T32973 DRUGINFO D0PV4H Legumain-cleavable doxorubicin prodrugs Phase 2/3 T32973 DRUGINFO D0W6HI PMID24775305C7u Investigative T63414 TARGETID T63414 T63414 FORMERID TTDC00218 T63414 UNIPROID P2RX7_HUMAN T63414 TARGNAME P2X purinoceptor 7 (P2RX7) T63414 GENENAME P2RX7 T63414 TARGTYPE Clinical trial T63414 SYNONYMS Purinergic receptor 7; P2Z receptor; P2X7; Adenosine P2X7 receptor; ATP receptor T63414 FUNCTION Responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules. Could function in both fast synaptic transmission and the ATP-mediated lysis of antigen-presenting cells. In the absence of its natural ligand, ATP, functions as a scavenger receptor in the recognition and engulfment of apoptotic cells. Receptor for ATP that acts as a ligand-gated ion channel. T63414 BIOCLASS ATP-gated P2X receptor cation channel T63414 SEQUENCE MPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQRKEPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTEGQEQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVYEGNQKTCEVSAWCPIEAVEEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGDIFRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCRPKYSFRRLDDKTTNVSLYPGYNFRYAKYYKENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSSNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRSLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCGSCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDSTNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY T63414 DRUGINFO D0F4JK CE-224535 Phase 2/3 T63414 DRUGINFO D0CS2C AZD9056 Phase 2 T63414 DRUGINFO DX5T4D LY3857210 Phase 2 T63414 DRUGINFO D02AIZ BIL010t Phase 1/2 T63414 DRUGINFO D01TLV EVT 401 Phase 1 T63414 DRUGINFO D02XAS SGM-1019 Phase 1 T63414 DRUGINFO D0I7BU GSK1482160 Phase 1 T63414 DRUGINFO D0OQ1A JNJ-55308942 Phase 1 T63414 DRUGINFO D0VI4N JNJ-54175446 Phase 1 T63414 DRUGINFO D07QTG JNJ-479655 Clinical trial T63414 DRUGINFO D00PVH Triazole derivative 2 Patented T63414 DRUGINFO D04QLC Benzamide derivative 13 Patented T63414 DRUGINFO D04SHK Isothiazolidine derivative 1 Patented T63414 DRUGINFO D05KRX Quinoline derivative 10 Patented T63414 DRUGINFO D06MSZ PMID27724045-Compound-19 Patented T63414 DRUGINFO D07EBW PMID27724045-Compound-17 Patented T63414 DRUGINFO D07VLC Fluorophenyl-substituted heterocyclic amide analog 1 Patented T63414 DRUGINFO D08OKB Bicyclic heteroaryl amide derivative 2 Patented T63414 DRUGINFO D08PQU PMID27724045-Compound-33 Patented T63414 DRUGINFO D08SFW PMID27724045-Compound-15 Patented T63414 DRUGINFO D09REZ PMID27724045-Compound-14 Patented T63414 DRUGINFO D0AI1I Fused triazoloamino-phenyl analog 1 Patented T63414 DRUGINFO D0C9WD Thiazole-fused cycloalkyl carboxamide derivative 1 Patented T63414 DRUGINFO D0EY5F Isoindole 1,3-dione analog 1 Patented T63414 DRUGINFO D0FR8L Chlorobenzamide derivative 2 Patented T63414 DRUGINFO D0GQ6D Aminobenzoxazole analog 1 Patented T63414 DRUGINFO D0L8QD Pyridazinone derivative 1 Patented T63414 DRUGINFO D0N2TV Benzamide derivative 12 Patented T63414 DRUGINFO D0N4RJ Triazolo-pyrazinone derivative 1 Patented T63414 DRUGINFO D0NG6O Piperidinone derivative 1 Patented T63414 DRUGINFO D0O8DL Dihydroisoquinoline carboxamide analog 1 Patented T63414 DRUGINFO D0OG3Z Bicyclic heteroaryl amide derivative 3 Patented T63414 DRUGINFO D0PI1X Bicyclic heteroaryl amide derivative 1 Patented T63414 DRUGINFO D0QC5O Piperazine derivative 6 Patented T63414 DRUGINFO D0R4IT Heterocyclic-fused piperazine derivative 1 Patented T63414 DRUGINFO D0RG4J Chlorobenzamide derivative 1 Patented T63414 DRUGINFO D0S9HE PMID27724045-Compound-29 Patented T63414 DRUGINFO D0T1JN Thiazole derivative 5 Patented T63414 DRUGINFO D0UC8I Tetrazole derivative 1 Patented T63414 DRUGINFO D0WI9M Imidazolidine derivative 1 Patented T63414 DRUGINFO D0ZY5M Indole carboxamide derivative 1 Patented T63414 DRUGINFO D01EBW Quinoline derivative 12 Patented T63414 DRUGINFO D0B7KM Quinoline derivative 13 Patented T63414 DRUGINFO D0L2KM Quinoline derivative 11 Patented T63414 DRUGINFO D00REB AZ11657312 (salt free) Investigative T63414 DRUGINFO D02EFX AZ11645373 Investigative T63414 DRUGINFO D02TNK STYLISSADINE B Investigative T63414 DRUGINFO D03HJZ AZ-11657312 Investigative T63414 DRUGINFO D05DLI STYLISSADINE A Investigative T63414 DRUGINFO D05QLT A438079 Investigative T63414 DRUGINFO D0M0XC A839977 Investigative T63414 DRUGINFO D0N1ST AFC-5128 Investigative T63414 DRUGINFO D0Q1PO A804598 Investigative T63414 DRUGINFO D0U5ML A-740003 Investigative T63414 DRUGINFO D05BFC ISOPPADS Investigative T63414 DRUGINFO D0T9ZL chelerythrine Investigative T63414 DRUGINFO D06KHR decavanadate Investigative T63414 DRUGINFO D0N6ES KN-62 Investigative T97589 TARGETID T97589 T97589 FORMERID TTDR00968 T97589 UNIPROID M3K5_HUMAN T97589 TARGNAME Apoptosis signal-regulating kinase 1 (MAP3K5) T97589 GENENAME MAP3K5 T97589 TARGTYPE Clinical trial T97589 SYNONYMS Mitogen-activated protein kinase kinase kinase 5; MEKK5; MEKK 5; MEK kinase 5; MAPKKK5; MAPK/ERK kinase kinase 5; ASK1; ASK-1 T97589 FUNCTION Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signaling for determination of cell fate such as differentiation and survival. Plays a crucial role in the apoptosis signal transduction pathway through mitochondria-dependent caspase activation. MAP3K5/ASK1 is required for the innate immune response, which is essential for host defense against a wide range of pathogens. Mediates signal transduction of various stressors like oxidative stress as well as by receptor-mediated inflammatory signals, such as the tumor necrosis factor (TNF) or lipopolysaccharide (LPS). Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K4/SEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs and c-jun N-terminal kinases (JNKs). Both p38 MAPK and JNKs control the transcription factors activator protein-1 (AP-1). Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. T97589 PDBSTRUC 6EJL; 6E2O; 6E2N; 6E2M; 5VIO T97589 BIOCLASS Kinase T97589 ECNUMBER EC 2.7.11.25 T97589 SEQUENCE MSTEADEGITFSVPPFAPSGFCTIPEGGICRRGGAAAVGEGEEHQLPPPPPGSFWNVESAAAPGIGCPAATSSSSATRGRGSSVGGGSRRTTVAYVINEASQGQLVVAESEALQSLREACETVGATLETLHFGKLDFGETTVLDRFYNADIAVVEMSDAFRQPSLFYHLGVRESFSMANNIILYCDTNSDSLQSLKEIICQKNTMCTGNYTFVPYMITPHNKVYCCDSSFMKGLTELMQPNFELLLGPICLPLVDRFIQLLKVAQASSSQYFRESILNDIRKARNLYTGKELAAELARIRQRVDNIEVLTADIVINLLLSYRDIQDYDSIVKLVETLEKLPTFDLASHHHVKFHYAFALNRRNLPGDRAKALDIMIPMVQSEGQVASDMYCLVGRIYKDMFLDSNFTDTESRDHGASWFKKAFESEPTLQSGINYAVLLLAAGHQFESSFELRKVGVKLSSLLGKKGNLEKLQSYWEVGFFLGASVLANDHMRVIQASEKLFKLKTPAWYLKSIVETILIYKHFVKLTTEQPVAKQELVDFWMDFLVEATKTDVTVVRFPVLILEPTKIYQPSYLSINNEVEEKTISIWHVLPDDKKGIHEWNFSASSVRGVSISKFEERCCFLYVLHNSDDFQIYFCTELHCKKFFEMVNTITEEKGRSTEEGDCESDLLEYDYEYDENGDRVVLGKGTYGIVYAGRDLSNQVRIAIKEIPERDSRYSQPLHEEIALHKHLKHKNIVQYLGSFSENGFIKIFMEQVPGGSLSALLRSKWGPLKDNEQTIGFYTKQILEGLKYLHDNQIVHRDIKGDNVLINTYSGVLKISDFGTSKRLAGINPCTETFTGTLQYMAPEIIDKGPRGYGKAADIWSLGCTIIEMATGKPPFYELGEPQAAMFKVGMFKVHPEIPESMSAEAKAFILKCFEPDPDKRACANDLLVDEFLKVSSKKKKTQPKLSALSAGSNEYLRSISLPVPVLVEDTSSSSEYGSVSPDTELKVDPFSFKTRAKSCGERDVKGIRTLFLGIPDENFEDHSAPPSPEEKDSGFFMLRKDSERRATLHRILTEDQDKIVRNLMESLAQGAEEPKLKWEHITTLIASLREFVRSTDRKIIATTLSKLKLELDFDSHGISQVQVVLFGFQDAVNKVLRNHNIKPHWMFALDSIIRKAVQTAITILVPELRPHFSLASESDTADQEDLDVEDDHEEQPSNQTVRRPQAVIEDAVATSGVSTLSSTVSHDSQSAHRSLNVQLGRMKIETNRLLEELVRKEKELQALLHRAIEEKDQEIKHLKLKSQPIEIPELPVFHLNSSGTNTEDSELTDWLRVNGADEDTISRFLAEDYTLLDVLYYVTRDDLKCLRLRGGMLCTLWKAIIDFRNKQT T97589 DRUGINFO D0D0OT GS-4977 Phase 2 T97589 DRUGINFO D0RN3S GS-4997 Phase 2 T97589 DRUGINFO D0F0XZ MSC2032964A Investigative T97589 DRUGINFO D0Q0YV PMID23147077C10 Investigative T18664 TARGETID T18664 T18664 FORMERID TTDI02646 T18664 UNIPROID MGLL_HUMAN T18664 TARGNAME Monoglyceride lipase (MAGL) T18664 GENENAME MGLL T18664 TARGTYPE Clinical trial T18664 SYNONYMS Monoacylglycerol lipase; MGL; Lysophospholipaselike; Lysophospholipase-like; Lysophospholipase homolog; HUK5; HU-K5 T18664 FUNCTION Hydrolyzes the endocannabinoid 2-arachidonoylglycerol, and thereby contributes to the regulation of endocannabinoid signaling, nociperception and perception of pain. Regulates the levels of fatty acids that serve as signaling molecules and promote cancer cell migration, invasion and tumor growth. Converts monoacylglycerides to free fatty acids and glycerol. T18664 PDBSTRUC 6BQ0; 6AX1; 5ZUN; 4UUQ; 3PE6 T18664 BIOCLASS Carboxylic ester hydrolase T18664 ECNUMBER EC 3.1.1.23 T18664 SEQUENCE MPEESSPRRTPQSIPYQDLPHLVNADGQYLFCRYWKPTGTPKALIFVSHGAGEHSGRYEELARMLMGLDLLVFAHDHVGHGQSEGERMVVSDFHVFVRDVLQHVDSMQKDYPGLPVFLLGHSMGGAIAILTAAERPGHFAGMVLISPLVLANPESATTFKVLAAKVLNLVLPNLSLGPIDSSVLSRNKTEVDIYNSDPLICRAGLKVCFGIQLLNAVSRVERALPKLTVPFLLLQGSADRLCDSKGAYLLMELAKSQDKTLKIYEGAYHVLHKELPEVTNSVFHEINMWVSQRTATAGTASPP T18664 DRUGINFO D0CW8S ABX-1431 Phase 1 T18664 DRUGINFO D00KFI Azetidinyl-piperazine derivative 3 Patented T18664 DRUGINFO D00PFS Azetidinyl-piperidine derivative 1 Patented T18664 DRUGINFO D00VBP PMID29053063-Compound-7f Patented T18664 DRUGINFO D03HHN PMID29053063-Compound-7b Patented T18664 DRUGINFO D03LKM PMID29053063-Compound-7a Patented T18664 DRUGINFO D04ZEX Pyrazole derivative 85 Patented T18664 DRUGINFO D05SWA Azetidinyl-piperidine derivative 3 Patented T18664 DRUGINFO D07YWE PMID29053063-Compound-5 Patented T18664 DRUGINFO D08EMW Carbamate derivative 15 Patented T18664 DRUGINFO D09LAD Piperazine carbamic compound 3 Patented T18664 DRUGINFO D0B5BT Azetidinyl-piperazine derivative 1 Patented T18664 DRUGINFO D0C5SQ Carbamate derivative 13 Patented T18664 DRUGINFO D0D2YG PMID29053063-Compound-7d Patented T18664 DRUGINFO D0FK7E Carbamate derivative 14 Patented T18664 DRUGINFO D0G9NQ PMID29053063-Compound-17 Patented T18664 DRUGINFO D0J0UC Azetidine-benzoxazin-3(4H)-one derivative 1 Patented T18664 DRUGINFO D0NK4T Carbamate derivative 12 Patented T18664 DRUGINFO D0OK3K Azetidinyl-piperazine derivative 2 Patented T18664 DRUGINFO D0Q4OB Carbamate derivative 11 Patented T18664 DRUGINFO D0S9MR Azetidine-benzoxazin-3(4H)-one derivative 2 Patented T18664 DRUGINFO D0TT7U PMID29053063-Compound-7c Patented T18664 DRUGINFO D0TW7K PMID29053063-Compound-7e Patented T18664 DRUGINFO D0UW6S PMID29053063-Compound-4 Patented T18664 DRUGINFO D0VS7X Azetidine-benzoxazin-3(4H)-one derivative 3 Patented T18664 DRUGINFO D0VY7R Azetidinyl-piperidine derivative 2 Patented T18664 DRUGINFO D00IPI Carbamide derivative 24 Patented T18664 DRUGINFO D00TVG Piperazine carbamic compound 4 Patented T18664 DRUGINFO D02ZUW Carbamide derivative 26 Patented T18664 DRUGINFO D05DBG Carbamate derivative 16 Patented T18664 DRUGINFO D08SMT Carbamate derivative 17 Patented T18664 DRUGINFO D09RGE Carbamide derivative 25 Patented T18664 DRUGINFO D0L6XG Carbamate derivative 9 Patented T18664 DRUGINFO D0S2JF Pyrazole derivative 83 Patented T18664 DRUGINFO D0TU6D PMID29053063-Compound-11c Patented T18664 DRUGINFO D0V7PO PMID29053063-Compound-14 Patented T18664 DRUGINFO D0Y7LM Carbamate derivative 10 Patented T18664 DRUGINFO D0YM0G Pyrazole derivative 84 Patented T18664 DRUGINFO D0Z7FL Piperazine carbamic compound 5 Patented T18664 DRUGINFO D0GT0I PMID29053063-Compound-11d Patented T18664 DRUGINFO D0J6TA Piperazine carbamic compound 1 Patented T18664 DRUGINFO D0LC5Y Piperazine carbamic compound 2 Patented T18664 DRUGINFO D0LL0X Pyrazole derivative 82 Patented T18664 DRUGINFO D0O9DS Pyrazole derivative 81 Patented T18664 DRUGINFO D0TL1G PMID29053063-Compound-15 Patented T18664 DRUGINFO D0X9GC Pyrazole derivative 80 Patented T18664 DRUGINFO D0G0MZ JZL184 Investigative T09572 TARGETID T09572 T09572 FORMERID TTDC00133 T09572 UNIPROID MCHR1_HUMAN T09572 TARGNAME Melanin-concentrating hormone receptor 1 (MCHR1) T09572 GENENAME MCHR1 T09572 TARGTYPE Clinical trial T09572 SYNONYMS Somatostatinreceptor-like protein; Somatostatin receptor-like protein; SLC1; SLC-1; Melanin-concentrating hormone receptor subtype 1; MCHR-1; MCHR; MCH1R; MCH-R1; MCH-1R; MCH(1) receptor; MCH receptor1; MCH receptor 1; GPR24; G-protein coupled receptor 24; G protein coupled receptor 24 T09572 FUNCTION Receptor for melanin-concentrating hormone, coupled to both G proteins that inhibit adenylyl cyclase and G proteins that activate phosphoinositide hydrolysis. T09572 BIOCLASS GPCR rhodopsin T09572 SEQUENCE MSVGAMKKGVGRAVGLGGGSGCQATEEDPLPNCGACAPGQGGRRWRLPQPAWVEGSSARLWEQATGTGWMDLEASLLPTGPNASNTSDGPDNLTSAGSPPRTGSISYINIIMPSVFGTICLLGIIGNSTVIFAVVKKSKLHWCNNVPDIFIINLSVVDLLFLLGMPFMIHQLMGNGVWHFGETMCTLITAMDANSQFTSTYILTAMAIDRYLATVHPISSTKFRKPSVATLVICLLWALSFISITPVWLYARLIPFPGGAVGCGIRLPNPDTDLYWFTLYQFFLAFALPFVVITAAYVRILQRMTSSVAPASQRSIRLRTKRVTRTAIAICLVFFVCWAPYYVLQLTQLSISRPTLTFVYLYNAAISLGYANSCLNPFVYIVLCETFRKRLVLSVKPAAQGQLRAVSNAQTADEERTESKGT T09572 DRUGINFO D01KMW BMS-830216 Phase 1 T09572 DRUGINFO D0A3CL AZD1979 Phase 1 T09572 DRUGINFO D00HQJ PMID25522065-Compound-27 Patented T09572 DRUGINFO D00RUE PMID25522065-Compound-29 Patented T09572 DRUGINFO D01RQE PMID25522065-Compound-34 Patented T09572 DRUGINFO D01SYN PMID25522065-Compound-39 Patented T09572 DRUGINFO D02MTQ PMID25522065-Compound-40 Patented T09572 DRUGINFO D03JJW PMID25522065-Compound-11 Patented T09572 DRUGINFO D03KWP PMID25522065-Compound-50 Patented T09572 DRUGINFO D03TCR PMID25522065-Compound-12 Patented T09572 DRUGINFO D04NIU PMID25522065-Compound-2 Patented T09572 DRUGINFO D07MJJ PMID25522065-Compound-8 Patented T09572 DRUGINFO D08JKR PMID25522065-Compound-9 Patented T09572 DRUGINFO D08JMZ PMID25522065-Compound-5 Patented T09572 DRUGINFO D09CER PMID25522065-Compound-44 Patented T09572 DRUGINFO D09UGQ PMID25522065-Compound-36 Patented T09572 DRUGINFO D0A2NT PMID25522065-Compound-46 Patented T09572 DRUGINFO D0BQ7K PMID25522065-Compound-33 Patented T09572 DRUGINFO D0C5RD PMID25522065-Compound-31 Patented T09572 DRUGINFO D0CC6Q PMID25522065-Compound-3 Patented T09572 DRUGINFO D0CV5F PMID25522065-Compound-18 Patented T09572 DRUGINFO D0DB8G PMID25522065-Compound-47 Patented T09572 DRUGINFO D0DN8Z PMID25522065-Compound-21 Patented T09572 DRUGINFO D0FQ4W PMID25522065-Compound-13 Patented T09572 DRUGINFO D0GH0Z PMID25522065-Compound-41 Patented T09572 DRUGINFO D0GN5K PMID25522065-Compound-23 Patented T09572 DRUGINFO D0HH1O PMID25522065-Compound-14 Patented T09572 DRUGINFO D0I6YT PMID25522065-Compound-42 Patented T09572 DRUGINFO D0I9BT PMID25522065-Compound-4 Patented T09572 DRUGINFO D0J6MM PMID25522065-Compound-37 Patented T09572 DRUGINFO D0JY4C PMID25522065-Compound-19 Patented T09572 DRUGINFO D0KF0X PMID25522065-Compound-10 Patented T09572 DRUGINFO D0KJ9U PMID25522065-Compound-28 Patented T09572 DRUGINFO D0L2EQ PMID25522065-Compound-7 Patented T09572 DRUGINFO D0L3ZZ PMID25522065-Compound-16 Patented T09572 DRUGINFO D0M8KC PMID25522065-Compound-48 Patented T09572 DRUGINFO D0M9JM PMID25522065-Compound-17 Patented T09572 DRUGINFO D0MT7T PMID25522065-Compound-49 Patented T09572 DRUGINFO D0N8CI PMID25522065-Compound-15 Patented T09572 DRUGINFO D0Q1NA PMID25522065-Compound-51 Patented T09572 DRUGINFO D0R0YB PMID25522065-Compound-6 Patented T09572 DRUGINFO D0RX2U PMID25522065-Compound-25 Patented T09572 DRUGINFO D0S2ED PMID25522065-Compound-35 Patented T09572 DRUGINFO D0S6DD PMID25522065-Compound-38 Patented T09572 DRUGINFO D0T6UX PMID25522065-Compound-24 Patented T09572 DRUGINFO D0TK2N PMID25522065-Compound-45 Patented T09572 DRUGINFO D0TK3S PMID25522065-Compound-43 Patented T09572 DRUGINFO D0TY8S PMID25522065-Compound-22 Patented T09572 DRUGINFO D0TZ6J PMID25522065-Compound-26 Patented T09572 DRUGINFO D0V3OD PMID25522065-Compound-32 Patented T09572 DRUGINFO D0V8FC PMID25522065-Compound-30 Patented T09572 DRUGINFO D0Y0RS PMID25522065-Compound-20 Patented T09572 DRUGINFO D0N1AS NGD-4715 Discontinued in Phase 1 T09572 DRUGINFO D0X4MC AMG 076 Discontinued in Phase 1 T09572 DRUGINFO D0U0YR SNAP-7941 Preclinical T09572 DRUGINFO D0K6NS T-226293 Preclinical T09572 DRUGINFO D0TV4N T-226296 Preclinical T09572 DRUGINFO D05SUA A-798 Terminated T09572 DRUGINFO D05VGS ALB-127158(a) Terminated T09572 DRUGINFO D00MSU 8-(2-Cyclopropyl-ethoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D01OYC 8-sec-Butoxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D01OZL 8-(2-Methyl-butoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D01PFN 8-Cyclobutylmethoxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D02FQG pyrrolidine MCHR1 antagonist 1 Investigative T09572 DRUGINFO D02QXF 8-(1-Methyl-butoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D03BIQ ADS-102891 Investigative T09572 DRUGINFO D03CDM 8-(2-Ethoxy-1-methyl-ethoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D03FJK 8-(1,3,3-Trimethyl-butoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D03FNQ ADS-103214 Investigative T09572 DRUGINFO D03SEC 8-Butoxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D04OOK Phenyl-N,N-bis(tosylmethyl)methanamine Investigative T09572 DRUGINFO D05CYD C3 Investigative T09572 DRUGINFO D05HFC 8-(1,2-Dimethyl-propoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D05MEW N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide Investigative T09572 DRUGINFO D05QTT tetralin_urea analogue (7o) Investigative T09572 DRUGINFO D05TVU A-224940 Investigative T09572 DRUGINFO D05UZY 7-fluorochromone-2-carboxamide Investigative T09572 DRUGINFO D06KLQ GNF-PF-1550 Investigative T09572 DRUGINFO D07EPU ADS-103254 Investigative T09572 DRUGINFO D07HQP 8-Pentyloxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D07IUE 8-Cyclopentylmethoxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D07WFH 2-phenyl-N,N-bis(o-tolylthiomethyl)ethanamine Investigative T09572 DRUGINFO D07XEA 8-Cycloheptyloxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D08OQO 8-Isopropoxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D08SOE PMID17125263C17 Investigative T09572 DRUGINFO D09RGM N,N-bis(tosylmethyl)hexan-1-amine Investigative T09572 DRUGINFO D0AT3U N-(4-amino-2-propylquinolin-6-yl)cinnamamide Investigative T09572 DRUGINFO D0AT5N 4-arylphthalazin-1(2H)-3,4-Di-F Investigative T09572 DRUGINFO D0AU6T 8-(3-Methoxy-3-methyl-butoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D0C5RQ SB-568849 Investigative T09572 DRUGINFO D0C7ED PMID22490048C(R)-10h Investigative T09572 DRUGINFO D0C9DP ADS-103168 Investigative T09572 DRUGINFO D0D7EK TPI-1361-17 Investigative T09572 DRUGINFO D0ES2Y 8-(2-Methyl-cyclohexyloxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D0F3VX 8-(2-Methoxy-1-methyl-ethoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D0G6DS 8-Hexyloxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D0I7FK 8-(3-Methyl-cyclohexyloxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D0J7MM ADS-103316 Investigative T09572 DRUGINFO D0K5JA 8-Cyclohexyloxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D0K5QJ ADS-103294 Investigative T09572 DRUGINFO D0K5XL ADS-103293 Investigative T09572 DRUGINFO D0L4WB 8-(4-Methyl-cyclohexyloxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D0LJ4Q 8-Propoxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D0M3HZ AZ13483342 Investigative T09572 DRUGINFO D0N1YW GNF-PF-2322 Investigative T09572 DRUGINFO D0P4CQ 8-(2-Ethyl-1-methyl-butoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D0P5QW MQ1 Investigative T09572 DRUGINFO D0PX3G [3H]SNAP-7941 Investigative T09572 DRUGINFO D0S7IJ 8-(3-Methyl-cyclopentyloxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D0U1OX 8-(3,3-Dimethyl-butoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D0V2IR 8-(1-Ethyl-propoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D0V9KF 8-(3,3,3-trifluoropropoxy)quinolin-2-amine Investigative T09572 DRUGINFO D0W7ZM 8-(3-Methyl-butoxy)-quinolin-2-ylamine Investigative T09572 DRUGINFO D00AWM GW803430 Investigative T09572 DRUGINFO D01BTF melanin-concentrating hormone Investigative T09572 DRUGINFO D01NOZ ADS-103274 Investigative T09572 DRUGINFO D0V5ZP ATC0065 Investigative T09572 DRUGINFO D0D2PL 8-Methoxy-quinolin-2-ylamine Investigative T09572 DRUGINFO D0K0KR AR-129330 Investigative T09572 DRUGINFO D0N6OL ADS-103253 Investigative T97136 TARGETID T97136 T97136 UNIPROID MKNK1_HUMAN T97136 TARGNAME MAPK signal-integrating kinase 1 (MKNK1) T97136 GENENAME MKNK1 T97136 TARGTYPE Clinical trial T97136 SYNONYMS Mnk1; MAP kinase signal-integrating kinase 1 T97136 FUNCTION May play a role in the response to environmental stress and cytokines. Appears to regulate translation by phosphorylating EIF4E, thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. T97136 PDBSTRUC 5WVD; 2Y9Q; 2HW6 T97136 BIOCLASS Protein kinase superfamily. CAMK Ser/Thr protein kinase family T97136 ECNUMBER EC 2.7.11.1 T97136 SEQUENCE MVSSQKLEKPIEMGSSEPLPIADGDRRRKKKRRGRATDSLPGKFEDMYKLTSELLGEGAYAKVQGAVSLQNGKEYAVKIIEKQAGHSRSRVFREVETLYQCQGNKNILELIEFFEDDTRFYLVFEKLQGGSILAHIQKQKHFNEREASRVVRDVAAALDFLHTKDKVSLCHLGWSAMAPSGLTAAPTSLGSSDPPTSASQVAGTTGIAHRDLKPENILCESPEKVSPVKICDFDLGSGMKLNNSCTPITTPELTTPCGSAEYMAPEVVEVFTDQATFYDKRCDLWSLGVVLYIMLSGYPPFVGHCGADCGWDRGEVCRVCQNKLFESIQEGKYEFPDKDWAHISSEAKDLISKLLVRDAKQRLSAAQVLQHPWVQGQAPEKGLPTPQVLQRNSSTMDLTLFAAEAIALNRQLSQHEENELAEEPEALADGLCSMKLSPPCKSRLARRRALAQAGRGEDRSPPTAL T97136 DRUGINFO D07XOV EFT508 Phase 2 T44682 TARGETID T44682 T44682 FORMERID TTDI02341 T44682 UNIPROID IL22_HUMAN T44682 TARGNAME Interleukin-22 (IL22) T44682 GENENAME IL22 T44682 TARGTYPE Clinical trial T44682 SYNONYMS ZCYTO18; UNQ3099/PRO10096; Interleukin22; ILTIF; IL10related Tcellderivedinducible factor; IL-TIF; IL-22; IL-10-related T-cell-derived-inducible factor; Cytokine Zcyto18 T44682 FUNCTION Cytokine that contributes to the inflammatory response in vivo. T44682 PDBSTRUC 3Q1S; 3G9V; 3DLQ; 3DGC; 1YKB T44682 BIOCLASS Cytokine: interleukin T44682 SEQUENCE MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLAKEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI T44682 DRUGINFO D01AIN Fezakinumab Phase 2 T44682 DRUGINFO D0G5BL RG7880 Phase 2 T44682 DRUGINFO DL2HO7 F-652 Phase 2 T44682 DRUGINFO D0A9GI ILV-095 Phase 1 T36467 TARGETID T36467 T36467 FORMERID TTDI02014 T36467 UNIPROID AICDA_HUMAN T36467 TARGNAME Cytosine deaminase (AICDA) T36467 GENENAME AICDA T36467 TARGTYPE Clinical trial T36467 SYNONYMS Activationinduced cytidine deaminase; AICDA T36467 FUNCTION Single-stranded DNA-specific cytidine deaminase. Involved in somatic hypermutation, gene conversion, and class- switch recombination in B-lymphocytes. Required for several crucial steps of B-cell terminal differentiation necessary for efficient antibody responses. May also play a role in the epigenetic regulation of gene expression by participating in DNA demethylation. T36467 PDBSTRUC 5W1C; 5W0Z; 5W0U; 5W0R; 5JJ4 T36467 BIOCLASS Carbon-nitrogen hydrolase T36467 ECNUMBER EC 3.5.4.38 T36467 SEQUENCE MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGL T36467 DRUGINFO D0H2YY JX-929 Phase 1 T08133 TARGETID T08133 T08133 FORMERID TTDR00350 T08133 UNIPROID TRPV6_HUMAN T08133 TARGNAME Transient receptor potential cation channel V6 (TRPV6) T08133 GENENAME TRPV6 T08133 TARGTYPE Clinical trial T08133 SYNONYMS Transient receptor potential cation channel subfamily V, member 6; TRPV6; HTRP8; ECaC2; Calcium transport protein CaT1; Calcium channel CAT1 T08133 FUNCTION Calcium selective cation channel probably involved in Ca(2+) uptake in various tissues, including Ca(2+) reabsorption in intestine. The channel is activated by low internal calcium level, probably including intracellular calcium store depletion, and the current exhibits an inward rectification. Inactivation includes both, a rapid Ca(2+)-dependent and a slower Ca(2+)-calmodulin- dependent mechanism, the lattermay be regulated by phosphorylation. In vitro, is slowly inhibited by Mg(2+) in a voltage-independent manner. Heteromeric assembly with TRPV5 seems to modify channel properties. TRPV5-TRPV6 heteromultimeric concatemers exhibit voltage-dependent gating. T08133 PDBSTRUC 6E2F; 6D7T; 6D7S; 6BOA; 6BO9 T08133 BIOCLASS Transient receptor potential catioin channel T08133 SEQUENCE MGPLQGDGGPALGGADVAPRLSPVRVWPRPQAPKEPALHPMGLSLPKEKGLILCLWSKFCRWFQRRESWAQSRDEQNLLQQKRIWESPLLLAAKDNDVQALNKLLKYEDCKVHQRGAMGETALHIAALYDNLEAAMVLMEAAPELVFEPMTSELYEGQTALHIAVVNQNMNLVRALLARRASVSARATGTAFRRSPCNLIYFGEHPLSFAACVNSEEIVRLLIEHGADIRAQDSLGNTVLHILILQPNKTFACQMYNLLLSYDRHGDHLQPLDLVPNHQGLTPFKLAGVEGNTVMFQHLMQKRKHTQWTYGPLTSTLYDLTEIDSSGDEQSLLELIITTKKREARQILDQTPVKELVSLKWKRYGRPYFCMLGAIYLLYIICFTMCCIYRPLKPRTNNRTSPRDNTLLQQKLLQEAYMTPKDDIRLVGELVTVIGAIIILLVEVPDIFRMGVTRFFGQTILGGPFHVLIITYAFMVLVTMVMRLISASGEVVPMSFALVLGWCNVMYFARGFQMLGPFTIMIQKMIFGDLMRFCWLMAVVILGFASAFYIIFQTEDPEELGHFYDYPMALFSTFELFLTIIDGPANYNVDLPFMYSITYAAFAIIATLLMLNLLIAMMGDTHWRVAHERDELWRAQIVATTVMLERKLPRCLWPRSGICGREYGLGDRWFLRVEDRQDLNRQRIQRYAQAFHTRGSEDLDKDSVEKLELGCPFSPHLSLPMPSVSRSTSRSSANWERLRQGTLRRDLRGIINRGLEDGESWEYQI T08133 DRUGINFO D06UWF SOR-C13 Phase 1 T08133 DRUGINFO D00HCI 2-APB Investigative T64213 TARGETID T64213 T64213 FORMERID TTDR01160 T64213 UNIPROID TRPV4_HUMAN T64213 TARGNAME Transient receptor potential cation channel V4 (TRPV4) T64213 GENENAME TRPV4 T64213 TARGTYPE Clinical trial T64213 SYNONYMS Vanilloid receptor-related osmotically-activated channel; Vanilloid receptor-like protein 2; Vanilloid receptor-like channel 2; VROAC; VRL2; VRL-2; VR-OAC; TrpV4; Transient receptor potential protein 12; Transient receptor potential cation channel subfamily V member 4; TRP12; Osm-9-like TRP channel 4; OTRPC4 T64213 FUNCTION Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity. Activation by exposure to hypotonicity within the physiological range exhibits an outward rectification. Also activated by heat, low pH, citrate and phorbol esters. Increase of intracellular Ca(2+) potentiates currents. Channel activity seems to be regulated by a calmodulin-dependent mechanism with a negative feedback mechanism. Promotes cell-cell junction formation in skin keratinocytes and plays an important role in the formation and/or maintenance of functional intercellular barriers (By similarity). Acts as a regulator of intracellular Ca(2+) in synoviocytes. Plays an obligatory role as a molecular component in the nonselective cation channel activation induced by 4-alpha-phorbol 12,13-didecanoate and hypotonic stimulation in synoviocytes and also regulates production of IL-8. Together with PKD2, forms mechano- and thermosensitive channels in cilium. Negatively regulates expression of PPARGC1A, UCP1, oxidative metabolism and respiration in adipocytes (By similarity). Regulates expression of chemokines and cytokines related to proinflammatory pathway in adipocytes (By similarity). Together with AQP5, controls regulatory volume decrease in salivary epithelial cells (By similarity). Required for normal development and maintenance of bone and cartilage. T64213 PDBSTRUC 4DX2; 4DX1 T64213 BIOCLASS Transient receptor potential catioin channel T64213 SEQUENCE MADSSEGPRAGPGEVAELPGDESGTPGGEAFPLSSLANLFEGEDGSLSPSPADASRPAGPGDGRPNLRMKFQGAFRKGVPNPIDLLESTLYESSVVPGPKKAPMDSLFDYGTYRHHSSDNKRWRKKIIEKQPQSPKAPAPQPPPILKVFNRPILFDIVSRGSTADLDGLLPFLLTHKKRLTDEEFREPSTGKTCLPKALLNLSNGRNDTIPVLLDIAERTGNMREFINSPFRDIYYRGQTALHIAIERRCKHYVELLVAQGADVHAQARGRFFQPKDEGGYFYFGELPLSLAACTNQPHIVNYLTENPHKKADMRRQDSRGNTVLHALVAIADNTRENTKFVTKMYDLLLLKCARLFPDSNLEAVLNNDGLSPLMMAAKTGKIGIFQHIIRREVTDEDTRHLSRKFKDWAYGPVYSSLYDLSSLDTCGEEASVLEILVYNSKIENRHEMLAVEPINELLRDKWRKFGAVSFYINVVSYLCAMVIFTLTAYYQPLEGTPPYPYRTTVDYLRLAGEVITLFTGVLFFFTNIKDLFMKKCPGVNSLFIDGSFQLLYFIYSVLVIVSAALYLAGIEAYLAVMVFALVLGWMNALYFTRGLKLTGTYSIMIQKILFKDLFRFLLVYLLFMIGYASALVSLLNPCANMKVCNEDQTNCTVPTYPSCRDSETFSTFLLDLFKLTIGMGDLEMLSSTKYPVVFIILLVTYIILTFVLLLNMLIALMGETVGQVSKESKHIWKLQWATTILDIERSFPVFLRKAFRSGEMVTVGKSSDGTPDRRWCFRVDEVNWSHWNQNLGIINEDPGKNETYQYYGFSHTVGRLRRDRWSSVVPRVVELNKNSNPDEVVVPLDSMGNPRCDGHQQGYPRKWRTDDAPL T64213 DRUGINFO D07HSR GSK2798745 Phase 2 T64213 DRUGINFO D09DHT phorbol 12-myristate 13-acetate Phase 2 T64213 DRUGINFO D02UVR bisandrographolide Investigative T64213 DRUGINFO D03HJW GSK1016790A Investigative T64213 DRUGINFO D03LVL GSK2193874 Investigative T64213 DRUGINFO D03OLU RN1734 Investigative T64213 DRUGINFO D09OHS 4alpha-PDD Investigative T64213 DRUGINFO D0A5LY RN1747 Investigative T64213 DRUGINFO D0B1QM HC067047 Investigative T64213 DRUGINFO D0D5BI 5,6-epoxyeicosatrienoic acid Investigative T64213 DRUGINFO D0J1SX 4alpha-PDH Investigative T64213 DRUGINFO D0N2QH 5'-iodoresiniferatoxin Investigative T64213 DRUGINFO D00ESG 4-Pyridin-2-yl-piperazine-1-carboxylic acid amide Investigative T64213 DRUGINFO D03KQG Pyrrolidin-1-yl-thiourea Investigative T64213 DRUGINFO D0G8BN CAPSAZEPINE Investigative T64213 DRUGINFO D0X7AM SC-0030 Investigative T64213 DRUGINFO D02RTS citric acid Investigative T51223 TARGETID T51223 T51223 FORMERID TTDNC00371 T51223 UNIPROID IL21_HUMAN T51223 TARGNAME Interleukin-21 (IL21) T51223 GENENAME IL21 T51223 TARGTYPE Clinical trial T51223 SYNONYMS Za11; Interleukin21; IL-21 T51223 FUNCTION May promote the transition between innate and adaptive immunity. Induces the production of IgG(1) and IgG(3) in B-cells. May play a role in proliferation and maturation of natural killer (NK) cells in synergy with IL15. May regulate proliferation of mature B- and T-cells in response to activating stimuli. In synergy with IL15 and IL18 stimulates interferon gamma production in T-cells and NK cells. During T-cell mediated immune response may inhibit dendritic cells (DC) activation and maturation. Cytokine with immunoregulatory activity. T51223 PDBSTRUC 3TGX; 2OQP T51223 BIOCLASS Cytokine: interleukin T51223 SEQUENCE MRSSPGNMERIVICLMVIFLGTLVHKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS T51223 DRUGINFO D07JWO IL-21 Phase 2 T51223 DRUGINFO D05ZSX NN-8828 Phase 1 T99160 TARGETID T99160 T99160 UNIPROID MKNK2_HUMAN T99160 TARGNAME MAP kinase signal-integrating kinase 2 (MKNK2) T99160 GENENAME MKNK2 T99160 TARGTYPE Clinical trial T99160 SYNONYMS Mnk2; MAPK signal-integrating kinase 2 T99160 FUNCTION Serine/threonine-protein kinase that phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. May play a role in the response to environmental stress and cytokines. Appears to regulate translation by phosphorylating EIF4E, thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. Required for mediating PP2A-inhibition-induced EIF4E phosphorylation. Triggers EIF4E shuttling from cytoplasm to nucleus. Isoform 1 displays a high basal kinase activity, but isoform 2 exhibits a very low kinase activity. Acts as a mediator of the suppressive effects of IFNgamma on hematopoiesis. Negative regulator for signals that control generation of arsenic trioxide As(2)O(3)-dependent apoptosis and anti-leukemic responses. Involved in anti-apoptotic signaling in response to serum withdrawal. T99160 PDBSTRUC 6CKI; 6CK6; 6CK3; 6CJY; 6CJW T99160 BIOCLASS Protein kinase superfamily. CAMK Ser/Thr protein kinase family T99160 ECNUMBER EC 2.7.11.1 T99160 SEQUENCE MVQKKPAELQGFHRSFKGQNPFELAFSLDQPDHGDSDFGLQCSARPDMPASQPIDIPDAKKRGKKKKRGRATDSFSGRFEDVYQLQEDVLGEGAHARVQTCINLITSQEYAVKIIEKQPGHIRSRVFREVEMLYQCQGHRNVLELIEFFEEEDRFYLVFEKMRGGSILSHIHKRRHFNELEASVVVQDVASALDFLHNKGIAHRDLKPENILCEHPNQVSPVKICDFDLGSGIKLNGDCSPISTPELLTPCGSAEYMAPEVVEAFSEEASIYDKRCDLWSLGVILYILLSGYPPFVGRCGSDCGWDRGEACPACQNMLFESIQEGKYEFPDKDWAHISCAAKDLISKLLVRDAKQRLSAAQVLQHPWVQGCAPENTLPTPMVLQRNSCAKDLTSFAAEAIAMNRQLAQHDEDLAEEEAAGQGQPVLVRATSRCLQLSPPSQSKLAQRRQRASLSSAPVVLVGDHA T99160 DRUGINFO D07XOV EFT508 Phase 2 T86264 TARGETID T86264 T86264 FORMERID TTDNC00532 T86264 UNIPROID S40A1_HUMAN T86264 TARGNAME Solute carrier family 40 member 1 (SLC40A1) T86264 GENENAME SLC40A1 T86264 TARGTYPE Clinical trial T86264 SYNONYMS SLC11A3; MSTP079; IREG1; Ferroportin-1; FPN1 T86264 FUNCTION Mediates iron efflux in the presence of a ferroxidase (hephaestin and/or ceruloplasmin). May be involved in iron export from duodenal epithelial cell and also in transfer of iron between maternal and fetal circulation. T86264 BIOCLASS Ferroportin protein T86264 SEQUENCE MTRAGDHNRQRGCCGSLADYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNSLLLTAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKHELLTMYHGWVLTSCYILIITIANIANLASTATAITIQRDWIVVVAGEDRSKLANMNATIRRIDQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYVLLWKVYQKTPALAVKAGLKEEETELKQLNLHKDTEPKPLEGTHLMGVKDSNIHELEHEQEPTCASQMAEPFRTFRDGWVSYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAFTWLRRKCGLVRTGLISGLAQLSCLILCVISVFMPGSPLDLSVSPFEDIRSRFIQGESITPTKIPEITTEIYMSNGSNSANIVPETSPESVPIISVSLLFAGVIAARIGLWSFDLTVTQLLQENVIESERGIINGVQNSMNYLLDLLHFIMVILAPNPEAFGLLVLISVSFVAMGHIMYFRFAQNTLGNKLFACGPDAKEVRKENQANTSVV T86264 DRUGINFO D0IN8Z LY2928057 Phase 2 T86264 DRUGINFO D07SQT Ferroportin mab Phase 1 T86264 DRUGINFO D5W7BG M012 Phase 1 T28717 TARGETID T28717 T28717 FORMERID TTDI02196 T28717 UNIPROID TNR12_HUMAN T28717 TARGNAME TNF superfamily receptor 12A (TNFRSF12A) T28717 GENENAME TNFRSF12A T28717 TARGTYPE Clinical trial T28717 SYNONYMS TweakR; Tweak-receptor; Tumor necrosis factor receptor superfamily member 12A; Fibroblast growth factor-inducible immediate-early response protein 14; FN14; FGF-inducible 14; CD266 T28717 FUNCTION Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins. Receptor for TNFSF12/TWEAK. T28717 PDBSTRUC 2RPJ; 2KMZ; 2EQP T28717 BIOCLASS Cytokine receptor T28717 SEQUENCE MARGSLRRLLRLLVLGLWLALLRSVAGEQAPGTAPCSRGSSWSADLDKCMDCASCRARPHSDFCLGCAAAPPAPFRLLWPILGGALSLTFVLGLLSGFLVWRRCRRREKFTTPIEETGGEGCPAVALIQ T28717 DRUGINFO D07UKJ Enavatuzumab Phase 1 T91451 TARGETID T91451 T91451 UNIPROID UBE2T_HUMAN T91451 TARGNAME E2 ubiquitin-conjugating enzyme T (UBE2T) T91451 GENENAME UBE2T T91451 TARGTYPE Clinical trial T91451 SYNONYMS Ubiquitin-protein ligase T; Ubiquitin carrier protein T; Cell proliferation-inducing gene 50 protein T91451 FUNCTION Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Catalyzes monoubiquitination. Involved in mitomycin-C (MMC)-induced DNA repair. Acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784, PubMed:28437106). Also mediates monoubiquitination of FANCL and FANCI (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784). May contribute to ubiquitination and degradation of BRCA1 (PubMed:19887602). In vitro able to promote polyubiquitination using all 7 ubiquitin Lys residues, but may prefer 'Lys-11'-, 'Lys-27'-, 'Lys-48'- and 'Lys-63'-linked polyubiquitination (PubMed:20061386). T91451 PDBSTRUC 5OJJ; 5NGZ; 4CCG; 1YH2 T91451 BIOCLASS Ubiquitin-conjugating enzyme family T91451 ECNUMBER EC 2.3.2.23 T91451 SEQUENCE MQRASRLKRELHMLATEPPPGITCWQDKDQMDDLRAQILGGANTPYEKGVFKLEVIIPERYPFEPPQIRFLTPIYHPNIDSAGRICLDVLKLPPKGAWRPSLNIATVLTSIQLLMSEPNPDDPLMADISSEFKYNKPAFLKNARQWTEKHARQKQKADEEEMLDNLPEAGDSRVHNSTQKRKASQLVGIEKKFHPDV T91451 DRUGINFO D0W3RW MK-2206 Phase 2 T11451 TARGETID T11451 T11451 FORMERID TTDC00107 T11451 UNIPROID TLR9_HUMAN T11451 TARGNAME Toll-like receptor 9 (TLR9) T11451 GENENAME TLR9 T11451 TARGTYPE Clinical trial T11451 SYNONYMS UNQ5798/PRO19605; TLR-9; CD289 T11451 FUNCTION Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Controls lymphocyte response to Helicobacter infection. Upon CpG stimulation, induces B-cell proliferation, activation, survival and antibody production. T11451 BIOCLASS Toll-like receptor T11451 SEQUENCE MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAAPRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFLAVPTLEELNLSYNNIMTVPALPKSLISLSLSHTNILMLDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNRIVKLAPEDLANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLNASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSFGSLVALKELDMHGIFFRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYVDLSDNRISGASELTATMGEADGGEKVWLQPGDLAPAPVDTPSSEDFRPNCSTLNFTLDLSRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSHNKLDLYHEHSFTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTSLRALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVLRLRDNYLAFFKWWSLHFLPKLEVLDLAGNQLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLSANALKTVDHSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVQAAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLAVALGLGVPMLHHLCGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEECRGRWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILSPDGRRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHHFYNRNFCQGPTAE T11451 DRUGINFO D08RJM SD-101 Phase 3 T11451 DRUGINFO D0F7YW MGN-1703 Phase 3 T11451 DRUGINFO D0FM5M IMO-2125 Phase 3 T11451 DRUGINFO D6YD0X Tilsotolimod Phase 3 T11451 DRUGINFO D0V0JR Cadi-05 Phase 3 T11451 DRUGINFO D02GIA BL-7040 Phase 2 T11451 DRUGINFO D09CEJ CYT003 Phase 2 T11451 DRUGINFO D0C6ZS CpG-10101 Phase 2 T11451 DRUGINFO D0D4LP JVRS-100 Phase 2 T11451 DRUGINFO D0GR5X Tolamba Phase 2 T11451 DRUGINFO D0W6HO IMO-2055 Phase 2 T11451 DRUGINFO DY46GM Lefitolimod Phase 2 T11451 DRUGINFO D01UHA MIS-416 Phase 2 T11451 DRUGINFO D08OXU IMO-3100 Phase 2 T11451 DRUGINFO D0C3VQ Zadaxin/lamivudine Phase 2 T11451 DRUGINFO D00CQL N-8295 Phase 1 T11451 DRUGINFO D01SPJ Litenimod Phase 1 T11451 DRUGINFO D02AWQ AZD1419 Phase 1 T11451 DRUGINFO D04CXX GNKG-168 Phase 1 T11451 DRUGINFO D05ZLY AST-008 Phase 1 T11451 DRUGINFO D0R8RO SAR-21609 Phase 1 T11451 DRUGINFO D0U8LD MGN-1706 Phase 1 T11451 DRUGINFO D0X8VX DV281 Phase 1 T11451 DRUGINFO D7T5AN CMP-001 Phase 1 T11451 DRUGINFO DBU13L Cavrotolimod Phase 1 T11451 DRUGINFO D00CGX DV-1179 Phase 1 T11451 DRUGINFO D0G1TY CPG 52364 Phase 1 T11451 DRUGINFO D03GAI IR-103 Discontinued in Phase 3 T11451 DRUGINFO D0D5FQ Agatolimod Discontinued in Phase 2 T11451 DRUGINFO D0H4XV IM0-8400 Discontinued in Phase 1/2 T11451 DRUGINFO D02ZWR IMO-2134 Preclinical T11451 DRUGINFO D0B6WN AVE0675 Terminated T11451 DRUGINFO D0Q2UW DIMS-9054 Investigative T11451 DRUGINFO DT6N0O ODN-2088 Investigative T11451 DRUGINFO DX45IW COV08-0064 Investigative T48703 TARGETID T48703 T48703 FORMERID TTDC00056 T48703 UNIPROID TLR8_HUMAN T48703 TARGNAME Toll-like receptor 8 (TLR8) T48703 GENENAME TLR8 T48703 TARGTYPE Clinical trial T48703 SYNONYMS UNQ249/PRO286; CD288 antigen; CD288 T48703 FUNCTION Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. T48703 PDBSTRUC 5Z15; 5Z14; 5WYZ; 5WYX; 5HDH T48703 BIOCLASS Toll-like receptor T48703 SEQUENCE MENMFLQSSMLTCIFLLISGSCELCAEENFSRSYPCDEKKQNDSVIAECSNRRLQEVPQTVGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQHQNGNPGIQSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTELSLIQNNIYNITKEGISRLINLKNLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNLTQLRYLNLSSTSLRKINAAWFKNMPHLKVLDLEFNYLVGEIASGAFLTMLPRLEILDLSFNYIKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLGINFIKQIDFKLFQNFSNLEIIYLSENRISPLVKDTRQSYANSSSFQRHIRKRRSTDFEFDPHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYTLTDKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRLDLSLNRLKHIPNEAFLNLPASLTELHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRTLLLSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGNPFECTCDIGDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTAVILFFFTFFITTMVMLAALAHHLFYWDVWFIYNVCLAKVKGYRSLSTSQTFYDAYISYDTKDASVTDWVINELRYHLEESRDKNVLLCLEERDWDPGLAIIDNLMQSINQSKKTVFVLTKKYAKSWNFKTAFYLALQRLMDENMDVIIFILLEPVLQHSQYLRLRQRICKSSILQWPDNPKAEGLFWQTLRNVVLTENDSRYNNMYVDSIKQY T48703 DRUGINFO DOV7J4 Selgantolimod Phase 2 T48703 DRUGINFO D0C8KF Resiquimod Phase 2 T48703 DRUGINFO DW0ZV1 Afimetoran Phase 2 T48703 DRUGINFO D8JN5H NKTR-262 Phase 1/2 T48703 DRUGINFO D05ASV VTX-1463 Phase 1 T48703 DRUGINFO D98FBH DN1508052 Phase 1 T48703 DRUGINFO DC3I7P GSK5251738 Phase 1 T48703 DRUGINFO D0L8HB MEDI9197 Phase 1 T48703 DRUGINFO DUA7P2 SBT6050 Phase 1 T48703 DRUGINFO D0G1TY CPG 52364 Phase 1 T48703 DRUGINFO DVU2H8 CV8102 Phase 1 T48703 DRUGINFO D0H3JF VTX-2337 Discontinued in Phase 2 T48703 DRUGINFO D0H4XV IM0-8400 Discontinued in Phase 1/2 T48703 DRUGINFO D01DSB VTX-744 Investigative T48703 DRUGINFO D0UI0B VTX-763 Investigative T48703 DRUGINFO D5S7JL ODN-1411 Investigative T31989 TARGETID T31989 T31989 FORMERID TTDC00058 T31989 UNIPROID SPHK2_HUMAN T31989 TARGNAME Sphingosine kinase 2 (SPHK2) T31989 GENENAME SPHK2 T31989 TARGTYPE Clinical trial T31989 SYNONYMS SPK 2; SK 2 T31989 FUNCTION Acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides. Catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (SPP), a lipid mediator with both intra- and extracellular functions. T31989 BIOCLASS Kinase T31989 ECNUMBER EC 2.7.1.91 T31989 SEQUENCE MNGHLEAEEQQDQRPDQELTGSWGHGPRSTLVRAKAMAPPPPPLAASTPLLHGEFGSYPARGPRFALTLTSQALHIQRLRPKPEARPRGGLVPLAEVSGCCTLRSRSPSDSAAYFCIYTYPRGRRGARRRATRTFRADGAATYEENRAEAQRWATALTCLLRGLPLPGDGEITPDLLPRPPRLLLLVNPFGGRGLAWQWCKNHVLPMISEAGLSFNLIQTERQNHARELVQGLSLSEWDGIVTVSGDGLLHEVLNGLLDRPDWEEAVKMPVGILPCGSGNALAGAVNQHGGFEPALGLDLLLNCSLLLCRGGGHPLDLLSVTLASGSRCFSFLSVAWGFVSDVDIQSERFRALGSARFTLGTVLGLATLHTYRGRLSYLPATVEPASPTPAHSLPRAKSELTLTPDPAPPMAHSPLHRSVSDLPLPLPQPALASPGSPEPLPILSLNGGGPELAGDWGGAGDAPLSPDPLLSSPPGSPKAALHSPVSEGAPVIPPSSGLPLPTPDARVGASTCGPPDHLLPPLGTPLPPDWVTLEGDFVLMLAISPSHLGADLVAAPHARFDDGLVHLCWVRSGISRAALLRLFLAMERGSHFSLGCPQLGYAAARAFRLEPLTPRGVLTVDGEQVEYGPLQAQMHPGIGTLLTGPPGCPGREP T31989 DRUGINFO D0X6BX ABC294640 Phase 3 T31989 DRUGINFO D01UUZ (R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide Investigative T31989 DRUGINFO D01XSX (S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide Investigative T31989 DRUGINFO D0E3LA (R)-2-amino-3-(4-octylphenylamino)propan-1-ol Investigative T31989 DRUGINFO D0H2LN ROMe Investigative T31989 DRUGINFO D0M9DT DIMETHYLSPINGOSINE Investigative T31989 DRUGINFO D0TC4I (S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide Investigative T42928 TARGETID T42928 T42928 FORMERID TTDI02071 T42928 UNIPROID FGF21_HUMAN T42928 TARGNAME Fibroblast growth factor-21 (FGF21) T42928 GENENAME FGF21 T42928 TARGTYPE Clinical trial T42928 SYNONYMS UNQ3115/PRO10196; Fibroblast growth factor 21; FGF-21 T42928 FUNCTION Activity requires the presence of KLB. Stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression (but not SLC2A4/GLUT4 expression). T42928 PDBSTRUC 5VAQ T42928 BIOCLASS Growth factor T42928 SEQUENCE MDSDETGFEHSGLWVSVLAGLLLGACQAHPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS T42928 DRUGINFO DZ2B3I Pegozafermin Phase 3 T42928 DRUGINFO D0PO0T BMS-986036 Phase 2 T42928 DRUGINFO D0WK6V PF-05231023 Phase 1 T42928 DRUGINFO D03OCG FGF-21 Discontinued in Phase 1/2 T55398 TARGETID T55398 T55398 FORMERID TTDR00045 T55398 UNIPROID IRAK4_HUMAN T55398 TARGNAME Renal carcinoma antigen NY-REN-64 (IRAK-4) T55398 GENENAME IRAK4 T55398 TARGTYPE Clinical trial T55398 SYNONYMS Interleukin-1 receptor-associated kinase 4; IRAK-4 T55398 FUNCTION Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation to form the Myddosome together with IRAK2. Phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation suggesting a similar mechanism during microbial infections. T55398 PDBSTRUC 6O9D; 6O95; 6O94; 6O8U; 6N8G T55398 BIOCLASS Kinase T55398 ECNUMBER EC 2.7.11.1 T55398 SEQUENCE MNKPITPSTYVRCLNVGLIRKLSDFIDPQEGWKKLAVAIKKPSGDDRYNQFHIRRFEALLQTGKSPTSELLFDWGTTNCTVGDLVDLLIQNEFFAPASLLLPDAVPKTANTLPSKEAITVQQKQMPFCDKDRTLMTPVQNLEQSYMPPDSSSPENKSLEVSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS T55398 DRUGINFO D5XVM6 Zabedosertib Phase 2 T55398 DRUGINFO DF1T2W GS-5718 Phase 2 T55398 DRUGINFO D0AY8A CA-4948 Phase 1 T55398 DRUGINFO D0CW9M SAR444656 Phase 1 T55398 DRUGINFO D0QQ7I BAY1834845 Phase 1 T55398 DRUGINFO D7MYO0 AZD6793 Phase 1 T55398 DRUGINFO D00WDA Indazole amide derivative 2 Patented T55398 DRUGINFO D04UIH Amidopyrazole derivative 1 Patented T55398 DRUGINFO D0A2BX Amidopyrazole derivative 3 Patented T55398 DRUGINFO D0DC8B Indazole amide derivative 1 Patented T55398 DRUGINFO D0DK0R Macrolactam derivative 3 Patented T55398 DRUGINFO D0G3NC Amidopyrazole derivative 2 Patented T55398 DRUGINFO D0GA8C Macrolactam derivative 1 Patented T55398 DRUGINFO D0L7OR Diaminopyridine analog 5 Patented T55398 DRUGINFO D0N4ZM Amidopyrazole derivative 6 Patented T55398 DRUGINFO D0N5WE Macrolactam derivative 2 Patented T55398 DRUGINFO D0Q7ZF Macrolactam derivative 4 Patented T55398 DRUGINFO D0S1DI Diaminopyridine analog 4 Patented T55398 DRUGINFO D0TV9G Amidopyrazole derivative 4 Patented T55398 DRUGINFO D0VD3P Amidopyrazole derivative 5 Patented T55398 DRUGINFO D0W3TL Fused benzoheterocycle amide derivative 2 Patented T55398 DRUGINFO D0YF6E Fused benzoheterocycle amide derivative 1 Patented T55398 DRUGINFO D0YJ1O Pyrazole N-1 aryl and heteroaryl derivative 1 Patented T55398 DRUGINFO D0E5AT Pyrazolopyrimidine and thienopyrimidine amide derivative 1 Patented T55398 DRUGINFO D0F2NW Pyrazolopyrimidine and thienopyrimidine amide derivative 2 Patented T55398 DRUGINFO D0NT8U Indazoletriazolephenyl derivative 1 Patented T55398 DRUGINFO D0O6GQ Indazoletriazolephenyl derivative 2 Patented T55398 DRUGINFO D00DSG PF-05313261 Investigative T55398 DRUGINFO D04CFM ND-2158 Investigative T55398 DRUGINFO D09JUD IRAK4 inhibitor 4b Investigative T55398 DRUGINFO D0J8VR IRAK4 inhibitor rac-45 Investigative T55398 DRUGINFO D0Y2ZC ND-2110 Investigative T55398 DRUGINFO D04ZIV WO2012007375C1 Investigative T55398 DRUGINFO D0I2FZ IRAK-1/4 inhibitor Investigative T55398 DRUGINFO D0T2NE WO2012007375C7 Investigative T22583 TARGETID T22583 T22583 FORMERID TTDC00158 T22583 UNIPROID SC5A4_HUMAN T22583 TARGNAME Sodium/glucose cotransporter 2 (SLC5A4) T22583 GENENAME SLC5A4 T22583 TARGTYPE Clinical trial T22583 SYNONYMS Sodium/glucose cotransporter 4; SLC5A4 T22583 FUNCTION Sodium-dependent glucose transporter. T22583 BIOCLASS Solute:sodium symporter T22583 SEQUENCE MASTVSPSTIAETPEPPPLSDHIRNAADISVIVIYFLVVMAVGLWAMLKTNRGTIGGFFLAGRDMAWWPMGASLFASNIGSNHYVGLAGTGAASGVATVTFEWTSSVMLLILGWIFVPIYIKSGVMTMPEYLKKRFGGERLQVYLSILSLFICVVLLISADIFAGAIFIKLALGLDLYLAIFILLAMTAVYTTTGGLASVIYTDTLQTIIMLIGSFILMGFAFNEVGGYESFTEKYVNATPSVVEGDNLTISASCYTPRADSFHIFRDAVTGDIPWPGIIFGMPITALWYWCTNQVIVQRCLCGKDMSHVKAACIMCAYLKLLPMFLMVMPGMISRILYTDMVACVVPSECVKHCGVDVGCTNYAYPTMVLELMPQGLRGLMLSVMLASLMSSLTSIFNSASTLFTIDLYTKMRKQASEKELLIAGRIFVLLLTVVSIVWVPLVQVSQNGQLIHYTESISSYLGPPIAAVFVLAIFCKRVNEQGAFWGLMVGLAMGLIRMITEFAYGTGSCLAPSNCPKIICGVHYLYFSIVLFFGSMLVTLGISLLTKPIPDVHLYRLCWVLRNSTEERIDIDAEEKSQEETDDGVEEDYPEKSRGCLKKAYDLFCGLQKGPKLTKEEEEALSKKLTDTSERPSWRTIVNINAILLLAVVVFIHGYYA T22583 DRUGINFO D04WQT RG7201 Phase 3 T22583 DRUGINFO D09XMX SaxaDapa FDC Phase 3 T22583 DRUGINFO D0I5ZM Remogli ozin-etabonate Phase 2 T22583 DRUGINFO D0V4MB Remogliflozin etabonate Phase 2 T22583 DRUGINFO D0U9TM Ponalrestat Discontinued in Phase 3 T94482 TARGETID T94482 T94482 FORMERID TTDR00855 T94482 UNIPROID IL20_HUMAN T94482 TARGNAME Interleukin-20 (IL20) T94482 GENENAME IL20 T94482 TARGTYPE Clinical trial T94482 SYNONYMS ZCYTO10; UNQ852/PRO1801; IL-20; Four alpha helix cytokine ZCYTO10; Cytokine Zcyto10 T94482 FUNCTION Angiogenic and proliferative activities are antagonized by IL10. May act through STAT3. Proinflammatory and angiogenic cytokine that may be involved in epidermal function and psoriasis. T94482 PDBSTRUC 4DOH T94482 BIOCLASS Cytokine: interleukin T94482 SEQUENCE MKASSLAFSLLSAAFYLLWTPSTGLKTLNLGSCVIATNLQEIRNGFSEIRGSVQAKDGNIDIRILRRTESLQDTKPANRCCLLRHLLRLYLDRVFKNYQTPDHYTLRKISSLANSFLTIKKDLRLCHAHMTCHCGEEAMKKYSQILSHFEKLEPQAAVVKALGELDILLQWMEETE T94482 DRUGINFO D00LGA NN-8226 Phase 2 T91286 TARGETID T91286 T91286 FORMERID TTDNC00499 T91286 UNIPROID STEA1_HUMAN T91286 TARGNAME Metalloreductase STEAP1 (STEAP1) T91286 GENENAME STEAP1 T91286 TARGTYPE Clinical trial T91286 SYNONYMS Sixtransmembrane epithelial antigen of prostate 1; STEAP1 T91286 FUNCTION Metalloreductase that has the ability to reduce both Fe(3+) to Fe(2+) and Cu(2+) to Cu(1+). Uses NAD(+) as acceptor. T91286 BIOCLASS Metal ion oxidoreductase T91286 ECNUMBER EC 1.16.1.- T91286 SEQUENCE MESRKDITNQEELWKMKPRRNLEEDDYLHKDTGETSMLKRPVLLHLHQTAHADEFDCPSELQHTQELFPQWHLPIKIAAIIASLTFLYTLLREVIHPLATSHQQYFYKIPILVINKVLPMVSITLLALVYLPGVIAAIVQLHNGTKYKKFPHWLDKWMLTRKQFGLLSFFFAVLHAIYSLSYPMRRSYRYKLLNWAYQQVQQNKEDAWIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQSKLGIVSLLLGTIHALIFAWNKWIDIKQFVWYTPPTFMIAVFLPIVVLIFKSILFLPCLRKKILKIRHGWEDVTKINKTEICSQL T91286 DRUGINFO D0O6YE RG7450 Phase 1 T91286 DRUGINFO DAX06Q AMG 509 Phase 1 T49072 TARGETID T49072 T49072 FORMERID TTDR00562 T49072 UNIPROID UR2R_HUMAN T49072 TARGNAME Urotensin II receptor (UTS2R) T49072 GENENAME UTS2R T49072 TARGTYPE Clinical trial T49072 SYNONYMS Urotensin-II receptor GPR14; UTS2R; UR-II-R; G protein coupled receptor 14 T49072 FUNCTION High affinity receptor for urotensin-2 and urotensin-2B. The activity of this receptor is mediated by a G-protein that activate a phosphatidylinositol-calcium second messenger system. T49072 BIOCLASS GPCR rhodopsin T49072 SEQUENCE MALTPESPSSFPGLAATGSSVPEPPGGPNATLNSSWASPTEPSSLEDLVATGTIGTLLSAMGVVGVVGNAYTLVVTCRSLRAVASMYVYVVNLALADLLYLLSIPFIVATYVTKEWHFGDVGCRVLFGLDFLTMHASIFTLTVMSSERYAAVLRPLDTVQRPKGYRKLLALGTWLLALLLTLPVMLAMRLVRRGPKSLCLPAWGPRAHRAYLTLLFATSIAGPGLLIGLLYARLARAYRRSQRASFKRARRPGARALRLVLGIVLLFWACFLPFWLWQLLAQYHQAPLAPRTARIVNYLTTCLTYGNSCANPFLYTLLTRNYRDHLRGRVRGPGSGGGRGPVPSLQPRARFQRCSGRSLSSCSPQPTDSLVLAPAAPARPAPEGPRAPA T49072 DRUGINFO D04LWT GSK1440115 Phase 1 T49072 DRUGINFO D0PQ8T SB-436811 Phase 1 T49072 DRUGINFO D08FGX PALOSURAN Discontinued in Phase 2 T49072 DRUGINFO D04LSH SAR101099 Discontinued in Phase 1 T49072 DRUGINFO D00CLB SB-328872 Investigative T49072 DRUGINFO D03AHQ Ac-[CFWKFC]-NH2 Investigative T49072 DRUGINFO D03JLK Ac-FWKY-NH2 Investigative T49072 DRUGINFO D03NCB Ac-[CFWkYC]-NH2 Investigative T49072 DRUGINFO D04UHT urotensin II-related peptide Investigative T49072 DRUGINFO D05WON SB-611812 Investigative T49072 DRUGINFO D07JDU SB-706375 Investigative T49072 DRUGINFO D0J7HS AGTAD[CFWKYC]V Investigative T49072 DRUGINFO D0M1BF S6716 Investigative T49072 DRUGINFO D0M9ZX FL104 Investigative T49072 DRUGINFO D0P1HC Ac-WKY-NH2 Investigative T49072 DRUGINFO D0R8GW AC-7954 Investigative T49072 DRUGINFO D0T0RI JNJ-28318706 Investigative T49072 DRUGINFO D0YY3T Ac-SFWKYS-NH2 Investigative T49072 DRUGINFO D03SAV ICI-199441 Investigative T42065 TARGETID T42065 T42065 FORMERID TTDI02080 T42065 UNIPROID GLCNE_HUMAN T42065 TARGNAME N-acetylmannosamine kinase (GNE) T42065 GENENAME GNE T42065 TARGTYPE Clinical trial T42065 SYNONYMS UDPGlcNAc2epimerase/ManAc kinase; GNE; Bifunctional UDPNacetylglucosamine 2epimerase/Nacetylmannosamine kinase T42065 FUNCTION Regulates and initiates biosynthesis of N- acetylneuraminic acid (NeuAc), a precursor of sialic acids. Plays an essential role in early development. Required for normal sialylation in hematopoietic cells. Sialylation is implicated in cell adhesion, signal transduction, tumorigenicity and metastatic behavior of malignant cells. {ECO:0000250, ECO:0000269|PubMed:10334995}. T42065 PDBSTRUC 4ZHT; 3EO3; 2YI1; 2YHY; 2YHW T42065 BIOCLASS Kinase T42065 SEQUENCE MEKNGNNRKLRVCVATCNRADYSKLAPIMFGIKTEPEFFELDVVVLGSHLIDDYGNTYRMIEQDDFDINTRLHTIVRGEDEAAMVESVGLALVKLPDVLNRLKPDIMIVHGDRFDALALATSAALMNIRILHIEGGEVSGTIDDSIRHAITKLAHYHVCCTRSAEQHLISMCEDHDRILLAGCPSYDKLLSAKNKDYMSIIRMWLGDDVKSKDYIVALQHPVTTDIKHSIKMFELTLDALISFNKRTLVLFPNIDAGSKEMVRVMRKKGIEHHPNFRAVKHVPFDQFIQLVAHAGCMIGNSSCGVREVGAFGTPVINLGTRQIGRETGENVLHVRDADTQDKILQALHLQFGKQYPCSKIYGDGNAVPRILKFLKSIDLQEPLQKKFCFPPVKENISQDIDHILETLSALAVDLGGTNLRVAIVSMKGEIVKKYTQFNPKTYEERINLILQMCVEAAAEAVKLNCRILGVGISTGGRVNPREGIVLHSTKLIQEWNSVDLRTPLSDTLHLPVWVDNDGNCAALAERKFGQGKGLENFVTLITGTGIGGGIIHQHELIHGSSFCAAELGHLVVSLDGPDCSCGSHGCIEAYASGMALQREAKKLHDEDLLLVEGMSVPKDEAVGALHLIQAAKLGNAKAQSILRTAGTALGLGVVNILHTMNPSLVILSGVLASHYIHIVKDVIRQQALSSVQDVDVVVSDLVDPALLGAASMVLDYTTRRIY T42065 DRUGINFO D0KX8B GNE Lipoplex Phase 1 T76508 TARGETID T76508 T76508 FORMERID TTDR00337 T76508 UNIPROID M3K2_HUMAN T76508 TARGNAME MAPK/ERK kinase kinase 2 (MAP3K2) T76508 GENENAME MAP3K2 T76508 TARGTYPE Clinical trial T76508 SYNONYMS Mitogen-activated protein kinase kinase kinase 2; MEKK2; MEKK 2; MEK kinase 2; MAPKKK2 T76508 FUNCTION Regulates the JNK and ERK5 pathways by phosphorylating and activating MAP2K5 and MAP2K7. Plays a role in caveolae kiss-and-run dynamics. Component of a protein kinase signal transduction cascade. T76508 PDBSTRUC 5HQ8; 5EX0; 2NPT; 2CU1 T76508 BIOCLASS Kinase T76508 ECNUMBER EC 2.7.11.25 T76508 SEQUENCE MDDQQALNSIMQDLAVLHKASRPALSLQETRKAKSSSPKKQNDVRVKFEHRGEKRILQFPRPVKLEDLRSKAKIAFGQSMDLHYTNNELVIPLTTQDDLDKAVELLDRSIHMKSLKILLVINGSTQATNLEPLPSLEDLDNTVFGAERKKRLSIIGPTSRDRSSPPPGYIPDELHQVARNGSFTSINSEGEFIPESMDQMLDPLSLSSPENSGSGSCPSLDSPLDGESYPKSRMPRAQSYPDNHQEFSDYDNPIFEKFGKGGTYPRRYHVSYHHQEYNDGRKTFPRARRTQGTSLRSPVSFSPTDHSLSTSSGSSIFTPEYDDSRIRRRGSDIDNPTLTVMDISPPSRSPRAPTNWRLGKLLGQGAFGRVYLCYDVDTGRELAVKQVQFDPDSPETSKEVNALECEIQLLKNLLHERIVQYYGCLRDPQEKTLSIFMEYMPGGSIKDQLKAYGALTENVTRKYTRQILEGVHYLHSNMIVHRDIKGANILRDSTGNVKLGDFGASKRLQTICLSGTGMKSVTGTPYWMSPEVISGEGYGRKADIWSVACTVVEMLTEKPPWAEFEAMAAIFKIATQPTNPKLPPHVSDYTRDFLKRIFVEAKLRPSADELLRHMFVHYH T76508 DRUGINFO D04BCG LLZ16407 Investigative T76508 DRUGINFO D0C1OZ Ro092210 Investigative T76508 DRUGINFO D0GD8Y U0126 Investigative T76508 DRUGINFO D07ADX URMC-099 Investigative T76508 DRUGINFO D0B9BU CI-1040 Investigative T33641 TARGETID T33641 T33641 FORMERID TTDI02047 T33641 UNIPROID CP46A_HUMAN T33641 TARGNAME Cholesterol 24-hydroxylase (CYP46A1) T33641 GENENAME CYP46A1 T33641 TARGTYPE Clinical trial T33641 SYNONYMS Cytochrome P450 46A1; CYP46; Cholesterol 24S-hydroxylase; Cholesterol 24-monooxygenase; CH24H T33641 FUNCTION Primarily catalyzes the hydroxylation (with S stereochemistry) at C-24 of cholesterol side chain, triggering cholesterol diffusion out of neurons and its further degradation. By promoting constant cholesterol elimination in neurons, may activate the mevalonate pathway and coordinate the synthesis of new cholesterol and nonsterol isoprenoids involved in synaptic activity and learning. Further hydroxylates cholesterol derivatives and hormone steroids on both the ring and side chain of these molecules, converting them into active oxysterols involved in lipid signaling and biosynthesis. Acts as an epoxidase converting cholesta-5,24-dien-3beta-ol/desmosterol into (24S),25-epoxycholesterol, an abundant lipid ligand of nuclear NR1H2 and NR1H3 receptors shown to promote neurogenesis in developing brain. May also catalyze the oxidative metabolism of xenobiotics, such as clotrimazole. P450 monooxygenase that plays a major role in cholesterol homeostasis in the brain. T33641 PDBSTRUC 4J14; 4FIA; 4ENH; 3MDV; 3MDT T33641 BIOCLASS Paired donor oxygen oxidoreductase T33641 ECNUMBER EC 1.14.14.25 T33641 SEQUENCE MSPGLLLLGSAVLLAFGLCCTFVHRARSRYEHIPGPPRPSFLLGHLPCFWKKDEVGGRVLQDVFLDWAKKYGPVVRVNVFHKTSVIVTSPESVKKFLMSTKYNKDSKMYRALQTVFGERLFGQGLVSECNYERWHKQRRVIDLAFSRSSLVSLMETFNEKAEQLVEILEAKADGQTPVSMQDMLTYTAMDILAKAAFGMETSMLLGAQKPLSQAVKLMLEGITASRNTLAKFLPGKRKQLREVRESIRFLRQVGRDWVQRRREALKRGEEVPADILTQILKAEEGAQDDEGLLDNFVTFFIAGHETSANHLAFTVMELSRQPEIVARLQAEVDEVIGSKRYLDFEDLGRLQYLSQVLKESLRLYPPAWGTFRLLEEETLIDGVRVPGNTPLLFSTYVMGRMDTYFEDPLTFNPDRFGPGAPKPRFTYFPFSLGHRSCIGQQFAQMEVKVVMAKLLQRLEFRLVPGQRFGLQEQATLKPLDPVLCTLRPRGWQPAPPPPPC T33641 DRUGINFO D06EHX TAK-935 Phase 2 T33641 DRUGINFO D01EEY PMID25514969-Compound-Figure3 Patented T33641 DRUGINFO D05TMN PMID25514969-Compound-8 Patented T33641 DRUGINFO D08HYS PMID25514969-Compound-10 Patented T33641 DRUGINFO D09RTV PMID25514969-Compound-9 Patented T33641 DRUGINFO D0L5NZ PMID25514969-Compound-Figure2-3 Patented T33641 DRUGINFO D0LW9K PMID25514969-Compound-11 Patented T33641 DRUGINFO D0M4XO PMID25514969-Compound-Figure2-4 Patented T33641 DRUGINFO D0RY9R PMID25514969-Compound-13 Patented T33641 DRUGINFO D0SQ4B PMID25514969-Compound-12 Patented T33641 DRUGINFO D0XJ3S PMID25514969-Compound-Figure2-2 Patented T41560 TARGETID T41560 T41560 FORMERID TTDI02249 T41560 UNIPROID EGFR_HUMAN T41560 TARGNAME EGFR messenger RNA (EGFR mRNA) T41560 GENENAME EGFR T41560 TARGTYPE Clinical trial T41560 SYNONYMS Receptor tyrosine-protein kinase erbB-1 (mRNA); Proto-oncogene c-ErbB-1 (mRNA); HER1 (mRNA); Epidermal growth factor receptor (mRNA); ERBB1 (mRNA); ERBB (mRNA); EGFR (mRNA) T41560 FUNCTION Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance. T41560 PDBSTRUC 6D8E; 6B3S; 6ARU; 5ZWJ; 5YU9 T41560 BIOCLASS mRNA target T41560 ECNUMBER EC 2.7.10.1 T41560 SEQUENCE MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA T41560 DRUGINFO D0FV3K AC0010 Phase 3 T41560 DRUGINFO D06VFF EGFR antisense DNA Phase 1/2 T41560 DRUGINFO D09BZS CK-101 Phase 1/2 T41560 DRUGINFO D0M8YM Pyrotinib Phase 1 T85651 TARGETID T85651 T85651 FORMERID TTDI02268 T85651 UNIPROID MYC_HUMAN T85651 TARGNAME Myc messenger RNA (MYC mRNA) T85651 GENENAME MYC T85651 TARGTYPE Clinical trial T85651 SYNONYMS bHLHe39 (mRNA); Transcription factor p64 (mRNA); Proto-oncogene c-Myc (mRNA); Myc proto-oncogene protein (mRNA); Class E basic helix-loop-helix protein 39 (mRNA); C-myc oncogene (mRNA); C-myc (mRNA) T85651 FUNCTION Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. T85651 PDBSTRUC 6G6L; 6G6K; 6G6J; 6C4U; 5I50 T85651 BIOCLASS mRNA target T85651 SEQUENCE MPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA T85651 DRUGINFO D01VDI AVI-5126 Phase 2 T85651 DRUGINFO D0M4MG Resten-NG Phase 2 T52953 TARGETID T52953 T52953 FORMERID TTDC00216 T52953 UNIPROID CRP_HUMAN T52953 TARGNAME CRP messenger RNA (CRP mRNA) T52953 GENENAME CRP T52953 TARGTYPE Clinical trial T52953 SYNONYMS PTX1 (mRNA); C-reactive protein (mRNA) T52953 FUNCTION Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. Displays several functions associated with host defense: it promotes agglutination, bacterial capsular swelling, phagocytosis and complement fixation through its calcium-dependent binding to phosphorylcholine. T52953 PDBSTRUC 3PVO; 3PVN; 3L2Y; 1LJ7; 1GNH T52953 BIOCLASS mRNA target T52953 SEQUENCE MEKLLCFLVLTSLSHAFGQTDMSRKAFVFPKESDTSYVSLKAPLTKPLKAFTVCLHFYTELSSTRGYSIFSYATKRQDNEILIFWSKDIGYSFTVGGSEILFEVPEVTVAPVHICTSWESASGIVEFWVDGKPRVRKSLKKGYTVGAEASIILGQEQDSFGGNFEGSQSLVGDIGNVNMWDFVLSPDEINTIYLGGPFSPNVLNWRALKYEVQGEVFTKPQLWP T52953 DRUGINFO D0H1TG ISIS-CRPRx Phase 2 T52953 DRUGINFO D06CIJ ISIS-CRP Phase 1 T52953 DRUGINFO D01EPD ISIS 133726 Investigative T52953 DRUGINFO D02OHL ISIS 133712 Investigative T52953 DRUGINFO D06TJI ISIS 140180 Investigative T52953 DRUGINFO D08XCL ISIS 330031 Investigative T52953 DRUGINFO D0C9FX ISIS 330012 Investigative T52953 DRUGINFO D0Q4HW ISIS 329956 Investigative T52953 DRUGINFO D0Q4JF Phosphocholine Investigative T87939 TARGETID T87939 T87939 FORMERID TTDI02261 T87939 UNIPROID KLKB1_HUMAN T87939 TARGNAME Plasma kallikrein messenger RNA (KLKB1 mRNA) T87939 GENENAME KLKB1 T87939 TARGTYPE Clinical trial T87939 SYNONYMS Plasma prekallikrein (mRNA); Plasma kallikrein light chain (mRNA); Plasma kallikrein heavy chain (mRNA); PKK (mRNA); Kininogenin (mRNA); KLK3 (mRNA); Fletcher factor (mRNA) T87939 FUNCTION It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin. The enzyme cleaves Lys-Arg and Arg-Ser bonds. T87939 PDBSTRUC 6O1S; 6O1G; 6I44; 5TJX; 5F8Z T87939 BIOCLASS mRNA target T87939 ECNUMBER EC 3.4.21.34 T87939 SEQUENCE MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA T87939 DRUGINFO D0HL1X ISIS-PKK Phase 3 T87939 DRUGINFO DR0B6F Donidalorsen Phase 3 T52316 TARGETID T52316 T52316 FORMERID TTDR00129 T52316 UNIPROID RAF1_HUMAN T52316 TARGNAME Raf messenger RNA (Raf mRNA) T52316 GENENAME RAF1 T52316 TARGTYPE Clinical trial T52316 SYNONYMS cRaf (mRNA); Raf-1 (mRNA); RAF proto-oncogene serine/threonine-protein kinase (mRNA); RAF (mRNA) T52316 FUNCTION RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation. Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. T52316 PDBSTRUC 4IHL; 4IEA; 4G3X; 4G0N; 4FJ3 T52316 BIOCLASS mRNA target T52316 ECNUMBER EC 2.7.11.1 T52316 SEQUENCE MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF T52316 DRUGINFO D07IEU MLN2480 Phase 2 T52316 DRUGINFO D0T4QA LXH254 Phase 1 T52316 DRUGINFO D0W2BK ICo-007 Phase 1 T52316 DRUGINFO D0W9QI LErafAON Phase 1 T52316 DRUGINFO D02DXC SPN-803 Phase 1 T52316 DRUGINFO D06EFW RG7304 Phase 1 T52316 DRUGINFO D01KEF ISIS 10707 Investigative T52316 DRUGINFO D01LYK ISIS 9058 Investigative T52316 DRUGINFO D05UPS 5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid Investigative T52316 DRUGINFO D07JHY ISIS 7853 Investigative T52316 DRUGINFO D07QVR ISIS 7855 Investigative T52316 DRUGINFO D07XKC ISIS 7851 Investigative T52316 DRUGINFO D08KOD ISIS 15770 Investigative T52316 DRUGINFO D09IOO ISIS 11061 Investigative T52316 DRUGINFO D0E7WU ISIS 7848 Investigative T52316 DRUGINFO D0K5WH ISIS 6717 Investigative T52316 DRUGINFO D0LG0E ISIS 6720 Investigative T52316 DRUGINFO D0OV7O ISIS 6729 Investigative T52316 DRUGINFO D0Q1UM ISIS 7849 Investigative T52316 DRUGINFO D0QN6U L-790070 Investigative T52316 DRUGINFO D0R9BP ISIS 7847 Investigative T52316 DRUGINFO D02TYK 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine Investigative T52316 DRUGINFO D06YMT PLX-ORI3 Investigative T52316 DRUGINFO D0BH7S 6-Benzylsulfanyl-9H-purine Investigative T52316 DRUGINFO D0Z5TQ GW-5074 Investigative T52316 DRUGINFO D00NWF ZM-336372 Investigative T52316 DRUGINFO D01WAI DEBROMOHYMENIALDISINE Investigative T82051 TARGETID T82051 T82051 FORMERID TTDI02325 T82051 UNIPROID P53_HUMAN T82051 TARGNAME P53 messenger RNA (TP53 mRNA) T82051 GENENAME TP53 T82051 TARGTYPE Clinical trial T82051 SYNONYMS Tumor suppressor p53 (mRNA); Phosphoprotein p53 (mRNA); P53 (mRNA); Antigen NY-CO-13 (mRNA) T82051 FUNCTION Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2. Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. T82051 PDBSTRUC 6GGF; 6GGE; 6GGD; 6GGC; 6GGB T82051 BIOCLASS mRNA target T82051 SEQUENCE MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD T82051 DRUGINFO D02CKH OPI-1002 Phase 2 T82051 DRUGINFO D0K4VW Cenersen Phase 2 T82051 DRUGINFO D0T8EL AHL Investigative T24555 TARGETID T24555 T24555 FORMERID TTDI02256 T24555 UNIPROID ADRB2_HUMAN T24555 TARGNAME ADRB2 messenger RNA (ADRB2 mRNA) T24555 GENENAME ADRB2 T24555 TARGTYPE Clinical trial T24555 SYNONYMS Beta-2 adrenoreceptor (mRNA); Beta-2 adrenoceptor (mRNA); Beta-2 adrenergic receptor (mRNA); B2AR (mRNA); ADRB2R (mRNA) T24555 FUNCTION The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. T24555 PDBSTRUC 6MXT; 5X7D; 5JQH; 5D6L; 5D5B T24555 BIOCLASS mRNA target T24555 SEQUENCE MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRFHVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL T24555 DRUGINFO D0Q8LL SYL-040012 Phase 2 T24555 DRUGINFO D4RD0C Bamosiran Phase 2 T38810 TARGETID T38810 T38810 FORMERID TTDI02266 T38810 UNIPROID APOA_HUMAN T38810 TARGNAME Apolipoprotein A messenger RNA (LPA mRNA) T38810 GENENAME LPA T38810 TARGTYPE Clinical trial T38810 SYNONYMS Lp(a) (mRNA); Apolipoprotein(a) (mRNA); Apo(a) (mRNA) T38810 FUNCTION It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330. Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). T38810 PDBSTRUC 4KIV; 4BVW; 4BVV; 4BVD; 4BVC T38810 BIOCLASS mRNA target T38810 ECNUMBER EC 3.4.21.- T38810 SEQUENCE MEHKEVVLLLLLFLKSAAPEQSHVVQDCYHGDGQSYRGTYSTTVTGRTCQAWSSMTPHQHNRTTENYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDPVAAPYCYTRDPSVRWEYCNLTQCSDAEGTAVAPPTITPIPSLEAPSEQAPTEQRPGVQECYHGNGQSYQGTYFITVTGRTCQAWSSMTPHSHSRTPAYYPNAGLIKNYCRNPDPVAAPWCYTTDPSVRWEYCNLTRCSDAEWTAFVPPNVILAPSLEAFFEQALTEETPGVQDCYYHYGQSYRGTYSTTVTGRTCQAWSSMTPHQHSRTPENYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCLVTESSVLATLTVVPDPSTEASSEEAPTEQSPGVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEISPWCYTMDPNVRWEYCNLTQCPVTESSVLATSTAVSEQAPTEQSPTVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCPVMESTLLTTPTVVPVPSTELPSEEAPTENSTGVQDCYRGDGQSYRGTLSTTITGRTCQSWSSMTPHWHRRIPLYYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTRCPVTESSVLTTPTVAPVPSTEAPSEQAPPEKSPVVQDCYHGDGRSYRGISSTTVTGRTCQSWSSMIPHWHQRTPENYPNAGLTENYCRNPDSGKQPWCYTTDPCVRWEYCNLTQCSETESGVLETPTVVPVPSMEAHSEAAPTEQTPVVRQCYHGNGQSYRGTFSTTVTGRTCQSWSSMTPHRHQRTPENYPNDGLTMNYCRNPDADTGPWCFTMDPSIRWEYCNLTRCSDTEGTVVAPPTVIQVPSLGPPSEQDCMFGNGKGYRGKKATTVTGTPCQEWAAQEPHRHSTFIPGTNKWAGLEKNYCRNPDGDINGPWCYTMNPRKLFDYCDIPLCASSSFDCGKPQVEPKKCPGSIVGGCVAHPHSWPWQVSLRTRFGKHFCGGTLISPEWVLTAAHCLKKSSRPSSYKVILGAHQEVNLESHVQEIEVSRLFLEPTQADIALLKLSRPAVITDKVMPACLPSPDYMVTARTECYITGWGETQGTFGTGLLKEAQLLVIENEVCNHYKYICAEHLARGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYARVSRFVTWIEGMMRNN T38810 DRUGINFO DKN63V Pelacarsen Phase 3 T38810 DRUGINFO D0Y0KY ISIS-APO(a) Phase 2 T38810 DRUGINFO D2SDM0 SLN360 Phase 2 T38810 DRUGINFO D81AQG AMG 890 Phase 2 T38810 DRUGINFO DT2N8D LY3819469 Phase 2 T90391 TARGETID T90391 T90391 FORMERID TTDI02262 T90391 UNIPROID CP3A4_HUMAN T90391 TARGNAME CYP3A4 messenger RNA (CYP3A4 mRNA) T90391 GENENAME CYP3A4 T90391 TARGTYPE Clinical trial T90391 SYNONYMS Taurochenodeoxycholate 6-alpha-hydroxylase (mRNA); Quinine 3-monooxygenase (mRNA); P450-PCN1 (mRNA); Nifedipine oxidase (mRNA); NF-25 (mRNA); HLp (mRNA); Cytochrome P450-PCN1 (mRNA); Cytochrome P450 NF-25 (mRNA); Cytochrome P450 HLp (mRNA); Cytochrome P450 3A4 (mRNA); Cytochrome P450 3A3 (mRNA); CYPIIIA4 (mRNA); CYPIIIA3 (mRNA); CYP3A3 (mRNA); Albendazole sulfoxidase (mRNA); Albendazole monooxygenase (sulfoxide-forming) (mRNA); 1,8-cineole 2-exo-monooxygenase (mRNA) T90391 FUNCTION In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e. g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide. Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole. Cytochromes P450 are a group of heme-thiolate monooxygenases. T90391 PDBSTRUC 6BDM; 6BDK; 6BDI; 6BDH; 6BD8 T90391 BIOCLASS mRNA target T90391 ECNUMBER EC 1.14.14.- T90391 SEQUENCE MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA T90391 DRUGINFO D0J6FE AVI-4557 Phase 2 T99740 TARGETID T99740 T99740 FORMERID TTDC00022 T99740 UNIPROID MYB_HUMAN T99740 TARGNAME Myb messenger RNA (MYB mRNA) T99740 GENENAME MYB T99740 TARGTYPE Clinical trial T99740 SYNONYMS Transcriptional activator Myb (mRNA); Proto-oncogene c-Myb (mRNA) T99740 FUNCTION Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells. Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'. T99740 BIOCLASS mRNA target T99740 SEQUENCE MARRPRHSIYSSDEDDEDFEMCDHDYDGLLPKSGKRHLGKTRWTREEDEKLKKLVEQNGTDDWKVIANYLPNRTDVQCQHRWQKVLNPELIKGPWTKEEDQRVIELVQKYGPKRWSVIAKHLKGRIGKQCRERWHNHLNPEVKKTSWTEEEDRIIYQAHKRLGNRWAEIAKLLPGRTDNAIKNHWNSTMRRKVEQEGYLQESSKASQPAVATSFQKNSHLMGFAQAPPTAQLPATGQPTVNNDYSYYHISEAQNVSSHVPYPVALHVNIVNVPQPAAAAIQRHYNDEDPEKEKRIKELELLLMSTENELKGQQVLPTQNHTCSYPGWHSTTIADHTRPHGDSAPVSCLGEHHSTPSLPADPGSLPEESASPARCMIVHQGTILDNVKNLLEFAETLQFIDSFLNTSSNHENSDLEMPSLTSTPLIGHKLTVTTPFHRDQTVKTQKENTVFRTPAIKRSILESSPRTPTPFKHALAAQEIKYGPLKMLPQTPSHLVEDLQDVIKQESDESGIVAEFQENGPPLLKKIKQEVESPTDKSGNFFCSHHWEGDSLNTQLFTQTSPVADAPNILTSSVLMAPASEDEDNVLKAFTVPKNRSLASPLQPCSSTWEPASCGKMEEQMTSSSQARKYVNAFSARTLVM T99740 DRUGINFO D01MZJ LR3001 Phase 2 T88430 TARGETID T88430 T88430 FORMERID TTDR01370 T88430 UNIPROID ARAF_HUMAN T88430 TARGNAME A-Raf messenger RNA (ARAF mRNA) T88430 GENENAME ARAF T88430 TARGTYPE Clinical trial T88430 SYNONYMS Serine/threonine-protein kinase A-Raf (mRNA); Proto-oncogene Pks (mRNA); Proto-oncogene A-Raf-1 (mRNA); Proto-oncogene A-Raf (mRNA); PKS2 (mRNA); PKS (mRNA); ARAF1 (mRNA) T88430 FUNCTION May also regulate the TOR signaling cascade. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. T88430 PDBSTRUC 2MSE; 1WXM T88430 BIOCLASS mRNA target T88430 ECNUMBER EC 2.7.11.1 T88430 SEQUENCE MEPPRGPPANGAEPSRAVGTVKVYLPNKQRTVVTVRDGMSVYDSLDKALKVRGLNQDCCVVYRLIKGRKTVTAWDTAIAPLDGEELIVEVLEDVPLTMHNFVRKTFFSLAFCDFCLKFLFHGFRCQTCGYKFHQHCSSKVPTVCVDMSTNRQQFYHSVQDLSGGSRQHEAPSNRPLNELLTPQGPSPRTQHCDPEHFPFPAPANAPLQRIRSTSTPNVHMVSTTAPMDSNLIQLTGQSFSTDAAGSRGGSDGTPRGSPSPASVSSGRKSPHSKSPAEQRERKSLADDKKKVKNLGYRDSGYYWEVPPSEVQLLKRIGTGSFGTVFRGRWHGDVAVKVLKVSQPTAEQAQAFKNEMQVLRKTRHVNILLFMGFMTRPGFAIITQWCEGSSLYHHLHVADTRFDMVQLIDVARQTAQGMDYLHAKNIIHRDLKSNNIFLHEGLTVKIGDFGLATVKTRWSGAQPLEQPSGSVLWMAAEVIRMQDPNPYSFQSDVYAYGVVLYELMTGSLPYSHIGCRDQIIFMVGRGYLSPDLSKISSNCPKAMRRLLSDCLKFQREERPLFPQILATIELLQRSLPKIERSASEPSLHRTQADELPACLLSAARLVP T88430 DRUGINFO D06EFW RG7304 Phase 1 T88430 DRUGINFO D00DRY ISIS 9065 Investigative T88430 DRUGINFO D00QGF ISIS 9063 Investigative T88430 DRUGINFO D01UOK ISIS 10228 Investigative T88430 DRUGINFO D03NLG ISIS 9064 Investigative T88430 DRUGINFO D04SUV ISIS 9061 Investigative T88430 DRUGINFO D04ZIA ISIS 9071 Investigative T88430 DRUGINFO D07XNO ISIS 9060 Investigative T88430 DRUGINFO D08AHE ISIS 9070 Investigative T88430 DRUGINFO D0F4GU ISIS 9069 Investigative T88430 DRUGINFO D0GG2F ISIS 9067 Investigative T88430 DRUGINFO D0R4QE ISIS 9062 Investigative T88430 DRUGINFO D0T3BZ ISIS 9068 Investigative T88430 DRUGINFO D0V2BG ISIS 9066 Investigative T47387 TARGETID T47387 T47387 FORMERID TTDI02260 T47387 UNIPROID BCL2_HUMAN T47387 TARGNAME BCL-2 messenger RNA (BCL2 mRNA) T47387 GENENAME BCL2 T47387 TARGTYPE Clinical trial T47387 SYNONYMS Bcl-2 (mRNA); Apoptosis regulator Bcl-2 (mRNA) T47387 FUNCTION Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release. Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. T47387 PDBSTRUC 6GL8; 5VAY; 5VAX; 5VAU; 5JSN T47387 BIOCLASS mRNA target T47387 SEQUENCE MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPAASRDPVARTSPLQTPAAPGAAAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFAEMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK T47387 DRUGINFO D07ACL PNT-2258 Phase 2 T47387 DRUGINFO D00GAM Beclanorsen Phase 1/2 T47387 DRUGINFO DBPV74 BP1002 Phase 1 T47387 DRUGINFO D00DDR G3139 + Thalidomide Investigative T47387 DRUGINFO D05IAN G3139 + Irinotecan Investigative T47387 DRUGINFO D0B0HK G3139 + G-CSF Investigative T47387 DRUGINFO D0LM3T G3139 + Fludarabine Investigative T47387 DRUGINFO D0Q5NZ BP-100-1.02 Investigative T47387 DRUGINFO D0S1FM G3139 + Paclitaxel Investigative T47387 DRUGINFO D0W8ZE G3139 + Dexamethasone Investigative T47387 DRUGINFO D0XU1I G3139 + Dacarbazine Investigative T47387 DRUGINFO D0XU9F G3139 + cytarabine (ARA-C) Investigative T95899 TARGETID T95899 T95899 FORMERID TTDC00142 T95899 UNIPROID CLUS_HUMAN T95899 TARGNAME Clusterin messenger RNA (Clusterin mRNA) T95899 GENENAME CLU T95899 TARGTYPE Clinical trial T95899 SYNONYMS Testosteronerepressed prostate message 2 (mRNA); Testosterone-repressed prostate message 2 (mRNA); TRPM-2 (mRNA); NA1/NA2 (mRNA); Ku70binding protein 1 (mRNA); Ku70-binding protein 1 (mRNA); KUB1 (mRNA); Complementassociated protein SP40,40 (mRNA); Complement-associated protein SP-40,40 (mRNA); Complement cytolysis inhibitor (mRNA); Clusterin alpha chain (mRNA); Clusterin (mRNA); CLI (mRNA); Apolipoprotein J (mRNA); ApoJ (mRNA); Apo-J (mRNA); Agingassociated gene 4 protein (mRNA); Aging-associated gene 4 protein (mRNA); AAG4 (mRNA) T95899 FUNCTION Prevents stress-induced aggregation of blood plasma proteins. Inhibits formation of amyloid fibrils by APP, APOC2, B2M, CALCA, CSN3, SNCA and aggregation-prone LYZ variants (in vitro). Does not require ATP. Maintains partially unfolded proteins in a state appropriate for subsequent refolding by other chaperones, such as HSPA8/HSC70. Does not refold proteins by itself. Binding to cell surface receptors triggers internalization of the chaperone-client complex and subsequent lysosomal or proteasomal degradation. Secreted isoform 1 protects cells against apoptosis and against cytolysis by complement. Intracellular isoforms interact with ubiquitin and SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complexes and promote the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes proteasomal degradation of COMMD1 and IKBKB. Modulates NF-kappa-B transcriptional activity. Nuclear isoforms promote apoptosis. Mitochondrial isoforms suppress BAX-dependent release of cytochrome c into the cytoplasm and inhibit apoptosis. Plays a role in the regulation of cell proliferation. Isoform 1 functions as extracellular chaperone that prevents aggregation of nonnative proteins. T95899 BIOCLASS mRNA target T95899 SEQUENCE MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSNQGSKYVNKEIQNAVNGVKQIKTLIEKTNEERKTLLSNLEEAKKKKEDALNETRESETKLKELPGVCNETMMALWEECKPCLKQTCMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHMLDVMQDHFSRASSIIDELFQDRFFTREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNFHAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKDQCDKCREILSVDCSTNNPSQAKLRRELDESLQVAERLTRKYNELLKSYQWKMLNTSSLLEQLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEVSRKNPKFMETVAEKALQEYRKKHREE T95899 DRUGINFO D0K3XS Custirsen Phase 3 T88847 TARGETID T88847 T88847 FORMERID TTDI02300 T88847 UNIPROID DMD_HUMAN T88847 TARGNAME Dystrophin messenger RNA (DMD mRNA) T88847 GENENAME DMD T88847 TARGTYPE Clinical trial T88847 SYNONYMS Dystrophin mRNA T88847 FUNCTION Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission. T88847 PDBSTRUC 3UUN; 1EG4; 1EG3; 1DXX T88847 BIOCLASS mRNA target T88847 SEQUENCE MLWWEEVEDCYEREDVQKKTFTKWVNAQFSKFGKQHIENLFSDLQDGRRLLDLLEGLTGQKLPKEKGSTRVHALNNVNKALRVLQNNNVDLVNIGSTDIVDGNHKLTLGLIWNIILHWQVKNVMKNIMAGLQQTNSEKILLSWVRQSTRNYPQVNVINFTTSWSDGLALNALIHSHRPDLFDWNSVVCQQSATQRLEHAFNIARYQLGIEKLLDPEDVDTTYPDKKSILMYITSLFQVLPQQVSIEAIQEVEMLPRPPKVTKEEHFQLHHQMHYSQQITVSLAQGYERTSSPKPRFKSYAYTQAAYVTTSDPTRSPFPSQHLEAPEDKSFGSSLMESEVNLDRYQTALEEVLSWLLSAEDTLQAQGEISNDVEVVKDQFHTHEGYMMDLTAHQGRVGNILQLGSKLIGTGKLSEDEETEVQEQMNLLNSRWECLRVASMEKQSNLHRVLMDLQNQKLKELNDWLTKTEERTRKMEEEPLGPDLEDLKRQVQQHKVLQEDLEQEQVRVNSLTHMVVVVDESSGDHATAALEEQLKVLGDRWANICRWTEDRWVLLQDILLKWQRLTEEQCLFSAWLSEKEDAVNKIHTTGFKDQNEMLSSLQKLAVLKADLEKKKQSMGKLYSLKQDLLSTLKNKSVTQKTEAWLDNFARCWDNLVQKLEKSTAQISQAVTTTQPSLTQTTVMETVTTVTTREQILVKHAQEELPPPPPQKKRQITVDSEIRKRLDVDITELHSWITRSEAVLQSPEFAIFRKEGNFSDLKEKVNAIEREKAEKFRKLQDASRSAQALVEQMVNEGVNADSIKQASEQLNSRWIEFCQLLSERLNWLEYQNNIIAFYNQLQQLEQMTTTAENWLKIQPTTPSEPTAIKSQLKICKDEVNRLSDLQPQIERLKIQSIALKEKGQGPMFLDADFVAFTNHFKQVFSDVQAREKELQTIFDTLPPMRYQETMSAIRTWVQQSETKLSIPQLSVTDYEIMEQRLGELQALQSSLQEQQSGLYYLSTTVKEMSKKAPSEISRKYQSEFEEIEGRWKKLSSQLVEHCQKLEEQMNKLRKIQNHIQTLKKWMAEVDVFLKEEWPALGDSEILKKQLKQCRLLVSDIQTIQPSLNSVNEGGQKIKNEAEPEFASRLETELKELNTQWDHMCQQVYARKEALKGGLEKTVSLQKDLSEMHEWMTQAEEEYLERDFEYKTPDELQKAVEEMKRAKEEAQQKEAKVKLLTESVNSVIAQAPPVAQEALKKELETLTTNYQWLCTRLNGKCKTLEEVWACWHELLSYLEKANKWLNEVEFKLKTTENIPGGAEEISEVLDSLENLMRHSEDNPNQIRILAQTLTDGGVMDELINEELETFNSRWRELHEEAVRRQKLLEQSIQSAQETEKSLHLIQESLTFIDKQLAAYIADKVDAAQMPQEAQKIQSDLTSHEISLEEMKKHNQGKEAAQRVLSQIDVAQKKLQDVSMKFRLFQKPANFEQRLQESKMILDEVKMHLPALETKSVEQEVVQSQLNHCVNLYKSLSEVKSEVEMVIKTGRQIVQKKQTENPKELDERVTALKLHYNELGAKVTERKQQLEKCLKLSRKMRKEMNVLTEWLAATDMELTKRSAVEGMPSNLDSEVAWGKATQKEIEKQKVHLKSITEVGEALKTVLGKKETLVEDKLSLLNSNWIAVTSRAEEWLNLLLEYQKHMETFDQNVDHITKWIIQADTLLDESEKKKPQQKEDVLKRLKAELNDIRPKVDSTRDQAANLMANRGDHCRKLVEPQISELNHRFAAISHRIKTGKASIPLKELEQFNSDIQKLLEPLEAEIQQGVNLKEEDFNKDMNEDNEGTVKELLQRGDNLQQRITDERKREEIKIKQQLLQTKHNALKDLRSQRRKKALEISHQWYQYKRQADDLLKCLDDIEKKLASLPEPRDERKIKEIDRELQKKKEELNAVRRQAEGLSEDGAAMAVEPTQIQLSKRWREIESKFAQFRRLNFAQIHTVREETMMVMTEDMPLEISYVPSTYLTEITHVSQALLEVEQLLNAPDLCAKDFEDLFKQEESLKNIKDSLQQSSGRIDIIHSKKTAALQSATPVERVKLQEALSQLDFQWEKVNKMYKDRQGRFDRSVEKWRRFHYDIKIFNQWLTEAEQFLRKTQIPENWEHAKYKWYLKELQDGIGQRQTVVRTLNATGEEIIQQSSKTDASILQEKLGSLNLRWQEVCKQLSDRKKRLEEQKNILSEFQRDLNEFVLWLEEADNIASIPLEPGKEQQLKEKLEQVKLLVEELPLRQGILKQLNETGGPVLVSAPISPEEQDKLENKLKQTNLQWIKVSRALPEKQGEIEAQIKDLGQLEKKLEDLEEQLNHLLLWLSPIRNQLEIYNQPNQEGPFDVKETEIAVQAKQPDVEEILSKGQHLYKEKPATQPVKRKLEDLSSEWKAVNRLLQELRAKQPDLAPGLTTIGASPTQTVTLVTQPVVTKETAISKLEMPSSLMLEVPALADFNRAWTELTDWLSLLDQVIKSQRVMVGDLEDINEMIIKQKATMQDLEQRRPQLEELITAAQNLKNKTSNQEARTIITDRIERIQNQWDEVQEHLQNRRQQLNEMLKDSTQWLEAKEEAEQVLGQARAKLESWKEGPYTVDAIQKKITETKQLAKDLRQWQTNVDVANDLALKLLRDYSADDTRKVHMITENINASWRSIHKRVSEREAALEETHRLLQQFPLDLEKFLAWLTEAETTANVLQDATRKERLLEDSKGVKELMKQWQDLQGEIEAHTDVYHNLDENSQKILRSLEGSDDAVLLQRRLDNMNFKWSELRKKSLNIRSHLEASSDQWKRLHLSLQELLVWLQLKDDELSRQAPIGGDFPAVQKQNDVHRAFKRELKTKEPVIMSTLETVRIFLTEQPLEGLEKLYQEPRELPPEERAQNVTRLLRKQAEEVNTEWEKLNLHSADWQRKIDETLERLQELQEATDELDLKLRQAEVIKGSWQPVGDLLIDSLQDHLEKVKALRGEIAPLKENVSHVNDLARQLTTLGIQLSPYNLSTLEDLNTRWKLLQVAVEDRVRQLHEAHRDFGPASQHFLSTSVQGPWERAISPNKVPYYINHETQTTCWDHPKMTELYQSLADLNNVRFSAYRTAMKLRRLQKALCLDLLSLSAACDALDQHNLKQNDQPMDILQIINCLTTIYDRLEQEHNNLVNVPLCVDMCLNWLLNVYDTGRTGRIRVLSFKTGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRLGLLLHDSIQIPRQLGEVASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLEPQSMVWLPVLHRVAAAETAKHQAKCNICKECPIIGFRYRSLKHFNYDICQSCFFSGRVAKGHKMHYPMVEYCTPTTSGEDVRDFAKVLKNKFRTKRYFAKHPRMGYLPVQTVLEGDNMETPVTLINFWPVDSAPASSPQLSHDDTHSRIEHYASRLAEMENSNGSYLNDSISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLESEERGELERILADLEEENRNLQAEYDRLKQQHEHKGLSPLPSPPEMMPTSPQSPRDAELIAEAKLLRQHKGRLEARMQILEDHNKQLESQLHRLRQLLEQPQAEAKVNGTTVSSPSTSLQRSDSSQPMLLRVVGSQTSDSMGEEDLLSPPQDTSTGLEEVMEQLNNSFPSSRGRNTPGKPMREDTM T88847 DRUGINFO D04AIV Eteplirsen Approved T88847 DRUGINFO D0PE2L GSK2402968 Phase 3 T88847 DRUGINFO D0X4DB Drisapersen Phase 3 T88847 DRUGINFO D4OZC7 Suvodirsen Phase 2/3 T88847 DRUGINFO D05DFV PRO-044 Phase 2 T78892 TARGETID T78892 T78892 FORMERID TTDR01371 T78892 UNIPROID ITA4_HUMAN T78892 TARGNAME ITGA4 messenger RNA (ITGA4 mRNA) T78892 GENENAME ITGA4 T78892 TARGTYPE Clinical trial T78892 SYNONYMS VLA4 subunit alpha (mRNA); VLA-4 subunit alpha (mRNA); Integrin alphaIV (mRNA); Integrin alpha4 (mRNA); Integrin alpha-IV (mRNA); Integrin alpha-4 (mRNA); CD49d (mRNA); CD49 antigenlike family member D (mRNA); CD49 antigen-like family member D (mRNA) T78892 FUNCTION Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGA4:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. T78892 PDBSTRUC 5FPI; 5C7Z; 4HKC; 3V4V; 3V4P T78892 BIOCLASS mRNA target T78892 SEQUENCE MAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD T78892 DRUGINFO D0E6SQ ATL1102 Phase 2 T78892 DRUGINFO D07FJI ISIS 24477 Investigative T78892 DRUGINFO D07NMV ISIS 24448 Investigative T78892 DRUGINFO D08PJN ISIS 24453 Investigative T78892 DRUGINFO D0CW7X ISIS 24475 Investigative T78892 DRUGINFO D0R6UO ISIS 24454 Investigative T78892 DRUGINFO D09XED MK-0668 Investigative T88714 TARGETID T88714 T88714 FORMERID TTDR00342 T88714 UNIPROID AA1R_HUMAN T88714 TARGNAME ADORA1 messenger RNA (ADORA1 mRNA) T88714 GENENAME ADORA1 T88714 TARGTYPE Clinical trial T88714 SYNONYMS Adenosine receptor A1 (mRNA); A(1) adenosine receptor (mRNA) T88714 FUNCTION The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Receptor for adenosine. T88714 PDBSTRUC 6D9H; 5UEN; 5N2S T88714 BIOCLASS mRNA target T88714 SEQUENCE MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGALVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVTPRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYMVYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALILFLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFLKIWNDHFRCQPAPPIDEDLPEERPDD T88714 DRUGINFO D0UD1Y Neladenoson bialanate Phase 2 T88714 DRUGINFO D0QH0B EPI-2010 Discontinued in Phase 2 T63986 TARGETID T63986 T63986 FORMERID TTDC00339 T63986 UNIPROID KIF11_HUMAN T63986 TARGNAME Kinesin spindle messenger RNA (KIF11 mRNA) T63986 GENENAME KIF11 T63986 TARGTYPE Clinical trial T63986 SYNONYMS Thyroid receptor-interacting protein 5 (mRNA); TRIP5 (mRNA); TRIP-5 (mRNA); TR-interacting protein 5 (mRNA); Kinesin-related motor protein Eg5 (mRNA); Kinesin-like spindle protein HKSP (mRNA); Kinesin-like protein KIF11 (mRNA); Kinesin-like protein 1 (mRNA); KNSL1 (mRNA); EG5 (mRNA) T63986 FUNCTION Required in non-mitotic cells for transport of secretory proteins from the Golgi complex to the cell surface. Motor protein required for establishing a bipolar spindle during mitosis. T63986 PDBSTRUC 6G6Z; 6G6Y; 5ZO9; 5ZO8; 5ZO7 T63986 BIOCLASS mRNA target T63986 SEQUENCE MASQPNSSAKKKEEKGKNIQVVVRCRPFNLAERKASAHSIVECDPVRKEVSVRTGGLADKSSRKTYTFDMVFGASTKQIDVYRSVVCPILDEVIMGYNCTIFAYGQTGTGKTFTMEGERSPNEEYTWEEDPLAGIIPRTLHQIFEKLTDNGTEFSVKVSLLEIYNEELFDLLNPSSDVSERLQMFDDPRNKRGVIIKGLEEITVHNKDEVYQILEKGAAKRTTAATLMNAYSSRSHSVFSVTIHMKETTIDGEELVKIGKLNLVDLAGSENIGRSGAVDKRAREAGNINQSLLTLGRVITALVERTPHVPYRESKLTRILQDSLGGRTRTSIIATISPASLNLEETLSTLEYAHRAKNILNKPEVNQKLTKKALIKEYTEEIERLKRDLAAAREKNGVYISEENFRVMSGKLTVQEEQIVELIEKIGAVEEELNRVTELFMDNKNELDQCKSDLQNKTQELETTQKHLQETKLQLVKEEYITSALESTEEKLHDAASKLLNTVEETTKDVSGLHSKLDRKKAVDQHNAEAQDIFGKNLNSLFNNMEELIKDGSSKQKAMLEVHKTLFGNLLSSSVSALDTITTVALGSLTSIPENVSTHVSQIFNMILKEQSLAAESKTVLQELINVLKTDLLSSLEMILSPTVVSILKINSQLKHIFKTSLTVADKIEDQKKELDGFLSILCNNLHELQENTICSLVESQKQCGNLTEDLKTIKQTHSQELCKLMNLWTERFCALEEKCENIQKPLSSVQENIQQKSKDIVNKMTFHSQKFCADSDGFSQELRNFNQEGTKLVEESVKHSDKLNGNLEKISQETEQRCESLNTRTVYFSEQWVSSLNEREQELHNLLEVVSQCCEASSSDITEKSDGRKAAHEKQHNIFLDQMTIDEDKLIAQNLELNETIKIGLTKLNCFLEQDLKLDIPTGTTPQRKSYLYPSTLVRTEPREHLLDQLKRKQPELLMMLNCSENNKEETIPDVDVEEAVLGQYTEEPLSQEPSVDAGVDCSSIGGVPFFQHKKSHGKDKENRGINTLERSKVEETTEHLVTKSRLPLRAQINL T63986 DRUGINFO D08JMI ALN-VSP Phase 1 T63986 DRUGINFO D0Q5QC EMD-534085 Phase 1 T63986 DRUGINFO D00HFV N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea Investigative T63986 DRUGINFO D00OZN N-[3'-(trifluoromethyl)-4-biphenylyl]urea Investigative T63986 DRUGINFO D00PRE 4'-(trifluoromethyl)-4-biphenylsulfonamide Investigative T63986 DRUGINFO D00WOE N-(4'-chloro-4-biphenylyl)methanesulfonamide Investigative T63986 DRUGINFO D00YYQ ISIS 183881 Investigative T63986 DRUGINFO D01DVS ISIS 183911 Investigative T63986 DRUGINFO D01ESV 4'-(trifluoromethyl)-4-biphenylyl carbamate Investigative T63986 DRUGINFO D02DAU ISIS 183910 Investigative T63986 DRUGINFO D02HMN 2-(difluoromethyl)-9H-carbazole Investigative T63986 DRUGINFO D02LDY N-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide Investigative T63986 DRUGINFO D02SDD ISIS 183882 Investigative T63986 DRUGINFO D02SGH Methyl 7-tert-butyl-9H-carbazole-3-carboxylate Investigative T63986 DRUGINFO D03ZHM ISIS 183912 Investigative T63986 DRUGINFO D05MQU N-{4'-[(trifluoromethyl)sulfonyl]-4-biphenyl}urea Investigative T63986 DRUGINFO D05OMR Methyl 9H-carbazole-2-carboxylate Investigative T63986 DRUGINFO D06HLH 2-tert-butyl-7-(trifluoromethyl)-9H-carbazole Investigative T63986 DRUGINFO D08FXD 2-isopropyl-9H-carbazole Investigative T63986 DRUGINFO D08MYP ISIS 183897 Investigative T63986 DRUGINFO D08RMK N-(4'-methyl-4-biphenylyl)urea Investigative T63986 DRUGINFO D09DGA 11H-benzo[a]carbazole Investigative T63986 DRUGINFO D09FZW 2-(trifluoromethoxy)-9H-carbazole Investigative T63986 DRUGINFO D09KFR (S)-dimethylenastron Investigative T63986 DRUGINFO D09MSF 2-tert-butyl-9H-carbazole Investigative T63986 DRUGINFO D09MXK 3-(trifluoromethyl)-9H-carbazole Investigative T63986 DRUGINFO D09PLT 3-tert-butyl-9H-carbazole Investigative T63986 DRUGINFO D0A9IB Methyl[4'-(trifluoromethyl)-4-biphenylyl]amine Investigative T63986 DRUGINFO D0AV3M N-(4'-isopropyl-4-biphenylyl)urea Investigative T63986 DRUGINFO D0D3FV 1-tert-butyl-9H-carbazole Investigative T63986 DRUGINFO D0E2KC 4'-(trifluoromethyl)-4-biphenylyl sulfamate Investigative T63986 DRUGINFO D0EC0B 6-fluoro-2-methyl-9H-carbazole Investigative T63986 DRUGINFO D0G1DW N-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide Investigative T63986 DRUGINFO D0H3OP 2-ethyl-9H-carbazole Investigative T63986 DRUGINFO D0H7ZS N-[4'-(ethylsulfonyl)-3-fluoro-4-biphenylyl]urea Investigative T63986 DRUGINFO D0J9UC N-[4'-(trifluoromethyl)-4-biphenylyl]urea Investigative T63986 DRUGINFO D0JN0N N-{4'-[(trifluoromethyl)thio]-4-biphenyl}urea Investigative T63986 DRUGINFO D0K7HV N-(4'-t-butyl-4-biphenylyl)urea Investigative T63986 DRUGINFO D0M3VA SB-731489 Investigative T63986 DRUGINFO D0M3ZV 9H-carbazole-3-carbaldehyde Investigative T63986 DRUGINFO D0M7KF 1-(7-methyl-9H-carbazol-3-yl)ethanone Investigative T63986 DRUGINFO D0MW5Z 2-methyl-6-(trifluoromethyl)-9H-carbazole Investigative T63986 DRUGINFO D0MZ8E ISIS 183901 Investigative T63986 DRUGINFO D0N5OD 4-(trifluoromethyl)biphenyl Investigative T63986 DRUGINFO D0N8FU 2-tert-butoxy-9H-carbazole Investigative T63986 DRUGINFO D0NJ8L N-(4'-bromo-3,3'-difluoro-4-biphenylyl)urea Investigative T63986 DRUGINFO D0O5SA Adociasulfate-2 Investigative T63986 DRUGINFO D0OF6C 2-(trifluoromethyl)-9H-carbazole Investigative T63986 DRUGINFO D0OS3L 1-(trifluoromethyl)-9H-carbazole Investigative T63986 DRUGINFO D0P9ZN 3-methyl-6-(trifluoromethyl)-9H-carbazole Investigative T63986 DRUGINFO D0RO7K 2-methyl-9H-carbazole Investigative T63986 DRUGINFO D0T6MF 7-tert-butyl-9H-carbazole-3-carboxylic acid Investigative T63986 DRUGINFO D0TN1F 4'-trifluoromethyl-biphenyl-4-ylamine Investigative T63986 DRUGINFO D0TR0R 9H-carbazole-2-carbaldehyde Investigative T63986 DRUGINFO D0U2HN ISIS 183883 Investigative T63986 DRUGINFO D0V6CM 2,3,4,11-tetrahydro-1H-benzo[a]carbazole Investigative T63986 DRUGINFO D0W4GY 4'-(trifluoromethyl)-4-biphenylol Investigative T63986 DRUGINFO D0Y6IQ 9-methyl-2-(trifluoromethyl)-9H-carbazole Investigative T63986 DRUGINFO D0YE2Z (S)-enastron Investigative T59273 TARGETID T59273 T59273 FORMERID TTDI02239 T59273 UNIPROID PLK1_HUMAN T59273 TARGNAME PLK1 messenger RNA (PLK1 mRNA) T59273 GENENAME PLK1 T59273 TARGTYPE Clinical trial T59273 SYNONYMS Serine/threonine-protein kinase PLK1 (mRNA); Serine/threonine-protein kinase 13 (mRNA); Serine-threonine protein kinase 13 (mRNA); STPK13 (mRNA); Plk1 (mRNA); PLK-1 (mRNA); PLK (mRNA); Mitoticserine-threonine kinase polo-like kinase 1 (mRNA) T59273 FUNCTION Polo-like kinase proteins acts by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates BORA, BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1, KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, KIZ, PPP1R12A/MYPT1, PRC1, RACGAP1/CYK4, SGO1, STAG2/SA2, TEX14, TOPORS, p73/TP73, TPT1, WEE1 and HNRNPU. Plays a key role in centrosome functions and the assembly of bipolar spindles by phosphorylating KIZ, NEDD1 and NINL. NEDD1 phosphorylation promotes subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. Phosphorylation of NINL component of the centrosome leads to NINL dissociation from other centrosomal proteins. Involved in mitosis exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2, CENPU, PRC1 and RACGAP1. Recruited at the central spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own docking sites on PRC1 and KIF20A/MKLP2 by mediating phosphorylation of sites subsequently recognized by the POLO box domains. Phosphorylates RACGAP1, thereby creating a docking site for the Rho GTP exchange factor ECT2 that is essential for the cleavage furrow formation. Promotes the central spindle recruitment of ECT2. Plays a central role in G2/M transition of mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, CENPU, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1. Part of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the positive regulator CDC25C and inhibiting the negative regulators WEE1 and PKMYT1/MYT1. Also acts by mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in prophase. Phosphorylates FOXM1, a key mitotic transcription regulator, leading to enhance FOXM1 transcriptional activity. Involved in kinetochore functions and sister chromatid cohesion by phosphorylating BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2. PLK1 is high on non-attached kinetochores suggesting a role of PLK1 in kinetochore attachment or in spindle assembly checkpoint (SAC) regulation. Required for kinetochore localization of BUB1B. Regulates the dissociation of cohesin from chromosomes by phosphorylating cohesin subunits such as STAG2/SA2. Phosphorylates SGO1: required for spindle pole localization of isoform 3 of SGO1 and plays a role in regulating its centriole cohesion function. Mediates phosphorylation of FBXO5/EMI1, a negative regulator of the APC/C complex during prophase, leading to FBXO5/EMI1 ubiquitination and degradation by the proteasome. Acts as a negative regulator of p53 family members: phosphorylates TOPORS, leading to inhibit the sumoylation of p53/TP53 and simultaneously enhance the ubiquitination and subsequent degradation of p53/TP53. Phosphorylates the transactivation domain of the transcription factor p73/TP73, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the degradation of BORA. Contributes to the regulation of AURKA function. Also required for recovery after DNA damage checkpoint and entry into mitosis. Phosphorylates MISP, leading to stabilization of cortical and astral microtubule attachments required for proper spindle positioning. Together with MEIKIN, acts as a regulator of kinetochore function during meiosis I: required both for mono-orientation of kinetochores on sister chromosomes and protection of centromeric cohesin from separase-mediated cleavage. Phosphorylates CEP68 and is required for its degradation. Regulates nuclear envelope breakdown during prophase by phosphorylating DCTN1 resulting in its localization in the nuclear envelope. Phosphorylates the heat shock transcription factor HSF1, promoting HSF1 nuclear translocation upon heat shock. Phosphorylates HSF1 also in the early mitotic period; this phosphorylation regulates HSF1 localization to the spindle pole, the recruitment of the SCF(BTRC) ubiquitin ligase complex induicing HSF1 degradation, and hence mitotic progression. Regulates mitotic progression by phosphorylating RIOK2. Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis. T59273 PDBSTRUC 6AX4; 5TA8; 5TA6; 5NN2; 5NN1 T59273 BIOCLASS mRNA target T59273 ECNUMBER EC 2.7.11.21 T59273 SEQUENCE MSAAVTAGKLARAPADPGKAGVPGVAAPGAPAAAPPAKEIPEVLVDPRSRRRYVRGRFLGKGGFAKCFEISDADTKEVFAGKIVPKSLLLKPHQREKMSMEISIHRSLAHQHVVGFHGFFEDNDFVFVVLELCRRRSLLELHKRRKALTEPEARYYLRQIVLGCQYLHRNRVIHRDLKLGNLFLNEDLEVKIGDFGLATKVEYDGERKKTLCGTPNYIAPEVLSKKGHSFEVDVWSIGCIMYTLLVGKPPFETSCLKETYLRIKKNEYSIPKHINPVAASLIQKMLQTDPTARPTINELLNDEFFTSGYIPARLPITCLTIPPRFSIAPSSLDPSNRKPLTVLNKGLENPLPERPREKEEPVVRETGEVVDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS T59273 DRUGINFO D06WNQ TKM-PLK1 Phase 1/2 T44771 TARGETID T44771 T44771 FORMERID TTDI02306 T44771 UNIPROID TGFB2_HUMAN T44771 TARGNAME TGF beta-2 messenger RNA (TGFB2 mRNA) T44771 GENENAME TGFB2 T44771 TARGTYPE Clinical trial T44771 SYNONYMS Transforming growth factor beta-2 proprotein (mRNA); TGF-beta 2 (mRNA); Polyergin (mRNA); Glioblastoma-derived T-cell suppressor factor (mRNA); G-TSF (mRNA); Cetermin (mRNA); BSC-1 cell growth inhibitor (mRNA) T44771 FUNCTION Transforming growth factor beta-2 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. T44771 PDBSTRUC 5TY4; 5TX4; 4KXZ; 2TGI; 1TFG T44771 BIOCLASS mRNA target T44771 SEQUENCE MHYCVLSAFLILHLVTVALSLSTCSTLDMDQFMRKRIEAIRGQILSKLKLTSPPEDYPEPEEVPPEVISIYNSTRDLLQEKASRRAAACERERSDEEYYAKEVYKIDMPPFFPSENAIPPTFYRPYFRIVRFDVSAMEKNASNLVKAEFRVFRLQNPKARVPEQRIELYQILKSKDLTSPTQRYIDSKVVKTRAEGEWLSFDVTDAVHEWLHHKDRNLGFKISLHCPCCTFVPSNNYIIPNKSEELEARFAGIDGTSTYTSGDQKTIKSTRKKNSGKTPHLLLMLLPSYRLESQQTNRRKKRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQHSRVLSLYNTINPEASASPCCVSQDLEPLTILYYIGKTPKIEQLSNMIVKSCKCS T44771 DRUGINFO D03OTH Belagenpumatucel-L Phase 3 T44771 DRUGINFO DO5H6K OT-101 Phase 2/3 T44771 DRUGINFO D0N5AY Ranagengliotucel-T Discontinued in Phase 3 T30926 TARGETID T30926 T30926 FORMERID TTDI02247 T30926 UNIPROID GRB2_HUMAN T30926 TARGNAME GRB2 messenger RNA (GRB2 mRNA) T30926 GENENAME GRB2 T30926 TARGTYPE Clinical trial T30926 SYNONYMS SH2/SH3 adapter GRB2 (mRNA); Protein Ash (mRNA); Growth factor receptor-bound protein 2 (mRNA); Adapter protein GRB2 (mRNA); ASH (mRNA) T30926 FUNCTION Adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway. T30926 PDBSTRUC 5CDW; 4P9Z; 4P9V; 3WA4; 3S8O T30926 BIOCLASS mRNA target T30926 SEQUENCE MEAIAKYDFKATADDELSFKRGDILKVLNEECDQNWYKAELNGKDGFIPKNYIEMKPHPWFFGKIPRAKAEEMLSKQRHDGAFLIRESESAPGDFSLSVKFGNDVQHFKVLRDGAGKYFLWVVKFNSLNELVDYHRSTSVSRNQQIFLRDIEQVPQQPTYVQALFDFDPQEDGELGFRRGDFIHVMDNSDPNWWKGACHGQTGMFPRNYVTPVNRNV T30926 DRUGINFO D0L3KA BP-100-1-01 Phase 2 T00238 TARGETID T00238 T00238 FORMERID TTDI02298 T00238 UNIPROID NFKB2_HUMAN T00238 TARGNAME NFKB messenger RNA (NFKB mRNA) T00238 GENENAME NFKB2 T00238 TARGTYPE Clinical trial T00238 SYNONYMS Oncogene Lyt-10 (mRNA); Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (mRNA); Nuclear factor NF-kappa-Bp52 subunit (mRNA); Nuclear factor NF-kappa-B p100 subunit (mRNA); Lyt10 (mRNA); Lymphocyte translocation chromosome 10 protein (mRNA); Lymphocyte translocation chromosome 10 (mRNA); H2TF1 (mRNA); DNA-binding factor KBF2 (mRNA) T00238 FUNCTION NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. T00238 PDBSTRUC 5ZMC; 4OT9; 3DO7; 2D96; 1A3Q T00238 BIOCLASS mRNA target T00238 SEQUENCE MESCYNPGLDGIIEYDDFKLNSSIVEPKEPAPETADGPYLVIVEQPKQRGFRFRYGCEGPSHGGLPGASSEKGRKTYPTVKICNYEGPAKIEVDLVTHSDPPRAHAHSLVGKQCSELGICAVSVGPKDMTAQFNNLGVLHVTKKNMMGTMIQKLQRQRLRSRPQGLTEAEQRELEQEAKELKKVMDLSIVRLRFSAFLRASDGSFSLPLKPVISQPIHDSKSPGASNLKISRMDKTAGSVRGGDEVYLLCDKVQKDDIEVRFYEDDENGWQAFGDFSPTDVHKQYAIVFRTPPYHKMKIERPVTVFLQLKRKRGGDVSDSKQFTYYPLVEDKEEVQRKRRKALPTFSQPFGGGSHMGGGSGGAAGGYGGAGGGGSLGFFPSSLAYSPYQSGAGPMGCYPGGGGGAQMAATVPSRDSGEEAAEPSAPSRTPQCEPQAPEMLQRAREYNARLFGLAQRSARALLDYGVTADARALLAGQRHLLTAQDENGDTPLHLAIIHGQTSVIEQIVYVIHHAQDLGVVNLTNHLHQTPLHLAVITGQTSVVSFLLRVGADPALLDRHGDSAMHLALRAGAGAPELLRALLQSGAPAVPQLLHMPDFEGLYPVHLAVRARSPECLDLLVDSGAEVEATERQGGRTALHLATEMEELGLVTHLVTKLRANVNARTFAGNTPLHLAAGLGYPTLTRLLLKAGADIHAENEEPLCPLPSPPTSDSDSDSEGPEKDTRSSFRGHTPLDLTCSTKVKTLLLNAAQNTMEPPLTPPSPAGPGLSLGDTALQNLEQLLDGPEAQGSWAELAERLGLRSLVDTYRQTTSPSGSLLRSYELAGGDLAGLLEALSDMGLEEGVRLLRGPETRDKLPSTAEVKEDSAYGSQSVEQEAEKLGPPPEPPGGLCHGHPQPQVH T00238 DRUGINFO D0U1HX DIMS-0150 Phase 3 T51748 TARGETID T51748 T51748 FORMERID TTDR01416 T51748 UNIPROID HIF1A_HUMAN T51748 TARGNAME HIF1-alpha messenger RNA (HIF1A mRNA) T51748 GENENAME HIF1A T51748 TARGTYPE Clinical trial T51748 SYNONYMS bHLHe78 (mRNA); Transcription factor HIF-1 (mRNA); PASD8 (mRNA); PAS domain-containing protein 8 (mRNA); Member of PAS protein 1 (mRNA); MOP1 (mRNA); Hypoxia-inducible transcription factor (HIF)-1 (mRNA); Hypoxia-inducible factor 1-alpha (mRNA); Hypoxia-inducible factor 1 (mRNA); Hypoxia inducible factor 1 (mRNA); HIF1-alpha (mRNA); HIF1 alpha (mRNA); HIF-1alpha (mRNA); HIF-1-alpha (mRNA); HIF-1 alpha (mRNA); Class E basic helix-loop-helix protein 78 (mRNA); Basic-helix-loop-helix-PAS protein MOP1 (mRNA); ARNT-interacting protein (mRNA); ARNT interacting protein (mRNA) T51748 FUNCTION Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300. Activity is enhanced by interaction with both, NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP. Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia. Functions as a master transcriptional regulator of the adaptive response to hypoxia. T51748 PDBSTRUC 6GMR; 6GFX; 5LAS; 5LA9; 5L9V T51748 BIOCLASS mRNA target T51748 SEQUENCE MEGAGGANDKKKISSERRKEKSRDAARSRRSKESEVFYELAHQLPLPHNVSSHLDKASVMRLTISYLRVRKLLDAGDLDIEDDMKAQMNCFYLKALDGFVMVLTDDGDMIYISDNVNKYMGLTQFELTGHSVFDFTHPCDHEEMREMLTHRNGLVKKGKEQNTQRSFFLRMKCTLTSRGRTMNIKSATWKVLHCTGHIHVYDTNSNQPQCGYKKPPMTCLVLICEPIPHPSNIEIPLDSKTFLSRHSLDMKFSYCDERITELMGYEPEELLGRSIYEYYHALDSDHLTKTHHDMFTKGQVTTGQYRMLAKRGGYVWVETQATVIYNTKNSQPQCIVCVNYVVSGIIQHDLIFSLQQTECVLKPVESSDMKMTQLFTKVESEDTSSLFDKLKKEPDALTLLAPAAGDTIISLDFGSNDTETDDQQLEEVPLYNDVMLPSPNEKLQNINLAMSPLPTAETPKPLRSSADPALNQEVALKLEPNPESLELSFTMPQIQDQTPSPSDGSTRQSSPEPNSPSEYCFYVDSDMVNEFKLELVEKLFAEDTEAKNPFSTQDTDLDLEMLAPYIPMDDDFQLRSFDQLSPLESSSASPESASPQSTVTVFQQTQIQEPTANATTTTATTDELKTVTKDRMEDIKILIASPSPTHIHKETTSATSSPYRDTQSRTASPNRAGKGVIEQTEKSHPRSPNVLSVALSQRTTVPEEELNPKILALQNAQRKRKMEHDGSLFQAVGIGTLLQQPDDHAATTSLSWKRVKGCKSSEQNGMEQKTIILIPSDLACRLLGQSMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN T51748 DRUGINFO D0C9PZ PT2385 Phase 2 T51748 DRUGINFO D00JHE ISIS 298697 Investigative T51748 DRUGINFO D01DDQ ISIS 298744 Investigative T51748 DRUGINFO D01ZCK ISIS 298746 Investigative T51748 DRUGINFO D07GVC ISIS 298745 Investigative T51748 DRUGINFO D09DCJ ISIS 298743 Investigative T51748 DRUGINFO D0B5LQ ISIS 298702 Investigative T51748 DRUGINFO D0C2IG ISIS 298700 Investigative T51748 DRUGINFO D0G9BP ISIS 175510 Investigative T51748 DRUGINFO D0L5ME ISIS 298699 Investigative T51748 DRUGINFO D0L9KW ISIS 298712 Investigative T51748 DRUGINFO D0SN5O ISIS 298711 Investigative T51748 DRUGINFO D0X8GB ISIS 298701 Investigative T51748 DRUGINFO D00REK (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol Investigative T37245 TARGETID T37245 T37245 FORMERID TTDC00241 T37245 UNIPROID DDIT4_HUMAN T37245 TARGNAME RTP801 messenger RNA (RTP801 mRNA) T37245 GENENAME DDIT4 T37245 TARGTYPE Clinical trial T37245 SYNONYMS RTP801 (mRNA); REDD1 (mRNA); REDD-1 (mRNA); Protein regulated in development and DNA damage response 1 (mRNA); HIF-1 responsive protein RTP801 (mRNA); DNA damage-inducible transcript 4 protein (mRNA) T37245 FUNCTION Inhibition of mTORC1 is mediated by a pathway that involves DDIT4/REDD1, AKT1, the TSC1-TSC2 complex and the GTPase RHEB. Plays an important role in responses to cellular energy levels and cellular stress, including responses to hypoxia and DNA damage. Regulates p53/TP53-mediated apoptosis in response to DNA damage via its effect on mTORC1 activity. Its role in the response to hypoxia depends on the cell type; it mediates mTORC1 inhibition in fibroblasts and thymocytes, but not in hepatocytes. Required for mTORC1-mediated defense against viral protein synthesis and virus replication. Inhibits neuronal differentiation and neurite outgrowth mediated by NGF via its effect on mTORC1 activity. Required for normal neuron migration during embryonic brain development. Plays a role in neuronal cell death. Regulates cell growth, proliferation and survival via inhibition of the activity of the mammalian target of rapamycin complex 1 (mTORC1). T37245 PDBSTRUC 3LQ9 T37245 BIOCLASS mRNA target T37245 SEQUENCE MPSLWDRFSSSSTSSSPSSLPRTPTPDRPPRSAWGSATREEGFDRSTSLESSDCESLDSSNSGFGPEEDTAYLDGVSLPDFELLSDPEDEHLCANLMQLLQESLAQARLGSRRPARLLMPSQLVSQVGKELLRLAYSEPCGLRGALLDVCVEQGKSCHSVGQLALDPSLVPTFQLTLVLRLDSRLWPKIQGLFSSANSPFLPGFSQSLTLSTGFRVIKKKLYSSEQLLIEEC T37245 DRUGINFO D0NN5H PF-4523655 Phase 2 T07448 TARGETID T07448 T07448 FORMERID TTDI02484 T07448 UNIPROID MASP2_HUMAN T07448 TARGNAME Mannan-binding lectin serine protease-2 (MASP2) T07448 GENENAME MASP2 T07448 TARGTYPE Clinical trial T07448 SYNONYMS Mannosebinding proteinassociated serine protease 2; Mannanbinding lectin serine protease 2 B chain; Mannanbinding lectin serine protease 2; MBLassociated serine protease 2; MASP2 T07448 FUNCTION Serum protease that plays an important role in the activation of the complement system via mannose-binding lectin. After activation by auto-catalytic cleavage it cleaves C2 and C4, leading to their activation and to the formation of C3 convertase. {ECO:0000269|PubMed:10946292}. T07448 PDBSTRUC 5JPM; 4FXG; 3TVJ; 1ZJK; 1SZB T07448 BIOCLASS Peptidase T07448 ECNUMBER EC 3.4.21.104 T07448 SEQUENCE MRLLTLLGLLCGSVATPLGPKWPEPVFGRLASPGFPGEYANDQERRWTLTAPPGYRLRLYFTHFDLELSHLCEYDFVKLSSGAKVLATLCGQESTDTERAPGKDTFYSLGSSLDITFRSDYSNEKPFTGFEAFYAAEDIDECQVAPGEAPTCDHHCHNHLGGFYCSCRAGYVLHRNKRTCSALCSGQVFTQRSGELSSPEYPRPYPKLSSCTYSISLEEGFSVILDFVESFDVETHPETLCPYDFLKIQTDREEHGPFCGKTLPHRIETKSNTVTITFVTDESGDHTGWKIHYTSTAQPCPYPMAPPNGHVSPVQAKYILKDSFSIFCETGYELLQGHLPLKSFTAVCQKDGSWDRPMPACSIVDCGPPDDLPSGRVEYITGPGVTTYKAVIQYSCEETFYTMKVNDGKYVCEADGFWTSSKGEKSLPVCEPVCGLSARTTGGRIYGGQKAKPGDFPWQVLILGGTTAAGALLYDNWVLTAAHAVYEQKHDASALDIRMGTLKRLSPHYTQAWSEAVFIHEGYTHDAGFDNDIALIKLNNKVVINSNITPICLPRKEAESFMRTDDIGTASGWGLTQRGFLARNLMYVDIPIVDHQKCTAAYEKPPYPRGSVTANMLCAGLESGGKDSCRGDSGGALVFLDSETERWFVGGIVSWGSMNCGEAGQYGVYTKVINYIPWIENIISDF T07448 DRUGINFO D0QU0H OMS721 Phase 3 T07448 DRUGINFO DTB64R Narsoplimab Phase 3 T52937 TARGETID T52937 T52937 FORMERID TTDR00096 T52937 UNIPROID AGRP_HUMAN T52937 TARGNAME Agouti-related protein (AGRP) T52937 GENENAME AGRP T52937 TARGTYPE Clinical trial T52937 SYNONYMS Agouti-related peptide; Agouti related protein; AGRP T52937 FUNCTION Plays a role in weight homeostasis. Involved in the control of feeding behavior through the central melanocortin system. Acts as alpha melanocyte-stimulating hormone antagonist by inhibiting cAMP production mediated by stimulation of melanocortin receptors within the hypothalamus and adrenal gland. Has very low activity with MC5R. Is an inverse agonist for MC3R and MC4R being able to suppress their constitutive activity. It promotes MC3R and MC4R endocytosis in an arrestin-dependent manner. T52937 PDBSTRUC 2IQV; 1MR0; 1HYK T52937 BIOCLASS Agouti protein T52937 SEQUENCE MLTAAVLSCALLLALPATRGAQMGLAPMEGIRRPDQALLPELPGLGLRAPLKKTTAEQAEEDLLQEAQALAEVLDLQDREPRSSRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTAMNPCSRT T52937 DRUGINFO D0PX8I TTP435 Phase 2 T76285 TARGETID T76285 T76285 UNIPROID ENPP3_HUMAN T76285 TARGNAME Phosphodiesterase I beta (ENPP3) T76285 GENENAME ENPP3 T76285 TARGTYPE Clinical trial T76285 SYNONYMS Phosphodiesterase I/nucleotide pyrophosphatase 3; PDNP3; PD-Ibeta; NPP3; Ectonucleotide pyrophosphatase/phosphodiesterase family member 3; E-NPP 3; CD203c T76285 FUNCTION Limits mast cell and basophil responses during inflammation and during the chronic phases of allergic responses by eliminating the extracellular ATP that functions as signaling molecule and activates basophils and mast cells and induces the release of inflammatory cytokines. Metabolizes extracellular ATP in the lumen of the small intestine, and thereby prevents ATP-induced apoptosis of intestinal plasmacytoid dendritic cells. Has also alkaline phosphodiesterase activity. Hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP and CTP. T76285 PDBSTRUC 6C02; 6C01 T76285 BIOCLASS Phosphoric diester hydrolase T76285 SEQUENCE MESTLTLATEQPVKKNTLKKYKIACIVLLALLVIMSLGLGLGLGLRKLEKQGSCRKKCFDASFRGLENCRCDVACKDRGDCCWDFEDTCVESTRIWMCNKFRCGETRLEASLCSCSDDCLQRKDCCADYKSVCQGETSWLEENCDTAQQSQCPEGFDLPPVILFSMDGFRAEYLYTWDTLMPNINKLKTCGIHSKYMRAMYPTKTFPNHYTIVTGLYPESHGIIDNNMYDVNLNKNFSLSSKEQNNPAWWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSFPSIYMPYNGSVPFEERISTLLKWLDLPKAERPRFYTMYFEEPDSSGHAGGPVSARVIKALQVVDHAFGMLMEGLKQRNLHNCVNIILLADHGMDQTYCNKMEYMTDYFPRINFFYMYEGPAPRIRAHNIPHDFFSFNSEEIVRNLSCRKPDQHFKPYLTPDLPKRLHYAKNVRIDKVHLFVDQQWLAVRSKSNTNCGGGNHGYNNEFRSMEAIFLAHGPSFKEKTEVEPFENIEVYNLMCDLLRIQPAPNNGTHGSLNHLLKVPFYEPSHAEEVSKFSVCGFANPLPTESLDCFCPHLQNSTQLEQVNQMLNLTQEEITATVKVNLPFGRPRVLQKNVDHCLLYHREYVSGFGKAMRMPMWSSYTVPQLGDTSPLPPTVPDCLRADVRVPPSESQKCSFYLADKNITHGFLYPPASNRTSDSQYDALITSNLVPMYEEFRKMWDYFHSVLLIKHATERNGVNVVSGPIFDYNYDGHFDAPDEITKHLANTDVPIPTHYFVVLTSCKNKSHTPENCPGWLDVLPFIIPHRPTNVESCPEGKPEALWVEERFTAHIARVRDVELLTGLDFYQDKVQPVSEILQLKTYLPTFETTI T76285 DRUGINFO D0XT5Q AGS-16C3F Phase 2 T82665 TARGETID T82665 T82665 FORMERID TTDI03486 T82665 UNIPROID ANM5_HUMAN T82665 TARGNAME Protein arginine methyltransferase 5 (PRMT5) T82665 GENENAME PRMT5 T82665 TARGTYPE Clinical trial T82665 SYNONYMS Shk1 kinase-binding protein 1 homolog; SKB1Hs; SKB1 homolog; SKB1; Protein arginine N-methyltransferase 5; Jak-binding protein 1; JBP1; IBP72; Histone-arginine N-methyltransferase PRMT5; HRMT1L5; 72 kDa ICln-binding protein T82665 FUNCTION Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles. Methylates SUPT5H and may regulate its transcriptional elongation properties. Mono- and dimethylates arginine residues of myelin basic protein (MBP) in vitro. May play a role in cytokine-activated transduction pathways. Negatively regulates cyclin E1 promoter activity and cellular proliferation. Methylates histone H2A and H4 'Arg-3' during germ cell development. Methylates histone H3 'Arg-8', which may repress transcription. Methylates the Piwi proteins (PIWIL1, PIWIL2 and PIWIL4), methylation of Piwi proteins being required for the interaction with Tudor domain-containing proteins and subsequent localization to the meiotic nuage. Methylates RPS10. Attenuates EGF signaling through the MAPK1/MAPK3 pathway acting at 2 levels. First, monomethylates EGFR; this enhances EGFR 'Tyr-1197' phosphorylation and PTPN6 recruitment, eventually leading to reduced SOS1 phosphorylation. Second, methylates RAF1 and probably BRAF, hence destabilizing these 2 signaling proteins and reducing their catalytic activity. Required for induction of E-selectin and VCAM-1, on the endothelial cells surface at sites of inflammation. Methylates HOXA9. Methylates and regulates SRGAP2 which is involved in cell migration and differentiation. Acts as a transcriptional corepressor in CRY1-mediated repression of the core circadian component PER1 by regulating the H4R3 dimethylation at the PER1 promoter. Methylates GM130/GOLGA2, regulating Golgi ribbon formation. Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner. Symmetrically methylates POLR2A, a modification that allows the recruitment to POLR2A of proteins including SMN1/SMN2 and SETX. This is required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. Along with LYAR, binds the promoter of gamma-globin HBG1/HBG2 and represses its expression. Symmetrically methylates NCL. Methylates TP53; methylation might possibly affect TP53 target gene specificity. Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. T82665 PDBSTRUC 6CKC; 5FA5; 5EMM; 5EML; 5EMK T82665 BIOCLASS Methyltransferase T82665 ECNUMBER EC 2.1.1.320 T82665 SEQUENCE MAAMAVGGAGGSRVSSGRDLNCVPEIADTLGAVAKQGFDFLCMPVFHPRFKREFIQEPAKNRPGPQTRSDLLLSGRDWNTLIVGKLSPWIRPDSKVEKIRRNSEAAMLQELNFGAYLGLPAFLLPLNQEDNTNLARVLTNHIHTGHHSSMFWMRVPLVAPEDLRDDIIENAPTTHTEEYSGEEKTWMWWHNFRTLCDYSKRIAVALEIGADLPSNHVIDRWLGEPIKAAILPTSIFLTNKKGFPVLSKMHQRLIFRLLKLEVQFIITGTNHHSEKEFCSYLQYLEYLSQNRPPPNAYELFAKGYEDYLQSPLQPLMDNLESQTYEVFEKDPIKYSQYQQAIYKCLLDRVPEEEKDTNVQVLMVLGAGRGPLVNASLRAAKQADRRIKLYAVEKNPNAVVTLENWQFEEWGSQVTVVSSDMREWVAPEKADIIVSELLGSFADNELSPECLDGAQHFLKDDGVSIPGEYTSFLAPISSSKLYNEVRACREKDRDPEAQFEMPYVVRLHNFHQLSAPQPCFTFSHPNRDPMIDNNRYCTLEFPVEVNTVLHGFAGYFETVLYQDITLSIRPETHSPGMFSWFPILFPIKQPITVREGQTICVRFWRCSNSKKVWYEWAVTAPVCSAIHNPTGRSYTIGL T82665 DRUGINFO D0CR7L GSK3326595 Phase 2 T82665 DRUGINFO D7I3JM AMG 193 Phase 2 T82665 DRUGINFO D1SL2W PRT811 Phase 1 T82665 DRUGINFO DC6UG5 PRT543 Phase 1 T82665 DRUGINFO DFZ0V3 JNJ-64619178 Phase 1 T82665 DRUGINFO DM1VE5 PF-06939999 Phase 1 T82665 DRUGINFO D04NZF cmp5 Investigative T82665 DRUGINFO D05XQD EPZ015666 Investigative T82665 DRUGINFO D00QZA DS-437 Investigative T79157 TARGETID T79157 T79157 FORMERID TTDI02062 T79157 UNIPROID EREG_HUMAN T79157 TARGNAME Epiregulin (EREG) T79157 GENENAME EREG T79157 TARGTYPE Clinical trial T79157 SYNONYMS l=Epiregulin; Proepiregulin; EPR T79157 FUNCTION Stimulates EGFR and ERBB4 tyrosine phosphorylation. Contributes to inflammation, wound healing, tissue repair, and oocyte maturation by regulating angiogenesis and vascular remodeling and by stimulating cell proliferation. Ligand of the EGF receptor/EGFR and ERBB4. T79157 PDBSTRUC 5WB7; 5E8D; 1K37; 1K36 T79157 BIOCLASS Growth factor T79157 SEQUENCE MTAGRRMEMLCAGRVPALLLCLGFHLLQAVLSTTVIPSCIPGESSDNCTALVQTEDNPRVAQVSITKCSSDMNGYCLHGQCIYLVDMSQNYCRCEVGYTGVRCEHFFLTVHQPLSKEYVALTVILIILFLITVVGSTYYFCRWYRNRKSKEPKKEYERVTSGDPELPQV T79157 DRUGINFO D08EIK LY3016859 Phase 1/2 T94695 TARGETID T94695 T94695 UNIPROID SMAD7_HUMAN T94695 TARGNAME Mothers against decapentaplegic homolog 7 (SMAD7) T94695 GENENAME SMAD7 T94695 TARGTYPE Clinical trial T94695 SYNONYMS hSMAD7; Smad7; SMAD family member 7; SMAD 7; Mothers against decapentaplegic homolog 8; Mothers against DPP homolog 8; MAD homolog 8 T94695 FUNCTION Antagonist of signaling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit TGF-beta (Transforming growth factor) and activin signaling by associating with their receptors thus preventing SMAD2 access. Functions as an adapter to recruit SMURF2 to the TGF-beta receptor complex. Also acts by recruiting the PPP1R15A-PP1 complex to TGFBR1, which promotes its dephosphorylation. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. T94695 PDBSTRUC 2LTZ; 2LTY; 2LTX; 2LTW; 2LTV T94695 BIOCLASS Dwarfin/SMAD family T94695 SEQUENCE MFRTKRSALVRRLWRSRAPGGEDEEEGAGGGGGGGELRGEGATDSRAHGAGGGGPGRAGCCLGKAVRGAKGHHHPHPPAAGAGAAGGAEADLKALTHSVLKKLKERQLELLLQAVESRGGTRTACLLLPGRLDCRLGPGAPAGAQPAQPPSSYSLPLLLCKVFRWPDLRHSSEVKRLCCCESYGKINPELVCCNPHHLSRLCELESPPPPYSRYPMDFLKPTADCPDAVPSSAETGGTNYLAPGGLSDSQLLLEPGDRSHWCVVAYWEEKTRVGRLYCVQEPSLDIFYDLPQGNGFCLGQLNSDNKSQLVQKVRSKIGCGIQLTREVDGVWVYNRSSYPIFIKSATLDNPDSRTLLVHKVFPGFSIKAFDYEKAYSLQRPNDHEFMQQPWTGFTVQISFVKGWGQCYTRQFISSCPCWLEVIFNSR T94695 DRUGINFO D09FKY GED-0301 Phase 3 T36741 TARGETID T36741 T36741 UNIPROID MDM4_HUMAN T36741 TARGNAME p53-binding protein Mdm4 (MDM4) T36741 GENENAME MDM4 T36741 TARGTYPE Clinical trial T36741 SYNONYMS Protein Mdmx; Mdm2-like p53-binding protein; Double minute 4 protein T36741 FUNCTION Inhibits p53/TP53- and TP73/p73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Inhibits degradation of MDM2. Can reverse MDM2-targeted degradation of TP53 while maintaining suppression of TP53 transactivation and apoptotic functions. T36741 PDBSTRUC 6Q9Y; 6Q9W; 6Q9U; 6Q9S; 6Q9Q T36741 BIOCLASS MDM2/MDM4 family T36741 SEQUENCE MTSFSTSAQCSTSDSACRISPGQINQVRPKLPLLKILHAAGAQGEMFTVKEVMHYLGQYIMVKQLYDQQEQHMVYCGGDLLGELLGRQSFSVKDPSPLYDMLRKNLVTLATATTDAAQTLALAQDHSMDIPSQDQLKQSAEESSTSRKRTTEDDIPTLPTSEHKCIHSREDEDLIENLAQDETSRLDLGFEEWDVAGLPWWFLGNLRSNYTPRSNGSTDLQTNQDVGTAIVSDTTDDLWFLNESVSEQLGVGIKVEAADTEQTSEEVGKVSDKKVIEVGKNDDLEDSKSLSDDTDVEVTSEDEWQCTECKKFNSPSKRYCFRCWALRKDWYSDCSKLTHSLSTSDITAIPEKENEGNDVPDCRRTISAPVVRPKDAYIKKENSKLFDPCNSVEFLDLAHSSESQETISSMGEQLDNLSEQRTDTENMEDCQNLLKPCSLCEKRPRDGNIIHGRTGHLVTCFHCARRLKKAGASCPICKKEIQLVIKVFIA T36741 DRUGINFO D07UKT ALRN-6924 Phase 2 T36741 DRUGINFO DPBE75 NSC-207895 Preclinical T19567 TARGETID T19567 T19567 FORMERID TTDI02633 T19567 UNIPROID OGA_HUMAN T19567 TARGNAME Beta-N-acetylhexosaminidase (OGA) T19567 GENENAME MGEA5 T19567 TARGTYPE Clinical trial T19567 SYNONYMS OGA; Nuclear cytoplasmic OGlcNAcase and acetyltransferase; Meningiomaexpressed antigen 5; MGEA5; Histone acetyltransferase; Bifunctional protein NCOAT T19567 FUNCTION Isoform 3: Cleaves GlcNAc but not GalNAc from O- glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc as substrate but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl- alpha-GlcNAc (in vitro), but has about six times lower specific activity than isoform1. {ECO:0000269|PubMed:20673219}. T19567 PDBSTRUC 6HKI; 5VVX; 5VVV; 5VVU; 5VVT T19567 BIOCLASS Glycosylase T19567 ECNUMBER EC 3.2.1.169 T19567 SEQUENCE MVQKESQATLEERESELSSNPAASAGASLEPPAAPAPGEDNPAGAGGAAVAGAAGGARRFLCGVVEGFYGRPWVMEQRKELFRRLQKWELNTYLYAPKDDYKHRMFWREMYSVEEAEQLMTLISAAREYEIEFIYAISPGLDITFSNPKEVSTLKRKLDQVSQFGCRSFALLFDDIDHNMCAADKEVFSSFAHAQVSITNEIYQYLGEPETFLFCPTEYCGTFCYPNVSQSPYLRTVGEKLLPGIEVLWTGPKVVSKEIPVESIEEVSKIIKRAPVIWDNIHANDYDQKRLFLGPYKGRSTELIPRLKGVLTNPNCEFEANYVAIHTLATWYKSNMNGVRKDVVMTDSEDSTVSIQIKLENEGSDEDIETDVLYSPQMALKLALTEWLQEFGVPHQYSSRQVAHSGAKASVVDGTPLVAAPSLNATTVVTTVYQEPIMSQGAALSGEPTTLTKEEEKKQPDEEPMDMVVEKQEETDHKNDNQILSEIVEAKMAEELKPMDTDKESIAESKSPEMSMQEDCISDIAPMQTDEQTNKEQFVPGPNEKPLYTAEPVTLEDLQLLADLFYLPYEHGPKGAQMLREFQWLRANSSVVSVNCKGKDSEKIEEWRSRAAKFEEMCGLVMGMFTRLSNCANRTILYDMYSYVWDIKSIMSMVKSFVQWLGCRSHSSAQFLIGDQEPWAFRGGLAGEFQRLLPIDGANDLFFQPPPLTPTSKVYTIRPYFPKDEASVYKICREMYDDGVGLPFQSQPDLIGDKLVGGLLSLSLDYCFVLEDEDGICGYALGTVDVTPFIKKCKISWIPFMQEKYTKPNGDKELSEAEKIMLSFHEEQEVLPETFLANFPSLIKMDIHKKVTDPSVAKSMMACLLSSLKANGSRGAFCEVRPDDKRILEFYSKLGCFEIAKMEGFPKDVVILGRSL T19567 DRUGINFO DVY0C6 LY3372689 Phase 2 T19567 DRUGINFO D03HDL MK 8719 Phase 1 T19567 DRUGINFO D2KV0F BIIB113 Phase 1 T19567 DRUGINFO DP6Y5N MK-8719 Phase 1 T19567 DRUGINFO DS70NZ ASN51 Phase 1 T43718 TARGETID T43718 T43718 FORMERID TTDI02191 T43718 UNIPROID TLR5_HUMAN T43718 TARGNAME Toll-like receptor 5 (TLR5) T43718 GENENAME TLR5 T43718 TARGTYPE Clinical trial T43718 SYNONYMS Toll/interleukin-1 receptor-like protein 3; TIL3 T43718 FUNCTION Recognizes small molecular motifs named pathogen-associated molecular pattern (PAMPs) expressed by pathogens and microbe-associated molecular patterns (MAMPs) usually expressed by resident microbiota. Upon ligand binding such as bacterial flagellins, recruits intracellular adapter proteins MYD88 and TRIF leading to NF-kappa-B activation, cytokine secretion and induction of the inflammatory response. Plays thereby an important role in the relationship between the intestinal epithelium and enteric microbes and contributes to the gut microbiota composition throughout life. Pattern recognition receptor (PRR) located on the cell surface that participates in the activation of innate immunity and inflammatory response. T43718 PDBSTRUC 3J0A; 1P95 T43718 BIOCLASS Toll-like receptor T43718 SEQUENCE MGDHLDLLLGVVLMAGPVFGIPSCSFDGRIAFYRFCNLTQVPQVLNTTERLLLSFNYIRTVTASSFPFLEQLQLLELGSQYTPLTIDKEAFRNLPNLRILDLGSSKIYFLHPDAFQGLFHLFELRLYFCGLSDAVLKDGYFRNLKALTRLDLSKNQIRSLYLHPSFGKLNSLKSIDFSSNQIFLVCEHELEPLQGKTLSFFSLAANSLYSRVSVDWGKCMNPFRNMVLEILDVSGNGWTVDITGNFSNAISKSQAFSLILAHHIMGAGFGFHNIKDPDQNTFAGLARSSVRHLDLSHGFVFSLNSRVFETLKDLKVLNLAYNKINKIADEAFYGLDNLQVLNLSYNLLGELYSSNFYGLPKVAYIDLQKNHIAIIQDQTFKFLEKLQTLDLRDNALTTIHFIPSIPDIFLSGNKLVTLPKINLTANLIHLSENRLENLDILYFLLRVPHLQILILNQNRFSSCSGDQTPSENPSLEQLFLGENMLQLAWETELCWDVFEGLSHLQVLYLNHNYLNSLPPGVFSHLTALRGLSLNSNRLTVLSHNDLPANLEILDISRNQLLAPNPDVFVSLSVLDITHNKFICECELSTFINWLNHTNVTIAGPPADIYCVYPDSFSGVSLFSLSTEGCDEEEVLKSLKFSLFIVCTVTLTLFLMTILTVTKFRGFCFICYKTAQRLVFKDHPQGTEPDMYKYDAYLCFSSKDFTWVQNALLKHLDTQYSDQNRFNLCFEERDFVPGENRIANIQDAIWNSRKIVCLVSRHFLRDGWCLEAFSYAQGRCLSDLNSALIMVVVGSLSQYQLMKHQSIRGFVQKQQYLRWPEDFQDVGWFLHKLSQQILKKEKEKKKDNNIPLQTVATIS T43718 DRUGINFO D0V4TV CBLB-502 Phase 2 T43718 DRUGINFO D0WZ3G Entolimod Phase 1 T43718 DRUGINFO DP2X4C STAT-600 Phase 1 T39797 TARGETID T39797 T39797 FORMERID TTDI02075 T39797 UNIPROID FZD7_HUMAN T39797 TARGNAME Frizzled-7 receptor (FZD7) T39797 GENENAME FZD7 T39797 TARGTYPE Clinical trial T39797 SYNONYMS hFz7; FzE3; Fz7; Fz-7; Frizzled7; Frizzled-7 T39797 FUNCTION Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. Receptor for Wnt proteins. T39797 PDBSTRUC 6O3B; 6O3A; 6NE4; 6NE2; 5WBS T39797 BIOCLASS GPCR frizzled T39797 SEQUENCE MRDPGAAAPLSSLGLCALVLALLGALSAGAGAQPYHGEKGISVPDHGFCQPISIPLCTDIAYNQTILPNLLGHTNQEDAGLEVHQFYPLVKVQCSPELRFFLCSMYAPVCTVLDQAIPPCRSLCERARQGCEALMNKFGFQWPERLRCENFPVHGAGEICVGQNTSDGSGGPGGGPTAYPTAPYLPDLPFTALPPGASDGRGRPAFPFSCPRQLKVPPYLGYRFLGERDCGAPCEPGRANGLMYFKEEERRFARLWVGVWSVLCCASTLFTVLTYLVDMRRFSYPERPIIFLSGCYFMVAVAHVAGFLLEDRAVCVERFSDDGYRTVAQGTKKEGCTILFMVLYFFGMASSIWWVILSLTWFLAAGMKWGHEAIEANSQYFHLAAWAVPAVKTITILAMGQVDGDLLSGVCYVGLSSVDALRGFVLAPLFVYLFIGTSFLLAGFVSLFRIRTIMKHDGTKTEKLEKLMVRIGVFSVLYTVPATIVLACYFYEQAFREHWERTWLLQTCKSYAVPCPPGHFPPMSPDFTVFMIKYLMTMIVGITTGFWIWSGKTLQSWRRFYHRLSHSSKGETAV T39797 DRUGINFO D00GPY OMP-18R5 Phase 1 T88569 TARGETID T88569 T88569 UNIPROID IDHC_HUMAN T88569 TARGNAME Mutated oxalosuccinate decarboxylase (mIDH1) T88569 GENENAME IDH1 T88569 TARGTYPE Clinical trial T88569 SYNONYMS PICD (mutated); Oxalosuccinate decarboxylase (mutated); NADP(+)-specific ICDH (mutated); Isocitrate dehydrogenase [NADP] cytoplasmic (mutated); IDP (mutated); IDH (mutated); Cytosolic NADP-isocitrate dehydrogenase (mutated) T88569 FUNCTION Catalyses the NADPH-dependent reduction of alpha-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). T88569 PDBSTRUC 6BL2; 6BL1; 6BL0; 6BKZ; 6BKY T88569 BIOCLASS Short-chain dehydrogenases reductase T88569 ECNUMBER EC 1.1.1.42 T88569 SEQUENCE MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGRHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL T88569 DRUGINFO D0C6RM BAY1436032 Phase 1 T14676 TARGETID T14676 T14676 FORMERID TTDNC00650 T14676 UNIPROID TNF13_HUMAN T14676 TARGNAME A proliferation-inducing ligand (APRIL) T14676 GENENAME TNFSF13 T14676 TARGTYPE Clinical trial T14676 SYNONYMS ZTNF2; UNQ383/PRO715; Tumor necrosis factor ligand superfamily member 13; TRDL-1; TNF-related death ligand 1; TNF- and APOL-related leukocyte expressed ligand 2; TALL2; TALL-2; CD256 T14676 FUNCTION Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes. Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. T14676 PDBSTRUC 4ZCH T14676 BIOCLASS Cytokine: tumor necrosis factor T14676 SEQUENCE MPASSPFLLAPKGPPGNMGGPVREPALSVALWLSWGAALGAVACAMALLTQQTELQSLRREVSRLQGTGGPSQNGEGYPWQSLPEQSSDALEAWENGERSRKRRAVLTQKQKKQHSVLHLVPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQVVSREGQGRQETLFRCIRSMPSHPDRAYNSCYSAGVFHLHQGDILSVIIPRARAKLNLSPHGTFLGFVKL T14676 DRUGINFO D04YWM Atacicept Phase 3 T99732 TARGETID T99732 T99732 FORMERID TTDI02070 T99732 UNIPROID FGF18_HUMAN T99732 TARGNAME Fibroblast growth factor-18 (FGF18) T99732 GENENAME FGF18 T99732 TARGTYPE Clinical trial T99732 SYNONYMS zFGF5; Fibroblast growth factor 18; FGF18 T99732 FUNCTION Plays an important role in the regulation of cell proliferation, cell differentiation and cell migration. Required for normal ossification and bone development. Stimulates hepatic and intestinal proliferation. T99732 PDBSTRUC 4CJM T99732 BIOCLASS Growth factor T99732 SEQUENCE MYSAPSACTCLCLHFLLLCFQVQVLVAEENVDFRIHVENQTRARDDVSRKQLRLYQLYSRTSGKHIQVLGRRISARGEDGDKYAQLLVETDTFGSQVRIKGKETEFYLCMNRKGKLVGKPDGTSKECVFIEKVLENNYTALMSAKYSGWYVGFTKKGRPRKGPKTRENQQDVHFMKRYPKGQPELQKPFKYTTVTKRSRRIRPTHPA T99732 DRUGINFO D04GKP AS-902330 Phase 2 T64969 TARGETID T64969 T64969 FORMERID TTDR00576 T64969 UNIPROID EGFR_HUMAN T64969 TARGNAME Epidermal growth factor receptor variant III (EGFR vIII) T64969 GENENAME EGFR T64969 TARGTYPE Clinical trial T64969 SYNONYMS ERBB1 variant III; ERBB variant III T64969 FUNCTION Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance (By similarity). T64969 PDBSTRUC 6D8E; 6B3S; 6ARU; 5ZWJ; 5YU9 T64969 BIOCLASS Kinase T64969 ECNUMBER EC 2.7.10.1 T64969 SEQUENCE MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA T64969 DRUGINFO D08RJY Anti-EGFRvIII CAR transduced PBL Phase 1/2 T64969 DRUGINFO D0LU4N EGFRvIII CAR Phase 1/2 T64969 DRUGINFO D0Q4EJ Anti-EGFR V III CAR-T cells Phase 1/2 T64969 DRUGINFO D01LWE EGFRvIII CAR T cells Phase 1 T64969 DRUGINFO D03CMZ CAR-T cells targeting EGFRviii Phase 1 T64969 DRUGINFO D09OSC Anti-EGFRvIII CAR T cells Phase 1 T64969 DRUGINFO D0B5PV CART-EGFRvIII T cells Phase 1 T64969 DRUGINFO D0PT2M EGFRvIII-CARs Phase 1 T64969 DRUGINFO D0ZQ6N CAR-T Cells targeting EGFRvIII Phase 1 T64969 DRUGINFO DF8X5N RG6156 Phase 1 T64969 DRUGINFO DOJ6E8 AMG 596 Phase 1 T64969 DRUGINFO DR4ND6 D2C7 Phase 1 T48598 TARGETID T48598 T48598 FORMERID TTDNC00549 T48598 UNIPROID RASK_HUMAN T48598 TARGNAME GTPase KRas (KRAS) T48598 GENENAME KRAS T48598 TARGTYPE Clinical trial T48598 SYNONYMS c-Ki-ras; c-K-ras; RASK2; Ki-Ras; KRAS2; K-Ras 2 T48598 FUNCTION Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation. Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. T48598 PDBSTRUC 6N2K; 6N2J; 6H47; 6H46; 6GQY T48598 BIOCLASS Small GTPase T48598 SEQUENCE MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM T48598 DRUGINFO D0DT5H AZD4785 Phase 1 T48598 DRUGINFO DR4K0V BI 1701963 Phase 1 T87350 TARGETID T87350 T87350 FORMERID TTDI02317 T87350 UNIPROID PDGFB_HUMAN T87350 TARGNAME Platelet-derived growth factor B (PDGFB) T87350 GENENAME PDGFB T87350 TARGTYPE Clinical trial T87350 SYNONYMS SIS; Protooncogene cSis; Proto-oncogene c-Sis; Plateletderived growth factor subunit B; Plateletderived growth factor beta polypeptide; Plateletderived growth factor B chain; Platelet-derived growth factor subunit B; Platelet-derived growth factor beta polypeptide; Platelet-derived growth factor B chain; PDGF2; PDGF-2; PDGF subunit B; Becaplermin T87350 FUNCTION Potent mitogen for cells of mesenchymal origin. Required for normal proliferation and recruitment of pericytes and vascular smooth muscle cells in the central nervous system, skin, lung, heart and placenta. Required for normal blood vessel development, and for normal development of kidney glomeruli. Plays an important role in wound healing. Signaling is modulated by the formation of heterodimers with PDGFA. Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. T87350 PDBSTRUC 4QCI; 4HQX; 4HQU; 3MJG; 1PDG T87350 BIOCLASS Growth factor T87350 SEQUENCE MNRCWALFLSLCCYLRLVSAEGDPIPEELYEMLSDHSIRSFDDLQRLLHGDPGEEDGAELDLNMTRSHSGGELESLARGRRSLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVTRSPGGSQEQRAKTPQTRVTIRTVRVRRPPKGKHRKFKHTHDKTALKETLGA T87350 DRUGINFO D04BVN PDGF-BB Phase 3 T87350 DRUGINFO D01GSE E-10030 Phase 2 T87350 DRUGINFO D0A6WA GAM-501 Phase 2 T87350 DRUGINFO D0W0GE CR-002 Phase 1 T00033 TARGETID T00033 T00033 FORMERID TTDR00181 T00033 UNIPROID TGFA_HUMAN T00033 TARGNAME Transforming growth factor alpha (TGFA) T00033 GENENAME TGFA T00033 TARGTYPE Clinical trial T00033 SYNONYMS TGF-alpha (40-89); TGF type 1 (40-89); Protransforming growth factor alpha (40-89); ETGF (40-89); EGF-like TGF (40-89) T00033 FUNCTION TGF alpha is a mitogenic polypeptide that is able to bind to the EGF receptor/EGFR and to act synergistically with TGF beta to promote anchorage-independent cell proliferation in soft agar. T00033 PDBSTRUC 5KN5; 4TGF; 3TGF; 3.00E+50; 2TGF T00033 BIOCLASS Growth factor T00033 SEQUENCE MVPSAGQLALFALGIVLAACQALENSTSPLSADPPVAAAVVSHFNDCPDSHTQFCFHGTCRFLVQEDKPACVCHSGYVGARCEHADLLAVVAASQKKQAITALVVVSIVALAVLIITCVLIHCCQVRKHCEWCRALICRHEKPSALLKGRTACCHSETVV T00033 DRUGINFO D08EIK LY3016859 Phase 1/2 T10092 TARGETID T10092 T10092 FORMERID TTDR00006 T10092 UNIPROID FSHB_HUMAN T10092 TARGNAME Follicle stimulating hormone (FSHB) T10092 GENENAME FSHB T10092 TARGTYPE Clinical trial T10092 SYNONYMS Follitropin subunit beta; Follitropin beta chain; Follicle-stimulating hormone beta subunit; FSH-beta; FSH-B T10092 FUNCTION Together with the alpha chain CGA constitutes follitropin, the follicle-stimulating hormone, and provides its biological specificity to the hormone heterodimer. Binds FSHR, a G protein-coupled receptor, on target cells to activate downstream signaling pathways. Follitropin is involved in follicle development and spermatogenesis in reproductive organs. T10092 PDBSTRUC 4MQW; 4AY9; 1XWD; 1FL7 T10092 BIOCLASS Hormone T10092 SEQUENCE MKTLQFFFLFCCWKAICCNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE T10092 DRUGINFO D0KM1B Follicle stimulating hormone Phase 2 T10092 DRUGINFO D08OHK AKP-501 Phase 1 T19784 TARGETID T19784 T19784 FORMERID TTDR01048 T19784 UNIPROID SOMA_HUMAN T19784 TARGNAME Somatotropin (GH1) T19784 GENENAME GH1 T19784 TARGTYPE Clinical trial T19784 SYNONYMS Pituitary growth hormone; Growth hormone 1; Growth hormone; GH-N; GH T19784 FUNCTION Plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF-1. It stimulates both the differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and protein synthesis in muscle and other tissues. T19784 PDBSTRUC 3HHR; 1KF9; 1HWH; 1HWG; 1HUW T19784 BIOCLASS Somatotropin/prolactin T19784 SEQUENCE MATGSRTSLLLAFGLLCLPWLQEGSAFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF T19784 DRUGINFO D0H8MH HGH-CTP Phase 3 T19784 DRUGINFO D0XN5L Albutropin Phase 3 T19784 DRUGINFO D0Y7VP VRS-317 Phase 3 T19784 DRUGINFO D0C9SW Somatropin intranasal rhGH Phase 2 T19784 DRUGINFO D00HZA YPEG-Somatropin Phase 1 T19784 DRUGINFO D01LFA ARX-201 Discontinued in Phase 2 T44919 TARGETID T44919 T44919 UNIPROID GLUC_HUMAN T44919 TARGNAME Glucagon (GCG) T44919 GENENAME GCG T44919 TARGTYPE Clinical trial T44919 SYNONYMS GRPP; GLP2; GLP1; GLP-1 T44919 FUNCTION Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. T44919 PDBSTRUC 6EDS; 5YQZ; 5VAI; 5OTX; 5OTW T44919 BIOCLASS Glucagon T44919 SEQUENCE MKSIYFVAGLFVMLVQGSWQRSLQDTEEKSRSFSASQADPLSDPDQMNEDKRHSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAKRHDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGRRDFPEEVAIVEELGRRHADGSFSDEMNTILDNLAARDFINWLIQTKITDRK T44919 DRUGINFO D09PCL JNJ-64565111 Phase 2 T44919 DRUGINFO D0MO0J MEDI0382 Phase 2 T44919 DRUGINFO DC5NS1 PT320 Phase 2 T44919 DRUGINFO D03MSV PB-1023 Phase 2 T44919 DRUGINFO D04CQK MK-8521 Phase 2 T44919 DRUGINFO D02URD SAR425899 Phase 1 T44919 DRUGINFO D0FW0B ZP2929 Phase 1 T35303 TARGETID T35303 T35303 FORMERID TTDI02211 T35303 UNIPROID PAHO_HUMAN T35303 TARGNAME Pancreatic hormone (PH) T35303 GENENAME PPY T35303 TARGTYPE Clinical trial T35303 SYNONYMS Pancreatic prohormone; Pancreatic polypeptide; Pancreatic icosapeptide; PPY; PP; PI; PH; Obinepitide T35303 FUNCTION The physiological role for the icosapeptide has notyet been elucidated. T35303 PDBSTRUC 1TZ5; 1TZ4 T35303 BIOCLASS Neuropeptide Y T35303 SEQUENCE APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY T35303 DRUGINFO D0DG9F PP-1420 Phase 1/2 T07958 TARGETID T07958 T07958 FORMERID TTDI01917 T07958 UNIPROID EPO_HUMAN T07958 TARGNAME Erythropoietin (EPO) T07958 GENENAME EPO T07958 TARGTYPE Clinical trial T07958 SYNONYMS Epoetin T07958 FUNCTION Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3. Hormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. T07958 PDBSTRUC 1EER; 1CN4; 1BUY T07958 SEQUENCE MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR T07958 DRUGINFO D0E1LB MK-2578 Phase 2 T07958 DRUGINFO DO0GJ1 LKA651 Phase 2 T07958 DRUGINFO D00ANG Erythropoietin-transfected autologous cell therapy Phase 1/2 T07958 DRUGINFO D04UTH Long-acting erythropoietin conjugate Phase 1 T07958 DRUGINFO D0KV1I GC-1113 Phase 1 T07958 DRUGINFO D0Q9WN FC EPO Discontinued in Phase 1 T07958 DRUGINFO D0OL4S GLY-515n Terminated T47415 TARGETID T47415 T47415 FORMERID TTDI02337 T47415 UNIPROID 1B07_HUMAN T47415 TARGNAME HLA class I antigen B-7 (HLA-B) T47415 GENENAME HLA-B T47415 TARGTYPE Clinical trial T47415 SYNONYMS MHC class I antigen B*7; HLAB; HLA class I histocompatibility antigen, B7 alpha chain; HLA class I histocompatibility antigen, B-7 alpha chain T47415 FUNCTION Involved in the presentation of foreign antigens to the immune system. T47415 PDBSTRUC 6AVG; 6AVF; 6AT5; 5WMP; 5WMO T47415 BIOCLASS MHC class I T47415 SEQUENCE MLVMAPRTVLLLLSAALALTETWAGSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHDQYAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEGECVEWLRRYLENGKDKLERADPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVVVIGAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSLTA T47415 DRUGINFO D0Y9YN Velimogene aliplasmid Phase 3 T00419 TARGETID T00419 T00419 FORMERID TTDI02195 T00419 UNIPROID TNNC2_HUMAN T00419 TARGNAME Fast skeletal muscle troponin complex (TNNC2) T00419 GENENAME TNNC2 T00419 TARGTYPE Clinical trial T00419 SYNONYMS fTnT; Troponin T, fast skeletal muscle; Troponin I, fast-twitch isoform; Troponin I, fast skeletal muscle; Troponin C, skeletal muscle; TnTf; TNNT3; TNNI2; TNNC2; Fast skeletal muscle troponin T; Beta-TnTF T00419 FUNCTION Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. T00419 BIOCLASS Troponin T00419 SEQUENCE MTDQQAEARSYLSEEMIAEFKAAFDMFDADGGGDISVKELGTVMRMLGQTPTKEELDAIIEEVDEDGSGTIDFEEFLVMMVRQMKEDAKGKSEEELAECFRIFDRNADGYIDPEELAEIFRASGEHVTDEEIESLMKDGDKNNDGRIDFDEFLKMMEGVQ T00419 DRUGINFO D07EBF CK-2017357 Phase 3 T00419 DRUGINFO D07ZUZ CK-2127107 Phase 2 T21689 TARGETID T21689 T21689 FORMERID TTDR00411 T21689 UNIPROID APOE_HUMAN T21689 TARGNAME Apolipoprotein E (APOE) T21689 GENENAME APOE T21689 TARGTYPE Clinical trial T21689 SYNONYMS ApoE; Apo-E T21689 FUNCTION APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance. Apoliproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma. As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles. Finally, APOE has also a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells. A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes. APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues. By participating to the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis. APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis. First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues. Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes. APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting. APOE in also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells. APOE, may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP. APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids. T21689 PDBSTRUC 6NCO; 6NCN; 2L7B; 2KNY; 2KC3 T21689 BIOCLASS Apolipoprotein T21689 SEQUENCE MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH T21689 DRUGINFO D07ADU AEM-28 Phase 2 T21689 DRUGINFO D0V6OZ CN-105 Phase 2 T21689 DRUGINFO D6UEI3 LX1001 Phase 1/2 T21689 DRUGINFO D02ADJ Apolipoprotein E Terminated T31518 TARGETID T31518 T31518 FORMERID TTDNC00616 T31518 UNIPROID APOC3_HUMAN T31518 TARGNAME Apolipoprotein C-III (ApoCIII) T31518 GENENAME APOC3 T31518 TARGTYPE Clinical trial T31518 SYNONYMS Apolipoprotein CIII; Apolipoprotein C3; ApoC-III; Apo-CIII T31518 FUNCTION Plays a multifaceted role in triglyceride homeostasis. Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners. Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma. T31518 PDBSTRUC 2JQ3 T31518 BIOCLASS Apolipoprotein T31518 SEQUENCE MQPRVLLVVALLALLASARASEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSEFWDLDPEVRPTSAVAA T54761 TARGETID T54761 T54761 FORMERID TTDI02324 T54761 UNIPROID MBP_HUMAN T54761 TARGNAME Myelin basic protein (MBP) T54761 GENENAME MBP T54761 TARGTYPE Clinical trial T54761 SYNONYMS Myelin membrane encephalitogenic protein; Myelin A1 protein T54761 FUNCTION The classic group of MBP isoforms (isoform 4-isoform 14) are with PLP the most abundant protein components of the myelin membrane in the CNS. They have a role in both its formation and stabilization. The smaller isoforms might have an important role in remyelination of denuded axons in multiple sclerosis. The non-classic group of MBP isoforms (isoform 1-isoform 3/Golli-MBPs) may preferentially have a role in the early developing brain long before myelination, maybe as components of transcriptional complexes, and may also be involved in signaling pathways in T-cells and neural cells. Differential splicing events combined with optional post-translational modifications give a wide spectrum of isomers, with each of them potentially having a specialized function. Induces T-cell proliferation. T54761 PDBSTRUC 1ZGL; 1YMM; 1QCL; 1K2D; 1HQR T54761 SEQUENCE MGNHAGKRELNAEKASTNSETNRGESEKKRNLGELSRTTSEDNEVFGEADANQNNGTSSQDTAVTDSKRTADPKNAWQDAHPADPGSRPHLIRLFSRDAPGREDNTFKDRPSESDELQTIQEDSAATSESLDVMASQKRPSQRHGSKYLATASTMDHARHGFLPRHRDTGILDSIGRFFGGDRGAPKRGSGKDSHHPARTAHYGSLPQKSHGRTQDENPVVHFFKNIVTPRTPPPSQGKGRGLSLSRFSWGAEGQRPGFGYGGRASDYKSAHKGFKGVDAQGTLSKIFKLGGRDSRSGSPMARR T54761 DRUGINFO D05QKO NBI-5788 Phase 2 T54761 DRUGINFO D0C5FQ BHT-3009 Phase 2 T10828 TARGETID T10828 T10828 FORMERID TTDR00679 T10828 UNIPROID FETA_HUMAN T10828 TARGNAME Alpha-fetoprotein (AFP) T10828 GENENAME AFP T10828 TARGTYPE Clinical trial T10828 SYNONYMS Alpha-fetoglobulin; Alpha-1-fetoprotein; AFP T10828 FUNCTION Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human AFP shows estrogen-binding properties. T10828 PDBSTRUC 3MRK T10828 BIOCLASS Serum albumin family T10828 SEQUENCE MKWVESIFLIFLLNFTESRTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDALTAIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQVPEPVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVTKELRESSLLNQHACAVMKNFGTRTFQAITVTKLSQKFTKVNFTEIQKLVLDVAHVHEHCCRGDVLDCLQDGEKIMSYICSQQDTLSNKITECCKLTTLERGQCIIHAENDEKPEGLSPNLNRFLGDRDFNQFSSGEKNIFLASFVHEYSRRHPQLAVSVILRVAKGYQELLEKCFQTENPLECQDKGEEELQKYIQESQALAKRSCGLFQKLGEYYLQNAFLVAYTKKAPQLTSSELMAITRKMAATAATCCQLSEDKLLACGEGAADIIIGHLCIRHEMTPVNPGVGQCCTSSYANRRPCFSSLVVDETYVPPAFSDDKFIFHKDLCQAQGVALQTMKQEFLINLVKQKPQITEEQLEAVIADFSGLLEKCCQGQEQEVCFAEEGQKLISKTRAALGV T10828 DRUGINFO D05RQY MM-093 Phase 2 T10828 DRUGINFO D4K2OF ET140202 Phase 1 T02617 TARGETID T02617 T02617 FORMERID TTDI02373 T02617 UNIPROID TRFE_HUMAN T02617 TARGNAME Transferrin (TF) T02617 GENENAME TF T02617 TARGTYPE Clinical trial T02617 SYNONYMS Siderophilin; Serotransferrin; PRO1400; Beta-1 metal-binding globulin T02617 FUNCTION It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation. Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. T02617 PDBSTRUC 6D05; 6D04; 6D03; 6CTC; 5Y6K T02617 BIOCLASS Transferrin T02617 SEQUENCE MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKCQSFRDHMKSVIPSDGPSVACVKKASYLDCIRAIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRDQYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARSMGGKEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAIAVVKKSASDLTWDNLKGKKSCHTAVGRTAGWNIPMGLLYNKINHCRFDEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAFRCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTRKPVEEYANCHLARAPNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKLHDRNTYEKYLGEEYVKAVGNLRKCSTSSLLEACTFRRP T02617 DRUGINFO D0A1GR CALAA-01 Phase 1 T02617 DRUGINFO D0QB8Q EP-2167 Preclinical T53811 TARGETID T53811 T53811 FORMERID TTDI02206 T53811 UNIPROID VE6_HPV16 T53811 TARGNAME Human papillomavirus protein E6 (HPV E6) T53811 GENENAME HPV E6 T53811 TARGTYPE Clinical trial T53811 SYNONYMS Protein E6; E6 T53811 FUNCTION Plays a major role in the induction and maintenance of cellular transformation. Acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. E6 associates with host E6-AP ubiquitin-protein ligase, and inactivates tumor suppressors TP53 and TP73 by targeting them to the 26S proteasome for degradation. In turn, DNA damage and chromosomal instabilities increase and lead to cell proliferation and cancer development. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1- 91, a repressor of human telomerase reverse transcriptase (hTERT). The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization. Other cellular targets including Bak, Fas-associated death domain- containing protein (FADD) and procaspase 8, are degraded by E6/E6AP causing inhibition of apoptosis. E6 also inhibits immune response by interacting with host IRF3 and TYK2. These interactions prevent IRF3 transcriptional activities and inhibit TYK2-mediated JAK-STAT activation by interferon alpha resulting in inhibition of the interferon signaling pathway. T53811 PDBSTRUC 6HKS; 4XR8; 4JOP; 4GIZ; 2LJZ T53811 BIOCLASS Papillomaviridae E protein T53811 SEQUENCE MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL T53811 DRUGINFO D00PMB VGX-3100 Phase 3 T53811 DRUGINFO D0P9QW Tipapkinogene sovacivec Phase 2 T83793 TARGETID T83793 T83793 FORMERID TTDR00778 T83793 UNIPROID NEF_HV1A2 T83793 TARGNAME Human immunodeficiency virus Negative factor (HIV nef) T83793 GENENAME HIV nef T83793 TARGTYPE Clinical trial T83793 SYNONYMS nef; Nef protein; F-protein; 3'ORF; 27 kDa protein T83793 FUNCTION Extracellular Nef protein targets CD4(+) T-lymphocytes for apoptosis by interacting with CXCR4 surface receptors. T83793 PDBSTRUC 6B72; 5XOV; 4U5W; 4U1N; 4U1M T83793 BIOCLASS Lentivirus primate group Nef T83793 SEQUENCE MGGKWSKRSMGGWSAIRERMRRAEPRAEPAADGVGAVSRDLEKHGAITSSNTAATNADCAWLEAQEEEEVGFPVRPQVPLRPMTYKAALDISHFLKEKGGLEGLIWSQRRQEILDLWIYHTQGYFPDWQNYTPGPGIRYPLTFGWCFKLVPVEPEKVEEANEGENNSLLHPMSLHGMEDAEKEVLVWRFDSKLAFHHMARELHPEYYKDC T83793 DRUGINFO D0R0SP LIPO-5 Phase 2 T83793 DRUGINFO D05GBH F4co vaccine Phase 2 T83793 DRUGINFO D0W9IH Ad35-GRIN Phase 1/2 T83793 DRUGINFO D09ZKB Ad35-GRIN/ENV Phase 1 T83793 DRUGINFO D02ESK GSK-732461 Discontinued in Phase 2 T83793 DRUGINFO D08OBF MYRISTIC ACID Investigative T46040 TARGETID T46040 T46040 FORMERID TTDI01964 T46040 UNIPROID FA11_HUMAN T46040 TARGNAME Coagulation factor XI (F11) T46040 GENENAME F11 T46040 TARGTYPE Clinical trial T46040 SYNONYMS Plasma thromboplastin antecedent; PTA; FXI T46040 FUNCTION Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. T46040 PDBSTRUC 6R8X; 6I58; 6C0S; 6AOD; 5WB6 T46040 BIOCLASS Peptidase T46040 ECNUMBER EC 3.4.21.27 T46040 SEQUENCE MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV T46040 DRUGINFO DHJ64U A186 IND submitted T46040 DRUGINFO D2HD0V Asundexian Phase 3 T46040 DRUGINFO D9DWC6 Abelacimab Phase 2 T46040 DRUGINFO DZD7W6 MK-2060 Phase 2 T46040 DRUGINFO D07LPT EP-7041 Phase 1 T46040 DRUGINFO D4P8YO AB023 Phase 1 T46040 DRUGINFO DU6SH2 A336 Phase 1 T91894 TARGETID T91894 T91894 FORMERID TTDI02313 T91894 UNIPROID MAS_HUMAN T91894 TARGNAME Proto-oncogene Mas (MAS) T91894 GENENAME MAS1 T91894 TARGTYPE Clinical trial T91894 SYNONYMS MGRA; MAS1 proto-oncogene, G protein-coupled receptor T91894 FUNCTION Acts specifically as a functional antagonist of AGTR1 (angiotensin-2 type 1 receptor), although it up-regulates AGTR1 receptor levels. Positive regulation of AGTR1 levels occurs through activation of the G-proteins GNA11 and GNAQ, and stimulation of the protein kinase C signaling cascade. The antagonist effect on AGTR1 function is probably due to AGTR1 being physically altered by MAS1. Receptor for angiotensin 1-7. T91894 BIOCLASS GPCR rhodopsin T91894 SEQUENCE MDGSNVTSFVVEEPTNISTGRNASVGNAHRQIPIVHWVIMSISPVGFVENGILLWFLCFRMRRNPFTVYITHLSIADISLLFCIFILSIDYALDYELSSGHYYTIVTLSVTFLFGYNTGLYLLTAISVERCLSVLYPIWYRCHRPKYQSALVCALLWALSCLVTTMEYVMCIDREEESHSRNDCRAVIIFIAILSFLVFTPLMLVSSTILVVKIRKNTWASHSSKLYIVIMVTIIIFLIFAMPMRLLYLLYYEYWSTFGNLHHISLLFSTINSSANPFIYFFVGSSKKKRFKESLKVVLTRAFKDEMQPRRQKDNCNTVTVETVV T91894 DRUGINFO D01TEA DSC-127 Phase 3 T91894 DRUGINFO D0MH8O Angiotensin-(1-7) Phase 3 T91894 DRUGINFO D02VJX AVE 0991 Investigative T91894 DRUGINFO D03QFD AR234960 Investigative T91894 DRUGINFO D0Z2FF AR244555 Investigative T86918 TARGETID T86918 T86918 FORMERID TTDS00397 T86918 UNIPROID AMYP_HUMAN T86918 TARGNAME Pancreatic alpha-amylase (AMY2A) T86918 GENENAME AMY2A T86918 TARGTYPE Clinical trial T86918 SYNONYMS PA; 1,4-alpha-D-glucan glucanohydrolase T86918 FUNCTION Hydrolyses alpha bonds of large, alpha-linked polysaccharides, such as starch and glycogen, yielding glucose and maltose. T86918 PDBSTRUC 5VA9; 5U3A; 5TD4; 5KEZ; 5EMY T86918 BIOCLASS Glycosylase T86918 ECNUMBER EC 3.2.1.1 T86918 SEQUENCE MKFFLLLFTIGFCWAQYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPPNENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGNAVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGLLDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAGSKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWGFVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWPRQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQPFTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGIKIYVSDDGKAHFSISNSAEDPFIAIHAESKL T86918 DRUGINFO D0A5DJ Pancrecarb NDA filed T86918 DRUGINFO D0T9LR Liprotamase Phase 3 T86918 DRUGINFO D03AHW Acarbose Derived Hexasaccharide Investigative T86918 DRUGINFO D06PCE Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam Investigative T86918 DRUGINFO D07WIB Hydroxycitric acid Investigative T86918 DRUGINFO D09WFG Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen Investigative T86918 DRUGINFO D0A5MA Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen Investigative T86918 DRUGINFO D0P8YV 5-Hydroxymethyl-Chonduritol Investigative T86918 DRUGINFO D0Y9RY 4,6-Dideoxy-4-Amino-Alpha-D-Glucose Investigative T86918 DRUGINFO D09CXQ Acanthus ilicifolius Linn Investigative T86918 DRUGINFO D0E0VN 6-Deoxy-Alpha-D-Glucose Investigative T86918 DRUGINFO D0U7QA Pyroglutamic Acid Investigative T86918 DRUGINFO D07ONX Beta-D-Glucose Investigative T96476 TARGETID T96476 T96476 FORMERID TTDI02129 T96476 UNIPROID MSP1_PLAFW T96476 TARGNAME Plasmodium Merozoite surface protein 1 (Malaria MSP-1) T96476 GENENAME Malaria MSP-1 T96476 TARGTYPE Clinical trial T96476 SYNONYMS p195; PMMSA; Merozoite surface protein 1; Merozoite surface antigens T96476 FUNCTION MSP-1 complex targets spectrin, a complex on the internal surface of the cell membrane of a red blood cell. The majority of the MSP-1 complex is shed upon entry into the red blood cell, but a small portion of the C-terminus, called MSP-119, is conserved. T96476 PDBSTRUC 2MUE; 2MU7; 2FLG; 1CEJ T96476 BIOCLASS Merozoite surface protein T96476 SEQUENCE MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLNEGTSGTAVTTSTPGSKGSVASGGSGGSVASGGSVASGGSVASGGSVASGGSGNSRRTNPSDNSSDSDAKSYADLKHRVRNYLLTIKELKYPQLFDLTNHMLTLCDNIHGFKYLIDGYEEINELLYKLNFYFDLLRAKLNDVCANDYCQIPFNLKIRANELDVLKKLVFGYRKPLDNIKDNVGKMEDYIKKNKKTIENINELIEESKKTIDKNKNATKEEEKKKLYQAQYDLSIYNKQLEEAHNLISVLEKRIDTLKKNENIKELLDKINEIKNPPPANSGNTPNTLLDKNKKIEEHEKEIKEIAKTIKFNIDSLFTDPLELEYYLREKNKNIDISAKVETKESTEPNEYPNGVTYPLSYNDINNALNELNSFGDLINPFDYTKEPSKNIYTDNERKKFINEIKEKIKIEKKKIESDKKSYEDRSKSLNDITKEYEKLLNEIYDSKFNNNIDLTNFEKMMGKRYSYKVEKLTHHNTFASYENSKHNLEKLTKALKYMEDYSLRNIVVEKELKYYKNLISKIENEIETLVENIKKDEEQLFEKKITKDENKPDEKILEVSDIVKVQVQKVLLMNKIDELKKTQLILKNVELKHNIHVPNSYKQENKQEPYYLIVLKKEIDKLKVFMPKVESLINEEKKNIKTEGQSDNSEPSTEGEITGQATTKPGQQAGSALEGDSVQAQAQEQKQAQPPVPVPVPEAKAQVPTPPAPVNNKTENVSKLDYLEKLYEFLNTSYICHKYILVSHSTMNEKILKQYKITKEEESKLSSCDPLDLLFNIQNNIPVMYSMFDSLNNSLSQLFMEIYEKEMVCNLYKLKDNDKIKNLLEEAKKVSTSVKTLSSSSMQPLSLTPQDKPEVSANDDTSHSTNLNNSLKLFENILSLGKNKNIYQELIGQKSSENFYEKILKDSDTFYNESFTNFVKSKADDINSLNDESKRKKLEEDINKLKKTLQLSFDLYNKYKLKLERLFDKKKTVGKYKMQIKKLTLLKEQLESKLNSLNNPKHVLQNFSVFFNKKKEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEESIQTEDNYASLENFKVLSKLEGKLKDNLNLEKKKLSYLSSGLHHLIAELKEVIKNKNYTGNSPSENNTDVNNALESYKKFLPEGTDVATVVSESGSDTLEQSQPKKPASTHVGAESNTITTSQNVDDEVDDVIIVPIFGESEEDYDDLGQVVTGEAVTPSVIDNILSKIENEYEVLYLKPLAGVYRSLKKQLENNVMTFNVNVKDILNSRFNKRENFKNVLESDLIPYKDLTSSNYVVKDPYKFLNKEKRDKFLSSYNYIKDSIDTDINFANDVLGYYKILSEKYKSDLDSIKKYINDKQGENEKYLPFLNNIETLYKTVNDKIDLFVIHLEAKVLNYTYEKSNVEVKIKELNYLKTIQDKLADFKKNNNFVGIADLSTDYNHNNLLTKFLSTGMVFENLAKTVLSNLLDGNLQGMLNISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNENNGGCDADAKCTEEDSGSNGKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILMLILYSFI T96476 DRUGINFO D0B1TT AdCh63-MSP1 Phase 1/2 T66120 TARGETID T66120 T66120 FORMERID TTDR00676 T66120 UNIPROID KDSB_ECOLI T66120 TARGNAME Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB) T66120 GENENAME Bact kdsB T66120 TARGTYPE Clinical trial T66120 SYNONYMS kdsB; CMP-KDO synthetase; CMP-2-keto-3-deoxyoctulosonic acid synthetase; CKS; 3-deoxy-D-manno-octulosonate cytidylytransferase T66120 FUNCTION Activates KDO (a required 8-carbon sugar) for incorporation into bacterial lipopolysaccharide in Gram-negative bacteria. T66120 PDBSTRUC 3K8E; 3K8D; 1VH1 T66120 BIOCLASS Kinase T66120 ECNUMBER EC 2.7.7.38 T66120 SEQUENCE MSFVVIIPARYASTRLPGKPLVDINGKPMIVHVLERARESGAERIIVATDHEDVARAVEAAGGEVCMTRADHQSGTERLAEVVEKCAFSDDTVIVNVQGDEPMIPATIIRQVADNLAQRQVGMATLAVPIHNAEEAFNPNAVKVVLDAEGYALYFSRATIPWDRDRFAEGLETVGDNFLRHLGIYGYRAGFIRRYVNWQPSPLEHIEMLEQLRVLWYGEKIHVAVAQEVPGTGVDTPEDLERVRAEMR T66120 DRUGINFO D03ZKM UX-001 Phase 3 T66120 DRUGINFO D0G7CG Cmp-2-Keto-3-Deoxy-Octulosonic Acid Investigative T66120 DRUGINFO D07XZT Cytidine-5'-Diphosphate Investigative T66120 DRUGINFO D0S2QZ Cytidine-5'-Monophosphate Investigative T11005 TARGETID T11005 T11005 FORMERID TTDI02097 T11005 UNIPROID IFNW1_HUMAN T11005 TARGNAME Interferon-omega (IFNW1) T11005 GENENAME IFNW1 T11005 TARGTYPE Clinical trial T11005 SYNONYMS Interferon omega1; Interferon omega-1; Interferon alphaII1; Interferon alpha-II-1 T11005 FUNCTION extracellular space, cytokine activity, cytokine receptor binding, type I interferon receptor binding, adaptive immune response, B cell differentiation, B cell proliferation, cell cycle arrest, cytokine-mediated signaling pathway, humoral immune response. T11005 PDBSTRUC 3SE4 T11005 BIOCLASS Cytokine: interferon T11005 SEQUENCE MALLFPLLAALVMTSYSPVGSLGCDLPQNHGLLSRNTLVLLHQMRRISPFLCLKDRRDFRFPQEMVKGSQLQKAHVMSVLHEMLQQIFSLFHTERSSAAWNMTLLDQLHTGLHQQLQHLETCLLQVVGEGESAGAISSPALTLRRYFQGIRVYLKEKKYSDCAWEVVRMEIMKSLFLSTNMQERLRSKDRDLGSS T11005 DRUGINFO D0Z0TU ITCA-638 Phase 2 T00239 TARGETID T00239 T00239 FORMERID TTDR00086 T00239 UNIPROID IL4_HUMAN T00239 TARGNAME Interleukin-4 (IL4) T00239 GENENAME IL4 T00239 TARGTYPE Clinical trial T00239 SYNONYMS Pitrakinra; Lymphocyte stimulatory factor 1; IL-4; Binetrakin; BSF-1; B-cell stimulatory factor 1 T00239 FUNCTION It is a costimulator of DNA-synthesis. It induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes. Positively regulates IL31RA expression in macrophages. Stimulates autophagy in dendritic cells by interfering with mTORC1 signaling and through the induction of RUFY4. Participates in at least several B-cell activation processes as well as of other cell types. T00239 PDBSTRUC 5FHX; 4YDY; 3QB7; 3BPN; 3BPL T00239 BIOCLASS Cytokine: interleukin T00239 SEQUENCE MGLTSQLLPPLFFLLACAGNFVHGHKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKNTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEANQSTLENFLERLKTIMREKYSKCSS T00239 DRUGINFO DP2UR8 Dexpramipexole Phase 3 T00239 DRUGINFO D0I9DN IL-4R Phase 2 T00239 DRUGINFO D0NO1L Pascolizumab Phase 2 T00239 DRUGINFO D00KQN PEGylated pitrakinra Phase 2 T00239 DRUGINFO D04WMR Tepoxalin Phase 2 T00239 DRUGINFO DF5R7E Romilkimab Phase 2 T00239 DRUGINFO D0O4SH SAR-156597 Phase 2 T00239 DRUGINFO D1LP4B PF-07264660 Phase 1 T00239 DRUGINFO DIWU14 PF-07275315 Phase 1 T44862 TARGETID T44862 T44862 FORMERID TTDI02329 T44862 UNIPROID PP65_HCMVA T44862 TARGNAME Cytomegalovirus 65kDa phosphoprotein (HCV UL83) T44862 GENENAME HCV UL83 T44862 TARGTYPE Clinical trial T44862 SYNONYMS pp65; UL83; Tegument protein UL83; Phosphoprotein UL83; 65 kDa phosphoprotein; 65 kDa matrix phosphoprotein T44862 FUNCTION Counteracts thehost antiviral immune response when activated and phosphorylated, by preventing IRF3 from entering the nucleus. Also participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoters pf these genes. T44862 PDBSTRUC 3GSO; 2X4T; 2X4R T44862 BIOCLASS Herpesviridae pp65 T44862 SEQUENCE MESRGRRCPEMISVLGPISGHVLKAVFSRGDTPVLPHETRLLQTGIHVRVSQPSLILVSQYTPDSTPCHRGDNQLQVQHTYFTGSEVENVSVNVHNPTGRSICPSQEPMSIYVYALPLKMLNIPSINVHHYPSAAERKHRHLPVADAVIHASGKQMWQARLTVSGLAWTRQQNQWKEPDVYYTSAFVFPTKDVALRHVVCAHELVCSMENTRATKMQVIGDQYVKVYLESFCEDVPSGKLFMHVTLGSDVEEDLTMTRNPQPFMRPHERNGFTVLCPKNMIIKPGKISHIMLDVAFTSHEHFGLLCPKSIPGLSISGNLLMNGQQIFLEVQAIRETVELRQYDPVAALFFFDIDLLLQRGPQYSEHPTFTSQYRIQGKLEYRHTWDRHDEGAAQGDDDVWTSGSDSDEELVTTERKTPRVTGGGAMAGASTSAGRKRKSASSATACTSGVMTRGRLKAESTVAPEEDTDEDSDNEIHNPAVFTWPPWQAGILARNLVPMVATVQGQNLKYQEFFWDANDIYRIFAELEGVWQPAAQPKRRRHRQDALPGPCIASTPKKHRG T44862 DRUGINFO D0V0VR CMVpp65-A0201 Phase 2 T67363 TARGETID T67363 T67363 FORMERID TTDI01789 T67363 UNIPROID ITAV_HUMAN-ITB3_HUMAN T67363 TARGNAME Integrin alpha-V/beta-3 (ITGAV/B3) T67363 GENENAME ITGAV-ITGB3 T67363 TARGTYPE Clinical trial T67363 SYNONYMS Integrin alphaVbeta3; Integrin alpha-v beta-3; Integrin alpha V beta 3; Alpha(v)beta(3) Integrin; Alpha v beta 3 integrin T67363 FUNCTION Receptor for phagocytosis on macrophages or dendritic cells. In cancer and other diseases, its role in angiogenesis is directly responsible to providing blood supply to problematic overgrowths. T67363 BIOCLASS Integrin T67363 SEQUENCE MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGTMAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET T67363 DRUGINFO D09ZXO Cilengitide Phase 3 T67363 DRUGINFO D09WCN Intetumumab Phase 2 T67363 DRUGINFO D0D7DU VLTS-589 Phase 2 T67363 DRUGINFO D0X4IH Fluciclatide F-18 Phase 2 T67363 DRUGINFO D00QVT ATN-161 Phase 2 T67363 DRUGINFO D0TT6L SF0166 Phase 1/2 T67363 DRUGINFO D08XBF AMEP Phase 1 T67363 DRUGINFO D04HLE Vitaxin Discontinued in Phase 2 T67363 DRUGINFO D0B9SR SB-273005 Discontinued in Phase 1 T67363 DRUGINFO D02VIP SB-267268 Discontinued in Phase 1 T67363 DRUGINFO D04YEY PS-388023 Terminated T67363 DRUGINFO D02DGT IS20I Investigative T67363 DRUGINFO D02SZF 18F-SMIBR-K5 Investigative T15167 TARGETID T15167 T15167 FORMERID TTDI01960 T15167 UNIPROID CO1A2_HUMAN T15167 TARGNAME Collagen I (COL1A2) T15167 GENENAME COL1A2 T15167 TARGTYPE Clinical trial T15167 SYNONYMS Collagen alpha-2(I) chain; Alpha-2 type I collagen T15167 FUNCTION Type I collagen is a member of group I collagen (fibrillar forming collagen). T15167 PDBSTRUC 5CVA; 5CTI; 5CTD T15167 SEQUENCE MLSFVDTRTLLLLAVTLCLATCQSLQEETVRKGPAGDRGPRGERGPPGPPGRDGEDGPTGPPGPPGPPGPPGLGGNFAAQYDGKGVGLGPGPMGLMGPRGPPGAAGAPGPQGFQGPAGEPGEPGQTGPAGARGPAGPPGKAGEDGHPGKPGRPGERGVVGPQGARGFPGTPGLPGFKGIRGHNGLDGLKGQPGAPGVKGEPGAPGENGTPGQTGARGLPGERGRVGAPGPAGARGSDGSVGPVGPAGPIGSAGPPGFPGAPGPKGEIGAVGNAGPAGPAGPRGEVGLPGLSGPVGPPGNPGANGLTGAKGAAGLPGVAGAPGLPGPRGIPGPVGAAGATGARGLVGEPGPAGSKGESGNKGEPGSAGPQGPPGPSGEEGKRGPNGEAGSAGPPGPPGLRGSPGSRGLPGADGRAGVMGPPGSRGASGPAGVRGPNGDAGRPGEPGLMGPRGLPGSPGNIGPAGKEGPVGLPGIDGRPGPIGPAGARGEPGNIGFPGPKGPTGDPGKNGDKGHAGLAGARGAPGPDGNNGAQGPPGPQGVQGGKGEQGPPGPPGFQGLPGPSGPAGEVGKPGERGLHGEFGLPGPAGPRGERGPPGESGAAGPTGPIGSRGPSGPPGPDGNKGEPGVVGAVGTAGPSGPSGLPGERGAAGIPGGKGEKGEPGLRGEIGNPGRDGARGAPGAVGAPGPAGATGDRGEAGAAGPAGPAGPRGSPGERGEVGPAGPNGFAGPAGAAGQPGAKGERGAKGPKGENGVVGPTGPVGAAGPAGPNGPPGPAGSRGDGGPPGMTGFPGAAGRTGPPGPSGISGPPGPPGPAGKEGLRGPRGDQGPVGRTGEVGAVGPPGFAGEKGPSGEAGTAGPPGTPGPQGLLGAPGILGLPGSRGERGLPGVAGAVGEPGPLGIAGPPGARGPPGAVGSPGVNGAPGEAGRDGNPGNDGPPGRDGQPGHKGERGYPGNIGPVGAAGAPGPHGPVGPAGKHGNRGETGPSGPVGPAGAVGPRGPSGPQGIRGDKGEPGEKGPRGLPGLKGHNGLQGLPGIAGHHGDQGAPGSVGPAGPRGPAGPSGPAGKDGRTGHPGTVGPAGIRGPQGHQGPAGPPGPPGPPGPPGVSGGGYDFGYDGDFYRADQPRSAPSLRPKDYEVDATLKSLNNQIETLLTPEGSRKNPARTCRDLRLSHPEWSSGYYWIDPNQGCTMDAIKVYCDFSTGETCIRAQPENIPAKNWYRSSKDKKHVWLGETINAGSQFEYNVEGVTSKEMATQLAFMRLLANYASQNITYHCKNSIAYMDEETGNLKKAVILQGSNDVELVAEGNSRFTYTVLVDGCSKKTNEWGKTIIEYKTNKPSRLPFLDIAPLDIGGADQEFFVDIGPVCFK T15167 DRUGINFO D02CFV Solubilized type 1 native bovine collagen Phase 2 T78114 TARGETID T78114 T78114 FORMERID TTDI02050 T78114 UNIPROID DAF_HUMAN T78114 TARGNAME Complement decay-accelerating factor (CD55) T78114 GENENAME CD55 T78114 TARGTYPE Clinical trial T78114 SYNONYMS DAF; Complement decayaccelerating factor; CR T78114 FUNCTION Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade. Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage. This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. T78114 PDBSTRUC 6ILK; 6ILJ; 5FOA; 3J24; 3IYP T78114 SEQUENCE MTVARPSVPAALPLLGELPRLLLLVLLCLPAVWGDCGLPPDVPNAQPALEGRTSFPEDTVITYKCEESFVKIPGEKDSVICLKGSQWSDIEEFCNRSCEVPTRLNSASLKQPYITQNYFPVGTVVEYECRPGYRREPSLSPKLTCLQNLKWSTAVEFCKKKSCPNPGEIRNGQIDVPGGILFGATISFSCNTGYKLFGSTSSFCLISGSSVQWSDPLPECREIYCPAPPQIDNGIIQGERDHYGYRQSVTYACNKGFTMIGEHSIYCTVNNDEGEWSGPPPECRGKSLTSKVPPTVQKPTTVNVPTTEVSPTSQKTTTKTTTPNAQATRSTPVSRTTKHFHETTPNKGSGTTSGTTRLLSGHTCFTLTGLLGTLVTMGLLT T78114 DRUGINFO D0C4BL Coxsackievirus A21 Phase 2 T78114 DRUGINFO D00UOQ PAT-SC1 Phase 1/2 T78114 DRUGINFO D02WLS Onyvax-105 Phase 1/2 T46263 TARGETID T46263 T46263 FORMERID TTDI02011 T46263 UNIPROID 4F2_HUMAN T46263 TARGNAME Lymphocyte activation antigen 4F2 (SLC3A2) T46263 GENENAME SLC3A2 T46263 TARGTYPE Clinical trial T46263 SYNONYMS SLC3A2; Lymphocyte activation antigen 4F2 large subunit; CD98; 4F2hc; 4F2 heavy chain antigen; 4F2 cellsurface antigen heavy chain T46263 FUNCTION Required for the function of light chain amino-acid transporters. Involved in sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan. Involved in guiding and targeting of LAT1 and LAT2 to the plasma membrane. When associated with SLC7A6 or SLC7A7 acts as an arginine/glutamine exchanger, following an antiport mechanism for amino acid transport, influencing arginine release in exchange for extracellular amino acids. Plays a role in nitric oxide synthesis in human umbilical vein endothelial cells (HUVECs) via transport of L-arginine. Required for normal and neoplastic cell growth. When associated with SLC7A5/LAT1, is also involved in the transport of L-DOPA across the blood-brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell membrane in tissues such as placenta. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. When associated with SLC7A5 or SLC7A8, involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L- nitrosocysteine (L-CNSO) across the transmembrane. Together with ICAM1, regulates the transport activity LAT2 in polarized intestinal cells, by generating and delivering intracellular signals. Whenassociated with SLC7A5, plays an important role in transporting L-leucine from the circulating blood to the retina across the inner blood-retinal barrier. T46263 PDBSTRUC 6IRT; 6IRS; 2DH3; 2DH2 T46263 SEQUENCE MELQPPEASIAVVSIPRQLPGSHSEAGVQGLSAGDDSELGSHCVAQTGLELLASGDPLPSASQNAEMIETGSDCVTQAGLQLLASSDPPALASKNAEVTGTMSQDTEVDMKEVELNELEPEKQPMNAASGAAMSLAGAEKNGLVKIKVAEDEAEAAAAAKFTGLSKEELLKVAGSPGWVRTRWALLLLFWLGWLGMLAGAVVIIVRAPRCRELPAQKWWHTGALYRIGDLQAFQGHGAGNLAGLKGRLDYLSSLKVKGLVLGPIHKNQKDDVAQTDLLQIDPNFGSKEDFDSLLQSAKKKSIRVILDLTPNYRGENSWFSTQVDTVATKVKDALEFWLQAGVDGFQVRDIENLKDASSFLAEWQNITKGFSEDRLLIAGTNSSDLQQILSLLESNKDLLLTSSYLSDSGSTGEHTKSLVTQYLNATGNRWCSWSLSQARLLTSFLPAQLLRLYQLMLFTLPGTPVFSYGDEIGLDAAALPGQPMEAPVMLWDESSFPDIPGAVSANMTVKGQSEDPGSLLSLFRRLSDQRSKERSLLHGDFHAFSAGPGLFSYIRHWDQNERFLVVLNFGDVGLSAGLQASDLPASASLPAKADLLLSTQPGREEGSPLELERLKLEPHEGLLLRFPYAA T46263 DRUGINFO D0OQ5R IGN523 Phase 1 T96623 TARGETID T96623 T96623 UNIPROID HS90B_HUMAN T96623 TARGNAME Heat shock protein 90 beta (HSP90B) T96623 GENENAME HSP90AB1 T96623 TARGTYPE Clinical trial T96623 SYNONYMS Heat shock 84 kDa; HSP84; HSP 84 T96623 FUNCTION Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:16478993, PubMed:19696785). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself. Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:27295069, PubMed:26991466). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels. In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues. Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment. Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation (PubMed:24613385). Promotes cell differentiation by chaperoning BIRC2 and thereby protecting from auto-ubiquitination and degradation by the proteasomal machinery (PubMed:18239673). Main chaperone that is involved in the phosphorylation/activation of the STAT1 by chaperoning both JAK2 and PRKCE under heat shock and in turn, activates its own transcription (PubMed:20353823). T96623 PDBSTRUC 5UCJ; 5UCI; 5UCH; 5UC4; 5FWP T96623 BIOCLASS Heat shock protein T96623 SEQUENCE MPEEVHHGEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNASDALDKIRYESLTDPSKLDSGKELKIDIIPNPQERTLTLVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVVVITKHNDDEQYAWESSAGGSFTVRADHGEPIGRGTKVILHLKEDQTEYLEERRVKEVVKKHSQFIGYPITLYLEKEREKEISDDEAEEEKGEKEEEDKDDEEKPKIEDVGSDEEDDSGKDKKKKTKKIKEKYIDQEELNKTKPIWTRNPDDITQEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFIPRRAPFDLFENKKKKNNIKLYVRRVFIMDSCDELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNIVKKCLELFSELAEDKENYKKFYEAFSKNLKLGIHEDSTNRRRLSELLRYHTSQSGDEMTSLSEYVSRMKETQKSIYYITGESKEQVANSAFVERVRKRGFEVVYMTEPIDEYCVQQLKEFDGKSLVSVTKEGLELPEDEEEKKKMEESKAKFENLCKLMKEILDKKVEKVTISNRLVSSPCCIVTSTYGWTANMERIMKAQALRDNSTMGYMMAKKHLEINPDHPIVETLRQKAEADKNDKAVKDLVVLLFETALLSSGFSLEDPQTHSNRIYRMIKLGLGIDEDEVAAEEPNAAVPDEIPPLEGDEDASRMEEVD T96623 DRUGINFO D07MPL SNX-5422 Phase 1/2 T96623 DRUGINFO D01FYA PU-H71 Phase 1 T96623 DRUGINFO D0F3NF TAS-116 Phase 1 T23212 TARGETID T23212 T23212 FORMERID TTDR00283 T23212 UNIPROID CD14_HUMAN T23212 TARGNAME Monocyte differentiation antigen CD14 (CD14) T23212 GENENAME CD14 T23212 TARGTYPE Clinical trial T23212 SYNONYMS Myeloid cell-specific leucine-rich glycoprotein T23212 FUNCTION In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Acts as a coreceptor for TLR2:TLR6 heterodimer in response to diacylated lipopeptides and for TLR2:TLR1 heterodimer in response to triacylated lipopeptides, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-). Coreceptor for bacterial lipopolysaccharide. T23212 PDBSTRUC 4GLP T23212 SEQUENCE MERASCLLLLLLPLVHVSATTPEPCELDDEDFRCVCNFSEPQPDWSEAFQCVSAVEVEIHAGGLNLEPFLKRVDADADPRQYADTVKALRVRRLTVGAAQVPAQLLVGALRVLAYSRLKELTLEDLKITGTMPPLPLEATGLALSSLRLRNVSWATGRSWLAELQQWLKPGLKVLSIAQAHSPAFSCEQVRAFPALTSLDLSDNPGLGERGLMAALCPHKFPAIQNLALRNTGMETPTGVCAALAAAGVQPHSLDLSHNSLRATVNPSAPRCMWSSALNSLNLSFAGLEQVPKGLPAKLRVLDLSCNRLNRAPQPDELPEVDNLTLDGNPFLVPGTALPHEGSMNSGVVPACARSTLSVGVSGTLVLLQGARGFA T23212 DRUGINFO D0UB5A IC14 Phase 2 T88806 TARGETID T88806 T88806 FORMERID TTDI01790 T88806 UNIPROID ITA5_HUMAN-ITB1_HUMAN T88806 TARGNAME Integrin alpha-5/beta-1 (ITGA5/B1) T88806 GENENAME ITGA5-ITGB1 T88806 TARGTYPE Clinical trial T88806 SYNONYMS alpha(5)beta(1) integrin; Alpha 5 beta 1 integrin T88806 FUNCTION binds to matrix macromolecules and proteinases and thereby stimulates angiogenesis. The interaction of VLA-5 with fibronectin plays an important role in regulating inflammatory cytokine production by human articular chondrocytes. T88806 BIOCLASS Integrin T88806 SEQUENCE MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMGSRTPESPLHAVQLRWGPRRRPPLLPLLLLLLPPPPRVGGFNLDAEAPAVLSGPPGSFFGFSVEFYRPGTDGVSVLVGAPKANTSQPGVLQGGAVYLCPWGASPTQCTPIEFDSKGSRLLESSLSSSEGEEPVEYKSLQWFGATVRAHGSSILACAPLYSWRTEKEPLSDPVGTCYLSTDNFTRILEYAPCRSDFSWAAGQGYCQGGFSAEFTKTGRVVLGGPGSYFWQGQILSATQEQIAESYYPEYLINLVQGQLQTRQASSIYDDSYLGYSVAVGEFSGDDTEDFVAGVPKGNLTYGYVTILNGSDIRSLYNFSGEQMASYFGYAVAATDVNGDGLDDLLVGAPLLMDRTPDGRPQEVGRVYVYLQHPAGIEPTPTLTLTGHDEFGRFGSSLTPLGDLDQDGYNDVAIGAPFGGETQQGVVFVFPGGPGGLGSKPSQVLQPLWAASHTPDFFGSALRGGRDLDGNGYPDLIVGSFGVDKAVVYRGRPIVSASASLTIFPAMFNPEERSCSLEGNPVACINLSFCLNASGKHVADSIGFTVELQLDWQKQKGGVRRALFLASRQATLTQTLLIQNGAREDCREMKIYLRNESEFRDKLSPIHIALNFSLDPQAPVDSHGLRPALHYQSKSRIEDKAQILLDCGEDNICVPDLQLEVFGEQNHVYLGDKNALNLTFHAQNVGEGGAYEAELRVTAPPEAEYSGLVRHPGNFSSLSCDYFAVNQSRLLVCDLGNPMKAGASLWGGLRFTVPHLRDTKKTIQFDFQILSKNLNNSQSDVVSFRLSVEAQAQVTLNGVSKPEAVLFPVSDWHPRDQPQKEEDLGPAVHHVYELINQGPSSISQGVLELSCPQALEGQQLLYVTRVTGLNCTTNHPINPKGLELDPEGSLHHQQKREAPSRSSASSGPQILKCPEAECFRLRCELGPLHQQESQSLQLHFRVWAKTFLQREHQPFSLQCEAVYKALKMPYRILPRQLPQKERQVATAVQWTKAEGSYGVPLWIIILAILFGLLLLGLLIYILYKLGFFKRSLPYGTAMEKAQLKPPATSDA T88806 DRUGINFO D06PVA Volociximab Phase 2 T88806 DRUGINFO D00QVT ATN-161 Phase 2 T88806 DRUGINFO D08XBF AMEP Phase 1 T88806 DRUGINFO D0ZV0R F-200 Terminated T72195 TARGETID T72195 T72195 FORMERID TTDI02019 T72195 UNIPROID ANXA5_HUMAN T72195 TARGNAME Annexin A5 (ANXA5) T72195 GENENAME ANXA5 T72195 TARGTYPE Clinical trial T72195 SYNONYMS Vascular anticoagulantalpha; Vascular anticoagulant-alpha; VACalpha; VAC-alpha; Thromboplastin inhibitor; Placental anticoagulant protein I; Placental anticoagulant protein 4; PP4; PAPI; PAP-I; Lipocortin V; Endonexin II; ENX2; Calphobindin I; CBPI; CBP-I; Annexin5; Annexin-5; Annexin V; Anchorin CII; ANX5 T72195 FUNCTION This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade. T72195 PDBSTRUC 2XO3; 2XO2; 1SAV; 1HVG; 1HVF T72195 BIOCLASS Annexin protein T72195 SEQUENCE MAQVLRGTVTDFPGFDERADAETLRKAMKGLGTDEESILTLLTSRSNAQRQEISAAFKTLFGRDLLDDLKSELTGKFEKLIVALMKPSRLYDAYELKHALKGAGTNEKVLTEIIASRTPEELRAIKQVYEEEYGSSLEDDVVGDTSGYYQRMLVVLLQANRDPDAGIDEAQVEQDAQALFQAGELKWGTDEEKFITIFGTRSVSHLRKVFDKYMTISGFQIEETIDRETSGNLEQLLLAVVKSIRSIPAYLAETLYYAMKGAGTDDHTLIRVMVSRSEIDLFNIRKEFRKNFATSLYSMIKGDTSGDYKKALLLLCGEDD T72195 DRUGINFO D07FQL Diannexin Phase 2 T41820 TARGETID T41820 T41820 FORMERID TTDI02185 T41820 UNIPROID SYIC_YEAST T41820 TARGNAME Fungal Isoleucyl t-RNA synthetase (Fung ILS1) T41820 GENENAME Fung ILS1 T41820 TARGTYPE Clinical trial T41820 SYNONYMS Fung Isoleucyl-tRNA synthetase; Fung Isoleucine--tRNA ligase, cytoplasmic; Fung IleRS T41820 FUNCTION Has aminoacyl-tRNA editing and isoleucine-tRNA ligase activity. T41820 BIOCLASS Carbon-oxygen ligase T41820 ECNUMBER EC 6.1.1.5 T41820 SEQUENCE MSESNAHFSFPKEEEKVLSLWDEIDAFHTSLELTKDKPEFSFFDGPPFATGTPHYGHILASTIKDIVPRYATMTGHHVERRFGWDTHGVPIEHIIDKKLGITGKDDVFKYGLENYNNECRSIVMTYASDWRKTIGRLGRWIDFDNDYKTMYPSFMESTWWAFKQLHEKGQVYRGFKVMPYSTGLTTPLSNFEAQQNYKDVNDPAVTIGFNVIGQEKTQLVAWTTTPWTLPSNLSLCVNADFEYVKIYDETRDRYFILLESLIKTLYKKPKNEKYKIVEKIKGSDLVGLKYEPLFPYFAEQFHETAFRVISDDYVTSDSGTGIVHNAPAFGEEDNAACLKNGVISEDSVLPNAIDDLGRFTKDVPDFEGVYVKDADKLIIKYLTNTGNLLLASQIRHSYPFCWRSDTPLLYRSVPAWFVRVKNIVPQMLDSVMKSHWVPNTIKEKRFANWIANARDWNVSRNRYWGTPIPLWVSDDFEEVVCVGSIKELEELTGVRNITDLHRDVIDKLTIPSKQGKGDLKRIEEVFDCWFESGSMPYASQHYPFENTEKFDERVPANFISEGLDQTRGWFYTLAVLGTHLFGSVPYKNVIVSGIVLAADGRKMSKSLKNYPDPSIVLNKYGADALRLYLINSPVLKAESLKFKEEGVKEVVSKVLLPWWNSFKFLDGQIALLKKMSNIDFQYDDSVKSDNVMDRWILASMQSLVQFIHEEMGQYKLYTVVPKLLNFIDELTNWYIRFNRRRLKGENGVEDCLKALNSLFDALFTFVRAMAPFTPFLSESIYLRLKEYIPEAVLAKYGKDGRSVHFLSYPVVKKEYFDEAIETAVSRMQSVIDLGRNIREKKTISLKTPLKTLVILHSDESYLKDVEALKNYIIEELNVRDVVITSDEAKYGVEYKAVADWPVLGKKLKKDAKKVKDALPSVTSEQVREYLESGKLEVAGIELVKGDLNAIRGLPESAVQAGQETRTDQDVLIIMDTNIYSELKSEGLARELVNRIQKLRKKCGLEATDDVLVEYELVKDTIDFEAIVKEHFDMLSKTCRSDIAKYDGSKTDPIGDEEQSINDTIFKLKVFKL T41820 DRUGINFO D09XUY Icofungipen Phase 2 T41820 DRUGINFO D0F1AX CB-102930 Terminated T83391 TARGETID T83391 T83391 FORMERID TTDC00152 T83391 UNIPROID F16P1_HUMAN; F16P2_HUMAN T83391 TARGNAME Fructose-1,6-bisphosphatase (FBP) T83391 GENENAME FBP1; FBP2 T83391 TARGTYPE Clinical trial T83391 SYNONYMS FBPase; D-fructose-1,6-bisphosphate 1-phosphohydrolase T83391 FUNCTION Catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate in the presence of divalent cations, acting as a rate-limiting enzyme in gluconeogenesis. Plays a role in regulating glucose sensing and insulin secretion of pancreatic beta-cells. Appears to modulate glycerol gluconeogenesis in liver. Important regulator of appetite and adiposity; increased expression of the protein in liver after nutrient excess increases circulating satiety hormones and reduces appetite-stimulating neuropeptides and thus seems to provide a feedback mechanism to limit weight gain. T83391 BIOCLASS Phosphoric monoester hydrolase T83391 SEQUENCE MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYARDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ T83391 DRUGINFO D0G2ZL Managlinat dialanetil Phase 2 T83391 DRUGINFO D0KU4M MB07803 Phase 2 T83391 DRUGINFO D00XCL 1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea Investigative T83391 DRUGINFO D0C2YL 2,5-Anhydroglucitol-1,6-Biphosphate Investigative T83391 DRUGINFO D0H3IJ Fructose-6-Phosphate Investigative T83391 DRUGINFO D0H6WG 1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea Investigative T83391 DRUGINFO D0J3EJ 4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol Investigative T83391 DRUGINFO D0L8EN 3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol Investigative T83391 DRUGINFO D0T5OW 2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol Investigative T83391 DRUGINFO D0X6YR N-(5-chlorobenzo[d]oxazol-2-yl)benzenesulfonamide Investigative T83391 DRUGINFO D01KOI 4-(2-amino-1,3-thiazol-4-yl)phenol Investigative T83391 DRUGINFO D03GBO 4,6-Dichloro-1H-indole-2-carboxylic acid Investigative T04321 TARGETID T04321 T04321 FORMERID TTDI02092 T04321 UNIPROID HLA_STAAU T04321 TARGNAME Staphylococcus Alpha-hemolysin (Stap-coc hly) T04321 GENENAME Stap-coc hly T04321 TARGTYPE Clinical trial T04321 SYNONYMS hla; Alpha-toxin; Alpha-hemolysin; Alpha-HL T04321 FUNCTION Alpha-toxin binds to the membrane of eukaryotic cells (particularly red blood cells, RBC) forming pores, resulting in hemolysis, with the release of low-molecular weight molecules leading to eventual osmotic RBC lysis. Human RBCs bind much less alpha-toxin than do rabbit RBCs. Heptamer oligomerization and pore formation is required for lytic activity. T04321 PDBSTRUC 7AHL; 4YHD; 4IDJ; 3M4E; 3M4D T04321 BIOCLASS Alpha-hemolysin channel-forming toxin T04321 SEQUENCE MKTRIVSSVTTTLLLGSILMNPVAGAADSDINIKTGTTDIGSNTTVKTGDLVTYDKENGMHKKVFYSFIDDKNHNKKLLVIRTKGTIAGQYRVYSEEGANKSGLAWPSAFKVQLQLPDNEVAQISDYYPRNSIDTKEYMSTLTYGFNGNVTGDDTGKIGGLIGANVSIGHTLKYVQPDFKTILESPTDKKVGWKVIFNNMVNQNWGPYDRDSWNPVYGNQLFMKTRNGSMKAADNFLDPNKASSLLSSGFSPDFATVITMDRKASKQQTNIDVIYERVRDDYQLHWTSTNWKGTNTKDKWTDRSSERYKIDWEKEEMTN T04321 DRUGINFO D0VP9E Cyrtominetin Phase 3 T04321 DRUGINFO DN8F1Z AR-301 Phase 3 T04321 DRUGINFO D0Q9XE MEDI4893 Phase 2b T04321 DRUGINFO D0Z2NJ ASN100 Phase 2 T49639 TARGETID T49639 T49639 FORMERID TTDR00169 T49639 UNIPROID HS71A_HUMAN; HS71B_HUMAN T49639 TARGNAME Heat shock protein 70 (HSP70) T49639 GENENAME HSPA1A; HSPA1B T49639 TARGTYPE Clinical trial T49639 SYNONYMS Heat shock 70 kDa protein; HSP72; HSP70 T49639 FUNCTION In unstressed cells, is present in a HSP90-containing multichaperone complex that maintains it in a non-DNA-binding inactivated monomeric form. Upon exposure to heat and other stress stimuli, undergoes homotrimerization and activates HSP gene transcription through binding to site-specific heat shock elements (HSEs) present in the promoter regions of HSP genes. Activation is reversible, and during the attenuation and recovery phase period of the HSR, returns to its unactivated form. Binds to inverted 5'-NGAAN-3' pentamer DNA sequences. Binds to chromatin at heat shock gene promoters. Plays also several other functions independently of its transcriptional activity. Involved in the repression of Ras-induced transcriptional activation of the c-fos gene in heat-stressed cells. Positively regulates pre-mRNA 3'-end processing and polyadenylation of HSP70 mRNA upon heat-stressed cells in a symplekin (SYMPK)-dependent manner. Plays a role in nuclear export of stress-induced HSP70 mRNA. Plays a role in the regulation of mitotic progression. Plays also a role as a negative regulator of non-homologous end joining (NHEJ) repair activity in a DNA damage-dependent manner. Involved in stress-induced cancer cell proliferation in a IER5-dependent manner. Function as a stress-inducible and DNA-binding transcription factor that plays a central role in the transcriptional activation of the heat shock response (HSR), leading to the expression of a large class of molecular chaperones heat shock proteins (HSPs) that protect cells from cellular insults' damage. T49639 BIOCLASS Heat shock protein T49639 SEQUENCE MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQGPKGGSGSGPTIEEVD T49639 DRUGINFO D06KIJ AG-858 Phase 2 T49639 DRUGINFO D09POH AEG-33773 Phase 2 T49639 DRUGINFO D05BSG Enkastim-ev Phase 1 T49639 DRUGINFO D05UFJ Minnelide 001 Phase 1 T49639 DRUGINFO D09VWI BRX-005 Phase 1 T49639 DRUGINFO D0GR1Y Minnelide Phase 1 T49639 DRUGINFO D0I7MG AG-707 Phase 1 T49639 DRUGINFO D0VZ1C H-103 Phase 1 T49639 DRUGINFO D0U1SI Bimoclomol Discontinued in Phase 2 T49639 DRUGINFO D0I3EI NK-1001 Discontinued in Phase 2 T49639 DRUGINFO D0ZW2F NSC-119910 Investigative T49639 DRUGINFO D0GP7D NSC-119911 Investigative T49639 DRUGINFO D0Z5LU NSC-119913 Investigative T49639 DRUGINFO D0A1CM ELLAGIC ACID Investigative T06575 TARGETID T06575 T06575 FORMERID TTDR00707 T06575 UNIPROID CGB3_HUMAN T06575 TARGNAME Choriogonadotropin beta (CG-beta) T06575 GENENAME CGB3 T06575 TARGTYPE Clinical trial T06575 SYNONYMS Chorionic gonadotropin beta subunit; Chorionic gonadotrophin beta subunit; CG-beta T06575 FUNCTION Stimulates the ovaries to synthesize the steroids that are essential for the maintenance of pregnancy. T06575 PDBSTRUC 1XUL; 1QFW; 1HRP; 1HCN T06575 BIOCLASS Hormone T06575 SEQUENCE MEMFQGLLLLLLLSMGGTWASKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ T06575 DRUGINFO D04REV CDX-1307 Phase 2 T24127 TARGETID T24127 T24127 FORMERID TTDR00943 T24127 UNIPROID PYY_HUMAN T24127 TARGNAME Peptide tyrosine tyrosine PYY (PYY) T24127 GENENAME PYY T24127 TARGTYPE Clinical trial T24127 SYNONYMS PYY-II T24127 FUNCTION This gut peptide inhibits exocrine pancreatic secretion, has a vasoconstrictory action and inhibitis jejunal and colonic mobility. T24127 PDBSTRUC 2NA5; 2L60; 2DF0; 2DEZ T24127 BIOCLASS NPY family T24127 SEQUENCE IKPEAPREDASPEELNRYYASLRHYLNLVTRQRY T24127 DRUGINFO D08CJM Peptide YY 3-36 Phase 2 T97765 TARGETID T97765 T97765 FORMERID TTDR00921 T97765 UNIPROID CCL3_HUMAN T97765 TARGNAME Macrophage inflammatory protein 1-alpha (CCL3) T97765 GENENAME CCL3 T97765 TARGTYPE Clinical trial T97765 SYNONYMS Tonsillar lymphocyte LD78 alpha protein; Small-inducible cytokine A3; SIS-beta; SCYA3; PAT 464.1; Macrophage Inflammatory Protein-1alpha Nuclear Protein; MNP; MIP1A; MIP-1-alpha; G0S19-1 protein; G0S19-1; G0/G1 switch regulatory protein 19-1; C-C motif chemokine 3 T97765 FUNCTION Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). Monokine with inflammatory and chemokinetic properties. T97765 PDBSTRUC 5D65; 5COR; 4ZKB; 4RA8; 3KBX T97765 BIOCLASS Cytokine: CC chemokine T97765 SEQUENCE MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA T97765 DRUGINFO D02PMT Nagrestipen Phase 1 T85616 TARGETID T85616 T85616 FORMERID TTDC00075 T85616 UNIPROID THIO_HUMAN T85616 TARGNAME Thioredoxin (TXN) T85616 GENENAME TXN T85616 TARGTYPE Clinical trial T85616 SYNONYMS Trx; TRX1; TRDX; Surface-associated sulphydryl protein; Surface associated sulphydryl protein; SASP; ATL-derived factor; ADF T85616 FUNCTION Plays a role in the reversible S-nitrosylation of cysteine residues in target proteins, and thereby contributes to the response to intracellular nitric oxide. Nitrosylates the active site Cys of CASP3 in response to nitric oxide (NO), and thereby inhibits caspase-3 activity. Induces the FOS/JUN AP-1 DNA-binding activity in ionizing radiation (IR) cells through its oxidation/reduction status and stimulates AP-1 transcriptional activity. Participates in various redox reactions through the reversible oxidation of its active center dithiol to a disulfide and catalyzes dithiol-disulfide exchange reactions. T85616 PDBSTRUC 5DQY; 4TRX; 4PUF; 4POM; 4POL T85616 SEQUENCE MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV T85616 DRUGINFO D04JTD PX-12 Phase 2 T85616 DRUGINFO D09TVP Cacodylate Ion Investigative T85616 DRUGINFO D0F2ME Acetate Ion Investigative T22978 TARGETID T22978 T22978 FORMERID TTDI02189 T22978 UNIPROID TGFB3_HUMAN T22978 TARGNAME Transforming growth factor beta 3 (TGFB3) T22978 GENENAME TGFB3 T22978 TARGTYPE Clinical trial T22978 SYNONYMS Transforming growth factor beta-3 proprotein; Transforming growth factor beta-3; TGF-beta-3; Latency-associated peptide T22978 FUNCTION Transforming growth factor beta-3 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-3 (TGF-beta-3) chains, which constitute the regulatory and active subunit of TGF-beta-3, respectively. T22978 PDBSTRUC 4UM9; 3EO1; 2PJY; 1TGK; 1TGJ T22978 BIOCLASS Growth factor T22978 SEQUENCE MKMHLQRALVVLALLNFATVSLSLSTCTTLDFGHIKKKRVEAIRGQILSKLRLTSPPEPTVMTHVPYQVLALYNSTRELLEEMHGEREEGCTQENTESEYYAKEIHKFDMIQGLAEHNELAVCPKGITSKVFRFNVSSVEKNRTNLFRAEFRVLRVPNPSSKRNEQRIELFQILRPDEHIAKQRYIGGKNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHTFQPNGDILENIHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHHNPHLILMMIPPHRLDNPGQGGQRKKRALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTTHSTVLGLYNTLNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKSCKCS T22978 DRUGINFO D0P9YQ Avotermin Phase 3 T45593 TARGETID T45593 T45593 FORMERID TTDI01945 T45593 UNIPROID TAU_HUMAN T45593 TARGNAME Microtubule-associated protein tau (MAPT) T45593 GENENAME MAPT T45593 TARGTYPE Clinical trial T45593 SYNONYMS tau; Paired helical filamenttau; Paired helical filament-tau; Neurofibrillary tangle protein; MTBT1; MAPTL T45593 FUNCTION The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. T45593 PDBSTRUC 6QJQ; 6QJP; 6QJM; 6QJH; 6NWQ T45593 SEQUENCE MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL T45593 DRUGINFO D0V1FF Davunetide Phase 3 T45593 DRUGINFO D5FSV8 TRx0237 Phase 3 T45593 DRUGINFO D05XDZ LMT-X Phase 3 T45593 DRUGINFO DQ02VJ E2814 Phase 2/3 T45593 DRUGINFO DQ02VJ E2814 Phase 2/3 T45593 DRUGINFO D00GXL PBT-2 Phase 2 T45593 DRUGINFO D01EJG RG6100 Phase 2 T45593 DRUGINFO D02IJA Tau-binding PET tracer Phase 2 T45593 DRUGINFO D0I8FS BIIB092 Phase 2 T45593 DRUGINFO DJH56Z JNJ‐63733657 Phase 2 T45593 DRUGINFO D96UBZ Semorinemab Phase 2 T45593 DRUGINFO DK6BL5 Bepranemab Phase 2 T45593 DRUGINFO DK6BL5 Bepranemab Phase 2 T45593 DRUGINFO D02DZK LY3303560 Phase 1 T45593 DRUGINFO D0P8YJ PTI-80 Phase 1 T45593 DRUGINFO DMSL68 PRX-005 Phase 1 T45593 DRUGINFO DO31MK APNmAb005 Phase 1 T45593 DRUGINFO DFM7X6 BEY2153 Phase 1 T45593 DRUGINFO DPU26Z Lu AF87908 Phase 1 T45593 DRUGINFO DPU26Z Lu AF87908 Phase 1 T45593 DRUGINFO D03LGX NI-105 Investigative T45593 DRUGINFO D0D2GZ AL-408 Investigative T45593 DRUGINFO D0T9PL BLV-0703 Investigative T78890 TARGETID T78890 T78890 FORMERID TTDI02330 T78890 UNIPROID TFPI1_HUMAN T78890 TARGNAME Tissue factor pathway inhibitor (TFPI) T78890 GENENAME TFPI T78890 TARGTYPE Clinical trial T78890 SYNONYMS TFPI1; Lipoprotein-associated coagulation inhibitor; LACI; Extrinsic pathway inhibitor; EPI T78890 FUNCTION It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma. Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. T78890 PDBSTRUC 6BX8; 5NMV; 4DTG; 4BQD; 1TFX T78890 SEQUENCE MIYTMKKVHALWASVCLLLNLAPAPLNADSEEDEEHTIITDTELPPLKLMHSFCAFKADDGPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQEKPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDGPNGFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIGKCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIKTKRKRKKQRVKIAYEEIFVKNM T78890 DRUGINFO D0B7VK Tifacogin Phase 3 T78890 DRUGINFO D19OMU PF-06741086 Phase 3 T78890 DRUGINFO D2FE7T Concizumab Phase 3 T78890 DRUGINFO D0U0XL NN-7415 Phase 1 T78890 DRUGINFO D0X4ZV BAX-499 Phase 1 T59550 TARGETID T59550 T59550 FORMERID TTDI02126 T59550 UNIPROID MPRI_HUMAN T59550 TARGNAME CI Man-6-P receptor (IGF2R) T59550 GENENAME IGF2R T59550 TARGTYPE Clinical trial T59550 SYNONYMS MPRI; MPR 300; M6PR; M6P/IGF2R; M6P/IGF2 receptor; Insulinlike growth factor II receptor; Insulinlike growth factor 2 receptor; Insulin-like growth factor II receptor; Insulin-like growth factor 2 receptor; IGFII receptor; IGF-II receptor; Cationindependent mannose6phosphate receptor; Cation-independent mannose-6-phosphate receptor; CIMPR; CI-MPR; CD222; 300 kDa mannose 6phosphate receptor; 300 kDa mannose 6-phosphate receptor T59550 FUNCTION Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. This receptor also binds IGF2. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. T59550 PDBSTRUC 5IEI; 2V5P; 2V5O; 2V5N; 2M6T T59550 BIOCLASS Mannose 6-phosphate receptor T59550 SEQUENCE MGAAAGRSPHLGPAPARRPQRSLLLLQLLLLVAAPGSTQAQAAPFPELCSYTWEAVDTKNNVLYKINICGSVDIVQCGPSSAVCMHDLKTRTYHSVGDSVLRSATRSLLEFNTTVSCDQQGTNHRVQSSIAFLCGKTLGTPEFVTATECVHYFEWRTTAACKKDIFKANKEVPCYVFDEELRKHDLNPLIKLSGAYLVDDSDPDTSLFINVCRDIDTLRDPGSQLRACPPGTAACLVRGHQAFDVGQPRDGLKLVRKDRLVLSYVREEAGKLDFCDGHSPAVTITFVCPSERREGTIPKLTAKSNCRYEIEWITEYACHRDYLESKTCSLSGEQQDVSIDLTPLAQSGGSSYISDGKEYLFYLNVCGETEIQFCNKKQAAVCQVKKSDTSQVKAAGRYHNQTLRYSDGDLTLIYFGGDECSSGFQRMSVINFECNKTAGNDGKGTPVFTGEVDCTYFFTWDTEYACVKEKEDLLCGATDGKKRYDLSALVRHAEPEQNWEAVDGSQTETEKKHFFINICHRVLQEGKARGCPEDAAVCAVDKNGSKNLGKFISSPMKEKGNIQLSYSDGDDCGHGKKIKTNITLVCKPGDLESAPVLRTSGEGGCFYEFEWHTAAACVLSKTEGENCTVFDSQAGFSFDLSPLTKKNGAYKVETKKYDFYINVCGPVSVSPCQPDSGACQVAKSDEKTWNLGLSNAKLSYYDGMIQLNYRGGTPYNNERHTPRATLITFLCDRDAGVGFPEYQEEDNSTYNFRWYTSYACPEEPLECVVTDPSTLEQYDLSSLAKSEGGLGGNWYAMDNSGEHVTWRKYYINVCRPLNPVPGCNRYASACQMKYEKDQGSFTEVVSISNLGMAKTGPVVEDSGSLLLEYVNGSACTTSDGRQTTYTTRIHLVCSRGRLNSHPIFSLNWECVVSFLWNTEAACPIQTTTDTDQACSIRDPNSGFVFNLNPLNSSQGYNVSGIGKIFMFNVCGTMPVCGTILGKPASGCEAETQTEELKNWKPARPVGIEKSLQLSTEGFITLTYKGPLSAKGTADAFIVRFVCNDDVYSGPLKFLHQDIDSGQGIRNTYFEFETALACVPSPVDCQVTDLAGNEYDLTGLSTVRKPWTAVDTSVDGRKRTFYLSVCNPLPYIPGCQGSAVGSCLVSEGNSWNLGVVQMSPQAAANGSLSIMYVNGDKCGNQRFSTRITFECAQISGSPAFQLQDGCEYVFIWRTVEACPVVRVEGDNCEVKDPRHGNLYDLKPLGLNDTIVSAGEYTYYFRVCGKLSSDVCPTSDKSKVVSSCQEKREPQGFHKVAGLLTQKLTYENGLLKMNFTGGDTCHKVYQRSTAIFFYCDRGTQRPVFLKETSDCSYLFEWRTQYACPPFDLTECSFKDGAGNSFDLSSLSRYSDNWEAITGTGDPEHYLINVCKSLAPQAGTEPCPPEAAACLLGGSKPVNLGRVRDGPQWRDGIIVLKYVDGDLCPDGIRKKSTTIRFTCSESQVNSRPMFISAVEDCEYTFAWPTATACPMKSNEHDDCQVTNPSTGHLFDLSSLSGRAGFTAAYSEKGLVYMSICGENENCPPGVGACFGQTRISVGKANKRLRYVDQVLQLVYKDGSPCPSKSGLSYKSVISFVCRPEARPTNRPMLISLDKQTCTLFFSWHTPLACEQATECSVRNGSSIVDLSPLIHRTGGYEAYDESEDDASDTNPDFYINICQPLNPMHGVPCPAGAAVCKVPIDGPPIDIGRVAGPPILNPIANEIYLNFESSTPCLADKHFNYTSLIAFHCKRGVSMGTPKLLRTSECDFVFEWETPVVCPDEVRMDGCTLTDEQLLYSFNLSSLSTSTFKVTRDSRTYSVGVCTFAVGPEQGGCKDGGVCLLSGTKGASFGRLQSMKLDYRHQDEAVVLSYVNGDRCPPETDDGVPCVFPFIFNGKSYEECIIESRAKLWCSTTADYDRDHEWGFCRHSNSYRTSSIIFKCDEDEDIGRPQVFSEVRGCDVTFEWKTKVVCPPKKLECKFVQKHKTYDLRLLSSLTGSWSLVHNGVSYYINLCQKIYKGPLGCSERASICRRTTTGDVQVLGLVHTQKLGVIGDKVVVTYSKGYPCGGNKTASSVIELTCTKTVGRPAFKRFDIDSCTYYFSWDSRAACAVKPQEVQMVNGTITNPINGKSFSLGDIYFKLFRASGDMRTNGDNYLYEIQLSSITSSRNPACSGANICQVKPNDQHFSRKVGTSDKTKYYLQDGDLDVVFASSSKCGKDKTKSVSSTIFFHCDPLVEDGIPEFSHETADCQYLFSWYTSAVCPLGVGFDSENPGDDGQMHKGLSERSQAVGAVLSLLLVALTCCLLALLLYKKERRETVISKLTTCCRRSSNVSYKYSKVNKEEETDENETEWLMEEIQLPPPRQGKEGQENGHITTKSVKALSSLHGDDQDSEDEVLTIPEVKVHSGRGAGAESSHPVRNAQSNALQEREDDRVGLVRGEKARKGKSSSAQQKTVSSTKLVSFHDDSDEDLLHI T59550 DRUGINFO D00WHL Juvidex Phase 2 T59550 DRUGINFO D00VFH PXS-25 Phase 1 T59550 DRUGINFO D0H3YC EP-128504 Preclinical T68383 TARGETID T68383 T68383 FORMERID TTDI01983 T68383 UNIPROID BMP2_HUMAN T68383 TARGNAME Bone morphogenetic protein 2 (BMP2) T68383 GENENAME BMP2 T68383 TARGTYPE Clinical trial T68383 SYNONYMS Bone morphogenetic protein 2A; BMP2A; BMP-2A; BMP-2 T68383 FUNCTION Stimulates the differentiation of myoblasts into osteoblasts via the EIF2AK3-EIF2A- ATF4 pathway. BMP2 activation of EIF2AK3 stimulates phosphorylation of EIF2A which leads to increased expression of ATF4 which plays a central role in osteoblast differentiation. In addition stimulates TMEM119, which upregulates the expression of ATF4. Induces cartilage and bone formation. T68383 PDBSTRUC 6OMN; 4UI2; 4UI1; 4UI0; 4UHZ T68383 BIOCLASS Growth factor T68383 SEQUENCE MVAGTRCLLALLLPQVLLGGAAGLVPELGRRKFAAASSGRPSSQPSDEVLSEFELRLLSMFGLKQRPTPSRDAVVPPYMLDLYRRHSGQPGSPAPDHRLERAASRANTVRSFHHEESLEELPETSGKTTRRFFFNLSSIPTEEFITSAELQVFREQMQDALGNNSSFHHRINIYEIIKPATANSKFPVTRLLDTRLVNQNASRWESFDVTPAVMRWTAQGHANHGFVVEVAHLEEKQGVSKRHVRISRSLHQDEHSWSQIRPLLVTFGHDGKGHPLHKREKRQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR T68383 DRUGINFO D03HDV DWP-431 Phase 3 T07507 TARGETID T07507 T07507 FORMERID TTDI02131 T07507 UNIPROID MYH7_HUMAN T07507 TARGNAME Myosin-7 (MYH7) T07507 GENENAME MYH7 T07507 TARGTYPE Clinical trial T07507 SYNONYMS Myosin heavy chain, cardiac muscle beta isoform; Myosin heavy chain slow isoform; Myosin heavy chain 7; MyHCslow; MyHCbeta; MYH7 T07507 FUNCTION Muscle contraction. T07507 PDBSTRUC 5WME; 5WLZ; 5WLQ; 5WJB; 5WJ7 T07507 BIOCLASS TRAFAC class myosin-kinesin ATPase T07507 SEQUENCE MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE T07507 DRUGINFO D0YO5Z UshStat Phase 1/2 T16263 TARGETID T16263 T16263 FORMERID TTDI02037 T16263 UNIPROID CCL5_HUMAN T16263 TARGNAME T-cell-specific protein RANTES (CCL5) T16263 GENENAME CCL5 T16263 TARGTYPE Clinical trial T16263 SYNONYMS Tcellspecific protein RANTES; TCP228; T cellspecific protein P228; T cell-specific protein P228; Smallinducible cytokine A5; Small-inducible cytokine A5; SISdelta; SIS-delta; SCYA5; RANTES(468); Eosinophil chemotactic cytokine; EoCP; D17S136E; CC motif chemokine 5; C-C motif chemokine 5 T16263 FUNCTION Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils. May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells. Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. T16263 PDBSTRUC 6FGP; 6C6D; 5UIW; 5L2U; 5DNF T16263 BIOCLASS Cytokine: CC chemokine T16263 SEQUENCE MKVSAAALAVILIATALCAPASASPYSSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS T16263 DRUGINFO D02MVA NI-0701 Phase 1 T86130 TARGETID T86130 T86130 FORMERID TTDI01797 T86130 UNIPROID ITA4_HUMAN-ITB1_HUMAN T86130 TARGNAME Integrin alpha-4/beta-1 (ITGA4/B1) T86130 GENENAME ITGA4-ITGB1 T86130 TARGTYPE Clinical trial T86130 SYNONYMS alpha(4)beta(1) integrin; Alpha 4 beta 1 integrin T86130 FUNCTION Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha- 4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha- 4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. T86130 BIOCLASS Integrin T86130 SEQUENCE MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD T86130 DRUGINFO D0M1WU AJM-300 Phase 3 T86130 DRUGINFO D04YJN R411 Phase 2 T86130 DRUGINFO D08MJO CDP323 Phase 2 T86130 DRUGINFO D0H8FY Firategrast Phase 2 T86130 DRUGINFO D0A2KH TRK-170 Phase 2 T86130 DRUGINFO D0L3DC HMR-1031 Phase 1 T86130 DRUGINFO D9XS2Y BIIB107 Phase 1 T86130 DRUGINFO D02WII TR-14035 Discontinued in Phase 1 T86130 DRUGINFO D0A1GJ CY-9652 Terminated T86130 DRUGINFO D08XWS TCS2314 Investigative T61729 TARGETID T61729 T61729 FORMERID TTDI01991 T61729 UNIPROID P4HA1_HUMAN T61729 TARGNAME Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1) T61729 GENENAME P4HA1 T61729 TARGTYPE Clinical trial T61729 SYNONYMS Prolyl 4-hydroxylase subunit alpha-1; Procollagenproline,2oxoglutarate4dioxygenase subunit alpha1; Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1; P4HA; 4PH alpha1; 4-PH alpha-1 T61729 FUNCTION Catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins. T61729 PDBSTRUC 4BTB; 4BTA; 4BT9; 4BT8; 2YQ8 T61729 BIOCLASS Paired donor oxygen oxidoreductase T61729 ECNUMBER EC 1.14.11.2 T61729 SEQUENCE MIWYILIIGILLPQSLAHPGFFTSIGQMTDLIHTEKDLVTSLKDYIKAEEDKLEQIKKWAEKLDRLTSTATKDPEGFVGHPVNAFKLMKRLNTEWSELENLVLKDMSDGFISNLTIQRQYFPNDEDQVGAAKALLRLQDTYNLDTDTISKGNLPGVKHKSFLTAEDCFELGKVAYTEADYYHTELWMEQALRQLDEGEISTIDKVSVLDYLSYAVYQQGDLDKALLLTKKLLELDPEHQRANGNLKYFEYIMAKEKDVNKSASDDQSDQKTTPKKKGVAVDYLPERQKYEMLCRGEGIKMTPRRQKKLFCRYHDGNRNPKFILAPAKQEDEWDKPRIIRFHDIISDAEIEIVKDLAKPRLRRATISNPITGDLETVHYRISKSAWLSGYENPVVSRINMRIQDLTGLDVSTAEELQVANYGVGGQYEPHFDFARKDEPDAFKELGTGNRIATWLFYMSDVSAGGATVFPEVGASVWPKKGTAVFWYNLFASGEGDYSTRHAACPVLVGNKWVSNKWLHERGQEFRRPCTLSELE T61729 DRUGINFO D01NCH Lufironil Phase 2 T61729 DRUGINFO D0P2BD SAFIRONIL Phase 1 T65889 TARGETID T65889 T65889 FORMERID TTDI02110 T65889 UNIPROID KPYM_HUMAN T65889 TARGNAME Pyruvate kinase M2 (PKM) T65889 GENENAME PKM T65889 TARGTYPE Clinical trial T65889 SYNONYMS p58; Tumor M2-PK; Thyroid hormone-binding protein 1; THBP1; Pyruvate kinase muscle isozyme; Pyruvate kinase isozymes M1/M2; Pyruvate kinase PKM; Pyruvate kinase 2/3; PKM2; PK3; PK2; Opa-interacting protein 3; OIP3; OIP-3; Cytosolic thyroid hormone-binding protein; CTHBP T65889 FUNCTION Stimulates POU5F1-mediated transcriptional activation. Plays a general role in caspase independent cell death of tumor cells. The ratio between the highly active tetrameric form and nearly inactive dimeric form determines whether glucose carbons are channeled to biosynthetic processes or used for glycolytic ATP production. The transition between the 2 forms contributes to the control of glycolysis and is important for tumor cell proliferation and survival. Promotes in a STAT1-dependent manner, the expression of the immune checkpoint protein CD274 in ARNTL/BMAL1-deficient macrophages. Glycolytic enzyme that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating ATP. T65889 PDBSTRUC 6GG6; 6GG5; 6GG4; 6B6U; 5X1W T65889 BIOCLASS Kinase T65889 ECNUMBER EC 2.7.1.40 T65889 SEQUENCE MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPVP T65889 DRUGINFO D09EFC CAP-232 Phase 2a T65889 DRUGINFO DLN0P8 TP-1454 Phase 1 T67658 TARGETID T67658 T67658 FORMERID TTDR00776 T67658 UNIPROID GLUT4_HUMAN T67658 TARGNAME Glucose transporter type 4 (SLC2A4) T67658 GENENAME SLC2A4 T67658 TARGTYPE Clinical trial T67658 SYNONYMS Solute carrier family 2, facilitated glucose transporter member 4; Glut4 protein; Glucose transporter type 4, insulin-responsive; GLUT4; GLUT-4 T67658 FUNCTION Insulin-regulated facilitative glucose transporter. T67658 BIOCLASS Major facilitator T67658 SEQUENCE MPSGFQQIGSEDGEPPQQRVTGTLVLAVFSAVLGSLQFGYNIGVINAPQKVIEQSYNETWLGRQGPEGPSSIPPGTLTTLWALSVAIFSVGGMISSFLIGIISQWLGRKRAMLVNNVLAVLGGSLMGLANAAASYEMLILGRFLIGAYSGLTSGLVPMYVGEIAPTHLRGALGTLNQLAIVIGILIAQVLGLESLLGTASLWPLLLGLTVLPALLQLVLLPFCPESPRYLYIIQNLEGPARKSLKRLTGWADVSGVLAELKDEKRKLERERPLSLLQLLGSRTHRQPLIIAVVLQLSQQLSGINAVFYYSTSIFETAGVGQPAYATIGAGVVNTVFTLVSVLLVERAGRRTLHLLGLAGMCGCAILMTVALLLLERVPAMSYVSIVAIFGFVAFFEIGPGPIPWFIVAELFSQGPRPAAMAVAGFSNWTSNFIIGMGFQYVAEAMGPYVFLLFAVLLLGFFIFTFLRVPETRGRTFDQISAAFHRTPSLLEQEVKPSTELEYLGPDEND T67658 DRUGINFO D03UZC DS-1150b Phase 1 T93283 TARGETID T93283 T93283 UNIPROID PPAP_HUMAN T93283 TARGNAME Prostatic acid phosphatase (ACPP) T93283 GENENAME ACPP T93283 TARGTYPE Clinical trial T93283 SYNONYMS Thiamine monophosphatase; TMPase; PAP T93283 FUNCTION A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins. Has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma. T93283 PDBSTRUC 3PPD; 2MG0; 2L79; 2L77; 2L3H T93283 ECNUMBER EC 3.1.3.2 T93283 SEQUENCE MRAAPLLLARAASLSLGFLFLLFFWLDRSVLAKELKFVTLVFRHGDRSPIDTFPTDPIKESSWPQGFGQLTQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNLAALFPPEGVSIWNPILLWQPIPVHTVPLSEDQLLYLPFRNCPRFQELESETLKSEEFQKRLHPYKDFIATLGKLSGLHGQDLFGIWSKVYDPLYCESVHNFTLPSWATEDTMTKLRELSELSLLSLYGIHKQKEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMYSAHDTTVSGLQMALDVYNGLLPPYASCHLTELYFEKGEYFVEMYYRNETQHEPYPLMLPGCSPSCPLERFAELVGPVIPQDWSTECMTTNSHQGTEDSTD T93283 DRUGINFO D09PGG MVI-816 Phase 2 T18779 TARGETID T18779 T18779 FORMERID TTDR00730 T18779 UNIPROID MUC1_HUMAN T18779 TARGNAME Mucin-1 (MUC1) T18779 GENENAME MUC1 T18779 TARGTYPE Clinical trial T18779 SYNONYMS Tumour-associated antigen mucin 1; Tumor-associated mucin; Tumor-associated epithelial membraneantigen; Tumor-associated epithelial membrane antigen; Polymorphic epithelial mucin; Peanut-reactive urinary mucin; PUM; PEMT; PEM; MUC-1; Krebs von den Lungen-6; KL-6; H23AG; Episialin; EMA; Carcinoma-associated mucin; Cancer antigen 15-3; CD227 antigen; CD227; CA 15-3; Breast carcinoma-associated antigen DF3 T18779 FUNCTION Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack. The alpha subunit has cell adhesive properties. T18779 PDBSTRUC 6FZR; 6FZQ; 5T78; 5T6P; 2FO4 T18779 SEQUENCE MTPGTQSPFFLLLLLTVLTVVTGSGHASSTPGGEKETSATQRSSVPSSTEKNAVSMTSSVLSSHSPGSGSSTTQGQDVTLAPATEPASGSAATWGQDVTSVPVTRPALGSTTPPAHDVTSAPDNKPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDNRPALGSTAPPVHNVTSASGSASGSASTLVHNGTSARATTTPASKSTPFSIPSHHSDTPTTLASHSTKTDASSTHHSSVPPLTSSNHSTSPQLSTGVSFFFLSFHISNLQFNSSLEDPSTDYYQELQRDISEMFLQIYKQGGFLGLSNIKFRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISDVSVSDVPFPFSAQSGAGVPGWGIALLVLVCVLVALAIVYLIALAVCQCRRKNYGQLDIFPARDTYHPMSEYPTYHTHGRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPAVAATSANL T18779 DRUGINFO D0V2KR Yttrium (90Y) clivatuzumab tetraxetan Phase 3 T18779 DRUGINFO D0ZW3R TG-4010 Phase 2/3 T18779 DRUGINFO D01YGD ICO-25 Phase 2 T18779 DRUGINFO D02HKC MUC1-Poly-ICLC Phase 2 T18779 DRUGINFO D04VOE AS-1402 Phase 2 T18779 DRUGINFO D05BPD Emepepimut-S Phase 2 T18779 DRUGINFO D07OAD GO-203-2c Phase 2 T18779 DRUGINFO D0G5YR SAR-566658 Phase 2 T18779 DRUGINFO D0T1KL Pankomab-GEX Phase 2 T18779 DRUGINFO D04UFI ImMucin Phase 1/2 T18779 DRUGINFO D04WHM G0-203-2c Phase 1/2 T18779 DRUGINFO D05CSS CAR-T cells targeting MucI Phase 1/2 T18779 DRUGINFO D08WII Anti-MUC1 CAR T Cells Phase 1/2 T18779 DRUGINFO D09KWN Anti-MUC1 CAR-T cells Phase 1/2 T18779 DRUGINFO D0AI7H Anti-MUC1 CAR T Cells Phase 1/2 T18779 DRUGINFO D0C9MJ Anti-MUC1 CAR-T cells Phase 1/2 T18779 DRUGINFO D0IN7R MUC-1 CART cell immunotherapy Phase 1/2 T18779 DRUGINFO D0IQ3E Muc1-specific gene-engineered T cells Phase 1/2 T18779 DRUGINFO D0M5JC BrevaRex Phase 1/2 T18779 DRUGINFO D0R1BA CAR-T cells targeting Muc1 Phase 1/2 T18779 DRUGINFO D04CYD ONT-10 Phase 1 T18779 DRUGINFO D06URX CAR-T Cells targeting MUCI Phase 1 T18779 DRUGINFO D0DJ8S CART-Muc1 cells Phase 1 T18779 DRUGINFO D0H2CF Anti-MUC1 mab Phase 1 T18779 DRUGINFO D0NU9N CAR-T cells targeting MUC1 Phase 1 T18779 DRUGINFO D0O0RG MUC-1 dendritic cancer vaccine Phase 1 T18779 DRUGINFO DKGB36 TnMUC-1 CAR-T cell therapy Phase 1 T18779 DRUGINFO DRZ1J4 HuMNC2-CAR44 T cells Phase 1 T18779 DRUGINFO D0JW9E CAR-T cells targeting Mucl Preclinical T18779 DRUGINFO D0GF2L TG-1031 Investigative T26226 TARGETID T26226 T26226 FORMERID TTDC00333 T26226 UNIPROID PRLR_HUMAN T26226 TARGNAME Prolactin receptor (PRLR) T26226 GENENAME PRLR T26226 TARGTYPE Clinical trial T26226 SYNONYMS PRL-R T26226 FUNCTION Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. Isoform 6 is unable to transduce prolactin signaling. This is a receptor for the anterior pituitary hormone prolactin (PRL). T26226 PDBSTRUC 4I18; 3NCF; 3NCE; 3NCC; 3NCB T26226 BIOCLASS Cytokine receptor T26226 SEQUENCE MKENVASATVFTLLLFLNTCLLNGQLPPGKPEIFKCRSPNKETFTCWWRPGTDGGLPTNYSLTYHREGETLMHECPDYITGGPNSCHFGKQYTSMWRTYIMMVNATNQMGSSFSDELYVDVTYIVQPDPPLELAVEVKQPEDRKPYLWIKWSPPTLIDLKTGWFTLLYEIRLKPEKAAEWEIHFAGQQTEFKILSLHPGQKYLVQVRCKPDHGYWSAWSPATFIQIPSDFTMNDTTVWISVAVLSAVICLIIVWAVALKGYSMVTCIFPPVPGPKIKGFDAHLLEKGKSEELLSALGCQDFPPTSDYEDLLVEYLEVDDSEDQHLMSVHSKEHPSQGMKPTYLDPDTDSGRGSCDSPSLLSEKCEEPQANPSTFYDPEVIEKPENPETTHTWDPQCISMEGKIPYFHAGGSKCSTWPLPQPSQHNPRSSYHNITDVCELAVGPAGAPATLLNEAGKDALKSSQTIKSREEGKATQQREVESFHSETDQDTPWLLPQEKTPFGSAKPLDYVEIHKVNKDGALSLLPKQRENSGKPKKPGTPENNKEYAKVSGVMDNNILVLVPDPHAKNVACFEESAKEAPPSLEQNQAEKALANFTATSSKCRLQLGGLDYLDPACFTHSFH T26226 DRUGINFO D0V6AH Endostatin Phase 2 T26226 DRUGINFO D0F1ZB LFA-102 Phase 1 T26226 DRUGINFO D0J1OG Prolanta Phase 1 T12409 TARGETID T12409 T12409 FORMERID TTDR00753 T12409 UNIPROID GLMS_ECOLI T12409 TARGNAME Bacterial Glucosamine-6-phosphate synthase (Bact glmS) T12409 GENENAME Bact glmS T12409 TARGTYPE Clinical trial T12409 SYNONYMS glmS; L-glutamine-D-fructose-6-phosphate amidotransferase; Hexosephosphate aminotransferase; Glucosamine--fructose-6-phosphate aminotransferase; GFAT; D-fructose-6-phosphate amidotransferase T12409 FUNCTION Catalyzesthe first step in hexosamine metabolism, converting fructose-6P into glucosamine-6P using glutamine as a nitrogen source. T12409 PDBSTRUC 4AMV; 3OOJ; 2VF5; 2VF4; 2J6H T12409 BIOCLASS Transaminase T12409 ECNUMBER EC 2.6.1.16 T12409 SEQUENCE MCGIVGAIAQRDVAEILLEGLRRLEYRGYDSAGLAVVDAEGHMTRLRRLGKVQMLAQAAEEHPLHGGTGIAHTRWATHGEPSEVNAHPHVSEHIVVVHNGIIENHEPLREELKARGYTFVSETDTEVIAHLVNWELKQGGTLREAVLRAIPQLRGAYGTVIMDSRHPDTLLAARSGSPLVIGLGMGENFIASDQLALLPVTRRFIFLEEGDIAEITRRSVNIFDKTGAEVKRQDIESNLQYDAGDKGIYRHYMQKEIYEQPNAIKNTLTGRISHGQVDLSELGPNADELLSKVEHIQILACGTSYNSGMVSRYWFESLAGIPCDVEIASEFRYRKSAVRRNSLMITLSQSGETADTLAGLRLSKELGYLGSLAICNVPGSSLVRESDLALMTNAGTEIGVASTKAFTTQLTVLLMLVAKLSRLKGLDASIEHDIVHGLQALPSRIEQMLSQDKRIEALAEDFSDKHHALFLGRGDQYPIALEGALKLKEISYIHAEAYAAGELKHGPLALIDADMPVIVVAPNNELLEKLKSNIEEVRARGGQLYVFADQDAGFVSSDNMHIIEMPHVEEVIAPIFYTVPLQLLAYHVALIKGTDVDQPRNLAKSVTVE T12409 DRUGINFO D05TIS Glucose-6-Phosphate Phase 1 T12409 DRUGINFO D0G9LM Glutamine Hydroxamate Investigative T12409 DRUGINFO D0O1LW 2-Deoxy-2-Amino Glucitol-6-Phosphate Investigative T12409 DRUGINFO D0Y8PY Glucosamine 6-Phosphate Investigative T12409 DRUGINFO D01AWD Alpha-D-Glucose-6-Phosphate Investigative T12409 DRUGINFO D07KZA 2-(N-Morpholino)-Ethanesulfonic Acid Investigative T12409 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T12409 DRUGINFO D0F2ME Acetate Ion Investigative T95371 TARGETID T95371 T95371 FORMERID TTDNC00373 T95371 UNIPROID INAR1_HUMAN T95371 TARGNAME Interferon alpha/beta receptor 1 (IFNAR1) T95371 GENENAME IFNAR1 T95371 TARGTYPE Clinical trial T95371 SYNONYMS Type I interferon receptor 1; IFNalpha/beta receptor 1; IFNR1; IFNAR; IFN-alpha/beta receptor 1; IFN-R-1; Cytokine receptor family 2 member 1; Cytokine receptor classII member 1; Cytokine receptor class-II member 1; CRF21; CRF2-1 T95371 FUNCTION Functions in general as heterodimer with IFNAR2. Type I interferon binding activates the JAK-STAT signaling cascade, and triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and the IFNR alpha- and beta-subunits themselves. Can form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway. Component of the receptor for type I interferons, including interferons alpha, IFNB1 and IFNW1. T95371 PDBSTRUC 4PO6; 3SE4; 3SE3; 3S98 T95371 BIOCLASS Cytokine receptor T95371 SEQUENCE MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVTFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSFTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERIENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQKGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTPVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSVFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDEYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSNEDESESKTSEELQQDFV T95371 DRUGINFO D02VBL EMZ701 Phase 2 T95371 DRUGINFO D06TME MEDI-546 Phase 2 T95371 DRUGINFO D0B3RL R-IFN-1a Phase 2 T95371 DRUGINFO D0C3VQ Zadaxin/lamivudine Phase 2 T95371 DRUGINFO D05ODU Belerofon Phase 1 T95371 DRUGINFO D00LXD Omega interferon Discontinued in Phase 2 T95371 DRUGINFO D0F0MU BLX-883 Discontinued in Phase 1 T95371 DRUGINFO D04TXB Ceplene/Peg-Intron/Rebetol Investigative T97353 TARGETID T97353 T97353 FORMERID TTDI01786 T97353 UNIPROID ITA2_HUMAN-ITB1_HUMAN T97353 TARGNAME Integrin alpha-2/beta-1 (ITGA2/B1) T97353 GENENAME ITGA2-ITGB1 T97353 TARGTYPE Clinical trial T97353 SYNONYMS alpha(2)beta(1) integrin; Integrin alpha(2)beta(1); Alpha 2 beta 1 integrin T97353 FUNCTION Integrin alpha-2/beta-1 isa receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-cadherin. It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. It is responsible for adhesion of platelets and other cells to collagens, modulation of collagen and collagenase gene expression, force generation and organization of newly synthesized extracellular matrix. T97353 BIOCLASS Integrin T97353 SEQUENCE MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMGPERTGAAPLPLLLVLALSQGILNCCLAYNVGLPEAKIFSGPSSEQFGYAVQQFINPKGNWLLVGSPWSGFPENRMGDVYKCPVDLSTATCEKLNLQTSTSIPNVTEMKTNMSLGLILTRNMGTGGFLTCGPLWAQQCGNQYYTTGVCSDISPDFQLSASFSPATQPCPSLIDVVVVCDESNSIYPWDAVKNFLEKFVQGLDIGPTKTQVGLIQYANNPRVVFNLNTYKTKEEMIVATSQTSQYGGDLTNTFGAIQYARKYAYSAASGGRRSATKVMVVVTDGESHDGSMLKAVIDQCNHDNILRFGIAVLGYLNRNALDTKNLIKEIKAIASIPTERYFFNVSDEAALLEKAGTLGEQIFSIEGTVQGGDNFQMEMSQVGFSADYSSQNDILMLGAVGAFGWSGTIVQKTSHGHLIFPKQAFDQILQDRNHSSYLGYSVAAISTGESTHFVAGAPRANYTGQIVLYSVNENGNITVIQAHRGDQIGSYFGSVLCSVDVDKDTITDVLLVGAPMYMSDLKKEEGRVYLFTIKKGILGQHQFLEGPEGIENTRFGSAIAALSDINMDGFNDVIVGSPLENQNSGAVYIYNGHQGTIRTKYSQKILGSDGAFRSHLQYFGRSLDGYGDLNGDSITDVSIGAFGQVVQLWSQSIADVAIEASFTPEKITLVNKNAQIILKLCFSAKFRPTKQNNQVAIVYNITLDADGFSSRVTSRGLFKENNERCLQKNMVVNQAQSCPEHIIYIQEPSDVVNSLDLRVDISLENPGTSPALEAYSETAKVFSIPFHKDCGEDGLCISDLVLDVRQIPAAQEQPFIVSNQNKRLTFSVTLKNKRESAYNTGIVVDFSENLFFASFSLPVDGTEVTCQVAASQKSVACDVGYPALKREQQVTFTINFDFNLQNLQNQASLSFQALSESQEENKADNLVNLKIPLLYDAEIHLTRSTNINFYEISSDGNVPSIVHSFEDVGPKFIFSLKVTTGSVPVSMATVIIHIPQYTKEKNPLMYLTGVQTDKAGDISCNADINPLKIGQTSSSVSFKSENFRHTKELNCRTASCSNVTCWLKDVHMKGEYFVNVTTRIWNGTFASSTFQTVQLTAAAEINTYNPEIYVIEDNTVTIPLMIMKPDEKAEVPTGVIIGSIIAGILLLLALVAILWKLGFFKRKYEKMTKNPDEIDETTELSS T97353 DRUGINFO D0KN0I Valetizumab Phase 2 T97353 DRUGINFO D0R9IH SAR-339658 Phase 2 T97353 DRUGINFO D0X9UA Vatelizumab Phase 2 T97353 DRUGINFO D05CGH Evatak Investigative T97353 DRUGINFO D0XF7N TCI15 Investigative T44479 TARGETID T44479 T44479 FORMERID TTDR00293 T44479 UNIPROID CXA1_HUMAN T44479 TARGNAME Gap junction alpha-1 protein (GJA1) T44479 GENENAME GJA1 T44479 TARGTYPE Clinical trial T44479 SYNONYMS Gap junction 43 kDa heart protein; GJAL; Cx43; Connexin-43; Connexin 43 T44479 FUNCTION A gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. May play a critical role in the physiology of hearing by participating in the recycling of potassium to the cochlear endolymph. Negative regulator of bladder functional capacity: acts by enhancing intercellular electrical and chemical transmission, thus sensitizing bladder muscles to cholinergic neural stimuli and causing them to contract. May play a role in cell growth inhibition through the regulation of NOV expression and localization. Plays an essential role in gap junction communication in the ventricles. Gap junction protein that acts as a regulator of bladder capacity. T44479 PDBSTRUC 2LL2 T44479 BIOCLASS Gap junction-forming connexin T44479 SEQUENCE MGDWSALGKLLDKVQAYSTAGGKVWLSVLFIFRILLLGTAVESAWGDEQSAFRCNTQQPGCENVCYDKSFPISHVRFWVLQIIFVSVPTLLYLAHVFYVMRKEEKLNKKEEELKVAQTDGVNVDMHLKQIEIKKFKYGIEEHGKVKMRGGLLRTYIISILFKSIFEVAFLLIQWYIYGFSLSAVYTCKRDPCPHQVDCFLSRPTEKTIFIIFMLVVSLVSLALNIIELFYVFFKGVKDRVKGKSDPYHATSGALSPAKDCGSQKYAYFNGCSSPTAPLSPMSPPGYKLVTGDRNNSSCRNYNKQASEQNWANYSAEQNRMGQAGSTISNSHAQPFDFPDDNQNSKKLAAGHELQPLAIVDQRPSSRASSRASSRPRPDDLEI T44479 DRUGINFO D01NWV Granexin gel Phase 3 T44479 DRUGINFO D04WBT Act1 Phase 3 T44479 DRUGINFO DZEF27 HCB1019 Phase 2 T44479 DRUGINFO DXAI94 ALMB-0168 Phase 1/2 T44479 DRUGINFO DJR71Z ALMB-0166 Phase 1 T44479 DRUGINFO D00VJY octanol Investigative T51499 TARGETID T51499 T51499 FORMERID TTDI02169 T51499 UNIPROID SAP3_HUMAN T51499 TARGNAME Ganglioside GM2 activator (GM2A) T51499 GENENAME GM2A T51499 TARGTYPE Clinical trial T51499 SYNONYMS Sphingolipid activator protein 3; SAP3; Ganglioside GM2 activator isoform short; GM2AP; GM2A; Cerebroside sulfate activator protein T51499 FUNCTION The large binding pocket can accommodate severalsingle chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity. Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents them in soluble form to beta- hexosaminidase A forcleavage of N-acetyl-D-galactosamine and conversion to GM3. T51499 PDBSTRUC 2AG9; 2AG4; 2AG2; 2AF9; 1TJJ T51499 SEQUENCE MQSLMQAPLLIALGLLLAAPAQAHLKKPSQLSSFSWDNCDEGKDPAVIRSLTLEPDPIIVPGNVTLSVMGSTSVPLSSPLKVDLVLEKEVAGLWIKIPCTDYIGSCTFEHFCDVLDMLIPTGEPCPEPLRTYGLPCHCPFKEGTYSLPKSEFVVPDLELPSWLTTGNYRIESVLSSSGKRLGCIKIAASLKGI T51499 DRUGINFO D0N6TD BIW-8962 Phase 1/2 T48457 TARGETID T48457 T48457 FORMERID TTDR00734 T48457 UNIPROID CR1_HUMAN T48457 TARGNAME Complement receptor type 1 (CR1) T48457 GENENAME CR1 T48457 TARGTYPE Clinical trial T48457 SYNONYMS CR1; CD35 antigen; C3b/C4b receptor T48457 FUNCTION Mediates cellular binding of particles and immunecomplexes that have activated complement. T48457 PDBSTRUC 5FO9; 2Q7Z; 2MCZ; 2MCY; 1PPQ T48457 BIOCLASS Receptor of complement activation T48457 SEQUENCE MGASSPRSPEPVGPPAPGLPFCCGGSLLAVVVLLALPVAWGQCNAPEWLPFARPTNLTDEFEFPIGTYLNYECRPGYSGRPFSIICLKNSVWTGAKDRCRRKSCRNPPDPVNGMVHVIKGIQFGSQIKYSCTKGYRLIGSSSATCIISGDTVIWDNETPICDRIPCGLPPTITNGDFISTNRENFHYGSVVTYRCNPGSGGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPNKCTPPNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRVCQPPPDVLHAERTQRDKDNFSPGQEVFYSCEPGYDLRGAASMRCTPQGDWSPAAPTCEVKSCDDFMGQLLNGRVLFPVNLQLGAKVDFVCDEGFQLKGSSASYCVLAGMESLWNSSVPVCEQIFCPSPPVIPNGRHTGKPLEVFPFGKTVNYTCDPHPDRGTSFDLIGESTIRCTSDPQGNGVWSSPAPRCGILGHCQAPDHFLFAKLKTQTNASDFPIGTSLKYECRPEYYGRPFSITCLDNLVWSSPKDVCKRKSCKTPPDPVNGMVHVITDIQVGSRINYSCTTGHRLIGHSSAECILSGNAAHWSTKPPICQRIPCGLPPTIANGDFISTNRENFHYGSVVTYRCNPGSGGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPNKCTPPNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRVCQPPPDVLHAERTQRDKDNFSPGQEVFYSCEPGYDLRGAASMRCTPQGDWSPAAPTCEVKSCDDFMGQLLNGRVLFPVNLQLGAKVDFVCDEGFQLKGSSASYCVLAGMESLWNSSVPVCEQIFCPSPPVIPNGRHTGKPLEVFPFGKAVNYTCDPHPDRGTSFDLIGESTIRCTSDPQGNGVWSSPAPRCGILGHCQAPDHFLFAKLKTQTNASDFPIGTSLKYECRPEYYGRPFSITCLDNLVWSSPKDVCKRKSCKTPPDPVNGMVHVITDIQVGSRINYSCTTGHRLIGHSSAECILSGNTAHWSTKPPICQRIPCGLPPTIANGDFISTNRENFHYGSVVTYRCNLGSRGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPNKCTPPNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRVCQPPPEILHGEHTPSHQDNFSPGQEVFYSCEPGYDLRGAASLHCTPQGDWSPEAPRCAVKSCDDFLGQLPHGRVLFPLNLQLGAKVSFVCDEGFRLKGSSVSHCVLVGMRSLWNNSVPVCEHIFCPNPPAILNGRHTGTPSGDIPYGKEISYTCDPHPDRGMTFNLIGESTIRCTSDPHGNGVWSSPAPRCELSVRAGHCKTPEQFPFASPTIPINDFEFPVGTSLNYECRPGYFGKMFSISCLENLVWSSVEDNCRRKSCGPPPEPFNGMVHINTDTQFGSTVNYSCNEGFRLIGSPSTTCLVSGNNVTWDKKAPICEIISCEPPPTISNGDFYSNNRTSFHNGTVVTYQCHTGPDGEQLFELVGERSIYCTSKDDQVGVWSSPPPRCISTNKCTAPEVENAIRVPGNRSFFSLTEIIRFRCQPGFVMVGSHTVQCQTNGRWGPKLPHCSRVCQPPPEILHGEHTLSHQDNFSPGQEVFYSCEPSYDLRGAASLHCTPQGDWSPEAPRCTVKSCDDFLGQLPHGRVLLPLNLQLGAKVSFVCDEGFRLKGRSASHCVLAGMKALWNSSVPVCEQIFCPNPPAILNGRHTGTPFGDIPYGKEISYACDTHPDRGMTFNLIGESSIRCTSDPQGNGVWSSPAPRCELSVPAACPHPPKIQNGHYIGGHVSLYLPGMTISYICDPGYLLVGKGFIFCTDQGIWSQLDHYCKEVNCSFPLFMNGISKELEMKKVYHYGDYVTLKCEDGYTLEGSPWSQCQADDRWDPPLAKCTSRTHDALIVGTLSGTIFFILLIIFLSWIILKHRKGNNAHENPKEVAIHLHSQGGSSVHPRTLQTNEENSRVLP T48457 DRUGINFO D0T4NV CDX-1135 Phase 1 T72038 TARGETID T72038 T72038 FORMERID TTDR00804 T72038 UNIPROID LEG3_HUMAN T72038 TARGNAME Galectin-3 (LGALS3) T72038 GENENAME LGALS3 T72038 TARGTYPE Clinical trial T72038 SYNONYMS Mac-2 antigen; MAC2; Lectin L-29; Laminin-binding protein; L-31; IgE-binding protein; Galactoside-binding protein; Galactose-specific lectin 3; Gal-3; GALBP; Carbohydrate-binding protein 35; Carbohydrate binding protein 35; CBP 35; Beta-galactoside-binding protein LGALS3; 35 kDa lectin T72038 FUNCTION May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. Together with DMBT1, required for terminal differentiation of columnar epithelial cells during early embryogenesis. In the nucleus: acts as a pre-mRNA splicing factor. Involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells. Together with TRIM16, coordinates the recognition of membrane damage with mobilization of the core autophagy regulators ATG16L1 and BECN1 in response to damaged endomembranes. Galactose-specific lectin which binds IgE. T72038 PDBSTRUC 6QGF; 6QGE; 6I78; 6I77; 6I76 T72038 SEQUENCE MADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPPGAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI T72038 DRUGINFO D06BKH GR-MD-02 Phase 2 T72038 DRUGINFO DU5G2B GB0139 Phase 2 T72038 DRUGINFO DU5G2B GB0139 Phase 2 T72038 DRUGINFO D03CDB PFFFFF Investigative T72038 DRUGINFO D0HB9G 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide Investigative T07045 TARGETID T07045 T07045 FORMERID TTDI02210 T07045 UNIPROID PACA_HUMAN T07045 TARGNAME Pituitary adenylate cyclase-activating 38 (PACAP-38) T07045 GENENAME ADCYAP1 T07045 TARGTYPE Clinical trial T07045 SYNONYMS Pituitary adenylate cyclase-activating polypeptide; PACAP38; PACAP27; PACAP-38; PACAP-27; PACAP; ADCYAP1 T07045 FUNCTION Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells. Promotes neuron projection development through the RAPGEF2/Rap1/B-Raf/ERK pathway. T07045 PDBSTRUC 2JOD; 2D2P; 1GEA T07045 BIOCLASS Glucagon T07045 SEQUENCE HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK T07045 DRUGINFO D00EGU PACAP38 Phase 1 T16868 TARGETID T16868 T16868 FORMERID TTDC00137 T16868 UNIPROID CADH2_HUMAN T16868 TARGNAME Neural cadherin (CDH2) T16868 GENENAME CDH2 T16868 TARGTYPE Clinical trial T16868 SYNONYMS NCAD; N-cadherin; Cadherin-2; CDw325; CDHN; CD325 T16868 FUNCTION Cadherins may thus contribute to the sorting of heterogeneous cell types. Acts as a regulator of neural stem cells quiescence by mediating anchorage of neural stem cells to ependymocytes in the adult subependymal zone: upon cleavage by MMP24, CDH2-mediated anchorage is affected, leading to modulate neural stem cell quiescence. CDH2 may be involved in neuronal recognition mechanism. In hippocampal neurons, may regulate dendritic spine density. Calcium-dependent cell adhesion protein; preferentially mediates homotypic cell-cell adhesion by dimerization with a CDH2 chain from another cell. T16868 BIOCLASS Cadherin protein T16868 SEQUENCE MCRIAGALRTLLPLLAALLQASVEASGEIALCKTGFPEDVYSAVLSKDVHEGQPLLNVKFSNCNGKRKVQYESSEPADFKVDEDGMVYAVRSFPLSSEHAKFLIYAQDKETQEKWQVAVKLSLKPTLTEESVKESAEVEEIVFPRQFSKHSGHLQRQKRDWVIPPINLPENSRGPFPQELVRIRSDRDKNLSLRYSVTGPGADQPPTGIFIINPISGQLSVTKPLDREQIARFHLRAHAVDINGNQVENPIDIVINVIDMNDNRPEFLHQVWNGTVPEGSKPGTYVMTVTAIDADDPNALNGMLRYRIVSQAPSTPSPNMFTINNETGDIITVAAGLDREKVQQYTLIIQATDMEGNPTYGLSNTATAVITVTDVNDNPPEFTAMTFYGEVPENRVDIIVANLTVTDKDQPHTPAWNAVYRISGGDPTGRFAIQTDPNSNDGLVTVVKPIDFETNRMFVLTVAAENQVPLAKGIQHPPQSTATVSVTVIDVNENPYFAPNPKIIRQEEGLHAGTMLTTFTAQDPDRYMQQNIRYTKLSDPANWLKIDPVNGQITTIAVLDRESPNVKNNIYNATFLASDNGIPPMSGTGTLQIYLLDINDNAPQVLPQEAETCETPDPNSINITALDYDIDPNAGPFAFDLPLSPVTIKRNWTITRLNGDFAQLNLKIKFLEAGIYEVPIIITDSGNPPKSNISILRVKVCQCDSNGDCTDVDRIVGAGLGTGAIIAILLCIIILLILVLMFVVWMKRRDKERQAKQLLIDPEDDVRDNILKYDEEGGGEEDQDYDLSQLQQPDTVEPDAIKPVGIRRMDERPIHAEPQYPVRSAAPHPGDIGDFINEGLKAADNDPTAPPYDSLLVFDYEGSGSTAGSLSSLNSSSSGGEQDYDYLNDWGPRFKKLADMYGGGDD T16868 DRUGINFO D0KK9E Exherin Phase 2 T06475 TARGETID T06475 T06475 FORMERID TTDR00575 T06475 UNIPROID NUCL_HUMAN T06475 TARGNAME Nucleolin (NCL) T06475 GENENAME NCL T06475 TARGTYPE Clinical trial T06475 SYNONYMS Protein C23 T06475 FUNCTION It is found associated with intranucleolar chromatin and pre-ribosomal particles. It induces chromatin decondensation by binding to histone H1. It is thought to play a role in pre-rRNA transcription and ribosome assembly. May play a role in the process of transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats. Nucleolin is the major nucleolar protein of growing eukaryotic cells. T06475 PDBSTRUC 2KRR; 2FC9; 2FC8 T06475 SEQUENCE MVKLAKAGKNQGDPKKMAPPPKEVEEDSEDEEMSEDEEDDSSGEEVVIPQKKGKKAAATSAKKVVVSPTKKVAVATPAKKAAVTPGKKAAATPAKKTVTPAKAVTTPGKKGATPGKALVATPGKKGAAIPAKGAKNGKNAKKEDSDEEEDDDSEEDEEDDEDEDEDEDEIEPAAMKAAAAAPASEDEDDEDDEDDEDDDDDEEDDSEEEAMETTPAKGKKAAKVVPVKAKNVAEDEDEEEDDEDEDDDDDEDDEDDDDEDDEEEEEEEEEEPVKEAPGKRKKEMAKQKAAPEAKKQKVEGTEPTTAFNLFVGNLNFNKSAPELKTGISDVFAKNDLAVVDVRIGMTRKFGYVDFESAEDLEKALELTGLKVFGNEIKLEKPKGKDSKKERDARTLLAKNLPYKVTQDELKEVFEDAAEIRLVSKDGKSKGIAYIEFKTEADAEKTFEEKQGTEIDGRSISLYYTGEKGQNQDYRGGKNSTWSGESKTLVLSNLSYSATEETLQEVFEKATFIKVPQNQNGKSKGYAFIEFASFEDAKEALNSCNKREIEGRAIRLELQGPRGSPNARSQPSKTLFVKGLSEDTTEETLKESFDGSVRARIVTDRETGSSKGFGFVDFNSEEDAKAAKEAMEDGEIDGNKVTLDWAKPKGEGGFGGRGGGRGGFGGRGGGRGGRGGFGGRGRGGFGGRGGFRGGRGGGGDHKPQGKKTKFE T06475 DRUGINFO D06XBN ACT-GRO-777 Phase 2 T06475 DRUGINFO D09ENR Itarnafloxin Phase 2 T06475 DRUGINFO D0Z1OR IPP-204106 Phase 1/2 T40192 TARGETID T40192 T40192 FORMERID TTDI01966 T40192 UNIPROID NFKB1_HUMAN T40192 TARGNAME DNA-binding factor KBF1 (p105) T40192 GENENAME NFKB1 T40192 TARGTYPE Clinical trial T40192 SYNONYMS Nuclear factor of kappa light polypeptide gene enhancer in Bcells 1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; Nuclear factor NFkappaB p50 subunit; Nuclear factor NFkappaB p105 subunit; Nuclear factor NF-kappa-B p105 subunit; EBP1; EBP-1; DNAbinding factor KBF1 T40192 FUNCTION NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105. NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. T40192 PDBSTRUC 3GUT; 2O61; 2DBF; 1SVC; 1NFI T40192 SEQUENCE MAEDDPYLGRPEQMFHLDPSLTHTIFNPEVFQPQMALPTDGPYLQILEQPKQRGFRFRYVCEGPSHGGLPGASSEKNKKSYPQVKICNYVGPAKVIVQLVTNGKNIHLHAHSLVGKHCEDGICTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACIRGYNPGLLVHPDLAYLQAEGGGDRQLGDREKELIRQAALQQTKEMDLSVVRLMFTAFLPDSTGSFTRRLEPVVSDAIYDSKAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGFGDFSPTDVHRQFAIVFKTPKYKDINITKPASVFVQLRRKSDLETSEPKPFLYYPEIKDKEEVQRKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGGTGSTGPGYSFPHYGFPTYGGITFHPGTTKSNAGMKHGTMDTESKKDPEGCDKSDDKNTVNLFGKVIETTEQDQEPSEATVGNGEVTLTYATGTKEESAGVQDNLFLEKAMQLAKRHANALFDYAVTGDVKMLLAVQRHLTAVQDENGDSVLHLAIIHLHSQLVRDLLEVTSGLISDDIINMRNDLYQTPLHLAVITKQEDVVEDLLRAGADLSLLDRLGNSVLHLAAKEGHDKVLSILLKHKKAALLLDHPNGDGLNAIHLAMMSNSLPCLLLLVAAGADVNAQEQKSGRTALHLAVEHDNISLAGCLLLEGDAHVDSTTYDGTTPLHIAAGRGSTRLAALLKAAGADPLVENFEPLYDLDDSWENAGEDEGVVPGTTPLDMATSWQVFDILNGKPYEPEFTSDDLLAQGDMKQLAEDVKLQLYKLLEIPDPDKNWATLAQKLGLGILNNAFRLSPAPSKTLMDNYEVSGGTVRELVEALRQMGYTEAIEVIQAASSPVKTTSQAHSLPLSPASTRQQIDELRDSDSVCDSGVETSFRKLSFTESLTSGASLLTLNKMPHDYGQEGPLEGKI T40192 DRUGINFO D0V3LM P54 Phase 2 T40192 DRUGINFO D06TZZ CAT 1004 Phase 2 T37808 TARGETID T37808 T37808 FORMERID TTDC00029 T37808 UNIPROID ANPRB_HUMAN T37808 TARGNAME Atrial natriuretic peptide receptor B (NPR2) T37808 GENENAME NPR2 T37808 TARGTYPE Clinical trial T37808 SYNONYMS NPR-B; Guanylate cyclase B; GC-B; Atrial natriuretic peptide receptor type B; Atrial natriuretic peptide receptor 2; ANPRB; ANPR-B; ANP-B T37808 FUNCTION Receptor for the C-type natriuretic peptide NPPC/CNP hormone. Has guanylate cyclase activity upon binding of its ligand. May play a role in the regulation of skeletal growth. T37808 BIOCLASS Phosphorus-oxygen lyase T37808 ECNUMBER EC 4.6.1.2 T37808 SEQUENCE MALPSLLLLVAALAGGVRPPGARNLTLAVVLPEHNLSYAWAWPRVGPAVALAVEALGRALPVDLRFVSSELEGACSEYLAPLSAVDLKLYHDPDLLLGPGCVYPAASVARFASHWRLPLLTAGAVASGFSAKNDHYRTLVRTGPSAPKLGEFVVTLHGHFNWTARAALLYLDARTDDRPHYFTIEGVFEALQGSNLSVQHQVYAREPGGPEQATHFIRANGRIVYICGPLEMLHEILLQAQRENLTNGDYVFFYLDVFGESLRAGPTRATGRPWQDNRTREQAQALREAFQTVLVITYREPPNPEYQEFQNRLLIRAREDFGVELGPSLMNLIAGCFYDGILLYAEVLNETIQEGGTREDGLRIVEKMQGRRYHGVTGLVVMDKNNDRETDFVLWAMGDLDSGDFQPAAHYSGAEKQIWWTGRPIPWVKGAPPSDNPPCAFDLDDPSCDKTPLSTLAIVALGTGITFIMFGVSSFLIFRKLMLEKELASMLWRIRWEELQFGNSERYHKGAGSRLTLSLRGSSYGSLMTAHGKYQIFANTGHFKGNVVAIKHVNKKRIELTRQVLFELKHMRDVQFNHLTRFIGACIDPPNICIVTEYCPRGSLQDILENDSINLDWMFRYSLINDLVKGMAFLHNSIISSHGSLKSSNCVVDSRFVLKITDYGLASFRSTAEPDDSHALYAKKLWTAPELLSGNPLPTTGMQKADVYSFGIILQEIALRSGPFYLEGLDLSPKEIVQKVRNGQRPYFRPSIDRTQLNEELVLLMERCWAQDPAERPDFGQIKGFIRRFNKEGGTSILDNLLLRMEQYANNLEKLVEERTQAYLEEKRKAEALLYQILPHSVAEQLKRGETVQAEAFDSVTIYFSDIVGFTALSAESTPMQVVTLLNDLYTCFDAIIDNFDVYKVETIGDAYMVVSGLPGRNGQRHAPEIARMALALLDAVSSFRIRHRPHDQLRLRIGVHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGQALKIHVSSTTKDALDELGCFQLELRGDVEMKGKGKMRTYWLLGERKGPPGLL T03556 TARGETID T03556 T03556 FORMERID TTDR00268 T03556 UNIPROID HNF1A_HUMAN T03556 TARGNAME Hepatocyte nuclear factor 1-alpha (HNF1A) T03556 GENENAME HNF1A T03556 TARGTYPE Clinical trial T03556 SYNONYMS Transcription factor-1; Transcription factor 1; TCF1; TCF-1; Liver-specific transcription factor LF-B1; Liver specific transcription factor LF-B1; LFB1; HNF-1A; HNF-1-alpha; HNF-1 alpha T03556 FUNCTION Binds to the inverted palindrome 5'-GTTAATNATTAAC-3'. Activates the transcription of CYP1A2, CYP2E1 and CYP3A11. Transcriptional activator that regulates the tissue specific expression of multiple genes, especially in pancreatic islet cells and in liver. T03556 PDBSTRUC 2GYP; 1IC8 T03556 SEQUENCE MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ T03556 DRUGINFO D00EFT Norleucine Phase 1/2 T87831 TARGETID T87831 T87831 FORMERID TTDR00011 T87831 UNIPROID FPR1_HUMAN T87831 TARGNAME N-formyl peptide receptor (FPR1) T87831 GENENAME FPR1 T87831 TARGTYPE Clinical trial T87831 SYNONYMS N-formylpeptide chemoattractant receptor; FPR1; FPR T87831 FUNCTION High affinity receptor for N-formyl-methionyl peptides (fMLP), which are powerful neutrophil chemotactic factors (PubMed:2161213, PubMed:2176894, PubMed:10514456, PubMed:15153520). Binding of fMLP to the receptor stimulates intracellular calcium mobilization and superoxide anion release (PubMed:2161213, PubMed:1712023, PubMed:15153520). This response is mediated via a G-protein that activates a phosphatidylinositol- calcium second messenger system(PubMed:1712023, PubMed:10514456). T87831 BIOCLASS GPCR rhodopsin T87831 SEQUENCE METNSSLPTNISGGTPAVSAGYLFLDIITYLVFAVTFVLGVLGNGLVIWVAGFRMTHTVTTISYLNLAVADFCFTSTLPFFMVRKAMGGHWPFGWFLCKFVFTIVDINLFGSVFLIALIALDRCVCVLHPVWTQNHRTVSLAKKVIIGPWVMALLLTLPVIIRVTTVPGKTGTVACTFNFSPWTNDPKERINVAVAMLTVRGIIRFIIGFSAPMSIVAVSYGLIATKIHKQGLIKSSRPLRVLSFVAAAFFLCWSPYQVVALIATVRIRELLQGMYKEIGIAVDVTSALAFFNSCLNPMLYVFMGQDFRERLIHALPASLERALTEDSTQTSDTATNSTLPSAEVELQAK T87831 DRUGINFO D03BQP Rebamipide Phase 3 T87831 DRUGINFO D00OMW group E 1682-2106 Investigative T87831 DRUGINFO D00XGW BVT173187 Investigative T87831 DRUGINFO D01VFQ CGEN-855 Investigative T87831 DRUGINFO D01VLV AG-11/03 Investigative T87831 DRUGINFO D05UWQ methionine benzimidazole 6 Investigative T87831 DRUGINFO D09DAP AG-09/1 Investigative T87831 DRUGINFO D0G5DH diamide 7 Investigative T87831 DRUGINFO D0M9RF 3570-0208 Investigative T87831 DRUGINFO D0Q8TJ AG-14 Investigative T87831 DRUGINFO D01EOQ PMID22607879CR-(-)-5f Investigative T87831 DRUGINFO D0M0YH fMet-Leu-Phe Investigative T87831 DRUGINFO D0WB8E pyrazolone, 1 Investigative T99397 TARGETID T99397 T99397 UNIPROID VDAC1_HUMAN T99397 TARGNAME Voltage-dependent anion-selective channel 1 (VDAC1) T99397 GENENAME VDAC1 T99397 TARGTYPE Clinical trial T99397 SYNONYMS Porin 31HM; Porin 31HL; Plasmalemmal porin; Outer mitochondrial membrane protein porin 1 T99397 FUNCTION Forms a channel through the mitochondrial outer membrane and also the plasma membrane. The channel at the outer mitochondrial membrane allows diffusion of small hydrophilic molecules; in the plasma membrane it is involved in cell volume regulation and apoptosis. It adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV. The open state has a weak anion selectivity whereas the closed state is cation-selective (PubMed:11845315, PubMed:18755977, PubMed:20230784, PubMed:8420959). May participate in the formation of the permeability transition pore complex (PTPC) responsible for the release of mitochondrial products that triggers apoptosis (PubMed:15033708, PubMed:25296756). T99397 PDBSTRUC 6G73; 6G6U; 5XDO; 5XDN; 5JDP T99397 BIOCLASS Eukaryotic mitochondrial porin T99397 SEQUENCE MAVPPTYADLGKSARDVFTKGYGFGLIKLDLKTKSENGLEFTSSGSANTETTKVTGSLETKYRWTEYGLTFTEKWNTDNTLGTEITVEDQLARGLKLTFDSSFSPNTGKKNAKIKTGYKREHINLGCDMDFDIAGPSIRGALVLGYEGWLAGYQMNFETAKSRVTQSNFAVGYKTDEFQLHTNVNDGTEFGGSIYQKVNKKLETAVNLAWTAGNSNTRFGIAAKYQIDPDACFSAKVNNSSLIGLGYTQTLKPGIKLTLSALLDGKNVNAGGHKLGLGLEFQA T99397 DRUGINFO D06QBX VDA-1102 Phase 2 T83905 TARGETID T83905 T83905 FORMERID TTDI02034 T83905 UNIPROID CADH3_HUMAN T83905 TARGNAME Placental cadherin (CDH3) T83905 GENENAME CDH3 T83905 TARGTYPE Clinical trial T83905 SYNONYMS Pcadherin; P-cadherin; Cadherin-3; CDHP T83905 FUNCTION Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. T83905 PDBSTRUC 5JYM; 5JYL; 4ZMZ; 4ZMY; 4ZMX T83905 BIOCLASS Cadherin protein T83905 SEQUENCE MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGFILPVLGAVLALLFLLLVLLLLVRKKRKIKEPLLLPEDDTRDNVFYYGEEGGGEEDQDYDITQLHRGLEARPEVVLRNDVAPTIIPTPMYRPRPANPDEIGNFIIENLKAANTDPTAPPYDTLLVFDYEGSGSDAASLSSLTSSASDQDQDYDYLNEWGSRFKKLADMYGGGEDD T83905 DRUGINFO D0P9KD PF-3732010 Phase 1 T83905 DRUGINFO D0Y0HC PF-06671008 Phase 1 T57034 TARGETID T57034 T57034 FORMERID TTDI02155 T57034 UNIPROID PTPRB_HUMAN T57034 TARGNAME Protein tyrosine phosphatase beta (PTPRB) T57034 GENENAME PTPRB T57034 TARGTYPE Clinical trial T57034 SYNONYMS Vascular endothelial protein tyrosine phosphatase; VE-PTP; Receptor-type tyrosine-protein phosphatase beta; R-PTP-beta; PTPRB T57034 FUNCTION Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce dephosphorylation of TEK/TIE2, CDH5/VE-cadherin and KDR/VEGFR-2. Regulates angiopoietin-TIE2 signaling in endothelial cells. Acts as a negative regulator of TIE2, and controls TIE2 driven endothelial cell proliferation, which in turn affects blood vessel remodeling during embryonic development and determines blood vessel size during perinatal growth. Essential for the maintenance of endothelial cell contact integrity and for the adhesive function of VE-cadherin in endothelial cells and this requires the presence of plakoglobin. T57034 PDBSTRUC 2I5X; 2I4H; 2I4G; 2I4E; 2I3U T57034 BIOCLASS Phosphoric monoester hydrolase T57034 ECNUMBER EC 3.1.3.48 T57034 SEQUENCE MLSHGAGLALWITLSLLQTGLAEPERCNFTLAESKASSHSVSIQWRILGSPCNFSLIYSSDTLGAALCPTFRIDNTTYGCNLQDLQAGTIYNFRIISLDEERTVVLQTDPLPPARFGVSKEKTTSTSLHVWWTPSSGKVTSYEVQLFDENNQKIQGVQIQESTSWNEYTFFNLTAGSKYNIAITAVSGGKRSFSVYTNGSTVPSPVKDIGISTKANSLLISWSHGSGNVERYRLMLMDKGILVHGGVVDKHATSYAFHGLTPGYLYNLTVMTEAAGLQNYRWKLVRTAPMEVSNLKVTNDGSLTSLKVKWQRPPGNVDSYNITLSHKGTIKESRVLAPWITETHFKELVPGRLYQVTVSCVSGELSAQKMAVGRTFPDKVANLEANNNGRMRSLVVSWSPPAGDWEQYRILLFNDSVVLLNITVGKEETQYVMDDTGLVPGRQYEVEVIVESGNLKNSERCQGRTVPLAVLQLRVKHANETSLSIMWQTPVAEWEKYIISLADRDLLLIHKSLSKDAKEFTFTDLVPGRKYMATVTSISGDLKNSSSVKGRTVPAQVTDLHVANQGMTSSLFTNWTQAQGDVEFYQVLLIHENVVIKNESISSETSRYSFHSLKSGSLYSVVVTTVSGGISSRQVVVEGRTVPSSVSGVTVNNSGRNDYLSVSWLLAPGDVDNYEVTLSHDGKVVQSLVIAKSVRECSFSSLTPGRLYTVTITTRSGKYENHSFSQERTVPDKVQGVSVSNSARSDYLRVSWVHATGDFDHYEVTIKNKNNFIQTKSIPKSENECVFVQLVPGRLYSVTVTTKSGQYEANEQGNGRTIPEPVKDLTLRNRSTEDLHVTWSGANGDVDQYEIQLLFNDMKVFPPFHLVNTATEYRFTSLTPGRQYKILVLTISGDVQQSAFIEGFTVPSAVKNIHISPNGATDSLTVNWTPGGGDVDSYTVSAFRHSQKVDSQTIPKHVFEHTFHRLEAGEQYQIMIASVSGSLKNQINVVGRTVPASVQGVIADNAYSSYSLIVSWQKAAGVAERYDILLLTENGILLRNTSEPATTKQHKFEDLTPGKKYKIQILTVSGGLFSKEAQTEGRTVPAAVTDLRITENSTRHLSFRWTASEGELSWYNIFLYNPDGNLQERAQVDPLVQSFSFQNLLQGRMYKMVIVTHSGELSNESFIFGRTVPASVSHLRGSNRNTTDSLWFNWSPASGDFDFYELILYNPNGTKKENWKDKDLTEWRFQGLVPGRKYVLWVVTHSGDLSNKVTAESRTAPSPPSLMSFADIANTSLAITWKGPPDWTDYNDFELQWLPRDALTVFNPYNNRKSEGRIVYGLRPGRSYQFNVKTVSGDSWKTYSKPIFGSVRTKPDKIQNLHCRPQNSTAIACSWIPPDSDFDGYSIECRKMDTQEVEFSRKLEKEKSLLNIMMLVPHKRYLVSIKVQSAGMTSEVVEDSTITMIDRPPPPPPHIRVNEKDVLISKSSINFTVNCSWFSDTNGAVKYFTVVVREADGSDELKPEQQHPLPSYLEYRHNASIRVYQTNYFASKCAENPNSNSKSFNIKLGAEMESLGGKCDPTQQKFCDGPLKPHTAYRISIRAFTQLFDEDLKEFTKPLYSDTFFSLPITTESEPLFGAIEGVSAGLFLIGMLVAVVALLICRQKVSHGRERPSARLSIRRDRPLSVHLNLGQKGNRKTSCPIKINQFEGHFMKLQADSNYLLSKEYEELKDVGRNQSCDIALLPENRGKNRYNNILPYDATRVKLSNVDDDPCSDYINASYIPGNNFRREYIVTQGPLPGTKDDFWKMVWEQNVHNIVMVTQCVEKGRVKCDHYWPADQDSLYYGDLILQMLSESVLPEWTIREFKICGEEQLDAHRLIRHFHYTVWPDHGVPETTQSLIQFVRTVRDYINRSPGAGPTVVHCSAGVGRTGTFIALDRILQQLDSKDSVDIYGAVHDLRLHRVHMVQTECQYVYLHQCVRDVLRARKLRSEQENPLFPIYENVNPEYHRDPVYSRH T57034 DRUGINFO D08VIS AKB-9778 Phase 2 T93122 TARGETID T93122 T93122 FORMERID TTDNC00645 T93122 UNIPROID BDNF_HUMAN T93122 TARGNAME Brain-derived neurotrophic factor (BDNF) T93122 GENENAME BDNF T93122 TARGTYPE Clinical trial T93122 SYNONYMS Brainderived neurotrophic factor; Abrineurin T93122 FUNCTION Participates in axonal growth, pathfinding and in the modulation of dendritic growth and morphology. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. During development, promotes the survival and differentiation of selected neuronal populations of the peripheral and central nervous systems. T93122 PDBSTRUC 1BND; 1B8M T93122 BIOCLASS Growth factor T93122 SEQUENCE MTILFLTMVISYFGCMKAAPMKEANIRGQGGLAYPGVRTHGTLESVNGPKAGSRGLTSLADTFEHVIEELLDEDQKVRPNEENNKDADLYTSRVMLSSQVPLEPPLLFLLEEYKNYLDAANMSMRVRRHSDPARRGELSVCDSISEWVTAADKKTAVDMSGGTVTVLEKVPVSKGQLKQYFYETKCNPMGYTKEGCRGIDKRHWNSQCRTTQSYVRALTMDSKKRIGWRFIRIDTSCVCTLTIKRGR T93122 DRUGINFO D0M2TG PYM-50028 Phase 2 T86254 TARGETID T86254 T86254 FORMERID TTDR00683 T86254 UNIPROID TENA_HUMAN T86254 TARGNAME Tenascin (TNC) T86254 GENENAME TNC T86254 TARGTYPE Clinical trial T86254 SYNONYMS Tenascin-C; TN-C; TN; Neuronectin; Myotendinous antigen; Miotendinous antigen; JI; Hexabrachion; HXB; Glioma-associated-extracellular matrix antigen; GP 150-225; GMEM; Cytotactin T86254 FUNCTION Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6. In tumors, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells. Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. T86254 PDBSTRUC 6QNV; 6BRB; 2RBL; 2RB8; 1TEN T86254 SEQUENCE MGAMTQLLAGVFLAFLALATEGGVLKKVIRHKRQSGVNATLPEENQPVVFNHVYNIKLPVGSQCSVDLESASGEKDLAPPSEPSESFQEHTVDGENQIVFTHRINIPRRACGCAAAPDVKELLSRLEELENLVSSLREQCTAGAGCCLQPATGRLDTRPFCSGRGNFSTEGCGCVCEPGWKGPNCSEPECPGNCHLRGRCIDGQCICDDGFTGEDCSQLACPSDCNDQGKCVNGVCICFEGYAGADCSREICPVPCSEEHGTCVDGLCVCHDGFAGDDCNKPLCLNNCYNRGRCVENECVCDEGFTGEDCSELICPNDCFDRGRCINGTCYCEEGFTGEDCGKPTCPHACHTQGRCEEGQCVCDEGFAGVDCSEKRCPADCHNRGRCVDGRCECDDGFTGADCGELKCPNGCSGHGRCVNGQCVCDEGYTGEDCSQLRCPNDCHSRGRCVEGKCVCEQGFKGYDCSDMSCPNDCHQHGRCVNGMCVCDDGYTGEDCRDRQCPRDCSNRGLCVDGQCVCEDGFTGPDCAELSCPNDCHGQGRCVNGQCVCHEGFMGKDCKEQRCPSDCHGQGRCVDGQCICHEGFTGLDCGQHSCPSDCNNLGQCVSGRCICNEGYSGEDCSEVSPPKDLVVTEVTEETVNLAWDNEMRVTEYLVVYTPTHEGGLEMQFRVPGDQTSTIIQELEPGVEYFIRVFAILENKKSIPVSARVATYLPAPEGLKFKSIKETSVEVEWDPLDIAFETWEIIFRNMNKEDEGEITKSLRRPETSYRQTGLAPGQEYEISLHIVKNNTRGPGLKRVTTTRLDAPSQIEVKDVTDTTALITWFKPLAEIDGIELTYGIKDVPGDRTTIDLTEDENQYSIGNLKPDTEYEVSLISRRGDMSSNPAKETFTTGLDAPRNLRRVSQTDNSITLEWRNGKAAIDSYRIKYAPISGGDHAEVDVPKSQQATTKTTLTGLRPGTEYGIGVSAVKEDKESNPATINAATELDTPKDLQVSETAETSLTLLWKTPLAKFDRYRLNYSLPTGQWVGVQLPRNTTSYVLRGLEPGQEYNVLLTAEKGRHKSKPARVKASTEQAPELENLTVTEVGWDGLRLNWTAADQAYEHFIIQVQEANKVEAARNLTVPGSLRAVDIPGLKAATPYTVSIYGVIQGYRTPVLSAEASTGETPNLGEVVVAEVGWDALKLNWTAPEGAYEYFFIQVQEADTVEAAQNLTVPGGLRSTDLPGLKAATHYTITIRGVTQDFSTTPLSVEVLTEEVPDMGNLTVTEVSWDALRLNWTTPDGTYDQFTIQVQEADQVEEAHNLTVPGSLRSMEIPGLRAGTPYTVTLHGEVRGHSTRPLAVEVVTEDLPQLGDLAVSEVGWDGLRLNWTAADNAYEHFVIQVQEVNKVEAAQNLTLPGSLRAVDIPGLEAATPYRVSIYGVIRGYRTPVLSAEASTAKEPEIGNLNVSDITPESFNLSWMATDGIFETFTIEIIDSNRLLETVEYNISGAERTAHISGLPPSTDFIVYLSGLAPSIRTKTISATATTEALPLLENLTISDINPYGFTVSWMASENAFDSFLVTVVDSGKLLDPQEFTLSGTQRKLELRGLITGIGYEVMVSGFTQGHQTKPLRAEIVTEAEPEVDNLLVSDATPDGFRLSWTADEGVFDNFVLKIRDTKKQSEPLEITLLAPERTRDITGLREATEYEIELYGISKGRRSQTVSAIATTAMGSPKEVIFSDITENSATVSWRAPTAQVESFRITYVPITGGTPSMVTVDGTKTQTRLVKLIPGVEYLVSIIAMKGFEESEPVSGSFTTALDGPSGLVTANITDSEALARWQPAIATVDSYVISYTGEKVPEITRTVSGNTVEYALTDLEPATEYTLRIFAEKGPQKSSTITAKFTTDLDSPRDLTATEVQSETALLTWRPPRASVTGYLLVYESVDGTVKEVIVGPDTTSYSLADLSPSTHYTAKIQALNGPLRSNMIQTIFTTIGLLYPFPKDCSQAMLNGDTTSGLYTIYLNGDKAEALEVFCDMTSDGGGWIVFLRRKNGRENFYQNWKAYAAGFGDRREEFWLGLDNLNKITAQGQYELRVDLRDHGETAFAVYDKFSVGDAKTRYKLKVEGYSGTAGDSMAYHNGRSFSTFDKDTDSAITNCALSYKGAFWYRNCHRVNLMGRYGDNNHSQGVNWFHWKGHEHSIQFAEMKLRPSNFRNLEGRRKRA T86254 DRUGINFO D0F1ZI F-16-IL-2 fusion protein Phase 2 T86254 DRUGINFO D0G1IG F-16-131I Phase 1/2 T86254 DRUGINFO D06JAL 8H9 Phase 1 T86254 DRUGINFO D07ZKK 131I-81C6 Terminated T85554 TARGETID T85554 T85554 FORMERID TTDNC00484 T85554 UNIPROID CD27_HUMAN T85554 TARGNAME T-cell activation antigen CD27 (CD27) T85554 GENENAME CD27 T85554 TARGTYPE Clinical trial T85554 SYNONYMS Tumor necrosis factor receptor superfamily member 7; Tcell activation antigen CD27; TNFRSF7; T14; CD27L receptor; CD27 antigen T85554 FUNCTION May play a role in survival of activated T-cells. May play a role in apoptosis through association with SIVA1. Receptor for CD70/CD27L. T85554 PDBSTRUC 5TLK; 5TLJ; 5TL5 T85554 BIOCLASS Cytokine receptor T85554 SEQUENCE MARPHPWWLCVLGTLVGLSATPAPKSCPERHYWAQGKLCCQMCEPGTFLVKDCDQHRKAAQCDPCIPGVSFSPDHHTRPHCESCRHCNSGLLVRNCTITANAECACRNGWQCRDKECTECDPLPNPSLTARSSQALSPHPQPTHLPYVSEMLEARTAGHMQTLADFRQLPARTLSTHWPPQRSLCSSDFIRILVIFSGMFLVFTLAGALFLHQRRKYRSNKGESPVEPAEPCHYSCPREEEGSTIPIQEDYRKPEPACSP T85554 DRUGINFO D0KV3M Varlilumab Phase 2 T85554 DRUGINFO D09RLQ CDX-1127 Phase 1 T85554 DRUGINFO D28MNU CDX-527 Phase 1 T47366 TARGETID T47366 T47366 FORMERID TTDNC00625 T47366 UNIPROID AVR2A_HUMAN T47366 TARGNAME Activin receptor type IIA (ACVR2A) T47366 GENENAME ACVR2A T47366 TARGTYPE Clinical trial T47366 SYNONYMS Activin receptor type2A; Activin receptor type-2A; ACVR2; ACTRIIA; ACTR-IIA T47366 FUNCTION Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A. Mediates induction of adipogenesis by GDF6. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. T47366 PDBSTRUC 5NH3; 4ASX; 3SOC; 3Q4T T47366 BIOCLASS Kinase T47366 ECNUMBER EC 2.7.11.30 T47366 SEQUENCE MGAAAKLAFAVFLISCSSGAILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPYYNILLYSLVPLMLIAGIVICAFWVYRHHKMAYPPVLVPTQDPGPPPPSPLLGLKPLQLLEVKARGRFGCVWKAQLLNEYVAVKIFPIQDKQSWQNEYEVYSLPGMKHENILQFIGAEKRGTSVDVDLWLITAFHEKGSLSDFLKANVVSWNELCHIAETMARGLAYLHEDIPGLKDGHKPAISHRDIKSKNVLLKNNLTACIADFGLALKFEAGKSAGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWELASRCTAADGPVDEYMLPFEEEIGQHPSLEDMQEVVVHKKKRPVLRDYWQKHAGMAMLCETIEECWDHDAEARLSAGCVGERITQMQRLTNIITTEDIVTVVTMVTNVDFPPKESSL T47366 DRUGINFO D0S5FF BYM338 Phase 3 T68887 TARGETID T68887 T68887 FORMERID TTDI01778 T68887 UNIPROID NMBR_HUMAN; GRPR_HUMAN; BRS3_HUMAN T68887 TARGNAME Bombesin receptor (BS) T68887 GENENAME NMBR; GRPR; BRS3 T68887 TARGTYPE Clinical trial T68887 SYNONYMS BB T68887 FUNCTION Bombesin receptor activity. G protein-coupled receptor activity. Receptor for neuromedin-B. G protein-coupled receptor signaling pathway. Phospholipase C-activating G protein-coupled receptor signaling pathway. T68887 BIOCLASS GPCR rhodopsin T68887 SEQUENCE MPSKSLSNLSVTTGANESGSVPEGWERDFLPASDGTTTELVIRCVIPSLYLLIITVGLLGNIMLVKIFITNSAMRSVPNIFISNLAAGDLLLLLTCVPVDASRYFFDEWMFGKVGCKLIPVIQLTSVGVSVFTLTALSADRYRAIVNPMDMQTSGALLRTCVKAMGIWVVSVLLAVPEAVFSEVARISSLDNSSFTACIPYPQTDELHPKIHSVLIFLVYFLIPLAIISIYYYHIAKTLIKSAHNLPGEYNEHTKKQMETRKRLAKIVLVFVGCFIFCWFPNHILYMYRSFNYNEIDPSLGHMIVTLVARVLSFGNSCVNPFALYLLSESFRRHFNSQLCCGRKSYQERGTSYLLSSSAVRMTSLKSNAKNMVTNSVLLNGHSMKQEMAL T68887 DRUGINFO D08EEO Demobesin Phase 1 T68887 DRUGINFO D0A4UW BAY-86-7548 Phase 1 T68887 DRUGINFO D02TPY bag-1 Investigative T68887 DRUGINFO D03JFB PMID12723954C21b Investigative T68887 DRUGINFO D03TEJ PD 165929 Investigative T68887 DRUGINFO D0A0DS [3H]bag-2 Investigative T68887 DRUGINFO D0A1FE PMID25497965C17c Investigative T68887 DRUGINFO D0D5IV PMID24412111C9f Investigative T68887 DRUGINFO D0H4LP PMID24412111C9g Investigative T68887 DRUGINFO D0PP7U phenylacetyl-Ala,DTrp-phenthylamide Investigative T68887 DRUGINFO D0RF6M ML-18 Investigative T68887 DRUGINFO D0T9VC PMID24900283C8a Investigative T68887 DRUGINFO D0U4ZS PMID20167483C22e Investigative T68887 DRUGINFO D01PWM kuwanon H Investigative T68887 DRUGINFO D02QOD bombesin Investigative T68887 DRUGINFO D07IAK PD 168368 Investigative T68887 DRUGINFO D08RQW MK-5046 Investigative T68887 DRUGINFO D09FOQ bantag-1 Investigative T68887 DRUGINFO D0E1EC ranatensin Investigative T68887 DRUGINFO D0I5CS PD 176252 Investigative T68887 DRUGINFO D0R8TG [(N4-Bzdig)0]BB(7-14) Investigative T68887 DRUGINFO D0S3XL neuromedin B Investigative T50444 TARGETID T50444 T50444 FORMERID TTDC00213 T50444 UNIPROID CTGF_HUMAN T50444 TARGNAME Connective tissue growth factor (CTGF) T50444 GENENAME CTGF T50444 TARGTYPE Clinical trial T50444 SYNONYMS Long; Insulin-like growth factor-binding protein 8; IGFBP8; IGFBP-8; IGF-binding protein 8; IBP-8; Hypertrophic chondrocyte-specific protein 24; HCS24; CCN2; CCN family member 2 T50444 FUNCTION Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis. Major connective tissue mitoattractant secreted by vascular endothelial cells. T50444 SEQUENCE MTAASMGPVRVAFVVLLALCSRPAVGQNCSGPCRCPDEPAPRCPAGVSLVLDGCGCCRVCAKQLGELCTERDPCDPHKGLFCHFGSPANRKIGVCTAKDGAPCIFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCDEPKDQTVVGPALAAYRLEDTFGPDPTMIRANCLVQTTEWSACSKTCGMGISTRVTNDNASCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA T50444 DRUGINFO D01FQR Ocaperidone Phase 2 T03573 TARGETID T03573 T03573 FORMERID TTDNC00464 T03573 UNIPROID FCG2B_HUMAN T03573 TARGNAME Immunoglobulin gamma Fc receptor IIB (FCGR2B) T03573 GENENAME FCGR2B T03573 TARGTYPE Clinical trial T03573 SYNONYMS Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; FcRII-b; Fc-gamma-RIIb; Fc-gamma RII-b; FCG2B; CDw32 B; CD32 B T03573 FUNCTION Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis. T03573 PDBSTRUC 5OCC; 3WJJ; 2FCB T03573 BIOCLASS Immunoglobulin T03573 SEQUENCE MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWINVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPNFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAAVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDALEEPDDQNRI T03573 DRUGINFO D00NXT Xmab 5871 Phase 2 T03573 DRUGINFO DD4H6V BI 1206 Phase 1/2 T03573 DRUGINFO D0QO6N MGD010 Phase 1 T44589 TARGETID T44589 T44589 FORMERID TTDI01800 T44589 UNIPROID IL3RB_HUMAN T44589 TARGNAME Interleukin 3 receptor (CSF2RB) T44589 GENENAME CSF2RB T44589 TARGTYPE Clinical trial T44589 SYNONYMS IL5RB; IL3RB; IL-5R; GM-CSF/IL-3/IL-5 receptor common beta subunit; Cytokine receptor common subunit beta; CDw131; CD131 T44589 FUNCTION High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor. T44589 PDBSTRUC 5DWU; 4NKQ; 2NA9; 2NA8; 2GYS T44589 BIOCLASS Cytokine receptor T44589 SEQUENCE MVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVTLIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLGTRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQDSWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPGDEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSLHTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWETMKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTGYNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPNPSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIEDPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSRSLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQGAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFTPNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSPRNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPSSPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC T44589 DRUGINFO D00GFV Leridistim Phase 2 T44589 DRUGINFO D02RPP TPI ASM8 Phase 2 T44589 DRUGINFO D08MKR DT388IL-3 Phase 1/2 T44589 DRUGINFO D0Z2ZY SL-401 Phase 1/2 T44589 DRUGINFO D0JF9Z CSL-362 Phase 1 T67805 TARGETID T67805 T67805 FORMERID TTDC00337 T67805 UNIPROID CD70_HUMAN T67805 TARGNAME CD70 antigen (CD27-L) T67805 GENENAME CD70 T67805 TARGTYPE Clinical trial T67805 SYNONYMS Tumor necrosis factor ligandsuperfamily member 7; Tumor necrosis factor ligand superfamily member 7; TNFSF7; CD27LG; CD27L; CD27 ligand T67805 FUNCTION Plays a role in T-cell activation. Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. Cytokine that binds to CD27. T67805 BIOCLASS Cytokine: tumor necrosis factor T67805 SEQUENCE MPEEGSGCSVRRRPYGCVLRAALVPLVAGLVICLVVCIQRFAQAQQQLPLESLGWDVAELQLNHTGPQQDPRLYWQGGPALGRSFLHGPELDKGQLRIHRDGIYMVHIQVTLAICSSTTASRHHPTTLAVGICSPASRSISLLRLSFHQGCTIASQRLTPLARGDTLCTNLTGTLLPSRNTDETFFGVQWVRP T67805 DRUGINFO D6Q5MG JNJ-74494550 Phase 2 T67805 DRUGINFO D02YRD 4SCAR19 and 4SCAR70 Phase 1/2 T67805 DRUGINFO D03KLF MDX-1203 Phase 1 T67805 DRUGINFO D03KVW MDX-1411 Phase 1 T67805 DRUGINFO D06FHQ BMS-936561 Phase 1 T67805 DRUGINFO D09PQP SGN-70 Phase 1 T67805 DRUGINFO D0E2ZX SGN-CD70A Phase 1 T67805 DRUGINFO D0JO9M Anti-hCD70 CAR transduced PBL Phase 1 T67805 DRUGINFO D0NC1Q AMG 172 Phase 1 T67805 DRUGINFO D6H9TE SEA-CD70 Phase 1 T67805 DRUGINFO DVIY25 CTX130 Phase 1 T67805 DRUGINFO D08WTE Vorsetuzumab mafodotin Discontinued in Phase 1 T67805 DRUGINFO D04PFD TriMixDC Investigative T39054 TARGETID T39054 T39054 FORMERID TTDI02587 T39054 UNIPROID DUT_HUMAN T39054 TARGNAME dUTP pyrophosphatase (DUT) T39054 GENENAME DUT T39054 TARGTYPE Clinical trial T39054 SYNONYMS Deoxyuridine 5' triphosphate nucleotidohydrolase, mitochondrial; DUT T39054 FUNCTION This enzyme is involved in nucleotide metabolism: it produces dUMP, the immediate precursor of thymidine nucleotides and it decreases the intracellular concentration of dUTP so that uracil cannot be incorporated into DNA. {ECO:0000269|PubMed:8805593}. T39054 PDBSTRUC 5H4J; 4MZ6; 4MZ5; 3EHW; 3ARN T39054 BIOCLASS Acid anhydrides hydrolase T39054 ECNUMBER EC 3.6.1.23 T39054 SEQUENCE MTPLCPRPALCYHFLTSLLRSAMQNARGARQRAEAAVLSGPGPPLGRAAQHGIPRPLSSAGRLSQGCRGASTVGAAGWKGELPKAGGSPAPGPETPAISPSKRARPAEVGGMQLRFARLSEHATAPTRGSARAAGYDLYSAYDYTIPPMEKAVVKTDIQIALPSGCYGRVAPRSGLAAKHFIDVGAGVIDEDYRGNVGVVLFNFGKEKFEVKKGDRIAQLICERIFYPEIEEVQALDDTERGSGGFGSTGKN T39054 DRUGINFO D0Z6KF TAS-114 Phase 2 T15497 TARGETID T15497 T15497 FORMERID TTDR00673 T15497 UNIPROID PE2R1_HUMAN T15497 TARGNAME Prostaglandin E2 receptor EP1 (PTGER1) T15497 GENENAME PTGER1 T15497 TARGTYPE Clinical trial T15497 SYNONYMS Prostanoid EP1 receptor; Prostaglandin E2 receptor EP1 subtype; PGE2 receptor EP1 subtype; PGE receptor, EP1 subtype; PGE receptor EP1 subtype; EP1 receptor T15497 FUNCTION The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues. Receptor for prostaglandin E2 (PGE2). T15497 BIOCLASS GPCR rhodopsin T15497 SEQUENCE MSPCGPLNLSLAGEATTCAAPWVPNTSAVPPSGASPALPIFSMTLGAVSNLLALALLAQAAGRLRRRRSAATFLLFVASLLATDLAGHVIPGALVLRLYTAGRAPAGGACHFLGGCMVFFGLCPLLLGCGMAVERCVGVTRPLLHAARVSVARARLALAAVAAVALAVALLPLARVGRYELQYPGTWCFIGLGPPGGWRQALLAGLFASLGLVALLAALVCNTLSGLALLRARWRRRSRRPPPASGPDSRRRWGAHGPRSASASSASSIASASTFFGGSRSSGSARRARAHDVEMVGQLVGIMVVSCICWSPMLVLVALAVGGWSSTSLQRPLFLAVRLASWNQILDPWVYILLRQAVLRQLLRLLPPRAGAKGGPAGLGLTPSAWEASSLRSSRHSGLSHF T15497 DRUGINFO D0D7UD AS-013 Phase 3 T15497 DRUGINFO D00HTY PGF2alpha Clinical trial T15497 DRUGINFO D0W2OT BUTAPROST Patented T15497 DRUGINFO D0T2TK ZD6416 Discontinued in Phase 2 T15497 DRUGINFO D0K6DG ONO-8130 Terminated T15497 DRUGINFO D0X2OV ONO-8711 Terminated T15497 DRUGINFO D02IVR ONO-DI-004 Investigative T15497 DRUGINFO D04IIT ZM 325802 Investigative T15497 DRUGINFO D0OA8M SC-19220 Investigative T15497 DRUGINFO D0R2TW GW848687X Investigative T15497 DRUGINFO D0S6NE MF266-1 Investigative T15497 DRUGINFO D0V9QT SC-51322 Investigative T15497 DRUGINFO D00QTX ZK110841 Investigative T15497 DRUGINFO D0T2GA ONO-8713 Investigative T15497 DRUGINFO D0X2MQ 17-phenyl-omega-trinor-PGE2 Investigative T15497 DRUGINFO D0J9PG AH6809 Investigative T15497 DRUGINFO D05SFA cicaprost Investigative T15497 DRUGINFO D0O9ES cloprostenol Investigative T15497 DRUGINFO D0BN1U M&B 28767 Investigative T15497 DRUGINFO D06KBO PGD2 Investigative T15497 DRUGINFO D0W7RI carbacyclin Investigative T15497 DRUGINFO D03PLH U46619 Investigative T54447 TARGETID T54447 T54447 FORMERID TTDC00252 T54447 UNIPROID PEDF_HUMAN T54447 TARGNAME Pigment epithelium-derived factor (SERPINF1) T54447 GENENAME SERPINF1 T54447 TARGTYPE Clinical trial T54447 SYNONYMS Serpin-F1; SERPINF1; PEDF; EPC-1 T54447 FUNCTION Neurotrophic protein; induces extensive neuronal differentiation in retinoblastoma cells. Potent inhibitor of angiogenesis. As it does not undergo the S (stressed) to R (relaxed) conformationaltransition characteristic of active serpins, it exhibits no serine protease inhibitory activity. T54447 PDBSTRUC 1IMV T54447 BIOCLASS Serpin protein T54447 SEQUENCE MQALVLLLCIGALLGHSSCQNPASPPEEGSPDPDSTGALVEEEDPFFKVPVNKLAAAVSNFGYDLYRVRSSTSPTTNVLLSPLSVATALSALSLGAEQRTESIIHRALYYDLISSPDIHGTYKELLDTVTAPQKNLKSASRIVFEKKLRIKSSFVAPLEKSYGTRPRVLTGNPRLDLQEINNWVQAQMKGKLARSTKEIPDEISILLLGVAHFKGQWVTKFDSRKTSLEDFYLDEERTVRVPMMSDPKAVLRYGLDSDLSCKIAQLPLTGSMSIIFFLPLKVTQNLTLIEESLTSEFIHDIDRELKTVQAVLTVPKLKLSYEGEVTKSLQEMKLQSLFDSPDFSKITGKPIKLTQVEHRAGFEWNEDGAGTTPSPGLQPAHLTFPLDYHLNQPFIFVLRDTDTGALLFIGKILDPRGP T54447 DRUGINFO D0G3GF AdPEDR Phase 2 T54447 DRUGINFO D0PF8B PEDF gene therapy Phase 1 T99909 TARGETID T99909 T99909 FORMERID TTDI02086 T99909 UNIPROID GRP75_HUMAN T99909 TARGNAME Mortalin (HSPA9) T99909 GENENAME HSPA9 T99909 TARGTYPE Clinical trial T99909 SYNONYMS mt-HSP70; Stress-70 protein, mitochondrial; Peptide-binding protein 74; PBP74; MOT; Heat shock 70 kDa protein 9; HSPA9B; GRP75; GRP-75; 75 kDa glucose-regulated protein T99909 FUNCTION Interacts with and stabilizes ISC cluster assembly proteins FXN, NFU1, NFS1 and ISCU. Regulates erythropoiesis via stabilization of ISC assembly. May play a role in the control of cell proliferation and cellular aging. Chaperone protein which plays an important role in mitochondrial iron-sulfur cluster (ISC) biogenesis. T99909 PDBSTRUC 6NHK; 4KBO; 3N8E T99909 BIOCLASS Heat shock protein T99909 SEQUENCE MISASRAAAARLVGAAASRGPTAARHQDSWNGLSHEAFRLVSRRDYASEAIKGAVVGIDLGTTNSCVAVMEGKQAKVLENAEGARTTPSVVAFTADGERLVGMPAKRQAVTNPNNTFYATKRLIGRRYDDPEVQKDIKNVPFKIVRASNGDAWVEAHGKLYSPSQIGAFVLMKMKETAENYLGHTAKNAVITVPAYFNDSQRQATKDAGQISGLNVLRVINEPTAAALAYGLDKSEDKVIAVYDLGGGTFDISILEIQKGVFEVKSTNGDTFLGGEDFDQALLRHIVKEFKRETGVDLTKDNMALQRVREAAEKAKCELSSSVQTDINLPYLTMDSSGPKHLNMKLTRAQFEGIVTDLIRRTIAPCQKAMQDAEVSKSDIGEVILVGGMTRMPKVQQTVQDLFGRAPSKAVNPDEAVAIGAAIQGGVLAGDVTDVLLLDVTPLSLGIETLGGVFTKLINRNTTIPTKKSQVFSTAADGQTQVEIKVCQGEREMAGDNKLLGQFTLIGIPPAPRGVPQIEVTFDIDANGIVHVSAKDKGTGREQQIVIQSSGGLSKDDIENMVKNAEKYAEEDRRKKERVEAVNMAEGIIHDTETKMEEFKDQLPADECNKLKEEISKMRELLARKDSETGENIRQAASSLQQASLKLFEMAYKKMASEREGSGSSGTGEQKEDQKEEKQ T99909 DRUGINFO D0X9HB MKT-077 Phase 2 T79160 TARGETID T79160 T79160 FORMERID TTDI02527 T79160 UNIPROID GDNF_HUMAN T79160 TARGNAME Glial cell line-derived neurotrophic factor (GDNF) T79160 GENENAME GDNF T79160 TARGTYPE Clinical trial T79160 SYNONYMS hGDNF; Glial cell linederived neurotrophic factor; Astrocytederived trophic factor; Astrocyte-derived trophic factor; ATF T79160 FUNCTION Neurotrophic factor that enhances survival and morphological differentiation of dopaminergic neurons and increases their high-affinity dopamine uptake. T79160 PDBSTRUC 4UX8; 3FUB; 2V5E T79160 BIOCLASS Growth factor T79160 SEQUENCE MKLWDVVAVCLVLLHTASAFPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMPEDYPDQFDDVMDFIQATIKRLKRSPDKQMAVLPRRERNRQAAAANPENSRGKGRRGQRGKNRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSDKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI T79160 DRUGINFO D0IN9G Liatermin Phase 1/2 T99379 TARGETID T99379 T99379 UNIPROID TPO_HUMAN T99379 TARGNAME Thrombopoietin (THPO) T99379 GENENAME THPO T99379 TARGTYPE Clinical trial T99379 SYNONYMS Myeloproliferative leukemia virus oncogene ligand; Megakaryocyte growth and development factor; Megakaryocyte colony-stimulating factor; ML; MGDF; C-mpl ligand T99379 FUNCTION Lineage-specific cytokine affecting the proliferation and maturation of megakaryocytes from their committed progenitor cells. It acts at a late stage of megakaryocyte development. It may be the major physiological regulator of circulating platelets. T99379 PDBSTRUC 1V7N; 1V7M T99379 BIOCLASS EPO/TPO family T99379 SEQUENCE MELTELLLVVMLLLTARLTLSSPAPPACDLRVLSKLLRDSHVLHSRLSQCPEVHPLPTPVLLPAVDFSLGEWKTQMEETKAQDILGAVTLLLEGVMAARGQLGPTCLSSLLGQLSGQVRLLLGALQSLLGTQLPPQGRTTAHKDPNAIFLSFQHLLRGKVRFLMLVGGSTLCVRRAPPTTAVPSRTSLVLTLNELPNRTSGLLETNFTASARTTGSGLLKWQQGFRAKIPGLLNQTSRSLDQIPGYLNRIHELLNGTRGLFPGPSRRTLGAPDISSGTSDTGSLPPNLQPGYSPSPTHPPTGQYTLFPLPPTLPTPVVQLHPLLPDPSAPTPTPTSPLLNTSYTHSQNLSQEG T99379 DRUGINFO D14VOX A157 IND submitted T99379 DRUGINFO D04KVA BVI-007 Phase 1 T96894 TARGETID T96894 T96894 FORMERID TTDI02361 T96894 UNIPROID LIFR_HUMAN T96894 TARGNAME Leukemia inhibitory factor receptor (LIFR) T96894 GENENAME LIFR T96894 TARGTYPE Clinical trial T96894 SYNONYMS LIF-R; LIF receptor; CD118 T96894 FUNCTION May have a common pathway with IL6ST. The soluble form inhibits the biological activity of LIF by blocking its binding to receptors on target cells. Signal-transducing molecule. T96894 PDBSTRUC 3E0G T96894 BIOCLASS Cytokine receptor T96894 SEQUENCE MMDIYVCLKRPSWMVDNKRMRTASNFQWLLSTFILLYLMNQVNSQKKGAPHDLKCVTNNLQVWNCSWKAPSGTGRGTDYEVCIENRSRSCYQLEKTSIKIPALSHGDYEITINSLHDFGSSTSKFTLNEQNVSLIPDTPEILNLSADFSTSTLYLKWNDRGSVFPHRSNVIWEIKVLRKESMELVKLVTHNTTLNGKDTLHHWSWASDMPLECAIHFVEIRCYIDNLHFSGLEEWSDWSPVKNISWIPDSQTKVFPQDKVILVGSDITFCCVSQEKVLSALIGHTNCPLIHLDGENVAIKIRNISVSASSGTNVVFTTEDNIFGTVIFAGYPPDTPQQLNCETHDLKEIICSWNPGRVTALVGPRATSYTLVESFSGKYVRLKRAEAPTNESYQLLFQMLPNQEIYNFTLNAHNPLGRSQSTILVNITEKVYPHTPTSFKVKDINSTAVKLSWHLPGNFAKINFLCEIEIKKSNSVQEQRNVTIKGVENSSYLVALDKLNPYTLYTFRIRCSTETFWKWSKWSNKKQHLTTEASPSKGPDTWREWSSDGKNLIIYWKPLPINEANGKILSYNVSCSSDEETQSLSEIPDPQHKAEIRLDKNDYIISVVAKNSVGSSPPSKIASMEIPNDDLKIEQVVGMGKGILLTWHYDPNMTCDYVIKWCNSSRSEPCLMDWRKVPSNSTETVIESDEFRPGIRYNFFLYGCRNQGYQLLRSMIGYIEELAPIVAPNFTVEDTSADSILVKWEDIPVEELRGFLRGYLFYFGKGERDTSKMRVLESGRSDIKVKNITDISQKTLRIADLQGKTSYHLVLRAYTDGGVGPEKSMYVVTKENSVGLIIAILIPVAVAVIVGVVTSILCYRKREWIKETFYPDIPNPENCKALQFQKSVCEGSSALKTLEMNPCTPNNVEVLETRSAFPKIEDTEIISPVAERPEDRSDAEPENHVVVSYCPPIIEEEIPNPAADEAGGTAQVIYIDVQSMYQPQAKPEEEQENDPVGGAGYKPQMHLPINSTVEDIAAEEDLDKTAGYRPQANVNTWNLVSPDSPRSIDSNSEIVSFGSPCSINSRQFLIPPKDEDSPKSNGGGWSFTNFFQNKPND T96894 DRUGINFO D0L1FN Emfilermin Phase 1/2 T34596 TARGETID T34596 T34596 FORMERID TTDR00178 T34596 UNIPROID GYRA_HAEIN T34596 TARGNAME Haemophilus influenzae DNA gyrase A (Hae-influ gyrA) T34596 GENENAME Hae-influ gyrA T34596 TARGTYPE Clinical trial T34596 SYNONYMS GyrA; DNA gyrase subunit A of Haemophilus influenzae T34596 FUNCTION DNA gyrasenegatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings. T34596 BIOCLASS ATP-hydrolyzing DNA topoisomerase T34596 ECNUMBER EC 5.6.2.3 T34596 SEQUENCE MTDSIQSSITPVNIEEELKSSYLDYAMSVIVGRALPDVRDGLKPVHRRVLFSMDREGNTANKKYVKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLRYMLVDGQGNFGSIDGDAPAAMRYTEVRMQKITQALLTDLDKETVNFSPNYDGELMIPDVLPTRIPALLANGSSGIAVGMATNIPPHNLNEVLNGCLAYIDKNEITIDELMQHIPGPDFPTAALINGRKGIEEAYRTGRGKVYVRARATVETNEKGREQIIVSELPYQVNKAKLVEKIAELIREKKIEGISNITDLSNKEGIRIEIDIKRDAVGEVVLNHLYSLTQMQVTFGINMVALDHGQPRLFNLKEIIEAFVLHRREVVTRRSIFELRKARERTHILEGLAVARSNIDEMIAIIRNSKNREEAATSISSRSWTLHSDIINLLDASARPDELEENLGIQGEQYYLSPAQVNAILELRLHRLTGIAFEEVIKEYEELLVKIADLLHILSSAERLMEVIREELEEVKAQFGDDRLTEITAASGDIDLEDLIAQEDVVVTLSHEGYVKYQPLTDYEAQRRGGKGKSATKMKEEDFIEKLLVANTHDTILCFSSRGRLYWLKVYQLPQASRGARGRPIVNILPLQENERITAILPVSAYEEDKFVVMATAGGIVKKIALTEFSRPRSNGIIALNLRDEDELIGVDITDGSNEIMLFSSQGRVVRFAENAVRAMGRLATGVRGIKLALTNDISDDESAVEIEDISDDNAEASLDLNIDKVVSLVVPKGEGAILTATQNGYGKRTQLSEYPTKSRNTKGVISIKVSERNGKVVAATQVEETDQIMLITDAGTLVRTRVSEVSIVGRNTQGVRLIRTADDEHVVSLERVCDADEDDSLEESSSEE T34596 DRUGINFO D07DTM Cetraxal Otic Phase 3 T34596 DRUGINFO D05LOY ACH-702 Investigative T07394 TARGETID T07394 T07394 FORMERID TTDNC00415 T07394 UNIPROID NOTC1_HUMAN T07394 TARGNAME Notch-1 receptor (NOTCH1) T07394 GENENAME NOTCH1 T07394 TARGTYPE Clinical trial T07394 SYNONYMS hN1; Translocationassociated notch protein TAN1; Translocation-associated notch protein TAN-1; TAN1; Notch 1 intracellular domain; Notch 1; Neurogenic locus notch homolog protein 1; NICD T07394 FUNCTION Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Involved in the maturation of both CD4(+) and CD8(+) cells in the thymus. Important for follicular differentiation and possibly cell fate selection within the follicle. During cerebellar development, functions as a receptor for neuronal DNER and is involved in the differentiation of Bergmann glia. Represses neuronal and myogenic differentiation. May play an essential role in postimplantation development, probably in some aspect of cell specification and/or differentiation. May be involved in mesoderm development, somite formation and neurogenesis. May enhance HIF1A function by sequestering HIF1AN away from HIF1A. Required for the THBS4 function in regulating protective astrogenesis from the subventricular zone (SVZ) niche after injury. Involved in determination of left/right symmetry by modulating the balance between motile and immotile (sensory) cilia at the left-right organiser (LRO). Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. T07394 PDBSTRUC 6IDF; 5UB5; 5L0R; 5KZO; 5FMA T07394 BIOCLASS Notch protein T07394 SEQUENCE MPPLLAPLLCLALLPALAARGPRCSQPGETCLNGGKCEAANGTEACVCGGAFVGPRCQDPNPCLSTPCKNAGTCHVVDRRGVADYACSCALGFSGPLCLTPLDNACLTNPCRNGGTCDLLTLTEYKCRCPPGWSGKSCQQADPCASNPCANGGQCLPFEASYICHCPPSFHGPTCRQDVNECGQKPGLCRHGGTCHNEVGSYRCVCRATHTGPNCERPYVPCSPSPCQNGGTCRPTGDVTHECACLPGFTGQNCEENIDDCPGNNCKNGGACVDGVNTYNCRCPPEWTGQYCTEDVDECQLMPNACQNGGTCHNTHGGYNCVCVNGWTGEDCSENIDDCASAACFHGATCHDRVASFYCECPHGRTGLLCHLNDACISNPCNEGSNCDTNPVNGKAICTCPSGYTGPACSQDVDECSLGANPCEHAGKCINTLGSFECQCLQGYTGPRCEIDVNECVSNPCQNDATCLDQIGEFQCICMPGYEGVHCEVNTDECASSPCLHNGRCLDKINEFQCECPTGFTGHLCQYDVDECASTPCKNGAKCLDGPNTYTCVCTEGYTGTHCEVDIDECDPDPCHYGSCKDGVATFTCLCRPGYTGHHCETNINECSSQPCRHGGTCQDRDNAYLCFCLKGTTGPNCEINLDDCASSPCDSGTCLDKIDGYECACEPGYTGSMCNINIDECAGNPCHNGGTCEDGINGFTCRCPEGYHDPTCLSEVNECNSNPCVHGACRDSLNGYKCDCDPGWSGTNCDINNNECESNPCVNGGTCKDMTSGYVCTCREGFSGPNCQTNINECASNPCLNQGTCIDDVAGYKCNCLLPYTGATCEVVLAPCAPSPCRNGGECRQSEDYESFSCVCPTGWQGQTCEVDINECVLSPCRHGASCQNTHGGYRCHCQAGYSGRNCETDIDDCRPNPCHNGGSCTDGINTAFCDCLPGFRGTFCEEDINECASDPCRNGANCTDCVDSYTCTCPAGFSGIHCENNTPDCTESSCFNGGTCVDGINSFTCLCPPGFTGSYCQHDVNECDSQPCLHGGTCQDGCGSYRCTCPQGYTGPNCQNLVHWCDSSPCKNGGKCWQTHTQYRCECPSGWTGLYCDVPSVSCEVAAQRQGVDVARLCQHGGLCVDAGNTHHCRCQAGYTGSYCEDLVDECSPSPCQNGATCTDYLGGYSCKCVAGYHGVNCSEEIDECLSHPCQNGGTCLDLPNTYKCSCPRGTQGVHCEINVDDCNPPVDPVSRSPKCFNNGTCVDQVGGYSCTCPPGFVGERCEGDVNECLSNPCDARGTQNCVQRVNDFHCECRAGHTGRRCESVINGCKGKPCKNGGTCAVASNTARGFICKCPAGFEGATCENDARTCGSLRCLNGGTCISGPRSPTCLCLGPFTGPECQFPASSPCLGGNPCYNQGTCEPTSESPFYRCLCPAKFNGLLCHILDYSFGGGAGRDIPPPLIEEACELPECQEDAGNKVCSLQCNNHACGWDGGDCSLNFNDPWKNCTQSLQCWKYFSDGHCDSQCNSAGCLFDGFDCQRAEGQCNPLYDQYCKDHFSDGHCDQGCNSAECEWDGLDCAEHVPERLAAGTLVVVVLMPPEQLRNSSFHFLRELSRVLHTNVVFKRDAHGQQMIFPYYGREEELRKHPIKRAAEGWAAPDALLGQVKASLLPGGSEGGRRRRELDPMDVRGSIVYLEIDNRQCVQASSQCFQSATDVAAFLGALASLGSLNIPYKIEAVQSETVEPPPPAQLHFMYVAAAAFVLLFFVGCGVLLSRKRRRQHGQLWFPEGFKVSEASKKKRREPLGEDSVGLKPLKNASDGALMDDNQNEWGDEDLETKKFRFEEPVVLPDLDDQTDHRQWTQQHLDAADLRMSAMAPTPPQGEVDADCMDVNVRGPDGFTPLMIASCSGGGLETGNSEEEEDAPAVISDFIYQGASLHNQTDRTGETALHLAARYSRSDAAKRLLEASADANIQDNMGRTPLHAAVSADAQGVFQILIRNRATDLDARMHDGTTPLILAARLAVEGMLEDLINSHADVNAVDDLGKSALHWAAAVNNVDAAVVLLKNGANKDMQNNREETPLFLAAREGSYETAKVLLDHFANRDITDHMDRLPRDIAQERMHHDIVRLLDEYNLVRSPQLHGAPLGGTPTLSPPLCSPNGYLGSLKPGVQGKKVRKPSSKGLACGSKEAKDLKARRKKSQDGKGCLLDSSGMLSPVDSLESPHGYLSDVASPPLLPSPFQQSPSVPLNHLPGMPDTHLGIGHLNVAAKPEMAALGGGGRLAFETGPPRLSHLPVASGTSTVLGSSSGGALNFTVGGSTSLNGQCEWLSRLQSGMVPNQYNPLRGSVAPGPLSTQAPSLQHGMVGPLHSSLAASALSQMMSYQGLPSTRLATQPHLVQTQQVQPQNLQMQQQNLQPANIQQQQSLQPPPPPPQPHLGVSSAASGHLGRSFLSGEPSQADVQPLGPSSLAVHTILPQESPALPTSLPSSLVPPVTAAQFLTPPSQHSYSSPVDNTPSHQLQVPEHPFLTPSPESPDQWSSSSPHSNVSDWSEGVSSPPTSMQSQIARIPEAFK T07394 DRUGINFO D08WOW LY3039478 Phase 1/2 T07394 DRUGINFO D0X3YY OMP-52M51 Phase 1 T98494 TARGETID T98494 T98494 FORMERID TTDI01803 T98494 UNIPROID GALR1_HUMAN; GALR2_HUMAN; GALR3_HUMAN T98494 TARGNAME Galanin receptor (GAL-R) T98494 GENENAME GALR1; GALR2; GALR3 T98494 TARGTYPE Clinical trial T98494 SYNONYMS GALR; GALNR; GAL-R T98494 FUNCTION Receptor for the hormone galanin. Receptor for the hormone spexin-1. T98494 BIOCLASS GPCR rhodopsin T98494 SEQUENCE MELAVGNLSEGNASWPEPPAPEPGPLFGIGVENFVTLVVFGLIFALGVLGNSLVITVLARSKPGKPRSTTNLFILNLSIADLAYLLFCIPFQATVYALPTWVLGAFICKFIHYFFTVSMLVSIFTLAAMSVDRYVAIVHSRRSSSLRVSRNALLGVGCIWALSIAMASPVAYHQGLFHPRASNQTFCWEQWPDPRHKKAYVVCTFVFGYLLPLLLICFCYAKVLNHLHKKLKNMSKKSEASKKKTAQTVLVVVVVFGISWLPHHIIHLWAEFGVFPLTPASFLFRITAHCLAYSNSSVNPIIYAFLSENFRKAYKQVFKCHIRKDSHLSDTKESKSRIDTPPSTNCTHV T98494 DRUGINFO D04AHY HT-2157 Phase 1/2 T98494 DRUGINFO D08FGR galmic Investigative T98494 DRUGINFO D09QPH Sch 202596 Investigative T98494 DRUGINFO D0A1QQ GalR3ant Investigative T98494 DRUGINFO D0E7BU CYM2503 Investigative T98494 DRUGINFO D0H0HM (E)-3-(4-chlorophenylimino)indolin-2-one Investigative T98494 DRUGINFO D0HH3R SNAP 398299 Investigative T98494 DRUGINFO D0R9KF (E)-3-(2,3-dichlorophenylimino)indolin-2-one Investigative T98494 DRUGINFO D0XR0L 2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide Investigative T98494 DRUGINFO D0Z8CP dithiipin-1,1,4,4-tetroxide analogue 7 Investigative T04773 TARGETID T04773 T04773 FORMERID TTDR00808 T04773 UNIPROID SDF1_HUMAN T04773 TARGNAME Stromal cell-derived factor 1 (CXCL12) T04773 GENENAME CXCL12 T04773 TARGTYPE Clinical trial T04773 SYNONYMS hSDF-1; SDF1B; SDF1A; SDF1; SDF-1; Pre-B cell growth-stimulating factor; Pre-B cell growth stimulating factor; PBSF; Intercrine reduced in hepatomas; IRH; HIRH; C-X-C motif chemokine 12 T04773 FUNCTION Activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. SDF-1-beta(3-72) and SDF-1-alpha(3-67) show a reduced chemotactic activity. Binding to cell surface proteoglycans seems to inhibit formation of SDF-1-alpha(3-67) and thus to preserve activity on local sites. Also binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. Binds to the allosteric site (site 2) of integrins and activates integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1 in a CXCR4-independent manner. Acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. Stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1, a ligand for beta-2 integrins. SDF1A/CXCR4 signaling axis inhibits beta-2 integrin LFA-1 mediated adhesion of monocytes to ICAM-1 through LYN kinase. Inhibits CXCR4-mediated infection by T-cell line-adapted HIV-1. Plays a protective role after myocardial infarction. Induces down-regulation and internalization of ACKR3 expressed in various cells. Has several critical functions during embryonic development; required for B-cell lymphopoiesis, myelopoiesis in bone marrow and heart ventricular septum formation. Stimulates the proliferation of bone marrow-derived B-cell progenitors in the presence of IL7 as well as growth of stromal cell-dependent pre-B-cells. Chemoattractant active on T-lymphocytes and monocytes but not neutrophils. T04773 PDBSTRUC 4UAI; 4LMQ; 3HP3; 3GV3; 2SDF T04773 BIOCLASS Cytokine: CXC chemokine T04773 SEQUENCE MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRFKM T04773 DRUGINFO D0DR4W MyoCell SDF-1 Phase 3 T04773 DRUGINFO D5VRX2 Dociparstat sodium Phase 3 T04773 DRUGINFO D07YLO SDF-1 Phase 2 T04773 DRUGINFO D0D8MG NOX-A12 Phase 1 T04773 DRUGINFO D0K6NW REC-02 Phase 1 T22032 TARGETID T22032 T22032 FORMERID TTDC00041 T22032 UNIPROID PTH2R_HUMAN T22032 TARGNAME Parathyroid hormone receptor (PTH2R) T22032 GENENAME PTH2R T22032 TARGTYPE Clinical trial T22032 SYNONYMS PTHR2; PTH2R; PTH2 receptor T22032 FUNCTION This is a specific receptor for parathyroid hormone. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. PTH2R may be responsible for PTH effects in a number of physiological systems. It may play asignificant role in pancreatic function. PTH2R presence in neurons indicates that it may function as a neurotransmitter receptor. T22032 BIOCLASS GPCR secretin T22032 SEQUENCE MAGLGASLHVWGWLMLGSCLLARAQLDSDGTITIEEQIVLVLKAKVQCELNITAQLQEGEGNCFPEWDGLICWPRGTVGKISAVPCPPYIYDFNHKGVAFRHCNPNGTWDFMHSLNKTWANYSDCLRFLQPDISIGKQEFFERLYVMYTVGYSISFGSLAVAILIIGYFRRLHCTRNYIHMHLFVSFMLRATSIFVKDRVVHAHIGVKELESLIMQDDPQNSIEATSVDKSQYIGCKIAVVMFIYFLATNYYWILVEGLYLHNLIFVAFFSDTKYLWGFILIGWGFPAAFVAAWAVARATLADARCWELSAGDIKWIYQAPILAAIGLNFILFLNTVRVLATKIWETNAVGHDTRKQYRKLAKSTLVLVLVFGVHYIVFVCLPHSFTGLGWEIRMHCELFFNSFQGFFVSIIYCYCNGEVQAEVKKMWSRWNLSVDWKRTPPCGSRRCGSVLTTVTHSTSSQSQVAASTRMVLISGKAAKIASRQPDSHITLPGYVWSNSEQDCLPHSFHEETKEDSGRQGDDILMEKPSRPMESNPDTEGCQGETEDVL T22032 DRUGINFO D0S2BU BA-058 Phase 3 T22032 DRUGINFO D0F5WX GSK768974 Phase 2 T22032 DRUGINFO D0R7IU NPSP-795 Phase 2 T22032 DRUGINFO D0X2EM UNI-PH (1-34) Phase 2 T22032 DRUGINFO D0H2DS PTH(7-34) liposomal cream Phase 1 T22032 DRUGINFO D0BB1T Semparatide Discontinued in Phase 2 T22032 DRUGINFO D00MCA BB-PTH 1-84 Investigative T22032 DRUGINFO D0A3SX PTHr pepducins Investigative T22032 DRUGINFO D0B0IU Hemoparatide Investigative T22032 DRUGINFO D0G3BK ZP-2307 Investigative T22032 DRUGINFO D0Z4GF SDZ-PTS-893 Investigative T51425 TARGETID T51425 T51425 FORMERID TTDNC00385 T51425 UNIPROID VEGFC_HUMAN T51425 TARGNAME Vascular endothelial growth factor C (VEGFC) T51425 GENENAME VEGFC T51425 TARGTYPE Clinical trial T51425 SYNONYMS Vascular endothelial growth factor-related protein; VRP; VEGF-C; Flt4-L; Flt4 ligand T51425 FUNCTION May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors. Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. T51425 PDBSTRUC 4BSK; 2X1X; 2X1W T51425 BIOCLASS Growth factor T51425 SEQUENCE MHLLGFFSVACSLLAAALLPGPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMTVLYPEYWKMYKCQLRKGGWQHNREQANLNSRTEETIKFAAAHYNTEILKSIDNEWRKTQCMPREVCIDVGKEFGVATNTFFKPPCVSVYRCGGCCNSEGLQCMNTSTSYLSKTLFEITVPLSQGPKPVTISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPTNYMWNNHICRCLAQEDFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSCQCVCKNKLFPSQCGANREFDENTCQCVCKRTCPRNQPLNPGKCACECTESPQKCLLKGKKFHHQTCSCYRRPCTNRQKACEPGFSYSEEVCRCVPSYWKRPQMS T51425 DRUGINFO DNA7I1 OPT-302 Phase 2 T51425 DRUGINFO D0GP0H VGX-100 Phase 1 T97740 TARGETID T97740 T97740 UNIPROID PPT1_HUMAN T97740 TARGNAME Palmitoyl-protein thioesterase 1 (PPT1) T97740 GENENAME PPT1 T97740 TARGTYPE Clinical trial T97740 SYNONYMS Palmitoyl-protein hydrolase 1; PPT-1; PPT; CLN1 T97740 FUNCTION Prefers acyl chain lengths of 14 to 18 carbons. Removes thioester-linked fatty acyl groups such as palmitate from modified cysteine residues in proteins or peptides during lysosomal degradation. T97740 PDBSTRUC 3GRO T97740 BIOCLASS Palmitoyl thioesterase T97740 ECNUMBER EC 3.1.2.22 T97740 SEQUENCE MASPGCLWLLAVALLPWTCASRALQHLDPPAPLPLVIWHGMGDSCCNPLSMGAIKKMVEKKIPGIYVLSLEIGKTLMEDVENSFFLNVNSQVTTVCQALAKDPKLQQGYNAMGFSQGGQFLRAVAQRCPSPPMINLISVGGQHQGVFGLPRCPGESSHICDFIRKTLNAGAYSKVVQERLVQAEYWHDPIKEDVYRNHSIFLADINQERGINESYKKNLMALKKFVMVKFLNDSIVDPVDSEWFGFYRSGQAKETIPLQETSLYTQDRLGLKEMDNAGQLVFLATEGDHLQLSEEWFYAHIIPFLG T97740 DRUGINFO D07QJK Plitidepsin Phase 3 T97740 DRUGINFO D7KQ6N TSHA-118 Phase 1/2 T72252 TARGETID T72252 T72252 FORMERID TTDI03090 T72252 UNIPROID CASP7_HUMAN T72252 TARGNAME Caspase-7 (CASP7) T72252 GENENAME CASP7 T72252 TARGTYPE Clinical trial T72252 SYNONYMS MCH3; ICE-like apoptotic protease 3; ICE-LAP3; CMH-1; CASP-7; Apoptotic protease Mch-3 T72252 FUNCTION Cleaves and activates sterol regulatory element binding proteins (SREBPs). Proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Overexpression promotes programmed cell death. Involved in the activation cascade of caspases responsible for apoptosis execution. T72252 PDBSTRUC 5V6Z; 5V6U; 5K20; 5IC6; 4ZVU T72252 BIOCLASS Peptidase T72252 ECNUMBER EC 3.4.22.60 T72252 SEQUENCE MADDQGCIEEQGVEDSANEDSVDAKPDRSSFVPSLFSKKKKNVTMRSIKTTRDRVPTYQYNMNFEKLGKCIIINNKNFDKVTGMGVRNGTDKDAEALFKCFRSLGFDVIVYNDCSCAKMQDLLKKASEEDHTNAACFACILLSHGEENVIYGKDGVTPIKDLTAHFRGDRCKTLLEKPKLFFIQACRGTELDDGIQADSGPINDTDANPRYKIPVEADFLFAYSTVPGYYSWRSPGRGSWFVQALCSILEEHGKDLEIMQILTRVNDRVARHFESQSDDPHFHEKKQIPCVVSMLTKELYFSQ T72252 DRUGINFO D0J3SU isatin sulfonamide 34 Clinical trial T72252 DRUGINFO D00YNW M826 Investigative T30940 TARGETID T30940 T30940 FORMERID TTDI02043 T30940 UNIPROID CH10_HUMAN T30940 TARGNAME Mitochondrial 10kDa heat shock protein (HSPE1) T30940 GENENAME HSPE1 T30940 TARGTYPE Clinical trial T30940 SYNONYMS Hsp10; Earlypregnancy factor; Early-pregnancy factor; EPF; Chaperonin 10; CPN10; 10 kDa heat shock protein, mitochondrial; 10 kDa chaperonin T30940 FUNCTION Together with Hsp60, facilitates the correct folding of imported proteins. May also prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under stress conditions in the mitochondrial matrix. The functional units of these chaperonins consist of heptameric rings of the large subunit Hsp60, which function as a back-to-back double ring. In a cyclic reaction, Hsp60 ring complexes bind one unfolded substrate protein per ring, followed by the binding of ATP and association with 2 heptameric rings of the co-chaperonin Hsp10. This leads to sequestration of the substrate protein in the inner cavity of Hsp60 where, for a certain period of time, it can fold undisturbed by other cell components. Synchronous hydrolysis of ATP in all Hsp60 subunits results in the dissociation of the chaperonin rings and the release of ADP and the folded substrate protein. Co-chaperonin implicated in mitochondrial protein import and macromolecular assembly. T30940 PDBSTRUC 4PJ1 T30940 BIOCLASS Heat shock protein T30940 SEQUENCE MAGQAFRKFLPLFDRVLVERSAAETVTKGGIMLPEKSQGKVLQATVVAVGSGSKGKGGEIQPVSVKVGDKVLLPEYGGTKVVLDDKDYFLFRDGDILGKYVD T30940 DRUGINFO D0FN4K XToll Phase 1/2 T58093 TARGETID T58093 T58093 FORMERID TTDR00267 T58093 UNIPROID DEF_STAAU T58093 TARGNAME Staphylococcus Peptide deformylase (Stap-coc def) T58093 GENENAME Stap-coc def T58093 TARGTYPE Clinical trial T58093 SYNONYMS def; Stap-coc Polypeptide deformylase T58093 FUNCTION Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions. T58093 PDBSTRUC 2AI9; 1Q1Y; 1LQW; 1LMH; 1LM4 T58093 BIOCLASS Carbon-nitrogen hydrolase T58093 SEQUENCE MLTMKDIIRDGHPTLRQKAAELELPLTKEEKETLIAMREFLVNSQDEEIAKRYGLRSGVGLAAPQINISKRMIAVLIPDDGSGKSYDYMLVNPKIVSHSVQEAYLPTGEGCLSVDDNVAGLVHRHNRITIKAKDIEGNDIQLRLKGYPAIVFQHEIDHLNGVMFYDHIDKNHPLQPHTDAVEV T58093 DRUGINFO D0S7BQ GSK1322322 Phase 2 T58093 DRUGINFO D0T2IQ Actinonin Terminated T58093 DRUGINFO D02XIF HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE Investigative T58093 DRUGINFO D02ZLE 2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE Investigative T58093 DRUGINFO D05JBZ [HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL Investigative T58093 DRUGINFO D0B4SJ VRC3375 Investigative T58093 DRUGINFO D0H7FP N-alkyl urea hydroxamic acids Investigative T58093 DRUGINFO D0N8YA Bb-3497 Investigative T58093 DRUGINFO D0Q8WN N-(2-Acetamido)Iminodiacetic Acid Investigative T58093 DRUGINFO D0VM0T NVP-PDF386 Investigative T58093 DRUGINFO D0E8JM 3-Sulfinoalanine Investigative T58093 DRUGINFO D05AMX Cysteinesulfonic Acid Investigative T58093 DRUGINFO D0H1GU Double Oxidized Cysteine Investigative T58093 DRUGINFO D06EWG Formic Acid Investigative T31825 TARGETID T31825 T31825 FORMERID TTDI01041 T31825 UNIPROID HBB_HUMAN T31825 TARGNAME Hemoglobin subunit beta (HBB) T31825 GENENAME HBB T31825 TARGTYPE Clinical trial T31825 SYNONYMS LVVhemorphin7; Hemoglobin beta chain; Betaglobin; Beta-globin T31825 FUNCTION Involved in oxygen transport from the lung to the various peripheral tissues. T31825 PDBSTRUC 6NBD; 6NBC; 6HBW; 6HAL; 6FQF T31825 BIOCLASS Pore-forming globin T31825 SEQUENCE MVHLTPEEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSELHCDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH T31825 DRUGINFO D0C9LQ LentiGlobin Phase 3 T31825 DRUGINFO D1RMS5 OTL-300 Phase 1/2 T31825 DRUGINFO DSEP59 PF-07059013 Phase 1 T49327 TARGETID T49327 T49327 FORMERID TTDI02222 T49327 UNIPROID ABCA4_HUMAN T49327 TARGNAME ATP-binding cassette transporter A4 (ABCA4) T49327 GENENAME ABCA4 T49327 TARGTYPE Clinical trial T49327 SYNONYMS Stargardt disease protein; RmP; Retinal-specific ATP-binding cassette transporter; RIM protein; RIM ABC transporter; ATP-binding cassette sub-family A member 4; ABCA4 T49327 FUNCTION In the visualcycle, acts as an inward-directed retinoid flipase, retinoid substrates imported by ABCA4 from the extracellular or intradiscal (rod) membrane surfaces to the cytoplasmic membrane surface are all-trans-retinaldehyde (ATR) and N-retinyl-phosphatidyl-ethanolamine (NR-PE). Once transported to the cytoplasmic surface, ATR is reduced to vitamin A by trans- retinol dehydrogenase (tRDH) and then transferred to the retinal pigment epithelium (RPE) where it is converted to 11-cis-retinal. May play a role in photoresponse, removing ATR/NR-PE from the extracellular photoreceptor surfaces during bleach recovery. T49327 BIOCLASS ABC transporter T49327 ECNUMBER EC 7.6.2.1 T49327 SEQUENCE MGFVRQIQLLLWKNWTLRKRQKIRFVVELVWPLSLFLVLIWLRNANPLYSHHECHFPNKAMPSAGMLPWLQGIFCNVNNPCFQSPTPGESPGIVSNYNNSILARVYRDFQELLMNAPESQHLGRIWTELHILSQFMDTLRTHPERIAGRGIRIRDILKDEETLTLFLIKNIGLSDSVVYLLINSQVRPEQFAHGVPDLALKDIACSEALLERFIIFSQRRGAKTVRYALCSLSQGTLQWIEDTLYANVDFFKLFRVLPTLLDSRSQGINLRSWGGILSDMSPRIQEFIHRPSMQDLLWVTRPLMQNGGPETFTKLMGILSDLLCGYPEGGGSRVLSFNWYEDNNYKAFLGIDSTRKDPIYSYDRRTTSFCNALIQSLESNPLTKIAWRAAKPLLMGKILYTPDSPAARRILKNANSTFEELEHVRKLVKAWEEVGPQIWYFFDNSTQMNMIRDTLGNPTVKDFLNRQLGEEGITAEAILNFLYKGPRESQADDMANFDWRDIFNITDRTLRLVNQYLECLVLDKFESYNDETQLTQRALSLLEENMFWAGVVFPDMYPWTSSLPPHVKYKIRMDIDVVEKTNKIKDRYWDSGPRADPVEDFRYIWGGFAYLQDMVEQGITRSQVQAEAPVGIYLQQMPYPCFVDDSFMIILNRCFPIFMVLAWIYSVSMTVKSIVLEKELRLKETLKNQGVSNAVIWCTWFLDSFSIMSMSIFLLTIFIMHGRILHYSDPFILFLFLLAFSTATIMLCFLLSTFFSKASLAAACSGVIYFTLYLPHILCFAWQDRMTAELKKAVSLLSPVAFGFGTEYLVRFEEQGLGLQWSNIGNSPTEGDEFSFLLSMQMMLLDAAVYGLLAWYLDQVFPGDYGTPLPWYFLLQESYWLGGEGCSTREERALEKTEPLTEETEDPEHPEGIHDSFFEREHPGWVPGVCVKNLVKIFEPCGRPAVDRLNITFYENQITAFLGHNGAGKTTTLSILTGLLPPTSGTVLVGGRDIETSLDAVRQSLGMCPQHNILFHHLTVAEHMLFYAQLKGKSQEEAQLEMEAMLEDTGLHHKRNEEAQDLSGGMQRKLSVAIAFVGDAKVVILDEPTSGVDPYSRRSIWDLLLKYRSGRTIIMSTHHMDEADLLGDRIAIIAQGRLYCSGTPLFLKNCFGTGLYLTLVRKMKNIQSQRKGSEGTCSCSSKGFSTTCPAHVDDLTPEQVLDGDVNELMDVVLHHVPEAKLVECIGQELIFLLPNKNFKHRAYASLFRELEETLADLGLSSFGISDTPLEEIFLKVTEDSDSGPLFAGGAQQKRENVNPRHPCLGPREKAGQTPQDSNVCSPGAPAAHPEGQPPPEPECPGPQLNTGTQLVLQHVQALLVKRFQHTIRSHKDFLAQIVLPATFVFLALMLSIVIPPFGEYPALTLHPWIYGQQYTFFSMDEPGSEQFTVLADVLLNKPGFGNRCLKEGWLPEYPCGNSTPWKTPSVSPNITQLFQKQKWTQVNPSPSCRCSTREKLTMLPECPEGAGGLPPPQRTQRSTEILQDLTDRNISDFLVKTYPALIRSSLKSKFWVNEQRYGGISIGGKLPVVPITGEALVGFLSDLGRIMNVSGGPITREASKEIPDFLKHLETEDNIKVWFNNKGWHALVSFLNVAHNAILRASLPKDRSPEEYGITVISQPLNLTKEQLSEITVLTTSVDAVVAICVIFSMSFVPASFVLYLIQERVNKSKHLQFISGVSPTTYWVTNFLWDIMNYSVSAGLVVGIFIGFQKKAYTSPENLPALVALLLLYGWAVIPMMYPASFLFDVPSTAYVALSCANLFIGINSSAITFILELFENNRTLLRFNAVLRKLLIVFPHFCLGRGLIDLALSQAVTDVYARFGEEHSANPFHWDLIGKNLFAMVVEGVVYFLLTLLVQRHFFLSQWIAEPTKEPIVDEDDDVAEERQRIITGGNKTDILRLHELTKIYPGTSSPAVDRLCVGVRPGECFGLLGVNGAGKTTTFKMLTGDTTVTSGDATVAGKSILTNISEVHQNMGYCPQFDAIDELLTGREHLYLYARLRGVPAEEIEKVANWSIKSLGLTVYADCLAGTYSGGNKRKLSTAIALIGCPPLVLLDEPTTGMDPQARRMLWNVIVSIIREGRAVVLTSHSMEECEALCTRLAIMVKGAFRCMGTIQHLKSKFGDGYIVTMKIKSPKDDLLPDLNPVEQFFQGNFPGSVQRERHYNMLQFQVSSSSLARIFQLLLSHKDSLLIEEYSVTQTTLDQVFVNFAKQQTESHDLPLHPRAAGASRQAQD T49327 DRUGINFO D0F6SY StarGen Phase 1/2 T55936 TARGETID T55936 T55936 FORMERID TTDR00622 T55936 UNIPROID PSS_MYCTU T55936 TARGNAME Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA) T55936 GENENAME MycB pssA T55936 TARGTYPE Clinical trial T55936 SYNONYMS pssA; PtdIns synthase; Phosphatidylinositol synthase; PI synthase T55936 FUNCTION Catalyzes the biosynthesis of phosphatidylinositol (ptdins) as well as ptdins:inositol exchange reaction. May thus act to reduce an excessive cellular ptdins content. The exchange activity is due to the reverse reaction of ptdins synthase. T55936 BIOCLASS Kinase T55936 ECNUMBER EC 2.7.8.8 T55936 SEQUENCE MIGKPRGRRGVNLQILPSAMTVLSICAGLTAIKFALEHQPKAAMALIAAAAILDGLDGRVARILDAQSRMGAEIDSLADAVNFGVTPALVLYVSMLSKWPVGWVVVLLYAVCVVLRLARYNALQDDGTQPAYAHEFFVGMPAPAGAVSMIGLLALKMQFGEGWWTSGWFLSFWVTGTSILLVSGIPMKKMHAVSVPPNYAAALLAVLAICAAAAVLAPYLLIWVIIIAYMCHIPFAVRSQRWLAQHPEVWDDKPKQRRAVRRASRRAHPYRPSMARLGLRKPGRRL T55936 DRUGINFO D03SHD Myo-inositol Phase 2 T55936 DRUGINFO D04DWJ Zn2+ Investigative T74203 TARGETID T74203 T74203 FORMERID TTDI02230 T74203 UNIPROID A85A_MYCTU T74203 TARGNAME Mycobacterium Antigen complex 85A (MycB fbpA) T74203 GENENAME MycB fbpA T74203 TARGTYPE Clinical trial T74203 SYNONYMS Fibronectinbinding protein A; Fbps A; Diacylglycerol acyltransferase/mycolyltransferase Ag85A; Antigen 85 complex A; Ag85A; AcylCoA:diacylglycerol acyltransferase; 85A T74203 FUNCTION The antigen 85 proteins (FbpA, FbpB, FbpC) are responsible for the high affinity of mycobacteria for fibronectin, a large adhesive glycoprotein, which facilitates the attachment of M.tuberculosis to murine alveolar macrophages (AMs). They also help to maintain the integrity of the cell wall by catalyzing the transfer of mycolic acids to cell wall arabinogalactan, and through the synthesis of alpha,alpha-trehalose dimycolate (TDM, cord factor). They catalyze the transfer of a mycoloyl residue from one molecule of alpha,alpha-trehalose monomycolate (TMM) to another TMM, leading to the formation of TDM. FbpA mediates triacylglycerol (TAG) formation with long-chain acyl-CoA as the acyl donor and 1,2-dipalmitoyl-sn-glycerol (1,2-dipalmitin) as the acyl acceptor. It has a preference for C26:0-CoAover C18:1-CoA. T74203 PDBSTRUC 1SFR T74203 BIOCLASS Acyltransferase T74203 SEQUENCE MQLVDRVRGAVTGMSRRLVVGAVGAALVSGLVGAVGGTATAGAFSRPGLPVEYLQVPSPSMGRDIKVQFQSGGANSPALYLLDGLRAQDDFSGWDINTPAFEWYDQSGLSVVMPVGGQSSFYSDWYQPACGKAGCQTYKWETFLTSELPGWLQANRHVKPTGSAVVGLSMAASSALTLAIYHPQQFVYAGAMSGLLDPSQAMGPTLIGLAMGDAGGYKASDMWGPKEDPAWQRNDPLLNVGKLIANNTRVWVYCGNGKPSDLGGNNLPAKFLEGFVRTSNIKFQDAYNAGGGHNGVFDFPDSGTHSWEYWGAQLNAMKPDLQRALGATPNTGPAPQGA T74203 DRUGINFO D07GMF MVA-85A Phase 2 T22956 TARGETID T22956 T22956 FORMERID TTDI02041 T22956 UNIPROID CDK3_HUMAN T22956 TARGNAME Cyclin-dependent kinase 3 (CDK3) T22956 GENENAME CDK3 T22956 TARGTYPE Clinical trial T22956 SYNONYMS Cyclindependent kinase 3; Cell division protein kinase 3; CDKN3 T22956 FUNCTION Interacts with CCNC/cyclin-C during interphase. Phosphorylates histone H1, ATF1, RB1 and CABLES1. ATF1 phosphorylation triggers ATF1 transactivation and transcriptional activities, and promotes cell proliferation and transformation. CDK3/cyclin-C mediated RB1 phosphorylation is required for G0-G1 transition. Promotes G1-S transition probably by contributing to the activation of E2F1, E2F2 and E2F3 in a RB1-independent manner. Serine/threonine-protein kinase that plays a critical role in the control of the eukaryotic cell cycle; involved in G0-G1 and G1-S cell cycle transitions. T22956 PDBSTRUC 1LFN T22956 BIOCLASS Kinase T22956 ECNUMBER EC 2.7.11.22 T22956 SEQUENCE MDMFQKVEKIGEGTYGVVYKAKNRETGQLVALKKIRLDLEMEGVPSTAIREISLLKELKHPNIVRLLDVVHNERKLYLVFEFLSQDLKKYMDSTPGSELPLHLIKSYLFQLLQGVSFCHSHRVIHRDLKPQNLLINELGAIKLADFGLARAFGVPLRTYTHEVVTLWYRAPEILLGSKFYTTAVDIWSIGCIFAEMVTRKALFPGDSEIDQLFRIFRMLGTPSEDTWPGVTQLPDYKGSFPKWTRKGLEEIVPNLEPEGRDLLMQLLQYDPSQRITAKTALAHPYFSSPEPSPAARQYVLQRFRH T22956 DRUGINFO D03DKV RGB-286638 Phase 1 T22956 DRUGINFO D0FQ6V PMID26161698-Compound-17 Patented T22956 DRUGINFO D0LK4L Nitrogen mustard derivative 1 Patented T22956 DRUGINFO D0M5DX Oxazolyl methylthiothiazole derivative 1 Patented T87871 TARGETID T87871 T87871 FORMERID TTDI01510 T87871 UNIPROID ROR1_HUMAN T87871 TARGNAME Neurotrophic tyrosine kinase ROR1 (ROR1) T87871 GENENAME ROR1 T87871 TARGTYPE Clinical trial T87871 SYNONYMS receptor tyrosine kinase-like orphan receptor 1; receptor tyrosine kinase like orphan receptor 1; neurotrophic tyrosine kinase, receptor-related 1; dJ537F10.1; Tyrosine-protein kinase transmembrane receptor ROR1; NTRKR1; Inactive tyrosine-protein kinase transmembrane receptor ROR1 T87871 FUNCTION Receptor for ligand WNT5A which activate downstream NFkB signaling pathway and may result in the inhibition of WNT3A-mediated signaling. In inner ear, crucial for spiral ganglion neurons to innervate auditory hair cells. Has very low kinase activity in vitro and is unlikely to function as a tyrosine kinase in vivo. T87871 PDBSTRUC 6BAN; 6BA5; 5Z55 T87871 BIOCLASS Kinase T87871 SEQUENCE MHRPRRRGTRPPLLALLAALLLAARGAAAQETELSVSAELVPTSSWNISSELNKDSYLTLDEPMNNITTSLGQTAELHCKVSGNPPPTIRWFKNDAPVVQEPRRLSFRSTIYGSRLRIRNLDTTDTGYFQCVATNGKEVVSSTGVLFVKFGPPPTASPGYSDEYEEDGFCQPYRGIACARFIGNRTVYMESLHMQGEIENQITAAFTMIGTSSHLSDKCSQFAIPSLCHYAFPYCDETSSVPKPRDLCRDECEILENVLCQTEYIFARSNPMILMRLKLPNCEDLPQPESPEAANCIRIGIPMADPINKNHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDSKEKNKMEILYILVPSVAIPLAIALLFFFICVCRNNQKSSSAPVQRQPKHVRGQNVEMSMLNAYKPKSKAKELPLSAVRFMEELGECAFGKIYKGHLYLPGMDHAQLVAIKTLKDYNNPQQWTEFQQEASLMAELHHPNIVCLLGAVTQEQPVCMLFEYINQGDLHEFLIMRSPHSDVGCSSDEDGTVKSSLDHGDFLHIAIQIAAGMEYLSSHFFVHKDLAARNILIGEQLHVKISDLGLSREIYSADYYRVQSKSLLPIRWMPPEAIMYGKFSSDSDIWSFGVVLWEIFSFGLQPYYGFSNQEVIEMVRKRQLLPCSEDCPPRMYSLMTECWNEIPSRRPRFKDIHVRLRSWEGLSSHTSSTTPSGGNATTQTTSLSASPVSNLSNPRYPNYMFPSQGITPQGQIAGFIGPPIPQNQRFIPINGYPIPPGYAAFPAAHYQPTGPPRVIQHCPPPKSRSPSSASGSTSTGHVTSLPSSGSNQEANIPLLPHMSIPNHPGGMGITVFGNKSQKPYKIDSKQASLLGDANIHGHTESMISAEL T87871 DRUGINFO D3YJZ7 Zilovertamab vedotin Phase 2/3 T87871 DRUGINFO D0P7PY Cirmtuzumab Phase 2 T87871 DRUGINFO D1CG5M VLS-101 Phase 2 T87871 DRUGINFO D8P1KS Zilovertamab Phase 2 T87871 DRUGINFO D79HBK NBE-002 Phase 1/2 T87871 DRUGINFO D0L5KK ROR1R-CAR-T Cell Phase 1 T87871 DRUGINFO D0Q8ML ROR1 CAR-specific Autologous T-Lymphocytes Phase 1 T60636 TARGETID T60636 T60636 UNIPROID ODO1_HUMAN T60636 TARGNAME Alpha-ketoglutarate dehydrogenase (OGDH) T60636 GENENAME OGDH T60636 TARGTYPE Clinical trial T60636 SYNONYMS OGDC-E1; 2-oxoglutarate dehydrogenase, mitochondrial; 2-oxoglutarate dehydrogenase complex component E1 T60636 FUNCTION The 2-oxoglutarate dehydrogenase complex catalyzes the overall conversion of 2-oxoglutarate to succinyl-CoA and CO(2). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion. A fraction of the 2-oxoglutarate dehydrogenase complex also localizes in the nucleus and is required for lysine succinylation of histones: associates with KAT2A on chromatin and provides succinyl-CoA to histone succinyltransferase KAT2A. 2-oxoglutarate dehydrogenase (E1) component of the 2-oxoglutarate dehydrogenase complex, which mediates the decarboxylation of alpha-ketoglutarate. T60636 PDBSTRUC 3ERY T60636 BIOCLASS Aldehyde/oxo donor oxidoreductase T60636 ECNUMBER EC 1.2.4.2 T60636 SEQUENCE MFHLRTCAAKLRPLTASQTVKTFSQNRPAAARTFQQIRCYSAPVAAEPFLSGTSSNYVEEMYCAWLENPKSVHKSWDIFFRNTNAGAPPGTAYQSPLPLSRGSLAAVAHAQSLVEAQPNVDKLVEDHLAVQSLIRAYQIRGHHVAQLDPLGILDADLDSSVPADIISSTDKLGFYGLDESDLDKVFHLPTTTFIGGQESALPLREIIRRLEMAYCQHIGVEFMFINDLEQCQWIRQKFETPGIMQFTNEEKRTLLARLVRSTRFEEFLQRKWSSEKRFGLEGCEVLIPALKTIIDKSSENGVDYVIMGMPHRGRLNVLANVIRKELEQIFCQFDSKLEAADEGSGDVKYHLGMYHRRINRVTDRNITLSLVANPSHLEAADPVVMGKTKAEQFYCGDTEGKKVMSILLHGDAAFAGQGIVYETFHLSDLPSYTTHGTVHVVVNNQIGFTTDPRMARSSPYPTDVARVVNAPIFHVNSDDPEAVMYVCKVAAEWRSTFHKDVVVDLVCYRRNGHNEMDEPMFTQPLMYKQIRKQKPVLQKYAELLVSQGVVNQPEYEEEISKYDKICEEAFARSKDEKILHIKHWLDSPWPGFFTLDGQPRSMSCPSTGLTEDILTHIGNVASSVPVENFTIHGGLSRILKTRGEMVKNRTVDWALAEYMAFGSLLKEGIHIRLSGQDVERGTFSHRHHVLHDQNVDKRTCIPMNHLWPNQAPYTVCNSSLSEYGVLGFELGFAMASPNALVLWEAQFGDFHNTAQCIIDQFICPGQAKWVRQNGIVLLLPHGMEGMGPEHSSARPERFLQMCNDDPDVLPDLKEANFDINQLYDCNWVVVNCSTPGNFFHVLRRQILLPFRKPLIIFTPKSLLRHPEARSSFDEMLPGTHFQRVIPEDGPAAQNPENVKRLLFCTGKVYYDLTRERKARDMVGQVAITRIEQLSPFPFDLLLKEVQKYPNAELAWCQEEHKNQGYYDYVKPRLRTTISRAKPVWYAGRDPAAAPATGNKKTHLTELQRLLDTAFDLDVFKNFS T60636 DRUGINFO D07NVI CPI-613 Phase 3 T89065 TARGETID T89065 T89065 FORMERID TTDR01222 T89065 UNIPROID PLOD1_HUMAN T89065 TARGNAME Lysyl hydroxylase 1 (PLOD1) T89065 GENENAME PLOD1 T89065 TARGTYPE Clinical trial T89065 SYNONYMS Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1; Peptidyllysine, 2-oxoglutarate:oxygen 5-oxidoreductase; PLOD; Lysyl hydroxylase; LLH; LH1; LH T89065 FUNCTION Forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen cross-links. Part of a complex composed of PLOD1, P3H3 and P3H4 that catalyzes hydroxylation of lysine residues in collagen alpha chains and is required for normal assembly and cross-linkling of collagen fibrils. T89065 BIOCLASS Paired donor oxygen oxidoreductase T89065 ECNUMBER EC 1.14.11.4 T89065 SEQUENCE MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGYENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPSLMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEGLPTTRGTRYIAVSFVDP T88656 TARGETID T88656 T88656 FORMERID TTDI02134 T88656 UNIPROID NOTC2_HUMAN T88656 TARGNAME Notch-2 receptor (NOTCH2) T88656 GENENAME NOTCH2 T88656 TARGTYPE Clinical trial T88656 SYNONYMS hN2; Notch 2 intracellular domain; Notch 2; Neurogenic locus notch homolog protein 2 T88656 FUNCTION Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation. Positively regulates self-renewal of liver cancer cells. Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. T88656 PDBSTRUC 5MWB; 2OO4 T88656 BIOCLASS Notch protein T88656 SEQUENCE MPALRPALLWALLALWLCCAAPAHALQCRDGYEPCVNEGMCVTYHNGTGYCKCPEGFLGEYCQHRDPCEKNRCQNGGTCVAQAMLGKATCRCASGFTGEDCQYSTSHPCFVSRPCLNGGTCHMLSRDTYECTCQVGFTGKECQWTDACLSHPCANGSTCTTVANQFSCKCLTGFTGQKCETDVNECDIPGHCQHGGTCLNLPGSYQCQCPQGFTGQYCDSLYVPCAPSPCVNGGTCRQTGDFTFECNCLPGFEGSTCERNIDDCPNHRCQNGGVCVDGVNTYNCRCPPQWTGQFCTEDVDECLLQPNACQNGGTCANRNGGYGCVCVNGWSGDDCSENIDDCAFASCTPGSTCIDRVASFSCMCPEGKAGLLCHLDDACISNPCHKGALCDTNPLNGQYICTCPQGYKGADCTEDVDECAMANSNPCEHAGKCVNTDGAFHCECLKGYAGPRCEMDINECHSDPCQNDATCLDKIGGFTCLCMPGFKGVHCELEINECQSNPCVNNGQCVDKVNRFQCLCPPGFTGPVCQIDIDDCSSTPCLNGAKCIDHPNGYECQCATGFTGVLCEENIDNCDPDPCHHGQCQDGIDSYTCICNPGYMGAICSDQIDECYSSPCLNDGRCIDLVNGYQCNCQPGTSGVNCEINFDDCASNPCIHGICMDGINRYSCVCSPGFTGQRCNIDIDECASNPCRKGATCINGVNGFRCICPEGPHHPSCYSQVNECLSNPCIHGNCTGGLSGYKCLCDAGWVGINCEVDKNECLSNPCQNGGTCDNLVNGYRCTCKKGFKGYNCQVNIDECASNPCLNQGTCFDDISGYTCHCVLPYTGKNCQTVLAPCSPNPCENAAVCKESPNFESYTCLCAPGWQGQRCTIDIDECISKPCMNHGLCHNTQGSYMCECPPGFSGMDCEEDIDDCLANPCQNGGSCMDGVNTFSCLCLPGFTGDKCQTDMNECLSEPCKNGGTCSDYVNSYTCKCQAGFDGVHCENNINECTESSCFNGGTCVDGINSFSCLCPVGFTGSFCLHEINECSSHPCLNEGTCVDGLGTYRCSCPLGYTGKNCQTLVNLCSRSPCKNKGTCVQKKAESQCLCPSGWAGAYCDVPNVSCDIAASRRGVLVEHLCQHSGVCINAGNTHYCQCPLGYTGSYCEEQLDECASNPCQHGATCSDFIGGYRCECVPGYQGVNCEYEVDECQNQPCQNGGTCIDLVNHFKCSCPPGTRGLLCEENIDDCARGPHCLNGGQCMDRIGGYSCRCLPGFAGERCEGDINECLSNPCSSEGSLDCIQLTNDYLCVCRSAFTGRHCETFVDVCPQMPCLNGGTCAVASNMPDGFICRCPPGFSGARCQSSCGQVKCRKGEQCVHTASGPRCFCPSPRDCESGCASSPCQHGGSCHPQRQPPYYSCQCAPPFSGSRCELYTAPPSTPPATCLSQYCADKARDGVCDEACNSHACQWDGGDCSLTMENPWANCSSPLPCWDYINNQCDELCNTVECLFDNFECQGNSKTCKYDKYCADHFKDNHCDQGCNSEECGWDGLDCAADQPENLAEGTLVIVVLMPPEQLLQDARSFLRALGTLLHTNLRIKRDSQGELMVYPYYGEKSAAMKKQRMTRRSLPGEQEQEVAGSKVFLEIDNRQCVQDSDHCFKNTDAAAALLASHAIQGTLSYPLVSVVSESLTPERTQLLYLLAVAVVIILFIILLGVIMAKRKRKHGSLWLPEGFTLRRDASNHKRREPVGQDAVGLKNLSVQVSEANLIGTGTSEHWVDDEGPQPKKVKAEDEALLSEEDDPIDRRPWTQQHLEAADIRRTPSLALTPPQAEQEVDVLDVNVRGPDGCTPLMLASLRGGSSDLSDEDEDAEDSSANIITDLVYQGASLQAQTDRTGEMALHLAARYSRADAAKRLLDAGADANAQDNMGRCPLHAAVAADAQGVFQILIRNRVTDLDARMNDGTTPLILAARLAVEGMVAELINCQADVNAVDDHGKSALHWAAAVNNVEATLLLLKNGANRDMQDNKEETPLFLAAREGSYEAAKILLDHFANRDITDHMDRLPRDVARDRMHHDIVRLLDEYNVTPSPPGTVLTSALSPVICGPNRSFLSLKHTPMGKKSRRPSAKSTMPTSLPNLAKEAKDAKGSRRKKSLSEKVQLSESSVTLSPVDSLESPHTYVSDTTSSPMITSPGILQASPNPMLATAAPPAPVHAQHALSFSNLHEMQPLAHGASTVLPSVSQLLSHHHIVSPGSGSAGSLSRLHPVPVPADWMNRMEVNETQYNEMFGMVLAPAEGTHPGIAPQSRPPEGKHITTPREPLPPIVTFQLIPKGSIAQPAGAPQPQSTCPPAVAGPLPTMYQIPEMARLPSVAFPTAMMPQQDGQVAQTILPAYHPFPASVGKYPTPPSQHSYASSNAAERTPSHSGHLQGEHPYLTPSPESPDQWSSSSPHSASDWSDVTTSPTPGGAGGGQRGPGTHMSEPPHNNMQVYA T88656 DRUGINFO D01QLP Tarextumab Phase 2 T93923 TARGETID T93923 T93923 FORMERID TTDNC00406 T93923 UNIPROID TNR9_HUMAN T93923 TARGNAME Co-stimulatory molecule 4-1BB (CD137) T93923 GENENAME TNFRSF9 T93923 TARGTYPE Clinical trial T93923 SYNONYMS Tumor necrosis factor receptor superfamily member 9; T-cell antigen ILA; T-cell antigen 4-1BB homolog; ILA; CDw137; 4-1BB ligand receptor T93923 FUNCTION Possibly active during T cell activation. Receptor for TNFSF9/4-1BBL. T93923 PDBSTRUC 6MI2; 6MHR; 6MGP; 6CU0; 6CPR T93923 BIOCLASS Cytokine receptor T93923 SEQUENCE MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPADLSPGASSVTPPAPAREPGHSPQIISFFLALTSTALLFLLFFLTLRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL T93923 DRUGINFO D02ZMB Urelumab Phase 2 T93923 DRUGINFO D06NAG Anti-CD137 Phase 2 T93923 DRUGINFO D03LUF CD137 CAR-T Cell Phase 1/2 T93923 DRUGINFO DB91HQ ADG106 Phase 1/2 T93923 DRUGINFO D0Q5GK MG7-CART Phase 1/2 T93923 DRUGINFO DUVH60 NM21-1480 Phase 1/2 T93923 DRUGINFO D01ZLR PF-05082566 Phase 1 T93923 DRUGINFO D4BC6I RG7827 Phase 1 T93923 DRUGINFO D4HDR2 LVGN6051 Phase 1 T93923 DRUGINFO D9DN5J RG6076 Phase 1 T93923 DRUGINFO DK6S3G CTX-471 Phase 1 T93923 DRUGINFO DL9ZT4 Utomilumab Phase 1 T93923 DRUGINFO DOA3J0 AGEN2373 Phase 1 T93923 DRUGINFO D0JY0M CD28 and CD137 CAR-T Cells Phase 1 T93923 DRUGINFO D2QY0Z MCLA-145 Phase 1 T93923 DRUGINFO D3HBJ1 GEN1046 Phase 1 T93923 DRUGINFO DA1X5W INBRX-105 Phase 1 T93923 DRUGINFO DN28KM GEN1042 Phase 1 T93923 DRUGINFO DN2F9A AMG 506 Phase 1 T93923 DRUGINFO D2L9MD RG6524 Phase 1 T93923 DRUGINFO D07RXX HG-1051 Investigative T93450 TARGETID T93450 T93450 FORMERID TTDI02335 T93450 UNIPROID IL24_HUMAN T93450 TARGNAME Interleukin-24 (IL24) T93450 GENENAME IL24 T93450 TARGTYPE Clinical trial T93450 SYNONYMS Suppression of tumorigenicity 16 protein; ST16; Melanoma differentiationassociated gene 7 protein; Melanoma differentiation-associated gene 7 protein; MDA7; MDA-7; Interleukin24; IL-24 T93450 FUNCTION Has antiproliferative properties on melanoma cells and may contribute to terminal cell differentiation. T93450 PDBSTRUC 6GG1; 6DF3 T93450 BIOCLASS Cytokine: interleukin T93450 SEQUENCE MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL T93450 DRUGINFO D02FTV INGN-241 Phase 2 T38875 TARGETID T38875 T38875 FORMERID TTDS00209 T38875 UNIPROID AAPK1_HUMAN; AAKB1_HUMAN; AAKG1_HUMAN T38875 TARGNAME AMP-activated protein kinase (AMPK) T38875 GENENAME PRKAA1; PRKAB1; PRKAG1 T38875 TARGTYPE Clinical trial T38875 SYNONYMS AMPK; 5'-AMP-activated protein kinase T38875 FUNCTION Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Regulates lipid synthesis by phosphorylating and inactivating lipid metabolic enzymes such as ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes, respectively. Regulates insulin-signaling and glycolysis by phosphorylating IRS1, PFKFB2 and PFKFB3. AMPK stimulates glucose uptake in muscle by increasing the translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane, possibly by mediating phosphorylation of TBC1D4/AS160. Regulates transcription and chromatin structure by phosphorylating transcription regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3, histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53, SREBF1, SREBF2 and PPARGC1A. Acts as a key regulator of glucose homeostasis in liver by phosphorylating CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm. In response to stress, phosphorylates 'Ser-36' of histone H2B (H2BS36ph), leading to promote transcription. Acts as a key regulator of cell growth and proliferation by phosphorylating TSC2, RPTOR and ATG1/ULK1: in response to nutrient limitation, negatively regulates the mTORC1 complex by phosphorylating RPTOR component of the mTORC1 complex and by phosphorylating and activating TSC2. In response to nutrient limitation, promotes autophagy by phosphorylating and activating ATG1/ULK1. AMPK also acts as a regulator of circadian rhythm by mediating phosphorylation of CRY1, leading to destabilize it. May regulate the Wnt signaling pathway by phosphorylating CTNNB1, leading to stabilize it. Also has tau-protein kinase activity: in response to amyloid beta A4 protein (APP) exposure, activated by CAMKK2, leading to phosphorylation of MAPT/TAU; however the relevance of such data remains unclear in vivo. Also phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1. T38875 BIOCLASS Kinase T38875 SEQUENCE MRRLSSWRKMATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNRQKIRSLDVVGKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNGRLDEKESRRLFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDGIFYTPQYLNPSVISLLKHMLQVDPMKRATIKDIREHEWFKQDLPKYLFPEDPSYSSTMIDDEALKEVCEKFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDSFLDDHHLTRPHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDIMAEVCRAIKQLDYEWKVVNPYYLRVRRKNPVTSTYSKMSLQLYQVDSRTYLLDFRSIDDEITEAKSGTATPQRSGSVSNYRSCQRSDSDAEAQGKSSEVSLTSSVTSLDSSPVDLTPRPGSHTIEFFEMCANLIKILAQ T38875 DRUGINFO D0R3MT Acadesine Phase 3 T38875 DRUGINFO D03JCA MB-11055 Phase 2 T38875 DRUGINFO D08PMB Imeglimin Phase 2 T38875 DRUGINFO D67AKN PXL-770 Phase 2 T38875 DRUGINFO DD3IE7 ENERGI-F701 Phase 2 T38875 DRUGINFO DL9F3C O-304 Phase 2 T38875 DRUGINFO D0Q5DT IM156 Phase 1 T38875 DRUGINFO D07XPE Phenformin Withdrawn from market T38875 DRUGINFO D01UVU 4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol Investigative T38875 DRUGINFO D0C1OJ Debio-0930 Investigative T38875 DRUGINFO D0C3GW TG-1022 Investigative T38875 DRUGINFO D0Y0BK Dorsomorphin Investigative T38875 DRUGINFO DCVO04 OSU-53 Investigative T38875 DRUGINFO D0CE3R SU 6656 Investigative T38875 DRUGINFO D0PP6Y PMID23639540C13a Investigative T38875 DRUGINFO D0O1YH 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative T48429 TARGETID T48429 T48429 FORMERID TTDI02093 T48429 UNIPROID I15RA_HUMAN T48429 TARGNAME Interleukin 15 receptor alpha (IL15RA) T48429 GENENAME IL15RA T48429 TARGTYPE Clinical trial T48429 SYNONYMS sIL15Ralpha; sIL15RA; sIL15 receptor subunit alpha; Soluble interleukin15 receptor subunit alpha; Interleukin-15 receptor subunit alpha; IL15Ralpha; IL15 receptor subunit alpha; IL-15RA; IL-15R-alpha; IL-15 receptor subunit alpha; CD215 T48429 FUNCTION Can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells. In neutrophils, binds and activates kinase SYK in response to IL15 stimulation. In neutrophils, required for IL15-induced phagocytosis in a SYK-dependent manner. Expression of different isoforms may alter or interfere with signal transduction. High-affinity receptor for interleukin-15. T48429 PDBSTRUC 4GS7; 2Z3R; 2Z3Q; 2ERS T48429 BIOCLASS Cytokine receptor T48429 SEQUENCE MAPRRARGCRTLGLPALLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPPSTVTTAGVTPQPESLSPSGKEPAASSPSSNNTAATTAAIVPGSQLMPSKSPSTGTTEISSHESSHGTPSQTTAKNWELTASASHQPPGVYPQGHSDTTVAISTSTVLLCGLSAVSLLACYLKSRQTPPLASVEMEAMEALPVTWGTSSRDEDLENCSHHL T48429 DRUGINFO D0FD7H ALT-803 Phase 2 T48429 DRUGINFO D2YN1W NKTR-255 Phase 1/2 T87108 TARGETID T87108 T87108 FORMERID TTDNC00477 T87108 UNIPROID MSLN_HUMAN T87108 TARGNAME Mesothelin (MSLN) T87108 GENENAME MSLN T87108 TARGTYPE Clinical trial T87108 SYNONYMS Prepromegakaryocytepotentiating factor; Pre-pro-megakaryocyte-potentiating factor; Mesothelin, cleaved form; MPF; CAK1 antigen T87108 FUNCTION Membrane-anchored forms may play a role in cellular adhesion. T87108 PDBSTRUC 4F3F T87108 SEQUENCE MALPTARPLLGSCGTPALGSLLFLLFSLGWVQPSRTLAGETGQEAAPLDGVLANPPNISSLSPRQLLGFPCAEVSGLSTERVRELAVALAQKNVKLSTEQLRCLAHRLSEPPEDLDALPLDLLLFLNPDAFSGPQACTRFFSRITKANVDLLPRGAPERQRLLPAALACWGVRGSLLSEADVRALGGLACDLPGRFVAESAEVLLPRLVSCPGPLDQDQQEAARAALQGGGPPYGPPSTWSVSTMDALRGLLPVLGQPIIRSIPQGIVAAWRQRSSRDPSWRQPERTILRPRFRREVEKTACPSGKKAREIDESLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELYPQGYPESVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQAPRRPLPQVATLIDRFVKGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPRQLDVLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATFMKLRTDAVLPLTVAEVQKLLGPHVEGLKAEERHRPVRDWILRQRQDDLDTLGLGLQGGIPNGYLVLDLSMQEALSGTPCLLGPGPVLTVLALLLASTLA T87108 DRUGINFO D02WSB CRS-207 Phase 2 T87108 DRUGINFO D0R6MJ MORAb-009 Phase 2 T87108 DRUGINFO D00YXG Anti-mesothelin CAR transduced PBL Phase 1/2 T87108 DRUGINFO D05FUP CAR-T cells targeting Mesothelin Phase 1/2 T87108 DRUGINFO D0BE6M Anti-Mesothelin CAR-T cells Phase 1/2 T87108 DRUGINFO D0HW1L HPN536 Phase 1/2 T87108 DRUGINFO D0KC2S CAR-T cells targeting mesothelin Phase 1/2 T87108 DRUGINFO DJA64B TC-510 Phase 1/2 T87108 DRUGINFO DX6O9V TC-210 Phase 1/2 T87108 DRUGINFO D03OIO Anti-Mesothelin CAR-T cells Phase 1 T87108 DRUGINFO D07YPB Hu-CART meso cells Phase 1 T87108 DRUGINFO D09YXN CAR-T cells targeting Mesothelin Phase 1 T87108 DRUGINFO D0CA3M Anti-meso-CAR T cells Phase 1 T87108 DRUGINFO D0D2LE Meso-CART Phase 1 T87108 DRUGINFO D0EB0Y Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 Phase 1 T87108 DRUGINFO D0G4GY Anti-meso-CAR vector transduced T cells Phase 1 T87108 DRUGINFO D0L7OJ CAR-T Cells targeting Mesothelin Phase 1 T87108 DRUGINFO D0O2XK Mesothelin-targeted T cells Phase 1 T87108 DRUGINFO D0P2GA CART-meso cells Phase 1 T87108 DRUGINFO D0P5MG BAY 94-9343 Phase 1 T87108 DRUGINFO D0PT5D Anti-mesothelin CAR T Cells Phase 1 T87108 DRUGINFO D0S9FI ICasp9M28z T cell Phase 1 T87108 DRUGINFO D0V7QW RG7882 Phase 1 T87108 DRUGINFO D0ZF9J HuCART-meso cells Phase 1 T87108 DRUGINFO D8EIB7 MCY-M11 Phase 1 T87108 DRUGINFO DF9S1L ATA2271 Phase 1 T87108 DRUGINFO DJ25DI 227Th-labelled MSLN-TTC Phase 1 T87108 DRUGINFO D0MD8S CARTmeso/19 Phase 1 T87108 DRUGINFO D0V5DD CART-meso-19 T cells Phase 1 T87108 DRUGINFO D04WZL CART-meso cells Clinical trial T87108 DRUGINFO D09YUK SS1(dsFv)-PE38 Discontinued in Phase 1 T87108 DRUGINFO D8AI0N ATA3271 Preclinical T99340 TARGETID T99340 T99340 FORMERID TTDI03510 T99340 UNIPROID RIPK1_HUMAN T99340 TARGNAME Receptor-interacting protein 1 (RIPK1) T99340 GENENAME RIPK1 T99340 TARGTYPE Clinical trial T99340 SYNONYMS Receptor-interacting serine/threonine-protein kinase 1; RIP1; RIP-1; RIP; Cell death protein RIP T99340 FUNCTION Upon activation of TNFR1 by the TNF-alpha family cytokines, TRADD and TRAF2 are recruited to the receptor. Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependent manner, and thereby activates the MAP3K5-JNK apoptotic cascade. Ubiquitination by TRAF2 via 'Lys-63'-link chains acts as a critical enhancer of communication with downstream signal transducers in the mitogen-activated protein kinase pathway and the NF-kappa-B pathway, which in turn mediate downstream events including the activation of genes encoding inflammatory molecules. Polyubiquitinated protein binds to IKBKG/NEMO, the regulatory subunit of the IKK complex, a critical event for NF-kappa-B activation. Interaction with other cellular RHIM-containing adapters initiates gene activation and cell death. RIPK1 and RIPK3 association, in particular, forms a necrosis-inducing complex. Serine-threonine kinase which transduces inflammatory and cell-death signals (programmed necrosis) following death receptors ligation, activation of pathogen recognition receptors (PRRs), and DNA damage. T99340 PDBSTRUC 6R5F; 6OCQ; 6NW2; 6HHO; 6C4D T99340 BIOCLASS Kinase T99340 ECNUMBER EC 2.7.11.1 T99340 SEQUENCE MQPDMSLNVIKMKSSDFLESAELDSGGFGKVSLCFHRTQGLMIMKTVYKGPNCIEHNEALLEEAKMMNRLRHSRVVKLLGVIIEEGKYSLVMEYMEKGNLMHVLKAEMSTPLSVKGRIILEIIEGMCYLHGKGVIHKDLKPENILVDNDFHIKIADLGLASFKMWSKLNNEEHNELREVDGTAKKNGGTLYYMAPEHLNDVNAKPTEKSDVYSFAVVLWAIFANKEPYENAICEQQLIMCIKSGNRPDVDDITEYCPREIISLMKLCWEANPEARPTFPGIEEKFRPFYLSQLEESVEEDVKSLKKEYSNENAVVKRMQSLQLDCVAVPSSRSNSATEQPGSLHSSQGLGMGPVEESWFAPSLEHPQEENEPSLQSKLQDEANYHLYGSRMDRQTKQQPRQNVAYNREEERRRRVSHDPFAQQRPYENFQNTEGKGTAYSSAASHGNAVHQPSGLTSQPQVLYQNNGLYSSHGFGTRPLDPGTAGPRVWYRPIPSHMPSLHNIPVPETNYLGNTPTMPFSSLPPTDESIKYTIYNSTGIQIGAYNYMEIGGTSSSLLDSTNTNFKEEPAAKYQAIFDNTTSLTDKHLDPIRENLGKHWKNCARKLGFTQSQIDEIDHDYERDGLKEKVYQMLQKWVMREGIKGATVGKLAQALHQCSRIDLLSSLIYVSQN T99340 DRUGINFO D0LQ3L GSK2982772 Phase 2 T99340 DRUGINFO D8GVM1 SAR443820 Phase 2 T99340 DRUGINFO DC1AV3 DNL758 Phase 2 T99340 DRUGINFO DWM2Y5 Eclitasertib Phase 2 T99340 DRUGINFO D0Z7BX GSK3145095 Phase 1/2 T99340 DRUGINFO D9FT0A R552 Phase 1 T99340 DRUGINFO DGH83L DNL747 Phase 1 T99340 DRUGINFO DHD2S9 DNL104 Phase 1 T99340 DRUGINFO D0AY2N Tricyclic compound 10 Patented T99340 DRUGINFO D0LF0B Tricyclic compound 8 Patented T99340 DRUGINFO D0M7WS Tricyclic compound 9 Patented T99340 DRUGINFO DW0D7G GNE684 Preclinical T99340 DRUGINFO D0K8YD PMID24900635C21 Investigative T99340 DRUGINFO D1N2BO GSK'963 Investigative T99340 DRUGINFO DEV97R PK68 Investigative T99340 DRUGINFO DF5C2I RIPA-56 Investigative T96892 TARGETID T96892 T96892 UNIPROID MELK_HUMAN T96892 TARGNAME Maternal embryonic leucine zipper kinase (MELK) T96892 GENENAME MELK T96892 TARGTYPE Clinical trial T96892 SYNONYMS Protein kinase PK38; Protein kinase Eg3 T96892 FUNCTION Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. Has a broad substrate specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 and ZNF622. Acts as an activator of apoptosis by phosphorylating and activating MAP3K5/ASK1. Acts as a regulator of cell cycle, notably by mediating phosphorylation of CDC25B, promoting localization of CDC25B to the centrosome and the spindle poles during mitosis. Plays a key role in cell proliferation and carcinogenesis. Required for proliferation of embryonic and postnatal multipotent neural progenitors. Phosphorylates and inhibits BCL2L14, possibly leading to affect mammary carcinogenesis by mediating inhibition of the pro-apoptotic function of BCL2L14. Also involved in the inhibition of spliceosome assembly during mitosis by phosphorylating ZNF622, thereby contributing to its redirection to the nucleus. May also play a role in primitive hematopoiesis. T96892 PDBSTRUC 5TX3; 5TWZ; 5TWY; 5TWU; 5TWL T96892 BIOCLASS Protein kinase superfamily. CAMK Ser/Thr protein kinase family T96892 ECNUMBER EC 2.7.11.1 T96892 SEQUENCE MKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGQASATPFTDIKSNNWSLEDVTASDKNYVAGLIDYDWCEDDLSTGAATPRTSQFTKYWTESNGVESKSLTPALCRTPANKLKNKENVYTPKSAVKNEEYFMFPEPKTPVNKNQHKREILTTPNRYTTPSKARNQCLKETPIKIPVNSTGTDKLMTGVISPERRCRSVELDLNQAHMEETPKRKGAKVFGSLERGLDKVITVLTRSKRKGSARDGPRRLKLHYNVTTTRLVNPDQLLNEIMSILPKKHVDFVQKGYTLKCQTQSDFGKVTMQFELEVCQLQKPDVVGIRRQRLKGDAWVYKRLVEDILSSCKV T96892 DRUGINFO D08FIX OTSSP167 Phase 1 T85523 TARGETID T85523 T85523 FORMERID TTDNC00586 T85523 UNIPROID MYPC3_HUMAN T85523 TARGNAME Cardiac myosin (MYBPC3) T85523 GENENAME MYBPC3 T85523 TARGTYPE Clinical trial T85523 SYNONYMS Myosinbinding protein C, cardiactype; Myosin-binding protein C, cardiac-type; Cprotein, cardiac muscle isoform; Cardiac MyBPC; Cardiac MyBP-C; C-protein, cardiac muscle isoform T85523 FUNCTION In vitro it binds MHC, F-actin and native thin filaments, and modifies the activity of actin-activated myosin ATPase. It may modulate muscle contraction or may play a more structural role. Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands. T85523 PDBSTRUC 6G2T; 6CXJ; 6CXI; 5K6P; 3CX2 T85523 BIOCLASS Immunoglobulin T85523 SEQUENCE MPEPGKKPVSAFSKKPRSVEVAAGSPAVFEAETERAGVKVRWQRGGSDISASNKYGLATEGTRHTLTVREVGPADQGSYAVIAGSSKVKFDLKVIEAEKAEPMLAPAPAPAEATGAPGEAPAPAAELGESAPSPKGSSSAALNGPTPGAPDDPIGLFVMRPQDGEVTVGGSITFSARVAGASLLKPPVVKWFKGKWVDLSSKVGQHLQLHDSYDRASKVYLFELHITDAQPAFTGSYRCEVSTKDKFDCSNFNLTVHEAMGTGDLDLLSAFRRTSLAGGGRRISDSHEDTGILDFSSLLKKRDSFRTPRDSKLEAPAEEDVWEILRQAPPSEYERIAFQYGVTDLRGMLKRLKGMRRDEKKSTAFQKKLEPAYQVSKGHKIRLTVELADHDAEVKWLKNGQEIQMSGSKYIFESIGAKRTLTISQCSLADDAAYQCVVGGEKCSTELFVKEPPVLITRPLEDQLVMVGQRVEFECEVSEEGAQVKWLKDGVELTREETFKYRFKKDGQRHHLIINEAMLEDAGHYALCTSGGQALAELIVQEKKLEVYQSIADLMVGAKDQAVFKCEVSDENVRGVWLKNGKELVPDSRIKVSHIGRVHKLTIDDVTPADEADYSFVPEGFACNLSAKLHFMEVKIDFVPRQEPPKIHLDCPGRIPDTIVVVAGNKLRLDVPISGDPAPTVIWQKAITQGNKAPARPAPDAPEDTGDSDEWVFDKKLLCETEGRVRVETTKDRSIFTVEGAEKEDEGVYTVTVKNPVGEDQVNLTVKVIDVPDAPAAPKISNVGEDSCTVQWEPPAYDGGQPILGYILERKKKKSYRWMRLNFDLIQELSHEARRMIEGVVYEMRVYAVNAIGMSRPSPASQPFMPIGPPSEPTHLAVEDVSDTTVSLKWRPPERVGAGGLDGYSVEYCPEGCSEWVAALQGLTEHTSILVKDLPTGARLLFRVRAHNMAGPGAPVTTTEPVTVQEILQRPRLQLPRHLRQTIQKKVGEPVNLLIPFQGKPRPQVTWTKEGQPLAGEEVSIRNSPTDTILFIRAARRVHSGTYQVTVRIENMEDKATLVLQVVDKPSPPQDLRVTDAWGLNVALEWKPPQDVGNTELWGYTVQKADKKTMEWFTVLEHYRRTHCVVPELIIGNGYYFRVFSQNMVGFSDRAATTKEPVFIPRPGITYEPPNYKALDFSEAPSFTQPLVNRSVIAGYTAMLCCAVRGSPKPKISWFKNGLDLGEDARFRMFSKQGVLTLEIRKPCPFDGGIYVCRATNLQGEARCECRLEVRVPQ T85523 DRUGINFO D0YL8U Omecamtiv mecarbil Phase 3 T85523 DRUGINFO D6SY9X Aficamten Phase 3 T17502 TARGETID T17502 T17502 FORMERID TTDI02295 T17502 UNIPROID RPE65_HUMAN T17502 TARGNAME Retinal pigment epithelium protein (RPE65) T17502 GENENAME RPE65 T17502 TARGTYPE Clinical trial T17502 SYNONYMS Retinol isomerase; Retinoid isomerohydrolase; Retinal pigment epithelium-specific 65 kDa protein; Meso-zeaxanthin isomerase; Lutein isomerase; All-trans-retinyl-palmitate hydrolase T17502 FUNCTION Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins. Catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol which is further oxidized by 11-cis retinol dehydrogenase to 11-cis-retinal for use as visual chromophore. Essential for the production of 11-cis retinal for both rod and cone photoreceptors. Also capable of catalyzing the isomerization of lutein to meso-zeaxanthin an eye-specific carotenoid. The soluble form binds vitamin A (all-trans-retinol), making it available for LRAT processing to all-trans-retinyl ester. The membrane form, palmitoylated by LRAT, binds all-trans-retinyl esters, making them available for IMH (isomerohydrolase) processing to all-cis-retinol. The soluble form is regenerated by transferring its palmitoyl groups onto 11-cis-retinol, a reaction catalyzed by LRAT (By similarity). T17502 BIOCLASS Carboxylic ester hydrolase T17502 ECNUMBER EC 3.1.1.64 T17502 SEQUENCE MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS T17502 DRUGINFO D01SRB AAV2-hRPE65v2 Phase 3 T17502 DRUGINFO D0GP1O Emixustat Phase 2/3 T17502 DRUGINFO D04FSD TgAAG76 Phase 1/2 T17502 DRUGINFO D0DX1F Leber's congenital amaurosis gene therapy Phase 1/2 T17502 DRUGINFO DDX95P AAV-RPE65 Phase 1/2 T94977 TARGETID T94977 T94977 FORMERID TTDNR00652 T94977 UNIPROID CTF1_HUMAN T94977 TARGNAME Cardiotrophin-1 (CTF1) T94977 GENENAME CTF1 T94977 TARGTYPE Clinical trial T94977 SYNONYMS CTF1; CT-1 T94977 FUNCTION Induces cardiac myocyte hypertrophy in vitro. Binds to and activates the ILST/gp130 receptor. T94977 BIOCLASS Cytokine: interleukin T94977 SEQUENCE MSRREGSLEDPQTDSSVSLLPHLEAKIRQTHSLAHLLTKYAEQLLQEYVQLQGDPFGLPSFSPPRLPVAGLSAPAPSHAGLPVHERLRLDAAALAALPPLLDAVCRRQAELNPRAPRLLRRLEDAARQARALGAAVEALLAALGAANRGPRAEPPAATASAASATGVFPAKVLGLRVCGLYREWLSRTEGDLGQLLPGGSA T94977 DRUGINFO D06IEX Cardiotrophin-1 Phase 1 T55610 TARGETID T55610 T55610 FORMERID TTDC00101 T55610 UNIPROID HIF1A_HUMAN T55610 TARGNAME Hypoxia-inducible factor 1 alpha (HIF-1A) T55610 GENENAME HIF1A T55610 TARGTYPE Clinical trial T55610 SYNONYMS bHLHe78; Transcription factor HIF-1; PASD8; PAS domain-containing protein 8; Member of PAS protein 1; MOP1; Hypoxia-inducible transcription factor (HIF)-1; Hypoxia-inducible factor 1-alpha; Hypoxia-inducible factor 1 A; Hypoxia inducible factor 1; HIF1-alpha; HIF1 alpha; HIF-1alpha; HIF-1-alpha; HIF-1 alpha; Class E basic helix-loop-helix protein 78; Basic-helix-loop-helix-PAS protein MOP1; ARNT-interacting protein; ARNT interacting protein T55610 FUNCTION Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300. Activity is enhanced by interaction with both, NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP. Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia. Functions as a master transcriptional regulator of the adaptive response to hypoxia. T55610 PDBSTRUC 6GMR; 6GFX; 5LAS; 5LA9; 5L9V T55610 SEQUENCE MEGAGGANDKKKISSERRKEKSRDAARSRRSKESEVFYELAHQLPLPHNVSSHLDKASVMRLTISYLRVRKLLDAGDLDIEDDMKAQMNCFYLKALDGFVMVLTDDGDMIYISDNVNKYMGLTQFELTGHSVFDFTHPCDHEEMREMLTHRNGLVKKGKEQNTQRSFFLRMKCTLTSRGRTMNIKSATWKVLHCTGHIHVYDTNSNQPQCGYKKPPMTCLVLICEPIPHPSNIEIPLDSKTFLSRHSLDMKFSYCDERITELMGYEPEELLGRSIYEYYHALDSDHLTKTHHDMFTKGQVTTGQYRMLAKRGGYVWVETQATVIYNTKNSQPQCIVCVNYVVSGIIQHDLIFSLQQTECVLKPVESSDMKMTQLFTKVESEDTSSLFDKLKKEPDALTLLAPAAGDTIISLDFGSNDTETDDQQLEEVPLYNDVMLPSPNEKLQNINLAMSPLPTAETPKPLRSSADPALNQEVALKLEPNPESLELSFTMPQIQDQTPSPSDGSTRQSSPEPNSPSEYCFYVDSDMVNEFKLELVEKLFAEDTEAKNPFSTQDTDLDLEMLAPYIPMDDDFQLRSFDQLSPLESSSASPESASPQSTVTVFQQTQIQEPTANATTTTATTDELKTVTKDRMEDIKILIASPSPTHIHKETTSATSSPYRDTQSRTASPNRAGKGVIEQTEKSHPRSPNVLSVALSQRTTVPEEELNPKILALQNAQRKRKMEHDGSLFQAVGIGTLLQQPDDHAATTSLSWKRVKGCKSSEQNGMEQKTIILIPSDLACRLLGQSMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN T55610 DRUGINFO D0B0AX HIF-1alpha Phase 4 T55610 DRUGINFO D06PEW IT-101 Phase 3 T55610 DRUGINFO D06NYA 2-Methoxyestradiol Phase 2 T55610 DRUGINFO D06ZVO PX-478 Phase 1 T55610 DRUGINFO D0NF5J EZN-2968 Phase 1 T55610 DRUGINFO D0Y5QD ENMD-1198 Phase 1 T55610 DRUGINFO D0Q2SE Pyrrolidine carboxamide derivative 1 Patented T23787 TARGETID T23787 T23787 FORMERID TTDI02065 T23787 UNIPROID F263_HUMAN T23787 TARGNAME Renal carcinoma antigen NY-REN-56 (PFKFB3) T23787 GENENAME PFKFB3 T23787 TARGTYPE Clinical trial T23787 SYNONYMS iPFK2; Renal carcinoma antigen NYREN56; PFKFB3; Fructose2,6bisphosphatase; 6phosphofructo2kinase/fructose2,6bisphosphatase 3; 6PF2K/Fru2,6P2ase brain/placentatype isozyme; 6PF2K/Fru2,6P2ase 3 T23787 FUNCTION Synthesis and degradation of fructose 2,6-bisphosphate. T23787 PDBSTRUC 6IC0; 6IBZ; 6IBY; 6IBX; 6HVJ T23787 BIOCLASS Kinase T23787 SEQUENCE MPLELTQSRVQKIWVPVDHRPSLPRSCGPKLTNSPTVIVMVGLPARGKTYISKKLTRYLNWIGVPTKVFNVGEYRREAVKQYSSYNFFRPDNEEAMKVRKQCALAALRDVKSYLAKEGGQIAVFDATNTTRERRHMILHFAKENDFKAFFIESVCDDPTVVASNIMEVKISSPDYKDCNSAEAMDDFMKRISCYEASYQPLDPDKCDRDLSLIKVIDVGRRFLVNRVQDHIQSRIVYYLMNIHVQPRTIYLCRHGENEHNLQGRIGGDSGLSSRGKKFASALSKFVEEQNLKDLRVWTSQLKSTIQTAEALRLPYEQWKALNEIDAGVCEELTYEEIRDTYPEEYALREQDKYYYRYPTGESYQDLVQRLEPVIMELERQENVLVICHQAVLRCLLAYFLDKSAEEMPYLKCPLHTVLKLTPVAYGCRVESIYLNVESVCTHRERSEDAKKGPNPLMRRNSVTPLASPEPTKKPRINSFEEHVASTSAALPSCLPPEVPTQLPGQNMKGSRSSADSSRKH T23787 DRUGINFO D0W0VR PFK-158 Phase 1 T23787 DRUGINFO D4RMB0 3PO Investigative T23036 TARGETID T23036 T23036 FORMERID TTDI02067 T23036 UNIPROID FABI_STAA8 T23036 TARGNAME Staphylococcus Enoyl ACP reductase (Stap-coc fabI) T23036 GENENAME Stap-coc fabI T23036 TARGTYPE Clinical trial T23036 SYNONYMS NADPHdependent enoylACP reductase; Enoyl[acylcarrierprotein] reductase [NADPH] FabI T23036 FUNCTION Catalyzes the reduction of a carbon-carbon double bond in an enoyl moiety that is covalently linked to an acyl carrier protein (ACP). It has a preference for a long chain (C12) substrate compared to the shorter (C4) acyl group. Involved in the elongation cycle of fatty acid which are used in the lipid metabolism. T23036 BIOCLASS Short-chain dehydrogenases reductase T23036 SEQUENCE MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQSDEEVINGFEQIGKDVGNIDGVYHSIAFANMEDLRGRFSETSREGFLLAQDISSYSLTIVAHEAKKLMPEGGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISASPIRTLSAKGVGGFNTILKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK T23036 DRUGINFO D00HYK AFN-1252 Phase 2 T23036 DRUGINFO D05PIX CG-400549 Phase 2 T23036 DRUGINFO D0D8UM Afabicin Phase 2 T23036 DRUGINFO D00KJO MUT-056399 Preclinical T32764 TARGETID T32764 T32764 UNIPROID AAK1_HUMAN T32764 TARGNAME Adaptor-associated kinase 1 (AAK1) T32764 GENENAME AAK1 T32764 TARGTYPE Clinical trial T32764 SYNONYMS Adaptor-associated kinase 1 T32764 FUNCTION Regulates clathrin-mediated endocytosis by phosphorylating the AP2M1/mu2 subunit of the adaptor protein complex 2 (AP-2) which ensures high affinity binding of AP-2 to cargo membrane proteins during the initial stages of endocytosis. Isoform 1 and isoform 2 display similar levels of kinase activity towards AP2M1. Regulates phosphorylation of other AP-2 subunits as well as AP-2 localization and AP-2-mediated internalization of ligand complexes. Phosphorylates NUMB and regulates its cellular localization, promoting NUMB localization to endosomes. Binds to and stabilizes the activated form of NOTCH1, increases its localization in endosomes and regulates its transcriptional activity. T32764 PDBSTRUC 5TE0; 5L4Q; 4WSQ T32764 BIOCLASS Kinase T32764 ECNUMBER EC 2.7.11.1 T32764 SEQUENCE MKKFFDSRREQGGSGLGSGSSGGGGSTSGLGSGYIGRVFGIGRQQVTVDEVLAEGGFAIVFLVRTSNGMKCALKRMFVNNEHDLQVCKREIQIMRDLSGHKNIVGYIDSSINNVSSGDVWEVLILMDFCRGGQVVNLMNQRLQTGFTENEVLQIFCDTCEAVARLHQCKTPIIHRDLKVENILLHDRGHYVLCDFGSATNKFQNPQTEGVNAVEDEIKKYTTLSYRAPEMVNLYSGKIITTKADIWALGCLLYKLCYFTLPFGESQVAICDGNFTIPDNSRYSQDMHCLIRYMLEPDPDKRPDIYQVSYFSFKLLKKECPIPNVQNSPIPAKLPEPVKASEAAAKKTQPKARLTDPIPTTETSIAPRQRPKAGQTQPNPGILPIQPALTPRKRATVQPPPQAAGSSNQPGLLASVPQPKPQAPPSQPLPQTQAKQPQAPPTPQQTPSTQAQGLPAQAQATPQHQQQLFLKQQQQQQQPPPAQQQPAGTFYQQQQAQTQQFQAVHPATQKPAIAQFPVVSQGGSQQQLMQNFYQQQQQQQQQQQQQQLATALHQQQLMTQQAALQQKPTMAAGQQPQPQPAAAPQPAPAQEPAIQAPVRQQPKVQTTPPPAVQGQKVGSLTPPSSPKTQRAGHRRILSDVTHSAVFGVPASKSTQLLQAAAAEASLNKSKSATTTPSGSPRTSQQNVYNPSEGSTWNPFDDDNFSKLTAEELLNKDFAKLGEGKHPEKLGGSAESLIPGFQSTQGDAFATTSFSAGTAEKRKGGQTVDSGLPLLSVSDPFIPLQVPDAPEKLIEGLKSPDTSLLLPDLLPMTDPFGSTSDAVIEKADVAVESLIPGLEPPVPQRLPSQTESVTSNRTDSLTGEDSLLDCSLLSNPTTDLLEEFAPTAISAPVHKAAEDSNLISGFDVPEGSDKVAEDEFDPIPVLITKNPQGGHSRNSSGSSESSLPNLARSLLLVDQLIDL T32764 DRUGINFO D05IQI LX9211 Phase 1 T91023 TARGETID T91023 T91023 FORMERID TTDI02163 T91023 UNIPROID RSPO1_HUMAN T91023 TARGNAME Roof plate-specific spondin-1 (RSPO1) T91023 GENENAME RSPO1 T91023 TARGTYPE Clinical trial T91023 SYNONYMS hRspo1; R-spondin-1 T91023 FUNCTION Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signaling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. Acts as a ligand for frizzled FZD8 and LRP6. May negatively regulate the TGF-beta pathway. Has a essential roles in ovary determination. Regulates Wnt signaling by antagonizing DKK1/KREM1-mediated internalization of LRP6 through an interaction with KREM1. Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors. T91023 PDBSTRUC 4QXF; 4LI2; 4KT1; 4KNG; 4CDK T91023 SEQUENCE MRLGLCVVALVLSWTHLTISSRGIKGKRQRRISAEGSQACAKGCELCSEVNGCLKCSPKLFILLERNDIRQVGVCLPSCPPGYFDARNPDMNKCIKCKIEHCEACFSHNFCTKCKEGLYLHKGRCYPACPEGSSAANGTMECSSPAQCEMSEWSPWGPCSKKQQLCGFRRGSEERTRRVLHAPVGDHAACSDTKETRRCTVRRVPCPEGQKRRKGGQGRRENANRNLARKESKEAGAGSRRRKGQQQQQQQGTVGPLTSAGPA T91023 DRUGINFO D08JVS NU-206 Phase 1 T56362 TARGETID T56362 T56362 FORMERID TTDC00340 T56362 UNIPROID CTL4_HUMAN T56362 TARGNAME Choline transporter-like protein 4 (SLC44A4) T56362 GENENAME SLC44A4 T56362 TARGTYPE Clinical trial T56362 SYNONYMS hTPPT1; Thiamine pyrophosphate transporter 1; Solute carrier family 44 member 4; NG22; CTL4; C6orf29 T56362 FUNCTION Choline transporter that plays a role in the choline-acetylcholine system and is required to the efferent innervation of hair cells in the olivocochlear bundle for the maintenance of physiological function of outer hair cells and the protection of hair cells from acoustic injury (By similarity). Also described as a thiamine pyrophosphate transporter in colon, may mediate the absorption of microbiota-generated thiamine pyrophosphate and contribute to host thiamine (vitamin B1) homeostasis. T56362 BIOCLASS Choline transporter-like T56362 SEQUENCE MGGKQRDEDDEAYGKPVKYDPSFRGPIKNRSCTDVICCVLFLLFILGYIVVGIVAWLYGDPRQVLYPRNSTGAYCGMGENKDKPYLLYFNIFSCILSSNIISVAENGLQCPTPQVCVSSCPEDPWTVGKNEFSQTVGEVFYTKNRNFCLPGVPWNMTVITSLQQELCPSFLLPSAPALGRCFPWTNVTPPALPGITNDTTIQQGISGLIDSLNARDISVKIFEDFAQSWYWILVALGVALVLSLLFILLLRLVAGPLVLVLILGVLGVLAYGIYYCWEEYRVLRDKGASISQLGFTTNLSAYQSVQETWLAALIVLAVLEAILLLMLIFLRQRIRIAIALLKEASKAVGQMMSTMFYPLVTFVLLLICIAYWAMTALYLATSGQPQYVLWASNISSPGCEKVPINTSCNPTAHLVNSSCPGLMCVFQGYSSKGLIQRSVFNLQIYGVLGLFWTLNWVLALGQCVLAGAFASFYWAFHKPQDIPTFPLISAFIRTLRYHTGSLAFGALILTLVQIARVILEYIDHKLRGVQNPVARCIMCCFKCCLWCLEKFIKFLNRNAYIMIAIYGKNFCVSAKNAFMLLMRNIVRVVVLDKVTDLLLFFGKLLVVGGVGVLSFFFFSGRIPGLGKDFKSPHLNYYWLPIMTSILGAYVIASGFFSVFGMCVDTLFLCFLEDLERNNGSLDRPYYMSKSLLKILGKKNEAPPDNKKRKK T56362 DRUGINFO D0BC6M ASG-5ME Phase 1 T08123 TARGETID T08123 T08123 FORMERID TTDI03347 T08123 UNIPROID LRRK2_HUMAN T08123 TARGNAME Leucine-rich repeat kinase 2 (LRRK2) T08123 GENENAME LRRK2 T08123 TARGTYPE Clinical trial T08123 SYNONYMS PARK8; Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin T08123 FUNCTION Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease. Plays an important role in recuiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization. T08123 PDBSTRUC 6DLP; 6DLO; 5MYC; 5MY9; 3D6T T08123 BIOCLASS Kinase T08123 ECNUMBER EC 2.7.11.1 T08123 SEQUENCE MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLVFTYSERASKLFQGKNIHVPLLIVLDSYMRVASVQQVGWSLLCKLIEVCPGTMQSLMGPQDVGNDWEVLGVHQLILKMLTVHNASVNLSVIGLKTLDLLLTSGKITLLILDEESDIFMLIFDAMHSFPANDEVQKLGCKALHVLFERVSEEQLTEFVENKDYMILLSALTNFKDEEEIVLHVLHCLHSLAIPCNNVEVLMSGNVRCYNIVVEAMKAFPMSERIQEVSCCLLHRLTLGNFFNILVLNEVHEFVVKAVQQYPENAALQISALSCLALLTETIFLNQDLEEKNENQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDEDGHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQKHIHSPEVAESGCKMLNHLFEGSNTSLDIMAAVVPKILTVMKRHETSLPVQLEALRAILHFIVPGMPEESREDTEFHHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKVISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLIGYLITKKNVFIGTGHLLAKILVSSLYRFKDVAEIQTKGFQTILAILKLSASFSKLLVHHSFDLVIFHQMSSNIMEQKDQQFLNLCCKCFAKVAMDDYLKNVMLERACDQNNSIMVECLLLLGADANQAKEGSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGKGDSQIISLLLRRLALDVANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEEGTASGSDGNFSEDVLSKFDEWTFIPDSSMDSVFAQSDDLDSEGSEGSFLVKKKSNSISVGEFYRDAVLQRCSPNLQRHSNSLGPIFDHEDLLKRKRKILSSDDSLRSSKLQSHMRHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMKLMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACMSKITKELLNKRGFPAIRDYHFVNATEESDALAKLRKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE T08123 DRUGINFO D03YBQ DNL151 Phase 1 T08123 DRUGINFO D0K6UV DNL201 Phase 1 T08123 DRUGINFO D2AO6J BIIB094 Phase 1 T08123 DRUGINFO D01EIT Pyrrolo-pyrimidine derivative 8 Patented T08123 DRUGINFO D01PFZ Pyridopyrimidinone derivative 2 Patented T08123 DRUGINFO D01YHY PMID28117607-Compound-20 Patented T08123 DRUGINFO D02YTB Pyrrolo-pyrimidine derivative 9 Patented T08123 DRUGINFO D03GDC Pyrrolo-pyridine derivative 1 Patented T08123 DRUGINFO D03HNU Hydrazide derivative 5 Patented T08123 DRUGINFO D04WND Pyridopyrimidinone derivative 1 Patented T08123 DRUGINFO D06FIH Azaindazole derivative 1 Patented T08123 DRUGINFO D07FFA PMID28117607-Compound-7 Patented T08123 DRUGINFO D07SEG Oxindole derivative 2 Patented T08123 DRUGINFO D08VBG PMID28117607-Compound-5 Patented T08123 DRUGINFO D0C5HR Pyrrolo-pyrimidine derivative 10 Patented T08123 DRUGINFO D0DP6U Azaindazole derivative 3 Patented T08123 DRUGINFO D0GJ4G Pyrrolo-pyrimidine derivative 1 Patented T08123 DRUGINFO D0HY0H Hydrazide derivative 4 Patented T08123 DRUGINFO D0M5BR PMID28117607-Compound-21 Patented T08123 DRUGINFO D0NO4O Azaindazole derivative 2 Patented T08123 DRUGINFO D0O8AP PMID28117607-Compound-4 Patented T08123 DRUGINFO D0PY1G Hydrazide derivative 3 Patented T08123 DRUGINFO D0Q6VL Pyrrolo-pyridazine derivative 1 Patented T08123 DRUGINFO D0S4IB Pyridopyrimidinone derivative 3 Patented T08123 DRUGINFO D0V8XG PMID28117607-Compound-6 Patented T08123 DRUGINFO D0X8LX Aminopyridine derivative 2 Patented T08123 DRUGINFO D0XY1J Pyrrolo-pyrimidine derivative 11 Patented T08123 DRUGINFO D0ZW5B Azaindazole derivative 4 Patented T08123 DRUGINFO D00FKF Pyrrolo-pyridine derivative 2 Patented T08123 DRUGINFO D00GWE Bidentate ligands of Markush derivative 2 Patented T08123 DRUGINFO D08WVK Oxindole derivative 3 Patented T08123 DRUGINFO D0D6DN Aminopyridine derivative 3 Patented T08123 DRUGINFO D0FS9X Fused thiophene derivative 1 Patented T08123 DRUGINFO D0QK7K Oxindole derivative 4 Patented T08123 DRUGINFO D0SV0D Bidentate ligands of Markush derivative 1 Patented T08123 DRUGINFO D01OXV GNE-9605 Investigative T08123 DRUGINFO D01XYD HMS3229G13 Investigative T08123 DRUGINFO D0B6KT PF-06454589 Investigative T08123 DRUGINFO D0WK9R PF-06447475 Investigative T08123 DRUGINFO D0J5FK GNE-7915 Investigative T08123 DRUGINFO D07ADX URMC-099 Investigative T00484 TARGETID T00484 T00484 FORMERID TTDI02336 T00484 UNIPROID IL23R_HUMAN T00484 TARGNAME Interleukin 23 receptor (IL23R) T00484 GENENAME IL23R T00484 TARGTYPE Clinical trial T00484 SYNONYMS Interleukin-23 receptor; IL23 receptor; IL-23R; IL-23 receptor T00484 FUNCTION Binds IL23 and mediates T-cells, NK cells and possibly certain macrophage/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade. IL23 functions in innate and adaptive immunity and may participate in acute response to infection in peripheral tissues. IL23 may be responsible for autoimmune inflammatory diseases and be important for tumorigenesis. Associates with IL12RB1 to form the interleukin-23 receptor. T00484 PDBSTRUC 5MZV T00484 BIOCLASS Cytokine receptor T00484 SEQUENCE MNQVTIQWDAVIALYILFSWCHGGITNINCSGHIWVEPATIFKMGMNISIYCQAAIKNCQPRKLHFYKNGIKERFQITRINKTTARLWYKNFLEPHASMYCTAECPKHFQETLICGKDISSGYPPDIPDEVTCVIYEYSGNMTCTWNAGKLTYIDTKYVVHVKSLETEEEQQYLTSSYINISTDSLQGGKKYLVWVQAANALGMEESKQLQIHLDDIVIPSAAVISRAETINATVPKTIIYWDSQTTIEKVSCEMRYKATTNQTWNVKEFDTNFTYVQQSEFYLEPNIKYVFQVRCQETGKRYWQPWSSLFFHKTPETVPQVTSKAFQHDTWNSGLTVASISTGHLTSDNRGDIGLLLGMIVFAVMLSILSLIGIFNRSFRTGIKRRILLLIPKWLYEDIPNMKNSNVVKMLQENSELMNNNSSEQVLYVDPMITEIKEIFIPEHKPTDYKKENTGPLETRDYPQNSLFDNTTVVYIPDLNTGYKPQISNFLPEGSHLSNNNEITSLTLKPPVDSLDSGNNPRLQKHPNFAFSVSSVNSLSNTIFLGELSLILNQGECSSPDIQNSVEEETTMLLENDSPSETIPEQTLLPDEFVSCLGIVNEELPSINTYFPQNILESHFNRISLLEK T00484 DRUGINFO D06ARV Anti-IL-23 Phase 3 T00484 DRUGINFO D0G0AQ ADC-1012 Investigative T00484 DRUGINFO D0Y0WW FM-303 Investigative T00484 DRUGINFO D0YZ1J APG-2305 Investigative T45612 TARGETID T45612 T45612 FORMERID TTDNC00398 T45612 UNIPROID CD276_HUMAN T45612 TARGNAME B7 homolog 3 (CD276) T45612 GENENAME CD276 T45612 TARGTYPE Clinical trial T45612 SYNONYMS UNQ309/PRO352; PSEC0249; Costimulatory molecule; CD276 antigen; B7H3; B7-H3; 4IgB7H3; 4Ig-B7-H3 T45612 FUNCTION May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling. May participate in the regulation of T-cell-mediated immune response. T45612 BIOCLASS Immunoglobulin T45612 SEQUENCE MLRRRGSPGMGVHVGAALGALWFCLTGALEVQVPEDPVVALVGTDATLCCSFSPEPGFSLAQLNLIWQLTDTKQLVHSFAEGQDQGSAYANRTALFPDLLAQGNASLRLQRVRVADEGSFTCFVSIRDFGSAAVSLQVAAPYSKPSMTLEPNKDLRPGDTVTITCSSYQGYPEAEVFWQDGQGVPLTGNVTTSQMANEQGLFDVHSILRVVLGANGTYSCLVRNPVLQQDAHSSVTITPQRSPTGAVEVQVPEDPVVALVGTDATLRCSFSPEPGFSLAQLNLIWQLTDTKQLVHSFTEGRDQGSAYANRTALFPDLLAQGNASLRLQRVRVADEGSFTCFVSIRDFGSAAVSLQVAAPYSKPSMTLEPNKDLRPGDTVTITCSSYRGYPEAEVFWQDGQGVPLTGNVTTSQMANEQGLFDVHSVLRVVLGANGTYSCLVRNPVLQQDAHGSVTITGQPMTFPPEALWVTVGLSVCLIALLVALAFVCWRKIKQSCEEENAGAEDQDGEGEGSKTALQPLKHSDSKEDDGQEIA T45612 DRUGINFO D08BZZ Omburtamab I-131 Phase 2/3 T45612 DRUGINFO DKJ93L 131 I-omburtamab Phase 2/3 T45612 DRUGINFO DUBW95 Omburtamab Phase 2/3 T45612 DRUGINFO D0S1WV Enoblituzumab Phase 2 T45612 DRUGINFO DHN9I5 TAK-280 Phase 2 T45612 DRUGINFO D0BI3K Omburtamab I-124 Phase 1/2 T45612 DRUGINFO DDP74J MGC018 Phase 1/2 T45612 DRUGINFO DT8R1L DS-7300 Phase 1/2 T45612 DRUGINFO D05FHZ MGD009 Phase 1 T45612 DRUGINFO D06UOU MGA271 Phase 1 T45612 DRUGINFO D0J7QC 124I-8H9 Phase 1 T45968 TARGETID T45968 T45968 UNIPROID RNF43_HUMAN T45968 TARGNAME RING finger protein 43 (RNF43) T45968 GENENAME RNF43 T45968 TARGTYPE Clinical trial T45968 SYNONYMS RING-type E3 ubiquitin transferase RNF43; E3 ubiquitin-protein ligase RNF43 T45968 FUNCTION E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signaling pathway by mediating the ubiquitination, endocytosis and subsequent degradation of Wnt receptor complex components Frizzled. Acts on both canonical and non-canonical Wnt signaling pathway. Along with RSPO2 and ZNRF3, constitutes a master switch that governs limb specification (By similarity). T45968 PDBSTRUC 4KNG T45968 ECNUMBER EC 2.3.2.27 T45968 SEQUENCE MSGGHQLQLAALWPWLLMATLQAGFGRTGLVLAAAVESERSAEQKAIIRVIPLKMDPTGKLNLTLEGVFAGVAEITPAEGKLMQSHPLYLCNASDDDNLEPGFISIVKLESPRRAPRPCLSLASKARMAGERGASAVLFDITEDRAAAEQLQQPLGLTWPVVLIWGNDAEKLMEFVYKNQKAHVRIELKEPPAWPDYDVWILMTVVGTIFVIILASVLRIRCRPRHSRPDPLQQRTAWAISQLATRRYQASCRQARGEWPDSGSSCSSAPVCAICLEEFSEGQELRVISCLHEFHRNCVDPWLHQHRTCPLCMFNITEGDSFSQSLGPSRSYQEPGRRLHLIRQHPGHAHYHLPAAYLLGPSRSAVARPPRPGPFLPSQEPGMGPRHHRFPRAAHPRAPGEQQRLAGAQHPYAQGWGLSHLQSTSQHPAACPVPLRRARPPDSSGSGESYCTERSGYLADGPASDSSSGPCHGSSSDSVVNCTDISLQGVHGSSSTFCSSLSSDFDPLVYCSPKGDPQRVDMQPSVTSRPRSLDSVVPTGETQVSSHVHYHRHRHHHYKKRFQWHGRKPGPETGVPQSRPPIPRTQPQPEPPSPDQQVTRSNSAAPSGRLSNPQCPRALPEPAPGPVDASSICPSTSSLFNLQKSSLSARHPQRKRRGGPSEPTPGSRPQDATVHPACQIFPHYTPSVAYPWSPEAHPLICGPPGLDKRLLPETPGPCYSNSQPVWLCLTPRQPLEPHPPGEGPSEWSSDTAEGRPCPYPHCQVLSAQPGSEEELEELCEQAV T45968 DRUGINFO D01EXL RNF43-721 Phase 2 T15855 TARGETID T15855 T15855 FORMERID TTDI03156 T15855 UNIPROID DPP8_HUMAN T15855 TARGNAME Dipeptidyl peptidase 8 (DPP-8) T15855 GENENAME DPP8 T15855 TARGTYPE Clinical trial T15855 SYNONYMS Prolyl dipeptidase DPP8; MSTP141; MSTP135; MSTP097; Dipeptidyl peptidase VIII; Dipeptidyl peptidase IV-related protein 1; DPRP1; DPRP-1; DPP VIII; DP8 T15855 FUNCTION Dipeptidyl peptidase that cleaves off N-terminal dipeptides from proteins having a Pro or Ala residue at position 2. T15855 PDBSTRUC 6EOT; 6EOS; 6EOP; 6EOO T15855 BIOCLASS Peptidase T15855 ECNUMBER EC 3.4.14.5 T15855 SEQUENCE MWKRSEQMKIKSGKCNMAAAMETEQLGVEIFETADCEENIESQDRPKLEPFYVERYSWSQLKKLLADTRKYHGYMMAKAPHDFMFVKRNDPDGPHSDRIYYLAMSGENRENTLFYSEIPKTINRAAVLMLSWKPLLDLFQATLDYGMYSREEELLRERKRIGTVGIASYDYHQGSGTFLFQAGSGIYHVKDGGPQGFTQQPLRPNLVETSCPNIRMDPKLCPADPDWIAFIHSNDIWISNIVTREERRLTYVHNELANMEEDARSAGVATFVLQEEFDRYSGYWWCPKAETTPSGGKILRILYEENDESEVEIIHVTSPMLETRRADSFRYPKTGTANPKVTFKMSEIMIDAEGRIIDVIDKELIQPFEILFEGVEYIARAGWTPEGKYAWSILLDRSQTRLQIVLISPELFIPVEDDVMERQRLIESVPDSVTPLIIYEETTDIWINIHDIFHVFPQSHEEEIEFIFASECKTGFRHLYKITSILKESKYKRSSGGLPAPSDFKCPIKEEIAITSGEWEVLGRHGSNIQVDEVRRLVYFEGTKDSPLEHHLYVVSYVNPGEVTRLTDRGYSHSCCISQHCDFFISKYSNQKNPHCVSLYKLSSPEDDPTCKTKEFWATILDSAGPLPDYTPPEIFSFESTTGFTLYGMLYKPHDLQPGKKYPTVLFIYGGPQVQLVNNRFKGVKYFRLNTLASLGYVVVVIDNRGSCHRGLKFEGAFKYKMGQIEIDDQVEGLQYLASRYDFIDLDRVGIHGWSYGGYLSLMALMQRSDIFRVAIAGAPVTLWIFYDTGYTERYMGHPDQNEQGYYLGSVAMQAEKFPSEPNRLLLLHGFLDENVHFAHTSILLSFLVRAGKPYDLQIYPQERHSIRVPESGEHYELHLLHYLQENLGSRIAALKVI T15855 DRUGINFO D0FQ2U Talabostat Phase 3 T15855 DRUGINFO D1PBC7 BXCL701 Phase 1/2 T15855 DRUGINFO D06HJX Thiomorpholine derivative 1 Patented T15855 DRUGINFO D0D4BP Thiomorpholine derivative 2 Patented T15855 DRUGINFO D02RDY PMID15664838C18 Investigative T15855 DRUGINFO D0CP1J 1G244 Investigative T15855 DRUGINFO D08NMS PMID20684603C24dd Investigative T66252 TARGETID T66252 T66252 FORMERID TTDI03157 T66252 UNIPROID DPP9_HUMAN T66252 TARGNAME Dipeptidyl peptidase 9 (DPP-9) T66252 GENENAME DPP9 T66252 TARGTYPE Clinical trial T66252 SYNONYMS Dipeptidyl peptidase-like protein 9; Dipeptidyl peptidase IX; Dipeptidyl peptidase IV-related protein 2; DPRP2; DPRP-2; DPP IX; DPLP9; DP9 T66252 FUNCTION Dipeptidyl peptidase that cleaves off N-terminal dipeptides from proteins having a Pro or Ala residue at position 2. T66252 PDBSTRUC 6EOR; 6EOQ T66252 BIOCLASS Peptidase T66252 ECNUMBER EC 3.4.14.5 T66252 SEQUENCE MATTGTPTADRGDAAATDDPAARFQVQKHSWDGLRSIIHGSRKYSGLIVNKAPHDFQFVQKTDESGPHSHRLYYLGMPYGSRENSLLYSEIPKKVRKEALLLLSWKQMLDHFQATPHHGVYSREEELLRERKRLGVFGITSYDFHSESGLFLFQASNSLFHCRDGGKNGFMVSPMKPLEIKTQCSGPRMDPKICPADPAFFSFINNSDLWVANIETGEERRLTFCHQGLSNVLDDPKSAGVATFVIQEEFDRFTGYWWCPTASWEGSEGLKTLRILYEEVDESEVEVIHVPSPALEERKTDSYRYPRTGSKNPKIALKLAEFQTDSQGKIVSTQEKELVQPFSSLFPKVEYIARAGWTRDGKYAWAMFLDRPQQWLQLVLLPPALFIPSTENEEQRLASARAVPRNVQPYVVYEEVTNVWINVHDIFYPFPQSEGEDELCFLRANECKTGFCHLYKVTAVLKSQGYDWSEPFSPGEDEFKCPIKEEIALTSGEWEVLARHGSKIWVNEETKLVYFQGTKDTPLEHHLYVVSYEAAGEIVRLTTPGFSHSCSMSQNFDMFVSHYSSVSTPPCVHVYKLSGPDDDPLHKQPRFWASMMEAASCPPDYVPPEIFHFHTRSDVRLYGMIYKPHALQPGKKHPTVLFVYGGPQVQLVNNSFKGIKYLRLNTLASLGYAVVVIDGRGSCQRGLRFEGALKNQMGQVEIEDQVEGLQFVAEKYGFIDLSRVAIHGWSYGGFLSLMGLIHKPQVFKVAIAGAPVTVWMAYDTGYTERYMDVPENNQHGYEAGSVALHVEKLPNEPNRLLILHGFLDENVHFFHTNFLVSQLIRAGKPYQLQIYPNERHSIRCPESGEHYEVTLLHFLQEYL T66252 DRUGINFO D0FQ2U Talabostat Phase 3 T66252 DRUGINFO D1PBC7 BXCL701 Phase 1/2 T66252 DRUGINFO D06HJX Thiomorpholine derivative 1 Patented T66252 DRUGINFO D0D4BP Thiomorpholine derivative 2 Patented T66252 DRUGINFO D0CP1J 1G244 Investigative T66252 DRUGINFO D08NMS PMID20684603C24dd Investigative T67063 TARGETID T67063 T67063 FORMERID TTDI01980 T67063 UNIPROID KCMB4_HUMAN T67063 TARGNAME Charybdotoxin receptor beta-4 (BKbeta4) T67063 GENENAME KCNMB4 T67063 TARGTYPE Clinical trial T67063 SYNONYMS KCNMB4; Calcium activated potassium KCNMA1 (maxiK) channel T67063 FUNCTION Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Increases the apparent Ca(2+)/voltage sensitivity of the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and alters its pharmacological properties. It slows down the activation and the deactivation kinetics of the channel. Acts as a negative regulator of smooth muscle contraction by enhancing the calcium sensitivity to KCNMA1. Its presence is also a requirement for internal binding of the KCNMA1 channel opener dehydrosoyasaponin I (DHS-1) triterpene glycoside and for external binding of the agonist hormone 17-beta-estradiol (E2). Increases the binding activity of charybdotoxin (CTX) toxin to KCNMA1 peptide blocker by increasing the CTX association rate and decreasing the dissociation rate. T67063 PDBSTRUC 5Y7L T67063 SEQUENCE MAKLRVAYEYTEAEDKSIRLGLFLIISGVVSLFIFGFCWLSPALQDLQATEANCTVLSVQQIGEVFECTFTCGADCRGTSQYPCVQVYVNNSESNSRALLHSDEHQLLTNPKCSYIPPCKRENQKNLESVMNWQQYWKDEIGSQPFTCYFNQHQRPDDVLLHRTHDEIVLLHCFLWPLVTFVVGVLIVVLTICAKSLAVKAEAMKKRKFS T67063 DRUGINFO D08PMW BMS-223131 Phase 2 T67063 DRUGINFO D09BVL NS-1619 Terminated T67063 DRUGINFO D0D1GV CNS-1237 Terminated T67063 DRUGINFO D0YS9J slotoxin Investigative T67063 DRUGINFO D0V4WT paxilline Investigative T67063 DRUGINFO D0O2TC iberiotoxin Investigative T67063 DRUGINFO D06PZZ [14C]TEA Investigative T99338 TARGETID T99338 T99338 UNIPROID STING_HUMAN T99338 TARGNAME Stimulator of interferon genes protein (TMEM173) T99338 GENENAME TMEM173 T99338 TARGTYPE Clinical trial T99338 SYNONYMS Mediator of IRF3 activation; Endoplasmic reticulum interferon stimulator; ERIS T99338 FUNCTION Facilitator of innate immune signaling that acts as a sensor of cytosolic DNA from bacteria and viruses and promotes the production of type I interferon (IFN-alpha and IFN-beta). Innate immune response is triggered in response to non-CpG double-stranded DNA from viruses and bacteria delivered to the cytoplasm. Acts by recognizing and binding cyclic di-GMP (c-di-GMP), a second messenger produced by bacteria, and cyclic GMP-AMP (cGAMP), a messenger produced in response to DNA virus in the cytosol: upon binding of c-di-GMP or cGAMP, autoinhibition is alleviated and TMEM173/STING is able to activate both NF-kappa-B and IRF3 transcription pathways to induce expression of type I interferon and exert a potent anti-viral state. May be involved in translocon function, the translocon possibly being able to influence the induction of type I interferons. May be involved in transduction of apoptotic signals via its association with the major histocompatibility complex class II (MHC-II). Mediates death signaling via activation of the extracellular signal-regulated kinase (ERK) pathway. Essential for the induction of IFN-beta in response to human herpes simplex virus 1 (HHV-1) infection. Exhibits 2',3' phosphodiester linkage-specific ligand recognition. Can bind both 2'-3' linked cGAMP and 3'-3' linked cGAMP but is preferentially activated by 2'-3' linked cGAMP (PubMed:26300263). T99338 PDBSTRUC 6O8C; 6O8B; 6NT5; 6MXE; 6MX3 T99338 BIOCLASS TMEM173 family T99338 SEQUENCE MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS T99338 DRUGINFO D0N6VS ADU-S100 Phase 2 T99338 DRUGINFO DCIX20 ADU- S100 Phase 2 T99338 DRUGINFO DQ4OU8 MK-1454 Phase 2 T99338 DRUGINFO DC37YW IMSA101 Phase 1/2 T99338 DRUGINFO D2KOX5 BMS-986301 Phase 1 T99338 DRUGINFO D4JU8H MK-2118 Phase 1 T99338 DRUGINFO D7AT3H XMT-2056 Phase 1 T99338 DRUGINFO D9ICV2 TAK-500 Phase 1 T99338 DRUGINFO DA79HM SB 11285 Phase 1 T99338 DRUGINFO DO7D1L E7766 Phase 1 T99338 DRUGINFO DQ6J0W GSK3745417 Phase 1 T99338 DRUGINFO DTV17S A296 Phase 1 T99338 DRUGINFO DTYQ45 TAK-676 Phase 1 T99338 DRUGINFO DUA7N4 SNX281 Phase 1 T99338 DRUGINFO DUR0F6 SYNB1891 Phase 1 T99338 DRUGINFO D7CI5F C-178 Investigative T99338 DRUGINFO DP2F6W C-176 Investigative T50823 TARGETID T50823 T50823 FORMERID TTDI02171 T50823 UNIPROID SEM4D_HUMAN T50823 TARGNAME Semaphorin-4D (SEMA4D) T50823 GENENAME SEMA4D T50823 TARGTYPE Clinical trial T50823 SYNONYMS SEMAJ; GR3; CD100; C9orf164; BB18; A8 T50823 FUNCTION Regulates GABAergic synapse development. Promotes the development of inhibitory synapses in a PLXNB1-dependent manner. Modulates the complexity and arborization of developing neurites in hippocampal neurons by activating PLXNB1 and interaction with PLXNB1 mediates activation of RHOA. Promotes the migration of cerebellar granule cells. Plays a role in the immune system; induces B-cells to aggregate and improves their viability (in vitro). Induces endothelial cell migration through the activation of PTK2B/PYK2, SRC, and the phosphatidylinositol 3-kinase-AKT pathway. Cell surface receptor for PLXNB1 and PLXNB2 that plays an important role in cell-cell signaling. T50823 PDBSTRUC 3OL2; 1OLZ T50823 SEQUENCE MRMCTPIRGLLMALAVMFGTAMAFAPIPRITWEHREVHLVQFHEPDIYNYSALLLSEDKDTLYIGAREAVFAVNALNISEKQHEVYWKVSEDKKAKCAEKGKSKQTECLNYIRVLQPLSATSLYVCGTNAFQPACDHLNLTSFKFLGKNEDGKGRCPFDPAHSYTSVMVDGELYSGTSYNFLGSEPIISRNSSHSPLRTEYAIPWLNEPSFVFADVIRKSPDSPDGEDDRVYFFFTEVSVEYEFVFRVLIPRIARVCKGDQGGLRTLQKKWTSFLKARLICSRPDSGLVFNVLRDVFVLRSPGLKVPVFYALFTPQLNNVGLSAVCAYNLSTAEEVFSHGKYMQSTTVEQSHTKWVRYNGPVPKPRPGACIDSEARAANYTSSLNLPDKTLQFVKDHPLMDDSVTPIDNRPRLIKKDVNYTQIVVDRTQALDGTVYDVMFVSTDRGALHKAISLEHAVHIIEETQLFQDFEPVQTLLLSSKKGNRFVYAGSNSGVVQAPLAFCGKHGTCEDCVLARDPYCAWSPPTATCVALHQTESPSRGLIQEMSGDASVCPDKSKGSYRQHFFKHGGTAELKCSQKSNLARVFWKFQNGVLKAESPKYGLMGRKNLLIFNLSEGDSGVYQCLSEERVKNKTVFQVVAKHVLEVKVVPKPVVAPTLSVVQTEGSRIATKVLVASTQGSSPPTPAVQATSSGAITLPPKPAPTGTSCEPKIVINTVPQLHSEKTMYLKSSDNRLLMSLFLFFFVLFLCLFFYNCYKGYLPRQCLKFRSALLIGKKKPKSDFCDREQSLKETLVEPGSFSQQNGEHPKPALDTGYETEQDTITSKVPTDREDSQRIDDLSARDKPFDVKCELKFADSDADGD T50823 DRUGINFO D0N1SH VX-15 Phase 2 T50823 DRUGINFO DG1ED2 Pepinemab Phase 1/2 T61317 TARGETID T61317 T61317 FORMERID TTDR00657 T61317 UNIPROID Q965D6_PLAFA T61317 TARGNAME Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) T61317 GENENAME Malaria fabG T61317 TARGTYPE Clinical trial T61317 SYNONYMS 3-oxoacyl-acyl-carrier protein reductase T61317 FUNCTION Participates in fatty acid biosynthesis and polyunsaturated fatty acid biosynthesis. Catalyzes the NADPH-dependent reduction of beta-ketoacyl-ACP substrates to beta-hydroxyacyl-ACP products, the first reductive step in the elongation cycle of fatty acid biosynthesis. T61317 BIOCLASS Short-chain dehydrogenases reductase T61317 ECNUMBER EC 1.1.1.100 T61317 SEQUENCE MSVLHRFYLFFLFTKFFHCYKISYVLKNAKLAPNHAIKNINSLNLLSENKKENYYYCGENKVALVTGAGRGIGREIAKMLAKSVSHVICISRTQKSCDSVVDEIKSFGYESSGYAGDVSKKEEISEVINKILTEHKNVDILVSNAGITRDNLFLRMKNDEWEDVLRTNLNSLFYITQPISKRMINNRYGRIINISSIVGLTGNVGQANYSSSKAGVIGFTKSLAKELASRNITVNAIAPGFISSDMTDKISEQIKKNIISNIPAGRMGTPEEVANLACFLSSDKSGYINGRVFVIDGGLSP T61317 DRUGINFO D0U2BH Epigallocatechin gallate Phase 3 T61317 DRUGINFO D03DWG NADPH Investigative T61317 DRUGINFO D07YDN ISORHAMNETIN Investigative T61317 DRUGINFO D05HRK 2-Hexadecynoic acid Investigative T61317 DRUGINFO D07KXK GALLOCATECHIN GALLATE Investigative T61317 DRUGINFO D01UYI Chrysin Investigative T61317 DRUGINFO D0MF5Y 3,7,3',4'-TETRAHYDROXYFLAVONE Investigative T61317 DRUGINFO D0RB1V (-)-CATECHINGALLATE Investigative T61317 DRUGINFO D0NJ4H MORIN Investigative T61317 DRUGINFO D0G3TK KAEMPFEROL Investigative T99313 TARGETID T99313 T99313 UNIPROID RGMA_HUMAN T99313 TARGNAME Repulsive guidance molecule A (RGMA) T99313 GENENAME RGMA T99313 TARGTYPE Clinical trial T99313 SYNONYMS RGM domain family member A T99313 FUNCTION Member of the repulsive guidance molecule (RGM) family that performs several functions in the developing and adult nervous system. Regulates cephalic neural tube closure, inhibits neurite outgrowth and cortical neuron branching, and the formation of mature synapses. Binding to its receptor NEO1/neogenin induces activation of RHOA-ROCK1/Rho-kinase signaling pathway through UNC5B-ARHGEF12/LARG-PTK2/FAK1 cascade, leading to collapse of the neuronal growth cone and neurite outgrowth inhibition. Furthermore, RGMA binding to NEO1/neogenin leads to HRAS inactivation by influencing HRAS-PTK2/FAK1-AKT1 pathway. It also functions as a bone morphogenetic protein (BMP) coreceptor that may signal through SMAD1, SMAD5, and SMAD8. T99313 PDBSTRUC 4UHY T99313 BIOCLASS Repulsive guidance molecule (RGM) family T99313 SEQUENCE MQPPRERLVVTGRAGWMGMGRGAGRSALGFWPTLAFLLCSFPAATSPCKILKCNSEFWSATSGSHAPASDDTPEFCAALRSYALCTRRTARTCRGDLAYHSAVHGIEDLMSQHNCSKDGPTSQPRLRTLPPAGDSQERSDSPEICHYEKSFHKHSATPNYTHCGLFGDPHLRTFTDRFQTCKVQGAWPLIDNNYLNVQVTNTPVLPGSAATATSKLTIIFKNFQECVDQKVYQAEMDELPAAFVDGSKNGGDKHGANSLKITEKVSGQHVEIQAKYIGTTIVVRQVGRYLTFAVRMPEEVVNAVEDWDSQGLYLCLRGCPLNQQIDFQAFHTNAEGTGARRLAAASPAPTAPETFPYETAVAKCKEKLPVEDLYYQACVFDLLTTGDVNFTLAAYYALEDVKMLHSNKDKLHLYDRTRDLPGRAAAGLPLAPRPLLGALVPLLALLPVFC T99313 DRUGINFO D0DV8Z Elezanumab Phase 2 T30790 TARGETID T30790 T30790 FORMERID TTDC00342 T30790 UNIPROID CRCM1_HUMAN T30790 TARGNAME Calcium-release activated calcium channel (CRACM) T30790 GENENAME ORAI1 T30790 TARGTYPE Clinical trial T30790 SYNONYMS Transmembrane protein 142A; TMEM142A; Protein orai-1; Calcium release-activated calcium channel protein 1; CRACM1 T30790 FUNCTION CRAC channels are the main pathway for Ca(2+) influx in T-cells and promote the immune response to pathogens by activating the transcription factor NFAT. Ca(2+) release-activated Ca(2+) (CRAC) channel subunit which mediates Ca(2+) influx following depletion of intracellular Ca(2+) stores and channel activation by the Ca(2+) sensor, STIM1. T30790 PDBSTRUC 4EHQ; 2MAK T30790 SEQUENCE MHPEPAPPPSRSSPELPPSGGSTTSGSRRSRRRSGDGEPPGAPPPPPSAVTYPDWIGQSYSEVMSLNEHSMQALSWRKLYLSRAKLKASSRTSALLSGFAMVAMVEVQLDADHDYPPGLLIAFSACTTVLVAVHLFALMISTCILPNIEAVSNVHNLNSVKESPHERMHRHIELAWAFSTVIGTLLFLAEVVLLCWVKFLPLKKQPGQPRPTSKPPASGAAANVSTSGITPGQAAAIASTTIMVPFGLIFIVFAVHFYRSLVSHKTDRQFQELNELAEFARLQDQLDHRGDHPLTPGSHYA T30790 DRUGINFO D09MJJ RP4010 Phase 1 T83687 TARGETID T83687 T83687 FORMERID TTDR00936 T83687 UNIPROID TR13C_HUMAN T83687 TARGNAME B-cell-activating factor receptor (TNFRSF13C) T83687 GENENAME TNFRSF13C T83687 TARGTYPE Clinical trial T83687 SYNONYMS Tumor necrosis factor receptor superfamily member 13C; CD268; BR3; BLyS receptor 3; BAFFR; BAFF-R; BAFF receptor; B cell-activating factor receptor T83687 FUNCTION Promotes the survival of mature B-cells and the B-cell response. B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. T83687 PDBSTRUC 4V46; 3V56; 2HFG; 1OSX; 1OQE T83687 BIOCLASS Cytokine receptor T83687 SEQUENCE MRRGPRSLRGRDAPAPTPCVPAECFDLLVRHCVACGLLRTPRPKPAGASSPAPRTALQPQESVGAGAGEAALPLPGLLFGAPALLGLALVLALVLVGLVSWRRRQRRLRGASSAEAPDGDKDAPEPLDKVIILSPGISDATAPAWPPPGEDPGTTPPGHSVPVPATELGSTELVTTKTAGPEQQ T83687 DRUGINFO D09SQM VAY736 Phase 2 T60330 TARGETID T60330 T60330 FORMERID TTDR01261 T60330 UNIPROID P2RX4_HUMAN T60330 TARGNAME P2X purinoceptor 4 (P2RX4) T60330 GENENAME P2RX4 T60330 TARGTYPE Clinical trial T60330 SYNONYMS P2X4; P2RX4 T60330 FUNCTION Receptor for ATP that acts as a ligand gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin. T60330 BIOCLASS ATP-gated P2X receptor cation channel T60330 SEQUENCE MAGCCAALAAFLFEYDTPRIVLIRSRKVGLMNRAVQLLILAYVIGWVFVWEKGYQETDSVVSSVTTKVKGVAVTNTSKLGFRIWDVADYVIPAQEENSLFVMTNVILTMNQTQGLCPEIPDATTVCKSDASCTAGSAGTHSNGVSTGRCVAFNGSVKTCEVAAWCPVEDDTHVPQPAFLKAAENFTLLVKNNIWYPKFNFSKRNILPNITTTYLKSCIYDAKTDPFCPIFRLGKIVENAGHSFQDMAVEGGIMGIQVNWDCNLDRAASLCLPRYSFRRLDTRDVEHNVSPGYNFRFAKYYRDLAGNEQRTLIKAYGIRFDIIVFGKAGKFDIIPTMINIGSGLALLGMATVLCDIIVLYCMKKRLYYREKKYKYVEDYEQGLASELDQ T60330 DRUGINFO D0U0KJ MRS-2160 Investigative T01283 TARGETID T01283 T01283 FORMERID TTDI02200 T01283 UNIPROID TS101_HUMAN T01283 TARGNAME Tumor susceptibility gene protein 101 (TSG101) T01283 GENENAME TSG101 T01283 TARGTYPE Clinical trial T01283 SYNONYMS Tumor susceptibility gene 101 protein; ESCRT-I complex subunit TSG101 T01283 FUNCTION Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses. Required for the exosomal release of SDCBP, CD63 and syndecan. It may also play a role in the extracellular release of microvesicles that differ from the exosomes. Component of the ESCRT-I complex, a regulator of vesicular trafficking process. T01283 PDBSTRUC 5VKG; 4ZNY; 4YC1; 4EJE; 3P9H T01283 BIOCLASS Ubiquitin-conjugating enzyme T01283 SEQUENCE MAVSESQLKKMVSKYKYRDLTVRETVNVITLYKDLKPVLDSYVFNDGSSRELMNLTGTIPVPYRGNTYNIPICLWLLDTYPYNPPICFVKPTSSMTIKTGKHVDANGKIYLPYLHEWKHPQSDLLGLIQVMIVVFGDEPPVFSRPISASYPPYQATGPPNTSYMPGMPGGISPYPSGYPPNPSGYPGCPYPPGGPYPATTSSQYPSQPPVTTVGPSRDGTISEDTIRASLISAVSDKLRWRMKEEMDRAQAELNALKRTEEDLKKGHQKLEEMVTRLDQEVAEVDKNIELLKKKDEELSSALEKMENQSENNDIDEVIIPTAPLYKQILNLYAEENAIEDTIFYLGEALRRGVIDLDVFLKHVRLLSRKQFQLRALMQKARKTAGLSDLY T01283 DRUGINFO D03RCB FGI-101-1A6 Phase 1 T27198 TARGETID T27198 T27198 FORMERID TTDR01063 T27198 UNIPROID SYM_STRP1 T27198 TARGNAME Streptococcus Methionyl-tRNA synthetase (Stre-coc metG) T27198 GENENAME Stre-coc metG T27198 TARGTYPE Clinical trial T27198 SYNONYMS metG; Methionyl-transferribonucleic acid synthetase; Methionyl-transferribonucleate synthetase; Methionyl-transferRNA synthetase; Methionyl t-RNA synthetase; Methionine-tRNA ligase; Methionine--tRNA ligase; Methionine translase; MetRS; MRS T27198 FUNCTION Is required not only for elongation of protein synthesis but also for the initiation of all mRNA translation through initiator tRNA(fMet) aminoacylation. T27198 BIOCLASS Carbon-oxygen ligase T27198 ECNUMBER EC 6.1.1.10 T27198 SEQUENCE MKKPFYITTPIYYPSGKLHIGSAYTTIACDVLARYKRLMGHEVFYLTGLDEHGQKIQTKAKEAGITPQTYVDNMAKDVKALWQLLDISYDTFIRTTDDYHEEVVAAVFEKLLAQDDIYLGEYSGWYSVSDEEFFTESQLKEVFRDEDGQVIGGIAPSGHEVEWVSEESYFLRLSKYDDRLVAFFKERPDFIQPDGRMNEMVKNFIEPGLEDLAVSRTTFTWGVPVPSDPKHVVYVWIDALLNYATALGYRQANHANFDKFWNGTVFHMVGKDILRFHSIYWPILLMMLDLPMPDRLIAHGWFVMKDGKMSKSKGNVVYPEMLVERFGLDPLRYYLMRSLPVGSDGTFTPEDYVGRINYELANDLGNLLNRTVAMINKYFDGTVPAYVDNGTAFDADLSQLIDAQLADYHKHMEAVDYPRALEAVWTIIARTNKYIDETAPWVLAKEDGDKAQLASVMAHLAASLRLVAHVIQPFMMETSAAIMAQLGLEPVSDLSTLALADFPANTKVVAKGTPIFPRLDMEAEIDYIKAQMGDSSAISQEKEWVPEEVALKSEKDVITFETFDAVEIRVAEVKEVSKVEGSEKLLRFRVDAGDGQDRQILSGIAKFYPNEQELVGKKLQIVANLKPRKMMKKYISQGMILSAEHGDQLTVLTVDSSVPNGSIIG T27198 DRUGINFO D01GXL REP8839 Phase 1 T27198 DRUGINFO D07YXL Difluoromethionine Investigative T27198 DRUGINFO D0V2YR 5'-O-[(L-Methionyl)-Sulphamoyl]Adenosine Investigative T27198 DRUGINFO D0Z2KB Methionine Phosphonate Investigative T21434 TARGETID T21434 T21434 FORMERID TTDC00242 T21434 UNIPROID ACH10_HUMAN T21434 TARGNAME Neuronal acetylcholine receptor alpha-10 (CHRNA10) T21434 GENENAME CHRNA10 T21434 TARGTYPE Clinical trial T21434 SYNONYMS Nicotinic acetylcholine receptor subunit alpha 10; NACHR alpha 10; CHRNA10 T21434 FUNCTION Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes thecell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma. T21434 BIOCLASS Neurotransmitter receptor T21434 SEQUENCE MGLRSHHLSLGLLLLFLLPAECLGAEGRLALKLFRDLFANYTSALRPVADTDQTLNVTLEVTLSQIIDMDERNQVLTLYLWIRQEWTDAYLRWDPNAYGGLDAIRIPSSLVWRPDIVLYNKADAQPPGSASTNVVLRHDGAVRWDAPAITRSSCRVDVAAFPFDAQHCGLTFGSWTHGGHQLDVRPRGAAASLADFVENVEWRVLGMPARRRVLTYGCCSEPYPDVTFTLLLRRRAAAYVCNLLLPCVLISLLAPLAFHLPADSGEKVSLGVTVLLALTVFQLLLAESMPPAESVPLIGKYYMATMTMVTFSTALTILIMNLHYCGPSVRPVPAWARALLLGHLARGLCVRERGEPCGQSRPPELSPSPQSPEGGAGPPAGPCHEPRCLCRQEALLHHVATIANTFRSHRAAQRCHEDWKRLARVMDRFFLAIFFSMALVMSLLVLVQAL T21434 DRUGINFO D00WPT ACV-1 Phase 1 T21434 DRUGINFO D09VJI [3H]methyllycaconitine Investigative T50089 TARGETID T50089 T50089 FORMERID TTDI02167 T50089 UNIPROID S1PR5_HUMAN T50089 TARGNAME Sphingosine-1-phosphate receptor 5 (S1PR5) T50089 GENENAME S1PR5 T50089 TARGTYPE Clinical trial T50089 SYNONYMS Sphingosine 1-phosphate receptor Edg-8; S1PR5; S1P5; S1P receptor Edg-8; S1P receptor 5; Endothelial differentiation G-protein-coupled receptor 8 T50089 FUNCTION Receptor for the lysosphingolipid sphingosine 1- phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. Is coupled to both the G(i/0)alpha and G(12) subclass of heteromeric G-proteins. May play a regulatory role in the transformation of radial glial cells into astrocytes and may affect proliferative activity of these cells. T50089 BIOCLASS GPCR rhodopsin T50089 SEQUENCE MESGLLRPAPVSEVIVLHYNYTGKLRGARYQPGAGLRADAVVCLAVCAFIVLENLAVLLVLGRHPRFHAPMFLLLGSLTLSDLLAGAAYAANILLSGPLTLKLSPALWFAREGGVFVALTASVLSLLAIALERSLTMARRGPAPVSSRGRTLAMAAAAWGVSLLLGLLPALGWNCLGRLDACSTVLPLYAKAYVLFCVLAFVGILAAICALYARIYCQVRANARRLPARPGTAGTTSTRARRKPRSLALLRTLSVVLLAFVACWGPLFLLLLLDVACPARTCPVLLQADPFLGLAMANSLLNPIIYTLTNRDLRHALLRLVCCGRHSCGRDPSGSQQSASAAEASGGLRRCLPPGLDGSFSGSERSSPQRDGLDTSGSTGSPGAPTAARTLVSEPAAD T50089 DRUGINFO D0Q0JI ASP-4058 Phase 1 T50089 DRUGINFO D06GFH VPC44116 Investigative T50089 DRUGINFO D05KEE AFD(R) Investigative T50089 DRUGINFO D06DYN FTY720-phosphate Investigative T50089 DRUGINFO D0W1ZW VPC03090-P Investigative T50089 DRUGINFO D03BRM AUY954 Investigative T86271 TARGETID T86271 T86271 FORMERID TTDI03308 T86271 UNIPROID KCNN2_HUMAN T86271 TARGNAME Calcium-activated potassium channel KCa2.2 (KCNN2) T86271 GENENAME KCNN2 T86271 TARGTYPE Clinical trial T86271 SYNONYMS Small conductance calcium-activated potassium channel protein 2; SKCa2; SKCa 2; SK2; KCa2.2 T86271 FUNCTION Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin. T86271 PDBSTRUC 6ALE; 5WC5; 5WBX; 5V02 T86271 BIOCLASS Voltage-gated ion channel T86271 SEQUENCE MSSCRYNGGVMRPLSNLSASRRNLHEMDSEAQPLQPPASVGGGGGASSPSAAAAAAAAVSSSAPEIVVSKPEHNNSNNLALYGTGGGGSTGGGGGGGGSGHGSSSGTKSSKKKNQNIGYKLGHRRALFEKRKRLSDYALIFGMFGIVVMVIETELSWGAYDKASLYSLALKCLISLSTIILLGLIIVYHAREIQLFMVDNGADDWRIAMTYERIFFICLEILVCAIHPIPGNYTFTWTARLAFSYAPSTTTADVDIILSIPMFLRLYLIARVMLLHSKLFTDASSRSIGALNKINFNTRFVMKTLMTICPGTVLLVFSISLWIIAAWTVRACERYHDQQDVTSNFLGAMWLISITFLSIGYGDMVPNTYCGKGVCLLTGIMGAGCTALVVAVVARKLELTKAEKHVHNFMMDTQLTKRVKNAAANVLRETWLIYKNTKLVKKIDHAKVRKHQRKFLQAIHQLRSVKMEQRKLNDQANTLVDLAKTQNIMYDMISDLNERSEDFEKRIVTLETKLETLIGSIHALPGLISQTIRQQQRDFIEAQMESYDKHVTYNAERSRSSSRRRRSSSTAPPTSSESS T86271 DRUGINFO D0I2FI dequalinium Clinical trial T86271 DRUGINFO D0N0LB zoxazolamine Terminated T86271 DRUGINFO D00DIF CyPPA Investigative T86271 DRUGINFO D00WMV UCL1684 Investigative T86271 DRUGINFO D0I6MA DC-EBIO Investigative T86271 DRUGINFO D0N1HE UCL1848 Investigative T86271 DRUGINFO D0VK9Y apamin Investigative T86271 DRUGINFO D0T0AG EBIO Investigative T86271 DRUGINFO D06PZZ [14C]TEA Investigative T19334 TARGETID T19334 T19334 FORMERID TTDI02099 T19334 UNIPROID IL21R_HUMAN T19334 TARGNAME Interleukin 21 receptor (IL21R) T19334 GENENAME IL21R T19334 TARGTYPE Clinical trial T19334 SYNONYMS UNQ3121/PRO10273; Novel interleukin receptor; NILR; Interleukin-21 receptor; IL21 receptor; IL-21R; IL-21 receptor; CD360 T19334 FUNCTION This is a receptor for interleukin-21. T19334 PDBSTRUC 4NZD; 3TGX T19334 BIOCLASS Cytokine receptor T19334 SEQUENCE MPRGWAAPLLLLLLQGGWGCPDLVCYTDYLQTVICILEMWNLHPSTLTLTWQDQYEELKDEATSCSLHRSAHNATHATYTCHMDVFHFMADDIFSVNITDQSGNYSQECGSFLLAESIKPAPPFNVTVTFSGQYNISWRSDYEDPAFYMLKGKLQYELQYRNRGDPWAVSPRRKLISVDSRSVSLLPLEFRKDSSYELQVRAGPMPGSSYQGTWSEWSDPVIFQTQSEELKEGWNPHLLLLLLLVIVFIPAFWSLKTHPLWRLWKKIWAVPSPERFFMPLYKGCSGDFKKWVGAPFTGSSLELGPWSPEVPSTLEVYSCHPPRSPAKRLQLTELQEPAELVESDGVPKPSFWPTAQNSGGSAYSEERDRPYGLVSIDTVTVLDAEGPCTWPCSCEDDGYPALDLDAGLEPSPGLEDPLLDAGTTVLSCGCVSAGSPGLGGPLGSLLDRLKPPLADGEDWAGGLPWGGRSPGGVSESEAGSPLAGLDMDTFDSGFVGSDCSSPVECDFTSPGDEGPPRSYLRQWVVIPPPLSSPGPQAS T19334 DRUGINFO D07KTA Ab-01 Phase 2 T19334 DRUGINFO D0M4MH ATR-107 Phase 1 T19334 DRUGINFO DHQ9S3 AMG 256 Phase 1 T60514 TARGETID T60514 T60514 FORMERID TTDI02085 T60514 UNIPROID GPVI_HUMAN T60514 TARGNAME Platelet glycoprotein VI (GP6) T60514 GENENAME GP6 T60514 TARGTYPE Clinical trial T60514 SYNONYMS Glycoprotein 6; GPVI T60514 FUNCTION Collagen receptor involved in collagen-induced platelet adhesion and activation. Plays a key role in platelet procoagulant activity and subsequent thrombin and fibrin formation. This procoagulant function may contribute to arterial and venous thrombus formation. The signaling pathway involves the FcR gamma-chain, the Src kinases (likely FYN or LYN) and SYK, the adapter protein LAT and leads to the activation of PLCG2. T60514 PDBSTRUC 5OU9; 5OU8; 5OU7; 2GI7 T60514 SEQUENCE MSPSPTALFCLGLCLGRVPAQSGPLPKPSLQALPSSLVPLEKPVTLRCQGPPGVDLYRLEKLSSSRYQDQAVLFIPAMKRSLAGRYRCSYQNGSLWSLPSDQLELVATGVFAKPSLSAQPGPAVSSGGDVTLQCQTRYGFDQFALYKEGDPAPYKNPERWYRASFPIITVTAAHSGTYRCYSFSSRDPYLWSAPSDPLELVVTGTSVTPSRLPTEPPSPVAEFSEATAELTVSFTNEVFTTETSRSITASPKESDSPAGPARQYYTKGNLVRICLGAVILIILAGFLAEDWHSRRKRLRHRGRAVQRPLPPLPPLPLTRKSNGGQDGGRQDVHSRGLCS T60514 DRUGINFO D03BAC Revacept Phase 2 T60514 DRUGINFO DPG5T9 ACT017 Phase 1/2 T29741 TARGETID T29741 T29741 FORMERID TTDI02136 T29741 UNIPROID NOX4_HUMAN T29741 TARGNAME NADPH oxidase 4 (NOX4) T29741 GENENAME NOX4 T29741 TARGTYPE Clinical trial T29741 SYNONYMS Renal NAD(P)Hoxidase; Renal NAD(P)H-oxidase; RENOX; Kidney superoxideproducing NADPH oxidase; Kidney superoxide-producing NADPH oxidase; Kidney oxidase1; Kidney oxidase-1; KOX1; KOX-1 T29741 FUNCTION Regulates signaling cascades probably through phosphatases inhibition. May function as an oxygen sensor regulating the KCNK3/TASK-1 potassium channel and HIF1A activity. May regulate insulin signaling cascade. May play a role in apoptosis, bone resorption and lipolysaccharide-mediated activation of NFKB. May produce superoxide in the nucleus and play a role in regulating gene expression upon cell stimulation. Isoform 3 is not functional. Isoform 5 and isoform 6 display reduced activity. Constitutive NADPH oxidase which generates superoxide intracellularly upon formation of a complex with CYBA/p22phox. T29741 BIOCLASS NADH/NADPH oxidoreductase T29741 ECNUMBER EC 1.6.3.- T29741 SEQUENCE MAVSWRSWLANEGVKHLCLFIWLSMNVLLFWKTFLLYNQGPEYHYLHQMLGLGLCLSRASASVLNLNCSLILLPMCRTLLAYLRGSQKVPSRRTRRLLDKSRTFHITCGVTICIFSGVHVAAHLVNALNFSVNYSEDFVELNAARYRDEDPRKLLFTTVPGLTGVCMVVVLFLMITASTYAIRVSNYDIFWYTHNLFFVFYMLLTLHVSGGLLKYQTNLDTHPPGCISLNRTSSQNISLPEYFSEHFHEPFPEGFSKPAEFTQHKFVKICMEEPRFQANFPQTWLWISGPLCLYCAERLYRYIRSNKPVTIISVMSHPSDVMEIRMVKENFKARPGQYITLHCPSVSALENHPFTLTMCPTETKATFGVHLKIVGDWTERFRDLLLPPSSQDSEILPFIQSRNYPKLYIDGPFGSPFEESLNYEVSLCVAGGIGVTPFASILNTLLDDWKPYKLRRLYFIWVCRDIQSFRWFADLLCMLHNKFWQENRPDYVNIQLYLSQTDGIQKIIGEKYHALNSRLFIGRPRWKLLFDEIAKYNRGKTVGVFCCGPNSLSKTLHKLSNQNNSYGTRFEYNKESFS T29741 DRUGINFO D04XVU GKT-137831 Phase 2 T74238 TARGETID T74238 T74238 FORMERID TTDI01916 T74238 UNIPROID CLTR2_HUMAN T74238 TARGNAME Leukotriene CysLT2 receptor (CYSLTR2) T74238 GENENAME CYSLTR2 T74238 TARGTYPE Clinical trial T74238 SYNONYMS hGPCR21; PSEC0146; HPN321; Gprotein coupled receptor HG57; Gprotein coupled receptor GPCR21; G-protein coupled receptor HG57; G-protein coupled receptor GPCR21; Cysteinyl leukotriene receptor 2; CysLTR2; CYSLT2R; CYSLT2 T74238 FUNCTION The response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium. The rank order of affinities for the leukotrienes is LTC4 = LTD4 >> LTE4. Receptor for cysteinyl leukotrienes. T74238 BIOCLASS GPCR rhodopsin T74238 SEQUENCE MERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSIYVFLQPYKKSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYVNMYSSIYFLTVLSVVRFLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNGSVTSCLELNLYKIAKLQTMNYIALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRVSHRKALTTIIITLIIFFLCFLPYHTLRTVHLTTWKVGLCKDRLHKALVITLALAAANACFNPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWLRKETRV T74238 DRUGINFO D0GY0O BAY-X-7195 Phase 2 T74238 DRUGINFO D0B6EU AS-35 Discontinued in Phase 2 T74238 DRUGINFO D0F4IG DS-4574 Discontinued in Phase 2 T74238 DRUGINFO D0G8UG Sulukast Discontinued in Phase 2 T74238 DRUGINFO D09ZVR MDL-43291 Terminated T74238 DRUGINFO D0D0XX LY-290154 Terminated T74238 DRUGINFO D0ZE5V FPL-55712 Terminated T74238 DRUGINFO D0J7UI ICI-198615 Terminated T74238 DRUGINFO D06AYN HAMI3379 Investigative T74238 DRUGINFO D0LK5P [3H]LTC4 Investigative T74238 DRUGINFO D03VGR N-methyl LTC4 Investigative T74238 DRUGINFO D04CZQ CGP-57698 Investigative T74238 DRUGINFO D05CNT BAYu9773 Investigative T74238 DRUGINFO D09JQU BayCysLT2 Investigative T74238 DRUGINFO D0G7OZ pobilukast Investigative T74238 DRUGINFO D03YBH LTD4 Investigative T74238 DRUGINFO D0EW6H LTC4 Investigative T74238 DRUGINFO D0C0KJ LTE4 Investigative T89054 TARGETID T89054 T89054 FORMERID TTDR00113 T89054 UNIPROID PURA_PLAFA T89054 TARGNAME Plasmodium Adenylosuccinate synthetase (Malaria Adss) T89054 GENENAME Malaria Adss T89054 TARGTYPE Clinical trial T89054 SYNONYMS IMP--aspartate ligase; Adenylosuccinate synthase; AdSS; AMPSase T89054 FUNCTION Plays an important role in the salvage pathway for purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP. T89054 PDBSTRUC 1P9B T89054 BIOCLASS Carbon-nitrogen ligase T89054 ECNUMBER EC 6.3.4.4 T89054 SEQUENCE MNIFDHQIKNVDKGNVVAILGAQWGDEGKGKIIDMLSEYSDITCRFNGGANAGHTISVNDKKYALHLLPCGVLYDNNISVLGNGMVIHVKSLMEEIESVGGKLLDRLYLSNKAHILFDIHQIIDSIQETKKLKEGKQIGTTKRGIGPCYSTKASRIGIRLGTLKNFENFKNMYSKLIDHLMDLYNITEYDKEKELNLFYNYHIKLRDRIVDVISFMNTNLENNKKVLIEGANAAMLDIDFGTYPYVTSSCTTVGGVFSGLGIHHKKLNLVVGVVKSYLTRVGCGPFLTELNNDVGQYLREKGHEYGTTTKRPRRCGWLDIPMLLYVKCINSIDMINLTKLDVLSGLEEILLCVNFKNKKTGELLEKGCYPVEEEISEEYEPVYEKFSGWKEDISTCNEFDELPENAKKYILAIEKYLKTPIVWIGVGPNRKNMIVKKNFNLN T89054 DRUGINFO D00HWD (Carboxyhydroxyamino)Ethanoic Acid Investigative T89054 DRUGINFO D03RLJ (C8-R)-Hydantocidin 5'-Phosphate Investigative T89054 DRUGINFO D0M5WP (C8-S)-Hydantocidin 5'-Phosphate Investigative T89054 DRUGINFO D0T6XN 6-O-Phosphoryl Inosine Monophosphate Investigative T89054 DRUGINFO D0VW5G Hydantocidin-5'-Monophosphate Investigative T89054 DRUGINFO D05EHM 6-Cl-IMP Investigative T89054 DRUGINFO D0R4PI Diphosphate Investigative T89054 DRUGINFO D0H2YT Inosinic Acid Investigative T89054 DRUGINFO D0C7LS Guanosine-5'-Diphosphate Investigative T89054 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T40010 TARGETID T40010 T40010 FORMERID TTDC00238 T40010 UNIPROID EGFL7_HUMAN T40010 TARGNAME Epidermal growth factor-like protein 7 (EGFL7) T40010 GENENAME EGFL7 T40010 TARGTYPE Clinical trial T40010 SYNONYMS ZNEU1; Vascular endothelial statin; VE-statin; UNQ187/PRO1449; NOTCH4-like protein; Multiple epidermal growth factor-like domains protein 7; Multiple epidermal growth factor-like domain protein 7; Multiple EGF-like domains protein 7; Multiple EGF-like domain protein 7; MEGF7; EGF-like protein 7 T40010 FUNCTION Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis. Regulates vascular tubulogenesis in vivo. T40010 BIOCLASS Growth factor T40010 SEQUENCE MRGSQEVLLMWLLVLAVGGTEHAYRPGRRVCAVRAHGDPVSESFVQRVYQPFLTTCDGHRACSTYRTIYRTAYRRSPGLAPARPRYACCPGWKRTSGLPGACGAAICQPPCRNGGSCVQPGRCRCPAGWRGDTCQSDVDECSARRGGCPQRCVNTAGSYWCQCWEGHSLSADGTLCVPKGGPPRVAPNPTGVDSAMKEEVQRLQSRVDLLEEKLQLVLAPLHSLASQALEHGLPDPGSLLVHSFQQLGRIDSLSEQISFLEEQLGSCSCKKDS T40010 DRUGINFO D01LES MEGF0444A Phase 2 T40010 DRUGINFO D08QTK Anti-EGFL7 Phase 1 T40010 DRUGINFO D01AFG RG7414 Discontinued in Phase 2 T45287 TARGETID T45287 T45287 FORMERID TTDI03026 T45287 UNIPROID DNPEP_HUMAN T45287 TARGNAME Aspartyl aminopeptidase (DNPEP) T45287 GENENAME DNPEP T45287 TARGTYPE Clinical trial T45287 SYNONYMS DAP; ASPEP T45287 FUNCTION Likely to play an important role in intracellular protein and peptide metabolism. Aminopeptidase with specificity towards an acidic amino acid at the N-terminus. T45287 PDBSTRUC 4DYO T45287 BIOCLASS Peptidase T45287 ECNUMBER EC 3.4.11.21 T45287 SEQUENCE MSGHSPTRGAMQVAMNGKARKEAVQTAAKELLKFVNRSPSPFHAVAECRNRLLQAGFSELKETEKWNIKPESKYFMTRNSSTIIAFAVGGQYVPGNGFSLIGAHTDSPCLRVKRRSRRSQVGFQQVGVETYGGGIWSTWFDRDLTLAGRVIVKCPTSGRLEQQLVHVERPILRIPHLAIHLQRNINENFGPNTEMHLVPILATAIQEELEKGTPEPGPLNAVDERHHSVLMSLLCAHLGLSPKDIVEMELCLADTQPAVLGGAYDEFIFAPRLDNLHSCFCALQALIDSCAGPGSLATEPHVRMVTLYDNEEVGSESAQGAQSLLTELVLRRISASCQHPTAFEEAIPKSFMISADMAHAVHPNYLDKHEENHRPLFHKGPVIKVNSKQRYASNAVSEALIREVANKVKVPLQDLMVRNDTPCGTTIGPILASRLGLRVLDLGSPQLAMHSIREMACTTGVLQTLTLFKGFFELFPSLSHNLLVD T45287 DRUGINFO D0C1JV QGC-001 Phase 2 T45287 DRUGINFO D0A7GO PMID1738140C9 Investigative T44684 TARGETID T44684 T44684 FORMERID TTDI02135 T44684 UNIPROID NOTC3_HUMAN T44684 TARGNAME Notch-3 receptor (NOTCH3) T44684 GENENAME NOTCH3 T44684 TARGTYPE Clinical trial T44684 SYNONYMS Notch 3 intracellular domain; Notch 3; Neurogenic locus notch homolog protein 3 T44684 FUNCTION Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. T44684 PDBSTRUC 5CZX; 5CZV; 4ZLP T44684 BIOCLASS Notch protein T44684 SEQUENCE MGPGARGRRRRRRPMSPPPPPPPVRALPLLLLLAGPGAAAPPCLDGSPCANGGRCTQLPSREAACLCPPGWVGERCQLEDPCHSGPCAGRGVCQSSVVAGTARFSCRCPRGFRGPDCSLPDPCLSSPCAHGARCSVGPDGRFLCSCPPGYQGRSCRSDVDECRVGEPCRHGGTCLNTPGSFRCQCPAGYTGPLCENPAVPCAPSPCRNGGTCRQSGDLTYDCACLPGFEGQNCEVNVDDCPGHRCLNGGTCVDGVNTYNCQCPPEWTGQFCTEDVDECQLQPNACHNGGTCFNTLGGHSCVCVNGWTGESCSQNIDDCATAVCFHGATCHDRVASFYCACPMGKTGLLCHLDDACVSNPCHEDAICDTNPVNGRAICTCPPGFTGGACDQDVDECSIGANPCEHLGRCVNTQGSFLCQCGRGYTGPRCETDVNECLSGPCRNQATCLDRIGQFTCICMAGFTGTYCEVDIDECQSSPCVNGGVCKDRVNGFSCTCPSGFSGSTCQLDVDECASTPCRNGAKCVDQPDGYECRCAEGFEGTLCDRNVDDCSPDPCHHGRCVDGIASFSCACAPGYTGTRCESQVDECRSQPCRHGGKCLDLVDKYLCRCPSGTTGVNCEVNIDDCASNPCTFGVCRDGINRYDCVCQPGFTGPLCNVEINECASSPCGEGGSCVDGENGFRCLCPPGSLPPLCLPPSHPCAHEPCSHGICYDAPGGFRCVCEPGWSGPRCSQSLARDACESQPCRAGGTCSSDGMGFHCTCPPGVQGRQCELLSPCTPNPCEHGGRCESAPGQLPVCSCPQGWQGPRCQQDVDECAGPAPCGPHGICTNLAGSFSCTCHGGYTGPSCDQDINDCDPNPCLNGGSCQDGVGSFSCSCLPGFAGPRCARDVDECLSNPCGPGTCTDHVASFTCTCPPGYGGFHCEQDLPDCSPSSCFNGGTCVDGVNSFSCLCRPGYTGAHCQHEADPCLSRPCLHGGVCSAAHPGFRCTCLESFTGPQCQTLVDWCSRQPCQNGGRCVQTGAYCLCPPGWSGRLCDIRSLPCREAAAQIGVRLEQLCQAGGQCVDEDSSHYCVCPEGRTGSHCEQEVDPCLAQPCQHGGTCRGYMGGYMCECLPGYNGDNCEDDVDECASQPCQHGGSCIDLVARYLCSCPPGTLGVLCEINEDDCGPGPPLDSGPRCLHNGTCVDLVGGFRCTCPPGYTGLRCEADINECRSGACHAAHTRDCLQDPGGGFRCLCHAGFSGPRCQTVLSPCESQPCQHGGQCRPSPGPGGGLTFTCHCAQPFWGPRCERVARSCRELQCPVGVPCQQTPRGPRCACPPGLSGPSCRSFPGSPPGASNASCAAAPCLHGGSCRPAPLAPFFRCACAQGWTGPRCEAPAAAPEVSEEPRCPRAACQAKRGDQRCDRECNSPGCGWDGGDCSLSVGDPWRQCEALQCWRLFNNSRCDPACSSPACLYDNFDCHAGGRERTCNPVYEKYCADHFADGRCDQGCNTEECGWDGLDCASEVPALLARGVLVLTVLLPPEELLRSSADFLQRLSAILRTSLRFRLDAHGQAMVFPYHRPSPGSEPRARRELAPEVIGSVVMLEIDNRLCLQSPENDHCFPDAQSAADYLGALSAVERLDFPYPLRDVRGEPLEPPEPSVPLLPLLVAGAVLLLVILVLGVMVARRKREHSTLWFPEGFSLHKDVASGHKGRREPVGQDALGMKNMAKGESLMGEVATDWMDTECPEAKRLKVEEPGMGAEEAVDCRQWTQHHLVAADIRVAPAMALTPPQGDADADGMDVNVRGPDGFTPLMLASFCGGALEPMPTEEDEADDTSASIISDLICQGAQLGARTDRTGETALHLAARYARADAAKRLLDAGADTNAQDHSGRTPLHTAVTADAQGVFQILIRNRSTDLDARMADGSTALILAARLAVEGMVEELIASHADVNAVDELGKSALHWAAAVNNVEATLALLKNGANKDMQDSKEETPLFLAAREGSYEAAKLLLDHFANREITDHLDRLPRDVAQERLHQDIVRLLDQPSGPRSPPGPHGLGPLLCPPGAFLPGLKAAQSGSKKSRRPPGKAGLGPQGPRGRGKKLTLACPGPLADSSVTLSPVDSLDSPRPFGGPPASPGGFPLEGPYAAATATAVSLAQLGGPGRAGLGRQPPGGCVLSLGLLNPVAVPLDWARLPPPAPPGPSFLLPLAPGPQLLNPGTPVSPQERPPPYLAVPGHGEEYPAAGAHSSPPKARFLRVPSEHPYLTPSPESPEHWASPSPPSLSDWSESTPSPATATGAMATTTGALPAQPLPLSVPSSLAQAQTQLGPQPEVTPKRQVLA T44684 DRUGINFO D01QLP Tarextumab Phase 2 T18299 TARGETID T18299 T18299 FORMERID TTDI02008 T18299 UNIPROID KCC2A_HUMAN; KCC2B_HUMAN; KCC2D_HUMAN; KCC2G_HUMAN T18299 TARGNAME CaM-kinase II (CAMK2) T18299 GENENAME CAMK2A; CAMK2B; CAMK2D; CAMK2G T18299 TARGTYPE Clinical trial T18299 SYNONYMS Calcium/calmodulin-dependent protein kinase type II; CaMK-II; CaM kinase II; CAMK T18299 FUNCTION CaM-kinase II (CAMK2) is a prominent kinase in the central nervous system that may function in long-term potentiation and neurotransmitter release. Member of the NMDAR signaling complex in excitatory synapses it may regulate NMDAR-dependent potentiation of the AMPAR and synaptic plasticity. T18299 BIOCLASS Kinase T18299 SEQUENCE MATITCTRFTEEYQLFEELGKGAFSVVRRCVKVLAGQEYAAKIINTKKLSARDHQKLEREARICRLLKHPNIVRLHDSISEEGHHYLIFDLVTGGELFEDIVAREYYSEADASHCIQQILEAVLHCHQMGVVHRDLKPENLLLASKLKGAAVKLADFGLAIEVEGEQQAWFGFAGTPGYLSPEVLRKDPYGKPVDLWACGVILYILLVGYPPFWDEDQHRLYQQIKAGAYDFPSPEWDTVTPEAKDLINKMLTINPSKRITAAEALKHPWISHRSTVASCMHRQETVDCLKKFNARRKLKGAILTTMLATRNFSGGKSGGNKKSDGVKESSESTNTTIEDEDTKVRKQEIIKVTEQLIEAISNGDFESYTKMCDPGMTAFEPEALGNLVEGLDFHRFYFENLWSRNSKPVHTTILNPHIHLMGDESACIAYIRITQYLDAGGIPRTAQSEETRVWHRRDGKWQIVHFHRSGAPSVLPH T18299 DRUGINFO D06PHH Rimacalib Phase 2 T18299 DRUGINFO D01EPO ABIO 09-01 Investigative T18299 DRUGINFO D0D7HR PMID18337095C27 Investigative T18299 DRUGINFO D0FH9J PMID18334293C15b Investigative T18299 DRUGINFO D0XT3Z KN-93 Investigative T64774 TARGETID T64774 T64774 FORMERID TTDC00061 T64774 UNIPROID VDAC3_HUMAN T64774 TARGNAME Voltage-dependent anion-selective channel 3 (VDAC3) T64774 GENENAME VDAC3 T64774 TARGTYPE Clinical trial T64774 SYNONYMS hVDAC3; VDAC3; VDAC-3; Outer mitochondrial membrane protein porin 3 T64774 FUNCTION Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules. T64774 BIOCLASS Eukaryotic mitochondrial porin T64774 SEQUENCE MCNTPTYCDLGKAAKDVFNKGYGFGMVKIDLKTKSCSGVEFSTSGHAYTDTGKASGNLETKYKVCNYGLTFTQKWNTDNTLGTEISWENKLAEGLKLTLDTIFVPNTGKKSGKLKASYKRDCFSVGSNVDIDFSGPTIYGWAVLAFEGWLAGYQMSFDTAKSKLSQNNFALGYKAADFQLHTHVNDGTEFGGSIYQKVNEKIETSINLAWTAGSNNTRFGIAAKYMLDCRTSLSAKVNNASLIGLGYTQTLRPGVKLTLSALIDGKNFSAGGHKVGLGFELEA T64774 DRUGINFO D0P0EI PRLX93936 Phase 1/2 T52037 TARGETID T52037 T52037 FORMERID TTDI02192 T52037 UNIPROID TLR6_HUMAN T52037 TARGNAME Toll-like receptor 6 (TLR6) T52037 GENENAME TLR6 T52037 TARGTYPE Clinical trial T52037 SYNONYMS CD286 T52037 FUNCTION Specifically recognizes diacylated and, to a lesser extent, triacylated lipopeptides. In response to diacylated lipopeptides, forms the activation cluster TLR2:TLR6:CD14:CD36, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B. burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR2. In complex with TLR4, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. Participates in the innate immune response to Gram-positive bacteria and fungi. T52037 PDBSTRUC 4OM7 T52037 BIOCLASS Toll-like receptor T52037 SEQUENCE MTKDKEPIVKSFHFVCLMIIIVGTRIQFSDGNEFAVDKSKRGLIHVPKDLPLKTKVLDMSQNYIAELQVSDMSFLSELTVLRLSHNRIQLLDLSVFKFNQDLEYLDLSHNQLQKISCHPIVSFRHLDLSFNDFKALPICKEFGNLSQLNFLGLSAMKLQKLDLLPIAHLHLSYILLDLRNYYIKENETESLQILNAKTLHLVFHPTSLFAIQVNISVNTLGCLQLTNIKLNDDNCQVFIKFLSELTRGSTLLNFTLNHIETTWKCLVRVFQFLWPKPVEYLNIYNLTIIESIREEDFTYSKTTLKALTIEHITNQVFLFSQTALYTVFSEMNIMMLTISDTPFIHMLCPHAPSTFKFLNFTQNVFTDSIFEKCSTLVKLETLILQKNGLKDLFKVGLMTKDMPSLEILDVSWNSLESGRHKENCTWVESIVVLNLSSNMLTDSVFRCLPPRIKVLDLHSNKIKSVPKQVVKLEALQELNVAFNSLTDLPGCGSFSSLSVLIIDHNSVSHPSADFFQSCQKMRSIKAGDNPFQCTCELREFVKNIDQVSSEVLEGWPDSYKCDYPESYRGSPLKDFHMSELSCNITLLIVTIGATMLVLAVTVTSLCIYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSEHDSAWVKSELVPYLEKEDIQICLHERNFVPGKSIVENIINCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFHEGSNNLILILLEPIPQNSIPNKYHKLKALMTQRTYLQWPKEKSKRGLFWANIRAAFNMKLTLVTENNDVKS T52037 DRUGINFO D0K3SM MALP-2S Phase 1/2 T95998 TARGETID T95998 T95998 FORMERID TTDR00172 T95998 UNIPROID PCY1B_HUMAN T95998 TARGNAME Cholinephosphate cytidylyltransferase (PCYT1B) T95998 GENENAME PCYT1B T95998 TARGTYPE Clinical trial T95998 SYNONYMS Phosphorylcholine transferase; PCYT1B; CTP:phosphocholine cytidylyltransferase; CT; CCT T95998 FUNCTION Controls phosphatidylcholine synthesis. T95998 BIOCLASS Nucleotidyltransferase T95998 ECNUMBER EC 2.7.7.15 T95998 SEQUENCE MPVVTTDAESETGIPKSLSNEPPSETMEEIEHTCPQPRLTLTAPAPFADETNCQCQAPHEKLTIAQARLGTPADRPVRVYADGIFDLFHSGHARALMQAKTLFPNSYLLVGVCSDDLTHKFKGFTVMNEAERYEALRHCRYVDEVIRDAPWTLTPEFLEKHKIDFVAHDDIPYSSAGSDDVYKHIKEAGMFVPTQRTEGISTSDIITRIVRDYDVYARRNLQRGYTAKELNVSFINEKRYRFQNQVDKMKEKVKNVEERSKEFVNRVEEKSHDLIQKWEEKSREFIGNFLELFGPDGAWKQMFQERSSRMLQALSPKQSPVSSPTRSRSPSRSPSPTFSWLPLKTSPPSSPKAASASISSMSEGDEDEK T95998 DRUGINFO D0V0DI CT-2584 Phase 3 T95998 DRUGINFO D0L0YG Sphingosine Phase 1 T95998 DRUGINFO D02DLW Cholesterol Investigative T15344 TARGETID T15344 T15344 FORMERID TTDI02197 T15344 UNIPROID TNR18_HUMAN T15344 TARGNAME Activation-inducible TNFR family receptor (TNFRSF18) T15344 GENENAME TNFRSF18 T15344 TARGTYPE Clinical trial T15344 SYNONYMS UNQ319/PRO364; Tumor necrosis factor receptor superfamily member 18; Glucocorticoid-induced TNFR-related protein; GITR; CD357; AITR T15344 FUNCTION Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. Mediated NF-kappa-B activation via the TRAF2/NIK pathway. Receptor for TNFSF18. T15344 BIOCLASS Cytokine receptor T15344 SEQUENCE MAQHGAMGAFRALCGLALLCALSLGQRPTGGPGCGPGRLLLGTGTDARCCRVHTTRCCRDYPGEECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSQGKFSFGFQCIDCASGTFSGGHEGHCKPWTDCTQFGFLTVFPGNKTHNAVCVPGSPPAEPLGWLTVVLLAVAACVLLLTSAQLGLHIWQLRSQCMWPRETQLLLEVPPSTEDARSCQFPEEERGERSAEEKGRLGDLWV T15344 DRUGINFO DOI7H2 INCAGN01876 Phase 2 T15344 DRUGINFO D06CJN INCAGN1876 Phase 1/2 T15344 DRUGINFO D0J1MO TRX-518 Phase 1/2 T15344 DRUGINFO D0Y2XZ MK-4166 Phase 1 T15344 DRUGINFO D8CFX3 REGN6569 Phase 1 T15344 DRUGINFO DG17UJ AMG 228 Phase 1 T15344 DRUGINFO DJ6NE2 TRX518 Phase 1 T15344 DRUGINFO DYSI03 ASP1951 Phase 1 T93661 TARGETID T93661 T93661 FORMERID TTDR01343 T93661 UNIPROID SMAD7_HUMAN T93661 TARGNAME Smad7 messenger RNA (Smad7 mRNA) T93661 GENENAME SMAD7 T93661 TARGTYPE Clinical trial T93661 SYNONYMS hSMAD7 (mRNA); Smad7 (mRNA); SMAD family member 7 (mRNA); SMAD 7 (mRNA); Mothers against decapentaplegic homolog 8 (mRNA); Mothers against decapentaplegic homolog 7 (mRNA); Mothers against DPP homolog 8 (mRNA); Mothers against DPP homolog 7 (mRNA); MADH8 (mRNA); MADH7 (mRNA); MAD homolog 8 (mRNA); MAD homolog 7 (mRNA) T93661 FUNCTION Functions as an adapter to recruit SMURF2 to the TGF-beta receptor complex. Also acts by recruiting the PPP1R15A-PP1 complex to TGFBR1, which promotes its dephosphorylation. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. Antagonist of signaling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit TGF-beta (Transforming growth factor) and activin signaling by associating with their receptors thus preventing SMAD2 access. T93661 PDBSTRUC 2LTZ; 2LTY; 2LTX; 2LTW; 2LTV T93661 BIOCLASS mRNA target T93661 SEQUENCE MFRTKRSALVRRLWRSRAPGGEDEEEGAGGGGGGGELRGEGATDSRAHGAGGGGPGRAGCCLGKAVRGAKGHHHPHPPAAGAGAAGGAEADLKALTHSVLKKLKERQLELLLQAVESRGGTRTACLLLPGRLDCRLGPGAPAGAQPAQPPSSYSLPLLLCKVFRWPDLRHSSEVKRLCCCESYGKINPELVCCNPHHLSRLCELESPPPPYSRYPMDFLKPTADCPDAVPSSAETGGTNYLAPGGLSDSQLLLEPGDRSHWCVVAYWEEKTRVGRLYCVQEPSLDIFYDLPQGNGFCLGQLNSDNKSQLVQKVRSKIGCGIQLTREVDGVWVYNRSSYPIFIKSATLDNPDSRTLLVHKVFPGFSIKAFDYEKAYSLQRPNDHEFMQQPWTGFTVQISFVKGWGQCYTRQFISSCPCWLEVIFNSR T93661 DRUGINFO D09FKY GED-0301 Phase 3 T93661 DRUGINFO D01VBU ISIS 28466 Investigative T93661 DRUGINFO D03BSQ ISIS 28477 Investigative T93661 DRUGINFO D0AL2R ISIS 28465 Investigative T93661 DRUGINFO D0E0WX ISIS 28472 Investigative T95515 TARGETID T95515 T95515 FORMERID TTDI02270 T95515 UNIPROID K2C6A_HUMAN T95515 TARGNAME Keratin 6A messenger RNA (KRT6A mRNA) T95515 GENENAME KRT6A T95515 TARGTYPE Clinical trial T95515 SYNONYMS Type-II keratin Kb6 (mRNA); Keratin-6A (mRNA); Keratin, type II cytoskeletal 6A (mRNA); KRT6D (mRNA); K6A (mRNA); Hom s 5 (mRNA); Cytokeratin-6D (mRNA); Cytokeratin-6A (mRNA); CK-6D (mRNA); CK-6A (mRNA) T95515 FUNCTION Involved in the activation of follicular keratinocytes after wounding, while it does not play a major role in keratinocyte proliferation or migration. Participates in the regulation of epithelial migration by inhibiting the activity of SRC during wound repair. Epidermis-specific type I keratin involved in wound healing. T95515 PDBSTRUC 5KI0 T95515 BIOCLASS mRNA target T95515 SEQUENCE MASTSTTIRSHSSSRRGFSANSARLPGVSRSGFSSVSVSRSRGSGGLGGACGGAGFGSRSLYGLGGSKRISIGGGSCAISGGYGSRAGGSYGFGGAGSGFGFGGGAGIGFGLGGGAGLAGGFGGPGFPVCPPGGIQEVTVNQSLLTPLNLQIDPTIQRVRAEEREQIKTLNNKFASFIDKVRFLEQQNKVLETKWTLLQEQGTKTVRQNLEPLFEQYINNLRRQLDSIVGERGRLDSELRGMQDLVEDFKNKYEDEINKRTAAENEFVTLKKDVDAAYMNKVELQAKADTLTDEINFLRALYDAELSQMQTHISDTSVVLSMDNNRNLDLDSIIAEVKAQYEEIAQRSRAEAESWYQTKYEELQVTAGRHGDDLRNTKQEIAEINRMIQRLRSEIDHVKKQCANLQAAIADAEQRGEMALKDAKNKLEGLEDALQKAKQDLARLLKEYQELMNVKLALDVEIATYRKLLEGEECRLNGEGVGQVNISVVQSTVSSGYGGASGVGSGLGLGGGSSYSYGSGLGVGGGFSSSSGRAIGGGLSSVGGGSSTIKYTTTSSSSRKSYKH T95515 DRUGINFO D06ECI TD-101 Phase 2 T87259 TARGETID T87259 T87259 FORMERID TTDC00282 T87259 UNIPROID ITAV_HUMAN T87259 TARGNAME ITGAV messenger RNA (ITGAV mRNA) T87259 GENENAME ITGAV T87259 TARGTYPE Clinical trial T87259 SYNONYMS Vitronectin receptor subunit alpha (mRNA); Vitronectin receptor alpha subunit (mRNA); Vitronectin receptor (mRNA); VTNR (mRNA); VNRA (mRNA); MSK8 (mRNA); CD51 antigen (mRNA); CD51 (mRNA) T87259 FUNCTION The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling. ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling. ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling. ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling. ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling. ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation. T87259 PDBSTRUC 6DJP; 6AVU; 6AVR; 6AVQ; 5NEU T87259 BIOCLASS mRNA target T87259 SEQUENCE MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET T87259 DRUGINFO D03TPI TV-1102 Phase 2 T15494 TARGETID T15494 T15494 FORMERID TTDC00345 T15494 UNIPROID GHR_HUMAN T15494 TARGNAME GHR messenger RNA (GHR mRNA) T15494 GENENAME GHR T15494 TARGTYPE Clinical trial T15494 SYNONYMS Somatotropin receptor (mRNA); Serum bindingprotein (mRNA); Growth hormone receptor (mRNA); GH receptor (mRNA) T15494 FUNCTION On ligand binding, couples to the JAK2/STAT5 pathway. Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. T15494 PDBSTRUC 5OHD; 5OEK; 3HHR; 2AEW; 1KF9 T15494 BIOCLASS mRNA target T15494 SEQUENCE MDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPERETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTSIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRNADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNYGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEESDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGEADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSSLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADAKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHIVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP T15494 DRUGINFO D0W3BC ATL1103 Phase 1 T86803 TARGETID T86803 T86803 FORMERID TTDR01387 T86803 UNIPROID STAT3_HUMAN T86803 TARGNAME STAT3 messenger RNA (STAT3 mRNA) T86803 GENENAME STAT3 T86803 TARGTYPE Clinical trial T86803 SYNONYMS Transcription factor STAT3 (mRNA); Stat3 (mRNA); Signal transducer and activator of transcription 3 (mRNA); Acute-phase response factor (mRNA); APRF (mRNA) T86803 FUNCTION Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the interleukin-6 (IL-6)-responsive elements identified in the promoters of various acute-phase protein genes. Activated by IL31 through IL31RA. Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): deacetylation and oxidation of lysine residues by LOXL3, leads to disrupt STAT3 dimerization and inhibit its transcription activity. Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1. Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation. May play an apoptotic role by transctivating BIRC5 expression under LEP activation. Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity. Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion. Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. T86803 PDBSTRUC 5U5S; 5AX3 T86803 BIOCLASS mRNA target T86803 SEQUENCE MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM T86803 DRUGINFO D0B4MK ISIS-STAT3 Phase 1/2 T86803 DRUGINFO D09CLC C188-9 Phase 1 T86803 DRUGINFO D03MRO ISIS 113187 Investigative T86803 DRUGINFO D07XRC ISIS 113176 Investigative T86803 DRUGINFO D09YBP ISIS 113209 Investigative T86803 DRUGINFO D0E3ZU ISIS 113210 Investigative T86803 DRUGINFO D0O3DZ ISIS 17148 Investigative T86803 DRUGINFO D0W2FY ISIS 17152 Investigative T81103 TARGETID T81103 T81103 FORMERID TTDI02255 T81103 UNIPROID CASP2_HUMAN T81103 TARGNAME Caspase 2 messenger RNA (CASP2 mRNA) T81103 GENENAME CASP2 T81103 TARGTYPE Clinical trial T81103 SYNONYMS Protease ICH1 (mRNA); Protease ICH-1 (mRNA); Neural precursor cell expressed developmentally downregulated protein 2 (mRNA); Neural precursor cell expressed developmentally down-regulated protein 2 (mRNA); NEDD2 (mRNA); NEDD-2 (mRNA); ICH1 (mRNA); Caspase2 subunit p12 (mRNA); CASP-2 (mRNA) T81103 FUNCTION Might function by either activating some proteins required for cell death or inactivating proteins necessary for cell survival. Associates with PIDD1 and CRADD to form the PIDDosome, a complex that activates CASP2 and triggers apoptosis in response to genotoxic stress. Involved in the activation cascade of caspases responsible for apoptosis execution. T81103 BIOCLASS mRNA target T81103 ECNUMBER EC 3.4.22.55 T81103 SEQUENCE MAAPSAGSWSTFQHKELMAADRGRRILGVCGMHPHHQETLKKNRVVLAKQLLLSELLEHLLEKDIITLEMRELIQAKVGSFSQNVELLNLLPKRGPQAFDAFCEALRETKQGHLEDMLLTTLSGLQHVLPPLSCDYDLSLPFPVCESCPLYKKLRLSTDTVEHSLDNKDGPVCLQVKPCTPEFYQTHFQLAYRLQSRPRGLALVLSNVHFTGEKELEFRSGGDVDHSTLVTLFKLLGYDVHVLCDQTAQEMQEKLQNFAQLPAHRVTDSCIVALLSHGVEGAIYGVDGKLLQLQEVFQLFDNANCPSLQNKPKMFFIQACRGDETDRGVDQQDGKNHAGSPGCEESDAGKEKLPKMRLPTRSDMICGYACLKGTAAMRNTKRGSWYIEALAQVFSERACDMHVADMLVKVNALIKDREGYAPGTEFHRCKEMSEYCSTLCRHLYLFPGHPPT T81103 DRUGINFO D06ZFV QPI-1007 Phase 3 T85228 TARGETID T85228 T85228 FORMERID TTDI02253 T85228 UNIPROID CCR3_HUMAN T85228 TARGNAME CCR3 messenger RNA (CCR3 mRNA) T85228 GENENAME CCR3 T85228 TARGTYPE Clinical trial T85228 SYNONYMS Eosinophil eotaxin receptor (mRNA); Chemokine receptor CCR3 (mRNA); CMKBR3 (mRNA); CKR3 (mRNA); CD193 (mRNA); CCR-3 (mRNA); CC-CKR-3 (mRNA); C-C chemokine receptor type 3 (mRNA); C-C CKR-3 (mRNA) T85228 FUNCTION Binds to eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES and MIP-1 delta. Subsequently transduces a signal by increasing the intracellular calcium ions level. Alternative coreceptor with CD4 for HIV-1 infection. Receptor for a C-C type chemokine. T85228 BIOCLASS mRNA target T85228 SEQUENCE MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILIKYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSEIFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEETLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRLIFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVIYAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF T85228 DRUGINFO D0L3IL ASM8 Phase 2 T85228 DRUGINFO D01JZV banyu (I) Investigative T85228 DRUGINFO D02BJB RO116-9132/238 Investigative T85228 DRUGINFO D05QAD RO320-2947/001 Investigative T85228 DRUGINFO D0B0NO RO116-4875/608 Investigative T85228 DRUGINFO D0JA5D RO330-0802/001 Investigative T68766 TARGETID T68766 T68766 FORMERID TTDI02257 T68766 UNIPROID DMPK_HUMAN T68766 TARGNAME DMPK messenger RNA (DMPK mRNA) T68766 GENENAME DMPK T68766 TARGTYPE Clinical trial T68766 SYNONYMS Myotonin-protein kinase (mRNA); Myotonic dystrophy protein kinase (mRNA); MT-PK (mRNA); MDPK (mRNA); DMPK (mRNA); DMK (mRNA); DM1PK (mRNA); DM1 protein kinase (mRNA); DM-kinase (mRNA) T68766 FUNCTION May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. May also phosphorylate PPP1R12A and inhibit the myosin phosphatase activity to regulate myosin phosphorylation. Also critical to the modulation of cardiac contractility and to the maintenance of proper cardiac conduction activity probably through the regulation of cellular calcium homeostasis. Phosphorylates PLN, a regulator of calcium pumps and may regulate sarcoplasmic reticulum calcium uptake in myocytes. May also phosphorylate FXYD1/PLM which is able to induce chloride currents. May also play a role in synaptic plasticity. Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function. T68766 PDBSTRUC 2VD5; 1WT6 T68766 BIOCLASS mRNA target T68766 ECNUMBER EC 2.7.11.1 T68766 SEQUENCE MSAEVRLRRLQQLVLDPGFLGLEPLLDLLLGVHQELGASELAQDKYVADFLQWAEPIVVRLKEVRLQRDDFEILKVIGRGAFSEVAVVKMKQTGQVYAMKIMNKWDMLKRGEVSCFREERDVLVNGDRRWITQLHFAFQDENYLYLVMEYYVGGDLLTLLSKFGERIPAEMARFYLAEIVMAIDSVHRLGYVHRDIKPDNILLDRCGHIRLADFGSCLKLRADGTVRSLVAVGTPDYLSPEILQAVGGGPGTGSYGPECDWWALGVFAYEMFYGQTPFYADSTAETYGKIVHYKEHLSLPLVDEGVPEEARDFIQRLLCPPETRLGRGGAGDFRTHPFFFGLDWDGLRDSVPPFTPDFEGATDTCNFDLVEDGLTAMVSGGGETLSDIREGAPLGVHLPFVGYSYSCMALRDSEVPGPTPMELEAEQLLEPHVQAPSLEPSVSPQDETAEVAVPAAVPAAEAEAEVTLRELQEALEEEVLTRQSLSREMEAIRTDNQNFASQLREAEARNRDLEAHVRQLQERMELLQAEGATAVTGVPSPRATDPPSHLDGPPAVAVGQCPLVGPGPMHRRHLLLPARVPRPGLSEALSLLLFAVVLSRAAALGCIGLVAHAGQLTAVWRRPGAARAP T68766 DRUGINFO D0X9WC ISIS-DMPK Phase 1/2 T68766 DRUGINFO D0N7HT PRO-135 Investigative T68766 DRUGINFO D0P4MA 2-MOE phosphorothioate gapmers Investigative T68766 DRUGINFO D03CPB RKI-1447 Investigative T80011 TARGETID T80011 T80011 FORMERID TTDR01411 T80011 UNIPROID 4EBP2_HUMAN T80011 TARGNAME eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA) T80011 GENENAME EIF4EBP2 T80011 TARGTYPE Clinical trial T80011 SYNONYMS eIF4E-binding protein 2 (mRNA); Eukaryotic translation initiation factor 4E-binding protein 2 (mRNA); 4E-BP2 (mRNA) T80011 FUNCTION Regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form of EIF4EBP2 competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress translation. In contrast, hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation. EIF4EBP2 is enriched in brain and acts as a regulator of synapse activity and neuronal stem cell renewal via its ability to repress translation initiation. Mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways. Repressor of translation initiation involved in synaptic plasticity, learning and memory formation. T80011 PDBSTRUC 3AM7; 2MX4 T80011 BIOCLASS mRNA target T80011 SEQUENCE MSSSAGSGHQPSQSRAIPTRTVAISDAAQLPHDYCTTPGGTLFSTTPGGTRIIYDRKFLLDRRNSPMAQTPPCHLPNIPGVTSPGTLIEDSKVEVNNLNNLNNHDRKHAVGDDAQFEMDI T80011 DRUGINFO D08HQI ISIS-EIF4E Phase 2 T80011 DRUGINFO D0FI9M ISIS 232828 Investigative T80011 DRUGINFO D0QE7H ISIS 347577 Investigative T80011 DRUGINFO D0W3RV ISIS 347573 Investigative T37298 TARGETID T37298 T37298 FORMERID TTDI02265 T37298 UNIPROID MYCBP_HUMAN T37298 TARGNAME MYCBP messenger RNA (MYCBP mRNA) T37298 GENENAME MYCBP T37298 TARGTYPE Clinical trial T37298 SYNONYMS c-Myc-binding protein (mRNA); Associate of Myc 1 (mRNA); AMY1 (mRNA); AMY-1 (mRNA) T37298 FUNCTION Stimulates the activation of E box-dependent transcription by MYC. May control the transcriptional activity of MYC. T37298 PDBSTRUC 2YY0 T37298 BIOCLASS mRNA target T37298 SEQUENCE MAHYKAADSKREQFRRYLEKSGVLDTLTKVLVALYEEPEKPNSALDFLKHHLGAATPENPEIELLRLELAEMKEKYEAIVEENKKLKAKLAQYEPPQEEKRAE T37298 DRUGINFO D02OZT DCR-MYC Phase 1/2 T41003 TARGETID T41003 T41003 FORMERID TTDR01423 T41003 UNIPROID EPAS1_HUMAN T41003 TARGNAME HIF2-alpha messenger RNA (EPAS1 mRNA) T41003 GENENAME EPAS1 T41003 TARGTYPE Clinical trial T41003 SYNONYMS PASD2 mRNA; PAS domain-containing protein 2 mRNA; Member of PAS protein 2 mRNA; MOP2 mRNA; Hypoxia-inducible factor 2-alpha mRNA; HLF mRNA; HIF2A mRNA; HIF2-alpha mRNA; HIF-2-alpha mRNA; HIF-1-alpha-like factor mRNA; Endothelial PAS domain-containing protein 1 mRNA; EPAS-1 mRNA; Class E basic helix-loop-helix protein 73 mRNA; Basic-helix-loop-helix-PAS protein MOP2 mRNA; BHLHE73 mRNA T41003 FUNCTION Transcription factor involved in the induction of oxygen regulated genes. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation requires recruitment of transcriptional coactivators such as CREBBP and probably EP300. Interaction with redox regulatory protein APEX seems to activate CTAD (By similarity). T41003 PDBSTRUC 6D0C; 6D0B; 6D09; 6CZW; 6BVB T41003 BIOCLASS mRNA target T41003 SEQUENCE MTADKEKKRSSSERRKEKSRDAARCRRSKETEVFYELAHELPLPHSVSSHLDKASIMRLAISFLRTHKLLSSVCSENESEAEADQQMDNLYLKALEGFIAVVTQDGDMIFLSENISKFMGLTQVELTGHSIFDFTHPCDHEEIRENLSLKNGSGFGKKSKDMSTERDFFMRMKCTVTNRGRTVNLKSATWKVLHCTGQVKVYNNCPPHNSLCGYKEPLLSCLIIMCEPIQHPSHMDIPLDSKTFLSRHSMDMKFTYCDDRITELIGYHPEELLGRSAYEFYHALDSENMTKSHQNLCTKGQVVSGQYRMLAKHGGYVWLETQGTVIYNPRNLQPQCIMCVNYVLSEIEKNDVVFSMDQTESLFKPHLMAMNSIFDSSGKGAVSEKSNFLFTKLKEEPEELAQLAPTPGDAIISLDFGNQNFEESSAYGKAILPPSQPWATELRSHSTQSEAGSLPAFTVPQAAAPGSTTPSATSSSSSCSTPNSPEDYYTSLDNDLKIEVIEKLFAMDTEAKDQCSTQTDFNELDLETLAPYIPMDGEDFQLSPICPEERLLAENPQSTPQHCFSAMTNIFQPLAPVAPHSPFLLDKFQQQLESKKTEPEHRPMSSIFFDAGSKASLPPCCGQASTPLSSMGGRSNTQWPPDPPLHFGPTKWAVGDQRTEFLGAAPLGPPVSPPHVSTFKTRSAKGFGARGPDVLSPAMVALSNKLKLKRQLEYEEQAFQDLSGGDPPGGSTSHLMWKRMKNLRGGSCPLMPDKPLSANVPNDKFTQNPMRGLGHPLRHLPLPQPPSAISPGENSKSRFPPQCYATQYQDYSLSSAHKVSGMASRLLGPSFESYLLPELTRYDCEVNVPVLGSSTLLQGGDLLRALDQAT T41003 DRUGINFO D0C9PZ PT2385 Phase 2 T41003 DRUGINFO DE8V1R ARO-HIF2 Phase 1 T41003 DRUGINFO D04PSH ISIS 222041 Investigative T41003 DRUGINFO D05THV ISIS 222035 Investigative T41003 DRUGINFO D06NHW ISIS 222039 Investigative T41003 DRUGINFO D06YSI ISIS 222001 Investigative T41003 DRUGINFO D0K2GT ISIS 222043 Investigative T88697 TARGETID T88697 T88697 FORMERID TTDI02240 T88697 UNIPROID ANGL3_HUMAN T88697 TARGNAME ANGPTL3 messenger RNA (ANGPTL3 mRNA) T88697 GENENAME ANGPTL3 T88697 TARGTYPE Clinical trial T88697 SYNONYMS UNQ153/PRO179 (mRNA); Angiopoietin-related protein 3 (mRNA); Angiopoietin-like protein 3 (mRNA); Angiopoietin-5 (mRNA); ANGPT5 (mRNA); ANG-5 (mRNA) T88697 FUNCTION Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake. Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1. Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids. Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol. Suppresses LPL specifically in oxidative tissues which is required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT. Contributes to lower plasma levels of low density lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway implicating APOE and LDLR. May stimulate hypothalamic LPL activity. Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. T88697 PDBSTRUC 6EUA T88697 BIOCLASS mRNA target T88697 SEQUENCE MFTIKLLLFIVPLVISSRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGLLQLGHGLKDFVHKTKGQINDIFQKLNIFDQSFYDLSLQTSEIKEEEKELRRTTYKLQVKNEEVKNMSLELNSKLESLLEEKILLQQKVKYLEEQLTNLIQNQPETPEHPEVTSLKTFVEKQDNSIKDLLQTVEDQYKQLNQQHSQIKEIENQLRRTSIQEPTEISLSSKPRAPRTTPFLQLNEIRNVKHDGIPAECTTIYNRGEHTSGMYAIRPSNSQVFHVYCDVISGSPWTLIQHRIDGSQNFNETWENYKYGFGRLDGEFWLGLEKIYSIVKQSNYVLRIELEDWKDNKHYIEYSFYLGNHETNYTLHLVAITGNVPNAIPENKDLVFSTWDHKAKGHFNCPEGYSGGWWWHDECGENNLNGKYNKPRAKSKPERRRGLSWKSQNGRLYSIKSTKMLIHPTDSESFE T88697 DRUGINFO D0RK1O ARO-ANG3 Phase 2 T88697 DRUGINFO DDU2Y0 Vupanorsen Phase 2 T88697 DRUGINFO D0T3RR ISIS-ANGPTL3 Phase 1 T10383 TARGETID T10383 T10383 FORMERID TTDI03468 T10383 UNIPROID PLD2_HUMAN T10383 TARGNAME Phospholipase D2 (PLD2) T10383 GENENAME PLD2 T10383 TARGTYPE Clinical trial T10383 SYNONYMS hPLD2; Phosphatidylcholine-hydrolyzing phospholipase D2; PLD1C; PLD 2; Choline phosphatase 2 T10383 FUNCTION May have a role in signal-induced cytoskeletal regulation and/or endocytosis. T10383 BIOCLASS Phosphoric diester hydrolase T10383 ECNUMBER EC 3.1.4.4 T10383 SEQUENCE MTATPESLFPTGDELDSSQLQMESDEVDTLKEGEDPADRMHPFLAIYELQSLKVHPLVFAPGVPVTAQVVGTERYTSGSKVGTCTLYSVRLTHGDFSWTTKKKYRHFQELHRDLLRHKVLMSLLPLARFAVAYSPARDAGNREMPSLPRAGPEGSTRHAASKQKYLENYLNRLLTMSFYRNYHAMTEFLEVSQLSFIPDLGRKGLEGMIRKRSGGHRVPGLTCCGRDQVCYRWSKRWLVVKDSFLLYMCLETGAISFVQLFDPGFEVQVGKRSTEARHGVRIDTSHRSLILKCSSYRQARWWAQEITELAQGPGRDFLQLHRHDSYAPPRPGTLARWFVNGAGYFAAVADAILRAQEEIFITDWWLSPEVYLKRPAHSDDWRLDIMLKRKAEEGVRVSILLFKEVELALGINSGYSKRALMLLHPNIKVMRHPDQVTLWAHHEKLLVVDQVVAFLGGLDLAYGRWDDLHYRLTDLGDSSESAASQPPTPRPDSPATPDLSHNQFFWLGKDYSNLITKDWVQLDRPFEDFIDRETTPRMPWRDVGVVVHGLPARDLARHFIQRWNFTKTTKAKYKTPTYPYLLPKSTSTANQLPFTLPGGQCTTVQVLRSVDRWSAGTLENSILNAYLHTIRESQHFLYIENQFFISCSDGRTVLNKVGDEIVDRILKAHKQGWCYRVYVLLPLLPGFEGDISTGGGNSIQAILHFTYRTLCRGEYSILHRLKAAMGTAWRDYISICGLRTHGELGGHPVSELIYIHSKVLIADDRTVIIGSANINDRSLLGKRDSELAVLIEDTETEPSLMNGAEYQAGRFALSLRKHCFGVILGANTRPDLDLRDPICDDFFQLWQDMAESNANIYEQIFRCLPSNATRSLRTLREYVAVEPLATVSPPLARSELTQVQGHLVHFPLKFLEDESLLPPLGSKEGMIPLEVWT T10383 DRUGINFO D03JRG VU0364739 Clinical trial T10383 DRUGINFO D07ZAJ PIP2 Investigative T54093 TARGETID T54093 T54093 FORMERID TTDI02029 T54093 UNIPROID TBXT_HUMAN T54093 TARGNAME T-box transcription factor T (TBXT) T54093 GENENAME T T54093 TARGTYPE Clinical trial T54093 SYNONYMS T; Protein T T54093 FUNCTION Involved in the transcriptional regulation of genes required for mesoderm formation and differentiation. Binds to a palindromic site (called T site) and activates gene transcription when bound to such a site. T54093 PDBSTRUC 6F59; 6F58 T54093 SEQUENCE MSSPGTESAGKSLQYRVDHLLSAVENELQAGSEKGDPTERELRVGLEESELWLRFKELTNEMIVTKNGRRMFPVLKVNVSGLDPNAMYSFLLDFVAADNHRWKYVNGEWVPGGKPEPQAPSCVYIHPDSPNFGAHWMKAPVSFSKVKLTNKLNGGGQIMLNSLHKYEPRIHIVRVGGPQRMITSHCFPETQFIAVTAYQNEEITALKIKYNPFAKAFLDAKERSDHKEMMEEPGDSQQPGYSQWGWLLPGTSTLCPPANPHPQFGGALSLPSTHSCDRYPTLRSHRSSPYPSPYAHRNNSPTYSDNSPACLSMLQSHDNWSSLGMPAHPSMLPVSHNASPPTSSSQYPSLWSVSNGAVTPGSQAAAVSNGLGAQFFRGSPAHYTPLTHPVSAPSSSGSPLYEGAAAATDIVDSQYDAAAQGRLIASWTPVSPPSM T54093 DRUGINFO D0S9WW GI-6301 Phase 2 T28213 TARGETID T28213 T28213 FORMERID TTDI02069 T28213 UNIPROID FFAR2_HUMAN T28213 TARGNAME Free fatty acid receptor 2 (FFAR2) T28213 GENENAME FFAR2 T28213 TARGTYPE Clinical trial T28213 SYNONYMS Gprotein coupled receptor 43; FFAR2 T28213 FUNCTION G protein-coupled receptor that is activated by a major product of dietary fiber digestion, the short chain fatty acids (SCFAs), and that plays a role in the regulation of whole-body energy homeostasis and in intestinal immunity. In omnivorous mammals, the short chain fatty acids acetate, propionate and butyrate are produced primarily by the gut microbiome that metabolizes dietary fibers. SCFAs serve as a source of energy but also act as signaling molecules. That G protein-coupled receptor is probably coupled to the pertussis toxin-sensitive, G(i/o)-alpha family of G proteins but also to the Gq family (PubMed:12496283, PubMed:12711604, PubMed:23589301). Its activation results in the formation of inositol 1,4,5-trisphosphate, the mobilization of intracellular calcium, the phosphorylation of the MAPK3/ERK1 and MAPK1/ERK2 kinases and the inhibition of intracellular cAMP accumulation. May play a role in glucose homeostasis by regulating the secretion of GLP-1, in response to short-chain fatty acids accumulating in the intestine. May also regulate the production of LEP/Leptin, a hormone acting on the central nervous system to inhibit food intake. Finally, may also regulate whole-body energy homeostasis through adipogenesis regulating both differentiation and lipid storage of adipocytes. In parallel to its role in energy homeostasis, may also mediate the activation of the inflammatory and immune responses by SCFA in the intestine, regulating the rapid production of chemokines and cytokines. May also play a role in the resolution of the inflammatory response and control chemotaxis in neutrophils. In addition to SCFAs, may also be activated by the extracellular lectin FCN1 in a process leading to activation of monocytes and inducing the secretion of interleukin- 8/IL-8 in response to the presence of microbes (PubMed:21037097). Among SCFAs, the fatty acids containing less than 6 carbons, the most potent activators are probably acetate, propionate and butyrate (PubMed:12496283, PubMed:12711604). Exhibits a SCFA- independent constitutive G protein-coupled receptor activity (PubMed:23066016). T28213 BIOCLASS GPCR rhodopsin T28213 SEQUENCE MLPDWKSSLILMAYIIIFLTGLPANLLALRAFVGRIRQPQPAPVHILLLSLTLADLLLLLLLPFKIIEAASNFRWYLPKVVCALTSFGFYSSIYCSTWLLAGISIERYLGVAFPVQYKLSRRPLYGVIAALVAWVMSFGHCTIVIIVQYLNTTEQVRSGNEITCYENFTDNQLDVVLPVRLELCLVLFFIPMAVTIFCYWRFVWIMLSQPLVGAQRRRRAVGLAVVTLLNFLVCFGPYNVSHLVGYHQRKSPWWRSIAVVFSSLNASLDPLLFYFSSSVVRRAFGRGLQVLRNQGSSLLGRRGKDTAEGTNEDRGVGQGEGMPSSDFTTE T28213 DRUGINFO D0TA4A GLPG0974 Phase 2 T28213 DRUGINFO D0W7AE HL-018 Phase 1 T28213 DRUGINFO D01THG trans-2-methylcrotonic acid Investigative T28213 DRUGINFO D07ITP AMG7703 Investigative T28213 DRUGINFO D09JXR PMID23589301C1 Investigative T28213 DRUGINFO D0L4UV CATPB Investigative T28213 DRUGINFO D05UBB (S)-4-CMTB Investigative T28213 DRUGINFO D06ZVB isobutyric acid Investigative T28213 DRUGINFO D07FPQ 1-methylcyclopropanecarboxylic acid Investigative T28213 DRUGINFO D0V6IE pentanoic acid Investigative T42724 TARGETID T42724 T42724 FORMERID TTDI03310 T42724 UNIPROID KCNN4_HUMAN T42724 TARGNAME Calcium-activated potassium channel KCa3.1 (KCNN4) T42724 GENENAME KCNN4 T42724 TARGTYPE Clinical trial T42724 SYNONYMS SKCa4; SKCa 4; SK4; Putative Gardos channel; KCa4; KCa3.1; Intermediate conductance calcium-activated potassium channel protein 4; IKCa1; IK1 T42724 FUNCTION Activation is followed by membrane hyperpolarization which promotes calcium influx. Required for maximal calcium influx and proliferation during the reactivation of naive T-cells. Plays a role in the late stages of EGF-induced macropinocytosis. Forms a voltage-independent potassium channel that is activated by intracellular calcium. T42724 PDBSTRUC 6D42; 6CNO; 6CNN; 6CNM T42724 BIOCLASS Voltage-gated ion channel T42724 SEQUENCE MGGDLVLGLGALRRRKRLLEQEKSLAGWALVLAGTGIGLMVLHAEMLWFGGCSWALYLFLVKCTISISTFLLLCLIVAFHAKEVQLFMTDNGLRDWRVALTGRQAAQIVLELVVCGLHPAPVRGPPCVQDLGAPLTSPQPWPGFLGQGEALLSLAMLLRLYLVPRAVLLRSGVLLNASYRSIGALNQVRFRHWFVAKLYMNTHPGRLLLGLTLGLWLTTAWVLSVAERQAVNATGHLSDTLWLIPITFLTIGYGDVVPGTMWGKIVCLCTGVMGVCCTALLVAVVARKLEFNKAEKHVHNFMMDIQYTKEMKESAARVLQEAWMFYKHTRRKESHAARRHQRKLLAAINAFRQVRLKHRKLREQVNSMVDISKMHMILYDLQQNLSSSHRALEKQIDTLAGKLDALTELLSTALGPRQLPEPSQQSK T42724 DRUGINFO DF0R5I ASP0819 Phase 2 T42724 DRUGINFO D00BUR ICA-17043 Phase 2 T42724 DRUGINFO D05PHX SKA-121 Investigative T42724 DRUGINFO D0M7LA PMID15603962Crac-16 Investigative T42724 DRUGINFO D0UL7R SKA-31 Investigative T42724 DRUGINFO D05RLR 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Investigative T42724 DRUGINFO D0I6MA DC-EBIO Investigative T42724 DRUGINFO D0T0AG EBIO Investigative T46524 TARGETID T46524 T46524 UNIPROID TNF12_HUMAN T46524 TARGNAME TNF-related weak inducer of apoptosis (TWEAK) T46524 GENENAME TNFSF12 T46524 TARGTYPE Clinical trial T46524 SYNONYMS Tumor necrosis factor ligand superfamily member 12; TWEAK; DR3LG; APO3L; APO3 ligand T46524 FUNCTION Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. Mediates NF-kappa-B activation. Promotes angiogenesis and the proliferation of endothelial cells. Also involved in induction of inflammatory cytokines. Promotes IL8 secretion. T46524 PDBSTRUC 4HT1 T46524 BIOCLASS Cytokine: tumor necrosis factor T46524 SEQUENCE MAARRSQRRRGRRGEPGTALLVPLALGLGLALACLGLLLAVVSLGSRASLSAQEPAQEELVAEEDQDPSELNPQTEESQDPAPFLNRLVRPRRSAPKGRKTRARRAIAAHYEVHPRPGQDGAQAGVDGTVSGWEEARINSSSPLRYNRQIGEFIVTRAGLYYLYCQVHFDEGKAVYLKLDLLVDGVLALRCLEEFSATAASSLGPQLRLCQVSGLLALRPGSSLRIRTLPWAHLKAAPFLTYFGLFQVH T46524 DRUGINFO D08YHB BIIB 023 Phase 2 T46524 DRUGINFO D0F3ZG RO-5458640 Phase 1 T74381 TARGETID T74381 T74381 FORMERID TTDNR00651 T74381 UNIPROID MAGC1_HUMAN T74381 TARGNAME Cancer/testis antigen MAGE-C1/CT7 (MAGEC1) T74381 GENENAME MAGEC1 T74381 TARGTYPE Clinical trial T74381 SYNONYMS Melanoma-associated antigen C1; MAGE-C1 antigen; Cancer/testis antigen 7.1; CT7.1 T74381 FUNCTION Tumor antigen. T74381 BIOCLASS Melanoma associated antigen family T74381 SEQUENCE MGDKDMPTAGMPSLLQSSSESPQSCPEGEDSQSPLQIPQSSPESDDTLYPLQSPQSRSEGEDSSDPLQRPPEGKDSQSPLQIPQSSPEGDDTQSPLQNSQSSPEGKDSLSPLEISQSPPEGEDVQSPLQNPASSFFSSALLSIFQSSPESTQSPFEGFPQSVLQIPVSAASSSTLVSIFQSSPESTQSPFEGFPQSPLQIPVSRSFSSTLLSIFQSSPERTQSTFEGFAQSPLQIPVSPSSSSTLLSLFQSFSERTQSTFEGFAQSSLQIPVSPSFSSTLVSLFQSSPERTQSTFEGFPQSPLQIPVSSSSSSTLLSLFQSSPERTHSTFEGFPQSLLQIPMTSSFSSTLLSIFQSSPESAQSTFEGFPQSPLQIPGSPSFSSTLLSLFQSSPERTHSTFEGFPQSPLQIPMTSSFSSTLLSILQSSPESAQSAFEGFPQSPLQIPVSSSFSYTLLSLFQSSPERTHSTFEGFPQSPLQIPVSSSSSSSTLLSLFQSSPECTQSTFEGFPQSPLQIPQSPPEGENTHSPLQIVPSLPEWEDSLSPHYFPQSPPQGEDSLSPHYFPQSPPQGEDSLSPHYFPQSPQGEDSLSPHYFPQSPPQGEDSMSPLYFPQSPLQGEEFQSSLQSPVSICSSSTPSSLPQSFPESSQSPPEGPVQSPLHSPQSPPEGMHSQSPLQSPESAPEGEDSLSPLQIPQSPLEGEDSLSSLHFPQSPPEWEDSLSPLHFPQFPPQGEDFQSSLQSPVSICSSSTSLSLPQSFPESPQSPPEGPAQSPLQRPVSSFFSYTLASLLQSSHESPQSPPEGPAQSPLQSPVSSFPSSTSSSLSQSSPVSSFPSSTSSSLSKSSPESPLQSPVISFSSSTSLSPFSEESSSPVDEYTSSSDTLLESDSLTDSESLIESEPLFTYTLDEKVDELARFLLLKYQVKQPITKAEMLTNVISRYTGYFPVIFRKAREFIEILFGISLREVDPDDSYVFVNTLDLTSEGCLSDEQGMSQNRLLILILSIIFIKGTYASEEVIWDVLSGIGVRAGREHFAFGEPRELLTKVWVQEHYLEYREVPNSSPPRYEFLWGPRAHSEVIKRKVVEFLAMLKNTVPITFPSSYKDALKDVEERAQAIIDTTDDSTATESASSSVMSPSFSSE T74381 DRUGINFO D02DVK CV-9201 Phase 1/2 T16144 TARGETID T16144 T16144 FORMERID TTDNC00463 T16144 UNIPROID ICOSL_HUMAN T16144 TARGNAME B7-related protein 1 (B7RP1) T16144 GENENAME ICOSLG T16144 TARGTYPE Clinical trial T16144 SYNONYMS KIAA0653; ICOSL; ICOS ligand; CD275; B7related protein 1; B7like protein Gl50; B7RP-1; B7H2; B7-like protein Gl50; B7-H2; B7 homolog 2 T16144 FUNCTION Acts as a costimulatory signal for T-cell proliferation and cytokine secretion; induces also B-cell proliferation and differentiation into plasma cells. Could play an important role in mediating local tissue responses to inflammatory conditions, as well as in modulating the secondary immune response by co-stimulating memory T-cell function. Ligand for the T-cell-specific cell surface receptor ICOS. T16144 BIOCLASS Immunoglobulin T16144 SEQUENCE MRLGSPGLLFLLFSSLRADTQEKEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFNVTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVAANFSVPVVSAPHSPSQDELTFTCTSINGYPRPNVYWINKTDNSLLDQALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQNLTVGSQTGNDIGERDKITENPVSTGEKNAATWSILAVLCLLVVVAVAIGWVCRDRCLQHSYAGAWAVSPETELTGHV T16144 DRUGINFO D0V0UH AMG 557 Phase 2 T16144 DRUGINFO DV2CR7 AMG 570 Phase 2 T83376 TARGETID T83376 T83376 FORMERID TTDI02202 T83376 UNIPROID TUSC2_HUMAN T83376 TARGNAME Tumor suppressor candidate 2 (TUSC2) T83376 GENENAME TUSC2 T83376 TARGTYPE Clinical trial T83376 SYNONYMS PDGFA-associated protein 2; PDAP2; LGCC; Fusion 1 protein; Fus-1 protein; FUS1; C3orf11 T83376 FUNCTION May function as a tumor suppressor, inhibiting colony formation, causing G1 arrest and ultimately inducing apoptosis in homozygous 3p21. 3 120-kb region-deficient cells. T83376 SEQUENCE MGASGSKARGLWPFASAAGGGGSEAAGAEQALVRPRGRAVPPFVFTRRGSMFYDEDGDLAHEFYEETIVTKNGQKRAKLRRVHKNLIPQGIVKLDHPRIHVDFPVILYEV T83376 DRUGINFO D03YJW Fus-1 tumor suppressor gene therapy Phase 1/2 T83376 DRUGINFO D04YIA CNVN-202 Phase 1/2 T83376 DRUGINFO DVD0E9 Quaratusugene ozeplasmid Phase 1/2 T86734 TARGETID T86734 T86734 FORMERID TTDI02002 T86734 UNIPROID GLSK_HUMAN; GLSL_HUMAN T86734 TARGNAME Glutaminase (GLS) T86734 GENENAME GLS; GLS2 T86734 TARGTYPE Clinical trial T86734 SYNONYMS L-glutamine amidohydrolase; Glutaminase, mitochondrial; GLS T86734 FUNCTION Plays a role in maintaining acid-base homeostasis. Regulates the levels of the neurotransmitter glutamate in the brain. Isoform 2 lacks catalytic activity. Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. T86734 BIOCLASS Carbon-nitrogen hydrolase T86734 SEQUENCE MMRLRGSGMLRDLLLRSPAGVSATLRRAQPLVTLCRRPRGGGRPAAGPAAAARLHPWWGGGGWPAEPLARGLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMDMLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKLDPRREGGDQRVKSVINLLFAAYTGDVSALRRFALSAMDMEQRDYDSRTALHVAAAEGHVEVVKFLLEACKVNPFPKDRWNNTPMDEALHFGHHDVFKILQEYQVQYTPQGDSDNGKENQTVHKNLDGLL T86734 DRUGINFO D01PBW CB-839 Phase 2 T86734 DRUGINFO D00KII PMID30273516-Compound-39 Patented T86734 DRUGINFO D01RUI PMID30273516-Compound-13 Patented T86734 DRUGINFO D02IVA PMID30273516-Compound-22a Patented T86734 DRUGINFO D05CXZ PMID30273516-Compound-37 Patented T86734 DRUGINFO D05TBZ PMID30273516-Compound-12 Patented T86734 DRUGINFO D07IQM PMID30273516-Compound-38 Patented T86734 DRUGINFO D07KON PMID30273516-Compound-22b Patented T86734 DRUGINFO D0G4YI PMID30273516-Compound-1 Patented T86734 DRUGINFO D0KN6L PMID30273516-Compound-15 Patented T86734 DRUGINFO D0KP4J PMID30273516-Compound-41 Patented T86734 DRUGINFO D0P0ES PMID30273516-Compound-40 Patented T86734 DRUGINFO D0YE0P PMID30273516-Compound-14 Patented T17710 TARGETID T17710 T17710 FORMERID TTDI02310 T17710 UNIPROID HPT_HUMAN T17710 TARGNAME Haptoglobin (HP) T17710 GENENAME HP T17710 TARGTYPE Clinical trial T17710 SYNONYMS Haptoglobin beta chain; HP T17710 FUNCTION Uncleaved haptoglogin, also known as zonulin, plays a role in intestinal permeability, allowing intercellular tight junction disassembly, and controlling the equilibrium between tolerance and immunity to non-self antigens. {ECO:0000269|PubMed:21248165}. T17710 PDBSTRUC 5HU6; 4X0L; 4WJG T17710 BIOCLASS Peptidase T17710 SEQUENCE MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN T17710 DRUGINFO D00GZY AT1001 Phase 3 T67364 TARGETID T67364 T67364 FORMERID TTDI01955 T67364 UNIPROID STRP_STREQ T67364 TARGNAME Streptococcus Streptokinase (Stre-coc skc) T67364 GENENAME Stre-coc skc T67364 TARGTYPE Clinical trial T67364 SYNONYMS skc; Streptokinase C T67364 FUNCTION This protein is not a protease, but it activates plasminogen by complexing with it. As a potential virulence factor, it is thought to prevent the formation of effective fibrin barriers around the site of infection, thereby contributing to the invasiveness of the cells. T67364 PDBSTRUC 1QQR; 1L4Z; 1L4D; 1BML T67364 BIOCLASS Staphylokinase streptokinase T67364 SEQUENCE MKNYLSFGMFALLFALTFGTVNSVQAIAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDISLKFFEIDLTSRPAHGGKTEQGLSPKSKPFATDSGAMSHKLEKADLLKAIQEQLIANVHSNDDYFEVIDFASDATITDRNGKVYFADKDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQAKSVDVEYTVQFTPLNPDDDFRPGLKDTKLLKTLAIGDTITSQELLAQAQSILNKNHPGYTIYERDSSIVTHDNDIFRTILPMDQEFTYRVKNREQAYRINKKSGLNEEINNTDLISEKYYVLKKGEKPYDPFDRSHLKLFTIKYVDVDTNELLKSEQLLTASERNLDFRDLYDPRDKAKLLYNNLDAFGIMDYTLTGKVEDNHDDTNRIITVYMGKRPEGENASYHLAYDKDRYTEEEREVYSYLRYTGTPIPDNPNDK T67364 DRUGINFO D0Y6DO Streptokinase rectal suppository Phase 3 T67364 DRUGINFO D0X9PA Heberkinasa Investigative T30731 TARGETID T30731 T30731 FORMERID TTDR00406 T30731 UNIPROID KNG1_HUMAN T30731 TARGNAME Kininogen (KNG1) T30731 GENENAME KNG1 T30731 TARGTYPE Clinical trial T30731 SYNONYMS KNG1; Bradykinin T30731 FUNCTION Kininogens are inhibitors of thiol proteases; hmw-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor xi next to factor xii; hmw-kininogen inhibits the thrombin-and plasmin- induced process. T30731 PDBSTRUC 6F3Y; 6F3X; 6F3W; 6F3V; 6F27 T30731 SEQUENCE MKLITILFLCSRLLLSLTQESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYRITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQYDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHSSLFMLNEVKRAQRQVVAGLNFRITYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQLRIASFSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKLNAENNATFYFKIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTESCETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMISLMKRPPGFSPFRSSRIGEIKEETTVSPPHTSMAPAQDEERDSGKEQGHTRRHDWGHEKQRKHNLGHGHKHERDQGHGHQRGHGLGHGHEQQHGLGHGHKFKLDDDLEHQGGHVLDHGHKHKHGHGHGKHKNKGKKNGKHNGWKTEHLASSSEDSTTPSAQTQEKTEGPTPIPSLAKPGVTVTFSDFQDSDLIATMMPPISPAPIQSDDDWIPDIQIDPNGLSFNPISDFPDTTSPKCPGRPWKSVSEINPTTQMKESYYFDLTDGLS T30731 DRUGINFO D0V4HO Avoralstat Phase 2/3 T30731 DRUGINFO D05NMK CU201 (B9870) Investigative T08156 TARGETID T08156 T08156 FORMERID TTDI02096 T08156 UNIPROID IFNA5_HUMAN T08156 TARGNAME Interferon-alpha 5 (IFNA5) T08156 GENENAME IFNA5 T08156 TARGTYPE Clinical trial T08156 SYNONYMS LeIF G; Interferon alphaG; Interferon alpha61; Interferon alpha5; Interferon alpha-G; Interferon alpha-61; Interferon alpha-5; IFNalpha5; IFN-alpha-5 T08156 FUNCTION Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. Produced by macrophages, IFN-alpha have antiviral activities. T08156 BIOCLASS Cytokine: interferon T08156 SEQUENCE MALPFVLLMALVVLNCKSICSLGCDLPQTHSLSNRRTLMIMAQMGRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSATWDETLLDKFYTELYQQLNDLEACMMQEVGVEDTPLMNVDSILTVRKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSANLQERLRRKE T08156 DRUGINFO D0E1FP Interferon alpha 5 Phase 1/2 T08156 DRUGINFO D0F2WN NAHE-001 Phase 1/2 T49146 TARGETID T49146 T49146 FORMERID TTDI01649 T49146 UNIPROID DRA_HUMAN; 2B1F_HUMAN; DRB3_HUMAN; DRB4_HUMAN; DRB5_HUMAN T49146 TARGNAME MHC class II antigen DR (HLA-DR) T49146 GENENAME HLA-DRA; HLA-DRB1; HLA-DRB3; HLA-DRB4; HLA-DRB5 T49146 TARGTYPE Clinical trial T49146 SYNONYMS HLA class II histocompatibility antigen T49146 FUNCTION Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of thiscomplex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class IImolecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DMand MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. T49146 BIOCLASS MHC class II T49146 SEQUENCE MAISGVPVLGFFIIAVLMSAQESWAIKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFIDKFTPPVVNVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYDCRVEHWGLDEPLLKHWEFDAPSPLPETTENVVCALGLTVGLVGIIIGTIFIIKGVRKSNAAERRGPL T49146 DRUGINFO D0W6WC Apolizumab Phase 2 T49146 DRUGINFO D0G7SM AEA-35p Phase 1 T49146 DRUGINFO D0P5PD IMMU-114 Phase 1 T85072 TARGETID T85072 T85072 FORMERID TTDI02207 T85072 UNIPROID VE7_HPV16 T85072 TARGNAME Human papillomavirus protein E7 (HPV E7) T85072 GENENAME HPV E7 T85072 TARGTYPE Clinical trial T85072 SYNONYMS Protein E7; E7 T85072 FUNCTION E7 protein has both transforming and trans-activating activities. Disrupts the function of host retinoblastoma protein RB1/pRb, which is a key regulator of the cell cycle. Induces the disassembly of the E2F1 transcription factors from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Inactivation of the ability of RB1 to arrest the cell cycle is critical for cellular transformation, uncontrolled cellular growth and proliferation induced by viral infection. Stimulation of progression from G1 to S phase allows the virus to efficiently use the cellular DNA replicating machinery to achieve viral genome replication. Interferes with histone deacetylation mediated by HDAC1 and HDAC2, leading to activation of transcription. T85072 PDBSTRUC 6APN; 4YOZ T85072 BIOCLASS Papillomaviridae E protein T85072 SEQUENCE MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP T85072 DRUGINFO D00PMB VGX-3100 Phase 3 T85072 DRUGINFO D04FFM ADXS-HPV Phase 2 T85072 DRUGINFO D0P9QW Tipapkinogene sovacivec Phase 2 T85072 DRUGINFO D0M2YX CIGB-228 Phase 1 T85072 DRUGINFO DHMO41 KITE-439 Phase 1 T53640 TARGETID T53640 T53640 FORMERID TTDI01988 T53640 UNIPROID HBSAG_HBVA3 T53640 TARGNAME Hepatitis B virus Large envelope protein (HBV S) T53640 GENENAME HBV S T53640 TARGTYPE Clinical trial T53640 SYNONYMS Major surface antigen; Large surface protein; Large envelope protein; Large S protein; LHB; L-HBsAg; L glycoprotein T53640 FUNCTION The large envelope protein exists in two topological conformations, one which is termed 'external' or Le-HBsAg and the other 'internal' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis. The large envelope protein also assures fusion between virion membrane and endosomal membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein. T53640 BIOCLASS Orthohepadnavirus major surface antigen T53640 SEQUENCE MGGWSSKPRKGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPVKDDWPAANQVGVGAFGPRLTPPHGGILGWSPQAQGILTTVSTIPPPASTNRQSGRQPTPISPPLRDSHPQAMQWNSTAFHQTLQDPRVRGLYLPAGGSSSGTVNPAPNIASHISSISARTGDPVTNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPSLYSIVSPFIPLLPIFFCLWVYI T53640 DRUGINFO D07FND Nabi-HB Approved T53640 DRUGINFO D0U4SM NASVAC Phase 3 T13409 TARGETID T13409 T13409 FORMERID TTDI02209 T13409 UNIPROID POL_HV1B1 T13409 TARGNAME Human immunodeficiency virus Matrix p17 (HIV MA) T13409 GENENAME HIV MA T13409 TARGTYPE Clinical trial T13409 SYNONYMS gag T13409 FUNCTION p6-gag: Plays a role in budding of the assembled particle by interacting with the host class E VPS proteins TSG101 and PDCD6IP/AIP1. T13409 PDBSTRUC 6OE3; 6HAK; 6ELI; 6DUH; 6DUG T13409 SEQUENCE GARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSSQVSQNY T13409 DRUGINFO D05GBH F4co vaccine Phase 2 T88360 TARGETID T88360 T88360 FORMERID TTDI02133 T88360 UNIPROID NCAP_HRSVA T88360 TARGNAME Respiratory syncytial virus protein N (RSV N) T88360 GENENAME RSV N T88360 TARGTYPE Clinical trial T88360 SYNONYMS RSV Protein N; RSV Nucleoprotein; RSV Nucleocapsid protein; N T88360 FUNCTION Encapsidates the genome, protecting it from nucleases. The nucleocapsid (NC) has a helical structure. The encapsidated genomic RNA is termed the NC and serves as template for transcription and replication. During replication, encapsidation by protein N is coupled to RNA synthesis and all replicative products are resistant to nucleases. T88360 PDBSTRUC 4UCE; 4UCD; 4UCC; 4UCB; 4UCA T88360 BIOCLASS Paramyxoviruses nucleocapsid T88360 SEQUENCE MALSKVKLNDTLNKDQLLSSSKYTIQRSTGDSIDTPNYDVQKHINKLCGMLLITEDANHKFTGLIGMLYAMSRLGREDTIKILRDAGYHVKANGVDVTTHRQDINGKEMKFEVLTLASLTTEIQINIEIESRKSYKKMLKEMGEVAPEYRHDSPDCGMIILCIAALVITKLAAGDRSGLTAVIRRANNVLKNEMKRYKGLLPKDIANSFYEVFEKHPHFIDVFVHFGIAQSSTRGGSRVEGIFAGLFMNAYGAGQVMLRWGVLAKSVKNIMLGHASVQAEMEQVVEVYEYAQKLGGEAGFYHILNNPKASLLSLTQFPHFSSVVLGNAAGLGIMGEYRGTPRNQDLYDAAKAYAEQLKENGVINYSVLDLTAEELEAIKHQLNPKDNDVEL T88360 DRUGINFO D09KNG RSV-604 Phase 2 T88360 DRUGINFO DA08WU EDP-938 Phase 2 T06869 TARGETID T06869 T06869 FORMERID TTDR01216 T06869 UNIPROID PDGFA_HUMAN T06869 TARGNAME Platelet-derived growth factor A (PDGFA) T06869 GENENAME PDGFA T06869 TARGTYPE Clinical trial T06869 SYNONYMS Platelet-derived growth factor subunit A; Platelet-derived growth factor alpha polypeptide; Platelet-derived growth factor A chain; Platelet derived growth factor; PDGF1; PDGF-1; PDGF subunit A; PDGF; C-SIS oncogene T06869 FUNCTION Potent mitogen for cells of mesenchymal origin. Required for normal lung alveolar septum formation during embryogenesis, normal development of the gastrointestinal tract, normal development of Leydig cells and spermatogenesis. Required for normal oligodendrocyte development and normal myelination in the spinal cord and cerebellum. Plays an important role in wound healing. Signaling is modulated by the formation of heterodimers with PDGFB. Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. T06869 PDBSTRUC 3MJK T06869 BIOCLASS Growth factor T06869 SEQUENCE MRTLACLLLLGCGYLAHVLAEEAEIPREVIERLARSQIHSIRDLQRLLEIDSVGSEDSLDTSLRAHGVHATKHVPEKRPLPIRRKRSIEEAVPAVCKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTGCCNTSSVKCQPSRVHHRSVKVAKVEYVRKKPKLKEVQVRLEEHLECACATTSLNPDYREEDTGRPRESGKKRKRKRLKPT T06869 DRUGINFO D07PVB Squalamine Phase 3 T07533 TARGETID T07533 T07533 FORMERID TTDC00331 T07533 UNIPROID APOB_HUMAN T07533 TARGNAME Apolipoprotein B-100 (APOB) T07533 GENENAME APOB T07533 TARGTYPE Clinical trial T07533 SYNONYMS Apolipoprotein B48; Apo B48; Apo B100; Apo B-100 T07533 FUNCTION Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). T07533 BIOCLASS Apolipoprotein T07533 SEQUENCE MDPPRPALLALLALPALLLLLLAGARAEEEMLENVSLVCPKDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKVELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEEFAAAMSRYELKLAIPEGKQVFLYPEKDEPTYILNIKRGIISALLVPPETEEAKQVLFLDTVYGNCSTHFTVKTRKGNVATEISTERDLGQCDRFKPIRTGISPLALIKGMTRPLSTLISSSQSCQYTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMVAQVTQTLKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPKQAEAVLKTLQELKKLTISEQNIQRANLFNKLVTELRGLSDEAVTSLLPQLIEVSSPITLQALVQCGQPQCSTHILQWLKRVHANPLLIDVVTYLVALIPEPSAQQLREIFNMARDQRSRATLYALSHAVNNYHKTNPTGTQELLDIANYLMEQIQDDCTGDEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPSLMIQKAAIQALRKMEPKDKDQEVLLQTFLDDASPGDKRLAAYLMLMRSPSQADINKIVQILPWEQNEQVKNFVASHIANILNSEELDIQDLKKLVKEALKESQLPTVMDFRKFSRNYQLYKSVSLPSLDPASAKIEGNLIFDPNNYLPKESMLKTTLTAFGFASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALYWVNGQVPDGVSKVLVDHFGYTKDDKHEQDMVNGIMLSVEKLIKDLKSKEVPEARAYLRILGEELGFASLHDLQLLGKLLLMGARTLQGIPQMIGEVIRKGSKNDFFLHYIFMENAFELPTGAGLQLQISSSGVIAPGAKAGVKLEVANMQAELVAKPSVSVEFVTNMGIIIPDFARSGVQMNTNFFHESGLEAHVALKAGKLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENRQSWSVCKQVFPGLNYCTSGAYSNASSTDSASYYPLTGDTRLELELRPTGEIEQYSVSATYELQREDRALVDTLKFVTQAEGAKQTEATMTFKYNRQSMTLSSEVQIPDFDVDLGTILRVNDESTEGKTSYRLTLDIQNKKITEVALMGHLSCDTKEERKIKGVISIPRLQAEARSEILAHWSPAKLLLQMDSSATAYGSTVSKRVAWHYDEEKIEFEWNTGTNVDTKKMTSNFPVDLSDYPKSLHMYANRLLDHRVPQTDMTFRHVGSKLIVAMSSWLQKASGSLPYTQTLQDHLNSLKEFNLQNMGLPDFHIPENLFLKSDGRVKYTLNKNSLKIEIPLPFGGKSSRDLKMLETVRTPALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDLSTNVYSNLYNWSASYSGGNTSTDHFSLRARYHMKADSVVDLLSYNVQGSGETTYDHKNTFTLSYDGSLRHKFLDSNIKFSHVEKLGNNPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHLFVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGESNLRFNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTASLKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRSEYQADYESLRFFSLLSGSLNSHGLELNADILGTDKINSGAHKATLRIGQDGISTSATTNLKCSLLVLENELNAELGLSGASMKLTTNGRFREHNAKFSLDGKAALTELSLGSAYQAMILGVDSKNIFNFKVSQEGLKLSNDMMGSYAEMKFDHTNSLNIAGLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTLNSDLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIYAISSAALSASYKADTVAKVQGVEFSHRLNTDIAGLASAIDMSTNYNSDSLHFSNVFRSVMAPFTMTIDAHTNGNGKLALWGEHTGQLYSKFLLKAEPLAFTFSHDYKGSTSHHLVSRKSISAALEHKVSALLTPAEQTGTWKLKTQFNNNEYSQDLDAYNTKDKIGVELTGRTLADLTLLDSPIKVPLLLSEPINIIDALEMRDAVEKPQEFTIVAFVKYDKNQDVHSINLPFFETLQEYFERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLPQQANDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIALDDAKINFNEKLSQLQTYMIQFDQYIKDSYDLHDLKIAIANIIDEIIEKLKSLDEHYHIRVNLVKTIHDLHLFIENIDFNKSGSSTASWIQNVDTKYQIRIQIQEKLQQLKRHIQNIDIQHLAGKLKQHIEAIDVRVLLDQLGTTISFERINDILEHVKHFVINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMDKLVELAHQYKLKETIQKLSNVLQQVKIKDYFEKLVGFIDDAVKKLNELSFKTFIEDVNKFLDMLIKKLKSFDYHQFVDETNDKIREVTQRLNGEIQALELPQKAEALKLFLEETKATVAVYLESLQDTKITLIINWLQEALSSASLAHMKAKFRETLEDTRDRMYQMDIQQELQRYLSLVGQVYSTLVTYISDWWTLAAKNLTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILGTMPAFEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIKIPSRFSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNSELQWPVPDIYLRDLKVEDIPLARITLPDFRLPEIAIPEFIIPTLNLNDFQVPDLHIPEFQLPHISHTIEVPTFGKLYSILKIQSPLFTLDANADIGNGTTSANEAGIAASITAKGESKLEVLNFDFQANAQLSNPKINPLALKESVKFSSKYLRTEHGSEMLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQLTLDSNTKYFHKLNIPKLDFSSQADLRNEIKTLLKAGHIAWTSSGKGSWKWACPRFSDEGTHESQISFTIEGPLTSFGLSNKINSKHLRVNQNLVYESGSLNFSKLEIQSQVDSQHVGHSVLTAKGMALFGEGKAEFTGRHDAHLNGKVIGTLKNSLFFSAQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALFLSPSAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGEANLDFLNIPLTIPEMRLPYTIITTPPLKDFSLWEKTGLKEFLKTTKQSFDLSVKAQYKKNKHRHSITNPLAVLCEFISQSIKSFDRHFEKNRNNALDFVTKSYNETKIKFDKYKAEKSHDELPRTFQIPGYTVPVVNVEVSPFTIEMSAFGYVFPKAVSMPSFSILGSDVRVPSYTLILPSLELPVLHVPRNLKLSLPDFKELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQSDIVAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALSLSNKFVEGSHNSTVSLTTKNMEVSVATTTKAQIPILRMNFKQELNGNTKSKPTVSSSMEFKYDFNSSMLYSTAKGAVDHKLSLESLTSYFSIESSTKGDVKGSVLSREYSGTIASEANTYLNSKSTRSSVKLQGTSKIDDIWNLEVKENFAGEATLQRIYSLWEHSTKNHLQLEGLFFTNGEHTSKATLELSPWQMSALVQVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRIHSGSFQSQVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVYDKSLWDFLKLDVTTSIGRRQHLRVSTAFVYTKNPNGYSFSIPVKVLADKFIIPGLKLNDLNSVLVMPTFHVPFTDLQVPSCKLDFREIQIYKKLRTSSFALNLPTLPEVKFPEVDVLTKYSQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAALDLNAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQALTARFEVDSPVYNATWSASLKNKADYVETVLDSTCSSTVQFLEYELNVLGTHKIEDGTLASKTKGTFAHRDFSAEYEEDGKYEGLQEWEGKAHLNIKSPAFTDLHLRYQKDKKGISTSAASPAVGTVGMDMDEDDDFSKWNFYYSPQSSPDKKLTIFKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVPKATGVLYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWVYQGAIRQIDDIDVRFQKAASGTTGTYQEWKDKAQNLYQELLTQEGQASFQGLKDNVFDGLVRVTQEFHMKVKHLIDSLIDFLNFPRFQFPGKPGIYTREELCTMFIREVGTVLSQVYSKVHNGSEILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEAQEVFKAIQSLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEMKFTYLINYIQDEINTIFSDYIPYVFKLLKENLCLNLHKFNEFIQNELQEASQELQQIHQYIMALREEYFDPSIVGWTVKYYELEEKIVSLIKNLLVALKDFHSEYIVSASNFTSQLSSQVEQFLHRNIQEYLSILTDPDGKGKEKIAELSATAQEIIKSQAIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRLIDLSIQNYHTFLIYITELLKKLQSTTVMNPYMKLAPGELTIIL T07533 DRUGINFO D0X1IL SPC4955 Phase 1 T38159 TARGETID T38159 T38159 FORMERID TTDI02188 T38159 UNIPROID TFF1_HUMAN T38159 TARGNAME Trefoil factor-1 (TFF1) T38159 GENENAME TFF1 T38159 TARGTYPE Clinical trial T38159 SYNONYMS hP1.A; Trefoil factor 1; Protein pS2; Polypeptide P1.A; PS2; PNR-2; Breast cancer estrogen-inducible protein; BCEI T38159 FUNCTION May inhibit the growth of calcium oxalate crystals in urine. Stabilizer of the mucous gel overlying the gastrointestinal mucosa that provides a physical barrier against various noxious agents. T38159 PDBSTRUC 1PS2; 1HI7 T38159 SEQUENCE MATMENKVICALVLVSMLALGTLAEAQTETCTVAPRERQNCGFPGVTPSQCANKGCCFDDTVRGVPWCFYPNTIDVPPEEECEF T38159 DRUGINFO D0IJ0F AG-013 Phase 2/3 T08231 TARGETID T08231 T08231 FORMERID TTDI02091 T08231 UNIPROID HG2A_HUMAN T08231 TARGNAME HLA-DR antigens-associated invariant (CD74) T08231 GENENAME CD74 T08231 TARGTYPE Clinical trial T08231 SYNONYMS Ii; Ia antigenassociated invariant chain; Ia antigen-associated invariant chain; HLADR antigensassociated invariant chain; HLA-DR antigens-associated invariant chain; HLA class II histocompatibility antigen gamma chain; DHLAG T08231 FUNCTION Serves as cell surface receptor for the cytokine MIF. Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. T08231 PDBSTRUC 5KSV; 5KSU; 4X5W; 4AH2; 4AEN T08231 SEQUENCE MHRRRSRSCREDQKPVMDDQRDLISNNEQLPMLGRRPGAPESKCSRGALYTGFSILVTLLLAGQATTAYFLYQQQGRLDKLTVTSQNLQLENLRMKLPKPPKPVSKMRMATPLLMQALPMGALPQGPMQNATKYGNMTEDHVMHLLQNADPLKVYPPLKGSFPENLRHLKNTMETIDWKVFESWMHHWLLFEMSRHSLEQKPTDAPPKVLTKCQEEVSHIPAVHPGSFRPKCDENGNYLPLQCYGSIGYCWCVFPNGTEVPNTRSRGHHNCSESLELEDPSSGLGVTKQDLGPVPM T08231 DRUGINFO D08SIF Milatuzumab Phase 1/2 T87206 TARGETID T87206 T87206 FORMERID TTDI02165 T87206 UNIPROID S100B_HUMAN T87206 TARGNAME S100 calcium-binding protein B (S100B) T87206 GENENAME S100B T87206 TARGTYPE Clinical trial T87206 SYNONYMS S-100 protein subunit beta; S-100 protein beta chain; Protein S100-B T87206 FUNCTION Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. Binds to and initiates the activation of STK38 by releasing autoinhibitory intramolecular interactions within the kinase. Interaction with AGER after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling. Could assist ATAD3A cytoplasmic processing, preventing aggregation and favoring mitochondrial localization. May mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, such as TPR-containing proteins, and modulating their activity. Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. T87206 PDBSTRUC 5D7F; 5CSN; 5CSJ; 5CSI; 5CSF T87206 BIOCLASS S100 calcium-binding protein T87206 SEQUENCE MSELEKAMVALIDVFHQYSGREGDKHKLKKSELKELINNELSHFLEEIKEQEVVDKVMETLDNDGDGECDFQEFMAFVAMVTTACHEFFEHE T87206 DRUGINFO D00GZW ONO-2506 Phase 2/3 T93627 TARGETID T93627 T93627 FORMERID TTDI01920 T93627 UNIPROID GAG_HV1H2 T93627 TARGNAME Human immunodeficiency virus GAG protein (HIV gag) T93627 GENENAME HIV gag T93627 TARGTYPE Clinical trial T93627 SYNONYMS Pr55Gag; Gag polyprotein T93627 FUNCTION Gag polyprotein: Mediates, with Gag-Pol polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). T93627 PDBSTRUC 6CQR; 6CQQ; 6CQN; 6CQL; 6CQJ T93627 SEQUENCE MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEGHQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPLTSLRSLFGNDPSSQ T93627 DRUGINFO D04MPB Bevirimat Phase 2 T93627 DRUGINFO D0R0SP LIPO-5 Phase 2 T93627 DRUGINFO D0W9IH Ad35-GRIN Phase 1/2 T93627 DRUGINFO D07LCY RVSVIN HIV-1 gag vaccine Phase 1 T93627 DRUGINFO D0W1MU TBC-M4 Phase 1 T93627 DRUGINFO D09ZKB Ad35-GRIN/ENV Phase 1 T93627 DRUGINFO D02ESK GSK-732461 Discontinued in Phase 2 T93627 DRUGINFO D08LDV PA-1050040 Discontinued in Phase 1 T93627 DRUGINFO D0AP4O Gem 92 Discontinued in Phase 1 T93627 DRUGINFO D0F8TS MPC-9055 Discontinued in Phase 1 T93627 DRUGINFO D03PCJ MPI-461359 Terminated T39921 TARGETID T39921 T39921 FORMERID TTDR01151 T39921 UNIPROID HSPB1_HUMAN T39921 TARGNAME Heat shock protein 20 (HSP20) T39921 GENENAME HSPB1 T39921 TARGTYPE Clinical trial T39921 SYNONYMS Stress-responsive protein 27; SRP27; HspB1; Heat shock protein beta-1; Heat shock 27 kDa protein; HSP28; HSP27; HSP 27; Estrogen-regulated 24 kDa protein; 28 kDa heat shock protein T39921 FUNCTION Small heat shock protein which functions as a molecular chaperone probably maintaining denatured proteins in a folding-competent state. Plays a role in stress resistance and actin organization. Through its molecular chaperone activity may regulate numerous biological processes including the phosphorylation and the axonal transport of neurofilament proteins. T39921 PDBSTRUC 4MJH; 3Q9Q; 3Q9P; 2N3J T39921 BIOCLASS Heat shock protein T39921 SEQUENCE MTERRVPFSLLRGPSWDPFRDWYPHSRLFDQAFGLPRLPEEWSQWLGGSSWPGYVRPLPPAAIESPAVAAPAYSRALSRQLSSGVSEIRHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLATQSNEITIPVTFESRAQLGGPEAAKSDETAAK T39921 DRUGINFO D09IGR AZX-100 Phase 2 T40909 TARGETID T40909 T40909 FORMERID TTDI01645 T40909 UNIPROID POLG_HRV2 T40909 TARGNAME Rhinovirus Protease 3C (HRV P3C) T40909 GENENAME HRV P3C T40909 TARGTYPE Clinical trial T40909 SYNONYMS Rhinovirus P3C T40909 FUNCTION Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host VLDLR to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity). T40909 PDBSTRUC 6FFS; 6FFN; 5FX6; 5FX5; 4L3B T40909 ECNUMBER EC 3.4.22.28 T40909 SEQUENCE MSLIKHNSCVITTENGKFTGLGVYDRFVVVPTHADPGKEIQVDGITTKVIDSYDLYNKNGIKLEITVLKLDRNEKFRDIRRYIPNNEDDYPNCNLALLANQPEPTIINVGDVVSYGNILLSGNQTARMLKYSYPTKSGYCGGVLYKIGQVLGIHVGGNGRDGFSAMLLRSYFTDVQGQITLS T40909 DRUGINFO D0S0SE Rupintrivir Phase 2 T11947 TARGETID T11947 T11947 FORMERID TTDI01939 T11947 UNIPROID F13B_HUMAN T11947 TARGNAME Coagulation factor XIII (F13B) T11947 GENENAME F13B T11947 TARGTYPE Clinical trial T11947 SYNONYMS F13B T11947 FUNCTION Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl- epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. T11947 BIOCLASS Acyltransferase T11947 SEQUENCE MRLKNLTFIIILIISGELYAEEKPCGFPHVENGRIAQYYYTFKSFYFPMSIDKKLSFFCLAGYTTESGRQEEQTTCTTEGWSPEPRCFKKCTKPDLSNGYISDVKLLYKIQENMRYGCASGYKTTGGKDEEVVQCLSDGWSSQPTCRKEHETCLAPELYNGNYSTTQKTFKVKDKVQYECATGYYTAGGKKTEEVECLTYGWSLTPKCTKLKCSSLRLIENGYFHPVKQTYEEGDVVQFFCHENYYLSGSDLIQCYNFGWYPESPVCEGRRNRCPPPPLPINSKIQTHSTTYRHGEIVHIECELNFEIHGSAEIRCEDGKWTEPPKCIEGQEKVACEEPPFIENGAANLHSKIYYNGDKVTYACKSGYLLHGSNEITCNRGKWTLPPECVENNENCKHPPVVMNGAVADGILASYATGSSVEYRCNEYYLLRGSKISRCEQGKWSSPPVCLEPCTVNVDYMNRNNIEMKWKYEGKVLHGDLIDFVCKQGYDLSPLTPLSELSVQCNRGEVKYPLCTRKESKGMCTSPPLIKHGVIISSTVDTYENGSSVEYRCFDHHFLEGSREAYCLDGMWTTPPLCLEPCTLSFTEMEKNNLLLKWDFDNRPHILHGEYIEFICRGDTYPAELYITGSILRMQCDRGQLKYPRCIPRQSTLSYQEPLRT T11947 DRUGINFO D0V2OL NN1841 Phase 3 T11947 DRUGINFO D0X3GA NN8717 Phase 3 T11947 DRUGINFO D0QF6E Tridegin Terminated T82958 TARGETID T82958 T82958 FORMERID TTDI02077 T82958 UNIPROID GB_HCMVA T82958 TARGNAME Cytomegalovirus Glycoprotein B (CMV gB) T82958 GENENAME CMV gB T82958 TARGTYPE Clinical trial T82958 SYNONYMS gB; Envelope glycoprotein B T82958 FUNCTION Viral ligand for CD209/DC-SIGN. This interaction allows capture of viral particles by dendritic (DCs) cells and subsequent virus transmission to permissive cells. DCs are professional antigen presenting cells, critical for host immunity by inducing specific immune responses against a broad variety of pathogens. They act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. CMV subverts the migration properties of dendritic cells to gain access to target organs or susceptible cells. T82958 PDBSTRUC 5CXF T82958 BIOCLASS Hepacivirus polyprotein T82958 SEQUENCE MESRIWCLVVCVNLCIVCLGAAVSSSSTSHATSSTHNGSHTSRTTSAQTRSVYSQHVTSSEAVSHRANETIYNTTLKYGDVVGVNTTKYPYRVCSMAQGTDLIRFERNIICTSMKPINEDLDEGIMVVYKRNIVAHTFKVRVYQKVLTFRRSYAYIYTTYLLGSNTEYVAPPMWEIHHINKFAQCYSSYSRVIGGTVFVAYHRDSYENKTMQLIPDDYSNTHSTRYVTVKDQWHSRGSTWLYRETCNLNCMLTITTARSKYPYHFFATSTGDVVYISPFYNGTNRNASYFGENADKFFIFPNYTIVSDFGRPNAAPETHRLVAFLERADSVISWDIQDEKNVTCQLTFWEASERTIRSEAEDSYHFSSAKMTATFLSKKQEVNMSDSALDCVRDEAINKLQQIFNTSYNQTYEKYGNVSVFETSGGLVVFWQGIKQKSLVELERLANRSSLNITHRTRRSTSDNNTTHLSSMESVHNLVYAQLQFTYDTLRGYINRALAQIAEAWCVDQRRTLEVFKELSKINPSAILSAIYNKPIAARFMGDVLGLASCVTINQTSVKVLRDMNVKESPGRCYSRPVVIFNFANSSYVQYGQLGEDNEILLGNHRTEECQLPSLKIFIAGNSAYEYVDYLFKRMIDLSSISTVDSMIALDIDPLENTDFRVLELYSQKELRSSNVFDLEEIMREFNSYKQRVKYVEDKVVDPLPPYLKGLDDLMSGLGAAGKAVGVAIGAVGGAVASVVEGVATFLKNPFGAFTIILVAIAVVIITYLIYTRQRRLCTQPLQNLFPYLVSADGTTVTSGSTKDTSLQAPPSYEESVYNSGRKGPGPPSSDASTAAPPYTNEQAYQMLLALARLDAEQRAQQNGTDSLDGQTGTQDKGQKPNLLDRLRHRKNGYRHLKDSDEEENV T82958 DRUGINFO D0V6KU CMV glycoprotein B subunit vaccine Phase 1 T02532 TARGETID T02532 T02532 FORMERID TTDS00368 T02532 UNIPROID CD2_HUMAN T02532 TARGNAME T-cell surface antigen CD2 (CD2) T02532 GENENAME CD2 T02532 TARGTYPE Clinical trial T02532 SYNONYMS T-cell surface antigen T11/Leu-5; SRBC; Rosette receptor; LFA-3 receptor; LFA-2; Erythrocyte receptor T02532 FUNCTION CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function. CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. T02532 PDBSTRUC 2J7I; 2J6O; 1QA9; 1L2Z; 1HNF T02532 SEQUENCE MSFPCKFVASFLLIFNVSSKGAVSKEITNALETWGALGQDINLDIPSFQMSDDIDDIKWEKTSDKKKIAQFRKEKETFKEKDTYKLFKNGTLKIKHLKTDDQDIYKVSIYDTKGKNVLEKIFDLKIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGKHLKLSQRVITHKWTTSLSAKFKCTAGNKVSKESSVEPVSCPEKGLDIYLIIGICGGGSLLMVFVALLVFYITKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN T02532 DRUGINFO D0A7NB Siplizumab Phase 2 T02532 DRUGINFO D06FTK Cyclo(1,12)PenIYDTKGKNVLC-OH Investigative T02532 DRUGINFO D0D6MO Pen(Acm)AQFRKEKETFC(Acm)-OH Investigative T02532 DRUGINFO D0GC3E Cyclo(1,11)H-ESIYDPGDDIK-OH Investigative T02532 DRUGINFO D0GD1A Cyclo(1,10)H-EIYDPGDDIK-OH Investigative T02532 DRUGINFO D0TL3X Cyclo(1,10)EIYDPGDDIK Investigative T02532 DRUGINFO D07LUR Alpha-D-Mannose Investigative T45591 TARGETID T45591 T45591 FORMERID TTDI02137 T45591 UNIPROID NPM_HUMAN T45591 TARGNAME Nucleophosmin (NPM1) T45591 GENENAME NPM1 T45591 TARGTYPE Clinical trial T45591 SYNONYMS Numatrin; Nucleolar protein NO38; Nucleolar phosphoprotein B23; NPM T45591 FUNCTION Binds ribosome presumably to drive ribosome nuclear export. Associated with nucleolar ribonucleoprotein structures and bind single-stranded nucleic acids. Acts as a chaperonin for the core histones H3, H2B and H4. Stimulates APEX1 endonuclease activity on apurinic/apyrimidinic (AP) double-stranded DNA but inhibits APEX1 endonuclease activity on AP single-stranded RNA. May exert a control of APEX1 endonuclease activity within nucleoli devoted to repair AP on rDNA and the removal of oxidized rRNA molecules. In concert with BRCA2, regulates centrosome duplication. Regulates centriole duplication: phosphorylation by PLK2 is able to trigger centriole replication. Negatively regulates the activation of EIF2AK2/PKR and suppresses apoptosis through inhibition of EIF2AK2/PKR autophosphorylation. Antagonizes the inhibitory effect of ATF5 on cell proliferation and relieves ATF5-induced G2/M blockade. In complex with MYC enhances the transcription of MYC target genes. Involved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors p53/TP53 and ARF. T45591 PDBSTRUC 5EHD; 2VXD; 2P1B; 2LLH T45591 SEQUENCE MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL T45591 DRUGINFO D0Z1OR IPP-204106 Phase 1/2 T32780 TARGETID T32780 T32780 UNIPROID ASGR1_HUMAN T32780 TARGNAME Asialoglycoprotein receptor 1 (ASGR1) T32780 GENENAME ASGR1 T32780 TARGTYPE Clinical trial T32780 SYNONYMS Hepatic lectin H1; HL-1; C-type lectin domain family 4 member H1 T32780 FUNCTION Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface. T32780 PDBSTRUC 5JQ1; 5JPV; 1DV8 T32780 SEQUENCE MTKEYQDLQHLDNEESDHHQLRKGPPPPQPLLQRLCSGPRLLLLSLGLSLLLLVVVCVIGSQNSQLQEELRGLRETFSNFTASTEAQVKGLSTQGGNVGRKMKSLESQLEKQQKDLSEDHSSLLLHVKQFVSDLRSLSCQMAALQGNGSERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQKFVQHHIGPVNTWMGLHDQNGPWKWVDGTDYETGFKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDDVCQRPYRWVCETELDKASQEPPLL T32780 DRUGINFO D09ZFJ AMG 529 Phase 1 T17427 TARGETID T17427 T17427 FORMERID TTDI02083 T17427 UNIPROID GP1BA_HUMAN T17427 TARGNAME Platelet glycoprotein Ib alpha (CD42b) T17427 GENENAME GP1BA T17427 TARGTYPE Clinical trial T17427 SYNONYMS Platelet glycoprotein Ib alpha chain; Glycoprotein Ibalpha; Glycocalicin; GPIbalpha; GPIbA; GPIb-alpha; GPIb alpha; GP-Ib alpha; Antigen CD42balpha; Antigen CD42b-alpha T17427 FUNCTION GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium. T17427 PDBSTRUC 4YR6; 4MGX; 4CH8; 4CH2; 4C2B T17427 SEQUENCE MPLLLLLLLLPSPLHPHPICEVSKVASHLEVNCDKRNLTALPPDLPKDTTILHLSENLLYTFSLATLMPYTRLTQLNLDRCELTKLQVDGTLPVLGTLDLSHNQLQSLPLLGQTLPALTVLDVSFNRLTSLPLGALRGLGELQELYLKGNELKTLPPGLLTPTPKLEKLSLANNNLTELPAGLLNGLENLDTLLLQENSLYTIPKGFFGSHLLPFAFLHGNPWLCNCEILYFRRWLQDNAENVYVWKQGVDVKAMTSNVASVQCDNSDKFPVYKYPGKGCPTLGDEGDTDLYDYYPEEDTEGDKVRATRTVVKFPTKAHTTPWGLFYSWSTASLDSQMPSSLHPTQESTKEQTTFPPRWTPNFTLHMESITFSKTPKSTTEPTPSPTTSEPVPEPAPNMTTLEPTPSPTTPEPTSEPAPSPTTPEPTSEPAPSPTTPEPTSEPAPSPTTPEPTPIPTIATSPTILVSATSLITPKSTFLTTTKPVSLLESTKKTIPELDQPPKLRGVLQGHLESSRNDPFLHPDFCCLLPLGFYVLGLFWLLFASVVLILLLSWVGHVKPQALDSGQGAALTTATQTTHLELQRGRQVTVPRAWLLFLRGSLPTFRSSLFLWVRPNGRVGPLVAGRRPSALSQGRGQDLLSTVSIRYSGHSL T17427 DRUGINFO D02TDV ZK-001 Phase 1/2 T17427 DRUGINFO D05HFU TGX-6B4 Preclinical T30784 TARGETID T30784 T30784 FORMERID TTDI02201 T30784 UNIPROID TSP1_HUMAN T30784 TARGNAME Thrombospondin-1 (THBS1) T30784 GENENAME THBS1 T30784 TARGTYPE Clinical trial T30784 SYNONYMS TSP1; TSP; Glycoprotein G T30784 FUNCTION Binds heparin. May play a role in dentinogenesis and/or maintenance of dentin and dental pulp. Ligand for CD36 mediating antiangiogenic properties. Plays a role in ER stress response, via its interaction with the activating transcription factor 6 alpha (ATF6) which produces adaptive ER stress response factors. Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. T30784 PDBSTRUC 5FOE; 3R6B; 2OUJ; 2OUH; 2ES3 T30784 SEQUENCE MGLAWGLGVLFLMHVCGTNRIPESGGDNSVFDIFELTGAARKGSGRRLVKGPDPSSPAFRIEDANLIPPVPDDKFQDLVDAVRAEKGFLLLASLRQMKKTRGTLLALERKDHSGQVFSVVSNGKAGTLDLSLTVQGKQHVVSVEEALLATGQWKSITLFVQEDRAQLYIDCEKMENAELDVPIQSVFTRDLASIARLRIAKGGVNDNFQGVLQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGSSPAIRTNYIGHKTKDLQAICGISCDELSSMVLELRGLRTIVTTLQDSIRKVTEENKELANELRRPPLCYHNGVQYRNNEEWTVDSCTECHCQNSVTICKKVSCPIMPCSNATVPDGECCPRCWPSDSADDGWSPWSEWTSCSTSCGNGIQQRGRSCDSLNNRCEGSSVQTRTCHIQECDKRFKQDGGWSHWSPWSSCSVTCGDGVITRIRLCNSPSPQMNGKPCEGEARETKACKKDACPINGGWGPWSPWDICSVTCGGGVQKRSRLCNNPTPQFGGKDCVGDVTENQICNKQDCPIDGCLSNPCFAGVKCTSYPDGSWKCGACPPGYSGNGIQCTDVDECKEVPDACFNHNGEHRCENTDPGYNCLPCPPRFTGSQPFGQGVEHATANKQVCKPRNPCTDGTHDCNKNAKCNYLGHYSDPMYRCECKPGYAGNGIICGEDTDLDGWPNENLVCVANATYHCKKDNCPNLPNSGQEDYDKDGIGDACDDDDDNDKIPDDRDNCPFHYNPAQYDYDRDDVGDRCDNCPYNHNPDQADTDNNGEGDACAADIDGDGILNERDNCQYVYNVDQRDTDMDGVGDQCDNCPLEHNPDQLDSDSDRIGDTCDNNQDIDEDGHQNNLDNCPYVPNANQADHDKDGKGDACDHDDDNDGIPDDKDNCRLVPNPDQKDSDGDGRGDACKDDFDHDSVPDIDDICPENVDISETDFRRFQMIPLDPKGTSQNDPNWVVRHQGKELVQTVNCDPGLAVGYDEFNAVDFSGTFFINTERDDDYAGFVFGYQSSSRFYVVMWKQVTQSYWDTNPTRAQGYSGLSVKVVNSTTGPGEHLRNALWHTGNTPGQVRTLWHDPRHIGWKDFTAYRWRLSHRPKTGFIRVVMYEGKKIMADSGPIYDKTYAGGRLGLFVFSQEMVFFSDLKYECRDP T30784 DRUGINFO D0G4MB ABT-510 Phase 2 T30784 DRUGINFO D0S0KP CVX-045 Phase 2 T07374 TARGETID T07374 T07374 FORMERID TTDI02128 T07374 UNIPROID MSMB_HUMAN T07374 TARGNAME Beta-microseminoprotein (MSMB) T07374 GENENAME MSMB T07374 TARGTYPE Clinical trial T07374 SYNONYMS Seminal plasma beta-inhibin; Prostate secretory protein of 94 amino acids; Prostate secreted seminal plasma protein; PSP94; PSP-94; PRSP; PN44; Immunoglobulin-binding factor; IGBF T07374 FUNCTION A member of the immunoglobulin binding factor family. May have a role as an autocrine paracrine factor in uterine, breast and other female reproductive tissues. Inhibits growth of cancer cells in an experimental model of prostate cancer, though this property is cell line specific. T07374 PDBSTRUC 3IX0; 2IZ3 T07374 SEQUENCE MNVLLGSVVIFATFVTLCNASCYFIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKTCSVSEWII T07374 DRUGINFO D0UN1S Tigapotide Phase 1 T71086 TARGETID T71086 T71086 FORMERID TTDI02042 T71086 UNIPROID CFAH_HUMAN T71086 TARGNAME Complement factor H (CFH) T71086 GENENAME CFH T71086 TARGTYPE Clinical trial T71086 SYNONYMS HF2; HF1; HF; H factor 1 T71086 FUNCTION Glycoprotein that plays an essential role in maintaining a well-balanced immune response by modulating complement activation. Acts as a soluble inhibitor of complement, where its binding to self markers such as glycan structures prevents complement activation and amplification on cell surfaces. Accelerates the decay of the complement alternative pathway (AP) C3 convertase C3bBb, thus preventing local formation of more C3b, the central player of the complement amplification loop. As a cofactor of the serine protease factor I, CFH also regulates proteolytic degradation of already-deposited C3b. In addition, mediates several cellular responses through interaction with specific receptors. For example, interacts with CR3/ITGAM receptor and thereby mediates the adhesion of human neutrophils to different pathogens. In turn, these pathogens are phagocytosed and destroyed. T71086 PDBSTRUC 6ATG; 5WTB; 5O35; 5O32; 5NBQ T71086 SEQUENCE MRLLAKIICLMLWAICVAEDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLGNVIMVCRKGEWVALNPLRKCQKRPCGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQLLGEINYRECDTDGWTNDIPICEVVKCLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNSGYKIEGDEEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKENERFQYKCNMGYEYSERGDAVCTESGWRPLPSCEEKSCDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYPATRGNTAKCTSTGWIPAPRCTLKPCDYPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEHFETPSGSYWDHIHCTQDGWSPAVPCLRKCYFPYLENGYNQNYGRKFVQGKSIDVACHPGYALPKAQTTVTCMENGWSPTPRCIRVKTCSKSSIDIENGFISESQYTYALKEKAKYQCKLGYVTADGETSGSITCGKDGWSAQPTCIKSCDIPVFMNARTKNDFTWFKLNDTLDYECHDGYESNTGSTTGSIVCGYNGWSDLPICYERECELPKIDVHLVPDRKKDQYKVGEVLKFSCKPGFTIVGPNSVQCYHFGLSPDLPICKEQVQSCGPPPELLNGNVKEKTKEEYGHSEVVEYYCNPRFLMKGPNKIQCVDGEWTTLPVCIVEESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCSESFTMIGHRSITCIHGVWTQLPQCVAIDKLKKCKSSNLIILEEHLKNKKEFDHNSNIRYRCRGKEGWIHTVCINGRWDPEVNCSMAQIQLCPPPPQIPNSHNMTTTLNYRDGEKVSVLCQENYLIQEGEEITCKDGRWQSIPLCVEKIPCSQPPQIEHGTINSSRSSQESYAHGTKLSYTCEGGFRISEENETTCYMGKWSSPPQCEGLPCKSPPEISHGVVAHMSDSYQYGEEVTYKCFEGFGIDGPAIAKCLGEKWSHPPSCIKTDCLSLPSFENAIPMGEKKDVYKAGEQVTYTCATYYKMDGASNVTCINSRWTGRPTCRDTSCVNPPTVQNAYIVSRQMSKYPSGERVRYQCRSPYEMFGDEEVMCLNGNWTEPPQCKDSTGKCGPPPPIDNGDITSFPLSVYAPASSVEYQCQNLYQLEGNKRITCRNGQWSEPPKCLHPCVISREIMENYNIALRWTAKQKLYSRTGESVEFVCKRGYRLSSRSHTLRTTCWDGKLEYPTCAKR T71086 DRUGINFO D00BZJ Trumenba Approved T71086 DRUGINFO DH2S8X GT103 Phase 1 T71086 DRUGINFO D01XQQ TT-30 Phase 1 T59001 TARGETID T59001 T59001 UNIPROID FCG3A_HUMAN T59001 TARGNAME Immunoglobulin gamma Fc receptor IIIA (FCGR3A) T59001 GENENAME FCGR3A T59001 TARGTYPE Clinical trial T59001 SYNONYMS FCGR3A T59001 FUNCTION Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis. T59001 PDBSTRUC 5YC5; 5XJF; 5XJE; 5VU0; 5MN2 T59001 BIOCLASS Immunoglobulin T59001 SEQUENCE MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKNVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDWKDHKFKWRKDPQDK T59001 DRUGINFO DZM2L1 AFM13 Phase 2 T59001 DRUGINFO DK8QG3 AFM24 Phase 1/2 T59001 DRUGINFO DC3Y7O RG6296 Phase 1 T18972 TARGETID T18972 T18972 FORMERID TTDNC00504 T18972 UNIPROID CD3G_HUMAN T18972 TARGNAME T-cell surface glycoprotein CD3 gamma (CD3G) T18972 GENENAME CD3G T18972 TARGTYPE Clinical trial T18972 SYNONYMS T3G; T-cell surface glycoprotein CD3 gamma chain; T-cell receptor T3 gamma chain; CD3g T18972 FUNCTION When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways. In addition to this role of signal transduction in T-cell activation, CD3G plays an essential role in the dynamic regulation of TCR expression at the cell surface. Indeed, constitutive TCR cycling is dependent on the di-leucine-based (diL) receptor-sorting motif present in CD3G. Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. T18972 PDBSTRUC 1SY6 T18972 SEQUENCE MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLFAEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLRRN T18972 DRUGINFO D0O2JI Ertumaxomab Phase 2 T18972 DRUGINFO D00PEN MGD007 Phase 1/2 T18972 DRUGINFO D0PY3L MEDI-565 Phase 1 T18972 DRUGINFO D00YOV MT-110 Phase 1 T18972 DRUGINFO D04UWG Autologous T-cell therapy Phase 1 T02702 TARGETID T02702 T02702 UNIPROID DYR_ECOLI T02702 TARGNAME Bacterial Dihydrofolate reductase (Bact DHFR) T02702 GENENAME Bact DHFR T02702 TARGTYPE Clinical trial T02702 SYNONYMS Bact Dihydrofolate reductase T02702 FUNCTION Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. T02702 PDBSTRUC 7DFR; 6MTH; 6MT8; 6MR9; 6DFR T02702 ECNUMBER EC 1.5.1.3 T02702 SEQUENCE MISLIAALAVDRVIGMENAMPWNLPADLAWFKRNTLNKPVIMGRHTWESIGRPLPGRKNIILSSQPGTDDRVTWVKSVDEAIAACGDVPEIMVIGGGRVYEQFLPKAQKLYLTHIDAEVEGDTHFPDYEPDDWESVFSEFHDADAQNSHSYCFEILERR T02702 DRUGINFO D04LBC Iclaprim Phase 3 T02702 DRUGINFO D03ICO AR-709 Terminated T02702 DRUGINFO D05AHQ Epiroprim Terminated T02702 DRUGINFO D0FC5T DIAVERIDINE Terminated T62187 TARGETID T62187 T62187 FORMERID TTDR00326 T62187 UNIPROID HEPA_HHV11 T62187 TARGNAME Herpes simplex virus Helicase-primase (HSV UL8) T62187 GENENAME HSV UL8 T62187 TARGTYPE Clinical trial T62187 SYNONYMS Primase-associated factor; HEPA; DNA helicase/primase complex-associated protein T62187 FUNCTION Component of the helicase/primase complex. Unwinds the DNA at the replication forks and generates single-stranded DNA for both leading and lagging strand synthesis. The primase synthesizes short RNA primers on the lagging strand that the polymerase presumably elongates using dNTPs. The primase-associated factor has no known catalytic activity in the complex and may serve to facilitate the formation of the replisome by directly interacting with the origin-binding protein and the polymerase. T62187 BIOCLASS Acid anhydrides hydrolase T62187 SEQUENCE MDTADIVWVEESVSAITLYAVWLPPRAREYFHALVYFVCRNAAGEGRARFAEVSVTATELRDFYGSADVSVQAVVAAARAATTPAASPLEPLENPTLWRALYACVLAALERQTGPVALFAPLRIGSDPRTGLVVKVERASWGPPAAPRAALLVAEANIDIDPMALAARVAEHPDARLAWARLAAIRDTPQCASAASLTVNITTGTALFAREYQTLAFPPIKKEGAFGDLVEVCEVGLRPRGHPQRVTARVLLPRDYDYFVSAGEKFSAPALVALFRQWHTTVHAAPGALAPVFAFLGPEFEVRGGPVPYFAVLGFPGWPTFTVPATAESARDLVRGAAAAYAALLGAWPAVGARVVLPPRAWPGVASAAAGCLLPAVREAVARWHPATKIIQLLDPPAAVGPVWTARFCFPGLRAQLLAALADLGGSGLADPHGRTGLARLDALVVAAPSEPWAGAVLERLVPDTCNACPALRQLLGGVMAAVCLQIEETASSVKFAVCGGDGGAFWGVFNVDPQDADAASGVIEDARRAIETAVGAVLRANAVRLRHPLCLALEGVYTHAVAWSQAGVWFWNSRDNTDHLGGFPLRGPAYTTAAGVVRDTLRRVLGLTTACVPEEDALTARGLMEDACDRLILDAFNKRLDAEYWSVRVSPFEASDPLPPTAFRGGALLDAEHYWRRVVRVCPGGGESVGVPVDLYPRPLVLPPVDCAHHLREILREIELVFTGVLAGVWGEGGKFVYPFDDKMSFLFA T62187 DRUGINFO D07PXQ ASP-2151 Phase 3 T62187 DRUGINFO D05ZXZ BAY 57-1293 Phase 2 T46616 TARGETID T46616 T46616 FORMERID TTDI01999 T46616 UNIPROID BXA1_CLOBO T46616 TARGNAME Bacterial Botulinum toxin A (Bact botA) T46616 GENENAME Bact botA T46616 TARGTYPE Clinical trial T46616 SYNONYMS botA T46616 FUNCTION Inhibits acetylcholine release. The botulinum toxin binds with high affinity to peripheral neuronal presynaptic membrane to the secretory vesicle protein SV2. It binds directly to the largest luminal loop of SV2A, SV2B and SV2C. It is then internalized by receptor-mediated endocytosis. The C-terminus of the heavy chain (H) is responsible for the adherence of the toxin to the cell surface while the N-terminus mediates transport of the light chain from the endocytic vesicle to the cytosol. After translocation, the light chain (L) hydrolyzes the 197-Gln-|-Arg- 198 bond in SNAP-25, thereby blocking neurotransmitter release. Inhibition of acetylcholine release results in flaccid paralysis, with frequent heart or respiratory failure. T46616 PDBSTRUC 6MHJ; 6DKK; 5VGX; 5VGV; 5V8U T46616 BIOCLASS Peptidase T46616 SEQUENCE MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL T46616 DRUGINFO D00UWY RT-001 Phase 2 T46616 DRUGINFO D0RD1I XOMA-3AB Phase 1 T97111 TARGETID T97111 T97111 FORMERID TTDNC00540 T97111 UNIPROID CD37_HUMAN T97111 TARGNAME Leukocyte antigen CD37 (CD37) T97111 GENENAME CD37 T97111 TARGTYPE Clinical trial T97111 SYNONYMS Tspan26; Tspan-26; Tetraspanin26; Tetraspanin-26 T97111 FUNCTION extracellular exosome, immunological synapse, integral component of plasma membrane, membrane, cell surface receptor signaling pathway. T97111 BIOCLASS Tetraspanin T97111 SEQUENCE MSAQESCLSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKVLAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRAQLERSLRDVVEKTIQKYGTNPEETAAEESWDYVQFQLRCCGWHYPQDWFQVLILRGNGSEAHRVPCSCYNLSATNDSTILDKVILPQLSRLGHLARSRHSADICAVPAESHIYREGCAQGLQKWLHNNLISIVGICLGVGLLELGFMTLSIFLCRNLDHVYNRLARYR T97111 DRUGINFO D08JGB Otlertuzumab Phase 2 T97111 DRUGINFO D09WKM BI-836826 Phase 2 T97111 DRUGINFO D0C0LO IMGN529 Phase 2 T97111 DRUGINFO D2R0UM Naratuximab emtansine Phase 2 T97111 DRUGINFO D0T7QC TRU-016 Phase 1/2 T97111 DRUGINFO D1W2DS GEN3009 Phase 1/2 T97111 DRUGINFO DI9ZQ6 212Pb-labelled aCD37 Preclinical T21782 TARGETID T21782 T21782 FORMERID TTDI00605 T21782 UNIPROID PCNA_HUMAN T21782 TARGNAME Proliferating cell nuclear antigen (PCNA) T21782 GENENAME PCNA T21782 TARGTYPE Clinical trial T21782 SYNONYMS Cyclin T21782 FUNCTION Induces a robust stimulatory effect on the 3'-5' exonuclease and 3'-phosphodiesterase, but not apurinic-apyrimidinic (AP) endonuclease, APEX2 activities. Has to be loaded onto DNA in order to be able to stimulate APEX2. Plays a key role in DNA damage response (DDR) by being conveniently positioned at the replication fork to coordinate DNA replication with DNA repair and DNA damage tolerance pathways. Acts as a loading platform to recruit DDR proteins that allow completion of DNA replication after DNA damage and promote postreplication repair: Monoubiquitinated PCNA leads to recruitment of translesion (TLS) polymerases, while 'Lys-63'-linked polyubiquitination of PCNA is involved in error-free pathway and employs recombination mechanisms to synthesize across the lesion. Auxiliary protein of DNA polymerase delta and is involved in the control of eukaryotic DNA replication by increasing the polymerase's processibility during elongation of the leading strand. T21782 PDBSTRUC 6QCG; 6QC0; 6HVO; 6GWS; 6GIS T21782 SEQUENCE MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTYRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMDLDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNIKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYKIADMGHLKYYLAPKIEDEEGS T21782 DRUGINFO D02PQB ATX-101 Phase 3 T21782 DRUGINFO D04XEO ChelASE Discontinued in Phase 1 T33636 TARGETID T33636 T33636 FORMERID TTDI02114 T33636 UNIPROID LMP2_EBVB9 T33636 TARGNAME Epstein-Barr virus Latent membrane protein 2 (EBV LMP2) T33636 GENENAME EBV LMP2 T33636 TARGTYPE Clinical trial T33636 SYNONYMS Terminal protein; Latent membrane protein 2 T33636 FUNCTION Isoform LMP2B may be a negative regulator of isoform LMP2A. T33636 PDBSTRUC 5GSD; 5GRD; 3REW; 3BVN; 2JO9 T33636 BIOCLASS Herpesviridae LMP-2 T33636 SEQUENCE MGSLEMVPMGAGPPSPGGDPDGYDGGNNSQYPSASGSSGNTPTPPNDEERESNEEPPPPYEDPYWGNGDRHSDYQPLGTQDQSLYLGLQHDGNDGLPPPPYSPRDDSSQHIYEEAGRGSMNPVCLPVIVAPYLFWLAAIAASCFTASVSTVVTATGLALSLLLLAAVASSYAAAQRKLLTPVTVLTAVVTFFAICLTWRIEDPPFNSLLFALLAAAGGLQGIYVLVMLVLLILAYRRRWRRLTVCGGIMFLACVLVLIVDAVLQLSPLLGAVTVVSMTLLLLAFVLWLSSPGGLGTLGAALLTLAAALALLASLILGTLNLTTMFLLMLLWTLVVLLICSSCSSCPLSKILLARLFLYALALLLLASALIAGGSILQTNFKSLSSTEFIPNLFCMLLLIVAGILFILAILTEWGSGNRTYGPVFMCLGGLLTMVAGAVWLTVMSNTLLSAWILTAGFLIFLIGFALFGVIRCCRYCCYYCLTLESEERPPTPYRNTV T33636 DRUGINFO D0Z6RW LMP-1/LMP-2 CTLs Phase 1 T33636 DRUGINFO D0Q8PF Ad5f35-LMPd1-2-transduced autologous dendritic cells Investigative T47864 TARGETID T47864 T47864 FORMERID TTDR01155 T47864 UNIPROID TDGF1_HUMAN T47864 TARGNAME Teratocarcinoma-derived growth factor 1 (TDGF1) T47864 GENENAME TDGF1 T47864 TARGTYPE Clinical trial T47864 SYNONYMS TDGF1; Epidermal growth factor-like cripto protein CR1; Cripto-1 growth factor; Cripto; CRGF T47864 FUNCTION Could play a role in the determination of the epiblastic cells that subsequently give rise to the mesoderm. T47864 BIOCLASS Growth factor T47864 SEQUENCE MDCRKMARFSYSVIWIMAISKVFELGLVAGLGHQEFARPSRGYLAFRDDSIWPQEEPAIRPRSSQRVPPMGIQHSKELNRTCCLNGGTCMLGSFCACPPSFYGRNCEHDVRKENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLVGICLSIQSYY T47864 DRUGINFO D08IRG BIIB 015 Phase 1 T86323 TARGETID T86323 T86323 UNIPROID NCAM1_HUMAN T86323 TARGNAME Neural cell adhesion molecule 1 (NCAM1) T86323 GENENAME NCAM1 T86323 TARGTYPE Clinical trial T86323 SYNONYMS NCAM-1; NCAM; N-CAM-1; MSK39; CD56 T86323 FUNCTION This protein is a cell adhesion molecule involved in neuron-neuron adhesion, neurite fasciculation, outgrowth of neurites, etc. T86323 PDBSTRUC 5LKN; 5AEA; 3MTR; 2VKX; 2VKW T86323 SEQUENCE MLQTKDLIWTLFFLGTAVSLQVDIVPSQGEISVGESKFFLCQVAGDAKDKDISWFSPNGEKLTPNQQRISVVWNDDSSSTLTIYNANIDDAGIYKCVVTGEDGSESEATVNVKIFQKLMFKNAPTPQEFREGEDAVIVCDVVSSLPPTIIWKHKGRDVILKKDVRFIVLSNNYLQIRGIKKTDEGTYRCEGRILARGEINFKDIQVIVNVPPTIQARQNIVNATANLGQSVTLVCDAEGFPEPTMSWTKDGEQIEQEEDDEKYIFSDDSSQLTIKKVDKNDEAEYICIAENKAGEQDATIHLKVFAKPKITYVENQTAMELEEQVTLTCEASGDPIPSITWRTSTRNISSEEKASWTRPEKQETLDGHMVVRSHARVSSLTLKSIQYTDAGEYICTASNTIGQDSQSMYLEVQYAPKLQGPVAVYTWEGNQVNITCEVFAYPSATISWFRDGQLLPSSNYSNIKIYNTPSASYLEVTPDSENDFGNYNCTAVNRIGQESLEFILVQADTPSSPSIDQVEPYSSTAQVQFDEPEATGGVPILKYKAEWRAVGEEVWHSKWYDAKEASMEGIVTIVGLKPETTYAVRLAALNGKGLGEISAASEFKTQPVQGEPSAPKLEGQMGEDGNSIKVNLIKQDDGGSPIRHYLVRYRALSSEWKPEIRLPSGSDHVMLKSLDWNAEYEVYVVAENQQGKSKAAHFVFRTSAQPTAIPANGSPTSGLSTGAIVGILIVIFVLLLVVVDITCYFLNKCGLFMCIAVNLCGKAGPGAKGKDMEEGKAAFSKDESKEPIVEVRTEEERTPNHDGGKHTEPNETTPLTEPEKGPVEAKPECQETETKPAPAEVKTVPNDATQTKENESKA T86323 DRUGINFO D03HML CD56-specific gene-engineered T cells Phase 1/2 T86323 DRUGINFO D0U1GP CD56 CAR T cells Phase 1/2 T86323 DRUGINFO D0YH5L CART-56 cells Phase 1 T86323 DRUGINFO D0V6WW CAR-T cells targeting CD56 Clinical trial T19556 TARGETID T19556 T19556 FORMERID TTDR00458 T19556 UNIPROID ONCM_HUMAN T19556 TARGNAME Oncostatin-M (OSM) T19556 GENENAME OSM T19556 TARGTYPE Clinical trial T19556 SYNONYMS OSM T19556 FUNCTION Growth regulator. Inhibits the proliferation of a number of tumor cell lines. Stimulates proliferation of AIDS-KS cells. It regulates cytokine production, including IL-6, G-CSF and GM-CSF from endothelial cells. Uses both type I OSM receptor (heterodimers composed of LIPR and IL6ST) and type II OSM receptor (heterodimers composed of OSMR and IL6ST). Involved in the maturation of fetal hepatocytes, thereby promoting liver development and regeneration. T19556 PDBSTRUC 1EVS T19556 SEQUENCE MGVLLTQRTLLSLVLALLFPSMASMAAIGSCSKEYRVLLGQLQKQTDLMQDTSRLLDPYIRIQGLDVPKLREHCRERPGAFPSEETLRGLGRRGFLQTLNATLGCVLHRLADLEQRLPKAQDLERSGLNIEDLEKLQMARPNILGLRNNIYCMAQLLDNSDTAEPTKAGRGASQPPTPTPASDAFQRKLEGCRFLHGYHRFMHSVGRVFSKWGESPNRSRRHSPHQALRKGVRRTRPSRKGKRLMTRGQLPR T19556 DRUGINFO D0D3TQ GSK2330811 Phase 2 T19556 DRUGINFO D04VCF ADR58 Investigative T93121 TARGETID T93121 T93121 UNIPROID ETS2_HUMAN T93121 TARGNAME Protein C-ets-2 (ETS2) T93121 GENENAME ETS2 T93121 TARGTYPE Clinical trial T93121 SYNONYMS ETS2IT1; ETS proto-oncogene 2, transcription factor T93121 FUNCTION Binds specifically the DNA GGAA/T core motif (Ets-binding site or EBS) in gene promoters and stimulates transcription. Transcription factor activating transcription. T93121 PDBSTRUC 4MHV; 4BQA T93121 BIOCLASS E26 transformation-specific ETS T93121 SEQUENCE MNDFGIKNMDQVAPVANSYRGTLKRQPAFDTFDGSLFAVFPSLNEEQTLQEVPTGLDSISHDSANCELPLLTPCSKAVMSQALKATFSGFKKEQRRLGIPKNPWLWSEQQVCQWLLWATNEFSLVNVNLQRFGMNGQMLCNLGKERFLELAPDFVGDILWEHLEQMIKENQEKTEDQYEENSHLTSVPHWINSNTLGFGTEQAPYGMQTQNYPKGGLLDSMCPASTPSVLSSEQEFQMFPKSRLSSVSVTYCSVSQDFPGSNLNLLTNNSGTPKDHDSPENGADSFESSDSLLQSWNSQSSLLDVQRVPSFESFEDDCSQSLCLNKPTMSFKDYIQERSDPVEQGKPVIPAAVLAGFTGSGPIQLWQFLLELLSDKSCQSFISWTGDGWEFKLADPDEVARRWGKRKNKPKMNYEKLSRGLRYYYDKNIIHKTSGKRYVYRFVCDLQNLLGFTPEELHAILGVQPDTED T93121 DRUGINFO D0HU0A TK216 Phase 1 T78319 TARGETID T78319 T78319 FORMERID TTDR00525 T78319 UNIPROID CD44_HUMAN T78319 TARGNAME Extracellular matrix receptor III (CD44) T78319 GENENAME CD44 T78319 TARGTYPE Clinical trial T78319 SYNONYMS Phagocytic glycoprotein I; Phagocytic glycoprotein 1; PGP-I; PGP-1; MIC4; MDU3; MDU2; LHR; Hyaluronate receptor; Hermes antigen; Heparan sulfate proteoglycan; HUTCH-I; GP90 lymphocyte homing/adhesion receptor; Extracellular matrix receptor-III; Epican; ECMR-III; CDw44; CD44 antigen T78319 FUNCTION Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection. Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases. Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signaling pathways promoting calcium mobilization and actin-mediated cytoskeleton reorganization essential for cell migration and adhesion. Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. T78319 PDBSTRUC 4PZ4; 4PZ3; 2I83; 1UUH; 1POZ T78319 SEQUENCE MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTLPTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSSGSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATTLMSTSATATETATKRQETWDWFSWLFLPSESKNHLHTTTQMAGTSSNTISAGWEPNEENEDERDRHLSFSGSGIDDDEDFISSTISTTPRAFDHTKQNQDWTQWNPSHSNPEVLLQTTTRMTDVDRNGTTAYEGNWNPEAHPPLIHHEHHEEEETPHSTSTIQATPSSTTEETATQKEQWFGNRWHEGYRQTPKEDSHSTTGTAAASAHTSHPMQGRTTPSPEDSSWTDFFNPISHPMGRGHQAGRRMDMDSSHSITLQPTANPNTGLVEDLDRTGPLSMTTQQSNSQSFSTSHEGLEEDKDHPTTSTLTSSNRNDVTGGRRDPNHSEGSTTLLEGYTSHYPHTKESRTFIPVTSAKTGSFGVTAVTVGDSNSNVNRSLSGDQDTFHPSGGSHTTHGSESDGHSHGSQEGGANTTSGPIRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLNGEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV T78319 DRUGINFO D0CT7M A-6 Phase 2 T78319 DRUGINFO D2C0DY SPL-108 Phase 2 T78319 DRUGINFO D05OXZ BIWA 4 Phase 1 T78319 DRUGINFO D0R6EQ Bivatuzumab mertansine Terminated T68230 TARGETID T68230 T68230 FORMERID TTDI01812 T68230 UNIPROID TOXA_CLODI T68230 TARGNAME Clostridium difficile Toxin A (CD toxA) T68230 GENENAME CD toxA T68230 TARGTYPE Clinical trial T68230 SYNONYMS Toxin A T68230 FUNCTION Only after the enteral delivery of the enterotoxin A may the characteristic disease called pseudomembranous colitis be induced. T68230 PDBSTRUC 5UQL; 5UQK; 5UMI; 4R04; 4DMW T68230 ECNUMBER EC 3.4.22.- T68230 SEQUENCE MSLISKEELIKLAYSIRPRENEYKTILTNLDEYNKLTTNNNENKYLQLKKLNESIDVFMNKYKTSSRNRALSNLKKDILKEVILIKNSNTSPVEKNLHFVWIGGEVSDIALEYIKQWADINAEYNIKLWYDSEAFLVNTLKKAIVESSTTEALQLLEEEIQNPQFDNMKFYKKRMEFIYDRQKRFINYYKSQINKPTVPTIDDIIKSHLVSEYNRDETVLESYRTNSLRKINSNHGIDIRANSLFTEQELLNIYSQELLNRGNLAAASDIVRLLALKNFGGVYLDVDMLPGIHSDLFKTISRPSSIGLDRWEMIKLEAIMKYKKYINNYTSENFDKLDQQLKDNFKLIIESKSEKSEIFSKLENLNVSDLEIKIAFALGSVINQALISKQGSYLTNLVIEQVKNRYQFLNQHLNPAIESDNNFTDTTKIFHDSLFNSATAENSMFLTKIAPYLQVGFMPEARSTISLSGPGAYASAYYDFINLQENTIEKTLKASDLIEFKFPENNLSQLTEQEINSLWSFDQASAKYQFEKYVRDYTGGSLSEDNGVDFNKNTALDKNYLLNNKIPSNNVEEAGSKNYVHYIIQLQGDDISYEATCNLFSKNPKNSIIIQRNMNESAKSYFLSDDGESILELNKYRIPERLKNKEKVKVTFIGHGKDEFNTSEFARLSVDSLSNEISSFLDTIKLDISPKNVEVNLLGCNMFSYDFNVEETYPGKLLLSIMDKITSTLPDVNKNSITIGANQYEVRINSEGRKELLAHSGKWINKEEAIMSDLSSKEYIFFDSIDNKLKAKSKNIPGLASISEDIKTLLLDASVSPDTKFILNNLKLNIESSIGDYIYYEKLEPVKNIIHNSIDDLIDEFNLLENVSDELYELKKLNNLDEKYLISFEDISKNNSTYSVRFINKSNGESVYVETEKEIFSKYSEHITKEISTIKNSIITDVNGNLLDNIQLDHTSQVNTLNAAFFIQSLIDYSSNKDVLNDLSTSVKVQLYAQLFSTGLNTIYDSIQLVNLISNAVNDTINVLPTITEGIPIVSTILDGINLGAAIKELLDEHDPLLKKELEAKVGVLAINMSLSIAATVASIVGIGAEVTIFLLPIAGISAGIPSLVNNELILHDKATSVVNYFNHLSESKKYGPLKTEDDKILVPIDDLVISEIDFNNNSIKLGTCNILAMEGGSGHTVTGNIDHFFSSPSISSHIPSLSIYSAIGIETENLDFSKKIMMLPNAPSRVFWWETGAVPGLRSLENDGTRLLDSIRDLYPGKFYWRFYAFFDYAITTLKPVYEDTNIKIKLDKDTRNFIMPTITTNEIRNKLSYSFDGAGGTYSLLLSSYPISTNINLSKDDLWIFNIDNEVREISIENGTIKKGKLIKDVLSKIDINKNKLIIGNQTIDFSGDIDNKDRYIFLTCELDDKISLIIEINLVAKSYSLLLSGDKNYLISNLSNTIEKINTLGLDSKNIAYNYTDESNNKYFGAISKTSQKSIIHYKKDSKNILEFYNDSTLEFNSKDFIAEDINVFMKDDINTITGKYYVDNNTDKSIDFSISLVSKNQVKVNGLYLNESVYSSYLDFVKNSDGHHNTSNFMNLFLDNISFWKLFGFENINFVIDKYFTLVGKTNLGYVEFICDNNKNIDIYFGEWKTSSSKSTIFSGNGRNVVVEPIYNPDTGEDISTSLDFSYEPLYGIDRYINKVLIAPDLYTSLININTNYYSNEYYPEIIVLNPNTFHKKVNINLDSSSFEYKWSTEGSDFILVRYLEESNKKILQKIRIKGILSNTQSFNKMSIDFKDIKKLSLGYIMSNFKSFNSENELDRDHLGFKIIDNKTYYYDEDSKLVKGLININNSLFYFDPIEFNLVTGWQTINGKKYYFDINTGAALTSYKIINGKHFYFNNDGVMQLGVFKGPDGFEYFAPANTQNNNIEGQAIVYQSKFLTLNGKKYYFDNNSKAVTGWRIINNEKYYFNPNNAIAAVGLQVIDNNKYYFNPDTAIISKGWQTVNGSRYYFDTDTAIAFNGYKTIDGKHFYFDSDCVVKIGVFSTSNGFEYFAPANTYNNNIEGQAIVYQSKFLTLNGKKYYFDNNSKAVTGLQTIDSKKYYFNTNTAEAATGWQTIDGKKYYFNTNTAEAATGWQTIDGKKYYFNTNTAIASTGYTIINGKHFYFNTDGIMQIGVFKGPNGFEYFAPANTDANNIEGQAILYQNEFLTLNGKKYYFGSDSKAVTGWRIINNKKYYFNPNNAIAAIHLCTINNDKYYFSYDGILQNGYITIERNNFYFDANNESKMVTGVFKGPNGFEYFAPANTHNNNIEGQAIVYQNKFLTLNGKKYYFDNDSKAVTGWQTIDGKKYYFNLNTAEAATGWQTIDGKKYYFNLNTAEAATGWQTIDGKKYYFNTNTFIASTGYTSINGKHFYFNTDGIMQIGVFKGPNGFEYFAPANTDANNIEGQAILYQNKFLTLNGKKYYFGSDSKAVTGLRTIDGKKYYFNTNTAVAVTGWQTINGKKYYFNTNTSIASTGYTIISGKHFYFNTDGIMQIGVFKGPDGFEYFAPANTDANNIEGQAIRYQNRFLYLHDNIYYFGNNSKAATGWVTIDGNRYYFEPNTAMGANGYKTIDNKNFYFRNGLPQIGVFKGSNGFEYFAPANTDANNIEGQAIRYQNRFLHLLGKIYYFGNNSKAVTGWQTINGKVYYFMPDTAMAAAGGLFEIDGVIYFFGVDGVKAPGIYG T68230 DRUGINFO D06IBG MK-3415A Phase 3 T47863 TARGETID T47863 T47863 FORMERID TTDR00765 T47863 UNIPROID EPCAM_HUMAN T47863 TARGNAME Tumor-associated calcium signal transducer 1 (EPCAM) T47863 GENENAME EPCAM T47863 TARGTYPE Clinical trial T47863 SYNONYMS hEGP314; TROP1; TACSTD1; Major gastrointestinal tumor-associated protein GA733-2; MIC18; M4S1; M1S2; KSA; KS 1/4 antigen; Gastrointestinal carcinoma antigen GA733; GA733-2; Epithelial glycoprotein 314; Epithelial glycoprotein; Epithelial cell surface antigen; Epithelial cell adhesion molecule; Ep-CAM; EGP314; EGP; Cell surface glycoprotein Trop-1; CD326; Adenocarcinoma-associated antigen T47863 FUNCTION Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E. May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. T47863 PDBSTRUC 6I07; 4MZV T47863 SEQUENCE MAPPQVLAFGLLLAAATATFAAAQEECVCENYKLAVNCFVNNNRQCQCTSVGAQNTVICSKLAAKCLVMKAEMNGSKLGRRAKPEGALQNNDGLYDPDCDESGLFKAKQCNGTSMCWCVNTAGVRRTDKDTEITCSERVRTYWIIIELKHKAREKPYDSKSLRTALQKEITTRYQLDPKFITSILYENNVITIDLVQNSSQKTQNDVDIADVAYYFEKDVKGESLFHSKKMDLTVNGEQLDLDPGQTLIYYVDEKAPEFSMQGLKAGVIAVIVVVVIAVVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA T47863 DRUGINFO DRP4Q9 Vicineum Phase 3 T47863 DRUGINFO D0Q3IS VB4-845 Phase 2/3 T47863 DRUGINFO D08QYW CAR-T Cells targeting EpCAM Phase 1/2 T47863 DRUGINFO D01TNK CAR-T cells targeting EpCAM Phase 1 T47863 DRUGINFO D04RNG CAR-T cells recognizing EpCAM Phase 1 T47863 DRUGINFO D05DOY ING-1 Phase 1 T47863 DRUGINFO D0C6ID Citatuzumab bogatox Phase 1 T47863 DRUGINFO D7FPZ4 A-337 Phase 1 T47863 DRUGINFO D00YOV MT-110 Phase 1 T47863 DRUGINFO D0T8DD EPCAM-targeted CAR-T cells Clinical trial T47863 DRUGINFO D0J9KC IGN-101 Discontinued in Phase 2 T50584 TARGETID T50584 T50584 FORMERID TTDI02028 T50584 UNIPROID BPI_HUMAN T50584 TARGNAME Protein bactericidal permeability-increasing (BPI) T50584 GENENAME BPI T50584 TARGTYPE Clinical trial T50584 SYNONYMS CAP 57; BPI T50584 FUNCTION The cytotoxic action of BPI is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. Has antibacterial activity against the Gram-nagative bacterium P.aeruginosa, this activity is inhibited by LPS from P.aeruginosa. {ECO:0000269|PubMed:1937776, ECO:0000269|PubMed:2722846}. T50584 PDBSTRUC 1EWF; 1BP1 T50584 BIOCLASS Bactericidal permeability increasing protein T50584 SEQUENCE MRENMARGPCNAPRWASLMVLVAIGTAVTAAVNPGVVVRISQKGLDYASQQGTAALQKELKRIKIPDYSDSFKIKHLGKGHYSFYSMDIREFQLPSSQISMVPNVGLKFSISNANIKISGKWKAQKRFLKMSGNFDLSIEGMSISADLKLGSNPTSGKPTITCSSCSSHINSVHVHISKSKVGWLIQLFHKKIESALRNKMNSQVCEKVTNSVSSELQPYFQTLPVMTKIDSVAGINYGLVAPPATTAETLDVQMKGEFYSENHHNPPPFAPPVMEFPAAHDRMVYLGLSDYFFNTAGLVYQEAGVLKMTLRDDMIPKESKFRLTTKFFGTFLPEVAKKFPNMKIQIHVSASTPPHLSVQPTGLTFYPAVDVQAFAVLPNSSLASLFLIGMHTTGSMEVSAESNRLVGELKLDRLLLELKHSNIGPFPVELLQDIMNYIVPILVLPRVNEKLQKGFPLPTPARVQLYNVVLQPHQNFLLFGADVVYK T50584 DRUGINFO D0UF8E XOMA-629 Phase 2 T92963 TARGETID T92963 T92963 FORMERID TTDI01819 T92963 UNIPROID ANPRC_HUMAN T92963 TARGNAME Natriuretic peptide receptor (NPR3) T92963 GENENAME NPR3 T92963 TARGTYPE Clinical trial T92963 SYNONYMS NPR3 T92963 FUNCTION Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand. T92963 PDBSTRUC 1YK1; 1YK0; 1JDP; 1JDN T92963 BIOCLASS Phosphorus-oxygen lyase T92963 SEQUENCE MPSLLVLTFSPCVLLGWALLAGGTGGGGVGGGGGGAGIGGGRQEREALPPQKIEVLVLLPQDDSYLFSLTRVRPAIEYALRSVEGNGTGRRLLPPGTRFQVAYEDSDCGNRALFSLVDRVAAARGAKPDLILGPVCEYAAAPVARLASHWDLPMLSAGALAAGFQHKDSEYSHLTRVAPAYAKMGEMMLALFRHHHWSRAALVYSDDKLERNCYFTLEGVHEVFQEEGLHTSIYSFDETKDLDLEDIVRNIQASERVVIMCASSDTIRSIMLVAHRHGMTSGDYAFFNIELFNSSSYGDGSWKRGDKHDFEAKQAYSSLQTVTLLRTVKPEFEKFSMEVKSSVEKQGLNMEDYVNMFVEGFHDAILLYVLALHEVLRAGYSKKDGGKIIQQTWNRTFEGIAGQVSIDANGDRYGDFSVIAMTDVEAGTQEVIGDYFGKEGRFEMRPNVKYPWGPLKLRIDENRIVEHTNSSPCKSSGGLEESAVTGIVVGALLGAGLLMAFYFFRKKYRITIERRTQQEESNLGKHRELREDSIRSHFSVA T92963 DRUGINFO D0SZ5G ANX-042 Phase 1 T92963 DRUGINFO D05ODA AP811 Investigative T92963 DRUGINFO D09CFD M372049 Investigative T22350 TARGETID T22350 T22350 FORMERID TTDR00642 T22350 UNIPROID EGLN_HUMAN T22350 TARGNAME Endoglin CD105 (ENG) T22350 GENENAME ENG T22350 TARGTYPE Clinical trial T22350 SYNONYMS Endoglin; END; CD105 T22350 FUNCTION Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis. Required for normal structure and integrity of adult vasculature. Regulates the migration of vascular endothelial cells. Required for normal extraembryonic angiogenesis and for embryonic heart development (By similarity). May regulate endothelial cell shape changes in response to blood flow, which drive vascular remodeling and establishment of normal vascular morphology during angiogenesis (By similarity). May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors. Acts as TGF-beta coreceptor and is involved in the TGF-beta/BMP signaling cascade that ultimately leads to the activation of SMAD transcription factors. Required for GDF2/BMP9 signaling through SMAD1 in endothelial cells and modulates TGFB1 signaling through SMAD3. T22350 PDBSTRUC 5I04; 5HZW; 5HZV T22350 SEQUENCE MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNAILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLSFCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVELSCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLLGEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQTKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASMISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVSPSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVPIPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAFLIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA T22350 DRUGINFO D00YQI TRC105 Phase 3 T22350 DRUGINFO DQ8K3R ENV-105 Phase 1 T27918 TARGETID T27918 T27918 UNIPROID DDX5_HUMAN T27918 TARGNAME ATP-dependent RNA helicase DDX5 (DDX5) T27918 GENENAME DDX5 T27918 TARGTYPE Clinical trial T27918 SYNONYMS RNA helicase p68; Probable ATP-dependent RNA helicase DDX5; HLR1; HELR; G17P1; DEAD box protein 5 T27918 FUNCTION Binds to the tau pre-mRNA in the stem-loop region downstream of exon 10. The rate of ATP hydrolysis is highly stimulated by single-stranded RNA. Involved in transcriptional regulation; the function is independent of the RNA helicase activity. Transcriptional coactivator for androgen receptor AR but probably not ESR1. Synergizes with DDX17 and SRA1 RNA to activate MYOD1 transcriptional activity and involved in skeletal muscle differentiation. Transcriptional coactivator for p53/TP53 and involved in p53/TP53 transcriptional response to DNA damage and p53/TP53-dependent apoptosis. Transcriptional coactivator for RUNX2 and involved in regulation of osteoblast differentiation. Acts as transcriptional repressor in a promoter-specific manner; the function probably involves association with histone deacetylases, such as HDAC1. As component of a large PER complex is involved in the inhibition of 3' transcriptional termination of circadian target genes such as PER1 and NR1D1 and the control of the circadian rhythms. Involved in the alternative regulation of pre-mRNA splicing; its RNA helicase activity is necessary for increasing tau exon 10 inclusion and occurs in a RBM4-dependent manner. T27918 PDBSTRUC 4A4D; 3FE2 T27918 ECNUMBER EC 3.6.4.13 T27918 SEQUENCE MSGYSSDRDRGRDRGFGAPRFGGSRAGPLSGKKFGNPGEKLVKKKWNLDELPKFEKNFYQEHPDLARRTAQEVETYRRSKEITVRGHNCPKPVLNFYEANFPANVMDVIARQNFTEPTAIQAQGWPVALSGLDMVGVAQTGSGKTLSYLLPAIVHINHQPFLERGDGPICLVLAPTRELAQQVQQVAAEYCRACRLKSTCIYGGAPKGPQIRDLERGVEICIATPGRLIDFLECGKTNLRRTTYLVLDEADRMLDMGFEPQIRKIVDQIRPDRQTLMWSATWPKEVRQLAEDFLKDYIHINIGALELSANHNILQIVDVCHDVEKDEKLIRLMEEIMSEKENKTIVFVETKRRCDELTRKMRRDGWPAMGIHGDKSQQERDWVLNEFKHGKAPILIATDVASRGLDVEDVKFVINYDYPNSSEDYIHRIGRTARSTKTGTAYTFFTPNNIKQVSDLISVLREANQAINPKLLQLVEDRGSGRSRGRGGMKDDRRDRYSAGKRGGFNTFRDRENYDRGYSSLLKRDFGAKTQNGVYSAANYTNGSFGSNFVSAGIQTSFRTGNPTGTYQNGYDSTQQYGSNVPNMHNGMNQQAYAYPATAAAPMIGYPMPTGYSQ T27918 DRUGINFO D0S1TI RX-5902 Phase 2 T93061 TARGETID T93061 T93061 UNIPROID DDX5_HUMAN T93061 TARGNAME Phosphorylated p68 RNA helicase (pDDX5) T93061 GENENAME DDX5 T93061 TARGTYPE Clinical trial T93061 SYNONYMS RNA helicase p68 (phosphorylated); Probable ATP-dependent RNA helicase DDX5 (phosphorylated); HLR1 (phosphorylated); HELR (phosphorylated); G17P1 (phosphorylated); DEAD box protein 5 (phosphorylated) T93061 FUNCTION Involved in the alternative regulation of pre-mRNA splicing; its RNA helicase activity is necessary for increasing tau exon 10 inclusion and occurs in a RBM4-dependent manner. Binds to the tau pre-mRNA in the stem-loop region downstream of exon 10. The rate of ATP hydrolysis is highly stimulated by single-stranded RNA. Involved in transcriptional regulation; the function is independent of the RNA helicase activity. Transcriptional coactivator for androgen receptor AR but probably not ESR1. Synergizes with DDX17 and SRA1 RNA to activate MYOD1 transcriptional activity and involved in skeletal muscle differentiation. Transcriptional coactivator for p53/TP53 and involved in p53/TP53 transcriptional response to DNA damage and p53/TP53-dependent apoptosis. Transcriptional coactivator for RUNX2 and involved in regulation of osteoblast differentiation. Acts as transcriptional repressor in a promoter-specific manner; the function probably involves association with histone deacetylases, such as HDAC1. As component of a large PER complex is involved in the inhibition of 3' transcriptional termination of circadian target genes such as PER1 and NR1D1 and the control of the circadian rhythms. T93061 PDBSTRUC 4A4D; 3FE2 T93061 ECNUMBER EC 3.6.4.13 T93061 SEQUENCE MSGYSSDRDRGRDRGFGAPRFGGSRAGPLSGKKFGNPGEKLVKKKWNLDELPKFEKNFYQEHPDLARRTAQEVETYRRSKEITVRGHNCPKPVLNFYEANFPANVMDVIARQNFTEPTAIQAQGWPVALSGLDMVGVAQTGSGKTLSYLLPAIVHINHQPFLERGDGPICLVLAPTRELAQQVQQVAAEYCRACRLKSTCIYGGAPKGPQIRDLERGVEICIATPGRLIDFLECGKTNLRRTTYLVLDEADRMLDMGFEPQIRKIVDQIRPDRQTLMWSATWPKEVRQLAEDFLKDYIHINIGALELSANHNILQIVDVCHDVEKDEKLIRLMEEIMSEKENKTIVFVETKRRCDELTRKMRRDGWPAMGIHGDKSQQERDWVLNEFKHGKAPILIATDVASRGLDVEDVKFVINYDYPNSSEDYIHRIGRTARSTKTGTAYTFFTPNNIKQVSDLISVLREANQAINPKLLQLVEDRGSGRSRGRGGMKDDRRDRYSAGKRGGFNTFRDRENYDRGYSSLLKRDFGAKTQNGVYSAANYTNGSFGSNFVSAGIQTSFRTGNPTGTYQNGYDSTQQYGSNVPNMHNGMNQQAYAYPATAAAPMIGYPMPTGYSQ T93061 DRUGINFO D0S1TI RX-5902 Phase 2 T32348 TARGETID T32348 T32348 FORMERID TTDI02059 T32348 UNIPROID EGR1_HUMAN T32348 TARGNAME Early growth response protein 1 (EGR-1) T32348 GENENAME EGR1 T32348 TARGTYPE Clinical trial T32348 SYNONYMS Zinc finger protein Krox24; Zinc finger protein Krox-24; Zinc finger protein 225; ZNF225; Transcription factor Zif268; Transcription factor ETR103; Nerve growth factorinduced protein A; Nerve growth factor-induced protein A; NGFIA; NGFI-A; KROX24; AT225 T32348 FUNCTION Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'(EGR-site) in the promoter region of target genes. Binds double-stranded target DNA, irrespective of the cytosine methylation status. Regulates the transcription of numerous target genes, and thereby plays an important role in regulating the response to growth factors, DNA damage, and ischemia. Plays a role in the regulation of cell survival, proliferation and cell death. Activates expression of p53/TP53 and TGFB1, and thereby helps prevent tumor formation. Required for normal progress through mitosis and normal proliferation of hepatocytes after partial hepatectomy. Mediates responses to ischemia and hypoxia; regulates the expression of proteins such as IL1B and CXCL2 that are involved in inflammatory processes and development of tissue damage after ischemia. Regulates biosynthesis of luteinizing hormone (LHB) in the pituitary. Regulates the amplitude of the expression rhythms of clock genes: ARNTL/BMAL1, PER2 and NR1D1 in the liver via the activation of PER1 (clock repressor) transcription. Regulates the rhythmic expression of core-clock gene ARNTL/BMAL1 in the suprachiasmatic nucleus (SCN). Transcriptional regulator. T32348 PDBSTRUC 5N14; 4X9J; 4R2D; 4R2C; 4R2A T32348 BIOCLASS EGR C2H2-type zinc-finger T32348 SEQUENCE MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDICGRKFARSDERKRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC T32348 DRUGINFO D01OIR AYX-1 Phase 2 T18059 TARGETID T18059 T18059 FORMERID TTDNC00676 T18059 UNIPROID CR2_HUMAN T18059 TARGNAME Complement receptor type 2 (CD21) T18059 GENENAME CR2 T18059 TARGTYPE Clinical trial T18059 SYNONYMS EpsteinBarr virus receptor; Epstein-Barr virus receptor; EBV receptor; Cr2; Complement C3d receptor; C3DR T18059 FUNCTION Participates in B lymphocytes activation. Receptor for complement C3, for the Epstein-Barr virus on human B-cells and T-cells and for HNRNPU. T18059 PDBSTRUC 3OED; 2GSX; 2ATY; 1W2S; 1W2R T18059 SEQUENCE MGAAGLLGVFLALVAPGVLGISCGSPPPILNGRISYYSTPIAVGTVIRYSCSGTFRLIGEKSLLCITKDKVDGTWDKPAPKCEYFNKYSSCPEPIVPGGYKIRGSTPYRHGDSVTFACKTNFSMNGNKSVWCQANNMWGPTRLPTCVSVFPLECPALPMIHNGHHTSENVGSIAPGLSVTYSCESGYLLVGEKIINCLSSGKWSAVPPTCEEARCKSLGRFPNGKVKEPPILRVGVTANFFCDEGYRLQGPPSSRCVIAGQGVAWTKMPVCEEIFCPSPPPILNGRHIGNSLANVSYGSIVTYTCDPDPEEGVNFILIGESTLRCTVDSQKTGTWSGPAPRCELSTSAVQCPHPQILRGRMVSGQKDRYTYNDTVIFACMFGFTLKGSKQIRCNAQGTWEPSAPVCEKECQAPPNILNGQKEDRHMVRFDPGTSIKYSCNPGYVLVGEESIQCTSEGVWTPPVPQCKVAACEATGRQLLTKPQHQFVRPDVNSSCGEGYKLSGSVYQECQGTIPWFMEIRLCKEITCPPPPVIYNGAHTGSSLEDFPYGTTVTYTCNPGPERGVEFSLIGESTIRCTSNDQERGTWSGPAPLCKLSLLAVQCSHVHIANGYKISGKEAPYFYNDTVTFKCYSGFTLKGSSQIRCKADNTWDPEIPVCEKETCQHVRQSLQELPAGSRVELVNTSCQDGYQLTGHAYQMCQDAENGIWFKKIPLCKVIHCHPPPVIVNGKHTGMMAENFLYGNEVSYECDQGFYLLGEKKLQCRSDSKGHGSWSGPSPQCLRSPPVTRCPNPEVKHGYKLNKTHSAYSHNDIVYVDCNPGFIMNGSRVIRCHTDNTWVPGVPTCIKKAFIGCPPPPKTPNGNHTGGNIARFSPGMSILYSCDQGYLLVGEALLLCTHEGTWSQPAPHCKEVNCSSPADMDGIQKGLEPRKMYQYGAVVTLECEDGYMLEGSPQSQCQSDHQWNPPLAVCRSRSLAPVLCGIAAGLILLTFLIVITLYVISKHRARNYYTDTSQKEAFHLEAREVYSVDPYNPAS T18059 DRUGINFO D01XQQ TT-30 Phase 1 T95286 TARGETID T95286 T95286 FORMERID TTDR01066 T95286 UNIPROID MAG_HUMAN T95286 TARGNAME Myelin-associated glycoprotein (MAG) T95286 GENENAME MAG T95286 TARGTYPE Clinical trial T95286 SYNONYMS MAG T95286 FUNCTION Adhesion molecule in postnatal neural development that mediates sialic-acid dependent cell-cell interactions between neuronal and myelinating cells. Preferentially binds to alpha-2,3- linked sialic acid. T95286 BIOCLASS Immunoglobulin T95286 SEQUENCE MIFLTALPLFWIMISASRGGHWGAWMPSSISAFEGTCVSIPCRFDFPDELRPAVVHGVWYFNSPYPKNYPPVVFKSRTQVVHESFQGRSRLLGDLGLRNCTLLLSNVSPELGGKYYFRGDLGGYNQYTFSEHSVLDIVNTPNIVVPPEVVAGTEVEVSCMVPDNCPELRPELSWLGHEGLGEPAVLGRLREDEGTWVQVSLLHFVPTREANGHRLGCQASFPNTTLQFEGYASMDVKYPPVIVEMNSSVEAIEGSHVSLLCGADSNPPPLLTWMRDGTVLREAVAESLLLELEEVTPAEDGVYACLAENAYGQDNRTVGLSVMYAPWKPTVNGTMVAVEGETVSILCSTQSNPDPILTIFKEKQILSTVIYESELQLELPAVSPEDDGEYWCVAENQYGQRATAFNLSVEFAPVLLLESHCAAARDTVQCLCVVKSNPEPSVAFELPSRNVTVNESEREFVYSERSGLVLTSILTLRGQAQAPPRVICTARNLYGAKSLELPFQGAHRLMWAKIGPVGAVVAFAILIAIVCYITQTRRKKNVTESPSFSAGDNPPVLFSSDFRISGAPEKYESERRLGSERRLLGLRGEPPELDLSYSHSDLGKRPTKDSYTLTEELAEYAEIRVK T95286 DRUGINFO D0JP8D GSK249320 Phase 2 T00750 TARGETID T00750 T00750 FORMERID TTDI02074 T00750 UNIPROID FUT3_HUMAN T00750 TARGNAME Galactoside 3(4)-L-fucosyltransferase (FUT3) T00750 GENENAME FUT3 T00750 TARGTYPE Clinical trial T00750 SYNONYMS Lewis FT; Fucosyltransferase III; Fucosyltransferase 3; FucTIII; FUT3; Blood group Lewis alpha4fucosyltransferase T00750 FUNCTION May catalyze alpha-1,3and alpha-1,4 glycosidic linkages involved in the expression of Vim-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination; Lewis-positive(Le(+)) individuals have an active enzyme while Lewis-negative (Le(-)) individuals have an inactive enzyme. Also acts on the corresponding 1,4-galactosyl derivative, forming 1,3-L-fucosyl links. T00750 BIOCLASS Hexosyltransferase T00750 ECNUMBER EC 2.4.1.65 T00750 SEQUENCE MDPLGAAKPQWPWRRCLAALLFQLLVAVCFFSYLRVSRDDATGSPRAPSGSSRQDTTPTRPTLLILLWTWPFHIPVALSRCSEMVPGTADCHITADRKVYPQADTVIVHHWDIMSNPKSRLPPSPRPQGQRWIWFNLEPPPNCQHLEALDRYFNLTMSYRSDSDIFTPYGWLEPWSGQPAHPPLNLSAKTELVAWAVSNWKPDSARVRYYQSLQAHLKVDVYGRSHKPLPKGTMMETLSRYKFYLAFENSLHPDYITEKLWRNALEAWAVPVVLGPSRSNYERFLPPDAFIHVDDFQSPKDLARYLQELDKDHARYLSYFRWRETLRPRSFSWALDFCKACWKLQQESRYQTVRSIAAWFT T00750 DRUGINFO D0I3OS Rebmab-100 Phase 2 T66161 TARGETID T66161 T66161 FORMERID TTDR00385 T66161 UNIPROID FLNA_HUMAN T66161 TARGNAME Filamin A (FLNA) T66161 GENENAME FLNA T66161 TARGTYPE Clinical trial T66161 SYNONYMS Nonmuscle filamin; Non-muscle filamin; Filamin-A; Filamin-1; Filamin 1; FLN1; FLN-A; FLN; Endothelial actin-binding protein; Endothelial actin cytoskeleton; Alpha-filamin; Actin-binding protein 280; ABP-280 T66161 FUNCTION Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking. Involved in ciliogenesis. Plays a role in cell-cell contacts and adherens junctions during the development of blood vessels, heart and brain organs. Plays a role in platelets morphology through interaction with SYK that regulates ITAM- and ITAM-like-containing receptor signaling, resulting in by platelet cytoskeleton organization maintenance. Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. T66161 PDBSTRUC 6EW1; 6D8C; 5XR1; 4P3W; 4M9P T66161 BIOCLASS Dystrophin protein T66161 SEQUENCE MSSSHSRAGQSAAGAAPGGGVDTRDAEMPATEKDLAEDAPWKKIQQNTFTRWCNEHLKCVSKRIANLQTDLSDGLRLIALLEVLSQKKMHRKHNQRPTFRQMQLENVSVALEFLDRESIKLVSIDSKAIVDGNLKLILGLIWTLILHYSISMPMWDEEEDEEAKKQTPKQRLLGWIQNKLPQLPITNFSRDWQSGRALGALVDSCAPGLCPDWDSWDASKPVTNAREAMQQADDWLGIPQVITPEEIVDPNVDEHSVMTYLSQFPKAKLKPGAPLRPKLNPKKARAYGPGIEPTGNMVKKRAEFTVETRSAGQGEVLVYVEDPAGHQEEAKVTANNDKNRTFSVWYVPEVTGTHKVTVLFAGQHIAKSPFEVYVDKSQGDASKVTAQGPGLEPSGNIANKTTYFEIFTAGAGTGEVEVVIQDPMGQKGTVEPQLEARGDSTYRCSYQPTMEGVHTVHVTFAGVPIPRSPYTVTVGQACNPSACRAVGRGLQPKGVRVKETADFKVYTKGAGSGELKVTVKGPKGEERVKQKDLGDGVYGFEYYPMVPGTYIVTITWGGQNIGRSPFEVKVGTECGNQKVRAWGPGLEGGVVGKSADFVVEAIGDDVGTLGFSVEGPSQAKIECDDKGDGSCDVRYWPQEAGEYAVHVLCNSEDIRLSPFMADIRDAPQDFHPDRVKARGPGLEKTGVAVNKPAEFTVDAKHGGKAPLRVQVQDNEGCPVEALVKDNGNGTYSCSYVPRKPVKHTAMVSWGGVSIPNSPFRVNVGAGSHPNKVKVYGPGVAKTGLKAHEPTYFTVDCAEAGQGDVSIGIKCAPGVVGPAEADIDFDIIRNDNDTFTVKYTPRGAGSYTIMVLFADQATPTSPIRVKVEPSHDASKVKAEGPGLSRTGVELGKPTHFTVNAKAAGKGKLDVQFSGLTKGDAVRDVDIIDHHDNTYTVKYTPVQQGPVGVNVTYGGDPIPKSPFSVAVSPSLDLSKIKVSGLGEKVDVGKDQEFTVKSKGAGGQGKVASKIVGPSGAAVPCKVEPGLGADNSVVRFLPREEGPYEVEVTYDGVPVPGSPFPLEAVAPTKPSKVKAFGPGLQGGSAGSPARFTIDTKGAGTGGLGLTVEGPCEAQLECLDNGDGTCSVSYVPTEPGDYNINILFADTHIPGSPFKAHVVPCFDASKVKCSGPGLERATAGEVGQFQVDCSSAGSAELTIEICSEAGLPAEVYIQDHGDGTHTITYIPLCPGAYTVTIKYGGQPVPNFPSKLQVEPAVDTSGVQCYGPGIEGQGVFREATTEFSVDARALTQTGGPHVKARVANPSGNLTETYVQDRGDGMYKVEYTPYEEGLHSVDVTYDGSPVPSSPFQVPVTEGCDPSRVRVHGPGIQSGTTNKPNKFTVETRGAGTGGLGLAVEGPSEAKMSCMDNKDGSCSVEYIPYEAGTYSLNVTYGGHQVPGSPFKVPVHDVTDASKVKCSGPGLSPGMVRANLPQSFQVDTSKAGVAPLQVKVQGPKGLVEPVDVVDNADGTQTVNYVPSREGPYSISVLYGDEEVPRSPFKVKVLPTHDASKVKASGPGLNTTGVPASLPVEFTIDAKDAGEGLLAVQITDPEGKPKKTHIQDNHDGTYTVAYVPDVTGRYTILIKYGGDEIPFSPYRVRAVPTGDASKCTVTVSIGGHGLGAGIGPTIQIGEETVITVDTKAAGKGKVTCTVCTPDGSEVDVDVVENEDGTFDIFYTAPQPGKYVICVRFGGEHVPNSPFQVTALAGDQPSVQPPLRSQQLAPQYTYAQGGQQTWAPERPLVGVNGLDVTSLRPFDLVIPFTIKKGEITGEVRMPSGKVAQPTITDNKDGTVTVRYAPSEAGLHEMDIRYDNMHIPGSPLQFYVDYVNCGHVTAYGPGLTHGVVNKPATFTVNTKDAGEGGLSLAIEGPSKAEISCTDNQDGTCSVSYLPVLPGDYSILVKYNEQHVPGSPFTARVTGDDSMRMSHLKVGSAADIPINISETDLSLLTATVVPPSGREEPCLLKRLRNGHVGISFVPKETGEHLVHVKKNGQHVASSPIPVVISQSEIGDASRVRVSGQGLHEGHTFEPAEFIIDTRDAGYGGLSLSIEGPSKVDINTEDLEDGTCRVTYCPTEPGNYIINIKFADQHVPGSPFSVKVTGEGRVKESITRRRRAPSVANVGSHCDLSLKIPEISIQDMTAQVTSPSGKTHEAEIVEGENHTYCIRFVPAEMGTHTVSVKYKGQHVPGSPFQFTVGPLGEGGAHKVRAGGPGLERAEAGVPAEFSIWTREAGAGGLAIAVEGPSKAEISFEDRKDGSCGVAYVVQEPGDYEVSVKFNEEHIPDSPFVVPVASPSGDARRLTVSSLQESGLKVNQPASFAVSLNGAKGAIDAKVHSPSGALEECYVTEIDQDKYAVRFIPRENGVYLIDVKFNGTHIPGSPFKIRVGEPGHGGDPGLVSAYGAGLEGGVTGNPAEFVVNTSNAGAGALSVTIDGPSKVKMDCQECPEGYRVTYTPMAPGSYLISIKYGGPYHIGGSPFKAKVTGPRLVSNHSLHETSSVFVDSLTKATCAPQHGAPGPGPADASKVVAKGLGLSKAYVGQKSSFTVDCSKAGNNMLLVGVHGPRTPCEEILVKHVGSRLYSVSYLLKDKGEYTLVVKWGDEHIPGSPYRVVVP T66161 DRUGINFO D6ETD2 PTI-125 Phase 2 T66161 DRUGINFO D0X2HJ PTI-125 Phase 1 T72042 TARGETID T72042 T72042 UNIPROID PUR2_HUMAN T72042 TARGNAME GAR transformylase (GART) T72042 GENENAME GART T72042 TARGTYPE Clinical trial T72042 SYNONYMS Phosphoribosylglycinamide formyltransferase; 5'-phosphoribosylglycinamide transformylase; GART T72042 FUNCTION A folate-dependent enzyme, essential for the de novo purine synthesis pathway. T72042 PDBSTRUC 5J9F; 4ZZ3; 4ZZ2; 4ZZ1; 4ZZ0 T72042 ECNUMBER EC 2.1.2.2 T72042 SEQUENCE VAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEE T72042 DRUGINFO D0A8LP AG2034 Phase 1 T72042 DRUGINFO D06YIB DDATHF Investigative T21291 TARGETID T21291 T21291 FORMERID TTDI02017 T21291 UNIPROID AMA1_PLAFF T21291 TARGNAME Plasmodium Apical membrane protein (Malaria AMA-1) T21291 GENENAME Malaria AMA-1 T21291 TARGTYPE Clinical trial T21291 SYNONYMS Merozoite surface antigen; Apical membrane antigen 1; AMA1; AMA-1 T21291 FUNCTION Involved in parasite invasion of erythrocytes. T21291 PDBSTRUC 2Q8B; 2Q8A; 1YXE T21291 BIOCLASS Apicomplexan parasites AMA1 T21291 SEQUENCE MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQKSDVYHPINEHREHPKEYQYPLHQEHTYQQEDSGEDENTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIEEVHGSGIRVDLGEDAEVAGTQYRLPSGKCPVFGKGIIIENSNTTFLTPVATGNQYLKDGGFAFPPTEPLMSPMTLDEMRHFYKDNKYVKNLDELTLCSRHAGNMIPDNDKNSNYKYPAVYDDKDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAKDISFQNYTYLSKNVVDNWEKVCPRKNLQNAKFGLWVDGNCEDIPHVNEFSAIDLFECNKLVFELSASDQPKQYEQHLTDYEKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNTETQKCEIFNVKPTCLINNSSYIATTALSHPIEVEHNFPCSLYKNEIMKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCPCDPEIVSNSTCNFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKPTYDKMKIIIASSAAVAVLATILMVYLYKRKGNAEKYDKMDEPQHYGKSNSRNDEMLDPEASFWGEEKRASHTTPVLMEKPYY T21291 DRUGINFO D02CLV AdCh63 AMA1 Phase 1/2 T21291 DRUGINFO D03KHQ DNA-Ad Phase 1/2 T21291 DRUGINFO D0H9OT PfAMA-1 Phase 1 T87689 TARGETID T87689 T87689 FORMERID TTDI02018 T87689 UNIPROID ANFC_HUMAN T87689 TARGNAME C-type natriuretic peptide (NPPC) T87689 GENENAME NPPC T87689 TARGTYPE Clinical trial T87689 SYNONYMS NPPC; Ctype natriuretic peptide; CNP53 T87689 FUNCTION Hormone which plays a role in endochondral ossification through regulation of cartilaginous growth plate chondrocytes proliferation and differentiation. May also be vasoactive and natriuretic. Specifically binds and stimulates the cGMP production of the NPR2 receptor. Binds the clearance receptor NPR3. T87689 PDBSTRUC 1JDP T87689 BIOCLASS C-type natriuretic peptide T87689 SEQUENCE MHLSQLLACALLLTLLSLRPSEAKPGAPPKVPRTPPAEELAEPQAAGGGQKKGDKAPGGGGANLKGDRSRLLRDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC T88729 TARGETID T88729 T88729 FORMERID TTDR00082 T88729 UNIPROID UCP1_HUMAN T88729 TARGNAME Mitochondrial uncoupling protein 1 (UCP1) T88729 GENENAME UCP1 T88729 TARGTYPE Clinical trial T88729 SYNONYMS UCP 1; UCP; Thermogenin; Solute carrier family 25 member 7; SLC25A7; Mitochondrial brown fat uncoupling protein 1 T88729 FUNCTION Functions as a long-chain fatty acid/LCFA and proton symporter, simultaneously transporting one LCFA and one proton through the inner mitochondrial membrane. However, LCFAs remaining associated with the transporter via their hydrophobic tails, it results in an apparent transport of protons activated by LCFAs. Thereby, dissipates the mitochondrial proton gradient and converts the energy of substrate oxydation into heat instead of ATP. Regulates the production of reactive oxygen species/ROS by mitochondria. Mitochondrial protein responsible for thermogenic respiration, a specialized capacity of brown adipose tissue and beige fat that participates to non-shivering adaptive thermogenesis to temperature and diet variations and more generally to the regulation of energy balance. T88729 BIOCLASS Mitochondrial carrier T88729 SEQUENCE MGGLTASDVHPTLGVQLFSAGIAACLADVITFPLDTAKVRLQVQGECPTSSVIRYKGVLGTITAVVKTEGRMKLYSGLPAGLQRQISSASLRIGLYDTVQEFLTAGKETAPSLGSKILAGLTTGGVAVFIGQPTEVVKVRLQAQSHLHGIKPRYTGTYNAYRIIATTEGLTGLWKGTTPNLMRSVIINCTELVTYDLMKEAFVKNNILADDVPCHLVSALIAGFCATAMSSPVDVVKTRFINSPPGQYKSVPNCAMKVFTNEGPTAFFKGLVPSFLRLGSWNVIMFVCFEQLKRELSKSRQTMDCAT T88729 DRUGINFO D07WHS CL-316,243 Phase 2 T88729 DRUGINFO D02CFE NC-2100 Investigative T04911 TARGETID T04911 T04911 FORMERID TTDI02214 T04911 UNIPROID POLG_HCV1 T04911 TARGNAME Hepatitis C virus Non-structural 4B (HCV NS4B) T04911 GENENAME HCV NS4B T04911 TARGTYPE Clinical trial T04911 SYNONYMS HCV p27 T04911 FUNCTION Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity). T04911 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T04911 BIOCLASS Hepacivirus polyprotein T04911 SEQUENCE SQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQKLETFWAKHMWNFISGIQYLAGLSTLPGNPAIASLMAFTAAVTSPLTTSQTLLFNILGGWVAAQLAAPGAATAFVGAGLAGAAIGSVGLGKVLIDILAGYGAGVAGALVAFKIMSGEVPSTEDLVNLLPAILSPGALVVGVVCAAILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTAILSSLTVTQLLRRLHQWISSECTTPC T04911 DRUGINFO D06XDJ Clemizole Phase 1 T15783 TARGETID T15783 T15783 FORMERID TTDNC00520 T15783 UNIPROID NKG2A_HUMAN T15783 TARGNAME NKG2-A/B-activating NK receptor (NKG2A) T15783 GENENAME KLRC1 T15783 TARGTYPE Clinical trial T15783 SYNONYMS NKG2A/NKG2B type II integral membrane protein; NKG2A/Bactivating NK receptor; NK cell receptor A; KLRC1; CD159a; CD159 antigenlike family member A T15783 FUNCTION Plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. T15783 PDBSTRUC 3CII; 3CDG; 3BDW; 2YU7; 2RMX T15783 SEQUENCE MDNQGVIYSDLNLPPNPKRQQRKPKGNKNSILATEQEITYAELNLQKASQDFQGNDKTYHCKDLPSAPEKLIVGILGIICLILMASVVTIVVIPSTLIQRHNNSSLNTRTQKARHCGHCPEEWITYSNSCYYIGKERRTWEESLLACTSKNSSLLSIDNEEEMKFLSIISPSSWIGVFRNSSHHPWVTMNGLAFKHEIKDSDNAELNCAVLQVNRLKSAQCGSSIIYHCKHKL T15783 DRUGINFO D07YNM NN8765 Phase 2 T15783 DRUGINFO D0RI6Q Monalizumab Phase 1/2 T15783 DRUGINFO D6XS7L BMS-986315 Phase 1/2 T15783 DRUGINFO DNUS02 IM1240 Preclinical T49736 TARGETID T49736 T49736 FORMERID TTDI02302 T49736 UNIPROID CD6_HUMAN T49736 TARGNAME T-cell differentiation antigen CD6 (TP120) T49736 GENENAME CD6 T49736 TARGTYPE Clinical trial T49736 SYNONYMS T12 T49736 FUNCTION Contributes to signaling cascades triggered by activation of the TCR/CD3 complex. Functions as costimulatory molecule; promotes T-cell activation and proliferation. Contributes to the formation and maturation of the immunological synapse. Functions as calcium-dependent pattern receptor that binds and aggregates both Gram-positive and Gram-negative bacteria. Binds both lipopolysaccharide (LPS) from Gram-negative bacteria and lipoteichoic acid from Gram-positive bacteria. LPS binding leads to the activation of signaling cascades and down-stream MAP kinases. Mediates activation of the inflammatory response and the secretion of pro-inflammatory cytokines in response to LPS. Cell adhesion molecule that mediates cell-cell contacts and regulates T-cell responses via its interaction with ALCAM/CD166. T49736 PDBSTRUC 5A2E T49736 SEQUENCE MWLFFGITGLLTAALSGHPSPAPPDQLNTSSAESELWEPGERLPVRLTNGSSSCSGTVEVRLEASWEPACGALWDSRAAEAVCRALGCGGAEAASQLAPPTPELPPPPAAGNTSVAANATLAGAPALLCSGAEWRLCEVVEHACRSDGRRARVTCAENRALRLVDGGGACAGRVEMLEHGEWGSVCDDTWDLEDAHVVCRQLGCGWAVQALPGLHFTPGRGPIHRDQVNCSGAEAYLWDCPGLPGQHYCGHKEDAGAVCSEHQSWRLTGGADRCEGQVEVHFRGVWNTVCDSEWYPSEAKVLCQSLGCGTAVERPKGLPHSLSGRMYYSCNGEELTLSNCSWRFNNSNLCSQSLAARVLCSASRSLHNLSTPEVPASVQTVTIESSVTVKIENKESRELMLLIPSIVLGILLLGSLIFIAFILLRIKGKYALPVMVNHQHLPTTIPAGSNSYQPVPITIPKEVFMLPIQVQAPPPEDSDSGSDSDYEHYDFSAQPPVALTTFYNSQRHRVTDEEVQQSRFQMPPLEEGLEELHASHIPTANPGHCITDPPSLGPQYHPRSNSESSTSSGEDYCNSPKSKLPPWNPQVFSSERSSFLEQPPNLELAGTQPAFSAGPPADDSSSTSSGEWYQNFQPPPQPPSEEQFGCPGSPSPQPDSTDNDDYDDISAA T49736 DRUGINFO D06QSN Itolizumab Phase 3 T54347 TARGETID T54347 T54347 FORMERID TTDI02044 T54347 UNIPROID CHS3_CANAX T54347 TARGNAME Candida Chitin synthase 3 (Candi CHS3) T54347 GENENAME Candi CHS3 T54347 TARGTYPE Clinical trial T54347 SYNONYMS ClassIV chitin synthase3; ChitinUDP acetylglucosaminyl transferase 3; Chitin synthase 3; CHS3 T54347 FUNCTION Formation and repair ofthe disk-shaped septum in yeast and the cross walls of the hyphal phase. T54347 BIOCLASS Hexosyltransferase T54347 ECNUMBER EC 2.4.1.16 T54347 SEQUENCE MSNFRDSSSPRRGYSEFDPESGEGLGRKKSLIRPERSRMDESHPRFHYTQVANQESNHIKVQPSSTGVDPRKSNELSTSRSHLSNYATPPHQEEEEDEGIPLMDIHNASPNVSSDQNNDLKGGREVYGLNDEINDYGSSPKKNQVISSSRPMNNEKPAKPKHDIYFWKVYCYAITFWAPAPLLKLFGLPTKDRQFAWREKIGLISCILYVGAFVAYLTFGFTKTVCSSQVVRTQINHVNGGYLIINGRAYDLTSSQHPKAAGIQAGSNVLYPPMNAGGKDASFLFQNVNGNCKGLIKPRDNCSIPYDGDELAWYMPCRLFNQDGSTKPNNTFAYYKGWACHTSETARDAYYKLKVNGDVYFTWDDVKNSSRNLVVYSGNVLDLDLINWIETDDVTYPELFDKLRDDETYRGLDISLVLTNSEERQAARCLTEIIKVGSIDTDTIGCIASKVVLYMSLVFILSVVVVKFIMACWFKWVTSRKQGATMYDSKAWAKRNREIEDWVDHDHGIGAEVKTVPVKARANYKAAKTNRQSVFHRAQKLSLGPNADLSQYYDNPNALSKTFKYTTMSTQAALLGRNGYGKRGNNANKSVSGGFNGRQSNLYLTDQGSSTDLLNRPVSSYNPFDSMGDDSIVINGLSPDIIHPDVVPQPPVEYQPFGYPLAHTINLVTCYSEDEEGIRITLDSIATTDYPNSHKLILVICDGIIKGSGNDETTPDIVLDMMSDLTVPRDEVEAYSYVAVAQGSKRHNMAKVYAGFYKYNDETVPPEKQQRIPMITIVKCGTPEEASAPKPGNRGKRDSQIILMSFLQKVVFDERMTSLEYEMLQSIWRITGLMAEFYEIVLMVDADTKVFPDSLTHMVAEMVKDPTIMGLCGETKISNKAQTWVTAIQVFEYYISHHQAKAFESIFGGVTCLPGCFCMYRIKAPKGSDGYWVPILANPDIVERYSDNVVDTLHRKNLLLLGEDRYLSSLMLRTFPTRKQVFVPKAACKTVVPDKFKVLLSQRRRWINSTVHNLFELVLVKDLCGTFCFSMQFVIFIELIGTLVLPAAITFTIYVIIVAIVSKPTPVMSLVLLAVIFGLPGCLIVITVSSLSYLVYFVIYLFALPIWNFVLPSYAYWKFDDFSWGETRTVAGGDKGDHSAVEGKFDSSKIAMKRWREWERERRSTENRKQQQQQQLTNNSSNNLAVPGAAWDPSNTGGNLIDDLSQGSSSGSS T54347 DRUGINFO D0SN1T Nikkomycin Z Phase 1/2 T80020 TARGETID T80020 T80020 UNIPROID L1CAM_HUMAN T80020 TARGNAME Neural cell adhesion molecule L1 (L1CAM) T80020 GENENAME L1CAM T80020 TARGTYPE Clinical trial T80020 SYNONYMS SPG1; S10; NCAM-L1; N-CAML1; N-CAM-L1; MIC5; MASA; L1 cell adhesion molecule; HSAS1; HSAS; CD171; CAML1 T80020 FUNCTION During brain development, critical in multiple processes, including neuronal migration, axonal growth and fasciculation, and synaptogenesis. In the mature brain, plays a role in the dynamics of neuronal structure and function, including synaptic plasticity. Neural cell adhesion molecule involved in the dynamics of cell adhesion and in the generation of transmembrane signals at tyrosine kinase receptors. T80020 BIOCLASS Immunoglobulin T80020 SEQUENCE MVVALRYVWPLLLCSPCLLIQIPEEYEGHHVMEPPVITEQSPRRLVVFPTDDISLKCEASGKPEVQFRWTRDGVHFKPKEELGVTVYQSPHSGSFTITGNNSNFAQRFQGIYRCFASNKLGTAMSHEIRLMAEGAPKWPKETVKPVEVEEGESVVLPCNPPPSAEPLRIYWMNSKILHIKQDERVTMGQNGNLYFANVLTSDNHSDYICHAHFPGTRTIIQKEPIDLRVKATNSMIDRKPRLLFPTNSSSHLVALQGQPLVLECIAEGFPTPTIKWLRPSGPMPADRVTYQNHNKTLQLLKVGEEDDGEYRCLAENSLGSARHAYYVTVEAAPYWLHKPQSHLYGPGETARLDCQVQGRPQPEVTWRINGIPVEELAKDQKYRIQRGALILSNVQPSDTMVTQCEARNRHGLLLANAYIYVVQLPAKILTADNQTYMAVQGSTAYLLCKAFGAPVPSVQWLDEDGTTVLQDERFFPYANGTLGIRDLQANDTGRYFCLAANDQNNVTIMANLKVKDATQITQGPRSTIEKKGSRVTFTCQASFDPSLQPSITWRGDGRDLQELGDSDKYFIEDGRLVIHSLDYSDQGNYSCVASTELDVVESRAQLLVVGSPGPVPRLVLSDLHLLTQSQVRVSWSPAEDHNAPIEKYDIEFEDKEMAPEKWYSLGKVPGNQTSTTLKLSPYVHYTFRVTAINKYGPGEPSPVSETVVTPEAAPEKNPVDVKGEGNETTNMVITWKPLRWMDWNAPQVQYRVQWRPQGTRGPWQEQIVSDPFLVVSNTSTFVPYEIKVQAVNSQGKGPEPQVTIGYSGEDYPQAIPELEGIEILNSSAVLVKWRPVDLAQVKGHLRGYNVTYWREGSQRKHSKRHIHKDHVVVPANTTSVILSGLRPYSSYHLEVQAFNGRGSGPASEFTFSTPEGVPGHPEALHLECQSNTSLLLRWQPPLSHNGVLTGYVLSYHPLDEGGKGQLSFNLRDPELRTHNLTDLSPHLRYRFQLQATTKEGPGEAIVREGGTMALSGISDFGNISATAGENYSVVSWVPKEGQCNFRFHILFKALGEEKGGASLSPQYVSYNQSSYTQWDLQPDTDYEIHLFKERMFRHQMAVKTNGTGRVRLPPAGFATEGWFIGFVSAIILLLLVLLILCFIKRSKGGKYSVKDKEDTQVDSEARPMKDETFGEYRSLESDNEEKAFGSSQPSLNGDIKPLGSDDSLADYGGSVDVQFNEDGSFIGQYSGKKEKEAAGGNDSSGATSPINPAVALE T80020 DRUGINFO D05KFH CD171 specific CAR T cells expressing EGFRt Phase 1 T80020 DRUGINFO D0M9TO JCAR023 Phase 1 T95302 TARGETID T95302 T95302 FORMERID TTDI02123 T95302 UNIPROID MC5R_HUMAN T95302 TARGNAME Melanocortin receptor 5 (MC5R) T95302 GENENAME MC5R T95302 TARGTYPE Clinical trial T95302 SYNONYMS MC5-R; MC2; MC-2 T95302 FUNCTION The activity of this receptor is mediated by G proteins which activate adenylate cyclase. This receptor is a possible mediator of the immunomodulation properties of melanocortins. Receptor for MSH (alpha, beta and gamma) and ACTH. T95302 BIOCLASS GPCR rhodopsin T95302 SEQUENCE MNSSFHLHFLDLNLNATEGNLSGPNVKNKSSPCEDMGIAVEVFLTLGVISLLENILVIGAIVKNKNLHSPMYFFVCSLAVADMLVSMSSAWETITIYLLNNKHLVIADAFVRHIDNVFDSMICISVVASMCSLLAIAVDRYVTIFYALRYHHIMTARRSGAIIAGIWAFCTGCGIVFILYSESTYVILCLISMFFAMLFLLVSLYIHMFLLARTHVKRIAALPGASSARQRTSMQGAVTVTMLLGVFTVCWAPFFLHLTLMLSCPQNLYCSRFMSHFNMYLILIMCNSVMDPLIYAFRSQEMRKTFKEIICCRGFRIACSFPRRD T95302 DRUGINFO D08ZCC MTC-896 Phase 2 T95302 DRUGINFO D0O6NA JNJ-10229570 Phase 2 T95302 DRUGINFO D0YB7F MT-II Investigative T75788 TARGETID T75788 T75788 FORMERID TTDI01940 T75788 UNIPROID COIA1_HUMAN T75788 TARGNAME Endostatin (COL18A1) T75788 GENENAME COL18A1 T75788 TARGTYPE Clinical trial T75788 SYNONYMS Collagen alpha1(XVIII) chain; Collagen alpha-1(XVIII) chain T75788 FUNCTION Probably plays a major role in determining the retinal structure as well as in the closure of the neural tube. T75788 PDBSTRUC 3HSH; 3HON; 1BNL T75788 SEQUENCE MAPYPCGCHILLLLFCCLAAARANLLNLNWLWFNNEDTSHAATTIPEPQGPLPVQPTADTTTHVTPRNGSTEPATAPGSPEPPSELLEDGQDTPTSAESPDAPEENIAGVGAEILNVAKGIRSFVQLWNDTVPTESLARAETLVLETPVGPLALAGPSSTPQENGTTLWPSRGIPSSPGAHTTEAGTLPAPTPSPPSLGRPWAPLTGPSVPPPSSGRASLSSLLGGAPPWGSLQDPDSQGLSPAAAAPSQQLQRPDVRLRTPLLHPLVMGSLGKHAAPSAFSSGLPGALSQVAVTTLTRDSGAWVSHVANSVGPGLANNSALLGADPEAPAGRCLPLPPSLPVCGHLGISRFWLPNHLHHESGEQVRAGARAWGGLLQTHCHPFLAWFFCLLLVPPCGSVPPPAPPPCCQFCEALQDACWSRLGGGRLPVACASLPTQEDGYCVLIGPAAERISEEVGLLQLLGDPPPQQVTQTDDPDVGLAYVFGPDANSGQVARYHFPSLFFRDFSLLFHIRPATEGPGVLFAITDSAQAMVLLGVKLSGVQDGHQDISLLYTEPGAGQTHTAASFRLPAFVGQWTHLALSVAGGFVALYVDCEEFQRMPLARSSRGLELEPGAGLFVAQAGGADPDKFQGVIAELKVRRDPQVSPMHCLDEEGDDSDGASGDSGSGLGDARELLREETGAALKPRLPAPPPVTTPPLAGGSSTEDSRSEEVEEQTTVASLGAQTLPGSDSVSTWDGSVRTPGGRVKEGGLKGQKGEPGVPGPPGRAGPPGSPCLPGPPGLPCPVSPLGPAGPALQTVPGPQGPPGPPGRDGTPGRDGEPGDPGEDGKPGDTGPQGFPGTPGDVGPKGDKGDPGVGERGPPGPQGPPGPPGPSFRHDKLTFIDMEGSGFGGDLEALRGPRGFPGPPGPPGVPGLPGEPGRFGVNSSDVPGPAGLPGVPGREGPPGFPGLPGPPGPPGREGPPGRTGQKGSLGEAGAPGHKGSKGAPGPAGARGESGLAGAPGPAGPPGPPGPPGPPGPGLPAGFDDMEGSGGPFWSTARSADGPQGPPGLPGLKGDPGVPGLPGAKGEVGADGVPGFPGLPGREGIAGPQGPKGDRGSRGEKGDPGKDGVGQPGLPGPPGPPGPVVYVSEQDGSVLSVPGPEGRPGFAGFPGPAGPKGNLGSKGERGSPGPKGEKGEPGSIFSPDGGALGPAQKGAKGEPGFRGPPGPYGRPGYKGEIGFPGRPGRPGMNGLKGEKGEPGDASLGFGMRGMPGPPGPPGPPGPPGTPVYDSNVFAESSRPGPPGLPGNQGPPGPKGAKGEVGPPGPPGQFPFDFLQLEAEMKGEKGDRGDAGQKGERGEPGGGGFFGSSLPGPPGPPGPPGPRGYPGIPGPKGESIRGQPGPPGPQGPPGIGYEGRQGPPGPPGPPGPPSFPGPHRQTISVPGPPGPPGPPGPPGTMGASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRGTDNEVAALQPPVVQLHDSNPYPRREHPHPTARPWRADDILASPPRLPEPQPYPGAPHHSSYVHLRPARPTSPPAHSHRDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIVRRADRAAVPIVNLKDELLFPSWEALFSGSEGPLKPGARIFSFDGKDVLRHPTWPQKSVWHGSDPNGRRLTESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFMTASK T75788 DRUGINFO D0RD0Y RetinoStat Phase 2 T75788 DRUGINFO D0O6ZH Endo-CD Investigative T81695 TARGETID T81695 T81695 FORMERID TTDI02143 T81695 UNIPROID OX2G_HUMAN T81695 TARGNAME Membrane glycoprotein OX2 (CD200) T81695 GENENAME CD200 T81695 TARGTYPE Clinical trial T81695 SYNONYMS OX2 membrane glycoprotein; OX-2 membrane glycoprotein; My033; MOX2; MOX1 T81695 FUNCTION May regulate myeloid cell activity in a variety of tissues. Costimulates T-cell proliferation. T81695 BIOCLASS Immunoglobulin T81695 SEQUENCE MERLVIRMPFSHLSTYSLVWVMAAVVLCTAQVQVVTQDEREQLYTPASLKCSLQNAQEALIVTWQKKKAVSPENMVTFSENHGVVIQPAYKDKINITQLGLQNSTITFWNITLEDEGCYMCLFNTFGFGKISGTACLTVYVQPIVSLHYKFSEDHLNITCSATARPAPMVFWKVPRSGIENSTVTLSHPNGTTSVTSILHIKDPKNQVGKEVICQVLHLGTVTDFKQTVNKGYWFSVPLLLSIVSLVILLVLISILLYWKRHRNQDRGELSQGVQKMT T81695 DRUGINFO D0OY9L ALXN6000 Phase 2 T83585 TARGETID T83585 T83585 FORMERID TTDI02221 T83585 UNIPROID WASP_HUMAN T83585 TARGNAME Wiskott-Aldrich syndrome protein (WAS) T83585 GENENAME WAS T83585 TARGTYPE Clinical trial T83585 SYNONYMS WASp; IMD2 T83585 FUNCTION Important for efficient actin polymerization. Possible regulator of lymphocyte and platelet function. Mediates actin filament reorganization and the formation of actin pedestals upon infection by pathogenic bacteria. In addition to its role in the cytoplasmic cytoskeleton, also promotes actin polymerization in the nucleus, thereby regulating gene transcription and repair of damaged DNA. Promotes homologous recombination (HR) repair in response to DNA damage by promoting nuclear actin polymerization, leading to drive motility of double-strand breaks (DSBs). Effector protein for Rho-type GTPases that regulates actin filament reorganization via its interaction with the Arp2/3 complex. T83585 PDBSTRUC 2OT0; 2K42; 2A3Z; 1T84; 1EJ5 T83585 SEQUENCE MSGGPMGGRPGGRGAPAVQQNIPSTLLQDHENQRLFEMLGRKCLTLATAVVQLYLALPPGAEHWTKEHCGAVCFVKDNPQKSYFIRLYGLQAGRLLWEQELYSQLVYSTPTPFFHTFAGDDCQAGLNFADEDEAQAFRALVQEKIQKRNQRQSGDRRQLPPPPTPANEERRGGLPPLPLHPGGDQGGPPVGPLSLGLATVDIQNPDITSSRYRGLPAPGPSPADKKRSGKKKISKADIGAPSGFKHVSHVGWDPQNGFDVNNLDPDLRSLFSRAGISEAQLTDAETSKLIYDFIEDQGGLEAVRQEMRRQEPLPPPPPPSRGGNQLPRPPIVGGNKGRSGPLPPVPLGIAPPPPTPRGPPPPGRGGPPPPPPPATGRSGPLPPPPPGAGGPPMPPPPPPPPPPPSSGNGPAPPPLPPALVPAGGLAPGGGRGALLDQIRQGIQLNKTPGAPESSALQPPPQSSEGLVGALMHVMQKRSRAIHSSDEGEDQAGDEDEDDEWDD T83585 DRUGINFO DY2WH5 OTL-103 Phase 3 T83585 DRUGINFO D01QQC Hematopoietic stem cell gene therapy Phase 1/2 T83585 DRUGINFO D0V4VQ WASP gene therapy Phase 1/2 T51693 TARGETID T51693 T51693 FORMERID TTDR00750 T51693 UNIPROID MAGA3_HUMAN T51693 TARGNAME Melanoma-associated antigen 3 (MAGEA3) T51693 GENENAME MAGEA3 T51693 TARGTYPE Clinical trial T51693 SYNONYMS Melanoma associated antigen-A3; Melanoma antigen 3; MAGE3; MAGE-A3 antigen; MAGE-A3; MAGE-3 antigen; Cancer/testis antigen 1.3; CT1.3; Antigen MZ2-D T51693 FUNCTION May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. T51693 PDBSTRUC 5BRZ; 4V0P; 1QEW T51693 BIOCLASS Melanoma associated antigen T51693 SEQUENCE MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASSLPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAELVHFLLLKYRAREPVTKAEMLGSVVGNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLYIFATCLGLSYDGLLGDNQIMPKAGLLIIVLAIIAREGDCAPEEKIWEELSVLEVFEGREDSILGDPKKLLTQHFVQENYLEYRQVPGSDPACYEFLWGPRALVETSYVKVLHHMVKISGGPHISYPPLHEWVLREGEE T51693 DRUGINFO D02XYA Astuprotimut-R Phase 3 T51693 DRUGINFO D08DUF GL-0817 Phase 2 T51693 DRUGINFO D03QMY IDM-2101 Phase 2 T51693 DRUGINFO D00DSV Polynoma-1 Phase 2 T51693 DRUGINFO DN46RL KITE-718 Phase 1 T51693 DRUGINFO D0C1EO Melanoma vaccine (ALVAC) Discontinued in Phase 2 T12097 TARGETID T12097 T12097 FORMERID TTDR00773 T12097 UNIPROID MAGA4_HUMAN T12097 TARGNAME Melanoma-associated antigen 4 (MAGEA4) T12097 GENENAME MAGEA4 T12097 TARGTYPE Clinical trial T12097 SYNONYMS MAGE4; MAGE-X2 antigen; MAGE-X2; MAGE-41 antigen; MAGE-41; MAGE-4 protein; MAGE-4 antigen; Cancer/testis antigen 1.4; CT1.4 T12097 FUNCTION Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression. T12097 PDBSTRUC 2WA0; 1I4F T12097 BIOCLASS Melanoma associated antigen T12097 SEQUENCE MSSEQKSQHCKPEEGVEAQEEALGLVGAQAPTTEEQEAAVSSSSPLVPGTLEEVPAAESAGPPQSPQGASALPTTISFTCWRQPNEGSSSQEEEGPSTSPDAESLFREALSNKVDELAHFLLRKYRAKELVTKAEMLERVIKNYKRCFPVIFGKASESLKMIFGIDVKEVDPASNTYTLVTCLGLSYDGLLGNNQIFPKTGLLIIVLGTIAMEGDSASEEEIWEELGVMGVYDGREHTVYGEPRKLLTQDWVQENYLEYRQVPGSNPARYEFLWGPRALAETSYVKVLEHVVRVNARVRIAYPSLREAALLEEEEGV T12097 DRUGINFO D2YT5I ADP-A2M4 Phase 2 T12097 DRUGINFO DFY5L8 Afamitresgene autoleucel Phase 2 T12097 DRUGINFO D0XZ2S CAR-T cells targeting MAGE-A4 Phase 1/2 T77515 TARGETID T77515 T77515 UNIPROID KI2S2_HUMAN T77515 TARGNAME MHC class I NK cell receptor 2DS2 (CD158j) T77515 GENENAME KIR2DS2 T77515 TARGTYPE Clinical trial T77515 SYNONYMS p58 natural killer cell receptor clone CL-49; p58 NK receptor CL-49; Natural killer-associated transcript 5; NKAT5; NKAT-5; NK receptor 183 ActI; MHC class I NK cell receptor; Killer cell immunoglobulin-like receptor 2DS2; CD158J; CD158 antigen-like family member J T77515 FUNCTION Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells. T77515 PDBSTRUC 4N8V; 1M4K T77515 BIOCLASS Immunoglobulin T77515 SEQUENCE MSLMVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVRFEHFLLHREGKYKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHERRFSAGPKVNGTFQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVTGNPSNSWPSPTEPSSKTGNPRHLHVLIGTSVVKIPFTILLFFLLHRWCSNKKNAAVMDQEPAGNRTVNSEDSDEQDHQEVSYA T77515 DRUGINFO D04IXD IPH-2101 Phase 2 T92281 TARGETID T92281 T92281 FORMERID TTDI02139 T92281 UNIPROID NPTX2_HUMAN T92281 TARGNAME Neuronal pentraxin-2 (NPTX2) T92281 GENENAME NPTX2 T92281 TARGTYPE Clinical trial T92281 SYNONYMS Neuronal pentraxin II; NPTX2; NPII; NP2 T92281 FUNCTION Likely to play role in the modification of cellular properties that underlie long-term plasticity. Binds to agar matrix in a calcium-dependent manner. T92281 BIOCLASS Pentaxin family T92281 SEQUENCE MLALLAASVALAVAAGAQDSPAPGSRFVCTALPPEAVHAGCPLPAMPMQGGAQSPEEELRAAVLQLRETVVQQKETLGAQREAIRELTGKLARCEGLAGGKARGAGATGKDTMGDLPRDPGHVVEQLSRSLQTLKDRLESLEHQLRANVSNAGLPGDFREVLQQRLGELERQLLRKVAELEDEKSLLHNETSAHRQKTESTLNALLQRVTELERGNSAFKSPDAFKVSLPLRTNYLYGKIKKTLPELYAFTICLWLRSSASPGIGTPFSYAVPGQANEIVLIEWGNNPIELLINDKVAQLPLFVSDGKWHHICVTWTTRDGMWEAFQDGEKLGTGENLAPWHPIKPGGVLILGQEQDTVGGRFDATQAFVGELSQFNIWDRVLRAQEIVNIANCSTNMPGNIIPWVDNNVDVFGGASKWPVETCEERLLDL T92281 DRUGINFO D09EDA PRM-151 Phase 2 T81386 TARGETID T81386 T81386 FORMERID TTDI02000 T81386 UNIPROID CDK9_HUMAN-CCNT1_HUMAN T81386 TARGNAME Positive transcription elongation factor b (P-TEFb) T81386 GENENAME CDK9-CCNT1 T81386 TARGTYPE Clinical trial T81386 SYNONYMS P-TEFb T81386 FUNCTION The elongin BC complex seems to be involved as an adapter protein in the proteasomal degradation of target proteins via different E3 ubiquitin ligase complexes, including the von Hippel-Lindau ubiquitination complex CBC(VHL). By binding to BC- box motifs it seems to link target recruitment subunits, like VHL and members of the SOCS box family, to Cullin/RBX1 modules that activate E2 ubiquitination enzymes. T81386 BIOCLASS S-phase kinase-associated protein T81386 SEQUENCE MEGERKNNNKRWYFTREQLENSPSRRFGVDPDKELSYRQQAANLLQDMGQRLNVSQLTINTAIVYMHRFYMIQSFTQFPGNSVAPAALFLAAKVEEQPKKLEHVIKVAHTCLHPQESLPDTRSEAYLQQVQDLVILESIILQTLGFELTIDHPHTHVVKCTQLVRASKDLAQTSYFMATNSLHLTTFSLQYTPPVVACVCIHLACKWSNWEIPVSTDGKHWWEYVDATVTLELLDELTHEFLQILEKTPNRLKRIWNWRACEAAKKTKADDRGTDEKTSEQTILNMISQSSSDTTIAGLMSMSTSTTSAVPSLPVSEESSSNLTSVEMLPGKRWLSSQPSFKLEPTQGHRTSENLALTGVDHSLPQDGSNAFISQKQNSKSVPSAKVSLKEYRAKHAEELAAQKRQLENMEANVKSQYAYAAQNLLSHHDSHSSVILKMPIEGSENPERPFLEKADKTALKMRIPVAGGDKAASSKPEEIKMRIKVHAAADKHNSVEDSVTKSREHKEKHKTHPSNHHHHHNHHSHKHSHSQLPVGTGNKRPGDPKHSSQTSNLAHKTYSLSSSFSSSSSTRKRGPSEETGGAVFDHPAKIAKSTKSSSLNFSFPSLPTMGQMPGHSSDTSGLSFSQPSCKTRVPHSKLDKGPTGANGHNTTQTIDYQDTVNMLHSLLSAQGVQPTQPTAFEFVRPYSDYLNPRSGGISSRSGNTDKPRPPPLPSEPPPPLPPLPKMAKQYDSVECPFCDEVSKYEKLAKIGQGTFGEVFKARHRKTGQKVALKKVLMENEKEGFPITALREIKILQLLKHENVVNLIEICRTKASPYNRCKGSIYLVFDFCEHDLAGLLSNVLVKFTLSEIKRVMQMLLNGLYYIHRNKILHRDMKAANVLITRDGVLKLADFGLARAFSLAKNSQPNRYTNRVVTLWYRPPELLLGERDYGPPIDLWGAGCIMAEMWTRSPIMQGNTEQHQLALISQLCGSITPEVWPNVDNYELYEKLELVKGQKRKVKDRLKAYVRDPYALDLIDKLLVLDPAQRIDSDDALNHDFFWSDPMPSDLKGMLSTHLTSMFEYLAPPRRKGSQITQQSTNQSRNPATTNQTEFERVF T81386 DRUGINFO D06HMN BAY1251152 Phase 1 T81386 DRUGINFO D06PSU BAY1143572 Phase 1 T25307 TARGETID T25307 T25307 FORMERID TTDI03508 T25307 UNIPROID RORG_HUMAN T25307 TARGNAME Nuclear receptor ROR-gamma (RORG) T25307 GENENAME RORC T25307 TARGTYPE Clinical trial T25307 SYNONYMS Retinoid-related orphan receptor-gamma; RZRG; RORG; RAR-related orphan receptor C; Nuclear receptor subfamily 1 group F member 3; Nuclear receptor RZR-gamma; NR1F3 T25307 FUNCTION Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of cellular differentiation, immunity, peripheral circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism. Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively. Recruits distinct combinations of cofactors to target gene regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates the circadian expression of clock genes such as CRY1, ARNTL/BMAL1 and NR1D1 in peripheral tissues and in a tissue-selective manner. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as ARNTL/BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORC-mediated activation of the expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock. Involved in the regulation of the rhythmic expression of genes involved in glucose and lipid metabolism, including PLIN2 and AVPR1A. Negative regulator of adipocyte differentiation through the regulation of early phase genes expression, such as MMP3. Controls adipogenesis as well as adipocyte size and modulates insulin sensitivity in obesity. In liver, has specific and redundant functions with RORA as positive or negative modulator of expression of genes encoding phase I and Phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as SULT1E1. Also plays also a role in the regulation of hepatocyte glucose metabolism through the regulation of G6PC and PCK1. Regulates the rhythmic expression of PROX1 and promotes its nuclear localization. Plays an indispensable role in the induction of IFN-gamma dependent anti-mycobacterial systemic immunity. T25307 PDBSTRUC 6O98; 6NAD; 6J1L; 6IVX; 6G07 T25307 BIOCLASS Nuclear hormone receptor T25307 SEQUENCE MDRAPQRQHRASRELLAAKKTHTSQIEVIPCKICGDKSSGIHYGVITCEGCKGFFRRSQRCNAAYSCTRQQNCPIDRTSRNRCQHCRLQKCLALGMSRDAVKFGRMSKKQRDSLHAEVQKQLQQRQQQQQEPVVKTPPAGAQGADTLTYTLGLPDGQLPLGSSPDLPEASACPPGLLKASGSGPSYSNNLAKAGLNGASCHLEYSPERGKAEGRESFYSTGSQLTPDRCGLRFEEHRHPGLGELGQGPDSYGSPSFRSTPEAPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFSTETESPVGLSK T25307 DRUGINFO D0BF4Z GSK2981278 Phase 2 T25307 DRUGINFO D0T7YE LYC-55716 Phase 2 T25307 DRUGINFO D0VB4X VTP-43742 Phase 2 T25307 DRUGINFO D0X1ST ESR0114 Phase 1/2 T25307 DRUGINFO D00BLS AZD0284 Phase 1 T25307 DRUGINFO D0A0ZW ARN-6039 Phase 1 T25307 DRUGINFO D0D7CH TAK-828 Phase 1 T25307 DRUGINFO D0FY4J BBI-6000 Phase 1 T25307 DRUGINFO D0K9YJ JNJ-3534 Phase 1 T25307 DRUGINFO D0W2RI JTE-451 Phase 1 T25307 DRUGINFO D92KUQ ARN-6039 Phase 1 T25307 DRUGINFO D4PG6A Nobiletin Preclinical T25307 DRUGINFO D8VH5Q ML209 Preclinical T25307 DRUGINFO DE7BZ4 SR2211 Preclinical T25307 DRUGINFO DW5R6Y SR1555 Preclinical T25307 DRUGINFO D9D6QN SR1078 Preclinical T25307 DRUGINFO D06OVX 25-hydroxycholesterol Investigative T25726 TARGETID T25726 T25726 FORMERID TTDI02084 T25726 UNIPROID GPC3_HUMAN T25726 TARGNAME Glypican-3 (GPC3) T25726 GENENAME GPC3 T25726 TARGTYPE Clinical trial T25726 SYNONYMS Secreted glypican3; OCI5; MXR7; Intestinal protein OCI5; Intestinal protein OCI-5; GTR22; GTR2-2 T25726 FUNCTION Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins. Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation. Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands. Positively regulates the non-canonical Wnt signaling pathway. Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression. Inhibits the dipeptidyl peptidase activity of DPP4. Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4. Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis. Required for coronary vascular development. Plays a role in regulating cell movements during gastrulation. Cell surface proteoglycan that bears heparan sulfate. T25726 SEQUENCE MAGTVRTACLVVAMLLSLDFPGQAQPPPPPPDATCHQVRSFFQRLQPGLKWVPETPVPGSDLQVCLPKGPTCCSRKMEEKYQLTARLNMEQLLQSASMELKFLIIQNAAVFQEAFEIVVRHAKNYTNAMFKNNYPSLTPQAFEFVGEFFTDVSLYILGSDINVDDMVNELFDSLFPVIYTQLMNPGLPDSALDINECLRGARRDLKVFGNFPKLIMTQVSKSLQVTRIFLQALNLGIEVINTTDHLKFSKDCGRMLTRMWYCSYCQGLMMVKPCGGYCNVVMQGCMAGVVEIDKYWREYILSLEELVNGMYRIYDMENVLLGLFSTIHDSIQYVQKNAGKLTTTIGKLCAHSQQRQYRSAYYPEDLFIDKKVLKVAHVEHEETLSSRRRELIQKLKSFISFYSALPGYICSHSPVAENDTLCWNGQELVERYSQKAARNGMKNQFNLHELKMKGPEPVVSQIIDKLKHINQLLRTMSMPKGRVLDKNLDEEGFESGDCGDDEDECIGGSGDGMIKVKNQLRFLAELAYDLDVDDAPGNSQQATPKDNEISTFHNLGNVHSPLKLLTSMAISVVCFFFLVH T25726 DRUGINFO D02ONR RG7686 Phase 2 T25726 DRUGINFO D05HZJ GPC-3298306 Phase 2 T25726 DRUGINFO D0P0BY Codrituzumab Phase 2 T25726 DRUGINFO D17HKT GC33 Phase 2 T25726 DRUGINFO DF6Z3C SAR444200 Phase 2 T25726 DRUGINFO D04CKC GPC3-CART cells Phase 1/2 T25726 DRUGINFO D0FY5E TAI-GPC3-CART cells Phase 1/2 T25726 DRUGINFO D0J2IN CAR-T cells targeting GPC3 Phase 1/2 T25726 DRUGINFO D0N0OV Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs Phase 1/2 T25726 DRUGINFO D0WN2Y CAR-T cells targeting Glypican-3 (GPC3) Phase 1/2 T25726 DRUGINFO D08UNC GPC3 targeting CAR-T cells Phase 1 T25726 DRUGINFO D0GD9E GAP T cells Phase 1 T25726 DRUGINFO D0H4UP CAR-GPC3 T Cells Phase 1 T25726 DRUGINFO D0IK5R ERY974 Phase 1 T25726 DRUGINFO D0IQ4V Anti-GPC3 CAR T Phase 1 T25726 DRUGINFO D0MA2E GLYCAR T cells Phase 1 T25726 DRUGINFO D2MZF8 TAK-102 Phase 1 T25726 DRUGINFO D09RPP CAR-GPC3 T cell Clinical trial T25726 DRUGINFO D0P1BM CAR-GPC3 T cells Clinical trial T16888 TARGETID T16888 T16888 FORMERID TTDI02036 T16888 UNIPROID CCL11_HUMAN T16888 TARGNAME Small-inducible cytokine A11 (CCL11) T16888 GENENAME CCL11 T16888 TARGTYPE Clinical trial T16888 SYNONYMS Smallinducible cytokine A11; SCYA11; Eotaxin; Eosinophil chemotactic protein; CC motif chemokine 11; C-C motif chemokine 11 T16888 FUNCTION Binds to CCR3. In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions. T16888 PDBSTRUC 2MPM; 2EOT; 1EOT T16888 BIOCLASS Cytokine: CC chemokine T16888 SEQUENCE MKVSAALLWLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP T16888 DRUGINFO D0V9LY Bertilimumab Phase 2 T76396 TARGETID T76396 T76396 FORMERID TTDR00229 T76396 UNIPROID PGTB1_HUMAN T76396 TARGNAME Geranylgeranyl transferase I (GGTase-I) T76396 GENENAME PGGT1B T76396 TARGTYPE Clinical trial T76396 SYNONYMS Type I protein geranyl-geranyltransferase subunit beta; Type I protein geranyl-geranyltransferase beta subunit of Saccharomyces cerevisiae; RAS proteins geranylgeranyltransferase beta subunit; PGGT; Geranylgeranyl transferase type-1 subunit beta; Geranylgeranyl transferase type I subunit beta; GGTase-I-beta of Saccharomyces cerevisiae; GGTase-I-beta; CDC43 T76396 FUNCTION Catalyzes the transfer of a geranyl-geranyl moiety from geranyl-geranyl pyrophosphate to a cysteine at the fourth position from the C-terminus of proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. Known substrates include RAC1, RAC2, RAP1A and RAP1B. T76396 BIOCLASS Alkyl aryl transferase T76396 ECNUMBER EC 2.5.1.59 T76396 SEQUENCE MAATEDERLAGSGEGERLDFLRDRHVRFFQRCLQVLPERYSSLETSRLTIAFFALSGLDMLDSLDVVNKDDIIEWIYSLQVLPTEDRSNLNRCGFRGSSYLGIPFNPSKAPGTAHPYDSGHIAMTYTGLSCLVILGDDLSRVNKEACLAGLRALQLEDGSFCAVPEGSENDMRFVYCASCICYMLNNWSGMDMKKAITYIRRSMSYDNGLAQGAGLESHGGSTFCGIASLCLMGKLEEVFSEKELNRIKRWCIMRQQNGYHGRPNKPVDTCYSFWVGATLKLLKIFQYTNFEKNRNYILSTQDRLVGGFAKWPDSHPDALHAYFGICGLSLMEESGICKVHPALNVSTRTSERLLDLHQSWKTKDSKQCSENVHIST T76396 DRUGINFO D0Q5VW L-778123 Phase 1 T76396 DRUGINFO D0D0WF GGTI-298 Terminated T76396 DRUGINFO D03OLA L-745631 Terminated T76396 DRUGINFO D0DD8I J-109,390 Investigative T76396 DRUGINFO D0Q5WB L-269,289 Investigative T76396 DRUGINFO D0T2SJ A-313326 Investigative T76396 DRUGINFO D06DSE PD-83176 Investigative T84560 TARGETID T84560 T84560 FORMERID TTDR00083 T84560 UNIPROID UCP2_HUMAN T84560 TARGNAME Mitochondrial uncoupling protein 2 (UCP2) T84560 GENENAME UCP2 T84560 TARGTYPE Clinical trial T84560 SYNONYMS UCPH; UCP 2; Solute carrier family 25 member 8; SLC25A8 T84560 FUNCTION UCP are mitochondrial transporter proteins that create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation from ATP synthesis. As a result, energy is dissipated in the form of heat. T84560 BIOCLASS Mitochondrial carrier T84560 SEQUENCE MVGFKATDVPPTATVKFLGAGTAACIADLITFPLDTAKVRLQIQGESQGPVRATASAQYRGVMGTILTMVRTEGPRSLYNGLVAGLQRQMSFASVRIGLYDSVKQFYTKGSEHASIGSRLLAGSTTGALAVAVAQPTDVVKVRFQAQARAGGGRRYQSTVNAYKTIAREEGFRGLWKGTSPNVARNAIVNCAELVTYDLIKDALLKANLMTDDLPCHFTSAFGAGFCTTVIASPVDVVKTRYMNSALGQYSSAGHCALTMLQKEGPRAFYKGFMPSFLRLGSWNVVMFVTYEQLKRALMAACTSREAPF T84560 DRUGINFO D07WHS CL-316,243 Phase 2 T84560 DRUGINFO D02CFE NC-2100 Investigative T69146 TARGETID T69146 T69146 FORMERID TTDR00084 T69146 UNIPROID UCP3_HUMAN T69146 TARGNAME Mitochondrial uncoupling protein 3 (UCP3) T69146 GENENAME UCP3 T69146 TARGTYPE Clinical trial T69146 SYNONYMS UCP 3; Solute carrier family 25 member 9; SLC25A9 T69146 FUNCTION UCP are mitochondrial transporter proteins that create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation. As a result, energy is dissipated in the form of heat. May play a role in the modulation of tissue respiratory control. Participates in thermogenesis and energy balance. T69146 BIOCLASS Mitochondrial carrier T69146 SEQUENCE MVGLKPSDVPPTMAVKFLGAGTAACFADLVTFPLDTAKVRLQIQGENQAVQTARLVQYRGVLGTILTMVRTEGPCSPYNGLVAGLQRQMSFASIRIGLYDSVKQVYTPKGADNSSLTTRILAGCTTGAMAVTCAQPTDVVKVRFQASIHLGPSRSDRKYSGTMDAYRTIAREEGVRGLWKGTLPNIMRNAIVNCAEVVTYDILKEKLLDYHLLTDNFPCHFVSAFGAGFCATVVASPVDVVKTRYMNSPPGQYFSPLDCMIKMVAQEGPTAFYKGFTPSFLRLGSWNVVMFVTYEQLKRALMKVQMLRESPF T69146 DRUGINFO D07WHS CL-316,243 Phase 2 T31818 TARGETID T31818 T31818 FORMERID TTDNC00372 T31818 UNIPROID ITA1_HUMAN T31818 TARGNAME Integrin alpha-1 (VLA-1) T31818 GENENAME ITGA1 T31818 TARGTYPE Clinical trial T31818 SYNONYMS Laminin and collagen receptor; Integrin alpha1; ITGA1; CD49a; CD49 antigenlike family member A T31818 FUNCTION Integrin alpha-1/beta-1 is a receptor for laminin and collagen. It recognizes the proline-hydroxylated sequence G-F-P-G- E-R in collagen. Involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth. T31818 PDBSTRUC 5HGJ; 4A0Q; 2M32; 2L8S; 1QCY T31818 BIOCLASS Integrin T31818 SEQUENCE MAPRPRARPGVAVACCWLLTVVLRCCVSFNVDVKNSMTFSGPVEDMFGYTVQQYENEEGKWVLIGSPLVGQPKNRTGDVYKCPVGRGESLPCVKLDLPVNTSIPNVTEVKENMTFGSTLVTNPNGGFLACGPLYAYRCGHLHYTTGICSDVSPTFQVVNSIAPVQECSTQLDIVIVLDGSNSIYPWDSVTAFLNDLLERMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEVLVAAKKIVQRGGRQTMTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNHRLKKVIQDCEDENIQRFSIAILGSYNRGNLSTEKFVEEIKSIASEPTEKHFFNVSDELALVTIVKTLGERIFALEATADQSAASFEMEMSQTGFSAHYSQDWVMLGAVGAYDWNGTVVMQKASQIIIPRNTTFNVESTKKNEPLASYLGYTVNSATASSGDVLYIAGQPRYNHTGQVIIYRMEDGNIKILQTLSGEQIGSYFGSILTTTDIDKDSNTDILLVGAPMYMGTEKEEQGKVYVYALNQTRFEYQMSLEPIKQTCCSSRQHNSCTTENKNEPCGARFGTAIAAVKDLNLDGFNDIVIGAPLEDDHGGAVYIYHGSGKTIRKEYAQRIPSGGDGKTLKFFGQSIHGEMDLNGDGLTDVTIGGLGGAALFWSRDVAVVKVTMNFEPNKVNIQKKNCHMEGKETVCINATVCFDVKLKSKEDTIYEADLQYRVTLDSLRQISRSFFSGTQERKVQRNITVRKSECTKHSFYMLDKHDFQDSVRITLDFNLTDPENGPVLDDSLPNSVHEYIPFAKDCGNKEKCISDLSLHVATTEKDLLIVRSQNDKFNVSLTVKNTKDSAYNTRTIVHYSPNLVFSGIEAIQKDSCESNHNITCKVGYPFLRRGEMVTFKILFQFNTSYLMENVTIYLSATSDSEEPPETLSDNVVNISIPVKYEVGLQFYSSASEYHISIAANETVPEVINSTEDIGNEINIFYLIRKSGSFPMPELKLSISFPNMTSNGYPVLYPTGLSSSENANCRPHIFEDPFSINSGKKMTTSTDHLKRGTILDCNTCKFATITCNLTSSDISQVNVSLILWKPTFIKSYFSSLNLTIRGELRSENASLVLSSSNQKRELAIQISKDGLPGRVPLWVILLSAFAGLLLLMLLILALWKIGFFKRPLKKKMEK T31818 DRUGINFO D0B5VA SAN-300 Phase 2 T65883 TARGETID T65883 T65883 FORMERID TTDI02045 T65883 UNIPROID CLD18_HUMAN T65883 TARGNAME Claudin-18 (CLDN18) T65883 GENENAME CLDN18 T65883 TARGTYPE Clinical trial T65883 SYNONYMS UNQ778/PRO1572; Claudin18 T65883 FUNCTION Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. T65883 SEQUENCE MSTTTCQVVAFLLSILGLAGCIAATGMDMWSTQDLYDNPVTSVFQYEGLWRSCVRQSSGFTECRPYFTILGLPAMLQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGLCAIAGVSVFANMLVTNFWMSTANMYTGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKIYDGGARTEDEVQSYPSKHDYV T65883 DRUGINFO D0B3ZC Claudiximab Phase 3 T65883 DRUGINFO D4HQ1F Zolbetuximab Phase 3 T65883 DRUGINFO D5R8YF RC118 Phase 1/2 T65883 DRUGINFO DJ6AW5 CT-041 Phase 1/2 T65883 DRUGINFO D56AJO SKB315 Phase 1 T65883 DRUGINFO DYCI37 TST001 Phase 1 T65883 DRUGINFO DEDP81 AMG 910 Phase 1 T65883 DRUGINFO DTQL30 ASP2138 Phase 1 T65883 DRUGINFO D06CWZ CAR-CLD18 T cell Clinical trial T65883 DRUGINFO D5E1QZ BNT212 Preclinical T04894 TARGETID T04894 T04894 FORMERID TTDI00043 T04894 UNIPROID CCL20_HUMAN T04894 TARGNAME Liver and activation-regulated chemokine (CCL20) T04894 GENENAME CCL20 T04894 TARGTYPE Clinical trial T04894 SYNONYMS Smallinducible cytokine A20; Small-inducible cytokine A20; SCYA20; Macrophage inflammatory protein 3 alpha; MIP3alpha; MIP3A; MIP-3-alpha; Liver and activationregulated chemokine; LARC; CCL20(270); CC motif chemokine 20; CC chemokine LARC; C-C motif chemokine 20; Betachemokine exodus1; Beta-chemokine exodus-1 T04894 FUNCTION Signals through binding and activation of CCR6 and induces a strong chemotactic response and mobilization of intracellular calcium ions. The ligand-receptor pair CCL20-CCR6 is responsible for the chemotaxis of dendritic cells (DC), effector/memory T-cells and B-cells and plays an important role at skin and mucosal surfaces under homeostatic and inflammatory conditions, as well as in pathology, including cancer and various autoimmune diseases. CCL20 acts as a chemotactic factor that attracts lymphocytes and, slightly, neutrophils, but not monocytes. Involved in the recruitment of both the proinflammatory IL17 producing helper T-cells (Th17) and the regulatory T-cells (Treg) to sites of inflammation. Required for optimal migration of thymic natural regulatory T cells (nTregs) and DN1 early thymocyte progenitor cells. C-terminal processed forms have been shown to be equally chemotactically active for leukocytes. Positively regulates sperm motility and chemotaxis via its binding to CCR6 which triggers Ca2+ mobilization in the sperm which is important for its motility. Inhibits proliferation of myeloid progenitors in colony formation assays. May be involved in formation and function of the mucosal lymphoid tissues by attracting lymphocytes and dendritic cells towards epithelial cells. Possesses antibacterial activity towards E. coli ATCC 25922 and S. aureus ATCC 29213. Acts as a ligand for C-C chemokine receptor CCR6. T04894 PDBSTRUC 5UR7; 2JYO; 2HCI; 1M8A T04894 BIOCLASS Cytokine: CC chemokine T04894 SEQUENCE MCCTKSLLLAALMSVLLLHLCGESEAASNFDCCLGYTDRILHPKFIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM T04894 DRUGINFO D0T3VF GSK3050002 Phase 1 T07247 TARGETID T07247 T07247 FORMERID TTDR00803 T07247 UNIPROID S10AC_HUMAN T07247 TARGNAME Calgranulin D (S100A12) T07247 GENENAME S100A12 T07247 TARGTYPE Clinical trial T07247 SYNONYMS S100 calcium-binding protein A12; Protein S100-A12; P6; Neutrophil S100 protein; Migration inhibitory factor-related protein 6; MRP-6; Extracellular newly identified RAGE-binding protein; EN-RAGE; Calgranulin-C; Calcium-binding protein in amniotic fluid 1; CGRP; CAGC; CAAF1 T07247 FUNCTION Its proinflammatory activity involves recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to receptor for advanced glycation endproducts (AGER). Binding to AGER activates the MAP-kinase and NF-kappa-B signaling pathways leading to production of proinflammatory cytokines and up-regulation of cell adhesion molecules ICAM1 and VCAM1. Acts as a monocyte and mast cell chemoattractant. Can stimulate mast cell degranulation and activation which generates chemokines, histamine and cytokines inducing further leukocyte recruitment to the sites of inflammation. Can inhibit the activity of matrix metalloproteinases; MMP2, MMP3 and MMP9 by chelating Zn(2+) from their active sites. Possesses filariacidal and filariastatic activity. Calcitermin possesses antifungal activity against C. albicans and is also active against E. coli and P. aeruginosa but not L. monocytogenes and S. aureus. S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. T07247 PDBSTRUC 2WCF; 2WCE; 2WCB; 2WC8; 2M9G T07247 BIOCLASS S100 calcium-binding protein T07247 SEQUENCE MTKLEEHLEGIVNIFHQYSVRKGHFDTLSKGELKQLLTKELANTIKNIKDKAVIDEIFQGLDANQDEQVDFQEFISLVAIALKAAHYHTHKE T27826 TARGETID T27826 T27826 FORMERID TTDI02181 T27826 UNIPROID SPTB2_HUMAN T27826 TARGNAME Spectrin non-erythroid beta chain 1 (SPTBN1) T27826 GENENAME SPTBN1 T27826 TARGTYPE Clinical trial T27826 SYNONYMS Spectrin, non-erythroid beta chain 1; Spectrin beta chain, non-erythrocytic 1; SPTB2; Fodrin beta chain; Beta-II spectrin T27826 FUNCTION Fodrin, which seems to be involved in secretion, interacts with calmodulin in a calcium-dependent manner and is thus candidate for the calcium-dependent movement of the cytoskeleton at the membrane. T27826 PDBSTRUC 3EDV; 1BKR; 1AA2 T27826 SEQUENCE MTTTVATDYDNIEIQQQYSDVNNRWDVDDWDNENSSARLFERSRIKALADEREAVQKKTFTKWVNSHLARVSCRITDLYTDLRDGRMLIKLLEVLSGERLPKPTKGRMRIHCLENVDKALQFLKEQRVHLENMGSHDIVDGNHRLTLGLIWTIILRFQIQDISVETEDNKEKKSAKDALLLWCQMKTAGYPNVNIHNFTTSWRDGMAFNALIHKHRPDLIDFDKLKKSNAHYNLQNAFNLAEQHLGLTKLLDPEDISVDHPDEKSIITYVVTYYHYFSKMKALAVEGKRIGKVLDNAIETEKMIEKYESLASDLLEWIEQTIIILNNRKFANSLVGVQQQLQAFNTYRTVEKPPKFTEKGNLEVLLFTIQSKMRANNQKVYMPREGKLISDINKAWERLEKAEHERELALRNELIRQEKLEQLARRFDRKAAMRETWLSENQRLVSQDNFGFDLPAVEAATKKHEAIETDIAAYEERVQAVVAVARELEAENYHDIKRITARKDNVIRLWEYLLELLRARRQRLEMNLGLQKIFQEMLYIMDWMDEMKVLVLSQDYGKHLLGVEDLLQKHTLVEADIGIQAERVRGVNASAQKFATDGEGYKPCDPQVIRDRVAHMEFCYQELCQLAAERRARLEESRRLWKFFWEMAEEEGWIREKEKILSSDDYGKDLTSVMRLLSKHRAFEDEMSGRSGHFEQAIKEGEDMIAEEHFGSEKIRERIIYIREQWANLEQLSAIRKKRLEEASLLHQFQADADDIDAWMLDILKIVSSSDVGHDEYSTQSLVKKHKDVAEEIANYRPTLDTLHEQASALPQEHAESPDVRGRLSGIEERYKEVAELTRLRKQALQDTLALYKMFSEADACELWIDEKEQWLNNMQIPEKLEDLEVIQHRFESLEPEMNNQASRVAVVNQIARQLMHSGHPSEKEIKAQQDKLNTRWSQFRELVDRKKDALLSALSIQNYHLECNETKSWIREKTKVIESTQDLGNDLAGVMALQRKLTGMERDLVAIEAKLSDLQKEAEKLESEHPDQAQAILSRLAEISDVWEEMKTTLKNREASLGEASKLQQFLRDLDDFQSWLSRTQTAIASEDMPNTLTEAEKLLTQHENIKNEIDNYEEDYQKMRDMGEMVTQGQTDAQYMFLRQRLQALDTGWNELHKMWENRQNLLSQSHAYQQFLRDTKQAEAFLNNQEYVLAHTEMPTTLEGAEAAIKKQEDFMTTMDANEEKINAVVETGRRLVSDGNINSDRIQEKVDSIDDRHRKNRETASELLMRLKDNRDLQKFLQDCQELSLWINEKMLTAQDMSYDEARNLHSKWLKHQAFMAELASNKEWLDKIEKEGMQLISEKPETEAVVKEKLTGLHKMWEVLESTTQTKAQRLFDANKAELFTQSCADLDKWLHGLESQIQSDDYGKDLTSVNILLKKQQMLENQMEVRKKEIEELQSQAQALSQEGKSTDEVDSKRLTVQTKFMELLEPLNERKHNLLASKEIHQFNRDVEDEILWVGERMPLATSTDHGHNLQTVQLLIKKNQTLQKEIQGHQPRIDDIFERSQNIVTDSSSLSAEAIRQRLADLKQLWGLLIEETEKRHRRLEEAHRAQQYYFDAAEAEAWMSEQELYMMSEEKAKDEQSAVSMLKKHQILEQAVEDYAETVHQLSKTSRALVADSHPESERISMRQSKVDKLYAGLKDLAEERRGKLDERHRLFQLNREVDDLEQWIAEREVVAGSHELGQDYEHVTMLQERFREFARDTGNIGQERVDTVNHLADELINSGHSDAATIAEWKDGLNEAWADLLELIDTRTQILAASYELHKFYHDAKEIFGRIQDKHKKLPEELGRDQNTVETLQRMHTTFEHDIQALGTQVRQLQEDAARLQAAYAGDKADDIQKRENEVLEAWKSLLDACESRRVRLVDTGDKFRFFSMVRDLMLWMEDVIRQIEAQEKPRDVSSVELLMNNHQGIKAEIDARNDSFTTCIELGKSLLARKHYASEEIKEKLLQLTEKRKEMIDKWEDRWEWLRLILEVHQFSRDASVAEAWLLGQEPYLSSREIGQSVDEVEKLIKRHEAFEKSAATWDERFSALERLTTLELLEVRRQQEEEERKRRPPSPEPSTKVSEEAESQQQWDTSKGEQVSQNGLPAEQGSPRMAETVDTSEMVNGATEQRTSSKESSPIPSPTSDRKAKTALPAQSAATLPARTQETPSAQMEGFLNRKHEWEAHNKKASSRSWHNVYCVINNQEMGFYKDAKTAASGIPYHSEVPVSLKEAVCEVALDYKKKKHVFKLRLNDGNEYLFQAKDDEEMNTWIQAISSAISSDKHEVSASTQSTPASSRAQTLPTSVVTITSESSPGKREKDKEKDKEKRFSLFGKKK T27826 DRUGINFO D01QKZ ABT-413 Phase 1 T57059 TARGETID T57059 T57059 FORMERID TTDNC00411 T57059 UNIPROID E2F1_HUMAN T57059 TARGNAME E2F transcription factor 1 (E2F1) T57059 GENENAME E2F1 T57059 TARGTYPE Clinical trial T57059 SYNONYMS pRB-binding protein E2F-1; Transcription factor E2F1; Retinoblastoma-binding protein 3; Retinoblastoma-associated protein 1; RBBP3; RBBP-3; RBAP-1; PBR3; E2F-1 T57059 FUNCTION The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F1 binds preferentially RB1 in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis. Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters. Positively regulates transcription of RRP1B. Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. T57059 PDBSTRUC 6G0P; 5M9O; 5M9N; 2AZE; 1O9K T57059 SEQUENCE MALAGAPAGGPCAPALEALLGAGALRLLDSSQIVIISAAQDASAPPAPTGPAAPAAGPCDPDLLLFATPQAPRPTPSAPRPALGRPPVKRRLDLETDHQYLAESSGPARGRGRHPGKGVKSPGEKSRYETSLNLTTKRFLELLSHSADGVVDLNWAAEVLKVQKRRIYDITNVLEGIQLIAKKSKNHIQWLGSHTTVGVGGRLEGLTQDLRQLQESEQQLDHLMNICTTQLRLLSEDTDSQRLAYVTCQDLRSIADPAEQMVMVIKAPPETQLQAVDSSENFQISLKSKQGPIDVFLCPEETVGGISPGKTPSQEVTSEEENRATDSATIVSPPPSSPPSSLTTDPSQSLLSLEQEPLLSRMGSLRAPVDEDRLSPLVAADSLLEHVREDFSGLLPEEFISLSPPHEALDYHFGLEEGEGIRDLFDCDFGDLTPLDF T57059 DRUGINFO D00SIA ARQ-171 Phase 1 T30356 TARGETID T30356 T30356 FORMERID TTDI01992 T30356 UNIPROID RHD_HUMAN T30356 TARGNAME Blood group Rh(D) polypeptide (RHD) T30356 GENENAME RHD T30356 TARGTYPE Clinical trial T30356 SYNONYMS Rhesus D antigen; RhPII; Rh polypeptide 2; RHXIII; RHD; CD240D T30356 FUNCTION May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane. T30356 BIOCLASS Ammonia transporter channel T30356 SEQUENCE MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF T30356 DRUGINFO D01ADL Roledumab Phase 2/3 T30356 DRUGINFO D06UPS Rozrolimupab Discontinued in Phase 2 T65198 TARGETID T65198 T65198 FORMERID TTDR00668 T65198 UNIPROID NRG1_HUMAN T65198 TARGNAME Pro-neuregulin-1 (Pro-NRG1) T65198 GENENAME NRG1 T65198 TARGTYPE Clinical trial T65198 SYNONYMS SMDF (20-241); Pro-neuregulin-1, membrane-bound isoform (20-241); NDF (20-241); Heregulin (20-241); HRGA (20-241); HGL (20-241); GGF (20-241) T65198 FUNCTION Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. The multiple isoforms perform diverse functions such as inducing growth and differentiation of epithelial, glial, neuronal, and skeletal muscle cells; inducing expression of acetylcholine receptor in synaptic vesicles during the formation of the neuromuscular junction; stimulating lobuloalveolar budding and milk production in the mammary gland and inducing differentiation of mammary tumor cells; stimulating Schwann cell proliferation; implication in the development of the myocardium such as trabeculation of the developing heart. Isoform 10 may play a role in motor and sensory neuron development. Binds to ERBB4. Binds to ERBB3. Acts as a ligand for integrins and binds (via EGF domain) to integrins ITGAV:ITGB3 or ITGA6:ITGB4. Its binding to integrins and subsequent ternary complex formation with integrins and ERRB3 are essential for NRG1-ERBB signaling. Induces the phosphorylation and activation of MAPK3/ERK1, MAPK1/ERK2 and AKT1. Ligand-dependent ERBB4 endocytosis is essential for the NRG1-mediated activation of these kinases in neurons. Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors. T65198 PDBSTRUC 3U7U; 1HRF; 1HRE; 1HAF; 1HAE T65198 SEQUENCE MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFKNGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTEGAYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCQPGFTGARCTENVPMKVQNQEKAEELYQKRVLTITGICIALLVVGIMCVVAYCKTKKQRKKLHDRLRQSLRSERNNMMNIANGPHHPNPPPENVQLVNQYVSKNVISSEHIVEREAETSFSTSHYTSTAHHSTTVTQTPSHSWSNGHTESILSESHSVIVMSSVENSRHSSPTGGPRGRLNGTGGPRECNSFLRHARETPDSYRDSPHSERYVSAMTTPARMSPVDFHTPSSPKSPPSEMSPPVSSMTVSMPSMAVSPFMEEERPLLLVTPPRLREKKFDHHPQQFSSFHHNPAHDSNSLPASPLRIVEDEEYETTQEYEPAQEPVKKLANSRRAKRTKPNGHIANRLEVDSNTSSQSSNSESETEDERVGEDTPFLGIQNPLAASLEATPAFRLADSRTNPAGRFSTQEEIQARLSSVIANQDPIAV T65198 DRUGINFO D00ZPR Neucardin Phase 3 T65198 DRUGINFO D08WNO GGF Phase 1b T65198 DRUGINFO D0H0YZ GGF-2 Phase 1 T92030 TARGETID T92030 T92030 FORMERID TTDNC00443 T92030 UNIPROID REG3A_HUMAN T92030 TARGNAME Regenerating human pro-islet peptide (REG3A) T92030 GENENAME REG3A T92030 TARGTYPE Clinical trial T92030 SYNONYMS Regenerating islet-derived protein III-alpha; Regenerating islet-derived protein 3-alpha 15 kDa form; Regenerating islet-derived protein 3-alpha; Reg III-alpha; REG3A; REG-3-alpha; Pancreatitis-associated protein 1; Human proislet peptide; Hepatointestinal pancreatic protein; HIP/PAP T92030 FUNCTION Bactericidal C-type lectin which acts exclusively against Gram-positive bacteria and mediates bacterial killing by binding to surface-exposed carbohydrate moieties of peptidoglycan. Regulates keratinocyte proliferation and differentiation after skin injury via activation of EXTL3-PI3K-AKT signaling pathway. T92030 PDBSTRUC 4MTH; 2GO0; 1UV0 T92030 SEQUENCE MLPPMALPSVSWMLLSCLMLLSQVQGEEPQRELPSARIRCPKGSKAYGSHCYALFLSPKSWTDADLACQKRPSGNLVSVLSGAEGSFVSSLVKSIGNSYSYVWIGLHDPTQGTEPNGEGWEWSSSDVMNYFAWERNPSTISSPGHCASLSRSTAFLRWKDYNCNVRLPYVCKFTD T92030 DRUGINFO D01FBS ALF-5755 Phase 2 T92030 DRUGINFO D0ZF8F HIP-2B Phase 1 T97766 TARGETID T97766 T97766 FORMERID TTDI02423 T97766 UNIPROID CD47_HUMAN T97766 TARGNAME Leukocyte surface antigen CD47 (CD47) T97766 GENENAME CD47 T97766 TARGTYPE Clinical trial T97766 SYNONYMS Protein MER6; MER6; Integrinassociated protein; Integrin-associated protein; IAP; Antigenic surface determinant protein OA3 T97766 FUNCTION Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection. Has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. T97766 PDBSTRUC 5TZU; 5TZT; 5TZ2; 5IWL; 4KJY T97766 BIOCLASS Osteoclast fusion complex T97766 SEQUENCE MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMMNDE T97766 DRUGINFO D09JYL Hu5F9-G4 Phase 3 T97766 DRUGINFO DRP8H0 Evorpacept Phase 2/3 T97766 DRUGINFO D6SJ0B PF-07901801 Phase 2 T97766 DRUGINFO D0J7UL ALX148 Phase 1/2 T97766 DRUGINFO D1WB6Z DSP-107 Phase 1/2 T97766 DRUGINFO DA4W1I AO-176 Phase 1/2 T97766 DRUGINFO D01CUO TTI-621 Phase 1 T97766 DRUGINFO D5FCP1 TTI-622 Phase 1 T97766 DRUGINFO D5V2HR IBI188 Phase 1 T97766 DRUGINFO DEUC70 TJC4 Phase 1 T97766 DRUGINFO DI8WC4 CC-90002 Phase 1 T97766 DRUGINFO DTHR46 IMC-002 Phase 1 T97766 DRUGINFO DY7D9A ZL-1201 Phase 1 T97766 DRUGINFO D1A7OP PF-07257876 Phase 1 T97766 DRUGINFO D8UNG2 TG-1801 Phase 1 T97766 DRUGINFO DKUF26 SL-172154 Phase 1 T88322 TARGETID T88322 T88322 FORMERID TTDI02183 T88322 UNIPROID SSRP1_HUMAN T88322 TARGNAME Facilitates chromatin transcription complex (FACT) T88322 GENENAME SSRP1 T88322 TARGTYPE Clinical trial T88322 SYNONYMS hSSRP1; T160; Structure-specific recognition protein 1; Recombination signal sequence recognition protein 1; Facilitates chromatin transcription complex subunit SSRP1; Facilitates chromatin transcription complex 80 kDa subunit; FACTp80; FACT80; FACT complex subunit SSRP1; FACT 80 kDa subunit; Chromatin-specific transcription elongation factor 80 kDa subunit T88322 FUNCTION The FACT complex is involved in multiple processes that require DNA as a template such as mRNA elongation, DNA replication and DNA repair. During transcription elongation the FACT complex acts as a histone chaperone that both destabilizes and restores nucleosomal structure. It facilitates the passage of RNA polymerase II and transcription by promoting the dissociation of one histone H2A-H2B dimer from the nucleosome, then subsequently promotes the reestablishment of the nucleosome following the passage of RNA polymerase II. The FACT complex is probably also involved in phosphorylation of 'Ser-392' of p53/TP53 via its association with CK2 (casein kinase II). Binds specifically to double-stranded DNA and at low levels to DNA modified by the antitumor agent cisplatin. May potentiate cisplatin-induced cell death by blocking replication and repair of modified DNA. Also acts as a transcriptional coactivator for p63/TP63. Component of the FACT complex, a general chromatin factor that acts to reorganize nucleosomes. T88322 PDBSTRUC 5VWE; 5UMS; 5UMR; 4IFS T88322 SEQUENCE MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLNMNEEEVEKRFEGRLTKNMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE T88322 DRUGINFO D0C8ES CBL0102 Phase 1/2 T88322 DRUGINFO D0Z0XM CBL0137 Phase 1 T68517 TARGETID T68517 T68517 FORMERID TTDNR00685 T68517 UNIPROID HSPB3_HUMAN T68517 TARGNAME Heat shock protein 27 (HSP27) T68517 GENENAME HSPB3 T68517 TARGTYPE Clinical trial T68517 SYNONYMS Protein 3; HspB3; Heat shock protein beta3; Heat shock 17 kDa protein; HSP 17 T68517 FUNCTION Inhibitor of actin polymerization. T68517 PDBSTRUC 6F2R T68517 BIOCLASS Heat shock protein T68517 SEQUENCE MAKIILRHLIEIPVRYQEEFEARGLEDCRLDHALYALPGPTIVDLRKTRAAQSPPVDSAAETPPREGKSHFQILLDVVQFLPEDIIIQTFEGWLLIKAQHGTRMDEHGFISRSFTRQYKLPDGVEIKDLSAVLCHDGILVVEVKDPVGTK T68517 DRUGINFO D0AX1N OGX-427 Phase 2 T68517 DRUGINFO D0I3EI NK-1001 Discontinued in Phase 2 T25739 TARGETID T25739 T25739 FORMERID TTDI02168 T25739 UNIPROID S39A6_HUMAN T25739 TARGNAME Solute carrier family 39 member 6 (SLC39A6) T25739 GENENAME SLC39A6 T25739 TARGTYPE Clinical trial T25739 SYNONYMS Zrt- and Irt-like protein 6; ZIP-6; SLC39A6; Estrogen-regulated protein LIV-1 T25739 FUNCTION May act as a zinc-influx transporter. T25739 SEQUENCE MARKLSVILILTFALSVTNPLHELKAAAFPQTTEKISPNWESGINVDLAISTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIHHDHDHHSDHEHHSDHERHSDHEHHSEHEHHSDHDHHSHHNHAASGKNKRKALCPDHDSDSSGKDPRNSQGKGAHRPEHASGRRNVKDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTSKSRVSRLAGRKTNESVSEPRKGFMYSRNTNENPQECFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHTSEKKAEIPPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALAVGTLSGDAFLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDVEIKKQLSKYESQLSTNEEKVDTDDRTEGYLRADSQEPSHFDSQQPAVLEEEEVMIAHAHPQEVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQRYSREELKDAGVATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHYAENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGMLLGFGIMLLISIFEHKIVFRINF T25739 DRUGINFO DS6B1L SGN-LIV1A Phase 2 T25739 DRUGINFO D06JBV SGN LIV1A Phase 1 T09058 TARGETID T09058 T09058 FORMERID TTDR00714 T09058 UNIPROID TPBG_HUMAN T09058 TARGNAME Oncotrophoblast glycoprotein 5T4 (TPBG) T09058 GENENAME TPBG T09058 TARGTYPE Clinical trial T09058 SYNONYMS Trophoblast glycoprotein; TPBG T09058 FUNCTION May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a- dependent LRP6 internalization. T09058 PDBSTRUC 4CNM; 4CNC T09058 SEQUENCE MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSPTSSASSFSSSAPFLASAVSAQPPLPDQCPALCECSEAARTVKCVNRNLTEVPTDLPAYVRNLFLTGNQLAVLPAGAFARRPPLAELAALNLSGSRLDEVRAGAFEHLPSLRQLDLSHNPLADLSPFAFSGSNASVSAPSPLVELILNHIVPPEDERQNRSFEGMVVAALLAGRALQGLRRLELASNHFLYLPRDVLAQLPSLRHLDLSNNSLVSLTYVSFRNLTHLESLHLEDNALKVLHNGTLAELQGLPHIRVFLDNNPWVCDCHMADMVTWLKETEVVQGKDRLTCAYPEKMRNRVLLELNSADLDCDPILPPSLQTSYVFLGIVLALIGAIFLLVLYLNRKGIKKWMHNIRDACRDHMEGYHYRYEINADPRLTNLSSNSDV T09058 DRUGINFO D0L1OT TroVax Phase 3 T09058 DRUGINFO D0T8HR Naptumomab estafenatox Phase 2/3 T09058 DRUGINFO D02DVK CV-9201 Phase 1/2 T09058 DRUGINFO D03JZC PF-06263507 Phase 1 T09058 DRUGINFO DQ15HJ GEN1044 Phase 1 T09058 DRUGINFO DNUS02 IM1240 Preclinical T09058 DRUGINFO D0W5NP Anatumomab mafenatox Terminated T21865 TARGETID T21865 T21865 FORMERID TTDR01112 T21865 UNIPROID SELPL_HUMAN T21865 TARGNAME P-selectin glycoprotein ligand 1 (SELPLG) T21865 GENENAME SELPLG T21865 TARGTYPE Clinical trial T21865 SYNONYMS Selectin P ligand; SPSGL-1; SELPLG; PSGL-1; P-selectin glycoprotein ligand-1; CD162 antigen T21865 FUNCTION A SLe(x)-type proteoglycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. Critical for the initial leukocyte capture. T21865 PDBSTRUC 1G1S T21865 SEQUENCE MPLQLLLLLILLGPGNSLQLWDTWADEAEKALGPLLARDRRQATEYEYLDYDFLPETEPPEMLRNSTDTTPLTGPGTPESTTVEPAARRSTGLDAGGAVTELTTELANMGNLSTDSAAMEIQTTQPAATEAQTTQPVPTEAQTTPLAATEAQTTRLTATEAQTTPLAATEAQTTPPAATEAQTTQPTGLEAQTTAPAAMEAQTTAPAAMEAQTTPPAAMEAQTTQTTAMEAQTTAPEATEAQTTQPTATEAQTTPLAAMEALSTEPSATEALSMEPTTKRGLFIPFSVSSVTHKGIPMAASNLSVNYPVGAPDHISVKQCLLAILILALVATIFFVCTVVLAVRLSRKGHMYPVRNYSPTEMVCISSLLPDGGEGPSATANGGLSKAKSPGLTPEPREDREGDDLTLHSFLP T21865 DRUGINFO D02YIP AbGn-168 Phase 2 T21865 DRUGINFO D0I6IQ Neihulizumab Phase 2 T21865 DRUGINFO D0M7VE RO-4905417 Phase 2 T21865 DRUGINFO DFTV08 SelK2 Phase 2 T61518 TARGETID T61518 T61518 UNIPROID MELK_HUMAN T61518 TARGNAME Tyrosine-protein kinase MELK (MELK) T61518 GENENAME MELK T61518 TARGTYPE Clinical trial T61518 SYNONYMS pEg3 kinase; hPK38; hMELK; MELK T61518 FUNCTION Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. Has a broad substrate specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 andZNF622. Acts as an activator of apoptosis by phosphorylating and activating MAP3K5/ASK1. Acts as a regulator of cell cycle, notably by mediating phosphorylation of CDC25B, promoting localization of CDC25B to the centrosome and the spindle poles during mitosis. Plays a key role in cell proliferation and carcinogenesis. Required for proliferation of embryonic and postnatal multipotent neural progenitors. Phosphorylates and inhibits BCL2L14, possibly leading to affect mammary carcinogenesis by mediating inhibition of the pro-apoptotic function of BCL2L14. Also involved in the inhibition of spliceosome assembly during mitosis by phosphorylating ZNF622, thereby contributing to its redirection to the nucleus. May also play a role in primitive hematopoiesis. {ECO:0000269|PubMed:11802789, ECO:0000269|PubMed:12400006, ECO:0000269|PubMed:14699119, ECO:0000269|PubMed:15908796, ECO:0000269|PubMed:16216881, ECO:0000269|PubMed:17280616}. T61518 PDBSTRUC 5TX3; 5TWZ; 5TWY; 5TWU; 5TWL T61518 ECNUMBER EC 2.7.11.1 T61518 SEQUENCE MKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGQASATPFTDIKSNNWSLEDVTASDKNYVAGLIDYDWCEDDLSTGAATPRTSQFTKYWTESNGVESKSLTPALCRTPANKLKNKENVYTPKSAVKNEEYFMFPEPKTPVNKNQHKREILTTPNRYTTPSKARNQCLKETPIKIPVNSTGTDKLMTGVISPERRCRSVELDLNQAHMEETPKRKGAKVFGSLERGLDKVITVLTRSKRKGSARDGPRRLKLHYNVTTTRLVNPDQLLNEIMSILPKKHVDFVQKGYTLKCQTQSDFGKVTMQFELEVCQLQKPDVVGIRRQRLKGDAWVYKRLVEDILSSCKV T61518 DRUGINFO D08FIX OTSSP167 Phase 1 T93995 TARGETID T93995 T93995 UNIPROID NEDD8_HUMAN T93995 TARGNAME Ubiquitin-like protein Nedd8 (NEDD8) T93995 GENENAME NEDD8 T93995 TARGTYPE Clinical trial T93995 SYNONYMS Neural precursor cell expressed developmentally down-regulated protein 8; Neddylin; NEDD-8 T93995 FUNCTION Ubiquitin-like protein which plays an important role in cell cycle control and embryogenesis. Covalent attachment to its substrates requires prior activation by the E1 complex UBE1C-APPBP1 and linkage to the E2 enzyme UBE2M. Attachment of NEDD8 to cullins activates their associated E3 ubiquitin ligase activity, and thus promotes polyubiquitination and proteasomal degradation of cyclins and other regulatory proteins. T93995 PDBSTRUC 4P5O; 4HCP; 4FBJ; 4F8C; 3GZN T93995 BIOCLASS Ubiquitin family T93995 SEQUENCE MLIKVKTLTGKEIEIDIEPTDKVERIKERVEEKEGIPPQQQRLIYSGKQMNDEKTAADYKILGGSVLHLVLALRGGGGLRQ T93995 DRUGINFO D0ZD2M MLN4924 Phase 3 T75256 TARGETID T75256 T75256 FORMERID TTDI02120 T75256 UNIPROID MAR1_HUMAN T75256 TARGNAME MART-1 melanoma antigen (MLANA) T75256 GENENAME MLANA T75256 TARGTYPE Clinical trial T75256 SYNONYMS Protein MelanA; Melanoma antigen recognized by Tcells 1; MLANA; MART1; Antigen SK29AA; Antigen LB39AA T75256 FUNCTION Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes. T75256 PDBSTRUC 6DKP; 6D78; 5NQK; 5NHT; 5E9D T75256 SEQUENCE MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYRALMDKSLHVGTQCALTRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLSAEQSPPPYSP T75256 DRUGINFO D0P5TG Multi-epitope peptide melanoma vaccine Phase 3 T75256 DRUGINFO D0U9MJ Melanoma vaccine Phase 3 T75256 DRUGINFO D0J7MQ MKC-1106-MT Phase 2 T75256 DRUGINFO D00DSV Polynoma-1 Phase 2 T75256 DRUGINFO D0C1EO Melanoma vaccine (ALVAC) Discontinued in Phase 2 T75256 DRUGINFO D07CQJ F-50040 Discontinued in Phase 1 T99532 TARGETID T99532 T99532 FORMERID TTDI02010 T99532 UNIPROID 2B1A_HUMAN T99532 TARGNAME HLA class II antigen DR10 (HLA-DRB1) T99532 GENENAME HLA-DRB1 T99532 TARGTYPE Clinical trial T99532 SYNONYMS MHC class II antigen DRB1*10; HLADRB1; HLA class II histocompatibility antigen, DRB110 beta chain; DRw10 T99532 FUNCTION Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete withthose derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading. T99532 BIOCLASS MHC class II T99532 SEQUENCE MVCLKLPGGSCMTALTVTLMVLSSPLALSGDTRPRFLWQPKRECHFFNGTERVRFLDRYFYNQEESVRFDSDVGEFRAVTELGRPDAEYWNSQKDILEQARAAVDTYCRHNYGVVESFTVQRRVQPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFLNGQEEKAGMVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS T40874 TARGETID T40874 T40874 UNIPROID TIGIT_HUMAN T40874 TARGNAME V-set and immunoglobulin domain-containing protein 9 (TIGIT) T40874 GENENAME TIGIT T40874 TARGTYPE Clinical trial T40874 SYNONYMS VSTM3; VSIG9; V-set and transmembrane domain-containing protein 3; T-cell immunoreceptor with Ig and ITIM domains T40874 FUNCTION Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. T40874 PDBSTRUC 5V52; 3UDW; 3UCR; 3RQ3; 3Q0H T40874 SEQUENCE MRWCLLLIWAQGLRQAPLASGMMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIPLLGAMAATLVVICTAVIVVVALTRKKKALRIHSVEGDLRRKSAGQEEWSPSAPSPPGSCVQAEAAPAGLCGEQRGEDCAELHDYFNVLSYRSLGNCSFFTETG T40874 DRUGINFO DFYL51 Ociperlimab Phase 3 T40874 DRUGINFO DT1FS0 AB154 Phase 3 T40874 DRUGINFO DQ72BV GSK4428859 Phase 2 T40874 DRUGINFO D4RMC9 Rilvegostomig Phase 1/2 T40874 DRUGINFO D0U9OC ASP8374 Phase 1 T40874 DRUGINFO D1AVT5 SEA-TGT Phase 1 T40874 DRUGINFO D9LA6Q COM902 Phase 1 T40874 DRUGINFO DA8MK6 M6223 Phase 1 T17248 TARGETID T17248 T17248 FORMERID TTDS00347 T17248 UNIPROID FUS_MEASC T17248 TARGNAME Measles virus Fusion glycoprotein (MeV F) T17248 GENENAME MeV F T17248 TARGTYPE Clinical trial T17248 SYNONYMS Measles virus fusion protein; MV fusion protein; Fusion protein T17248 FUNCTION Class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and plasma cell membrane fusion,the heptad repeat (HR) regions assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and plasma cell membranes. Directs fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm. This fusion is pH independent and occurs directly at the outer cell membrane. The trimer of F1-F2 (F protein) probably interacts with HN at the virion surface. Upon HN binding to its cellular receptor, the hydrophobic fusion peptide is unmasked and interacts with the cellular membrane, inducing the fusion between cell and virion membranes. Later in infection, F proteins expressed at the plasma membrane of infected cells could mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis. T17248 PDBSTRUC 5YZD; 5YZC; 5YXW T17248 BIOCLASS Paramyxoviruses fusion glycoprotein T17248 SEQUENCE MGLKVNVSAIFMAVLLTLQTPTGQIHWGNLSKIGVVGIGSASYKVMTRSSHQSLVIKLMPNITLLNNCTRVEIAEYRRLLRTVLEPIRDALNAMTQNIRPVQSVASSRRHKRFAGVVLAGAALGVATAAQITAGIALHQSMLNSQAIDNLRASLETTNQAIEAIRQAGQEMILAVQGVQDYINNELIPSMNQLSCDLIGQKLGLKLLRYYTEILSLFGPSLRDPISAEISIQALSYALGGDINKVLEKLGYSGGDLLGILESRGIKARITHVDTESYFIVLSIAYPTLSEIKGVIVHRLEGVSYNIGSQEWYTTVPKYVATQGYLISNFDESSCTFMPEGTVCSQNALYPMSPLLQECLRGSTKSCARTLVSGSFGNRFILSQGNLIANCASILCKCYTTGTIINQDPDKILTYIAADHCPVVEVNGVTIQVGSRRYPDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLEDAKELLESSDQILRSMKGLSSTSIVYILIAVCLGGLIGIPALICCCRGRCNKKGEQVGMSRPGLKPDLTGTSKSYVRSL T17248 DRUGINFO D06KCU MLN1202 Phase 2 T17248 DRUGINFO D0VT1S TTP889 Phase 2 T17248 DRUGINFO D02MZD AMG 876 Phase 1 T17248 DRUGINFO D0NN7L AC 165198 Phase 1 T84885 TARGETID T84885 T84885 FORMERID TTDI02332 T84885 UNIPROID CAPSD_NVN68 T84885 TARGNAME Picornavirus Capsid protein VP1 (PicVir VP1) T84885 GENENAME PicVir VP1 T84885 TARGTYPE Clinical trial T84885 SYNONYMS p30; Soluble capsid protein; ORF2; Capsid protein VP1; CP of Norwalk virus T84885 FUNCTION Soluble capsid protein may play arole in viral immunoevasion. T84885 PDBSTRUC 6H72; 6H71; 6H70; 6H6Z; 6H6Y T84885 BIOCLASS Caliciviridae capsid protein T84885 SEQUENCE MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIINNFVQAPQGEFTISPNNTPGDVLFDLSLGPHLNPFLLHLSQMYNGWVGNMRVRIMLAGNAFTAGKIIVSCIPPGFGSHNLTIAQATLFPHVIADVRTLDPIEVPLEDVRNVLFHNNDRNQQTMRLVCMLYTPLRTGGGTGDSFVVAGRVMTCPSPDFNFLFLVPPTVEQKTRPFTLPNLPLSSLSNSRAPLPISSMGISPDNVQSVQFQNGRCTLDGRLVGTTPVSLSHVAKIRGTSNGTVINLTELDGTPFHPFEGPAPIGFPDLGGCDWHINMTQFGHSSQTQYDVDTTPDTFVPHLGSIQANGIGSGNYVGVLSWISPPSHPSGSQVDLWKIPNYGSSITEATHLAPSVYPPGFGEVLVFFMSKMPGPGAYNLPCLLPQEYISHLASEQAPTVGEAALLHYVDPDTGRNLGEFKAYPDGFLTCVPNGASSGPQQLPINGVFVFVSWVSRFYQLKPVGTASSARGRLGLRR T84885 DRUGINFO D0W1US PLECONARIL Phase 2 T14110 TARGETID T14110 T14110 FORMERID TTDNR00650 T14110 UNIPROID KLOTB_HUMAN T14110 TARGNAME Beta-klotho (KLB) T14110 GENENAME KLB T14110 TARGTYPE Clinical trial T14110 SYNONYMS Klotho beta-like protein; BetaKlotho; BKL T14110 FUNCTION Probably inactive as a glycosidase. Increases the ability of FGFR1 and FGFR4 to bind FGF21. Contributes to the transcriptional repression of cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis. T14110 PDBSTRUC 6NFJ; 5WI9; 5VAQ; 5VAN; 5VAK T14110 BIOCLASS Glycosylase T14110 SEQUENCE MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAVTGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSWKKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQFSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPLALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGYGTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITLGSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFSVLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREALNWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLDEIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYKQIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHLYVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFALDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLGLPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDIYNRSGNDTYGAAHNLLVAHALAWRLYDRQFRPSQRGAVSLSLHADWAEPANPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSSSALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFLQDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDDRLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFKAKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFLGCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS T14110 DRUGINFO DR8CM0 MK-3655 Phase 2 T14110 DRUGINFO D0DJ0S NGM313 Phase 1 T94255 TARGETID T94255 T94255 FORMERID TTDI03595 T94255 UNIPROID TRPM4_HUMAN T94255 TARGNAME Long transient receptor potential channel 4 (TRPM4) T94255 GENENAME TRPM4 T94255 TARGTYPE Clinical trial T94255 SYNONYMS hTRPM4; Transient receptor potential cation channel subfamily M member 4; Melastatin-4; LTrpC4; LTrpC-4; Calcium-activated non-selective cation channel 1 T94255 FUNCTION Calcium-activated non selective (CAN) cation channel that mediates membrane depolarization. While it is activated by increase in intracellular Ca(2+), it is impermeable to it. Mediates transport of monovalent cations (Na(+) > K(+) > Cs(+) > Li(+)), leading to depolarize the membrane. It thereby plays a central role in cadiomyocytes, neurons from entorhinal cortex, dorsal root and vomeronasal neurons, endocrine pancreas cells, kidney epithelial cells, cochlea hair cells etc. Participates in T-cell activation by modulating Ca(2+) oscillations after T lymphocyte activation, which is required for NFAT-dependent IL2 production. Involved in myogenic constriction of cerebral arteries. Controls insulin secretion in pancreatic beta-cells. May also be involved in pacemaking or could cause irregular electrical activity under conditions of Ca(2+) overload. Affects T-helper 1 (Th1) and T-helper 2 (Th2) cell motility and cytokine production through differential regulation of calcium signaling and NFATC1 localization. Enhances cell proliferation through up-regulation of the beta-catenin signaling pathway. T94255 PDBSTRUC 6BWI; 6BQV; 6BQR; 5WP6 T94255 BIOCLASS Transient receptor potential catioin channel T94255 SEQUENCE MVVPEKEQSWIPKIFKKKTCTTFIVDSTDPGGTLCQCGRPRTAHPAVAMEDAFGAAVVTVWDSDAHTTEKPTDAYGELDFTGAGRKHSNFLRLSDRTDPAAVYSLVTRTWGFRAPNLVVSVLGGSGGPVLQTWLQDLLRRGLVRAAQSTGAWIVTGGLHTGIGRHVGVAVRDHQMASTGGTKVVAMGVAPWGVVRNRDTLINPKGSFPARYRWRGDPEDGVQFPLDYNYSAFFLVDDGTHGCLGGENRFRLRLESYISQQKTGVGGTGIDIPVLLLLIDGDEKMLTRIENATQAQLPCLLVAGSGGAADCLAETLEDTLAPGSGGARQGEARDRIRRFFPKGDLEVLQAQVERIMTRKELLTVYSSEDGSEEFETIVLKALVKACGSSEASAYLDELRLAVAWNRVDIAQSELFRGDIQWRSFHLEASLMDALLNDRPEFVRLLISHGLSLGHFLTPMRLAQLYSAAPSNSLIRNLLDQASHSAGTKAPALKGGAAELRPPDVGHVLRMLLGKMCAPRYPSGGAWDPHPGQGFGESMYLLSDKATSPLSLDAGLGQAPWSDLLLWALLLNRAQMAMYFWEMGSNAVSSALGACLLLRVMARLEPDAEEAARRKDLAFKFEGMGVDLFGECYRSSEVRAARLLLRRCPLWGDATCLQLAMQADARAFFAQDGVQSLLTQKWWGDMASTTPIWALVLAFFCPPLIYTRLITFRKSEEEPTREELEFDMDSVINGEGPVGTADPAEKTPLGVPRQSGRPGCCGGRCGGRRCLRRWFHFWGAPVTIFMGNVVSYLLFLLLFSRVLLVDFQPAPPGSLELLLYFWAFTLLCEELRQGLSGGGGSLASGGPGPGHASLSQRLRLYLADSWNQCDLVALTCFLLGVGCRLTPGLYHLGRTVLCIDFMVFTVRLLHIFTVNKQLGPKIVIVSKMMKDVFFFLFFLGVWLVAYGVATEGLLRPRDSDFPSILRRVFYRPYLQIFGQIPQEDMDVALMEHSNCSSEPGFWAHPPGAQAGTCVSQYANWLVVLLLVIFLLVANILLVNLLIAMFSYTFGKVQGNSDLYWKAQRYRLIREFHSRPALAPPFIVISHLRLLLRQLCRRPRSPQPSSPALEHFRVYLSKEAERKLLTWESVHKENFLLARARDKRESDSERLKRTSQKVDLALKQLGHIREYEQRLKVLEREVQQCSRVLGWVAEALSRSALLPPGGPPPPDLPGSKD T94255 DRUGINFO D0G2MU 9-phenanthrol Investigative T94255 DRUGINFO D0JV2P BTP2 Investigative T94255 DRUGINFO D05NWF adenosine diphosphate Investigative T94255 DRUGINFO D06KHR decavanadate Investigative T94255 DRUGINFO D07ZAJ PIP2 Investigative T94255 DRUGINFO D00ICA AMP-PNP Investigative T76233 TARGETID T76233 T76233 FORMERID TTDNR00686 T76233 UNIPROID HAVR2_HUMAN T76233 TARGNAME Hepatitis A virus cellular receptor 2 (TIM3) T76233 GENENAME Hepatitis A virus HAVCR2 T76233 TARGTYPE Clinical trial T76233 SYNONYMS TIMD3; TIMD-3; TIM3; TIM-3; T-cell membrane protein 3; T-cell immunoglobulin mucin receptor 3; T-cell immunoglobulin and mucin domain-containing protein 3; HAVcr-2; HAVCR2; CD366 T76233 FUNCTION Generally accepted to have an inhibiting function. Reports on stimulating functions suggest that the activity may be influenced by the cellular context and/or the respective ligand. Regulates macrophage activation. Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. In CD8+ cells attenuates TCR-induced signaling, specifically by blocking NF-kappaB and NFAT promoter activities resulting in the loss of IL-2 secretion. The function may implicate its association with LCK proposed to impair phosphorylation of TCR subunits, and/or LGALS9-dependent recruitment of PTPRC to the immunological synapse. In contrast, shown to activate TCR-induced signaling in T-cells probably implicating ZAP70, LCP2, LCK and FYN. Expressed on Treg cells can inhibit Th17 cell responses. Receptor for LGALS9. Binding to LGALS9 is believed to result in suppression of T-cell responses; the resulting apoptosis of antigen-specific cells may implicate HAVCR2 phosphorylation and disruption of its association with BAG6. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens. Expressed on Th1 cells interacts with LGALS9 expressed on Mycobacterium tuberculosis-infected macrophages to stimulate antibactericidal activity including IL-1 beta secretion and to restrict intracellular bacterial growth. However, the function as receptor for LGALS9 has been challenged. Also reported to enhance CD8+ T-cell responses to an acute infection such as by Listeria monocytogenes. Receptor for phosphatidylserine (PtSer); PtSer-binding is calcium-dependent. May recognize PtSer on apoptotic cells leading to their phagocytosis. Mediates the engulfment of apoptotic cells by dendritic cells. Expressed on T-cells, promotes conjugation but not engulfment of apoptotic cells. Expressed on dendritic cells (DCs) positively regulates innate immune response and in synergy with Toll-like receptors promotes secretion of TNF-alpha. In tumor-imfiltrating DCs suppresses nucleic acid-mediated innate immune repsonse by interaction with HMGB1 and interfering with nucleic acid-sensing and trafficking of nucleid acids to endosomes. Expressed on natural killer (NK) cells acts as a coreceptor to enhance IFN-gamma production in response to LGALS9. In contrast, shown to suppress NK cell-mediated cytotoxicity. Negatively regulates NK cell function in LPS-induced endotoxic shock. Cell surface receptor implicated in modulating innate and adaptive immune responses. T76233 PDBSTRUC 6DHB; 5F71; 5DZL T76233 BIOCLASS Immunoglobulin T76233 SEQUENCE MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGPAETQTLGSLPDINLTQISTLANELRDSRLANDLRDSGATIRIGIYIGAGICAGLALALIFGALIFKWYSHSKEKIQNLSLISLANLPPSGLANAVAEGIRSEENIYTIEENVYEVEEPNEYYCYVSSRQQPSQPLGCRFAMP T76233 DRUGINFO D0AE6Q MBG453 Phase 3 T76233 DRUGINFO DW7J9D TB006 Phase 2 T76233 DRUGINFO DZW53X GSK4069889 Phase 2 T76233 DRUGINFO DNI7E3 AZD7789 Phase 2 T76233 DRUGINFO DQM48O RO7121661 Phase 2 T76233 DRUGINFO D7UIZ1 BGB-A425 Phase 1/2 T76233 DRUGINFO D09YXT LY3321367 Phase 1 T76233 DRUGINFO DEU8O6 Sym023 Phase 1 T76233 DRUGINFO DVA36E INCAGN2390 Phase 1 T76233 DRUGINFO DC8HR6 LY3415244 Phase 1 T05938 TARGETID T05938 T05938 FORMERID TTDI02319 T05938 UNIPROID MUC16_HUMAN T05938 TARGNAME Ovarian carcinoma antigen CA125 (MUC16) T05938 GENENAME MUC16 T05938 TARGTYPE Clinical trial T05938 SYNONYMS Ovarian cancerrelated tumor marker CA125; Mucin16; MUC16; CA125 T05938 FUNCTION Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. T05938 BIOCLASS Mucin T05938 SEQUENCE MLKPSGLPGSSSPTRSLMTGSRSTKATPEMDSGLTGATLSPKTSTGAIVVTEHTLPFTSPDKTLASPTSSVVGRTTQSLGVMSSALPESTSRGMTHSEQRTSPSLSPQVNGTPSRNYPATSMVSGLSSPRTRTSSTEGNFTKEASTYTLTVETTSGPVTEKYTVPTETSTTEGDSTETPWDTRYIPVKITSPMKTFADSTASKENAPVSMTPAETTVTDSHTPGRTNPSFGTLYSSFLDLSPKGTPNSRGETSLELILSTTGYPFSSPEPGSAGHSRISTSAPLSSSASVLDNKISETSIFSGQSLTSPLSPGVPEARASTMPNSAIPFSMTLSNAETSAERVRSTISSLGTPSISTKQTAETILTFHAFAETMDIPSTHIAKTLASEWLGSPGTLGGTSTSALTTTSPSTTLVSEETNTHHSTSGKETEGTLNTSMTPLETSAPGEESEMTATLVPTLGFTTLDSKIRSPSQVSSSHPTRELRTTGSTSGRQSSSTAAHGSSDILRATTSSTSKASSWTSESTAQQFSEPQHTQWVETSPSMKTERPPASTSVAAPITTSVPSVVSGFTTLKTSSTKGIWLEETSADTLIGESTAGPTTHQFAVPTGISMTGGSSTRGSQGTTHLLTRATASSETSADLTLATNGVPVSVSPAVSKTAAGSSPPGGTKPSYTMVSSVIPETSSLQSSAFREGTSLGLTPLNTRHPFSSPEPDSAGHTKISTSIPLLSSASVLEDKVSATSTFSHHKATSSITTGTPEISTKTKPSSAVLSSMTLSNAATSPERVRNATSPLTHPSPSGEETAGSVLTLSTSAETTDSPNIHPTGTLTSESSESPSTLSLPSVSGVKTTFSSSTPSTHLFTSGEETEETSNPSVSQPETSVSRVRTTLASTSVPTPVFPTMDTWPTRSAQFSSSHLVSELRATSSTSVTNSTGSALPKISHLTGTATMSQTNRDTFNDSAAPQSTTWPETSPRFKTGLPSATTTVSTSATSLSATVMVSKFTSPATSSMEATSIREPSTTILTTETTNGPGSMAVASTNIPIGKGYITEGRLDTSHLPIGTTASSETSMDFTMAKESVSMSVSPSQSMDAAGSSTPGRTSQFVDTFSDDVYHLTSREITIPRDGTSSALTPQMTATHPPSPDPGSARSTWLGILSSSPSSPTPKVTMSSTFSTQRVTTSMIMDTVETSRWNMPNLPSTTSLTPSNIPTSGAIGKSTLVPLDTPSPATSLEASEGGLPTLSTYPESTNTPSIHLGAHASSESPSTIKLTMASVVKPGSYTPLTFPSIETHIHVSTARMAYSSGSSPEMTAPGETNTGSTWDPTTYITTTDPKDTSSAQVSTPHSVRTLRTTENHPKTESATPAAYSGSPKISSSPNLTSPATKAWTITDTTEHSTQLHYTKLAEKSSGFETQSAPGPVSVVIPTSPTIGSSTLELTSDVPGEPLVLAPSEQTTITLPMATWLSTSLTEEMASTDLDISSPSSPMSTFAIFPPMSTPSHELSKSEADTSAIRNTDSTTLDQHLGIRSLGRTGDLTTVPITPLTTTWTSVIEHSTQAQDTLSATMSPTHVTQSLKDQTSIPASASPSHLTEVYPELGTQGRSSSEATTFWKPSTDTLSREIETGPTNIQSTPPMDNTTTGSSSSGVTLGIAHLPIGTSSPAETSTNMALERRSSTATVSMAGTMGLLVTSAPGRSISQSLGRVSSVLSESTTEGVTDSSKGSSPRLNTQGNTALSSSLEPSYAEGSQMSTSIPLTSSPTTPDVEFIGGSTFWTKEVTTVMTSDISKSSARTESSSATLMSTALGSTENTGKEKLRTASMDLPSPTPSMEVTPWISLTLSNAPNTTDSLDLSHGVHTSSAGTLATDRSLNTGVTRASRLENGSDTSSKSLSMGNSTHTSMTYTEKSEVSSSIHPRPETSAPGAETTLTSTPGNRAISLTLPFSSIPVEEVISTGITSGPDINSAPMTHSPITPPTIVWTSTGTIEQSTQPLHAVSSEKVSVQTQSTPYVNSVAVSASPTHENSVSSGSSTSSPYSSASLESLDSTISRRNAITSWLWDLTTSLPTTTWPSTSLSEALSSGHSGVSNPSSTTTEFPLFSAASTSAAKQRNPETETHGPQNTAASTLNTDASSVTGLSETPVGASISSEVPLPMAITSRSDVSGLTSESTANPSLGTASSAGTKLTRTISLPTSESLVSFRMNKDPWTVSIPLGSHPTTNTETSIPVNSAGPPGLSTVASDVIDTPSDGAESIPTVSFSPSPDTEVTTISHFPEKTTHSFRTISSLTHELTSRVTPIPGDWMSSAMSTKPTGASPSITLGERRTITSAAPTTSPIVLTASFTETSTVSLDNETTVKTSDILDARKTNELPSDSSSSSDLINTSIASSTMDVTKTASISPTSISGMTASSSPSLFSSDRPQVPTSTTETNTATSPSVSSNTYSLDGGSNVGGTPSTLPPFTITHPVETSSALLAWSRPVRTFSTMVSTDTASGENPTSSNSVVTSVPAPGTWTSVGSTTDLPAMGFLKTSPAGEAHSLLASTIEPATAFTPHLSAAVVTGSSATSEASLLTTSESKAIHSSPQTPTTPTSGANWETSATPESLLVVTETSDTTLTSKILVTDTILFSTVSTPPSKFPSTGTLSGASFPTLLPDTPAIPLTATEPTSSLATSFDSTPLVTIASDSLGTVPETTLTMSETSNGDALVLKTVSNPDRSIPGITIQGVTESPLHPSSTSPSKIVAPRNTTYEGSITVALSTLPAGTTGSLVFSQSSENSETTALVDSSAGLERASVMPLTTGSQGMASSGGIRSGSTHSTGTKTFSSLPLTMNPGEVTAMSEITTNRLTATQSTAPKGIPVKPTSAESGLLTPVSASSSPSKAFASLTTAPPTWGIPQSTLTFEFSEVPSLDTKSASLPTPGQSLNTIPDSDASTASSSLSKSPEKNPRARMMTSTKAISASSFQSTGFTETPEGSASPSMAGHEPRVPTSGTGDPRYASESMSYPDPSKASSAMTSTSLASKLTTLFSTGQAARSGSSSSPISLSTEKETSFLSPTASTSRKTSLFLGPSMARQPNILVHLQTSALTLSPTSTLNMSQEEPPELTSSQTIAEEEGTTAETQTLTFTPSETPTSLLPVSSPTEPTARRKSSPETWASSISVPAKTSLVETTDGTLVTTIKMSSQAAQGNSTWPAPAEETGSSPAGTSPGSPEMSTTLKIMSSKEPSISPEIRSTVRNSPWKTPETTVPMETTVEPVTLQSTALGSGSTSISHLPTGTTSPTKSPTENMLATERVSLSPSPPEAWTNLYSGTPGGTRQSLATMSSVSLESPTARSITGTGQQSSPELVSKTTGMEFSMWHGSTGGTTGDTHVSLSTSSNILEDPVTSPNSVSSLTDKSKHKTETWVSTTAIPSTVLNNKIMAAEQQTSRSVDEAYSSTSSWSDQTSGSDITLGASPDVTNTLYITSTAQTTSLVSLPSGDQGITSLTNPSGGKTSSASSVTSPSIGLETLRANVSAVKSDIAPTAGHLSQTSSPAEVSILDVTTAPTPGISTTITTMGTNSISTTTPNPEVGMSTMDSTPATERRTTSTEHPSTWSSTAASDSWTVTDMTSNLKVARSPGTISTMHTTSFLASSTELDSMSTPHGRITVIGTSLVTPSSDASAVKTETSTSERTLSPSDTTASTPISTFSRVQRMSISVPDILSTSWTPSSTEAEDVPVSMVSTDHASTKTDPNTPLSTFLFDSLSTLDWDTGRSLSSATATTSAPQGATTPQELTLETMISPATSQLPFSIGHITSAVTPAAMARSSGVTFSRPDPTSKKAEQTSTQLPTTTSAHPGQVPRSAATTLDVIPHTAKTPDATFQRQGQTALTTEARATSDSWNEKEKSTPSAPWITEMMNSVSEDTIKEVTSSSSVLRTLNTLDINLESGTTSSPSWKSSPYERIAPSESTTDKEAIHPSTNTVETTGWVTSSEHASHSTIPAHSASSKLTSPVVTTSTREQAIVSMSTTTWPESTRARTEPNSFLTIELRDVSPYMDTSSTTQTSIISSPGSTAITKGPRTEITSSKRISSSFLAQSMRSSDSPSEAITRLSNFPAMTESGGMILAMQTSPPGATSLSAPTLDTSATASWTGTPLATTQRFTYSEKTTLFSKGPEDTSQPSPPSVEETSSSSSLVPIHATTSPSNILLTSQGHSPSSTPPVTSVFLSETSGLGKTTDMSRISLEPGTSLPPNLSSTAGEALSTYEASRDTKAIHHSADTAVTNMEATSSEYSPIPGHTKPSKATSPLVTSHIMGDITSSTSVFGSSETTEIETVSSVNQGLQERSTSQVASSATETSTVITHVSSGDATTHVTKTQATFSSGTSISSPHQFITSTNTFTDVSTNPSTSLIMTESSGVTITTQTGPTGAATQGPYLLDTSTMPYLTETPLAVTPDFMQSEKTTLISKGPKDVSWTSPPSVAETSYPSSLTPFLVTTIPPATSTLQGQHTSSPVSATSVLTSGLVKTTDMLNTSMEPVTNSPQNLNNPSNEILATLAATTDIETIHPSINKAVTNMGTASSAHVLHSTLPVSSEPSTATSPMVPASSMGDALASISIPGSETTDIEGEPTSSLTAGRKENSTLQEMNSTTESNIILSNVSVGAITEATKMEVPSFDATFIPTPAQSTKFPDIFSVASSRLSNSPPMTISTHMTTTQTGSSGATSKIPLALDTSTLETSAGTPSVVTEGFAHSKITTAMNNDVKDVSQTNPPFQDEASSPSSQAPVLVTTLPSSVAFTPQWHSTSSPVSMSSVLTSSLVKTAGKVDTSLETVTSSPQSMSNTLDDISVTSAATTDIETTHPSINTVVTNVGTTGSAFESHSTVSAYPEPSKVTSPNVTTSTMEDTTISRSIPKSSKTTRTETETTSSLTPKLRETSISQEITSSTETSTVPYKELTGATTEVSRTDVTSSSSTSFPGPDQSTVSLDISTETNTRLSTSPIMTESAEITITTQTGPHGATSQDTFTMDPSNTTPQAGIHSAMTHGFSQLDVTTLMSRIPQDVSWTSPPSVDKTSSPSSFLSSPAMTTPSLISSTLPEDKLSSPMTSLLTSGLVKITDILRTRLEPVTSSLPNFSSTSDKILATSKDSKDTKEIFPSINTEETNVKANNSGHESHSPALADSETPKATTQMVITTTVGDPAPSTSMPVHGSSETTNIKREPTYFLTPRLRETSTSQESSFPTDTSFLLSKVPTGTITEVSSTGVNSSSKISTPDHDKSTVPPDTFTGEIPRVFTSSIKTKSAEMTITTQASPPESASHSTLPLDTSTTLSQGGTHSTVTQGFPYSEVTTLMGMGPGNVSWMTTPPVEETSSVSSLMSSPAMTSPSPVSSTSPQSIPSSPLPVTALPTSVLVTTTDVLGTTSPESVTSSPPNLSSITHERPATYKDTAHTEAAMHHSTNTAVTNVGTSGSGHKSQSSVLADSETSKATPLMSTTSTLGDTSVSTSTPNISQTNQIQTEPTASLSPRLRESSTSEKTSSTTETNTAFSYVPTGAITQASRTEISSSRTSISDLDRPTIAPDISTGMITRLFTSPIMTKSAEMTVTTQTTTPGATSQGILPWDTSTTLFQGGTHSTVSQGFPHSEITTLRSRTPGDVSWMTTPPVEETSSGFSLMSPSMTSPSPVSSTSPESIPSSPLPVTALLTSVLVTTTNVLGTTSPEPVTSSPPNLSSPTQERLTTYKDTAHTEAMHASMHTNTAVANVGTSISGHESQSSVPADSHTSKATSPMGITFAMGDTSVSTSTPAFFETRIQTESTSSLIPGLRDTRTSEEINTVTETSTVLSEVPTTTTTEVSRTEVITSSRTTISGPDHSKMSPYISTETITRLSTFPFVTGSTEMAITNQTGPIGTISQATLTLDTSSTASWEGTHSPVTQRFPHSEETTTMSRSTKGVSWQSPPSVEETSSPSSPVPLPAITSHSSLYSAVSGSSPTSALPVTSLLTSGRRKTIDMLDTHSELVTSSLPSASSFSGEILTSEASTNTETIHFSENTAETNMGTTNSMHKLHSSVSIHSQPSGHTPPKVTGSMMEDAIVSTSTPGSPETKNVDRDSTSPLTPELKEDSTALVMNSTTESNTVFSSVSLDAATEVSRAEVTYYDPTFMPASAQSTKSPDISPEASSSHSNSPPLTISTHKTIATQTGPSGVTSLGQLTLDTSTIATSAGTPSARTQDFVDSETTSVMNNDLNDVLKTSPFSAEEANSLSSQAPLLVTTSPSPVTSTLQEHSTSSLVSVTSVPTPTLAKITDMDTNLEPVTRSPQNLRNTLATSEATTDTHTMHPSINTAVANVGTTSSPNEFYFTVSPDSDPYKATSAVVITSTSGDSIVSTSMPRSSAMKKIESETTFSLIFRLRETSTSQKIGSSSDTSTVFDKAFTAATTEVSRTELTSSSRTSIQGTEKPTMSPDTSTRSVTMLSTFAGLTKSEERTIATQTGPHRATSQGTLTWDTSITTSQAGTHSAMTHGFSQLDLSTLTSRVPEYISGTSPPSVEKTSSSSSLLSLPAITSPSPVPTTLPESRPSSPVHLTSLPTSGLVKTTDMLASVASLPPNLGSTSHKIPTTSEDIKDTEKMYPSTNIAVTNVGTTTSEKESYSSVPAYSEPPKVTSPMVTSFNIRDTIVSTSMPGSSEITRIEMESTFSLAHGLKGTSTSQDPIVSTEKSAVLHKLTTGATETSRTEVASSRRTSIPGPDHSTESPDISTEVIPSLPISLGITESSNMTIITRTGPPLGSTSQGTFTLDTPTTSSRAGTHSMATQEFPHSEMTTVMNKDPEILSWTIPPSIEKTSFSSSLMPSPAMTSPPVSSTLPKTIHTTPSPMTSLLTPSLVMTTDTLGTSPEPTTSSPPNLSSTSHEILTTDEDTTAIEAMHPSTSTAATNVETTSSGHGSQSSVLADSEKTKATAPMDTTSTMGHTTVSTSMSVSSETTKIKRESTYSLTPGLRETSISQNASFSTDTSIVLSEVPTGTTAEVSRTEVTSSGRTSIPGPSQSTVLPEISTRTMTRLFASPTMTESAEMTIPTQTGPSGSTSQDTLTLDTSTTKSQAKTHSTLTQRFPHSEMTTLMSRGPGDMSWQSSPSLENPSSLPSLLSLPATTSPPPISSTLPVTISSSPLPVTSLLTSSPVTTTDMLHTSPELVTSSPPKLSHTSDERLTTGKDTTNTEAVHPSTNTAASNVEIPSSGHESPSSALADSETSKATSPMFITSTQEDTTVAISTPHFLETSRIQKESISSLSPKLRETGSSVETSSAIETSAVLSEVSIGATTEISRTEVTSSSRTSISGSAESTMLPEISTTRKIIKFPTSPILAESSEMTIKTQTSPPGSTSESTFTLDTSTTPSLVITHSTMTQRLPHSEITTLVSRGAGDVPRPSSLPVEETSPPSSQLSLSAMISPSPVSSTLPASSHSSSASVTSLLTPGQVKTTEVLDASAEPETSSPPSLSSTSVEILATSEVTTDTEKIHPFSNTAVTKVGTSSSGHESPSSVLPDSETTKATSAMGTISIMGDTSVSTLTPALSNTRKIQSEPASSLTTRLRETSTSEETSLATEANTVLSKVSTGATTEVSRTEAISFSRTSMSGPEQSTMSQDISIGTIPRISASSVLTESAKMTITTQTGPSESTLESTLNLNTATTPSWVETHSIVIQGFPHPEMTTSMGRGPGGVSWPSPPFVKETSPPSSPLSLPAVTSPHPVSTTFLAHIPPSPLPVTSLLTSGPATTTDILGTSTEPGTSSSSSLSTTSHERLTTYKDTAHTEAVHPSTNTGGTNVATTSSGYKSQSSVLADSSPMCTTSTMGDTSVLTSTPAFLETRRIQTELASSLTPGLRESSGSEGTSSGTKMSTVLSKVPTGATTEISKEDVTSIPGPAQSTISPDISTRTVSWFSTSPVMTESAEITMNTHTSPLGATTQGTSTLDTSSTTSLTMTHSTISQGFSHSQMSTLMRRGPEDVSWMSPPLLEKTRPSFSLMSSPATTSPSPVSSTLPESISSSPLPVTSLLTSGLAKTTDMLHKSSEPVTNSPANLSSTSVEILATSEVTTDTEKTHPSSNRTVTDVGTSSSGHESTSFVLADSQTSKVTSPMVITSTMEDTSVSTSTPGFFETSRIQTEPTSSLTLGLRKTSSSEGTSLATEMSTVLSGVPTGATAEVSRTEVTSSSRTSISGFAQLTVSPETSTETITRLPTSSIMTESAEMMIKTQTDPPGSTPESTHTVDISTTPNWVETHSTVTQRFSHSEMTTLVSRSPGDMLWPSQSSVEETSSASSLLSLPATTSPSPVSSTLVEDFPSASLPVTSLLNPGLVITTDRMGISREPGTSSTSNLSSTSHERLTTLEDTVDTEDMQPSTHTAVTNVRTSISGHESQSSVLSDSETPKATSPMGTTYTMGETSVSISTSDFFETSRIQIEPTSSLTSGLRETSSSERISSATEGSTVLSEVPSGATTEVSRTEVISSRGTSMSGPDQFTISPDISTEAITRLSTSPIMTESAESAITIETGSPGATSEGTLTLDTSTTTFWSGTHSTASPGFSHSEMTTLMSRTPGDVPWPSLPSVEEASSVSSSLSSPAMTSTSFFSTLPESISSSPHPVTALLTLGPVKTTDMLRTSSEPETSSPPNLSSTSAEILATSEVTKDREKIHPSSNTPVVNVGTVIYKHLSPSSVLADLVTTKPTSPMATTSTLGNTSVSTSTPAFPETMMTQPTSSLTSGLREISTSQETSSATERSASLSGMPTGATTKVSRTEALSLGRTSTPGPAQSTISPEISTETITRISTPLTTTGSAEMTITPKTGHSGASSQGTFTLDTSSRASWPGTHSAATHRSPHSGMTTPMSRGPEDVSWPSRPSVEKTSPPSSLVSLSAVTSPSPLYSTPSESSHSSPLRVTSLFTPVMMKTTDMLDTSLEPVTTSPPSMNITSDESLATSKATMETEAIQLSENTAVTQMGTISARQEFYSSYPGLPEPSKVTSPVVTSSTIKDIVSTTIPASSEITRIEMESTSTLTPTPRETSTSQEIHSATKPSTVPYKALTSATIEDSMTQVMSSSRGPSPDQSTMSQDISTEVITRLSTSPIKTESTEMTITTQTGSPGATSRGTLTLDTSTTFMSGTHSTASQGFSHSQMTALMSRTPGDVPWLSHPSVEEASSASFSLSSPVMTSSSPVSSTLPDSIHSSSLPVTSLLTSGLVKTTELLGTSSEPETSSPPNLSSTSAEILAITEVTTDTEKLEMTNVVTSGYTHESPSSVLADSVTTKATSSMGITYPTGDTNVLTSTPAFSDTSRIQTKSKLSLTPGLMETSISEETSSATEKSTVLSSVPTGATTEVSRTEAISSSRTSIPGPAQSTMSSDTSMETITRISTPLTRKESTDMAITPKTGPSGATSQGTFTLDSSSTASWPGTHSATTQRFPQSVVTTPMSRGPEDVSWPSPLSVEKNSPPSSLVSSSSVTSPSPLYSTPSGSSHSSPVPVTSLFTSIMMKATDMLDASLEPETTSAPNMNITSDESLAASKATTETEAIHVFENTAASHVETTSATEELYSSSPGFSEPTKVISPVVTSSSIRDNMVSTTMPGSSGITRIEIESMSSLTPGLRETRTSQDITSSTETSTVLYKMPSGATPEVSRTEVMPSSRTSIPGPAQSTMSLDISDEVVTRLSTSPIMTESAEITITTQTGYSLATSQVTLPLGTSMTFLSGTHSTMSQGLSHSEMTNLMSRGPESLSWTSPRFVETTRSSSSLTSLPLTTSLSPVSSTLLDSSPSSPLPVTSLILPGLVKTTEVLDTSSEPKTSSSPNLSSTSVEIPATSEIMTDTEKIHPSSNTAVAKVRTSSSVHESHSSVLADSETTITIPSMGITSAVDDTTVFTSNPAFSETRRIPTEPTFSLTPGFRETSTSEETTSITETSAVLYGVPTSATTEVSMTEIMSSNRIHIPDSDQSTMSPDIITEVITRLSSSSMMSESTQMTITTQKSSPGATAQSTLTLATTTAPLARTHSTVPPRFLHSEMTTLMSRSPENPSWKSSLFVEKTSSSSSLLSLPVTTSPSVSSTLPQSIPSSSFSVTSLLTPGMVKTTDTSTEPGTSLSPNLSGTSVEILAASEVTTDTEKIHPSSSMAVTNVGTTSSGHELYSSVSIHSEPSKATYPVGTPSSMAETSISTSMPANFETTGFEAEPFSHLTSGFRKTNMSLDTSSVTPTNTPSSPGSTHLLQSSKTDFTSSAKTSSPDWPPASQYTEIPVDIITPFNASPSITESTGITSFPESRFTMSVTESTHHLSTDLLPSAETISTGTVMPSLSEAMTSFATTGVPRAISGSGSPFSRTESGPGDATLSTIAESLPSSTPVPFSSSTFTTTDSSTIPALHEITSSSATPYRVDTSLGTESSTTEGRLVMVSTLDTSSQPGRTSSSPILDTRMTESVELGTVTSAYQVPSLSTRLTRTDGIMEHITKIPNEAAHRGTIRPVKGPQTSTSPASPKGLHTGGTKRMETTTTALKTTTTALKTTSRATLTTSVYTPTLGTLTPLNASMQMASTIPTEMMITTPYVFPDVPETTSSLATSLGAETSTALPRTTPSVFNRESETTASLVSRSGAERSPVIQTLDVSSSEPDTTASWVIHPAETIPTVSKTTPNFFHSELDTVSSTATSHGADVSSAIPTNISPSELDALTPLVTISGTDTSTTFPTLTKSPHETETRTTWLTHPAETSSTIPRTIPNFSHHESDATPSIATSPGAETSSAIPIMTVSPGAEDLVTSQVTSSGTDRNMTIPTLTLSPGEPKTIASLVTHPEAQTSSAIPTSTISPAVSRLVTSMVTSLAAKTSTTNRALTNSPGEPATTVSLVTHPAQTSPTVPWTTSIFFHSKSDTTPSMTTSHGAESSSAVPTPTVSTEVPGVVTPLVTSSRAVISTTIPILTLSPGEPETTPSMATSHGEEASSAIPTPTVSPGVPGVVTSLVTSSRAVTSTTIPILTFSLGEPETTPSMATSHGTEAGSAVPTVLPEVPGMVTSLVASSRAVTSTTLPTLTLSPGEPETTPSMATSHGAEASSTVPTVSPEVPGVVTSLVTSSSGVNSTSIPTLILSPGELETTPSMATSHGAEASSAVPTPTVSPGVSGVVTPLVTSSRAVTSTTIPILTLSSSEPETTPSMATSHGVEASSAVLTVSPEVPGMVTSLVTSSRAVTSTTIPTLTISSDEPETTTSLVTHSEAKMISAIPTLAVSPTVQGLVTSLVTSSGSETSAFSNLTVASSQPETIDSWVAHPGTEASSVVPTLTVSTGEPFTNISLVTHPAESSSTLPRTTSRFSHSELDTMPSTVTSPEAESSSAISTTISPGIPGVLTSLVTSSGRDISATFPTVPESPHESEATASWVTHPAVTSTTVPRTTPNYSHSEPDTTPSIATSPGAEATSDFPTITVSPDVPDMVTSQVTSSGTDTSITIPTLTLSSGEPETTTSFITYSETHTSSAIPTLPVSPGASKMLTSLVISSGTDSTTTFPTLTETPYEPETTAIQLIHPAETNTMVPRTTPKFSHSKSDTTLPVAITSPGPEASSAVSTTTISPDMSDLVTSLVPSSGTDTSTTFPTLSETPYEPETTATWLTHPAETSTTVSGTIPNFSHRGSDTAPSMVTSPGVDTRSGVPTTTIPPSIPGVVTSQVTSSATDTSTAIPTLTPSPGEPETTASSATHPGTQTGFTVPIRTVPSSEPDTMASWVTHPPQTSTPVSRTTSSFSHSSPDATPVMATSPRTEASSAVLTTISPGAPEMVTSQITSSGAATSTTVPTLTHSPGMPETTALLSTHPRTETSKTFPASTVFPQVSETTASLTIRPGAETSTALPTQTTSSLFTLLVTGTSRVDLSPTASPGVSAKTAPLSTHPGTETSTMIPTSTLSLGLLETTGLLATSSSAETSTSTLTLTVSPAVSGLSSASITTDKPQTVTSWNTETSPSVTSVGPPEFSRTVTGTTMTLIPSEMPTPPKTSHGEGVSPTTILRTTMVEATNLATTGSSPTVAKTTTTFNTLAGSLFTPLTTPGMSTLASESVTSRTSYNHRSWISTTSSYNRRYWTPATSTPVTSTFSPGISTSSIPSSTAATVPFMVPFTLNFTITNLQYEEDMRHPGSRKFNATERELQGLLKPLFRNSSLEYLYSGCRLASLRPEKDSSATAVDAICTHRPDPEDLGLDRERLYWELSNLTNGIQELGPYTLDRNSLYVNGFTHRSSMPTTSTPGTSTVDVGTSGTPSSSPSPTTAGPLLMPFTLNFTITNLQYEEDMRRTGSRKFNTMESVLQGLLKPLFKNTSVGPLYSGCRLTLLRPEKDGAATGVDAICTHRLDPKSPGLNREQLYWELSKLTNDIEELGPYTLDRNSLYVNGFTHQSSVSTTSTPGTSTVDLRTSGTPSSLSSPTIMAAGPLLVPFTLNFTITNLQYGEDMGHPGSRKFNTTERVLQGLLGPIFKNTSVGPLYSGCRLTSLRSEKDGAATGVDAICIHHLDPKSPGLNRERLYWELSQLTNGIKELGPYTLDRNSLYVNGFTHRTSVPTSSTPGTSTVDLGTSGTPFSLPSPATAGPLLVLFTLNFTITNLKYEEDMHRPGSRKFNTTERVLQTLLGPMFKNTSVGLLYSGCRLTLLRSEKDGAATGVDAICTHRLDPKSPGVDREQLYWELSQLTNGIKELGPYTLDRNSLYVNGFTHWIPVPTSSTPGTSTVDLGSGTPSSLPSPTTAGPLLVPFTLNFTITNLKYEEDMHCPGSRKFNTTERVLQSLLGPMFKNTSVGPLYSGCRLTLLRSEKDGAATGVDAICTHRLDPKSPGVDREQLYWELSQLTNGIKELGPYTLDRNSLYVNGFTHQTSAPNTSTPGTSTVDLGTSGTPSSLPSPTSAGPLLVPFTLNFTITNLQYEEDMHHPGSRKFNTTERVLQGLLGPMFKNTSVGLLYSGCRLTLLRPEKNGAATGMDAICSHRLDPKSPGLNREQLYWELSQLTHGIKELGPYTLDRNSLYVNGFTHRSSVAPTSTPGTSTVDLGTSGTPSSLPSPTTAVPLLVPFTLNFTITNLQYGEDMRHPGSRKFNTTERVLQGLLGPLFKNSSVGPLYSGCRLISLRSEKDGAATGVDAICTHHLNPQSPGLDREQLYWQLSQMTNGIKELGPYTLDRNSLYVNGFTHRSSGLTTSTPWTSTVDLGTSGTPSPVPSPTTTGPLLVPFTLNFTITNLQYEENMGHPGSRKFNITESVLQGLLKPLFKSTSVGPLYSGCRLTLLRPEKDGVATRVDAICTHRPDPKIPGLDRQQLYWELSQLTHSITELGPYTLDRDSLYVNGFTQRSSVPTTSTPGTFTVQPETSETPSSLPGPTATGPVLLPFTLNFTITNLQYEEDMRRPGSRKFNTTERVLQGLLMPLFKNTSVSSLYSGCRLTLLRPEKDGAATRVDAVCTHRPDPKSPGLDRERLYWKLSQLTHGITELGPYTLDRHSLYVNGFTHQSSMTTTRTPDTSTMHLATSRTPASLSGPMTASPLLVLFTINFTITNLRYEENMHHPGSRKFNTTERVLQGLLRPVFKNTSVGPLYSGCRLTLLRPKKDGAATKVDAICTYRPDPKSPGLDREQLYWELSQLTHSITELGPYTLDRDSLYVNGFTQRSSVPTTSIPGTPTVDLGTSGTPVSKPGPSAASPLLVLFTLNFTITNLRYEENMQHPGSRKFNTTERVLQGLLRSLFKSTSVGPLYSGCRLTLLRPEKDGTATGVDAICTHHPDPKSPRLDREQLYWELSQLTHNITELGPYALDNDSLFVNGFTHRSSVSTTSTPGTPTVYLGASKTPASIFGPSAASHLLILFTLNFTITNLRYEENMWPGSRKFNTTERVLQGLLRPLFKNTSVGPLYSGCRLTLLRPEKDGEATGVDAICTHRPDPTGPGLDREQLYLELSQLTHSITELGPYTLDRDSLYVNGFTHRSSVPTTSTGVVSEEPFTLNFTINNLRYMADMGQPGSLKFNITDNVMQHLLSPLFQRSSLGARYTGCRVIALRSVKNGAETRVDLLCTYLQPLSGPGLPIKQVFHELSQQTHGITRLGPYSLDKDSLYLNGYNEPGPDEPPTTPKPATTFLPPLSEATTAMGYHLKTLTLNFTISNLQYSPDMGKGSATFNSTEGVLQHLLRPLFQKSSMGPFYLGCQLISLRPEKDGAATGVDTTCTYHPDPVGPGLDIQQLYWELSQLTHGVTQLGFYVLDRDSLFINGYAPQNLSIRGEYQINFHIVNWNLSNPDPTSSEYITLLRDIQDKVTTLYKGSQLHDTFRFCLVTNLTMDSVLVTVKALFSSNLDPSLVEQVFLDKTLNASFHWLGSTYQLVDIHVTEMESSVYQPTSSSSTQHFYLNFTITNLPYSQDKAQPGTTNYQRNKRNIEDALNQLFRNSSIKSYFSDCQVSTFRSVPNRHHTGVDSLCNFSPLARRVDRVAIYEEFLRMTRNGTQLQNFTLDRSSVLVDGYSPNRNEPLTGNSDLPFWAVILIGLAGLLGVITCLICGVLVTTRRRKKEGEYNVQQQCPGYYQSHLDLEDLQ T05938 DRUGINFO D07HUW Oregovomab Phase 3 T05938 DRUGINFO D00KGB Abagovomab Phase 2/3 T05938 DRUGINFO D0LA9K REGN4018 Phase 1/2 T05938 DRUGINFO DT1R9E REGN5668 Phase 1/2 T05938 DRUGINFO D04ZIZ DMUC-5754A Phase 1 T05938 DRUGINFO D0I0FA JCAR020 Phase 1 T05938 DRUGINFO D12AIV PRGN-3005 Phase 1 T05938 DRUGINFO D0G9ZJ RG7458 Discontinued in Phase 1 T17986 TARGETID T17986 T17986 FORMERID TTDI03173 T17986 UNIPROID EZH1_HUMAN T17986 TARGNAME Enhancer of zeste homolog 1 (EZH1) T17986 GENENAME EZH1 T17986 TARGTYPE Clinical trial T17986 SYNONYMS KIAA0388; Histone-lysine N-methyltransferase EZH1; ENX-2 T17986 FUNCTION Catalytic subunit of the PRC2/EED-EZH1 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Required for embryonic stem cell derivation and self-renewal, suggesting that it is involved in safeguarding embryonic stem cell identity. Compared to EZH2-containing complexes, it is less abundant in embryonic stem cells, has weak methyltransferase activity and plays a less critical role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. Polycomb group (PcG) protein. T17986 BIOCLASS Methyltransferase T17986 ECNUMBER EC 2.1.1.43 T17986 SEQUENCE MEIPNPPTSKCITYWKRKVKSEYMRLRQLKRLQANMGAKALYVANFAKVQEKTQILNEEWKKLRVQPVQSMKPVSGHPFLKKCTIESIFPGFASQHMLMRSLNTVALVPIMYSWSPLQQNFMVEDETVLCNIPYMGDEVKEEDETFIEELINNYDGKVHGEEEMIPGSVLISDAVFLELVDALNQYSDEEEEGHNDTSDGKQDDSKEDLPVTRKRKRHAIEGNKKSSKKQFPNDMIFSAIASMFPENGVPDDMKERYRELTEMSDPNALPPQCTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNVYKRKNKEIKIEPEPCGTDCFLLLEGAKEYAMLHNPRSKCSGRRRRRHHIVSASCSNASASAVAETKEGDSDRDTGNDWASSSSEANSRCQTPTKQKASPAPPQLCVVEAPSEPVEWTGAEESLFRVFHGTYFNNFCSIARLLGTKTCKQVFQFAVKESLILKLPTDELMNPSQKKKRKHRLWAAHCRKIQLKKDNSSTQVYNYQPCDHPDRPCDSTCPCIMTQNFCEKFCQCNPDCQNRFPGCRCKTQCNTKQCPCYLAVRECDPDLCLTCGASEHWDCKVVSCKNCSIQRGLKKHLLLAPSDVAGWGTFIKESVQKNEFISEYCGELISQDEADRRGKVYDKYMSSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVVMVNGDHRIGIFAKRAIQAGEELFFDYRYSQADALKYVGIERETDVL T17986 DRUGINFO DNM79H DS-3201b Phase 2 T17986 DRUGINFO D0LG8T DS-3201 Phase 1 T17986 DRUGINFO D6EU7R HH2853 Phase 1 T17986 DRUGINFO D02TVQ GSK343 Investigative T07063 TARGETID T07063 T07063 FORMERID TTDR01001 T07063 UNIPROID SC5A5_HUMAN T07063 TARGNAME Sodium/iodide cotransporter (SLC5A5) T07063 GENENAME SLC5A5 T07063 TARGTYPE Clinical trial T07063 SYNONYMS Solute carrier family 5 member 5; Sodium/iodide symporter; Sodium-iodide symporter; Na+/I-symporter; Na(+)/I(-) symporter; Na(+)/I(-) cotransporter; NIS T07063 FUNCTION Mediates iodide uptake in the thyroid gland. T07063 BIOCLASS Solute:sodium symporter T07063 SEQUENCE MEAVETGERPTFGAWDYGVFALMLLVSTGIGLWVGLARGGQRSAEDFFTGGRRLAALPVGLSLSASFMSAVQVLGVPSEAYRYGLKFLWMCLGQLLNSVLTALLFMPVFYRLGLTSTYEYLEMRFSRAVRLCGTLQYIVATMLYTGIVIYAPALILNQVTGLDIWASLLSTGIICTFYTAVGGMKAVVWTDVFQVVVMLSGFWVVLARGVMLVGGPRQVLTLAQNHSRINLMDFNPDPRSRYTFWTFVVGGTLVWLSMYGVNQAQVQRYVACRTEKQAKLALLINQVGLFLIVSSAACCGIVMFVFYTDCDPLLLGRISAPDQYMPLLVLDIFEDLPGVPGLFLACAYSGTLSTASTSINAMAAVTVEDLIKPRLRSLAPRKLVIISKGLSLIYGSACLTVAALSSLLGGGVLQGSFTVMGVISGPLLGAFILGMFLPACNTPGVLAGLGAGLALSLWVALGATLYPPSEQTMRVLPSSAARCVALSVNASGLLDPALLPANDSSRAPSSGMDASRPALADSFYAISYLYYGALGTLTTVLCGALISCLTGPTKRSTLAPGLLWWDLARQTASVAPKEEVAILDDNLVKGPEELPTGNKKPPGFLPTNEDRLFFLGQKELEGAGSWTPCVGHDGGRDQQETNL T07063 DRUGINFO D0G8DV Ad5CMV-NIS Phase 1 T01943 TARGETID T01943 T01943 UNIPROID Q965D7_PLAFA T01943 TARGNAME Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) T01943 GENENAME Malaria FabZ T01943 TARGTYPE Clinical trial T01943 SYNONYMS fabZ; Fatty acid synthesis protein; Beta-hydroxyacyl-ACP dehydratase; 17 kDa actomyosin component; (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase; (3R)-hydroxymyristoyl-ACP dehydrase T01943 FUNCTION Involved in unsaturated fatty acids biosynthesis. Catalyzes the dehydration of short chain beta-hydroxyacyl-ACPs and long chain saturated and unsaturated beta-hydroxyacyl-ACPs. T01943 PDBSTRUC 3AZB; 3AZA; 3AZ9; 3AZ8; 2OKI T01943 SEQUENCE MRFLIIHIAVIVLPFVLMIDVKRENSFFLRHSPKRLYKKADYNNMYDKIIKKQQNRIYDVSSQINQDNINGQNISFNLTFPNYDTSIDIEDIKKILPHRYPFLLVDKVIYMQPNKTIIGLKQVSTNEPFFNGHFPQKQIMPGVLQIEALAQLAGILCLKSDDSQKNNLFLFAGVDGVRWKKPVLPGDTLTMQANLISFKSSLGIAKLSGVGYVNGKVVINISEMTFALSK T01943 DRUGINFO D0U2BH Epigallocatechin gallate Phase 3 T01943 DRUGINFO D05HRK 2-Hexadecynoic acid Investigative T01943 DRUGINFO D07KXK GALLOCATECHIN GALLATE Investigative T01943 DRUGINFO D0MF5Y 3,7,3',4'-TETRAHYDROXYFLAVONE Investigative T01943 DRUGINFO D0RB1V (-)-CATECHINGALLATE Investigative T01943 DRUGINFO D0S9YX biochanin A Investigative T01943 DRUGINFO D0NJ4H MORIN Investigative T49453 TARGETID T49453 T49453 FORMERID TTDI01779 T49453 UNIPROID NOTC4_HUMAN T49453 TARGNAME Notch-4 receptor (NOTCH4) T49453 GENENAME NOTCH4 T49453 TARGTYPE Clinical trial T49453 SYNONYMS hNotch4; Notch 4; Neurogenic locus notch homolog protein 4; INT3 T49453 FUNCTION Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. May regulate branching morphogenesis in the developing vascular system. Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. T49453 BIOCLASS Notch protein T49453 SEQUENCE MQPPSLLLLLLLLLLLCVSVVRPRGLLCGSFPEPCANGGTCLSLSLGQGTCQCAPGFLGETCQFPDPCQNAQLCQNGGSCQALLPAPLGLPSSPSPLTPSFLCTCLPGFTGERCQAKLEDPCPPSFCSKRGRCHIQASGRPQCSCMPGWTGEQCQLRDFCSANPCVNGGVCLATYPQIQCHCPPGFEGHACERDVNECFQDPGPCPKGTSCHNTLGSFQCLCPVGQEGPRCELRAGPCPPRGCSNGGTCQLMPEKDSTFHLCLCPPGFIGPDCEVNPDNCVSHQCQNGGTCQDGLDTYTCLCPETWTGWDCSEDVDECETQGPPHCRNGGTCQNSAGSFHCVCVSGWGGTSCEENLDDCIAATCAPGSTCIDRVGSFSCLCPPGRTGLLCHLEDMCLSQPCHGDAQCSTNPLTGSTLCLCQPGYSGPTCHQDLDECLMAQQGPSPCEHGGSCLNTPGSFNCLCPPGYTGSRCEADHNECLSQPCHPGSTCLDLLATFHCLCPPGLEGQLCEVETNECASAPCLNHADCHDLLNGFQCICLPGFSGTRCEEDIDECRSSPCANGGQCQDQPGAFHCKCLPGFEGPRCQTEVDECLSDPCPVGASCLDLPGAFFCLCPSGFTGQLCEVPLCAPNLCQPKQICKDQKDKANCLCPDGSPGCAPPEDNCTCHHGHCQRSSCVCDVGWTGPECEAELGGCISAPCAHGGTCYPQPSGYNCTCPTGYTGPTCSEEMTACHSGPCLNGGSCNPSPGGYYCTCPPSHTGPQCQTSTDYCVSAPCFNGGTCVNRPGTFSCLCAMGFQGPRCEGKLRPSCADSPCRNRATCQDSPQGPRCLCPTGYTGGSCQTLMDLCAQKPCPRNSHCLQTGPSFHCLCLQGWTGPLCNLPLSSCQKAALSQGIDVSSLCHNGGLCVDSGPSYFCHCPPGFQGSLCQDHVNPCESRPCQNGATCMAQPSGYLCQCAPGYDGQNCSKELDACQSQPCHNHGTCTPKPGGFHCACPPGFVGLRCEGDVDECLDQPCHPTGTAACHSLANAFYCQCLPGHTGQWCEVEIDPCHSQPCFHGGTCEATAGSPLGFICHCPKGFEGPTCSHRAPSCGFHHCHHGGLCLPSPKPGFPPRCACLSGYGGPDCLTPPAPKGCGPPSPCLYNGSCSETTGLGGPGFRCSCPHSSPGPRCQKPGAKGCEGRSGDGACDAGCSGPGGNWDGGDCSLGVPDPWKGCPSHSRCWLLFRDGQCHPQCDSEECLFDGYDCETPPACTPAYDQYCHDHFHNGHCEKGCNTAECGWDGGDCRPEDGDPEWGPSLALLVVLSPPALDQQLFALARVLSLTLRVGLWVRKDRDGRDMVYPYPGARAEEKLGGTRDPTYQERAAPQTQPLGKETDSLSAGFVVVMGVDLSRCGPDHPASRCPWDPGLLLRFLAAMAAVGALEPLLPGPLLAVHPHAGTAPPANQLPWPVLCSPVAGVILLALGALLVLQLIRRRRREHGALWLPPGFTRRPRTQSAPHRRRPPLGEDSIGLKALKPKAEVDEDGVVMCSGPEEGEEVGQAEETGPPSTCQLWSLSGGCGALPQAAMLTPPQESEMEAPDLDTRGPDGVTPLMSAVCCGEVQSGTFQGAWLGCPEPWEPLLDGGACPQAHTVGTGETPLHLAARFSRPTAARRLLEAGANPNQPDRAGRTPLHAAVAADAREVCQLLLRSRQTAVDARTEDGTTPLMLAARLAVEDLVEELIAAQADVGARDKWGKTALHWAAAVNNARAARSLLQAGADKDAQDNREQTPLFLAAREGAVEVAQLLLGLGAARELRDQAGLAPADVAHQRNHWDLLTLLEGAGPPEARHKATPGREAGPFPRARTVSVSVPPHGGGALPRCRTLSAGAGPRGGGACLQARTWSVDLAARGGGAYSHCRSLSGVGAGGGPTPRGRRFSAGMRGPRPNPAIMRGRYGVAAGRGGRVSTDDWPCDWVALGACGSASNIPIPPPCLTPSPERGSPQLDCGPPALQEMPINQGGEGKK T49453 DRUGINFO D08WOW LY3039478 Phase 1/2 T57001 TARGETID T57001 T57001 FORMERID TTDR00892 T57001 UNIPROID GPA33_HUMAN T57001 TARGNAME Cell surface A33 antigen (GPA33) T57001 GENENAME GPA33 T57001 TARGTYPE Clinical trial T57001 SYNONYMS GPA33; A33 cognate antigen; A33 antigen T57001 FUNCTION May play a role in cell-cell recognition and signaling. T57001 BIOCLASS Immunoglobulin T57001 SEQUENCE MVGKMWPVLWTLCAVRVTVDAISVETPQDVLRASQGKSVTLPCTYHTSTSSREGLIQWDKLLLTHTERVVIWPFSNKNYIHGELYKNRVSISNNAEQSDASITIDQLTMADNGTYECSVSLMSDLEGNTKSRVRLLVLVPPSKPECGIEGETIIGNNIQLTCQSKEGSPTPQYSWKRYNILNQEQPLAQPASGQPVSLKNISTDTSGYYICTSSNEEGTQFCNITVAVRSPSMNVALYVGIAVGVVAALIIIGIIIYCCCCRGKDDNTEDKEDARPNREAYEEPPEQLRELSREREEEDDYRQEEQRSTGRESPDHLDQ T57001 DRUGINFO D07GNO KRN-330 Phase 1/2 T57001 DRUGINFO D00PEN MGD007 Phase 1/2 T57001 DRUGINFO D08IDB HuA33 Phase 1 T57001 DRUGINFO D0LY0C Radiolabelled-huA33 Phase 1 T54519 TARGETID T54519 T54519 FORMERID TTDI01929 T54519 UNIPROID Q9BMI9_SCHMA T54519 TARGNAME Schistosoma Purine nucleoside phosphorylase (sch PNP) T54519 GENENAME sch PNP T54519 TARGTYPE Clinical trial T54519 SYNONYMS sch Purine nucleoside phosphorylase; sch Inosine-guanosine phosphorylase T54519 FUNCTION The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. T54519 PDBSTRUC 3IEX; 3FNQ; 3FB1; 3FAZ; 3F8W T54519 ECNUMBER EC 2.4.2.1 T54519 SEQUENCE MHESVTANIENVKKVAHHIQKLTSIVPEIGIICGSGLGKLADGVKDKITIPYTKIPNFPQTSVVGHSGNLIFGTLSGRKVVVMQGRFHMYEGYSNDTVALPIRVMKLLGVKILMVSNAAGGLNRSLKLGDFVILKDHIYLPGLGLNNILVGPNQEAFGTRFPALSNAYDRDLRKLAVQVAEENGFGNLVHQGVYVMNGGPCYETPAECTMLLNMGCDVVGMSTIPEVVIARHCGIQVFAVSLVTNISVLDVESDLKPNHEEVLATGAQRAELMQSWFEKIIEKLPKD T54519 DRUGINFO D01OOQ FP-253-GDEPT Phase 1 T79162 TARGETID T79162 T79162 UNIPROID RSPO3_HUMAN T79162 TARGNAME R-spondin-3 (RSPO3) T79162 GENENAME RSPO3 T79162 TARGTYPE Clinical trial T79162 SYNONYMS hRspo3; hPWTSR; Thrombospondin type-1 domain-containing protein 2; Roof plate-specific spondin-3; Protein with TSP type-1 repeat T79162 FUNCTION Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors, which acts as a key regulator of angiogenesis. Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signaling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. Acts as a ligand for frizzled FZD8 and LRP6. May negatively regulate the TGF-beta pathway. Acts as a key regulator of angiogenesis by controlling vascular stability and pruning: acts by activating the non-canonical Wnt signaling pathway in endothelial cells. Can also amplify Wnt signaling pathway independently of LGR4-6 receptors, possibly by acting as a direct antagonistic ligand to RNF43 and ZNRF3. T79162 BIOCLASS R-spondin family T79162 SEQUENCE MHLRLISWLFIILNFMEYIGSQNASRGRRQRRMHPNVSQGCQGGCATCSDYNGCLSCKPRLFFALERIGMKQIGVCLSSCPSGYYGTRYPDINKCTKCKADCDTCFNKNFCTKCKSGFYLHLGKCLDNCPEGLEANNHTMECVSIVHCEVSEWNPWSPCTKKGKTCGFKRGTETRVREIIQHPSAKGNLCPPTNETRKCTVQRKKCQKGERGKKGRERKRKKPNKGESKEAIPDSKSLESSKEIPEQRENKQQQKKRKVQDKQKSVSVSTVH T79162 DRUGINFO D0J3TI Rosmantuzumab Phase 1 T79162 DRUGINFO DPIR35 OMP-131R10 Phase 1 T79747 TARGETID T79747 T79747 FORMERID TTDI02152 T79747 UNIPROID PORCN_HUMAN T79747 TARGNAME Protein-serine O-palmitoleoyltransferase porcupine (PORCN) T79747 GENENAME PORCN T79747 TARGTYPE Clinical trial T79747 SYNONYMS Protein-cysteine N-palmitoyltransferase porcupine; Protein MG61; PORCN T79747 FUNCTION protein-cysteine N-palmitoyltransferase that modulates the processingof Wnt proteins by mediating serine palmitoylation of Wnt family members. T79747 BIOCLASS Acyltransferase T79747 ECNUMBER EC 2.3.1.250 T79747 SEQUENCE MATFSRQEFFQQLLQGCLLPTAQQGLDQIWLLLAICLACRLLWRLGLPSYLKHASTVAGGFFSLYHFFQLHMVWVVLLSLLCYLVLFLCRHSSHRGVFLSVTILIYLLMGEMHMVDTVTWHKMRGAQMIVAMKAVSLGFDLDRGEVGTVPSPVEFMGYLYFVGTIVFGPWISFHSYLQAVQGRPLSCRWLQKVARSLALALLCLVLSTCVGPYLFPYFIPLNGDRLLRNKKRKARGTMVRWLRAYESAVSFHFSNYFVGFLSEATATLAGAGFTEEKDHLEWDLTVSKPLNVELPRSMVEVVTSWNLPMSYWLNNYVFKNALRLGTFSAVLVTYAASALLHGFSFHLAAVLLSLAFITYVEHVLRKRLARILSACVLSKRCPPDCSHQHRLGLGVRALNLLFGALAIFHLAYLGSLFDVDVDDTTEEQGYGMAYTVHKWSELSWASHWVTFGCWIFYRLIG T79747 DRUGINFO D05FKU ETC-1922159 Phase 1 T79747 DRUGINFO D0J5HR LGK974 Phase 1 T79747 DRUGINFO DYA4W9 RXC006 Phase 1 T62241 TARGETID T62241 T62241 FORMERID TTDI01796 T62241 UNIPROID IL25_HUMAN T62241 TARGNAME Interleukin-25 (IL25) T62241 GENENAME IL25 T62241 TARGTYPE Clinical trial T62241 SYNONYMS UNQ3120/PRO10272; Interleukin-17E; IL17E; IL-25; IL-17E T62241 FUNCTION Proinflammatory cytokine favoring Th2-type immune responses. Induces activation of NF-kappa-B and stimulates production of the proinflammatory chemokine IL-8. T62241 BIOCLASS Cytokine: interleukin T62241 SEQUENCE MRERPRLGEDSSLISLFLQVVAFLAMVMGTHTYSHWPSCCPSKGQDTSEELLRWSTVPVPPLEPARPNRHPESCRASEDGPLNSRAISPWRYELDRDLNRLPQDLYHARCLCPHCVSLQTGSHMDPRGNSELLYHNQTVFYRRPCHGEKGTHKGYCLERRLYRVSLACVCVRPRVMG T62241 DRUGINFO D0B5UH ALX-0761 Phase 1 T84397 TARGETID T84397 T84397 FORMERID TTDI00967 T84397 UNIPROID TBB1_HUMAN T84397 TARGNAME Tubulin beta-1 chain (TUBB1) T84397 GENENAME TUBB1 T84397 TARGTYPE Clinical trial T84397 SYNONYMS TUBB1 T84397 FUNCTION Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. T84397 BIOCLASS Tubulin family T84397 SEQUENCE MREIVHIQIGQCGNQIGAKFWEMIGEEHGIDLAGSDRGASALQLERISVYYNEAYGRKYVPRAVLVDLEPGTMDSIRSSKLGALFQPDSFVHGNSGAGNNWAKGHYTEGAELIENVLEVVRHESESCDCLQGFQIVHSLGGGTGSGMGTLLMNKIREEYPDRIMNSFSVMPSPKVSDTVVEPYNAVLSIHQLIENADACFCIDNEALYDICFRTLKLTTPTYGDLNHLVSLTMSGITTSLRFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTAQGSQQYRALSVAELTQQMFDARNTMAACDLRRGRYLTVACIFRGKMSTKEVDQQLLSVQTRNSSCFVEWIPNNVKVAVCDIPPRGLSMAATFIGNNTAIQEIFNRVSEHFSAMFKRKAFVHWYTSEGMDINEFGEAENNIHDLVSEYQQFQDAKAVLEEDEEVTEEAEMEPEDKGH T84397 DRUGINFO D0K8LB PI-88/Taxotere Phase 2 T84397 DRUGINFO D03UDW AI-850 Phase 1 T84397 DRUGINFO D05CHN Irofulven/Taxotere Phase 1 T84397 DRUGINFO D01WYV Angiostatin/paclitaxel/carboplatin Investigative T73696 TARGETID T73696 T73696 FORMERID TTDI02307 T73696 UNIPROID RXFP1_HUMAN T73696 TARGNAME Relaxin receptor 1 (RXFP1) T73696 GENENAME RXFP1 T73696 TARGTYPE Clinical trial T73696 SYNONYMS Relaxin family peptide receptor 1; RXFP1; Leucine-rich repeat-containing G-protein coupled receptor 7 T73696 FUNCTION Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activity of a phosphodiesterase that degrades cAMP. T73696 PDBSTRUC 2M7P; 2JM4 T73696 BIOCLASS GPCR rhodopsin T73696 SEQUENCE MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADEDNCGDNNGWSLQFDKYFASYYKMTSQYPFEAETPECLVGSVPVQCLCQGLELDCDETNLRAVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLYLQNNKITSISIYAFRGLNSLTKLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMNNVLTRLPDKPLCQHMPRLHWLDLEGNHIHNLRNLTFISCSNLTVLVMRKNKINHLNENTFAPLQKLDELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLEGIEISNIQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCKPNTDGISSLENLLASIIQRVFVWVVSAVTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGGFDLKFRGEYNKHAQLWMESTHCQLVGSLAILSTEVSVLLLTFLTLEKYICIVYPFRCVRPGKCRTITVLILIWITGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIIVFSYGSMFYSVHQSAITATEIRNQVKKEMILAKRFFFIVFTDALCWIPIFVVKFLSLLQVEIPGTITSWVVIFILPINSALNPILYTLTTRPFKEMIHRFWYNYRQRKSMDSKGQKTYAPSFIWVEMWPLQEMPPELMKPDLFTYPCEMSLISQSTRLNSYS T73696 DRUGINFO D0T3FN RLX030 Approval submitted T73696 DRUGINFO D0CI3Z AZD5462 Phase 1 T73696 DRUGINFO D01WWO ML290 Investigative T23050 TARGETID T23050 T23050 UNIPROID LPTD_PSEAE T23050 TARGNAME Pseudomonas LPS-assembly protein LptD (Pseudo lptD) T23050 GENENAME Pseudo lptD T23050 TARGTYPE Clinical trial T23050 SYNONYMS ostA; Pseudo imp T23050 FUNCTION Together with LptE, is involved in the assembly of lipopolysaccharide (LPS) at the surface of the outer membrane. T23050 PDBSTRUC 5IVA T23050 BIOCLASS LptD family T23050 SEQUENCE MAVKSLVFRRKFPLLVTGSLLALQPVAALTVQAADQFDCKVSATGGWDCSPLQNANANLPPRPAHTATSVSTAAAGSSVSGSGGETVEAEPTQRLVTESGGRALKSRSADYSHLDWIPREKLTAAQLAEIGPYCGGSYIEPVRPGMDDGAPSDESPTYVSAKASRYEQEKQIATLAGDVVLRQGSMQVEGDEANLHQLENRGELVGNVKLRDKGMLVVGDHAQVQLDNGEAQVDNAEYVIHKAHARGSALYAKRSENAIIMLKDGTYTRCEPSSNAWTLKGNNVKLNPATGFGTATNATLRVKDFPVFYTPYIYFPIDDRRQSGFLPPSFSSTSDTGFTLVTPYYFNLAPNYDATLYPRYMAKRGMMLEGEFRYLTHSSEGIVNAAYLNDKDDHREGFPDYSKDRWLYGLKNTTGLDSRWLAEVDYTRISDPYYFQDLDTDLGVGSTTYVNQRGTLTYRGDTFTGRLNAQAYQLATTTDVTPYDRLPQITFDGFLPYNPGGMQFTYGTEFVRFDRDLDENIYFNDDGSIRGKRPDASLQGLARATGDRMHLEPGMSLPMTRSWGYVTPTLKYLYTKYDLDLDSQGKTDLNKRDESFDSNQDRSLPLVKVDSGLYFDRDTTFAGTPFRQTLEPRAMYLYVPYKDQDSLPVFDTSEPSFSYDSLWRENRFTGKDRIGDANQLSLGVTSRFIEENGFERASISAGQIYYFRDRRVQLPGLTEKDLKRLNLDPSGLDNDSWRSPYAFAGQYRFNRDWRINSDFNWNPNTSRTESGSAIFHYQPEVDPGKVVNVGYRYRADARRFDSSRGTFRYGNENDIIKQHDFSVIWPLVPQWSVLARWQYDYNKNRTLEAFGGFEYDSCCWKLRLINRYWLDVDDDAFLVQSEKADRGIFLQIVLKGLGGIVGNKTEMFLDKGIQGYRQREDQAM T23050 DRUGINFO D00IVF Murepavadin Phase 3 T70062 TARGETID T70062 T70062 FORMERID TTDI02164 T70062 UNIPROID RTN4_HUMAN T70062 TARGNAME Reticulon-4 (RTN4) T70062 GENENAME RTN4 T70062 TARGTYPE Clinical trial T70062 SYNONYMS SP1507; My043 T70062 FUNCTION Required to induce the formation and stabilization of endoplasmic reticulum (ER) tubules. They regulate membrane morphogenesis in the ER by promoting tubular ER production. They influence nuclear envelope expansion, nuclear pore complex formation and proper localization of inner nuclear membrane proteins. However each isoform have specific functions mainly depending on their tissue expression specificities. T70062 PDBSTRUC 2JV5; 2G31 T70062 SEQUENCE MEDLDQSPLVSSSDSPPRPQPAFKYQFVREPEDEEEEEEEEEEDEDEDLEELEVLERKPAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVPAPSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKRRGSSGSVDETLFALPAASEPVIRSSAENMDLKEQPGNTISAGQEDFPSVLLETAASLPSLSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEYSEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKEDEVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDSDMLAAGGKIESNLESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIATNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLTKVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEASSVNYESIKHEPENPPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDFSDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETSFESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEELSTAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVSHKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDVSALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE T70062 DRUGINFO D0M0WM ATI-355 Phase 1 T55273 TARGETID T55273 T55273 FORMERID TTDNC00397 T55273 UNIPROID DLL4_HUMAN T55273 TARGNAME Delta-like protein 4 (DLL4) T55273 GENENAME DLL4 T55273 TARGTYPE Clinical trial T55273 SYNONYMS UNQ1895/PRO4341; Drosophila Delta homolog 4; Deltalike protein 4; Delta4 T55273 FUNCTION Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types. During spinal cord neurogenesis, inhibits V2a interneuron fate. Involved in the Notch signaling pathway as Notch ligand. T55273 PDBSTRUC 5MVX T55273 SEQUENCE MAAASRSASGWALLLLVALWQQRAAGSGVFQLQLQEFINERGVLASGRPCEPGCRTFFRVCLKHFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIEAWHAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECLCRPGWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCTHHSPCKNGATCSNSGQRSYTCTCRPGYTGVDCELELSECDSNPCRNGGSCKDQEDGYHCLCPPGYYGLHCEHSTLSCADSPCFNGGSCRERNQGANYACECPPNFTGSNCEKKVDRCTSNPCANGGQCLNRGPSRMCRCRPGFTGTYCELHVSDCARNPCAHGGTCHDLENGLMCTCPAGFSGRRCEVRTSIDACASSPCFNRATCYTDLSTDTFVCNCPYGFVGSRCEFPVGLPPSFPWVAVSLGVGLAVLLVLLGMVAVAVRQLRLRRPDDGSREAMNNLSDFQKDNLIPAAQLKNTNQKKELEVDCGLDKSNCGKQQNHTLDYNLAPGPLGRGTMPGKFPHSDKSLGEKAPLRLHSEKPECRISAICSPRDSMYQSVCLISEERNECVIATEV T55273 DRUGINFO DMEV15 Dilpacimab Phase 2 T55273 DRUGINFO D06VCC REGN-421 Phase 1 T55273 DRUGINFO D0GS9X OMP-21M18 Phase 1 T55273 DRUGINFO D00IVN Navicixizumab Phase 1 T55273 DRUGINFO D0PP6A ABT-165 Phase 1 T55273 DRUGINFO DIPY14 NOV1501 Phase 1 T57718 TARGETID T57718 T57718 FORMERID TTDI02217 T57718 UNIPROID MAGC2_HUMAN T57718 TARGNAME Melanoma-associated antigen C2 (MAGEC2) T57718 GENENAME MAGEC2 T57718 TARGTYPE Clinical trial T57718 SYNONYMS MAGEE1 antigen; MAGEE1; MAGEC2 antigen; MAGE-E1 antigen; MAGE-C2 antigen; Hepatocellular carcinomaassociated antigen 587; Hepatocellular carcinoma-associated antigen 587; HCA587; Cancer/testis antigen 10; CT10 T57718 FUNCTION In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. T57718 BIOCLASS Melanoma associated antigen T57718 SEQUENCE MPPVPGVPFRNVDNDSPTSVELEDWVDAQHPTDEEEEEASSASSTLYLVFSPSSFSTSSSLILGGPEEEEVPSGVIPNLTESIPSSPPQGPPQGPSQSPLSSCCSSFSWSSFSEESSSQKGEDTGTCQGLPDSESSFTYTLDEKVAELVEFLLLKYEAEEPVTEAEMLMIVIKYKDYFPVILKRAREFMELLFGLALIEVGPDHFCVFANTVGLTDEGSDDEGMPENSLLIIILSVIFIKGNCASEEVIWEVLNAVGVYAGREHFVYGEPRELLTKVWVQGHYLEYREVPHSSPPYYEFLWGPRAHSESIKKKVLEFLAKLNNTVPSSFPSWYKDALKDVEERVQATIDTADDATVMASESLSVMSSNVSFSE T57718 DRUGINFO D02DVK CV-9201 Phase 1/2 T96916 TARGETID T96916 T96916 UNIPROID DKK3_HUMAN T96916 TARGNAME Dickkopf-related protein 3 (DKK3) T96916 GENENAME DKK3 T96916 TARGTYPE Clinical trial T96916 SYNONYMS hDkk-3; UNQ258/PRO295; REIC; Dkk-3; Dickkopf-3 T96916 FUNCTION DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease. Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6. T96916 BIOCLASS Dickkopf protein T96916 SEQUENCE MQRLGATLLCLLLAAAVPTAPAPAPTATSAPVKPGPALSYPQEEATLNEMFREVEELMEDTQHKLRSAVEEMEAEEAAAKASSEVNLANLPPSYHNETNTDTKVGNNTIHVHREIHKITNNQTGQMVFSETVITSVGDEEGRRSHECIIDEDCGPSMYCQFASFQYTCQPCRGQRMLCTRDSECCGDQLCVWGHCTKMATRGSNGTICDNQRDCQPGLCCAFQRGLLFPVCTPLPVEGELCHDPASRLLDLITWELEPDGALDRCPCASGLLCQPHSHSLVYVCKPTFVGSRDQDGEILLPREVPDEYEVGSFMEEVRQELEDLERSLTEEMALREPAAAAAALLGGEEI T96916 DRUGINFO D0D2XA REIC gene therapy Phase 1/2 T06850 TARGETID T06850 T06850 FORMERID TTDR00583 T06850 UNIPROID GHRL_HUMAN T06850 TARGNAME Ghrelin (GHRL) T06850 GENENAME GHRL T06850 TARGTYPE Clinical trial T06850 SYNONYMS UNQ524/PRO1066; Motilin-related peptide; M46 protein; Growth hormone secretagogue; Growth hormone releasing peptide; Gastric peptide ghrelin; GHRL T06850 FUNCTION Specific ligand for the growth hormone secretagogue receptor type 1 (ghsr) inducing the release of growth hormone from the pituitary. Has an appetite-stimulating effect, induces adiposity and stimulates gastric acid secretion.Involved in growth regulation. T06850 PDBSTRUC 1P7X T06850 SEQUENCE MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPEDGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK T06850 DRUGINFO D01TDY Unacylated ghrelin Phase 1 T95923 TARGETID T95923 T95923 FORMERID TTDI02116 T95923 UNIPROID LPAR3_HUMAN T95923 TARGNAME Lysophosphatidate-3 receptor (LPAR3) T95923 GENENAME LPAR3 T95923 TARGTYPE Clinical trial T95923 SYNONYMS Lysophosphatidic acid receptor Edg7; Lysophosphatidic acid receptor 3; LPAR3; LPA3; LPA receptor 3 T95923 FUNCTION Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer. Seems to be coupled to the G(i)/G(o) and G(q) families of heteromeric G proteins. T95923 BIOCLASS GPCR rhodopsin T95923 SEQUENCE MNECHYDKHMDFFYNRSNTDTVDDWTGTKLVIVLCVGTFFCLFIFFSNSLVIAAVIKNRKFHFPFYYLLANLAAADFFAGIAYVFLMFNTGPVSKTLTVNRWFLRQGLLDSSLTASLTNLLVIAVERHMSIMRMRVHSNLTKKRVTLLILLVWAIAIFMGAVPTLGWNCLCNISACSSLAPIYSRSYLVFWTVSNLMAFLIMVVVYLRIYVYVKRKTNVLSPHTSGSISRRRTPMKLMKTVMTVLGAFVVCWTPGLVVLLLDGLNCRQCGVQHVKRWFLLLALLNSVVNPIIYSYKDEDMYGTMKKMICCFSQENPERRPSRIPSTVLSRSDTGSQYIEDSISQGAVCNKSTS T95923 DRUGINFO D07WCT SAR-100842 Phase 2 T95923 DRUGINFO D0D5OY alpha-fluoromethylenephosphonate Investigative T95923 DRUGINFO D0H6DZ OMPT Investigative T95923 DRUGINFO D0SH0M PMID19800804C12 Investigative T95923 DRUGINFO D0FZ6A dodecylphosphate Investigative T95923 DRUGINFO D0S6CW VPC32183 Investigative T95923 DRUGINFO D0X0OP alkyl OMPT Investigative T95923 DRUGINFO D0Z6DG T13 Investigative T95923 DRUGINFO D04KQT dodecyl-thiophosphate Investigative T95923 DRUGINFO D0K3GQ oleoyl-thiophosphate Investigative T95923 DRUGINFO D0PI4H VPC12249 Investigative T95923 DRUGINFO D0R8LB NAEPA Investigative T95923 DRUGINFO D02LXI Ki16425 Investigative T95923 DRUGINFO D0G6XT dioctanoylglycerol pyrophosphate Investigative T95923 DRUGINFO D0R2VH 2-oleoyl-LPA Investigative T95923 DRUGINFO D0X0UR LPA Investigative T27611 TARGETID T27611 T27611 FORMERID TTDI02218 T27611 UNIPROID GDF2_HUMAN T27611 TARGNAME Growth/differentiation factor 2 (GDF2) T27611 GENENAME GDF2 T27611 TARGTYPE Clinical trial T27611 SYNONYMS GDF2; Bone morphogenetic protein 9; BMP9 T27611 FUNCTION Potent circulating inhibitor of angiogenesis. Couldbe involved in bone formation. Signals through the type I activin receptor ACVRL1 but not other Alks. Signaling through SMAD1 in endothelial cells requires TGF-beta coreceptor endoglin/ENG. T27611 PDBSTRUC 5I05; 5HZW; 4YCI; 4YCG; 4MPL T27611 BIOCLASS Growth factor T27611 SEQUENCE MCPGALWVALPLLSLLAGSLQGKPLQSWGRGSAGGNAHSPLGVPGGGLPEHTFNLKMFLENVKVDFLRSLNLSGVPSQDKTRVEPPQYMIDLYNRYTSDKSTTPASNIVRSFSMEDAISITATEDFPFQKHILLFNISIPRHEQITRAELRLYVSCQNHVDPSHDLKGSVVIYDVLDGTDAWDSATETKTFLVSQDIQDEGWETLEVSSAVKRWVRSDSTKSKNKLEVTVESHRKGCDTLDISVPPGSRNLPFFVVFSNDHSSGTKETRLELREMISHEQESVLKKLSKDGSTEAGESSHEEDTDGHVAAGSTLARRKRSAGAGSHCQKTSLRVNFEDIGWDSWIIAPKEYEAYECKGGCFFPLADDVTPTKHAIVQTLVHLKFPTKVGKACCVPTKLSPISVLYKDDMGVPTLKYHYEGMSVAECGCR T27611 DRUGINFO D0N9PL ACE-041 Phase 1 T00156 TARGETID T00156 T00156 FORMERID TTDI02490 T00156 UNIPROID TRPC5_HUMAN T00156 TARGNAME Short transient receptor potential channel 5 (TRPC5) T00156 GENENAME TRPC5 T00156 TARGTYPE Clinical trial T00156 SYNONYMS hTRP5; hTRP-5; TrpC5; Transient receptor protein 5; TRP-5 T00156 FUNCTION Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Has also been shown to be calcium-selective. May also be activated by intracellular calcium store depletion. T00156 BIOCLASS Transient receptor potential catioin channel T00156 SEQUENCE MAQLYYKKVNYSPYRDRIPLQIVRAETELSAEEKAFLNAVEKGDYATVKQALQEAEIYYNVNINCMDPLGRSALLIAIENENLEIMELLLNHSVYVGDALLYAIRKEVVGAVELLLSYRRPSGEKQVPTLMMDTQFSEFTPDITPIMLAAHTNNYEIIKLLVQKRVTIPRPHQIRCNCVECVSSSEVDSLRHSRSRLNIYKALASPSLIALSSEDPILTAFRLGWELKELSKVENEFKAEYEELSQQCKLFAKDLLDQARSSRELEIILNHRDDHSEELDPQKYHDLAKLKVAIKYHQKEFVAQPNCQQLLATLWYDGFPGWRRKHWVVKLLTCMTIGFLFPMLSIAYLISPRSNLGLFIKKPFIKFICHTASYLTFLFMLLLASQHIVRTDLHVQGPPPTVVEWMILPWVLGFIWGEIKEMWDGGFTEYIHDWWNLMDFAMNSLYLATISLKIVAYVKYNGSRPREEWEMWHPTLIAEALFAISNILSSLRLISLFTANSHLGPLQISLGRMLLDILKFLFIYCLVLLAFANGLNQLYFYYETRAIDEPNNCKGIRCEKQNNAFSTLFETLQSLFWSVFGLLNLYVTNVKARHEFTEFVGATMFGTYNVISLVVLLNMLIAMMNNSYQLIADHADIEWKFARTKLWMSYFDEGGTLPPPFNIIPSPKSFLYLGNWFNNTFCPKRDPDGRRRRRNLRSFTERNADSLIQNQHYQEVIRNLVKRYVAAMIRNSKTHEGLTEENFKELKQDISSFRYEVLDLLGNRKHPRSFSTSSTELSQRDDNNDGSGGARAKSKSVSFNLGCKKKTCHGPPLIRTMPRSSGAQGKSKAESSSKRSFMGPSLKKLGLLFSKFNGHMSEPSSEPMYTISDGIVQQHCMWQDIRYSQMEKGKAEACSQSEINLSEVELGEVQGAAQSSECPLACSSSLHCASSICSSNSKLLDSSEDVFETWGEACDLLMHKWGDGQEEQVTTRL T00156 DRUGINFO D1IFS2 GFB-887 Phase 2 T00156 DRUGINFO DD1ZV6 BI 1358894 Phase 2 T00156 DRUGINFO D09YUL bromoenol lactone Investigative T00156 DRUGINFO D0G8FT ML204 Investigative T00156 DRUGINFO D0M6VZ (-)-englerin A Investigative T00156 DRUGINFO D0F4FK KB-R7943 Investigative T00156 DRUGINFO D0JV2P BTP2 Investigative T00156 DRUGINFO D0KT5E lysophosphatidylcholine Investigative T00156 DRUGINFO D0SY2M daidzein Investigative T00156 DRUGINFO D00HCI 2-APB Investigative T58741 TARGETID T58741 T58741 FORMERID TTDI02461 T58741 UNIPROID SCN8A_HUMAN T58741 TARGNAME Voltage-gated sodium channel alpha Nav1.6 (SCN8A) T58741 GENENAME SCN8A T58741 TARGTYPE Clinical trial T58741 SYNONYMS Voltage-gated sodium channel subunit alpha Nav1.6; Sodium channel protein type VIII subunit alpha; Sodium channel protein type 8 subunit alpha; SCN8A T58741 FUNCTION Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. In macrophages and melanoma cells, isoform 5 may participate in the control of podosome and invadopodia formation. T58741 BIOCLASS Voltage-gated ion channel T58741 SEQUENCE MAARLLAPPGPDSFKPFTPESLANIERRIAESKLKKPPKADGSHREDDEDSKPKPNSDLEAGKSLPFIYGDIPQGLVAVPLEDFDPYYLTQKTFVVLNRGKTLFRFSATPALYILSPFNLIRRIAIKILIHSVFSMIIMCTILTNCVFMTFSNPPDWSKNVEYTFTGIYTFESLVKIIARGFCIDGFTFLRDPWNWLDFSVIMMAYITEFVNLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCVVWPINFNESYLENGTKGFDWEEYINNKTNFYTVPGMLEPLLCGNSSDAGQCPEGYQCMKAGRNPNYGYTSFDTFSWAFLALFRLMTQDYWENLYQLTLRAAGKTYMIFFVLVIFVGSFYLVNLILAVVAMAYEEQNQATLEEAEQKEAEFKAMLEQLKKQQEEAQAAAMATSAGTVSEDAIEEEGEEGGGSPRSSSEISKLSSKSAKERRNRRKKRKQKELSEGEEKGDPEKVFKSESEDGMRRKAFRLPDNRIGRKFSIMNQSLLSIPGSPFLSRHNSKSSIFSFRGPGRFRDPGSENEFADDEHSTVEESEGRRDSLFIPIRARERRSSYSGYSGYSQGSRSSRIFPSLRRSVKRNSTVDCNGVVSLIGGPGSHIGGRLLPEATTEVEIKKKGPGSLLVSMDQLASYGRKDRINSIMSVVTNTLVEELEESQRKCPPCWYKFANTFLIWECHPYWIKLKEIVNLIVMDPFVDLAITICIVLNTLFMAMEHHPMTPQFEHVLAVGNLVFTGIFTAEMFLKLIAMDPYYYFQEGWNIFDGFIVSLSLMELSLADVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKINQDCELPRWHMHDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLIVFMMVMVIGNLVVLNLFLALLLSSFSADNLAATDDDGEMNNLQISVIRIKKGVAWTKLKVHAFMQAHFKQREADEVKPLDELYEKKANCIANHTGADIHRNGDFQKNGNGTTSGIGSSVEKYIIDEDHMSFINNPNLTVRVPIAVGESDFENLNTEDVSSESDPEGSKDKLDDTSSSEGSTIDIKPEVEEVPVEQPEEYLDPDACFTEGCVQRFKCCQVNIEEGLGKSWWILRKTCFLIVEHNWFETFIIFMILLSSGALAFEDIYIEQRKTIRTILEYADKVFTYIFILEMLLKWTAYGFVKFFTNAWCWLDFLIVAVSLVSLIANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKYHYCFNETSEIRFEIEDVNNKTECEKLMEGNNTEIRWKNVKINFDNVGAGYLALLQVATFKGWMDIMYAAVDSRKPDEQPKYEDNIYMYIYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKIQGIVFDFVTQQAFDIVIMMLICLNMVTMMVETDTQSKQMENILYWINLVFVIFFTCECVLKMFALRHYYFTIGWNIFDFVVVILSIVGMFLADIIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIFSIFGMSNFAYVKHEAGIDDMFNFETFGNSMICLFQITTSAGWDGLLLPILNRPPDCSLDKEHPGSGFKGDCGNPSVGIFFFVSYIIISFLIVVNMYIAIILENFSVATEESADPLSEDDFETFYEIWEKFDPDATQFIEYCKLADFADALEHPLRVPKPNTIELIAMDLPMVSGDRIHCLDILFAFTKRVLGDSGELDILRQQMEERFVASNPSKVSYEPITTTLRRKQEEVSAVVLQRAYRGHLARRGFICKKTTSNKLENGGTHREKKESTPSTASLPSYDSVTKPEKEKQQRAEEGRRERAKRQKEVRESKC T58741 DRUGINFO DMT4U6 NBI-921352 Phase 2 T58741 DRUGINFO D01QTJ XEN901 Phase 1 T58741 DRUGINFO D0R0JN PRAX-330 Phase 1 T58741 DRUGINFO D04HXU 4,9-anhydro-tetrodotoxin Investigative T58741 DRUGINFO D0G9WE batrachotoxin Investigative T58741 DRUGINFO D0S4MN veratridine Investigative T02469 TARGETID T02469 T02469 UNIPROID FYV1_HUMAN T02469 TARGNAME Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3) T02469 GENENAME PIKFYVE T02469 TARGTYPE Clinical trial T02469 SYNONYMS Type III PIP kinase; Phosphatidylinositol 3-phosphate 5-kinase type III; PIPkin-III; PIKfyve; FYVE finger-containing phosphoinositide kinase T02469 FUNCTION The PI(3,5)P2 regulatory complex regulates both the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). Catalyzes the phosphorylation of phosphatidylinositol 3-phosphate on the fifth hydroxyl of the myo-inositol ring, to form phosphatidylinositol 3,5-bisphosphate. Required for endocytic-vacuolar pathway and nuclear migration. Plays a role in the biogenesis of endosome carrier vesicles (ECV)/ multivesicular bodies (MVB) transport intermediates from early endosomes. T02469 ECNUMBER EC 2.7.1.150 T02469 SEQUENCE MATDDKTSPTLDSANDLPRSPTSPSHLTHFKPLTPDQDEPPFKSAYSSFVNLFRFNKERAEGGQGEQQPLSGSWTSPQLPSRTQSVRSPTPYKKQLNEELQRRSSALDTRRKAEPTFGGHDPRTAVQLRSLSTVLKRLKEIMEGKSQDSDLKQYWMPDSQCKECYDCSEKFTTFRRRHHCRLCGQIFCSRCCNQEIPGKFMGYTGDLRACTYCRKIALSYAHSTDSNSIGEDLNALSDSACSVSVLDPSEPRTPVGSRKASRNIFLEDDLAWQSLIHPDSSNTPLSTRLVSVQEDAGKSPARNRSASITNLSLDRSGSPMVPSYETSVSPQANRTYVRTETTEDERKILLDSVQLKDLWKKICHHSSGMEFQDHRYWLRTHPNCIVGKELVNWLIRNGHIATRAQAIAIGQAMVDGRWLDCVSHHDQLFRDEYALYRPLQSTEFSETPSPDSDSVNSVEGHSEPSWFKDIKFDDSDTEQIAEEGDDNLANSASPSKRTSVSSFQSTVDSDSAASISLNVELDNVNFHIKKPSKYPHVPPHPADQKEYLISDTGGQQLSISDAFIKESLFNRRVEEKSKELPFTPLGWHHNNLELLREENGEKQAMERLLSANHNHMMALLQQLLHSDSLSSSWRDIIVSLVCQVVQTVRPDVKNQDDDMDIRQFVHIKKIPGGKKFDSVVVNGFVCTKNIAHKKMSSCIKNPKILLLKCSIEYLYREETKFTCIDPIVLQEREFLKNYVQRIVDVRPTLVLVEKTVSRIAQDMLLEHGITLVINVKSQVLERISRMTQGDLVMSMDQLLTKPHLGTCHKFYMQIFQLPNEQTKTLMFFEGCPQHLGCTIKLRGGSDYELARVKEILIFMICVAYHSQLEISFLMDEFAMPPTLMQNPSFHSLIEGRGHEGAVQEQYGGGSIPWDPDIPPESLPCDDSSLLELRIVFEKGEQENKNLPQAVASVKHQEHSTTACPAGLPCAFFAPVPESLLPLPVDDQQDALGSEQPETLQQTVVLQDPKSQIRAFRDPLQDDTGLYVTEEVTSSEDKRKTYSLAFKQELKDVILCISPVITFREPFLLTEKGMRCSTRDYFAEQVYWSPLLNKEFKEMENRRKKQLLRDLSGLQGMNGSIQAKSIQVLPSHELVSTRIAEHLGDSQSLGRMLADYRARGGRIQPKNSDPFAHSKDASSTSSGQSGSKNEGDEERGLILSDAVWSTKVDCLNPINHQRLCVLFSSSSAQSSNAPSACVSPWIVTMEFYGKNDLTLGIFLERYCFRPSYQCPSMFCDTPMVHHIRRFVHGQGCVQIILKELDSPVPGYQHTILTYSWCRICKQVTPVVALSNESWSMSFAKYLELRFYGHQYTRRANAEPCGHSIHHDYHQYFSYNQMVASFSYSPIRLLEVCVPLPKIFIKRQAPLKVSLLQDLKDFFQKVSQVYVAIDERLASLKTDTFSKTREEKMEDIFAQKEMEEGEFKNWIEKMQARLMSSSVDTPQQLQSVFESLIAKKQSLCEVLQAWNNRLQDLFQQEKGRKRPSVPPSPGRLRQGEESKISAMDASPRNISPGLQNGEKEDRFLTTLSSQSSTSSTHLQLPTPPEVMSEQSVGGPPELDTASSSEDVFDGHLLGSTDSQVKEKSTMKAIFANLLPGNSYNPIPFPFDPDKHYLMYEHERVPIAVCEKEPSSIIAFALSCKEYRNALEELSKATQWNSAEEGLPTNSTSDSRPKSSSPIRLPEMSGGQTNRTTETEPQPTKKASGMLSFFRGTAGKSPDLSSQKRETLRGADSAYYQVGQTGKEGTENQGVEPQDEVDGGDTQKKQLINPHVELQFSDANAKFYCRLYYAGEFHKMREVILDSSEEDFIRSLSHSSPWQARGGKSGAAFYATEDDRFILKQMPRLEVQSFLDFAPHYFNYITNAVQQKRPTALAKILGVYRIGYKNSQNNTEKKLDLLVMENLFYGRKMAQVFDLKGSLRNRNVKTDTGKESCDVVLLDENLLKMVRDNPLYIRSHSKAVLRTSIHSDSHFLSSHLIIDYSLLVGRDDTSNELVVGIIDYIRTFTWDKKLEMVVKSTGILGGQGKMPTVVSPELYRTRFCEAMDKYFLMVPDHWTGLGLNC T02469 DRUGINFO D03SUQ Apilimod dimesylate Phase 2 T02469 DRUGINFO D0JW6R LAM-002 Phase 2 T02469 DRUGINFO DPN2R7 YM-201636 Preclinical T25637 TARGETID T25637 T25637 FORMERID TTDI02115 T25637 UNIPROID LOXL2_HUMAN T25637 TARGNAME Lysyl oxidase homolog 2 (LOXL2) T25637 GENENAME LOXL2 T25637 TARGTYPE Clinical trial T25637 SYNONYMS Lysyl oxidaserelated protein WS914; Lysyl oxidaserelated protein 2; Lysyl oxidaselike protein 2; LOXL2 T25637 FUNCTION Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). When secreted in extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. When nuclear, acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E- cadherin, probably by mediating deamination of histone H3. Also involved in E-cadherin repression following hypoxia, a hallmark of epithelial to mesenchymal transition believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression. Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation. T25637 PDBSTRUC 5ZE3 T25637 ECNUMBER EC 1.4.3.13 T25637 SEQUENCE MERPLCSHLCSCLAMLALLSPLSLAQYDSWPHYPEYFQQPAPEYHQPQAPANVAKIQLRLAGQKRKHSEGRVEVYYDGQWGTVCDDDFSIHAAHVVCRELGYVEAKSWTASSSYGKGEGPIWLDNLHCTGNEATLAACTSNGWGVTDCKHTEDVGVVCSDKRIPGFKFDNSLINQIENLNIQVEDIRIRAILSTYRKRTPVMEGYVEVKEGKTWKQICDKHWTAKNSRVVCGMFGFPGERTYNTKVYKMFASRRKQRYWPFSMDCTGTEAHISSCKLGPQVSLDPMKNVTCENGLPAVVSCVPGQVFSPDGPSRFRKAYKPEQPLVRLRGGAYIGEGRVEVLKNGEWGTVCDDKWDLVSASVVCRELGFGSAKEAVTGSRLGQGIGPIHLNEIQCTGNEKSIIDCKFNAESQGCNHEEDAGVRCNTPAMGLQKKLRLNGGRNPYEGRVEVLVERNGSLVWGMVCGQNWGIVEAMVVCRQLGLGFASNAFQETWYWHGDVNSNKVVMSGVKCSGTELSLAHCRHDGEDVACPQGGVQYGAGVACSETAPDLVLNAEMVQQTTYLEDRPMFMLQCAMEENCLSASAAQTDPTTGYRRLLRFSSQIHNNGQSDFRPKNGRHAWIWHDCHRHYHSMEVFTHYDLLNLNGTKVAEGHKASFCLEDTECEGDIQKNYECANFGDQGITMGCWDMYRHDIDCQWVDITDVPPGDYLFQVVINPNFEVAESDYSNNIMKCRSRYDGHRIWMYNCHIGGSFSEETEKKFEHFSGLLNNQLSPQ T25637 DRUGINFO D09NCU GS-6624 Phase 2 T25637 DRUGINFO D7ZXE5 Beta-aminopropionitrile Preclinical T01280 TARGETID T01280 T01280 FORMERID TTDI03051 T01280 UNIPROID BACE2_HUMAN T01280 TARGNAME Beta-site APP-cleaving enzyme 2 (BACE2) T01280 GENENAME BACE2 T01280 TARGTYPE Clinical trial T01280 SYNONYMS Theta-secretase; Membrane-associated aspartic protease 1; Memapsin-1; Down region aspartic protease; DRAP; Beta-site amyloid precursor protein cleaving enzyme 2; Beta-site APP cleaving enzyme 2; Beta-secretase 2; Aspartyl protease 1; Aspartic-like protease 56 kDa; Asp 1; ASP21; ASP1; ALP56; AEPLC T01280 FUNCTION Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves APP, between residues 690 and 691, leading to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. It has also been shown that it can cleave APP between residues 671 and 672. Responsible also for the proteolytic processing of CLTRN in pancreatic beta cells. T01280 PDBSTRUC 4BFB; 4BEL; 3ZLQ; 3ZL7; 3ZKX T01280 ECNUMBER EC 3.4.23.45 T01280 SEQUENCE MGALARALLLPLLAQWLLRAAPELAPAPFTLPLRVAAATNRVVAPTPGPGTPAERHADGLALALEPALASPAGAANFLAMVDNLQGDSGRGYYLEMLIGTPPQKLQILVDTGSSNFAVAGTPHSYIDTYFDTERSSTYRSKGFDVTVKYTQGSWTGFVGEDLVTIPKGFNTSFLVNIATIFESENFFLPGIKWNGILGLAYATLAKPSSSLETFFDSLVTQANIPNVFSMQMCGAGLPVAGSGTNGGSLVLGGIEPSLYKGDIWYTPIKEEWYYQIEILKLEIGGQSLNLDCREYNADKAIVDSGTTLLRLPQKVFDAVVEAVARASLIPEFSDGFWTGSQLACWTNSETPWSYFPKISIYLRDENSSRSFRITILPQLYIQPMMGAGLNYECYRFGISPSTNALVIGATVMEGFYVIFDRAQKRVGFAASPCAEIAGAAVSEISGPFSTEDVASNCVPAQSLSEPILWIVSYALMSVCGAILLVLIVLLLLPFRCQRRPRDPEVVNDESSLVRHRWK T01280 DRUGINFO D0O7HP example 98 (WO2011020806) Clinical trial T01280 DRUGINFO D07IXP example 20 (WO2010128058) Investigative T01280 DRUGINFO D09OCY example 41 (WO2012028563) Investigative T01280 DRUGINFO D0HO1O 2ewy Investigative T01280 DRUGINFO D0Z4JT example 92 (WO2012095521) Investigative T01280 DRUGINFO D00SDQ PMID21907142CJ Investigative T01280 DRUGINFO D0O0GW example 2 (WO2013004676) Investigative T62705 TARGETID T62705 T62705 FORMERID TTDR01123 T62705 UNIPROID ICOS_HUMAN T62705 TARGNAME Inducible T-cell costimulator (ICOS) T62705 GENENAME ICOS T62705 TARGTYPE Clinical trial T62705 SYNONYMS Inducible costimulator; Inducible T-cell co-stimulator; Inducible COSTIMULATOR precursor; CD278; Activation-inducible lymphocyte immunomediatory molecule; AILIM T62705 FUNCTION Essential both for efficient interaction between T and B-cells and for normal antibody responses to T-cell dependent antigens. Does not up-regulate the production of interleukin-2, but superinduces the synthesis of interleukin-10. Prevents the apoptosis of pre-activated T-cells. Plays a critical role in CD40-mediated class switching of immunoglobin isotypes. Enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. T62705 BIOCLASS Immunoglobulin T62705 SEQUENCE MKSGLWYFFLFCLRIKVLTGEINGSANYEMFIFHNGGVQILCKYPDIVQQFKMQLLKGGQILCDLTKTKGSGNTVSIKSLKFCHSQLSNNSVSFFLYNLDHSHANYYFCNLSIFDPPPFKVTLTGGYLHIYESQLCCQLKFWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL T62705 DRUGINFO D0EL5Q JTX-2011 Phase 2 T62705 DRUGINFO DALG29 KY1044 Phase 1/2 T62705 DRUGINFO D0E6NH MEDI-570 Phase 1 T62705 DRUGINFO D8FJ9K XmAb23104 Phase 1 T60568 TARGETID T60568 T60568 FORMERID TTDC00274 T60568 UNIPROID TAT_HV1H2 T60568 TARGNAME Human immunodeficiency virus Tat messenger RNA (HIV tat mRNA) T60568 GENENAME HIV tat mRNA T60568 TARGTYPE Clinical trial T60568 SYNONYMS tat (mRNA); Transactivating regulatory protein (mRNA); Protein Tat (mRNA) T60568 FUNCTION Acts as a sequence-specific molecular adapter, directing components of the cellular transcription machinery to the viral RNA to promote processive transcription elongation by the RNA polymerase II (RNA pol II) complex, thereby increasing the level of full-length transcripts. In the absence of Tat, the RNA Pol II generates short or non-processive transcripts that terminate at approximately 60 bp from the initiation site. Tat associates with the CCNT1/cyclin-T1 component of the P-TEFb complex (CDK9 and CCNT1), which promotes RNA chain elongation. This binding increases Tat's affinity for a hairpin structure at the 5'-end of all nascent viral mRNAs referred to as the transactivation responsive RNA element (TAR RNA) and allows Tat/P-TEFb complex to bind cooperatively to TAR RNA. The CDK9 component of P-TEFb and other Tat-activated kinases hyperphosphorylate the C-terminus of RNA Pol II that becomes stabilized and much more processive. Other factors such as HTATSF1/Tat-SF1, SUPT5H/SPT5, and HTATIP2 are also important for Tat's function. Besides its effect on RNA Pol II processivity, Tat induces chromatin remodeling of proviral genes by recruiting the histone acetyltransferases (HATs) CREBBP, EP300 and PCAF to the chromatin. This also contributes to the increase in proviral transcription rate, especially when the provirus integrates in transcriptionally silent region of the host genome. To ensure maximal activation of the LTR, Tat mediates nuclear translocation of NF-kappa-B by interacting with host RELA. Through its interaction with host TBP, Tat may also modulate transcription initiation. Tat can reactivate a latently infected cell by penetrating in it and transactivating its LTR promoter. In the cytoplasm, Tat is thought to act as a translational activator of HIV-1 mRNAs. Nuclear transcriptional activator of viral gene expression, that is essential for viral transcription from the LTR promoter and replication. T60568 PDBSTRUC 6MCF; 6MCE; 5V61; 4OR5; 3MIA T60568 BIOCLASS mRNA target T60568 SEQUENCE MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKE T60568 DRUGINFO D0JZ8X HGTV43 Phase 2 T62739 TARGETID T62739 T62739 FORMERID TTDI02269 T62739 UNIPROID STMN1_HUMAN T62739 TARGNAME STMN1 messenger RNA (STMN1 mRNA) T62739 GENENAME STMN1 T62739 TARGTYPE Clinical trial T62739 SYNONYMS pp19 (mRNA); pp17 (mRNA); Stathmin (mRNA); Protein Pr22 (mRNA); Prosolin (mRNA); Phosphoprotein p19 (mRNA); Op18 (mRNA); Oncoprotein 18 (mRNA); Metablastin (mRNA); Leukemia-associated phosphoprotein p18 (mRNA); LAP18 (mRNA); C1orf215 (mRNA) T62739 FUNCTION Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis. Involved in the control of the learned and innate fear. Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules. T62739 BIOCLASS mRNA target T62739 SEQUENCE MASSDIQVKELEKRASGQAFELILSPRSKESVPEFPLSPPKKKDLSLEEIQKKLEAAEERRKSHEAEVLKQLAEKREHEKEVLQKAIEENNNFSKMAEEKLTHKMEANKENREAQMAAKLERLREKDKHIEEVRKNKESKDPADETEAD T62739 DRUGINFO DSE59Z pbi-shRNA STMN1 Phase 1 T16605 TARGETID T16605 T16605 FORMERID TTDI02267 T16605 UNIPROID NCAP_MABVM T16605 TARGNAME Marburg virus NP messenger RNA (MV NP mRNA) T16605 GENENAME MV NP mRNA T16605 TARGTYPE Clinical trial T16605 SYNONYMS Protein N (mRNA); Nucleoprotein (mRNA); Nucleocapsid protein (mRNA) T16605 FUNCTION The encapsidated genomic RNA is termed the nucleocapsid and serves as template for transcription and replication. During replication, encapsidation by NP is coupled to RNA synthesis and all replicative products are resistant to nucleases. Encapsidates the genome, protecting it from nucleases. T16605 PDBSTRUC 6APP; 5T3W; 4W2Q; 4W2O T16605 BIOCLASS mRNA target T16605 SEQUENCE MDLHSLLELGTKPTAPHVRNKKVILFDTNHQVSICNQIIDAINSGIDLGDLLEGGLLTLCVEHYYNSDKDKFNTSPVAKYLRDAGYEFDVIKNADATRFLDVSPNEPHYSPLILALKTLESTESQRGRIGLFLSFCSLFLPKLVVGDRASIEKALRQVTVHQEQGIVTYPNHWLTTGHMKVIFGILRSSFILKFVLIHQGVNLVTGHDAYDSIISNSVGQTRFSGLLIVKTVLEFILQKTDSGVTLHPLVRTSKVKNEVASFKQALSNLARHGEYAPFARVLNLSGINNLEHGLYPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAAHDAEVKLQRRHEHQEIQAIAEDDEERKILEQFHLQKTEITHSQTLAVLSQKREKLARLAAEIENNIVEDQGFKQSQNRVSQSFLNDPTPVEVTVQARPMNRPTALPPPVDDKIEHESTEDSSSSSSFVDLNDPFALLNEDEDTLDDSVMIPGTTSREFQGIPEPPRQSQDLNNSQGKQEDESTNRIKKQFLRYQELPPVQEDDESEYTTDSQESIDQPGSDNEQGVDLPPPPLYAQEKRQDPIQHPAANPQDPFGSIGDVNGDILEPIRSPSSPSAPQEDTRMREAYELSPDFTNDEDNQQNWPQRVVTKKGRTFLYPNDLLQTNPPESLITALVEEYQNPVSAKELQADWPDMSFDERRHVAMNL T16605 DRUGINFO D07CXM AVI-7288 Phase 1 T00039 TARGETID T00039 T00039 FORMERID TTDC00335 T00039 UNIPROID CTGF_HUMAN T00039 TARGNAME CTGF messenger RNA (CTGF mRNA) T00039 GENENAME CTGF T00039 TARGTYPE Clinical trial T00039 SYNONYMS Long (mRNA); Insulin-like growth factor-binding protein 8 (mRNA); IGFBP8 (mRNA); IGFBP-8 (mRNA); IGF-binding protein 8 (mRNA); IBP-8 (mRNA); Hypertrophic chondrocyte-specific protein 24 (mRNA); HCS24 (mRNA); Connective tissue growth factor (mRNA); CCN2 (mRNA); CCN family member 2 (mRNA) T00039 FUNCTION Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis. Major connective tissue mitoattractant secreted by vascular endothelial cells. T00039 BIOCLASS mRNA target T00039 SEQUENCE MTAASMGPVRVAFVVLLALCSRPAVGQNCSGPCRCPDEPAPRCPAGVSLVLDGCGCCRVCAKQLGELCTERDPCDPHKGLFCHFGSPANRKIGVCTAKDGAPCIFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCDEPKDQTVVGPALAAYRLEDTFGPDPTMIRANCLVQTTEWSACSKTCGMGISTRVTNDNASCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA T00039 DRUGINFO D0R3LQ EXC 001 Phase 2 T97752 TARGETID T97752 T97752 FORMERID TTDI02246 T97752 UNIPROID VP24_EBOSU T97752 TARGNAME Ebola virus VP24 messenger RNA (EV VP24 mRNA) T97752 GENENAME EV VP24 mRNA T97752 TARGTYPE Clinical trial T97752 SYNONYMS rVP24 (mRNA); VP24 (mRNA); Reston VP24 (mRNA); Membrane-associated protein VP24 (mRNA) T97752 FUNCTION Blocks the IFN-induced nuclear accumulation of host phosphorylated STAT1, by interacting with the STAT1-binding region of host importin alpha-1/KPNA1 protein, thereby inhibiting the latter. Without the activity of this protein, activated STAT1 would not enter the nucleus and be unable to activate IFN-induced genes. Plays a role in assembly of viral nucleocapsid and virion budding. May act as a minor matrix protein that plays a role in assembly of viral nucleocapsid and virion budding. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways. T97752 PDBSTRUC 3VNF; 3VNE T97752 BIOCLASS mRNA target T97752 SEQUENCE MAKATGRYNLVTPKRELEQGVVFSDLCNFLVTPTVQGWKVYWAGLEFDVNQKGITLLNRLKVNDFAPAWAMTRNLFPHLFKNQQSEVQTPIWALRVILAAGILDQLMDHSLIEPLSGALNLIADWLLTTSTNHFNMRTQRVKDQLSMRMLSLIRSNIINFINKLETLHVVNYKGLLSSVEIGTPSYAIIITRTNMGYLVEVQEPDKSAMDIRHPGPVKFSLLHESTLKPVATPKPSSITSLIMEFNSSLAI T97752 DRUGINFO D09ELC AVI-7537 Phase 1 T97752 DRUGINFO D04LIH AVI-6002 Phase 1 T97752 DRUGINFO D0CB6N AVI-6003 Phase 1 T12059 TARGETID T12059 T12059 FORMERID TTDI02293 T12059 UNIPROID MA2B1_HUMAN; MA2B2_HUMAN; MA2C1_HUMAN T12059 TARGNAME Alpha-mannosidase (MANA) T12059 GENENAME MAN2B1; MAN2B2; MAN2C1 T12059 TARGTYPE Clinical trial T12059 SYNONYMS Mannosidase alpha class 2 T12059 FUNCTION Necessary for the catabolism of N-linked carbohydrates released during glycoprotein turnover. Cleaves all known types of alpha-mannosidic linkages. T12059 BIOCLASS Glycosylase T12059 SEQUENCE MGAYARASGVCARGCLDSAGPWTMSRALRPPLPPLCFFLLLLAAAGARAGGYETCPTVQPNMLNVHLLPHTHDDVGWLKTVDQYFYGIKNDIQHAGVQYILDSVISALLADPTRRFIYVEIAFFSRWWHQQTNATQEVVRDLVRQGRLEFANGGWVMNDEAATHYGAIVDQMTLGLRFLEDTFGNDGRPRVAWHIDPFGHSREQASLFAQMGFDGFFFGRLDYQDKWVRMQKLEMEQVWRASTSLKPPTADLFTGVLPNGYNPPRNLCWDVLCVDQPLVEDPRSPEYNAKELVDYFLNVATAQGRYYRTNHTVMTMGSDFQYENANMWFKNLDKLIRLVNAQQAKGSSVHVLYSTPACYLWELNKANLTWSVKHDDFFPYADGPHQFWTGYFSSRPALKRYERLSYNFLQVCNQLEALVGLAANVGPYGSGDSAPLNEAMAVLQHHDAVSGTSRQHVANDYARQLAAGWGPCEVLLSNALARLRGFKDHFTFCQQLNISICPLSQTAARFQVIVYNPLGRKVNWMVRLPVSEGVFVVKDPNGRTVPSDVVIFPSSDSQAHPPELLFSASLPALGFSTYSVAQVPRWKPQARAPQPIPRRSWSPALTIENEHIRATFDPDTGLLMEIMNMNQQLLLPVRQTFFWYNASIGDNESDQASGAYIFRPNQQKPLPVSRWAQIHLVKTPLVQEVHQNFSAWCSQVVRLYPGQRHLELEWSVGPIPVGDTWGKEVISRFDTPLETKGRFYTDSNGREILERRRDYRPTWKLNQTEPVAGNYYPVNTRIYITDGNMQLTVLTDRSQGGSSLRDGSLELMVHRRLLKDDGRGVSEPLMENGSGAWVRGRHLVLLDTAQAAAAGHRLLAEQEVLAPQVVLAPGGGAAYNLGAPPRTQFSGLRRDLPPSVHLLTLASWGPEMVLLRLEHQFAVGEDSGRNLSAPVTLNLRDLFSTFTITRLQETTLVANQLREAASRLKWTTNTGPTPHQTPYQLDPANITLEPMEIRTFLASVQWKEVDG T12059 DRUGINFO D06SVC M-0011 Phase 3 T15795 TARGETID T15795 T15795 UNIPROID KCNK3_HUMAN T15795 TARGNAME TWIK-related acid-sensitive potassium channel 1 (TASK1) T15795 GENENAME KCNK3 T15795 TARGTYPE Clinical trial T15795 SYNONYMS Two pore potassium channel KT3.1; Two pore K(+) channel KT3.1; TWIK-related acid-sensitive K(+) channel 1; Acid-sensitive potassium channel protein TASK-1 T15795 FUNCTION pH-dependent, voltage-insensitive, background potassium channel protein. Rectification direction results from potassium ion concentration on either side of the membrane. Acts as an outward rectifier when external potassium concentration is low. When external potassium concentration is high, current is inward. T15795 SEQUENCE MKRQNVRTLALIVCTFTYLLVGAAVFDALESEPELIERQRLELRQQELRARYNLSQGGYEELERVVLRLKPHKAGVQWRFAGSFYFAITVITTIGYGHAAPSTDGGKVFCMFYALLGIPLTLVMFQSLGERINTLVRYLLHRAKKGLGMRRADVSMANMVLIGFFSCISTLCIGAAAFSHYEHWTFFQAYYYCFITLTTIGFGDYVALQKDQALQTQPQYVAFSFVYILTGLTVIGAFLNLVVLRFMTMNAEDEKRDAEHRALLTRNGQAGGGGGGGSAHTTDTASSTAAAGGGGFRNVYAEVLHFQSMCSCLWYKSREKLQYSIPMIIPRDLSTSDTCVEQSHSSPGGGGRYSDTPSRRCLCSGAPRSAISSVSTGLHSLSTFRGLMKRRSSV T15795 DRUGINFO D0E7XM BAY-2253651 Phase 2 T15795 DRUGINFO D85NEG BAY 2253651 Phase 2 T80024 TARGETID T80024 T80024 FORMERID TTDI01235 T80024 UNIPROID GDF8_HUMAN T80024 TARGNAME Myostatin (MSTN) T80024 GENENAME MSTN T80024 TARGTYPE Clinical trial T80024 SYNONYMS GDF-8 T80024 FUNCTION Acts specifically as a negative regulator of skeletal muscle growth. T80024 PDBSTRUC 5NXS; 5NTU; 5F3H; 5F3B T80024 SEQUENCE MQKLQLCVYIYLFMLIVAGPVDLNENSEQKENVEKEGLCNACTWRQNTKSSRIEAIKIQILSKLRLETAPNISKDVIRQLLPKAPPLRELIDQYDVQRDDSSDGSLEDDDYHATTETIITMPTESDFLMQVDGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVETPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGEDGLNPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPINMLYFNGKEQIIYGKIPAMVVDRCGCS T80024 DRUGINFO DN5J9R SRK-015 Phase 2 T80024 DRUGINFO D0T5QC AAV1-FS344 Phase 1/2 T99394 TARGETID T99394 T99394 FORMERID TTDR00935 T99394 UNIPROID TR13B_HUMAN T99394 TARGNAME Transmembrane activator and CAML interactor (TNFRSF13B) T99394 GENENAME TNFRSF13B T99394 TARGTYPE Clinical trial T99394 SYNONYMS Tumor necrosis factor receptor superfamily member 13B; TACI; CD267 T99394 FUNCTION Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. T99394 PDBSTRUC 1XUT; 1XU1 T99394 SEQUENCE MSGLGRSRRGGRSRVDQEERFPQGLWTGVAMRSCPEEQYWDPLLGTCMSCKTICNHQSQRTCAAFCRSLSCRKEQGKFYDHLLRDCISCASICGQHPKQCAYFCENKLRSPVNLPPELRRQRSGEVENNSDNSGRYQGLEHRGSEASPALPGLKLSADQVALVYSTLGLCLCAVLCCFLVAVACFLKKRGDPCSCQPRSRPRQSPAKSSQDHAMEAGSPVSTSPEPVETCSFCFPECRAPTQESAVTPGTPDPTCAGRWGCHTRTTVLQPCPHIPDSGLGIVCVPAQEGGPGA T99394 DRUGINFO D0B8UW AUTO2 Phase 1/2 T81916 TARGETID T81916 T81916 FORMERID TTDI02109 T81916 UNIPROID KLF4_HUMAN T81916 TARGNAME Kruppel like factor 4 (KLF4) T81916 GENENAME KLF4 T81916 TARGTYPE Clinical trial T81916 SYNONYMS Krueppellike factor 4; Krueppel-like factor 4; Gutenriched krueppellike factor; Gut-enriched krueppel-like factor; GKLF; Epithelial zinc finger protein EZF; EZF T81916 FUNCTION Binds the 5'-CACCC-3' core sequence. Binds to the promoter region of its own gene and can activate its own transcription. Regulates the expression of key transcription factors during embryonic development. Plays an important role in maintaining embryonic stem cells, and in preventing their differentiation. Required for establishing the barrier function of the skin and for postnatal maturation and maintenance of the ocular surface. Involved in the differentiation of epithelial cells and may also function in skeletal and kidney development. Contributes to the down-regulation of p53/TP53 transcription. Transcription factor; can act both as activator and as repressor. T81916 SEQUENCE MRQPPGESDMAVSDALLPSFSTFASGPAGREKTLRQAGAPNNRWREELSHMKRLPPVLPGRPYDLAAATVATDLESGGAGAACGGSNLAPLPRRETEEFNDLLDLDFILSNSLTHPPESVAATVSSSASASSSSSPSSSGPASAPSTCSFTYPIRAGNDPGVAPGGTGGGLLYGRESAPPPTAPFNLADINDVSPSGGFVAELLRPELDPVYIPPQQPQPPGGGLMGKFVLKASLSAPGSEYGSPSVISVSKGSPDGSHPVVVAPYNGGPPRTCPKIKQEAVSSCTHLGAGPPLSNGHRPAAHDFPLGRQLPSRTTPTLGLEEVLSSRDCHPALPLPPGFHPHPGPNYPSFLPDQMQPQVPPLHYQGQSRGFVARAGEPCVCWPHFGTHGMMLTPPSSPLELMPPGSCMPEEPKPKRGRRSWPRKRTATHTCDYAGCGKTYTKSSHLKAHLRTHTGEKPYHCDWDGCGWKFARSDELTRHYRKHTGHRPFQCQKCDRAFSRSDHLALHMKRHF T81916 DRUGINFO D07TRP APTO-253 Phase 1 T37434 TARGETID T37434 T37434 FORMERID TTDI02154 T37434 UNIPROID PROM1_HUMAN T37434 TARGNAME Prominin-1 (PROM1) T37434 GENENAME PROM1 T37434 TARGTYPE Clinical trial T37434 SYNONYMS Promininlike protein 1; Prominin1; Prominin-like protein 1; PROML1; MSTP061; CD133; Antigen AC133 T37434 FUNCTION Binds cholesterol in cholesterol-containing plasma membrane microdomains and may play a role in the organization of the apical plasma membrane in epithelial cells. During early retinal development acts as a key regulator of disk morphogenesis. Involved in regulation of MAPK and Akt signaling pathways. In neuroblastoma cells suppresses cell differentiation such as neurite outgrowth in a RET-dependent manner. May play a role in cell differentiation, proliferation and apoptosis. T37434 SEQUENCE MALVLGSLLLLGLCGNSFSGGQPSSTDAPKAWNYELPATNYETQDSHKAGPIGILFELVHIFLYVVQPRDFPEDTLRKFLQKAYESKIDYDKPETVILGLKIVYYEAGIILCCVLGLLFIILMPLVGYFFCMCRCCNKCGGEMHQRQKENGPFLRKCFAISLLVICIIISIGIFYGFVANHQVRTRIKRSRKLADSNFKDLRTLLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGGGILDRLRPNIIPVLDEIKSMATAIKETKEALENMNSTLKSLHQQSTQLSSSLTSVKTSLRSSLNDPLCLVHPSSETCNSIRLSLSQLNSNPELRQLPPVDAELDNVNNVLRTDLDGLVQQGYQSLNDIPDRVQRQTTTVVAGIKRVLNSIGSDIDNVTQRLPIQDILSAFSVYVNNTESYIHRNLPTLEEYDSYWWLGGLVICSLLTLIVIFYYLGLLCGVCGYDRHATPTTRGCVSNTGGVFLMVGVGLSFLFCWILMIIVVLTFVFGANVEKLICEPYTSKELFRVLDTPYLLNEDWEYYLSGKLFNKSKMKLTFEQVYSDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELESLKVNLNIFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGKSPAGVNLLSFAYDLEAKANSLPPGNLRNSLKRDAQTIKTIHQQRVLPIEQSLSTLYQSVKILQRTGNGLLERVTRILASLDFAQNFITNNTSSVIIEETKKYGRTIIGYFEHYLQWIEFSISEKVASCKPVATALDTAVDVFLCSYIIDPLNLFWFGIGKATVFLLPALIFAVKLAKYYRRMDSEDVYDDVETIPMKNMENGNNGYHKDHVYGIHNPVMTSPSQH T37434 DRUGINFO D09HRH Anti-CD133-CAR vector-transduced T cells Phase 1 T37434 DRUGINFO D09NBH ICT-121 Phase 1 T37434 DRUGINFO D04JSI CAR-T cells targeting CD133 Preclinical T92042 TARGETID T92042 T92042 UNIPROID GFRA3_HUMAN T92042 TARGNAME GDNF receptor alpha-3 (GFRA3) T92042 GENENAME GFRA3 T92042 TARGTYPE Clinical trial T92042 SYNONYMS UNQ339/PRO538/PRO3664; GFR-alpha-3; GDNFR-alpha-3; GDNF family receptor alpha-3 T92042 FUNCTION Mediates the artemin-induced autophosphorylation and activation of the RET receptor tyrosine kinase. Receptor for the glial cell line-derived neurotrophic factor, ARTN (artemin). T92042 PDBSTRUC 2GH0 T92042 SEQUENCE MVRPLNPRPLPPVVLMLLLLLPPSPLPLAAGDPLPTESRLMNSCLQARRKCQADPTCSAAYHHLDSCTSSISTPLPSEEPSVPADCLEAAQQLRNSSLIGCMCHRRMKNQVACLDIYWTVHRARSLGNYELDVSPYEDTVTSKPWKMNLSKLNMLKPDSDLCLKFAMLCTLNDKCDRLRKAYGEACSGPHCQRHVCLRQLLTFFEKAAEPHAQGLLLCPCAPNDRGCGERRRNTIAPNCALPPVAPNCLELRRLCFSDPLCRSRLVDFQTHCHPMDILGTCATEQSRCLRAYLGLIGTAMTPNFVSNVNTSVALSCTCRGSGNLQEECEMLEGFFSHNPCLTEAIAAKMRFHSQLFSQDWPHPTFAVMAHQNENPAVRPQPWVPSLFSCTLPLILLLSLW T92042 DRUGINFO D08ZXQ Neublastin Phase 2 T44916 TARGETID T44916 T44916 UNIPROID EED_HUMAN T44916 TARGNAME Embryonic ectoderm development protein (EED) T44916 GENENAME EED T44916 TARGTYPE Clinical trial T44916 SYNONYMS hEED; WD protein associating with integrin cytoplasmic tails 1; WAIT-1 T44916 FUNCTION Polycomb group (PcG) protein. Component of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Also recognizes 'Lys-26' trimethylated histone H1 with the effect of inhibiting PRC2 complex methyltransferase activity on nucleosomal histone H3 'Lys-27', whereas H3 'Lys-27' recognition has the opposite effect, enabling the propagation of this repressive mark. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A. T44916 PDBSTRUC 6C24; 6C23; 6B3W; 5WUK; 5WP3 T44916 SEQUENCE MSEREVSTAPAGTDMPAAKKQKLSSDENSNPDLSGDENDDAVSIESGTNTERPDTPTNTPNAPGRKSWGKGKWKSKKCKYSFKCVNSLKEDHNQPLFGVQFNWHSKEGDPLVFATVGSNRVTLYECHSQGEIRLLQSYVDADADENFYTCAWTYDSNTSHPLLAVAGSRGIIRIINPITMQCIKHYVGHGNAINELKFHPRDPNLLLSVSKDHALRLWNIQTDTLVAIFGGVEGHRDEVLSADYDLLGEKIMSCGMDHSLKLWRINSKRMMNAIKESYDYNPNKTNRPFISQKIHFPDFSTRDIHRNYVDCVRWLGDLILSKSCENAIVCWKPGKMEDDIDKIKPSESNVTILGRFDYSQCDIWYMRFSMDFWQKMLALGNQVGKLYVWDLEVEDPHKAKCTTLTHHKCGAAIRQTSFSRDSSILIAVCDDASIWRWDRLR T44916 DRUGINFO D0UO0C MAK683 Phase 1/2 T44916 DRUGINFO DPS29T ORIC-944 Phase 1 T44916 DRUGINFO DQ0V7Y A-395 Investigative T03046 TARGETID T03046 T03046 FORMERID TTDI01322 T03046 UNIPROID RASK_HUMAN T03046 TARGNAME Mutated KRAS (mKRAS) T03046 GENENAME KRAS T03046 TARGTYPE Clinical trial T03046 SYNONYMS c-Ki-ras (mutated); c-K-ras (mutated); RASK2 (mutated); Ki-Ras (mutated); KRAS2 (mutated); K-Ras 2 (mutated); GTPase KRas (mutated) T03046 FUNCTION Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation. Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. T03046 PDBSTRUC 6N2K; 6N2J; 6H47; 6H46; 6GQY T03046 SEQUENCE MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM T03046 DRUGINFO D0KK9V GI-4000 + gemcitabine Phase 2 T90572 TARGETID T90572 T90572 FORMERID TTDR00252 T90572 UNIPROID IGF2_HUMAN T90572 TARGNAME Insulin-like growth factor-II (IGF2) T90572 GENENAME IGF2 T90572 TARGTYPE Clinical trial T90572 SYNONYMS T3M-11-derived growth factor; Somatomedin-A; Somatomedin A; PP1446; Insulin-like growth factor II; Insulin-like growth factor 2; IGF-II T90572 FUNCTION Major fetal growth hormone in mammals. Plays a key role in regulating fetoplacental development. IGF-II is influenced by placental lactogen. Also involved in tissue differentiation. Positively regulates myogenic transcription factor MYOD1 function by facilitating the recruitment of transcriptional coactivators, thereby controlling muscle terminal differentiation. In adults, involved in glucose metabolism in adipose tissue, skeletal muscle and liver. Acts as a ligand for integrin which is required for IGF2 signaling. The insulin-like growth factors possess growth-promoting activity. T90572 PDBSTRUC 5L3N; 5L3M; 5L3L; 3KR3; 3E4Z T90572 SEQUENCE MGIPMGKSMLVLLTFLAFASCCIAAYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSRGIVEECCFRSCDLALLETYCATPAKSERDVSTPPTVLPDNFPRYPVGKFFQYDTWKQSTQRLRRGLPALLRARRGHVLAKELEAFREAKRHRPLIALPTQDPAHGGAPPEMASNRK T90572 DRUGINFO D09TQY Dusigitumab Phase 2 T90572 DRUGINFO D04DNB Xentuzumab Phase 2 T20978 TARGETID T20978 T20978 FORMERID TTDI01957 T20978 UNIPROID CD8A_HUMAN; CD8B_HUMAN T20978 TARGNAME T-cell surface glycoprotein CD8 (CD8) T20978 GENENAME CD8A; CD8B T20978 TARGTYPE Clinical trial T20978 SYNONYMS T-lymphocyte differentiation antigen T8/Leu-2; CD8 T20978 FUNCTION Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3 domains. T20978 SEQUENCE MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQPRGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSGDKPSLSARYV T20978 DRUGINFO D0C8AL Fluoropeptide vaccine Phase 2 T20978 DRUGINFO D0U6BQ Anti-VEGFR2 CD8 cell therapy Phase 1/2 T20978 DRUGINFO D0T7LV LIPO-4 Phase 1 T99557 TARGETID T99557 T99557 UNIPROID TRBC1_HUMAN T99557 TARGNAME T-cell receptor beta constant 1 (TRBC1) T99557 GENENAME TRBC1 T99557 TARGTYPE Clinical trial T99557 SYNONYMS TCRBC1; BV05S1J2.2 T99557 FUNCTION Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens. Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn, ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation. The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity. Constant region of T cell receptor (TR) alpha chain. T99557 PDBSTRUC 4ZDH; 4X6D; 4X6C; 4X6B; 4PRP T99557 SEQUENCE DLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF T99557 DRUGINFO D01MDX TRBC1 Phase 1/2 T97036 TARGETID T97036 T97036 FORMERID TTDI00662 T97036 UNIPROID FETUA_HUMAN T97036 TARGNAME Connecting peptide (C-peptide) T97036 GENENAME AHSG T97036 TARGTYPE Clinical trial T97036 SYNONYMS Fetuin-A; Alpha-2-Z-globulin; Alpha-2-HS-glycoprotein chainB; Alpha-2-HS-glycoprotein (301-340); AHSG T97036 FUNCTION Promotes endocytosis, possesses opsonic properties and influences the mineral phase of bone. Shows affinity for calcium and barium ions. T97036 BIOCLASS Fetuin family T97036 SEQUENCE LAAPPGHQLHRAHYDLRHTFMGVVSLGSPSGEVSHPRKTR T97036 DRUGINFO D0N3BB CBX-129801 Phase 2 T15107 TARGETID T15107 T15107 FORMERID TTDI02213 T15107 UNIPROID POL_HV1B1 T15107 TARGNAME Human immunodeficiency virus Nucleocapsid p7 (HIV p7) T15107 GENENAME HIV p7 T15107 TARGTYPE Clinical trial T15107 SYNONYMS HIV NC T15107 FUNCTION Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation. T15107 PDBSTRUC 6OE3; 6HAK; 6ELI; 6DUH; 6DUG T15107 SEQUENCE MQRGNFRNQRKMVKCFNCGKEGHTARNCRAPRKKGCWKCGKEGHQMKDCTERQAN T15107 DRUGINFO D0A0SK HPH-116 Phase 2 T57654 TARGETID T57654 T57654 FORMERID TTDI01738 T57654 UNIPROID PB2_I34A1 T57654 TARGNAME Influenza Polymerase basic protein 2 (Influ PB2) T57654 GENENAME Influ PB2 T57654 TARGTYPE Clinical trial T57654 SYNONYMS RNA-directed RNA polymerase subunit P3; Polymerase basic protein 2 T57654 FUNCTION Plays an essential role in transcription initiation and cap-stealing mechanism, in which cellular capped pre-mRNAs are used to generate primers for viral transcription. Recognizes and binds the 7-methylguanosine-containing cap of the target pre-RNA which is subsequently cleaved after 10-13 nucleotides by the viral protein PA. Plays a role in the initiation of the viral genome replication and modulates the activity of the ribonucleoprotein (RNP) complex. In addition, participates in the inhibition of type I interferon induction through interaction with and inhibition of the host mitochondrial antiviral signaling protein MAVS. T57654 PDBSTRUC 4U6O; 4J2R; 4ENF; 3WI1; 3WI0 T57654 SEQUENCE MERIKELRNLMSQSRTREILTKTTVDHMAIIKKYTSGRQEKNPALRMKWMMAMKYPITADKRITEMIPERNEQGQTLWSKMNDAGSDRVMVSPLAVTWWNRNGPITNTVHYPKIYKTYFERVERLKHGTFGPVHFRNQVKIRRRVDINPGHADLSAKEAQDVIMEVVFPNEVGARILTSESQLTITKEKKEELQDCKISPLMVAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQGTCWEQMYTPGGEVRNDDVDQSLIIAARNIVRRAAVSADPLASLLEMCHSTQIGGIRMVDILRQNPTEEQAVDICKAAMGLRISSSFSFGGFTFKRTSGSSVKREEEVLTGNLQTLKIRVHEGYEEFTMVGRRATAILRKATRRLIQLIVSGRDEQSIAEAIIVAMVFSQEDCMIKAVRGDLNFVNRANQRLNPMHQLLRHFQKDAKVLFQNWGVEPIDNVMGMIGILPDMTPSIEMSMRGVRISKMGVDEYSSTERVVVSIDRFLRIRDQRGNVLLSPEEVSETQGTEKLTITYSSSMMWEINGPESVLVNTYQWIIRNWETVKIQWSQNPTMLYNKMEFEPFQSLVPKAIRGQYSGFVRTLFQQMRDVLGTFDTAQIIKLLPFAAAPPKQSRMQFSSFTVNVRGSGMRILVRGNSPVFNYNKATKRLTVLGKDAGTLTEDPDEGTAGVESAVLRGFLILGKEDKRYGPALSINELSNLAKGEKANVLIGQGDVVLVMKRKRDSSILTDSQTATKRIRMAIN T57654 DRUGINFO D08DHN VX-787 Phase 3 T02591 TARGETID T02591 T02591 FORMERID TTDI01959 T02591 UNIPROID ENV_HV1H2 T02591 TARGNAME Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) T02591 GENENAME HIV env T02591 TARGTYPE Clinical trial T02591 SYNONYMS Envelope glycoprotein gp160; Env polyprotein T02591 FUNCTION Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41. T02591 PDBSTRUC 6DLN; 6DE7; 6BXQ; 6BXP; 6B9K T02591 SEQUENCE MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL T02591 DRUGINFO D0G7LC PENNVAX-6 Phase 1 T02591 DRUGINFO D0OX1Y Ad5-ENVA-48 Phase 1 T02591 DRUGINFO D0W1MU TBC-M4 Phase 1 T02591 DRUGINFO DRI97M MGD014 Phase 1 T02591 DRUGINFO D09ZKB Ad35-GRIN/ENV Phase 1 T02591 DRUGINFO D0A9JW GPG Discontinued in Phase 1/2 T00420 TARGETID T00420 T00420 FORMERID TTDI02157 T00420 UNIPROID REV_HV1H2 T00420 TARGNAME Human immunodeficiency virus Rev protein (HIV rev) T00420 GENENAME HIV rev T00420 TARGTYPE Clinical trial T00420 SYNONYMS rev; Regulator of expression of viral proteins; Anti-repression transactivator; ART/TRS T00420 FUNCTION Escorts unspliced or incompletely spliced viral pre- mRNAs (late transcripts) out of the nucleus of infected cells. These pre-mRNAs carry a recognition sequence called Rev responsive element (RRE) located in the env gene, that is not present in fully spliced viral mRNAs (early transcripts). This function is essential since most viral proteins are translated from unspliced or partially spliced pre-mRNAs which cannot exit the nucleus by the pathway used by fully processed cellular mRNAs. Rev itself is translated from a fully spliced mRNA that readily exits the nucleus. Rev's nuclear localization signal (NLS) bindsdirectly to KPNB1/Importin beta-1 without previous binding to KPNA1/Importin alpha-1. KPNB1 binds to the GDP bound form of RAN (Ran-GDP) and targets Rev to the nucleus. In the nucleus, the conversionfrom Ran-GDP to Ran-GTP dissociates Rev from KPNB1 and allows Rev's binding to the RRE in viral pre-mRNAs. Rev multimerization on the RRE via cooperative assembly exposes its nuclear export signal (NES) to the surface. Rev can then form a complex with XPO1/CRM1 and Ran-GTP, leading to nuclear export of the complex. Conversion from Ran-GTP to Ran-GDP mediates dissociation of the Rev/RRE/XPO1/RAN complex, so that Rev can return to the nucleus for a subsequent round of export. Beside KPNB1, also seems to interact with TNPO1/Transportin-1, RANBP5/IPO5 and IPO7/RANBP7 for nuclear import. The nucleoporin-like HRB/RIP is an essential cofactor that probably indirectly interacts with Rev to release HIV RNAs from the perinuclear region to the cytoplasm. Interacts with DDX1; the interaction is necessary for proper subcellular localization of this protein. T00420 SEQUENCE MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQRQIHSISERILGTYLGRSAEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE T00420 DRUGINFO D0N2GQ ATI-0917 Phase 1 T00420 DRUGINFO D09ZKB Ad35-GRIN/ENV Phase 1 T60930 TARGETID T60930 T60930 FORMERID TTDI02228 T60930 UNIPROID IGF1_HUMAN T60930 TARGNAME Insulin-like growth factor-I (IGF1) T60930 GENENAME IGF1 T60930 TARGTYPE Clinical trial T60930 SYNONYMS SomatomedinC; Somatomedin-C; Mechano growth factor; Insulin-like growth factor I; IGFI; IGF-I T60930 FUNCTION May be a physiological regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblasts. Stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin, not only regarding glycogen and DNA synthesis but also with regard to enhancing glucose uptake. May play a role in synapse maturation. Ca(2+)-dependent exocytosis of IGF1 is required for sensory perception of smell in the olfactory bulb. Acts as a ligand for IGF1R. Binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiatiating a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. Binds to integrins ITGAV:ITGB3 and ITGA6:ITGB4. Its binding to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling. Induces the phosphorylation and activation of IGFR1, MAPK3/ERK1, MAPK1/ERK2 and AKT1. The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity. T60930 PDBSTRUC 6FF3; 5U8Q; 4XSS; 3LRI; 3GF1 T60930 SEQUENCE MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQKYQPPSTNKNTKSQRRKGWPKTHPGGEQKEGTEASLQIRGKKKEQRREIGSRNAECRGKKGK T60930 DRUGINFO D04DNB Xentuzumab Phase 2 T60930 DRUGINFO D0F2IM MEDI-573 Phase 1 T60930 DRUGINFO D0X4KN BI-836845 Phase 1 T45151 TARGETID T45151 T45151 FORMERID TTDI01754 T45151 UNIPROID PAI1_HUMAN; PAI2_HUMAN; IPSP_HUMAN T45151 TARGNAME Plasminogen activator inhibitor (PAI) T45151 GENENAME SERPINE1; SERPINB2; SERPINA5 T45151 TARGTYPE Clinical trial T45151 SYNONYMS Serpin; PAI T45151 FUNCTION Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation offibrinolysis. T45151 SEQUENCE MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP T45151 DRUGINFO D0JI2E Aleplasinin Phase 1 T45151 DRUGINFO D07MWY XR-1853 Terminated T45151 DRUGINFO D08EIX T-686 Terminated T45151 DRUGINFO D0J9JQ XR-5082 Terminated T45151 DRUGINFO D0Z0KE BX-044 Terminated T71141 TARGETID T71141 T71141 FORMERID TTDI01813 T71141 UNIPROID ITAV_HUMAN-ITB6_HUMAN T71141 TARGNAME Integrin alpha-V/beta-6 (ITGAV/B6) T71141 GENENAME ITGAV-ITGB6 T71141 TARGTYPE Clinical trial T71141 SYNONYMS alpha(V)beta(6) integrin; Alpha V beta 6 integrin T71141 FUNCTION It is expressed exclusively on subsets of epithelial cells, especially during development, after injury or inflammation, or on many carcinomas. T71141 BIOCLASS Integrin T71141 SEQUENCE MGIELLCLFFLFLGRNDHVQGGCALGGAETCEDCLLIGPQCAWCAQENFTHPSGVGERCDTPANLLAKGCQLNFIENPVSQVEILKNKPLSVGRQKNSSDIVQIAPQSLILKLRPGGAQTLQVHVRQTEDYPVDLYYLMDLSASMDDDLNTIKELGSRLSKEMSKLTSNFRLGFGSFVEKPVSPFVKTTPEEIANPCSSIPYFCLPTFGFKHILPLTNDAERFNEIVKNQKISANIDTPEGGFDAIMQAAVCKEKIGWRNDSLHLLVFVSDADSHFGMDSKLAGIVIPNDGLCHLDSKNEYSMSTVLEYPTIGQLIDKLVQNNVLLIFAVTQEQVHLYENYAKLIPGATVGLLQKDSGNILQLIISAYEELRSEVELEVLGDTEGLNLSFTAICNNGTLFQHQKKCSHMKVGDTASFSVTVNIPHCERRSRHIIIKPVGLGDALELLVSPECNCDCQKEVEVNSSKCHHGNGSFQCGVCACHPGHMGPRCECGEDMLSTDSCKEAPDHPSCSGRGDCYCGQCICHLSPYGNIYGPYCQCDNFSCVRHKGLLCGGNGDCDCGECVCRSGWTGEYCNCTTSTDSCVSEDGVLCSGRGDCVCGKCVCTNPGASGPTCERCPTCGDPCNSKRSCIECHLSAAGQAREECVDKCKLAGATISEEEDFSKDGSVSCSLQGENECLITFLITTDNEGKTIIHSINEKDCPKPPNIPMIMLGVSLAILLIGVVLLCIWKLLVSFHDRKEVAKFEAERSKAKWQTGTNPLYRGSTSTFKNVTYKHREKQKVDLSTDCMAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET T71141 DRUGINFO D0WL4D STX-100 Phase 2 T71141 DRUGINFO D3MG8W PLN-74809 Phase 2 T71141 DRUGINFO D0ALN1 CWHM-12 Preclinical T61544 TARGETID T61544 T61544 FORMERID TTDI02178 T61544 UNIPROID SP1_HUMAN T61544 TARGNAME Transcription factor Sp1 (SP1) T61544 GENENAME SP1 T61544 TARGTYPE Clinical trial T61544 SYNONYMS TSFP1 T61544 FUNCTION Transcription factor that can activate or repress transcription in response to physiological and pathological stimuli. Binds with high affinity to GC-rich motifs and regulates the expression of a large number of genes involved in a variety of processes such as cell growth, apoptosis, differentiation and immune responses. Highly regulated by post-translational modifications (phosphorylations, sumoylation, proteolytic cleavage, glycosylation and acetylation). Binds also the PDGFR-alpha G-box promoter. May have a role in modulating the cellular response to DNA damage. Implicated in chromatin remodeling. Plays an essential role in the regulation of FE65 gene expression. In complex with ATF7IP, maintains telomerase activity in cancer cells by inducing TERT and TERC gene expression. Isoform 3 is a stronger activator of transcription than isoform 1. Positively regulates the transcription of the core clock component ARNTL/BMAL1. Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. Plays a role in protecting cells against oxidative stress following brain injury by regulating the expression of RNF112 (By similarity). T61544 PDBSTRUC 1VA3; 1VA2; 1VA1; 1SP2; 1SP1 T61544 SEQUENCE MSDQDHSMDEMTAVVKIEKGVGGNNGGNGNGGGAFSQARSSSTGSSSSTGGGGQESQPSPLALLAATCSRIESPNENSNNSQGPSQSGGTGELDLTATQLSQGANGWQIISSSSGATPTSKEQSGSSTNGSNGSESSKNRTVSGGQYVVAAAPNLQNQQVLTGLPGVMPNIQYQVIPQFQTVDGQQLQFAATGAQVQQDGSGQIQIIPGANQQIITNRGSGGNIIAAMPNLLQQAVPLQGLANNVLSGQTQYVTNVPVALNGNITLLPVNSVSAATLTPSSQAVTISSSGSQESGSQPVTSGTTISSASLVSSQASSSSFFTNANSYSTTTTTSNMGIMNFTTSGSSGTNSQGQTPQRVSGLQGSDALNIQQNQTSGGSLQAGQQKEGEQNQQTQQQQILIQPQLVQGGQALQALQAAPLSGQTFTTQAISQETLQNLQLQAVPNSGPIIIRTPTVGPNGQVSWQTLQLQNLQVQNPQAQTITLAPMQGVSLGQTSSSNTTLTPIASAASIPAGTVTVNAAQLSSMPGLQTINLSALGTSGIQVHPIQGLPLAIANAPGDHGAQLGLHGAGGDGIHDDTAGGEEGENSPDAQPQAGRRTRREACTCPYCKDSEGRGSGDPGKKKQHICHIQGCGKVYGKTSHLRAHLRWHTGERPFMCTWSYCGKRFTRSDELQRHKRTHTGEKKFACPECPKRFMRSDHLSKHIKTHQNKKGGPGVALSVGTLPLDSGAGSEGSGTATPSALITTNMVAMEAICPEGIARLANSGINVMQVADLQSINISGNGF T61544 DRUGINFO D00UDP Terameprocol Phase 2 T96837 TARGETID T96837 T96837 UNIPROID IGG1_HUMAN T96837 TARGNAME Immunoglobulin gamma-1 heavy NIE (NIE) T96837 GENENAME NIE T96837 TARGTYPE Clinical trial T96837 SYNONYMS Immunoglobulin gamma-1 heavy chain NIE T96837 FUNCTION Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170). T96837 PDBSTRUC 6OGE; 6N35; 6N32; 6N2X; 6MUB T96837 SEQUENCE QVQLVQSGGGVVQPGRSLRLSCAASGFTFSRYTIHWVRQAPGKGLEWVAVMSYNGNNKHYADSVNGRFTISRNDSKNTLYLNMNSLRPEDTAVYYCARIRDTAMFFAHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK T96837 DRUGINFO D0B0VD MORAb-022 Phase 1 T02779 TARGETID T02779 T02779 FORMERID TTDI01538 T02779 UNIPROID DMD_HUMAN T02779 TARGNAME Dystrophin nonsense mutant (DMD) T02779 GENENAME DMD T02779 TARGTYPE Clinical trial T02779 SYNONYMS MRX85 nonsense mutant; DXS272 nonsense mutant; DXS270 nonsense mutant; DXS269 nonsense mutant; DXS268 nonsense mutant; DXS239 nonsense mutant; DXS230 nonsense mutant; DXS206 nonsense mutant; DXS164 nonsense mutant; DXS142 nonsense mutant; CMD3B nonsense mutant; BMD nonsense mutant T02779 FUNCTION Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission. Anchors the extracellular matrix to the cytoskeleton via F-actin. T02779 PDBSTRUC 3UUN; 1EG4; 1EG3; 1DXX T02779 SEQUENCE MLWWEEVEDCYEREDVQKKTFTKWVNAQFSKFGKQHIENLFSDLQDGRRLLDLLEGLTGQKLPKEKGSTRVHALNNVNKALRVLQNNNVDLVNIGSTDIVDGNHKLTLGLIWNIILHWQVKNVMKNIMAGLQQTNSEKILLSWVRQSTRNYPQVNVINFTTSWSDGLALNALIHSHRPDLFDWNSVVCQQSATQRLEHAFNIARYQLGIEKLLDPEDVDTTYPDKKSILMYITSLFQVLPQQVSIEAIQEVEMLPRPPKVTKEEHFQLHHQMHYSQQITVSLAQGYERTSSPKPRFKSYAYTQAAYVTTSDPTRSPFPSQHLEAPEDKSFGSSLMESEVNLDRYQTALEEVLSWLLSAEDTLQAQGEISNDVEVVKDQFHTHEGYMMDLTAHQGRVGNILQLGSKLIGTGKLSEDEETEVQEQMNLLNSRWECLRVASMEKQSNLHRVLMDLQNQKLKELNDWLTKTEERTRKMEEEPLGPDLEDLKRQVQQHKVLQEDLEQEQVRVNSLTHMVVVVDESSGDHATAALEEQLKVLGDRWANICRWTEDRWVLLQDILLKWQRLTEEQCLFSAWLSEKEDAVNKIHTTGFKDQNEMLSSLQKLAVLKADLEKKKQSMGKLYSLKQDLLSTLKNKSVTQKTEAWLDNFARCWDNLVQKLEKSTAQISQAVTTTQPSLTQTTVMETVTTVTTREQILVKHAQEELPPPPPQKKRQITVDSEIRKRLDVDITELHSWITRSEAVLQSPEFAIFRKEGNFSDLKEKVNAIEREKAEKFRKLQDASRSAQALVEQMVNEGVNADSIKQASEQLNSRWIEFCQLLSERLNWLEYQNNIIAFYNQLQQLEQMTTTAENWLKIQPTTPSEPTAIKSQLKICKDEVNRLSDLQPQIERLKIQSIALKEKGQGPMFLDADFVAFTNHFKQVFSDVQAREKELQTIFDTLPPMRYQETMSAIRTWVQQSETKLSIPQLSVTDYEIMEQRLGELQALQSSLQEQQSGLYYLSTTVKEMSKKAPSEISRKYQSEFEEIEGRWKKLSSQLVEHCQKLEEQMNKLRKIQNHIQTLKKWMAEVDVFLKEEWPALGDSEILKKQLKQCRLLVSDIQTIQPSLNSVNEGGQKIKNEAEPEFASRLETELKELNTQWDHMCQQVYARKEALKGGLEKTVSLQKDLSEMHEWMTQAEEEYLERDFEYKTPDELQKAVEEMKRAKEEAQQKEAKVKLLTESVNSVIAQAPPVAQEALKKELETLTTNYQWLCTRLNGKCKTLEEVWACWHELLSYLEKANKWLNEVEFKLKTTENIPGGAEEISEVLDSLENLMRHSEDNPNQIRILAQTLTDGGVMDELINEELETFNSRWRELHEEAVRRQKLLEQSIQSAQETEKSLHLIQESLTFIDKQLAAYIADKVDAAQMPQEAQKIQSDLTSHEISLEEMKKHNQGKEAAQRVLSQIDVAQKKLQDVSMKFRLFQKPANFEQRLQESKMILDEVKMHLPALETKSVEQEVVQSQLNHCVNLYKSLSEVKSEVEMVIKTGRQIVQKKQTENPKELDERVTALKLHYNELGAKVTERKQQLEKCLKLSRKMRKEMNVLTEWLAATDMELTKRSAVEGMPSNLDSEVAWGKATQKEIEKQKVHLKSITEVGEALKTVLGKKETLVEDKLSLLNSNWIAVTSRAEEWLNLLLEYQKHMETFDQNVDHITKWIIQADTLLDESEKKKPQQKEDVLKRLKAELNDIRPKVDSTRDQAANLMANRGDHCRKLVEPQISELNHRFAAISHRIKTGKASIPLKELEQFNSDIQKLLEPLEAEIQQGVNLKEEDFNKDMNEDNEGTVKELLQRGDNLQQRITDERKREEIKIKQQLLQTKHNALKDLRSQRRKKALEISHQWYQYKRQADDLLKCLDDIEKKLASLPEPRDERKIKEIDRELQKKKEELNAVRRQAEGLSEDGAAMAVEPTQIQLSKRWREIESKFAQFRRLNFAQIHTVREETMMVMTEDMPLEISYVPSTYLTEITHVSQALLEVEQLLNAPDLCAKDFEDLFKQEESLKNIKDSLQQSSGRIDIIHSKKTAALQSATPVERVKLQEALSQLDFQWEKVNKMYKDRQGRFDRSVEKWRRFHYDIKIFNQWLTEAEQFLRKTQIPENWEHAKYKWYLKELQDGIGQRQTVVRTLNATGEEIIQQSSKTDASILQEKLGSLNLRWQEVCKQLSDRKKRLEEQKNILSEFQRDLNEFVLWLEEADNIASIPLEPGKEQQLKEKLEQVKLLVEELPLRQGILKQLNETGGPVLVSAPISPEEQDKLENKLKQTNLQWIKVSRALPEKQGEIEAQIKDLGQLEKKLEDLEEQLNHLLLWLSPIRNQLEIYNQPNQEGPFDVKETEIAVQAKQPDVEEILSKGQHLYKEKPATQPVKRKLEDLSSEWKAVNRLLQELRAKQPDLAPGLTTIGASPTQTVTLVTQPVVTKETAISKLEMPSSLMLEVPALADFNRAWTELTDWLSLLDQVIKSQRVMVGDLEDINEMIIKQKATMQDLEQRRPQLEELITAAQNLKNKTSNQEARTIITDRIERIQNQWDEVQEHLQNRRQQLNEMLKDSTQWLEAKEEAEQVLGQARAKLESWKEGPYTVDAIQKKITETKQLAKDLRQWQTNVDVANDLALKLLRDYSADDTRKVHMITENINASWRSIHKRVSEREAALEETHRLLQQFPLDLEKFLAWLTEAETTANVLQDATRKERLLEDSKGVKELMKQWQDLQGEIEAHTDVYHNLDENSQKILRSLEGSDDAVLLQRRLDNMNFKWSELRKKSLNIRSHLEASSDQWKRLHLSLQELLVWLQLKDDELSRQAPIGGDFPAVQKQNDVHRAFKRELKTKEPVIMSTLETVRIFLTEQPLEGLEKLYQEPRELPPEERAQNVTRLLRKQAEEVNTEWEKLNLHSADWQRKIDETLERLQELQEATDELDLKLRQAEVIKGSWQPVGDLLIDSLQDHLEKVKALRGEIAPLKENVSHVNDLARQLTTLGIQLSPYNLSTLEDLNTRWKLLQVAVEDRVRQLHEAHRDFGPASQHFLSTSVQGPWERAISPNKVPYYINHETQTTCWDHPKMTELYQSLADLNNVRFSAYRTAMKLRRLQKALCLDLLSLSAACDALDQHNLKQNDQPMDILQIINCLTTIYDRLEQEHNNLVNVPLCVDMCLNWLLNVYDTGRTGRIRVLSFKTGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRLGLLLHDSIQIPRQLGEVASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLEPQSMVWLPVLHRVAAAETAKHQAKCNICKECPIIGFRYRSLKHFNYDICQSCFFSGRVAKGHKMHYPMVEYCTPTTSGEDVRDFAKVLKNKFRTKRYFAKHPRMGYLPVQTVLEGDNMETPVTLINFWPVDSAPASSPQLSHDDTHSRIEHYASRLAEMENSNGSYLNDSISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLESEERGELERILADLEEENRNLQAEYDRLKQQHEHKGLSPLPSPPEMMPTSPQSPRDAELIAEAKLLRQHKGRLEARMQILEDHNKQLESQLHRLRQLLEQPQAEAKVNGTTVSSPSTSLQRSDSSQPMLLRVVGSQTSDSMGEEDLLSPPQDTSTGLEEVMEQLNNSFPSSRGRNTPGKPMREDTM T02779 DRUGINFO D09IRQ Ataluren Phase 3 T70532 TARGETID T70532 T70532 FORMERID TTDI00106 T70532 UNIPROID NCK1_HUMAN T70532 TARGNAME NCK adaptor protein 1 (NCK1) T70532 GENENAME NCK1 T70532 TARGTYPE Clinical trial T70532 SYNONYMS SH2/SH3 adaptor protein NCKalpha; SH2/SH3 adaptor protein NCK-alpha; Nck1; Nck-1; NCK; Cytoplasmic protein NCK1 T70532 FUNCTION Maintains low levels of EIF2S1 phosphorylation by promoting its dephosphorylation by PP1. Plays a role in the DNA damage response, not in the detection of the damage by ATM/ATR, but for efficient activation of downstream effectors, such as that of CHEK2. Plays a role in ELK1-dependent transcriptional activation in response to activated Ras signaling. Modulates the activation of EIF2AK2/PKR by dsRNA. May play a role in cell adhesion and migration through interaction with ephrin receptors. Adapter protein which associates with tyrosine-phosphorylated growth factor receptors, such as KDR and PDGFRB, or their cellular substrates. T70532 PDBSTRUC 2JW4; 2JS2; 2JS0; 2CUB; 2CI9 T70532 SEQUENCE MAEEVVVVAKFDYVAQQEQELDIKKNERLWLLDDSKSWWRVRNSMNKTGFVPSNYVERKNSARKASIVKNLKDTLGIGKVKRKPSVPDSASPADDSFVDPGERLYDLNMPAYVKFNYMAEREDELSLIKGTKVIVMEKCSDGWWRGSYNGQVGWFPSNYVTEEGDSPLGDHVGSLSEKLAAVVNNLNTGQVLHVVQALYPFSSSNDEELNFEKGDVMDVIEKPENDPEWWKCRKINGMVGLVPKNYVTVMQNNPLTSGLEPSPPQCDYIRPSLTGKFAGNPWYYGKVTRHQAEMALNERGHEGDFLIRDSESSPNDFSVSLKAQGKNKHFKVQLKETVYCIGQRKFSTMEELVEHYKKAPIFTSEQGEKLYLVKHLS T70532 DRUGINFO D00JDJ AX-024 Phase 1 T08884 TARGETID T08884 T08884 FORMERID TTDI01713 T08884 UNIPROID TRAP_PLAFA T08884 TARGNAME Plasmodium Thrombospondin relate anonymous protein (Plasm TRAP) T08884 GENENAME Plasm TRAP T08884 TARGTYPE Clinical trial T08884 SYNONYMS Thrombospondin-related anonymous protein T08884 FUNCTION A type 1 membrane protein that possesses multiple adhesive domains in its extracellular region. Essential for sporozoite motility and for liver cell invasion. T08884 PDBSTRUC 2BBX T08884 SEQUENCE MNHLGNVKYLVIVFLIFFDLFLVNGRDVQNNIVDEIKYSEEVCNDQVDLYLLMDCSGSIRRHNWVNHAVPLAMKLIQQLNLNDNAIHLYVNVFSNNAKEIIRLHSDASKNKEKALIIIRSLLSTNLPYGRTNLTDALLQVRKHLNDRINRENANQLVVILTDGIPDSIQDSLKESRKLSDRGVKIAVFGIGQGINVAFNRFLVGCHPSDGKCNLYADSAWENVKNVIGPFMKAVCVEVEKTASCGVWDEWSPCSVTCGKGTRSRKREILHEGCTSEIQEQCEEERCPPKWEPLDVPDEPEDDQPRPRGDNSSVQKPEENIIDNNPQEPSPNPEEGKDENPNGFDLDENPENPPNPDIPEQKPNIPEDSEKEVPSDVPKNPEDDREENFDIPKKPENKHDNQNNLPNDKSDRNIPYSPLPPKVLDNERKQSDPQSQDNNGNRHVPNSEDRETRPHGRNNENRSYNRKYNDTPKHPEREEHEKPDNNKKKGESDNKYKIAGGIAGGLALLACAGLAYKFVVPGAATPYAGEPAPFDETLGEEDKDLDEPEQFRLPEENEWN T08884 DRUGINFO D0K4OF PlaMavax Phase 2 T58920 TARGETID T58920 T58920 UNIPROID TRH_HUMAN T58920 TARGNAME Thyrotropin-releasing hormone (TRH) T58920 GENENAME TRH T58920 TARGTYPE Clinical trial T58920 SYNONYMS Prothyroliberin; Pro-thyrotropin-releasing hormone; Pro-TRH T58920 FUNCTION As a component of the hypothalamic-pituitary-thyroid axis, it controls the secretion of thyroid-stimulating hormone (TSH) and is involved in thyroid hormone synthesis regulation. It also operates as modulator of hair growth. It promotes hair-shaft elongation, prolongs the hair cycle growth phase (anagen) and antagonizes its termination (catagen) by TGFB2. It stimulates proliferation and inhibits apoptosis of hair matrix keratinocytes. T58920 SEQUENCE MPGPWLLLALALTLNLTGVPGGRAQPEAAQQEAVTAAEHPGLDDFLRQVERLLFLRENIQRLQGDQGEHSASQIFQSDWLSKRQHPGKREEEEEEGVEEEEEEEGGAVGPHKRQHPGRREDEASWSVDVTQHKRQHPGRRSPWLAYAVPKRQHPGRRLADPKAQRSWEEEEEEEEREEDLMPEKRQHPGKRALGGPCGPQGAYGQAGLLLGLLDDLSRSQGAEEKRQHPGRRAAWVREPLEE T58920 DRUGINFO D01WWD KPS-0373 Phase 3 T58920 DRUGINFO D01JOJ RX-77368 Discontinued in Phase 2 T19852 TARGETID T19852 T19852 UNIPROID FGF7_HUMAN T19852 TARGNAME Keratinocyte growth factor (FGF7) T19852 GENENAME FGF7 T19852 TARGTYPE Clinical trial T19852 SYNONYMS KGF; Heparin-binding growth factor 7; HBGF-7; Fibroblast growth factor 7; FGF-7 T19852 FUNCTION Required for normal branching morphogenesis. Growth factor active on keratinocytes. Possible major paracrine effector of normal epithelial cell proliferation. Plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. T19852 BIOCLASS Growth factor T19852 SEQUENCE MHKWILTWILPTLLYRSCFHIICLVGTISLACNDMTPEQMATNVNCSSPERHTRSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT T19852 DRUGINFO D0WA1R Keratinocyte growth factor Phase 1 T37876 TARGETID T37876 T37876 FORMERID TTDI01627 T37876 UNIPROID POLG_HRV1A T37876 TARGNAME Rhinovirus Capsid protein (HRV VP) T37876 GENENAME HRV VP T37876 TARGTYPE Clinical trial T37876 SYNONYMS Rhinovirus Virion protein T37876 FUNCTION Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity). T37876 PDBSTRUC 2HWF; 2HWE; 2HWD; 1R1A; 1AYN T37876 SEQUENCE GAQVSRQNVGTHSTQNSVSNGSSLNYFNINYFKDAASSGASRLDFSQDPSKFTDPVKDVLEKGIPTLQSPSVEACGYSDRIMQITRGDSTITSQDVANAVVGYGVWPHYLTPQDATAIDKPTQPDTSSNRFYTLESKHWNGSSKGWWWKLPDALKDMGIFGENMYYHFLGRSGYTVHVQCNASKFHQGTLLVAMIPEHQLASAKHGSVTAGYKLTHPGEAGRDVSQERDASLRQPSDDSWLNFDGTLLGNLLIFPHQFINLRSNNSATLIVPYVNAVPMDSMLRHNNWSLVIIPISPLRSETTSSNIVPITVSISPMCAEFSGARAKNIKQGLPVYITPGSGQFMTTDDMQSPCALPWYHPTKEISIPGEVKNLIEMCQVDTLIPVNNVGNNVGNVSMYTVQLGNQTGMAQKVFSIKVDITSQPLATTLIGEIASYYTHWTGSLRFSFMFCGTANTTLKLLLAYTPPGIDEPTTRKDAMLGTHVVWDVGLQSTISLVVPWVSASHFRLTADNKYSMAGYITCWYQTNLVVPPSTPQTADMLCFVSACKDFCLRMARDTDLHIQSGPIEQNPVENYIDEVLNEVLVVPNIKESHHTTSNSAPLLDAAETGHTSNVQPEDAIETRYVITSQTRDEMSIESFLGRSGCVHISRIKVDYTDYNGQDINFTKWKITLQEMAQIRRKFELFTYVRFDSEITLVPCIAGRGDDIGHIVMQYMYVPPGAPIPSKRNDFSWQSGTNMSIFWQHGQPFPRFSLPFLSIASAYYMFYDGYDGDNTSSKYGSVVTNDMGTICSRIVTEKQKHSVVITTHIYHKAKHTKAWCPRPPRAVPYTHSHVTNYMPETGDVTTAIVRRNTITTA T37876 DRUGINFO D0FZ1W BTA-798 Phase 2 T37876 DRUGINFO D02GVH PIRODAVIR Discontinued in Phase 2 T97759 TARGETID T97759 T97759 FORMERID TTDI02215 T97759 UNIPROID POLG_HCV1 T97759 TARGNAME Hepatitis C virus Envelope glycoprotein E2 (HCV NS1) T97759 GENENAME HCV NS1 T97759 TARGTYPE Clinical trial T97759 SYNONYMS Hepacivirus polyprotein T97759 FUNCTION NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication. T97759 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T97759 SEQUENCE ETHVTGGSAGHTVSGFVSLLAPGAKQNVQLINTNGSWHLNSTALNCNDSLNTGWLAGLFYHHKFNSSGCPERLASCRPLTDFDQGWGPISYANGSGPDQRPYCWHYPPKPCGIVPAKSVCGPVYCFTPSPVVVGTTDRSGAPTYSWGENDTDVFVLNNTRPPLGNWFGCTWMNSTGFTKVCGAPPCVIGGAGNNTLHCPTDCFRKHPDATYSRCGSGPWITPRCLVDYPYRLWHYPCTINYTIFKIRMYVGGVEHRLEAACNWTRGERCDLEDRDRSELSPLLLTTTQWQVLPCSFTTLPALSTGLIHLHQNIVDVQYLYGVGSSIASWAIKWEYVVLLFLLLADARVCSCLWMMLLISQAEA T97759 DRUGINFO D0T3QU MBL-HCV1 Phase 2 T97759 DRUGINFO D0MU1F XTL-6865 Phase 1 T97759 DRUGINFO D0CY2Z HuMax-HepC Terminated T34997 TARGETID T34997 T34997 UNIPROID POLG_HCV1 T34997 TARGNAME Hepatitis C virus Serine protease NS4A (HCV NS4A) T34997 GENENAME HCV NS4A T34997 TARGTYPE Clinical trial T34997 SYNONYMS HCV p8 T34997 FUNCTION Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity). T34997 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T34997 SEQUENCE STWVLVGGVLAALAAYCLSTGCVVIVGRVVLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQKLETFWAKHMWNFISGIQYLAGLSTLPGNPAIASLMAFTAAVTSPLTTSQTLLFNILGGWVAAQLAAPGAATAFVGAGLAGAAIGSVGLGKVLIDILAGYGAGVAGALVAFKIMSGEVPSTEDLVNLLPAILSPGALVVGVVCAAILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTAILSSLTVTQLLRRLHQWISSECTTPC T34997 DRUGINFO D04ZQO TG-2349 Phase 2 T34997 DRUGINFO D02BAW MK-6325 Phase 1 T34997 DRUGINFO D07OBJ PHX-1766 Phase 1 T34997 DRUGINFO D09VTB IDX-320 Discontinued in Phase 1/2 T34997 DRUGINFO D0S7LN GS-9132 Discontinued in Phase 1/2 T35289 TARGETID T35289 T35289 FORMERID TTDI02343 T35289 UNIPROID NKG2D_HUMAN T35289 TARGNAME NKG2 D activating NK receptor (KLRK1) T35289 GENENAME KLRK1 T35289 TARGTYPE Clinical trial T35289 SYNONYMS NKG2Dactivating NK receptor; NKG2D type II integral membrane protein; NKG2D; NKG2-D-activating NK receptor; NKG2-D type II integral membrane protein; NK cell receptor D; Killer cell lectinlike receptor subfamily K member 1; Killer cell lectin-like receptor subfamily K member 1; D12S2489E; CD314 T35289 FUNCTION Provides both stimulatory and costimulatory innate immune responses on activated killer (NK) cells, leading to cytotoxic activity. Acts as a costimulatory receptor for T-cell receptor (TCR) in CD8(+) T-cell-mediated adaptive immune responses by amplifying T-cell activation. Stimulates perforin-mediated elimination of ligand-expressing tumor cells. Signaling involves calcium influx, culminating in the expression of TNF-alpha. Participates in NK cell-mediated bone marrow graft rejection. May play a regulatory role in differentiation and survival of NK cells. Binds to ligands belonging to various subfamilies of MHC class I-related glycoproteins including MICA, MICB, RAET1E, RAET1G, RAET1L/ULBP6, ULBP1, ULBP2, ULBP3 (ULBP2>ULBP1>ULBP3) and ULBP4. Function as an activating and costimulatory receptor involved in immunosurveillance upon binding to various cellular stress-inducible ligands displayed at the surface of autologous tumor cells and virus-infected cells. T35289 PDBSTRUC 4S0U; 4PDC; 1MPU; 1KCG; 1HYR T35289 SEQUENCE MGWIRGRRSRHSWEMSEFHNYNLDLKKSDFSTRWQKQRCPVVKSKCRENASPFFFCCFIAVAMGIRFIIMVAIWSAVFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTV T35289 DRUGINFO D06JUE NN8555 Phase 2 T35289 DRUGINFO D08YHE NKR-2 CAR-T Cells Phase 1 T35289 DRUGINFO D0FB4W CYAD-101 Phase 1 T35289 DRUGINFO D0NC9M CM-CS1 T-cell Phase 1 T35289 DRUGINFO D0QR2K NKR-2 cells Phase 1 T66426 TARGETID T66426 T66426 FORMERID TTDI02038 T66426 UNIPROID CD34_HUMAN T66426 TARGNAME Hematopoietic progenitor cell antigen CD34 (CD34) T66426 GENENAME CD34 T66426 TARGTYPE Clinical trial T66426 SYNONYMS CD34 molecule T66426 FUNCTION Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. Presents carbohydrate ligands to selectins. Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. T66426 SEQUENCE MLVRRGARAGPRMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIALVTSGALLAVLGITGYFLMNRRSWSPTGERLGEDPYYTENGGGQGYSSGPGTSPEAQGKASVNRGAQENGTGQATSRNGHSARQHVVADTEL T66426 DRUGINFO D08GVB AMR-001 Phase 2 T66426 DRUGINFO D0NY1Y CART-34 cells Phase 1 T66426 DRUGINFO D08ABX CAR-T cells targeting CD34 Preclinical T05351 TARGETID T05351 T05351 FORMERID TTDI02121 T05351 UNIPROID MARCS_HUMAN T05351 TARGNAME Myristoylated alanine-rich C-kinase substrate (MARCKS) T05351 GENENAME MARCKS T05351 TARGTYPE Clinical trial T05351 SYNONYMS Protein kinase C substrate, 80 kDa protein, light chain; PRKCSL; PKCSL; Myristoylated alaninerich Ckinase substrate; MACS; 80KL protein; 80K-L protein T05351 FUNCTION MARCKS is the most prominent cellular substrate for protein kinase C. This protein binds calmodulin, actin, and synapsin. MARCKS is a filamentous (F) actin cross-linking protein. T05351 SEQUENCE MGAQFSKTAAKGEAAAERPGEAAVASSPSKANGQENGHVKVNGDASPAAAESGAKEELQANGSAPAADKEEPAAAGSGAASPSAAEKGEPAAAAAPEAGASPVEKEAPAEGEAAEPGSPTAAEGEAASAASSTSSPKAEDGATPSPSNETPKKKKKRFSFKKSFKLSGFSFKKNKKEAGEGGEAEAPAAEGGKDEAAGGAAAAAAEAGAASGEQAAAPGEEAAAGEEGAAGGDPQEAKPQEAAVAPEKPPASDETKAAEEPSKVEEKKAEEAGASAAACEAPSAAGPGAPPEQEAAPAEEPAAAAASSACAAPSQEAQPECSPEAPPAEAAE T05351 DRUGINFO D0C3XD BIO-11006 Phase 2 T05351 DRUGINFO DQM0X1 BIO-11006 Phase 2 T62753 TARGETID T62753 T62753 FORMERID TTDI01285 T62753 UNIPROID AKT1_HUMAN; AKT2_HUMAN; AKT3_HUMAN T62753 TARGNAME Phosphorylated protein kinase B (pAKT) T62753 GENENAME AKT1; AKT2; AKT3 T62753 TARGTYPE Clinical trial T62753 SYNONYMS RAC-serine/threonine-protein kinase; RAC-PK; Protein kinase B; Protein kinase Akt; PKB T62753 FUNCTION AKT kinases are 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3), and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53. T62753 BIOCLASS Kinase T62753 SEQUENCE MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA T62753 DRUGINFO D0F5VX MNX-100 Phase 2 T09528 TARGETID T09528 T09528 FORMERID TTDR00287 T09528 UNIPROID CXCR5_HUMAN T09528 TARGNAME C-X-C chemokine receptor type 5 (CXCR5) T09528 GENENAME CXCR5 T09528 TARGTYPE Clinical trial T09528 SYNONYMS Monocyte-derived receptor15; Monocyte-derived receptor 15; MDR15; MDR-15; Chemokine receptor CXCR5; CXCR-5; CXC-R5; CD185; Burkitt'S lymphoma receptor 1; Burkitt lymphoma receptor 1; BLR1 T09528 FUNCTION Involved in B-cell migration into B-cell follicles of spleen and Peyer patches but not into those of mesenteric or peripheral lymph nodes. May have a regulatory function in Burkitt lymphoma (BL) lymphomagenesis and/or B-cell differentiation. Cytokine receptor that binds to B-lymphocyte chemoattractant (BLC). T09528 BIOCLASS GPCR rhodopsin T09528 SEQUENCE MNYPLTLEMDLENLEDLFWELDRLDNYNDTSLVENHLCPATEGPLMASFKAVFVPVAYSLIFLLGVIGNVLVLVILERHRQTRSSTETFLFHLAVADLLLVFILPFAVAEGSVGWVLGTFLCKTVIALHKVNFYCSSLLLACIAVDRYLAIVHAVHAYRHRRLLSIHITCGTIWLVGFLLALPEILFAKVSQGHHNNSLPRCTFSQENQAETHAWFTSRFLYHVAGFLLPMLVMGWCYVGVVHRLRQAQRRPQRQKAVRVAILVTSIFFLCWSPYHIVIFLDTLARLKAVDNTCKLNGSLPVAITMCEFLGLAHCCLNPMLYTFAGVKFRSDLSRLLTKLGCTGPASLCQLFPSWRRSSLSESENATSLTTF T09528 DRUGINFO D2W0LG PF-06835375 Phase 2 T09528 DRUGINFO D0T6RG SAR113244 Phase 1 T09528 DRUGINFO D82DGN JT08 Preclinical T65783 TARGETID T65783 T65783 FORMERID TTDR01277 T65783 UNIPROID APJ_HUMAN T65783 TARGNAME Apelin receptor (APLNR) T65783 GENENAME APLNR T65783 TARGTYPE Clinical trial T65783 SYNONYMS G-protein coupled receptor HG11; G-protein coupled receptor APJ; Angiotensin receptor-like 1; APJ; AGTRL1 T65783 FUNCTION Receptor for apelin receptor early endogenous ligand (APELA) and apelin (APLN) hormones coupled to G proteins that inhibit adenylate cyclase activity. Plays a key role in early development such as gastrulation, blood vessels formation and heart morphogenesis by acting as a receptor for APELA hormone (By similarity). May promote angioblast migration toward the embryonic midline, i.e. the position of the future vessel formation, during vasculogenesis (By similarity). Promotes sinus venosus (SV)-derived endothelial cells migration into the developing heart to promote coronary blood vessel development (By similarity). Plays also a role in various processes in adults such as regulation of blood vessel formation, blood pressure, heart contractility and heart failure. T65783 PDBSTRUC 5VBL; 2LOW; 2LOV; 2LOU; 2LOT T65783 SEQUENCE MEEGGDFDNYYGADNQSECEYTDWKSSGALIPAIYMLVFLLGTTGNGLVLWTVFRSSREKRRSADIFIASLAVADLTFVVTLPLWATYTYRDYDWPFGTFFCKLSSYLIFVNMYASVFCLTGLSFDRYLAIVRPVANARLRLRVSGAVATAVLWVLAALLAMPVMVLRTTGDLENTTKVQCYMDYSMVATVSSEWAWEVGLGVSSTTVGFVVPFTIMLTCYFFIAQTIAGHFRKERIEGLRKRRRLLSIIVVLVVTFALCWMPYHLVKTLYMLGSLLHWPCDFDLFLMNIFPYCTCISYVNSCLNPFLYAFFDPRFRQACTSMLCCGQSRCAGTSHSSSGEKSASYSSGHSQGPGPNMGKGGEQMHEKSIPYSQETLVVD T65783 DRUGINFO D0QX9K AMG 986 Phase 1 T65783 DRUGINFO D00QYH apelin-13 Investigative T65783 DRUGINFO D05NXX ML221 Investigative T65783 DRUGINFO D0I8TR ML233 Investigative T65783 DRUGINFO D0J6UH E339-3D6 Investigative T92185 TARGETID T92185 T92185 FORMERID TTDI03440 T92185 UNIPROID PACR_HUMAN T92185 TARGNAME PACAP type I receptor (PAC1R) T92185 GENENAME ADCYAP1R1 T92185 TARGTYPE Clinical trial T92185 SYNONYMS Pituitary adenylate cyclase-activating polypeptide type I receptor; PACAP-R1; PACAP-R-1 T92185 FUNCTION This is a receptor for PACAP-27 and PACAP-38. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. May regulate the release of adrenocorticotropin, luteinizing hormone, growth hormone, prolactin, epinephrine, and catecholamine. May play a role in spermatogenesis and sperm motility. Causes smooth muscle relaxation and secretion in the gastrointestinal tract. T92185 PDBSTRUC 3N94; 2JOD T92185 SEQUENCE MAGVVHVSLAALLLLPMAPAMHSDCIFKKEQAMCLEKIQRANELMGFNDSSPGCPGMWDNITCWKPAHVGEMVLVSCPELFRIFNPDQVWETETIGESDFGDSNSLDLSDMGVVSRNCTEDGWSEPFPHYFDACGFDEYESETGDQDYYYLSVKALYTVGYSTSLVTLTTAMVILCRFRKLHCTRNFIHMNLFVSFMLRAISVFIKDWILYAEQDSNHCFISTVECKAVMVFFHYCVVSNYFWLFIEGLYLFTLLVETFFPERRYFYWYTIIGWGTPTVCVTVWATLRLYFDDTGCWDMNDSTALWWVIKGPVVGSIMVNFVLFIGIIVILVQKLQSPDMGGNESSIYLRLARSTLLLIPLFGIHYTVFAFSPENVSKRERLVFELGLGSFQGFVVAVLYCFLNGEVQAEIKRKWRSWKVNRYFAVDFKHRHPSLASSGVNGGTQLSILSKSSSQIRMSGLPADNLAT T92185 DRUGINFO D0CO2W AMG 301 Phase 2 T92185 DRUGINFO D0MC5J PACAP-27 Investigative T28217 TARGETID T28217 T28217 FORMERID TTDI02397 T28217 UNIPROID KI3L2_HUMAN T28217 TARGNAME MHC class I NK cell receptor 3DL2 (CD158k) T28217 GENENAME KIR3DL2 T28217 TARGTYPE Clinical trial T28217 SYNONYMS p70 natural killer cell receptor clone CL5; p70 NK receptor CL5; Natural killerassociated transcript 4; NKAT4; KIR3DL2; CD158k; CD158 antigenlike family member K T28217 FUNCTION Receptor on natural killer (NK) cells for HLA-A alleles. Inhibits the activity of NK cells thus preventing cell lysis. T28217 BIOCLASS Immunoglobulin T28217 SEQUENCE MSLTVVSMACVGFFLLQGAWPLMGGQDKPFLSARPSTVVPRGGHVALQCHYRRGFNNFMLYKEDRSHVPIFHGRIFQESFIMGPVTPAHAGTYRCRGSRPHSLTGWSAPSNPLVIMVTGNHRKPSLLAHPGPLLKSGETVILQCWSDVMFEHFFLHREGISEDPSRLVGQIHDGVSKANFSIGPLMPVLAGTYRCYGSVPHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVQAGENVTLSCSSWSSYDIYHLSREGEAHERRLRAVPKVNRTFQADFPLGPATHGGTYRCFGSFRALPCVWSNSSDPLLVSVTGNPSSSWPSPTEPSSKSGICRHLHVLIGTSVVIFLFILLLFFLLYRWCSNKKNAAVMDQEPAGDRTVNRQDSDEQDPQEVTYAQLDHCVFIQRKISRPSQRPKTPLTDTSVYTELPNAEPRSKVVSCPRAPQSGLEGVF T28217 DRUGINFO D0GO4T IPH4102 Phase 2 T85421 TARGETID T85421 T85421 FORMERID TTDR00289 T85421 UNIPROID MK08_HUMAN; MK09_HUMAN; MK10_HUMAN T85421 TARGNAME Jun N terminal kinase (JNK) T85421 GENENAME MAPK8; MAPK9; MAPK10 T85421 TARGTYPE Clinical trial T85421 SYNONYMS c-Jun N-terminal kinase; Stress-activated protein kinase JNK; SAPK1; PRKM; MAP kinase; JNK T85421 FUNCTION Associates with scaffold proteins JNK interacting proteins as well as their upstream kinases JNKK1 and JNKK2 following their activation. Modifies the activity of numerous proteins that reside at the mitochondria or act in the nucleus. Downstream molecules that are activated by JNK include c-Jun, ATF2, ELK1, SMAD4, p53 and HSF1. Involved in apoptosis, neurodegeneration, cell differentiation and proliferation, inflammatory conditions and cytokine production mediated by AP-1 (activation protein 1) such as RANTES, IL-8 and GM-CSF. T85421 BIOCLASS Kinase T85421 SEQUENCE MSRSKRDNNFYSVEIGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSKMLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEVMDLEERTKNGVIRGQPSPLGAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR T85421 DRUGINFO D0N7WG AM-111 Phase 3 T85421 DRUGINFO D04UUD CC-401 Phase 2 T85421 DRUGINFO D0X4MN CC-930 Phase 2 T85421 DRUGINFO D08LRV BGP-15 Phase 2 T85421 DRUGINFO D03MTX PMID25991433-Compound-O1 Patented T85421 DRUGINFO D0V7UQ PMID25991433-Compound-Q1 Patented T85421 DRUGINFO D02PVB 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One Investigative T38200 TARGETID T38200 T38200 FORMERID TTDR01163 T38200 UNIPROID S6A11_HUMAN T38200 TARGNAME GABA transporter-3 (SLC6A11) T38200 GENENAME SLC6A11 T38200 TARGTYPE Clinical trial T38200 SYNONYMS Solute carrier family 6 member 11; Sodium- and chloride-dependent GABA transporter 3; GAT3; GAT-3; GABT3 T38200 FUNCTION Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals. T38200 SEQUENCE MTAEKALPLGNGKAAEEARESEAPGGGCSSGGAAPARHPRVKRDKAVHERGHWNNKVEFVLSVAGEIIGLGNVWRFPYLCYKNGGGAFLIPYVVFFICCGIPVFFLETALGQFTSEGGITCWRKVCPLFEGIGYATQVIEAHLNVYYIIILAWAIFYLSNCFTTELPWATCGHEWNTENCVEFQKLNVSNYSHVSLQNATSPVMEFWEHRVLAISDGIEHIGNLRWELALCLLAAWTICYFCIWKGTKSTGKVVYVTATFPYIMLLILLIRGVTLPGASEGIKFYLYPDLSRLSDPQVWVDAGTQIFFSYAICLGCLTALGSYNNYNNNCYRDCIMLCCLNSGTSFVAGFAIFSVLGFMAYEQGVPIAEVAESGPGLAFIAYPKAVTMMPLSPLWATLFFMMLIFLGLDSQFVCVESLVTAVVDMYPKVFRRGYRRELLILALSVISYFLGLVMLTEGGMYIFQLFDSYAASGMCLLFVAIFECICIGWVYGSNRFYDNIEDMIGYRPPSLIKWCWMIMTPGICAGIFIFFLIKYKPLKYNNIYTYPAWGYGIGWLMALSSMLCIPLWICITVWKTEGTLPEKLQKLTTPSTDLKMRGKLGVSPRMVTVNDCDAKLKSDGTIAAITEKETHF T38200 DRUGINFO D0C9XA GSK683699 Phase 2 T38200 DRUGINFO D0W8SX Beta-Alanine Investigative T38200 DRUGINFO D0ER1G 4-Hydroxy-piperidine-3-carboxylic acid Investigative T38200 DRUGINFO D09TTI 2,4-Diamino-butyric acid(GABA) Investigative T38200 DRUGINFO D0RF2M NIPECOTIC ACID Investigative T82277 TARGETID T82277 T82277 FORMERID TTDNC00483 T82277 UNIPROID CTG1B_HUMAN T82277 TARGNAME Cancer/testis antigen 1 (NY-ESO-1) T82277 GENENAME CTAG1A T82277 TARGTYPE Clinical trial T82277 SYNONYMS LAGE2B; LAGE2A; LAGE2; LAGE-2; L antigen family member 2; ESO1; Cancer/testis antigen 6.1; CTAG1B; CTAG1; CTAG; CT6.1; Autoimmunogenic cancer/testis antigen NYESO1; Autoimmunogenic cancer/testis antigen NY-ESO-1 T82277 FUNCTION Immunogenic protein. Its aberrant re-expression is induced by molecular mechanisms including: DNA demethylation, histone post-translational modification, and microRNA-mediated regulation. The effect of DNA demethylation is evident by the capability of demethylating agents, like 5-aza-2-deoxycytidine, to induce the re-expression of NY-ESO-1 in tumour cells but not in normal epithelial cells. T82277 PDBSTRUC 6AVG; 6AVF; 6AT5; 3KLA; 3HAE T82277 SEQUENCE MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPGGGAPRGPHGGAASGLNGCCRCGARGPESRLLEFYLAMPFATPMEAELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAADHRQLQLSISSCLQQLSLLMWITQCFLPVFLAQPPSGQRR T82277 DRUGINFO D09TCY CDX-1401 Phase 2 T82277 DRUGINFO D0LJ2S Anti-NY-ESO-1 CAR-T cells Phase 1/2 T82277 DRUGINFO D02DVK CV-9201 Phase 1/2 T82277 DRUGINFO D09XOF NY-ESO-1 vaccine Phase 1 T82277 DRUGINFO D0IA5O GSK-2241658A Phase 1 T82277 DRUGINFO DHS3X7 GSK3901961 Phase 1 T82277 DRUGINFO DS39MT GSK3845097 Phase 1 T82277 DRUGINFO D0C1EO Melanoma vaccine (ALVAC) Discontinued in Phase 2 T82913 TARGETID T82913 T82913 FORMERID TTDR00359 T82913 UNIPROID EF1A_PLAFK T82913 TARGNAME Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1) T82913 GENENAME Malaria MEF-1 T82913 TARGTYPE Clinical trial T82913 SYNONYMS MEF-1; Elongation factor Tu of Plasmodium falciparum; Elongation factor 1 A-1; EF-Tu; EF-1-alpha-1 of Plasmodium falciparum; EEF1A-1 T82913 FUNCTION This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. T82913 BIOCLASS Acid anhydrides hydrolase T82913 SEQUENCE MGKEKTHINLVVIGHVDSGKSTTTGHIIYKLGGIDRRTIEKFEKESAEMGKGSFKYAWVLDKLKAERERGITIDIALWKFETPRYFFTVIDAPGHKDFIKNMITGTSQADVALLVVPADVGGFDGAFSKEGQTKEHVLLAFTLGVKQIVVGVNKMDTVKYSEDRYEEIKKEVKDYLKKVGYQADKVDFIPISGFEGDNLIEKSDKTPWYKGRTLIEALDTMQPPKRPYDKPLRIPLQGVYKIGGIGTVPVGRVETGILKAGMVLNFAPSAVVSECKSVEMHKEVLEEARPGDNIGFNVKNVSVKEIKRGYVASDTKNEPAKGCSKFTAQVIILNHPGEIKNGYTPLLDCHTSHISCKFLNIDSKIDKRSGKVVEENPKAIKSGDSALVSLEPKKPMVVETFTEYPPLGRFAIRDMRQTIAVGIINQLKRKNLGAVTAKAPAKK T82913 DRUGINFO D0Y3XA Ge2270a Phase 1 T82913 DRUGINFO D05CNB Amythiamicin Investigative T82913 DRUGINFO D0C7LS Guanosine-5'-Diphosphate Investigative T08014 TARGETID T08014 T08014 FORMERID TTDI02548 T08014 UNIPROID TADBP_HUMAN T08014 TARGNAME TAR DNA binding protein 43 (TARDBP) T08014 GENENAME TARDBP T08014 TARGTYPE Clinical trial T08014 SYNONYMS TDP43; TDP-43; TAR DNA-binding protein 43 T08014 FUNCTION RNA-binding protein that is involved in various steps of RNA biogenesis and processing. Preferentially binds, via its two RNA recognition motifs RRM1 and RRM2, to GU-repeats on RNA molecules predominantly localized within long introns and in the 3'UTR of mRNAs. In turn, regulates the splicing of many non-coding and protein-coding RNAs including proteins involved in neuronal survival, as well as mRNAs that encode proteins relevant for neurodegenerative diseases. Plays a role in maintaining mitochondrial homeostasis by regulating the processing of mitochondrial transcripts. Regulates also mRNA stability by recruiting CNOT7/CAF1 deadenylase on mRNA 3'UTR leading to poly(A) tail deadenylation and thus shortening. In response to oxidative insult, associates with stalled ribosomes localized to stress granules (SGs) and contributes to cell survival. Participates also in the normal skeletal muscle formation and regeneration, forming cytoplasmic myo-granules and binding mRNAs that encode sarcomeric proteins. Plays a role in the maintenance of the circadian clock periodicity via stabilization of the CRY1 and CRY2 proteins in a FBXL3-dependent manner. T08014 PDBSTRUC 6CFH; 6CF4; 6B1G; 5X4F; 5WKD T08014 SEQUENCE MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM T08014 DRUGINFO D05XDZ LMT-X Phase 3 T08014 DRUGINFO DVX18N PP-007 Phase 1 T68525 TARGETID T68525 T68525 UNIPROID PTK7_HUMAN T68525 TARGNAME Inactive tyrosine-protein kinase 7 (PTK7) T68525 GENENAME PTK7 T68525 TARGTYPE Clinical trial T68525 SYNONYMS Tyrosine-protein kinase-like 7; Pseudo tyrosine kinase receptor 7; Protein-tyrosine kinase 7; Colon carcinoma kinase 4; CCK-4 T68525 FUNCTION Inactive tyrosine kinase involved in Wnt signaling pathway. Component of both the non-canonical (also known as the Wnt/planar cell polarity signaling) and the canonical Wnt signaling pathway. Functions in cell adhesion, cell migration, cell polarity, proliferation, actin cytoskeleton reorganization and apoptosis. Has a role in embryogenesis, epithelial tissue organization and angiogenesis. T68525 BIOCLASS Protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily T68525 SEQUENCE MGAARGSPARPRRLPLLSVLLLPLLGGTQTAIVFIKQPSSQDALQGRRALLRCEVEAPGPVHVYWLLDGAPVQDTERRFAQGSSLSFAAVDRLQDSGTFQCVARDDVTGEEARSANASFNIKWIEAGPVVLKHPASEAEIQPQTQVTLRCHIDGHPRPTYQWFRDGTPLSDGQSNHTVSSKERNLTLRPAGPEHSGLYSCCAHSAFGQACSSQNFTLSIADESFARVVLAPQDVVVARYEEAMFHCQFSAQPPPSLQWLFEDETPITNRSRPPHLRRATVFANGSLLLTQVRPRNAGIYRCIGQGQRGPPIILEATLHLAEIEDMPLFEPRVFTAGSEERVTCLPPKGLPEPSVWWEHAGVRLPTHGRVYQKGHELVLANIAESDAGVYTCHAANLAGQRRQDVNITVATVPSWLKKPQDSQLEEGKPGYLDCLTQATPKPTVVWYRNQMLISEDSRFEVFKNGTLRINSVEVYDGTWYRCMSSTPAGSIEAQARVQVLEKLKFTPPPQPQQCMEFDKEATVPCSATGREKPTIKWERADGSSLPEWVTDNAGTLHFARVTRDDAGNYTCIASNGPQGQIRAHVQLTVAVFITFKVEPERTTVYQGHTALLQCEAQGDPKPLIQWKGKDRILDPTKLGPRMHIFQNGSLVIHDVAPEDSGRYTCIAGNSCNIKHTEAPLYVVDKPVPEESEGPGSPPPYKMIQTIGLSVGAAVAYIIAVLGLMFYCKKRCKAKRLQKQPEGEEPEMECLNGGPLQNGQPSAEIQEEVALTSLGSGPAATNKRHSTSDKMHFPRSSLQPITTLGKSEFGEVFLAKAQGLEEGVAETLVLVKSLQSKDEQQQLDFRRELEMFGKLNHANVVRLLGLCREAEPHYMVLEYVDLGDLKQFLRISKSKDEKLKSQPLSTKQKVALCTQVALGMEHLSNNRFVHKDLAARNCLVSAQRQVKVSALGLSKDVYNSEYYHFRQAWVPLRWMSPEAILEGDFSTKSDVWAFGVLMWEVFTHGEMPHGGQADDEVLADLQAGKARLPQPEGCPSKLYRLMQRCWALSPKDRPSFSEIASALGDSTVDSKP T68525 DRUGINFO D0AD3V PF-06647020 Phase 1 T29736 TARGETID T29736 T29736 FORMERID TTDR01057 T29736 UNIPROID LAMB3_HUMAN T29736 TARGNAME Laminin beta-3 chain (LAMB3) T29736 GENENAME LAMB3 T29736 TARGTYPE Clinical trial T29736 SYNONYMS Nicein subunit beta; Laminin5beta3; Laminin-5 subunit beta; Laminin subunit beta-3; Laminin B1k chain; Laminin 5 beta 3; LAMNB1; Kalinin subunit beta; Kalinin B1 chain; Epiligrin subunit bata T29736 FUNCTION Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. T29736 SEQUENCE MRPFFLLCFALPGLLHAQQACSRGACYPPVGDLLVGRTRFLRASSTCGLTKPETYCTQYGEWQMKCCKCDSRQPHNYYSHRVENVASSSGPMRWWQSQNDVNPVSLQLDLDRRFQLQEVMMEFQGPMPAGMLIERSSDFGKTWRVYQYLAADCTSTFPRVRQGRPQSWQDVRCQSLPQRPNARLNGGKVQLNLMDLVSGIPATQSQKIQEVGEITNLRVNFTRLAPVPQRGYHPPSAYYAVSQLRLQGSCFCHGHADRCAPKPGASAGPSTAVQVHDVCVCQHNTAGPNCERCAPFYNNRPWRPAEGQDAHECQRCDCNGHSETCHFDPAVFAASQGAYGGVCDNCRDHTEGKNCERCQLHYFRNRRPGASIQETCISCECDPDGAVPGAPCDPVTGQCVCKEHVQGERCDLCKPGFTGLTYANPQGCHRCDCNILGSRRDMPCDEESGRCLCLPNVVGPKCDQCAPYHWKLASGQGCEPCACDPHNSLSPQCNQFTGQCPCREGFGGLMCSAAAIRQCPDRTYGDVATGCRACDCDFRGTEGPGCDKASGRCLCRPGLTGPRCDQCQRGYCNRYPVCVACHPCFQTYDADLREQALRFGRLRNATASLWSGPGLEDRGLASRILDAKSKIEQIRAVLSSPAVTEQEVAQVASAILSLRRTLQGLQLDLPLEEETLSLPRDLESLDRSFNGLLTMYQRKREQFEKISSADPSGAFRMLSTAYEQSAQAAQQVSDSSRLLDQLRDSRREAERLVRQAGGGGGTGSPKLVALRLEMSSLPDLTPTFNKLCGNSRQMACTPISCPGELCPQDNGTACGSRCRGVLPRAGGAFLMAGQVAEQLRGFNAQLQRTRQMIRAAEESASQIQSSAQRLETQVSASRSQMEEDVRRTRLLIQQVRDFLTDPDTDAATIQEVSEAVLALWLPTDSATVLQKMNEIQAIAARLPNVDLVLSQTKQDIARARRLQAEAEEARSRAHAVEGQVEDVVGNLRQGTVALQEAQDTMQGTSRSLRLIQDRVAEVQQVLRPAEKLVTSMTKQLGDFWTRMEELRHQARQQGAEAVQAQQLAEGASEQALSAQEGFERIKQKYAELKDRLGQSSMLGEQGARIQSVKTEAEELFGETMEMMDRMKDMELELLRGSQAIMLRSADLTGLEKRVEQIRDHINGRVLYYATCK T29736 DRUGINFO D09PFR LAMB3-transduced autologous epidermal stem cells Phase 1 T32720 TARGETID T32720 T32720 UNIPROID KI2S1_HUMAN T32720 TARGNAME MHC class I NK cell receptor 2DS1 (CD158h) T32720 GENENAME KIR2DS1 T32720 TARGTYPE Clinical trial T32720 SYNONYMS MHC class I NK cell receptor Eb6 ActI; Killer cell immunoglobulin-like receptor 2DS1; CD158h; CD158 antigen-like family member H T32720 FUNCTION Receptor on natural killer (NK) cells for some HLA-C alleles such as w6. Does not inhibit the activity of NK cells. T32720 BIOCLASS Immunoglobulin T32720 SEQUENCE MSLTVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGRLVKSEETVILQCWSDVMFEHFLLHREGMFNDTLRLIGEHHDGVSKANFSISRMKQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVIIGLYEKPSLSAQPGPTVLAGENVTLSCSSRSSYDMYHLSREGEAHERRLPAGTKVNGTFQANFPLGPATHGGTYRCFGSFRDSPYEWSKSSDPLLVSVTGNPSNSWPSPTEPSSETGNPRHLHVLIGTSVVKIPFTILLFFLLHRWCSDKKNAAVMDQEPAGNRTVNSEDSDEQDHQEVSYA T32720 DRUGINFO D04IXD IPH-2101 Phase 2 T18872 TARGETID T18872 T18872 FORMERID TTDR01010 T18872 UNIPROID KISS1_HUMAN T18872 TARGNAME Metastasis-suppressor KiSS-1 (KISS1) T18872 GENENAME KISS1 T18872 TARGTYPE Clinical trial T18872 SYNONYMS KiSS-1; KISS1 T18872 FUNCTION Metastasis suppressor protein in malignant melanomas and in some breast cancers. May regulate events downstream of cell- matrix adhesion, perhaps involving cytoskeletal reorganization. Generates a C-terminally amidated peptide, metastin which functions as the endogenous ligand of the G-protein coupled receptor GPR54. Activation of the receptor inhibits cell proliferation and cell migration, key characteristics of tumor metastasis. Kp-10 is a decapeptide derived from the primary translation product, isolated in conditioned medium of first trimester trophoblast. Kp-10, but not other kisspeptins, increased intracellular Ca(2+) levels in isolated first trimester trophoblasts. Kp-10 is a paracrine/endocrine regulator in fine- tuning trophoblast invasion generated by the trophoblast itself. The receptor is also essential for normal gonadotropin-released hormone physiology and for puberty. The hypothalamic KiSS1/GPR54 system is a pivotal factor in central regulation of the gonadotropic axis at puberty and in adulthood. T18872 SEQUENCE MNSLVSWQLLLFLCATHFGEPLEKVASVGNSRPTGQQLESLGLLAPGEQSLPCTERKPAATARLSRRGTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRFGKREAAPGNHGRSAGRG T18872 DRUGINFO D04GEI TAK-448 Phase 2 T27736 TARGETID T27736 T27736 FORMERID TTDI02146 T27736 UNIPROID PDCD2_HUMAN T27736 TARGNAME Programmed cell death protein 2 (PD-2) T27736 GENENAME PDCD2 T27736 TARGTYPE Clinical trial T27736 SYNONYMS Zinc finger protein Rp8; Zinc finger protein Rp-8; Zinc finger MYND domaincontaining protein 7; Zinc finger MYND domain-containing protein 7; ZMYND7; RP8 T27736 FUNCTION May play an important role in cell death and/or in regulation of cell proliferation. May be a DNA-binding protein with a regulatory function. T27736 SEQUENCE MAAAGARPVELGFAESAPAWRLRSEQFPSKVGGRPAWLGAAGLPGPQALACELCGRPLSFLLQVYAPLPGRPDAFHRCIFLFCCREQPCCAGLRVFRNQLPRKNDFYSYEPPSENPPPETGESVCLQLKSGAHLCRVCGCLGPKTCSRCHKAYYCSKEHQTLDWRLGHKQACAQPDHLDHIIPDHNFLFPEFEIVIETEDEIMPEVVEKEDYSEIIGSMGEALEEELDSMAKHESREDKIFQKFKTQIALEPEQILRYGRGIAPIWISGENIPQEKDIPDCPCGAKRILEFQVMPQLLNYLKADRLGKSIDWGILAVFTCAESCSLGTGYTEEFVWKQDVTDTP T27736 DRUGINFO D07BNG RHIgM12B7 Phase 1 T84584 TARGETID T84584 T84584 FORMERID TTDI02220 T84584 UNIPROID SGCA_HUMAN T84584 TARGNAME Sarcoglycan alpha (SGCA) T84584 GENENAME SGCA T84584 TARGTYPE Clinical trial T84584 SYNONYMS SGCA; Dystroglycan2; Alphasarcoglycan; AlphaSG; Adhalin; 50DAG; 50 kDa dystrophinassociated glycoprotein T84584 FUNCTION Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix. T84584 BIOCLASS Sarcoglycan T84584 SEQUENCE MAETLFWTPLLVVLLAGLGDTEAQQTTLHPLVGRVFVHTLDHETFLSLPEHVAVPPAVHITYHAHLQGHPDLPRWLRYTQRSPHHPGFLYGSATPEDRGLQVIEVTAYNRDSFDTTRQRLVLEIGDPEGPLLPYQAEFLVRSHDAEEVLPSTPASRFLSALGGLWEPGELQLLNVTSALDRGGRVPLPIEGRKEGVYIKVGSASPFSTCLKMVASPDSHARCAQGQPPLLSCYDTLAPHFRVDWCNVTLVDKSVPEPADEVPTPGDGILEHDPFFCPPTEAPDRDFLVDALVTLLVPLLVALLLTLLLAYVMCCRREGRLKRDLATSDIQMVHHCTIHGNTEELRQMAASREVPRPLSTLPMFNVHTGERLPPRVDSAQVPLILDQH T84584 DRUGINFO DUIA46 SRP-9004 Phase 1/2 T84584 DRUGINFO D05HID rAAV1.tMCK.human-alpha-sarcoglycan Phase 1 T66903 TARGETID T66903 T66903 FORMERID TTDR00829 T66903 UNIPROID FSCN1_HUMAN T66903 TARGNAME Fascin (FSCN1) T66903 GENENAME FSCN1 T66903 TARGTYPE Clinical trial T66903 SYNONYMS Singed-like protein; SNL; HSN; FAN1; 55 kDa actin-bundling protein; 55 kDa actin bundling protein T66903 FUNCTION Plays a role in the organization of actin filament bundles and the formation of microspikes, membrane ruffles, and stress fibers. Important for the formation of a diverse set of cell protrusions, such as filopodia, and for cell motility and migration. Organizes filamentous actin into bundles with a minimum of 4. 1:1 actin/fascin ratio. T66903 PDBSTRUC 6I18; 6I17; 6I16; 6I15; 6I14 T66903 SEQUENCE MTANGTAEAVQIQFGLINCGNKYLTAEAFGFKVNASASSLKKKQIWTLEQPPDEAGSAAVCLRSHLGRYLAADKDGNVTCEREVPGPDCRFLIVAHDDGRWSLQSEAHRRYFGGTEDRLSCFAQTVSPAEKWSVHIAMHPQVNIYSVTRKRYAHLSARPADEIAVDRDVPWGVDSLITLAFQDQRYSVQTADHRFLRHDGRLVARPEPATGYTLEFRSGKVAFRDCEGRYLAPSGPSGTLKAGKATKVGKDELFALEQSCAQVVLQAANERNVSTRQGMDLSANQDEETDQETFQLEIDRDTKKCAFRTHTGKYWTLTATGGVQSTASSKNASCYFDIEWRDRRITLRASNGKFVTSKKNGQLAASVETAGDSELFLMKLINRPIIVFRGEHGFIGCRKVTGTLDANRSSYDVFQLEFNDGAYNIKDSTGKYWTVGSDSAVTSSGDTPVDFFFEFCDYNKVAIKVGGRYLKGDHAGVLKASAETVDPASLWEY T66903 DRUGINFO D0C2NT NP-G2-044 Phase 1 T64526 TARGETID T64526 T64526 FORMERID TTDI01711 T64526 UNIPROID CLFA_STAA8 T64526 TARGNAME Staphylococcus Clumping factor A (Stap-coc ClfA) T64526 GENENAME Stap-coc ClfA T64526 TARGTYPE Clinical trial T64526 SYNONYMS Fibrinogen-binding protein A; Fibrinogen receptor A; Clumping factor A T64526 FUNCTION Cell surface-associated protein implicated in virulence. Promotes bacterial attachment exclusively to the gamma-chain of human fibrinogen. Induces formation of bacterial clumps, which diminish the ability of group IIA phospholipase A2 to cause bacterial phospholipid hydrolysis and killing. Significantly decreases macrophage phagocytosis possibly thanks to the clumps, clumped bacteria being too large to be phagocytosed. Dominant factor responsible for human platelet aggregation, which may be an important mechanism for initiating infective endocarditis. Enhances spleen cell proliferative response in vitro, contributing significantly to the immunostimulatory activity of S.aureus. T64526 PDBSTRUC 2VR3 T64526 SEQUENCE MNMKKKEKHAIRKKSIGVASVLVGTLIGFGLLSSKEADASENSVTQSDSASNESKSNDSSSVSAAPKTDDTNVSDTKTSSNTNNGETSVAQNPAQQETTQSSSTNATTEETPVTGEATTTTTNQANTPATTQSSNTNAEELVNQTSNETTSNDTNTVSSVNSPQNSTNAENVSTTQDTSTEATPSNNESAPQSTDASNKDVVNQAVNTSAPRMRAFSLAAVAADAPVAGTDITNQLTNVTVGIDSGTTVYPHQAGYVKLNYGFSVPNSAVKGDTFKITVPKELNLNGVTSTAKVPPIMAGDQVLANGVIDSDGNVIYTFTDYVNTKDDVKATLTMPAYIDPENVKKTGNVTLATGIGSTTANKTVLVDYEKYGKFYNLSIKGTIDQIDKTNNTYRQTIYVNPSGDNVIAPVLTGNLKPNTDSNALIDQQNTSIKVYKVDNAADLSESYFVNPENFEDVTNSVNITFPNPNQYKVEFNTPDDQITTPYIVVVNGHIDPNSKGDLALRSTLYGYNSNIIWRSMSWDNEVAFNNGSGSGDGIDKPVVPEQPDEPGEIEPIPEDSDSDPGSDSGSDSNSDSGSDSGSDSTSDSGSDSASDSDSASDSDSASDSDSASDSDSASDSDSDNDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSASDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSESDSDSDSDSDSDSDSDSDSDSDSASDSDSGSDSDSSSDSDSESDSNSDSESVSNNNVVPPNSPKNGTNASNKNEAKDSKEPLPDTGSEDEANTSLIWGLLASIGSLLLFRRKKENKDKK T64526 DRUGINFO D01DXI PF-06290510 Phase 2 T24626 TARGETID T24626 T24626 UNIPROID LPXC_HAEI8 T24626 TARGNAME Haemophilus influenzae Acetylglucosamine deacetylase (Hae-influ lpxC) T24626 GENENAME Hae-influ lpxC T24626 TARGTYPE Clinical trial T24626 SYNONYMS UDP-3-O-acyl-N-acetylglucosamine deacetylase; UDP-3-O-[R-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase; Hae-influ UDP-3-O-acyl-GlcNAc deacetylase T24626 FUNCTION Catalyzes the hydrolysis of UDP-3-O-myristoyl-N-acetylglucosamine to form UDP-3-O-myristoylglucosamine and acetate, the committed step in lipid A biosynthesis. T24626 ECNUMBER EC 3.5.1.108 T24626 SEQUENCE MIKQRTLKQSIKVTGVGLHSGNKVTLTLRPAMPNTGVVYYRTDLNPAVAFPADPNSVRDTMLCTALINDQGVRISTVEHLNAALAGLGIDNIIIEVDAPEIPIMDGSASPFIYLLLDAGIEEQNAAKKFIRIKEYVRVEDGDKWAEFKPYNGFRLDFTIDFDHPAIGKDVRNYEMNFSAQAFVHQISRARTFGFMKDIEYLQSQGLALGGSLDNAIVLDDYRILNEDGLRFKDELVRHKMLDAIGDLYMAGYNIIGDFKAYKSGHGLNNKLLRAVLANQEAWEFVTFEDKEQVPQGYVAPAQVLI T24626 DRUGINFO D08FKL ACHN-975 Phase 1 T45674 TARGETID T45674 T45674 UNIPROID SGMR2_HUMAN T45674 TARGNAME Sigma intracellular receptor 2 (TMEM97) T45674 GENENAME TMEM97 T45674 TARGTYPE Clinical trial T45674 SYNONYMS Transmembrane protein 97; Sigma2 receptor; Sigma-2 receptor; Meningioma-associated protein 30; MAC30 T45674 FUNCTION Intracellular orphan receptor that binds numerous drugs and which is highly expressed in various proliferating cancer cells. Corresponds to the sigma-2 receptor, which is thought to play important role in regulating cell survival, morphology and differentiation. Under investigation for its potential diagnostic and therapeutic uses. May play a role as a regulator of cellular cholesterol homeostasis. May function as sterol isomerase. May alter the activity of some cytochrome P450 proteins. T45674 BIOCLASS TMEM97/sigma-2 receptor T45674 SEQUENCE MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK T45674 DRUGINFO D0L7TA MIN-101 Phase 3 T45674 DRUGINFO D0FX8N CT1812 Phase 2 T45674 DRUGINFO D01IVR Piperazinyl methyl quinazolinone derivative 2 Patented T45674 DRUGINFO D02ZGY PMID30185082-Compound-53 Patented T45674 DRUGINFO D03DNE Benzamide derivative 3 Patented T45674 DRUGINFO D04BSD Piperazinyl norbenzomorphane compound 1 Patented T45674 DRUGINFO D04OPJ Bicyclo-heptan-2-amine derivative 1 Patented T45674 DRUGINFO D04PDM Benzamide derivative 2 Patented T45674 DRUGINFO D04WKL Piperazinyl methyl quinazolinone derivative 3 Patented T45674 DRUGINFO D05MST PMID30185082-Compound-27 Patented T45674 DRUGINFO D06HRI PMID28051882-Compound-XI Patented T45674 DRUGINFO D0A1DV PMID30185082-Compound-28 Patented T45674 DRUGINFO D0AT9E Piperazinyl methyl quinazolinone derivative 1 Patented T45674 DRUGINFO D0BI1O PMID28051882-Compound-Figure9 Patented T45674 DRUGINFO D0CK6M Fused aryl carbocycle derivative 3 Patented T45674 DRUGINFO D0DZ5H PMID30185082-Compound-54 Patented T45674 DRUGINFO D0E3OT PMID30185082-Compound-14 Patented T45674 DRUGINFO D0E9CV Benzamide derivative 4 Patented T45674 DRUGINFO D0FH5K N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 2 Patented T45674 DRUGINFO D0FU2M Bicyclo-heptan-2-amine derivative 3 Patented T45674 DRUGINFO D0HY9M Fused aryl carbocycle derivative 4 Patented T45674 DRUGINFO D0K7CD Fused aryl carbocycle derivative 8 Patented T45674 DRUGINFO D0LN2J Fused aryl carbocycle derivative 2 Patented T45674 DRUGINFO D0LP3P PMID30185082-Compound-55 Patented T45674 DRUGINFO D0LV1G Piperazinyl norbenzomorphane compound 4 Patented T45674 DRUGINFO D0M4BI Benzamide derivative 1 Patented T45674 DRUGINFO D0M5LL PMID30185082-Compound-56 Patented T45674 DRUGINFO D0N5JQ PMID30185082-Compound-63 Patented T45674 DRUGINFO D0N6JH N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 3 Patented T45674 DRUGINFO D0OZ1P Fused aryl carbocycle derivative 9 Patented T45674 DRUGINFO D0PF9X Bicyclo-heptan-2-amine derivative 2 Patented T45674 DRUGINFO D0R1QI Aryl azepine derivative 2 Patented T45674 DRUGINFO D0U6OY Piperazinyl norbenzomorphane compound 2 Patented T45674 DRUGINFO D0V4KJ N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 1 Patented T45674 DRUGINFO D0VC0P Piperazinyl norbenzomorphane compound 3 Patented T45674 DRUGINFO D0VE8R Fused aryl carbocycle derivative 1 Patented T45674 DRUGINFO D0WE5J Aryl azepine derivative 1 Patented T45674 DRUGINFO D0Y2NR Bicyclo-heptan-2-amine derivative 4 Patented T45674 DRUGINFO D03MKY Benzamide derivative 9 Patented T45674 DRUGINFO D05YFF Benzamide derivative 10 Patented T45674 DRUGINFO D0DW1D PMID30185082-Compound-57 Patented T45674 DRUGINFO D0EO9Z PMID28051882-Compound-XIV Patented T45674 DRUGINFO D0H2SE Benzamide derivative 8 Patented T45674 DRUGINFO D0J9SL Piperazine derivative 7 Patented T45674 DRUGINFO D0RS2J Benzamide derivative 7 Patented T45674 DRUGINFO D0SG9W PMID30185082-Compound-64 Patented T45674 DRUGINFO D0T5SO Piperidine derivative 6 Patented T45674 DRUGINFO D0W3TS Benzamide derivative 11 Patented T45674 DRUGINFO D0X9RA Piperidine derivative 5 Patented T45674 DRUGINFO D02NPB Isoindoline derivative 5 Patented T45674 DRUGINFO D06FNA Isoindoline derivative 3 Patented T45674 DRUGINFO D0EK3Z Isoindoline derivative 4 Patented T45674 DRUGINFO D0F8XU Isoindoline derivative 2 Patented T45674 DRUGINFO D0S3ON Isoindoline derivative 1 Patented T45674 DRUGINFO D0M6OW ANAVEX 1007 Preclinical T45674 DRUGINFO D0X7BG SM 21 Investigative T45674 DRUGINFO D02WJT 1,3-ditolylguanidine Investigative T02262 TARGETID T02262 T02262 FORMERID TTDI03324 T02262 UNIPROID KCNT1_HUMAN T02262 TARGNAME Calcium-activated potassium channel KCa4.1 (KCNT1) T02262 GENENAME KCNT1 T02262 TARGTYPE Clinical trial T02262 SYNONYMS Potassium channel subfamily T member 1; KIAA1422; KCa4.1 T02262 FUNCTION Outwardly rectifying potassium channel subunit that may coassemble with other Slo-type channel subunits. Activated by high intracellular sodium or chloride levels. Activated upon stimulation of G-protein coupled receptors, such as CHRM1 and GRIA1. May be regulated by calcium in the absence of sodium ions (in vitro) (By similarity). T02262 BIOCLASS Voltage-gated ion channel T02262 SEQUENCE MARAKLPRSPSEGKAGPGGAPAGAAAPEEPHGLSPLLPARGGGSVGSDVGQRLPVEDFSLDSSLSQVQVEFYVNENTFKERLKLFFIKNQRSSLRIRLFNFSLKLLTCLLYIVRVLLDDPALGIGCWGCPKQNYSFNDSSSEINWAPILWVERKMTLWAIQVIVAIISFLETMLLIYLSYKGNIWEQIFRVSFVLEMINTLPFIITIFWPPLRNLFIPVFLNCWLAKHALENMINDFHRAILRTQSAMFNQVLILFCTLLCLVFTGTCGIQHLERAGENLSLLTSFYFCIVTFSTVGYGDVTPKIWPSQLLVVIMICVALVVLPLQFEELVYLWMERQKSGGNYSRHRAQTEKHVVLCVSSLKIDLLMDFLNEFYAHPRLQDYYVVILCPTEMDVQVRRVLQIPLWSQRVIYLQGSALKDQDLMRAKMDNGEACFILSSRNEVDRTAADHQTILRAWAVKDFAPNCPLYVQILKPENKFHVKFADHVVCEEECKYAMLALNCICPATSTLITLLVHTSRGQEGQESPEQWQRMYGRCSGNEVYHIRMGDSKFFREYEGKSFTYAAFHAHKKYGVCLIGLKREDNKSILLNPGPRHILAASDTCFYINITKEENSAFIFKQEEKRKKRAFSGQGLHEGPARLPVHSIIASMGTVAMDLQGTEHRPTQSGGGGGGSKLALPTENGSGSRRPSIAPVLELADSSALLPCDLLSDQSEDEVTPSDDEGLSVVEYVKGYPPNSPYIGSSPTLCHLLPVKAPFCCLRLDKGCKHNSYEDAKAYGFKNKLIIVSAETAGNGLYNFIVPLRAYYRSRKELNPIVLLLDNKPDHHFLEAICCFPMVYYMEGSVDNLDSLLQCGIIYADNLVVVDKESTMSAEEDYMADAKTIVNVQTMFRLFPSLSITTELTHPSNMRFMQFRAKDSYSLALSKLEKRERENGSNLAFMFRLPFAAGRVFSISMLDTLLYQSFVKDYMITITRLLLGLDTTPGSGYLCAMKITEGDLWIRTYGRLFQKLCSSSAEIPIGIYRTESHVFSTSESQISVNVEDCEDTREVKGPWGSRAGTGGSSQGRHTGGGDPAEHPLLRRKSLQWARRLSRKAPKQAGRAAAAEWISQQRLSLYRRSERQELSELVKNRMKHLGLPTTGYEDVANLTASDVMNRVNLGYLQDEMNDHQNTLSYVLINPPPDTRLEPSDIVYLIRSDPLAHVASSSQSRKSSCSHKLSSCNPETRDETQL T02262 DRUGINFO D09DHT phorbol 12-myristate 13-acetate Phase 2 T02262 DRUGINFO D0O2TC iberiotoxin Investigative T02262 DRUGINFO D06PZZ [14C]TEA Investigative T11701 TARGETID T11701 T11701 FORMERID TTDI02100 T11701 UNIPROID IL31_HUMAN T11701 TARGNAME Interleukin-31 (IL31) T11701 GENENAME IL31 T11701 TARGTYPE Clinical trial T11701 SYNONYMS Interleukin31; IL-31 T11701 FUNCTION May function in skin immunity. Enhances myeloid progenitor cell survival in vitro. Induces RETNLA and serum amyloid A protein expression in macrophages. Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR. T11701 BIOCLASS Cytokine: interleukin T11701 SEQUENCE MASHSGPSTSVLFLFCCLGGWLASHTLPVRLLRPSDDVQKIVEELQSLSKMLLKDVEEEKGVLVSQNYTLPCLSPDAQPPNNIHSPAIRAYLKTIRQLDNKSVIDEIIEHLDKLIFQDAPETNISVPTDTHECKRFILTISQQFSECMDLALKSLTSGAQQATT T11701 DRUGINFO D09KEW KPL-716 Phase 1 T76855 TARGETID T76855 T76855 FORMERID TTDI02058 T76855 UNIPROID EFTU_STAAS T76855 TARGNAME Staphylococcus Elongation factor Tu (Stap-coc tuf) T76855 GENENAME Stap-coc tuf T76855 TARGTYPE Clinical trial T76855 SYNONYMS tuf; Elongation factor Tu of Staphylococcus aureus; EFTu T76855 FUNCTION This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. T76855 BIOCLASS TRAFAC class translation factor GTPase T76855 SEQUENCE MAKEKFDRSKEHANIGTIGHVDHGKTTLTAAIATVLAKNGDSVAQSYDMIDNAPEEKERGITINTSHIEYQTDKRHYAHVDCPGHADYVKNMITGAAQMDGGILVVSAADGPMPQTREHILLSRNVGVPALVVFLNKVDMVDDEELLELVEMEVRDLLSEYDFPGDDVPVIAGSALKALEGDAQYEEKILELMEAVDTYIPTPERDSDKPFMMPVEDVFSITGRGTVATGRVERGQIKVGEEVEIIGLHDTSKTTVTGVEMFRKLLDYAEAGDNIGALLRGVAREDVQRGQVLAAPGSITPHTEFKAEVYVLSKDEGGRHTPFFSNYRPQFYFRTTDVTGVVHLPEGTEMVMPGDNVEMTVELIAPIAIEDGTRFSIREGGRTVGSGVVTEIIK T76855 DRUGINFO D0Z1UB NAI-acne Phase 2 T76855 DRUGINFO D0S4XZ GE-1170A Phase 1 T31600 TARGETID T31600 T31600 UNIPROID PKN3_HUMAN T31600 TARGNAME Protein kinase N3 (PKN3) T31600 GENENAME PKN3 T31600 TARGTYPE Clinical trial T31600 SYNONYMS Serine/threonine-protein kinase N3; Protein-kinase C-related kinase 3; Protein kinase PKN-beta; PKNBETA T31600 FUNCTION Contributes to invasiveness in malignant prostate cancer. T31600 ECNUMBER EC 2.7.11.13 T31600 SEQUENCE MEEGAPRQPGPSQWPPEDEKEVIRRAIQKELKIKEGVENLRRVATDRRHLGHVQQLLRSSNRRLEQLHGELRELHARILLPGPGPGPAEPVASGPRPWAEQLRARHLEALRRQLHVELKVKQGAENMTHTCASGTPKERKLLAAAQQMLRDSQLKVALLRMKISSLEASGSPEPGPELLAEELQHRLHVEAAVAEGAKNVVKLLSSRRTQDRKALAEAQAQLQESSQKLDLLRLALEQLLEQLPPAHPLRSRVTRELRAAVPGYPQPSGTPVKPTALTGTLQVRLLGCEQLLTAVPGRSPAAALASSPSEGWLRTKAKHQRGRGELASEVLAVLKVDNRVVGQTGWGQVAEQSWDQTFVIPLERARELEIGVHWRDWRQLCGVAFLRLEDFLDNACHQLSLSLVPQGLLFAQVTFCDPVIERRPRLQRQERIFSKRRGQDFLRASQMNLGMAAWGRLVMNLLPPCSSPSTISPPKGCPRTPTTLREASDPATPSNFLPKKTPLGEEMTPPPKPPRLYLPQEPTSEETPRTKRPHMEPRTRRGPSPPASPTRKPPRLQDFRCLAVLGRGHFGKVLLVQFKGTGKYYAIKALKKQEVLSRDEIESLYCEKRILEAVGCTGHPFLLSLLACFQTSSHACFVTEFVPGGDLMMQIHEDVFPEPQARFYVACVVLGLQFLHEKKIIYRDLKLDNLLLDAQGFLKIADFGLCKEGIGFGDRTSTFCGTPEFLAPEVLTQEAYTRAVDWWGLGVLLYEMLVGECPFPGDTEEEVFDCIVNMDAPYPGFLSVQGLEFIQKLLQKCPEKRLGAGEQDAEEIKVQPFFRTTNWQALLARTIQPPFVPTLCGPADLRYFEGEFTGLPPALTPPAPHSLLTARQQAAFRDFDFVSERFLEP T31600 DRUGINFO D09TGT Atu-027 Phase 1 T78318 TARGETID T78318 T78318 FORMERID TTDI03325 T78318 UNIPROID KCNT2_HUMAN T78318 TARGNAME Calcium-activated potassium channel KCa4.2 (KCNT2) T78318 GENENAME KCNT2 T78318 TARGTYPE Clinical trial T78318 SYNONYMS Sodium and chloride-activated ATP-sensitive potassium channel Slo2.1; Sequence like an intermediate conductance potassium channel subunit; SLICK; Potassium channel subfamily T member 2 T78318 FUNCTION Outward rectifying potassium channel. Produces rapidly activating outward rectifier K(+) currents. Activated by high intracellular sodium and chloride levels. Channel activity is inhibited by ATP and by inhalation anesthetics, such as isoflurane (By similarity). Inhibited upon stimulation of G-protein coupled receptors, such as CHRM1 and GRM1. T78318 BIOCLASS Voltage-gated ion channel T78318 SEQUENCE MVDLESEVPPLPPRYRFRDLLLGDQGWQNDDRVQVEFYMNENTFKERLKLFFIKNQRSSLRIRLFNFSLKLLSCLLYIIRVLLENPSQGNEWSHIFWVNRSLPLWGLQVSVALISLFETILLGYLSYKGNIWEQILRIPFILEIINAVPFIISIFWPSLRNLFVPVFLNCWLAKHALENMINDLHRAIQRTQSAMFNQVLILISTLLCLIFTCICGIQHLERIGKKLNLFDSLYFCIVTFSTVGFGDVTPETWSSKLFVVAMICVALVVLPIQFEQLAYLWMERQKSGGNYSRHRAQTEKHVVLCVSSLKIDLLMDFLNEFYAHPRLQDYYVVILCPTEMDVQVRRVLQIPMWSQRVIYLQGSALKDQDLLRAKMDDAEACFILSSRCEVDRTSSDHQTILRAWAVKDFAPNCPLYVQILKPENKFHIKFADHVVCEEEFKYAMLALNCICPATSTLITLLVHTSRGQEGQQSPEQWQKMYGRCSGNEVYHIVLEESTFFAEYEGKSFTYASFHAHKKFGVCLIGVRREDNKNILLNPGPRYIMNSTDICFYINITKEENSAFKNQDQQRKSNVSRSFYHGPSRLPVHSIIASMGTVAIDLQDTSCRSASGPTLSLPTEGSKEIRRPSIAPVLEVADTSSIQTCDLLSDQSEDETTPDEEMSSNLEYAKGYPPYSPYIGSSPTFCHLLHEKVPFCCLRLDKSCQHNYYEDAKAYGFKNKLIIVAAETAGNGLYNFIVPLRAYYRPKKELNPIVLLLDNPPDMHFLDAICWFPMVYYMVGSIDNLDDLLRCGVTFAANMVVVDKESTMSAEEDYMADAKTIVNVQTLFRLFSSLSIITELTHPANMRFMQFRAKDCYSLALSKLEKKERERGSNLAFMFRLPFAAGRVFSISMLDTLLYQSFVKDYMISITRLLLGLDTTPGSGFLCSMKITADDLWIRTYARLYQKLCSSTGDVPIGIYRTESQKLTTSESQISISVEEWEDTKDSKEQGHHRSNHRNSTSSDQSDHPLLRRKSMQWARRLSRKGPKHSGKTAEKITQQRLNLYRRSERQELAELVKNRMKHLGLSTVGYDEMNDHQSTLSYILINPSPDTRIELNDVVYLIRPDPLAYLPNSEPSRRNSICNVTGQDSREETQL T78318 DRUGINFO D09DHT phorbol 12-myristate 13-acetate Phase 2 T78318 DRUGINFO D0O2TC iberiotoxin Investigative T78318 DRUGINFO D06PZZ [14C]TEA Investigative T42521 TARGETID T42521 T42521 UNIPROID Q7DJJ2_ECOLX T42521 TARGNAME Bacterial Shiga toxin 2 subunit B (Bact stxII) T42521 GENENAME Bact stxII T42521 TARGTYPE Clinical trial T42521 SYNONYMS Stx2B protein; Stx2B; Stx2 holotoxin subunit B; Stx2 holotoxin B subunit; Shiga-like toxin type II B subunit; Shiga toxin subunit B; Shiga toxin 2v subunit A; Shiga toxin 2B; Shiga toxin 2, subunit B; Shiga toxin 2 B subunit T42521 FUNCTION Shiga toxin, one of the most potent bacterial toxins known. Binds to the cellular receptor, globotriaosylceramide, Gb3, found primarily on endothelial cells. T42521 PDBSTRUC 4M1U T42521 SEQUENCE MKKMFMAVLFALVSVNAMAADCAKGKIEFSKYNEDDTFTVKVDGKEYWTSRWNLQPLLQSAQLTGMTVTIKSSTCESGSGFAEVQFNND T42521 DRUGINFO D07YPW Shigamabs Phase 3 T68967 TARGETID T68967 T68967 FORMERID TTDI02006 T68967 UNIPROID SMS1_HUMAN; SMS2_HUMAN T68967 TARGNAME Sphingomyelin synthase (SMS) T68967 GENENAME SGMS1; SGMS2 T68967 TARGTYPE Clinical trial T68967 SYNONYMS SMS; Phosphatidylcholine:ceramide cholinephosphotransferase T68967 FUNCTION Sphingomyelin synthases synthesize the sphingolipid, sphingomyelin, through transfer of the phosphatidyl head group, phosphatidylcholine, on to the primary hydroxyl of ceramide. The reaction is bidirectional depending on the respective levels of the sphingolipid and ceramide. Golgi apparatus SMS1 directly and specifically recognizes the choline head group on the substrate, requiring two fatty chains on the choline-P donor molecule inorder to be recognized efficiently as a substrate. Major form in macrophages. Required for cell growth in certain cell types such as HeLa cells. Suppresses BAX-mediated apoptosis and also prevents cell death in response to stimuli such as hydrogen peroxide, osmotic stress, elevated temperature and exogenously supplied sphingolipids. May protect against cell death by reversing the stress-inducibleincrease in levels of proapoptotic ceramide. T68967 BIOCLASS Sphingomyelin synthase T68967 SEQUENCE MKEVVYWSPKKVADWLLENAMPEYCEPLEHFTGQDLINLTQEDFKKPPLCRVSSDNGQRLLDMIETLKMEHHLEAHKNGHANGHLNIGVDIPTPDGSFSIKIKPNGMPNGYRKEMIKIPMPELERSQYPMEWGKTFLAFLYALSCFVLTTVMISVVHERVPPKEVQPPLPDTFFDHFNRVQWAFSICEINGMILVGLWLIQWLLLKYKSIISRRFFCIVGTLYLYRCITMYVTTLPVPGMHFNCSPKLFGDWEAQLRRIMKLIAGGGLSITGSHNMCGDYLYSGHTVMLTLTYLFIKEYSPRRLWWYHWICWLLSVVGIFCILLAHDHYTVDVVVAYYITTRLFWWYHTMANQQVLKEASQMNLLARVWWYRPFQYFEKNVQGIVPRSYHWPFPWPVVHLSRQVKYSRLVNDT T68967 DRUGINFO D02DWK 2-hydroxyoleic acid Phase 1/2 T84614 TARGETID T84614 T84614 UNIPROID IL31R_HUMAN T84614 TARGNAME Interleukin 31 receptor (IL31R) T84614 GENENAME IL31RA T84614 TARGTYPE Clinical trial T84614 SYNONYMS hGLM-R; ZcytoR17; UNQ6368/PRO21073/PRO21384; Interleukin-31 receptor subunit alpha; IL-31RA; IL-31R-alpha; IL-31R subunit alpha; IL-31R; IL-31 receptor subunit alpha; Gp130-like receptor; Gp130-like monocyte receptor; GPL; GLM-R; Cytokine receptor-like 3; CRL3 T84614 FUNCTION May function in skin immunity. Mediates IL31-induced itch, probably in a manner dependent on cation channels TRPA1 and TRPV1. Positively regulates numbers and cycling status of immature subsets of myeloid progenitor cells in bone marrow in vivo and enhances myeloid progenitor cell survival in vitro. Associates with OSMR to form the interleukin-31 receptor which activates STAT3 and to a lower extent STAT1 and STAT5. T84614 BIOCLASS Cytokine receptor T84614 SEQUENCE MMWTWALWMLPSLCKFSLAALPAKPENISCVYYYRKNLTCTWSPGKETSYTQYTVKRTYAFGEKHDNCTTNSSTSENRASCSFFLPRITIPDNYTIEVEAENGDGVIKSHMTYWRLENIAKTEPPKIFRVKPVLGIKRMIQIEWIKPELAPVSSDLKYTLRFRTVNSTSWMEVNFAKNRKDKNQTYNLTGLQPFTEYVIALRCAVKESKFWSDWSQEKMGMTEEEAPCGLELWRVLKPAEADGRRPVRLLWKKARGAPVLEKTLGYNIWYYPESNTNLTETMNTTNQQLELHLGGESFWVSMISYNSLGKSPVATLRIPAIQEKSFQCIEVMQACVAEDQLVVKWQSSALDVNTWMIEWFPDVDSEPTTLSWESVSQATNWTIQQDKLKPFWCYNISVYPMLHDKVGEPYSIQAYAKEGVPSEGPETKVENIGVKTVTITWKEIPKSERKGIICNYTIFYQAEGGKGFSKTVNSSILQYGLESLKRKTSYIVQVMASTSAGGTNGTSINFKTLSFSVFEIILITSLIGGGLLILIILTVAYGLKKPNKLTHLCWPTVPNPAESSIATWHGDDFKDKLNLKESDDSVNTEDRILKPCSTPSDKLVIDKLVVNFGNVLQEIFTDEARTGQENNLGGEKNGYVTCPFRPDCPLGKSFEELPVSPEIPPRKSQYLRSRMPEGTRPEAKEQLLFSGQSLVPDHLCEEGAPNPYLKNSVTAREFLVSEKLPEHTKGEV T84614 DRUGINFO D0B2IR Nemolizumab Phase 3 T77990 TARGETID T77990 T77990 FORMERID TTDI02103 T77990 UNIPROID ISDB_STAAW T77990 TARGNAME Staphylococcus Iron-regulated surface determinant B (Stap-coc isdB) T77990 GENENAME Stap-coc isdB T77990 TARGTYPE Clinical trial T77990 SYNONYMS isdB; Staphylococcus aureus surface protein J; Staphylococcal ironregulated protein H; Ironregulated surface determinant protein B; Furregulated protein B T77990 FUNCTION Seems to function as the primary receptor for hemoglobin since its inactivation inhibits the ability of S.aureus to bind hemoglobin. Binds hemoglobin in a dose-dependent way. Required for S.aureus growth using hemoglobin as the sole iron source. Also required for virulence. IsdA and/or IsdB promote resistance to hydrogen peroxide and killing by neutrophils. T77990 PDBSTRUC 2MOQ T77990 SEQUENCE MNKQQKEFKSFYSIRKSSLGVASVAISTLLLLMSNGEAQAAAEETGGTNTEAQPKTEAVASPTTTSEKAPETKPVANAVSVSNKEVEAPTSETKEAKEVKEVKAPKETKEVKPAAKATNNTYPILNQELREAIKNPAIKDKDHSAPNSRPIDFEMKKKDGTQQFYHYASSVKPARVIFTDSKPEIELGLQSGQFWRKFEVYEGDKKLPIKLVSYDTVKDYAYIRFSVSNGTKAVKIVSSTHFNNKEEKYDYTLMEFAQPIYNSADKFKTEEDYKAEKLLAPYKKAKTLERQVYELNKIQDKLPEKLKAEYKKKLEDTKKALDEQVKSAITEFQNVQPTNEKMTDLQDTKYVVYESVENNESMMDTFVKHPIKTGMLNGKKYMVMETTNDDYWKDFMVEGQRVRTISKDAKNNTRTIIFPYVEGKTLYDAIVKVHVKTIDYDGQYHVRIVDKEAFTKANTDKSNKKEQQDNSAKKEATPATPSKPTPSPVEKESQKQDSQKDDNKQLPSVEKENDASSESGKDKTPATKPTKGEVESSSTTPTKVVSTTQNVAKPTTASSKTTKDVVQTSAGSSEAKDSAPLQKANIKNTNDGHTQSQNNKNTQENKAKSLPQTGEESNKDMTLPLMALLALSSIVAFVLPRKRKN T77990 DRUGINFO D0SQ8R V-710 Phase 2/3 T11911 TARGETID T11911 T11911 FORMERID TTDI03307 T11911 UNIPROID KCNN1_HUMAN T11911 TARGNAME Calcium-activated potassium channel KCa2.1 (KCNN1) T11911 GENENAME KCNN1 T11911 TARGTYPE Clinical trial T11911 SYNONYMS Small conductance calcium-activated potassium channel protein 1; SKCa1; SKCa 1; SK1; SK; KCa2.1 T11911 FUNCTION Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin (By similarity). T11911 BIOCLASS Voltage-gated ion channel T11911 SEQUENCE MNSHSYNGSVGRPLGSGPGALGRDPPDPEAGHPPQPPHSPGLQVVVAKSEPARPSPGSPRGQPQDQDDDEDDEEDEAGRQRASGKPSNVGHRLGHRRALFEKRKRLSDYALIFGMFGIVVMVTETELSWGVYTKESLYSFALKCLISLSTAILLGLVVLYHAREIQLFMVDNGADDWRIAMTCERVFLISLELAVCAIHPVPGHYRFTWTARLAFTYAPSVAEADVDVLLSIPMFLRLYLLGRVMLLHSKIFTDASSRSIGALNKITFNTRFVMKTLMTICPGTVLLVFSISSWIIAAWTVRVCERYHDKQEVTSNFLGAMWLISITFLSIGYGDMVPHTYCGKGVCLLTGIMGAGCTALVVAVVARKLELTKAEKHVHNFMMDTQLTKRVKNAAANVLRETWLIYKHTRLVKKPDQARVRKHQRKFLQAIHQAQKLRSVKIEQGKLNDQANTLTDLAKTQTVMYDLVSELHAQHEELEARLATLESRLDALGASLQALPGLIAQAIRPPPPPLPPRPGPGPQDQAARSSPCRWTPVAPSDCG T11911 DRUGINFO D0I2FI dequalinium Clinical trial T11911 DRUGINFO D00WMV UCL1684 Investigative T11911 DRUGINFO D0N1HE UCL1848 Investigative T11911 DRUGINFO D0VK9Y apamin Investigative T11911 DRUGINFO D0T0AG EBIO Investigative T11911 DRUGINFO D06PZZ [14C]TEA Investigative T08499 TARGETID T08499 T08499 FORMERID TTDI03405 T08499 UNIPROID NLRP3_HUMAN T08499 TARGNAME Caterpiller protein 1.1 (NLRP3) T08499 GENENAME NLRP3 T08499 TARGTYPE Clinical trial T08499 SYNONYMS PYRIN-containing APAF1-like protein 1; PYPAF1; NALP3; NACHT, LRR and PYD domains-containing protein 3; Cryopyrin; Cold-induced autoinflammatory syndrome 1 protein; CLR1.1; CIAS1; C1orf7; Angiotensin/vasopressin receptor AII/AVP-like T08499 FUNCTION In response to pathogens and other damage-associated signals, initiates the formation of the inflammasome polymeric complex, made of NLRP3, PYCARD and CASP1 (and possibly CASP4 and CASP5). Recruitment of proCASP1 to the inflammasome promotes its activation and CASP1-catalyzed IL1B and IL18 maturation and secretion in the extracellular milieu. Activation of NLRP3 inflammasome is also required for HMGB1 secretion. The active cytokines and HMGB1 stimulate inflammatory responses. Inflammasomes can also induce pyroptosis, an inflammatory form of programmed cell death. Under resting conditions, NLRP3 is autoinhibited. NLRP3 activation stimuli include extracellular ATP, reactive oxygen species, K(+) efflux, crystals of monosodium urate or cholesterol, amyloid-beta fibers, environmental or industrial particles and nanoparticles, cytosolic dsRNA, etc. However, it is unclear what constitutes the direct NLRP3 activator. Activation in presence of cytosolic dsRNA is mediated by DHX33. Independently of inflammasome activation, regulates the differentiation of T helper 2 (Th2) cells and has a role in Th2 cell-dependent asthma and tumor growth. During Th2 differentiation, required for optimal IRF4 binding to IL4 promoter and for IRF4-dependent IL4 transcription. Binds to the consensus DNA sequence 5'-GRRGGNRGAG-3'. May also participate in the transcription of IL5, IL13, GATA3, CCR3, CCR4 and MAF. As the sensor component of the NLRP3 inflammasome, plays a crucial role in innate immunity and inflammation. T08499 PDBSTRUC 3QF2; 2NAQ T08499 SEQUENCE MKMASTRCKLARYLEDLEDVDLKKFKMHLEDYPPQKGCIPLPRGQTEKADHVDLATLMIDFNGEEKAWAMAVWIFAAINRRDLYEKAKRDEPKWGSDNARVSNPTVICQEDSIEEEWMGLLEYLSRISICKMKKDYRKKYRKYVRSRFQCIEDRNARLGESVSLNKRYTRLRLIKEHRSQQEREQELLAIGKTKTCESPVSPIKMELLFDPDDEHSEPVHTVVFQGAAGIGKTILARKMMLDWASGTLYQDRFDYLFYIHCREVSLVTQRSLGDLIMSCCPDPNPPIHKIVRKPSRILFLMDGFDELQGAFDEHIGPLCTDWQKAERGDILLSSLIRKKLLPEASLLITTRPVALEKLQHLLDHPRHVEILGFSEAKRKEYFFKYFSDEAQARAAFSLIQENEVLFTMCFIPLVCWIVCTGLKQQMESGKSLAQTSKTTTAVYVFFLSSLLQPRGGSQEHGLCAHLWGLCSLAADGIWNQKILFEESDLRNHGLQKADVSAFLRMNLFQKEVDCEKFYSFIHMTFQEFFAAMYYLLEEEKEGRTNVPGSRLKLPSRDVTVLLENYGKFEKGYLIFVVRFLFGLVNQERTSYLEKKLSCKISQQIRLELLKWIEVKAKAKKLQIQPSQLELFYCLYEMQEEDFVQRAMDYFPKIEINLSTRMDHMVSSFCIENCHRVESLSLGFLHNMPKEEEEEEKEGRHLDMVQCVLPSSSHAACSHGLVNSHLTSSFCRGLFSVLSTSQSLTELDLSDNSLGDPGMRVLCETLQHPGCNIRRLWLGRCGLSHECCFDISLVLSSNQKLVELDLSDNALGDFGIRLLCVGLKHLLCNLKKLWLVSCCLTSACCQDLASVLSTSHSLTRLYVGENALGDSGVAILCEKAKNPQCNLQKLGLVNSGLTSVCCSALSSVLSTNQNLTHLYLRGNTLGDKGIKLLCEGLLHPDCKLQVLELDNCNLTSHCCWDLSTLLTSSQSLRKLSLGNNDLGDLGVMMFCEVLKQQSCLLQNLGLSEMYFNYETKSALETLQEEKPELTVVFEPSW T08499 DRUGINFO D0TH5H Dapansutrile Phase 2 T08499 DRUGINFO D75LNO BMS-986299 Phase 1 T08499 DRUGINFO D7KRB9 Selnoflast Phase 1 T08499 DRUGINFO D09FGL MCC950 Investigative T27861 TARGETID T27861 T27861 FORMERID TTDI01546 T27861 UNIPROID CRBN_HUMAN T27861 TARGNAME Protein cereblon (CRBN) T27861 GENENAME CRBN T27861 TARGTYPE Clinical trial T27861 SYNONYMS Protein cereblon T27861 FUNCTION Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly and neuronal surface expression of large-conductance calcium-activated potassium channels in brain regions involved in memory and learning via its interaction with KCNT1. Binding of pomalidomide and other thalidomide-related drugs changes the substrate specificity of the human protein, leading to decreased degradation of MEIS2 and other target proteins and increased degradation of MYC, IRF4, IKZF1 and IKZF3. T27861 PDBSTRUC 6H0G; 6H0F; 6BOY; 6BNB; 6BN9 T27861 SEQUENCE MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETLTVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRSALLPTIPDTEDEISPDKVILCL T27861 DRUGINFO D01XVX CC-220 Phase 2 T27861 DRUGINFO D03QZJ CC-122 Phase 1 T85544 TARGETID T85544 T85544 FORMERID TTDNC00529 T85544 UNIPROID SIN1_HUMAN T85544 TARGNAME Target of rapamycin complex 2 MAPKAP1 (MTORC2) T85544 GENENAME MAPKAP1 T85544 TARGTYPE Clinical trial T85544 SYNONYMS mSIN1; Target of rapamycin complex 2 subunit MAPKAP1; TORC2 subunit MAPKAP1; Stress-activated map kinase-interacting protein 1; SIN1; SAPK-interacting protein 1; Mitogen-activated protein kinase 2-associated protein 1; MIP1 T85544 FUNCTION mTORC2 is activated by growth factors, but, in contrast to mTORC1, seems to be nutrient-insensitive. mTORC2 seems to function upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation of stress-fibers or F-actin. mTORC2 plays a critical role in AKT1 'Ser-473' phosphorylation, which may facilitate the phosphorylation of the activation loop of AKT1 on 'Thr-308' by PDK1 which is a prerequisite for full activation. mTORC2 regulates the phosphorylation of SGK1 at 'Ser-422'. mTORC2 also modulates the phosphorylation of PRKCA on 'Ser-657'. Within mTORC2, MAPKAP1 is required for complex formation and mTORC2 kinase activity. MAPKAP1 inhibits MAP3K2 by preventing its dimerization and autophosphorylation. Inhibits HRAS and KRAS signaling. Enhances osmotic stress-induced phosphorylation of ATF2 and ATF2-mediated transcription. Involved in ciliogenesis, regulates cilia length through its interaction with CCDC28B independently of mTORC2 complex. Subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals. T85544 PDBSTRUC 5ZCS; 3VOQ T85544 SEQUENCE MAFLDNPTIILAHIRQSHVTSDDTGMCEMVLIDHDVDLEKIHPPSMPGDSGSEIQGSNGETQGYVYAQSVDITSSWDFGIRRRSNTAQRLERLRKERQNQIKCKNIQWKERNSKQSAQELKSLFEKKSLKEKPPISGKQSILSVRLEQCPLQLNNPFNEYSKFDGKGHVGTTATKKIDVYLPLHSSQDRLLPMTVVTMASARVQDLIGLICWQYTSEGREPKLNDNVSAYCLHIAEDDGEVDTDFPPLDSNEPIHKFGFSTLALVEKYSSPGLTSKESLFVRINAAHGFSLIQVDNTKVTMKEILLKAVKRRKGSQKVSGPQYRLEKQSEPNVAVDLDSTLESQSAWEFCLVRENSSRADGVFEEDSQIDIATVQDMLSSHHYKSFKVSMIHRLRFTTDVQLGISGDKVEIDPVTNQKASTKFWIKQKPISIDSDLLCACDLAEEKSPSHAIFKLTYLSNHDYKHLYFESDAATVNEIVLKVNYILESRASTARADYFAQKQRKLNRRTSFSFQKEKKSGQQ T85544 DRUGINFO D0Z2UQ AZD2014 Phase 2 T85544 DRUGINFO D03IXK ME-344 Phase 1/2 T85544 DRUGINFO DP17AI Palomid-529 Phase 1 T85544 DRUGINFO D0U3DP VS-5584 Phase 1 T77190 TARGETID T77190 T77190 FORMERID TTDI02175 T77190 UNIPROID SLIK6_HUMAN T77190 TARGNAME SLIT and NTRK-like family member 6 (SLITRK6) T77190 GENENAME SLITRK6 T77190 TARGTYPE Clinical trial T77190 SYNONYMS SLITRK6; SLIT and NTRK-like protein 6 T77190 FUNCTION Regulator of neurite outgrowth required for normal hearing and vision. T77190 SEQUENCE MKLWIHLFYSSLLACISLHSQTPVLSSRGSCDSLCNCEEKDGTMLINCEAKGIKMVSEISVPPSRPFQLSLLNNGLTMLHTNDFSGLTNAISIHLGFNNIADIEIGAFNGLGLLKQLHINHNSLEILKEDTFHGLENLEFLQADNNFITVIEPSAFSKLNRLKVLILNDNAIESLPPNIFRFVPLTHLDLRGNQLQTLPYVGFLEHIGRILDLQLEDNKWACNCDLLQLKTWLENMPPQSIIGDVVCNSPPFFKGSILSRLKKESICPTPPVYEEHEDPSGSLHLAATSSINDSRMSTKTTSILKLPTKAPGLIPYITKPSTQLPGPYCPIPCNCKVLSPSGLLIHCQERNIESLSDLRPPPQNPRKLILAGNIIHSLMKSDLVEYFTLEMLHLGNNRIEVLEEGSFMNLTRLQKLYLNGNHLTKLSKGMFLGLHNLEYLYLEYNAIKEILPGTFNPMPKLKVLYLNNNLLQVLPPHIFSGVPLTKVNLKTNQFTHLPVSNILDDLDLLTQIDLEDNPWDCSCDLVGLQQWIQKLSKNTVTDDILCTSPGHLDKKELKALNSEILCPGLVNNPSMPTQTSYLMVTTPATTTNTADTILRSLTDAVPLSVLILGLLIMFITIVFCAAGIVVLVLHRRRRYKKKQVDEQMRDNSPVHLQYSMYGHKTTHHTTERPSASLYEQHMVSPMVHVYRSPSFGPKHLEEEEERNEKEGSDAKHLQRSLLEQENHSPLTGSNMKYKTTNQSTEFLSFQDASSLYRNILEKERELQQLGITEYLRKNIAQLQPDMEAHYPGAHEELKLMETLMYSRPRKVLVEQTKNEYFELKANLHAEPDYLEVLEQQT T77190 DRUGINFO D0UM4S ASG-15ME Phase 1 T99704 TARGETID T99704 T99704 UNIPROID VISTA_HUMAN T99704 TARGNAME V-set immunoregulatory receptor (VSIR) T99704 GENENAME VSIR T99704 TARGTYPE Clinical trial T99704 SYNONYMS VISTA; V-set domain-containing immunoregulatory receptor; Stress-induced secreted protein-1; Sisp-1; SISP1; Platelet receptor Gi24; C10orf54 T99704 FUNCTION Immunoregulatory receptor which inhibits the T-cell response (PubMed:24691993). May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling. May stimulate MMP14-mediated MMP2 activation (PubMed:20666777). T99704 SEQUENCE MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGIENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLDPVPDSPNFEVI T99704 DRUGINFO D0PE3Z JNJ-61610588 Phase 1 T99704 DRUGINFO DXF93J CI-8993 Phase 1 T99704 DRUGINFO D09PPU CA-170 Phase 1 T75643 TARGETID T75643 T75643 FORMERID TTDI01990 T75643 UNIPROID NOD2_HUMAN T75643 TARGNAME Pattern recognition receptor NOD2 (NOD2) T75643 GENENAME NOD2 T75643 TARGTYPE Clinical trial T75643 SYNONYMS Nucleotidebinding oligomerization domaincontaining protein 2; Nucleotide-binding oligomerization domain-containing protein 2; Inflammatory bowel disease protein 1; IBD1; Caspase recruitment domaincontaining protein 15; Caspase recruitment domain-containing protein 15; CARD15 T75643 FUNCTION Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3, INAVA and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages. Component of an autophagy-mediated antibacterial pathway together with ATG16L1. Plays also a role in sensing single-stranded RNA (ssRNA) from viruses. Interacts with mitochondrial antiviral signaling/MAVS, leading to activation of interferon regulatory factor-3/IRF3 and expression of type I interferon. Involved in gastrointestinal immunity. T75643 SEQUENCE MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQPLSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERGFVSQYECDEIRLPIFTPSQRARRLLDLATVKANGLAAFLLQHVQELPVPLALPLEAATCKKYMAKLRTTVSAQSRFLSTYDGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQDFQEFLFVFPFSCRQLQCMAKPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDPTSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRLIRLLQETSALHGLCHLPVFSWMVSKCHQELLLQEGGSPKTTTDMYLLILQHFLLHATPPDSASQGLGPSLLRGRLPTLLHLGRLALWGLGMCCYVFSAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAFYLALSADVPPALLRHLFNCGRPGNSPMARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFHSIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTECAALAFVLQHLRRPVALQLDYNSVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLTDGCAHSMAKLLACRQNFLALRLGNNYITAAGAQVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEELCLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL T75643 DRUGINFO D01UHA MIS-416 Phase 2 T75643 DRUGINFO D04HQC SB-9200 Phase 2 T75643 DRUGINFO D05UGC muramyl dipeptide Investigative T86748 TARGETID T86748 T86748 FORMERID TTDNC00350 T86748 UNIPROID CD248_HUMAN T86748 TARGNAME Endosialin (CD248) T86748 GENENAME CD248 T86748 TARGTYPE Clinical trial T86748 SYNONYMS Tumor endothelial marker 1; Tumor Endothelial Marker 1 (TEM-1); TEM1; CD164L1 T86748 FUNCTION May play a role in tumor angiogenesis. T86748 SEQUENCE MLLRLLLAWAAAGPTLGQDPWAAEPRAACGPSSCYALFPRRRTFLEAWRACRELGGDLATPRTPEEAQRVDSLVGAGPASRLLWIGLQRQARQCQLQRPLRGFTWTTGDQDTAFTNWAQPASGGPCPAQRCVALEASGEHRWLEGSCTLAVDGYLCQFGFEGACPALQDEAGQAGPAVYTTPFHLVSTEFEWLPFGSVAAVQCQAGRGASLLCVKQPEGGVGWSRAGPLCLGTGCSPDNGGCEHECVEEVDGHVSCRCTEGFRLAADGRSCEDPCAQAPCEQQCEPGGPQGYSCHCRLGFRPAEDDPHRCVDTDECQIAGVCQQMCVNYVGGFECYCSEGHELEADGISCSPAGAMGAQASQDLGDELLDDGEDEEDEDEAWKAFNGGWTEMPGILWMEPTQPPDFALAYRPSFPEDREPQIPYPEPTWPPPLSAPRVPYHSSVLSVTRPVVVSATHPTLPSAHQPPVIPATHPALSRDHQIPVIAANYPDLPSAYQPGILSVSHSAQPPAHQPPMISTKYPELFPAHQSPMFPDTRVAGTQTTTHLPGIPPNHAPLVTTLGAQLPPQAPDALVLRTQATQLPIIPTAQPSLTTTSRSPVSPAHQISVPAATQPAALPTLLPSQSPTNQTSPISPTHPHSKAPQIPREDGPSPKLALWLPSPAPTAAPTALGEAGLAEHSQRDDRWLLVALLVPTCVFLVVLLALGIVYCTRCGPHAPNKRITDCYRWVIHAGSKSPTEPMPPRGSLTGVQTCRTSV T86748 DRUGINFO D02RKG MORAb-004 Phase 2 T86748 DRUGINFO D0FK9H Ontuxizumab Phase 2 T42882 TARGETID T42882 T42882 FORMERID TTDI01243 T42882 UNIPROID Q9I1N2_PSEAE T42882 TARGNAME Pseudomonas Psl exopolysaccharide (Pseudo pslG) T42882 GENENAME Pseudo pslG T42882 TARGTYPE Clinical trial T42882 SYNONYMS PslG T42882 FUNCTION A extracellular matrix component of P. aeruginosa biofilms. A galactose-rich and mannose-rich exopolysaccharide. T42882 PDBSTRUC 5BXA; 5BX9; 4ZN2 T42882 SEQUENCE MARKGLYLGGSALLLAVVLLLVFWGRPADAEIQVLKAPRAVVWKDFLGVNAQFLWFSPERYNKQIDRLQDLGLEWVRLDLHWDRLETAEDQYQLASLDQLVKDLEARQLKSVFYLVGSARFITTAPFYSPFQDQYPPRDPEVFARRMAMLSQRYPSVAAWQVWNEPNLIGFWRPKADPEGYAKLLQASTIALRMVDPEKPVVSAGMAFFSEMPDGRTMFDALGHLGVESLGTIATYHPYTQLPEGNYPWNLDFVSHANQINRALRNAGVPAIWSTEWGWSAYKGPKELQDIIGVEGQADYVLRRLALMSALDYDRIFLFTLSDLDQRASVRDRDYGLLDLDANPKPVYLALQRFLKVTGPKLRPADPPVTEDLPDGSFSIGWTREDGRNVWLFWSARGGNVRLPKLKEATLHDPLSGKVTPLSGSDGLEVPVKSSLQMLVWE T42882 DRUGINFO D05IYA MEDI3902 Phase 2 T31329 TARGETID T31329 T31329 FORMERID TTDI01928 T31329 UNIPROID Q9NJG8_LEIDO T31329 TARGNAME Leishmania DNA topoisomerase I (Leishm TOP1) T31329 GENENAME Leishm TOP1 T31329 TARGTYPE Clinical trial T31329 SYNONYMS Leishm DNA topoisomerase I; DNA topoisomerase 1 T31329 FUNCTION Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at the specific target site 5'-[CT]CCTTp site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then undergoes passage around the unbroken strand thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone. T31329 ECNUMBER EC 5.6.2.2 T31329 SEQUENCE MPLPGGGTEVLKGITLLTQHHGLKPVQPMSFCYLSFLNRHTHEHHLRLHCCRPHAYARAHPCTCLIDFPLTSYPISQQCAPRLLPLPRQPPLSSQPAEAPSQIGTKDGLLLFRVSNRPQWVFCVCVCVRACPSFPLPRSCDFNRRGAVSPLSSPPRRAPVCCWRFFFHSCSFFFLVLYLLSAPYFCSLWARCANEEDKQNKLRIKQHETKKETPFRVCGGDCPSCCVGLSSHLFFPRWRLLVPPLPYTLDSNNSIFCVFHLFIYFLVCLFVSLAPSTYPFVPLCQLRTLHLYEPRPHIGTPLRCFCCHRDSIRRIMKVENSKMGVKREQSHSNEDEEINEEDLNWWEQENLRIAMKGERRWETLAHNGVLFPPEYEPHGIPIFYDGREFKMTPEEEEVATMFAVMKEHDYYRMEVFRRNFFESWREILDKRQHPIRRLELCDFEPIYQWHLVQREKKLSRTKEEKKAIKEKQDAEAEPYRYCVWDGRREQVANFRVEPPGLFRGRGKHPLMGKLKVRVQPEDITINIGETAEVPVPPAGHKWAAVQHDHTVTWLAMWRDSVAGNMKYVMLAPSSSVKGQSDMVKFEKARKLKDKVDDIRASYMEDFKSNDLHVAQRAVAMYIDRLALRVGNEKGEDEADTVGCCSLRVEHIQLMPDNIVRFDFLGKDSIRYQNDVAVLPEVYALLQRFTRRKSPGMDIFDQLNPTQLNDHLKSFMDGLSAKVFRTYNASITLDRWFKEKPVDPKWSTADKLAYFNKANTEVAILCNHQKSVSKNFKLQMMQLTTKSEYTRKTIELLEKAEVTAKKKSVEEAAKEFLEEQDRMQREWLESYGTEEQKKEFEEIVAKRAAPRVRSEKKKSTSGAKKAESASGKKRAAKKKKSAKKGGKMLSKKAASKSSKKAPKKLKEEDEDDVPLVSVAAKTKKTAGVKRQRANKVVSDDDDVPLAALRV T31329 DRUGINFO D09BBW Sodium stibogluconate Phase 2 T83561 TARGETID T83561 T83561 FORMERID TTDR01171 T83561 UNIPROID DDIT4_HUMAN T83561 TARGNAME HIF-1 responsive protein RTP801 (DDIT4) T83561 GENENAME DDIT4 T83561 TARGTYPE Clinical trial T83561 SYNONYMS RTP801; REDD1; REDD-1; Protein regulated in development and DNA damage response 1; DNA damage-inducible transcript 4 protein T83561 FUNCTION Regulates cell growth, proliferation and survival via inhibition of the activity of the mammalian target of rapamycin complex 1 (mTORC1). Inhibition of mTORC1 is mediated by a pathway that involves DDIT4/REDD1, AKT1, the TSC1-TSC2 complex and the GTPase RHEB. Plays an important role in responses to cellular energy levels and cellular stress, including responses to hypoxia and DNA damage. Regulates p53/TP53-mediated apoptosis in response to DNA damage via its effect on mTORC1 activity. Its role in the response to hypoxia depends on the cell type; it mediates mTORC1 inhibition in fibroblasts and thymocytes, but not in hepatocytes (By similarity). Required for mTORC1-mediated defense against viral protein synthesis and virus replication (By similarity). Inhibits neuronal differentiation and neurite outgrowth mediated by NGF via its effect on mTORC1 activity. Required for normal neuron migration during embryonic brain development. Plays a role in neuronal cell death. T83561 PDBSTRUC 3LQ9 T83561 SEQUENCE MPSLWDRFSSSSTSSSPSSLPRTPTPDRPPRSAWGSATREEGFDRSTSLESSDCESLDSSNSGFGPEEDTAYLDGVSLPDFELLSDPEDEHLCANLMQLLQESLAQARLGSRRPARLLMPSQLVSQVGKELLRLAYSEPCGLRGALLDVCVEQGKSCHSVGQLALDPSLVPTFQLTLVLRLDSRLWPKIQGLFSSANSPFLPGFSQSLTLSTGFRVIKKKLYSSEQLLIEEC T83561 DRUGINFO D01VVL PF-04523655 Phase 2 T75716 TARGETID T75716 T75716 UNIPROID DLL3_HUMAN T75716 TARGNAME Delta-like protein 3 (DLL3) T75716 GENENAME DLL3 T75716 TARGTYPE Clinical trial T75716 SYNONYMS pudgy; pu; delta like canonical Notch ligand 3; SCDO1; Drosophila Delta homolog 3; Delta3 T75716 FUNCTION May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. Inhibits primary neurogenesis. T75716 SEQUENCE MVSPRMSGLLSQTVILALIFLPQTRPAGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESPCALGAALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIETWREELGDQIGGPAWSLLARVAGRRRLAAGGPWARDIQRAGAWELRFSYRARCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSPEHGFCEQPGECRCLEGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPGPCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGPCFNGGLCVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALRCRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDCRERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASALPAAPPGLRPGDPQRYLLPPALGLLVAAGVAGAALLLVHVRRRGHSQDAGSRLLAGTPEPSVHALPDALNNLRTQEGSGDGPSSSVDWNRPEDVDPQGIYVISAPSIYAREVATPLFPPLHTGRAGQRQHLLFPYPSSILSVK T75716 DRUGINFO D06WOF Rova-T Phase 3 T75716 DRUGINFO DRH03S Tarlatamab Phase 2 T75716 DRUGINFO DM14CQ HPN328 Phase 1/2 T75716 DRUGINFO D9FGB3 AMG 119 Phase 1 T75716 DRUGINFO D7IA0N AMG 757 Phase 1 T75716 DRUGINFO D2L9MD RG6524 Phase 1 T13741 TARGETID T13741 T13741 FORMERID TTDI02229 T13741 UNIPROID OGFR_HUMAN T13741 TARGNAME Opioid receptor zeta (OGFR) T13741 GENENAME OGFR T13741 TARGTYPE Clinical trial T13741 SYNONYMS Zetatype opioid receptor; Zeta-type opioid receptor; Protein 760; Protein 7-60; Opioid growth factor receptor; OGFr T13741 FUNCTION Seems to be involved in growth regulation. Receptor for opioid growth factor (OGF), also known as Met-enkephalin. T13741 BIOCLASS GPCR rhodopsin T13741 SEQUENCE MDDPDCDSTWEEDEEDAEDAEDEDCEDGEAAGARDADAGDEDEESEEPRAARPSSFQSRMTGSRNWRATRDMCRYRHNYPDLVERDCNGDTPNLSFYRNEIRFLPNGCFIEDILQNWTDNYDLLEDNHSYIQWLFPLREPGVNWHAKPLTLREVEVFKSSQEIQERLVRAYELMLGFYGIRLEDRGTGTVGRAQNYQKRFQNLNWRSHNNLRITRILKSLGELGLEHFQAPLVRFFLEETLVRRELPGVRQSALDYFMFAVRCRHQRRQLVHFAWEHFRPRCKFVWGPQDKLRRFKPSSLPHPLEGSRKVEEEGSPGDPDHEASTQGRTCGPEHSKGGGRVDEGPQPRSVEPQDAGPLERSQGDEAGGHGEDRPEPLSPKESKKRKLELSRREQPPTEPGPQSASEVEKIALNLEGCALSQGSLRTGTQEVGGQDPGEAVQPCRQPLGARVADKVRKRRKVDEGAGDSAAVASGGAQTLALAGSPAPSGHPKAGHSENGVEEDTEGRTGPKEGTPGSPSETPGPSPAGPAGDEPAESPSETPGPRPAGPAGDEPAESPSETPGPRPAGPAGDEPAESPSETPGPSPAGPTRDEPAESPSETPGPRPAGPAGDEPAESPSETPGPRPAGPAGDEPAESPSETPGPSPAGPTRDEPAKAGEAAELQDAEVESSAKSGKP T13741 DRUGINFO D0J5UK IRT-102 Phase 2 T13741 DRUGINFO D08KYN INNO-105 Phase 1 T82391 TARGETID T82391 T82391 FORMERID TTDI02301 T82391 UNIPROID NDUAD_HUMAN T82391 TARGNAME Mitochondrial complex I (NDUFA13) T82391 GENENAME NDUFA13 T82391 TARGTYPE Clinical trial T82391 SYNONYMS NADH-ubiquinone oxidoreductase B16.6 subunit; NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13; Gene associated with retinoic and interferon-induced mortality 19 protein; Gene associated with retinoic and IFN-induced mortality 19 protein; GRIM19; GRIM-19; Complex I-B16.6; Cell death regulatory protein GRIM-19; CI-B16.6; CGI-39; CDA016 T82391 FUNCTION Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone. Involved in the interferon/all-trans-retinoic acid (IFN/RA) induced cell death. This apoptotic activity is inhibited by interaction with viral IRF1. Prevents the transactivation of STAT3 target genes. May play a role in CARD15-mediated innate mucosal responses and serve to regulate intestinal epithelial cell responses to microbes. Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. T82391 PDBSTRUC 5XTI; 5XTH; 5XTD; 5XTC; 5XTB T82391 SEQUENCE MAASKVKQDMPPPGGYGPIDYKRNLPRRGLSGYSMLAIGIGTLIYGHWSIMKWNRERRRLQIEDFEARIALLPLLQAETDRRTLQMLRENLEEEAIIMKDVPDWKVGESVFHTTRWVPPLIGELYGLRTTEEALHASHGFMWYT T82391 DRUGINFO D0U1VZ Flurpiridaz F 18 Phase 3 T91558 TARGETID T91558 T91558 FORMERID TTDI03591 T91558 UNIPROID TRPC4_HUMAN T91558 TARGNAME Short transient receptor potential channel 4 (TRPC4) T91558 GENENAME TRPC4 T91558 TARGTYPE Clinical trial T91558 SYNONYMS hTrp4; hTrp-4; TrpC4; Trp-related protein 4 T91558 FUNCTION Form a receptor-activated non-selective calcium permeant cation channel. Acts as a cell-cell contact-dependent endothelial calcium entry channel. Probably operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Mediates cation entry, with an enhanced permeability to barium over calcium. May also be activated by intracellular calcium store depletion. T91558 BIOCLASS Transient receptor potential catioin channel T91558 SEQUENCE MAQFYYKRNVNAPYRDRIPLRIVRAESELSPSEKAYLNAVEKGDYASVKKSLEEAEIYFKININCIDPLGRTALLIAIENENLELIELLLSFNVYVGDALLHAIRKEVVGAVELLLNHKKPSGEKQVPPILLDKQFSEFTPDITPIILAAHTNNYEIIKLLVQKGVSVPRPHEVRCNCVECVSSSDVDSLRHSRSRLNIYKALASPSLIALSSEDPFLTAFQLSWELQELSKVENEFKSEYEELSRQCKQFAKDLLDQTRSSRELEIILNYRDDNSLIEEQSGNDLARLKLAIKYRQKEFVAQPNCQQLLASRWYDEFPGWRRRHWAVKMVTCFIIGLLFPVFSVCYLIAPKSPLGLFIRKPFIKFICHTASYLTFLFLLLLASQHIDRSDLNRQGPPPTIVEWMILPWVLGFIWGEIKQMWDGGLQDYIHDWWNLMDFVMNSLYLATISLKIVAFVKYSALNPRESWDMWHPTLVAEALFAIANIFSSLRLISLFTANSHLGPLQISLGRMLLDILKFLFIYCLVLLAFANGLNQLYFYYEETKGLTCKGIRCEKQNNAFSTLFETLQSLFWSIFGLINLYVTNVKAQHEFTEFVGATMFGTYNVISLVVLLNMLIAMMNNSYQLIADHADIEWKFARTKLWMSYFEEGGTLPTPFNVIPSPKSLWYLIKWIWTHLCKKKMRRKPESFGTIGRRAADNLRRHHQYQEVMRNLVKRYVAAMIRDAKTEEGLTEENFKELKQDISSFRFEVLGLLRGSKLSTIQSANASKESSNSADSDEKSDSEGNSKDKKKNFSLFDLTTLIHPRSAAIASERHNISNGSALVVQEPPREKQRKVNFVTDIKNFGLFHRRSKQNAAEQNANQIFSVSEEVARQQAAGPLERNIQLESRGLASRGDLSIPGLSEQCVLVDHRERNTDTLGLQVGKRVCPFKSEKVVVEDTVPIIPKEKHAKEEDSSIDYDLNLPDTVTHEDYVTTRL T91558 DRUGINFO DD1ZV6 BI 1358894 Phase 2 T91558 DRUGINFO D0G8FT ML204 Investigative T91558 DRUGINFO D0M6VZ (-)-englerin A Investigative T91558 DRUGINFO D00HCI 2-APB Investigative T04388 TARGETID T04388 T04388 FORMERID TTDI03309 T04388 UNIPROID KCNN3_HUMAN T04388 TARGNAME Calcium-activated potassium channel KCa2.3 (KCNN3) T04388 GENENAME KCNN3 T04388 TARGTYPE Clinical trial T04388 SYNONYMS Small conductance calcium-activated potassium channel protein 3; SKCa3; SKCa 3; SK3; KCa2.3; K3 T04388 FUNCTION Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin. T04388 BIOCLASS Voltage-gated ion channel T04388 SEQUENCE MDTSGHFHDSGVGDLDEDPKCPCPSSGDEQQQQQQQQQQQQPPPPAPPAAPQQPLGPSLQPQPPQLQQQQQQQQQQQQQQPPHPLSQLAQLQSQPVHPGLLHSSPTAFRAPPSSNSTAILHPSSRQGSQLNLNDHLLGHSPSSTATSGPGGGSRHRQASPLVHRRDSNPFTEIAMSSCKYSGGVMKPLSRLSASRRNLIEAETEGQPLQLFSPSNPPEIVISSREDNHAHQTLLHHPNATHNHQHAGTTASSTTFPKANKRKNQNIGYKLGHRRALFEKRKRLSDYALIFGMFGIVVMVIETELSWGLYSKDSMFSLALKCLISLSTIILLGLIIAYHTREVQLFVIDNGADDWRIAMTYERILYISLEMLVCAIHPIPGEYKFFWTARLAFSYTPSRAEADVDIILSIPMFLRLYLIARVMLLHSKLFTDASSRSIGALNKINFNTRFVMKTLMTICPGTVLLVFSISLWIIAAWTVRVCERYHDQQDVTSNFLGAMWLISITFLSIGYGDMVPHTYCGKGVCLLTGIMGAGCTALVVAVVARKLELTKAEKHVHNFMMDTQLTKRIKNAAANVLRETWLIYKHTKLLKKIDHAKVRKHQRKFLQAIHQLRSVKMEQRKLSDQANTLVDLSKMQNVMYDLITELNDRSEDLEKQIGSLESKLEHLTASFNSLPLLIADTLRQQQQQLLSAIIEARGVSVAVGTTHTPISDSPIGVSSTSFPTPYTSSSSC T04388 DRUGINFO D0I2FI dequalinium Clinical trial T04388 DRUGINFO D00DIF CyPPA Investigative T04388 DRUGINFO D00WMV UCL1684 Investigative T04388 DRUGINFO D0I6MA DC-EBIO Investigative T04388 DRUGINFO D0N1HE UCL1848 Investigative T04388 DRUGINFO D0VK9Y apamin Investigative T04388 DRUGINFO D0T0AG EBIO Investigative T04388 DRUGINFO D06PZZ [14C]TEA Investigative T19368 TARGETID T19368 T19368 FORMERID TTDI03354 T19368 UNIPROID LIPE_HUMAN T19368 TARGNAME Endothelial lipase (LIPG) T19368 GENENAME LIPG T19368 TARGTYPE Clinical trial T19368 SYNONYMS Endothelial cell-derived lipase; EL; EDL T19368 FUNCTION Has phospholipase and triglyceride lipase activities. Hydrolyzes high density lipoproteins (HDL) more efficiently than other lipoproteins. Binds heparin. T19368 ECNUMBER EC 3.1.1.3 T19368 SEQUENCE MSNSVPLLCFWSLCYCFAAGSPVPFGPEGRLEDKLHKPKATQTEVKPSVRFNLRTSKDPEHEGCYLSVGHSQPLEDCSFNMTAKTFFIIHGWTMSGIFENWLHKLVSALHTREKDANVVVVDWLPLAHQLYTDAVNNTRVVGHSIARMLDWLQEKDDFSLGNVHLIGYSLGAHVAGYAGNFVKGTVGRITGLDPAGPMFEGADIHKRLSPDDADFVDVLHTYTRSFGLSIGIQMPVGHIDIYPNGGDFQPGCGLNDVLGSIAYGTITEVVKCEHERAVHLFVDSLVNQDKPSFAFQCTDSNRFKKGICLSCRKNRCNSIGYNAKKMRNKRNSKMYLKTRAGMPFRVYHYQMKIHVFSYKNMGEIEPTFYVTLYGTNADSQTLPLEIVERIEQNATNTFLVYTEEDLGDLLKIQLTWEGASQSWYNLWKEFRSYLSQPRNPGRELNIRRIRVKSGETQRKLTFCTEDPENTSISPGRELWFRKCRDGWRMKNETSPTVELP T19368 DRUGINFO D0D4VK REG-101 Phase 2 T19368 DRUGINFO D02NHW GSK-264220A Clinical trial T61547 TARGETID T61547 T61547 FORMERID TTDI01711 T61547 UNIPROID W8TNQ9_STAAU T61547 TARGNAME Staphylococcus Manganese transporter C (Stap-coc MntC) T61547 GENENAME Stap-coc MntC T61547 TARGTYPE Clinical trial T61547 SYNONYMS Metal ABC transporter substrate-binding protein; Manganese ABC transporter substrate-binding protein; Manganese ABC transporter substrate-binding lipoprotein; ABC transporter substrate-binding protein; ABC superfamily ATP binding cassette transporter, binding protein T61547 FUNCTION A component of Mnt comples, conserved across the staphylococcal species group. Expressed on the cell surface of S. aureus in biofilms generated in in vivo models of infection. T61547 PDBSTRUC 5HDQ T61547 SEQUENCE MKKLVPLLLALLLLVAACGTGGKQSSDKSNGKLKVVTTNSILYDMAKNVGGDNVDIHSIVPVGQDPHEYEVKPKDIKKLTDADVILYNGLNLETGNGWFEKALEQAGKSLKDKKVIAVSKDVKPIYLNGEEGNKDKQDPHAWLSLDNGIKYVKTIQQTFIDNDKKHKADYEKQGNKYIAQLEKLNNDSKDKFNDIPKEQRAMITSEGAFKYFSKQYGITPGYIWEINTEKQGTPEQMRQAIEFVKKHKLKHLLVETSVDKKAMESLSEETKKDIFGEVYTDSIGKEGTKGDSYYKMMKSNIETVHGSMK T61547 DRUGINFO D01DXI PF-06290510 Phase 2 T57364 TARGETID T57364 T57364 FORMERID TTDC00274 T57364 UNIPROID REV_HV1H2 T57364 TARGNAME Human immunodeficiency virus Rev messenger RNA (HIV rev mRNA) T57364 GENENAME HIV rev mRNA T57364 TARGTYPE Clinical trial T57364 SYNONYMS rev (mRNA); Regulator of expression of viral proteins (mRNA); Protein Rev (mRNA); Anti-repression transactivator (mRNA); ART/TRS (mRNA) T57364 FUNCTION These pre-mRNAs carry a recognition sequence called Rev responsive element (RRE) located in the env gene, that is not present in fully spliced viral mRNAs (early transcripts). This function is essential since most viral proteins are translated from unspliced or partially spliced pre-mRNAs which cannot exit the nucleus by the pathway used by fully processed cellular mRNAs. Rev itself is translated from a fully spliced mRNA that readily exits the nucleus. Rev's nuclear localization signal (NLS) binds directly to KPNB1/Importin beta-1 without previous binding to KPNA1/Importin alpha-1. KPNB1 binds to the GDP bound form of RAN (Ran-GDP) and targets Rev to the nucleus. In the nucleus, the conversion from Ran-GDP to Ran-GTP dissociates Rev from KPNB1 and allows Rev's binding to the RRE in viral pre-mRNAs. Rev multimerization on the RRE via cooperative assembly exposes its nuclear export signal (NES) to the surface. Rev can then form a complex with XPO1/CRM1 and Ran-GTP, leading to nuclear export of the complex. Conversion from Ran-GTP to Ran-GDP mediates dissociation of the Rev/RRE/XPO1/RAN complex, so that Rev can return to the nucleus for a subsequent round of export. Beside KPNB1, also seems to interact with TNPO1/Transportin-1, RANBP5/IPO5 and IPO7/RANBP7 for nuclear import. The nucleoporin-like HRB/RIP is an essential cofactor that probably indirectly interacts with Rev to release HIV RNAs from the perinuclear region to the cytoplasm. Escorts unspliced or incompletely spliced viral pre-mRNAs (late transcripts) out of the nucleus of infected cells. T57364 BIOCLASS mRNA target T57364 SEQUENCE MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQRQIHSISERILGTYLGRSAEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE T57364 DRUGINFO D0JZ8X HGTV43 Phase 2 T09037 TARGETID T09037 T09037 FORMERID TTDI02242 T09037 UNIPROID VP35_EBOSU T09037 TARGNAME Ebola virus VP35 messenger RNA (EV VP35 mRNA) T09037 GENENAME EV VP35 mRNA T09037 TARGTYPE Clinical trial T09037 SYNONYMS VP35 (mRNA); Polymerase cofactor VP35 (mRNA) T09037 FUNCTION Prevents establishment of cellular antiviral state by blocking virus-induced phosphorylation and activation of interferon regulatory factor 3 (IRF3), a transcription factor critical for the induction of interferons alpha and beta. This blockage is produced through the interaction with and inhibition host IKBKE and TBK1 producing a strong inhibition of the phosphorylation and activation of IRF3. Also inhibits the antiviral effect mediated by the interferon-induced, double-stranded RNA-activated protein kinase EIF2AK2/PKR. Acts as a polymerase cofactor in the RNA polymerase transcription and replication complex. T09037 BIOCLASS mRNA target T09037 SEQUENCE MQQDRTYRHHGPEVSGWFSEQLMTGKIPLTEVFVDVENKPSPAPITIISKNPKTTRKSDKQVQTDDASSLLTEEVKAAINSVISAVRRQTNAIESLEGRVTTLEASLKPVQDMAKTISSLNRSCAEMVAKYDLLVMTTGRATATAAATEAYWNEHGQAPPGPSLYEDDAIKAKLKDPNGKVPESVKQAYINLDSTSALNEENFGRPYISAKDLKEIIYDHLPGFGTAFHQLVQVICKIGKDNNILDIIHAEFQASLAEGDSPQCALIQITKRIPAFQDASPPIVHIKSRGDIPKACQKSLRPVPPSPKIDRGWVCIFQFQDGKALGLKI T09037 DRUGINFO D04LIH AVI-6002 Phase 1 T09037 DRUGINFO D0CB6N AVI-6003 Phase 1 T01110 TARGETID T01110 T01110 FORMERID TTDNC00521 T01110 UNIPROID E9PEK4_HUMAN T01110 TARGNAME Colony stimulating factor-1 receptor (CSF-1R) T01110 GENENAME CSF1R T01110 TARGTYPE Clinical trial T01110 SYNONYMS Macrophage colony-stimulating factor 1 receptor T01110 FUNCTION A cytokine which controls the production, differentiation, and function of macrophages. T01110 SEQUENCE MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEWDGPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLYVKDPARPWNVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMRHTNYSFSPWHGFTIHRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIPGPPALTLVPAELVRIRGEAAQIVCSASSVDVNFDVFLQHNNTKLAIPQQSDFHNNRYQKVLTLNLDQVDFQHAGNYSCVASNVQGKHSTSMFFRVVESAYLNLSSEQNLIQEVTVGEGLNLKVMVEAYPGLQGFNWTYLGPFSDHQPEPKLANATTKDTYRHTFTLSLPRLKPSEAGRYSFLARNPGGWRALTFELTLRYPPEVSVIWTFINGSGTLLCAASGYPQPNVTWLQCSGHTDRCDEAQVLQVWDDPYPEVLSQEPFHKVTVQSLLTVETLEHNQTYECRAHNSVGSGSWAFIPISAGAHTHPPDEFLFTPVVVACMSIMALLLLLLLLLLYKYKQKPKYQVRWKIIESYEGNSYTFIDPTQLPYNEKWEFPRNNLQFGKTLGAGAFGKVVEATAFGLGKEDAVLKVAVKMLKSTAHADEKEALMSELKIMSHLGQHENIVNLLGACTHGGTVASPARVWTPMWR T01110 DRUGINFO D04EAT MCS-110 Phase 2 T01110 DRUGINFO D0C5JQ JNJ-40346527 Phase 2 T01110 DRUGINFO D0S1UZ PD-360324 Phase 2 T01110 DRUGINFO D05JAA ARRY-382 Phase 2 T01110 DRUGINFO D06NQH RG7155 Phase 2 T01110 DRUGINFO D08ZQI FPA-008 Phase 1/2 T01110 DRUGINFO D0CN7I IMC-CS4 Phase 1 T01110 DRUGINFO D0I8DX AMG 820 Phase 1 T22415 TARGETID T22415 T22415 FORMERID TTDI02142 T22415 UNIPROID O30527_PSEAI T22415 TARGNAME Pseudomonas PcrV protein type III (Pseudo pcrV) T22415 GENENAME Pseudo pcrV T22415 TARGTYPE Clinical trial T22415 SYNONYMS Type III secretion protein PcrV; Pseudo Virulence-associated V antigen; Pseudo Low calcium response locus protein V; PcrV T22415 FUNCTION Essential for cytotoxicity. Found both within the bacterial cytoplasm and localized extracellularly. T22415 SEQUENCE MEVRNLNAARELFLDELLAASAAPASAEQEELLALLRSERIVLAHAGQPLSEAQVLKALAWLLAANPSAPPGQGLEVLREVLQARRQPGAQWDLREFLVSAYFSLHGRLDEDVIGVYKDVLQTQDGKRKALLDELKALTAELKVYSVIQSQINAALSAKQGIRIDAGGIDLVDPTLYGYAVGDPRWKDSPEYALLSNLDTFSGKLSIKDFLSGSPKQSGELKGLSDEYPFEKDNNPVGNFATTVSDRSRPLNDKVNEKTTLLNDTSSRYNSAVEALNRFIQKYDSVLRDILSAI T22415 DRUGINFO DI6G5U KB001A Phase 2 T22415 DRUGINFO D05IYA MEDI3902 Phase 2 T23953 TARGETID T23953 T23953 FORMERID TTDR00392 T23953 UNIPROID PSCA_HUMAN T23953 TARGNAME Prostate stem cell antigen (PSCA) T23953 GENENAME PSCA T23953 TARGTYPE Clinical trial T23953 SYNONYMS UNQ206/PRO232 T23953 FUNCTION Has a cell-proliferation inhibition activity in vitro. May be involved in the regulation of cell proliferation. T23953 SEQUENCE MAGLALQPGTALLCYSCKAQVSNEDCLQVENCTQLGEQCWTARIRAVGLLTVISKGCSLNCVDDSQDYYVGKKNITCCDTDLCNASGAHALQPAAAILALLPALGLLLWGPGQL T23953 DRUGINFO D0G7ZT Anti-PSCA mab Phase 2 T23953 DRUGINFO D0TY6U BPX-601 Phase 1/2 T23953 DRUGINFO D02MYI CAR-T Cells targeting PSCA Phase 1 T23953 DRUGINFO D0MG3Z CAR-T cells targeting PSCA Phase 1 T23953 DRUGINFO D1L7DE GEM3PSCA Phase 1 T23953 DRUGINFO DD4XR3 MB-105 Phase 1 T02258 TARGETID T02258 T02258 FORMERID TTDI01628 T02258 UNIPROID DPOLQ_HUMAN; DPOLN_HUMAN; DPOLB_HUMAN; DPOG2_HUMAN; DPOG1_HUMAN; DPOE2_HUMAN; DPOD4_HUMAN; DPOD1_HUMAN T02258 TARGNAME DNA-dependent DNA polymerase (DPOL) T02258 GENENAME POLQ; POLN; POLB; POLG2; POLG; POLE2; POLD4; ;POLD1 T02258 TARGTYPE Clinical trial T02258 SYNONYMS DNA polymerase T02258 FUNCTION Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Repair polymerase that plays a key role in base-excision repair. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases. T02258 SEQUENCE MNLLRRSGKRRRSESGSDSFSGSGGDSSASPQFLSGSVLSPPPGLGRCLKAAAAGECKPTVPDYERDKLLLANWGLPKAVLEKYHSFGVKKMFEWQAECLLLGQVLEGKNLVYSAPTSAGKTLVAELLILKRVLEMRKKALFILPFVSVAKEKKYYLQSLFQEVGIKVDGYMGSTSPSRHFSSLDIAVCTIERANGLINRLIEENKMDLLGMVVVDELHMLGDSHRGYLLELLLTKICYITRKSASCQADLASSLSNAVQIVGMSATLPNLELVASWLNAELYHTDFRPVPLLESVKVGNSIYDSSMKLVREFEPMLQVKGDEDHVVSLCYETICDNHSVLLFCPSKKWCEKLADIIAREFYNLHHQAEGLVKPSECPPVILEQKELLEVMDQLRRLPSGLDSVLQKTVPWGVAFHHAGLTFEERDIIEGAFRQGLIRVLAATSTLSSGVNLPARRVIIRTPIFGGRPLDILTYKQMVGRAGRKGVDTVGESILICKNSEKSKGIALLQGSLKPVRSCLQRREGEEVTGSMIRAILEIIVGGVASTSQDMHTYAACTFLAASMKEGKQGIQRNQESVQLGAIEACVMWLLENEFIQSTEASDGTEGKVYHPTHLGSATLSSSLSPADTLDIFADLQRAMKGFVLENDLHILYLVTPMFEDWTTIDWYRFFCLWEKLPTSMKRVAELVGVEEGFLARCVKGKVVARTERQHRQMAIHKRFFTSLVLLDLISEVPLREINQKYGCNRGQIQSLQQSAAVYAGMITVFSNRLGWHNMELLLSQFQKRLTFGIQRELCDLVRVSLLNAQRARVLYASGFHTVADLARANIVEVEVILKNAVPFKSARKAVDEEEEAVEERRNMRTIWVTGRKGLTEREAAALIVEEARMILQQDLVEMGVQWNPCALLHSSTCSLTHSESEVKEHTFISQTKSSYKKLTSKNKSNTIFSDSYIKHSPNIVQDLNKSREHTSSFNCNFQNGNQEHQTCSIFRARKRASLDINKEKPGASQNEGKTSDKKVVQTFSQKTKKAPLNFNSEKMSRSFRSWKRRKHLKRSRDSSPLKDSGACRIHLQGQTLSNPSLCEDPFTLDEKKTEFRNSGPFAKNVSLSGKEKDNKTSFPLQIKQNCSWNITLTNDNFVEHIVTGSQSKNVTCQATSVVSEKGRGVAVEAEKINEVLIQNGSKNQNVYMKHHDIHPINQYLRKQSHEQTSTITKQKNIIERQMPCEAVSSYINRDSNVTINCERIKLNTEENKPSHFQALGDDISRTVIPSEVLPSAGAFSKSEGQHENFLNISRLQEKTGTYTTNKTKNNHVSDLGLVLCDFEDSFYLDTQSEKIIQQMATENAKLGAKDTNLAAGIMQKSLVQQNSMNSFQKECHIPFPAEQHPLGATKIDHLDLKTVGTMKQSSDSHGVDILTPESPIFHSPILLEENGLFLKKNEVSVTDSQLNSFLQGYQTQETVKPVILLIPQKRTPTGVEGECLPVPETSLNMSDSLLFDSFSDDYLVKEQLPDMQMKEPLPSEVTSNHFSDSLCLQEDLIKKSNVNENQDTHQQLTCSNDESIIFSEMDSVQMVEALDNVDIFPVQEKNHTVVSPRALELSDPVLDEHHQGDQDGGDQDERAEKSKLTGTRQNHSFIWSGASFDLSPGLQRILDKVSSPLENEKLKSMTINFSSLNRKNTELNEEQEVISNLETKQVQGISFSSNNEVKSKIEMLENNANHDETSSLLPRKESNIVDDNGLIPPTPIPTSASKLTFPGILETPVNPWKTNNVLQPGESYLFGSPSDIKNHDLSPGSRNGFKDNSPISDTSFSLQLSQDGLQLTPASSSSESLSIIDVASDQNLFQTFIKEWRCKKRFSISLACEKIRSLTSSKTATIGSRFKQASSPQEIPIRDDGFPIKGCDDTLVVGLAVCWGGRDAYYFSLQKEQKHSEISASLVPPSLDPSLTLKDRMWYLQSCLRKESDKECSVVIYDFIQSYKILLLSCGISLEQSYEDPKVACWLLDPDSQEPTLHSIVTSFLPHELPLLEGMETSQGIQSLGLNAGSEHSGRYRASVESILIFNSMNQLNSLLQKENLQDVFRKVEMPSQYCLALLELNGIGFSTAECESQKHIMQAKLDAIETQAYQLAGHSFSFTSSDDIAEVLFLELKLPPNREMKNQGSKKTLGSTRRGIDNGRKLRLGRQFSTSKDVLNKLKALHPLPGLILEWRRITNAITKVVFPLQREKCLNPFLGMERIYPVSQSHTATGRITFTEPNIQNVPRDFEIKMPTLVGESPPSQAVGKGLLPMGRGKYKKGFSVNPRCQAQMEERAADRGMPFSISMRHAFVPFPGGSILAADYSQLELRILAHLSHDRRLIQVLNTGADVFRSIAAEWKMIEPESVGDDLRQQAKQICYGIIYGMGAKSLGEQMGIKENDAACYIDSFKSRYTGINQFMTETVKNCKRDGFVQTILGRRRYLPGIKDNNPYRKAHAERQAINTIVQGSAADIVKIATVNIQKQLETFHSTFKSHGHREGMLQSDQTGLSRKRKLQGMFCPIRGGFFILQLHDELLYEVAEEDVVQVAQIVKNEMESAVKLSVKLKVKVKIGASWGELKDFDV T02258 DRUGINFO D0W5NW CMX-001 Phase 3 T02258 DRUGINFO DE8S2F DFP-14927 Phase 1 T57560 TARGETID T57560 T57560 FORMERID TTDR00093 T57560 UNIPROID PBPA_ECOLI; PBPB_ECOLI; PBPC_ECOLI T57560 TARGNAME Bacterial Penicillin binding protein 1 (Bact pbp) T57560 GENENAME Bact mrcA; Bact mrcB; Bact pbpC T57560 TARGTYPE Clinical trial T57560 SYNONYMS Penicillin-binding protein 1; PBP1; PBP-1; Bact pon T57560 FUNCTION Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits). T57560 SEQUENCE MKFVKYFLILAVCCILLGAGSIYGLYRYIEPQLPDVATLKDVRLQIPMQIYSADGELIAQYGEKRRIPVTLDQIPPEMVKAFIATEDSRFYEHHGVDPVGIFRAASVALFSGHASQGASTITQQLARNFFLSPERTLMRKIKEVFLAIRIEQLLTKDEILELYLNKIYLGYRAYGVGAAAQVYFGKTVDQLTLNEMAVIAGLPKAPSTFNPLYSMDRAVARRNVVLSRMLDEGYITQQQFDQTRTEAINANYHAPEIAFSAPYLSEMVRQEMYNRYGESAYEDGYRIYTTITRKVQQAAQQAVRNNVLDYDMRHGYRGPANVLWKVGESAWDNNKITDTLKALPTYGPLLPAAVTSANPQQATAMLADGSTVALSMEGVRWARPYRSDTQQGPTPRKVTDVLQTGQQIWVRQVGDAWWLAQVPEVNSALVSINPQNGAVMALVGGFDFNQSKFNRATQALRQVGSNIKPFLYTAAMDKGLTLASMLNDVPISRWDASAGSDWQPKNSPPQYAGPIRLRQGLGQSKNVVMVRAMRAMGVDYAAEYLQRFGFPAQNIVHTESLALGSASFTPMQVARGYAVMANGGFLVDPWFISKIENDQGGVIFEAKPKVACPECDIPVIYGDTQKSNVLENNDVEDVAISREQQNVSVPMPQLEQANQALVAKTGAQEYAPHVINTPLAFLIKSALNTNIFGEPGWQGTGWRAGRDLQRRDIGGKTGTTNSSKDAWFSGYGPGVVTSVWIGFDDHRRNLGHTTASGAIKDQISGYEGGAKSAQPAWDAYMKAVLEGVPEQPLTPPPGIVTVNIDRSTGQLANGGNSREEYFIEGTQPTQQAVHEVGTTIIDNGEAQELF T57560 DRUGINFO D00QAR Benzylpenicillin Phase 3 T29144 TARGETID T29144 T29144 UNIPROID ARGI1_HUMAN; ARGI2_HUMAN T29144 TARGNAME Arginase (ARG) T29144 GENENAME ARG1; ARG2 T29144 TARGTYPE Clinical trial T29144 SYNONYMS L-arginase; Canavanase; Arginine transamidinase; Arginine amidinase T29144 FUNCTION Arginase I functions in the urea cycle, and is located primarily in the cytoplasm of hepatocytes (liver cells); Arginase II, implicated in the regulation of intracellular arginine/ornithine levels is located in mitochondria of several tissues in the body, with most abundance in the kidney and prostate. T29144 SEQUENCE MSAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDVKDYGDLPFADIPNDSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRISLVLGGDHSLAIGSISGHARVHPDLGVIWVDAHTDINTPLTTTSGNLHGQPVSFLLKELKGKIPDVPGFSWVTPCISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGLDPSFTPATGTPVVGGLTYREGLYITEEIYKTGLLSGLDIMEVNPSLGKTPEEVTRTVNTAVAITLACFGLAREGNHKPIDYLNPPK T29144 DRUGINFO D06XAT BCT-100 Phase 1/2 T29144 DRUGINFO D0XI3E INCB01158 Phase 1/2 T17514 TARGETID T17514 T17514 FORMERID TTDR01275 T17514 UNIPROID INHBA_HUMAN; INHBB_HUMAN; INHBC_HUMAN; INHBE_HUMAN T17514 TARGNAME Activin (ACT) T17514 GENENAME INHBA; INHBB; INHBC; INHBE T17514 TARGTYPE Clinical trial T17514 SYNONYMS Inhibin beta; Activin beta T17514 FUNCTION Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins. T17514 SEQUENCE MPLLWLRGFLLASCWIIVRSSPTPGSEGHSAAPDCPSCALAALPKDVPNSQPEMVEAVKKHILNMLHLKKRPDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIGRRAEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTRTKVTIRLFQQQKHPQGSLDTGEEAEEVGLKGERSELLLSEKVVDARKSTWHVFPVSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLGKKKKKEEEGEGKKKGGGEGGAGADEEKEQSHRPFLMLQARQSEDHPHRRRRRGLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS T17514 DRUGINFO D0X6DC STM 434 Phase 1 T66266 TARGETID T66266 T66266 UNIPROID CD7_HUMAN T66266 TARGNAME T-cell antigen CD7 (CD7) T66266 GENENAME CD7 T66266 TARGTYPE Clinical trial T66266 SYNONYMS Tp40; TP41; T-cell surface antigen Leu-9; T-cell leukemia antigen; LEU-9; GP40; CD7 molecule T66266 FUNCTION Not yet known. T66266 SEQUENCE MAGPPRLLLLPLLLALARGLPGALAAQEVQQSPHCTTVPVGASVNITCSTSGGLRGIYLRQLGPQPQDIIYYEDGVVPTTDRRFRGRIDFSGSQDNLTITMHRLQLSDTGTYTCQAITEVNVYGSGTLVLVTEEQSQGWHRCSDAPPRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQIKKLCSWRDKNSAACVVYEDMSHSRCNTLSSPNQYQ T66266 DRUGINFO D09ICH CD7.CAR/28zeta CAR T cells Phase 1 T66266 DRUGINFO D09SBE Anti-CD7 CAR-T cells Phase 1 T64987 TARGETID T64987 T64987 FORMERID TTDR00919 T64987 UNIPROID LMP1_EBVG T64987 TARGNAME Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) T64987 GENENAME EBV LMP1 T64987 TARGTYPE Clinical trial T64987 SYNONYMS Protein p63; P63; Latent membrane protein 1; LMP1; LMP-1; BNLF1 T64987 FUNCTION Functions as a constitutively active tumor necrosis factor receptor that induces the activation of several signaling pathways, including those of the NF-kappa-B family. LMP1 signaling leads to up-regulation of antiapoptotic proteins and provide growth signals in latently infected cells. Interacts with host UBE2I and subsequently affects the sumoylation state of several cellular proteins. For example, induces the sumoylation of host IRF7 thereby limiting its transcriptional activity and modulating the activation of innate immune responses. Acts as a CD40 functional homolog to prevent apoptosis of infected B-lymphocytes and drive their proliferation. T64987 SEQUENCE MERDLERGPPGPPRPPLGPPLSSSIGLALLLLLLALLFWLYIVLSNWTGGALLVLYSFALMLIIIILIIFIFRRDLLCPLGGLGLLLLMVTLLLIALWNLHGQALYLGIVLFIFGCLLVLGLWIYFLEILWRLGATIWQLLAFILAFFLAIILLIIALYLQQNWWTLLVDLLWLLLFMAILIWMYFHGPRHTDEHHHDDSLPHPQQATDDSSHESDSNSNEGRHHLLVSGAGDGPPLCSQNLGAPGGGPDNGPQDPDNTDDNGPQDPDNTDDNGNTDDNGPQDPDNTDDNGPHDPLPHNPSDSAGNDGGPPNLTEEVENKGGDRGPPSMTDGGGGDPHLPTLLLGTSGSGGDDDDPHGPVQLSYYD T64987 DRUGINFO D0RJ2V LMP1-CAR-T cells Phase 1/2 T64987 DRUGINFO D0Z6RW LMP-1/LMP-2 CTLs Phase 1 T64987 DRUGINFO D0Q8PF Ad5f35-LMPd1-2-transduced autologous dendritic cells Investigative T51883 TARGETID T51883 T51883 UNIPROID ARAF_HUMAN; BRAF_HUMAN; RAF1_HUMAN T51883 TARGNAME Serine/threonine-protein kinase Raf (RAF) T51883 GENENAME ARAF; BRAF; RAF1 T51883 TARGTYPE Clinical trial T51883 SYNONYMS Proto-oncogene Raf T51883 FUNCTION Participate in the RAS-RAF-MEK-ERK signal transduction cascade, also referred to as the mitogen-activated protein kinase (MAPK) cascade. Activation of RAF kinases requires interaction with RAS-GTPases. T51883 SEQUENCE MEPPRGPPANGAEPSRAVGTVKVYLPNKQRTVVTVRDGMSVYDSLDKALKVRGLNQDCCVVYRLIKGRKTVTAWDTAIAPLDGEELIVEVLEDVPLTMHNFVRKTFFSLAFCDFCLKFLFHGFRCQTCGYKFHQHCSSKVPTVCVDMSTNRQQFYHSVQDLSGGSRQHEAPSNRPLNELLTPQGPSPRTQHCDPEHFPFPAPANAPLQRIRSTSTPNVHMVSTTAPMDSNLIQLTGQSFSTDAAGSRGGSDGTPRGSPSPASVSSGRKSPHSKSPAEQRERKSLADDKKKVKNLGYRDSGYYWEVPPSEVQLLKRIGTGSFGTVFRGRWHGDVAVKVLKVSQPTAEQAQAFKNEMQVLRKTRHVNILLFMGFMTRPGFAIITQWCEGSSLYHHLHVADTRFDMVQLIDVARQTAQGMDYLHAKNIIHRDLKSNNIFLHEGLTVKIGDFGLATVKTRWSGAQPLEQPSGSVLWMAAEVIRMQDPNPYSFQSDVYAYGVVLYELMTGSLPYSHIGCRDQIIFMVGRGYLSPDLSKISSNCPKAMRRLLSDCLKFQREERPLFPQILATIELLQRSLPKIERSASEPSLHRTQADELPACLLSAARLVP T51883 DRUGINFO D0M6BD RO-5126766 Phase 2 T51883 DRUGINFO D07IEU MLN2480 Phase 2 T51883 DRUGINFO D04AHQ LY3009120 Phase 1 T90286 TARGETID T90286 T90286 UNIPROID FGFR3_HUMAN-TACC3_HUMAN T90286 TARGNAME Fusion protein FGFR3-TACC3 (FGFR3-TACC3) T90286 GENENAME FGFR3-TACC3 T90286 TARGTYPE Clinical trial T90286 SYNONYMS FGFR3-TACC3 gene fusion; FGFR3-TACC3 T90286 FUNCTION An oncogenic function in respiratory epithelium. T90286 SEQUENCE MSLQVLNDKNVSNEKNTENCDFLFSPPEVTGRSSVLRVSQKENVPPKNLAKAMKVTFQTPLRDPQTHRILSPSMASKLEAPFTQDDTLGLENSHPVWTQKENQQLIKEVDAKTTHGILQKPVEADTDLLGDASPAFGSGSSSESGPGALADLDCSSSSQSPGSSENQMVSPGKVSGSPEQAVEENLSSYSLDRRVTPASETLEDPCRTESQHKAETPHGAEEECKAETPHGAEEECRHGGVCAPAAVATSPPGAIPKEACGGAPLQGLPGEALGCPAGVGTPVPADGTQTLTCAHTSAPESTAPTNHLVAGRAMTLSPQEEVAAGQMASSSRSGPVKLEFDVSDGATSKRAPPPRRLGERSGLKPPLRKAAVRQQKAPQEVEEDDGRSGAGEDPPMPASRGSYHLDWDKMDDPNFIPFGGDTKSGCSEAQPPESPETRLGQPAAEQLHAGPATEEPGPCLSQQLHSASAEDTPVVQLAAETPTAESKERALNSASTSLPTSCPGSEPVPTHQQGQPALELKEESFRDPAEVLGTGAEVDYLEQFGTSSFKESALRKQSLYLKFDPLLRDSPGRPVPVATETSSMHGANETPSGRPREAKLVEFDFLGALDIPVPGPPPGVPAPGGPPLSTGPIVDLLQYSQKDLDAVVKATQEENRELRSRCEELHGKNLELGKIMDRFEEVVYQAMEEVQKQKELSKAEIQKVLKEKDQLTTDLNSMEKSFSDLFKRFEKQKEVIEGYRKNEESLKKCVEDYLARITQEGQRYQALKAHAEEKLQLANEEIAQVRSKAQAEALALQASLRKEQMRIQSLEKTVEQKTKENEELTRICDDLISKMEKIMGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGPDGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQVARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT T90286 DRUGINFO D0VF6E PD173074 Investigative T93798 TARGETID T93798 T93798 FORMERID TTDI03120 T93798 UNIPROID CNGA1_HUMAN T93798 TARGNAME Cyclic nucleotide-gated channel alpha-1 (CNGA1) T93798 GENENAME CNGA1 T93798 TARGTYPE Clinical trial T93798 SYNONYMS cGMP-gated cation channel alpha-1; Rod photoreceptor cGMP-gated channel subunit alpha; Cyclic nucleotide-gated channel, photoreceptor; Cyclic nucleotide-gated cation channel 1; CNG1; CNG-1; CNG channel alpha-1; CNCG1; CNCG T93798 FUNCTION Visual signal transduction is mediated by a G-protein coupled cascade using cGMP as second messenger. This protein can be activated by cyclic GMP which leads to an opening of the cation channel and thereby causing a depolarization of rod photoreceptors. T93798 SEQUENCE MKLSMKNNIINTQQSFVTMPNVIVPDIEKEIRRMENGACSSFSEDDDSASTSEESENENPHARGSFSYKSLRKGGPSQREQYLPGAIALFNVNNSSNKDQEPEEKKKKKKEKKSKSDDKNENKNDPEKKKKKKDKEKKKKEEKSKDKKEEEKKEVVVIDPSGNTYYNWLFCITLPVMYNWTMVIARACFDELQSDYLEYWLILDYVSDIVYLIDMFVRTRTGYLEQGLLVKEELKLINKYKSNLQFKLDVLSLIPTDLLYFKLGWNYPEIRLNRLLRFSRMFEFFQRTETRTNYPNIFRISNLVMYIVIIIHWNACVFYSISKAIGFGNDTWVYPDINDPEFGRLARKYVYSLYWSTLTLTTIGETPPPVRDSEYVFVVVDFLIGVLIFATIVGNIGSMISNMNAARAEFQARIDAIKQYMHFRNVSKDMEKRVIKWFDYLWTNKKTVDEKEVLKYLPDKLRAEIAINVHLDTLKKVRIFADCEAGLLVELVLKLQPQVYSPGDYICKKGDIGREMYIIKEGKLAVVADDGVTQFVVLSDGSYFGEISILNIKGSKAGNRRTANIKSIGYSDLFCLSKDDLMEALTEYPDAKTMLEEKGKQILMKDGLLDLNIANAGSDPKDLEEKVTRMEGSVDLLQTRFARILAEYESMQQKLKQRLTKVEKFLKPLIDTEFSSIEGPGAESGPIDST T93798 DRUGINFO D0I2FI dequalinium Clinical trial T93798 DRUGINFO D02NGU H-8 Investigative T93798 DRUGINFO D00YNI L-(cis)-diltiazem Investigative T54606 TARGETID T54606 T54606 UNIPROID LUKF_STAAU T54606 TARGNAME Staphylococcus Five leukocidin toxins (Stap-coc lukF) T54606 GENENAME Stap-coc lukF T54606 TARGTYPE Clinical trial T54606 SYNONYMS lukF T54606 FUNCTION Leukocidin causes cytotoxic changes in polymorphonuclear leukocytes. Gamma-hemolysin causes hemolysis in red blood cells. T54606 SEQUENCE MKMNKLVKSSVATSMALLLLSGTANAEGKITPVSVKKVDDKVTLYKTTATADSDKFKISQILTFNFIKDKSYDKDTLVLKATGNINSGFVKPNPNDYDFSKLYWGAKYNVSISSQSNDSVNAVDYAPKNQNEEFQVQNTLGYTFGGDISISNGLSGGLNGNTAFSETINYKQESYRTLSRNTNYKNVGWGVEAHKIMNGWGPYGRDSFHPTYGNELFLAGRQSSAYAGQNFIAQHQMPLLSRSNFNPEFLSVLSHRQDRAKKSKITVTYQREMDLYQIRWNGFYWAGANYKNFKTRTFKSTYEIDWENHKVKLLDTKETENNK T54606 DRUGINFO D0Z2NJ ASN100 Phase 2 T14463 TARGETID T14463 T14463 UNIPROID SOAT1_HUMAN; SOAT2_HUMAN T14463 TARGNAME Sterol O-acyltransferase (SOAT) T14463 GENENAME SOAT1; SOAT2 T14463 TARGTYPE Clinical trial T14463 SYNONYMS Cholesterol acyltransferase; Acyl-coenzyme A:cholesterol acyltransferase; ACAT; ACACT T14463 FUNCTION Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol. Plays a role in lipoprotein assembly and dietary cholesterol absorption. In addition to its acyltransferase activity, it may act as a ligase. May provide cholesteryl esters for lipoprotein secretion from hepatocytes and intestinal mucosa. T14463 SEQUENCE MVGEEKMSLRNRLSKSRENPEEDEDQRNPAKESLETPSNGRIDIKQLIAKKIKLTAEAEELKPFFMKEVGSHFDDFVTNLIEKSASLDNGGCALTTFSVLEGEKNNHRAKDLRAPPEQGKIFIARRSLLDELLEVDHIRTIYHMFIALLILFILSTLVVDYIDEGRLVLEFSLLSYAFGKFPTVVWTWWIMFLSTFSVPYFLFQHWATGYSKSSHPLIRSLFHGFLFMIFQIGVLGFGPTYVVLAYTLPPASRFIIIFEQIRFVMKAHSFVRENVPRVLNSAKEKSSTVPIPTVNQYLYFLFAPTLIYRDSYPRNPTVRWGYVAMKFAQVFGCFFYVYYIFERLCAPLFRNIKQEPFSARVLVLCVFNSILPGVLILFLTFFAFLHCWLNAFAEMLRFGDRMFYKDWWNSTSYSNYYRTWNVVVHDWLYYYAYKDFLWFFSKRFKSAAMLAVFAVSAVVHEYALAVCLSFFYPVLFVLFMFFGMAFNFIVNDSRKKPIWNVLMWTSLFLGNGVLLCFYSQEWYARQHCPLKNPTFLDYVRPRSWTCRYVF T14463 DRUGINFO D0MB2Z ATR-101 Phase 1 T58772 TARGETID T58772 T58772 FORMERID TTDNC00528 T58772 UNIPROID MTOR_HUMAN-RPTOR_HUMAN-LST8_HUMAN-AKTS1_HUMAN-DPTOR_HUMAN T58772 TARGNAME Mammalian target of rapamycin complex 1 (mTORC1) T58772 GENENAME MTOR-RPTORA-MLST8-KT1S1-DEPTOR T58772 TARGTYPE Clinical trial T58772 SYNONYMS mTORC1; Mechanistic target of rapamycin complex 1 T58772 FUNCTION Functions as a nutrient/energy/redox sensor and controls protein synthesis. Activate translation of proteins. Invovled in autophagy, lysosomal damage and reactive oxygen species. T58772 SEQUENCE MNTSPGTVGSDPVILATAGYDHTVRFWQAHSGICTRTVQHQDSQVNALEVTPDRSMIAAAGYQHIRMYDLNSNNPNPIISYDGVNKNIASVGFHEDGRWMYTGGEDCTARIWDLRSRNLQCQRIFQVNAPINCVCLHPNQAELIVGDQSGAIHIWDLKTDHNEQLIPEPEVSITSAHIDPDASYMAAVNSTGNCYVWNLTGGIGDEVTQLIPKTKIPAHTRYALQCRFSPDSTLLATCSADQTCKIWRTSNFSLMTELSIKSGNPGESSRGWMWGCAFSGDSQYIVTASSDNLARLWCVETGEIKREYGGHQKAVVCLAFNDSVLGMLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFWMESEMLQSPLLGLGEEDEADLTDWNLPLAFMKKRHCEKIEGSKSLAQSWRMKDRMKTVSVALVLCLNVGVDPPDVVKTTPCARLECWIDPLSMGPQKALETIGANLQKQYENWQPRARYKQSLDPTVDEVKKLCTSLRRNAKEERVLFHYNGHGVPRPTVNGEVWVFNKNYTQYIPLSIYDLQTWMGSPSIFVYDCSNAGLIVKSFKQFALQREQELEVAAINPNHPLAQMPLPPSMKNCIQLAACEATELLPMIPDLPADLFTSCLTTPIKIALRWFCMQKCVSLVPGVTLDLIEKIPGRLNDRRTPLGELNWIFTAITDTIAWNVLPRDLFQKLFRQDLLVASLFRNFLLAERIMRSYNCTPVSSPRLPPTYMHAMWQAWDLAVDICLSQLPTIIEEGTAFRHSPFFAEQLTAFQVWLTMGVENRNPPEQLPIVLQVLLSQVHRLRALDLLGRFLDLGPWAVSLALSVGIFPYVLKLLQSSARELRPLLVFIWAKILAVDSSCQADLVKDNGHKYFLSVLADPYMPAEHRTMTAFILAVIVNSYHTGQEACLQGNLIAICLEQLNDPHPLLRQWVAICLGRIWQNFDSARWCGVRDSAHEKLYSLLSDPIPEVRCAAVFALGTFVGNSAERTDHSTTIDHNVAMMLAQLVSDGSPMVRKELVVALSHLVVQYESNFCTVALQFIEEEKNYALPSPATTEGGSLTPVRDSPCTPRLRSVSSYGNIRAVATARSLNKSLQNLSLTEESGGAVAFSPGNLSTSSSASSTLGSPENEEHILSFETIDKMRRASSYSSLNSLIGVSFNSVYTQIWRVLLHLAADPYPEVSDVAMKVLNSIAYKATVNARPQRVLDTSSLTQSAPASPTNKGVHIHQAGGSPPASSTSSSSLTNDVAKQPVSRDLPSGRPGTTGPAGAQYTPHSHQFPRTRKMFDKGPEQTADDADDAAGHKSFISATVQTGFCDWSARYFAQPVMKIPEEHDLESQIRKEREWRFLRNSRVRRQAQQVIQKGITRLDDQIFLNRNPGVPSVVKFHPFTPCIAVADKDSICFWDWEKGEKLDYFHNGNPRYTRVTAMEYLNGQDCSLLLTATDDGAIRVWKNFADLEKNPEMVTAWQGLSDMLPTTRGAGMVVDWEQETGLLMSSGDVRIVRIWDTDREMKVQDIPTGADSCVTSLSCDSHRSLIVAGLGDGSIRVYDRRMALSECRVMTYREHTAWVVKASLQKRPDGHIVSVSVNGDVRIFDPRMPESVNVLQIVKGLTALDIHPQADLIACGSVNQFTAIYNSSGELINNIKYYDGFMGQRVGAISCLAFHPHWPHLAVGSNDYYISVYSVEKRVRMEEGGSTGSAGSDSSTSGSGGAQQRELERMAEVLVTGEQLRLRLHEEKVIKDRRHHLKTYPNCFVAKELIDWLIEHKEASDRETAIKLMQKLADRGIIHHVCDEHKEFKDVKLFYRFRKDDGTFPLDNEVKAFMRGQRLYEKLMSPENTLLQPREEEGVKYERTFMASEFLDWLVQEGEATTRKEAEQLCHRLMEHGIIQHVSNKHPFVDSNLLYQFRMNFRRRRRLMELLNEKSPSSQETHDSPFCLRKQSHDNRKSTSFMSVSPSKEIKIVSAVRRSSMSSCGSSGYFSSSPTLSSSPPVLCNPKSVLKRPVTSEELLTPGAPYARKTFTIVGDAVGWGFVVRGSKPCHIQAVDPSGPAAAAGMKVCQFVVSVNGLNVLHVDYRTVSNLILTGPRTIVMEVMEELECMASGRPEELWEAVVGAAERFRARTGTELVLLTAAPPPPPRPGPCAYAAHGRGALAEAARRCLHDIALAHRAATAARPPAPPPAPQPPSPTPSPPRPTLAREDNEEDEDEPTETETSGEQLGISDNGGLFVMDEDATLQDLPPFCESDPESTDDGSLSEETPAGPPTCSVPPASALPTQQYAKSLPVSVPVWGFKEKRTEARSSDEENGPPSSPDLDRIAASMRALVLREAEDTQVFGDLPRPRLNTSDFQKLKRKY T58772 DRUGINFO D0NO0K RBT-101 Phase 3 T58772 DRUGINFO D0Z2UQ AZD2014 Phase 2 T58772 DRUGINFO D03IXK ME-344 Phase 1/2 T58772 DRUGINFO DAT0U5 NV-5138 Phase 1 T58772 DRUGINFO DP17AI Palomid-529 Phase 1 T58772 DRUGINFO D0U3DP VS-5584 Phase 1 T00890 TARGETID T00890 T00890 FORMERID TTDI03253 T00890 UNIPROID HCAR3_HUMAN T00890 TARGNAME Hydroxycarboxylic acid receptor 3 (HCAR3) T00890 GENENAME HCAR3 T00890 TARGTYPE Clinical trial T00890 SYNONYMS Nicotinic acid receptor 2; Niacin receptor 2; NIACR2; HM74B; HCA3; GPR109B; G-protein coupled receptor HM74B; G-protein coupled receptor HM74; G-protein coupled receptor 109B T00890 FUNCTION Receptor for 3-OH-octanoid acid mediates a negative feedback regulation of adipocyte lipolysis to counteract prolipolytic influences under conditions of physiological or pathological increases in beta-oxidation rates. Acts as a low affinity receptor for nicotinic acid. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. T00890 SEQUENCE MNRHHLQDHFLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWKSSRIFLFNLAVADFLLIICLPFVMDYYVRRSDWKFGDIPCRLVLFMFAMNRQGSIIFLTVVAVDRYFRVVHPHHALNKISNWTAAIISCLLWGITVGLTVHLLKKKLLIQNGTANVCISFSICHTFRWHEAMFLLEFFLPLGIILFCSARIIWSLRQRQMDRHAKIKRAITFIMVVAIVFVICFLPSVVVRIHIFWLLHTSGTQNCEVYRSVDLAFFITLSFTYMNSMLDPVVYYFSSPSFPNFFSTLINRCLQRKITGEPDNNRSTSVELTGDPNKTRGAPEALIANSGEPWSPSYLGPTSNNHSKKGHCHQEPASLEKQLGCCIE T00890 DRUGINFO D01VMZ ARI-3037MO Phase 2 T00890 DRUGINFO D0V0WE NIA-114 Clinical trial T00890 DRUGINFO D00FTQ 3-hydroxyoctanoic acid Investigative T00890 DRUGINFO D02GRY PMID17358052C5b Investigative T00890 DRUGINFO D08CBB D-tryptophan Investigative T00890 DRUGINFO D09DXN D-kynurenine Investigative T00890 DRUGINFO D0J7LY 5-methyl-5-(5-methylthiophen-3-yl)-4-oxo-4,5-dihydrofuran-2-carboxylic acid Investigative T00890 DRUGINFO D0K3LQ 4-(n-propyl)amino-3-nitrobenzoic acid Investigative T00890 DRUGINFO D0Q3QI 2-hydroxyoctanoic acid Investigative T00890 DRUGINFO D0T2KY PMID19524438C6o Investigative T00890 DRUGINFO D0VE9G IBC 293 Investigative T28385 TARGETID T28385 T28385 FORMERID TTDI02352 T28385 UNIPROID CAD11_HUMAN T28385 TARGNAME Osteoblast cadherin (CDH11) T28385 GENENAME CDH11 T28385 TARGTYPE Clinical trial T28385 SYNONYMS OSF4; OSF-4; OBcadherin; OB-cadherin; Cadherin-11 T28385 FUNCTION Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. T28385 SEQUENCE MKENYCLQAALVCLGMLCHSHAFAPERRGHLRPSFHGHHEKGKEGQVLQRSKRGWVWNQFFVIEEYTGPDPVLVGRLHSDIDSGDGNIKYILSGEGAGTIFVIDDKSGNIHATKTLDREERAQYTLMAQAVDRDTNRPLEPPSEFIVKVQDINDNPPEFLHETYHANVPERSNVGTSVIQVTASDADDPTYGNSAKLVYSILEGQPYFSVEAQTGIIRTALPNMDREAKEEYHVVIQAKDMGGHMGGLSGTTKVTITLTDVNDNPPKFPQSVYQMSVSEAAVPGEEVGRVKAKDPDIGENGLVTYNIVDGDGMESFEITTDYETQEGVIKLKKPVDFETKRAYSLKVEAANVHIDPKFISNGPFKDTVTVKISVEDADEPPMFLAPSYIHEVQENAAAGTVVGRVHAKDPDAANSPIRYSIDRHTDLDRFFTINPEDGFIKTTKPLDREETAWLNITVFAAEIHNRHQEAKVPVAIRVLDVNDNAPKFAAPYEGFICESDQTKPLSNQPIVTISADDKDDTANGPRFIFSLPPEIIHNPNFTVRDNRDNTAGVYARRGGFSRQKQDLYLLPIVISDGGIPPMSSTNTLTIKVCGCDVNGALLSCNAEAYILNAGLSTGALIAILACIVILLVIVVLFVTLRRQKKEPLIVFEEEDVRENIITYDDEGGGEEDTEAFDIATLQNPDGINGFIPRKDIKPEYQYMPRPGLRPAPNSVDVDDFINTRIQEADNDPTAPPYDSIQIYGYEGRGSVAGSLSSLESATTDSDLDYDYLQNWGPRFKKLADLYGSKDTFDDDS T28385 DRUGINFO D0X8RS RG6125 Phase 1 T16738 TARGETID T16738 T16738 FORMERID TTDNR00732 T16738 UNIPROID DLK1_HUMAN T16738 TARGNAME Protein delta homolog 1 (DLK1) T16738 GENENAME DLK1 T16738 TARGTYPE Clinical trial T16738 SYNONYMS pG2; DLK-1 T16738 FUNCTION May have a role in neuroendocrine differentiation. T16738 SEQUENCE MTATEALLRVLLLLLAFGHSTYGAECFPACNPQNGFCEDDNVCRCQPGWQGPLCDQCVTSPGCLHGLCGEPGQCICTDGWDGELCDRDVRACSSAPCANNRTCVSLDDGLYECSCAPGYSGKDCQKKDGPCVINGSPCQHGGTCVDDEGRASHASCLCPPGFSGNFCEIVANSCTPNPCENDGVCTDIGGDFRCRCPAGFIDKTCSRPVTNCASSPCQNGGTCLQHTQVSYECLCKPEFTGLTCVKKRALSPQQVTRLPSGYGLAYRLTPGVHELPVQQPEHRILKVSMKELNKKTPLLTEGQAICFTILGVLTSLVVLGTVGIVFLNKCETWVSNLRYNHMLRKKKNLLLQYNSGEDLAVNIIFPEKIDMTTFSKEAGDEEI T16738 DRUGINFO D0Y1FU GDC0134 Phase 1 T61683 TARGETID T61683 T61683 FORMERID TTDI01686 T61683 UNIPROID XIAP_HUMAN; BIRC2_HUMAN; BIRC3_HUMAN; BIRC1_HUMAN; BIRC7_HUMAN; BIRC5_HUMAN T61683 TARGNAME Inhibitor of apoptosis protein (hIAP) T61683 GENENAME XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7 T61683 TARGTYPE Clinical trial T61683 SYNONYMS Baculoviral IAP repeat-containing protein T61683 FUNCTION A class of key apoptosis regulators. Influences a multitude of other cellular processes, such as ubiquitin (Ub) dependent signaling events that regulate activation of nuclear factor B (NFB), which in turn drive the expression of genes important for inflammation, immunity, cell migration and cell survival. Modulates signaling events that promote the activation of cell motility kinases and metastasis11 and they regulate mitogenic kinase signaling, proliferation and mitosis. T61683 SEQUENCE MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDTVRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENYLGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLTPRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSESDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTPSLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKDSMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDKCPMCYTVITFKQKIFMS T61683 DRUGINFO D03MXK AT-406 Phase 3 T61683 DRUGINFO D09MIN LCL161 Phase 2 T61683 DRUGINFO D0NP8P APG-1387 Phase 1 T86992 TARGETID T86992 T86992 FORMERID TTDNC00457 T86992 UNIPROID PPE42_MYCTU-ESXV_MYCTU-ESXW_MYCTU-Y1813_MYCTU T86992 TARGNAME Mycobacterium Fusion protein Rv2608-Rv3619-Rv3620-Rv1813 (MycB antigens) T86992 GENENAME MycB antigens T86992 TARGTYPE Clinical trial T86992 SYNONYMS Mycobacterium Fusion protein PPE42-esxV-esxW-MTY16F9.01 T86992 FUNCTION Invovled in immune response. T86992 SEQUENCE MTSRFMTDPHAMRDMAGRFEVHAQTVEDEARRMWASAQNISGAGWSGMAEATSLDTMTQMNQAFRNIVNMLHGVRDGLVRDANNYEQQEQASQQILSSMTINYQFGDVDAHGAMIRAQAGSLEAEHQAIISDVLTASDFWGGAGSAACQGFITQLGRNFQVIYEQANAHGQKVQAAGNNMAQTDSAVGSSWAMNFAVLPPEVNSARIFAGAGLGPMLAAASAWDGLAEELHAAAGSFASVTTGLAGDAWHGPASLAMTRAASPYVGWLNTAAGQAAQAAGQARLAASAFEATLAATVSPAMVAANRTRLASLVAANLLGQNAPAIAAAEAEYEQIWAQDVAAMFGYHSAASAVATQLAPIQEGLQQQLQNVLAQLASGNLGSGNVGVGNIGNDNIGNANIGFGNRGDANIGIGNIGDRNLGIGNTGNWNIGIGITGNGQIGFGKPANPDVLVVGNGGPGVTALVMGGTDSLLPLPNIPLLEYAARFITPVHPGYTATFLETPSQFFPFTGLNSLTYDVSVAQGVTNLHTAIMAQLAAGNEVVVFGTSQSATIATFEMRYLQSLPAHLRPGLDELSFTLTGNPNRPDGGILTRFGFSIPQLGFTLSGATPADAYPTVDYAFQYDGVNDFPKYPLNVFATANAIAGILFLHSGLIALPPDLASGVVQPVSSPDVLTTYILLPSQDLPLLVPLRAIPLLGNPLADLIQPDLRVLVELGYDRTAHQDVPSPFGLFPDVDWAEVAADLQQGAVQGVNDALSGLGLPPPWQPALPRLFMITNLRRRTAMAAAGLGAALGLGILLVPTVDAHLANGSMSEVMMSEIAGLPIPPIIHYGAIAYAPSGASGKAWHQRTPARAEQVALEKCGDKTCKVVSRFTRCGAVAYNGSKYQGGTGLTRRAAEDDAVNRLEGGRIVNWACN T86992 DRUGINFO D01KQW ID-93/GLA-SE Phase 2 T03410 TARGETID T03410 T03410 FORMERID TTDI02125 T03410 UNIPROID MMPL3_MYCTU T03410 TARGNAME Mycobacterium Membrane protein mmpL3 (MycB mmpL3) T03410 GENENAME MycB mmpL3 T03410 TARGTYPE Clinical trial T03410 SYNONYMS Trehalose monomycolate exporter MmpL3; TMM exporter MmpL3 T03410 FUNCTION Transports trehalose monomycolate (TMM) across the inner membrane. Could also be part of a heme-iron acquisition system. T03410 SEQUENCE MFAWWGRTVYRYRFIVIGVMVALCLGGGVFGLSLGKHVTQSGFYDDGSQSVQASVLGDQVYGRDRSGHIVAIFQAPAGKTVDDPAWSKKVVDELNRFQQDHPDQVLGWAGYLRASQATGMATADKKYTFVSIPLKGDDDDTILNNYKAIAPDLQRLDGGTVKLAGLQPVAEALTGTIATDQRRMEVLALPLVAVVLFFVFGGVIAAGLPVMVGGLCIAGALGIMRFLAIFGPVHYFAQPVVSLIGLGIAIDYGLFIVSRFREEIAEGYDTETAVRRTVITAGRTVTFSAVLIVASAIGLLLFPQGFLKSLTYATIASVMLSAILSITVLPACLGILGKHVDALGVRTLFRVPFLANWKISAAYLNWLADRLQRTKTREEVEAGFWGKLVNRVMKRPVLFAAPIVIIMILLIIPVGKLSLGGISEKYLPPTNSVRQAQEEFDKLFPGYRTNPLTLVIQTSNHQPVTDAQIADIRSKAMAIGGFIEPDNDPANMWQERAYAVGASKDPSVRVLQNGLINPADASKKLTELRAITPPKGITVLVGGTPALELDSIHGLFAKMPLMVVILLTTTIVLMFLAFGSVVLPIKATLMSALTLGSTMGILTWIFVDGHFSKWLNFTPTPLTAPVIGLIIALVFGLSTDYEVFLVSRMVEARERGMSTQEAIRIGTAATGRIITAAALIVAVVAGAFVFSDLVMMKYLAFGLMAALLLDATVVRMFLVPSVMKLLGDDCWWAPRWARRLQTRIGLGEIHLPDERKRPVSNGRPARPPVTAGLVAARAAGDPRPPHDPTHPLAESPRPARSSPASSPELTPALEATAAPAAPSGASTTRMQIGSSTEPPTTRLAAAGRSVQSPASTPPPTPTPPSAPSAGQTRAMPLAANRSTDAAGDPAEPTAALPIIRSDGDDSEAATEQLNARGTSDKTRQRRRGGGALSAQDLLRREGRL T03410 DRUGINFO D0K8DI SQ-109 Phase 2 T03410 DRUGINFO D0D4VH BM-212 Phase 1 T01447 TARGETID T01447 T01447 UNIPROID ULA1_HUMAN; UBA3_HUMAN T01447 TARGNAME NEDD8-activating enzyme (NAE) T01447 GENENAME NAE1; UBA3 T01447 TARGTYPE Clinical trial T01447 SYNONYMS NEDD8-activating enzyme E1 T01447 FUNCTION Subunit of the dimeric UBA3-NAE1 E1 enzyme. E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Necessary for cell cycle progression. T01447 SEQUENCE MAQLGKLLKEQKYDRQLRLWGDHGQEALESAHVCLINATATGTEILKNLVLPGIGSFTIIDGNQVSGEDAGNNFFLQRSSIGKNRAEAAMEFLQELNSDVSGSFVEESPENLLDNDPSFFCRFTVVVATQLPESTSLRLADVLWNSQIPLLICRTYGLVGYMRIIIKEHPVIESHPDNALEDLRLDKPFPELREHFQSYDLDHMEKKDHSHTPWIVIIAKYLAQWYSETNGRIPKTYKEKEDFRDLIRQGILKNENGAPEDEENFEEAIKNVNTALNTTQIPSSIEDIFNDDRCINITKQTPSFWILARALKEFVAKEGQGNLPVRGTIPDMIADSGKYIKLQNVYREKAKKDAAAVGNHVAKLLQSIGQAPESISEKELKLLCSNSAFLRVVRCRSLAEEYGLDTINKDEIISSMDNPDNEIVLYLMLRAVDRFHKQQGRYPGVSNYQVEEDIGKLKSCLTGFLQEYGLSVMVKDDYVHEFCRYGAAEPHTIAAFLGGAAAQEVIKIITKQFVIFNNTYIYSGMSQTSATFQL T01447 DRUGINFO D0ZD2M MLN4924 Phase 3 T85581 TARGETID T85581 T85581 FORMERID TTDI01811 T85581 UNIPROID S12A1_HUMAN; S12A2_HUMAN T85581 TARGNAME Na-K-Cl cotransporter (NKCC) T85581 GENENAME SLC12A1; SLC12A2 T85581 TARGTYPE Clinical trial T85581 SYNONYMS Solute carrier family 12; Na-K-Cl symporter; NKCC; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter T85581 FUNCTION Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume. T85581 SEQUENCE MSLNNSSNVFLDSVPSNTNRFQVSVINENHESSAAADDNTDPPHYEETSFGDEAQKRLRISFRPGNQECYDNFLQSGETAKTDASFHAYDSHTNTYYLQTFGHNTMDAVPKIEYYRNTGSISGPKVNRPSLLEIHEQLAKNVAVTPSSADRVANGDGIPGDEQAENKEDDQAGVVKFGWVKGVLVRCMLNIWGVMLFIRLSWIVGEAGIGLGVLIILLSTMVTSITGLSTSAIATNGFVRGGGAYYLISRSLGPEFGGSIGLIFAFANAVAVAMYVVGFAETVVDLLKESDSMMVDPTNDIRIIGSITVVILLGISVAGMEWEAKAQVILLVILLIAIANFFIGTVIPSNNEKKSRGFFNYQASIFAENFGPRFTKGEGFFSVFAIFFPAATGILAGANISGDLEDPQDAIPRGTMLAIFITTVAYLGVAICVGACVVRDATGNMNDTIISGMNCNGSAACGLGYDFSRCRHEPCQYGLMNNFQVMSMVSGFGPLITAGIFSATLSSALASLVSAPKVFQALCKDNIYKALQFFAKGYGKNNEPLRGYILTFLIAMAFILIAELNTIAPIISNFFLASYALINFSCFHASYAKSPGWRPAYGIYNMWVSLFGAVLCCAVMFVINWWAAVITYVIEFFLYVYVTCKKPDVNWGSSTQALSYVSALDNALELTTVEDHVKNFRPQCIVLTGGPMTRPALLDITHAFTKNSGLCICCEVFVGPRKLCVKEMNSGMAKKQAWLIKNKIKAFYAAVAADCFRDGVRSLLQASGLGRMKPNTLVIGYKKNWRKAPLTEIENYVGIIHDAFDFEIGVVIVRISQGFDISQVLQVQEELERLEQERLALEATIKDNECEEESGGIRGLFKKAGKLNITKTTPKKDGSINTSQSMHVGEFNQKLVEASTQFKKKQEKGTIDVWWLFDDGGLTLLIPYILTLRKKWKDCKLRIYVGGKINRIEEEKIVMASLLSKFRIKFADIHIIGDINIRPNKESWKVFEEMIEPYRLHESCKDLTTAEKLKRETPWKITDAELEAVKEKSYRQVRLNELLQEHSRAANLIVLSLPVARKGSISDLLYMAWLEILTKNLPPVLLVRGNHKNVLTFYS T85581 DRUGINFO D0D1ZS CLP-1001 Phase 2 T84591 TARGETID T84591 T84591 UNIPROID EI2BA_HUMAN; EI2BB_HUMAN T84591 TARGNAME Guanine nucleotide exchange factor (GNEF) T84591 GENENAME EIF2B1; EIF2B2 T84591 TARGTYPE Clinical trial T84591 SYNONYMS eIF-2B GDP-GTP exchange factor; Translation initiation factor eIF-2B; EIF2B T84591 FUNCTION Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP. T84591 SEQUENCE MDDKELIEYFKSQMKEDPDMASAVAAIRTLLEFLKRDKGETIQGLRANLTSAIETLCGVDSSVAVSSGGELFLRFISLASLEYSDYSKCKKIMIERGELFLRRISLSRNKIADLCHTFIKDGATILTHAYSRVVLRVLEAAVAAKKRFSVYVTESQPDLSGKKMAKALCHLNVPVTVVLDAAVGYIMEKADLVIVGAEGVVENGGIINKIGTNQMAVCAKAQNKPFYVVAESFKFVRLFPLNQQDVPDKFKYKADTLKVAQTGQDLKEEHPWVDYTAPSLITLLFTDLGVLTPSAVSDELIKLYL T84591 DRUGINFO D0ZE1O Plinabulin Phase 3 T34204 TARGETID T34204 T34204 FORMERID TTDI03121 T34204 UNIPROID CNGA2_HUMAN T34204 TARGNAME Cyclic nucleotide-gated channel alpha-2 (CNGA2) T34204 GENENAME CNGA2 T34204 TARGTYPE Clinical trial T34204 SYNONYMS Cyclic nucleotide-gated olfactory channel; Cyclic nucleotide-gated cation channel 2; CNG2; CNG-2; CNG channel alpha-2; CNCG2; CNCA1; CNCA T34204 FUNCTION Odorant signal transduction is probably mediated by a G-protein coupled cascade using cAMP as second messenger. The olfactory channel can be shown to be activated by cyclic nucleotides which leads to a depolarization of olfactory sensory neurons. T34204 SEQUENCE MTEKTNGVKSSPANNHNHHAPPAIKANGKDDHRTSSRPHSAADDDTSSELQRLADVDAPQQGRSGFRRIVRLVGIIREWANKNFREEEPRPDSFLERFRGPELQTVTTQEGDGKGDKDGEDKGTKKKFELFVLDPAGDWYYCWLFVIAMPVLYNWCLLVARACFSDLQKGYYLVWLVLDYVSDVVYIADLFIRLRTGFLEQGLLVKDTKKLRDNYIHTLQFKLDVASIIPTDLIYFAVDIHSPEVRFNRLLHFARMFEFFDRTETRTNYPNIFRISNLVLYILVIIHWNACIYYAISKSIGFGVDTWVYPNITDPEYGYLAREYIYCLYWSTLTLTTIGETPPPVKDEEYLFVIFDFLIGVLIFATIVGNVGSMISNMNATRAEFQAKIDAVKHYMQFRKVSKGMEAKVIRWFDYLWTNKKTVDEREILKNLPAKLRAEIAINVHLSTLKKVRIFHDCEAGLLVELVLKLRPQVFSPGDYICRKGDIGKEMYIIKEGKLAVVADDGVTQYALLSAGSCFGEISILNIKGSKMGNRRTANIRSLGYSDLFCLSKDDLMEAVTEYPDAKKVLEERGREILMKEGLLDENEVATSMEVDVQEKLGQLETNMETLYTRFGRLLAEYTGAQQKLKQRITVLETKMKQNNEDDYLSDGMNSPELAAADEP T34204 DRUGINFO D0I2FI dequalinium Clinical trial T34204 DRUGINFO D05SOU all-trans-retinal Investigative T34204 DRUGINFO D0S3UR PIP3 Investigative T34204 DRUGINFO D00YNI L-(cis)-diltiazem Investigative T71205 TARGETID T71205 T71205 UNIPROID CL12A_HUMAN T71205 TARGNAME Myeloid inhibitory C-type lectin-like receptor (CD371) T71205 GENENAME CLEC12A T71205 TARGTYPE Clinical trial T71205 SYNONYMS MICL; Dendritic cell-associated lectin 2; DCAL2; DCAL-2; CLL1; CLL-1; C-type lectin-like molecule 1; C-type lectin domain family 12 member A T71205 FUNCTION Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. T71205 SEQUENCE MSEEVTYADLQFQNSSEMEKIPEIGKFGEKAPPAPSHVWRPAALFLTLLCLLLLIGLGVLASMFHVTLKIEMKKMNKLQNISEELQRNISLQLMSNMNISNKIRNLSTTLQTIATKLCRELYSKEQEHKCKPCPRRWIWHKDSCYFLSDDVQTWQESKMACAAQNASLLKINNKNALEFIKSQSRSYDYWLGLSPEEDSTRGMRVDNIINSSAWVIRNAPDLNNMYCGYINRLYVQYYHCTYKKRMICEKMANPVQLGSTYFREA T71205 DRUGINFO D0RF4J CLL1 CAR-T Cell Phase 2/3 T71205 DRUGINFO D04GGG CD123/CLL1 CAR-T Cells Phase 2/3 T71205 DRUGINFO D00QWK CLL1-specific gene-engineered T cells Phase 1/2 T71205 DRUGINFO D0DO8E CAR-T cells targeting CLL1 Phase 1/2 T71205 DRUGINFO D4UQ2B KITE-222 Phase 1 T71205 DRUGINFO DW01LJ CLT030 Phase 1 T71205 DRUGINFO D2Q3VY Tepoditamab Phase 1 T71205 DRUGINFO D5T9GZ CLL1-CD33 cCART cell therapy Phase 1 T71205 DRUGINFO DIW58H UCART-CLL1 Preclinical T84439 TARGETID T84439 T84439 FORMERID TTDI03232 T84439 UNIPROID GP139_HUMAN T84439 TARGNAME G-protein-coupled receptor PGR3 (GPR139) T84439 GENENAME GPR139 T84439 TARGTYPE Clinical trial T84439 SYNONYMS Probable G-protein coupled receptor 139; PGR3; GPRG1; G(q)-coupled orphan receptor GPRg1 T84439 FUNCTION Orphan receptor. Seems to act through a G(q/11)-mediated pathway. T84439 SEQUENCE MEHTHAHLAANSSLSWWSPGSACGLGFVPVVYYSLLLCLGLPANILTVIILSQLVARRQKSSYNYLLALAAADILVLFFIVFVDFLLEDFILNMQMPQVPDKIIEVLEFSSIHTSIWITVPLTIDRYIAVCHPLKYHTVSYPARTRKVIVSVYITCFLTSIPYYWWPNIWTEDYISTSVHHVLIWIHCFTVYLVPCSIFFILNSIIVYKLRRKSNFRLRGYSTGKTTAILFTITSIFATLWAPRIIMILYHLYGAPIQNRWLVHIMSDIANMLALLNTAINFFLYCFISKRFRTMAAATLKAFFKCQKQPVQFYTNHNFSITSSPWISPANSHCIKMLVYQYDKNGKPIKVSP T84439 DRUGINFO D01GTC TAK-041 Phase 1 T84439 DRUGINFO D04ZMM PMID24900311C1a Investigative T98196 TARGETID T98196 T98196 FORMERID TTDI01314 T98196 UNIPROID MOCS1_HUMAN T98196 TARGNAME Cyclic pyranopterin monophosphate synthase (MOCS1) T98196 GENENAME MOCS1 T98196 TARGTYPE Clinical trial T98196 SYNONYMS Molybdenum cofactor synthesis-step 1 protein A-B (414-636); Molybdenum cofactor biosynthesis protein 1 (414-636); MOCS1 (414-636); MIG11 (414-636); Cell migration-inducing gene 11 protein (414-636) T98196 FUNCTION MOCS1A catalyzes the cyclization of GTP to (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate and MOCS1B catalyzes the subsequent conversion of (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate to cPMP. Isoform MOCS1A and isoform MOCS1B probably form a complex that catalyzes the conversion of 5'-GTP to cyclic pyranopterin monophosphate (cPMP). T98196 SEQUENCE MAARPLSRMLRRLLRSSARSCSSGAPVTQPCPGESARAASEEVSRRRQFLREHAAPFSAFLTDSFGRQHSYLRISLTEKCNLRCQYCMPEEGVPLTPKANLLTTEEILTLARLFVKEGIDKIRLTGGEPLIRPDVVDIVAQLQRLEGLRTIGVTTNGINLARLLPQLQKAGLSAINISLDTLVPAKFEFIVRRKGFHKVMEGIHKAIELGYNPVKVNCVVMRGLNEDELLDFAALTEGLPLDVRFIEYMPFDGNKWNFKKMVSYKEMLDTVRQQWPELEKVPEEESSTAKAFKIPGFQGQISFITSMSEHFCGTCNRLRITADGNLKVCLFGNSEVSLRDHLRAGASEQELLRIIGAAVGRKKRQHAGMFSISQMKNRPMILIELFLMFPNSPPANPSIFSWDPLHVQGLRPRMSFSSQVATLWKGCRVPQTPPLAQQRLGSGSFQRHYTSRADSDANSKCLSPGSWASAAPSGPQLTSEQLTHVDSEGRAAMVDVGRKPDTERVAVASAVVLLGPVAFKLVQQNQLKKGDALVVAQLAGVQAAKVTSQLIPLCHHVALSHIQVQLELDSTRHAVKIQASCRARGPTGVEMEALTSAAVAALTLYDMCKAVSRDIVLEEIKLISKTGGQRGDFHRA T98196 DRUGINFO D01AKK ALXN1101 Phase 2/3 T66093 TARGETID T66093 T66093 FORMERID TTDI02264 T66093 TARGNAME Hepatitis C virus microRNA miR-122 (HCV MIR122) T66093 TARGTYPE Clinical trial T66093 BIOCLASS Non-coding RNA target T66093 DRUGINFO D0O6DE RG-101 Phase 2 T66093 DRUGINFO D0SQ2K Miravirsen Phase 2 T88483 TARGETID T88483 T88483 TARGNAME microRNA hsa-miR-155 (MIR155) T88483 TARGTYPE Clinical trial T88483 BIOCLASS Non-coding RNA target T88483 DRUGINFO D0P9XM Cobomarsen Phase 2 T88483 DRUGINFO D08WZQ MRG-201 Phase 2 T51803 TARGETID T51803 T51803 FORMERID TTDI02263 T51803 TARGNAME microRNA hsa-miR-34 (MIR34) T51803 TARGTYPE Clinical trial T51803 BIOCLASS Non-coding RNA target T51803 DRUGINFO D08SJY MRX34 Phase 1 T71164 TARGETID T71164 T71164 FORMERID TTDI01230 T71164 TARGNAME Ganglioside GD2 (GD2) T71164 TARGTYPE Clinical trial T71164 SYNONYMS Ganglioside G2; GD2 T71164 DRUGINFO D06EVZ Anti-GD2 CART Phase 2 T71164 DRUGINFO D0R4UA Hu3F8 mAb Phase 2 T71164 DRUGINFO DG5K6D APN301 Phase 2 T71164 DRUGINFO DI57MF Nivatrotamab Phase 2 T71164 DRUGINFO D01YCF 4SCAR-GD2 Phase 1/2 T71164 DRUGINFO D06TWS CAR-T cells targeting CD2 Phase 1/2 T71164 DRUGINFO D0E1ST CAR-T cells targeting GD2 Phase 1/2 T71164 DRUGINFO D0MA4F GD2-CART01 Phase 1/2 T71164 DRUGINFO D0S4GT CAR-T cells targeting GD2 Phase 1/2 T71164 DRUGINFO D01SFN IC9-GD2-CD28-OX40 Phase 1 T71164 DRUGINFO D04UNY Anti-GD2 T-cells (1RG-CART) Phase 1 T71164 DRUGINFO D09DND Anti-GD2-CAR engineered T cells Phase 1 T71164 DRUGINFO D0DA1U C7R-GD2.CART cells Phase 1 T71164 DRUGINFO D0H0LK IC9.GD2.CAR.IL-15 T-cells Phase 1 T71164 DRUGINFO D0Q5QV MVT-5873 Phase 1 T71164 DRUGINFO D0QB7N GD2 T cells Phase 1 T71164 DRUGINFO D7AFK9 KUR-501 Phase 1 T71164 DRUGINFO D0RI8E GD2-targeted CAR-T cells Clinical trial T72737 TARGETID T72737 T72737 FORMERID TTDI01277 T72737 TARGNAME Cytomegalovirus Deoxyribonucleic acid (CMV DNA) T72737 TARGTYPE Clinical trial T72737 DRUGINFO D0S4WA ASP0113 Phase 3 T99566 TARGETID T99566 T99566 FORMERID TTDI01220 T99566 TARGNAME Free radical (FRD) T99566 TARGTYPE Clinical trial T99566 DRUGINFO D0F3WG Disufenton sodium Phase 3 T99566 DRUGINFO D0X8TS RRx-001 Phase 3 T99566 DRUGINFO D03ZDX SM-88 Phase 2/3 T01822 TARGETID T01822 T01822 FORMERID TTDI01208 T01822 TARGNAME Haematin (HA) T01822 TARGTYPE Clinical trial T01822 DRUGINFO D0I6YM Ferroquine Phase 2 T74034 TARGETID T74034 T74034 FORMERID TTDI01225 T74034 TARGNAME Hepatitis C virus Deoxyribonucleic acid (HCV DNA) T74034 TARGTYPE Clinical trial T74034 DRUGINFO D0V5LG ChronVac-C hepatitis C DNA vaccine Phase 1/2 T48470 TARGETID T48470 T48470 FORMERID TTDI01237 T48470 TARGNAME Hormone unspecific (HOM) T48470 TARGTYPE Clinical trial T48470 DRUGINFO D03KJU NV-04 Phase 1 T48470 DRUGINFO D0ZB2E NV-07a Investigative T29525 TARGETID T29525 T29525 FORMERID TTDI01153 T29525 TARGNAME Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA) T29525 TARGTYPE Clinical trial T29525 DRUGINFO D09ZSY CI-1012 Phase 2 T29525 DRUGINFO D05UJF PBSVax Phase 1 T88479 TARGETID T88479 T88479 TARGNAME Malondialdehyde (MDA) T88479 TARGTYPE Clinical trial T88479 DRUGINFO D0ZG3S Reproxalap Phase 3 T91450 TARGETID T91450 T91450 FORMERID TTDI01998 T91450 TARGNAME Poly-N-acetyl glucosamine (PNAG) T91450 TARGTYPE Clinical trial T91450 DRUGINFO D00MTG SAR279356 Phase 2 T59955 TARGETID T59955 T59955 FORMERID TTDI01183 T59955 TARGNAME Progesterone (PG) T59955 TARGTYPE Clinical trial T59955 DRUGINFO D0L3HU BAY 86-5044 Phase 2 T59955 DRUGINFO D0C5KG ORG-33628 Discontinued in Phase 2 T25698 TARGETID T25698 T25698 TARGNAME Pseudomonas Lipopolysaccharide (Pseudo LPS) T25698 TARGTYPE Clinical trial T25698 DRUGINFO D03PSP Panobacumab Phase 2 T22295 TARGETID T22295 T22295 FORMERID TTDI01711 T22295 TARGNAME Staphylococcus Capsular polysaccharide CP5 (Stap-coc CP5) T22295 TARGTYPE Clinical trial T22295 DRUGINFO D01DXI PF-06290510 Phase 2 T67058 TARGETID T67058 T67058 FORMERID TTDI01711 T67058 TARGNAME Staphylococcus Capsular polysaccharide CP8 (Stap-coc CP8) T67058 TARGTYPE Clinical trial T67058 DRUGINFO D01DXI PF-06290510 Phase 2 T26327 TARGETID T26327 T26327 FORMERID TTDI01185 T26327 TARGNAME Superoxide anion (SPA) T26327 TARGTYPE Clinical trial T26327 DRUGINFO D0F4RX OPC-14117 Phase 1 T28887 TARGETID T28887 T28887 FORMERID TTDR01337 T28887 UNIPROID HDAC8_HUMAN T28887 TARGNAME Histone deacetylase 8 (HDAC8) T28887 GENENAME HDAC8 T28887 TARGTYPE Clinical trial T28887 SYNONYMS Histone deacetylase-8; HDACL1; HD8; CDA07 T28887 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Also involved in the deacetylation of cohesin complex protein SMC3 regulating release of cohesin complexes from chromatin. May play a role in smooth muscle cell contractility. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). T28887 PDBSTRUC 6HSK; 5VI6; 5THV; 5THU; 5THT T28887 BIOCLASS Carbon-nitrogen hydrolase T28887 ECNUMBER EC 3.5.1.98 T28887 SEQUENCE MEEPEEPADSGQSLVPVYIYSPEYVSMCDSLAKIPKRASMVHSLIEAYALHKQMRIVKPKVASMEEMATFHTDAYLQHLQKVSQEGDDDHPDSIEYGLGYDCPATEGIFDYAAAIGGATITAAQCLIDGMCKVAINWSGGWHHAKKDEASGFCYLNDAVLGILRLRRKFERILYVDLDLHHGDGVEDAFSFTSKVMTVSLHKFSPGFFPGTGDVSDVGLGKGRYYSVNVPIQDGIQDEKYYQICESVLKEVYQAFNPKAVVLQLGADTIAGDPMCSFNMTPVGIGKCLKYILQWQLATLILGGGGYNLANTARCWTYLTGVILGKTLSSEIPDHEFFTAYGPDYVLEITPSCRPDRNEPHRIQQILNYIKGNLKHVV T28887 DRUGINFO D0SOG8 NBM-BMX Phase 1 T28887 DRUGINFO D04UGJ PMID29671355-Compound-37 Patented T28887 DRUGINFO D04JWR PMID29671355-Compound-36 Patented T28887 DRUGINFO D0GD6R PMID29671355-Compound-68b Patented T28887 DRUGINFO D0ZG5X PMID29671355-Compound-13 Patented T28887 DRUGINFO D0JB4S PMID29671355-Compound-61 Patented T28887 DRUGINFO D00HXJ PMID29671355-Compound-23 Patented T28887 DRUGINFO D0N2DK PMID29671355-Compound-44 Patented T28887 DRUGINFO D0CH8Q PMID29671355-Compound-56 Patented T28887 DRUGINFO D0M0RE PMID29671355-Compound-67 Patented T28887 DRUGINFO D0DI9S PMID29671355-Compound-31 Patented T28887 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T28887 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T28887 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T28887 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T28887 DRUGINFO D00DQZ S-2,9-dioxo-9-(phenylamino)nonyl ethanethioate Investigative T28887 DRUGINFO D01BCK N-hydroxy-1-naphthamide Investigative T28887 DRUGINFO D05PTL NMB-T-BMX-OS01 Investigative T28887 DRUGINFO D09LVY 9-mercapto-8-oxo-N-phenylnonanamide Investigative T28887 DRUGINFO D0P3SU N-hydroxy-3-phenoxybenzamide Investigative T28887 DRUGINFO D0Q5MC PCI-34051 Investigative T28887 DRUGINFO D0R2HF 6-(2-mercaptoacetamido)-N-phenylhexanamide Investigative T28887 DRUGINFO D0V1HA N-hydroxy-3-(naphthalen-1-yl)acrylamide Investigative T28887 DRUGINFO D03HNC N-hydroxy-4-(naphthalen-1-yl)benzamide Investigative T28887 DRUGINFO D06THS Desclasinose Azithromycinarylalkyl Hydroxamate Investigative T28887 DRUGINFO D0D7KH Azithromycin-N-benzyltriazolyloctahydroxamic Acid Investigative T28887 DRUGINFO D0H3RO Azithromycin-N-benzyltriazolylnonahydroxamic Acid Investigative T28887 DRUGINFO D0I5XM Azithromycin-N-benzyltriazolylhexahydroxamic Acid Investigative T28887 DRUGINFO D0L7HP NILTUBACIN Investigative T28887 DRUGINFO D0P9CQ Azithromycinarylalkylhydroxamic Acid Investigative T28887 DRUGINFO D00VXM droxinostat Investigative T28887 DRUGINFO D02NWS 4-Phenylbutyrohydroxamic acid Investigative T28887 DRUGINFO D01YBR ST-3050 Investigative T28887 DRUGINFO D07YZZ Octanedioic acid bis-hydroxyamide Investigative T28887 DRUGINFO D0N9AK ST-2986 Investigative T28887 DRUGINFO D00KFF 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative T28887 DRUGINFO D00SEE 7-Mercapto-heptanoic acid phenylamide Investigative T28887 DRUGINFO D00ZSD 6-benzenesulfinylhexanoic acid hydroxamide Investigative T28887 DRUGINFO D01MFV N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative T28887 DRUGINFO D01XWZ 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative T28887 DRUGINFO D01XXN N-Hydroxy-4-phenylacetylamino-benzamide Investigative T28887 DRUGINFO D02MQM 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative T28887 DRUGINFO D02UTC N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative T28887 DRUGINFO D02WZK 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T28887 DRUGINFO D04GGW Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative T28887 DRUGINFO D04HSS N-(6-Mercapto-hexyl)-benzamide Investigative T28887 DRUGINFO D04NSP 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T28887 DRUGINFO D04ZDI N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative T28887 DRUGINFO D05AHZ 6-benzenesulfonylhexanoic acid hydroxamide Investigative T28887 DRUGINFO D05FEJ 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative T28887 DRUGINFO D05GVY Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative T28887 DRUGINFO D05LLX 4-Butyrylamino-N-hydroxy-benzamide Investigative T28887 DRUGINFO D05VFP 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T28887 DRUGINFO D05XAN 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative T28887 DRUGINFO D06IQB 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative T28887 DRUGINFO D06VBN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative T28887 DRUGINFO D06XNP 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative T28887 DRUGINFO D07FJU 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative T28887 DRUGINFO D09YBN 6-Phenoxy-hexane-1-thiol Investigative T28887 DRUGINFO D09ZNU 4-Benzoylamino-N-hydroxy-benzamide Investigative T28887 DRUGINFO D0A5LS 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T28887 DRUGINFO D0AX7B 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative T28887 DRUGINFO D0B2ZJ 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T28887 DRUGINFO D0B3ZM 6-Mercapto-hexanoic acid phenylamide Investigative T28887 DRUGINFO D0C0VP Cyclostellettamine derivative Investigative T28887 DRUGINFO D0C2KD N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative T28887 DRUGINFO D0D2KE 5-Mercapto-pentanoic acid phenylamide Investigative T28887 DRUGINFO D0E8KR Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative T28887 DRUGINFO D0F0KS N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative T28887 DRUGINFO D0H1FZ 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative T28887 DRUGINFO D0KE3I (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative T28887 DRUGINFO D0QO0L N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative T28887 DRUGINFO D0R4BS N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative T28887 DRUGINFO D0R5VG N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative T28887 DRUGINFO D0RU1X 8-Oxo-8-phenyl-octanoic acid Investigative T28887 DRUGINFO D0S7WQ N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative T28887 DRUGINFO D0S9JF 6-phenylsulfanylhexanoic acid hydroxamide Investigative T28887 DRUGINFO D0T0SK ST-2987 Investigative T28887 DRUGINFO D0T4IY 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative T28887 DRUGINFO D0V2ZO 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative T28887 DRUGINFO D0XZ9Q 8-Mercapto-octanoic acid phenylamide Investigative T28887 DRUGINFO D0YY9M N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative T28887 DRUGINFO D0Z3BM 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative T28887 DRUGINFO D0Z5KX 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative T28887 DRUGINFO D0Z7YS N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative T28887 DRUGINFO D0N0TS PSAMMAPLIN A Investigative T05387 TARGETID T05387 T05387 FORMERID TTDC00120 T05387 UNIPROID TGM2_HUMAN T05387 TARGNAME Tissue transglutaminase (TG2) T05387 GENENAME TGM2 T05387 TARGTYPE Clinical trial T05387 SYNONYMS Transglutaminase-2; Transglutaminase H; Transglutaminase C; Transglutaminase 2; Tranglutaminase 2; TTg; TGase-H; TGase-2; TGase H; TGase C; TGC; TG(C)Protein-glutamine gamma-glutamyltransferase; TG(C); Protein-glutamine gamma-glutamyltransferase 2 T05387 FUNCTION Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins. T05387 PDBSTRUC 6A8P; 4PYG; 3S3S; 3S3P; 3S3J T05387 BIOCLASS Acyltransferase T05387 ECNUMBER EC 2.3.2.13 T05387 SEQUENCE MAEELVLERCDLELETNGRDHHTADLCREKLVVRRGQPFWLTLHFEGRNYEASVDSLTFSVVTGPAPSQEAGTKARFPLRDAVEEGDWTATVVDQQDCTLSLQLTTPANAPIGLYRLSLEASTGYQGSSFVLGHFILLFNAWCPADAVYLDSEEERQEYVLTQQGFIYQGSAKFIKNIPWNFGQFEDGILDICLILLDVNPKFLKNAGRDCSRRSSPVYVGRVVSGMVNCNDDQGVLLGRWDNNYGDGVSPMSWIGSVDILRRWKNHGCQRVKYGQCWVFAAVACTVLRCLGIPTRVVTNYNSAHDQNSNLLIEYFRNEFGEIQGDKSEMIWNFHCWVESWMTRPDLQPGYEGWQALDPTPQEKSEGTYCCGPVPVRAIKEGDLSTKYDAPFVFAEVNADVVDWIQQDDGSVHKSINRSLIVGLKISTKSVGRDEREDITHTYKYPEGSSEEREAFTRANHLNKLAEKEETGMAMRIRVGQSMNMGSDFDVFAHITNNTAEEYVCRLLLCARTVSYNGILGPECGTKYLLNLNLEPFSEKSVPLCILYEKYRDCLTESNLIKVRALLVEPVINSYLLAERDLYLENPEIKIRILGEPKQKRKLVAEVSLQNPLPVALEGCTFTVEGAGLTEEQKTVEIPDPVEAGEEVKVRMDLLPLHMGLHKLVVNFESDKLKAVKGFRNVIIGPA T05387 DRUGINFO DB2V8K ZED1227 Phase 2 T05387 DRUGINFO D00SAH PMID26560530-Compound-54 Patented T05387 DRUGINFO D01CCT Triazole derivative 1 Patented T05387 DRUGINFO D01EKS Acyl piperidine derivative 3 Patented T05387 DRUGINFO D02LBZ PMID26560530-Compound-14 Patented T05387 DRUGINFO D02OXG PMID26560530-Compound-1 Patented T05387 DRUGINFO D02XDG PMID26560530-Compound-3 Patented T05387 DRUGINFO D03JCI PMID26560530-Compound-11 Patented T05387 DRUGINFO D04LLK Chloroacetyl ester derivative 1 Patented T05387 DRUGINFO D04MQZ PMID26560530-Compound-7 Patented T05387 DRUGINFO D05ZTV Dipeptide analog 2 Patented T05387 DRUGINFO D06TXR PMID26560530-Compound-16 Patented T05387 DRUGINFO D06YBF Acyl piperidine derivative 2 Patented T05387 DRUGINFO D08QGR PMID26560530-Compound-34 Patented T05387 DRUGINFO D08UFW PMID26560530-Compound-48 Patented T05387 DRUGINFO D0A9OC PMID26560530-Compound-4 Patented T05387 DRUGINFO D0C2QU PMID26560530-Compound-25 Patented T05387 DRUGINFO D0CL1D Dihydroisoxazole derivative 2 Patented T05387 DRUGINFO D0DK4I PMID26560530-Compound-24 Patented T05387 DRUGINFO D0EA3E PMID26560530-Compound-26 Patented T05387 DRUGINFO D0EZ6C PMID26560530-Compound-27 Patented T05387 DRUGINFO D0G0EG PMID26560530-Compound-15 Patented T05387 DRUGINFO D0G3QD Chalcone derivative 5 Patented T05387 DRUGINFO D0GR1X Pyrazolodiazepine derivative 1 Patented T05387 DRUGINFO D0H2DL PMID26560530-Compound-50 Patented T05387 DRUGINFO D0H4PF Dipeptide analog 3 Patented T05387 DRUGINFO D0IE9E PMID26560530-Compound-6 Patented T05387 DRUGINFO D0IQ8I PMID26560530-Compound-23 Patented T05387 DRUGINFO D0J4IP PMID26560530-Compound-31 Patented T05387 DRUGINFO D0K6SZ Dipeptide analog 4 Patented T05387 DRUGINFO D0KZ6T PMID26560530-Compound-47 Patented T05387 DRUGINFO D0L7MP 3-acylidene-2-oxoindole derivative 2 Patented T05387 DRUGINFO D0LO0I PMID26560530-Compound-18 Patented T05387 DRUGINFO D0MA2H PMID26560530-Compound-2 Patented T05387 DRUGINFO D0MF2V PMID26560530-Compound-33 Patented T05387 DRUGINFO D0NB4O PMID26560530-Compound-12 Patented T05387 DRUGINFO D0NX1O PMID26560530-Compound-17 Patented T05387 DRUGINFO D0O6LL PMID26560530-Compound-8 Patented T05387 DRUGINFO D0O9JZ PMID26560530-Compound-49 Patented T05387 DRUGINFO D0PM3J Dihydroisoxazole derivative 1 Patented T05387 DRUGINFO D0QR0U PMID26560530-Compound-35 Patented T05387 DRUGINFO D0QX6W Benzotriazole derivative 1 Patented T05387 DRUGINFO D0RX6D 3-acylidene-2-oxoindole derivative 1 Patented T05387 DRUGINFO D0S4YD Peptide analog 52 Patented T05387 DRUGINFO D0U6CU Sulfonamide derivative 9 Patented T05387 DRUGINFO D0UR1H Peptide analog 54 Patented T05387 DRUGINFO D0VC9V 2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivative 1 Patented T05387 DRUGINFO D0W5ND Azachalcone derivative 1 Patented T05387 DRUGINFO D0Y3YK PMID26560530-Compound-5 Patented T05387 DRUGINFO D0Y6TX PMID26560530-Compound-32 Patented T05387 DRUGINFO D0Y7FK Peptide analog 53 Patented T05387 DRUGINFO D0YP7A Isothiocyanate derivative 1 Patented T05387 DRUGINFO D0Z1VM PMID26560530-Compound-46 Patented T05387 DRUGINFO D0KK6L PMID26560530-Compound-13 Patented T05387 DRUGINFO D1Y6RQ NTU281 Preclinical T05387 DRUGINFO D0C7LS Guanosine-5'-Diphosphate Investigative T44818 TARGETID T44818 T44818 UNIPROID T23O_HUMAN T44818 TARGNAME Tryptophan 2,3-dioxygenase (TDO) T44818 GENENAME TDO2 T44818 TARGTYPE Clinical trial T44818 SYNONYMS Tryptophanase; Tryptophan pyrrolase; Tryptophan oxygenase; Tryptamin 2,3-dioxygenase; TRPO; TO T44818 FUNCTION Catalyzes the oxidative cleavage of the indole moiety. Heme-dependent dioxygenase that catalyzes the oxidative cleavage of the L-tryptophan (L-Trp) pyrrole ring and converts L-tryptophan to N-formyl-L-kynurenine. T44818 PDBSTRUC 6A4I; 5TIA; 5TI9; 4PW8 T44818 BIOCLASS Oxygenase T44818 ECNUMBER EC 1.13.11.11 T44818 SEQUENCE MSGCPFLGNNFGYTFKKLPVEGSEEDKSQTGVNRASKGGLIYGNYLHLEKVLNAQELQSETKGNKIHDEHLFIITHQAYELWFKQILWELDSVREIFQNGHVRDERNMLKVVSRMHRVSVILKLLVQQFSILETMTALDFNDFREYLSPASGFQSLQFRLLENKIGVLQNMRVPYNRRHYRDNFKGEENELLLKSEQEKTLLELVEAWLERTPGLEPHGFNFWGKLEKNITRGLEEEFIRIQAKEESEEKEEQVAEFQKQKEVLLSLFDEKRHEHLLSKGERRLSYRALQGALMIYFYREEPRFQVPFQLLTSLMDIDSLMTKWRYNHVCMVHRMLGSKAGTGGSSGYHYLRSTVSDRYKVFVDLFNLSTYLIPRHWIPKMNPTIHKFLYTAEYCDSSYFSSDESD T44818 DRUGINFO D9S7XO DN1406131 Phase 1 T44818 DRUGINFO DB53NH HTI-1090 Phase 1 T44818 DRUGINFO D0E8XV 2,3-diamino-benzo[b]thiophene derivative 3 Patented T44818 DRUGINFO D0F4MN PMID29473428-Compound-76 Patented T44818 DRUGINFO D0JB1V Indazole derivative 3 Patented T44818 DRUGINFO D04BZI 2,3-diamino-benzo[b]thiophene derivative 4 Patented T44818 DRUGINFO D04MIQ PMID27172114-Compound-30 Patented T44818 DRUGINFO D05TIP 2,3-diamino-benzo[b]thiophene derivative 2 Patented T44818 DRUGINFO D05ZGX 2,3-diamino-benzo[b]thiophene derivative 8 Patented T44818 DRUGINFO D0F4VD 2,3-diamino-benzo[b]thiophene derivative 7 Patented T44818 DRUGINFO D0FF6H 2,3-diamino-benzo[b]thiophene derivative 6 Patented T44818 DRUGINFO D0HV0Y 2,3-diamino-benzo[b]thiophene derivative 5 Patented T44818 DRUGINFO D0RA7I 2,3-diamino-benzo[b]thiophene derivative 1 Patented T44818 DRUGINFO D83YSR 680C91 Preclinical T44818 DRUGINFO D9Y2KA 4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine Preclinical T44818 DRUGINFO DZ8UP4 LM10 Preclinical T44818 DRUGINFO D9P8LE RG70099 Preclinical T44818 DRUGINFO DZK24C EPL-1410 Preclinical T10822 TARGETID T10822 T10822 FORMERID TTDR00298 T10822 UNIPROID CDK8_HUMAN T10822 TARGNAME Cyclin-dependent kinase 8 (CDK8) T10822 GENENAME CDK8 T10822 TARGTYPE Clinical trial T10822 SYNONYMS Protein kinase K35; Mediator of RNA polymerase II transcription subunit CDK8; Mediator complex subunit CDK8; Cell division protein kinase 8 T10822 FUNCTION Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Phosphorylates the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAp II), which may inhibit the formation of a transcription initiation complex. Phosphorylates CCNH leading to down-regulation of the TFIIH complex and transcriptional repression. Recruited through interaction with MAML1 to hyperphosphorylate the intracellular domain of NOTCH, leading to its degradation. Component of the Mediator complex, a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes. T10822 PDBSTRUC 5XS2; 5XQX; 5IDP; 5IDN; 5ICP T10822 BIOCLASS Kinase T10822 ECNUMBER EC 2.7.11.22 T10822 SEQUENCE MDYDFKVKLSSERERVEDLFEYEGCKVGRGTYGHVYKAKRKDGKDDKDYALKQIEGTGISMSACREIALLRELKHPNVISLQKVFLSHADRKVWLLFDYAEHDLWHIIKFHRASKANKKPVQLPRGMVKSLLYQILDGIHYLHANWVLHRDLKPANILVMGEGPERGRVKIADMGFARLFNSPLKPLADLDPVVVTFWYRAPELLLGARHYTKAIDIWAIGCIFAELLTSEPIFHCRQEDIKTSNPYHHDQLDRIFNVMGFPADKDWEDIKKMPEHSTLMKDFRRNTYTNCSLIKYMEKHKVKPDSKAFHLLQKLLTMDPIKRITSEQAMQDPYFLEDPLPTSDVFAGCQIPYPKREFLTEEEPDDKGDKKNQQQQQGNNHTNGTGHPGNQDSSHTQGPPLKKVRVVPPTTTSGGLIMTSDYQRSNPHAAYPNPGPSTSQPQSSMGYSATSQQPPQYSHQTHRY T10822 DRUGINFO DOJG79 SEL120 Phase 1 T10822 DRUGINFO D03OIA Macrocycle derivative 14 Patented T10822 DRUGINFO D0NY7M Tricyclic benzimidazole derivative 1 Patented T10822 DRUGINFO D70HIN CCT251545 Preclinical T10822 DRUGINFO D03ALC Oxindole 16 (compound 3) Investigative T10822 DRUGINFO D0VC0I Oxindole 94 Investigative T58298 TARGETID T58298 T58298 FORMERID TTDR00537 T58298 UNIPROID ENTP1_HUMAN T58298 TARGNAME Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) T58298 GENENAME ENTPD1 T58298 TARGTYPE Clinical trial T58298 SYNONYMS NTPDase1; NTPDase 1; Lymphoid cell activation antigen; Ecto-nucleotidase CD-39; Ecto-apyrase; Ecto-ATPase 1; Ecto-ATPDase 1; Ecto-ATP diphosphohydrolase 1; Ecto-ATP diphosphohydrolase; CD39 antigen; ATPDase T58298 FUNCTION Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. In the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. T58298 BIOCLASS Acid anhydride hydrolase T58298 ECNUMBER EC 3.6.1.5 T58298 SEQUENCE MEDTKESNVKTFCSKNILAILGFSSIIAVIALLAVGLTQNKALPENVKYGIVLDAGSSHTSLYIYKWPAEKENDTGVVHQVEECRVKGPGISKFVQKVNEIGIYLTDCMERAREVIPRSQHQETPVYLGATAGMRLLRMESEELADRVLDVVERSLSNYPFDFQGARIITGQEEGAYGWITINYLLGKFSQKTRWFSIVPYETNNQETFGALDLGGASTQVTFVPQNQTIESPDNALQFRLYGKDYNVYTHSFLCYGKDQALWQKLAKDIQVASNEILRDPCFHPGYKKVVNVSDLYKTPCTKRFEMTLPFQQFEIQGIGNYQQCHQSILELFNTSYCPYSQCAFNGIFLPPLQGDFGAFSAFYFVMKFLNLTSEKVSQEKVTEMMKKFCAQPWEEIKTSYAGVKEKYLSEYCFSGTYILSLLLQGYHFTADSWEHIHFIGKIQGSDAGWTLGYMLNLTNMIPAEQPLSTPLSHSTYVFLMVLFSLVLFTVAIIGLLIFHKPSYFWKDMV T58298 DRUGINFO D87PWZ IPH5201 Phase 1 T58298 DRUGINFO D9M0KJ SRF617 Phase 1 T58298 DRUGINFO DCMG03 TTX-030 Phase 1 T58298 DRUGINFO D0R2UZ PSB-6426 Investigative T58298 DRUGINFO D06GQY PSB-0963 Investigative T63512 TARGETID T63512 T63512 UNIPROID ENPP2_HUMAN T63512 TARGNAME Extracellular lysophospholipase D (E-NPP2) T63512 GENENAME ENPP2 T63512 TARGTYPE Clinical trial T63512 SYNONYMS LysoPLD; Ectonucleotide pyrophosphatase/phosphodiesterase family member 2; E-NPP 2; Autotaxin; ATX T63512 FUNCTION Hydrolyzes lysophospholipids to produce the signaling molecule lysophosphatidic acid (LPA) in extracellular fluids. Major substrate is lysophosphatidylcholine. Also can act on sphingosylphosphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility. Can hydrolyze, in vitro, bis-pNPP, to some extent pNP-TMP, and barely ATP. Involved in several motility-related processes such as angiogenesis and neurite outgrowth. Acts as an angiogenic factor by stimulating migration of smooth muscle cells and microtubule formation. Stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein. May have a role in induction of parturition. Possible involvement in cell proliferation and adipose tissue development (Probable). Tumor cell motility-stimulating factor. T63512 PDBSTRUC 5MHP; 5M7M; 5KXA; 4ZGA; 4ZG9 T63512 BIOCLASS Phosphoric diester hydrolase T63512 ECNUMBER EC 3.1.4.39 T63512 SEQUENCE MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEI T63512 DRUGINFO DN9V3S Cudetaxestat Phase 2 T63512 DRUGINFO D00LWY PMID28447479-Compound-24 Patented T63512 DRUGINFO D00PJE Tetra-hydro-carboline derivative 2 Patented T63512 DRUGINFO D02BGU Pyrido/pyrrolo-fused pyrimidine derivative 1 Patented T63512 DRUGINFO D02FWT PMID28447479-Compound-14 Patented T63512 DRUGINFO D03RAU Pyrimidinone derivative 5 Patented T63512 DRUGINFO D04TUG Heteroaromatic ring derivative 3 Patented T63512 DRUGINFO D06ZAE Pyrazolo[3,4-c]pyridine derivative 1 Patented T63512 DRUGINFO D07JTJ Pyrazole derivative 87 Patented T63512 DRUGINFO D07UNH Pyridine and pyrimidine derivative 1 Patented T63512 DRUGINFO D09IKN Imidazopyrimidinone derivative 1 Patented T63512 DRUGINFO D0B7KP PMID28447479-Compound-21 Patented T63512 DRUGINFO D0E3ED Octahydro-pyrrolo[3,4-c]-pyrrole derivative 1 Patented T63512 DRUGINFO D0F1FD Complex heterocyclic compound 1 Patented T63512 DRUGINFO D0F7NL PMID28447479-Compound-20 Patented T63512 DRUGINFO D0FM6Y PMID28447479-Compound-22 Patented T63512 DRUGINFO D0FN8Y Heteroaromatic ring derivative 4 Patented T63512 DRUGINFO D0FO4C Dihydropyrido pyrimidine derivative 1 Patented T63512 DRUGINFO D0GA6X PMID28447479-Compound-4 Patented T63512 DRUGINFO D0J5GC Heteroaromatic ring derivative 1 Patented T63512 DRUGINFO D0NG8Q Heteroaromatic ring derivative 2 Patented T63512 DRUGINFO D0PI2I PMID28447479-Compound-26 Patented T63512 DRUGINFO D0RB6K Tetra-hydro-carboline derivative 1 Patented T63512 DRUGINFO D0S8EH PMID28447479-Compound-11 Patented T63512 DRUGINFO D0U8BD PMID28447479-Compound-23 Patented T63512 DRUGINFO D0WD8Z Piperazine derivative 8 Patented T63512 DRUGINFO D0WL5E PMID28447479-Compound-27 Patented T63512 DRUGINFO D0WX7F PMID28447479-Compound-10 Patented T15776 TARGETID T15776 T15776 UNIPROID PDK1_HUMAN T15776 TARGNAME Pyruvate dehydrogenase kinase 1 (PDHK1) T15776 GENENAME PDK1 T15776 TARGTYPE Clinical trial T15776 SYNONYMS Pyruvate dehydrogenase kinase isoform 1; Pyruvate dehydrogenase (acetyl-transferring) kinase isozyme 1, mitochondrial; PDHK1; PDH kinase 1 T15776 FUNCTION Kinase that plays a key role in regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate. Plays an important role in cellular responses to hypoxia and is important for cell proliferation under hypoxia. Protects cells against apoptosis in response to hypoxia and oxidative stress. T15776 PDBSTRUC 2Q8H; 2Q8G; 2Q8F T15776 BIOCLASS Kinase T15776 ECNUMBER EC 2.7.11.2 T15776 SEQUENCE MRLARLLRGAALAGPGPGLRAAGFSRSFSSDSGSSPASERGVPGQVDFYARFSPSPLSMKQFLDFGSVNACEKTSFMFLRQELPVRLANIMKEISLLPDNLLRTPSVQLVQSWYIQSLQELLDFKDKSAEDAKAIYDFTDTVIRIRNRHNDVIPTMAQGVIEYKESFGVDPVTSQNVQYFLDRFYMSRISIRMLLNQHSLLFGGKGKGSPSHRKHIGSINPNCNVLEVIKDGYENARRLCDLYYINSPELELEELNAKSPGQPIQVVYVPSHLYHMVFELFKNAMRATMEHHANRGVYPPIQVHVTLGNEDLTVKMSDRGGGVPLRKIDRLFNYMYSTAPRPRVETSRAVPLAGFGYGLPISRLYAQYFQGDLKLYSLEGYGTDAVIYIKALSTDSIERLPVYNKAAWKHYNTNHEADDWCVPSREPKDMTTFRSA T15776 DRUGINFO D7I9JH Dichloroacetate Phase 4 T15776 DRUGINFO D00LMA Heteroaryl-carboxamide derivative 4 Patented T15776 DRUGINFO D00MLJ Pyrazole derivative 61 Patented T15776 DRUGINFO D00SVK PMID25684022-Compound-WO2011137219 37(4-6) Patented T15776 DRUGINFO D00ZXR Heteroaryl-carboxamide derivative 3 Patented T15776 DRUGINFO D02MMG Pyrimidine derivative 3 Patented T15776 DRUGINFO D02USE Heterocyclic derivative 15 Patented T15776 DRUGINFO D03GFZ Thieno[3,2-c]pyridine-7-carboxamide derivative 2 Patented T15776 DRUGINFO D03WFI Heteroaryl-carboxamide derivative 9 Patented T15776 DRUGINFO D04BBA Thiazole carboxamide derivative 24 Patented T15776 DRUGINFO D04BBT Heterocyclic derivative 12 Patented T15776 DRUGINFO D04EDM PMID25684022-Compound-US20120277229 41(1.3) Patented T15776 DRUGINFO D04MHV Heterocyclic derivative 17 Patented T15776 DRUGINFO D04QRX Thiazole carboxamide derivative 27 Patented T15776 DRUGINFO D04UHW PMID25684022-Compound-WO2008079988 Patented T15776 DRUGINFO D05GMT Pyridinone carboxamide derivative 1 Patented T15776 DRUGINFO D05OTD Heterocyclic derivative 4 Patented T15776 DRUGINFO D06BSG Thieno[3,2-c]pyridine-7-carboxamide derivative 1 Patented T15776 DRUGINFO D06LCB Thiazole carboxamide derivative 9 Patented T15776 DRUGINFO D06LLS PMID25684022-Compound-WO2009153313 Patented T15776 DRUGINFO D06LSZ PMID25684022-Compound-US20120277229 40(1.2) Patented T15776 DRUGINFO D06PTW Thiazole carboxamide derivative 12 Patented T15776 DRUGINFO D06RGW PMID25684022-Compound-WO2004087707 Patented T15776 DRUGINFO D06WAN Benzimidazole and imidazopyridine derivative 1 Patented T15776 DRUGINFO D06WXJ Thiazole carboxamide derivative 14 Patented T15776 DRUGINFO D07FMW PMID25684022-Compound-US20130053382 38(5-7) Patented T15776 DRUGINFO D07HOA Heterocyclic derivative 9 Patented T15776 DRUGINFO D07IQE Heterocyclic derivative 10 Patented T15776 DRUGINFO D07MSB Thiazole carboxamide derivative 11 Patented T15776 DRUGINFO D07XBA PMID25684022-Compound-US20130053382 36(3-5) Patented T15776 DRUGINFO D07ZKE PMID25684022-Compound-US20120277229 45(1.5) Patented T15776 DRUGINFO D07ZMG Thiazole carboxamide derivative 29 Patented T15776 DRUGINFO D08EGT PMID25684022-Compound-WO2008005457 Patented T15776 DRUGINFO D08SNT Heteroaryl-carboxamide derivative 2 Patented T15776 DRUGINFO D08YPQ Thiazole carboxamide derivative 7 Patented T15776 DRUGINFO D09BNP Heterocyclic derivative 11 Patented T15776 DRUGINFO D09FQP PMID25684022-Compound-US20120277229 39(1.1) Patented T15776 DRUGINFO D0AM2D Heterocyclic derivative 8 Patented T15776 DRUGINFO D0B2GM Thiazole carboxamide derivative 20 Patented T15776 DRUGINFO D0B8OB PMID25684022-Compound-WO2011137219 36(3-5) Patented T15776 DRUGINFO D0C6VX PMID25684022-Compound-WO2010127754 Patented T15776 DRUGINFO D0CK8H Indazole derivative 1 Patented T15776 DRUGINFO D0CQ1M Heterocyclic-carboxamide derivative 2 Patented T15776 DRUGINFO D0D0ML Heterocyclic derivative 6 Patented T15776 DRUGINFO D0D5YE Imidazo quinoline derivative 1 Patented T15776 DRUGINFO D0D8PF Thiazole carboxamide derivative 16 Patented T15776 DRUGINFO D0DC2P PMID25684022-Compound-WO2012135799 42(1.4) Patented T15776 DRUGINFO D0DM2G Bis-indolylmaleimide derivative 1 Patented T15776 DRUGINFO D0DO6K Thiazole carboxamide derivative 23 Patented T15776 DRUGINFO D0EH9Z Heterocyclic derivative 14 Patented T15776 DRUGINFO D0FJ4A Thiazole carboxamide derivative 18 Patented T15776 DRUGINFO D0FW3M Heterocyclic derivative 18 Patented T15776 DRUGINFO D0GE6F Thiazole carboxamide derivative 17 Patented T15776 DRUGINFO D0GH9W Heteroaryl-carboxamide derivative 6 Patented T15776 DRUGINFO D0GY8G Thiazole carboxamide derivative 19 Patented T15776 DRUGINFO D0H6AF Thiazole carboxamide derivative 4 Patented T15776 DRUGINFO D0H7SO Heteroaryl-carboxamide derivative 1 Patented T15776 DRUGINFO D0HI8X Heterocyclic derivative 13 Patented T15776 DRUGINFO D0HP8K Thiazole carboxamide derivative 2 Patented T15776 DRUGINFO D0I1YQ Pyrazolopyridines and imidazopyridine derivative 1 Patented T15776 DRUGINFO D0I5KI Dibenzo [c,f]-[2,7]naphthyridine derivative 1 Patented T15776 DRUGINFO D0IO2X PMID25684022-Compound-WO2011137219 38(5-7) Patented T15776 DRUGINFO D0IR8B Benzonaphthyridine derivative 2 Patented T15776 DRUGINFO D0J9DI Heterocyclic derivative 5 Patented T15776 DRUGINFO D0JR0F Thiazole carboxamide derivative 25 Patented T15776 DRUGINFO D0K8XT Thiazole carboxamide derivative 10 Patented T15776 DRUGINFO D0KN7T Thiazole carboxamide derivative 22 Patented T15776 DRUGINFO D0MG4D Heteroaryl-carboxamide derivative 5 Patented T15776 DRUGINFO D0MI3E PMID25684022-Compound-WO2008107444 Patented T15776 DRUGINFO D0MW7L Heteroaryl-carboxamide derivative 7 Patented T15776 DRUGINFO D0P0WF PMID25684022-Compound-WO2011137219 35(1-11) Patented T15776 DRUGINFO D0P1VT Pyrimidinone derivative 1 Patented T15776 DRUGINFO D0P6PT Thiazole carboxamide derivative 21 Patented T15776 DRUGINFO D0PD2I Thiazole carboxamide derivative 8 Patented T15776 DRUGINFO D0PJ7M 1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1 Patented T15776 DRUGINFO D0Q6RC Thiazole carboxamide derivative 1 Patented T15776 DRUGINFO D0Q8JK Thiazole carboxamide derivative 15 Patented T15776 DRUGINFO D0QV1E Thiazole carboxamide derivative 28 Patented T15776 DRUGINFO D0R0SJ PMID25684022-Compound-WO2012135799 43(1.5) Patented T15776 DRUGINFO D0R3VG Thiazole carboxamide derivative 3 Patented T15776 DRUGINFO D0RE3R PMID25684022-Compound-US20120277229 44(1.4) Patented T15776 DRUGINFO D0RH6G Heterocyclic derivative 16 Patented T15776 DRUGINFO D0RP4U PMID25684022-Compound-WO2006015124 Patented T15776 DRUGINFO D0RY6M Heterocyclic-carboxamide derivative 1 Patented T15776 DRUGINFO D0SB4A PMID25684022-Compound-US20130053382 35(1-11) Patented T15776 DRUGINFO D0TB2H Heteroaryl-carboxamide derivative 10 Patented T15776 DRUGINFO D0U3IS Benzonaphthyridine derivative 1 Patented T15776 DRUGINFO D0U5HB Thiazole carboxamide derivative 5 Patented T15776 DRUGINFO D0U7LW Thiazole carboxamide derivative 26 Patented T15776 DRUGINFO D0W3JC Heterocyclic derivative 7 Patented T15776 DRUGINFO D0WT9J Heteroaryl-carboxamide derivative 8 Patented T15776 DRUGINFO D0WX4H Heterocyclic derivative 19 Patented T15776 DRUGINFO D0Y0RG PMID25684022-Compound-US20130053382 37(4-6) Patented T15776 DRUGINFO D0YD1Q PMID25684022-Compound-EP20041486488 Patented T15776 DRUGINFO D0Z3HW Thiazole carboxamide derivative 30 Patented T15776 DRUGINFO D0Z5HL Thiazole carboxamide derivative 6 Patented T15776 DRUGINFO D0ZE5U Indolinone derivative 1 Patented T15776 DRUGINFO D0ZG0K Thiazole carboxamide derivative 13 Patented T15776 DRUGINFO D0ZV9P Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1 Patented T40812 TARGETID T40812 T40812 UNIPROID PARP2_HUMAN T40812 TARGNAME Poly [ADP-ribose] polymerase 2 (PARP2) T40812 GENENAME PARP2 T40812 TARGTYPE Clinical trial T40812 SYNONYMS pADPRT-2; hPARP-2; Protein poly-ADP-ribosyltransferase PARP2; Poly[ADP-ribose] synthase 2; PARP-2; NAD(+) ADP-ribosyltransferase 2; DNA ADP-ribosyltransferase PARP2; ARTD2; ADPRTL2; ADPRT2; ADPRT-2; ADP-ribosyltransferase diphtheria toxin-like 2 T40812 FUNCTION Mainly mediates glutamate and aspartate ADP-ribosylation of target proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of glutamate and aspartate residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. ADP-ribosylation follows DNA damage and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Also mediates serine ADP-ribosylation of target proteins following interaction with HPF1; HPF1 conferring serine specificity. In addition to proteins, also able to ADP-ribosylate DNA: preferentially acts on 5'-terminal phosphates at DNA strand breaks termini in nicked duplex. Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. T40812 PDBSTRUC 6F5F; 6F5B; 6F1K; 5DSY; 5D5K T40812 BIOCLASS Glycosyltransferases T40812 ECNUMBER EC 2.4.2.30 T40812 SEQUENCE MAARRRRSTGGGRARALNESKRVNNGNTAPEDSSPAKKTRRCQRQESKKMPVAGGKANKDRTEDKQDGMPGRSWASKRVSESVKALLLKGKAPVDPECTAKVGKAHVYCEGNDVYDVMLNQTNLQFNNNKYYLIQLLEDDAQRNFSVWMRWGRVGKMGQHSLVACSGNLNKAKEIFQKKFLDKTKNNWEDREKFEKVPGKYDMLQMDYATNTQDEEETKKEESLKSPLKPESQLDLRVQELIKLICNVQAMEEMMMEMKYNTKKAPLGKLTVAQIKAGYQSLKKIEDCIRAGQHGRALMEACNEFYTRIPHDFGLRTPPLIRTQKELSEKIQLLEALGDIEIAIKLVKTELQSPEHPLDQHYRNLHCALRPLDHESYEFKVISQYLQSTHAPTHSDYTMTLLDLFEVEKDGEKEAFREDLHNRMLLWHGSRMSNWVGILSHGLRIAPPEAPITGYMFGKGIYFADMSSKSANYCFASRLKNTGLLLLSEVALGQCNELLEANPKAEGLLQGKHSTKGLGKMAPSSAHFVTLNGSTVPLGPASDTGILNPDGYTLNYNEYIVYNPNQVRMRYLLKVQFNFLQLW T40812 DRUGINFO D0F5TD PMID27841036-Compound-37 Phase 2 T40812 DRUGINFO DP48WE Stenoparib Phase 2 T40812 DRUGINFO D8TE4F AMXI 5001 Phase 1/2 T40812 DRUGINFO D0P3YA Dihydrodiazepinocarbazolone derivative 1 Patented T40812 DRUGINFO D0Z8IR Tetra-cyclic pyridophthalazinone derivative 1 Patented T40812 DRUGINFO D0TD8R 3-phenyl isoquinolin-1(2H) derivative 1 Patented T50973 TARGETID T50973 T50973 FORMERID TTDI02605 T50973 UNIPROID KMO_HUMAN T50973 TARGNAME Kynurenine 3-hydroxylase (KMO) T50973 GENENAME KMO T50973 TARGTYPE Clinical trial T50973 SYNONYMS Kynurenine 3monooxygenase; Kynurenine 3-monooxygenase T50973 FUNCTION Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract. Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn). T50973 PDBSTRUC 5X68 T50973 BIOCLASS Paired donor oxygen oxidoreductase T50973 ECNUMBER EC 1.14.13.9 T50973 SEQUENCE MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAREDTRVATFTRGRSINLALSHRGRQALKAVGLEDQIVSQGIPMRARMIHSLSGKKSAIPYGTKSQYILSVSRENLNKDLLTAAEKYPNVKMHFNHRLLKCNPEEGMITVLGSDKVPKDVTCDLIVGCDGAYSTVRSHLMKKPRFDYSQQYIPHGYMELTIPPKNGDYAMEPNYLHIWPRNTFMMIALPNMNKSFTCTLFMPFEEFEKLLTSNDVVDFFQKYFPDAIPLIGEKLLVQDFFLLPAQPMISVKCSSFHFKSHCVLLGDAAHAIVPFFGQGMNAGFEDCLVFDELMDKFSNDLSLCLPVFSRLRIPDDHAISDLSMYNYIEMRAHVNSSWFIFQKNMERFLHAIMPSTFIPLYTMVTFSRIRYHEAVQRWHWQKKVINKGLFFLGSLIAISSTYLLIHYMSPRSFLRLRRPWNWIAHFRNTTCFPAKAVDSLEQISNLISR T50973 DRUGINFO DGV8K5 GSK065 Phase 1 T50973 DRUGINFO D00XMF Isoxazoles and isoxazoline derivative 2 Patented T50973 DRUGINFO D01TDT Aryl pyrimidine derivative 7 Patented T50973 DRUGINFO D03EYJ Isoxazoles and isoxazoline derivative 1 Patented T50973 DRUGINFO D03ROY Aryl pyrimidine derivative 2 Patented T50973 DRUGINFO D04BYB Cyclopropane 1-carboxylic acid derivative 6 Patented T50973 DRUGINFO D06EDH PMID27172114-Compound-47 Patented T50973 DRUGINFO D06KFU Isoxazoles and isoxazoline derivative 4 Patented T50973 DRUGINFO D0BU9N Cyclopropane 1-carboxylic acid derivative 2 Patented T50973 DRUGINFO D0DB7W Cyclopropane 1-carboxylic acid derivative 9 Patented T50973 DRUGINFO D0FW5Q Cyclopropane 1-carboxylic acid derivative 10 Patented T50973 DRUGINFO D0G6DW Cyclopropane 1-carboxylic acid derivative 3 Patented T50973 DRUGINFO D0JZ9L Cyclopropane 1-carboxylic acid derivative 4 Patented T50973 DRUGINFO D0LM5V Benzene sulfonamide derivative 5 Patented T50973 DRUGINFO D0MV3E Aryl pyrimidine derivative 4 Patented T50973 DRUGINFO D0N9WZ Benzene sulfonamide derivative 6 Patented T50973 DRUGINFO D0O8MJ Cyclopropane 1-carboxylic acid derivative 7 Patented T50973 DRUGINFO D0O9IS Cyclopropane 1-carboxylic acid derivative 8 Patented T50973 DRUGINFO D0OM6D Pyrimidine benzenesulfonamide derivative 3 Patented T50973 DRUGINFO D0P1BE Benzene sulfonamide derivative 3 Patented T50973 DRUGINFO D0PI7V Cyclopropane 1-carboxylic acid derivative 1 Patented T50973 DRUGINFO D0Q7NM Isoxazoles and isoxazoline derivative 5 Patented T50973 DRUGINFO D0R3JM Benzene sulfonamide derivative 7 Patented T50973 DRUGINFO D0R5HG Pyrimidine benzenesulfonamide derivative 2 Patented T50973 DRUGINFO D0S0DL Benzene sulfonamide derivative 2 Patented T50973 DRUGINFO D0T8AS Pyrimidine benzenesulfonamide derivative 1 Patented T50973 DRUGINFO D0TK3W Isoxazoles and isoxazoline derivative 3 Patented T50973 DRUGINFO D0UF8Z Aryl pyrimidine derivative 9 Patented T50973 DRUGINFO D0UJ8Z Cyclopropane 1-carboxylic acid derivative 5 Patented T50973 DRUGINFO D0VI4S Benzene sulfonamide derivative 4 Patented T50973 DRUGINFO D0WL1Z Isoxazoles and isoxazoline derivative 6 Patented T50973 DRUGINFO D0X5OC PMID27172114-Compound-49 Patented T50973 DRUGINFO D0XR0Z Aryl pyrimidine derivative 6 Patented T50973 DRUGINFO D0Z2JJ Aryl pyrimidine derivative 5 Patented T50973 DRUGINFO D0ZB9T Aryl pyrimidine derivative 3 Patented T50973 DRUGINFO D0ZL9P Benzene sulfonamide derivative 1 Patented T50973 DRUGINFO D0ZY4T Aryl pyrimidine derivative 8 Patented T50973 DRUGINFO DF1S3A GSK180 Preclinical T50973 DRUGINFO DJ7Z5W Ro 61-8048 Preclinical T50973 DRUGINFO DP3J2W UPF-648 Preclinical T50973 DRUGINFO DV8A1L CHDI-340246 Preclinical T50973 DRUGINFO DY0HV9 GSK366 Preclinical T39231 TARGETID T39231 T39231 UNIPROID TNKS1_HUMAN T39231 TARGNAME Tankyrase-1 (TNKS-1) T39231 GENENAME TNKS T39231 TARGTYPE Clinical trial T39231 SYNONYMS Tankyrase I; TRF1-interacting ankyrin-related ADP-ribose polymerase; TNKS1; TINF1; TIN1; TANK1; Protein poly-ADP-ribosyltransferase tankyrase-1; Poly [ADP-ribose] polymerase tankyrase-1; Poly [ADP-ribose] polymerase 5A; PARPL; PARP5A; ARTD5; ADP-ribosyltransferase diphtheria toxin-like 5 T39231 FUNCTION Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates PARsylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates PARsylation of TERF1, thereby contributing to the regulation of telomere length. Involved in centrosome maturation during prometaphase by mediating PARsylation of HEPACAM2/MIKI. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles. May be involved in spindle pole assembly through PARsylation of NUMA1. Stimulates 26S proteasome activity. Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. T39231 PDBSTRUC 5KNI; 5JU5; 5JTI; 5JHQ; 5GP7 T39231 BIOCLASS Glycosyltransferases T39231 ECNUMBER EC 2.4.2.30 T39231 SEQUENCE MAASRRSQHHHHHHQQQLQPAPGASAPPPPPPPPLSPGLAPGTTPASPTASGLAPFASPRHGLALPEGDGSRDPPDRPRSPDPVDGTSCCSTTSTICTVAAAPVVPAVSTSSAAGVAPNPAGSGSNNSPSSSSSPTSSSSSSPSSPGSSLAESPEAAGVSSTAPLGPGAAGPGTGVPAVSGALRELLEACRNGDVSRVKRLVDAANVNAKDMAGRKSSPLHFAAGFGRKDVVEHLLQMGANVHARDDGGLIPLHNACSFGHAEVVSLLLCQGADPNARDNWNYTPLHEAAIKGKIDVCIVLLQHGADPNIRNTDGKSALDLADPSAKAVLTGEYKKDELLEAARSGNEEKLMALLTPLNVNCHASDGRKSTPLHLAAGYNRVRIVQLLLQHGADVHAKDKGGLVPLHNACSYGHYEVTELLLKHGACVNAMDLWQFTPLHEAASKNRVEVCSLLLSHGADPTLVNCHGKSAVDMAPTPELRERLTYEFKGHSLLQAAREADLAKVKKTLALEIINFKQPQSHETALHCAVASLHPKRKQVTELLLRKGANVNEKNKDFMTPLHVAAERAHNDVMEVLHKHGAKMNALDTLGQTALHRAALAGHLQTCRLLLSYGSDPSIISLQGFTAAQMGNEAVQQILSESTPIRTSDVDYRLLEASKAGDLETVKQLCSSQNVNCRDLEGRHSTPLHFAAGYNRVSVVEYLLHHGADVHAKDKGGLVPLHNACSYGHYEVAELLVRHGASVNVADLWKFTPLHEAAAKGKYEICKLLLKHGADPTKKNRDGNTPLDLVKEGDTDIQDLLRGDAALLDAAKKGCLARVQKLCTPENINCRDTQGRNSTPLHLAAGYNNLEVAEYLLEHGADVNAQDKGGLIPLHNAASYGHVDIAALLIKYNTCVNATDKWAFTPLHEAAQKGRTQLCALLLAHGADPTMKNQEGQTPLDLATADDIRALLIDAMPPEALPTCFKPQATVVSASLISPASTPSCLSAASSIDNLTGPLAELAVGGASNAGDGAAGTERKEGEVAGLDMNISQFLKSLGLEHLRDIFETEQITLDVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQGTNPYLTFHCVNQGTILLDLAPEDKEYQSVEEEMQSTIREHRDGGNAGGIFNRYNVIRIQKVVNKKLRERFCHRQKEVSEENHNHHNERMLFHGSPFINAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPTHKDRSCYICHRQMLFCRVTLGKSFLQFSTMKMAHAPPGHHSVIGRPSVNGLAYAEYVIYRGEQAYPEYLITYQIMKPEAPSQTATAAEQKT T39231 DRUGINFO D0F5TD PMID27841036-Compound-37 Phase 2 T39231 DRUGINFO DP48WE Stenoparib Phase 2 T77350 TARGETID T77350 T77350 FORMERID TTDI03483 T77350 UNIPROID PSB8_HUMAN T77350 TARGNAME Proteasome beta-8 (PS beta-8) T77350 GENENAME PSMB8 T77350 TARGTYPE Clinical trial T77350 SYNONYMS Y2; Really interesting new gene 10 protein; RING10; Proteasome subunit beta-5i; Proteasome subunit beta type-8; Proteasome component C13; PSMB5i; Multicatalytic endopeptidase complex subunit C13; Macropain subunit C13; Low molecular mass protein 7; LMP7 T77350 FUNCTION The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes. The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. T77350 PDBSTRUC 6AVO; 5M2B; 5LTT; 5L5V; 5L5U T77350 BIOCLASS Peptidase T77350 ECNUMBER EC 3.4.25.1 T77350 SEQUENCE MALLDVCGAPRGQRPESALPVAGSGRRSDPGHYSFSMRSPELALPRGMQPTEFFQSLGGDGERNVQIEMAHGTTTLAFKFQHGVIAAVDSRASAGSYISALRVNKVIEINPYLLGTMSGCAADCQYWERLLAKECRLYYLRNGERISVSAASKLLSNMMCQYRGMGLSMGSMICGWDKKGPGLYYVDEHGTRLSGNMFSTGSGNTYAYGVMDSGYRPNLSPEEAYDLGRRAIAYATHRDSYSGGVVNMYHMKEDGWVKVESTDVSDLLHQYREANQ T77350 DRUGINFO D7X8AQ M3258 Phase 1 T77350 DRUGINFO D02KPK PMID29865878-Compound-58 Patented T77350 DRUGINFO D04HMP PMID29865878-Compound-61 Patented T77350 DRUGINFO D0E5WC PMID29865878-Compound-59 Patented T77350 DRUGINFO D0GI4S PMID29865878-Compound-64 Patented T77350 DRUGINFO D0J6LT PMID29865878-Compound-57 Patented T77350 DRUGINFO D0RK3U PMID29865878-Compound-63 Patented T77350 DRUGINFO D0RY9I PMID29865878-Compound-62 Patented T77350 DRUGINFO D02SYR Peptide analog 27 Patented T77350 DRUGINFO D03JMZ Peptide analog 28 Patented T77350 DRUGINFO D05MVF Peptide analog 34 Patented T77350 DRUGINFO D06OXO Peptide analog 33 Patented T77350 DRUGINFO D07SSU Peptide analog 31 Patented T77350 DRUGINFO D08HPR PMID29865878-Compound-44 Patented T77350 DRUGINFO D09WUW PMID29865878-Compound-43 Patented T77350 DRUGINFO D0AR6B Peptide analog 13 Patented T77350 DRUGINFO D0B0GG Dipeptide analog 1 Patented T77350 DRUGINFO D0DK3R Peptide analog 25 Patented T77350 DRUGINFO D0E6ED Peptide analog 11 Patented T77350 DRUGINFO D0L1TT Peptide analog 17 Patented T77350 DRUGINFO D0P8VL PMID29865878-Compound-8 Patented T77350 DRUGINFO D0Q0XN Peptide analog 19 Patented T77350 DRUGINFO D01VMN PMID29865878-Compound-53 Patented T77350 DRUGINFO D03CMD PMID29865878-Compound-55 Patented T77350 DRUGINFO D0C2MH PMID29865878-Compound-46 Patented T77350 DRUGINFO D0K0GJ PMID29865878-Compound-48 Patented T77350 DRUGINFO D0NE8M PMID29865878-Compound-51 Patented T77350 DRUGINFO D0TU5R PMID29865878-Compound-49 Patented T77350 DRUGINFO D01OOO Peptide analog 41 Patented T77350 DRUGINFO D02PJI Peptide analog 21 Patented T77350 DRUGINFO D0T1YB Peptide analog 23 Patented T77350 DRUGINFO D0K7CX HT1042 Investigative T62841 TARGETID T62841 T62841 FORMERID TTDR00109 T62841 UNIPROID PAR2_HUMAN T62841 TARGNAME Proteinase activated receptor 2 (PAR2) T62841 GENENAME F2RL1 T62841 TARGTYPE Clinical trial T62841 SYNONYMS Thrombin receptor-like 1; Proteinase-activated receptor-2; Proteinase-activated receptor 2; Protease activated receptor 2; PAR-2; GPR11; G-protein coupled receptor 11; Coagulation factor II receptor-like 1 T62841 FUNCTION Its function is mediated through the activation of several signaling pathways including phospholipase C (PLC), intracellular calcium, mitogen-activated protein kinase (MAPK), I-kappaB kinase/NF-kappaB and Rho. Can also be transactivated by cleaved F2R/PAR1. Involved in modulation of inflammatory responses and regulation of innate and adaptive immunity, and acts as a sensor for proteolytic enzymes generated during infection. Generally is promoting inflammation. Can signal synergistically with TLR4 and probably TLR2 in inflammatory responses and modulates TLR3 signaling. Has a protective role in establishing the endothelial barrier; the activity involves coagulation factor X. Regulates endothelial cell barrier integrity during neutrophil extravasation, probably following proteolytic cleavage by PRTN3. Proposed to have a bronchoprotective role in airway epithelium, but also shown to compromise the airway epithelial barrier by interrupting E-cadherin adhesion. Involved in the regulation of vascular tone; activation results in hypotension presumably mediated by vasodilation. Associates with a subset of G proteins alpha subunits such as GNAQ, GNA11, GNA14, GNA12 and GNA13, but probably not with G(o) alpha, G(i) subunit alpha-1 and G(i) subunit alpha-2. However, according to can signal through G(i) subunit alpha. Believed to be a class B receptor which internalizes as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptor, for extended periods of time. Mediates inhibition of TNF-alpha stimulated JNK phosphorylation via coupling to GNAQ and GNA11; the function involves dissociation of RIPK1 and TRADD from TNFR1. Mediates phosphorylation of nuclear factor NF-kappa-B RELA subunit at 'Ser-536'; the function involves IKBKB and is predominantly independent of G proteins. Involved in cellular migration. Involved in cytoskeletal rearrangement and chemotaxis through beta-arrestin-promoted scaffolds; the function is independent of GNAQ and GNA11 and involves promotion of cofilin dephosphorylation and actin filament severing. Induces redistribution of COPS5 from the plasma membrane to the cytosol and activation of the JNK cascade is mediated by COPS5. Involved in the recruitment of leukocytes to the sites of inflammation and is the major PAR receptor capable of modulating eosinophil function such as proinflammatory cytokine secretion, superoxide production and degranulation. During inflammation promotes dendritic cell maturation, trafficking to the lymph nodes and subsequent T-cell activation. Involved in antimicrobial response of innate immnune cells; activation enhances phagocytosis of Gram-positive and killing of Gram-negative bacteria. Acts synergistically with interferon-gamma in enhancing antiviral responses. Implicated in a number of acute and chronic inflammatory diseases such as of the joints, lungs, brain, gastrointestinal tract, periodontium, skin, and vascular systems, and in autoimmune disorders. Receptor for trypsin and trypsin-like enzymes coupled to G proteins. T62841 PDBSTRUC 5NJ6; 5NDZ; 5NDD T62841 BIOCLASS GPCR rhodopsin T62841 SEQUENCE MRSPSAAWLLGAAILLAASLSCSGTIQGTNRSSKGRSLIGKVDGTSHVTGKGVTVETVFSVDEFSASVLTGKLTTVFLPIVYTIVFVVGLPSNGMALWVFLFRTKKKHPAVIYMANLALADLLSVIWFPLKIAYHIHGNNWIYGEALCNVLIGFFYGNMYCSILFMTCLSVQRYWVIVNPMGHSRKKANIAIGISLAIWLLILLVTIPLYVVKQTIFIPALNITTCHDVLPEQLLVGDMFNYFLSLAIGVFLFPAFLTASAYVLMIRMLRSSAMDENSEKKRKRAIKLIVTVLAMYLICFTPSNLLLVVHYFLIKSQGQSHVYALYIVALCLSTLNSCIDPFVYYFVSHDFRDHAKNALLCRSVRTVKQMQVSLTSKKHSRKSSSYSSSSTTVKTSY T62841 DRUGINFO DBNJ30 MEDI0618 Phase 1 T62841 DRUGINFO D02SJB Imidazopyridazine derivative 8 Patented T62841 DRUGINFO D04GIJ Piperazine urea derivative 4 Patented T62841 DRUGINFO D04YKO Piperidine derivative 2 Patented T62841 DRUGINFO D05VXK Benzimidazole derivative 10 Patented T62841 DRUGINFO D06XWQ Benzothiazine-carboxamide compound 2 Patented T62841 DRUGINFO D07AXK Peptide analog 71 Patented T62841 DRUGINFO D07HJT Amidine compound 3 Patented T62841 DRUGINFO D07OVM Benzothiazine-carboxamide compound 4 Patented T62841 DRUGINFO D08ZEM Quinazoline derivative 11 Patented T62841 DRUGINFO D09EIX PMID26936077-Compound-13 Patented T62841 DRUGINFO D0AK6L Amidine compound 4 Patented T62841 DRUGINFO D0CM5P Quinazoline derivative 10 Patented T62841 DRUGINFO D0D2PU Peptidomimetic analog 6 Patented T62841 DRUGINFO D0EC3H Quinazoline derivative 12 Patented T62841 DRUGINFO D0G2EP Amidine compound 6 Patented T62841 DRUGINFO D0G7KY Imidazopyridazine derivative 5 Patented T62841 DRUGINFO D0H1JS Piperazine urea derivative 3 Patented T62841 DRUGINFO D0H4SE Benzothiazine-carboxamide compound 6 Patented T62841 DRUGINFO D0I2RS PMID26936077-Compound-34 Patented T62841 DRUGINFO D0JT0B Amidine compound 5 Patented T62841 DRUGINFO D0K9QH Benzothiazine-carboxamide compound 3 Patented T62841 DRUGINFO D0LT5Y Piperazine derivative 5 Patented T62841 DRUGINFO D0N3AF Imidazopyridazine derivative 7 Patented T62841 DRUGINFO D0P2BJ Quinazoline derivative 13 Patented T62841 DRUGINFO D0P7UB Benzothiazine-carboxamide compound 1 Patented T62841 DRUGINFO D0Q8MQ Benzothiazine-carboxamide compound 5 Patented T62841 DRUGINFO D0S6SJ Piperidine derivative 3 Patented T62841 DRUGINFO D0T6SP Benzimidazole derivative 9 Patented T62841 DRUGINFO D0UD6X Imidazopyridazine derivative 3 Patented T62841 DRUGINFO D0UN9X Imidazopyridazine derivative 4 Patented T62841 DRUGINFO D0VN2U Amidine compound 1 Patented T62841 DRUGINFO D0W9AB Imidazopyridazine derivative 6 Patented T62841 DRUGINFO D0WH1K Amidine compound 2 Patented T62841 DRUGINFO D0Y9UV Peptide analog 72 Patented T62841 DRUGINFO D0Z4SW Benzimidazole derivative 8 Patented T62841 DRUGINFO D07ZNP GB110 Investigative T62841 DRUGINFO D0A5GJ GB88 Investigative T62841 DRUGINFO D0G7FS ASKH95 Investigative T12091 TARGETID T12091 T12091 FORMERID TTDI03010 T12091 UNIPROID ACVR1_HUMAN T12091 TARGNAME Activin receptor-like kinase 2 (ALK-2) T12091 GENENAME ACVR1 T12091 TARGTYPE Clinical trial T12091 SYNONYMS TSR-I; TGF-B superfamily receptor type I; Serine/threonine-protein kinase receptor R1; SKR1; Activin receptor type-1; Activin receptor type I; ACVRLK2; ACTR-I T12091 FUNCTION Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin. May be involved for left-right pattern formation during embryogenesis. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. T12091 PDBSTRUC 6GIP; 6GIN; 6GI6; 6EIX; 6ACR T12091 BIOCLASS Kinase T12091 ECNUMBER EC 2.7.11.30 T12091 SEQUENCE MVDGVMILPVLIMIALPSPSMEDEKPKVNPKLYMCVCEGLSCGNEDHCEGQQCFSSLSINDGFHVYQKGCFQVYEQGKMTCKTPPSPGQAVECCQGDWCNRNITAQLPTKGKSFPGTQNFHLEVGLIILSVVFAVCLLACLLGVALRKFKRRNQERLNPRDVEYGTIEGLITTNVGDSTLADLLDHSCTSGSGSGLPFLVQRTVARQITLLECVGKGRYGEVWRGSWQGENVAVKIFSSRDEKSWFRETELYNTVMLRHENILGFIASDMTSRHSSTQLWLITHYHEMGSLYDYLQLTTLDTVSCLRIVLSIASGLAHLHIEIFGTQGKPAIAHRDLKSKNILVKKNGQCCIADLGLAVMHSQSTNQLDVGNNPRVGTKRYMAPEVLDETIQVDCFDSYKRVDIWAFGLVLWEVARRMVSNGIVEDYKPPFYDVVPNDPSFEDMRKVVCVDQQRPNIPNRWFSDPTLTSLAKLMKECWYQNPSARLTALRIKKTLTKIDNSLDKLKTDC T12091 DRUGINFO D50OLM INCB00928 Phase 2 T12091 DRUGINFO DNI28K TP-0184 Phase 1 T12091 DRUGINFO D0A8BV PMID27774822-Compound-Figure10Compound12 Patented T12091 DRUGINFO D0AE0M PMID27774822-Compound-Figure10Compound4 Patented T12091 DRUGINFO D0RF7O ML347 Investigative T12091 DRUGINFO D06CMG LDN-214117 Investigative T12091 DRUGINFO D05NEC PMID23639540C13r Investigative T12091 DRUGINFO D0F2MP PMID23639540C13d Investigative T12091 DRUGINFO D0PP6Y PMID23639540C13a Investigative T38087 TARGETID T38087 T38087 UNIPROID TNKS2_HUMAN T38087 TARGNAME Tankyrase-2 (TNKS-2) T38087 GENENAME TNKS2 T38087 TARGTYPE Clinical trial T38087 SYNONYMS Tankyrase-related protein; Tankyrase-like protein; Tankyrase II; TRF1-interacting ankyrin-related ADP-ribose polymerase 2; TNKL; TANK2; Protein poly-ADP-ribosyltransferase tankyrase-2; Poly [ADP-ribose] polymerase tankyrase-2; Poly [ADP-ribose] polymerase 5B; PARP5B; ARTD6; ADP-ribosyltransferase diphtheria toxin-like 6 T38087 FUNCTION Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. Stimulates 26S proteasome activity. Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. T38087 PDBSTRUC 5OWT; 5OWS; 5NUT; 5NSP; 5NOB T38087 BIOCLASS Glycosyltransferases T38087 ECNUMBER EC 2.4.2.30 T38087 SEQUENCE MSGRRCAGGGAACASAAAEAVEPAARELFEACRNGDVERVKRLVTPEKVNSRDTAGRKSTPLHFAAGFGRKDVVEYLLQNGANVQARDDGGLIPLHNACSFGHAEVVNLLLRHGADPNARDNWNYTPLHEAAIKGKIDVCIVLLQHGAEPTIRNTDGRTALDLADPSAKAVLTGEYKKDELLESARSGNEEKMMALLTPLNVNCHASDGRKSTPLHLAAGYNRVKIVQLLLQHGADVHAKDKGDLVPLHNACSYGHYEVTELLVKHGACVNAMDLWQFTPLHEAASKNRVEVCSLLLSYGADPTLLNCHNKSAIDLAPTPQLKERLAYEFKGHSLLQAAREADVTRIKKHLSLEMVNFKHPQTHETALHCAAASPYPKRKQICELLLRKGANINEKTKEFLTPLHVASEKAHNDVVEVVVKHEAKVNALDNLGQTSLHRAAYCGHLQTCRLLLSYGCDPNIISLQGFTALQMGNENVQQLLQEGISLGNSEADRQLLEAAKAGDVETVKKLCTVQSVNCRDIEGRQSTPLHFAAGYNRVSVVEYLLQHGADVHAKDKGGLVPLHNACSYGHYEVAELLVKHGAVVNVADLWKFTPLHEAAAKGKYEICKLLLQHGADPTKKNRDGNTPLDLVKDGDTDIQDLLRGDAALLDAAKKGCLARVKKLSSPDNVNCRDTQGRHSTPLHLAAGYNNLEVAEYLLQHGADVNAQDKGGLIPLHNAASYGHVDVAALLIKYNACVNATDKWAFTPLHEAAQKGRTQLCALLLAHGADPTLKNQEGQTPLDLVSADDVSALLTAAMPPSALPSCYKPQVLNGVRSPGATADALSSGPSSPSSLSAASSLDNLSGSFSELSSVVSSSGTEGASSLEKKEVPGVDFSITQFVRNLGLEHLMDIFEREQITLDVLVEMGHKELKEIGINAYGHRHKLIKGVERLISGQQGLNPYLTLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEGMVDG T38087 DRUGINFO D0F5TD PMID27841036-Compound-37 Phase 2 T38087 DRUGINFO DP48WE Stenoparib Phase 2 T13176 TARGETID T13176 T13176 FORMERID TTDI03189 T13176 UNIPROID E2AK3_HUMAN T13176 TARGNAME PRKR-like endoplasmic reticulum kinase (PERK) T13176 GENENAME EIF2AK3 T13176 TARGTYPE Clinical trial T13176 SYNONYMS PEK T13176 FUNCTION Converts phosphorylated eIF-2-alpha/EIF2S1 either in a global protein synthesis inhibitor, leading to a reduced overall utilization of amino acids, or to a translation initiation activator of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function. Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the unfolded protein response (UPR) and in response to low amino acid availability. T13176 PDBSTRUC 5SV7; 4YZS; 4X7O; 4X7N; 4X7L T13176 BIOCLASS Kinase T13176 ECNUMBER EC 2.7.11.1 T13176 SEQUENCE MERAISPGLLVRALLLLLLLLGLAARTVAAGRARGLPAPTAEAAFGLGAAAAPTSATRVPAAGAVAAAEVTVEDAEALPAAAGEQEPRGPEPDDETELRPRGRSLVIISTLDGRIAALDPENHGKKQWDLDVGSGSLVSSSLSKPEVFGNKMIIPSLDGALFQWDQDRESMETVPFTVESLLESSYKFGDDVVLVGGKSLTTYGLSAYSGKVRYICSALGCRQWDSDEMEQEEDILLLQRTQKTVRAVGPRSGNEKWNFSVGHFELRYIPDMETRAGFIESTFKPNENTEESKIISDVEEQEAAIMDIVIKVSVADWKVMAFSKKGGHLEWEYQFCTPIASAWLLKDGKVIPISLFDDTSYTSNDDVLEDEEDIVEAARGATENSVYLGMYRGQLYLQSSVRISEKFPSSPKALESVTNENAIIPLPTIKWKPLIHSPSRTPVLVGSDEFDKCLSNDKFSHEEYSNGALSILQYPYDNGYYLPYYKRERNKRSTQITVRFLDNPHYNKNIRKKDPVLLLHWWKEIVATILFCIIATTFIVRRLFHPHPHRQRKESETQCQTENKYDSVSGEANDSSWNDIKNSGYISRYLTDFEPIQCLGRGGFGVVFEAKNKVDDCNYAIKRIRLPNRELAREKVMREVKALAKLEHPGIVRYFNAWLEAPPEKWQEKMDEIWLKDESTDWPLSSPSPMDAPSVKIRRMDPFATKEHIEIIAPSPQRSRSFSVGISCDQTSSSESQFSPLEFSGMDHEDISESVDAAYNLQDSCLTDCDVEDGTMDGNDEGHSFELCPSEASPYVRSRERTSSSIVFEDSGCDNASSKEEPKTNRLHIGNHCANKLTAFKPTSSKSSSEATLSISPPRPTTLSLDLTKNTTEKLQPSSPKVYLYIQMQLCRKENLKDWMNGRCTIEERERSVCLHIFLQIAEAVEFLHSKGLMHRDLKPSNIFFTMDDVVKVGDFGLVTAMDQDEEEQTVLTPMPAYARHTGQVGTKLYMSPEQIHGNSYSHKVDIFSLGLILFELLYPFSTQMERVRTLTDVRNLKFPPLFTQKYPCEYVMVQDMLSPSPMERPEAINIIENAVFEDLDFPGKTVLRQRSRSLSSSGTKHSRQSNNSHSPLPSN T13176 DRUGINFO DJQ96R HC-5404 Phase 1 T13176 DRUGINFO D04AMY Phenylpyrrolidinone derivative 3 Patented T13176 DRUGINFO D06PIO Indoline derivative 6 Patented T13176 DRUGINFO D08HTR Tricyclic isoxazoloquinazoline derivative 1 Patented T13176 DRUGINFO D08JII Phenylpyrrolidinone derivative 1 Patented T13176 DRUGINFO D0D4FR Phenylpyrrolidinone derivative 5 Patented T13176 DRUGINFO D0DY3E Indoline derivative 3 Patented T13176 DRUGINFO D0G5EI Indoline derivative 11 Patented T13176 DRUGINFO D0H1WN Indoline derivative 8 Patented T13176 DRUGINFO D0KH5D Indoline derivative 2 Patented T13176 DRUGINFO D0NA2Q Indoline derivative 9 Patented T13176 DRUGINFO D0RX8U Indoline derivative 10 Patented T13176 DRUGINFO D0U8IL Phenylpyrrolidinone derivative 2 Patented T13176 DRUGINFO D0YF7Q Indoline derivative 7 Patented T13176 DRUGINFO D0Z5NP Phenylpyrrolidinone derivative 4 Patented T13176 DRUGINFO D06GGI Tricyclic isoxazoloquinazoline derivative 2 Patented T13176 DRUGINFO D0JC8E Tricyclic isoxazoloquinazoline derivative 4 Patented T13176 DRUGINFO D0WK2S Tricyclic isoxazoloquinazoline derivative 3 Patented T13176 DRUGINFO D0N4LR GSK2606414 Investigative T80886 TARGETID T80886 T80886 UNIPROID BACH1_HUMAN T80886 TARGNAME Transcription regulator protein BACH1 (Bach1) T80886 GENENAME BACH1 T80886 TARGTYPE Clinical trial T80886 SYNONYMS HA2303; BTB and CNC homolog 1 T80886 FUNCTION Binds to NF-E2 DNA binding sites. Play important roles in coordinating transcription activation and repression by MAFK. Together with MAF, represses the transcription of genes under the control of the NFE2L2 oxidative stress pathway. Transcriptional regulator that acts as repressor or activator, depending on the context. T80886 PDBSTRUC 2IHC T80886 BIOCLASS Basic leucine zipper bZIP T80886 SEQUENCE MSLSENSVFAYESSVHSTNVLLSLNDQRKKDVLCDVTIFVEGQRFRAHRSVLAACSSYFHSRIVGQADGELNITLPEEVTVKGFEPLIQFAYTAKLILSKENVDEVCKCVEFLSVHNIEESCFQFLKFKFLDSTADQQECPRKKCFSSHCQKTDLKLSLLDQRDLETDEVEEFLENKNVQTPQCKLRRYQGNAKASPPLQDSASQTYESMCLEKDAALALPSLCPKYRKFQKAFGTDRVRTGESSVKDIHASVQPNERSENECLGGVPECRDLQVMLKCDESKLAMEPEETKKDPASQCPTEKSEVTPFPHNSSIDPHGLYSLSLLHTYDQYGDLNFAGMQNTTVLTEKPLSGTDVQEKTFGESQDLPLKSDLGTREDSSVASSDRSSVEREVAEHLAKGFWSDICSTDTPCQMQLSPAVAKDGSEQISQKRSECPWLGIRISESPEPGQRTFTTLSSVNCPFISTLSTEGCSSNLEIGNDDYVSEPQQEPCPYACVISLGDDSETDTEGDSESCSAREQECEVKLPFNAQRIISLSRNDFQSLLKMHKLTPEQLDCIHDIRRRSKNRIAAQRCRKRKLDCIQNLESEIEKLQSEKESLLKERDHILSTLGETKQNLTGLCQKVCKEAALSQEQIQILAKYSAADCPLSFLISEKDKSTPDGELALPSIFSLSDRPPAVLPPCARGNSEPGYARGQESQQMSTATSEQAGPAEQCRQSGGISDFCQQMTDKCTTDE T80886 DRUGINFO DPIE08 ASP8731 Phase 1 T46526 TARGETID T46526 T46526 UNIPROID FIMH_ECOLI T46526 TARGNAME Bacterial Fimbrin D-mannose adhesin (Bact FimH) T46526 GENENAME Bact FimH T46526 TARGTYPE Clinical trial T46526 SYNONYMS fimH; b4320; Type 1 fimbrin D-mannose specific adhesin; Protein FimH; JW4283 T46526 FUNCTION Adhesin responsible for the binding to D-mannose. It is laterally positioned at intervals in the structure of the type 1 fimbriae. In order to integrate FimH in the fimbriae FimF and FimG are needed. Involved in regulation of length and mediation of adhesion of type 1 fimbriae (but not necessary for the production of fimbriae). T46526 PDBSTRUC 6GTY; 6GTX; 6G2S; 6G2R; 6.00E+15 T46526 SEQUENCE MKRVITLFAVLLMGWSVNAWSFACKTANGTAIPIGGGSANVYVNLAPVVNVGQNLVVDLSTQIFCHNDYPETITDYVTLQRGSAYGGVLSNFSGTVKYSGSSYPFPTTSETPRVVYNSRTDKPWPVALYLTPVSSAGGVAIKAGSLIAVLILRQTNNYNSDDFQFVWNIYANNDVVVPTGGCDVSARDVTVTLPDYPGSVPIPLTVYCAKSQNLGYYLSGTTADAGNSIFTNTASFSPAQGVGVQLTRNGTIIPANNTVSLGAVGTSAVSLGLTANYARTGGQVTAGNVQSIIGVTFVYQ T46526 DRUGINFO D72HXF EB8018 Phase 2 T46526 DRUGINFO D7PFL1 GSK3882347 Phase 1 T46526 DRUGINFO D7PFL1 GSK3882347 Phase 1 T46526 DRUGINFO D00COH Biaryl mannoside derivative 24 Patented T46526 DRUGINFO D00KKD PMID26651364-Compound-5 Patented T46526 DRUGINFO D00RDO PMID26651364-Compound-116 Patented T46526 DRUGINFO D00RQW Biaryl mannoside derivative 8 Patented T46526 DRUGINFO D00XEM Beta-cyclodextrin conjugate derivative 3 Patented T46526 DRUGINFO D00XKE PMID26651364-Compound-109 Patented T46526 DRUGINFO D01CND PMID26651364-Compound-114 Patented T46526 DRUGINFO D01PBX Biphenyl mannoside derivative 6 Patented T46526 DRUGINFO D01RHK PMID26651364-Compound-5d Patented T46526 DRUGINFO D01ZKE Biaryl mannoside derivative 21 Patented T46526 DRUGINFO D02AAD Biaryl mannoside derivative 31 Patented T46526 DRUGINFO D02DFJ Biaryl mannoside derivative 10 Patented T46526 DRUGINFO D02HPF Biaryl mannoside derivative 9 Patented T46526 DRUGINFO D02NDP PMID26651364-Compound-7a Patented T46526 DRUGINFO D02UDO PMID26651364-Compound-9d Patented T46526 DRUGINFO D02WWT Aryl mannoside derivative 19 Patented T46526 DRUGINFO D02XNH C-linked disaccharide biphenyl mannoside derivative 6 Patented T46526 DRUGINFO D02ZYV Biaryl mannoside derivative 15 Patented T46526 DRUGINFO D03CTH Biphenyl mannoside derivative 10 Patented T46526 DRUGINFO D03HHG PMID26651364-Compound-121 Patented T46526 DRUGINFO D03ITZ Aryl mannoside derivative 4 Patented T46526 DRUGINFO D03JFJ PMID26651364-Compound-108 Patented T46526 DRUGINFO D03KAV Biphenyl mannoside derivative 12 Patented T46526 DRUGINFO D03RXE Biphenyl mannoside derivative 3 Patented T46526 DRUGINFO D03WJB Biphenyl mannoside derivative 25 Patented T46526 DRUGINFO D03WXM C-linked disaccharide biphenyl mannoside derivative 4 Patented T46526 DRUGINFO D04NXG PMID26651364-Compound-128 Patented T46526 DRUGINFO D04PKX PMID26651364-Compound-125 Patented T46526 DRUGINFO D05AZE Biphenyl mannoside derivative 30 Patented T46526 DRUGINFO D05BTL PMID26651364-Compound-126c Patented T46526 DRUGINFO D05BUD Mannoside derivative 10 Patented T46526 DRUGINFO D05CBP PMID26651364-Compound-9a Patented T46526 DRUGINFO D05HKC PMID26651364-Compound-123 Patented T46526 DRUGINFO D05JAS Biphenyl mannoside derivative 5 Patented T46526 DRUGINFO D05OMO PMID26651364-Compound-11b Patented T46526 DRUGINFO D05WWX Biphenyl mannoside derivative 14 Patented T46526 DRUGINFO D05XGH PMID26651364-Compound-6e Patented T46526 DRUGINFO D05ZHZ PMID26651364-Compound-5e Patented T46526 DRUGINFO D06PNN Biaryl mannoside derivative 26 Patented T46526 DRUGINFO D06SWT Aryl mannoside derivative 5 Patented T46526 DRUGINFO D07GAN Biaryl mannoside derivative 12 Patented T46526 DRUGINFO D07HOP Alkyl mannoside derivative 9 Patented T46526 DRUGINFO D07KCA Aryl mannoside derivative 22 Patented T46526 DRUGINFO D07POS Alkyl mannoside derivative 12 Patented T46526 DRUGINFO D07PVX Aryl mannoside derivative 21 Patented T46526 DRUGINFO D07QAH Biaryl mannoside derivative 17 Patented T46526 DRUGINFO D07RAA PMID26651364-Compound-119 Patented T46526 DRUGINFO D07RQA Alkyl mannoside derivative 8 Patented T46526 DRUGINFO D08BLZ Aryl mannoside derivative 23 Patented T46526 DRUGINFO D08BNB Biaryl mannoside derivative 5 Patented T46526 DRUGINFO D08OXD Mannoside derivative 8 Patented T46526 DRUGINFO D08WZC PMID26651364-Compound-48 Patented T46526 DRUGINFO D09BGB Aryl mannoside derivative 1 Patented T46526 DRUGINFO D09EIQ Biaryl mannoside derivative 18 Patented T46526 DRUGINFO D09EXQ PMID26651364-Compound-8a Patented T46526 DRUGINFO D09JDV PMID26651364-Compound-5a Patented T46526 DRUGINFO D09LWP PMID26651364-Compound-105 Patented T46526 DRUGINFO D09LWZ Mannoside derivative 7 Patented T46526 DRUGINFO D09SLI Aryl mannoside derivative 13 Patented T46526 DRUGINFO D09TKY Biaryl mannoside derivative 7 Patented T46526 DRUGINFO D09ZCA Biphenyl mannoside derivative 24 Patented T46526 DRUGINFO D0A3PP Biphenyl mannoside derivative 4 Patented T46526 DRUGINFO D0A8GW PMID26651364-Compound-9e Patented T46526 DRUGINFO D0A8RV Biaryl mannoside derivative 4 Patented T46526 DRUGINFO D0AK2Y PMID26651364-Compound-7b Patented T46526 DRUGINFO D0AM0A Aryl mannoside derivative 15 Patented T46526 DRUGINFO D0AY0H PMID26651364-Compound-10c Patented T46526 DRUGINFO D0B1HT Biaryl mannoside derivative 20 Patented T46526 DRUGINFO D0B3CU C-linked disaccharide biphenyl mannoside derivative 5 Patented T46526 DRUGINFO D0B8RU Aryl mannoside derivative 14 Patented T46526 DRUGINFO D0B9LM PMID26651364-Compound-8b Patented T46526 DRUGINFO D0BR9C Biphenyl mannoside derivative 2 Patented T46526 DRUGINFO D0BS3E Biphenyl mannoside derivative 21 Patented T46526 DRUGINFO D0C8EB PMID26651364-Compound-45 Patented T46526 DRUGINFO D0CD7Q Beta-cyclodextrin conjugate derivative 4 Patented T46526 DRUGINFO D0CN6Q PMID26651364-Compound-5c Patented T46526 DRUGINFO D0CN7A PMID26651364-Compound-7c Patented T46526 DRUGINFO D0CR8J Biphenyl mannoside derivative 26 Patented T46526 DRUGINFO D0D2QE PMID26651364-Compound-117b Patented T46526 DRUGINFO D0D6HS Mannoside derivative 12 Patented T46526 DRUGINFO D0D6OM Alkyl mannoside derivative 7 Patented T46526 DRUGINFO D0D9MV Aryl mannoside derivative 17 Patented T46526 DRUGINFO D0DH0Y Aryl mannoside derivative 12 Patented T46526 DRUGINFO D0DI1T Biaryl mannoside derivative 16 Patented T46526 DRUGINFO D0DI6U Alkyl mannoside derivative 10 Patented T46526 DRUGINFO D0DW7A PMID26651364-Compound-6b Patented T46526 DRUGINFO D0E1GC PMID26651364-Compound-5g Patented T46526 DRUGINFO D0E3DS Alkyl mannoside derivative 11 Patented T46526 DRUGINFO D0E9GD Biphenyl mannoside derivative 15 Patented T46526 DRUGINFO D0EA9Y Biaryl mannoside derivative 14 Patented T46526 DRUGINFO D0ET9M Biaryl mannoside derivative 30 Patented T46526 DRUGINFO D0F6TN Mannoside derivative 6 Patented T46526 DRUGINFO D0FI3Q Biaryl mannoside derivative 13 Patented T46526 DRUGINFO D0FL3H PMID26651364-Compound-6a Patented T46526 DRUGINFO D0FS9V PMID26651364-Compound-120 Patented T46526 DRUGINFO D0FT4P Aryl mannoside derivative 3 Patented T46526 DRUGINFO D0G9KS Aryl mannoside derivative 2 Patented T46526 DRUGINFO D0GB6Y PMID26651364-Compound-10a Patented T46526 DRUGINFO D0GM6O Biphenyl mannoside derivative 9 Patented T46526 DRUGINFO D0GP7L PMID26651364-Compound-115 Patented T46526 DRUGINFO D0GR3C Biphenyl mannoside derivative 22 Patented T46526 DRUGINFO D0GV9F Biaryl mannoside derivative 2 Patented T46526 DRUGINFO D0H1BZ Biaryl mannoside derivative 19 Patented T46526 DRUGINFO D0H4CL C-linked disaccharide biphenyl mannoside derivative 1 Patented T46526 DRUGINFO D0H7UR Mannoside derivative 11 Patented T46526 DRUGINFO D0HE3B Biphenyl mannoside derivative 18 Patented T46526 DRUGINFO D0I2MR PMID26651364-Compound-9f Patented T46526 DRUGINFO D0IB8D PMID26651364-Compound-117a Patented T46526 DRUGINFO D0IF4J PMID26651364-Compound-110 Patented T46526 DRUGINFO D0J0LC PMID26651364-Compound-4 Patented T46526 DRUGINFO D0J8HJ PMID26651364-Compound-127 Patented T46526 DRUGINFO D0K2AA Biaryl mannoside derivative 11 Patented T46526 DRUGINFO D0K3DA PMID26651364-Compound-112 Patented T46526 DRUGINFO D0K7TE Biaryl mannoside derivative 27 Patented T46526 DRUGINFO D0KE8Q PMID26651364-Compound-46 Patented T46526 DRUGINFO D0KG5U PMID26651364-Compound-9b Patented T46526 DRUGINFO D0KX1A Aryl mannoside derivative 6 Patented T46526 DRUGINFO D0L1PO Alkyl mannoside derivative 4 Patented T46526 DRUGINFO D0L2QZ Biphenyl mannoside derivative 27 Patented T46526 DRUGINFO D0L3JL Aryl mannoside derivative 8 Patented T46526 DRUGINFO D0L5OP PMID26651364-Compound-6c Patented T46526 DRUGINFO D0LZ1W PMID26651364-Compound-122 Patented T46526 DRUGINFO D0M7XB Beta-cyclodextrin conjugate derivative 1 Patented T46526 DRUGINFO D0MO0Z Alkyl mannoside derivative 5 Patented T46526 DRUGINFO D0MZ8J PMID26651364-Compound-10d Patented T46526 DRUGINFO D0N2AI Biphenyl mannoside derivative 19 Patented T46526 DRUGINFO D0N4TO Biphenyl mannoside derivative 11 Patented T46526 DRUGINFO D0N4WW PMID26651364-Compound-106 Patented T46526 DRUGINFO D0NB5P Biphenyl mannoside derivative 8 Patented T46526 DRUGINFO D0O4TC PMID26651364-Compound-10b Patented T46526 DRUGINFO D0O8EX PMID26651364-Compound-8c Patented T46526 DRUGINFO D0OQ2R Mannoside derivative 1 Patented T46526 DRUGINFO D0OW1V Biaryl mannoside derivative 25 Patented T46526 DRUGINFO D0OW6O PMID26651364-Compound-11c Patented T46526 DRUGINFO D0P3SL PMID26651364-Compound-8d Patented T46526 DRUGINFO D0Q0XC PMID26651364-Compound-9c Patented T46526 DRUGINFO D0Q1SX PMID26651364-Compound-7e Patented T46526 DRUGINFO D0Q7QK Mannoside derivative 13 Patented T46526 DRUGINFO D0QL0X Biaryl mannoside derivative 23 Patented T46526 DRUGINFO D0QM2O PMID26651364-Compound-5f Patented T46526 DRUGINFO D0QQ5W Beta-cyclodextrin conjugate derivative 2 Patented T46526 DRUGINFO D0QU6N PMID26651364-Compound-47 Patented T46526 DRUGINFO D0R1GD Aryl mannoside derivative 16 Patented T46526 DRUGINFO D0R1SQ Biaryl mannoside derivative 1 Patented T46526 DRUGINFO D0R2GA Biaryl mannoside derivative 29 Patented T46526 DRUGINFO D0R6FO Aryl mannoside derivative 10 Patented T46526 DRUGINFO D0R7YN Mannoside derivative 3 Patented T46526 DRUGINFO D0RE0F Biphenyl mannoside derivative 13 Patented T46526 DRUGINFO D0RG1Z Biaryl mannoside derivative 22 Patented T46526 DRUGINFO D0RZ5E Biphenyl mannoside derivative 17 Patented T46526 DRUGINFO D0SD4Q Aryl mannoside derivative 11 Patented T46526 DRUGINFO D0SE7V Alkyl mannoside derivative 3 Patented T46526 DRUGINFO D0SR8I PMID26651364-Compound-124 Patented T46526 DRUGINFO D0SU0E Biphenyl mannoside derivative 1 Patented T46526 DRUGINFO D0T6NX Biphenyl mannoside derivative 29 Patented T46526 DRUGINFO D0T7VN Aryl mannoside derivative 20 Patented T46526 DRUGINFO D0TP8T PMID26651364-Compound-113 Patented T46526 DRUGINFO D0TY1Q Mannoside derivative 9 Patented T46526 DRUGINFO D0UB8U Alkyl mannoside derivative 6 Patented T46526 DRUGINFO D0UE3F Biphenyl mannoside derivative 28 Patented T46526 DRUGINFO D0UG9S Biphenyl mannoside derivative 7 Patented T46526 DRUGINFO D0UK1S PMID26651364-Compound-126a Patented T46526 DRUGINFO D0US5I C-linked disaccharide biphenyl mannoside derivative 2 Patented T46526 DRUGINFO D0UZ2S PMID26651364-Compound-6d Patented T46526 DRUGINFO D0VA1D Alkyl mannoside derivative 1 Patented T46526 DRUGINFO D0VB4T Aryl mannoside derivative 9 Patented T46526 DRUGINFO D0VF5B PMID26651364-Compound-107 Patented T46526 DRUGINFO D0VG0F Biphenyl mannoside derivative 23 Patented T46526 DRUGINFO D0W1SE PMID26651364-Compound-5b Patented T46526 DRUGINFO D0W7VE Biphenyl mannoside derivative 20 Patented T46526 DRUGINFO D0WO2I PMID26651364-Compound-111 Patented T46526 DRUGINFO D0WO6C PMID26651364-Compound-49 Patented T46526 DRUGINFO D0WV9J Beta-cyclodextrin conjugate derivative 5 Patented T46526 DRUGINFO D0WW9B Aryl mannoside derivative 18 Patented T46526 DRUGINFO D0X4TV PMID26651364-Compound-118 Patented T46526 DRUGINFO D0X7HN PMID26651364-Compound-50 Patented T46526 DRUGINFO D0X8AB Mannoside derivative 4 Patented T46526 DRUGINFO D0XH4K C-linked disaccharide biphenyl mannoside derivative 3 Patented T46526 DRUGINFO D0XP5X Mannoside derivative 5 Patented T46526 DRUGINFO D0XR1C Biaryl mannoside derivative 28 Patented T46526 DRUGINFO D0Y0SI Aryl mannoside derivative 7 Patented T46526 DRUGINFO D0Y3UB PMID26651364-Compound-7d Patented T46526 DRUGINFO D0YX4L PMID26651364-Compound-126b Patented T46526 DRUGINFO D0Z1YF Biphenyl mannoside derivative 16 Patented T46526 DRUGINFO D0Z1ZA Mannoside derivative 2 Patented T46526 DRUGINFO D0Z6PF Alkyl mannoside derivative 2 Patented T46526 DRUGINFO D0ZD6N Biaryl mannoside derivative 3 Patented T46526 DRUGINFO D0ZR2O Biaryl mannoside derivative 6 Patented T46526 DRUGINFO DV19IS mAb926 Preclinical T22496 TARGETID T22496 T22496 FORMERID TTDI02645 T22496 UNIPROID HD_HUMAN T22496 TARGNAME Huntingtin (HTT) T22496 GENENAME HTT T22496 TARGTYPE Clinical trial T22496 SYNONYMS IT15; Huntington disease protein; HD protein; HD T22496 FUNCTION May play a role in microtubule-mediated transport or vesicle function. T22496 PDBSTRUC 6N8C; 6EZ8; 4RAV; 4FED; 4FEC T22496 SEQUENCE MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQPPPPPPPPPPPQLPQPPPQAQPLLPQPQPPPPPPPPPPGPAVAEEPLHRPKKELSATKKDRVNHCLTICENIVAQSVRNSPEFQKLLGIAMELFLLCSDDAESDVRMVADECLNKVIKALMDSNLPRLQLELYKEIKKNGAPRSLRAALWRFAELAHLVRPQKCRPYLVNLLPCLTRTSKRPEESVQETLAAAVPKIMASFGNFANDNEIKVLLKAFIANLKSSSPTIRRTAAGSAVSICQHSRRTQYFYSWLLNVLLGLLVPVEDEHSTLLILGVLLTLRYLVPLLQQQVKDTSLKGSFGVTRKEMEVSPSAEQLVQVYELTLHHTQHQDHNVVTGALELLQQLFRTPPPELLQTLTAVGGIGQLTAAKEESGGRSRSGSIVELIAGGGSSCSPVLSRKQKGKVLLGEEEALEDDSESRSDVSSSALTASVKDEISGELAASSGVSTPGSAGHDIITEQPRSQHTLQADSVDLASCDLTSSATDGDEEDILSHSSSQVSAVPSDPAMDLNDGTQASSPISDSSQTTTEGPDSAVTPSDSSEIVLDGTDNQYLGLQIGQPQDEDEEATGILPDEASEAFRNSSMALQQAHLLKNMSHCRQPSDSSVDKFVLRDEATEPGDQENKPCRIKGDIGQSTDDDSAPLVHCVRLLSASFLLTGGKNVLVPDRDVRVSVKALALSCVGAAVALHPESFFSKLYKVPLDTTEYPEEQYVSDILNYIDHGDPQVRGATAILCGTLICSILSRSRFHVGDWMGTIRTLTGNTFSLADCIPLLRKTLKDESSVTCKLACTAVRNCVMSLCSSSYSELGLQLIIDVLTLRNSSYWLVRTELLETLAEIDFRLVSFLEAKAENLHRGAHHYTGLLKLQERVLNNVVIHLLGDEDPRVRHVAAASLIRLVPKLFYKCDQGQADPVVAVARDQSSVYLKLLMHETQPPSHFSVSTITRIYRGYNLLPSITDVTMENNLSRVIAAVSHELITSTTRALTFGCCEALCLLSTAFPVCIWSLGWHCGVPPLSASDESRKSCTVGMATMILTLLSSAWFPLDLSAHQDALILAGNLLAASAPKSLRSSWASEEEANPAATKQEEVWPALGDRALVPMVEQLFSHLLKVINICAHVLDDVAPGPAIKAALPSLTNPPSLSPIRRKGKEKEPGEQASVPLSPKKGSEASAASRQSDTSGPVTTSKSSSLGSFYHLPSYLKLHDVLKATHANYKVTLDLQNSTEKFGGFLRSALDVLSQILELATLQDIGKCVEEILGYLKSCFSREPMMATVCVQQLLKTLFGTNLASQFDGLSSNPSKSQGRAQRLGSSSVRPGLYHYCFMAPYTHFTQALADASLRNMVQAEQENDTSGWFDVLQKVSTQLKTNLTSVTKNRADKNAIHNHIRLFEPLVIKALKQYTTTTCVQLQKQVLDLLAQLVQLRVNYCLLDSDQVFIGFVLKQFEYIEVGQFRESEAIIPNIFFFLVLLSYERYHSKQIIGIPKIIQLCDGIMASGRKAVTHAIPALQPIVHDLFVLRGTNKADAGKELETQKEVVVSMLLRLIQYHQVLEMFILVLQQCHKENEDKWKRLSRQIADIILPMLAKQQMHIDSHEALGVLNTLFEILAPSSLRPVDMLLRSMFVTPNTMASVSTVQLWISGILAILRVLISQSTEDIVLSRIQELSFSPYLISCTVINRLRDGDSTSTLEEHSEGKQIKNLPEETFSRFLLQLVGILLEDIVTKQLKVEMSEQQHTFYCQELGTLLMCLIHIFKSGMFRRITAAATRLFRSDGCGGSFYTLDSLNLRARSMITTHPALVLLWCQILLLVNHTDYRWWAEVQQTPKRHSLSSTKLLSPQMSGEEEDSDLAAKLGMCNREIVRRGALILFCDYVCQNLHDSEHLTWLIVNHIQDLISLSHEPPVQDFISAVHRNSAASGLFIQAIQSRCENLSTPTMLKKTLQCLEGIHLSQSGAVLTLYVDRLLCTPFRVLARMVDILACRRVEMLLAANLQSSMAQLPMEELNRIQEYLQSSGLAQRHQRLYSLLDRFRLSTMQDSLSPSPPVSSHPLDGDGHVSLETVSPDKDWYVHLVKSQCWTRSDSALLEGAELVNRIPAEDMNAFMMNSEFNLSLLAPCLSLGMSEISGGQKSALFEAAREVTLARVSGTVQQLPAVHHVFQPELPAEPAAYWSKLNDLFGDAALYQSLPTLARALAQYLVVVSKLPSHLHLPPEKEKDIVKFVVATLEALSWHLIHEQIPLSLDLQAGLDCCCLALQLPGLWSVVSSTEFVTHACSLIYCVHFILEAVAVQPGEQLLSPERRTNTPKAISEEEEEVDPNTQNPKYITAACEMVAEMVESLQSVLALGHKRNSGVPAFLTPLLRNIIISLARLPLVNSYTRVPPLVWKLGWSPKPGGDFGTAFPEIPVEFLQEKEVFKEFIYRINTLGWTSRTQFEETWATLLGVLVTQPLVMEQEESPPEEDTERTQINVLAVQAITSLVLSAMTVPVAGNPAVSCLEQQPRNKPLKALDTRFGRKLSIIRGIVEQEIQAMVSKRENIATHHLYQAWDPVPSLSPATTGALISHEKLLLQINPERELGSMSYKLGQVSIHSVWLGNSITPLREEEWDEEEEEEADAPAPSSPPTSPVNSRKHRAGVDIHSCSQFLLELYSRWILPSSSARRTPAILISEVVRSLLVVSDLFTERNQFELMYVTLTELRRVHPSEDEILAQYLVPATCKAAAVLGMDKAVAEPVSRLLESTLRSSHLPSRVGALHGVLYVLECDLLDDTAKQLIPVISDYLLSNLKGIAHCVNIHSQQHVLVMCATAFYLIENYPLDVGPEFSASIIQMCGVMLSGSEESTPSIIYHCALRGLERLLLSEQLSRLDAESLVKLSVDRVNVHSPHRAMAALGLMLTCMYTGKEKVSPGRTSDPNPAAPDSESVIVAMERVSVLFDRIRKGFPCEARVVARILPQFLDDFFPPQDIMNKVIGEFLSNQQPYPQFMATVVYKVFQTLHSTGQSSMVRDWVMLSLSNFTQRAPVAMATWSLSCFFVSASTSPWVAAILPHVISRMGKLEQVDVNLFCLVATDFYRHQIEEELDRRAFQSVLEVVAAPGSPYHRLLTCLRNVHKVTTC T22496 DRUGINFO DMOV12 Tominersen Phase 3 T22496 DRUGINFO D09ROP AMT-130 Phase 1/2 T83198 TARGETID T83198 T83198 UNIPROID KEAP1_HUMAN T83198 TARGNAME Cysteines of Keap1 (KEAP1 Cysteines) T83198 GENENAME KEAP1 T83198 TARGTYPE Clinical trial T83198 SYNONYMS Kelch-like protein 19-Cysteines; Kelch-like ECH-associated protein 1-Cysteines; KLHL19-Cysteines; KIAA0132-Cysteines; INrf2-Cysteines; Cytosolic inhibitor of Nrf2-Cysteines T83198 FUNCTION Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. T83198 PDBSTRUC 6FMQ; 6FMP; 6FFM; 5X54; 5WIY T83198 SEQUENCE MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVRCESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDYLVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVETETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAVTMEPCRKQIDQQNCTC T83198 DRUGINFO DF1JO7 CXA10 Phase 2 T83198 DRUGINFO D01GTU PMID28454500-Compound-8 Patented T83198 DRUGINFO D01MZI Pyrazino[2,1-a]isoquinolin derivative 4 Patented T83198 DRUGINFO D01PKZ PMID28454500-Compound-36 Patented T83198 DRUGINFO D02SPI Chalcone derivative 4 Patented T83198 DRUGINFO D02YNU 2-hydroxybenzamide derivative 1 Patented T83198 DRUGINFO D04ILM Vinyl sulfone derivative 1 Patented T83198 DRUGINFO D06LEF Pyrazino[2,1-a]isoquinolin derivative 2 Patented T83198 DRUGINFO D09FZF Diterpenoid derivative 1 Patented T83198 DRUGINFO D0AJ2T PMID28454500-Compound-13 Patented T83198 DRUGINFO D0AX4Q PMID28454500-Compound-12 Patented T83198 DRUGINFO D0AZ8T Pyrazino[2,1-a]isoquinolin derivative 1 Patented T83198 DRUGINFO D0C1PB PMID28454500-Compound-41 Patented T83198 DRUGINFO D0EO3S Chalcone derivative 2 Patented T83198 DRUGINFO D0FH6P PMID28454500-Compound-34 Patented T83198 DRUGINFO D0FM3Q PMID28454500-Compound-33 Patented T83198 DRUGINFO D0G1LS Chalcone derivative 3 Patented T83198 DRUGINFO D0G4EK PMID28454500-Compound-50 Patented T83198 DRUGINFO D0JH8Z PMID28454500-Compound-3 Patented T83198 DRUGINFO D0KX0J Pyridyl compound 1 Patented T83198 DRUGINFO D0L1JQ PMID28454500-Compound-32 Patented T83198 DRUGINFO D0MQ3X PMID28454500-Compound-40 Patented T83198 DRUGINFO D0MX0Q PMID28454500-Compound-35 Patented T83198 DRUGINFO D0N1VC PMID28454500-Compound-49 Patented T83198 DRUGINFO D0N9GH PMID28454500-Compound-9 Patented T83198 DRUGINFO D0Q9QQ Diterpenoid derivative 2 Patented T83198 DRUGINFO D0RM4V PMID28454500-Compound-11 Patented T83198 DRUGINFO D0SA1N PMID28454500-Compound-37 Patented T83198 DRUGINFO D0U9TR Chalcone derivative 1 Patented T83198 DRUGINFO D0VA2G Pyrazino[2,1-a]isoquinolin derivative 3 Patented T83198 DRUGINFO D0VW9H 2-hydroxybenzamide derivative 2 Patented T83198 DRUGINFO D0WN1Y PMID28454500-Compound-10 Patented T83198 DRUGINFO D0XL2V Trepenoid derivative 1 Patented T83198 DRUGINFO D46EBX VCB101 Preclinical T83198 DRUGINFO DG07UD VCB102 Preclinical T68001 TARGETID T68001 T68001 UNIPROID BTLA_HUMAN T68001 TARGNAME B- and T-lymphocyte attenuator (BTLA) T68001 GENENAME BTLA T68001 TARGTYPE Clinical trial T68001 SYNONYMS CD272; B- and T-lymphocyte-associated protein T68001 FUNCTION May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells. Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. T68001 PDBSTRUC 2AW2 T68001 SEQUENCE MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDPFELECPVKYCANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVLPNDNGSYRCSANFQSNLIESHSTTLYVTDVKSASERPSKDEMASRPWLLYRLLPLGGLPLLITTCFCLFCCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEASTRQNSQVLLSETGIYDNDPDLCFRMQEGSEVYSNPCLEENKPGIVYASLNHSVIGPNSRLARNVKEAPTEYASICVRS T68001 DRUGINFO D1O4MP LY3361237 Phase 2 T68001 DRUGINFO D0GMN2 JS004 Phase 1 T10513 TARGETID T10513 T10513 FORMERID TTDR01170 T10513 UNIPROID ITB2_HUMAN T10513 TARGNAME Integrin beta-2 (ITGB2) T10513 GENENAME ITGB2 T10513 TARGTYPE Clinical trial T10513 SYNONYMS MFI7; Integrin alpha-M/beta-2; Complement receptor C3 subunit beta; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; CD18 T10513 FUNCTION Integrin ITGAL/ITGB2 is also a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL. Integrins ITGAM/ITGB2 and ITGAX/ITGB2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin ITGAX/ITGB2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin ITGAM/ITGB2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin ITGAM/ITGB2 is also a receptor for factor X. Integrin ITGAD/ITGB2 is a receptor for ICAM3 and VCAM1. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation. Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages. In association with alpha subunit ITGAM/CD11b, required for CD177-PRTN3-mediated activation of TNF primed neutrophils. Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. T10513 PDBSTRUC 5ZAZ; 5XR1; 5ES4; 5E6X; 5E6W T10513 BIOCLASS Integrin T10513 SEQUENCE MLGLRPPLLALVGLLSLGCVLSQECTKFKVSSCRECIESGPGCTWCQKLNFTGPGDPDSIRCDTRPQLLMRGCAADDIMDPTSLAETQEDHNGGQKQLSPQKVTLYLRPGQAAAFNVTFRRAKGYPIDLYYLMDLSYSMLDDLRNVKKLGGDLLRALNEITESGRIGFGSFVDKTVLPFVNTHPDKLRNPCPNKEKECQPPFAFRHVLKLTNNSNQFQTEVGKQLISGNLDAPEGGLDAMMQVAACPEEIGWRNVTRLLVFATDDGFHFAGDGKLGAILTPNDGRCHLEDNLYKRSNEFDYPSVGQLAHKLAENNIQPIFAVTSRMVKTYEKLTEIIPKSAVGELSEDSSNVVQLIKNAYNKLSSRVFLDHNALPDTLKVTYDSFCSNGVTHRNQPRGDCDGVQINVPITFQVKVTATECIQEQSFVIRALGFTDIVTVQVLPQCECRCRDQSRDRSLCHGKGFLECGICRCDTGYIGKNCECQTQGRSSQELEGSCRKDNNSIICSGLGDCVCGQCLCHTSDVPGKLIYGQYCECDTINCERYNGQVCGGPGRGLCFCGKCRCHPGFEGSACQCERTTEGCLNPRRVECSGRGRCRCNVCECHSGYQLPLCQECPGCPSPCGKYISCAECLKFEKGPFGKNCSAACPGLQLSNNPVKGRTCKERDSEGCWVAYTLEQQDGMDRYLIYVDESRECVAGPNIAAIVGGTVAGIVLIGILLLVIWKALIHLSDLREYRRFEKEKLKSQWNNDNPLFKSATTTVMNPKFAES T10513 DRUGINFO DQ0I4N RP-L201 Phase 1/2 T10513 DRUGINFO D04ZWH UK-279,276 Discontinued in Phase 2 T10513 DRUGINFO D0GT8W BMS-587101 Discontinued in Phase 2 T10513 DRUGINFO D07NYF MLN-2201 Discontinued in Phase 1 T10513 DRUGINFO D07XCA A-286982 Investigative T93062 TARGETID T93062 T93062 FORMERID TTDC00030 T93062 UNIPROID MDR3_HUMAN T93062 TARGNAME Multidrug resistance protein 3 (ABCB4) T93062 GENENAME ABCB4 T93062 TARGTYPE Clinical trial T93062 SYNONYMS PGY3; MDR3; ATP-binding cassette sub-family B member 4; ABCB4 T93062 FUNCTION Mediates ATP-dependent export of organic anions and drugs from the cytoplasm. Hydrolyzes ATP with low efficiency. Not capable of conferring drug resistance. Mediates the translocation of phosphatidylcholine across the canalicular membrane of the hepatocyte. T93062 BIOCLASS Acid anhydrides hydrolase T93062 ECNUMBER EC 7.6.2.1 T93062 SEQUENCE MDLEAAKNGTAWRPTSAEGDFELGISSKQKRKKTKTVKMIGVLTLFRYSDWQDKLFMSLGTIMAIAHGSGLPLMMIVFGEMTDKFVDTAGNFSFPVNFSLSLLNPGKILEEEMTRYAYYYSGLGAGVLVAAYIQVSFWTLAAGRQIRKIRQKFFHAILRQEIGWFDINDTTELNTRLTDDISKISEGIGDKVGMFFQAVATFFAGFIVGFIRGWKLTLVIMAISPILGLSAAVWAKILSAFSDKELAAYAKAGAVAEEALGAIRTVIAFGGQNKELERYQKHLENAKEIGIKKAISANISMGIAFLLIYASYALAFWYGSTLVISKEYTIGNAMTVFFSILIGAFSVGQAAPCIDAFANARGAAYVIFDIIDNNPKIDSFSERGHKPDSIKGNLEFNDVHFSYPSRANVKILKGLNLKVQSGQTVALVGSSGCGKSTTVQLIQRLYDPDEGTINIDGQDIRNFNVNYLREIIGVVSQEPVLFSTTIAENICYGRGNVTMDEIKKAVKEANAYEFIMKLPQKFDTLVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALDTESEAEVQAALDKAREGRTTIVIAHRLSTVRNADVIAGFEDGVIVEQGSHSELMKKEGVYFKLVNMQTSGSQIQSEEFELNDEKAATRMAPNGWKSRLFRHSTQKNLKNSQMCQKSLDVETDGLEANVPPVSFLKVLKLNKTEWPYFVVGTVCAIANGGLQPAFSVIFSEIIAIFGPGDDAVKQQKCNIFSLIFLFLGIISFFTFFLQGFTFGKAGEILTRRLRSMAFKAMLRQDMSWFDDHKNSTGALSTRLATDAAQVQGATGTRLALIAQNIANLGTGIIISFIYGWQLTLLLLAVVPIIAVSGIVEMKLLAGNAKRDKKELEAAGKIATEAIENIRTVVSLTQERKFESMYVEKLYGPYRNSVQKAHIYGITFSISQAFMYFSYAGCFRFGAYLIVNGHMRFRDVILVFSAIVFGAVALGHASSFAPDYAKAKLSAAHLFMLFERQPLIDSYSEEGLKPDKFEGNITFNEVVFNYPTRANVPVLQGLSLEVKKGQTLALVGSSGCGKSTVVQLLERFYDPLAGTVFVDFGFQLLDGQEAKKLNVQWLRAQLGIVSQEPILFDCSIAENIAYGDNSRVVSQDEIVSAAKAANIHPFIETLPHKYETRVGDKGTQLSGGQKQRIAIARALIRQPQILLLDEATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQLLAQKGIYFSMVSVQAGTQNL T93062 DRUGINFO D9UGX7 Encequidar Phase 2 T93062 DRUGINFO D0H0EM Dofequidar fumarate Discontinued in Phase 3 T93062 DRUGINFO D06DCL LY335979 Discontinued in Phase 3 T93062 DRUGINFO D0A5MI LANIQUIDAR Discontinued in Phase 2 T93062 DRUGINFO D0B1MJ Dexniguldipine Discontinued in Phase 2 T20575 TARGETID T20575 T20575 FORMERID TTDR00763 T20575 UNIPROID CCR8_HUMAN T20575 TARGNAME C-C chemokine receptor type 8 (CCR8) T20575 GENENAME CCR8 T20575 TARGTYPE Clinical trial T20575 SYNONYMS TER1; GPRCY6; GPR-CY6; Chemokine receptor-like 1; Chemokine receptor CCR8; CMKBRL2; CMKBR8; CKRL1; CKR-L1; CDw198; CCR-8; CC-chemokine receptor CHEMR1; CC-CKR-8; CC chemokine receptor CHEMR1; C-C CKR-8 T20575 FUNCTION May regulate monocyte chemotaxis and thymic cell line apoptosis. Alternative coreceptor with CD4 for HIV-1 infection. Receptor for the chemokine CCL1/SCYA1/I-309. T20575 BIOCLASS GPCR rhodopsin T20575 SEQUENCE MDYTLDLSVTTVTDYYYPDIFSSPCDAELIQTNGKLLLAVFYCLLFVFSLLGNSLVILVLVVCKKLRSITDVYLLNLALSDLLFVFSFPFQTYYLLDQWVFGTVMCKVVSGFYYIGFYSSMFFITLMSVDRYLAVVHAVYALKVRTIRMGTTLCLAVWLTAIMATIPLLVFYQVASEDGVLQCYSFYNQQTLKWKIFTNFKMNILGLLIPFTIFMFCYIKILHQLKRCQNHNKTKAIRLVLIVVIASLLFWVPFNVVLFLTSLHSMHILDGCSISQQLTYATHVTEIISFTHCCVNPVIYAFVGEKFKKHLSEIFQKSCSQIFNYLGRQMPRESCEKSSSCQQHSSRSSSVDYIL T20575 DRUGINFO DRAL63 GS-1811 Phase 1 T20575 DRUGINFO D04HZX CCX-832 Discontinued in Phase 1 T20575 DRUGINFO D03DTZ ZK 756326 Investigative T20575 DRUGINFO D0K5QW I-309 Investigative T20575 DRUGINFO D0K8BZ N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide Investigative T20575 DRUGINFO D0M1AE N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide Investigative T20575 DRUGINFO D09PZD viral macrophage inflammatory protein-II Investigative T63803 TARGETID T63803 T63803 FORMERID TTDR01251 T63803 UNIPROID VEGFD_HUMAN T63803 TARGNAME Vascular endothelial growth factor D (VEGFD) T63803 GENENAME VEGFD T63803 TARGTYPE Clinical trial T63803 SYNONYMS c-Fos-induced growth factor; VEGFD; VEGF-D; FIGF T63803 FUNCTION Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formationof the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors. T63803 PDBSTRUC 2XV7 T63803 BIOCLASS Growth factor T63803 SEQUENCE MYREWVVVNVFMMLYVQLVQGSSNEHGPVKRSSQSTLERSEQQIRAASSLEELLRITHSEDWKLWRCRLRLKSFTSMDSRSASHRSTRFAATFYDIETLKVIDEEWQRTQCSPRETCVEVASELGKSTNTFFKPPCVNVFRCGGCCNEESLICMNTSTSYISKQLFEISVPLTSVPELVPVKVANHTGCKCLPTAPRHPYSIIRRSIQIPEEDRCSHSKKLCPIDMLWDSNKCKCVLQEENPLAGTEDHSHLQEPALCGPHMMFDEDRCECVCKTPCPKDLIQHPKNCSCFECKESLETCCQKHKLFHPDTCSCEDRCPFHTRPCASGKTACAKHCRFPKEKRAAQGPHSRKNP T63803 DRUGINFO DNA7I1 OPT-302 Phase 2 T63803 DRUGINFO D01RLU EG-016 Discontinued in Phase 1/2 T63803 DRUGINFO D0H3HB EG-011 Discontinued in Phase 1/2 T49630 TARGETID T49630 T49630 FORMERID TTDR00861 T49630 UNIPROID OLR1_HUMAN T49630 TARGNAME Lectin-like oxidized LDL receptor (OLR1) T49630 GENENAME OLR1 T49630 TARGTYPE Clinical trial T49630 SYNONYMS hLOX-1; Oxidized low-density lipoprotein receptor 1; Oxidized low-density lipoprotein receptor; Oxidised low density lipoprotein (Lectin-like) receptor 1; Ox-LDL receptor 1; Lectin-type oxidized LDL receptor 1; Lectin-type oxidized LDL receptor; Lectin-like oxidized low-density lipoprotein receptor-1; Lectin-like oxidized LDL receptor-1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; LOX1; LOX-1; CLEC8A; C-type lectin domain family 8 member A T49630 FUNCTION OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria. Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. T49630 PDBSTRUC 3VLG; 1YXK; 1YXJ; 1YPU; 1YPQ T49630 SEQUENCE MTFDDLKIQTVKDQPDEKSNGKKAKGLQFLYSPWWCLAAATLGVLCLGLVVTIMVLGMQLSQVSDLLTQEQANLTHQKKKLEGQISARQQAEEASQESENELKEMIETLARKLNEKSKEQMELHHQNLNLQETLKRVANCSAPCPQDWIWHGENCYLFSSGSFNWEKSQEKCLSLDAKLLKINSTADLDFIQQAISYSSFPFWMGLSRRNPSYPWLWEDGSPLMPHLFRVRGAVSQTYPSGTCAYIQRGAVYAENCILAAFSICQKKANLRAQ T49630 DRUGINFO DFG87U MEDI6570 Phase 2 T49630 DRUGINFO D0MH1R RG7418 Discontinued in Phase 1 T30834 TARGETID T30834 T30834 FORMERID TTDI01947 T30834 UNIPROID CALCR_HUMAN-RAMP1_HUMAN/RAMP2_HUMAN/RAMP3_HUMAN T30834 TARGNAME Amylin receptor (IAPPR) T30834 GENENAME CALCR-RAMP1/RAMP2/RAMP3 T30834 TARGTYPE Clinical trial T30834 SYNONYMS Complex of Calcitonin receptor and Receptor activity-modifying protein T30834 FUNCTION Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. Acts as a receptor for calcitonin-gene-related peptide (CGRP) together with CALCRL. T30834 SEQUENCE MRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYVVGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDFDPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFTLVISLGIFVFFRSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVVPNGELVRRDPVSCKILHFFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTKMRETHEAESHMYLKAVKATMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFFVATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQEPRNEPANNQGEESAEIIPLNIIEQESSAMARALCRLPRRGLWLLLAHHLFMTTACQEANYGALLRELCLTQFQVDMEAVGETLWCDWGRTIRSYRELADCTWHMAEKLGCFWPNAEVDRFFLAVHGRYFRSCPISGRAVRDPPGSILYPFIVVPITVTLLVTALVVWQSKRTEGIV T30834 DRUGINFO DW3J9N DACRA 089 Phase 1 T30834 DRUGINFO D0H4TC Davalintide Discontinued in Phase 2 T30834 DRUGINFO D00RXR AC-253 Discontinued in Phase 1 T30834 DRUGINFO D0Q9NJ AC-625 Discontinued in Phase 1 T30834 DRUGINFO D00PZH AC-187 Terminated T00523 TARGETID T00523 T00523 FORMERID TTDI01558 T00523 UNIPROID GTR9_HUMAN T00523 TARGNAME Glucose transporter type 9 (GLUT9) T00523 GENENAME SLC2A9 T00523 TARGTYPE Clinical trial T00523 SYNONYMS Urate transporter; Solute carrier family 2, facilitated glucose transporter member 9; GLUT9; GLUT-9 T00523 FUNCTION Urate transporter, which may play a role in the urate reabsorption by proximal tubules. Does not transport glucose, fructose or galactose. T00523 SEQUENCE MARKQNRNSKELGLVPLTDDTSHAGPPGPGRALLECDHLRSGVPGGRRRKDWSCSLLVASLAGAFGSSFLYGYNLSVVNAPTPYIKAFYNESWERRHGRPIDPDTLTLLWSVTVSIFAIGGLVGTLIVKMIGKVLGRKHTLLANNGFAISAALLMACSLQAGAFEMLIVGRFIMGIDGGVALSVLPMYLSEISPKEIRGSLGQVTAIFICIGVFTGQLLGLPELLGKESTWPYLFGVIVVPAVVQLLSLPFLPDSPRYLLLEKHNEARAVKAFQTFLGKADVSQEVEEVLAESRVQRSIRLVSVLELLRAPYVRWQVVTVIVTMACYQLCGLNAIWFYTNSIFGKAGIPPAKIPYVTLSTGGIETLAAVFSGLVIEHLGRRPLLIGGFGLMGLFFGTLTITLTLQDHAPWVPYLSIVGILAIIASFCSGPGGIPFILTGEFFQQSQRPAAFIIAGTVNWLSNFAVGLLFPFIQKSLDTYCFLVFATICITGAIYLYFVLPETKNRTYAEISQAFSKRNKAYPPEEKIDSAVTDGKINGRP T00523 DRUGINFO D89BQK SAP-001 Phase 2 T00523 DRUGINFO D05RZI AA-193 Discontinued in Phase 2 T51843 TARGETID T51843 T51843 FORMERID TTDC00001 T51843 UNIPROID POLG_HCVJA T51843 TARGNAME Virus RNA-dependent RNA polymerase (Viru RdRP) T51843 GENENAME Viru RdRP T51843 TARGTYPE Clinical trial T51843 SYNONYMS HCV NS5B; HCV p68 T51843 FUNCTION Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity). T51843 PDBSTRUC 4KTC; 4JMY; 4I33; 4I32; 4I31 T51843 BIOCLASS Kinase T51843 ECNUMBER EC 2.7.7.48 T51843 SEQUENCE SMSYTWTGALITPCAAEESKLPINPLSNSLLRHHSMVYSTTSRSASLRQKKVTFDRLQVLDDHYRDVLKEMKAKASTVKARLLSIEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIRSVWEDLLEDTETPIDTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMALYDVVSTLPQAVMGPSYGFQYSPGQRVEFLVNTWKSKKCPMGFSYDTRCFDSTVTENDIRTEESIYQCCDLAPEARQAIRSLTERLYVGGPLTNSKGQNCGYRRCRASGVLTTSCGNTLTCYLKATAACRAAKLQDCTMLVNGDDLVVICESAGTQEDAAALRAFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDASGKRVYYLTRDPTTPLARAAWETVRHTPVNSWLGNIIMYAPTLWARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPGEINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAATCGKYLFNWAVKTKLKLTPIPAASQLDLSGWFVAGYNGGDIYHSLSRARPRWFMLCLLLLSVGVGIYLLPNR T51843 DRUGINFO D5AV3Q AT-527 Phase 2 T51843 DRUGINFO D05TSP Thiadiazolo[2,3-a]pyrimidine Investigative T51843 DRUGINFO D09VHW T-1105 Investigative T51843 DRUGINFO D0B0PW Pyrimidinyl acylthiourea Investigative T51843 DRUGINFO D0C0WE FdG Investigative T51843 DRUGINFO D0ZU6O T-1106 Investigative T51843 DRUGINFO D0EQ4T Guanosine-5'-Triphosphate Investigative T51843 DRUGINFO D0A1DU Pyrophosphate 2- Investigative T49755 TARGETID T49755 T49755 FORMERID TTDNR00702 T49755 UNIPROID LRP6_HUMAN T49755 TARGNAME LDL receptor related protein-6 (LRP-6) T49755 GENENAME LRP6 T49755 TARGTYPE Clinical trial T49755 SYNONYMS Low-density lipoprotein receptor-related protein 6 T49755 FUNCTION Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Required for posterior patterning of the epiblast during gastrulation. Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. T49755 PDBSTRUC 6H16; 6H15; 5GJE; 5FWW; 5AIR T49755 BIOCLASS Low density lipoprotein receptor T49755 SEQUENCE MGAVLRSLLACSFCVLLRAAPLLLYANRRDLRLVDATNGKENATIVVGGLEDAAAVDFVFSHGLIYWSDVSEEAIKRTEFNKTESVQNVVVSGLLSPDGLACDWLGEKLYWTDSETNRIEVSNLDGSLRKVLFWQELDQPRAIALDPSSGFMYWTDWGEVPKIERAGMDGSSRFIIINSEIYWPNGLTLDYEEQKLYWADAKLNFIHKSNLDGTNRQAVVKGSLPHPFALTLFEDILYWTDWSTHSILACNKYTGEGLREIHSDIFSPMDIHAFSQQRQPNATNPCGIDNGGCSHLCLMSPVKPFYQCACPTGVKLLENGKTCKDGATELLLLARRTDLRRISLDTPDFTDIVLQLEDIRHAIAIDYDPVEGYIYWTDDEVRAIRRSFIDGSGSQFVVTAQIAHPDGIAVDWVARNLYWTDTGTDRIEVTRLNGTMRKILISEDLEEPRAIVLDPMVGYMYWTDWGEIPKIERAALDGSDRVVLVNTSLGWPNGLALDYDEGKIYWGDAKTDKIEVMNTDGTGRRVLVEDKIPHIFGFTLLGDYVYWTDWQRRSIERVHKRSAEREVIIDQLPDLMGLKATNVHRVIGSNPCAEENGGCSHLCLYRPQGLRCACPIGFELISDMKTCIVPEAFLLFSRRADIRRISLETNNNNVAIPLTGVKEASALDFDVTDNRIYWTDISLKTISRAFMNGSALEHVVEFGLDYPEGMAVDWLGKNLYWADTGTNRIEVSKLDGQHRQVLVWKDLDSPRALALDPAEGFMYWTEWGGKPKIDRAAMDGSERTTLVPNVGRANGLTIDYAKRRLYWTDLDTNLIESSNMLGLNREVIADDLPHPFGLTQYQDYIYWTDWSRRSIERANKTSGQNRTIIQGHLDYVMDILVFHSSRQSGWNECASSNGHCSHLCLAVPVGGFVCGCPAHYSLNADNRTCSAPTTFLLFSQKSAINRMVIDEQQSPDIILPIHSLRNVRAIDYDPLDKQLYWIDSRQNMIRKAQEDGSQGFTVVVSSVPSQNLEIQPYDLSIDIYSRYIYWTCEATNVINVTRLDGRSVGVVLKGEQDRPRAVVVNPEKGYMYFTNLQERSPKIERAALDGTEREVLFFSGLSKPIALALDSRLGKLFWADSDLRRIESSDLSGANRIVLEDSNILQPVGLTVFENWLYWIDKQQQMIEKIDMTGREGRTKVQARIAQLSDIHAVKELNLQEYRQHPCAQDNGGCSHICLVKGDGTTRCSCPMHLVLLQDELSCGEPPTCSPQQFTCFTGEIDCIPVAWRCDGFTECEDHSDELNCPVCSESQFQCASGQCIDGALRCNGDANCQDKSDEKNCEVLCLIDQFRCANGQCIGKHKKCDHNVDCSDKSDELDCYPTEEPAPQATNTVGSVIGVIVTIFVSGTVYFICQRMLCPRMKGDGETMTNDYVVHGPASVPLGYVPHPSSLSGSLPGMSRGKSMISSLSIMGGSSGPPYDRAHVTGASSSSSSSTKGTYFPAILNPPPSPATERSHYTMEFGYSSNSPSTHRSYSYRPYSYRHFAPPTTPCSTDVCDSDYAPSRRMTSVATAKGYTSDLNYDSEPVPPPPTPRSQYLSAEENYESCPPSPYTERSYSHHLYPPPPSPCTDSS T49755 DRUGINFO DTB43H BI 905677 Phase 1 T11453 TARGETID T11453 T11453 FORMERID TTDR00432 T11453 UNIPROID GIP_HUMAN T11453 TARGNAME Gastric inhibitory polypeptide (GIP) T11453 GENENAME GIP T11453 TARGTYPE Clinical trial T11453 SYNONYMS Glucose-dependent insulinotropic polypeptide; GIP T11453 FUNCTION Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion. T11453 PDBSTRUC 2QKH; 2OBU; 2L71; 2L70; 2B4N T11453 BIOCLASS Glucagon T11453 SEQUENCE MVATKTFALLLLSLFLAVGLGEKKEGHFSALPSLPVGSHAKVSSPQPRGPRYAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQREARALELASQANRKEEEAVEPQSSPAKNPSDEDLLRDLLIQELLACLLDQTNLCRLRSR T11453 DRUGINFO DVB59Y LY3493269 Phase 1 T81503 TARGETID T81503 T81503 FORMERID TTDR00228 T81503 UNIPROID GYRB_ECOLI T81503 TARGNAME Bacterial DNA gyrase B (Bact gyrB) T81503 GENENAME Bact gyrB T81503 TARGTYPE Clinical trial T81503 SYNONYMS gyrB; DNA gyrase subunit B T81503 FUNCTION DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings. T81503 PDBSTRUC 6ENG; 5Z9Q; 5Z9N; 5Z9M; 5Z9L T81503 BIOCLASS ATP-hydrolyzing DNA topoisomerase T81503 ECNUMBER EC 5.6.2.3 T81503 SEQUENCE MSNSYDSSSIKVLKGLDAVRKRPGMYIGDTDDGTGLHHMVFEVVDNAIDEALAGHCKEIIVTIHADNSVSVQDDGRGIPTGIHPEEGVSAAEVIMTVLHAGGKFDDNSYKVSGGLHGVGVSVVNALSQKLELVIQREGKIHRQIYEHGVPQAPLAVTGETEKTGTMVRFWPSLETFTNVTEFEYEILAKRLRELSFLNSGVSIRLRDKRDGKEDHFHYEGGIKAFVEYLNKNKTPIHPNIFYFSTEKDGIGVEVALQWNDGFQENIYCFTNNIPQRDGGTHLAGFRAAMTRTLNAYMDKEGYSKKAKVSATGDDAREGLIAVVSVKVPDPKFSSQTKDKLVSSEVKSAVEQQMNELLAEYLLENPTDAKIVVGKIIDAARAREAARRAREMTRRKGALDLAGLPGKLADCQERDPALSELYLVEGDSAGGSAKQGRNRKNQAILPLKGKILNVEKARFDKMLSSQEVATLITALGCGIGRDEYNPDKLRYHSIIIMTDADVDGSHIRTLLLTFFYRQMPEIVERGHVYIAQPPLYKVKKGKQEQYIKDDEAMDQYQISIALDGATLHTNASAPALAGEALEKLVSEYNATQKMINRMERRYPKAMLKELIYQPTLTEADLSDEQTVTRWVNALVSELNDKEQHGSQWKFDVHTNAEQNLFEPIVRVRTHGVDTDYPLDHEFITGGEYRRICTLGEKLRGLLEEDAFIERGERRQPVASFEQALDWLVKESRRGLSIQRYKGLGEMNPEQLWETTMDPESRRMLRVTVKDAIAADQLFTTLMGDAVEPRRAFIEENALKAANIDI T81503 DRUGINFO DURD59 SPR720 Phase 1/2 T81503 DRUGINFO D00DXV BAY 50-7952 Investigative T81503 DRUGINFO D0X3FT Coumermycin Investigative T85309 TARGETID T85309 T85309 FORMERID TTDR00526 T85309 UNIPROID CBS_HUMAN T85309 TARGNAME Cystathionine beta-synthase (CBS) T85309 GENENAME CBS T85309 TARGTYPE Clinical trial T85309 SYNONYMS Serine sulfhydrase; Beta-thionase T85309 FUNCTION Hydro-lyase catalyzing the first step of the transsulfuration pathway, where the hydroxyl group of L-serine is displaced by L-homocysteine in a beta-replacement reaction to form L-cystathionine, the precursor of L-cysteine. This catabolic route allows the elimination of L-methionine and the toxic metabolite L-homocysteine. Also involved in the production of hydrogen sulfide, a gasotransmitter with signaling and cytoprotective effects on neurons. T85309 PDBSTRUC 5MMS; 4UUU; 4PCU; 4L3V; 4L28 T85309 BIOCLASS Alpha-carbonic anhydrase T85309 ECNUMBER EC 4.2.1.22 T85309 SEQUENCE MPSETPQAEVGPTGCPHRSGPHSAKGSLEKGSPEDKEAKEPLWIRPDAPSRCTWQLGRPASESPHHHTAPAKSPKILPDILKKIGDTPMVRINKIGKKFGLKCELLAKCEFFNAGGSVKDRISLRMIEDAERDGTLKPGDTIIEPTSGNTGIGLALAAAVRGYRCIIVMPEKMSSEKVDVLRALGAEIVRTPTNARFDSPESHVGVAWRLKNEIPNSHILDQYRNASNPLAHYDTTADEILQQCDGKLDMLVASVGTGGTITGIARKLKEKCPGCRIIGVDPEGSILAEPEELNQTEQTTYEVEGIGYDFIPTVLDRTVVDKWFKSNDEEAFTFARMLIAQEGLLCGGSAGSTVAVAVKAAQELQEGQRCVVILPDSVRNYMTKFLSDRWMLQKGFLKEEDLTEKKPWWWHLRVQELGLSAPLTVLPTITCGHTIEILREKGFDQAPVVDEAGVILGMVTLGNMLSSLLAGKVQPSDQVGKVIYKQFKQIRLTDTLGRLSHILEMDHFALVVHEQIQYHSTGKSSQRQMVFGVVTAIDLLNFVAAQERDQK T85309 DRUGINFO D87TMY OT-58 Phase 1/2 T85309 DRUGINFO D01BTV aminooxyacetic acid Investigative T85309 DRUGINFO D0UU1I Heme Investigative T66538 TARGETID T66538 T66538 FORMERID TTDI01971 T66538 UNIPROID KCMA1_HUMAN T66538 TARGNAME Calcium-activated potassium channel KCa1.1 (KCNMA1) T66538 GENENAME KCNMA1 T66538 TARGTYPE Clinical trial T66538 SYNONYMS hSlo; Slowpoke homolog; Slo1; Slo-alpha; Slo homolog; SLO; MaxiK; Maxi K channel; KCa1.1; KCNMA; K(VCA)alpha; Calcium-activated potassium channel, subfamily M subunit alpha-1; Calcium-activated potassium channel subunit alpha-1; BKCA alpha; BK channel T66538 FUNCTION Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX). T66538 PDBSTRUC 3NAF; 3MT5; 2K44 T66538 BIOCLASS Voltage-gated ion channel T66538 SEQUENCE MANGGGGGGGSSGGGGGGGGSSLRMSSNIHANHLSLDASSSSSSSSSSSSSSSSSSSSSSVHEPKMDALIIPVTMEVPCDSRGQRMWWAFLASSMVTFFGGLFIILLWRTLKYLWTVCCHCGGKTKEAQKINNGSSQADGTLKPVDEKEEAVAAEVGWMTSVKDWAGVMISAQTLTGRVLVVLVFALSIGALVIYFIDSSNPIESCQNFYKDFTLQIDMAFNVFFLLYFGLRFIAANDKLWFWLEVNSVVDFFTVPPVFVSVYLNRSWLGLRFLRALRLIQFSEILQFLNILKTSNSIKLVNLLSIFISTWLTAAGFIHLVENSGDPWENFQNNQALTYWECVYLLMVTMSTVGYGDVYAKTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRKKYGGSYSAVSGRKHIVVCGHITLESVSNFLKDFLHKDRDDVNVEIVFLHNISPNLELEALFKRHFTQVEFYQGSVLNPHDLARVKIESADACLILANKYCADPDAEDASNIMRVISIKNYHPKIRIITQMLQYHNKAHLLNIPSWNWKEGDDAICLAELKLGFIAQSCLAQGLSTMLANLFSMRSFIKIEEDTWQKYYLEGVSNEMYTEYLSSAFVGLSFPTVCELCFVKLKLLMIAIEYKSANRESRILINPGNHLKIQEGTLGFFIASDAKEVKRAFFYCKACHDDITDPKRIKKCGCKRPKMSIYKRMRRACCFDCGRSERDCSCMSGRVRGNVDTLERAFPLSSVSVNDCSTSFRAFEDEQPSTLSPKKKQRNGGMRNSPNTSPKLMRHDPLLIPGNDQIDNMDSNVKKYDSTGMFHWCAPKEIEKVILTRSEAAMTVLSGHVVVCIFGDVSSALIGLRNLVMPLRASNFHYHELKHIVFVGSIEYLKREWETLHNFPKVSILPGTPLSRADLRAVNINLCDMCVILSANQNNIDDTSLQDKECILASLNIKSMQFDDSIGVLQANSQGFTPPGMDRSSPDNSPVHGMLRQPSITTGVNIPIITELVNDTNVQFLDQDDDDDPDTELYLTQPFACGTAFAVSVLDSLMSATYFNDNILTLIRTLVTGGATPELEALIAEENALRGGYSTPQTLANRDRCRVAQLALLDGPFADLGDGGCYGDLFCKALKTYNMLCFGIYRLRDAHLSTPSQCTKRYVITNPPYEFELVPTDLIFCLMQFDHNAGQSRASLSHSSHSSQSSSKKSSSVHSIPSTANRQNRPKSRESRDKQKYVQEERL T66538 DRUGINFO D0VZ9S CROMOGLYCATE LISETIL HYDROCHLORIDE Phase 2 T66538 DRUGINFO DMVJ21 URO-902 Phase 2 T22976 TARGETID T22976 T22976 FORMERID TTDR00783 T22976 UNIPROID KITM_HUMAN T22976 TARGNAME Thymidine kinase 2 (Mt-TK2) T22976 GENENAME dnk T22976 TARGTYPE Clinical trial T22976 SYNONYMS dnk; Multispecific deoxynucleoside kinase; Dm-Dnk; Deoxyribonucleoside kinase T22976 FUNCTION Deoxyribonucleoside kinase that has a broad specificity phosphorylating thymidine, deoxyadenosine, deoxycytidine and deoxyguanosine. Specificity is higher for pyrimidine nucleosides. Several anti-viral and anti-cancer nucleoside analogs are also efficiently phosphorylated. T22976 BIOCLASS Kinase T22976 ECNUMBER EC 2.7.1.21 T22976 SEQUENCE MLLWPLRGWAARALRCFGPGSRGSPASGPGPRRVQRRAWPPDKEQEKEKKSVICVEGNIASGKTTCLEFFSNATDVEVLTEPVSKWRNVRGHNPLGLMYHDASRWGLTLQTYVQLTMLDRHTRPQVSSVRLMERSIHSARYIFVENLYRSGKMPEVDYVVLSEWFDWILRNMDVSVDLIVYLRTNPETCYQRLKKRCREEEKVIPLEYLEAIHHLHEEWLIKGSLFPMAAPVLVIEADHHMERMLELFEQNRDRILTPENRKHCP T22976 DRUGINFO DI4SM3 MT-1621 Phase 3 T22976 DRUGINFO D00KWL 1-[5-(triphenylmethoxy)pentyl]thymine Investigative T22976 DRUGINFO D02CCD 1-[6-(triphenylmethoxy)hexyl]thymine Investigative T22976 DRUGINFO D0I6UV 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine Investigative T14231 TARGETID T14231 T14231 FORMERID TTDR00417 T14231 UNIPROID LGR5_HUMAN T14231 TARGNAME Leucine-rich repeat-containing GPCR 5 (LGR5) T14231 GENENAME LGR5 T14231 TARGTYPE Clinical trial T14231 SYNONYMS Orphan G protein-coupled receptor HG38; Leucine-rich repeat-containing G-protein coupled receptor 5; Gpr49; GPR67; G-protein coupled receptor HG38; G-protein coupled receptor 67; G-protein coupled receptor 49; G protein-coupled receptor 49 T14231 FUNCTION Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. In contrast to classical G-protein coupled receptors, does not activate heterotrimeric G-proteins to transduce the signal. Involved in the development and/or maintenance of the adult intestinal stem cells during postembryonic development. Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. T14231 PDBSTRUC 4UFS; 4UFR; 4KNG; 4BSU; 4BST T14231 BIOCLASS GPCR rhodopsin T14231 SEQUENCE MDTSRLGVLLSLPVLLQLATGGSSPRSGVLLRGCPTHCHCEPDGRMLLRVDCSDLGLSELPSNLSVFTSYLDLSMNNISQLLPNPLPSLRFLEELRLAGNALTYIPKGAFTGLYSLKVLMLQNNQLRHVPTEALQNLRSLQSLRLDANHISYVPPSCFSGLHSLRHLWLDDNALTEIPVQAFRSLSALQAMTLALNKIHHIPDYAFGNLSSLVVLHLHNNRIHSLGKKCFDGLHSLETLDLNYNNLDEFPTAIRTLSNLKELGFHSNNIRSIPEKAFVGNPSLITIHFYDNPIQFVGRSAFQHLPELRTLTLNGASQITEFPDLTGTANLESLTLTGAQISSLPQTVCNQLPNLQVLDLSYNLLEDLPSFSVCQKLQKIDLRHNEIYEIKVDTFQQLLSLRSLNLAWNKIAIIHPNAFSTLPSLIKLDLSSNLLSSFPITGLHGLTHLKLTGNHALQSLISSENFPELKVIEMPYAYQCCAFGVCENAYKISNQWNKGDNSSMDDLHKKDAGMFQAQDERDLEDFLLDFEEDLKALHSVQCSPSPGPFKPCEHLLDGWLIRIGVWTIAVLALTCNALVTSTVFRSPLYISPIKLLIGVIAAVNMLTGVSSAVLAGVDAFTFGSFARHGAWWENGVGCHVIGFLSIFASESSVFLLTLAALERGFSVKYSAKFETKAPFSSLKVIILLCALLALTMAAVPLLGGSKYGASPLCLPLPFGEPSTMGYMVALILLNSLCFLMMTIAYTKLYCNLDKGDLENIWDCSMVKHIALLLFTNCILNCPVAFLSFSSLINLTFISPEVIKFILLVVVPLPACLNPLLYILFNPHFKEDLVSLRKQTYVWTRSKHPSLMSINSDDVEKQSCDSTQALVTFTSSSITYDLPPSSVPSPAYPVTESCHLSSVAFVPCL T14231 DRUGINFO DD6AZ5 BNC-101 Phase 1 T14231 DRUGINFO DV8I4Q MCLA-158 Phase 1 T14231 DRUGINFO D2ZI3H BNC-102 Preclinical T14231 DRUGINFO D0X1YZ KM-4056 Investigative T93325 TARGETID T93325 T93325 UNIPROID SF3B1_HUMAN T93325 TARGNAME Spliceosome-associated protein 155 (SF3B1) T93325 GENENAME SF3B1 T93325 TARGTYPE Clinical trial T93325 SYNONYMS Splicing factor 3B subunit 1; SF3b155; SAP155; SAP 155; Pre-mRNA-splicing factor SF3b 155 kDa subunit T93325 FUNCTION Involved in pre-mRNA splicing as a component of the splicing factor SF3B complex. SF3B complex is required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA. Sequence independent binding of SF3A/SF3B complex upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA. May also be involved in the assembly of the 'E' complex. Belongs also to the minor U12-dependent spliceosome, which is involved in the splicing of rare class of nuclear pre-mRNA intron. T93325 PDBSTRUC 6QX9; 6N3E; 6FF7; 6FF4; 6EN4 T93325 BIOCLASS SF3B1 family T93325 SEQUENCE MAKIAKTHEDIEAQIREIQGKKAALDEAQGVGLDSTGYYDQEIYGGSDSRFAGYVTSIAATELEDDDDDYSSSTSLLGQKKPGYHAPVALLNDIPQSTEQYDPFAEHRPPKIADREDEYKKHRRTMIISPERLDPFADGGKTPDPKMNARTYMDVMREQHLTKEEREIRQQLAEKAKAGELKVVNGAAASQPPSKRKRRWDQTADQTPGATPKKLSSWDQAETPGHTPSLRWDETPGRAKGSETPGATPGSKIWDPTPSHTPAGAATPGRGDTPGHATPGHGGATSSARKNRWDETPKTERDTPGHGSGWAETPRTDRGGDSIGETPTPGASKRKSRWDETPASQMGGSTPVLTPGKTPIGTPAMNMATPTPGHIMSMTPEQLQAWRWEREIDERNRPLSDEELDAMFPEGYKVLPPPAGYVPIRTPARKLTATPTPLGGMTGFHMQTEDRTMKSVNDQPSGNLPFLKPDDIQYFDKLLVDVDESTLSPEEQKERKIMKLLLKIKNGTPPMRKAALRQITDKAREFGAGPLFNQILPLLMSPTLEDQERHLLVKVIDRILYKLDDLVRPYVHKILVVIEPLLIDEDYYARVEGREIISNLAKAAGLATMISTMRPDIDNMDEYVRNTTARAFAVVASALGIPSLLPFLKAVCKSKKSWQARHTGIKIVQQIAILMGCAILPHLRSLVEIIEHGLVDEQQKVRTISALAIAALAEAATPYGIESFDSVLKPLWKGIRQHRGKGLAAFLKAIGYLIPLMDAEYANYYTREVMLILIREFQSPDEEMKKIVLKVVKQCCGTDGVEANYIKTEILPPFFKHFWQHRMALDRRNYRQLVDTTVELANKVGAAEIISRIVDDLKDEAEQYRKMVMETIEKIMGNLGAADIDHKLEEQLIDGILYAFQEQTTEDSVMLNGFGTVVNALGKRVKPYLPQICGTVLWRLNNKSAKVRQQAADLISRTAVVMKTCQEEKLMGHLGVVLYEYLGEEYPEVLGSILGALKAIVNVIGMHKMTPPIKDLLPRLTPILKNRHEKVQENCIDLVGRIADRGAEYVSAREWMRICFELLELLKAHKKAIRRATVNTFGYIAKAIGPHDVLATLLNNLKVQERQNRVCTTVAIAIVAETCSPFTVLPALMNEYRVPELNVQNGVLKSLSFLFEYIGEMGKDYIYAVTPLLEDALMDRDLVHRQTASAVVQHMSLGVYGFGCEDSLNHLLNYVWPNVFETSPHVIQAVMGALEGLRVAIGPCRMLQYCLQGLFHPARKVRDVYWKIYNSIYIGSQDALIAHYPRIYNDDKNTYIRYELDYIL T47888 TARGETID T47888 T47888 FORMERID TTDI02522 T47888 UNIPROID S1PR2_HUMAN T47888 TARGNAME Sphingosine-1-phosphate receptor 2 (S1PR2) T47888 GENENAME S1PR2 T47888 TARGTYPE Clinical trial T47888 SYNONYMS Sphingosine 1-phosphate receptor Edg-5; S1PR2; S1P2; S1P receptor Edg-5; S1P receptor 2; Endothelial differentiation G-protein coupled receptor 5 T47888 FUNCTION Receptor for the lysosphingolipid sphingosine 1- phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. When expressed in rat HTC4 hepatoma cells, is capable of mediating S1P-induced cell proliferation and suppression of apoptosis. T47888 PDBSTRUC 1ZTI T47888 BIOCLASS GPCR rhodopsin T47888 SEQUENCE MGSLYSEYLNPNKVQEHYNYTKETLETQETTSRQVASAFIVILCCAIVVENLLVLIAVARNSKFHSAMYLFLGNLAASDLLAGVAFVANTLLSGSVTLRLTPVQWFAREGSAFITLSASVFSLLAIAIERHVAIAKVKLYGSDKSCRMLLLIGASWLISLVLGGLPILGWNCLGHLEACSTVLPLYAKHYVLCVVTIFSIILLAIVALYVRIYCVVRSSHADMAAPQTLALLKTVTIVLGVFIVCWLPAFSILLLDYACPVHSCPILYKAHYFFAVSTLNSLLNPVIYTWRSRDLRREVLRPLQCWRPGVGVQGRRRGGTPGHHLLPLRSSSSLERGMHMPTSPTFLEGNTVV T47888 DRUGINFO D2E4CG Amiselimod Phase 2 T47888 DRUGINFO D0C4AW US8975409, Example 13 Patented T47888 DRUGINFO D0J5YV SCHEMBL15295829 Patented T47888 DRUGINFO D0K4BI Jte 013 Patented T47888 DRUGINFO D0PW0R US8975409, Example 9(3) Patented T47888 DRUGINFO D0QU9I Unii-R228S06soh Patented T47888 DRUGINFO D0T8FV US8975409, Comparative compound B Patented T47888 DRUGINFO D03BRM AUY954 Investigative T98397 TARGETID T98397 T98397 FORMERID TTDI00964 T98397 UNIPROID TYSY_HUMAN T98397 TARGNAME Thymidylate synthase (TYMS) T98397 GENENAME TYMS T98397 TARGTYPE Clinical trial T98397 SYNONYMS TSase; TS T98397 FUNCTION Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. T98397 PDBSTRUC 6R2E; 6QYQ; 6QXH; 6QXG; 5X69 T98397 BIOCLASS Methyltransferase T98397 ECNUMBER EC 2.1.1.45 T98397 SEQUENCE MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV T98397 DRUGINFO D04FYZ Plevitrexed (R)-isomer Phase 2 T98397 DRUGINFO DQ9B8C NUC-3373 Phase 1 T98397 DRUGINFO D0Q0EB ICI-198583 Investigative T13075 TARGETID T13075 T13075 FORMERID TTDI03079 T13075 UNIPROID KC1A_HUMAN T13075 TARGNAME Casein kinase I alpha (CSNK1A1) T13075 GENENAME CSNK1A1 T13075 TARGTYPE Clinical trial T13075 SYNONYMS Casein kinase I isoform alpha; CKI-alpha; CK1 T13075 FUNCTION It can phosphorylate a large number of proteins. Participates in Wnt signaling. Phosphorylates CTNNB1 at 'Ser-45'. May phosphorylate PER1 and PER2. May play a role in segregating chromosomes during mitosis. May play a role in keratin cytoskeleton disassembly and thereby, it may regulate epithelial cell migration. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. T13075 PDBSTRUC 6GZD; 5FQD T13075 BIOCLASS Kinase T13075 ECNUMBER EC 2.7.11.1 T13075 SEQUENCE MASSSGSKAEFIVGGKYKLVRKIGSGSFGDIYLAINITNGEEVAVKLESQKARHPQLLYESKLYKILQGGVGIPHIRWYGQEKDYNVLVMDLLGPSLEDLFNFCSRRFTMKTVLMLADQMISRIEYVHTKNFIHRDIKPDNFLMGIGRHCNKLFLIDFGLAKKYRDNRTRQHIPYREDKNLTGTARYASINAHLGIEQSRRDDMESLGYVLMYFNRTSLPWQGLKAATKKQKYEKISEKKMSTPVEVLCKGFPAEFAMYLNYCRGLRFEEAPDYMYLRQLFRILFRTLNHQYDYTFDWTMLKQKAAQQAASSSGQGQQAQTPTGKQTDKTKSNMKGF T13075 DRUGINFO D5VMP4 BTX-A51 Phase 1 T13075 DRUGINFO D0MN6V US9096594, 3 Patented T13075 DRUGINFO D00JGL D-4476 Preclinical T13075 DRUGINFO D0UN8H IC261 Preclinical T13075 DRUGINFO D0H4VB PMID24900428C14 Investigative T25956 TARGETID T25956 T25956 FORMERID TTDI02489 T25956 UNIPROID EP300_HUMAN T25956 TARGNAME Histone acetyltransferase p300 (EP300) T25956 GENENAME EP300 T25956 TARGTYPE Clinical trial T25956 SYNONYMS p300 HAT; Protein propionyltransferase p300; P300; Histone crotonyltransferase p300; Histone butyryltransferase p300; E1Aassociated protein p300; E1A-associated protein p300 T25956 FUNCTION Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Mediates acetylation of histone H3 at 'Lys-122' (H3K122ac), a modification that localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Mediates acetylation of histone H3 at 'Lys-27' (H3K27ac). Also functions as acetyltransferase for non-histone targets, such as ALX1, HDAC1, PRMT1 or SIRT2. Acetylates 'Lys-131' of ALX1 and acts as its coactivator. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Acetylates FOXO1 and enhances its transcriptional activity. Acetylates BCL6 wich disrupts its ability to recruit histone deacetylases and hinders its transcriptional repressor activity. Participates in CLOCK or NPAS2-regulated rhythmic gene transcription; exhibits a circadian association with CLOCK or NPAS2, correlating with increase in PER1/2 mRNA and histone H3 acetylation on the PER1/2 promoter. Acetylates MTA1 at 'Lys-626' which is essential for its transcriptional coactivator activity. Acetylates XBP1 isoform 2; acetylation increases protein stability of XBP1 isoform 2 and enhances its transcriptional activity. Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER). Acetylates MEF2D. Acetylates and stabilizes ZBTB7B protein by antagonizing ubiquitin conjugation and degragation, this mechanism may be involved in CD4/CD8 lineage differentiation. In addition to protein acetyltransferase, can use different acyl-CoA substrates, such as (2E)-butenoyl-CoA (crotonyl-CoA), butanoyl-CoA (butyryl-CoA) or propanoyl-CoA (propionyl-CoA), and is able to mediate protein crotonylation, butyrylation or propionylation, respectively. Acts as a histone crotonyltransferase; crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. Histone crotonyltransferase activity is dependent on the concentration of (2E)-butenoyl-CoA (crotonyl-CoA) substrate and such activity is weak when (E)-but-2-enoyl-CoA (crotonyl-CoA) concentration is low. Also acts as a histone butyryltransferase; butyrylation marks active promoters. Functions as a transcriptional coactivator for SMAD4 in the TGF-beta signaling pathway. Acetylates PCK1 and promotes PCK1 anaplerotic activity. Functions as histone acetyltransferase and regulates transcription via chromatin remodeling. T25956 PDBSTRUC 6GYT; 6GYR; 6FGS; 6FGN; 6DS6 T25956 BIOCLASS Acyltransferase T25956 ECNUMBER EC 2.3.1.48 T25956 SEQUENCE MAENVVEPGPPSAKRPKLSSPALSASASDGTDFGSLFDLEHDLPDELINSTELGLTNGGDINQLQTSLGMVQDAASKHKQLSELLRSGSSPNLNMGVGGPGQVMASQAQQSSPGLGLINSMVKSPMTQAGLTSPNMGMGTSGPNQGPTQSTGMMNSPVNQPAMGMNTGMNAGMNPGMLAAGNGQGIMPNQVMNGSIGAGRGRQNMQYPNPGMGSAGNLLTEPLQQGSPQMGGQTGLRGPQPLKMGMMNNPNPYGSPYTQNPGQQIGASGLGLQIQTKTVLSNNLSPFAMDKKAVPGGGMPNMGQQPAPQVQQPGLVTPVAQGMGSGAHTADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRQCNLPHCRTMKNVLNHMTHCQSGKSCQVAHCASSRQIISHWKNCTRHDCPVCLPLKNAGDKRNQQPILTGAPVGLGNPSSLGVGQQSAPNLSTVSQIDPSSIERAYAALGLPYQVNQMPTQPQVQAKNQQNQQPGQSPQGMRPMSNMSASPMGVNGGVGVQTPSLLSDSMLHSAINSQNPMMSENASVPSLGPMPTAAQPSTTGIRKQWHEDITQDLRNHLVHKLVQAIFPTPDPAALKDRRMENLVAYARKVEGDMYESANNRAEYYHLLAEKIYKIQKELEEKRRTRLQKQNMLPNAAGMVPVSMNPGPNMGQPQPGMTSNGPLPDPSMIRGSVPNQMMPRITPQSGLNQFGQMSMAQPPIVPRQTPPLQHHGQLAQPGALNPPMGYGPRMQQPSNQGQFLPQTQFPSQGMNVTNIPLAPSSGQAPVSQAQMSSSSCPVNSPIMPPGSQGSHIHCPQLPQPALHQNSPSPVPSRTPTPHHTPPSIGAQQPPATTIPAPVPTPPAMPPGPQSQALHPPPRQTPTPPTTQLPQQVQPSLPAAPSADQPQQQPRSQQSTAASVPTPTAPLLPPQPATPLSQPAVSIEGQVSNPPSTSSTEVNSQAIAEKQPSQEVKMEAKMEVDQPEPADTQPEDISESKVEDCKMESTETEERSTELKTEIKEEEDQPSTSATQSSPAPGQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCCGRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAVSERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKREENTSNESTDVTKGDSKNAKKKNNKKTSKNKSSLSRGNKKKPGMPNVSNDLSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRRAQWSTMCMLVELHTQSQDRFVYTCNECKHHVETRWHCTVCEDYDLCITCYNTKNHDHKMEKLGLGLDDESNNQQAAATQSPGDSRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICKQLIALCCYHAKHCQENKCPVPFCLNIKQKLRQQQLQHRLQQAQMLRRRMASMQRTGVVGQQQGLPSPTPATPTTPTGQQPTTPQTPQPTSQPQPTPPNSMPPYLPRTQAAGPVSQGKAAGQVTPPTPPQTAQPPLPGPPPAAVEMAMQIQRAAETQRQMAHVQIFQRPIQHQMPPMTPMAPMGMNPPPMTRGPSGHLEPGMGPTGMQQQPPWSQGGLPQPQQLQSGMPRPAMMSVAQHGQPLNMAPQPGLGQVGISPLKPGTVSQQALQNLLRTLRSPSSPLQQQQVLSILHANPQLLAAFIKQRAAKYANSNPQPIPGQPGMPQGQPGLQPPTMPGQQGVHSNPAMQNMNPMQAGVQRAGLPQQQPQQQLQPPMGGMSPQAQQMNMNHNTMPSQFRDILRRQQMMQQQQQQGAGPGIGPGMANHNQFQQPQGVGYPPQQQQRMQHHMQQMQQGNMGQIGQLPQALGAEAGASLQAYQQRLLQQQMGSPVQPNPMSPQQHMLPNQAQSPHLQGQQIPNSLSNQVRSPQPVPSPRPQSQPPHSSPSPRMQPQPSPHHVSPQTSSPHPGLVAAQANPMEQGHFASPDQNSMLSQLASNPGMANLHGASATDLGLSTDNSDLNSNLSQSTLDIH T25956 DRUGINFO DIY4C2 CCS1477 Phase 1/2 T25956 DRUGINFO DT8IL6 FT-7051 Phase 1 T00749 TARGETID T00749 T00749 FORMERID TTDNR00707 T00749 UNIPROID M4K1_HUMAN T00749 TARGNAME MEK kinase kinase 1 (MAP4K1) T00749 GENENAME MAP4K1 T00749 TARGTYPE Clinical trial T00749 SYNONYMS Mitogen-activated protein kinase kinase kinase kinase 1; MEKKK 1; MAPK/ERK kinase kinase kinase 1; Hematopoietic progenitor kinase; HPK1 T00749 FUNCTION Appears to act upstream of the JUN N-terminal pathway. May play a role in hematopoietic lineage decisions and growth regulation. Able to autophosphorylate. Serine/threonine-protein kinase, which may play a role in the response to environmental stress. T00749 PDBSTRUC 6NG0; 6NFZ; 6NFY; 6CQF; 6CQE T00749 BIOCLASS Kinase T00749 ECNUMBER EC 2.7.11.1 T00749 SEQUENCE MDVVDPDIFNRDPRDHYDLLQRLGGGTYGEVFKARDKVSGDLVALKMVKMEPDDDVSTLQKEILILKTCRHANIVAYHGSYLWLQKLWICMEFCGAGSLQDIYQVTGSLSELQISYVCREVLQGLAYLHSQKKIHRDIKGANILINDAGEVRLADFGISAQIGATLARRLSFIGTPYWMAPEVAAVALKGGYNELCDIWSLGITAIELAELQPPLFDVHPLRVLFLMTKSGYQPPRLKEKGKWSAAFHNFIKVTLTKSPKKRPSATKMLSHQLVSQPGLNRGLILDLLDKLKNPGKGPSIGDIEDEEPELPPAIPRRIRSTHRSSSLGIPDADCCRRHMEFRKLRGMETRPPANTARLQPPRDLRSSSPRKQLSESSDDDYDDVDIPTPAEDTPPPLPPKPKFRSPSDEGPGSMGDDGQLSPGVLVRCASGPPPNSPRPGPPPSTSSPHLTAHSEPSLWNPPSRELDKPPLLPPKKEKMKRKGCALLVKLFNGCPLRIHSTAAWTHPSTKDQHLLLGAEEGIFILNRNDQEATLEMLFPSRTTWVYSINNVLMSLSGKTPHLYSHSILGLLERKETRAGNPIAHISPHRLLARKNMVSTKIQDTKGCRACCVAEGASSGGPFLCGALETSVVLLQWYQPMNKFLLVRQVLFPLPTPLSVFALLTGPGSELPAVCIGVSPGRPGKSVLFHTVRFGALSCWLGEMSTEHRGPVQVTQVEEDMVMVLMDGSVKLVTPEGSPVRGLRTPEIPMTEAVEAVAMVGGQLQAFWKHGVQVWALGSDQLLQELRDPTLTFRLLGSPRLECSGTISPHCNLLLPGSSNSPASASRVAGITGL T00749 DRUGINFO DXK49H CFI-402411 Phase 1/2 T00749 DRUGINFO D8MS6C BGB-15025 Phase 1 T00749 DRUGINFO DV3J1P PF-07265028 Phase 1 T50445 TARGETID T50445 T50445 FORMERID TTDR01381 T50445 UNIPROID TNR5_HUMAN T50445 TARGNAME CD40 messenger RNA (CD40 mRNA) T50445 GENENAME CD40 T50445 TARGTYPE Clinical trial T50445 SYNONYMS Tumor necrosis factor receptor superfamily member 5 (mRNA); TNFRSF5 (mRNA); CDw40 (mRNA); CD40L receptor (mRNA); Bp50 (mRNA); B-cell surfaceantigen CD40 (mRNA); B-cell surface antigen CD40 (mRNA) T50445 FUNCTION Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion. Receptor for TNFSF5/CD40LG. T50445 PDBSTRUC 6FAX; 5IHL; 5DMJ; 5DMI; 3QD6 T50445 BIOCLASS mRNA target T50445 SEQUENCE MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ T50445 DRUGINFO D1BT2M NJA-730 Phase 1 T50445 DRUGINFO D02NEY ISIS 19213 Investigative T50445 DRUGINFO D05LSD ISIS 19211 Investigative T50445 DRUGINFO D07UKR ISIS 19220 Investigative T50445 DRUGINFO D08IOW ISIS 19219 Investigative T50445 DRUGINFO D09KVB ISIS 19221 Investigative T50445 DRUGINFO D0F8KX ISIS 19218 Investigative T50445 DRUGINFO D0U6HC ISIS 19217 Investigative T50445 DRUGINFO D0Z9NS ISIS 19212 Investigative T48881 TARGETID T48881 T48881 FORMERID TTDI02564 T48881 UNIPROID TNF14_HUMAN T48881 TARGNAME Herpes virus entry mediator ligand (CD258) T48881 GENENAME TNFSF14 T48881 TARGTYPE Clinical trial T48881 SYNONYMS UNQ391/PRO726; Tumor necrosis factor ligand superfamily member 14, soluble form; Tumor necrosis factor ligand superfamily member 14; LIGHT; Herpesvirus entry mediator ligand; HVEML; HVEM-L T48881 FUNCTION Binding to the decoy receptor TNFRSF6B modulates its effects. Acts as a ligand for TNFRSF14/HVEM. Upon binding to TNFRSF14/HVEM, delivers costimulatory signals to T cells, leading to T cell proliferation and IFNG production. Cytokine that binds to TNFRSF3/LTBR. T48881 PDBSTRUC 4RSU; 4KGQ; 4KGG; 4KG8; 4J6G T48881 BIOCLASS Cytokine: tumor necrosis factor T48881 SEQUENCE MEESVVRPSVFVVDGQTDIPFTRLGRSHRRQSCSVARVGLGLLLLLMGAGLAVQGWFLLQLHWRLGEMVTRLPDGPAGSWEQLIQERRSHEVNPAAHLTGANSSLTGSGGPLLWETQLGLAFLRGLSYHDGALVVTKAGYYYIYSKVQLGGVGCPLGLASTITHGLYKRTPRYPEELELLVSQQSPCGRATSSSRVWWDSSFLGGVVHLEAGEKVVVRVLDERLVRLRDGTRSYFGAFMV T48881 DRUGINFO DBU4N1 AVTX-002 Phase 2 T73708 TARGETID T73708 T73708 FORMERID TTDI02494 T73708 UNIPROID NRP2_HUMAN T73708 TARGNAME Neuropilin-2 (NRP2) T73708 GENENAME NRP2 T73708 TARGTYPE Clinical trial T73708 SYNONYMS Vascular endothelial cell growth factor 165 receptor 2; VEGF165R2; Neuropilin2 T73708 FUNCTION High affinity receptor for semaphorins 3C, 3F, VEGF-165 and VEGF-145 isoforms of VEGF, and the PLGF-2 isoform of PGF. T73708 PDBSTRUC 6GH8; 5DQ0; 5DN2; 4QDS; 4QDR T73708 BIOCLASS Neuropilin and tolloid-like T73708 SEQUENCE MDMFPLTWVFLALYFSRHQVRGQPDPPCGGRLNSKDAGYITSPGYPQDYPSHQNCEWIVYAPEPNQKIVLNFNPHFEIEKHDCKYDFIEIRDGDSESADLLGKHCGNIAPPTIISSGSMLYIKFTSDYARQGAGFSLRYEIFKTGSEDCSKNFTSPNGTIESPGFPEKYPHNLDCTFTILAKPKMEIILQFLIFDLEHDPLQVGEGDCKYDWLDIWDGIPHVGPLIGKYCGTKTPSELRSSTGILSLTFHTDMAVAKDGFSARYYLVHQEPLENFQCNVPLGMESGRIANEQISASSTYSDGRWTPQQSRLHGDDNGWTPNLDSNKEYLQVDLRFLTMLTAIATQGAISRETQNGYYVKSYKLEVSTNGEDWMVYRHGKNHKVFQANNDATEVVLNKLHAPLLTRFVRIRPQTWHSGIALRLELFGCRVTDAPCSNMLGMLSGLIADSQISASSTQEYLWSPSAARLVSSRSGWFPRIPQAQPGEEWLQVDLGTPKTVKGVIIQGARGGDSITAVEARAFVRKFKVSYSLNGKDWEYIQDPRTQQPKLFEGNMHYDTPDIRRFDPIPAQYVRVYPERWSPAGIGMRLEVLGCDWTDSKPTVETLGPTVKSEETTTPYPTEEEATECGENCSFEDDKDLQLPSGFNCNFDFLEEPCGWMYDHAKWLRTTWASSSSPNDRTFPDDRNFLRLQSDSQREGQYARLISPPVHLPRSPVCMEFQYQATGGRGVALQVVREASQESKLLWVIREDQGGEWKHGRIILPSYDMEYQIVFEGVIGKGRSGEIAIDDIRISTDVPLENCMEPISAFAGENFKVDIPEIHEREGYEDEIDDEYEVDWSNSSSATSGSGAPSTDKEKSWLYTLDPILITIIAMSSLGVLLGATCAGLLLYCTCSYSGLSSRSCTTLENYNFELYDGLKHKVKMNHQKCCSEA T73708 DRUGINFO DN2W9I ATYR1923 Phase 3 T01003 TARGETID T01003 T01003 FORMERID TTDI03172 T01003 UNIPROID ERN1_HUMAN T01003 TARGNAME Endoplasmic reticulum to nucleus signaling 1 (ERN1) T01003 GENENAME ERN1 T01003 TARGTYPE Clinical trial T01003 SYNONYMS Serine/threonine-protein kinase/endoribonuclease IRE1; Ire1-alpha; IRE1a; IRE1; Inositol-requiring protein 1; hIRE1p; Endoplasmic reticulum-to-nucleus signaling 1 T01003 FUNCTION In unstressed cells, the endoplasmic reticulum luminal domain is maintained in its inactive monomeric state by binding to the endoplasmic reticulum chaperone HSPA5/BiP. Accumulation of misfolded protein in the endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal domain to homodimerize, promoting autophosphorylation of the kinase domain and subsequent activation of the endoribonuclease activity. The endoribonuclease activity is specific for XBP1 mRNA and excises 26 nucleotides from XBP1 mRNA. The resulting spliced transcript of XBP1 encodes a transcriptional activator protein that up-regulates expression of UPR target genes. Acts as an upstream signal for ER stress-induced GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of CFTR to cell membrane by modulating the expression and localization of SEC16A. Serine/threonine-protein kinase and endoribonuclease that acts as a key sensor for the endoplasmic reticulum unfolded protein response (UPR). T01003 PDBSTRUC 6HX1; 6HV0; 5HGI; 4Z7H; 4Z7G T01003 BIOCLASS Kinase T01003 SEQUENCE MPARRLLLLLTLLLPGLGIFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEEPAFLPDPNDGSLYTLGSKNNEGLTKLPFTIPELVQASPCRSSDGILYMGKKQDIWYVIDLLTGEKQQTLSSAFADSLCPSTSLLYLGRTEYTITMYDTKTRELRWNATYFDYAASLPEDDVDYKMSHFVSNGDGLVVTVDSESGDVLWIQNYASPVVAFYVWQREGLRKVMHINVAVETLRYLTFMSGEVGRITKWKYPFPKETEAKSKLTPTLYVGKYSTSLYASPSMVHEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDVKFDPGLKSKNKLNYLRNYWLLIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKKSFEEVINLVDQTSENAPTTVSRDVEEKPAHAPARPEAPVDSMLKDMATIILSTFLLIGWVAFIITYPLSMHQQQQLQHQQFQKELEKIQLLQQQQQQLPFHPPGDTAQDGELLDTSGPYSESSGTSSPSTSPRASNHSLCSGSSASKAGSSPSLEQDDGDEETSVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPPEPQPPVTPDAL T01003 DRUGINFO DK3QD9 ORIN1001 Phase 1/2 T01003 DRUGINFO D00OUG US9040714, 7 Patented T01003 DRUGINFO D01UPA T8361 Patented T01003 DRUGINFO D0AV6X US8614253, 29-1 Patented T01003 DRUGINFO D0DV4H US8614253, 32-5 Patented T01003 DRUGINFO D0GK1K US8614253, 29-19 Patented T01003 DRUGINFO D0KF0D 879325-11-8 Patented T01003 DRUGINFO D0M2TO AC1LE05K Patented T01003 DRUGINFO D0TA9C US8614253, 32-4 Patented T01003 DRUGINFO D0VP7R BB 0223767 Patented T01003 DRUGINFO D0XX5N US9241942, 32-12 Patented T01003 DRUGINFO D0ZP0G US9040714, 155 Patented T01003 DRUGINFO D0E3CB PMID24749861C34 Investigative T01003 DRUGINFO D1BCW8 APY29 Investigative T34601 TARGETID T34601 T34601 FORMERID TTDI02407 T34601 UNIPROID DYSF_HUMAN T34601 TARGNAME Dysferlin (DYSF) T34601 GENENAME DYSF T34601 TARGTYPE Clinical trial T34601 SYNONYMS Fer1like protein 1; Dystrophyassociated fer1like protein; DYSF T34601 FUNCTION Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress.{ECO:0000250}. T34601 PDBSTRUC 4IQH; 4IHB; 4CAI; 4CAH T34601 BIOCLASS Synaptosomal vesicle fusion pore T34601 SEQUENCE MLRVFILYAENVHTPDTDISDAYCSAVFAGVKKRTKVIKNSVNPVWNEGFEWDLKGIPLDQGSELHVVVKDHETMGRNRFLGEAKVPLREVLATPSLSASFNAPLLDTKKQPTGASLVLQVSYTPLPGAVPLFPPPTPLEPSPTLPDLDVVADTGGEEDTEDQGLTGDEAEPFLDQSGGPGAPTTPRKLPSRPPPHYPGIKRKRSAPTSRKLLSDKPQDFQIRVQVIEGRQLPGVNIKPVVKVTAAGQTKRTRIHKGNSPLFNETLFFNLFDSPGELFDEPIFITVVDSRSLRTDALLGEFRMDVGTIYREPRHAYLRKWLLLSDPDDFSAGARGYLKTSLCVLGPGDEAPLERKDPSEDKEDIESNLLRPTGVALRGAHFCLKVFRAEDLPQMDDAVMDNVKQIFGFESNKKNLVDPFVEVSFAGKMLCSKILEKTANPQWNQNITLPAMFPSMCEKMRIRIIDWDRLTHNDIVATTYLSMSKISAPGGEIEEEPAGAVKPSKASDLDDYLGFLPTFGPCYINLYGSPREFTGFPDPYTELNTGKGEGVAYRGRLLLSLETKLVEHSEQKVEDLPADDILRVEKYLRRRKYSLFAAFYSATMLQDVDDAIQFEVSIGNYGNKFDMTCLPLASTTQYSRAVFDGCHYYYLPWGNVKPVVVLSSYWEDISHRIETQNQLLGIADRLEAGLEQVHLALKAQCSTEDVDSLVAQLTDELIAGCSQPLGDIHETPSATHLDQYLYQLRTHHLSQITEAALALKLGHSELPAALEQAEDWLLRLRALAEEPQNSLPDIVIWMLQGDKRVAYQRVPAHQVLFSRRGANYCGKNCGKLQTIFLKYPMEKVPGARMPVQIRVKLWFGLSVDEKEFNQFAEGKLSVFAETYENETKLALVGNWGTTGLTYPKFSDVTGKIKLPKDSFRPSAGWTWAGDWFVCPEKTLLHDMDAGHLSFVEEVFENQTRLPGGQWIYMSDNYTDVNGEKVLPKDDIECPLGWKWEDEEWSTDLNRAVDEQGWEYSITIPPERKPKHWVPAEKMYYTHRRRRWVRLRRRDLSQMEALKRHRQAEAEGEGWEYASLFGWKFHLEYRKTDAFRRRRWRRRMEPLEKTGPAAVFALEGALGGVMDDKSEDSMSVSTLSFGVNRPTISCIFDYGNRYHLRCYMYQARDLAAMDKDSFSDPYAIVSFLHQSQKTVVVKNTLNPTWDQTLIFYEIEIFGEPATVAEQPPSIVVELYDHDTYGADEFMGRCICQPSLERMPRLAWFPLTRGSQPSGELLASFELIQREKPAIHHIPGFEVQETSRILDESEDTDLPYPPPQREANIYMVPQNIKPALQRTAIEILAWGLRNMKSYQLANISSPSLVVECGGQTVQSCVIRNLRKNPNFDICTLFMEVMLPREELYCPPITVKVIDNRQFGRRPVVGQCTIRSLESFLCDPYSAESPSPQGGPDDVSLLSPGEDVLIDIDDKEPLIPIQEEEFIDWWSKFFASIGEREKCGSYLEKDFDTLKVYDTQLENVEAFEGLSDFCNTFKLYRGKTQEETEDPSVIGEFKGLFKIYPLPEDPAIPMPPRQFHQLAAQGPQECLVRIYIVRAFGLQPKDPNGKCDPYIKISIGKKSVSDQDNYIPCTLEPVFGKMFELTCTLPLEKDLKITLYDYDLLSKDEKIGETVVDLENRLLSKFGARCGLPQTYCVSGPNQWRDQLRPSQLLHLFCQQHRVKAPVYRTDRVMFQDKEYSIEEIEAGRIPNPHLGPVEERLALHVLQQQGLVPEHVESRPLYSPLQPDIEQGKLQMWVDLFPKALGRPGPPFNITPRRARRFFLRCIIWNTRDVILDDLSLTGEKMSDIYVKGWMIGFEEHKQKTDVHYRSLGGEGNFNWRFIFPFDYLPAEQVCTIAKKDAFWRLDKTESKIPARVVFQIWDNDKFSFDDFLGSLQLDLNRMPKPAKTAKKCSLDQLDDAFHPEWFVSLFEQKTVKGWWPCVAEEGEKKILAGKLEMTLEIVAESEHEERPAGQGRDEPNMNPKLEDPRRPDTSFLWFTSPYKTMKFILWRRFRWAIILFIILFILLLFLAIFIYAFPNYAAMKLVKPFS T34601 DRUGINFO DMD0H5 SRP-6004 Phase 1 T35212 TARGETID T35212 T35212 FORMERID TTDI02565 T35212 UNIPROID TNF15_HUMAN T35212 TARGNAME Vascular endothelial cell growth inhibitor (TNFSF15) T35212 GENENAME TNFSF15 T35212 TARGTYPE Clinical trial T35212 SYNONYMS Tumor necrosis factor ligand superfamily member 15, secreted form; Tumor necrosis factor ligand superfamily member 15; TNFSF15; TNF ligand-related molecule 1 T35212 FUNCTION Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis. T35212 PDBSTRUC 3MI8; 3K51; 2RJL; 2RJK; 2RE9 T35212 BIOCLASS Cytokine: tumor necrosis factor T35212 SEQUENCE MAEDLGLSFGETASVEMLPEHGSCRPKARSSSARWALTCCLVLLPFLAGLTTYLLVSQLRAQGEACVQFQALKGQEFAPSHQQVYAPLRADGDKPRAHLTVVRQTPTQHFKNQFPALHWEHELGLAFTKNRMNYTNKFLLIPESGDYFIYSQVTFRGMTSECSEIRQAGRPNKPDSITVVITKVTDSYPEPTQLLMGTKSVCEVGSNWFQPIYLGAMFSLQEGDKLMVNVSDISLVDYTKEDKTFFGAFLL T35212 DRUGINFO D61PGU PRA023 Phase 2 T35212 DRUGINFO D82MSU TEV-48574 Phase 2 T35212 DRUGINFO DMA7E5 PF-07261271 Phase 1 T55703 TARGETID T55703 T55703 FORMERID TTDI02366 T55703 UNIPROID RET4_HUMAN T55703 TARGNAME Plasma retinol-binding protein (RBP4) T55703 GENENAME RBP4 T55703 TARGTYPE Clinical trial T55703 SYNONYMS Retinol-binding protein 4; RBP4; RBP; Plasma retinol-binding protein(1-176); PRBP T55703 FUNCTION Delivers retinol from the liver stores to the peripheral tissues. In plasma, the RBP-retinol complex interacts with transthyretin, this prevents its loss by filtration through the kidney glomeruli. T55703 PDBSTRUC 5NUB; 5NUA; 5NU9; 5NU8; 5NU7 T55703 BIOCLASS Calycin family T55703 SEQUENCE MKWVWALLLLAALGSGRAERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNLL T55703 DRUGINFO DCD0M4 Tinlarebant Phase 3 T55703 DRUGINFO D01KKC A1-10436 Patented T55703 DRUGINFO D02TPQ US9434727, 93 Patented T55703 DRUGINFO D04BAA US9434727, 153 Patented T55703 DRUGINFO D05AIC US9434727, 40 Patented T55703 DRUGINFO D08PYU US8586571, 12 Patented T55703 DRUGINFO D0D5AI A1-10438 Patented T55703 DRUGINFO D0I1LE US8586571, 36 Patented T55703 DRUGINFO D0IV0E US8853215, 3 Patented T55703 DRUGINFO D0J9YV US8586571, 6 Patented T55703 DRUGINFO D0K0IZ US9434727, 120 Patented T55703 DRUGINFO D0YU9U US9434727, 63 Patented T33976 TARGETID T33976 T33976 FORMERID TTDR01147 T33976 UNIPROID TFR1_HUMAN T33976 TARGNAME Transferrin receptor protein 1 (TFRC) T33976 GENENAME TFRC T33976 TARGTYPE Clinical trial T33976 SYNONYMS Trfr; TfR1; TfR; TR protein; T9; P90; CD71 antigen; CD71 T33976 FUNCTION Endosomal acidification leads to iron release. The apotransferrin-receptor complex is then recycled to the cell surface with a return to neutral pH and the concomitant loss of affinity of apotransferrin for its receptor. Transferrin receptor is necessary for development of erythrocytes and the nervous system. A second ligand, the heditary hemochromatosis protein HFE, competes for binding with transferrin for an overlapping C-terminal binding site. Positively regulates T and B cell proliferation through iron uptake. Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. T33976 PDBSTRUC 6H5I; 6GSR; 6D05; 6D04; 6D03 T33976 BIOCLASS Peptidase T33976 SEQUENCE MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKANVTKPKRCSGSICYGTIAVIVFFLIGFMIGYLGYCKGVEPKTECERLAGTESPVREEPGEDFPAARRLYWDDLKRKLSEKLDSTDFTGTIKLLNENSYVPREAGSQKDENLALYVENQFREFKLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAEKLFGNMEGDCPSDWKTDSTCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFVEPDHYVVVGAQRDAWGPGAAKSGVGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWSAGDFGSVGATEWLEGYLSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWASKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVARAAAEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARGDFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRHVFWGSGSHTLPALLENLKLRKQNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF T33976 DRUGINFO DZ1F3N CX2029 Phase 1/2 T33976 DRUGINFO D58AMF ABBV-CX-2029 Phase 1 T95616 TARGETID T95616 T95616 FORMERID TTDR00699 T95616 UNIPROID ITAM_HUMAN T95616 TARGNAME Integrin alpha-M (ITGAM) T95616 GENENAME ITGAM T95616 TARGTYPE Clinical trial T95616 SYNONYMS Neutrophil adherence receptor; Leukocyte adhesion receptor MO1; Cell surface glycoprotein Mac-1; Cell surface glycoprotein MAC-1 subunit alpha; Cell surface glycoprotein MAC-1 alpha subunit; CR3A; CR-3 alpha chain; CD11b; CD11 antigen-like family member B T95616 FUNCTION It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It probably recognizes the R-G-D peptide in C3b. Integrin ITGAM/ITGB2 is also a receptor for fibrinogen, factor X and ICAM1. It recognizes P1 and P2 peptides of fibrinogen gamma chain. Regulates neutrophil migration. In association with beta subunit ITGB2/CD18, required for CD177-PRTN3-mediated activation of TNF primed neutrophils. May regulate phagocytosis-induced apoptosis in extravasated neutrophils. May play a role in mast cell development. Required with TYROBP/DAP12 in microglia to control production of microglial superoxide ions which promote the neuronal apoptosis that occurs during brain development. Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens. T95616 PDBSTRUC 4XW2; 4M76; 3QA3; 3Q3G; 2LKJ T95616 BIOCLASS Integrin T95616 SEQUENCE MALRVLLLTALTLCHGFNLDTENAMTFQENARGFGQSVVQLQGSRVVVGAPQEIVAANQRGSLYQCDYSTGSCEPIRLQVPVEAVNMSLGLSLAATTSPPQLLACGPTVHQTCSENTYVKGLCFLFGSNLRQQPQKFPEALRGCPQEDSDIAFLIDGSGSIIPHDFRRMKEFVSTVMEQLKKSKTLFSLMQYSEEFRIHFTFKEFQNNPNPRSLVKPITQLLGRTHTATGIRKVVRELFNITNGARKNAFKILVVITDGEKFGDPLGYEDVIPEADREGVIRYVIGVGDAFRSEKSRQELNTIASKPPRDHVFQVNNFEALKTIQNQLREKIFAIEGTQTGSSSSFEHEMSQEGFSAAITSNGPLLSTVGSYDWAGGVFLYTSKEKSTFINMTRVDSDMNDAYLGYAAAIILRNRVQSLVLGAPRYQHIGLVAMFRQNTGMWESNANVKGTQIGAYFGASLCSVDVDSNGSTDLVLIGAPHYYEQTRGGQVSVCPLPRGRARWQCDAVLYGEQGQPWGRFGAALTVLGDVNGDKLTDVAIGAPGEEDNRGAVYLFHGTSGSGISPSHSQRIAGSKLSPRLQYFGQSLSGGQDLTMDGLVDLTVGAQGHVLLLRSQPVLRVKAIMEFNPREVARNVFECNDQVVKGKEAGEVRVCLHVQKSTRDRLREGQIQSVVTYDLALDSGRPHSRAVFNETKNSTRRQTQVLGLTQTCETLKLQLPNCIEDPVSPIVLRLNFSLVGTPLSAFGNLRPVLAEDAQRLFTALFPFEKNCGNDNICQDDLSITFSFMSLDCLVVGGPREFNVTVTVRNDGEDSYRTQVTFFFPLDLSYRKVSTLQNQRSQRSWRLACESASSTEVSGALKSTSCSINHPIFPENSEVTFNITFDVDSKASLGNKLLLKANVTSENNMPRTNKTEFQLELPVKYAVYMVVTSHGVSTKYLNFTASENTSRVMQHQYQVSNLGQRSLPISLVFLVPVRLNQTVIWDRPQVTFSENLSSTCHTKERLPSHSDFLAELRKAPVVNCSIAVCQRIQCDIPFFGIQEEFNATLKGNLSFDWYIKTSHNHLLIVSTAEILFNDSVFTLLPGQGAFVRSQTETKVEPFEVPNPLPLIVGSSVGGLLLLALITAALYKLGFFKRQYKDMMSEGGPPGAEPQ T95616 DRUGINFO DZ5K6F GB1275 Phase 1/2 T73134 TARGETID T73134 T73134 UNIPROID BGAL_HUMAN T73134 TARGNAME Beta-galactosidase (GLB1) T73134 GENENAME GLB1 T73134 TARGTYPE Clinical trial T73134 SYNONYMS Lactase; Elastin receptor 1; ELNR1; Acid beta-galactosidase T73134 FUNCTION Isoform 1: Cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans. T73134 PDBSTRUC 3WF4; 3WF3; 3WF2; 3WF1; 3WF0 T73134 ECNUMBER EC 3.2.1.23 T73134 SEQUENCE MPGFLVRILPLLLVLLLLGPTRGLRNATQRMFEIDYSRDSFLKDGQPFRYISGSIHYSRVPRFYWKDRLLKMKMAGLNAIQTYVPWNFHEPWPGQYQFSEDHDVEYFLRLAHELGLLVILRPGPYICAEWEMGGLPAWLLEKESILLRSSDPDYLAAVDKWLGVLLPKMKPLLYQNGGPVITVQVENEYGSYFACDFDYLRFLQKRFRHHLGDDVVLFTTDGAHKTFLKCGALQGLYTTVDFGTGSNITDAFLSQRKCEPKGPLINSEFYTGWLDHWGQPHSTIKTEAVASSLYDILARGASVNLYMFIGGTNFAYWNGANSPYAAQPTSYDYDAPLSEAGDLTEKYFALRNIIQKFEKVPEGPIPPSTPKFAYGKVTLEKLKTVGAALDILCPSGPIKSLYPLTFIQVKQHYGFVLYRTTLPQDCSNPAPLSSPLNGVHDRAYVAVDGIPQGVLERNNVITLNITGKAGATLDLLVENMGRVNYGAYINDFKGLVSNLTLSSNILTDWTIFPLDTEDAVRSHLGGWGHRDSGHHDEAWAHNSSNYTLPAFYMGNFSIPSGIPDLPQDTFIQFPGWTKGQVWINGFNLGRYWPARGPQLTLFVPQHILMTSAPNTITVLELEWAPCSSDDPELCAVTFVDRPVIGSSVTYDHPSKPVEKRLMPPPPQKNKDSWLDHV T73134 DRUGINFO D93JPW PBGM01 Phase 1/2 T73134 DRUGINFO DN4O0S AXO-AAV-GM1 Phase 1/2 T73134 DRUGINFO DY8D2C LYS-GM-101 Phase 1/2 T73134 DRUGINFO D2DLN9 5N,6S-(N'-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin Preclinical T73134 DRUGINFO DBJ5Z0 N-Octyl-4-epi-beta-valienamine Preclinical T64597 TARGETID T64597 T64597 FORMERID TTDNR00693 T64597 UNIPROID ITB8_HUMAN T64597 TARGNAME Integrin beta-8 (ITGB8) T64597 GENENAME ITGB8 T64597 TARGTYPE Clinical trial T64597 SYNONYMS Integrin subunit beta 8 T64597 FUNCTION It recognizes the sequence R-G-D in its ligands. Integrin alpha-V:beta-6 (ITGAV:ITGB6) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation on the surface of activated regulatory T-cells (Tregs). Required during vasculogenesis. Integrin alpha-V:beta-8 (ITGAV:ITGB8) is a receptor for fibronectin. T64597 PDBSTRUC 6DJP T64597 BIOCLASS Integrin T64597 SEQUENCE MCGSALAFFTAAFVCLQNDRRGPASFLWAAWVFSLVLGLGQGEDNRCASSNAASCARCLALGPECGWCVQEDFISGGSRSERCDIVSNLISKGCSVDSIEYPSVHVIIPTENEINTQVTPGEVSIQLRPGAEANFMLKVHPLKKYPVDLYYLVDVSASMHNNIEKLNSVGNDLSRKMAFFSRDFRLGFGSYVDKTVSPYISIHPERIHNQCSDYNLDCMPPHGYIHVLSLTENITEFEKAVHRQKISGNIDTPEGGFDAMLQAAVCESHIGWRKEAKRLLLVMTDQTSHLALDSKLAGIVVPNDGNCHLKNNVYVKSTTMEHPSLGQLSEKLIDNNINVIFAVQGKQFHWYKDLLPLLPGTIAGEIESKAANLNNLVVEAYQKLISEVKVQVENQVQGIYFNITAICPDGSRKPGMEGCRNVTSNDEVLFNVTVTMKKCDVTGGKNYAIIKPIGFNETAKIHIHRNCSCQCEDNRGPKGKCVDETFLDSKCFQCDENKCHFDEDQFSSESCKSHKDQPVCSGRGVCVCGKCSCHKIKLGKVYGKYCEKDDFSCPYHHGNLCAGHGECEAGRCQCFSGWEGDRCQCPSAAAQHCVNSKGQVCSGRGTCVCGRCECTDPRSIGRFCEHCPTCYTACKENWNCMQCLHPHNLSQAILDQCKTSCALMEQQHYVDQTSECFSSPSYLRIFFIIFIVTFLIGLLKVLIIRQVILQWNSNKIKSSSDYRVSASKKDKLILQSVCTRAVTYRREKPEEIKMDISKLNAHETFRCNF T64597 DRUGINFO D37AYZ MEDI8367 Phase 1 T64597 DRUGINFO D04KXV US10035778, Example 16 Patented T64597 DRUGINFO D0QG9P US10035778, Example 1 Patented T64597 DRUGINFO D0UB5E US10035778, Example 12 Patented T44057 TARGETID T44057 T44057 FORMERID TTDI03034 T44057 UNIPROID AQP1_HUMAN T44057 TARGNAME Aquaporin-1 (AQP1) T44057 GENENAME AQP1 T44057 TARGTYPE Clinical trial T44057 SYNONYMS Water channel protein for red blood cells and kidney proximal tubule; Urine water channel; CHIP28; Aquaporin-CHIP; AQP-1 T44057 FUNCTION Forms a water-specific channel that provides the plasma membranes of red cells and kidney proximal tubules with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient. T44057 PDBSTRUC 4CSK; 1IH5; 1H6I; 1FQY T44057 BIOCLASS Major intrinsic protein T44057 SEQUENCE MASEFKKKLFWRAVVAEFLATTLFVFISIGSALGFKYPVGNNQTAVQDNVKVSLAFGLSIATLAQSVGHISGAHLNPAVTLGLLLSCQISIFRALMYIIAQCVGAIVATAILSGITSSLTGNSLGRNDLADGVNSGQGLGIEIIGTLQLVLCVLATTDRRRRDLGGSAPLAIGLSVALGHLLAIDYTGCGINPARSFGSAVITHNFSNHWIFWVGPFIGGALAVLIYDFILAPRSSDLTDRVKVWTSGQVEEYDLDADDINSRVEMKPK T44057 DRUGINFO D4IWF1 AAV-AQP1 Phase 1/2 T44057 DRUGINFO D06PZZ [14C]TEA Investigative T74066 TARGETID T74066 T74066 FORMERID TTDI02553 T74066 UNIPROID BMI1_HUMAN T74066 TARGNAME Polycomb complex protein BMI-1 (BMI1) T74066 GENENAME BMI1 T74066 TARGTYPE Clinical trial T74066 SYNONYMS RNF51; RING finger protein 51; Polycomb group RING finger protein 4; PCGF4 T74066 FUNCTION PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility. The complex composed of RNF2, UB2D3 and BMI1 binds nucleosomes, and has activity only with nucleosomal histone H2A. In the PRC1-like complex, regulates the E3 ubiquitin-protein ligase activity of RNF2/RING2. Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. T74066 PDBSTRUC 5FR6; 4R8P; 3RPG; 2NA1; 2H0D T74066 BIOCLASS Zinc-finger T74066 SEQUENCE MHRTTRIKITELNPHLMCVLCGGYFIDATTIIECLHSFCKTCIVRYLETSKYCPICDVQVHKTRPLLNIRSDKTLQDIVYKLVPGLFKNEMKRRRDFYAAHPSADAANGSNEDRGEVADEDKRIITDDEIISLSIEFFDQNRLDRKVNKDKEKSKEEVNDKRYLRCPAAMTVMHLRKFLRSKMDIPNTFQIDVMYEEEPLKDYYTLMDIAYIYTWRRNGPLPLKYRVRPTCKRMKISHQRDGLTNAGELESDSGSDKANSPAGGIPSTSSCLPSPSTPVQSPHPQFPHISSTMNGTSNSPSGNHQSSFANRPRKSSVNGSSATSSG T74066 DRUGINFO DUH2E6 Unesbulin Phase 2/3 T20629 TARGETID T20629 T20629 FORMERID TTDR00834 T20629 UNIPROID ADML_HUMAN T20629 TARGNAME Adrenomedullin (ADM) T20629 GENENAME ADM T20629 TARGTYPE Clinical trial T20629 SYNONYMS AM; ADM T20629 FUNCTION AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels. T20629 PDBSTRUC 5V6Y; 4RWF; 2L7S; 2FLY T20629 BIOCLASS Adrenomedullin T20629 SEQUENCE MKLVSVALMYLGSLAFLGADTARLDVASEFRKKWNKWALSRGKRELRMSSSYPTGLADVKAGPAQTLIRPQDMKGASRSPEDSSPDAARIRVKRYRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGYGRRRRRSLPEAGPGRTLVSSKPQAHGAPAPPSGSAPHFL T20629 DRUGINFO DK8BS7 BAY1097761 Phase 2 T85221 TARGETID T85221 T85221 FORMERID TTDR00474 T85221 UNIPROID G6PC_HUMAN T85221 TARGNAME Glucose-6-phosphatase (G6PC) T85221 GENENAME G6PC T85221 TARGTYPE Clinical trial T85221 SYNONYMS Glucose-6-phosphatase alpha; G6Pase-alpha; G6Pase; G6PT; G-6-Pase T85221 FUNCTION Forms with the glucose-6-phosphate transporter (SLC37A4/G6PT) the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it is the key enzyme in homeostatic regulation of blood glucose levels. Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum. T85221 BIOCLASS Phosphoric monoester hydrolase T85221 ECNUMBER EC 3.1.3.9 T85221 SEQUENCE MEEGMNVLHDFGIQSTHYLQVNYQDSQDWFILVSVIADLRNAFYVLFPIWFHLQEAVGIKLLWVAVIGDWLNLVFKWILFGQRPYWWVLDTDYYSNTSVPLIKQFPVTCETGPGSPSGHAMGTAGVYYVMVTSTLSIFQGKIKPTYRFRCLNVILWLGFWAVQLNVCLSRIYLAAHFPHQVVAGVLSGIAVAETFSHIHSIYNASLKKYFLITFFLFSFAIGFYLLLKGLGVDLLWTLEKAQRWCEQPEWVHIDTTPFASLLKNLGTLFGLGLALNSSMYRESCKGKLSKWLPFRLSSIVASLVLLHVFDSLKPPSQVELVFYVLSFCKSAVVPLASVSVIPYCLAQVLGQPHKKSL T85221 DRUGINFO D5WAG1 DTX401 Phase 1 T44513 TARGETID T44513 T44513 FORMERID TTDR01128 T44513 UNIPROID CEAM6_HUMAN T44513 TARGNAME Normal cross-reacting antigen (CD66c) T44513 GENENAME CEACAM6 T44513 TARGTYPE Clinical trial T44513 SYNONYMS Nonspecific crossreacting antigen; Non-specific crossreacting antigen; NCA; Carcinoembryonic antigen-related cell adhesion molecule 6; CD66c antigen T44513 FUNCTION Intercellular adhesion occurs in a calcium- and fibronectin-independent manner. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8. Heterophilic interaction with CEACAM8 occurs in activated neutrophils. Plays a role in neutrophil adhesion to cytokine-activated endothelial cells. Plays a role as an oncogene by promoting tumor progression; positively regulates cell migration, cell adhesion to endothelial cells and cell invasion. Also involved in the metastatic cascade process by inducing gain resistance to anoikis of pancreatic adenocarcinoma and colorectal carcinoma cells. Cell surface glycoprotein that plays a role in cell adhesion and tumor progression. T44513 PDBSTRUC 4YIQ; 4Y8A; 4WTZ; 4WHC T44513 BIOCLASS Immunoglobulin T44513 SEQUENCE MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLYGPDGPTISPSKANYRPGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGSYMCQAHNSATGLNRTTVTMITVSGSAPVLSAVATVGITIGVLARVALI T44513 DRUGINFO D5T1RN BAY 1834942 Phase 1 T00852 TARGETID T00852 T00852 FORMERID TTDI01377 T00852 UNIPROID M3K8_HUMAN T00852 TARGNAME Serine/threonine-protein kinase cot (COT) T00852 GENENAME MAP3K8 T00852 TARGTYPE Clinical trial T00852 SYNONYMS Tumor progression locus 2; TPL-2; Proto-oncogene c-Cot; Mitogen-activated protein kinase kinase kinase 8; ESTF; Cancer Osaka thyroid oncogene; COT T00852 FUNCTION Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. T00852 PDBSTRUC 5IU2; 4Y85; 4Y83 T00852 ECNUMBER EC 2.7.11.25 T00852 SEQUENCE MEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPTLEYG T00852 DRUGINFO D1BA7Z GS-5290 Phase 1 T72024 TARGETID T72024 T72024 FORMERID TTDI02614 T72024 UNIPROID GALC_HUMAN T72024 TARGNAME Galactocerebrosidase (GALC) T72024 GENENAME GALC T72024 TARGTYPE Clinical trial T72024 SYNONYMS Galactosylceramide betagalactosidase; Galactosylceramide beta-galactosidase; Galactosylceramidase; Galactocerebroside betagalactosidase; Galactocerebroside beta-galactosidase; GALCERase T72024 FUNCTION Enzyme with very low activity responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon. Hydrolyzes the galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride. T72024 BIOCLASS Glycosylase T72024 ECNUMBER EC 3.2.1.46 T72024 SEQUENCE MAEWLLSASWQRRAKAMTAAAGSAGRAAVPLLLCALLAPGGAYVLDDSDGLGREFDGIGAVSGGGATSRLLVNYPEPYRSQILDYLFKPNFGASLHILKVEIGGDGQTTDGTEPSHMHYALDENYFRGYEWWLMKEAKKRNPNITLIGLPWSFPGWLGKGFDWPYVNLQLTAYYVVTWIVGAKRYHDLDIDYIGIWNERSYNANYIKILRKMLNYQGLQRVKIIASDNLWESISASMLLDAELFKVVDVIGAHYPGTHSAKDAKLTGKKLWSSEDFSTLNSDMGAGCWGRILNQNYINGYMTSTIAWNLVASYYEQLPYGRCGLMTAQEPWSGHYVVESPVWVSAHTTQFTQPGWYYLKTVGHLEKGGSYVALTDGLGNLTIIIETMSHKHSKCIRPFLPYFNVSQQFATFVLKGSFSEIPELQVWYTKLGKTSERFLFKQLDSLWLLDSDGSFTLSLHEDELFTLTTLTTGRKGSYPLPPKSQPFPSTYKDDFNVDYPFFSEAPNFADQTGVFEYFTNIEDPGEHHFTLRQVLNQRPITWAADASNTISIIGDYNWTNLTIKCDVYIETPDTGGVFIAGRVNKGGILIRSARGIFFWIFANGSYRVTGDLAGWIIYALGRVEVTAKKWYTLTLTIKGHFTSGMLNDKSLWTDIPVNFPKNGWAAIGTHSFEFAQFDNFLVEATR T72024 DRUGINFO D0LJ4H PBKR03 Phase 1/2 T72024 DRUGINFO D62OSE FBX-101 Phase 1/2 T59554 TARGETID T59554 T59554 FORMERID TTDI01430 T59554 UNIPROID DPRE1_MYCTU T59554 TARGNAME Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) T59554 GENENAME McyB dprE1 T59554 TARGTYPE Clinical trial T59554 SYNONYMS FAD-dependent decaprenylphosphoryl-beta-D-ribofuranose 2-oxidase; Decaprenylphosphoryl-beta-D-ribose oxidase; Decaprenylphosphoryl-beta-D-ribose 2-epimerase flavoprotein subunit; Decaprenylphosphoryl-beta-D-ribofuranose 2'-oxidase; Decaprenylphosphoryl-beta-D-ribofuranose 2'-epimerase subunit DprE1; Decaprenylphospho-beta-D-ribofuranose 2-dehydrogenase; Decaprenyl-phosphoribose 2'-epimerase subunit 1 T59554 FUNCTION Component of the DprE1-DprE2 complex that catalyzes the 2-step epimerization of decaprenyl-phospho-ribose (DPR) to decaprenyl-phospho-arabinose (DPA), a key precursor that serves as the arabinose donor required for the synthesis of cell-wall arabinans. DprE1 catalyzes the first step of epimerization, namely FAD-dependent oxidation of the C2' hydroxyl of DPR to yield the keto intermediate decaprenyl-phospho-2'-keto-D-arabinose (DPX). The intermediate DPX is then transferred to DprE2 subunit of the epimerase complex, most probably through a 'substrate channel' at the interface of DprE1-DprE2 complex. Can also use farnesyl-phosphoryl-beta-D-ribofuranose (FPR) as substrate in vitro. Appears to be essential for the growth and survival of M.tuberculosis. T59554 PDBSTRUC 6HFW; 6HFV; 6HF3; 6HF0; 6HEZ T59554 ECNUMBER EC 1.1.98.3 T59554 SEQUENCE MLSVGATTTATRLTGWGRTAPSVANVLRTPDAEMIVKAVARVAESGGGRGAIARGLGRSYGDNAQNGGGLVIDMTPLNTIHSIDADTKLVDIDAGVNLDQLMKAALPFGLWVPVLPGTRQVTVGGAIACDIHGKNHHSAGSFGNHVRSMDLLTADGEIRHLTPTGEDAELFWATVGGNGLTGIIMRATIEMTPTSTAYFIADGDVTASLDETIALHSDGSEARYTYSSAWFDAISAPPKLGRAAVSRGRLATVEQLPAKLRSEPLKFDAPQLLTLPDVFPNGLANKYTFGPIGELWYRKSGTYRGKVQNLTQFYHPLDMFGEWNRAYGPAGFLQYQFVIPTEAVDEFKKIIGVIQASGHYSFLNVFKLFGPRNQAPLSFPIPGWNICVDFPIKDGLGKFVSELDRRVLEFGGRLYTAKDSRTTAETFHAMYPRVDEWISVRRKVDPLRVFASDMARRLELL T59554 DRUGINFO DCYV91 TBA-7371 Phase 2 T59554 DRUGINFO DVK21S BTZ-043 Phase 2 T59554 DRUGINFO D8AF1M OPC-167832 Phase 1/2 T59554 DRUGINFO DTO06Y Macozinone Phase 1 T94880 TARGETID T94880 T94880 FORMERID TTDI03607 T94880 UNIPROID TYRO3_HUMAN T94880 TARGNAME TYRO3 tyrosine kinase receptor (TYRO3) T94880 GENENAME TYRO3 T94880 TARGTYPE Clinical trial T94880 SYNONYMS Tyrosine-protein kinase receptor TYRO3; Tyrosine-protein kinase TIF; Tyrosine-protein kinase SKY; Tyrosine-protein kinase RSE; Tyrosine-protein kinase DTK; Tyrosine-protein kinase BYK; TIF; SKY; RSE; DTK; BYK T94880 FUNCTION Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including TULP1 or GAS6. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of TYRO3 on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with PIK3R1 and thereby enhances PI3-kinase activity. Activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 signaling plays a role in various processes such as neuron protection from excitotoxic injury, platelet aggregation and cytoskeleton reorganization. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3. T94880 PDBSTRUC 1RHF T94880 ECNUMBER EC 2.7.10.1 T94880 SEQUENCE MALRRSMGRPGLPPLPLPPPPRLGLLLAALASLLLPESAAAGLKLMGAPVKLTVSQGQPVKLNCSVEGMEEPDIQWVKDGAVVQNLDQLYIPVSEQHWIGFLSLKSVERSDAGRYWCQVEDGGETEISQPVWLTVEGVPFFTVEPKDLAVPPNAPFQLSCEAVGPPEPVTIVWWRGTTKIGGPAPSPSVLNVTGVTQSTMFSCEAHNLKGLASSRTATVHLQALPAAPFNITVTKLSSSNASVAWMPGADGRALLQSCTVQVTQAPGGWEVLAVVVPVPPFTCLLRDLVPATNYSLRVRCANALGPSPYADWVPFQTKGLAPASAPQNLHAIRTDSGLILEWEEVIPEAPLEGPLGPYKLSWVQDNGTQDELTVEGTRANLTGWDPQKDLIVRVCVSNAVGCGPWSQPLVVSSHDRAGQQGPPHSRTSWVPVVLGVLTALVTAAALALILLRKRRKETRFGQAFDSVMARGEPAVHFRAARSFNRERPERIEATLDSLGISDELKEKLEDVLIPEQQFTLGRMLGKGEFGSVREAQLKQEDGSFVKVAVKMLKADIIASSDIEEFLREAACMKEFDHPHVAKLVGVSLRSRAKGRLPIPMVILPFMKHGDLHAFLLASRIGENPFNLPLQTLIRFMVDIACGMEYLSSRNFIHRDLAARNCMLAEDMTVCVADFGLSRKIYSGDYYRQGCASKLPVKWLALESLADNLYTVQSDVWAFGVTMWEIMTRGQTPYAGIENAEIYNYLIGGNRLKQPPECMEDVYDLMYQCWSADPKQRPSFTCLRMELENILGQLSVLSASQDPLYINIERAEEPTAGGSLELPGRDQPYSGAGDGSGMGAVGGTPSDCRYILTPGGLAEQPGQAEHQPESPLNETQRLLLLQQGLLPHSSC T94880 DRUGINFO D7HZ3T RXDX-106 Phase 1 T94880 DRUGINFO D03RHV BDBM50444058 Patented T94880 DRUGINFO D08OEW BDBM50444062 Patented T94880 DRUGINFO D0E0YY KRDULPYOVRWKMA-UHFFFAOYSA-N Patented T94880 DRUGINFO D0M9TR BDBM50444059 Patented T94880 DRUGINFO D0N8QO US10053465, 8 Patented T94880 DRUGINFO D0X7WG US10053465, 12 Patented T94880 DRUGINFO D0ZY9S US10053465, 5 Patented T94880 DRUGINFO D09TFN LDC1267 Investigative T63083 TARGETID T63083 T63083 FORMERID TTDR00922 T63083 UNIPROID RAD51_HUMAN T63083 TARGNAME DNA repair protein RAD51 homolog 1 (RAD51) T63083 GENENAME RAD51 T63083 TARGTYPE Clinical trial T63083 SYNONYMS hRAD51; RECA; RAD51A; RAD51 homolog A; HsRAD51 T63083 FUNCTION Plays an important role in homologous strand exchange, a key step in DNA repair through homologous recombination (HR). Binds to single and double-stranded DNA and exhibits DNA-dependent ATPase activity. Catalyzes the recognition of homology and strand exchange between homologous DNA partners to form a joint molecule between a processed DNA break and the repair template. Binds to single-stranded DNA in an ATP-dependent manner to form nucleoprotein filaments which are essential for the homology search and strand exchange. Part of a PALB2-scaffolded HR complex containing BRCA2 and RAD51C and which is thought to play a role in DNA repair by HR. Plays a role in regulating mitochondrial DNA copy number under conditions of oxidative stress in the presence of RAD51C and XRCC3. Also involved in interstrand cross-link repair. T63083 PDBSTRUC 5NWL; 5NP7; 5JZC; 5H1C; 5H1B T63083 SEQUENCE MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAVAYAPKKELINIKGISEAKADKILAEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERLLAVAERYGLSGSDVLDNVAYARAFNTDHQTQLLYQASAMMVESRYALLIVDSATALYRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGGNIIAHASTTRLYLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD T63083 DRUGINFO DR5VQ1 CYT-0851 Phase 1/2 T63083 DRUGINFO D00ICA AMP-PNP Investigative T73404 TARGETID T73404 T73404 FORMERID TTDI02500 T73404 UNIPROID CD166_HUMAN T73404 TARGNAME Activated leukocyte cell adhesionmolecule (ALCAM) T73404 GENENAME ALCAM T73404 TARGTYPE Clinical trial T73404 SYNONYMS MEMD; CD166 antigen; CD166; Activated leukocyte cell adhesion molecule T73404 FUNCTION Promotes T-cell activation and proliferation via its interactions with CD6. Contributes to the formation and maturation of the immunological synapse via its interactions with CD6. Mediates homotypic interactions with cells that express ALCAM. Required for normal hematopoietic stem cell engraftment in the bone marrow. Mediates attachment of dendritic cells onto endothelial cells via homotypic interaction. Inhibits endothelial cell migration and promotes endothelial tube formation via homotypic interactions. Required for normal organization of the lymph vessel network. Required for normal hematopoietic stem cell engraftment in the bone marrow. Plays a role in hematopoiesis; required for normal numbers of hematopoietic stem cells in bone marrow. Promotes in vitro osteoblast proliferation and differentiation. Promotes neurite extension, axon growth and axon guidance; axons grow preferentially on surfaces that contain ALCAM. Mediates outgrowth and pathfinding for retinal ganglion cell axons. Cell adhesion molecule that mediates both heterotypic cell-cell contacts via its interaction with CD6, as well as homotypic cell-cell contacts. T73404 PDBSTRUC 5A2F; 1KJC T73404 BIOCLASS Basigin protein T73404 SEQUENCE MESKGASSCRLLFCLLISATVFRPGLGWYTVNSAYGDTIIIPCRLDVPQNLMFGKWKYEKPDGSPVFIAFRSSTKKSVQYDDVPEYKDRLNLSENYTLSISNARISDEKRFVCMLVTEDNVFEAPTIVKVFKQPSKPEIVSKALFLETEQLKKLGDCISEDSYPDGNITWYRNGKVLHPLEGAVVIIFKKEMDPVTQLYTMTSTLEYKTTKADIQMPFTCSVTYYGPSGQKTIHSEQAVFDIYYPTEQVTIQVLPPKNAIKEGDNITLKCLGNGNPPPEEFLFYLPGQPEGIRSSNTYTLTDVRRNATGDYKCSLIDKKSMIASTAITVHYLDLSLNPSGEVTRQIGDALPVSCTISASRNATVVWMKDNIRLRSSPSFSSLHYQDAGNYVCETALQEVEGLKKRESLTLIVEGKPQIKMTKKTDPSGLSKTIICHVEGFPKPAIQWTITGSGSVINQTEESPYINGRYYSKIIISPEENVTLTCTAENQLERTVNSLNVSAISIPEHDEADEISDENREKVNDQAKLIVGIVVGLLLAALVAGVVYWLYMKKSKTASKHVNKDLGNMEENKKLEENNHKTEA T73404 DRUGINFO D1PC9J CX2009 Phase 2 T35423 TARGETID T35423 T35423 FORMERID TTDI02638 T35423 UNIPROID VTCN1_HUMAN T35423 TARGNAME Immune costimulatory protein B7H4 (VTCN1) T35423 GENENAME VTCN1 T35423 TARGTYPE Clinical trial T35423 SYNONYMS VTCN1; V-set domain-containing T-cell activation inhibitor 1; T-cell costimulatory molecule B7x; Protein B7S1; B7h.5 T35423 FUNCTION Negatively regulates T-cell-mediated immune response byinhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor- associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation. T35423 PDBSTRUC 4GOS T35423 BIOCLASS Immunoglobulin T35423 SEQUENCE MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK T35423 DRUGINFO DD10IZ AZD8205 Phase 2 T35423 DRUGINFO D7WMF3 PF-07260437 Phase 1 T26900 TARGETID T26900 T26900 FORMERID TTDI03226 T26900 UNIPROID DCE1_HUMAN T26900 TARGNAME Glutamic acid decarboxylase 1 (GAD1) T26900 GENENAME GAD1 T26900 TARGTYPE Clinical trial T26900 SYNONYMS Glutamate decarboxylase 67 kDa isoform; Glutamate decarboxylase 1; GAD67; GAD-67; GAD; 67 kDa glutamic acid decarboxylase T26900 FUNCTION Catalyzes the production of GABA. T26900 PDBSTRUC 3VP6; 2OKJ T26900 ECNUMBER EC 4.1.1.15 T26900 SEQUENCE MASSTPSSSATSSNAGADPNTTNLRPTTYDTWCGVAHGCTRKLGLKICGFLQRTNSLEEKSRLVSAFKERQSSKNLLSCENSDRDARFRRTETDFSNLFARDLLPAKNGEEQTVQFLLEVVDILLNYVRKTFDRSTKVLDFHHPHQLLEGMEGFNLELSDHPESLEQILVDCRDTLKYGVRTGHPRFFNQLSTGLDIIGLAGEWLTSTANTNMFTYEIAPVFVLMEQITLKKMREIVGWSSKDGDGIFSPGGAISNMYSIMAARYKYFPEVKTKGMAAVPKLVLFTSEQSHYSIKKAGAALGFGTDNVILIKCNERGKIIPADFEAKILEAKQKGYVPFYVNATAGTTVYGAFDPIQEIADICEKYNLWLHVDAAWGGGLLMSRKHRHKLNGIERANSVTWNPHKMMGVLLQCSAILVKEKGILQGCNQMCAGYLFQPDKQYDVSYDTGDKAIQCGRHVDIFKFWLMWKAKGTVGFENQINKCLELAEYLYAKIKNREEFEMVFNGEPEHTNVCFWYIPQSLRGVPDSPQRREKLHKVAPKIKALMMESGTTMVGYQPQGDKANFFRMVISNPAATQSDIDFLIEEIERLGQDL T26900 DRUGINFO D6CS1B AAV-GAD Phase 2 T26900 DRUGINFO D09OTM s-allylglycine Investigative T16808 TARGETID T16808 T16808 FORMERID TTDI03484 T16808 UNIPROID ANM1_HUMAN T16808 TARGNAME Protein arginine methyltransferase 1 (PRMT1) T16808 GENENAME PRMT1 T16808 TARGTYPE Clinical trial T16808 SYNONYMS Protein arginine N-methyltransferase 1; Interferon receptor 1-bound protein 4; IR1B4; Histone-arginine N-methyltransferase PRMT1; HRMT1L2; HMT2 T16808 FUNCTION Constitutes the main enzyme that mediates monomethylation and asymmetric dimethylation of histone H4 'Arg-4' (H4R3me1 and H4R3me2a, respectively), a specific tag for epigenetic transcriptional activation. May be involved in the regulation of TAF15 transcriptional activity, act as an activator of estrogen receptor (ER)-mediated transactivation, play a key role in neurite outgrowth and act as a negative regulator of megakaryocytic differentiation, by modulating p38 MAPK pathway. Methylates RBM15, promoting ubiquitination and degradation of RBM15. Methylates FOXO1 and retains it in the nucleus increasing its transcriptional activity. Methylates CHTOP and this methylation is critical for its 5-hydroxymethylcytosine (5hmC)-binding activity. Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner. Arginine methyltransferase that methylates (mono and asymmetric dimethylation) the guanidino nitrogens of arginyl residues present in proteins such as ESR1, histone H2, H3 and H4, ILF3, HNRNPA1, HNRNPD, NFATC2IP, SUPT5H, TAF15, EWS, HABP4 and SERBP1. T16808 BIOCLASS Methyltransferase T16808 ECNUMBER EC 2.1.1.319 T16808 SEQUENCE MAAAEAANCIMENFVATLANGMSLQPPLEEVSCGQAESSEKPNAEDMTSKDYYFDSYAHFGIHEEMLKDEVRTLTYRNSMFHNRHLFKDKVVLDVGSGTGILCMFAAKAGARKVIGIECSSISDYAVKIVKANKLDHVVTIIKGKVEEVELPVEKVDIIISEWMGYCLFYESMLNTVLYARDKWLAPDGLIFPDRATLYVTAIEDRQYKDYKIHWWENVYGFDMSCIKDVAIKEPLVDVVDPKQLVTNACLIKEVDIYTVKVEDLTFTSPFCLQVKRNDYVHALVAYFNIEFTRCHKRTGFSTSPESPYTHWKQTVFYMEDYLTVKTGEEIFGTIGMRPNAKNNRDLDFTIDLDFKGQLCELSCSTDYRMR T16808 DRUGINFO DHYZ53 GSK3368715 Phase 1 T16808 DRUGINFO D05UWW RM65 Investigative T16808 DRUGINFO D09AFM AMI-1 Investigative T33245 TARGETID T33245 T33245 FORMERID TTDI01723 T33245 UNIPROID GDF15_HUMAN T33245 TARGNAME Growth/differentiation factor 15 (GDF15) T33245 GENENAME GDF15 T33245 TARGTYPE Clinical trial T33245 SYNONYMS Prostate differentiation factor; Placental bone morphogenetic protein; Placental TGF-beta; NSAID-regulated gene 1 protein; NSAID-activated gene 1 protein; NRG-1; NAG-1; Macrophage inhibitory cytokine 1; MIC1; MIC-1; GDF-15 T33245 FUNCTION Regulates food intake, energy expenditure and body weight in response to metabolic and toxin-induced stresses. Binds to its receptor, GFRAL, and activates GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem. It then triggers the activation of neurons localized within the parabrachial nucleus and central amygdala, which contitutes part of the 'emergency circuit' that shapes feeding responses to stressful conditions. On hepatocytes, inhibits growth hormone signaling (By similarity). T33245 PDBSTRUC 5VZ4; 5VZ3; 5VT2 T33245 BIOCLASS Growth factor T33245 SEQUENCE MPGQELRTVNGSQMLLVLLVLSWLPHGGALSLAEASRASFPGPSELHSEDSRFRELRKRYEDLLTRLRANQSWEDSNTDLVPAPAVRILTPEVRLGSGGHLHLRISRAALPEGLPEASRLHRALFRLSPTASRSWDVTRPLRRQLSLARPQAPALHLRLSPPPSQSDQLLAESSSARPQLELHLRPQAARGRRRARARNGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPREVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDLLAKDCHCI T33245 DRUGINFO D97BHT Ponsegromab Phase 2 T33245 DRUGINFO D2OEG6 CIN-109 Phase 1 T33245 DRUGINFO D7FL3H CIN-209 Preclinical T30495 TARGETID T30495 T30495 FORMERID TTDR01323 T30495 UNIPROID SIK2_HUMAN T30495 TARGNAME Salt-inducible kinase 2 (SIK2) T30495 GENENAME SIK2 T30495 TARGTYPE Clinical trial T30495 SYNONYMS Serine/threonine-protein kinase SNF1-like kinase 2; Serine/threonine-protein kinase SIK2; SNF1LK2; SIK-2; Qin-induced kinase; QIK; KIAA0781 T30495 FUNCTION Phosphorylates 'Ser-794' of IRS1 in insulin-stimulated adipocytes, potentially modulating the efficiency of insulin signal transduction. Inhibits CREB activity by phosphorylating and repressing TORCs, the CREB-specific coactivators. T30495 ECNUMBER EC 2.7.11.1 T30495 SEQUENCE MVMADGPRHLQRGPVRVGFYDIEGTLGKGNFAVVKLGRHRITKTEVAIKIIDKSQLDAVNLEKIYREVQIMKMLDHPHIIKLYQVMETKSMLYLVTEYAKNGEIFDYLANHGRLNESEARRKFWQILSAVDYCHGRKIVHRDLKAENLLLDNNMNIKIADFGFGNFFKSGELLATWCGSPPYAAPEVFEGQQYEGPQLDIWSMGVVLYVLVCGALPFDGPTLPILRQRVLEGRFRIPYFMSEDCEHLIRRMLVLDPSKRLTIAQIKEHKWMLIEVPVQRPVLYPQEQENEPSIGEFNEQVLRLMHSLGIDQQKTIESLQNKSYNHFAAIYFLLVERLKSHRSSFPVEQRLDGRQRRPSTIAEQTVAKAQTVGLPVTMHSPNMRLLRSALLPQASNVEAFSFPASGCQAEAAFMEEECVDTPKVNGCLLDPVPPVLVRKGCQSLPSNMMETSIDEGLETEGEAEEDPAHAFEAFQSTRSGQRRHTLSEVTNQLVVMPGAGKIFSMNDSPSLDSVDSEYDMGSVQRDLNFLEDNPSLKDIMLANQPSPRMTSPFISLRPTNPAMQALSSQKREVHNRSPVSFREGRRASDTSLTQGIVAFRQHLQNLARTKGILELNKVQLLYEQIGPEADPNLAPAAPQLQDLASSCPQEEVSQQQESVSTLPASVHPQLSPRQSLETQYLQHRLQKPSLLSKAQNTCQLYCKEPPRSLEQQLQEHRLQQKRLFLQKQSQLQAYFNQMQIAESSYPQPSQQLPLPRQETPPPSQQAPPFSLTQPLSPVLEPSSEQMQYSPFLSQYQEMQLQPLPSTSGPRAAPPLPTQLQQQQPPPPPPPPPPRQPGAAPAPLQFSYQTCELPSAASPAPDYPTPCQYPVDGAQQSDLTGPDCPRSPGLQEAPSSYDPLALSELPGLFDCEMLDAVDPQHNGYVLVN T30495 DRUGINFO D40NQW GRN-300 Phase 1 T30495 DRUGINFO D03YVB HG-9-91-01 Investigative T53669 TARGETID T53669 T53669 FORMERID TTDI02048 T53669 UNIPROID CRLF2_HUMAN T53669 TARGNAME Thymic stromal lymphoprotein receptor (CRLF2) T53669 GENENAME CRLF2 T53669 TARGTYPE Clinical trial T53669 SYNONYMS Thymic stromal lymphopoietin protein receptor; TSLP receptor; ILXR; Cytokine receptorlike factor 2; Cytokine receptorlike 2; CRLF2 T53669 FUNCTION Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2. Implicated in the development of the hematopoietic system. T53669 PDBSTRUC 5J12; 5J11 T53669 BIOCLASS Cytokine receptor T53669 SEQUENCE MGRLVLLWGAAVFLLGGWMALGQGGAAEGVQIQIIYFNLETVQVTWNASKYSRTNLTFHYRFNGDEAYDQCTNYLLQEGHTSGCLLDAEQRDDILYFSIRNGTHPVFTASRWMVYYLKPSSPKHVRFSWHQDAVTVTCSDLSYGDLLYEVQYRSPFDTEWQSKQENTCNVTIEGLDAEKCYSFWVRVKAMEDVYGPDTYPSDWSEVTCWQRGEIRDACAETPTPPKPKLSKFILISSLAILLMVSLLLLSLWKLWRVKKFLIPSVPDPKSIFPGLFEIHQGNFQEWITDTQNVAHLHKMAGAEQESGPEEPLVVQLAKTEAESPRMLDPQTEEKEASGGSLQLPHQPLQGGDVVTIGGFTFVMNDRSYVAL T53669 DRUGINFO D7EJI9 UPB-101 Phase 1 T02974 TARGETID T02974 T02974 FORMERID TTDI02609 T02974 UNIPROID IL1AP_HUMAN T02974 TARGNAME Interleukin 1 receptor accessory protein (IL1RAP) T02974 GENENAME IL1RAP T02974 TARGTYPE Clinical trial T02974 SYNONYMS Interleukin1 receptor 3; Interleukin-1 receptor accessory protein; Interleukin-1 receptor 3; IL1RAcP; IL1R3; IL1 receptor accessory protein; IL-1RAcP; IL-1R3; IL-1R-3; IL-1 receptor accessory protein; C3orf13 T02974 FUNCTION Coreceptor with IL1R1 in the IL-1 signaling system. Associates with IL1R1 bound to IL1B to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Recruits TOLLIP to the signaling complex. Does not bind to interleukin-1 alone; binding of IL1RN to IL1R1, prevents its association with IL1R1 to form a signaling complex. The cellular response is modulated through a non-signaling association with the membrane IL1R2 decoy receptor. Coreceptor for IL1RL1 in the IL-33 signaling system. Can bidirectionally induce pre- and postsynaptic differentiation of neurons by trans-synaptically binding to PTPRD. May play a role in IL1B-mediated costimulation of IFNG production from T-helper 1 (Th1) cells. Coreceptor for IL1RL2 in the IL-36 signaling system. T02974 PDBSTRUC 4DEP; 3O4O T02974 BIOCLASS Cytokine receptor T02974 SEQUENCE MTLLWCVVSLYFYGILQSDASERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMDSRNEVWWTIDGKKPDDITIDVTINESISHSRTEDETRTQILSIKKVTSEDLKRSYVCHARSAKGEVAKAAKVKQKVPAPRYTVELACGFGATVLLVVILIVVYHVYWLEMVLFYRAHFGTDETILDGKEYDIYVSYARNAEEEEFVLLTLRGVLENEFGYKLCIFDRDSLPGGIVTDETLSFIQKSRRLLVVLSPNYVLQGTQALLELKAGLENMASRGNINVILVQYKAVKETKVKELKRAKTVLTVIKWKGEKSKYPQGRFWKQLQVAMPVKKSPRRSSSDEQGLSYSSLKNV T02974 DRUGINFO DB5UO0 CAN04 Phase 1 T12541 TARGETID T12541 T12541 FORMERID TTDI03461 T12541 UNIPROID PI4KB_HUMAN T12541 TARGNAME Phosphatidylinositol-4-kinase beta (PI4KB) T12541 GENENAME PI4KB T12541 TARGTYPE Clinical trial T12541 SYNONYMS PtdIns 4-kinase beta; Phosphatidylinositol 4-kinase beta; PIK4CB; PI4Kbeta; PI4K92; PI4K-beta; NPIK T12541 FUNCTION Phosphorylates phosphatidylinositol (PI) in the first committed step in the production of the second messenger inositol-1,4,5,-trisphosphate (PIP). May regulate Golgi disintegration/reorganization during mitosis, possibly via its phosphorylation. Involved in Golgi-to-plasma membrane trafficking (By similarity). T12541 PDBSTRUC 6GL3; 5NAS; 5LX2; 5FBW; 5FBV T12541 ECNUMBER EC 2.7.1.67 T12541 SEQUENCE MGDTVVEPAPLKPTSEPTSGPPGNNGGSLLSVITEGVGELSVIDPEVAQKACQEVLEKVKLLHGGVAVSSRGTPLELVNGDGVDSEIRCLDDPPAQIREEEDEMGAAVASGTAKGARRRRQNNSAKQSWLLRLFESKLFDISMAISYLYNSKEPGVQAYIGNRLFCFRNEDVDFYLPQLLNMYIHMDEDVGDAIKPYIVHRCRQSINFSLQCALLLGAYSSDMHISTQRHSRGTKLRKLILSDELKPAHRKRELPSLSPAPDTGLSPSKRTHQRSKSDATASISLSSNLKRTASNPKVENEDEELSSSTESIDNSFSSPVRLAPEREFIKSLMAIGKRLATLPTKEQKTQRLISELSLLNHKLPARVWLPTAGFDHHVVRVPHTQAVVLNSKDKAPYLIYVEVLECENFDTTSVPARIPENRIRSTRSVENLPECGITHEQRAGSFSTVPNYDNDDEAWSVDDIGELQVELPEVHTNSCDNISQFSVDSITSQESKEPVFIAAGDIRRRLSEQLAHTPTAFKRDPEDPSAVALKEPWQEKVRRIREGSPYGHLPNWRLLSVIVKCGDDLRQELLAFQVLKQLQSIWEQERVPLWIKPYKILVISADSGMIEPVVNAVSIHQVKKQSQLSLLDYFLQEHGSYTTEAFLSAQRNFVQSCAGYCLVCYLLQVKDRHNGNILLDAEGHIIHIDFGFILSSSPRNLGFETSAFKLTTEFVDVMGGLDGDMFNYYKMLMLQGLIAARKHMDKVVQIVEIMQQGSQLPCFHGSSTIRNLKERFHMSMTEEQLQLLVEQMVDGSMRSITTKLYDGFQYLTNGIM T12541 DRUGINFO D5KX2H GSK3923868 Phase 1 T12541 DRUGINFO D5KX2H GSK3923868 Phase 1 T12541 DRUGINFO D0S5YV PIK-93 Investigative T23359 TARGETID T23359 T23359 FORMERID TTDR01098 T23359 UNIPROID A4_HUMAN T23359 TARGNAME APP messenger RNA (APP mRNA) T23359 GENENAME APP T23359 TARGTYPE Clinical trial T23359 SYNONYMS Vascular beta-amyloid (mRNA); Protease nexin-II (mRNA); PreA4 (mRNA); PN-II (mRNA); Cerebral vascular amyloidpeptide (mRNA); Cerebral vascular amyloid peptide (mRNA); CVAP (mRNA); Beta-amyloid peptide (mRNA); Amyloid-beta precursor protein (mRNA); Amyloid-beta A4 protein (mRNA); Amyloid precursor protein (mRNA); Amyloid beta precursor protein (mRNA); Alzheimer's disease amyloid protein (mRNA); Alzheimer disease amyloid protein (mRNA); APPI (mRNA); AD1 (mRNA); ABPP (mRNA); A4 (mRNA) T23359 FUNCTION Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity. Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. T23359 PDBSTRUC 6IYC; 6GFI; 6CO3; 5W3P; 5VZY T23359 BIOCLASS mRNA target T23359 SEQUENCE MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN T23359 DRUGINFO D8W0NQ ALN-APP Phase 1 T27816 TARGETID T27816 T27816 FORMERID TTDI02663 T27816 UNIPROID SYUA_HUMAN T27816 TARGNAME SNCA messenger RNA (SNCA mRNA) T27816 GENENAME SNCA T27816 TARGTYPE Clinical trial T27816 SYNONYMS PARK1 (mRNA); NonA4 component of amyloid precursor (mRNA); NonA beta component of AD amyloid (mRNA); Non-A4 component of amyloid precursor (mRNA); Non-A beta component of AD amyloid (mRNA); NACP (mRNA) T27816 FUNCTION Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis. Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. This chaperone activity is important to sustain normal SNARE-complex assembly during aging. Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity. Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. T27816 PDBSTRUC 6H6B; 6FLT; 6CU8; 6CU7; 6CT7 T27816 BIOCLASS mRNA target T27816 SEQUENCE MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA T27816 DRUGINFO D23VYO ION464 Phase 1 T95695 TARGETID T95695 T95695 FORMERID TTDI02294 T95695 UNIPROID SMN_HUMAN T95695 TARGNAME SMN1 messenger RNA (SMN1 mRNA) T95695 GENENAME SMN1 T95695 TARGTYPE Clinical trial T95695 SYNONYMS Survival motor neuron protein mRNA; SMNT mRNA; SMNC mRNA; SMN mRNA; Gemin-1 mRNA; Component of gems 1 mRNA T95695 FUNCTION The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. Thereby, plays an important role in the splicing of cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP. Dissociation by the SMN complex of CLNS1A from the trapped Sm proteins and their transfer to an SMN-Sm complex triggers the assembly of core snRNPs and their transport to the nucleus. Ensures the correct splicing of U12 intron-containing genes that may be important for normal motor and proprioceptive neurons development. Also required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs). T95695 PDBSTRUC 5XJU; 5XJT; 5XJS; 5XJR; 5XJQ T95695 BIOCLASS mRNA target T95695 SEQUENCE MAMSSGGSGGGVPEQEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASFKHALKNGDICETSGKPKTTPKRKPAKKNKSQKKNTAASLQQWKVGDKCSAIWSEDGCIYPATIASIDFKRETCVVVYTGYGNREEQNLSDLLSPICEVANNIEQNAQENENESQVSTDESENSRSPGNKSDNIKPKSAPWNSFLPPPPPMPGPRLGPGKPGLKFNGPPPPPPPPPPHLLSCWLPPFPSGPPIIPPPPPICPDSLDDADALGSMLISWYMSGYHTGYYMGFRQNQKEGRCSHSLN T95695 DRUGINFO D05MZI nusinersen Approved T95695 DRUGINFO DUWB31 BIIB115 Phase 1 T54031 TARGETID T54031 T54031 FORMERID TTDI02588 T54031 UNIPROID XLRS1_HUMAN T54031 TARGNAME Retinoschisin (RS1) T54031 GENENAME RS1 T54031 TARGTYPE Clinical trial T54031 SYNONYMS X-linked juvenile retinoschisis protein; RS1 T54031 FUNCTION May be active in cell adhesion processes during retinal development. T54031 PDBSTRUC 5N6W; 3JD6 T54031 SEQUENCE MSRKIEGFLLLLLFGYEATLGLSSTEDEGEDPWYQKACKCDCQGGPNALWSAGATSLDCIPECPYHKPLGFESGEVTPDQITCSNPEQYVGWYSSWTANKARLNSQGFGCAWLSKFQDSSQWLQIDLKEIKVISGILTQGRCDIDEWMTKYSVQYRTDERLNWIYYKDQTGNNRVFYGNSDRTSTVQNLLRPPIISRFIRLIPLGWHVRIAIRMELLECVSKCA T54031 DRUGINFO D1U4BC BIIB-087 Phase 1/2 T80002 TARGETID T80002 T80002 FORMERID TTDI02117 T80002 UNIPROID LY75_HUMAN T80002 TARGNAME Lymphocyte antigen 75 (LY75) T80002 GENENAME LY75 T80002 TARGTYPE Clinical trial T80002 SYNONYMS gp200MR6; Ly75; DEC205; Ctype lectin domain family 13 member B; CD205 T80002 FUNCTION Acts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen- processing compartment. Causes reduced proliferation of B-lymphocytes. T80002 BIOCLASS C-type lectin T80002 SEQUENCE MRTGWATPRRPAGLLMLLFWFFDLAEPSGRAANDPFTIVHGNTGKCIKPVYGWIVADDCDETEDKLWKWVSQHRLFHLHSQKCLGLDITKSVNELRMFSCDSSAMLWWKCEHHSLYGAARYRLALKDGHGTAISNASDVWKKGGSEESLCDQPYHEIYTRDGNSYGRPCEFPFLIDGTWHHDCILDEDHSGPWCATTLNYEYDRKWGICLKPENGCEDNWEKNEQFGSCYQFNTQTALSWKEAYVSCQNQGADLLSINSAAELTYLKEKEGIAKIFWIGLNQLYSARGWEWSDHKPLNFLNWDPDRPSAPTIGGSSCARMDAESGLWQSFSCEAQLPYVCRKPLNNTVELTDVWTYSDTRCDAGWLPNNGFCYLLVNESNSWDKAHAKCKAFSSDLISIHSLADVEVVVTKLHNEDIKEEVWIGLKNINIPTLFQWSDGTEVTLTYWDENEPNVPYNKTPNCVSYLGELGQWKVQSCEEKLKYVCKRKGEKLNDASSDKMCPPDEGWKRHGETCYKIYEDEVPFGTNCNLTITSRFEQEYLNDLMKKYDKSLRKYFWTGLRDVDSCGEYNWATVGGRRRAVTFSNWNFLEPASPGGCVAMSTGKSVGKWEVKDCRSFKALSICKKMSGPLGPEEASPKPDDPCPEGWQSFPASLSCYKVFHAERIVRKRNWEEAERFCQALGAHLSSFSHVDEIKEFLHFLTDQFSGQHWLWIGLNKRSPDLQGSWQWSDRTPVSTIIMPNEFQQDYDIRDCAAVKVFHRPWRRGWHFYDDREFIYLRPFACDTKLEWVCQIPKGRTPKTPDWYNPDRAGIHGPPLIIEGSEYWFVADLHLNYEEAVLYCASNHSFLATITSFVGLKAIKNKIANISGDGQKWWIRISEWPIDDHFTYSRYPWHRFPVTFGEECLYMSAKTWLIDLGKPTDCSTKLPFICEKYNVSSLEKYSPDSAAKVQCSEQWIPFQNKCFLKIKPVSLTFSQASDTCHSYGGTLPSVLSQIEQDFITSLLPDMEATLWIGLRWTAYEKINKWTDNRELTYSNFHPLLVSGRLRIPENFFEEESRYHCALILNLQKSPFTGTWNFTSCSERHFVSLCQKYSEVKSRQTLQNASETVKYLNNLYKIIPKTLTWHSAKRECLKSNMQLVSITDPYQQAFLSVQALLHNSSLWIGLFSQDDELNFGWSDGKRLHFSRWAETNGQLEDCVVLDTDGFWKTVDCNDNQPGAICYYSGNETEKEVKPVDSVKCPSPVLNTPWIPFQNCCYNFIITKNRHMATTQDEVHTKCQKLNPKSHILSIRDEKENNFVLEQLLYFNYMASWVMLGITYRNKSLMWFDKTPLSYTHWRAGRPTIKNEKFLAGLSTDGFWDIQTFKVIEEAVYFHQHSILACKIEMVDYKEEYNTTLPQFMPYEDGIYSVIQKKVTWYEALNMCSQSGGHLASVHNQNGQLFLEDIVKRDGFPLWVGLSSHDGSESSFEWSDGSTFDYIPWKGQTSPGNCVLLDPKGTWKHEKCNSVKDGAICYKPTKSKKLSRLTYSSRCPAAKENGSRWIQYKGHCYKSDQALHSFSEAKKLCSKHDHSATIVSIKDEDENKFVSRLMRENNNITMRVWLGLSQHSVDQSWSWLDGSEVTFVKWENKSKSGVGRCSMLIASNETWKKVECEHGFGRVVCKVPLGPDYTAIAIIVATLSILVLMGGLIWFLFQRHRLHLAGFSSVRYAQGVNEDEIMLPSFHD T80002 DRUGINFO D8DJX0 OBT076 Phase 1 T40490 TARGETID T40490 T40490 FORMERID TTDI01424 T40490 UNIPROID NCTR1_HUMAN T40490 TARGNAME Natural cytotoxic triggering receptor 1 (NCR1) T40490 GENENAME NCR1 T40490 TARGTYPE Clinical trial T40490 SYNONYMS hNKp46; Natural killer cell p46-related protein; Natural cytotoxicity triggering receptor 1; NKp46; NK-p46; NK cell-activating receptor; Lymphocyte antigen 94 homolog; LY94; CD335 T40490 FUNCTION Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis. T40490 PDBSTRUC 1P6F; 1OLL T40490 SEQUENCE MSSTLPALLCVGLCLSQRISAQQQTLPKPFIWAEPHFMVPKEKQVTICCQGNYGAVEYQLHFEGSLFAVDRPKPPERINKVKFYIPDMNSRMAGQYSCIYRVGELWSEPSNLLDLVVTEMYDTPTLSVHPGPEVISGEKVTFYCRLDTATSMFLLLKEGRSSHVQRGYGKVQAEFPLGPVTTAHRGTYRCFGSYNNHAWSFPSEPVKLLVTGDIENTSLAPEDPTFPADTWGTYLLTTETGLQKDHALWDHTAQNLLRMGLAFLVLVALVWFLVEDWLSRKRTRERASRASTWEGRRRLNTQTL T40490 DRUGINFO DMKG40 SAR443579 Phase 1 T98798 TARGETID T98798 T98798 FORMERID TTDI02138 T98798 UNIPROID NPT2B_HUMAN T98798 TARGNAME Sodium/phosphate cotransporter 2B (SLC34A2) T98798 GENENAME SLC34A2 T98798 TARGTYPE Clinical trial T98798 SYNONYMS Solute carrier family 34 member 2; Sodium-phosphate transport protein 2B; Sodium-dependent phosphate transport protein 2B; NaPi3b; NaPi-2b; Na(+)/Pi cotransporter 2B; Na(+)-dependent phosphate cotransporter 2B T98798 FUNCTION It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli. May be involved in actively transporting phosphate into cells via Na(+) cotransport. T98798 BIOCLASS Phosphate:sodium symporter T98798 SEQUENCE MAPWPELGDAQPNPDKYLEGAAGQQPTAPDKSKETNKTDNTEAPVTKIELLPSYSTATLIDEPTEVDDPWNLPTLQDSGIKWSERDTKGKILCFFQGIGRLILLLGFLYFFVCSLDILSSAFQLVGGKMAGQFFSNSSIMSNPLLGLVIGVLVTVLVQSSSTSTSIVVSMVSSSLLTVRAAIPIIMGANIGTSITNTIVALMQVGDRSEFRRAFAGATVHDFFNWLSVLVLLPVEVATHYLEIITQLIVESFHFKNGEDAPDLLKVITKPFTKLIVQLDKKVISQIAMNDEKAKNKSLVKIWCKTFTNKTQINVTVPSTANCTSPSLCWTDGIQNWTMKNVTYKENIAKCQHIFVNFHLPDLAVGTILLILSLLVLCGCLIMIVKILGSVLKGQVATVIKKTINTDFPFPFAWLTGYLAILVGAGMTFIVQSSSVFTSALTPLIGIGVITIERAYPLTLGSNIGTTTTAILAALASPGNALRSSLQIALCHFFFNISGILLWYPIPFTRLPIRMAKGLGNISAKYRWFAVFYLIIFFFLIPLTVFGLSLAGWRVLVGVGVPVVFIIILVLCLRLLQSRCPRVLPKKLQNWNFLPLWMRSLKPWDAVVSKFTGCFQMRCCCCCRVCCRACCLLCDCPKCCRCSKCCEDLEEAQEGQDVPVKAPETFDNITISREAQGEVPASDSKTECTAL T98798 DRUGINFO D0QFD2 Upifitamab rilsodotin Phase 3 T98798 DRUGINFO DDL79K XMT-1592 Phase 1/2 T56269 TARGETID T56269 T56269 FORMERID TTDR01025 T56269 UNIPROID IAPP_HUMAN T56269 TARGNAME Islet amyloid polypeptide (IAPP) T56269 GENENAME IAPP T56269 TARGTYPE Clinical trial T56269 SYNONYMS Insulinoma amyloid peptide; IAPP; Diabetes-associated peptide; Amylin T56269 FUNCTION Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism. T56269 PDBSTRUC 5MGQ; 5KO0; 5KNZ; 5K5G; 3HGZ T56269 SEQUENCE MGILKLQVFLIVLSVALNHLKATPIESHQVEKRKCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYGKRNAVEVLKREPLNYLPL T56269 DRUGINFO D93YJK LY 3541105 Phase 1 T78552 TARGETID T78552 T78552 FORMERID TTDI02529 T78552 UNIPROID CD59_HUMAN T78552 TARGNAME Membrane inhibitor of reactive lysis (CD59) T78552 GENENAME CD59 T78552 TARGTYPE Clinical trial T78552 SYNONYMS Protectin; Membrane attack complex inhibition factor; MSK21; MIRL; MIN3; MIN2; MIN1; MIC11; MEM43 antigen; MACinhibitory protein; MACIP; MACIF; MAC-inhibitory protein; MAC-IP; HRF20; HRF-20; CD59 glycoprotein; 20 kDa homologous restriction factor; 1F5 antigen T78552 FUNCTION Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase. Potent inhibitor of the complement membrane attack complex (MAC) action. T78552 PDBSTRUC 5IMY; 5IMT; 4BIK; 2UX2; 2UWR T78552 SEQUENCE MGIQGGSVLFGLLLVLAVFCHSGHSLQCYNCPNPTADCKTAVNCSSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLRENELTYYCCKKDLCNFNEQLENGGTSLSEKTVLLLVTPFLAAAWSLHP T78552 DRUGINFO DEI4U0 HMR59 Phase 2 T29774 TARGETID T29774 T29774 FORMERID TTDR00422 T29774 UNIPROID LIF_HUMAN T29774 TARGNAME Leukemia inhibitory factor (LIF) T29774 GENENAME LIF T29774 TARGTYPE Clinical trial T29774 SYNONYMS Melanoma-derived LPL inhibitor; MLPLI; HILDA; Emfilermin; Differentiation-stimulating factor; D factor T29774 FUNCTION Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes. LIF has the capacity to induce terminal differentiation in leukemic cells. T29774 PDBSTRUC 2Q7N; 1PVH; 1EMR T29774 SEQUENCE MKVLAAGVVPLLLVLHWKHGAGSPLPITPVNATCAIRHPCHNNLMNQIRSQLAQLNGSANALFILYYTAQGEPFPNNLDKLCGPNVTDFPPFHANGTEKAKLVELYRIVVYLGTSLGNITRDQKILNPSALSLHSKLNATADILRGLLSNVLCRLCSKYHVGHVDVTYGPDTSGKDVFQKKKLGCQLLGKYKQIIAVLAQAF T29774 DRUGINFO DX5T9B MSC-1 Phase 1 T21395 TARGETID T21395 T21395 FORMERID TTDI02362 T21395 UNIPROID MCP_HUMAN T21395 TARGNAME Membrane cofactor protein (CD46) T21395 GENENAME CD46 T21395 TARGTYPE Clinical trial T21395 SYNONYMS Trophoblast leukocyte common antigen; TLX; MIC10; MCP T21395 FUNCTION May be involved in the fusion of the spermatozoa with the oocyte during fertilization. Also acts as a costimulatory factor for T-cells which induces the differentiation of CD4+ into T-regulatory 1 cells. T-regulatory 1 cells suppress immune responses by secreting interleukin-10, and therefore are thought to prevent autoimmunity. Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissue. T21395 PDBSTRUC 5FO8; 3O8E; 3L89; 3INB; 2O39 T21395 SEQUENCE MEPPGRRECPFPSWRFPGLLLAAMVLLLYSFSDACEEPPTFEAMELIGKPKPYYEIGERVDYKCKKGYFYIPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQAVPANGTYEFGYQMHFICNEGYYLIGEEILYCELKGSVAIWSGKPPICEKVLCTPPPKIKNGKHTFSEVEVFEYLDAVTYSCDPAPGPDPFSLIGESTIYCGDNSVWSRAAPECKVVKCRFPVVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPPVPKCLKVLPPSSTKPPALSHSVSTSSTTKSPASSASGPRPTYKPPVSNYPGYPKPEEGILDSLDVWVIAVIVIAIVVGVAVICVVPYRYLQRRKKKGTYLTDETHREVKFTSL T21395 DRUGINFO D48ZBO FOR46 Phase 1 T33455 TARGETID T33455 T33455 FORMERID TTDR00449 T33455 UNIPROID IBP3_HUMAN T33455 TARGNAME Insulin-like growth factor-binding protein 3 (IGFBP3) T33455 GENENAME IGFBP3 T33455 TARGTYPE Clinical trial T33455 SYNONYMS IGFBP-3; IGF-binding protein 3; IBP3; IBP-3 T33455 FUNCTION IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R. T33455 BIOCLASS Insulin-like growth factor binding T33455 SEQUENCE MQRARPTLWAAALTLLVLLRGPPVARAGASSAGLGPVVRCEPCDARALAQCAPPPAVCAELVREPGCGCCLTCALSEGQPCGIYTERCGSGLRCQPSPDEARPLQALLDGRGLCVNASAVSRLRAYLLPAPPAPGNASESEEDRSAGSVESPSVSSTHRVSDPKFHPLHSKIIIIKKGHAKDSQRYKVDYESQSTDTQNFSSESKRETEYGPCRREMEDTLNHLKFLNVLSPRGVHIPNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYTTKGKEDVHCYSMQSK T33455 DRUGINFO D2GV9Q Salvianolic acid B Phase 2 T08029 TARGETID T08029 T08029 FORMERID TTDI02375 T08029 UNIPROID PROP_HUMAN T08029 TARGNAME Complement factor P (CFP) T08029 GENENAME CFP T08029 TARGTYPE Clinical trial T08029 SYNONYMS Properdin; CFP T08029 FUNCTION A positive regulator of the alternate pathway of complement. It binds to and stabilizes the C3- and C5-convertase enzyme complexes. T08029 PDBSTRUC 1W0S; 1W0R T08029 SEQUENCE MITEGAQAPRLLLPPLLLLLTLPATGSDPVLCFTQYEESSGKCKGLLGGGVSVEDCCLNTAFAYQKRSGGLCQPCRSPRWSLWSTWAPCSVTCSEGSQLRYRRCVGWNGQCSGKVAPGTLEWQLQACEDQQCCPEMGGWSGWGPWEPCSVTCSKGTRTRRRACNHPAPKCGGHCPGQAQESEACDTQQVCPTHGAWATWGPWTPCSASCHGGPHEPKETRSRKCSAPEPSQKPPGKPCPGLAYEQRRCTGLPPCPVAGGWGPWGPVSPCPVTCGLGQTMEQRTCNHPVPQHGGPFCAGDATRTHICNTAVPCPVDGEWDSWGEWSPCIRRNMKSISCQEIPGQQSRGRTCRGRKFDGHRCAGQQQDIRHCYSIQHCPLKGSWSEWSTWGLCMPPCGPNPTRARQRLCTPLLPKYPPTVSMVEGQGEKNVTFWGRPLPRCEELQGQKLVVEEKRPCLHVPACKDPEEEEL T08029 DRUGINFO D4LJO9 CLG561 Phase 2 T08029 DRUGINFO DVYW59 ALXN1820 Phase 2 T45182 TARGETID T45182 T45182 FORMERID TTDI01434 T45182 UNIPROID GRN_HUMAN T45182 TARGNAME Progranulin (PGRN) T45182 GENENAME GRN T45182 TARGTYPE Clinical trial T45182 SYNONYMS Proepithelin; PGRN; PEPI; PCDGF; PC cell-derived growth factor; Granulin precursor; Glycoprotein of 88 Kda; Glycoprotein 88; GP88; Epithelin precursor; Acrogranin T45182 FUNCTION Secreted proteins that act as key regulator of lysosomal function and as a growth factor involved in inflammation, wound healing and cell proliferation. Functions as regulator of proteins trafficking to lysosome and activity of lysosomal enzymes. Facilitates also the acidification of lysosomes, causing degradation of mature CTSD by CTSB. In addition, functions as wound-related growth factor that acts directly on dermal fibroblasts and endothelial cells to promote division, migration and the formation of capillary-like tubule structure (By similarity). Also promotes epithelial cell proliferation by blocking TNF-mediated neutrophil activation preventing release of oxidants and proteases. Moreover, modulates inflammation in neuron by preserving neuron survival, axonal outgrowth and neuronal integrity. T45182 PDBSTRUC 2JYV; 2JYU; 2JYT; 2JYE; 1G26 T45182 SEQUENCE MWTLVSWVALTAGLVAGTRCPDGQFCPVACCLDPGGASYSCCRPLLDKWPTTLSRHLGGPCQVDAHCSAGHSCIFTVSGTSSCCPFPEAVACGDGHHCCPRGFHCSADGRSCFQRSGNNSVGAIQCPDSQFECPDFSTCCVMVDGSWGCCPMPQASCCEDRVHCCPHGAFCDLVHTRCITPTGTHPLAKKLPAQRTNRAVALSSSVMCPDARSRCPDGSTCCELPSGKYGCCPMPNATCCSDHLHCCPQDTVCDLIQSKCLSKENATTDLLTKLPAHTVGDVKCDMEVSCPDGYTCCRLQSGAWGCCPFTQAVCCEDHIHCCPAGFTCDTQKGTCEQGPHQVPWMEKAPAHLSLPDPQALKRDVPCDNVSSCPSSDTCCQLTSGEWGCCPIPEAVCCSDHQHCCPQGYTCVAEGQCQRGSEIVAGLEKMPARRASLSHPRDIGCDQHTSCPVGQTCCPSLGGSWACCQLPHAVCCEDRQHCCPAGYTCNVKARSCEKEVVSAQPATFLARSPHVGVKDVECGEGHFCHDNQTCCRDNRQGWACCPYRQGVCCADRRHCCPAGFRCAARGTKCLRREAPRWDAPLRDPALRQLL T45182 DRUGINFO D2AG4O DNL593 Phase 1/2 T45182 DRUGINFO D5C4YE PR-006 Phase 1/2 T45182 DRUGINFO D8FX9H PBFT02 Phase 1/2 T84981 TARGETID T84981 T84981 FORMERID TTDI02506 T84981 UNIPROID CCR7_HUMAN T84981 TARGNAME C-C chemokine receptor type 7 (CCR7) T84981 GENENAME CCR7 T84981 TARGTYPE Clinical trial T84981 SYNONYMS MIP3 beta receptor; MIP-3 beta receptor; EpsteinBarr virusinduced Gprotein coupled receptor 1; Epstein-Barr virus-induced G-protein coupled receptor 1; EVI1; EBVinduced Gprotein coupled receptor 1; EBV-induced G-protein coupled receptor 1; EBI1; CMKBR7; CDw197; CD197; CCR-7; CCCKR7; CC-CKR-7; CC chemokine receptor type 7; CC CKR7; C-C CKR-7; BLR2 T84981 FUNCTION Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions. Receptor for the MIP-3-beta chemokine. T84981 BIOCLASS GPCR rhodopsin T84981 SEQUENCE MDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP T84981 DRUGINFO DQVR30 JBH492 Phase 1 T84981 DRUGINFO DSYN57 CAP-100 Clinical trial T81281 TARGETID T81281 T81281 FORMERID TTDI02403 T81281 UNIPROID DSG3_HUMAN T81281 TARGNAME Desmoglein-3 (DSG3) T81281 GENENAME DSG3 T81281 TARGTYPE Clinical trial T81281 SYNONYMS PVA; DSG3; Cadherin family member 6; 130 kDa pemphigus vulgaris antigen T81281 FUNCTION Component of intercellular desmosome junctions. Involved in the interaction of plaque proteins and intermediate filaments mediating cell-cell adhesion. T81281 PDBSTRUC 5EQX T81281 SEQUENCE MMGLFPRTTGALAIFVVVILVHGELRIETKGQYDEEEMTMQQAKRRQKREWVKFAKPCREGEDNSKRNPIAKITSDYQATQKITYRISGVGIDQPPFGIFVVDKNTGDINITAIVDREETPSFLITCRALNAQGLDVEKPLILTVKILDINDNPPVFSQQIFMGEIEENSASNSLVMILNATDADEPNHLNSKIAFKIVSQEPAGTPMFLLSRNTGEVRTLTNSLDREQASSYRLVVSGADKDGEGLSTQCECNIKVKDVNDNFPMFRDSQYSARIEENILSSELLRFQVTDLDEEYTDNWLAVYFFTSGNEGNWFEIQTDPRTNEGILKVVKALDYEQLQSVKLSIAVKNKAEFHQSVISRYRVQSTPVTIQVINVREGIAFRPASKTFTVQKGISSKKLVDYILGTYQAIDEDTNKAASNVKYVMGRNDGGYLMIDSKTAEIKFVKNMNRDSTFIVNKTITAEVLAIDEYTGKTSTGTVYVRVPDFNDNCPTAVLEKDAVCSSSPSVVVSARTLNNRYTGPYTFALEDQPVKLPAVWSITTLNATSALLRAQEQIPPGVYHISLVLTDSQNNRCEMPRSLTLEVCQCDNRGICGTSYPTTSPGTRYGRPHSGRLGPAAIGLLLLGLLLLLLAPLLLLTCDCGAGSTGGVTGGFIPVPDGSEGTIHQWGIEGAHPEDKEITNICVPPVTANGADFMESSEVCTNTYARGTAVEGTSGMEMTTKLGAATESGGAAGFATGTVSGAASGFGAATGVGICSSGQSGTMRTRHSTGGTNKDYADGAISMNFLDSYFSQKAFACAEEDDGQEANDCLLIYDNEGADATGSPVGSVGCCSFIADDLDDSFLDSLGPKFKKLAEISLGVDGEGKEVQPPSKDSGYGIESCGHPIEVQQTGFVKCQTLSGSQGASALSTSGSVQPAVSIPDPLQHGNYLVTETYSASGSLVQPSTAGFDPLLTQNVIVTERVICPISSVPGNLAGPTQLRGSHTMLCTEDPCSRLI T81281 DRUGINFO DE1XF0 DSG3-CAART Phase 1 T15510 TARGETID T15510 T15510 FORMERID TTDI02453 T15510 UNIPROID IRS1_HUMAN T15510 TARGNAME Insulin receptor substrate-1 (IRS1) T15510 GENENAME IRS1 T15510 TARGTYPE Clinical trial T15510 SYNONYMS Insulin receptor substrate 1; IRS-1 T15510 FUNCTION When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit. May mediate the control of various cellular processes by insulin. T15510 PDBSTRUC 6BNT; 5U1M; 2Z8C; 1QQG; 1K3A T15510 SEQUENCE MASPPESDGFSDVRKVGYLRKPKSMHKRFFVLRAASEAGGPARLEYYENEKKWRHKSSAPKRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIAADSEAEQDSWYQALLQLHNRAKGHHDGAAALGAGGGGGSCSGSSGLGEAGEDLSYGDVPPGPAFKEVWQVILKPKGLGQTKNLIGIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHSENFFFIEVGRSAVTGPGEFWMQVDDSVVAQNMHETILEAMRAMSDEFRPRSKSQSSSNCSNPISVPLRRHHLNNPPPSQVGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGTMSRPASVDGSPVSPSTNRTHAHRHRGSARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHGSTSDCLFPRRSSASVSGSPSDGGFISSDEYGSSPCDFRSSFRSVTPDSLGHTPPARGEEELSNYICMGGKGPSTLTAPNGHYILSRGGNGHRCTPGTGLGTSPALAGDEAASAADLDNRFRKRTHSAGTSPTITHQKTPSQSSVASIEEYTEMMPAYPPGGGSGGRLPGHRHSAFVPTRSYPEEGLEMHPLERRGGHHRPDSSTLHTDDGYMPMSPGVAPVPSGRKGSGDYMPMSPKSVSAPQQIINPIRRHPQRVDPNGYMMMSPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGHHSHVLPHPKPPVESSGGKLLPCTGDYMNMSPVGDSNTSSPSDCYYGPEDPQHKPVLSYYSLPRSFKHTQRPGEPEEGARHQHLRLSTSSGRLLYAATADDSSSSTSSDSLGGGYCGARLEPSLPHPHHQVLQPHLPRKVDTAAQTNSRLARPTRLSLGDPKASTLPRAREQQQQQQPLLHPPEPKSPGEYVNIEFGSDQSGYLSGPVAFHSSPSVRCPSQLQPAPREEETGTEEYMKMDLGPGRRAAWQESTGVEMGRLGPAPPGAASICRPTRAVPSSRGDYMTMQMSCPRQSYVDTSPAAPVSYADMRTGIAAEEVSLPRATMAAASSSSAASASPTGPQGAAELAAHSSLLGGPQGPGGMSAFTRVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGNTVPFGAGAAVGGGGGSSSSSEDVKRHSSASFENVWLRPGELGGAPKEPAKLCGAAGGLENGLNYIDLDLVKDFKQCPQECTPEPQPPPPPPPHQPLGSGESSSTRRSSEDLSAYASISFQKQPEDRQ T15510 DRUGINFO DUI59O NT219 Phase 1/2 T82075 TARGETID T82075 T82075 FORMERID TTDR00969 T82075 UNIPROID FTSZ_WOLSP T82075 TARGNAME Bacterial Celldivision protein FtsZ (Bact ftsZ) T82075 GENENAME Bact ftsZ T82075 TARGTYPE Clinical trial T82075 SYNONYMS FtsZprotein; FtsZ T82075 FUNCTION Essential cell division protein that forms a contractile ring structure (Z ring) at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. One of the functions of the FtsZ ring is to recruit other cell division proteins to the septum to produce a new cell wall between the dividing cells. Binds GTP and shows GTPase activity. T82075 BIOCLASS Peptidase T82075 SEQUENCE MSIDLSLPELPILHPRITVVGVGGAGGNAVNNMIQSNLQGVNFVVANTDAQALEKSLCDKKIQLGINLTKGLGAGALPDVGKGAAEESIDEIMEHIKDSHMLFITAGMGGGTGTGAAPVIAKAAREARAAVKDRAPKEKKILTVGVVTKPFGFEGVRRMPIAELGLEELQKYVDTLIVIPNQNLFRIANEKTTFSDAFKLADNVLHIGIRGVTDLMVMPGLINLDFADIETVMSEMGKAMIGTGEAEGEDRAISAAEAAISNPLLDNVSMKGAQGILINITGGGDMTLFEVDAAANRVREEVDENANIIFGATFDQAMEGRVRVSVLATGIDGRNNKSETSPISQSEDSEKEKFKWPYSQSESTQDKTLETKPAEQVSEGAKWGSNIYDIPAYLRRKK T82075 DRUGINFO DVY5D9 TXA709 Phase 1 T82075 DRUGINFO D0H2TZ Phosphomethylphosphonic Acid Guanylate Ester Investigative T82075 DRUGINFO D0Q5XD 5'-Guanosine-Diphosphate-Monothiophosphate Investigative T82075 DRUGINFO D0C7LS Guanosine-5'-Diphosphate Investigative T59686 TARGETID T59686 T59686 FORMERID TTDI00041 T59686 UNIPROID MECP2_HUMAN T59686 TARGNAME Methyl cpg binding protein 2 (MECP2) T59686 GENENAME MECP2 T59686 TARGTYPE Clinical trial T59686 SYNONYMS MethylCpGbinding protein 2; Methyl-CpG-binding protein 2; MeCp2 protein; MeCp2; MeCp-2 protein T59686 FUNCTION It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. Mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A. Binds both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)-containing DNA, with a preference for 5-methylcytosine (5mC). Chromosomal protein that binds to methylated DNA. T59686 PDBSTRUC 6OGK; 6OGJ; 6C1Y; 5BT2; 3C2I T59686 SEQUENCE MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS T59686 DRUGINFO DE94CW AVXS-201 Phase 1 T42974 TARGETID T42974 T42974 FORMERID TTDR01221 T42974 UNIPROID GAS6_HUMAN T42974 TARGNAME AXL receptor tyrosine kinase ligand (GAS6) T42974 GENENAME GAS6 T42974 TARGTYPE Clinical trial T42974 SYNONYMS Growth arrest-specific protein 6; GAS-6; AXLLG T42974 FUNCTION Ligand for tyrosine-protein kinase receptors AXL, TYRO3 and MER whose signaling is implicated in cell growth and survival, cell adhesion and cell migration. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. T42974 PDBSTRUC 5VXZ; 4RA0; 2C5D; 1H30 T42974 SEQUENCE MAPSLSPGPAALRRAPQLLLLLLAAECALAALLPAREATQFLRPRQRRAFQVFEEAKQGHLERECVEELCSREEAREVFENDPETDYFYPRYLDCINKYGSPYTKNSGFATCVQNLPDQCTPNPCDRKGTQACQDLMGNFFCLCKAGWGGRLCDKDVNECSQENGGCLQICHNKPGSFHCSCHSGFELSSDGRTCQDIDECADSEACGEARCKNLPGSYSCLCDEGFAYSSQEKACRDVDECLQGRCEQVCVNSPGSYTCHCDGRGGLKLSQDMDTCEDILPCVPFSVAKSVKSLYLGRMFSGTPVIRLRFKRLQPTRLVAEFDFRTFDPEGILLFAGGHQDSTWIVLALRAGRLELQLRYNGVGRVTSSGPVINHGMWQTISVEELARNLVIKVNRDAVMKIAVAGDLFQPERGLYHLNLTVGGIPFHEKDLVQPINPRLDGCMRSWNWLNGEDTTIQETVKVNTRMQCFSVTERGSFYPGSGFAFYSLDYMRTPLDVGTESTWEVEVVAHIRPAADTGVLFALWAPDLRAVPLSVALVDYHSTKKLKKQLVVLAVEHTALALMEIKVCDGQEHVVTVSLRDGEATLEVDGTRGQSEVSAAQLQERLAVLERHLRSPVLTFAGGLPDVPVTSAPVTAFYRGCMTLEVNRRLLDLDEAAYKHSDITAHSCPPVEPAAA T42974 DRUGINFO DDRX30 Batiraxcept Phase 3 T42974 DRUGINFO D8PE7D AVB-500 Phase 2 T78510 TARGETID T78510 T78510 FORMERID TTDI03122 T78510 UNIPROID CNGA3_HUMAN T78510 TARGNAME Cyclic nucleotide-gated channel alpha-3 (CNGA3) T78510 GENENAME CNGA3 T78510 TARGTYPE Clinical trial T78510 SYNONYMS Cyclic nucleotide-gated cation channel alpha-3; Cone photoreceptor cGMP-gated channel subunit alpha; CNG3; CNG-3; CNG channel alpha-3; CNCG3 T78510 FUNCTION Visual signal transduction is mediated by a G-protein coupled cascade using cGMP as second messenger. This protein can be activated by cyclic GMP which leads to an opening of the cation channel and thereby causing a depolarization of cone photoreceptors. Induced a flickering channel gating, weakened the outward rectification in the presence of extracellular calcium, increased sensitivity for L-cis diltiazem and enhanced the cAMP efficacy of the channel when coexpressed with CNGB3 (By similarity). Essential for the generation of light-evoked electrical responses in the red-, green- and blue sensitive cones. T78510 PDBSTRUC 3SWY T78510 SEQUENCE MAKINTQYSHPSRTHLKVKTSDRDLNRAENGLSRAHSSSEETSSVLQPGIAMETRGLADSGQGSFTGQGIARLSRLIFLLRRWAARHVHHQDQGPDSFPDRFRGAELKEVSSQESNAQANVGSQEPADRGRSAWPLAKCNTNTSNNTEEEKKTKKKDAIVVDPSSNLYYRWLTAIALPVFYNWYLLICRACFDELQSEYLMLWLVLDYSADVLYVLDVLVRARTGFLEQGLMVSDTNRLWQHYKTTTQFKLDVLSLVPTDLAYLKVGTNYPEVRFNRLLKFSRLFEFFDRTETRTNYPNMFRIGNLVLYILIIIHWNACIYFAISKFIGFGTDSWVYPNISIPEHGRLSRKYIYSLYWSTLTLTTIGETPPPVKDEEYLFVVVDFLVGVLIFATIVGNVGSMISNMNASRAEFQAKIDSIKQYMQFRKVTKDLETRVIRWFDYLWANKKTVDEKEVLKSLPDKLKAEIAINVHLDTLKKVRIFQDCEAGLLVELVLKLRPTVFSPGDYICKKGDIGKEMYIINEGKLAVVADDGVTQFVVLSDGSYFGEISILNIKGSKSGNRRTANIRSIGYSDLFCLSKDDLMEALTEYPEAKKALEEKGRQILMKDNLIDEELARAGADPKDLEEKVEQLGSSLDTLQTRFARLLAEYNATQMKMKQRLSQLESQVKGGGDKPLADGEVPGDATKTEDKQQ T78510 DRUGINFO D3M6SN ACHM-CNGA3 Phase 1/2 T78510 DRUGINFO DM90BJ AAV-CNGA3 Phase 1/2 T78510 DRUGINFO D00YNI L-(cis)-diltiazem Investigative T85507 TARGETID T85507 T85507 FORMERID TTDI00182 T85507 UNIPROID SIG15_HUMAN T85507 TARGNAME Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15) T85507 GENENAME SIGLEC15 T85507 TARGTYPE Clinical trial T85507 SYNONYMS Siglec-15; SIGLEC15; CD33 antigen-like 3 T85507 FUNCTION Binds sialylated glycoproteins. T85507 BIOCLASS Immunoglobulin T85507 SEQUENCE MEKSIWLLACLAWVLPTGSFVRTKIDTTENLLNTEVHSSPAQRWSMQVPPEVSAEAGDAAVLPCTFTHPHRHYDGPLTAIWRAGEPYAGPQVFRCAAARGSELCQTALSLHGRFRLLGNPRRNDLSLRVERLALADDRRYFCRVEFAGDVHDRYESRHGVRLHVTAAPRIVNISVLPSPAHAFRALCTAEGEPPPALAWSGPALGNSLAAVRSPREGHGHLVTAELPALTHDGRYTCTAANSLGRSEASVYLFRFHGASGASTVALLLGALGFKALLLLGVLAARAARRRPEHLDTPDTPPRSQAQESNYENLSQMNPRSPPATMCSP T85507 DRUGINFO D9UZ5Q NC318 Phase 2 T41171 TARGETID T41171 T41171 FORMERID TTDI02628 T41171 UNIPROID IL17D_HUMAN T41171 TARGNAME Interleukin-27 (IL27) T41171 GENENAME IL17D T41171 TARGTYPE Clinical trial T41171 SYNONYMS UNQ3096/PRO21175; Interleukin27; Interleukin17D; Interleukin-17D; IL-27; IL-17D T41171 FUNCTION Induces expression of IL6, CXCL8/IL8, and CSF2/GM-CSF from endothelial cells. T41171 BIOCLASS Cytokine: interleukin T41171 SEQUENCE MLVAGFLLALPPSWAAGAPRAGRRPARPRGCADRPEELLEQLYGRLAAGVLSAFHHTLQLGPREQARNASCPAGGRPADRRFRPPTNLRSVSPWAYRISYDPARYPRYLPEAYCLCRGCLTGLFGEEDVRFRSAPVYMPTVVLRRTPACAGGRSVYTEAYVTIPVGCTCVPEPEKDADSINSSIDKQGAKLLLGPNDAPAGP T41171 DRUGINFO DLY89F SRF388 Phase 1 T00496 TARGETID T00496 T00496 FORMERID TTDR01316 T00496 UNIPROID PAWR_HUMAN T00496 TARGNAME Prostate apoptosis response-4 (PAWR) T00496 GENENAME PAWR T00496 TARGTYPE Clinical trial T00496 SYNONYMS Prostate apoptosis response 4 protein; PRKC apoptosis WT1 regulator protein; PAR4 T00496 FUNCTION Pro-apoptopic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by itself. May be directly involved in regulating the amyloid precursor protein (APP) cleavage activity of BACE1. T00496 PDBSTRUC 2JK9 T00496 SEQUENCE MATGGYRTSSGLGGSTTDFLEEWKAKREKMRAKQNPPGPAPPGGGSSDAAGKPPAGALGTPAAAAANELNNNLPGGAPAAPAVPGPGGVNCAVGSAMLTRAAPGPRRSEDEPPAASASAAPPPQRDEEEPDGVPEKGKSSGPSARKGKGQIEKRKLREKRRSTGVVNIPAAECLDEYEDDEAGQKERKREDAITQQNTIQNEAVNLLDPGSSYLLQEPPRTVSGRYKSTTSVSEEDVSSRYSRTDRSGFPRYNRDANVSGTLVSSSTLEKKIEDLEKEVVRERQENLRLVRLMQDKEEMIGKLKEEIDLLNRDLDDIEDENEQLKQENKTLLKVVGQLTR T00496 DRUGINFO D3AIE0 BMS-986141 Phase 2 T00496 DRUGINFO DUM25X BMS-986120 Phase 1 T32227 TARGETID T32227 T32227 FORMERID TTDI02530 T32227 UNIPROID CNGB3_HUMAN T32227 TARGNAME Cyclic nucleotide-gated channel beta-3 (CNGB3) T32227 GENENAME CNGB3 T32227 TARGTYPE Clinical trial T32227 SYNONYMS Cyclic nucleotidegated channel beta3; Cyclic nucleotidegated cation channel modulatory subunit; Cyclic nucleotidegated cation channel beta3; Cyclic nucleotide-gated cation channel modulatory subunit; Cyclic nucleotide-gated cation channel beta-3; Cone photoreceptor cGMPgated channel subunit beta; Cone photoreceptor cGMP-gated channel subunit beta; CNG channel beta3; CNG channel beta-3 T32227 FUNCTION Visual signal transduction is mediated by a G-protein coupled cascade using cGMP as second messenger. This protein can be activated by cGMP which leads to an opening of the cation channel and thereby causing a depolarization of rod photoreceptors. Induced a flickering channel gating, weakened the outward rectification in the presence of extracellular calcium, increased sensitivity for L-cis diltiazem and enhanced the cAMP efficiency of the channel when coexpressed with CNGA3 (By similarity). Essential for the generation of light-evoked electrical responses in the red-, green- and blue sensitive cones. T32227 SEQUENCE MFKSLTKVNKVKPIGENNENEQSSRRNEEGSHPSNQSQQTTAQEENKGEEKSLKTKSTPVTSEEPHTNIQDKLSKKNSSGDLTTNPDPQNAAEPTGTVPEQKEMDPGKEGPNSPQNKPPAAPVINEYADAQLHNLVKRMRQRTALYKKKLVEGDLSSPEASPQTAKPTAVPPVKESDDKPTEHYYRLLWFKVKKMPLTEYLKRIKLPNSIDSYTDRLYLLWLLLVTLAYNWNCCFIPLRLVFPYQTADNIHYWLIADIICDIIYLYDMLFIQPRLQFVRGGDIIVDSNELRKHYRTSTKFQLDVASIIPFDICYLFFGFNPMFRANRMLKYTSFFEFNHHLESIMDKAYIYRVIRTTGYLLFILHINACVYYWASNYEGIGTTRWVYDGEGNEYLRCYYWAVRTLITIGGLPEPQTLFEIVFQLLNFFSGVFVFSSLIGQMRDVIGAATANQNYFRACMDDTIAYMNNYSIPKLVQKRVRTWYEYTWDSQRMLDESDLLKTLPTTVQLALAIDVNFSIISKVDLFKGCDTQMIYDMLLRLKSVLYLPGDFVCKKGEIGKEMYIIKHGEVQVLGGPDGTKVLVTLKAGSVFGEISLLAAGGGNRRTANVVAHGFANLLTLDKKTLQEILVHYPDSERILMKKARVLLKQKAKTAEATPPRKDLALLFPPKEETPKLFKTLLGGTGKASLARLLKLKREQAAQKKENSEGGEEEGKENEDKQKENEDKQKENEDKGKENEDKDKGREPEEKPLDRPECTASPIAVEEEPHSVRRTVLPRGTSRQSLIISMAPSAEGGEEVLTIEVKEKAKQ T32227 DRUGINFO D56WJV AAV-CNGB3 Phase 1/2 T32227 DRUGINFO DYRC18 ACHM-CNGB3 Phase 1/2 T32227 DRUGINFO D00YNI L-(cis)-diltiazem Investigative T45086 TARGETID T45086 T45086 FORMERID TTDI01447 T45086 UNIPROID TREM2_HUMAN T45086 TARGNAME Triggering receptor expressed on monocytes 2 (TREM2) T45086 GENENAME TREM2 T45086 TARGTYPE Clinical trial T45086 SYNONYMS Triggering receptor expressed on myeloid cells 2; TREM-2 T45086 FUNCTION Forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding. Acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia. Binding to amyloid-beta 42 mediates microglial activation, proliferation, migration, apoptosis and expression of pro-inflammatory cytokines, such as IL6R and CCL3, and the anti-inflammatory cytokine ARG1 (By similarity). Acts as a receptor for lipoprotein particles such as LDL, VLDL, and HDL and for apolipoproteins such as APOA1, APOA2, APOB, APOE, APOE2, APOE3, APOE4, and CLU and enhances their uptake in microglia. Binds phospholipids (preferably anionic lipids) such as phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol and sphingomyelin. Regulates microglial proliferation by acting as an upstream regulator of the Wnt/beta-catenin signaling cascade (By similarity). Required for microglial phagocytosis of apoptotic neurons. Also required for microglial activation and phagocytosis of myelin debris after neuronal injury and of neuronal synapses during synapse elimination in the developing brain (By similarity). Regulates microglial chemotaxis and process outgrowth, and also the microglial response to oxidative stress and lipopolysaccharide (By similarity). It suppresses PI3K and NF-kappa-B signaling in response to lipopolysaccharide; thus promoting phagocytosis, suppressing pro-inflammatory cytokine and nitric oxide production, inhibiting apoptosis and increasing expression of IL10 and TGFB (By similarity). During oxidative stress, it promotes anti-apoptotic NF-kappa-B signaling and ERK signaling (By similarity). Plays a role in microglial MTOR activation and metabolism (By similarity). Regulates age-related changes in microglial numbers. Triggers activation of the immune responses in macrophages and dendritic cells. Mediates cytokine-induced formation of multinucleated giant cells which are formed by the fusion of macrophages (By similarity). In dendritic cells, it mediates up-regulation of chemokine receptor CCR7 and dendritic cell maturation and survival. Involved in the positive regulation of osteoclast differentiation. T45086 PDBSTRUC 6B8O; 5UD8; 5UD7; 5ELI T45086 SEQUENCE MEPLRLLILLFVTELSGAHNTTVFQGVAGQSLQVSCPYDSMKHWGRRKAWCRQLGEKGPCQRVVSTHNLWLLSFLRRWNGSTAITDDTLGGTLTITLRNLQPHDAGLYQCQSLHGSEADTLRKVLVEVLADPLDHRDAGDLWFPGESESFEDAHVEHSISRSLLEGEIPFPPTSILLLLACIFLIKILAASALWAAAWHGQKPGTHPPSELDCGHDPGYQLQTLPGLRDT T45086 DRUGINFO DYT9B4 AL002 Phase 2 T45086 DRUGINFO DN48GC DNL919 Phase 1 T11615 TARGETID T11615 T11615 FORMERID TTDR01200 T11615 UNIPROID XCT_HUMAN T11615 TARGNAME Cystine/glutamate transporter (SLC7A11) T11615 GENENAME SLC7A11 T11615 TARGTYPE Clinical trial T11615 SYNONYMS XCT; X(c)-cystine transporter; X(c)- plasma membrane cystine transporter; Solute carrier family 7 member 11; Calcium channel blocker resistance protein CCBR1; Amino acid transport system xc-; Amino acid transport system XCT T11615 FUNCTION Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate. T11615 BIOCLASS Amino acid-polyamine-organocation T11615 SEQUENCE MVRKPVVSTISKGGYLQGNVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGVSIIIGTIIGAGIFISPKGVLQNTGSVGMSLTIWTVCGVLSLFGALSYAELGTTIKKSGGHYTYILEVFGPLPAFVRVWVELLIIRPAATAVISLAFGRYILEPFFIQCEIPELAIKLITAVGITVVMVLNSMSVSWSARIQIFLTFCKLTAILIIIVPGVMQLIKGQTQNFKDAFSGRDSSITRLPLAFYYGMYAYAGWFYLNFVTEEVENPEKTIPLAICISMAIVTIGYVLTNVAYFTTINAEELLLSNAVAVTFSERLLGNFSLAVPIFVALSCFGSMNGGVFAVSRLFYVASREGHLPEILSMIHVRKHTPLPAVIVLHPLTMIMLFSGDLDSLLNFLSFARWLFIGLAVAGLIYLRYKCPDMHRPFKVPLFIPALFSFTCLFMVALSLYSDPFSTGIGFVITLTGVPAYYLFIIWDKKPRWFRIMSEKITRTLQIILEVVPEEDKL T11615 DRUGINFO D1KO3P SXC-2023 Phase 2 T81830 TARGETID T81830 T81830 FORMERID TTDI03546 T81830 UNIPROID SIK3_HUMAN T81830 TARGNAME SIK family kinase 3 (SIK3) T81830 GENENAME SIK3 T81830 TARGTYPE Clinical trial T81830 SYNONYMS Serine/threonine-protein kinase SIK3; Serine/threonine-protein kinase QSK; Salt-inducible kinase 3; SIK-3; KIAA0999 T81830 FUNCTION Positive regulator of mTOR signaling that functions by triggering the degradation of DEPTOR, an mTOR inhibitor. Involved in the dynamic regulation of mTOR signaling in chondrocyte differentiation during skeletogenesis. Negatively regulates cAMP signaling pathway possibly by acting on CRTC2/TORC2 and CRTC3/TORC3 (Probable). Prevents HDAC4 translocation to the nucleus (By similarity). T81830 ECNUMBER EC 2.7.11.1 T81830 SEQUENCE MAAAAASGAGGAAGAGTGGAGPAGRLLPPPAPGSPAAPAAVSPAAGQPRPPAPASRGPMPARIGYYEIDRTIGKGNFAVVKRATHLVTKAKVAIKIIDKTQLDEENLKKIFREVQIMKMLCHPHIIRLYQVMETERMIYLVTEYASGGEIFDHLVAHGRMAEKEARRKFKQIVTAVYFCHCRNIVHRDLKAENLLLDANLNIKIADFGFSNLFTPGQLLKTWCGSPPYAAPELFEGKEYDGPKVDIWSLGVVLYVLVCGALPFDGSTLQNLRARVLSGKFRIPFFMSTECEHLIRHMLVLDPNKRLSMEQICKHKWMKLGDADPNFDRLIAECQQLKEERQVDPLNEDVLLAMEDMGLDKEQTLQSLRSDAYDHYSAIYSLLCDRHKRHKTLRLGALPSMPRALAFQAPVNIQAEQAGTAMNISVPQVQLINPENQIVEPDGTLNLDSDEGEEPSPEALVRYLSMRRHTVGVADPRTEVMEDLQKLLPGFPGVNPQAPFLQVAPNVNFMHNLLPMQNLQPTGQLEYKEQSLLQPPTLQLLNGMGPLGRRASDGGANIQLHAQQLLKRPRGPSPLVTMTPAVPAVTPVDEESSDGEPDQEAVQSSTYKDSNTLHLPTERFSPVRRFSDGAASIQAFKAHLEKMGNNSSIKQLQQECEQLQKMYGGQIDERTLEKTQQQHMLYQQEQHHQILQQQIQDSICPPQPSPPLQAACENQPALLTHQLQRLRIQPSSPPPNHPNNHLFRQPSNSPPPMSSAMIQPHGAASSSQFQGLPSRSAIFQQQPENCSSPPNVALTCLGMQQPAQSQQVTIQVQEPVDMLSNMPGTAAGSSGRGISISPSAGQMQMQHRTNLMATLSYGHRPLSKQLSADSAEAHSLNVNRFSPANYDQAHLHPHLFSDQSRGSPSSYSPSTGVGFSPTQALKVPPLDQFPTFPPSAHQQPPHYTTSALQQALLSPTPPDYTRHQQVPHILQGLLSPRHSLTGHSDIRLPPTEFAQLIKRQQQQRQQQQQQQQQQEYQELFRHMNQGDAGSLAPSLGGQSMTERQALSYQNADSYHHHTSPQHLLQIRAQECVSQASSPTPPHGYAHQPALMHSESMEEDCSCEGAKDGFQDSKSSSTLTKGCHDSPLLLSTGGPGDPESLLGTVSHAQELGIHPYGHQPTAAFSKNKVPSREPVIGNCMDRSSPGQAVELPDHNGLGYPARPSVHEHHRPRALQRHHTIQNSDDAYVQLDNLPGMSLVAGKALSSARMSDAVLSQSSLMGSQQFQDGENEECGASLGGHEHPDLSDGSQHLNSSCYPSTCITDILLSYKHPEVSFSMEQAGV T81830 DRUGINFO D40NQW GRN-300 Phase 1 T81830 DRUGINFO D03YVB HG-9-91-01 Investigative T66540 TARGETID T66540 T66540 FORMERID TTDI02664 T66540 UNIPROID TRPV1_HUMAN T66540 TARGNAME TRPV1 messenger RNA (TRPV1 mRNA) T66540 GENENAME TRPV1 T66540 TARGTYPE Clinical trial T66540 SYNONYMS Vanilloid receptor 1 (mRNA); VR1 (mRNA); TrpV1 (mRNA); Transient receptor potential cation channel subfamily V member 1 (mRNA); Osm-9-like TRP channel 1 (mRNA); OTRPC1 (mRNA); Capsaicin receptor (mRNA) T66540 FUNCTION Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Activation by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6. 5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis. Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. T66540 BIOCLASS mRNA target T66540 SEQUENCE MKKWSSTDLGAAADPLQKDTCPDPLDGDPNSRPPPAKPQLSTAKSRTRLFGKGDSEEAFPVDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLRLYDRRSIFEAVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLHDGQNTTIPLLLEIARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGADVQAAAHGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNTVLHALVEVADNTADNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYYRPVDGLPPFKMEKTGDYFRVTGEILSVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLYFSHLKEYVASMVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIEDGKNDSLPSESTSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWNTNVGIINEDPGNCEGVKRTLSFSLRSSRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDAEVFKSPAASGEK T66540 DRUGINFO DRA84P Tivanisiran Phase 3 T03189 TARGETID T03189 T03189 FORMERID TTDI02153 T03189 UNIPROID PRAME_HUMAN T03189 TARGNAME Tumor expressed melanoma antigen (PRAME) T03189 GENENAME PRAME T03189 TARGTYPE Clinical trial T03189 SYNONYMS Preferentially expressed antigen of melanoma; Opa-interacting protein 4; OIP-4; Melanoma antigen preferentially expressed in tumors; MAPE T03189 FUNCTION Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. Prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis. T03189 SEQUENCE MERRRLWGSIQSRYISMSVWTSPRRLVELAGQSLLKDEALAIAALELLPRELFPPLFMAAFDGRHSQTLKAMVQAWPFTCLPLGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWKLQVLDLRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKKRKVDGLSTEAEQPFIPVEVLVDLFLKEGACDELFSYLIEKVKRKKNVLRLCCKKLKIFAMPMQDIKMILKMVQLDSIEDLEVTCTWKLPTLAKFSPYLGQMINLRRLLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQALYVDSLFFLRGRLDQLLRHVMNPLETLSITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVMLTDVSPEPLQALLERASATLQDLVFDECGITDDQLLALLPSLSHCSQLTTLSFYGNSISISALQSLLQHLIGLSNLTHVLYPVPLESYEDIHGTLHLERLAYLHARLRELLCELGRPSMVWLSANPCPHCGDRTFYDPEPILCPCFMPN T03189 DRUGINFO D0X8TK IMC-F106C Phase 1/2 T03189 DRUGINFO D0V6MX IMA 203 Phase 1 T96876 TARGETID T96876 T96876 FORMERID TTDI02479 T96876 UNIPROID CO7A1_HUMAN T96876 TARGNAME Collagen VII (COL7A1) T96876 GENENAME COL7A1 T96876 TARGTYPE Clinical trial T96876 SYNONYMS Longchain collagen; Long-chain collagen; LC collagen; Collagen alpha1(VII) chain; Collagen alpha-1(VII) chain T96876 FUNCTION Stratified squamous epithelial basement membrane protein that forms anchoring fibrils which may contribute to epithelial basement membrane organization and adherence by interacting with extracellular matrix (ECM) proteins such as type IV collagen. T96876 SEQUENCE MTLRLLVAALCAGILAEAPRVRAQHRERVTCTRLYAADIVFLLDGSSSIGRSNFREVRSFLEGLVLPFSGAASAQGVRFATVQYSDDPRTEFGLDALGSGGDVIRAIRELSYKGGNTRTGAAILHVADHVFLPQLARPGVPKVCILITDGKSQDLVDTAAQRLKGQGVKLFAVGIKNADPEELKRVASQPTSDFFFFVNDFSILRTLLPLVSRRVCTTAGGVPVTRPPDDSTSAPRDLVLSEPSSQSLRVQWTAASGPVTGYKVQYTPLTGLGQPLPSERQEVNVPAGETSVRLRGLRPLTEYQVTVIALYANSIGEAVSGTARTTALEGPELTIQNTTAHSLLVAWRSVPGATGYRVTWRVLSGGPTQQQELGPGQGSVLLRDLEPGTDYEVTVSTLFGRSVGPATSLMARTDASVEQTLRPVILGPTSILLSWNLVPEARGYRLEWRRETGLEPPQKVVLPSDVTRYQLDGLQPGTEYRLTLYTLLEGHEVATPATVVPTGPELPVSPVTDLQATELPGQRVRVSWSPVPGATQYRIIVRSTQGVERTLVLPGSQTAFDLDDVQAGLSYTVRVSARVGPREGSASVLTVRREPETPLAVPGLRVVVSDATRVRVAWGPVPGASGFRISWSTGSGPESSQTLPPDSTATDITGLQPGTTYQVAVSVLRGREEGPAAVIVARTDPLGPVRTVHVTQASSSSVTITWTRVPGATGYRVSWHSAHGPEKSQLVSGEATVAELDGLEPDTEYTVHVRAHVAGVDGPPASVVVRTAPEPVGRVSRLQILNASSDVLRITWVGVTGATAYRLAWGRSEGGPMRHQILPGNTDSAEIRGLEGGVSYSVRVTALVGDREGTPVSIVVTTPPEAPPALGTLHVVQRGEHSLRLRWEPVPRAQGFLLHWQPEGGQEQSRVLGPELSSYHLDGLEPATQYRVRLSVLGPAGEGPSAEVTARTESPRVPSIELRVVDTSIDSVTLAWTPVSRASSYILSWRPLRGPGQEVPGSPQTLPGISSSQRVTGLEPGVSYIFSLTPVLDGVRGPEASVTQTPVCPRGLADVVFLPHATQDNAHRAEATRRVLERLVLALGPLGPQAVQVGLLSYSHRPSPLFPLNGSHDLGIILQRIRDMPYMDPSGNNLGTAVVTAHRYMLAPDAPGRRQHVPGVMVLLVDEPLRGDIFSPIREAQASGLNVVMLGMAGADPEQLRRLAPGMDSVQTFFAVDDGPSLDQAVSGLATALCQASFTTQPRPEPCPVYCPKGQKGEPGEMGLRGQVGPPGDPGLPGRTGAPGPQGPPGSATAKGERGFPGADGRPGSPGRAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGQVIGGEGPGLPGRKGDPGPSGPPGPRGPLGDPGPRGPPGLPGTAMKGDKGDRGERGPPGPGEGGIAPGEPGLPGLPGSPGPQGPVGPPGKKGEKGDSEDGAPGLPGQPGSPGEQGPRGPPGAIGPKGDRGFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGRQGEKGEPGRPGDPAVVGPAVAGPKGEKGDVGPAGPRGATGVQGERGPPGLVLPGDPGPKGDPGDRGPIGLTGRAGPPGDSGPPGEKGDPGRPGPPGPVGPRGRDGEVGEKGDEGPPGDPGLPGKAGERGLRGAPGVRGPVGEKGDQGDPGEDGRNGSPGSSGPKGDRGEPGPPGPPGRLVDTGPGAREKGEPGDRGQEGPRGPKGDPGLPGAPGERGIEGFRGPPGPQGDPGVRGPAGEKGDRGPPGLDGRSGLDGKPGAAGPSGPNGAAGKAGDPGRDGLPGLRGEQGLPGPSGPPGLPGKPGEDGKPGLNGKNGEPGDPGEDGRKGEKGDSGASGREGRDGPKGERGAPGILGPQGPPGLPGPVGPPGQGFPGVPGGTGPKGDRGETGSKGEQGLPGERGLRGEPGSVPNVDRLLETAGIKASALREIVETWDESSGSFLPVPERRRGPKGDSGEQGPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLALGERGPPGPSGLAGEPGKPGIPGLPGRAGGVGEAGRPGERGERGEKGERGEQGRDGPPGLPGTPGPPGPPGPKVSVDEPGPGLSGEQGPPGLKGAKGEPGSNGDQGPKGDRGVPGIKGDRGEPGPRGQDGNPGLPGERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGEPGETGPPGRGLTGPTGAVGLPGPPGPSGLVGPQGSPGLPGQVGETGKPGAPGRDGASGKDGDRGSPGVPGSPGLPGPVGPKGEPGPTGAPGQAVVGLPGAKGEKGAPGGLAGDLVGEPGAKGDRGLPGPRGEKGEAGRAGEPGDPGEDGQKGAPGPKGFKGDPGVGVPGSPGPPGPPGVKGDLGLPGLPGAPGVVGFPGQTGPRGEMGQPGPSGERGLAGPPGREGIPGPLGPPGPPGSVGPPGASGLKGDKGDPGVGLPGPRGERGEPGIRGEDGRPGQEGPRGLTGPPGSRGERGEKGDVGSAGLKGDKGDSAVILGPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGDKGSAGLPGLRGLLGPQGQPGAAGIPGDPGSPGKDGVPGIRGEKGDVGFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLAGHKGEMGEPGVPGQSGAPGKEGLIGPKGDRGFDGQPGPKGDQGEKGERGTPGIGGFPGPSGNDGSAGPPGPPGSVGPRGPEGLQGQKGERGPPGERVVGAPGVPGAPGERGEQGRPGPAGPRGEKGEAALTEDDIRGFVRQEMSQHCACQGQFIASGSRPLPSYAADTAGSQLHAVPVLRVSHAEEEERVPPEDDEYSEYSEYSVEEYQDPEAPWDSDDPCSLPLDEGSCTAYTLRWYHRAVTGSTEACHPFVYGGCGGNANRFGTREACERRCPPRVVQSQGTGTAQD T96876 DRUGINFO D8CW9E Beremagene geperpavec Phase 3 T80912 TARGETID T80912 T80912 FORMERID TTDNR00766 T80912 UNIPROID VPP3_HUMAN T80912 TARGNAME T-cell immune regulator 1 (TCIRG1) T80912 GENENAME TCIRG1 T80912 TARGTYPE Clinical trial T80912 SYNONYMS Vacuolar proton translocating ATPase 116 kDa subunit a isoform 3; V-ATPase 116 kDa isoform a3; TIRC7; TCIRG1; T-cell immune response cDNA7 protein; Osteoclastic proton pump 116 kDa subunit; OC116; OC-116 kDa T80912 FUNCTION Part of the proton channel of V-ATPases. Seems to be directly involved in T-cell activation. T80912 SEQUENCE MGSMFRSEEVALVQLFLPTAAAYTCVSRLGELGLVEFRDLNASVSAFQRRFVVDVRRCEELEKTFTFLQEEVRRAGLVLPPPKGRLPAPPPRDLLRIQEETERLAQELRDVRGNQQALRAQLHQLQLHAAVLRQGHEPQLAAAHTDGASERTPLLQAPGGPHQDLRVNFVAGAVEPHKAPALERLLWRACRGFLIASFRELEQPLEHPVTGEPATWMTFLISYWGEQIGQKIRKITDCFHCHVFPFLQQEEARLGALQQLQQQSQELQEVLGETERFLSQVLGRVLQLLPPGQVQVHKMKAVYLALNQCSVSTTHKCLIAEAWCSVRDLPALQEALRDSSMEEGVSAVAHRIPCRDMPPTLIRTNRFTASFQGIVDAYGVGRYQEVNPAPYTIITFPFLFAVMFGDVGHGLLMFLFALAMVLAENRPAVKAAQNEIWQTFFRGRYLLLLMGLFSIYTGFIYNECFSRATSIFPSGWSVAAMANQSGWSDAFLAQHTMLTLDPNVTGVFLGPYPFGIDPIWSLAANHLSFLNSFKMKMSVILGVVHMAFGVVLGVFNHVHFGQRHRLLLETLPELTFLLGLFGYLVFLVIYKWLCVWAARAASAPSILIHFINMFLFSHSPSNRLLYPRQEVVQATLVVLALAMVPILLLGTPLHLLHRHRRRLRRRPADRQEENKAGLLDLPDASVNGWSSDEEKAGGLDDEEEAELVPSEVLMHQAIHTIEFCLGCVSNTASYLRLWALSLAHAQLSEVLWAMVMRIGLGLGREVGVAAVVLVPIFAAFAVMTVAILLVMEGLSAFLHALRLHWVEFQNKFYSGTGYKLSPFTFAATDD T80912 DRUGINFO DFP0R6 RP-L401 Phase 1 T20017 TARGETID T20017 T20017 FORMERID TTDNC00392 T20017 UNIPROID CRTC1_HUMAN T20017 TARGNAME CREB-regulated transcription coactivator 1 (TORC1) T20017 GENENAME CRTC1 T20017 TARGTYPE Clinical trial T20017 SYNONYMS WAMTP1; Transducer of regulated cAMP response elementbinding protein 1; Transducer of regulated cAMP response element-binding protein 1; Transducer of CREB protein 1; TORC1; TORC-1; Mucoepidermoid carcinoma translocated protein 1; MECT1; KIAA0616; CREBregulated transcription coactivator 1 T20017 FUNCTION Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates the expression of specific CREB-activated genes such as the steroidogenic gene, StAR. Potent coactivator of PGC1alpha and inducer of mitochondrial biogenesis in muscle cells. In the hippocampus, involved in late-phase long-term potentiation (L-LTP) maintenance at the Schaffer collateral-CA1 synapses. May be required for dendritic growth of developing cortical neurons. In concert with SIK1, regulates the light-induced entrainment of the circadian clock. In response to light stimulus, coactivates the CREB-mediated transcription of PER1 which plays an important role in the photic entrainment of the circadian clock. Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. T20017 SEQUENCE MATSNNPRKFSEKIALHNQKQAEETAAFEEVMKDLSLTRAARLQLQKSQYLQLGPSRGQYYGGSLPNVNQIGSGTMDLPFQTPFQSSGLDTSRTTRHHGLVDRVYRERGRLGSPHRRPLSVDKHGRQADSCPYGTMYLSPPADTSWRRTNSDSALHQSTMTPTQPESFSSGSQDVHQKRVLLLTVPGMEETTSEADKNLSKQAWDTKKTGSRPKSCEVPGINIFPSADQENTTALIPATHNTGGSLPDLTNIHFPSPLPTPLDPEEPTFPALSSSSSTGNLAANLTHLGIGGAGQGMSTPGSSPQHRPAGVSPLSLSTEARRQQASPTLSPLSPITQAVAMDALSLEQQLPYAFFTQAGSQQPPPQPQPPPPPPPASQQPPPPPPPQAPVRLPPGGPLLPSASLTRGPQPPPLAVTVPSSLPQSPPENPGQPSMGIDIASAPALQQYRTSAGSPANQSPTSPVSNQGFSPGSSPQHTSTLGSVFGDAYYEQQMAARQANALSHQLEQFNMMENAISSSSLYSPGSTLNYSQAAMMGLTGSHGSLPDSQQLGYASHSGIPNIILTVTGESPPSLSKELTSSLAGVGDVSFDSDSQFPLDELKIDPLTLDGLHMLNDPDMVLADPATEDTFRMDRL T20017 DRUGINFO DFY58O RTB101 Phase 3 T98091 TARGETID T98091 T98091 FORMERID TTDI03248 T98091 UNIPROID GPR84_HUMAN T98091 TARGNAME Inflammation-related GPCR EX33 (GPR84) T98091 GENENAME GPR84 T98091 TARGTYPE Clinical trial T98091 SYNONYMS Inflammation-related G-protein coupled receptor EX33; G-protein coupled receptor 84; EX33 T98091 FUNCTION Receptor for medium-chain free fatty acid (FFA) with carbon chain lengths of C9 to C14. Capric acid (C10:0), undecanoic acid (C11:0) and lauric acid (C12:0) are the most potent agonists. Not activated by short-chain and long-chain saturated and unsaturated FFAs. Activation by medium-chain free fatty acid is coupled to a pertussis toxin sensitive G(i/o) protein pathway. May have important roles in processes from fatty acid metabolism to regulation of the immune system. T98091 SEQUENCE MWNSSDANFSCYHESVLGYRYVAVSWGVVVAVTGTVGNVLTLLALAIQPKLRTRFNLLIANLTLADLLYCTLLQPFSVDTYLHLHWRTGATFCRVFGLLLFASNSVSILTLCLIALGRYLLIAHPKLFPQVFSAKGIVLALVSTWVVGVASFAPLWPIYILVPVVCTCSFDRIRGRPYTTILMGIYFVLGLSSVGIFYCLIHRQVKRAAQALDQYKLRQASIHSNHVARTDEAMPGRFQELDSRLASGGPSEGISSEPVSAATTQTLEGDSSEVGDQINSKRAKQMAEKSPPEASAKAQPIKGARRAPDSSSEFGKVTRMCFAVFLCFALSYIPFLLLNILDARVQAPRVVHMLAANLTWLNGCINPVLYAAMNRQFRQAYGSILKRGPRSFHRLH T98091 DRUGINFO DT56YX PBI-4050 Phase 2 T98091 DRUGINFO DZLM72 SHR0534 Phase 1 T98091 DRUGINFO D03GHN 3-hydroxy capric acid Investigative T98091 DRUGINFO D0E1UA 2-hydroxy capric acid Investigative T98091 DRUGINFO D0R1MM 6-n-octylaminouracil Investigative T98091 DRUGINFO D0T2CG 3-hydroxylauric acid Investigative T98091 DRUGINFO D0T4BP 2-hydroxylauric acid Investigative T98091 DRUGINFO D0X0PF undecanoic acid Investigative T41202 TARGETID T41202 T41202 FORMERID TTDI00186 T41202 TARGNAME microRNA hsa-miR-29b (MIR29b) T41202 TARGTYPE Clinical trial T41202 BIOCLASS Non-coding RNA target T41202 DRUGINFO DC7UF3 Remlarsen Phase 2 T73992 TARGETID T73992 T73992 FORMERID TTDC00092 T73992 TARGNAME Beta-secretase (BACE) T73992 TARGTYPE Clinical trial T73992 SYNONYMS Transmembrane aspartic protease; Beta-site amyloid precursor protein cleaving enzyme; Beta-site AbetaPP-cleaving enzyme; BACE1 T73992 FUNCTION Responsible for the proteolytic processing of the amyloid precursor protein (app). Cleaves at the amino terminus of the a-beta peptide sequence, between residues 671 and 672 of app, leads to the generation and extracellular release of beta-cleaved soluble liquid. T73992 BIOCLASS Peptidase T73992 DRUGINFO D0G2IC (S)-FLURBIPROFEN Preregistration T73992 DRUGINFO D0Y0EP Lanabecestat Phase 3 T73992 DRUGINFO D08MHD E-2609 Phase 3 T73992 DRUGINFO D0R4KK verubecestat Phase 3 T73992 DRUGINFO D01AYX AZD3293 Phase 2/3 T73992 DRUGINFO D0T2FP JNJ-54861911 Phase 2/3 T73992 DRUGINFO D0F8GK LY2886721 Phase 2 T73992 DRUGINFO D0XD5N LY3202626 Phase 2 T73992 DRUGINFO D05FGR R-flurbiprofen Phase 2 T73992 DRUGINFO D04OSA AZD-3839 Phase 1 T73992 DRUGINFO D04VZS CTS-21166 Phase 1 T73992 DRUGINFO D08TVI HPP-854 Phase 1 T73992 DRUGINFO D0N1BF LY-2811376 Phase 1 T73992 DRUGINFO D0O8UB RG7129 Phase 1 T73992 DRUGINFO D00XKB AZ-4217 Clinical trial T73992 DRUGINFO D0CG8S oxazine 89 Clinical trial T73992 DRUGINFO D0H6AG PMID23981898C11d Clinical trial T73992 DRUGINFO D0Q6NN TAK-070 Clinical trial T73992 DRUGINFO D0T7BV PMID22911925C2 Clinical trial T73992 DRUGINFO D0E3SX SCH-1359113 Preclinical T73992 DRUGINFO D0K3WN DNP-004089 Terminated T73992 DRUGINFO D00CYX Glu-Leu-Asp-Leu-(CHOH-CH2)-Ala-Ala-Glu-Phe Investigative T73992 DRUGINFO D00LZS KMI-538 Investigative T73992 DRUGINFO D02WYE 4-(2-aminoethyl)-2-cyclohexylphenol Investigative T73992 DRUGINFO D03VQF (2S)-2'-methoxy kurarinone Investigative T73992 DRUGINFO D04RSC OM00-3 Investigative T73992 DRUGINFO D06MYZ N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide Investigative T73992 DRUGINFO D06ZJQ KMI-172 Investigative T73992 DRUGINFO D07EWF PMID23412139C16 Investigative T73992 DRUGINFO D08ALW MMI-175 Investigative T73992 DRUGINFO D08HZD N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE Investigative T73992 DRUGINFO D08MZY Eckol Investigative T73992 DRUGINFO D08UYP DIECKOL Investigative T73992 DRUGINFO D09SOY 5,5-Diphenyl-2-iminohydantoin Investigative T73992 DRUGINFO D0A0RO N~3~-BENZYLPYRIDINE-2,3-DIAMINE Investigative T73992 DRUGINFO D0D4FV LEACHIANONE A Investigative T73992 DRUGINFO D0H0SE TRIPHLOROETHOL A Investigative T73992 DRUGINFO D0I8KC 6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE Investigative T73992 DRUGINFO D0K5OZ AZ3971 Investigative T73992 DRUGINFO D0L7AT 7-Phloroethol Investigative T73992 DRUGINFO D0M4IR KMI-494 Investigative T73992 DRUGINFO D0M4ND 4-(2-aminoethyl)-2-ethylphenol Investigative T73992 DRUGINFO D0O0FA KUSHENOL A Investigative T73992 DRUGINFO D0PR9E KMI-596 Investigative T73992 DRUGINFO D0Q5XM GSK-188909 Investigative T73992 DRUGINFO D0S0BN PHLOROFUCOFUROECKOL A Investigative T73992 DRUGINFO D0V4PB 4-(4-FLUOROBENZYL)PIPERIDINE Investigative T73992 DRUGINFO D0WA9S DIOXINODEHYDROECKOL Investigative T73992 DRUGINFO D00SDQ PMID21907142CJ Investigative T73992 DRUGINFO D02LCH GRL-7234 Investigative T73992 DRUGINFO D0H3EJ Carbocyclic Peptidomimetic Investigative T73992 DRUGINFO D0O0GW example 2 (WO2013004676) Investigative T73992 DRUGINFO D0S1MC AP-2243 Investigative T73992 DRUGINFO D01PNM KURARINONE Investigative T73992 DRUGINFO D0M4IE Bis-7-tacrine Investigative T73992 DRUGINFO D0RB1V (-)-CATECHINGALLATE Investigative T92138 TARGETID T92138 T92138 FORMERID TTDC00315 T92138 TARGNAME Phosphodiesterase (PDE) T92138 TARGTYPE Clinical trial T92138 SYNONYMS Human phosphodiesterase T92138 FUNCTION Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones. T92138 BIOCLASS Phosphoric diester hydrolase T92138 DRUGINFO D0A8KX M-518101 Phase 3 T92138 DRUGINFO D06LFV NM-702 Phase 3 T92138 DRUGINFO D08FOX Piroximone Discontinued in Phase 3 T92138 DRUGINFO D0B2OL AA-2379 Discontinued in Phase 2 T92138 DRUGINFO D0C1TJ HN-10200 Discontinued in Phase 2 T92138 DRUGINFO D0X1EX TIBENELAST Discontinued in Phase 2 T92138 DRUGINFO D04ONP ALBIFYLLINE Discontinued in Phase 1 T92138 DRUGINFO D05VLN Isomazole Terminated T92138 DRUGINFO D0E1ZE BBB-022 Terminated T92138 DRUGINFO D0J0MK JTT-608 Terminated T92138 DRUGINFO D00MEV Sch-45752 Terminated T92138 DRUGINFO D09TDK DPN-205-734 Investigative T86192 TARGETID T86192 T86192 FORMERID TTDI01791 T86192 TARGNAME Voltage-gated potassium channel Kv7 (KCNQ) T86192 TARGTYPE Clinical trial T86192 SYNONYMS Voltage-gated potassium channel subunit Kv7; Potassium voltage-gated channel subfamily KQT; Kv7; KVLQT; KQT-like; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT; IKs producing slow voltage-gated potassium channel alpha subunit KvLQT T86192 BIOCLASS Voltage-gated ion channel T86192 DRUGINFO D0X7GL Retigabine Approved T86192 DRUGINFO D0SD9V Flupirtine Phase 2 T86192 DRUGINFO D0D7MJ CNSB-001 Phase 2 T86192 DRUGINFO D0W7IR DMP-543 Discontinued in Phase 2 T67747 TARGETID T67747 T67747 FORMERID TTDI02258 T67747 TARGNAME NF-kappa-B messenger RNA (NFKB mRNA) T67747 TARGTYPE Clinical trial T67747 SYNONYMS mRNA of NF-kappaB; NF-kappaB mRNA T67747 FUNCTION NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65,RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105. T67747 BIOCLASS mRNA target T90768 TARGETID T90768 T90768 FORMERID TTDC00274 T90768 TARGNAME Human immunodeficiency virus Trans-activation response element (HIV TAR RNA element) T90768 TARGTYPE Clinical trial T90768 SYNONYMS HIV TAR element T90768 BIOCLASS mRNA target T90768 DRUGINFO D0JZ8X HGTV43 Phase 2 T75251 TARGETID T75251 T75251 FORMERID TTDI01923 T75251 TARGNAME Tubulin receptor (TUBR) T75251 TARGTYPE Clinical trial T75251 SYNONYMS Tubulin protein T75251 FUNCTION Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. T75251 DRUGINFO D00YBZ OC-10X Phase 1 T25537 TARGETID T25537 T25537 FORMERID TTDI01585 T25537 TARGNAME Mitogen-activated protein kinase (MAPK) T25537 TARGTYPE Clinical trial T25537 SYNONYMS MAPK; Extracellular signal-regulated kinase; ERK T25537 BIOCLASS Kinase T25537 DRUGINFO D0C4GX GBL-310 Phase 2 T25537 DRUGINFO D0TA8O LTT462 Phase 1 T25537 DRUGINFO DQ5YV2 PF-07799544 Phase 1 T25537 DRUGINFO D01FTR PMID25991433-Compound-C3 Patented T25537 DRUGINFO D04JVY PMID25991433-Compound-J6 Patented T25537 DRUGINFO D09EWC PMID25991433-Compound-L Patented T25537 DRUGINFO D0CS9R PMID25991433-Compound-B1 Patented T25537 DRUGINFO D0GX7W PMID25991433-Compound-P3 Patented T25537 DRUGINFO D0J8PJ PMID25991433-Compound-B3 Patented T25537 DRUGINFO D0O2EF PMID25991433-Compound-Q2 Patented T25537 DRUGINFO D0PG5N PMID25991433-Compound-J1 Patented T25537 DRUGINFO D0QK6D PMID25991433-Compound-C2 Patented T25537 DRUGINFO D0UY9Y PMID25991433-Compound-P2 Patented T25537 DRUGINFO D0W7MG PMID25991433-Compound-F1 Patented T25537 DRUGINFO D0X7OF PMID25991433-Compound-N2 Patented T25537 DRUGINFO D0Y4KU PMID25991433-Compound-B2 Patented T25537 DRUGINFO D00GWE Bidentate ligands of Markush derivative 2 Patented T25537 DRUGINFO D0SV0D Bidentate ligands of Markush derivative 1 Patented T25537 DRUGINFO D0V7UQ PMID25991433-Compound-Q1 Patented T25537 DRUGINFO D08OJQ PMID25991433-Compound-L2 Patented T25537 DRUGINFO D0G7LB PMID25991433-Compound-L3 Patented T25537 DRUGINFO D0GD8Y U0126 Investigative T45597 TARGETID T45597 T45597 TARGNAME Ribosomal protein S6 kinase (S6K) T45597 TARGTYPE Clinical trial T45597 SYNONYMS Ribosomal s6 kinase T45597 BIOCLASS Kinase T45597 DRUGINFO D0VO5S LY-2584702 Phase 1 T45597 DRUGINFO D00DXH LYS-6KAKT1 Phase 1 T45597 DRUGINFO D0Q0PO LY2780301 Phase 1 T45597 DRUGINFO D0X2JM XL418 Phase 1 T45597 DRUGINFO D0M0AK PMID27410995-Compound-Figure3k Patented T58998 TARGETID T58998 T58998 FORMERID TTDNC00380 T58998 TARGNAME Bromodomain and extraterminal domain protein (BET) T58998 TARGTYPE Clinical trial T58998 SYNONYMS Bromodomain and Extra Terminal protein T58998 DRUGINFO D01LVE CPI-0610 Phase 3 T58998 DRUGINFO D8VJT5 ZEN-3694 Phase 2 T58998 DRUGINFO D06ILL BMS-986158 Phase 1/2 T58998 DRUGINFO D4Y0IM INCB054329 Phase 1/2 T58998 DRUGINFO D7FJQ3 INCB057643 Phase 1/2 T58998 DRUGINFO DA91HS ODM-207 Phase 1/2 T58998 DRUGINFO D02YNI OTX-015 Phase 1/2 T58998 DRUGINFO D03JLR PLX51107 Phase 1 T58998 DRUGINFO D06QBV BI 894999 Phase 1 T58998 DRUGINFO D08KSV RG6146 Phase 1 T58998 DRUGINFO D0M2TS Mivebresib Phase 1 T58998 DRUGINFO D0N8RA GS-5829 Phase 1 T58998 DRUGINFO D0TM0Y FT-1101 Phase 1 T58998 DRUGINFO D0UL2X CC-90010 Phase 1 T58998 DRUGINFO D15ZUR RO6870810 Phase 1 T58998 DRUGINFO D3TW6X ZEN003694 Phase 1 T58998 DRUGINFO DIX61C CC-90010 Phase 1 T58998 DRUGINFO DM2Y8T GSK2820151 Phase 1 T58998 DRUGINFO DRK7Q1 BAY 1238097 Phase 1 T58998 DRUGINFO DV1R0X CC-95775 Phase 1 T58998 DRUGINFO D07OFM GSK525762 Phase 1 T58998 DRUGINFO D0ZW4W (+)-JQ1 Phase 1 T58998 DRUGINFO D04WNN PMID26924192-Compound-53 Patented T58998 DRUGINFO D05GPL Isoxazole-based bicyclic compound 4 Patented T58998 DRUGINFO D05PZG Tetra-hydro-quinoline derivative 4 Patented T58998 DRUGINFO D08IZA Isoxazole-based bicyclic compound 17 Patented T58998 DRUGINFO D09ENS Quinazolinone derivative 3 Patented T58998 DRUGINFO D0A4RP Isoxazole-based bicyclic compound 19 Patented T58998 DRUGINFO D0B8GA Isoxazole-based bicyclic compound 5 Patented T58998 DRUGINFO D0BH7X Isoxazole-based bicyclic compound 6 Patented T58998 DRUGINFO D0C1HS Dihydropyrido pyrazinone compound 1 Patented T58998 DRUGINFO D0CY3L Isoxazole-based bicyclic compound 8 Patented T58998 DRUGINFO D0CY9X Isoxazole-based bicyclic compound 7 Patented T58998 DRUGINFO D0E4UV PMID26924192-Compound-51 Patented T58998 DRUGINFO D0FC0Z Isoxazole-based bicyclic compound 13 Patented T58998 DRUGINFO D0FY9K Quinazolinone derivative 4 Patented T58998 DRUGINFO D0G5UR PMID26924192-Compound-52 Patented T58998 DRUGINFO D0G8IM Isoxazole-based bicyclic compound 9 Patented T58998 DRUGINFO D0HB3F Pyrimido-indole derivative 1 Patented T58998 DRUGINFO D0I6HB Quinazolinone derivative 5 Patented T58998 DRUGINFO D0JR5G PMID26924192-Compound-50 Patented T58998 DRUGINFO D0KG1T Pyrimido-indole derivative 2 Patented T58998 DRUGINFO D0OJ1R PMID26924192-Compound-57 Patented T58998 DRUGINFO D0ON7G Isoxazole-based bicyclic compound 3 Patented T58998 DRUGINFO D0P5SF Pyrimido-indole derivative 3 Patented T58998 DRUGINFO D0P8PE Isoxazole-based bicyclic compound 14 Patented T58998 DRUGINFO D0PK4M Isoxazole-based bicyclic compound 18 Patented T58998 DRUGINFO D0QA4O Isoxazole-based bicyclic compound 10 Patented T58998 DRUGINFO D0R6KH PMID26924192-Compound-56 Patented T58998 DRUGINFO D0R8CR PMID26924192-Compound-54 Patented T58998 DRUGINFO D0SG9F Isoxazole-based bicyclic compound 1 Patented T58998 DRUGINFO D0SV2S Tetra-hydro-quinoline derivative 3 Patented T58998 DRUGINFO D0T8DH Isoxazole-based bicyclic compound 15 Patented T58998 DRUGINFO D0T9ZO PMID26924192-Compound-55 Patented T58998 DRUGINFO D0TF2N Isoxazole-based bicyclic compound 16 Patented T58998 DRUGINFO D0U5BE Tetra-hydro-quinoline derivative 2 Patented T58998 DRUGINFO D0UU2U Isoxazole-based bicyclic compound 11 Patented T58998 DRUGINFO D0W3NX Isoxazole-based bicyclic compound 12 Patented T58998 DRUGINFO D0WM3Y Isoxazole-based bicyclic compound 2 Patented T85574 TARGETID T85574 T85574 FORMERID TTDI01751 T85574 TARGNAME Angiotensin II receptor (AGTR) T85574 TARGTYPE Clinical trial T85574 FUNCTION Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. T85574 DRUGINFO D0I7BD CYT-006-AngQb Phase 2 T85574 DRUGINFO D0HJ7I DA-727 Phase 1 T85574 DRUGINFO D00NTW BIBR-363 Discontinued in Phase 2 T85574 DRUGINFO D03OKG FK-739 Discontinued in Phase 2 T85574 DRUGINFO D05EEJ ETRX-101 Discontinued in Phase 2 T85574 DRUGINFO D0CE6T Elisartan potassium Discontinued in Phase 2 T85574 DRUGINFO D0F2HA ICI-D-8731 Discontinued in Phase 2 T85574 DRUGINFO D0M7PS E-4177 Discontinued in Phase 2 T85574 DRUGINFO D00BIY CGP-48369 Discontinued in Phase 1 T85574 DRUGINFO D0L3EW ICI-D-6888 Discontinued in Phase 1 T85574 DRUGINFO D0N1EW DuP-532 Discontinued in Phase 1 T85574 DRUGINFO D00FWB L-163017 Terminated T85574 DRUGINFO D00MSP FR-149581 Terminated T85574 DRUGINFO D02ABS BMS-180560 Terminated T85574 DRUGINFO D02ZKB WAY-126227 Terminated T85574 DRUGINFO D04FXE KW-3433 Terminated T85574 DRUGINFO D07GQA ZD-7155 Terminated T85574 DRUGINFO D07LEW BIBS-39 Terminated T85574 DRUGINFO D08VTA EXP-6803 Terminated T85574 DRUGINFO D0A8HL DMP-811 Terminated T85574 DRUGINFO D0F0TW SL-910102 Terminated T85574 DRUGINFO D0N5CT BIBS-222 Terminated T85574 DRUGINFO D0O0QG SC-51316 Terminated T85574 DRUGINFO D0O0RK A-81282 Terminated T85574 DRUGINFO D0T5SG ME-3221 Terminated T85574 DRUGINFO D0XI9O RWJ-46458 Terminated T85574 DRUGINFO D0Y8PH CI-996 Terminated T85574 DRUGINFO D06MUI A-81988 Terminated T85574 DRUGINFO D0XG0Z A-82186 Investigative T95241 TARGETID T95241 T95241 FORMERID TTDNR00751 T95241 TARGNAME Calcium-activated potassium channel KCa2 (KCNN) T95241 TARGTYPE Clinical trial T95241 FUNCTION Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blockedby apamin. T95241 BIOCLASS Voltage-gated ion channel T95241 DRUGINFO D08ANJ AP-30663 Phase 1/2 T95241 DRUGINFO D0FI1L CAD-1883 Phase 1/2 T95241 DRUGINFO D0WM8D CAD-1833 Phase 1 T67022 TARGETID T67022 T67022 FORMERID TTDR00960 T67022 TARGNAME Caspase (CASP) T67022 TARGTYPE Clinical trial T67022 BIOCLASS Peptidase T67022 DRUGINFO D09BTK NCX-1000 Phase 2 T67022 DRUGINFO D2D9CN Z-VAD-fmk Preclinical T67022 DRUGINFO DM16YT VX-166 Preclinical T67022 DRUGINFO D0J1WJ ALS-769 Terminated T67022 DRUGINFO D0O7HF IDN-1965 Investigative T67022 DRUGINFO D0L9AX Ac-DEVD-CHO Investigative T67022 DRUGINFO DAQ31P 2-aminophenoxazine-3-one Investigative T67022 DRUGINFO D0V6DX Isoquinoline-1,3,4(2H)-trione Investigative T95488 TARGETID T95488 T95488 FORMERID TTDC00300 T95488 TARGNAME Interleukin-1 (IL1) T95488 TARGTYPE Clinical trial T95488 SYNONYMS IL-1 T95488 DRUGINFO D00IUD K-832 Phase 2 T10445 TARGETID T10445 T10445 FORMERID TTDS00064 T10445 TARGNAME Lipase unspecific (LIP) T10445 TARGTYPE Clinical trial T10445 BIOCLASS Ester hydrolase T10445 DRUGINFO D01CGX ApoC-III Phase 3 T10445 DRUGINFO D0Y1VZ GT-389255 Discontinued in Phase 2 T10445 DRUGINFO D05JYE Butylphosphonate Investigative T45457 TARGETID T45457 T45457 FORMERID TTDR00057 T45457 TARGNAME Melanocortin receptor (MCR) T45457 TARGTYPE Clinical trial T45457 SYNONYMS Melanocortin receptor T45457 DRUGINFO D0B2SW ASP-3291 Phase 2 T45457 DRUGINFO D09LXL Ac-His-DPhe(pBr)-Arg-Trp-NH2 Investigative T45457 DRUGINFO D0G3GE Ac-His-DPhe(3,4-diCl)-Arg-Trp-NH2 Investigative T45457 DRUGINFO D0J0DK Ac-His-DNal(2)-Arg-Trp-NH2 Investigative T45457 DRUGINFO D0O6WF Ac-His-DPhe(pCF3)-Arg-Trp-NH2 Investigative T45457 DRUGINFO D0V1JT Ac-His-DPhe(pI)-Arg-Trp-NH2 Investigative T45457 DRUGINFO D01VMU C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2 Investigative T45457 DRUGINFO D0B9NH C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D00NOG MK-11 Investigative T45457 DRUGINFO D00TSX C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D01HTX C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D02MPZ C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D04YZZ C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T45457 DRUGINFO D05WNC C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D07UXW C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D08DND C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2 Investigative T45457 DRUGINFO D09UUC MK-10 Investigative T45457 DRUGINFO D0M4EF C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D0P4GI C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D0VD7R C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D0W1SM C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D0XQ5U C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T45457 DRUGINFO D02JVA C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D03AZC Ac-YRMEHdFRWG-NH2 Investigative T45457 DRUGINFO D05LLI C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D06RTP C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D07SFD C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D07TBR Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 Investigative T45457 DRUGINFO D09PDT C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T45457 DRUGINFO D0AU4C AEKKDEGPYRMEHFRWGSPPKD Investigative T45457 DRUGINFO D0B4OL Ac-YRMEHdFRWGSPPKD-NH2 Investigative T45457 DRUGINFO D0CK0K Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 Investigative T45457 DRUGINFO D0I8SJ NDP-SYSMEHFRWGKPVG Investigative T45457 DRUGINFO D0ID5M GPYRMEHFRWGSPPKD-NH2 Investigative T45457 DRUGINFO D0L1MJ C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T45457 DRUGINFO D0R0BY Ac-YR[CEH(pCl-dF)RWC]-NH2 Investigative T45457 DRUGINFO D0WG8P Ac-YR[CEH(pF-dF)RWC]-NH2 Investigative T45457 DRUGINFO D0WI8M C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T45457 DRUGINFO D0X1YL Ac-YRC(Me)*EHdFRWC(Me)NH2 Investigative T45457 DRUGINFO D0YB7F MT-II Investigative T32137 TARGETID T32137 T32137 FORMERID TTDNC00395 T32137 TARGNAME NADPH oxidase (NOX) T32137 TARGTYPE Clinical trial T32137 FUNCTION NOH-1S is a voltage-gated proton channel that mediates the H(+) currents of resting phagocytes and other tissues. It participates in the regulation of cellular pH and is blocked by zinc. NOH-1L is a pyridine nucleotide-dependent oxidoreductase that generates superoxide and might conduct H(+) ions as part of its electron transport mechanism, whereas NOH-1S does not contain an electron transport chain. T32137 DRUGINFO D04XVU GKT-137831 Phase 2 T32137 DRUGINFO D0F9WF SINOMENINE Discontinued in Phase 2 T47165 TARGETID T47165 T47165 FORMERID TTDI02005 T47165 TARGNAME Neural cell adhesion molecule (NCAM) T47165 TARGTYPE Clinical trial T47165 BIOCLASS Immunoglobulin T47165 DRUGINFO D09THN IMGN901 Phase 2 T47165 DRUGINFO D06EXI FGLL Phase 1 T47165 DRUGINFO D0NP8B ERIC-1 Terminated T88318 TARGETID T88318 T88318 FORMERID TTDC00181 T88318 TARGNAME Protein kinase C (PRKC) T88318 TARGTYPE Clinical trial T88318 BIOCLASS Kinase T88318 DRUGINFO D0M3BB Synthetic hypericin Phase 3 T88318 DRUGINFO D00DPP CYCLOPLATAM Phase 2 T88318 DRUGINFO D0LA1R AEB07 Phase 2 T88318 DRUGINFO D0O3XU HO/03/03 Phase 2 T88318 DRUGINFO DD8L0V Bryostatin-1 Phase 2 T88318 DRUGINFO D08VAR APH-0812 Phase 2 T88318 DRUGINFO D0R7HL LXS196 Phase 1/2 T88318 DRUGINFO D07CAQ SAFINGOL Phase 1 T88318 DRUGINFO D0B2NF AEB701 Phase 1 T88318 DRUGINFO D07HYR GCC-1290K Phase 1 T88318 DRUGINFO D00YSJ Tecadenoson Discontinued in Phase 3 T88318 DRUGINFO D0R1JI Rottlerin Preclinical T88318 DRUGINFO D06AHQ Ro-31-8830 Terminated T88318 DRUGINFO D0S6XD Calphostin C Terminated T88318 DRUGINFO D0E3TC Staurosporine Investigative T88318 DRUGINFO D08JPU G6976 Investigative T88318 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T09227 TARGETID T09227 T09227 FORMERID TTDR00845 T09227 TARGNAME Protein tyrosine phosphatase (PTP) T09227 TARGTYPE Clinical trial T09227 SYNONYMS PTPase; PTPN T09227 BIOCLASS Phosphoric monoester hydrolase T09227 DRUGINFO D05XLO INCB13739 Phase 2a T09227 DRUGINFO D0I1QJ KP-100 Phase 1/2 T09227 DRUGINFO D0J0KC Pervanadate Investigative T09227 DRUGINFO D0X9TG Diamide Investigative T93145 TARGETID T93145 T93145 TARGNAME Pyruvate dehydrogenase kinase (PDHK) T93145 TARGTYPE Clinical trial T93145 SYNONYMS PDH kinase T93145 BIOCLASS Kinase T93145 DRUGINFO D0E3EO JTT-251 Phase 2 T93145 DRUGINFO D52MXY JTT-861 Phase 1 T74073 TARGETID T74073 T74073 FORMERID TTDI01794 T74073 TARGNAME Serine/threonine-protein kinase pim (PIM) T74073 TARGTYPE Clinical trial T74073 FUNCTION Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling throughphosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl- X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A proteinstability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post- translational levels. Phosphorylation of CDKN1B,induces 14-3-3- proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Actsalso as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis. T74073 BIOCLASS Kinase T74073 DRUGINFO D06FQU INCB53914 Phase 1/2 T74073 DRUGINFO D0V2ZC SEL24 Phase 1/2 T74073 DRUGINFO D01QNR PIM447 Phase 1 T74073 DRUGINFO D7Z1CR TP-3654 Phase 1 T72478 TARGETID T72478 T72478 FORMERID TTDR00490 T72478 TARGNAME Sodium/calcium exchanger (SLC) T72478 TARGTYPE Clinical trial T72478 SYNONYMS NaCaX; Na(+)/Ca(2+) exchanger; Mitochondrial sodium-calcium exchanger T72478 DRUGINFO D06FOL CALDARET HYDRATE Phase 2 T72478 DRUGINFO D0IK1U SEA-0400 Investigative T34624 TARGETID T34624 T34624 FORMERID TTDR00365 T34624 TARGNAME Stress-activated protein kinase (p38) T34624 TARGTYPE Clinical trial T34624 SYNONYMS p38) Stress-activated protein kinase; P38 MAPK; P38 MAP kinase; Mitogen-activated protein kinase p38 T34624 BIOCLASS Kinase T34624 DRUGINFO DL14SU PF-07265803 Phase 3 T34624 DRUGINFO D04SPJ AZD7624 Phase 2 T34624 DRUGINFO D06GUA GSK2269557 Phase 2 T34624 DRUGINFO D0O6ZO TAK-715 Phase 2 T34624 DRUGINFO D38LQO MW150 Phase 2 T34624 DRUGINFO D02LBK ARRY-797 Phase 2 T34624 DRUGINFO D0Q0AP BMS-582949 Phase 2 T34624 DRUGINFO D08WYH LY-2228820 Phase 1/2 T34624 DRUGINFO DG2EK3 PUR1800 Phase 1 T34624 DRUGINFO D02LCI TA-5493 Discontinued in Phase 1 T34624 DRUGINFO D03KWN AZD-6703 Discontinued in Phase 1 T34624 DRUGINFO D08CQE AVE-9940 Discontinued in Phase 1 T34624 DRUGINFO D0W3AX SB-281832 Discontinued in Phase 1 T34624 DRUGINFO D0ML0L ARRY-614 Discontinued in Phase 1 T34624 DRUGINFO D02MVG AMG-548 Terminated T83059 TARGETID T83059 T83059 FORMERID TTDI01798 T83059 TARGNAME Tankyrase (TNKS) T83059 TARGTYPE Clinical trial T83059 FUNCTION Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates PARsylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates PARsylation of TERF1, thereby contributing to the regulation of telomere length. Involved in centrosome maturation during prometaphase by mediating PARsylation of HEPACAM2/MIKI. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles. May be involved in spindle pole assembly through PARsylation of NUMA1. Stimulates 26S proteasome activity. T83059 BIOCLASS Glycosyltransferases T83059 DRUGINFO D0D9IQ BGB-290 Phase 2 T83059 DRUGINFO D0SZ9R 2X-121 Phase 2 T83059 DRUGINFO D5P3SI STP1002 Phase 1 T06011 TARGETID T06011 T06011 FORMERID TTDC00203 T06011 TARGNAME Transforming growth factor beta (TGFB) T06011 TARGTYPE Clinical trial T06011 SYNONYMS TGF-beta T06011 DRUGINFO D07VHU NIS793 Phase 2 T06011 DRUGINFO D32PZT LY2382770 Phase 2 T06011 DRUGINFO DB35WK Fresolimumab Phase 2 T06011 DRUGINFO D0MR0B TEW-7197 Phase 2 T06011 DRUGINFO D5J3BL Bintrafusp alfa Phase 2 T06011 DRUGINFO D05FPZ M7824 Phase 2 T06011 DRUGINFO D0F7GX ACE-011 Phase 1 T06011 DRUGINFO D1ONZ8 AVID200 Phase 1 T06011 DRUGINFO DIBP49 RG6440 Phase 1 T06011 DRUGINFO D0U7XJ BCA101 Phase 1 T06011 DRUGINFO DG6V7E GS-1423 Phase 1 T06011 DRUGINFO DD9NG5 SHP-627 Preclinical T52258 TARGETID T52258 T52258 FORMERID TTDI01242 T52258 TARGNAME Hepatitis B virus messenger RNA (HBV mRNA) T52258 TARGTYPE Clinical trial T52258 SYNONYMS mRNA of HBV protein T52258 BIOCLASS mRNA target T52258 DRUGINFO D08NDA ISIS-HBV Phase 2 T52258 DRUGINFO DO9B3Y AB-729 Phase 2 T52258 DRUGINFO DWS5G1 ARO-HBV Phase 1/2 T41963 TARGETID T41963 T41963 FORMERID TTDR00939 T41963 TARGNAME Toll-like receptor (TLR) T41963 TARGTYPE Clinical trial T41963 SYNONYMS Toll-like receptor T41963 DRUGINFO D03VPM DPV-001 Phase 2 T41963 DRUGINFO D08SIC BDB001 Phase 2 T41963 DRUGINFO D0I0XF IMO-8400 Phase 2 T41963 DRUGINFO D0UF8M IMO-9200 Phase 1 T41963 DRUGINFO D06IVC PMID30280939-Compound-WO2009082440 Patented T41963 DRUGINFO D07NEI PMID30280939-Compound-US20179642901 Patented T41963 DRUGINFO D08TOM PMID30280939-Compound-WO2015150568 Patented T41963 DRUGINFO D0AF4V PMID30280939-Compound-WO200606195 Patented T41963 DRUGINFO D0BW2B PMID30280939-Compound-WO2005070959 Patented T41963 DRUGINFO D0H9SD PMID30280939-Compound-WO2013148426 Patented T41963 DRUGINFO D0HK3A PMID30280939-Compound-WO2013148427 Patented T41963 DRUGINFO D0IH8R PMID30280939-Compound-WO2008009652 Patented T41963 DRUGINFO D0K4CX PMID30280939-Compound-WO2015035128 Patented T41963 DRUGINFO D0P8VT PMID30280939-Compound-US20170128558 Patented T41963 DRUGINFO D0QW0C PMID30280939-Compound-WO2013119856 Patented T41963 DRUGINFO D0T8XY PMID30280939-Compound-WO2015091734 Patented T41963 DRUGINFO D06PKS ONO-4007 Discontinued in Phase 2 T70508 TARGETID T70508 T70508 FORMERID TTDNC00434 T70508 TARGNAME Cyclin-dependent kinase (CDK) T70508 TARGTYPE Clinical trial T70508 SYNONYMS Cyclin dependent kinase T70508 DRUGINFO D0LF1U Flavopiridol Phase 2 T70508 DRUGINFO D05ADP R-roscovitine Phase 2 T70508 DRUGINFO D0P0KN TG02 Phase 1/2 T70508 DRUGINFO D0V2LL PF-06873600 Phase 1 T70508 DRUGINFO D01UAL Purine derivative 4 Patented T70508 DRUGINFO D0BU1L Indole-based analog 12 Patented T70508 DRUGINFO D0U4ZO PMID26161698-Compound-10 Patented T70508 DRUGINFO D0G6QW PMID26161698-Compound-44 Patented T70508 DRUGINFO D01MNK BS-194 Investigative T70888 TARGETID T70888 T70888 TARGNAME TNF receptor (TNFR) T70888 TARGTYPE Clinical trial T70888 SYNONYMS TNFR T70888 DRUGINFO D09KIG ETX201 Phase 1 T70888 DRUGINFO D0H6CA Lenercept Discontinued in Phase 3 T70888 DRUGINFO D01EYM BB-2275 Terminated T03513 TARGETID T03513 T03513 TARGNAME Dopamine receptor (DR) T03513 TARGTYPE Clinical trial T03513 SYNONYMS Human dopamine receptor T03513 DRUGINFO D81KMY Neupro Phase 4 T03513 DRUGINFO D0T5VD EVK-001 Phase 3 T03513 DRUGINFO DP7GK8 ABBV-951 Phase 3 T03513 DRUGINFO D07XQS ONC201 Phase 2 T03513 DRUGINFO D0J4AZ L-piperazino-3-phenyl-indane derivative 1 Patented T93430 TARGETID T93430 T93430 FORMERID TTDI01708 T93430 TARGNAME ATP-binding cassette transporter (ABCA) T93430 TARGTYPE Clinical trial T93430 BIOCLASS ABC transporter T93430 DRUGINFO D06RIM LIM-0705 Phase 2 T61484 TARGETID T61484 T61484 FORMERID TTDI01946 T61484 TARGNAME Chymotrypsin (CTR) T61484 TARGTYPE Clinical trial T61484 BIOCLASS Peptidase T61484 DRUGINFO D0A5DJ Pancrecarb NDA filed T61484 DRUGINFO D0Q9HM CM-AT Phase 3 T61484 DRUGINFO D0T9LR Liprotamase Phase 3 T61484 DRUGINFO D08SMN POP-1 Investigative T61484 DRUGINFO D0JR9V JBP-1 Investigative T20474 TARGETID T20474 T20474 FORMERID TTDR00142 T20474 TARGNAME DNA topoisomerase (TOP) T20474 TARGTYPE Clinical trial T20474 DRUGINFO D02CZK Karenitecin Phase 3 T20474 DRUGINFO D09XUY Icofungipen Phase 2 T20474 DRUGINFO D02GNX N*4*-Benzyl-6-chloro-pyrimidine-2,4-diamine Investigative T20474 DRUGINFO D07ZFN 5-Bromo-6-p-tolylamino-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0A6LX 6-Benzylamino-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0AW7G 6-(3-Bromo-phenylamino)-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0C1VA 6-(Indan-5-ylamino)-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0D0DV 6-Benzylamino-5-bromo-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0G2RY 2-Amino-6-(indan-5-ylamino)-3H-pyrimidin-4-one Investigative T20474 DRUGINFO D0KN0K 6-Benzylamino-5-iodo-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0M9JU 6-(Naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0NW9G 3-(9-Acridinylamino)-5-(hydroxymethyl)aniline (AHMA) Investigative T20474 DRUGINFO D0QH5P 6-(3-Iodo-phenylamino)-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0X6LS 6-p-Tolylamino-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0H6VK 6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione Investigative T20474 DRUGINFO D0L8BN TOPOSTATIN Investigative T68315 TARGETID T68315 T68315 FORMERID TTDR01207 T68315 TARGNAME Endothelin receptor (EDNR) T68315 TARGTYPE Clinical trial T68315 SYNONYMS Human endothelin receptor T68315 DRUGINFO D0H2RJ Clazosentan Phase 3 T68315 DRUGINFO D0QG1B Aprocitentan Phase 2 T68315 DRUGINFO D0P0DT TAK-044 Discontinued in Phase 2 T68315 DRUGINFO D0J5HU Ro-46-2005 Terminated T70071 TARGETID T70071 T70071 FORMERID TTDR00416 T70071 TARGNAME Endothelin-converting enzyme (ECE) T70071 TARGTYPE Clinical trial T70071 SYNONYMS Endothelin converting enzyme T70071 DRUGINFO D01HDP SLV 306 Phase 2 T70071 DRUGINFO D03CPM SLV-334 Phase 2 T70071 DRUGINFO D00CLC SLV-338 Phase 1 T70071 DRUGINFO D08GQK WS-75624B Terminated T70071 DRUGINFO D0M3JI SM-19712 Terminated T70071 DRUGINFO D09NAJ Phosphoramidon Investigative T84472 TARGETID T84472 T84472 TARGNAME Geranylgeranyl transferase (GGTase) T84472 TARGTYPE Clinical trial T84472 SYNONYMS Geranylgeranyltransferase T84472 DRUGINFO D0NX0S PTX-100 Phase 1 T03963 TARGETID T03963 T03963 FORMERID TTDI01291 T03963 TARGNAME Heat shock protein 90 (HSP90) T03963 TARGTYPE Clinical trial T03963 BIOCLASS Heat shock protein T03963 DRUGINFO D0N9AD RNS-60 Phase 2 T03963 DRUGINFO D1FH8R ADX-1612 Phase 1 T03963 DRUGINFO D20IMG LAM-003 Phase 1 T03963 DRUGINFO DWOY01 RTA 901 Phase 1 T37308 TARGETID T37308 T37308 FORMERID TTDS00132 T37308 TARGNAME Immunoglobulin E (IgE) T37308 TARGTYPE Clinical trial T37308 SYNONYMS IgE T37308 DRUGINFO DS4U1W Ligelizumab Phase 3 T37308 DRUGINFO D01LSB MEMP1972A Phase 2 T37308 DRUGINFO D0JQ4S Xmab-7195 Phase 1 T37308 DRUGINFO D0K2HU PF-06444752 Phase 1 T37308 DRUGINFO D0O5CV MEDI4212 Phase 1 T37308 DRUGINFO D0P9YP AVP-13358 Phase 1 T37308 DRUGINFO D01IYQ TAK-201 Discontinued in Phase 2 T37308 DRUGINFO D0C3TE TEI-9874 Terminated T37308 DRUGINFO D0X7YC IGE-026 Terminated T37308 DRUGINFO D03ILU D17.4 Investigative T37308 DRUGINFO D0T7XO IGEL1.2 Investigative T73671 TARGETID T73671 T73671 FORMERID TTDI01664 T73671 TARGNAME Interferon (IFN) T73671 TARGTYPE Clinical trial T73671 SYNONYMS Interferon protein T73671 DRUGINFO D0G1RM Interferon Phase 2 T59735 TARGETID T59735 T59735 FORMERID TTDI01567 T59735 TARGNAME Interferon receptor (IFNR) T59735 TARGTYPE Clinical trial T59735 SYNONYMS Interferon receptor T59735 DRUGINFO D05DQR HDV-interferon Phase 2 T59735 DRUGINFO D0O4NJ Z-100 Phase 1 T59735 DRUGINFO D07RPR Bropirimine Discontinued in Phase 3 T59735 DRUGINFO D0M9FT Omniferon Terminated T83103 TARGETID T83103 T83103 FORMERID TTDI01712 T83103 TARGNAME Interleukin (IL) T83103 TARGTYPE Clinical trial T83103 SYNONYMS Interleukin T83103 DRUGINFO D06NXG PF-04236921 Phase 2 T29649 TARGETID T29649 T29649 FORMERID TTDI01555 T29649 TARGNAME Leukotriene receptor (LTR) T29649 TARGTYPE Clinical trial T29649 SYNONYMS Human leukotriene receptor T29649 DRUGINFO D00MHP SR-2640 Phase 2 T29649 DRUGINFO D08ZKJ Ontazolast Phase 2 T29649 DRUGINFO D0S2UR PIRODOMAST Phase 2 T29649 DRUGINFO D0MA0F WF-11605 Phase 1 T29649 DRUGINFO D00AKY SK&F-S-106203 Discontinued in Phase 2 T29649 DRUGINFO D0E6UD FK-664 Discontinued in Phase 2 T29649 DRUGINFO D00WWU SMP-028 Discontinued in Phase 1 T29649 DRUGINFO D02ANJ NZ-107 Discontinued in Phase 1 T29649 DRUGINFO D0GB3A ABT-080 Discontinued in Phase 1 T29649 DRUGINFO D0Y3RN BAY-Y-1015 Discontinued in Phase 1 T29649 DRUGINFO D05JQF Tipredane Terminated T29649 DRUGINFO D0J7UI ICI-198615 Terminated T29649 DRUGINFO D0C7LA MAR--99 Investigative T71167 TARGETID T71167 T71167 TARGNAME Oxysterols receptor LXR (NR1H) T71167 TARGTYPE Clinical trial T71167 BIOCLASS Nuclear hormone receptor T71167 DRUGINFO D0CT5O ALX-101 Phase 2 T71167 DRUGINFO D0YZ1Q RGX-104 Phase 1/2 T71167 DRUGINFO D00QWU BMS-779788 Phase 1 T71167 DRUGINFO D0GY1Y CS-8080 Phase 1 T71167 DRUGINFO D0H4DR BMS-852927 Phase 1 T71167 DRUGINFO D0L0DZ XL-041 Phase 1 T71167 DRUGINFO D0O5XJ XL652/XL014 Phase 1 T71167 DRUGINFO D0R4EN LXR 623 Phase 1 T71167 DRUGINFO D0B5FC T0901317 Investigative T77534 TARGETID T77534 T77534 FORMERID TTDI01761 T77534 TARGNAME Phospholipase C (PLC) T77534 TARGTYPE Clinical trial T77534 BIOCLASS Phosphoric diester hydrolase T77534 DRUGINFO D0J7ML D-20133 Phase 1 T77534 DRUGINFO D01NNL Phosphonate Terminated T78874 TARGETID T78874 T78874 FORMERID TTDR01081 T78874 TARGNAME Protein kinase (PK) T78874 TARGTYPE Clinical trial T78874 BIOCLASS Kinase T78874 DRUGINFO D05BLN MGCD516 Phase 2/3 T78874 DRUGINFO D0A5HC RV-568 Phase 2 T78874 DRUGINFO D06EGV LY2801653 Phase 2 T78874 DRUGINFO D08FDX MGCD265 Phase 2 T78874 DRUGINFO D0S7HM ENMD-2076 Phase 2 T78874 DRUGINFO D09XZL LX-7101 Phase 1/2 T78874 DRUGINFO D0P0KN TG02 Phase 1/2 T78874 DRUGINFO D0Z8LA Cyclocreatine Discontinued in Phase 1 T31458 TARGETID T31458 T31458 FORMERID TTDI01313 T31458 TARGNAME Pyruvate kinase (PK) T31458 TARGTYPE Clinical trial T31458 BIOCLASS Kinase T31458 DRUGINFO D5U4MY Etavopivat Phase 2/3 T31458 DRUGINFO D08WHX AGS-348 Phase 1 T95289 TARGETID T95289 T95289 TARGNAME Retinoic acid receptor RXR (RXR) T95289 TARGTYPE Clinical trial T95289 SYNONYMS RXR T95289 DRUGINFO D09DJC IRX4204 Phase 1 T95289 DRUGINFO D0T3DO IRX-5183 Phase 1 T93092 TARGETID T93092 T93092 TARGNAME Serine/threonine PP2A (PP2A) T93092 TARGTYPE Clinical trial T93092 SYNONYMS PP2A T93092 DRUGINFO D02RNR LB-100 Phase 2 T54378 TARGETID T54378 T54378 FORMERID TTDI01827 T54378 TARGNAME TRAIL receptor (TRAIL-R) T54378 TARGTYPE Clinical trial T54378 FUNCTION Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADDrecruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF- kappa-B. T45083 TARGETID T45083 T45083 FORMERID TTDI01792 T45083 TARGNAME Tryptophan 5-hydroxylase (TPH) T45083 TARGTYPE Clinical trial T45083 BIOCLASS Paired donor oxygen oxidoreductase T45083 DRUGINFO D0H9WR LX-1031 Phase 2 T97701 TARGETID T97701 T97701 TARGNAME Voltage-gated T-type calcium channel (T-CaC) T97701 TARGTYPE Clinical trial T97701 BIOCLASS Voltage-gated ion channel T97701 DRUGINFO D0A0YQ CX-8998 Phase 2 T66514 TARGETID T66514 T66514 FORMERID TTDI01677 T66514 TARGNAME Carbohydrate antigen Lewis-Y (Lewis-Y) T66514 TARGTYPE Clinical trial T66514 SYNONYMS Lewis-Y carbohydrate antigen; Lewis-Y T66514 DRUGINFO D04RDW CAR-T cells targeting Lewis-Y Phase 1 T66514 DRUGINFO D08QJD IGN-311 Terminated T15867 TARGETID T15867 T15867 TARGNAME Gastric carcinoma-associated antigen MG7 (MG7) T15867 TARGTYPE Clinical trial T15867 SYNONYMS MG7-Ag T15867 DRUGINFO D0Q5GK MG7-CART Phase 1/2 T31299 TARGETID T31299 T31299 TARGNAME HLA-A02/AFP complex (HLA-A02/AFP) T31299 TARGTYPE Clinical trial T31299 SYNONYMS HLA-A2/AFP complex T31299 DRUGINFO D09TGO Autologous ET1402L1-CART cells Phase 1 T60628 TARGETID T60628 T60628 FORMERID TTDI02098 T60628 TARGNAME Kappa myeloma antigen (KMA) T60628 TARGTYPE Clinical trial T60628 BIOCLASS Kappa myeloma antigen T60628 DRUGINFO D0G6EB MDX-1097 Phase 2 T39031 TARGETID T39031 T39031 FORMERID TTDI02144 T39031 TARGNAME Tumor antigen NGcGM3 (NGcGM3) T39031 TARGTYPE Clinical trial T39031 SYNONYMS Tumor antigen N-glycolyl-GM3 T39031 DRUGINFO D08ECW Racotumomab Phase 2 T02598 TARGETID T02598 T02598 FORMERID TTDI01310 T02598 TARGNAME Leukocyte (WBC) T02598 TARGTYPE Clinical trial T02598 SYNONYMS Human leukocyte T02598 DRUGINFO D01KGP IPL 550,260 Phase 1 T01232 TARGETID T01232 T01232 FORMERID TTDI01328 T01232 TARGNAME T-cells (T-cells) T01232 TARGTYPE Clinical trial T01232 SYNONYMS T cells T01232 DRUGINFO D0O0QB ATG-Fresenius S Phase 3 T01232 DRUGINFO D04BOK DiabeCell Phase 2 T01232 DRUGINFO D0JH5K TVI-Kidney-1 Phase 2 T01232 DRUGINFO D0WK1M Baltaleucel-T Phase 2 T01232 DRUGINFO D0X6EM T2c-001 Phase 2 T01232 DRUGINFO D06LYI BPX-501 Phase 1/2 T01232 DRUGINFO D0M1DG RTL-1000 Phase 1 T01232 DRUGINFO D00JDJ AX-024 Phase 1 T45516 TARGETID T45516 T45516 FORMERID TTDI01178 T45516 TARGNAME Cyclin D1 synthesis (CCND1 synthesis) T45516 TARGTYPE Clinical trial T45516 SYNONYMS Cyclin D1 biosynthesis T45516 DRUGINFO D0KW3Z GORALATIDE Phase 2 T22608 TARGETID T22608 T22608 FORMERID TTDI01843 T22608 TARGNAME TNF alpha production (TNFA produ) T22608 TARGTYPE Clinical trial T22608 SYNONYMS Tumor necrosis factor alpha production T22608 DRUGINFO D00ICD SH-529 Phase 2 T29075 TARGETID T29075 T29075 TARGNAME TNF-alpha signaling pathway (TNFA pathway) T29075 TARGTYPE Clinical trial T29075 BIOCLASS Viral DNA polymerase T29075 DRUGINFO D05UJS ADVAX Phase 1 T65054 TARGETID T65054 T65054 FORMERID TTDR00658 T65054 TARGNAME Actin (ACT) T65054 TARGTYPE Clinical trial T65054 DRUGINFO D0P6JD RGN-259 Phase 2 T08743 TARGETID T08743 T08743 FORMERID TTDI01635 T08743 TARGNAME Aminopeptidase (AMP) T08743 TARGTYPE Clinical trial T08743 DRUGINFO D0F2JS CHR-2797 Phase 2 T49571 TARGETID T49571 T49571 FORMERID TTDI01614 T49571 TARGNAME Aminotransferase (AT) T49571 TARGTYPE Clinical trial T49571 DRUGINFO D00AKV F-351 Phase 2 T04389 TARGETID T04389 T04389 FORMERID TTDI01568 T04389 TARGNAME ATP phosphatase (ATPase) T04389 TARGTYPE Clinical trial T04389 DRUGINFO D07KIE LYC-30937 Phase 2 T04389 DRUGINFO D09PGM BY-1949 Discontinued in Phase 2 T04389 DRUGINFO D0IX7G FR-76830 Terminated T84894 TARGETID T84894 T84894 FORMERID TTDI03085 T84894 TARGNAME Casein kinase II (CSNK2) T84894 TARGTYPE Clinical trial T84894 DRUGINFO D0IQ1V CIGB-300 Phase 3 T84894 DRUGINFO D09JEJ CX-4945 Phase 2 T84894 DRUGINFO D06KDU Tetrabromocinnamic acid Investigative T68039 TARGETID T68039 T68039 FORMERID TTDI01581 T68039 TARGNAME Cell adhesion molecule (CADM) T68039 TARGTYPE Clinical trial T68039 DRUGINFO D0L0DA PRX003 Phase 1 T68039 DRUGINFO D0G7YG ABX-MA1 Discontinued in Phase 1 T68039 DRUGINFO D05GBZ ABS-205 Terminated T68039 DRUGINFO D0J1RH CY-1748 Terminated T68039 DRUGINFO D0JS4E ICM-3 Terminated T68039 DRUGINFO D0T2DL GM-7050 Terminated T68039 DRUGINFO D0U3OY Rovelizumab Terminated T68039 DRUGINFO D0Z3AK NPC-17923 Terminated T78383 TARGETID T78383 T78383 FORMERID TTDI01721 T78383 TARGNAME Chemosensory receptor (CheR) T78383 TARGTYPE Clinical trial T78383 DRUGINFO D0F7IG PH10 nasal spray Phase 2 T51209 TARGETID T51209 T51209 FORMERID TTDI01275 T51209 TARGNAME Clostridium difficile Toxin (CD tox) T51209 TARGTYPE Clinical trial T87946 TARGETID T87946 T87946 FORMERID TTDI01559 T87946 TARGNAME Cytokine receptor unspecific (CRF) T87946 TARGTYPE Clinical trial T87946 DRUGINFO D03YKQ AD-452 Phase 2 T87946 DRUGINFO D0KS6F IRX-2 Phase 2 T87946 DRUGINFO D0E6FO JTE-607 Discontinued in Phase 2 T87946 DRUGINFO D0Y8IS VP-025 Discontinued in Phase 1 T87946 DRUGINFO D02WEL VG-106 Terminated T93703 TARGETID T93703 T93703 FORMERID TTDR00437 T93703 TARGNAME Cytokine unspecific (CYK) T93703 TARGTYPE Clinical trial T93703 DRUGINFO D0V4XL BMEC-1217B Phase 1 T93703 DRUGINFO D0W6YR PF-06817024 Phase 1 T64376 TARGETID T64376 T64376 FORMERID TTDI01740 T64376 TARGNAME Fibroblast growth factor (FGF) T64376 TARGTYPE Clinical trial T64376 DRUGINFO D07WTG Recombinant acidic fibroblast growth factor Phase 3 T64376 DRUGINFO D0P0LT GSK3052230 Phase 1 T27106 TARGETID T27106 T27106 FORMERID TTDI01175 T27106 TARGNAME FK506-binding protein (FKBP) T27106 TARGTYPE Clinical trial T27106 DRUGINFO D0SL8J Ascrolimus Phase 2 T27106 DRUGINFO D0VT2C FK-505 Phase 2 T27106 DRUGINFO D0F6TV Timcodar dimesilate Phase 1/2 T27106 DRUGINFO D0ML9K T-506 Discontinued in Phase 2 T96747 TARGETID T96747 T96747 FORMERID TTDI01706 T96747 TARGNAME Galactosyltransferase (GALT) T96747 TARGTYPE Clinical trial T96747 DRUGINFO D00HSK Algenpantucel-L Phase 3 T06320 TARGETID T06320 T06320 FORMERID TTDI01239 T06320 TARGNAME Galectin (LGALS) T06320 TARGTYPE Clinical trial T06320 DRUGINFO D0JW0V GCS-100 Phase 2 T87742 TARGETID T87742 T87742 FORMERID TTDI01602 T87742 TARGNAME Gap junction protein (GJP) T87742 TARGTYPE Clinical trial T87742 DRUGINFO D0C4QN ROTIGAPTIDE Phase 2 T87742 DRUGINFO D0KQ0C Danegaptide Phase 2 T67310 TARGETID T67310 T67310 FORMERID TTDI01582 T67310 TARGNAME Glutamate receptor ionotropic (GRI) T67310 TARGTYPE Clinical trial T67310 DRUGINFO D02QZR LY-545694 Phase 2 T67310 DRUGINFO D0A2IK NPS-846 Terminated T93368 TARGETID T93368 T93368 FORMERID TTDI01638 T93368 TARGNAME Haemophilus influenzae Outer membrane protein (Hae-influ OMP) T93368 TARGTYPE Clinical trial T55643 TARGETID T55643 T55643 FORMERID TTDI01415 T55643 TARGNAME Heat shock protein (HSP) T55643 TARGTYPE Clinical trial T55643 DRUGINFO D0F2PD Arimoclomol Phase 2/3 T55643 DRUGINFO D08QYS Heat shock protein vaccine Phase 2 T38763 TARGETID T38763 T38763 FORMERID TTDI01630 T38763 TARGNAME Hepatitis C virus Non-structural 5 (HCV NS5) T38763 TARGTYPE Clinical trial T38763 DRUGINFO D0SY7H IDX-184 Phase 1/2 T49689 TARGETID T49689 T49689 FORMERID TTDI01731 T49689 TARGNAME Immunoglobulin G1k (IgG1k) T49689 TARGTYPE Clinical trial T49689 DRUGINFO D0D5LX NKTT-120 Phase 1 T55012 TARGETID T55012 T55012 FORMERID TTDI01612 T55012 TARGNAME Ion channel unspecific (IC) T55012 TARGTYPE Clinical trial T55012 DRUGINFO D01WLB Lu-AA39959 Phase 2 T55012 DRUGINFO D04TGF AZD-2927 Phase 2 T55012 DRUGINFO D0N1TH ATI-2042 Phase 2 T55012 DRUGINFO D06VPE Lu-AA38466 Discontinued in Phase 1 T55012 DRUGINFO D0F7LE AZD-0902 Terminated T10339 TARGETID T10339 T10339 FORMERID TTDI01597 T10339 TARGNAME Lipoxygenase (ALOX) T10339 TARGTYPE Clinical trial T10339 DRUGINFO D0B6VN TZI-41078 Phase 2 T10339 DRUGINFO D0G6PG CPA-926 Discontinued in Phase 2 T10339 DRUGINFO D0T8VV FLM-5011 Discontinued in Phase 1 T11069 TARGETID T11069 T11069 FORMERID TTDI01593 T11069 TARGNAME Lyase unspecific (LYA) T11069 TARGTYPE Clinical trial T11069 DRUGINFO D0D2LF YM-116 Phase 1 T28481 TARGETID T28481 T28481 FORMERID TTDI01626 T28481 TARGNAME Lysosphingolipid receptor (LSPR) T28481 TARGTYPE Clinical trial T28481 DRUGINFO D0UR4K Cenerimod Phase 2 T88537 TARGETID T88537 T88537 TARGNAME Mitochondrial protein unspecific (MP) T88537 TARGTYPE Clinical trial T88537 DRUGINFO D00SWQ Mitoglitazone Phase 2 T88537 DRUGINFO D05TPI EPICATECHIN Phase 1/2 T80452 TARGETID T80452 T80452 FORMERID TTDI01556 T80452 TARGNAME Mucin (MUC) T80452 TARGTYPE Clinical trial T80452 DRUGINFO D02HRD KLS-0611 Phase 2 T80452 DRUGINFO D0D6ZK 15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon Discontinued in Phase 3 T47891 TARGETID T47891 T47891 FORMERID TTDI01718 T47891 TARGNAME Natural killer cell receptor (NKCR) T47891 TARGTYPE Clinical trial T47891 DRUGINFO D0U4SM NASVAC Phase 3 T29815 TARGETID T29815 T29815 FORMERID TTDI01704 T29815 TARGNAME Neoplasm antigen (NA) T29815 TARGTYPE Clinical trial T29815 DRUGINFO D0T2FC NPC-1C Phase 2 T14056 TARGETID T14056 T14056 TARGNAME Netrin (NET) T14056 TARGTYPE Clinical trial T14056 DRUGINFO D0U1MO CERE-120 Phase 2 T37405 TARGETID T37405 T37405 FORMERID TTDI01631 T37405 TARGNAME Neuropeptide receptor (NPR) T37405 TARGTYPE Clinical trial T21351 TARGETID T21351 T21351 FORMERID TTDI01600 T21351 TARGNAME Nuclear receptor unspecific (NR) T21351 TARGTYPE Clinical trial T21351 DRUGINFO D0H9YO FLUASTERONE Phase 2 T02221 TARGETID T02221 T02221 FORMERID TTDI01665 T02221 TARGNAME Nucleoside DNA polymerase (DPOL) T02221 TARGTYPE Clinical trial T13910 TARGETID T13910 T13910 FORMERID TTDI01705 T13910 TARGNAME Phosphofructokinase 2 (PFK2) T13910 TARGTYPE Clinical trial T13910 DRUGINFO D0N4VN INGAP peptide Phase 2 T28746 TARGETID T28746 T28746 FORMERID TTDNS00552 T28746 TARGNAME Protein kinase unspecific (PK) T28746 TARGTYPE Clinical trial T28746 DRUGINFO D0Q0AP BMS-582949 Phase 2 T93026 TARGETID T93026 T93026 TARGNAME Quinone reductase (NQO) T93026 TARGTYPE Clinical trial T93026 DRUGINFO D09XJF EPI 589 Phase 2 T09937 TARGETID T09937 T09937 FORMERID TTDI01650 T09937 TARGNAME Receptor unspecific (Rec) T09937 TARGTYPE Clinical trial T09937 DRUGINFO D04XBU ATL-104 Phase 2 T09937 DRUGINFO D0UK1Q Prosaptide TX14(A) Phase 2 T09937 DRUGINFO D06ZHN Lactermin Phase 1 T09937 DRUGINFO D0F9TL BT-063 Phase 1 T09937 DRUGINFO D0N7ML PV-707 Discontinued in Phase 2 T09937 DRUGINFO D0YB6P YP-004 Terminated T40663 TARGETID T40663 T40663 FORMERID TTDI01653 T40663 TARGNAME Regulatory protein unspecific (RGP) T40663 TARGTYPE Clinical trial T40663 DRUGINFO D0OH8W Visilizumab Phase 3 T40663 DRUGINFO D0R8LV NI-0401 Phase 1/2 T40663 DRUGINFO D06ZZL MEDI-500 Terminated T50461 TARGETID T50461 T50461 FORMERID TTDI01632 T50461 TARGNAME Ribonuclease (RNase) T50461 TARGTYPE Clinical trial T50461 DRUGINFO D0B8ZR NTO-1151 Phase 2 T50461 DRUGINFO D0I8QJ Ranpirnase Phase 2 T50461 DRUGINFO D06FZH MazF gene therapy Phase 1 T50461 DRUGINFO D0W1YM AS-1406 Terminated T11164 TARGETID T11164 T11164 TARGNAME Secretory phospholipase A2 (sPLA2) T11164 TARGTYPE Clinical trial T11164 DRUGINFO D07KFB Varespladib methyl Phase 3 T95379 TARGETID T95379 T95379 TARGNAME Selectin (SEL) T95379 TARGTYPE Clinical trial T95379 DRUGINFO D0N4EO GMI-1070 Phase 3 T97553 TARGETID T97553 T97553 TARGNAME Serine/threonine-protein kinase (STK) T97553 TARGTYPE Clinical trial T97553 DRUGINFO D0L9XF BBI503 Phase 2 T26220 TARGETID T26220 T26220 TARGNAME Somatostatin receptor (SSTR) T26220 TARGTYPE Clinical trial T26220 DRUGINFO D02ZHW 177Lu-DOTA-octreotate Phase 3 T26220 DRUGINFO DQP87H 177-Lu-oxodotreotide Phase 3 T26220 DRUGINFO D08YNI Somatoprim Phase 2 T26220 DRUGINFO D0J8PI Edotreotide Phase 2 T26220 DRUGINFO D0O3TC FK-962 Phase 2 T26220 DRUGINFO D0M5VV 177Lu-DOTATATE Phase 2 T26220 DRUGINFO DP85ES 177Lu-labelled DOTA-JR11 Phase 1/2 T26220 DRUGINFO D0OV2F 212Pb-labelled DOTAMTATE Phase 1 T26220 DRUGINFO DDV8H5 AlphaMedix Phase 1 T26220 DRUGINFO D00RMD FK-960 Discontinued in Phase 2 T26220 DRUGINFO D09JXL SEGLITIDE Discontinued in Phase 2 T26220 DRUGINFO D0M4LW BIM-23268 Discontinued in Phase 2 T26220 DRUGINFO D0WS8K Ilatreotide Investigative T82494 TARGETID T82494 T82494 FORMERID TTDI01634 T82494 TARGNAME T-cell receptor (TCR) T82494 TARGTYPE Clinical trial T82494 DRUGINFO D0T3CH RGI-2001 Phase 2 T82494 DRUGINFO D0Z1CZ IR502 Phase 2 T82494 DRUGINFO DF6Z3C SAR444200 Phase 2 T82494 DRUGINFO D07AKD TOL-101 Phase 1/2 T82494 DRUGINFO D0L1CO MAGE-A10 TCR Phase 1/2 T82494 DRUGINFO D0TN1N NY-ESO-TCR Phase 1/2 T82494 DRUGINFO D0M1MN AFP TCR Phase 1 T82494 DRUGINFO D0ZA1K BPX-701 Phase 1 T20059 TARGETID T20059 T20059 TARGNAME TGF-beta receptor (TGFBR) T20059 TARGTYPE Clinical trial T20059 DRUGINFO D0P0TA GC-1008 Phase 1 T43760 TARGETID T43760 T43760 FORMERID TTDR00272 T43760 TARGNAME Thyroid hormone receptor (THR) T43760 TARGTYPE Clinical trial T43760 DRUGINFO D01QXY B7-2/GM-CSF Phase 1 T43760 DRUGINFO D0V1GK KB-5359 Terminated T43760 DRUGINFO D09WBM GC-14 Investigative T43760 DRUGINFO D0A5XG NH-3 Investigative T43760 DRUGINFO D0E2IR NH-4 Investigative T43760 DRUGINFO D0R2QS Neplanocin A Investigative T70227 TARGETID T70227 T70227 FORMERID TTDI01619 T70227 TARGNAME Transcription factor unspecific (TF) T70227 TARGTYPE Clinical trial T70227 DRUGINFO D0CN8U PF-06763809 Phase 1 T21701 TARGETID T21701 T21701 FORMERID TTDI01405 T21701 TARGNAME Transforming protein Rho (RHO) T21701 TARGTYPE Clinical trial T21701 DRUGINFO D0O9EQ VX-210 Phase 2/3 T49578 TARGETID T49578 T49578 FORMERID TTDI01350 T49578 TARGNAME Transient receptor potential channel (TRP channel) T49578 TARGTYPE Clinical trial T49578 DRUGINFO D0TI3R FLX-787 Phase 2 T49578 DRUGINFO D0D6MC HC-030031 Investigative T00100 TARGETID T00100 T00100 FORMERID TTDI01666 T00100 TARGNAME Ubiquitin-activating enzyme (UBA) T00100 TARGTYPE Clinical trial T00100 DRUGINFO D0T4PA TAK-243 Phase 1 T00100 DRUGINFO D0Z0FA MLN7243 Phase 1 T96299 TARGETID T96299 T96299 FORMERID TTDI01553 T96299 TARGNAME Wnt protein (WNT) T96299 TARGTYPE Clinical trial T96299 DRUGINFO D0Z6AM Ipafricept Phase 1 T96299 DRUGINFO D02LUP RN-1005 Terminated T15639 TARGETID T15639 T15639 FORMERID TTDI01657 T15639 TARGNAME Zinc finger protein (ZNF) T15639 TARGTYPE Clinical trial T15639 DRUGINFO D01PHK PCL-016 Phase 2 T64721 TARGETID T64721 T64721 FORMERID TTDI01636 T64721 TARGNAME Cancer stemness kinase (CSK) T64721 TARGTYPE Clinical trial T64721 DRUGINFO D0L9XF BBI503 Phase 2 T30383 TARGETID T30383 T30383 FORMERID TTDNC00508 T30383 TARGNAME Endogenous gut peptide (EGP) T30383 TARGTYPE Clinical trial T30383 DRUGINFO D09AGG GSK2890457 Phase 2 T96257 TARGETID T96257 T96257 FORMERID TTDI01246 T96257 TARGNAME Haemophilus influenzae CRM197 (Hae-influ CRM197) T96257 TARGTYPE Clinical trial T96257 DRUGINFO D09RMZ HibTITER Phase 2 T96257 DRUGINFO D0R0GK NU300 Phase 2 T94493 TARGETID T94493 T94493 FORMERID TTDI01651 T94493 TARGNAME Human immunodeficiency virus Adenovector Ad35 (HIV Ad35) T94493 TARGTYPE Clinical trial T94493 DRUGINFO D0H5KA VRC-HIVDNA016-00-VP Phase 2 T22778 TARGETID T22778 T22778 FORMERID TTDI01596 T22778 TARGNAME Intracellular nitroreductase (INR) T22778 TARGTYPE Clinical trial T22778 DRUGINFO D0Z3LC SR-4554 Phase 1 T79422 TARGETID T79422 T79422 FORMERID TTDC00323 T79422 TARGNAME M1-prime segment of membrane-expressed IgE (M1 IgE) T79422 TARGTYPE Clinical trial T79422 DRUGINFO D04CWS Anti-M1 prime Phase 2 T61052 TARGETID T61052 T61052 FORMERID TTDI01289 T61052 TARGNAME Neuroepithelial receptor (NR) T61052 TARGTYPE Clinical trial T61052 DRUGINFO D04FQD PH-80 Phase 3 T33275 TARGETID T33275 T33275 FORMERID TTDI01683 T33275 TARGNAME Tuftsin receptor (TR) T33275 TARGTYPE Clinical trial T33275 DRUGINFO D00QOJ 99mTc-RP-128 Phase 2 T19829 TARGETID T19829 T19829 FORMERID TTDI01236 T19829 TARGNAME Helper-inducer T-lymphocyte (HITL) T19829 TARGTYPE Clinical trial T33629 TARGETID T33629 T33629 FORMERID TTDI01830 T33629 TARGNAME Prostate cance cell (PCC) T33629 TARGTYPE Clinical trial T33629 DRUGINFO D0N3IA HE3235 Phase 2 T58184 TARGETID T58184 T58184 FORMERID TTDI01700 T58184 TARGNAME Ribosome (hRBS) T58184 TARGTYPE Clinical trial T58184 DRUGINFO D18ATS ELX-02 Phase 2 T58184 DRUGINFO D01NSM TST-10088 Phase 1 T07601 TARGETID T07601 T07601 FORMERID TTDR00122 T07601 UNIPROID CAMLG_HUMAN T07601 TARGNAME Calcium signal-modulating cyclophilin ligand (CAML) T07601 GENENAME CAMLG; CAML T07601 TARGTYPE Clinical trial T07601 SYNONYMS cyclophilin T07601 FUNCTION Likely involved in the mobilization of calcium as a result of the TCR/CD3 complex interaction. Binds to cyclophilin B. T07601 SEQUENCE MESMAVATDGGERPGVPAGSGLSASQRRAELRRRKLLMNSEQRINRIMGFHRPGSGAEEESQTKSKQQDSDKLNSLSVPSVSKRVVLGDSVSTGTTDQQGGVAEVKGTQLGDKLDSFIKPPECSSDVNLELRQRNRGDLTADSVQRGSRHGLEQYLSRFEEAMKLRKQLISEKPSQEDGNTTEEFDSFRIFRLVGCALLALGVRAFVCKYLSIFAPFLTLQLAYMGLYKYFPKSEKKIKTTVLTAALLLSGIPAEVINRSMDTYSKMGEVFTDLCVYFFTFIFCHELLDYWGSEVP T07601 DRUGINFO D0CE0O Alisporivir Phase 3 T07601 DRUGINFO D02EEJ SCY-635 Phase 2 T07601 DRUGINFO D0TP7T SCY-641 Preclinical T07601 DRUGINFO D00CEG D-43787 Terminated T74437 TARGETID T74437 T74437 FORMERID TTDI01566 T74437 TARGNAME Actin polymerization (Actin poly) T74437 TARGTYPE Clinical trial T74437 DRUGINFO D0DJ4A Preverex Phase 2 T62166 TARGETID T62166 T62166 FORMERID TTDI01147 T62166 TARGNAME Adenine synthesis (Adeni synth) T62166 TARGTYPE Clinical trial T62166 DRUGINFO D02ELS L-alanosine Phase 2 T45196 TARGETID T45196 T45196 FORMERID TTDNC00541 T45196 TARGNAME Angiogenesis (AGG) T45196 TARGTYPE Clinical trial T45196 DRUGINFO D00VUN TRX-818 Phase 1 T45196 DRUGINFO D0P4KU ABI-011 Phase 1 T40160 TARGETID T40160 T40160 FORMERID TTDI01196 T40160 TARGNAME Aryl hydrocarbon receptor signaling pathway (AhR pathway) T40160 TARGTYPE Clinical trial T40160 DRUGINFO D09HFS AFP464 Phase 2 T52534 TARGETID T52534 T52534 FORMERID TTDI01188 T52534 TARGNAME Bacterial Protein synthesis (Bact PROS) T52534 TARGTYPE Clinical trial T52534 DRUGINFO D00WZK BC-3781 intravenous Phase 2 T52534 DRUGINFO D0BW4W Sutezolid Phase 2 T52534 DRUGINFO D0W5PN Radezolid Phase 2 T76310 TARGETID T76310 T76310 FORMERID TTDI01160 T76310 TARGNAME Calcium release (Ca rele) T76310 TARGTYPE Clinical trial T76310 DRUGINFO D01ASM NPC-15199 Phase 2 T44008 TARGETID T44008 T44008 FORMERID TTDI01166 T44008 TARGNAME cAMP formation (cAMP form) T44008 TARGTYPE Clinical trial T44008 DRUGINFO D0Z3RF UCB-11056 Phase 2 T01358 TARGETID T01358 T01358 FORMERID TTDI01280 T01358 TARGNAME Cell cycle (CC) T01358 TARGTYPE Clinical trial T01358 DRUGINFO D08KPA BZL-101 Phase 2 T87237 TARGETID T87237 T87237 FORMERID TTDI01238 T87237 TARGNAME Cell differentiation (CD) T87237 TARGTYPE Clinical trial T87237 DRUGINFO D02BVW FF-10501-01 Phase 1/2 T59870 TARGETID T59870 T59870 FORMERID TTDNC00554 T59870 TARGNAME Cholesterol absorption (Chole absorp) T59870 TARGTYPE Clinical trial T59870 DRUGINFO D02UMF KT6-971 Phase 2 T59870 DRUGINFO D0O6RK MD-0727 Phase 2 T59870 DRUGINFO D04IME SCH-48461 Discontinued in Phase 2 T59870 DRUGINFO D0T1YN Tiqueside Discontinued in Phase 2 T67233 TARGETID T67233 T67233 FORMERID TTDI01609 T67233 TARGNAME Cholesterol uptake (Chole uptake) T67233 TARGTYPE Clinical trial T67233 DRUGINFO D0F4ZN PAMAQUESIDE Phase 3 T46658 TARGETID T46658 T46658 FORMERID TTDI01259 T46658 TARGNAME Eosinophil/lymphocyte-rich accumulation (ELR accum) T46658 TARGTYPE Clinical trial T46658 DRUGINFO D0Q9IY PNU-142731A Phase 2 T49040 TARGETID T49040 T49040 FORMERID TTDI01254 T49040 TARGNAME Glucose metabolism (Glucose metab) T49040 TARGTYPE Clinical trial T49040 DRUGINFO D01JMX INS-1 Phase 2 T30208 TARGETID T30208 T30208 FORMERID TTDI01264 T30208 TARGNAME Growth hormone secretion (GH secr) T30208 TARGTYPE Clinical trial T30208 DRUGINFO D0X9GE CIGB-500 Phase 1 T93485 TARGETID T93485 T93485 FORMERID TTDI01174 T93485 TARGNAME Hepatitis B virus Reverse transcriptase priming/DNA synthesis (HBV RTP/DS) T93485 TARGTYPE Clinical trial T93485 DRUGINFO D0QK5C ALAMIFOVIR Phase 1/2 T43902 TARGETID T43902 T43902 FORMERID TTDI01169 T43902 TARGNAME Histamine release (His rele) T43902 TARGTYPE Clinical trial T43902 DRUGINFO D07TAS CI-959 Phase 1 T43902 DRUGINFO D09ZPX HSR-6071 Discontinued in Phase 1 T10249 TARGETID T10249 T10249 FORMERID TTDI01162 T10249 TARGNAME Histamine/peptide leukotriene release (His/p-LT rele) T10249 TARGTYPE Clinical trial T10249 DRUGINFO D09YDO Quinotolast Phase 3 T99907 TARGETID T99907 T99907 FORMERID TTDI01240 T99907 TARGNAME Human immunodeficiency virus Maturation (HIV Mat) T99907 TARGTYPE Clinical trial T99907 DRUGINFO D0I2VW GSK2838232 Phase 2 T99907 DRUGINFO D0K5TE BMS-955176 Phase 2 T99907 DRUGINFO DB2U3O GSK3640254 Phase 2 T83335 TARGETID T83335 T83335 FORMERID TTDI01295 T83335 TARGNAME Human immunodeficiency virus Transmission (HIV Tran) T83335 TARGTYPE Clinical trial T83335 DRUGINFO D0ER8I Ushercell Phase 3 T33917 TARGETID T33917 T33917 FORMERID TTDI01209 T33917 TARGNAME Hydroxy radical elimination (HYRE) T33917 TARGTYPE Clinical trial T33917 DRUGINFO D07ZMQ HD-003 Phase 2 T07861 TARGETID T07861 T07861 FORMERID TTDI01156 T07861 TARGNAME IL-1 synthesis/release (IL-1 synth/rele) T07861 TARGTYPE Clinical trial T07861 DRUGINFO D00NVO Flezelastine Phase 2 T21312 TARGETID T21312 T21312 FORMERID TTDI01554 T21312 TARGNAME Immune checkpoint (ICH) T21312 TARGTYPE Clinical trial T21312 DRUGINFO D01HQU AK107 Phase 1 T21312 DRUGINFO D06MHZ NLG919 Phase 1 T53684 TARGETID T53684 T53684 FORMERID TTDI01292 T53684 TARGNAME Inflammation pathogenesis (IP) T53684 TARGTYPE Clinical trial T53684 DRUGINFO D0G6DF HMPL-004 Phase 3 T71479 TARGETID T71479 T71479 FORMERID TTDI01221 T71479 TARGNAME JAK-STAT signaling pathway (JAK-STAT pathway) T71479 TARGTYPE Clinical trial T71479 DRUGINFO D0IV4C WP-1066 Phase 1/2 T71479 DRUGINFO D0C3AA CKD-712 Phase 1 T71479 DRUGINFO D07PTU Imidazo[4,5-c]pyridine derivative 1 Patented T71479 DRUGINFO D09ALF Aminotriazolopyridine derivative 1 Patented T71479 DRUGINFO D0VJ1R Imidazo[4,5-c]pyridine derivative 2 Patented T71479 DRUGINFO D0YR8S PMID27774824-Compound-Figure11Example1up Patented T45596 TARGETID T45596 T45596 FORMERID TTDI01542 T45596 TARGNAME JNK signaling pathway (JNK pathway) T45596 TARGTYPE Clinical trial T45596 DRUGINFO D0B5RO REN-1654 Phase 2 T08383 TARGETID T08383 T08383 FORMERID TTDI01149 T08383 TARGNAME Ketogenesis (KG) T08383 TARGTYPE Clinical trial T08383 DRUGINFO D01IHR AC-1202 Phase 2 T27770 TARGETID T27770 T27770 FORMERID TTDI01297 T27770 TARGNAME Late inward sodium current (LISC) T27770 TARGTYPE Clinical trial T27770 DRUGINFO D0A4UC GS-6615 Phase 3 T15784 TARGETID T15784 T15784 FORMERID TTDI01215 T15784 TARGNAME Lipid peroxidation (LPO) T15784 TARGTYPE Clinical trial T15784 DRUGINFO D04GKL RAXOFELAST Phase 2 T15784 DRUGINFO D0E8HA T-817MA Phase 2 T15784 DRUGINFO D0G6ES TAK-218 Discontinued in Phase 2 T15784 DRUGINFO D0R0OC U-104067F Discontinued in Phase 1 T15784 DRUGINFO D0Q5II G009 Investigative T39554 TARGETID T39554 T39554 FORMERID TTDI01541 T39554 TARGNAME MAPK/ERK signaling pathway (MAPK pathway) T39554 TARGTYPE Clinical trial T39554 DRUGINFO D0B5RO REN-1654 Phase 2 T36846 TARGETID T36846 T36846 FORMERID TTDI01204 T36846 TARGNAME Mitochondrial function (MF) T36846 TARGTYPE Clinical trial T36846 DRUGINFO D01WZG Creatine ALS-08 Phase 3 T09347 TARGETID T09347 T09347 FORMERID TTDI01176 T09347 TARGNAME Neurotransmitter release (NT rele) T09347 TARGTYPE Clinical trial T09347 DRUGINFO D0N9KZ TN-871 Phase 2 T74402 TARGETID T74402 T74402 FORMERID TTDI01274 T74402 TARGNAME NF-kappa-B-p38 signaling pathway (NFKB-p38 pathway) T74402 TARGTYPE Clinical trial T74402 DRUGINFO D03QEB VGX-1027 Phase 1 T65731 TARGETID T65731 T65731 FORMERID TTDI01311 T65731 TARGNAME Nitric oxide elimination (NOE) T65731 TARGTYPE Clinical trial T65731 DRUGINFO D07ELT NOX-700 Phase 1 T36658 TARGETID T36658 T36658 FORMERID TTDI01201 T36658 TARGNAME Oxidative stress (OS) T36658 TARGTYPE Clinical trial T36658 DRUGINFO D0E7AS SUN-N8075 Phase 1 T36658 DRUGINFO D0L8OE AC3056 Discontinued in Phase 1 T04079 TARGETID T04079 T04079 FORMERID TTDI01187 T04079 TARGNAME Plasmodial phospholipid metabolism (PPP metab) T04079 TARGTYPE Clinical trial T04079 DRUGINFO D02ETY SAR97276 Phase 2 T04079 DRUGINFO D0R3XI CDRI-97/78 Phase 1 T65667 TARGETID T65667 T65667 FORMERID TTDI01598 T65667 TARGNAME PMN apoptosis and chemotaxis (PMNAC) T65667 TARGTYPE Clinical trial T65667 DRUGINFO D07ANO Synthetic neutrophil inhibitor peptide Phase 1 T77158 TARGETID T77158 T77158 FORMERID TTDI01308 T77158 TARGNAME Protein synthesis (hPRO synth) T77158 TARGTYPE Clinical trial T77158 DRUGINFO D0BE0Z Contezolid acefosamil Phase 2 T77158 DRUGINFO D0I2GS Contezolid Phase 2 T77158 DRUGINFO D36JFT ARV-1801 Phase 2 T77158 DRUGINFO D0T4OT Zilascorb (2H) Discontinued in Phase 2 T32456 TARGETID T32456 T32456 FORMERID TTDI01186 T32456 TARGNAME Second phase insulin secretion (SPI secr) T32456 TARGTYPE Clinical trial T32456 DRUGINFO D0X1VJ AGI-1067 Phase 3 T21617 TARGETID T21617 T21617 FORMERID TTDI01551 T21617 TARGNAME Signal transduction unspecific (ST) T21617 TARGTYPE Clinical trial T21617 DRUGINFO D0W5LC Forigerimod Phase 3 T21617 DRUGINFO D0J8AE OMN-54 Phase 1 T98015 TARGETID T98015 T98015 FORMERID TTDI01562 T98015 TARGNAME Sodium/potassium transport (Na/K trans) T98015 TARGTYPE Clinical trial T98015 DRUGINFO D05ZHA Alilusem Phase 3 T08769 TARGETID T08769 T08769 FORMERID TTDI01327 T08769 TARGNAME STAT3-Beta-catenin pathway (SBC pathway) T08769 TARGTYPE Clinical trial T80518 TARGETID T80518 T80518 TARGNAME Synaptic transmission (ST) T80518 TARGTYPE Clinical trial T80518 DRUGINFO D00YAH E2730 Phase 1 T58902 TARGETID T58902 T58902 FORMERID TTDI01298 T58902 TARGNAME Tau protein aggregation (TauA) T58902 TARGTYPE Clinical trial T58902 DRUGINFO D05XDZ LMT-X Phase 3 T49833 TARGETID T49833 T49833 FORMERID TTDI01290 T49833 TARGNAME TNF/IL-10 release (TNF/IL10 rele) T49833 TARGTYPE Clinical trial T49833 DRUGINFO D05DZA PUR-0110 Phase 2 T72182 TARGETID T72182 T72182 FORMERID TTDI01155 T72182 TARGNAME TNF-alpha/IL-1 beta production (TNFA/IL1B produ) T72182 TARGTYPE Clinical trial T72182 DRUGINFO D0MY7X Esonarimod Phase 3 T60136 TARGETID T60136 T60136 FORMERID TTDI01316 T60136 TARGNAME Trigeminal ganglion stimulation-induced response (TGSR) T60136 TARGTYPE Clinical trial T60136 DRUGINFO D05TLP Carabersat Phase 2 T08441 TARGETID T08441 T08441 FORMERID TTDI01234 T08441 TARGNAME Viral Maturation (VM) T08441 TARGTYPE Clinical trial T08441 DRUGINFO D0C5OK Drug 2838232 Phase 1 T97725 TARGETID T97725 T97725 TARGNAME Virus Replication (Viru Repli) T97725 TARGTYPE Clinical trial T97725 DRUGINFO D0UU4B CLS006 Phase 3 T97725 DRUGINFO D06ZPX BTL-TML-001 Phase 2 T97725 DRUGINFO D09BXF CLS003 Phase 2 T72437 TARGETID T72437 T72437 FORMERID TTDI01320 T72437 TARGNAME VWF-dependent platelet-collagen conversion (VDDPCC) T72437 TARGTYPE Clinical trial T72437 DRUGINFO D05BBB Saratin Phase 2 T54379 TARGETID T54379 T54379 FORMERID TTDNC00429 T54379 TARGNAME Wnt signaling pathway (Wnt pathway) T54379 TARGTYPE Clinical trial T54379 DRUGINFO D0I9AC SM04554 Phase 2/3 T54379 DRUGINFO D05ZIS SM-04690 Phase 2 T54379 DRUGINFO D07AYI CWP232291 Phase 1/2 T54379 DRUGINFO D09YPJ SM08502 Phase 1 T54379 DRUGINFO D0P5XM SM04755 Phase 1 T01011 TARGETID T01011 T01011 TARGNAME Aurora kinase (AURK) T01011 TARGTYPE Clinical trial T01011 SYNONYMS Serine/threonine kinase T01011 DRUGINFO DXD69J AZD2811 Phase 2 T01011 DRUGINFO D0LR2Y Diamidothiazole derivative 1 Patented T19947 TARGETID T19947 T19947 TARGNAME Immunoproteasome complex (IP) T19947 TARGTYPE Clinical trial T19947 SYNONYMS i-proteasome complex T19947 DRUGINFO DME75T KZR-616 Phase 2 T19947 DRUGINFO D01NCJ Peptide analog 10 Patented T19947 DRUGINFO D01OBB Peptide analog 40 Patented T19947 DRUGINFO D01VHD PMID29865878-Compound-41 Patented T19947 DRUGINFO D03JWM PMID29865878-Compound-38 Patented T19947 DRUGINFO D04HPR Peptide analog 30 Patented T19947 DRUGINFO D06GDM Peptide analog 16 Patented T19947 DRUGINFO D06SJU Peptide analog 26 Patented T19947 DRUGINFO D08RXZ Peptide analog 24 Patented T19947 DRUGINFO D09EGD PMID29865878-Compound-54 Patented T19947 DRUGINFO D0A0VU PMID29865878-Compound-56 Patented T19947 DRUGINFO D0B0VK Peptide analog 32 Patented T19947 DRUGINFO D0C4JQ Peptide analog 43 Patented T19947 DRUGINFO D0D2PS PMID29865878-Compound-52 Patented T19947 DRUGINFO D0DU4H Peptide analog 12 Patented T19947 DRUGINFO D0FJ8E Peptide analog 18 Patented T19947 DRUGINFO D0HM4V PMID29865878-Compound-50 Patented T19947 DRUGINFO D0HV3N PMID29865878-Compound-60 Patented T19947 DRUGINFO D0JI5X PMID29865878-Compound-42 Patented T19947 DRUGINFO D0JK0Y Peptide analog 35 Patented T19947 DRUGINFO D0NO3H Peptide analog 42 Patented T19947 DRUGINFO D0O9YJ PMID29865878-Compound-47 Patented T19947 DRUGINFO D0P9YR Peptide analog 29 Patented T19947 DRUGINFO D0R5FU Peptide analog 9 Patented T19947 DRUGINFO D0RF5E PMID29865878-Compound-39 Patented T19947 DRUGINFO D0UZ4S Peptide analog 22 Patented T19947 DRUGINFO D0WF1F PMID29865878-Compound-45 Patented T19947 DRUGINFO D0WJ3T Peptide analog 15 Patented T19947 DRUGINFO D0X4HJ Peptide analog 20 Patented T19947 DRUGINFO D0ZH3O PMID29865878-Compound-40 Patented T04977 TARGETID T04977 T04977 FORMERID TTDI01684 T04977 TARGNAME Oxalate absorption (Oxalate absor) T04977 TARGTYPE Clinical trial T04977 DRUGINFO D1TED8 Reloxaliase Phase 3 T04977 DRUGINFO D0N9SJ ALTU-237 Discontinued in Phase 1 T38143 TARGETID T38143 T38143 FORMERID TTDR01029 T38143 TARGNAME Phosphodiesterase 5 (PDE5) T38143 TARGTYPE Clinical trial T38143 SYNONYMS Phosphosdiesterase-5; PDE5; PDE-V; PDE-5 T38143 BIOCLASS Phosphoric diester hydrolase T38143 DRUGINFO D1OM8E AR1001 Phase 3 T38143 DRUGINFO D1OM8E AR1001 Phase 3 T60348 TARGETID T60348 T60348 FORMERID TTDI01788 T60348 TARGNAME Voltage-dependent anion channel (VDAC) T60348 TARGTYPE Clinical trial T60348 FUNCTION Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules. T60348 BIOCLASS Eukaryotic mitochondrial porin T60348 DRUGINFO DK6P5A VDA-1102 Phase 2 T63551 TARGETID T63551 T63551 FORMERID TTDNC00629 T63551 TARGNAME Integrin (ITG) T63551 TARGTYPE Clinical trial T63551 SYNONYMS Integrin protein T63551 DRUGINFO DS6OV9 THR-687 Phase 1 T18204 TARGETID T18204 T18204 FORMERID TTDI01734 T18204 TARGNAME Alpha-secretase (ASE) T18204 TARGTYPE Clinical trial T18204 DRUGINFO DH6G1L APH-1105 Phase 2 T18204 DRUGINFO DM95PZ ID1201 Phase 2 T18204 DRUGINFO DNH51Q APH-1104 Phase 1 T01674 TARGETID T01674 T01674 UNIPROID CE290_HUMAN T01674 TARGNAME CEP290 messenger RNA (CEP290 mRNA) T01674 GENENAME CEP290 T01674 TARGTYPE Clinical trial T01674 SYNONYMS Cep290; Bardet-Biedl syndrome 14 protein; Cancer/testis antigen 87; CT87; Nephrocystin-6; Tumor antigen se2-2 T01674 FUNCTION Involved in early and late steps in cilia formation. Its association with CCP110 is required for inhibition of primary cilia formation by CCP110. May play a role in early ciliogenesis in the disappearance of centriolar satellites and in the transition of primary ciliar vesicles (PCVs) to capped ciliary vesicles (CCVs). Required for the centrosomal recruitment of RAB8A and for the targeting of centriole satellite proteins to centrosomes such as of PCM1. Required for the correct localization of ciliary and phototransduction proteins in retinal photoreceptor cells; may play a role in ciliary transport processes (By similarity). Required for efficient recruitment of RAB8A to primary cilium. In the ciliary transition zone is part of the tectonic-like complex which is required for tissue-specific ciliogenesis and may regulate ciliary membrane composition (By similarity). Involved in regulation of the BBSome complex integrity, specifically for presence of BBS2, BBS5 and BBS8/TTC8 in the complex, and in ciliary targeting of selected BBSome cargos. May play a role in controlling entry of the BBSome complex to cilia possibly implicating IQCB1/NPHP5. Activates ATF4-mediated transcription. T01674 BIOCLASS mRNA target T01674 SEQUENCE MPPNINWKEIMKVDPDDLPRQEELADNLLISLSKVEVNELKSEKQENVIHLFRITQSLMKMKAQEVELALEEVEKAGEEQAKFENQLKTKVMKLENELEMAQQSAGGRDTRFLRNEICQLEKQLEQKDRELEDMEKELEKEKKVNEQLALRNEEAENENSKLRRENKRLKKKNEQLCQDIIDYQKQIDSQKETLLSRRGEDSDYRSQLSKKNYELIQYLDEIQTLTEANEKIEVQNQEMRKNLEESVQEMEKMTDEYNRMKAIVHQTDNVIDQLKKENDHYQLQVQELTDLLKSKNEEDDPIMVAVNAKVEEWKLILSSKDDEIIEYQQMLHNLREKLKNAQLDADKSNVMALQQGIQERDSQIKMLTEQVEQYTKEMEKNTCIIEDLKNELQRNKGASTLSQQTHMKIQSTLDILKEKTKEAERTAELAEADAREKDKELVEALKRLKDYESGVYGLEDAVVEIKNCKNQIKIRDREIEILTKEINKLELKISDFLDENEALRERVGLEPKTMIDLTEFRNSKHLKQQQYRAENQILLKEIESLEEERLDLKKKIRQMAQERGKRSATSGLTTEDLNLTENISQGDRISERKLDLLSLKNMSEAQSKNEFLSRELIEKERDLERSRTVIAKFQNKLKELVEENKQLEEGMKEILQAIKEMQKDPDVKGGETSLIIPSLERLVNAIESKNAEGIFDASLHLKAQVDQLTGRNEELRQELRESRKEAINYSQQLAKANLKIDHLEKETSLLRQSEGSNVVFKGIDLPDGIAPSSASIINSQNEYLIHLLQELENKEKKLKNLEDSLEDYNRKFAVIRHQQSLLYKEYLSEKETWKTESKTIKEEKRKLEDQVQQDAIKVKEYNNLLNALQMDSDEMKKILAENSRKITVLQVNEKSLIRQYTTLVELERQLRKENEKQKNELLSMEAEVCEKIGCLQRFKEMAIFKIAALQKVVDNSVSLSELELANKQYNELTAKYRDILQKDNMLVQRTSNLEHLECENISLKEQVESINKELEITKEKLHTIEQAWEQETKLGNESSMDKAKKSITNSDIVSISKKITMLEMKELNERQRAEHCQKMYEHLRTSLKQMEERNFELETKFAELTKINLDAQKVEQMLRDELADSVSKAVSDADRQRILELEKNEMELKVEVSKLREISDIARRQVEILNAQQQSRDKEVESLRMQLLDYQAQSDEKSLIAKLHQHNVSLQLSEATALGKLESITSKLQKMEAYNLRLEQKLDEKEQALYYARLEGRNRAKHLRQTIQSLRRQFSGALPLAQQEKFSKTMIQLQNDKLKIMQEMKNSQQEHRNMENKTLEMELKLKGLEELISTLKDTKGAQKVINWHMKIEELRLQELKLNRELVKDKEEIKYLNNIISEYERTISSLEEEIVQQNKFHEERQMAWDQREVDLERQLDIFDRQQNEILNAAQKFEEATGSIPDPSLPLPNQLEIALRKIKENIRIILETRATCKSLEEKLKEKESALRLAEQNILSRDKVINELRLRLPATAEREKLIAELGRKEMEPKSHHTLKIAHQTIANMQARLNQKEEVLKKYQRLLEKAREEQREIVKKHEEDLHILHHRLELQADSSLNKFKQTAWDLMKQSPTPVPTNKHFIRLAEMEQTVAEQDDSLSSLLVKLKKVSQDLERQREITELKVKEFENIKLQLQENHEDEVKKVKAEVEDLKYLLDQSQKESQCLKSELQAQKEANSRAPTTTMRNLVERLKSQLALKEKQQKALSRALLELRAEMTAAAEERIISATSQKEAHLNVQQIVDRHTRELKTQVEDLNENLLKLKEALKTSKNRENSLTDNLNDLNNELQKKQKAYNKILREKEEIDQENDELKRQIKRLTSGLQGKPLTDNKQSLIEELQRKVKKLENQLEGKVEEVDLKPMKEKNAKEELIRWEEGKKWQAKIEGIRNKLKEKEGEVFTLTKQLNTLKDLFAKADKEKLTLQRKLKTTGMTVDQVLGIRALESEKELEELKKRNLDLENDILYMRAHQALPRDSVVEDLHLQNRYLQEKLHALEKQFSKDTYSKPSISGIESDDHCQREQELQKENLKLSSENIELKFQLEQANKDLPRLKNQVRDLKEMCEFLKKEKAEVQRKLGHVRGSGRSGKTIPELEKTIGLMKKVVEKVQRENEQLKKASGILTSEKMANIEQENEKLKAELEKLKAHLGHQLSMHYESKTKGTEKIIAENERLRKELKKETDAAEKLRIAKNNLEILNEKMTVQLEETGKRLQFAESRGPQLEGADSKSWKSIVVTRMYETKLKELETDIAKKNQSITDLKQLVKEATEREQKVNKYNEDLEQQIKILKHVPEGAETEQGLKRELQVLRLANHQLDKEKAELIHQIEANKDQSGAESTIPDADQLKEKIKDLETQLKMSDLEKQHLKEEIKKLKKELENFDPSFFEEIEDLKYNYKEEVKKNILLEEKVKKLSEQLGVELTSPVAASEEFEDEEESPVNFPIY T01674 DRUGINFO DS14FO Sepofarsen Phase 2/3 T02584 TARGETID T02584 T02584 UNIPROID SYL_MYCTU T02584 TARGNAME Mycobacterium Leucine-tRNA ligase (MycB leuS) T02584 GENENAME MycB leuS T02584 TARGTYPE Clinical trial T02584 SYNONYMS Leucyl-tRNA synthetase; LeuRS T02584 ECNUMBER EC 6.1.1.4 T02584 SEQUENCE MTESPTAGPGGVPRADDADSDVPRYRYTAELAARLERTWQENWARLGTFNVPNPVGSLAPPDGAAVPDDKLFVQDMFPYPSGEGLHVGHPLGYIATDVYARYFRMVGRNVLHALGFDAFGLPAEQYAVQTGTHPRTRTEANVVNFRRQLGRLGFGHDSRRSFSTTDVDFYRWTQWIFLQIYNAWFDTTANKARPISELVAEFESGARCLDGGRDWAKLTAGERADVIDEYRLVYRADSLVNWCPGLGTVLANEEVTADGRSDRGNFPVFRKRLRQWMMRITAYADRLLDDLDVLDWPEQVKTMQRNWIGRSTGAVALFSARAASDDGFEVDIEVFTTRPDTLFGATYLVLAPEHDLVDELVAASWPAGVNPLWTYGGGTPGEAIAAYRRAIAAKSDLERQESREKTGVFLGSYAINPANGEPVPIFIADYVLAGYGTGAIMAVPGHDQRDWDFARAFGLPIVEVIAGGNISESAYTGDGILVNSDYLNGMSVPAAKRAIVDRLESAGRGRARIEFKLRDWLFARQRYWGEPFPIVYDSDGRPHALDEAALPVELPDVPDYSPVLFDPDDADSEPSPPLAKATEWVHVDLDLGDGLKPYSRDTNVMPQWAGSSWYELRYTDPHNSERFCAKENEAYWMGPRPAEHGPDDPGGVDLYVGGAEHAVLHLLYSRFWHKVLYDLGHVSSREPYRRLVNQGYIQAYAYTDARGSYVPAEQVIERGDRFVYPGPDGEVEVFQEFGKIGKSLKNSVSPDEICDAYGADTLRVYEMSMGPLEASRPWATKDVVGAYRFLQRVWRLVVDEHTGETRVADGVELDIDTLRALHRTIVGVSEDFAALRNNTATAKLIEYTNHLTKKHRDAVPRAAVEPLVQMLAPLAPHIAEELWLRLGNTTSLAHGPFPKADAAYLVDETVEYPVQVNGKVRGRVVVAADTDEETLKAAVLTDEKVQAFLAGATPRKVIVVAGRLVNLVI T02584 DRUGINFO DUSB35 GSK3036656 Phase 2 T03485 TARGETID T03485 T03485 UNIPROID CFAB_HUMAN T03485 TARGNAME CFB messenger RNA (CFB mRNA) T03485 GENENAME CFB T03485 TARGTYPE Clinical trial T03485 SYNONYMS C3/C5 convertase; Glycine-rich beta glycoprotein; GBG; PBF2; Properdin factor B T03485 FUNCTION Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes. T03485 BIOCLASS mRNA target T03485 ECNUMBER EC 3.4.21.47 T03485 SEQUENCE MGSNLSPQLCLMPFILGLLSGGVTTTPWSLARPQGSCSLEGVEIKGGSFRLLQEGQALEYVCPSGFYPYPVQTRTCRSTGSWSTLKTQDQKTVRKAECRAIHCPRPHDFENGEYWPRSPYYNVSDEISFHCYDGYTLRGSANRTCQVNGRWSGQTAICDNGAGYCSNPGIPIGTRKVGSQYRLEDSVTYHCSRGLTLRGSQRRTCQEGGSWSGTEPSCQDSFMYDTPQEVAEAFLSSLTETIEGVDAEDGHGPGEQQKRKIVLDPSGSMNIYLVLDGSDSIGASNFTGAKKCLVNLIEKVASYGVKPRYGLVTYATYPKIWVKVSEADSSNADWVTKQLNEINYEDHKLKSGTNTKKALQAVYSMMSWPDDVPPEGWNRTRHVIILMTDGLHNMGGDPITVIDEIRDLLYIGKDRKNPREDYLDVYVFGVGPLVNQVNINALASKKDNEQHVFKVKDMENLEDVFYQMIDESQSLSLCGMVWEHRKGTDYHKQPWQAKISVIRPSKGHESCMGAVVSEYFVLTAAHCFTVDDKEHSIKVSVGGEKRDLEIEVVLFHPNYNINGKKEAGIPEFYDYDVALIKLKNKLKYGQTIRPICLPCTEGTTRALRLPPTTTCQQQKEELLPAQDIKALFVSEEEKKLTRKEVYIKNGDKKGSCERDAQYAPGYDKVKDISEVVTPRFLCTGGVSPYADPNTCRGDSGGPLIVHKRSRFIQVGVISWGVVDVCKNQKRQKQVPAHARDFHINLFQVLPWLKEKLQDEDLGFL T03485 DRUGINFO DQ2Y7L IONIS-FB-LRx Phase 2 T03672 TARGETID T03672 T03672 UNIPROID ADAM9_HUMAN T03672 TARGNAME Cellular disintegrin-related protein (ADAM9) T03672 GENENAME ADAM9 T03672 TARGTYPE Clinical trial T03672 SYNONYMS ADAM 9; Cellular disintegrin-related protein; Meltrin-gamma; Metalloprotease/disintegrin/cysteine-rich protein 9; Myeloma cell metalloproteinase T03672 FUNCTION Cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis, such as TEK, KDR, EPHB4, CD40, VCAM1 and CDH5. May mediate cell-cell, cell-matrix interactions and regulate the motility of cells via interactions with integrins. T03672 ECNUMBER EC 3.4.24.- T03672 SEQUENCE MGSGARFPSGTLRVRWLLLLGLVGPVLGAARPGFQQTSHLSSYEIITPWRLTRERREAPRPYSKQVSYVIQAEGKEHIIHLERNKDLLPEDFVVYTYNKEGTLITDHPNIQNHCHYRGYVEGVHNSSIALSDCFGLRGLLHLENASYGIEPLQNSSHFEHIIYRMDDVYKEPLKCGVSNKDIEKETAKDEEEEPPSMTQLLRRRRAVLPQTRYVELFIVVDKERYDMMGRNQTAVREEMILLANYLDSMYIMLNIRIVLVGLEIWTNGNLINIVGGAGDVLGNFVQWREKFLITRRRHDSAQLVLKKGFGGTAGMAFVGTVCSRSHAGGINVFGQITVETFASIVAHELGHNLGMNHDDGRDCSCGAKSCIMNSGASGSRNFSSCSAEDFEKLTLNKGGNCLLNIPKPDEAYSAPSCGNKLVDAGEECDCGTPKECELDPCCEGSTCKLKSFAECAYGDCCKDCRFLPGGTLCRGKTSECDVPEYCNGSSQFCQPDVFIQNGYPCQNNKAYCYNGMCQYYDAQCQVIFGSKAKAAPKDCFIEVNSKGDRFGNCGFSGNEYKKCATGNALCGKLQCENVQEIPVFGIVPAIIQTPSRGTKCWGVDFQLGSDVPDPGMVNEGTKCGAGKICRNFQCVDASVLNYDCDVQKKCHGHGVCNSNKNCHCENGWAPPNCETKGYGGSVDSGPTYNEMNTALRDGLLVFFFLIVPLIVCAIFIFIKRDQLWRSYFRKKRSQTYESDGKNQANPSRQPGSVPRHVSPVTPPREVPIYANRFAVPTYAAKQPQQFPSRPPPPQPKVSSQGNLIPARPAPAPPLYSSLT T03672 DRUGINFO DA4O8C IMGC936 Phase 1 T06128 TARGETID T06128 T06128 UNIPROID IRS2_HUMAN T06128 TARGNAME Insulin receptor substrate 2 (IRS2) T06128 GENENAME IRS2 T06128 TARGTYPE Clinical trial T06128 SYNONYMS IRS-2 T06128 FUNCTION May mediate the control of various cellular processes by insulin. T06128 SEQUENCE MASPPRHGPPGPASGDGPNLNNNNNNNNHSVRKCGYLRKQKHGHKRFFVLRGPGAGGDEATAGGGSAPQPPRLEYYESEKKWRSKAGAPKRVIALDCCLNINKRADAKHKYLIALYTKDEYFAVAAENEQEQEGWYRALTDLVSEGRAAAGDAPPAAAPAASCSASLPGALGGSAGAAGAEDSYGLVAPATAAYREVWQVNLKPKGLGQSKNLTGVYRLCLSARTIGFVKLNCEQPSVTLQLMNIRRCGHSDSFFFIEVGRSAVTGPGELWMQADDSVVAQNIHETILEAMKALKELFEFRPRSKSQSSGSSATHPISVPGARRHHHLVNLPPSQTGLVRRSRTDSLAATPPAAKCSSCRVRTASEGDGGAAAGAAAAGARPVSVAGSPLSPGPVRAPLSRSHTLSGGCGGRGSKVALLPAGGALQHSRSMSMPVAHSPPAATSPGSLSSSSGHGSGSYPPPPGPHPPLPHPLHHGPGQRPSSGSASASGSPSDPGFMSLDEYGSSPGDLRAFCSHRSNTPESIAETPPARDGGGGGEFYGYMTMDRPLSHCGRSYRRVSGDAAQDLDRGLRKRTYSLTTPARQRPVPQPSSASLDEYTLMRATFSGSAGRLCPSCPASSPKVAYHPYPEDYGDIEIGSHRSSSSNLGADDGYMPMTPGAALAGSGSGSCRSDDYMPMSPASVSAPKQILQPRAAAAAAAAVPSAGPAGPAPTSAAGRTFPASGGGYKASSPAESSPEDSGYMRMWCGSKLSMEHADGKLLPNGDYLNVSPSDAVTTGTPPDFFSAALHPGGEPLRGVPGCCYSSLPRSYKAPYTCGGDSDQYVLMSSPVGRILEEERLEPQATPGPSQAASAFGAGPTQPPHPVVPSPVRPSGGRPEGFLGQRGRAVRPTRLSLEGLPSLPSMHEYPLPPEPKSPGEYINIDFGEPGARLSPPAPPLLASAASSSSLLSASSPASSLGSGTPGTSSDSRQRSPLSDYMNLDFSSPKSPKPGAPSGHPVGSLDGLLSPEASSPYPPLPPRPSASPSSSLQPPPPPPAPGELYRLPPASAVATAQGPGAASSLSSDTGDNGDYTEMAFGVAATPPQPIAAPPKPEAARVASPTSGVKRLSLMEQVSGVEAFLQASQPPDPHRGAKVIRADPQGGRRRHSSETFSSTTTVTPVSPSFAHNPKRHNSASVENVSLRKSSEGGVGVGPGGGDEPPTSPRQLQPAPPLAPQGRPWTPGQPGGLVGCPGSGGSPMRRETSAGFQNGLNYIAIDVREEPGLPPQPQPPPPPLPQPGDKSSWGRTRSLGGLISAVGVGSTGGGCGGPGPGALPPANTYASIDFLSHHLKEATIVKE T06128 DRUGINFO DUI59O NT219 Phase 1/2 T06958 TARGETID T06958 T06958 UNIPROID DPOLB_HUMAN T06958 TARGNAME DNA polymerase beta (POLB) T06958 GENENAME POLB T06958 TARGTYPE Clinical trial T06958 FUNCTION Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases. T06958 ECNUMBER EC 2.7.7.7 T06958 SEQUENCE MSKRKAPQETLNGGITDMLTELANFEKNVSQAIHKYNAYRKAASVIAKYPHKIKSGAEAKKLPGVGTKIAEKIDEFLATGKLRKLEKIRQDDTSSSINFLTRVSGIGPSAARKFVDEGIKTLEDLRKNEDKLNHHQRIGLKYFGDFEKRIPREEMLQMQDIVLNEVKKVDSEYIATVCGSFRRGAESSGDMDVLLTHPSFTSESTKQPKLLHQVVEQLQKVHFITDTLSKGETKFMGVCQLPSKNDEKEYPHRRIDIRLIPKDQYYCGVLYFTGSDIFNKNMRAHALEKGFTINEYTIRPLGVTGVAGEPLPVDSEKDIFDYIQWKYREPKDRSE T06958 DRUGINFO DL30JC FF-10502 Phase 1/2 T07816 TARGETID T07816 T07816 UNIPROID Q4QH56_LEIMA; Q4Q1Q9_LEIMA T07816 TARGNAME Leishmania major Proteasome (Leishm Proteasome) T07816 TARGTYPE Clinical trial T07816 DRUGINFO DA6C8N LXE408 Phase 2 T07893 TARGETID T07893 T07893 TARGNAME Polyamine transport (Poly trans) T07893 TARGTYPE Clinical trial T07893 DRUGINFO DRL76S AMXT1501 Phase 1 T07931 TARGETID T07931 T07931 UNIPROID LIRB2_HUMAN T07931 TARGNAME Leukocyte immunoglobulin-like receptor B2 (LILRB2) T07931 GENENAME LILRB2 T07931 TARGTYPE Clinical trial T07931 SYNONYMS LIR-2; Leukocyte immunoglobulin-like receptor 2; CD85 antigen-like family member D; Immunoglobulin-like transcript 4; ILT-4; Monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; DE AltName: CD_antigen=CD85d T07931 FUNCTION Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Involved in the down-regulation of the immune response and the development of tolerance. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M) triggering differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance. Competes with CD8A for binding to class I MHC antigens. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. T07931 SEQUENCE MTPIVTVLICLGLSLGPRTHVQTGTIPKPTLWAEPDSVITQGSPVTLSCQGSLEAQEYRLYREKKSASWITRIRPELVKNGQFHIPSITWEHTGRYGCQYYSRARWSELSDPLVLVMTGAYPKPTLSAQPSPVVTSGGRVTLQCESQVAFGGFILCKEGEEEHPQCLNSQPHARGSSRAIFSVGPVSPNRRWSHRCYGYDLNSPYVWSSPSDLLELLVPGVSKKPSLSVQPGPVVAPGESLTLQCVSDVGYDRFVLYKEGERDLRQLPGRQPQAGLSQANFTLGPVSRSYGGQYRCYGAHNLSSECSAPSDPLDILITGQIRGTPFISVQPGPTVASGENVTLLCQSWRQFHTFLLTKAGAADAPLRLRSIHEYPKYQAEFPMSPVTSAHAGTYRCYGSLNSDPYLLSHPSEPLELVVSGPSMGSSPPPTGPISTPAGPEDQPLTPTGSDPQSGLGRHLGVVIGILVAVVLLLLLLLLLFLILRHRRQGKHWTSTQRKADFQHPAGAVGPEPTDRGLQWRSSPAADAQEENLYAAVKDTQPEDGVEMDTRAAASEAPQDVTYAQLHSLTLRRKATEPPPSQEREPPAEPSIYATLAIH T07931 DRUGINFO DE61WB NGM707 Phase 2 T07931 DRUGINFO DK4I9R MK-4830 Phase 1 T08139 TARGETID T08139 T08139 UNIPROID FANCA_HUMAN T08139 TARGNAME Fanconi anemia group A protein (FANCA) T08139 GENENAME FANCA T08139 TARGTYPE Clinical trial T08139 SYNONYMS Protein FACA T08139 FUNCTION DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. T08139 SEQUENCE MSDSWVPNSASGQDPGGRRRAWAELLAGRVKREKYNPERAQKLKESAVRLLRSHQDLNALLLEVEGPLCKKLSLSKVIDCDSSEAYANHSSSFIGSALQDQASRLGVPVGILSAGMVASSVGQICTAPAETSHPVLLTVEQRKKLSSLLEFAQYLLAHSMFSRLSFCQELWKIQSSLLLEAVWHLHVQGIVSLQELLESHPDMHAVGSWLFRNLCCLCEQMEASCQHADVARAMLSDFVQMFVLRGFQKNSDLRRTVEPEKMPQVTVDVLQRMLIFALDALAAGVQEESSTHKIVRCWFGVFSGHTLGSVISTDPLKRFFSHTLTQILTHSPVLKASDAVQMQREWSFARTHPLLTSLYRRLFVMLSAEELVGHLQEVLETQEVHWQRVLSFVSALVVCFPEAQQLLEDWVARLMAQAFESCQLDSMVTAFLVVRQAALEGPSAFLSYADWFKASFGSTRGYHGCSKKALVFLFTFLSELVPFESPRYLQVHILHPPLVPGKYRSLLTDYISLAKTRLADLKVSIENMGLYEDLSSAGDITEPHSQALQDVEKAIMVFEHTGNIPVTVMEASIFRRPYYVSHFLPALLTPRVLPKVPDSRVAFIESLKRADKIPPSLYSTYCQACSAAEEKPEDAALGVRAEPNSAEEPLGQLTAALGELRASMTDPSQRDVISAQVAVISERLRAVLGHNEDDSSVEISKIQLSINTPRLEPREHMAVDLLLTSFCQNLMAASSVAPPERQGPWAALFVRTMCGRVLPAVLTRLCQLLRHQGPSLSAPHVLGLAALAVHLGESRSALPEVDVGPPAPGAGLPVPALFDSLLTCRTRDSLFFCLKFCTAAISYSLCKFSSQSRDTLCSCLSPGLIKKFQFLMFRLFSEARQPLSEEDVASLSWRPLHLPSADWQRAALSLWTHRTFREVLKEEDVHLTYQDWLHLELEIQPEADALSDTERQDFHQWAIHEHFLPESSASGGCDGDLQAACTILVNALMDFHQSSRSYDHSENSDLVFGGRTGNEDIISRLQEMVADLELQQDLIVPLGHTPSQEHFLFEIFRRRLQALTSGWSVAASLQRQRELLMYKRILLRLPSSVLCGSSFQAEQPITARCEQFFHLVNSEMRNFCSHGGALTQDITAHFFRGLLNACLRSRDPSLMVDFILAKCQTKCPLILTSALVWWPSLEPVLLCRWRRHCQSPLPRELQKLQEGRQFASDFLSPEAASPAPNPDWLSAAALHFAIQQVREENIRKQLKKLDCEREELLVFLFFFSLMGLLSSHLTSNSTTDLPKAFHVCAAILECLEKRKISWLALFQLTESDLRLGRLLLRVAPDQHTRLLPFAFYSLLSYFHEDAAIREEAFLHVAVDMYLKLVQLFVAGDTSTVSPPAGRSLELKGQGNPVELITKARLFLLQLIPRCPKKSFSHVAELLADRGDCDPEVSAALQSRQQAAPDADLSQEPHLF T08139 DRUGINFO DL7HD5 RP-L102 Phase 2 T08326 TARGETID T08326 T08326 UNIPROID CDK12_HUMAN T08326 TARGNAME Cyclin-dependent kinase 12 (CDK12) T08326 GENENAME CDK12 T08326 TARGTYPE Clinical trial T08326 SYNONYMS Cdc2-related kinase, arginine/serine-rich; CrkRS; Cell division cycle 2-related protein kinase 7; CDC2-related protein kinase 7; Cell division protein kinase 12; hCDK12 T08326 FUNCTION Cyclin-dependent kinase that phosphorylates the C-terminal domain (CTD) of the large subunit of RNA polymerase II (POLR2A), thereby acting as a key regulator of transcription elongation. Regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability. Preferentially phosphorylates 'Ser-5' in CTD repeats that are already phosphorylated at 'Ser-7', but can also phosphorylate 'Ser-2'. Required for RNA splicing, possibly by phosphorylating SRSF1/SF2. Involved in regulation of MAP kinase activity, possibly leading to affect the response to estrogen inhibitors. T08326 BIOCLASS Kinase T08326 ECNUMBER EC 2.7.11.22 T08326 SEQUENCE MPNSERHGGKKDGSGGASGTLQPSSGGGSSNSRERHRLVSKHKRHKSKHSKDMGLVTPEAASLGTVIKPLVEYDDISSDSDTFSDDMAFKLDRRENDERRGSDRSDRLHKHRHHQHRRSRDLLKAKQTEKEKSQEVSSKSGSMKDRISGSSKRSNEETDDYGKAQVAKSSSKESRSSKLHKEKTRKERELKSGHKDRSKSHRKRETPKSYKTVDSPKRRSRSPHRKWSDSSKQDDSPSGASYGQDYDLSPSRSHTSSNYDSYKKSPGSTSRRQSVSPPYKEPSAYQSSTRSPSPYSRRQRSVSPYSRRRSSSYERSGSYSGRSPSPYGRRRSSSPFLSKRSLSRSPLPSRKSMKSRSRSPAYSRHSSSHSKKKRSSSRSRHSSISPVRLPLNSSLGAELSRKKKERAAAAAAAKMDGKESKGSPVFLPRKENSSVEAKDSGLESKKLPRSVKLEKSAPDTELVNVTHLNTEVKNSSDTGKVKLDENSEKHLVKDLKAQGTRDSKPIALKEEIVTPKETETSEKETPPPLPTIASPPPPLPTTTPPPQTPPLPPLPPIPALPQQPPLPPSQPAFSQVPASSTSTLPPSTHSKTSAVSSQANSQPPVQVSVKTQVSVTAAIPHLKTSTLPPLPLPPLLPGDDDMDSPKETLPSKPVKKEKEQRTRHLLTDLPLPPELPGGDLSPPDSPEPKAITPPQQPYKKRPKICCPRYGERRQTESDWGKRCVDKFDIIGIIGEGTYGQVYKAKDKDTGELVALKKVRLDNEKEGFPITAIREIKILRQLIHRSVVNMKEIVTDKQDALDFKKDKGAFYLVFEYMDHDLMGLLESGLVHFSEDHIKSFMKQLMEGLEYCHKKNFLHRDIKCSNILLNNSGQIKLADFGLARLYNSEESRPYTNKVITLWYRPPELLLGEERYTPAIDVWSCGCILGELFTKKPIFQANLELAQLELISRLCGSPCPAVWPDVIKLPYFNTMKPKKQYRRRLREEFSFIPSAALDLLDHMLTLDPSKRCTAEQTLQSDFLKDVELSKMAPPDLPHWQDCHELWSKKRRRQRQSGVVVEEPPPSKTSRKETTSGTSTEPVKNSSPAPPQPAPGKVESGAGDAIGLADITQQLNQSELAVLLNLLQSQTDLSIPQMAQLLNIHSNPEMQQQLEALNQSISALTEATSQQQDSETMAPEESLKEAPSAPVILPSAEQTTLEASSTPADMQNILAVLLSQLMKTQEPAGSLEENNSDKNSGPQGPRRTPTMPQEEAAACPPHILPPEKRPPEPPGPPPPPPPPPLVEGDLSSAPQELNPAVTAALLQLLSQPEAEPPGHLPHEHQALRPMEYSTRPRPNRTYGNTDGPETGFSAIDTDERNSGPALTESLVQTLVKNRTFSGSLSHLGESSSYQGTGSVQFPGDQDLRFARVPLALHPVVGQPFLKAEGSSNSVVHAETKLQNYGELGPGTTGASSSGAGLHWGGPTQSSAYGKLYRGPTRVPPRGGRGRGVPY T08326 DRUGINFO DN9IC4 GSK3186899 Phase 1 T08326 DRUGINFO D7RK2M THZ531 Investigative T09483 TARGETID T09483 T09483 UNIPROID EGR1_HUMAN T09483 TARGNAME EGR1 messenger RNA (EGR1 mRNA) T09483 GENENAME EGR1 T09483 TARGTYPE Clinical trial T09483 SYNONYMS EGR-1; AT225; Nerve growth factor-induced protein A; NGFI-A; Transcription factor ETR103; Transcription factor Zif268; Zinc finger protein 225; Zinc finger protein Krox-24 T09483 FUNCTION Transcriptional regulator. Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'(EGR-site) in the promoter region of target genes (By similarity). Binds double-stranded target DNA, irrespective of the cytosine methylation status. Regulates the transcription of numerous target genes, and thereby plays an important role in regulating the response to growth factors, DNA damage, and ischemia. Plays a role in the regulation of cell survival, proliferation and cell death. Activates expression of p53/TP53 and TGFB1, and thereby helps prevent tumor formation. Required for normal progress through mitosis and normal proliferation of hepatocytes after partial hepatectomy. Mediates responses to ischemia and hypoxia; regulates the expression of proteins such as IL1B and CXCL2 that are involved in inflammatory processes and development of tissue damage after ischemia. Regulates biosynthesis of luteinizing hormone (LHB) in the pituitary (By similarity). Regulates the amplitude of the expression rhythms of clock genes: ARNTL/BMAL1, PER2 and NR1D1 in the liver via the activation of PER1 (clock repressor) transcription. Regulates the rhythmic expression of core-clock gene ARNTL/BMAL1 in the suprachiasmatic nucleus (SCN) (By similarity). T09483 BIOCLASS mRNA target T09483 SEQUENCE MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDICGRKFARSDERKRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC T09483 DRUGINFO DG9QY7 Brivoligide Phase 2 T10592 TARGETID T10592 T10592 UNIPROID DYN2_HUMAN T10592 TARGNAME DNM2 messenger RNA (DNM2 mRNA) T10592 GENENAME DNM2 T10592 TARGTYPE Clinical trial T10592 FUNCTION Microtubule-associated force-producing protein involved in producing microtubule bundles and able to bind and hydrolyze GTP. Plays a role in the regulation of neuron morphology, axon growth and formation of neuronal growth cones (By similarity). Plays an important role in vesicular trafficking processes, in particular endocytosis. Involved in cytokinesis. Regulates maturation of apoptotic cell corpse-containing phagosomes by recruiting PIK3C3 to the phagosome membrane (By similarity). T10592 BIOCLASS mRNA target T10592 ECNUMBER EC 3.6.5.5 T10592 SEQUENCE MGNRGMEELIPLVNKLQDAFSSIGQSCHLDLPQIAVVGGQSAGKSSVLENFVGRDFLPRGSGIVTRRPLILQLIFSKTEHAEFLHCKSKKFTDFDEVRQEIEAETDRVTGTNKGISPVPINLRVYSPHVLNLTLIDLPGITKVPVGDQPPDIEYQIKDMILQFISRESSLILAVTPANMDLANSDALKLAKEVDPQGLRTIGVITKLDLMDEGTDARDVLENKLLPLRRGYIGVVNRSQKDIEGKKDIRAALAAERKFFLSHPAYRHMADRMGTPHLQKTLNQQLTNHIRESLPALRSKLQSQLLSLEKEVEEYKNFRPDDPTRKTKALLQMVQQFGVDFEKRIEGSGDQVDTLELSGGARINRIFHERFPFELVKMEFDEKDLRREISYAIKNIHGVRTGLFTPDLAFEAIVKKQVVKLKEPCLKCVDLVIQELINTVRQCTSKLSSYPRLREETERIVTTYIREREGRTKDQILLLIDIEQSYINTNHEDFIGFANAQQRSTQLNKKRAIPNQGEILVIRRGWLTINNISLMKGGSKEYWFVLTAESLSWYKDEEEKEKKYMLPLDNLKIRDVEKGFMSNKHVFAIFNTEQRNVYKDLRQIELACDSQEDVDSWKASFLRAGVYPEKDQAENEDGAQENTFSMDPQLERQVETIRNLVDSYVAIINKSIRDLMPKTIMHLMINNTKAFIHHELLAYLYSSADQSSLMEESADQAQRRDDMLRMYHALKEALNIIGDISTSTVSTPVPPPVDDTWLQSASSHSPTPQRRPVSSIHPPGRPPAVRGPTPGPPLIPVPVGAAASFSAPPIPSRPGPQSVFANSDLFPAPPQIPSRPVRIPPGIPPGVPSRRPPAAPSRPTIIRPAEPSLLD T10592 DRUGINFO DLCB65 IONIS-DNM2-2.5Rx Phase 2 T10592 DRUGINFO D1ZAW4 DYN101 Phase 1/2 T10762 TARGETID T10762 T10762 UNIPROID BMP6_HUMAN T10762 TARGNAME Bone morphogenetic protein 6 (BMP6) T10762 GENENAME BMP6 T10762 TARGTYPE Clinical trial T10762 SYNONYMS BMP-6; VG-1-related protein; VG-1-R; VGR-1 T10762 FUNCTION Induces cartilage and bone formation. T10762 SEQUENCE MPGLGRRAQWLCWWWGLLCSCCGPPPLRPPLPAAAAAAAGGQLLGDGGSPGRTEQPPPSPQSSSGFLYRRLKTQEKREMQKEILSVLGLPHRPRPLHGLQQPQPPALRQQEEQQQQQQLPRGEPPPGRLKSAPLFMLDLYNALSADNDEDGASEGERQQSWPHEAASSSQRRQPPPGAAHPLNRKSLLAPGSGSGGASPLTSAQDSAFLNDADMVMSFVNLVEYDKEFSPRQRHHKEFKFNLSQIPEGEVVTAAEFRIYKDCVMGSFKNQTFLISIYQVLQEHQHRDSDLFLLDTRVVWASEEGWLEFDITATSNLWVVTPQHNMGLQLSVVTRDGVHVHPRAAGLVGRDGPYDKQPFMVAFFKVSEVHVRTTRSASSRRRQQSRNRSTQSQDVARVSSASDYNSSELKTACRKHELYVSFQDLGWQDWIIAPKGYAANYCDGECSFPLNAHMNATNHAIVQTLVHLMNPEYVPKPCCAPTKLNAISVLYFDDNSNVILKKYRNMVVRACGCH T10762 DRUGINFO DNV17I LY3113593 Phase 2 T13209 TARGETID T13209 T13209 UNIPROID AVR2A_HUMAN; AVR2B_HUMAN T13209 TARGNAME Activin receptor type II (ACVR2) T13209 TARGTYPE Clinical trial T13209 DRUGINFO DW43DG Bimagrumab Phase 2 T13568 TARGETID T13568 T13568 TARGNAME Methamphetamine (Meth) T13568 TARGTYPE Clinical trial T13568 DRUGINFO D6FNV9 IXT-m200 Phase 2 T14037 TARGETID T14037 T14037 UNIPROID AKT1_HUMAN; AKT2_HUMAN; AKT3_HUMAN T14037 TARGNAME RAC serine/threonine-protein kinase (AKT) T14037 TARGTYPE Clinical trial T14037 DRUGINFO DRI23U ARQ-751 Phase 1 T15894 TARGETID T15894 T15894 UNIPROID CUL4A_HUMAN/CUL4B_HUMAN-DDB1_HUMAN-CRBN_HUMAN T15894 TARGNAME Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase) T15894 GENENAME CUL4A/CUL4B-DDB1-CRBN T15894 TARGTYPE Clinical trial T15894 DRUGINFO DB8J2U KPG-818 Phase 1 T15894 DRUGINFO DN3B5E KPG-121 Phase 1 T16087 TARGETID T16087 T16087 UNIPROID TMPS6_HUMAN T16087 TARGNAME TMPRSS6 messenger RNA (TMPRSS6 mRNA) T16087 GENENAME TMPRSS6 T16087 TARGTYPE Clinical trial T16087 SYNONYMS Matriptase-2 T16087 FUNCTION Serine protease which hydrolyzes a range of proteins including type I collagen, fibronectin and fibrinogen. Can also activate urokinase-type plasminogen activator with low efficiency. May play a specialized role in matrix remodeling processes in liver. Through the cleavage of HJV, a regulator of the expression of the iron absorption-regulating hormone hepicidin/HAMP, plays a role in iron homeostasis. T16087 BIOCLASS mRNA target T16087 ECNUMBER EC 3.4.21.- T16087 SEQUENCE MLLLFHSKRMPVAEAPQVAGGQGDGGDGEEAEPEGMFKACEDSKRKARGYLRLVPLFVLLALLVLASAGVLLWYFLGYKAEVMVSQVYSGSLRVLNRHFSQDLTRRESSAFRSETAKAQKMLKELITSTRLGTYYNSSSVYSFGEGPLTCFFWFILQIPEHRRLMLSPEVVQALLVEELLSTVNSSAAVPYRAEYEVDPEGLVILEASVKDIAALNSTLGCYRYSYVGQGQVLRLKGPDHLASSCLWHLQGPKDLMLKLRLEWTLAECRDRLAMYDVAGPLEKRLITSVYGCSRQEPVVEVLASGAIMAVVWKKGLHSYYDPFVLSVQPVVFQACEVNLTLDNRLDSQGVLSTPYFPSYYSPQTHCSWHLTVPSLDYGLALWFDAYALRRQKYDLPCTQGQWTIQNRRLCGLRILQPYAERIPVVATAGITINFTSQISLTGPGVRVHYGLYNQSDPCPGEFLCSVNGLCVPACDGVKDCPNGLDERNCVCRATFQCKEDSTCISLPKVCDGQPDCLNGSDEEQCQEGVPCGTFTFQCEDRSCVKKPNPQCDGRPDCRDGSDEEHCDCGLQGPSSRIVGGAVSSEGEWPWQASLQVRGRHICGGALIADRWVITAAHCFQEDSMASTVLWTVFLGKVWQNSRWPGEVSFKVSRLLLHPYHEEDSHDYDVALLQLDHPVVRSAAVRPVCLPARSHFFEPGLHCWITGWGALREGGPISNALQKVDVQLIPQDLCSEVYRYQVTPRMLCAGYRKGKKDACQGDSGGPLVCKALSGRWFLAGLVSWGLGCGRPNYFGVYTRITGVISWIQQVVT T16087 DRUGINFO D2MA0E IONIS-TMPRSS6-LRx Phase 2 T16087 DRUGINFO D9VR6X Sapablursen Phase 2 T16087 DRUGINFO DJ5XY8 SLN124 Phase 1 T16087 DRUGINFO D6MEX0 ALN-TMP Preclinical T16784 TARGETID T16784 T16784 TARGNAME Microtubule polymerization (MicroTu poly) T16784 TARGTYPE Clinical trial T16784 DRUGINFO D8TE4F AMXI 5001 Phase 1/2 T16802 TARGETID T16802 T16802 TARGNAME Human immunodeficiency virus Attachment (HIV att) T16802 TARGTYPE Clinical trial T16802 DRUGINFO DNET17 GSK3810109 Phase 2 T17485 TARGETID T17485 T17485 UNIPROID MEN1_HUMAN-KMT2A_HUMAN T17485 TARGNAME Menin-MLL1 interaction (MEN1-KMT2A PPI) T17485 GENENAME MEN1-KMT2A T17485 TARGTYPE Clinical trial T17485 DRUGINFO D97YGW SNDX-5613 Phase 1/2 T17485 DRUGINFO DS4JE8 KO-539 Phase 1/2 T17485 DRUGINFO DYJ76M JNJ-75276617 Phase 1 T18356 TARGETID T18356 T18356 UNIPROID GLYC_LASSG T18356 TARGNAME Lassa virus Pre-glycoprotein polyprotein GP complex (LASV GPC) T18356 GENENAME LASV GPC T18356 TARGTYPE Clinical trial T18356 SYNONYMS Pre-GP-C T18356 BIOCLASS Arenaviridae GPC protein T18356 SEQUENCE MGQIVTFFQEVPHVIEEVMNIVLIALSILAILKGLYNVATCGLIGLVTFLLLSGRSCSLIYKGTYELQTLELNMETLNMTMPLSCTKNNSHHYIRVGNETGLELTLTNTSILNHKFCNLSDAHKRNLYDHSLMSIISTFHLSIPNFNQYEAMSCDFNGGKITVQYNLSHSFAVDAAGHCGTLANGVLQTFMRMAWGGSYIALDSGRGNWDCIMTSYQYLIIQNTTWDDHCQFSRPSPIGYLGLLSQRTRDIYISRRLLGTFTWTLSDSEGNETPGGYCLTRWMLIEAELKCFGNTAVAKCNEKHDEEFCDMLRLFDFNKQAIRRLKTEAQMSIQLINKAVNALINDQLIMKNHLRDIMGIPYCNYSRYWYLNHTSTGKTSLPRCWLISNGSYLNETKFSDDIEQQADNMITEMLQKEYIDRQGKTPLGLVDLFVFSTSFYLISIFLHLVKIPTHRHIVGKPCPKPHRLNHMGICSCGLYKQPGVPVRWKR T18356 DRUGINFO DY03KH LHF-535 Phase 1 T20185 TARGETID T20185 T20185 TARGNAME Fucosyl GM1 (FucGM1) T20185 TARGTYPE Clinical trial T20185 DRUGINFO D2QO5J BMS-986012 Phase 2 T20593 TARGETID T20593 T20593 TARGNAME Tumor-associated glycan antigen (TAGA) T20593 TARGTYPE Clinical trial T20593 DRUGINFO D1FO9C GNX102 Phase 1 T20741 TARGETID T20741 T20741 UNIPROID SC6A8_HUMAN T20741 TARGNAME Solute carrier family 6 member 8 (SLC6A8) T20741 GENENAME SLC6A8 T20741 TARGTYPE Clinical trial T20741 SYNONYMS CT1; Creatine transporter 1; Solute carrier family 6 member 8 T20741 FUNCTION Required for the uptake of creatine in muscles and brain. T20741 SEQUENCE MAKKSAENGIYSVSGDEKKGPLIAPGPDGAPAKGDGPVGLGTPGGRLAVPPRETWTRQMDFIMSCVGFAVGLGNVWRFPYLCYKNGGGVFLIPYVLIALVGGIPIFFLEISLGQFMKAGSINVWNICPLFKGLGYASMVIVFYCNTYYIMVLAWGFYYLVKSFTTTLPWATCGHTWNTPDCVEIFRHEDCANASLANLTCDQLADRRSPVIEFWENKVLRLSGGLEVPGALNWEVTLCLLACWVLVYFCVWKGVKSTGKIVYFTATFPYVVLVVLLVRGVLLPGALDGIIYYLKPDWSKLGSPQVWIDAGTQIFFSYAIGLGALTALGSYNRFNNNCYKDAIILALINSGTSFFAGFVVFSILGFMAAEQGVHISKVAESGPGLAFIAYPRAVTLMPVAPLWAALFFFMLLLLGLDSQFVGVEGFITGLLDLLPASYYFRFQREISVALCCALCFVIDLSMVTDGGMYVFQLFDYYSASGTTLLWQAFWECVVVAWVYGADRFMDDIACMIGYRPCPWMKWCWSFFTPLVCMGIFIFNVVYYEPLVYNNTYVYPWWGEAMGWAFALSSMLCVPLHLLGCLLRAKGTMAERWQHLTQPIWGLHHLEYRAQDADVRGLTTLTPVSESSKVVVVESVM T20741 DRUGINFO D0UO9R RGX-202 Phase 1 T23178 TARGETID T23178 T23178 UNIPROID ITB6_HUMAN T23178 TARGNAME Integrin beta-6 (ITGB6) T23178 GENENAME ITGB6 T23178 TARGTYPE Clinical trial T23178 FUNCTION Integrin alpha-V:beta-6 (ITGAV:ITGB6) is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V/beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. ITGAV:ITGB6 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V:beta-6 (ITGAV:ITGB6) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation. T23178 SEQUENCE MGIELLCLFFLFLGRNDHVQGGCALGGAETCEDCLLIGPQCAWCAQENFTHPSGVGERCDTPANLLAKGCQLNFIENPVSQVEILKNKPLSVGRQKNSSDIVQIAPQSLILKLRPGGAQTLQVHVRQTEDYPVDLYYLMDLSASMDDDLNTIKELGSRLSKEMSKLTSNFRLGFGSFVEKPVSPFVKTTPEEIANPCSSIPYFCLPTFGFKHILPLTNDAERFNEIVKNQKISANIDTPEGGFDAIMQAAVCKEKIGWRNDSLHLLVFVSDADSHFGMDSKLAGIVIPNDGLCHLDSKNEYSMSTVLEYPTIGQLIDKLVQNNVLLIFAVTQEQVHLYENYAKLIPGATVGLLQKDSGNILQLIISAYEELRSEVELEVLGDTEGLNLSFTAICNNGTLFQHQKKCSHMKVGDTASFSVTVNIPHCERRSRHIIIKPVGLGDALELLVSPECNCDCQKEVEVNSSKCHHGNGSFQCGVCACHPGHMGPRCECGEDMLSTDSCKEAPDHPSCSGRGDCYCGQCICHLSPYGNIYGPYCQCDNFSCVRHKGLLCGGNGDCDCGECVCRSGWTGEYCNCTTSTDSCVSEDGVLCSGRGDCVCGKCVCTNPGASGPTCERCPTCGDPCNSKRSCIECHLSAAGQAREECVDKCKLAGATISEEEDFSKDGSVSCSLQGENECLITFLITTDNEGKTIIHSINEKDCPKPPNIPMIMLGVSLAILLIGVVLLCIWKLLVSFHDRKEVAKFEAERSKAKWQTGTNPLYRGSTSTFKNVTYKHREKQKVDLSTDC T23178 DRUGINFO DJYD13 SGN-B6A Phase 1 T25419 TARGETID T25419 T25419 UNIPROID NTRK1_HUMAN; NTRK2_HUMAN; NTRK3_HUMAN T25419 TARGNAME Tropomyosin receptor kinase (Trk) T25419 TARGTYPE Clinical trial T25419 DRUGINFO D2KV8B AB-106 Phase 2 T26170 TARGETID T26170 T26170 UNIPROID TNR25_HUMAN T26170 TARGNAME Tumor necrosis factor receptor member 25 (TNFRSF25) T26170 GENENAME TNFRSF25 T26170 TARGTYPE Clinical trial T26170 SYNONYMS Apo-3; Apoptosis-inducing receptor AIR; Apoptosis-mediating receptor DR3; Apoptosis-mediating receptor TRAMP; Death receptor 3; Lymphocyte-associated receptor of death; LARD; Protein WSL; Protein WSL-1 T26170 FUNCTION Receptor for TNFSF12/APO3L/TWEAK. Interacts directly with the adapter TRADD. Mediates activation of NF-kappa-B and induces apoptosis. May play a role in regulating lymphocyte homeostasis. T26170 SEQUENCE MEQRPRGCAAVAAALLLVLLGARAQGGTRSPRCDCAGDFHKKIGLFCCRGCPAGHYLKAPCTEPCGNSTCLVCPQDTFLAWENHHNSECARCQACDEQASQVALENCSAVADTRCGCKPGWFVECQVSQCVSSSPFYCQPCLDCGALHRHTRLLCSRRDTDCGTCLPGFYEHGDGCVSCPTSTLGSCPERCAAVCGWRQMFWVQVLLAGLVVPLLLGATLTYTYRHCWPHKPLVTADEAGMEALTPPPATHLSPLDSAHTLLAPPDSSEKICTVQLVGNSWTPGYPETQEALCPQVTWSWDQLPSRALGPAAAPTLSPESPAGSPAMMLQPGPQLYDVMDAVPARRWKEFVRTLGLREAEIEAVEVEIGRFRDQQYEMLKRWRQQQPAGLGAVYAALERMGLDGCVEDLRSRLQRGP T26170 DRUGINFO DBGD91 PTX-35 Phase 1 T26470 TARGETID T26470 T26470 UNIPROID BC11A_HUMAN T26470 TARGNAME B-cell lymphoma/leukemia 11A (BCL11A) T26470 GENENAME BCL11A T26470 TARGTYPE Clinical trial T26470 SYNONYMS BCL-11A; B-cell CLL/lymphoma 11A; COUP-TF-interacting protein 1; Ecotropic viral integration site 9 protein homolog; EVI-9; Zinc finger protein 856; BCL-11A; B-cell CLL/lymphoma 11A; COUP-TF-interacting protein 1; Ecotropic viral integration site 9 protein homolog; EVI-9; Zinc finger protein 856 T26470 FUNCTION Transcription factor associated with the BAF SWI/SNF chromatin remodeling complex (By similarity). Repressor of fetal hemoglobin (HbF) level. Involved in brain development. May play a role in hematopoiesis. Essential factor in lymphopoiesis required for B-cell formation in fetal liver. May function as a modulator of the transcriptional repression activity of ARP1 (By similarity). T26470 SEQUENCE MSRRKQGKPQHLSKREFSPEPLEAILTDDEPDHGPLGAPEGDHDLLTCGQCQMNFPLGDILIFIEHKRKQCNGSLCLEKAVDKPPSPSPIEMKKASNPVEVGIQVTPEDDDCLSTSSRGICPKQEHIADKLLHWRGLSSPRSAHGALIPTPGMSAEYAPQGICKDEPSSYTCTTCKQPFTSAWFLLQHAQNTHGLRIYLESEHGSPLTPRVGIPSGLGAECPSQPPLHGIHIADNNPFNLLRIPGSVSREASGLAEGRFPPTPPLFSPPPRHHLDPHRIERLGAEEMALATHHPSAFDRVLRLNPMAMEPPAMDFSRRLRELAGNTSSPPLSPGRPSPMQRLLQPFQPGSKPPFLATPPLPPLQSAPPPSQPPVKSKSCEFCGKTFKFQSNLVVHRRSHTGEKPYKCNLCDHACTQASKLKRHMKTHMHKSSPMTVKSDDGLSTASSPEPGTSDLVGSASSALKSVVAKFKSENDPNLIPENGDEEEEEDDEEEEEEEEEEEEELTESERVDYGFGLSLEAARHHENSSRGAVVGVGDESRALPDVMQGMVLSSMQHFSEAFHQVLGEKHKRGHLAEAEGHRDTCDEDSVAGESDRIDDGTVNGRGCSPGESASGGLSKKLLLGSPSSLSPFSKRIKLEKEFDLPPAAMPNTENVYSQWLAGYAASRQLKDPFLSFGDSRQSPFASSSEHSSENGSLRFSTPPGELDGGISGRSGTGSGGSTPHISGPGPGRPSSKEGRRSDTCEYCGKVFKNCSNLTVHRRSHTGERPYKCELCNYACAQSSKLTRHMKTHGQVGKDVYKCEICKMPFSVYSTLEKHMKKWHSDRVLNNDIKTE T26470 DRUGINFO DVU2Y5 CTX001 Phase 1/2 T28093 TARGETID T28093 T28093 UNIPROID FAF1_HUMAN T28093 TARGNAME FAS-associated factor 1 (FAF1) T28093 GENENAME FAF1 T28093 TARGTYPE Clinical trial T28093 SYNONYMS hFAF1; UBX domain-containing protein 12; UBX domain-containing protein 3A T28093 FUNCTION Ubiquitin-binding protein. Required for the progression of DNA replication forks by targeting DNA replication licensing factor CDT1 for degradation. Potentiates but cannot initiate FAS-induced apoptosis (By similarity). T28093 SEQUENCE MASNMDREMILADFQACTGIENIDEAITLLEQNNWDLVAAINGVIPQENGILQSEYGGETIPGPAFNPASHPASAPTSSSSSAFRPVMPSRQIVERQPRMLDFRVEYRDRNVDVVLEDTCTVGEIKQILENELQIPVSKMLLKGWKTGDVEDSTVLKSLHLPKNNSLYVLTPDLPPPSSSSHAGALQESLNQNFMLIITHREVQREYNLNFSGSSTIQEVKRNVYDLTSIPVRHQLWEGWPTSATDDSMCLAESGLSYPCHRLTVGRRSSPAQTREQSEEQITDVHMVSDSDGDDFEDATEFGVDDGEVFGMASSALRKSPMMPENAENEGDALLQFTAEFSSRYGDCHPVFFIGSLEAAFQEAFYVKARDRKLLAIYLHHDESVLTNVFCSQMLCAESIVSYLSQNFITWAWDLTKDSNRARFLTMCNRHFGSVVAQTIRTQKTDQFPLFLIIMGKRSSNEVLNVIQGNTTVDELMMRLMAAMEIFTAQQQEDIKDEDEREARENVKREQDEAYRLSLEADRAKREAHEREMAEQFRLEQIRKEQEEEREAIRLSLEQALPPEPKEENAEPVSKLRIRTPSGEFLERRFLASNKLQIVFDFVASKGFPWDEYKLLSTFPRRDVTQLDPNKSLLEVKLFPQETLFLEAKE T28093 DRUGINFO DYNT08 KM-819 Phase 1 T29036 TARGETID T29036 T29036 UNIPROID CCN2_HUMAN T29036 TARGNAME CCN2 messenger RNA (CCN2 mRNA) T29036 GENENAME CCN2 T29036 TARGTYPE Clinical trial T29036 SYNONYMS Cellular communication network factor 2; Connective tissue growth factor; Hypertrophic chondrocyte-specific protein 24; Insulin-like growth factor-binding protein 8; IBP-8; IGF-binding protein 8; IGFBP-8 T29036 FUNCTION Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis. T29036 BIOCLASS mRNA target T29036 SEQUENCE MTAASMGPVRVAFVVLLALCSRPAVGQNCSGPCRCPDEPAPRCPAGVSLVLDGCGCCRVCAKQLGELCTERDPCDPHKGLFCHFGSPANRKIGVCTAKDGAPCIFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCDEPKDQTVVGPALAAYRLEDTFGPDPTMIRANCLVQTTEWSACSKTCGMGISTRVTNDNASCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA T29036 DRUGINFO D2AYS0 PF-06473871 Phase 2 T29036 DRUGINFO D4ZLC2 RXI-109 Phase 2 T29036 DRUGINFO DHB2K8 OLX10010 Phase 2 T29345 TARGETID T29345 T29345 UNIPROID MUC17_HUMAN T29345 TARGNAME Mucin-17 (MUC17) T29345 GENENAME MUC17 T29345 TARGTYPE Clinical trial T29345 SYNONYMS MUC-17; Small intestinal mucin-3; MUC-3 T29345 FUNCTION Probably plays a role in maintaining homeostasis on mucosal surfaces. T29345 SEQUENCE MPRPGTMALCLLTLVLSLLPPQAAAEQDLSVNRAVWDGGGCISQGDVLNRQCQQLSQHVRTGSAANTATGTTSTNVVEPRMYLSCSTNPEMTSIESSVTSDTPGVSSTRMTPTESRTTSESTSDSTTLFPSSTEDTSSPTTPEGTDVPMSTPSEESISSTMAFVSTAPLPSFEAYTSLTYKVDMSTPLTTSTQASSSPTTPESTTIPKSTNSEGSTPLTSMPASTMKVASSEAITLLTTPVEISTPVTISAQASSSPTTAEGPSLSNSAPSGGSTPLTRMPLSVMLVVSSEASTLSTTPAATNIPVITSTEASSSPTTAEGTSIPTSTYTEGSTPLTSTPASTMPVATSEMSTLSITPVDTSTLVTTSTEPSSLPTTAEATSMLTSTLSEGSTPLTNMPVSTILVASSEASTTSTIPVDSKTFVTTASEASSSPTTAEDTSIATSTPSEGSTPLTSMPVSTTPVASSEASNLSTTPVDSKTQVTTSTEASSSPPTAEVNSMPTSTPSEGSTPLTSMSVSTMPVASSEASTLSTTPVDTSTPVTTSSEASSSSTTPEGTSIPTSTPSEGSTPLTNMPVSTRLVVSSEASTTSTTPADSNTFVTTSSEASSSSTTAEGTSMPTSTYSERGTTITSMSVSTTLVASSEASTLSTTPVDSNTPVTTSTEATSSSTTAEGTSMPTSTYTEGSTPLTSMPVNTTLVASSEASTLSTTPVDTSTPVTTSTEASSSPTTADGASMPTSTPSEGSTPLTSMPVSKTLLTSSEASTLSTTPLDTSTHITTSTEASCSPTTTEGTSMPISTPSEGSPLLTSIPVSITPVTSPEASTLSTTPVDSNSPVTTSTEVSSSPTPAEGTSMPTSTYSEGRTPLTSMPVSTTLVATSAISTLSTTPVDTSTPVTNSTEARSSPTTSEGTSMPTSTPGEGSTPLTSMPDSTTPVVSSEARTLSATPVDTSTPVTTSTEATSSPTTAEGTSIPTSTPSEGTTPLTSTPVSHTLVANSEASTLSTTPVDSNTPLTTSTEASSPPPTAEGTSMPTSTPSEGSTPLTRMPVSTTMVASSETSTLSTTPADTSTPVTTYSQASSSSTTADGTSMPTSTYSEGSTPLTSVPVSTRLVVSSEASTLSTTPVDTSIPVTTSTEASSSPTTAEGTSIPTSPPSEGTTPLASMPVSTTLVVSSEANTLSTTPVDSKTQVATSTEASSPPPTAEVTSMPTSTPGERSTPLTSMPVRHTPVASSEASTLSTSPVDTSTPVTTSAETSSSPTTAEGTSLPTSTTSEGSTLLTSIPVSTTLVTSPEASTLLTTPVDTKGPVVTSNEVSSSPTPAEGTSMPTSTYSEGRTPLTSIPVNTTLVASSAISILSTTPVDNSTPVTTSTEACSSPTTSEGTSMPNSNPSEGTTPLTSIPVSTTPVVSSEASTLSATPVDTSTPGTTSAEATSSPTTAEGISIPTSTPSEGKTPLKSIPVSNTPVANSEASTLSTTPVDSNSPVVTSTAVSSSPTPAEGTSIAISTPSEGSTALTSIPVSTTTVASSEINSLSTTPAVTSTPVTTYSQASSSPTTADGTSMQTSTYSEGSTPLTSLPVSTMLVVSSEANTLSTTPIDSKTQVTASTEASSSTTAEGSSMTISTPSEGSPLLTSIPVSTTPVASPEASTLSTTPVDSNSPVITSTEVSSSPTPAEGTSMPTSTYTEGRTPLTSITVRTTPVASSAISTLSTTPVDNSTPVTTSTEARSSPTTSEGTSMPNSTPSEGTTPLTSIPVSTTPVLSSEASTLSATPIDTSTPVTTSTEATSSPTTAEGTSIPTSTLSEGMTPLTSTPVSHTLVANSEASTLSTTPVDSNSPVVTSTAVSSSPTPAEGTSIATSTPSEGSTALTSIPVSTTTVASSETNTLSTTPAVTSTPVTTYAQVSSSPTTADGSSMPTSTPREGRPPLTSIPVSTTTVASSEINTLSTTLADTRTPVTTYSQASSSPTTADGTSMPTPAYSEGSTPLTSMPLSTTLVVSSEASTLSTTPVDTSTPATTSTEGSSSPTTAGGTSIQTSTPSERTTPLAGMPVSTTLVVSSEGNTLSTTPVDSKTQVTNSTEASSSATAEGSSMTISAPSEGSPLLTSIPLSTTPVASPEASTLSTTPVDSNSPVITSTEVSSSPIPTEGTSMQTSTYSDRRTPLTSMPVSTTVVASSAISTLSTTPVDTSTPVTNSTEARSSPTTSEGTSMPTSTPSEGSTPFTSMPVSTMPVVTSEASTLSATPVDTSTPVTTSTEATSSPTTAEGTSIPTSTLSEGTTPLTSIPVSHTLVANSEVSTLSTTPVDSNTPFTTSTEASSPPPTAEGTSMPTSTSSEGNTPLTRMPVSTTMVASFETSTLSTTPADTSTPVTTYSQAGSSPTTADDTSMPTSTYSEGSTPLTSVPVSTMPVVSSEASTHSTTPVDTSTPVTTSTEASSSPTTAEGTSIPTSPPSEGTTPLASMPVSTTPVVSSEAGTLSTTPVDTSTPMTTSTEASSSPTTAEDIVVPISTASEGSTLLTSIPVSTTPVASPEASTLSTTPVDSNSPVVTSTEISSSATSAEGTSMPTSTYSEGSTPLRSMPVSTKPLASSEASTLSTTPVDTSIPVTTSTETSSSPTTAKDTSMPISTPSEVSTSLTSILVSTMPVASSEASTLSTTPVDTRTLVTTSTGTSSSPTTAEGSSMPTSTPGERSTPLTNILVSTTLLANSEASTLSTTPVDTSTPVTTSAEASSSPTTAEGTSMRISTPSDGSTPLTSILVSTLPVASSEASTVSTTAVDTSIPVTTSTEASSSPTTAEVTSMPTSTPSETSTPLTSMPVNHTPVASSEAGTLSTTPVDTSTPVTTSTKASSSPTTAEGIVVPISTASEGSTLLTSIPVSTTPVASSEASTLSTTPVDTSIPVTTSTEGSSSPTTAEGTSMPISTPSEVSTPLTSILVSTVPVAGSEASTLSTTPVDTRTPVTTSAEASSSPTTAEGTSMPISTPGERRTPLTSMSVSTMPVASSEASTLSRTPADTSTPVTTSTEASSSPTTAEGTGIPISTPSEGSTPLTSIPVSTTPVAIPEASTLSTTPVDSNSPVVTSTEVSSSPTPAEGTSMPISTYSEGSTPLTGVPVSTTPVTSSAISTLSTTPVDTSTPVTTSTEAHSSPTTSEGTSMPTSTPSEGSTPLTYMPVSTMLVVSSEDSTLSATPVDTSTPVTTSTEATSSTTAEGTSIPTSTPSEGMTPLTSVPVSNTPVASSEASILSTTPVDSNTPLTTSTEASSSPPTAEGTSMPTSTPSEGSTPLTSMPVSTTTVASSETSTLSTTPADTSTPVTTYSQASSSPPIADGTSMPTSTYSEGSTPLTNMSFSTTPVVSSEASTLSTTPVDTSTPVTTSTEASLSPTTAEGTSIPTSSPSEGTTPLASMPVSTTPVVSSEVNTLSTTPVDSNTLVTTSTEASSSPTIAEGTSLPTSTTSEGSTPLSIMPLSTTPVASSEASTLSTTPVDTSTPVTTSSPTNSSPTTAEVTSMPTSTAGEGSTPLTNMPVSTTPVASSEASTLSTTPVDSNTFVTSSSQASSSPATLQVTTMRMSTPSEGSSSLTTMLLSSTYVTSSEASTPSTPSVDRSTPVTTSTQSNSTPTPPEVITLPMSTPSEVSTPLTIMPVSTTSVTISEAGTASTLPVDTSTPVITSTQVSSSPVTPEGTTMPIWTPSEGSTPLTTMPVSTTRVTSSEGSTLSTPSVVTSTPVTTSTEAISSSATLDSTTMSVSMPMEISTLGTTILVSTTPVTRFPESSTPSIPSVYTSMSMTTASEGSSSPTTLEGTTTMPMSTTSERSTLLTTVLISPISVMSPSEASTLSTPPGDTSTPLLTSTKAGSFSIPAEVTTIRISITSERSTPLTTLLVSTTLPTSFPGASIASTPPLDTSTTFTPSTDTASTPTIPVATTISVSVITEGSTPGTTIFIPSTPVTSSTADVFPATTGAVSTPVITSTELNTPSTSSSSTTTSFSTTKEFTTPAMTTAAPLTYVTMSTAPSTPRTTSRGCTTSASTLSATSTPHTSTSVTTRPVTPSSESSRPSTITSHTIPPTFPPAHSSTPPTTSASSTTVNPEAVTTMTTRTKPSTRTTSFPTVTTTAVPTNTTIKSNPTSTPTVPRTTTCFGDGCQNTASRCKNGGTWDGLKCQCPNLYYGELCEEVVSSIDIGPPETISAQMELTVTVTSVKFTEELKNHSSQEFQEFKQTFTEQMNIVYSGIPEYVGVNITKLRLGSVVVEHDVLLRTKYTPEYKTVLDNATEVVKEKITKVTTQQIMINDICSDMMCFNTTGTQVQNITVTQYDPEEDCRKMAKEYGDYFVVEYRDQKPYCISPCEPGFSVSKNCNLGKCQMSLSGPQCLCVTTETHWYSGETCNQGTQKSLVYGLVGAGVVLMLIILVALLMLVFRSKREVKRQKYRLSQLYKWQEEDSGPAPGTFQNIGFDICQDDDSIHLESIYSNFQPSLRHIDPETKIRIQRPQVMTTSF T29345 DRUGINFO DEP3Z8 AMG 199 Phase 1 T30827 TARGETID T30827 T30827 UNIPROID PLF4_HUMAN T30827 TARGNAME Platelet factor 4 (PF4) T30827 GENENAME PF4 T30827 TARGTYPE Clinical trial T30827 SYNONYMS PF-4; C-X-C motif chemokine 4; Iroplact; Oncostatin-A T30827 FUNCTION Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form. T30827 SEQUENCE MSSAAGFCASRPGLLFLGLLLLPLVVAFASAEAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES T30827 DRUGINFO D5VRX2 Dociparstat sodium Phase 3 T30846 TARGETID T30846 T30846 UNIPROID LIRB4_HUMAN T30846 TARGNAME Leukocyte immunoglobulin-like receptor B4 (LILRB4) T30846 GENENAME LILRB4 T30846 TARGTYPE Clinical trial T30846 SYNONYMS CD85 antigen-like family member K; Immunoglobulin-like transcript 3; ILT-3; Leukocyte immunoglobulin-like receptor 5; LIR-5; Monocyte inhibitory receptor HM18; DE AltName: CD_antigen=CD85k T30846 FUNCTION Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Involved in the down-regulation of the immune response and the development of tolerance, e.g. towards transplants. Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. T30846 SEQUENCE MIPTFTALLCLGLSLGPRTHMQAGPLPKPTLWAEPGSVISWGNSVTIWCQGTLEAREYRLDKEESPAPWDRQNPLEPKNKARFSIPSMTEDYAGRYRCYYRSPVGWSQPSDPLELVMTGAYSKPTLSALPSPLVTSGKSVTLLCQSRSPMDTFLLIKERAAHPLLHLRSEHGAQQHQAEFPMSPVTSVHGGTYRCFSSHGFSHYLLSHPSDPLELIVSGSLEDPRPSPTRSVSTAAGPEDQPLMPTGSVPHSGLRRHWEVLIGVLVVSILLLSLLLFLLLQHWRQGKHRTLAQRQADFQRPPGAAEPEPKDGGLQRRSSPAADVQGENFCAAVKNTQPEDGVEMDTRQSPHDEDPQAVTYAKVKHSRPRREMASPPSPLSGEFLDTKDRQAEEDRQMDTEAAASEAPQDVTYAQLHSFTLRQKATEPPPSQEGASPAEPSVYATLAIH T30846 DRUGINFO DM9GO4 IO-202 Phase 1 T31072 TARGETID T31072 T31072 UNIPROID IL12A_HUMAN; IL12B_HUMAN T31072 TARGNAME Interleukine 12 (IL-12) T31072 TARGTYPE Clinical trial T31072 DRUGINFO DVT8O0 ABP 654 Phase 3 T31072 DRUGINFO D90UZW Ad-RTS-hIL-12 Phase 2 T31072 DRUGINFO DRT2P7 GEN-1 Phase 2 T31072 DRUGINFO DT7O8R Tavokinogene telseplasmid Phase 2 T31072 DRUGINFO DG0NA1 MEDI1191 Phase 1 T31072 DRUGINFO DO8W9E M9241 Phase 1 T31072 DRUGINFO DBTI39 YH010 Investigative T32984 TARGETID T32984 T32984 TARGNAME Microtubule (MicroTu) T32984 TARGTYPE Clinical trial T32984 DRUGINFO D3X2TH TPI-287 Phase 2 T36479 TARGETID T36479 T36479 UNIPROID TACT_HUMAN T36479 TARGNAME T-cell surface protein tactile (CD96) T36479 GENENAME CD96 T36479 TARGTYPE Clinical trial T36479 SYNONYMS Cell surface antigen CD96; T cell-activated increased late expression protein; DE AltName: CD_antigen=CD96 T36479 FUNCTION May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation. T36479 SEQUENCE MEKKWKYCAVYYIIQIHFVKGVWEKTVNTEENVYATLGSDVNLTCQTQTVGFFVQMQWSKVTNKIDLIAVYHPQYGFYCAYGRPCESLVTFTETPENGSKWTLHLRNMSCSVSGRYECMLVLYPEGIQTKIYNLLIQTHVTADEWNSNHTIEIEINQTLEIPCFQNSSSKISSEFTYAWSVENSSTDSWVLLSKGIKEDNGTQETLISQNHLISNSTLLKDRVKLGTDYRLHLSPVQIFDDGRKFSCHIRVGPNKILRSSTTVKVFAKPEIPVIVENNSTDVLVERRFTCLLKNVFPKANITWFIDGSFLHDEKEGIYITNEERKGKDGFLELKSVLTRVHSNKPAQSDNLTIWCMALSPVPGNKVWNISSEKITFLLGSEISSTDPPLSVTESTLDTQPSPASSVSPARYPATSSVTLVDVSALRPNTTPQPSNSSMTTRGFNYPWTSSGTDTKKSVSRIPSETYSSSPSGAGSTLHDNVFTSTARAFSEVPTTANGSTKTNHVHITGIVVNKPKDGMSWPVIVAALLFCCMILFGLGVRKWCQYQKEIMERPPPFKPPPPPIKYTCIQEPNESDLPYHEMETL T36479 DRUGINFO DY36LD GSK6097608 Phase 1 T36958 TARGETID T36958 T36958 UNIPROID FOXP3_HUMAN T36958 TARGNAME FOXP3 messenger RNA (FOXP3 mRNA) T36958 GENENAME FOXP3 T36958 TARGTYPE Clinical trial T36958 SYNONYMS Scurfin T36958 FUNCTION Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells. Can act either as a transcriptional repressor or a transcriptional activator depending on its interactions with other transcription factors, histone acetylases and deacetylases. The suppressive activity of Treg involves the coordinate activation of many genes, including CTLA4 and TNFRSF18 by FOXP3 along with repression of genes encoding cytokines such as interleukin-2 (IL2) and interferon-gamma (IFNG). Inhibits cytokine production and T-cell effector function by repressing the activity of two key transcription factors, RELA and NFATC2. Mediates transcriptional repression of IL2 via its association with histone acetylase KAT5 and histone deacetylase HDAC7. Can activate the expression of TNFRSF18, IL2RA and CTLA4 and repress the expression of IL2 and IFNG via its association with transcription factor RUNX1. Inhibits the differentiation of IL17 producing helper T-cells (Th17) by antagonizing RORC function, leading to down-regulation of IL17 expression, favoring Treg development. Inhibits the transcriptional activator activity of RORA. Can repress the expression of IL2 and IFNG via its association with transcription factor IKZF4 (By similarity). T36958 BIOCLASS mRNA target T36958 SEQUENCE MPNPRPGKPSAPSLALGPSPGASPSWRAAPKASDLLGARGPGGTFQGRDLRGGAHASSSSLNPMPPSQLQLPTLPLVMVAPSGARLGPLPHLQALLQDRPHFMHQLSTVDAHARTPVLQVHPLESPAMISLTPPTTATGVFSLKARPGLPPGINVASLEWVSREPALLCTFPNPSAPRKDSTLSAVPQSSYPLLANGVCKWPGCEKVFEEPEDFLKHCQADHLLDEKGRAQCLLQREMVQSLEQQLVLEKEKLSAMQAHLAGKMALTKASSVASSDKGSCCIVAAGSQGPVVPAWSGPREAPDSLFAVRRHLWGSHGNSTFPEFLHNMDYFKFHNMRPPFTYATLIRWAILEAPEKQRTLNEIYHWFTRMFAFFRNHPATWKNAIRHNLSLHKCFVRVESEKGAVWTVDELEFRKKRSQRPSRCSNPTPGP T36958 DRUGINFO DX9T0N AZD8701 Phase 1 T37012 TARGETID T37012 T37012 UNIPROID GFRAL_HUMAN T37012 TARGNAME GDNF family receptor alpha-like (GFRAL) T37012 GENENAME GFRAL T37012 TARGTYPE Clinical trial T37012 FUNCTION Brainstem-restricted receptor for GDF15 which regulates food intake, energy expenditure and body weight in response to metabolic and toxin-induced stresses. Upon interaction with its ligand, GDF15, interacts with RET and induces cellular signaling through activation of MAPK- and AKT- signaling pathways. T37012 SEQUENCE MIVFIFLAMGLSLENEYTSQTNNCTYLREQCLRDANGCKHAWRVMEDACNDSDPGDPCKMRNSSYCNLSIQYLVESNFQFKECLCTDDFYCTVNKLLGKKCINKSDNVKEDKFKWNLTTRSHHGFKGMWSCLEVAEACVGDVVCNAQLASYLKACSANGNPCDLKQCQAAIRFFYQNIPFNIAQMLAFCDCAQSDIPCQQSKEALHSKTCAVNMVPPPTCLSVIRSCQNDELCRRHYRTFQSKCWQRVTRKCHEDENCISTLSKQDLTCSGSDDCKAAYIDILGTVLQVQCTCRTITQSEESLCKIFQHMLHRKSCFNYPTLSNVKGMALYTRKHANKITLTGFHSPFNGEVIYAAMCMTVTCGILLLVMVKLRTSRISSKARDPSSIQIPGEL T37012 DRUGINFO D2VRE1 NGM120 Phase 1 T37048 TARGETID T37048 T37048 UNIPROID SPA_STAA8 T37048 TARGNAME Staphylococcus IgG binding protein A (Stap-coc SpA) T37048 GENENAME Stap-coc SpA T37048 TARGTYPE Clinical trial T37048 SYNONYMS IgG-binding protein A; Staphylococcal protein A; SpA T37048 FUNCTION Plays a role in the inhibition of the host innate and adaptive immune responses. Possesses five immunoglobulin-binding domains that capture both the fragment crystallizable region (Fc region) and the Fab region (part of Ig that identifies antigen) of immunoglobulins. In turn, Staphylococcus aureus is protected from phagocytic killing via inhibition of Ig Fc region. In addition, the host elicited B-cell response is prevented due to a decrease of antibody-secreting cell proliferation that enter the bone marrow, thereby decreasing long-term antibody production. Inhibits osteogenesis by preventing osteoblast proliferation and expression of alkaline phosphatase, type I collagen, osteopontin and osteocalcin. Acts directly as a proinflammatory factor in the lung through its ability to bind and activate tumor necrosis factor alpha receptor 1/TNFRSF1A (By similarity). T37048 SEQUENCE MKKKNIYSIRKLGVGIASVTLGTLLISGGVTPAANAAQHDEAQQNAFYQVLNMPNLNADQRNGFIQSLKDDPSQSANVLGEAQKLNDSQAPKADAQQNNFNKDQQSAFYEILNMPNLNEAQRNGFIQSLKDDPSQSTNVLGEAKKLNESQAPKADNNFNKEQQNAFYEILNMPNLNEEQRNGFIQSLKDDPSQSANLLSEAKKLNESQAPKADNKFNKEQQNAFYEILHLPNLNEEQRNGFIQSLKDDPSQSANLLAEAKKLNDAQAPKADNKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKEEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKEDNKKPGKEDGNKPGKEDNKKPGKEDGNKPGKEDGNKPGKEDGNGVHVVKPGDTVNDIAKANGTTADKIAADNKLADKNMIKPGQELVVDKKQPANHADANKAQALPETGEENPFIGTTVFGGLSLALGAALLAGRRREL T37048 DRUGINFO D51VYQ 514G3 Phase 1/2 T38201 TARGETID T38201 T38201 UNIPROID PARPT_HUMAN T38201 TARGNAME Protein mono-ADP-ribosyltransferase TIPARP (TIPARP) T38201 GENENAME TIPARP T38201 TARGTYPE Clinical trial T38201 SYNONYMS ADP-ribosyltransferase diphtheria toxin-like 14; ARTD14; Poly [ADP-ribose] polymerase 7; PARP-7; TCDD-inducible poly [ADP-ribose] polymerase T38201 FUNCTION ADP-ribosyltransferase that mediates mono-ADP-ribosylation of glutamate, aspartate and cysteine residues on target proteins. Acts as a negative regulator of AHR by mediating mono-ADP-ribosylation of AHR, leading to inhibit transcription activator activity of AHR. T38201 ECNUMBER EC 2.4.2.- T38201 SEQUENCE MEMETTEPEPDCVVQPPSPPDDFSCQMRLSEKITPLKTCFKKKDQKRLGTGTLRSLRPILNTLLESGSLDGVFRSRNQSTDENSLHEPMMKKAMEINSSCPPAENNMSVLIPDRTNVGDQIPEAHPSTEAPERVVPIQDHSFPSETLSGTVADSTPAHFQTDLLHPVSSDVPTSPDCLDKVIDYVPGIFQENSFTIQYILDTSDKLSTELFQDKSEEASLDLVFELVNQLQYHTHQENGIEICMDFLQGTCIYGRDCLKHHTVLPYHWQIKRTTTQKWQSVFNDSQEHLERFYCNPENDRMRMKYGGQEFWADLNAMNVYETTEFDQLRRLSTPPSSNVNSIYHTVWKFFCRDHFGWREYPESVIRLIEEANSRGLKEVRFMMWNNHYILHNSFFRREIKRRPLFRSCFILLPYLQTLGGVPTQAPPPLEATSSSQIICPDGVTSANFYPETWVYMHPSQDFIQVPVSAEDKSYRIIYNLFHKTVPEFKYRILQILRVQNQFLWEKYKRKKEYMNRKMFGRDRIINERHLFHGTSQDVVDGICKHNFDPRVCGKHATMFGQGSYFAKKASYSHNFSKKSSKGVHFMFLAKVLTGRYTMGSHGMRRPPPVNPGSVTSDLYDSCVDNFFEPQIFVIFNDDQSYPYFVIQYEEVSNTVSI T38201 DRUGINFO DJ7K9G RBN-2397 Phase 1 T38509 TARGETID T38509 T38509 UNIPROID FA12_HUMAN T38509 TARGNAME Coagulation factor XII (F12) T38509 GENENAME F12 T38509 TARGTYPE Clinical trial T38509 SYNONYMS Hageman factor; HAF T38509 BIOCLASS Peptidase T38509 ECNUMBER EC 3.4.21.38 T38509 SEQUENCE MRALLLLGFLLVSLESTLSIPPWEAPKEHKYKAEEHTVVLTVTGEPCHFPFQYHRQLYHKCTHKGRPGPQPWCATTPNFDQDQRWGYCLEPKKVKDHCSKHSPCQKGGTCVNMPSGPHCLCPQHLTGNHCQKEKCFEPQLLRFFHKNEIWYRTEQAAVARCQCKGPDAHCQRLASQACRTNPCLHGGRCLEVEGHRLCHCPVGYTGAFCDVDTKASCYDGRGLSYRGLARTTLSGAPCQPWASEATYRNVTAEQARNWGLGGHAFCRNPDNDIRPWCFVLNRDRLSWEYCDLAQCQTPTQAAPPTPVSPRLHVPLMPAQPAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTRNGPLSCGQRLRKSLSSMTRVVGGLVALRGAHPYIAALYWGHSFCAGSLIAPCWVLTAAHCLQDRPAPEDLTVVLGQERRNHSCEPCQTLAVRSYRLHEAFSPVSYQHDLALLRLQEDADGSCALLSPYVQPVCLPSGAARPSETTLCQVAGWGHQFEGAEEYASFLQEAQVPFLSLERCSAPDVHGSSILPGMLCAGFLEGGTDACQGDSGGPLVCEDQAAERRLTLQGIISWGSGCGDRNKPGVYTDVAYYLAWIREHTVS T38509 DRUGINFO DR49KB CSL312 Phase 3 T38509 DRUGINFO D5EP4C ION547 Phase 1 T39047 TARGETID T39047 T39047 UNIPROID LAIR1_HUMAN T39047 TARGNAME Leukocyte-associated Ig-like receptor 1 (LAIR1) T39047 GENENAME LAIR1 T39047 TARGTYPE Clinical trial T39047 SYNONYMS LAIR-1; hLAIR1; DE AltName: CD_antigen=CD305 T39047 FUNCTION Functions as an inhibitory receptor that plays a constitutive negative regulatory role on cytolytic function of natural killer (NK) cells, B-cells and T-cells. Activation by Tyr phosphorylation results in recruitment and activation of the phosphatases PTPN6 and PTPN11. It also reduces the increase of intracellular calcium evoked by B-cell receptor ligation. May also play its inhibitory role independently of SH2-containing phosphatases. Modulates cytokine production in CD4+ T-cells, down-regulating IL2 and IFNG production while inducing secretion of transforming growth factor beta. Down-regulates also IgG and IgE production in B-cells as well as IL8, IL10 and TNF secretion. Inhibits proliferation and induces apoptosis in myeloid leukemia cell lines as well as prevents nuclear translocation of NF-kappa-B p65 subunit/RELA and phosphorylation of I-kappa-B alpha/CHUK in these cells. Inhibits the differentiation of peripheral blood precursors towards dendritic cells. T39047 SEQUENCE MSPHPTALLGLVLCLAQTIHTQEEDLPRPSISAEPGTVIPLGSHVTFVCRGPVGVQTFRLERESRSTYNDTEDVSQASPSESEARFRIDSVSEGNAGPYRCIYYKPPKWSEQSDYLELLVKETSGGPDSPDTEPGSSAGPTQRPSDNSHNEHAPASQGLKAEHLYILIGVSVVFLFCLLLLVLFCLHRQNQIKQGPPRSKDEEQKPQQRPDLAVDVLERTADKATVNGLPEKDRETDTSALAAGSSQEVTYAQLDHWALTQRTARAVSPQSTKPMAESITYAAVARH T39047 DRUGINFO DK6J7M NC410 Phase 1/2 T39047 DRUGINFO DF8ZT3 NGM438 Phase 1 T41239 TARGETID T41239 T41239 TARGNAME Hydroxyapatite (HA) T41239 TARGTYPE Clinical trial T41239 DRUGINFO DD76HZ SNF472 Phase 3 T41380 TARGETID T41380 T41380 UNIPROID LRC32_HUMAN T41380 TARGNAME Transforming growth factor beta activator LRRC32 (LRRC32) T41380 GENENAME LRRC32 T41380 TARGTYPE Clinical trial T41380 SYNONYMS Garpin; Glycoprotein A repetitions predominant; GARP; Leucine-rich repeat-containing protein 32 T41380 FUNCTION Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space. Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta. Able to outcompete LTBP1 for binding to LAP regulatory chain of TGF-beta. Controls activation of TGF-beta-1 (TGFB1) on the surface of activated regulatory T-cells (Tregs). Required for epithelial fusion during palate development by regulating activation of TGF-beta-3 (TGFB3) (By similarity). T41380 SEQUENCE MRPQILLLLALLTLGLAAQHQDKVPCKMVDKKVSCQVLGLLQVPSVLPPDTETLDLSGNQLRSILASPLGFYTALRHLDLSTNEISFLQPGAFQALTHLEHLSLAHNRLAMATALSAGGLGPLPRVTSLDLSGNSLYSGLLERLLGEAPSLHTLSLAENSLTRLTRHTFRDMPALEQLDLHSNVLMDIEDGAFEGLPRLTHLNLSRNSLTCISDFSLQQLRVLDLSCNSIEAFQTASQPQAEFQLTWLDLRENKLLHFPDLAALPRLIYLNLSNNLIRLPTGPPQDSKGIHAPSEGWSALPLSAPSGNASGRPLSQLLNLDLSYNEIELIPDSFLEHLTSLCFLNLSRNCLRTFEARRLGSLPCLMLLDLSHNALETLELGARALGSLRTLLLQGNALRDLPPYTFANLASLQRLNLQGNRVSPCGGPDEPGPSGCVAFSGITSLRSLSLVDNEIELLRAGAFLHTPLTELDLSSNPGLEVATGALGGLEASLEVLALQGNGLMVLQVDLPCFICLKRLNLAENRLSHLPAWTQAVSLEVLDLRNNSFSLLPGSAMGGLETSLRRLYLQGNPLSCCGNGWLAAQLHQGRVDVDATQDLICRFSSQEEVSLSHVRPEDCEKGGLKNINLIIILTFILVSAILLTTLAACCCVRRQKFNQQYKA T41380 DRUGINFO DB6GK4 DS-1055 Phase 1 T41597 TARGETID T41597 T41597 UNIPROID DGAT2_HUMAN T41597 TARGNAME DGAT2 messenger RNA (DGAT2 mRNA) T41597 GENENAME DGAT2 T41597 TARGTYPE Clinical trial T41597 SYNONYMS Acyl-CoA retinol O-fatty-acyltransferase; ARAT; Retinol O-fatty-acyltransferase; Diglyceride acyltransferase 2 T41597 FUNCTION Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides. Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Functions also as an acyl-CoA retinol acyltransferase (ARAT) (By similarity). Also able to use 1-monoalkylglycerol (1-MAkG) as an acyl acceptor for the synthesis of monoalkyl-monoacylglycerol (MAMAG). T41597 BIOCLASS mRNA target T41597 ECNUMBER EC 2.3.1.20 T41597 SEQUENCE MKTLIAAYSGVLRGERQAEADRSQRSHGGPALSREGSGRWGTGSSILSALQDLFSVTWLNRSKVEKQLQVISVLQWVLSFLVLGVACSAILMYIFCTDCWLIAVLYFTWLVFDWNTPKKGGRRSQWVRNWAVWRYFRDYFPIQLVKTHNLLTTRNYIFGYHPHGIMGLGAFCNFSTEATEVSKKFPGIRPYLATLAGNFRMPVLREYLMSGGICPVSRDTIDYLLSKNGSGNAIIIVVGGAAESLSSMPGKNAVTLRNRKGFVKLALRHGADLVPIYSFGENEVYKQVIFEEGSWGRWVQKKFQKYIGFAPCIFHGRGLFSSDTWGLVPYSKPITTVVGEPITIPKLEHPTQQDIDLYHTMYMEALVKLFDKHKTKFGLPETEVLEVN T41597 DRUGINFO DK28NV ION 224 Phase 1 T41756 TARGETID T41756 T41756 UNIPROID VP1_POVBK T41756 TARGNAME BV virus Major capsid protein VP1 (BKV VP1) T41756 GENENAME BKV VP1 T41756 TARGTYPE Clinical trial T41756 SYNONYMS Major structural protein VP1 T41756 FUNCTION Forms an icosahedral capsid with a T=7 symmetry and a 50 nm diameter. The capsid is composed of 72 pentamers linked to each other by disulfide bonds and associated with VP2 or VP3 proteins. Interacts with gangliosides GT1b and GD1b containing terminal alpha(2-8)-linked sialic acids on the cell surface to provide virion attachment to target cell. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis and traffics to the endoplasmic reticulum. Inside the endoplasmic reticulum, the protein folding machinery isomerizes VP1 interpentamer disulfide bonds, thereby triggering initial uncoating. Next, the virion uses the endoplasmic reticulum-associated degradation machinery to probably translocate in the cytosol before reaching the nucleus. Nuclear entry of the viral DNA involves the selective exposure and importin recognition of VP2/Vp3 nuclear localization signal. In late phase of infection, neo-synthesized VP1 encapsulates replicated genomic DNA in the nucleus, and participates in rearranging nucleosomes around the viral DNA. T41756 SEQUENCE MAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEVKTGVDAITEVECFLNPEMGDPDENLRGFSLKLSAENDFSSDSPERKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVQTEVIGITSMLNLHAGSQKVHEHGGGKPIQGSNFHFFAVGGEPLEMQGVLMNYRSKYPDGTITPKNPTAQSQVMNTDHKAYLDKNNAYPVECWVPDPSRNENARYFGTFTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVKNPYPISFLLSDLINRRTQRVDGQPMYGMESQVEEVRVFDGTERLPGDPDMIRYIDKQGQLQTKML T41756 DRUGINFO DPTM94 MAU868 Phase 1 T42760 TARGETID T42760 T42760 UNIPROID KS6B2_HUMAN T42760 TARGNAME Ribosomal protein S6 kinase beta-2 (RPS6KB2) T42760 GENENAME RPS6KB2 T42760 TARGTYPE Clinical trial T42760 SYNONYMS S6K-beta-2; S6K2; 70 kDa ribosomal protein S6 kinase 2; P70S6K2; p70-S6K 2; S6 kinase-related kinase; SRK; Serine/threonine-protein kinase 14B; p70 ribosomal S6 kinase beta; S6K-beta; p70 S6 kinase beta; p70 S6K-beta; p70 S6KB; p70-beta T42760 FUNCTION Phosphorylates specifically ribosomal protein S6. Seems to act downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression in an alternative pathway regulated by MEAK7. T42760 BIOCLASS Kinase T42760 ECNUMBER EC 2.7.11.1 T42760 SEQUENCE MAAVFDLDLETEEGSEGEGEPELSPADACPLAELRAAGLEPVGHYEEVELTETSVNVGPERIGPHCFELLRVLGKGGYGKVFQVRKVQGTNLGKIYAMKVLRKAKIVRNAKDTAHTRAERNILESVKHPFIVELAYAFQTGGKLYLILECLSGGELFTHLEREGIFLEDTACFYLAEITLALGHLHSQGIIYRDLKPENIMLSSQGHIKLTDFGLCKESIHEGAVTHTFCGTIEYMAPEILVRSGHNRAVDWWSLGALMYDMLTGSPPFTAENRKKTMDKIIRGKLALPPYLTPDARDLVKKFLKRNPSQRIGGGPGDAADVQRHPFFRHMNWDDLLAWRVDPPFRPCLQSEEDVSQFDTRFTRQTPVDSPDDTALSESANQAFLGFTYVAPSVLDSIKEGFSFQPKLRSPRRLNSSPRAPVSPLKFSPFEGFRPSPSLPEPTELPLPPLLPPPPPSTTAPLPIRPPSGTKKSKRGRGRPGR T42760 DRUGINFO DJR94F PMD-026 Phase 1 T43658 TARGETID T43658 T43658 UNIPROID HAOX1_HUMAN T43658 TARGNAME HAO1 messenger RNA (HAO1 mRNA) T43658 GENENAME HAO1 T43658 TARGTYPE Clinical trial T43658 SYNONYMS HAOX1; Glycolate oxidase; GOX T43658 FUNCTION Has 2-hydroxyacid oxidase activity. Most active on the 2-carbon substrate glycolate, but is also active on 2-hydroxy fatty acids, with high activity towards 2-hydroxy palmitate and 2-hydroxy octanoate. T43658 BIOCLASS mRNA target T43658 ECNUMBER EC 1.1.3.15 T43658 SEQUENCE MLPRLICINDYEQHAKSVLPKSIYDYYRSGANDEETLADNIAAFSRWKLYPRMLRNVAETDLSTSVLGQRVSMPICVGATAMQRMAHVDGELATVRACQSLGTGMMLSSWATSSIEEVAEAGPEALRWLQLYIYKDREVTKKLVRQAEKMGYKAIFVTVDTPYLGNRLDDVRNRFKLPPQLRMKNFETSTLSFSPEENFGDDSGLAAYVAKAIDPSISWEDIKWLRRLTSLPIVAKGILRGDDAREAVKHGLNGILVSNHGARQLDGVPATIDVLPEIVEAVEGKVEVFLDGGVRKGTDVLKALALGAKAVFVGRPIVWGLAFQGEKGVQDVLEILKEEFRLAMALSGCQNVKVIDKTLVRKNPLAVSKI T43658 DRUGINFO DD1GK8 Lumasiran Approved T43980 TARGETID T43980 T43980 UNIPROID ILDR2_HUMAN T43980 TARGNAME Ig-like domain-containing receptor 2 (ILDR2) T43980 GENENAME ILDR2 T43980 TARGTYPE Clinical trial T43980 FUNCTION May be involved in lipid homeostasis and ER stress pathways. T43980 SEQUENCE MDRVLLRWISLFWLTAMVEGLQVTVPDKKKVAMLFQPTVLRCHFSTSSHQPAVVQWKFKSYCQDRMGESLGMSSTRAQSLSKRNLEWDPYLDCLDSRRTVRVVASKQGSTVTLGDFYRGREITIVHDADLQIGKLMWGDSGLYYCIITTPDDLEGKNEDSVELLVLGRTGLLADLLPSFAVEIMPEWVFVGLVLLGVFLFFVLVGICWCQCCPHSCCCYVRCPCCPDSCCCPQALYEAGKAAKAGYPPSVSGVPGPYSIPSVPLGGAPSSGMLMDKPHPPPLAPSDSTGGSHSVRKGYRIQADKERDSMKVLYYVEKELAQFDPARRMRGRYNNTISELSSLHEEDSNFRQSFHQMRSKQFPVSGDLESNPDYWSGVMGGSSGASRGPSAMEYNKEDRESFRHSQPRSKSEMLSRKNFATGVPAVSMDELAAFADSYGQRPRRADGNSHEARGGSRFERSESRAHSGFYQDDSLEEYYGQRSRSREPLTDADRGWAFSPARRRPAEDAHLPRLVSRTPGTAPKYDHSYLGSARERQARPEGASRGGSLETPSKRSAQLGPRSASYYAWSPPGTYKAGSSQDDQEDASDDALPPYSELELTRGPSYRGRDLPYHSNSEKKRKKEPAKKTNDFPTRMSLVV T43980 DRUGINFO D3SPE5 BAY 1905254 Phase 1 T45760 TARGETID T45760 T45760 UNIPROID L_HRSVA T45760 TARGNAME HRSV RNA-directed RNA polymerase L (HRSV L) T45760 GENENAME HRSV L T45760 TARGTYPE Clinical trial T45760 SYNONYMS Protein L; Large structural protein; Replicase; Transcriptase T45760 FUNCTION Responsible for RNA synthesis (replicase and transcriptase), cap addition, and cap methylation. Performs also the polyadenylation of subgenomic mRNAs by a stuttering mechanism at a slipery stop site present at the end of viral genes. The template is composed of the viral RNA tightly encapsidated by the nucleoprotein (N) (Probable). The viral polymerase binds to the genomic RNA at two differents sites in the 3' leader promoter thereby initiating either genome replication or mRNA transcription. In the transcription mode, the polymerase performs the sequential transcription of all mRNAs using a termination-reinitiation mechanism responding to gene start and gene end signals. Some polymerase disengage from the template at each gene junction, resulting in a decreasing abundance of transcripts from the 3' to the 5' end of the genome (Probable). The first gene is the most transcribed, and the last the least transcribed (Probable). Needs as cofactors the phosphoprotein for processivity and the M2-1 anti-termination protein. Polyribonucleotidyl transferase (PRNTase) adds the cap structure when the nascent RNA chain length has reached few nucleotides. Ribose 2'-O methylation of viral mRNA cap precedes and facilitates subsequent guanine-N-7 methylation (By similarity). In the replication mode, the polymerase replicates the whole viral genome without recognizing the gene end transcriptional signals. The ability of the polymerase to override the gene end signals as it is producing the antigenome is probably due to replicative RNA becoming encapsidated with nucleoprotein as it is synthesized. T45760 SEQUENCE MDPIINGNSANVYLTDSYLKGVISFSECNALGSYIFNGPYLKNDYTNLISRQNPLIEHMNLKKLNITQSLISKYHKGEIKLEEPTYFQSLLMTYKSMTSSEQIATTNLLKKIIRRAIEISDVKVYAILNKLGLKEKDKIKSNNGQDEDNSVITTIIKDDILSAVKDNQSHLKADKNHSTKQKDTIKTTLLKKLMCSMQHPPSWLIHWFNLYTKLNNILTQYRSNEVKNHGFTLIDNQTLSGFQFILNQYGCIVYHKELKRITVTTYNQFLTWKDISLSRLNVCLITWISNCLNTLNKSLGLRCGFNNVILTQLFLYGDCILKLFHNEGFYIIKEVEGFIMSLILNITEEDQFRKRFYNSMLNNITDAANKAQKNLLSRVCHTLLDKTVSDNIINGRWIILLSKFLKLIKLAGDNNLNNLSELYFLFRIFGHPMVDERQAMDAVKINCNETKFYLLSSLSMLRGAFIYRIIKGFVNNYNRWPTLRNAIVLPLRWLTYYKLNTYPSLLELTERDLIVLSGLRFYREFRLPKKVDLEMIINDKAISPPKNLIWTSFPRNYMPSHIQNYIEHEKLKFSESDKSRRVLEYYLRDNKFNECDLYNCVVNQSYLNNPNHVVSLTGKERELSVGRMFAMQPGMFRQVQILAEKMIAENILQFFPESLTRYGDLELQKILELKAGISNKSNRYNDNYNNYISKCSIITDLSKFNQAFRYETSCICSDVLDELHGVQSLFSWLHLTIPHVTIICTYRHAPPYIGDHIVDLNNVDEQSGLYRYHMGGIEGWCQKLWTIEAISLLDLISLKGKFSITALINGDNQSIDISKPIRLMEGQTHAQADYLLALNSLKLLYKEYAGIGHKLKGTETYISRDMQFMSKTIQHNGVYYPASIKKVLRVGPWINTILDDFKVSLESIGSLTQELEYRGESLLCSLIFRNVWLYNQIALQLKNHALCNNKLYLDILKVLKHLKTFFNLDNIDTALTLYMNLPMLFGGGDPNLLYRSFYRRTPDFLTEAIVHSVFILSYYTNHDLKDKLQDLSDDRLNKFLTCIITFDKNPNAEFVTLMRDPQALGSERQAKITSEINRLAVTEVLSTAPNKIFSKSAQHYTTTEIDLNDIMQNIEPTYPHGLRVVYESLPFYKAEKIVNLISGTKSITNILEKTSAIDLTDIDRATEMMRKNITLLIRILPLDCNRDKREILSMENLSITELSKYVRERSWSLSNIVGVTSPSIMYTMDIKYTTSTISSGIIIEKYNVNSLTRGERGPTKPWVGSSTQEKKTMPVYNRQVLTKKQRDQIDLLAKLDWVYASIDNKDEFMEELSIGTLGLTYEKAKKLFPQYLSVNYLHRLTVSSRPCEFPASIPAYRTTNYHFDTSPINRILTEKYGDEDIDIVFQNCISFGLSLMSVVEQFTNVCPNRIILIPKLNEIHLMKPPIFTGDVDIHKLKQVIQKQHMFLPDKISLTQYVELFLSNKTLKSGSHVNSNLILAHKISDYFHNTYILSTNLAGHWILIIQLMKDSKGIFEKDWGEGYITDHMFINLKVFFNAYKTYLLCFHKGYGKAKLECDMNTSDLLCVLELIDSSYWKSMSKVFLEQKVIKYILSQDASLHRVKGCHSFKLWFLKRLNVAEFTVCPWVVNIDYHPTHMKAILTYIDLVRMGLINIDRIHIKNKHKFNDEFYTSNLFYINYNFSDNTHLLTKHIRIANSELENNYNKLYHPTPETLENILANPIKSNDKKTLNDYCIGKNVDSIMLPLLSNKKLIKSSAMIRTNYSKQDLYNLFPMVVIDRIIDHSGNTAKSNQLYTTTSHQISLVHNSTSLYCMLPWHHINRFNFVFSSTGCKISIEYILKDLKIKDPNCIAFIGEGAGNLLLRTVVELHPDIRYIYRSLKDCNDHSLPIEFLRLYNGHINIDYGENLTIPATDATNNIHWSYLHIKFAEPISLFVCDAELSVTVNWSKIIIEWSKHVRKCKYCSSVNKCMLIVKYHAQDDIDFKLDNITILKTYVCLGSKLKGSEVYLVLTIGPANIFPVFNVVQNAKLILSRTKNFIMPKKADKESIDANIKSLIPFLCYPITKKGINTALSKLKSVVSGDILSYSIAGRNEVFSNKLINHKHMNILKWFNHVLNFRSTELNYNHLYMVESTYPYLSELLNSLTTNELKKLIKITGSLLYNFHNE T45760 DRUGINFO D0TMF3 JNJ-64417184 Phase 1 T46052 TARGETID T46052 T46052 UNIPROID LAMP2_HUMAN T46052 TARGNAME Lysosome-associated membrane glycoprotein 2 (LAMP2) T46052 GENENAME LAMP2 T46052 TARGTYPE Clinical trial T46052 SYNONYMS LAMP-2; Lysosome-associated membrane protein 2; CD107 antigen-like family member B; LGP-96; DE AltName: CD_antigen=CD107b T46052 FUNCTION Plays an important role in chaperone-mediated autophagy, a process that mediates lysosomal degradation of proteins in response to various stresses and as part of the normal turnover of proteins with a long biological half-live. Functions by binding target proteins, such as GAPDH and MLLT11, and targeting them for lysosomal degradation. Plays a role in lysosomal protein degradation in response to starvation (By similarity). Required for the fusion of autophagosomes with lysosomes during autophagy. Cells that lack LAMP2 express normal levels of VAMP8, but fail to accumulate STX17 on autophagosomes, which is the most likely explanation for the lack of fusion between autophagosomes and lysosomes. Required for normal degradation of the contents of autophagosomes. Required for efficient MHCII-mediated presentation of exogenous antigens via its function in lysosomal protein degradation; antigenic peptides generated by proteases in the endosomal/lysosomal compartment are captured by nascent MHCII subunits. Is not required for efficient MHCII-mediated presentation of endogenous antigens. T46052 SEQUENCE MVCFRLFPVPGSGLVLVCLVLGAVRSYALELNLTDSENATCLYAKWQMNFTVRYETTNKTYKTVTISDHGTVTYNGSICGDDQNGPKIAVQFGPGFSWIANFTKAASTYSIDSVSFSYNTGDNTTFPDAEDKGILTVDELLAIRIPLNDLFRCNSLSTLEKNDVVQHYWDVLVQAFVQNGTVSTNEFLCDKDKTSTVAPTIHTTVPSPTTTPTPKEKPEAGTYSVNNGNDTCLLATMGLQLNITQDKVASVININPNTTHSTGSCRSHTALLRLNSSTIKYLDFVFAVKNENRFYLKEVNISMYLVNGSVFSIANNNLSYWDAPLGSSYMCNKEQTVSVSGAFQINTFDLRVQPFNVTQGKYSTAQDCSADDDNFLVPIAVGAALAGVLILVLLAYFIGLKHHHAGYEQF T46052 DRUGINFO DX36OY RP-A501 Phase 1 T46789 TARGETID T46789 T46789 UNIPROID SHPS1_HUMAN T46789 TARGNAME Inhibitory receptor SHPS-1 (SIRPA) T46789 GENENAME SIRPA T46789 TARGTYPE Clinical trial T46789 SYNONYMS SHP substrate 1; SHPS-1; Brain Ig-like molecule with tyrosine-based activation motifs; Bit; CD172 antigen-like family member A; Macrophage fusion receptor; MyD-1 antigen; Signal-regulatory protein alpha-1; Sirp-alpha-1; Signal-regulatory protein alpha-2; Sirp-alpha-2; Signal-regulatory protein alpha-3; Sirp-alpha-3; p84; DE AltName: CD_antigen=CD172a T46789 FUNCTION Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. Supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment. May play a key role in intracellular signaling during synaptogenesis and in synaptic function (By similarity). Involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin. Mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. T46789 SEQUENCE MEPAGPAPGRLGPLLCLLLAASCAWSGVAGEEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVICEVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVNVTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNTAAENTGSNERNIYIVVGVVCTLLVALLMAALYLVRIRQKKAQGSTSSTRLHEPEKNAREITQDTNDITYADLNLPKGKKPAPQAAEPNNHTEYASIQTSPQPASEDTLTYADLDMVHLNRTPKQPAPKPEPSFSEYASVQVPRK T46789 DRUGINFO DJ29KW FSI-189 Phase 1 T46789 DRUGINFO DKL3Z7 CC-95251 Phase 1 T46789 DRUGINFO DZBV67 BI 765063 Phase 1 T47381 TARGETID T47381 T47381 UNIPROID GSTP1_HUMAN T47381 TARGNAME GSTP1 messenger RNA (GSTP1 mRNA) T47381 GENENAME GSTP1 T47381 TARGTYPE Clinical trial T47381 SYNONYMS GST class-pi; GSTP1-1 T47381 FUNCTION Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2). Participates in the formation of novel hepoxilin regioisomers. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration. T47381 BIOCLASS mRNA target T47381 ECNUMBER EC 2.5.1.18 T47381 SEQUENCE MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ T47381 DRUGINFO D8UZ5R NBF-006 Phase 1 T49105 TARGETID T49105 T49105 UNIPROID PVRIG_HUMAN T49105 TARGNAME Transmembrane protein PVRIG (PVRIG) T49105 GENENAME PVRIG T49105 TARGTYPE Clinical trial T49105 SYNONYMS CD112 receptor; CD112R; Poliovirus receptor-related immunoglobulin domain-containing protein T49105 FUNCTION Cell surface receptor for NECTIN2. May act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals. Following interaction with NECTIN2, inhibits T-cell proliferation. Competes with CD226 for NECTIN2-binding. T49105 SEQUENCE MRTEAQVPALQPPEPGLEGAMGHRTLVLPWVLLTLCVTAGTPEVWVQVRMEATELSSFTIRCGFLGSGSISLVTVSWGGPNGAGGTTLAVLHPERGIRQWAPARQARWETQSSISLILEGSGASSPCANTTFCCKFASFPEGSWEACGSLPPSSDPGLSAPPTPAPILRADLAGILGVSGVLLFGCVYLLHLLRRHKHRPAPRLQPSRTSPQAPRARAWAPSQASQAALHVPYATINTSCRPATLDTAHPHGGPSWWASLPTHAAHRPQGPAAWASTPIPARGSFVSVENGLYAQAGERPPHTGPGLTLFPDPRGPRAMEGPLGVR T49105 DRUGINFO D7WOL5 COM701 Phase 1 T49105 DRUGINFO DM1F3R GSK4381562 Phase 1 T49156 TARGETID T49156 T49156 UNIPROID PTN2_HUMAN T49156 TARGNAME Tyrosine-protein phosphatase non-receptor type 2 (PTPN2) T49156 GENENAME PTPN2 T49156 TARGTYPE Clinical trial T49156 SYNONYMS T-cell protein-tyrosine phosphatase; TCPTP T49156 FUNCTION Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. Also dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3 and STAT6 either in the nucleus or the cytoplasm. Negatively regulates numerous signaling pathways and biological processes like hematopoiesis, inflammatory response, cell proliferation and differentiation, and glucose homeostasis. Plays a multifaceted and important role in the development of the immune system. Functions in T-cell receptor signaling through dephosphorylation of FYN and LCK to control T-cells differentiation and activation. Dephosphorylates CSF1R, negatively regulating its downstream signaling and macrophage differentiation. Negatively regulates cytokine (IL2/interleukin-2 and interferon)-mediated signaling through dephosphorylation of the cytoplasmic kinases JAK1, JAK3 and their substrate STAT1, that propagate signaling downstream of the cytokine receptors. Also regulates the IL6/interleukin-6 and IL4/interleukin-4 cytokine signaling through dephosphorylation of STAT3 and STAT6 respectively. In addition to the immune system, it is involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth. Activated by the integrin ITGA1/ITGB1, it dephosphorylates EGFR and negatively regulates EGF signaling. Dephosphorylates PDGFRB and negatively regulates platelet-derived growth factor receptor-beta signaling pathway and therefore cell proliferation. Negatively regulates tumor necrosis factor-mediated signaling downstream via MAPK through SRC dephosphorylation. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of the hepatocyte growth factor receptor MET. Plays also an important role in glucose homeostasis. For instance, negatively regulates the insulin receptor signaling pathway through the dephosphorylation of INSR and control gluconeogenesis and liver glucose production through negative regulation of the IL6 signaling pathways. May also bind DNA. T49156 ECNUMBER EC 3.1.3.48 T49156 SEQUENCE MPTTIEREFEELDTQRRWQPLYLEIRNESHDYPHRVAKFPENRNRNRYRDVSPYDHSRVKLQNAENDYINASLVDIEEAQRSYILTQGPLPNTCCHFWLMVWQQKTKAVVMLNRIVEKESVKCAQYWPTDDQEMLFKETGFSVKLLSEDVKSYYTVHLLQLENINSGETRTISHFHYTTWPDFGVPESPASFLNFLFKVRESGSLNPDHGPAVIHCSAGIGRSGTFSLVDTCLVLMEKGDDINIKQVLLNMRKYRMGLIQTPDQLRFSYMAIIEGAKCIKGDSSIQKRWKELSKEDLSPAFDHSPNKIMTEKYNGNRIGLEEEKLTGDRCTGLSSKMQDTMEENSESALRKRIREDRKATTAQKVQQMKQRLNENERKRKRWLYWQPILTKMGFMSVILVGAFVGWTLFFQQNAL T49156 DRUGINFO D5EOV9 ABBV-CLS-579 Phase 1 T50289 TARGETID T50289 T50289 UNIPROID BMP7_HUMAN T50289 TARGNAME Bone morphogenetic protein 7 (BMP7) T50289 GENENAME BMP7 T50289 TARGTYPE Clinical trial T50289 SYNONYMS BMP-7; Osteogenic protein 1; OP-1; Eptotermin alfa T50289 FUNCTION Induces cartilage and bone formation. May be the osteoinductive factor responsible for the phenomenon of epithelial osteogenesis. Plays a role in calcium regulation and bone homeostasis. Promotes brown adipocyte differentiation by P38 MAPK pathway-mediated activation of target genes, including members of the SOX family of transcription factors. T50289 SEQUENCE MHVRSLRAAAPHSFVALWAPLFLLRSALADFSLDNEVHSSFIHRRLRSQERREMQREILSILGLPHRPRPHLQGKHNSAPMFMLDLYNAMAVEEGGGPGGQGFSYPYKAVFSTQGPPLASLQDSHFLTDADMVMSFVNLVEHDKEFFHPRYHHREFRFDLSKIPEGEAVTAAEFRIYKDYIRERFDNETFRISVYQVLQEHLGRESDLFLLDSRTLWASEEGWLVFDITATSNHWVVNPRHNLGLQLSVETLDGQSINPKLAGLIGRHGPQNKQPFMVAFFKATEVHFRSIRSTGSKQRSQNRSKTPKNQEALRMANVAENSSSDQRQACKKHELYVSFRDLGWQDWIIAPEGYAAYYCEGECAFPLNSYMNATNHAIVQTLVHFINPETVPKPCCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH T50289 DRUGINFO DP9SF6 THR-184 Phase 2 T51468 TARGETID T51468 T51468 UNIPROID CLK1_HUMAN; CLK2_HUMAN; CLK3_HUMAN; CLK4_HUMAN T51468 TARGNAME Cdc-like kinase (CLK) T51468 TARGTYPE Clinical trial T51468 DRUGINFO DS4M1A SM09419 Phase 1 T51672 TARGETID T51672 T51672 UNIPROID IKBA_HUMAN T51672 TARGNAME NF-kappa-B inhibitor alpha (NFKBIA) T51672 GENENAME NFKBIA T51672 TARGTYPE Clinical trial T51672 SYNONYMS I-kappa-B-alpha; IkB-alpha; IkappaBalpha; Major histocompatibility complex enhancer-binding protein MAD3 T51672 FUNCTION Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription. T51672 SEQUENCE MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL T51672 DRUGINFO DN62DG I3C Phase 3 T51672 DRUGINFO DEZ3D7 Fucoxanthin Phase 2 T52034 TARGETID T52034 T52034 UNIPROID SERPH_HUMAN T52034 TARGNAME SERPINH1 messenger RNA (SERPINH1 mRNA) T52034 GENENAME SERPINH1 T52034 TARGTYPE Clinical trial T52034 SYNONYMS 47 kDa heat shock protein; Arsenic-transactivated protein 3; AsTP3; Cell proliferation-inducing gene 14 protein; Collagen-binding protein; Colligin; Rheumatoid arthritis-related antigen RA-A47 T52034 FUNCTION Binds specifically to collagen. Could be involved as a chaperone in the biosynthetic pathway of collagen. T52034 BIOCLASS mRNA target T52034 SEQUENCE MRSLLLLSAFCLLEAALAAEVKKPAAAAAPGTAEKLSPKAATLAERSAGLAFSLYQAMAKDQAVENILVSPVVVASSLGLVSLGGKATTASQAKAVLSAEQLRDEEVHAGLGELLRSLSNSTARNVTWKLGSRLYGPSSVSFADDFVRSSKQHYNCEHSKINFRDKRSALQSINEWAAQTTDGKLPEVTKDVERTDGALLVNAMFFKPHWDEKFHHKMVDNRGFMVTRSYTVGVMMMHRTGLYNYYDDEKEKLQIVEMPLAHKLSSLIILMPHHVEPLERLEKLLTKEQLKIWMGKMQKKAVAISLPKGVVEVTHDLQKHLAGLGLTEAIDKNKADLSRMSGKKDLYLASVFHATAFELDTDGNPFDQDIYGREELRSPKLFYADHPFIFLVRDTQSGSLLFIGRLVRPKGDKMRDEL T52034 DRUGINFO D2H4RZ BMS-986263 Phase 2 T52098 TARGETID T52098 T52098 UNIPROID OTC_HUMAN T52098 TARGNAME Ornithine transcarbamylase (OTC) T52098 GENENAME OTC T52098 TARGTYPE Clinical trial T52098 SYNONYMS OTCase; Ornithine carbamoyltransferase, mitochondrial T52098 FUNCTION Catalyzes the second step of the urea cycle, the condensation of carbamoyl phosphate with L-ornithine to form L-citrulline. The urea cycle ensures the detoxification of ammonia by converting it to urea for excretion. T52098 ECNUMBER EC 2.1.3.3 T52098 SEQUENCE MLFNLRILLNNAAFRNGHNFMVRNFRCGQPLQNKVQLKGRDLLTLKNFTGEEIKYMLWLSADLKFRIKQKGEYLPLLQGKSLGMIFEKRSTRTRLSTETGFALLGGHPCFLTTQDIHLGVNESLTDTARVLSSMADAVLARVYKQSDLDTLAKEASIPIINGLSDLYHPIQILADYLTLQEHYSSLKGLTLSWIGDGNNILHSIMMSAAKFGMHLQAATPKGYEPDASVTKLAEQYAKENGTKLLLTNDPLEAAHGGNVLITDTWISMGQEEEKKKRLQAFQGYQVTMKTAKVAASDWTFLHCLPRKPEEVDDEVFYSPRSLVFPEAENRKWTIMAVMVSLLTDYSPQLQKPKF T52098 DRUGINFO D6V9FN Avalotcagene ontaparvovec Phase 3 T52098 DRUGINFO DQ7I6M ARCT-810 Phase 2 T52098 DRUGINFO D6XMS1 DTX301 Phase 1/2 T52138 TARGETID T52138 T52138 UNIPROID HBSAG_HBVD3 T52138 TARGNAME Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA) T52138 GENENAME HBV S mRNA T52138 TARGTYPE Clinical trial T52138 SYNONYMS L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen; L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen T52138 FUNCTION The large envelope protein exists in two topological conformations, one which is termed 'external' or Le-HBsAg and the other 'internal' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis. The large envelope protein also assures fusion between virion membrane and endosomal membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein. T52138 BIOCLASS mRNA target T52138 SEQUENCE MGQNLSTSNPLGFFPDHQLDPAFRANTANPDWDFNPNKDTWPDANKVGAGAFGLGFTPPHGGLLGWSPQAQGILQTLPANPPPASTNRQSGRQPTPLSPPLRNTHPQAMQWNSTTFHQTLQDPRVRGLYFPAGGSSSGTVNPVLTTASPLSSIFSRIGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTTAQGTSMYPSCCCTKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIFFCLWVYI T52138 DRUGINFO D2U5CW GSK3228836 Phase 2 T52138 DRUGINFO DOE7C4 GSK3389404 Phase 2 T52138 DRUGINFO D5LB7Y RG6346 Phase 1 T52489 TARGETID T52489 T52489 UNIPROID RPGF3_HUMAN T52489 TARGNAME Rap guanine nucleotide exchange factor 3 (RAPGEF3) T52489 GENENAME RAPGEF3 T52489 TARGTYPE Clinical trial T52489 SYNONYMS Exchange factor directly activated by cAMP 1; Exchange protein directly activated by cAMP 1; EPAC 1; Rap1 guanine-nucleotide-exchange factor directly activated by cAMP; cAMP-regulated guanine nucleotide exchange factor I; cAMP-GEFI T52489 FUNCTION Guanine nucleotide exchange factor (GEF) for RAP1A and RAP2A small GTPases that is activated by binding cAMP. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which it activates the PI3K gamma complex and which is involved in angiogenesis. Plays a role in the modulation of the cAMP-induced dynamic control of endothelial barrier function through a pathway that is independent on Rho-mediated signaling. Required for the actin rearrangement at cell-cell junctions, such as stress fibers and junctional actin. T52489 SEQUENCE MKVGWPGESCWQVGLAVEDSPALGAPRVGALPDVVPEGTLLNMVLRRMHRPRSCSYQLLLEHQRPSCIQGLRWTPLTNSEESLDFSESLEQASTERVLRAGRQLHRHLLATCPNLIRDRKYHLRLYRQCCSGRELVDGILALGLGVHSRSQVVGICQVLLDEGALCHVKHDWAFQDRDAQFYRFPGPEPEPVRTHEMEEELAEAVALLSQRGPDALLTVALRKPPGQRTDEELDLIFEELLHIKAVAHLSNSVKRELAAVLLFEPHSKAGTVLFSQGDKGTSWYIIWKGSVNVVTHGKGLVTTLHEGDDFGQLALVNDAPRAATIILREDNCHFLRVDKQDFNRIIKDVEAKTMRLEEHGKVVLVLERASQGAGPSRPPTPGRNRYTVMSGTPEKILELLLEAMGPDSSAHDPTETFLSDFLLTHRVFMPSAQLCAALLHHFHVEPAGGSEQERSTYVCNKRQQILRLVSQWVALYGSMLHTDPVATSFLQKLSDLVGRDTRLSNLLREQWPERRRCHRLENGCGNASPQMKARNLPVWLPNQDEPLPGSSCAIQVGDKVPYDICRPDHSVLTLQLPVTASVREVMAALAQEDGWTKGQVLVKVNSAGDAIGLQPDARGVATSLGLNERLFVVNPQEVHELIPHPDQLGPTVGSAEGLDLVSAKDLAGQLTDHDWSLFNSIHQVELIHYVLGPQHLRDVTTANLERFMRRFNELQYWVATELCLCPVPGPRAQLLRKFIKLAAHLKEQKNLNSFFAVMFGLSNSAISRLAHTWERLPHKVRKLYSALERLLDPSWNHRVYRLALAKLSPPVIPFMPLLLKDMTFIHEGNHTLVENLINFEKMRMMARAARMLHHCRSHNPVPLSPLRSRVSHLHEDSQVARISTCSEQSLSTRSPASTWAYVQQLKVIDNQRELSRLSRELEP T52489 DRUGINFO D1UA2E AM001 Phase 2 T54789 TARGETID T54789 T54789 UNIPROID RPGR_HUMAN T54789 TARGNAME X-linked retinitis pigmentosa GTPase regulator (RPGR) T54789 GENENAME RPGR T54789 TARGTYPE Clinical trial T54789 FUNCTION Could be a guanine-nucleotide releasing factor. Plays a role in ciliogenesis. Probably regulates cilia formation by regulating actin stress filaments and cell contractility. Plays an important role in photoreceptor integrity. May play a critical role in spermatogenesis and in intraflagellar transport processes (By similarity). May be involved in microtubule organization and regulation of transport in primary cilia. T54789 SEQUENCE MREPEELMPDSGAVFTFGKSKFAENNPGKFWFKNDVPVHLSCGDEHSAVVTGNNKLYMFGSNNWGQLGLGSKSAISKPTCVKALKPEKVKLAACGRNHTLVSTEGGNVYATGGNNEGQLGLGDTEERNTFHVISFFTSEHKIKQLSAGSNTSAALTEDGRLFMWGDNSEGQIGLKNVSNVCVPQQVTIGKPVSWISCGYYHSAFVTTDGELYVFGEPENGKLGLPNQLLGNHRTPQLVSEIPEKVIQVACGGEHTVVLTENAVYTFGLGQFGQLGLGTFLFETSEPKVIENIRDQTISYISCGENHTALITDIGLMYTFGDGRHGKLGLGLENFTNHFIPTLCSNFLRFIVKLVACGGCHMVVFAAPHRGVAKEIEFDEINDTCLSVATFLPYSSLTSGNVLQRTLSARMRRRERERSPDSFSMRRTLPPIEGTLGLSACFLPNSVFPRCSERNLQESVLSEQDLMQPEEPDYLLDEMTKEAEIDNSSTVESLGETTDILNMTHIMSLNSNEKSLKLSPVQKQKKQQTIGELTQDTALTENDDSDEYEEMSEMKEGKACKQHVSQGIFMTQPATTIEAFSDEEVGNDTGQVGPQADTDGEGLQKEVYRHENNNGVDQLDAKEIEKESDGGHSQKESEAEEIDSEKETKLAEIAGMKDLREREKSTKKMSPFFGNLPDRGMNTESEENKDFVKKRESCKQDVIFDSERESVEKPDSYMEGASESQQGIADGFQQPEAIEFSSGEKEDDEVETDQNIRYGRKLIEQGNEKETKPIISKSMAKYDFKCDRLSEIPEEKEGAEDSKGNGIEEQEVEANEENVKVHGGRKEKTEILSDDLTDKAEDHEFSKTEELKLEDVDEEINAENVESKKKTVGDDESVPTGYHSKTEGAERTNDDSSAETIEKKEKANLEERAICEYNENPKGYMLDDADSSSLEILENSETTPSKDMKKTKKIFLFKRVPSINQKIVKNNNEPLPEIKSIGDQIILKSDNKDADQNHMSQNHQNIPPTNTERRSKSCTIL T54789 DRUGINFO DU7XQ3 BIIB112 Phase 3 T54789 DRUGINFO DKH94Z BIIB-088 Phase 2/3 T54789 DRUGINFO DO76YM AGTC-501 Phase 1/2 T54789 DRUGINFO DZ8FV2 AAV-RPGR Phase 1/2 T56349 TARGETID T56349 T56349 UNIPROID CXCL9_HUMAN T56349 TARGNAME C-X-C motif chemokine 9 (CXCL9) T56349 GENENAME CXCL9 T56349 TARGTYPE Clinical trial T56349 SYNONYMS Gamma-interferon-induced monokine; Monokine induced by interferon-gamma; HuMIG; MIG; Small-inducible cytokine B9 T56349 FUNCTION Cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. Chemotactic for activated T-cells. Binds to CXCR3. T56349 SEQUENCE MKKSGVLFLLGIILLVLIGVQGTPVVRKGRCSCISTNQGTIHLQSLKDLKQFAPSPSCEKIEIIATLKNGVQTCLNPDSADVKELIKKWEKQVSQKKKQKNGKKHQKKKVLKVRKSQRSRQKKTT T56349 DRUGINFO D1A8NU NG-641 Phase 1 T57941 TARGETID T57941 T57941 UNIPROID MAGA6_HUMAN T57941 TARGNAME Melanoma-associated antigen 6 (MAGEA6) T57941 GENENAME MAGEA6 T57941 TARGTYPE Clinical trial T57941 SYNONYMS Cancer/testis antigen 1.6; CT1.6; MAGE-6 antigen; MAGE3B antigen T57941 FUNCTION Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. T57941 SEQUENCE MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASSLPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAKLVHFLLLKYRAREPVTKAEMLGSVVGNWQYFFPVIFSKASDSLQLVFGIELMEVDPIGHVYIFATCLGLSYDGLLGDNQIMPKTGFLIIILAIIAKEGDCAPEEKIWEELSVLEVFEGREDSIFGDPKKLLTQYFVQENYLEYRQVPGSDPACYEFLWGPRALIETSYVKVLHHMVKISGGPRISYPLLHEWALREGEE T57941 DRUGINFO DN46RL KITE-718 Phase 1 T58679 TARGETID T58679 T58679 UNIPROID PABP1_HUMAN T58679 TARGNAME Polyadenylate-binding protein 1 (PABPC1) T58679 GENENAME PABPC1 T58679 TARGTYPE Clinical trial T58679 SYNONYMS PABP-1; Poly(A)-binding protein 1 T58679 FUNCTION Binds the poly(A) tail of mRNA, including that of its own transcript, and regulates processes of mRNA metabolism such as pre-mRNA splicing and mRNA stability. Its function in translational initiation regulation can either be enhanced by PAIP1 or repressed by PAIP2. Can probably bind to cytoplasmic RNA sequences other than poly(A) in vivo. Involved in translationally coupled mRNA turnover. Implicated with other RNA-binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding-region determinant of instability (mCRD) domain. Involved in regulation of nonsense-mediated decay (NMD) of mRNAs containing premature stop codons; for the recognition of premature termination codons (PTC) and initiation of NMD a competitive interaction between UPF1 and PABPC1 with the ribosome-bound release factors is proposed. By binding to long poly(A) tails, may protect them from uridylation by ZCCHC6/ZCCHC11 and hence contribute to mRNA stability. T58679 SEQUENCE MNPSAPSYPMASLYVGDLHPDVTEAMLYEKFSPAGPILSIRVCRDMITRRSLGYAYVNFQQPADAERALDTMNFDVIKGKPVRIMWSQRDPSLRKSGVGNIFIKNLDKSIDNKALYDTFSAFGNILSCKVVCDENGSKGYGFVHFETQEAAERAIEKMNGMLLNDRKVFVGRFKSRKEREAELGARAKEFTNVYIKNFGEDMDDERLKDLFGKFGPALSVKVMTDESGKSKGFGFVSFERHEDAQKAVDEMNGKELNGKQIYVGRAQKKVERQTELKRKFEQMKQDRITRYQGVNLYVKNLDDGIDDERLRKEFSPFGTITSAKVMMEGGRSKGFGFVCFSSPEEATKAVTEMNGRIVATKPLYVALAQRKEERQAHLTNQYMQRMASVRAVPNPVINPYQPAPPSGYFMAAIPQTQNRAAYYPPSQIAQLRPSPRWTAQGARPHPFQNMPGAIRPAAPRPPFSTMRPASSQVPRVMSTQRVANTSTQTMGPRPAAAAAAATPAVRTVPQYKYAAGVRNPQQHLNAQPQVTMQQPAVHVQGQEPLTASMLASAPPQEQKQMLGERLFPLIQAMHPTLAGKITGMLLEIDNSELLHMLESPESLRSKVDEAVAVLQAHQAKEAAQKAVNSATGVPTV T58679 DRUGINFO DO20LT ATRC-101 Phase 1 T59382 TARGETID T59382 T59382 UNIPROID SGCB_HUMAN T59382 TARGNAME Beta-sarcoglycan (SGCB) T59382 GENENAME SGCB T59382 TARGTYPE Clinical trial T59382 SYNONYMS Beta-SG; 43 kDa dystrophin-associated glycoprotein; 43DAG; A3b T59382 FUNCTION Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix. T59382 SEQUENCE MAAAAAAAAEQQSSNGPVKKSMREKAVERRSVNKEHNSNFKAGYIPIDEDRLHKTGLRGRKGNLAICVIILLFILAVINLIITLVIWAVIRIGPNGCDSMEFHESGLLRFKQVSDMGVIHPLYKSTVGGRRNENLVITGNNQPIVFQQGTTKLSVENNKTSITSDIGMQFFDPRTQNILFSTDYETHEFHLPSGVKSLNVQKASTERITSNATSDLNIKVDGRAIVRGNEGVFIMGKTIEFHMGGNMELKAENSIILNGSVMVSTTRLPSSSSGDQLGSGDWVRYKLCMCADGTLFKVQVTSQNMGCQISDNPCGNTH T59382 DRUGINFO D3RT4A SRP-9003 Phase 1/2 T59463 TARGETID T59463 T59463 UNIPROID RASK_HUMAN T59463 TARGNAME KRAS G12D mutant messenger RNA (KRAS mRNA) T59463 GENENAME KRAS T59463 TARGTYPE Clinical trial T59463 SYNONYMS K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras T59463 FUNCTION Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation. Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. T59463 BIOCLASS mRNA target T59463 ECNUMBER EC 3.6.5.2 T59463 SEQUENCE MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM T59463 DRUGINFO DNH67V SiG12D-LODER Phase 2 T59702 TARGETID T59702 T59702 UNIPROID FZD10_HUMAN T59702 TARGNAME Frizzled-10 (FZD10) T59702 GENENAME FZD10 T59702 TARGTYPE Clinical trial T59702 SYNONYMS Fz-10; hFz10; FzE7; DE AltName: CD_antigen=CD350 T59702 FUNCTION Receptor for Wnt proteins. Functions in the canonical Wnt/beta-catenin signaling pathway (By similarity). The canonical Wnt/beta-catenin signaling pathway leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues (Probable). T59702 SEQUENCE MQRPGPRLWLVLQVMGSCAAISSMDMERPGDGKCQPIEIPMCKDIGYNMTRMPNLMGHENQREAAIQLHEFAPLVEYGCHGHLRFFLCSLYAPMCTEQVSTPIPACRVMCEQARLKCSPIMEQFNFKWPDSLDCRKLPNKNDPNYLCMEAPNNGSDEPTRGSGLFPPLFRPQRPHSAQEHPLKDGGPGRGGCDNPGKFHHVEKSASCAPLCTPGVDVYWSREDKRFAVVWLAIWAVLCFFSSAFTVLTFLIDPARFRYPERPIIFLSMCYCVYSVGYLIRLFAGAESIACDRDSGQLYVIQEGLESTGCTLVFLVLYYFGMASSLWWVVLTLTWFLAAGKKWGHEAIEANSSYFHLAAWAIPAVKTILILVMRRVAGDELTGVCYVGSMDVNALTGFVLIPLACYLVIGTSFILSGFVALFHIRRVMKTGGENTDKLEKLMVRIGLFSVLYTVPATCVIACYFYERLNMDYWKILAAQHKCKMNNQTKTLDCLMAASIPAVEIFMVKIFMLLVVGITSGMWIWTSKTLQSWQQVCSRRLKKKSRRKPASVITSGGIYKKAQHPQKTHHGKYEIPAQSPTCV T59702 DRUGINFO D1ZG5E OTSA-101-DTPA-90Y Phase 1 T62047 TARGETID T62047 T62047 UNIPROID HBSAG_HBVD3 T62047 TARGNAME Hepatitis B virus Large envelope protein (HBV S) T62047 GENENAME HBV S T62047 TARGTYPE Clinical trial T62047 SYNONYMS L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen; L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen T62047 FUNCTION The large envelope protein exists in two topological conformations, one which is termed 'external' or Le-HBsAg and the other 'internal' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis. The large envelope protein also assures fusion between virion membrane and endosomal membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein. T62047 BIOCLASS Orthohepadnavirus major surface antigen T62047 SEQUENCE MGQNLSTSNPLGFFPDHQLDPAFRANTANPDWDFNPNKDTWPDANKVGAGAFGLGFTPPHGGLLGWSPQAQGILQTLPANPPPASTNRQSGRQPTPLSPPLRNTHPQAMQWNSTTFHQTLQDPRVRGLYFPAGGSSSGTVNPVLTTASPLSSIFSRIGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTTAQGTSMYPSCCCTKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIFFCLWVYI T62047 DRUGINFO DQ1OJ4 VIR-2218 Phase 2 T65074 TARGETID T65074 T65074 TARGNAME microRNA hsa-miR-92 (MIR92) T65074 TARGTYPE Clinical trial T65074 DRUGINFO DBE87X MRG-110 Phase 1 T65429 TARGETID T65429 T65429 UNIPROID GPR20_HUMAN T65429 TARGNAME G-protein coupled receptor 20 (GPR20) T65429 GENENAME GPR20 T65429 TARGTYPE Clinical trial T65429 FUNCTION Orphan receptor with constitutive G(i) signaling activity that activate cyclic AMP. T65429 BIOCLASS G-protein coupled receptor 1 family T65429 SEQUENCE MPSVSPAGPSAGAVPNATAVTTVRTNASGLEVPLFHLFARLDEELHGTFPGLWLALMAVHGAIFLAGLVLNGLALYVFCCRTRAKTPSVIYTINLVVTDLLVGLSLPTRFAVYYGARGCLRCAFPHVLGYFLNMHCSILFLTCICVDRYLAIVRPEGSRRCRQPACARAVCAFVWLAAGAVTLSVLGVTGSRPCCRVFALTVLEFLLPLLVISVFTGRIMCALSRPGLLHQGRQRRVRAMQLLLTVLIIFLVCFTPFHARQVAVALWPDMPHHTSLVVYHVAVTLSSLNSCMDPIVYCFVTSGFQATVRGLFGQHGEREPSSGDVVSMHRSSKGSGRHHILSAGPHALTQALANGPEA T65429 DRUGINFO DJ4X7D DS-6157 Phase 1 T65941 TARGETID T65941 T65941 UNIPROID A1AT_HUMAN T65941 TARGNAME SERPINA1 messenger RNA (SERPINA1 mRNA) T65941 GENENAME SERPINA1 T65941 TARGTYPE Clinical trial T65941 SYNONYMS Alpha-1 protease inhibitor; Alpha-1-antiproteinase; Serpin A1 T65941 FUNCTION Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin. T65941 BIOCLASS mRNA target T65941 SEQUENCE MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK T65941 DRUGINFO DQ4FR9 Fazirsiran Phase 3 T65941 DRUGINFO DOE96M Belcesiran Phase 2 T65941 DRUGINFO DR7EV6 ARO-AAT Phase 2 T67089 TARGETID T67089 T67089 UNIPROID ANT3_HUMAN T67089 TARGNAME SERPINC1 messenger RNA (SERPINC1 mRNA) T67089 GENENAME SERPINC1 T67089 TARGTYPE Clinical trial T67089 SYNONYMS ATIII; Serpin C1 T67089 FUNCTION Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin. T67089 BIOCLASS mRNA target T67089 SEQUENCE MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK T67089 DRUGINFO D46RKC Fitusiran Phase 3 T67908 TARGETID T67908 T67908 TARGNAME Globohexaosylceramide (Globo H) T67908 TARGTYPE Clinical trial T67908 DRUGINFO D2H6NI OBI-999 Phase 1/2 T67908 DRUGINFO D59OTG OBI-888 Phase 1/2 T69823 TARGETID T69823 T69823 UNIPROID P53_HUMAN T69823 TARGNAME P53 Y220C mutant (TP53 Y220C) T69823 GENENAME TP53 T69823 TARGTYPE Clinical trial T69823 SEQUENCE MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD T69823 DRUGINFO D53CGK PC14586 Phase 1/2 T70134 TARGETID T70134 T70134 UNIPROID CI072_HUMAN T70134 TARGNAME C9orf72 messenger RNA (C9orf72 mRNA) T70134 GENENAME C9orf72 T70134 TARGTYPE Clinical trial T70134 FUNCTION Component of the C9orf72-SMCR8 complex, a complex that has guanine nucleotide exchange factor (GEF) activity and regulates autophagy. In the complex, C9orf72 and SMCR8 probably constitute the catalytic subunits that promote the exchange of GDP to GTP, converting inactive GDP-bound RAB8A and RAB39B into their active GTP-bound form, thereby promoting autophagosome maturation. The C9orf72-SMCR8 complex also acts as a regulator of autophagy initiation by interacting with the ATG1/ULK1 kinase complex and modulating its protein kinase activity. Positively regulates initiation of autophagy by regulating the RAB1A-dependent trafficking of the ATG1/ULK1 kinase complex to the phagophore which leads to autophagosome formation. Acts as a regulator of mTORC1 signaling by promoting phosphorylation of mTORC1 substrates. Plays a role in endosomal trafficking. May be involved in regulating the maturation of phagosomes to lysosomes (By similarity). Regulates actin dynamics in motor neurons by inhibiting the GTP-binding activity of ARF6, leading to ARF6 inactivation. This reduces the activity of the LIMK1 and LIMK2 kinases which are responsible for phosphorylation and inactivation of cofilin, leading to cofilin activation. Positively regulates axon extension and axon growth cone size in spinal motor neurons. Plays a role within the hematopoietic system in restricting inflammation and the development of autoimmunity (By similarity). T70134 BIOCLASS mRNA target T70134 SEQUENCE MSTLCPPPSPAVAKTEIALSGKSPLLAATFAYWDNILGPRVRHIWAPKTEQVLLSDGEITFLANHTLNGEILRNAESGAIDVKFFVLSEKGVIIVSLIFDGNWNGDRSTYGLSIILPQTELSFYLPLHRVCVDRLTHIIRKGRIWMHKERQENVQKIILEGTERMEDQGQSIIPMLTGEVIPVMELLSSMKSHSVPEEIDIADTVLNDDDIGDSCHEGFLLNAISSHLQTCGCSVVVGSSAEKVNKIVRTLCLFLTPAERKCSRLCEAESSFKYESGLFVQGLLKDSTGSFVLPFRQVMYAPYPTTHIDVDVNTVKQMPPCHEHIYNQRRYMRSELTAFWRATSEEDMAQDTIIYTDESFTPDLNIFQDVLHRDTLVKAFLDQVFQLKPGLSLRSTFLAQFLLVLHRKALTLIKYIEDDTQKGKKPFKSLRNLKIDLDLTAEGDLNIIMALAEKIKPGLHSFIFGRPFYTSVQERDVLMTF T70134 DRUGINFO DQ7PB1 IONIS-C9Rx Phase 2 T71039 TARGETID T71039 T71039 TARGNAME Carbohydrate antigen 19-9 (CA 19-9) T71039 TARGTYPE Clinical trial T71039 DRUGINFO D7AOL8 BNT321 Phase 2 T71369 TARGETID T71369 T71369 UNIPROID BC11A_HUMAN T71369 TARGNAME BCL11A messenger RNA (BCL11A mRNA) T71369 GENENAME BCL11A T71369 TARGTYPE Clinical trial T71369 SYNONYMS BCL-11A; B-cell CLL/lymphoma 11A; COUP-TF-interacting protein 1; Ecotropic viral integration site 9 protein homolog; EVI-9; Zinc finger protein 856; BCL-11A; B-cell CLL/lymphoma 11A; COUP-TF-interacting protein 1; Ecotropic viral integration site 9 protein homolog; EVI-9; Zinc finger protein 856 T71369 FUNCTION Transcription factor associated with the BAF SWI/SNF chromatin remodeling complex (By similarity). Repressor of fetal hemoglobin (HbF) level. Involved in brain development. May play a role in hematopoiesis. Essential factor in lymphopoiesis required for B-cell formation in fetal liver. May function as a modulator of the transcriptional repression activity of ARP1 (By similarity). T71369 BIOCLASS mRNA target T71369 SEQUENCE MSRRKQGKPQHLSKREFSPEPLEAILTDDEPDHGPLGAPEGDHDLLTCGQCQMNFPLGDILIFIEHKRKQCNGSLCLEKAVDKPPSPSPIEMKKASNPVEVGIQVTPEDDDCLSTSSRGICPKQEHIADKLLHWRGLSSPRSAHGALIPTPGMSAEYAPQGICKDEPSSYTCTTCKQPFTSAWFLLQHAQNTHGLRIYLESEHGSPLTPRVGIPSGLGAECPSQPPLHGIHIADNNPFNLLRIPGSVSREASGLAEGRFPPTPPLFSPPPRHHLDPHRIERLGAEEMALATHHPSAFDRVLRLNPMAMEPPAMDFSRRLRELAGNTSSPPLSPGRPSPMQRLLQPFQPGSKPPFLATPPLPPLQSAPPPSQPPVKSKSCEFCGKTFKFQSNLVVHRRSHTGEKPYKCNLCDHACTQASKLKRHMKTHMHKSSPMTVKSDDGLSTASSPEPGTSDLVGSASSALKSVVAKFKSENDPNLIPENGDEEEEEDDEEEEEEEEEEEEELTESERVDYGFGLSLEAARHHENSSRGAVVGVGDESRALPDVMQGMVLSSMQHFSEAFHQVLGEKHKRGHLAEAEGHRDTCDEDSVAGESDRIDDGTVNGRGCSPGESASGGLSKKLLLGSPSSLSPFSKRIKLEKEFDLPPAAMPNTENVYSQWLAGYAASRQLKDPFLSFGDSRQSPFASSSEHSSENGSLRFSTPPGELDGGISGRSGTGSGGSTPHISGPGPGRPSSKEGRRSDTCEYCGKVFKNCSNLTVHRRSHTGERPYKCELCNYACAQSSKLTRHMKTHGQVGKDVYKCEICKMPFSVYSTLEKHMKKWHSDRVLNNDIKTE T71369 DRUGINFO D95GKC BCL11a shRNA Phase 1 T72514 TARGETID T72514 T72514 UNIPROID IL36G_HUMAN T72514 TARGNAME Interleukin-36 gamma (IL36G) T72514 GENENAME IL36G T72514 TARGTYPE Clinical trial T72514 SYNONYMS IL-1-related protein 2; IL-1RP2; Interleukin-1 epsilon; IL-1 epsilon; Interleukin-1 family member 9; IL-1F9; Interleukin-1 homolog 1; IL-1H1 T72514 FUNCTION Cytokine that binds to and signals through the IL1RL2/IL-36R receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response; similar to the IL-1 system with which it shares the coreceptor IL1RAP. Seems to be involved in skin inflammatory response by acting on keratinocytes, dendritic cells and indirectly on T-cells to drive tissue infiltration, cell maturation and cell proliferation. In cultured keratinocytes induces the expression of macrophage, T-cell, and neutrophil chemokines, such as CCL3, CCL4, CCL5, CCL2, CCL17, CCL22, CL20, CCL5, CCL2, CCL17, CCL22, CXCL8, CCL20 and CXCL1; also stimulates its own expression and that of the prototypic cutaneous proinflammatory parameters TNF-alpha, S100A7/psoriasin and inducible NOS. May play a role in proinflammatory responses during particular neutrophilic airway inflammation: activates mitogen-activated protein kinases and NF-kappa B in primary lung fibroblasts, and stimulates the expression of IL-8 and CXCL3 and Th17 chemokine CCL20 in lung fibroblasts. May be involved in the innate immune response to fungal pathogens, such as Aspergillus fumigatus. T72514 SEQUENCE MRGTPGDADGGGRAVYQSMCKPITGTINDLNQQVWTLQGQNLVAVPRSDSVTPVTVAVITCKYPEALEQGRGDPIYLGIQNPEMCLYCEKVGEQPTLQLKEQKIMDLYGQPEPVKPFLFYRAKTGRTSTLESVAFPDWFIASSKRDQPIILTSELGKSYNTAFELNIND T72514 DRUGINFO DC5A9Q mRNA-2752 Phase 1 T73019 TARGETID T73019 T73019 UNIPROID PDE7A_HUMAN; PDE7B_HUMAN T73019 TARGNAME Phosphodiesterase 7 (PDE7) T73019 TARGTYPE Clinical trial T73019 DRUGINFO DH1OY4 OMS527 Phase 1 T79051 TARGETID T79051 T79051 UNIPROID EWS_HUMAN-FLI1_HUMAN T79051 TARGNAME EWS-FLI1 fusion gene mRNA (EWS-FLI1 mRNA) T79051 GENENAME EWS-FLI1 T79051 TARGTYPE Clinical trial T79051 BIOCLASS mRNA target T79051 DRUGINFO D31ZLD pbi-shRNA EWS-FLI-Type 1 Phase 1 T79368 TARGETID T79368 T79368 UNIPROID CEBPA_HUMAN T79368 TARGNAME CEBPA messenger RNA (CEBPA mRNA) T79368 GENENAME CEBPA T79368 TARGTYPE Clinical trial T79368 SYNONYMS C/EBP alpha T79368 FUNCTION Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes. During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Downregulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex. In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC1. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity). T79368 BIOCLASS mRNA target T79368 SEQUENCE MESADFYEAEPRPPMSSHLQSPPHAPSSAAFGFPRGAGPAQPPAPPAAPEPLGGICEHETSIDISAYIDPAAFNDEFLADLFQHSRQQEKAKAAVGPTGGGGGGDFDYPGAPAGPGGAVMPGGAHGPPPGYGCAAAGYLDGRLEPLYERVGAPALRPLVIKQEPREEDEAKQLALAGLFPYQPPPPPPPSHPHPHPPPAHLAAPHLQFQIAHCGQTTMHLQPGHPTPPPTPVPSPHPAPALGAAGLPGPGSALKGLGAAHPDLRASGGSGAGKAKKSVDKNSNEYRVRRERNNIAVRKSRDKAKQRNVETQQKVLELTSDNDRLRKRVEQLSRELDTLRGIFRQLPESSLVKAMGNCA T79368 DRUGINFO DA01IB MTL-CEPBA Phase 1/2 T81569 TARGETID T81569 T81569 UNIPROID IKZF2_HUMAN T81569 TARGNAME Zinc finger protein Helios (IKZF2) T81569 GENENAME IKZF2 T81569 TARGTYPE Clinical trial T81569 SYNONYMS Ikaros family zinc finger protein 2 T81569 FUNCTION Associates with Ikaros at centromeric heterochromatin. T81569 SEQUENCE METEAIDGYITCDNELSPEREHSNMAIDLTSSTPNGQHASPSHMTSTNSVKLEMQSDEECDRKPLSREDEIRGHDEGSSLEEPLIESSEVADNRKVQELQGEGGIRLPNGKLKCDVCGMVCIGPNVLMVHKRSHTGERPFHCNQCGASFTQKGNLLRHIKLHSGEKPFKCPFCSYACRRRDALTGHLRTHSVGKPHKCNYCGRSYKQRSSLEEHKERCHNYLQNVSMEAAGQVMSHHVPPMEDCKEQEPIMDNNISLVPFERPAVIEKLTGNMGKRKSSTPQKFVGEKLMRFSYPDIHFDMNLTYEKEAELMQSHMMDQAINNAITYLGAEALHPLMQHPPSTIAEVAPVISSAYSQVYHPNRIERPISRETADSHENNMDGPISLIRPKSRPQEREASPSNSCLDSTDSESSHDDHQSYQGHPALNPKRKQSPAYMKEDVKALDTTKAPKGSLKDIYKVFNGEGEQIRAFKCEHCRVLFLDHVMYTIHMGCHGYRDPLECNICGYRSQDRYEFSSHIVRGEHTFH T81569 DRUGINFO DG9LF8 DKY709 Phase 1 T82105 TARGETID T82105 T82105 UNIPROID CEAM1_HUMAN T82105 TARGNAME Biliary glycoprotein 1 (CEACAM1) T82105 GENENAME CEACAM1 T82105 TARGTYPE Clinical trial T82105 SYNONYMS Biliary glycoprotein 1; BGP-1; DE AltName: CD_antigen=CD66a T82105 FUNCTION Cell adhesion protein that mediates homophilic cell adhesion in a calcium-independent manner (By similarity). Plays a role as coinhibitory receptor in immune response, insulin action and functions also as an activator during angiogenesis. Its coinhibitory receptor function is phosphorylation- and PTPN6 -dependent, which in turn, suppress signal transduction of associated receptors by dephosphorylation of their downstream effectors. Plays a role in immune response, of T cells, natural killer (NK) and neutrophils. Upon TCR/CD3 complex stimulation, inhibits TCR-mediated cytotoxicity by blocking granule exocytosis by mediating homophilic binding to adjacent cells, allowing interaction with and phosphorylation by LCK and interaction with the TCR/CD3 complex which recruits PTPN6 resulting in dephosphorylation of CD247 and ZAP70. Also inhibits T cell proliferation and cytokine production through inhibition of JNK cascade and plays a crucial role in regulating autoimmunity and anti-tumor immunity by inhibiting T cell through its interaction with HAVCR2. Upon natural killer (NK) cells activation, inhibit KLRK1-mediated cytolysis of CEACAM1-bearing tumor cells by trans-homophilic interactions with CEACAM1 on the target cell and lead to cis-interaction between CEACAM1 and KLRK1, allowing PTPN6 recruitment and then VAV1 dephosphorylation. Upon neutrophils activation negatively regulates IL1B production by recruiting PTPN6 to a SYK-TLR4-CEACAM1 complex, that dephosphorylates SYK, reducing the production of reactive oxygen species (ROS) and lysosome disruption, which in turn, reduces the activity of the inflammasome. Downregulates neutrophil production by acting as a coinhibitory receptor for CSF3R by downregulating the CSF3R-STAT3 pathway through recruitment of PTPN6 that dephosphorylates CSF3R (By similarity). Also regulates insulin action by promoting INS clearance and regulating lipogenesis in liver through regulating insulin signaling (By similarity). Upon INS stimulation, undergoes phosphorylation by INSR leading to INS clearance by increasing receptor-mediated insulin endocytosis. This inernalization promotes interaction with FASN leading to receptor-mediated insulin degradation and to reduction of FASN activity leading to negative regulation of fatty acid synthesis. INSR-mediated phosphorylation also provokes a down-regulation of cell proliferation through SHC1 interaction resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 and phosphatidylinositol 3-kinase pathways (By similarity). Functions as activator in angiogenesis by promoting blood vessel remodeling through endothelial cell differentiation and migration and in arteriogenesis by increasing the number of collateral arteries and collateral vessel calibers after ischemia. Also regulates vascular permeability through the VEGFR2 signaling pathway resulting in control of nitric oxide production (By similarity). Downregulates cell growth in response to EGF through its interaction with SHC1 that mediates interaction with EGFR resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 pathway (By similarity). Negatively regulates platelet aggregation by decreasing platelet adhesion on type I collagen through the GPVI-FcRgamma complex (By similarity). Inhibits cell migration and cell scattering through interaction with FLNA; interfers with the interaction of FLNA with RALA. Mediates bile acid transport activity in a phosphorylation dependent manner (By similarity). Negatively regulates osteoclastogenesis (By similarity). T82105 SEQUENCE MGHLSAPLHRVRVPWQGLLLTASLLTFWNPPTTAQLTTESMPFNVAEGKEVLLLVHNLPQQLFGYSWYKGERVDGNRQIVGYAIGTQQATPGPANSGRETIYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPETQDTTYLWWINNQSLPVSPRLQLSNGNRTLTLLSVTRNDTGPYECEIQNPVSANRSDPVTLNVTYGPDTPTISPSDTYYRPGANLSLSCYAASNPPAQYSWLINGTFQQSTQELFIPNITVNNSGSYTCHANNSVTGCNRTTVKTIIVTELSPVVAKPQIKASKTTVTGDKDSVNLTCSTNDTGISIRWFFKNQSLPSSERMKLSQGNTTLSINPVKREDAGTYWCEVFNPISKNQSDPIMLNVNYNALPQENGLSPGAIAGIVIGVVALVALIAVALACFLHFGKTGRASDQRDLTEHKPSVSNHTQDHSNDPPNKMNEVTYSTLNFEAQQPTQPTSASPSLTATEIIYSEVKKQ T82105 DRUGINFO DR5F9A CM24 Phase 1/2 T82105 DRUGINFO D7K5XP NEO-201 Phase 1 T82463 TARGETID T82463 T82463 TARGNAME Cocaine (Coca) T82463 TARGTYPE Clinical trial T82463 DRUGINFO DS79KP TNX-1300 Phase 2 T82943 TARGETID T82943 T82943 TARGNAME microRNA hsa-miR-17 (MIR17) T82943 TARGTYPE Clinical trial T82943 DRUGINFO D8XK7F RGLS4326 Phase 1 T85042 TARGETID T85042 T85042 UNIPROID PPARA_HUMAN; PPARD_HUMAN; PPARG_HUMAN T85042 TARGNAME Peroxisome proliferator-activated receptor (PPAR) T85042 TARGTYPE Clinical trial T85042 DRUGINFO D39PWR A278 IND submitted T85042 DRUGINFO DX6RV3 IVA337 Phase 2 T85042 DRUGINFO DMBQ10 ABTL0812 Phase 1/2 T85076 TARGETID T85076 T85076 UNIPROID CBLB_HUMAN T85076 TARGNAME CBLB messenger RNA (CBLB mRNA) T85076 GENENAME CBLB T85076 TARGTYPE Clinical trial T85076 SYNONYMS Casitas B-lineage lymphoma proto-oncogene b; RING finger protein 56; RING-type E3 ubiquitin transferase CBL-B; SH3-binding protein CBL-B; Signal transduction protein CBL-B T85076 FUNCTION E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBL, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity). T85076 BIOCLASS mRNA target T85076 ECNUMBER EC 2.3.2.27 T85076 SEQUENCE MANSMNGRNPGGRGGNPRKGRILGIIDAIQDAVGPPKQAAADRRTVEKTWKLMDKVVRLCQNPKLQLKNSPPYILDILPDTYQHLRLILSKYDDNQKLAQLSENEYFKIYIDSLMKKSKRAIRLFKEGKERMYEEQSQDRRNLTKLSLIFSHMLAEIKAIFPNGQFQGDNFRITKADAAEFWRKFFGDKTIVPWKVFRQCLHEVHQISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWGSILRNWNFLAVTHPGYMAFLTYDEVKARLQKYSTKPGSYIFRLSCTRLGQWAIGYVTGDGNILQTIPHNKPLFQALIDGSREGFYLYPDGRSYNPDLTGLCEPTPHDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTAWQESDGQGCPFCRCEIKGTEPIIVDPFDPRDEGSRCCSIIDPFGMPMLDLDDDDDREESLMMNRLANVRKCTDRQNSPVTSPGSSPLAQRRKPQPDPLQIPHLSLPPVPPRLDLIQKGIVRSPCGSPTGSPKSSPCMVRKQDKPLPAPPPPLRDPPPPPPERPPPIPPDNRLSRHIHHVESVPSRDPPMPLEAWCPRDVFGTNQLVGCRLLGEGSPKPGITASSNVNGRHSRVGSDPVLMRKHRRHDLPLEGAKVFSNGHLGSEEYDVPPRLSPPPPVTTLLPSIKCTGPLANSLSEKTRDPVEEDDDEYKIPSSHPVSLNSQPSHCHNVKPPVRSCDNGHCMLNGTHGPSSEKKSNIPDLSIYLKGDVFDSASDPVPLPPARPPTRDNPKHGSSLNRTPSDYDLLIPPLGEDAFDALPPSLPPPPPPARHSLIEHSKPPGSSSRPSSGQDLFLLPSDPFVDLASGQVPLPPARRLPGENVKTNRTSQDYDQLPSCSDGSQAPARPPKPRPRRTAPEIHHRKPHGPEAALENVDAKIAKLMGEGYAFEEVKRALEIAQNNVEVARSILREFAFPPPVSPRLNL T85076 DRUGINFO D1RIW2 APN401 Phase 2 T85426 TARGETID T85426 T85426 UNIPROID CAPSD_HBVD3 T85426 TARGNAME Hepatitis B virus Capsid protein (HBV C) T85426 GENENAME HBV C T85426 TARGTYPE Clinical trial T85426 SYNONYMS Core antigen; Core protein; HBcAg; p21.5 T85426 FUNCTION Self assembles to form an icosahedral capsid. Most capsid appear to be large particles with an icosahedral symmetry of T=4 and consist of 240 copies of capsid protein, though a fraction forms smaller T=3 particles consisting of 180 capsid proteins. Entering capsid are transported along microtubules to the nucleus. Phosphorylation of the capsid is thought to induce exposure of nuclear localization signal in the C-terminal portion of the capsid protein that allows binding to the nuclear pore complex via the importin (karyopherin-) alpha and beta. Capsids are imported in intact form through the nuclear pore into the nuclear basket, where it probably binds NUP153. Only capsids that contain the mature viral genome can release the viral DNA and capsid protein into the nucleoplasm. Immature capsids get stucked in the basket. Capsids encapsulate the pre-genomic RNA and the P protein. Pre-genomic RNA is reverse transcribed into DNA while the capsid is still in the cytoplasm. The capsid can then either be directed to the nucleus, providing more genome for transcription, or bud through the endoplasmic reticulum to provide new virions. T85426 SEQUENCE MDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREALESPEHCSPHHTALRQAILCWGELMTLATWVGVNLEDPASRDLVVSYVNTNMGLKFRQLLWFHISCLTFGRETVIEYLVSFGVWIRTPPAYRPPNAPILSTLPETTVVRRRGRSPRRRTPSPRRRRSQSPRRRRSQSRESQC T85426 DRUGINFO D1X2VT JNJ-56136379 Phase 2 T85426 DRUGINFO D6DPI4 ABI-H2158 Phase 2 T85426 DRUGINFO DHY3Q9 ABI-H0731 Phase 2 T85426 DRUGINFO D49YEO ABI-H3733 Phase 1 T85426 DRUGINFO DDY51F EDP-514 Phase 1 T85426 DRUGINFO DTOM05 A204 Phase 1 T85426 DRUGINFO DW5Z1R RG7907 Phase 1 T85426 DRUGINFO DWX4A0 ZM-H1505R Phase 1 T86072 TARGETID T86072 T86072 UNIPROID LRP5_HUMAN T86072 TARGNAME Low-density lipoprotein receptor-related protein 5 (LRP5) T86072 GENENAME LRP5 T86072 TARGTYPE Clinical trial T86072 SYNONYMS LRP-5; Low-density lipoprotein receptor-related protein 7; LRP-7 T86072 FUNCTION Acts as a coreceptor with members of the frizzled family of seven-transmembrane spanning receptors to transduce signal by Wnt proteins. Activates the canonical Wnt signaling pathway that controls cell fate determination and self-renewal during embryonic development and adult tissue regeneration. In particular, may play an important role in the development of the posterior patterning of the epiblast during gastrulation (By similarity). During bone development, regulates osteoblast proliferation and differentiation thus determining bone mass. Mechanistically, the formation of the signaling complex between Wnt ligand, frizzled receptor and LRP5 coreceptor promotes the recruitment of AXIN1 to LRP5, stabilizing beta-catenin/CTNNB1 and activating TCF/LEF-mediated transcriptional programs. Acts as a coreceptor for non-Wnt proteins, such as norrin/NDP. Binding of norrin/NDP to frizzled 4/FZD4-LRP5 receptor complex triggers beta-catenin/CTNNB1-dependent signaling known to be required for retinal vascular development. Plays a role in controlling postnatal vascular regression in retina via macrophage-induced endothelial cell apoptosis (By similarity). T86072 SEQUENCE MEAAPPGPPWPLLLLLLLLLALCGCPAPAAASPLLLFANRRDVRLVDAGGVKLESTIVVSGLEDAAAVDFQFSKGAVYWTDVSEEAIKQTYLNQTGAAVQNVVISGLVSPDGLACDWVGKKLYWTDSETNRIEVANLNGTSRKVLFWQDLDQPRAIALDPAHGYMYWTDWGETPRIERAGMDGSTRKIIVDSDIYWPNGLTIDLEEQKLYWADAKLSFIHRANLDGSFRQKVVEGSLTHPFALTLSGDTLYWTDWQTRSIHACNKRTGGKRKEILSALYSPMDIQVLSQERQPFFHTRCEEDNGGCSHLCLLSPSEPFYTCACPTGVQLQDNGRTCKAGAEEVLLLARRTDLRRISLDTPDFTDIVLQVDDIRHAIAIDYDPLEGYVYWTDDEVRAIRRAYLDGSGAQTLVNTEINDPDGIAVDWVARNLYWTDTGTDRIEVTRLNGTSRKILVSEDLDEPRAIALHPVMGLMYWTDWGENPKIECANLDGQERRVLVNASLGWPNGLALDLQEGKLYWGDAKTDKIEVINVDGTKRRTLLEDKLPHIFGFTLLGDFIYWTDWQRRSIERVHKVKASRDVIIDQLPDLMGLKAVNVAKVVGTNPCADRNGGCSHLCFFTPHATRCGCPIGLELLSDMKTCIVPEAFLVFTSRAAIHRISLETNNNDVAIPLTGVKEASALDFDVSNNHIYWTDVSLKTISRAFMNGSSVEHVVEFGLDYPEGMAVDWMGKNLYWADTGTNRIEVARLDGQFRQVLVWRDLDNPRSLALDPTKGYIYWTEWGGKPRIVRAFMDGTNCMTLVDKVGRANDLTIDYADQRLYWTDLDTNMIESSNMLGQERVVIADDLPHPFGLTQYSDYIYWTDWNLHSIERADKTSGRNRTLIQGHLDFVMDILVFHSSRQDGLNDCMHNNGQCGQLCLAIPGGHRCGCASHYTLDPSSRNCSPPTTFLLFSQKSAISRMIPDDQHSPDLILPLHGLRNVKAIDYDPLDKFIYWVDGRQNIKRAKDDGTQPFVLTSLSQGQNPDRQPHDLSIDIYSRTLFWTCEATNTINVHRLSGEAMGVVLRGDRDKPRAIVVNAERGYLYFTNMQDRAAKIERAALDGTEREVLFTTGLIRPVALVVDNTLGKLFWVDADLKRIESCDLSGANRLTLEDANIVQPLGLTILGKHLYWIDRQQQMIERVEKTTGDKRTRIQGRVAHLTGIHAVEEVSLEEFSAHPCARDNGGCSHICIAKGDGTPRCSCPVHLVLLQNLLTCGEPPTCSPDQFACATGEIDCIPGAWRCDGFPECDDQSDEEGCPVCSAAQFPCARGQCVDLRLRCDGEADCQDRSDEADCDAICLPNQFRCASGQCVLIKQQCDSFPDCIDGSDELMCEITKPPSDDSPAHSSAIGPVIGIILSLFVMGGVYFVCQRVVCQRYAGANGPFPHEYVSGTPHVPLNFIAPGGSQHGPFTGIACGKSMMSSVSLMGGRGGVPLYDRNHVTGASSSSSSSTKATLYPPILNPPPSPATDPSLYNMDMFYSSNIPATARPYRPYIIRGMAPPTTPCSTDVCDSDYSASRWKASKYYLDLNSDSDPYPPPPTPHSQYLSAEDSCPPSPATERSYFHLFPPPPSPCTDSS T86072 DRUGINFO D9DQ1I BI 905681 Phase 1 T86072 DRUGINFO DTB43H BI 905677 Phase 1 T86321 TARGETID T86321 T86321 UNIPROID SULF2_HUMAN T86321 TARGNAME Extracellular sulfatase Sulf-2 (SULF2) T86321 GENENAME SULF2 T86321 TARGTYPE Clinical trial T86321 SYNONYMS hSulf-2 T86321 FUNCTION Exhibits arylsulfatase activity and highly specific endoglucosamine-6-sulfatase activity. It can remove sulfate from the C-6 position of glucosamine within specific subregions of intact heparin. T86321 ECNUMBER EC 3.1.6.- T86321 SEQUENCE MGPPSLVLCLLSATVFSLLGGSSAFLSHHRLKGRFQRDRRNIRPNIILVLTDDQDVELGSMQVMNKTRRIMEQGGAHFINAFVTTPMCCPSRSSILTGKYVHNHNTYTNNENCSSPSWQAQHESRTFAVYLNSTGYRTAFFGKYLNEYNGSYVPPGWKEWVGLLKNSRFYNYTLCRNGVKEKHGSDYSKDYLTDLITNDSVSFFRTSKKMYPHRPVLMVISHAAPHGPEDSAPQYSRLFPNASQHITPSYNYAPNPDKHWIMRYTGPMKPIHMEFTNMLQRKRLQTLMSVDDSMETIYNMLVETGELDNTYIVYTADHGYHIGQFGLVKGKSMPYEFDIRVPFYVRGPNVEAGCLNPHIVLNIDLAPTILDIAGLDIPADMDGKSILKLLDTERPVNRFHLKKKMRVWRDSFLVERGKLLHKRDNDKVDAQEENFLPKYQRVKDLCQRAEYQTACEQLGQKWQCVEDATGKLKLHKCKGPMRLGGSRALSNLVPKYYGQGSEACTCDSGDYKLSLAGRRKKLFKKKYKASYVRSRSIRSVAIEVDGRVYHVGLGDAAQPRNLTKRHWPGAPEDQDDKDGGDFSGTGGLPDYSAANPIKVTHRCYILENDTVQCDLDLYKSLQAWKDHKLHIDHEIETLQNKIKNLREVRGHLKKKRPEECDCHKISYHTQHKGRLKHRGSSLHPFRKGLQEKDKVWLLREQKRKKKLRKLLKRLQNNDTCSMPGLTCFTHDNQHWQTAPFWTLGPFCACTSANNNTYWCMRTINETHNFLFCEFATGFLEYFDLNTDPYQLMNAVNTLDRDVLNQLHVQLMELRSCKGYKQCNPRTRNMDLGLKDGGSYEQYRQFQRRKWPEMKRPSSKSLGQLWEGWEG T86321 DRUGINFO D7M3JN Disufenton Phase 2 T89176 TARGETID T89176 T89176 UNIPROID GYRA_CLOAB; GYRB_CLOAB T89176 TARGNAME Clostridium difficile DNA gyrase (CD gyr) T89176 GENENAME CD gyrA; CD gyrB T89176 TARGTYPE Clinical trial T89176 DRUGINFO DWJ3A7 DS-2969 Phase 1 T89234 TARGETID T89234 T89234 UNIPROID CO5_HUMAN T89234 TARGNAME C5 messenger RNA (C5 mRNA) T89234 GENENAME C5 T89234 TARGTYPE Clinical trial T89234 SYNONYMS C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 T89234 FUNCTION Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. T89234 BIOCLASS mRNA target T89234 SEQUENCE MGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYPDKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPITYDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHIGIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGYKNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVTFDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATPLFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASFVLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGEHLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRLLVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWVALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANADDSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLVPRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQLKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTVLPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFPYRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFYVFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTAFALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEARENSLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDKTHPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLNLKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHKGALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLKIDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLKALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHRPDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYAYKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIMGKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC T89234 DRUGINFO D3J9XC Cemdisiran Phase 2 T89234 DRUGINFO DHTN76 ALN-CC5 Phase 2 T89251 TARGETID T89251 T89251 UNIPROID BAX_HUMAN T89251 TARGNAME Apoptosis regulator BAX (BAX) T89251 GENENAME BAX T89251 TARGTYPE Clinical trial T89251 SYNONYMS Bcl-2-like protein 4; Bcl2-L-4 T89251 FUNCTION Plays a role in the mitochondrial apoptotic process. Under normal conditions, BAX is largely cytosolic via constant retrotranslocation from mitochondria to the cytosol mediated by BCL2L1/Bcl-xL, which avoids accumulation of toxic BAX levels at the mitochondrial outer membrane (MOM). Under stress conditions, undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis. Promotes activation of CASP3, and thereby apoptosis. T89251 SEQUENCE MDGSGEQPRGGGPTSSEQIMKTGALLLQGFIQDRAGRMGGEAPELALDPVPQDASTKKLSECLKRIGDELDSNMELQRMIAAVDTDSPREVFFRVAADMFSDGNFNWGRVVALFYFASKLVLKALCTKVPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIFVAGVLTASLTIWKKMG T89251 DRUGINFO DY4OZ6 Thymoquinone Phase 2/3 T90457 TARGETID T90457 T90457 UNIPROID PD1L1_HUMAN T90457 TARGNAME CD274 messenger RNA (CD274 mRNA) T90457 GENENAME CD274 T90457 TARGTYPE Clinical trial T90457 SYNONYMS PD-L1; PDCD1 ligand 1; Programmed death ligand 1; hPD-L1; B7 homolog 1; B7-H1; DE AltName: CD_antigen=CD274 T90457 FUNCTION Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). T90457 BIOCLASS mRNA target T90457 SEQUENCE MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET T90457 DRUGINFO DJX7K9 RG6084 Phase 1 T90628 TARGETID T90628 T90628 UNIPROID RAE1_HUMAN T90628 TARGNAME Rab proteins geranylgeranyltransferase component A 1 (CHM) T90628 GENENAME CHM T90628 TARGTYPE Clinical trial T90628 SYNONYMS Choroideremia protein; Rab escort protein 1; REP-1; TCD protein T90628 FUNCTION Substrate-binding subunit of the Rab geranylgeranyltransferase (GGTase) complex. Binds unprenylated Rab proteins and presents the substrate peptide to the catalytic component B composed of RABGGTA and RABGGTB, and remains bound to it after the geranylgeranyl transfer reaction. The component A is thought to be regenerated by transferring its prenylated Rab back to the donor membrane. Besides, a pre-formed complex consisting of CHM and the Rab GGTase dimer (RGGT or component B) can bind to and prenylate Rab proteins; this alternative pathway is proposed to be the predominant pathway for Rab protein geranylgeranylation. T90628 SEQUENCE MADTLPSEFDVIVIGTGLPESIIAAACSRSGRRVLHVDSRSYYGGNWASFSFSGLLSWLKEYQENSDIVSDSPVWQDQILENEEAIALSRKDKTIQHVEVFCYASQDLHEDVEEAGALQKNHALVTSANSTEAADSAFLPTEDESLSTMSCEMLTEQTPSSDPENALEVNGAEVTGEKENHCDDKTCVPSTSAEDMSENVPIAEDTTEQPKKNRITYSQIIKEGRRFNIDLVSKLLYSRGLLIDLLIKSNVSRYAEFKNITRILAFREGRVEQVPCSRADVFNSKQLTMVEKRMLMKFLTFCMEYEKYPDEYKGYEEITFYEYLKTQKLTPNLQYIVMHSIAMTSETASSTIDGLKATKNFLHCLGRYGNTPFLFPLYGQGELPQCFCRMCAVFGGIYCLRHSVQCLVVDKESRKCKAIIDQFGQRIISEHFLVEDSYFPENMCSRVQYRQISRAVLITDRSVLKTDSDQQISILTVPAEEPGTFAVRVIELCSSTMTCMKGTYLVHLTCTSSKTAREDLESVVQKLFVPYTEMEIENEQVEKPRILWALYFNMRDSSDISRSCYNDLPSNVYVCSGPDCGLGNDNAVKQAETLFQEICPNEDFCPPPPNPEDIILDGDSLQPEASESSAIPEANSETFKESTNLGNLEESSE T90628 DRUGINFO DW1OK0 BIIB111 Phase 3 T90628 DRUGINFO DPS6V0 SPK-7001 Phase 1/2 T90628 DRUGINFO D3UQO1 4D-110 Phase 1 T90835 TARGETID T90835 T90835 UNIPROID IL1R1_HUMAN; IL1R2_HUMAN T90835 TARGNAME Interleukin-1 receptor (IL1R) T90835 GENENAME IL1R1; IL1R2 T90835 TARGTYPE Clinical trial T90835 DRUGINFO DOD24G Isunakinra Phase 1/2 T92678 TARGETID T92678 T92678 UNIPROID MALT1_HUMAN T92678 TARGNAME MALT lymphoma-associated translocation (MALT1) T92678 GENENAME MALT1 T92678 TARGTYPE Clinical trial T92678 SYNONYMS MALT lymphoma-associated translocation; Paracaspase T92678 FUNCTION Protease that enhances BCL10-induced activation of NF-kappa-B by mediating its cleavage. MALT1-dependent BCL10 cleavage plays an important role in T-cell antigen receptor-induced integrin adhesion. Involved in the induction of T helper 17 cells (Th17) differentiation. Cleaves RC3H1 and ZC3H12A in response to T-cell receptor (TCR) stimulation which releases their cooperatively repressed targets to promote Th17 cell differentiation (By similarity). Also mediates cleavage of N4BP1 in T-cells following TCR-mediated activation, leading to N4BP1 inactivation. Also has ubiquitin ligase activity: binds to TRAF6, inducing TRAF6 oligomerization and activation of its ligase activity. T92678 BIOCLASS Peptidase T92678 ECNUMBER EC 3.4.22.- T92678 SEQUENCE MSLLGDPLQALPPSAAPTGPLLAPPAGATLNRLREPLLRRLSELLDQAPEGRGWRRLAELAGSRGRLRLSCLDLEQCSLKVLEPEGSPSLCLLKLMGEKGCTVTELSDFLQAMEHTEVLQLLSPPGIKITVNPESKAVLAGQFVKLCCRATGHPFVQYQWFKMNKEIPNGNTSELIFNAVHVKDAGFYVCRVNNNFTFEFSQWSQLDVCDIPESFQRSVDGVSESKLQICVEPTSQKLMPGSTLVLQCVAVGSPIPHYQWFKNELPLTHETKKLYMVPYVDLEHQGTYWCHVYNDRDSQDSKKVEIIIGRTDEAVECTEDELNNLGHPDNKEQTTDQPLAKDKVALLIGNMNYREHPKLKAPLVDVYELTNLLRQLDFKVVSLLDLTEYEMRNAVDEFLLLLDKGVYGLLYYAGHGYENFGNSFMVPVDAPNPYRSENCLCVQNILKLMQEKETGLNVFLLDMCRKRNDYDDTIPILDALKVTANIVFGYATCQGAEAFEIQHSGLANGIFMKFLKDRLLEDKKITVLLDEVAEDMGKCHLTKGKQALEIRSSLSEKRALTDPIQGTEYSAESLVRNLQWAKAHELPESMCLKFDCGVQIQLGFAAEFSNVMIIYTSIVYKPPEIIMCDAYVTDFPLDLDIDPKDANKGTPEETGSYLVSKDLPKHCLYTRLSSLQKLKEHLVFTVCLSYQYSGLEDTVEDKQEVNVGKPLIAKLDMHRGLGRKTCFQTCLMSNGPYQSSAATSGGAGHYHSLQDPFHGVYHSHPGNPSNVTPADSCHCSRTPDAFISSFAHHASCHFSRSNVPVETTDEIPFSFSDRLRISEK T92678 DRUGINFO D3GIQ9 JNJ-67856633 Phase 1 T93480 TARGETID T93480 T93480 UNIPROID UD11_HUMAN T93480 TARGNAME UDP-glucuronosyltransferase 1A1 (UGT1A1) T93480 GENENAME UGT1A1 T93480 TARGTYPE Clinical trial T93480 SYNONYMS UGT1A1; Bilirubin-specific UDPGT isozyme 1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDPGT 1-1; UGT1*1; UGT1-01; UGT1.1; UDP-glucuronosyltransferase 1A isoform 1 T93480 FUNCTION UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol, estrone and estriol. Involved in the glucuronidation of bilirubin, a degradation product occurring in the normal catabolic pathway that breaks down heme in vertebrates. Also catalyzes the glucuronidation the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties. Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, a drug which can inhibit the effect of angiotensin II. Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan. T93480 ECNUMBER EC 2.4.1.17 T93480 SEQUENCE MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKNMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPNMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH T93480 DRUGINFO D84EGX AT-342 Phase 1/2 T93548 TARGETID T93548 T93548 UNIPROID ITAV_HUMAN-ITB8_HUMAN T93548 TARGNAME Integrin alpha-V/beta-8 (ITGAV/B8) T93548 GENENAME ITGAV-ITGB8 T93548 TARGTYPE Clinical trial T93548 DRUGINFO DO3E7R PF-06940434 Phase 1 T94781 TARGETID T94781 T94781 UNIPROID NCAP_HRSVA T94781 TARGNAME HRSV Nucleoprotein messenger RNA (HRSV N mRNA) T94781 GENENAME HRSV N mRNA T94781 TARGTYPE Clinical trial T94781 SYNONYMS Protein N; Nucleocapsid protein T94781 FUNCTION Encapsidates the viral RNA genome by forming a left-handed helical nucleocapsid that protects the RNA from nucleases. RNA replication depends on the availability of soluble nucleoprotein. The encapsidated genomic RNA is termed the NC and serves as template for transcription and replication. Together with the phosphoprotein, sequesters host NF-kappa-B in inclusion bodies (IBs) thereby inhibiting this host defense pathway. May also act as a modulator of the innate immune response by sequestration of host IFIH1/MDA5 and MAVS into IBs. T94781 BIOCLASS mRNA target T94781 SEQUENCE MALSKVKLNDTLNKDQLLSSSKYTIQRSTGDSIDTPNYDVQKHINKLCGMLLITEDANHKFTGLIGMLYAMSRLGREDTIKILRDAGYHVKANGVDVTTHRQDINGKEMKFEVLTLASLTTEIQINIEIESRKSYKKMLKEMGEVAPEYRHDSPDCGMIILCIAALVITKLAAGDRSGLTAVIRRANNVLKNEMKRYKGLLPKDIANSFYEVFEKHPHFIDVFVHFGIAQSSTRGGSRVEGIFAGLFMNAYGAGQVMLRWGVLAKSVKNIMLGHASVQAEMEQVVEVYEYAQKLGGEAGFYHILNNPKASLLSLTQFPHFSSVVLGNAAGLGIMGEYRGTPRNQDLYDAAKAYAEQLKENGVINYSVLDLTAEELEAIKHQLNPKDNDVEL T94781 DRUGINFO DNM9C4 ALN-RSV01 Phase 2 T95108 TARGETID T95108 T95108 UNIPROID HLAG_HUMAN T95108 TARGNAME MHC class I antigen G (HLA-G) T95108 GENENAME HLA-G T95108 TARGTYPE Clinical trial T95108 SYNONYMS HLA G antigen; MHC class I antigen G T95108 FUNCTION Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface. In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins. Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance. Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy. Through interaction with KIR2DL4 receptor on decidual macrophages induces proinflammatory cytokine production mainly associated with tissue remodeling. Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance. May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells. Reprograms B cells toward an immune suppressive phenotype via LILRB1. May induce immune activation/suppression via intercellular membrane transfer (trogocytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes. Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites. T95108 BIOCLASS MHC class I T95108 SEQUENCE MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGYYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEMLQRADPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWKQSSLPTIPIMGIVAGLVVLAAVVTGAAVAAVLWRKKSSD T95108 DRUGINFO D7J2NK TTX-080 Phase 1 T95410 TARGETID T95410 T95410 UNIPROID G5EB61_EMENI T95410 TARGNAME Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH) T95410 TARGTYPE Clinical trial T95410 SYNONYMS Dihydroorotate oxidase T95410 ECNUMBER EC 1.3.5.2 T95410 SEQUENCE MATNSFRKLTFSGASRLGGCRRLPLTCRQLRFASDSGAAAATTKATAESAAESASINVKEAPKKAGRGLRRTVLGTSLALTLLVGYVYGTDTRASVHRYGVVPLIRALYPDAEDAHHIGVDTLKMLYKYGLHPRERGDPDGDGALATEVFGYTLSNPIGISGGLDKHAEIPDPLFAIGPAIVEVGGTTPLPQDGNPRPRVFRLPSQRAMINRYGLNSKGADHMAAILEQRVRDFAYANGFGAYDAAKQRVLDGEAGVPPGSLQPGKLLAVQVAKNKATPDGDIEAIKRDYVYCVDRVAKYADILVVNVSSPNTPGLRDLQATAPLTAILSAVVGAAKSVNRKTKPYVMVKVSPDEDSDEQVSGICDAVRASGVDGVIVGNTTNRRPDPIPQGYTLPAKEQATLKETGGYSGPQLFDRTVALVARYRSMLDAESETAGSAKDSAATIAQTEPGSENVPPVEAPSGLPRKVIFASGGITNGKQAHAVLDTGASVAMMYTGVVYGGVGTVTRVKQELRTAKKE T95410 DRUGINFO DJ8CY4 F901318 Phase 2 T96723 TARGETID T96723 T96723 UNIPROID SF3B1_HUMAN-SF3B2_HUMAN-SF3B3_HUMAN-SF3B4_HUMAN-SF3B5_HUMAN-SF3B6_HUMAN T96723 TARGNAME SF3b complex (SF3b) T96723 GENENAME SF3B1-SF3B2-SF3B3-SF3B4-SF3B5-SF3B6 T96723 TARGTYPE Clinical trial T96723 DRUGINFO DB5O1U H3B-8800 Phase 1 T97632 TARGETID T97632 T97632 UNIPROID HOS2_YEAST T97632 TARGNAME Fungal Probable histone deacetylase HOS2 (Fung HOS2) T97632 GENENAME Fung HOS2 T97632 TARGTYPE Clinical trial T97632 FUNCTION Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). It is apparently involved in transcriptional activation. T97632 ECNUMBER EC 3.5.1.98 T97632 SEQUENCE MSGTFSYDVKTKENEPLFEFNSAYSPRVSYHFNSKVSHYHYGVKHPMKPFRLMLTDHLVSSYGLHKIMDLYETRSATRDELLQFHSEDYVNFLSKVSPENANKLPRGTLENFNIGDDCPIFQNLYDYTTLYTGASLDATRKLINNQSDIAINWSGGLHHAKKNSPSGFCYVNDIVLSILNLLRYHPRILYIDIDLHHGDGVQEAFYTTDRVFTLSFHKYNGEFFPGTGDLTEIGCDKGKHFALNVPLEDGIDDDSYINLFKSIVDPLIMTFKPTLIVQQCGADSLGHDRLGCFNLNIKAHGECVKFVKSFGLPMLVVGGGGYTPRNVSRLWTYETGILNDVLLPEDIPEDIPFRDSFGPDYSLYPMLDDLYENKNSKKLLEDIRIRCLENIRYLQGAPSVRMDAECIPTQDISALTEEEDKIIQEMNEETEADSSNRLEEMEKENSGLIAFS T97632 DRUGINFO DG61OC MGCD290 Phase 2 T98034 TARGETID T98034 T98034 UNIPROID CDK19_HUMAN T98034 TARGNAME Cyclin-dependent kinase 19 (CDK19) T98034 GENENAME CDK19 T98034 TARGTYPE Clinical trial T98034 SYNONYMS CDC2-related protein kinase 6; Cell division cycle 2-like protein kinase 6; Cell division protein kinase 19; Cyclin-dependent kinase 11; Death-preventing kinase T98034 FUNCTION cytosol, mediator complex, nucleus, cyclin-dependent protein serine/threonine kinase activity, RNA polymerase II CTD heptapeptide repeat kinase activity, protein phosphorylation T98034 BIOCLASS Kinase T98034 ECNUMBER EC 2.7.11.22 T98034 SEQUENCE MDYDFKAKLAAERERVEDLFEYEGCKVGRGTYGHVYKARRKDGKDEKEYALKQIEGTGISMSACREIALLRELKHPNVIALQKVFLSHSDRKVWLLFDYAEHDLWHIIKFHRASKANKKPMQLPRSMVKSLLYQILDGIHYLHANWVLHRDLKPANILVMGEGPERGRVKIADMGFARLFNSPLKPLADLDPVVVTFWYRAPELLLGARHYTKAIDIWAIGCIFAELLTSEPIFHCRQEDIKTSNPFHHDQLDRIFSVMGFPADKDWEDIRKMPEYPTLQKDFRRTTYANSSLIKYMEKHKVKPDSKVFLLLQKLLTMDPTKRITSEQALQDPYFQEDPLPTLDVFAGCQIPYPKREFLNEDDPEEKGDKNQQQQQNQHQQPTAPPQQAAAPPQAPPPQQNSTQTNGTAGGAGAGVGGTGAGLQHSQDSSLNQVPPNKKPRLGPSGANSGGPVMPSDYQHSSSRLNYQSSVQGSSQSQSTLGYSSSSQQSSQYHPSHQAHRY T98034 DRUGINFO DOJG79 SEL120 Phase 1 T98234 TARGETID T98234 T98234 UNIPROID TRFM_HUMAN T98234 TARGNAME Melanotransferrin (MELTF) T98234 GENENAME MELTF T98234 TARGTYPE Clinical trial T98234 SYNONYMS Melanoma-associated antigen p97; DE AltName: CD_antigen=CD228 T98234 FUNCTION Involved in iron cellular uptake. Seems to be internalized and then recycled back to the cell membrane. Binds a single atom of iron per subunit. Could also bind zinc. T98234 BIOCLASS Transferrin T98234 SEQUENCE MRGPSGALWLLLALRTVLGGMEVRWCATSDPEQHKCGNMSEAFREAGIQPSLLCVRGTSADHCVQLIAAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTSYYAVAVVRRSSHVTIDTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCDVLKAVSDYFGGSCVPGAGETSYSESLCRLCRGDSSGEGVCDKSPLERYYDYSGAFRCLAEGAGDVAFVKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADVTEWRQCHLARVPAHAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSEAYGQKDLLFKDSTSELVPIATQTYEAWLGHEYLHAMKGLLCDPNRLPPYLRWCVLSTPEIQKCGDMAVAFRRQRLKPEIQCVSAKSPQHCMERIQAEQVDAVTLSGEDIYTAGKTYGLVPAAGEHYAPEDSSNSYYVVAVVRRDSSHAFTLDELRGKRSCHAGFGSPAGWDVPVGALIQRGFIRPKDCDVLTAVSEFFNASCVPVNNPKNYPSSLCALCVGDEQGRNKCVGNSQERYYGYRGAFRCLVENAGDVAFVRHTTVFDNTNGHNSEPWAAELRSEDYELLCPNGARAEVSQFAACNLAQIPPHAVMVRPDTNIFTVYGLLDKAQDLFGDDHNKNGFKMFDSSNYHGQDLLFKDATVRAVPVGEKTTYRGWLGLDYVAALEGMSSQQCSGAAAPAPGAPLLPLLLPALAARLLPPAL T98234 DRUGINFO DS6BE2 SGN-CD228A Phase 1 T98430 TARGETID T98430 T98430 UNIPROID IDUA_HUMAN T98430 TARGNAME Alpha-L-iduronidase (IDUA) T98430 GENENAME IDUA T98430 TARGTYPE Clinical trial T98430 FUNCTION extracellular exosome, lysosomal lumen, hydrolase activity, hydrolyzing O-glycosyl compounds, L-iduronidase activity, chondroitin sulfate catabolic process, dermatan sulfate catabolic process, disaccharide metabolic process, glycosaminoglycan catabolic process, heparin catabolic process T98430 BIOCLASS Glycosyl hydrolase T98430 ECNUMBER EC 3.2.1.76 T98430 SEQUENCE MRPLRPRAALLALLASLLAAPPVAPAEAPHLVHVDAARALWPLRRFWRSTGFCPPLPHSQADQYVLSWDQQLNLAYVGAVPHRGIKQVRTHWLLELVTTRGSTGRGLSYNFTHLDGYLDLLRENQLLPGFELMGSASGHFTDFEDKQQVFEWKDLVSSLARRYIGRYGLAHVSKWNFETWNEPDHHDFDNVSMTMQGFLNYYDACSEGLRAASPALRLGGPGDSFHTPPRSPLSWGLLRHCHDGTNFFTGEAGVRLDYISLHRKGARSSISILEQEKVVAQQIRQLFPKFADTPIYNDEADPLVGWSLPQPWRADVTYAAMVVKVIAQHQNLLLANTTSAFPYALLSNDNAFLSYHPHPFAQRTLTARFQVNNTRPPHVQLLRKPVLTAMGLLALLDEEQLWAEVSQAGTVLDSNHTVGVLASAHRPQGPADAWRAAVLIYASDDTRAHPNRSVAVTLRLRGVPPGPGLVYVTRYLDNGLCSPDGEWRRLGRPVFPTAEQFRRMRAAEDPVAAAPRPLPAGGRLTLRPALRLPSLLLVHVCARPEKPPGQVTRLRALPLTQGQLVLVWSDEHVGSKCLWTYEIQFSQDGKAYTPVSRKPSTFNLFVFSPDTGAVSGSYRVRALDYWARPGPFSDPVPYLEVPVPRGPPSPGNP T98430 DRUGINFO DYWK46 SB-318 Phase 1/2 T98430 DRUGINFO D8XHT1 RGX-111 Phase 1 T63246 TARGETID T63246 T63246 UNIPROID CTNS_HUMAN T63246 TARGNAME Cystinosin (CTNS) T63246 GENENAME CTNS T63246 TARGTYPE Clinical trial T63246 FUNCTION Cystine/H(+) symporter that mediates export of cystine, the oxidized dimer of cysteine, from lysosomes (PubMed:11689434, PubMed:18337546, PubMed:22232659, PubMed:29467429, PubMed:33208952, PubMed:15128704). Plays an important role in melanin synthesis by catalyzing cystine export from melanosomes, possibly by inhibiting pheomelanin synthesis (PubMed:22649030). In addition to cystine export, also acts as a positive regulator of mTORC1 signaling in kidney proximal tubular cells, via interactions with components of the v-ATPase and Ragulator complexes (By similarity). Also involved in small GTPase-regulated vesicle trafficking and lysosomal localization of LAMP2A, independently of cystine transporter activity (By similarity). {ECO:0000250|UniProtKB:P57757, ECO:0000269|PubMed:11689434, ECO:0000269|PubMed:15128704, ECO:0000269|PubMed:18337546, ECO:0000269|PubMed:22232659, ECO:0000269|PubMed:22649030, ECO:0000269|PubMed:29467429, ECO:0000269|PubMed:33208952}. T63246 PDBSTRUC 8DKE;8DKI;8DKM;8DKW;8DKX;8DYP T63246 SEQUENCE MIRNWLTIFILFPLKLVEKCESSVSLTVPPVVKLENGSSTNVSLTLRPPLNATLVITFEITFRSKNITILELPDEVVVPPGVTNSSFQVTSQNVGQLTVYLHGNHSNQTGPRIRFLVIRSSAISIINQVIGWIYFVAWSISFYPQVIMNWRRKSVIGLSFDFVALNLTGFVAYSVFNIGLLWVPYIKEQFLLKYPNGVNPVNSNDVFFSLHAVVLTLIIIVQCCLYERGGQRVSWPAIGFLVLAWLFAFVTMIVAAVGVTTWLQFLFCFSYIKLAVTLVKYFPQAYMNFYYKSTEGWSIGNVLLDFTGGSFSLLQMFLQSYNNDQWTLIFGDPTKFGLGVFSIVFDVVFFIQHFCLYRKRPGYDQLN T63246 DRUGINFO DO4YS2 AVR-RD-04 Clinical trial T63163 TARGETID T63163 T63163 UNIPROID BCKD_HUMAN T63163 TARGNAME [3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK) T63163 GENENAME BCKDK T63163 TARGTYPE Clinical trial T63163 SYNONYMS Branched-chain alpha-ketoacid dehydrogenase kinase; BCKD-kinase; BCKDHKIN T63163 FUNCTION Catalyzes the phosphorylation and inactivation of the branched-chain alpha-ketoacid dehydrogenase complex, the key regulatory enzyme of the valine, leucine and isoleucine catabolic pathways. Key enzyme that regulate the activity state of the BCKD complex. {ECO:0000269|PubMed:24449431}. T63163 PDBSTRUC 8F5F;8F5J;8F5S T63163 BIOCLASS Kinase T63163 ECNUMBER EC 2.7.11.4 T63163 SEQUENCE MILASVLRSGPGGGLPLRPLLGPALALRARSTSATDTHHVEMARERSKTVTSFYNQSAIDAAAEKPSVRLTPTMMLYAGRSQDGSHLLKSARYLQQELPVRIAHRIKGFRCLPFIIGCNPTILHVHELYIRAFQKLTDFPPIKDQADEAQYCQLVRQLLDDHKDVVTLLAEGLRESRKHIEDEKLVRYFLDKTLTSRLGIRMLATHHLALHEDKPDFVGIICTRLSPKKIIEKWVDFARRLCEHKYGNAPRVRINGHVAARFPFIPMPLDYILPELLKNAMRATMESHLDTPYNVPDVVITIANNDVDLIIRISDRGGGIAHKDLDRVMDYHFTTAEASTQDPRISPLFGHLDMHSGAQSGPMHGFGFGLPTSRAYAEYLGGSLQLQSLQGIGTDVYLRLRHIDGREESFRI T63163 DRUGINFO D0S5XD PF-07328948 Phase 1 T63164 TARGETID T63164 T63164 UNIPROID CADH6_HUMAN T63164 TARGNAME Cadherin-6 (CDH6) T63164 GENENAME CDH6 T63164 TARGTYPE Clinical trial T63164 SYNONYMS Kidney cadherin; K-cadherin T63164 FUNCTION Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. T63164 PDBSTRUC 5VEB T63164 SEQUENCE MRTYRYFLLLFWVGQPYPTLSTPLSKRTSGFPAKKRALELSGNSKNELNRSKRSWMWNQFFLLEEYTGSDYQYVGKLHSDQDRGDGSLKYILSGDGAGDLFIINENTGDIQATKRLDREEKPVYILRAQAINRRTGRPVEPESEFIIKIHDINDNEPIFTKEVYTATVPEMSDVGTFVVQVTATDADDPTYGNSAKVVYSILQGQPYFSVESETGIIKTALLNMDRENREQYQVVIQAKDMGGQMGGLSGTTTVNITLTDVNDNPPRFPQSTYQFKTPESSPPGTPIGRIKASDADVGENAEIEYSITDGEGLDMFDVITDQETQEGIITVKKLLDFEKKKVYTLKVEASNPYVEPRFLYLGPFKDSATVRIVVEDVDEPPVFSKLAYILQIREDAQINTTIGSVTAQDPDAARNPVKYSVDRHTDMDRIFNIDSGNGSIFTSKLLDRETLLWHNITVIATEINNPKQSSRVPLYIKVLDVNDNAPEFAEFYETFVCEKAKADQLIQTLHAVDKDDPYSGHQFSFSLAPEAASGSNFTIQDNKDNTAGILTRKNGYNRHEMSTYLLPVVISDNDYPVQSSTGTVTVRVCACDHHGNMQSCHAEALIHPTGLSTGALVAILLCIVILLVTVVLFAALRRQRKKEPLIISKEDIRDNIVSYNDEGGGEEDTQAFDIGTLRNPEAIEDNKLRRDIVPEALFLPRRTPTARDNTDVRDFINQRLKENDTDPTAPPYDSLATYAYEGTGSVADSLSSLESVTTDADQDYDYLSDWGPRFKKLADMYGGVDSDKDS T63164 DRUGINFO DISJ28 DS-6000 Phase 1 T63165 TARGETID T63165 T63165 UNIPROID CCR6_HUMAN T63165 TARGNAME C-C chemokine receptor type 6 (CCR6) T63165 GENENAME CCR6 T63165 TARGTYPE Clinical trial T63165 SYNONYMS C-C CKR-6; CC-CKR-6; CCR-6; Chemokine receptor-like 3; CKR-L3; DRY6; G-protein coupled receptor 29; GPR-CY4; GPRCY4; LARC receptor; CD196 T63165 FUNCTION Receptor for the C-C type chemokine CCL20 (PubMed:9169459). Binds to CCL20 and subsequently transduces a signal by increasing the intracellular calcium ion levels (PubMed:20068036). Although CCL20 is its major ligand it can also act as a receptor for non-chemokine ligands such as beta-defensins (PubMed:25585877). Binds to defensin DEFB1 leading to increase in intracellular calcium ions and cAMP levels. Its binding to DEFB1 is essential for the function of DEFB1 in regulating sperm motility and bactericidal activity (PubMed:25122636). Binds to defensins DEFB4 and DEFB4A/B and mediates their chemotactic effects (PubMed:20068036). The ligand-receptor pair CCL20-CCR6 is responsible for the chemotaxis of dendritic cells (DC), effector/ memory T-cells and B-cells and plays an important role at skin and mucosal surfaces under homeostatic and inflammatory conditions, as well as in pathology, including cancer and various autoimmune diseases. CCR6-mediated signals are essential for immune responses to microbes in the intestinal mucosa and in the modulation of inflammatory responses initiated by tissue insult and trauma (PubMed:21376174). CCR6 is essential for the recruitment of both the pro-inflammatory IL17 producing helper T-cells (Th17) and the regulatory T-cells (Treg) to sites of inflammation. Required for the normal migration of Th17 cells in Peyers-patches and other related tissue sites of the intestine and plays a role in regulating effector T-cell balance and distribution in inflamed intestine. Plays an important role in the coordination of early thymocyte precursor migration events important for normal subsequent thymocyte precursor development, but is not required for the formation of normal thymic natural regulatory T-cells (nTregs). Required for optimal differentiation of DN2 and DN3 thymocyte precursors. Essential for B-cell localization in the subepithelial dome of Peyers-patches and for efficient B-cell isotype switching to IgA in the Peyers-patches. Essential for appropriate anatomical distribution of memory B-cells in the spleen and for the secondary recall response of memory B-cells (By similarity). Positively regulates sperm motility and chemotaxis via its binding to CCL20 (PubMed:23765988). {ECO:0000250|UniProtKB:O54689, ECO:0000269|PubMed:20068036, ECO:0000269|PubMed:23765988, ECO:0000269|PubMed:25122636, ECO:0000269|PubMed:9169459, ECO:0000303|PubMed:21376174, ECO:0000303|PubMed:25585877}. T63165 PDBSTRUC 6WWZ T63165 BIOCLASS G-protein coupled receptor 1 family T63165 SEQUENCE MSGESMNFSDVFDSSEDYFVSVNTSYYSVDSEMLLCSLQEVRQFSRLFVPIAYSLICVFGLLGNILVVITFAFYKKARSMTDVYLLNMAIADILFVLTLPFWAVSHATGAWVFSNATCKLLKGIYAINFNCGMLLLTCISMDRYIAIVQATKSFRLRSRTLPRSKIICLVVWGLSVIISSSTFVFNQKYNTQGSDVCEPKYQTVSEPIRWKLLMLGLELLFGFFIPLMFMIFCYTFIVKTLVQAQNSKRHKAIRVIIAVVLVFLACQIPHNMVLLVTAANLGKMNRSCQSEKLIGYTKTVTEVLAFLHCCLNPVLYAFIGQKFRNYFLKILKDLWCVRRKYKSSGFSCAGRYSENISRQTSETADNDNASSFTM T63165 DRUGINFO D1TS9A PF-07054894 Phase 1 T63166 TARGETID T63166 T63166 UNIPROID CLD6_HUMAN T63166 TARGNAME Claudin-6 (CLDN6) T63166 GENENAME CLDN6 T63166 TARGTYPE Clinical trial T63166 SYNONYMS Skullin T63166 FUNCTION Plays a major role in tight junction-specific obliteration of the intercellular space. {ECO:0000250}.; (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) entry into hepatic cells. {ECO:0000269|PubMed:17804490, ECO:0000269|PubMed:20375010}. T63166 SEQUENCE MASAGMQILGVVLTLLGWVNGLVSCALPMWKVTAFIGNSIVVAQVVWEGLWMSCVVQSTGQMQCKVYDSLLALPQDLQAARALCVIALLVALFGLLVYLAGAKCTTCVEEKDSKARLVLTSGIVFVISGVLTLIPVCWTAHAIIRDFYNPLVAEAQKRELGASLYLGWAASGLLLLGGGLLCCTCPSGGSQGPSHYMARYSTSAPAISRGPSEYPTKNYV T63166 DRUGINFO D9QPI0 AMG 794 Phase 1 T63168 TARGETID T63168 T63168 UNIPROID ENTP3_HUMAN T63168 TARGNAME Ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3) T63168 GENENAME ENTPD3 T63168 TARGTYPE Clinical trial T63168 SYNONYMS NTPDase 3; CD39 antigen-like 3; Ecto-ATP diphosphohydrolase 3; Ecto-ATPDase 3; Ecto-ATPase 3; Ecto-apyrase 3; HB6 T63168 FUNCTION Has a threefold preference for the hydrolysis of ATP over ADP. {ECO:0000269|PubMed:10231536, ECO:0000269|PubMed:11300774}. T63168 ECNUMBER EC 3.6.1.5 T63168 SEQUENCE MFTVLTRQPCEQAGLKALYRTPTIIALVVLLVSIVVLVSITVIQIHKQEVLPPGLKYGIVLDAGSSRTTVYVYQWPAEKENNTGVVSQTFKCSVKGSGISSYGNNPQDVPRAFEECMQKVKGQVPSHLHGSTPIHLGATAGMRLLRLQNETAANEVLESIQSYFKSQPFDFRGAQIISGQEEGVYGWITANYLMGNFLEKNLWHMWVHPHGVETTGALDLGGASTQISFVAGEKMDLNTSDIMQVSLYGYVYTLYTHSFQCYGRNEAEKKFLAMLLQNSPTKNHLTNPCYPRDYSISFTMGHVFDSLCTVDQRPESYNPNDVITFEGTGDPSLCKEKVASIFDFKACHDQETCSFDGVYQPKIKGPFVAFAGFYYTASALNLSGSFSLDTFNSSTWNFCSQNWSQLPLLLPKFDEVYARSYCFSANYIYHLFVNGYKFTEETWPQIHFEKEVGNSSIAWSLGYMLSLTNQIPAESPLIRLPIEPPVFVGTLAFFTAAALLCLAFLAYLCSATRRKRHSEHAFDHAVDSD T63168 DRUGINFO DKOY58 AZD3366 Phase 1 T63170 TARGETID T63170 T63170 UNIPROID HAOX1_HUMAN T63170 TARGNAME 2-Hydroxyacid oxidase 1 (HAO1) T63170 GENENAME HAO1 T63170 TARGTYPE Clinical trial T63170 SYNONYMS HAOX1; Glycolate oxidase; GO; GOX; Glyoxylate oxidase T63170 FUNCTION Broad substrate specificity (S)-2-hydroxy-acid oxidase that preferentially oxidizes glycolate (PubMed:10777549, PubMed:17669354, PubMed:18215067, PubMed:10978532). The glyoxylate produced by the oxidation of glycolate can then be utilized by alanine-glyoxylate aminotransferase for the peroxisomal synthesis of glycine; this pathway appears to be an important step for the detoxification of glyoxylate which, if allowed to accumulate, may be metabolized to oxalate with formation of kidney stones (PubMed:10978532, PubMed:17669354). Can also catalyze the oxidation of glyoxylate, and long chain hydroxyacids such as 2-hydroxyhexadecanoate and 2-hydroxyoctanoate, albeit with much lower catalytic efficiency (PubMed:10777549, PubMed:17669354, PubMed:18215067). Active in vitro with the artificial electron acceptor 2,6-dichlorophenolindophenol (DCIP), but O2 is believed to be the physiological electron acceptor, leading to the production of H2O2 (PubMed:10777549, PubMed:17669354, PubMed:18215067, PubMed:10978532). Is not active on L-lactate and 2-hydroxybutanoate (PubMed:10777549). {ECO:0000269|PubMed:10777549, ECO:0000269|PubMed:10978532, ECO:0000269|PubMed:17669354, ECO:0000269|PubMed:18215067, ECO:0000303|PubMed:10978532, ECO:0000303|PubMed:17669354}. T63170 PDBSTRUC 2NZL;2RDT;2RDU;2RDW;2W0U;5QIB;5QIC;5QID;5QIE;5QIF;5QIG;5QIH;6GMB;6GMC;6W44;6W45;6W4C;7M2O;7R4N;7R4O;7R4P T63170 ECNUMBER EC 1.1.3.15; EC 1.2.3.5 T63170 SEQUENCE MLPRLICINDYEQHAKSVLPKSIYDYYRSGANDEETLADNIAAFSRWKLYPRMLRNVAETDLSTSVLGQRVSMPICVGATAMQRMAHVDGELATVRACQSLGTGMMLSSWATSSIEEVAEAGPEALRWLQLYIYKDREVTKKLVRQAEKMGYKAIFVTVDTPYLGNRLDDVRNRFKLPPQLRMKNFETSTLSFSPEENFGDDSGLAAYVAKAIDPSISWEDIKWLRRLTSLPIVAKGILRGDDAREAVKHGLNGILVSNHGARQLDGVPATIDVLPEIVEAVEGKVEVFLDGGVRKGTDVLKALALGAKAVFVGRPIVWGLAFQGEKGVQDVLEILKEEFRLAMALSGCQNVKVIDKTLVRKNPLAVSKI T63170 DRUGINFO D1R9KZ BBP-711 Phase 1 T63173 TARGETID T63173 T63173 UNIPROID IKZF3_HUMAN T63173 TARGNAME Zinc finger protein Aiolos (IKZF3) T63173 GENENAME IKZF3 T63173 TARGTYPE Clinical trial T63173 SYNONYMS Ikaros family zinc finger protein 3 T63173 FUNCTION Transcription factor that plays an important role in the regulation of lymphocyte differentiation. Plays an essential role in regulation of B-cell differentiation, proliferation and maturation to an effector state. Involved in regulating BCL2 expression and controlling apoptosis in T-cells in an IL2-dependent manner. {ECO:0000269|PubMed:10369681, ECO:0000269|PubMed:34155405}. T63173 SEQUENCE MEDIQTNAELKSTQEQSVPAESAAVLNDYSLTKSHEMENVDSGEGPANEDEDIGDDSMKVKDEYSERDENVLKSEPMGNAEEPEIPYSYSREYNEYENIKLERHVVSFDSSRPTSGKMNCDVCGLSCISFNVLMVHKRSHTGERPFQCNQCGASFTQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDALTGHLRTHSVEKPYKCEFCGRSYKQRSSLEEHKERCRTFLQSTDPGDTASAEARHIKAEMGSERALVLDRLASNVAKRKSSMPQKFIGEKRHCFDVNYNSSYMYEKESELIQTRMMDQAINNAISYLGAEALRPLVQTPPAPTSEMVPVISSMYPIALTRAEMSNGAPQELEKKSIHLPEKSVPSERGLSPNNSGHDSTDTDSNHEERQNHIYQQNHMVLSRARNGMPLLKEVPRSYELLKPPPICPRDSVKVINKEGEVMDVYRCDHCRVLFLDYVMFTIHMGCHGFRDPFECNMCGYRSHDRYEFSSHIARGEHRALLK T63173 DRUGINFO D7YN4H NX-2127 Phase 1 T63174 TARGETID T63174 T63174 UNIPROID IL1RA_HUMAN T63174 TARGNAME Interleukin-1 receptor antagonist protein (IL1RN) T63174 GENENAME IL1RN T63174 TARGTYPE Clinical trial T63174 SYNONYMS IL-1RN; IL-1ra; IRAP; ICIL-1RA; IL1 inhibitor; Anakinra T63174 FUNCTION Anti-inflammatory antagonist of interleukin-1 family of proinflammatory cytokines such as interleukin-1beta/IL1B and interleukin-1alpha/IL1A. Protects from immune dysregulation and uncontrolled systemic inflammation triggered by IL1 for a range of innate stimulatory agents such as pathogens. {ECO:0000250|UniProtKB:P25085, ECO:0000269|PubMed:7775431}. T63174 PDBSTRUC 1ILR;1ILT;1IRA;1IRP;2IRT T63174 SEQUENCE MEICRGLRSHLITLLLFLFHSETICRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE T63174 DRUGINFO D4SE2H Humantakinogene hadenovec Phase 1 T63174 DRUGINFO DVC36K GNSC-001 Phase 1 T63175 TARGETID T63175 T63175 UNIPROID KAT6A_HUMAN T63175 TARGNAME Histone acetyltransferase KAT6A (KAT6A) T63175 GENENAME KAT6A T63175 TARGTYPE Clinical trial T63175 SYNONYMS MOZ, YBF2/SAS3, SAS2 and TIP60 protein 3; MYST-3; Monocytic leukemia zinc finger protein; Runt-related transcription factor-binding protein 2; Zinc finger protein 220 T63175 FUNCTION Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2. Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls its transcriptional activity via association with PML. {ECO:0000269|PubMed:11742995, ECO:0000269|PubMed:11965546, ECO:0000269|PubMed:12771199, ECO:0000269|PubMed:16387653, ECO:0000269|PubMed:17925393, ECO:0000269|PubMed:23431171}. T63175 PDBSTRUC 1M36;2LN0;2OZU;2RC4;3V43;4LJN;4LK9;4LKA;4LLB;5B75;5B76;5B77;5B78;6LSB;7Y43;8DD5;8H7A T63175 ECNUMBER EC 2.3.1.48 T63175 SEQUENCE MVKLANPLYTEWILEAIKKVKKQKQRPSEERICNAVSSSHGLDRKTVLEQLELSVKDGTILKVSNKGLNSYKDPDNPGRIALPKPRNHGKLDNKQNVDWNKLIKRAVEGLAESGGSTLKSIERFLKGQKDVSALFGGSAASGFHQQLRLAIKRAIGHGRLLKDGPLYRLNTKATNVDGKESCESLSCLPPVSLLPHEKDKPVAEPIPICSFCLGTKEQNREKKPEELISCADCGNSGHPSCLKFSPELTVRVKALRWQCIECKTCSSCRDQGKNADNMLFCDSCDRGFHMECCDPPLTRMPKGMWICQICRPRKKGRKLLQKKAAQIKRRYTNPIGRPKNRLKKQNTVSKGPFSKVRTGPGRGRKRKITLSSQSASSSSEEGYLERIDGLDFCRDSNVSLKFNKKTKGLIDGLTKFFTPSPDGRKARGEVVDYSEQYRIRKRGNRKSSTSDWPTDNQDGWDGKQENEERLFGSQEIMTEKDMELFRDIQEQALQKVGVTGPPDPQVRCPSVIEFGKYEIHTWYSSPYPQEYSRLPKLYLCEFCLKYMKSRTILQQHMKKCGWFHPPANEIYRKNNISVFEVDGNVSTIYCQNLCLLAKLFLDHKTLYYDVEPFLFYVLTQNDVKGCHLVGYFSKEKHCQQKYNVSCIMILPQYQRKGYGRFLIDFSYLLSKREGQAGSPEKPLSDLGRLSYMAYWKSVILECLYHQNDKQISIKKLSKLTGICPQDITSTLHHLRMLDFRSDQFVIIRREKLIQDHMAKLQLNLRPVDVDPECLRWTPVIVSNSVVSEEEEEEAEEGENEEPQCQERELEISVGKSVSHENKEQDSYSVESEKKPEVMAPVSSTRLSKQVLPHDSLPANSQPSRRGRWGRKNRKTQERFGDKDSKLLLEETSSAPQEQYGECGEKSEATQEQYTESEEQLVASEEQPSQDGKPDLPKRRLSEGVEPWRGQLKKSPEALKCRLTEGSERLPRRYSEGDRAVLRGFSESSEEEEEPESPRSSSPPILTKPTLKRKKPFLHRRRRVRKRKHHNSSVVTETISETTEVLDEPFEDSDSERPMPRLEPTFEIDEEEEEEDENELFPREYFRRLSSQDVLRCQSSSKRKSKDEEEDEESDDADDTPILKPVSLLRKRDVKNSPLEPDTSTPLKKKKGWPKGKSRKPIHWKKRPGRKPGFKLSREIMPVSTQACVIEPIVSIPKAGRKPKIQESEETVEPKEDMPLPEERKEEEEMQAEAEEAEEGEEEDAASSEVPAASPADSSNSPETETKEPEVEEEEEKPRVSEEQRQSEEEQQELEEPEPEEEEDAAAETAQNDDHDADDEDDGHLESTKKKELEEQPTREDVKEEPGVQESFLDANMQKSREKIKDKEETELDSEEEQPSHDTSVVSEQMAGSEDDHEEDSHTKEELIELKEEEEIPHSELDLETVQAVQSLTQEESSEHEGAYQDCEETLAACQTLQSYTQADEDPQMSMVEDCHASEHNSPISSVQSHPSQSVRSVSSPNVPALESGYTQISPEQGSLSAPSMQNMETSPMMDVPSVSDHSQQVVDSGFSDLGSIESTTENYENPSSYDSTMGGSICGNSSSQSSCSYGGLSSSSSLTQSSCVVTQQMASMGSSCSMMQQSSVQPAANCSIKSPQSCVVERPPSNQQQQPPPPPPQQPQPPPPQPQPAPQPPPPQQQPQQQPQPQPQQPPPPPPPQQQPPLSQCSMNNSFTPAPMIMEIPESGSTGNISIYERIPGDFGAGSYSQPSATFSLAKLQQLTNTIMDPHAMPYSHSPAVTSYATSVSLSNTGLAQLAPSHPLAGTPQAQATMTPPPNLASTTMNLTSPLLQCNMSATNIGIPHTQRLQGQMPVKGHISIRSKSAPLPSAAAHQQQLYGRSPSAVAMQAGPRALAVQRGMNMGVNLMPTPAYNVNSMNMNTLNAMNSYRMTQPMMNSSYHSNPAYMNQTAQYPMQMQMGMMGSQAYTQQPMQPNPHGNMMYTGPSHHSYMNAAGVPKQSLNGPYMRR T63175 DRUGINFO DX31VA PF-07248144 Phase 1 T63178 TARGETID T63178 T63178 UNIPROID MAGAA_HUMAN T63178 TARGNAME Melanoma-associated antigen 10 (MAGEA10) T63178 GENENAME MAGEA10 T63178 TARGTYPE Clinical trial T63178 SYNONYMS Cancer/testis antigen 1.10; CT1.10; MAGE-10 antigen T63178 FUNCTION Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression. T63178 PDBSTRUC 7PBC;7PDW;7QPJ T63178 SEQUENCE MPRAPKRQRCMPEEDLQSQSETQGLEGAQAPLAVEEDASSSTSTSSSFPSSFPSSSSSSSSSCYPLIPSTPEEVSADDETPNPPQSAQIACSSPSVVASLPLDQSDEGSSSQKEESPSTLQVLPDSESLPRSEIDEKVTDLVQFLLFKYQMKEPITKAEILESVIRNYEDHFPLLFSEASECMLLVFGIDVKEVDPTGHSFVLVTSLGLTYDGMLSDVQSMPKTGILILILSIVFIEGYCTPEEVIWEALNMMGLYDGMEHLIYGEPRKLLTQDWVQENYLEYRQVPGSDPARYEFLWGPRAHAEIRKMSLLKFLAKVNGSDPRSFPLWYEEALKDEEERAQDRIATTDDTTAMASASSSATGSFSYPE T63178 DRUGINFO DM38KC ADP-A2M10 Phase 1 T63245 TARGETID T63245 T63245 UNIPROID MOGT2_HUMAN T63245 TARGNAME 2-acylglycerol O-acyltransferase 2 (MOGAT2) T63245 GENENAME MOGAT2 T63245 TARGTYPE Clinical trial T63245 SYNONYMS Acyl-CoA:monoacylglycerol acyltransferase 2; MGAT2; hMGAT2; Diacylglycerol O-acyltransferase candidate 5; hDC5; Diacylglycerol acyltransferase 2-like protein 5; Monoacylglycerol O-acyltransferase 2 T63245 FUNCTION Catalyzes the formation of diacylglycerol from 2-monoacylglycerol and fatty acyl-CoA. Has a preference toward monoacylglycerols containing unsaturated fatty acids in an order of C18:3 > C18:2 > C18:1 > C18:0. Plays a central role in absorption of dietary fat in the small intestine by catalyzing the resynthesis of triacylglycerol in enterocytes. May play a role in diet-induced obesity. Also able to use 1-monoalkylglycerol (1-MAkG) as an acyl acceptor for the synthesis of monoalkyl-monoacylglycerol (MAMAG) (PubMed:28420705). {ECO:0000269|PubMed:12621063, ECO:0000269|PubMed:27184406, ECO:0000269|PubMed:28420705}. T63245 ECNUMBER EC 2.3.1.22 T63245 SEQUENCE MVEFAPLFMPWERRLQTLAVLQFVFSFLALAEICTVGFIALLFTRFWLLTVLYAAWWYLDRDKPRQGGRHIQAIRCWTIWKYMKDYFPISLVKTAELDPSRNYIAGFHPHGVLAVGAFANLCTESTGFSSIFPGIRPHLMMLTLWFRAPFFRDYIMSAGLVTSEKESAAHILNRKGGGNLLGIIVGGAQEALDARPGSFTLLLRNRKGFVRLALTHGAPLVPIFSFGENDLFDQIPNSSGSWLRYIQNRLQKIMGISLPLFHGRGVFQYSFGLIPYRRPITTVVGKPIEVQKTLHPSEEEVNQLHQRYIKELCNLFEAHKLKFNIPADQHLEFC T63245 DRUGINFO DJ3M0Q S-309309 Phase 1 T63182 TARGETID T63182 T63182 UNIPROID NCAP_SARS2 T63182 TARGNAME Nucleoprotein (N) T63182 GENENAME N T63182 TARGTYPE Clinical trial T63182 SYNONYMS N; Nucleocapsid protein; NC; Protein N T63182 FUNCTION Packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M (PubMed:33264373). Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. {ECO:0000269|PubMed:32974389, ECO:0000269|PubMed:33264373}.; May block host chemokine function in vivo, facilitating viral replication and transmission (PubMed:35921414). Acts by being secreted into the extracellular space where it competes to host chemokines for binding to host glycosaminoglycans (GAG) (PubMed:35921414). {ECO:0000269|PubMed:35921414}.; May induce inflammasome responses in cultured cells and mice. Acts by interacting with host NLRP3 to facilitate inflammasome assembly, which induces cytokine release that may play a role in COVID lung injury. {ECO:0000269|PubMed:34341353}. T63182 PDBSTRUC 6M3M;6VYO;6WJI;6WKP;6WZO;6WZQ;6YI3;6YUN;6ZCO;7ACS;7ACT;7C22;7CDZ;7CE0;7CR5;7DE1;7F2B;7F2E;7KGO;7KGP;7KGQ;7KGR;7KGS;7KGT;7LGD;7LTU;7LUX;7LUZ;7LV2;7N0I;7N0R;7N3C;7N3D;7O05;7O35;7O36;7PKU;7QIK;7QIP;7R98;7SD4;7STR;7STS;7SUE;7SUO;7UW3;7UXX;7UXZ;7VBD;7VBE;7VBF;7VNU;7WKJ;7WZO;7XWX;7XWZ;7XX1;7XXK;7ZIT;8DNT;8FD5;8FG2 T63182 SEQUENCE MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA T63182 DRUGINFO DUE5G9 PF-07923567 Phase 1 T63183 TARGETID T63183 T63183 UNIPROID PANK3_HUMAN T63183 TARGNAME Pantothenate kinase 3 (PANK3) T63183 GENENAME PANK3 T63183 TARGTYPE Clinical trial T63183 SYNONYMS hPanK3; Pantothenic acid kinase 3 T63183 FUNCTION Catalyzes the phosphorylation of pantothenate to generate 4'-phosphopantothenate in the first and rate-determining step of coenzyme A (CoA) synthesis. {ECO:0000269|PubMed:17631502, ECO:0000269|PubMed:20797618, ECO:0000269|PubMed:27555321, ECO:0000269|PubMed:30927326}. T63183 PDBSTRUC 2I7P;3MK6;3SMS;5KPR;5KPT;5KPZ;5KQ8;5KQD;6B3V;6PE6;6X4J;6X4K;6X4L;7UE3;7UE4;7UE5;7UE6;7UE7;7UE8;7UEO;7UEP;7UEQ;7UER;7UES;7UET;7UEU;7UEV;7UEX;7UEY T63183 BIOCLASS Kinase T63183 ECNUMBER EC 2.7.1.33 T63183 SEQUENCE MKIKDAKKPSFPWFGMDIGGTLVKLSYFEPIDITAEEEQEEVESLKSIRKYLTSNVAYGSTGIRDVHLELKDLTLFGRRGNLHFIRFPTQDLPTFIQMGRDKNFSTLQTVLCATGGGAYKFEKDFRTIGNLHLHKLDELDCLVKGLLYIDSVSFNGQAECYYFANASEPERCQKMPFNLDDPYPLLVVNIGSGVSILAVHSKDNYKRVTGTSLGGGTFLGLCSLLTGCESFEEALEMASKGDSTQADKLVRDIYGGDYERFGLPGWAVASSFGNMIYKEKRESVSKEDLARATLVTITNNIGSVARMCAVNEKINRVVFVGNFLRVNTLSMKLLAYALDYWSKGQLKALFLEHEGYFGAVGALLGLPNFS T63183 DRUGINFO DXB8M6 BBP-671 Phase 1 T63187 TARGETID T63187 T63187 UNIPROID TBL1X_HUMAN T63187 TARGNAME F-box-like/WD repeat-containing protein TBL1X (TBL1X) T63187 GENENAME TBL1X T63187 TARGTYPE Clinical trial T63187 SYNONYMS SMAP55; Transducin beta-like protein 1X; Transducin-beta-like protein 1, X-linked T63187 FUNCTION F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units (PubMed:14980219). Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of corepressor complexes that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of transcription repressor complexes, thereby allowing cofactor exchange (PubMed:21240272). {ECO:0000269|PubMed:14980219, ECO:0000269|PubMed:21240272}. T63187 PDBSTRUC 2XTC;2XTD;2XTE T63187 SEQUENCE MTELAGASSSCCHRPAGRGAMQSVLHHFQRLRGREGGSHFINTSSPRGEAKMSITSDEVNFLVYRYLQESGFSHSAFTFGIESHISQSNINGTLVPPAALISILQKGLQYVEAEISINEDGTVFDGRPIESLSLIDAVMPDVVQTRQQAFREKLAQQQASAAAAAAAATAAATAATTTSAGVSHQNPSKNREATVNGEENRAHSVNNHAKPMEIDGEVEIPSSKATVLRGHESEVFICAWNPVSDLLASGSGDSTARIWNLNENSNGGSTQLVLRHCIREGGHDVPSNKDVTSLDWNTNGTLLATGSYDGFARIWTEDGNLASTLGQHKGPIFALKWNRKGNYILSAGVDKTTIIWDAHTGEAKQQFPFHSAPALDVDWQNNTTFASCSTDMCIHVCRLGCDRPVKTFQGHTNEVNAIKWDPSGMLLASCSDDMTLKIWSMKQEVCIHDLQAHNKEIYTIKWSPTGPATSNPNSNIMLASASFDSTVRLWDIERGVCTHTLTKHQEPVYSVAFSPDGKYLASGSFDKCVHIWNTQSGNLVHSYRGTGGIFEVCWNARGDKVGASASDGSVCVLDLRK T63187 DRUGINFO DJ4B2E SY-2101 Phase 1 T63187 DRUGINFO D54WUR Tegavivint Phase 1 T63188 TARGETID T63188 T63188 UNIPROID ACY2_HUMAN T63188 TARGNAME Aspartoacylase (ASPA) T63188 GENENAME ASPA T63188 TARGTYPE Clinical trial T63188 SYNONYMS Aminoacylase-2; ACY-2 T63188 FUNCTION Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. In other tissues it acts as a scavenger of NAA from body fluids. T63188 PDBSTRUC 2I3C;2O4H;2O53;2Q51;4MRI;4MXU;4NFR;4TNU T63188 ECNUMBER EC 3.5.1.15 T63188 SEQUENCE MTSCHIAEEHIQKVAIFGGTHGNELTGVFLVKHWLENGAEIQRTGLEVKPFITNPRAVKKCTRYIDCDLNRIFDLENLGKKMSEDLPYEVRRAQEINHLFGPKDSEDSYDIIFDLHNTTSNMGCTLILEDSRNNFLIQMFHYIKTSLAPLPCYVYLIEHPSLKYATTRSIAKYPVGIEVGPQPQGVLRADILDQMRKMIKHALDFIHHFNEGKEFPPCAIEVYKIIEKVDYPRDENGEIAAIIHPNLQDQDWKPLHPGDPMFLTLDGKTIPLGGDCTVYPVFVNEAAYYEKKEAFAKTTKLTLNAKSIRCCLH T63188 DRUGINFO DBKE38 BBP-812 Phase 1/2 T63189 TARGETID T63189 T63189 UNIPROID CD123_HUMAN T63189 TARGNAME Cell division cycle protein 123 (CDC123) T63189 GENENAME CDC123 T63189 TARGTYPE Clinical trial T63189 SYNONYMS Protein D123; HT-1080; PZ32 T63189 FUNCTION Required for S phase entry of the cell cycle. {ECO:0000250}. T63189 SEQUENCE MKKEHVLHCQFSAWYPFFRGVTIKSVILPLPQNVKDYLLDDGTLVVSGRDDPPTHSQPDSDDEAEEIQWSDDENTATLTAPEFPEFATKVQEAINSLGGSVFPKLNWSAPRDAYWIAMNSSLKCKTLSDIFLLFKSSDFITRDFTQPFIHCTDDSPDPCIEYELVLRKWCELIPGAEFRCFVKENKLIGISQRDYTQYYDHISKQKEEIRRCIQDFFKKHIQYKFLDEDFVFDIYRDSRGKVWLIDFNPFGEVTDSLLFTWEELISENNLNGDFSEVDAQEQDSPAFRCTNSEVTVQPSPYLSYRLPKDFVDLSTGEDAHKLIDFLKLKRNQQEDD T63189 DRUGINFO DMKG40 SAR443579 Phase 1 T63190 TARGETID T63190 T63190 UNIPROID CLN3_HUMAN T63190 TARGNAME Battenin (CLN3) T63190 GENENAME CLN3 T63190 TARGTYPE Clinical trial T63190 SYNONYMS Batten disease protein; Protein CLN3 T63190 FUNCTION Mediates microtubule-dependent, anterograde transport connecting the Golgi network, endosomes, autophagosomes, lysosomes and plasma membrane, and participates in several cellular processes such as regulation of lysosomal pH, lysosome protein degradation, receptor-mediated endocytosis, autophagy, transport of proteins and lipids from the TGN, apoptosis and synaptic transmission (PubMed:10924275, PubMed:18817525, PubMed:18317235, PubMed:22261744, PubMed:15471887, PubMed:20850431). Facilitates the proteins transport from trans-Golgi network (TGN)-to other membrane compartments such as transport of microdomain-associated proteins to the plasma membrane, IGF2R transport to the lysosome where it regulates the CTSD release leading to regulation of CTSD maturation and thereby APP intracellular processing (PubMed:10924275, PubMed:18817525). Moreover regulates CTSD activity in response to osmotic stress (PubMed:23840424, PubMed:28390177). Also binds galactosylceramide and transports it from the trans Golgi to the rafts, which may have immediate and downstream effects on cell survival by modulating ceramide synthesis (PubMed:18317235). At the plasma membrane, regulates actin-dependent events including filopodia formation, cell migration, and pinocytosis through ARF1-CDC42 pathway and also the cytoskeleton organization through interaction with MYH10 and fodrin leading to the regulation of the plasma membrane association of Na+, K+ ATPase complex (PubMed:20850431). Regulates synaptic transmission in the amygdala, hippocampus, and cerebellum through regulation of synaptic vesicles density and their proximity to active zones leading to modulation of short-term plasticity and age-dependent anxious behavior, learning and memory (By similarity). Regulates autophagic vacuoles (AVs) maturation by modulating the trafficking between endocytic and autophagolysosomal/lysosomal compartments, which involves vesicle fusion leading to regulation of degradation process (By similarity). Participates also in cellular homeostasis of compounds such as, water, ions, amino acids, proteins and lipids in several tissue namely in brain and kidney through regulation of their transport and synthesis (PubMed:17482562). {ECO:0000250|UniProtKB:Q61124, ECO:0000269|PubMed:10924275, ECO:0000269|PubMed:15471887, ECO:0000269|PubMed:17482562, ECO:0000269|PubMed:18317235, ECO:0000269|PubMed:18817525, ECO:0000269|PubMed:20850431, ECO:0000269|PubMed:22261744, ECO:0000269|PubMed:23840424, ECO:0000269|PubMed:28390177}. T63190 SEQUENCE MGGCAGSRRRFSDSEGEETVPEPRLPLLDHQGAHWKNAVGFWLLGLCNNFSYVVMLSAAHDILSHKRTSGNQSHVDPGPTPIPHNSSSRFDCNSVSTAAVLLADILPTLVIKLLAPLGLHLLPYSPRVLVSGICAAGSFVLVAFSHSVGTSLCGVVFASISSGLGEVTFLSLTAFYPRAVISWWSSGTGGAGLLGALSYLGLTQAGLSPQQTLLSMLGIPALLLASYFLLLTSPEAQDPGGEEEAESAARQPLIRTEAPESKPGSSSSLSLRERWTVFKGLLWYIVPLVVVYFAEYFINQGLFELLFFWNTSLSHAQQYRWYQMLYQAGVFASRSSLRCCRIRFTWALALLQCLNLVFLLADVWFGFLPSIYLVFLIILYEGLLGGAAYVNTFHNIALETSDEHREFAMAATCISDTLGISLSGLLALPLHDFLCQLS T63190 DRUGINFO DF7R6C AT-GTX-502 Phase 1/2 T63191 TARGETID T63191 T63191 UNIPROID CLN6_HUMAN T63191 TARGNAME Ceroid-lipofuscinosis neuronal protein 6 (CLN6) T63191 GENENAME CLN6 T63191 TARGTYPE Clinical trial T63191 SYNONYMS Protein CLN6 T63191 SEQUENCE MEATRRRQHLGATGGPGAQLGASFLQARHGSVSADEAARTAPFHLDLWFYFTLQNWVLDFGRPIAMLVFPLEWFPLNKPSVGDYFHMAYNVITPFLLLKLIERSPRTLPRSITYVSIIIFIMGASIHLVGDSVNHRLLFSGYQHHLSVRENPIIKNLKPETLIDSFELLYYYDEYLGHCMWYIPFFLILFMYFSGCFTASKAESLIPGPALLLVAPSGLYYWYLVTEGQIFILFIFTFFAMLALVLHQKRKRLFLDSNGLFLFSSFALTLLLVALWVAWLWNDPVLRKKYPGVIYVPEPWAFYTLHVSSRH T63191 DRUGINFO D0TBF3 AT-GTX-501 Phase 1/2 T63192 TARGETID T63192 T63192 UNIPROID CP21A_HUMAN T63192 TARGNAME Steroid 21-hydroxylase (CYP21A2) T63192 GENENAME CYP21A2 T63192 TARGTYPE Clinical trial T63192 SYNONYMS 21-OHase; Cytochrome P-450c21; Cytochrome P450 21; Cytochrome P450 XXI; Cytochrome P450-C21; Cytochrome P450-C21B T63192 FUNCTION A cytochrome P450 monooxygenase that plays a major role in adrenal steroidogenesis. Catalyzes the hydroxylation at C-21 of progesterone and 17alpha-hydroxyprogesterone to respectively form 11-deoxycorticosterone and 11-deoxycortisol, intermediate metabolites in the biosynthetic pathway of mineralocorticoids and glucocorticoids (PubMed:25855791, PubMed:10602386, PubMed:16984992, PubMed:22014889, PubMed:27721825). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:25855791). {ECO:0000269|PubMed:10602386, ECO:0000269|PubMed:16984992, ECO:0000269|PubMed:22014889, ECO:0000269|PubMed:25855791, ECO:0000269|PubMed:27721825}. T63192 PDBSTRUC 4Y8W T63192 BIOCLASS Cytochrome P450 family T63192 ECNUMBER EC 1.14.14.16 T63192 SEQUENCE MLLLGLLLLPLLAGARLLWNWWKLRSLHLPPLAPGFLHLLQPDLPIYLLGLTQKFGPIYRLHLGLQDVVVLNSKRTIEEAMVKKWADFAGRPEPLTYKLVSKNYPDLSLGDYSLLWKAHKKLTRSALLLGIRDSMEPVVEQLTQEFCERMRAQPGTPVAIEEEFSLLTCSIICYLTFGDKIKDDNLMPAYYKCIQEVLKTWSHWSIQIVDVIPFLRFFPNPGLRRLKQAIEKRDHIVEMQLRQHKESLVAGQWRDMMDYMLQGVAQPSMEEGSGQLLEGHVHMAAVDLLIGGTETTANTLSWAVVFLLHHPEIQQRLQEELDHELGPGASSSRVPYKDRARLPLLNATIAEVLRLRPVVPLALPHRTTRPSSISGYDIPEGTVIIPNLQGAHLDETVWERPHEFWPDRFLEPGKNSRALAFGCGARVCLGEPLARLELFVVLTRLLQAFTLLPSGDALPSLQPLPHCSVILKMQPFQVRLQPRGMGAHSPGQNQ T63192 DRUGINFO DP58GD BBP-631 Phase 1/2 T63193 TARGETID T63193 T63193 UNIPROID DGKZ_HUMAN T63193 TARGNAME Diacylglycerol kinase zeta (DGKZ) T63193 GENENAME DGKZ T63193 TARGTYPE Clinical trial T63193 SYNONYMS DAG kinase zeta; Diglyceride kinase zeta; DGK-zeta T63193 FUNCTION Diacylglycerol kinase that converts diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and regulates the respective levels of these two bioactive lipids (PubMed:9159104, PubMed:15544348, PubMed:18004883, PubMed:19744926, PubMed:22108654, PubMed:22627129, PubMed:23949095). Thereby, acts as a central switch between the signaling pathways activated by these second messengers with different cellular targets and opposite effects in numerous biological processes (PubMed:9159104, PubMed:15544348, PubMed:18004883, PubMed:19744926, PubMed:22108654, PubMed:22627129, PubMed:23949095). Also plays an important role in the biosynthesis of complex lipids (Probable). Does not exhibit an acyl chain-dependent substrate specificity among diacylglycerol species (PubMed:9159104, PubMed:19744926, PubMed:22108654). Can also phosphorylate 1-alkyl-2-acylglycerol in vitro but less efficiently and with a preference for alkylacylglycerols containing an arachidonoyl group (PubMed:15544348, PubMed:19744926, PubMed:22627129). The biological processes it is involved in include T cell activation since it negatively regulates T-cell receptor signaling which is in part mediated by diacylglycerol (By similarity). By generating phosphatidic acid, stimulates PIP5KIA activity which regulates actin polymerization (PubMed:15157668). Through the same mechanism could also positively regulate insulin-induced translocation of SLC2A4 to the cell membrane (By similarity). {ECO:0000250|UniProtKB:Q80UP3, ECO:0000269|PubMed:15157668, ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:18004883, ECO:0000269|PubMed:19744926, ECO:0000269|PubMed:22108654, ECO:0000269|PubMed:22627129, ECO:0000269|PubMed:23949095, ECO:0000269|PubMed:9159104, ECO:0000305|PubMed:8626588}.; [Isoform 1]: Regulates RASGRP1 activity. {ECO:0000269|PubMed:11257115}.; [Isoform 2]: Does not regulate RASGRP1 activity. {ECO:0000269|PubMed:11257115}. T63193 PDBSTRUC 5ELQ T63193 BIOCLASS Kinase T63193 ECNUMBER EC 2.7.1.107 T63193 SEQUENCE MEPRDGSPEARSSDSESASASSSGSERDAGPEPDKAPRRLNKRRFPGLRLFGHRKAITKSGLQHLAPPPPTPGAPCSESERQIRSTVDWSESATYGEHIWFETNVSGDFCYVGEQYCVARMLKSVSRRKCAACKIVVHTPCIEQLEKINFRCKPSFRESGSRNVREPTFVRHHWVHRRRQDGKCRHCGKGFQQKFTFHSKEIVAISCSWCKQAYHSKVSCFMLQQIEEPCSLGVHAAVVIPPTWILRARRPQNTLKASKKKKRASFKRKSSKKGPEEGRWRPFIIRPTPSPLMKPLLVFVNPKSGGNQGAKIIQSFLWYLNPRQVFDLSQGGPKEALEMYRKVHNLRILACGGDGTVGWILSTLDQLRLKPPPPVAILPLGTGNDLARTLNWGGGYTDEPVSKILSHVEEGNVVQLDRWDLHAEPNPEAGPEDRDEGATDRLPLDVFNNYFSLGFDAHVTLEFHESREANPEKFNSRFRNKMFYAGTAFSDFLMGSSKDLAKHIRVVCDGMDLTPKIQDLKPQCVVFLNIPRYCAGTMPWGHPGEHHDFEPQRHDDGYLEVIGFTMTSLAALQVGGHGERLTQCREVVLTTSKAIPVQVDGEPCKLAASRIRIALRNQATMVQKAKRRSAAPLHSDQQPVPEQLRIQVSRVSMHDYEALHYDKEQLKEASVPLGTVVVPGDSDLELCRAHIERLQQEPDGAGAKSPTCQKLSPKWCFLDATTASRFYRIDRAQEHLNYVTEIAQDEIYILDPELLGASARPDLPTPTSPLPTSPCSPTPRSLQGDAAPPQGEELIEAAKRNDFCKLQELHRAGGDLMHRDEQSRTLLHHAVSTGSKDVVRYLLDHAPPEILDAVEENGETCLHQAAALGQRTICHYIVEAGASLMKTDQQGDTPRQRAEKAQDTELAAYLENRQHYQMIQREDQETAV T63193 DRUGINFO D5GVZ1 ASP1570 Phase 1/2 T63194 TARGETID T63194 T63194 UNIPROID ENPP1_HUMAN T63194 TARGNAME Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) T63194 GENENAME ENPP1 T63194 TARGTYPE Clinical trial T63194 SYNONYMS E-NPP 1; Membrane component chromosome 6 surface marker 1; Phosphodiesterase I/nucleotide pyrophosphatase 1; Plasma-cell membrane glycoprotein PC-1 T63194 FUNCTION Nucleotide pyrophosphatase that generates diphosphate (PPi) and functions in bone mineralization and soft tissue calcification by regulating pyrophosphate levels (By similarity). PPi inhibits bone mineralization and soft tissue calcification by binding to nascent hydroxyapatite crystals, thereby preventing further growth of these crystals (PubMed:11004006). Preferentially hydrolyzes ATP, but can also hydrolyze other nucleoside 5' triphosphates such as GTP, CTP and UTP to their corresponding monophosphates with release of pyrophosphate, as well as diadenosine polyphosphates, and also 3',5'-cAMP to AMP (PubMed:27467858, PubMed:8001561, PubMed:25344812, PubMed:28011303, PubMed:35147247). May also be involved in the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling (PubMed:27467858, PubMed:8001561). Inhibits ectopic joint calcification and maintains articular chondrocytes by repressing hedgehog signaling; it is however unclear whether hedgehog inhibition is direct or indirect (By similarity). Appears to modulate insulin sensitivity and function (PubMed:10615944). Also involved in melanogenesis (PubMed:28964717). Also able to hydrolyze 2',3'-cGAMP (cyclic GMP-AMP), a second messenger that activates TMEM173/STING and triggers type-I interferon production (PubMed:25344812). 2',3'-cGAMP degradation takes place in the lumen or extracellular space, and not in the cytosol where it is produced; the role of 2',3'-cGAMP hydrolysis is therefore unclear (PubMed:25344812). Not able to hydrolyze the 2',3'-cGAMP linkage isomer 3'-3'-cGAMP (PubMed:25344812). {ECO:0000250|UniProtKB:P06802, ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:25344812, ECO:0000269|PubMed:27467858, ECO:0000269|PubMed:28011303, ECO:0000269|PubMed:28964717, ECO:0000269|PubMed:35147247, ECO:0000269|PubMed:8001561, ECO:0000305|PubMed:11004006}. T63194 PDBSTRUC 2YS0;6WET;6WEU;6WEV;6WEW;6WFJ T63194 ECNUMBER EC 3.1.4.1; EC 3.6.1.9 T63194 SEQUENCE MERDGCAGGGSRGGEGGRAPREGPAGNGRDRGRSHAAEAPGDPQAAASLLAPMDVGEEPLEKAARARTAKDPNTYKVLSLVLSVCVLTTILGCIFGLKPSCAKEVKSCKGRCFERTFGNCRCDAACVELGNCCLDYQETCIEPEHIWTCNKFRCGEKRLTRSLCACSDDCKDKGDCCINYSSVCQGEKSWVEEPCESINEPQCPAGFETPPTLLFSLDGFRAEYLHTWGGLLPVISKLKKCGTYTKNMRPVYPTKTFPNHYSIVTGLYPESHGIIDNKMYDPKMNASFSLKSKEKFNPEWYKGEPIWVTAKYQGLKSGTFFWPGSDVEINGIFPDIYKMYNGSVPFEERILAVLQWLQLPKDERPHFYTLYLEEPDSSGHSYGPVSSEVIKALQRVDGMVGMLMDGLKELNLHRCLNLILISDHGMEQGSCKKYIYLNKYLGDVKNIKVIYGPAARLRPSDVPDKYYSFNYEGIARNLSCREPNQHFKPYLKHFLPKRLHFAKSDRIEPLTFYLDPQWQLALNPSERKYCGSGFHGSDNVFSNMQALFVGYGPGFKHGIEADTFENIEVYNLMCDLLNLTPAPNNGTHGSLNHLLKNPVYTPKHPKEVHPLVQCPFTRNPRDNLGCSCNPSILPIEDFQTQFNLTVAEEKIIKHETLPYGRPRVLQKENTICLLSQHQFMSGYSQDILMPLWTSYTVDRNDSFSTEDFSNCLYQDFRIPLSPVHKCSFYKNNTKVSYGFLSPPQLNKNSSGIYSEALLTTNIVPMYQSFQVIWRYFHDTLLRKYAEERNGVNVVSGPVFDFDYDGRCDSLENLRQKRRVIRNQEILIPTHFFIVLTSCKDTSQTPLHCENLDTLAFILPHRTDNSESCVHGKHDSSWVEELLMLHRARITDVEHITGLSFYQQRKEPVSDILKLKTHLPTFSQED T63194 DRUGINFO DK0B7G INZ-701 Phase 1/2 T63195 TARGETID T63195 T63195 UNIPROID GAN_HUMAN T63195 TARGNAME Gigaxonin (GAN) T63195 GENENAME GAN T63195 TARGTYPE Clinical trial T63195 SYNONYMS Kelch-like protein 16 T63195 FUNCTION Probable cytoskeletal component that directly or indirectly plays an important role in neurofilament architecture. May act as a substrate-specific adapter of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Controls degradation of TBCB. Controls degradation of MAP1B and MAP1S, and is critical for neuronal maintenance and survival. {ECO:0000269|PubMed:12147674, ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:16227972, ECO:0000269|PubMed:16303566}. T63195 PDBSTRUC 2PPI;3HVE T63195 SEQUENCE MAEGSAVSDPQHAARLLRALSSFREESRFCDAHLVLDGEEIPVQKNILAAASPYIRTKLNYNPPKDDGSTYKIELEGISVMVMREILDYIFSGQIRLNEDTIQDVVQAADLLLLTDLKTLCCEFLEGCIAAENCIGIRDFALHYCLHHVHYLATEYLETHFRDVSSTEEFLELSPQKLKEVISLEKLNVGNERYVFEAVIRWIAHDTEIRKVHMKDVMSALWVSGLDSSYLREQMLNEPLVREIVKECSNIPLSQPQQGEAMLANFKPRGYSECIVTVGGEERVSRKPTAAMRCMCPLYDPNRQLWIELAPLSMPRINHGVLSAEGFLFVFGGQDENKQTLSSGEKYDPDANTWTALPPMNEARHNFGIVEIDGMLYILGGEDGEKELISMECYDIYSKTWTKQPDLTMVRKIGCYAAMKKKIYAMGGGSYGKLFESVECYDPRTQQWTAICPLKERRFGAVACGVAMELYVFGGVRSREDAQGSEMVTCKSEFYHDEFKRWIYLNDQNLCIPASSSFVYGAVPIGASIYVIGDLDTGTNYDYVREFKRSTGTWHHTKPLLPSDLRRTGCAALRIANCKLFRLQLQQGLFRIRVHSP T63195 DRUGINFO DZ40HL TSHA-120 Phase 1/2 T63196 TARGETID T63196 T63196 UNIPROID HEXA_HUMAN T63196 TARGNAME Beta-hexosaminidase subunit alpha (HEXA) T63196 GENENAME HEXA T63196 TARGTYPE Clinical trial T63196 SYNONYMS Beta-N-acetylhexosaminidase subunit alpha; Hexosaminidase subunit A; N-acetyl-beta-glucosaminidase subunit alpha T63196 FUNCTION Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:9694901, PubMed:8672428, PubMed:8123671). The isozyme S is as active as the isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-sulfate trisaccharide (C6S-3), and the dermatan sulfate pentasaccharide, and the sulfated glycosphingolipid SM2 (PubMed:11707436). The isozyme B does not hydrolyze each of these substrates, however hydrolyzes efficiently neutral oligosaccharide (PubMed:11707436). Only the isozyme A is responsible for the degradation of GM2 gangliosides in the presence of GM2A (PubMed:9694901, PubMed:8672428, PubMed:8123671). {ECO:0000269|PubMed:11707436, ECO:0000269|PubMed:8123671, ECO:0000269|PubMed:8672428, ECO:0000269|PubMed:9694901}. T63196 PDBSTRUC 2GJX;2GK1 T63196 BIOCLASS Glycosyl hydrolase T63196 ECNUMBER EC 3.2.1.52 T63196 SEQUENCE MTSSRLWFSLLLAAAFAGRATALWPWPQNFQTSDQRYVLYPNNFQFQYDVSSAAQPGCSVLDEAFQRYRDLLFGSGSWPRPYLTGKRHTLEKNVLVVSVVTPGCNQLPTLESVENYTLTINDDQCLLLSETVWGALRGLETFSQLVWKSAEGTFFINKTEIEDFPRFPHRGLLLDTSRHYLPLSSILDTLDVMAYNKLNVFHWHLVDDPSFPYESFTFPELMRKGSYNPVTHIYTAQDVKEVIEYARLRGIRVLAEFDTPGHTLSWGPGIPGLLTPCYSGSEPSGTFGPVNPSLNNTYEFMSTFFLEVSSVFPDFYLHLGGDEVDFTCWKSNPEIQDFMRKKGFGEDFKQLESFYIQTLLDIVSSYGKGYVVWQEVFDNKVKIQPDTIIQVWREDIPVNYMKELELVTKAGFRALLSAPWYLNRISYGPDWKDFYIVEPLAFEGTPEQKALVIGGEACMWGEYVDNTNLVPRLWPRAGAVAERLWSNKLTSDLTFAYERLSHFRCELLRRGVQAQPLNVGFCEQEFEQT T63196 DRUGINFO D1TS4V TSHA-101 Phase 1/2 T63196 DRUGINFO DYK9H4 AXO-AAV-GM2 Phase 1 T63197 TARGETID T63197 T63197 UNIPROID HEXB_HUMAN T63197 TARGNAME Beta-hexosaminidase subunit beta (HEXB) T63197 GENENAME HEXB T63197 TARGTYPE Clinical trial T63197 SYNONYMS Beta-N-acetylhexosaminidase subunit beta; Hexosaminidase subunit B; Cervical cancer proto-oncogene 7 protein; HCC-7; N-acetyl-beta-glucosaminidase subunit beta T63197 FUNCTION Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:9694901, PubMed:8672428, PubMed:8123671). The isozyme B does not hydrolyze each of these substrates, however hydrolyzes efficiently neutral oligosaccharide (PubMed:11707436). Only the isozyme A is responsible for the degradation of GM2 gangliosides in the presence of GM2A (PubMed:9694901, PubMed:8672428, PubMed:8123671). During fertilization is responsible, at least in part, for the zona block to polyspermy. Present in the cortical granules of non-activated oocytes, is exocytosed during the cortical reaction in response to oocyte activation and inactivates the sperm galactosyltransferase-binding site, accounting for the block in sperm binding to the zona pellucida (By similarity). {ECO:0000250|UniProtKB:P20060, ECO:0000269|PubMed:11707436, ECO:0000269|PubMed:8123671, ECO:0000269|PubMed:8672428, ECO:0000269|PubMed:9694901}. T63197 PDBSTRUC 1NOU;1NOW;1NP0;1O7A;2GJX;2GK1;3LMY;5BRO T63197 BIOCLASS Glycosyl hydrolase T63197 ECNUMBER EC 3.2.1.52 T63197 SEQUENCE MELCGLGLPRPPMLLALLLATLLAAMLALLTQVALVVQVAEAARAPSVSAKPGPALWPLPLLVKMTPNLLHLAPENFYISHSPNSTAGPSCTLLEEAFRRYHGYIFGFYKWHHEPAEFQAKTQVQQLLVSITLQSECDAFPNISSDESYTLLVKEPVAVLKANRVWGALRGLETFSQLVYQDSYGTFTINESTIIDSPRFSHRGILIDTSRHYLPVKIILKTLDAMAFNKFNVLHWHIVDDQSFPYQSITFPELSNKGSYSLSHVYTPNDVRMVIEYARLRGIRVLPEFDTPGHTLSWGKGQKDLLTPCYSRQNKLDSFGPINPTLNTTYSFLTTFFKEISEVFPDQFIHLGGDEVEFKCWESNPKIQDFMRQKGFGTDFKKLESFYIQKVLDIIATINKGSIVWQEVFDDKAKLAPGTIVEVWKDSAYPEELSRVTASGFPVILSAPWYLDLISYGQDWRKYYKVEPLDFGGTQKQKQLFIGGEACLWGEYVDATNLTPRLWPRASAVGERLWSSKDVRDMDDAYDRLTRHRCRMVERGIAAQPLYAGYCNHENM T63197 DRUGINFO D1TS4V TSHA-101 Phase 1/2 T63197 DRUGINFO DYK9H4 AXO-AAV-GM2 Phase 1 T63202 TARGETID T63202 T63202 UNIPROID ATP7B_HUMAN T63202 TARGNAME Copper-transporting ATPase 2 (ATP7B) T63202 GENENAME ATP7B T63202 TARGTYPE Clinical trial T63202 SYNONYMS Copper pump 2; Wilson disease-associated protein T63202 FUNCTION Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. {ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:26004889}. T63202 PDBSTRUC 2ARF;2EW9;2KOY;2LQB;2N7Y;2ROP;6A71;6A72;7XUK;7XUM;7XUN;7XUO;8IOY T63202 ECNUMBER EC 7.2.2.8 T63202 SEQUENCE MPEQERQITAREGASRKILSKLSLPTRAWEPAMKKSFAFDNVGYEGGLDGLGPSSQVATSTVRILGMTCQSCVKSIEDRISNLKGIISMKVSLEQGSATVKYVPSVVCLQQVCHQIGDMGFEASIAEGKAASWPSRSLPAQEAVVKLRVEGMTCQSCVSSIEGKVRKLQGVVRVKVSLSNQEAVITYQPYLIQPEDLRDHVNDMGFEAAIKSKVAPLSLGPIDIERLQSTNPKRPLSSANQNFNNSETLGHQGSHVVTLQLRIDGMHCKSCVLNIEENIGQLLGVQSIQVSLENKTAQVKYDPSCTSPVALQRAIEALPPGNFKVSLPDGAEGSGTDHRSSSSHSPGSPPRNQVQGTCSTTLIAIAGMTCASCVHSIEGMISQLEGVQQISVSLAEGTATVLYNPSVISPEELRAAIEDMGFEASVVSESCSTNPLGNHSAGNSMVQTTDGTPTSVQEVAPHTGRLPANHAPDILAKSPQSTRAVAPQKCFLQIKGMTCASCVSNIERNLQKEAGVLSVLVALMAGKAEIKYDPEVIQPLEIAQFIQDLGFEAAVMEDYAGSDGNIELTITGMTCASCVHNIESKLTRTNGITYASVALATSKALVKFDPEIIGPRDIIKIIEEIGFHASLAQRNPNAHHLDHKMEIKQWKKSFLCSLVFGIPVMALMIYMLIPSNEPHQSMVLDHNIIPGLSILNLIFFILCTFVQLLGGWYFYVQAYKSLRHRSANMDVLIVLATSIAYVYSLVILVVAVAEKAERSPVTFFDTPPMLFVFIALGRWLEHLAKSKTSEALAKLMSLQATEATVVTLGEDNLIIREEQVPMELVQRGDIVKVVPGGKFPVDGKVLEGNTMADESLITGEAMPVTKKPGSTVIAGSINAHGSVLIKATHVGNDTTLAQIVKLVEEAQMSKAPIQQLADRFSGYFVPFIIIMSTLTLVVWIVIGFIDFGVVQRYFPNPNKHISQTEVIIRFAFQTSITVLCIACPCSLGLATPTAVMVGTGVAAQNGILIKGGKPLEMAHKIKTVMFDKTGTITHGVPRVMRVLLLGDVATLPLRKVLAVVGTAEASSEHPLGVAVTKYCKEELGTETLGYCTDFQAVPGCGIGCKVSNVEGILAHSERPLSAPASHLNEAGSLPAEKDAVPQTFSVLIGNREWLRRNGLTISSDVSDAMTDHEMKGQTAILVAIDGVLCGMIAIADAVKQEAALAVHTLQSMGVDVVLITGDNRKTARAIATQVGINKVFAEVLPSHKVAKVQELQNKGKKVAMVGDGVNDSPALAQADMGVAIGTGTDVAIEAADVVLIRNDLLDVVASIHLSKRTVRRIRINLVLALIYNLVGIPIAAGVFMPIGIVLQPWMGSAAMAASSVSVVLSSLQLKCYKKPDLERYEAQAHGHMKPLTASQVSVHIGMDDRWRDSPRATPWDQVSYVSQVSLSSLTSDKPSRHSAAADDDGDKWSLLLNGRDEEQYI T63202 DRUGINFO DOJ2A5 VTX-801 Phase 2 T63202 DRUGINFO DCY10V UX701 Phase 1/2 T63244 TARGETID T63244 T63244 UNIPROID FGF19_HUMAN T63244 TARGNAME Fibroblast growth factor 19 (FGF19) T63244 GENENAME FGF19 T63244 TARGTYPE Clinical trial T63244 SYNONYMS FGF-19 T63244 FUNCTION Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4. {ECO:0000269|PubMed:12815072, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:19085950}. T63244 PDBSTRUC 1PWA;2P23;6KTR;6NFJ T63244 BIOCLASS Heparin-binding growth factors family T63244 SEQUENCE MRSGCVVVHVWILAGLWLAVAGRPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK T63244 DRUGINFO D5TJ6M Aldafermin Phase 2 T63207 TARGETID T63207 T63207 UNIPROID LANC2_HUMAN T63207 TARGNAME LanC-like protein 2 (LANCL2) T63207 GENENAME LANCL2 T63207 TARGTYPE Clinical trial T63207 SYNONYMS Testis-specific adriamycin sensitivity protein T63207 FUNCTION Necessary for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes. {ECO:0000269|PubMed:19667068}. T63207 PDBSTRUC 6WQ1 T63207 SEQUENCE MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD T63207 DRUGINFO DC7JQ8 Omilancor Phase 2 T63207 DRUGINFO DN2Z5C LABP-104 Phase 1 T63208 TARGETID T63208 T63208 UNIPROID LIRA4_HUMAN T63208 TARGNAME Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4) T63208 GENENAME LILRA4 T63208 TARGTYPE Clinical trial T63208 SYNONYMS CD85 antigen-like family member G; Immunoglobulin-like transcript 7; ILT-7; CD85g T63208 FUNCTION Functions coreceptor to limit the innate immune responses to viral infections; signaling occurs via FCER1G (PubMed:16735691, PubMed:19564354). Down-regulates the production of IFNA1, IFNA2, IFNA4, IFNB1 and TNF by plasmacytoid dendritic cells that have been exposed to influenza virus or cytidine-phosphate-guanosine (CpG) dinucleotides, indicating it functions as negative regulator of TLR7 and TLR9 signaling cascades (PubMed:16735691, PubMed:19564354, PubMed:24586760). Down-regulates interferon production in response to interaction with BST2 on HIV-1 infected cells (PubMed:26172439). Activates a signaling cascade in complex with FCER1G that results in phosphorylation of Src family and Syk kinases and thereby triggers mobilization of intracellular Ca(2+) (PubMed:16735691, PubMed:19564354). Does not interfere with the differentiation of plasmacytoid dendritic cells into antigen-presenting cells (PubMed:24586760). {ECO:0000269|PubMed:16735691, ECO:0000269|PubMed:19564354, ECO:0000269|PubMed:24586760, ECO:0000269|PubMed:26172439}. T63208 SEQUENCE MTLILTSLLFFGLSLGPRTRVQAENLLKPILWAEPGPVITWHNPVTIWCQGTLEAQGYRLDKEGNSMSRHILKTLESENKVKLSIPSMMWEHAGRYHCYYQSPAGWSEPSDPLELVVTAYSRPTLSALPSPVVTSGVNVTLRCASRLGLGRFTLIEEGDHRLSWTLNSHQHNHGKFQALFPMGPLTFSNRGTFRCYGYENNTPYVWSEPSDPLQLLVSGVSRKPSLLTLQGPVVTPGENLTLQCGSDVGYIRYTLYKEGADGLPQRPGRQPQAGLSQANFTLSPVSRSYGGQYRCYGAHNVSSEWSAPSDPLDILIAGQISDRPSLSVQPGPTVTSGEKVTLLCQSWDPMFTFLLTKEGAAHPPLRLRSMYGAHKYQAEFPMSPVTSAHAGTYRCYGSRSSNPYLLSHPSEPLELVVSGATETLNPAQKKSDSKTAPHLQDYTVENLIRMGVAGLVLLFLGILLFEAQHSQRSPPRCSQEANSRKDNAPFRVVEPWEQI T63208 DRUGINFO DVG1O0 Daxdilimab Phase 2 T63209 TARGETID T63209 T63209 UNIPROID LIRB1_HUMAN T63209 TARGNAME Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) T63209 GENENAME LILRB1 T63209 TARGTYPE Clinical trial T63209 SYNONYMS LIR-1; Leukocyte immunoglobulin-like receptor 1; CD85 antigen-like family member J; Immunoglobulin-like transcript 2; ILT-2; Monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD85j T63209 FUNCTION Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11907092, PubMed:9285411, PubMed:9842885). Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (PubMed:16455647). Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells (PubMed:29262349, PubMed:19304799). Reprograms B cells toward an immune suppressive phenotype (PubMed:24453251). {ECO:0000269|PubMed:11907092, ECO:0000269|PubMed:16455647, ECO:0000269|PubMed:19304799, ECO:0000269|PubMed:24453251, ECO:0000269|PubMed:28636952, ECO:0000269|PubMed:29262349, ECO:0000269|PubMed:9285411, ECO:0000269|PubMed:9842885}. T63209 PDBSTRUC 1G0X;1P7Q;1UFU;1UGN;1VDG;3D2U;4LL9;4NO0;5KNM;6AEE;6EWA;6EWC;6EWO;6K60;6ZDX;7KFK T63209 SEQUENCE MTPILTVLICLGLSLGPRTHVQAGHLPKPTLWAEPGSVITQGSPVTLRCQGGQETQEYRLYREKKTALWITRIPQELVKKGQFPIPSITWEHAGRYRCYYGSDTAGRSESSDPLELVVTGAYIKPTLSAQPSPVVNSGGNVILQCDSQVAFDGFSLCKEGEDEHPQCLNSQPHARGSSRAIFSVGPVSPSRRWWYRCYAYDSNSPYEWSLPSDLLELLVLGVSKKPSLSVQPGPIVAPEETLTLQCGSDAGYNRFVLYKDGERDFLQLAGAQPQAGLSQANFTLGPVSRSYGGQYRCYGAHNLSSEWSAPSDPLDILIAGQFYDRVSLSVQPGPTVASGENVTLLCQSQGWMQTFLLTKEGAADDPWRLRSTYQSQKYQAEFPMGPVTSAHAGTYRCYGSQSSKPYLLTHPSDPLELVVSGPSGGPSSPTTGPTSTSGPEDQPLTPTGSDPQSGLGRHLGVVIGILVAVILLLLLLLLLFLILRHRRQGKHWTSTQRKADFQHPAGAVGPEPTDRGLQWRSSPAADAQEENLYAAVKHTQPEDGVEMDTRSPHDEDPQAVTYAEVKHSRPRREMASPPSPLSGEFLDTKDRQAEEDRQMDTEAAASEAPQDVTYAQLHSLTLRREATEPPPSQEGPSPAVPSIYATLAIH T63209 DRUGINFO DE61WB NGM707 Phase 2 T63209 DRUGINFO D0M3NW SAR444881 Phase 1 T63210 TARGETID T63210 T63210 UNIPROID LX12B_HUMAN T63210 TARGNAME Arachidonate 12-lipoxygenase, 12R-type (ALOX12B) T63210 GENENAME ALOX12B T63210 TARGTYPE Clinical trial T63210 SYNONYMS 12R-LOX; 12R-lipoxygenase; Epidermis-type lipoxygenase 12 T63210 FUNCTION Catalyzes the regio and stereo-specific incorporation of a single molecule of dioxygen into free and esterified polyunsaturated fatty acids generating lipid hydroperoxides that can be further reduced to the corresponding hydroxy species (PubMed:9837935, PubMed:9618483, PubMed:21558561). In the skin, acts upstream of ALOXE3 on the lineolate moiety of esterified omega-hydroxyacyl-sphingosine (EOS) ceramides to produce an epoxy-ketone derivative, a crucial step in the conjugation of omega-hydroxyceramide to membrane proteins (PubMed:21558561). Therefore plays a crucial role in the synthesis of corneocytes lipid envelope and the establishment of the skin barrier to water loss (PubMed:21558561). May also play a role in the regulation of the expression of airway mucins (PubMed:22441738). {ECO:0000269|PubMed:21558561, ECO:0000269|PubMed:22441738, ECO:0000269|PubMed:9618483, ECO:0000269|PubMed:9837935}. T63210 ECNUMBER EC 1.13.11.- T63210 SEQUENCE MATYKVRVATGTDLLSGTRDSISLTIVGTQGESHKQLLNHFGRDFATGAVGQYTVQCPQDLGELIIIRLHKERYAFFPKDPWYCNYVQICAPNGRIYHFPAYQWMDGYETLALREATGKTTADDSLPVLLEHRKEEIRAKQDFYHWRVFLPGLPSYVHIPSYRPPVRRHRNPNRPEWNGYIPGFPILINFKATKFLNLNLRYSFLKTASFFVRLGPMALAFKVRGLLDCKHSWKRLKDIRKIFPGKKSVVSEYVAEHWAEDTFFGYQYLNGVNPGLIRRCTRIPDKFPVTDDMVAPFLGEGTCLQAELEKGNIYLADYRIMEGIPTVELSGRKQHHCAPLCLLHFGPEGKMMPIAIQLSQTPGPDCPIFLPSDSEWDWLLAKTWVRYAEFYSHEAIAHLLETHLIAEAFCLALLRNLPMCHPLYKLLIPHTRYTVQINSIGRAVLLNEGGLSAKGMSLGVEGFAGVMVRALSELTYDSLYLPNDFVERGVQDLPGYYYRDDSLAVWNALEKYVTEIITYYYPSDAAVEGDPELQSWVQEIFKECLLGRESSGFPRCLRTVPELIRYVTIVIYTCSAKHAAVNTGQMEFTAWMPNFPASMRNPPIQTKGLTTLETFMDTLPDVKTTCITLLVLWTLSREPDDRRPLGHFPDIHFVEEAPRRSIEAFRQRLNQISHDIRQRNKCLPIPYYYLDPVLIENSISI T63210 DRUGINFO DD1E6R VLX-1005 Phase 2 T63211 TARGETID T63211 T63211 UNIPROID NLRX1_HUMAN T63211 TARGNAME NLR family member X1 (NLRX1) T63211 GENENAME NLRX1 T63211 TARGTYPE Clinical trial T63211 SYNONYMS Caterpiller protein 11.3; CLR11.3; Nucleotide-binding oligomerization domain protein 5; Nucleotide-binding oligomerization domain protein 9 T63211 FUNCTION Participates in antiviral signaling. Acts as a negative regulator of MAVS-mediated antiviral responses, through the inhibition of the virus-induced RLH (RIG-like helicase)-MAVS interaction (PubMed:18200010). Instead, promotes autophagy by interacting with TUFM and subsequently recruiting the autophagy-related proteins ATG5 and ATG12 (PubMed:22749352). Regulates also MAVS-dependent NLRP3 inflammasome activation to attenuate apoptosis (PubMed:27393910). Has no inhibitory function on NF-kappa-B signaling pathway, but enhances NF-kappa-B and JUN N-terminal kinase dependent signaling through the production of reactive oxygen species (PubMed:18219313). Regulates viral mediated-inflammation and energy metabolism in a sex-dependent manner (By similarity). In females, prevents uncontrolled inflammation and energy metabolism and thus, may contribute to the sex differences observed in infectious and inflammatory diseases (By similarity). {ECO:0000250|UniProtKB:Q3TL44, ECO:0000269|PubMed:18200010, ECO:0000269|PubMed:18219313, ECO:0000269|PubMed:22749352, ECO:0000269|PubMed:27393910}. T63211 PDBSTRUC 3UN9 T63211 BIOCLASS NLRP family T63211 SEQUENCE MRWGHHLPRASWGSGFRRALQRPDDRIPFLIHWSWPLQGERPFGPPRAFIRHHGSSVDSAPPPGRHGRLFPSASATEAIQRHRRNLAEWFSRLPREERQFGPTFALDTVHVDPVIRESTPDELLRPPAELALEHQPPQAGLPPLALSQLFNPDACGRRVQTVVLYGTVGTGKSTLVRKMVLDWCYGRLPAFELLIPFSCEDLSSLGPAPASLCQLVAQRYTPLKEVLPLMAAAGSHLLFVLHGLEHLNLDFRLAGTGLCSDPEEPQEPAAIIVNLLRKYMLPQASILVTTRPSAIGRIPSKYVGRYGEICGFSDTNLQKLYFQLRLNQPYCGYAVGGSGVSATPAQRDHLVQMLSRNLEGHHQIAAACFLPSYCWLVCATLHFLHAPTPAGQTLTSIYTSFLRLNFSGETLDSTDPSNLSLMAYAARTMGKLAYEGVSSRKTYFSEEDVCGCLEAGIRTEEEFQLLHIFRRDALRFFLAPCVEPGRAGTFVFTVPAMQEYLAALYIVLGLRKTTLQKVGKEVAELVGRVGEDVSLVLGIMAKLLPLRALPLLFNLIKVVPRVFGRMVGKSREAVAQAMVLEMFREEDYYNDDVLDQMGASILGVEGPRRHPDEPPEDEVFELFPMFMGGLLSAHNRAVLAQLGCPIKNLDALENAQAIKKKLGKLGRQVLPPSELLDHLFFHYEFQNQRFSAEVLSSLRQLNLAGVRMTPVKCTVVAAVLGSGRHALDEVNLASCQLDPAGLRTLLPVFLRARKLGLQLNSLGPEACKDLRDLLLHDQCQITTLRLSNNPLTAAGVAVLMEGLAGNTSVTHLSLLHTGLGDEGLELLAAQLDRNRQLQELNVAYNGAGDTAALALARAAREHPSLELLHLYFNELSSEGRQVLRDLGGAAEGGARVVVSLTEGTAVSEYWSVILSEVQRNLNSWDRARVQRHLELLLRDLEDSRGATLNPWRKAQLLRVEGEVRALLEQLGSSGS T63211 DRUGINFO D4W2AC NX-13 Phase 2 T63215 TARGETID T63215 T63215 UNIPROID SEM3A_HUMAN T63215 TARGNAME Semaphorin-3A (SEMA3A) T63215 GENENAME SEMA3A T63215 TARGTYPE Clinical trial T63215 SYNONYMS Semaphorin III; Sema III T63215 FUNCTION Involved in the development of the olfactory system and in neuronal control of puberty. Induces the collapse and paralysis of neuronal growth cones. Could serve as a ligand that guides specific growth cones by a motility-inhibiting mechanism. Binds to the complex neuropilin-1/plexin-1. {ECO:0000269|PubMed:22416012}. T63215 SEQUENCE MGWLTRIVCLFWGVLLTARANYQNGKNNVPRLKLSYKEMLESNNVITFNGLANSSSYHTFLLDEERSRLYVGAKDHIFSFDLVNIKDFQKIVWPVSYTRRDECKWAGKDILKECANFIKVLKAYNQTHLYACGTGAFHPICTYIEIGHHPEDNIFKLENSHFENGRGKSPYDPKLLTASLLIDGELYSGTAADFMGRDFAIFRTLGHHHPIRTEQHDSRWLNDPKFISAHLISESDNPEDDKVYFFFRENAIDGEHSGKATHARIGQICKNDFGGHRSLVNKWTTFLKARLICSVPGPNGIDTHFDELQDVFLMNFKDPKNPVVYGVFTTSSNIFKGSAVCMYSMSDVRRVFLGPYAHRDGPNYQWVPYQGRVPYPRPGTCPSKTFGGFDSTKDLPDDVITFARSHPAMYNPVFPMNNRPIVIKTDVNYQFTQIVVDRVDAEDGQYDVMFIGTDVGTVLKVVSIPKETWYDLEEVLLEEMTVFREPTAISAMELSTKQQQLYIGSTAGVAQLPLHRCDIYGKACAECCLARDPYCAWDGSACSRYFPTAKRRTRRQDIRNGDPLTHCSDLHHDNHHGHSPEERIIYGVENSSTFLECSPKSQRALVYWQFQRRNEERKEEIRVDDHIIRTDQGLLLRSLQQKDSGNYLCHAVEHGFIQTLLKVTLEVIDTEHLEELLHKDDDGDGSKTKEMSNSMTPSQKVWYRDFMQLINHPNLNTMDEFCEQVWKRDRKQRRQRPGHTPGNSNKWKHLQENKKGRNRRTHEFERAPRSV T63215 DRUGINFO DJF1S3 BI 764524 Phase 2 T63216 TARGETID T63216 T63216 UNIPROID SLIT2_HUMAN T63216 TARGNAME Slit homolog 2 protein (SLIT2) T63216 GENENAME SLIT2 T63216 TARGTYPE Clinical trial T63216 SYNONYMS Slit-2 T63216 FUNCTION Thought to act as molecular guidance cue in cellular migration, and function appears to be mediated by interaction with roundabout homolog receptors. During neural development involved in axonal navigation at the ventral midline of the neural tube and projection of axons to different regions. SLIT1 and SLIT2 seem to be essential for midline guidance in the forebrain by acting as repulsive signal preventing inappropriate midline crossing by axons projecting from the olfactory bulb. In spinal cord development may play a role in guiding commissural axons once they reached the floor plate by modulating the response to netrin. In vitro, silences the attractive effect of NTN1 but not its growth-stimulatory effect and silencing requires the formation of a ROBO1-DCC complex. May be implicated in spinal cord midline post-crossing axon repulsion. In vitro, only commissural axons that crossed the midline responded to SLIT2. In the developing visual system appears to function as repellent for retinal ganglion axons by providing a repulsion that directs these axons along their appropriate paths prior to, and after passage through, the optic chiasm. In vitro, collapses and repels retinal ganglion cell growth cones. Seems to play a role in branching and arborization of CNS sensory axons, and in neuronal cell migration. In vitro, Slit homolog 2 protein N-product, but not Slit homolog 2 protein C-product, repels olfactory bulb (OB) but not dorsal root ganglia (DRG) axons, induces OB growth cones collapse and induces branching of DRG axons. Seems to be involved in regulating leukocyte migration. {ECO:0000269|PubMed:10102268, ECO:0000269|PubMed:10864954, ECO:0000269|PubMed:10975526, ECO:0000269|PubMed:11239147, ECO:0000269|PubMed:11309622, ECO:0000269|PubMed:11404413}. T63216 PDBSTRUC 2V70;2V9S;2V9T;2WFH T63216 SEQUENCE MRGVGWQMLSLSLGLVLAILNKVAPQACPAQCSCSGSTVDCHGLALRSVPRNIPRNTERLDLNGNNITRITKTDFAGLRHLRVLQLMENKISTIERGAFQDLKELERLRLNRNHLQLFPELLFLGTAKLYRLDLSENQIQAIPRKAFRGAVDIKNLQLDYNQISCIEDGAFRALRDLEVLTLNNNNITRLSVASFNHMPKLRTFRLHSNNLYCDCHLAWLSDWLRQRPRVGLYTQCMGPSHLRGHNVAEVQKREFVCSGHQSFMAPSCSVLHCPAACTCSNNIVDCRGKGLTEIPTNLPETITEIRLEQNTIKVIPPGAFSPYKKLRRIDLSNNQISELAPDAFQGLRSLNSLVLYGNKITELPKSLFEGLFSLQLLLLNANKINCLRVDAFQDLHNLNLLSLYDNKLQTIAKGTFSPLRAIQTMHLAQNPFICDCHLKWLADYLHTNPIETSGARCTSPRRLANKRIGQIKSKKFRCSAKEQYFIPGTEDYRSKLSGDCFADLACPEKCRCEGTTVDCSNQKLNKIPEHIPQYTAELRLNNNEFTVLEATGIFKKLPQLRKINFSNNKITDIEEGAFEGASGVNEILLTSNRLENVQHKMFKGLESLKTLMLRSNRITCVGNDSFIGLSSVRLLSLYDNQITTVAPGAFDTLHSLSTLNLLANPFNCNCYLAWLGEWLRKKRIVTGNPRCQKPYFLKEIPIQDVAIQDFTCDDGNDDNSCSPLSRCPTECTCLDTVVRCSNKGLKVLPKGIPRDVTELYLDGNQFTLVPKELSNYKHLTLIDLSNNRISTLSNQSFSNMTQLLTLILSYNRLRCIPPRTFDGLKSLRLLSLHGNDISVVPEGAFNDLSALSHLAIGANPLYCDCNMQWLSDWVKSEYKEPGIARCAGPGEMADKLLLTTPSKKFTCQGPVDVNILAKCNPCLSNPCKNDGTCNSDPVDFYRCTCPYGFKGQDCDVPIHACISNPCKHGGTCHLKEGEEDGFWCICADGFEGENCEVNVDDCEDNDCENNSTCVDGINNYTCLCPPEYTGELCEEKLDFCAQDLNPCQHDSKCILTPKGFKCDCTPGYVGEHCDIDFDDCQDNKCKNGAHCTDAVNGYTCICPEGYSGLFCEFSPPMVLPRTSPCDNFDCQNGAQCIVRINEPICQCLPGYQGEKCEKLVSVNFINKESYLQIPSAKVRPQTNITLQIATDEDSGILLYKGDKDHIAVELYRGRVRASYDTGSHPASAIYSVETINDGNFHIVELLALDQSLSLSVDGGNPKIITNLSKQSTLNFDSPLYVGGMPGKSNVASLRQAPGQNGTSFHGCIRNLYINSELQDFQKVPMQTGILPGCEPCHKKVCAHGTCQPSSQAGFTCECQEGWMGPLCDQRTNDPCLGNKCVHGTCLPINAFSYSCKCLEGHGGVLCDEEEDLFNPCQAIKCKHGKCRLSGLGQPYCECSSGYTGDSCDREISCRGERIRDYYQKQQGYAACQTTKKVSRLECRGGCAGGQCCGPLRSKRRKYSFECTDGSSFVDEVEKVVKCGCTRCVS T63216 DRUGINFO D6TS7K PF-06730512 Phase 2 T63217 TARGETID T63217 T63217 UNIPROID TGM1_HUMAN T63217 TARGNAME Protein-glutamine gamma-glutamyltransferase K (TGM1) T63217 GENENAME TGM1 T63217 TARGTYPE Clinical trial T63217 SYNONYMS Epidermal TGase; Transglutaminase K; TG(K); TGK; TGase K; Transglutaminase-1; TGase-1 T63217 FUNCTION Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins. Responsible for cross-linking epidermal proteins during formation of the stratum corneum. Involved in cell proliferation (PubMed:26220141). {ECO:0000269|PubMed:26220141}. T63217 PDBSTRUC 2XZZ T63217 ECNUMBER EC 2.3.2.13 T63217 SEQUENCE MMDGPRSDVGRWGGNPLQPPTTPSPEPEPEPDGRSRRGGGRSFWARCCGCCSCRNAADDDWGPEPSDSRGRGSSSGTRRPGSRGSDSRRPVSRGSGVNAAGDGTIREGMLVVNGVDLLSSRSDQNRREHHTDEYEYDELIVRRGQPFHMLLLLSRTYESSDRITLELLIGNNPEVGKGTHVIIPVGKGGSGGWKAQVVKASGQNLNLRVHTSPNAIIGKFQFTVRTQSDAGEFQLPFDPRNEIYILFNPWCPEDIVYVDHEDWRQEYVLNESGRIYYGTEAQIGERTWNYGQFDHGVLDACLYILDRRGMPYGGRGDPVNVSRVISAMVNSLDDNGVLIGNWSGDYSRGTNPSAWVGSVEILLSYLRTGYSVPYGQCWVFAGVTTTVLRCLGLATRTVTNFNSAHDTDTSLTMDIYFDENMKPLEHLNHDSVWNFHVWNDCWMKRPDLPSGFDGWQVVDATPQETSSGIFCCGPCSVESIKNGLVYMKYDTPFIFAEVNSDKVYWQRQDDGSFKIVYVEEKAIGTLIVTKAISSNMREDITYLYKHPEGSDAERKAVETAAAHGSKPNVYANRGSAEDVAMQVEAQDAVMGQDLMVSVMLINHSSSRRTVKLHLYLSVTFYTGVSGTIFKETKKEVELAPGASDRVTMPVAYKEYRPHLVDQGAMLLNVSGHVKESGQVLAKQHTFRLRTPDLSLTLLGAAVVGQECEVQIVFKNPLPVTLTNVVFRLEGSGLQRPKILNVGDIGGNETVTLRQSFVPVRPGPRQLIASLDSPQLSQVHGVIQVDVAPAPGDGGFFSDAGGDSHLGETIPMASRGGA T63217 DRUGINFO DQ8X4A KB105 Phase 2 T63218 TARGETID T63218 T63218 UNIPROID THIM_HUMAN T63218 TARGNAME 3-ketoacyl-CoA thiolase, mitochondrial (ACAA2) T63218 GENENAME ACAA2 T63218 TARGTYPE Clinical trial T63218 SYNONYMS Acetyl-CoA acetyltransferase; Acetyl-CoA acyltransferase; Acyl-CoA hydrolase, mitochondrial; Beta-ketothiolase; Mitochondrial 3-oxoacyl-CoA thiolase; T1 T63218 FUNCTION In the production of energy from fats, this is one of the enzymes that catalyzes the last step of the mitochondrial beta-oxidation pathway, an aerobic process breaking down fatty acids into acetyl-CoA (Probable). Using free coenzyme A/CoA, catalyzes the thiolytic cleavage of medium- to long-chain unbranched 3-oxoacyl-CoAs into acetyl-CoA and a fatty acyl-CoA shortened by two carbon atoms (Probable). Also catalyzes the condensation of two acetyl-CoA molecules into acetoacetyl-CoA and could be involved in the production of ketone bodies (Probable). Also displays hydrolase activity on various fatty acyl-CoAs (PubMed:25478839). Thereby, could be responsible for the production of acetate in a side reaction to beta-oxidation (Probable). Abolishes BNIP3-mediated apoptosis and mitochondrial damage (PubMed:18371312). {ECO:0000269|PubMed:18371312, ECO:0000269|PubMed:25478839, ECO:0000305|PubMed:25478839}. T63218 PDBSTRUC 4C2J;4C2K T63218 ECNUMBER EC 2.3.1.16; EC 2.3.1.9; EC 3.1.2.-; EC 3.1.2.1; EC 3.1.2.2 T63218 SEQUENCE MALLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAIYLARHVGLRVGIPKETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFGTKLGSDIKLEDSLWVSLTDQHVQLPMAMTAENLAVKHKISREECDKYALQSQQRWKAANDAGYFNDEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFKKDGTVTAGNASGVADGAGAVIIASEDAVKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVNEAFAPQYLAVERSLDLDISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA T63218 DRUGINFO DVZJ75 IMB-101 Phase 2 T63243 TARGETID T63243 T63243 UNIPROID GBA1_HUMAN T63243 TARGNAME Lysosomal acid glucosylceramidase (GBA1) T63243 GENENAME GBA1 T63243 TARGTYPE Clinical trial T63243 SYNONYMS Lysosomal acid GCase; Acid beta-glucosidase; Alglucerase; Beta-glucocerebrosidase; Beta-GC; Beta-glucosylceramidase 1; Cholesterol glucosyltransferase; SGTase; Cholesteryl-beta-glucosidase; D-glucosyl-N-acylsphingosine glucohydrolase; Glucosylceramidase beta 1; Imiglucerase; Lysosomal cholesterol glycosyltransferase; Lysosomal galactosylceramidase; Lysosomal glycosylceramidase T63243 FUNCTION Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose (PubMed:9201993, PubMed:24211208, PubMed:15916907, PubMed:32144204). Plays a central role in the degradation of complex lipids and the turnover of cellular membranes (PubMed:27378698). Through the production of ceramides, participates in the PKC-activated salvage pathway of ceramide formation (PubMed:19279011). Catalyzes the glucosylation of cholesterol, through a transglucosylation reaction where glucose is transferred from GlcCer to cholesterol (PubMed:24211208, PubMed:26724485, PubMed:32144204). GlcCer containing mono-unsaturated fatty acids (such as beta-D-glucosyl-N-(9Z-octadecenoyl)-sphing-4-enine) are preferred as glucose donors for cholesterol glucosylation when compared with GlcCer containing same chain length of saturated fatty acids (such as beta-D-glucosyl-N-octadecanoyl-sphing-4-enine) (PubMed:24211208). Under specific conditions, may alternatively catalyze the reverse reaction, transferring glucose from cholesteryl 3-beta-D-glucoside to ceramide (PubMed:26724485) (Probable). Can also hydrolyze cholesteryl 3-beta-D-glucoside producing glucose and cholesterol (PubMed:24211208, PubMed:26724485). Catalyzes the hydrolysis of galactosylceramides/GalCers (such as beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine), as well as the transfer of galactose between GalCers and cholesterol in vitro, but with lower activity than with GlcCers (PubMed:32144204). Contrary to GlcCer and GalCer, xylosylceramide/XylCer (such as beta-D-xyosyl-(1<->1')-N-acylsphing-4-enine) is not a good substrate for hydrolysis, however it is a good xylose donor for transxylosylation activity to form cholesteryl 3-beta-D-xyloside (PubMed:33361282). {ECO:0000269|PubMed:15916907, ECO:0000269|PubMed:19279011, ECO:0000269|PubMed:24211208, ECO:0000269|PubMed:26724485, ECO:0000269|PubMed:27378698, ECO:0000269|PubMed:32144204, ECO:0000269|PubMed:33361282, ECO:0000269|PubMed:9201993, ECO:0000305|PubMed:32144204}. T63243 PDBSTRUC 1OGS;1Y7V;2F61;2J25;2NSX;2NT0;2NT1;2V3D;2V3E;2V3F;2VT0;2WCG;2WKL;2XWD;2XWE;3GXD;3GXF;3GXI;3GXM;3KE0;3KEH;3RIK;3RIL;5LVX;6MOZ;6Q1N;6Q1P;6Q6K;6Q6L;6Q6N;6T13;6TJJ;6TJK;6TJQ;6TN1;6YTP;6YTR;6YUT;6YV3;6Z39;6Z3I;7NWV T63243 BIOCLASS Glycosyl hydrolase T63243 ECNUMBER EC 2.4.1.-; EC 3.2.1.-; EC 3.2.1.45; EC 3.2.1.46 T63243 SEQUENCE MEFSSPSREECPKPLSRVSIMAGSLTGLLLLQAVSWASGARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ T63243 DRUGINFO D23CDU AVR-RD-02 Phase 2/3 T63243 DRUGINFO D0XZ4Y PR001 Phase 1/2 T63221 TARGETID T63221 T63221 UNIPROID KLRG1_HUMAN T63221 TARGNAME Killer cell lectin-like receptor subfamily G member 1 (KLRG1) T63221 GENENAME KLRG1 T63221 TARGTYPE Clinical trial T63221 SYNONYMS C-type lectin domain family 15 member A; ITIM-containing receptor MAFA-L; MAFA-like receptor; Mast cell function-associated antigen T63221 FUNCTION Plays an inhibitory role on natural killer (NK) cells and T-cell functions upon binding to their non-MHC ligands. May mediate missing self recognition by binding to a highly conserved site on classical cadherins, enabling it to monitor expression of E-cadherin/CDH1, N-cadherin/CDH2 and R-cadherin/CDH4 on target cells. {ECO:0000269|PubMed:19604491}. T63221 PDBSTRUC 3FF7 T63221 SEQUENCE MTDSVIYSMLELPTATQAQNDYGPQQKSSSSRPSCSCLVAIALGLLTAVLLSVLLYQWILCQGSNYSTCASCPSCPDRWMKYGNHCYYFSVEEKDWNSSLEFCLARDSHLLVITDNQEMSLLQVFLSEAFCWIGLRNNSGWRWEDGSPLNFSRISSNSFVQTCGAINKNGLQASSCEVPLHWVCKKCPFADQALF T63221 DRUGINFO D3WA2V ABC008 Phase 2/3 T63224 TARGETID T63224 T63224 UNIPROID ARGI1_HUMAN T63224 TARGNAME Arginase-1 (ARG1) T63224 GENENAME ARG1 T63224 TARGTYPE Clinical trial T63224 SYNONYMS Liver-type arginase; Type I arginase T63224 FUNCTION Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively; the urea cycle takes place primarily in the liver and, to a lesser extent, in the kidneys. {ECO:0000305}.; Functions in L-arginine homeostasis in nonhepatic tissues characterized by the competition between nitric oxide synthase (NOS) and arginase for the available intracellular substrate arginine. Arginine metabolism is a critical regulator of innate and adaptive immune responses. Involved in an antimicrobial effector pathway in polymorphonuclear granulocytes (PMN). Upon PMN cell death is liberated from the phagolysosome and depletes arginine in the microenvironment leading to suppressed T cell and natural killer (NK) cell proliferation and cytokine secretion (PubMed:15546957, PubMed:16709924, PubMed:19380772). In group 2 innate lymphoid cells (ILC2s) promotes acute type 2 inflammation in the lung and is involved in optimal ILC2 proliferation but not survival (By similarity). In humans, the immunological role in the monocytic/macrophage/dendritic cell (DC) lineage is unsure. {ECO:0000250|UniProtKB:Q61176, ECO:0000269|PubMed:15546957, ECO:0000269|PubMed:16709924, ECO:0000269|PubMed:19380772}. T63224 PDBSTRUC 1WVA;1WVB;2AEB;2PHA;2PHO;2PLL;2ZAV;3DJ8;3E6K;3E6V;3F80;3GMZ;3GN0;3KV2;3LP4;3LP7;3MFV;3MFW;3MJL;3SJT;3SKK;3TF3;3TH7;3THE;3THH;3THJ;4FCI;4FCK;4GSM;4GSV;4GSZ;4GWC;4GWD;4HWW;4HXQ;4IE1;6Q92;6Q9P;6QAF;6V7C;6V7D;6V7E;6V7F;7K4G;7K4H;7K4I;7K4J;7K4K;7KLK;7KLL;7KLM;7LEX;7LEY;7LEZ;7LF0;7LF1;7LF2;8AUP;8E5M;8E5N T63224 ECNUMBER EC 3.5.3.1 T63224 SEQUENCE MSAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDVKDYGDLPFADIPNDSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRISLVLGGDHSLAIGSISGHARVHPDLGVIWVDAHTDINTPLTTTSGNLHGQPVSFLLKELKGKIPDVPGFSWVTPCISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGLDPSFTPATGTPVVGGLTYREGLYITEEIYKTGLLSGLDIMEVNPSLGKTPEEVTRTVNTAVAITLACFGLAREGNHKPIDYLNPPK T63224 DRUGINFO DX2H9P Pegzilarginase Phase 3 T63225 TARGETID T63225 T63225 UNIPROID ATS13_HUMAN T63225 TARGNAME A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) T63225 GENENAME ADAMTS13 T63225 TARGTYPE Clinical trial T63225 SYNONYMS ADAM-TS 13; ADAM-TS13; ADAMTS-13; von Willebrand factor-cleaving protease; vWF-CP; vWF-cleaving protease T63225 FUNCTION Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation. {ECO:0000269|PubMed:19880749}. T63225 PDBSTRUC 3GHM;3GHN;3VN4;6QIG;7B01 T63225 ECNUMBER EC 3.4.24.87 T63225 SEQUENCE MHQRHPRARCPPLCVAGILACGFLLGCWGPSHFQQSCLQALEPQAVSSYLSPGAPLKGRPPSPGFQRQRQRQRRAAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWSCLITEDTGFDLGVTIAHEIGHSFGLEHDGAPGSGCGPSGHVMASDGAAPRAGLAWSPCSRRQLLSLLSAGRARCVWDPPRPQPGSAGHPPDAQPGLYYSANEQCRVAFGPKAVACTFAREHLDMCQALSCHTDPLDQSSCSRLLVPLLDGTECGVEKWCSKGRCRSLVELTPIAAVHGRWSSWGPRSPCSRSCGGGVVTRRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSQQCARTDGQPLRSSPGGASFYHWGAAVPHSQGDALCRHMCRAIGESFIMKRGDSFLDGTRCMPSGPREDGTLSLCVSGSCRTFGCDGRMDSQQVWDRCQVCGGDNSTCSPRKGSFTAGRAREYVTFLTVTPNLTSVYIANHRPLFTHLAVRIGGRYVVAGKMSISPNTTYPSLLEDGRVEYRVALTEDRLPRLEEIRIWGPLQEDADIQVYRRYGEEYGNLTRPDITFTYFQPKPRQAWVWAAVRGPCSVSCGAGLRWVNYSCLDQARKELVETVQCQGSQQPPAWPEACVLEPCPPYWAVGDFGPCSASCGGGLRERPVRCVEAQGSLLKTLPPARCRAGAQQPAVALETCNPQPCPARWEVSEPSSCTSAGGAGLALENETCVPGADGLEAPVTEGPGSVDEKLPAPEPCVGMSCPPGWGHLDATSAGEKAPSPWGSIRTGAQAAHVWTPAAGSCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRREVCQAVPCPARWQYKLAACSVSCGRGVVRRILYCARAHGEDDGEEILLDTQCQGLPRPEPQEACSLEPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACAALVRPEASVPCLIADCTYRWHVGTWMECSVSCGDGIQRRRDTCLGPQAQAPVPADFCQHLPKPVTVRGCWAGPCVGQGTPSLVPHEEAAAPGRTTATPAGASLEWSQARGLLFSPAPQPRRLLPGPQENSVQSSACGRQHLEPTGTIDMRGPGQADCAVAIGRPLGEVVTLRVLESSLNCSAGDMLLLWGRLTWRKMCRKLLDMTFSSKTNTLVVRQRCGRPGGGVLLRYGSQLAPETFYRECDMQLFGPWGEIVSPSLSPATSNAGGCRLFINVAPHARIAIHALATNMGAGTEGANASYILIRDTHSLRTTAFHGQQVLYWESESSQAEMEFSEGFLKAQASLRGQYWTLQSWVPEMQDPQSWKGKEGT T63225 DRUGINFO D6PMR7 TAK-755 Phase 3 T63226 TARGETID T63226 T63226 UNIPROID CLC4C_HUMAN T63226 TARGNAME C-type lectin domain family 4 member C (CLEC4C) T63226 GENENAME CLEC4C T63226 TARGTYPE Clinical trial T63226 SYNONYMS Blood dendritic cell antigen 2; BDCA-2; C-type lectin superfamily member 7; Dendritic lectin; CD303 T63226 FUNCTION Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cells (PubMed:11748283, PubMed:21880719, PubMed:25995448). Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man (PubMed:21880719, PubMed:25995448). Binds to serum IgG (PubMed:25995448). Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells (PubMed:11748283). May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells (PubMed:11748283, PubMed:21880719). May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium (PubMed:11748283). {ECO:0000269|PubMed:11748283, ECO:0000269|PubMed:21880719, ECO:0000269|PubMed:25995448}. T63226 PDBSTRUC 3WBP;3WBQ;3WBR;4ZES;4ZET T63226 SEQUENCE MVPEEEPQDREKGLWWFQLKVWSMAVVSILLLSVCFTVSSVVPHNFMYSKTVKRLSKLREYQQYHPSLTCVMEGKDIEDWSCCPTPWTSFQSSCYFISTGMQSWTKSQKNCSVMGADLVVINTREEQDFIIQNLKRNSSYFLGLSDPGGRRHWQWVDQTPYNENVTFWHSGEPNNLDERCAIINFRSSEEWGWNDIHCHVPQKSICKMKKIYI T63226 DRUGINFO DMT2F4 Litifilimab Phase 3 T63229 TARGETID T63229 T63229 UNIPROID ILRL1_HUMAN T63229 TARGNAME Interleukin-1 receptor-like 1 (IL1RL1) T63229 GENENAME IL1RL1 T63229 TARGTYPE Clinical trial T63229 SYNONYMS Protein ST2 T63229 FUNCTION Receptor for interleukin-33 (IL-33) which plays crucial roles in innate and adaptive immunity, contributing to tissue homeostasis and responses to environmental stresses together with coreceptor IL1RAP (PubMed:35238669). Its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. Possibly involved in helper T-cell function (PubMed:16286016) (Probable). Upon tissue injury, induces UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages (By similarity). {ECO:0000250|UniProtKB:P14719, ECO:0000269|PubMed:16286016, ECO:0000269|PubMed:35238669, ECO:0000305|PubMed:19836339}.; [Isoform B]: Inhibits IL-33 signaling. {ECO:0000250|UniProtKB:P14719}. T63229 PDBSTRUC 4KC3 T63229 ECNUMBER EC 3.2.2.6 T63229 SEQUENCE MGFWILAILTILMYSTAAKFSKQSWGLENEALIVRCPRQGKPSYTVDWYYSQTNKSIPTQERNRVFASGQLLKFLPAAVADSGIYTCIVRSPTFNRTGYANVTIYKKQSDCNVPDYLMYSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYRAHKSFLVIDNVMTEDAGDYTCKFIHNENGANYSVTATRSFTVKDEQGFSLFPVIGAPAQNEIKEVEIGKNANLTCSACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQEEGQNQSFSNGLACLDMVLRIADVKEEDLLLQYDCLALNLHGLRRHTVRLSRKNPIDHHSIYCIIAVCSVFLMLINVLVIILKMFWIEATLLWRDIAKPYKTRNDGKLYDAYVVYPRNYKSSTDGASRVEHFVHQILPDVLENKCGYTLCIYGRDMLPGEDVVTAVETNIRKSRRHIFILTPQITHNKEFAYEQEVALHCALIQNDAKVILIEMEALSELDMLQAEALQDSLQHLMKVQGTIKWREDHIANKRSLNSKFWKHVRYQMPVPSKIPRKASSLTPLAAQKQ T63229 DRUGINFO DBAL18 Astegolimab Phase 3 T63229 DRUGINFO DCSZ97 GSK3772847 Phase 2 T63230 TARGETID T63230 T63230 UNIPROID INHBA_HUMAN T63230 TARGNAME Inhibin beta A chain (INHBA) T63230 GENENAME INHBA T63230 TARGTYPE Clinical trial T63230 SYNONYMS Activin beta-A chain; Erythroid differentiation protein; EDF T63230 FUNCTION Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins. T63230 PDBSTRUC 1NYS;1NYU;1S4Y;2ARP;2ARV;2B0U;2P6A;3B4V;4MID;5HLY;5HLZ;6Y6N;6Y6O;7OLY;7U5P T63230 SEQUENCE MPLLWLRGFLLASCWIIVRSSPTPGSEGHSAAPDCPSCALAALPKDVPNSQPEMVEAVKKHILNMLHLKKRPDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIGRRAEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTRTKVTIRLFQQQKHPQGSLDTGEEAEEVGLKGERSELLLSEKVVDARKSTWHVFPVSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLGKKKKKEEEGEGKKKGGGEGGAGADEEKEQSHRPFLMLQARQSEDHPHRRRRRGLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS T63230 DRUGINFO DKP80T Garetosmab Phase 3 T63233 TARGETID T63233 T63233 UNIPROID SORT_HUMAN T63233 TARGNAME Sortilin (SORT1) T63233 GENENAME SORT1 T63233 TARGTYPE Clinical trial T63233 SYNONYMS 100 kDa NT receptor; Glycoprotein 95; Gp95; Neurotensin receptor 3; NT3; NTR3 T63233 FUNCTION Functions as a sorting receptor in the Golgi compartment and as a clearance receptor on the cell surface. Required for protein transport from the Golgi apparatus to the lysosomes by a pathway that is independent of the mannose-6-phosphate receptor (M6PR). Lysosomal proteins bind specifically to the receptor in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelysosomal compartment where the low pH mediates the dissociation of the complex (PubMed:16787399). The receptor is then recycled back to the Golgi for another round of trafficking through its binding to the retromer. Also required for protein transport from the Golgi apparatus to the endosomes. Promotes neuronal apoptosis by mediating endocytosis of the proapoptotic precursor forms of BDNF (proBDNF) and NGFB (proNGFB). Also acts as a receptor for neurotensin. May promote mineralization of the extracellular matrix during osteogenic differentiation by scavenging extracellular LPL. Probably required in adipocytes for the formation of specialized storage vesicles containing the glucose transporter SLC2A4/GLUT4 (GLUT4 storage vesicles, or GSVs). These vesicles provide a stable pool of SLC2A4 and confer increased responsiveness to insulin. May also mediate transport from the endoplasmic reticulum to the Golgi. {ECO:0000269|PubMed:10085125, ECO:0000269|PubMed:11331584, ECO:0000269|PubMed:11390366, ECO:0000269|PubMed:12209882, ECO:0000269|PubMed:12598608, ECO:0000269|PubMed:14657016, ECO:0000269|PubMed:14985763, ECO:0000269|PubMed:15313463, ECO:0000269|PubMed:15930396, ECO:0000269|PubMed:15987945, ECO:0000269|PubMed:16787399, ECO:0000269|PubMed:18817523}. T63233 PDBSTRUC 3F6K;3G2U;3G2V;4MSL;4N7E;4PO7;5MRH;5MRI;6EHO;6X3L;6X48;6X4H T63233 SEQUENCE MERPWGAADGLSRWPHGLGLLLLLQLLPPSTLSQDRLDAPPPPAAPLPRWSGPIGVSWGLRAAAAGGAFPRGGRWRRSAPGEDEECGRVRDFVAKLANNTHQHVFDDLRGSVSLSWVGDSTGVILVLTTFHVPLVIMTFGQSKLYRSEDYGKNFKDITDLINNTFIRTEFGMAIGPENSGKVVLTAEVSGGSRGGRIFRSSDFAKNFVQTDLPFHPLTQMMYSPQNSDYLLALSTENGLWVSKNFGGKWEEIHKAVCLAKWGSDNTIFFTTYANGSCKADLGALELWRTSDLGKSFKTIGVKIYSFGLGGRFLFASVMADKDTTRRIHVSTDQGDTWSMAQLPSVGQEQFYSILAANDDMVFMHVDEPGDTGFGTIFTSDDRGIVYSKSLDRHLYTTTGGETDFTNVTSLRGVYITSVLSEDNSIQTMITFDQGGRWTHLRKPENSECDATAKNKNECSLHIHASYSISQKLNVPMAPLSEPNAVGIVIAHGSVGDAISVMVPDVYISDDGGYSWTKMLEGPHYYTILDSGGIIVAIEHSSRPINVIKFSTDEGQCWQTYTFTRDPIYFTGLASEPGARSMNISIWGFTESFLTSQWVSYTIDFKDILERNCEEKDYTIWLAHSTDPEDYEDGCILGYKEQFLRLRKSSVCQNGRDYVVTKQPSICLCSLEDFLCDFGYYRPENDSKCVEQPELKGHDLEFCLYGREEHLTTNGYRKIPGDKCQGGVNPVREVKDLKKKCTSNFLSPEKQNSKSNSVPIILAIVGLMLVTVVAGVLIVKKYVCGGRFLVHRYSVLQQHAEANGVDGVDALDTASHTNKSGYHDDSDEDLLE T63233 DRUGINFO DO57XC AL001 Phase 3 T63233 DRUGINFO DW0E3K GSK4527223 Phase 3 T63233 DRUGINFO DG15YL GSK4527226 Phase 1 T63236 TARGETID T63236 T63236 UNIPROID CCL17_HUMAN T63236 TARGNAME C-C motif chemokine 17 (CCL17) T63236 GENENAME CCL17 T63236 TARGTYPE Clinical trial T63236 SYNONYMS CC chemokine TARC; Small-inducible cytokine A17; Thymus and activation-regulated chemokine T63236 FUNCTION Chemokine, which displays chemotactic activity for T lymphocytes, preferentially Th2 cells, but not monocytes or granulocytes. Therefore plays an important role in a wide range of inflammatory and immunological processes (PubMed:8702936, PubMed:9169480). Acts by binding to CCR4 at T-cell surface (PubMed:9169480, PubMed:10540332). Mediates GM-CSF/CSF2-driven pain and inflammation (PubMed:27525438). In the brain, required to maintain the typical, highly branched morphology of hippocampal microglia under homeostatic conditions. May be important for the appropriate adaptation of microglial morphology and synaptic plasticity to acute lipopolysaccharide (LPS)-induced neuroinflammation (By similarity). Plays a role in wound healing, mainly by inducing fibroblast migration into the wound (By similarity). {ECO:0000250|UniProtKB:Q9WUZ6, ECO:0000269|PubMed:10540332, ECO:0000269|PubMed:27525438, ECO:0000269|PubMed:8702936, ECO:0000269|PubMed:9169480}. T63236 PDBSTRUC 1NR2;1NR4;5WK3;7S4N;7SCV;8FJ2;8SKK T63236 SEQUENCE MAPLKMLALVTLLLGASLQHIHAARGTNVGRECCLEYFKGAIPLRKLKTWYQTSEDCSRDAIVFVTVQGRAICSDPNNKRVKNAVKYLQSLERS T63236 DRUGINFO D21SVO GSK3858279 Phase 2 T63237 TARGETID T63237 T63237 UNIPROID DHB13_HUMAN T63237 TARGNAME 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) T63237 GENENAME HSD17B13 T63237 TARGTYPE Clinical trial T63237 SYNONYMS 17-beta-HSD 13; Hepatic retinol/retinal dehydrogenase; Short chain dehydrogenase/reductase family 16C member 3; Short-chain dehydrogenase/reductase 9 T63237 FUNCTION Plays a pivotal role in hepatic lipid metabolism (PubMed:29562163). In vitro, it catalyzes the oxidation of a variety of lipid substrates, including 17beta-estradiol, retinol, retinal, and leukotriene B4 (PubMed:29562163, PubMed:30415504, PubMed:32973038). {ECO:0000269|PubMed:29562163, ECO:0000269|PubMed:30415504, ECO:0000269|PubMed:32973038}.; [Isoform 2]: Has retinol/retinal dehydrogenase activity in vitro. {ECO:0000269|PubMed:30415504, ECO:0000269|PubMed:32973038}.; [Isoform 1]: Does not have retinol/retinal dehydrogenase activity in vitro. {ECO:0000269|PubMed:30415504}. T63237 ECNUMBER EC 1.1.1.-; EC 1.1.1.105; EC 1.1.1.62 T63237 SEQUENCE MNIILEILLLLITIIYSYLESLVKFFIPQRRKSVAGEIVLITGAGHGIGRQTTYEFAKRQSILVLWDINKRGVEETAAECRKLGVTAHAYVVDCSNREEIYRSLNQVKKEVGDVTIVVNNAGTVYPADLLSTKDEEITKTFEVNILGHFWITKALLPSMMERNHGHIVTVASVCGHEGIPYLIPYCSSKFAAVGFHRGLTSELQALGKTGIKTSCLCPVFVNTGFTKNPSTRLWPVLETDEVVRSLIDGILTNKKMIFVPSYINIFLRLQKFLPERASAILNRMQNIQFEAVVGHKIKMK T63237 DRUGINFO DB34JE GSK4532990 Phase 2 T63238 TARGETID T63238 T63238 UNIPROID GPR6_HUMAN T63238 TARGNAME G-protein coupled receptor 6 (GPR6) T63238 GENENAME GPR6 T63238 TARGTYPE Clinical trial T63238 SYNONYMS Sphingosine 1-phosphate receptor GPR6 T63238 FUNCTION Orphan receptor with constitutive G(s) signaling activity that activate cyclic AMP. Promotes neurite outgrowth and blocks myelin inhibition in neurons (By similarity). {ECO:0000250}. T63238 BIOCLASS G-protein coupled receptor 1 family T63238 SEQUENCE MNASAASLNDSQVVVVAAEGAAAAATAAGGPDTGEWGPPAAAALGAGGGANGSLELSSQLSAGPPGLLLPAVNPWDVLLCVSGTVIAGENALVVALIASTPALRTPMFVLVGSLATADLLAGCGLILHFVFQYLVPSETVSLLTVGFLVASFAASVSSLLAITVDRYLSLYNALTYYSRRTLLGVHLLLAATWTVSLGLGLLPVLGWNCLAERAACSVVRPLARSHVALLSAAFFMVFGIMLHLYVRICQVVWRHAHQIALQQHCLAPPHLAATRKGVGTLAVVLGTFGASWLPFAIYCVVGSHEDPAVYTYATLLPATYNSMINPIIYAFRNQEIQRALWLLLCGCFQSKVPFRSRSPSEV T63238 DRUGINFO DH3S7V CVN424 Phase 2 T63239 TARGETID T63239 T63239 UNIPROID HLAA_HUMAN T63239 TARGNAME HLA class I histocompatibility antigen, A alpha chain (HLA-A) T63239 GENENAME HLA-A T63239 TARGTYPE Clinical trial T63239 SYNONYMS Human leukocyte antigen A; HLA-A T63239 FUNCTION Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:2456340, PubMed:2784196, PubMed:1402688, PubMed:7504010, PubMed:9862734, PubMed:10449296, PubMed:12138174, PubMed:12393434, PubMed:15893615, PubMed:17189421, PubMed:19543285, PubMed:21498667, PubMed:24192765, PubMed:7694806, PubMed:24395804, PubMed:28250417). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed:25880248, PubMed:7506728, PubMed:7679507). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed:12796775, PubMed:18275829, PubMed:19542454, PubMed:28250417). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via IFNG-induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme (PubMed:17189421, PubMed:20364150, PubMed:17079320, PubMed:26929325, PubMed:27049119). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed:7504010, PubMed:9862734). {ECO:0000269|PubMed:10449296, ECO:0000269|PubMed:12138174, ECO:0000269|PubMed:12393434, ECO:0000269|PubMed:12796775, ECO:0000269|PubMed:1402688, ECO:0000269|PubMed:15893615, ECO:0000269|PubMed:17079320, ECO:0000269|PubMed:17189421, ECO:0000269|PubMed:18275829, ECO:0000269|PubMed:19542454, ECO:0000269|PubMed:19543285, ECO:0000269|PubMed:20364150, ECO:0000269|PubMed:21498667, ECO:0000269|PubMed:24192765, ECO:0000269|PubMed:24395804, ECO:0000269|PubMed:2456340, ECO:0000269|PubMed:25880248, ECO:0000269|PubMed:26929325, ECO:0000269|PubMed:27049119, ECO:0000269|PubMed:2784196, ECO:0000269|PubMed:28250417, ECO:0000269|PubMed:7504010, ECO:0000269|PubMed:7506728, ECO:0000269|PubMed:7679507, ECO:0000269|PubMed:7694806, ECO:0000269|PubMed:9862734}.; Allele A*01:01: Presents a restricted peptide repertoire including viral epitopes derived from IAV NP/nucleoprotein (CTELKLSDY), IAV PB1/polymerase basic protein 1 (VSDGGPNLY), HAdV-11 capsid L3/hexon protein (LTDLGQNLLY), SARS-CoV-2 3a/ORF3a (FTSDYYQLY) as well as tumor peptide antigens including MAGE1 (EADPTGHSY), MAGEA3 (EVDPIGHLY) and WT1 (TSEKRPFMCAY), all having in common a canonical motif with a negatively charged Asp or Glu residue at position 3 and a Tyr anchor residue at the C-terminus (PubMed:1402688, PubMed:7504010, PubMed:17189421, PubMed:20364150, PubMed:25880248, PubMed:30530481, PubMed:19177349, PubMed:24395804, PubMed:26758806, PubMed:32887977). A number of HLA-A*01:01-restricted peptides carry a post-translational modification with oxidation and N-terminal acetylation being the most frequent (PubMed:25880248). Fails to present highly immunogenic peptides from the EBV latent antigens (PubMed:18779413). {ECO:0000269|PubMed:1402688, ECO:0000269|PubMed:17189421, ECO:0000269|PubMed:18779413, ECO:0000269|PubMed:19177349, ECO:0000269|PubMed:20364150, ECO:0000269|PubMed:24395804, ECO:0000269|PubMed:25880248, ECO:0000269|PubMed:26758806, ECO:0000269|PubMed:30530481, ECO:0000269|PubMed:7504010}.; Allele A*02:01: A major allele in human populations, presents immunodominant viral epitopes derived from IAV M/matrix protein 1 (GILGFVFTL), HIV-1 env (TLTSCNTSV), HIV-1 gag-pol (ILKEPVHGV), HTLV-1 Tax (LLFGYPVYV), HBV C/core antigen (FLPSDFFPS), HCMV UL83/pp65 (NLVPMVATV) as well as tumor peptide antigens including MAGEA4 (GVYDGREHTV), WT1 (RMFPNAPYL) and CTAG1A/NY-ESO-1 (SLLMWITQC), all having in common hydrophobic amino acids at position 2 and at the C-terminal anchors. {ECO:0000269|PubMed:11502003, ECO:0000269|PubMed:12138174, ECO:0000269|PubMed:12796775, ECO:0000269|PubMed:17079320, ECO:0000269|PubMed:18275829, ECO:0000269|PubMed:19542454, ECO:0000269|PubMed:20619457, ECO:0000269|PubMed:22245737, ECO:0000269|PubMed:26929325, ECO:0000269|PubMed:2784196, ECO:0000269|PubMed:28250417, ECO:0000269|PubMed:7694806, ECO:0000269|PubMed:7935798, ECO:0000269|PubMed:8630735, ECO:0000269|PubMed:8805302, ECO:0000269|PubMed:8906788, ECO:0000269|PubMed:9177355}.; Allele A*03:01: Presents viral epitopes derived from IAV NP (ILRGSVAHK), HIV-1 nef (QVPLRPMTYK), HIV-1 gag-pol (AIFQSSMTK), SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) as well as tumor peptide antigens including PMEL (LIYRRRLMK), NODAL (HAYIQSLLK), TRP-2 (RMYNMVPFF), all having in common hydrophobic amino acids at position 2 and Lys or Arg anchor residues at the C-terminus (PubMed:7504010, PubMed:7679507, PubMed:9862734, PubMed:19543285, PubMed:21943705, PubMed:2456340, PubMed:32887977). May also display spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein (PubMed:27049119). {ECO:0000269|PubMed:19543285, ECO:0000269|PubMed:21943705, ECO:0000269|PubMed:2456340, ECO:0000269|PubMed:27049119, ECO:0000269|PubMed:7504010, ECO:0000269|PubMed:7679507, ECO:0000269|PubMed:9862734}.; Allele A*11:01: Presents several immunodominant epitopes derived from HIV-1 gag-pol and HHV-4 EBNA4, containing the peptide motif with Val, Ile, Thr, Leu, Tyr or Phe at position 2 and Lys anchor residue at the C-terminus. Important in the control of HIV-1, EBV and HBV infections (PubMed:10449296). Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) (PubMed:32887977). {ECO:0000269|PubMed:10449296, ECO:0000269|PubMed:32887977}.; Allele A*23:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response. {ECO:0000269|PubMed:17182537}.; Allele A*24:02: Presents viral epitopes derived from HIV-1 nef (RYPLTFGWCF), EBV lytic- and latent-cycle antigens BRLF1 (TYPVLEEMF), BMLF1 (DYNFVKQLF) and LMP2 (IYVLVMLVL), SARS-CoV nucleocapsid/N (QFKDNVILL), as well as tumor peptide antigens including PRAME (LYVDSLFFL), all sharing a common signature motif, namely an aromatic residue Tyr or Phe at position 2 and a nonhydrophobic anchor residue Phe, Leu or Iso at the C-terminus (PubMed:9047241, PubMed:12393434, PubMed:24192765, PubMed:20844028). Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response (PubMed:17182537, PubMed:18502829). {ECO:0000269|PubMed:12393434, ECO:0000269|PubMed:17182537, ECO:0000269|PubMed:18502829, ECO:0000269|PubMed:20844028, ECO:0000269|PubMed:24192765, ECO:0000269|PubMed:9047241}.; Allele A*26:01: Presents several epitopes derived from HIV-1 gag-pol (EVIPMFSAL, ETKLGKAGY) and env (LVSDGGPNLY), carrying as anchor residues preferentially Glu at position 1, Val or Thr at position 2 and Tyr at the C-terminus. {ECO:0000269|PubMed:15893615}.; Allele A*29:02: Presents peptides having a common motif, namely a Glu residue at position 2 and Tyr or Leu anchor residues at the C-terminus. {ECO:0000269|PubMed:8622959}.; Allele A*32:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response. {ECO:0000269|PubMed:17182537}.; Allele A*68:01: Presents viral epitopes derived from IAV NP (KTGGPIYKR) and HIV-1 tat (ITKGLGISYGR), having a common signature motif namely, Val or Thr at position 2 and positively charged residues Arg or Lys at the C-terminal anchor. {ECO:0000269|PubMed:1448153, ECO:0000269|PubMed:1448154, ECO:0000269|PubMed:2784196}.; Allele A*74:01: Presents immunodominant HIV-1 epitopes derived from gag-pol (GQMVHQAISPR, QIYPGIKVR) and rev (RQIHSISER), carrying an aliphatic residue at position 2 and Arg anchor residue at the C-terminus. May contribute to viral load control in chronic HIV-1 infection. {ECO:0000269|PubMed:21498667}. T63239 PDBSTRUC 1AKJ;1AO7;1AQD;1B0G;1B0R;1BD2;1DUY;1DUZ;1EEY;1EEZ;1HHG;1HHH;1HHI;1HHJ;1HHK;1HLA;1HSB;1I1F;1I1Y;1I4F;1I7R;1I7T;1I7U;1IM3;1JF1;1JHT;1LP9;1OGA;1P7Q;1Q94;1QEW;1QR1;1QRN;1QSE;1QSF;1QVO;1S8D;1S9W;1S9X;1S9Y;1T1W;1T1X;1T1Y;1T1Z;1T20;1T21;1T22;1TMC;1TVB;1TVH;1W72;1X7Q;2AV1;2AV7;2BCK;2BNQ;2BNR;2C7U;2CLR;2F53;2F54;2GIT;2GJ6;2GT9;2GTW;2GTZ;2GUO;2HLA;2HN7;2J8U;2JCC;2P5E;2P5W;2PYE;2UWE;2V2W;2V2X;2VLJ;2VLK;2VLL;2VLR;2X4N;2X4O;2X4P;2X4Q;2X4R;2X4S;2X4T;2X4U;2X70;2XPG;3BGM;3BH8;3BH9;3BHB;3BO8;3D25;3D39;3D3V;3FQN;3FQR;3FQT;3FQU;3FQW;3FQX;3FT2;3FT3;3FT4;3GIV;3GJF;3GSN;3GSO;3GSQ;3GSR;3GSU;3GSV;3GSW;3GSX;3H7B;3H9H;3H9S;3HAE;3HLA;3HPJ;3I6G;3I6K;3I6L;3IXA;3KLA;3MGO;3MGT;3MR9;3MRB;3MRC;3MRD;3MRE;3MRF;3MRG;3MRH;3MRI;3MRJ;3MRK;3MRL;3MRM;3MRN;3MRO;3MRP;3MRQ;3MRR;3MYJ;3NFN;3O3A;3O3B;3O3D;3O3E;3O4L;3PWJ;3PWL;3PWN;3PWP;3QDG;3QDJ;3QDM;3QEQ;3QFD;3QFJ;3QZW;3REW;3RL1;3RL2;3TO2;3UTQ;3UTS;3UTT;3V5D;3V5H;3V5K;3VXM;3VXN;3VXO;3VXP;3VXR;3VXS;3VXU;3W0W;3WL9;3WLB;4E5X;4EMZ;4EN2;4EUP;4F7M;4F7P;4F7T;4FTV;4GKN;4GKS;4HWZ;4HX1;4I48;4I4W;4JFD;4JFE;4JFF;4JFO;4JFP;4JFQ;4K7F;4L29;4L3C;4L3E;4MJ5;4MJ6;4MNQ;4N8V;4NNX;4NNY;4NO0;4NO2;4NO3;4NO5;4NQV;4NQX;4OV5;4QOK;4U6X;4U6Y;4UQ2;4UQ3;4WJ5;4WU5;4WU7;4WUU;5BRZ;5BS0;5C07;5C08;5C09;5C0A;5C0B;5C0C;5C0D;5C0E;5C0F;5C0G;5C0I;5C0J;5D2L;5D2N;5D9S;5DDH;5E00;5E6I;5E9D;5ENW;5EOT;5EU3;5EU4;5EU5;5EU6;5EUO;5F7D;5F9J;5FA3;5FA4;5FDW;5GRD;5GRG;5GSD;5HGA;5HGB;5HGD;5HGH;5HHM;5HHN;5HHO;5HHP;5HHQ;5HYJ;5IRO;5ISZ;5JHD;5JZI;5MEN;5MEO;5MEP;5MEQ;5MER;5N1Y;5N6B;5NHT;5NME;5NMF;5NMG;5NMH;5NMK;5NQK;5SWQ;5TEZ;5W1W;5WJL;5WJN;5WKF;5WKH;5WSH;5WWI;5WWJ;5WWU;5WXC;5WXD;5XOV;5YXN;5YXU;6AM5;6AMT;6AMU;6APN;6AT9;6D78;6D7G;6DKP;6EI2;6ENY;6EQA;6EQB;6EWA;6EWC;6EWO;6G3J;6G3K;6ID4;6J1W;6J29;6J2A;6JOZ;6JP3;6MPP;6NCA;6O9B;6O9C;6OPD;6PBH;6PTB;6PTE;6Q3K;6Q3S;6R2L;6RP9;6RPA;6RPB;6RSY;6SS7;6SS8;6SS9;6SSA;7L1B;7L1C;7L1D;7MLE;7PHR;7QPD;7RK7;7RM4;7RRG;7STF;7UC5;7UX3;8D4C;8D4D;8D4E;8D4F;8D4G;8D9R;8D9S;8D9T;8D9U;8D9V;8D9W;8DVG T63239 BIOCLASS MHC class I T63239 SEQUENCE MAVMAPRTLLLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYGCDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQLRAYLDGTCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPIVGIIAGLVLLGAVITGAVVAAVMWRRKSSDRKGGSYTQAASSDSAQGSDVSLTACKV T63239 DRUGINFO DHWF68 RG6007 Phase 1 T63240 TARGETID T63240 T63240 UNIPROID LEP_ECOLI T63240 TARGNAME Signal peptidase I (lepB) T63240 GENENAME lepB T63240 TARGTYPE Clinical trial T63240 SYNONYMS SPase I; Leader peptidase I T63240 PDBSTRUC 1B12;1KN9;1T7D;3IIQ;3S04;6B88 T63240 BIOCLASS Peptidase T63240 ECNUMBER EC 3.4.21.89 T63240 SEQUENCE MANMFALILVIATLVTGILWCVDKFFFAPKRRERQAAAQAAAGDSLDKATLKKVAPKPGWLETGASVFPVLAIVLIVRSFIYEPFQIPSGSMMPTLLIGDFILVEKFAYGIKDPIYQKTLIETGHPKRGDIVVFKYPEDPKLDYIKRAVGLPGDKVTYDPVSKELTIQPGCSSGQACENALPVTYSNVEPSDFVQTFSRRNGGEATSGFFEVPKNETKENGIRLSERKETLGDVTHRILTVPIAQDQVGMYYQQPGQQLATWIVPPGQYFMMGDNRDNSADSRYWGFVPEANLVGRATAIWMSFDKQEGEWPTGLRLSRIGGIH T63240 DRUGINFO DT7GB8 RG6319 Phase 1 T63241 TARGETID T63241 T63241 UNIPROID PAPD5_HUMAN T63241 TARGNAME Terminal nucleotidyltransferase 4B (TENT4B) T63241 GENENAME TENT4B T63241 TARGTYPE Clinical trial T63241 SYNONYMS Non-canonical poly(A) RNA polymerase PAPD5; PAP-associated domain-containing protein 5; Terminal guanylyltransferase; Terminal uridylyltransferase 3; TUTase 3; Topoisomerase-related function protein 4-2; TRF4-2 T63241 FUNCTION Terminal nucleotidyltransferase that catalyzes preferentially the transfer of ATP and GTP on RNA 3' poly(A) tail creating a heterogeneous 3' poly(A) tail leading to mRNAs stabilization by protecting mRNAs from active deadenylation (PubMed:21788334, PubMed:30026317). Also functions as a catalytic subunit of a TRAMP-like complex which has a poly(A) RNA polymerase activity and is involved in a post-transcriptional quality control mechanism. Polyadenylation with short oligo(A) tails is required for the degradative activity of the exosome on several of its nuclear RNA substrates. Doesn't need a cofactor for polyadenylation activity (in vitro) (PubMed:21788334, PubMed:21855801). Required for cytoplasmic polyadenylation of mRNAs involved in carbohydrate metabolism, including the glucose transporter SLC2A1/GLUT1 (PubMed:28383716). Plays a role in replication-dependent histone mRNA degradation, probably through terminal uridylation of mature histone mRNAs. May play a role in sister chromatid cohesion (PubMed:18172165). Mediates 3' adenylation of the microRNA MIR21 followed by its 3'-to-5' trimming by the exoribonuclease PARN leading to degradation (PubMed:25049417). Mediates 3' adenylation of H/ACA box snoRNAs (small nucleolar RNAs) followed by its 3'-to-5' trimming by the exoribonuclease PARN which enhances snoRNA stability and maturation (PubMed:22442037). {ECO:0000269|PubMed:18172165, ECO:0000269|PubMed:21788334, ECO:0000269|PubMed:21855801, ECO:0000269|PubMed:22442037, ECO:0000269|PubMed:25049417, ECO:0000269|PubMed:28383716, ECO:0000269|PubMed:30026317}. T63241 BIOCLASS DNA polymerase type-B T63241 ECNUMBER EC 2.7.7.-; EC 2.7.7.19 T63241 SEQUENCE MYRSGERLLGSHALPAEQRDFLPLETTNNNNNHHQPGAWARRAGSSASSPPSASSSPHPSAAVPAADPADSASGSSNKRKRDNKASGGRAAGGGRADGGGVVYSGTPWKRRNYNQGVVGLHEEISDFYEYMSPRPEEEKMRMEVVNRIESVIKELWPSADVQIFGSFKTGLYLPTSDIDLVVFGKWENLPLWTLEEALRKHKVADEDSVKVLDKATVPIIKLTDSFTEVKVDISFNVQNGVRAADLIKDFTKKYPVLPYLVLVLKQFLLQRDLNEVFTGGIGSYSLFLMAVSFLQLHPREDACIPNTNYGVLLIEFFELYGRHFNYLKTGIRIKDGGSYVAKDEVQKNMLDGYRPSMLYIEDPLQPGNDVGRSSYGAMQVKQAFDYAYVVLSHAVSPIAKYYPNNETESILGRIIRVTDEVATYRDWISKQWGLKNRPEPSCNGPVSSSSATQSSSSDVDSDATPCKTPKQLLCRPSTGNRVGSQDVSLESSQAVGKMQSTQTTNTSNSTNKSQHGSARLFRSSSKGFQGTTQTSHGSLMTNKQHQGKSNNQYYHGKKRKHKRDAPLSDLCR T63241 DRUGINFO D7PWY2 GSK3965193 Phase 1 T63242 TARGETID T63242 T63242 UNIPROID PAPD7_HUMAN T63242 TARGNAME Terminal nucleotidyltransferase 4A (TENT4A) T63242 GENENAME TENT4A T63242 TARGTYPE Clinical trial T63242 SYNONYMS DNA polymerase sigma; LAK-1; Non-canonical poly(A) RNA polymerase PAPD7; PAP-associated domain-containing protein 7; TRAMP-like complex polyadenylate polymerase; Terminal guanylyltransferase; Terminal uridylyltransferase 5; TUTase 5; Topoisomerase-related function protein 4-1; TRF4-1 T63242 FUNCTION Terminal nucleotidyltransferase that catalyzes preferentially the transfer of ATP and GTP on RNA 3' poly(A) tail creating a heterogeneous 3' poly(A) tail leading to mRNAs stabilization by protecting mRNAs from active deadenylation (PubMed:23376078, PubMed:30026317). Also functions as a catalytic subunit of a TRAMP-like complex which has a poly(A) RNA polymerase activity and is involved in a post-transcriptional quality control mechanism. Polyadenylation with short oligo(A) tails is required for the degradative activity of the exosome on several of its nuclear RNA substrates. Has no terminal uridylyltransferase activity, and does not play a role in replication-dependent histone mRNA degradation via uridylation (PubMed:23376078). {ECO:0000269|PubMed:23376078, ECO:0000269|PubMed:30026317}. T63242 BIOCLASS DNA polymerase type-B T63242 ECNUMBER EC 2.7.7.-; EC 2.7.7.19 T63242 SEQUENCE MDPRVAWIQPEQKGPANALWMQIWETSQGVGRGGSGFASYFCLNSPALDTAAAAGAAGRGSGGLGPALPAASPPPPGPTAPAALPPALLTALGPAAEGARRLHKSPSLSSSSSSSSSNAESGTESPGCSSSSSSSASLGRPGGGRGGAFFNFADGAPSAPGTANGHPGPRGPAPAGSPSQHQFHPGRRKRENKASTYGLNYLLSGSRAAALSGGGGPGAQAPRPGTPWKSRAYSPGIQGLHEEIIDFYNFMSPCPEEAAMRREVVKRIETVVKDLWPTADVQIFGSFSTGLYLPTSDIDLVVFGKWERPPLQLLEQALRKHNVAEPCSIKVLDKATVPIIKLTDQETEVKVDISFNMETGVRAAEFIKNYMKKYSLLPYLILVLKQFLLQRDLNEVFTGGISSYSLILMAISFLQLHPRIDARRADENLGMLLVEFFELYGRNFNYLKTGIRIKEGGAYIAKEEIMKAMTSGYRPSMLCIEDPLLPGNDVGRSSYGAMQVKQVFDYAYIVLSHAVSPLARSYPNRDAESTLGRIIKVTQEVIDYRRWIKEKWGSKAHPSPGMDSRIKIKERIATCNGEQTQNREPESPYGQRLTLSLSSPQLLSSGSSASSVSSLSGSDVDSDTPPCTTPSVYQFSLQAPAPLMAGLPTALPMPSGKPQPTTSRTLIMTTNNQTRFTIPPPTLGVAPVPCRQAGVEGTASLKAVHHMSSPAIPSASPNPLSSPHLYHKQHNGMKLSMKGSHGHTQGGGYSSVGSGGVRPPVGNRGHHQYNRTGWRRKKHTHTRDSLPVSLSR T63242 DRUGINFO D7PWY2 GSK3965193 Phase 1 T63160 TARGETID T63160 T63160 UNIPROID APOL1_HUMAN T63160 TARGNAME Apolipoprotein L1 messenger RNA (APOL1 mRNA) T63160 GENENAME APOL1 T63160 TARGTYPE Clinical trial T63160 SYNONYMS Apolipoprotein L (mRNA); Apo-L (mRNA); ApoL (mRNA); Apolipoprotein L-I (mRNA); ApoL-I (mRNA) T63160 FUNCTION May play a role in lipid exchange and transport throughout the body. May participate in reverse cholesterol transport from peripheral cells to the liver. T63160 PDBSTRUC 7L6K;7LF7;7LFA;7LFB;7LFD T63160 BIOCLASS mRNA target T63160 SEQUENCE MEGAALLRVSVLCIWMSALFLGVGVRAEEAGARVQQNVPSGTDTGDPQSKPLGDWAAGTMDPESSIFIEDAIKYFKEKVSTQNLLLLLTDNEAWNGFVAAAELPRNEADELRKALDNLARQMIMKDKNWHDKGQQYRNWFLKEFPRLKSELEDNIRRLRALADGVQKVHKGTTIANVVSGSLSISSGILTLVGMGLAPFTEGGSLVLLEPGMELGITAALTGITSSTMDYGKKWWTQAQAHDLVIKSLDKLKEVREFLGENISNFLSLAGNTYQLTRGIGKDIRALRRARANLQSVPHASASRPRVTEPISAESGEQVERVNEPSILEMSRGVKLTDVAPVSFFLVLDVVYLVYESKHLHEGAKSETAEELKKVAQELEEKLNILNNNYKILQADQEL T63160 DRUGINFO DR07FQ ION532 Phase 1 T63161 TARGETID T63161 T63161 UNIPROID ATX3_HUMAN T63161 TARGNAME Ataxin-3 messenger RNA (ATXN3 mRNA) T63161 GENENAME ATXN3 T63161 TARGTYPE Clinical trial T63161 SYNONYMS Machado-Joseph disease protein 1 (mRNA); Spinocerebellar ataxia type 3 protein (mRNA) T63161 FUNCTION Deubiquitinating enzyme involved in protein homeostasis maintenance, transcription, cytoskeleton regulation, myogenesis and degradation of misfolded chaperone substrates (PubMed:12297501, PubMed:17696782, PubMed:23625928, PubMed:28445460, PubMed:33157014, PubMed:16118278). Binds long polyubiquitin chains and trims them, while it has weak or no activity against chains of 4 or less ubiquitins (PubMed:17696782). Involved in degradation of misfolded chaperone substrates via its interaction with STUB1/CHIP: recruited to monoubiquitinated STUB1/CHIP, and restricts the length of ubiquitin chain attached to STUB1/CHIP substrates and preventing further chain extension (By similarity). Interacts with key regulators of transcription and represses transcription: acts as a histone-binding protein that regulates transcription (PubMed:12297501). Acts as a negative regulator of mTORC1 signaling in response to amino acid deprivation by mediating deubiquitination of RHEB, thereby promoting RHEB inactivation by the TSC-TBC complex (PubMed:33157014). Regulates autophagy via the deubiquitination of 'Lys-402' of BECN1 leading to the stabilization of BECN1 (PubMed:28445460). {ECO:0000250|UniProtKB:Q9CVD2, ECO:0000269|PubMed:12297501, ECO:0000269|PubMed:16118278, ECO:0000269|PubMed:17696782, ECO:0000269|PubMed:23625928, ECO:0000269|PubMed:28445460, ECO:0000269|PubMed:33157014}. T63161 PDBSTRUC 1YZB;2AGA;2DOS;2JRI;2KLZ;4WTH;4YS9 T63161 BIOCLASS mRNA target T63161 ECNUMBER EC 3.4.19.12 T63161 SEQUENCE MESIFHEKQEGSLCAQHCLNNLLQGEYFSPVELSSIAHQLDEEERMRMAEGGVTSEDYRTFLQQPSGNMDDSGFFSIQVISNALKVWGLELILFNSPEYQRLRIDPINERSFICNYKEHWFTVRKLGKQWFNLNSLLTGPELISDTYLALFLAQLQQEGYSIFVVKGDLPDCEADQLLQMIRVQQMHRPKLIGEELAQLKEQRVHKTDLERVLEANDGSGMLDEDEEDLQRALALSRQEIDMEDEEADLRRAIQLSMQGSSRNISQDMTQTSGTNLTSEELRKRREAYFEKQQQKQQQQQQQQQQGDLSGQSSHPCERPATSSGALGSDLGDAMSEEDMLQAAVTMSLETVRNDLKTEGKK T63161 DRUGINFO DFXP94 BIIB132 Phase 1 T63161 DRUGINFO DP5J8S ION260 Phase 1 T63167 TARGETID T63167 T63167 UNIPROID CO3_HUMAN T63167 TARGNAME Complement C3 messenger RNA (C3 mRNA) T63167 GENENAME C3 T63167 TARGTYPE Clinical trial T63167 SYNONYMS C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 (mRNA) T63167 FUNCTION C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.; Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. {ECO:0000250}.; [C3-beta-c]: Acts as a chemoattractant for neutrophils in chronic inflammation. {ECO:0000250}.; [Acylation stimulating protein]: Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750). {ECO:0000269|PubMed:10432298, ECO:0000269|PubMed:15833747, ECO:0000269|PubMed:16333141, ECO:0000269|PubMed:19615750, ECO:0000269|PubMed:2909530, ECO:0000269|PubMed:8376604, ECO:0000269|PubMed:9059512}. T63167 PDBSTRUC 1C3D;1GHQ;1W2S;2A73;2A74;2GOX;2I07;2ICE;2ICF;2NOJ;2QKI;2WII;2WIN;2WY7;2WY8;2XQW;2XWB;2XWJ;3D5R;3D5S;3G6J;3L3O;3L5N;3NMS;3OED;3OHX;3OXU;3RJ3;3T4A;4HW5;4HWJ;4I6O;4M76;4ONT;4ZH1;5FO7;5FO8;5FO9;5FOA;5FOB;5NBQ;5O32;5O35;6EHG;6RMT;6RMU;6RUR;6RUV;6S0B;6YO6;7AKK;7BAG;7NOZ;7PI6;7QIV;7TV9;7UE9;7ZGK;8HK2 T63167 BIOCLASS mRNA target T63167 SEQUENCE MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVHDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKVVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSLSSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTEKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEVVLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKTPKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPLSITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMDRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGASGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDKGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAELQCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEACKKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKEPPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVVRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVIVPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKEDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTPTVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTAYVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKDMALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMGRLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLRSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDAKNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSDRNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDGKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDEYIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSYIIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN T63167 DRUGINFO D2O5WA ALXN2030 Phase 1 T63169 TARGETID T63169 T63169 UNIPROID G6PC1_HUMAN T63169 TARGNAME Glucose-6-phosphatase catalytic subunit 1 messenger RNA (G6PC1 mRNA) T63169 GENENAME G6PC1 T63169 TARGTYPE Clinical trial T63169 SYNONYMS Glucose-6-phosphatase (mRNA); G-6-Pase (mRNA); G6Pase (mRNA); Glucose-6-phosphatase alpha (mRNA); G6Pase-alpha (mRNA) T63169 FUNCTION Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum. Forms with the glucose-6-phosphate transporter (SLC37A4/G6PT) the complex responsible for glucose production in the terminal step of glycogenolysis and gluconeogenesis. Hence, it is the key enzyme in homeostatic regulation of blood glucose levels. {ECO:0000269|PubMed:10960498, ECO:0000269|PubMed:12093795, ECO:0000269|PubMed:15542400, ECO:0000269|PubMed:9332655, ECO:0000269|PubMed:9497333}. T63169 BIOCLASS mRNA target T63169 ECNUMBER EC 3.1.3.9 T63169 SEQUENCE MEEGMNVLHDFGIQSTHYLQVNYQDSQDWFILVSVIADLRNAFYVLFPIWFHLQEAVGIKLLWVAVIGDWLNLVFKWILFGQRPYWWVLDTDYYSNTSVPLIKQFPVTCETGPGSPSGHAMGTAGVYYVMVTSTLSIFQGKIKPTYRFRCLNVILWLGFWAVQLNVCLSRIYLAAHFPHQVVAGVLSGIAVAETFSHIHSIYNASLKKYFLITFFLFSFAIGFYLLLKGLGVDLLWTLEKAQRWCEQPEWVHIDTTPFASLLKNLGTLFGLGLALNSSMYRESCKGKLSKWLPFRLSSIVASLVLLHVFDSLKPPSQVELVFYVLSFCKSAVVPLASVSVIPYCLAQVLGQPHKKSL T63169 DRUGINFO DO40BQ mRNA-3745 Phase 1 T63177 TARGETID T63177 T63177 UNIPROID LRRK2_HUMAN T63177 TARGNAME Leucine-rich repeat serine/threonine-protein kinase 2 messenger RNA (LRRK2 mRNA) T63177 GENENAME LRRK2 T63177 TARGTYPE Clinical trial T63177 SYNONYMS Dardarin (mRNA) T63177 FUNCTION Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:20949042, PubMed:22012985, PubMed:26824392, PubMed:27830463, PubMed:29125462, PubMed:28720718, PubMed:29127255, PubMed:30398148, PubMed:29212815, PubMed:30635421, PubMed:21850687, PubMed:23395371, PubMed:17114044, PubMed:24687852, PubMed:26014385, PubMed:25201882). Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation (PubMed:26824392, PubMed:28720718, PubMed:29127255, PubMed:30398148, PubMed:29212815, PubMed:29125462, PubMed:30635421). Phosphorylates RAB3A, RAB3B, RAB3C, RAB3D, RAB5A, RAB5B, RAB5C, RAB8A, RAB8B, RAB10, RAB12, RAB35, and RAB43 (PubMed:26824392, PubMed:28720718, PubMed:29127255, PubMed:30398148, PubMed:29212815, PubMed:29125462, PubMed:30635421, PubMed:23395371). Regulates the RAB3IP-catalyzed GDP/GTP exchange for RAB8A through the phosphorylation of 'Thr-72' on RAB8A (PubMed:26824392). Inhibits the interaction between RAB8A and GDI1 and/or GDI2 by phosphorylating 'Thr-72' on RAB8A (PubMed:26824392). Regulates primary ciliogenesis through phosphorylation of RAB8A and RAB10, which promotes SHH signaling in the brain (PubMed:29125462, PubMed:30398148). Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner (PubMed:23395371). Regulates neuronal process morphology in the intact central nervous system (CNS) (PubMed:17114044). Plays a role in synaptic vesicle trafficking (PubMed:24687852). Plays an important role in recruiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization (PubMed:25201882). Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway (PubMed:22012985). The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes (PubMed:22012985). Phosphorylates PRDX3 (PubMed:21850687). By phosphorylating APP on 'Thr-743', which promotes the production and the nuclear translocation of the APP intracellular domain (AICD), regulates dopaminergic neuron apoptosis (PubMed:28720718). Acts as a positive regulator of innate immunity by mediating phosphorylation of RIPK2 downstream of NOD1 and NOD2, thereby enhancing RIPK2 activation (PubMed:27830463). Independent of its kinase activity, inhibits the proteasomal degradation of MAPT, thus promoting MAPT oligomerization and secretion (PubMed:26014385). In addition, has GTPase activity via its Roc domain which regulates LRRK2 kinase activity (PubMed:18230735, PubMed:26824392, PubMed:29125462, PubMed:28720718, PubMed:29212815). {ECO:0000269|PubMed:17114044, ECO:0000269|PubMed:18230735, ECO:0000269|PubMed:20949042, ECO:0000269|PubMed:21850687, ECO:0000269|PubMed:22012985, ECO:0000269|PubMed:23395371, ECO:0000269|PubMed:24687852, ECO:0000269|PubMed:25201882, ECO:0000269|PubMed:26014385, ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:27830463, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29127255, ECO:0000269|PubMed:29212815, ECO:0000269|PubMed:30398148, ECO:0000269|PubMed:30635421}. T63177 PDBSTRUC 2ZEJ;3D6T;5MY9;5MYC;6DLO;6DLP;6OJE;6OJF;6VNO;6VP6;6VP7;6XAF;6XR4;7LHT;7LHW;7LI3;7LI4;7THY;7THZ T63177 BIOCLASS mRNA target T63177 ECNUMBER EC 2.7.11.1; EC 3.6.5.- T63177 SEQUENCE MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLVFTYSERASKLFQGKNIHVPLLIVLDSYMRVASVQQVGWSLLCKLIEVCPGTMQSLMGPQDVGNDWEVLGVHQLILKMLTVHNASVNLSVIGLKTLDLLLTSGKITLLILDEESDIFMLIFDAMHSFPANDEVQKLGCKALHVLFERVSEEQLTEFVENKDYMILLSALTNFKDEEEIVLHVLHCLHSLAIPCNNVEVLMSGNVRCYNIVVEAMKAFPMSERIQEVSCCLLHRLTLGNFFNILVLNEVHEFVVKAVQQYPENAALQISALSCLALLTETIFLNQDLEEKNENQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDEDGHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQKHIHSPEVAESGCKMLNHLFEGSNTSLDIMAAVVPKILTVMKRHETSLPVQLEALRAILHFIVPGMPEESREDTEFHHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKVISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLIGYLITKKNVFIGTGHLLAKILVSSLYRFKDVAEIQTKGFQTILAILKLSASFSKLLVHHSFDLVIFHQMSSNIMEQKDQQFLNLCCKCFAKVAMDDYLKNVMLERACDQNNSIMVECLLLLGADANQAKEGSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGKGDSQIISLLLRRLALDVANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEEGTASGSDGNFSEDVLSKFDEWTFIPDSSMDSVFAQSDDLDSEGSEGSFLVKKKSNSISVGEFYRDAVLQRCSPNLQRHSNSLGPIFDHEDLLKRKRKILSSDDSLRSSKLQSHMRHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMKLMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACMSKITKELLNKRGFPAIRDYHFVNATEESDALAKLRKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE T63177 DRUGINFO D2AO6J BIIB094 Phase 1 T63180 TARGETID T63180 T63180 UNIPROID MUC5A_HUMAN T63180 TARGNAME Mucin-5AC messenger RNA (MUC5AC mRNA) T63180 GENENAME MUC5AC T63180 TARGTYPE Clinical trial T63180 SYNONYMS MUC-5AC (mRNA); Gastric mucin (mRNA); Major airway glycoprotein (mRNA); Mucin-5 subtype AC, tracheobronchial (mRNA); Tracheobronchial mucin (mRNA); TBM (mRNA) T63180 FUNCTION Gel-forming glycoprotein of gastric and respiratory tract epithelia that protects the mucosa from infection and chemical damage by binding to inhaled microorganisms and particles that are subsequently removed by the mucociliary system (PubMed:14535999, PubMed:14718370). Interacts with H.pylori in the gastric epithelium, Barrett's esophagus as well as in gastric metaplasia of the duodenum (GMD) (PubMed:14535999). {ECO:0000269|PubMed:14535999, ECO:0000303|PubMed:14535999, ECO:0000303|PubMed:14718370}. T63180 PDBSTRUC 5AJN;5AJO;5AJP T63180 BIOCLASS mRNA target T63180 SEQUENCE MSVGRRKLALLWALALALACTRHTGHAQDGSSESSYKHHPALSPIARGPSGVPLRGATVFPSLRTIPVVRASNPAHNGRVCSTWGSFHYKTFDGDVFRFPGLCNYVFSEHCGAAYEDFNIQLRRSQESAAPTLSRVLMKVDGVVIQLTKGSVLVNGHPVLLPFSQSGVLIQQSSSYTKVEARLGLVLMWNHDDSLLLELDTKYANKTCGLCGDFNGMPVVSELLSHNTKLTPMEFGNLQKMDDPTDQCQDPVPEPPRNCSTGFGICEELLHGQLFSGCVALVDVGSYLEACRQDLCFCEDTDLLSCVCHTLAEYSRQCTHAGGLPQDWRGPDFCPQKCPNNMQYHECRSPCADTCSNQEHSRACEDHCVAGCFCPEGTVLDDIGQTGCVPVSKCACVYNGAAYAPGATYSTDCTNCTCSGGRWSCQEVPCPGTCSVLGGAHFSTFDGKQYTVHGDCSYVLTKPCDSSAFTVLAELRRCGLTDSETCLKSVTLSLDGAQTVVVIKASGEVFLNQIYTQLPISAANVTIFRPSTFFIIAQTSLGLQLNLQLVPTMQLFMQLAPKLRGQTCGLCGNFNSIQADDFRTLSGVVEATAAAFFNTFKTQAACPNIRNSFEDPCSLSVENEKYAQHWCSQLTDADGPFGRCHAAVKPGTYYSNCMFDTCNCERSEDCLCAALSSYVHACAAKGVQLGGWRDGVCTKPMTTCPKSMTYHYHVSTCQPTCRSLSEGDITCSVGFIPVDGCICPKGTFLDDTGKCVQASNCPCYHRGSMIPNGESVHDSGAICTCTHGKLSCIGGQAPAPVCAAPMVFFDCRNATPGDTGAGCQKSCHTLDMTCYSPQCVPGCVCPDGLVADGEGGCITAEDCPCVHNEASYRAGQTIRVGCNTCTCDSRMWRCTDDPCLATCAVYGDGHYLTFDGQSYSFNGDCEYTLVQNHCGGKDSTQDSFRVVTENVPCGTTGTTCSKAIKIFLGGFELKLSHGKVEVIGTDESQEVPYTIRQMGIYLVVDTDIGLVLLWDKKTSIFINLSPEFKGRVCGLCGNFDDIAVNDFATRSRSVVGDVLEFGNSWKLSPSCPDALAPKDPCTANPFRKSWAQKQCSILHGPTFAACHAHVEPARYYEACVNDACACDSGGDCECFCTAVAAYAQACHEVGLCVSWRTPSICPLFCDYYNPEGQCEWHYQPCGVPCLRTCRNPRGDCLRDVRGLEGCYPKCPPEAPIFDEDKMQCVATCPTPPLPPRCHVHGKSYRPGAVVPSDKNCQSCLCTERGVECTYKAEACVCTYNGQRFHPGDVIYHTTDGTGGCISARCGANGTIERRVYPCSPTTPVPPTTFSFSTPPLVVSSTHTPSNGPSSAHTGPPSSAWPTTAGTSPRTRLPTASASLPPVCGEKCLWSPWMDVSRPGRGTDSGDFDTLENLRAHGYRVCESPRSVECRAEDAPGVPLRALGQRVQCSPDVGLTCRNREQASGLCYNYQIRVQCCTPLPCSTSSSPAQTTPPTTSKTTETRASGSSAPSSTPGTVSLSTARTTPAPGTATSVKKTFSTPSPPPVPATSTSSMSTTAPGTSVVSSKPTPTEPSTSSCLQELCTWTEWIDGSYPAPGINGGDFDTFQNLRDEGYTFCESPRSVQCRAESFPNTPLADLGQDVICSHTEGLICLNKNQLPPICYNYEIRIQCCETVNVCRDITRLPKTVATTRPTPHPTGAQTQTTFTTHMPSASTEQPTATSRGGPTATSVTQGTHTTLVTRNCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPRGCHMTSTPGSTSSSPAQTTPSTTSKTTETQASGSSAPSSTPGTVSLSTARTTPAPGTATSVKKTFSTPSPPPVPATSTSSMSTTAPGTSVVSSKPTPTEPSTSSCLQELCTWTEWIDGSYPAPGINGGDFDTFQNLRDEGYTFCESPRSVQCRAESFPNTPLADLGQDVICSHTEGLICLNKNQLPPICYNYEIRIQCCETVNVCRDITRPPKTVATTRPTPHPTGAQTQTTFTTHMPSASTEQPTATSRGGPTATSVTQGTHTTPVTRNCHPRCTWTTWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTYAHTTSTTSAPTARTTSAPTTRTTSASPASTTSGPGNTPSPVPTTSTISAPTTSITSAPTTSTTSAPTSSTTSGPGTTPSPVPTTSITSAPTTSTTSAPTTSTTSARTSSTTSATTTSRISGPETTPSPVPTTSTTSATTTSTTSAPTTSTTSAPTSSTTSSPQTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPTTRTTSAPKSSTTSAATTSTTSGPETTPRPVPTTSTTSSPTTSTTSAPTTSTTSASTTSTTSGAGTTPSPVPTTSTTSAPTTSTTSAPISSTTSATTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSAVPTTSITSAPTTSTNSAPISSTTSATTTSRISGPETTPSPVPTASTTSASTTSTTSGPGTTPSPVPTTSTISVPTTSTTSASTTSTTSASTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSAPTTSTISAPTTSTTSATTTSTTSAPTPRRTSAPTTSTISASTTSTTSATTTSTTSATTTSTISAPTTSTTLSPTTSTTSTTITSTTSAPISSTTSTPQTSTTSAPTTSTTSGPGTTSSPVPTTSTTSAPTTSTTSAPTTRTTSVPTSSTTSTATTSTTSGPGTTPSPVPTTSTTSAPTTRTTSAPTTSTTSAPTTSTTSAPTSSTTSATTTSTISVPTTSTTSVPGTTPSPVPTTSTISVPTTSTTSASTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSAPTTSTISAPTTSTPSAPTTSTTLAPTTSTTSAPTTSTTSTPTSSTTSSPQTSTTSASTTSITSGPGTTPSPVPTTSTTSAPTTSTTSAATTSTISAPTTSTTSAPTTSTTSASTASKTSGLGTTPSPIPTTSTTSPPTTSTTSASTASKTSGPGTTPSPVPTTSTIFAPRTSTTSASTTSTTPGPGTTPSPVPTTSTASVSKTSTSHVSISKTTHSQPVTRDCHLRCTWTKWFDIDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTSAPTTSTTSAPTTSTTSAPTTSTTSTPQTSISSAPTSSTTSAPTSSTISARTTSIISAPTTSTTSSPTTSTTSATTTSTTSAPTSSTTSTPQTSKTSAATSSTTSGSGTTPSPVTTTSTASVSKTSTSHVSVSKTTHSQPVTRDCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTSVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTSSITSTTQTSTTSAPTTSTTPASIPSTTSAPTTSTTSAPTTSTTSAPTTSTTSTPQTTTSSAPTSSTTSAPTTSTISAPTTSTISAPTTSTTSAPTASTTSAPTSTSSAPTTNTTSAPTTSTTSAPITSTISAPTTSTTSTPQTSTISSPTTSTTSTPQTSTTSSPTTSTTSAPTTSTTSAPTTSTTSTPQTSISSAPTSSTTSAPTASTISAPTTSTTSFHTTSTTSPPTSSTSSTPQTSKTSAATSSTTSGSGTTPSPVPTTSTASVSKTSTSHVSVSKTTHSQPVTRDCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTSAPTTSTIPASTPSTTSAPTTSTTSAPTTSTTSAPTHRTTSGPTTSTTLAPTTSTTSAPTTSTNSAPTTSTISASTTSTISAPTTSTISSPTSSTTSTPQTSKTSAATSSTTSGSGTTPSPVPTTSTTSASTTSTTSAPTTSTTSGPGTTPSPVPSTSTTSAATTSTTSAPTTRTTSAPTSSMTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPITSTTSGPGSTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTTPSPVPTTSTTSAPTTRTTSASTASTTSGPGSTPSPVPTTSTTSAPTTRTTPASTASTTSGPGTTPSPVPTTSTTSASTTSTISLPTTSTTSAPITSMTSGPGTTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTSLSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTPVSKTSTSHLSVSKTTHSQPVTSDCHPLCAWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVNIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPRGCPVTSVTPYGTSPTNALYPSLSTSMVSASVASTSVASSSVASSSVAYSTQTCFCNVADRLYPAGSTIYRHRDLAGHCYYALCSQDCQVVRGVDSDCPSTTLPPAPATSPSISTSEPVTELGCPNAVPPRKKGETWATPNCSEATCEGNNVISLRPRTCPRVEKPTCANGYPAVKVADQDGCCHHYQCQCVCSGWGDPHYITFDGTYYTFLDNCTYVLVQQIVPVYGHFRVLVDNYFCGAEDGLSCPRSIILEYHQDRVVLTRKPVHGVMTNEIIFNNKVVSPGFRKNGIVVSRIGVKMYATIPELGVQVMFSGLIFSVEVPFSKFANNTEGQCGTCTNDRKDECRTPRGTVVASCSEMSGLWNVSIPDQPACHRPHPTPTTVGPTTVGSTTVGPTTVGSTTVGPTTPPAPCLPSPICQLILSKVFEPCHTVIPPLLFYEGCVFDRCHMTDLDVVCSSLELYAALCASHDICIDWRGRTGHMCPFTCPADKVYQPCGPSNPSYCYGNDSASLGALPEAGPITEGCFCPEGMTLFSTSAQVCVPTGCPRCLGPHGEPVKVGHTVGMDCQECTCEAATWTLTCRPKLCPLPPACPLPGFVPVPAAPQAGQCCPQYSCACNTSRCPAPVGCPEGARAIPTYQEGACCPVQNCSWTVCSINGTLYQPGAVVSSSLCETCRCELPGGPPSDAFVVSCETQICNTHCPVGFEYQEQSGQCCGTCVQVACVTNTSKSPAHLFYPGETWSDAGNHCVTHQCEKHQDGLVVVTTKKACPPLSCSLDEARMSKDGCCRFCPPPPPPYQNQSTCAVYHRSLIIQQQGCSSSEPVRLAYCRGNCGDSSSMYSLEGNTVEHRCQCCQELRTSLRNVTLHCTDGSSRAFSYTEVEECGCMGRRCPAPGDTQHSEEAEPEPSQEAESGSWERGVPVSPMH T63180 DRUGINFO D17DXO ARO-MUC5AC Phase 1 T63184 TARGETID T63184 T63184 UNIPROID RAGE_HUMAN T63184 TARGNAME Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA) T63184 GENENAME AGER T63184 TARGTYPE Clinical trial T63184 SYNONYMS Receptor for advanced glycosylation end products (mRNA) T63184 FUNCTION Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, phospholipids and glycosaminoglycans (PubMed:27572515, PubMed:28515150, PubMed:34743181). Advanced glycosylation end products are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes (PubMed:21565706). These ligands accumulate at inflammatory sites during the pathogenesis of various diseases, including diabetes, vascular complications, neurodegenerative disorders, and cancers and RAGE transduces their binding into pro-inflammatory responses. Upon ligand binding, uses TIRAP and MYD88 as adapters to transduce the signal ultimately leading to the induction or inflammatory cytokines IL6, IL8 and TNFalpha through activation of NF-kappa-B (PubMed:21829704). Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key pro-inflammatory mediators (PubMed:19386136). Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons (PubMed:19906677). ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Participates in endothelial albumin transcytosis together with HMGB1 through the RAGE/SRC/Caveolin-1 pathway, leading to endothelial hyperpermeability (PubMed:27572515). Mediates the loading of HMGB1 in extracellular vesicles (EVs) that shuttle HMGB1 to hepatocytes by transferrin-mediated endocytosis and subsequently promote hepatocyte pyroptosis by activating the NLRP3 inflammasome (PubMed:34743181). Promotes also extracellular hypomethylated DNA (CpG DNA) uptake by cells via the endosomal route to activate inflammatory responses (PubMed:24081950, PubMed:28515150). {ECO:0000250|UniProtKB:Q62151, ECO:0000269|PubMed:19906677, ECO:0000269|PubMed:20943659, ECO:0000269|PubMed:21559403, ECO:0000269|PubMed:21565706, ECO:0000269|PubMed:21829704, ECO:0000269|PubMed:24081950, ECO:0000269|PubMed:27572515, ECO:0000269|PubMed:28515150, ECO:0000269|PubMed:34743181}. T63184 PDBSTRUC 2E5E;2ENS;2L7U;2LE9;2LMB;2M1K;2MJW;2MOV;3CJJ;3O3U;4LP4;4LP5;4OF5;4OFV;4OI7;4OI8;4P2Y;4XYN;4YBH;5D7F;6VXG;6XQ1;6XQ3;6XQ5;6XQ6;6XQ7;6XQ8;6XQ9;7LML;7LMW T63184 BIOCLASS mRNA target T63184 SEQUENCE MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGVILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP T63184 DRUGINFO D8JN6C ARO-RAGE Phase 1 T63200 TARGETID T63200 T63200 UNIPROID XDH_HUMAN T63200 TARGNAME Xanthine dehydrogenase/oxidase messenger RNA (XDH mRNA) T63200 GENENAME XDH T63200 TARGTYPE Clinical trial T63200 FUNCTION Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro). {ECO:0000269|PubMed:17301077}. T63200 PDBSTRUC 2CKJ;2E1Q T63200 BIOCLASS mRNA target T63200 ECNUMBER EC 1.17.1.4; EC 1.17.3.2 T63200 SEQUENCE MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDRLQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGIVMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCCMNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQASTLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFGAACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISDLNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSAFKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKEELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLDPTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRYENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDKVTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDLKKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKMLGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGRHPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGRLCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKLEGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGALLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAASVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLGYSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAFVQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAVGEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVTGVPENCKPWSVRV T63200 DRUGINFO DZDL28 ALN-XDH Phase 1/2 T63201 TARGETID T63201 T63201 UNIPROID ANGT_HUMAN T63201 TARGNAME Angiotensinogen messenger RNA (AGT mRNA) T63201 GENENAME AGT T63201 TARGTYPE Clinical trial T63201 SYNONYMS Serpin A8 (mRNA) T63201 FUNCTION Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis. {ECO:0000269|PubMed:10619573, ECO:0000269|PubMed:1132082, ECO:0000269|PubMed:17138938}.; [Angiotensin-2]: Acts directly on vascular smooth muscle as a potent vasoconstrictor, affects cardiac contractility and heart rate through its action on the sympathetic nervous system, and alters renal sodium and water absorption through its ability to stimulate the zona glomerulosa cells of the adrenal cortex to synthesize and secrete aldosterone (PubMed:10619573, PubMed:17138938). Acts by binding to angiotensin receptors AGTR1 and AGTR2 (PubMed:1567413). Also binds the DEAR/FBXW7-AS1 receptor (By similarity). {ECO:0000250|UniProtKB:P01015, ECO:0000269|PubMed:10619573, ECO:0000269|PubMed:1567413, ECO:0000269|PubMed:17138938}.; [Angiotensin-3]: Stimulates aldosterone release. {ECO:0000269|PubMed:1132082}.; [Angiotensin 1-7]: Is a ligand for the G-protein coupled receptor MAS1 (By similarity). Has vasodilator and antidiuretic effects. Has an antithrombotic effect that involves MAS1-mediated release of nitric oxide from platelets (By similarity). {ECO:0000250|UniProtKB:P11859}. T63201 PDBSTRUC 1N9U;1N9V;2JP8;2WXW;2X0B;3CK0;3WOO;3WOR;4AA1;4APH;4FYS;5E2Q;5M3X;5M3Y;5XJM;6I3F;6I3I;6JOD;6OS0;7C6A T63201 BIOCLASS mRNA target T63201 SEQUENCE MRKRAPQSEMAPAGVSLRATILCLLAWAGLAAGDRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGALDHTADRLQAILGVPWKDKNCTSRLDAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGCSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDNSTSVSVPMLSGMGTFQHWSDIQDNFSVTQVPFTESACLLLIQPHYASDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIRVGEVLNSIFFELEADEREPTESTQQLNKPEVLEVTLNRPFLFAVYDQSATALHFLGRVANPLSTA T63201 DRUGINFO D30EZF Zilebesiran Phase 2 T63201 DRUGINFO DLQS16 ION904 Phase 2 T63203 TARGETID T63203 T63203 UNIPROID ATX2_HUMAN T63203 TARGNAME Ataxin-2 messenger RNA (ATXN2 mRNA) T63203 GENENAME ATXN2 T63203 TARGTYPE Clinical trial T63203 SYNONYMS Spinocerebellar ataxia type 2 protein (mRNA); Trinucleotide repeat-containing gene 13 protein (mRNA) T63203 FUNCTION Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane. {ECO:0000269|PubMed:18602463}. T63203 PDBSTRUC 3KTR T63203 BIOCLASS mRNA target T63203 SEQUENCE MRSAAAAPRSPAVATESRRFAAARWPGWRSLQRPARRSGRGGGGAAPGPYPSAAPPPPGPGPPPSRQSSPPSASDCFGSNGNGGGAFRPGSRRLLGLGGPPRPFVVLLLPLASPGAPPAAPTRASPLGARASPPRSGVSLARPAPGCPRPACEPVYGPLTMSLKPQQQQQQQQQQQQQQQQQQQQQQQPPPAAANVRKPGGSGLLASPAAAPSPSSSSVSSSSATAPSSVVAATSGGGRPGLGRGRNSNKGLPQSTISFDGIYANMRMVHILTSVVGSKCEVQVKNGGIYEGVFKTYSPKCDLVLDAAHEKSTESSSGPKREEIMESILFKCSDFVVVQFKDMDSSYAKRDAFTDSAISAKVNGEHKEKDLEPWDAGELTANEELEALENDVSNGWDPNDMFRYNEENYGVVSTYDSSLSSYTVPLERDNSEEFLKREARANQLAEEIESSAQYKARVALENDDRSEEEKYTAVQRNSSEREGHSINTRENKYIPPGQRNREVISWGSGRQNSPRMGQPGSGSMPSRSTSHTSDFNPNSGSDQRVVNGGVPWPSPCPSPSSRPPSRYQSGPNSLPPRAATPTRPPSRPPSRPSRPPSHPSAHGSPAPVSTMPKRMSSEGPPRMSPKAQRHPRNHRVSAGRGSISSGLEFVSHNPPSEAATPPVARTSPSGGTWSSVVSGVPRLSPKTHRPRSPRQNSIGNTPSGPVLASPQAGIIPTEAVAMPIPAASPTPASPASNRAVTPSSEAKDSRLQDQRQNSPAGNKENIKPNETSPSFSKAENKGISPVVSEHRKQIDDLKKFKNDFRLQPSSTSESMDQLLNKNREGEKSRDLIKDKIEPSAKDSFIENSSSNCTSGSSKPNSPSISPSILSNTEHKRGPEVTSQGVQTSSPACKQEKDDKEEKKDAAEQVRKSTLNPNAKEFNPRSFSQPKPSTTPTSPRPQAQPSPSMVGHQQPTPVYTQPVCFAPNMMYPVPVSPGVQPLYPIPMTPMPVNQAKTYRAVPNMPQQRQDQHHQSAMMHPASAAGPPIAATPPAYSTQYVAYSPQQFPNQPLVQHVPHYQSQHPHVYSPVIQGNARMMAPPTHAQPGLVSSSATQYGAHEQTHAMYACPKLPYNKETSPSFYFAISTGSLAQQYAHPNATLHPHTPHPQPSATPTGQQQSQHGGSHPAPSPVQHHQHQAAQALHLASPQQQSAIYHAGLAPTPPSMTPASNTQSPQNSFPAAQQTVFTIHPSHVQPAYTNPPHMAHVPQAHVQSGMVPSHPTAHAPMMLMTTQPPGGPQAALAQSALQPIPVSTTAHFPYMTHPSVQAHHQQQL T63203 DRUGINFO D3L7YG BIIB105 Phase 2 T63212 TARGETID T63212 T63212 UNIPROID PCCA_HUMAN T63212 TARGNAME Propionyl-CoA carboxylase alpha chain, mitochondrial messenger RNA (PCCA mRNA) T63212 GENENAME PCCA T63212 TARGTYPE Clinical trial T63212 SYNONYMS PCCase subunit alpha (mRNA); Propanoyl-CoA:carbon dioxide ligase subunit alpha (mRNA) T63212 FUNCTION This is one of the 2 subunits of the biotin-dependent propionyl-CoA carboxylase (PCC), a mitochondrial enzyme involved in the catabolism of odd chain fatty acids, branched-chain amino acids isoleucine, threonine, methionine, and valine and other metabolites (PubMed:8434582, PubMed:6765947). Propionyl-CoA carboxylase catalyzes the carboxylation of propionyl-CoA/propanoyl-CoA to D-methylmalonyl-CoA/(S)-methylmalonyl-CoA (PubMed:8434582, PubMed:6765947, PubMed:10101253). Within the holoenzyme, the alpha subunit catalyzes the ATP-dependent carboxylation of the biotin carried by the biotin carboxyl carrier (BCC) domain, while the beta subunit then transfers the carboxyl group from carboxylated biotin to propionyl-CoA (By similarity). Propionyl-CoA carboxylase also significantly acts on butyryl-CoA/butanoyl-CoA, which is converted to ethylmalonyl-CoA/(2S)-ethylmalonyl-CoA at a much lower rate (PubMed:6765947). Other alternative minor substrates include (2E)-butenoyl-CoA/crotonoyl-CoA (By similarity). {ECO:0000250|UniProtKB:P0DTA4, ECO:0000250|UniProtKB:Q5LUF3, ECO:0000269|PubMed:10101253, ECO:0000269|PubMed:6765947, ECO:0000269|PubMed:8434582}. T63212 PDBSTRUC 2CQY;2JKU;7YBU T63212 BIOCLASS mRNA target T63212 ECNUMBER EC 6.4.1.3 T63212 SEQUENCE MAGFWVGTAPLVAAGRRGRWPPQQLMLSAALRTLKHVLYYSRQCLMVSRNLGSVGYDPNEKTFDKILVANRGEIACRVIRTCKKMGIKTVAIHSDVDASSVHVKMADEAVCVGPAPTSKSYLNMDAIMEAIKKTRAQAVHPGYGFLSENKEFARCLAAEDVVFIGPDTHAIQAMGDKIESKLLAKKAEVNTIPGFDGVVKDAEEAVRIAREIGYPVMIKASAGGGGKGMRIAWDDEETRDGFRLSSQEAASSFGDDRLLIEKFIDNPRHIEIQVLGDKHGNALWLNERECSIQRRNQKVVEEAPSIFLDAETRRAMGEQAVALARAVKYSSAGTVEFLVDSKKNFYFLEMNTRLQVEHPVTECITGLDLVQEMIRVAKGYPLRHKQADIRINGWAVECRVYAEDPYKSFGLPSIGRLSQYQEPLHLPGVRVDSGIQPGSDISIYYDPMISKLITYGSDRTEALKRMADALDNYVIRGVTHNIALLREVIINSRFVKGDISTKFLSDVYPDGFKGHMLTKSEKNQLLAIASSLFVAFQLRAQHFQENSRMPVIKPDIANWELSVKLHDKVHTVVASNNGSVFSVEVDGSKLNVTSTWNLASPLLSVSVDGTQRTVQCLSREAGGNMSIQFLGTVYKVNILTRLAAELNKFMLEKVTEDTSSVLRSPMPGVVVAVSVKPGDAVAEGQEICVIEAMKMQNSMTAGKTGTVKSVHCQAGDTVGEGDLLVELE T63212 DRUGINFO DSC3P4 mRNA-3927 Phase 2 T63213 TARGETID T63213 T63213 UNIPROID PCCB_HUMAN T63213 TARGNAME Propionyl-CoA carboxylase beta chain, mitochondrial messenger RNA (PCCB mRNA) T63213 GENENAME PCCB T63213 TARGTYPE Clinical trial T63213 SYNONYMS PCCase subunit beta (mRNA); Propanoyl-CoA:carbon dioxide ligase subunit beta (mRNA) T63213 FUNCTION This is one of the 2 subunits of the biotin-dependent propionyl-CoA carboxylase (PCC), a mitochondrial enzyme involved in the catabolism of odd chain fatty acids, branched-chain amino acids isoleucine, threonine, methionine, and valine and other metabolites (PubMed:6765947, PubMed:15890657). Propionyl-CoA carboxylase catalyzes the carboxylation of propionyl-CoA/propanoyl-CoA to D-methylmalonyl-CoA/(S)-methylmalonyl-CoA (PubMed:6765947, PubMed:15890657). Within the holoenzyme, the alpha subunit catalyzes the ATP-dependent carboxylation of the biotin carried by the biotin carboxyl carrier (BCC) domain, while the beta subunit then transfers the carboxyl group from carboxylated biotin to propionyl-CoA (By similarity). Propionyl-CoA carboxylase also significantly acts on butyryl-CoA/butanoyl-CoA, which is converted to ethylmalonyl-CoA/(2S)-ethylmalonyl-CoA at a much lower rate (PubMed:6765947). Other alternative minor substrates include (2E)-butenoyl-CoA/crotonoyl-CoA (By similarity). {ECO:0000250|UniProtKB:P79384, ECO:0000250|UniProtKB:Q168G2, ECO:0000269|PubMed:15890657, ECO:0000269|PubMed:6765947}. T63213 PDBSTRUC 7YBU T63213 BIOCLASS mRNA target T63213 ECNUMBER EC 6.4.1.3 T63213 SEQUENCE MAAALRVAAVGARLSVLASGLRAAVRSLCSQATSVNERIENKRRTALLGGGQRRIDAQHKRGKLTARERISLLLDPGSFVESDMFVEHRCADFGMAADKNKFPGDSVVTGRGRINGRLVYVFSQDFTVFGGSLSGAHAQKICKIMDQAITVGAPVIGLNDSGGARIQEGVESLAGYADIFLRNVTASGVIPQISLIMGPCAGGAVYSPALTDFTFMVKDTSYLFITGPDVVKSVTNEDVTQEELGGAKTHTTMSGVAHRAFENDVDALCNLRDFFNYLPLSSQDPAPVRECHDPSDRLVPELDTIVPLESTKAYNMVDIIHSVVDEREFFEIMPNYAKNIIVGFARMNGRTVGIVGNQPKVASGCLDINSSVKGARFVRFCDAFNIPLITFVDVPGFLPGTAQEYGGIIRHGAKLLYAFAEATVPKVTVITRKAYGGAYDVMSSKHLCGDTNYAWPTAEIAVMGAKGAVEIIFKGHENVEAAQAEYIEKFANPFPAAVRGFVDDIIQPSSTRARICCDLDVLASKKVQRPWRKHANIPL T63213 DRUGINFO DSC3P4 mRNA-3927 Phase 2 T63214 TARGETID T63214 T63214 UNIPROID PLPL3_HUMAN T63214 TARGNAME 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 messenger RNA (PNPLA3 mRNA) T63214 GENENAME PNPLA3 T63214 TARGTYPE Clinical trial T63214 SYNONYMS Acylglycerol transacylase (mRNA); Adiponutrin (mRNA); ADPN (mRNA); Calcium-independent phospholipase A2-epsilon (mRNA); iPLA2-epsilon (mRNA); Lysophosphatidic acid acyltransferase (mRNA); Patatin-like phospholipase domain-containing protein 3 (mRNA) T63214 FUNCTION Specifically catalyzes coenzyme A (CoA)-dependent acylation of 1-acyl-sn-glycerol 3-phosphate (2-lysophosphatidic acid/LPA) to generate phosphatidic acid (PA), an important metabolic intermediate and precursor for both triglycerides and glycerophospholipids. Does not esterify other lysophospholipids. Acyl donors are long chain (at least C16) fatty acyl-CoAs: arachidonoyl-CoA, linoleoyl-CoA, oleoyl-CoA and at a lesser extent palmitoyl-CoA (PubMed:22560221). Additionally possesses low triacylglycerol lipase and CoA-independent acylglycerol transacylase activities and thus may play a role in acyl-chain remodeling of triglycerides (PubMed:15364929, PubMed:20034933, PubMed:22560221). In vitro may express hydrolytic activity against glycerolipids triacylglycerol, diacylglycerol and monoacylglycerol, with a strong preference for oleic acid as the acyl moiety (PubMed:21878620). However, the triacylglycerol hydrolase activity is controversial and may be very low (PubMed:22560221). Possesses phospholipase A2 activity (PubMed:15364929). {ECO:0000269|PubMed:15364929, ECO:0000269|PubMed:20034933, ECO:0000269|PubMed:21878620, ECO:0000269|PubMed:22560221}. T63214 BIOCLASS mRNA target T63214 ECNUMBER EC 2.3.1.51; EC 3.1.1.3; EC 3.1.1.4 T63214 SEQUENCE MYDAERGWSLSFAGCGFLGFYHVGATRCLSEHAPHLLRDARMLFGASAGALHCVGVLSGIPLEQTLQVLSDLVRKARSRNIGIFHPSFNLSKFLRQGLCKCLPANVHQLISGKIGISLTRVSDGENVLVSDFRSKDEVVDALVCSCFIPFYSGLIPPSFRGVRYVDGGVSDNVPFIDAKTTITVSPFYGEYDICPKVKSTNFLHVDITKLSLRLCTGNLYLLSRAFVPPDLKVLGEICLRGYLDAFRFLEEKGICNRPQPGLKSSSEGMDPEVAMPSWANMSLDSSPESAALAVRLEGDELLDHLRLSILPWDESILDTLSPRLATALSEEMKDKGGYMSKICNLLPIRIMSYVMLPCTLPVESAIAIVQRLVTWLPDMPDDVLWLQWVTSQVFTRVLMCLLPASRSQMPVSSQQASPCTPEQDWPCWTPCSPKGCPAETKAEATPRSILRSSLNFFLGNKVPAGAEGLSTFPSFSLEKSL T63214 DRUGINFO DC86WO ION839 Phase 2 T63214 DRUGINFO D3DM8Y AMG 609 Phase 1 T63222 TARGETID T63222 T63222 UNIPROID USH2A_HUMAN T63222 TARGNAME Usherin messenger RNA (USH2A mRNA) T63222 GENENAME USH2A T63222 TARGTYPE Clinical trial T63222 SYNONYMS Usher syndrome type IIa protein (mRNA); Usher syndrome type-2A protein (mRNA) T63222 FUNCTION Involved in hearing and vision as member of the USH2 complex. In the inner ear, required for the maintenance of the hair bundle ankle formation, which connects growing stereocilia in developing cochlear hair cells. In retina photoreceptors, the USH2 complex is required for the maintenance of periciliary membrane complex that seems to play a role in regulating intracellular protein transport. {ECO:0000250|UniProtKB:Q2QI47}. T63222 BIOCLASS mRNA target T63222 SEQUENCE MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL T63222 DRUGINFO D21URW QR-421a Phase 2/3 T63227 TARGETID T63227 T63227 UNIPROID FUS_HUMAN T63227 TARGNAME RNA-binding protein FUS messenger RNA (FUS mRNA) T63227 GENENAME FUS T63227 TARGTYPE Clinical trial T63227 SYNONYMS 75 kDa DNA-pairing protein (mRNA); Oncogene FUS (mRNA); Oncogene TLS (mRNA); POMp75 (mRNA); Translocated in liposarcoma protein (mRNA) T63227 FUNCTION DNA/RNA-binding protein that plays a role in various cellular processes such as transcription regulation, RNA splicing, RNA transport, DNA repair and damage response (PubMed:27731383). Binds to nascent pre-mRNAs and acts as a molecular mediator between RNA polymerase II and U1 small nuclear ribonucleoprotein thereby coupling transcription and splicing (PubMed:26124092). Binds also its own pre-mRNA and autoregulates its expression; this autoregulation mechanism is mediated by non-sense-mediated decay (PubMed:24204307). Plays a role in DNA repair mechanisms by promoting D-loop formation and homologous recombination during DNA double-strand break repair (PubMed:10567410). In neuronal cells, plays crucial roles in dendritic spine formation and stability, RNA transport, mRNA stability and synaptic homeostasis (By similarity). {ECO:0000250|UniProtKB:P56959, ECO:0000269|PubMed:10567410, ECO:0000269|PubMed:24204307, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27731383}. T63227 PDBSTRUC 2LA6;2LCW;4FDD;4FQ3;5W3N;5XRR;5XSG;5YVG;5YVH;5YVI;6BWZ;6BXV;6BZP;6G99;6GBM;6KJ1;6KJ2;6KJ3;6KJ4;6SNJ;6XFM;7CYL;7VQQ T63227 BIOCLASS mRNA target T63227 SEQUENCE MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYEPRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIESVADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFSGNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY T63227 DRUGINFO DCRJ78 ION363 Phase 3 T63228 TARGETID T63228 T63228 UNIPROID GFAP_HUMAN T63228 TARGNAME Glial fibrillary acidic protein messenger RNA (GFAP mRNA) T63228 GENENAME GFAP T63228 TARGTYPE Clinical trial T63228 SYNONYMS GFAP (mRNA) T63228 FUNCTION GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. T63228 PDBSTRUC 6A9P T63228 BIOCLASS mRNA target T63228 SEQUENCE MERRRITSAARRSYVSSGEMMVGGLAPGRRLGPGTRLSLARMPPPLPTRVDFSLAGALNAGFKETRASERAEMMELNDRFASYIEKVRFLEQQNKALAAELNQLRAKEPTKLADVYQAELRELRLRLDQLTANSARLEVERDNLAQDLATVRQKLQDETNLRLEAENNLAAYRQEADEATLARLDLERKIESLEEEIRFLRKIHEEEVRELQEQLARQQVHVELDVAKPDLTAALKEIRTQYEAMASSNMHEAEEWYRSKFADLTDAAARNAELLRQAKHEANDYRRQLQSLTCDLESLRGTNESLERQMREQEERHVREAASYQEALARLEEEGQSLKDEMARHLQEYQDLLNVKLALDIEIATYRKLLEGEENRITIPVQTFSNLQIRETSLDTKSVSEGHLKRNIVVKTVEMRDGEVIKESKQEHKDVM T63228 DRUGINFO DYR8T5 ION373 Phase 3 T63185 TARGETID T63185 T63185 UNIPROID RASK_HUMAN T63185 TARGNAME KRas D816V mutant (KRAS D816V) T63185 GENENAME KRAS T63185 TARGTYPE Clinical trial T63185 SYNONYMS K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras T63185 FUNCTION Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306). {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24623306, ECO:0000305}. T63185 PDBSTRUC 1D8D;1D8E;1KZO;1KZP;1N4P;1N4Q;1N4R;1N4S;3GFT;4DSN;4DSO;4EPR;4EPT;4EPV;4EPW;4EPX;4EPY;4L8G;4LDJ;4LPK;4LRW;4LUC;4LV6;4LYF;4LYH;4LYJ;4M1O;4M1S;4M1T;4M1W;4M1Y;4M21;4M22;4NMM;4OBE;4PZY;4PZZ;4Q01;4Q02;4Q03;4QL3;4TQ9;4TQA;4WA7;5F2E;5KYK;5MLA;5MLB;5O2S;5O2T;5OCG;5OCO;5OCT;5TAR;5TB5;5UFE;5UFQ;5UK9;5UQW;5US4;5USJ;5V6S;5V6V;5V71;5V9L;5V9O;5V9U;5VBM;5VP7;5VPI;5VPY;5VPZ;5VQ0;5VQ1;5VQ2;5VQ6;5VQ8;5W22;5WHA;5WHB;5WHD;5WHE;5WLB;5WPM;5XCO;5YXZ;5YY1;6ARK;6ASA;6ASE;6B0V;6B0Y;6BOF;6BP1;6CC9;6CCH;6CCX;6CU6;6E6F;6E6G;6EPL;6EPM;6EPN;6EPO;6EPP;6F76;6FA1;6FA2;6FA3;6FA4;6GJ5;6GJ6;6GJ7;6GJ8;6GOD;6GOE;6GOF;6GOG;6GOM;6GQT;6GQW;6GQX;6GQY;6H46;6H47;6JTN;6JTO;6JTP;6M9W;6MBQ;6MBT;6MBU;6MNX;6MQG;6MQN;6MS9;6MTA;6N2J;6N2K;6O36;6O46;6O4Y;6O4Z;6O51;6O53;6OB2;6OB3;6OIM;6P0Z;6P8W;6P8X;6P8Y;6P8Z;6PGO;6PGP;6PQ3;6PTS;6PTW;6QUU;6QUV;6QUW;6QUX;6T5B;6T5U;6T5V;6TAM;6TAN;6USX;6USZ;6UT0;6V5L;6V65;6V6F;6VC8;6VJJ;6W4E;6W4F;6WGN;6WS2;6WS4;6XGU;6XGV;6XHA;6XHB;6YR8;6YXW;6ZL5;6ZLI;7A1W;7A1X;7A1Y;7A47;7ACA;7ACF;7ACH;7ACQ;7C40;7C41;7EW9;7EWA;7EWB;7EYX;7F0W;7KFZ;7KMR;7KYZ;7LC1;7LC2;7LGI;7LZ5;7MDP;7MQU;7NY8;7O70;7OK3;7OK4;7OO7;7Q9U;7R0M;7R0N;7R0Q;7ROV;7RP2;7RP3;7RP4;7RPZ;7RSC;7RSE;7RT1;7RT2;7RT3;7RT4;7RT5;7SCW;7SCX;7T1F;7T47;7TLE;7TLG;7TLK;7U8H;7VVB;7W5R;7YCC;7YCE;8AFB;8AFC;8AFD;8AQ5;8AQ7;8AZR;8AZV;8AZX;8AZY;8AZZ;8B00;8B6I;8B78;8CX5;8DNI;8DNJ;8DNK;8EPW;8EZG;8ONV T63185 ECNUMBER EC 3.6.5.2 T63185 SEQUENCE MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM T63185 DRUGINFO DL81ME ASP3082 Phase 1 T63231 TARGETID T63231 T63231 UNIPROID KIT_HUMAN T63231 TARGNAME KIT D816V mutant (KIT D816V) T63231 GENENAME KIT T63231 TARGTYPE Clinical trial T63231 SYNONYMS SCFR; Piebald trait protein; PBT; Proto-oncogene c-Kit; Tyrosine-protein kinase Kit; p145 c-kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CD117 T63231 FUNCTION Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1. {ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12444928, ECO:0000269|PubMed:12511554, ECO:0000269|PubMed:12878163, ECO:0000269|PubMed:17904548, ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:9528781}. T63231 PDBSTRUC 1PKG;1T45;1T46;2E9W;2EC8;2IUH;2VIF;3G0E;3G0F;4HVS;4K94;4K9E;4PGZ;4U0I;6GQJ;6GQK;6GQL;6GQM;6HH1;6ITT;6ITV;6KLA;6MOB;6XV9;6XVA;6XVB;7KHG;7KHJ;7KHK;7ZW8;8DFM;8DFP;8DFQ T63231 BIOCLASS Kinase T63231 ECNUMBER EC 2.7.10.1 T63231 SEQUENCE MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTPLLIGFVIVAGMMCIIVMILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELKVLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAALYKNLLHSKESSCSDSTNEYMDMKPGVSYVVPTKADKRRSVRIGSYIERDVTPAIMEDDELALDLEDLLSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLARDIKNDSNYVVKGNARLPVKWMAPESIFNCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMLSPEHAPAEMYDIMKTCWDADPLKRPTFKQIVQLIEKQISESTNHIYSNLANCSPNRQKPVVDHSVRINSVGSTASSSQPLLVHDDV T63231 DRUGINFO DLC7Y9 Bezuclastinib Phase 3 T63235 TARGETID T63235 T63235 UNIPROID BRAF_HUMAN T63235 TARGNAME BRAF V600E mutant (BRAF V600E) T63235 GENENAME BRAF T63235 TARGTYPE Clinical trial T63235 SYNONYMS Proto-oncogene B-Raf; p94; v-Raf murine sarcoma viral oncogene homolog B1 T63235 FUNCTION Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789, ECO:0000305}. T63235 PDBSTRUC 1UWH;1UWJ;2FB8;2L05;3C4C;3D4Q;3IDP;3II5;3NY5;3OG7;3PPJ;3PPK;3PRF;3PRI;3PSB;3PSD;3Q4C;3Q96;3SKC;3TV4;3TV6;4CQE;4DBN;4E26;4E4X;4EHE;4EHG;4FC0;4FK3;4G9C;4G9R;4H58;4JVG;4KSP;4KSQ;4MBJ;4MNE;4MNF;4PP7;4R5Y;4RZV;4RZW;4WO5;4XV1;4XV2;4XV3;4XV9;4YHT;5C9C;5CSW;5CSX;5CT7;5FD2;5HI2;5HID;5HIE;5ITA;5J17;5J18;5J2R;5JRQ;5JSM;5JT2;5VAL;5VAM;5VR3;5VYK;6B8U;6CAD;6N0P;6N0Q;6NSQ;6NYB;6P3D;6P7G;6PP9;6Q0J;6Q0K;6Q0T;6U2G;6U2H;6UAN;6UUO;6V2U;6V2W;6V34;6XAG;6XFP;6XLO;7K0V;7M0T;7M0U;7M0V;7M0W;7M0X;7M0Y;7M0Z;7MFD;7MFE;7MFF;7P3V;7SHV;7ZR0;7ZR5;7ZR6;8C7X;8C7Y;8DGS;8DGT;8F7O;8F7P T63235 BIOCLASS Kinase T63235 ECNUMBER EC 2.7.11.1 T63235 SEQUENCE MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH T63235 DRUGINFO DSF65Q RG6344 Phase 1 T63198 TARGETID T63198 T63198 UNIPROID OPSD_HUMAN T63198 TARGNAME Rhodopsin P23H mutant messenger RNA (RHO P23H mRNA) T63198 GENENAME RHO T63198 TARGTYPE Clinical trial T63198 SYNONYMS Opsin-2 T63198 FUNCTION Photoreceptor required for image-forming vision at low light intensity (PubMed:8107847, PubMed:7846071). Required for photoreceptor cell viability after birth (PubMed:2215617, PubMed:12566452). Light-induced isomerization of the chromophore 11-cis-retinal to all-trans-retinal triggers a conformational change that activates signaling via G-proteins (PubMed:8107847, PubMed:28524165, PubMed:26200343, PubMed:28753425). Subsequent receptor phosphorylation mediates displacement of the bound G-protein alpha subunit by the arrestin SAG and terminates signaling (PubMed:28524165, PubMed:26200343). {ECO:0000269|PubMed:12566452, ECO:0000269|PubMed:2215617, ECO:0000269|PubMed:26200343, ECO:0000269|PubMed:28753425, ECO:0000269|PubMed:7846071, ECO:0000269|PubMed:8107847, ECO:0000305|PubMed:28524165}. T63198 PDBSTRUC 4ZWJ;5DGY;5W0P;6CMO T63198 BIOCLASS mRNA target T63198 SEQUENCE MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLYVTVQHKKLRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLGGEIALWSLVVLAIERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIPEGLQCSCGIDYYTLKPEVNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQESATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAIYNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASATVSKTETSQVAPA T63198 DRUGINFO DX71CK QR1123 Phase 1/2 T63176 TARGETID T63176 T63176 UNIPROID LIRB4_HUMAN-FINC_HUMAN T63176 TARGNAME CD85k-Fibronectin interaction (LILRB4-FN1 PPI) T63176 TARGTYPE Clinical trial T63176 DRUGINFO DY0IS1 NGM831 Phase 1 T63204 TARGETID T63204 T63204 UNIPROID CD47_HUMAN-SHPS1_HUMAN T63204 TARGNAME CD47-SHPS1 interaction (CD47-SHPS1 PPI) T63204 TARGTYPE Clinical trial T63204 DRUGINFO D6SJ0B PF-07901801 Phase 2 T63206 TARGETID T63206 T63206 UNIPROID ITAV_HUMAN-ITB1_HUMAN T63206 TARGNAME Integrin alpha-5/beta-1 (ITGA5/B1) T63206 TARGTYPE Clinical trial T63206 DRUGINFO D3MG8W PLN-74809 Phase 2 T61746 TARGETID T61746 T61746 FORMERID TTDR00886 T61746 UNIPROID CATB_HUMAN T61746 TARGNAME Cathepsin B (CTSB) T61746 GENENAME CTSB T61746 TARGTYPE Preclinical T61746 SYNONYMS Ctsb; Cathepsins B; Cathepsin-B; Cathepsin B1; CPSB; APPS; APP secretase T61746 FUNCTION Cleaves matrix extracellular phosphoglycoprotein MEPE. Has also been implicated in tumor invasion and metastasis. Thiol protease which is believed to participate in intracellular degradation and turnover of proteins. T61746 PDBSTRUC 6AY2; 5MBM; 5MBL; 3PBH; 3K9M T61746 BIOCLASS Peptidase T61746 ECNUMBER EC 3.4.22.1 T61746 SEQUENCE MWQLWASLCCLLVLANARSRPSFHPLSDELVNYVNKRNTTWQAGHNFYNVDMSYLKRLCGTFLGGPKPPQRVMFTEDLKLPASFDAREQWPQCPTIKEIRDQGSCGSCWAFGAVEAISDRICIHTNAHVSVEVSAEDLLTCCGSMCGDGCNGGYPAEAWNFWTRKGLVSGGLYESHVGCRPYSIPPCEHHVNGSRPPCTGEGDTPKCSKICEPGYSPTYKQDKHYGYNSYSVSNSEKDIMAEIYKNGPVEGAFSVYSDFLLYKSGVYQHVTGEMMGGHAIRILGWGVENGTPYWLVANSWNTDWGDNGFFKILRGQDHCGIESEVVAGIPRTDQYWEKI T61746 DRUGINFO D0A2NA PMID27998201-Compound-11 Patented T61746 DRUGINFO D0E2AF PMID27998201-Compound-2 Patented T61746 DRUGINFO D0KG9M PMID27998201-Compound-22 Patented T61746 DRUGINFO D0L1PP PMID27998201-Compound-13 Patented T61746 DRUGINFO D0UX4J Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 Patented T61746 DRUGINFO D0WO4T PMID27998201-Compound-24 Patented T61746 DRUGINFO D06XTA PMID27998201-Compound-17 Patented T61746 DRUGINFO D04VGR PMID27998201-Compound-9 Patented T61746 DRUGINFO D05OIU PMID27998201-Compound-5 Patented T61746 DRUGINFO D06XCD PMID27998201-Compound-12 Patented T61746 DRUGINFO D9MT4S CA-074Me Preclinical T61746 DRUGINFO DCZ16N SD1002 Preclinical T61746 DRUGINFO DM69TL Z-Phe-Ala-diazomethylketone Preclinical T61746 DRUGINFO DSM03D SD1003 Preclinical T61746 DRUGINFO D0Z0PR L-006235-1 Preclinical T61746 DRUGINFO D06FCP Gold trichloride sodium chloride Investigative T61746 DRUGINFO D0A5WN PTosyl-Glu(OtBu)-Ala-LeuVSMe Investigative T61746 DRUGINFO D0B5MF 2-Aminoethanimidic Acid Investigative T61746 DRUGINFO D0D6MZ 3-Amino-4-Oxybenzyl-2-Butanone Investigative T61746 DRUGINFO D0NI5C 2-Pyridinethiol Investigative T61746 DRUGINFO D0Q4UA Z-Arg-Leu-Val-Agly-Ile-Val-OMe Investigative T61746 DRUGINFO D0X0IT Diphenylacetic Acid Investigative T61746 DRUGINFO D0X8ZS 3-Methylphenylalanine Investigative T61746 DRUGINFO D00NVC Z-Ala-Leu-Nal-Agly-Ile-Val-OMe Investigative T61746 DRUGINFO D01BIZ Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2 Investigative T61746 DRUGINFO D01TFO Z-Ala-Leu-lle-Agly-Ile-Val-OMe Investigative T61746 DRUGINFO D03ETT Z-Ala-Leu-His-Agly-Ile-Val-OMe Investigative T61746 DRUGINFO D03FJH Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2 Investigative T61746 DRUGINFO D03JYN 1-(phenyl(p-tolyl)methylene)thiosemicarbazide Investigative T61746 DRUGINFO D03VHO Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe Investigative T61746 DRUGINFO D04DFX Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone Investigative T61746 DRUGINFO D05VEV Ac-hPhe-Leu-Ala-LeuVSMe Investigative T61746 DRUGINFO D06NEB Ac-hPhe-Leu-Phe-LeuVSMe Investigative T61746 DRUGINFO D06QJT Z-leu-Val-Agly-Val-OBzl Investigative T61746 DRUGINFO D07JLV Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl Investigative T61746 DRUGINFO D07RDV Z-Ala-Leu-Phe-Agly-Ile-Val-OMe Investigative T61746 DRUGINFO D0B2JC [(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone Investigative T61746 DRUGINFO D0H8TE Z-Arg-Leu-Val-Agly-Ala-Gly-NH2 Investigative T61746 DRUGINFO D0I0MU Cbz-Ile-Leu-Ala-LeuVSMe Investigative T61746 DRUGINFO D0N7BP Z-Arg-Leu-Val-Agly-Val-Ala-NH2 Investigative T61746 DRUGINFO D0Q4YY Z-Arg-Leu-Val-Agly-Ileu-Val-OMe Investigative T61746 DRUGINFO D0QY3R Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe Investigative T61746 DRUGINFO D0VE0F (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate Investigative T61746 DRUGINFO D0D0LD L-873724 Investigative T61746 DRUGINFO D0L9VP GNF-PF-5434 Investigative T69375 TARGETID T69375 T69375 FORMERID TTDR00334 T69375 UNIPROID MK09_HUMAN T69375 TARGNAME Stress-activated protein kinase JNK2 (JNK2) T69375 GENENAME MAPK9 T69375 TARGTYPE Preclinical T69375 SYNONYMS Stress-activated protein kinase 1a; SAPK1a; PRKM9; Mitogen-activated protein kinase 9; Mitogen-activated protein kinase 8-interacting protein 2; MAPK 9; MAP kinase 9; Jun-N-terminal kinase 2; JNK-interacting protein 2; JNK-55; JNK MAP kinase scaffold protein 2; JIP-2; Islet-brain-2; IB-2; C-jun-amino-terminal kinase interacting protein 2; C-Jun N-terminal kinase 2 T69375 FUNCTION Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. In response to oxidative or ribotoxic stresses, inhibits rRNA synthesis by phosphorylating and inactivating the RNA polymerase 1-specific transcription initiation factor RRN3. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including TP53 and YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Upon T-cell receptor (TCR) stimulation, is activated by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels. Plays an important role in the osmotic stress-induced epithelial tight-junctions disruption. When activated, promotes beta-catenin/CTNNB1 degradation and inhibits the canonical Wnt signaling pathway. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock. Phosphorylates POU5F1, which results in the inhibition of POU5F1's transcriptional activity and enhances its proteosomal degradation. Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. T69375 PDBSTRUC 3NPC; 3E7O T69375 BIOCLASS Kinase T69375 ECNUMBER EC 2.7.11.24 T69375 SEQUENCE MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR T69375 DRUGINFO D07KVU PMID25991433-Compound-C1 Patented T69375 DRUGINFO D03HEK PMID25991433-Compound-A10 Patented T69375 DRUGINFO D04JUD PMID25991433-Compound-A6 Patented T69375 DRUGINFO D07JQX PMID25991433-Compound-D2 Patented T69375 DRUGINFO D09YEH PMID25991433-Compound-A11 Patented T69375 DRUGINFO D0AM2B PMID25991433-Compound-A8 Patented T69375 DRUGINFO D0B4IH PMID25991433-Compound-D1 Patented T69375 DRUGINFO D0RV2Z PMID25991433-Compound-A2 Patented T69375 DRUGINFO D0S1OV PMID25991433-Compound-A7 Patented T69375 DRUGINFO D0S3AP PMID25991433-Compound-A9 Patented T69375 DRUGINFO D0V1CB PMID25991433-Compound-A5 Patented T69375 DRUGINFO D0VE3Y PMID25991433-Compound-A3 Patented T69375 DRUGINFO D05SJB 7-azaindole derivative 1 Patented T69375 DRUGINFO D07KMK 7-azaindole derivative 5 Patented T69375 DRUGINFO D08DNZ PMID25991433-Compound-P6 Patented T69375 DRUGINFO D08JOC PMID25991433-Compound-J3 Patented T69375 DRUGINFO D0L2MS PMID25991433-Compound-P1 Patented T69375 DRUGINFO D0Q4WA PMID25991433-Compound-O3 Patented T69375 DRUGINFO D0RQ8Q PMID25991433-Compound-J2 Patented T69375 DRUGINFO D0T6IZ 7-azaindole derivative 3 Patented T69375 DRUGINFO D0VR1O 7-azaindole derivative 2 Patented T69375 DRUGINFO D0W8BL PMID25991433-Compound-P5 Patented T69375 DRUGINFO D0X2SG PMID25991433-Compound-P4 Patented T69375 DRUGINFO D0ZU8L PMID25991433-Compound-J5 Patented T69375 DRUGINFO D06JRV PMID25991433-Compound-F2 Patented T69375 DRUGINFO D0H4HD PMID25991433-Compound-A1 Patented T69375 DRUGINFO DOJ6D9 COR-D Preclinical T69375 DRUGINFO D02PVB 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One Investigative T14875 TARGETID T14875 T14875 UNIPROID UBP14_HUMAN T14875 TARGNAME Ubiquitin carboxyl-terminal hydrolase 14 (USP14) T14875 GENENAME USP14 T14875 TARGTYPE Preclinical T14875 SYNONYMS Ubiquitin-specific-processing protease 14; Ubiquitin thioesterase 14; TGT; Deubiquitinating enzyme 14 T14875 FUNCTION Ensures the regeneration of ubiquitin at the proteasome. Is a reversibly associated subunit of the proteasome and a large fraction of proteasome-free protein exists within the cell. Required for the degradation of the chemokine receptor CXCR4 which is critical for CXCL12-induced cell chemotaxis. Serves also as a physiological inhibitor of endoplasmic reticulum-associated degradation (ERAD) under the non-stressed condition by inhibiting the degradation of unfolded endoplasmic reticulum proteins via interaction with ERN1. Indispensable for synaptic development and function at neuromuscular junctions (NMJs). Plays a role in the innate immune defense against viruses by stabilizing the viral DNA sensor CGAS and thus inhibiting its autophagic degradation. Proteasome-associated deubiquitinase which releases ubiquitin from the proteasome targeted ubiquitinated proteins. T14875 PDBSTRUC 6IIN; 6IIM; 6IIL; 6IIK; 5GJQ T14875 BIOCLASS Peptidase T14875 ECNUMBER EC 3.4.19.12 T14875 SEQUENCE MPLYSVTVKWGKEKFEGVELNTDEPPMVFKAQLFALTGVQPARQKVMVKGGTLKDDDWGNIKIKNGMTLLMMGSADALPEEPSAKTVFVEDMTEEQLASAMELPCGLTNLGNTCYMNATVQCIRSVPELKDALKRYAGALRASGEMASAQYITAALRDLFDSMDKTSSSIPPIILLQFLHMAFPQFAEKGEQGQYLQQDANECWIQMMRVLQQKLEAIEDDSVKETDSSSASAATPSKKKSLIDQFFGVEFETTMKCTESEEEEVTKGKENQLQLSCFINQEVKYLFTGLKLRLQEEITKQSPTLQRNALYIKSSKISRLPAYLTIQMVRFFYKEKESVNAKVLKDVKFPLMLDMYELCTPELQEKMVSFRSKFKDLEDKKVNQQPNTSDKKSSPQKEVKYEPFSFADDIGSNNCGYYDLQAVLTHQGRSSSSGHYVSWVKRKQDEWIKFDDDKVSIVTPEDILRLSGGGDWHIAYVLLYGPRRVEIMEEESEQ T14875 DRUGINFO D09CIC Tricyclic heterocycle derivative 4 Patented T14875 DRUGINFO D0A8EN PMID26077642-Compound-Figure3A Patented T14875 DRUGINFO DW0Z1Y IU1 Preclinical T14875 DRUGINFO DGP6V3 BAP-15 Preclinical T35445 TARGETID T35445 T35445 FORMERID TTDR00819 T35445 UNIPROID SMAD3_HUMAN T35445 TARGNAME Mothers against decapentaplegic homolog 3 (SMAD3) T35445 GENENAME SMAD3 T35445 TARGTYPE Preclinical T35445 SYNONYMS TGF-beta response effector Smad3; Smad3; SMAD family member 3; SMAD 3; Mothers against DPP homolog 3; Mad3; MMad3; MADH3; MAD homolog 3; JV15-2; HSMAD3; HMAD-3 T35445 FUNCTION Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. T35445 PDBSTRUC 5XOC; 5ODG; 5OD6; 2LB2; 2LAJ T35445 SEQUENCE MSSILPFTPPIVKRLLGWKKGEQNGQEEKWCEKAVKSLVKKLKKTGQLDELEKAITTQNVNTKCITIPRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELRAMELCEFAFNMKKDEVCVNPYHYQRVETPVLPPVLVPRHTEIPAEFPPLDDYSHSIPENTNFPAGIEPQSNIPETPPPGYLSEDGETSDHQMNHSMDAGSPNLSPNPMSPAHNNLDLQPVTYCEPAFWCSISYYELNQRVGETFHASQPSMTVDGFTDPSNSERFCLGLLSNVNRNAAVELTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSIRCSSVS T35445 DRUGINFO DF90DS SIS-3 Preclinical T35445 DRUGINFO D0P0CM GNF-PF-2272 Investigative T35445 DRUGINFO D0A1CM ELLAGIC ACID Investigative T42658 TARGETID T42658 T42658 FORMERID TTDI02456 T42658 UNIPROID UBP7_HUMAN T42658 TARGNAME Herpesvirus ubiquitin-specific protease (HAUSP) T42658 GENENAME USP7 T42658 TARGTYPE Preclinical T42658 SYNONYMS Ubiquitin-specific-processing protease 7; Ubiquitin thioesterase 7; Ubiquitin carboxyl-terminal hydrolase 7; Herpesvirus-associated ubiquitin-specific protease; Deubiquitinating enzyme 7 T42658 FUNCTION Together with DAXX, prevents MDM2 self-ubiquitination and enhances the E3 ligase activity of MDM2 towards p53/TP53, thereby promoting p53/TP53 ubiquitination and proteasomal degradation. Deubiquitinates p53/TP53, preventing degradation of p53/TP53, and enhances p53/TP53-dependent transcription regulation, cell growth repression and apoptosis. Deubiquitinates p53/TP53 and MDM2 and strongly stabilizes p53/TP53 even in the presence of excess MDM2, and also induces p53/TP53-dependent cell growth repression and apoptosis. Deubiquitination of FOXO4 in presence of hydrogen peroxide is not dependent on p53/TP53 and inhibits FOXO4-induced transcriptional activity. In association with DAXX, is involved in the deubiquitination and translocation of PTEN from the nucleus to the cytoplasm, both processes that are counteracted by PML. Deubiquitinates KMT2E/MLL5 preventing KMT2E/MLL5 proteasomal-mediated degradation. Involved in cell proliferation during early embryonic development. Involved in transcription-coupled nucleotide excision repair (TC-NER) in response to UV damage: recruited to DNA damage sites following interaction with KIAA1530/UVSSA and promotes deubiquitination of ERCC6, preventing UV-induced degradation of ERCC6. Involved in maintenance of DNA methylation via its interaction with UHRF1 and DNMT1: acts by mediating deubiquitination of UHRF1 and DNMT1, preventing their degradation and promoting DNA methylation by DNMT1. Deubiquitinates alkylation repair enzyme ALKBH3. OTUD4 recruits USP7 and USP9X to stabilize ALKBH3, thereby promoting the repair of alkylated DNA lesions. Acts as a chromatin regulator via its association with the Polycomb group (PcG) multiprotein PRC1-like complex; may act by deubiquitinating components of the PRC1-like complex. Able to mediate deubiquitination of histone H2B; it is however unsure whether this activity takes place in vivo. Exhibits a preference towards 'Lys-48'-linked ubiquitin chains. Increases regulatory T-cells (Treg) suppressive capacity by deubiquitinating and stabilizing the transcription factor FOXP3 which is crucial for Treg cell function. Plays a role in the maintenance of the circadian clock periodicity via deubiquitination and stabilization of the CRY1 and CRY2 proteins. Deubiquitinates REST, thereby stabilizing REST and promoting the maintenance of neural progenitor cells. Hydrolase that deubiquitinates target proteins such as FOXO4, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN, KMT2E/MLL5 and DAXX. T42658 PDBSTRUC 6F5H; 5WHC; 5VSK; 5VSB; 5VS6 T42658 BIOCLASS Peptidase T42658 ECNUMBER EC 3.4.19.12 T42658 SEQUENCE MNHQQQQQQQKAGEQQLSEPEDMEMEAGDTDDPPRITQNPVINGNVALSDGHNTAEEDMEDDTSWRSEATFQFTVERFSRLSESVLSPPCFVRNLPWKIMVMPRFYPDRPHQKSVGFFLQCNAESDSTSWSCHAQAVLKIINYRDDEKSFSRRISHLFFHKENDWGFSNFMAWSEVTDPEKGFIDDDKVTFEVFVQADAPHGVAWDSKKHTGYVGLKNQGATCYMNSLLQTLFFTNQLRKAVYMMPTEGDDSSKSVPLALQRVFYELQHSDKPVGTKKLTKSFGWETLDSFMQHDVQELCRVLLDNVENKMKGTCVEGTIPKLFRGKMVSYIQCKEVDYRSDRREDYYDIQLSIKGKKNIFESFVDYVAVEQLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIKINDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSGDNHGGHYVVYLNPKGDGKWCKFDDDVVSRCTKEEAIEHNYGGHDDDLSVRHCTNAYMLVYIRESKLSEVLQAVTDHDIPQQLVERLQEEKRIEAQKRKERQEAHLYMQVQIVAEDQFCGHQGNDMYDEEKVKYTVFKVLKNSSLAEFVQSLSQTMGFPQDQIRLWPMQARSNGTKRPAMLDNEADGNKTMIELSDNENPWTIFLETVDPELAASGATLPKFDKDHDVMLFLKMYDPKTRSLNYCGHIYTPISCKIRDLLPVMCDRAGFIQDTSLILYEEVKPNLTERIQDYDVSLDKALDELMDGDIIVFQKDDPENDNSELPTAKEYFRDLYHRVDVIFCDKTIPNDPGFVVTLSNRMNYFQVAKTVAQRLNTDPMLLQFFKSQGYRDGPGNPLRHNYEGTLRDLLQFFKPRQPKKLYYQQLKMKITDFENRRSFKCIWLNSQFREEEITLYPDKHGCVRDLLEECKKAVELGEKASGKLRLLEIVSYKIIGVHQEDELLECLSPATSRTFRIEEIPLDQVDIDKENEMLVTVAHFHKEVFGTFGIPFLLRIHQGEHFREVMKRIQSLLDIQEKEFEKFKFAIVMMGRHQYINEDEYEVNLKDFEPQPGNMSHPRPWLGLDHFNKAPKRSRYTYLEKAIKIHN T42658 DRUGINFO D03EML PMID26077642-Compound-Vif2 Patented T42658 DRUGINFO D0PT1W PMID26077642-Compound-Vif1 Patented T42658 DRUGINFO D0AN9V ADC-03 Preclinical T42658 DRUGINFO D2K6DU P22077 Preclinical T42658 DRUGINFO DA0OZ2 HBX19818 Preclinical T42658 DRUGINFO DRJU35 ADC-01 Preclinical T42658 DRUGINFO DV3KC5 P5091 Preclinical T25315 TARGETID T25315 T25315 FORMERID TTDC00125 T25315 UNIPROID CXCR3_HUMAN T25315 TARGNAME C-X-C chemokine receptor type 3 (CXCR3) T25315 GENENAME CXCR3 T25315 TARGTYPE Preclinical T25315 SYNONYMS Interferon-inducible protein 10 receptor; IP-10 receptor; GPR9; G protein-coupled receptor 9; Chemokine receptor CXCR3/interferon-inducible protein-10; Chemokine receptor CXCR3; CXCR3/IP-10; CXCR-3; CXC-R3; CKR-L2; CD183 antigen; CD183 T25315 FUNCTION Binds to CCL21. Probably promotes cell chemotaxis response. Isoform 1: Receptor for the C-X-C chemokine CXCL9, CXCL10 and CXCL11 and mediates the proliferation, survival and angiogenic activity of human mesangial cells (HMC) through a heterotrimeric G-protein signaling pathway. T25315 BIOCLASS GPCR rhodopsin T25315 SEQUENCE MVLEVSDHQVLNDAEVAALLENFSSSYDYGENESDSCCTSPPCPQDFSLNFDRAFLPALYSLLFLLGLLGNGAVAAVLLSRRTALSSTDTFLLHLAVADTLLVLTLPLWAVDAAVQWVFGSGLCKVAGALFNINFYAGALLLACISFDRYLNIVHATQLYRRGPPARVTLTCLAVWGLCLLFALPDFIFLSAHHDERLNATHCQYNFPQVGRTALRVLQLVAGFLLPLLVMAYCYAHILAVLLVSRGQRRLRAMRLVVVVVVAFALCWTPYHLVVLVDILMDLGALARNCGRESRVDVAKSVTSGLGYMHCCLNPLLYAFVGVKFRERMWMLLLRLGCPNQRGLQRQPSSSRRDSSWSETSEASYSGL T25315 DRUGINFO D0E6DI T487 Discontinued in Phase 2 T25315 DRUGINFO D0F2AD dioscin Preclinical T25315 DRUGINFO DBJ36R JT07 Preclinical T25315 DRUGINFO D09LGT kallstroemin D Investigative T25315 DRUGINFO D0A8PV NBI-74330 Investigative T25315 DRUGINFO D0EK9K Sch-900875 Investigative T25315 DRUGINFO D0T1PA hypoglaucin A Investigative T10491 TARGETID T10491 T10491 FORMERID TTDI02326 T10491 UNIPROID ACKR3_HUMAN T10491 TARGNAME C-X-C chemokine receptor type 7 (ACKR3) T10491 GENENAME ACKR3 T10491 TARGTYPE Preclinical T10491 SYNONYMS RDC1; RDC-1; Gprotein coupled receptor RDC1 homolog; Gprotein coupled receptor 159; GPR159; G-protein coupled receptor RDC1 homolog; G-protein coupled receptor 159; Chemokine orphan receptor 1; CXCR7; CXCR-7; CXC-R7; CXC chemokine receptor type 7; CMKOR1; Atypical chemokine receptor 3 T10491 FUNCTION Known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1. Chemokine binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization and activation of MAPK signaling pathway. Required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness. In glioma cells, transduces signals via MEK/ERK pathway, mediating resistance to apoptosis. Promotes cell growth and survival. Not involved in cell migration, adhesion or proliferation of normal hematopoietic progenitors but activated by CXCL11 in malignant hemapoietic cells, leading to phosphorylation of ERK1/2 (MAPK3/MAPK1) and enhanced cell adhesion and migration. Plays a regulatory role in CXCR4-mediated activation of cell surface integrins by CXCL12. Required for heart valve development. Acts as coreceptor with CXCR4 for a restricted number of HIV isolates. Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. T10491 BIOCLASS GPCR rhodopsin T10491 SEQUENCE MDLHLFDYSEPGNFSDISWPCNSSDCIVVDTVMCPNMPNKSVLLYTLSFIYIFIFVIGMIANSVVVWVNIQAKTTGYDTHCYILNLAIADLWVVLTIPVWVVSLVQHNQWPMGELTCKVTHLIFSINLFGSIFFLTCMSVDRYLSITYFTNTPSSRKKMVRRVVCILVWLLAFCVSLPDTYYLKTVTSASNNETYCRSFYPEHSIKEWLIGMELVSVVLGFAVPFSIIAVFYFLLARAISASSDQEKHSSRKIIFSYVVVFLVCWLPYHVAVLLDIFSILHYIPFTCRLEHALFTALHVTQCLSLVHCCVNPVLYSFINRNYRYELMKAFIFKYSAKTGLTKLIDASRVSETEYSALEQSTK T10491 DRUGINFO D0N2FI GW-766994 Discontinued in Phase 2 T10491 DRUGINFO DBJ36R JT07 Preclinical T10491 DRUGINFO D03LCX CCX-662 Investigative T85944 TARGETID T85944 T85944 FORMERID TTDR00865 T85944 UNIPROID LPXC_PSEAE T85944 TARGNAME Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) T85944 GENENAME Pseudo lpxC T85944 TARGTYPE Preclinical T85944 SYNONYMS Pseudo UDP-3-O-acyl-GlcNAc deacetylase; EnvA protein T85944 FUNCTION Involved in the biosynthesis of lipid A, a phosphorylated glycolipid that anchors the lipopolysaccharide to the outer membrane of the cell. T85944 PDBSTRUC 6MAE; 6CAX; 6C9C; 5VWM; 5UPG T85944 BIOCLASS Carbon-nitrogen hydrolase T85944 ECNUMBER EC 3.5.1.108 T85944 SEQUENCE MIKQRTLKNIIRATGVGLHSGEKVYLTLKPAPVDTGIVFCRTDLDPVVEIPARAENVGETTMSTTLVKGDVKVDTVEHLLSAMAGLGIDNAYVELSASEVPIMDGSAGPFVFLIQSAGLQEQEAAKKFIRIKREVSVEEGDKRAVFVPFDGFKVSFEIDFDHPVFRGRTQQASVDFSSTSFVKEVSRARTFGFMRDIEYLRSQNLALGGSVENAIVVDENRVLNEDGLRYEDEFVKHKILDAIGDLYLLGNSLIGEFRGFKSGHALNNQLLRTLIADKDAWEVVTFEDARTAPISYMRPAAAV T85944 DRUGINFO DB1P9T LpxC-1 Preclinical T85944 DRUGINFO DC9FD4 RC-01 Terminated T85944 DRUGINFO D02TRN Palmitoleic Acid Investigative T85944 DRUGINFO D05MXM 3-(heptyloxy)benzoic acid Investigative T85944 DRUGINFO D07WFG BB-78484 Investigative T85944 DRUGINFO D0J7FD BB-78485 Investigative T85944 DRUGINFO D0J8BO Tu-514 Investigative T85944 DRUGINFO D09TVP Cacodylate Ion Investigative T85944 DRUGINFO D08OBF MYRISTIC ACID Investigative T56051 TARGETID T56051 T56051 FORMERID TTDR01141 T56051 UNIPROID UCHL1_HUMAN T56051 TARGNAME Ubiquitin thioesterase L1 (UCHL1) T56051 GENENAME UCHL1 T56051 TARGTYPE Preclinical T56051 SYNONYMS Ubiquitin thiolesterase L1; Ubiquitin carboxyl-terminal hydrolase isozyme L1; Ubiquitin carboxy-terminal hydrolase L1; UCH-L1; PGP9.5; PGP 9.5; Neuron cytoplasmic protein 9.5 T56051 FUNCTION Ubiquitin-protein hydrolase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Also binds to free monoubiquitin and may prevent its degradation in lysosomes. The homodimer may have ATP-independent ubiquitin ligase activity. T56051 PDBSTRUC 4JKJ; 4DM9; 3KW5; 3KVF; 3IRT T56051 BIOCLASS Peptidase T56051 ECNUMBER EC 3.4.19.12 T56051 SEQUENCE MQLKPMEINPEMLNKVLSRLGVAGQWRFVDVLGLEEESLGSVPAPACALLLLFPLTAQHENFRKKQIEELKGQEVSPKVYFMKQTIGNSCGTIGLIHAVANNQDKLGFEDGSVLKQFLSETEKMSPEDRAKCFEKNEAIQAAHDAVAQEGQCRVDDKVNFHFILFNNVDGHLYELDGRMPFPVNHGASSEDTLLKDAAKVCREFTEREQGEVRFSAVALCKAA T56051 DRUGINFO DCIP24 LDN-57444 Preclinical T56051 DRUGINFO DRT90B NSC632839 Preclinical T56051 DRUGINFO D0N6BC LDN-91946 Investigative T68706 TARGETID T68706 T68706 FORMERID TTDI02227 T68706 UNIPROID FURIN_HUMAN T68706 TARGNAME Dibasic-processing enzyme (Furin) T68706 GENENAME FURIN T68706 TARGTYPE Preclinical T68706 SYNONYMS Paired basic amino acid residuecleaving enzyme; Paired basic amino acid residue-cleaving enzyme; PCSK3; PACE; FUR; Dibasicprocessing enzyme T68706 FUNCTION Mediates processing of TGFB1, an essential step in TGF-beta-1 activation. Ubiquitous endoprotease within constitutive secretory pathways capable of cleavage at the RX(K/R)R consensus motif. T68706 PDBSTRUC 6HZD; 6HZC; 6HZB; 6HZA; 6HLE T68706 BIOCLASS Peptidase T68706 ECNUMBER EC 3.4.21.75 T68706 SEQUENCE MELRPWLLWVVAATGTLVLLAADAQGQKVFTNTWAVRIPGGPAVANSVARKHGFLNLGQIFGDYYHFWHRGVTKRSLSPHRPRHSRLQREPQVQWLEQQVAKRRTKRDVYQEPTDPKFPQQWYLSGVTQRDLNVKAAWAQGYTGHGIVVSILDDGIEKNHPDLAGNYDPGASFDVNDQDPDPQPRYTQMNDNRHGTRCAGEVAAVANNGVCGVGVAYNARIGGVRMLDGEVTDAVEARSLGLNPNHIHIYSASWGPEDDGKTVDGPARLAEEAFFRGVSQGRGGLGSIFVWASGNGGREHDSCNCDGYTNSIYTLSISSATQFGNVPWYSEACSSTLATTYSSGNQNEKQIVTTDLRQKCTESHTGTSASAPLAAGIIALTLEANKNLTWRDMQHLVVQTSKPAHLNANDWATNGVGRKVSHSYGYGLLDAGAMVALAQNWTTVAPQRKCIIDILTEPKDIGKRLEVRKTVTACLGEPNHITRLEHAQARLTLSYNRRGDLAIHLVSPMGTRSTLLAARPHDYSADGFNDWAFMTTHSWDEDPSGEWVLEIENTSEANNYGTLTKFTLVLYGTAPEGLPVPPESSGCKTLTSSQACVVCEEGFSLHQKSCVQHCPPGFAPQVLDTHYSTENDVETIRASVCAPCHASCATCQGPALTDCLSCPSHASLDPVEQTCSRQSQSSRESPPQQQPPRLPPEVEAGQRLRAGLLPSHLPEVVAGLSCAFIVLVFVTVFLVLQLRSGFSFRGVKVYTMDRGLISYKGLPPEAWQEECPSDSEEDEGRGERTAFIKDQSAL T68706 DRUGINFO D02QTG US9266828, E Patented T68706 DRUGINFO D0R9MA US9266828, C Patented T68706 DRUGINFO D0W2BO US9266828, B Patented T68706 DRUGINFO DXNT71 DecRVKRCMK Preclinical T68706 DRUGINFO D08VTS MI-1148 Investigative T68706 DRUGINFO D0A6FZ peptide 18 Investigative T68706 DRUGINFO D05JJL furin inhibitor peptide Investigative T99912 TARGETID T99912 T99912 FORMERID TTDR00950 T99912 UNIPROID KYNU_HUMAN T99912 TARGNAME Kynureninase (KYNU) T99912 GENENAME KYNU T99912 TARGTYPE Preclinical T99912 SYNONYMS L-kynurenine hydrolase; KYNU T99912 FUNCTION Catalyzes the cleavage of L-kynurenine (L-Kyn) and L-3- hydroxykynurenine (L-3OHKyn) into anthranilic acid (AA) and 3- hydroxyanthranilic acid (3-OHAA), respectively. Has a preference for the L-3-hydroxy form. Also has cysteine-conjugate-beta-lyase activity. T99912 PDBSTRUC 3E9K; 2HZP T99912 BIOCLASS Carbon-carbon bonds hydrolase T99912 ECNUMBER EC 3.7.1.3 T99912 SEQUENCE MEPSSLELPADTVQRIAAELKCHPTDERVALHLDEEDKLRHFRECFYIPKIQDLPPVDLSLVNKDENAIYFLGNSLGLQPKMVKTYLEEELDKWAKIAAYGHEVGKRPWITGDESIVGLMKDIVGANEKEIALMNALTVNLHLLMLSFFKPTPKRYKILLEAKAFPSDHYAIESQLQLHGLNIEESMRMIKPREGEETLRIEDILEVIEKEGDSIAVILFSGVHFYTGQHFNIPAITKAGQAKGCYVGFDLAHAVGNVELYLHDWGVDFACWCSYKYLNAGAGGIAGAFIHEKHAHTIKPALVGWFGHELSTRFKMDNKLQLIPGVCGFRISNPPILLVCSLHASLEIFKQATMKALRKKSVLLTGYLEYLIKHNYGKDKAATKKPVVNIITPSHVEERGCQLTITFSVPNKDVFQELEKRGVVCDKRNPNGIRVAPVPLYNSFHDVYKFTNLLTSILDSAETKN T99912 DRUGINFO D17TRG 2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid Preclinical T99912 DRUGINFO D6QA4N S-(2-Aminophenyl)-L-cysteine S,S-dioxide Preclinical T99912 DRUGINFO D00ASH 3-methoxydesaminokynurenine Investigative T99912 DRUGINFO D05JZS 3-Hydroxyhippuric acid Investigative T99912 DRUGINFO D0V4AX 3-hydroxydesaminokynurenine Investigative T99912 DRUGINFO D02DWE 3,6,9,12,15-Pentaoxaheptadecane Investigative T15797 TARGETID T15797 T15797 FORMERID TTDI00213 T15797 UNIPROID SMYD2_HUMAN T15797 TARGNAME SET and MYND domain-containing protein 2 (SMYD2) T15797 GENENAME SMYD2 T15797 TARGTYPE Preclinical T15797 SYNONYMS Nlysine methyltransferase SMYD2; N-lysine methyltransferase SMYD2; Lysine Nmethyltransferase 3C; Lysine N-methyltransferase 3C; KMT3C; Histone methyltransferase SMYD2; HSKMB; HSKM-B T15797 FUNCTION Specifically methylates histone H3 'Lys-4' (H3K4me) and dimethylates histone H3 'Lys-36' (H3K36me2). Shows even higher methyltransferase activity on p53/TP53. Monomethylates 'Lys-370' of p53/TP53, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity of p53/TP53. Monomethylates RB1 at 'Lys-860'. Protein-lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53/TP53 and RB1. T15797 PDBSTRUC 6MON; 6CBY; 6CBX; 5WCG; 5V3H T15797 BIOCLASS Methyltransferase T15797 ECNUMBER EC 2.1.1.- T15797 SEQUENCE MRAEGLGGLERFCSPGKGRGLRALQPFQVGDLLFSCPAYAYVLTVNERGNHCEYCFTRKEGLSKCGRCKQAFYCNVECQKEDWPMHKLECSPMVVFGENWNPSETVRLTARILAKQKIHPERTPSEKLLAVKEFESHLDKLDNEKKDLIQSDIAALHHFYSKHLGFPDNDSLVVLFAQVNCNGFTIEDEELSHLGSAIFPDVALMNHSCCPNVIVTYKGTLAEVRAVQEIKPGEEVFTSYIDLLYPTEDRNDRLRDSYFFTCECQECTTKDKDKAKVEIRKLSDPPKAEAIRDMVRYARNVIEEFRRAKHYKSPSELLEICELSQEKMSSVFEDSNVYMLHMMYQAMGVCLYMQDWEGALQYGQKIIKPYSKHYPLYSLNVASMWLKLGRLYMGLEHKAAGEKALKKAIAIMEVAHGKDHPYISEIKQEIESH T15797 DRUGINFO D06ONB AZ505 Preclinical T15797 DRUGINFO D0X3RK LLY-507 Preclinical T15797 DRUGINFO D35SKV EPZ032597 Preclinical T15797 DRUGINFO DDC63W EPZ033294 Preclinical T15797 DRUGINFO DELC48 A-893 Preclinical T15797 DRUGINFO DT6P8M BAY 598 Preclinical T95183 TARGETID T95183 T95183 FORMERID TTDI02577 T95183 UNIPROID UBP2_HUMAN T95183 TARGNAME Ubiquitin carboxyl-terminal hydrolase 2 (USP2) T95183 GENENAME USP2 T95183 TARGTYPE Preclinical T95183 SYNONYMS Ubiquitin-specific-processing protease 2; Ubiquitin thioesterase 2; UBP41; Deubiquitinating enzyme 2; 41 kDa ubiquitin-specific protease T95183 FUNCTION Isoform 1 and isoform 4 possess both ubiquitin-specific peptidase and isopeptidase activities. Deubiquitinates MDM2 without reversing MDM2-mediated p53/TP53 ubiquitination and thus indirectly promotes p53/TP53 degradation and limits p53 activity. Has no deubiquitinase activity against p53/TP53. Prevents MDM2-mediated degradation of MDM4. Plays a role in the G1/S cell-cycle progression in normal and cancer cells. Regulates the circadian clock by modulating its intrinsic circadian rhythm and its capacity to respond to external cues. Associates with clock proteins and deubiquitinates core clock component PER1 but does not affect its overall stability. Regulates the nucleocytoplasmic shuttling and nuclear retention of PER1 and its repressive role on the clock transcription factors CLOCK and ARNTL/BMAL1. Plays a role in the regulation of myogenic differentiation of embryonic muscle cells. Hydrolase that deubiquitinates polyubiquitinated target proteins such as MDM2, MDM4 and CCND1. T95183 PDBSTRUC 6DGF; 5XVE; 5XU8; 3V6E; 3V6C T95183 BIOCLASS Peptidase T95183 ECNUMBER EC 3.4.19.12 T95183 SEQUENCE MSQLSSTLKRYTESARYTDAHYAKSGYGAYTPSSYGANLAASLLEKEKLGFKPVPTSSFLTRPRTYGPSSLLDYDRGRPLLRPDITGGGKRAESQTRGTERPLGSGLSGGSGFPYGVTNNCLSYLPINAYDQGVTLTQKLDSQSDLARDFSSLRTSDSYRIDPRNLGRSPMLARTRKELCTLQGLYQTASCPEYLVDYLENYGRKGSASQVPSQAPPSRVPEIISPTYRPIGRYTLWETGKGQAPGPSRSSSPGRDGMNSKSAQGLAGLRNLGNTCFMNSILQCLSNTRELRDYCLQRLYMRDLHHGSNAHTALVEEFAKLIQTIWTSSPNDVVSPSEFKTQIQRYAPRFVGYNQQDAQEFLRFLLDGLHNEVNRVTLRPKSNPENLDHLPDDEKGRQMWRKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDLSLPIAKRGYPEVTLMDCMRLFTKEDVLDGDEKPTCCRCRGRKRCIKKFSIQRFPKILVLHLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVYNLYAVSNHSGTTMGGHYTAYCRSPGTGEWHTFNDSSVTPMSSSQVRTSDAYLLFYELASPPSRM T95183 DRUGINFO DWR6A9 ML364 Preclinical T43206 TARGETID T43206 T43206 FORMERID TTDR00593 T43206 UNIPROID RORA_HUMAN T43206 TARGNAME Nuclear receptor ROR-alpha (RORA) T43206 GENENAME RORA T43206 TARGTYPE Preclinical T43206 SYNONYMS Retinoid-related orphan receptor-alpha; Retinoic acid-related orphan receptor alpha; RZRA; RAR-related orphan receptor A; Nuclear receptor subfamily 1 group F member 1; Nuclear receptor RZR-alpha; NR1F1 T43206 FUNCTION Key regulator of embryonic development, cellular differentiation, immunity, circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism. Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively. Recruits distinct combinations of cofactors to target genes regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates genes involved in photoreceptor development including OPN1SW, OPN1SM and ARR3 and skeletal muscle development with MYOD1. Required for proper cerebellum development. Regulates SHH gene expression, among others, to induce granule cells proliferation as well as expression of genes involved in calcium-mediated signal transduction. Regulates the circadian expression of several clock genes, including CLOCK, ARNTL/BMAL1, NPAS2 and CRY1. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as ARNTL/BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORA-mediated activation of clock genes expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock. Regulates genes involved in lipid metabolism such as apolipoproteins APOA1, APOA5, APOC3 and PPARG. In liver, has specific and redundant functions with RORC as positive or negative modulator of expression of genes encoding phase I and phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as CYP7B1 and SULT2A1. Induces a rhythmic expression of some of these genes. In addition, interplays functionally with NR1H2 and NR1H3 for the regulation of genes involved in cholesterol metabolism. Also involved in the regulation of hepatic glucose metabolism through the modulation of G6PC and PCK1. In adipose tissue, plays a role as negative regulator of adipocyte differentiation, probably acting through dual mechanisms. May suppress CEBPB-dependent adipogenesis through direct interaction and PPARG-dependent adipogenesis through competition for DNA-binding. Downstream of IL6 and TGFB and synergistically with RORC isoform 2, is implicated in the lineage specification of uncommitted CD4(+) T-helper (T(H)) cells into T(H)17 cells, antagonizing the T(H)1 program. Probably regulates IL17 and IL17F expression on T(H) by binding to the essential enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F locus. Involved in hypoxia signaling by interacting with and activating the transcriptional activity of HIF1A. May inhibit cell growth in response to cellular stress. May exert an anti-inflammatory role by inducing CHUK expression and inhibiting NF-kappa-B signaling. Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. T43206 PDBSTRUC 4S15; 1S0X; 1N83 T43206 BIOCLASS Nuclear hormone receptor T43206 SEQUENCE MESAPAAPDPAASEPGSSGADAAAGSRETPLNQESARKSEPPAPVRRQSYSSTSRGISVTKKTHTSQIEIIPCKICGDKSSGIHYGVITCEGCKGFFRRSQQSNATYSCPRQKNCLIDRTSRNRCQHCRLQKCLAVGMSRDAVKFGRMSKKQRDSLYAEVQKHRMQQQQRDHQQQPGEAEPLTPTYNISANGLTELHDDLSNYIDGHTPEGSKADSAVSSFYLDIQPSPDQSGLDINGIKPEPICDYTPASGFFPYCSFTNGETSPTVSMAELEHLAQNISKSHLETCQYLREELQQITWQTFLQEEIENYQNKQREVMWQLCAIKITEAIQYVVEFAKRIDGFMELCQNDQIVLLKAGSLEVVFIRMCRAFDSQNNTVYFDGKYASPDVFKSLGCEDFISFVFEFGKSLCSMHLTEDEIALFSAFVLMSADRSWLQEKVKIEKLQQKIQLALQHVLQKNHREDGILTKLICKVSTLRALCGRHTEKLMAFKAIYPDIVRLHFPPLYKELFTSEFEPAMQIDG T43206 DRUGINFO D0SK3V US9598431, 3 Patented T43206 DRUGINFO DZ28EB SR3335 Preclinical T43206 DRUGINFO D9D6QN SR1078 Preclinical T43206 DRUGINFO D01USH 7-hydroxycholesterol Investigative T83982 TARGETID T83982 T83982 FORMERID TTDI02457 T83982 UNIPROID UBP8_HUMAN T83982 TARGNAME Ubiquitin isopeptidase Y (USP8) T83982 GENENAME USP8 T83982 TARGTYPE Preclinical T83982 SYNONYMS hUBPy; Ubiquitin-specific-processing protease 8; Ubiquitin thioesterase 8; Ubiquitin carboxyl-terminal hydrolase 8; UBPY; KIAA0055; Deubiquitinating enzyme 8 T83982 FUNCTION Converts both 'Lys-48' an 'Lys-63'-linked ubiquitin chains. Catalytic activity is enhanced in the M phase. Involved in cell proliferation. Required to enter into S phase in response to serum stimulation. May regulate T-cell anergy mediated by RNF128 via the formation of a complex containing RNF128 and OTUB1. Probably regulates the stability of STAM2 and RASGRF1. Regulates endosomal ubiquitin dynamics, cargo sorting, membrane traffic at early endosomes, and maintenance of ESCRT-0 stability. The level of protein ubiquitination on endosomes is essential for maintaining the morphology of the organelle. Deubiquitinates EPS15 and controles tyrosine kinase stability. Removes conjugated ubiquitin from EGFR thus regulating EGFR degradation and downstream MAPK signaling. Involved in acrosome biogenesis through interaction with the spermatid ESCRT-0 complex and microtubules. Deubiquitinates BIRC6/bruce and KIF23/MKLP1. Deubiquitinates BACE1 which inhibits BACE1 lysosomal degradation and modulates BACE-medaited APP cleavage and amyloid-beta formation. Hydrolase that can remove conjugated ubiquitin from proteins and therefore plays an important regulatory role at the level of protein turnover by preventing degradation. T83982 PDBSTRUC 6F09; 3N3K; 2GWF; 2GFO; 2A9U T83982 BIOCLASS Peptidase T83982 ECNUMBER EC 3.4.19.12 T83982 SEQUENCE MPAVASVPKELYLSSSLKDLNKKTEVKPEKISTKSYVHSALKIFKTAEECRLDRDEERAYVLYMKYVTVYNLIKKRPDFKQQQDYFHSILGPGNIKKAVEEAERLSESLKLRYEEAEVRKKLEEKDRQEEAQRLQQKRQETGREDGGTLAKGSLENVLDSKDKTQKSNGEKNEKCETKEKGAITAKELYTMMTDKNISLIIMDARRMQDYQDSCILHSLSVPEEAISPGVTASWIEAHLPDDSKDTWKKRGNVEYVVLLDWFSSAKDLQIGTTLRSLKDALFKWESKTVLRNEPLVLEGGYENWLLCYPQYTTNAKVTPPPRRQNEEVSISLDFTYPSLEESIPSKPAAQTPPASIEVDENIELISGQNERMGPLNISTPVEPVAASKSDVSPIIQPVPSIKNVPQIDRTKKPAVKLPEEHRIKSESTNHEQQSPQSGKVIPDRSTKPVVFSPTLMLTDEEKARIHAETALLMEKNKQEKELRERQQEEQKEKLRKEEQEQKAKKKQEAEENEITEKQQKAKEEMEKKESEQAKKEDKETSAKRGKEITGVKRQSKSEHETSDAKKSVEDRGKRCPTPEIQKKSTGDVPHTSVTGDSGSGKPFKIKGQPESGILRTGTFREDTDDTERNKAQREPLTRARSEEMGRIVPGLPSGWAKFLDPITGTFRYYHSPTNTVHMYPPEMAPSSAPPSTPPTHKAKPQIPAERDREPSKLKRSYSSPDITQAIQEEEKRKPTVTPTVNRENKPTCYPKAEISRLSASQIRNLNPVFGGSGPALTGLRNLGNTCYMNSILQCLCNAPHLADYFNRNCYQDDINRSNLLGHKGEVAEEFGIIMKALWTGQYRYISPKDFKITIGKINDQFAGYSQQDSQELLLFLMDGLHEDLNKADNRKRYKEENNDHLDDFKAAEHAWQKHKQLNESIIVALFQGQFKSTVQCLTCHKKSRTFEAFMYLSLPLASTSKCTLQDCLRLFSKEEKLTDNNRFYCSHCRARRDSLKKIEIWKLPPVLLVHLKRFSYDGRWKQKLQTSVDFPLENLDLSQYVIGPKNNLKKYNLFSVSNHYGGLDGGHYTAYCKNAARQRWFKFDDHEVSDISVSSVKSSAAYILFYTSLGPRVTDVAT T83982 DRUGINFO D4X9MD 9-(Ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile Preclinical T17067 TARGETID T17067 T17067 FORMERID TTDI03611 T17067 UNIPROID UBP5_HUMAN T17067 TARGNAME Isopeptidase T (USP5) T17067 GENENAME USP5 T17067 TARGTYPE Preclinical T17067 SYNONYMS Ubiquitin-specific-processing protease 5; Ubiquitin thioesterase 5; Ubiquitin carboxyl-terminal hydrolase 5; ISOT; Deubiquitinating enzyme 5 T17067 FUNCTION Involved in unanchored 'Lys-48'-linked polyubiquitin disassembly. Binds linear and 'Lys-63'-linked polyubiquitin with a lower affinity. Knock-down of USP5 causes the accumulation of p53/TP53 and an increase in p53/TP53 transcriptional activity because the unanchored polyubiquitin that accumulates is able to compete with ubiquitinated p53/TP53 but not with MDM2 for proteasomal recognition. Cleaves linear and branched multiubiquitin polymers with a marked preference for branched polymers. T17067 PDBSTRUC 6NFT; 6DXT; 6DXH; 3IHP; 2G45 T17067 BIOCLASS Peptidase T17067 ECNUMBER EC 3.4.19.12 T17067 SEQUENCE MAELSEEALLSVLPTIRVPKAGDRVHKDECAFSFDTPESEGGLYICMNTFLGFGKQYVERHFNKTGQRVYLHLRRTRRPKEEDPATGTGDPPRKKPTRLAIGVEGGFDLSEEKFELDEDVKIVILPDYLEIARDGLGGLPDIVRDRVTSAVEALLSADSASRKQEVQAWDGEVRQVSKHAFSLKQLDNPARIPPCGWKCSKCDMRENLWLNLTDGSILCGRRYFDGSGGNNHAVEHYRETGYPLAVKLGTITPDGADVYSYDEDDMVLDPSLAEHLSHFGIDMLKMQKTDKTMTELEIDMNQRIGEWELIQESGVPLKPLFGPGYTGIRNLGNSCYLNSVVQVLFSIPDFQRKYVDKLEKIFQNAPTDPTQDFSTQVAKLGHGLLSGEYSKPVPESGDGERVPEQKEVQDGIAPRMFKALIGKGHPEFSTNRQQDAQEFFLHLINMVERNCRSSENPNEVFRFLVEEKIKCLATEKVKYTQRVDYIMQLPVPMDAALNKEELLEYEEKKRQAEEEKMALPELVRAQVPFSSCLEAYGAPEQVDDFWSTALQAKSVAVKTTRFASFPDYLVIQIKKFTFGLDWVPKKLDVSIEMPEELDISQLRGTGLQPGEEELPDIAPPLVTPDEPKGSLGFYGNEDEDSFCSPHFSSPTSPMLDESVIIQLVEMGFPMDACRKAVYYTGNSGAEAAMNWVMSHMDDPDFANPLILPGSSGPGSTSAAADPPPEDCVTTIVSMGFSRDQALKALRATNNSLERAVDWIFSHIDDLDAEAAMDISEGRSAADSISESVPVGPKVRDGPGKYQLFAFISHMGTSTMCGHYVCHIKKEGRWVIYNDQKVCASEKPPKDLGYIYFYQRVAS T17067 DRUGINFO D0Y7OI vialinin A Preclinical T17067 DRUGINFO DGP6V3 BAP-15 Preclinical T87109 TARGETID T87109 T87109 FORMERID TTDI03080 T87109 UNIPROID KC1D_HUMAN T87109 TARGNAME Casein kinase I delta (CSNK1D) T87109 GENENAME CSNK1D T87109 TARGTYPE Preclinical T87109 SYNONYMS Tau-protein kinase CSNK1D; HCKID; Casein kinase I isoform delta; CKId; CKI-delta T87109 FUNCTION It can phosphorylate a large number of proteins. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. In balance with PP1, determines the circadian period length through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. Controls PER1 and PER2 nuclear transport and degradation. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated ubiquitination and subsequent degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation. Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that controls neurite outgrowth. EIF6 phosphorylation promotes its nuclear export. Triggers down-regulation of dopamine receptors in the forebrain. Activates DCK in vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable complex formation. May regulate the formation of the mitotic spindle apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap junction assembly by phosphorylation. Probably involved in lymphocyte physiology. Regulates fast synaptic transmission mediated by glutamate. Essential serine/threonine-protein kinase that regulates diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. T87109 PDBSTRUC 6GZM; 6F26; 6F1W; 5W4W; 5OKT T87109 BIOCLASS Kinase T87109 ECNUMBER EC 2.7.11.1 T87109 SEQUENCE MELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLKFGASRAADDAERERRDREERLRHSRNPATRGLPSTASGRLRGTQEVAPPTPLTPTSHTANTSPRPVSGMERERKVSMRLHRGAPVNISSSDLTGRQDTSRMSTSQIPGRVASSGLQSVVHR T87109 DRUGINFO D00JGL D-4476 Preclinical T87109 DRUGINFO D06QYR PF-4800567 Preclinical T87109 DRUGINFO DZK7E0 PF-670462 Preclinical T87109 DRUGINFO D0UN8H IC261 Preclinical T87109 DRUGINFO D0H4VB PMID24900428C14 Investigative T82668 TARGETID T82668 T82668 FORMERID TTDI02559 T82668 UNIPROID AADAT_HUMAN T82668 TARGNAME Kynurenine oxoglutarate transaminase II (AADAT) T82668 GENENAME AADAT T82668 TARGTYPE Preclinical T82668 SYNONYMS Kynurenineoxoglutarate transaminase II; Kynurenineoxoglutarate transaminase 2; Kynurenineoxoglutarate aminotransferase II; Kynurenine/alphaaminoadipate aminotransferase, mitochondrial; Kynurenine aminotransferase II; KAT/AadAT; Alphaaminoadipate aminotransferase; AadAT; 2aminoadipate transaminase; 2aminoadipate aminotransferase T82668 FUNCTION Transaminase with broad substrate specificity. Has transaminase activity towards aminoadipate, kynurenine, methionine and glutamate. Shows activity also towards tryptophan, aspartate and hydroxykynurenine. Accepts a variety of oxo-acids as amino- group acceptors, with a preference for 2-oxoglutarate, 2- oxocaproic acid, phenylpyruvate and alpha-oxo-gamma-methiol butyric acid. Can also use glyoxylate as amino-group acceptor (in vitro). T82668 PDBSTRUC 6D0A; 5TF5; 5EUN; 5EFS; 4GEB T82668 BIOCLASS Transaminase T82668 ECNUMBER EC 2.6.1.39 T82668 SEQUENCE MNYARFITAASAARNPSPIRTMTDILSRGPKSMISLAGGLPNPNMFPFKTAVITVENGKTIQFGEEMMKRALQYSPSAGIPELLSWLKQLQIKLHNPPTIHYPPSQGQMDLCVTSGSQQGLCKVFEMIINPGDNVLLDEPAYSGTLQSLHPLGCNIINVASDESGIVPDSLRDILSRWKPEDAKNPQKNTPKFLYTVPNGNNPTGNSLTSERKKEIYELARKYDFLIIEDDPYYFLQFNKFRVPTFLSMDVDGRVIRADSFSKIISSGLRIGFLTGPKPLIERVILHIQVSTLHPSTFNQLMISQLLHEWGEEGFMAHVDRVIDFYSNQKDAILAAADKWLTGLAEWHVPAAGMFLWIKVKGINDVKELIEEKAVKMGVLMLPGNAFYVDSSAPSPYLRASFSSASPEQMDVAFQVLAQLIKESL T82668 DRUGINFO D03DSN US10065972, Example 560 Patented T82668 DRUGINFO D07JBL US8933095, 1 Patented T82668 DRUGINFO D08ETC US10065972, Example 281 Patented T82668 DRUGINFO D09JPJ US8933095, 16 Patented T82668 DRUGINFO D0QE9Q US10065972, Example 396 Patented T82668 DRUGINFO D0RR5C US8933095, 18 Patented T82668 DRUGINFO D0SZ7H US8933095, 14 Patented T82668 DRUGINFO D9PBQ8 PF-04859989 Preclinical T82668 DRUGINFO DPQ4U3 BFF-122 Preclinical T82668 DRUGINFO DVQ37G (S)-4-(Ethylsulfonyl)benzoylalanine Preclinical T53251 TARGETID T53251 T53251 FORMERID TTDI03186 T53251 UNIPROID EHMT2_HUMAN T53251 TARGNAME Histone-lysine N-methyltransferase EHMT2 (EHMT2) T53251 GENENAME EHMT2 T53251 TARGTYPE Preclinical T53251 SYNONYMS Protein G9a; NG36; Lysine N-methyltransferase 1C; KMT1C; Histone H3-K9 methyltransferase 3; HLA-B-associated transcript 8; H3-K9-HMTase 3; G9A; Euchromatic histone-lysine N-methyltransferase 2; C6orf30; BAT8 T53251 FUNCTION H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones. Also mediates monomethylation of 'Lys-56' of histone H3 (H3K56me1) in G1 phase, leading to promote interaction between histone H3 and PCNA and regulating DNA replication. Also weakly methylates 'Lys-27' of histone H3 (H3K27me). Also required for DNA methylation, the histone methyltransferase activity is not required for DNA methylation, suggesting that these 2 activities function independently. Probably targeted to histone H3 by different DNA-binding proteins like E2F6, MGA, MAX and/or DP1. May also methylate histone H1. In addition to the histone methyltransferase activity, also methylates non-histone proteins: mediates dimethylation of 'Lys-373' of p53/TP53. Also methylates CDYL, WIZ, ACIN1, DNMT1, HDAC1, ERCC6, KLF12 and itself. Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. T53251 PDBSTRUC 5VSE; 5VSC; 5V9I; 5TUY; 5TTF T53251 BIOCLASS Methyltransferase T53251 ECNUMBER EC 2.1.1.- T53251 SEQUENCE MAAAAGAAAAAAAEGEAPAEMGALLLEKETRGATERVHGSLGDTPRSEETLPKATPDSLEPAGPSSPASVTVTVGDEGADTPVGATPLIGDESENLEGDGDLRGGRILLGHATKSFPSSPSKGGSCPSRAKMSMTGAGKSPPSVQSLAMRLLSMPGAQGAAAAGSEPPPATTSPEGQPKVHRARKTMSKPGNGQPPVPEKRPPEIQHFRMSDDVHSLGKVTSDLAKRRKLNSGGGLSEELGSARRSGEVTLTKGDPGSLEEWETVVGDDFSLYYDSYSVDERVDSDSKSEVEALTEQLSEEEEEEEEEEEEEEEEEEEEEEEEDEESGNQSDRSGSSGRRKAKKKWRKDSPWVKPSRKRRKREPPRAKEPRGVNGVGSSGPSEYMEVPLGSLELPSEGTLSPNHAGVSNDTSSLETERGFEELPLCSCRMEAPKIDRISERAGHKCMATESVDGELSGCNAAILKRETMRPSSRVALMVLCETHRARMVKHHCCPGCGYFCTAGTFLECHPDFRVAHRFHKACVSQLNGMVFCPHCGEDASEAQEVTIPRGDGVTPPAGTAAPAPPPLSQDVPGRADTSQPSARMRGHGEPRRPPCDPLADTIDSSGPSLTLPNGGCLSAVGLPLGPGREALEKALVIQESERRKKLRFHPRQLYLSVKQGELQKVILMLLDNLDPNFQSDQQSKRTPLHAAAQKGSVEICHVLLQAGANINAVDKQQRTPLMEAVVNNHLEVARYMVQRGGCVYSKEEDGSTCLHHAAKIGNLEMVSLLLSTGQVDVNAQDSGGWTPIIWAAEHKHIEVIRMLLTRGADVTLTDNEENICLHWASFTGSAAIAEVLLNARCDLHAVNYHGDTPLHIAARESYHDCVLLFLSRGANPELRNKEGDTAWDLTPERSDVWFALQLNRKLRLGVGNRAIRTEKIICRDVARGYENVPIPCVNGVDGEPCPEDYKYISENCETSTMNIDRNITHLQHCTCVDDCSSSNCLCGQLSIRCWYDKDGRLLQEFNKIEPPLIFECNQACSCWRNCKNRVVQSGIKVRLQLYRTAKMGWGVRALQTIPQGTFICEYVGELISDAEADVREDDSYLFDLDNKDGEVYCIDARYYGNISRFINHLCDPNIIPVRVFMLHQDLRFPRIAFFSSRDIRTGEELGFDYGDRFWDIKSKYFTCQCGSEKCKHSAEAIALEQSRLARLDPHPELLPELGSLPPVNT T53251 DRUGINFO DJ1Q9B MS012 Preclinical T53251 DRUGINFO D06PPL BIX-01294 Preclinical T53251 DRUGINFO D0C5EG A-366 Preclinical T53251 DRUGINFO D0CX4W UNC0321 Investigative T53251 DRUGINFO D0RO9T BRD9539 Investigative T53251 DRUGINFO D0BI4T UNC0642 Investigative T53251 DRUGINFO D0GK7A UNC0638 Investigative T94201 TARGETID T94201 T94201 FORMERID TTDI03560 T94201 UNIPROID SRPK1_HUMAN T94201 TARGNAME SRSF protein kinase 1 (SRPK1) T94201 GENENAME SRPK1 T94201 TARGTYPE Preclinical T94201 SYNONYMS Serine/arginine-rich protein-specific kinase 1; SR-protein-specific kinase 1; SFRS protein kinase 1 T94201 FUNCTION Plays a central role in the regulatory network for splicing, controlling the intranuclear distribution of splicing factors in interphase cells and the reorganization of nuclear speckles during mitosis. Can influence additional steps of mRNA maturation, as well as other cellular activities, such as chromatin reorganization in somatic and sperm cells and cell cycle progression. Isoform 2 phosphorylates SFRS2, ZRSR2, LBR and PRM1. Isoform 2 phosphorylates SRSF1 using a directional (C-terminal to N-terminal) and a dual-track mechanism incorporating both processive phosphorylation (in which the kinase stays attached to the substrate after each round of phosphorylation) and distributive phosphorylation steps (in which the kinase and substrate dissociate after each phosphorylation event). The RS domain of SRSF1 binds first to a docking groove in the large lobe of the kinase domain of SRPK1. This induces certain structural changes in SRPK1 and/or RRM2 domain of SRSF1, allowing RRM2 to bind the kinase and initiate phosphorylation. The cycles continue for several phosphorylation steps in a processive manner (steps 1-8) until the last few phosphorylation steps (approximately steps 9-12). During that time, a mechanical stress induces the unfolding of the beta-4 motif in RRM2, which then docks at the docking groove of SRPK1. This also signals RRM2 to begin to dissociate, which facilitates SRSF1 dissociation after phosphorylation is completed. Isoform 2 can mediate hepatitis B virus (HBV) core protein phosphorylation. It plays a negative role in the regulation of HBV replication through a mechanism not involving the phosphorylation of the core protein but by reducing the packaging efficiency of the pregenomic RNA (pgRNA) without affecting the formation of the viral core particles. Isoform 1 and isoform 2 can induce splicing of exon 10 in MAPT/TAU. The ratio of isoform 1/isoform 2 plays a decisive role in determining cell fate in K-562 leukaemic cell line: isoform 2 favors proliferation where as isoform 1 favors differentiation. Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is involved in the phosphorylation of SR splicing factors and the regulation of splicing. T94201 PDBSTRUC 5XV7; 5NNG; 5MY8; 5MXX; 4WUA T94201 BIOCLASS Kinase T94201 ECNUMBER EC 2.7.11.1 T94201 SEQUENCE MERKVLALQARKKRTKAKKDKAQRKSETQHRGSAPHSESDLPEQEEEILGSDDDEQEDPNDYCKGGYHLVKIGDLFNGRYHVIRKLGWGHFSTVWLSWDIQGKKFVAMKVVKSAEHYTETALDEIRLLKSVRNSDPNDPNREMVVQLLDDFKISGVNGTHICMVFEVLGHHLLKWIIKSNYQGLPLPCVKKIIQQVLQGLDYLHTKCRIIHTDIKPENILLSVNEQYIRRLAAEATEWQRSGAPPPSGSAVSTAPQPKPADKMSKNKKKKLKKKQKRQAELLEKRMQEIEEMEKESGPGQKRPNKQEESESPVERPLKENPPNKMTQEKLEESSTIGQDQTLMERDTEGGAAEINCNGVIEVINYTQNSNNETLRHKEDLHNANDCDVQNLNQESSFLSSQNGDSSTSQETDSCTPITSEVSDTMVCQSSSTVGQSFSEQHISQLQESIRAEIPCEDEQEQEHNGPLDNKGKSTAGNFLVNPLEPKNAEKLKVKIADLGNACWVHKHFTEDIQTRQYRSLEVLIGSGYNTPADIWSTACMAFELATGDYLFEPHSGEEYTRDEDHIALIIELLGKVPRKLIVAGKYSKEFFTKKGDLKHITKLKPWGLFEVLVEKYEWSQEEAAGFTDFLLPMLELIPEKRATAAECLRHPWLNS T94201 DRUGINFO D03OBN ZINC959121 Patented T94201 DRUGINFO D0LA9D Sphinx Patented T94201 DRUGINFO D0NY4A SPHINX scaffold, 3 Patented T94201 DRUGINFO D86ILE SPHINX31 Preclinical T94201 DRUGINFO D0J1JB PMID15925511C13 Investigative T30420 TARGETID T30420 T30420 FORMERID TTDI03543 T30420 UNIPROID KMT5A_HUMAN T30420 TARGNAME SET domain containing 8 (KMT5A) T30420 GENENAME KMT5A T30420 TARGTYPE Preclinical T30420 SYNONYMS SETD8; SET8; SET07; SET domain-containing protein 8; PRSET7; PR/SET07; PR/SET domain-containing protein 07; PR-Set7; N-lysine methyltransferase KMT5A; Lysine-specific methylase 5A; Lysine N-methyltransferase 5A; Histone-lysine N-methyltransferase KMT5A; H4-K20-HMTase KMT5A T30420 FUNCTION Specifically monomethylates 'Lys-20' of histone H4 (H4K20me1). H4K20me1 is enriched during mitosis and represents a specific tag for epigenetic transcriptional repression. Mainly functions in euchromatin regions, thereby playing a central role in the silencing of euchromatic genes. Required for cell proliferation, probably by contributing to the maintenance of proper higher-order structure of DNA during mitosis. Involved in chromosome condensation and proper cytokinesis. Nucleosomes are preferred as substrate compared to free histones. Mediates monomethylation of p53/TP53 at 'Lys-382', leading to repress p53/TP53-target genes. Plays a negative role in TGF-beta response regulation and a positive role in cell migration. Protein-lysine N-methyltransferase that monomethylates both histones and non-histone proteins. T30420 PDBSTRUC 6BOZ; 5W1Y; 5V2N; 5TH7; 5TEG T30420 BIOCLASS Methyltransferase T30420 ECNUMBER EC 2.1.1.- T30420 SEQUENCE MGEGGAAAALVAAAAAAAAAAAAVVAGQRRRRLGRRARCHGPGRAAGGKMSKPCAVEAAAAAVAATAPGPEMVERRGPGRPRTDGENVFTGQSKIYSYMSPNKCSGMRFPLQEENSVTHHEVKCQGKPLAGIYRKREEKRNAGNAVRSAMKSEEQKIKDARKGPLVPFPNQKSEAAEPPKTPPSSCDSTNAAIAKQALKKPIKGKQAPRKKAQGKTQQNRKLTDFYPVRRSSRKSKAELQSEERKRIDELIESGKEEGMKIDLIDGKGRGVIATKQFSRGDFVVEYHGDLIEITDAKKREALYAQDPSTGCYMYYFQYLSKTYCVDATRETNRLGRLINHSKCGNCQTKLHDIDGVPHLILIASRDIAAGEELLYDYGDRSKASIEAHPWLKH T30420 DRUGINFO D4V0SI MS2177 Preclinical T30420 DRUGINFO DB4D2N UNC0379 Preclinical T30420 DRUGINFO D0I4DG nahuoic acid A Investigative T30420 DRUGINFO D83QVW MS453 Investigative T89458 TARGETID T89458 T89458 FORMERID TTDR00963 T89458 UNIPROID GTR1_HUMAN T89458 TARGNAME HepG2 glucose transporter (SLC2A1) T89458 GENENAME SLC2A1 T89458 TARGTYPE Preclinical T89458 SYNONYMS Solute carrier family 2, facilitated glucose transporter member 1; HepG2 glucosetransporter; Glucose transporter type 1, erythrocyte/brain; GLUT1; GLUT-1 T89458 FUNCTION Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses. T89458 PDBSTRUC 5EQI; 5EQH; 5EQG; 4PYP; 1SUK T89458 BIOCLASS Major facilitator T89458 SEQUENCE MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWVHRYGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVSAVLMGFSKLGKSFEMLILGRFIIGVYCGLTTGFVPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIMGNKDLWPLLLSIIFIPALLQCIVLPFCPESPRFLLINRNEENRAKSVLKKLRGTADVTHDLQEMKEESRQMMREKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEKAGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRRTLHLIGLAGMAGCAILMTIALALLEQLPWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGMCFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQGGASQSDKTPEELFHPLGADSQV T89458 DRUGINFO DCL8J5 WZB-117 Preclinical T01521 TARGETID T01521 T01521 UNIPROID GSTO1_HUMAN T01521 TARGNAME Glutathione S-transferase omega-1 (GSTO-1) T01521 GENENAME GSTO1 T01521 TARGTYPE Preclinical T01521 SYNONYMS SPG-R; S-(Phenacyl)glutathione reductase; Monomethylarsonic acid reductase; MMA(V) reductase; Glutathione-dependent dehydroascorbate reductase; Glutathione S-transferase omega 1-1; GSTTLP28; GSTO-1; GSTO 1-1 T01521 FUNCTION Exhibits glutathione-dependent thiol transferase and dehydroascorbate reductase activities. Has S-(phenacyl)glutathione reductase activity. Has also glutathione S-transferase activity. Participates in the biotransformation of inorganic arsenic and reduces monomethylarsonic acid (MMA) and dimethylarsonic acid. T01521 PDBSTRUC 6MHD; 6MHC; 6MHB; 5YVO; 5YVN T01521 ECNUMBER EC 2.5.1.18 T01521 SEQUENCE MSGESARSLGKGSAPPGPVPEGSIRIYSMRFCPFAERTRLVLKAKGIRHEVININLKNKPEWFFKKNPFGLVPVLENSQGQLIYESAITCEYLDEAYPGKKLLPDDPYEKACQKMILELFSKVPSLVGSFIRSQNKEDYAGLKEEFRKEFTKLEEVLTNKKTTFFGGNSISMIDYLIWPWFERLEAMKLNECVDHTPKLKLWMAAMKEDPTVSALLTSEKDWQGFLELYLQNSPEACDYGL T01521 DRUGINFO D5R7AE Piperlongumine Preclinical T00254 TARGETID T00254 T00254 FORMERID TTDI03516 T00254 UNIPROID NR1D1_HUMAN T00254 TARGNAME V-erbA-related protein 1 (NR1D1) T00254 GENENAME NR1D1 T00254 TARGTYPE Preclinical T00254 SYNONYMS THRAL; Rev-erbA-alpha; Nuclear receptor subfamily 1 group D member 1; HREV; EAR1; EAR-1 T00254 FUNCTION Transcriptional repressor which coordinates circadian rhythm and metabolic pathways in a heme-dependent manner. Integral component of the complex transcription machinery that governs circadian rhythmicity and forms a critical negative limb of the circadian clock by directly repressing the expression of core clock components ARTNL/BMAL1, CLOCK and CRY1. Also regulates genes involved in metabolic functions, including lipid and bile acid metabolism, adipogenesis, gluconeogenesis and the macrophage inflammatory response. Acts as a receptor for heme which stimulates its interaction with the NCOR1/HDAC3 corepressor complex, enhancing transcriptional repression. Recognizes two classes of DNA response elements within the promoter of its target genes and can bind to DNA as either monomers or homodimers, depending on the nature of the response element. Binds as a monomer to a response element composed of the consensus half-site motif 5'-[A/G]GGTCA-3' preceded by an A/T-rich 5' sequence (RevRE), or as a homodimer to a direct repeat of the core motif spaced by two nucleotides (RevDR-2). Acts as a potent competitive repressor of ROR alpha (RORA) function and regulates the levels of its ligand heme by repressing the expression of PPARGC1A, a potent inducer of heme synthesis. Regulates lipid metabolism by repressing the expression of APOC3 and by influencing the activity of sterol response element binding proteins (SREBPs); represses INSIG2 which interferes with the proteolytic activation of SREBPs which in turn govern the rhythmic expression of enzymes with key functions in sterol and fatty acid synthesis. Regulates gluconeogenesis via repression of G6PC and PEPCK and adipocyte differentiation via repression of PPARG. Regulates glucagon release in pancreatic alpha-cells via the AMPK-NAMPT-SIRT1 pathway and the proliferation, glucose-induced insulin secretion and expression of key lipogenic genes in pancreatic-beta cells. Positively regulates bile acid synthesis by increasing hepatic expression of CYP7A1 via repression of NR0B2 and NFIL3 which are negative regulators of CYP7A1. Modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy; controls mitochondrial biogenesis and respiration by interfering with the STK11-PRKAA1/2-SIRT1-PPARGC1A signaling pathway. Represses the expression of SERPINE1/PAI1, an important modulator of cardiovascular disease and the expression of inflammatory cytokines and chemokines in macrophages. Represses gene expression at a distance in macrophages by inhibiting the transcription of enhancer-derived RNAs (eRNAs). Plays a role in the circadian regulation of body temperature and negatively regulates thermogenic transcriptional programs in brown adipose tissue (BAT); imposes a circadian oscillation in BAT activity, increasing body temperature when awake and depressing thermogenesis during sleep. In concert with NR2E3, regulates transcriptional networks critical for photoreceptor development and function. In addition to its activity as a repressor, can also act as a transcriptional activator. In the ovarian granulosa cells acts as a transcriptional activator of STAR which plays a role in steroid biosynthesis. In collaboration with SP1, activates GJA1 transcription in a heme-independent manner. Represses the transcription of CYP2B10, CYP4A10 and CYP4A14 (By similarity). Represses the transcription of CES2 (By similarity). Represses and regulates the circadian expression of TSHB in a NCOR1-dependent manner (By similarity). Negatively regulates the protein stability of NR3C1 and influences the time-dependent subcellular distribution of NR3C1, thereby affecting its transcriptional regulatory activity (By similarity). Plays a critical role in the circadian control of neutrophilic inflammation in the lung; under resting, non-stress conditions, acts as a rhythmic repressor to limit inflammatory activity whereas in the presence of inflammatory triggers undergoes ubiquitin-mediated degradation thereby relieving inhibition of the inflammatory response (By similarity). Plays a key role in the circadian regulation of microglial activation and neuroinflammation; suppresses microglial activation through the NF-kappaB pathway in the central nervous system (By similarity). Plays a role in the regulation of the diurnal rhythms of lipid and protein metabolism in the skeletal muscle via transcriptional repression of genes controlling lipid and amino acid metabolism in the muscle (By similarity). T00254 PDBSTRUC 3N00; 1HLZ; 1GA5; 1EF6; 1A6Y T00254 SEQUENCE MTTLDSNNNTGGVITYIGSSGSSPSRTSPESLYSDNSNGSFQSLTQGCPTYFPPSPTGSLTQDPARSFGSIPPSLSDDGSPSSSSSSSSSSSSFYNGSPPGSLQVAMEDSSRVSPSKSTSNITKLNGMVLLCKVCGDVASGFHYGVHACEGCKGFFRRSIQQNIQYKRCLKNENCSIVRINRNRCQQCRFKKCLSVGMSRDAVRFGRIPKREKQRMLAEMQSAMNLANNQLSSQCPLETSPTQHPTPGPMGPSPPPAPVPSPLVGFSQFPQQLTPPRSPSPEPTVEDVISQVARAHREIFTYAHDKLGSSPGNFNANHASGSPPATTPHRWENQGCPPAPNDNNTLAAQRHNEALNGLRQAPSSYPPTWPPGPAHHSCHQSNSNGHRLCPTHVYAAPEGKAPANSPRQGNSKNVLLACPMNMYPHGRSGRTVQEIWEDFSMSFTPAVREVVEFAKHIPGFRDLSQHDQVTLLKAGTFEVLMVRFASLFNVKDQTVMFLSRTTYSLQELGAMGMGDLLSAMFDFSEKLNSLALTEEELGLFTAVVLVSADRSGMENSASVEQLQETLLRALRALVLKNRPLETSRFTKLLLKLPDLRTLNNMHSEKLLSFRVDAQ T00254 DRUGINFO D07IZG GSK4112 Preclinical T00254 DRUGINFO D0K1VV SR8278 Preclinical T00254 DRUGINFO D40DVS SR9009 Preclinical T00254 DRUGINFO DW18LK SR9011 Preclinical T28309 TARGETID T28309 T28309 FORMERID TTDI03598 T28309 UNIPROID MCLN1_HUMAN T28309 TARGNAME Mucolipin-1 (TRPML1) T28309 GENENAME MCOLN1 T28309 TARGTYPE Preclinical T28309 SYNONYMS Transient receptor potential channel mucolipin 1; TRPML1; Mucolipidin; MSTP080; ML4; ML1; MG-2 T28309 FUNCTION Nonselective cation channel probably playing a role in the regulation of membrane trafficking events and of metal homeostasis. Proposed to play a major role in Ca(2+) release from late endosome and lysosome vesicles to the cytoplasm, which is important for many lysosome-dependent cellular events, including the fusion and trafficking of these organelles, exocytosis and autophagy. Required for efficient uptake of large particles in macrophages in which Ca(2+) release from the lysosomes triggers lysosomal exocytosis. May also play a role in phagosome-lysosome fusion (By similarity). Involved in lactosylceramide trafficking indicative for a role in the regulation of late endocytic membrane fusion/fission events. By mediating lysosomal Ca(2+) release is involved in regulation of mTORC1 signaling and in mTOR/TFEB-dependent lysosomal adaptation to environmental cues such as nutrient levels. Seems to act as lysosomal active oxygen species (ROS) sensor involved in ROS-induced TFEB activation and autophagy. Functions as a Fe(2+) permeable channel in late endosomes and lysosomes. Proposed to play a role in zinc homeostasis probably implicating its association with TMEM163 In adaptive immunity, TRPML2 and TRPML1 may play redundant roles in the function of the specialized lysosomes of B cells (By similarity). T28309 PDBSTRUC 6E7Z; 6E7Y; 6E7P; 5WJ9; 5WJ5 T28309 SEQUENCE MTAPAGPRGSETERLLTPNPGYGTQAGPSPAPPTPPEEEDLRRRLKYFFMSPCDKFRAKGRKPCKLMLQVVKILVVTVQLILFGLSNQLAVTFREENTIAFRHLFLLGYSDGADDTFAAYTREQLYQAIFHAVDQYLALPDVSLGRYAYVRGGGDPWTNGSGLALCQRYYHRGHVDPANDTFDIDPMVVTDCIQVDPPERPPPPPSDDLTLLESSSSYKNLTLKFHKLVNVTIHFRLKTINLQSLINNEIPDCYTFSVLITFDNKAHSGRIPISLETQAHIQECKHPSVFQHGDNSFRLLFDVVVILTCSLSFLLCARSLLRGFLLQNEFVGFMWRQRGRVISLWERLEFVNGWYILLVTSDVLTISGTIMKIGIEAKNLASYDVCSILLGTSTLLVWVGVIRYLTFFHNYNILIATLRVALPSVMRFCCCVAVIYLGYCFCGWIVLGPYHVKFRSLSMVSECLFSLINGDDMFVTFAAMQAQQGRSSLVWLFSQLYLYSFISLFIYMVLSLFIALITGAYDTIKHPGGAGAEESELQAYIAQCQDSPTSGKFRRGSGSACSLLCCCGRDPSEEHSLLVN T28309 DRUGINFO DNL2F1 MK6-83 Preclinical T28309 DRUGINFO D01ZCI phosphatidyl (3,5) inositol biphosphate Investigative T99765 TARGETID T99765 T99765 FORMERID TTDI01737 T99765 UNIPROID SUMO1_HUMAN; SUMO2_HUMAN; SUMO3_HUMAN; SUMO4_HUMAN; SUMO5_HUMAN T99765 TARGNAME Small ubiquitin-related modifier (SUMO) T99765 GENENAME SUMO1; SUMO2; SUMO3; SUMO4; SUMO1P1 T99765 TARGTYPE Preclinical T99765 SYNONYMS Ubiquitin-like protein; SUMO; SMT3 homolog 1 T99765 FUNCTION Ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Covalently attached to the voltage-gated potassium channel KCNB1; this modulates the gating characteristics of KCNB1. Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Covalently attached to ZFHX3. T99765 SEQUENCE MSDQEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTTHLKKLKESYCQRQGVPMNSLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGGHSTV T99765 DRUGINFO D4UFT5 2-D08 Preclinical T12108 TARGETID T12108 T12108 FORMERID TTDI03124 T12108 UNIPROID CRY1_HUMAN T12108 TARGNAME Cryptochrome circadian clock 1 (CRY1) T12108 GENENAME CRY1 T12108 TARGTYPE Preclinical T12108 SYNONYMS PHLL1; Cryptochrome-1 T12108 FUNCTION The circadian clock, an internal time-keeping system, regulates various physiological processes through the generation of approximately 24 hour circadian rhythms in gene expression, which are translated into rhythms in metabolism and behavior. It is derived from the Latin roots 'circa' (about) and 'diem' (day) and acts as an important regulator of a wide array of physiological functions including metabolism, sleep, body temperature, blood pressure, endocrine, immune, cardiovascular, and renal function. Consists of two major components: the central clock, residing in the suprachiasmatic nucleus (SCN) of the brain, and the peripheral clocks that are present in nearly every tissue and organ system. Both the central and peripheral clocks can be reset by environmental cues, also known as Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the central clock is light, which is sensed by retina and signals directly to the SCN. The central clock entrains the peripheral clocks through neuronal and hormonal signals, body temperature and feeding-related cues, aligning all clocks with the external light/dark cycle. Circadian rhythms allow an organism to achieve temporal homeostasis with its environment at the molecular level by regulating gene expression to create a peak of protein expression once every 24 hours to control when a particular physiological process is most active with respect to the solar day. Transcription and translation of core clock components (CLOCK, NPAS2, ARNTL/BMAL1, ARNTL2/BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a critical role in rhythm generation, whereas delays imposed by post-translational modifications (PTMs) are important for determining the period (tau) of the rhythms (tau refers to the period of a rhythm and is the length, in time, of one complete cycle). A diurnal rhythm is synchronized with the day/night cycle, while the ultradian and infradian rhythms have a period shorter and longer than 24 hours, respectively. Disruptions in the circadian rhythms contribute to the pathology of cardiovascular diseases, cancer, metabolic syndromes and aging. A transcription/translation feedback loop (TTFL) forms the core of the molecular circadian clock mechanism. Transcription factors, CLOCK or NPAS2 and ARNTL/BMAL1 or ARNTL2/BMAL2, form the positive limb of the feedback loop, act in the form of a heterodimer and activate the transcription of core clock genes and clock-controlled genes (involved in key metabolic processes), harboring E-box elements (5'-CACGTG-3') within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which are transcriptional repressors form the negative limb of the feedback loop and interact with the CLOCK|NPAS2-ARNTL/BMAL1|ARNTL2/BMAL2 heterodimer inhibiting its activity and thereby negatively regulating their own expression. This heterodimer also activates nuclear receptors NR1D1/2 and RORA/B/G, which form a second feedback loop and which activate and repress ARNTL/BMAL1 transcription, respectively. CRY1 and CRY2 have redundant functions but also differential and selective contributions at least in defining the pace of the SCN circadian clock and its circadian transcriptional outputs. More potent transcriptional repressor in cerebellum and liver than CRY2, though more effective in lengthening the period of the SCN oscillator. On its side, CRY2 seems to play a critical role in tuning SCN circadian period by opposing the action of CRY1. With CRY2, is dispensable for circadian rhythm generation but necessary for the development of intercellular networks for rhythm synchrony. Capable of translocating circadian clock core proteins such as PER proteins to the nucleus. Interacts with CLOCK-ARNTL/BMAL1 independently of PER proteins and is found at CLOCK-ARNTL/BMAL1-bound sites, suggesting that CRY may act as a molecular gatekeeper to maintain CLOCK-ARNTL/BMAL1 in a poised and repressed state until the proper time for transcriptional activation. Represses the CLOCK-ARNTL/BMAL1 induced transcription of BHLHE40/DEC1. Represses the CLOCK-ARNTL/BMAL1 induced transcription of ATF4, MTA1, KLF10 and NAMPT. May repress circadian target genes expression in collaboration with HDAC1 and HDAC2 through histone deacetylation. Mediates the clock-control activation of ATR and modulates ATR-mediated DNA damage checkpoint. In liver, mediates circadian regulation of cAMP signaling and gluconeogenesis by binding to membrane-coupled G proteins and blocking glucagon-mediated increases in intracellular cAMP concentrations and CREB1 phosphorylation. Inhibits hepatic gluconeogenesis by decreasing nuclear FOXO1 levels that downregulates gluconeogenic gene expression. Besides its role in the maintenance of the circadian clock, is also involved in the regulation of other processes. Represses glucocorticoid receptor NR3C1/GR-induced transcriptional activity by binding to glucocorticoid response elements (GREs). Plays a key role in glucose and lipid metabolism modulation, in part, through the transcriptional regulation of genes involved in these pathways, such as LEP or ACSL4. Represses PPARD and its target genes in the skeletal muscle and limits exercise capacity. Plays an essential role in the generation of circadian rhythms in the retina. Represses the transcriptional activity of NR1I2. Transcriptional repressor which forms a core component of the circadian clock. T12108 SEQUENCE MGVNAVHWFRKGLRLHDNPALKECIQGADTIRCVYILDPWFAGSSNVGINRWRFLLQCLEDLDANLRKLNSRLFVIRGQPADVFPRLFKEWNITKLSIEYDSEPFGKERDAAIKKLATEAGVEVIVRISHTLYDLDKIIELNGGQPPLTYKRFQTLISKMEPLEIPVETITSEVIEKCTTPLSDDHDEKYGVPSLEELGFDTDGLSSAVWPGGETEALTRLERHLERKAWVANFERPRMNANSLLASPTGLSPYLRFGCLSCRLFYFKLTDLYKKVKKNSSPPLSLYGQLLWREFFYTAATNNPRFDKMEGNPICVQIPWDKNPEALAKWAEGRTGFPWIDAIMTQLRQEGWIHHLARHAVACFLTRGDLWISWEEGMKVFEELLLDADWSINAGSWMWLSCSSFFQQFFHCYCPVGFGRRTDPNGDYIRRYLPVLRGFPAKYIYDPWNAPEGIQKVAKCLIGVNYPKPMVNHAEASRLNIERMKQIYQQLSRYRGLGLLASVPSNPNGNGGFMGYSAENIPGCSSSGSCSQGSGILHYAHGDSQQTHLLKQGRSSMGTGLSGGKRPSQEEDTQSIGPKVQRQSTN T12108 DRUGINFO D4RGV9 2-Ethoxypropanoic acid Preclinical T12108 DRUGINFO D95KWS KL001 Preclinical T12108 DRUGINFO DG90VQ SHP656 Preclinical T12108 DRUGINFO DOZQ70 TH301 Preclinical T12108 DRUGINFO D0H0EC KL044 Investigative T20103 TARGETID T20103 T20103 FORMERID TTDR00563 T20103 TARGNAME Vacuolar-type proton ATPase (v-ATPase) T20103 TARGTYPE Preclinical T20103 SYNONYMS Vacuolar-ATPase; Vacuolar ATPase; V-ATPase T20103 BIOCLASS Acid anhydrides hydrolase T20103 DRUGINFO D0N1EC WY-47766 Discontinued in Phase 2 T20103 DRUGINFO D04CFL SB 242784 Preclinical T20103 DRUGINFO D07JSI Salicylihalamide A Preclinical T20103 DRUGINFO D0KB2E FR167356 Preclinical T20103 DRUGINFO D05OJY Lobatamide A Investigative T20103 DRUGINFO D06LUW Lobatamide C Investigative T20103 DRUGINFO D07SKL Oximidine II Investigative T20103 DRUGINFO D08XYK Lobatamide D Investigative T20103 DRUGINFO D0FK6J Lobatamide B Investigative T20103 DRUGINFO D0O9DH Oximidine I Investigative T20103 DRUGINFO D0Y8VQ Lobatamide F Investigative T20103 DRUGINFO D4VBY6 Bafilomycin A1 Investigative T20103 DRUGINFO DY9CM8 BRD1240 Investigative T43025 TARGETID T43025 T43025 FORMERID TTDI01390 T43025 TARGNAME Alpha-crystallin (CRYA) T43025 TARGTYPE Preclinical T43025 DRUGINFO D0OMC3 2E9IgA1 Preclinical T05164 TARGETID T05164 T05164 UNIPROID KMT5B_HUMAN T05164 TARGNAME Histone-lysine N-methyltransferase KMT5B (KMT5B) T05164 GENENAME KMT5B T05164 TARGTYPE Preclinical T05164 SYNONYMS Lysine N-methyltransferase 5B; Lysine-specific methyltransferase 5B; Suppressor of variegation 4-20 homolog 1; Su(var)4-20 homolog 1; Suv4-20h1; [histone H4]-N-methyl-L-lysine20 N-methyltransferase KMT5B; [histone H4]-lysine20 N-methyltransferase KMT5B T05164 FUNCTION Histone methyltransferase that specifically methylates monomethylated 'Lys-20' (H4K20me1) and dimethylated 'Lys-20' (H4K20me2) of histone H4 to produce respectively dimethylated 'Lys-20' (H4K20me2) and trimethylated 'Lys-20' (H4K20me3) and thus regulates transcription and maintenance of genome integrity. In vitro also methylates unmodified 'Lys-20' (H4K20me0) of histone H4 and nucleosomes. H4 'Lys-20' trimethylation represents a specific tag for epigenetic transcriptional repression. Mainly functions in pericentric heterochromatin regions, thereby playing a central role in the establishment of constitutive heterochromatin in these regions. KMT5B is targeted to histone H3 via its interaction with RB1 family proteins (RB1, RBL1 and RBL2) (By similarity). Plays a role in myogenesis by regulating the expression of target genes, such as EID3. Facilitates TP53BP1 foci formation upon DNA damage and proficient non-homologous end-joining (NHEJ)-directed DNA repair by catalyzing the di- and trimethylation of 'Lys-20' of histone H4. May play a role in class switch reconbination by catalyzing the di- and trimethylation of 'Lys-20' of histone H4 (By similarity). T05164 ECNUMBER EC 2.1.1.361 T05164 SEQUENCE MKWLGESKNMVVNGRRNGGKLSNDHQQNQSKLQHTGKDTLKAGKNAVERRSNRCNGNSGFEGQSRYVPSSGMSAKELCENDDLATSLVLDPYLGFQTHKMNTSAFPSRSSRHFSKSDSFSHNNPVRFRPIKGRQEELKEVIERFKKDEHLEKAFKCLTSGEWARHYFLNKNKMQEKLFKEHVFIYLRMFATDSGFEILPCNRYSSEQNGAKIVATKEWKRNDKIELLVGCIAELSEIEENMLLRHGENDFSVMYSTRKNCAQLWLGPAAFINHDCRPNCKFVSTGRDTACVKALRDIEPGEEISCYYGDGFFGENNEFCECYTCERRGTGAFKSRVGLPAPAPVINSKYGLRETDKRLNRLKKLGDSSKNSDSQSVSSNTDADTTQEKNNATSNRKSSVGVKKNSKSRTLTRQSMSRIPASSNSTSSKLTHINNSRVPKKLKKPAKPLLSKIKLRNHCKRLEQKNASRKLEMGNLVLKEPKVVLYKNLPIKKDKEPEGPAQAAVASGCLTRHAAREHRQNPVRGAHSQGESSPCTYITRRSVRTRTNLKEASDIKLEPNTLNGYKSSVTEPCPDSGEQLQPAPVLQEEELAHETAQKGEAKCHKSDTGMSKKKSRQGKLVKQFAKIEESTPVHDSPGKDDAVPDLMGPHSDQGEHSGTVGVPVSYTDCAPSPVGCSVVTSDSFKTKDSFRTAKSKKKRRITRYDAQLILENNSGIPKLTLRRRHDSSSKTNDQENDGMNSSKISIKLSKDHDNDNNLYVAKLNNGFNSGSGSSSTKLKIQLKRDEENRGSYTEGLHENGVCCSDPLSLLESRMEVDDYSQYEEESTDDSSSSEGDEEEDDYDDDFEDDFIPLPPAKRLRLIVGKDSIDIDISSRRREDQSLRLNA T05164 DRUGINFO D0P2EH A-196 Preclinical T06281 TARGETID T06281 T06281 UNIPROID FM3_KLEPN T06281 TARGNAME Klebsiella Fimbrial subunit type 3 (Klebsiella mrkA) T06281 GENENAME Klebsiella mrkA T06281 TARGTYPE Preclinical T06281 SEQUENCE MKKVLLSAAMATAFFGMAAANAADTNVGGGQVNFFGKVTDVSCTVSVNGQGSDANVYLSPVTLTEVKAAAADTYLKPKSFTIDVSDCQAADGTKQDDVSKLGVNWTGGNLLAGATAKQQGYLANTEAAGAQNIQLVLSTDNATALTNKIIPGDSTQPKAAGDASAVQDGARFTYYVGYATSTPTTVTTGVVNSYATYEITYQ T06281 DRUGINFO DP8T7K KP3 Preclinical T07584 TARGETID T07584 T07584 UNIPROID UBP13_HUMAN T07584 TARGNAME Ubiquitin carboxyl-terminal hydrolase 13 (USP13) T07584 GENENAME USP13 T07584 TARGTYPE Preclinical T07584 SYNONYMS Deubiquitinating enzyme 13; Isopeptidase T-3; ISOT-3; Ubiquitin thioesterase 13; Ubiquitin-specific-processing protease 13 T07584 FUNCTION Deubiquitinase that mediates deubiquitination of target proteins such as BECN1, MITF, SKP2 and USP10 and is involved in various processes such as autophagy and endoplasmic reticulum-associated degradation (ERAD). Component of a regulatory loop that controls autophagy and p53/TP53 levels: mediates deubiquitination of BECN1, a key regulator of autophagy, leading to stabilize the PIK3C3/VPS34-containing complexes. Also deubiquitinates USP10, an essential regulator of p53/TP53 stability. In turn, PIK3C3/VPS34-containing complexes regulate USP13 stability, suggesting the existence of a regulatory system by which PIK3C3/VPS34-containing complexes regulate p53/TP53 protein levels via USP10 and USP13. Recruited by nuclear UFD1 and mediates deubiquitination of SKP2, thereby regulating endoplasmic reticulum-associated degradation (ERAD). Also regulates ERAD through the deubiquitination of UBL4A a component of the BAG6/BAT3 complex. Mediates stabilization of SIAH2 independently of deubiquitinase activity: binds ubiquitinated SIAH2 and acts by impairing SIAH2 autoubiquitination. Has a weak deubiquitinase activity in vitro and preferentially cleaves 'Lys-63'-linked polyubiquitin chains. In contrast to USP5, it is not able to mediate unanchored polyubiquitin disassembly. Able to cleave ISG15 in vitro; however, additional experiments are required to confirm such data. T07584 BIOCLASS Peptidase T07584 ECNUMBER EC 3.4.19.12 T07584 SEQUENCE MQRRGALFGMPGGSGGRKMAAGDIGELLVPHMPTIRVPRSGDRVYKNECAFSYDSPNSEGGLYVCMNTFLAFGREHVERHFRKTGQSVYMHLKRHVREKVRGASGGALPKRRNSKIFLDLDTDDDLNSDDYEYEDEAKLVIFPDHYEIALPNIEELPALVTIACDAVLSSKSPYRKQDPDTWENELPVSKYANNLTQLDNGVRIPPSGWKCARCDLRENLWLNLTDGSVLCGKWFFDSSGGNGHALEHYRDMGYPLAVKLGTITPDGADVYSFQEEEPVLDPHLAKHLAHFGIDMLHMHGTENGLQDNDIKLRVSEWEVIQESGTKLKPMYGPGYTGLKNLGNSCYLSSVMQAIFSIPEFQRAYVGNLPRIFDYSPLDPTQDFNTQMTKLGHGLLSGQYSKPPVKSELIEQVMKEEHKPQQNGISPRMFKAFVSKSHPEFSSNRQQDAQEFFLHLVNLVERNRIGSENPSDVFRFLVEERIQCCQTRKVRYTERVDYLMQLPVAMEAATNKDELIAYELTRREAEANRRPLPELVRAKIPFSACLQAFSEPENVDDFWSSALQAKSAGVKTSRFASFPEYLVVQIKKFTFGLDWVPKKFDVSIDMPDLLDINHLRARGLQPGEEELPDISPPIVIPDDSKDRLMNQLIDPSDIDESSVMQLAEMGFPLEACRKAVYFTGNMGAEVAFNWIIVHMEEPDFAEPLTMPGYGGAASAGASVFGASGLDNQPPEEIVAIITSMGFQRNQAIQALRATNNNLERALDWIFSHPEFEEDSDFVIEMENNANANIISEAKPEGPRVKDGSGTYELFAFISHMGTSTMSGHYICHIKKEGRWVIYNDHKVCASERPPKDLGYMYFYRRIPS T07584 DRUGINFO DB0V3R Spautin 1 Preclinical T14705 TARGETID T14705 T14705 UNIPROID BGLR_ECOLI T14705 TARGNAME Bacterial Beta-glucuronidase (Bact uidA) T14705 GENENAME Bact uidA T14705 TARGTYPE Preclinical T14705 SYNONYMS GUS; Beta-D-glucuronoside glucuronosohydrolase T14705 FUNCTION cytosol, protein-containing complex, beta-glucuronidase activity, carbohydrate binding, identical protein binding, glucuronoside catabolic process T14705 BIOCLASS Glycosyl hydrolase T14705 ECNUMBER EC 3.2.1.31 T14705 SEQUENCE MLRPVETPTREIKKLDGLWAFSLDRENCGIDQRWWESALQESRAIAVPGSFNDQFADADIRNYAGNVWYQREVFIPKGWAGQRIVLRFDAVTHYGKVWVNNQEVMEHQGGYTPFEADVTPYVIAGKSVRITVCVNNELNWQTIPPGMVITDENGKKKQSYFHDFFNYAGIHRSVMLYTTPNTWVDDITVVTHVAQDCNHASVDWQVVANGDVSVELRDADQQVVATGQGTSGTLQVVNPHLWQPGEGYLYELCVTAKSQTECDIYPLRVGIRSVAVKGEQFLINHKPFYFTGFGRHEDADLRGKGFDNVLMVHDHALMDWIGANSYRTSHYPYAEEMLDWADEHGIVVIDETAAVGFNLSLGIGFEAGNKPKELYSEEAVNGETQQAHLQAIKELIARDKNHPSVVMWSIANEPDTRPQGAREYFAPLAEATRKLDPTRPITCVNVMFCDAHTDTISDLFDVLCLNRYYGWYVQSGDLETAEKVLEKELLAWQEKLHQPIIITEYGVDTLAGLHSMYTDMWSEEYQCAWLDMYHRVFDRVSAVVGEQVWNFADFATSQGILRVGGNKKGIFTRDRKPKSAAFLLQKRWTGMNFGEKPQQGGKQ T14705 DRUGINFO D86ALC SBX-101 Preclinical T20534 TARGETID T20534 T20534 UNIPROID LASR_PSEAE T20534 TARGNAME Pseudomonas Transcriptional activator protein LasR (Pseudo LasR) T20534 GENENAME Pseudo LasR T20534 TARGTYPE Preclinical T20534 FUNCTION Transcriptional activator of elastase structural gene (LasB). Binds to the PAI autoinducer. T20534 SEQUENCE MALVDGFLELERSSGKLEWSAILQKMASDLGFSKILFGLLPKDSQDYENAFIVGNYPAAWREHYDRAGYARVDPTVSHCTQSVLPIFWEPSIYQTRKQHEFFEEASAAGLVYGLTMPLHGARGELGALSLSVEAENRAEANRFMESVLPTLWMLKDYALQSGAGLAFEHPVSKPVVLTSREKEVLQWCAIGKTSWEISVICNCSEANVNFHMGNIRRKFGVTSRRVAAIMAVNLGLITL T20534 DRUGINFO D16JNF 3-Oxo-C12-(2-amino-cyclohexanone) Preclinical T20534 DRUGINFO D9SMC5 C30 Preclinical T24835 TARGETID T24835 T24835 TARGNAME Mycobacterial lipoarabinomannan (MycB LAM) T24835 TARGTYPE Preclinical T24835 DRUGINFO DT29OQ SMITB14 Preclinical T25064 TARGETID T25064 T25064 UNIPROID D6H5M4_NEIGO T25064 TARGNAME Neisseria gonorrhoeae Enoyl-[acyl-carrier-protein] reductase (Neisseria fabI) T25064 TARGTYPE Preclinical T25064 ECNUMBER EC 1.3.1.9 T25064 SEQUENCE MGFLQGKKILITGMISERSIAYGIAKACREQGAELAFTYVVDKLEERVRKMAAELDSELVFRCDVASDDEINQVFADLGKHWDGLDGLVHSIGFAPKEALSGDFLDSISREAFNTAHEISAYSLPALAKAARPMMRGRNSAIVALSYLGAVRAIPNYNVMGMAKASLEAGIRFTAACLGKEGIRCNGISAGPIKTLAASGIADFGKLLGHVAAHNPLRRNVTIEEVGNTAAFLLSDLSSGITGEITYVDGGYSINALSTEG T25064 DRUGINFO D3Q1OL Debio1453 Preclinical T35792 TARGETID T35792 T35792 UNIPROID SMYD3_HUMAN T35792 TARGNAME Histone-lysine N-methyltransferase SMYD3 (SMYD3) T35792 GENENAME SMYD3 T35792 TARGTYPE Preclinical T35792 SYNONYMS SET and MYND domain-containing protein 3; Zinc finger MYND domain-containing protein 1 T35792 FUNCTION Histone methyltransferase. Specifically methylates 'Lys-4' of histone H3, inducing di- and tri-methylation, but not monomethylation . Also methylates 'Lys-5' of histone H4. Plays an important role in transcriptional activation as a member of an RNA polymerase complex. Binds DNA containing 5'-CCCTCC-3' or 5'-GAGGGG-3' sequences. T35792 ECNUMBER EC 2.1.1.354 T35792 SEQUENCE MEPLKVEKFATAKRGNGLRAVTPLRPGELLFRSDPLAYTVCKGSRGVVCDRCLLGKEKLMRCSQCRVAKYCSAKCQKKAWPDHKRECKCLKSCKPRYPPDSVRLLGRVVFKLMDGAPSESEKLYSFYDLESNINKLTEDKKEGLRQLVMTFQHFMREEIQDASQLPPAFDLFEAFAKVICNSFTICNAEMQEVGVGLYPSISLLNHSCDPNCSIVFNGPHLLLRAVRDIEVGEELTICYLDMLMTSEERRKQLRDQYCFECDCFRCQTQDKDADMLTGDEQVWKEVQESLKKIEELKAHWKWEQVLAMCQAIISSNSERLPDINIYQLKVLDCAMDACINLGLLEEALFYGTRTMEPYRIFFPGSHPVRGVQVMKVGKLQLHQGMFPQAMKNLRLAFDIMRVTHGREHSLIEDLILLLEECDANIRAS T35792 DRUGINFO D0X7OH EPZ028862 Preclinical T35792 DRUGINFO DSHE52 EPZ031686 Preclinical T35792 DRUGINFO DV74TF EPZ0330456 Preclinical T35792 DRUGINFO DWF98V GSK2807 Preclinical T40126 TARGETID T40126 T40126 UNIPROID Q9I235_PSEAE T40126 TARGNAME Pseudomonas Kynureninase (Pseudo kynU) T40126 GENENAME Pseudo kynU T40126 TARGTYPE Preclinical T40126 SYNONYMS L-kynurenine hydrolase T40126 FUNCTION Catalyzes the cleavage of L-kynurenine (L-Kyn) and L-3-hydroxykynurenine (L-3OHKyn) into anthranilic acid (AA) and 3-hydroxyanthranilic acid (3-OHAA), respectively. T40126 ECNUMBER EC 3.7.1.3 T40126 SEQUENCE MTTRDDCLALDAGDPLADLRQLFALPDGVIYLDGNSLGARPRAAVERAAEVVAAEWGEGLIRSWNSADWRGLPERLGDKLAPLIGARAGEVVITDTTSINLFKVLSAALRIQEEDAPGRKVIVSESSNFPTDLYIAEGLTDMLQRGYRLRLVDDPEQLPAAIDADTAVVMLSHVNYKTGYLHDMREVTRLVHENGALAIWDLAHSAGALPLDLHAADADYAIGCTYKYLNGGPGSPAYVWVAPRLRERVWQPLSGWFGHSRQFAMEPRYQPGEGITRFLCGTQPITSLALVECGLDIFARTDMQRLRDKSLALADLFIELVESRCERFGLTLVTPREHARRGSHVSFEHAQGYAIVQALIDRGVIGDYREPGILRFGFTPLYTRFVEVWDAVQALLEILQSEAWKEPRYQVRHKVT T40126 DRUGINFO DB1U9N S-Phenyl-L-cysteine sulfoxide Preclinical T51908 TARGETID T51908 T51908 UNIPROID CRY2_HUMAN T51908 TARGNAME Cryptochrome-2 (CRY2) T51908 GENENAME CRY2 T51908 TARGTYPE Preclinical T51908 FUNCTION Transcriptional repressor which forms a core component of the circadian clock. The circadian clock, an internal time-keeping system, regulates various physiological processes through the generation of approximately 24 hour circadian rhythms in gene expression, which are translated into rhythms in metabolism and behavior. It is derived from the Latin roots 'circa' (about) and 'diem' (day) and acts as an important regulator of a wide array of physiological functions including metabolism, sleep, body temperature, blood pressure, endocrine, immune, cardiovascular, and renal function. Consists of two major components: the central clock, residing in the suprachiasmatic nucleus (SCN) of the brain, and the peripheral clocks that are present in nearly every tissue and organ system. Both the central and peripheral clocks can be reset by environmental cues, also known as Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the central clock is light, which is sensed by retina and signals directly to the SCN. The central clock entrains the peripheral clocks through neuronal and hormonal signals, body temperature and feeding-related cues, aligning all clocks with the external light/dark cycle. Circadian rhythms allow an organism to achieve temporal homeostasis with its environment at the molecular level by regulating gene expression to create a peak of protein expression once every 24 hours to control when a particular physiological process is most active with respect to the solar day. Transcription and translation of core clock components (CLOCK, NPAS2, ARNTL/BMAL1, ARNTL2/BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a critical role in rhythm generation, whereas delays imposed by post-translational modifications (PTMs) are important for determining the period (tau) of the rhythms (tau refers to the period of a rhythm and is the length, in time, of one complete cycle). A diurnal rhythm is synchronized with the day/night cycle, while the ultradian and infradian rhythms have a period shorter and longer than 24 hours, respectively. Disruptions in the circadian rhythms contribute to the pathology of cardiovascular diseases, cancer, metabolic syndromes and aging. A transcription/translation feedback loop (TTFL) forms the core of the molecular circadian clock mechanism. Transcription factors, CLOCK or NPAS2 and ARNTL/BMAL1 or ARNTL2/BMAL2, form the positive limb of the feedback loop, act in the form of a heterodimer and activate the transcription of core clock genes and clock-controlled genes (involved in key metabolic processes), harboring E-box elements (5'-CACGTG-3') within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which are transcriptional repressors form the negative limb of the feedback loop and interact with the CLOCK|NPAS2-ARNTL/BMAL1|ARNTL2/BMAL2 heterodimer inhibiting its activity and thereby negatively regulating their own expression. This heterodimer also activates nuclear receptors NR1D1/2 and RORA/B/G, which form a second feedback loop and which activate and repress ARNTL/BMAL1 transcription, respectively. CRY1 and CRY2 have redundant functions but also differential and selective contributions at least in defining the pace of the SCN circadian clock and its circadian transcriptional outputs. Less potent transcriptional repressor in cerebellum and liver than CRY1, though less effective in lengthening the period of the SCN oscillator. Seems to play a critical role in tuning SCN circadian period by opposing the action of CRY1. With CRY1, dispensable for circadian rhythm generation but necessary for the development of intercellular networks for rhythm synchrony. May mediate circadian regulation of cAMP signaling and gluconeogenesis by blocking glucagon-mediated increases in intracellular cAMP concentrations and in CREB1 phosphorylation. Besides its role in the maintenance of the circadian clock, is also involved in the regulation of other processes. Plays a key role in glucose and lipid metabolism modulation, in part, through the transcriptional regulation of genes involved in these pathways, such as LEP or ACSL4. Represses glucocorticoid receptor NR3C1/GR-induced transcriptional activity by binding to glucocorticoid response elements (GREs). Represses the CLOCK-ARNTL/BMAL1 induced transcription of BHLHE40/DEC1. Represses the CLOCK-ARNTL/BMAL1 induced transcription of NAMPT (By similarity). Represses PPARD and its target genes in the skeletal muscle and limits exercise capacity (By similarity). Represses the transcriptional activity of NR1I2 (By similarity). T51908 SEQUENCE MAATVATAAAVAPAPAPGTDSASSVHWFRKGLRLHDNPALLAAVRGARCVRCVYILDPWFAASSSVGINRWRFLLQSLEDLDTSLRKLNSRLFVVRGQPADVFPRLFKEWGVTRLTFEYDSEPFGKERDAAIMKMAKEAGVEVVTENSHTLYDLDRIIELNGQKPPLTYKRFQAIISRMELPKKPVGLVTSQQMESCRAEIQENHDETYGVPSLEELGFPTEGLGPAVWQGGETEALARLDKHLERKAWVANYERPRMNANSLLASPTGLSPYLRFGCLSCRLFYYRLWDLYKKVKRNSTPPLSLFGQLLWREFFYTAATNNPRFDRMEGNPICIQIPWDRNPEALAKWAEGKTGFPWIDAIMTQLRQEGWIHHLARHAVACFLTRGDLWVSWESGVRVFDELLLDADFSVNAGSWMWLSCSAFFQQFFHCYCPVGFGRRTDPSGDYIRRYLPKLKAFPSRYIYEPWNAPESIQKAAKCIIGVDYPRPIVNHAETSRLNIERMKQIYQQLSRYRGLCLLASVPSCVEDLSHPVAEPSSSQAGSMSSAGPRPLPSGPASPKRKLEAAEEPPGEELSKRARVAELPTPELPSKDA T51908 DRUGINFO D4RGV9 2-Ethoxypropanoic acid Preclinical T51908 DRUGINFO D95KWS KL001 Preclinical T51908 DRUGINFO DG90VQ SHP656 Preclinical T51908 DRUGINFO DOZQ70 TH301 Preclinical T52036 TARGETID T52036 T52036 UNIPROID UBP20_HUMAN T52036 TARGNAME Ubiquitin carboxyl-terminal hydrolase 20 (USP20) T52036 GENENAME USP20 T52036 TARGTYPE Preclinical T52036 SYNONYMS Deubiquitinating enzyme 20; Ubiquitin thioesterase 20; Ubiquitin-specific-processing protease 20; VHL-interacting deubiquitinating enzyme 2; hVDU2 T52036 FUNCTION Deubiquitinating enzyme involved in beta-2 adrenergic receptor (ADRB2) recycling. Acts as a regulator of G-protein coupled receptor (GPCR) signaling by mediating the deubiquitination beta-2 adrenergic receptor (ADRB2). Plays a central role in ADRB2 recycling and resensitization after prolonged agonist stimulation by constitutively binding ADRB2, mediating deubiquitination of ADRB2 and inhibiting lysosomal trafficking of ADRB2. Upon dissociation, it is probably transferred to the translocated beta-arrestins, possibly leading to beta-arrestins deubiquitination and disengagement from ADRB2. This suggests the existence of a dynamic exchange between the ADRB2 and beta-arrestins. Deubiquitinates DIO2, thereby regulating thyroid hormone regulation. Deubiquitinates HIF1A, leading to stabilize HIF1A and enhance HIF1A-mediated activity. Mediates deubiquitination of both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. T52036 BIOCLASS Peptidase T52036 ECNUMBER EC 3.4.19.12 T52036 SEQUENCE MGDSRDLCPHLDSIGEVTKEDLLLKSKGTCQSCGVTGPNLWACLQVACPYVGCGESFADHSTIHAQAKKHNLTVNLTTFRLWCYACEKEVFLEQRLAAPLLGSSSKFSEQDSPPPSHPLKAVPIAVADEGESESEDDDLKPRGLTGMKNLGNSCYMNAALQALSNCPPLTQFFLECGGLVRTDKKPALCKSYQKLVSEVWHKKRPSYVVPTSLSHGIKLVNPMFRGYAQQDTQEFLRCLMDQLHEELKEPVVATVALTEARDSDSSDTDEKREGDRSPSEDEFLSCDSSSDRGEGDGQGRGGGSSQAETELLIPDEAGRAISEKERMKDRKFSWGQQRTNSEQVDEDADVDTAMAALDDQPAEAQPPSPRSSSPCRTPEPDNDAHLRSSSRPCSPVHHHEGHAKLSSSPPRASPVRMAPSYVLKKAQVLSAGSRRRKEQRYRSVISDIFDGSILSLVQCLTCDRVSTTVETFQDLSLPIPGKEDLAKLHSAIYQNVPAKPGACGDSYAAQGWLAFIVEYIRRFVVSCTPSWFWGPVVTLEDCLAAFFAADELKGDNMYSCERCKKLRNGVKYCKVLRLPEILCIHLKRFRHEVMYSFKINSHVSFPLEGLDLRPFLAKECTSQITTYDLLSVICHHGTAGSGHYIAYCQNVINGQWYEFDDQYVTEVHETVVQNAEGYVLFYRKSSEEAMRERQQVVSLAAMREPSLLRFYVSREWLNKFNTFAEPGPITNQTFLCSHGGIPPHKYHYIDDLVVILPQNVWEHLYNRFGGGPAVNHLYVCSICQVEIEALAKRRRIEIDTFIKLNKAFQAEESPGVIYCISMQWFREWEAFVKGKDNEPPGPIDNSRIAQVKGSGHVQLKQGADYGQISEETWTYLNSLYGGGPEIAIRQSVAQPLGPENLHGEQKIEAETRAV T52036 DRUGINFO DAD9V4 GSK2643943A Preclinical T52349 TARGETID T52349 T52349 UNIPROID C3VD18_ENTFC T52349 TARGNAME Enterococcus fsrC (Ente-cocc fsrC) T52349 GENENAME Ente-cocc fsrC T52349 TARGTYPE Preclinical T52349 SEQUENCE MILSLLATNVLLVSSFIVFVFLRVTLIKIECKIPLLSLLIVINLCSFAALMLGYSWLIYALTVVVFTGFLLIHKKRFSIFKAIFLSVFTLLMVSFINYTEQTILSVFFQQIYQNKLLWIASNVLLLLINIWIALKIPNSVFLRLNRVLENSRIFFGCLLLLLILLLLFVFLISPEISPDFMRGFVTVNSSKLELLISVGLFLILIGLVIEAYLEEQRINTQLLNNLTIYTEKIESINEELAMFRHDYKNLLYSLQIAISYEDILEIKRIYEETIAPTKKIIDNEEFELMKLNRLKNMELKALISMKINTAKQAKLKVIVDVPEVFILDTSIDLVVVIRLLAILLDNAIENSAKSELKMFAISIFNKNETQEFVITNSVQAEFDFKVMKKTKFSSKSNPEEHGWGLLYVKEIVDFSDQFDLQTSFNEGAVTQHLIIEKNHNSKKVVNE T52349 DRUGINFO DNE4B9 ZBzl-YAA5911 Preclinical T52873 TARGETID T52873 T52873 TARGNAME 3-oxo-dodecanoyl-homoserine lactone (C12) T52873 TARGTYPE Preclinical T52873 DRUGINFO D7TIB0 RS2-1G9 Preclinical T52910 TARGETID T52910 T52910 UNIPROID UBP30_HUMAN T52910 TARGNAME Ubiquitin carboxyl-terminal hydrolase 30 (USP30) T52910 GENENAME USP30 T52910 TARGTYPE Preclinical T52910 SYNONYMS Deubiquitinating enzyme 30; Ubiquitin thioesterase 30; Ubiquitin-specific-processing protease 30; Ub-specific protease 30 T52910 FUNCTION Deubiquitinating enzyme tethered to the mitochondrial outer membrane that acts as a key inhibitor of mitophagy by counteracting the action of parkin (PRKN): hydrolyzes ubiquitin attached by parkin on target proteins, such as RHOT1/MIRO1 and TOMM20, thereby blocking parkin's ability to drive mitophagy. Preferentially cleaves 'Lys-6'- and 'Lys-11'-linked polyubiquitin chains, 2 types of linkage that participate in mitophagic signaling. Does not cleave efficiently polyubiquitin phosphorylated at 'Ser-65'. Acts as negative regulator of mitochondrial fusion by mediating deubiquitination of MFN1 and MFN2 (By similarity). T52910 BIOCLASS Peptidase T52910 ECNUMBER EC 3.4.19.12 T52910 SEQUENCE MLSSRAEAAMTAADRAIQRFLRTGAAVRYKVMKNWGVIGGIAAALAAGIYVIWGPITERKKRRKGLVPGLVNLGNTCFMNSLLQGLSACPAFIRWLEEFTSQYSRDQKEPPSHQYLSLTLLHLLKALSCQEVTDDEVLDASCLLDVLRMYRWQISSFEEQDAHELFHVITSSLEDERDRQPRVTHLFDVHSLEQQSEITPKQITCRTRGSPHPTSNHWKSQHPFHGRLTSNMVCKHCEHQSPVRFDTFDSLSLSIPAATWGHPLTLDHCLHHFISSESVRDVVCDNCTKIEAKGTLNGEKVEHQRTTFVKQLKLGKLPQCLCIHLQRLSWSSHGTPLKRHEHVQFNEFLMMDIYKYHLLGHKPSQHNPKLNKNPGPTLELQDGPGAPTPVLNQPGAPKTQIFMNGACSPSLLPTLSAPMPFPLPVVPDYSSSTYLFRLMAVVVHHGDMHSGHFVTYRRSPPSARNPLSTSNQWLWVSDDTVRKASLQEVLSSSAYLLFYERVLSRMQHQSQECKSEE T52910 DRUGINFO DAQ4G0 NC043 Preclinical T56824 TARGETID T56824 T56824 UNIPROID TCPN_VIBCH T56824 TARGNAME Vibrio TCP pilus virulence regulatory protein (Vibrio tcpN) T56824 GENENAME Vibrio tcpN T56824 TARGTYPE Preclinical T56824 FUNCTION Probable regulatory protein for the tcp operon. T56824 SEQUENCE MIGKKSFQTNVYRMSKFDTYIFNNLYINDYKMFWIDSGIAKLIDKNCLVSYEINSSSIILLKKNSIQRFSLTSLSDENINVSVITISDSFIRSLKSYILGDLMIRNLYSENKDLLLWNCEHNDIAVLSEVVNGFREINYSDEFLKVFFSGFFSKVEKKYNSIFITDDLDAMEKISCLVKSDITRNWRWADICGELRTNRMILKKELESRGVKFRELINSIRISYSISLMKTGEFKIKQIAYQSGFASVSYFSTVFKSTMNVAPSEYLFMLTGVAEK T56824 DRUGINFO DL74RO Virstatin Preclinical T65978 TARGETID T65978 T65978 UNIPROID MVFR_PSEAE T65978 TARGNAME Pseudomonas Multiple virulence factor regulator MvfR (Pseudo MvfR) T65978 GENENAME Pseudo MvfR T65978 TARGTYPE Preclinical T65978 SYNONYMS Transcriptional regulator MvfR T65978 FUNCTION Transcription regulator that plays a critical role in virulence by positively regulating the expression of multiple quorum sensing (QS)-regulated virulence factors, genes involved in protein secretion, translation, response to oxidative stress and the phnAB operon. At the stationary phase, negatively autoregulates its function through cleavage and translocation to the extracellular space. T65978 SEQUENCE MPIHNLNHVNMFLQVIASGSISSAARILRKSHTAVSSAVSNLEIDLCVELVRRDGYKVEPTEQALRLIPYMRSLLNYQQLIGDIAFNLNKGPRNLRVLLDTAIPPSFCDTVSSVLLDDFNMVSLIRTSPADSLATIKQDNAEIDIAITIDEELKISRFNQCVLGYTKAFVVAHPQHPLCNASLHSIASLANYRQISLGSRSGQHSNLLRPVSDKVLFVENFDDMLRLVEAGVGWGIAPHYFVEERLRNGTLAVLSELYEPGGIDTKVYCYYNTALESERSFLRFLESARQRLRELGRQRFDDAPAWQPSIVETAQRRSGPKALAYRQRAAPE T65978 DRUGINFO DS58AE M64 Preclinical T68490 TARGETID T68490 T68490 UNIPROID KMT5C_HUMAN T68490 TARGNAME Histone-lysine N-methyltransferase KMT5C (KMT5C) T68490 GENENAME KMT5C T68490 TARGTYPE Preclinical T68490 SYNONYMS Lysine N-methyltransferase 5C; Lysine-specific methyltransferase 5C; Suppressor of variegation 4-20 homolog 2; Su(var)4-20 homolog 2; Suv4-20h2; [histone H4]-N-methyl-L-lysine20 N-methyltransferase KMT5B; [histone H4]-lysine20 N-methyltransferase KMT5B T68490 FUNCTION Histone methyltransferase that specifically methylates monomethylated 'Lys-20' (H4K20me1) and dimethylated 'Lys-20' (H4K20me2) of histone H4 to produce respectively dimethylated 'Lys-20' (H4K20me2) and trimethylated 'Lys-20' (H4K20me3) and thus regulates transcription and maintenance of genome integrity. In vitro also methylates unmodified 'Lys-20' (H4K20me0) of histone H4 and nucleosomes. H4 'Lys-20' trimethylation represents a specific tag for epigenetic transcriptional repression. Mainly functions in pericentric heterochromatin regions, thereby playing a central role in the establishment of constitutive heterochromatin in these regions. KMT5C is targeted to histone H3 via its interaction with RB1 family proteins (RB1, RBL1 and RBL2) (By similarity). Facilitates TP53BP1 foci formation upon DNA damage and proficient non-homologous end-joining (NHEJ)-directed DNA repair by catalyzing the di- and trimethylation of 'Lys-20' of histone H4. May play a role in class switch reconbination by catalyzing the di- and trimethylation of 'Lys-20' of histone H4 (By similarity). T68490 ECNUMBER EC 2.1.1.361 T68490 SEQUENCE MGPDRVTARELCENDDLATSLVLDPYLGFRTHKMNVSPVPPLRRQQHLRSALETFLRQRDLEAAYRALTLGGWTARYFQSRGPRQEAALKTHVYRYLRAFLPESGFTILPCTRYSMETNGAKIVSTRAWKKNEKLELLVGCIAELREADEGLLRAGENDFSIMYSTRKRSAQLWLGPAAFINHDCKPNCKFVPADGNAACVKVLRDIEPGDEVTCFYGEGFFGEKNEHCECHTCERKGEGAFRTRPREPALPPRPLDKYQLRETKRRLQQGLDSGSRQGLLGPRACVHPSPLRRDPFCAACQPLRLPACSARPDTSPLWLQWLPQPQPRVRPRKRRRPRPRRAPVLSTHHAARVSLHRWGGCGPHCRLRGEALVALGQPPHARWAPQQDWHWARRYGLPYVVRVDLRRLAPAPPATPAPAGTPGPILIPKQALAFAPFSPPKRLRLVVSHGSIDLDVGGEEL T68490 DRUGINFO D0P2EH A-196 Preclinical T72915 TARGETID T72915 T72915 UNIPROID KC1A_HUMAN; KC1D_HUMAN; KC1E_HUMAN; KC1G1_HUMAN; KC1G2_HUMAN; KC1G3_HUMAN T72915 TARGNAME Casein kinase 1 (CK1) T72915 TARGTYPE Preclinical T72915 DRUGINFO DLKQ59 LH846 Preclinical T72915 DRUGINFO DONA19 CKI-7 Preclinical T73582 TARGETID T73582 T73582 UNIPROID UBP10_HUMAN T73582 TARGNAME Ubiquitin carboxyl-terminal hydrolase 10 (USP10) T73582 GENENAME USP10 T73582 TARGTYPE Preclinical T73582 SYNONYMS Deubiquitinating enzyme 10; Ubiquitin thioesterase 10; Ubiquitin-specific-processing protease 10 T73582 FUNCTION Hydrolase that can remove conjugated ubiquitin from target proteins such as p53/TP53, BECN1, SNX3 and CFTR. Acts as an essential regulator of p53/TP53 stability: in unstressed cells, specifically deubiquitinates p53/TP53 in the cytoplasm, leading to counteract MDM2 action and stabilize p53/TP53. Following DNA damage, translocates to the nucleus and deubiquitinates p53/TP53, leading to regulate the p53/TP53-dependent DNA damage response. Component of a regulatory loop that controls autophagy and p53/TP53 levels: mediates deubiquitination of BECN1, a key regulator of autophagy, leading to stabilize the PIK3C3/VPS34-containing complexes. In turn, PIK3C3/VPS34-containing complexes regulate USP10 stability, suggesting the existence of a regulatory system by which PIK3C3/VPS34-containing complexes regulate p53/TP53 protein levels via USP10 and USP13. Does not deubiquitinate MDM2. Deubiquitinates CFTR in early endosomes, enhancing its endocytic recycling. Involved in a TANK-dependent negative feedback response to attenuate NF-kappaB activation via deubiquitinating IKBKG or TRAF6 in response to interleukin-1-beta (IL1B) stimulation or upon DNA damage. Deubiquitinates TBX21 leading to its stabilization. T73582 BIOCLASS Peptidase T73582 ECNUMBER EC 3.4.19.12 T73582 SEQUENCE MALHSPQYIFGDFSPDEFNQFFVTPRSSVELPPYSGTVLCGTQAVDKLPDGQEYQRIEFGVDEVIEPSDTLPRTPSYSISSTLNPQAPEFILGCTASKITPDGITKEASYGSIDCQYPGSALALDGSSNVEAEVLENDGVSGGLGQRERKKKKKRPPGYYSYLKDGGDDSISTEALVNGHANSAVPNSVSAEDAEFMGDMPPSVTPRTCNSPQNSTDSVSDIVPDSPFPGALGSDTRTAGQPEGGPGADFGQSCFPAEAGRDTLSRTAGAQPCVGTDTTENLGVANGQILESSGEGTATNGVELHTTESIDLDPTKPESASPPADGTGSASGTLPVSQPKSWASLFHDSKPSSSSPVAYVETKYSPPAISPLVSEKQVEVKEGLVPVSEDPVAIKIAELLENVTLIHKPVSLQPRGLINKGNWCYINATLQALVACPPMYHLMKFIPLYSKVQRPCTSTPMIDSFVRLMNEFTNMPVPPKPRQALGDKIVRDIRPGAAFEPTYIYRLLTVNKSSLSEKGRQEDAEEYLGFILNGLHEEMLNLKKLLSPSNEKLTISNGPKNHSVNEEEQEEQGEGSEDEWEQVGPRNKTSVTRQADFVQTPITGIFGGHIRSVVYQQSSKESATLQPFFTLQLDIQSDKIRTVQDALESLVARESVQGYTTKTKQEVEISRRVTLEKLPPVLVLHLKRFVYEKTGGCQKLIKNIEYPVDLEISKELLSPGVKNKNFKCHRTYRLFAVVYHHGNSATGGHYTTDVFQIGLNGWLRIDDQTVKVINQYQVVKPTAERTAYLLYYRRVDLL T73582 DRUGINFO DB0V3R Spautin 1 Preclinical T75819 TARGETID T75819 T75819 UNIPROID FBX3_HUMAN T75819 TARGNAME F-box only protein 3 (FBXO3) T75819 GENENAME FBXO3 T75819 TARGTYPE Preclinical T75819 FUNCTION Substrate recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Mediates the ubiquitination of HIPK2 and probably that of EP300, leading to rapid degradation by the proteasome. In the presence of PML, HIPK2 ubiquitination still occurs, but degradation is prevented. PML, HIPK2 and FBXO3 may act synergically to activate p53/TP53-dependent transactivation. T75819 SEQUENCE MAAMETETAPLTLESLPTDPLLLILSFLDYRDLINCCYVSRRLSQLSSHDPLWRRHCKKYWLISEEEKTQKNQCWKSLFIDTYSDVGRYIDHYAAIKKAWDDLKKYLEPRCPRMVLSLKEGAREEDLDAVEAQIGCKLPDDYRCSYRIHNGQKLVVPGLLGSMALSNHYRSEDLLDVDTAAGGFQQRQGLKYCLPLTFCIHTGLSQYIAVEAAEGRNKNEVFYQCPDQMARNPAAIDMFIIGATFTDWFTSYVKNVVSGGFPIIRDQIFRYVHDPECVATTGDITVSVSTSFLPELSSVHPPHYFFTYRIRIEMSKDALPEKACQLDSRYWRITNAKGDVEEVQGPGVVGEFPIISPGRVYEYTSCTTFSTTSGYMEGYYTFHFLYFKDKIFNVAIPRFHMACPTFRVSIARLEMGPDEYEEMEEEEEEEEEEDEDDDSADMDESDEDDEEERRRRVFDVPIRRRRCSRLF T75819 DRUGINFO DA5RC6 BC-1215 Preclinical T79184 TARGETID T79184 T79184 UNIPROID AGRA_STAAU T79184 TARGNAME Staphylococcus Accessory gene regulator protein A (Stap-coc agrA) T79184 GENENAME Stap-coc agrA T79184 TARGTYPE Preclinical T79184 FUNCTION Required for high-level post-exponential phase expression of a series of secreted proteins. T79184 SEQUENCE MKIFICEDDPKQRENMVTIIKNYIMIEEKPMEIALATDNPYEVLEQAKNMNDIGCYFLDIQLSTDINGIKLGSEIRKHDPVGNIIFVTSHSELTYLTFVYKVAAMDFIFKDDPAELRTRIIDCLETAHTRLQLLSKDNSVETIELKRGSNSVYVQYDDIMFFESSTKSHRLIAHLDNRQIEFYGNLKELSQLDDRFFRCHNSFVVNRHNIESIDSKERIVYFKNKEHCYASVRNVKKI T79184 DRUGINFO DS19UZ Savirin Preclinical T79401 TARGETID T79401 T79401 UNIPROID POLG_DEN1W (281-775) T79401 TARGNAME Dengue virus Envelope (DENV E) T79401 GENENAME DENV E T79401 TARGTYPE Preclinical T79401 DRUGINFO DI8ZG7 VIS513 Preclinical T85241 TARGETID T85241 T85241 UNIPROID CDC20_HUMAN T85241 TARGNAME Cell division cycle protein 20 homolog (CDC20) T85241 GENENAME CDC20 T85241 TARGTYPE Preclinical T85241 SYNONYMS p55CDC T85241 FUNCTION Required for full ubiquitin ligase activity of the anaphase promoting complex/cyclosome (APC/C) and may confer substrate specificity upon the complex. Is regulated by MAD2L1: in metaphase the MAD2L1-CDC20-APC/C ternary complex is inactive and in anaphase the CDC20-APC/C binary complex is active in degrading substrates. The CDC20-APC/C complex positively regulates the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. CDC20-APC/C-induced degradation of NEUROD2 induces presynaptic differentiation. T85241 SEQUENCE MAQFAFESDLHSLLQLDAPIPNAPPARWQRKAKEAAGPAPSPMRAANRSHSAGRTPGRTPGKSSSKVQTTPSKPGGDRYIPHRSAAQMEVASFLLSKENQPENSQTPTKKEHQKAWALNLNGFDVEEAKILRLSGKPQNAPEGYQNRLKVLYSQKATPGSSRKTCRYIPSLPDRILDAPEIRNDYYLNLVDWSSGNVLAVALDNSVYLWSASSGDILQLLQMEQPGEYISSVAWIKEGNYLAVGTSSAEVQLWDVQQQKRLRNMTSHSARVGSLSWNSYILSSGSRSGHIHHHDVRVAEHHVATLSGHSQEVCGLRWAPDGRHLASGGNDNLVNVWPSAPGEGGWVPLQTFTQHQGAVKAVAWCPWQSNVLATGGGTSDRHIRIWNVCSGACLSAVDAHSQVCSILWSPHYKELISGHGFAQNQLVIWKYPTMAKVAELKGHTSRVLSLTMSPDGATVASAAADETLRLWRCFELDPARRREREKASAAKSSLIHQGIR T85241 DRUGINFO DSU7K2 Tosyl-l-arginine methyl ester Preclinical T89573 TARGETID T89573 T89573 UNIPROID SRTA_STAA8 T89573 TARGNAME Staphylococcus Sortase A (Stap-coc srtA) T89573 GENENAME Stap-coc srtA T89573 TARGTYPE Preclinical T89573 SYNONYMS Surface protein sorting A T89573 FUNCTION Transpeptidase that anchors surface proteins to the cell wall. Recognizes and modifies its substrate by proteolytic cleavage of a C-terminal sorting signal. Following cleavage, a covalent intermediate is formed via a thioester bond between the sortase and its substrate, which is then transferred and covalently attached to the cell wall. This sortase recognizes a Leu-Pro-x-Thr-Gly (LPXTG) motif, which is cleaved by the sortase between the threonine and glycine residues. Utilizes lipid II as the peptidoglycan substrate for the sorting reaction. Responsible for the display of important virulence factors. Important for interactions with the host and host colonization during infection. T89573 ECNUMBER EC 3.4.22.70 T89573 SEQUENCE MKKWTNRLMTIAGVVLILVAAYLFAKPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK T89573 DRUGINFO D8WBZ2 PMID25197057-Compound6e Preclinical T90672 TARGETID T90672 T90672 UNIPROID LGR4_HUMAN T90672 TARGNAME G-protein coupled receptor 48 (LGR4) T90672 GENENAME LGR4 T90672 TARGTYPE Preclinical T90672 SYNONYMS G-protein coupled receptor 48 T90672 FUNCTION Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and is involved in the formation of various organs. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. In contrast to classical G-protein coupled receptors, does not activate heterotrimeric G-proteins to transduce the signal. Its function as activator of the Wnt signaling pathway is required for the development of various organs, including liver, kidney, intestine, bone, reproductive tract and eye. May also act as a receptor for norrin (NDP), such results however require additional confirmation in vivo. Required during spermatogenesis to activate the Wnt signaling pathway in peritubular myoid cells. Required for the maintenance of intestinal stem cells and Paneth cell differentiation in postnatal intestinal crypts. Acts as a regulator of bone formation and remodeling. Involved in kidney development; required for maintaining the ureteric bud in an undifferentiated state. Involved in the development of the anterior segment of the eye. Required during erythropoiesis. Also acts as a negative regulator of innate immunity by inhibiting TLR2/TLR4 associated pattern-recognition and proinflammatory cytokine production. Plays an important role in regulating the circadian rhythms of plasma lipids, partially through regulating the rhythmic expression of MTTP (By similarity). T90672 BIOCLASS G-protein coupled receptor 1 family T90672 SEQUENCE MPGPLGLLCFLALGLLGSAGPSGAAPPLCAAPCSCDGDRRVDCSGKGLTAVPEGLSAFTQALDISMNNITQLPEDAFKNFPFLEELQLAGNDLSFIHPKALSGLKELKVLTLQNNQLKTVPSEAIRGLSALQSLRLDANHITSVPEDSFEGLVQLRHLWLDDNSLTEVPVHPLSNLPTLQALTLALNKISSIPDFAFTNLSSLVVLHLHNNKIRSLSQHCFDGLDNLETLDLNYNNLGEFPQAIKALPSLKELGFHSNSISVIPDGAFDGNPLLRTIHLYDNPLSFVGNSAFHNLSDLHSLVIRGASMVQQFPNLTGTVHLESLTLTGTKISSIPNNLCQEQKMLRTLDLSYNNIRDLPSFNGCHALEEISLQRNQIYQIKEGTFQGLISLRILDLSRNLIHEIHSRAFATLGPITNLDVSFNELTSFPTEGLNGLNQLKLVGNFKLKEALAAKDFVNLRSLSVPYAYQCCAFWGCDSYANLNTEDNSLQDHSVAQEKGTADAANVTSTLENEEHSQIIIHCTPSTGAFKPCEYLLGSWMIRLTVWFIFLVALFFNLLVILTTFASCTSLPSSKLFIGLISVSNLFMGIYTGILTFLDAVSWGRFAEFGIWWETGSGCKVAGFLAVFSSESAIFLLMLATVERSLSAKDIMKNGKSNHLKQFRVAALLAFLGATVAGCFPLFHRGEYSASPLCLPFPTGETPSLGFTVTLVLLNSLAFLLMAVIYTKLYCNLEKEDLSENSQSSMIKHVAWLIFTNCIFFCPVAFFSFAPLITAISISPEIMKSVTLIFFPLPACLNPVLYVFFNPKFKEDWKLLKRRVTKKSGSVSVSISSQGGCLEQDFYYDCGMYSHLQGNLTVCDCCESFLLTKPVSCKHLIKSHSCPALAVASCQRPEGYWSDCGTQSAHSDYADEEDSFVSDSSDQVQACGRACFYQSRGFPLVRYAYNLPRVKD T90672 DRUGINFO D2ZI3H BNC-102 Preclinical T95860 TARGETID T95860 T95860 UNIPROID FOXO4_HUMAN-P53_HUMAN T95860 TARGNAME FOXO4-P53 interaction (FOXO4-P53 PPI) T95860 GENENAME FOXO4-TP53 T95860 TARGTYPE Preclinical T95860 DRUGINFO DRO7H6 FOXO4-DRI Preclinical T96321 TARGETID T96321 T96321 TARGNAME Bacillus poly-gamma-d-glutamic acid (Bacillus PGA) T96321 TARGTYPE Preclinical T96321 DRUGINFO D23FRK F26G3 Preclinical T96321 DRUGINFO DNE73Q F26G4 Preclinical T96321 DRUGINFO DX1U8I F24F2 Preclinical T63234 TARGETID T63234 T63234 UNIPROID QCRB_MYCTU T63234 TARGNAME Cytochrome bc1 complex cytochrome b subunit (qcrB) T63234 GENENAME qcrB T63234 TARGTYPE Preclinical T63234 SYNONYMS Cytochrome bc1 reductase complex subunit QcrB; Ubiquinol--cytochrome c reductase cytochrome b subunit T63234 FUNCTION Cytochrome b subunit of the cytochrome bc1 complex, an essential component of the respiratory electron transport chain required for ATP synthesis. The bc1 complex catalyzes the oxidation of ubiquinol and the reduction of cytochrome c in the respiratory chain. The bc1 complex operates through a Q-cycle mechanism that couples electron transfer to generation of the proton gradient that drives ATP synthesis. The cytochrome b subunit contains two ubiquinol reactive sites: the oxidation (QP) site and the reduction (QN) site. {ECO:0000305, ECO:0000305|PubMed:23913123, ECO:0000305|PubMed:26158909}. T63234 PDBSTRUC 7E1V;7E1W;7E1X T63234 BIOCLASS Cytochrome b family T63234 ECNUMBER EC 7.1.1.8 T63234 SEQUENCE MSPKLSPPNIGEVLARQAEDIDTRYHPSAALRRQLNKVFPTHWSFLLGEIALYSFVVLLITGVYLTLFFDPSMVDVTYNGVYQPLRGVEMSRAYQSALDISFEVRGGLFVRQIHHWAALMFAAAIMVHLARIFFTGAFRRPRETNWVIGSLLLILAMFEGYFGYSLPDDLLSGLGLRAALSSITLGMPVIGTWLHWALFGGDFPGTILIPRLYALHILLLPGIILALIGLHLALVWFQKHTQFPGPGRTEHNVVGVRVMPVFAFKSGAFFAAIVGVLGLMGGLLQINPIWNLGPYKPSQVSAGSQPDFYMMWTEGLARIWPPWEFYFWHHTIPAPVWVAVIMGLVFVLLPAYPFLEKRFTGDYAHHNLLQRPRDVPVRTAIGAMAIAFYMVLTLAAMNDIIALKFHISLNATTWIGRIGMVILPPFVYFITYRWCIGLQRSDRSVLEHGVETGIIKRLPHGAYIELHQPLGPVDEHGHPIPLQYQGAPLPKRMNKLGSAGSPGSGSFLFADSAAEDAALREAGHAAEQRALAALREHQDSIMGSPDGEH T63234 DRUGINFO D5Q4NY TB47 Preclinical T81850 TARGETID T81850 T81850 FORMERID TTDC00106 T81850 UNIPROID FDFT_HUMAN T81850 TARGNAME Squalene synthetase (FDFT1) T81850 GENENAME FDFT1 T81850 TARGTYPE Discontinued T81850 SYNONYMS Squalene synthase; SS; SQS; Farnesyl-diphosphate farnesyltransferase; FPP:FPP farnesyltransferase T81850 FUNCTION Participates in the isoprenoid biosynthetic pathway, catalyzing a two-step reaction in which two identical molecules of farnesyl pyrophosphate (FPP) are converted into squalene, with the consumption of NADPH. T81850 PDBSTRUC 3WSA; 3WEK; 3WEJ; 3WEI; 3WEH T81850 BIOCLASS Alkyl aryl transferase T81850 ECNUMBER EC 2.5.1.21 T81850 SEQUENCE MEFVKCLGHPEEFYNLVRFRIGGKRKVMPKMDQDSLSSSLKTCYKYLNQTSRSFAAVIQALDGEMRNAVCIFYLVLRALDTLEDDMTISVEKKVPLLHNFHSFLYQPDWRFMESKEKDRQVLEDFPTISLEFRNLAEKYQTVIADICRRMGIGMAEFLDKHVTSEQEWDKYCHYVAGLVGIGLSRLFSASEFEDPLVGEDTERANSMGLFLQKTNIIRDYLEDQQGGREFWPQEVWSRYVKKLGDFAKPENIDLAVQCLNELITNALHHIPDVITYLSRLRNQSVFNFCAIPQVMAIATLAACYNNQQVFKGAVKIRKGQAVTLMMDATNMPAVKAIIYQYMEEIYHRIPDSDPSSSKTRQIISTIRTQNLPNCQLISRSHYSPIYLSFVMLLAALSWQYLTTLSQVTEDYVQTGEH T81850 DRUGINFO D02FXU Lapaquistat acetate Discontinued in Phase 3 T81850 DRUGINFO D0N5HO SQ-32709 Discontinued in Phase 2 T81850 DRUGINFO D0W1MX BMS-187745 Discontinued in Phase 2 T81850 DRUGINFO D04KDA A-87049 Terminated T81850 DRUGINFO D08ALQ RPR-101821 Terminated T81850 DRUGINFO D0RU3M SQ-34919 Terminated T81850 DRUGINFO D0O1AV Squalestatin 1 Terminated T81850 DRUGINFO D00CEN L-735021 Investigative T81850 DRUGINFO D00KMC PMID19191557C32 Investigative T81850 DRUGINFO D00OPO PMID9871507C14 Investigative T81850 DRUGINFO D00QFL PMID19456099C13 Investigative T81850 DRUGINFO D00YIS PMID19191557C14 Investigative T81850 DRUGINFO D01UKV 3-[1'-{4'-(Benzyloxy)-phenyl}]-quinuclidine-2-ene Investigative T81850 DRUGINFO D02VUM L-731120 Investigative T81850 DRUGINFO D03CUH PMID7966163C6c Investigative T81850 DRUGINFO D03DCE BPH-830 Investigative T81850 DRUGINFO D04AAT PMID18754614C7 Investigative T81850 DRUGINFO D04DZS PMID8576905C4 Investigative T81850 DRUGINFO D04GSN Zaragozic Acid C Investigative T81850 DRUGINFO D05OHM PMID9216829C5j Investigative T81850 DRUGINFO D05URH Zaragozic Acid D Investigative T81850 DRUGINFO D06AJN PMID7629799C6 Investigative T81850 DRUGINFO D06MMN PMID7966163C4e Investigative T81850 DRUGINFO D06PMR PMID18754614C18 Investigative T81850 DRUGINFO D06RCI L-731128 Investigative T81850 DRUGINFO D06VOJ J-104118 Investigative T81850 DRUGINFO D07ABI (Z)-3-[2-(9H-fluoren-2-yloxy)ethylidene]-quinuclidine hydrochloride 31 Investigative T81850 DRUGINFO D07ICD PMID12238936C3a Investigative T81850 DRUGINFO D07JLS E5700 Investigative T81850 DRUGINFO D07KJI PMID7966163C3f Investigative T81850 DRUGINFO D09ATQ PMID19191557C19 Investigative T81850 DRUGINFO D09HKR PMID20299227C12 Investigative T81850 DRUGINFO D09IQG PMID7966163C6g Investigative T81850 DRUGINFO D09TKC PMID18754614C8 Investigative T81850 DRUGINFO D0A7FI PMID18754614C19 Investigative T81850 DRUGINFO D0AP5M PMID19191557C3 Investigative T81850 DRUGINFO D0B9EV PMID19456099C15 Investigative T81850 DRUGINFO D0D7IQ PMID18754614C4 Investigative T81850 DRUGINFO D0E1BR PMID19191557C35 Investigative T81850 DRUGINFO D0E9TE PMID22464687C15a Investigative T81850 DRUGINFO D0G4ZT CP-294838 Investigative T81850 DRUGINFO D0G9LW PMID19191557C21 Investigative T81850 DRUGINFO D0I3TX J-104123 Investigative T81850 DRUGINFO D0K1QV 2-[4-(2-Thienyl)phenyl]-4-methylmorpholin-2-ol Investigative T81850 DRUGINFO D0K7GL PMID7473541C19 Investigative T81850 DRUGINFO D0KJ7C PMID7629799C2e Investigative T81850 DRUGINFO D0L1ND PMID8709131C2a (+) Investigative T81850 DRUGINFO D0LT7Y PMID7473541C11 Investigative T81850 DRUGINFO D0M0HE YM-75440 Investigative T81850 DRUGINFO D0M1QJ PMID18754614C10 Investigative T81850 DRUGINFO D0MA8Q PMID8709131C17 Investigative T81850 DRUGINFO D0MM5G PMID7629799C2d Investigative T81850 DRUGINFO D0N4BQ PMID8709131C4 Investigative T81850 DRUGINFO D0NL2L 3-[7'-(Methoxy)-napht-2'-yl]-quinuclidine-2-ene Investigative T81850 DRUGINFO D0OF1X PMID8709131C15 Investigative T81850 DRUGINFO D0OI4E ZARAGOZIC ACID B Investigative T81850 DRUGINFO D0PP5M BPH-652 Investigative T81850 DRUGINFO D0Q1XK PMID18754614C9 Investigative T81850 DRUGINFO D0Q3DY PMID12238936C3f Investigative T81850 DRUGINFO D0R8NC PMID7473541C20 Investigative T81850 DRUGINFO D0RN8T PMID20299227C20 Investigative T81850 DRUGINFO D0S4LW PMID9216829C5m Investigative T81850 DRUGINFO D0S4UA 1-allyl-2-[3-(isopropylamino)propoxy]-9H-xanthen-9-one Investigative T81850 DRUGINFO D0SC4X Zaragozic Acid D2 Investigative T81850 DRUGINFO D0T2DP PMID8496919C7 Investigative T81850 DRUGINFO D0U0NT ER-119884 Investigative T81850 DRUGINFO D0U9GN PMID18754614C17 Investigative T81850 DRUGINFO D0V4FC PMID7650673C4q Investigative T81850 DRUGINFO D0WG7H PMID19191557C8 Investigative T81850 DRUGINFO D0X4OP 1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole Investigative T81850 DRUGINFO D0XN1T PMID8709131C23 Investigative T81850 DRUGINFO D0Z5BQ PMID17709461C4g Investigative T81850 DRUGINFO D0ZD1B PMID7473541C21 Investigative T81850 DRUGINFO D0ZT0F PMID7966163C6d Investigative T20331 TARGETID T20331 T20331 FORMERID TTDC00089 T20331 UNIPROID NPY5R_HUMAN T20331 TARGNAME Neuropeptide Y receptor type 5 (NPY5R) T20331 GENENAME NPY5R T20331 TARGTYPE Discontinued T20331 SYNONYMS Y5 receptor; Neuropeptide Y receptor Y5; Neuropeptide Y (NPY) Y(5) receptor; NPYY5; NPY5R; NPY5-R; NPY-Y5 receptor T20331 FUNCTION Receptor for neuropeptide Y and peptide YY. The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity. Seems to be associated with food intake. Could be involved in feeding disorders. T20331 PDBSTRUC 2HE6 T20331 BIOCLASS GPCR rhodopsin T20331 SEQUENCE MDLELDEYYNKTLATENNTAATRNSDFPVWDDYKSSVDDLQYFLIGLYTFVSLLGFMGNLLILMALMKKRNQKTTVNFLIGNLAFSDILVVLFCSPFTLTSVLLDQWMFGKVMCHIMPFLQCVSVLVSTLILISIAIVRYHMIKHPISNNLTANHGYFLIATVWTLGFAICSPLPVFHSLVELQETFGSALLSSRYLCVESWPSDSYRIAFTISLLLVQYILPLVCLTVSHTSVCRSISCGLSNKENRLEENEMINLTLHPSKKSGPQVKLSGSHKWSYSFIKKHRRRYSKKTACVLPAPERPSQENHSRILPENFGSVRSQLSSSSKFIPGVPTCFEIKPEENSDVHELRVKRSVTRIKKRSRSVFYRLTILILVFAVSWMPLHLFHVVTDFNDNLISNRHFKLVYCICHLLGMMSCCLNPILYGFLNNGIKADLVSLIHCLHM T20331 DRUGINFO D0W7UO CGP71683A Discontinued in Phase 3 T20331 DRUGINFO D0K4NZ Velneperit Discontinued in Phase 2 T20331 DRUGINFO D0E2KT S-234462 Discontinued in Phase 1 T20331 DRUGINFO D0MV3Q Axovan-3 Discontinued in Phase 1 T20331 DRUGINFO D02NMO FR-79620 Preclinical T20331 DRUGINFO D0I3TS GW-594884A Preclinical T20331 DRUGINFO D0I5HE NPY5RA-972 Preclinical T20331 DRUGINFO D05ALG RWJ-49815 Terminated T20331 DRUGINFO D01HFL 2,4,4-triphenylimidazoline Investigative T20331 DRUGINFO D07XFL FR-226928 Investigative T20331 DRUGINFO D09BGI JCF 109 Investigative T20331 DRUGINFO D09VTY FMS586 Investigative T20331 DRUGINFO D0C9XD L-152,804 Investigative T20331 DRUGINFO D0F6WW LU-AA33810 Investigative T20331 DRUGINFO D0K3QL FR-230481 Investigative T20331 DRUGINFO D0L9OS FR-73966 Investigative T20331 DRUGINFO D0N6HL FR-233118 Investigative T20331 DRUGINFO D08ROQ S-25585 Investigative T20331 DRUGINFO D0NY7A S-19528 Investigative T20331 DRUGINFO D0K0KR AR-129330 Investigative T20331 DRUGINFO D0O7PT Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] Investigative T93566 TARGETID T93566 T93566 FORMERID TTDR01369 T93566 UNIPROID LOX5_HUMAN T93566 TARGNAME LOX-5 messenger RNA (ALOX5 mRNA) T93566 GENENAME ALOX5 T93566 TARGTYPE Discontinued T93566 SYNONYMS LOG5 (mRNA); 5-lipoxygenase (mRNA); 5-LO (mRNA) T93566 FUNCTION Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes. T93566 PDBSTRUC 3V99; 3V98; 3V92; 3O8Y; 2ABV T93566 BIOCLASS mRNA target T93566 ECNUMBER EC 1.13.11.34 T93566 SEQUENCE MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDEELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLARDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVLNYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNGCNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDPCTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDFHVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECGLFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWEAIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYLTVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCWHLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPYYYLSPDRIPNSVAI T93566 DRUGINFO D07HBI ZD-2138 Discontinued in Phase 2 T93566 DRUGINFO D0P3KA TEBUFELONE Discontinued in Phase 2 T93566 DRUGINFO D05WPQ BW A4C Terminated T93566 DRUGINFO D00DYQ ISIS 2177 Investigative T93566 DRUGINFO D00OWZ 4-methoxy-N-(thiazol-2-yl)benzamide Investigative T93566 DRUGINFO D01GSW ISAINDIGOTONE Investigative T93566 DRUGINFO D01IMJ N-(4-methylthiazol-2-yl)benzamide Investigative T93566 DRUGINFO D02GJI 3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide Investigative T93566 DRUGINFO D03WDY N-(1,3,4-thiadiazol-2-yl)benzamide Investigative T93566 DRUGINFO D04QVX N-(5-methylthiazol-2-yl)benzamide Investigative T93566 DRUGINFO D05DAE 2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide Investigative T93566 DRUGINFO D05FKT L-689065 Investigative T93566 DRUGINFO D05IQL Methyl 2-(Benzylamino)-1H-indole-3-carboxylate Investigative T93566 DRUGINFO D05OFR N-(5-methylthiazol-2-yl)-2-phenylacetamide Investigative T93566 DRUGINFO D05WGA 2-(4-methoxyphenyl)-N-(thiazol-2-yl)acetamide Investigative T93566 DRUGINFO D06DCK L-746530 Investigative T93566 DRUGINFO D06IVU N-(4-methylthiazol-2-yl)-2-phenylacetamide Investigative T93566 DRUGINFO D07TWV 2-(benzyloxy)naphthalene Investigative T93566 DRUGINFO D08IRN 2,4,5-Triarylimidazole analogue Investigative T93566 DRUGINFO D09DBH 2-phenyl-N-(thiazol-2-yl)acetamide Investigative T93566 DRUGINFO D09MTV 4-(dimethylamino)-N-(thiazol-2-yl)benzamide Investigative T93566 DRUGINFO D09XWS 1-(4-methoxyphenyl)-3-(1,3,4-thiadiazol-2-yl)urea Investigative T93566 DRUGINFO D0EK3T ISIS 1831 Investigative T93566 DRUGINFO D0G3SF 1-(4-methoxyphenyl)-3-(4-methylthiazol-2-yl)urea Investigative T93566 DRUGINFO D0L4NE ISIS 1820 Investigative T93566 DRUGINFO D0PP1I ISIS 1822 Investigative T93566 DRUGINFO D0Q9TL L-702-539 Investigative T93566 DRUGINFO D0SS4S Methyl 2-(Diallylamino)-1H-indole-3-carboxylate Investigative T93566 DRUGINFO D0UH6R (N-(3-phenoxycinnamyl)-acetohydroxamic acid Investigative T93566 DRUGINFO D0V8MX 3,4,5-trimethoxy-N-(thiazol-2-yl)benzamide Investigative T93566 DRUGINFO D0W1XD ISIS 1827 Investigative T93566 DRUGINFO D0W3ZN PD-169316 Investigative T93566 DRUGINFO D0X5AY 1-(4-methoxyphenyl)-3-(5-methylthiazol-2-yl)urea Investigative T93566 DRUGINFO D0Y1TA 2,4'-Diacetoxy-5,3'-di-(2-propenyl)-biphenyl Investigative T93566 DRUGINFO D0Y8VJ ISIS 1821 Investigative T93566 DRUGINFO D0Z7QZ N-(thiazol-2-yl)benzamide Investigative T93566 DRUGINFO D01KTM (-)-pinoresinol Investigative T93566 DRUGINFO D01PBO (+)-3,3'-bisdemethyltanegool Investigative T93566 DRUGINFO D07EAJ JASPAQUINOL Investigative T93566 DRUGINFO D0K7XQ N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea Investigative T93566 DRUGINFO D0L3RY 3-methoxy-N-(4-methylthiazol-2-yl)benzamide Investigative T93566 DRUGINFO D0N7XM (-)-3,3'-bisdemethylpinoresinol Investigative T93566 DRUGINFO D0S7ZQ 4'-Methoxy-5,3'-dipropyl-biphenyl-2ol Investigative T93566 DRUGINFO D01JYF 2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl Investigative T93566 DRUGINFO D01OFH METHYLHONOKIOL Investigative T93566 DRUGINFO D04DQJ HONOKIOL Investigative T93566 DRUGINFO D05FJM PUUPEHEDIONE Investigative T93566 DRUGINFO D07BXV PUUPEHENONE Investigative T93566 DRUGINFO D0F9FG Isojaspic acid Investigative T93566 DRUGINFO D0R6ZC 5,3'-Dipropyl-biphenyl-2,4'-diol Investigative T93566 DRUGINFO D0G3TK KAEMPFEROL Investigative T69085 TARGETID T69085 T69085 FORMERID TTDC00119 T69085 UNIPROID JUN_HUMAN T69085 TARGNAME Transcription factor AP-1 (JUN) T69085 GENENAME JUN T69085 TARGTYPE Discontinued T69085 SYNONYMS V-jun avian sarcoma virus 17 oncogene homolog; Proto-oncogene c-jun; P39; C-jun proto-oncogene; Activator protein-1; Activator protein 1; AP1; AP-1 transcription factor T69085 FUNCTION Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. Binds to the USP28 promoter in colorectal cancer (CRC) cells. Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. T69085 PDBSTRUC 5T01; 5FV8; 1T2K; 1S9K; 1JNM T69085 BIOCLASS Basic leucine zipper bZIP T69085 SEQUENCE MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAELHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGALSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHVNSGCQLMLTQQLQTF T69085 DRUGINFO D02LCL T-5224 Discontinued in Phase 2 T69085 DRUGINFO D06OWM PNRI-299 Investigative T69085 DRUGINFO D0AH5T TAM-67 Investigative T69085 DRUGINFO D0T8KR TWS-119 Investigative T37735 TARGETID T37735 T37735 FORMERID TTDI02082 T37735 UNIPROID GLNA_HUMAN T37735 TARGNAME Glutamate decarboxylase (GLUL) T37735 GENENAME GLUL T37735 TARGTYPE Discontinued T37735 SYNONYMS Glutamateammonia ligase T37735 FUNCTION Its role depends on tissue localization: in the brain, it regulates the levels of toxic ammonia and converts neurotoxic glutamate to harmless glutamine, whereas in the liver, it is one of the enzymes responsible for the removal of ammonia. Essential for proliferation of fetal skin fibroblasts. Independently of its glutamine synthetase activity, required for endothelial cell migration during vascular development: acts by regulating membrane localization and activation of the GTPase RHOJ, possibly by promoting RHOJ palmitoylation. May act as a palmitoyltransferase for RHOJ: able to autopalmitoylate and then transfer the palmitoyl group to RHOJ. Plays a role in ribosomal 40S subunit biogenesis. Glutamine synthetase that catalyzes the ATP-dependent conversion of glutamate and ammonia to glutamine. T37735 PDBSTRUC 2QC8; 2OJW T37735 BIOCLASS Carbon-nitrogen ligase T37735 ECNUMBER EC 6.3.1.2 T37735 SEQUENCE MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELPEWNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHTCKRIMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRDIVEAHYRACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIATFDPKPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGLDNARRLTGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRTCLLNETGDEPFQYKN T37735 DRUGINFO D0VT0T NLX-P101 Discontinued in Phase 2 T95446 TARGETID T95446 T95446 FORMERID TTDI01943 T95446 UNIPROID NCPR_HUMAN T95446 TARGNAME Cytochrome P450 reductase (P450) T95446 GENENAME POR T95446 TARGTYPE Discontinued T95446 SYNONYMS P450R; NADPH--cytochrome P450 reductase; CYPOR; CPR T95446 FUNCTION This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5. T95446 PDBSTRUC 5FA6; 5EMN; 3QFT; 3QFS; 3QFR T95446 BIOCLASS NADH/NADPH oxidoreductase T95446 ECNUMBER EC 1.6.2.4 T95446 SEQUENCE MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTLTSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHLMHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVDYIKKLMTKGRYSLDVWS T95446 DRUGINFO D0X6XF VTP-201227 Discontinued in Phase 2 T95446 DRUGINFO D03PBT DuP-983 Terminated T95446 DRUGINFO D04ICN DuP-630 Terminated T27137 TARGETID T27137 T27137 FORMERID TTDC00220 T27137 UNIPROID GRM1_HUMAN T27137 TARGNAME Metabotropic glutamate receptor 1 (mGluR1) T27137 GENENAME GRM1 T27137 TARGTYPE Discontinued T27137 SYNONYMS mGLUR1; Glutamate receptor mGLU1; GPRC1A T27137 FUNCTION Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-calcium second messenger system. May participate in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum. G-protein coupled receptor for glutamate. T27137 PDBSTRUC 4OR2; 3KS9 T27137 BIOCLASS GPCR glutamate T27137 SEQUENCE MVGLLLFFFPAIFLEVSLLPRSPGRKVLLAGASSQRSVARMDGDVIIGALFSVHHQPPAEKVPERKCGEIREQYGIQRVEAMFHTLDKINADPVLLPNITLGSEIRDSCWHSSVALEQSIEFIRDSLISIRDEKDGINRCLPDGQSLPPGRTKKPIAGVIGPGSSSVAIQVQNLLQLFDIPQIAYSATSIDLSDKTLYKYFLRVVPSDTLQARAMLDIVKRYNWTYVSAVHTEGNYGESGMDAFKELAAQEGLCIAHSDKIYSNAGEKSFDRLLRKLRERLPKARVVVCFCEGMTVRGLLSAMRRLGVVGEFSLIGSDGWADRDEVIEGYEVEANGGITIKLQSPEVRSFDDYFLKLRLDTNTRNPWFPEFWQHRFQCRLPGHLLENPNFKRICTGNESLEENYVQDSKMGFVINAIYAMAHGLQNMHHALCPGHVGLCDAMKPIDGSKLLDFLIKSSFIGVSGEEVWFDEKGDAPGRYDIMNLQYTEANRYDYVHVGTWHEGVLNIDDYKIQMNKSGVVRSVCSEPCLKGQIKVIRKGEVSCCWICTACKENEYVQDEFTCKACDLGWWPNADLTGCEPIPVRYLEWSNIESIIAIAFSCLGILVTLFVTLIFVLYRDTPVVKSSSRELCYIILAGIFLGYVCPFTLIAKPTTTSCYLQRLLVGLSSAMCYSALVTKTNRIARILAGSKKKICTRKPRFMSAWAQVIIASILISVQLTLVVTLIIMEPPMPILSYPSIKEVYLICNTSNLGVVAPLGYNGLLIMSCTYYAFKTRNVPANFNEAKYIAFTMYTTCIIWLAFVPIYFGSNYKIITTCFAVSLSVTVALGCMFTPKMYIIIAKPERNVRSAFTTSDVVRMHVGDGKLPCRSNTFLNIFRRKKAGAGNANSNGKSVSWSEPGGGQVPKGQHMWHRLSVHVKTNETACNQTAVIKPLTKSYQGSGKSLTFSDTSTKTLYNVEEEEDAQPIRFSPPGSPSMVVHRRVPSAATTPPLPSHLTAEETPLFLAEPALPKGLPPPLQQQQQPPPQQKSLMDQLQGVVSNFSTAIPDFHAVLAGPGGPGNGLRSLYPPPPPPQHLQMLPLQLSTFGEELVSPPADDDDDSERFKLLQEYVYEHEREGNTEEDELEEEEEDLQAASKLTPDDSPALTPPSPFRDSVASGSSVPSSPVSESVLCTPPNVSYASVILRDYKQSSSTL T27137 DRUGINFO D07ESH PF-1913539 Discontinued in Phase 3 T27137 DRUGINFO D01FUB AZD8529 Discontinued in Phase 2 T27137 DRUGINFO D0E3SD AZD-9272 Discontinued in Phase 1 T27137 DRUGINFO D06LYZ A-841720 Preclinical T27137 DRUGINFO D0W0XM NPS-2390 Preclinical T27137 DRUGINFO D04JQR LY-367385 Terminated T27137 DRUGINFO D00DJE N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine Investigative T27137 DRUGINFO D00REW [11C]MMTP Investigative T27137 DRUGINFO D00ZDX CFMMC Investigative T27137 DRUGINFO D01AZJ [18F]FPIT Investigative T27137 DRUGINFO D01ERW CFMTI Investigative T27137 DRUGINFO D01EVA CPCCOEt Investigative T27137 DRUGINFO D01PGO DM-PPP Investigative T27137 DRUGINFO D01TMC PMID16099654C4b Investigative T27137 DRUGINFO D02AYD PMID19289283C32 Investigative T27137 DRUGINFO D02FTR 3,5-dimethyl PPP Investigative T27137 DRUGINFO D02NMN PMID19433355C11s Investigative T27137 DRUGINFO D02NNU PMID17929793C23h Investigative T27137 DRUGINFO D02YGR PMID12470711C3 Investigative T27137 DRUGINFO D03MEI VU0080241 Investigative T27137 DRUGINFO D03NFW PMID19289283C22 Investigative T27137 DRUGINFO D03YJD VU-71 Investigative T27137 DRUGINFO D03ZUB Ro67-7476 Investigative T27137 DRUGINFO D04JKL AIDA Investigative T27137 DRUGINFO D04MVR A-794282 Investigative T27137 DRUGINFO D04RYE PMID20346665C27 Investigative T27137 DRUGINFO D04VOI PMID17064898C29 Investigative T27137 DRUGINFO D05DCW PMID20346665C24 Investigative T27137 DRUGINFO D05KSC A-850002 Investigative T27137 DRUGINFO D05KSW N-phenethylquinoxaline-2-carboxamide Investigative T27137 DRUGINFO D05NTV (S)-TBPG Investigative T27137 DRUGINFO D05WPH Quinoline-3-carboxylic acid adamantan-1-ylamide Investigative T27137 DRUGINFO D05YMP [3H]EM-TBPC Investigative T27137 DRUGINFO D06GNR N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide Investigative T27137 DRUGINFO D06GPP (E)-4,4-Dimethyl-1-quinolin-3-yl-pent-1-en-3-one Investigative T27137 DRUGINFO D06RID 4-(cyclohexyloxy)quinazoline Investigative T27137 DRUGINFO D06TYA PMID17929793C23c Investigative T27137 DRUGINFO D07XMV YM-202074 Investigative T27137 DRUGINFO D08KIG Ro01-6128 Investigative T27137 DRUGINFO D0B3HH JNJ-16567083 Investigative T27137 DRUGINFO D0B4GX LY456066 Investigative T27137 DRUGINFO D0C2IE N-(2-phenylpropyl)quinoxaline-2-carboxamide Investigative T27137 DRUGINFO D0DC4E PMID16099654C3a Investigative T27137 DRUGINFO D0E6GG Ro67-4853 Investigative T27137 DRUGINFO D0EI9B BAY 367620 Investigative T27137 DRUGINFO D0G4BW PMID17929793C23e Investigative T27137 DRUGINFO D0GX5C PMID23084894C9n Investigative T27137 DRUGINFO D0H6YH N-cyclohexylquinolin-4-amine Investigative T27137 DRUGINFO D0J7ZK N-cyclohexylquinazolin-4-amine Investigative T27137 DRUGINFO D0JR0W [18F]FITM Investigative T27137 DRUGINFO D0M2CT LY456236 Investigative T27137 DRUGINFO D0N2TF R214127 Investigative T27137 DRUGINFO D0O8WT Ro0711401 Investigative T27137 DRUGINFO D0OA3L VU0469650 Investigative T27137 DRUGINFO D0OS8Y MK-5435 Investigative T27137 DRUGINFO D0P6HX FPTQ Investigative T27137 DRUGINFO D0QC9F PMID22266036C12e Investigative T27137 DRUGINFO D0QN5E Quinoline-2-carboxylic acid adamantan-1-ylamide Investigative T27137 DRUGINFO D0R1YT [18F]MK-1312 Investigative T27137 DRUGINFO D0R8EU FTIDC Investigative T27137 DRUGINFO D0S9TZ YM298198 Investigative T27137 DRUGINFO D0S9WV Pyrazine-2-carboxylic acid adamantan-1-ylamide Investigative T27137 DRUGINFO D0SB7U PMID23084894C10i Investigative T27137 DRUGINFO D0SF9Z PMID22266036C9a Investigative T27137 DRUGINFO D0SG6Q PMID19433355C11q Investigative T27137 DRUGINFO D0T7UG N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine Investigative T27137 DRUGINFO D0T9TC PMID17276684C22 Investigative T27137 DRUGINFO D0V3YX A-794278 Investigative T27137 DRUGINFO D0VN5D PMID17929793C11c Investigative T27137 DRUGINFO D0W0NJ PMID17532216C2f Investigative T27137 DRUGINFO D0W2GG PMID17929793C23i Investigative T27137 DRUGINFO D0W6YX (3,4-dimethylphenyl)(4-phenoxyphenyl)methanone Investigative T27137 DRUGINFO D0Y3EG 3-MATIDA Investigative T27137 DRUGINFO D01YEN ibotenate Investigative T27137 DRUGINFO D02FMR 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine Investigative T27137 DRUGINFO D03VAO N-(3-bromophenyl)-6-fluoroquinazolin-4-amine Investigative T27137 DRUGINFO D04ODF LY-3390334 Investigative T27137 DRUGINFO D0B5RX (E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone Investigative T27137 DRUGINFO D0E7LU 3,5-DHPG Investigative T27137 DRUGINFO D0OH2P (S)-(+)-CBPG Investigative T27137 DRUGINFO D0P3XO (S)-4CPG Investigative T27137 DRUGINFO D0R6ZS N-(3-bromophenyl)-6-chloroquinazolin-4-amine Investigative T27137 DRUGINFO D0U5YT (S)-3HPG Investigative T27137 DRUGINFO D0H6BG PHCCC Investigative T27137 DRUGINFO D0IO8J 2-methyl-6-(phenylethynyl)pyridine Investigative T27137 DRUGINFO D0S6DK (S)-4C3HPG Investigative T27137 DRUGINFO D0J8OW (+)-MCPG Investigative T27137 DRUGINFO D04DKM (1S,3R)-ACPD Investigative T27137 DRUGINFO D06DUE [3H]quisqualate Investigative T27137 DRUGINFO D0Z7CZ L-CCG-I Investigative T11253 TARGETID T11253 T11253 FORMERID TTDC00269 T11253 UNIPROID HSPB1_HUMAN T11253 TARGNAME HSPB1 messenger RNA (HSPB1 mRNA) T11253 GENENAME HSPB1 T11253 TARGTYPE Discontinued T11253 SYNONYMS Stress-responsive protein 27 (mRNA); SRP27 (mRNA); HspB1 (mRNA); Heat shock protein beta-1 (mRNA); Heat shock 27 kDa protein (mRNA); HSP28 (mRNA); HSP 27 (mRNA); Estrogen-regulated 24 kDa protein (mRNA); 28 kDa heat shock protein (mRNA) T11253 FUNCTION Plays a role in stress resistance and actin organization. Through its molecular chaperone activity may regulate numerous biological processes including the phosphorylation and the axonal transport of neurofilament proteins. Small heat shock protein which functions as a molecular chaperone probably maintaining denatured proteins in a folding-competent state. T11253 PDBSTRUC 4MJH; 3Q9Q; 3Q9P; 2N3J T11253 BIOCLASS mRNA target T11253 SEQUENCE MTERRVPFSLLRGPSWDPFRDWYPHSRLFDQAFGLPRLPEEWSQWLGGSSWPGYVRPLPPAAIESPAVAAPAYSRALSRQLSSGVSEIRHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLATQSNEITIPVTFESRAQLGGPEAAKSDETAAK T11253 DRUGINFO D0A9KI SB-242235 Discontinued in Phase 1 T11253 DRUGINFO D00ZBZ OGX-427 + Paclitaxel Investigative T23355 TARGETID T23355 T23355 FORMERID TTDR01362 T23355 UNIPROID ITB3_HUMAN T23355 TARGNAME ITGB3 messenger RNA (ITGB3 mRNA) T23355 GENENAME ITGB3 T23355 TARGTYPE Discontinued T23355 SYNONYMS Platelet membrane glycoprotein IIIa (mRNA); Integrin beta-3 (mRNA); GPIIIa (mRNA); GP3A (mRNA); CD61 (mRNA) T23355 FUNCTION Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling. ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling. ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling. ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling. ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling. ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. T23355 PDBSTRUC 6CKB; 6BXJ; 6BXF; 6BXB; 6AVU T23355 BIOCLASS mRNA target T23355 SEQUENCE MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT T23355 DRUGINFO D07EXV XEMILOFIBAN Discontinued in Phase 3 T23355 DRUGINFO D0K0NP DMP-802 Discontinued in Phase 1 T23355 DRUGINFO D03GCN L-709780 Terminated T23355 DRUGINFO D03QHI Ro-43-8857 Terminated T23355 DRUGINFO D08CQL SKF-107260 Terminated T23355 DRUGINFO D08LIG L-738167 Terminated T23355 DRUGINFO D0U4ZY DMP-757 Terminated T23355 DRUGINFO D0Z0XQ Ro-43-5054 Terminated T23355 DRUGINFO D0G9BX SC-47643 Terminated T23355 DRUGINFO D0LT1S SB-223245 Terminated T23355 DRUGINFO D01XUU L-739758 Investigative T23355 DRUGINFO D02MYZ ISIS 25237 Investigative T23355 DRUGINFO D04BHL ROXIFIBAN Investigative T23355 DRUGINFO D04XTP RWJ-53419 Investigative T23355 DRUGINFO D05AGK L-750034 Investigative T23355 DRUGINFO D06LHH L-756568 Investigative T23355 DRUGINFO D08RLR SC-54701A Investigative T23355 DRUGINFO D0C8LA L-734115 Investigative T23355 DRUGINFO D0M7KS SB-207043 Investigative T23355 DRUGINFO D0Q2ZS ISIS 196103 Investigative T23355 DRUGINFO D0S8DT L-746233 Investigative T23355 DRUGINFO D0W5ZK L-767679 Investigative T23355 DRUGINFO D00YBU C(RGDfF) Investigative T23355 DRUGINFO D01AXA Ac-Asp-Arg-Leu-Asp-Ser-OH Investigative T23355 DRUGINFO D01BZH C[-Arg-Gly-Asp-Acpca21-] Investigative T23355 DRUGINFO D01MGI C-[-Arg-Gly-Asp-Acpca32-] Investigative T23355 DRUGINFO D01ZJF 3-(3-(carbamoyl)benzamido)propanoic acid Investigative T23355 DRUGINFO D03KLT Cyclo-[-Arg-Gly-Asp-Amp22-] Investigative T23355 DRUGINFO D03YLY Cyclo-[-Arg-Gly-Asp-Amp21-] Investigative T23355 DRUGINFO D04MCL Cypate-[(RGD)2-NH2]2 Investigative T23355 DRUGINFO D04WVG C[-Arg-Gly-Asp-Acpca35-] Investigative T23355 DRUGINFO D05EWB C[RGDf-(S)-alpha-TfmV] Investigative T23355 DRUGINFO D05GXK Cyclo-[-Arg-Gly-Asp-Amp26-] Investigative T23355 DRUGINFO D05MJG E[c(RGDyK)]2 Investigative T23355 DRUGINFO D05VEC C-[-Arg-Gly-Asp-Acpca30-] Investigative T23355 DRUGINFO D06JLN C[-Arg-Gly-Asp-Acpca36-] Investigative T23355 DRUGINFO D06LKH Gly-Arg-Gly-Asp-Ser Investigative T23355 DRUGINFO D07QJD Cyclo-[-Arg-Gly-Asp-Amp25-] Investigative T23355 DRUGINFO D07UOF C(RGDfMeF) Investigative T23355 DRUGINFO D08CFM C[RGDf-(R)-alpha-TfmV] Investigative T23355 DRUGINFO D08DSG C(Arg-Gly-Asp-D-Phe-Val) Investigative T23355 DRUGINFO D09PLA C-[-Arg-Gly-Asp-Acpca31-] Investigative T23355 DRUGINFO D0D4QZ RGDechi Investigative T23355 DRUGINFO D0G7QJ 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid Investigative T23355 DRUGINFO D0G8JI Cyclo(RGDfV) (control) Investigative T23355 DRUGINFO D0H4EK C[RGDf-(R)-N-Me-alpha-TfmF] Investigative T23355 DRUGINFO D0H4MB ISONIPECOTAMIDE Investigative T23355 DRUGINFO D0I5BY C[RGDf-(S)-alpha-TfmF] Investigative T23355 DRUGINFO D0ID6U CYCLORGDFV Investigative T23355 DRUGINFO D0J6SP Cyclo-[-Arg-Gly-Asp-Amp28-] Investigative T23355 DRUGINFO D0K5DM E[c(RGDyK)]2-PTX conjugate Investigative T23355 DRUGINFO D0L2PQ Cypate-[(RGD)3-NH2]1 Investigative T23355 DRUGINFO D0LF7W C[-Arg-Gly-Asp-Acpca19-] Investigative T23355 DRUGINFO D0LV6B Gly-Arg-Gly-Asp-Ser-Pro-Lys Investigative T23355 DRUGINFO D0M0BN C[RGDf-(R)-alpha-TfmF] Investigative T23355 DRUGINFO D0M6NQ C[RGDf-(S)-N-Me-alpha-TfmF] Investigative T23355 DRUGINFO D0N9NA Cypate-[(RGD)4-NH2]2 Investigative T23355 DRUGINFO D0O6DN C[-Arg-Gly-Asp-Acpca34-] Investigative T23355 DRUGINFO D0O9FL Cyclo-[-Arg-Gly-Asp-Amp24-] Investigative T23355 DRUGINFO D0P4RB Cypate-[(RGD)2-NH2]1 Investigative T23355 DRUGINFO D0R9AD N-(3,5-dichlorophenyl)imidodicarbonimidic diamide Investigative T23355 DRUGINFO D0R9GW C[-Arg-Gly-Asp-Acpca22-] Investigative T23355 DRUGINFO D0R9SJ ST-1646 Investigative T23355 DRUGINFO D0T1II Cyclo[RGDfK(cypate)] Investigative T23355 DRUGINFO D0TP8S 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid Investigative T23355 DRUGINFO D0U0VF Cyclo-[-Arg-Gly-Asp-Amp27-] Investigative T23355 DRUGINFO D0U2NV C[RGD-(R)-alpha-TfmfV] Investigative T23355 DRUGINFO D0UE7H C-[-Arg-Gly-Asp-Acpca33-] Investigative T23355 DRUGINFO D0UO0Y Cypate-[(RGD)3-NH2]2 Investigative T23355 DRUGINFO D0V0JC C[RGD-(S)-alpha-TfmfV] Investigative T23355 DRUGINFO D0W6CJ C[-Arg-Gly-Asp-Acpca20-] Investigative T23355 DRUGINFO D0WK2F C[RGDf-(S,R)-alpha-Dfm-F] Investigative T23355 DRUGINFO D0X4EE AcDRGDS Investigative T23355 DRUGINFO D0Y8UD Cypate-[(RGD)4-NH2]1 Investigative T23355 DRUGINFO D0Z6WZ Cyclo-[-Arg-Gly-Asp-Amp23-] Investigative T23355 DRUGINFO D0R3CY SB-265123 Investigative T23355 DRUGINFO D0B4JU C(-GRGDfL-) Investigative T58940 TARGETID T58940 T58940 FORMERID TTDC00009 T58940 UNIPROID 5HT3B_HUMAN T58940 TARGNAME 5-HT 3B receptor (HTR3B) T58940 GENENAME HTR3B T58940 TARGTYPE Discontinued T58940 SYNONYMS Serotonin receptor 3B; 5-hydroxytryptamine receptor 3B; 5-HT3B; 5-HT3-B; 5-HT-3B T58940 FUNCTION This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel. T58940 BIOCLASS GPCR rhodopsin T58940 SEQUENCE MLSSVMAPLWACILVAAGILATDTHHPQDSALYHLSKQLLQKYHKEVRPVYNWTKATTVYLDLFVHAILDVDAENQILKTSVWYQEVWNDEFLSWNSSMFDEIREISLPLSAIWAPDIIINEFVDIERYPDLPYVYVNSSGTIENYKPIQVVSACSLETYAFPFDVQNCSLTFKSILHTVEDVDLAFLRSPEDIQHDKKAFLNDSEWELLSVSSTYSILQSSAGGFAQIQFNVVMRRHPLVYVVSLLIPSIFLMLVDLGSFYLPPNCRARIVFKTSVLVGYTVFRVNMSNQVPRSVGSTPLIGHFFTICMAFLVLSLAKSIVLVKFLHDEQRGGQEQPFLCLRGDTDADRPRVEPRAQRAVVTESSLYGEHLAQPGTLKEVWSQLQSISNYLQTQDQTDQQEAEWLVLLSRFDRLLFQSYLFMLGIYTITLCSLWALWGGV T58940 DRUGINFO D0V3GT BEMESETRON Discontinued in Phase 3 T58940 DRUGINFO D00PCE BRL-24682 Investigative T58940 DRUGINFO D04AXY 6-(4-Methyl-piperazin-1-yl)-phenanthridine Investigative T58940 DRUGINFO D06IRE trichloroethanol Investigative T58940 DRUGINFO D0H4NK 1-phenylbiguanide Investigative T58940 DRUGINFO D0I4BZ (S)-zacopride Investigative T58940 DRUGINFO D0L1NS 2-(4-Benzyl-piperazin-1-yl)-benzothiazole Investigative T58940 DRUGINFO D0P2HR [3H]granisetron Investigative T58940 DRUGINFO D0SA4A meta-chlorphenylbiguanide Investigative T58940 DRUGINFO D0TJ6Z 2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole Investigative T58940 DRUGINFO D0B0TK bilobalide Investigative T58940 DRUGINFO D0G2BS 2-(4-Methyl-piperazin-1-yl)-quinoline Investigative T58940 DRUGINFO D0K5NZ MESULERGINE Investigative T58940 DRUGINFO D08BCF QUIPAZINE Investigative T58940 DRUGINFO D00CRA 2-methyl-5-HT Investigative T58940 DRUGINFO D0F6CD SEROTONIN Investigative T32282 TARGETID T32282 T32282 FORMERID TTDR00418 T32282 UNIPROID PRL_HUMAN T32282 TARGNAME Prolactin (PRL) T32282 GENENAME PRL T32282 TARGTYPE Discontinued T32282 SYNONYMS GHA1 T32282 FUNCTION Prolactin acts primarily on the mammary gland by promoting lactation. T32282 PDBSTRUC 3NPZ; 3NCF; 3NCE; 3NCC; 3NCB T32282 BIOCLASS Somatotropin/prolactin T32282 SEQUENCE MNIKGSPWKGSLLLLLVSNLLLCQSVAPLPICPGGAARCQVTLRDLFDRAVVLSHYIHNLSSEMFSEFDKRYTHGRGFITKAINSCHTSSLATPEDKEQAQQMNQKDFLSLIVSILRSWNEPLYHLVTEVRGMQEAPEAILSKAVEIEEQTKRLLEGMELIVSQVHPETKENEIYPVWSGLPSLQMADEESRLSAYYNLLHCLRRDSHKIDNYLKLLKCRIIHNNNC T32282 DRUGINFO D0F2IC NTx-488 Discontinued in Phase 2 T46642 TARGETID T46642 T46642 FORMERID TTDC00062 T46642 UNIPROID AL5AP_HUMAN T46642 TARGNAME Arachidonate 5-lipoxygenase activating protein (FLAP) T46642 GENENAME ALOX5AP T46642 TARGTYPE Discontinued T46642 SYNONYMS MK-886-binding protein; FLAP; ALOX5AP T46642 FUNCTION Required for leukotrienebiosynthesis by ALOX5 (5- lipoxygenase). Anchors ALOX5 to the membrane. Binds arachidonic acid, and could play an essential role in the transfer of arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes. T46642 PDBSTRUC 2Q7R; 2Q7M T46642 SEQUENCE MDQETVGNVVLLAIVTLISVVQNGFFAHKVEHESRTQNGRSFQRTGTLAFERVYTANQNCVDAYPTFLAVLWSAGLLCSQVPAAFAGLMYLFVRQKYFVGYLGERTQSTPGYIFGKRIILFLFLMSVAGIFNYYLIFFFGSDFENYIKTISTTISPLLLIP T46642 DRUGINFO D0S6VB DG031 Discontinued in Phase 3 T46642 DRUGINFO D05MCS GSK2190915 Discontinued in Phase 2 T46642 DRUGINFO D06UYI AM103 Discontinued in Phase 2 T46642 DRUGINFO D07ATG GSK2190914 Discontinued in Phase 2 T46642 DRUGINFO D02RZL AZD4769 Discontinued in Phase 1 T46642 DRUGINFO D0IL8R A-93178 Terminated T46642 DRUGINFO D01YCW L-671,480 Investigative T46642 DRUGINFO D06VWH L-689,037 Investigative T32855 TARGETID T32855 T32855 FORMERID TTDR00478 T32855 UNIPROID NTF3_HUMAN T32855 TARGNAME Neurotrophin-3 (NTF3) T32855 GENENAME NTF3 T32855 TARGTYPE Discontinued T32855 SYNONYMS Neurotrophic factor; Nerve growth factor 2; NT-3; NGF-2; HDNF T32855 FUNCTION Seems to promote the survival of visceral and proprioceptive sensory neurons. T32855 PDBSTRUC 3BUK; 1NT3; 1BND; 1B8K T32855 BIOCLASS Growth factor T32855 SEQUENCE MSILFYVIFLAYLRGIQGNNMDQRSLPEDSLNSLIIKLIQADILKNKLSKQMVDVKENYQSTLPKAEAPREPERGGPAKSAFQPVIAMDTELLRQQRRYNSPRVLLSDSTPLEPPPLYLMEDYVGSPVVANRTSRRKRYAEHKSHRGEYSVCDSESLWVTDKSSAIDIRGHQVTVLGEIKTGNSPVKQYFYETRCKEARPVKNGCRGIDDKHWNSQCKTSQTYVRALTSENNKLVGWRWIRIDTSCVCALSRKIGRT T32855 DRUGINFO D00YUB NT-3 Discontinued in Phase 2 T32855 DRUGINFO D0P3SH ReN-1826 Terminated T56625 TARGETID T56625 T56625 FORMERID TTDR01033 T56625 UNIPROID TPP2_HUMAN T56625 TARGNAME Tripeptidyl-peptidase II (TPP2) T56625 GENENAME TPP2 T56625 TARGTYPE Discontinued T56625 SYNONYMS Tripeptidyl aminopeptidase; TPP2; TPP-II; TPP II; CCK-inactivating peptidase tripeptidyl peptidase T56625 FUNCTION Component of the proteolytic cascade acting downstream of the 26S proteasome in the ubiquitin-proteasome pathway. May be able to complement the 26S proteasome function to some extent under conditions in which the latter is inhibited. Stimulates adipogenesis. T56625 BIOCLASS Peptidase T56625 ECNUMBER EC 3.4.14.10 T56625 SEQUENCE MATAATEEPFPFHGLLPKKETGAASFLCRYPEYDGRGVLIAVLDTGVDPGAPGMQVTTDGKPKIVDIIDTTGSGDVNTATEVEPKDGEIVGLSGRVLKIPASWTNPSGKYHIGIKNGYDFYPKALKERIQKERKEKIWDPVHRVALAEACRKQEEFDVANNGSSQANKLIKEELQSQVELLNSFEKKYSDPGPVYDCLVWHDGEVWRACIDSNEDGDLSKSTVLRNYKEAQEYGSFGTAEMLNYSVNIYDDGNLLSIVTSGGAHGTHVASIAAGHFPEEPERNGVAPGAQILSIKIGDTRLSTMETGTGLIRAMIEVINHKCDLVNYSYGEATHWPNSGRICEVINEAVWKHNIIYVSSAGNNGPCLSTVGCPGGTTSSVIGVGAYVSPDMMVAEYSLREKLPANQYTWSSRGPSADGALGVSISAPGGAIASVPNWTLRGTQLMNGTSMSSPNACGGIALILSGLKANNIDYTVHSVRRALENTAVKADNIEVFAQGHGIIQVDKAYDYLVQNTSFANKLGFTVTVGNNRGIYLRDPVQVAAPSDHGVGIEPVFPENTENSEKISLQLHLALTSNSSWVQCPSHLELMNQCRHINIRVDPRGLREGLHYTEVCGYDIASPNAGPLFRVPITAVIAAKVNESSHYDLAFTDVHFKPGQIRRHFIEVPEGATWAEVTVCSCSSEVSAKFVLHAVQLVKQRAYRSHEFYKFCSLPEKGTLTEAFPVLGGKAIEFCIARWWASLSDVNIDYTISFHGIVCTAPQLNIHASEGINRFDVQSSLKYEDLAPCITLKNWVQTLRPVSAKTKPLGSRDVLPNNRQLYEMVLTYNFHQPKSGEVTPSCPLLCELLYESEFDSQLWIIFDQNKRQMGSGDAYPHQYSLKLEKGDYTIRLQIRHEQISDLERLKDLPFIVSHRLSNTLSLDIHENHSFALLGKKKSSNLTLPPKYNQPFFVTSLPDDKIPKGAGPGCYLAGSLTLSKTELGKKADVIPVHYYLIPPPTKTKNGSKDKEKDSEKEKDLKEEFTEALRDLKIQWMTKLDSSDIYNELKETYPNYLPLYVARLHQLDAEKERMKRLNEIVDAANAVISHIDQTALAVYIAMKTDPRPDAATIKNDMDKQKSTLVDALCRKGCALADHLLHTQAQDGAISTDAEGKEEEGESPLDSLAETFWETTKWTDLFDNKVLTFAYKHALVNKMYGRGLKFATKLVEEKPTKENWKNCIQLMKLLGWTHCASFTENWLPIMYPPDYCVF T56625 DRUGINFO D0T7CM UCL-2000; butabindide Discontinued in Phase 1 T56625 DRUGINFO D00DDH (2S)-aminobutyryl-L-proline-(2S)-methylbutylamide Investigative T56625 DRUGINFO D00IPP L-valyl-L-prolinamide Investigative T56625 DRUGINFO D00KTE (2S)-aminobutyryl-L-proline n-butylamide Investigative T56625 DRUGINFO D02QDW L-norvalyl-L-prolinamide Investigative T56625 DRUGINFO D03KXQ L-valyl-L-proline benzylamide Investigative T56625 DRUGINFO D07PHW (2S)-aminobutyryl-L-prolinamide Investigative T56625 DRUGINFO D0D5XX peptide 4 Investigative T56625 DRUGINFO D0E4KI example 8 [WO1999033801A1] Investigative T56625 DRUGINFO D0G2NF (2S)-aminobutyryl-(R)-pipecolinic acid amide Investigative T56625 DRUGINFO D0H9VQ L-norleucyl-L-prolinamide Investigative T56625 DRUGINFO D0K2GB (2S)-aminobutyryl-L-proline n-propylamide Investigative T56625 DRUGINFO D0L4DW (2S)-aminobutyryl-L-proline n-pentylamide Investigative T56625 DRUGINFO D0L4NF Alpha-methylalanyl-L-proline butylamide Investigative T56625 DRUGINFO D0M0TS (2S)-aminobutyryl-L-proline (R)-sec-butylamide Investigative T56625 DRUGINFO D0P9II (2S)-aminobutyryl-L-proline isobutylamide Investigative T56625 DRUGINFO D0R3DP L-valyl-L-proline hexylamide Investigative T56625 DRUGINFO D0X6BT L-leucyl-L-prolinamide Investigative T56625 DRUGINFO D0ZW8E L-isoleucyl-L-prolinamide Investigative T02752 TARGETID T02752 T02752 FORMERID TTDC00207 T02752 UNIPROID CCR3_HUMAN T02752 TARGNAME C-C chemokine receptor type 3 (CCR3) T02752 GENENAME CCR3 T02752 TARGTYPE Discontinued T02752 SYNONYMS Eosinophil eotaxin receptor; Chemokine receptor CCR3; CMKBR3; CKR3; CD193; CCR-3; CC-CKR-3; C-C CKR-3 T02752 FUNCTION Binds to eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES and MIP-1 delta. Subsequently transduces a signal by increasing the intracellular calcium ions level. Alternative coreceptor with CD4 for HIV-1 infection. Receptor for a C-C type chemokine. T02752 BIOCLASS GPCR rhodopsin T02752 SEQUENCE MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILIKYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSEIFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEETLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRLIFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVIYAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF T02752 DRUGINFO DFA0W6 AKST4290 Phase 2 T02752 DRUGINFO D0C2IA DPC-168 Discontinued in Phase 1 T02752 DRUGINFO D09UXP AZD-1744 Discontinued in Phase 1 T02752 DRUGINFO D04EIL YM-344031 Preclinical T02752 DRUGINFO D0Y6TI YM-355179 Preclinical T02752 DRUGINFO D0Y4PL QAP-642 Terminated T96736 TARGETID T96736 T96736 FORMERID TTDI02159 T96736 UNIPROID RHOA_HUMAN T96736 TARGNAME Transforming protein RhoA (RHOA) T96736 GENENAME RHOA T96736 TARGTYPE Discontinued T96736 SYNONYMS h12; Rho cDNA clone 12; RHO12; ARHA; ARH12 T96736 FUNCTION Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. Stimulates PKN2 kinase activity. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Regulates KCNA2 potassium channel activity by reducing its location at the cell surface in response to CHRM1 activation; promotes KCNA2 endocytosis. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. T96736 PDBSTRUC 6R3V; 6BCB; 6BCA; 6BC0; 5ZHX T96736 BIOCLASS Small GTPase T96736 ECNUMBER EC 3.6.5.2 T96736 SEQUENCE MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKDLRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQARRGKKKSGCLVL T96736 DRUGINFO D08SUQ ES-285 Discontinued in Phase 1 T39523 TARGETID T39523 T39523 FORMERID TTDI01951 T39523 UNIPROID PDE7A_HUMAN T39523 TARGNAME Phosphodiesterase 7A (PDE7A) T39523 GENENAME PDE7A T39523 TARGTYPE Discontinued T39523 SYNONYMS TM22; High affinity cAMPspecific 3',5'cyclic phosphodiesterase 7A; High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A T39523 FUNCTION May have a role in muscle signal transduction. Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. T39523 PDBSTRUC 4Y2B; 4PM0; 3G3N; 1ZKL T39523 BIOCLASS Phosphoric diester hydrolase T39523 ECNUMBER EC 3.1.4.53 T39523 SEQUENCE MEVCYQLPVLPLDRPVPQHVLSRRGAISFSSSSALFGCPNPRQLSQRRGAISYDSSDQTALYIRMLGDVRVRSRAGFESERRGSHPYIDFRIFHSQSEIEVSVSARNIRRLLSFQRYLRSSRFFRGTAVSNSLNILDDDYNGQAKCMLEKVGNWNFDIFLFDRLTNGNSLVSLTFHLFSLHGLIEYFHLDMMKLRRFLVMIQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLANSVTPWDILLSLIAAATHDLDHPGVNQPFLIKTNHYLATLYKNTSVLENHHWRSAVGLLRESGLFSHLPLESRQQMETQIGALILATDISRQNEYLSLFRSHLDRGDLCLEDTRHRHLVLQMALKCADICNPCRTWELSKQWSEKVTEEFFHQGDIEKKYHLGVSPLCDRHTESIANIQIGFMTYLVEPLFTEWARFSNTRLSQTMLGHVGLNKASWKGLQREQSSSEDTDAAFELNSQLLPQENRLS T39523 DRUGINFO D0PZ4Y PF-3557156 Discontinued in Phase 1 T29754 TARGETID T29754 T29754 FORMERID TTDI02542 T29754 UNIPROID MAPK5_HUMAN T29754 TARGNAME MAPK-activated protein kinase 5 (MAPKAPK5) T29754 GENENAME MAPKAPK5 T29754 TARGTYPE Discontinued T29754 SYNONYMS p38regulated/activated protein kinase; p38-regulated/activated protein kinase; PRAK; MK5; MK-5; MAPKactivated protein kinase 5; MAPKAPK-5; MAPKAP-K5; MAPKAP kinase 5; MAP kinaseactivated protein kinase 5; MAP kinase-activated protein kinase 5 T29754 FUNCTION Phosphorylates FOXO3, ERK3/MAPK6, ERK4/MAPK4, HSP27/HSPB1, p53/TP53 and RHEB. Acts as a tumor suppressor by mediating Ras-induced senescence and phosphorylating p53/TP53. Involved in post-transcriptional regulation of MYC by mediating phosphorylation of FOXO3: phosphorylation of FOXO3 leads to promote nuclear localization of FOXO3, enabling expression of miR-34b and miR-34c, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent MYC translation. Acts as a negative regulator of mTORC1 signaling by mediating phosphorylation and inhibition of RHEB. Part of the atypical MAPK signaling via its interaction with ERK3/MAPK6 or ERK4/MAPK4: the precise role of the complex formed with ERK3/MAPK6 or ERK4/MAPK4 is still unclear, but the complex follows a complex set of phosphorylation events: upon interaction with atypical MAPK (ERK3/MAPK6 or ERK4/MAPK4), ERK3/MAPK6 (or ERK4/MAPK4) is phosphorylated and then mediates phosphorylation and activation of MAPKAPK5, which in turn phosphorylates ERK3/MAPK6 (or ERK4/MAPK4). Mediates phosphorylation of HSP27/HSPB1 in response to PKA/PRKACA stimulation, inducing F-actin rearrangement. Tumor suppressor serine/threonine-protein kinase involved in mTORC1 signaling and post-transcriptional regulation. T29754 BIOCLASS Kinase T29754 ECNUMBER EC 2.7.11.1 T29754 SEQUENCE MSEESDMDKAIKETSILEEYSINWTQKLGAGISGPVRVCVKKSTQERFALKILLDRPKARNEVRLHMMCATHPNIVQIIEVFANSVQFPHESSPRARLLIVMEMMEGGELFHRISQHRHFTEKQASQVTKQIALALRHCHLLNIAHRDLKPENLLFKDNSLDAPVKLCDFGFAKIDQGDLMTPQFTPYYVAPQVLEAQRRHQKEKSGIIPTSPTPYTYNKSCDLWSLGVIIYVMLCGYPPFYSKHHSRTIPKDMRRKIMTGSFEFPEEEWSQISEMAKDVVRKLLKVKPEERLTIEGVLDHPWLNSTEALDNVLPSAQLMMDKAVVAGIQQAHAEQLANMRIQDLKVSLKPLHSVNNPILRKRKLLGTKPKDSVYIHDHENGAEDSNVALEKLRDVIAQCILPQAGKGENEDEKLNEVMQEAWKYNRECKLLRDTLQSFSWNGRGFTDKVDRLKLAEIVKQVIEEQTTSHESQ T29754 DRUGINFO D06NPB GLPG-0259 Discontinued in Phase 2 T29754 DRUGINFO D0EW9J PMID17480064C16 Investigative T39123 TARGETID T39123 T39123 FORMERID TTDC00231 T39123 UNIPROID KISSR_HUMAN T39123 TARGNAME G-protein coupled receptor 54 (KISS1R) T39123 GENENAME KISS1R T39123 TARGTYPE Discontinued T39123 SYNONYMS KiSS-1 receptor GPR54; KISS1R; GPR54 T39123 FUNCTION Receptor for metastin(kisspeptin-54 or kp-54), a C- terminally amidated peptide of KiSS1. KiSS1 is a metastasis suppressor protein that suppresses metastases in malignant melanomas and in some breast carcinomas without affecting tumorigenicity. The metastasis suppressor properties may be mediated in part by cell cycle arrest and induction of apoptosis in malignant cells. The receptor is essential for normal gonadotropin-released hormone physiology and for puberty. The hypothalamic KiSS1/KISS1R system is a pivotal factor in central regulation of the gonadotropic axis at puberty and in adulthood. The receptor is also probably involved in the regulation and fine- tuning of trophoblast invasion generated by the trophoblast itself. Analysis of the transduction pathways activated by the receptor identifies couplingto phospholipase C and intracellular calcium release through pertussis toxin-insensitive G(q) proteins. T39123 BIOCLASS GPCR rhodopsin T39123 SEQUENCE MHTVATSGPNASWGAPANASGCPGCGANASDGPVPSPRAVDAWLVPLFFAALMLLGLVGNSLVIYVICRHKPMRTVTNFYIANLAATDVTFLLCCVPFTALLYPLPGWVLGDFMCKFVNYIQQVSVQATCATLTAMSVDRWYVTVFPLRALHRRTPRLALAVSLSIWVGSAAVSAPVLALHRLSPGPRAYCSEAFPSRALERAFALYNLLALYLLPLLATCACYAAMLRHLGRVAVRPAPADSALQGQVLAERAGAVRAKVSRLVAAVVLLFAACWGPIQLFLVLQALGPAGSWHPRSYAAYALKTWAHCMSYSNSALNPLLYAFLGSHFRQAFRRVCPCAPRRPRRPRRPGPSDPAAPHAELLRLGSHPAPARAQKPGSSGLAARGLCVLGEDNAPL T39123 DRUGINFO D0P9KL TAK-683 Discontinued in Phase 1 T39123 DRUGINFO D01VSI kisspeptin-10 Investigative T39123 DRUGINFO D0JE3Z 4-fluorobenzoyl-Phe-Gly-Leu-Arg-Trp-NH2 Investigative T20578 TARGETID T20578 T20578 FORMERID TTDI01952 T20578 UNIPROID PDE7B_HUMAN T20578 TARGNAME Phosphodiesterase 7B (PDE7B) T20578 GENENAME PDE7B T20578 TARGTYPE Discontinued T20578 SYNONYMS cAMPspecific 3',5'cyclic phosphodiesterase 7B; cAMP-specific 3',5'-cyclic phosphodiesterase 7B T20578 FUNCTION May be involved in the control of cAMP-mediated neural activity and cAMP metabolism in the brain. Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. T20578 PDBSTRUC 1LXW T20578 BIOCLASS Phosphoric diester hydrolase T20578 ECNUMBER EC 3.1.4.53 T20578 SEQUENCE MSCLMVERCGEILFENPDQNAKCVCMLGDIRLRGQTGVRAERRGSYPFIDFRLLNSTTYSGEIGTKKKVKRLLSFQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLLCHLFNTHGLIHHFKLDMVTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPLDIMLGLLAAAAHDVDHPGVNQPFLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRLKAHLHNKDLRLEDAQDRHFMLQIALKCADICNPCRIWEMSKQWSERVCEEFYRQGELEQKFELEISPLCNQQKDSIPSIQIGFMSYIVEPLFREWAHFTGNSTLSENMLGHLAHNKAQWKSLLPRQHRSRGSSGSGPDHDHAGQGTESEEQEGDSP T20578 DRUGINFO D0PZ4Y PF-3557156 Discontinued in Phase 1 T20578 DRUGINFO D00MBG BRL50481 Investigative T20578 DRUGINFO D02VHD SCH51866 Investigative T58716 TARGETID T58716 T58716 FORMERID TTDC00057 T58716 UNIPROID NSMA3_HUMAN T58716 TARGNAME Sphingomyelin phosphodiesterase 4 (SMPD4) T58716 GENENAME SMPD4 T58716 TARGTYPE Discontinued T58716 SYNONYMS nSMase3; nSMase-3; SKNY; Neutral sphingomyelinase III; Neutral sphingomyelinase 3; KIAA1418 T58716 FUNCTION Catalyzes the hydrolysis of membrane sphingomyelin to form phosphorylcholine and ceramide. May sensitize cells to DNA damage-induced apoptosis. T58716 BIOCLASS Phosphoric diester hydrolase T58716 ECNUMBER EC 3.1.4.12 T58716 SEQUENCE MTTFGAVAEWRLPSLRRATLWIPQWFAKKAIFNSPLEAAMAFPHLQQPSFLLASLKADSINKPFAQQCQDLVKVIEDFPAKELHTIFPWLVESIFGSLDGVLVGWNLRCLQGRVNPVEYSIVMEFLDPGGPMMKLVYKLQAEDYKFDFPVSYLPGPVKASIQECILPDSPLYHNKVQFTPTGGLGLNLALNPFEYYIFFFALSLITQKPLPVSLHVRTSDCAYFILVDRYLSWFLPTEGSVPPPLSSSPGGTSPSPPPRTPAIPFASYGLHHTSLLKRHISHQTSVNADPASHEIWRSETLLQVFVEMWLHHYSLEMYQKMQSPHAKLEVLHYRLSVSSALYSPAQPSLQALHAYQESFTPTEEHVLVVRLLLKHLHAFANSLKPEQASPSAHSHATSPLEEFKRAAVPRFVQQKLYLFLQHCFGHWPLDASFRAVLEMWLSYLQPWRYAPDKQAPGSDSQPRCVSEKWAPFVQENLLMYTKLFVGFLNRALRTDLVSPKHALMVFRVAKVFAQPNLAEMIQKGEQLFLEPELVIPHRQHRLFTAPTFTGSFLSPWPPAVTDASFKVKSHVYSLEGQDCKYTPMFGPEARTLVLRLAQLITQAKHTAKSISDQCAESPAGHSFLSWLGFSSMDTNGSYTANDLDEMGQDSVRKTDEYLEKALEYLRQIFRLSEAQLRQFTLALGTTQDENGKKQLPDCIVGEDGLILTPLGRYQIINGLRRFEIEYQGDPELQPIRSYEIASLVRTLFRLSSAINHRFAGQMAALCSRDDFLGSFCRYHLTEPGLASRHLLSPVGRRQVAGHTRGPRLSLRFLGSYRTLVSLLLAFFVASLFCVGPLPCTLLLTLGYVLYASAMTLLTERGKLHQP T58716 DRUGINFO D00ACC ND1251 Discontinued in Phase 1 T89747 TARGETID T89747 T89747 FORMERID TTDI02385 T89747 UNIPROID ABL1_HUMAN T89747 TARGNAME ABL messenger RNA (ABL mRNA) T89747 GENENAME ABL1 T89747 TARGTYPE Discontinued T89747 SYNONYMS p150 (mRNA); Proto-oncogene tyrosine-protein kinase ABL1 (mRNA); Proto-oncogene c-Abl (mRNA); JTK7 (mRNA); C-ABL (mRNA); Abl (mRNA); Abelson tyrosine-protein kinase 1 (mRNA); Abelson murine leukemia viral oncogene homolog 1 (mRNA) T89747 FUNCTION Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717'. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E. coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H. pylori, or AnkA (ankyrin repeat-containing protein A) of A. phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner. Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity. Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. T89747 PDBSTRUC 6NPV; 6NPU; 6NPE; 6BL8; 6AMW T89747 BIOCLASS mRNA target T89747 ECNUMBER EC 2.7.10.2 T89747 SEQUENCE MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR T89747 DRUGINFO D05RUJ G-1128 Discontinued in Phase 2 T89747 DRUGINFO D0Q8BK GNF-5 Investigative T89747 DRUGINFO D0JR3W PMID23441572C24 Investigative T89747 DRUGINFO D02BXJ PMID21561767C8h Investigative T89747 DRUGINFO D03EHM PP121 Investigative T89747 DRUGINFO D0E7VO PMID24900538C2c Investigative T40045 TARGETID T40045 T40045 FORMERID TTDI02344 T40045 UNIPROID RIR1_HUMAN T40045 TARGNAME RRM1 messenger RNA (RRM1 mRNA) T40045 GENENAME RRM1 T40045 TARGTYPE Discontinued T40045 SYNONYMS Ribonucleotide reductase large subunit (mRNA); Ribonucleoside-diphosphate reductase subunit M1 (mRNA); Ribonucleoside-diphosphate reductase large subunit (mRNA); RR1 (mRNA) T40045 FUNCTION Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Provides the precursors necessary for DNA synthesis. T40045 PDBSTRUC 6AUI; 5TUS; 5D1Y; 4X3V; 3HNF T40045 BIOCLASS mRNA target T40045 ECNUMBER EC 1.17.4.1 T40045 SEQUENCE MHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSGVTTVELDTLAAETAATLTTKHPDYAILAARIAVSNLHKETKKVFSDVMEDLYNYINPHNGKHSPMVAKSTLDIVLANKDRLNSAIIYDRDFSYNYFGFKTLERSYLLKINGKVAERPQHMLMRVSVGIHKEDIDAAIETYNLLSERWFTHASPTLFNAGTNRPQLSSCFLLSMKDDSIEGIYDTLKQCALISKSAGGIGVAVSCIRATGSYIAGTNGNSNGLVPMLRVYNNTARYVDQGGNKRPGAFAIYLEPWHLDIFEFLDLKKNTGKEEQRARDLFFALWIPDLFMKRVETNQDWSLMCPNECPGLDEVWGEEFEKLYASYEKQGRVRKVVKAQQLWYAIIESQTETGTPYMLYKDSCNRKSNQQNLGTIKCSNLCTEIVEYTSKDEVAVCNLASLALNMYVTSEHTYDFKKLAEVTKVVVRNLNKIIDINYYPVPEACLSNKRHRPIGIGVQGLADAFILMRYPFESAEAQLLNKQIFETIYYGALEASCDLAKEQGPYETYEGSPVSKGILQYDMWNVTPTDLWDWKVLKEKIAKYGIRNSLLIAPMPTASTAQILGNNESIEPYTSNIYTRRVLSGEFQIVNPHLLKDLTERGLWHEEMKNQIIACNGSIQSIPEIPDDLKQLYKTVWEISQKTVLKMAAERGAFIDQSQSLNIHIAEPNYGKLTSMHFYGWKQGLKTGMYYLRTRPAANPIQFTLNKEKLKDKEKVSKEEEEKERNTAAMVCSLENRDECLMCGS T40045 DRUGINFO D0K4OL LOR-2501 Discontinued in Phase 1 T14825 TARGETID T14825 T14825 FORMERID TTDC00288 T14825 UNIPROID VGFR2_HUMAN T14825 TARGNAME VEGFR2 messenger RNA (VEGFR2 mRNA) T14825 GENENAME KDR T14825 TARGTYPE Discontinued T14825 SYNONYMS VEGFR2 (mRNA); VEGFR-2 (mRNA); VEGF-2 receptor (mRNA); Protein-tyrosine kinase receptor flk-1 (mRNA); Kinase insert domain receptor (mRNA); Fetal liver kinase 1 (mRNA); FLK1 (mRNA); FLK-1 (mRNA); CD309 (mRNA) T14825 FUNCTION Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. T14825 PDBSTRUC 6GQQ; 6GQP; 6GQO; 5OYJ; 5EW3 T14825 BIOCLASS mRNA target T14825 ECNUMBER EC 2.7.10.1 T14825 SEQUENCE MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWLLLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPLGRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVNLLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLKRRLDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLASRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTMLDCWHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVSCMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDSGMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYSSEEAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV T14825 DRUGINFO D08NYL AGN211745 Discontinued in Phase 2 T62763 TARGETID T62763 T62763 FORMERID TTDI02323 T62763 UNIPROID FGF10_HUMAN T62763 TARGNAME Fibroblast growth factor-10 (FGF10) T62763 GENENAME FGF10 T62763 TARGTYPE Discontinued T62763 SYNONYMS Fibroblast growth factor 10; FGF10 T62763 FUNCTION Plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. Required for normal branching morphogenesis. May play a role in wound healing. T62763 PDBSTRUC 1NUN T62763 BIOCLASS Growth factor T62763 SEQUENCE MWKWILTHCASAFPHLPGCCCCCFLLLFLVSSVPVTCQALGQDMVSPEATNSSSSSFSSPSSAGRHVRSYNHLQGDVRWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSILEITSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVALNGKGAPRRGQKTRRKNTSAHFLPMVVHS T62763 DRUGINFO D0P4RA Repifermin Discontinued in Phase 2 T92424 TARGETID T92424 T92424 FORMERID TTDI01781 T92424 UNIPROID ITAV_HUMAN-ITB5_HUMAN T92424 TARGNAME Integrin alpha-V/beta-5 (ITGAV/B5) T92424 GENENAME ITGAV-ITGB5 T92424 TARGTYPE Discontinued T92424 SYNONYMS Integrin; Vitronectin receptor T92424 FUNCTION Binds to matrix macromolecules and proteinases and thereby stimulates angiogenesis. However, it inhibits angiogenesis. T92424 BIOCLASS Integrin T92424 SEQUENCE MPRAPAPLYACLLGLCALLPRLAGLNICTSGSATSCEECLLIHPKCAWCSKEDFGSPRSITSRCDLRANLVKNGCGGEIESPASSFHVLRSLPLSSKGSGSAGWDVIQMTPQEIAVNLRPGDKTTFQLQVRQVEDYPVDLYYLMDLSLSMKDDLDNIRSLGTKLAEEMRKLTSNFRLGFGSFVDKDISPFSYTAPRYQTNPCIGYKLFPNCVPSFGFRHLLPLTDRVDSFNEEVRKQRVSRNRDAPEGGFDAVLQAAVCKEKIGWRKDALHLLVFTTDDVPHIALDGKLGGLVQPHDGQCHLNEANEYTASNQMDYPSLALLGEKLAENNINLIFAVTKNHYMLYKNFTALIPGTTVEILDGDSKNIIQLIINAYNSIRSKVELSVWDQPEDLNLFFTATCQDGVSYPGQRKCEGLKIGDTASFEVSLEARSCPSRHTEHVFALRPVGFRDSLEVGVTYNCTCGCSVGLEPNSARCNGSGTYVCGLCECSPGYLGTRCECQDGENQSVYQNLCREAEGKPLCSGRGDCSCNQCSCFESEFGKIYGPFCECDNFSCARNKGVLCSGHGECHCGECKCHAGYIGDNCNCSTDISTCRGRDGQICSERGHCLCGQCQCTEPGAFGEMCEKCPTCPDACSTKRDCVECLLLHSGKPDNQTCHSLCRDEVITWVDTIVKDDQEAVLCFYKTAKDCVMMFTYVELPSGKSNLTVLREPECGNTPNAMTILLAVVGSILLVGLALLAIWKLLVTIHDRREFAKFQSERSRARYEMASNPLYRKPISTHTVDFTFNKFNKSYNGTVDMAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET T92424 DRUGINFO D02VIP SB-267268 Discontinued in Phase 1 T92424 DRUGINFO D04YEY PS-388023 Terminated T08583 TARGETID T08583 T08583 FORMERID TTDR00395 T08583 UNIPROID TRBM_HUMAN T08583 TARGNAME Thrombomodulin (THBD) T08583 GENENAME THBD T08583 TARGTYPE Discontinued T08583 SYNONYMS TM; THRM; Fetomodulin; CD141 antigen; CD141 T08583 FUNCTION Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated. T08583 PDBSTRUC 5TO3; 3GIS; 2ADX; 1ZAQ; 1TMR T08583 BIOCLASS Growth factor T08583 SEQUENCE MLGVLVLGALALAGLGFPAPAEPQPGGSQCVEHDCFALYPGPATFLNASQICDGLRGHLMTVRSSVAADVISLLLNGDGGVGRRRLWIGLQLPPGCGDPKRLGPLRGFQWVTGDNNTSYSRWARLDLNGAPLCGPLCVAVSAAEATVPSEPIWEEQQCEVKADGFLCEFHFPATCRPLAVEPGAAAAAVSITYGTPFAARGADFQALPVGSSAAVAPLGLQLMCTAPPGAVQGHWAREAPGAWDCSVENGGCEHACNAIPGAPRCQCPAGAALQADGRSCTASATQSCNDLCEHFCVPNPDQPGSYSCMCETGYRLAADQHRCEDVDDCILEPSPCPQRCVNTQGGFECHCYPNYDLVDGECVEPVDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECICGPDSALARHIGTDCDSGKVDGGDSGSGEPPPSPTPGSTLTPPAVGLVHSGLLIGISIASLCLVVALLALLCHLRKKQGAARAKMEYKCAAPSKEVVLQHVRTERTPQRL T08583 DRUGINFO D0Y4EM Thrombomodulin Discontinued in Phase 3 T26463 TARGETID T26463 T26463 UNIPROID DPOLA_HUMAN T26463 TARGNAME DNA polymerase alpha catalytic p180 (POLA1) T26463 GENENAME POLA1 T26463 TARGTYPE Discontinued T26463 SYNONYMS POLA; DNA polymerase alpha catalytic subunit p180; DNA polymerase alpha catalytic subunit T26463 FUNCTION During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1/p180, a regulatory subunit POLA2/p70 and two primase subunits PRIM1/p49 and PRIM2/p58) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands. These primers are initially extended by the polymerase alpha catalytic subunit and subsequently transferred to polymerase delta and polymerase epsilon for processive synthesis on the lagging and leading strand, respectively. The reason this transfer occurs is because the polymerase alpha has limited processivity and lacks intrinsic 3' exonuclease activity for proofreading error, and therefore is not well suited for replicating long complexes. In the cytosol, responsible for a substantial proportion of the physiological concentration of cytosolic RNA:DNA hybrids, which are necessary to prevent spontaneous activation of type I interferon responses. Plays an essential role in the initiation of DNA replication. T26463 PDBSTRUC 6AS7; 5IUD; 5EXR; 4Y97; 4QCL T26463 BIOCLASS Kinase T26463 ECNUMBER EC 2.7.7.7 T26463 SEQUENCE MAPVHGDDSLSDSGSFVSSRARREKKSKKGRQEALERLKKAKAGEKYKYEVEDFTGVYEEVDEEQYSKLVQARQDDDWIVDDDGIGYVEDGREIFDDDLEDDALDADEKGKDGKARNKDKRNVKKLAVTKPNNIKSMFIACAGKKTADKAVDLSKDGLLGDILQDLNTETPQITPPPVMILKKKRSIGASPNPFSVHTATAVPSGKIASPVSRKEPPLTPVPLKRAEFAGDDVQVESTEEEQESGAMEFEDGDFDEPMEVEEVDLEPMAAKAWDKESEPAEEVKQEADSGKGTVSYLGSFLPDVSCWDIDQEGDSSFSVQEVQVDSSHLPLVKGADEEQVFHFYWLDAYEDQYNQPGVVFLFGKVWIESAETHVSCCVMVKNIERTLYFLPREMKIDLNTGKETGTPISMKDVYEEFDEKIATKYKIMKFKSKPVEKNYAFEIPDVPEKSEYLEVKYSAEMPQLPQDLKGETFSHVFGTNTSSLELFLMNRKIKGPCWLEVKSPQLLNQPVSWCKVEAMALKPDLVNVIKDVSPPPLVVMAFSMKTMQNAKNHQNEIIAMAALVHHSFALDKAAPKPPFQSHFCVVSKPKDCIFPYAFKEVIEKKNVKVEVAATERTLLGFFLAKVHKIDPDIIVGHNIYGFELEVLLQRINVCKAPHWSKIGRLKRSNMPKLGGRSGFGERNATCGRMICDVEISAKELIRCKSYHLSELVQQILKTERVVIPMENIQNMYSESSQLLYLLEHTWKDAKFILQIMCELNVLPLALQITNIAGNIMSRTLMGGRSERNEFLLLHAFYENNYIVPDKQIFRKPQQKLGDEDEEIDGDTNKYKKGRKKAAYAGGLVLDPKVGFYDKFILLLDFNSLYPSIIQEFNICFTTVQRVASEAQKVTEDGEQEQIPELPDPSLEMGILPREIRKLVERRKQVKQLMKQQDLNPDLILQYDIRQKALKLTANSMYGCLGFSYSRFYAKPLAALVTYKGREILMHTKEMVQKMNLEVIYGDTDSIMINTNSTNLEEVFKLGNKVKSEVNKLYKLLEIDIDGVFKSLLLLKKKKYAALVVEPTSDGNYVTKQELKGLDIVRRDWCDLAKDTGNFVIGQILSDQSRDTIVENIQKRLIEIGENVLNGSVPVSQFEINKALTKDPQDYPDKKSLPHVHVALWINSQGGRKVKAGDTVSYVICQDGSNLTASQRAYAPEQLQKQDNLTIDTQYYLAQQIHPVVARICEPIDGIDAVLIATWLGLDPTQFRVHHYHKDEENDALLGGPAQLTDEEKYRDCERFKCPCPTCGTENIYDNVFDGSGTDMEPSLYRCSNIDCKASPLTFTVQLSNKLIMDIRRFIKKYYDGWLICEEPTCRNRTRHLPLQFSRTGPLCPACMKATLQPEYSDKSLYTQLCFYRYIFDAECALEKLTTDHEKDKLKKQFFTPKVLQDYRKLKNTAEQFLSRSGYSEVNLSKLFAGCAVKS T26463 DRUGINFO D02PIH HO-221 Discontinued in Phase 1 T77473 TARGETID T77473 T77473 FORMERID TTDI02369 T77473 UNIPROID TCTP_HUMAN T77473 TARGNAME Translationally-controlled tumor protein (TPT1) T77473 GENENAME TPT1 T77473 TARGTYPE Discontinued T77473 SYNONYMS p23; TPT1; TCTP; Histamine-releasing factor; HRF; Fortilin T77473 FUNCTION Involved in calcium binding and microtubule stabilization. T77473 PDBSTRUC 5O9M; 5O9L; 4Z9V; 3EBM; 2HR9 T77473 SEQUENCE MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPYMIFFKDGLEMEKC T77473 DRUGINFO D01CEQ CER-227185 Discontinued in Phase 1/2 T92328 TARGETID T92328 T92328 FORMERID TTDS00165 T92328 UNIPROID RYR1_HUMAN T92328 TARGNAME Ryanodine receptor 1 (RYR1) T92328 GENENAME RYR1 T92328 TARGTYPE Discontinued T92328 SYNONYMS Type 1 ryanodine receptor; Skeletal muscle-type ryanodine receptor; Skeletal muscle ryanodine receptor; Skeletal muscle calcium release channel; RyR1; RyR; RYR-1; RYDR; Cardiac muscleryanodine receptor-calcium release channel; Cardiac muscle-type ryanodine receptor; Brain-type ryanodine receptor; Brain ryanodine receptor-calcium release channel T92328 FUNCTION Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. Can also mediate the release of Ca(2+) from intracellular stores in neurons, and may thereby promote prolonged Ca(2+) signaling in the brain. Required for normal embryonic development of muscle fibers and skeletal muscle. Required for normal heart morphogenesis, skin development and ossification during embryogenesis. Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. T92328 BIOCLASS Ryanodine-inositol 1,4,5-triphosphate receptor calcium channel T92328 SEQUENCE MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS T92328 DRUGINFO D0T2LP ARM036 Discontinued in Phase 2 T92328 DRUGINFO D0C3HS CDP-1050 Discontinued in Phase 1 T92328 DRUGINFO D01MHP Benzyloxycarbonyl-glycylryanodine Investigative T92328 DRUGINFO D02DZN Ruthenium red Investigative T92328 DRUGINFO D04QNI (O10eq)-beta-alanyl-anhydro-ryanodine Investigative T92328 DRUGINFO D05QKM GLYCYLRYANODINE Investigative T92328 DRUGINFO D05VJH N-methyl ryanodine-succinamidate Investigative T92328 DRUGINFO D08LUJ Ryanodine Investigative T92328 DRUGINFO D0G2RB Di-Benzyloxycarbonyl-guanidino acetylryanodine Investigative T92328 DRUGINFO D0GM8V (O10eq)-beta-guanidinopropionylryanodine Investigative T92328 DRUGINFO D0J6WG (O10eq)-guanidino acetylryanodine Investigative T92328 DRUGINFO D0S6KD (O10eq)-beta-alanylryanodine Investigative T92328 DRUGINFO D0U3DW ANHYDRORYANIDINE Investigative T92328 DRUGINFO D0WT2Z (O10eq)-Benzyloxycarbonyl-beta-alanylryanodine Investigative T45074 TARGETID T45074 T45074 FORMERID TTDI01936 T45074 UNIPROID CACP_HUMAN T45074 TARGNAME Carnitine acyltransferase (CRAT) T45074 GENENAME CRAT T45074 TARGTYPE Discontinued T45074 SYNONYMS Carnitine acetylase; Carnitine O-acetyltransferase; CRAT T45074 FUNCTION Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion. Plays an important role in triglyceride metabolism. T45074 PDBSTRUC 1S5O; 1NM8 T45074 BIOCLASS Acyltransferase T45074 ECNUMBER EC 2.3.1.7 T45074 SEQUENCE MLAFAARTVVKPLGFLKPFSLMKASSRFKAHQDALPRLPVPPLQQSLDHYLKALQPIVSEEEWAHTKQLVDEFQASGGVGERLQKGLERRARKTENWLSEWWLKTAYLQYRQPVVIYSSPGVMLPKQDFVDLQGQLRFAAKLIEGVLDFKVMIDNETLPVEYLGGKPLCMNQYYQILSSCRVPGPKQDTVSNFSKTKKPPTHITVVHNYQFFELDVYHSDGTPLTADQIFVQLEKIWNSSLQTNKEPVGILTSNHRNSWAKAYNTLIKDKVNRDSVRSIQKSIFTVCLDATMPRVSEDVYRSHVAGQMLHGGGSRLNSGNRWFDKTLQFIVAEDGSCGLVYEHAAAEGPPIVTLLDYVIEYTKKPELVRSPLVPLPMPKKLRFNITPEIKSDIEKAKQNLSIMIQDLDITVMVFHHFGKDFPKSEKLSPDAFIQMALQLAYYRIYGQACATYESASLRMFHLGRTDTIRSASMDSLTFVKAMDDSSVTEHQKVELLRKAVQAHRGYTDRAIRGEAFDRHLLGLKLQAIEDLVSMPDIFMDTSYAIAMHFHLSTSQVPAKTDCVMFFGPVVPDGYGVCYNPMEAHINFSLSAYNSCAETNAARLAHYLEKALLDMRALLQSHPRAKL T45074 DRUGINFO D01FCK Teglicar Discontinued in Phase 2 T45074 DRUGINFO D0LR2Q LXR-015-2 Terminated T45074 DRUGINFO D0W3NA Coenzyme A Investigative T73075 TARGETID T73075 T73075 FORMERID TTDI01967 T73075 UNIPROID PGBM_HUMAN T73075 TARGNAME Perlecan (HSPG) T73075 GENENAME HSPG2 T73075 TARGTYPE Discontinued T73075 SYNONYMS LG3 peptide; Basement membranespecific heparan sulfate proteoglycan coreprotein; Basement membrane-specific heparan sulfate proteoglycan core protein T73075 FUNCTION Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development. Integral component of basement membranes. T73075 PDBSTRUC 3SH5; 3SH4 T73075 SEQUENCE MGWRAAGALLLALLLHGRLLAVTHGLRAYDGLSLPEDIETVTASQMRWTHSYLSDDEDMLADSISGDDLGSGDLGSGDFQMVYFRALVNFTRSIEYSPQLEDAGSREFREVSEAVVDTLESEYLKIPGDQVVSVVFIKELDGWVFVELDVGSEGNADGAQIQEMLLRVISSGSVASYVTSPQGFQFRRLGTVPQFPRACTEAEFACHSYNECVALEYRCDRRPDCRDMSDELNCEEPVLGISPTFSLLVETTSLPPRPETTIMRQPPVTHAPQPLLPGSVRPLPCGPQEAACRNGHCIPRDYLCDGQEDCEDGSDELDCGPPPPCEPNEFPCGNGHCALKLWRCDGDFDCEDRTDEANCPTKRPEEVCGPTQFRCVSTNMCIPASFHCDEESDCPDRSDEFGCMPPQVVTPPRESIQASRGQTVTFTCVAIGVPTPIINWRLNWGHIPSHPRVTVTSEGGRGTLIIRDVKESDQGAYTCEAMNARGMVFGIPDGVLELVPQRGPCPDGHFYLEHSAACLPCFCFGITSVCQSTRRFRDQIRLRFDQPDDFKGVNVTMPAQPGTPPLSSTQLQIDPSLHEFQLVDLSRRFLVHDSFWALPEQFLGNKVDSYGGSLRYNVRYELARGMLEPVQRPDVVLMGAGYRLLSRGHTPTQPGALNQRQVQFSEEHWVHESGRPVQRAELLQVLQSLEAVLIQTVYNTKMASVGLSDIAMDTTVTHATSHGRAHSVEECRCPIGYSGLSCESCDAHFTRVPGGPYLGTCSGCNCNGHASSCDPVYGHCLNCQHNTEGPQCNKCKAGFFGDAMKATATSCRPCPCPYIDASRRFSDTCFLDTDGQATCDACAPGYTGRRCESCAPGYEGNPIQPGGKCRPVNQEIVRCDERGSMGTSGEACRCKNNVVGRLCNECADGSFHLSTRNPDGCLKCFCMGVSRHCTSSSWSRAQLHGASEEPGHFSLTNAASTHTTNEGIFSPTPGELGFSSFHRLLSGPYFWSLPSRFLGDKVTSYGGELRFTVTQRSQPGSTPLHGQPLVVLQGNNIILEHHVAQEPSPGQPSTFIVPFREQAWQRPDGQPATREHLLMALAGIDTLLIRASYAQQPAESRVSGISMDVAVPEETGQDPALEVEQCSCPPGYRGPSCQDCDTGYTRTPSGLYLGTCERCSCHGHSEACEPETGACQGCQHHTEGPRCEQCQPGYYGDAQRGTPQDCQLCPCYGDPAAGQAAHTCFLDTDGHPTCDACSPGHSGRHCERCAPGYYGNPSQGQPCQRDSQVPGPIGCNCDPQGSVSSQCDAAGQCQCKAQVEGLTCSHCRPHHFHLSASNPDGCLPCFCMGITQQCASSAYTRHLISTHFAPGDFQGFALVNPQRNSRLTGEFTVEPVPEGAQLSFGNFAQLGHESFYWQLPETYQGDKVAAYGGKLRYTLSYTAGPQGSPLSDPDVQITGNNIMLVASQPALQGPERRSYEIMFREEFWRRPDGQPATREHLLMALADLDELLIRATFSSVPLAASISAVSLEVAQPGPSNRPRALEVEECRCPPGYIGLSCQDCAPGYTRTGSGLYLGHCELCECNGHSDLCHPETGACSQCQHNAAGEFCELCAPGYYGDATAGTPEDCQPCACPLTNPENMFSRTCESLGAGGYRCTACEPGYTGQYCEQCGPGYVGNPSVQGGQCLPETNQAPLVVEVHPARSIVPQGGSHSLRCQVSGSPPHYFYWSREDGRPVPSGTQQRHQGSELHFPSVQPSDAGVYICTCRNLHQSNTSRAELLVTEAPSKPITVTVEEQRSQSVRPGADVTFICTAKSKSPAYTLVWTRLHNGKLPTRAMDFNGILTIRNVQLSDAGTYVCTGSNMFAMDQGTATLHVQASGTLSAPVVSIHPPQLTVQPGQLAEFRCSATGSPTPTLEWTGGPGGQLPAKAQIHGGILRLPAVEPTDQAQYLCRAHSSAGQQVARAVLHVHGGGGPRVQVSPERTQVHAGRTVRLYCRAAGVPSATITWRKEGGSLPPQARSERTDIATLLIPAITTADAGFYLCVATSPAGTAQARIQVVVLSASDASPPPVKIESSSPSVTEGQTLDLNCVVAGSAHAQVTWYRRGGSLPPHTQVHGSRLRLPQVSPADSGEYVCRVENGSGPKEASITVSVLHGTHSGPSYTPVPGSTRPIRIEPSSSHVAEGQTLDLNCVVPGQAHAQVTWHKRGGSLPARHQTHGSLLRLHQVTPADSGEYVCHVVGTSGPLEASVLVTIEASVIPGPIPPVRIESSSSTVAEGQTLDLSCVVAGQAHAQVTWYKRGGSLPARHQVRGSRLYIFQASPADAGQYVCRASNGMEASITVTVTGTQGANLAYPAGSTQPIRIEPSSSQVAEGQTLDLNCVVPGQSHAQVTWHKRGGSLPVRHQTHGSLLRLYQASPADSGEYVCRVLGSSVPLEASVLVTIEPAGSVPALGVTPTVRIESSSSQVAEGQTLDLNCLVAGQAHAQVTWHKRGGSLPARHQVHGSRLRLLQVTPADSGEYVCRVVGSSGTQEASVLVTIQQRLSGSHSQGVAYPVRIESSSASLANGHTLDLNCLVASQAPHTITWYKRGGSLPSRHQIVGSRLRIPQVTPADSGEYVCHVSNGAGSRETSLIVTIQGSGSSHVPSVSPPIRIESSSPTVVEGQTLDLNCVVARQPQAIITWYKRGGSLPSRHQTHGSHLRLHQMSVADSGEYVCRANNNIDALEASIVISVSPSAGSPSAPGSSMPIRIESSSSHVAEGETLDLNCVVPGQAHAQVTWHKRGGSLPSHHQTRGSRLRLHHVSPADSGEYVCRVMGSSGPLEASVLVTIEASGSSAVHVPAPGGAPPIRIEPSSSRVAEGQTLDLKCVVPGQAHAQVTWHKRGGNLPARHQVHGPLLRLNQVSPADSGEYSCQVTGSSGTLEASVLVTIEPSSPGPIPAPGLAQPIYIEASSSHVTEGQTLDLNCVVPGQAHAQVTWYKRGGSLPARHQTHGSQLRLHLVSPADSGEYVCRAASGPGPEQEASFTVTVPPSEGSSYRLRSPVISIDPPSSTVQQGQDASFKCLIHDGAAPISLEWKTRNQELEDNVHISPNGSIITIVGTRPSNHGTYRCVASNAYGVAQSVVNLSVHGPPTVSVLPEGPVWVKVGKAVTLECVSAGEPRSSARWTRISSTPAKLEQRTYGLMDSHAVLQISSAKPSDAGTYVCLAQNALGTAQKQVEVIVDTGAMAPGAPQVQAEEAELTVEAGHTATLRCSATGSPAPTIHWSKLRSPLPWQHRLEGDTLIIPRVAQQDSGQYICNATSPAGHAEATIILHVESPPYATTVPEHASVQAGETVQLQCLAHGTPPLTFQWSRVGSSLPGRATARNELLHFERAAPEDSGRYRCRVTNKVGSAEAFAQLLVQGPPGSLPATSIPAGSTPTVQVTPQLETKSIGASVEFHCAVPSDRGTQLRWFKEGGQLPPGHSVQDGVLRIQNLDQSCQGTYICQAHGPWGKAQASAQLVIQALPSVLINIRTSVQTVVVGHAVEFECLALGDPKPQVTWSKVGGHLRPGIVQSGGVVRIAHVELADAGQYRCTATNAAGTTQSHVLLLVQALPQISMPQEVRVPAGSAAVFPCIASGYPTPDISWSKLDGSLPPDSRLENNMLMLPSVRPQDAGTYVCTATNRQGKVKAFAHLQVPERVVPYFTQTPYSFLPLPTIKDAYRKFEIKITFRPDSADGMLLYNGQKRVPGSPTNLANRQPDFISFGLVGGRPEFRFDAGSGMATIRHPTPLALGHFHTVTLLRSLTQGSLIVGDLAPVNGTSQGKFQGLDLNEELYLGGYPDYGAIPKAGLSSGFIGCVRELRIQGEEIVFHDLNLTAHGISHCPTCRDRPCQNGGQCHDSESSSYVCVCPAGFTGSRCEHSQALHCHPEACGPDATCVNRPDGRGYTCRCHLGRSGLRCEEGVTVTTPSLSGAGSYLALPALTNTHHELRLDVEFKPLAPDGVLLFSGGKSGPVEDFVSLAMVGGHLEFRYELGSGLAVLRSAEPLALGRWHRVSAERLNKDGSLRVNGGRPVLRSSPGKSQGLNLHTLLYLGGVEPSVPLSPATNMSAHFRGCVGEVSVNGKRLDLTYSFLGSQGIGQCYDSSPCERQPCQHGATCMPAGEYEFQCLCRDGFKGDLCEHEENPCQLREPCLHGGTCQGTRCLCLPGFSGPRCQQGSGHGIAESDWHLEGSGGNDAPGQYGAYFHDDGFLAFPGHVFSRSLPEVPETIELEVRTSTASGLLLWQGVEVGEAGQGKDFISLGLQDGHLVFRYQLGSGEARLVSEDPINDGEWHRVTALREGRRGSIQVDGEELVSGRSPGPNVAVNAKGSVYIGGAPDVATLTGGRFSSGITGCVKNLVLHSARPGAPPPQPLDLQHRAQAGANTRPCPS T73075 DRUGINFO D0ZD6Y RUS 3108 Discontinued in Phase 1 T68668 TARGETID T68668 T68668 FORMERID TTDI02374 T68668 UNIPROID MA2A1_HUMAN T68668 TARGNAME Golgi alpha-mannosidase II (MAN2A1) T68668 GENENAME MAN2A1 T68668 TARGTYPE Discontinued T68668 SYNONYMS Mannosyloligosaccharide 1,31,6alphamannosidase; Mannosidase alpha class 2A member 1; Man II; MAN2A1; Alphamannosidase 2; AMan II T68668 FUNCTION Catalyzes the first committed step in the biosynthesis of complex N-glycans. It controls conversion of high mannose to complex N-glycans; the final hydrolytic step in the N-glycan maturation pathway. T68668 BIOCLASS Glycosylase T68668 ECNUMBER EC 3.2.1.114 T68668 SEQUENCE MKLSRQFTVFGSAIFCVVIFSLYLMLDRGHLDYPRNPRREGSFPQGQLSMLQEKIDHLERLLAENNEIISNIRDSVINLSESVEDGPKSSQSNFSQGAGSHLLPSQLSLSVDTADCLFASQSGSHNSDVQMLDVYSLISFDNPDGGVWKQGFDITYESNEWDTEPLQVFVVPHSHNDPGWLKTFNDYFRDKTQYIFNNMVLKLKEDSRRKFIWSEISYLSKWWDIIDIQKKDAVKSLIENGQLEIVTGGWVMPDEATPHYFALIDQLIEGHQWLENNIGVKPRSGWAIDPFGHSPTMAYLLNRAGLSHMLIQRVHYAVKKHFALHKTLEFFWRQNWDLGSVTDILCHMMPFYSYDIPHTCGPDPKICCQFDFKRLPGGRFGCPWGVPPETIHPGNVQSRARMLLDQYRKKSKLFRTKVLLAPLGDDFRYCEYTEWDLQFKNYQQLFDYMNSQSKFKVKIQFGTLSDFFDALDKADETQRDKGQSMFPVLSGDFFTYADRDDHYWSGYFTSRPFYKRMDRIMESHLRAAEILYYFALRQAHKYKINKFLSSSLYTALTEARRNLGLFQHHDAITGTAKDWVVVDYGTRLFHSLMVLEKIIGNSAFLLILKDKLTYDSYSPDTFLEMDLKQKSQDSLPQKNIIRLSAEPRYLVVYNPLEQDRISLVSVYVSSPTVQVFSASGKPVEVQVSAVWDTANTISETAYEISFRAHIPPLGLKVYKILESASSNSHLADYVLYKNKVEDSGIFTIKNMINTEEGITLENSFVLLRFDQTGLMKQMMTKEDGKHHEVNVQFSWYGTTIKRDKSGAYLFLPDGNAKPYVYTTPPFVRVTHGRIYSEVTCFFDHVTHRVRLYHIQGIEGQSVEVSNIVDIRKVYNREIAMKISSDIKSQNRFYTDLNGYQIQPRMTLSKLPLQANVYPMTTMAYIQDAKHRLTLLSAQSLGVSSLNSGQIEVIMDRRLMQDDNRGLEQGIQDNKITANLFRILLEKRSAVNTEEEKKSVSYPSLLSHITSSLMNHPVIPMANKFSSPTLELQGEFSPLQSSLPCDIHLVNLRTIQSKVGNGHSNEAALILHRKGFDCRFSSKGTGLFCSTTQGKILVQKLLNKFIVESLTPSSLSLMHSPPGTQNISEINLSPMEISTFRIQLR T68668 DRUGINFO D0S1AD Tridolgosir Discontinued in Phase 2 T03871 TARGETID T03871 T03871 FORMERID TTDR01356 T03871 UNIPROID RASH_HUMAN T03871 TARGNAME H-ras messenger RNA (HRAS mRNA) T03871 GENENAME HRAS T03871 TARGTYPE Discontinued T03871 SYNONYMS p21ras (mRNA); cHras (mRNA); c-H-ras (mRNA); Transforming protein p21 (mRNA); HaRas (mRNA); Ha-Ras (mRNA); H-Ras-1 (mRNA); GTPase HRas, Nterminally processed (mRNA); GTPase HRas (mRNA) T03871 FUNCTION Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Involved in the activation of Ras protein signal transduction. T03871 PDBSTRUC 821P; 721P; 6Q21; 6D5W; 6D5V T03871 BIOCLASS mRNA target T03871 SEQUENCE MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS T03871 DRUGINFO D01XDN ISIS 2503 Discontinued in Phase 2 T03871 DRUGINFO D05VBN ISIS 6186 Investigative T03871 DRUGINFO D07WCX ISIS 2502 Investigative T03871 DRUGINFO D0O8BP ISIS 13920 Investigative T16486 TARGETID T16486 T16486 FORMERID TTDI02380 T16486 UNIPROID TNFA_HUMAN T16486 TARGNAME TNFA messenger RNA (TNF mRNA) T16486 GENENAME TNF T16486 TARGTYPE Discontinued T16486 SYNONYMS Tumour necrosis factor alpha (mRNA); Tumour necrosis factor (mRNA); Tumor necrosis factor ligand superfamily member 2 (mRNA); Tumor necrosis factor (mRNA); TNFalpha (mRNA); TNFSF2 (mRNA); TNFA (mRNA); TNF-alpha (mRNA); TNF-a (mRNA); TNF alpha (mRNA); Cachectin (mRNA) T16486 FUNCTION It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line. Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. T16486 PDBSTRUC 5YOY; 5WUX; 5UUI; 5TSW; 5MU8 T16486 BIOCLASS mRNA target T16486 SEQUENCE MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL T16486 DRUGINFO D0FX3P ISIS 104838 Discontinued in Phase 2 T16486 DRUGINFO D06LKM PNU-282987 Terminated T47087 TARGETID T47087 T47087 FORMERID TTDC00277 T47087 UNIPROID VE1_HPV11 T47087 TARGNAME Human papillomavirus E1 region messenger RNA (HPV E1 mRNA) T47087 GENENAME HPV E1 mRNA T47087 TARGTYPE Discontinued T47087 SYNONYMS Replication protein E1 (mRNA); E1 (mRNA); ATP-dependent helicase E1 (mRNA) T47087 FUNCTION It forms a complex with the viral E2 protein. The E1-E2 complex binds to the replication origin which contains binding sites for both proteins. During the initial step, a dimer of E1 interacts with a dimer of protein E2 leading to a complex that binds the viral origin of replication with high specificity. Then, a second dimer of E1 displaces the E2 dimer in an ATP-dependent manner to form the E1 tetramer. Following this, two E1 monomers are added to each half of the site, which results in the formation of two E1 trimers on the viral ori. Subsequently, two hexamers will be created. The double hexamer acts as a bi-directional helicase machinery and unwinds the viral DNA and then recruits the host DNA polymerase to start replication. ATP-dependent DNA helicase required for initiation of viral DNA replication. T47087 BIOCLASS mRNA target T47087 ECNUMBER EC 3.6.4.12 T47087 SEQUENCE MADDSGTENEGSGCTGWFMVEAIVEHTTGTQISEDEEEEVEDSGYDMVDFIDDRHITQNSVEAQALFNRQEADAHYATVQDLKRKYLGSPYVSPISNVANAVESEISPRLDAIKLTTQPKKVKRRLFETRELTDSGYGYSEVEAATQVEKHGDPENGGDGQERDTGRDIEGEGVEHREAEAVDDSTREHADTSGILELLKCKDIRSTLHGKFKDCFGLSFVDLIRPFKSDRTTCADWVVAGFGIHHSIADAFQKLIEPLSLYAHIQWLTNAWGMVLLVLIRFKVNKSRCTVARTLGTLLNIPENHMLIEPPKIQSGVRALYWFRTGISNASTVIGEAPEWITRQTVIEHSLADSQFKLTEMVQWAYDNDICEESEIAFEYAQRGDFDSNARAFLNSNMQAKYVKDCAIMCRHYKHAEMKKMSIKQWIKYRGTKVDSVGNWKPIVQFLRHQNIEFIPFLSKLKLWLHGTPKKNCIAIVGPPDTGKSCFCMSLIKFLGGTVISYVNSCSHFWLQPLTDAKVALLDDATQPCWTYMDTYMRNLLDGNPMSIDRKHRALTLIKCPPLLVTSNIDISKEEKYKYLHSRVTTFTFPNPFPFDRNGNAVYELSDANWKCFFERLSSSLDIEDSEDEEDGSNSQAFRCVPGSVVRTL T47087 DRUGINFO D0C9AQ MBI 1121 Discontinued in Phase 1 T57211 TARGETID T57211 T57211 FORMERID TTDR01367 T57211 UNIPROID DPOL_HCMVA T57211 TARGNAME Cytomegalovirus DNA polymerase messenger RNA (CMV DNA polymerase mRNA) T57211 GENENAME CMV DNA polymerase mRNA T57211 TARGTYPE Discontinued T57211 SYNONYMS UL54 (mRNA); HFLF2 (mRNA); DNA polymerase catalytic subunit (mRNA) T57211 FUNCTION The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. Replicates viral genomic DNA in the late phase of lytic infection, producing long concatemeric DNA. T57211 PDBSTRUC 1YYP T57211 BIOCLASS mRNA target T57211 ECNUMBER EC 2.7.7.7 T57211 SEQUENCE MFFNPYLSGGVTGGAVAGGRRQRSQPGSAQGSGKRPPQKQFLQIVPRGVMFDGQTGLIKHKTGRLPLMFYREIKHLLSHDMVWPCPWRETLVGRVVGPIRFHTYDQTDAVLFFDSPENVSPRYRQHLVPSGNVLRFFGATEHGYSICVNVFGQRSYFYCEYSDTDRLREVIASVGELVPEPRTPYAVSVTPATKTSIYGYGTRPVPDLQCVSISNWTMARKIGEYLLEQGFPVYEVRVDPLTRLVIDRRITTFGWCSVNRYDWRQQGRASTCDIEVDCDVSDLVAVPDDSSWPRYRCLSFDIECMSGEGGFPCAEKSDDIVIQISCVCYETGGNTAVDQGIPNGNDGRGCTSEGVIFGHSGLHLFTIGTCGQVGPDVDVYEFPSEYELLLGFMLFFQRYAPAFVTGYNINSFDLKYILTRLEYLYKVDSQRFCKLPTAQGGRFFLHSPAVGFKRQYAAAFPSASHNNPASTAATKVYIAGSVVIDMYPVCMAKTNSPNYKLNTMAELYLRQRKDDLSYKDIPRCFVANAEGRAQVGRYCLQDAVLVRDLFNTINFHYEAGAIARLAKIPLRRVIFDGQQIRIYTSLLDECACRDFILPNHYSKGTTVPETNSVAVSPNAAIISTAAVPGDAGSVAAMFQMSPPLQSAPSSQDGVSPGSGSNSSSSVGVFSVGSGSSGGVGVSNDNHGAGGTAAVSYQGATVFEPEVGYYNDPVAVFDFASLYPSIIMAHNLCYSTLLVPGGEYPVDPADVYSVTLENGVTHRFVRASVRVSVLSELLNKWVSQRRAVRECMRECQDPVRRMLLDKEQMALKVTCNAFYGFTGVVNGMMPCLPIAASITRIGRDMLERTARFIKDNFSEPCFLHNFFNQEDYVVGTREGDSEESSALPEGLETSSGGSNERRVEARVIYGDTDSVFVRFRGLTPQALVARGPSLAHYVTACLFVEPVKLEFEKVFVSLMMICKKRYIGKVEGASGLSMKGVDLVRKTACEFVKGVTRDVLSLLFEDREVSEAAVRLSRLSLDEVKKYGVPRGFWRILRRLVQARDDLYLHRVRVEDLVLSSVLSKDISLYRQSNLPHIAVIKRLAARSEELPSVGDRVFYVLTAPGVRTAPQGSSDNGDSVTAGVVSRSDAIDGTDDDADGGGVEESNRRGGEPAKKRARKPPSAVCNYEVAEDPSYVREHGVPIHADKYFEQVLKAVTNVLSPVFPGGETARKDKFLHMVLPRRLHLEPAFLPYSVKAHECC T57211 DRUGINFO D0G1GP ISIS 2922 Withdrawn from market T53903 TARGETID T53903 T53903 FORMERID TTDC00275 T53903 UNIPROID POLG_HCV1 T53903 TARGNAME Hepatitis C virus NS3 helicase messenger RNA (HCV NS3 mRNA) T53903 GENENAME HCV NS3 mRNA T53903 TARGTYPE Discontinued T53903 SYNONYMS HCV Hepacivirin mRNA; HCV NS3P mRNA; HCV p70 Mrna T53903 FUNCTION Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity). T53903 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T53903 ECNUMBER EC 3.4.21.98 T53903 SEQUENCE APITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVVT T53903 DRUGINFO D0W8KT AVI-4065 Discontinued in Phase 1/2 T86885 TARGETID T86885 T86885 FORMERID TTDC00264 T86885 UNIPROID APOH_HUMAN T86885 TARGNAME Beta-2-glycoprotein 1 (APOH) T86885 GENENAME APOH T86885 TARGTYPE Discontinued T86885 SYNONYMS Beta-2-glycoprotein I; Beta(2)GPI; B2GPI; Apolipoprotein H; Apo-H; Anticardiolipin cofactor; Activated protein C-binding protein; APOH; APC inhibitor T86885 FUNCTION Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells. T86885 PDBSTRUC 4JHS; 3OP8; 2KRI; 1QUB; 1G4G T86885 SEQUENCE MISPVLILFSSFLCHVAIAGRTCPKPDDLPFSTVVPLKTFYEPGEEITYSCKPGYVSRGGMRKFICPLTGLWPINTLKCTPRVCPFAGILENGAVRYTTFEYPNTISFSCNTGFYLNGADSAKCTEEGKWSPELPVCAPIICPPPSIPTFATLRVYKPSAGNNSLYRDTAVFECLPQHAMFGNDTITCTTHGNWTKLPECREVKCPFPSRPDNGFVNYPAKPTLYYKDKATFGCHDGYSLDGPEEIECTKLGNWSAMPSCKASCKVPVKKATVVYQGERVKIQEKFKNGMLHGDKVSFFCKNKEKKCSYTEDAQCIDGTIEVPKCFKEHSSLAFWKTDASDVKPC T86885 DRUGINFO D0Y8PM LJP-1082 Discontinued in Phase 1 T86885 DRUGINFO D07LUR Alpha-D-Mannose Investigative T62553 TARGETID T62553 T62553 FORMERID TTDS00246 T62553 UNIPROID RIR1_HHV11 T62553 TARGNAME Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1) T62553 GENENAME HSV RIR1 T62553 TARGTYPE Discontinued T62553 SYNONYMS HSV Ribonucleotide reductase; HSV Ribonucleoside diphosphate reductase; HSV RIR1 T62553 FUNCTION Ribonucleoside-diphosphate reductase holoenzyme provides the precursors necessary for viral DNA synthesis. Allows virus growth in non-dividing cells, as well as reactivation from latency in infected hosts. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. The N-terminal region confers antiapoptotic activity in differentiated cells such as neurons and is importantfor viral reactivation to increase neural survivability. T62553 BIOCLASS CH/CH(2) oxidoreductase T62553 SEQUENCE MASRPAASSPVEARAPVGGQEAGGPSAATQGEAAGAPLAHGHHVYCQRVNGVMVLSDKTPGSASYRISDNNFVQCGSNCTMIIDGDVVRGRPQDPGAAASPAPFVAVTNIGAGSDGGTAVVAFGGTPRRSAGTSTGTQTADVPTEALGGPPPPPRFTLGGGCCSCRDTRRRSAVFGGEGDPVGPAEFVSDDRSSDSDSDDSEDTDSETLSHASSDVSGGATYDDALDSDSSSDDSLQIDGPVCRPWSNDTAPLDVCPGTPGPGADAGGPSAVDPHAPTPEAGAGLAADPAVARDDAEGLSDPRPRLGTGTAYPVPLELTPENAEAVARFLGDAVNREPALMLEYFCRCAREETKRVPPRTFGSPPRLTEDDFGLLNYALVEMQRLCLDVPPVPPNAYMPYYLREYVTRLVNGFKPLVSRSARLYRILGVLVHLRIRTREASFEEWLRSKEVALDFGLTERLREHEAQLVILAQALDHYDCLIHSTPHTLVERGLQSALKYEEFYLKRFGGHYMESVFQMYTRIAGFLACRATRGMRHIALGREGSWWEMFKFFFHRLYDHQIVPSTPAMLNLGTRNYYTSSCYLVNPQATTNKATLRAITSNVSAILARNGGIGLCVQAFNDSGPGTASVMPALKVLDSLVAAHNKESARPTGACVYLEPWHTDVRAVLRMKGVLAGEEAQRCDNIFSALWMPDLFFKRLIRHLDGEKNVTWTLFDRDTSMSLADFHGEEFEKLYQHLEVMGFGEQIPIQELAYGIVRSAATTGSPFVMFKDAVNRHYIYDTQGAAIAGSNLCTEIVHPASKRSSGVCNLGSVNLARCVSRQTFDFGRLRDAVQACVLMVNIMIDSTLQPTPQCTRGNDNLRSMGIGMQGLHTACLKLGLDLESAEFQDLNKHIAEVMLLSAMKTSNALCVRGARPFNHFKRSMYRAGRFHWERFPDARPRYEGEWEMLRQSMMKHGLRNSQFVALMPTAASAQISDVSEGFAPLFTNLFSKVTRDGETLRPNTLLLKELERTFSGKRLLEVMDSLDAKQWSVAQALPCLEPTHPLRRFKTAFDYDQKLLIDLCADRAPYVDHSQSMTLYVTEKADGTLPASTLVRLLVHAYKRGLKTGMYYCKVRKATNSGVFGGDDNIVCMSCAL T62553 DRUGINFO D00FRY BILD-1351 Terminated T62553 DRUGINFO D0HP3M BILD-1263 Terminated T62553 DRUGINFO D0QM0N BILD-733 Terminated T62553 DRUGINFO D0U4WY BILD-1357 Terminated T71011 TARGETID T71011 T71011 FORMERID TTDI02345 T71011 UNIPROID STXB_BP933 T71011 TARGNAME Enterobacteria Shiga-like toxin 2B (EntBac stxB2) T71011 GENENAME EntBac stxB2 T71011 TARGTYPE Discontinued T71011 SYNONYMS stxB2; Verotoxin 2 subunit B; Verocytotoxin 2 subunit B; Shiga-like toxin 2 subunit B; SLT-IIb; SLT-2b; SLT-2 B subunit T71011 FUNCTION TheB subunit is responsible for the binding of the holotoxin to specific receptors on the target cell surface, such as globotriaosylceramide (Gb3) in human intestinal microvilli. T71011 PDBSTRUC 6FE4; 2GA4; 1R4P T71011 BIOCLASS Shiga-like toxin beta T71011 SEQUENCE MKKMFMAVLFALASVNAMAADCAKGKIEFSKYNEDDTFTVKVDGKEYWTSRWNLQPLLQSAQLTGMTVTIKSSTCESGSGFAEVQFNND T71011 DRUGINFO D03VCF Urtoxazumab Discontinued in Phase 2 T40730 TARGETID T40730 T40730 FORMERID TTDR00690 T40730 UNIPROID FOLB_ECOLI T40730 TARGNAME Bacterial Dihydroneopterinaldolase (Bact folB) T40730 GENENAME Bact folB T40730 TARGTYPE Discontinued T40730 SYNONYMS folB of Escherichia coli; FOLB of Escherichia coli; DHNA of Escherichia coli; 7,8-Dihydroneopterin aldolase T40730 FUNCTION Catalyzes the conversion of 7,8-dihydroneopterin to 6- hydroxymethyl-7,8-dihydropterin. Can use L-threo-dihydroneopterin and D-erythro-dihydroneopterin as substrates for the formation of 6-hydroxymethyldihydropterin,but it can also catalyze the epimerization of carbon 2' of dihydroneopterin and dihydromonapterin at appreciable velocity. T40730 PDBSTRUC 2O90 T40730 BIOCLASS Carbon-carbon lyase T40730 SEQUENCE MDIVFIEQLSVITTIGVYDWEQTIEQKLVFDIEMAWDNRKAAKSDDVADCLSYADIAETVVSHVEGARFALVERVAEEVAELLLARFNSPWVRIKLSKPGAVARAANVGVIIERGNNLKENN T40730 DRUGINFO D07RPR Bropirimine Discontinued in Phase 3 T40730 DRUGINFO D00RAK 7,8-Dihydroneopterin Investigative T40730 DRUGINFO D07IWK 9-Methylguanine Investigative T40730 DRUGINFO D0V0HJ 8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione Investigative T40730 DRUGINFO D0W0NE 6-Hydroxymethyl-7,8-Dihydropterin Investigative T40730 DRUGINFO D0F3XT 7,8-dihydrobiopterin Investigative T95399 TARGETID T95399 T95399 UNIPROID PYGM_HUMAN T95399 TARGNAME Myophosphorylase (PYGM) T95399 GENENAME PYGM T95399 TARGTYPE Discontinued T95399 SYNONYMS Glycogen phosphorylase, muscle form; Myophosphorylase T95399 FUNCTION Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties. T95399 PDBSTRUC 1Z8D T95399 ECNUMBER EC 2.4.1.1 T95399 SEQUENCE MSRPLSDQEKRKQISVRGLAGVENVTELKKNFNRHLHFTLVKDRNVATPRDYYFALAHTVRDHLVGRWIRTQQHYYEKDPKRIYYLSLEFYMGRTLQNTMVNLALENACDEATYQLGLDMEELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKISGGWQMEEADDWLRYGNPWEKARPEFTLPVHFYGHVEHTSQGAKWVDTQVVLAMPYDTPVPGYRNNVVNTMRLWSAKAPNDFNLKDFNVGGYIQAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKSSKFGCRDPVRTNFDAFPDKVAIQLNDTHPSLAIPELMRILVDLERMDWDKAWDVTVRTCAYTNHTVLPEALERWPVHLLETLLPRHLQIIYEINQRFLNRVAAAFPGDVDRLRRMSLVEEGAVKRINMAHLCIAGSHAVNGVARIHSEILKKTIFKDFYELEPHKFQNKTNGITPRRWLVLCNPGLAEVIAERIGEDFISDLDQLRKLLSFVDDEAFIRDVAKVKQENKLKFAAYLEREYKVHINPNSLFDIQVKRIHEYKRQLLNCLHVITLYNRIKREPNKFFVPRTVMIGGKAAPGYHMAKMIIRLVTAIGDVVNHDPAVGDRLRVIFLENYRVSLAEKVIPAADLSEQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGEENFFIFGMRVEDVDKLDQRGYNAQEYYDRIPELRQVIEQLSSGFFSPKQPDLFKDIVNMLMHHDRFKVFADYEDYIKCQEKVSALYKNPREWTRMVIRNIATSGKFSSDRTIAQYAREIWGVEPSRQRLPAPDEAI T95399 DRUGINFO D0LF1U Flavopiridol Phase 2 T95399 DRUGINFO D0P7WJ PSN357 Discontinued in Phase 2 T95399 DRUGINFO D0AL0S GSK-1362885 Discontinued in Phase 1 T45737 TARGETID T45737 T45737 FORMERID TTDR00310 T45737 UNIPROID FCAR_HUMAN T45737 TARGNAME Immunoglobulin alpha Fc receptor (FCAR) T45737 GENENAME FCAR T45737 TARGTYPE Discontinued T45737 SYNONYMS IgA Fc receptor; FCAR; CD89 antigen; CD89 T45737 FUNCTION Binds to the fc region of immunoglobulins alpha. Mediates several functions including cytokine production. T45737 PDBSTRUC 1UCT; 1OW0; 1OVZ T45737 SEQUENCE MDPKQTTLLCLVLCLGQRIQAQEGDFPMPFISAKSSPVIPLDGSVKIQCQAIREAYLTQLMIIKNSTYREIGRRLKFWNETDPEFVIDHMDANKAGRYQCQYRIGHYRFRYSDTLELVVTGLYGKPFLSADRGLVLMPGENISLTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSLGPVDLNVSGIYRCYGWYNRSPYLWSFPSNALELVVTDSIHQDYTTQNLIRMAVAGLVLVALLAILVENWHSHTALNKEASADVAEPSWSQQMCQPGLTFARTPSVCK T45737 DRUGINFO D08PXM MDX-214 Discontinued in Phase 1/2 T64242 TARGETID T64242 T64242 FORMERID TTDI01680 T64242 UNIPROID CP46A_HUMAN T64242 TARGNAME Cholesterol 24-monooxygenase (CYP46A1) T64242 GENENAME CYP46A1 T64242 TARGTYPE Discontinued T64242 SYNONYMS Cytochrome P450 46A1; Cholesterol 24S-hydroxylase; CYP46; CH24H T64242 FUNCTION P450 monooxygenase that plays a major role in cholesterol homeostasis in the brain. Primarily catalyzes the hydroxylation (with S stereochemistry) at C-24 of cholesterol side chain, triggering cholesterol diffusion out of neurons and its further degradation. By promoting constant cholesterol elimination in neurons, may activate the mevalonate pathway and coordinate the synthesis of new cholesterol and nonsterol isoprenoids involved in synaptic activity and learning (By similarity). Further hydroxylates cholesterol derivatives and hormone steroids on both the ring and side chain of these molecules, converting them into active oxysterols involved in lipid signaling and biosynthesis. Acts as an epoxidase converting cholesta-5,24-dien-3beta-ol/desmosterol into (24S),25-epoxycholesterol, an abundant lipid ligand of nuclear NR1H2 and NR1H3 receptors shown to promote neurogenesis in developing brain. May also catalyze the oxidative metabolism of xenobiotics, such as clotrimazole. T64242 PDBSTRUC 4J14; 4FIA; 4ENH; 3MDV; 3MDT T64242 ECNUMBER EC 1.14.14.25 T64242 SEQUENCE MSPGLLLLGSAVLLAFGLCCTFVHRARSRYEHIPGPPRPSFLLGHLPCFWKKDEVGGRVLQDVFLDWAKKYGPVVRVNVFHKTSVIVTSPESVKKFLMSTKYNKDSKMYRALQTVFGERLFGQGLVSECNYERWHKQRRVIDLAFSRSSLVSLMETFNEKAEQLVEILEAKADGQTPVSMQDMLTYTAMDILAKAAFGMETSMLLGAQKPLSQAVKLMLEGITASRNTLAKFLPGKRKQLREVRESIRFLRQVGRDWVQRRREALKRGEEVPADILTQILKAEEGAQDDEGLLDNFVTFFIAGHETSANHLAFTVMELSRQPEIVARLQAEVDEVIGSKRYLDFEDLGRLQYLSQVLKESLRLYPPAWGTFRLLEEETLIDGVRVPGNTPLLFSTYVMGRMDTYFEDPLTFNPDRFGPGAPKPRFTYFPFSLGHRSCIGQQFAQMEVKVVMAKLLQRLEFRLVPGQRFGLQEQATLKPLDPVLCTLRPRGWQPAPPPPPC T64242 DRUGINFO D09WTQ RC-8800 Discontinued in Phase 1 T12279 TARGETID T12279 T12279 FORMERID TTDR01366 T12279 UNIPROID VE2_HPV18 T12279 TARGNAME Human papillomavirus E2 transactivator messenger RNA (HPV E2 mRNA) T12279 GENENAME HPV E2 mRNA T12279 TARGTYPE Discontinued T12279 SYNONYMS Regulatory protein E2 (mRNA) T12279 FUNCTION A dimer of E2 interacts with a dimer of E1 in order to improve specificity of E1 DNA binding activity. Once the complex recognizes and binds DNA at specific sites, the E2 dimer is removed from DNA. E2 also regulates viral transcription through binding to the E2RE response element (5'-ACCNNNNNNGGT-3') present in multiple copies in the regulatory regions of the viral genome. Activates or represses transcription depending on E2RE's position with regards to proximal promoter elements including the TATA-box. Repression occurs by sterically hindering the assembly of the transcription initiation complex. Plays a role in the initiation of viral DNA replication. T12279 PDBSTRUC 1TUE; 1QQH; 1JJ4; 1F9F T12279 BIOCLASS mRNA target T12279 SEQUENCE MQTPKETLSERLSCVQDKIIDHYENDSKDIDSQIQYWQLIRWENAIFFAAREHGIQTLNHQVVPAYNISKSKAHKAIELQMALQGLAQSAYKTEDWTLQDTCEELWNTEPTHCFKKGGQTVQVYFDGNKDNCMTYVAWDSVYYMTDAGTWDKTATCVSHRGLYYVKEGYNTFYIEFKSECEKYGNTGTWEVHFGNNVIDCNDSMCSTSDDTVSATQLVKQLQHTPSPYSSTVSVGTAKTYGQTSAATRPGHCGLAEKQHCGPVNPLLGAATPTGNNKRRKLCSGNTTPIIHLKGDRNSLKCLRYRLRKHSDHYRDISSTWHWTGAGNEKTGILTVTYHSETQRTKFLNTVAIPDSVQILVGYMTM T12279 DRUGINFO D0NC9Y ISIS 2105 Discontinued in Phase 2 T13609 TARGETID T13609 T13609 FORMERID TTDR00258 T13609 UNIPROID E9BCR2_LEIDB T13609 TARGNAME Leishmania Carbamoyl-phosphate synthase (Leishm CPS) T13609 GENENAME Leishm CPS T13609 TARGTYPE Discontinued T13609 SYNONYMS Carbamoyl-phosphate synthase, putative T13609 FUNCTION Catalyses the formation of carbamoyl phosphate from L-glutamine, bicarbonate, and 2 moles of MgATP. T13609 BIOCLASS Carbon-nitrogen ligase T13609 SEQUENCE MEHYAKAELVLHGGERFEGYSFGYEESVAGEVVFATGMVGYPESLSDPSYHGQILVLTSPMVGNYGVPRVEEDLFGVTKYFESTDGQIHVSAVVVQEYCDQPDHWEMYETLGTWLRKNKVPGMMMVDTRSIVLKLRDMGTALGKVLVAGNDVPFMDPNTRNLVAEVSTKTRVTHGHGTLRILVIDMGVKLNTLRCLLKHDVTLIVVPHDWDITTEVYDGLFITNGPGNPQICTSTIRSVRWALQQDKPIFGICMGNQMLCLAAGGTTYKMKYGHRGQNQPCKCNIDGRVVITTQNHGFAVDFKTLPSGEWEEYFTNSNDGSNEGLWHKTKPFCSVQFHPEGRCGPQDTEYLFSEYVCRVKESKVREVAKFKPRKVLVLGAGGIVIAQAGEFDYSGSQCLKSLREEGMETVLINPNIATVQTDDEMADHIYFVPLTVEAVERVIEKERPDGILLGWGGQTALNCGVKLDELGVLKKYNVQVLGTPVSVIAVTEDRELFRDTLLQINEQVAKSAAVMSVEEAVAASKDIGFPMMVRAAYCLGGQGSGIVENMEELRHKVEVALAASPQVLLEESVAGWKEIEYEVVRDIYDNCITVCNMENFDPMGVHTGESIVVAPSQTLSNDEFHMLRSASIKIIRHLGIVGECNIQYGLDPFSHRYVVIEVNARLSRSSALASKATGYPLAHVATKIALGKGLFEITNGVTKTTMACFEPSMDYIAVKMPRWDLHKFNMVSEEIGSMMKSVGEVMSIGRTFEEALQKAIRMVDPSYTGFSLPDRFAGVDFDYMEHIRHPTPYRLFALCRALLDGHSAEELYQMTKITRFFLYKLEKLVRLSKATSTLYANKLTEMPRENLLNMKAHGFSDRQLAQLLNSTAADVRARRVELNVMPLIKQIDTVAGEYPAAQCCYLYSTYNAQRDDVPFTERMYAVLGCGVYRIGNSVEFDYGGVLVARELRRLGNKVILINYNPETVSTDYDECDRLYFDEVSEETVLDILTKERVRGVVISLGGQIVQNMALSLKKSGLPILGTDPANIDMAEDRNKFSKMCDELGVPQPEWISATSVEQVHEFCDTVGYPALVRPSYVLSGSAMAVIANKEDVTRYLKEASFVSGEHPVVVSKYYEAATEYDVDIVAHHGRVLCYAICEHVENAGVHSGDATMFLPPQNTDKDTMKRIYDSVNRIAEKLDVVGPMNVQFLLTAEGQLRVIEANVRSSRSVPFVSKTLGISFPSVMVSAFLARKDQNLVPIKRAKMTHIGCKASMFSFNRLAGADPILGVEMASTGEIGVFGRDKHEVFLKAMLCQNFKIPQKGVFFSSDVDSQTEALCPYIQHLVRRGLKVYGTTKTAAVLHEYGIQCEVLLQRGELPSGDASESNRLAVYDEEVAKKEKFDLVIQLRDKRRDFVLRRCTRETAPPDYWVRRLAVDYNIPLLTEPSIVKMFCECMDLPASSIEIEPFRHYVPKIYHKVENNNCAMLRCHKVGLMITNNNDSKVLALRLSQEGLNITCFHAYLGGSDIDHFEQAFQSLNVPVEVVDLRSEIANSAFDLIMCQSADERHNWHLSKLSWYIFGKYLIPVMRQRRMSVVAQTSKQNKKEAGFEKYVQSNCPEMGVYNAWRDARLMEDFETVADQISFLRKHGIKATVKSNVQVHSSVCGSTYYGDDMRSLPAPSLVKPVRECSVTPEFVSLTFRGARCVNINGIDVTPLLALQMANEIAGRNGVGITRTREGAMYETPGMNLLSVGLQFLYDVSFDRCAADLFRIYSRHVSQNIGAGQLSEKHTQSAIEAVRFLTSDVSGVVELELHQGEIIFLKLSHVQNPVDRRVAPQLVTEEELEEVFQPGNGSFSDVQW T13609 DRUGINFO D02JUT Acivicin Discontinued in Phase 3 T03985 TARGETID T03985 T03985 FORMERID TTDI01742 T03985 UNIPROID L0P818_PNEJ8 T03985 TARGNAME Pneumocystis jirovecii DNA topoisomerase 2 (PJ top2) T03985 GENENAME PJ top2 T03985 TARGTYPE Discontinued T03985 SYNONYMS PJ DNA topoisomerase 2 T03985 FUNCTION Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. T03985 ECNUMBER EC 5.6.2.3 T03985 SEQUENCE MLRETSSDDSDMSFSLKRKYTNVSKNIKKIRNADVGFDSERQLCSEIASVGRTISENLSYSRHENFSDTVDTIESKNHLLATKTTSEIYQKLSQLEHILKRPDTYIGSIEFTSQHIWVYDDNTNAMKYRQVSIVPGLYKIFDEILVNAADNKIRDPNMDTIKVEFSREKNVISIYNNGRGIPIEIHNKEKVWIPELIFGHLLTSSNYDDEEKKVTGGRNGYGAKLCNIFSTEFIVETADRATKKTYKQVFLNNMTKKKDPVIKENKKDEEYTRITFKPDLERFGMKEIDSDLESVFKRRVYDLAGSVKNVKVFLNGERIKVKSFKQYIEMYLNSDDSENNLKPTIIHEVVNDRWEVAFTVSDGQFNQVSFVNSIATTRGGTHVNYVSDQIVLKLIEAVKKKNKNIPIKPFQVKNHIWVFINSLIENPSFDSQTKETLTLKQTAFGSKCILSDDFIKKVLKTPIMEKILDTAQKKADQLMKKTDGSKKMRITGLPKLEDANKAGTKEGHKCTLILTEGDSAKSLAMSGIGVVGRDYFGVYPLRGKLLNVREASHEQISKNAEINAIKQIMGLQHKKVYTSTSELRYGHLMIMTDQDHDGSHIKGLIINYLESSFPSLLEIPGFLIEFITPIVKATKGTQEKTFFTIPEYEYWKESVDNAKGWKIKYYKGLGTSYGNDVKKYFSDLDTHLKEFHSIREGDKELIDMAFSKKKADERKEWLRLFKPGTYMDHTLDKIPISDFINKELILFSMADNIRSIPSVVDGLKPGQRKVIFGCFKRKLKSEIKVAQLSGYISEHTAYHHGEQSLTQTIIGLAQTFVGSNNINLMKPNGQFGTRLQGGKDAASPRYIFTELSPLTRKIFVESDDALLNYLNEDGQSIEPLWYVPIIPLILVNGCEGIGTGWSSYIPNFNPIDLVNNIRRMMNGEKLEPMHPWYRGFNGSIEKQGDKYKISGCIRQIDDTTVEITELPIRFWTQDMKEFLELSVVGSDKVQPFIKDYSEYHTDTVVHFIIKLTEKGMAESLAQGLEEKFKLIKIQNMTNMVAFDSSGRIKKYNSVEEILLEFYNIRLQFYQKRKDYLVNELESQYNKLSNQVRFVKMVINKEQDFLNRKRKDLLDDLKLKGFIPFPKNKHISVDNATETSNNLAENDDDDATGYDYLLSMPLWSLTAEKVEKLLKDKLDKENELESLLKLTVKDLWNKDLDNFVEEWEMFLKHDENLTSKVKNLKKDKRNSQKLGIVTQKSVVKKRAVNSQNKPSDVDYKPFSKKTLLSAKQTTLPFSVKNVKDTDVDFLKNQESSNKVINESVVAVENDQVFAKTDATAERKYGANAIIVPSLKGDLSDDSDTDYMDDLVKKYTINPSGGKSMTSYIKSVSPSPKKTKIALSTKSRSPPKMSTLLDSSPDYVVPITKSSTKTIHKKKKTLARKININDSEIDIPVRSDISQRPRRQVAVQARQRVVAIINSDDNDTTLDRSSLSSEFDGSSS T03985 DRUGINFO D00RIB RG-201 Discontinued in Phase 1 T28532 TARGETID T28532 T28532 FORMERID TTDI01572 T28532 UNIPROID RPP14_HUMAN; RPP21_HUMAN T28532 TARGNAME Ribonuclease P protein (RPP) T28532 GENENAME RPP14; RPP21 T28532 TARGTYPE Discontinued T28532 SYNONYMS Ribonuclease P protein T28532 FUNCTION Acts as a catalyst in the same way that a protein-based enzyme would. Its function is to cleave off an extra, or precursor, sequence of RNA on tRNA molecules. T28532 BIOCLASS Endoribonucleases T28532 SEQUENCE MPAPAATYERVVYKNPSEYHYMKVCLEFQDCGVGLNAAQFKQLLISAVKDLFGEVDAALPLDILTYEEKTLSAILRICSSGLVKLWSSLTLLGSYKGKKCAFRVIQVSPFLLALSGNSRELVLD T28532 DRUGINFO D0FQ6O Etarotene Discontinued in Phase 3 T81694 TARGETID T81694 T81694 FORMERID TTDI01604 T81694 UNIPROID POLG_HRV1B T81694 TARGNAME Rhinovirus Protein 1 (HRV P1D) T81694 GENENAME HRV P1D T81694 TARGTYPE Discontinued T81694 SYNONYMS Rhinovirus Capsid protein VP1; Rhinovirus P1D; Rhinovirus Virion protein 1 T81694 FUNCTION Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity). T81694 PDBSTRUC 1XR6 T81694 SEQUENCE PIEQNPVENYIDEVLNEVLVVPNIKESHHTTSNSAPLLDAAETGHTSNVQPEDAIETRYVMTSQTRDEMSIESFLGRSGCVHISRIKVDYNDYNGVNKNFTTWKITLQEMAQIRRKFELFTYVRFDSEVTLVPCIAGRGDDIGHVVMQYMYVPPGAPIPKTRNDFSWQSGTNMSIFWQHGQPFPRFSLPFLSIASAYYMFYDGYDGDNSSSKYGSIVTNDMGTICSRIVTEKQEHPVVITTHIYHKAKHTKAWCPRPPRAVPYTHSRVTNYVPKTGDVTTAIVPRASMKTV T81694 DRUGINFO D0O7DZ R-61837 Discontinued in Phase 2 T82083 TARGETID T82083 T82083 FORMERID TTDI03439 T82083 UNIPROID P2RY4_HUMAN T82083 TARGNAME P2Y purinoceptor 4 (P2RY4) T82083 GENENAME P2RY4 T82083 TARGTYPE Discontinued T82083 SYNONYMS Uridine nucleotide receptor; UNR; P2Y4; P2P; NRU T82083 FUNCTION Receptor for UTP and UDP coupled to G-proteins that activate a phosphatidylinositol-calcium second messenger system. Not activated by ATP or ADP. T82083 PDBSTRUC 2B6Q T82083 SEQUENCE MASTESSLLRSLGLSPGPGSSEVELDCWFDEDFKFILLPVSYAVVFVLGLGLNAPTLWLFIFRLRPWDATATYMFHLALSDTLYVLSLPTLIYYYAAHNHWPFGTEICKFVRFLFYWNLYCSVLFLTCISVHRYLGICHPLRALRWGRPRLAGLLCLAVWLVVAGCLVPNLFFVTTSNKGTTVLCHDTTRPEEFDHYVHFSSAVMGLLFGVPCLVTLVCYGLMARRLYQPLPGSAQSSSRLRSLRTIAVVLTVFAVCFVPFHITRTIYYLARLLEADCRVLNIVNVVYKVTRPLASANSCLDPVLYLLTGDKYRRQLRQLCGGGKPQPRTAASSLALVSLPEDSSCRWAATPQDSSCSTPRADRL T82083 DRUGINFO D0Z7FU INS 316 Discontinued in Phase 3 T82083 DRUGINFO D00PQC CTP Investigative T82083 DRUGINFO D00WOK ITP Investigative T82083 DRUGINFO D01ZZJ 2-amino-uridine-5'-monophosphate Investigative T82083 DRUGINFO D02NRP MRS2927 Investigative T82083 DRUGINFO D06PIW MRS4062 Investigative T82083 DRUGINFO D07LYU N4-phenylethoxycytidine-5'-triphosphate Investigative T82083 DRUGINFO D0M8DU (N)methanocarba-UTP Investigative T82083 DRUGINFO D02OAJ UTPgammaS Investigative T82083 DRUGINFO D07QYU PPADS Investigative T54931 TARGETID T54931 T54931 FORMERID TTDR00195 T54931 UNIPROID ACHA2_HUMAN; ACHA3_HUMAN T54931 TARGNAME Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3) T54931 GENENAME CHRNA2-CHRNA3 T54931 TARGTYPE Discontinued T54931 SYNONYMS CHRNA; nAChR T54931 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. T54931 BIOCLASS Neurotransmitter receptor T54931 SEQUENCE MGPSCPVFLSFTKLSLWWLLLTPAGGEEAKRPPPRAPGDPLSSPSPTALPQGGSHTETEDRLFKHLFRGYNRWARPVPNTSDVVIVRFGLSIAQLIDVDEKNQMMTTNVWLKQEWSDYKLRWNPTDFGNITSLRVPSEMIWIPDIVLYNNADGEFAVTHMTKAHLFSTGTVHWVPPAIYKSSCSIDVTFFPFDQQNCKMKFGSWTYDKAKIDLEQMEQTVDLKDYWESGEWAIVNATGTYNSKKYDCCAEIYPDVTYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSDCGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPSTHTMPHWVRGALLGCVPRWLLMNRPPPPVELCHPLRLKLSPSYHWLESNVDAEEREVVVEEEDRWACAGHVAPSVGTLCSHGHLHSGASGPKAEALLQEGELLLSPHMQKALEGVHYIADHLRSEDADSSVKEDWKYVAMVIDRIFLWLFIIVCFLGTIGLFLPPFLAGMI T54931 DRUGINFO D0F7FX AZD-9684 Discontinued in Phase 2 T54931 DRUGINFO D02IJB SIB-1533A Investigative T54931 DRUGINFO D08BKH 18-Methoxycoronaridine Investigative T54931 DRUGINFO D0P0XA Ibogaine Investigative T89772 TARGETID T89772 T89772 FORMERID TTDI03614 T89772 UNIPROID VACHT_HUMAN T89772 TARGNAME Vesicular acetylcholine transporter (SLC18A3) T89772 GENENAME SLC18A3 T89772 TARGTYPE Discontinued T89772 SYNONYMS VAChT; Solute carrier family 18 member 3 T89772 FUNCTION Involved in acetylcholine transport into synaptic vesicles. T89772 SEQUENCE MESAEPAGQARAAATKLSEAVGAALQEPRRQRRLVLVIVCVALLLDNMLYMVIVPIVPDYIAHMRGGGEGPTRTPEVWEPTLPLPTPANASAYTANTSASPTAAWPAGSALRPRYPTESEDVKIGVLFASKAILQLLVNPLSGPFIDRMSYDVPLLIGLGVMFASTVLFAFAEDYATLFAARSLQGLGSAFADTSGIAMIADKYPEEPERSRALGVALAFISFGSLVAPPFGGILYEFAGKRVPFLVLAAVSLFDALLLLAVAKPFSAAARARANLPVGTPIHRLMLDPYIAVVAGALTTCNIPLAFLEPTIATWMKHTMAASEWEMGMAWLPAFVPHVLGVYLTVRLAARYPHLQWLYGALGLAVIGASSCIVPACRSFAPLVVSLCGLCFGIALVDTALLPTLAFLVDVRHVSVYGSVYAIADISYSVAYALGPIVAGHIVHSLGFEQLSLGMGLANLLYAPVLLLLRNVGLLTRSRSERDVLLDEPPQGLYDAVRLRERPVSGQDGEPRSPPGPFDACEDDYNYYYTRS T89772 DRUGINFO D03NZM T-588 Discontinued in Phase 2 T89772 DRUGINFO D07EMU [3H]vesamicol Investigative T89772 DRUGINFO D09AWB [123I]iodobenzovesamicol Investigative T89772 DRUGINFO D0I1QF vesamicol Investigative T89772 DRUGINFO D0N8WR aminobenzovesamicol Investigative T35817 TARGETID T35817 T35817 FORMERID TTDI00121 T35817 UNIPROID MSI2H_HUMAN T35817 TARGNAME RNA-binding protein Musashi-2 (MSI2) T35817 GENENAME MSI2 T35817 TARGTYPE Discontinued T35817 SYNONYMS RNA-binding protein Musashi homolog 2; Musashi-2 T35817 FUNCTION May play a role in the proliferation and maintenance of stem cells in the central nervous system. RNA binding protein that regulates the expression of target mRNAs at the translation level. T35817 PDBSTRUC 6DBP; 6C8U T35817 SEQUENCE MEANGSQGTSGSANDSQHDPGKMFIGGLSWQTSPDSLRDYFSKFGEIRECMVMRDPTTKRSRGFGFVTFADPASVDKVLGQPHHELDSKTIDPKVAFPRRAQPKMVTRTKKIFVGGLSANTVVEDVKQYFEQFGKVEDAMLMFDKTTNRHRGFGFVTFENEDVVEKVCEIHFHEINNKMVECKKAQPKEVMFPPGTRGRARGLPYTMDAFMLGMGMLGYPNFVATYGRGYPGFAPSYGYQFPGFPAAAYGPVAAAAVAAARGSGSNPARPGGFPGANSPGPVADLYGPASQDSGVGNYISAASPQPGSGFGHGIAGPLIATAFTNGYH T92689 TARGETID T92689 T92689 FORMERID TTDI03436 T92689 UNIPROID P2Y11_HUMAN T92689 TARGNAME P2Y purinoceptor 11 (P2RY11) T92689 GENENAME P2RY11 T92689 TARGTYPE Discontinued T92689 SYNONYMS P2Y11 T92689 FUNCTION Receptor for ATP and ADP coupled to G-proteins that activate both phosphatidylinositol-calcium and adenylyl cyclase second messenger systems. Not activated by UTP or UDP. T92689 PDBSTRUC 2B6S T92689 SEQUENCE MAANVSGAKSCPANFLAAADDKLSGFQGDFLWPILVVEFLVAVASNGLALYRFSIRKQRPWHPAVVFSVQLAVSDLLCALTLPPLAAYLYPPKHWRYGEAACRLERFLFTCNLLGSVIFITCISLNRYLGIVHPFFARSHLRPKHAWAVSAAGWVLAALLAMPTLSFSHLKRPQQGAGNCSVARPEACIKCLGTADHGLAAYRAYSLVLAGLGCGLPLLLTLAAYGALGRAVLRSPGMTVAEKLRVAALVASGVALYASSYVPYHIMRVLNVDARRRWSTRCPSFADIAQATAALELGPYVGYQVMRGLMPLAFCVHPLLYMAAVPSLGCCCRHCPGYRDSWNPEDAKSTGQALPLNATAAPKPSEPQSRELSQ T92689 DRUGINFO D0Z7FU INS 316 Discontinued in Phase 3 T92689 DRUGINFO D03PEA NF546 Investigative T92689 DRUGINFO D0D8CZ dATP Investigative T92689 DRUGINFO D0M6TB NF157 Investigative T92689 DRUGINFO D0OR6C NF340 Investigative T92689 DRUGINFO D07RTQ NAADP Investigative T92689 DRUGINFO D06HDW BzATP Investigative T92689 DRUGINFO D0S3WN ATPgammaS Investigative T92689 DRUGINFO D0U1OJ 2MeSATP Investigative T30802 TARGETID T30802 T30802 FORMERID TTDR01220 T30802 UNIPROID CALY_HUMAN T30802 TARGNAME Neuron-specific vesicular protein calcyon (CALY) T30802 GENENAME CALY T30802 TARGTYPE Discontinued T30802 SYNONYMS Neuronspecific vesicular protein calcyon; CALY T30802 FUNCTION Interacts with clathrin light chain A and stimulates clathrin self-assembly and clathrin-mediated endocytosis. T30802 SEQUENCE MVKLGCSFSGKPGKDPGDQDGAAMDSVPLISPLDISQLQPPLPDQVVIKTQTEYQLSSPDQQNFPDLEGQRLNCSHPEEGRRLPTARMIAFAMALLGCVLIMYKAIWYDQFTCPDGFLLRHKICTPLTLEMYYTEMDPERHRSILAAIGAYPLSRKHGTETPAAWGDGYRAAKEERKGPTQAGAAAAATEPPGKPSAKAEKEAARKAAGSAAPPPAQ T30802 DRUGINFO D0BQ8M CY-208243 Discontinued in Phase 2 T30802 DRUGINFO D0B6QP Apomorphine SL Investigative T80701 TARGETID T80701 T80701 FORMERID TTDI01154 T80701 UNIPROID IBP1_HUMAN; IBP2_HUMAN; IBP3_HUMAN T80701 TARGNAME Bone resorption factor (BRF) T80701 GENENAME IGFBP1; IGFBP2; IGFBP3 T80701 TARGTYPE Discontinued T80701 SYNONYMS Insulin-like growth factor-binding protein; IGFBP; IGF-binding protein; IBP T80701 FUNCTION IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R. T80701 SEQUENCE MSEVPVARVWLVLLLLTVQVGVTAGAPWQCAPCSAEKLALCPPVSASCSEVTRSAGCGCCPMCALPLGAACGVATARCARGLSCRALPGEQQPLHALTRGQGACVQESDASAPHAAEAGSPESPESTEITEEELLDNFHLMAPSEEDHSILWDAISTYDGSKALHVTNIKKWKEPCRIELYRVVESLAKAQETSGEEISKFYLPNCNKNGFYHSRQCETSMDGEAGLCWCVYPWNGKRIPGSPEIRGDPNCQIYFNVQN T80701 DRUGINFO D0B5KE EB-1053 Discontinued in Phase 2 T81548 TARGETID T81548 T81548 FORMERID TTDI01648 T81548 UNIPROID CH602_MYCBO T81548 TARGNAME Mycobacterium Heat shock protein 65 (MycB groL2) T81548 GENENAME MycB groL2 T81548 TARGTYPE Discontinued T81548 SYNONYMS Protein Cpn60-2; Heat shock protein 65; GroEL protein 2; Cell wall protein A; Antigen A; 65 kDa antigen; 60 kDa chaperonin 2 T81548 FUNCTION Prevents misfolding and promotes the refolding and proper assembly of unfolded polypeptides generated under stress conditions. T81548 SEQUENCE MAKTIAYDEEARRGLERGLNALADAVKVTLGPKGRNVVLEKKWGAPTITNDGVSIAKEIELEDPYEKIGAELVKEVAKKTDDVAGDGTTTATVLAQALVREGLRNVAAGANPLGLKRGIEKAVEKVTETLLKGAKEVETKEQIAATAAISAGDQSIGDLIAEAMDKVGNEGVITVEESNTFGLQLELTEGMRFDKGYISGYFVTDPERQEAVLEDPYILLVSSKVSTVKDLLPLLEKVIGAGKPLLIIAEDVEGEALSTLVVNKIRGTFKSVAVKAPGFGDRRKAMLQDMAILTGGQVISEEVGLTLENADLSLLGKARKVVVTKDETTIVEGAGDTDAIAGRVAQIRQEIENSDSDYDREKLQERLAKLAGGVAVIKAGAATEVELKERKHRIEDAVRNAKAAVEEGIVAGGGVTLLQAAPTLDELKLEGDEATGANIVKVALEAPLKQIAFNSGLEPGVVAEKVRNLPAGHGLNAQTGVYEDLLAAGVADPVKVTRSALQNAASIAGLFLTTEAVVADKPEKEKASVPGGGDMGGMDF T81548 DRUGINFO D06VJK Verpasep caltespen Discontinued in Phase 3 T09756 TARGETID T09756 T09756 FORMERID TTDI01599 T09756 TARGNAME Polyamine unspecific (PLA) T09756 TARGTYPE Discontinued T09756 DRUGINFO D0VR5T BEPH Discontinued in Phase 1 T78244 TARGETID T78244 T78244 FORMERID TTDR00114 T78244 TARGNAME Vasoactive intestinal polypeptide receptor (VIPR) T78244 TARGTYPE Discontinued T78244 SYNONYMS VIP-R; VIP receptor T78244 BIOCLASS GPCR secretin T78244 DRUGINFO D0F6JI AR-D-111421 Discontinued in Phase 2 T78244 DRUGINFO D0O5WV Ac-HSDAVFTDQYTRLRKQVAAKKYLQSIKQKRYC Investigative T92035 TARGETID T92035 T92035 FORMERID TTDC00270 T92035 TARGNAME Hepatitis C virus Internal ribosome entry site messenger RNA (HCV IRES mRNA) T92035 TARGTYPE Discontinued T92035 SYNONYMS mRNA of HCV IRES T92035 BIOCLASS mRNA target T92035 DRUGINFO D0VB9J ISIS 14803 Discontinued in Phase 2 T12189 TARGETID T12189 T12189 FORMERID TTDR00551 T12189 TARGNAME Telomerase messenger RNA (Telomerase mRNA) T12189 TARGTYPE Discontinued T12189 SYNONYMS mRNA of Terminal transferase T12189 BIOCLASS mRNA target T12189 DRUGINFO D0N8MQ GSK-159797 Discontinued in Phase 2 T92653 TARGETID T92653 T92653 FORMERID TTDR00973 T92653 TARGNAME Neuropeptide Y receptor (NPYR) T92653 TARGTYPE Discontinued T92653 SYNONYMS NPY receptor T92653 DRUGINFO D06LEJ Lu-AA44608 Discontinued in Phase 1 T76701 TARGETID T76701 T76701 FORMERID TTDI01543 T76701 TARGNAME Cyclin D1/E2F pathway (CCND1/E2F pathway) T76701 TARGTYPE Discontinued T76701 SYNONYMS Cyclin D1/E2F pathway signalling T76701 DRUGINFO D08PNQ Trombodipine Discontinued in Phase 2 T72957 TARGETID T72957 T72957 FORMERID TTDR00426 T72957 TARGNAME Chemokine receptor (CHR) T72957 TARGTYPE Discontinued T72957 DRUGINFO D09RGW AZD-3778 Discontinued in Phase 2 T72957 DRUGINFO D07TTI AZD-8309 Discontinued in Phase 1 T72957 DRUGINFO D0NQ5R AZD-4750 Discontinued in Phase 1 T72957 DRUGINFO D0TN3D AZD-7140 Discontinued in Phase 1 T72957 DRUGINFO D03DYB AZD-0275 Terminated T67084 TARGETID T67084 T67084 FORMERID TTDI01603 T67084 TARGNAME Glucosidase unspecific (GAN) T67084 TARGTYPE Discontinued T67084 DRUGINFO D09NYB CASTANOSPERMINE Discontinued in Phase 2 T74225 TARGETID T74225 T74225 FORMERID TTDI01557 T74225 TARGNAME GPCR secretin protein unspecific (GPCRB) T74225 TARGTYPE Discontinued T74225 DRUGINFO D06BHQ YM-17K Discontinued in Phase 2 T74225 DRUGINFO D03FAP A-75729 Terminated T99935 TARGETID T99935 T99935 FORMERID TTDI01589 T99935 TARGNAME GPCR unspecific (GPCR) T99935 TARGTYPE Discontinued T99935 DRUGINFO D0K1LO R-873 Discontinued in Phase 2 T99935 DRUGINFO D07GZL R-701 Discontinued in Phase 1 T99935 DRUGINFO D0L9ZK R-1068 Discontinued in Phase 1 T99935 DRUGINFO D0ZM2S R1204 Discontinued in Phase 1 T99935 DRUGINFO D02RLS R-1554 Terminated T99935 DRUGINFO D0CX2J R-1315 Terminated T99935 DRUGINFO D0F6CI R-1437 Terminated T89846 TARGETID T89846 T89846 FORMERID TTDI01595 T89846 TARGNAME Herpesvirus DNA polymerase (KSHV DNAP) T89846 TARGTYPE Discontinued T89846 DRUGINFO D04RZZ A-5021 Discontinued in Phase 2 T21324 TARGETID T21324 T21324 FORMERID TTDI01577 T21324 TARGNAME Isomerase unspecific (IsoM) T21324 TARGTYPE Discontinued T21324 DRUGINFO D0OO6A Isbogrel Discontinued in Preregistration T21324 DRUGINFO D0DT2P Nafagrel Discontinued in Phase 2 T20278 TARGETID T20278 T20278 FORMERID TTDI01647 T20278 TARGNAME Major histocompatibility complex (MHC) T20278 TARGTYPE Discontinued T20278 DRUGINFO D0N8JA Theradigm-HBV Discontinued in Phase 2 T55269 TARGETID T55269 T55269 FORMERID TTDI01606 T55269 TARGNAME Nucleoside transporter (SLC) T55269 TARGTYPE Discontinued T55269 DRUGINFO D04NWP DRAFLAZINE Discontinued in Phase 2 T96592 TARGETID T96592 T96592 FORMERID TTDI01678 T96592 TARGNAME Phosphoric monoester hydrolase (PMH) T96592 TARGTYPE Discontinued T96592 DRUGINFO D07KOR INOC-002 Discontinued in Phase 1 T98906 TARGETID T98906 T98906 FORMERID TTDI01584 T98906 TARGNAME Polymerase unspecific (POL) T98906 TARGTYPE Discontinued T98906 DRUGINFO D0B9GM Oxibendazole Discontinued in Phase 3 T52969 TARGETID T52969 T52969 FORMERID TTDR00281 T52969 TARGNAME CAP-dependent endonuclease (CDE) T52969 TARGTYPE Discontinued T52969 DRUGINFO D0R3EL GSK184072 Discontinued in Phase 2 T52969 DRUGINFO D0V7RG 4-substituted 2,4-dioxobutanoic acids Investigative T53549 TARGETID T53549 T53549 FORMERID TTDI01583 T53549 TARGNAME Protein thiol group (PTG) T53549 TARGTYPE Discontinued T53549 DRUGINFO D0W2SO Orazipone Discontinued in Phase 1 T25950 TARGETID T25950 T25950 FORMERID TTDI01228 T25950 TARGNAME Bone metabolism (Bone metab) T25950 TARGTYPE Discontinued T25950 DRUGINFO D05RBO OPM-3023 Discontinued in Phase 2 T12719 TARGETID T12719 T12719 FORMERID TTDI01222 T12719 TARGNAME Cytomegalovirus Replication (CMV replication) T12719 TARGTYPE Discontinued T12719 DRUGINFO D0W9SZ T611 Discontinued in Phase 2 T27288 TARGETID T27288 T27288 FORMERID TTDI01257 T27288 TARGNAME Food intake (FI) T27288 TARGTYPE Discontinued T27288 DRUGINFO D00ZNP HMR-1426 Discontinued in Phase 2 T51694 TARGETID T51694 T51694 FORMERID TTDI01181 T51694 TARGNAME Histone synthesis (Histone synth) T51694 TARGTYPE Discontinued T51694 DRUGINFO D0J5DL L-4-OXALYSINE Discontinued in Phase 2 T87608 TARGETID T87608 T87608 FORMERID TTDI01159 T87608 TARGNAME Mitochondrial gene transcription (MGT) T87608 TARGTYPE Discontinued T87608 DRUGINFO D0S2YX Mofarotene Discontinued in Phase 1 T79534 TARGETID T79534 T79534 FORMERID TTDI01219 T79534 TARGNAME P450-dependent ergosterol synthesis (PDE synth) T79534 TARGTYPE Discontinued T79534 DRUGINFO D0T5NI Saperconazole Discontinued in Phase 2 T78590 TARGETID T78590 T78590 FORMERID TTDI01580 T78590 TARGNAME Polymorphonuclear neutrophil adhesion (PMNA) T78590 TARGTYPE Discontinued T78590 DRUGINFO D0OB7J NPC-15669 Discontinued in Phase 1 T86702 TARGETID T86702 T86702 FORMERID TTDC00105 T86702 UNIPROID MMP3_HUMAN T86702 TARGNAME Matrix metalloproteinase-3 (MMP-3) T86702 GENENAME MMP3 T86702 TARGTYPE Patented-recorded T86702 SYNONYMS Transin-1; Stromelysin-1; STMY1; SL-1; MMP-3 T86702 FUNCTION Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase. T86702 PDBSTRUC 6N9D; 6MAV; 4JA1; 4G9L; 4DPE T86702 BIOCLASS Peptidase T86702 ECNUMBER EC 3.4.24.17 T86702 SEQUENCE MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNC T86702 DRUGINFO D05GAP PMID29130358-Compound-Figure10(2a) Patented T86702 DRUGINFO D08ZKN PG-530742 Discontinued in Phase 2 T86702 DRUGINFO D03BOZ RS-130830 Discontinued in Phase 2 T86702 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T86702 DRUGINFO D0P8YC Batimastat Preclinical T86702 DRUGINFO D08CEE L-696418 Terminated T86702 DRUGINFO D0E5GY RO-319790 Terminated T86702 DRUGINFO D05VNG BB-1101 Terminated T86702 DRUGINFO D0Y1XT SC-44463 Terminated T86702 DRUGINFO D09EUH FUTOENONE Investigative T86702 DRUGINFO D0J5EZ AM-2S Investigative T86702 DRUGINFO D0W3ME PNU-142372 Investigative T86702 DRUGINFO D02EFQ PD-169469 Investigative T86702 DRUGINFO D03MUZ 8-chloro-quinoline-3-carbonitrile Investigative T86702 DRUGINFO D05HOS Hydroxyaminovaline Investigative T86702 DRUGINFO D07OME 1-Methyloxy-4-Sulfone-Benzene Investigative T86702 DRUGINFO D0F7BE PNU-107859 Investigative T86702 DRUGINFO D0JM0Z 3-Methylpyridine Investigative T86702 DRUGINFO D0OR6O CM-352 Investigative T86702 DRUGINFO D0BI8T RS-39066 Investigative T86702 DRUGINFO D0Y7NV 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione Investigative T86702 DRUGINFO D0H2PA PKF-242-484 Investigative T86702 DRUGINFO D0NP8A UK-356618 Investigative T86702 DRUGINFO D0XL8K Ro-37-9790 Investigative T86702 DRUGINFO D0W2UK IK-862 Investigative T86702 DRUGINFO D0A4TC MMI270 Investigative T98062 TARGETID T98062 T98062 FORMERID TTDC00099 T98062 UNIPROID PYGM_HUMAN T98062 TARGNAME Glycogen phosphorylase muscle form (GP) T98062 GENENAME PYGM T98062 TARGTYPE Patented-recorded T98062 SYNONYMS Muscle glycogen phosphorylase; Glycogen phosphorylase, muscle form; Glycogen phosphorylase b T98062 FUNCTION Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties. Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. T98062 PDBSTRUC 1Z8D T98062 BIOCLASS Glycosyltransferases T98062 ECNUMBER EC 2.4.1.1 T98062 SEQUENCE MSRPLSDQEKRKQISVRGLAGVENVTELKKNFNRHLHFTLVKDRNVATPRDYYFALAHTVRDHLVGRWIRTQQHYYEKDPKRIYYLSLEFYMGRTLQNTMVNLALENACDEATYQLGLDMEELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKISGGWQMEEADDWLRYGNPWEKARPEFTLPVHFYGHVEHTSQGAKWVDTQVVLAMPYDTPVPGYRNNVVNTMRLWSAKAPNDFNLKDFNVGGYIQAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKSSKFGCRDPVRTNFDAFPDKVAIQLNDTHPSLAIPELMRILVDLERMDWDKAWDVTVRTCAYTNHTVLPEALERWPVHLLETLLPRHLQIIYEINQRFLNRVAAAFPGDVDRLRRMSLVEEGAVKRINMAHLCIAGSHAVNGVARIHSEILKKTIFKDFYELEPHKFQNKTNGITPRRWLVLCNPGLAEVIAERIGEDFISDLDQLRKLLSFVDDEAFIRDVAKVKQENKLKFAAYLEREYKVHINPNSLFDIQVKRIHEYKRQLLNCLHVITLYNRIKREPNKFFVPRTVMIGGKAAPGYHMAKMIIRLVTAIGDVVNHDPAVGDRLRVIFLENYRVSLAEKVIPAADLSEQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGEENFFIFGMRVEDVDKLDQRGYNAQEYYDRIPELRQVIEQLSSGFFSPKQPDLFKDIVNMLMHHDRFKVFADYEDYIKCQEKVSALYKNPREWTRMVIRNIATSGKFSSDRTIAQYAREIWGVEPSRQRLPAPDEAI T98062 DRUGINFO D07LUJ URSOLIC ACID Phase 2 T98062 DRUGINFO D09HAL JTT-651 Discontinued in Phase 1 T98062 DRUGINFO D00ASL N-Butyl 2beta-hydroxyolean-12-en-28-oate Investigative T98062 DRUGINFO D02AFI 1-D-glucopyranosyl cytosine Investigative T98062 DRUGINFO D03DUN C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide Investigative T98062 DRUGINFO D03EDR N-Acetyl-N'-Beta-D-Glucopyranosyl Urea Investigative T98062 DRUGINFO D03WQK Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide Investigative T98062 DRUGINFO D05DGE Fluoro-Phosphite Ion Investigative T98062 DRUGINFO D05KJY BETULIN Investigative T98062 DRUGINFO D05LDI 2-isoursolic acid Investigative T98062 DRUGINFO D05WSU Beta-D-Glucopyranose Spirohydantoin Investigative T98062 DRUGINFO D06YDW 23-hydroxybetulinic acid Investigative T98062 DRUGINFO D07MTU 3alpha-Hydroxyurs-12-en-28-oic Acid Investigative T98062 DRUGINFO D07ZJM 2-Oxoolean-12-en-28-oic acid Investigative T98062 DRUGINFO D08VUO Ethyl 2beta-hydroxyolean-12-en-28-oate Investigative T98062 DRUGINFO D08ZIA 2-isooleanolic acid Investigative T98062 DRUGINFO D09NIM Benzyl 2-hydroxyiminoolean-12-en-28-oate Investigative T98062 DRUGINFO D0BU6J 2beta,3alpha-dihydroxyurs-12-en-28-oic acid Investigative T98062 DRUGINFO D0E4SM 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid Investigative T98062 DRUGINFO D0G9FQ 2-Hydroxyiminours-12-en-28-oic acid Investigative T98062 DRUGINFO D0I9PG 1-N-Acetyl-Beta-D-Glucosamine Investigative T98062 DRUGINFO D0J3YD 2-Hydroxyiminoolean-12-en-28-oic acid Investigative T98062 DRUGINFO D0J6KJ 1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose Investigative T98062 DRUGINFO D0KS6A 2alpha-Hydroxyurs-12-en-28-oic acid Investigative T98062 DRUGINFO D0LC7K ASIATIC ACID Investigative T98062 DRUGINFO D0N2SM 2beta,3alpha-dihydroxyolean-12-en-28-oic acid Investigative T98062 DRUGINFO D0P1XH 1-D-glucopyranosyl uracil Investigative T98062 DRUGINFO D0Q7SP Acurea Investigative T98062 DRUGINFO D0T9CW Heptulose-2-Phosphate Investigative T98062 DRUGINFO D0U8RR 2-Deoxy-Glucose-6-Phosphate Investigative T98062 DRUGINFO D0W8RS C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide Investigative T98062 DRUGINFO D0X5YM 2alpha-Hydroxyolean-12-en-28-oic acid Investigative T98062 DRUGINFO D0X7IZ N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea Investigative T98062 DRUGINFO D02KKU Oleanonic acid Investigative T98062 DRUGINFO D0E2BH Nojirimycine Tetrazole Investigative T98062 DRUGINFO D0S5WE Alpha-D-Glucose-1-Phosphate Investigative T98062 DRUGINFO D0SJ2Q OLEANOLIC_ACID Investigative T98062 DRUGINFO D01AWD Alpha-D-Glucose-6-Phosphate Investigative T98062 DRUGINFO D0I5PZ N'-Pyridoxyl-Lysine-5'-Monophosphate Investigative T98062 DRUGINFO D0G2CT Indirubin-5-sulfonate Investigative T98062 DRUGINFO D0H2YT Inosinic Acid Investigative T98062 DRUGINFO D07ONX Beta-D-Glucose Investigative T98062 DRUGINFO D07PZQ L-serine-O-phosphate Investigative T16042 TARGETID T16042 T16042 FORMERID TTDR00234 T16042 UNIPROID LOX15_HUMAN T16042 TARGNAME Arachidonate 15-lipoxygenase (15-LOX) T16042 GENENAME ALOX15 T16042 TARGTYPE Patented-recorded T16042 SYNONYMS LOG15; Arachidonate omega-6 lipoxygenase; Arachidonate 12-lipoxygenase, leukocyte-type; 15-Lipoxygenase; 15-LOX-1; 12/15-lipoxygenase; 12-LOX T16042 FUNCTION Converts arachidonic acid into 12-hydroperoxyeicosatetraenoic acid/12-HPETE and 15-hydroperoxyeicosatetraenoic acid/15-HPETE. Also converts linoleic acid to 13-hydroperoxyoctadecadienoic acid. May also act on (12S)-hydroperoxyeicosatetraenoic acid/(12S)-HPETE to produce hepoxilin A3. Probably plays an important role in the immune and inflammatory responses. Through the oxygenation of membrane-bound phosphatidylethanolamine in macrophages may favor clearance of apoptotic cells during inflammation by resident macrophages and prevent an autoimmune response associated with the clearance of apoptotic cells by inflammatory monocytes. In parallel, may regulate actin polymerization which is crucial for several biological processes, including macrophage function. May also regulate macrophage function through regulation of the peroxisome proliferator activated receptor signaling pathway. Finally, it is also involved in the cellular response to IL13/interleukin-13. In addition to its role in the immune and inflammatory responses, may play a role in epithelial wound healing in the cornea maybe through production of lipoxin A4. May also play a role in endoplasmic reticulum stress response and the regulation of bone mass. Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators. T16042 PDBSTRUC 2ABT T16042 BIOCLASS Oxygenase T16042 ECNUMBER EC 1.13.11.33 T16042 SEQUENCE MGLYRIRVSTGASLYAGSNNQVQLWLVGQHGEAALGKRLWPARGKETELKVEVPEYLGPLLFVKLRKRHLLKDDAWFCNWISVQGPGAGDEVRFPCYRWVEGNGVLSLPEGTGRTVGEDPQGLFQKHREEELEERRKLYRWGNWKDGLILNMAGAKLYDLPVDERFLEDKRVDFEVSLAKGLADLAIKDSLNVLTCWKDLDDFNRIFWCGQSKLAERVRDSWKEDALFGYQFLNGANPVVLRRSAHLPARLVFPPGMEELQAQLEKELEGGTLFEADFSLLDGIKANVILCSQQHLAAPLVMLKLQPDGKLLPMVIQLQLPRTGSPPPPLFLPTDPPMAWLLAKCWVRSSDFQLHELQSHLLRGHLMAEVIVVATMRCLPSIHPIFKLIIPHLRYTLEINVRARTGLVSDMGIFDQIMSTGGGGHVQLLKQAGAFLTYSSFCPPDDLADRGLLGVKSSFYAQDALRLWEIIYRYVEGIVSLHYKTDVAVKDDPELQTWCREITEIGLQGAQDRGFPVSLQARDQVCHFVTMCIFTCTGQHASVHLGQLDWYSWVPNAPCTMRLPPPTTKDATLETVMATLPNFHQASLQMSITWQLGRRQPVMVAVGQHEEEYFSGPEPKAVLKKFREELAALDKEIEIRNAKLDMPYEYLRPSVVENSVAI T16042 DRUGINFO D00NVU Imidazole derivative 10 Patented T16042 DRUGINFO D02AAR Indole and benzimidazole derivative 1 Patented T16042 DRUGINFO D09AXR Triazole derivative 3 Patented T16042 DRUGINFO D09ZAJ Isothiazolone derivative 1 Patented T16042 DRUGINFO D0GL1X PMID26560362-Compound-90 Patented T16042 DRUGINFO D0IA4F Imidazole derivative 11 Patented T16042 DRUGINFO D0OW2D Tri-substituted benzene derivative 1 Patented T16042 DRUGINFO D00CKV Indolizine derivative 1 Patented T16042 DRUGINFO D0F4JL NSC-661755 Terminated T16042 DRUGINFO D03NLE IGERNELLIN Investigative T16042 DRUGINFO D05QOR SCOPOLETIN Investigative T16042 DRUGINFO D0A8OW Subersic acid Investigative T16042 DRUGINFO D0E0RW ISOSCOPOLETIN Investigative T16042 DRUGINFO D0ES6Z (2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID Investigative T16042 DRUGINFO D0F1VR 3,4-Dibromo-2-(5-bromo-2-hydroxy-phenoxy)-phenol Investigative T16042 DRUGINFO D0NQ7I SPONGIADIOXIN A Investigative T16042 DRUGINFO D0NU1W 3,6,8-Tribromo-dibenzo[1,4]dioxin-1-ol Investigative T16042 DRUGINFO D01KTM (-)-pinoresinol Investigative T16042 DRUGINFO D01PBO (+)-3,3'-bisdemethyltanegool Investigative T16042 DRUGINFO D02LUF (+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol Investigative T16042 DRUGINFO D03YMX 3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol Investigative T16042 DRUGINFO D07EAJ JASPAQUINOL Investigative T16042 DRUGINFO D07JRW Jaspic acid Investigative T16042 DRUGINFO D08WDW DYSIDENIN Investigative T16042 DRUGINFO D0A3QB Polybrominated diphenyl ether derivative Investigative T16042 DRUGINFO D0A5BH Hydrohalisulfate 1 Investigative T16042 DRUGINFO D0H8FG (+)-(5S,8S,9R,10S)-20-methoxypuupehenone Investigative T16042 DRUGINFO D0I6ZS Dimethylnordihydroguarierate acid Investigative T16042 DRUGINFO D0K0QU (+)-(5S,8S,10S)-20-methoxypuupehenol Investigative T16042 DRUGINFO D0M9VY Halisulfate 1 Investigative T16042 DRUGINFO D0N7XM (-)-3,3'-bisdemethylpinoresinol Investigative T16042 DRUGINFO D0W5DZ CHLOROPUUPEHENONE Investigative T16042 DRUGINFO D0X4BT NSC-172033 Investigative T16042 DRUGINFO D0X4CI 2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol Investigative T16042 DRUGINFO D05FJM PUUPEHEDIONE Investigative T16042 DRUGINFO D06PRC MANGOSTIN Investigative T16042 DRUGINFO D07BXV PUUPEHENONE Investigative T16042 DRUGINFO D0F9FG Isojaspic acid Investigative T16042 DRUGINFO D0G3TK KAEMPFEROL Investigative T00663 TARGETID T00663 T00663 FORMERID TTDR00928 T00663 UNIPROID MK10_HUMAN T00663 TARGNAME Stress-activated protein kinase JNK3 (JNK3) T00663 GENENAME MAPK10 T00663 TARGTYPE Patented-recorded T00663 SYNONYMS Stress-activated protein kinase 1b; SAPK1b; PRKM10; Mitogen-activated protein kinase 10; MAPK 10; MAP kinase p49 3F12; MAP kinase 10; JNK3A; C-Jun N-terminal kinase 3 T00663 FUNCTION Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK10/JNK3. In turn, MAPK10/JNK3 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. Plays regulatory roles in the signaling pathways during neuronal apoptosis. Phosphorylates the neuronal microtubule regulator STMN2. Acts in the regulation of the amyloid-beta precursor protein/APP signaling during neuronal differentiation by phosphorylating APP. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the photic regulation of the circadian clock. Serine/threonine-protein kinase involved in various processes such as neuronal proliferation, differentiation, migration and programmed cell death. T00663 PDBSTRUC 6EQ9; 6EMH; 6EKD; 4Z9L; 4Y5H T00663 BIOCLASS Kinase T00663 ECNUMBER EC 2.7.11.24 T00663 SEQUENCE MSLHFLYYCSEPTLDVKIAFCQGFDKQVDVSYIAKHYNMSKSKVDNQFYSVEVGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAVLDRNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGEMVRHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRNYVENRPKYAGLTFPKLFPDSLFPADSEHNKLKASQARDLLSKMLVIDPAKRISVDDALQHPYINVWYDPAEVEAPPPQIYDKQLDEREHTIEEWKELIYKEVMNSEEKTKNGVVKGQPSPSGAAVNSSESLPPSSSVNDISSMSTDQTLASDTDSSLEASAGPLGCCR T00663 DRUGINFO D04BIF 7-azaindole derivative 7 Patented T00663 DRUGINFO D0JB7I 7-azaindole derivative 4 Patented T00663 DRUGINFO D0U9RB 7-azaindole derivative 6 Patented T00663 DRUGINFO D05SJB 7-azaindole derivative 1 Patented T00663 DRUGINFO D07KMK 7-azaindole derivative 5 Patented T00663 DRUGINFO D08DNZ PMID25991433-Compound-P6 Patented T00663 DRUGINFO D08JOC PMID25991433-Compound-J3 Patented T00663 DRUGINFO D0L2MS PMID25991433-Compound-P1 Patented T00663 DRUGINFO D0Q4WA PMID25991433-Compound-O3 Patented T00663 DRUGINFO D0RQ8Q PMID25991433-Compound-J2 Patented T00663 DRUGINFO D0T6IZ 7-azaindole derivative 3 Patented T00663 DRUGINFO D0VR1O 7-azaindole derivative 2 Patented T00663 DRUGINFO D0W8BL PMID25991433-Compound-P5 Patented T00663 DRUGINFO D0X2SG PMID25991433-Compound-P4 Patented T00663 DRUGINFO D0ZU8L PMID25991433-Compound-J5 Patented T00663 DRUGINFO D06JRV PMID25991433-Compound-F2 Patented T00663 DRUGINFO D0H4HD PMID25991433-Compound-A1 Patented T00663 DRUGINFO D0E3KD 9-(4-Hydroxyphenyl)-2,7-Phenanthroline Investigative T00663 DRUGINFO D0YA6U ELN-864709 Investigative T00663 DRUGINFO D0B4CA NSC-656158 Investigative T00663 DRUGINFO D0H2PE Phenyl-(3-phenyl-1H-indazol-6-yl)-amine Investigative T00663 DRUGINFO D0L0HG AC1LG8KT Investigative T00663 DRUGINFO D00HVA Aminopyridine deriv. 2 Investigative T00663 DRUGINFO D0Q3NG N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide Investigative T00663 DRUGINFO D0VJ2S JNK-IN-8 Investigative T00663 DRUGINFO D04QCF AS-601245 Investigative T00663 DRUGINFO D02PVB 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One Investigative T00663 DRUGINFO D0S7IE N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide Investigative T00663 DRUGINFO D00ICA AMP-PNP Investigative T20973 TARGETID T20973 T20973 FORMERID TTDR00296 T20973 UNIPROID CDK5_HUMAN T20973 TARGNAME Cyclin-dependent kinase 5 (CDK5) T20973 GENENAME CDK5 T20973 TARGTYPE Patented-recorded T20973 SYNONYMS Tau protein kinase II catalytic subunit; TPKII catalytic subunit; Serine/threonine-protein kinase PSSALRE; Serine/threonine protein kinase PSSALRE; Proline-directed protein kinase F(A) (PDPK F(A)); Proline-directed protein kinase 33 kDa subunit; PDPK; Cyclin-dependent-like kinase 5; Cyclin-dependent kinase 5 (CDK5); Cell division protein kinase 5; CDKN5 T20973 FUNCTION Interacts with D1 and D3-type G1 cyclins. Phosphorylates SRC, NOS3, VIM/vimentin, p35/CDK5R1, MEF2A, SIPA1L1, SH3GLB1, PXN, PAK1, MCAM/MUC18, SEPT5, SYN1, DNM1, AMPH, SYNJ1, CDK16, RAC1, RHOA, CDC42, TONEBP/NFAT5, MAPT/TAU, MAP1B, histone H1, p53/TP53, HDAC1, APEX1, PTK2/FAK1, huntingtin/HTT, ATM, MAP2, NEFH and NEFM. Regulates several neuronal development and physiological processes including neuronal survival, migration and differentiation, axonal and neurite growth, synaptogenesis, oligodendrocyte differentiation, synaptic plasticity and neurotransmission, by phosphorylating key proteins. Activated by interaction with CDK5R1 (p35) and CDK5R2 (p39), especially in post-mitotic neurons, and promotes CDK5R1 (p35) expression in an autostimulation loop. Phosphorylates many downstream substrates such as Rho and Ras family small GTPases (e. g. PAK1, RAC1, RHOA, CDC42) or microtubule-binding proteins (e. g. MAPT/TAU, MAP2, MAP1B), and modulates actin dynamics to regulate neurite growth and/or spine morphogenesis. Phosphorylates also exocytosis associated proteins such as MCAM/MUC18, SEPT5, SYN1, and CDK16/PCTAIRE1 as well as endocytosis associated proteins such as DNM1, AMPH and SYNJ1 at synaptic terminals. In the mature central nervous system (CNS), regulates neurotransmitter movements by phosphorylating substrates associated with neurotransmitter release and synapse plasticity; synaptic vesicle exocytosis, vesicles fusion with the presynaptic membrane, and endocytosis. Promotes cell survival by activating anti-apoptotic proteins BCL2 and STAT3, and negatively regulating of JNK3/MAPK10 activity. Phosphorylation of p53/TP53 in response to genotoxic and oxidative stresses enhances its stabilization by preventing ubiquitin ligase-mediated proteasomal degradation, and induces transactivation of p53/TP53 target genes, thus regulating apoptosis. Phosphorylation of p35/CDK5R1 enhances its stabilization by preventing calpain-mediated proteolysis producing p25/CDK5R1 and avoiding ubiquitin ligase-mediated proteasomal degradation. During aberrant cell-cycle activity and DNA damage, p25/CDK5 activity elicits cell-cycle activity and double-strand DNA breaks that precedes neuronal death by deregulating HDAC1. DNA damage triggered phosphorylation of huntingtin/HTT in nuclei of neurons protects neurons against polyglutamine expansion as well as DNA damage mediated toxicity. Phosphorylation of PXN reduces its interaction with PTK2/FAK1 in matrix-cell focal adhesions (MCFA) during oligodendrocytes (OLs) differentiation. Negative regulator of Wnt/beta-catenin signaling pathway. Activator of the GAIT (IFN-gamma-activated inhibitor of translation) pathway, which suppresses expression of a post-transcriptional regulon of proinflammatory genes in myeloid cells; phosphorylates the linker domain of glutamyl-prolyl tRNA synthetase (EPRS) in a IFN-gamma-dependent manner, the initial event in assembly of the GAIT complex. Phosphorylation of SH3GLB1 is required for autophagy induction in starved neurons. Phosphorylation of TONEBP/NFAT5 in response to osmotic stress mediates its rapid nuclear localization. MEF2 is inactivated by phosphorylation in nucleus in response to neurotoxin, thus leading to neuronal apoptosis. APEX1 AP-endodeoxyribonuclease is repressed by phosphorylation, resulting in accumulation of DNA damage and contributing to neuronal death. NOS3 phosphorylation down regulates NOS3-derived nitrite (NO) levels. SRC phosphorylation mediates its ubiquitin-dependent degradation and thus leads to cytoskeletal reorganization. May regulate endothelial cell migration and angiogenesis via the modulation of lamellipodia formation. Involved in dendritic spine morphogenesis by mediating the EFNA1-EPHA4 signaling. The complex p35/CDK5 participates in the regulation of the circadian clock by modulating the function of CLOCK protein: phosphorylates CLOCK at 'Thr-451' and 'Thr-461' and regulates the transcriptional activity of the CLOCK-ARNTL/BMAL1 heterodimer in association with altered stability and subcellular distribution. Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arrest and differentiation and may be involved in apoptotic cell death in neuronal diseases by triggering abortive cell cycle re-entry. T20973 PDBSTRUC 4AU8; 3O0G; 1UNL; 1UNH; 1UNG T20973 BIOCLASS Kinase T20973 ECNUMBER EC 2.7.11.1 T20973 SEQUENCE MQKYEKLEKIGEGTYGTVFKAKNRETHEIVALKRVRLDDDDEGVPSSALREICLLKELKHKNIVRLHDVLHSDKKLTLVFEFCDQDLKKYFDSCNGDLDPEIVKSFLFQLLKGLGFCHSRNVLHRDLKPQNLLINRNGELKLADFGLARAFGIPVRCYSAEVVTLWYRPPDVLFGAKLYSTSIDMWSAGCIFAELANAGRPLFPGNDVDDQLKRIFRLLGTPTEEQWPSMTKLPDYKPYPMYPATTSLVNVVPKLNATGRDLLQNLLKCNPVQRISAEEALQHPYFSDFCPP T20973 DRUGINFO D0KP8N Flavonoid derivative 7 Patented T20973 DRUGINFO D0F7DS PMID26161698-Compound-18 Patented T20973 DRUGINFO D08WJG Naphthyridine and isoquinoline derivative 1 Patented T20973 DRUGINFO D01CJE 4-(thiazol-5-yl)-pyrimidine derivative 2 Patented T20973 DRUGINFO D0NB7Y Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 Patented T20973 DRUGINFO D07DUX Roscovitine derivative 1 Patented T20973 DRUGINFO D0NY7M Tricyclic benzimidazole derivative 1 Patented T20973 DRUGINFO D00PWQ KENPAULLONE Patented T20973 DRUGINFO D0WS1V L-751250 Preclinical T20973 DRUGINFO D00BPA Olomoucine Terminated T20973 DRUGINFO D04AEG 3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one Investigative T20973 DRUGINFO D0YE4B 1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea Investigative T20973 DRUGINFO D03ALC Oxindole 16 (compound 3) Investigative T20973 DRUGINFO D0MS4R Oxindole 95 Investigative T20973 DRUGINFO D0Q4QF MANZAMINE A Investigative T20973 DRUGINFO D0F0AX 10Z-Hymenialdisine Investigative T20973 DRUGINFO D0G2GA aminopurvalanol A Investigative T20973 DRUGINFO D0H3EV 9-Nitropaullone Investigative T20973 DRUGINFO D0L3FK SU9516 Investigative T20973 DRUGINFO D0R5FH Quinoxaline1 Investigative T20973 DRUGINFO D0DR8N AZAKENPAULLONE Investigative T20973 DRUGINFO D0TF9P Thieno analogue of kenpaullone Investigative T20973 DRUGINFO D0G2CT Indirubin-5-sulfonate Investigative T20973 DRUGINFO D02XHC aloisine A Investigative T20973 DRUGINFO D04WFN NU6140 Investigative T20973 DRUGINFO D0Y0ES Indirubin-3'-monoxime Investigative T15700 TARGETID T15700 T15700 FORMERID TTDR00433 T15700 UNIPROID CASP8_HUMAN T15700 TARGNAME Caspase-8 (CASP8) T15700 GENENAME CASP8 T15700 TARGTYPE Patented-recorded T15700 SYNONYMS MORT1-associated CED-3 homolog; MCH5; MACH; ICE-like apoptotic protease 5; FLICE; FADD-like ICE; FADD-homologous ICE/CED-3-like protease; CASP-8; CAP4; Apoptotic protease Mch-5; Apoptotic cysteine protease T15700 FUNCTION Binding to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolytic activation. The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases. Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC. Cleaves and activates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. May participate in the GZMB apoptotic pathways. Cleaves ADPRT. Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC. Likely target for the cowpox virus CRMA death inhibitory protein. Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalytic site and may interfere with the pro-apoptotic activity of the complex. Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNFRSF1A induced cell death. T15700 PDBSTRUC 5L08; 5JQE; 5H33; 5H31; 4ZBW T15700 BIOCLASS Peptidase T15700 ECNUMBER EC 3.4.22.61 T15700 SEQUENCE MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKERSSSLEGSPDEFSNGEELCGVMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIINNHNFAKAREKVPKLHSIRDRNGTHLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQLMDHSNMDCFICCILSHGDKGIIYGTDGQEAPIYELTSQFTGLKCPSLAGKPKVFFIQACQGDNYQKGIPVETDSEEQPYLEMDLSSPQTRYIPDEADFLLGMATVNNCVSYRNPAEGTWYIQSLCQSLRERCPRGDDILTILTEVNYEVSNKDDKKNMGKQMPQPTFTLRKKLVFPSD T15700 DRUGINFO D08LIU Amooranin Investigative T15700 DRUGINFO D0N8TA Acetyl-Ile-Glu-Thr-Asp-aldehyde Investigative T15700 DRUGINFO D0Y2TI Glionitrin A Investigative T94324 TARGETID T94324 T94324 FORMERID TTDR01338 T94324 UNIPROID HDA10_HUMAN T94324 TARGNAME Histone deacetylase 10 (HDAC10) T94324 GENENAME HDAC10 T94324 TARGTYPE Patented-recorded T94324 SYNONYMS Polyamine deacetylase HDAC10; HD10 T94324 FUNCTION Exhibits attenuated catalytic activity toward N(1),N(8)-diacetylspermidine and very low activity, if any, toward N(1)-acetylspermidine. Histone deacetylase activity has been observed in vitro. Has also been shown to be involved in MSH2 deacetylation. The physiological relevance of protein/histone deacetylase activity is unclear and could be very weak. May play a role in the promotion of late stages of autophagy, possibly autophagosome-lysosome fusion and/or lysosomal exocytosis in neuroblastoma cells. May play a role in homologous recombination. May promote DNA mismatch repair. Polyamine deacetylase (PDAC), which acts preferentially on N(8)-acetylspermidine, and also on acetylcadaverine and acetylputrescine. T94324 BIOCLASS Carbon-nitrogen hydrolase T94324 ECNUMBER EC 3.5.1.48 T94324 SEQUENCE MGTALVYHEDMTATRLLWDDPECEIERPERLTAALDRLRQRGLEQRCLRLSAREASEEELGLVHSPEYVSLVRETQVLGKEELQALSGQFDAIYFHPSTFHCARLAAGAGLQLVDAVLTGAVQNGLALVRPPGHHGQRAAANGFCVFNNVAIAAAHAKQKHGLHRILVVDWDVHHGQGIQYLFEDDPSVLYFSWHRYEHGRFWPFLRESDADAVGRGQGLGFTVNLPWNQVGMGNADYVAAFLHLLLPLAFEFDPELVLVSAGFDSAIGDPEGQMQATPECFAHLTQLLQVLAGGRVCAVLEGGYHLESLAESVCMTVQTLLGDPAPPLSGPMAPCQSALESIQSARAAQAPHWKSLQQQDVTAVPMSPSSHSPEGRPPPLLPGGPVCKAAASAPSSLLDQPCLCPAPSVRTAVALTTPDITLVLPPDVIQQEASALREETEAWARPHESLAREEALTALGKLLYLLDGMLDGQVNSGIAATPASAAAATLDVAVRRGLSHGAQRLLCVALGQLDRPPDLAHDGRSLWLNIRGKEAAALSMFHVSTPLPVMTGGFLSCILGLVLPLAYGFQPDLVLVALGPGHGLQGPHAALLAAMLRGLAGGRVLALLEENSTPQLAGILARVLNGEAPPSLGPSSVASPEDVQALMYLRGQLEPQWKMLQCHPHLVA T94324 DRUGINFO D0LN1T PMID29671355-Compound-8 Patented T94324 DRUGINFO D0N2DK PMID29671355-Compound-44 Patented T94324 DRUGINFO D0CH8Q PMID29671355-Compound-56 Patented T94324 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T94324 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T94324 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T94324 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T94324 DRUGINFO D01YBR ST-3050 Investigative T94324 DRUGINFO D0N9AK ST-2986 Investigative T94324 DRUGINFO D00KFF 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative T94324 DRUGINFO D00SEE 7-Mercapto-heptanoic acid phenylamide Investigative T94324 DRUGINFO D00ZSD 6-benzenesulfinylhexanoic acid hydroxamide Investigative T94324 DRUGINFO D01MFV N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative T94324 DRUGINFO D01XWZ 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative T94324 DRUGINFO D01XXN N-Hydroxy-4-phenylacetylamino-benzamide Investigative T94324 DRUGINFO D02MQM 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative T94324 DRUGINFO D02UTC N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative T94324 DRUGINFO D02WZK 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T94324 DRUGINFO D04GGW Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative T94324 DRUGINFO D04HSS N-(6-Mercapto-hexyl)-benzamide Investigative T94324 DRUGINFO D04NSP 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T94324 DRUGINFO D04ZDI N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative T94324 DRUGINFO D05AHZ 6-benzenesulfonylhexanoic acid hydroxamide Investigative T94324 DRUGINFO D05FEJ 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative T94324 DRUGINFO D05GVY Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative T94324 DRUGINFO D05LLX 4-Butyrylamino-N-hydroxy-benzamide Investigative T94324 DRUGINFO D05VFP 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T94324 DRUGINFO D05XAN 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative T94324 DRUGINFO D06IQB 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative T94324 DRUGINFO D06VBN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative T94324 DRUGINFO D06XNP 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative T94324 DRUGINFO D07FJU 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative T94324 DRUGINFO D09YBN 6-Phenoxy-hexane-1-thiol Investigative T94324 DRUGINFO D09ZNU 4-Benzoylamino-N-hydroxy-benzamide Investigative T94324 DRUGINFO D0A5LS 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative T94324 DRUGINFO D0AX7B 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative T94324 DRUGINFO D0B2ZJ 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative T94324 DRUGINFO D0B3ZM 6-Mercapto-hexanoic acid phenylamide Investigative T94324 DRUGINFO D0C0VP Cyclostellettamine derivative Investigative T94324 DRUGINFO D0C2KD N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative T94324 DRUGINFO D0D2KE 5-Mercapto-pentanoic acid phenylamide Investigative T94324 DRUGINFO D0E8KR Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative T94324 DRUGINFO D0F0KS N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative T94324 DRUGINFO D0H1FZ 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative T94324 DRUGINFO D0KE3I (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative T94324 DRUGINFO D0QO0L N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative T94324 DRUGINFO D0R4BS N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative T94324 DRUGINFO D0R5VG N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative T94324 DRUGINFO D0RU1X 8-Oxo-8-phenyl-octanoic acid Investigative T94324 DRUGINFO D0S7WQ N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative T94324 DRUGINFO D0S9JF 6-phenylsulfanylhexanoic acid hydroxamide Investigative T94324 DRUGINFO D0T0SK ST-2987 Investigative T94324 DRUGINFO D0T4IY 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative T94324 DRUGINFO D0V2ZO 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative T94324 DRUGINFO D0XZ9Q 8-Mercapto-octanoic acid phenylamide Investigative T94324 DRUGINFO D0YY9M N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative T94324 DRUGINFO D0Z3BM 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative T94324 DRUGINFO D0Z5KX 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative T94324 DRUGINFO D0Z7YS N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative T94324 DRUGINFO D0N0TS PSAMMAPLIN A Investigative T77236 TARGETID T77236 T77236 FORMERID TTDR01032 T77236 UNIPROID CATF_HUMAN T77236 TARGNAME Cathepsin F (CTSF) T77236 GENENAME CTSF T77236 TARGTYPE Patented-recorded T77236 SYNONYMS CATSF T77236 FUNCTION Has also been implicated in tumor invasion and metastasis. Thiol protease which is believed to participate in intracellular degradation and turnover of proteins. T77236 PDBSTRUC 1M6D; 1D5U T77236 BIOCLASS Peptidase T77236 ECNUMBER EC 3.4.22.41 T77236 SEQUENCE MAPWLQLLSLLGLLPGAVAAPAQPRAASFQAWGPPSPELLAPTRFALEMFNRGRAAGTRAVLGLVRGRVRRAGQGSLYSLEATLEEPPCNDPMVCRLPVSKKTLLCSFQVLDELGRHVLLRKDCGPVDTKVPGAGEPKSAFTQGSAMISSLSQNHPDNRNETFSSVISLLNEDPLSQDLPVKMASIFKNFVITYNRTYESKEEARWRLSVFVNNMVRAQKIQALDRGTAQYGVTKFSDLTEEEFRTIYLNTLLRKEPGNKMKQAKSVGDLAPPEWDWRSKGAVTKVKDQGMCGSCWAFSVTGNVEGQWFLNQGTLLSLSEQELLDCDKMDKACMGGLPSNAYSAIKNLGGLETEDDYSYQGHMQSCNFSAEKAKVYINDSVELSQNEQKLAAWLAKRGPISVAINAFGMQFYRHGISRPLRPLCSPWLIDHAVLLVGYGNRSDVPFWAIKNSWGTDWGEKGYYYLHRGSGACGVNTMASSAVVD T77236 DRUGINFO D05OIU PMID27998201-Compound-5 Patented T77236 DRUGINFO D06XCD PMID27998201-Compound-12 Patented T77236 DRUGINFO D0L4OT HOMOPHENYLALANINYLMETHANE Investigative T77236 DRUGINFO D0X6WQ BENZOYL-TYROSINE-ALANINE-METHYL KETONE Investigative T77236 DRUGINFO D06WQP PMID22686657C(R)-26 Investigative T77236 DRUGINFO D0B5IL WRR-99 Investigative T77236 DRUGINFO D0L5WS Benzoyl-Arginine-Alanine-Methyl Ketone Investigative T77236 DRUGINFO D0T0IX WRR-112 Investigative T93653 TARGETID T93653 T93653 FORMERID TTDI02353 T93653 UNIPROID CATL2_HUMAN T93653 TARGNAME Cathepsin V (CTSV) T93653 GENENAME CTSV T93653 TARGTYPE Patented-recorded T93653 SYNONYMS UNQ268/PRO305; Cathepsin U; Cathepsin L2; CTSU; CTSL2; CATL2 T93653 FUNCTION May have an important role in corneal physiology. Cysteine protease. T93653 PDBSTRUC 3KFQ; 3H6S; 1FH0 T93653 BIOCLASS Peptidase T93653 ECNUMBER EC 3.4.22.43 T93653 SEQUENCE MNLSLVLAAFCLGIASAVPKFDQNLDTKWYQWKATHRRLYGANEEGWRRAVWEKNMKMIELHNGEYSQGKHGFTMAMNAFGDMTNEEFRQMMGCFRNQKFRKGKVFREPLFLDLPKSVDWRKKGYVTPVKNQKQCGSCWAFSATGALEGQMFRKTGKLVSLSEQNLVDCSRPQGNQGCNGGFMARAFQYVKENGGLDSEESYPYVAVDEICKYRPENSVANDTGFTVVAPGKEKALMKAVATVGPISVAMDAGHSSFQFYKSGIYFEPDCSSKNLDHGVLVVGYGFEGANSNNSKYWLVKNSWGPEWGSNGYVKIAKDKNNHCGIATAASYPNV T93653 DRUGINFO D06XCD PMID27998201-Compound-12 Patented T93653 DRUGINFO D04URI PMID21277783C7 Investigative T30803 TARGETID T30803 T30803 FORMERID TTDI00816 T30803 UNIPROID GSHR_HUMAN T30803 TARGNAME Glutathione reductase (GR) T30803 GENENAME GSR T30803 TARGTYPE Patented-recorded T30803 SYNONYMS Glutathione reductase, mitochondrial; GRase; GRD1; GLUR T30803 FUNCTION Maintains high levels of reduced glutathione in the cytosol. T30803 PDBSTRUC 5GRT; 4GRT; 4GR1; 3SQP; 3GRT T30803 BIOCLASS Sulfur donor oxidoreductase T30803 ECNUMBER EC 1.8.1.7 T30803 SEQUENCE MALLPRALSAGAGPSWRRAARAFRGFLLLLPEPAALTRALSRAMACRQEPQPQGPPPAAGAVASYDYLVIGGGSGGLASARRAAELGARAAVVESHKLGGTCVNVGCVPKKVMWNTAVHSEFMHDHADYGFPSCEGKFNWRVIKEKRDAYVSRLNAIYQNNLTKSHIEIIRGHAAFTSDPKPTIEVSGKKYTAPHILIATGGMPSTPHESQIPGASLGITSDGFFQLEELPGRSVIVGAGYIAVEMAGILSALGSKTSLMIRHDKVLRSFDSMISTNCTEELENAGVEVLKFSQVKEVKKTLSGLEVSMVTAVPGRLPVMTMIPDVDCLLWAIGRVPNTKDLSLNKLGIQTDDKGHIIVDEFQNTNVKGIYAVGDVCGKALLTPVAIAAGRKLAHRLFEYKEDSKLDYNNIPTVVFSHPPIGTVGLTEDEAIHKYGIENVKTYSTSFTPMYHAVTKRKTKCVMKMVCANKEEKVVGIHMQGLGCDEMLQGFAVAVKMGATKADFDNTVAIHPTSSEELVTLR T30803 DRUGINFO D0V4TY Oxidized glutathione Approved T30803 DRUGINFO D02NYT Golden phosphorous acetyletic compound 2 Patented T30803 DRUGINFO D03BPZ Terpyridineplatinum(II) complexe 3 Patented T30803 DRUGINFO D05SHW Terpyridineplatinum(II) complexe 4 Patented T30803 DRUGINFO D0W1DK Golden phosphorous acetyletic compound 1 Patented T30803 DRUGINFO D0Z2MX Acyl oxymethyl acrylamide ester derivative 1 Patented T30803 DRUGINFO D03MJM Trans-(R(S))-2-Hydroxy-1-phenylethyl nitrate Investigative T30803 DRUGINFO D06ZXT N-6547 Investigative T30803 DRUGINFO D07FGO 3,6-Dihydroxy-Xanthene-9-Propionic Acid Investigative T30803 DRUGINFO D0F4SI N-9xxx Investigative T30803 DRUGINFO D0K1AW Meta-Nitro-Tyrosine Investigative T30803 DRUGINFO D0L1AV Trans-(1S(R),2S(R))-2-Hydroxycyclooctyl nitrate Investigative T30803 DRUGINFO D0P5LX N-6060 Investigative T30803 DRUGINFO D0T9NZ Glutathionylspermidine Disulfide Investigative T30803 DRUGINFO D0V8FG 4-nitrobenzo[c][1,2,5]thiadiazole Investigative T30803 DRUGINFO D0W4IK 3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol Investigative T30803 DRUGINFO D0YQ0G 2,4,6 trinitrobenzene sulfonate 1,3-bis (2-chlorethyl)-1-nitrosourea Investigative T30803 DRUGINFO D0I8HK 1-(2'-chlorophenyl)penta-1,4-dien-3-one Investigative T30803 DRUGINFO D0E8JM 3-Sulfinoalanine Investigative T30803 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T30803 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T66925 TARGETID T66925 T66925 UNIPROID F13A_HUMAN T66925 TARGNAME Coagulation factor XIIIA (F13A1) T66925 GENENAME F13A1 T66925 TARGTYPE Patented-recorded T66925 SYNONYMS Transglutaminase A chain; Protein-glutamine gamma-glutamyltransferase A chain; F13A; Coagulation factor XIII A chain T66925 FUNCTION Cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. T66925 PDBSTRUC 5MHO; 5MHN; 5MHM; 5MHL; 4KTY T66925 BIOCLASS Acyltransferase T66925 ECNUMBER EC 2.3.2.13 T66925 SEQUENCE MSETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVVPRGVNLQEFLNVTSVHLFKERWDTNKVDHHTDKYENNKLIVRRGQSFYVQIDFSRPYDPRRDLFRVEYVIGRYPQENKGTYIPVPIVSELQSGKWGAKIVMREDRSVRLSIQSSPKCIVGKFRMYVAVWTPYGVLRTSRNPETDTYILFNPWCEDDAVYLDNEKEREEYVLNDIGVIFYGEVNDIKTRSWSYGQFEDGILDTCLYVMDRAQMDLSGRGNPIKVSRVGSAMVNAKDDEGVLVGSWDNIYAYGVPPSAWTGSVDILLEYRSSENPVRYGQCWVFAGVFNTFLRCLGIPARIVTNYFSAHDNDANLQMDIFLEEDGNVNSKLTKDSVWNYHCWNEAWMTRPDLPVGFGGWQAVDSTPQENSDGMYRCGPASVQAIKHGHVCFQFDAPFVFAEVNSDLIYITAKKDGTHVVENVDATHIGKLIVTKQIGGDGMMDITDTYKFQEGQEEERLALETALMYGAKKPLNTEGVMKSRSNVDMDFEVENAVLGKDFKLSITFRNNSHNRYTITAYLSANITFYTGVPKAEFKKETFDVTLEPLSFKKEAVLIQAGEYMGQLLEQASLHFFVTARINETRDVLAKQKSTVLTIPEIIIKVRGTQVVGSDMTVTVQFTNPLKETLRNVWVHLDGPGVTRPMKKMFREIRPNSTVQWEEVCRPWVSGHRKLIASMSSDSLRHVYGELDVQIQRRPSM T66925 DRUGINFO D0KK6L PMID26560530-Compound-13 Patented T98459 TARGETID T98459 T98459 FORMERID TTDR00152 T98459 UNIPROID CCNB1_HUMAN T98459 TARGNAME G2/mitotic-specific cyclin B1 (CCNB1) T98459 GENENAME CCNB1 T98459 TARGTYPE Patented-recorded T98459 SYNONYMS G2/mitotic-specific cyclin-B1; Cyclin B1; CCNB T98459 FUNCTION Essential for the control of the cell cycle at the G2/M (mitosis) transition. T98459 PDBSTRUC 6GU4; 6GU3; 6GU2; 5LQF; 5HQ0 T98459 BIOCLASS Eukaryotic nuclear pore complex T98459 SEQUENCE MALRVTRNSKINAENKAKINMAGAKRVPTAPAATSKPGLRPRTALGDIGNKVSEQLQAKMPMKKEAKPSATGKVIDKKLPKPLEKVPMLVPVPVSEPVPEPEPEPEPEPVKEEKLSPEPILVDTASPSPMETSGCAPAEEDLCQAFSDVILAVNDVDAEDGADPNLCSEYVKDIYAYLRQLEEEQAVRPKYLLGREVTGNMRAILIDWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKKMLQLVGVTAMFIASKYEEMYPPEIGDFAFVTDNTYTKHQIRQMEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDYDMVHFPPSQIAAGAFCLALKILDNGEWTPTLQHYLSYTEESLLPVMQHLAKNVVMVNQGLTKHMTVKNKYATSKHAKISTLPQLNSALVQDLAKAVAKV T98459 DRUGINFO D00PWQ KENPAULLONE Patented T98459 DRUGINFO D07HRP 3,4-bis(indol-3-yl)maleimide derivative Investigative T98459 DRUGINFO D0L5GS 4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine Investigative T98459 DRUGINFO D0Y7QZ 4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine Investigative T98459 DRUGINFO D0DR8N AZAKENPAULLONE Investigative T98459 DRUGINFO D0TF9P Thieno analogue of kenpaullone Investigative T98459 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T98459 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T98459 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T98459 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T98459 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T98459 DRUGINFO D0L8HO RO-316233 Investigative T07217 TARGETID T07217 T07217 FORMERID TTDR00476 T07217 UNIPROID FABP4_HUMAN T07217 TARGNAME Fatty acid-binding protein 4 (FABP4) T07217 GENENAME FABP4 T07217 TARGTYPE Patented-recorded T07217 SYNONYMS Fatty acid-binding protein, adipocyte; Adipocyte-type fatty acid-binding protein; Adipocyte lipid-binding protein; Adipocyte fatty-acid-binding protein; Adipocyte fatty binding protein; ALBP; AFABP; A-FABP T07217 FUNCTION Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus. Lipid transport protein in adipocytes. T07217 PDBSTRUC 6AYL; 5Y13; 5Y12; 5Y0X; 5Y0G T07217 BIOCLASS Fatty acid binding protein T07217 SEQUENCE MCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERA T07217 DRUGINFO D05UGS PMID27109571-Compound-11 Patented T07217 DRUGINFO D08SLP PMID27109571-Compound-9 Patented T07217 DRUGINFO D0L4EU PMID27109571-Compound-8 Patented T07217 DRUGINFO D0MO1P PMID27109571-Compound-10 Patented T07217 DRUGINFO D0Q9LM PMID27109571-Compound-7 Patented T07217 DRUGINFO D00KCT PMID27109571-Compound-27 Patented T07217 DRUGINFO D00RDL PMID27109571-Compound-31 Patented T07217 DRUGINFO D01CDK PMID27109571-Compound-16 Patented T07217 DRUGINFO D01GOO PMID27109571-Compound-14 Patented T07217 DRUGINFO D01NVM PMID27109571-Compound-25 Patented T07217 DRUGINFO D01TJW PMID27109571-Compound-30 Patented T07217 DRUGINFO D03CJT PMID27109571-Compound-29 Patented T07217 DRUGINFO D05WXM PMID27109571-Compound-18 Patented T07217 DRUGINFO D05XAT PMID27109571-Compound-28 Patented T07217 DRUGINFO D06JEA PMID27109571-Compound-20 Patented T07217 DRUGINFO D07PLJ PMID27109571-Compound-17 Patented T07217 DRUGINFO D08IIV PMID27109571-Compound-22 Patented T07217 DRUGINFO D08SNH PMID27109571-Compound-15 Patented T07217 DRUGINFO D09VOD PMID27109571-Compound-12 Patented T07217 DRUGINFO D0CT9O PMID27109571-Compound-26 Patented T07217 DRUGINFO D0ND3H PMID27109571-Compound-13 Patented T07217 DRUGINFO D0R9RK PMID27109571-Compound-23 Patented T07217 DRUGINFO D0RZ9C PMID27109571-Compound-19 Patented T07217 DRUGINFO D0SK0L PMID27109571-Compound-24 Patented T07217 DRUGINFO D0U2SI PMID27109571-Compound-21 Patented T07217 DRUGINFO D03DUX 2-(4-Methyl-indole-1-sulfonyl)-benzoic acid Investigative T07217 DRUGINFO D03LOG LINOLEIC ACID Investigative T07217 DRUGINFO D05GVL 2-(6-Methoxy-indole-1-sulfonyl)-benzoic acid Investigative T07217 DRUGINFO D07OKT 3-Carbazol-9-yl-propionic acid Investigative T07217 DRUGINFO D0H2UM 2-(5-Bromo-indole-1-sulfonyl)-benzoic acid Investigative T07217 DRUGINFO D0I1RP 2-(4-Fluoro-indole-1-sulfonyl)-benzoic acid Investigative T07217 DRUGINFO D0Y8JN 2-(3-Methyl-indole-1-sulfonyl)-benzoic acid Investigative T07217 DRUGINFO D0YW9C 1-benzyl-2,3-dimethyl-1H-indole-7-carboxylic acid Investigative T07217 DRUGINFO D00ORM 5-Carbazol-9-yl-pentanoic acid Investigative T07217 DRUGINFO D05JAH 4-Carbazol-9-yl-butyric acid Investigative T07217 DRUGINFO D08KLL 2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid Investigative T07217 DRUGINFO D0A4EA OLEIC ACID Investigative T07217 DRUGINFO D0C1DG 2-(Carbazole-9-sulfonyl)-benzoic acid Investigative T07217 DRUGINFO D0WF7I BMS-480404 Investigative T07217 DRUGINFO D02TVS Hexadecanoic acid Investigative T06792 TARGETID T06792 T06792 UNIPROID PSB9_HUMAN T06792 TARGNAME Proteasome beta-9 (PS beta-9) T06792 GENENAME PSMB9 T06792 TARGTYPE Patented-recorded T06792 SYNONYMS Really interesting new gene 12 protein; RING12; Proteasome subunit beta-1i; Proteasome subunit beta type-9; Proteasome chain 7; PSMB6i; Multicatalytic endopeptidase complex chain 7; Macropain chain 7; Low molecular mass protein 2; LMP2 T06792 FUNCTION The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB6 by PSMB9 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. T06792 PDBSTRUC 6AVO T06792 BIOCLASS Peptidase T06792 ECNUMBER EC 3.4.25.1 T06792 SEQUENCE MLRAGAPTGDLPRAGEVHTGTTIMAVEFDGGVVMGSDSRVSAGEAVVNRVFDKLSPLHERIYCALSGSAADAQAVADMAAYQLELHGIELEEPPLVLAAANVVRNISYKYREDLSAHLMVAGWDQREGGQVYGTLGGMLTRQPFAIGGSGSTFIYGYVDAAYKPGMSPEECRRFTTDAIALAMSRDGSSGGVIYLVTITAAGVDHRVILGNELPKFYDE T06792 DRUGINFO D0R8XD Peptide analog 14 Patented T06792 DRUGINFO D0B0GG Dipeptide analog 1 Patented T06792 DRUGINFO D01VMN PMID29865878-Compound-53 Patented T06792 DRUGINFO D03CMD PMID29865878-Compound-55 Patented T06792 DRUGINFO D0C2MH PMID29865878-Compound-46 Patented T06792 DRUGINFO D0K0GJ PMID29865878-Compound-48 Patented T06792 DRUGINFO D0NE8M PMID29865878-Compound-51 Patented T06792 DRUGINFO D0TU5R PMID29865878-Compound-49 Patented T06792 DRUGINFO D01OOO Peptide analog 41 Patented T06792 DRUGINFO D02PJI Peptide analog 21 Patented T06792 DRUGINFO D0T1YB Peptide analog 23 Patented T49031 TARGETID T49031 T49031 FORMERID TTDI03482 T49031 UNIPROID PSB5_HUMAN T49031 TARGNAME Proteasome beta-5 (PS beta-5) T49031 GENENAME PSMB5 T49031 TARGTYPE Patented-recorded T49031 SYNONYMS Proteasome subunit beta type-5; Proteasome subunit X; Proteasome subunit MB1; Proteasome epsilon chain; Proteasome chain 6; Multicatalytic endopeptidase complex epsilon chain; Macropain epsilon chain; MB1; LMPX T49031 FUNCTION Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB5 displays a chymotrypsin-like activity. T49031 PDBSTRUC 6MSK; 6MSJ; 6MSH; 6MSG; 6MSE T49031 BIOCLASS Peptidase T49031 ECNUMBER EC 3.4.25.1 T49031 SEQUENCE MALASVLERPLPVNQRGFFGLGGRADLLDLGPGSLSDGLSLAAPGWGVPEEPGIEMLHGTTTLAFKFRHGVIVAADSRATAGAYIASQTVKKVIEINPYLLGTMAGGAADCSFWERLLARQCRIYELRNKERISVAAASKLLANMVYQYKGMGLSMGTMICGWDKRGPGLYYVDSEGNRISGATFSVGSGSVYAYGVMDRGYSYDLEVEQAYDLARRAIYQATYRDAYSGGAVNLYHVREDGWIRVSSDNVADLHEKYSGSTP T49031 DRUGINFO D02SYR Peptide analog 27 Patented T49031 DRUGINFO D03JMZ Peptide analog 28 Patented T49031 DRUGINFO D05MVF Peptide analog 34 Patented T49031 DRUGINFO D06OXO Peptide analog 33 Patented T49031 DRUGINFO D07SSU Peptide analog 31 Patented T49031 DRUGINFO D08HPR PMID29865878-Compound-44 Patented T49031 DRUGINFO D09WUW PMID29865878-Compound-43 Patented T49031 DRUGINFO D0AR6B Peptide analog 13 Patented T49031 DRUGINFO D0DK3R Peptide analog 25 Patented T49031 DRUGINFO D0E6ED Peptide analog 11 Patented T49031 DRUGINFO D0L1TT Peptide analog 17 Patented T49031 DRUGINFO D0P8VL PMID29865878-Compound-8 Patented T49031 DRUGINFO D0Q0XN Peptide analog 19 Patented T49031 DRUGINFO D00GGB Peptide analog 37 Patented T49031 DRUGINFO D01GON Peptide analog 38 Patented T49031 DRUGINFO D02CQG Peptide analog 39 Patented T49031 DRUGINFO D0DY3A Peptide analog 36 Patented T49031 DRUGINFO D01VMN PMID29865878-Compound-53 Patented T49031 DRUGINFO D03CMD PMID29865878-Compound-55 Patented T49031 DRUGINFO D0C2MH PMID29865878-Compound-46 Patented T49031 DRUGINFO D0K0GJ PMID29865878-Compound-48 Patented T49031 DRUGINFO D0NE8M PMID29865878-Compound-51 Patented T49031 DRUGINFO D0TU5R PMID29865878-Compound-49 Patented T49031 DRUGINFO D01OOO Peptide analog 41 Patented T49031 DRUGINFO D02PJI Peptide analog 21 Patented T49031 DRUGINFO D0T1YB Peptide analog 23 Patented T49031 DRUGINFO D0Y6HD PMID24946214C3b Investigative T09022 TARGETID T09022 T09022 UNIPROID PSB10_HUMAN T09022 TARGNAME Proteasome beta-10 (PS beta-10) T09022 GENENAME PSMB10 T09022 TARGTYPE Patented-recorded T09022 SYNONYMS Proteasome subunit beta-2i; Proteasome subunit beta type-10; Proteasome MECl-1; Multicatalytic endopeptidase complex subunit MECl-1; Macropain subunit MECl-1; MECL1; Low molecular mass protein 10; LMP10 T09022 FUNCTION The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. T09022 PDBSTRUC 6HVW; 6HVV; 6HVU; 6HVT; 6HVS T09022 BIOCLASS Peptidase T09022 ECNUMBER EC 3.4.25.1 T09022 SEQUENCE MLKPALEPRGGFSFENCQRNASLERVLPGLKVPHARKTGTTIAGLVFQDGVILGADTRATNDSVVADKSCEKIHFIAPKIYCCGAGVAADAEMTTRMVASKMELHALSTGREPRVATVTRILRQTLFRYQGHVGASLIVGGVDLTGPQLYGVHPHGSYSRLPFTALGSGQDAALAVLEDRFQPNMTLEAAQGLLVEAVTAGILGDLGSGGNVDACVITKTGAKLLRTLSSPTEPVKRSGRYHFVPGTTAVLTQTVKPLTLELVEETVQAMEVE T09022 DRUGINFO D00GGB Peptide analog 37 Patented T09022 DRUGINFO D01GON Peptide analog 38 Patented T09022 DRUGINFO D0DY3A Peptide analog 36 Patented T09022 DRUGINFO D02PJI Peptide analog 21 Patented T09022 DRUGINFO D0T1YB Peptide analog 23 Patented T64205 TARGETID T64205 T64205 FORMERID TTDC00113 T64205 UNIPROID STAT1_HUMAN T64205 TARGNAME Signal transducer and activator of transcription 1 (STAT1) T64205 GENENAME STAT1 T64205 TARGTYPE Patented-recorded T64205 SYNONYMS Transcription factor ISGF-3 components p91/p84; Signal transducers and activators of transcription factor; Signal transducer and activator of transcription 1-alpha/beta; STAT-1; P91 T64205 FUNCTION Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signaling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state. Becomes activated in response to KITLG/SCF and KIT signaling. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. T64205 PDBSTRUC 3WWT; 2KA6; 1YVL; 1BF5 T64205 BIOCLASS Transcription factor T64205 SEQUENCE MSQWYELQQLDSKFLEQVHQLYDDSFPMEIRQYLAQWLEKQDWEHAANDVSFATIRFHDLLSQLDDQYSRFSLENNFLLQHNIRKSKRNLQDNFQEDPIQMSMIIYSCLKEERKILENAQRFNQAQSGNIQSTVMLDKQKELDSKVRNVKDKVMCIEHEIKSLEDLQDEYDFKCKTLQNREHETNGVAKSDQKQEQLLLKKMYLMLDNKRKEVVHKIIELLNVTELTQNALINDELVEWKRRQQSACIGGPPNACLDQLQNWFTIVAESLQQVRQQLKKLEELEQKYTYEHDPITKNKQVLWDRTFSLFQQLIQSSFVVERQPCMPTHPQRPLVLKTGVQFTVKLRLLVKLQELNYNLKVKVLFDKDVNERNTVKGFRKFNILGTHTKVMNMEESTNGSLAAEFRHLQLKEQKNAGTRTNEGPLIVTEELHSLSFETQLCQPGLVIDLETTSLPVVVISNVSQLPSGWASILWYNMLVAEPRNLSFFLTPPCARWAQLSEVLSWQFSSVTKRGLNVDQLNMLGEKLLGPNASPDGLIPWTRFCKENINDKNFPFWLWIESILELIKKHLLPLWNDGCIMGFISKERERALLKDQQPGTFLLRFSESSREGAITFTWVERSQNGGEPDFHAVEPYTKKELSAVTFPDIIRNYKVMAAENIPENPLKYLYPNIDKDHAFGKYYSRPKEAPEPMELDGPKGTGYIKTELISVSEVHPSRLQTTDNLLPMSPEEFDEVSRIVGSVEFDSMMNTV T64205 DRUGINFO D0JF5K Peptide analog 8 Patented T64205 DRUGINFO D0EZ6V Oxazole derivative 1 Patented T64205 DRUGINFO D0XQ3F Peptidomimetic analog 5 Patented T64205 DRUGINFO D01BVU Platinum IV complexe 1 Patented T64205 DRUGINFO D0TU0X PMID26394986-Compound-10 Patented T64205 DRUGINFO D03WRN AVT-02 UE Discontinued in Phase 2 T46685 TARGETID T46685 T46685 FORMERID TTDI00245 T46685 UNIPROID CLK1_HUMAN T46685 TARGNAME CDC-like kinase 1 (CLK1) T46685 GENENAME CLK1 T46685 TARGTYPE Patented-recorded T46685 SYNONYMS Dual specificity protein kinase CLK1; CLK; CDClike kinase 1 T46685 FUNCTION Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex and may be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing. Phosphorylates: SRSF1, SRSF3 and PTPN1. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells and adenovirus E1A pre-mRNA. Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. T46685 PDBSTRUC 6RAA; 6Q8P; 6Q8K; 6I5L; 6I5K T46685 BIOCLASS Kinase T46685 ECNUMBER EC 2.7.12.1 T46685 SEQUENCE MRHSKRTYCPDWDDKDWDYGKWRSSSSHKRRKRSHSSAQENKRCKYNHSKMCDSHYLESRSINEKDYHSRRYIDEYRNDYTQGCEPGHRQRDHESRYQNHSSKSSGRSGRSSYKSKHRIHHSTSHRRSHGKSHRRKRTRSVEDDEEGHLICQSGDVLSARYEIVDTLGEGAFGKVVECIDHKAGGRHVAVKIVKNVDRYCEAARSEIQVLEHLNTTDPNSTFRCVQMLEWFEHHGHICIVFELLGLSTYDFIKENGFLPFRLDHIRKMAYQICKSVNFLHSNKLTHTDLKPENILFVQSDYTEAYNPKIKRDERTLINPDIKVVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPCDVWSIGCILIEYYLGFTVFPTHDSKEHLAMMERILGPLPKHMIQKTRKRKYFHHDRLDWDEHSSAGRYVSRRCKPLKEFMLSQDVEHERLFDLIQKMLEYDPAKRITLREALKHPFFDLLKKSI T46685 DRUGINFO D06MBI TG003 Patented T46685 DRUGINFO D00BAJ KH-CB19 Investigative T46685 DRUGINFO D0UI7U ML315 Investigative T46685 DRUGINFO D06CXU PMID23642479C17 Investigative T46685 DRUGINFO D04IMY leucettine L41 Investigative T79155 TARGETID T79155 T79155 FORMERID TTDR00457 T79155 UNIPROID KLK7_HUMAN T79155 TARGNAME Kallikrein-7 (KLK7) T79155 GENENAME KLK7 T79155 TARGTYPE Patented-recorded T79155 SYNONYMS hK7; Stratum corneum chymotryptic enzyme; Serine protease 6; SCCE; PRSS6; HSCCE T79155 FUNCTION Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at '14-Tyr-|-Gln-15' and insulin B chain at '6-Leu-|-Cys-7', '16-Tyr-|-Leu-17', '25-Phe-|-Tyr-26' and '26-Tyr-|-Thr-27'. Could play a role in the activation of precursors to inflammatory cytokines. May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. T79155 PDBSTRUC 5YJK; 5Y9L; 5FAH; 3BSQ; 2QXJ T79155 BIOCLASS Peptidase T79155 ECNUMBER EC 3.4.21.117 T79155 SEQUENCE MARSLLLPLQILLLSLALETAGEEAQGDKIIDGAPCARGSHPWQVALLSGNQLHCGGVLVNERWVLTAAHCKMNEYTVHLGSDTLGDRRAQRIKASKSFRHPGYSTQTHVNDLMLVKLNSQARLSSMVKKVRLPSRCEPPGTTCTVSGWGTTTSPDVTFPSDLMCVDVKLISPQDCTKVYKDLLENSMLCAGIPDSKKNACNGDSGGPLVCRGTLQGLVSWGTFPCGQPNDPGVYTQVCKFTKWINDTMKKHR T79155 DRUGINFO D01JCX Antileukoprotease (ALP) Investigative T79155 DRUGINFO D00LOL PMID23849879C3 Investigative T79155 DRUGINFO D07OQF PMID25489658C4d Investigative T04123 TARGETID T04123 T04123 UNIPROID PPP5_HUMAN T04123 TARGNAME Serine/threonine-protein phosphatase 5 (PPP5C) T04123 GENENAME PPP5C T04123 TARGTYPE Patented-recorded T04123 SYNONYMS Protein phosphatase T; PPT protein; PPP5; PP5; PP-T T04123 FUNCTION Implicated in wide ranging cellular processes, including apoptosis, differentiation, DNA damage response, cell survival, regulation of ion channels or circadian rhythms, in response to steroid and thyroid hormones, calcium, fatty acids, TGF-beta as well as oxidative and genotoxic stresses. Participates in the control of DNA damage response mechanisms such as checkpoint activation and DNA damage repair through, for instance, the regulation ATM/ATR-signaling and dephosphorylation of PRKDC and TP53BP1. Inhibits ASK1/MAP3K5-mediated apoptosis induced by oxidative stress. Plays a positive role in adipogenesis, mainly through the dephosphorylation and activation of PPARG transactivation function. Also dephosphorylates and inhibits the anti-adipogenic effect of NR3C1. Regulates the circadian rhythms, through the dephosphorylation and activation of CSNK1E. May modulate TGF-beta signaling pathway by the regulation of SMAD3 phosphorylation and protein expression levels. Dephosphorylates and may play a role in the regulation of TAU/MAPT. Through their dephosphorylation, may play a role in the regulation of ions channels such as KCNH2. Serine/threonine-protein phosphatase that dephosphorylates a myriad of proteins involved in different signaling pathways including the kinases CSNK1E, ASK1/MAP3K5, PRKDC and RAF1, the nuclear receptors NR3C1, PPARG, ESR1 and ESR2, SMAD proteins and TAU/MAPT. T04123 PDBSTRUC 5WG8; 5UI1; 5HPE; 4ZX2; 4ZVZ T04123 BIOCLASS Phosphoric monoester hydrolase T04123 ECNUMBER EC 3.1.3.16 T04123 SEQUENCE MAMAEGERTECAEPPRDEPPADGALKRAEELKTQANDYFKAKDYENAIKFYSQAIELNPSNAIYYGNRSLAYLRTECYGYALGDATRAIELDKKYIKGYYRRAASNMALGKFRAALRDYETVVKVKPHDKDAKMKYQECNKIVKQKAFERAIAGDEHKRSVVDSLDIESMTIEDEYSGPKLEDGKVTISFMKELMQWYKDQKKLHRKCAYQILVQVKEVLSKLSTLVETTLKETEKITVCGDTHGQFYDLLNIFELNGLPSETNPYIFNGDFVDRGSFSVEVILTLFGFKLLYPDHFHLLRGNHETDNMNQIYGFEGEVKAKYTAQMYELFSEVFEWLPLAQCINGKVLIMHGGLFSEDGVTLDDIRKIERNRQPPDSGPMCDLLWSDPQPQNGRSISKRGVSCQFGPDVTKAFLEENNLDYIIRSHEVKAEGYEVAHGGRCVTVFSAPNYCDQMGNKASYIHLQGSDLRPQFHQFTAVPHPNVKPMAYANTLLQLGMM T20600 TARGETID T20600 T20600 UNIPROID CASP6_HUMAN T20600 TARGNAME Caspase-6 (CASP6) T20600 GENENAME CASP6 T20600 TARGTYPE Patented-recorded T20600 SYNONYMS MCH2; Caspase-6 subunit p18; Caspase-6 subunit p11; CASP-6; Apoptotic protease Mch-2 T20600 FUNCTION Cleaves poly(ADP-ribose) polymerase in vitro, as well as lamins. Overexpression promotes programmed cell death. Involved in the activation cascade of caspases responsible for apoptosis execution. T20600 PDBSTRUC 6DEV; 6DEU; 4NBN; 4NBL; 4NBK T20600 BIOCLASS Peptidase T20600 ECNUMBER EC 3.4.22.59 T20600 SEQUENCE MSSASGLRRGHPAGGEENMTETDAFYKREMFDPAEKYKMDHRRRGIALIFNHERFFWHLTLPERRGTCADRDNLTRRFSDLGFEVKCFNDLKAEELLLKIHEVSTVSHADADCFVCVFLSHGEGNHIYAYDAKIEIQTLTGLFKGDKCHSLVGKPKIFIIQACRGNQHDVPVIPLDVVDNQTEKLDTNITEVDAASVYTLPAGADFLMCYSVAEGYYSHRETVNGSWYIQDLCEMLGKYGSSLEFTELLTLVNRKVSQRRVDFCKDPSAIGKKQVPCFASMLTKKLHFFPKSN T21507 TARGETID T21507 T21507 FORMERID TTDR00309 T21507 UNIPROID FABP5_HUMAN T21507 TARGNAME Fatty acid-binding protein 5 (FABP5) T21507 GENENAME FABP5 T21507 TARGTYPE Patented-recorded T21507 SYNONYMS Psoriasis-associated fatty acid-binding protein homolog; PA-FABP; Fatty acid-binding protein, epidermal; Fatty Acid BindingProtein mal1; Epidermal-type fatty acid-binding protein; E-FABP T21507 FUNCTION Intracellular carrier for long-chain fatty acids and related active lipids, such as the endocannabinoid, that regulates the metabolism and actions of the ligands they bind. In addition to the cytosolic transport, selectively delivers specific fatty acids from the cytosol to the nucleus, wherein they activate nuclear receptors. Delivers retinoic acid to the nuclear receptor peroxisome proliferator-activated receptor delta; which promotes proliferation and survival. May also serve as a synaptic carrier of endocannabinoid at central synapses and thus controls retrograde endocannabinoid signaling. Modulates inflammation by regulating PTGES induction via NF-kappa-B activation, and prostaglandin E2 (PGE2) biosynthesis during inflammation. May be involved in keratinocyte differentiation. T21507 PDBSTRUC 5UR9; 5HZ5; 4LKT; 4LKP; 4AZR T21507 BIOCLASS Fatty acid binding protein T21507 SEQUENCE MATVQQLEGRWRLVDSKGFDEYMKELGVGIALRKMGAMAKPDCIITCDGKNLTIKTESTLKTTQFSCTLGEKFEETTADGRKTQTVCNFTDGALVQHQEWDGKESTITRKLKDGKLVVECVMNNVTCTRIYEKVE T21507 DRUGINFO D00KCT PMID27109571-Compound-27 Patented T21507 DRUGINFO D00RDL PMID27109571-Compound-31 Patented T21507 DRUGINFO D01CDK PMID27109571-Compound-16 Patented T21507 DRUGINFO D01GOO PMID27109571-Compound-14 Patented T21507 DRUGINFO D01NVM PMID27109571-Compound-25 Patented T21507 DRUGINFO D01TJW PMID27109571-Compound-30 Patented T21507 DRUGINFO D03CJT PMID27109571-Compound-29 Patented T21507 DRUGINFO D05WXM PMID27109571-Compound-18 Patented T21507 DRUGINFO D05XAT PMID27109571-Compound-28 Patented T21507 DRUGINFO D06JEA PMID27109571-Compound-20 Patented T21507 DRUGINFO D07PLJ PMID27109571-Compound-17 Patented T21507 DRUGINFO D08IIV PMID27109571-Compound-22 Patented T21507 DRUGINFO D08SNH PMID27109571-Compound-15 Patented T21507 DRUGINFO D09VOD PMID27109571-Compound-12 Patented T21507 DRUGINFO D0CT9O PMID27109571-Compound-26 Patented T21507 DRUGINFO D0ND3H PMID27109571-Compound-13 Patented T21507 DRUGINFO D0R9RK PMID27109571-Compound-23 Patented T21507 DRUGINFO D0RZ9C PMID27109571-Compound-19 Patented T21507 DRUGINFO D0SK0L PMID27109571-Compound-24 Patented T21507 DRUGINFO D0U2SI PMID27109571-Compound-21 Patented T21507 DRUGINFO D00ORM 5-Carbazol-9-yl-pentanoic acid Investigative T21507 DRUGINFO D05JAH 4-Carbazol-9-yl-butyric acid Investigative T21507 DRUGINFO D08KLL 2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid Investigative T21507 DRUGINFO D0C1DG 2-(Carbazole-9-sulfonyl)-benzoic acid Investigative T21507 DRUGINFO D0WF7I BMS-480404 Investigative T21507 DRUGINFO D02TVS Hexadecanoic acid Investigative T67812 TARGETID T67812 T67812 UNIPROID MGAT2_HUMAN T67812 TARGNAME Mannoside acetylglucosaminyltransferase 2 (MGAT2) T67812 GENENAME MGAT2 T67812 TARGTYPE Patented-recorded T67812 SYNONYMS N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase II; GlcNAc-T II; GNT-II; Beta-1,2-N-acetylglucosaminyltransferase II; Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase T67812 FUNCTION Catalyzes the transfer of N-acetylglucosamine (GlcNAc) onto the free terminal mannose moiety in the core structure of the nascent N-linked glycan chain, giving rise to the second branch in complex glycans. Plays an essential role in protein N-glycosylation. T67812 PDBSTRUC 5VCS; 5VCR; 5VCM T67812 BIOCLASS Glycosyltransferases T67812 ECNUMBER EC 2.4.1.143 T67812 SEQUENCE MRFRIYKRKVLILTLVVAACGFVLWSSNGRQRKNEALAPPLLDAEPARGAGGRGGDHPSVAVGIRRVSNVSAASLVPAVPQPEADNLTLRYRSLVYQLNFDQTLRNVDKAGTWAPRELVLVVQVHNRPEYLRLLLDSLRKAQGIDNVLVIFSHDFWSTEINQLIAGVNFCPVLQVFFPFSIQLYPNEFPGSDPRDCPRDLPKNAALKLGCINAEYPDSFGHYREAKFSQTKHHWWWKLHFVWERVKILRDYAGLILFLEEDHYLAPDFYHVFKKMWKLKQQECPECDVLSLGTYSASRSFYGMADKVDVKTWKSTEHNMGLALTRNAYQKLIECTDTFCTYDDYNWDWTLQYLTVSCLPKFWKVLVPQIPRIFHAGDCGMHHKKTCRPSTQSAQIESLLNNNKQYMFPETLTISEKFTVVAISPPRKNGGWGDIRDHELCKSYRRLQ T67812 DRUGINFO D0B7JY Phenylmethanesulfonamide derivative 1 Patented T67812 DRUGINFO D0F2KN Dihydropyrimidinone derivative 3 Patented T67812 DRUGINFO D0MH7K Pyrimidine-4(3H)-one derivative 1 Patented T67812 DRUGINFO D0NY3W N-containing heterocyclic derivative 1 Patented T67812 DRUGINFO D0RC4W Bicyclic pyrimidine derivative 1 Patented T67812 DRUGINFO D0U2WQ Dihydropyrimidinone derivative 4 Patented T55986 TARGETID T55986 T55986 UNIPROID PSB7_HUMAN T55986 TARGNAME Proteasome beta-2 (PS beta-2) T55986 GENENAME PSMB7 T55986 TARGTYPE Patented-recorded T55986 SYNONYMS Proteasome subunit beta type-7; Proteasome subunit Z; Multicatalytic endopeptidase complex chain Z; Macropain chain Z T55986 FUNCTION Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB7 displays a trypsin-like activity. T55986 PDBSTRUC 6MSK; 6MSJ; 6MSH; 6MSG; 6MSE T55986 BIOCLASS Peptidase T55986 ECNUMBER EC 3.4.25.1 T55986 SEQUENCE MAAVSVYAPPVGGFSFDNCRRNAVLEADFAKRGYKLPKVRKTGTTIAGVVYKDGIVLGADTRATEGMVVADKNCSKIHFISPNIYCCGAGTAADTDMTTQLISSNLELHSLSTGRLPRVVTANRMLKQMLFRYQGYIGAALVLGGVDVTGPHLYSIYPHGSTDKLPYVTMGSGSLAAMAVFEDKFRPDMEEEEAKNLVSEAIAAGIFNDLGSGSNIDLCVISKNKLDFLRPYTVPNKKGTRLGRYRCEKGTTAVLTEKITPLEIEVLEETVQTMDTS T55986 DRUGINFO D00GGB Peptide analog 37 Patented T55986 DRUGINFO D01GON Peptide analog 38 Patented T55986 DRUGINFO D02CQG Peptide analog 39 Patented T55986 DRUGINFO D0DY3A Peptide analog 36 Patented T55986 DRUGINFO D01OOO Peptide analog 41 Patented T55986 DRUGINFO D02PJI Peptide analog 21 Patented T55986 DRUGINFO D0T1YB Peptide analog 23 Patented T29355 TARGETID T29355 T29355 UNIPROID DNM3A_HUMAN T29355 TARGNAME DNA [cytosine-5]-methyltransferase 3A (DNMT3A) T29355 GENENAME DNMT3A T29355 TARGTYPE Patented-recorded T29355 SYNONYMS M.HsaIIIA; Dnmt3a; DNA methyltransferase HsaIIIA; DNA MTase HsaIIIA; DNA (cytosine-5)-methyltransferase 3A T29355 FUNCTION DNA methylation is coordinated with methylation of histones. It modifies DNA in a non-processive manner and also methylates non-CpG sites. May preferentially methylate DNA linker between 2 nucleosomal cores and is inhibited by histone H1. Plays a role in paternal and maternal imprinting. Required for methylation of most imprinted loci in germ cells. Acts as a transcriptional corepressor for ZBTB18. Recruited to trimethylated 'Lys-36' of histone H3 (H3K36me3) sites. Can actively repress transcription through the recruitment of HDAC activity. Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development. T29355 PDBSTRUC 6F57; 6BRR; 5YX2; 4U7T; 4U7P T29355 BIOCLASS Methyltransferase T29355 ECNUMBER EC 2.1.1.37 T29355 SEQUENCE MPAMPSSGPGDTSSSAAEREEDRKDGEEQEEPRGKEERQEPSTTARKVGRPGRKRKHPPVESGDTPKDPAVISKSPSMAQDSGASELLPNGDLEKRSEPQPEEGSPAGGQKGGAPAEGEGAAETLPEASRAVENGCCTPKEGRGAPAEAGKEQKETNIESMKMEGSRGRLRGGLGWESSLRQRPMPRLTFQAGDPYYISKRKRDEWLARWKREAEKKAKVIAGMNAVEENQGPGESQKVEEASPPAVQQPTDPASPTVATTPEPVGSDAGDKNATKAGDDEPEYEDGRGFGIGELVWGKLRGFSWWPGRIVSWWMTGRSRAAEGTRWVMWFGDGKFSVVCVEKLMPLSSFCSAFHQATYNKQPMYRKAIYEVLQVASSRAGKLFPVCHDSDESDTAKAVEVQNKPMIEWALGGFQPSGPKGLEPPEEEKNPYKEVYTDMWVEPEAAAYAPPPPAKKPRKSTAEKPKVKEIIDERTRERLVYEVRQKCRNIEDICISCGSLNVTLEHPLFVGGMCQNCKNCFLECAYQYDDDGYQSYCTICCGGREVLMCGNNNCCRCFCVECVDLLVGPGAAQAAIKEDPWNCYMCGHKGTYGLLRRREDWPSRLQMFFANNHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDISRFLESNPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVRTITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQRLLGRSWSVPVIRHLFAPLKEYFACV T29355 DRUGINFO D02VTV PMID27376512-Compound-Figure3CN Patented T29355 DRUGINFO D03LZO PMID27376512-Compound-Figure3CG Patented T29355 DRUGINFO D0F8AB PMID27376512-Compound-Figure3CM Patented T29355 DRUGINFO D01LUJ PMID27376512-Compound-Figure2aExample1 Patented T29355 DRUGINFO D02WRM PMID27376512-Compound-MTC-424 Patented T29355 DRUGINFO D0HA0J PMID27376512-Compound-MTC-427 Patented T29355 DRUGINFO D0QY0N PMID27376512-Compound-MTC-422 Patented T29355 DRUGINFO D0W9VZ PMID27376512-Compound-MTC-423 Patented T17036 TARGETID T17036 T17036 UNIPROID KDM4E_HUMAN T17036 TARGNAME Lysine-specific demethylase 4E (KDM4E) T17036 GENENAME KDM4E T17036 TARGTYPE Patented-recorded T17036 SYNONYMS Lysine-specific demethylase 4D-like; KDM4DL; KDM4D-like protein T17036 FUNCTION Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code. T17036 PDBSTRUC 2W2I T17036 BIOCLASS Paired donor oxygen oxidoreductase T17036 ECNUMBER EC 1.14.11.- T17036 SEQUENCE MKSVHSSPQNTSHTIMTFYPTMEEFADFNTYVAYMESQGAHQAGLAKVIPPKEWKARQMYDDIEDILIATPLQQVTSGQGGVFTQYHKKKKAMRVGQYRRLANSKKYQTPPHQNFADLEQRYWKSHPGNPPIYGADISGSLFEESTKQWNLGHLGTILDLLEQECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHFGEPKTWYVVPPEHGQHLERLARELFPDISRGCEAFLRHKVALISPTVLKENGIPFNCMTQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGESTVTFSMDPFVRIVQPESYELWKHRQDLAIVEHTEPRVAESQELSNWRDDIVLRRAALGLRLLPNLTAQCPTQPVSSGHCYNPKGCGTDAVPGSAFQSSAYHTQTQSLTLGMSARVLLPSTGSWGSGRGRGRGQGQGRGCSRGRGHGCCTRELGTEEPTVQPASKRRLLMGTRSRAQGHRPQLPLANDLMTNLSL T17036 DRUGINFO D00VLQ Hydroxyqunoline analog 1 Patented T17036 DRUGINFO D03EOJ N-oxalyl-D-tyrosine derivative 2 Patented T17036 DRUGINFO D03TPE Hydroxyqunoline analog 2 Patented T17036 DRUGINFO D06MHK N-oxalyl-D-tyrosine derivative 7 Patented T17036 DRUGINFO D06ZPF Pyridine-2,4-dicarboxylic acid analog 4 Patented T17036 DRUGINFO D08KYP Hydroxyqunoline analog 5 Patented T17036 DRUGINFO D0C8CI N-oxalyl-D-tyrosine derivative 9 Patented T17036 DRUGINFO D0D0WU Pyridine-2,4-dicarboxylic acid analog 2 Patented T17036 DRUGINFO D0L7HC N-oxalyl-D-tyrosine derivative 5 Patented T17036 DRUGINFO D0LU7U N-oxalyl-D-tyrosine derivative 4 Patented T17036 DRUGINFO D0O9WS Pyridine-2,4-dicarboxylic acid analog 1 Patented T17036 DRUGINFO D0OR0K Pyridine-2,4-dicarboxylic acid analog 3 Patented T17036 DRUGINFO D0P5MY N-oxalyl-D-tyrosine derivative 3 Patented T17036 DRUGINFO D0P7ZY N-oxalyl-D-tyrosine derivative 1 Patented T17036 DRUGINFO D0P8YL Hydroxyqunoline analog 3 Patented T17036 DRUGINFO D0VS3A Hydroxyqunoline analog 4 Patented T17036 DRUGINFO D0WC4Z N-oxalyl-D-tyrosine derivative 8 Patented T17036 DRUGINFO D0YF2M N-oxalyl-D-tyrosine derivative 6 Patented T17036 DRUGINFO D09NCT PMID25468267-Compound-46 Patented T34389 TARGETID T34389 T34389 UNIPROID FAAH1_HUMAN T34389 TARGNAME Fatty-acid amide hydrolase 1 (FAAH1) T34389 GENENAME FAAH1 T34389 TARGTYPE Patented-recorded T34389 SYNONYMS Oleamide hydrolase 1 of mouse; Oleamide hydrolase 1; FAAH; Anandamide amidohydrolase 1 of mouse; Anandamide amidohydrolase 1 T34389 FUNCTION Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates. Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. T34389 BIOCLASS Carbon-nitrogen hydrolase T34389 ECNUMBER EC 3.5.1.99 T34389 SEQUENCE MVQYELWAALPGASGVALACCFVAAAVALRWSGRRTARGAVVRARQRQRAGLENMDRAAQRFRLQNPDLDSEALLALPLPQLVQKLHSRELAPEAVLFTYVGKAWEVNKGTNCVTSYLADCETQLSQAPRQGLLYGVPVSLKECFTYKGQDSTLGLSLNEGVPAECDSVVVHVLKLQGAVPFVHTNVPQSMFSYDCSNPLFGQTVNPWKSSKSPGGSSGGEGALIGSGGSPLGLGTDIGGSIRFPSSFCGICGLKPTGNRLSKSGLKGCVYGQEAVRLSVGPMARDVESLALCLRALLCEDMFRLDPTVPPLPFREEVYTSSQPLRVGYYETDNYTMPSPAMRRAVLETKQSLEAAGHTLVPFLPSNIPHALETLSTGGLFSDGGHTFLQNFKGDFVDPCLGDLVSILKLPQWLKGLLAFLVKPLLPRLSAFLSNMKSRSAGKLWELQHEIEVYRKTVIAQWRALDLDVVLTPMLAPALDLNAPGRATGAVSYTMLYNCLDFPAGVVPVTTVTAEDEAQMEHYRGYFGDIWDKMLQKGMKKSVGLPVAVQCVALPWQEELCLRFMREVERLMTPEKQSS T34389 DRUGINFO D00ZCD Piperazine urea derivative 2 Patented T34389 DRUGINFO D0C3OH Carbamoyl oxime derivative 1 Patented T34389 DRUGINFO D0I6VK Carbamate derivative 6 Patented T34389 DRUGINFO D0X9GL Carbamate derivative 5 Patented T34389 DRUGINFO D0ZU3R Carbamate derivative 4 Patented T34389 DRUGINFO D01THA Ethylaminopyrimidine derivative 1 Patented T34389 DRUGINFO D0B7CW PMID26413912-Compound-84 Patented T34389 DRUGINFO D0IA7Z Carbamide derivative 1 Patented T34389 DRUGINFO D0M1ND Pyrimidinyl ethylenediamine derivative 1 Patented T34389 DRUGINFO D0S8TB Carbamate derivative 2 Patented T97149 TARGETID T97149 T97149 FORMERID TTDI03165 T97149 UNIPROID DYRK3_HUMAN T97149 TARGNAME Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3) T97149 GENENAME DYRK3 T97149 TARGTYPE Patented-recorded T97149 SYNONYMS Regulatory erythroid kinase; REDK; Dual specificity tyrosine-phosphorylation-regulated kinase 3 T97149 FUNCTION Dual-specificity tyrosine-regulated kinases (DYRKs) autophosphorylate a critical tyrosine residue in their activation loop and phosphorylate their substrate on serine and threonine residues. Acts as a central dissolvase of membraneless organelles during the G2-to-M transition, after the nuclear-envelope breakdown: acts by mediating phosphorylation of multiple serine and threonine residues in unstructured domains of proteins, such as SRRM1 and PCM1. Does not mediate disassembly of all membraneless organelles: disassembly of P-body and nucleolus is not regulated by DYRK3. Dissolution of membraneless organelles at the onset of mitosis is also required to release mitotic regulators, such as ZNF207, from liquid-unmixed organelles where they are sequestered and keep them dissolved during mitosis. Regulates mTORC1 by mediating the dissolution of stress granules: during stressful conditions, DYRK3 partitions from the cytosol to the stress granule, together with mTORC1 components, which prevents mTORC1 signaling. When stress signals are gone, the kinase activity of DYRK3 is required for the dissolution of stress granule and mTORC1 relocation to the cytosol: acts by mediating the phosphorylation of the mTORC1 inhibitor AKT1S1, allowing full reactivation of mTORC1 signaling. Also acts as a negative regulator of EPO-dependent erythropoiesis: may place an upper limit on red cell production during stress erythropoiesis. Inhibits cell death due to cytokine withdrawal in hematopoietic progenitor cells. Promotes cell survival upon genotoxic stress through phosphorylation of SIRT1: this in turn inhibits p53/TP53 activity and apoptosis. Dual-specificity protein kinase that promotes disassembly of several types of membraneless organelles during mitosis, such as stress granules, nuclear speckles and pericentriolar material. T97149 PDBSTRUC 5Y86 T97149 BIOCLASS Kinase T97149 ECNUMBER EC 2.7.12.1 T97149 SEQUENCE MGGTARGPGRKDAGPPGAGLPPQQRRLGDGVYDTFMMIDETKCPPCSNVLCNPSEPPPPRRLNMTTEQFTGDHTQHFLDGGEMKVEQLFQEFGNRKSNTIQSDGISDSEKCSPTVSQGKSSDCLNTVKSNSSSKAPKVVPLTPEQALKQYKHHLTAYEKLEIINYPEIYFVGPNAKKRHGVIGGPNNGGYDDADGAYIHVPRDHLAYRYEVLKIIGKGSFGQVARVYDHKLRQYVALKMVRNEKRFHRQAAEEIRILEHLKKQDKTGSMNVIHMLESFTFRNHVCMAFELLSIDLYELIKKNKFQGFSVQLVRKFAQSILQSLDALHKNKIIHCDLKPENILLKHHGRSSTKVIDFGSSCFEYQKLYTYIQSRFYRAPEIILGSRYSTPIDIWSFGCILAELLTGQPLFPGEDEGDQLACMMELLGMPPPKLLEQSKRAKYFINSKGIPRYCSVTTQADGRVVLVGGRSRRGKKRGPPGSKDWGTALKGCDDYLFIEFLKRCLHWDPSARLTPAQALRHPWISKSVPRPLTTIDKVSGKRVVNPASAFQGLGSKLPPVVGIANKLKANLMSETNGSIPLCSVLPKLIS T97149 DRUGINFO D00OWF Harmine Patented T97149 DRUGINFO D02DBH PMID28766366-Compound-Scheme21Left Patented T97149 DRUGINFO D07BWC PMID28766366-Compound-Scheme21Right Patented T97149 DRUGINFO D04TPA PMID24900749C1a Investigative T18904 TARGETID T18904 T18904 UNIPROID KDM4A_HUMAN T18904 TARGNAME Lysine-specific demethylase 4A (KDM4A) T18904 GENENAME KDM4A T18904 TARGTYPE Patented-recorded T18904 SYNONYMS KIAA0677; Jumonji domain-containing protein 2A; JmjC domain-containing histone demethylation protein 3A; JMJD2A; JMJD2; JHDM3A T18904 FUNCTION Histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27' nor H4 'Lys-20'. Demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residue, while it has no activity on mono- and dimethylated residues. Demethylation of Lys residue generates formaldehyde and succinate. Participates in transcriptional repression of ASCL2 and E2F-responsive promoters via the recruitment of histone deacetylases and NCOR1, respectively. T18904 PDBSTRUC 6H8P; 6G5X; 6G5W; 6CG2; 6CG1 T18904 BIOCLASS Paired donor oxygen oxidoreductase T18904 ECNUMBER EC 1.14.11.- T18904 SEQUENCE MASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESELPPRAGNEEECPEEDMEGVEDGEEGDLKTSLAKHRIGTKRHRVCLEIPQEVSQSELFPKEDLSSEQYEMTECPAALAPVRPTHSSVRQVEDGLTFPDYSDSTEVKFEELKNVKLEEEDEEEEQAAAALDLSVNPASVGGRLVFSGSKKKSSSSLGSGSSRDSISSDSETSEPLSCRAQGQTGVLTVHSYAKGDGRVTVGEPCTRKKGSAARSFSERELAEVADEYMFSLEENKKSKGRRQPLSKLPRHHPLVLQECVSDDETSEQLTPEEEAEETEAWAKPLSQLWQNRPPNFEAEKEFNETMAQQAPHCAVCMIFQTYHQVEFGGFNQNCGNASDLAPQKQRTKPLIPEMCFTSTGCSTDINLSTPYLEEDGTSILVSCKKCSVRVHASCYGVPPAKASEDWMCSRCSANALEEDCCLCSLRGGALQRANDDRWVHVSCAVAILEARFVNIAERSPVDVSKIPLPRFKLKCIFCKKRRKRTAGCCVQCSHGRCPTAFHVSCAQAAGVMMQPDDWPFVVFITCFRHKIPNLERAKGALQSITAGQKVISKHKNGRFYQCEVVRLTTETFYEVNFDDGSFSDNLYPEDIVSQDCLQFGPPAEGEVVQVRWTDGQVYGAKFVASHPIQMYQVEFEDGSQLVVKRDDVYTLDEELPKRVKSRLSVASDMRFNEIFTEKEVKQEKKRQRVINSRYREDYIEPALYRAIME T18904 DRUGINFO D05PXW Disulfiram analog 1 Patented T18904 DRUGINFO D09YFD Selenium compound 2 Patented T18904 DRUGINFO D0JQ9Z Disulfiram analog 2 Patented T18904 DRUGINFO D0X2AU Selenium compound 1 Patented T18904 DRUGINFO D0X6SJ Selenium compound 3 Patented T18904 DRUGINFO D01CIK Heteroaryl-cyclopropylamine derivative 4 Patented T18904 DRUGINFO D07MQD PMID27019002-Compound-21b Patented T18904 DRUGINFO D0MJ4L Hydroxamate analog 1 Patented T18904 DRUGINFO D0UE4K PMID27019002-Compound-21c Patented T18904 DRUGINFO D09NCT PMID25468267-Compound-46 Patented T18904 DRUGINFO D0UL9U N-(2-phenylcyclopropyl) amino acid derivative 1 Patented T00348 TARGETID T00348 T00348 UNIPROID ABL1_HUMAN T00348 TARGNAME ABL T315I mutant (ABL T315I) T00348 GENENAME ABL1 T00348 TARGTYPE Patented-recorded T00348 SYNONYMS p150 T315I; T315I Abl; Proto-oncogene tyrosine-protein kinase ABL1 T315I; Proto-oncogene c-Abl T315I; JTK7 T315I; C-ABL T315I; Abl T315I; Abelson tyrosine-protein kinase 1 T315I; Abelson murine leukemia viral oncogene homolog 1 T315I T00348 FUNCTION Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717'. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E. coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H. pylori, or AnkA (ankyrin repeat-containing protein A) of A. phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner. Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity. Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. T00348 PDBSTRUC 6NPV; 6NPU; 6NPE; 6BL8; 6AMW T00348 BIOCLASS Kinase T00348 ECNUMBER EC 2.7.10.2 T00348 SEQUENCE MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR T00348 DRUGINFO D0MX5B Indazole derivative 5 Patented T00348 DRUGINFO D0ZH4I PMID25656651-Compound-42 Patented T92517 TARGETID T92517 T92517 UNIPROID CAN1_HUMAN T92517 TARGNAME Calpain-1 (CAPN1) T92517 GENENAME CAPN1 T92517 TARGTYPE Patented-recorded T92517 SYNONYMS muCANP; PIG30; Micromolar-calpain; Cell proliferation-inducing gene 30 protein; Calpain-1 large subunit; Calpain-1 catalytic subunit; Calpain mu-type; Calcium-activated neutral proteinase 1; CANPL1; CANP 1 T92517 FUNCTION Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction. T92517 BIOCLASS Peptidase T92517 ECNUMBER EC 3.4.22.52 T92517 SEQUENCE MSEEIITPVYCTGVSAQVQKQRARELGLGRHENAIKYLGQDYEQLRVRCLQSGTLFRDEAFPPVPQSLGYKDLGPNSSKTYGIKWKRPTELLSNPQFIVDGATRTDICQGALGDCWLLAAIASLTLNDTLLHRVVPHGQSFQNGYAGIFHFQLWQFGEWVDVVVDDLLPIKDGKLVFVHSAEGNEFWSALLEKAYAKVNGSYEALSGGSTSEGFEDFTGGVTEWYELRKAPSDLYQIILKALERGSLLGCSIDISSVLDMEAITFKKLVKGHAYSVTGAKQVNYRGQVVSLIRMRNPWGEVEWTGAWSDSSSEWNNVDPYERDQLRVKMEDGEFWMSFRDFMREFTRLEICNLTPDALKSRTIRKWNTTLYEGTWRRGSTAGGCRNYPATFWVNPQFKIRLDETDDPDDYGDRESGCSFVLALMQKHRRRERRFGRDMETIGFAVYEVPPELVGQPAVHLKRDFFLANASRARSEQFINLREVSTRFRLPPGEYVVVPSTFEPNKEGDFVLRFFSEKSAGTVELDDQIQANLPDEQVLSEEEIDENFKALFRQLAGEDMEISVKELRTILNRIISKHKDLRTKGFSLESCRSMVNLMDRDGNGKLGLVEFNILWNRIRNYLSIFRKFDLDKSGSMSAYEMRMAIESAGFKLNKKLYELIITRYSEPDLAVDFDNFVCCLVRLETMFRFFKTLDTDLDGVVTFDLFKWLQLTMFA T92517 DRUGINFO D08VAT Undecylenic acid derivative 1 Patented T16685 TARGETID T16685 T16685 UNIPROID RET_HUMAN T16685 TARGNAME RET G691S mutant (RET G691S) T16685 GENENAME RET T16685 TARGTYPE Patented-recorded T16685 SYNONYMS RET51 G691S mutant; Proto-oncogene tyrosine-protein kinase receptor Ret G691S mutant; Proto-oncogene c-Ret G691S mutant; PTC G691S mutant; Cadherin family member 12 G691S mutant; CDHR16 G691S mutant; CDHF12 G691S mutant T16685 FUNCTION Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. T16685 PDBSTRUC 6FEK; 5FM3; 5FM2; 5AMN; 4UX8 T16685 BIOCLASS Kinase T16685 ECNUMBER EC 2.7.10.1 T16685 SEQUENCE MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS T16685 DRUGINFO D0O9JD Benzo(b)carbazol-11-one compound 2 Patented T17134 TARGETID T17134 T17134 UNIPROID RET_HUMAN T17134 TARGNAME RET M918T mutant (RET M918T) T17134 GENENAME RET T17134 TARGTYPE Patented-recorded T17134 SYNONYMS RET51 M918T mutant; Proto-oncogene tyrosine-protein kinase receptor Ret M918T mutant; Proto-oncogene c-Ret M918T mutant; PTC M918T mutant; Cadherin family member 12 M918T mutant; CDHR16 M918T mutant; CDHF12 M918T mutant T17134 FUNCTION Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. T17134 PDBSTRUC 6FEK; 5FM3; 5FM2; 5AMN; 4UX8 T17134 BIOCLASS Kinase T17134 ECNUMBER EC 2.7.10.1 T17134 SEQUENCE MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS T17134 DRUGINFO D0O9JD Benzo(b)carbazol-11-one compound 2 Patented T17279 TARGETID T17279 T17279 UNIPROID RET_HUMAN T17279 TARGNAME RET S891A mutant (RET S891A) T17279 GENENAME RET T17279 TARGTYPE Patented-recorded T17279 SYNONYMS RET51 S891A mutant; Proto-oncogene tyrosine-protein kinase receptor Ret S891A mutant; Proto-oncogene c-Ret S891A mutant; PTC S891A mutant; Cadherin family member 12 S891A mutant; CDHR16 S891A mutant; CDHF12 S891A mutant T17279 FUNCTION Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. T17279 PDBSTRUC 6FEK; 5FM3; 5FM2; 5AMN; 4UX8 T17279 BIOCLASS Kinase T17279 ECNUMBER EC 2.7.10.1 T17279 SEQUENCE MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS T17279 DRUGINFO D0O9JD Benzo(b)carbazol-11-one compound 2 Patented T17566 TARGETID T17566 T17566 UNIPROID RET_HUMAN T17566 TARGNAME RET V804L mutant (RET V804L) T17566 GENENAME RET T17566 TARGTYPE Patented-recorded T17566 SYNONYMS RET51 V804L mutant; Proto-oncogene tyrosine-protein kinase receptor Ret V804L mutant; Proto-oncogene c-Ret V804L mutant; PTC V804L mutant; Cadherin family member 12 V804L mutant; CDHR16 V804L mutant; CDHF12 V804L mutant T17566 FUNCTION Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. T17566 PDBSTRUC 6FEK; 5FM3; 5FM2; 5AMN; 4UX8 T17566 BIOCLASS Kinase T17566 ECNUMBER EC 2.7.10.1 T17566 SEQUENCE MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS T17566 DRUGINFO D0O9JD Benzo(b)carbazol-11-one compound 2 Patented T17919 TARGETID T17919 T17919 UNIPROID RET_HUMAN T17919 TARGNAME RET V804M mutant (RET V804M) T17919 GENENAME RET T17919 TARGTYPE Patented-recorded T17919 SYNONYMS RET51 V804M mutant; Proto-oncogene tyrosine-protein kinase receptor Ret V804M mutant; Proto-oncogene c-Ret V804M mutant; PTC V804M mutant; Cadherin family member 12 V804M mutant; CDHR16 V804M mutant; CDHF12 V804M mutant T17919 FUNCTION Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. T17919 PDBSTRUC 6FEK; 5FM3; 5FM2; 5AMN; 4UX8 T17919 BIOCLASS Kinase T17919 ECNUMBER EC 2.7.10.1 T17919 SEQUENCE MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS T17919 DRUGINFO D0O9JD Benzo(b)carbazol-11-one compound 2 Patented T18250 TARGETID T18250 T18250 UNIPROID RET_HUMAN T18250 TARGNAME RET Y791F mutant (RET Y791F) T18250 GENENAME RET T18250 TARGTYPE Patented-recorded T18250 SYNONYMS RET51 Y791F mutant; Proto-oncogene tyrosine-protein kinase receptor Ret Y791F mutant; Proto-oncogene c-Ret Y791F mutant; PTC Y791F mutant; Cadherin family member 12 Y791F mutant; CDHR16 Y791F mutant; CDHF12 Y791F mutant T18250 FUNCTION Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. T18250 PDBSTRUC 6FEK; 5FM3; 5FM2; 5AMN; 4UX8 T18250 BIOCLASS Kinase T18250 ECNUMBER EC 2.7.10.1 T18250 SEQUENCE MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS T18250 DRUGINFO D0O9JD Benzo(b)carbazol-11-one compound 2 Patented T54973 TARGETID T54973 T54973 UNIPROID PSB6_HUMAN T54973 TARGNAME Proteasome beta-1 (PS beta-1) T54973 GENENAME PSMB6 T54973 TARGTYPE Patented-recorded T54973 SYNONYMS Proteasome subunit beta type-6; Proteasome subunit Y; Proteasome delta chain; Multicatalytic endopeptidase complex delta chain; Macropain delta chain; LMPY T54973 FUNCTION Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB6 displays a peptidylglutamyl-hydrolizing activity also termed postacidic or caspase-like activity, meaning that the peptides bond hydrolysis occurs directly after acidic residues. T54973 PDBSTRUC 6MSK; 6MSJ; 6MSH; 6MSG; 6MSE T54973 BIOCLASS Peptidase T54973 ECNUMBER EC 3.4.25.1 T54973 SEQUENCE MAATLLAARGAGPAPAWGPEAFTPDWESREVSTGTTIMAVQFDGGVVLGADSRTTTGSYIANRVTDKLTPIHDRIFCCRSGSAADTQAVADAVTYQLGFHSIELNEPPLVHTAASLFKEMCYRYREDLMAGIIIAGWDPQEGGQVYSVPMGGMMVRQSFAIGGSGSSYIYGYVDATYREGMTKEECLQFTANALALAMERDGSSGGVIRLAAIAESGVERQVLLGDQIPKFAVATLPPA T54973 DRUGINFO D02CQG Peptide analog 39 Patented T54973 DRUGINFO D01VMN PMID29865878-Compound-53 Patented T54973 DRUGINFO D03CMD PMID29865878-Compound-55 Patented T54973 DRUGINFO D0C2MH PMID29865878-Compound-46 Patented T54973 DRUGINFO D0K0GJ PMID29865878-Compound-48 Patented T54973 DRUGINFO D0NE8M PMID29865878-Compound-51 Patented T54973 DRUGINFO D0TU5R PMID29865878-Compound-49 Patented T54973 DRUGINFO D01OOO Peptide analog 41 Patented T54973 DRUGINFO D02PJI Peptide analog 21 Patented T54973 DRUGINFO D0T1YB Peptide analog 23 Patented T15848 TARGETID T15848 T15848 FORMERID TTDI03573 T15848 UNIPROID TEC_HUMAN T15848 TARGNAME Tyrosine-protein kinase Tec (PSCTK4) T15848 GENENAME TEC T15848 TARGTYPE Patented-recorded T15848 SYNONYMS Tec protein tyrosine kinase T15848 FUNCTION Plays a redundant role to ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. Required for TCR-dependent IL2 gene induction. Phosphorylates DOK1, one CD28-specific substrate, and contributes to CD28-signaling. Mediates signals that negatively regulate IL2RA expression induced by TCR cross-linking. Plays a redundant role to BTK in BCR-signaling for B-cell development and activation, especially by phosphorylating STAP1, a BCR-signaling protein. Required in mast cells for efficient cytokine production. Involved in both growth and differentiation mechanisms of myeloid cells through activation by the granulocyte colony-stimulating factor CSF3, a critical cytokine to promoting the growth, differentiation, and functional activation of myeloid cells. Participates in platelet signaling downstream of integrin activation. Cooperates with JAK2 through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. GRB10, a negative modifier of the FOS activation pathway, is another substrate of TEC. TEC is involved in G protein-coupled receptor- and integrin-mediated signalings in blood platelets. Plays a role in hepatocyte proliferation and liver regeneration and is involved in HGF-induced ERK signaling pathway. TEC regulates also FGF2 unconventional secretion (endoplasmic reticulum (ER)/Golgi-independent mechanism) under various physiological conditions through phosphorylation of FGF2 'Tyr-215'. May also be involved in the regulation of osteoclast differentiation. Non-receptor tyrosine kinase that contributes to signaling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. T15848 PDBSTRUC 2LUL T15848 BIOCLASS Kinase T15848 ECNUMBER EC 2.7.10.2 T15848 SEQUENCE MNFNTILEEILIKRSQQKKKTSPLNYKERLFVLTKSMLTYYEGRAEKKYRKGFIDVSKIKCVEIVKNDDGVIPCQNKYPFQVVHDANTLYIFAPSPQSRDLWVKKLKEEIKNNNNIMIKYHPKFWTDGSYQCCRQTEKLAPGCEKYNLFESSIRKALPPAPETKKRRPPPPIPLEEEDNSEEIVVAMYDFQAAEGHDLRLERGQEYLILEKNDVHWWRARDKYGNEGYIPSNYVTGKKSNNLDQYEWYCRNMNRSKAEQLLRSEDKEGGFMVRDSSQPGLYTVSLYTKFGGEGSSGFRHYHIKETTTSPKKYYLAEKHAFGSIPEIIEYHKHNAAGLVTRLRYPVSVKGKNAPTTAGFSYEKWEINPSELTFMRELGSGLFGVVRLGKWRAQYKVAIKAIREGAMCEEDFIEEAKVMMKLTHPKLVQLYGVCTQQKPIYIVTEFMERGCLLNFLRQRQGHFSRDVLLSMCQDVCEGMEYLERNSFIHRDLAARNCLVSEAGVVKVSDFGMARYVLDDQYTSSSGAKFPVKWCPPEVFNYSRFSSKSDVWSFGVLMWEVFTEGRMPFEKYTNYEVVTMVTRGHRLYQPKLASNYVYEVMLRCWQEKPEGRPSFEDLLRTIDELVECEETFGR T15848 DRUGINFO D09PIS Pyrazolo[4,3-c]pyridine derivative 2 Patented T15848 DRUGINFO D01RHR PMID24915291C31 Investigative T15848 DRUGINFO D06BJG PMID24915291C38 Investigative T20371 TARGETID T20371 T20371 FORMERID TTDI03476 T20371 UNIPROID PCP_HUMAN T20371 TARGNAME Prolylcarboxypeptidase (PRCP) T20371 GENENAME PRCP T20371 TARGTYPE Patented-recorded T20371 SYNONYMS Proline carboxypeptidase; PCP; Lysosomal carboxypeptidase C; Lysosomal Pro-X carboxypeptidase; Angiotensinase C T20371 FUNCTION Cleaves C-terminal amino acids linked to proline in peptides such as angiotensin II, III and des-Arg9-bradykinin. This cleavage occurs at acidic pH, but enzymatic activity is retained with some substrates at neutral pH. T20371 PDBSTRUC 3N2Z T20371 BIOCLASS Peptidase T20371 ECNUMBER EC 3.4.16.2 T20371 SEQUENCE MGRRALLLLLLSFLAPWATIALRPALRALGSLHLPTNPTSLPAVAKNYSVLYFQQKVDHFGFNTVKTFNQRYLVADKYWKKNGGSILFYTGNEGDIIWFCNNTGFMWDVAEELKAMLVFAEHRYYGESLPFGDNSFKDSRHLNFLTSEQALADFAELIKHLKRTIPGAENQPVIAIGGSYGGMLAAWFRMKYPHMVVGALAASAPIWQFEDLVPCGVFMKIVTTDFRKSGPHCSESIHRSWDAINRLSNTGSGLQWLTGALHLCSPLTSQDIQHLKDWISETWVNLAMVDYPYASNFLQPLPAWPIKVVCQYLKNPNVSDSLLLQNIFQALNVYYNYSGQVKCLNISETATSSLGTLGWSYQACTEVVMPFCTNGVDDMFEPHSWNLKELSDDCFQQWGVRPRPSWITTMYGGKNISSHTNIVFSNGELDPWSGGGVTKDITDTLVAVTISEGAHHLDLRTKNALDPMSVLLARSLEVRHMKNWIRDFYDSAGKQH T20371 DRUGINFO D00YYA Cyclopentane carboxamide derivative 2 Patented T20371 DRUGINFO D01GEE Piperidinyl pyrazole derivative 4 Patented T20371 DRUGINFO D01RBE Pyrrolidine carboxamide derivative 2 Patented T20371 DRUGINFO D03ASG Piperidinyl pyrazole derivative 1 Patented T20371 DRUGINFO D03GPW Benzodihydroisofuran derivative 1 Patented T20371 DRUGINFO D03WDH Cyclohexane carboxamide derivative 2 Patented T20371 DRUGINFO D05NQZ Benzodihydroisofuran derivative 3 Patented T20371 DRUGINFO D07KNI Benzodihydroisofuran derivative 4 Patented T20371 DRUGINFO D07RIZ Piperidinyl triazole derivative 4 Patented T20371 DRUGINFO D0A0QQ Piperidinyl triazole derivative 5 Patented T20371 DRUGINFO D0A6QI Proline amide derivative 1 Patented T20371 DRUGINFO D0AF0O Cyclohexane carboxamide derivative 1 Patented T20371 DRUGINFO D0J3TN Piperidinyl pyrazole derivative 2 Patented T20371 DRUGINFO D0K1GJ Piperidinyl triazole derivative 1 Patented T20371 DRUGINFO D0L6CM Imidazole derivative 8 Patented T20371 DRUGINFO D0L8VH Cyclopentane carboxamide derivative 1 Patented T20371 DRUGINFO D0LZ4A Benzodihydroisofuran derivative 2 Patented T20371 DRUGINFO D0NT8N Piperidinyl triazole derivative 3 Patented T20371 DRUGINFO D0QM9Q Cyclohexane carboxamide derivative 3 Patented T20371 DRUGINFO D0R3WH Piperidinyl pyrazole derivative 3 Patented T20371 DRUGINFO D0S3AL Piperidinyl triazole derivative 2 Patented T20371 DRUGINFO D0S4XV Piperidinyl triazole derivative 6 Patented T20371 DRUGINFO D0X8ZF Imidazole derivative 9 Patented T20371 DRUGINFO D0N6AM PMID24157366C35 Investigative T37541 TARGETID T37541 T37541 UNIPROID CAH7_HUMAN T37541 TARGNAME Carbonic anhydrase VII (CA-VII) T37541 GENENAME CA7 T37541 TARGTYPE Patented-recorded T37541 SYNONYMS Carbonic anhydrase 7; Carbonate dehydratase VII T37541 FUNCTION Reversible hydration of carbon dioxide. T37541 PDBSTRUC 6H38; 6H37; 6H36; 6G4T; 3ML5 T37541 BIOCLASS Alpha-carbonic anhydrase T37541 ECNUMBER EC 4.2.1.1 T37541 SEQUENCE MTGHHGWGYGQDDGPSHWHKLYPIAQGDRQSPINIISSQAVYSPSLQPLELSYEACMSLSITNNGHSVQVDFNDSDDRTVVTGGPLEGPYRLKQFHFHWGKKHDVGSEHTVDGKSFPSELHLVHWNAKKYSTFGEAASAPDGLAVVGVFLETGDEHPSMNRLTDALYMVRFKGTKAQFSCFNPKCLLPASRHYWTYPGSLTTPPLSESVTWIVLREPICISERQMGKFRSLLFTSEDDERIHMVNNFRPPQPLKGRVVKASFRA T73725 TARGETID T73725 T73725 FORMERID TTDI03103 T73725 UNIPROID CLK2_HUMAN T73725 TARGNAME CDC-like kinase 2 (CLK2) T73725 GENENAME CLK2 T73725 TARGTYPE Patented-recorded T73725 SYNONYMS Dual specificity protein kinase CLK2 T73725 FUNCTION Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Acts as a suppressor of hepatic gluconeogenesis and glucose output by repressing PPARGC1A transcriptional activity on gluconeogenic genes via its phosphorylation. Phosphorylates PPP2R5B thereby stimulating the assembly of PP2A phosphatase with the PPP2R5B-AKT1 complex leading to dephosphorylation of AKT1. Phosphorylates: PTPN1, SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. T73725 PDBSTRUC 6FYL; 6FYK; 6FYI; 5UNP; 3NR9 T73725 BIOCLASS Kinase T73725 ECNUMBER EC 2.7.12.1 T73725 SEQUENCE MPHPRRYHSSERGSRGSYREHYRSRKHKRRRSRSWSSSSDRTRRRRREDSYHVRSRSSYDDRSSDRRVYDRRYCGSYRRNDYSRDRGDAYYDTDYRHSYEYQRENSSYRSQRSSRRKHRRRRRRSRTFSRSSSQHSSRRAKSVEDDAEGHLIYHVGDWLQERYEIVSTLGEGTFGRVVQCVDHRRGGARVALKIIKNVEKYKEAARLEINVLEKINEKDPDNKNLCVQMFDWFDYHGHMCISFELLGLSTFDFLKDNNYLPYPIHQVRHMAFQLCQAVKFLHDNKLTHTDLKPENILFVNSDYELTYNLEKKRDERSVKSTAVRVVDFGSATFDHEHHSTIVSTRHYRAPEVILELGWSQPCDVWSIGCIIFEYYVGFTLFQTHDNREHLAMMERILGPIPSRMIRKTRKQKYFYRGRLDWDENTSAGRYVRENCKPLRRYLTSEAEEHHQLFDLIESMLEYEPAKRLTLGEALQHPFFARLRAEPPNKLWDSSRDISR T73725 DRUGINFO D06MBI TG003 Patented T73725 DRUGINFO D0UI7U ML315 Investigative T73725 DRUGINFO D06CXU PMID23642479C17 Investigative T63846 TARGETID T63846 T63846 FORMERID TTDI03277 T63846 UNIPROID IRAK1_HUMAN T63846 TARGNAME IL-1 receptor-associated kinase 1 (IRAK1) T63846 GENENAME IRAK1 T63846 TARGTYPE Patented-recorded T63846 SYNONYMS Interleukin-1 receptor-associated kinase 1; IRAK-1; IRAK T63846 FUNCTION Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates the interferon regulatory factor 7 (IRF7) to induce its activation and translocation to the nucleus, resulting in transcriptional activation of type I IFN genes, which drive the cell in an antiviral state. When sumoylated, translocates to the nucleus and phosphorylates STAT3. Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. T63846 PDBSTRUC 6BFN T63846 BIOCLASS Kinase T63846 ECNUMBER EC 2.7.11.1 T63846 SEQUENCE MAGGPGPGEPAAPGAQHFLYEVPPWVMCRFYKVMDALEPADWCQFAALIVRDQTELRLCERSGQRTASVLWPWINRNARVADLVHILTHLQLLRARDIITAWHPPAPLPSPGTTAPRPSSIPAPAEAEAWSPRKLPSSASTFLSPAFPGSQTHSGPELGLVPSPASLWPPPPSPAPSSTKPGPESSVSLLQGARPFPFCWPLCEISRGTHNFSEELKIGEGGFGCVYRAVMRNTVYAVKRLKENADLEWTAVKQSFLTEVEQLSRFRHPNIVDFAGYCAQNGFYCLVYGFLPNGSLEDRLHCQTQACPPLSWPQRLDILLGTARAIQFLHQDSPSLIHGDIKSSNVLLDERLTPKLGDFGLARFSRFAGSSPSQSSMVARTQTVRGTLAYLPEEYIKTGRLAVDTDTFSFGVVVLETLAGQRAVKTHGARTKYLKDLVEEEAEEAGVALRSTQSTLQAGLAADAWAAPIAMQIYKKHLDPRPGPCPPELGLGLGQLACCCLHRRAKRRPPMTQVYERLEKLQAVVAGVPGHSEAASCIPPSPQENSYVSSTGRAHSGAAPWQPLAAPSGASAQAAEQLQRGPNQPVESDESLGGLSAALRSWHLTPSCPLDPAPLREAGCPQGDTAGESSWGSGPGSRPTAVEGLALGSSASSSSEPPQIIINPARQKMVQKLALYEDGALDSLQLLSSSSLPGLGLEQDRQGPEESDEFQS T63846 DRUGINFO D0E5AT Pyrazolopyrimidine and thienopyrimidine amide derivative 1 Patented T63846 DRUGINFO D0F2NW Pyrazolopyrimidine and thienopyrimidine amide derivative 2 Patented T63846 DRUGINFO D0NT8U Indazoletriazolephenyl derivative 1 Patented T63846 DRUGINFO D0O6GQ Indazoletriazolephenyl derivative 2 Patented T63846 DRUGINFO D04ZIV WO2012007375C1 Investigative T63846 DRUGINFO D0I2FZ IRAK-1/4 inhibitor Investigative T63846 DRUGINFO D0T2NE WO2012007375C7 Investigative T03279 TARGETID T03279 T03279 FORMERID TTDI03520 T03279 UNIPROID KS6A3_HUMAN T03279 TARGNAME Ribosomal protein S6 kinase alpha-3 (RSK3) T03279 GENENAME RPS6KA3 T03279 TARGTYPE Patented-recorded T03279 SYNONYMS pp90RSK2; p90RSK3; p90-RSK 3; S6K-alpha-3; Ribosomal S6 kinase 2; RSK2; RSK-2; MAPKAPK1B; MAPKAPK-1b; MAPKAP kinase 1b; MAPK-activated protein kinase 1b; MAP kinase-activated protein kinase 1b; Insulin-stimulated protein kinase 1; ISPK1; ISPK-1; 90 kDa ribosomal protein S6 kinase 3 T03279 FUNCTION In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3. Negatively regulates EGF-induced MAPK1/3 phosphorylation via phosphorylation of SOS1. Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and YWHAE binding sites and which contribute to the negative regulation of MAPK1/3 phosphorylation. Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration. Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. T03279 PDBSTRUC 5D9L; 5D9K; 4NW6; 4NW5; 4NUS T03279 BIOCLASS Kinase T03279 ECNUMBER EC 2.7.11.1 T03279 SEQUENCE MPLAQLADPWQKMAVESPSDSAENGQQIMDEPMGEEEINPQTEEVSIKEIAITHHVKEGHEKADPSQFELLKVLGQGSFGKVFLVKKISGSDARQLYAMKVLKKATLKVRDRVRTKMERDILVEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENILLDEEGHIKLTDFGLSKESIDHEKKAYSFCGTVEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGTLPFQGKDRKETMTMILKAKLGMPQFLSPEAQSLLRMLFKRNPANRLGAGPDGVEEIKRHSFFSTIDWNKLYRREIHPPFKPATGRPEDTFYFDPEFTAKTPKDSPGIPPSANAHQLFRGFSFVAITSDDESQAMQTVGVHSIVQQLHRNSIQFTDGYEVKEDIGVGSYSVCKRCIHKATNMEFAVKIIDKSKRDPTEEIEILLRYGQHPNIITLKDVYDDGKYVYVVTELMKGGELLDKILRQKFFSEREASAVLFTITKTVEYLHAQGVVHRDLKPSNILYVDESGNPESIRICDFGFAKQLRAENGLLMTPCYTANFVAPEVLKRQGYDAACDIWSLGVLLYTMLTGYTPFANGPDDTPEEILARIGSGKFSLSGGYWNSVSDTAKDLVSKMLHVDPHQRLTAALVLRHPWIVHWDQLPQYQLNRQDAPHLVKGAMAATYSALNRNQSPVLEPVGRSTLAQRRGIKKITSTAL T03279 DRUGINFO D01IOH Indole-based analog 14 Patented T03279 DRUGINFO D0X8YV Pyrrolo[2,3-d]pyrimidine derivative 35 Patented T03279 DRUGINFO D0O6TG PMID27410995-Compound-Figure3j Patented T03279 DRUGINFO D02VBF BI-D1870 Preclinical T03279 DRUGINFO D0U3NI BIX 02565 Investigative T03279 DRUGINFO D09AID PMID22564207C25b Investigative T03279 DRUGINFO D0C2GE PMID22765894C8h Investigative T04820 TARGETID T04820 T04820 FORMERID TTDR00301 T04820 UNIPROID P90584_PLAFA T04820 TARGNAME Plasmodium CDK Pfmrk (Malaria Pfmrk) T04820 GENENAME Malaria Pfmrk T04820 TARGTYPE Patented-recorded T04820 SYNONYMS Pfmrk; MO15-related protein kinase Pfmrk T04820 FUNCTION Association of Pfmrk with human cyclin H (the cyclin partner for hCDK7) or Pfcyc-1 (a cyclin homologue in P. falciparum) stimulates kinase activity in vitro. T04820 BIOCLASS Kinase T04820 ECNUMBER EC 2.7.1.37 T04820 SEQUENCE MENNSTERYIFKPNFLGEGSYGKVYKAYDTILKKEVAIKKMKLNEISNYIDDCGINFVLLREIKIMKEIKHKNIMSALDLYCEKDYINLVMEIMDYDLSKIINRKIFLTDSQKKCILLQILNGLNVLHKYYFMHRDLSPANIFINKKGEVKLADFGLCTKYGYDMYSDKLFRDKYKKNLNLTSKVVTLWYRAPELLLGSNKYNSSIDMWSFGCIFAELLLQKALFPGENEIDQLGKIFFLLGTPNENNWPEALCLPLYTEFTKATKKDFKTYFKIDDDDCIDLLTSFLKLNAHERISAEDAMKHRYFFNDPLPCDISQLPFNDL T04820 DRUGINFO D00PWQ KENPAULLONE Patented T04820 DRUGINFO D04PTI WR-289010 Investigative T04820 DRUGINFO D05SZP WR-080539 Investigative T04820 DRUGINFO D06CTS 5-chloro-4-nitrothiophene-2-sulfonamide Investigative T04820 DRUGINFO D06YUR Oxindole derivative Investigative T04820 DRUGINFO D08FZK WR-203581 Investigative T04820 DRUGINFO D0A6YW WR-289009 Investigative T04820 DRUGINFO D0C8BV N-(2-aminoethyl)isoquinoline-5-sulfonamide Investigative T04820 DRUGINFO D0D8MA 2-chloro-N-(o-tolylcarbamoyl)benzamide Investigative T04820 DRUGINFO D0E4AB N'-(2-fluorobenzoyl)-2-naphthohydrazide Investigative T04820 DRUGINFO D0F1KM WR-190706 Investigative T04820 DRUGINFO D0G2DQ 5-Nitro-1H-indole-2,3-dione Investigative T04820 DRUGINFO D0Q3RF (E)-1-(4-Nitro-phenyl)-3-pyridin-2-yl-propenone Investigative T04820 DRUGINFO D0Q4PQ WR-089120 Investigative T04820 DRUGINFO D0UH0Q 3-[3-(2-Hydroxy-ethoxy)-phenyl]-1H-quinolin-2-one Investigative T04820 DRUGINFO D0V5ZI WR-289012 Investigative T04820 DRUGINFO D0V8JJ WR-289016 Investigative T04820 DRUGINFO D0W1NH Thiophene sulfonamide Investigative T04820 DRUGINFO D0Z6LR 2,5-dichloro-N-phenylthiophene-3-sulfonamide Investigative T04820 DRUGINFO D06WUE 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide Investigative T04820 DRUGINFO D00RIX APIGENIN Investigative T70851 TARGETID T70851 T70851 FORMERID TTDI03378 T70851 UNIPROID MK07_HUMAN T70851 TARGNAME Extracellular signal-regulated kinase 5 (ERK5) T70851 GENENAME MAPK7 T70851 TARGTYPE Patented-recorded T70851 SYNONYMS PRKM7; Mitogen-activated protein kinase 7; MAPK 7; MAP kinase 7; ERK-5; Big MAP kinase 1; BMK1; BMK-1 T70851 FUNCTION The upstream activator of MAPK7 is the MAPK kinase MAP2K5. Upon activation, it translocates to the nucleus and phosphorylates various downstream targets including MEF2C. EGF activates MAPK7 through a Ras-independent and MAP2K5-dependent pathway. May have a role in muscle cell differentiation. May be important for endothelial function and maintenance of blood vessel integrity. MAP2K5 and MAPK7 interact specifically with one another and not with MEK1/ERK1 or MEK2/ERK2 pathways. Phosphorylates SGK1 at Ser-78 and this is required for growth factor-induced cell cycle progression. Involved in the regulation of p53/TP53 by disrupting the PML-MDM2 interaction. Plays a role in various cellular processes such as proliferation, differentiation and cell survival. T70851 PDBSTRUC 6HKN; 6HKM; 5O7I; 5BYZ; 5BYY T70851 BIOCLASS Kinase T70851 ECNUMBER EC 2.7.11.24 T70851 SEQUENCE MAEPLKEEDGEDGSAEPPGPVKAEPAHTAASVAAKNLALLKARSFDVTFDVGDEYEIIETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEFKSVYVVLDLMESDLHQIIHSSQPLTLEHVRYFLYQLLRGLKYMHSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCTSPAEHQYFMTEYVATRWYRAPELMLSLHEYTQAIDLWSVGCIFGEMLARRQLFPGKNYVHQLQLIMMVLGTPSPAVIQAVGAERVRAYIQSLPPRQPVPWETVYPGADRQALSLLGRMLRFEPSARISAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARREGIRQQIRFQPSLQPVASEPGCPDVEMPSPWAPSGDCAMESPPPAPPPCPGPAPDTIDLTLQPPPPVSEPAPPKKDGAISDNTKAALKAALLKSLRSRLRDGPSAPLEAPEPRKPVTAQERQREREEKRRRRQERAKEREKRRQERERKERGAGASGGPSTDPLAGLVLSDNDRSLLERWTRMARPAAPALTSVPAPAPAPTPTPTPVQPTSPPPGPVAQPTGPQPQSAGSTSGPVPQPACPPPGPAPHPTGPPGPIPVPAPPQIATSTSLLAAQSLVPPPGLPGSSTPGVLPYFPPGLPPPDAGGAPQSSMSESPDVNLVTQQLSKSQVEDPLPPVFSGTPKGSGAGYGVGFDLEEFLNQSFDMGVADGPQDGQADSASLSASLLADWLEGHGMNPADIESLQREIQMDSPMLLADLPDLQDP T70851 DRUGINFO D0L7SK PMID26924192-Compound-30 Patented T70851 DRUGINFO D0SB3H PMID26924192-Compound-32 Patented T70851 DRUGINFO D0VB3P PMID26924192-Compound-33 Patented T70851 DRUGINFO D0M0QQ XMD8-92 Investigative T92803 TARGETID T92803 T92803 FORMERID TTDI03162 T92803 UNIPROID DYR1A_HUMAN T92803 TARGNAME Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) T92803 GENENAME DYRK1A T92803 TARGTYPE Patented-recorded T92803 SYNONYMS hMNB; Protein kinase minibrain homolog; MNBH; MNB; HP86; Dual specificity tyrosine-phosphorylation-regulated kinase 1A; Dual specificity YAK1-related kinase; DYRK T92803 FUNCTION Dual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities. May play a role in a signaling pathway regulating nuclear functions of cell proliferation. Modulates alternative splicing by phosphorylating the splice factor SRSF6 (By similarity). Exhibits a substrate preference for proline at position P+1 and arginine at position P-3. Has pro-survival function and negatively regulates the apoptotic process. Promotes cell survival upon genotoxic stress through phosphorylation of SIRT1. This in turn inhibits TP53 activity and apoptosis (By similarity). T92803 PDBSTRUC 6EJ4; 6EIV; 6EIS; 6EIR; 6EIQ T92803 BIOCLASS Kinase T92803 ECNUMBER EC 2.7.12.1 T92803 SEQUENCE MHTGGETSACKPSSVRLAPSFSFHAAGLQMAGQMPHSHQYSDRRQPNISDQQVSALSYSDQIQQPLTNQVMPDIVMLQRRMPQTFRDPATAPLRKLSVDLIKTYKHINEVYYAKKKRRHQQGQGDDSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADEGTNTSNSVSTSPAMEQSQSSGTTSSTSSSSGGSSGTSNSGRARSDPTHQHRHSGGHFTAAVQAMDCETHSPQVRQQFPAPLGWSGTEAPTQVTVETHPVQETTFHVAPQQNALHHHHGNSSHHHHHHHHHHHHHGQQALGNRTRPRVYNSPTNSSSTQDSMEVGHSHHSMTSLSSSTTSSSTSSSSTGNQGNQAYQNRPVAANTLDFGQNGAMDVNLTVYSNPRQETGIAGHPTYQFSANTGPAHYMTEGHLTMRQGADREESPMTGVCVQQSPVASS T92803 DRUGINFO D03TFJ Benzimidazole Patented T92803 DRUGINFO D05BVP PMID28766366-Compound-Scheme8NCGC-00010037 Patented T92803 DRUGINFO D05ZHR PMID28766366-Compound-Scheme12-3 Patented T92803 DRUGINFO D06TIU PMID28766366-Compound-Scheme12-1 Patented T92803 DRUGINFO D09UNF PMID28766366-Compound-Scheme24Paprotrain Patented T92803 DRUGINFO D0A7CE PMID28766366-Compound-Scheme15-1 Patented T92803 DRUGINFO D0B0AS PMID28766366-Compound-Scheme27LeucettineL41derivatives Patented T92803 DRUGINFO D0GV3X PMID28766366-Compound-Scheme24-11H-pyrido[4,3-a]carbazole Patented T92803 DRUGINFO D0I8CT PMID28766366-Compound-Scheme15-2 Patented T92803 DRUGINFO D0JQ0Z PMID28766366-Compound-Scheme8NCGC-00189310 Patented T92803 DRUGINFO D0K2BT PMID28766366-Compound-Scheme12-4 Patented T92803 DRUGINFO D0L2XV PMID28766366-Compound-Scheme18 Patented T92803 DRUGINFO D0NS6I PMID28766366-Compound-Scheme27LeucettamineB Patented T92803 DRUGINFO D0O9WA PMID28766366-Compound-Scheme23MPPDerivatives Patented T92803 DRUGINFO D0PM1B PMID28766366-Compound-Scheme12-2 Patented T92803 DRUGINFO D0Q3VZ PMID28766366-Compound-Scheme27LeucettineL41 Patented T92803 DRUGINFO D0RG1T PMID28766366-Compound-Scheme13INDY Patented T92803 DRUGINFO D0UY8K PMID28766366-Compound-Scheme8NCGC-00185981 Patented T92803 DRUGINFO D0X0ZC PMID28766366-Compound-Scheme15-3 Patented T92803 DRUGINFO D0X5MW PMID28766366-Compound-Scheme1WO2011135259 Patented T92803 DRUGINFO D0X8NN PMID28766366-Compound-Scheme11 Patented T92803 DRUGINFO D0YT1S PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines Patented T92803 DRUGINFO D00TFF PMID28766366-Compound-Scheme2WO2012/098065bottom Patented T92803 DRUGINFO D02GEJ PMID28766366-Compound-Scheme16DMAT Patented T92803 DRUGINFO D05CLL PMID28766366-Compound-Scheme7WO2012/098070upper Patented T92803 DRUGINFO D08CUF PMID28766366-Compound-Scheme9EHT1610 Patented T92803 DRUGINFO D08DIJ PMID28766366-Compound-Scheme9EHT5372 Patented T92803 DRUGINFO D09CDR PMID28766366-Compound-Scheme25-2 Patented T92803 DRUGINFO D0B8IQ PMID28766366-Compound-Scheme2WO2012/098065upper Patented T92803 DRUGINFO D0BP6J PMID28766366-Compound-Scheme7WO2012/098070bottom Patented T92803 DRUGINFO D0C0BP PMID28766366-Compound-Scheme4Upper Patented T92803 DRUGINFO D0CC7E PMID28766366-Compound-Scheme25-3 Patented T92803 DRUGINFO D0DT5I PMID28766366-Compound-Scheme9EHT3356 Patented T92803 DRUGINFO D0GE4F PMID28766366-Compound-Scheme25-4 Patented T92803 DRUGINFO D0O9BK PMID28766366-Compound-Scheme9EHT6840 Patented T92803 DRUGINFO D0P7QO PMID28766366-Compound-Scheme5 Patented T92803 DRUGINFO D0PJ1W PMID28766366-Compound-Scheme9EHT9851 Patented T92803 DRUGINFO D0SB1W PMID28766366-Compound-Scheme4Bottom Patented T92803 DRUGINFO D04SYJ PMID28766366-Compound-Scheme14BINDY Patented T92803 DRUGINFO D06MBI TG003 Patented T92803 DRUGINFO D00OWF Harmine Patented T92803 DRUGINFO D02DBH PMID28766366-Compound-Scheme21Left Patented T92803 DRUGINFO D07BWC PMID28766366-Compound-Scheme21Right Patented T92803 DRUGINFO D00AQR WO2013026806C72 Investigative T92803 DRUGINFO D0X9PI PMID24900699C68 Investigative T92803 DRUGINFO D00BAJ KH-CB19 Investigative T92803 DRUGINFO D0UI7U ML315 Investigative T92803 DRUGINFO D06CXU PMID23642479C17 Investigative T92803 DRUGINFO D04IMY leucettine L41 Investigative T42932 TARGETID T42932 T42932 UNIPROID TLR1_HUMAN T42932 TARGNAME Toll-like receptor 1 (TLR1) T42932 GENENAME TLR1 T42932 TARGTYPE Patented-recorded T42932 SYNONYMS Toll/interleukin-1 receptor-like protein; TIL; KIAA0012; CD281 T42932 FUNCTION Specifically recognizes diacylated and triacylated lipopeptides. Cooperates with TLR2 to mediate the innate immune response to bacterial lipoproteins or lipopeptides. Forms the activation cluster TLR2:TLR1:CD14 in response to triacylated lipopeptides, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Participates in the innate immune response to microbial agents. T42932 PDBSTRUC 6NIH; 2Z7X; 1FYV T42932 BIOCLASS Toll-like receptor T42932 SEQUENCE MTSIFHFAIIFMLILQIRIQLSEESEFLVDRSKNGLIHVPKDLSQKTTILNISQNYISELWTSDILSLSKLRILIISHNRIQYLDISVFKFNQELEYLDLSHNKLVKISCHPTVNLKHLDLSFNAFDALPICKEFGNMSQLKFLGLSTTHLEKSSVLPIAHLNISKVLLVLGETYGEKEDPEGLQDFNTESLHIVFPTNKEFHFILDVSVKTVANLELSNIKCVLEDNKCSYFLSILAKLQTNPKLSNLTLNNIETTWNSFIRILQLVWHTTVWYFSISNVKLQGQLDFRDFDYSGTSLKALSIHQVVSDVFGFPQSYIYEIFSNMNIKNFTVSGTRMVHMLCPSKISPFLHLDFSNNLLTDTVFENCGHLTELETLILQMNQLKELSKIAEMTTQMKSLQQLDISQNSVSYDEKKGDCSWTKSLLSLNMSSNILTDTIFRCLPPRIKVLDLHSNKIKSIPKQVVKLEALQELNVAFNSLTDLPGCGSFSSLSVLIIDHNSVSHPSADFFQSCQKMRSIKAGDNPFQCTCELGEFVKNIDQVSSEVLEGWPDSYKCDYPESYRGTLLKDFHMSELSCNITLLIVTIVATMLVLAVTVTSLCSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSGHDSFWVKNELLPNLEKEGMQICLHERNFVPGKSIVENIITCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFHEGSNSLILILLEPIPQYSIPSSYHKLKSLMARRTYLEWPKEKSKRGLFWANLRAAINIKLTEQAKK T83202 TARGETID T83202 T83202 FORMERID TTDI03518 T83202 UNIPROID KS6A1_HUMAN T83202 TARGNAME Ribosomal protein S6 kinase alpha-1 (RSK1) T83202 GENENAME RPS6KA1 T83202 TARGTYPE Patented-recorded T83202 SYNONYMS p90S6K; p90RSK1; p90-RSK 1; S6K-alpha-1; Ribosomal S6 kinase 1; RSK-1; MAPKAPK1A; MAPKAPK-1a; MAPKAP kinase 1a; MAPK-activated protein kinase 1a; MAP kinase-activated protein kinase 1a; 90 kDa ribosomal protein S6 kinase 1 T83202 FUNCTION In fibroblast, is required for EGF-stimulated phosphorylation of CREB1, which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the pre-initiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Mediates induction of hepatocyte prolifration by TGFA through phosphorylation of CEBPB. Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration. Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. T83202 PDBSTRUC 5V62; 5V61; 5N7G; 5N7F; 5N7D T83202 BIOCLASS Kinase T83202 ECNUMBER EC 2.7.11.1 T83202 SEQUENCE MPLAQLKEPWPLMELVPLDPENGQTSGEEAGLQPSKDEGVLKEISITHHVKAGSEKADPSHFELLKVLGQGSFGKVFLVRKVTRPDSGHLYAMKVLKKATLKVRDRVRTKMERDILADVNHPFVVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALGLDHLHSLGIIYRDLKPENILLDEEGHIKLTDFGLSKEAIDHEKKAYSFCGTVEYMAPEVVNRQGHSHSADWWSYGVLMFEMLTGSLPFQGKDRKETMTLILKAKLGMPQFLSTEAQSLLRALFKRNPANRLGSGPDGAEEIKRHVFYSTIDWNKLYRREIKPPFKPAVAQPDDTFYFDTEFTSRTPKDSPGIPPSAGAHQLFRGFSFVATGLMEDDGKPRAPQAPLHSVVQQLHGKNLVFSDGYVVKETIGVGSYSECKRCVHKATNMEYAVKVIDKSKRDPSEEIEILLRYGQHPNIITLKDVYDDGKHVYLVTELMRGGELLDKILRQKFFSEREASFVLHTIGKTVEYLHSQGVVHRDLKPSNILYVDESGNPECLRICDFGFAKQLRAENGLLMTPCYTANFVAPEVLKRQGYDEGCDIWSLGILLYTMLAGYTPFANGPSDTPEEILTRIGSGKFTLSGGNWNTVSETAKDLVSKMLHVDPHQRLTAKQVLQHPWVTQKDKLPQSQLSHQDLQLVKGAMAATYSALNSSKPTPQLKPIESSILAQRRVRKLPSTTL T83202 DRUGINFO D00RPW 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1 Patented T83202 DRUGINFO D08QMJ Heterocyclic derivative 26 Patented T83202 DRUGINFO D0I3YK 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2 Patented T83202 DRUGINFO D0R0DW Pyrrolo[2,3-d]pyrimidine derivative 1 Patented T83202 DRUGINFO D0T2CA Pyrrolo[2,3-d]pyrimidine derivative 2 Patented T83202 DRUGINFO D02VBF BI-D1870 Preclinical T83202 DRUGINFO D06PJW GSK-1838705A Investigative T83202 DRUGINFO D01YWE PMID19364658C33 Investigative T09197 TARGETID T09197 T09197 UNIPROID LRRK2_HUMAN T09197 TARGNAME Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) T09197 GENENAME LRRK2 T09197 TARGTYPE Patented-recorded T09197 SYNONYMS PARK8 G2019S mutant; LRRK2 G2019S mutant; Dardarin G2019S mutant T09197 FUNCTION The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease. Plays an important role in recuiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. T09197 PDBSTRUC 6DLP; 6DLO; 5MYC; 5MY9; 3D6T T09197 BIOCLASS Kinase T09197 ECNUMBER EC 2.7.11.1 T09197 SEQUENCE MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLVFTYSERASKLFQGKNIHVPLLIVLDSYMRVASVQQVGWSLLCKLIEVCPGTMQSLMGPQDVGNDWEVLGVHQLILKMLTVHNASVNLSVIGLKTLDLLLTSGKITLLILDEESDIFMLIFDAMHSFPANDEVQKLGCKALHVLFERVSEEQLTEFVENKDYMILLSALTNFKDEEEIVLHVLHCLHSLAIPCNNVEVLMSGNVRCYNIVVEAMKAFPMSERIQEVSCCLLHRLTLGNFFNILVLNEVHEFVVKAVQQYPENAALQISALSCLALLTETIFLNQDLEEKNENQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDEDGHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQKHIHSPEVAESGCKMLNHLFEGSNTSLDIMAAVVPKILTVMKRHETSLPVQLEALRAILHFIVPGMPEESREDTEFHHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKVISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLIGYLITKKNVFIGTGHLLAKILVSSLYRFKDVAEIQTKGFQTILAILKLSASFSKLLVHHSFDLVIFHQMSSNIMEQKDQQFLNLCCKCFAKVAMDDYLKNVMLERACDQNNSIMVECLLLLGADANQAKEGSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGKGDSQIISLLLRRLALDVANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEEGTASGSDGNFSEDVLSKFDEWTFIPDSSMDSVFAQSDDLDSEGSEGSFLVKKKSNSISVGEFYRDAVLQRCSPNLQRHSNSLGPIFDHEDLLKRKRKILSSDDSLRSSKLQSHMRHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMKLMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACMSKITKELLNKRGFPAIRDYHFVNATEESDALAKLRKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE T09197 DRUGINFO D00FKF Pyrrolo-pyridine derivative 2 Patented T09197 DRUGINFO D08WVK Oxindole derivative 3 Patented T09197 DRUGINFO D0D6DN Aminopyridine derivative 3 Patented T09197 DRUGINFO D0QK7K Oxindole derivative 4 Patented T09977 TARGETID T09977 T09977 UNIPROID LRRK2_HUMAN T09977 TARGNAME Leucine-rich repeat kinase 2 S935 phosphorylation (LRRK2 pS935) T09977 GENENAME LRRK2 T09977 TARGTYPE Patented-recorded T09977 SYNONYMS PARK8 S935 phosphorylation; LRRK2 S935 phosphorylation; Dardarin S935 phosphorylation T09977 FUNCTION The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease. Plays an important role in recuiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. T09977 PDBSTRUC 6DLP; 6DLO; 5MYC; 5MY9; 3D6T T09977 BIOCLASS Kinase T09977 ECNUMBER EC 2.7.11.1 T09977 SEQUENCE MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLVFTYSERASKLFQGKNIHVPLLIVLDSYMRVASVQQVGWSLLCKLIEVCPGTMQSLMGPQDVGNDWEVLGVHQLILKMLTVHNASVNLSVIGLKTLDLLLTSGKITLLILDEESDIFMLIFDAMHSFPANDEVQKLGCKALHVLFERVSEEQLTEFVENKDYMILLSALTNFKDEEEIVLHVLHCLHSLAIPCNNVEVLMSGNVRCYNIVVEAMKAFPMSERIQEVSCCLLHRLTLGNFFNILVLNEVHEFVVKAVQQYPENAALQISALSCLALLTETIFLNQDLEEKNENQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDEDGHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQKHIHSPEVAESGCKMLNHLFEGSNTSLDIMAAVVPKILTVMKRHETSLPVQLEALRAILHFIVPGMPEESREDTEFHHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKVISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLIGYLITKKNVFIGTGHLLAKILVSSLYRFKDVAEIQTKGFQTILAILKLSASFSKLLVHHSFDLVIFHQMSSNIMEQKDQQFLNLCCKCFAKVAMDDYLKNVMLERACDQNNSIMVECLLLLGADANQAKEGSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGKGDSQIISLLLRRLALDVANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEEGTASGSDGNFSEDVLSKFDEWTFIPDSSMDSVFAQSDDLDSEGSEGSFLVKKKSNSISVGEFYRDAVLQRCSPNLQRHSNSLGPIFDHEDLLKRKRKILSSDDSLRSSKLQSHMRHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMKLMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACMSKITKELLNKRGFPAIRDYHFVNATEESDALAKLRKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE T09977 DRUGINFO D0FS9X Fused thiophene derivative 1 Patented T62266 TARGETID T62266 T62266 UNIPROID I23O2_HUMAN T62266 TARGNAME Indoleamine 2,3-dioxygenase 2 (IDO2) T62266 GENENAME IDO2 T62266 TARGTYPE Patented-recorded T62266 SYNONYMS Indoleamine-pyrrole 2,3-dioxygenase-like protein 1; Indoleamine 2,3-dioxygenase-like protein 1; INDOL1; IDO-2 T62266 FUNCTION Involved in immune regulation. May not play a significant role in tryptophan-related tumoral resistance. Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway. T62266 BIOCLASS Oxygenase T62266 ECNUMBER EC 1.13.11.- T62266 SEQUENCE MLHFHYYDTSNKIMEPHRPNVKTAVPLSLESYHISEEYGFLLPDSLKELPDHYRPWMEIANKLPQLIDAHQLQAHVDKMPLLSCQFLKGHREQRLAHLVLSFLTMGYVWQEGEAQPAEVLPRNLALPFVEVSRNLGLPPILVHSDLVLTNWTKKDPDGFLEIGNLETIISFPGGESLHGFILVTALVEKEAVPGIKALVQATNAILQPNQEALLQALQRLRLSIQDITKTLGQMHDYVDPDIFYAGIRIFLSGWKDNPAMPAGLMYEGVSQEPLKYSGGSAAQSTVLHAFDEFLGIRHSKESGDFLYRMRDYMPPSHKAFIEDIHSAPSLRDYILSSGQDHLLTAYNQCVQALAELRSYHITMVTKYLITAAAKAKHGKPNHLPGPPQALKDRGTGGTAVMSFLKSVRDKTLESILHPRG T62266 DRUGINFO D04BZI 2,3-diamino-benzo[b]thiophene derivative 4 Patented T62266 DRUGINFO D04MIQ PMID27172114-Compound-30 Patented T62266 DRUGINFO D05TIP 2,3-diamino-benzo[b]thiophene derivative 2 Patented T62266 DRUGINFO D05ZGX 2,3-diamino-benzo[b]thiophene derivative 8 Patented T62266 DRUGINFO D0F4VD 2,3-diamino-benzo[b]thiophene derivative 7 Patented T62266 DRUGINFO D0FF6H 2,3-diamino-benzo[b]thiophene derivative 6 Patented T62266 DRUGINFO D0HV0Y 2,3-diamino-benzo[b]thiophene derivative 5 Patented T62266 DRUGINFO D0RA7I 2,3-diamino-benzo[b]thiophene derivative 1 Patented T24823 TARGETID T24823 T24823 UNIPROID KDM1B_HUMAN T24823 TARGNAME Lysine-specific histone demethylase 1B (KDM1B) T24823 GENENAME KDM1B T24823 TARGTYPE Patented-recorded T24823 SYNONYMS Lysine-specific histone demethylase 2; LSD2; Flavin-containing amine oxidase domain-containing protein 1; C6orf193; AOF1 T24823 FUNCTION Required for de novo DNA methylation of a subset of imprinted genes during oogenesis. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. Demethylates both mono- and di-methylated 'Lys-4' of histone H3. Has no effect on tri-methylated 'Lys-4', mono-, di- or tri-methylated 'Lys-9', mono-, di- or tri-methylated 'Lys-27', mono-, di- or tri-methylated 'Lys-36' of histone H3, or on mono-, di- or tri-methylated 'Lys-20' of histone H4. Histone demethylase that demethylates 'Lys-4' of histone H3, a specific tag for epigenetic transcriptional activation, thereby acting as a corepressor. T24823 PDBSTRUC 6R25; 6R1U; 4HSU; 4GUU; 4GUT T24823 BIOCLASS CH-NH(2) donor oxidoreductase T24823 ECNUMBER EC 1.-.-.- T24823 SEQUENCE MATPRGRTKKKASFDHSPDSLPLRSSGRQAKKKATETTDEDEDGGSEKKYRKCEKAGCTATCPVCFASASERCAKNGYTSRWYHLSCGEHFCNECFDHYYRSHKDGYDKYTTWKKIWTSNGKTEPSPKAFMADQQLPYWVQCTKPECRKWRQLTKEIQLTPQIAKTYRCGMKPNTAIKPETSDHCSLPEDLRVLEVSNHWWYSMLILPPLLKDSVAAPLLSAYYPDCVGMSPSCTSTNRAAATGNASPGKLEHSKAALSVHVPGMNRYFQPFYQPNECGKALCVRPDVMELDELYEFPEYSRDPTMYLALRNLILALWYTNCKEALTPQKCIPHIIVRGLVRIRCVQEVERILYFMTRKGLINTGVLSVGADQYLLPKDYHNKSVIIIGAGPAGLAAARQLHNFGIKVTVLEAKDRIGGRVWDDKSFKGVTVGRGAQIVNGCINNPVALMCEQLGISMHKFGERCDLIQEGGRITDPTIDKRMDFHFNALLDVVSEWRKDKTQLQDVPLGEKIEEIYKAFIKESGIQFSELEGQVLQFHLSNLEYACGSNLHQVSARSWDHNEFFAQFAGDHTLLTPGYSVIIEKLAEGLDIQLKSPVQCIDYSGDEVQVTTTDGTGYSAQKVLVTVPLALLQKGAIQFNPPLSEKKMKAINSLGAGIIEKIALQFPYRFWDSKVQGADFFGHVPPSASKRGLFAVFYDMDPQKKHSVLMSVIAGEAVASVRTLDDKQVLQQCMATLRELFKEQEVPDPTKYFVTRWSTDPWIQMAYSFVKTGGSGEAYDIIAEDIQGTVFFAGEATNRHFPQTVTGAYLSGVREASKIAAF T24823 DRUGINFO D09OMM PMID27019002-Compound-48 Patented T24823 DRUGINFO D0WO5W PMID27019002-Compound-47 Patented T24823 DRUGINFO D0Z7HE PMID27019002-Compound-46 Patented T24823 DRUGINFO D04OHC Tarnylcypromine derivative 2 Patented T24823 DRUGINFO D0O7IH Tarnylcypromine derivative 3 Patented T12952 TARGETID T12952 T12952 UNIPROID UBP33_HUMAN T12952 TARGNAME VHL-interacting deubiquitinating enzyme 1 (VDU1) T12952 GENENAME USP33 T12952 TARGTYPE Patented-recorded T12952 SYNONYMS hVDU1; Ubiquitin-specific-processing protease 33; Ubiquitin thioesterase 33; Ubiquitin carboxyl-terminal hydrolase 33; KIAA1097; Deubiquitinating enzyme 33 T12952 FUNCTION Involved in regulation of centrosome duplication by mediating deubiquitination of CCP110 in S and G2/M phase, leading to stabilize CCP110 during the period which centrioles duplicate and elongate. Involved in cell migration via its interaction with intracellular domain of ROBO1, leading to regulate the Slit signaling. Plays a role in commissural axon guidance cross the ventral midline of the neural tube in a Slit-dependent manner, possibly by mediating the deubiquitination of ROBO1. Acts as a regulator of G-protein coupled receptor (GPCR) signaling by mediating the deubiquitination of beta-arrestins (ARRB1 and ARRB2) and beta-2 adrenergic receptor (ADRB2). Plays a central role in ADRB2 recycling and resensitization after prolonged agonist stimulation by constitutively binding ADRB2, mediating deubiquitination of ADRB2 and inhibiting lysosomal trafficking of ADRB2. Upon dissociation, it is probably transferred to the translocated beta-arrestins, leading to beta-arrestins deubiquitination and disengagement from ADRB2. This suggests the existence of a dynamic exchange between the ADRB2 and beta-arrestins. Deubiquitinates DIO2, thereby regulating thyroid hormone regulation. Mediates deubiquitination of both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. Deubiquitinating enzyme involved in various processes such as centrosome duplication, cellular migration and beta-2 adrenergic receptor/ADRB2 recycling. T12952 PDBSTRUC 2UZG T12952 BIOCLASS Peptidase T12952 ECNUMBER EC 3.4.19.12 T12952 SEQUENCE MTGSNSHITILTLKVLPHFESLGKQEKIPNKMSAFRNHCPHLDSVGEITKEDLIQKSLGTCQDCKVQGPNLWACLENRCSYVGCGESQVDHSTIHSQETKHYLTVNLTTLRVWCYACSKEVFLDRKLGTQPSLPHVRQPHQIQENSVQDFKIPSNTTLKTPLVAVFDDLDIEADEEDELRARGLTGLKNIGNTCYMNAALQALSNCPPLTQFFLDCGGLARTDKKPAICKSYLKLMTELWHKSRPGSVVPTTLFQGIKTVNPTFRGYSQQDAQEFLRCLMDLLHEELKEQVMEVEEDPQTITTEETMEEDKSQSDVDFQSCESCSNSDRAENENGSRCFSEDNNETTMLIQDDENNSEMSKDWQKEKMCNKINKVNSEGEFDKDRDSISETVDLNNQETVKVQIHSRASEYITDVHSNDLSTPQILPSNEGVNPRLSASPPKSGNLWPGLAPPHKKAQSASPKRKKQHKKYRSVISDIFDGTIISSVQCLTCDRVSVTLETFQDLSLPIPGKEDLAKLHSSSHPTSIVKAGSCGEAYAPQGWIAFFMEYVKRFVVSCVPSWFWGPVVTLQDCLAAFFARDELKGDNMYSCEKCKKLRNGVKFCKVQNFPEILCIHLKRFRHELMFSTKISTHVSFPLEGLDLQPFLAKDSPAQIVTYDLLSVICHHGTASSGHYIAYCRNNLNNLWYEFDDQSVTEVSESTVQNAEAYVLFYRKSSEEAQKERRRISNLLNIMEPSLLQFYISRQWLNKFKTFAEPGPISNNDFLCIHGGVPPRKAGYIEDLVLMLPQNIWDNLYSRYGGGPAVNHLYICHTCQIEAEKIEKRRKTELEIFIRLNRAFQKEDSPATFYCISMQWFREWESFVKGKDGDPPGPIDNTKIAVTKCGNVMLRQGADSGQISEETWNFLQSIYGGGPEVILRPPVVHVDPDILQAEEKIEVETRSL T98698 TARGETID T98698 T98698 FORMERID TTDI03261 T98698 UNIPROID HDAC7_HUMAN T98698 TARGNAME Histone deacetylase 7 (HDAC7) T98698 GENENAME HDAC7 T98698 TARGTYPE Patented-recorded T98698 SYNONYMS Histone deacetylase 7A; HDAC7A; HD7a; HD7 T98698 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation by repressing transcription of myocyte enhancer factors such as MEF2A, MEF2B and MEF2C. During muscle differentiation, it shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors. May be involved in Epstein-Barr virus (EBV) latency, possibly by repressing the viral BZLF1 gene. Positively regulates the transcriptional repressor activity of FOXP3. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). T98698 PDBSTRUC 3ZNS; 3ZNR; 3C10; 3C0Z; 3C0Y T98698 BIOCLASS Carbon-nitrogen hydrolase T98698 ECNUMBER EC 3.5.1.98 T98698 SEQUENCE MDLRVGQRPPVEPPPEPTLLALQRPQRLHHHLFLAGLQQQRSVEPMRLSMDTPMPELQVGPQEQELRQLLHKDKSKRSAVASSVVKQKLAEVILKKQQAALERTVHPNSPGIPYRTLEPLETEGATRSMLSSFLPPVPSLPSDPPEHFPLRKTVSEPNLKLRYKPKKSLERRKNPLLRKESAPPSLRRRPAETLGDSSPSSSSTPASGCSSPNDSEHGPNPILGSEALLGQRLRLQETSVAPFALPTVSLLPAITLGLPAPARADSDRRTHPTLGPRGPILGSPHTPLFLPHGLEPEAGGTLPSRLQPILLLDPSGSHAPLLTVPGLGPLPFHFAQSLMTTERLSGSGLHWPLSRTRSEPLPPSATAPPPPGPMQPRLEQLKTHVQVIKRSAKPSEKPRLRQIPSAEDLETDGGGPGQVVDDGLEHRELGHGQPEARGPAPLQQHPQVLLWEQQRLAGRLPRGSTGDTVLLPLAQGGHRPLSRAQSSPAAPASLSAPEPASQARVLSSSETPARTLPFTTGLIYDSVMLKHQCSCGDNSRHPEHAGRIQSIWSRLQERGLRSQCECLRGRKASLEELQSVHSERHVLLYGTNPLSRLKLDNGKLAGLLAQRMFVMLPCGGVGVDTDTIWNELHSSNAARWAAGSVTDLAFKVASRELKNGFAVVRPPGHHADHSTAMGFCFFNSVAIACRQLQQQSKASKILIVDWDVHHGNGTQQTFYQDPSVLYISLHRHDDGNFFPGSGAVDEVGAGSGEGFNVNVAWAGGLDPPMGDPEYLAAFRIVVMPIAREFSPDLVLVSAGFDAAEGHPAPLGGYHVSAKCFGYMTQQLMNLAGGAVVLALEGGHDLTAICDASEACVAALLGNRVDPLSEEGWKQKPNLNAIRSLEAVIRVHSKYWGCMQRLASCPDSWVPRVPGADKEEVEAVTALASLSVGILAEDRPSEQLVEEEEPMNL T98698 DRUGINFO D0YN2T PMID29671355-Compound-45a Patented T98698 DRUGINFO D0CH8Q PMID29671355-Compound-56 Patented T98698 DRUGINFO D0M0RE PMID29671355-Compound-67 Patented T98698 DRUGINFO D0DI9S PMID29671355-Compound-31 Patented T98698 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T98698 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T98698 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T98698 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T98698 DRUGINFO D0R7JA TMP269 Investigative T39486 TARGETID T39486 T39486 FORMERID TTDI03164 T39486 UNIPROID DYRK2_HUMAN T39486 TARGNAME Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) T39486 GENENAME DYRK2 T39486 TARGTYPE Patented-recorded T39486 SYNONYMS Dual specificity tyrosine-phosphorylation-regulated kinase 2 T39486 FUNCTION Functions in part via its role in ubiquitin-dependent proteasomal protein degradation. Functions downstream of ATM and phosphorylates p53/TP53 at 'Ser-46', and thereby contributes to the induction of apoptosis in response to DNA damage. Phosphorylates NFATC1, and thereby inhibits its accumulation in the nucleus and its transcription factor activity. Phosphorylates EIF2B5 at 'Ser-544', enabling its subsequent phosphorylation and inhibition by GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May play a general role in the priming of GSK3 substrates. Inactivates GYS1 by phosphorylation at 'Ser-641', and potentially also a second phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP E3 ligase complex formation and is required for the phosphorylation and subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', promoting TERT ubiquitination by the EDVP complex. Phosphorylates SIAH2, and thereby increases its ubiquitin ligase activity. Promotes the proteasomal degradation of MYC and JUN, and thereby regulates progress through the mitotic cell cycle and cell proliferation. Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a role in smoothened and sonic hedgehog signaling. Plays a role in cytoskeleton organization and neurite outgrowth via its phosphorylation of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro). Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth. T39486 PDBSTRUC 5ZTN; 5LXD; 5LXC; 4AZF; 3KVW T39486 BIOCLASS Kinase T39486 ECNUMBER EC 2.7.12.1 T39486 SEQUENCE MLTRKPSAAAPAAYPTGRGGDSAVRQLQASPGLGAGATRSGVGTGPPSPIALPPLRASNAAAAAHTIGGSKHTMNDHLHVGSHAHGQIQVQQLFEDNSNKRTVLTTQPNGLTTVGKTGLPVVPERQLDSIHRRQGSSTSLKSMEGMGKVKATPMTPEQAMKQYMQKLTAFEHHEIFSYPEIYFLGLNAKKRQGMTGGPNNGGYDDDQGSYVQVPHDHVAYRYEVLKVIGKGSFGQVVKAYDHKVHQHVALKMVRNEKRFHRQAAEEIRILEHLRKQDKDNTMNVIHMLENFTFRNHICMTFELLSMNLYELIKKNKFQGFSLPLVRKFAHSILQCLDALHKNRIIHCDLKPENILLKQQGRSGIKVIDFGSSCYEHQRVYTYIQSRFYRAPEVILGARYGMPIDMWSLGCILAELLTGYPLLPGEDEGDQLACMIELLGMPSQKLLDASKRAKNFVSSKGYPRYCTVTTLSDGSVVLNGGRSRRGKLRGPPESREWGNALKGCDDPLFLDFLKQCLEWDPAVRMTPGQALRHPWLRRRLPKPPTGEKTSVKRITESTGAITSISKLPPPSSSASKLRTNLAQMTDANGNIQQRTVLPKLVS T39486 DRUGINFO D02GEJ PMID28766366-Compound-Scheme16DMAT Patented T39486 DRUGINFO D04SYJ PMID28766366-Compound-Scheme14BINDY Patented T39486 DRUGINFO D00OWF Harmine Patented T39486 DRUGINFO D02DBH PMID28766366-Compound-Scheme21Left Patented T39486 DRUGINFO D07BWC PMID28766366-Compound-Scheme21Right Patented T39486 DRUGINFO D04IMY leucettine L41 Investigative T14894 TARGETID T14894 T14894 UNIPROID CASPA_HUMAN T14894 TARGNAME Caspase-10 (CASP10) T14894 GENENAME CASP10 T14894 TARGTYPE Patented-recorded T14894 SYNONYMS MCH4; ICE-like apoptotic protease 4; FLICE2; FAS-associated death domain protein interleukin-1B-converting enzyme 2; Caspase-10 subunit p23/17; Caspase-10 subunit p12; CASP-10; Apoptotic protease Mch-4 T14894 FUNCTION Recruited to both Fas- and TNFR-1 receptors in a FADD dependent manner. May participate in the granzyme B apoptotic pathways. Cleaves and activates caspase-3, -4, -6, -7, -8, and -9. Hydrolyzes the small- molecule substrates, Tyr-Val-Ala-Asp-|-AMC and Asp-Glu-Val-Asp-|-AMC. Involved in the activation cascade of caspases responsible for apoptosis execution. T14894 BIOCLASS Peptidase T14894 ECNUMBER EC 3.4.22.63 T14894 SEQUENCE MKSQGQHWYSSSDKNCKVSFREKLLIIDSNLGVQDVENLKFLCIGLVPNKKLEKSSSASDVFEHLLAEDLLSEEDPFFLAELLYIIRQKKLLQHLNCTKEEVERLLPTRQRVSLFRNLLYELSEGIDSENLKDMIFLLKDSLPKTEMTSLSFLAFLEKQGKIDEDNLTCLEDLCKTVVPKLLRNIEKYKREKAIQIVTPPVDKEAESYQGEEELVSQTDVKTFLEALPQESWQNKHAGSNGNRATNGAPSLVSRGMQGASANTLNSETSTKRAAVYRMNRNHRGLCVIVNNHSFTSLKDRQGTHKDAEILSHVFQWLGFTVHIHNNVTKVEMEMVLQKQKCNPAHADGDCFVFCILTHGRFGAVYSSDEALIPIREIMSHFTALQCPRLAEKPKLFFIQACQGEEIQPSVSIEADALNPEQAPTSLQDSIPAEADFLLGLATVPGYVSFRHVEEGSWYIQSLCNHLKKLVPRMLKFLEKTMEIRGRKRTVWGAKQISATSLPTAISAQTPRPPMRRWSSVS T57050 TARGETID T57050 T57050 UNIPROID ZUP1_HUMAN T57050 TARGNAME Zinc finger-containing ubiquitin peptidase 1 (ZUP1) T57050 GENENAME ZUP1 T57050 TARGTYPE Patented-recorded T57050 SYNONYMS Zinc finger with UFM1-specific peptidase domain protein; ZUFSP; Lys-63-specific deubiquitinase ZUFSP; DUB; C6orf113 T57050 FUNCTION Shows only weak activity against 'Lys-11' and 'Lys-48'-linked chains. Plays an important role in genome stability pathways, functioning to prevent spontaneous DNA damage and also promote cellular survival in response to exogenous DNA damage. Modulates the ubiquitination status of replication protein A (RPA) complex proteins in response to replication stress. Deubiquitinase with endodeubiquitinase activity that specifically interacts with and cleaves 'Lys-63'-linked long polyubiquitin chains. T57050 PDBSTRUC 6FGE; 6EI1 T57050 BIOCLASS Peptidase T57050 ECNUMBER EC 3.4.19.12 T57050 SEQUENCE MLSCNICGETVTSEPDMKAHLIVHMESEIICPFCKLSGVNYDEMCFHIETAHFEQNTLERNFERINTVQYGTSDNKKDNTLQCGMEVNSSILSGCASNHPKNSAQNLTKDSTLKHEGFYSENLTESRKFLKSREKQSSLTEIKGSVYETTYSPPECPFCGKIEEHSEDMETHVKTKHANLLDIPLEDCDQPLYDCPMCGLICTNYHILQEHVDLHLEENSFQQGMDRVQCSGDLQLAHQLQQEEDRKRRSEESRQEIEEFQKLQRQYGLDNSGGYKQQQLRNMEIEVNRGRMPPSEFHRRKADMMESLALGFDDGKTKTSGIIEALHRYYQNAATDVRRVWLSSVVDHFHSSLGDKGWGCGYRNFQMLLSSLLQNDAYNDCLKGMLIPCIPKIQSMIEDAWKEGFDPQGASQLNNRLQGTKAWIGACEVYILLTSLRVKCHIVDFHKSTGPLGTHPRLFEWILNYYSSEGEGSPKVVCTSKPPIYLQHQGHSRTVIGIEEKKNRTLCLLILDPGCPSREMQKLLKQDIEASSLKQLRKSMGNLKHKQYQILAVEGALSLEEKLARRQASQVFTAEKIP T57050 DRUGINFO D04MQF Tricyclic heterocycle derivative 3 Patented T57050 DRUGINFO D0EG8Y PMID26077642-Compound-Figure3H Patented T57050 DRUGINFO D0EM8D PMID26077642-Compound-Figure3G Patented T57050 DRUGINFO D0HQ8X Azepan-4-one derivative 1 Patented T57050 DRUGINFO D0PY0H Azepan-4-one derivative 2 Patented T42247 TARGETID T42247 T42247 FORMERID TTDI03049 T42247 UNIPROID BIRC7_HUMAN T42247 TARGNAME Melanoma inhibitor of apoptosis protein (ML-IAP) T42247 GENENAME BIRC7 T42247 TARGTYPE Patented-recorded T42247 SYNONYMS UNQ5800/PRO19607/PRO21344; RNF50; RING-type E3 ubiquitin transferase BIRC7; RING finger protein 50; MLIAP; Livin; Kidney inhibitor of apoptosis protein; KIAP; Baculoviral IAP repeat-containing protein 7 T42247 FUNCTION Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing. Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. T42247 PDBSTRUC 4AUQ; 3UW5; 3GTA; 3GT9; 3F7I T42247 BIOCLASS Acyltransferase T42247 ECNUMBER EC 2.3.2.27 T42247 SEQUENCE MGPKDSAKCLHRGPQPSHWAAGDGPTQERCGPRSLGSPVLGLDTCRAWDHVDGQILGQLRPLTEEEEEEGAGATLSRGPAFPGMGSEELRLASFYDWPLTAEVPPELLAAAGFFHTGHQDKVRCFFCYGGLQSWKRGDDPWTEHAKWFPSCQFLLRSKGRDFVHSVQETHSQLLGSWDPWEEPEDAAPVAPSVPASGYPELPTPRREVQSESAQEPGGVSPAEAQRAWWVLEPPGARDVEAQLRRLQEERTCKVCLDRAVSIVFVPCGHLVCAECAPGLQLCPICRAPVRSRVRTFLS T42247 DRUGINFO D09VAX PMID25980951-Compound-6 Patented T97903 TARGETID T97903 T97903 UNIPROID HDA11_HUMAN T97903 TARGNAME Histone deacetylase 11 (HDAC11) T97903 GENENAME HDAC11 T97903 TARGTYPE Patented-recorded T97903 SYNONYMS HD11 T97903 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). T97903 BIOCLASS Carbon-nitrogen hydrolase T97903 ECNUMBER EC 3.5.1.98 T97903 SEQUENCE MLHTTQLYQHVPETRWPIVYSPRYNITFMGLEKLHPFDAGKWGKVINFLKEEKLLSDSMLVEAREASEEDLLVVHTRRYLNELKWSFAVATITEIPPVIFLPNFLVQRKVLRPLRTQTGGTIMAGKLAVERGWAINVGGGFHHCSSDRGGGFCAYADITLAIKFLFERVEGISRATIIDLDAHQGNGHERDFMDDKRVYIMDVYNRHIYPGDRFAKQAIRRKVELEWGTEDDEYLDKVERNIKKSLQEHLPDVVVYNAGTDILEGDRLGGLSISPAGIVKRDELVFRMVRGRRVPILMVTSGGYQKRTARIIADSILNLFGLGLIGPESPSVSAQNSDTPLLPPAVP T97903 DRUGINFO D04JWR PMID29671355-Compound-36 Patented T97903 DRUGINFO D00HXJ PMID29671355-Compound-23 Patented T97903 DRUGINFO D0N2DK PMID29671355-Compound-44 Patented T97903 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T97903 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T97903 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T97903 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T81452 TARGETID T81452 T81452 UNIPROID ABHD6_HUMAN T81452 TARGNAME Monoacylglycerol lipase ABHD6 (ABHD6) T81452 GENENAME ABHD6 T81452 TARGTYPE Patented-recorded T81452 SYNONYMS Abhydrolase domain-containing protein 6; 2-arachidonoylglycerol hydrolase T81452 FUNCTION Lipase that preferentially hydrolysis medium-chain saturated monoacylglycerols including 2-arachidonoylglycerol. Through 2-arachidonoylglycerol degradation may regulate endocannabinoid signaling pathways. Also has a lysophosphatidyl lipase activity with a preference for lysophosphatidylglycerol among other lysophospholipids. Also able to degrade bis(monoacylglycero)phosphate (BMP) and constitutes the major enzyme for BMP catabolism. BMP, also known as lysobisphosphatidic acid, is enriched in late endosomes and lysosomes and plays a key role in the formation of intraluminal vesicles and in lipid sorting. T81452 BIOCLASS Carboxylic ester hydrolase T81452 ECNUMBER EC 3.1.1.23 T81452 SEQUENCE MDLDVVNMFVIAGGTLAIPILAFVASFLLWPSALIRIYYWYWRRTLGMQVRYVHHEDYQFCYSFRGRPGHKPSILMLHGFSAHKDMWLSVVKFLPKNLHLVCVDMPGHEGTTRSSLDDLSIDGQVKRIHQFVECLKLNKKPFHLVGTSMGGQVAGVYAAYYPSDVSSLCLVCPAGLQYSTDNQFVQRLKELQGSAAVEKIPLIPSTPEEMSEMLQLCSYVRFKVPQQILQGLVDVRIPHNNFYRKLFLEIVSEKSRYSLHQNMDKIKVPTQIIWGKQDQVLDVSGADMLAKSIANCQVELLENCGHSVVMERPRKTAKLIIDFLASVHNTDNNKKLD T81452 DRUGINFO D00TVG Piperazine carbamic compound 4 Patented T81452 DRUGINFO D0TU6D PMID29053063-Compound-11c Patented T81452 DRUGINFO D0Z7FL Piperazine carbamic compound 5 Patented T81452 DRUGINFO D0GT0I PMID29053063-Compound-11d Patented T81452 DRUGINFO D0J6TA Piperazine carbamic compound 1 Patented T81452 DRUGINFO D0LC5Y Piperazine carbamic compound 2 Patented T81452 DRUGINFO D0LL0X Pyrazole derivative 82 Patented T81452 DRUGINFO D0O9DS Pyrazole derivative 81 Patented T81452 DRUGINFO D0X9GC Pyrazole derivative 80 Patented T73863 TARGETID T73863 T73863 FORMERID TTDI03362 T73863 UNIPROID KDM4C_HUMAN T73863 TARGNAME Lysine-specific demethylase 4C (KDM4C) T73863 GENENAME KDM4C T73863 TARGTYPE Patented-recorded T73863 SYNONYMS KIAA0780; Jumonji domain-containing protein 2C; JmjC domain-containing histone demethylation protein 3C; JMJD2C; JHDM3C; Gene amplified in squamous cell carcinoma 1 protein; GASC1; GASC-1 protein T73863 FUNCTION Does not demethylate histone H3 'Lys-4', H3 'Lys-27' nor H4 'Lys-20'. Demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residue, while it has no activity on mono- and dimethylated residues. Demethylation of Lys residue generates formaldehyde and succinate. Histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, thereby playing a central role in histone code. T73863 PDBSTRUC 5KR7; 5FJK; 5FJH; 4XDP; 4XDO T73863 BIOCLASS Paired donor oxygen oxidoreductase T73863 ECNUMBER EC 1.14.11.- T73863 SEQUENCE MEVAEVESPLNPSCKIMTFRPSMEEFREFNKYLAYMESKGAHRAGLAKVIPPKEWKPRQCYDDIDNLLIPAPIQQMVTGQSGLFTQYNIQKKAMTVKEFRQLANSGKYCTPRYLDYEDLERKYWKNLTFVAPIYGADINGSIYDEGVDEWNIARLNTVLDVVEEECGISIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHFGEPKSWYAIPPEHGKRLERLAQGFFPSSSQGCDAFLRHKMTLISPSVLKKYGIPFDKITQEAGEFMITFPYGYHAGFNHGFNCAESTNFATVRWIDYGKVAKLCTCRKDMVKISMDIFVRKFQPDRYQLWKQGKDIYTIDHTKPTPASTPEVKAWLQRRRKVRKASRSFQCARSTSKRPKADEEEEVSDEVDGAEVPNPDSVTDDLKVSEKSEAAVKLRNTEASSEEESSASRMQVEQNLSDHIKLSGNSCLSTSVTEDIKTEDDKAYAYRSVPSISSEADDSIPLSSGYEKPEKSDPSELSWPKSPESCSSVAESNGVLTEGEESDVESHGNGLEPGEIPAVPSGERNSFKVPSIAEGENKTSKSWRHPLSRPPARSPMTLVKQQAPSDEELPEVLSIEEEVEETESWAKPLIHLWQTKSPNFAAEQEYNATVARMKPHCAICTLLMPYHKPDSSNEENDARWETKLDEVVTSEGKTKPLIPEMCFIYSEENIEYSPPNAFLEEDGTSLLISCAKCCVRVHASCYGIPSHEICDGWLCARCKRNAWTAECCLCNLRGGALKQTKNNKWAHVMCAVAVPEVRFTNVPERTQIDVGRIPLQRLKLKCIFCRHRVKRVSGACIQCSYGRCPASFHVTCAHAAGVLMEPDDWPYVVNITCFRHKVNPNVKSKACEKVISVGQTVITKHRNTRYYSCRVMAVTSQTFYEVMFDDGSFSRDTFPEDIVSRDCLKLGPPAEGEVVQVKWPDGKLYGAKYFGSNIAHMYQVEFEDGSQIAMKREDIYTLDEELPKRVKARFSTASDMRFEDTFYGADIIQGERKRQRVLSSRFKNEYVADPVYRTFLKSSFQKKCQKRQ T73863 DRUGINFO D02FWO Pyrido[1,2-a]indole-1.-carboxylic acid analog 4 Patented T73863 DRUGINFO D04KUD Pyrido[1,2-a]indole-1.-carboxylic acid analog 1 Patented T73863 DRUGINFO D07CYB PMID25468267-Compound-56 Patented T73863 DRUGINFO D0BK5N Pyrido[1,2-a]indole-1.-carboxylic acid analog 5 Patented T73863 DRUGINFO D0L5RA PMID25468267-Compound-47 Patented T73863 DRUGINFO D0Q5IR Pyrido[1,2-a]indole-1.-carboxylic acid analog 7 Patented T73863 DRUGINFO D0RP4W Pyrido[1,2-a]indole-1.-carboxylic acid analog 3 Patented T73863 DRUGINFO D0S8AZ Flavonoid derivative 6 Patented T73863 DRUGINFO D0U3KT PMID25468267-Compound-55 Patented T73863 DRUGINFO D0UQ2R Pyrido[1,2-a]indole-1.-carboxylic acid analog 2 Patented T73863 DRUGINFO D0Z2YB Pyrido[1,2-a]indole-1.-carboxylic acid analog 6 Patented T73863 DRUGINFO D0MJ4L Hydroxamate analog 1 Patented T73863 DRUGINFO D09NCT PMID25468267-Compound-46 Patented T73863 DRUGINFO D0X5US IOX1 Investigative T33492 TARGETID T33492 T33492 FORMERID TTDI02629 T33492 UNIPROID TYDP1_HUMAN T33492 TARGNAME Tyrosyl-DNA phosphodiesterase 1 (TDP1) T33492 GENENAME TDP1 T33492 TARGTYPE Patented-recorded T33492 SYNONYMS Tyr-DNA phosphodiesterase 1 T33492 FUNCTION Catalyzes the hydrolysis of dead-end complexes between DNA and the topoisomerase I active site tyrosine residue. Hydrolyzes 3'-phosphoglycolates on protruding 3' ends on DNA double-strand breaks due to DNA damage by radiation and free radicals. Acts on blunt-ended double-strand DNA breaks and on single-stranded DNA. Has low 3'exonuclease activity and can remove a single nucleoside from the 3'end of DNA and RNA molecules with 3'hydroxyl groups. Has no exonuclease activity towards DNA or RNA with a 3'phosphate. DNA repair enzyme that can remove a variety of covalent adducts from DNA through hydrolysis of a 3'-phosphodiester bond, giving rise to DNA with a free 3' phosphate. T33492 PDBSTRUC 5NWA; 5NW9; 1RH0; 1RGU; 1RGT T33492 BIOCLASS Phosphoric diester hydrolase T33492 ECNUMBER EC 3.1.4.- T33492 SEQUENCE MSQEGDYGRWTISSSDESEEEKPKPDKPSTSSLLCARQGAANEPRYTCSEAQKAAHKRKISPVKFSNTDSVLPPKRQKSGSQEDLGWCLSSSDDELQPEMPQKQAEKVVIKKEKDISAPNDGTAQRTENHGAPACHRLKEEEDEYETSGEGQDIWDMLDKGNPFQFYLTRVSGVKPKYNSGALHIKDILSPLFGTLVSSAQFNYCFDVDWLVKQYPPEFRKKPILLVHGDKREAKAHLHAQAKPYENISLCQAKLDIAFGTHHTKMMLLLYEEGLRVVIHTSNLIHADWHQKTQGIWLSPLYPRIADGTHKSGESPTHFKADLISYLMAYNAPSLKEWIDVIHKHDLSETNVYLIGSTPGRFQGSQKDNWGHFRLKKLLKDHASSMPNAESWPVVGQFSSVGSLGADESKWLCSEFKESMLTLGKESKTPGKSSVPLYLIYPSVENVRTSLEGYPAGGSLPYSIQTAEKQNWLHSYFHKWSAETSGRSNAMPHIKTYMRPSPDFSKIAWFLVTSANLSKAAWGALEKNGTQLMIRSYELGVLFLPSAFGLDSFKVKQKFFAGSQEPMATFPVPYDLPPELYGSKDRPWIWNIPYVKAPDTHGNMWVPS T63024 TARGETID T63024 T63024 FORMERID TTDI03570 T63024 UNIPROID TBK1_HUMAN T63024 TARGNAME NF-kappa-B-activating kinase (TBK1) T63024 GENENAME TBK1 T63024 TARGTYPE Patented-recorded T63024 SYNONYMS TANK-binding kinase 1; T2K; Serine/threonine-protein kinase TBK1; NAK T63024 FUNCTION Following activation of toll-like receptors by viral or bacterial components, associates with TRAF3 and TANK and phosphorylates interferon regulatory factors (IRFs) IRF3 and IRF7 as well as DDX3X. This activity allows subsequent homodimerization and nuclear translocation of the IRFs leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNA and IFNB. In order to establish such an antiviral state, TBK1 form several different complexes whose composition depends on the type of cell and cellular stimuli. Plays a key role in IRF3 activation: acts by first phosphorylating innate adapter proteins MAVS, TMEM173/STING and TICAM1 on their pLxIS motif, leading to recruitment of IRF3, thereby licensing IRF3 for phosphorylation by TBK1. Phosphorylated IRF3 dissociates from the adapter proteins, dimerizes, and then enters the nucleus to induce expression of interferons. Thus, several scaffolding molecules including FADD, TRADD, MAVS, AZI2, TANK or TBKBP1/SINTBAD can be recruited to the TBK1-containing-complexes. Under particular conditions, functions as a NF-kappa-B effector by phosphorylating NF-kappa-B inhibitor alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the nucleus. Restricts bacterial proliferation by phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-177', thus enhancing LC3 binding affinity and antibacterial autophagy. Phosphorylates SMCR8 component of the C9orf72-SMCR8 complex, promoting autophagosome maturation. Phosphorylates and activates AKT1. Seems to play a role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, wich leads to a negative impact on insulin sensitivity. Attenuates retroviral budding by phosphorylating the endosomal sorting complex required for transport-I (ESCRT-I) subunit VPS37C. Phosphorylates Borna disease virus (BDV) P protein. Plays an essential role in the TLR3- and IFN-dependent control of herpes virus HSV-1 and HSV-2 infections in the central nervous system. Serine/threonine kinase that plays an essential role in regulating inflammatory responses to foreign agents. T63024 PDBSTRUC 6O8B; 6NT9; 6CQ5; 6CQ4; 6CQ0 T63024 BIOCLASS Kinase T63024 ECNUMBER EC 2.7.11.1 T63024 SEQUENCE MQSTSNHLWLLSDILGQGATANVFRGRHKKTGDLFAIKVFNNISFLRPVDVQMREFEVLKKLNHKNIVKLFAIEEETTTRHKVLIMEFCPCGSLYTVLEEPSNAYGLPESEFLIVLRDVVGGMNHLRENGIVHRDIKPGNIMRVIGEDGQSVYKLTDFGAARELEDDEQFVSLYGTEEYLHPDMYERAVLRKDHQKKYGATVDLWSIGVTFYHAATGSLPFRPFEGPRRNKEVMYKIITGKPSGAISGVQKAENGPIDWSGDMPVSCSLSRGLQVLLTPVLANILEADQEKCWGFDQFFAETSDILHRMVIHVFSLQQMTAHKIYIHSYNTATIFHELVYKQTKIISSNQELIYEGRRLVLEPGRLAQHFPKTTEENPIFVVSREPLNTIGLIYEKISLPKVHPRYDLDGDASMAKAITGVVCYACRIASTLLLYQELMRKGIRWLIELIKDDYNETVHKKTEVVITLDFCIRNIEKTVKVYEKLMKINLEAAELGEISDIHTKLLRLSSSQGTIETSLQDIDSRLSPGGSLADAWAHQEGTHPKDRNVEKLQVLLNCMTEIYYQFKKDKAERRLAYNEEQIHKFDKQKLYYHATKAMTHFTDECVKKYEAFLNKSEEWIRKMLHLRKQLLSLTNQCFDIEEEVSKYQEYTNELQETLPQKMFTASSGIKHTMTPIYPSSNTLVEMTLGMKKLKEEMEGVVKELAENNHILERFGSLTMDGGLRNVDCL T63024 DRUGINFO D00PFT PMID26293650-Compound-34 Patented T63024 DRUGINFO D02EHR PMID26293650-Compound-35 Patented T63024 DRUGINFO D09FGW Pyrimidinyl compound 4 Patented T63024 DRUGINFO D09JVJ Aminopyrimidine derivative 10 Patented T63024 DRUGINFO D09WTI Pyrimidinyl compound 7 Patented T63024 DRUGINFO D0D2LC Pyrimidinyl compound 1 Patented T63024 DRUGINFO D0IF0T Aminopyrimidine derivative 7 Patented T63024 DRUGINFO D0IF3G Pyrimidinyl compound 3 Patented T63024 DRUGINFO D0J4GP Aminopyrimidine derivative 9 Patented T63024 DRUGINFO D0JU7T Pyrimidinyl compound 2 Patented T63024 DRUGINFO D0SA6L Aminopyrimidine derivative 8 Patented T63024 DRUGINFO D0SM9Y Pyrimidinyl compound 6 Patented T63024 DRUGINFO D0TK5U Aminopyrimidine derivative 6 Patented T63024 DRUGINFO D0YU2R Pyrimidinyl compound 5 Patented T63024 DRUGINFO D06ZIO MRT67307 Investigative T63024 DRUGINFO D03BJF PMID23099093C17d Investigative T07930 TARGETID T07930 T07930 FORMERID TTDI03260 T07930 UNIPROID HDAC5_HUMAN T07930 TARGNAME Histone deacetylase 5 (HDAC5) T07930 GENENAME HDAC5 T07930 TARGTYPE Patented-recorded T07930 SYNONYMS KIAA0600; HD5; Antigen NY-CO-9 T07930 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation by repressing transcription of myocyte enhancer MEF2C. During muscle differentiation, it shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). T07930 PDBSTRUC 5UWI T07930 BIOCLASS Carbon-nitrogen hydrolase T07930 ECNUMBER EC 3.5.1.98 T07930 SEQUENCE MNSPNESDGMSGREPSLEILPRTSLHSIPVTVEVKPVLPRAMPSSMGGGGGGSPSPVELRGALVGSVDPTLREQQLQQELLALKQQQQLQKQLLFAEFQKQHDHLTRQHEVQLQKHLKQQQEMLAAKQQQEMLAAKRQQELEQQRQREQQRQEELEKQRLEQQLLILRNKEKSKESAIASTEVKLRLQEFLLSKSKEPTPGGLNHSLPQHPKCWGAHHASLDQSSPPQSGPPGTPPSYKLPLPGPYDSRDDFPLRKTASEPNLKVRSRLKQKVAERRSSPLLRRKDGTVISTFKKRAVEITGAGPGASSVCNSAPGSGPSSPNSSHSTIAENGFTGSVPNIPTEMLPQHRALPLDSSPNQFSLYTSPSLPNISLGLQATVTVTNSHLTASPKLSTQQEAERQALQSLRQGGTLTGKFMSTSSIPGCLLGVALEGDGSPHGHASLLQHVLLLEQARQQSTLIAVPLHGQSPLVTGERVATSMRTVGKLPRHRPLSRTQSSPLPQSPQALQQLVMQQQHQQFLEKQKQQQLQLGKILTKTGELPRQPTTHPEETEEELTEQQEVLLGEGALTMPREGSTESESTQEDLEEEDEEDDGEEEEDCIQVKDEEGESGAEEGPDLEEPGAGYKKLFSDAQPLQPLQVYQAPLSLATVPHQALGRTQSSPAAPGGMKSPPDQPVKHLFTTGVVYDTFMLKHQCMCGNTHVHPEHAGRIQSIWSRLQETGLLSKCERIRGRKATLDEIQTVHSEYHTLLYGTSPLNRQKLDSKKLLGPISQKMYAVLPCGGIGVDSDTVWNEMHSSSAVRMAVGCLLELAFKVAAGELKNGFAIIRPPGHHAEESTAMGFCFFNSVAITAKLLQQKLNVGKVLIVDWDIHHGNGTQQAFYNDPSVLYISLHRYDNGNFFPGSGAPEEVGGGPGVGYNVNVAWTGGVDPPIGDVEYLTAFRTVVMPIAHEFSPDVVLVSAGFDAVEGHLSPLGGYSVTARCFGHLTRQLMTLAGGRVVLALEGGHDLTAICDASEACVSALLSVELQPLDEAVLQQKPNINAVATLEKVIEIQSKHWSCVQKFAAGLGRSLREAQAGETEEAETVSAMALLSVGAEQAQAAAAREHSPRPAEEPMEQEPAL T07930 DRUGINFO D0YN2T PMID29671355-Compound-45a Patented T07930 DRUGINFO D00HXJ PMID29671355-Compound-23 Patented T07930 DRUGINFO D0M0RE PMID29671355-Compound-67 Patented T07930 DRUGINFO D0DI9S PMID29671355-Compound-31 Patented T07930 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T07930 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T07930 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T07930 DRUGINFO D0R7JA TMP269 Investigative T11808 TARGETID T11808 T11808 FORMERID TTDI03306 T11808 UNIPROID KLK5_HUMAN T11808 TARGNAME Kallikrein-5 (KLK5) T11808 GENENAME KLK5 T11808 TARGTYPE Patented-recorded T11808 SYNONYMS UNQ570/PRO1132; Stratum corneum tryptic enzyme; SCTE; Kallikrein-like protein 2; KLK-L2 T11808 FUNCTION May be involved in desquamation. T11808 PDBSTRUC 6QFE; 2PSY; 2PSX T11808 BIOCLASS Peptidase T11808 ECNUMBER EC 3.4.21.- T11808 SEQUENCE MATARPPWMWVLCALITALLLGVTEHVLANNDVSCDHPSNTVPSGSNQDLGAGAGEDARSDDSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMFQGVKSIPHPGYSHPGHSNDLMLIKLNRRIRPTKDVRPINVSSHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQANS T11808 DRUGINFO D00LOL PMID23849879C3 Investigative T11808 DRUGINFO D07OQF PMID25489658C4d Investigative T58307 TARGETID T58307 T58307 FORMERID TTDI03498 T58307 UNIPROID PPME1_HUMAN T58307 TARGNAME Protein phosphatase methylesterase 1 (PME-1) T58307 GENENAME PPME1 T58307 TARGTYPE Patented-recorded T58307 SYNONYMS PRO0750; PP2593; PME1 T58307 FUNCTION Demethylates PPP2CB (in vitro) and PPP2CA. Binding to PPP2CA displaces the manganese ion and inactivates the enzyme. Demethylates proteins that have been reversibly carboxymethylated. T58307 PDBSTRUC 3C5W; 3C5V T58307 BIOCLASS Carboxylic ester hydrolase T58307 ECNUMBER EC 3.1.1.89 T58307 SEQUENCE MSALEKSMHLGRLPSRPPLPGSGGSQSGAKMRMGPGRKRDFSPVPWSQYFESMEDVEVENETGKDTFRVYKSGSEGPVLLLLHGGGHSALSWAVFTAAIISRVQCRIVALDLRSHGETKVKNPEDLSAETMAKDVGNVVEAMYGDLPPPIMLIGHSMGGAIAVHTASSNLVPSLLGLCMIDVVEGTAMDALNSMQNFLRGRPKTFKSLENAIEWSVKSGQIRNLESARVSMVGQVKQCEGITSPEGSKSIVEGIIEEEEEDEEGSESISKRKKEDDMETKKDHPYTWRIELAKTEKYWDGWFRGLSNLFLSCPIPKLLLLAGVDRLDKDLTIGQMQGKFQMQVLPQCGHAVHEDAPDKVAEAVATFLIRHRFAEPIGGFQCVFPGC T58307 DRUGINFO D0YH7K ABL127 Investigative T79400 TARGETID T79400 T79400 FORMERID TTDI00054 T79400 UNIPROID KLK4_HUMAN T79400 TARGNAME Kallikrein-4 (KLK4) T79400 GENENAME KLK4 T79400 TARGTYPE Patented-recorded T79400 SYNONYMS Serine protease 17; Prostase; PSTS; PRSS17; Kallikreinlike protein 1; Kallikrein4; Kallikrein-like protein 1; KLKL1; KLK-L1; Enamel matrix serine proteinase 1; EMSP1 T79400 FUNCTION Required during the maturation stage of tooth development for clearance of enamel proteins and normal structural patterning of the crystalline matrix. Has a major role in enamel formation. T79400 PDBSTRUC 4KGA; 4KEL; 4K8Y; 4K1E; 2BDI T79400 BIOCLASS Peptidase T79400 ECNUMBER EC 3.4.21.- T79400 SEQUENCE MATAGNPWGWFLGYLILGVAGSLVSGSCSQIINGEDCSPHSQPWQAALVMENELFCSGVLVHPQWVLSAAHCFQNSYTIGLGLHSLEADQEPGSQMVEASLSVRHPEYNRPLLANDLMLIKLDESVSESDTIRSISIASQCPTAGNSCLVSGWGLLANGRMPTVLQCVNVSVVSEEVCSKLYDPLYHPSMFCAGGGHDQKDSCNGDSGGPLICNGYLQGLVSFGKAPCGQVGVPGVYTNLCKFTEWIEKTVQAS T79400 DRUGINFO D02MGJ Benzoxazinone derivative 2 Patented T15441 TARGETID T15441 T15441 UNIPROID UCHL5_HUMAN T15441 TARGNAME Ubiquitin C-terminal hydrolase UCH37 (UCHL5) T15441 GENENAME UCHL5 T15441 TARGTYPE Patented-recorded T15441 SYNONYMS Ubiquitin thioesterase L5; Ubiquitin carboxyl-terminal hydrolase isozyme L5; UCH37; UCH-L5; CGI-70; AD-019 T15441 FUNCTION Deubiquitinating enzyme associated with the 19S regulatory subunit of the 26S proteasome. Putative regulatory component of the INO80 complex; however is inactive in the INO80 complex and is activated by a transient interaction of the INO80 complex with the proteasome via ADRM1. Protease that specifically cleaves 'Lys-48'-linked polyubiquitin chains. T15441 PDBSTRUC 4WLP; 4UF6; 4UF5; 4UEM; 4UEL T15441 BIOCLASS Peptidase T15441 ECNUMBER EC 3.4.19.12 T15441 SEQUENCE MTGNAGEWCLMESDPGVFTELIKGFGCRGAQVEEIWSLEPENFEKLKPVHGLIFLFKWQPGEEPAGSVVQDSRLDTIFFAKQVINNACATQAIVSVLLNCTHQDVHLGETLSEFKEFSQSFDAAMKGLALSNSDVIRQVHNSFARQQMFEFDTKTSAKEEDAFHFVSYVPVNGRLYELDGLREGPIDLGACNQDDWISAVRPVIEKRIQKYSEGEIRFNLMAIVSDRKMIYEQKIAELQRQLAEEEPMDTDQGNSMLSAIQSEVAKNQMLIEEEVQKLKRYKIENIRRKHNYLPFIMELLKTLAEHQQLIPLVEKAKEKQNAKKAQETK T15441 DRUGINFO D0A8EN PMID26077642-Compound-Figure3A Patented T17228 TARGETID T17228 T17228 FORMERID TTDI03472 T17228 UNIPROID PARP3_HUMAN T17228 TARGNAME Poly [ADP-ribose] polymerase 3 (PARP3) T17228 GENENAME PARP3 T17228 TARGTYPE Patented-recorded T17228 SYNONYMS pADPRT-3; hPARP-3; Protein mono-ADP-ribosyltransferase PARP3; Poly[ADP-ribose] synthase 3; PARP-3; NAD(+) ADP-ribosyltransferase 3; IRT1; DNA ADP-ribosyltransferase PARP3; ARTD3; ADPRTL3; ADPRT3; ADPRT-3; ADP-ribosyltransferase diphtheria toxin-like 3 T17228 FUNCTION Mediates mono-ADP-ribosylation of glutamate, aspartate or lysine residues on target proteins. In contrast to PARP1 and PARP2, it is not able to mediate poly-ADP-ribosylation. Associates with a number of DNA repair factors and is involved in the response to exogenous and endogenous DNA strand breaks. Together with APLF, promotes the retention of the LIG4-XRCC4 complex on chromatin and accelerate DNA ligation during non-homologous end-joining (NHEJ). Cooperates with the XRRC6-XRCC5 (Ku70-Ku80) heterodimer to limit end-resection thereby promoting accurate NHEJ. Involved in DNA repair by mediating mono-ADP-ribosylation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism, such as XRRC5 and XRCC6. ADP-ribosylation follows DNA damage and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. May link the DNA damage surveillance network to the mitotic fidelity checkpoint. In addition to proteins, also able to ADP-ribosylate DNA: mediates DNA mono-ADP-ribosylation of DNA strand break termini via covalent addition of a single ADP-ribose moiety to a 5'- or 3'-terminal phosphate residues in DNA containing multiple strand breaks. Acts as a negative regulator of immunoglobulin class switch recombination, probably by controlling the level of AICDA /AID on the chromatin. Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins and plays a key role in the response to DNA damage. T17228 PDBSTRUC 4L7U; 4L7R; 4L7P; 4L7O; 4L7N T17228 BIOCLASS Glycosyltransferases T17228 ECNUMBER EC 2.4.2.- T17228 SEQUENCE MAPKPKPWVQTEGPEKKKGRQAGREEDPFRSTAEALKAIPAEKRIIRVDPTCPLSSNPGTQVYEDYNCTLNQTNIENNNNKFYIIQLLQDSNRFFTCWNRWGRVGEVGQSKINHFTRLEDAKKDFEKKFREKTKNNWAERDHFVSHPGKYTLIEVQAEDEAQEAVVKVDRGPVRTVTKRVQPCSLDPATQKLITNIFSKEMFKNTMALMDLDVKKMPLGKLSKQQIARGFEALEALEEALKGPTDGGQSLEELSSHFYTVIPHNFGHSQPPPINSPELLQAKKDMLLVLADIELAQALQAVSEQEKTVEEVPHPLDRDYQLLKCQLQLLDSGAPEYKVIQTYLEQTGSNHRCPTLQHIWKVNQEGEEDRFQAHSKLGNRKLLWHGTNMAVVAAILTSGLRIMPHSGGRVGKGIYFASENSKSAGYVIGMKCGAHHVGYMFLGEVALGREHHINTDNPSLKSPPPGFDSVIARGHTEPDPTQDTELELDGQQVVVPQGQPVPCPEFSSSTFSQSEYLIYQESQCRLRYLLEVHL T17228 DRUGINFO D0TD8R 3-phenyl isoquinolin-1(2H) derivative 1 Patented T17228 DRUGINFO D04QRM ME0328 Investigative T80853 TARGETID T80853 T80853 UNIPROID RSSA_HUMAN T80853 TARGNAME Laminin receptor 37/67kDa (LRP/LR) T80853 GENENAME RPSA T80853 TARGTYPE Patented-recorded T80853 SYNONYMS Small ribosomal subunit protein uS2; NEM/1CHD4; Multidrug resistance-associated protein MGr1-Ag; Laminin-binding protein precursor p40; Laminin receptor 1; LamR; LBP/p40; LAMR1; LAMBR; Colon carcinoma laminin-binding protein; 67LR; 67 kDa laminin receptor; 40S ribosomal protein SA; 37LRP; 37/67 kDa laminin receptor; 37 kDa laminin receptor precursor T80853 FUNCTION Required for the processing of the 20S rRNA-precursor to mature 18S rRNA in a late step of the maturation of 40S ribosomal subunits. Also functions as a cell surface receptor for laminin. Plays a role in cell adhesion to the basement membrane and in the consequent activation of signaling transduction pathways. May play a role in cell fate determination and tissue morphogenesis. Acts as a PPP1R16B-dependent substrate of PPP1CA. Required for the assembly and/or stability of the 40S ribosomal subunit. T80853 PDBSTRUC 6QZP; 6G5I; 6G5H; 6G53; 6G51 T80853 SEQUENCE MSGALDVLQMKEEDVLKFLAAGTHLGGTNLDFQMEQYIYKRKSDGIYIINLKRTWEKLLLAARAIVAIENPADVSVISSRNTGQRAVLKFAAATGATPIAGRFTPGTFTNQIQAAFREPRLLVVTDPRADHQPLTEASYVNLPTIALCNTDSPLRYVDIAIPCNNKGAHSVGLMWWMLAREVLRMRGTISREHPWEVMPDLYFYRDPEEIEKEEQAAAEKAVTKEEFQGEWTAPAPEFTATQPEVADWSEGVQVPSVPIQQFPTEDWSAQPATEDWSAAPTAQATEWVGATTDWS T80853 DRUGINFO D02DOE PMID25747044-Compound-miRNA Patented T90167 TARGETID T90167 T90167 UNIPROID UBC_HUMAN T90167 TARGNAME Polyubiquitin-C (UBC) T90167 GENENAME UBC T90167 TARGTYPE Patented-recorded T90167 SYNONYMS ubiquitin C; HMG20 T90167 FUNCTION When covalently bound, it is conjugated to target proteins via an isopeptide bond either as a monomer (monoubiquitin), a polymer linked via different Lys residues of the ubiquitin (polyubiquitin chains) or a linear polymer linked via the initiator Met of the ubiquitin (linear polyubiquitin chains). Polyubiquitin chains, when attached to a target protein, have different functions depending on the Lys residue of the ubiquitin that is linked: Lys-6-linked may be involved in DNA repair; Lys-11-linked is involved in ERAD (endoplasmic reticulum-associated degradation) and in cell-cycle regulation; Lys-29-linked is involved in lysosomal degradation; Lys-33-linked is involved in kinase modification; Lys-48-linked is involved in protein degradation via the proteasome; Lys-63-linked is involved in endocytosis, DNA-damage responses as well as in signaling processes leading to activation of the transcription factor NF-kappa-B. Linear polymer chains formed via attachment by the initiator Met lead to cell signaling. Ubiquitin is usually conjugated to Lys residues of target proteins, however, in rare cases, conjugation to Cys or Ser residues has been observed. When polyubiquitin is free (unanchored-polyubiquitin), it also has distinct roles, such as in activation of protein kinases, and in signaling. Ubiquitin: Exists either covalently attached to another protein, or free (unanchored). T90167 PDBSTRUC 6OI4; 6NQA; 6N13; 6EQI; 6B7O T90167 SEQUENCE MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGV T90167 DRUGINFO D0B2AE PMID25553724-Compound-US20130237529 36 Patented T90167 DRUGINFO D0JA8J PMID25553724-Compound-US20130237529 35 Patented T09128 TARGETID T09128 T09128 FORMERID TTDI02492 T09128 UNIPROID CASP2_HUMAN T09128 TARGNAME Caspase-2 (CASP2) T09128 GENENAME CASP2 T09128 TARGTYPE Patented-recorded T09128 SYNONYMS Protease ICH1; Protease ICH-1; Neural precursor cell expressed developmentally downregulated protein 2; Neural precursor cell expressed developmentally down-regulated protein 2; NEDD2; NEDD-2; ICH1; Caspase2 subunit p12; CASP-2 T09128 FUNCTION Might function by either activating some proteins required for cell death or inactivating proteins necessary for cell survival. Associates with PIDD1 and CRADD to form the PIDDosome, a complex that activates CASP2 and triggers apoptosis in response to genotoxic stress. Involved in the activation cascade of caspases responsible for apoptosis execution. T09128 BIOCLASS Peptidase T09128 ECNUMBER EC 3.4.22.55 T09128 SEQUENCE MAAPSAGSWSTFQHKELMAADRGRRILGVCGMHPHHQETLKKNRVVLAKQLLLSELLEHLLEKDIITLEMRELIQAKVGSFSQNVELLNLLPKRGPQAFDAFCEALRETKQGHLEDMLLTTLSGLQHVLPPLSCDYDLSLPFPVCESCPLYKKLRLSTDTVEHSLDNKDGPVCLQVKPCTPEFYQTHFQLAYRLQSRPRGLALVLSNVHFTGEKELEFRSGGDVDHSTLVTLFKLLGYDVHVLCDQTAQEMQEKLQNFAQLPAHRVTDSCIVALLSHGVEGAIYGVDGKLLQLQEVFQLFDNANCPSLQNKPKMFFIQACRGDETDRGVDQQDGKNHAGSPGCEESDAGKEKLPKMRLPTRSDMICGYACLKGTAAMRNTKRGSWYIEALAQVFSERACDMHVADMLVKVNALIKDREGYAPGTEFHRCKEMSEYCSTLCRHLYLFPGHPPT T53469 TARGETID T53469 T53469 FORMERID TTDI03088 T53469 UNIPROID CASP4_HUMAN T53469 TARGNAME Caspase-4 (CASP4) T53469 GENENAME CASP4 T53469 TARGTYPE Patented-recorded T53469 SYNONYMS Protease TX; Mih1; ICH2; ICH-2; ICE(rel)-II; ICE and Ced-3 homolog 2; CASP-4 T53469 FUNCTION Essential effector of NLRP3 inflammasome-dependent CASP1 activation and IL1B and IL18 secretion in response to non-canonical activators, such as UVB radiation, cholera enterotoxin subunit B and cytosolic LPS. Independently of NLRP3 inflammasome and CASP1, promotes pyroptosis, through GSDMD cleavage and activation, and IL1A, IL18 and HMGB1 release in response to non-canonical inflammasome activators. Plays a crucial role in the restriction of Salmonella typhimurium replication in colonic epithelial cells during infection. In later stages of the infection, LPS from cytosolic Salmonella triggers CASP4 activation, which ultimately results in pyroptosis of infected cells and their extrusion into the gut lumen, as well as in IL18 secretion. Pyroptosis limits bacterial replication, while cytokine secretion promotes the recruitment and activation of immune cells and triggers mucosal inflammation. Involved in LPS-induced IL6 secretion; this activity may not require caspase enzymatic activity. Involved in cell death induced by endoplasmic reticulum stress and by treatment with cytotoxic APP peptides found Alzheimer's patient brains. Activated by direct binding to LPS without the need of an upstream sensor. Does not directly process IL1B. During non-canonical inflammasome activation, cuts CGAS and may play a role in the regulation of antiviral innate immune activation. Inflammatory caspase. T53469 BIOCLASS Peptidase T53469 ECNUMBER EC 3.4.22.57 T53469 SEQUENCE MAEGNHRKKPLKVLESLGKDFLTGVLDNLVEQNVLNWKEEEKKKYYDAKTEDKVRVMADSMQEKQRMAGQMLLQTFFNIDQISPNKKAHPNMEAGPPESGESTDALKLCPHEEFLRLCKERAEEIYPIKERNNRTRLALIICNTEFDHLPPRNGADFDITGMKELLEGLDYSVDVEENLTARDMESALRAFATRPEHKSSDSTFLVLMSHGILEGICGTVHDEKKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGANRGELWVRDSPASLEVASSQSSENLEEDAVYKTHVEKDFIAFCSSTPHNVSWRDSTMGSIFITQLITCFQKYSWCCHLEEVFRKVQQSFETPRAKAQMPTIERLSMTRYFYLFPGN T53469 DRUGINFO D0Q9XX casp 4 inhib Investigative T53469 DRUGINFO D00YNW M826 Investigative T74307 TARGETID T74307 T74307 FORMERID TTDI03053 T74307 UNIPROID BLK_HUMAN T74307 TARGNAME B lymphocyte kinase (BLK) T74307 GENENAME BLK T74307 TARGTYPE Patented-recorded T74307 SYNONYMS p55-Blk; Tyrosine-protein kinase Blk T74307 FUNCTION B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose. Phosphorylates CGAS, promoting retention of CGAS in the cytosol. Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. T74307 BIOCLASS Kinase T74307 ECNUMBER EC 2.7.10.2 T74307 SEQUENCE MGLVSSKKPDKEKPIKEKDKGQWSPLKVSAQDKDAPPLPPLVVFNHLTPPPPDEHLDEDKHFVVALYDYTAMNDRDLQMLKGEKLQVLKGTGDWWLARSLVTGREGYVPSNFVARVESLEMERWFFRSQGRKEAERQLLAPINKAGSFLIRESETNKGAFSLSVKDVTTQGELIKHYKIRCLDEGGYYISPRITFPSLQALVQHYSKKGDGLCQRLTLPCVRPAPQNPWAQDEWEIPRQSLRLVRKLGSGQFGEVWMGYYKNNMKVAIKTLKEGTMSPEAFLGEANVMKALQHERLVRLYAVVTKEPIYIVTEYMARGCLLDFLKTDEGSRLSLPRLIDMSAQIAEGMAYIERMNSIHRDLRAANILVSEALCCKIADFGLARIIDSEYTAQEGAKFPIKWTAPEAIHFGVFTIKADVWSFGVLLMEVVTYGRVPYPGMSNPEVIRNLERGYRMPRPDTCPPELYRGVIAECWRSRPEERPTFEFLQSVLEDFYTATERQYELQP T74307 DRUGINFO D09PIS Pyrazolo[4,3-c]pyridine derivative 2 Patented T74307 DRUGINFO D01RHR PMID24915291C31 Investigative T74307 DRUGINFO D08RZB PMID15546730C2 Investigative T74307 DRUGINFO D06BJG PMID24915291C38 Investigative T89565 TARGETID T89565 T89565 FORMERID TTDI03089 T89565 UNIPROID CASP5_HUMAN T89565 TARGNAME Caspase-5 (CASP5) T89565 GENENAME CASP5 T89565 TARGTYPE Patented-recorded T89565 SYNONYMS Protease TY; Protease ICH-3; ICH3; ICE(rel)-III; CASP-5 T89565 FUNCTION During non-canonical inflammasome activation, cuts CGAS and may play a role in the regulation of antiviral innate immune activation. Mediator of programmed cell death (apoptosis). T89565 BIOCLASS Peptidase T89565 ECNUMBER EC 3.4.22.58 T89565 SEQUENCE MAEDSGKKKRRKNFEAMFKGILQSGLDNFVINHMLKNNVAGQTSIQTLVPNTDQKSTSVKKDNHKKKTVKMLEYLGKDVLHGVFNYLAKHDVLTLKEEEKKKYYDTKIEDKALILVDSLRKNRVAHQMFTQTLLNMDQKITSVKPLLQIEAGPPESAESTNILKLCPREEFLRLCKKNHDEIYPIKKREDRRRLALIICNTKFDHLPARNGAHYDIVGMKRLLQGLGYTVVDEKNLTARDMESVLRAFAARPEHKSSDSTFLVLMSHGILEGICGTAHKKKKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGEKHGELWVRDSPASLALISSQSSENLEADSVCKIHEEKDFIAFCSSTPHNVSWRDRTRGSIFITELITCFQKYSCCCHLMEIFRKVQKSFEVPQAKAQMPTIERATLTRDFYLFPGN T89565 DRUGINFO D00YNW M826 Investigative T43814 TARGETID T43814 T43814 UNIPROID TIRAP_HUMAN T43814 TARGNAME Toll/interleukin-1 receptor domain-containing adapter (TIRAP) T43814 GENENAME TIRAP T43814 TARGTYPE Patented-recorded T43814 SYNONYMS Toll/interleukin-1 receptor domain-containing adapter protein; TIR domain-containing adapter protein; MyD88-2; MyD88 adapter-like protein; MAL; Adaptor protein Wyatt T43814 FUNCTION Acts via IRAK2 and TRAF-6, leading to the activation of NF-kappa-B, MAPK1, MAPK3 and JNK, and resulting in cytokine secretion and the inflammatory response. Positively regulates the production of TNF-alpha and interleukin-6. Adapter involved in TLR2 and TLR4 signaling pathways in the innate immune response. T43814 PDBSTRUC 5UZB; 5T7Q; 4LQD; 4FZ5; 3UB4 T43814 SEQUENCE MASSTSLPAPGSRPKKPLGKMADWFRQTLLKKPKKRPNSPESTSSDASQPTSQDSPLPPSLSSVTSPSLPPTHASDSGSSRWSKDYDVCVCHSEEDLVAAQDLVSYLEGSTASLRCFLQLRDATPGGAIVSELCQALSSSHCRVLLITPGFLQDPWCKYQMLQALTEAPGAEGCTIPLLSGLSRAAYPPELRFMYYVDGRGPDGGFRQVKEAVMRYLQTLS T07191 TARGETID T07191 T07191 FORMERID TTDI03384 T07191 UNIPROID M4K2_HUMAN T07191 TARGNAME MEK kinase kinase 2 (MAP4K2) T07191 GENENAME MAP4K2 T07191 TARGTYPE Patented-recorded T07191 SYNONYMS Rab8-interacting protein; RAB8IP; Mitogen-activated protein kinase kinase kinase kinase 2; MEKKK 2; MAPK/ERK kinase kinase kinase 2; Germinal center kinase; GCK; GC kinase; B lymphocyte serine/threonine-protein kinase T07191 FUNCTION Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion. Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. T07191 BIOCLASS Kinase T07191 ECNUMBER EC 2.7.11.1 T07191 SEQUENCE MALLRDVSLQDPRDRFELLQRVGAGTYGDVYKARDTVTSELAAVKIVKLDPGDDISSLQQEITILRECRHPNVVAYIGSYLRNDRLWICMEFCGGGSLQEIYHATGPLEERQIAYVCREALKGLHHLHSQGKIHRDIKGANLLLTLQGDVKLADFGVSGELTASVAKRRSFIGTPYWMAPEVAAVERKGGYNELCDVWALGITAIELGELQPPLFHLHPMRALMLMSKSSFQPPKLRDKTRWTQNFHHFLKLALTKNPKKRPTAEKLLQHPFTTQQLPRALLTQLLDKASDPHLGTPSPEDCELETYDMFPDTIHSRGQHGPAERTPSEIQFHQVKFGAPRRKETDPLNEPWEEEWTLLGKEELSGSLLQSVQEALEERSLTIRSASEFQELDSPDDTMGTIKRAPFLGPLPTDPPAEEPLSSPPGTLPPPPSGPNSSPLLPTAWATMKQREDPERSSCHGLPPTPKVHMGACFSKVFNGCPLRIHAAVTWIHPVTRDQFLVVGAEEGIYTLNLHELHEDTLEKLISHRCSWLYCVNNVLLSLSGKSTHIWAHDLPGLFEQRRLQQQVPLSIPTNRLTQRIIPRRFALSTKIPDTKGCLQCRVVRNPYTGATFLLAALPTSLLLLQWYEPLQKFLLLKNFSSPLPSPAGMLEPLVLDGKELPQVCVGAEGPEGPGCRVLFHVLPLEAGLTPDILIPPEGIPGSAQQVIQVDRDTILVSFERCVRIVNMQGEPTATLAPELTFDFPIETVVCLQDSVLAFWSHGMQGRSLDTNEVTQEITDETRIFRVLGAHRDIILESIPTDNPEAHSNLYILTGHQSTY T07191 DRUGINFO D02GNH Quinazoline derivative 9 Phase 1 T07191 DRUGINFO D0X7IC NG-25 Investigative T04512 TARGETID T04512 T04512 UNIPROID EZH2_HUMAN T04512 TARGNAME EZH2 Y641F mutant (EZH2 Y641F) T04512 GENENAME EZH2 T04512 TARGTYPE Patented-recorded T04512 SYNONYMS Lysine Nmethyltransferase 6 Y641F mutant; Lysine N-methyltransferase 6 Y641F mutant; KMT6 Y641F mutant; Histonelysine Nmethyltransferase EZH2 Y641F mutant; Histone-lysine N-methyltransferase EZH2 Y641F mutant; EZH2 Y641F mutations; ENX1 Y641F mutant; ENX-1 Y641F mutant T04512 FUNCTION Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. Polycomb group (PcG) protein. T04512 PDBSTRUC 6C24; 6C23; 5WUK; 5WG6; 5U62 T04512 ECNUMBER EC 2.1.1.43 T04512 SEQUENCE MGQTGKKSEKGPVCWRKRVKSEYMRLRQLKRFRRADEVKSMFSSNRQKILERTEILNQEWKQRRIQPVHILTSVSSLRGTRECSVTSDLDFPTQVIPLKTLNAVASVPIMYSWSPLQQNFMVEDETVLHNIPYMGDEVLDQDGTFIEELIKNYDGKVHGDRECGFINDEIFVELVNALGQYNDDDDDDDGDDPEEREEKQKDLEDHRDDKESRPPRKFPSDKIFEAISSMFPDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPSTPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAEASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKIQLKKDGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSSECQNRFPGCRCKAQCNTKQCPCYLAVRECDPDLCLTCGAADHWDSKNVSCKNCSIQRGSKKHLLLAPSDVAGWGIFIKDPVQKNEFISEYCGEIISQDEADRRGKVYDKYMCSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAIQTGEELFFDYRYSQADALKYVGIEREMEIP T04512 DRUGINFO D0MH5C PMID28394193-Compound-11 Patented T04512 DRUGINFO D0MZ9P PMID28394193-Compound-10 Patented T04512 DRUGINFO D0GT7A PMID28394193-Compound-14 Patented T04512 DRUGINFO D0H8VN PMID28394193-Compound-12 Patented T04512 DRUGINFO D0TA4N PMID28394193-Compound-13 Patented T04980 TARGETID T04980 T04980 UNIPROID EZH2_HUMAN T04980 TARGNAME EZH2 Y641N mutant (EZH2 Y641N) T04980 GENENAME EZH2 T04980 TARGTYPE Patented-recorded T04980 SYNONYMS Lysine Nmethyltransferase 6 Y641N mutant; Lysine N-methyltransferase 6 Y641N mutant; KMT6 Y641N mutant; Histonelysine Nmethyltransferase EZH2 Y641N mutant; Histone-lysine N-methyltransferase EZH2 Y641N mutant; EZH2 Y641N mutations; ENX1 Y641N mutant; ENX-1 Y641N mutant T04980 FUNCTION Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. Polycomb group (PcG) protein. T04980 PDBSTRUC 6C24; 6C23; 5WUK; 5WG6; 5U62 T04980 ECNUMBER EC 2.1.1.43 T04980 SEQUENCE MGQTGKKSEKGPVCWRKRVKSEYMRLRQLKRFRRADEVKSMFSSNRQKILERTEILNQEWKQRRIQPVHILTSVSSLRGTRECSVTSDLDFPTQVIPLKTLNAVASVPIMYSWSPLQQNFMVEDETVLHNIPYMGDEVLDQDGTFIEELIKNYDGKVHGDRECGFINDEIFVELVNALGQYNDDDDDDDGDDPEEREEKQKDLEDHRDDKESRPPRKFPSDKIFEAISSMFPDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPSTPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAEASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKIQLKKDGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSSECQNRFPGCRCKAQCNTKQCPCYLAVRECDPDLCLTCGAADHWDSKNVSCKNCSIQRGSKKHLLLAPSDVAGWGIFIKDPVQKNEFISEYCGEIISQDEADRRGKVYDKYMCSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAIQTGEELFFDYRYSQADALKYVGIEREMEIP T04980 DRUGINFO D01PZZ PMID28394193-Compound-56 Patented T04980 DRUGINFO D0D4UH PMID28394193-Compound-46 Patented T04980 DRUGINFO D0G1JR PMID28394193-Compound-57 Patented T04980 DRUGINFO D0M4LK PMID28394193-Compound-55 Patented T04980 DRUGINFO D0M8AA PMID28394193-Compound-45 Patented T42157 TARGETID T42157 T42157 FORMERID TTDI03382 T42157 UNIPROID M3K19_HUMAN T42157 TARGNAME SPS1/STE20-related protein kinase YSK4 (YSK4) T42157 GENENAME MAP3K19 T42157 TARGTYPE Patented-recorded T42157 SYNONYMS Regulated in COPD, protein kinase; RCK; Mitogen-activated protein kinase kinase kinase 19 T42157 FUNCTION Protein serine/threonine kinase activity, activation of protein kinase activity, signal transduction by protein phosphorylation, stress-activated protein kinase signaling cascade. T42157 BIOCLASS Kinase T42157 ECNUMBER EC 2.7.11.1 T42157 SEQUENCE MSSMPKPERHAESLLDICHDTNSSPTDLMTVTKNQNIILQSISRSEEFDQDGDCSHSTLVNEEEDPSGGRQDWQPRTEGVEITVTFPRDVSPPQEMSQEDLKEKNLINSSLQEWAQAHAVSHPNEIETVELRKKKLTMRPLVLQKEESSRELCNVNLGFLLPRSCLELNISKSVTREDAPHFLKEQQRKSEEFSTSHMKYSGRSIKFLLPPLSLLPTRSGVLTIPQNHKFPKEKERNIPSLTSFVPKLSVSVRQSDELSPSNEPPGALVKSLMDPTLRSSDGFIWSRNMCSFPKTNHHRQCLEKEENWKSKEIEECNKIEITHFEKGQSLVSFENLKEGNIPAVREEDIDCHGSKTRKPEEENSQYLSSRKNESSVAKNYEQDPEIVCTIPSKFQETQHSEITPSQDEEMRNNKAASKRVSLHKNEAMEPNNILEECTVLKSLSSVVFDDPIDKLPEGCSSMETNIKISIAERAKPEMSRMVPLIHITFPVDGSPKEPVIAKPSLQTRKGTIHNNHSVNIPVHQENDKHKMNSHRSKLDSKTKTSKKTPQNFVISTEGPIKPTMHKTSIKTQIFPALGLVDPRPWQLPRFQKKMPQIAKKQSTHRTQKPKKQSFPCICKNPGTQKSCVPLSVQPTEPRLNYLDLKYSDMFKEINSTANGPGIYEMFGTPVYCHVRETERDENTYYREICSAPSGRRITNKCRSSHSERKSNIRTRLSQKKTHMKCPKTSFGIKQEHKVLISKEKSSKAVHSNLHDIENGDGISEPDWQIKSSGNEFLSSKDEIHPMNLAQTPEQSMKQNEFPPVSDLSIVEEVSMEESTGDRDISNNQILTTSLRDLQELEELHHQIPFIPSEDSWAVPSEKNSNKYVQQEKQNTASLSKVNASRILTNDLEFDSVSDHSKTLTNFSFQAKQESASSQTYQYWVHYLDHDSLANKSITYQMFGKTLSGTNSISQEIMDSVNNEELTDELLGCLAAELLALDEKDNNSCQKMANETDPENLNLVLRWRGSTPKEMGRETTKVKIQRHSSGLRIYDREEKFLISNEKKIFSENSLKSEEPILWTKGEILGKGAYGTVYCGLTSQGQLIAVKQVALDTSNKLAAEKEYRKLQEEVDLLKALKHVNIVAYLGTCLQENTVSIFMEFVPGGSISSIINRFGPLPEMVFCKYTKQILQGVAYLHENCVVHRDIKGNNVMLMPTGIIKLIDFGCARRLAWAGLNGTHSDMLKSMHGTPYWMAPEVINESGYGRKSDIWSIGCTVFEMATGKPPLASMDRMAAMFYIGAHRGLMPPLPDHFSENAADFVRMCLTRDQHERPSALQLLKHSFLERSH T42157 DRUGINFO D02GNH Quinazoline derivative 9 Phase 1 T44190 TARGETID T44190 T44190 UNIPROID TCAM1_HUMAN T44190 TARGNAME TIR domain-containing adapter molecule 1 (TICAM1) T44190 GENENAME TICAM1 T44190 TARGTYPE Patented-recorded T44190 SYNONYMS Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta; TRIF; TIR domain-containing adapter protein inducing IFN-beta; TICAM-1; Putative NF-kappa-B-activating protein 502H; Proline-rich, vinculin and TIR domain-containing protein B; PRVTIRB; MyD88-3 T44190 FUNCTION Adapter used by TLR3, TLR4 (through TICAM2) and TLR5 to mediate NF-kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis. Ligand binding to these receptors results in TRIF recruitment through its TIR domain. Distinct protein-interaction motifs allow recruitment of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to the activation of transcription factors IRF3 and IRF7, NF-kappa-B and FADD respectively. Phosphorylation by TBK1 on the pLxIS motif leads to recruitment and subsequent activation of the transcription factor IRF3 to induce expression of type I interferon and exert a potent immunity against invading pathogens. Component of a multi-helicase-TICAM1 complex that acts as a cytoplasmic sensor of viral double-stranded RNA (dsRNA) and plays a role in the activation of a cascade of antiviral responses including the induction of proinflammatory cytokines. Involved in innate immunity against invading pathogens. T44190 PDBSTRUC 5JEL; 4C0M; 4BSX; 3RC4; 2M63 T44190 SEQUENCE MACTGPSLPSAFDILGAAGQDKLLYLKHKLKTPRPGCQGQDLLHAMVLLKLGQETEARISLEALKADAVARLVARQWAGVDSTEDPEEPPDVSWAVARLYHLLAEEKLCPASLRDVAYQEAVRTLSSRDDHRLGELQDEARNRCGWDIAGDPGSIRTLQSNLGCLPPSSALPSGTRSLPRPIDGVSDWSQGCSLRSTGSPASLASNLEISQSPTMPFLSLHRSPHGPSKLCDDPQASLVPEPVPGGCQEPEEMSWPPSGEIASPPELPSSPPPGLPEVAPDATSTGLPDTPAAPETSTNYPVECTEGSAGPQSLPLPILEPVKNPCSVKDQTPLQLSVEDTTSPNTKPCPPTPTTPETSPPPPPPPPSSTPCSAHLTPSSLFPSSLESSSEQKFYNFVILHARADEHIALRVREKLEALGVPDGATFCEDFQVPGRGELSCLQDAIDHSAFIILLLTSNFDCRLSLHQVNQAMMSNLTRQGSPDCVIPFLPLESSPAQLSSDTASLLSGLVRLDEHSQIFARKVANTFKPHRLQARKAMWRKEQDTRALREQSQHLDGERMQAAALNAAYSAYLQSYLSYQAQMEQLQVAFGSHMSFGTGAPYGARMPFGGQVPLGAPPPFPTWPGCPQPPPLHAWQAGTPPPPSPQPAAFPQSLPFPQSPAFPTASPAPPQSPGLQPLIIHHAQMVQLGLNNHMWNQRGSQAPEDKTQEAE T15518 TARGETID T15518 T15518 FORMERID TTDI03421 T15518 UNIPROID SO2A1_HUMAN T15518 TARGNAME Prostaglandin transporter (SLC21A2) T15518 GENENAME SLCO2A1 T15518 TARGTYPE Patented-recorded T15518 SYNONYMS Solute carrier organic anion transporter family member 2A1; Solute carrier family 21 member 2; PGT; OATP2A1 T15518 FUNCTION Transports PGD2, as well as PGE1, PGE2 and PGF2A. May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. T15518 PDBSTRUC 3MRR T15518 BIOCLASS Organo anion transporter T15518 SEQUENCE MGLLPKLGASQGSDTSTSRAGRCARSVFGNIKVFVLCQGLLQLCQLLYSAYFKSSLTTIEKRFGLSSSSSGLISSLNEISNAILIIFVSYFGSRVHRPRLIGIGGLFLAAGAFILTLPHFLSEPYQYTLASTGNNSRLQAELCQKHWQDLPPSKCHSTTQNPQKETSSMWGLMVVAQLLAGIGTVPIQPFGISYVDDFSEPSNSPLYISILFAISVFGPAFGYLLGSVMLQIFVDYGRVNTAAVNLVPGDPRWIGAWWLGLLISSALLVLTSFPFFFFPRAMPIGAKRAPATADEARKLEEAKSRGSLVDFIKRFPCIFLRLLMNSLFVLVVLAQCTFSSVIAGLSTFLNKFLEKQYGTSAAYANFLIGAVNLPAAALGMLFGGILMKRFVFSLQAIPRIATTIITISMILCVPLFFMGCSTPTVAEVYPPSTSSSIHPQSPACRRDCSCPDSIFHPVCGDNGIEYLSPCHAGCSNINMSSATSKQLIYLNCSCVTGGSASAKTGSCPVPCAHFLLPAIFLISFVSLIACISHNPLYMMVLRVVNQEEKSFAIGVQFLLMRLLAWLPSPALYGLTIDHSCIRWNSLCLGRRGACAYYDNDALRDRYLGLQMGYKALGMLLLCFISWRVKKNKEYNVQKAAGLI T15518 DRUGINFO D07XPI PMID26099857-Compound-WO2011037610Formula(I) Patented T15518 DRUGINFO D0KO9R bromocresol green Investigative T15518 DRUGINFO D0W8GY bromsulphthalein Investigative T45228 TARGETID T45228 T45228 FORMERID TTDI02621 T45228 UNIPROID MBOA4_HUMAN T45228 TARGNAME Ghrelin O acyltransferase (GOAT) T45228 GENENAME MBOAT4 T45228 TARGTYPE Patented-recorded T45228 SYNONYMS Oacyltransferase domaincontaining protein 4; OACT4; O-acyltransferase domain-containing protein 4; Membranebound Oacyltransferase domaincontaining protein 4; Membrane-bound O-acyltransferase domain-containing protein 4; Ghrelin Oacyltransferase; Ghrelin O-acyltransferase; FKSG89 T45228 FUNCTION Can use a variety of fatty acids as substrates including octanoic acid, decanoic acid and tetradecanoic acid. Mediates the octanoylation of ghrelin at 'Ser-3'. T45228 BIOCLASS Acyltransferase T45228 ECNUMBER EC 2.3.1.- T45228 SEQUENCE MEWLWLFFLHPISFYQGAAFPFALLFNYLCIMDSFSTRARYLFLLTGGGALAVAAMGSYAVLVFTPAVCAVALLCSLAPQQVHRWTFCFQMSWQTLCHLGLHYTEYYLHEPPSVRFCITLSSLMLLTQRVTSLSLDICEGKVKAASGGFRSRSSLSEHVCKALPYFSYLLFFPALLGGSLCSFQRFQARVQGSSALHPRHSFWALSWRGLQILGLECLNVAVSRVVDAGAGLTDCQQFECIYVVWTTAGLFKLTYYSHWILDDSLLHAAGFGPELGQSPGEEGYVPDADIWTLERTHRISVFSRKWNQSTARWLRRLVFQHSRAWPLLQTFAFSAWWHGLHPGQVFGFVCWAVMVEADYLIHSFANEFIRSWPMRLFYRTLTWAHTQLIIAYIMLAVEVRSLSSLWLLCNSYNSVFPMVYCILLLLLAKRKHKCN T45228 DRUGINFO D0YY8N PMID25470667-Compound-GO-CoA-Tat Patented T16215 TARGETID T16215 T16215 UNIPROID SMO_HUMAN T16215 TARGNAME Smoothened D473H mutant (SMO D473H) T16215 GENENAME SMO T16215 TARGTYPE Patented-recorded T16215 SYNONYMS Smo-D473H mutant; SMOH D473H mutant; Protein Gx D473H mutant T16215 FUNCTION Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7, GLI2 and GLI3 in the cilia. Interacts with DLG5 at the ciliary base to induce the accumulation of KIF7 and GLI2 at the ciliary tip for GLI2 activation. G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. T16215 PDBSTRUC 5V57; 5V56; 5L7I; 5L7D; 4QIN T16215 BIOCLASS GPCR frizzled T16215 SEQUENCE MAAARPARGPELPLLGLLLLLLLGDPGRGAASSGNATGPGPRSAGGSARRSAAVTGPPPPLSHCGRAAPCEPLRYNVCLGSVLPYGATSTLLAGDSDSQEEAHGKLVLWSGLRNAPRCWAVIQPLLCAVYMPKCENDRVELPSRTLCQATRGPCAIVERERGWPDFLRCTPDRFPEGCTNEVQNIKFNSSGQCEVPLVRTDNPKSWYEDVEGCGIQCQNPLFTEAEHQDMHSYIAAFGAVTGLCTLFTLATFVADWRNSNRYPAVILFYVNACFFVGSIGWLAQFMDGARREIVCRADGTMRLGEPTSNETLSCVIIFVIVYYALMAGVVWFVVLTYAWHTSFKALGTTYQPLSGKTSYFHLLTWSLPFVLTVAILAVAQVDGDSVSGICFVGYKNYRYRAGFVLAPIGLVLIVGGYFLIRGVMTLFSIKSNHPGLLSEKAASKINETMLRLGIFGFLAFGFVLITFSCHFYDFFNQAEWERSFRDYVLCQANVTIGLPTKQPIPDCEIKNRPSLLVEKINLFAMFGTGIAMSTWVWTKATLLIWRRTWCRLTGQSDDEPKRIKKSKMIAKAFSKRHELLQNPGQELSFSMHTVSHDGPVAGLAFDLNEPSADVSSAWAQHVTKMVARRGAILPQDISVTPVATPVPPEEQANLWLVEAEISPELQKRLGRKKKRRKRKKEVCPLAPPPELHPPAPAPSTIPRLPQLPRQKCLVAAGAWGAGDSCRQGAWTLVSNPFCPEPSPPQDPFLPSAPAPVAWAHGRRQGLGPIHSRTNLMDTELMDADSDF T16215 DRUGINFO D07BIQ PMID25726713-Compound-17 Patented T50035 TARGETID T50035 T50035 UNIPROID PD1L2_HUMAN T50035 TARGNAME Programmed cell death 1 ligand 2 (PD-L2) T50035 GENENAME PDCD1LG2 T50035 TARGTYPE Patented-recorded T50035 SYNONYMS Programmed death ligand 2; PDL2; PDCD1L2; PDCD1 ligand 2; PD-1 ligand 2; CD273; Butyrophilin B7-DC; B7DC; B7-DC T50035 FUNCTION Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production. Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. T50035 BIOCLASS Immunoglobulin T50035 SEQUENCE MIFLLLMLSLELQLHQIAALFTVTVPKELYIIEHGSNVTLECNFDTGSHVNLGAITASLQKVENDTSPHRERATLLEEQLPLGKASFHIPQVQVRDEGQYQCIIIYGVAWDYKYLTLKVKASYRKINTHILKVPETDEVELTCQATGYPLAEVSWPNVSVPANTSHSRTPEGLYQVTSVLRLKPPPGRNFSCVFWNTHVRELTLASIDLQSQMEPRTHPTWLLHIFIPFCIIAFIFIATVIALRKQLCQKLYSSKDTTKRPVTTTKREVNSAI T39195 TARGETID T39195 T39195 FORMERID TTDI03305 T39195 UNIPROID KLK14_HUMAN T39195 TARGNAME Kallikrein-14 (KLK14) T39195 GENENAME KLK14 T39195 TARGTYPE Patented-recorded T39195 SYNONYMS hK14; Kallikrein-like protein 6; KLKL6; KLK-L6 T39195 FUNCTION May activate/inactivate the proteinase-activated receptors F2R, F2RL1 and F2RL3 and other kallikreins including KLK1, KLK3, KLK5 and KLK11. May function in seminal clot liquefaction through direct cleavage of the semenogelin SEMG1 and SEMG2 and activation of KLK3. May function through desmoglein DSG1 cleavage in epidermal desquamation a process by which the most superficial corneocytes are shed from the skin surface. May be involved in several aspects of tumor progression including growth, invasion and angiogenesis. Serine-type endopeptidase with a dual trypsin-like and chymotrypsin-like substrate specificity. T39195 BIOCLASS Peptidase T39195 ECNUMBER EC 3.4.21.- T39195 SEQUENCE MSLRVLGSGTWPSAPKMFLLLTALQVLAIAMTQSQEDENKIIGGHTCTRSSQPWQAALLAGPRRRFLCGGALLSGQWVITAAHCGRPILQVALGKHNLRRWEATQQVLRVVRQVTHPNYNSRTHDNDLMLLQLQQPARIGRAVRPIEVTQACASPGTSCRVSGWGTISSPIARYPASLQCVNINISPDEVCQKAYPRTITPGMVCAGVPQGGKDSCQGDSGGPLVCRGQLQGLVSWGMERCALPGYPGVYTNLCKYRSWIEETMRDK T39195 DRUGINFO D00LOL PMID23849879C3 Investigative T39195 DRUGINFO D07OQF PMID25489658C4d Investigative T03687 TARGETID T03687 T03687 FORMERID TTDI03262 T03687 UNIPROID HDAC9_HUMAN T03687 TARGNAME Histone deacetylase 9 (HDAC9) T03687 GENENAME HDAC9 T03687 TARGTYPE Patented-recorded T03687 SYNONYMS MITR; MEF2-interacting transcription repressor MITR; KIAA0744; Histone deacetylase-related protein; Histone deacetylase 7B; HDRP; HDAC7B; HDAC7; HD9; HD7b T03687 FUNCTION Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). T03687 BIOCLASS Carbon-nitrogen hydrolase T03687 ECNUMBER EC 3.5.1.98 T03687 SEQUENCE MHSMISSVDVKSEVPVGLEPISPLDLRTDLRMMMPVVDPVVREKQLQQELLLIQQQQQIQKQLLIAEFQKQHENLTRQHQAQLQEHIKELLAIKQQQELLEKEQKLEQQRQEQEVERHRREQQLPPLRGKDRGRERAVASTEVKQKLQEFLLSKSATKDTPTNGKNHSVSRHPKLWYTAAHHTSLDQSSPPLSGTSPSYKYTLPGAQDAKDDFPLRKTASEPNLKVRSRLKQKVAERRSSPLLRRKDGNVVTSFKKRMFEVTESSVSSSSPGSGPSSPNNGPTGSVTENETSVLPPTPHAEQMVSQQRILIHEDSMNLLSLYTSPSLPNITLGLPAVPSQLNASNSLKEKQKCETQTLRQGVPLPGQYGGSIPASSSHPHVTLEGKPPNSSHQALLQHLLLKEQMRQQKLLVAGGVPLHPQSPLATKERISPGIRGTHKLPRHRPLNRTQSAPLPQSTLAQLVIQQQHQQFLEKQKQYQQQIHMNKLLSKSIEQLKQPGSHLEEAEEELQGDQAMQEDRAPSSGNSTRSDSSACVDDTLGQVGAVKVKEEPVDSDEDAQIQEMESGEQAAFMQQPFLEPTHTRALSVRQAPLAAVGMDGLEKHRLVSRTHSSPAASVLPHPAMDRPLQPGSATGIAYDPLMLKHQCVCGNSTTHPEHAGRIQSIWSRLQETGLLNKCERIQGRKASLEEIQLVHSEHHSLLYGTNPLDGQKLDPRILLGDDSQKFFSSLPCGGLGVDSDTIWNELHSSGAARMAVGCVIELASKVASGELKNGFAVVRPPGHHAEESTAMGFCFFNSVAITAKYLRDQLNISKILIVDLDVHHGNGTQQAFYADPSILYISLHRYDEGNFFPGSGAPNEVGTGLGEGYNINIAWTGGLDPPMGDVEYLEAFRTIVKPVAKEFDPDMVLVSAGFDALEGHTPPLGGYKVTAKCFGHLTKQLMTLADGRVVLALEGGHDLTAICDASEACVNALLGNELEPLAEDILHQSPNMNAVISLQKIIEIQSMSLKFS T03687 DRUGINFO D0T7OQ PMID29671355-Compound-73 Patented T03687 DRUGINFO D0YN2T PMID29671355-Compound-45a Patented T03687 DRUGINFO D0DI9S PMID29671355-Compound-31 Patented T03687 DRUGINFO D0LP1K PMID29671355-Compound-21 Patented T03687 DRUGINFO D07WAT PMID29671355-Compound-62 Patented T03687 DRUGINFO D0BP8I PMID29671355-Compound-43 Patented T03687 DRUGINFO D0RA0D PMID29671355-Compound-25 Patented T03687 DRUGINFO D0R7JA TMP269 Investigative T59459 TARGETID T59459 T59459 UNIPROID JIP1_HUMAN T59459 TARGNAME JNK-interacting protein 1 peptide (pepJIP1) T59459 GENENAME MAPK8IP1 T59459 TARGTYPE Patented-recorded T59459 SYNONYMS PRKM8IP; Mitogen-activated protein kinase 8-interacting protein 1; JNK-interacting protein 1; JNK MAP kinase scaffold protein 1; JIP1; JIP-1; Islet-brain 1; IB1; IB-1; C-Jun-amino-terminal kinase-interacting protein 1 T59459 FUNCTION Required for JNK activation in response to excitotoxic stress. Cytoplasmic MAPK8IP1 causes inhibition of JNK-regulated activity by retaining JNK in the cytoplasm and inhibiting JNK phosphorylation of c-Jun. May also participate in ApoER2-specific reelin signaling. Directly, or indirectly, regulates GLUT2 gene expression and beta-cell function. Appears to have a role in cell signaling in mature and developing nerve terminals. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins. Functions as an anti-apoptotic protein and whose level seems to influence the beta-cell death or survival response. Acts as a scaffold protein that coordinates with SH3RF1 in organizing different components of the JNK pathway, including RAC1 or RAC2, MAP3K11/MLK3 or MAP3K7/TAK1, MAP2K7/MKK7, MAPK8/JNK1 and/or MAPK9/JNK2 into a functional multiprotein complex to ensure the effective activation of the JNK signaling pathway. Regulates the activation of MAPK8/JNK1 and differentiation of CD8(+) T-cells. The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. T59459 PDBSTRUC 6FUZ; 5LW1; 4IZY; 4HYU; 4HYS T59459 SEQUENCE MAERESGGLGGGAASPPAASPFLGLHIASPPNFRLTHDISLEEFEDEDLSEITDECGISLQCKDTLSLRPPRAGLLSAGGGGAGSRLQAEMLQMDLIDATGDTPGAEDDEEDDDEERAARRPGAGPPKAESGQEPASRGQGQSQGQSQGPGSGDTYRPKRPTTLNLFPQVPRSQDTLNNNSLGKKHSWQDRVSRSSSPLKTGEQTPPHEHICLSDELPPQSGPAPTTDRGTSTDSPCRRSTATQMAPPGGPPAAPPGGRGHSHRDRIHYQADVRLEATEEIYLTPVQRPPDAAEPTSAFLPPTESRMSVSSDPDPAAYPSTAGRPHPSISEEEEGFDCLSSPERAEPPGGGWRGSLGEPPPPPRASLSSDTSALSYDSVKYTLVVDEHAQLELVSLRPCFGDYSDESDSATVYDNCASVSSPYESAIGEEYEEAPRPQPPACLSEDSTPDEPDVHFSKKFLNVFMSGRSRSSSAESFGLFSCIINGEEQEQTHRAIFRFVPRHEDELELEVDDPLLVELQAEDYWYEAYNMRTGARGVFPAYYAIEVTKEPEHMAALAKNSDWVDQFRVKFLGSVQVPYHKGNDVLCAAMQKIATTRRLTVHFNPPSSCVLEISVRGVKIGVKADDSQEAKGNKCSHFFQLKNISFCGYHPKNNKYFGFITKHPADHRFACHVFVSEDSTKALAESVGRAFQQFYKQFVEYTCPTEDIYLE T59459 DRUGINFO D0ID4H PMID25991433-Compound-N1 Patented T82720 TARGETID T82720 T82720 FORMERID TTDI03163 T82720 UNIPROID DYR1B_HUMAN T82720 TARGNAME Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) T82720 GENENAME DYRK1B T82720 TARGTYPE Patented-recorded T82720 SYNONYMS Minibrain-related kinase; MIRK; Dual specificity tyrosine-phosphorylation-regulated kinase 1B T82720 FUNCTION Enhances the transcriptional activity of TCF1/HNF1A and FOXO1. Inhibits epithelial cell migration. Mediates colon carcinoma cell survival in mitogen-poor environments. Inhibits the SHH and WNT1 pathways, thereby enhancing adipogenesis. In addition, promotes expression of the gluconeogenic enzyme glucose-6-phosphatase (G6PC). Dual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities. T82720 BIOCLASS Kinase T82720 ECNUMBER EC 2.7.12.1 T82720 SEQUENCE MAVPPGHGPFSGFPGPQEHTQVLPDVRLLPRRLPLAFRDATSAPLRKLSVDLIKTYKHINEVYYAKKKRRAQQAPPQDSSNKKEKKVLNHGYDDDNHDYIVRSGERWLERYEIDSLIGKGSFGQVVKAYDHQTQELVAIKIIKNKKAFLNQAQIELRLLELMNQHDTEMKYYIVHLKRHFMFRNHLCLVFELLSYNLYDLLRNTHFRGVSLNLTRKLAQQLCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGTPYDLAIDMWSLGCILVEMHTGEPLFSGSNEVDQMNRIVEVLGIPPAAMLDQAPKARKYFERLPGGGWTLRRTKELRKDYQGPGTRRLQEVLGVQTGGPGGRRAGEPGHSPADYLRFQDLVLRMLEYEPAARISPLGALQHGFFRRTADEATNTGPAGSSASTSPAPLDTCPSSSTASSISSSGGSSGSSSDNRTYRYSNRYCGGPGPPITDCEMNSPQVPPSQPLRPWAGGDVPHKTHQAPASASSLPGTGAQLPPQPRYLGRPPSPTSPPPPELMDVSLVGGPADCSPPHPAPAPQHPAASALRTRMTGGRPPLPPPDDPATLGPHLGLRGVPQSTAASS T82720 DRUGINFO D00TFF PMID28766366-Compound-Scheme2WO2012/098065bottom Patented T82720 DRUGINFO D05CLL PMID28766366-Compound-Scheme7WO2012/098070upper Patented T82720 DRUGINFO D08CUF PMID28766366-Compound-Scheme9EHT1610 Patented T82720 DRUGINFO D08DIJ PMID28766366-Compound-Scheme9EHT5372 Patented T82720 DRUGINFO D09CDR PMID28766366-Compound-Scheme25-2 Patented T82720 DRUGINFO D0B8IQ PMID28766366-Compound-Scheme2WO2012/098065upper Patented T82720 DRUGINFO D0BP6J PMID28766366-Compound-Scheme7WO2012/098070bottom Patented T82720 DRUGINFO D0C0BP PMID28766366-Compound-Scheme4Upper Patented T82720 DRUGINFO D0CC7E PMID28766366-Compound-Scheme25-3 Patented T82720 DRUGINFO D0DT5I PMID28766366-Compound-Scheme9EHT3356 Patented T82720 DRUGINFO D0GE4F PMID28766366-Compound-Scheme25-4 Patented T82720 DRUGINFO D0O9BK PMID28766366-Compound-Scheme9EHT6840 Patented T82720 DRUGINFO D0P7QO PMID28766366-Compound-Scheme5 Patented T82720 DRUGINFO D0PJ1W PMID28766366-Compound-Scheme9EHT9851 Patented T82720 DRUGINFO D0SB1W PMID28766366-Compound-Scheme4Bottom Patented T82720 DRUGINFO D04SYJ PMID28766366-Compound-Scheme14BINDY Patented T82720 DRUGINFO D02DBH PMID28766366-Compound-Scheme21Left Patented T82720 DRUGINFO D07BWC PMID28766366-Compound-Scheme21Right Patented T82720 DRUGINFO D00AQR WO2013026806C72 Investigative T82720 DRUGINFO D0X9PI PMID24900699C68 Investigative T82720 DRUGINFO D06CXU PMID23642479C17 Investigative T03150 TARGETID T03150 T03150 UNIPROID DGLA_HUMAN T03150 TARGNAME Diacylglycerol lipase alpha (DAGLA) T03150 GENENAME DAGLA T03150 TARGTYPE Patented-recorded T03150 SYNONYMS Sn1-specific diacylglycerol lipase alpha; Neural stem cell-derived dendrite regulator; NSDDR; KIAA0659; DGL-alpha; C11orf11 T03150 FUNCTION Catalyzes the hydrolysis of diacylglycerol (DAG) to 2-arachidonoyl-glycerol (2-AG), the most abundant endocannabinoid in tissues. Required for axonal growth during development and for retrograde synaptic signaling at mature synapses. T03150 BIOCLASS Carboxylic ester hydrolase T03150 ECNUMBER EC 3.1.1.- T03150 SEQUENCE MPGIVVFRRRWSVGSDDLVLPAIFLFLLHTTWFVILSVVLFGLVYNPHEACSLNLVDHGRGYLGILLSCMIAEMAIIWLSMRGGILYTEPRDSMQYVLYVRLAILVIEFIYAIVGIVWLTQYYTSCNDLTAKNVTLGMVVCNWVVILSVCITVLCVFDPTGRTFVKLRATKRRQRNLRTYNLRHRLEEGQATSWSRRLKVFLCCTRTKDSQSDAYSEIAYLFAEFFRDLDIVPSDIIAGLVLLRQRQRAKRNAVLDEANNDILAFLSGMPVTRNTKYLDLKNSQEMLRYKEVCYYMLFALAAYGWPMYLMRKPACGLCQLARSCSCCLCPARPRFAPGVTIEEDNCCGCNAIAIRRHFLDENMTAVDIVYTSCHDAVYETPFYVAVDHDKKKVVISIRGTLSPKDALTDLTGDAERLPVEGHHGTWLGHKGMVLSAEYIKKKLEQEMVLSQAFGRDLGRGTKHYGLIVVGHSLGAGTAAILSFLLRPQYPTLKCFAYSPPGGLLSEDAMEYSKEFVTAVVLGKDLVPRIGLSQLEGFRRQLLDVLQRSTKPKWRIIVGATKCIPKSELPEEVEVTTLASTRLWTHPSDLTIALSASTPLYPPGRIIHVVHNHPAEQCCCCEQEEPTYFAIWGDNKAFNEVIISPAMLHEHLPYVVMEGLNKVLENYNKGKTALLSAAKVMVSPTEVDLTPELIFQQQPLPTGPPMPTGLALELPTADHRNSSVRSKSQSEMSLEGFSEGRLLSPVVAAAARQDPVELLLLSTQERLAAELQARRAPLATMESLSDTESLYSFDSRRSSGFRSIRGSPSLHAVLERDEGHLFYIDPAIPEENPSLSSRTELLAADSLSKHSQDTQPLEAALGSGGVTPERPPSAAANDEEEEVGGGGGGPASRGELALHNGRLGDSPSPQVLEFAEFIDSLFNLDSKSSSFQDLYCMVVPESPTSDYAEGPKSPSQQEILLRAQFEPNLVPKPPRLFAGSADPSSGISLSPSFPLSSSGELMDLTPTGLSSQECLAADKIRTSTPTGHGASPAKQDELVISAR T03150 DRUGINFO D0TL1G PMID29053063-Compound-15 Patented T03150 DRUGINFO D05LXG RHC80267 Investigative T22104 TARGETID T22104 T22104 FORMERID TTDR00888 T22104 UNIPROID GREM1_HUMAN T22104 TARGNAME Gremlin-1 (Gremlin-1) T22104 GENENAME GREM1 T22104 TARGTYPE Patented-recorded T22104 SYNONYMS Proliferation-inducing gene 2; PIG2; Increased in high glucose protein 2; IHG-2; Down-regulated in Mos-transformed cells protein; DRM; DAND2; DAN domain family member 2; Cysteine knot superfamily 1, BMP antagonist 1; Cell proliferation-inducing gene 2 protein; CKTSF1B1 T22104 FUNCTION Down-regulates the BMP4 signaling in a dose-dependent manner. Antagonist of BMP2; inhibits BMP2-mediated differentiation of osteoblasts (in vitro). Acts as inhibitor of monocyte chemotaxis. Can inhibit the growth or viability of normal cells but not transformed cells when is overexpressed. Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback loop. T22104 PDBSTRUC 5AEJ T22104 SEQUENCE MSRTAYTVGALLLLLGTLLPAAEGKKKGSQGAIPPPDKAQHNDSEQTQSPQQPGSRNRGRGQGRGTAMPGEEVLESSQEALHVTERKYLKRDWCKTQPLKQTIHEEGCNSRTIINRFCYGQCNSFYIPRHIRKEEGSFQSCSFCKPKKFTTMMVTLNCPELQPPTKKKRVTRVKQCRCISIDLD T22104 DRUGINFO D0MP8N Antibodie derivative 5 Patented T19184 TARGETID T19184 T19184 UNIPROID PYGL_HUMAN; PYGM_HUMAN; PYGB_HUMAN T19184 TARGNAME Glycogen phosphorylase (PYG) T19184 GENENAME PYGL; PYGM; PYGB T19184 TARGTYPE Patented-recorded T19184 SYNONYMS Glycogen phosphorylase T19184 FUNCTION Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties. T19184 BIOCLASS Glycosyltransferases T19184 SEQUENCE MAKPLTDQEKRRQISIRGIVGVENVAELKKSFNRHLHFTLVKDRNVATTRDYYFALAHTVRDHLVGRWIRTQQHYYDKCPKRVYYLSLEFYMGRTLQNTMINLGLQNACDEAIYQLGLDIEELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEYGIFNQKIRDGWQVEEADDWLRYGNPWEKSRPEFMLPVHFYGKVEHTNTGTKWIDTQVVLALPYDTPVPGYMNNTVNTMRLWSARAPNDFNLRDFNVGDYIQAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKASKFGSTRGAGTVFDAFPDQVAIQLNDTHPALAIPELMRIFVDIEKLPWSKAWELTQKTFAYTNHTVLPEALERWPVDLVEKLLPRHLEIIYEINQKHLDRIVALFPKDVDRLRRMSLIEEEGSKRINMAHLCIVGSHAVNGVAKIHSDIVKTKVFKDFSELEPDKFQNKTNGITPRRWLLLCNPGLAELIAEKIGEDYVKDLSQLTKLHSFLGDDVFLRELAKVKQENKLKFSQFLETEYKVKINPSSMFDVQVKRIHEYKRQLLNCLHVITMYNRIKKDPKKLFVPRTVIIGGKAAPGYHMAKMIIKLITSVADVVNNDPMVGSKLKVIFLENYRVSLAEKVIPATDLSEQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGEENLFIFGMRIDDVAALDKKGYEAKEYYEALPELKLVIDQIDNGFFSPKQPDLFKDIINMLFYHDRFKVFADYEAYVKCQDKVSQLYMNPKAWNTMVLKNIAASGKFSSDRTIKEYAQNIWNVEPSDLKISLSNESNKVNGN T19184 DRUGINFO D00PEV PMID26666989-Compound-Figure9middle03 Patented T19184 DRUGINFO D01DXB PMID26666989-Compound-Figure9middle11 Patented T19184 DRUGINFO D02KWZ PMID26666989-Compound-Figure9middle04 Patented T19184 DRUGINFO D03WPO PMID26666989-Compound-Figure9middle10 Patented T19184 DRUGINFO D06PSM PMID26666989-Compound-Figure9bottomright Patented T19184 DRUGINFO D06TPL PMID26666989-Compound-Figure11topright Patented T19184 DRUGINFO D07POD PMID26666989-Compound-Figure9middle05 Patented T19184 DRUGINFO D08GSN PMID26666989-Compound-Figure9middle12 Patented T19184 DRUGINFO D08KMR PMID26666989-Compound-Figure12bottomright Patented T19184 DRUGINFO D09PAZ PMID26666989-Compound-Figure9middle08 Patented T19184 DRUGINFO D09YQO PMID26666989-Compound-Figure12topmiddile Patented T19184 DRUGINFO D0AJ3H PMID26666989-Compound-Figure9middle07 Patented T19184 DRUGINFO D0H0XX PMID26666989-Compound-Figure12bottommiddle01 Patented T19184 DRUGINFO D0JO2A PMID26666989-Compound-Figure9left01 Patented T19184 DRUGINFO D0KK0E PMID26666989-Compound-Figure9topright01 Patented T19184 DRUGINFO D0MT6D PMID26666989-Compound-Figure9middle13 Patented T19184 DRUGINFO D0N1IA PMID26666989-Compound-Figure9middle02 Patented T19184 DRUGINFO D0S5CP PMID26666989-Compound-Figure12left Patented T19184 DRUGINFO D0TE4S PMID26666989-Compound-Figure11Ala down Patented T19184 DRUGINFO D0TY4L PMID26666989-Compound-Figure9middle06 Patented T19184 DRUGINFO D0U7WQ PMID26666989-Compound-Figure11Ala up Patented T19184 DRUGINFO D0VJ0N PMID26666989-Compound-Figure9left02 Patented T19184 DRUGINFO D0W5DU PMID26666989-Compound-Figure9toprightR02 Patented T19184 DRUGINFO D0Y4KB PMID26666989-Compound-Figure12bottommiddle02 Patented T19184 DRUGINFO D0YE8Q PMID26666989-Compound-Figure9middle01 Patented T40890 TARGETID T40890 T40890 FORMERID TTDR01298 T40890 UNIPROID GLI1_HUMAN T40890 TARGNAME Zinc finger protein GLI1 (Gli1) T40890 GENENAME GLI1 T40890 TARGTYPE Patented-recorded T40890 SYNONYMS Oncogene GLI; Glioma-associated oncogene; GLI T40890 FUNCTION Binds to the DNA consensus sequence 5'-GACCACCCA-3'. Regulates the transcription of specific genes during normal development. Plays a role in craniofacial development and digital development, as well as development of the central nervous system and gastrointestinal tract. Mediates SHH signaling. Plays a role in cell proliferation and differentiation via its role in SHH signaling. Acts as a transcriptional activator. T40890 PDBSTRUC 5OM0; 4KMD; 4BLB; 2GLI T40890 SEQUENCE MFNSMTPPPISSYGEPCCLRPLPSQGAPSVGTEGLSGPPFCHQANLMSGPHSYGPARETNSCTEGPLFSSPRSAVKLTKKRALSISPLSDASLDLQTVIRTSPSSLVAFINSRCTSPGGSYGHLSIGTMSPSLGFPAQMNHQKGPSPSFGVQPCGPHDSARGGMIPHPQSRGPFPTCQLKSELDMLVGKCREEPLEGDMSSPNSTGIQDPLLGMLDGREDLEREEKREPESVYETDCRWDGCSQEFDSQEQLVHHINSEHIHGERKEFVCHWGGCSRELRPFKAQYMLVVHMRRHTGEKPHKCTFEGCRKSYSRLENLKTHLRSHTGEKPYMCEHEGCSKAFSNASDRAKHQNRTHSNEKPYVCKLPGCTKRYTDPSSLRKHVKTVHGPDAHVTKRHRGDGPLPRAPSISTVEPKREREGGPIREESRLTVPEGAMKPQPSPGAQSSCSSDHSPAGSAANTDSGVEMTGNAGGSTEDLSSLDEGPCIAGTGLSTLRRLENLRLDQLHQLRPIGTRGLKLPSLSHTGTTVSRRVGPPVSLERRSSSSSSISSAYTVSRRSSLASPFPPGSPPENGASSLPGLMPAQHYLLRARYASARGGGTSPTAASSLDRIGGLPMPPWRSRAEYPGYNPNAGVTRRASDPAQAADRPAPARVQRFKSLGCVHTPPTVAGGGQNFDPYLPTSVYSPQPPSITENAAMDARGLQEEPEVGTSMVGSGLNPYMDFPPTDTLGYGGPEGAAAEPYGARGPGSLPLGPGPPTNYGPNPCPQQASYPDPTQETWGEFPSHSGLYPGPKALGGTYSQCPRLEHYGQVQVKPEQGCPVGSDSTGLAPCLNAHPSEGPPHPQPLFSHYPQPSPPQYLQSGPYTQPPPDYLPSEPRPCLDFDSPTHSTGQLKAQLVCNYVQSQQELLWEGGGREDAPAQEPSYQSPKFLGGSQVSPSRAKAPVNTYGPGFGPNLPNHKSGSYPTPSPCHENFVVGANRASHRAAAPPRLLPPLPTCYGPLKVGGTNPSCGHPEVGRLGGGPALYPPPEGQVCNPLDSLDLDNTQLDFVAILDEPQGLSPPPSHDQRGSSGHTPPPSGPPNMAVGNMSVLLRSLPGETEFLNSSA T40890 DRUGINFO D00KXJ PMID26666870-Compound-16 Patented T40890 DRUGINFO D0FL0T Imidazo bicyclic iminium derivative 1 Patented T40890 DRUGINFO D0II7X Imidazo bicyclic iminium derivative 2 Patented T40890 DRUGINFO D00RRB Isoflavone derivative 1 Patented T40890 DRUGINFO D01BGG Isoflavone derivative 5 Patented T40890 DRUGINFO D04IFL Isoflavone derivative 7 Patented T40890 DRUGINFO D05NRG Isoflavone derivative 8 Patented T40890 DRUGINFO D09VIE Isoflavone derivative 9 Patented T40890 DRUGINFO D0J1RB Isoflavone derivative 6 Patented T40890 DRUGINFO D0TP0S Isoflavone derivative 3 Patented T40890 DRUGINFO D0WI1G Isoflavone derivative 2 Patented T40890 DRUGINFO D0Z6IS Isoflavone derivative 4 Patented T63303 TARGETID T63303 T63303 UNIPROID MMP2_HUMAN; MMP9_HUMAN T63303 TARGNAME Gelatinase (GEL) T63303 GENENAME MMP2; MMP9 T63303 TARGTYPE Patented-recorded T63303 SYNONYMS Matrix metalloproteinase GEL; Gelatinase B; Gelatinase A; Collagenase IV; CLG4 T63303 FUNCTION A proteolytic enzyme that allows a living organism to hydrolyse gelatin into its sub-compounds (polypeptides, peptides, and amino acids) that can cross the cell membrane and be used by the organism. It is not a pepsin. T63303 BIOCLASS Peptidase T63303 SEQUENCE MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGCPKESCNLFVLKDTLKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWDKNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGDGYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFNGKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGTSYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKYESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGALMAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQIRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEYWIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYIFAGDKFWRYNEVKKKMDPGFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLENQSLKSVKFGSIKSDWLGC T63303 DRUGINFO D01KYS PMID29130358-Compound-Figure15(8) Patented T63303 DRUGINFO D02YCN PMID29130358-Compound-Figure14(5) Patented T63303 DRUGINFO D0I6IR PMID29130358-Compound-Figure14(6) Patented T63303 DRUGINFO D0NF2E PMID29130358-Compound-Figure9(1) Patented T63303 DRUGINFO D0VM8G PMID29130358-Compound-Figure15(7) Patented T11824 TARGETID T11824 T11824 UNIPROID TAU_HUMAN T11824 TARGNAME Microtubule-associated protein tau phosphorylation (MAPT p) T11824 GENENAME MAPT T11824 TARGTYPE Patented-recorded T11824 SYNONYMS tau phosphorylation; Paired helical filamenttau phosphorylation; Paired helical filament-tau phosphorylation; PHFtau; PHF-tau; Neurofibrillary tangle protein phosphorylation; MTBT1 phosphorylation; MAPTL phosphorylation T11824 FUNCTION The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. T11824 PDBSTRUC 6QJQ; 6QJP; 6QJM; 6QJH; 6NWQ T11824 SEQUENCE MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL T11824 DRUGINFO D0I3LY PMID28766366-Compound-Scheme22Middle Patented T01271 TARGETID T01271 T01271 UNIPROID BCR_HUMAN-ABL1_HUMAN T01271 TARGNAME Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) T01271 GENENAME BCR-ABL1 T01271 TARGTYPE Patented-recorded T01271 SYNONYMS T315I BCR-ABL; BCR-ABL T315I mutant T01271 FUNCTION Difficult to inhibit with ATP mimetics. The mutation eliminates a critical hydrogen bonding interaction required for high-affinity binding of imatinib, nilotinib, and dasatinib and alters the topology of the ATP-binding pocket. T01271 BIOCLASS Kinase T01271 SEQUENCE MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEPRASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNVEFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPPWPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTYRMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQDGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTSQQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDAKDPTTKNSLETLLYKPVDRVTRSTLVLHDLLKHTPASHPDHPLLQDALRISQNFLSSINEEITPRRQSMTVKKGEHRQLLKDSFMVELVEGARKLRHVFLFTDLLLCTKLKKQSGGKTQQYDCKWYIPLTDLSFQMVDELEAVPNIPLVPDEELDALKIKISQIKNDIQREKRANKGSKATERLKKKLSEQESLLLLMSPSMAFRVHSRNGKSYTFLISSDYERAEWRENIREQQKKCFRSFSLTSVELQMLTNSCVKLQTVHSIPLTINKEDDESPGLYGFLNVIVHSATGFKQSSNLYCTLEVDSFGYFVNKAKTRVYRDTAEPNWNEEFEIELEGSQTLRILCYEKCYNKTKIPKEDGESTDRLMGKGQVQLDPQALQDRDWQRTVIAMNGIEVKLSVKFNSREFSLKRMPSRKQTGVFGVKIAVVTKRERSKVPYIVRQCVEEIERRGMEEVGIYRVSGVATDIQALKAAFDVNNKDVSVMMSEMDVNAIAGTLKLYFRELPEPLFTDEFYPNFAEGIALSDPVAKESCMLNLLLSLPEANLLTFLFLLDHLKRVAEKEAVNKMSLHNLATVFGPTLLRPSEKESKLPANPSQPITMTDSWSLEVMSQVQVLLYFLQLEAIPAPDSKRQSILFSTEVMLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR T01271 DRUGINFO D01LMW Pyrrolo[2,3-b]pyridine derivative 4 Patented T01271 DRUGINFO D01UTX PMID25656651-Compound-31c Patented T01271 DRUGINFO D0C2YI Alkynyl-heteroaromatic ring compound 1 Patented T01271 DRUGINFO D0FB1Q PMID25656651-Compound-31b Patented T01271 DRUGINFO D0H3VI PMID25656651-Compound-31a Patented T01271 DRUGINFO D01KIJ PMID25656651-Compound-37b Patented T01271 DRUGINFO D02KNW PMID25656651-Compound-36a Patented T01271 DRUGINFO D08IUE PMID25656651-Compound-37c Patented T01271 DRUGINFO D09WKF PMID25656651-Compound-36d Patented T01271 DRUGINFO D09ZFM PMID25656651-Compound-36b Patented T01271 DRUGINFO D0BK6R PMID25656651-Compound-36c Patented T01271 DRUGINFO D0E6EP PMID25656651-Compound-19b Patented T01271 DRUGINFO D0IA4G PMID25656651-Compound-37a Patented T01271 DRUGINFO D0JY1I PMID25656651-Compound-19a Patented T01271 DRUGINFO D0MX5B Indazole derivative 5 Patented T01271 DRUGINFO D0A7XQ ON-044580 Investigative T01271 DRUGINFO D0D3RL AP-24163 Investigative T80423 TARGETID T80423 T80423 FORMERID TTDI02613 T80423 UNIPROID VHL_HUMAN T80423 TARGNAME von Hippel-Lindau disease tumor suppressor (VHL) T80423 GENENAME VHL T80423 TARGTYPE Patented-recorded T80423 SYNONYMS pVHL; Protein G7 T80423 FUNCTION Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2. Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. T80423 PDBSTRUC 6GMX; 6GMR; 6GMQ; 6GMN; 6GFZ T80423 SEQUENCE MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD T80423 DRUGINFO D0Q2SE Pyrrolidine carboxamide derivative 1 Patented T78710 TARGETID T78710 T78710 FORMERID TTDI03314 T78710 UNIPROID KCNJ1_HUMAN T78710 TARGNAME Inward rectifier potassium channel Kir1.1 (KCNJ1) T78710 GENENAME KCNJ1 T78710 TARGTYPE Patented-recorded T78710 SYNONYMS ROMK1; Potassium channel, inwardly rectifying subfamily J member 1; Inward rectifier K(+) channel Kir1.1; ATP-sensitive inward rectifier potassium channel 1 T78710 FUNCTION Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This channel is activated by internal ATP and can be blocked by external barium. In the kidney, probably plays a major role in potassium homeostasis. T78710 BIOCLASS Inward rectifier potassium channel T78710 SEQUENCE MNASSRNVFDTLIRVLTESMFKHLRKWVVTRFFGHSRQRARLVSKDGRCNIEFGNVEAQSRFIFFVDIWTTVLDLKWRYKMTIFITAFLGSWFFFGLLWYAVAYIHKDLPEFHPSANHTPCVENINGLTSAFLFSLETQVTIGYGFRCVTEQCATAIFLLIFQSILGVIINSFMCGAILAKISRPKKRAKTITFSKNAVISKRGGKLCLLIRVANLRKSLLIGSHIYGKLLKTTVTPEGETIILDQININFVVDAGNENLFFISPLTIYHVIDHNSPFFHMAAETLLQQDFELVVFLDGTVESTSATCQVRTSYVPEEVLWGYRFAPIVSKTKEGKYRVDFHNFSKTVEVETPHCAMCLYNEKDVRARMKRGYDNPNFILSEVNETDDTKM T78710 DRUGINFO D00ALX PMID26004420-Compound-US20140309213B Patented T78710 DRUGINFO D00CMX PMID26004420-Compound-WO2013062900A Patented T78710 DRUGINFO D00JVQ PMID26004420-Compound-WO2014099633D Patented T78710 DRUGINFO D00SLD PMID26004420-Compound-WO2013028474C Patented T78710 DRUGINFO D00WZH PMID26004420-Compound-WO2015017305F Patented T78710 DRUGINFO D01JCZ PMID26004420-Compound-U2014S0288042C Patented T78710 DRUGINFO D02HOM PMID26004420-Compound-WO2013062900B Patented T78710 DRUGINFO D02ZGO PMID26004420-Compound-WO2010129379A Patented T78710 DRUGINFO D03JCN PMID26004420-Compound-US20140142115C Patented T78710 DRUGINFO D03PRT PMID26004420-Compound-WO2014015495A Patented T78710 DRUGINFO D03TGG PMID26004420-Compound-WO2012058134C Patented T78710 DRUGINFO D05AJX PMID26004420-Compound-WO2013062892E Patented T78710 DRUGINFO D06CGQ PMID26004420-Compound-US20140031349B Patented T78710 DRUGINFO D06FLB PMID26004420-Compound-WO2014150132C Patented T78710 DRUGINFO D06TPB PMID26004420-Compound-WO2013039802C Patented T78710 DRUGINFO D07CMZ PMID26004420-Compound-WO2014099633E Patented T78710 DRUGINFO D07TUN PMID26004420-Compound-WO2014085210B Patented T78710 DRUGINFO D07VUL PMID26004420-Compound-WO2013039802B Patented T78710 DRUGINFO D08HBF PMID26004420-Compound-U2014S0288042A Patented T78710 DRUGINFO D08TDJ PMID26004420-Compound-WO2014126944A Patented T78710 DRUGINFO D08UXR PMID26004420-Compound-WO2014150132B Patented T78710 DRUGINFO D09KCN PMID26004420-Compound-WO2015017305E Patented T78710 DRUGINFO D09WRT PMID26004420-Compound-WO2013039802A Patented T78710 DRUGINFO D0A6EX PMID26004420-Compound-WO2013062892D Patented T78710 DRUGINFO D0C4BJ PMID26004420-Compound-WO2014126944B Patented T78710 DRUGINFO D0CC7A PMID26004420-Compound-WO2010129379C Patented T78710 DRUGINFO D0CI2I PMID26004420-Compound-WO2012058116B Patented T78710 DRUGINFO D0CI6Y PMID26004420-Compound-US20140336177D Patented T78710 DRUGINFO D0D7AI PMID26004420-Compound-WO2013028474B Patented T78710 DRUGINFO D0DG4A PMID26004420-Compound-WO2014015495B Patented T78710 DRUGINFO D0DX8P PMID26004420-Compound-WO2010129379B Patented T78710 DRUGINFO D0E2WS PMID26004420-Compound-US20140275020E Patented T78710 DRUGINFO D0EX9E PMID26004420-Compound-US20140309213A Patented T78710 DRUGINFO D0F0TY PMID26004420-Compound-US20140031349C Patented T78710 DRUGINFO D0FC5J PMID26004420-Compound-US20140031349D Patented T78710 DRUGINFO D0J9JB PMID26004420-Compound-WO2012058116C Patented T78710 DRUGINFO D0L8FE PMID26004420-Compound-WO2012058116A Patented T78710 DRUGINFO D0M6JD PMID26004420-Compound-WO2014085210C Patented T78710 DRUGINFO D0N4DY PMID26004420-Compound-WO2015017305D Patented T78710 DRUGINFO D0O1RL PMID26004420-Compound-WO2014015495D Patented T78710 DRUGINFO D0RM6C PMID26004420-Compound-WO2012058134A Patented T78710 DRUGINFO D0TH5W PMID26004420-Compound-WO2013062900C Patented T78710 DRUGINFO D0TO9J PMID26004420-Compound-US20140031349A Patented T78710 DRUGINFO D0U0ZN PMID26004420-Compound-US20140275020D Patented T78710 DRUGINFO D0UY1A PMID26004420-Compound-US20140142115B Patented T78710 DRUGINFO D0V0OD PMID26004420-Compound-WO2014015495C Patented T78710 DRUGINFO D0WP1P PMID26004420-Compound-WO2014085210A Patented T78710 DRUGINFO D0WX4U PMID26004420-Compound-US20140142115A Patented T78710 DRUGINFO D0X8YT PMID26004420-Compound-WO2014150132A Patented T78710 DRUGINFO D0XK7H PMID26004420-Compound-US20140336177E Patented T78710 DRUGINFO D0XM8F PMID26004420-Compound-WO2012058134B Patented T78710 DRUGINFO D0ZX6S PMID26004420-Compound-WO2013028474A Patented T78710 DRUGINFO D05LBC VU591 Investigative T46702 TARGETID T46702 T46702 UNIPROID PLA2R_HUMAN T46702 TARGNAME Secretory phospholipase A2 receptor (PLA2R) T46702 GENENAME PLA2R1 T46702 TARGTYPE Patented-recorded T46702 SYNONYMS Soluble secretory phospholipase A2 receptor; Soluble PLA2R; Soluble PLA2-R; PLA2-R; M-type receptor; CLEC13C; C-type lectin domain family 13 member C; 180 kDa secretory phospholipase A2 receptor T46702 FUNCTION Acts as a receptor for phosholipase sPLA2-IB/PLA2G1B but not sPLA2-IIA/PLA2G2A. Also able to bind to snake PA2-like toxins. Although its precise function remains unclear, binding of sPLA2 to its receptor participates in both positive and negative regulation of sPLA2 functions as well as clearance of sPLA2. Binding of sPLA2-IB/PLA2G1B induces various effects depending on the cell type, such as activation of the mitogen-activated protein kinase (MAPK) cascade to induce cell proliferation, the production of lipid mediators, selective release of arachidonic acid in bone marrow-derived mast cells. In neutrophils, binding of sPLA2-IB/PLA2G1B can activate p38 MAPK to stimulate elastase release and cell adhesion. May be involved in responses in proinflammatory cytokine productions during endotoxic shock. Also has endocytic properties and rapidly internalizes sPLA2 ligands, which is particularly important for the clearance of extracellular sPLA2s to protect their potent enzymatic activities. The soluble secretory phospholipase A2 receptor form is circulating and acts as a negative regulator of sPLA2 functions by blocking the biological functions of sPLA2-IB/PLA2G1B. Receptor for secretory phospholipase A2 (sPLA2). T46702 SEQUENCE MLLSPSLLLLLLLGAPRGCAEGVAAALTPERLLEWQDKGIFVIQSESLKKCIQAGKSVLTLENCKQANKHMLWKWVSNHGLFNIGGSGCLGLNFSAPEQPLSLYECDSTLVSLRWRCNRKMITGPLQYSVQVAHDNTVVASRKYIHKWISYGSGGGDICEYLHKDLHTIKGNTHGMPCMFPFQYNHQWHHECTREGREDDLLWCATTSRYERDEKWGFCPDPTSAEVGCDTIWEKDLNSHICYQFNLLSSLSWSEAHSSCQMQGGTLLSITDETEENFIREHMSSKTVEVWMGLNQLDEHAGWQWSDGTPLNYLNWSPEVNFEPFVEDHCGTFSSFMPSAWRSRDCESTLPYICKKYLNHIDHEIVEKDAWKYYATHCEPGWNPYNRNCYKLQKEEKTWHEALRSCQADNSALIDITSLAEVEFLVTLLGDENASETWIGLSSNKIPVSFEWSNDSSVIFTNWHTLEPHIFPNRSQLCVSAEQSEGHWKVKNCEERLFYICKKAGHVLSDAESGCQEGWERHGGFCYKIDTVLRSFDQASSGYYCPPALVTITNRFEQAFITSLISSVVKMKDSYFWIALQDQNDTGEYTWKPVGQKPEPVQYTHWNTHQPRYSGGCVAMRGRHPLGRWEVKHCRHFKAMSLCKQPVENQEKAEYEERWPFHPCYLDWESEPGLASCFKVFHSEKVLMKRTWREAEAFCEEFGAHLASFAHIEEENFVNELLHSKFNWTEERQFWIGFNKRNPLNAGSWEWSDRTPVVSSFLDNTYFGEDARNCAVYKANKTLLPLHCGSKREWICKIPRDVKPKIPFWYQYDVPWLFYQDAEYLFHTFASEWLNFEFVCSWLHSDLLTIHSAHEQEFIHSKIKALSKYGASWWIGLQEERANDEFRWRDGTPVIYQNWDTGRERTVNNQSQRCGFISSITGLWGSEECSVSMPSICKRKKVWLIEKKKDTPKQHGTCPKGWLYFNYKCLLLNIPKDPSSWKNWTHAQHFCAEEGGTLVAIESEVEQAFITMNLFGQTTSVWIGLQNDDYETWLNGKPVVYSNWSPFDIINIPSHNTTEVQKHIPLCALLSSNPNFHFTGKWYFEDCGKEGYGFVCEKMQDTSGHGVNTSDMYPMPNTLEYGNRTYKIINANMTWYAAIKTCLMHKAQLVSITDQYHQSFLTVVLNRLGYAHWIGLFTTDNGLNFDWSDGTKSSFTFWKDEESSLLGDCVFADSNGRWHSTACESFLQGAICHVPPETRQSEHPELCSETSIPWIKFKSNCYSFSTVLDSMSFEAAHEFCKKEGSNLLTIKDEAENAFLLEELFAFGSSVQMVWLNAQFDGNNETIKWFDGTPTDQSNWGIRKPDTDYFKPHHCVALRIPEGLWQLSPCQEKKGFICKMEADIHTAEALPEKGPSHSIIPLAVVLTLIVIVAICTLSFCIYKHNGGFFRRLAGFRNPYYPATNFSTVYLEENILISDLEKSDQ T03145 TARGETID T03145 T03145 UNIPROID TLR1_HUMAN-TLR2_HUMAN T03145 TARGNAME TLR1-TLR2 complex (TLR1/2) T03145 GENENAME TLR1-TLR2 T03145 TARGTYPE Patented-recorded T03145 SYNONYMS Toll-like receptor 1 and 2 complex T03145 FUNCTION Mediates the innate immune response to bacterial lipoproteins or lipopeptides. T03145 BIOCLASS Toll-like receptor T03145 SEQUENCE MTSIFHFAIIFMLILQIRIQLSEESEFLVDRSKNGLIHVPKDLSQKTTILNISQNYISELWTSDILSLSKLRILIISHNRIQYLDISVFKFNQELEYLDLSHNKLVKISCHPTVNLKHLDLSFNAFDALPICKEFGNMSQLKFLGLSTTHLEKSSVLPIAHLNISKVLLVLGETYGEKEDPEGLQDFNTESLHIVFPTNKEFHFILDVSVKTVANLELSNIKCVLEDNKCSYFLSILAKLQTNPKLSNLTLNNIETTWNSFIRILQLVWHTTVWYFSISNVKLQGQLDFRDFDYSGTSLKALSIHQVVSDVFGFPQSYIYEIFSNMNIKNFTVSGTRMVHMLCPSKISPFLHLDFSNNLLTDTVFENCGHLTELETLILQMNQLKELSKIAEMTTQMKSLQQLDISQNSVSYDEKKGDCSWTKSLLSLNMSSNILTDTIFRCLPPRIKVLDLHSNKIKSIPKQVVKLEALQELNVAFNSLTDLPGCGSFSSLSVLIIDHNSVSHPSADFFQSCQKMRSIKAGDNPFQCTCELGEFVKNIDQVSSEVLEGWPDSYKCDYPESYRGTLLKDFHMSELSCNITLLIVTIVATMLVLAVTVTSLCSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSGHDSFWVKNELLPNLEKEGMQICLHERNFVPGKSIVENIITCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFHEGSNSLILILLEPIPQYSIPSSYHKLKSLMARRTYLEWPKEKSKRGLFWANLRAAINIKLTEQAKKMPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLSNNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWFKPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELEIDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFSELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDNDRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLKSLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDISKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLKELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCEFLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFLLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMVQELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFSHFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRAAIKS T20958 TARGETID T20958 T20958 FORMERID TTDI02517 T20958 UNIPROID NPSR1_HUMAN T20958 TARGNAME Neuropeptide S receptor (NPSR) T20958 GENENAME NPSR1 T20958 TARGTYPE Patented-recorded T20958 SYNONYMS PGR14; Gprotein coupled receptor for asthma susceptibility; Gprotein coupled receptor PGR14; Gprotein coupled receptor 154; GPRA; GPR154; G-protein coupled receptor for asthma susceptibility; G-protein coupled receptor PGR14; G-protein coupled receptor 154 T20958 FUNCTION Promotes mobilization of intracellular Ca(2+) stores. Inhibits cell growth in response to NPS binding. Involved in pathogenesis of asthma and other IgE-mediated diseases. G-protein coupled receptor for neuropeptide S (NPS). T20958 BIOCLASS GPCR rhodopsin T20958 SEQUENCE MPANFTEGSFDSSGTGQTLDSSPVACTETVTFTEVVEGKEWGSFYYSFKTEQLITLWVLFVFTIVGNSVVLFSTWRRKKKSRMTFFVTQLAITDSFTGLVNILTDINWRFTGDFTAPDLVCRVVRYLQVVLLYASTYVLVSLSIDRYHAIVYPMKFLQGEKQARVLIVIAWSLSFLFSIPTLIIFGKRTLSNGEVQCWALWPDDSYWTPYMTIVAFLVYFIPLTIISIMYGIVIRTIWIKSKTYETVISNCSDGKLCSSYNRGLISKAKIKAIKYSIIIILAFICCWSPYFLFDILDNFNLLPDTQERFYASVIIQNLPALNSAINPLIYCVFSSSISFPCREQRSQDSRMTFRERTERHEMQILSKPEFI T20958 DRUGINFO D00IVM PMID27788040-Compound-6 Patented T20958 DRUGINFO D00JCQ Oxazolo[3,4-a]pyrazine derivative 4 Patented T20958 DRUGINFO D00ODC Imidazo pyridine derivative 4 Patented T20958 DRUGINFO D02BPJ 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 1 Patented T20958 DRUGINFO D06FJL Oxazolo[3,4-a]pyrazine derivative 2 Patented T20958 DRUGINFO D06FUK Imidazo pyridine derivative 6 Patented T20958 DRUGINFO D06TFC 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 3 Patented T20958 DRUGINFO D09AVU PMID27788040-Compound-6b Patented T20958 DRUGINFO D09DZI Indandione derivative 2 Patented T20958 DRUGINFO D09JFR 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 4 Patented T20958 DRUGINFO D0AT0A PMID27788040-Compound-5a Patented T20958 DRUGINFO D0H1LQ PMID27788040-Compound-6c Patented T20958 DRUGINFO D0I0BN Oxazolo[3,4-a]pyrazine derivative 3 Patented T20958 DRUGINFO D0I8ZE PMID27788040-Compound-5b Patented T20958 DRUGINFO D0K1ZY 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 2 Patented T20958 DRUGINFO D0K7OV Imidazo pyridine derivative 5 Patented T20958 DRUGINFO D0M3DM Indandione derivative 1 Patented T20958 DRUGINFO D0O4ML Indandione derivative 3 Patented T20958 DRUGINFO D0QN7I Oxazolo[3,4-a]pyrazine derivative 6 Patented T20958 DRUGINFO D0QY3L Oxazolo[3,4-a]pyrazine derivative 5 Patented T20958 DRUGINFO D0S1AT Oxazolo[3,4-a]pyrazine derivative 1 Patented T20958 DRUGINFO D0S3TL Oxazolo[3,4-a]pyrazine derivative 7 Patented T20958 DRUGINFO D0WI0P PMID27788040-Compound-5c Patented T20958 DRUGINFO D0X8JD PMID27788040-Compound-5 Patented T20958 DRUGINFO D0Y9XS Indanone and indandione derivative 1 Patented T20958 DRUGINFO D0YU5R PMID27788040-Compound-6a Patented T20958 DRUGINFO D03EJP SHA 68 Investigative T20958 DRUGINFO D09RIC PI1 Investigative T20958 DRUGINFO D0TX8L QA1 Investigative T80487 TARGETID T80487 T80487 UNIPROID DNM3L_HUMAN T80487 TARGNAME DNA [cytosine-5]-methyltransferase 3-like (DNMT3L) T80487 GENENAME DNMT3L T80487 TARGTYPE Patented-recorded T80487 SYNONYMS DNA (cytosine-5)-methyltransferase 3-like T80487 FUNCTION Essential for the function of DNMT3A and DNMT3B: activates DNMT3A and DNMT3B by binding to their catalytic domain. Acts by accelerating the binding of DNA and S-adenosyl-L-methionine (AdoMet) to the methyltransferases and dissociates from the complex after DNA binding to the methyltransferases. Recognizes unmethylated histone H3 lysine 4 (H3K4me0) and induces de novo DNA methylation by recruitment or activation of DNMT3. Plays a key role in embryonic stem cells and germ cells. In germ cells, required for the methylation of imprinted loci together with DNMT3A. In male germ cells, specifically required to methylate retrotransposons, preventing their mobilization. Plays a key role in embryonic stem cells (ESCs) by acting both as an positive and negative regulator of DNA methylation. While it promotes DNA methylation of housekeeping genes together with DNMT3A and DNMT3B, it also acts as an inhibitor of DNA methylation at the promoter of bivalent genes. Interacts with the EZH2 component of the PRC2/EED-EZH2 complex, preventing interaction of DNMT3A and DNMT3B with the PRC2/EED-EZH2 complex, leading to maintain low methylation levels at the promoters of bivalent genes. Promotes differentiation of ESCs into primordial germ cells by inhibiting DNA methylation at the promoter of RHOX5, thereby activating its expression. Catalytically inactive regulatory factor of DNA methyltransferases that can either promote or inhibit DNA methylation depending on the context. T80487 PDBSTRUC 6F57; 6BRR; 5YX2; 4U7T; 4U7P T80487 SEQUENCE MAAIPALDPEAEPSMDVILVGSSELSSSVSPGTGRDLIAYEVKANQRNIEDICICCGSLQVHTQHPLFEGGICAPCKDKFLDALFLYDDDGYQSYCSICCSGETLLICGNPDCTRCYCFECVDSLVGPGTSGKVHAMSNWVCYLCLPSSRSGLLQRRRKWRSQLKAFYDRESENPLEMFETVPVWRRQPVRVLSLFEDIKKELTSLGFLESGSDPGQLKHVVDVTDTVRKDVEEWGPFDLVYGATPPLGHTCDRPPSWYLFQFHRLLQYARPKPGSPRPFFWMFVDNLVLNKEDLDVASRFLEMEPVTIPDVHGGSLQNAVRVWSNIPAIRSRHWALVSEEELSLLAQNKQSSKLAAKWPTKLVKNCFLPLREYFKYFSTELTSSL T80487 DRUGINFO D01LUJ PMID27376512-Compound-Figure2aExample1 Patented T18551 TARGETID T18551 T18551 UNIPROID CD80_HUMAN-PD1L1_HUMAN T18551 TARGNAME CD80-PD-L1 interaction (CD80/PD-L1 PPI) T18551 GENENAME CD80-CD274 T18551 TARGTYPE Patented-recorded T18551 SYNONYMS T-lymphocyte activation antigen CD80/Programmed cell death 1 ligand 1 PPI T18551 FUNCTION Augments activated alloreactive CD4+ T cell proliferation and apoptosis and ameliorates acute graft versus host disease T18551 SEQUENCE MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEETMGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV T18551 DRUGINFO D03BCV Macrocycle derivative 6 Patented T18551 DRUGINFO D04PCT PMID30107136-Compound-Example12 Patented T18551 DRUGINFO D06VTI Macrocycle derivative 1 Patented T18551 DRUGINFO D07ZQS Macrocycle derivative 9 Patented T18551 DRUGINFO D08EHL Macrocycle derivative 2 Patented T18551 DRUGINFO D0D3RS Biaryl compound 1 Patented T18551 DRUGINFO D0J4UO Macrocycle derivative 3 Patented T18551 DRUGINFO D0M6WW PMID30107136-Compound-Example11 Patented T18551 DRUGINFO D0N4TZ Macrocycle derivative 8 Patented T18551 DRUGINFO D0N5NV Biaryl compound 2 Patented T18551 DRUGINFO D0NI2B Macrocycle derivative 5 Patented T18551 DRUGINFO D0QF4W Macrocycle derivative 7 Patented T18551 DRUGINFO D0R7JW Macrocycle derivative 4 Patented T20027 TARGETID T20027 T20027 UNIPROID STA5A_HUMAN; STA5B_HUMAN T20027 TARGNAME Signal transducer and activator of transcription 5 (STAT5) T20027 GENENAME STAT5A; STAT5B T20027 TARGTYPE Patented-recorded T20027 SYNONYMS Signal transducer and activator of transcription 5 T20027 FUNCTION Involved in cytosolic signalling and in mediating the expression of specific genes. Aberrant STAT5 activity has been shown to be closely connected to a wide range of human cancers, and silencing this aberrant activity is an area of active research in medicinal chemistry. T20027 SEQUENCE MAGWIQAQQLQGDALRQMQVLYGQHFPIEVRHYLAQWIESQPWDAIDLDNPQDRAQATQLLEGLVQELQKKAEHQVGEDGFLLKIKLGHYATQLQKTYDRCPLELVRCIRHILYNEQRLVREANNCSSPAGILVDAMSQKHLQINQTFEELRLVTQDTENELKKLQQTQEYFIIQYQESLRIQAQFAQLAQLSPQERLSRETALQQKQVSLEAWLQREAQTLQQYRVELAEKHQKTLQLLRKQQTIILDDELIQWKRRQQLAGNGGPPEGSLDVLQSWCEKLAEIIWQNRQQIRRAEHLCQQLPIPGPVEEMLAEVNATITDIISALVTSTFIIEKQPPQVLKTQTKFAATVRLLVGGKLNVHMNPPQVKATIISEQQAKSLLKNENTRNECSGEILNNCCVMEYHQATGTLSAHFRNMSLKRIKRADRRGAESVTEEKFTVLFESQFSVGSNELVFQVKTLSLPVVVIVHGSQDHNATATVLWDNAFAEPGRVPFAVPDKVLWPQLCEALNMKFKAEVQSNRGLTKENLVFLAQKLFNNSSSHLEDYSGLSVSWSQFNRENLPGWNYTFWQWFDGVMEVLKKHHKPHWNDGAILGFVNKQQAHDLLINKPDGTFLLRFSDSEIGGITIAWKFDSPERNLWNLKPFTTRDFSIRSLADRLGDLSYLIYVFPDRPKDEVFSKYYTPVLAKAVDGYVKPQIKQVVPEFVNASADAGGSSATYMDQAPSPAVCPQAPYNMYPQNPDHVLDQDGEFDLDETMDVARHVEELLRRPMDSLDSRLSPPAGLFTSARGSLS T20027 DRUGINFO D02MAG PMID26394986-Compound-56 Patented T20027 DRUGINFO D0T8PK Indirubin derivative 1 Patented T20027 DRUGINFO D0W5GX PMID26394986-Compound-57 Patented T20027 DRUGINFO D01BVU Platinum IV complexe 1 Patented T20027 DRUGINFO D0TU0X PMID26394986-Compound-10 Patented T72491 TARGETID T72491 T72491 UNIPROID KEAP1_HUMAN-NF2L2_HUMAN T72491 TARGNAME Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) T72491 GENENAME KEAP1-NFE2L2 T72491 TARGTYPE Patented-recorded T72491 SYNONYMS Kelch-like protein 19-Nrf2[dual DLG and ETGE]; Kelch-like ECH-associated protein 1-Nrf2[dual DLG and ETGE]; KLHL19-Nrf2[dual DLG and ETGE]; KIAA0132-Nrf2[dual DLG and ETGE]; INrf2-Nrf2[dual DLG and ETGE]; Cytosolic inhibitor of Nrf2-Nrf2[dual DLG and ETGE] T72491 FUNCTION Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. T72491 SEQUENCE MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVRCESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDYLVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVETETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAVTMEPCRKQIDQQNCTCMMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDEETGEFLPIQPAQHIQSETSGSANYSQVAHIPKSDALYFDDCMQLLAQTFPFVDDNEVSSATFQSLVPDIPGHIESPVFIATNQAQSPETSVAQVAPVDLDGMQQDIEQVWEELLSIPELQCLNIENDKLVETTMVPSPEAKLTEVDNYHFYSSIPSMEKEVGNCSPHFLNAFEDSFSSILSTEDPNQLTVNSLNSDATVNTDFGDEFYSAFIAEPSISNSMPSPATLSHSLSELLNGPIDVSDLSLCKAFNQNHPESTAEFNDSDSGISLNTSPSVASPEHSVESSSYGDTLLGLSDSEVEELDSAPGSVKQNGPKTPVHSSGDMVQPLSPSQGQSTHVHDAQCENTPEKELPVSPGHRKTPFTKDKHSSRLEAHLTRDELRAKALHIPFPVEKIINLPVVDFNEMMSKEQFNEAQLALIRDIRRRGKNKVAAQNCRKRKLENIVELEQDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLYLEVFSMLRDEDGKPYSPSEYSLQQTRDGNVFLVPKSKKPDVKKN T72491 DRUGINFO D00TVL PMID28454500-Compound-57 Patented T72491 DRUGINFO D02FWA Naphthalene derivative 1 Patented T72491 DRUGINFO D02JFV PMID28454500-Compound-58 Patented T72491 DRUGINFO D0LL7V PMID28454500-Compound-60 Patented T72491 DRUGINFO D0O3KN PMID28454500-Compound-59 Patented T72491 DRUGINFO D0Q8JZ 3-phenyl propanoic derivative 3 Patented T72491 DRUGINFO D0WR1I 1,2,3,4-tetrahydroisoquinoline derivative 1 Patented T76454 TARGETID T76454 T76454 UNIPROID KEAP1_HUMAN-NF2L2_HUMAN T76454 TARGNAME Keap1-Nrf2[ETGE] PPI (KEAP1-Nrf2 ETGE) T76454 GENENAME KEAP1-NFE2L2 T76454 TARGTYPE Patented-recorded T76454 SYNONYMS Kelch-like protein 19-Nrf2[ETGE]; Kelch-like ECH-associated protein 1-Nrf2[ETGE]; KLHL19-Nrf2[ETGE]; KIAA0132-Nrf2[ETGE]; INrf2-Nrf2[ETGE]; Cytosolic inhibitor of Nrf2-Nrf2[ETGE] T76454 FUNCTION Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. T76454 SEQUENCE MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVRCESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDYLVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVETETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAVTMEPCRKQIDQQNCTCMMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDEETGEFLPIQPAQHIQSETSGSANYSQVAHIPKSDALYFDDCMQLLAQTFPFVDDNEVSSATFQSLVPDIPGHIESPVFIATNQAQSPETSVAQVAPVDLDGMQQDIEQVWEELLSIPELQCLNIENDKLVETTMVPSPEAKLTEVDNYHFYSSIPSMEKEVGNCSPHFLNAFEDSFSSILSTEDPNQLTVNSLNSDATVNTDFGDEFYSAFIAEPSISNSMPSPATLSHSLSELLNGPIDVSDLSLCKAFNQNHPESTAEFNDSDSGISLNTSPSVASPEHSVESSSYGDTLLGLSDSEVEELDSAPGSVKQNGPKTPVHSSGDMVQPLSPSQGQSTHVHDAQCENTPEKELPVSPGHRKTPFTKDKHSSRLEAHLTRDELRAKALHIPFPVEKIINLPVVDFNEMMSKEQFNEAQLALIRDIRRRGKNKVAAQNCRKRKLENIVELEQDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLYLEVFSMLRDEDGKPYSPSEYSLQQTRDGNVFLVPKSKKPDVKKN T76454 DRUGINFO D0MS7G 3-phenyl propanoic derivative 2 Patented T76454 DRUGINFO D0O6LW 3-phenyl propanoic derivative 1 Patented T80959 TARGETID T80959 T80959 UNIPROID KEAP1_HUMAN-NF2L2_HUMAN T80959 TARGNAME Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) T80959 GENENAME KEAP1-NFE2L2 T80959 TARGTYPE Patented-recorded T80959 SYNONYMS Kelch-like protein 19-Nrf2[DLG]; Kelch-like ECH-associated protein 1-Nrf2[DLG]; KLHL19-Nrf2[DLG]; KIAA0132-Nrf2[DLG]; INrf2-Nrf2[DLG]; Cytosolic inhibitor of Nrf2-Nrf2[DLG] T80959 FUNCTION Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. T80959 SEQUENCE MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVRCESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDYLVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVETETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAVTMEPCRKQIDQQNCTCMMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDEETGEFLPIQPAQHIQSETSGSANYSQVAHIPKSDALYFDDCMQLLAQTFPFVDDNEVSSATFQSLVPDIPGHIESPVFIATNQAQSPETSVAQVAPVDLDGMQQDIEQVWEELLSIPELQCLNIENDKLVETTMVPSPEAKLTEVDNYHFYSSIPSMEKEVGNCSPHFLNAFEDSFSSILSTEDPNQLTVNSLNSDATVNTDFGDEFYSAFIAEPSISNSMPSPATLSHSLSELLNGPIDVSDLSLCKAFNQNHPESTAEFNDSDSGISLNTSPSVASPEHSVESSSYGDTLLGLSDSEVEELDSAPGSVKQNGPKTPVHSSGDMVQPLSPSQGQSTHVHDAQCENTPEKELPVSPGHRKTPFTKDKHSSRLEAHLTRDELRAKALHIPFPVEKIINLPVVDFNEMMSKEQFNEAQLALIRDIRRRGKNKVAAQNCRKRKLENIVELEQDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLYLEVFSMLRDEDGKPYSPSEYSLQQTRDGNVFLVPKSKKPDVKKN T80959 DRUGINFO D09MSN 1-phenyl-1,3,4-triazole derivative 1 Patented T80959 DRUGINFO D0AR0L 1-phenyl-1,3,4-triazole derivative 2 Patented T80959 DRUGINFO D0I2DV 1-phenyl-1,3,4-triazole derivative 3 Patented T13629 TARGETID T13629 T13629 UNIPROID PDCD1_HUMAN-PD1L1_HUMAN T13629 TARGNAME PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) T13629 GENENAME PDCD1-CD274 T13629 TARGTYPE Patented-recorded T13629 SYNONYMS Programmed cell death 1/Programmed cell death 1 ligand 1 PPI T13629 FUNCTION The PD-1/PD-L1 axis is probably also important for immune evasion of B-cell lymphomas with a viral aetiology, including those associated with human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV). T13629 SEQUENCE MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEETMQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL T13629 DRUGINFO D00CRQ Phenylate derivative 1 Patented T13629 DRUGINFO D01AYP Bromo benzyl ether derivative 1 Patented T13629 DRUGINFO D01MSP PMID30107136-Compound-Example3 Patented T13629 DRUGINFO D01OQQ PMID30107136-Compound-Example50 Patented T13629 DRUGINFO D01PJZ Cyclic peptidomimetic derivative 1 Patented T13629 DRUGINFO D02SES Peptide analog 2 Patented T13629 DRUGINFO D02UJS PMID30107136-Compound-Example49 Patented T13629 DRUGINFO D02XVC Phenylate derivative 2 Patented T13629 DRUGINFO D03HAA PMID30107136-Compound-Example45 Patented T13629 DRUGINFO D03TWD PMID30107136-Compound-Example4 Patented T13629 DRUGINFO D04CCX PMID30107136-Compound-Example14 Patented T13629 DRUGINFO D04ESH PMID30107136-Compound-Example8 Patented T13629 DRUGINFO D04HBL PMID30107136-Compound-Example59 Patented T13629 DRUGINFO D04TLQ Cyclic peptidomimetic derivative 2 Patented T13629 DRUGINFO D05COE PMID30107136-Compound-Example52 Patented T13629 DRUGINFO D06BSV PMID30107136-Compound-Example46 Patented T13629 DRUGINFO D08JWY PMID30107136-Compound-Example43 Patented T13629 DRUGINFO D08RET PMID30107136-Compound-Example47 Patented T13629 DRUGINFO D0A5OT Aromatic ethylene derivative 1 Patented T13629 DRUGINFO D0B2VS Benzyl phenyl ether derivative 1 Patented T13629 DRUGINFO D0CH8E Macrocyclic peptide analog 2 Patented T13629 DRUGINFO D0DP8E PMID30107136-Compound-Example57 Patented T13629 DRUGINFO D0EI4B N-phenyl-pyridine-2-carboxamide derivative 2 Patented T13629 DRUGINFO D0EW3O Cyclic peptidomimetic derivative 3 Patented T13629 DRUGINFO D0EY9S 1,2,4-oxadiazole derivative 4 Patented T13629 DRUGINFO D0F4IF N-phenyl-pyridine-2-carboxamide derivative 1 Patented T13629 DRUGINFO D0FJ1N PMID30107136-Compound-Example42 Patented T13629 DRUGINFO D0FK4P PMID30107136-Compound-Example48 Patented T13629 DRUGINFO D0FK6N Peptide analog 5 Patented T13629 DRUGINFO D0FM9V PMID30107136-Compound-Example60 Patented T13629 DRUGINFO D0H0CH PMID30107136-Compound-Example54 Patented T13629 DRUGINFO D0H0MO 1,3,4-oxadiazole derivative 5 Patented T13629 DRUGINFO D0H6AL 1,3,4-oxadiazole derivative 4 Patented T13629 DRUGINFO D0HC9K PMID30107136-Compound-Example41 Patented T13629 DRUGINFO D0HE8M 1,2,4-oxadiazole derivative 5 Patented T13629 DRUGINFO D0HF7V Peptide analog 3 Patented T13629 DRUGINFO D0I0JE 1,3,4-thiadiazole derivative 1 Patented T13629 DRUGINFO D0I6RC Benzyl phenyl ether derivative 2 Patented T13629 DRUGINFO D0I7UZ Peptide analog 6 Patented T13629 DRUGINFO D0J4LV PMID30107136-Compound-Example53 Patented T13629 DRUGINFO D0KA7I PMID30107136-Compound-Example7 Patented T13629 DRUGINFO D0MG6V 3-substituted-1,2,4-oxadiazole derivative 2 Patented T13629 DRUGINFO D0MK2F Macrocyclic peptide analog 3 Patented T13629 DRUGINFO D0N6NA 1,3,4-thiadiazole derivative 2 Patented T13629 DRUGINFO D0O8FI 1,3-dihydroxy phenyl derivative 1 Patented T13629 DRUGINFO D0R7CP Bromo benzyl ether derivative 2 Patented T13629 DRUGINFO D0R7YI PMID30107136-Compound-Example13 Patented T13629 DRUGINFO D0RK4V Aromatic acetylene derivative 1 Patented T13629 DRUGINFO D0S0OF Macrocyclic peptide analog 1 Patented T13629 DRUGINFO D0TJ4D PMID30107136-Compound-Example58 Patented T13629 DRUGINFO D0VB9M Peptide analog 1 Patented T13629 DRUGINFO D0W0MT PMID30107136-Compound-Example51 Patented T13629 DRUGINFO D0W0PC 1,2,4-oxadiazole derivative 7 Patented T13629 DRUGINFO D0W1RQ PMID30107136-Compound-Example44 Patented T13629 DRUGINFO D0X5IV 1,2,4-oxadiazole derivative 6 Patented T13629 DRUGINFO D0XV7Y 1,3-dihydroxy phenyl derivative 2 Patented T13629 DRUGINFO D0YK8M 1,3,4-oxadiazole derivative 3 Patented T13629 DRUGINFO D0Z0KL 1,3,4-oxadiazole derivative 6 Patented T13629 DRUGINFO D0Z4QT 3-substituted-1,2,4-oxadiazole derivative 1 Patented T13629 DRUGINFO D0Z9UJ Peptide analog 4 Patented T13629 DRUGINFO D03BCV Macrocycle derivative 6 Patented T13629 DRUGINFO D04PCT PMID30107136-Compound-Example12 Patented T13629 DRUGINFO D06VTI Macrocycle derivative 1 Patented T13629 DRUGINFO D07ZQS Macrocycle derivative 9 Patented T13629 DRUGINFO D08EHL Macrocycle derivative 2 Patented T13629 DRUGINFO D0D3RS Biaryl compound 1 Patented T13629 DRUGINFO D0J4UO Macrocycle derivative 3 Patented T13629 DRUGINFO D0M6WW PMID30107136-Compound-Example11 Patented T13629 DRUGINFO D0N4TZ Macrocycle derivative 8 Patented T13629 DRUGINFO D0N5NV Biaryl compound 2 Patented T13629 DRUGINFO D0NI2B Macrocycle derivative 5 Patented T13629 DRUGINFO D0QF4W Macrocycle derivative 7 Patented T13629 DRUGINFO D0R7JW Macrocycle derivative 4 Patented T13629 DRUGINFO D0ZS1I MAX-10129 Preclinical T13629 DRUGINFO D00VMX PMID30247903-Compound-General structure26 Investigative T13629 DRUGINFO D00VOK PMID30247903-Compound-General structure37 Investigative T13629 DRUGINFO D02OAS PMID30247903-Compound-General structure40 Investigative T13629 DRUGINFO D03UCG PMID30247903-Compound-General structure29 Investigative T13629 DRUGINFO D06BVI PMID30247903-Compound-General structure44 Investigative T13629 DRUGINFO D08EEA PMID30247903-Compound-General structure36 Investigative T13629 DRUGINFO D09MJX PMID30247903-Compound-General structure41 Investigative T13629 DRUGINFO D0BE5U PMID30247903-Compound-General structure30 Investigative T13629 DRUGINFO D0JF0B PMID30247903-Compound-General structure19 Investigative T13629 DRUGINFO D0M8KV PMID30247903-Compound-General structure39 Investigative T13629 DRUGINFO D0ML0X PMID30247903-Compound-General structure38 Investigative T13629 DRUGINFO D0NC8Z PMID30247903-Compound-General structure45 Investigative T13629 DRUGINFO D0P9RV PMID30247903-Compound-General structure33 Investigative T13629 DRUGINFO D0PX7G PMID30247903-Compound-General structure42 Investigative T13629 DRUGINFO D0R6GO PMID30247903-Compound-General structure43 Investigative T13629 DRUGINFO D0TN0G PMID30247903-Compound-General structure46 Investigative T13629 DRUGINFO D0U4JP PMID30247903-Compound-General structure31 Investigative T13629 DRUGINFO D0U5UY PMID30247903-Compound-General structure18 Investigative T13629 DRUGINFO D0U8YP PMID30247903-Compound-General structure28 Investigative T13629 DRUGINFO D0V1CW PMID30247903-Compound-General structure35 Investigative T13629 DRUGINFO D0V4JV PMID30247903-Compound-General structure27 Investigative T13629 DRUGINFO D0YC6Z PMID30247903-Compound-General structure34 Investigative T13629 DRUGINFO D0ZO7D PMID30247903-Compound-General structure32 Investigative T05880 TARGETID T05880 T05880 UNIPROID APH1A_HUMAN-APH1B_HUMAN T05880 TARGNAME Gamma-secretase subunit APH-1A/1B (APH-1) T05880 GENENAME APH1A-APH1B T05880 TARGTYPE Patented-recorded T05880 SYNONYMS Anterior pharynx-defective 1 T05880 FUNCTION The gamma-secretase complex plays a role in Notch and Wnt signaling cascades and regulation of downstream processes via its role in processing key regulatory proteins, and by regulating cytosolic CTNNB1 levels. T05880 SEQUENCE MTAAVFFGCAFIAFGPALALYVFTIATEPLRIIFLIAGAFFWLVSLLISSLVWFMARVIIDNKDGPTQKYLLIFGAFVSVYIQEMFRFAYYKLLKKASEGLKSINPGETAPSMRLLAYVSGLGFGIMSGVFSFVNTLSDSLGPGTVGIHGDSPQFFLYSAFMTLVIILLHVFWGIVFFDGCEKKKWGILLIVLLTHLLVSAQTFISSYYGINLASAFIILVLMGTWAFLAAGGSCRSLKLCLLCQDKNFLLYNQRSRMGAAVFFGCTFVAFGPAFALFLITVAGDPLRVIILVAGAFFWLVSLLLASVVWFILVHVTDRSDARLQYGLLIFGAAVSVLLQEVFRFAYYKLLKKADEGLASLSEDGRSPISIRQMAYVSGLSFGIISGVFSVINILADALGPGVVGIHGDSPYYFLTSAFLTAAIILLHTFWGVVFFDACERRRYWALGLVVGSHLLTSGLTFLNPWYEASLLPIYAVTVSMGLWAFITAGGSLRSIQRSLLCRRQEDSRVMVYSALRIPPED T05880 DRUGINFO D04NCC PMID28350212-Compound-18 Patented T05880 DRUGINFO D08VTV PMID28350212-Compound-7 Patented T05880 DRUGINFO D09SSG PMID28350212-Compound-24 Patented T05880 DRUGINFO D09UJB PMID28350212-Compound-19 Patented T05880 DRUGINFO D0A0UX PMID28350212-Compound-35 Patented T05880 DRUGINFO D0C6OW PMID28350212-Compound-23 Patented T05880 DRUGINFO D0D2BV PMID28350212-Compound-25 Patented T05880 DRUGINFO D0D8IZ PMID28350212-Compound-22 Patented T05880 DRUGINFO D0E9IY PMID28350212-Compound-13 Patented T05880 DRUGINFO D0FV9R PMID28350212-Compound-1 Patented T05880 DRUGINFO D0HL6X PMID28350212-Compound-36 Patented T05880 DRUGINFO D0I9VU PMID28350212-Compound-20 Patented T05880 DRUGINFO D0J4PC PMID28350212-Compound-15 Patented T05880 DRUGINFO D0K2YO Sulfonamide derivative 15 Patented T05880 DRUGINFO D0OL7Q PMID28350212-Compound-21 Patented T05880 DRUGINFO D0PG2V PMID28350212-Compound-12 Patented T05880 DRUGINFO D0PS0J PMID28350212-Compound-16 Patented T05880 DRUGINFO D0S5BD PMID28350212-Compound-30 Patented T79570 TARGETID T79570 T79570 FORMERID TTDR00696 T79570 UNIPROID ATS4_HUMAN T79570 TARGNAME Aggrecanase-1 (ADAMTS4) T79570 GENENAME ADAMTS4 T79570 TARGTYPE Patented-recorded T79570 SYNONYMS Aggrecanase 1; ADMP-1; ADAMTS4; ADAM-TS4; ADAM-TS 4; A disintegrin and metalloproteinase with thrombospondin motifs 4 T79570 FUNCTION Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. Could also be a critical factor in the exacerbation of neurodegeneration in Alzheimer disease. Cleaves aggrecan at the '392-Glu-|-Ala-393' site. T79570 PDBSTRUC 4WKI; 4WKE; 4WK7; 3B2Z; 2RJP T79570 BIOCLASS Peptidase T79570 ECNUMBER EC 3.4.24.82 T79570 SEQUENCE MSQTGSHPGRGLAGRWLWGAQPCLLLPIVPLSWLVWLLLLLLASLLPSARLASPLPREEEIVFPEKLNGSVLPGSGAPARLLCRLQAFGETLLLELEQDSGVQVEGLTVQYLGQAPELLGGAEPGTYLTGTINGDPESVASLHWDGGALLGVLQYRGAELHLQPLEGGTPNSAGGPGAHILRRKSPASGQGPMCNVKAPLGSPSPRPRRAKRFASLSRFVETLVVADDKMAAFHGAGLKRYLLTVMAAAAKAFKHPSIRNPVSLVVTRLVILGSGEEGPQVGPSAAQTLRSFCAWQRGLNTPEDSDPDHFDTAILFTRQDLCGVSTCDTLGMADVGTVCDPARSCAIVEDDGLQSAFTAAHELGHVFNMLHDNSKPCISLNGPLSTSRHVMAPVMAHVDPEEPWSPCSARFITDFLDNGYGHCLLDKPEAPLHLPVTFPGKDYDADRQCQLTFGPDSRHCPQLPPPCAALWCSGHLNGHAMCQTKHSPWADGTPCGPAQACMGGRCLHMDQLQDFNIPQAGGWGPWGPWGDCSRTCGGGVQFSSRDCTRPVPRNGGKYCEGRRTRFRSCNTEDCPTGSALTFREEQCAAYNHRTDLFKSFPGPMDWVPRYTGVAPQDQCKLTCQAQALGYYYVLEPRVVDGTPCSPDSSSVCVQGRCIHAGCDRIIGSKKKFDKCMVCGGDGSGCSKQSGSFRKFRYGYNNVVTIPAGATHILVRQQGNPGHRSIYLALKLPDGSYALNGEYTLMPSPTDVVLPGAVSLRYSGATAASETLSGHGPLAQPLTLQVLVAGNPQDTRLRYSFFVPRPTPSTPRPTPQDWLHRRAQILEILRRRPWAGRK T79570 DRUGINFO D0G1LL 1607004-34-1 Patented T79570 DRUGINFO D0N6ZA US9206139, 4 Patented T79570 DRUGINFO D0UM5R US9206139, 5 Patented T79570 DRUGINFO D0Y1XT SC-44463 Terminated T79570 DRUGINFO D0Y1NM (R)-2-(biphenyl-4-sulfonylamino)-propionic acid Investigative T79570 DRUGINFO D0A4TC MMI270 Investigative T98264 TARGETID T98264 T98264 FORMERID TTDC00032 T98264 UNIPROID PTN6_HUMAN T98264 TARGNAME Protein-tyrosine phosphatase SHP-1 (PTPN6) T98264 GENENAME PTPN6 T98264 TARGTYPE Patented-recorded T98264 SYNONYMS Tyrosine-protein phosphatase non-receptor type 6; SH-PTP1; Protein-tyrosine phosphatase 1C; PTP1C; PTP-1C; Hematopoietic cell protein-tyrosine phosphatase; HCP T98264 FUNCTION The SH2 regions may interact with other cellular components to modulate its own phosphatase activity against interacting substrates. Together with MTUS1, induces UBE2V2 expression upon angiotensin II stimulation. Plays a key role in hematopoiesis. Modulates signaling by tyrosine phosphorylated cell surface receptors such as KIT and the EGF receptor/EGFR. T98264 PDBSTRUC 4HJQ; 4HJP; 4GS0; 4GRZ; 4GRY T98264 BIOCLASS Phosphoric monoester hydrolase T98264 ECNUMBER EC 3.1.3.48 T98264 SEQUENCE MVRWFHRDLSGLDAETLLKGRGVHGSFLARPSRKNQGDFSLSVRVGDQVTHIRIQNSGDFYDLYGGEKFATLTELVEYYTQQQGVLQDRDGTIIHLKYPLNCSDPTSERWYHGHMSGGQAETLLQAKGEPWTFLVRESLSQPGDFVLSVLSDQPKAGPGSPLRVTHIKVMCEGGRYTVGGLETFDSLTDLVEHFKKTGIEEASGAFVYLRQPYYATRVNAADIENRVLELNKKQESEDTAKAGFWEEFESLQKQEVKNLHQRLEGQRPENKGKNRYKNILPFDHSRVILQGRDSNIPGSDYINANYIKNQLLGPDENAKTYIASQGCLEATVNDFWQMAWQENSRVIVMTTREVEKGRNKCVPYWPEVGMQRAYGPYSVTNCGEHDTTEYKLRTLQVSPLDNGDLIREIWHYQYLSWPDHGVPSEPGGVLSFLDQINQRQESLPHAGPIIVHCSAGIGRTGTIIVIDMLMENISTKGLDCDIDIQKTIQMVRAQRSGMVQTEAQYKFIYVAIAQFIETTKKKLEVLQSQKGQESEYGNITYPPAMKNAHAKASRTSSKHKEDVYENLHTKNKREEKVKKQRSADKEKSKGSLKRK T98264 DRUGINFO D0I2AN BDBM50054344 Patented T98264 DRUGINFO D00MFW NSC-87877 Patented T59190 TARGETID T59190 T59190 FORMERID TTDR00557 T59190 UNIPROID KPCZ_HUMAN T59190 TARGNAME Protein kinase C zeta (PRKCZ) T59190 GENENAME PRKCZ T59190 TARGTYPE Patented-recorded T59190 SYNONYMS Protein kinase C zeta type; PKC2; NPKC-zeta T59190 FUNCTION Upon lipopolysaccharide (LPS) treatment in macrophages, or following mitogenic stimuli, functions downstream of PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently of RAF1 activation. Required for insulin-dependent activation of AKT3, but may function as an adapter rather than a direct activator. Upon insulin treatment may act as a downstream effector of PI3K and contribute to the activation of translocation of the glucose transporter SLC2A4/GLUT4 and subsequent glucose transport in adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity and can activate JUN promoter through MEF2C. Through binding with SQSTM1/p62, functions in interleukin-1 signaling and activation of NF-kappa-B with the specific adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in turn leads to the degradation of NF-kappa-B inhibitors. In migrating astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CDC42 to function in the establishment of cell polarity along with the microtubule motor and dynein. In association with FEZ1, stimulates neuronal differentiation in PC12 cells. In the inflammatory response, is required for the T-helper 2 (Th2) differentiation process, including interleukin production, efficient activation of JAK1 and the subsequent phosphorylation and nuclear translocation of STAT6. May be involved in development of allergic airway inflammation (asthma), a process dependent on Th2 immune response. In the NF-kappa-B-mediated inflammatory response, can relieve SETD6-dependent repression of NF-kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. In vein endothelial cells treated with the oxidant peroxynitrite, phosphorylates STK11 leading to nuclear export of STK11, subsequent inhibition of PI3K/Akt signaling, and increased apoptosis. Phosphorylates VAMP2 in vitro. Calcium- and diacylglycerol-independent serine/threonine-protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated protein (MAP) kinase cascade, and is involved in NF-kappa-B activation, mitogenic signaling, cell proliferation, cell polarity, inflammatory response and maintenance of long-term potentiation (LTP). T59190 BIOCLASS Kinase T59190 ECNUMBER EC 2.7.11.13 T59190 SEQUENCE MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQQHPLTLKWVDSEGDPCTVSSQMELEEAFRLARQCRDEGLIIHVFPSTPEQPGLPCPGEDKSIYRRGARRWRKLYRANGHLFQAKRFNRRAYCGQCSERIWGLARQGYRCINCKLLVHKRCHGLVPLTCRKHMDSVMPSQEPPVDDKNEDADLPSEETDGIAYISSSRKHDSIKDDSEDLKPVIDGMDGIKISQGLGLQDFDLIRVIGRGSYAKVLLVRLKKNDQIYAMKVVKKELVHDDEDIDWVQTEKHVFEQASSNPFLVGLHSCFQTTSRLFLVIEYVNGGDLMFHMQRQRKLPEEHARFYAAEICIALNFLHERGIIYRDLKLDNVLLDADGHIKLTDYGMCKEGLGPGDTTSTFCGTPNYIAPEILRGEEYGFSVDWWALGVLMFEMMAGRSPFDIITDNPDMNTEDYLFQVILEKPIRIPRFLSVKASHVLKGFLNKDPKERLGCRPQTGFSDIKSHAFFRSIDWDLLEKKQALPPFQPQITDDYGLDNFDTQFTSEPVQLTPDDEDAIKRIDQSEFEGFEYINPLLLSTEESV T59190 DRUGINFO D03VKC Methyl 2-amino-4-phenylthiophene-3-carboxylate Patented T59190 DRUGINFO D0CV8T Y-9680 Patented T59190 DRUGINFO D0T2KT US8889696, 39 Patented T59190 DRUGINFO D0Y7KX US8889672, 252-036-001 Patented T59190 DRUGINFO D0X0HN LY-317644 Terminated T59190 DRUGINFO D0R5ZR RO-320432 Terminated T59190 DRUGINFO D08JPU G6976 Investigative T59190 DRUGINFO D00TWA [2,2':5',2'']Terthiophen-4-yl-methanol Investigative T59190 DRUGINFO D02PUV 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol Investigative T59190 DRUGINFO D02QME 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile Investigative T59190 DRUGINFO D05LRV [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde Investigative T59190 DRUGINFO D09TSC Ro-32-0557 Investigative T59190 DRUGINFO D09XIE 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile Investigative T59190 DRUGINFO D0A8MN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile Investigative T59190 DRUGINFO D0D3MR [2,2':5',2'']Terthiophene-4-carbaldehyde Investigative T59190 DRUGINFO D0Q3GQ 4-cycloheptyliden(4-hydroxyphenyl)methylphenol Investigative T59190 DRUGINFO D0S9UK 2,3,3-Triphenyl-acrylonitrile Investigative T59190 DRUGINFO D0T0UH 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile Investigative T59190 DRUGINFO D0V9SW 4-cyclohexyliden(4-hydroxyphenyl)methylphenol Investigative T59190 DRUGINFO D06ZCX LY-326449 Investigative T59190 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T59190 DRUGINFO D0L8HO RO-316233 Investigative T21357 TARGETID T21357 T21357 FORMERID TTDI02147 T21357 UNIPROID PDE3B_HUMAN T21357 TARGNAME Phosphodiesterase 3B (PDE3B) T21357 GENENAME PDE3B T21357 TARGTYPE Patented-recorded T21357 SYNONYMS cGMPinhibited 3',5'cyclic phosphodiesterase B; cGMP-inhibited 3',5'-cyclic phosphodiesterase B; Cyclic GMPinhibited phosphodiesterase B; Cyclic GMP-inhibited phosphodiesterase B; CGIPDE1; CGIPDE B; CGIP1; CGI-PDE B T21357 FUNCTION May play a role in fat metabolism. Regulates cAMP binding of RAPGEF3. Through simultaneous binding to RAPGEF3 and PIK3R6 assembles a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis. Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. T21357 PDBSTRUC 1SOJ; 1SO2 T21357 BIOCLASS Phosphoric diester hydrolase T21357 ECNUMBER EC 3.1.4.17 T21357 SEQUENCE MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE T21357 DRUGINFO D0SG9Q US9388139, 12 Patented T21357 DRUGINFO D0X5XB US8741907-compound-3 Patented T38996 TARGETID T38996 T38996 FORMERID TTDR00374 T38996 UNIPROID PLD1_HUMAN T38996 TARGNAME Phospholipase D1 (PLD1) T38996 GENENAME PLD1 T38996 TARGTYPE Patented-recorded T38996 SYNONYMS Phosphatidylcholine-hydrolyzing phospholipase D1; PLD 1; HPLD1; Choline phosphatase 1 T38996 FUNCTION May be involved in the regulation of perinuclear intravesicular membrane traffic. Implicated as a critical step in numerous cellular pathways, including signal transduction, membrane trafficking, and the regulation of mitosis. T38996 BIOCLASS Phosphoric diester hydrolase T38996 ECNUMBER EC 3.1.4.4 T38996 SEQUENCE MSLKNEPRVNTSALQKIAADMSNIIENLDTRELHFEGEEVDYDVSPSDPKIQEVYIPFSAIYNTQGFKEPNIQTYLSGCPIKAQVLEVERFTSTTRVPSINLYTIELTHGEFKWQVKRKFKHFQEFHRELLKYKAFIRIPIPTRRHTFRRQNVREEPREMPSLPRSSENMIREEQFLGRRKQLEDYLTKILKMPMYRNYHATTEFLDISQLSFIHDLGPKGIEGMIMKRSGGHRIPGLNCCGQGRACYRWSKRWLIVKDSFLLYMKPDSGAIAFVLLVDKEFKIKVGKKETETKYGIRIDNLSRTLILKCNSYRHARWWGGAIEEFIQKHGTNFLKDHRFGSYAAIQENALAKWYVNAKGYFEDVANAMEEANEEIFITDWWLSPEIFLKRPVVEGNRWRLDCILKRKAQQGVRIFIMLYKEVELALGINSEYTKRTLMRLHPNIKVMRHPDHVSSTVYLWAHHEKLVIIDQSVAFVGGIDLAYGRWDDNEHRLTDVGSVKRVTSGPSLGSLPPAAMESMESLRLKDKNEPVQNLPIQKSIDDVDSKLKGIGKPRKFSKFSLYKQLHRHHLHDADSISSIDSTSSYFNHYRSHHNLIHGLKPHFKLFHPSSESEQGLTRPHADTGSIRSLQTGVGELHGETRFWHGKDYCNFVFKDWVQLDKPFADFIDRYSTPRMPWHDIASAVHGKAARDVARHFIQRWNFTKIMKSKYRSLSYPFLLPKSQTTAHELRYQVPGSVHANVQLLRSAADWSAGIKYHEESIHAAYVHVIENSRHYIYIENQFFISCADDKVVFNKIGDAIAQRILKAHRENQKYRVYVVIPLLPGFEGDISTGGGNALQAIMHFNYRTMCRGENSILGQLKAELGNQWINYISFCGLRTHAELEGNLVTELIYVHSKLLIADDNTVIIGSANINDRSMLGKRDSEMAVIVQDTETVPSVMDGKEYQAGRFARGLRLQCFRVVLGYLDDPSEDIQDPVSDKFFKEVWVSTAARNATIYDKVFRCLPNDEVHNLIQLRDFINKPVLAKEDPIRAEEELKKIRGFLVQFPFYFLSEESLLPSVGTKEAIVPMEVWT T38996 DRUGINFO D06OKT US9127005, P2C Patented T38996 DRUGINFO D08SLU US9453017, 1 Patented T38996 DRUGINFO D09BSA US9127005, P2B Patented T38996 DRUGINFO D0CI4A ML272 Patented T38996 DRUGINFO D0OX9E US9127005, P0L Patented T38996 DRUGINFO D0X0NV US9453017, 2 Patented T38996 DRUGINFO D0T3HK 1-(pyridin-4-yl)piperazine Investigative T38996 DRUGINFO D07RPV HALOPEMIDE Investigative T38996 DRUGINFO D07JMN 1-(pyridin-2-yl)piperazine Investigative T31543 TARGETID T31543 T31543 FORMERID TTDR00644 T31543 UNIPROID ST14_HUMAN T31543 TARGNAME Suppressor of tumorigenicity 14 protein (ST14) T31543 GENENAME ST14 T31543 TARGTYPE Patented-recorded T31543 SYNONYMS Tumor-associated differentially-expressed gene 15 protein; Tumor associated differentially-expressed gene-15 protein; TADG15; Serine protease TADG-15; Serine protease 14; SNC19; Prostamin; PRSS14; Membrane-type serine protease 1; Membrane type serine protease 1; Matriptase; MT-SP1 T31543 FUNCTION Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing. Degrades extracellular matrix. T31543 PDBSTRUC 5LYO; 4R0I; 4O9V; 4O97; 4JZI T31543 BIOCLASS Peptidase T31543 ECNUMBER EC 3.4.21.109 T31543 SEQUENCE MGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAAVLIGLLLVLLGIGFLVWHLQYRDVRVQKVFNGYMRITNENFVDAYENSNSTEFVSLASKVKDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERVVMLPPRARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLHARGVELMRFTTPGFPDSPYPAHARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALVQLCGTYPPSYNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMSSCGGRLRKAQGTFNSPYYPGHYPPNIDCTWNIEVPNNQHVKVRFKFFYLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTSNSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRCDGWADCTDHSDELNCSCDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGCSCPAQTFRCSNGKCLSKSQQCNGKDDCGDGSDEASCPKVNVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEKDCDCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYIDDRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKPAEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVINQTTCENLLPQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYTRLPLFRDWIKENTGV T31543 DRUGINFO D0CN2Q US8569313, Inhibitor 18 Patented T31543 DRUGINFO D0PY4S US8569313, Inhibitor 14 Patented T31543 DRUGINFO D0RN9V US8569313, Inhibitor 19 Patented T31543 DRUGINFO D0U4EO US8569313, Inhibitor 15 Patented T31543 DRUGINFO D01TWD 3-tapap Investigative T31543 DRUGINFO D0SP2I 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine Investigative T31543 DRUGINFO D0W2SV Inhibitor 1 [Colombo et al., 2012] Investigative T31543 DRUGINFO D00LOL PMID23849879C3 Investigative T31543 DRUGINFO D07OQF PMID25489658C4d Investigative T31543 DRUGINFO D07SFI Benzamidine Investigative T20669 TARGETID T20669 T20669 FORMERID TTDR01375 T20669 UNIPROID KAPCA_HUMAN T20669 TARGNAME PRKACA messenger RNA (PRKACA mRNA) T20669 GENENAME PRKACA T20669 TARGTYPE Patented-recorded T20669 SYNONYMS cAMP-dependent protein kinase catalytic subunit alpha (mRNA); PKACA (mRNA); PKA C-alpha (mRNA) T20669 FUNCTION Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis. Phosphorylates CDC25B, ABL1, NFKB1, CLDN3, PSMC5/RPT6, PJA2, RYR2, RORA and VASP. RORA is activated by phosphorylation. Required for glucose-mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts. Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP. Prevents the antiproliferative and anti-invasive effects of alpha-difluoromethylornithine in breast cancer cells when activated. RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and resting cytosolic Ca(2+). PSMC5/RPT6 activation by phosphorylation stimulates proteasome. Negatively regulates tight junctions (TJs) in ovarian cancer cells via CLDN3 phosphorylation. NFKB1 phosphorylation promotes NF-kappa-B p50-p50 DNA binding. Involved in embryonic development by down-regulating the Hedgehog (Hh) signaling pathway that determines embryo pattern formation and morphogenesis. Prevents meiosis resumption in prophase-arrested oocytes via CDC25B inactivation by phosphorylation. May also regulate rapid eye movement (REM) sleep in the pedunculopontine tegmental (PPT). Phosphorylates APOBEC3G and AICDA. Isoform 2 phosphorylates and activates ABL1 in sperm flagellum to promote spermatozoa capacitation. Phosphorylates HSF1; this phosphorylation promotes HSF1 nuclear localization and transcriptional activity upon heat shock. Phosphorylates a large number of substrates in the cytoplasm and the nucleus. T20669 PDBSTRUC 6FRX; 6C0U; 6BYS; 6BYR; 5UZK T20669 BIOCLASS mRNA target T20669 ECNUMBER EC 2.7.11.11 T20669 SEQUENCE MGNAAAAKKGSEQESVKEFLAKAKEDFLKKWESPAQNTAHLDQFERIKTLGTGSFGRVMLVKHKETGNHYAMKILDKQKVVKLKQIEHTLNEKRILQAVNFPFLVKLEFSFKDNSNLYMVMEYVPGGEMFSHLRRIGRFSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPENLLIDQQGYIQVTDFGFAKRVKGRTWTLCGTPEYLAPEIILSKGYNKAVDWWALGVLIYEMAAGYPPFFADQPIQIYEKIVSGKVRFPSHFSSDLKDLLRNLLQVDLTKRFGNLKNGVNDIKNHKWFATTDWIAIYQRKVEAPFIPKFKGPGDTSNFDDYEEEEIRVSINEKCGKEFSEF T20669 DRUGINFO D00QNV VFEDEOUBYBLDKN-AAFJCEBUSA-N Patented T20669 DRUGINFO D06GXM XHPNYYOUZWOWNT-PYUWXLGESA-N Patented T20669 DRUGINFO D0B6VY AGGGWZCOULSEER-PYUWXLGESA-N Patented T20669 DRUGINFO D0R2TM BALANOL Terminated T20669 DRUGINFO D00ERI ISIS 102633 Investigative T20669 DRUGINFO D00ODF ISIS 102604 Investigative T20669 DRUGINFO D00WZE ISIS 102619 Investigative T20669 DRUGINFO D00YID ISIS 102462 Investigative T20669 DRUGINFO D02XQB ISIS 102563 Investigative T20669 DRUGINFO D03RKU ISIS 102490 Investigative T20669 DRUGINFO D04GPC ISIS 102664 Investigative T20669 DRUGINFO D04OUT ISIS 102584 Investigative T20669 DRUGINFO D06JUQ ISIS 102629 Investigative T20669 DRUGINFO D06NSN ISIS 102614 Investigative T20669 DRUGINFO D08FVO ISIS 102450 Investigative T20669 DRUGINFO D09FFE H-89 Investigative T20669 DRUGINFO D0A5FV ISIS 102558 Investigative T20669 DRUGINFO D0CE4H ISIS 102599 Investigative T20669 DRUGINFO D0D4BR ISIS 102676 Investigative T20669 DRUGINFO D0K7PJ ISIS 102486 Investigative T20669 DRUGINFO D0KL5K ISIS 102668 Investigative T20669 DRUGINFO D0L0IR ISIS 102454 Investigative T20669 DRUGINFO D0M4NN ISIS 102466 Investigative T20669 DRUGINFO D0P0SY ISIS 102609 Investigative T20669 DRUGINFO D0S7SN ISIS 102478 Investigative T20669 DRUGINFO D0T3GH ISIS 102624 Investigative T20669 DRUGINFO D0U3ML ISIS 102660 Investigative T20669 DRUGINFO D0V2VB ISIS 102458 Investigative T20669 DRUGINFO D0Z2QO ISIS 102482 Investigative T20669 DRUGINFO D0GT8N NM-PP1 Investigative T20669 DRUGINFO D09XIL Ro-4396686 Investigative T20669 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T71367 TARGETID T71367 T71367 FORMERID TTDI00079 T71367 UNIPROID M4K4_HUMAN T71367 TARGNAME MEK kinase kinase 4 (MAP4K4) T71367 GENENAME MAP4K4 T71367 TARGTYPE Patented-recorded T71367 SYNONYMS Nckinteracting kinase; Nck-interacting kinase; Mitogenactivated protein kinase kinase kinase kinase 4; Mitogen-activated protein kinase kinase kinase kinase 4; MEKKK 4; MAPK/ERK kinase kinase kinase 4; KIAA0687; HPK/GCKlike kinase HGK; HPK/GCK-like kinase HGK; HGK T71367 FUNCTION Appears to act upstream of the JUN N-terminal pathway. Phosphorylates SMAD1 on Thr-322. Serine/threonine kinase that may play a role in the response to environmental stress and cytokines such as TNF-alpha. T71367 PDBSTRUC 5W5Q; 5J95; 5DI1; 4ZP5; 4ZK5 T71367 BIOCLASS Kinase T71367 ECNUMBER EC 2.7.11.1 T71367 SEQUENCE MANDSPAKSLVDIDLSSLRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKLEINMLKKYSHHRNIATYYGAFIKKSPPGHDDQLWLVMEFCGAGSITDLVKNTKGNTLKEDWIAYISREILRGLAHLHIHHVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDLWSCGITAIEMAEGAPPLCDMHPMRALFLIPRNPPPRLKSKKWSKKFFSFIEGCLVKNYMQRPSTEQLLKHPFIRDQPNERQVRIQLKDHIDRTRKKRGEKDETEYEYSGSEEEEEEVPEQEGEPSSIVNVPGESTLRRDFLRLQQENKERSEALRRQQLLQEQQLREQEEYKRQLLAERQKRIEQQKEQRRRLEEQQRREREARRQQEREQRRREQEEKRRLEELERRRKEEEERRRAEEEKRRVEREQEYIRRQLEEEQRHLEVLQQQLLQEQAMLLECRWREMEEHRQAERLQRQLQQEQAYLLSLQHDHRRPHPQHSQQPPPPQQERSKPSFHAPEPKAHYEPADRAREVEDRFRKTNHSSPEAQSKQTGRVLEPPVPSRSESFSNGNSESVHPALQRPAEPQVPVRTTSRSPVLSRRDSPLQGSGQQNSQAGQRNSTSIEPRLLWERVEKLVPRPGSGSSSGSSNSGSQPGSHPGSQSGSGERFRVRSSSKSEGSPSQRLENAVKKPEDKKEVFRPLKPADLTALAKELRAVEDVRPPHKVTDYSSSSEESGTTDEEDDDVEQEGADESTSGPEDTRAASSLNLSNGETESVKTMIVHDDVESEPAMTPSKEGTLIVRQTQSASSTLQKHKSSSSFTPFIDPRLLQISPSSGTTVTSVVGFSCDGMRPEAIRQDPTRKGSVVNVNPTNTRPQSDTPEIRKYKKRFNSEILCAALWGVNLLVGTESGLMLLDRSGQGKVYPLINRRRFQQMDVLEGLNVLVTISGKKDKLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDLEGCVHYKVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFGELVHKPLLVDLTVEEGQRLKVIYGSCAGFHAVDVDSGSVYDIYLPTHIQCSIKPHAIIILPNTDGMELLVCYEDEGVYVNTYGRITKDVVLQWGEMPTSVAYIRSNQTMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVYFMTLGRTSLLSW T71367 DRUGINFO D00SDR BDBM50011553 Patented T71367 DRUGINFO D0HK8C 6-Phenylquinazolin-4-amine Patented T71367 DRUGINFO D0L2FW BDBM50011552 Patented T71367 DRUGINFO D0NY6U PMID24673130C26 Investigative T71367 DRUGINFO D0O6OH PMID23312943C21 Investigative T73471 TARGETID T73471 T73471 FORMERID TTDR00510 T73471 UNIPROID HEPS_HUMAN T73471 TARGNAME Serine protease hepsin (HPN) T73471 GENENAME HPN T73471 TARGTYPE Patented-recorded T73471 SYNONYMS Transmembrane protease, serine 1; HPN; HEPSIN T73471 FUNCTION Plays an essential role in cell growth and maintenance of cell morphology. May mediate the activating cleavage of HGF and MST1/HGFL. Plays a role in the proteolytic processing of ACE2. T73471 PDBSTRUC 5CE1; 3T2N; 1Z8G; 1P57; 1O5F T73471 BIOCLASS Peptidase T73471 ECNUMBER EC 3.4.21.106 T73471 SEQUENCE MAQKEGGRTVPCCSRPKVAALTAGTLLLLTAIGAASWAIVAVLLRSDQEPLYPVQVSSADARLMVFDKTEGTWRLLCSSRSNARVAGLSCEEMGFLRALTHSELDVRTAGANGTSGFFCVDEGRLPHTQRLLEVISVCDCPRGRFLAAICQDCGRRKLPVDRIVGGRDTSLGRWPWQVSLRYDGAHLCGGSLLSGDWVLTAAHCFPERNRVLSRWRVFAGAVAQASPHGLQLGVQAVVYHGGYLPFRDPNSEENSNDIALVHLSSPLPLTEYIQPVCLPAAGQALVDGKICTVTGWGNTQYYGQQAGVLQEARVPIISNDVCNGADFYGNQIKPKMFCAGYPEGGIDACQGDSGGPFVCEDSISRTPRWRLCGIVSWGTGCALAQKPGVYTKVSDFREWIFQAIKTHSEASGMVTQL T73471 DRUGINFO D04LWZ AC1LFXA6 Patented T73471 DRUGINFO D06MTX CRA_1144 Investigative T73471 DRUGINFO D0PA1G Benzylsulfinic Acid Investigative T04831 TARGETID T04831 T04831 FORMERID TTDNR00694 T04831 UNIPROID E2AK2_HUMAN T04831 TARGNAME Tyrosine-protein kinase EIF2AK2 (p68) T04831 GENENAME EIF2AK2 T04831 TARGTYPE Patented-recorded T04831 SYNONYMS p68 kinase; Proteinkinase RNA-activated; Interferon-inducible RNA-dependent protein kinase p68; Interferon-induced, double-stranded RNA-activated protein kinase p68 T04831 FUNCTION Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1). Inhibits viral replication via phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (EIF2S1), this phosphorylation impairs the recycling of EIF2S1 between successive rounds of initiation leading to inhibition of translation which eventually results in shutdown of cellular and viral protein synthesis. Also phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein US11. In addition to serine/threonine-protein kinase activity, also has tyrosine-protein kinase activity and phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and proteosomal degradation. Either as an adapter protein and/or via its kinase activity, can regulate various signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in the expression of genes encoding proinflammatory cytokines and IFNs. Activates the NF-kappa-B pathway via interaction with IKBKB and TRAF family of proteins and activates the p38 MAP kinase pathway via interaction with MAP2K6. Can act as both a positive and negative regulator of the insulin signaling pathway (ISP). Negatively regulates ISP by inducing the inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A which activates FOXO1, which in turn up-regulates the expression of insulin receptor substrate 2 (IRS2). Can regulate NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 and NLRC4 inflammasomes. Can trigger apoptosis via FADD-mediated activation of CASP8. Plays a role in the regulation of the cytoskeleton by binding to gelsolin (GSN), sequestering the protein in an inactive conformation away from actin. IFN-induced dsRNA-dependent serine/threonine-protein kinase which plays a key role in the innate immune response to viral infection and is also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation. T04831 PDBSTRUC 3UIU; 2A1A; 2A19; 1QU6 T04831 BIOCLASS Kinase T04831 ECNUMBER EC 2.7.11.1 T04831 SEQUENCE MAGDLSAGFFMEELNTYRQKQGVVLKYQELPNSGPPHDRRFTFQVIIDGREFPEGEGRSKKEAKNAAAKLAVEILNKEKKAVSPLLLTTTNSSEGLSMGNYIGLINRIAQKKRLTVNYEQCASGVHGPEGFHYKCKMGQKEYSIGTGSTKQEAKQLAAKLAYLQILSEETSVKSDYLSSGSFATTCESQSNSLVTSTLASESSSEGDFSADTSEINSNSDSLNSSSLLMNGLRNNQRKAKRSLAPRFDLPDMKETKYTVDKRFGMDFKEIELIGSGGFGQVFKAKHRIDGKTYVIKRVKYNNEKAEREVKALAKLDHVNIVHYNGCWDGFDYDPETSDDSLESSDYDPENSKNSSRSKTKCLFIQMEFCDKGTLEQWIEKRRGEKLDKVLALELFEQITKGVDYIHSKKLIHRDLKPSNIFLVDTKQVKIGDFGLVTSLKNDGKRTRSKGTLRYMSPEQISSQDYGKEVDLYALGLILAELLHVCDTAFETSKFFTDLRDGIISDIFDKKEKTLLQKLLSKKPEDRPNTSEILRTLTVWKKSPEKNERHTC T04831 DRUGINFO D05GPF US9650366, 12 Patented T04831 DRUGINFO D0QZ4B US9650366, 2 Patented T04831 DRUGINFO D0Z0BQ US9650366, 9 Patented T04831 DRUGINFO D0C1DQ ASN-11124542 Investigative T04831 DRUGINFO D0N9DU indirubin derivative E804 Investigative T04831 DRUGINFO D04WFN NU6140 Investigative T41666 TARGETID T41666 T41666 FORMERID TTDR00219 T41666 UNIPROID HGXR_PLAFG T41666 TARGNAME Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) T41666 GENENAME Malaria LACZ T41666 TARGTYPE Patented-recorded T41666 SYNONYMS LACZ of Plasmodium falciparum (isolate FCR-3 / Gambia); Hypoxanthine phosphoribosyltransferase; HPRT; HGPRTase; HGPRT of Plasmodium falciparum (isolate FCR-3 / Gambia); Guanine phosphoribosyltransferase; GPRT T41666 FUNCTION Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5- phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Plays a central role in the generation of purine nucleotides through the purine salvage pathway. T41666 PDBSTRUC 3OZG; 3OZF; 2VFA; 1CJB T41666 BIOCLASS Pentosyltransferase T41666 SEQUENCE MPIPNNPGAGENAFDPVFVNDDDGYDLDSFMIPAHYKKYLTKVLVPNGVIKNRIEKLAYDIKKVYNNEEFHILCLLKGSRGFFTALLKHLSRIHNYSAVETSKPLFGEHYVRVKSYCNDQSTGTLEIVSEDLSCLKGKHVLIVEDIIDTGKTLVKFCEYLKKFEIKTVAIACLFIKRTPLWNGFKADFVGFSIPDHFVVGYSLDYNEIFRDLDHCCLVNDEGKKKYKATSL T41666 DRUGINFO D06TXN US9200020, Table 3, Compound 1B Patented T41666 DRUGINFO D0A5NU US9200020, Table 3, Compound 2B Patented T41666 DRUGINFO D0J6BK US9200020, Table 3 compound 8 Patented T41666 DRUGINFO D00GHB Carboxylic PRPP Investigative T41666 DRUGINFO D01IPS 5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine Investigative T41666 DRUGINFO D03VOB 9-[2-(1-Phosphonopropan-2-yloxy)ethyl]guanine Investigative T41666 DRUGINFO D04ZAO 7-Hydroxy-Pyrazolo[4,3-D]Pyrimidine Investigative T41666 DRUGINFO D06NCQ 3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol Investigative T41666 DRUGINFO D0O7WT 9-[2-(1-Phosphonobutan-2-yloxy)ethyl]hypoxanthine Investigative T41666 DRUGINFO D0Q7WP 9-[2-(1-Phosphonobutan-2-yloxy)ethyl]guanine Investigative T41666 DRUGINFO D0X2GF 9-Deazaguanine Investigative T41666 DRUGINFO D0X2VN Formycin B Investigative T41666 DRUGINFO D0XB1H Guanosine-5',3'-Tetraphosphate Investigative T41666 DRUGINFO D08NFH Alpha-Phosphoribosylpyrophosphoric Acid Investigative T41666 DRUGINFO D04AWP Guanosine-5'-Monophosphate Investigative T41666 DRUGINFO D0H2YT Inosinic Acid Investigative T41666 DRUGINFO D0A1DU Pyrophosphate 2- Investigative T41666 DRUGINFO D06EWG Formic Acid Investigative T41666 DRUGINFO D0F2ME Acetate Ion Investigative T62548 TARGETID T62548 T62548 FORMERID TTDR00280 T62548 UNIPROID ARBK1_HUMAN T62548 TARGNAME Beta-adrenergic receptor kinase 1 (ADRBK1) T62548 GENENAME GRK2 T62548 TARGTYPE Patented-recorded T62548 SYNONYMS GRK2; G-protein coupled receptor kinase 2; BetaARK1; Beta-ARK-1; Beta ARK1 T62548 FUNCTION Specifically phosphorylates the agonist-occupied form of the beta-adrenergic and closely related receptors, probably inducing a desensitization of them. Key regulator of LPAR1 signaling. Competes with RALA for binding to LPAR1 thus affecting the signaling properties of the receptor. Desensitizes LPAR1 and LPAR2 in a phosphorylation-independent manner. T62548 PDBSTRUC 6C2Y; 5WG5; 5WG4; 5WG3; 5UVC T62548 BIOCLASS Kinase T62548 ECNUMBER EC 2.7.11.15 T62548 SEQUENCE MADLEAVLADVSYLMAMEKSKATPAARASKKILLPEPSIRSVMQKYLEDRGEVTFEKIFSQKLGYLLFRDFCLNHLEEARPLVEFYEEIKKYEKLETEEERVARSREIFDSYIMKELLACSHPFSKSATEHVQGHLGKKQVPPDLFQPYIEEICQNLRGDVFQKFIESDKFTRFCQWKNVELNIHLTMNDFSVHRIIGRGGFGEVYGCRKADTGKMYAMKCLDKKRIKMKQGETLALNERIMLSLVSTGDCPFIVCMSYAFHTPDKLSFILDLMNGGDLHYHLSQHGVFSEADMRFYAAEIILGLEHMHNRFVVYRDLKPANILLDEHGHVRISDLGLACDFSKKKPHASVGTHGYMAPEVLQKGVAYDSSADWFSLGCMLFKLLRGHSPFRQHKTKDKHEIDRMTLTMAVELPDSFSPELRSLLEGLLQRDVNRRLGCLGRGAQEVKESPFFRSLDWQMVFLQKYPPPLIPPRGEVNAADAFDIGSFDEEDTKGIKLLDSDQELYRNFPLTISERWQQEVAETVFDTINAETDRLEARKKAKNKQLGHEEDYALGKDCIMHGYMSKMGNPFLTQWQRRYFYLFPNRLEWRGEGEAPQSLLTMEEIQSVEETQIKERKCLLLKIRGGKQFILQCDSDPELVQWKKELRDAYREAQQLVQRVPKMKNKPRSPVVELSKVPLVQRGSANGL T62548 DRUGINFO D04WNI US9493490, E Patented T62548 DRUGINFO D0OE2R US9493490, D Patented T62548 DRUGINFO D0YB5B US9493490, C Patented T62548 DRUGINFO D0YD7S BDBM50173306 Patented T62548 DRUGINFO D0ZS0I US9493490, L Patented T62548 DRUGINFO D02TYC BetaARKct Investigative T62548 DRUGINFO D0U8UK PMID21596927C101 Investigative T62548 DRUGINFO D04CUA PMID24210504C1o Investigative T64553 TARGETID T64553 T64553 FORMERID TTDI02371 T64553 UNIPROID ZAP70_HUMAN T64553 TARGNAME Tyrosine-protein kinase ZAP-70 (ZAP-70) T64553 GENENAME ZAP70 T64553 TARGTYPE Patented-recorded T64553 SYNONYMS Syk-related tyrosine kinase; SRK; 70 kDa zeta-chain associated protein T64553 FUNCTION Regulates motility, adhesion and cytokine expression of mature T-cells, as well as thymocyte development. Contributes also to the development and activation of primary B-lymphocytes. When antigen presenting cells (APC) activate T-cell receptor (TCR), a serie of phosphorylations lead to the recruitment of ZAP70 to the doubly phosphorylated TCR component CD247/CD3Z through ITAM motif at the plasma membrane. This recruitment serves to localization to the stimulated TCR and to relieve its autoinhibited conformation. Release of ZAP70 active conformation is further stabilized by phosphorylation mediated by LCK. Subsequently, ZAP70 phosphorylates at least 2 essential adapter proteins: LAT and LCP2. In turn, a large number of signaling molecules are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Furthermore, ZAP70 controls cytoskeleton modifications, adhesion and mobility of T-lymphocytes, thus ensuring correct delivery of effectors to the APC. ZAP70 is also required for TCR-CD247/CD3Z internalization and degradation through interaction with the E3 ubiquitin-protein ligase CBL and adapter proteins SLA and SLA2. Thus, ZAP70 regulates both T-cell activation switch on and switch off by modulating TCR expression at the T-cell surface. During thymocyte development, ZAP70 promotes survival and cell-cycle progression of developing thymocytes before positive selection (when cells are still CD4/CD8 double negative). Additionally, ZAP70-dependent signaling pathway may also contribute to primary B-cells formation and activation through B-cell receptor (BCR). Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. T64553 PDBSTRUC 5O76; 4XZ1; 4XZ0; 4K2R; 4A4C T64553 BIOCLASS Kinase T64553 ECNUMBER EC 2.7.10.2 T64553 SEQUENCE MPDPAAHLPFFYGSISRAEAEEHLKLAGMADGLFLLRQCLRSLGGYVLSLVHDVRFHHFPIERQLNGTYAIAGGKAHCGPAELCEFYSRDPDGLPCNLRKPCNRPSGLEPQPGVFDCLRDAMVRDYVRQTWKLEGEALEQAIISQAPQVEKLIATTAHERMPWYHSSLTREEAERKLYSGAQTDGKFLLRPRKEQGTYALSLIYGKTVYHYLISQDKAGKYCIPEGTKFDTLWQLVEYLKLKADGLIYCLKEACPNSSASNASGAAAPTLPAHPSTLTHPQRRIDTLNSDGYTPEPARITSPDKPRPMPMDTSVYESPYSDPEELKDKKLFLKRDNLLIADIELGCGNFGSVRQGVYRMRKKQIDVAIKVLKQGTEKADTEEMMREAQIMHQLDNPYIVRLIGVCQAEALMLVMEMAGGGPLHKFLVGKREEIPVSNVAELLHQVSMGMKYLEEKNFVHRDLAARNVLLVNRHYAKISDFGLSKALGADDSYYTARSAGKWPLKWYAPECINFRKFSSRSDVWSYGVTMWEALSYGQKPYKKMKGPEVMAFIEQGKRMECPPECPPELYALMSDCWIYKWEDRPDFLTVEQRMRACYYSLASKVEGPPGSTQKAEAACA T64553 DRUGINFO D00HGD US8546370, 102 Patented T64553 DRUGINFO D09OGH US8546370, 11 Patented T64553 DRUGINFO D0VE2A US8546370, 17 Patented T64553 DRUGINFO D0T4MJ K00592a Investigative T64553 DRUGINFO D00SEC aloisine Investigative T46465 TARGETID T46465 T46465 FORMERID TTDR00106 T46465 UNIPROID PLM2_PLAFA T46465 TARGNAME Plasmodium Plasmepsin 2 (Malaria PLA2) T46465 GENENAME Malaria PLA2 T46465 TARGTYPE Patented-recorded T46465 SYNONYMS Plasmepsin-2; PFAPD; Aspartic hemoglobinase II T46465 FUNCTION Hydrolysis of the bonds linking certain hydrophobic residues in hemoglobin or globin. Also cleaves small molecules substrates such as Ala-Leu-Glu-Arg-Thr-Phe-|-Phe(NO(2))-Ser-Phe-Pro-Thr. T46465 PDBSTRUC 5BWY; 4Z22; 4YA8; 4Y6M; 4CKU T46465 BIOCLASS Peptidase T46465 ECNUMBER EC 3.4.23.39 T46465 SEQUENCE MDITVREHDFKHGFIKSNSTFDGLNIDNSKNKKKIQKGFQILYVLLFCSVMCGLFYYVYENVWLQRDNEMNEILKNSEHLTIGFKVENAHDRILKTIKTHKLKNYIKESVNFLNSGLTKTNYLGSSNDNIELVDFQNIMFYGDAEVGDNQQPFTFILDTGSANLWVPSVKCTTAGCLTKHLYDSSKSRTYEKDGTKVEMNYVSGTVSGFFSKDLVTVGNLSLPYKFIEVIDTNGFEPTYTASTFDGILGLGWKDLSIGSVDPIVVELKNQNKIENALFTFYLPVHDKHTGFLTIGGIEERFYEGPLTYEKLNHDLYWQITLDAHVGNIMLEKANCIVDSGTSAITVPTDFLNKMLQNLDVIKVPFLPFYVTLCNNSKLPTFEFTSENGKYTLEPEYYLQHIEDVGPGLCMLNIIGLDFPVPTFILGDPFMRKYFTVFDYDNHSVGIALAKKNL T46465 DRUGINFO D03OLC US9353089, 135 Patented T46465 DRUGINFO D0H4IY US9353089, 330 Patented T46465 DRUGINFO D0QX1S US9353089, 327 Patented T46465 DRUGINFO D04ZIJ Pepstatin Terminated T46465 DRUGINFO D00QMZ PS-662477 Investigative T46465 DRUGINFO D00ZMK KNI-10740 Investigative T46465 DRUGINFO D01RIP KNI-10265 Investigative T46465 DRUGINFO D01TFQ KNI-10124 Investigative T46465 DRUGINFO D02BVS KNI-10761 Investigative T46465 DRUGINFO D02CKL KNI-10113 Investigative T46465 DRUGINFO D03BZY KNI-10313 Investigative T46465 DRUGINFO D03TFP KNI-10758 Investigative T46465 DRUGINFO D04QEO KNI-10332 Investigative T46465 DRUGINFO D04QUO KNI-10282 Investigative T46465 DRUGINFO D04RUS KNI-10074 Investigative T46465 DRUGINFO D05DNU KNI-1293 Investigative T46465 DRUGINFO D05GIB KNI-10033 Investigative T46465 DRUGINFO D05HFQ KNI-10342 Investigative T46465 DRUGINFO D05KWN KNI-10737 Investigative T46465 DRUGINFO D05XTX KNI-10095 Investigative T46465 DRUGINFO D06EJX KNI-10538 Investigative T46465 DRUGINFO D06MPP KNI-10094 Investigative T46465 DRUGINFO D06MZB KNI-10081 Investigative T46465 DRUGINFO D06NEW KNI-10217 Investigative T46465 DRUGINFO D06QBK KNI-10763 Investigative T46465 DRUGINFO D07NFJ PS-444035 Investigative T46465 DRUGINFO D08FQX KNI-10526 Investigative T46465 DRUGINFO D08IXO KNI-10232 Investigative T46465 DRUGINFO D08SCG PS-222036 Investigative T46465 DRUGINFO D08XLM PS-725074 Investigative T46465 DRUGINFO D09DNT KNI-10061 Investigative T46465 DRUGINFO D09XFQ KNI-10125 Investigative T46465 DRUGINFO D0A5AT KNI-10079 Investigative T46465 DRUGINFO D0D5GN KNI-10314 Investigative T46465 DRUGINFO D0E6JX KNI-10088 Investigative T46465 DRUGINFO D0E7XR KNI-10283 Investigative T46465 DRUGINFO D0F8OH KNI-10260 Investigative T46465 DRUGINFO D0G0JA KNI-10255 Investigative T46465 DRUGINFO D0G1AF KNI-10155 Investigative T46465 DRUGINFO D0G6SP KNI-10529 Investigative T46465 DRUGINFO D0H1ZT KNI-10216 Investigative T46465 DRUGINFO D0H6LQ KNI-10266 Investigative T46465 DRUGINFO D0H6UX KNI-10762 Investigative T46465 DRUGINFO D0IM5H KNI-10541 Investigative T46465 DRUGINFO D0J4NN KNI-10742 Investigative T46465 DRUGINFO D0JI2X PS-154636-1 Investigative T46465 DRUGINFO D0JV0F KNI-10106 Investigative T46465 DRUGINFO D0K4WS KNI-10152 Investigative T46465 DRUGINFO D0M4JP KNI-10759 Investigative T46465 DRUGINFO D0M9UG KNI-10368 Investigative T46465 DRUGINFO D0N9ON KNI-10092 Investigative T46465 DRUGINFO D0O0EA KNI-10087 Investigative T46465 DRUGINFO D0O1JH KNI-727 Investigative T46465 DRUGINFO D0O2YF KNI-10315 Investigative T46465 DRUGINFO D0O8JQ KNI-10256 Investigative T46465 DRUGINFO D0P1MT KNI-10743 Investigative T46465 DRUGINFO D0PW4M KNI-10741 Investigative T46465 DRUGINFO D0Q9EB KNI-227 Investigative T46465 DRUGINFO D0R0ZC KNI-10539 Investigative T46465 DRUGINFO D0S4BV N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl) Investigative T46465 DRUGINFO D0T3KK KNI-10093 Investigative T46465 DRUGINFO D0UX4C KNI-10316 Investigative T46465 DRUGINFO D0V2ER KNI-10080 Investigative T46465 DRUGINFO D0X2CX KNI-10062 Investigative T46465 DRUGINFO D0XU6H KNI-10372 Investigative T46465 DRUGINFO D0Y1VG KNI-10369 Investigative T46465 DRUGINFO D0YL4X KNI-10341 Investigative T46465 DRUGINFO D0Z3GC KNI-10760 Investigative T46465 DRUGINFO D0Z5MR KNI-10527 Investigative T46465 DRUGINFO D0ZU3S PS-777621 Investigative T46465 DRUGINFO D0S3BO KNI-10006 Investigative T46465 DRUGINFO D08KCA Leupeptin Investigative T46465 DRUGINFO D09FGQ E-64 Investigative T77613 TARGETID T77613 T77613 FORMERID TTDI02454 T77613 UNIPROID PDE1B_HUMAN T77613 TARGNAME Phosphodiesterase 1B (PDE1B) T77613 GENENAME PDE1B T77613 TARGTYPE Patented-recorded T77613 SYNONYMS PDES1B; PDE1B1; CamPDE 1B; Cam-PDE 1B; Calcium/calmodulindependent 3',5'cyclicnucleotide phosphodiesterase 1B; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; 63 kDa CamPDE; 63 kDa Cam-PDE T77613 FUNCTION Has a preference for cGMP as a substrate. Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. T77613 PDBSTRUC 5W6E; 5UP0; 5UOY; 5B25; 4NPW T77613 BIOCLASS Phosphoric diester hydrolase T77613 ECNUMBER EC 3.1.4.17 T77613 SEQUENCE MELSPRSPPEMLEESDCPSPLELKSAPSKKMWIKLRSLLRYMVKQLENGEINIEELKKNLEYTASLLEAVYIDETRQILDTEDELQELRSDAVPSEVRDWLASTFTQQARAKGRRAEEKPKFRSIVHAVQAGIFVERMFRRTYTSVGPTYSTAVLNCLKNLDLWCFDVFSLNQAADDHALRTIVFELLTRHNLISRFKIPTVFLMSFLDALETGYGKYKNPYHNQIHAADVTQTVHCFLLRTGMVHCLSEIELLAIIFAAAIHDYEHTGTTNSFHIQTKSECAIVYNDRSVLENHHISSVFRLMQDDEMNIFINLTKDEFVELRALVIEMVLATDMSCHFQQVKTMKTALQQLERIDKPKALSLLLHAADISHPTKQWLVHSRWTKALMEEFFRQGDKEAELGLPFSPLCDRTSTLVAQSQIGFIDFIVEPTFSVLTDVAEKSVQPLADEDSKSKNQPSFQWRQPSLDVEVGDPNPDVVSFRSTWVKRIQENKQKWKERAASGITNQMSIDELSPCEEEAPPSPAEDEHNQNGNLD T77613 DRUGINFO D00LVD US10034861, Example 165 Patented T77613 DRUGINFO D03GTM US10092575, Example 101 Patented T77613 DRUGINFO D06WJK US10034861, Example 164 Patented T77613 DRUGINFO D0A0ZU AC1MOZOL Patented T77613 DRUGINFO D0E9JC US9073936, 1 Patented T77613 DRUGINFO D0HO1Q US9073936, 2 Patented T77613 DRUGINFO D0J1LK US10092575, Example 158 Patented T77613 DRUGINFO D0NI7A AC1LDDOQ Patented T77613 DRUGINFO D0V8ZY US10034861, Example 1 Patented T77613 DRUGINFO D0WS3T US10092575, Example 141 Patented T77613 DRUGINFO D0Z1CK US9073936, 3 Patented T77613 DRUGINFO D01BZR IC-041 Investigative T77613 DRUGINFO D02VHD SCH51866 Investigative T63220 TARGETID T63220 T63220 FORMERID TTDI02471 T63220 UNIPROID ACK1_HUMAN T63220 TARGNAME Activated CDC42 kinase 1 (ACK-1) T63220 GENENAME TNK2 T63220 TARGTYPE Patented-recorded T63220 SYNONYMS Tyrosine kinase non-receptor protein 2; ACK1; ACK-1 T63220 FUNCTION Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin. Binds to both poly- and mono-ubiquitin and regulates ligand-induced degradation of EGFR, thereby contributing to the accumulation of EGFR at the limiting membrane of early endosomes. Downstream effector of CDC42 which mediates CDC42-dependent cell migration via phosphorylation of BCAR1. May be involved both in adult synaptic function and plasticity and in brain development. Activates AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' and 'Tyr-363' thereby promoting its recruitment to androgen-responsive enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates MCF2, thereby enhancing its activity as a guanine nucleotide exchange factor (GEF) toward Rho family proteins. Contributes to the control of AXL receptor levels. Confers metastatic properties on cancer cells and promotes tumor growth by negatively regulating tumor suppressor such as WWOX and positively regulating pro-survival factors such as AKT1 and AR. Phosphorylates WASP. T63220 PDBSTRUC 5ZXB; 4ID7; 4HZS; 4HZR; 4EWH T63220 BIOCLASS Kinase T63220 ECNUMBER EC 2.7.10.2 T63220 SEQUENCE MQPEEGTGWLLELLSEVQLQQYFLRLRDDLNVTRLSHFEYVKNEDLEKIGMGRPGQRRLWEAVKRRKALCKRKSWMSKVFSGKRLEAEFPPHHSQSTFRKTSPAPGGPAGEGPLQSLTCLIGEKDLRLLEKLGDGSFGVVRRGEWDAPSGKTVSVAVKCLKPDVLSQPEAMDDFIREVNAMHSLDHRNLIRLYGVVLTPPMKMVTELAPLGSLLDRLRKHQGHFLLGTLSRYAVQVAEGMGYLESKRFIHRDLAARNLLLATRDLVKIGDFGLMRALPQNDDHYVMQEHRKVPFAWCAPESLKTRTFSHASDTWMFGVTLWEMFTYGQEPWIGLNGSQILHKIDKEGERLPRPEDCPQDIYNVMVQCWAHKPEDRPTFVALRDFLLEAQPTDMRALQDFEEPDKLHIQMNDVITVIEGRAENYWWRGQNTRTLCVGPFPRNVVTSVAGLSAQDISQPLQNSFIHTGHGDSDPRHCWGFPDRIDELYLGNPMDPPDLLSVELSTSRPPQHLGGVKKPTYDPVSEDQDPLSSDFKRLGLRKPGLPRGLWLAKPSARVPGTKASRGSGAEVTLIDFGEEPVVPALRPCAPSLAQLAMDACSLLDETPPQSPTRALPRPLHPTPVVDWDARPLPPPPAYDDVAQDEDDFEICSINSTLVGAGVPAGPSQGQTNYAFVPEQARPPPPLEDNLFLPPQGGGKPPSSAQTAEIFQALQQECMRQLQAPAGSPAPSPSPGGDDKPQVPPRVPIPPRPTRPHVQLSPAPPGEEETSQWPGPASPPRVPPREPLSPQGSRTPSPLVPPGSSPLPPRLSSSPGKTMPTTQSFASDPKYATPQVIQAPGPRAGPCILPIVRDGKKVSSTHYYLLPERPSYLERYQRFLREAQSPEEPTPLPVPLLLPPPSTPAPAAPTATVRPMPQAALDPKANFSTNNSNPGARPPPPRATARLPQRGCPGDGPEAGRPADKIQMAMVHGVTTEECQAALQCHGWSVQRAAQYLKVEQLFGLGLRPRGECHKVLEMFDWNLEQAGCHLLGSWGPAHHKR T63220 DRUGINFO D04SWX BDBM50379214 Patented T63220 DRUGINFO D0PX1D US8481733, 95 Patented T63220 DRUGINFO D0SZ3I US8481733, 106 Patented T63220 DRUGINFO D0T9JA US8481733, 118 Patented T63220 DRUGINFO D0D5KZ PMID17280833C30 Investigative T52297 TARGETID T52297 T52297 FORMERID TTDR00420 T52297 UNIPROID NR1H3_HUMAN T52297 TARGNAME Oxysterols receptor LXR-alpha (NR1H3) T52297 GENENAME NR1H3 T52297 TARGTYPE Patented-recorded T52297 SYNONYMS Nuclear receptor subfamily 1 group H member 3; Nuclear receptor LXRalpha; Nuclear orphan receptor LXR-alpha; Liver X receptor alpha; LXRalpha; LXRA T52297 FUNCTION Interaction with retinoic acid receptor (RXR) shifts RXR from its role as a silent DNA-binding partner to an active ligand-binding subunit in mediating retinoid responses through target genes defined by LXRES. LXRES are DR4-type response elements characterized by direct repeats of two similar hexanuclotide half-sites spaced by four nucleotides. Plays an important role in the regulation of cholesterol homeostasis, regulating cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8. Interplays functionally with RORA for the regulation of genes involved in liver metabolism. Nuclear receptor that exhibits a ligand-dependent transcriptional activation activity. T52297 PDBSTRUC 5HJS; 5AVL; 5AVI; 3IPU; 3IPS T52297 BIOCLASS Nuclear hormone receptor T52297 SEQUENCE MSLWLGAPVPDIPPDSAVELWKPGAQDASSQAQGGSSCILREEARMPHSAGGTAGVGLEAAEPTALLTRAEPPSEPTEIRPQKRKKGPAPKMLGNELCSVCGDKASGFHYNVLSCEGCKGFFRRSVIKGAHYICHSGGHCPMDTYMRRKCQECRLRKCRQAGMREECVLSEEQIRLKKLKRQEEEQAHATSLPPRASSPPQILPQLSPEQLGMIEKLVAAQQQCNRRSFSDRLRVTPWPMAPDPHSREARQQRFAHFTELAIVSVQEIVDFAKQLPGFLQLSREDQIALLKTSAIEVMLLETSRRYNPGSESITFLKDFSYNREDFAKAGLQVEFINPIFEFSRAMNELQLNDAEFALLIAISIFSADRPNVQDQLQVERLQHTYVEALHAYVSIHHPHDRLMFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE T52297 DRUGINFO D03UAE US9073931, E2 Patented T52297 DRUGINFO D04XII BDBM50177019 Patented T52297 DRUGINFO D07QIZ US9006244, E2b Patented T52297 DRUGINFO D07QYV US9073931, E1 Patented T52297 DRUGINFO D0K8GC US9006244, E1 Patented T52297 DRUGINFO D0TG1V BDBM50177012 Patented T52297 DRUGINFO D0U2EG US9006244, E2a Patented T52297 DRUGINFO D0W1XE 67S Patented T52297 DRUGINFO D0Y7ZA US9073931, E3 Patented T52297 DRUGINFO D07OBG 5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione Investigative T52297 DRUGINFO D07XLQ N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide Investigative T52297 DRUGINFO D09VLE 4,12,17-dehydroxyriccardin C Investigative T52297 DRUGINFO D0D8FE Guttiferone I Investigative T52297 DRUGINFO D0L1CX N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide Investigative T52297 DRUGINFO D0U4TN 2-(2-hexylphenyl)isoindoline-1,3-dione Investigative T52297 DRUGINFO D0X2HK N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide Investigative T52297 DRUGINFO D0X5DT 2-(2-phenethylphenyl)isoindoline-1,3-dione Investigative T52297 DRUGINFO D00DLU GSK-9772 Investigative T52297 DRUGINFO D00HVP Riccardin C Investigative T52297 DRUGINFO D01HDD 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione Investigative T52297 DRUGINFO D03YUL AZ12260493 Investigative T52297 DRUGINFO D06VRA 4,17-dehydroxyriccardin C Investigative T52297 DRUGINFO D08URT 24(S)-hydroxycholesterol Investigative T52297 DRUGINFO D09UND 12,17-dehydroxyriccardin C Investigative T52297 DRUGINFO D0A1WR SR9238 Investigative T52297 DRUGINFO D0C2CY WAY-254011 Investigative T52297 DRUGINFO D0C6QI acetyl-podocarpic dimer Investigative T52297 DRUGINFO D0HA0U 12-dehydroxyriccardin C Investigative T52297 DRUGINFO D0IZ9O 4-dehydroxyriccardin C Investigative T52297 DRUGINFO D0PL4F GW-3965 Investigative T52297 DRUGINFO D0Q2RP 24(S), 25-epoxycholesterol Investigative T52297 DRUGINFO D0R8LN N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide Investigative T52297 DRUGINFO D0V4WT paxilline Investigative T52297 DRUGINFO D0Z3TJ GSK2033 Investigative T52297 DRUGINFO D0Z8LE 17-dehydroxyriccardin C Investigative T52297 DRUGINFO D0Z8RH 2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole Investigative T52297 DRUGINFO D01RNA desmosterol Investigative T52297 DRUGINFO D0H2YM 27-hydroxycholesterol Investigative T52297 DRUGINFO D0K4GK 22R-hydroxycholesterol Investigative T52297 DRUGINFO D08QXD L-783483 Investigative T52297 DRUGINFO D0V4RZ WAY-214950 Investigative T13616 TARGETID T13616 T13616 FORMERID TTDR00485 T13616 UNIPROID ILK_HUMAN T13616 TARGNAME Integrin-linked protein kinase 1 (ILK) T13616 GENENAME ILK T13616 TARGTYPE Patented-recorded T13616 SYNONYMS P59ILK; Integrin-linked protein kinase; Integrin-linked kinase; ILK2; ILK1; ILK-2; ILK-1; Beta-integrin-linked kinase; 59 kDa serine/threonine-protein kinase; 59 kDa serine/threonine protein kinase T13616 FUNCTION May act as a mediator of inside-out integrin signaling. Focal adhesion protein part of the complex ILK-PINCH. This complex is considered to be one of the convergence points of integrin- and growth factor-signaling pathway. Could be implicated in mediating cell architecture, adhesion to integrin substrates and anchorage-dependent growth in epithelial cells. Phosphorylates beta-1 and beta-3 integrin subunit on serine and threonine residues, but also AKT1 and GSK3B. Receptor-proximal protein kinase regulating integrin-mediated signal transduction. T13616 PDBSTRUC 6MIB; 4HI9; 4HI8; 3REP; 3KMW T13616 BIOCLASS Kinase T13616 ECNUMBER EC 2.7.11.1 T13616 SEQUENCE MDDIFTQCREGNAVAVRLWLDNTENDLNQGDDHGFSPLHWACREGRSAVVEMLIMRGARINVMNRGDDTPLHLAASHGHRDIVQKLLQYKADINAVNEHGNVPLHYACFWGQDQVAEDLVANGALVSICNKYGEMPVDKAKAPLRELLRERAEKMGQNLNRIPYKDTFWKGTTRTRPRNGTLNKHSGIDFKQLNFLTKLNENHSGELWKGRWQGNDIVVKVLKVRDWSTRKSRDFNEECPRLRIFSHPNVLPVLGACQSPPAPHPTLITHWMPYGSLYNVLHEGTNFVVDQSQAVKFALDMARGMAFLHTLEPLIPRHALNSRSVMIDEDMTARISMADVKFSFQCPGRMYAPAWVAPEALQKKPEDTNRRSADMWSFAVLLWELVTREVPFADLSNMEIGMKVALEGLRPTIPPGISPHVCKLMKICMNEDPAKRPKFDMIVPILEKMQDK T13616 DRUGINFO D09CNM US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine Patented T13616 DRUGINFO D0FL7J US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine Patented T13616 DRUGINFO D0Q7KI US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide Patented T13616 DRUGINFO D01CTM PMID21823616C22 Investigative T13616 DRUGINFO D09VFU MST-400 Investigative T83904 TARGETID T83904 T83904 FORMERID TTDNC00633 T83904 UNIPROID SIR2_HUMAN T83904 TARGNAME NAD-dependent deacetylase sirtuin-2 (SIRT2) T83904 GENENAME SIRT2 T83904 TARGTYPE Patented-recorded T83904 SYNONYMS SIR2like protein 2; SIR2L2; SIR2L; SIR2-like protein 2; Regulatory protein SIR2 homolog 2; NADdependent protein deacetylase sirtuin2; NAD-dependent protein deacetylase sirtuin-2 T83904 FUNCTION Participates in the modulation of multiple and diverse biological processes such as cell cycle control, genomic integrity, microtubule dynamics, cell differentiation, metabolic networks, and autophagy. Plays a major role in the control of cell cycle progression and genomic stability. Functions in the antephase checkpoint preventing precocious mitotic entry in response to microtubule stress agents, and hence allowing proper inheritance of chromosomes. Positively regulates the anaphase promoting complex/cyclosome (APC/C) ubiquitin ligase complex activity by deacetylating CDC20 and FZR1, then allowing progression through mitosis. Associates both with chromatin at transcriptional start sites (TSSs) and enhancers of active genes. Plays a role in cell cycle and chromatin compaction through epigenetic modulation of the regulation of histone H4 'Lys-20' methylation (H4K20me1) during early mitosis. Specifically deacetylates histone H4 at 'Lys-16' (H4K16ac) between the G2/M transition and metaphase enabling H4K20me1 deposition by KMT5A leading to ulterior levels of H4K20me2 and H4K20me3 deposition throughout cell cycle, and mitotic S-phase progression. Deacetylates KMT5A modulating KMT5A chromatin localization during the mitotic stress response. Deacetylates also histone H3 at 'Lys-57' (H3K56ac) during the mitotic G2/M transition. Upon bacterium Listeria monocytogenes infection, deacetylates 'Lys-18' of histone H3 in a receptor tyrosine kinase MET- and PI3K/Akt-dependent manner, thereby inhibiting transcriptional activity and promoting late stages of listeria infection. During oocyte meiosis progression, may deacetylate histone H4 at 'Lys-16' (H4K16ac) and alpha-tubulin, regulating spindle assembly and chromosome alignment by influencing microtubule dynamics and kinetochore function. Deacetylates histone H4 at 'Lys-16' (H4K16ac) at the VEGFA promoter and thereby contributes to regulate expression of VEGFA, a key regulator of angiogenesis. Deacetylates alpha-tubulin at 'Lys-40' and hence controls neuronal motility, oligodendroglial cell arbor projection processes and proliferation of non-neuronal cells. Phosphorylation at Ser-368 by a G1/S-specific cyclin E-CDK2 complex inactivates SIRT2-mediated alpha-tubulin deacetylation, negatively regulating cell adhesion, cell migration and neurite outgrowth during neuronal differentiation. Deacetylates PARD3 and participates in the regulation of Schwann cell peripheral myelination formation during early postnatal development and during postinjury remyelination. Involved in several cellular metabolic pathways. Plays a role in the regulation of blood glucose homeostasis by deacetylating and stabilizing phosphoenolpyruvate carboxykinase PCK1 activity in response to low nutrient availability. Acts as a key regulator in the pentose phosphate pathway (PPP) by deacetylating and activating the glucose-6-phosphate G6PD enzyme, and therefore, stimulates the production of cytosolic NADPH to counteract oxidative damage. Maintains energy homeostasis in response to nutrient deprivation as well as energy expenditure by inhibiting adipogenesis and promoting lipolysis. Attenuates adipocyte differentiation by deacetylating and promoting FOXO1 interaction to PPARG and subsequent repression of PPARG-dependent transcriptional activity. Plays a role in the regulation of lysosome-mediated degradation of protein aggregates by autophagy in neuronal cells. Deacetylates FOXO1 in response to oxidative stress or serum deprivation, thereby negatively regulating FOXO1-mediated autophagy. Deacetylates a broad range of transcription factors and co-regulators regulating target gene expression. Deacetylates transcriptional factor FOXO3 stimulating the ubiquitin ligase SCF(SKP2)-mediated FOXO3 ubiquitination and degradation. Deacetylates HIF1A and therefore promotes HIF1A degradation and inhibition of HIF1A transcriptional activity in tumor cells in response to hypoxia. Deacetylates RELA in the cytoplasm inhibiting NF-kappaB-dependent transcription activation upon TNF-alpha stimulation. Inhibits transcriptional activation by deacetylating p53/TP53 and EP300. Deacetylates also EIF5A. Functions as a negative regulator on oxidative stress-tolerance in response to anoxia-reoxygenation conditions. Plays a role as tumor suppressor. NAD-dependent protein deacetylase, which deacetylates internal lysines on histone and alpha-tubulin as well as many other proteins such as key transcription factors. T83904 PDBSTRUC 5YQO; 5YQN; 5YQM; 5YQL; 5Y5N T83904 BIOCLASS Carbon-nitrogen hydrolase T83904 ECNUMBER EC 3.5.1.- T83904 SEQUENCE MAEPDPSHPLETQAGKVQEAQDSDSDSEGGAAGGEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQSGAGVPNPSTSASPKKSPPPAKDEARTTEREKPQ T83904 DRUGINFO D00RNS BDBM50363780 Patented T83904 DRUGINFO D07NKC BDBM50363782 Patented T83904 DRUGINFO D07YHN AC1LFGWU Patented T83904 DRUGINFO D0F6NT ZINC915379 Patented T83904 DRUGINFO D0MW0K US9359293, TM Patented T83904 DRUGINFO D0PL1I US9359293, TA Patented T83904 DRUGINFO D0V2UZ BDBM50363773 Patented T83904 DRUGINFO D0X9SE US9359293, TB Patented T83904 DRUGINFO D0Y1WA AC1LOJYQ Patented T83904 DRUGINFO D0E3NT AGK2 Investigative T83904 DRUGINFO D0IR8J INDUS-815C Investigative T32880 TARGETID T32880 T32880 FORMERID TTDI02433 T32880 UNIPROID EGLN1_HUMAN T32880 TARGNAME HIF-prolyl hydroxylase 2 (HPH-2) T32880 GENENAME EGLN1 T32880 TARGTYPE Patented-recorded T32880 SYNONYMS SM-20; Prolyl hydroxylase domain-containing protein 2; PHD2; Hypoxia-inducible factor prolyl hydroxylase 2; HPH-2; HIF-PH2; Egl nine homolog 1; C1orf12 T32880 FUNCTION Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF1B. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN1 is the most important isozyme under normoxia and, through regulating the stability of HIF1, involved in various hypoxia-influenced processes such as angiogenesis in retinal and cardiac functionality. Target proteins are preferentially recognized via a LXXLAP motif. T32880 PDBSTRUC 6NMQ; 5V18; 5OX6; 5OX5; 5LBF T32880 BIOCLASS Paired donor oxygen oxidoreductase T32880 ECNUMBER EC 1.14.11.29 T32880 SEQUENCE MANDSGGPGGPSPSERDRQYCELCGKMENLLRCSRCRSSFYCCKEHQRQDWKKHKLVCQGSEGALGHGVGPHQHSGPAPPAAVPPPRAGAREPRKAAARRDNASGDAAKGKVKAKPPADPAAAASPCRAAAGGQGSAVAAEAEPGKEEPPARSSLFQEKANLYPPSNTPGDALSPGGGLRPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF T32880 DRUGINFO D03YKE FG-4592 Phase 3 T32880 DRUGINFO D00CAO US9422240, 1-298 Patented T32880 DRUGINFO D00ECX US8598210, Table XV, 2 Patented T32880 DRUGINFO D00IKR US8536181, A41 Patented T32880 DRUGINFO D00XHH US8598210, Table XV, 5 Patented T32880 DRUGINFO D01PPR US8536181, C17 Patented T32880 DRUGINFO D01XZT US8598210, Table XV, 4 Patented T32880 DRUGINFO D02IRO US8921389, 210 Patented T32880 DRUGINFO D03PGC US8536181, C35 Patented T32880 DRUGINFO D04BTN US10100051, Compound 2 Patented T32880 DRUGINFO D04YMG US8921389, 2 Patented T32880 DRUGINFO D05EHX US9422240, 1-282 Patented T32880 DRUGINFO D05FDR US10100051, Compound 1 Patented T32880 DRUGINFO D05TTX US10100051, Compound 10 Patented T32880 DRUGINFO D0D8AV US9340511, 2 Patented T32880 DRUGINFO D0F0DX US10149841, Compound 19 Patented T32880 DRUGINFO D0HN5O US8536181, C14 Patented T32880 DRUGINFO D0I4PX US8921389, 22 Patented T32880 DRUGINFO D0JR2Q US10149841, Compound 1 Patented T32880 DRUGINFO D0K5UR US9422240, 1-297 Patented T32880 DRUGINFO D0L9XU US9422240, 1-286 Patented T32880 DRUGINFO D0LO2C US9340511, 5 Patented T32880 DRUGINFO D0MS5W US9340511, 6 Patented T32880 DRUGINFO D0OR4X US10149841, Compound 5 Patented T32880 DRUGINFO D0Q9AF US8598210, Table XV, 1 Patented T32880 DRUGINFO D0QI0J US10149841, Compound 9 Patented T32880 DRUGINFO D0R4CX US9409892, 59 Patented T32880 DRUGINFO D0SM8Z US9409892, 148 Patented T32880 DRUGINFO D0V6AZ US9340511, 7 Patented T32880 DRUGINFO D0V9WU US9409892, 19 Patented T32880 DRUGINFO D0VI2M US10100051, Compound 11 Patented T32880 DRUGINFO D0VK5C US9409892, 136 Patented T32880 DRUGINFO D0Y3NI US8921389, 123 Patented T32880 DRUGINFO D0YY5J US8921389, 1 Patented T32880 DRUGINFO D09SXR KRH-102053 Investigative T32880 DRUGINFO D0WA3E IOX2 Investigative T32880 DRUGINFO D0X5US IOX1 Investigative T59654 TARGETID T59654 T59654 FORMERID TTDI02482 T59654 UNIPROID PLK2_HUMAN T59654 TARGNAME Polo-like kinase 2 (PLK2) T59654 GENENAME PLK2 T59654 TARGTYPE Patented-recorded T59654 SYNONYMS hSNK; hPlk2; Serum-inducible kinase; Serine/threonine-protein kinase SNK; Serine/threonine-protein kinase PLK2; SNK; PLK-2 T59654 FUNCTION Polo-like kinases act by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates CENPJ, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and SYNGAP1. Plays a key role in synaptic plasticity and memory by regulating the Ras and Rap protein signaling: required for overactivity-dependent spine remodeling by phosphorylating the Ras activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their degradation by the proteasome. Conversely, phosphorylates the Rap activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their activity. Also regulates synaptic plasticity independently of kinase activity, via its interaction with NSF that disrupts the interaction between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown of AMPAR-mediated current that occludes long term depression. Required for procentriole formation and centriole duplication by phosphorylating CENPJ and NPM1, respectively. Its induction by p53/TP53 suggests that it may participate in the mitotic checkpoint following stress. Tumor suppressor serine/threonine-protein kinase involved in synaptic plasticity, centriole duplication and G1/S phase transition. T59654 PDBSTRUC 4XB0; 4RS6; 4I6H; 4I6F; 4I6B T59654 BIOCLASS Kinase T59654 ECNUMBER EC 2.7.11.21 T59654 SEQUENCE MELLRTITYQPAASTKMCEQALGKGCGADSKKKRPPQPPEESQPPQSQAQVPPAAPHHHHHHSHSGPEISRIIVDPTTGKRYCRGKVLGKGGFAKCYEMTDLTNNKVYAAKIIPHSRVAKPHQREKIDKEIELHRILHHKHVVQFYHYFEDKENIYILLEYCSRRSMAHILKARKVLTEPEVRYYLRQIVSGLKYLHEQEILHRDLKLGNFFINEAMELKVGDFGLAARLEPLEHRRRTICGTPNYLSPEVLNKQGHGCESDIWALGCVMYTMLLGRPPFETTNLKETYRCIREARYTMPSSLLAPAKHLIASMLSKNPEDRPSLDDIIRHDFFLQGFTPDRLSSSCCHTVPDFHLSSPAKNFFKKAAAALFGGKKDKARYIDTHNRVSKEDEDIYKLRHDLKKTSITQQPSKHRTDEELQPPTTTVARSGTPAVENKQQIGDAIRMIVRGTLGSCSSSSECLEDSTMGSVADTVARVLRGCLENMPEADCIPKEQLSTSFQWVTKWVDYSNKYGFGYQLSDHTVGVLFNNGAHMSLLPDKKTVHYYAELGQCSVFPATDAPEQFISQVTVLKYFSHYMEENLMDGGDLPSVTDIRRPRLYLLQWLKSDKALMMLFNDGTFQVNFYHDHTKIIICSQNEEYLLTYINEDRISTTFRLTTLLMSGCSSELKNRMEYALNMLLQRCN T59654 DRUGINFO D0IQ6R US8598172, 1 Patented T59654 DRUGINFO D02IZN ON-123 Investigative T09672 TARGETID T09672 T09672 FORMERID TTDR01407 T09672 UNIPROID PTN13_HUMAN T09672 TARGNAME FAP-1 messenger RNA (PTPN13 mRNA) T09672 GENENAME PTPN13 T09672 TARGTYPE Patented-recorded T09672 SYNONYMS hPTPE1 (mRNA); Tyrosine-protein phosphatase non-receptor type 13 (mRNA); Protein-tyrosine phosphatase PTPL1 (mRNA); Protein-tyrosine phosphatase 1E (mRNA); PTPL1 (mRNA); PTP1E (mRNA); PTP-E1 (mRNA); PTP-BAS (mRNA); PNP1 (mRNA); Fas-associated protein-tyrosine phosphatase 1 (mRNA); FAP-1 (mRNA) T09672 FUNCTION May regulate phosphoinositide 3-kinase (PI3K) signaling through dephosphorylation of PIK3R2. Tyrosine phosphatase which regulates negatively FAS-induced apoptosis and NGFR-mediated pro-apoptotic signaling. T09672 PDBSTRUC 5GLJ; 3PDZ; 3LNY; 3LNX; 2M10 T09672 BIOCLASS mRNA target T09672 ECNUMBER EC 3.1.3.48 T09672 SEQUENCE MHVSLAEALEVRGGPLQEEEIWAVLNQSAESLQELFRKVSLADPAALGFIISPWSLLLLPSGSVSFTDENISNQDLRAFTAPEVLQNQSLTSLSDVEKIHIYSLGMTLYWGADYEVPQSQPIKLGDHLNSILLGMCEDVIYARVSVRTVLDACSAHIRNSNCAPSFSYVKHLVKLVLGNLSGTDQLSCNSEQKPDRSQAIRDRLRGKGLPTGRSSTSDVLDIQKPPLSHQTFLNKGLSKSMGFLSIKDTQDENYFKDILSDNSGREDSENTFSPYQFKTSGPEKKPIPGIDVLSKKKIWASSMDLLCTADRDFSSGETATYRRCHPEAVTVRTSTTPRKKEARYSDGSIALDIFGPQKMDPIYHTRELPTSSAISSALDRIRERQKKLQVLREAMNVEEPVRRYKTYHGDVFSTSSESPSIISSESDFRQVRRSEASKRFESSSGLPGVDETLSQGQSQRPSRQYETPFEGNLINQEIMLKRQEEELMQLQAKMALRQSRLSLYPGDTIKASMLDITRDPLREIALETAMTQRKLRNFFGPEFVKMTIEPFISLDLPRSILTKKGKNEDNRRKVNIMLLNGQRLELTCDTKTICKDVFDMVVAHIGLVEHHLFALATLKDNEYFFVDPDLKLTKVAPEGWKEEPKKKTKATVNFTLFFRIKFFMDDVSLIQHTLTCHQYYLQLRKDILEERMHCDDETSLLLASLALQAEYGDYQPEVHGVSYFRMEHYLPARVMEKLDLSYIKEELPKLHNTYVGASEKETELEFLKVCQRLTEYGVHFHRVHPEKKSQTGILLGVCSKGVLVFEVHNGVRTLVLRFPWRETKKISFSKKKITLQNTSDGIKHGFQTDNSKICQYLLHLCSYQHKFQLQMRARQSNQDAQDIERASFRSLNLQAESVRGFNMGRAISTGSLASSTLNKLAVRPLSVQAEILKRLSCSELSLYQPLQNSSKEKNDKASWEEKPREMSKSYHDLSQASLYPHRKNVIVNMEPPPQTVAELVGKPSHQMSRSDAESLAGVTKLNNSKSVASLNRSPERRKHESDSSSIEDPGQAYVLGMTMHSSGNSSSQVPLKENDVLHKRWSIVSSPEREITLVNLKKDAKYGLGFQIIGGEKMGRLDLGIFISSVAPGGPADLDGCLKPGDRLISVNSVSLEGVSHHAAIEILQNAPEDVTLVISQPKEKISKVPSTPVHLTNEMKNYMKKSSYMQDSAIDSSSKDHHWSRGTLRHISENSFGPSGGLREGSLSSQDSRTESASLSQSQVNGFFASHLGDQTWQESQHGSPSPSVISKATEKETFTDSNQSKTKKPGISDVTDYSDRGDSDMDEATYSSSQDHQTPKQESSSSVNTSNKMNFKTFSSSPPKPGDIFEVELAKNDNSLGISVTGGVNTSVRHGGIYVKAVIPQGAAESDGRIHKGDRVLAVNGVSLEGATHKQAVETLRNTGQVVHLLLEKGQSPTSKEHVPVTPQCTLSDQNAQGQGPEKVKKTTQVKDYSFVTEENTFEVKLFKNSSGLGFSFSREDNLIPEQINASIVRVKKLFPGQPAAESGKIDVGDVILKVNGASLKGLSQQEVISALRGTAPEVFLLLCRPPPGVLPEIDTALLTPLQSPAQVLPNSSKDSSQPSCVEQSTSSDENEMSDKSKKQCKSPSRRDSYSDSSGSGEDDLVTAPANISNSTWSSALHQTLSNMVSQAQSHHEAPKSQEDTICTMFYYPQKIPNKPEFEDSNPSPLPPDMAPGQSYQPQSESASSSSMDKYHIHHISEPTRQENWTPLKNDLENHLEDFELEVELLITLIKSEKGSLGFTVTKGNQRIGCYVHDVIQDPAKSDGRLKPGDRLIKVNDTDVTNMTHTDAVNLLRAASKTVRLVIGRVLELPRIPMLPHLLPDITLTCNKEELGFSLCGGHDSLYQVVYISDINPRSVAAIEGNLQLLDVIHYVNGVSTQGMTLEEVNRALDMSLPSLVLKATRNDLPVVPSSKRSAVSAPKSTKGNGSYSVGSCSQPALTPNDSFSTVAGEEINEISYPKGKCSTYQIKGSPNLTLPKESYIQEDDIYDDSQEAEVIQSLLDVVDEEAQNLLNENNAAGYSCGPGTLKMNGKLSEERTEDTDCDGSPLPEYFTEATKMNGCEEYCEEKVKSESLIQKPQEKKTDDDEITWGNDELPIERTNHEDSDKDHSFLTNDELAVLPVVKVLPSGKYTGANLKSVIRVLRGLLDQGIPSKELENLQELKPLDQCLIGQTKENRRKNRYKNILPYDATRVPLGDEGGYINASFIKIPVGKEEFVYIACQGPLPTTVGDFWQMIWEQKSTVIAMMTQEVEGEKIKCQRYWPNILGKTTMVSNRLRLALVRMQQLKGFVVRAMTLEDIQTREVRHISHLNFTAWPDHDTPSQPDDLLTFISYMRHIHRSGPIITHCSAGIGRSGTLICIDVVLGLISQDLDFDISDLVRCMRLQRHGMVQTEDQYIFCYQVILYVLTRLQAEEEQKQQPQLLK T09672 DRUGINFO D0CW5D US9217012, 10 Patented T09672 DRUGINFO D09VLX ISIS 18473 Investigative T20953 TARGETID T20953 T20953 FORMERID TTDI03066 T20953 UNIPROID BUB1_HUMAN T20953 TARGNAME BUB1 mitotic checkpoint serine/threonine kinase (BUB1) T20953 GENENAME BUB1 T20953 TARGTYPE Patented-recorded T20953 SYNONYMS hBUB1; Mitotic checkpoint serine/threonine-protein kinase BUB1; BUB1L; BUB1A T20953 FUNCTION Has a key role in the assembly of checkpoint proteins at the kinetochore, being required for the subsequent localization of CENPF, BUB1B, CENPE and MAD2L1. Required for the kinetochore localization of PLK1. Required for centromeric enrichment of AUKRB in prometaphase. Plays an important role in defining SGO1 localization and thereby affects sister chromatid cohesion. Acts as a substrate for anaphase-promoting complex or cyclosome (APC/C) in complex with its activator CDH1 (APC/C-Cdh1). Necessary for ensuring proper chromosome segregation and binding to BUB3 is essential for this function. Can regulate chromosome segregation in a kinetochore-independent manner. Can phosphorylate BUB3. The BUB1-BUB3 complex plays a role in the inhibition of APC/C when spindle-assembly checkpoint is activated and inhibits the ubiquitin ligase activity of APC/C by phosphorylating its activator CDC20. This complex can also phosphorylate MAD1L1. Kinase activity is essential for inhibition of APC/CCDC20 and for chromosome alignment but does not play a major role in the spindle-assembly checkpoint activity. Mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. Serine/threonine-protein kinase that performs 2 crucial functions during mitosis: it is essential for spindle-assembly checkpoint signaling and for correct chromosome alignment. T20953 PDBSTRUC 6F7B; 5DMZ; 4R8Q; 4QPM; 4A1G T20953 BIOCLASS Kinase T20953 ECNUMBER EC 2.7.11.1 T20953 SEQUENCE MDTPENVLQMLEAHMQSYKGNDPLGEWERYIQWVEENFPENKEYLITLLEHLMKEFLDKKKYHNDPRFISYCLKFAEYNSDLHQFFEFLYNHGIGTLSSPLYIAWAGHLEAQGELQHASAVLQRGIQNQAEPREFLQQQYRLFQTRLTETHLPAQARTSEPLHNVQVLNQMITSKSNPGNNMACISKNQGSELSGVISSACDKESNMERRVITISKSEYSVHSSLASKVDVEQVVMYCKEKLIRGESEFSFEELRAQKYNQRRKHEQWVNEDRHYMKRKEANAFEEQLLKQKMDELHKKLHQVVETSHEDLPASQERSEVNPARMGPSVGSQQELRAPCLPVTYQQTPVNMEKNPREAPPVVPPLANAISAALVSPATSQSIAPPVPLKAQTVTDSMFAVASKDAGCVNKSTHEFKPQSGAEIKEGCETHKVANTSSFHTTPNTSLGMVQATPSKVQPSPTVHTKEALGFIMNMFQAPTLPDISDDKDEWQSLDQNEDAFEAQFQKNVRSSGAWGVNKIISSLSSAFHVFEDGNKENYGLPQPKNKPTGARTFGERSVSRLPSKPKEEVPHAEEFLDDSTVWGIRCNKTLAPSPKSPGDFTSAAQLASTPFHKLPVESVHILEDKENVVAKQCTQATLDSCEENMVVPSRDGKFSPIQEKSPKQALSSHMYSASLLRLSQPAAGGVLTCEAELGVEACRLTDTDAAIAEDPPDAIAGLQAEWMQMSSLGTVDAPNFIVGNPWDDKLIFKLLSGLSKPVSSYPNTFEWQCKLPAIKPKTEFQLGSKLVYVHHLLGEGAFAQVYEATQGDLNDAKNKQKFVLKVQKPANPWEFYIGTQLMERLKPSMQHMFMKFYSAHLFQNGSVLVGELYSYGTLLNAINLYKNTPEKVMPQGLVISFAMRMLYMIEQVHDCEIIHGDIKPDNFILGNGFLEQDDEDDLSAGLALIDLGQSIDMKLFPKGTIFTAKCETSGFQCVEMLSNKPWNYQIDYFGVAATVYCMLFGTYMKVKNEGGECKPEGLFRRLPHLDMWNEFFHVMLNIPDCHHLPSLDLLRQKLKKVFQQHYTNKIRALRNRLIVLLLECKRSRK T20953 DRUGINFO D01EUT SCHEMBL16322760 Patented T20953 DRUGINFO D03RBY SCHEMBL17766424 Patented T20953 DRUGINFO D0I3PZ SCHEMBL16365841 Patented T20953 DRUGINFO D09BXA PMID24900824C2-1-1 Investigative T20953 DRUGINFO D0F9DD PMID24900824C2-13-1 Investigative T20953 DRUGINFO D0JP7S PMID24900824C2-3-1 Investigative T20953 DRUGINFO D0P4YY PMID24900824C2-3-2 Investigative T05904 TARGETID T05904 T05904 FORMERID TTDR01310 T05904 UNIPROID PDE8A_HUMAN T05904 TARGNAME Phosphodiesterase 8 (PDE8) T05904 GENENAME PDE8A T05904 TARGTYPE Patented-recorded T05904 SYNONYMS High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A T05904 FUNCTION May be involved in maintaining basal levels of the cyclic nucleotide and/or in the cAMP regulation of germ cell development. Binding to RAF1 reduces RAF1 'Ser-259' inhibitory-phosphorylation and stimulates RAF1-dependent EGF-activated ERK-signaling. Protects against cell death induced by hydrogen peroxide and staurosporine. Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. T05904 PDBSTRUC 3ECN; 3ECM; 1LXX; 1LHQ T05904 BIOCLASS Phosphoric diester hydrolase T05904 ECNUMBER EC 3.1.4.53 T05904 SEQUENCE MGCAPSIHISERLVAEDAPSPAAPPLSSGGPRLPQGQKTAALPRTRGAGLLESELRDGSGKKVAVADVQFGPMRFHQDQLQVLLVFTKEDNQCNGFCRACEKAGFKCTVTKEAQAVLACFLDKHHDIIIIDHRNPRQLDAEALCRSIRSSKLSENTVIVGVVRRVDREELSVMPFISAGFTRRYVENPNIMACYNELLQLEFGEVRSQLKLRACNSVFTALENSEDAIEITSEDRFIQYANPAFETTMGYQSGELIGKELGEVPINEKKADLLDTINSCIRIGKEWQGIYYAKKKNGDNIQQNVKIIPVIGQGGKIRHYVSIIRVCNGNNKAEKISECVQSDTHTDNQTGKHKDRRKGSLDVKAVASRATEVSSQRRHSSMARIHSMTIEAPITKVINIINAAQESSPMPVTEALDRVLEILRTTELYSPQFGAKDDDPHANDLVGGLMSDGLRRLSGNEYVLSTKNTQMVSSNIITPISLDDVPPRIARAMENEEYWDFDIFELEAATHNRPLIYLGLKMFARFGICEFLHCSESTLRSWLQIIEANYHSSNPYHNSTHSADVLHATAYFLSKERIKETLDPIDEVAALIAATIHDVDHPGRTNSFLCNAGSELAILYNDTAVLESHHAALAFQLTTGDDKCNIFKNMERNDYRTLRQGIIDMVLATEMTKHFEHVNKFVNSINKPLATLEENGETDKNQEVINTMLRTPENRTLIKRMLIKCADVSNPCRPLQYCIEWAARISEEYFSQTDEEKQQGLPVVMPVFDRNTCSIPKSQISFIDYFITDMFDAWDAFVDLPDLMQHLDNNFKYWKGLDEMKLRNLRPPPE T05904 DRUGINFO D05SRL US8846654, 294 Patented T05904 DRUGINFO D0A5JS US8846654, 251 Patented T05904 DRUGINFO D0EF6R US8846654, 11 Patented T05904 DRUGINFO D0EN2M US9493447, 1001 Patented T05904 DRUGINFO D0SH7F BC11-28 Patented T05904 DRUGINFO D0Z7YQ AC1M1SP5 Patented T05904 DRUGINFO D04TZA PF-04957325 Investigative T05904 DRUGINFO D0TE9G PF-4957325-00 Investigative T50224 TARGETID T50224 T50224 FORMERID TTDI03521 T50224 UNIPROID KS6A5_HUMAN T50224 TARGNAME Ribosomal protein S6 kinase alpha-5 (RSK5) T50224 GENENAME RPS6KA5 T50224 TARGTYPE Patented-recorded T50224 SYNONYMS S6K-alpha-5; RSKL; RSK-like protein kinase; Nuclear mitogen- and stress-activated protein kinase 1; MSK1; 90 kDa ribosomal protein S6 kinase 5 T50224 FUNCTION Phosphorylates CREB1 and ATF1 in response to mitogenic or stress stimuli such as UV-C irradiation, epidermal growth factor (EGF) and anisomycin. Plays an essential role in the control of RELA transcriptional activity in response to TNF and upon glucocorticoid, associates in the cytoplasm with the glucocorticoid receptor NR3C1 and contributes to RELA inhibition and repression of inflammatory gene expression. In skeletal myoblasts is required for phosphorylation of RELA at 'Ser-276' during oxidative stress. In erythropoietin-stimulated cells, is necessary for the 'Ser-727' phosphorylation of STAT3 and regulation of its transcriptional potential. Phosphorylates ETV1/ER81 at 'Ser-191' and 'Ser-216', and thereby regulates its ability to stimulate transcription, which may be important during development and breast tumor formation. Directly represses transcription via phosphorylation of 'Ser-1' of histone H2A. Phosphorylates 'Ser-10' of histone H3 in response to mitogenics, stress stimuli and EGF, which results in the transcriptional activation of several immediate early genes, including proto-oncogenes c-fos/FOS and c-jun/JUN. May also phosphorylate 'Ser-28' of histone H3. Mediates the mitogen- and stress-induced phosphorylation of high mobility group protein 1 (HMGN1/HMG14). In lipopolysaccharide-stimulated primary macrophages, acts downstream of the Toll-like receptor TLR4 to limit the production of pro-inflammatory cytokines. Functions probably by inducing transcription of the MAP kinase phosphatase DUSP1 and the anti-inflammatory cytokine interleukin 10 (IL10), via CREB1 and ATF1 transcription factors. Plays a role in neuronal cell death by mediating the downstream effects of excitotoxic injury. Phosphorylates TRIM7 at 'Ser-107' in response to growth factor signaling via the MEK/ERK pathway, thereby stimulating its ubiquitin ligase activity. Serine/threonine-protein kinase that is required for the mitogen or stress-induced phosphorylation of the transcription factors CREB1 and ATF1 and for the regulation of the transcription factors RELA, STAT3 and ETV1/ER81, and that contributes to gene activation by histone phosphorylation and functions in the regulation of inflammatory genes. T50224 PDBSTRUC 3KN6; 3KN5; 1VZO T50224 BIOCLASS Kinase T50224 ECNUMBER EC 2.7.11.1 T50224 SEQUENCE MEEEGGSSGGAAGTSADGGDGGEQLLTVKHELRTANLTGHAEKVGIENFELLKVLGTGAYGKVFLVRKISGHDTGKLYAMKVLKKATIVQKAKTTEHTRTERQVLEHIRQSPFLVTLHYAFQTETKLHLILDYINGGELFTHLSQRERFTEHEVQIYVGEIVLALEHLHKLGIIYRDIKLENILLDSNGHVVLTDFGLSKEFVADETERAYSFCGTIEYMAPDIVRGGDSGHDKAVDWWSLGVLMYELLTGASPFTVDGEKNSQAEISRRILKSEPPYPQEMSALAKDLIQRLLMKDPKKRLGCGPRDADEIKEHLFFQKINWDDLAAKKVPAPFKPVIRDELDVSNFAEEFTEMDPTYSPAALPQSSEKLFQGYSFVAPSILFKRNAAVIDPLQFHMGVERPGVTNVARSAMMKDSPFYQHYDLDLKDKPLGEGSFSICRKCVHKKSNQAFAVKIISKRMEANTQKEITALKLCEGHPNIVKLHEVFHDQLHTFLVMELLNGGELFERIKKKKHFSETEASYIMRKLVSAVSHMHDVGVVHRDLKPENLLFTDENDNLEIKIIDFGFARLKPPDNQPLKTPCFTLHYAAPELLNQNGYDESCDLWSLGVILYTMLSGQVPFQSHDRSLTCTSAVEIMKKIKKGDFSFEGEAWKNVSQEAKDLIQGLLTVDPNKRLKMSGLRYNEWLQDGSQLSSNPLMTPDILGSSGAAVHTCVKATFHAFNKYKREGFCLQNVDKAPLAKRRKMKKTSTSTETRSSSSESSHSSSSHSHGKTTPTKTLQPSNPADSNNPETLFQFSDSVA T50224 DRUGINFO D0Y3AM US9365572, 5 Patented T50224 DRUGINFO D05GSF PMID15955699C24 Investigative T31406 TARGETID T31406 T31406 FORMERID TTDI03254 T31406 UNIPROID HCK_HUMAN T31406 TARGNAME Hematopoietic cell kinase (HCK) T31406 GENENAME HCK T31406 TARGTYPE Patented-recorded T31406 SYNONYMS p61Hck; p59Hck; p59-HCK/p60-HCK; Tyrosine-protein kinase HCK; Hemopoietic cell kinase T31406 FUNCTION Acts downstream of receptors that bind the Fc region of immunoglobulins, such as FCGR1A and FCGR2A, but also CSF3R, PLAUR, the receptors for IFNG, IL2, IL6 and IL8, and integrins, such as ITGB1 and ITGB2. During the phagocytic process, mediates mobilization of secretory lysosomes, degranulation, and activation of NADPH oxidase to bring about the respiratory burst. Plays a role in the release of inflammatory molecules. Promotes reorganization of the actin cytoskeleton and actin polymerization, formation of podosomes and cell protrusions. Inhibits TP73-mediated transcription activation and TP73-mediated apoptosis. Phosphorylates CBL in response to activation of immunoglobulin gamma Fc region receptors. Phosphorylates ADAM15, BCR, ELMO1, FCGR2A, GAB1, GAB2, RAPGEF1, STAT5B, TP73, VAV1 and WAS. Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, including neutrophil, monocyte, macrophage and mast cell functions, phagocytosis, cell survival and proliferation, cell adhesion and migration. T31406 PDBSTRUC 5ZJ6; 5NUH; 5HCK; 5H0H; 5H0G T31406 BIOCLASS Kinase T31406 ECNUMBER EC 2.7.10.2 T31406 SEQUENCE MGGRSSCEDPGCPRDEERAPRMGCMKSKFLQVGGNTFSKTETSASPHCPVYVPDPTSTIKPGPNSHNSNTPGIREAGSEDIIVVALYDYEAIHHEDLSFQKGDQMVVLEESGEWWKARSLATRKEGYIPSNYVARVDSLETEEWFFKGISRKDAERQLLAPGNMLGSFMIRDSETTKGSYSLSVRDYDPRQGDTVKHYKIRTLDNGGFYISPRSTFSTLQELVDHYKKGNDGLCQKLSVPCMSSKPQKPWEKDAWEIPRESLKLEKKLGAGQFGEVWMATYNKHTKVAVKTMKPGSMSVEAFLAEANVMKTLQHDKLVKLHAVVTKEPIYIITEFMAKGSLLDFLKSDEGSKQPLPKLIDFSAQIAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGSFTIKSDVWSFGILLMEIVTYGRIPYPGMSNPEVIRALERGYRMPRPENCPEELYNIMMRCWKNRPEERPTFEYIQSVLDDFYTATESQYQQQP T31406 DRUGINFO D04XHJ BK3 Patented T31406 DRUGINFO D05CDF Doramapimod Patented T31406 DRUGINFO D07FAF 3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine Patented T31406 DRUGINFO D07PDQ Unii-I92MU0V408 Patented T31406 DRUGINFO D0B7VP US8933228, 3 Patented T31406 DRUGINFO D0D5PL SB19065 Patented T31406 DRUGINFO D0H0SM US9108950, 1 Patented T31406 DRUGINFO D0Y4TK US8933228, Ref 2 Patented T31406 DRUGINFO D0Y9PK BK7 Patented T31406 DRUGINFO D08RZB PMID15546730C2 Investigative T31406 DRUGINFO D03EHM PP121 Investigative T40488 TARGETID T40488 T40488 FORMERID TTDI03388 T40488 UNIPROID MMP10_HUMAN T40488 TARGNAME Matrix metalloproteinase-10 (MMP-10) T40488 GENENAME MMP10 T40488 TARGTYPE Patented-recorded T40488 SYNONYMS Transin-2; Stromelysin-2; STMY2; SL-2 T40488 FUNCTION Activates procollagenase. Can degrade fibronectin, gelatins of type I, III, IV, and V; weakly collagens III, IV, and V. T40488 PDBSTRUC 4ILW; 3V96; 1Q3A T40488 BIOCLASS Peptidase T40488 ECNUMBER EC 3.4.24.22 T40488 SEQUENCE MMHLAFLVLLCLPVCSAYPLSGAAKEEDSNKDLAQQYLEKYYNLEKDVKQFRRKDSNLIVKKIQGMQKFLGLEVTGKLDTDTLEVMRKPRCGVPDVGHFSSFPGMPKWRKTHLTYRIVNYTPDLPRDAVDSAIEKALKVWEEVTPLTFSRLYEGEADIMISFAVKEHGDFYSFDGPGHSLAHAYPPGPGLYGDIHFDDDEKWTEDASGTNLFLVAAHELGHSLGLFHSANTEALMYPLYNSFTELAQFRLSQDDVNGIQSLYGPPPASTEEPLVPTKSVPSGSEMPAKCDPALSFDAISTLRGEYLFFKDRYFWRRSHWNPEPEFHLISAFWPSLPSYLDAAYEVNSRDTVFIFKGNEFWAIRGNEVQAGYPRGIHTLGFPPTIRKIDAAVSDKEKKKTYFFAADKYWRFDENSQSMEQGFPRLIADDFPGVEPKVDAVLQAFGFFYFFSGSSQFEFDPNARMVTHILKSNSWLHC T40488 DRUGINFO D09GMS EEA Patented T40488 DRUGINFO D0KZ0M 3ts4 Patented T40488 DRUGINFO D0MK8L EEC Patented T40488 DRUGINFO D0OR6O CM-352 Investigative T88126 TARGETID T88126 T88126 FORMERID TTDR00348 T88126 UNIPROID NADD_ECOLI T88126 TARGNAME Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD) T88126 GENENAME Bact nadD T88126 TARGTYPE Patented-recorded T88126 SYNONYMS nadD of Escherichia coli (strain K12); Nicotinate mononucleotide adenylyltransferase of Escherichia coli (strain K12); NaMN adenylyltransferase of Escherichia coli (strain K12); Deamido-NAD(+)Nicotinate-nucleotide adenylyltransferase pyrophosphorylase of Escherichia coli (strain K12); Deamido-NAD(+) pyrophosphorylase of Escherichia coli (strain K12); Deamido-NAD(+) diphosphorylase of Escherichia coli (strain K12) T88126 FUNCTION Catalyzes the reversible adenylation of nicotinate mononucleotide (namn) to nicotinic acid adenine dinucleotide (naad). T88126 PDBSTRUC 1K4M; 1K4K T88126 BIOCLASS Kinase T88126 ECNUMBER EC 2.7.7.18 T88126 SEQUENCE MKSLQALFGGTFDPVHYGHLKPVETLANLIGLTRVTIIPNNVPPHRPQPEANSVQRKHMLELAIADKPLFTLDERELKRNAPSYTAQTLKEWRQEQGPDVPLAFIIGQDSLLTFPTWYEYETILDNAHLIVCRRPGYPLEMAQPQYQQWLEDHLTHNPEDLHLQPAGKIYLAETPWFNISATIIRERLQNGESCEDLLPEPVLTYINQQGLYR T88126 DRUGINFO D0A0BS DZ9 Patented T88126 DRUGINFO D0ND9W AC1LJNG0 Patented T88126 DRUGINFO D0UF5V STK696827 Patented T88126 DRUGINFO D0Y6LK Deamido-NAD Investigative T88126 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T36725 TARGETID T36725 T36725 FORMERID TTDI03076 T36725 UNIPROID CBPB1_HUMAN T36725 TARGNAME Carboxypeptidase B1 (CPB1) T36725 GENENAME CPB1 T36725 TARGTYPE Patented-recorded T36725 SYNONYMS Pancreas-specific protein; PASP; Carboxypeptidase B; CPB T36725 FUNCTION A carboxypeptidase that preferentially acts upon basic amino acids, such as arginine and lysine. Responsible for rapidly metabolizing the C5a protein into C5a des-Arg, with one less amino acid. T36725 PDBSTRUC 1ZLI; 1KWM T36725 BIOCLASS Peptidase T36725 ECNUMBER EC 3.4.17.2 T36725 SEQUENCE MLALLVLVTVALASAHHGGEHFEGEKVFRVNVEDENHINIIRELASTTQIDFWKPDSVTQIKPHSTVDFRVKAEDTVTVENVLKQNELQYKVLISNLRNVVEAQFDSRVRATGHSYEKYNKWETIEAWTQQVATENPALISRSVIGTTFEGRAIYLLKVGKAGQNKPAIFMDCGFHAREWISPAFCQWFVREAVRTYGREIQVTELLDKLDFYVLPVLNIDGYIYTWTKSRFWRKTRSTHTGSSCIGTDPNRNFDAGWCEIGASRNPCDETYCGPAAESEKETKALADFIRNKLSSIKAYLTIHSYSQMMIYPYSYAYKLGENNAELNALAKATVKELASLHGTKYTYGPGATTIYPAAGGSDDWAYDQGIRYSFTFELRDTGRYGFLLPESQIRATCEETFLAIKYVASYVLEHLY T36725 DRUGINFO D01OFO US8710232, 8 Patented T36725 DRUGINFO D01XTB US8710232, 1 Patented T36725 DRUGINFO D0YI7A US8710232, 7 Patented T36725 DRUGINFO D0O3QJ PMID19954973C4 Investigative T36725 DRUGINFO D0XA0N PMID14640538C3 Investigative T80526 TARGETID T80526 T80526 FORMERID TTDI03086 T80526 UNIPROID CSK22_HUMAN T80526 TARGNAME Casein kinase II alpha prime (CSNK2A2) T80526 GENENAME CSNK2A2 T80526 TARGTYPE Patented-recorded T80526 SYNONYMS Casein kinase II subunit alpha'; CK2A2; CK II alpha' T80526 FUNCTION Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV. Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. T80526 PDBSTRUC 6QY9; 6HMQ; 6HMD; 6HMC; 6HMB T80526 BIOCLASS Kinase T80526 ECNUMBER EC 2.7.11.1 T80526 SEQUENCE MPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGNQDDYQLVRKLGRGKYSEVFEAINITNNERVVVKILKPVKKKKIKREVKILENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNTDFKQLYQILTDFDIRFYMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLAEFYHPAQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRREPFFHGQDNYDQLVRIAKVLGTEELYGYLKKYHIDLDPHFNDILGQHSRKRWENFIHSENRHLVSPEALDLLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQSQPCADNAVLSSGLTAAR T80526 DRUGINFO D01QPX US8940736, 6 Patented T80526 DRUGINFO D0D2CR US8940736, 23 Patented T80526 DRUGINFO D0E7ZS US8791257, 38 Patented T80526 DRUGINFO D0H6DS US8791257, 4 Patented T80526 DRUGINFO D0NM6I US8791257, 17 Patented T80526 DRUGINFO D0XY1Z US8940736, 7 Patented T80526 DRUGINFO D0K6BI PMID22115617C2c Investigative T28052 TARGETID T28052 T28052 FORMERID TTDNR00703 T28052 UNIPROID KDM5A_HUMAN T28052 TARGNAME Lysine-specific demethylase 5A (KDM5A) T28052 GENENAME KDM5A T28052 TARGTYPE Patented-recorded T28052 SYNONYMS Retinoblastoma-binding protein 2; RBP2; RBBP2; RBBP-2; Jumonji/ARID domain-containing protein 1A; JARID1A; Histone demethylase JARID1A T28052 FUNCTION Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Regulates specific gene transcription through DNA-binding on 5'-CCGCCC-3' motif. May stimulate transcription mediated by nuclear receptors. Involved in transcriptional regulation of Hox proteins during cell differentiation. May participate in transcriptional repression of cytokines such as CXCL12. Plays a role in the regulation of the circadian rhythm and in maintaining the normal periodicity of the circadian clock. In a histone demethylase-independent manner, acts as a coactivator of the CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER1/2 and other clock-controlled genes and increases histone acetylation at PER1/2 promoters by inhibiting the activity of HDAC1. Seems to act as a transcriptional corepressor for some genes such as MT1F and to favor the proliferation of cancer cells. Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. T28052 PDBSTRUC 6DQB; 6DQA; 6DQ9; 6DQ8; 6DQ6 T28052 BIOCLASS Paired donor oxygen oxidoreductase T28052 ECNUMBER EC 1.14.11.- T28052 SEQUENCE MAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRLDFLDQLAKFWELQGSTLKIPVVERKILDLYALSKIVASKGGFEMVTKEKKWSKVGSRLGYLPGKGTGSLLKSHYERILYPYELFQSGVSLMGVQMPNLDLKEKVEPEVLSTDTQTSPEPGTRMNILPKRTRRVKTQSESGDVSRNTELKKLQIFGAGPKVVGLAMGTKDKEDEVTRRRKVTNRSDAFNMQMRQRKGTLSVNFVDLYVCMFCGRGNNEDKLLLCDGCDDSYHTFCLIPPLPDVPKGDWRCPKCVAEECSKPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCTADWLPIGRQCVNHYRRLRRHCVFSHEELIFKMAADPECLDVGLAAMVCKELTLMTEEETRLRESVVQMGVLMSEEEVFELVPDDERQCSACRTTCFLSALTCSCNPERLVCLYHPTDLCPCPMQKKCLRYRYPLEDLPSLLYGVKVRAQSYDTWVSRVTEALSANFNHKKDLIELRVMLEDAEDRKYPENDLFRKLRDAVKEAETCASVAQLLLSKKQKHRQSPDSGRTRTKLTVEELKAFVQQLFSLPCVISQARQVKNLLDDVEEFHERAQEAMMDETPDSSKLQMLIDMGSSLYVELPELPRLKQELQQARWLDEVRLTLSDPQQVTLDVMKKLIDSGVGLAPHHAVEKAMAELQELLTVSERWEEKAKVCLQARPRHSVASLESIVNEAKNIPAFLPNVLSLKEALQKAREWTAKVEAIQSGSNYAYLEQLESLSAKGRPIPVRLEALPQVESQVAAARAWRERTGRTFLKKNSSHTLLQVLSPRTDIGVYGSGKNRRKKVKELIEKEKEKDLDLEPLSDLEEGLEETRDTAMVVAVFKEREQKEIEAMHSLRAANLAKMTMVDRIEEVKFCICRKTASGFMLQCELCKDWFHNSCVPLPKSSSQKKGSSWQAKEVKFLCPLCMRSRRPRLETILSLLVSLQKLPVRLPEGEALQCLTERAMSWQDRARQALATDELSSALAKLSVLSQRMVEQAAREKTEKIISAELQKAAANPDLQGHLPSFQQSAFNRVVSSVSSSPRQTMDYDDEETDSDEDIRETYGYDMKDTASVKSSSSLEPNLFCDEEIPIKSEEVVTHMWTAPSFCAEHAYSSASKSCSQGSSTPRKQPRKSPLVPRSLEPPVLELSPGAKAQLEELMMVGDLLEVSLDETQHIWRILQATHPPSEDRFLHIMEDDSMEEKPLKVKGKDSSEKKRKRKLEKVEQLFGEGKQKSKELKKMDKPRKKKLKLGADKSKELNKLAKKLAKEEERKKKKEKAAAAKVELVKESTEKKREKKVLDIPSKYDWSGAEESDDENAVCAAQNCQRPCKDKVDWVQCDGGCDEWFHQVCVGVSPEMAENEDYICINCAKKQGPVSPGPAPPPSFIMSYKLPMEDLKETS T28052 DRUGINFO D00SUC 6EP Patented T28052 DRUGINFO D01WHH BDBM50158803 Patented T28052 DRUGINFO D03POM US10022354, Example 151 Patented T28052 DRUGINFO D03TKM US9714230, 12 Patented T28052 DRUGINFO D05CCY BDBM50158791 Patented T28052 DRUGINFO D06TKT US10040779, Example 4 Patented T28052 DRUGINFO D09CWB US9611221, Example 9 Patented T28052 DRUGINFO D0F3TL US9714230, 46 Patented T28052 DRUGINFO D0G8QR BDBM50158794 Patented T28052 DRUGINFO D0GH8J BDBM50158703 Patented T28052 DRUGINFO D0HT9Q AKOS020330656 Patented T28052 DRUGINFO D0K4LW BDBM50158755 Patented T28052 DRUGINFO D0N9JZ US10174026, Example 99 Patented T28052 DRUGINFO D0NG8M AKOS020330481 Patented T28052 DRUGINFO D0NM3B US10022354, Example 5 Patented T28052 DRUGINFO D0PQ5P NCGC00381656-01 Patented T28052 DRUGINFO D0R2GT US10174026, Example 2 Patented T28052 DRUGINFO D0T8YT US10022354, Example 152 Patented T28052 DRUGINFO D0VZ5E US10040779, Example 1 Patented T28052 DRUGINFO D0ZJ0Z 1190312-92-5 Patented T28052 DRUGINFO D0IQ7Y PBIT Investigative T08741 TARGETID T08741 T08741 FORMERID TTDI03125 T08741 UNIPROID CSK_HUMAN T08741 TARGNAME Tyrosine-protein kinase CSK (CSK) T08741 GENENAME CSK T08741 TARGTYPE Patented-recorded T08741 SYNONYMS Protein-tyrosine kinase CYL; C-Src kinase T08741 FUNCTION Phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs) including LCK, SRC, HCK, FYN, LYN, CSK or YES1. Upon tail phosphorylation, Src-family members engage in intramolecular interactions between the phosphotyrosine tail and the SH2 domain that result in an inactive conformation. To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. Suppresses signaling by various surface receptors, including T-cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating and maintaining inactive several positive effectors such as FYN or LCK. Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response. T08741 PDBSTRUC 3EAZ; 3EAC; 3D7U; 3D7T; 1CSK T08741 BIOCLASS Kinase T08741 ECNUMBER EC 2.7.10.2 T08741 SEQUENCE MSAIQAAWPSGTECIAKYNFHGTAEQDLPFCKGDVLTIVAVTKDPNWYKAKNKVGREGIIPANYVQKREGVKAGTKLSLMPWFHGKITREQAERLLYPPETGLFLVRESTNYPGDYTLCVSCDGKVEHYRIMYHASKLSIDEEVYFENLMQLVEHYTSDADGLCTRLIKPKVMEGTVAAQDEFYRSGWALNMKELKLLQTIGKGEFGDVMLGDYRGNKVAVKCIKNDATAQAFLAEASVMTQLRHSNLVQLLGVIVEEKGGLYIVTEYMAKGSLVDYLRSRGRSVLGGDCLLKFSLDVCEAMEYLEGNNFVHRDLAARNVLVSEDNVAKVSDFGLTKEASSTQDTGKLPVKWTAPEALREKKFSTKSDVWSFGILLWEIYSFGRVPYPRIPLKDVVPRVEKGYKMDAPDGCPPAVYEVMKNCWHLDAAMRPSFLQLREQLEHIKTHELHL T08741 DRUGINFO D02DJP 936563-93-8 Patented T08741 DRUGINFO D0X7IC NG-25 Investigative T99990 TARGETID T99990 T99990 FORMERID TTDI03055 T99990 UNIPROID BMX_HUMAN T99990 TARGNAME Tyrosine-protein kinase BMX (BMX) T99990 GENENAME BMX T99990 TARGTYPE Patented-recorded T99990 SYNONYMS NTK38; Epithelial and endothelial tyrosine kinase; ETK; Cytoplasmic tyrosine-protein kinase BMX; Bone marrow tyrosine kinase gene in chromosome X protein T99990 FUNCTION Non-receptor tyrosine kinase that plays central but diverse modulatory roles in various signaling processes involved in the regulation of actin reorganization, cell migration, cell proliferation and survival, cell adhesion, and apoptosis. Participates in signal transduction stimulated by growth factor receptors, cytokine receptors, G-protein coupled receptors, antigen receptors and integrins. Induces tyrosine phosphorylation of BCAR1 in response to integrin regulation. Activation of BMX by integrins is mediated by PTK2/FAK1, a key mediator of integrin signaling events leading to the regulation of actin cytoskeleton and cell motility. Plays a critical role in TNF-induced angiogenesis, and implicated in the signaling of TEK and FLT1 receptors, 2 important receptor families essential for angiogenesis. Required for the phosphorylation and activation of STAT3, a transcription factor involved in cell differentiation. Also involved in interleukin-6 (IL6) induced differentiation. Plays also a role in programming adaptive cytoprotection against extracellular stress in different cell systems, salivary epithelial cells, brain endothelial cells, and dermal fibroblasts. May be involved in regulation of endocytosis through its interaction with an endosomal protein RUFY1. May also play a role in the growth and differentiation of hematopoietic cells; as well as in signal transduction in endocardial and arterial endothelial cells. T99990 PDBSTRUC 3SXS; 3SXR; 2YS2; 2EKX T99990 BIOCLASS Kinase T99990 ECNUMBER EC 2.7.10.2 T99990 SEQUENCE MDTKSILEELLLKRSQQKKKMSPNNYKERLFVLTKTNLSYYEYDKMKRGSRKGSIEIKKIRCVEKVNLEEQTPVERQYPFQIVYKDGLLYVYASNEESRSQWLKALQKEIRGNPHLLVKYHSGFFVDGKFLCCQQSCKAAPGCTLWEAYANLHTAVNEEKHRVPTFPDRVLKIPRAVPVLKMDAPSSSTTLAQYDNESKKNYGSQPPSSSTSLAQYDSNSKKIYGSQPNFNMQYIPREDFPDWWQVRKLKSSSSSEDVASSNQKERNVNHTTSKISWEFPESSSSEEEENLDDYDWFAGNISRSQSEQLLRQKGKEGAFMVRNSSQVGMYTVSLFSKAVNDKKGTVKHYHVHTNAENKLYLAENYCFDSIPKLIHYHQHNSAGMITRLRHPVSTKANKVPDSVSLGNGIWELKREEITLLKELGSGQFGVVQLGKWKGQYDVAVKMIKEGSMSEDEFFQEAQTMMKLSHPKLVKFYGVCSKEYPIYIVTEYISNGCLLNYLRSHGKGLEPSQLLEMCYDVCEGMAFLESHQFIHRDLAARNCLVDRDLCVKVSDFGMTRYVLDDQYVSSVGTKFPVKWSAPEVFHYFKYSSKSDVWAFGILMWEVFSLGKQPYDLYDNSQVVLKVSQGHRLYRPHLASDTIYQIMYSCWHELPEKRPTFQQLLSSIEPLREKDKH T99990 DRUGINFO D01RHR PMID24915291C31 Investigative T99990 DRUGINFO D06BJG PMID24915291C38 Investigative T75772 TARGETID T75772 T75772 FORMERID TTDNR00667 T75772 UNIPROID ENTK_HUMAN T75772 TARGNAME Enteropeptidase (TMPRSS15) T75772 GENENAME TMPRSS15 T75772 TARGTYPE Patented-recorded T75772 SYNONYMS Transmembrane protease serine 15; TMPRSS15; Serine protease 7; Enterokinase T75772 FUNCTION Responsible for initiating activation of pancreatic proteolytic proenzymes (trypsin, chymotrypsin and carboxypeptidase A). It catalyzes the conversion of trypsinogen to trypsin which in turn activates other proenzymes including chymotrypsinogen, procarboxypeptidases, and proelastases. T75772 PDBSTRUC 4DGJ T75772 BIOCLASS Peptidase T75772 ECNUMBER EC 3.4.21.9 T75772 SEQUENCE MGSKRGISSRHHSLSSYEIMFAALFAILVVLCAGLIAVSCLTIKESQRGAALGQSHEARATFKITSGVTYNPNLQDKLSVDFKVLAFDLQQMIDEIFLSSNLKNEYKNSRVLQFENGSIIVVFDLFFAQWVSDENVKEELIQGLEANKSSQLVTFHIDLNSVDILDKLTTTSHLATPGNVSIECLPGSSPCTDALTCIKADLFCDGEVNCPDGSDEDNKMCATVCDGRFLLTGSSGSFQATHYPKPSETSVVCQWIIRVNQGLSIKLSFDDFNTYYTDILDIYEGVGSSKILRASIWETNPGTIRIFSNQVTATFLIESDESDYVGFNATYTAFNSSELNNYEKINCNFEDGFCFWVQDLNDDNEWERIQGSTFSPFTGPNFDHTFGNASGFYISTPTGPGGRQERVGLLSLPLDPTLEPACLSFWYHMYGENVHKLSINISNDQNMEKTVFQKEGNYGDNWNYGQVTLNETVKFKVAFNAFKNKILSDIALDDISLTYGICNGSLYPEPTLVPTPPPELPTDCGGPFELWEPNTTFSSTNFPNSYPNLAFCVWILNAQKGKNIQLHFQEFDLENINDVVEIRDGEEADSLLLAVYTGPGPVKDVFSTTNRMTVLLITNDVLARGGFKANFTTGYHLGIPEPCKADHFQCKNGECVPLVNLCDGHLHCEDGSDEADCVRFFNGTTNNNGLVRFRIQSIWHTACAENWTTQISNDVCQLLGLGSGNSSKPIFPTDGGPFVKLNTAPDGHLILTPSQQCLQDSLIRLQCNHKSCGKKLAAQDITPKIVGGSNAKEGAWPWVVGLYYGGRLLCGASLVSSDWLVSAAHCVYGRNLEPSKWTAILGLHMKSNLTSPQTVPRLIDEIVINPHYNRRRKDNDIAMMHLEFKVNYTDYIQPICLPEENQVFPPGRNCSIAGWGTVVYQGTTANILQEADVPLLSNERCQQQMPEYNITENMICAGYEEGGIDSCQGDSGGPLMCQENNRWFLAGVTSFGYKCALPNRPGVYARVSRFTEWIQSFLH T75772 DRUGINFO D01MPC US9024044, 62 Patented T75772 DRUGINFO D03SHV US9346821, B-42 Patented T75772 DRUGINFO D09KTX US9346821, A-20 Patented T75772 DRUGINFO D09VFP US9346821, B-13 Patented T75772 DRUGINFO D0G2TL US8609715, A-1 Patented T75772 DRUGINFO D0G4ZU US8609715, A-26 Patented T75772 DRUGINFO D0K3IO US9024044, 4 Patented T75772 DRUGINFO D0L8BY US8609715, B-61 Patented T75772 DRUGINFO D0VE7D US9024044, 3 Patented T75772 DRUGINFO D0W6MZ US9024044, 1 Patented T75772 DRUGINFO D0ZN0D US9024044, 2 Patented T09185 TARGETID T09185 T09185 FORMERID TTDI03158 T09185 UNIPROID DDR1_HUMAN T09185 TARGNAME Epithelial discoidin domain receptor 1 (DDR1) T09185 GENENAME DDR1 T09185 TARGTYPE Patented-recorded T09185 SYNONYMS Tyrosine-protein kinase CAK; Tyrosine kinase DDR; TRKE; TRK E; RTK6; Protein-tyrosine kinase RTK-6; Protein-tyrosine kinase 3A; PTK3A; NTRK4; NEP; Mammary carcinoma kinase 10; MCK-10; HGK2; Epithelial discoidin domain-containing receptor 1; EDDR1; Discoidin receptor tyrosine kinase; Cell adhesion kinase; CD167a; CD167 antigen-like family member A T09185 FUNCTION Collagen binding triggers a signaling pathway that involves SRC and leads to the activation of MAP kinases. Regulates remodeling of the extracellular matrix by up-regulation of the matrix metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates cell migration and wound healing. Required for normal blastocyst implantation during pregnancy, for normal mammary gland differentiation and normal lactation. Required for normal ear morphology and normal hearing. Promotes smooth muscle cell migration, and thereby contributes to arterial wound healing. Also plays a role in tumor cell invasion. Phosphorylates PTPN11. Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, differentiation, survival and cell proliferation. T09185 PDBSTRUC 6HP9; 6GWR; 6FIQ; 6FIO; 6FIN T09185 BIOCLASS Kinase T09185 ECNUMBER EC 2.7.10.1 T09185 SEQUENCE MGPEALSSLLLLLLVASGDADMKGHFDPAKCRYALGMQDRTIPDSDISASSSWSDSTAARHSRLESSDGDGAWCPAGSVFPKEEEYLQVDLQRLHLVALVGTQGRHAGGLGKEFSRSYRLRYSRDGRRWMGWKDRWGQEVISGNEDPEGVVLKDLGPPMVARLVRFYPRADRVMSVCLRVELYGCLWRDGLLSYTAPVGQTMYLSEAVYLNDSTYDGHTVGGLQYGGLGQLADGVVGLDDFRKSQELRVWPGYDYVGWSNHSFSSGYVEMEFEFDRLRAFQAMQVHCNNMHTLGARLPGGVECRFRRGPAMAWEGEPMRHNLGGNLGDPRARAVSVPLGGRVARFLQCRFLFAGPWLLFSEISFISDVVNNSSPALGGTFPPAPWWPPGPPPTNFSSLELEPRGQQPVAKAEGSPTAILIGCLVAIILLLLLIIALMLWRLHWRRLLSKAERRVLEEELTVHLSVPGDTILINNRPGPREPPPYQEPRPRGNPPHSAPCVPNGSALLLSNPAYRLLLATYARPPRGPGPPTPAWAKPTNTQAYSGDYMEPEKPGAPLLPPPPQNSVPHYAEADIVTLQGVTGGNTYAVPALPPGAVGDGPPRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPDATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLEDKAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTIKIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLCRAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQLHRFLAEDALNTV T09185 DRUGINFO D00UAQ US9567304, Compound N-9 Patented T09185 DRUGINFO D0BW9L US9156852, 83 Patented T09185 DRUGINFO D0DA4Y US9695118, 8 Patented T09185 DRUGINFO D0GT9T NG7 Patented T09185 DRUGINFO D0H0GL US9567304, Compound F-54 Patented T09185 DRUGINFO D0LL1P VAPBGCRAUJRZPO-UHFFFAOYSA-N Patented T09185 DRUGINFO D0Y3FD BDBM50080408 Patented T09185 DRUGINFO D0ZK5P US9695118, 4 Patented T09185 DRUGINFO D0BL0O PMID23521020C7k Investigative T12081 TARGETID T12081 T12081 FORMERID TTDI03445 T12081 UNIPROID PDE4C_HUMAN T12081 TARGNAME Phosphodiesterase 4C (PDE4C) T12081 GENENAME PDE4C T12081 TARGTYPE Patented-recorded T12081 SYNONYMS cAMP-specific 3',5'-cyclic phosphodiesterase 4C; PDE21; DPDE1 T12081 FUNCTION Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. T12081 PDBSTRUC 2QYM; 1LXU T12081 BIOCLASS Phosphoric diester hydrolase T12081 ECNUMBER EC 3.1.4.53 T12081 SEQUENCE MENLGVGEGAEACSRLSRSRGRHSMTRAPKHLWRQPRRPIRIQQRFYSDPDKSAGCRERDLSPRPELRKSRLSWPVSSCRRFDLENGLSCGRRALDPQSSPGLGRIMQAPVPHSQRRESFLYRSDSDYELSPKAMSRNSSVASDLHGEDMIVTPFAQVLASLRTVRSNVAALARQQCLGAAKQGPVGNPSSSNQLPPAEDTGQKLALETLDELDWCLDQLETLQTRHSVGEMASNKFKRILNRELTHLSETSRSGNQVSEYISRTFLDQQTEVELPKVTAEEAPQPMSRISGLHGLCHSASLSSATVPRFGVQTDQEEQLAKELEDTNKWGLDVFKVAELSGNRPLTAIIFSIFQERDLLKTFQIPADTLATYLLMLEGHYHANVAYHNSLHAADVAQSTHVLLATPALEAVFTDLEILAALFASAIHDVDHPGVSNQFLINTNSELALMYNDASVLENHHLAVGFKLLQAENCDIFQNLSAKQRLSLRRMVIDMVLATDMSKHMNLLADLKTMVETKKVTSLGVLLLDNYSDRIQVLQNLVHCADLSNPTKPLPLYRQWTDRIMAEFFQQGDRERESGLDISPMCDKHTASVEKSQVGFIDYIAHPLWETWADLVHPDAQDLLDTLEDNREWYQSKIPRSPSDLTNPERDGPDRFQFELTLEEAEEEDEEEEEEGEETALAKEALELPDTELLSPEAGPDPGDLPLDNQRT T12081 DRUGINFO D04VJX ZINC584606052 Patented T12081 DRUGINFO D05TQB US10077269, Example 6 Patented T12081 DRUGINFO D0W5OE CS-W011402 Patented T12081 DRUGINFO D0P2HX RS-25344 Investigative T94449 TARGETID T94449 T94449 FORMERID TTDNC00446 T94449 UNIPROID PTPRJ_HUMAN T94449 TARGNAME Protein-tyrosine phosphatase eta (HPTP) T94449 GENENAME PTPRJ T94449 TARGTYPE Patented-recorded T94449 SYNONYMS Receptor-type tyrosine-protein phosphatase eta; R-PTP-eta; R-PTP-J; Protein-tyrosine phosphatase receptor type J; HPTP eta; Density-enhanced phosphatase 1; DEP1; DEP-1; CD148 T94449 FUNCTION Plays a role in cell adhesion, migration, proliferation and differentiation. Involved in vascular development. Regulator of macrophage adhesion and spreading. Positively affects cell-matrix adhesion. Positive regulator of platelet activation and thrombosis. Negative regulator of cell proliferation. Negative regulator of PDGF-stimulated cell migration; through dephosphorylation of PDGFR. Positive regulator of endothelial cell survival, as well as of VEGF-induced SRC and AKT activation; through KDR dephosphorylation. Negative regulator of EGFR signaling pathway; through EGFR dephosphorylation. Enhances the barrier function of epithelial junctions during reassembly. Negatively regulates T-cell receptor (TCR) signaling. Upon T-cell TCR activation, it is up-regulated and excluded from the immunological synapses, while upon T-cell-antigen presenting cells (APC) disengagement, it is no longer excluded and can dephosphorylate PLCG1 and LAT to down-regulate prolongation of signaling. Tyrosine phosphatase which dephosphorylates or contributes to the dephosphorylation of CTNND1, FLT3, PDGFRB, MET, RET (variant MEN2A), KDR, LYN, SRC, MAPK1, MAPK3, EGFR, TJP1, OCLN, PIK3R1 and PIK3R2. T94449 PDBSTRUC 2NZ6; 2DLE; 2CFV T94449 BIOCLASS Phosphoric monoester hydrolase T94449 ECNUMBER EC 3.1.3.48 T94449 SEQUENCE MKPAAREARLPPRSPGLRWALPLLLLLLRLGQILCAGGTPSPIPDPSVATVATGENGITQISSTAESFHKQNGTGTPQVETNTSEDGESSGANDSLRTPEQGSNGTDGASQKTPSSTGPSPVFDIKAVSISPTNVILTWKSNDTAASEYKYVVKHKMENEKTITVVHQPWCNITGLRPATSYVFSITPGIGNETWGDPRVIKVITEPIPVSDLRVALTGVRKAALSWSNGNGTASCRVLLESIGSHEELTQDSRLQVNISGLKPGVQYNINPYLLQSNKTKGDPLGTEGGLDASNTERSRAGSPTAPVHDESLVGPVDPSSGQQSRDTEVLLVGLEPGTRYNATVYSQAANGTEGQPQAIEFRTNAIQVFDVTAVNISATSLTLIWKVSDNESSSNYTYKIHVAGETDSSNLNVSEPRAVIPGLRSSTFYNITVCPVLGDIEGTPGFLQVHTPPVPVSDFRVTVVSTTEIGLAWSSHDAESFQMHITQEGAGNSRVEITTNQSIIIGGLFPGTKYCFEIVPKGPNGTEGASRTVCNRTVPSAVFDIHVVYVTTTEMWLDWKSPDGASEYVYHLVIESKHGSNHTSTYDKAITLQGLIPGTLYNITISPEVDHVWGDPNSTAQYTRPSNVSNIDVSTNTTAATLSWQNFDDASPTYSYCLLIEKAGNSSNATQVVTDIGITDATVTELIPGSSYTVEIFAQVGDGIKSLEPGRKSFCTDPASMASFDCEVVPKEPALVLKWTCPPGANAGFELEVSSGAWNNATHLESCSSENGTEYRTEVTYLNFSTSYNISITTVSCGKMAAPTRNTCTTGITDPPPPDGSPNITSVSHNSVKVKFSGFEASHGPIKAYAVILTTGEAGHPSADVLKYTYEDFKKGASDTYVTYLIRTEEKGRSQSLSEVLKYEIDVGNESTTLGYYNGKLEPLGSYRACVAGFTNITFHPQNKGLIDGAESYVSFSRYSDAVSLPQDPGVICGAVFGCIFGALVIVTVGGFIFWRKKRKDAKNNEVSFSQIKPKKSKLIRVENFEAYFKKQQADSNCGFAEEYEDLKLVGISQPKYAAELAENRGKNRYNNVLPYDISRVKLSVQTHSTDDYINANYMPGYHSKKDFIATQGPLPNTLKDFWRMVWEKNVYAIIMLTKCVEQGRTKCEEYWPSKQAQDYGDITVAMTSEIVLPEWTIRDFTVKNIQTSESHPLRQFHFTSWPDHGVPDTTDLLINFRYLVRDYMKQSPPESPILVHCSAGVGRTGTFIAIDRLIYQIENENTVDVYGIVYDLRMHRPLMVQTEDQYVFLNQCVLDIVRSQKDSKVDLIYQNTTAMTIYENLAPVTTFGKTNGYIA T94449 DRUGINFO D0H6LK US9340574, 7 Patented T11764 TARGETID T11764 T11764 FORMERID TTDNR00661 T11764 UNIPROID DDR2_HUMAN T11764 TARGNAME Discoidin domain-containing receptor 2 (DDR2) T11764 GENENAME DDR2 T11764 TARGTYPE Patented-recorded T11764 SYNONYMS Tyrosine-protein kinase TYRO10; Receptor protein-tyrosine kinase TKT; Neurotrophic tyrosine kinase, receptor-related 3; Discoidin domain-containing receptor tyrosine kinase 2; Discoidin domain receptor 2; DDR2; CD167 antigen-like family member B T11764 FUNCTION Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell differentiation, remodeling of the extracellular matrix, cell migration and cell proliferation. Required for normal bone development. Regulates osteoblast differentiation and chondrocyte maturation via a signaling pathway that involves MAP kinases and leads to the activation of the transcription factor RUNX2. Regulates remodeling of the extracellular matrix by up-regulation of the collagenases MMP1, MMP2 and MMP13, and thereby facilitates cell migration and tumor cell invasion. Promotes fibroblast migration and proliferation, and thereby contributes to cutaneous wound healing. T11764 PDBSTRUC 6FER; 2Z4F; 2WUH T11764 BIOCLASS Kinase T11764 ECNUMBER EC 2.7.10.1 T11764 SEQUENCE MILIPRMLLVLFLLLPILSSAKAQVNPAICRYPLGMSGGQIPDEDITASSQWSESTAAKYGRLDSEEGDGAWCPEIPVEPDDLKEFLQIDLHTLHFITLVGTQGRHAGGHGIEFAPMYKINYSRDGTRWISWRNRHGKQVLDGNSNPYDIFLKDLEPPIVARFVRFIPVTDHSMNVCMRVELYGCVWLDGLVSYNAPAGQQFVLPGGSIIYLNDSVYDGAVGYSMTEGLGQLTDGVSGLDDFTQTHEYHVWPGYDYVGWRNESATNGYIEIMFEFDRIRNFTTMKVHCNNMFAKGVKIFKEVQCYFRSEASEWEPNAISFPLVLDDVNPSARFVTVPLHHRMASAIKCQYHFADTWMMFSEITFQSDAAMYNNSEALPTSPMAPTTYDPMLKVDDSNTRILIGCLVAIIFILLAIIVIILWRQFWQKMLEKASRRMLDDEMTVSLSLPSDSSMFNNNRSSSPSEQGSNSTYDRIFPLRPDYQEPSRLIRKLPEFAPGEEESGCSGVVKPVQPSGPEGVPHYAEADIVNLQGVTGGNTYSVPAVTMDLLSGKDVAVEEFPRKLLTFKEKLGEGQFGEVHLCEVEGMEKFKDKDFALDVSANQPVLVAVKMLRADANKNARNDFLKEIKIMSRLKDPNIIHLLAVCITDDPLCMITEYMENGDLNQFLSRHEPPNSSSSDVRTVSYTNLKFMATQIASGMKYLSSLNFVHRDLATRNCLVGKNYTIKIADFGMSRNLYSGDYYRIQGRAVLPIRWMSWESILLGKFTTASDVWAFGVTLWETFTFCQEQPYSQLSDEQVIENTGEFFRDQGRQTYLPQPAICPDSVYKLMLSCWRRDTKNRPSFQEIHLLLLQQGDE T11764 DRUGINFO D05AFD US9156852, 38 Patented T11764 DRUGINFO D0CI3N US9156852, 1 Patented T11764 DRUGINFO D0T8BO US9156852, 105 Patented T72881 TARGETID T72881 T72881 FORMERID TTDR00232 T72881 UNIPROID LTC4S_HUMAN T72881 TARGNAME Leukotriene C4 synthase (LTC4S) T72881 GENENAME LTC4S T72881 TARGTYPE Patented-recorded T72881 SYNONYMS Leukotriene-C(4)Leukotriene C4 synthase synthase; Leukotriene-C(4) synthase; LTC4 synthase T72881 FUNCTION Catalyzes the conjugation of leukotriene A4 with reduced glutathione to form leukotriene C4. T72881 PDBSTRUC 5HV9; 4WAB; 4JRZ; 4JCZ; 4JC7 T72881 BIOCLASS Carbon-sulfur lyase T72881 ECNUMBER EC 4.4.1.20 T72881 SEQUENCE MKDEVALLAAVTLLGVLLQAYFSLQVISARRAFRVSPPLTTGPPEFERVYRAQVNCSEYFPLFLATLWVAGIFFHEGAAALCGLVYLFARLRYFQGYARSAQLRLAPLYASARALWLLVALAALGLLAHFLPAALRAALLGRLRTLLPWA T72881 DRUGINFO D08NHT US20160326143, 50 Patented T72881 DRUGINFO D0CT4T US20160326143, 28 Patented T72881 DRUGINFO D0L5VH US20160326143, 3 Patented T72881 DRUGINFO D0V6RN US20160326143, 38 Patented T16596 TARGETID T16596 T16596 FORMERID TTDI02151 T16596 UNIPROID PIM3_HUMAN T16596 TARGNAME PIM-3 protein kinase (PIM3) T16596 GENENAME PIM3 T16596 TARGTYPE Patented-recorded T16596 SYNONYMS Serine/threonine-protein kinase pim-3 T16596 FUNCTION May contribute to tumorigenesis through: the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), the regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. Additionally to this role on tumorigenesis, can also negatively regulate insulin secretion by inhibiting the activation of MAPK1/3 (ERK1/2), through SOCS6. Involved also in the control of energy metabolism and regulation of AMPK activity in modulating MYC and PPARGC1A protein levels and cell growth. Proto-oncogene with serine/threonine kinase activity that can prevent apoptosis, promote cell survival and protein translation. T16596 BIOCLASS Kinase T16596 ECNUMBER EC 2.7.11.1 T16596 SEQUENCE MLLSKFGSLAHLCGPGGVDHLPVKILQPAKADKESFEKAYQVGAVLGSGGFGTVYAGSRIADGLPVAVKHVVKERVTEWGSLGGATVPLEVVLLRKVGAAGGARGVIRLLDWFERPDGFLLVLERPEPAQDLFDFITERGALDEPLARRFFAQVLAAVRHCHSCGVVHRDIKDENLLVDLRSGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSATVWSLGVLLYDMVCGDIPFEQDEEILRGRLLFRRRVSPECQQLIRWCLSLRPSERPSLDQIAAHPWMLGADGGVPESCDLRLCTLDPDDVASTTSSSESL T16596 DRUGINFO D00HBJ US9682991, 23 Patented T16596 DRUGINFO D04JJM US8889696, Staurosporine Patented T16596 DRUGINFO D04MCF US8829193, 3 Patented T16596 DRUGINFO D04VSB BDBM50061601 Patented T16596 DRUGINFO D05ZQI US9580418, Example 8 Patented T16596 DRUGINFO D06OKX BDBM50061608 Patented T16596 DRUGINFO D06TGF US8481586, 15 Patented T16596 DRUGINFO D07SHE US9434725, 315 Patented T16596 DRUGINFO D08JUU BDBM50061612 Patented T16596 DRUGINFO D0D0WQ US8669361, 102 Patented T16596 DRUGINFO D0DT0E US8669361, 105 Patented T16596 DRUGINFO D0EH6G US9682991, 7 Patented T16596 DRUGINFO D0GV1S US8759338, 2 Patented T16596 DRUGINFO D0I0CN US8669361, 107 Patented T16596 DRUGINFO D0J6HN N-{4 Patented T16596 DRUGINFO D0JL8G US9434725, 285 Patented T16596 DRUGINFO D0LK3O US8987457, 117 Patented T16596 DRUGINFO D0M0TH US8481586, 40 Patented T16596 DRUGINFO D0NE0N US8481586, 5 Patented T16596 DRUGINFO D0NX6B US8987457, 198 Patented T16596 DRUGINFO D0OS2I US8592455, 3 Patented T16596 DRUGINFO D0P4NQ US8759338, 12 Patented T16596 DRUGINFO D0P9UF US8829193, 1 Patented T16596 DRUGINFO D0QU7N US9580418, Example 11 Patented T16596 DRUGINFO D0V5JW US9682991, 2 Patented T16596 DRUGINFO D0WH9N US8669361, 103 Patented T16596 DRUGINFO D0WU1C US8987457, 15 Patented T16596 DRUGINFO D0X0BB US8592455, 90 Patented T16596 DRUGINFO D0XJ2J US8759338, 1 Patented T16596 DRUGINFO D0ZC0E US8829193, 2 Patented T16596 DRUGINFO D0ZY3D US9434725, 113 Patented T16596 DRUGINFO D04TPA PMID24900749C1a Investigative T16596 DRUGINFO D06HVH PMID22136433C20 Investigative T16596 DRUGINFO D06UKS PMID21982499C14k Investigative T82262 TARGETID T82262 T82262 FORMERID TTDI03072 T82262 UNIPROID KKCC2_HUMAN T82262 TARGNAME Calmodulin-dependent kinase II (CAMKK2) T82262 GENENAME CAMKK2 T82262 TARGTYPE Patented-recorded T82262 SYNONYMS KIAA0787; Calcium/calmodulin-dependent protein kinase kinase beta; Calcium/calmodulin-dependent protein kinase kinase 2; CaMKK beta; CaMKK 2; CaM-kinase kinase beta; CaM-kinase kinase 2; CaM-KK beta; CaM-KK 2; CAMKKB T82262 FUNCTION Calcium/calmodulin-dependent protein kinase belonging to a proposed calcium-triggered signaling cascade involved in a number of cellular processes. Isoform 1, isoform 2 and isoform 3 phosphorylate CAMK1 and CAMK4. Isoform 3 phosphorylates CAMK1D. Isoform 4, isoform 5 and isoform 6 lacking part of the calmodulin-binding domain are inactive. Efficiently phosphorylates 5'-AMP-activated protein kinase (AMPK) trimer, including that consisting of PRKAA1, PRKAB1 and PRKAG1. This phosphorylation is stimulated in response to Ca(2+) signals (By similarity). Seems to be involved in hippocampal activation of CREB1 (By similarity). May play a role in neurite growth. Isoform 3 may promote neurite elongation, while isoform 1 may promoter neurite branching. T82262 PDBSTRUC 6FEL; 6EWW; 6CMJ; 6BRC; 6BQQ T82262 BIOCLASS Kinase T82262 ECNUMBER EC 2.7.11.17 T82262 SEQUENCE MSSCVSSQPSSNRAAPQDELGGRGSSSSESQKPCEALRGLSSLSIHLGMESFIVVTECEPGCAVDLGLARDRPLEADGQEVPLDTSGSQARPHLSGRKLSLQERSQGGLAAGGSLDMNGRCICPSLPYSPVSSPQSSPRLPRRPTVESHHVSITGMQDCVQLNQYTLKDEIGKGSYGVVKLAYNENDNTYYAMKVLSKKKLIRQAGFPRRPPPRGTRPAPGGCIQPRGPIEQVYQEIAILKKLDHPNVVKLVEVLDDPNEDHLYMVFELVNQGPVMEVPTLKPLSEDQARFYFQDLIKGIEYLHYQKIIHRDIKPSNLLVGEDGHIKIADFGVSNEFKGSDALLSNTVGTPAFMAPESLSETRKIFSGKALDVWAMGVTLYCFVFGQCPFMDERIMCLHSKIKSQALEFPDQPDIAEDLKDLITRMLDKNPESRIVVPEIKLHPWVTRHGAEPLPSEDENCTLVEVTEEEVENSVKHIPSLATVILVKTMIRKRSFGNPFEGSRREERSLSAPGNLLTKKPTRECESLSELKEARQRRQPPGHRPAPRGGGGSALVRGSPCVESCWAPAPGSPARMHPLRPEEAMEPE T82262 DRUGINFO D01UIJ US9623028, Compound 101 Patented T82262 DRUGINFO D0PO8N CQ7 Patented T82262 DRUGINFO D0XF1S US9623028, Compound 79 Patented T82262 DRUGINFO D0HZ8U STO609 Investigative T82262 DRUGINFO D06HVH PMID22136433C20 Investigative T11192 TARGETID T11192 T11192 FORMERID TTDR00889 T11192 UNIPROID ADA33_HUMAN T11192 TARGNAME ADAM metallopeptidase 33 (ADAM33) T11192 GENENAME ADAM33 T11192 TARGTYPE Patented-recorded T11192 SYNONYMS UNQ873/PRO1891; Disintegrin and metalloproteinase domain-containing protein 33; C20orf153; ADAM 33 T11192 FUNCTION Membrane-anchored protein structurally related to snake venom disintegrins. Invovled in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. T11192 PDBSTRUC 1R55; 1R54 T11192 BIOCLASS Peptidase T11192 ECNUMBER EC 3.4.24.- T11192 SEQUENCE MGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQPWPLDPENSHEPSSHPEKPLPAVSPDPQADQVQMPRSCLW T11192 DRUGINFO D02XAR US8772478, 5 Patented T11192 DRUGINFO D0NW8W US8772478, 3 Patented T11192 DRUGINFO D0O1NA US8772478, 1 Patented T11192 DRUGINFO D0Z7FD US8772478, 2 Patented T11192 DRUGINFO D0W2UK IK-862 Investigative T11192 DRUGINFO D07LUR Alpha-D-Mannose Investigative T97537 TARGETID T97537 T97537 FORMERID TTDI03348 T97537 UNIPROID LCAP_HUMAN T97537 TARGNAME Leucyl-cysteinyl aminopeptidase (LNPEP) T97537 GENENAME LNPEP T97537 TARGTYPE Patented-recorded T97537 SYNONYMS Placental leucine aminopeptidase; P-LAP; Oxytocinase; OTase; Leucyl-cystinyl aminopeptidase; Insulin-responsive aminopeptidase; Insulin-regulated membrane aminopeptidase; IRAP; Cystinyl aminopeptidase T97537 FUNCTION Degrades peptide hormones such as oxytocin, vasopressin and angiotensin III, and plays a role in maintaining homeostasis during pregnancy. May be involved in the inactivation of neuronal peptides in the brain. Cleaves Met-enkephalin and dynorphin. Binds angiotensin IV and may be the angiotensin IV receptor in the brain. Release of an N-terminal amino acid, cleaves before cysteine, leucine as well as other amino acids. T97537 PDBSTRUC 5MJ6; 5JHQ; 5C97; 4Z7I; 4PJ6 T97537 BIOCLASS Peptidase T97537 ECNUMBER EC 3.4.11.3 T97537 SEQUENCE MEPFTNDRLQLPRNMIENSMFEEEPDVVDLAKEPCLHPLEPDEVEYEPRGSRLLVRGLGEHEMEEDEEDYESSAKLLGMSFMNRSSGLRNSATGYRQSPDGACSVPSARTMVVCAFVIVVAVSVIMVIYLLPRCTFTKEGCHKKNQSIGLIQPFATNGKLFPWAQIRLPTAVVPLRYELSLHPNLTSMTFRGSVTISVQALQVTWNIILHSTGHNISRVTFMSAVSSQEKQAEILEYAYHGQIAIVAPEALLAGHNYTLKIEYSANISSSYYGFYGFSYTDESNEKKYFAATQFEPLAARSAFPCFDEPAFKATFIIKIIRDEQYTALSNMPKKSSVVLDDGLVQDEFSESVKMSTYLVAFIVGEMKNLSQDVNGTLVSIYAVPEKIGQVHYALETTVKLLEFFQNYFEIQYPLKKLDLVAIPDFEAGAMENWGLLTFREETLLYDSNTSSMADRKLVTKIIAHELAHQWFGNLVTMKWWNDLWLNEGFATFMEYFSLEKIFKELSSYEDFLDARFKTMKKDSLNSSHPISSSVQSSEQIEEMFDSLSYFKGSSLLLMLKTYLSEDVFQHAVVLYLHNHSYASIQSDDLWDSFNEVTNQTLDVKRMMKTWTLQKGFPLVTVQKKGKELFIQQERFFLNMKPEIQPSDTSYLWHIPLSYVTEGRNYSKYQSVSLLDKKSGVINLTEEVLWVKVNINMNGYYIVHYADDDWEALIHQLKINPYVLSDKDRANLINNIFELAGLGKVPLKRAFDLINYLGNENHTAPITEALFQTDLIYNLLEKLGYMDLASRLVTRVFKLLQNQIQQQTWTDEGTPSMRELRSALLEFACTHNLGNCSTTAMKLFDDWMASNGTQSLPTDVMTTVFKVGAKTDKGWSFLLGKYISIGSEAEKNKILEALASSEDVRKLYWLMKSSLNGDNFRTQKLSFIIRTVGRHFPGHLLAWDFVKENWNKLVQKFPLGSYTIQNIVAGSTYLFSTKTHLSEVQAFFENQSEATFRLRCVQEALEVIQLNIQWMEKNLKSLTWWL T97537 DRUGINFO D04AFR US10059720, Example 80 Patented T97537 DRUGINFO D05ZEZ US10059720, Example 82 Patented T97537 DRUGINFO D06JLW US10059720, Example 84 Patented T97537 DRUGINFO D0HO8O US10023583, Example 5 Patented T97537 DRUGINFO D0IC5Y US10023583, Example 24 Patented T97537 DRUGINFO D0V4YX US10023583, Example 13 Patented T97537 DRUGINFO D0X2XN US10023583, Example 8 Patented T97537 DRUGINFO D04DTE inhibitor 19 Investigative T97537 DRUGINFO D02MNM PMID23916253C17 Investigative T52888 TARGETID T52888 T52888 FORMERID TTDI02158 T52888 UNIPROID RGS16_HUMAN T52888 TARGNAME Regulator of G-protein signaling 16 (RGS16) T52888 GENENAME RGS16 T52888 TARGTYPE Patented-recorded T52888 SYNONYMS hRGS-r; Retinally abundant regulator of G-protein signaling; Retinal-specific RGS; RGSR; RGS-r; A28-RGS14P T52888 FUNCTION Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. Plays an important role in the phototransduction cascade by regulating the lifetime and effective concentration of activated transducin alpha. May regulate extra and intracellular mitogenic signals. Regulates G protein-coupled receptor signaling cascades. T52888 PDBSTRUC 2IK8; 2BT2 T52888 SEQUENCE MCRTLAAFPTTCLERAKEFKTRLGIFLHKSELGCDTGSTGKFEWGSKHSKENRNFSEDVLGWRESFDLLLSSKNGVAAFHAFLKTEFSEENLEFWLACEEFKKIRSATKLASRAHQIFEEFICSEAPKEVNIDHETHELTRMNLQTATATCFDAAQGKTRTLMEKDSYPRFLKSPAYRDLAAQASAASATLSSCSLDEPSHT T42881 TARGETID T42881 T42881 FORMERID TTDR00590 T42881 UNIPROID SCAF_HCMVA T42881 TARGNAME Cytomegalovirus Protease (CMV UL80) T42881 GENENAME CMV UL80 T42881 TARGTYPE Patented-recorded T42881 SYNONYMS UL80; Capsid protein P40; Assemblin T42881 FUNCTION Assembly protein plays a major role in capsid assembly. Acts as a scaffold protein by binding major capsid protein UL86. Multimerizes in the nucleus such as protein UL86 forms the icosahedral T=16 capsid. Cleaved by assemblin after capsid completion. The cleavages products are evicted from the capsid before or during DNA packaging. T42881 PDBSTRUC 2WPO; 1WPO; 1NKM; 1NKK; 1NJU T42881 BIOCLASS Peptidase T42881 SEQUENCE MTMDEQQSQAVAPVYVGGFLARYDQSPDEAELLLPRDVVEHWLHAQGQGQPSLSVALPLNINHDDTAVVGHVAAMQSVRDGLFCLGCVTSPRFLEIVRRASEKSELVSRGPVSPLQPDKVVEFLSGSYAGLSLSSRRCDDVEAATSLSGSETTPFKHVALCSVGRRRGTLAVYGRDPEWVTQRFPDLTAADRDGLRAQWQRCGSTAVDASGDPFRSDSYGLLGNSVDALYIRERLPKLRYDKQLVGVTERESYVKASVSPEAACDIKAASAERSGDSRSQAATPAAGARVPSSSPSPPVEPPSPVQPPALPASPSVLPAESPPSLSPSEPAEAASMSHPLSAAVPAATAPPGATVAGASPAVSSLAWPHDGVYLPKDAFFSLLGASRSAVPVMYPGAVAAPPSASPAPLPLPSYPASYGAPVVGYDQLAARHFADYVDPHYPGWGRRYEPAPSLHPSYPVPPPPSPAYYRRRDSPGGMDEPPSGWERYDGGHRGQSQKQHRHGGSGGHNKRRKETAAASSSSSDEDLSFPGEAEHGRARKRLKSHVNSDGGSGGHAGSNQQQQQRYDELRDAIHELKRDLFAARQSSTLLSAALPSAASSSPTTTTVCTPTGELTSGGGETPTALLSGGAKVAERAQAGVVNASCRLATASGSEAATAGPSTAGSSSCPASVVLAAAAAQAAAASQSPPKDMVDLNRRIFVAALNKLE T42881 DRUGINFO D0N6ZR US10071110, Compound cCDV Patented T42881 DRUGINFO D0XA0Y C06909 Patented T42881 DRUGINFO D08ROT N-(1-PHENYL-PROPYL)-FORMAMIDE Investigative T42881 DRUGINFO D0Y0FC O-Benzylsulfonyl-Serine Investigative T42881 DRUGINFO D0NL4Z Monoisopropyl Ester Phosphonic Acid Group Investigative T42881 DRUGINFO D08TGY S-(Dimethylarsenic)Cysteine Investigative T81780 TARGETID T81780 T81780 FORMERID TTDR01334 T81780 UNIPROID UBA1_HUMAN T81780 TARGNAME Ubiquitin-activating enzyme E1 (UBAE1) T81780 GENENAME UBA1 T81780 TARGTYPE Patented-recorded T81780 SYNONYMS Ubiquitin-like modifier-activating enzyme 1; UBE1; Protein A1S9; A1S9T T81780 FUNCTION Catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation through the ubiquitin-proteasome system. Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP. Essential for the formation of radiation-induced foci, timely DNA repair and for response to replication stress. Promotes the recruitment of TP53BP1 and BRCA1 at DNA damage sites. T81780 PDBSTRUC 6DC6; 4P22 T81780 ECNUMBER EC 6.2.1.45 T81780 SEQUENCE MSSSPLSKKRRVSGPDPKPGSNCSPAQSVLSEVPSVPTNGMAKNGSEADIDEGLYSRQLYVLGHEAMKRLQTSSVLVSGLRGLGVEIAKNIILGGVKAVTLHDQGTAQWADLSSQFYLREEDIGKNRAEVSQPRLAELNSYVPVTAYTGPLVEDFLSGFQVVVLTNTPLEDQLRVGEFCHNRGIKLVVADTRGLFGQLFCDFGEEMILTDSNGEQPLSAMVSMVTKDNPGVVTCLDEARHGFESGDFVSFSEVQGMVELNGNQPMEIKVLGPYTFSICDTSNFSDYIRGGIVSQVKVPKKISFKSLVASLAEPDFVVTDFAKFSRPAQLHIGFQALHQFCAQHGRPPRPRNEEDAAELVALAQAVNARALPAVQQNNLDEDLIRKLAYVAAGDLAPINAFIGGLAAQEVMKACSGKFMPIMQWLYFDALECLPEDKEVLTEDKCLQRQNRYDGQVAVFGSDLQEKLGKQKYFLVGAGAIGCELLKNFAMIGLGCGEGGEIIVTDMDTIEKSNLNRQFLFRPWDVTKLKSDTAAAAVRQMNPHIRVTSHQNRVGPDTERIYDDDFFQNLDGVANALDNVDARMYMDRRCVYYRKPLLESGTLGTKGNVQVVIPFLTESYSSSQDPPEKSIPICTLKNFPNAIEHTLQWARDEFEGLFKQPAENVNQYLTDPKFVERTLRLAGTQPLEVLEAVQRSLVLQRPQTWADCVTWACHHWHTQYSNNIRQLLHNFPPDQLTSSGAPFWSGPKRCPHPLTFDVNNPLHLDYVMAAANLFAQTYGLTGSQDRAAVATFLQSVQVPEFTPKSGVKIHVSDQELQSANASVDDSRLEELKATLPSPDKLPGFKMYPIDFEKDDDSNFHMDFIVAASNLRAENYDIPSADRHKSKLIAGKIIPAIATTTAAVVGLVCLELYKVVQGHRQLDSYKNGFLNLALPFFGFSEPLAAPRHQYYNQEWTLWDRFEVQGLQPNGEEMTLKQFLDYFKTEHKLEITMLSQGVSMLYSFFMPAAKLKERLDQPMTEIVSRVSKRKLGRHVRALVLELCCNDESGEDVEVPYVRYTIR T81780 DRUGINFO D0P3PT SCHEMBL15198145 Patented T81780 DRUGINFO D0QQ3B SCHEMBL15198146 Patented T81780 DRUGINFO D0YE0V QCPOIDRINIAUKU-SRBBEKPSSA-N Patented T81780 DRUGINFO D0A0YZ PYZD-4409 Investigative T12241 TARGETID T12241 T12241 FORMERID TTDI03149 T12241 UNIPROID CGL_HUMAN T12241 TARGNAME Cystathionine gamma-lyase (CTH) T12241 GENENAME CTH T12241 TARGTYPE Patented-recorded T12241 SYNONYMS Gamma-cystathionase; Cysteine-protein sulfhydrase T12241 FUNCTION Catalyzes the last step in the trans-sulfuration pathway from methionine to cysteine. Has broad substrate specificity. Converts cystathionine to cysteine, ammonia and 2-oxobutanoate. Converts two cysteine molecules to lanthionine and hydrogen sulfide. Can also accept homocysteine as substrate. Specificity depends on the levels of the endogenous substrates. Generates the endogenous signaling molecule hydrogen sulfide (H2S), and so contributes to the regulation of blood pressure. Acts as a cysteine-protein sulfhydrase by mediating sulfhydration of target proteins: sulfhydration consists of converting -SH groups into -SSH on specific cysteine residues of target proteins such as GAPDH, PTPN1 and NF-kappa-B subunit RELA, thereby regulating their function. T12241 PDBSTRUC 5TT2; 5TSU; 5EIG; 3ELP; 3COG T12241 ECNUMBER EC 4.4.1.1 T12241 SEQUENCE MQEKDASSQGFLPHFQHFATQAIHVGQDPEQWTSRAVVPPISLSTTFKQGAPGQHSGFEYSRSGNPTRNCLEKAVAALDGAKYCLAFASGLAATVTITHLLKAGDQIICMDDVYGGTNRYFRQVASEFGLKISFVDCSKIKLLEAAITPETKLVWIETPTNPTQKVIDIEGCAHIVHKHGDIILVVDNTFMSPYFQRPLALGADISMYSATKYMNGHSDVVMGLVSVNCESLHNRLRFLQNSLGAVPSPIDCYLCNRGLKTLHVRMEKHFKNGMAVAQFLESNPWVEKVIYPGLPSHPQHELVKRQCTGCTGMVTFYIKGTLQHAEIFLKNLKLFTLAESLGGFESLAELPAIMTHASVLKNDRDVLGISDTLIRLSVGLEDEEDLLEDLDQALKAAHPPSGSHS T12241 DRUGINFO D06BHM AKOS003197197 Patented T12241 DRUGINFO D0BB4J Hydrazinoacetic acid Patented T12241 DRUGINFO D0EC1A 5-Hydrazino-1H-tetrazole Patented T12241 DRUGINFO D06HNS propargylglycine Investigative T69612 TARGETID T69612 T69612 FORMERID TTDI03205 T69612 UNIPROID GRK5_HUMAN T69612 TARGNAME G protein-coupled receptor kinase 5 (GRK5) T69612 GENENAME GRK5 T69612 TARGTYPE Patented-recorded T69612 SYNONYMS GPRK5; G protein-coupled receptor kinase GRK5 T69612 FUNCTION Serine/threonine kinase that phosphorylates preferentially the activated forms of a variety of G-protein-coupled receptors (GPCRs). Such receptor phosphorylation initiates beta-arrestin-mediated receptor desensitization, internalization, and signaling events leading to their down-regulation. Phosphorylates a variety of GPCRs, including adrenergic receptors, muscarinic acetylcholine receptors (more specifically Gi-coupled M2/M4 subtypes), dopamine receptors and opioid receptors. In addition to GPCRs, also phosphorylates various substrates: Hsc70-interacting protein/ST13, TP53/p53, HDAC5, and arrestin-1/ARRB1. Phosphorylation of ARRB1 by GRK5 inhibits G-protein independent MAPK1/MAPK3 signaling downstream of 5HT4-receptors. Phosphorylation of HDAC5, a repressor of myocyte enhancer factor 2 (MEF2) leading to nuclear export of HDAC5 and allowing MEF2-mediated transcription. Phosphorylation of TP53/p53, a crucial tumor suppressor, inhibits TP53/p53-mediated apoptosis. Phosphorylation of ST13 regulates internalization of the chemokine receptor. Phosphorylates rhodopsin (RHO) (in vitro) and a non G-protein-coupled receptor, LRP6 during Wnt signaling (in vitro). T69612 PDBSTRUC 4TND; 4TNB T69612 ECNUMBER EC 2.7.11.16 T69612 SEQUENCE MELENIVANTVLLKAREGGGGKRKGKSKKWKEILKFPHISQCEDLRRTIDRDYCSLCDKQPIGRLLFRQFCETRPGLECYIQFLDSVAEYEVTPDEKLGEKGKEIMTKYLTPKSPVFIAQVGQDLVSQTEEKLLQKPCKELFSACAQSVHEYLRGEPFHEYLDSMFFDRFLQWKWLERQPVTKNTFRQYRVLGKGGFGEVCACQVRATGKMYACKRLEKKRIKKRKGESMALNEKQILEKVNSQFVVNLAYAYETKDALCLVLTIMNGGDLKFHIYNMGNPGFEEERALFYAAEILCGLEDLHRENTVYRDLKPENILLDDYGHIRISDLGLAVKIPEGDLIRGRVGTVGYMAPEVLNNQRYGLSPDYWGLGCLIYEMIEGQSPFRGRKEKVKREEVDRRVLETEEVYSHKFSEEAKSICKMLLTKDAKQRLGCQEEGAAEVKRHPFFRNMNFKRLEAGMLDPPFVPDPRAVYCKDVLDIEQFSTVKGVNLDHTDDDFYSKFSTGSVSIPWQNEMIETECFKELNVFGPNGTLPPDLNRNHPPEPPKKGLLQRLFKRQHQNNSKSSPSSKTSFNHHINSNHVSSNSTGSS T69612 DRUGINFO D00YYO BDBM50173323 Patented T69612 DRUGINFO D05PTF BDBM50173330 Patented T69612 DRUGINFO D0U5IW BDBM50173327 Patented T69612 DRUGINFO D04CUA PMID24210504C1o Investigative T47594 TARGETID T47594 T47594 FORMERID TTDI03011 T47594 UNIPROID ACV1B_HUMAN T47594 TARGNAME Activin receptor type IB (ACVR1B) T47594 GENENAME ACVR1B T47594 TARGTYPE Patented-recorded T47594 SYNONYMS Serine/threonine-protein kinase receptor R2; SKR2; Activin receptor-like kinase 4; Activin receptor type-1B; ALK4; ALK-4; ACVRLK4; ACTR-IB T47594 FUNCTION Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating a many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, type-2 receptors (ACVR2A and/or ACVR2B) act as a primary activin receptors whereas the type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor such as ACVR1B. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor. ACVR1B also phosphorylates TDP2. Transmembrane serine/threonine kinase activin type-1 receptor forming an activin receptor complex with activin receptor type-2 (ACVR2A or ACVR2B). T47594 BIOCLASS Kinase T47594 ECNUMBER EC 2.7.11.30 T47594 SEQUENCE MAESAGASSFFPLVVLLLAGSGGSGPRGVQALLCACTSCLQANYTCETDGACMVSIFNLDGMEHHVRTCIPKVELVPAGKPFYCLSSEDLRNTHCCYTDYCNRIDLRVPSGHLKEPEHPSMWGPVELVGIIAGPVFLLFLIIIIVFLVINYHQRVYHNRQRLDMEDPSCEMCLSKDKTLQDLVYDLSTSGSGSGLPLFVQRTVARTIVLQEIIGKGRFGEVWRGRWRGGDVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTIEGMIKLALSAASGLAHLHMEIVGTQGKPGIAHRDLKSKNILVKKNGMCAIADLGLAVRHDAVTDTIDIAPNQRVGTKRYMAPEVLDETINMKHFDSFKCADIYALGLVYWEIARRCNSGGVHEEYQLPYYDLVPSDPSIEEMRKVVCDQKLRPNIPNWWQSYEALRVMGKMMRECWYANGAARLTALRIKKTLSQLSVQEDVKI T47594 DRUGINFO D01RXV US9682983, 1 Patented T47594 DRUGINFO D05YMG BDBM108945 Patented T47594 DRUGINFO D0E9VJ US10030004, Compound 19 Patented T47594 DRUGINFO D0F7CA US9682983, 33 Patented T47594 DRUGINFO D0IA7H US10030004, Compound 33 Patented T47594 DRUGINFO D0Z9FM US10030004, Compound 11a Patented T47594 DRUGINFO D05NEC PMID23639540C13r Investigative T47594 DRUGINFO D0F2MP PMID23639540C13d Investigative T52447 TARGETID T52447 T52447 FORMERID TTDR00907 T52447 UNIPROID PPID_HUMAN T52447 TARGNAME Rotamase D (PPID) T52447 GENENAME PPID T52447 TARGTYPE Patented-recorded T52447 SYNONYMS Peptidylprolyl isomerase D; Peptidyl-prolyl cis-trans isomerase D; PPIase D; Cyclophilin-related protein; Cyclophilin-40; CYP40; CYP-40; 40 kDa peptidyl-prolyl cis-trans isomerase T52447 FUNCTION Proposed to act as a co-chaperone in HSP90 complexes such as in unligated steroid receptors heterocomplexes. Different co-chaperones seem to compete for association with HSP90 thus establishing distinct HSP90-co-chaperone-receptor complexes with the potential to exert tissue-specific receptor activity control. May have a preference for estrogen receptor complexes and is not found in glucocorticoid receptor complexes. May be involved in cytoplasmic dynein-dependent movement of the receptor from the cytoplasm to the nucleus. May regulate MYB by inhibiting its DNA-binding activity. Involved in regulation of AHR signaling by promoting the formation of the AHR:ARNT dimer; the function is independent of HSP90 but requires the chaperone activity. Involved in regulation of UV radiation-induced apoptosis. Promotes cell viability in anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK+ ALCL) cell lines. PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. T52447 BIOCLASS Cis-trans-isomerase T52447 ECNUMBER EC 5.2.1.8 T52447 SEQUENCE MSHPSPQAKPSNPSNPRVFFDVDIGGERVGRIVLELFADIVPKTAENFRALCTGEKGIGHTTGKPLHFKGCPFHRIIKKFMIQGGDFSNQNGTGGESIYGEKFEDENFHYKHDREGLLSMANAGRNTNGSQFFITTVPTPHLDGKHVVFGQVIKGIGVARILENVEVKGEKPAKLCVIAECGELKEGDDGGIFPKDGSGDSHPDFPEDADIDLKDVDKILLITEDLKNIGNTFFKSQNWEMAIKKYAEVLRYVDSSKAVIETADRAKLQPIALSCVLNIGACKLKMSNWQGAIDSCLEALELDPSNTKALYRRAQGWQGLKEYDQALADLKKAQGIAPEDKAIQAELLKVKQKIKAQKDKEKAVYAKMFA T52447 DRUGINFO D08YMT US8901295, F609 Patented T52447 DRUGINFO D0KO5D US8901295, F673 Patented T52447 DRUGINFO D0M2OY 1313212-89-3 Patented T85115 TARGETID T85115 T85115 FORMERID TTDI02521 T85115 UNIPROID PKR1_HUMAN T85115 TARGNAME Prokineticin receptor-1 (PROKR1) T85115 GENENAME PROKR1 T85115 TARGTYPE Patented-recorded T85115 SYNONYMS Prokineticin receptor 1; PROKR1; Gprotein coupled receptor ZAQ; Gprotein coupled receptor 73; GPR73a T85115 FUNCTION Receptor for prokineticin 1. Exclusively coupled to the G(q) subclass of heteromeric G proteins. Activation leads to mobilization of calcium, stimulation of phosphoinositide turnover and activation of p44/p42 mitogen-activated protein kinase. May play a role during early pregnancy. T85115 BIOCLASS GPCR rhodopsin T85115 SEQUENCE METTMGFMDDNATNTSTSFLSVLNPHGAHATSFPFNFSYSDYDMPLDEDEDVTNSRTFFAAKIVIGMALVGIMLVCGIGNFIFIAALVRYKKLRNLTNLLIANLAISDFLVAIVCCPFEMDYYVVRQLSWEHGHVLCTSVNYLRTVSLYVSTNALLAIAIDRYLAIVHPLRPRMKCQTATGLIALVWTVSILIAIPSAYFTTETVLVIVKSQEKIFCGQIWPVDQQLYYKSYFLFIFGIEFVGPVVTMTLCYARISRELWFKAVPGFQTEQIRKRLRCRRKTVLVLMCILTAYVLCWAPFYGFTIVRDFFPTVFVKEKHYLTAFYIVECIAMSNSMINTLCFVTVKNDTVKYFKKIMLLHWKASYNGGKSSADLDLKTIGMPATEEVDCIRLK T85115 DRUGINFO D00LHT US9475795, 80 Patented T85115 DRUGINFO D04LJF ZINC19658740 Patented T85115 DRUGINFO D0U5VO US9475795, 89 Patented T85115 DRUGINFO D0X1ZY US9475795, 19 Patented T85115 DRUGINFO D0P5QU IS1 Investigative T85115 DRUGINFO D0R5NA IS20 Investigative T85115 DRUGINFO D02VQO triazine compound PC10 Investigative T11241 TARGETID T11241 T11241 FORMERID TTDI02523 T11241 UNIPROID S1PR3_HUMAN T11241 TARGNAME Sphingosine-1-phosphate receptor 3 (S1PR3) T11241 GENENAME S1PR3 T11241 TARGTYPE Patented-recorded T11241 SYNONYMS Sphingosine 1-phosphate receptor Edg-3; S1PR3; S1P3; S1P receptor Edg-3; S1P receptor 3; Endothelial differentiation G-protein coupled receptor 3 T11241 FUNCTION Receptor for the lysosphingolipid sphingosine 1- phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. When expressed in rat HTC4 hepatoma cells, is capable of mediating S1P-induced cell proliferation and suppression of apoptosis. T11241 BIOCLASS GPCR rhodopsin T11241 SEQUENCE MATALPPRLQPVRGNETLREHYQYVGKLAGRLKEASEGSTLTTVLFLVICSFIVLENLMVLIAIWKNNKFHNRMYFFIGNLALCDLLAGIAYKVNILMSGKKTFSLSPTVWFLREGSMFVALGASTCSLLAIAIERHLTMIKMRPYDANKRHRVFLLIGMCWLIAFTLGALPILGWNCLHNLPDCSTILPLYSKKYIAFCISIFTAILVTIVILYARIYFLVKSSSRKVANHNNSERSMALLRTVVIVVSVFIACWSPLFILFLIDVACRVQACPILFKAQWFIVLAVLNSAMNPVIYTLASKEMRRAFFRLVCNCLVRGRGARASPIQPALDPSRSKSSSSNNSSHSPKVKEDLPHTAPSSCIMDKNAALQNGIFCN T11241 DRUGINFO D02WVW US9522888, 575 Patented T11241 DRUGINFO D04NEO US9617250, Example 1 Example 204 of D1 Patented T11241 DRUGINFO D04UXN YYDJCLCSBYCSCO-UHFFFAOYSA-N Patented T11241 DRUGINFO D06DRH US9216972, 61 Patented T11241 DRUGINFO D07JOR US9670220, 77 Patented T11241 DRUGINFO D08BFF US10179791, Compound 296 Patented T11241 DRUGINFO D09LDU JCXGHZCWAHCYGY-UHFFFAOYSA-N Patented T11241 DRUGINFO D09RDP US9216972, 67 Patented T11241 DRUGINFO D09SKG US10166249, Example 695 Patented T11241 DRUGINFO D0A0VI US9181182, 40 Patented T11241 DRUGINFO D0AK7K US9187437, 8 Patented T11241 DRUGINFO D0CV8R US8524917, 12 Patented T11241 DRUGINFO D0E5OA US9522888, 412 Patented T11241 DRUGINFO D0EP8Y BDBM50080563 Patented T11241 DRUGINFO D0F4TB US8563594, 152 Patented T11241 DRUGINFO D0HW8T BDBM50080570 Patented T11241 DRUGINFO D0I5TH MHHFJYABEVJNEG-UHFFFAOYSA-N Patented T11241 DRUGINFO D0IL0J US9522888, 695 Patented T11241 DRUGINFO D0K8FK US8524917, 11 Patented T11241 DRUGINFO D0LT2N ZNFTXQFGUIKQQE-UHFFFAOYSA-N Patented T11241 DRUGINFO D0LT5U US10179791, Compound 171 Patented T11241 DRUGINFO D0MH3Y US9181182, 34 Patented T11241 DRUGINFO D0O4RX US10179791, Compound 176 Patented T11241 DRUGINFO D0OH0T US9522888, 618 Patented T11241 DRUGINFO D0OW3S US9187437, 38 Patented T11241 DRUGINFO D0Q4XE US9670220, 33 Patented T11241 DRUGINFO D0R7ED BDBM50080559 Patented T11241 DRUGINFO D0RL7G US8524917, 60 Patented T11241 DRUGINFO D0RQ0B US9187437, 24 Patented T11241 DRUGINFO D0S0MC US8524917, 10 Patented T11241 DRUGINFO D0T4SV US9216972, 132 Patented T11241 DRUGINFO D0U4IE US9181182, 47 Patented T11241 DRUGINFO D0VJ8Y US9707205, 40 Patented T11241 DRUGINFO D0WA4F US9216972, 94 Patented T11241 DRUGINFO D0WC1D US9670220, 76 Patented T11241 DRUGINFO D0Q2HM EDD7H9 Preclinical T11241 DRUGINFO D05EDD VPC23019 Investigative T11241 DRUGINFO D06GFH VPC44116 Investigative T11241 DRUGINFO D0PI4H VPC12249 Investigative T11241 DRUGINFO D05KEE AFD(R) Investigative T11241 DRUGINFO D06DYN FTY720-phosphate Investigative T11241 DRUGINFO D0W1ZW VPC03090-P Investigative T11241 DRUGINFO D03BRM AUY954 Investigative T10118 TARGETID T10118 T10118 FORMERID TTDI03111 T10118 UNIPROID CTRC_HUMAN T10118 TARGNAME Chymotrypsin-C (CLCR) T10118 GENENAME CTRC T10118 TARGTYPE Patented-recorded T10118 SYNONYMS Caldecrin; CLCR T10118 FUNCTION Regulates activation and degradation of trypsinogens and procarboxypeptidases by targeting specific cleavage sites within their zymogen precursors. Has chymotrypsin-type protease activity and hypocalcemic activity. T10118 PDBSTRUC 4H4F T10118 ECNUMBER EC 3.4.21.2 T10118 SEQUENCE MLGITVLAALLACASSCGVPSFPPNLSARVVGGEDARPHSWPWQISLQYLKNDTWRHTCGGTLIASNFVLTAAHCISNTRTYRVAVGKNNLEVEDEEGSLFVGVDTIHVHKRWNALLLRNDIALIKLAEHVELSDTIQVACLPEKDSLLPKDYPCYVTGWGRLWTNGPIADKLQQGLQPVVDHATCSRIDWWGFRVKKTMVCAGGDGVISACNGDSGGPLNCQLENGSWEVFGIVSFGSRRGCNTRKKPVVYTRVSAYIDWINEKMQL T10118 DRUGINFO D00PVE Z223457004 Patented T10118 DRUGINFO D01IXT STK296197 Patented T10118 DRUGINFO D05CJM Z90308237 Patented T10118 DRUGINFO D0P0OH AC1LCOK0 Patented T10118 DRUGINFO D0Q7ST PMID12372533C20 Investigative T50773 TARGETID T50773 T50773 FORMERID TTDI03155 T50773 UNIPROID DPP2_HUMAN T50773 TARGNAME Dipeptidyl-peptidase 7 (DPP7) T50773 GENENAME DPP7 T50773 TARGTYPE Patented-recorded T50773 SYNONYMS Quiescent cell proline dipeptidase; QPP; Dipeptidyl peptidase II; Dipeptidyl peptidase 7; Dipeptidyl peptidase 2; Dipeptidyl aminopeptidase II; DPP2; DPP II T50773 FUNCTION Plays an important role in the degradation of some oligopeptides. T50773 PDBSTRUC 4EBB; 3N0T; 3JYH T50773 ECNUMBER EC 3.4.14.2 T50773 SEQUENCE MGSAPWAPVLLLALGLRGLQAGARRAPDPGFQERFFQQRLDHFNFERFGNKTFPQRFLVSDRFWVRGEGPIFFYTGNEGDVWAFANNSAFVAELAAERGALLVFAEHRYYGKSLPFGAQSTQRGHTELLTVEQALADFAELLRALRRDLGAQDAPAIAFGGSYGGMLSAYLRMKYPHLVAGALAASAPVLAVAGLGDSNQFFRDVTADFEGQSPKCTQGVREAFRQIKDLFLQGAYDTVRWEFGTCQPLSDEKDLTQLFMFARNAFTVLAMMDYPYPTDFLGPLPANPVKVGCDRLLSEAQRITGLRALAGLVYNASGSEHCYDIYRLYHSCADPTGCGTGPDARAWDYQACTEINLTFASNNVTDMFPDLPFTDELRQRYCLDTWGVWPRPDWLLTSFWGGDLRAASNIIFSNGNLDPWAGGGIRRNLSASVIAVTIQGGAHHLDLRASHPEDPASVVEARKLEATIIGEWVKAARREQQPALRGGPRLSL T50773 DRUGINFO D05FMP BDBM50382283 Patented T50773 DRUGINFO D07JHU BDBM50434165 Patented T50773 DRUGINFO D0C6NX BDBM50434164 Patented T50773 DRUGINFO D0M6CN US8470836, 5 Patented T50773 DRUGINFO D0MF7O US8470836, 8 Patented T50773 DRUGINFO D0QX2U CRWCYVOHVXAEMF-LBPRGKRZSA-N Patented T50773 DRUGINFO D0S8CH US8470836, 2 Patented T50773 DRUGINFO D0SH7G US8470836, 6 Patented T50773 DRUGINFO D07ALM N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine Investigative T95878 TARGETID T95878 T95878 FORMERID TTDI03522 T95878 UNIPROID KS6A6_HUMAN T95878 TARGNAME Ribosomal protein S6 kinase alpha-6 (RSK6) T95878 GENENAME RPS6KA6 T95878 TARGTYPE Patented-recorded T95878 SYNONYMS pp90RSK4; p90RSK6; p90-RSK 6; S6K-alpha-6; Ribosomal S6 kinase 4; RSK4; RSK-4; 90 kDa ribosomal protein S6 kinase 6 T95878 FUNCTION Constitutively active serine/threonine-protein kinase that exhibits growth-factor-independent kinase activity and that may participate in p53/TP53-dependent cell growth arrest signaling and play an inhibitory role during embryogenesis. T95878 PDBSTRUC 6G78; 6G77; 6G76 T95878 ECNUMBER EC 2.7.11.1 T95878 SEQUENCE MLPFAPQDEPWDREMEVFSGGGASSGEVNGLKMVDEPMEEGEADSCHDEGVVKEIPITHHVKEGYEKADPAQFELLKVLGQGSFGKVFLVRKKTGPDAGQLYAMKVLKKASLKVRDRVRTKMERDILVEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDVFTRLSKEVLFTEEDVKFYLAELALALDHLHQLGIVYRDLKPENILLDEIGHIKLTDFGLSKESVDQEKKAYSFCGTVEYMAPEVVNRRGHSQSADWWSYGVLMFEMLTGTLPFQGKDRNETMNMILKAKLGMPQFLSAEAQSLLRMLFKRNPANRLGSEGVEEIKRHLFFANIDWDKLYKREVQPPFKPASGKPDDTFCFDPEFTAKTPKDSPGLPASANAHQLFKGFSFVATSIAEEYKITPITSANVLPIVQINGNAAQFGEVYELKEDIGVGSYSVCKRCIHATTNMEFAVKIIDKSKRDPSEEIEILMRYGQHPNIITLKDVFDDGRYVYLVTDLMKGGELLDRILKQKCFSEREASDILYVISKTVDYLHCQGVVHRDLKPSNILYMDESASADSIRICDFGFAKQLRGENGLLLTPCYTANFVAPEVLMQQGYDAACDIWSLGVLFYTMLAGYTPFANGPNDTPEEILLRIGNGKFSLSGGNWDNISDGAKDLLSHMLHMDPHQRYTAEQILKHSWITHRDQLPNDQPKRNDVSHVVKGAMVATYSALTHKTFQPVLEPVAASSLAQRRSMKKRTSTGL T95878 DRUGINFO D0X7ZB US10081632, Compound 25 Patented T95878 DRUGINFO D0Z6IH CID 138805970 Patented T95878 DRUGINFO D02VBF BI-D1870 Preclinical T95878 DRUGINFO D09AID PMID22564207C25b Investigative T09874 TARGETID T09874 T09874 FORMERID TTDR01382 T09874 UNIPROID POLG_HCV1 T09874 TARGNAME Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) T09874 GENENAME HCV Core mRNA T09874 TARGTYPE Patented-recorded T09874 SYNONYMS p70 (2-191) (mRNA); p56 (2-191) (mRNA); p27 (2-191) (mRNA); gp70 (2-191) (mRNA); gp68 (2-191) (mRNA); gp35 (2-191) (mRNA); gp32 (2-191) (mRNA); NS5B (2-191) (mRNA); NS3P (2-191) (mRNA); NS1 (2-191) (mRNA); Hepacivirin (2-191) (mRNA); Genome polyprotein (2-191) (mRNA); Capsid protein C (mRNA) T09874 FUNCTION Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis). Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. T09874 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T09874 BIOCLASS mRNA target T09874 SEQUENCE MSTNPKPQKKNKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPKARRPEGRTWAQPGYPWPLYGNEGCGWAGWLLSPRGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARALAHGVRVLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVRNSTGLYHVTNDCPNSSIVYEAADAILHTPGCVPCVREGNASRCWVAMTPTVATRDGKLPATQLRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWTTQGCNCSIYPGHITGHRMAWDMMMNWSPTTALVMAQLLRIPQAILDMIAGAHWGVLAGIAYFSMVGNWAKVLVVLLLFAGVDAETHVTGGSAGHTVSGFVSLLAPGAKQNVQLINTNGSWHLNSTALNCNDSLNTGWLAGLFYHHKFNSSGCPERLASCRPLTDFDQGWGPISYANGSGPDQRPYCWHYPPKPCGIVPAKSVCGPVYCFTPSPVVVGTTDRSGAPTYSWGENDTDVFVLNNTRPPLGNWFGCTWMNSTGFTKVCGAPPCVIGGAGNNTLHCPTDCFRKHPDATYSRCGSGPWITPRCLVDYPYRLWHYPCTINYTIFKIRMYVGGVEHRLEAACNWTRGERCDLEDRDRSELSPLLLTTTQWQVLPCSFTTLPALSTGLIHLHQNIVDVQYLYGVGSSIASWAIKWEYVVLLFLLLADARVCSCLWMMLLISQAEAALENLVILNAASLAGTHGLVSFLVFFCFAWYLKGKWVPGAVYTFYGMWPLLLLLLALPQRAYALDTEVAASCGGVVLVGLMALTLSPYYKRYISWCLWWLQYFLTRVEAQLHVWIPPLNVRGGRDAVILLMCAVHPTLVFDITKLLLAVFGPLWILQASLLKVPYFVRVQGLLRFCALARKMIGGHYVQMVIIKLGALTGTYVYNHLTPLRDWAHNGLRDLAVAVEPVVFSQMETKLITWGADTAACGDIINGLPVSARRGREILLGPADGMVSKGWRLLAPITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVVTSTWVLVGGVLAALAAYCLSTGCVVIVGRVVLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQKLETFWAKHMWNFISGIQYLAGLSTLPGNPAIASLMAFTAAVTSPLTTSQTLLFNILGGWVAAQLAAPGAATAFVGAGLAGAAIGSVGLGKVLIDILAGYGAGVAGALVAFKIMSGEVPSTEDLVNLLPAILSPGALVVGVVCAAILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTAILSSLTVTQLLRRLHQWISSECTTPCSGSWLRDIWDWICEVLSDFKTWLKAKLMPQLPGIPFVSCQRGYKGVWRVDGIMHTRCHCGAEITGHVKNGTMRIVGPRTCRNMWSGTFPINAYTTGPCTPLPAPNYTFALWRVSAEEYVEIRQVGDFHYVTGMTTDNLKCPCQVPSPEFFTELDGVRLHRFAPPCKPLLREEVSFRVGLHEYPVGSQLPCEPEPDVAVLTSMLTDPSHITAEAAGRRLARGSPPSVASSSASQLSAPSLKATCTANHDSPDAELIEANLLWRQEMGGNITRVESENKVVILDSFDPLVAEEDEREISVPAEILRKSRRFAQALPVWARPDYNPPLVETWKKPDYEPPVVHGCPLPPPKSPPVPPPRKKRTVVLTESTLSTALAELATRSFGSSSTSGITGDNTTTSSEPAPSGCPPDSDAESYSSMPPLEGEPGDPDLSDGSWSTVSSEANAEDVVCCSMSYSWTGALVTPCAAEEQKLPINALSNSLLRHHNLVYSTTSRSACQRQKKVTFDRLQVLDSHYQDVLKEVKAAASKVKANLLSVEEACSLTPPHSAKSKFGYGAKDVRCHARKAVTHINSVWKDLLEDNVTPIDTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMALYDVVTKLPLAVMGSSYGFQYSPGQRVEFLVQAWKSKKTPMGFSYDTRCFDSTVTESDIRTEEAIYQCCDLDPQARVAIKSLTERLYVGGPLTNSRGENCGYRRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCTMLVCGDDLVVICESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDGAGKRVYYLTRDPTTPLARAAWETARHTPVNSWLGNIIMFAPTLWARMILMTHFFSVLIARDQLEQALDCEIYGACYSIEPLDLPPIIQRLHGLSAFSLHSYSPGEINRVAACLRKLGVPPLRAWRHRARSVRARLLARGGRAAICGKYLFNWAVRTKLKLTPIAAAGQLDLSGWFTAGYSGGDIYHSVSHARPRWIWFCLLLLAAGVGIYLLPNR T09874 DRUGINFO D04NQY US10087167, Compound 4001 Patented T09874 DRUGINFO D05ETL US10087167, Compound 3002 Patented T09874 DRUGINFO D08VSV US10150740, Example 4 Patented T09874 DRUGINFO D0CD5P US10150740, Example 9 Patented T09874 DRUGINFO D0E7TM US8877733, 27 Patented T09874 DRUGINFO D0G4LV US10087167, Compound 3003 Patented T09874 DRUGINFO D0L3TL US8877733, 28 Patented T09874 DRUGINFO D0PG7W US10150740, Example 1 Patented T09874 DRUGINFO D00KVH ISIS 11155 Investigative T58440 TARGETID T58440 T58440 FORMERID TTDI02682 T58440 UNIPROID SCN1A_HUMAN T58440 TARGNAME SCN1A messenger RNA (SCN1A mRNA) T58440 GENENAME SCN1A T58440 TARGTYPE Patented-recorded T58440 SYNONYMS Voltage-gated sodium channel subunit alpha Nav1.1 (mRNA); Sodium channel protein type I subunit alpha (mRNA); Sodium channel protein type 1 subunit alpha (mRNA); Sodium channel protein brain I subunit alpha (mRNA); SCN1 (mRNA) T58440 FUNCTION Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. Plays a key role in brain, probably by regulating the moment when neurotransmitters are released in neurons. Involved in sensory perception of mechanical pain: activation in somatosensory neurons induces pain without neurogenic inflammation and produces hypersensitivity to mechanical, but not thermal stimuli. Mediates the voltage-dependent sodium ion permeability of excitable membranes. T58440 BIOCLASS mRNA target T58440 SEQUENCE MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPKPNSDLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVLNKGKAIFRFSATSALYILTPFNPLRKIAIKILVHSLFSMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKIIARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCIQWPPTNASLEEHSIEKNITVNYNGTLINETVFEFDWKSYIQDSRYHYFLEGFLDALLCGNSSDAGQCPEGYMCVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTLRAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMIEQLKKQQEAAQQAATATASEHSREPSAAGRLSDSSSEASKLSSKSAKERRNRRKKRKQKEQSGGEEKDEDEFQKSESEDSIRRKGFRFSIEGNRLTYEKRYSSPHQSLLSIRGSLFSPRRNSRTSLFSFRGRAKDVGSENDFADDEHSTFEDNESRRDSLFVPRRHGERRNSNLSQTSRSSRMLAVFPANGKMHSTVDCNGVVSLVGGPSVPTSPVGQLLPEVIIDKPATDDNGTTTETEMRKRRSSSFHVSMDFLEDPSQRQRAMSIASILTNTVEELEESRQKCPPCWYKFSNIFLIWDCSPYWLKVKHVVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTDHFNNVLTVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVTLSLVELGLANVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKDCVCKIASDCQLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLTVFMMVMVIGNLVVLNLFLALLLSSFSADNLAATDDDNEMNNLQIAVDRMHKGVAYVKRKIYEFIQQSFIRKQKILDEIKPLDDLNNKKDSCMSNHTAEIGKDLDYLKDVNGTTSGIGTGSSVEKYIIDESDYMSFINNPSLTVTVPIAVGESDFENLNTEDFSSESDLEESKEKLNESSSSSEGSTVDIGAPVEEQPVVEPEETLEPEACFTEGCVQRFKCCQINVEEGRGKQWWNLRRTCFRIVEHNWFETFIVFMILLSSGALAFEDIYIDQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGYQTYFTNAWCWLDFLIVDVSLVSLTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYHCINTTTGDRFDIEDVNNHTDCLKLIERNETARWKNVKVNFDNVGFGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEESLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKFQGMVFDFVTRQVFDISIMILICLNMVTMMVETDDQSEYVTTILSRINLVFIVLFTGECVLKLISLRHYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSKPPDCDPNKVNPGSSVKGDCGNPSVGIFFFVSYIIISFLVVVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFMEFEKLSQFAAALEPPLNLPQPNKLQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMASNPSKVSYQPITTTLKRKQEEVSAVIIQRAYRRHLLKRTVKQASFTYNKNKIKGGANLLIKEDMIIDRINENSITEKTDLTMSTAACPPSYDRVTKPIVEKHEQEGKDEKAKGK T58440 DRUGINFO D05EMC US9694002, 495 Patented T58440 DRUGINFO D05HMS US9694002, 59 Patented T58440 DRUGINFO D05YDJ US9694002, 129 Patented T58440 DRUGINFO D0G9WE batrachotoxin Investigative T58440 DRUGINFO D0S4MN veratridine Investigative T11791 TARGETID T11791 T11791 FORMERID TTDI03007 T11791 UNIPROID ACATN_HUMAN T11791 TARGNAME Acetyl-CoA transporter (SLC33A1) T11791 GENENAME SLC33A1 T11791 TARGTYPE Patented-recorded T11791 SYNONYMS Solute carrier family 33 member 1; Acetyl-coenzyme A transporter 1; Acetyl-CoA transporter 1; AT1 protein; AT-1; ACATN T11791 FUNCTION Negatively regulates BMP signaling. Probable acetyl-CoA transporter necessary for O-acetylation of gangliosides. T11791 BIOCLASS Major facilitator T11791 SEQUENCE MSPTISHKDSSRQRRPGNFSHSLDMKSGPLPPGGWDDSHLDSAGREGDREALLGDTGTGDFLKAPQSFRAELSSILLLLFLYVLQGIPLGLAGSIPLILQSKNVSYTDQAFFSFVFWPFSLKLLWAPLVDAVYVKNFGRRKSWLVPTQYILGLFMIYLSTQVDRLLGNTDDRTPDVIALTVAFFLFEFLAATQDIAVDGWALTMLSRENVGYASTCNSVGQTAGYFLGNVLFLALESADFCNKYLRFQPQPRGIVTLSDFLFFWGTVFLITTTLVALLKKENEVSVVKEETQGITDTYKLLFAIIKMPAVLTFCLLILTAKIGFSAADAVTGLKLVEEGVPKEHLALLAVPMVPLQIILPLIISKYTAGPQPLNTFYKAMPYRLLLGLEYALLVWWTPKVEHQGGFPIYYYIVVLLSYALHQVTVYSMYVSIMAFNAKVSDPLIGGTYMTLLNTVSNLGGNWPSTVALWLVDPLTVKECVGASNQNCRTPDAVELCKKLGGSCVTALDGYYVESIICVFIGFGWWFFLGPKFKKLQDEGSSSWKCKRNN T11791 DRUGINFO D0K8EF US8592431, 457 Patented T11791 DRUGINFO D0TI5Y US8592431, 181 Patented T11791 DRUGINFO D0Z5GO US8592431, 185 Patented T11791 DRUGINFO D0K0FZ [14C]acetylCoA Investigative T83196 TARGETID T83196 T83196 FORMERID TTDNR00700 T83196 UNIPROID PSIP1_HUMAN T83196 TARGNAME PC4 and SFRS1-interacting protein (PSIP1) T83196 GENENAME PSIP1 T83196 TARGTYPE Patented-recorded T83196 SYNONYMS Transcriptional coactivator p75/p52; PSIP2; Lens epithelium-derived growth factor; LEDGF; Dense fine speckles 70 kDa protein; DFS70; DFS 70; CLL-associated antigen KW-7 T83196 FUNCTION Transcriptional coactivator involved in neuroepithelial stem cell differentiation and neurogenesis. Involved in particular in lens epithelial cell gene regulation and stress responses. May play an important role in lens epithelial to fiber cell terminal differentiation. May play a protective role during stress-induced apoptosis. Isoform 2 is a more general and stronger transcriptional coactivator. Isoform 2 may also act as an adapter to coordinate pre-mRNA splicing. Cellular cofactor for lentiviral integration. T83196 PDBSTRUC 6EMR; 6EMQ; 6EMP; 6EMO; 5YI9 T83196 SEQUENCE MTRDFKPGDLIFAKMKGYPHWPARVDEVPDGAVKPPTNKLPIFFFGTHETAFLGPKDIFPYSENKEKYGKPNKRKGFNEGLWEIDNNPKVKFSSQQAATKQSNASSDVEVEEKETSVSKEDTDHEEKASNEDVTKAVDITTPKAARRGRKRKAEKQVETEEAGVVTTATASVNLKVSPKRGRPAATEVKIPKPRGRPKMVKQPCPSESDIITEEDKSKKKGQEEKQPKKQPKKDEEGQKEEDKPRKEPDKKEGKKEVESKRKNLAKTGVTSTSDSEEEGDDQEGEKKRKGGRNFQTAHRRNMLKGQHEKEAADRKRKQEEQMETEQQNKDEGKKPEVKKVEKKRETSMDSRLQRIHAEIKNSLKIDNLDVNRCIEALDELASLQVTMQQAQKHTEMITTLKKIRRFKVSQVIMEKSTMLYNKFKNMFLVGEGDSVITQVLNKSLAEQRQHEEANKTKDQGKKGPNKKLEKEQTGSKTLNGGSDAQDGNQPQHNGESNEDSKDNHEASTKKKPSSEERETEISLKDSTLDN T83196 DRUGINFO D08LBW US9132129, Cpd023 Patented T83196 DRUGINFO D09SDN US9132129, Cpd002 Patented T83196 DRUGINFO D0RP0H US9132129, Cpd047 Patented T09544 TARGETID T09544 T09544 FORMERID TTDI02573 T09544 UNIPROID LEG1_HUMAN T09544 TARGNAME Galectin-1 (LGALS1) T09544 GENENAME LGALS1 T09544 TARGTYPE Patented-recorded T09544 SYNONYMS SLac lectin 1; S-Lac lectin 1; Putative MAPKactivating protein PM12; Putative MAPK-activating protein PM12; Lectin galactosidebinding soluble 1; Lectin galactoside-binding soluble 1; Lactosebinding lectin 1; Lactose-binding lectin 1; HPL; HLBP14; HBL; Galaptin; Gal1; Gal-1; Betagalactosidebinding lectin L14I; Beta-galactoside-binding lectin L-14-I; 14 kDa lectin; 14 kDa lamininbinding protein; 14 kDa laminin-binding protein T09544 FUNCTION Plays a role in regulating apoptosis, cell proliferation and cell differentiation. Inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. Strong inducer of T-cell apoptosis. Lectin that binds beta-galactoside and a wide array of complex carbohydrates. T09544 PDBSTRUC 6F83; 6B94; 5MWX; 5MWT; 4Y24 T09544 SEQUENCE MACGLVASNLNLKPGECLRVRGEVAPDAKSFVLNLGKDSNNLCLHFNPRFNAHGDANTIVCNSKDGGAWGTEQREAVFPFQPGSVAEVCITFDQANLTVKLPDGYEFKFPNRLNLEAINYMAADGDFKIKCVAFD T09544 DRUGINFO D0D1JC US8703720, 15 Patented T09544 DRUGINFO D0N0DD US8703720, Reference Compound 1 Patented T09544 DRUGINFO D0N5RH US8703720, Reference Compound 2 Patented T90751 TARGETID T90751 T90751 UNIPROID MGAT1_HUMAN T90751 TARGNAME N-acetylglucosaminyltransferase I (NAGAT1) T90751 GENENAME MGAT1 T90751 TARGTYPE Patented-recorded T90751 SYNONYMS N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase I; MGAT; GlcNAc-T I; GNT-I; GLCT1; GGNT1; Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase T90751 FUNCTION Initiates complex N-linked carbohydrate formation. Essential for the conversion of high-mannose to hybrid and complex N-glycans. T90751 ECNUMBER EC 2.4.1.101 T90751 SEQUENCE MLKKQSAGLVLWGAILFVAWNALLLLFFWTRPAPGRPPSVSALDGDPASLTREVIRLAQDAEVELERQRGLLQQIGDALSSQRGRVPTAAPPAQPRVPVTPAPAVIPILVIACDRSTVRRCLDKLLHYRPSAELFPIIVSQDCGHEETAQAIASYGSAVTHIRQPDLSSIAVPPDHRKFQGYYKIARHYRWALGQVFRQFRFPAAVVVEDDLEVAPDFFEYFRATYPLLKADPSLWCVSAWNDNGKEQMVDASRPELLYRTDFFPGLGWLLLAELWAELEPKWPKAFWDDWMRRPEQRQGRACIRPEISRTMTFGRKGVSHGQFFDQHLKFIKLNQQFVHFTQLDLSYLQREAYDRDFLARVYGAPQLQVEKVRTNDRKELGEVRVQYTGRDSFKAFAKALGVMDDLKSGVPRAGYRGIVTFQFRGRRVHLAPPLTWEGYDPSWN T90751 DRUGINFO D01DYO US9656955, Example 652 Patented T90751 DRUGINFO D01OZO US9586945, 1 Patented T90751 DRUGINFO D06WEY US9586945, 19a Patented T90751 DRUGINFO D0A0ND US9586942, 2 Patented T90751 DRUGINFO D0BJ3R US9656955, Example 540 Patented T90751 DRUGINFO D0L5AE US9586942, 16 Patented T90751 DRUGINFO D0NT3V US9586942, 3* Patented T90751 DRUGINFO D0V1PW US9656955, Example 351 Patented T90751 DRUGINFO D0Y6FF US9586945, 5 Patented T03529 TARGETID T03529 T03529 FORMERID TTDI03513 T03529 UNIPROID RGS8_HUMAN T03529 TARGNAME Regulator of G-protein signaling 8 (RGS8) T03529 GENENAME RGS8 T03529 TARGTYPE Patented-recorded T03529 SYNONYMS RGS8 T03529 FUNCTION Regulates G protein-coupled receptor signaling cascades, including signaling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2 (By similarity). Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. Modulates the activity of potassium channels that are activated in response to DRD2 and CHRM2 signaling (By similarity). T03529 PDBSTRUC 5DO9; 2ODE; 2IHD T03529 SEQUENCE MAALLMPRRNKGMRTRLGCLSHKSDSCSDFTAILPDKPNRALKRLSTEEATRWADSFDVLLSHKYGVAAFRAFLKTEFSEENLEFWLACEEFKKTRSTAKLVSKAHRIFEEFVDVQAPREVNIDFQTREATRKNLQEPSLTCFDQAQGKVHSLMEKDSYPRFLRSKMYLDLLSQSQRRLS T03529 DRUGINFO D01GFH 1-Benzyl-3-bromo-1H-pyrrole-2,5-dione Patented T03529 DRUGINFO D0E9JL 1-Benzyl-3-p-tolyl-1H-pyrrole-2,5-dione Patented T03529 DRUGINFO D05AMQ thiadiazolidinone (TDZD) deriv. 6 Investigative T03529 DRUGINFO D0C2GR CCG-50014 Investigative T03529 DRUGINFO D0M5DR RGS4 inhibitor 13 Investigative T12797 TARGETID T12797 T12797 FORMERID TTDR00711 T12797 UNIPROID B2LA1_HUMAN T12797 TARGNAME Bcl-2-related protein A1 (BCL2A1) T12797 GENENAME BCL2A1 T12797 TARGTYPE Patented-recorded T12797 SYNONYMS Protein GRS; Protein BFL-1; Hemopoietic-specific early response protein; HBPA1; GRS; Bcl2-L-5; Bcl-2-like protein 5; BFL1; BCL2L5 T12797 FUNCTION Retards apoptosis induced by IL-3 deprivation. May function in the response of hemopoietic cells to external signals and in maintaining endothelial survival during infection (By similarity). Can inhibit apoptosis induced by serum starvation in the mammary epithelial cell line HC11 (By similarity). T12797 PDBSTRUC 6MBC; 6MBB; 6E3J; 6E3I; 5WHI T12797 SEQUENCE MTDCEFGYIYRLAQDYLQCVLQIPQPGSGPSKTSRVLQNVAFSVQKEVEKNLKSCLDNVNVVSVDTARTLFNQVMEKEFEDGIINWGRIVTIFAFEGILIKKLLRQQIAPDVDTYKEISYFVAEFIMNNTGEWIRQNGGWENGFVKKFEPKSGWMTFLEVTGKICEMLSLLKQYC T12797 DRUGINFO D03TTE Apogossypolone Patented T12797 DRUGINFO D0B1UL US8937193-compound-7 Patented T12797 DRUGINFO D0CR9A US8937193-compound-6b Patented T48812 TARGETID T48812 T48812 FORMERID TTDI03507 T48812 UNIPROID RORB_HUMAN T48812 TARGNAME RAR-related orphan receptor-beta (RORB) T48812 GENENAME RORB T48812 TARGTYPE Patented-recorded T48812 SYNONYMS Retinoid-related orphan receptor-beta; RZRB; Nuclear receptor subfamily 1 group F member 2; Nuclear receptor RZR-beta; Nuclear receptor ROR-beta; NR1F2 T48812 FUNCTION Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Considered to have intrinsic transcriptional activity, have some natural ligands such as all-trans retinoic acid (ATRA) and other retinoids which act as inverse agonists repressing the transcriptional activity. Required for normal postnatal development of rod and cone photoreceptor cells. Modulates rod photoreceptors differentiation at least by inducing the transcription factor NRL-mediated pathway. In cone photoreceptor cells, regulates transcription of OPN1SW. Involved in the regulation of the period length and stability of the circadian rhythm. May control cytoarchitectural patterning of neocortical neurons during development. May act in a dose-dependent manner to regulate barrel formation upon innervation of layer IV neurons by thalamocortical axons. May play a role in the suppression of osteoblastic differentiation through the inhibition of RUNX2 transcriptional activity (By similarity). T48812 SEQUENCE MCENQLKTKADATAQIEVIPCKICGDKSSGIHYGVITCEGCKGFFRRSQQNNASYSCPRQRNCLIDRTNRNRCQHCRLQKCLALGMSRDAVKFGRMSKKQRDSLYAEVQKHQQRLQEQRQQQSGEAEALARVYSSSISNGLSNLNNETSGTYANGHVIDLPKSEGYYNVDSGQPSPDQSGLDMTGIKQIKQEPIYDLTSVPNLFTYSSFNNGQLAPGITMTEIDRIAQNIIKSHLETCQYTMEELHQLAWQTHTYEEIKAYQSKSREALWQQCAIQITHAIQYVVEFAKRITGFMELCQNDQILLLKSGCLEVVLVRMCRAFNPLNNTVLFEGKYGGMQMFKALGSDDLVNEAFDFAKNLCSLQLTEEEIALFSSAVLISPDRAWLIEPRKVQKLQEKIYFALQHVIQKNHLDDETLAKLIAKIPTITAVCNLHGEKLQVFKQSHPEIVNTLFPPLYKELFNPDCATGCK T48812 DRUGINFO D09YHB US9598431, 5 Patented T48812 DRUGINFO D0A9KU US9598431, 2 Patented T48812 DRUGINFO D0ZX6M US9598431, 1 Patented T48812 DRUGINFO D02EMH all-trans-4-oxo-retinoic acid Investigative T32335 TARGETID T32335 T32335 FORMERID TTDC00222 T32335 TARGNAME Inhibitor of nuclear factor kappa-B kinase (IKK) T32335 TARGTYPE Patented-recorded T32335 SYNONYMS IB kinase; IkappaB kinase; IKK T32335 FUNCTION Serine kinase that plays an essential role in the NF- kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators sincethey exert a negative regulation on canonical IKKs. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation. T32335 DRUGINFO D04HQH Dihydrothieno [2,3-e]indazole derivative 1 Patented T32335 DRUGINFO D07DBU Dihydrothieno [2,3-e]indazole derivative 4 Patented T32335 DRUGINFO D0EX5A Dihydrothieno [2,3-e]indazole derivative 3 Patented T32335 DRUGINFO D0T1MA Dihydrothieno [2,3-e]indazole derivative 2 Patented T32335 DRUGINFO D00YTQ BMS-345541 Investigative T32335 DRUGINFO D08UPA 4-hydroxy-2-nonenal Investigative T32335 DRUGINFO D0E0XV TPCA-1 Investigative T32335 DRUGINFO D0I7YL S1627 Investigative T32335 DRUGINFO D0T8IS MLN-120B Investigative T32335 DRUGINFO D0X8KC Arsenite Investigative T32335 DRUGINFO D06ZIO MRT67307 Investigative T32335 DRUGINFO D07MQC PS-1145 Investigative T32335 DRUGINFO D01OBJ 5-Bromo-6-methoxy-9H-beta-carboline Investigative T32335 DRUGINFO D03BJF PMID23099093C17d Investigative T05034 TARGETID T05034 T05034 TARGNAME Fatty acid-binding protein (FABP) T05034 TARGTYPE Patented-recorded T05034 SYNONYMS Fatty acid binding protein T05034 DRUGINFO D00PES PMID27109571-Compound-5 Patented T05034 DRUGINFO D00SAR PMID27109571-Compound-41 Patented T05034 DRUGINFO D01ENV PMID27109571-Compound-4 Patented T05034 DRUGINFO D03JDH PMID27109571-Compound-32 Patented T05034 DRUGINFO D04OXI PMID27109571-Compound-42 Patented T05034 DRUGINFO D06RWL PMID27109571-Compound-35 Patented T05034 DRUGINFO D07SSO PMID27109571-Compound-39 Patented T05034 DRUGINFO D08KCW PMID27109571-Compound-37 Patented T05034 DRUGINFO D0A6TU PMID27109571-Compound-40 Patented T05034 DRUGINFO D0FM6W PMID27109571-Compound-34 Patented T05034 DRUGINFO D0G4IS PMID27109571-Compound-2 Patented T05034 DRUGINFO D0J5AB PMID27109571-Compound-44 Patented T05034 DRUGINFO D0JI3T PMID27109571-Compound-43 Patented T05034 DRUGINFO D0KI1H PMID27109571-Compound-33 Patented T05034 DRUGINFO D0M6MM PMID27109571-Compound-3 Patented T05034 DRUGINFO D0MM7U PMID27109571-Compound-36 Patented T05034 DRUGINFO D0ST2K PMID27109571-Compound-6 Patented T05034 DRUGINFO D0XH0I PMID27109571-Compound-38 Patented T05034 DRUGINFO D0ZC2K PMID27109571-Compound-1 Patented T05034 DRUGINFO D0U5NW BVT-24834 Terminated T67054 TARGETID T67054 T67054 FORMERID TTDR00155 T67054 TARGNAME 5-HT 1 receptor (5HT1R) T67054 TARGTYPE Patented-recorded T67054 SYNONYMS Serotonin receptor 1; 5-hydroxytryptamine receptor 1; 5-HT1 receptor T67054 BIOCLASS GPCR rhodopsin T67054 DRUGINFO D0F9TY Aryl piperazine derivative 16 Patented T67054 DRUGINFO D0M9LM Aryl piperazine derivative 14 Patented T67054 DRUGINFO D0T7HK Aryl piperazine derivative 15 Patented T67054 DRUGINFO D03PJW RU 24969 Terminated T67054 DRUGINFO D0IJ5I Befiperide Terminated T67054 DRUGINFO D0MS1D FCE-25876 Terminated T67054 DRUGINFO D0O8UF SRSS-023 Terminated T67054 DRUGINFO D0X8ZA Cyanopindolol Investigative T02629 TARGETID T02629 T02629 TARGNAME JNK-interacting protein peptide (pepJIP) T02629 TARGTYPE Patented-recorded T02629 SYNONYMS pepJIP T02629 DRUGINFO D08JIS PMID25991433-Compound-N3 Patented T02629 DRUGINFO D08OJQ PMID25991433-Compound-L2 Patented T02629 DRUGINFO D0G7LB PMID25991433-Compound-L3 Patented T02629 DRUGINFO D0Q8CR PMID25991433-Compound-L1 Patented T06773 TARGETID T06773 T06773 TARGNAME Hypoxia-inducible factor 1 (HIF-1) T06773 TARGTYPE Patented-recorded T06773 SYNONYMS HIF-1 T06773 DRUGINFO D00GOM 2,2-dimethylbenzopyran derivative 2 Patented T06773 DRUGINFO D00KDT Oligooxopiperazine derivative 1 Patented T06773 DRUGINFO D00WZJ 2,2-dimethylbenzopyran derivative 3 Patented T06773 DRUGINFO D01DSL Triptolidenol analog 1 Patented T06773 DRUGINFO D02JDR Aromatic and heteroaryl compound 1 Patented T06773 DRUGINFO D02PFE Steroid derivative 4 Patented T06773 DRUGINFO D03OYJ PMID26882240-Compound-32 Patented T06773 DRUGINFO D04AQR Imidazo [1,2-a]pyridine compound 1 Patented T06773 DRUGINFO D05MTZ PMID26882240-Compound-7 Patented T06773 DRUGINFO D06CBI PMID26882240-Compound-4 Patented T06773 DRUGINFO D07MRK Tlouidine sulfonamide derivative 1 Patented T06773 DRUGINFO D08VON PMID26882240-Compound-15 Patented T06773 DRUGINFO D09BXO Steroid derivative 2 Patented T06773 DRUGINFO D09GXN Benzanilide compound 2 Patented T06773 DRUGINFO D09NFI Steroid derivative 3 Patented T06773 DRUGINFO D0AY8W Benzanilide compound 1 Patented T06773 DRUGINFO D0E6VS Steroid derivative 1 Patented T06773 DRUGINFO D0EO1L PMID26882240-Compound-3 Patented T06773 DRUGINFO D0FB3R Alkaloid derivative 4 Patented T06773 DRUGINFO D0H4WT Peptidomimetic analog 7 Patented T06773 DRUGINFO D0HJ2J Cyclic octapeptide derivative 1 Patented T06773 DRUGINFO D0J3NY Benzene sulfonamide derivative 8 Patented T06773 DRUGINFO D0JJ1N Matairesinol derivative 1 Patented T06773 DRUGINFO D0K0PG PMID26882240-Compound-6 Patented T06773 DRUGINFO D0LK6V 2,2-dimethylbenzopyran derivative 1 Patented T06773 DRUGINFO D0M0UE PMID26882240-Compound-2 Patented T06773 DRUGINFO D0N4ON Aryl methoxyacrylate derivative 1 Patented T06773 DRUGINFO D0OQ2S PMID26882240-Compound-14 Patented T06773 DRUGINFO D0RT4U Aryl carbamate analog 1 Patented T06773 DRUGINFO D0TV4O Aryl methoxyacrylate derivative 2 Patented T06773 DRUGINFO D0V7OU PMID26882240-Compound-8 Patented T06773 DRUGINFO D0L1TA PMID26882240-Compound-1 Patented T10565 TARGETID T10565 T10565 TARGNAME Lysine-specific demethylase 4 (KDM4) T10565 TARGTYPE Patented-recorded T10565 SYNONYMS KDM4 T10565 DRUGINFO D01IYF N-oxalylglycine derivative 2 Patented T10565 DRUGINFO D02URA Pyridine-2,4-dicarboxylic acid derivative 1 Patented T10565 DRUGINFO D05HBS Hydroxamate analog 3 Patented T10565 DRUGINFO D05YBG PMID25468267-Compound-51 Patented T10565 DRUGINFO D06XXJ PMID25468267-Compound-54 Patented T10565 DRUGINFO D07GAP N-oxalylglycine derivative 3 Patented T10565 DRUGINFO D0B4VO PMID25468267-Compound-48 Patented T10565 DRUGINFO D0B5WF Pyridine-2,4-dicarboxylic acid derivative 2 Patented T10565 DRUGINFO D0B7GQ 2,2-bipyridyl derivative 5 Patented T10565 DRUGINFO D0C1CV Pyridine-2,4-dicarboxylic acid derivative 3 Patented T10565 DRUGINFO D0EY9Y PMID25468267-Compound-53 Patented T10565 DRUGINFO D0G8SB 2,2-bipyridyl derivative 3 Patented T10565 DRUGINFO D0J1OK N-oxalylglycine derivative 1 Patented T10565 DRUGINFO D0J6OC PMID25468267-Compound-52 Patented T10565 DRUGINFO D0K1PP Hydroxamate analog 2 Patented T10565 DRUGINFO D0K2OT 2,2-bipyridyl derivative 2 Patented T10565 DRUGINFO D0R1OG 2,2-bipyridyl derivative 1 Patented T10565 DRUGINFO D0TH2W PMID25468267-Compound-49 Patented T10565 DRUGINFO D0YZ1B PMID25468267-Compound-50 Patented T10565 DRUGINFO D0ZW5H 2,2-bipyridyl derivative 4 Patented T12183 TARGETID T12183 T12183 TARGNAME NAD-dependent deacetylase sirtuin (SIRT) T12183 TARGTYPE Patented-recorded T12183 SYNONYMS NAD+-dependent deacetylase SIRT T12183 DRUGINFO D04MTT PMID25435179-Compound-WO2012006391H3K9TSu Patented T12183 DRUGINFO D06XWC PMID25435179-Compound-WO2014110399Splitomycin Patented T12183 DRUGINFO D09HHL Quinoline derivative 19 Patented T12183 DRUGINFO D0D7MV Quinoline derivative 18 Patented T12183 DRUGINFO D0F5ND PMID25435179-Compound-WO2013059594(IV) Patented T12183 DRUGINFO D0FU6L Quinoline derivative 20 Patented T12183 DRUGINFO D0GD7H PMID25435179-Compound-WO2013059594(III) Patented T12183 DRUGINFO D0IG7E H3K7T Patented T12183 DRUGINFO D0JN5O PMID25435179-Compound-EP20142759295NP-1 Patented T12183 DRUGINFO D0N9RD PMID25435179-Compound-US2012165330(I) Patented T12183 DRUGINFO D0OQ7S PMID25435179-Compound-WO2013059587(VI, 2nd set) Patented T12183 DRUGINFO D0Q8VI PMID25435179-Compound-WO2013059587(V, 1st set) Patented T12183 DRUGINFO D0WW2H Triazolo[4,3-b]pyridazine derivative 1 Patented T12183 DRUGINFO D0X2BO PMID25435179-Compound-WO2012149608USYDS1 Patented T15923 TARGETID T15923 T15923 TARGNAME Serine/threonine-protein phosphatase (PSP) T15923 TARGTYPE Patented-recorded T15923 SYNONYMS Protein serine/threonine phosphatase T16224 TARGETID T16224 T16224 TARGNAME Sphingosine kinase (SphK) T16224 TARGTYPE Patented-recorded T16224 SYNONYMS SphK T16224 DRUGINFO D01XFM 2-piperidine thiazole derivative 2 Patented T16224 DRUGINFO D0A9KH PMID27539678-Compound-3 Patented T16224 DRUGINFO D0AH8N Imidamide derivative 1 Patented T16224 DRUGINFO D0AR5O PMID27539678-Compound-4 Patented T16224 DRUGINFO D0GS2P 2-piperidine thiazole derivative 1 Patented T16224 DRUGINFO D0I8RX Sulfonamide derivative 17 Patented T16224 DRUGINFO D0IH3T PMID27539678-Compound-8 Patented T19543 TARGETID T19543 T19543 TARGNAME Phosphoprotein phosphatases 1 (PP1) T19543 TARGTYPE Patented-recorded T19543 SYNONYMS Protein phosphatase 1 T12819 TARGETID T12819 T12819 FORMERID TTDI01954 T12819 UNIPROID COP1_HUMAN T12819 TARGNAME E3 ubiquitin-protein ligase COP1 (RFWD2) T12819 GENENAME RFWD2 T12819 TARGTYPE Literature-reported T12819 SYNONYMS hCOP1; RNF200; RING-type E3 ubiquitin transferase RFWD2; RING finger protein 200; RING finger and WD repeat domain protein 2; E3 ubiquitinprotein ligase RFWD2; Constitutive photomorphogenesis protein 1 homolog; COP1 T12819 FUNCTION E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Involved in JUN ubiquitination and degradation. Directly involved in p53 (TP53) ubiquitination and degradation, thereby abolishing p53-dependent transcription and apoptosis. Ubiquitinates p53 independently of MDM2 or RCHY1. Probably mediates E3 ubiquitin ligase activity by functioning as the essential RING domain subunit of larger E3 complexes. In contrast, it does not constitute the catalytic RING subunit in the DCX DET1-COP1 complex that negatively regulates JUN, the ubiquitin ligase activity being mediated by RBX1. Involved in 14-3-3 protein sigma/SFN ubiquitination and proteasomal degradation, leading to AKT activation and promotion of cell survival. Ubiquitinates MTA1 leading to its proteasomal degradation. Upon binding to TRIB1, ubiquitinates CEBPA, which lacks a canonical COP1-binding motif. E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins. T12819 PDBSTRUC 5IGQ; 5HQG T12819 BIOCLASS Acyltransferase T12819 ECNUMBER EC 2.3.2.27 T12819 SEQUENCE MSGSRQAGSGSAGTSPGSSAASSVTSASSSLSSSPSPPSVAVSAAALVSGGVAQAAGSGGLGGPVRPVLVAPAVSGSGGGAVSTGLSRHSCAARPSAGVGGSSSSLGSGSRKRPLLAPLCNGLINSYEDKSNDFVCPICFDMIEEAYMTKCGHSFCYKCIHQSLEDNNRCPKCNYVVDNIDHLYPNFLVNELILKQKQRFEEKRFKLDHSVSSTNGHRWQIFQDWLGTDQDNLDLANVNLMLELLVQKKKQLEAESHAAQLQILMEFLKVARRNKREQLEQIQKELSVLEEDIKRVEEMSGLYSPVSEDSTVPQFEAPSPSHSSIIDSTEYSQPPGFSGSSQTKKQPWYNSTLASRRKRLTAHFEDLEQCYFSTRMSRISDDSRTASQLDEFQECLSKFTRYNSVRPLATLSYASDLYNGSSIVSSIEFDRDCDYFAIAGVTKKIKVYEYDTVIQDAVDIHYPENEMTCNSKISCISWSSYHKNLLASSDYEGTVILWDGFTGQRSKVYQEHEKRCWSVDFNLMDPKLLASGSDDAKVKLWSTNLDNSVASIEAKANVCCVKFSPSSRYHLAFGCADHCVHYYDLRNTKQPIMVFKGHRKAVSYAKFVSGEEIVSASTDSQLKLWNVGKPYCLRSFKGHINEKNFVGLASNGDYIACGSENNSLYLYYKGLSKTLLTFKFDTVKSVLDKDRKEDDTNEFVSAVCWRALPDGESNVLIAANSQGTIKVLELV T99295 TARGETID T99295 T99295 UNIPROID PI4KA_HUMAN T99295 TARGNAME Phosphatidylinositol-4-kinase alpha (PI4KA) T99295 GENENAME PI4KA T99295 TARGTYPE Literature-reported T99295 SYNONYMS PtdIns-4-kinase alpha; PI4K-alpha; PI4-kinase alpha T99295 FUNCTION Acts on phosphatidylinositol (PtdIns) in the first committed step in the production of the second messenger inositol-1,4,5,-trisphosphate. T99295 PDBSTRUC 6BQ1 T99295 BIOCLASS PI3/PI4-kinase family. Type III PI4K subfamily T99295 ECNUMBER EC 2.7.1.67 T99295 SEQUENCE MAAAPARGGGGGGGGGGGCSGSGSSASRGFYFNTVLSLARSLAVQRPASLEKVQKLLCMCPVDFHGIFQLDERRRDAVIALGIFLIESDLQHKDCVVPYLLRLLKGLPKVYWVEESTARKGRGALPVAESFSFCLVTLLSDVAYRDPSLRDEILEVLLQVLHVLLGMCQALEIQDKEYLCKYAIPCLIGISRAFGRYSNMEESLLSKLFPKIPPHSLRVLEELEGVRRRSFNDFRSILPSNLLTVCQEGTLKRKTSSVSSISQVSPERGMPPPSSPGGSAFHYFEASCLPDGTALEPEYYFSTISSSFSVSPLFNGVTYKEFNIPLEMLRELLNLVKKIVEEAVLKSLDAIVASVMEANPSADLYYTSFSDPLYLTMFKMLRDTLYYMKDLPTSFVKEIHDFVLEQFNTSQGELQKILHDADRIHNELSPLKLRCQANAACVDLMVWAVKDEQGAENLCIKLSEKLQSKTSSKVIIAHLPLLICCLQGLGRLCERFPVVVHSVTPSLRDFLVIPSPVLVKLYKYHSQYHTVAGNDIKISVTNEHSESTLNVMSGKKSQPSMYEQLRDIAIDNICRCLKAGLTVDPVIVEAFLASLSNRLYISQESDKDAHLIPDHTIRALGHIAVALRDTPKVMEPILQILQQKFCQPPSPLDVLIIDQLGCLVITGNQYIYQEVWNLFQQISVKASSVVYSATKDYKDHGYRHCSLAVINALANIAANIQDEHLVDELLMNLLELFVQLGLEGKRASERASEKGPALKASSSAGNLGVLIPVIAVLTRRLPPIKEAKPRLQKLFRDFWLYSVLMGFAVEGSGLWPEEWYEGVCEIATKSPLLTFPSKEPLRSVLQYNSAMKNDTVTPAELSELRSTIINLLDPPPEVSALINKLDFAMSTYLLSVYRLEYMRVLRSTDPDRFQVMFCYFEDKAIQKDKSGMMQCVIAVADKVFDAFLNMMADKAKTKENEEELERHAQFLLVNFNHIHKRIRRVADKYLSGLVDKFPHLLWSGTVLKTMLDILQTLSLSLSADIHKDQPYYDIPDAPYRITVPDTYEARESIVKDFAARCGMILQEAMKWAPTVTKSHLQEYLNKHQNWVSGLSQHTGLAMATESILHFAGYNKQNTTLGATQLSERPACVKKDYSNFMASLNLRNRYAGEVYGMIRFSGTTGQMSDLNKMMVQDLHSALDRSHPQHYTQAMFKLTAMLISSKDCDPQLLHHLCWGPLRMFNEHGMETALACWEWLLAGKDGVEVPFMREMAGAWHMTVEQKFGLFSAEIKEADPLAASEASQPKPCPPEVTPHYIWIDFLVQRFEIAKYCSSDQVEIFSSLLQRSMSLNIGGAKGSMNRHVAAIGPRFKLLTLGLSLLHADVVPNATIRNVLREKIYSTAFDYFSCPPKFPTQGEKRLREDISIMIKFWTAMFSDKKYLTASQLVPPDNQDTRSNLDITVGSRQQATQGWINTYPLSSGMSTISKKSGMSKKTNRGSQLHKYYMKRRTLLLSLLATEIERLITWYNPLSAPELELDQAGENSVANWRSKYISLSEKQWKDNVNLAWSISPYLAVQLPARFKNTEAIGNEVTRLVRLDPGAVSDVPEAIKFLVTWHTIDADAPELSHVLCWAPTDPPTGLSYFSSMYPPHPLTAQYGVKVLRSFPPDAILFYIPQIVQALRYDKMGYVREYILWAASKSQLLAHQFIWNMKTNIYLDEEGHQKDPDIGDLLDQLVEEITGSLSGPAKDFYQREFDFFNKITNVSAIIKPYPKGDERKKACLSALSEVKVQPGCYLPSNPEAIVLDIDYKSGTPMQSAAKAPYLAKFKVKRCGVSELEKEGLRCRSDSEDECSTQEADGQKISWQAAIFKVGDDCRQDMLALQIIDLFKNIFQLVGLDLFVFPYRVVATAPGCGVIECIPDCTSRDQLGRQTDFGMYDYFTRQYGDESTLAFQQARYNFIRSMAAYSLLLFLLQIKDRHNGNIMLDKKGHIIHIDFGFMFESSPGGNLGWEPDIKLTDEMVMIMGGKMEATPFKWFMEMCVRGYLAVRPYMDAVVSLVTLMLDTGLPCFRGQTIKLLKHRFSPNMTEREAANFIMKVIQSCFLSNRSRTYDMIQYYQNDIPY T88451 TARGETID T88451 T88451 UNIPROID KIT_HUMAN T88451 TARGNAME Mutated tyrosine-protein kinase Kit (mKIT) T88451 GENENAME KIT T88451 TARGTYPE Literature-reported T88451 SYNONYMS v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (mutated); p145 c-kit (mutated); Tyrosine-protein kinase Kit (mutated); SCFR; Proto-oncogene c-Kit (mutated); Piebald trait protein (mutated); PBT (mutated); Mast/stem cell growth factor receptor Kit (mutated); CD117 (mutated) T88451 FUNCTION Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1. T88451 PDBSTRUC 6GQM; 6GQL; 6GQK; 6GQJ; 4U0I T88451 BIOCLASS Kinase T88451 ECNUMBER EC 2.7.10.1 T88451 SEQUENCE MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTPLLIGFVIVAGMMCIIVMILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELKVLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAALYKNLLHSKESSCSDSTNEYMDMKPGVSYVVPTKADKRRSVRIGSYIERDVTPAIMEDDELALDLEDLLSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLARDIKNDSNYVVKGNARLPVKWMAPESIFNCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMLSPEHAPAEMYDIMKTCWDADPLKRPTFKQIVQLIEKQISESTNHIYSNLANCSPNRQKPVVDHSVRINSVGSTASSSQPLLVHDDV T98134 TARGETID T98134 T98134 FORMERID TTDI03415 T98134 UNIPROID NUCB1_HUMAN T98134 TARGNAME Nucleobindin-1 (NUCB1) T98134 GENENAME NUCB1 T98134 TARGTYPE Literature-reported T98134 SYNONYMS NUC; CALNUC T98134 FUNCTION Major calcium-binding protein of the Golgi. May have a role in calcium homeostasis (By similarity). T98134 PDBSTRUC 1SNL T98134 SEQUENCE MPPSGPRGTLLLLPLLLLLLLRAVLAVPLERGAPNKEETPATESPDTGLYYHRYLQEVIDVLETDGHFREKLQAANAEDIKSGKLSRELDFVSHHVRTKLDELKRQEVSRLRMLLKAKMDAEQDPNVQVDHLNLLKQFEHLDPQNQHTFEARDLELLIQTATRDLAQYDAAHHEEFKRYEMLKEHERRRYLESLGEEQRKEAERKLEEQQRRHREHPKVNVPGSQAQLKEVWEELDGLDPNRFNPKTFFILHDINSDGVLDEQELEALFTKELEKVYDPKNEEDDMREMEEERLRMREHVMKNVDTNQDRLVTLEEFLASTQRKEFGDTGEGWETVEMHPAYTEEELRRFEEELAAREAELNAKAQRLSQETEALGRSQGRLEAQKRELQQAVLHMEQRKQQQQQQQGHKAPAAHPEGQLKFHPDTDDVPVPAPAGDQKEVDTSEKKLLERLPEVEVPQHL T98134 DRUGINFO D01XLZ MJN228 Investigative T98134 DRUGINFO D0S9AT KML110 Investigative T95295 TARGETID T95295 T95295 UNIPROID RPB1_HUMAN; RPB2_HUMAN; RPB3_HUMAN T95295 TARGNAME DNA-directed RNA polymerase II (RNAP II) T95295 GENENAME POLR2A; POLR2B; POLR2C T95295 TARGTYPE Literature-reported T95295 SYNONYMS RPB; RNA-directed RNA polymerase II; RNA polymerase II T95295 FUNCTION DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1/RPB2/RPB3 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. T95295 SEQUENCE MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERTGRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQPKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKHVNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARNQDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLKQRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRRGNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRILPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTAVRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDDEDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWLLIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDARDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYGPESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSINQVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNELEREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKLVIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVGALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKDILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDRKLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNMLTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSNDIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLMKCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAAGPTGMFFGSAPSPMGGISPAMTPWNQGATPAYGAWSPSVGSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPSYSPTSPAYEPRSPGGYTPQSPSYSPTSPSYSPTSPSYSPTSPNYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPNYSPTSPNYTPTSPSYSPTSPSYSPTSPNYTPTSPNYSPTSPSYSPTSPSYSPTSPSYSPSSPRYTPQSPTYTPSSPSYSPSSPSYSPASPKYTPTSPSYSPSSPEYTPTSPKYSPTSPKYSPTSPKYSPTSPTYSPTTPKYSPTSPTYSPTSPVYTPTSPKYSPTSPTYSPTSPKYSPTSPTYSPTSPKGSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN T03818 TARGETID T03818 T03818 FORMERID TTDR01386 T03818 UNIPROID PPARG_HUMAN T03818 TARGNAME PPAR-gamma messenger RNA (PPARG mRNA) T03818 GENENAME PPARG T03818 TARGTYPE Literature-reported T03818 SYNONYMS Transcription factor PPAR gamma receptor (mRNA); Peroxisome proliferator-activated receptor gamma (mRNA); PPARgamma (mRNA); PPAR-gamma (mRNA); Nuclear receptor subfamily 1 group C member 3 (mRNA); NR1C3 (mRNA) T03818 FUNCTION Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels. Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. T03818 PDBSTRUC 6MD4; 6MD2; 6MD1; 6MD0; 6MCZ T03818 BIOCLASS mRNA target T03818 SEQUENCE MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY T03818 DRUGINFO D0JU5X Bardoxolone methyl Phase 3 T03818 DRUGINFO D0LB4T AD-5075 Terminated T03818 DRUGINFO D01RPM (E)-9-nitrooctadec-9-enoic acid Investigative T03818 DRUGINFO D01UVA tagitinin A Investigative T03818 DRUGINFO D03BPG T0070907 Investigative T03818 DRUGINFO D04DYM GW1929 Investigative T03818 DRUGINFO D04FVX (E)-9-Nitrohexadec-9-enoicAcid Investigative T03818 DRUGINFO D06IHG (E)-10-nitrooctadec-9-enoic acid Investigative T03818 DRUGINFO D06NHI SB-213068 Investigative T03818 DRUGINFO D06OBX tirotundin Investigative T03818 DRUGINFO D06UVY L-Tryptophan-L-aspartic acid Investigative T03818 DRUGINFO D07IHY BRL-48482 Investigative T03818 DRUGINFO D08QKF nTzDpa Investigative T03818 DRUGINFO D0A1SP COOH Investigative T03818 DRUGINFO D0B2UF ISIS 105990 Investigative T03818 DRUGINFO D0B9MZ ISIS 106008 Investigative T03818 DRUGINFO D0D0FQ CHLOROCYCLINONE A Investigative T03818 DRUGINFO D0G3IV ISIS 105987 Investigative T03818 DRUGINFO D0G9AI L-Tryptophan-L-glutamine Investigative T03818 DRUGINFO D0HI6O PAT5A Investigative T03818 DRUGINFO D0I2DF GNF-PF-2893 Investigative T03818 DRUGINFO D0IW8V L-Tryptophan-L-asparagine Investigative T03818 DRUGINFO D0J9ZA L-Tryptophan-L-2-aminoadipic acid Investigative T03818 DRUGINFO D0L4PT L-764406 Investigative T03818 DRUGINFO D0M7AT L-Tryptophan-L-arginine Investigative T03818 DRUGINFO D0NW8N ISIS 105989 Investigative T03818 DRUGINFO D0P1US [125I]SB-236636 Investigative T03818 DRUGINFO D0Q4EU BADGE Investigative T03818 DRUGINFO D0Q4UD (E)-5-Nitrooctadec-5-enoic Acid Investigative T03818 DRUGINFO D0R9VV CHLOROCYCLINONE C Investigative T03818 DRUGINFO D0RL8P CHLOROCYCLINONE B Investigative T03818 DRUGINFO D0SO9Q GW0072 Investigative T03818 DRUGINFO D0T8JM [3H]GW2331 Investigative T03818 DRUGINFO D0U5HX CHLOROCYCLINONE D Investigative T03818 DRUGINFO D0W9WU (E)-10-Nitrohexadec-9-enoic Acid Investigative T03818 DRUGINFO D0X3RZ L-Tryptophan-L-leucine Investigative T03818 DRUGINFO D0X9UJ PD-068235 Investigative T03818 DRUGINFO D0Z2CY Ploglitazone Investigative T03818 DRUGINFO D0Z4NW (E)-6-Nitrooctadec-5-enoic Acid Investigative T03818 DRUGINFO D00EOP AD-5061 Investigative T03818 DRUGINFO D04JOG TZD18 Investigative T03818 DRUGINFO D06GYO (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid Investigative T03818 DRUGINFO D08XGH reglitazar Investigative T03818 DRUGINFO D0M8VN DRF 2519 Investigative T03818 DRUGINFO D0M9LL (E)-12-Nitrooctadec-12-enoic Acid Investigative T03818 DRUGINFO D0P5QM (E)-13-Nitrooctadec-12-enoic Acid Investigative T03818 DRUGINFO D0P8XE GNF-PF-3037 Investigative T03818 DRUGINFO D0Z7OX LY-465608 Investigative T03818 DRUGINFO D00ACX 2-chloro-5-nitro-N-phenylbenzamide Investigative T03818 DRUGINFO D09JII L-796449 Investigative T03818 DRUGINFO D0F0MP L-165461 Investigative T03818 DRUGINFO D08QXD L-783483 Investigative T03818 DRUGINFO D0Q9FZ LG100754 Investigative T85250 TARGETID T85250 T85250 FORMERID TTDR01394 T85250 UNIPROID GSK3A_HUMAN T85250 TARGNAME GSK3A messenger RNA (GSK3A mRNA) T85250 GENENAME GSK3A T85250 TARGTYPE Literature-reported T85250 SYNONYMS Serine/threonineprotein kinase GSK3A (mRNA); Serine/threonine-protein kinase GSK3A (mRNA); Glycogen synthase kinase3 alpha (mRNA); Glycogen synthase kinase 3 (mRNA); GSK3 alpha (mRNA); GSK-3 alpha (mRNA); GSK-3 (mRNA) T85250 FUNCTION Requires primed phosphorylation of the majority of its substrates. Contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. Regulates glycogen metabolism in liver, but not in muscle. May also mediate the development of insulin resistance by regulating activation of transcription factors. In Wnt signaling, regulates the level and transcriptional activity of nuclear CTNNB1/beta-catenin. Facilitates amyloid precursor protein (APP) processing and the generation of APP-derived amyloid plaques found in Alzheimer disease. May be involved in the regulation of replication in pancreatic beta-cells. Is necessary for the establishment of neuronal polarity and axon outgrowth. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, leading to activate KAT5/TIP60 acetyltransferase activity and promote acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer. Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), CTNNB1/beta-catenin, APC and AXIN1. T85250 PDBSTRUC 2DFM T85250 BIOCLASS mRNA target T85250 ECNUMBER EC 2.7.11.26 T85250 SEQUENCE MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGVGASSSGGGPGGSGGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYTDIKVIGNGSFGVVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGVCHRDIKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFKSRTPPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRCLGTQLPNNRPLPPLFNFSAGELSIQPSLNAILIPPHLRSPAGTTTLTPSSQALTETPTSSDWQSTDATPTLTNSS T85250 DRUGINFO D01YSX ISIS 116625 Investigative T85250 DRUGINFO D02EIC ISIS 116648 Investigative T85250 DRUGINFO D03YXG ISIS 116632 Investigative T85250 DRUGINFO D05PRC ISIS 116631 Investigative T85250 DRUGINFO D0H1OB ISIS 116670 Investigative T85250 DRUGINFO D0O7MX ISIS 116654 Investigative T85250 DRUGINFO D04ZWF CHIR-98014 Investigative T85250 DRUGINFO D0B3ZB indirubin deriv. 8a Investigative T85250 DRUGINFO D0K1DR LEUCETTAMINE B Investigative T85250 DRUGINFO D02XHC aloisine A Investigative T75386 TARGETID T75386 T75386 FORMERID TTDR01352 T75386 UNIPROID DGAT1_HUMAN T75386 TARGNAME DGAT1 messenger RNA (DGAT1 mRNA) T75386 GENENAME DGAT1 T75386 TARGTYPE Literature-reported T75386 SYNONYMS Retinol O-fatty-acyltransferase (mRNA); Diglyceride acyltransferase (mRNA); Diacylglycerol O-acyltransferase 1 (mRNA); DGAT (mRNA); Acyl-CoA retinol O-fatty-acyltransferase (mRNA); ARAT (mRNA); AGRP1 (mRNA); ACAT-related gene product 1 (mRNA) T75386 FUNCTION In contrast to DGAT2 it is not essential for survival. May be involved in VLDL (very low density lipoprotein) assembly. In liver, plays a role in esterifying exogenous fatty acids to glycerol. Functions as the major acyl-CoA retinol acyltransferase (ARAT) in the skin, where it acts to maintain retinoid homeostasis and prevent retinoid toxicity leading to skin and hair disorders. Catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. T75386 BIOCLASS mRNA target T75386 ECNUMBER EC 2.3.1.20 T75386 SEQUENCE MGDRGSSRRRRTGSRPSSHGGGGPAAAEEEVRDAAAGPDVGAAGDAPAPAPNKDGDAGVGSGHWELRCHRLQDSLFSSDSGFSNYRGILNWCVVMLILSNARLFLENLIKYGILVDPIQVVSLFLKDPYSWPAPCLVIAANVFAVAAFQVEKRLAVGALTEQAGLLLHVANLATILCFPAAVVLLVESITPVGSLLALMAHTILFLKLFSYRDVNSWCRRARAKAASAGKKASSAAAPHTVSYPDNLTYRDLYYFLFAPTLCYELNFPRSPRIRKRFLLRRILEMLFFTQLQVGLIQQWMVPTIQNSMKPFKDMDYSRIIERLLKLAVPNHLIWLIFFYWLFHSCLNAVAELMQFGDREFYRDWWNSESVTYFWQNWNIPVHKWCIRHFYKPMLRRGSSKWMARTGVFLASAFFHEYLVSVPLRMFRLWAFTGMMAQIPLAWFVGRFFQGNYGNAAVWLSLIIGQPIAVLMYVHDYYVLNYEAPAAEA T75386 DRUGINFO D01PKX ISIS 191731 Investigative T75386 DRUGINFO D01ZCH ISIS 191756 Investigative T75386 DRUGINFO D06YZW ISIS 191755 Investigative T75386 DRUGINFO D0D0OO ISIS 191759 Investigative T75386 DRUGINFO D0I4JB ISIS 191761 Investigative T75386 DRUGINFO D0T7SU ISIS 191729 Investigative T28043 TARGETID T28043 T28043 FORMERID TTDI03519 T28043 UNIPROID KS6A2_HUMAN T28043 TARGNAME Ribosomal protein S6 kinase alpha-2 (RSK2) T28043 GENENAME RPS6KA2 T28043 TARGTYPE Literature-reported T28043 SYNONYMS pp90RSK3; p90RSK2; p90-RSK 2; S6K-alpha-2; Ribosomal S6 kinase 3; RSK3; RSK-3; MAPKAPK1C; MAPKAPK-1c; MAPKAP kinase 1c; MAPK-activated protein kinase 1c; MAP kinase-activated protein kinase 1c; 90 kDa ribosomal protein S6 kinase 2 T28043 FUNCTION May function as tumor suppressor in epithelial ovarian cancer cells. Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of transcription factors, regulates translation, and mediates cellular proliferation, survival, and differentiation. T28043 BIOCLASS Kinase T28043 ECNUMBER EC 2.7.11.1 T28043 SEQUENCE MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRLEEEGVVKEIDISHHVKEGFEKADPSQFELLKVLGQGSYGKVFLVRKVKGSDAGQLYAMKVLKKATLKVRDRVRSKMERDILAEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENILLDEEGHIKITDFGLSKEAIDHDKRAYSFCGTIEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGSLPFQGKDRKETMALILKAKLGMPQFLSGEAQSLLRALFKRNPCNRLGAGIDGVEEIKRHPFFVTIDWNTLYRKEIKPPFKPAVGRPEDTFHFDPEFTARTPTDSPGVPPSANAHHLFRGFSFVASSLIQEPSQQDLHKVPVHPIVQQLHGNNIHFTDGYEIKEDIGVGSYSVCKRCVHKATDTEYAVKIIDKSKRDPSEEIEILLRYGQHPNIITLKDVYDDGKFVYLVMELMRGGELLDRILRQRYFSEREASDVLCTITKTMDYLHSQGVVHRDLKPSNILYRDESGSPESIRVCDFGFAKQLRAGNGLLMTPCYTANFVAPEVLKRQGYDAACDIWSLGILLYTMLAGFTPFANGPDDTPEEILARIGSGKYALSGGNWDSISDAAKDVVSKMLHVDPHQRLTAMQVLKHPWVVNREYLSPNQLSRQDVHLVKGAMAATYFALNRTPQAPRLEPVLSSNLAQRRGMKRLTSTRL T28043 DRUGINFO D02VBF BI-D1870 Preclinical T28043 DRUGINFO D09AID PMID22564207C25b Investigative T51385 TARGETID T51385 T51385 FORMERID TTDI02509 T51385 UNIPROID FFAR4_HUMAN T51385 TARGNAME G-protein coupled receptor 120 (GPR120) T51385 GENENAME FFAR4 T51385 TARGTYPE Literature-reported T51385 SYNONYMS PGR4; Omega3 fatty acid receptor 1; Omega-3 fatty acid receptor 1; O3FAR1; Gprotein coupled receptor PGR4; Gprotein coupled receptor GT01; Gprotein coupled receptor 129; GPR129; G-protein coupled receptor PGR4; G-protein coupled receptor GT01; G-protein coupled receptor 129; Free fatty acid receptor 4 T51385 FUNCTION Signals via a G(q)/G(11)-coupled pathway. Acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, particularly in macrophages and fat cells. The anti-inflammatory effects involve inhibition of TAK1 through a beta-arrestin 2 (ARRB2)/TAB1-dependent effect, but independent of the G(q)/G(11)-coupled pathway. Mediates potent insulin sensitizing and antidiabetic effects by repressing macrophage-induced tissue inflammation. May mediate the taste of fatty acids. Mediates FFA-induced inhibition of apoptosis in enteroendocrine cells. May play a role in the regulation of adipocyte development and differentiation. Receptor for medium and long-chain free fatty acids (FFAs). T51385 BIOCLASS GPCR rhodopsin T51385 SEQUENCE MSPECARAAGDAPLRSLEQANRTRFPFFSDVKGDHRLVLAAVETTVLVLIFAVSLLGNVCALVLVARRRRRGATACLVLNLFCADLLFISAIPLVLAVRWTEAWLLGPVACHLLFYVMTLSGSVTILTLAAVSLERMVCIVHLQRGVRGPGRRARAVLLALIWGYSAVAALPLCVFFRVVPQRLPGADQEISICTLIWPTIPGEISWDVSFVTLNFLVPGLVIVISYSKILQITKASRKRLTVSLAYSESHQIRVSQQDFRLFRTLFLLMVSFFIMWSPIIITILLILIQNFKQDLVIWPSLFFWVVAFTFANSALNPILYNMTLCRNEWKKIFCCFWFPEKGAILTDTSVKRNDLSIISG T51385 DRUGINFO D01VIX PMID24997608CA Investigative T51385 DRUGINFO D0E9AY grifolic acid Investigative T51385 DRUGINFO D0K6EG TUG-891 Investigative T51385 DRUGINFO D0N9SV NCG21 Investigative T51385 DRUGINFO D08ZYC GW9508 Investigative T51385 DRUGINFO D0C5SV alpha-linolenic acid Investigative T75476 TARGETID T75476 T75476 FORMERID TTDR01108 T75476 UNIPROID MYD88_HUMAN T75476 TARGNAME Myeloid differentiation primary response protein MyD88 (MYD88) T75476 GENENAME MYD88 T75476 TARGTYPE Literature-reported T75476 SYNONYMS MyD88 T75476 FUNCTION Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription. Involved in IL-18-mediated signaling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. MyD88-mediated signaling in intestinal epithelial cells is crucial for maintenance of gut homeostasis and controls the expression of the antimicrobial lectin REG3G in the small intestine. Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response. T75476 PDBSTRUC 4EO7; 4DOM; 3MOP; 2Z5V; 2JS7 T75476 SEQUENCE MAAGGPGAGSAAPVSSTSSLPLAALNMRVRRRLSLFLNVRTQVAADWTALAEEMDFEYLEIRQLETQADPTGRLLDAWQGRPGASVGRLLELLTKLGRDDVLLELGPSIEEDCQKYILKQQQEEAEKPLQVAAVDSSVPRTAELAGITTLDDPLGHMPERFDAFICYCPSDIQFVQEMIRQLEQTNYRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDYLQSKECDFQTKFALSLSPGAHQKRLIPIKYKAMKKEFPSILRFITVCDYTNPCTKSWFWTRLAKALSLP T96311 TARGETID T96311 T96311 FORMERID TTDC00245 T96311 UNIPROID UBA3_HUMAN T96311 TARGNAME NEDD8-activating enzyme E1C (UBA3) T96311 GENENAME UBA3 T96311 TARGTYPE Literature-reported T96311 SYNONYMS Ubiquitin-like modifier-activating enzyme 3; Ubiquitin-activating enzyme E1C; Ubiquitin-activating enzyme 3; UBE1C; NEDD8-activating enzyme E1 catalytic subunit T96311 FUNCTION E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Down-regulates steroid receptor activity. Necessary for cell cycle progression. Catalytic subunit of the dimeric UBA3-NAE1 E1 enzyme. T96311 PDBSTRUC 5JJM; 3GZN; 3FN1; 3DBR; 3DBL T96311 BIOCLASS Carbon-sulfur ligase T96311 ECNUMBER EC 6.2.1.- T96311 SEQUENCE MADGEEPEKKRRRIEELLAEKMAVDGGCGDTGDWEGRWNHVKKFLERSGPFTHPDFEPSTESLQFLLDTCKVLVIGAGGLGCELLKNLALSGFRQIHVIDMDTIDVSNLNRQFLFRPKDIGRPKAEVAAEFLNDRVPNCNVVPHFNKIQDFNDTFYRQFHIIVCGLDSIIARRWINGMLISLLNYEDGVLDPSSIVPLIDGGTEGFKGNARVILPGMTACIECTLELYPPQVNFPMCTIASMPRLPEHCIEYVRMLQWPKEQPFGEGVPLDGDDPEHIQWIFQKSLERASQYNIRGVTYRLTQGVVKRIIPAVASTNAVIAAVCATEVFKIATSAYIPLNNYLVFNDVDGLYTYTFEAERKENCPACSQLPQNIQFSPSAKLQEVLDYLTNSASLQMKSPAITATLEGKNRTLYLQSVTSIEERTRPNLSKTLKELGLVDGQELAVADVTTPQTVLFKLHFTS T77997 TARGETID T77997 T77997 FORMERID TTDR01342 T77997 UNIPROID ADA10_HUMAN T77997 TARGNAME ADAM10 messenger RNA (ADAM10 mRNA) T77997 GENENAME ADAM10 T77997 TARGTYPE Literature-reported T77997 SYNONYMS Mammalian disintegrinmetalloprotease (mRNA); MADM (mRNA); Kuzbanian protein homolog (mRNA); KUZ (mRNA); Disintegrin and metalloproteinase domaincontaining protein 10 (mRNA); Disintegrin and metalloproteinase domain-containing protein 10 (mRNA); CDw156 (mRNA); CD156c (mRNA); ADAM 10 (mRNA) T77997 FUNCTION Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth-like factor, ephrin-A2, CD44, CDH2 and for constitutive and regulated alpha-secretase cleavage of amyloid precursor protein (APP). Contributes to the normal cleavage of the cellular prion protein. Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity. Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis. Responsible for the FasL ectodomain shedding and for the generation of the remnant ADAM10-processed FasL (FasL APL) transmembrane form. Also cleaves the ectodomain of the integral membrane proteins CORIN and ITM2B. Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3. May regulate the EFNA5-EPHA3 signaling. Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-|-Val-77' to its mature soluble form. T77997 PDBSTRUC 6BE6; 6BDZ; 1M1I T77997 BIOCLASS mRNA target T77997 ECNUMBER EC 3.4.24.81 T77997 SEQUENCE MVLLRVLILLLSWAAGMGGQYGNPLNKYIRHYEGLSYNVDSLHQKHQRAKRAVSHEDQFLRLDFHAHGRHFNLRMKRDTSLFSDEFKVETSNKVLDYDTSHIYTGHIYGEEGSFSHGSVIDGRFEGFIQTRGGTFYVEPAERYIKDRTLPFHSVIYHEDDINYPHKYGPQGGCADHSVFERMRKYQMTGVEEVTQIPQEEHAANGPELLRKKRTTSAEKNTCQLYIQTDHLFFKYYGTREAVIAQISSHVKAIDTIYQTTDFSGIRNISFMVKRIRINTTADEKDPTNPFRFPNIGVEKFLELNSEQNHDDYCLAYVFTDRDFDDGVLGLAWVGAPSGSSGGICEKSKLYSDGKKKSLNTGIITVQNYGSHVPPKVSHITFAHEVGHNFGSPHDSGTECTPGESKNLGQKENGNYIMYARATSGDKLNNNKFSLCSIRNISQVLEKKRNNCFVESGQPICGNGMVEQGEECDCGYSDQCKDECCFDANQPEGRKCKLKPGKQCSPSQGPCCTAQCAFKSKSEKCRDDSDCAREGICNGFTALCPASDPKPNFTDCNRHTQVCINGQCAGSICEKYGLEECTCASSDGKDDKELCHVCCMKKMDPSTCASTGSVQWSRHFSGRTITLQPGSPCNDFRGYCDVFMRCRLVDADGPLARLKKAIFSPELYENIAEWIVAHWWAVLLMGIALIMLMAGFIKICSVHTPSSNPKLPPPKPLPGTLKRRRPPQPIQQPQRQRPRESYQMGHMRR T77997 DRUGINFO D02CNG ISIS 100748 Investigative T77997 DRUGINFO D0J2VN ISIS 100742 Investigative T77997 DRUGINFO D0JV0I ISIS 100743 Investigative T77997 DRUGINFO D0Q6MK ISIS 100749 Investigative T77997 DRUGINFO D0VI2A PMID18068976C25 Investigative T77997 DRUGINFO D0X7FV ISIS 100750 Investigative T28705 TARGETID T28705 T28705 FORMERID TTDR01413 T28705 UNIPROID CASP8_HUMAN T28705 TARGNAME Caspase 8 messenger RNA (CASP8 mRNA) T28705 GENENAME CASP8 T28705 TARGTYPE Literature-reported T28705 SYNONYMS MORT1-associated CED-3 homolog (mRNA); MCH5 (mRNA); MACH (mRNA); ICE-like apoptotic protease 5 (mRNA); FLICE (mRNA); FADD-like ICE (mRNA); FADD-homologous ICE/CED-3-like protease (mRNA); CASP-8 (mRNA); CAP4 (mRNA); Apoptotic protease Mch-5 (mRNA); Apoptotic cysteine protease (mRNA) T28705 FUNCTION Binding to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolytic activation. The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases. Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC. Cleaves and activates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. May participate in the GZMB apoptotic pathways. Cleaves ADPRT. Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC. Likely target for the cowpox virus CRMA death inhibitory protein. Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalytic site and may interfere with the pro-apoptotic activity of the complex. Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNFRSF1A induced cell death. T28705 PDBSTRUC 5L08; 5JQE; 5H33; 5H31; 4ZBW T28705 BIOCLASS mRNA target T28705 ECNUMBER EC 3.4.22.61 T28705 SEQUENCE MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKERSSSLEGSPDEFSNGEELCGVMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIINNHNFAKAREKVPKLHSIRDRNGTHLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQLMDHSNMDCFICCILSHGDKGIIYGTDGQEAPIYELTSQFTGLKCPSLAGKPKVFFIQACQGDNYQKGIPVETDSEEQPYLEMDLSSPQTRYIPDEADFLLGMATVNNCVSYRNPAEGTWYIQSLCQSLRERCPRGDDILTILTEVNYEVSNKDDKKNMGKQMPQPTFTLRKKLVFPSD T28705 DRUGINFO D00JXJ ISIS 107612 Investigative T28705 DRUGINFO D04RGM ISIS 107676 Investigative T28705 DRUGINFO D06YDM ISIS 107681 Investigative T28705 DRUGINFO D06ZTM ISIS 107652 Investigative T28705 DRUGINFO D07QZA ISIS 107642 Investigative T28705 DRUGINFO D0N8TA Acetyl-Ile-Glu-Thr-Asp-aldehyde Investigative T28705 DRUGINFO D0V6DX Isoquinoline-1,3,4(2H)-trione Investigative T94788 TARGETID T94788 T94788 FORMERID TTDR01028 T94788 UNIPROID BCAT2_HUMAN T94788 TARGNAME Branched-chain-amino-acid transaminase 2 (BCAT2) T94788 GENENAME BCAT2 T94788 TARGTYPE Literature-reported T94788 SYNONYMS Placental protein 18; PP18; ECA39 protein; Branched-chain amino acid aminotransferase; BCAT2; BCAT(m); BCAT T94788 FUNCTION Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. May also function as a transporter of branched chain alpha-keto acids. T94788 PDBSTRUC 5MPR; 5I60; 5I5Y; 5I5X; 5I5W T94788 BIOCLASS Transaminase T94788 ECNUMBER EC 2.6.1.42 T94788 SEQUENCE MAAAALGQIWARKLLSVPWLLCGPRRYASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV T94788 DRUGINFO D03NOU Alpha-ketoisovalerate Investigative T94788 DRUGINFO D05QCG N-[O-Phosphono-Pyridoxyl]-Isoleucine Investigative T94788 DRUGINFO D0AW6C N'-(phenylsulfonyl)benzofuran-2-carbohydrazide Investigative T94788 DRUGINFO D0W0FI N'-(phenylsulfonyl)quinoline-6-carbohydrazide Investigative T94788 DRUGINFO D01NBK Pyridoxamine-5'-Phosphate Investigative T72444 TARGETID T72444 T72444 FORMERID TTDR00361 T72444 UNIPROID FABH_ECOLI T72444 TARGNAME Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) T72444 GENENAME Bact fabH T72444 TARGTYPE Literature-reported T72444 SYNONYMS KAS III; FabH; EcFabH; Condensing enzyme FabH; Beta-ketoacyl-acyl carrier protein synthase III; Acetoacetyl-acyl carrier protein synthase; Acetoacetyl-ACP synthase; 3-oxoacyl-[acyl-carrier-protein] synthase III T72444 FUNCTION Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role in governing the total rate of fatty acid production. Possesses both acetoacetyl-ACP synthase and acetyl transacylase activities. Has some substrate specificity for acetyl-CoA. Its substrate specificity determines the biosynthesis of straight-chain of fatty acids instead of branched-chain. T72444 PDBSTRUC 5BNS; 5BNR; 5BNM; 4Z8D; 3IL9 T72444 BIOCLASS Acyltransferase T72444 ECNUMBER EC 2.3.1.180 T72444 SEQUENCE MYTKIIGTGSYLPEQVRTNADLEKMVDTSDEWIVTRTGIRERHIAAPNETVSTMGFEAATRAIEMAGIEKDQIGLIVVATTSATHAFPSAACQIQSMLGIKGCPAFDVAAACAGFTYALSVADQYVKSGAVKYALVVGSDVLARTCDPTDRGTIIIFGDGAGAAVLAASEEPGIISTHLHADGSYGELLTLPNADRVNPENSIHLTMAGNEVFKVAVTELAHIVDETLAANNLDRSQLDWLVPHQANLRIISATAKKLGMSMDNVVVTLDRHGNTSAASVPCALDEAVRDGRIKPGQLVLLEAFGGGFTWGSALVRF T72444 DRUGINFO D00GIB 2-(4-Bromo-3-phenoxy-benzoylamino)-benzoic acid Investigative T72444 DRUGINFO D09EYO 2-(4-Fluoro-3-phenoxy-benzoylamino)-benzoic acid Investigative T72444 DRUGINFO D09RXJ 2-Hydroxy-6-(3-phenoxy-benzoylamino)-benzoic acid Investigative T72444 DRUGINFO D0A0CZ 2-Tosylnaphthalene-1,4-diol Investigative T72444 DRUGINFO D0BT1W 2-(p-tolylthio)naphthalene-1,4-dione Investigative T72444 DRUGINFO D0GU4M 2-tosylnaphthalene Investigative T72444 DRUGINFO D0I7IH 2-(4-propylphenylsulfonyl)naphthalene-1,4-diol Investigative T72444 DRUGINFO D0J3DB 2-tosylanthracene-1,4-diol Investigative T72444 DRUGINFO D0K1CU 2-(4-chlorophenylsulfonyl)naphthalene-1,4-diol Investigative T72444 DRUGINFO D0K9GC 2-[3-(Pyridin-4-yloxy)-benzoylamino]-benzoic acid Investigative T72444 DRUGINFO D0MF1G 2-(naphthalen-2-ylsulfonyl)naphthalene-1,4-diol Investigative T72444 DRUGINFO D0O4IV 2-Fluoro-6-(3-phenoxy-benzoylamino)-benzoic acid Investigative T72444 DRUGINFO D0O5KG 2-(3-Phenoxy-benzoylamino)-benzoic acid Investigative T72444 DRUGINFO D0OL2D 2-(phenylsulfonyl)naphthalene-1,4-diol Investigative T72444 DRUGINFO D0TU2Z 2-tosylbenzene-1,4-diol Investigative T72444 DRUGINFO D0W0IX 2-tosylnaphthalene-1,4-dione Investigative T72444 DRUGINFO D0W7JJ 2-(methylsulfonyl)naphthalene-1,4-diol Investigative T72444 DRUGINFO D04JTY Thiolactomycin Investigative T53350 TARGETID T53350 T53350 FORMERID TTDR01035 T53350 UNIPROID BMP1_HUMAN T53350 TARGNAME Bone morphogenetic protein 1 (BMP1) T53350 GENENAME BMP1 T53350 TARGTYPE Literature-reported T53350 SYNONYMS Procollagen C-proteinase; PCP protein; PCOLC; Mammalian tolloid protein; MTld; BMP-1 T53350 FUNCTION Induces cartilage and bone formation. May participate in dorsoventral patterning during early development by cleaving chordin (CHRD). Responsible for the proteolytic activation of lysyl oxidase LOX. Cleaves the C-terminal propeptides of procollagen I, II and III. T53350 PDBSTRUC 6BTQ; 6BTP; 6BTO; 6BTN; 6BSM T53350 BIOCLASS Peptidase T53350 ECNUMBER EC 3.4.24.19 T53350 SEQUENCE MPGVARLPLLLGLLLLPRPGRPLDLADYTYDLAEEDDSEPLNYKDPCKAAAFLGDIALDEEDLRAFQVQQAVDLRRHTARKSSIKAAVPGNTSTPSCQSTNGQPQRGACGRWRGRSRSRRAATSRPERVWPDGVIPFVIGGNFTGSQRAVFRQAMRHWEKHTCVTFLERTDEDSYIVFTYRPCGCCSYVGRRGGGPQAISIGKNCDKFGIVVHELGHVVGFWHEHTRPDRDRHVSIVRENIQPGQEYNFLKMEPQEVESLGETYDFDSIMHYARNTFSRGIFLDTIVPKYEVNGVKPPIGQRTRLSKGDIAQARKLYKCPACGETLQDSTGNFSSPEYPNGYSAHMHCVWRISVTPGEKIILNFTSLDLYRSRLCWYDYVEVRDGFWRKAPLRGRFCGSKLPEPIVSTDSRLWVEFRSSSNWVGKGFFAVYEAICGGDVKKDYGHIQSPNYPDDYRPSKVCIWRIQVSEGFHVGLTFQSFEIERHDSCAYDYLEVRDGHSESSTLIGRYCGYEKPDDIKSTSSRLWLKFVSDGSINKAGFAVNFFKEVDECSRPNRGGCEQRCLNTLGSYKCSCDPGYELAPDKRRCEAACGGFLTKLNGSITSPGWPKEYPPNKNCIWQLVAPTQYRISLQFDFFETEGNDVCKYDFVEVRSGLTADSKLHGKFCGSEKPEVITSQYNNMRVEFKSDNTVSKKGFKAHFFSDKDECSKDNGGCQQDCVNTFGSYECQCRSGFVLHDNKHDCKEAGCDHKVTSTSGTITSPNWPDKYPSKKECTWAISSTPGHRVKLTFMEMDIESQPECAYDHLEVFDGRDAKAPVLGRFCGSKKPEPVLATGSRMFLRFYSDNSVQRKGFQASHATECGGQVRADVKTKDLYSHAQFGDNNYPGGVDCEWVIVAEEGYGVELVFQTFEVEEETDCGYDYMELFDGYDSTAPRLGRYCGSGPPEEVYSAGDSVLVKFHSDDTITKKGFHLRYTSTKFQDTLHSRK T53350 DRUGINFO D02DQT PMID11934595C2 Investigative T53350 DRUGINFO D0P2TS UK-383367 Investigative T35527 TARGETID T35527 T35527 FORMERID TTDR00239 T35527 UNIPROID LOX12_HUMAN T35527 TARGNAME Arachidonate 12-lipoxygenase (12-LOX) T35527 GENENAME ALOX12 T35527 TARGTYPE Literature-reported T35527 SYNONYMS Platelet-type lipoxygenase 12; Lipoxin synthase 12-LO; LOG12; Arachidonate 12-lipoxygenase, 12S-type; 12S-lipoxygenase; 12S-LOX; 12LO; 12-lipoxygenase T35527 FUNCTION Mainly converts arachidonic acid to (12S)-hydroperoxyeicosatetraenoic acid/(12S)-HPETE but can also metabolize linoleic acid. Has a dual activity since it also converts leukotriene A4/LTA4 into both the bioactive lipoxin A4/LXA4 and lipoxin B4/LXB4. Through the production of specific bioactive lipids like (12S)-HPETE it regulates different biological processes including platelet activation. It also probably positively regulates angiogenesis through regulation of the expression of the vascular endothelial growth factor. Plays a role in apoptotic process, promoting the survival of vascular smooth muscle cells for instance. May also play a role in the control of cell migration and proliferation. Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators. T35527 PDBSTRUC 3D3L; 2ABU T35527 BIOCLASS Oxygenase T35527 ECNUMBER EC 1.13.11.31 T35527 SEQUENCE MGRYRIRVATGAWLFSGSYNRVQLWLVGTRGEAELELQLRPARGEEEEFDHDVAEDLGLLQFVRLRKHHWLVDDAWFCDRITVQGPGACAEVAFPCYRWVQGEDILSLPEGTARLPGDNALDMFQKHREKELKDRQQIYCWATWKEGLPLTIAADRKDDLPPNMRFHEEKRLDFEWTLKAGALEMALKRVYTLLSSWNCLEDFDQIFWGQKSALAEKVRQCWQDDELFSYQFLNGANPMLLRRSTSLPSRLVLPSGMEELQAQLEKELQNGSLFEADFILLDGIPANVIRGEKQYLAAPLVMLKMEPNGKLQPMVIQIQPPNPSSPTPTLFLPSDPPLAWLLAKSWVRNSDFQLHEIQYHLLNTHLVAEVIAVATMRCLPGLHPIFKFLIPHIRYTMEINTRARTQLISDGGIFDKAVSTGGGGHVQLLRRAAAQLTYCSLCPPDDLADRGLLGLPGALYAHDALRLWEIIARYVEGIVHLFYQRDDIVKGDPELQAWCREITEVGLCQAQDRGFPVSFQSQSQLCHFLTMCVFTCTAQHAAINQGQLDWYAWVPNAPCTMRMPPPTTKEDVTMATVMGSLPDVRQACLQMAISWHLSRRQPDMVPLGHHKEKYFSGPKPKAVLNQFRTDLEKLEKEITARNEQLDWPYEYLKPSCIENSVTI T35527 DRUGINFO D0F4JL NSC-661755 Terminated T35527 DRUGINFO D0M6KL (-)-7-N-methyldibromophakellin Investigative T35527 DRUGINFO D0Q0LD NEODYSIDENIN Investigative T35527 DRUGINFO D0S7AY NSC-125034 Investigative T35527 DRUGINFO D02LUF (+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol Investigative T35527 DRUGINFO D03YMX 3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol Investigative T35527 DRUGINFO D04JWS NSC-292213 Investigative T35527 DRUGINFO D07JRW Jaspic acid Investigative T35527 DRUGINFO D08WDW DYSIDENIN Investigative T35527 DRUGINFO D0A3QB Polybrominated diphenyl ether derivative Investigative T35527 DRUGINFO D0H8FG (+)-(5S,8S,9R,10S)-20-methoxypuupehenone Investigative T35527 DRUGINFO D0I6ZS Dimethylnordihydroguarierate acid Investigative T35527 DRUGINFO D0K0QU (+)-(5S,8S,10S)-20-methoxypuupehenol Investigative T35527 DRUGINFO D0W5DZ CHLOROPUUPEHENONE Investigative T35527 DRUGINFO D0X4BT NSC-172033 Investigative T35527 DRUGINFO D0X4CI 2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol Investigative T35527 DRUGINFO D05FJM PUUPEHEDIONE Investigative T35527 DRUGINFO D06PRC MANGOSTIN Investigative T35527 DRUGINFO D07BXV PUUPEHENONE Investigative T35527 DRUGINFO D0F9FG Isojaspic acid Investigative T68698 TARGETID T68698 T68698 FORMERID TTDR00957 T68698 UNIPROID SAHH_HUMAN T68698 TARGNAME Adenosylhomocysteinase (AHCY) T68698 GENENAME AHCY T68698 TARGTYPE Literature-reported T68698 SYNONYMS SAHH; SAH hydrolase; S-adenosyl-L-homocysteine hydrolase T68698 FUNCTION Adenosylhomocysteine is a competitive inhibitor of S-adenosyl-L-methionine-dependent methyl transferase reactions; therefore adenosylhomocysteinase may play a key role in the control of methylations via regulation of the intracellular concentration of adenosylhomocysteine. T68698 PDBSTRUC 5W4B; 5W49; 4YVF; 4PGF; 4PFJ T68698 BIOCLASS Ether bond hydrolase T68698 ECNUMBER EC 3.3.1.1 T68698 SEQUENCE MSDKLPYKVADIGLAAWGRKALDIAENEMPGLMRMRERYSASKPLKGARIAGCLHMTVETAVLIETLVTLGAEVQWSSCNIFSTQDHAAAAIAKAGIPVYAWKGETDEEYLWCIEQTLYFKDGPLNMILDDGGDLTNLIHTKYPQLLPGIRGISEETTTGVHNLYKMMANGILKVPAINVNDSVTKSKFDNLYGCRESLIDGIKRATDVMIAGKVAVVAGYGDVGKGCAQALRGFGARVIITEIDPINALQAAMEGYEVTTMDEACQEGNIFVTTTGCIDIILGRHFEQMKDDAIVCNIGHFDVEIDVKWLNENAVEKVNIKPQVDRYRLKNGRRIILLAEGRLVNLGCAMGHPSFVMSNSFTNQVMAQIELWTHPDKYPVGVHFLPKKLDEAVAEAHLGKLNVKLTKLTEKQAQYLGMSCDGPFKPDHYRY T68698 DRUGINFO D0I7BL ARISTEROMYCIN Terminated T68698 DRUGINFO D02YYQ 5'-deoxy-5'-ureidoadenosine Investigative T68698 DRUGINFO D0B0QY 5(E)-(5'-Deoxyadenosin-5'-ylidene)pentanoic acid Investigative T68698 DRUGINFO D0D2MS 5-methylenearisteromycin Investigative T68698 DRUGINFO D0F5AJ NORARISTEROMYCIN Investigative T68698 DRUGINFO D0G3CQ D-Eritadenine Investigative T68698 DRUGINFO D0LM6A 5'-S-ethyl-5'-thioadenosine Investigative T68698 DRUGINFO D0O2CM FLUORO-NEPLANOCIN A Investigative T68698 DRUGINFO D0S1VT 4(Z)-(5'-Deoxyadenosin-5'-ylidene)butanoic acid Investigative T68698 DRUGINFO D0T7QT 3'-Oxo-Adenosine Investigative T68698 DRUGINFO D0X3MK DZNep Investigative T68698 DRUGINFO D0R2QS Neplanocin A Investigative T68698 DRUGINFO D0W7LK 2-Propanol, Isopropanol Investigative T68698 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T30823 TARGETID T30823 T30823 FORMERID TTDR00202 T30823 UNIPROID MPIP1_HUMAN T30823 TARGNAME M-phase inducer phosphatase 1 (MPIP1) T30823 GENENAME CDC25A T30823 TARGTYPE Literature-reported T30823 SYNONYMS Dual specificity phosphatase Cdc25A; Cdc25A phosphatase T30823 FUNCTION Directly dephosphorylates CDK1 and stimulates its kinase activity. Also dephosphorylates CDK2 in complex with cyclin E, in vitro. Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. T30823 PDBSTRUC 1C25 T30823 BIOCLASS Phosphoric monoester hydrolase T30823 ECNUMBER EC 3.1.3.48 T30823 SEQUENCE MELGPEPPHRRRLLFACSPPPASQPVVKALFGASAAGGLSPVTNLTVTMDQLQGLGSDYEQPLEVKNNSNLQRMGSSESTDSGFCLDSPGPLDSKENLENPMRRIHSLPQKLLGCSPALKRSHSDSLDHDIFQLIDPDENKENEAFEFKKPVRPVSRGCLHSHGLQEGKDLFTQRQNSAPARMLSSNERDSSEPGNFIPLFTPQSPVTATLSDEDDGFVDLLDGENLKNEEETPSCMASLWTAPLVMRTTNLDNRCKLFDSPSLCSSSTRSVLKRPERSQEESPPGSTKRRKSMSGASPKESTNPEKAHETLHQSLSLASSPKGTIENILDNDPRDLIGDFSKGYLFHTVAGKHQDLKYISPEIMASVLNGKFANLIKEFVIIDCRYPYEYEGGHIKGAVNLHMEEEVEDFLLKKPIVPTDGKRVIVVFHCEFSSERGPRMCRYVRERDRLGNEYPKLHYPELYVLKGGYKEFFMKCQSYCEPPSYRPMHHEDFKEDLKKFRTKSRTWAGEKSKREMYSRLKKL T30823 DRUGINFO D07FHZ Ro 20-1724 Terminated T30823 DRUGINFO D06REJ MX-7065 Terminated T30823 DRUGINFO D00SAA 3-isopropylnaphthalene-1,2-dione Investigative T30823 DRUGINFO D0CJ6P 2-(1-dodecyl-1H-indol-3-yl)acetic acid Investigative T30823 DRUGINFO D0GE3O (E)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid Investigative T30823 DRUGINFO D0W1SP (Z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid Investigative T30823 DRUGINFO D00ANJ 1-dodecyl-1H-indole-2,3-dione Investigative T30823 DRUGINFO D07JRA 3-isopropyl-4-phenylnaphthalene-1,2-dione Investigative T30823 DRUGINFO D0J1KH NSC-95397 Investigative T30823 DRUGINFO D0X5WD 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione Investigative T30823 DRUGINFO D08GWQ 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione Investigative T30823 DRUGINFO D0N7YT 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione Investigative T19011 TARGETID T19011 T19011 FORMERID TTDR00208 T19011 UNIPROID MPIP3_HUMAN T19011 TARGNAME M-phase inducer phosphatase 3 (MPIP3) T19011 GENENAME CDC25C T19011 TARGTYPE Literature-reported T19011 SYNONYMS Dual specificity phosphatase Cdc25C; Cdc25C phosphatase T19011 FUNCTION Tyrosine protein phosphatase required for progression of the cell cycle. When phosphorylated, highly effective in activating G2 cells into prophase. Directly dephosphorylates CDK1 and activates its kinase activity. Functions as a dosage-dependent inducer in mitotic control. T19011 PDBSTRUC 5M37; 5M36; 5M35; 3OP3; 3BZI T19011 BIOCLASS Phosphoric monoester hydrolase T19011 ECNUMBER EC 3.1.3.48 T19011 SEQUENCE MSTELFSSTREEGSSGSGPSFRSNQRKMLNLLLERDTSFTVCPDVPRTPVGKFLGDSANLSILSGGTPKRCLDLSNLSSGEITATQLTTSADLDETGHLDSSGLQEVHLAGMNHDQHLMKCSPAQLLCSTPNGLDRGHRKRDAMCSSSANKENDNGNLVDSEMKYLGSPITTVPKLDKNPNLGEDQAEEISDELMEFSLKDQEAKVSRSGLYRSPSMPENLNRPRLKQVEKFKDNTIPDKVKKKYFSGQGKLRKGLCLKKTVSLCDITITQMLEEDSNQGHLIGDFSKVCALPTVSGKHQDLKYVNPETVAALLSGKFQGLIEKFYVIDCRYPYEYLGGHIQGALNLYSQEELFNFFLKKPIVPLDTQKRIIIVFHCEFSSERGPRMCRCLREEDRSLNQYPALYYPELYILKGGYRDFFPEYMELCEPQSYCPMHHQDHKTELLRCRSQSKVQEGERQLREQIALLVKDMSP T19011 DRUGINFO D06REJ MX-7065 Terminated T19011 DRUGINFO D0G8AG BN-82685 Investigative T19011 DRUGINFO D0GX8F BN-82002 Investigative T19011 DRUGINFO D0XU7M NSC-663284 Investigative T50970 TARGETID T50970 T50970 FORMERID TTDR00135 T50970 UNIPROID ECE1_HUMAN T50970 TARGNAME Endothelin-converting enzyme 1 (ECE1) T50970 GENENAME ECE1 T50970 TARGTYPE Literature-reported T50970 SYNONYMS ECE-1 T50970 FUNCTION Converts big endothelin-1 to endothelin-1. T50970 PDBSTRUC 3DWB T50970 BIOCLASS Peptidase T50970 ECNUMBER EC 3.4.24.71 T50970 SEQUENCE MRGVWPPPVSALLSALGMSTYKRATLDEEDLVDSLSEGDAYPNGLQVNFHSPRSGQRCWAARTQVEKRLVVLVVLLAAGLVACLAALGIQYQTRSPSVCLSEACVSVTSSILSSMDPTVDPCHDFFSYACGGWIKANPVPDGHSRWGTFSNLWEHNQAIIKHLLENSTASVSEAERKAQVYYRACMNETRIEELRAKPLMELIERLGGWNITGPWAKDNFQDTLQVVTAHYRTSPFFSVYVSADSKNSNSNVIQVDQSGLGLPSRDYYLNKTENEKVLTGYLNYMVQLGKLLGGGDEEAIRPQMQQILDFETALANITIPQEKRRDEELIYHKVTAAELQTLAPAINWLPFLNTIFYPVEINESEPIVVYDKEYLEQISTLINTTDRCLLNNYMIWNLVRKTSSFLDQRFQDADEKFMEVMYGTKKTCLPRWKFCVSDTENNLGFALGPMFVKATFAEDSKSIATEIILEIKKAFEESLSTLKWMDEETRKSAKEKADAIYNMIGYPNFIMDPKELDKVFNDYTAVPDLYFENAMRFFNFSWRVTADQLRKAPNRDQWSMTPPMVNAYYSPTKNEIVFPAGILQAPFYTRSSPKALNFGGIGVVVGHELTHAFDDQGREYDKDGNLRPWWKNSSVEAFKRQTECMVEQYSNYSVNGEPVNGRHTLGENIADNGGLKAAYRAYQNWVKKNGAEHSLPTLGLTNNQLFFLGFAQVWCSVRTPESSHEGLITDPHSPSRFRVIGSLSNSKEFSEHFRCPPGSPMNPPHKCEVW T50970 DRUGINFO D0K9YR SCH-54470 Terminated T50970 DRUGINFO D02FGF PO3 2-Nle-Trp-O-3K Investigative T50970 DRUGINFO D0F8AR PMID19899765C22 Investigative T50970 DRUGINFO D0I6EU PO3 2-Leu-Trp-O-3K Investigative T50970 DRUGINFO D0I6RE 5-(2-hydroxyethyl)nonane-1,9-diol Investigative T50970 DRUGINFO D0P1UW PO3 2-Ile-Trp-O-3K Investigative T50970 DRUGINFO D0U0ST PD159790 Investigative T50970 DRUGINFO D0ZY2T PO3 2-Leu-Nal-O-3K Investigative T50970 DRUGINFO D0G9UX CGS 35066 Investigative T50970 DRUGINFO D07APP LY-292223 Investigative T56175 TARGETID T56175 T56175 FORMERID TTDR00866 T56175 UNIPROID ERG7_HUMAN T56175 TARGNAME Lanosterol synthase (LSS) T56175 GENENAME LSS T56175 TARGTYPE Literature-reported T56175 SYNONYMS Oxidosqualene--lanosterol cyclase; Oxidosqualene cyclase; OSC; LSS; 2,3-epoxysqualene--lanosterol cyclase T56175 FUNCTION Catalyzes the cyclization of (S)-2,3 oxidosqualene to lanosterol, a reaction that forms the sterol nucleus. T56175 PDBSTRUC 1W6K; 1W6J T56175 BIOCLASS Intramolecular transferases T56175 ECNUMBER EC 5.4.99.7 T56175 SEQUENCE MTEGTCLRRRGGPYKTEPATDLGRWRLNCERGRQTWTYLQDERAGREQTGLEAYALGLDTKNYFKDLPKAHTAFEGALNGMTFYVGLQAEDGHWTGDYGGPLFLLPGLLITCHVARIPLPAGYREEIVRYLRSVQLPDGGWGLHIEDKSTVFGTALNYVSLRILGVGPDDPDLVRARNILHKKGGAVAIPSWGKFWLAVLNVYSWEGLNTLFPEMWLFPDWAPAHPSTLWCHCRQVYLPMSYCYAVRLSAAEDPLVQSLRQELYVEDFASIDWLAQRNNVAPDELYTPHSWLLRVVYALLNLYEHHHSAHLRQRAVQKLYEHIVADDRFTKSISIGPISKTINMLVRWYVDGPASTAFQEHVSRIPDYLWMGLDGMKMQGTNGSQIWDTAFAIQALLEAGGHHRPEFSSCLQKAHEFLRLSQVPDNPPDYQKYYRQMRKGGFSFSTLDCGWIVSDCTAEALKAVLLLQEKCPHVTEHIPRERLCDAVAVLLNMRNPDGGFATYETKRGGHLLELLNPSEVFGDIMIDYTYVECTSAVMQALKYFHKRFPEHRAAEIRETLTQGLEFCRRQQRADGSWEGSWGVCFTYGTWFGLEAFACMGQTYRDGTACAEVSRACDFLLSRQMADGGWGEDFESCEERRYLQSAQSQIHNTCWAMMGLMAVRHPDIEAQERGVRCLLEKQLPNGDWPQENIAGVFNKSCAISYTSYRNIFPIWALGRFSQLYPERALAGHP T56175 DRUGINFO D04GJX ZD-9720 Terminated T56175 DRUGINFO D0I2YV BIBB-515 Terminated T56175 DRUGINFO D0S1XO BIBX-79 Terminated T56175 DRUGINFO D00XPB PMID22533316C1 Investigative T56175 DRUGINFO D00ZEY PMID22533316C4 Investigative T56175 DRUGINFO D05VRO PMID9003518C4 Investigative T56175 DRUGINFO D0C4PT 29-methylidene-2,3-oxidosqualene Investigative T56175 DRUGINFO D0J0JY Tetradecane Investigative T56175 DRUGINFO D0K3TQ PMID9003518C3 Investigative T56175 DRUGINFO D0P4PQ Lanosterol Investigative T56175 DRUGINFO D0R1EO [3-(Biphenyl-4-yloxy)-propyl]-dimethyl-amine Investigative T56175 DRUGINFO D0X3GG Ro48-8071 Investigative T56175 DRUGINFO D0Z3CK PMID22533316C3 Investigative T56175 DRUGINFO D02UVH B-Octylglucoside Investigative T86428 TARGETID T86428 T86428 FORMERID TTDR01076 T86428 UNIPROID FNTB_HUMAN T86428 TARGNAME CAAX farnesyltransferase beta (FNTB) T86428 GENENAME FNTB T86428 TARGTYPE Literature-reported T86428 SYNONYMS RAS proteins prenyltransferasebeta; FTase-beta; FNTB; CAAX farnesyltransferase beta subunit T86428 FUNCTION Essential subunit of the farnesyltransferase complex. Catalyzes the transfer of a farnesyl moiety from farnesyl diphosphate to a cysteine at the fourth position from the C- terminus of several proteins having the C-terminal sequence Cys- aliphatic-aliphatic-X. T86428 PDBSTRUC 3.00E+37; 2IEJ; 2H6I; 2H6H; 2H6G T86428 BIOCLASS Alkyl aryl transferase T86428 ECNUMBER EC 2.5.1.58 T86428 SEQUENCE MASPSSFTYYCPPSSSPVWSEPLYSLRPEHARERLQDDSVETVTSIEQAKVEEKIQEVFSSYKFNHLVPRLVLQREKHFHYLKRGLRQLTDAYECLDASRPWLCYWILHSLELLDEPIPQIVATDVCQFLELCQSPEGGFGGGPGQYPHLAPTYAAVNALCIIGTEEAYDIINREKLLQYLYSLKQPDGSFLMHVGGEVDVRSAYCAASVASLTNIITPDLFEGTAEWIARCQNWEGGIGGVPGMEAHGGYTFCGLAALVILKRERSLNLKSLLQWVTSRQMRFEGGFQGRCNKLVDGCYSFWQAGLLPLLHRALHAQGDPALSMSHWMFHQQALQEYILMCCQCPAGGLLDKPGKSRDFYHTCYCLSGLSIAQHFGSGAMLHDVVLGVPENALQPTHPVYNIGPDKVIQATTYFLQKPVPGFEELKDETSAEPATD T86428 DRUGINFO D03FZA FUSIDIENOL Terminated T86428 DRUGINFO D05XTO ABT-100 Terminated T86428 DRUGINFO D07PAY B-956 Terminated T86428 DRUGINFO D09DLN L-739749 Terminated T86428 DRUGINFO D0E7BP CP-663427 Terminated T86428 DRUGINFO D0H2AM XR-3054 Terminated T86428 DRUGINFO D0I9AR BMS-185857 Terminated T86428 DRUGINFO D0O1XU XR-3005 Terminated T86428 DRUGINFO D0V3WQ Sch-207758 Terminated T86428 DRUGINFO D0W3OQ BMS-182566 Terminated T86428 DRUGINFO D04DYZ ABT-839 Terminated T86428 DRUGINFO D0C2UY MANUMYCIN A Terminated T86428 DRUGINFO D0EY9P SCH-44342 Terminated T86428 DRUGINFO D0H5VF RPR-113829 Terminated T86428 DRUGINFO D0L5AS RPR-114334 Terminated T86428 DRUGINFO D0W2ED L-731735 Terminated T86428 DRUGINFO D03OLA L-745631 Terminated T86428 DRUGINFO D00OMV Arteminolide Investigative T86428 DRUGINFO D04ETB CYLINDROL A Investigative T86428 DRUGINFO D05IVD PREUSSOMERIN Investigative T86428 DRUGINFO D07ZTG L-739750 Investigative T86428 DRUGINFO D08SZO F-12458 Investigative T86428 DRUGINFO D08VBE LB42908 Investigative T86428 DRUGINFO D0M5PB FTI 276 Investigative T86428 DRUGINFO D0OC3P Prenyl pyrophosphate analogue Investigative T86428 DRUGINFO D0PK8Y BMS-316810 Investigative T86428 DRUGINFO D0X5KQ H-SMGLPCVVM-OH Investigative T86428 DRUGINFO D00LAR BMS-404683 Investigative T86428 DRUGINFO D01DTW FARNESYL Investigative T86428 DRUGINFO D01OFD ACTINOPLANIC ACID A Investigative T86428 DRUGINFO D06JMV PB-27 Investigative T86428 DRUGINFO D0H4QM PB-80 Investigative T86428 DRUGINFO D0L4RX PB-81 Investigative T86428 DRUGINFO D0R3PD CLAVARINONE Investigative T86428 DRUGINFO D0T2SJ A-313326 Investigative T86428 DRUGINFO D0TC4Z ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID Investigative T86428 DRUGINFO D0VD2C (Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid Investigative T86428 DRUGINFO D06DSE PD-83176 Investigative T86428 DRUGINFO D0QX6B GERANYLGERANYL DIPHOSPHATE Investigative T62265 TARGETID T62265 T62265 FORMERID TTDR00848 T62265 UNIPROID DHYS_HUMAN T62265 TARGNAME Deoxyhypusine synthase (DHPS) T62265 GENENAME DHPS T62265 TARGTYPE Literature-reported T62265 SYNONYMS DHS T62265 FUNCTION Catalyzes the NAD-dependent oxidativecleavage of spermidine and the subsequent transfer of the butylamine moiety of spermidine to the epsilon-amino group of a specific lysine residue of the eIF-5A precursor protein to form the intermediate deoxyhypusine residue. T62265 PDBSTRUC 1RQD; 1ROZ; 1RLZ; 1DHS T62265 BIOCLASS Alkyl aryl transferase T62265 ECNUMBER EC 2.5.1.46 T62265 SEQUENCE MEGSLEREAPAGALAAVLKHSSTLPPESTQVRGYDFNRGVNYRALLEAFGTTGFQATNFGRAVQQVNAMIEKKLEPLSQDEDQHADLTQSRRPLTSCTIFLGYTSNLISSGIRETIRYLVQHNMVDVLVTTAGGVEEDLIKCLAPTYLGEFSLRGKELRENGINRIGNLLVPNENYCKFEDWLMPILDQMVMEQNTEGVKWTPSKMIARLGKEINNPESVYYWAQKNHIPVFSPALTDGSLGDMIFFHSYKNPGLVLDIVEDLRLINTQAIFAKCTGMIILGGGVVKHHIANANLMRNGADYAVYINTAQEFDGSDSGARPDEAVSWGKIRVDAQPVKVYADASLVFPLLVAETFAQKMDAFMHEKNED T62265 DRUGINFO D00UDX 1-Guanidinium-7-Aminoheptane Investigative T62265 DRUGINFO D08PKS N-guanyl-1,7-diaminoheptane Investigative T62265 DRUGINFO D0FI8L N1-guanyl-1,7-diaminoheptane Investigative T62265 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T55916 TARGETID T55916 T55916 FORMERID TTDS00149 T55916 UNIPROID KCNQ4_HUMAN T55916 TARGNAME Voltage-gated potassium channel Kv7.4 (KCNQ4) T55916 GENENAME KCNQ4 T55916 TARGTYPE Literature-reported T55916 SYNONYMS Voltage-gated potassium channel subunit Kv7.4; Potassium channel alpha subunit KvLQT4; KQT-like 4; KCNQ4 T55916 FUNCTION Probably important in the regulation of neuronal excitability. May underlie a potassium current involved in regulating the excitability of sensory cells of the cochlea. KCNQ4 channels are blocked by linopirdin, XE991 and bepridil, whereas clofilium is without significant effect. Muscarinic agonist oxotremorine-M strongly suppress KCNQ4 current in CHO cells in which cloned KCNQ4 channels were coexpressed with M1muscarinic receptors. T55916 PDBSTRUC 6N5W; 4GOW; 2OVC T55916 BIOCLASS Voltage-gated ion channel T55916 SEQUENCE MAEAPPRRLGLGPPPGDAPRAELVALTAVQSEQGEAGGGGSPRRLGLLGSPLPPGAPLPGPGSGSGSACGQRSSAAHKRYRRLQNWVYNVLERPRGWAFVYHVFIFLLVFSCLVLSVLSTIQEHQELANECLLILEFVMIVVFGLEYIVRVWSAGCCCRYRGWQGRFRFARKPFCVIDFIVFVASVAVIAAGTQGNIFATSALRSMRFLQILRMVRMDRRGGTWKLLGSVVYAHSKELITAWYIGFLVLIFASFLVYLAEKDANSDFSSYADSLWWGTITLTTIGYGDKTPHTWLGRVLAAGFALLGISFFALPAGILGSGFALKVQEQHRQKHFEKRRMPAANLIQAAWRLYSTDMSRAYLTATWYYYDSILPSFRELALLFEHVQRARNGGLRPLEVRRAPVPDGAPSRYPPVATCHRPGSTSFCPGESSRMGIKDRIRMGSSQRRTGPSKQHLAPPTMPTSPSSEQVGEATSPTKVQKSWSFNDRTRFRASLRLKPRTSAEDAPSEEVAEEKSYQCELTVDDIMPAVKTVIRSIRILKFLVAKRKFKETLRPYDVKDVIEQYSAGHLDMLGRIKSLQTRVDQIVGRGPGDRKAREKGDKGPSDAEVVDEISMMGRVVKVEKQVQSIEHKLDLLLGFYSRCLRSGTSASLGAVQVPLFDPDITSDYHSPVDHEDISVSAQTLSISRSVSTNMD T55916 DRUGINFO D0FR6J NC00075159 Investigative T55916 DRUGINFO D0XY2M ML213 Investigative T55916 DRUGINFO D02BGR (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide Investigative T55916 DRUGINFO D07FTI zinc pyrithione Investigative T55916 DRUGINFO D0P8PH XE991 Investigative T55916 DRUGINFO D07ZAJ PIP2 Investigative T55916 DRUGINFO D06PZZ [14C]TEA Investigative T44515 TARGETID T44515 T44515 FORMERID TTDR00633 T44515 UNIPROID NADC_MYCTU T44515 TARGNAME Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC) T44515 GENENAME MycB nadC T44515 TARGTYPE Literature-reported T44515 SYNONYMS nadC; Quinolinic acid phosphoribosyltransferase; Quinolinate phosphoribosyltransferase [decarboxylating]; QAPRTase T44515 FUNCTION Involved in the catabolism of quinolinic acid (QA). T44515 PDBSTRUC 1QPR; 1QPQ; 1QPO; 1QPN T44515 BIOCLASS Pentosyltransferase T44515 ECNUMBER EC 2.4.2.19 T44515 SEQUENCE MGLSDWELAAARAAIARGLDEDLRYGPDVTTLATVPASATTTASLVTREAGVVAGLDVALLTLNEVLGTNGYRVLDRVEDGARVPPGEALMTLEAQTRGLLTAERTMLNLVGHLSGIATATAAWVDAVRGTKAKIRDTRKTLPGLRALQKYAVRTGGGVNHRLGLGDAALIKDNHVAAAGSVVDALRAVRNAAPDLPCEVEVDSLEQLDAVLPEKPELILLDNFAVWQTQTAVQRRDSRAPTVMLESSGGLSLQTAATYAETGVDYLAVGALTHSVRVLDIGLDM T44515 DRUGINFO D08PEM 5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate Investigative T44515 DRUGINFO D0L8CF Quinolinic Acid Investigative T44515 DRUGINFO D0OP3Y Namn Investigative T44515 DRUGINFO D0VH8M Phthalic Acid Investigative T94400 TARGETID T94400 T94400 FORMERID TTDR00929 T94400 UNIPROID KTHY_MYCTU T94400 TARGNAME Mycobacterium Thymidine monophosphate kinase (MycB tmk) T94400 GENENAME MycB tmk T94400 TARGTYPE Literature-reported T94400 SYNONYMS tmk; Thymidylic kinase; Thymidylic acid kinase; Thymidylate monophosphate kinase; Thymidylate kinase; Thymidine 5'-monophosphate kinase; TMPK; Deoxythymidine 5'-monophosphate kinase; DTMPkinase T94400 FUNCTION Catalyzes the reversible phosphorylation of deoxythymidine monophosphate (dTMP) to deoxythymidine diphosphate (dTDP), using ATP as its preferred phosphoryl donor. Situated at the junction of both de novo and salvage pathways of deoxythymidine triphosphate (dTTP) synthesis, is essential for DNA synthesis and cellular growth. Has a broad specificity for nucleoside triphosphates, being highly active withATP or dATP as phosphate donors, and less active with ITP, GTP, CTP and UTP. T94400 PDBSTRUC 5NRQ; 5NRN; 5NR7; 5NQ5; 4UNS T94400 BIOCLASS Kinase T94400 ECNUMBER EC 2.7.4.9 T94400 SEQUENCE MLIAIEGVDGAGKRTLVEKLSGAFRAAGRSVATLAFPRYGQSVAADIAAEALHGEHGDLASSVYAMATLFALDRAGAVHTIQGLCRGYDVVILDRYVASNAAYSAARLHENAAGKAAAWVQRIEFARLGLPKPDWQVLLAVSAELAGERSRGRAQRDPGRARDNYERDAELQQRTGAVYAELAAQGWGGRWLVVGADVDPGRLAATLAPPDVPS T94400 DRUGINFO D0A2IQ 3'-Azido-3'-Deoxythymidine-5'-Monophosphate Investigative T94400 DRUGINFO D0I9ZJ 5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate Investigative T94400 DRUGINFO D0K6QS CHLORODEOXYURIDINE Investigative T94400 DRUGINFO D0M4MA BROMODEOXYURIDINE Investigative T94400 DRUGINFO D0P2IN 5'-amino-5'-deoxy-alpha-D-thymidine Investigative T94400 DRUGINFO D0SC7C 2',3'-Dideoxythymidine-5'-Monophosphate Investigative T94400 DRUGINFO D0U2KT 5'-deoxythymidine Investigative T94400 DRUGINFO D01GLG Deoxythymidine Investigative T94400 DRUGINFO D04BBF P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate Investigative T94400 DRUGINFO D0R4PI Diphosphate Investigative T94400 DRUGINFO D0ZH0I Thymidine-5'-Phosphate Investigative T94400 DRUGINFO D09WYY 2'-deoxythymidine triphosphate Investigative T94400 DRUGINFO D00ICA AMP-PNP Investigative T94400 DRUGINFO D0F2ME Acetate Ion Investigative T09215 TARGETID T09215 T09215 FORMERID TTDR00619 T09215 UNIPROID ACEA_MYCTU T09215 TARGNAME Mycobacterium Isocitrate lyase (MycB icl) T09215 GENENAME MycB icl T09215 TARGTYPE Literature-reported T09215 SYNONYMS Isocitratase; Isocitrase; ICL T09215 FUNCTION Catalyzes the formation of succinate and glyoxylate from isocitrate, a key step of the glyoxylate cycle. May be involved in the assimilation of one-carbon compounds via the isocitrate lyase- positive serine pathway. T09215 PDBSTRUC 5DQL; 1F8M; 1F8I; 1F61 T09215 BIOCLASS Carbon-carbon lyase T09215 ECNUMBER EC 4.1.3.1 T09215 SEQUENCE MSVVGTPKSAEQIQQEWDTNPRWKDVTRTYSAEDVVALQGSVVEEHTLARRGAEVLWEQLHDLEWVNALGALTGNMAVQQVRAGLKAIYLSGWQVAGDANLSGHTYPDQSLYPANSVPQVVRRINNALQRADQIAKIEGDTSVENWLAPIVADGEAGFGGALNVYELQKALIAAGVAGSHWEDQLASEKKCGHLGGKVLIPTQQHIRTLTSARLAADVADVPTVVIARTDAEAATLITSDVDERDQPFITGERTREGFYRTKNGIEPCIARAKAYAPFADLIWMETGTPDLEAARQFSEAVKAEYPDQMLAYNCSPSFNWKKHLDDATIAKFQKELAAMGFKFQFITLAGFHALNYSMFDLAYGYAQNQMSAYVELQEREFAAEERGYTATKHQREVGAGYFDRIATTVDPNSSTTALTGSTEEGQFH T09215 DRUGINFO D03SKE 2,2',3-Tribromo-4,4',5,5'-tetrahydroxybibenzyl Investigative T09215 DRUGINFO D05FWW Bis(2,3-dibromo-4,5-dihydroxyphenyl)ether Investigative T09215 DRUGINFO D08MOJ 3-bromopyruvate Investigative T09215 DRUGINFO D0B2NG Bis(3-bromo-4,5-dihydroxyphenyl)methanone Investigative T09215 DRUGINFO D0C0DM 5,5'-methylenebis(3,4-dibromobenzene-1,2-diol) Investigative T09215 DRUGINFO D0U9EW Glyoxalate, Glyoxylate Investigative T09215 DRUGINFO D0Z1ZI 3-nitropropionate Investigative T09215 DRUGINFO D0A5BH Hydrohalisulfate 1 Investigative T09215 DRUGINFO D0M9VY Halisulfate 1 Investigative T89323 TARGETID T89323 T89323 FORMERID TTDR00340 T89323 UNIPROID M3K10_HUMAN T89323 TARGNAME Mixed lineage kinase 2 (MAP3K10) T89323 GENENAME MAP3K10 T89323 TARGTYPE Literature-reported T89323 SYNONYMS Protein kinase MST; Mitogen-activated protein kinase kinase kinase 10; MST; MLK2 T89323 FUNCTION Activates the JUN N-terminal pathway. T89323 PDBSTRUC 2RF0 T89323 BIOCLASS Kinase T89323 ECNUMBER EC 2.7.11.25 T89323 SEQUENCE MEEEEGAVAKEWGTTPAGPVWTAVFDYEAAGDEELTLRRGDRVQVLSQDCAVSGDEGWWTGQLPSGRVGVFPSNYVAPGAPAAPAGLQLPQEIPFHELQLEEIIGVGGFGKVYRALWRGEEVAVKAARLDPEKDPAVTAEQVCQEARLFGALQHPNIIALRGACLNPPHLCLVMEYARGGALSRVLAGRRVPPHVLVNWAVQVARGMNYLHNDAPVPIIHRDLKSINILILEAIENHNLADTVLKITDFGLAREWHKTTKMSAAGTYAWMAPEVIRLSLFSKSSDVWSFGVLLWELLTGEVPYREIDALAVAYGVAMNKLTLPIPSTCPEPFARLLEECWDPDPHGRPDFGSILKRLEVIEQSALFQMPLESFHSLQEDWKLEIQHMFDDLRTKEKELRSREEELLRAAQEQRFQEEQLRRREQELAEREMDIVERELHLLMCQLSQEKPRVRKRKGNFKRSRLLKLREGGSHISLPSGFEHKITVQASPTLDKRKGSDGASPPASPSIIPRLRAIRLTPVDCGGSSSGSSSGGSGTWSRGGPPKKEELVGGKKKGRTWGPSSTLQKERVGGEERLKGLGEGSKQWSSSAPNLGKSPKHTPIAPGFASLNEMEEFAEAEDGGSSVPPSPYSTPSYLSVPLPAEPSPGARAPWEPTPSAPPARWGHGARRRCDLALLGCATLLGAVGLGADVAEARAADGEEQRRWLDGLFFPRAGRFPRGLSPPARPHGRREDVGPGLGLAPSATLVSLSSVSDCNSTRSLLRSDSDEAAPAAPSPPPSPPAPTPTPSPSTNPLVDLELESFKKDPRQSLTPTHVTAACAVSRGHRRTPSDGALGQRGPPEPAGHGPGPRDLLDFPRLPDPQALFPARRRPPEFPGRPTTLTFAPRPRPAASRPRLDPWKLVSFGRTLTISPPSRPDTPESPGPPSVQPTLLDMDMEGQNQDSTVPLCGAHGSH T89323 DRUGINFO D0V4IH CEP1348 Investigative T89323 DRUGINFO D07IHM CEP-6331 Investigative T89323 DRUGINFO D09QBA CEP-5104 Investigative T89323 DRUGINFO D07ADX URMC-099 Investigative T96014 TARGETID T96014 T96014 FORMERID TTDR00662 T96014 UNIPROID GALE_HUMAN T96014 TARGNAME UDP-glucose 4-epimerase (GALE) T96014 GENENAME GALE T96014 TARGTYPE Literature-reported T96014 SYNONYMS UDP-galactose4-epimerase; UDP-galactose4'-epimerase; UDP-galactose 4-epimerase; UDP-N-acetylglucosamine 4-epimerase; UDP-N-acetylgalactosamine 4-epimerase; UDP-GlcNAc 4-epimerase; UDP-GalNAc 4-epimerase; Galactowaldenase T96014 FUNCTION The reaction with UDP-Gal plays a critical role in the Leloir pathway of galactose catabolism in which galactose is converted to the glycolytic intermediate glucose 6-phosphate. It contributes to the catabolism of dietary galactose and enables the endogenous biosynthesis of both UDP-Gal and UDP-GalNAc when exogenous sources are limited. Both UDP-sugar interconversions are important in the synthesis of glycoproteins and glycolipids. Catalyzes two distinct but analogous reactions: the reversible epimerization of UDP-glucose to UDP-galactose and the reversible epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. T96014 PDBSTRUC 1I3N; 1I3M; 1I3L; 1I3K; 1HZJ T96014 BIOCLASS Racemases and epimerase T96014 ECNUMBER EC 5.1.3.2 T96014 SEQUENCE MAEKVLVTGGAGYIGSHTVLELLEAGYLPVVIDNFHNAFRGGGSLPESLRRVQELTGRSVEFEEMDILDQGALQRLFKKYSFMAVIHFAGLKAVGESVQKPLDYYRVNLTGTIQLLEIMKAHGVKNLVFSSSATVYGNPQYLPLDEAHPTGGCTNPYGKSKFFIEEMIRDLCQADKTWNAVLLRYFNPTGAHASGCIGEDPQGIPNNLMPYVSQVAIGRREALNVFGNDYDTEDGTGVRDYIHVVDLAKGHIAALRKLKEQCGCRIYNLGTGTGYSVLQMVQAMEKASGKKIPYKVVARREGDVAACYANPSLAQEELGWTAALGLDRMCEDLWRWQKQNPSGFGTQA T96014 DRUGINFO D02HAL Uridine-5'-Diphosphate Investigative T96014 DRUGINFO D05PNI Phenyl-Uridine-5'-Diphosphate Investigative T96014 DRUGINFO D0K7WW Uridine Diphosphate Galactose Investigative T96014 DRUGINFO D0T9SK Tetramethylammonium Ion Investigative T96014 DRUGINFO D0Z9JO Uridine-5'-Diphosphate-Mannose Investigative T96014 DRUGINFO D06UGK Uridine-Diphosphate-N-Acetylgalactosamine Investigative T96014 DRUGINFO D0KC2Z Uridine-Diphosphate-N-Acetylglucosamine Investigative T96014 DRUGINFO D07MIE UDP-glucose Investigative T96014 DRUGINFO D0N0TS PSAMMAPLIN A Investigative T96014 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T00820 TARGETID T00820 T00820 FORMERID TTDR01270 T00820 UNIPROID KCJ11_HUMAN T00820 TARGNAME Inward rectifier potassium channel Kir6.2 (KCNJ11) T00820 GENENAME KCNJ11 T00820 TARGTYPE Literature-reported T00820 SYNONYMS Potassium channel, inwardly rectifying, subfamily J, member 11; KCNJ11; KATP channel (Kir6.2/SUR2A); Inward rectifier K+ channel Kir6.2; IKATP T00820 FUNCTION This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium. Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with ABCC9. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation. T00820 PDBSTRUC 6C3P; 6C3O T00820 BIOCLASS Inward rectifier potassium channel T00820 SEQUENCE MLSRKGIIPEEYVLTRLAEDPAEPRYRARQRRARFVSKKGNCNVAHKNIREQGRFLQDVFTTLVDLKWPHTLLIFTMSFLCSWLLFAMAWWLIAFAHGDLAPSEGTAEPCVTSIHSFSSAFLFSIEVQVTIGFGGRMVTEECPLAILILIVQNIVGLMINAIMLGCIFMKTAQAHRRAETLIFSKHAVIALRHGRLCFMLRVGDLRKSMIISATIHMQVVRKTTSPEGEVVPLHQVDIPMENGVGGNSIFLVAPLIIYHVIDANSPLYDLAPSDLHHHQDLEIIVILEGVVETTGITTQARTSYLADEILWGQRFVPIVAEEDGRYSVDYSKFGNTIKVPTPLCTARQLDEDHSLLEALTLASARGPLRKRSVPMAKAKPKFSISPDSLS T00820 DRUGINFO D0U1XJ HBR-985 Investigative T12126 TARGETID T12126 T12126 FORMERID TTDR00341 T12126 UNIPROID M3K11_HUMAN T12126 TARGNAME Mixed lineage kinase 3 (MAP3K11) T12126 GENENAME MAP3K11 T12126 TARGTYPE Literature-reported T12126 SYNONYMS Src-homology 3 domain-containing proline-rich kinase; SPRK; SH3 domain-containing proline-rich kinase; Protein-tyrosine kinase PTK1; PTK1; Mixed-lineage protein kinase 3; Mitogen-activated protein kinase kinase kinase 11; MLK3 T12126 FUNCTION Required for serum-stimulated cell proliferation and for mitogen and cytokine activation of MAPK14 (p38), MAPK3 (ERK) and MAPK8 (JNK1) through phosphorylation and activation of MAP2K4/MKK4 and MAP2K7/MKK7. Plays a role in mitogen-stimulated phosphorylation and activation of BRAF, but does not phosphorylate BRAF directly. Influences microtubule organization during the cell cycle. Activates the JUN N-terminal pathway. T12126 PDBSTRUC 6CQ7; 6AQB; 5K28; 5K26 T12126 BIOCLASS Kinase T12126 ECNUMBER EC 2.7.11.25 T12126 SEQUENCE MEPLKSLFLKSPLGSWNGSGSGGGGGGGGGRPEGSPKAAGYANPVWTALFDYEPSGQDELALRKGDRVEVLSRDAAISGDEGWWAGQVGGQVGIFPSNYVSRGGGPPPCEVASFQELRLEEVIGIGGFGKVYRGSWRGELVAVKAARQDPDEDISVTAESVRQEARLFAMLAHPNIIALKAVCLEEPNLCLVMEYAAGGPLSRALAGRRVPPHVLVNWAVQIARGMHYLHCEALVPVIHRDLKSNNILLLQPIESDDMEHKTLKITDFGLAREWHKTTQMSAAGTYAWMAPEVIKASTFSKGSDVWSFGVLLWELLTGEVPYRGIDCLAVAYGVAVNKLTLPIPSTCPEPFAQLMADCWAQDPHRRPDFASILQQLEALEAQVLREMPRDSFHSMQEGWKREIQGLFDELRAKEKELLSREEELTRAAREQRSQAEQLRRREHLLAQWELEVFERELTLLLQQVDRERPHVRRRRGTFKRSKLRARDGGERISMPLDFKHRITVQASPGLDRRRNVFEVGPGDSPTFPRFRAIQLEPAEPGQAWGRQSPRRLEDSSNGERRACWAWGPSSPKPGEAQNGRRRSRMDEATWYLDSDDSSPLGSPSTPPALNGNPPRPSLEPEEPKRPVPAERGSSSGTPKLIQRALLRGTALLASLGLGRDLQPPGGPGRERGESPTTPPTPTPAPCPTEPPPSPLICFSLKTPDSPPTPAPLLLDLGIPVGQRSAKSPRREEEPRGGTVSPPPGTSRSAPGTPGTPRSPPLGLISRPRPSPLRSRIDPWSFVSAGPRPSPLPSPQPAPRRAPWTLFPDSDPFWDSPPANPFQGGPQDCRAQTKDMGAQAPWVPEAGP T12126 DRUGINFO D0O7HD CEP1349 Investigative T12126 DRUGINFO D0YQ8V PMID24044867C8 Investigative T12126 DRUGINFO D07IHM CEP-6331 Investigative T12126 DRUGINFO D09QBA CEP-5104 Investigative T12126 DRUGINFO D07ADX URMC-099 Investigative T26774 TARGETID T26774 T26774 FORMERID TTDR00489 T26774 UNIPROID NCOA3_HUMAN T26774 TARGNAME Nuclear receptor coactivator 3 (NCOA3) T26774 GENENAME NCOA3 T26774 TARGTYPE Literature-reported T26774 SYNONYMS bHLHe42; Thyroid hormone receptor activator molecule 1; TRAM1; TRAM-1; Steroid receptor coactivator protein 3; SRC-3; Receptor-associated coactivator 3; RAC3; RAC-3; PCIP; NCoA-3; Class E basic helix-loop-helix protein 42; CBP-interacting protein; Amplified in breast cancer-1 protein; Amplified in breast cancer 1 protein; AIB1 (SRC-3); AIB1; AIB-1; ACTR T26774 FUNCTION Plays a central role in creating a multisubunit coactivator complex, which probably acts via remodeling of chromatin. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ER), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). Displays histone acetyltransferase activity. Also involved in the coactivation of the NF-kappa-B pathway via its interaction with the NFKB1 subunit. Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. T26774 PDBSTRUC 6ES7; 3L3Z; 3L3X; 1KBH T26774 BIOCLASS Acyltransferase T26774 ECNUMBER EC 2.3.1.48 T26774 SEQUENCE MSGLGENLDPLASDSRKRKLPCDTPGQGLTCSGEKRRREQESKYIEELAELISANLSDIDNFNVKPDKCAILKETVRQIRQIKEQGKTISNDDDVQKADVSSTGQGVIDKDSLGPLLLQALDGFLFVVNRDGNIVFVSENVTQYLQYKQEDLVNTSVYNILHEEDRKDFLKNLPKSTVNGVSWTNETQRQKSHTFNCRMLMKTPHDILEDINASPEMRQRYETMQCFALSQPRAMMEEGEDLQSCMICVARRITTGERTFPSNPESFITRHDLSGKVVNIDTNSLRSSMRPGFEDIIRRCIQRFFSLNDGQSWSQKRHYQEAYLNGHAETPVYRFSLADGTIVTAQTKSKLFRNPVTNDRHGFVSTHFLQREQNGYRPNPNPVGQGIRPPMAGCNSSVGGMSMSPNQGLQMPSSRAYGLADPSTTGQMSGARYGGSSNIASLTPGPGMQSPSSYQNNNYGLNMSSPPHGSPGLAPNQQNIMISPRNRGSPKIASHQFSPVAGVHSPMASSGNTGNHSFSSSSLSALQAISEGVGTSLLSTLSSPGPKLDNSPNMNITQPSKVSNQDSKSPLGFYCDQNPVESSMCQSNSRDHLSDKESKESSVEGAENQRGPLESKGHKKLLQLLTCSSDDRGHSSLTNSPLDSSCKESSVSVTSPSGVSSSTSGGVSSTSNMHGSLLQEKHRILHKLLQNGNSPAEVAKITAEATGKDTSSITSCGDGNVVKQEQLSPKKKENNALLRYLLDRDDPSDALSKELQPQVEGVDNKMSQCTSSTIPSSSQEKDPKIKTETSEEGSGDLDNLDAILGDLTSSDFYNNSISSNGSHLGTKQQVFQGTNSLGLKSSQSVQSIRPPYNRAVSLDSPVSVGSSPPVKNISAFPMLPKQPMLGGNPRMMDSQENYGSSMGGPNRNVTVTQTPSSGDWGLPNSKAGRMEPMNSNSMGRPGGDYNTSLPRPALGGSIPTLPLRSNSIPGARPVLQQQQQMLQMRPGEIPMGMGANPYGQAAASNQLGSWPDGMLSMEQVSHGTQNRPLLRNSLDDLVGPPSNLEGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPKQDAFQGQEAAVMMDQKAGLYGQTYPAQGPPMQGGFHLQGQSPSFNSMMNQMNQQGNFPLQGMHPRANIMRPRTNTPKQLRMQLQQRLQGQQFLNQSRQALELKMENPTAGGAAVMRPMMQPQVSSQQGFLNAQMVAQRSRELLSHHFRQQRVAMMMQQQQQQQQQQQQQQQQQQQQQQQQQQQQQTQAFSPPPNVTASPSMDGLLAGPTMPQAPPQQFPYQPNYGMGQQPDPAFGRVSSPPNAMMSSRMGPSQNPMMQHPQAASIYQSSEMKGWPSGNLARNSSFSQQQFAHQGNPAVYSMVHMNGSSGHMGQMNMNPMPMSGMPMGPDQKYC T26774 DRUGINFO D09ESF GNF-PF-78 Investigative T26774 DRUGINFO D0R2ZN GNF-PF-826 Investigative T91173 TARGETID T91173 T91173 FORMERID TTDR01344 T91173 UNIPROID IKKA_HUMAN T91173 TARGNAME IKKA messenger RNA (IKKA mRNA) T91173 GENENAME CHUK T91173 TARGTYPE Literature-reported T91173 SYNONYMS Transcription factor 16 (mRNA); TCF16 (mRNA); TCF-16 (mRNA); Nuclear factor NFkappaB inhibitor kinase alpha (mRNA); Nuclear factor NF-kappa-B inhibitor kinase alpha (mRNA); NFKBIKA (mRNA); Inhibitory kappa B kinasea (mRNA); Inhibitor of nuclear factor kappa-B kinase subunit alpha (mRNA); IkappaB kinase (mRNA); IkBKA (mRNA); IKK1 (mRNA); IKK-alpha (mRNA); IKK-A (mRNA); I-kappa-B kinase alpha (mRNA); I-kappa-B kinase 1 (mRNA); I kappa-B kinase alpha (mRNA); Conserved helix-loop-helix ubiquitous kinase (mRNA) T91173 FUNCTION Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor. Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. T91173 PDBSTRUC 5TQY; 5TQX; 5TQW; 5EBZ; 3BRT T91173 BIOCLASS mRNA target T91173 ECNUMBER EC 2.7.11.10 T91173 SEQUENCE MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCHEIQIMKKLNHANVVKACDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQILSLLSDIGSGIRYLHENKIIHRDLKPENIVLQDVGGKIIHKIIDLGYAKDVDQGSLCTSFVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWHEKIKKKDPKCIFACEEMSGEVRFSSHLPQPNSLCSLVVEPMENWLQLMLNWDPQQRGGPVDLTLKQPRCFVLMDHILNLKIVHILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGISLDPRKPASQCVLDGVRGCDSYMVYLFDKSKTVYEGPFASRSLSDCVNYIVQDSKIQLPIIQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTLISASQQLKAKLEFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAEIMELQKSPYGRRQGDLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKIIDLLPKVEVALSNIKEADNTVMFMQGKRQKEIWHLLKIACTQSSARSLVGSSLEGAVTPQTSAWLPPTSAEHDHSLSCVVTPQDGETSAQMIEENLNCLGHLSTIIHEANEEQGNSMMNLDWSWLTE T91173 DRUGINFO D06UNC ISIS 23559 Investigative T91173 DRUGINFO D0AJ5N ISIS 23544 Investigative T91173 DRUGINFO D01OBJ 5-Bromo-6-methoxy-9H-beta-carboline Investigative T91173 DRUGINFO D0S7IE N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide Investigative T08074 TARGETID T08074 T08074 FORMERID TTDR01345 T08074 UNIPROID PDPK1_HUMAN T08074 TARGNAME PDK-1 messenger RNA (PDK-1 mRNA) T08074 GENENAME PDPK1 T08074 TARGTYPE Literature-reported T08074 SYNONYMS PDK1 (mRNA); HPDK1 (mRNA); 3-phosphoinositide-dependent protein kinase 1 (mRNA); 3-Phosphoinositide-dependent kinase-1 (mRNA); 3'-phosphoinositide dependent kinase 1 (mRNA) T08074 FUNCTION Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated kinase-1 (PAK1), protein kinase PKN (PKN1 and PKN2). Plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. Negatively regulates the TGF-beta-induced signaling by: modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta. Activates PPARG transcriptional activity and promotes adipocyte differentiation. Activates the NF-kappa-B pathway via phosphorylation of IKKB. The tyrosine phosphorylated form is crucial for the regulation of focal adhesions by angiotensin II. Controls proliferation, survival, and growth of developing pancreatic cells. Participates in the regulation of Ca(2+) entry and Ca(2+)-activated K(+) channels of mast cells. Essential for the motility of vascular endothelial cells (ECs) and is involved in the regulation of their chemotaxis. Plays a critical role in cardiac homeostasis by serving as a dual effector for cell survival and beta-adrenergic response. Plays an important role during thymocyte development by regulating the expression of key nutrient receptors on the surface of pre-T cells and mediating Notch-induced cell growth and proliferative responses. Provides negative feedback inhibition to toll-like receptor-mediated NF-kappa-B activation in macrophages. Isoform 3 is catalytically inactive. Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. T08074 PDBSTRUC 5MRD; 5LVP; 5LVO; 5LVN; 5LVM T08074 BIOCLASS mRNA target T08074 ECNUMBER EC 2.7.11.1 T08074 SEQUENCE MARTTSQLYDAVPIQSSVVLCSCPSPSMVRTQTESSTPPGIPGGSRQGPAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLTAYLPAMSEDDEDCYGNYDNLLSQFGCMQVSSSSSSHSLSASDTGLPQRSGSNIEQYIHDLDSNSFELDLQFSEDEKRLLLEKQAGGNPWHQFVENNLILKMGPVDKRKGLFARRRQLLLTEGPHLYYVDPVNKVLKGEIPWSQELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQEVWRQRYQSHPDAAVQ T08074 DRUGINFO D00SNI ISIS 29475 Investigative T08074 DRUGINFO D00XPD ISIS 29233 Investigative T08074 DRUGINFO D01IHU ISIS 29471 Investigative T08074 DRUGINFO D03RER ISIS 29470 Investigative T08074 DRUGINFO D04REL ISIS 29477 Investigative T08074 DRUGINFO D08OLG ISIS 29239 Investigative T08074 DRUGINFO D09EAE SU-6689 Investigative T08074 DRUGINFO D09NFR ISIS 29257 Investigative T08074 DRUGINFO D09OFM MiR-375 Investigative T08074 DRUGINFO D0A3PB ISIS 29256 Investigative T08074 DRUGINFO D0C1ZW ISIS 29232 Investigative T08074 DRUGINFO D0CS4K ISIS 29224 Investigative T08074 DRUGINFO D0D3MV ISIS 29255 Investigative T08074 DRUGINFO D0H6DN ISIS 29469 Investigative T08074 DRUGINFO D0I8KZ ISIS 29223 Investigative T08074 DRUGINFO D0K8NI ISIS 29246 Investigative T08074 DRUGINFO D0M5DM ISIS 29236 Investigative T08074 DRUGINFO D0ML3Q ISIS 29243 Investigative T08074 DRUGINFO D0PY4Z ISIS 29219 Investigative T08074 DRUGINFO D0S4RZ ISIS 29234 Investigative T08074 DRUGINFO D0V6GX BX-201 Investigative T08074 DRUGINFO D0ZL8O ISIS 29244 Investigative T08074 DRUGINFO D0ZQ0Y ISIS 29237 Investigative T08074 DRUGINFO D0L5AB BX-517 Investigative T08074 DRUGINFO D00ATA (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one Investigative T08074 DRUGINFO D0Y5RO NU-6102 Investigative T98315 TARGETID T98315 T98315 FORMERID TTDR01353 T98315 UNIPROID SOAT2_HUMAN T98315 TARGNAME SOAT2 messenger RNA (SOAT2 mRNA) T98315 GENENAME SOAT2 T98315 TARGTYPE Literature-reported T98315 SYNONYMS Sterol O-acyltransferase 2 (mRNA); Cholesterol acyltransferase 2 (mRNA); Acyl-coenzyme A:cholesterol acyltransferase 2 (mRNA); ACAT2 (mRNA); ACAT-2 (mRNA); ACACT2 (mRNA) T98315 FUNCTION Plays a role in lipoprotein assembly and dietary cholesterol absorption. In addition to its acyltransferase activity, it may act as a ligase. May provide cholesteryl esters for lipoprotein secretion from hepatocytes and intestinal mucosa. T98315 BIOCLASS mRNA target T98315 ECNUMBER EC 2.3.1.26 T98315 SEQUENCE MEPGGARLRLQRTEGLGGERERQPCGDGNTETHRAPDLVQWTRHMEAVKAQLLEQAQGQLRELLDRAMREAIQSYPSQDKPLPPPPPGSLSRTQEPSLGKQKVFIIRKSLLDELMEVQHFRTIYHMFIAGLCVFIISTLAIDFIDEGRLLLEFDLLIFSFGQLPLALVTWVPMFLSTLLAPYQALRLWARGTWTQATGLGCALLAAHAVVLCALPVHVAVEHQLPPASRCVLVFEQVRFLMKSYSFLREAVPGTLRARRGEGIQAPSFSSYLYFLFCPTLIYRETYPRTPYVRWNYVAKNFAQALGCVLYACFILGRLCVPVFANMSREPFSTRALVLSILHATLPGIFMLLLIFFAFLHCWLNAFAEMLRFGDRMFYRDWWNSTSFSNYYRTWNVVVHDWLYSYVYQDGLRLLGARARGVAMLGVFLVSAVAHEYIFCFVLGFFYPVMLILFLVIGGMLNFMMHDQRTGPAWNVLMWTMLFLGQGIQVSLYCQEWYARRHCPLPQATFWGLVTPRSWSCHT T98315 DRUGINFO D02YNE ISIS 140158 Investigative T98315 DRUGINFO D0A9LB ISIS 140153 Investigative T98315 DRUGINFO D0B1US ISIS 140157 Investigative T98315 DRUGINFO D0I2SY ISIS 140148 Investigative T98315 DRUGINFO D0O1CN ISIS 140161 Investigative T98315 DRUGINFO D0A2NK PYRIPYROPENE A Investigative T98315 DRUGINFO D0T7YM Oleic acid anilide Investigative T48614 TARGETID T48614 T48614 FORMERID TTDC00228 T48614 UNIPROID IF4E_HUMAN T48614 TARGNAME EIF4E messenger RNA (EIF4E mRNA) T48614 GENENAME EIF4E T48614 TARGTYPE Literature-reported T48614 SYNONYMS mRNA capbinding protein (mRNA); mRNA cap-binding protein (mRNA); eIF4F 25 kDa subunit (mRNA); eIF4E (mRNA); eIF-4F 25 kDa subunit (mRNA); eIF-4E (mRNA); Eukaryotic translation initiation factor 4E (mRNA); EIF4F (mRNA); EIF4EL1 (mRNA) T48614 FUNCTION Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap. Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures. T48614 PDBSTRUC 5ZML; 5ZK9; 5ZK7; 5ZK5; 5ZJZ T48614 BIOCLASS mRNA target T48614 SEQUENCE MATVEPETTPTPNPPTTEEEKTESNQEVANPEHYIKHPLQNRWALWFFKNDKSKTWQANLRLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLFKDGIEPMWEDEKNKRGGRWLITLNKQQRRSDLDRFWLETLLCLIGESFDDYSDDVCGAVVNVRAKGDKIAIWTTECENREAVTHIGRVYKERLGLPPKIVIGYQSHADTATKSGSTTKNRFVV T48614 DRUGINFO D00FPT 7-Methyl-Guanosine-5'-Triphosphate Investigative T48614 DRUGINFO D00MZD 7n-Methyl-8-Hydroguanosine-5'-Diphosphate Investigative T48614 DRUGINFO D06NGR 7-Methyl-Gpppa Investigative T55414 TARGETID T55414 T55414 FORMERID TTDI02252 T55414 UNIPROID CSF1R_HUMAN T55414 TARGNAME CSF1R messenger RNA (CSF1R mRNA) T55414 GENENAME CSF1R T55414 TARGTYPE Literature-reported T55414 SYNONYMS Proto-oncogene c-Fms (mRNA); M-CSF-R (mRNA); FMS (mRNA); CSF-1R (mRNA); CSF-1-R (mRNA); CSF-1 receptor (mRNA); CD115 (mRNA) T55414 FUNCTION Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone and tooth development. Required for normal male and female fertility, and for normal development of milk ducts and acinar structures in the mammary gland during pregnancy. Promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration, and promotes cancer cell invasion. Activates several signaling pathways in response to ligand binding. Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL. Activation of PLCG2 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, that then lead to the activation of protein kinase C family members, especially PRKCD. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to activation of the AKT1 signaling pathway. Activated CSF1R also mediates activation of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1, and of the SRC family kinases SRC, FYN and YES1. Activated CSF1R transmits signals both via proteins that directly interact with phosphorylated tyrosine residues in its intracellular domain, or via adapter proteins, such as GRB2. Promotes activation of STAT family members STAT3, STAT5A and/or STAT5B. Promotes tyrosine phosphorylation of SHC1 and INPP5D/SHIP-1. Receptor signaling is down-regulated by protein phosphatases, such as INPP5D/SHIP-1, that dephosphorylate the receptor and its downstream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. T55414 PDBSTRUC 4WRM; 4WRL; 4R7I; 4R7H; 4LIQ T55414 BIOCLASS mRNA target T55414 ECNUMBER EC 2.7.10.1 T55414 SEQUENCE MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEWDGPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLYVKDPARPWNVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMRHTNYSFSPWHGFTIHRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIPGPPALTLVPAELVRIRGEAAQIVCSASSVDVNFDVFLQHNNTKLAIPQQSDFHNNRYQKVLTLNLDQVDFQHAGNYSCVASNVQGKHSTSMFFRVVESAYLNLSSEQNLIQEVTVGEGLNLKVMVEAYPGLQGFNWTYLGPFSDHQPEPKLANATTKDTYRHTFTLSLPRLKPSEAGRYSFLARNPGGWRALTFELTLRYPPEVSVIWTFINGSGTLLCAASGYPQPNVTWLQCSGHTDRCDEAQVLQVWDDPYPEVLSQEPFHKVTVQSLLTVETLEHNQTYECRAHNSVGSGSWAFIPISAGAHTHPPDEFLFTPVVVACMSIMALLLLLLLLLLYKYKQKPKYQVRWKIIESYEGNSYTFIDPTQLPYNEKWEFPRNNLQFGKTLGAGAFGKVVEATAFGLGKEDAVLKVAVKMLKSTAHADEKEALMSELKIMSHLGQHENIVNLLGACTHGGPVLVITEYCCYGDLLNFLRRKAEAMLGPSLSPGQDPEGGVDYKNIHLEKKYVRRDSGFSSQGVDTYVEMRPVSTSSNDSFSEQDLDKEDGRPLELRDLLHFSSQVAQGMAFLASKNCIHRDVAARNVLLTNGHVAKIGDFGLARDIMNDSNYIVKGNARLPVKWMAPESIFDCVYTVQSDVWSYGILLWEIFSLGLNPYPGILVNSKFYKLVKDGYQMAQPAFAPKNIYSIMQACWALEPTHRPTFQQICSFLQEQAQEDRRERDYTNLPSSSRSGGSGSSSSELEEESSSEHLTCCEQGDIAQPLLQPNNYQFC T55414 DRUGINFO D0D6MH GW-2580 Investigative T55414 DRUGINFO D08BJR Ki-20227 Investigative T55414 DRUGINFO D0UN9O GTP-14564 Investigative T55414 DRUGINFO D0Y4BL JNJ-28312141 Investigative T78393 TARGETID T78393 T78393 FORMERID TTDR01372 T78393 UNIPROID MIF_HUMAN T78393 TARGNAME MIF messenger RNA (MIF mRNA) T78393 GENENAME MIF T78393 TARGTYPE Literature-reported T78393 SYNONYMS Phenylpyruvate tautomerase (mRNA); MMIF (mRNA); L-dopachrome tautomerase (mRNA); L-dopachrome isomerase (mRNA); Glycosylation-inhibiting factor (mRNA); GLIF (mRNA); GIF (mRNA) T78393 FUNCTION Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity. Pro-inflammatory cytokine. T78393 PDBSTRUC 6FVH; 6FVE; 6CBH; 6CBG; 6CBF T78393 BIOCLASS mRNA target T78393 ECNUMBER EC 5.3.2.1 T78393 SEQUENCE MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA T78393 DRUGINFO D01DCZ ISIS 112690 Investigative T78393 DRUGINFO D01HJN Ethyl 7-hydroxy-2-oxo-2H-chromene-3-carboxylate Investigative T78393 DRUGINFO D02CBE ISIS 112724 Investigative T78393 DRUGINFO D03IWC 3-benzyl-6-methylbenzo[d]oxazol-2(3H)-one Investigative T78393 DRUGINFO D03QDS 2-(4-hydroxystyryl)quinolin-8-ol Investigative T78393 DRUGINFO D03QNS 7-hydroxy-3-phenyl-2H-chromen-2-one Investigative T78393 DRUGINFO D04MZK 6-phenylpyridazin-3-yl thiophene-2-carboxylate Investigative T78393 DRUGINFO D05RSQ 3-benzyl-5-fluorobenzo[d]oxazol-2(3H)-one Investigative T78393 DRUGINFO D06HPB ISIS 112696 Investigative T78393 DRUGINFO D07OLL 4-((pyridin-4-ylthio)methyl)benzene-1,2-diol Investigative T78393 DRUGINFO D09BVA 3-acetyl-7-hydroxy-2H-chromen-2-one Investigative T78393 DRUGINFO D0A5XY N-(2-bromobenzoyloxy)-4-chlorobenzamide Investigative T78393 DRUGINFO D0C4ET ISIS 112592 Investigative T78393 DRUGINFO D0E1HP 3,3,3-tris(4-chlorophenyl)propanoic acid Investigative T78393 DRUGINFO D0G2XI 4-(4-benzyl-1H-1,2,3-triazol-1-yl)phenol Investigative T78393 DRUGINFO D0G9JB ISIS 112699 Investigative T78393 DRUGINFO D0O4BU S-benzo[d]oxazol-2-yl O-butyl carbonothioate Investigative T78393 DRUGINFO D0R4LX ISIS 112590 Investigative T78393 DRUGINFO D0S0YQ 1-(2-chlorophenyl)-3-(pyridin-2-yl)thiourea Investigative T78393 DRUGINFO D0T3FE ISIS 112711 Investigative T78393 DRUGINFO D0TX9P 3-(1H-pyrazol-3-yl)benzoic acid Investigative T78393 DRUGINFO D0V4SG 3-benzyl-5-methylbenzo[d]oxazol-2(3H)-one Investigative T78393 DRUGINFO D0W0QS ISIS 112580 Investigative T78393 DRUGINFO D0W1WF 4-iodo-6-phenylpyrimidine Investigative T78393 DRUGINFO D0WO4V ISIS 112599 Investigative T78393 DRUGINFO D0X3TX ISIS 112694 Investigative T78393 DRUGINFO D0Y2OB Benzofuran-2-yl(indolin-1-yl)methanone Investigative T78393 DRUGINFO D0YY2W 1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea Investigative T40149 TARGETID T40149 T40149 FORMERID TTDR01379 T40149 UNIPROID KPCL_HUMAN T40149 TARGNAME PKC-eta messenger RNA (PRKCH mRNA) T40149 GENENAME PRKCH T40149 TARGTYPE Literature-reported T40149 SYNONYMS nPKC-eta (mRNA); Protein kinase C eta type (mRNA); PRKCL (mRNA); PKCL (mRNA); PKC-L (mRNA) T40149 FUNCTION In keratinocytes, binds and activates the tyrosine kinase FYN, which in turn blocks epidermal growth factor receptor (EGFR) signaling and leads to keratinocyte growth arrest and differentiation. Associates with the cyclin CCNE1-CDK2-CDKN1B complex and inhibits CDK2 kinase activity, leading to RB1 dephosphorylation and thereby G1 arrest in keratinocytes. In association with RALA activates actin depolymerization, which is necessary for keratinocyte differentiation. In the pre-B cell receptor signaling, functions downstream of BLNK by up-regulating IRF4, which in turn activates L chain gene rearrangement. Regulates epithelial tight junctions (TJs) by phosphorylating occludin (OCLN) on threonine residues, which is necessary for the assembly and maintenance of TJs. In association with PLD2 and via TLR4 signaling, is involved in lipopolysaccharide (LPS)-induced RGS2 down-regulation and foam cell formation. Upon PMA stimulation, mediates glioblastoma cell proliferation by activating the mTOR pathway, the PI3K/AKT pathway and the ERK1-dependent phosphorylation of ELK1. Involved in the protection of glioblastoma cells from irradiation-induced apoptosis by preventing caspase-9 activation. In camptothecin-treated MCF-7 cells, regulates NF-kappa-B upstream signaling by activating IKBKB, and confers protection against DNA damage-induced apoptosis. Promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Phosphorylates ATF2 which promotes its nuclear retention and transcriptional activity and negatively regulates its mitochondrial localization. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in the regulation of cell differentiation in keratinocytes and pre-B cell receptor, mediates regulation of epithelial tight junction integrity and foam cell formation, and is required for glioblastoma proliferation and apoptosis prevention in MCF-7 cells. T40149 PDBSTRUC 3TXO; 2FK9 T40149 BIOCLASS mRNA target T40149 ECNUMBER EC 2.7.11.13 T40149 SEQUENCE MSSGTMKFNGYLRVRIGEAVGLQPTRWSLRHSLFKKGHQLLDPYLTVSVDQVRVGQTSTKQKTNKPTYNEEFCANVTDGGHLELAVFHETPLGYDHFVANCTLQFQELLRTTGASDTFEGWVDLEPEGKVFVVITLTGSFTEATLQRDRIFKHFTRKRQRAMRRRVHQINGHKFMATYLRQPTYCSHCREFIWGVFGKQGYQCQVCTCVVHKRCHHLIVTACTCQNNINKVDSKIAEQRFGINIPHKFSIHNYKVPTFCDHCGSLLWGIMRQGLQCKICKMNVHIRCQANVAPNCGVNAVELAKTLAGMGLQPGNISPTSKLVSRSTLRRQGKESSKEGNGIGVNSSNRLGIDNFEFIRVLGKGSFGKVMLARVKETGDLYAVKVLKKDVILQDDDVECTMTEKRILSLARNHPFLTQLFCCFQTPDRLFFVMEFVNGGDLMFHIQKSRRFDEARARFYAAEIISALMFLHDKGIIYRDLKLDNVLLDHEGHCKLADFGMCKEGICNGVTTATFCGTPDYIAPEILQEMLYGPAVDWWAMGVLLYEMLCGHAPFEAENEDDLFEAILNDEVVYPTWLHEDATGILKSFMTKNPTMRLGSLTQGGEHAILRHPFFKEIDWAQLNHRQIEPPFRPRIKSREDVSNFDPDFIKEEPVLTPIDEGHLPMINQDEFRNFSYVSPELQP T40149 DRUGINFO D0R2TM BALANOL Terminated T40149 DRUGINFO D01YJD ISIS 6445 Investigative T40149 DRUGINFO D02NUN ISIS 6432 Investigative T40149 DRUGINFO D04YKA ISIS 6553 Investigative T40149 DRUGINFO D05ZZH ISIS 6581 Investigative T40149 DRUGINFO D07TMI ISIS 6442 Investigative T40149 DRUGINFO D0DS2V ISIS 6434 Investigative T40149 DRUGINFO D0HU4L ISIS 6431 Investigative T40149 DRUGINFO D0LL1H ISIS 6603 Investigative T40149 DRUGINFO D0UH5I ISIS 6443 Investigative T40149 DRUGINFO D0Z3TU ISIS 6435 Investigative T40149 DRUGINFO D04AXH 8-Octyl-benzolactam-V9 Investigative T40149 DRUGINFO D04JNZ PROSTRATIN Investigative T40149 DRUGINFO D06ZCX LY-326449 Investigative T54779 TARGETID T54779 T54779 FORMERID TTDI02259 T54779 UNIPROID RIR2_HUMAN T54779 TARGNAME RRM2 messenger RNA (RRM2 mRNA) T54779 GENENAME RRM2 T54779 TARGTYPE Literature-reported T54779 SYNONYMS Ribonucleotide reductase small subunit (mRNA); Ribonucleotide reductase small chain (mRNA); Ribonucleoside-diphosphate reductase subunit M2 (mRNA); RR2 (mRNA) T54779 FUNCTION Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signaling. Provides the precursors necessary for DNA synthesis. T54779 PDBSTRUC 3VPO; 3VPN; 3VPM; 3OLJ; 2UW2 T54779 BIOCLASS mRNA target T54779 ECNUMBER EC 1.17.4.1 T54779 SEQUENCE MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARRIFQEPTEPKTKAAAPGVEDEPLLRENPRRFVIFPIEYHDIWQMYKKAEASFWTAEEVDLSKDIQHWESLKPEERYFISHVLAFFAASDGIVNENLVERFSQEVQITEARCFYGFQIAMENIHSEMYSLLIDTYIKDPKEREFLFNAIETMPCVKKKADWALRWIGDKEATYGERVVAFAAVEGIFFSGSFASIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFKHLVHKPSEERVREIIINAVRIEQEFLTEALPVKLIGMNCTLMKQYIEFVADRLMLELGFSKVFRVENPFDFMENISLEGKTNFFEKRVGEYQRMGVMSSPTENSFTLDADF T31032 TARGETID T31032 T31032 FORMERID TTDR01385 T31032 UNIPROID MP2K2_HUMAN T31032 TARGNAME MEK2 messenger RNA (MEK2 mRNA) T31032 GENENAME MAP2K2 T31032 TARGTYPE Literature-reported T31032 SYNONYMS PRKMK2 (mRNA); MKK2 (mRNA); MEK 2 (mRNA); MAPKK 2 (mRNA); MAPK/ERK kinase 2 (mRNA); MAP kinase kinase 2 (mRNA); Dual specificity mitogenactivated protein kinase kinase 2 (mRNA); Dual specificity mitogen-activated protein kinase kinase 2 (mRNA) T31032 FUNCTION Activates the ERK1 and ERK2 MAP kinases. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. T31032 PDBSTRUC 4H3Q; 1S9I T31032 BIOCLASS mRNA target T31032 ECNUMBER EC 2.7.12.2 T31032 SEQUENCE MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV T31032 DRUGINFO D01KTB ISIS 25080 Investigative T31032 DRUGINFO D02YXE ISIS 25124 Investigative T31032 DRUGINFO D04CYY ISIS 25123 Investigative T31032 DRUGINFO D04LLB ISIS 25078 Investigative T31032 DRUGINFO D05GCI ISIS 25082 Investigative T31032 DRUGINFO D06DMT ISIS 25074 Investigative T31032 DRUGINFO D07ZWS ISIS 25126 Investigative T31032 DRUGINFO D08DCT ISIS 25079 Investigative T31032 DRUGINFO D09LKE ISIS 25113 Investigative T31032 DRUGINFO D0C3UV ISIS 25117 Investigative T31032 DRUGINFO D0F8LL ISIS 25115 Investigative T31032 DRUGINFO D0H2LG ISIS 25128 Investigative T31032 DRUGINFO D0LS4V ISIS 25081 Investigative T31032 DRUGINFO D0M3UJ ISIS 25073 Investigative T31032 DRUGINFO D0M7OE ISIS 25127 Investigative T31032 DRUGINFO D0OV0A ISIS 25114 Investigative T31032 DRUGINFO D0PK2K ISIS 25125 Investigative T31032 DRUGINFO D0RX1E ISIS 25116 Investigative T31032 DRUGINFO D0TY2O ISIS 25075 Investigative T31032 DRUGINFO D0U4ZT ISIS 25118 Investigative T46700 TARGETID T46700 T46700 FORMERID TTDR01388 T46700 UNIPROID M3K8_HUMAN T46700 TARGNAME Cot oncogene messenger RNA (MAP3K8 mRNA) T46700 GENENAME MAP3K8 T46700 TARGTYPE Literature-reported T46700 SYNONYMS Tumor progression locus 2 (mRNA); TPL-2 (mRNA); Serine/threonine-protein kinase cot (mRNA); Proto-oncogene c-Cot (mRNA); Mitogen-activated protein kinase kinase kinase 8 (mRNA); ESTF (mRNA); Cancer Osaka thyroid oncogene (mRNA); COT (mRNA) T46700 FUNCTION Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. T46700 PDBSTRUC 5IU2; 4Y85; 4Y83 T46700 BIOCLASS mRNA target T46700 ECNUMBER EC 2.7.11.25 T46700 SEQUENCE MEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPTLEYG T46700 DRUGINFO D03JVY ISIS 116361 Investigative T46700 DRUGINFO D06KSF Tpl2 kinase inhibitor Investigative T46700 DRUGINFO D09WUL ISIS 116414 Investigative T46700 DRUGINFO D0C5VI ISIS 116360 Investigative T46700 DRUGINFO D0I1AW ISIS 116359 Investigative T46700 DRUGINFO D0M6ZQ ISIS 116362 Investigative T46700 DRUGINFO D0TQ1F ISIS 116363 Investigative T46700 DRUGINFO D03MUZ 8-chloro-quinoline-3-carbonitrile Investigative T46700 DRUGINFO D0V0QJ NSC-686549 Investigative T06037 TARGETID T06037 T06037 FORMERID TTDR01391 T06037 UNIPROID MK09_HUMAN T06037 TARGNAME JNK2 messenger RNA (JNK2 mRNA) T06037 GENENAME MAPK9 T06037 TARGTYPE Literature-reported T06037 SYNONYMS Stress-activated protein kinase 1a (mRNA); SAPK1a (mRNA); PRKM9 (mRNA); Mitogen-activated protein kinase 9 (mRNA); Mitogen-activated protein kinase 8-interacting protein 2 (mRNA); MAPK 9 (mRNA); MAP kinase 9 (mRNA); Jun-N-terminal kinase 2 (mRNA); JNK-interacting protein 2 (mRNA); JNK-55 (mRNA); JNK MAP kinase scaffold protein 2 (mRNA); JIP-2 (mRNA); Islet-brain-2 (mRNA); IB-2 (mRNA); C-jun-amino-terminal kinase interacting protein 2 (mRNA); C-Jun N-terminal kinase 2 (mRNA) T06037 FUNCTION Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. In response to oxidative or ribotoxic stresses, inhibits rRNA synthesis by phosphorylating and inactivating the RNA polymerase 1-specific transcription initiation factor RRN3. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including TP53 and YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Upon T-cell receptor (TCR) stimulation, is activated by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels. Plays an important role in the osmotic stress-induced epithelial tight-junctions disruption. When activated, promotes beta-catenin/CTNNB1 degradation and inhibits the canonical Wnt signaling pathway. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock. Phosphorylates POU5F1, which results in the inhibition of POU5F1's transcriptional activity and enhances its proteosomal degradation. Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. T06037 PDBSTRUC 3NPC; 3E7O T06037 BIOCLASS mRNA target T06037 ECNUMBER EC 2.7.11.24 T06037 SEQUENCE MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR T06037 DRUGINFO D0I3QU ISIS 18078 Investigative T06037 DRUGINFO D0F5BY N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide Investigative T06037 DRUGINFO D0L0HG AC1LG8KT Investigative T06037 DRUGINFO D00HVA Aminopyridine deriv. 2 Investigative T06037 DRUGINFO D0H6ZP IN-1166 Investigative T06037 DRUGINFO D0Q3NG N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide Investigative T06037 DRUGINFO D0VJ2S JNK-IN-8 Investigative T06037 DRUGINFO D04QCF AS-601245 Investigative T06037 DRUGINFO D0S7IE N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide Investigative T25927 TARGETID T25927 T25927 FORMERID TTDR01396 T25927 UNIPROID CASP6_HUMAN T25927 TARGNAME Caspase 6 messenger RNA (CASP6 mRNA) T25927 GENENAME CASP6 T25927 TARGTYPE Literature-reported T25927 SYNONYMS MCH2 (mRNA); Caspase-6 subunit p18 (mRNA); Caspase-6 subunit p11 (mRNA); CASP-6 (mRNA); Apoptotic protease Mch-2 (mRNA) T25927 FUNCTION Cleaves poly(ADP-ribose) polymerase in vitro, as well as lamins. Overexpression promotes programmed cell death. Involved in the activation cascade of caspases responsible for apoptosis execution. T25927 PDBSTRUC 6DEV; 6DEU; 4NBN; 4NBL; 4NBK T25927 BIOCLASS mRNA target T25927 ECNUMBER EC 3.4.22.59 T25927 SEQUENCE MSSASGLRRGHPAGGEENMTETDAFYKREMFDPAEKYKMDHRRRGIALIFNHERFFWHLTLPERRGTCADRDNLTRRFSDLGFEVKCFNDLKAEELLLKIHEVSTVSHADADCFVCVFLSHGEGNHIYAYDAKIEIQTLTGLFKGDKCHSLVGKPKIFIIQACRGNQHDVPVIPLDVVDNQTEKLDTNITEVDAASVYTLPAGADFLMCYSVAEGYYSHRETVNGSWYIQDLCEMLGKYGSSLEFTELLTLVNRKVSQRRVDFCKDPSAIGKKQVPCFASMLTKKLHFFPKSN T25927 DRUGINFO D01GTL ISIS 134602 Investigative T25927 DRUGINFO D04EVL ISIS 134583 Investigative T25927 DRUGINFO D04VQC ISIS 134566 Investigative T25927 DRUGINFO D05CCZ ISIS 134524 Investigative T25927 DRUGINFO D05ZQZ ISIS 134532 Investigative T25927 DRUGINFO D08ORM Ac-VEID-CHO Investigative T25927 DRUGINFO D08WXD ISIS 134609 Investigative T25927 DRUGINFO D0D3QG ISIS 134608 Investigative T25927 DRUGINFO D0I1FS ISIS 134499 Investigative T25927 DRUGINFO D0J5PL ISIS 134528 Investigative T25927 DRUGINFO D0J7EZ ISIS 134604 Investigative T25927 DRUGINFO D0K9BQ ISIS 134603 Investigative T25927 DRUGINFO D0L7AG ISIS 134564 Investigative T25927 DRUGINFO D0L8WW ISIS 134606 Investigative T25927 DRUGINFO D0M7ZC ISIS 134605 Investigative T25927 DRUGINFO D0P4WQ ISIS 134565 Investigative T25927 DRUGINFO D0Q4SJ ISIS 134607 Investigative T25927 DRUGINFO D0S5MC ISIS 134601 Investigative T25927 DRUGINFO D0V1PK ISIS 134563 Investigative T25927 DRUGINFO D0V6DX Isoquinoline-1,3,4(2H)-trione Investigative T10937 TARGETID T10937 T10937 FORMERID TTDR01399 T10937 UNIPROID MDM2_HUMAN T10937 TARGNAME Mdm2 messenger RNA (MDM2 mRNA) T10937 GENENAME MDM2 T10937 TARGTYPE Literature-reported T10937 SYNONYMS RING-type E3 ubiquitin transferase Mdm2 (mRNA); P53-binding protein Mdm2 (mRNA); Oncoprotein Mdm2 (mRNA); MDM2 protein (mRNA); Hdm2 (mRNA); E3 ubiquitin-protein ligase Mdm2 (mRNA); Double minute 2 protein (mRNA) T10937 FUNCTION Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation. Ubiquitinates DCX, leading to DCX degradation and reduction of the dendritic spine density of olfactory bulb granule cells. Ubiquitinates DLG4, leading to proteasomal degradation of DLG4 which is required for AMPA receptor endocytosis. E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. T10937 PDBSTRUC 6Q9O; 6Q9L; 6Q9H; 6Q96; 6IM9 T10937 BIOCLASS mRNA target T10937 ECNUMBER EC 2.3.2.27 T10937 SEQUENCE MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFP T10937 DRUGINFO D02JFF ISIS 16518 Investigative T10937 DRUGINFO D08YAF PLSQETFSDLWKLLPEN-NH2 Investigative T10937 DRUGINFO D0C0TN NSC-66811 Investigative T10937 DRUGINFO D0Y3JR ISIS 16507 Investigative T10937 DRUGINFO D01QKK NUTLIN-3 Investigative T10937 DRUGINFO D0F1SN NU-8231 Investigative T93262 TARGETID T93262 T93262 FORMERID TTDR01401 T93262 UNIPROID KPCE_HUMAN T93262 TARGNAME PKC-epsilon messenger RNA (PRKCE mRNA) T93262 GENENAME PRKCE T93262 TARGTYPE Literature-reported T93262 SYNONYMS Protein kinase C epsilon type (mRNA); Protein Kinase C epsilon (mRNA); PKCE (mRNA); PKC epsilon (mRNA); NPKC-epsilon (mRNA) T93262 FUNCTION Mediates cell adhesion to the extracellular matrix via integrin-dependent signaling, by mediating angiotensin-2-induced activation of integrin beta-1 (ITGB1) in cardiac fibroblasts. Phosphorylates MARCKS, which phosphorylates and activates PTK2/FAK, leading to the spread of cardiomyocytes. Involved in the control of the directional transport of ITGB1 in mesenchymal cells by phosphorylating vimentin (VIM), an intermediate filament (IF) protein. In epithelial cells, associates with and phosphorylates keratin-8 (KRT8), which induces targeting of desmoplakin at desmosomes and regulates cell-cell contact. Phosphorylates IQGAP1, which binds to CDC42, mediating epithelial cell-cell detachment prior to migration. In HeLa cells, contributes to hepatocyte growth factor (HGF)-induced cell migration, and in human corneal epithelial cells, plays a critical role in wound healing after activation by HGF. During cytokinesis, forms a complex with YWHAB, which is crucial for daughter cell separation, and facilitates abscission by a mechanism which may implicate the regulation of RHOA. In cardiac myocytes, regulates myofilament function and excitation coupling at the Z-lines, where it is indirectly associated with F-actin via interaction with COPB1. During endothelin-induced cardiomyocyte hypertrophy, mediates activation of PTK2/FAK, which is critical for cardiomyocyte survival and regulation of sarcomere length. Plays a role in the pathogenesis of dilated cardiomyopathy via persistent phosphorylation of troponin I (TNNI3). Involved in nerve growth factor (NFG)-induced neurite outgrowth and neuron morphological change independently of its kinase activity, by inhibition of RHOA pathway, activation of CDC42 and cytoskeletal rearrangement. May be involved in presynaptic facilitation by mediating phorbol ester-induced synaptic potentiation. Phosphorylates gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2), which reduces the response of GABA receptors to ethanol and benzodiazepines and may mediate acute tolerance to the intoxicating effects of ethanol. Upon PMA treatment, phosphorylates the capsaicin- and heat-activated cation channel TRPV1, which is required for bradykinin-induced sensitization of the heat response in nociceptive neurons. Is able to form a complex with PDLIM5 and N-type calcium channel, and may enhance channel activities and potentiates fast synaptic transmission by phosphorylating the pore-forming alpha subunit CACNA1B (CaV2. 2). In prostate cancer cells, interacts with and phosphorylates STAT3, which increases DNA-binding and transcriptional activity of STAT3 and seems to be essential for prostate cancer cell invasion. Downstream of TLR4, plays an important role in the lipopolysaccharide (LPS)-induced immune response by phosphorylating and activating TICAM2/TRAM, which in turn activates the transcription factor IRF3 and subsequent cytokines production. In differentiating erythroid progenitors, is regulated by EPO and controls the protection against the TNFSF10/TRAIL-mediated apoptosis, via BCL2. May be involved in the regulation of the insulin-induced phosphorylation and activation of AKT1. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motility, migration and cell cycle, functions in neuron growth and ion channel regulation, and is involved in immune response, cancer cell invasion and regulation of apoptosis. T93262 PDBSTRUC 5LIH; 2WH0 T93262 BIOCLASS mRNA target T93262 ECNUMBER EC 2.7.11.13 T93262 SEQUENCE MVVFNGLLKIKICEAVSLKPTAWSLRHAVGPRPQTFLLDPYIALNVDDSRIGQTATKQKTNSPAWHDEFVTDVCNGRKIELAVFHDAPIGYDDFVANCTIQFEELLQNGSRHFEDWIDLEPEGRVYVIIDLSGSSGEAPKDNEERVFRERMRPRKRQGAVRRRVHQVNGHKFMATYLRQPTYCSHCRDFIWGVIGKQGYQCQVCTCVVHKRCHELIITKCAGLKKQETPDQVGSQRFSVNMPHKFGIHNYKVPTFCDHCGSLLWGLLRQGLQCKVCKMNVHRRCETNVAPNCGVDARGIAKVLADLGVTPDKITNSGQRRKKLIAGAESPQPASGSSPSEEDRSKSAPTSPCDQEIKELENNIRKALSFDNRGEEHRAASSPDGQLMSPGENGEVRQGQAKRLGLDEFNFIKVLGKGSFGKVMLAELKGKDEVYAVKVLKKDVILQDDDVDCTMTEKRILALARKHPYLTQLYCCFQTKDRLFFVMEYVNGGDLMFQIQRSRKFDEPRSRFYAAEVTSALMFLHQHGVIYRDLKLDNILLDAEGHCKLADFGMCKEGILNGVTTTTFCGTPDYIAPEILQELEYGPSVDWWALGVLMYEMMAGQPPFEADNEDDLFESILHDDVLYPVWLSKEAVSILKAFMTKNPHKRLGCVASQNGEDAIKQHPFFKEIDWVLLEQKKIKPPFKPRIKTKRDVNNFDQDFTREEPVLTLVDEAIVKQINQEEFKGFSYFGEDLMP T93262 DRUGINFO D0R2TM BALANOL Terminated T93262 DRUGINFO D02VLL ISIS 7942 Investigative T93262 DRUGINFO D09RFD ISIS 7948 Investigative T93262 DRUGINFO D0T9ZL chelerythrine Investigative T93262 DRUGINFO D04AXH 8-Octyl-benzolactam-V9 Investigative T93262 DRUGINFO D04JNZ PROSTRATIN Investigative T93262 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T93262 DRUGINFO D0L8HO RO-316233 Investigative T72295 TARGETID T72295 T72295 FORMERID TTDR01402 T72295 UNIPROID KPCT_HUMAN T72295 TARGNAME PKC-theta messenger RNA (PRKCQ mRNA) T72295 GENENAME PRKCQ T72295 TARGTYPE Literature-reported T72295 SYNONYMS Protein kinase C theta type (mRNA); PRKCT (mRNA); NPKC-theta (mRNA) T72295 FUNCTION In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates in the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response. Upon TCR stimulation, mediates T-cell protective survival signal by phosphorylating BAD, thus protecting T-cells from BAD-induced apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF-kappa-B and JUN pathways. In platelets, regulates signal transduction downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, playing a positive role in 'outside-in' signaling and granule secretion signal transduction. May relay signals from the activated ITGA2B receptor by regulating the uncoupling of WASP and WIPF1, thereby permitting the regulation of actin filament nucleation and branching activity of the Arp2/3 complex. May mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1, which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at 'Ser-504' and 'Ser-532' and negatively regulates its ability to phosphorylate PKB/AKT1. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. T72295 PDBSTRUC 5F9E; 4RA5; 4Q9Z; 2JED; 2ENZ T72295 BIOCLASS mRNA target T72295 ECNUMBER EC 2.7.11.13 T72295 SEQUENCE MSPFLRIGLSNFDCGSCQSCQGEAVNPYCAVLVKEYVESENGQMYIQKKPTMYPPWDSTFDAHINKGRVMQIIVKGKNVDLISETTVELYSLAERCRKNNGKTEIWLELKPQGRMLMNARYFLEMSDTKDMNEFETEGFFALHQRRGAIKQAKVHHVKCHEFTATFFPQPTFCSVCHEFVWGLNKQGYQCRQCNAAIHKKCIDKVIAKCTGSAINSRETMFHKERFKIDMPHRFKVYNYKSPTFCEHCGTLLWGLARQGLKCDACGMNVHHRCQTKVANLCGINQKLMAEALAMIESTQQARCLRDTEQIFREGPVEIGLPCSIKNEARPPCLPTPGKREPQGISWESPLDEVDKMCHLPEPELNKERPSLQIKLKIEDFILHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDDDVECTMVEKRVLSLAWEHPFLTHMFCTFQTKENLFFVMEYLNGGDLMYHIQSCHKFDLSRATFYAAEIILGLQFLHSKGIVYRDLKLDNILLDKDGHIKIADFGMCKENMLGDAKTNTFCGTPDYIAPEILLGQKYNHSVDWWSFGVLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPRWLEKEAKDLLVKLFVREPEKRLGVRGDIRQHPLFREINWEELERKEIDPPFRPKVKSPFDCSNFDKEFLNEKPRLSFADRALINSMDQNMFRNFSFMNPGMERLIS T72295 DRUGINFO D00NQN ISIS 109351 Investigative T72295 DRUGINFO D00PYD ISIS 109352 Investigative T72295 DRUGINFO D00XRM ISIS 109353 Investigative T72295 DRUGINFO D05QWZ ISIS 109355 Investigative T72295 DRUGINFO D08HCY 4-(1H-indol-6-ylamino)-5-styrylnicotinonitrile Investigative T72295 DRUGINFO D0S7UD 4-(1H-indol-5-yloxy)-5-styrylnicotinonitrile Investigative T72295 DRUGINFO D0TT6X ISIS 109354 Investigative T72295 DRUGINFO D0U9YY 4-(1H-indol-5-ylamino)-5-styrylnicotinonitrile Investigative T72295 DRUGINFO D0W1FM 4-(3H-indol-4-ylamino)-5-styrylnicotinonitrile Investigative T72295 DRUGINFO D04AXH 8-Octyl-benzolactam-V9 Investigative T72295 DRUGINFO D04JNZ PROSTRATIN Investigative T49368 TARGETID T49368 T49368 FORMERID TTDR01404 T49368 UNIPROID KPCD_HUMAN T49368 TARGNAME PKC-delta messenger RNA (PRKCD mRNA) T49368 GENENAME PRKCD T49368 TARGTYPE Literature-reported T49368 SYNONYMS nPKC-delta (mRNA); Tyrosine-protein kinase PRKCD (mRNA); SDK1 (mRNA); Protein kinase C delta type catalytic subunit (mRNA); Protein kinase C delta type (mRNA); Protein Kinase C delta (mRNA); PKC-delta (mRNA) T49368 FUNCTION Negatively regulates B cell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and apoptosis. In response to oxidative stress, interact with and activate CHUK/IKKA in the nucleus, causing the phosphorylation of p53/TP53. In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53/TP53. In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2/M DNA damage checkpoint activation. Can protect glioma cells from the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1. Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by direct phosphorylation and activation of NCF1 or indirectly through MAPK1/3 (ERK1/2) signaling pathways. May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA. In collagen-induced platelet aggregation, acts a negative regulator of filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation. Downstream of PAR1, PAR4 and CD36/GP4 receptors, regulates differentially platelet dense granule secretion; acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion. Phosphorylates ELAVL1 in response to angiotensin-2 treatment. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses. T49368 PDBSTRUC 2YUU; 1YRK T49368 BIOCLASS mRNA target T49368 ECNUMBER EC 2.7.11.13 T49368 SEQUENCE MAPFLRIAFNSYELGSLQAEDEANQPFCAVKMKEALSTERGKTLVQKKPTMYPEWKSTFDAHIYEGRVIQIVLMRAAEEPVSEVTVGVSVLAERCKKNNGKAEFWLDLQPQAKVLMSVQYFLEDVDCKQSMRSEDEAKFPTMNRRGAIKQAKIHYIKNHEFIATFFGQPTFCSVCKDFVWGLNKQGYKCRQCNAAIHKKCIDKIIGRCTGTAANSRDTIFQKERFNIDMPHRFKVHNYMSPTFCDHCGSLLWGLVKQGLKCEDCGMNVHHKCREKVANLCGINQKLLAEALNQVTQRASRRSDSASSEPVGIYQGFEKKTGVAGEDMQDNSGTYGKIWEGSSKCNINNFIFHKVLGKGSFGKVLLGELKGRGEYFAIKALKKDVVLIDDDVECTMVEKRVLTLAAENPFLTHLICTFQTKDHLFFVMEFLNGGDLMYHIQDKGRFELYRATFYAAEIMCGLQFLHSKGIIYRDLKLDNVLLDRDGHIKIADFGMCKENIFGESRASTFCGTPDYIAPEILQGLKYTFSVDWWSFGVLLYEMLIGQSPFHGDDEDELFESIRVDTPHYPRWITKESKDILEKLFEREPTKRLGVTGNIKIHPFFKTINWTLLEKRRLEPPFRPKVKSPRDYSNFDQEFLNEKARLSYSDKNLIDSMDQSAFAGFSFVNPKFEHLLED T49368 DRUGINFO D0R2TM BALANOL Terminated T49368 DRUGINFO D07WBD ISIS 10310 Investigative T49368 DRUGINFO D08CMT ISIS 17252 Investigative T49368 DRUGINFO D08SPM ISIS 10303 Investigative T49368 DRUGINFO D0M0JF ISIS 10311 Investigative T49368 DRUGINFO D05SLL Diheptan-3-yl 5-(hydroxymethyl)isophthalate Investigative T49368 DRUGINFO D0J4NI Dihexan-3-yl 5-(hydroxymethyl)isophthalate Investigative T49368 DRUGINFO D04AXH 8-Octyl-benzolactam-V9 Investigative T49368 DRUGINFO D06TLL Go 6983 Investigative T49368 DRUGINFO D04JNZ PROSTRATIN Investigative T49368 DRUGINFO D06ZCX LY-326449 Investigative T49368 DRUGINFO D0TO6S Bisindolylmaleimide-I Investigative T19923 TARGETID T19923 T19923 FORMERID TTDR01405 T19923 UNIPROID B2CL1_HUMAN T19923 TARGNAME Bcl-x messenger RNA (BCL2L1 mRNA) T19923 GENENAME BCL2L1 T19923 TARGTYPE Literature-reported T19923 SYNONYMS Bcl2like protein 1 (mRNA); Bcl2L1 (mRNA); Bcl2-L-1 (mRNA); Bcl-XL (mRNA); Bcl-2-like protein 1 (mRNA); BCLX (mRNA); BCL2L (mRNA); Apoptosis regulator Bcl-X (mRNA) T19923 FUNCTION Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis. Potent inhibitor of cell death. T19923 PDBSTRUC 6IJQ; 6F46; 6DCO; 6DCN; 6BF2 T19923 BIOCLASS mRNA target T19923 SEQUENCE MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK T19923 DRUGINFO D0R7MJ PURPUROGALLIN Terminated T19923 DRUGINFO D00AJF ISIS 11219 Investigative T19923 DRUGINFO D04YWU ISIS 11220 Investigative T19923 DRUGINFO D05RJQ ISIS 11224 Investigative T19923 DRUGINFO D06LOB ISIS 11223 Investigative T19923 DRUGINFO D07NIM ISIS 16010 Investigative T19923 DRUGINFO D0A6NK ISIS 16009 Investigative T19923 DRUGINFO D0C1YA ISIS 15998 Investigative T19923 DRUGINFO D0DX4W ISIS 11221 Investigative T19923 DRUGINFO D0H5MZ ISIS 15999 Investigative T19923 DRUGINFO D0S6MQ ISIS 16005 Investigative T19923 DRUGINFO D0D6BH 4,5-dibenzylbenzene-1,2-diol Investigative T19923 DRUGINFO D00LHS TW-37 Investigative T19923 DRUGINFO D0S6IW QEDIIRNIARHLAQVGDSMDR Investigative T59479 TARGETID T59479 T59479 FORMERID TTDR01410 T59479 UNIPROID BIRC3_HUMAN T59479 TARGNAME Apoptosis-2 messenger RNA (BIRC3 mRNA) T59479 GENENAME BIRC3 T59479 TARGTYPE Literature-reported T59479 SYNONYMS hIAP1 (mRNA); hIAP-1 (mRNA); TNFR2TRAFsignaling complex protein 1 (mRNA); TNFR2-TRAF-signaling complex protein 1 (mRNA); RNF49 (mRNA); RING-type E3 ubiquitin transferase BIRC3 (mRNA); RING finger protein 49 (mRNA); MIHC (mRNA); Inhibitor of apoptosis protein 1 (mRNA); IAP1 (mRNA); IAP homolog C (mRNA); CIAP2 (mRNA); C-IAP2 (mRNA); Baculoviral IAP repeatcontaining protein3 (mRNA); Baculoviral IAP repeat-containing protein 3 (mRNA); Apoptosis inhibitor 2 (mRNA); API2 (mRNA) T59479 FUNCTION Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. T59479 PDBSTRUC 3M0D; 3M0A; 3EB6; 3EB5; 2UVL T59479 BIOCLASS mRNA target T59479 ECNUMBER EC 2.3.2.27 T59479 SEQUENCE MNIVENSIFLSNLMKSANTFELKYDLSCELYRMSTYSTFPAGVPVSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKRGDSPTEKHKKLYPSCRFVQSLNSVNNLEATSQPTFPSSVTNSTHSLLPGTENSGYFRGSYSNSPSNPVNSRANQDFSALMRSSYHCAMNNENARLLTFQTWPLTFLSPTDLAKAGFYYIGPGDRVACFACGGKLSNWEPKDNAMSEHLRHFPKCPFIENQLQDTSRYTVSNLSMQTHAARFKTFFNWPSSVLVNPEQLASAGFYYVGNSDDVKCFCCDGGLRCWESGDDPWVQHAKWFPRCEYLIRIKGQEFIRQVQASYPHLLEQLLSTSDSPGDENAESSIIHFEPGEDHSEDAIMMNTPVINAAVEMGFSRSLVKQTVQRKILATGENYRLVNDLVLDLLNAEDEIREEERERATEEKESNDLLLIRKNRMALFQHLTCVIPILDSLLTAGIINEQEHDVIKQKTQTSLQARELIDTILVKGNIAATVFRNSLQEAEAVLYEHLFVQQDIKYIPTEDVSDLPVEEQLRRLQEERTCKVCMDKEVSIVFIPCGHLVVCKDCAPSLRKCPICRSTIKGTVRTFLS T59479 DRUGINFO D00UDL ISIS 23452 Investigative T59479 DRUGINFO D01MCF ISIS 23454 Investigative T59479 DRUGINFO D03SQZ ISIS 23459 Investigative T59479 DRUGINFO D09LXC ISIS 23414 Investigative T59479 DRUGINFO D0AI1L ISIS 23416 Investigative T59479 DRUGINFO D0H6LU ISIS 23412 Investigative T59479 DRUGINFO D03KZH SM-337 Investigative T59479 DRUGINFO D0BW7P SM-131 Investigative T59479 DRUGINFO D0Q7TL SM-122 Investigative T06559 TARGETID T06559 T06559 FORMERID TTDR01414 T06559 UNIPROID ERBB4_HUMAN T06559 TARGNAME HER4 messenger RNA (ERBB4 mRNA) T06559 GENENAME ERBB4 T06559 TARGTYPE Literature-reported T06559 SYNONYMS Tyrosine kinase-type cell surface receptor HER4 (mRNA); Receptor tyrosine-protein kinase erbB-4 (mRNA); Proto-oncogene-like protein c-ErbB-4 (mRNA); P180erbB4 (mRNA); HER4 (mRNA) T06559 FUNCTION Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis. Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. T06559 PDBSTRUC 3U9U; 3U7U; 3U2P; 3BCE; 3BBW T06559 BIOCLASS mRNA target T06559 ECNUMBER EC 2.7.10.1 T06559 SEQUENCE MKPATGLWVWVSLLVAAGTVQPSDSQSVCAGTENKLSSLSDLEQQYRALRKYYENCEVVMGNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGTKLYEDRYALAIFLNYRKDGNFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTLVSTNGSSGCGRCHKSCTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPYVSDCCHRECAGGCSGPKDTDCFACMNFNDSGACVTQCPQTFVYNPTTFQLEHNFNAKYTYGAFCVKKCPHNFVVDSSSCVRACPSSKMEVEENGIKMCKPCTDICPKACDGIGTGSLMSAQTVDSSNIDKFINCTKINGNLIFLVTGIHGDPYNAIEAIDPEKLNVFRTVREITGFLNIQSWPPNMTDFSVFSNLVTIGGRVLYSGLSLLILKQQGITSLQFQSLKEISAGNIYITDNSNLCYYHTINWTTLFSTINQRIVIRDNRKAENCTAEGMVCNHLCSSDGCWGPGPDQCLSCRRFSRGRICIESCNLYDGEFREFENGSICVECDPQCEKMEDGLLTCHGPGPDNCTKCSHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCNGPTSHDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRALRRFLETELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETTGPKANVEFMDEALIMASMDHPHLVRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHKDNIGSQLLLNWCVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLEGDEKEYNADGGKMPIKWMALECIHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKGERLPQPPICTIDVYMVMVKCWMIDADSRPKFKELAAEFSRMARDPQRYLVIQGDDRMKLPSPNDSKFFQNLLDEEDLEDMMDAEEYLVPQAFNIPPPIYTSRARIDSNRSEIGHSPPPAYTPMSGNQFVYRDGGFAAEQGVSVPYRAPTSTIPEAPVAQGATAEIFDDSCCNGTLRKPVAPHVQEDSSTQRYSADPTVFAPERSPRGELDEEGYMTPMRDKPKQEYLNPVEENPFVSRRKNGDLQALDNPEYHNASNGPPKAEDEYVNEPLYLNTFANTLGKAEYLKNNILSMPEKAKKAFDNPDYWNHSLPPRSTLQHPDYLQEYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV T06559 DRUGINFO D01IRX ISIS 19657 Investigative T06559 DRUGINFO D02DXI ISIS 19650 Investigative T06559 DRUGINFO D08FVS ISIS 19647 Investigative T06559 DRUGINFO D0C3LW ISIS 19649 Investigative T06559 DRUGINFO D0DO6G ISIS 19677 Investigative T06559 DRUGINFO D0I0DE ISIS 19658 Investigative T06559 DRUGINFO D0I9GE ISIS 19659 Investigative T06559 DRUGINFO D0M8BV ISIS 19651 Investigative T06559 DRUGINFO D0T0SR ISIS 19676 Investigative T06559 DRUGINFO D0W0QO ISIS 19639 Investigative T06559 DRUGINFO D0Z0XJ ISIS 19675 Investigative T06559 DRUGINFO D0Z7BO ISIS 19634 Investigative T06559 DRUGINFO D00TZD CL-387785 Investigative T41766 TARGETID T41766 T41766 FORMERID TTDR01426 T41766 UNIPROID IRAK4_HUMAN T41766 TARGNAME IRAK4 messenger RNA (IRAK4 mRNA) T41766 GENENAME IRAK4 T41766 TARGTYPE Literature-reported T41766 SYNONYMS Renal carcinoma antigenNYREN64 (mRNA); Renal carcinoma antigen NY-REN-64 (mRNA); NY-REN-64 antigen (mRNA); Interleukin1 receptorassociated kinase 4 (mRNA); Interleukin-1 receptor-associated kinase 4 (mRNA); IRAK-4 (mRNA) T41766 FUNCTION Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation to form the Myddosome together with IRAK2. Phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation suggesting a similar mechanism during microbial infections. Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. T41766 PDBSTRUC 6O9D; 6O95; 6O94; 6O8U; 6N8G T41766 BIOCLASS mRNA target T41766 ECNUMBER EC 2.7.11.1 T41766 SEQUENCE MNKPITPSTYVRCLNVGLIRKLSDFIDPQEGWKKLAVAIKKPSGDDRYNQFHIRRFEALLQTGKSPTSELLFDWGTTNCTVGDLVDLLIQNEFFAPASLLLPDAVPKTANTLPSKEAITVQQKQMPFCDKDRTLMTPVQNLEQSYMPPDSSSPENKSLEVSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS T41766 DRUGINFO D02AMI ISIS 156452 Investigative T41766 DRUGINFO D02JBK ISIS 156453 Investigative T41766 DRUGINFO D02JIL N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide Investigative T41766 DRUGINFO D06DVW ISIS 156451 Investigative T41766 DRUGINFO D06LVL ISIS 156473 Investigative T41766 DRUGINFO D0B2EL ISIS 156449 Investigative T41766 DRUGINFO D0B5OL ISIS 156474 Investigative T41766 DRUGINFO D0F5SD ISIS 156475 Investigative T41766 DRUGINFO D0LY5S N-(1H-benzo[d]imidazol-2-yl)-3-cyanobenzamide Investigative T41766 DRUGINFO D0N4TF ISIS 156472 Investigative T41766 DRUGINFO D0U9JR ISIS 156471 Investigative T91149 TARGETID T91149 T91149 FORMERID TTDR01431 T91149 UNIPROID AKT3_HUMAN T91149 TARGNAME AKT3 messenger RNA (AKT3 mRNA) T91149 GENENAME AKT3 T91149 TARGTYPE Literature-reported T91149 SYNONYMS STK-2 (mRNA); RAC-PK-gamma (mRNA); Protein kinase B gamma (mRNA); Protein kinase Akt-3 (mRNA); PKBG (mRNA); PKB gamma (mRNA) T91149 FUNCTION AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. T91149 PDBSTRUC 2X18 T91149 BIOCLASS mRNA target T91149 ECNUMBER EC 2.7.11.1 T91149 SEQUENCE MSDVTIVKEGWVQKRGEYIKNWRPRYFLLKTDGSFIGYKEKPQDVDLPYPLNNFSVAKCQLMKTERPKPNTFIIRCLQWTTVIERTFHVDTPEEREEWTEAIQAVADRLQRQEEERMNCSPTSQIDNIGEEEMDASTTHHKRKTMNDFDYLKLLGKGTFGKVILVREKASGKYYAMKILKKEVIIAKDEVAHTLTESRVLKNTRHPFLTSLKYSFQTKDRLCFVMEYVNGGELFFHLSRERVFSEDRTRFYGAEIVSALDYLHSGKIVYRDLKLENLMLDKDGHIKITDFGLCKEGITDAATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEDIKFPRTLSSDAKSLLSGLLIKDPNKRLGGGPDDAKEIMRHSFFSGVNWQDVYDKKLVPPFKPQVTSETDTRYFDEEFTAQTITITPPEKYDEDGMDCMDNERRPHFPQFSYSASGRE T91149 DRUGINFO D00NPN ISIS 29202 Investigative T91149 DRUGINFO D02UHI ISIS 29136 Investigative T91149 DRUGINFO D03EYM ISIS 29112 Investigative T91149 DRUGINFO D04IBO ISIS 29161 Investigative T91149 DRUGINFO D04QYU ISIS 29200 Investigative T91149 DRUGINFO D04YQN ISIS 29135 Investigative T91149 DRUGINFO D05BFX ISIS 29177 Investigative T91149 DRUGINFO D06AOQ ISIS 29160 Investigative T91149 DRUGINFO D06AZX ISIS 29176 Investigative T91149 DRUGINFO D07CCC ISIS 29159 Investigative T91149 DRUGINFO D0AH5P ISIS 29201 Investigative T91149 DRUGINFO D0M2JX ISIS 29137 Investigative T91149 DRUGINFO D0N7AF ISIS 29155 Investigative T91149 DRUGINFO D0N9AT ISIS 29178 Investigative T91149 DRUGINFO D0O7OI ISIS 29138 Investigative T91149 DRUGINFO D0Q0FZ ISIS 29139 Investigative T91149 DRUGINFO D0U1QU ISIS 29156 Investigative T91149 DRUGINFO D0W4XP ISIS 29154 Investigative T91149 DRUGINFO D0I1FJ SB-747651A Investigative T77548 TARGETID T77548 T77548 FORMERID TTDR00755 T77548 UNIPROID GRM8_HUMAN T77548 TARGNAME Metabotropic glutamate receptor 8 (mGluR8) T77548 GENENAME GRM8 T77548 TARGTYPE Literature-reported T77548 SYNONYMS MGluR8a; MGLUR8; Glutamate receptor mGLU8; GRM8 T77548 FUNCTION Receptor for glutamate. The activity of this receptor is mediated by a g-protein that inhibits adenylate cyclase activity. T77548 PDBSTRUC 6E5V; 6BT5; 6BSZ T77548 BIOCLASS GPCR glutamate T77548 SEQUENCE MVCEGKRSASCPCFFLLTAKFYWILTMMQRTHSQEYAHSIRVDGDIILGGLFPVHAKGERGVPCGELKKEKGIHRLEAMLYAIDQINKDPDLLSNITLGVRILDTCSRDTYALEQSLTFVQALIEKDASDVKCANGDPPIFTKPDKISGVIGAAASSVSIMVANILRLFKIPQISYASTAPELSDNTRYDFFSRVVPPDSYQAQAMVDIVTALGWNYVSTLASEGNYGESGVEAFTQISREIGGVCIAQSQKIPREPRPGEFEKIIKRLLETPNARAVIMFANEDDIRRILEAAKKLNQSGHFLWIGSDSWGSKIAPVYQQEEIAEGAVTILPKRASIDGFDRYFRSRTLANNRRNVWFAEFWEENFGCKLGSHGKRNSHIKKCTGLERIARDSSYEQEGKVQFVIDAVYSMAYALHNMHKDLCPGYIGLCPRMSTIDGKELLGYIRAVNFNGSAGTPVTFNENGDAPGRYDIFQYQITNKSTEYKVIGHWTNQLHLKVEDMQWAHREHTHPASVCSLPCKPGERKKTVKGVPCCWHCERCEGYNYQVDELSCELCPLDQRPNMNRTGCQLIPIIKLEWHSPWAVVPVFVAILGIIATTFVIVTFVRYNDTPIVRASGRELSYVLLTGIFLCYSITFLMIAAPDTIICSFRRVFLGLGMCFSYAALLTKTNRIHRIFEQGKKSVTAPKFISPASQLVITFSLISVQLLGVFVWFVVDPPHIIIDYGEQRTLDPEKARGVLKCDISDLSLICSLGYSILLMVTCTVYAIKTRGVPETFNEAKPIGFTMYTTCIIWLAFIPIFFGTAQSAEKMYIQTTTLTVSMSLSASVSLGMLYMPKVYIIIFHPEQNVQKRKRSFKAVVTAATMQSKLIQKGNDRPNGEVKSELCESLETNTSSTKTTYISYSNHSI T77548 DRUGINFO D00IGI 2-Amino-4-phosphono-butyric acid Investigative T77548 DRUGINFO D09AQK (R,S)-4-phosphonophenylglycine Investigative T77548 DRUGINFO D0G7TT D-AP4 Investigative T77548 DRUGINFO D0H8XQ AZ12216052 Investigative T77548 DRUGINFO D06PHE CPPG Investigative T77548 DRUGINFO D0LC5O (S)-3,4-DCPG Investigative T77548 DRUGINFO D0W3PY ACPT-I Investigative T77548 DRUGINFO D09SXN MAP4 Investigative T77548 DRUGINFO D0D2GL MPPG Investigative T77548 DRUGINFO D0O8AK alpha-methylserine-O-phosphate Investigative T77548 DRUGINFO D0PN6Z L-AP4 Investigative T77548 DRUGINFO D04DKM (1S,3R)-ACPD Investigative T77548 DRUGINFO D06DUE [3H]quisqualate Investigative T77548 DRUGINFO D0Z7CZ L-CCG-I Investigative T77548 DRUGINFO D07PZQ L-serine-O-phosphate Investigative T76522 TARGETID T76522 T76522 FORMERID TTDR01201 T76522 UNIPROID PDXK_HUMAN T76522 TARGNAME Pyridoxal kinase (PDXK) T76522 GENENAME PDXK T76522 TARGTYPE Literature-reported T76522 SYNONYMS Pyridoxine kinase; PDXK T76522 FUNCTION Required for synthesisof pyridoxal-5-phosphate from vitamin B6. T76522 PDBSTRUC 4EOH; 4EN4; 3KEU; 3FHY; 3FHX T76522 BIOCLASS Kinase T76522 ECNUMBER EC 2.7.1.35 T76522 SEQUENCE MEEECRVLSIQSHVIRGYVGNRAATFPLQVLGFEIDAVNSVQFSNHTGYAHWKGQVLNSDELQELYEGLRLNNMNKYDYVLTGYTRDKSFLAMVVDIVQELKQQNPRLVYVCDPVLGDKWDGEGSMYVPEDLLPVYKEKVVPLADIITPNQFEAELLSGRKIHSQEEALRVMDMLHSMGPDTVVITSSDLPSPQGSNYLIVLGSQRRRNPAGSVVMERIRMDIRKVDAVFVGTGDLFAAMLLAWTHKHPNNLKVACEKTVSTLHHVLQRTIQCAKAQAGEGVRPSPMQLELRMVQSKRDIEDPEIVVQATVL T76522 DRUGINFO D0UG4S L-betagamma-meATP Investigative T76012 TARGETID T76012 T76012 FORMERID TTDR01202 T76012 UNIPROID IMPA2_HUMAN T76012 TARGNAME Inositol-1(or4)-monophosphatase (IMPA2) T76012 GENENAME IMPA2 T76012 TARGTYPE Literature-reported T76012 SYNONYMS Myo-inositol-1-phosphate phosphohydrolase; Myo-inositol monophosphatase: IMP.18p; Lithium-sensitive myo-inositol monophosphatase A1; Inositol monophosphatase; IMPase; IMPA2; IMP T76012 FUNCTION Can use myo-inositol monophosphates, scylloinositol 1,4- diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2'- AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain. T76012 PDBSTRUC 2FVZ; 2DDK; 2CZK; 2CZI; 2CZH T76012 BIOCLASS Phosphoric monoester hydrolase T76012 ECNUMBER EC 3.1.3.25 T76012 SEQUENCE MKPSGEDQAALAAGPWEECFQAAVQLALRAGQIIRKALTEEKRVSTKTSAADLVTETDHLVEDLIISELRERFPSHRFIAEEAAASGAKCVLTHSPTWIIDPIDGTCNFVHRFPTVAVSIGFAVRQELEFGVIYHCTEERLYTGRRGRGAFCNGQRLRVSGETDLSKALVLTEIGPKRDPATLKLFLSNMERLLHAKAHGVRVIGSSTLALCHLASGAADAYYQFGLHCWDLAAATVIIREAGGIVIDTSGGPLDLMACRVVAASTREMAMLIAQALQTINYGRDDEK T76012 DRUGINFO D08MFC L-Myo-Inositol-1-Phosphate Investigative T65879 TARGETID T65879 T65879 FORMERID TTDR00255 T65879 UNIPROID IKKA_HUMAN T65879 TARGNAME Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) T65879 GENENAME CHUK T65879 TARGTYPE Literature-reported T65879 SYNONYMS Transcription factor 16; TCF16; TCF-16; Nuclear factor NFkappaB inhibitor kinase alpha; Nuclear factor NF-kappa-B inhibitor kinase alpha; NFKBIKA; Inhibitory kappa B kinasea; Inhibitor of nuclear factor kappa-B kinase subunit alpha; IkappaB kinase A; IkBKA; IKK1; IKK-alpha; IKK-A; I-kappa-B kinase alpha; I-kappa-B kinase 1; I kappa-B kinase alpha; Conserved helix-loop-helix ubiquitous kinase T65879 FUNCTION Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor. Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. T65879 PDBSTRUC 5TQY; 5TQX; 5TQW; 5EBZ; 3BRT T65879 BIOCLASS Kinase T65879 ECNUMBER EC 2.7.11.10 T65879 SEQUENCE MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCHEIQIMKKLNHANVVKACDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQILSLLSDIGSGIRYLHENKIIHRDLKPENIVLQDVGGKIIHKIIDLGYAKDVDQGSLCTSFVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWHEKIKKKDPKCIFACEEMSGEVRFSSHLPQPNSLCSLVVEPMENWLQLMLNWDPQQRGGPVDLTLKQPRCFVLMDHILNLKIVHILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGISLDPRKPASQCVLDGVRGCDSYMVYLFDKSKTVYEGPFASRSLSDCVNYIVQDSKIQLPIIQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTLISASQQLKAKLEFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAEIMELQKSPYGRRQGDLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKIIDLLPKVEVALSNIKEADNTVMFMQGKRQKEIWHLLKIACTQSSARSLVGSSLEGAVTPQTSAWLPPTSAEHDHSLSCVVTPQDGETSAQMIEENLNCLGHLSTIIHEANEEQGNSMMNLDWSWLTE T65879 DRUGINFO D03JMF IKI-1 Investigative T08280 TARGETID T08280 T08280 FORMERID TTDR00635 T08280 UNIPROID PFKA_TRYBB T08280 TARGNAME Trypanosoma Pyrophosphate-dependent phosphofructokinase (Trypano pfk) T08280 GENENAME Trypano pfk T08280 TARGTYPE Literature-reported T08280 SYNONYMS Pyrophosphate-dependent 6-phosphofructose-1-kinase; Pyrophosphate--fructose 6-phosphate 1-phosphotransferase alpha subunit; PPi-PFK; PFP-ALPHA; PFP; 6-phosphofructokinase, pyrophosphate dependent T08280 FUNCTION Regulatory subunit of pyrophosphate--fructose 6- phosphate 1-phosphotransferase. T08280 PDBSTRUC 3F5M; 3CVL; 2HIG T08280 BIOCLASS Kinase T08280 ECNUMBER EC 2.7.1.11 T08280 SEQUENCE MAVESRSRVTSKLVKAHRAMLNSVTQEDLKVDRLPGADYPNPSKKYSSRTEFRDKTDYIMYNPRPRDEPSSENPVSVSPLLCELAAARSRIHFNPTETTIGIVTCGGICPGLNDVIRSITLTGINVYNVKRVIGFRFGYWGLSKKGSQTAIELHRGRVTNIHHYGGTILGSSRGPQDPKEMVDTLERLGVNILFTVGGDGTQRGALVISQEAKRRGVDISVFGVPKTIDNDLSFSHRTFGFQTAVEKAVQAIRAAYAEAVSANYGVGVVKLMGRDSGFIAAQAAVASAQANICLVPENPISEQEVMSLLERRFCHSRSCVIIVAEGFGQDWGRGSGGYDASGNKKLIDIGVILTEKVKAFLKANKSRYPDSTVKYIDPSYMIRACPPSANDALFCATLATLAVHEAMAGATGCIIAMRHNNYILVPIKVATSVRRVLDLRGQLWRQVREITVDLGSDVRLARKLEIRRELEAINRNRDRLHEELAKL T08280 DRUGINFO D0M5KC POLYSIN Investigative T04361 TARGETID T04361 T04361 FORMERID TTDNR00706 T04361 UNIPROID M3K7_HUMAN T04361 TARGNAME TGF-beta-activated kinase 1 (MAP3K7) T04361 GENENAME MAP3K7 T04361 TARGTYPE Literature-reported T04361 SYNONYMS Transforming growth factor-beta-activated kinase 1; TAK1; Mitogen-activated protein kinase kinase kinase 7 T04361 FUNCTION Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. T04361 PDBSTRUC 5V5N; 5JK3; 5JH6; 5JGD; 5JGB T04361 BIOCLASS Kinase T04361 ECNUMBER EC 2.7.11.25 T04361 SEQUENCE MSTASAASSSSSSSAGEMIEAPSQVLNFEEIDYKEIEVEEVVGRGAFGVVCKAKWRAKDVAIKQIESESERKAFIVELRQLSRVNHPNIVKLYGACLNPVCLVMEYAEGGSLYNVLHGAEPLPYYTAAHAMSWCLQCSQGVAYLHSMQPKALIHRDLKPPNLLLVAGGTVLKICDFGTACDIQTHMTNNKGSAAWMAPEVFEGSNYSEKCDVFSWGIILWEVITRRKPFDEIGGPAFRIMWAVHNGTRPPLIKNLPKPIESLMTRCWSKDPSQRPSMEEIVKIMTHLMRYFPGADEPLQYPCQYSDEGQSNSATSTGSFMDIASTNTSNKSDTNMEQVPATNDTIKRLESKLLKNQAKQQSESGRLSLGASRGSSVESLPPTSEGKRMSADMSEIEARIAATTAYSKPKRGHRKTASFGNILDVPEIVISGNGQPRRRSIQDLTVTGTEPGQVSSRSSSPSVRMITTSGPTSEKPTRSHPWTPDDSTDTNGSDNSIPMAYLTLDHQLQPLAPCPNSKESMAVFEQHCKMAQEYMKVQTEIALLLQRKQELVAELDQDEKDQQNTSRLVQEHKKLLDENKSLSTYYQQCKKQLEVIRSQQQKRQGTS T04361 DRUGINFO D0H9QN AZ-TAK1 Investigative T04361 DRUGINFO D03BJF PMID23099093C17d Investigative T04361 DRUGINFO D0X7IC NG-25 Investigative T82702 TARGETID T82702 T82702 FORMERID TTDR01273 T82702 UNIPROID NR1I2_HUMAN T82702 TARGNAME Pregnane X receptor (NR1I2) T82702 GENENAME NR1I2 T82702 TARGTYPE Literature-reported T82702 SYNONYMS Steroid and xenobiotic receptor; SXR; PXR; Orphan nuclear receptor PXR; Orphan nuclear receptor PAR1; Nuclear receptor subfamily 1 group I member 2 T82702 FUNCTION Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes. Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. T82702 PDBSTRUC 6DUP; 6BNS; 5X0R; 5A86; 4XHD T82702 BIOCLASS Nuclear hormone receptor T82702 SEQUENCE MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATGYHFNVMTCEGCKGFFRRAMKRNARLRCPFRKGACEITRKTRRQCQACRLRKCLESGMKKEMIMSDEAVEERRALIKRKKSERTGTQPLGVQGLTEEQRMMIRELMDAQMKTFDTTFSHFKNFRLPGVLSSGCELPESLQAPSREEAAKWSQVRKDLCSLKVSLQLRGEDGSVWNYKPPADSGGKEIFSLLPHMADMSTYMFKGIISFAKVISYFRDLPIEDQISLLKGAAFELCQLRFNTVFNAETGTWECGRLSYCLEDTAGGFQQLLLEPMLKFHYMLKKLQLHEEEYVLMQAISLFSPDRPGVLQHRVVDQLQEQFAITLKSYIECNRPQPAHRFLFLKIMAMLTELRSINAQHTQRLLRIQDIHPFATPLMQELFGITGS T82702 DRUGINFO D01BJB pregnenolone-16alpha-carbonitrile Investigative T82702 DRUGINFO D0FI7B trihydroxycholestane Investigative T82702 DRUGINFO D0Y4YV schisandrin A Investigative T82702 DRUGINFO D06RBG 3-keto-lithocholic acid Investigative T82702 DRUGINFO D09VTJ Hyperforin Investigative T82702 DRUGINFO D0V4RZ WAY-214950 Investigative T91605 TARGETID T91605 T91605 UNIPROID TRI37_HUMAN T91605 TARGNAME E3 ubiquitin-protein ligase TRIM37 (TRIM37) T91605 GENENAME TRIM37 T91605 TARGTYPE Literature-reported T91605 SYNONYMS Tripartite motif-containing protein 37; RING-type E3 ubiquitin transferase TRIM37; Mulibrey nanism protein T91605 FUNCTION E3 ubiquitin-protein ligase required to prevent centriole reduplication (PubMed:15885686, PubMed:23769972). Probably acts by ubiquitinating positive regulators of centriole reduplication (PubMed:23769972). Mediates monoubiquitination of 'Lys-119' of histone H2A (H2AK119Ub), a specific tag for epigenetic transcriptional repression: associates with some Polycomb group (PcG) multiprotein PRC2-like complex and mediates repression of target genes (PubMed:25470042). Has anti-HIV activity (PubMed:24317724). T91605 PDBSTRUC 3LRQ T91605 BIOCLASS TRIM/RBCC family T91605 ECNUMBER EC 2.3.2.27 T91605 SEQUENCE MDEQSVESIAEVFRCFICMEKLRDARLCPHCSKLCCFSCIRRWLTEQRAQCPHCRAPLQLRELVNCRWAEEVTQQLDTLQLCSLTKHEENEKDKCENHHEKLSVFCWTCKKCICHQCALWGGMHGGHTFKPLAEIYEQHVTKVNEEVAKLRRRLMELISLVQEVERNVEAVRNAKDERVREIRNAVEMMIARLDTQLKNKLITLMGQKTSLTQETELLESLLQEVEHQLRSCSKSELISKSSEILMMFQQVHRKPMASFVTTPVPPDFTSELVPSYDSATFVLENFSTLRQRADPVYSPPLQVSGLCWRLKVYPDGNGVVRGYYLSVFLELSAGLPETSKYEYRVEMVHQSCNDPTKNIIREFASDFEVGECWGYNRFFRLDLLANEGYLNPQNDTVILRFQVRSPTFFQKSRDQHWYITQLEAAQTSYIQQINNLKERLTIELSRTQKSRDLSPPDNHLSPQNDDALETRAKKSACSDMLLEGGPTTASVREAKEDEEDEEKIQNEDYHHELSDGDLDLDLVYEDEVNQLDGSSSSASSTATSNTEENDIDEETMSGENDVEYNNMELEEGELMEDAAAAGPAGSSHGYVGSSSRISRRTHLCSAATSSLLDIDPLILIHLLDLKDRSSIENLWGLQPRPPASLLQPTASYSRKDKDQRKQQAMWRVPSDLKMLKRLKTQMAEVRCMKTDVKNTLSEIKSSSAASGDMQTSLFSADQAALAACGTENSGRLQDLGMELLAKSSVANCYIRNSTNKKSNSPKPARSSVAGSLSLRRAVDPGENSRSKGDCQTLSEGSPGSSQSGSRHSSPRALIHGSIGDILPKTEDRQCKALDSDAVVVAVFSGLPAVEKRRKMVTLGANAKGGHLEGLQMTDLENNSETGELQPVLPEGASAAPEEGMSSDSDIECDTENEEQEEHTSVGGFHDSFMVMTQPPDEDTHSSFPDGEQIGPEDLSFNTDENSGR T63159 TARGETID T63159 T63159 FORMERID TTDR00916 T63159 UNIPROID AMP1_PLAFQ T63159 TARGNAME Plasmodium M1-family aminopeptidase (Malaria MFA) T63159 GENENAME Malaria MFA T63159 TARGTYPE Literature-reported T63159 SYNONYMS Pfa-M1 T63159 FUNCTION Displays aminopeptidase activity with a broad substrate specificity. Preferentially hydrolyzes L-Lys-AMC but also shows strong activity against L-Ala-AMC, L-Arg-AMC and L-Leu-AMC. T63159 PDBSTRUC 6EED; 6EE6; 6EE4; 6EE3; 6EAB T63159 BIOCLASS Peptidase T63159 ECNUMBER EC 3.4.11.- T63159 SEQUENCE MKLTKGCAYKYIIFTVLILANILYDNKKRCMIKKNLRISSCGIISRLLKSNSNYNSFNKNYNFTSAISELQFSNFWNLDILQKDIFSNIHNNKNKPQSYIIHKRLMSEKGDNNNNNHQNNNGNDNKKRLGSVVNNEENTCSDKRMKPFEEGHGITQVDKMNNNSDHLQQNGVMNLNSNNVENNNNNNSVVVKKNEPKIHYRKDYKPSGFIINNVTLNINIHDNETIVRSVLDMDISKHNVGEDLVFDGVGLKINEISINNKKLVEGEEYTYDNEFLTIFSKFVPKSKFAFSSEVIIHPETNYALTGLYKSKNIIVSQCEATGFRRITFFIDRPDMMAKYDVTVTADKEKYPVLLSNGDKVNEFEIPGGRHGARFNDPHLKPCYLFAVVAGDLKHLSATYITKYTKKKVELYVFSEEKYVSKLQWALECLKKSMAFDEDYFGLEYDLSRLNLVAVSDFNVGAMENKGLNIFNANSLLASKKNSIDFSYARILTVVGHEYFHNYTGNRVTLRDWFQLTLKEGLTVHRENLFSEEMTKTVTTRLSHVDLLRSVQFLEDSSPLSHPIRPESYVSMENFYTTTVYDKGSEVMRMYLTILGEEYYKKGFDIYIKKNDGNTATCEDFNYAMEQAYKMKKADNSANLNQYLLWFSQSGTPHVSFKYNYDAEKKQYSIHVNQYTKPDENQKEKKPLFIPISVGLINPENGKEMISQTTLELTKESDTFVFNNIAVKPIPSLFRGFSAPVYIEDNLTDEERILLLKYDSDAFVRYNSCTNIYMKQILMNYNEFLKAKNEKLESFNLTPVNAQFIDAIKYLLEDPHADAGFKSYIVSLPQDRYIINFVSNLDTDVLADTKEYIYKQIGDKLNDVYYKMFKSLEAKADDLTYFNDESHVDFDQMNMRTLRNTLLSLLSKAQYPNILNEIIEHSKSPYPSNWLTSLSVSAYFDKYFELYDKTYKLSKDDELLLQEWLKTVSRSDRKDIYEILKKLENEVLKDSKNPNDIRAVYLPFTNNLRRFHDISGKGYKLIAEVITKTDKFNPMVATQLCEPFKLWNKLDTKRQELMLNEMNTMLQEPNISNNLKEYLLRLTNKL T63159 DRUGINFO D03MLC EUPAFOLIN Investigative T36121 TARGETID T36121 T36121 FORMERID TTDC00271 T36121 UNIPROID MYC_HUMAN T36121 TARGNAME Proto-oncogene c-Myc (MYC) T36121 GENENAME MYC T36121 TARGTYPE Literature-reported T36121 SYNONYMS Transcription factor p64; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; BHLHE39 T36121 FUNCTION Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. T36121 PDBSTRUC 6G6L; 6G6K; 6G6J; 6C4U; 5I50 T36121 SEQUENCE MPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA T36121 DRUGINFO D0T8KR TWS-119 Investigative T09694 TARGETID T09694 T09694 FORMERID TTDC00205 T09694 UNIPROID GLUC_HUMAN T09694 TARGNAME Glucagon-like peptide 1 (GLP-1:7-37) T09694 GENENAME GCG T09694 TARGTYPE Literature-reported T09694 SYNONYMS Glucagon-like peptide-1(7-36)-amide; GLP-1 (92-128); GLP; GCG T09694 FUNCTION Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. T09694 PDBSTRUC 6EDS; 5YQZ; 5VAI; 5OTX; 5OTW T09694 BIOCLASS Glucagon T09694 SEQUENCE HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG T54229 TARGETID T54229 T54229 FORMERID TTDR00240 T54229 UNIPROID ANGI_HUMAN T54229 TARGNAME Angiogenin (ANG) T54229 GENENAME ANG T54229 TARGTYPE Literature-reported T54229 SYNONYMS Ribonuclease 5; RNase 5; RNASE5 T54229 FUNCTION Stimulates ribosomal RNA synthesis including that containing the initiation site sequences of 45S rRNA. Cleaves tRNA within anticodon loops to produce tRNA-derived stress-induced fragments (tiRNAs) which inhibit protein synthesis and triggers the assembly of stress granules (SGs). Angiogenin induces vascularization of normal and malignant tissues. Angiogenic activity is regulated by interaction with RNH1 in vivo. Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus. T54229 PDBSTRUC 5M9V; 5M9T; 5M9S; 5M9R; 5M9Q T54229 BIOCLASS Endoribonucleases T54229 ECNUMBER EC 3.1.27.- T54229 SEQUENCE MVMGLGVLLLVFVLGLGLTPPTLAQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP T54229 DRUGINFO D0U7QA Pyroglutamic Acid Investigative T54229 DRUGINFO D0A1DU Pyrophosphate 2- Investigative T62073 TARGETID T62073 T62073 FORMERID TTDR00249 T62073 UNIPROID OAT_HUMAN T62073 TARGNAME Ornithine delta-aminotransferase (OAT) T62073 GENENAME OAT T62073 TARGTYPE Literature-reported T62073 SYNONYMS Ornithine--oxo-acid aminotransferase; Ornithine aminotransferase, mitochondrial T62073 FUNCTION Catalyzes the transfer of the delta-amino group from L-ornithine. T62073 PDBSTRUC 5VWO; 2OAT; 2CAN; 2BYL; 2BYJ T62073 BIOCLASS Transaminase T62073 ECNUMBER EC 2.6.1.13 T62073 SEQUENCE MFSKLAHLQRFAVLSRGVHSSVASATSVATKKTVQGPPTSDDIFEREYKYGAHNYHPLPVALERGKGIYLWDVEGRKYFDFLSSYSAVNQGHCHPKIVNALKSQVDKLTLTSRAFYNNVLGEYEEYITKLFNYHKVLPMNTGVEAGETACKLARKWGYTVKGIQKYKAKIVFAAGNFWGRTLSAISSSTDPTSYDGFGPFMPGFDIIPYNDLPALERALQDPNVAAFMVEPIQGEAGVVVPDPGYLMGVRELCTRHQVLFIADEIQTGLARTGRWLAVDYENVRPDIVLLGKALSGGLYPVSAVLCDDDIMLTIKPGEHGSTYGGNPLGCRVAIAALEVLEEENLAENADKLGIILRNELMKLPSDVVTAVRGKGLLNAIVIKETKDWDAWKVCLRLRDNGLLAKPTHGDIIRFAPPLVIKEDELRESIEIINKTILSF T62073 DRUGINFO D08KEZ Canaline Investigative T92750 TARGETID T92750 T92750 FORMERID TTDI02355 T92750 UNIPROID CFAI_HUMAN T92750 TARGNAME Complement factor I (CFI) T92750 GENENAME CFI T92750 TARGTYPE Literature-reported T92750 SYNONYMS IF; Complement factor I light chain; C3B/C4B inactivator T92750 FUNCTION Inhibits these pathways by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins. Essential cofactors for these reactions include factor H and C4BP in the fluid phase and membrane cofactor protein/CD46 and CR1 on cell surfaces. The presence of these cofactors on healthy cells allows degradation of deposited C3b by CFI in order to prevent undesired complement activation, while in apoptotic cells or microbes, the absence of such cofactors leads to C3b-mediated complement activation and subsequent opsonization. Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. T92750 PDBSTRUC 5O32; 2XRC T92750 BIOCLASS Peptidase T92750 ECNUMBER EC 3.4.21.45 T92750 SEQUENCE MKLLHVFLLFLCFHLRFCKVTYTSQEDLVEKKCLAKKYTHLSCDKVFCQPWQRCIEGTCVCKLPYQCPKNGTAVCATNRRSFPTYCQQKSLECLHPGTKFLNNGTCTAEGKFSVSLKHGNTDSEGIVEVKLVDQDKTMFICKSSWSMREANVACLDLGFQQGADTQRRFKLSDLSINSTECLHVHCRGLETSLAECTFTKRRTMGYQDFADVVCYTQKADSPMDDFFQCVNGKYISQMKACDGINDCGDQSDELCCKACQGKGFHCKSGVCIPSQYQCNGEVDCITGEDEVGCAGFASVTQEETEILTADMDAERRRIKSLLPKLSCGVKNRMHIRRKRIVGGKRAQLGDLPWQVAIKDASGITCGGIYIGGCWILTAAHCLRASKTHRYQIWTTVVDWIHPDLKRIVIEYVDRIIFHENYNAGTYQNDIALIEMKKDGNKKDCELPRSIPACVPWSPYLFQPNDTCIVSGWGREKDNERVFSLQWGEVKLISNCSKFYGNRFYEKEMECAGTYDGSIDACKGDSGGPLVCMDANNVTYVWGVVSWGENCGKPEFPGVYTKVANYFDWISYHVGRPFISQYNV T92750 DRUGINFO D03QSR TP-20 Terminated T40000 TARGETID T40000 T40000 FORMERID TTDI02552 T40000 UNIPROID KLK1_HUMAN T40000 TARGNAME Tissue kallikrein (KLK1) T40000 GENENAME KLK1 T40000 TARGTYPE Literature-reported T40000 SYNONYMS Kidney/pancreas/salivary gland kallikrein; Kallikrein1; Kallikrein-1 T40000 FUNCTION Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin. T40000 PDBSTRUC 1SPJ T40000 BIOCLASS Peptidase T40000 ECNUMBER EC 3.4.21.35 T40000 SEQUENCE MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS T40000 DRUGINFO D00LAA VA-118020 Investigative T40000 DRUGINFO D0D1WN SBTI Investigative T40000 DRUGINFO D0Q9VD example 131 [WO2009133348] Investigative T24334 TARGETID T24334 T24334 FORMERID TTDR00596 T24334 UNIPROID DUT_ECOLI T24334 TARGNAME Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) T24334 GENENAME Bact dut T24334 TARGTYPE Literature-reported T24334 SYNONYMS Deoxyuridine triphosphate nucleotidohydrolase; Deoxyuridine 5'-triphosphate nucleotidohydrolase; DUTPase; DUTP pyrophosphatase of Escherichia coli; Bact dut T24334 FUNCTION This enzyme is involved in nucleotide metabolism: it produces dUMP, the immediate precursor of thymidine nucleotides and it decreases the intracellular concentration of dUTP so that uracil cannot be incorporated into DNA. T24334 PDBSTRUC 2HRM; 2HR6; 1SYL; 1SEH; 1RNJ T24334 BIOCLASS Acid anhydrides hydrolase T24334 SEQUENCE MMKKIDVKILDPRVGKEFPLPTYATSGSAGLDLRACLNDAVELAPGDTTLVPTGLAIHIADPSLAAMMLPRSGLGHKHGIVLGNLVGLIDSDYQGQLMISVWNRGQDSFTIQPGERIAQMIFVPVVQAEFNLVEDFDATDRGEGGFGHSGRQ T24334 DRUGINFO D01PSS Deoxyuridine-5'-Triphosphate Investigative T24334 DRUGINFO D01SLZ 1-[(Z)-4-trityloxy-2-butenyl]uracil Investigative T24334 DRUGINFO D03EQN 2'-deoxyuridine 5'-alpha,beta-imido-diphosphate Investigative T24334 DRUGINFO D0E2IH 1-[2-(trityloxy)ethoxymethyl]uracil Investigative T24334 DRUGINFO D0K4DP 1-[4-hydroxy-3-(tritylaminomethyl)butyl]uracil Investigative T24334 DRUGINFO D0RV7M Deoxyuridine-5'-Diphosphate Investigative T24334 DRUGINFO D0W5QR 1-(3-tritylaminopropyl)uracil Investigative T24334 DRUGINFO D0Z9TM 2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate Investigative T24334 DRUGINFO D0CZ3C 2'-deoxyuridylic acid Investigative T24334 DRUGINFO D0F2ME Acetate Ion Investigative T10091 TARGETID T10091 T10091 FORMERID TTDR00221 T10091 UNIPROID OPSD_HUMAN T10091 TARGNAME Rhodopsin (RHO) T10091 GENENAME RHO T10091 TARGTYPE Literature-reported T10091 SYNONYMS Opsin-2; OPN2 T10091 FUNCTION Required for photoreceptor cell viability after birth. Light-induced isomerization of the chromophore 11-cis-retinal to all-trans-retinal triggers a conformational change that activates signaling via G-proteins. Subsequent receptor phosphorylation mediates displacement of the bound G-protein alpha subunit by the arrestin SAG and terminates signaling. Photoreceptor required for image-forming vision at low light intensity. T10091 PDBSTRUC 6CMO; 5W0P; 5DGY; 4ZWJ T10091 BIOCLASS GPCR rhodopsin T10091 SEQUENCE MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLYVTVQHKKLRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLGGEIALWSLVVLAIERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIPEGLQCSCGIDYYTLKPEVNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQESATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAIYNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASATVSKTETSQVAPA T10091 DRUGINFO D03YHE N-Acetylmethionine Investigative T10091 DRUGINFO D06PXR Hexadecanal Investigative T10091 DRUGINFO D0I2IS Heptane-1,2,3-Triol Investigative T10091 DRUGINFO D0NW6E Heptyl 1-Thiohexopyranoside Investigative T10091 DRUGINFO D01ILH B-2-Octylglucoside Investigative T10091 DRUGINFO D06PVF (Hydroxyethyloxy)Tri(Ethyloxy)Octane Investigative T10091 DRUGINFO D0K1UI B-Nonylglucoside Investigative T10091 DRUGINFO D02TVS Hexadecanoic acid Investigative T10091 DRUGINFO D09KUE NSC-88915 Investigative T10091 DRUGINFO D0C7PY Lauryl Dimethylamine-N-Oxide Investigative T10091 DRUGINFO D0SD9H Beta-D-Mannose Investigative T10091 DRUGINFO D05BHG Phosphonothreonine Investigative T10091 DRUGINFO D07PZQ L-serine-O-phosphate Investigative T10091 DRUGINFO D02UVH B-Octylglucoside Investigative T10091 DRUGINFO D07LUR Alpha-D-Mannose Investigative T08298 TARGETID T08298 T08298 FORMERID TTDI02550 T08298 UNIPROID GRAB_HUMAN T08298 TARGNAME Granzyme B (GZMB) T08298 GENENAME GZMB T08298 TARGTYPE Literature-reported T08298 SYNONYMS Tcell serine protease 13E; SECT; Lymphocyte protease; Human lymphocyte protein; Granzyme2; GZMB; Fragmentin2; Cytotoxic Tlymphocyte proteinase 2; Cathepsin Glike 1; CTSGL1; CTLA1; C11 T08298 FUNCTION This enzyme is necessary for target cell lysis in cell- mediated immune responses. It cleaves after Asp. Seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution. Cleaves caspase-3, -7, -9and 10 to give rise to active enzymes mediating apoptosis. T08298 PDBSTRUC 1IAU; 1FQ3 T08298 BIOCLASS Peptidase T08298 ECNUMBER EC 3.4.21.79 T08298 SEQUENCE MQPILLLLAFLLLPRADAGEIIGGHEAKPHSRPYMAYLMIWDQKSLKRCGGFLIRDDFVLTAAHCWGSSINVTLGAHNIKEQEPTQQFIPVKRPIPHPAYNPKNFSNDIMLLQLERKAKRTRAVQPLRLPSNKAQVKPGQTCSVAGWGQTAPLGKHSHTLQEVKMTVQEDRKCESDLRHYYDSTIELCVGDPEIKKTSFKGDSGGPLVCNKVAQGIVSYGRNNGMPPRACTKVSSFVHWIKKTMKRY T08298 DRUGINFO D06UZS VDA-1124 Investigative T08298 DRUGINFO D0Y7HC PMID12127536C20 Investigative T08813 TARGETID T08813 T08813 FORMERID TTDR00977 T08813 UNIPROID KAP0_HUMAN T08813 TARGNAME cAMP-dependent protein kinase A type I (PRKAR1A) T08813 GENENAME PRKAR1A T08813 TARGTYPE Literature-reported T08813 SYNONYMS cAMP-dependent protein kinase type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1; PRKAR1; PKR1 T08813 FUNCTION Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. T08813 PDBSTRUC 5KJZ; 5KJY; 5KJX T08813 BIOCLASS Kinase T08813 SEQUENCE MESGSTAASEEARSLRECELYVQKHNIQALLKDSIVQLCTARPERPMAFLREYFERLEKEEAKQIQNLQKAGTRTDSREDEISPPPPNPVVKGRRRRGAISAEVYTEEDAASYVRKVIPKDYKTMAALAKAIEKNVLFSHLDDNERSDIFDAMFSVSFIAGETVIQQGDEGDNFYVIDQGETDVYVNNEWATSVGEGGSFGELALIYGTPRAATVKAKTNVKLWGIDRDSYRRILMGSTLRKRKMYEEFLSKVSILESLDKWERLTVADALEPVQFEDGQKIVVQGEPGDEFFIILEGSAAVLQRRSENEEFVEVGRLGPSDYFGEIALLMNRPRAATVVARGPLKCVKLDRPRFERVLGPCSDILKRNIQQYNSFVSLSV T08813 DRUGINFO D0H1BF Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate Investigative T08813 DRUGINFO D0Z3CZ 5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline Investigative T08813 DRUGINFO D00OCS AdcAhxArg4NH(CH2)6NH2 Investigative T08813 DRUGINFO D02GEW AdcAhxArg4Lys-PEGOMe Investigative T08813 DRUGINFO D02ZWX AdoC(GABA)Arg6 Investigative T08813 DRUGINFO D03GNM AdcAhxArg4Lys(biotin)-PEG-OMe Investigative T08813 DRUGINFO D08GIG AdoC(Aun)Arg6 Investigative T08813 DRUGINFO D09LAQ Cyclic Guanosine Monophosphate Investigative T08813 DRUGINFO D0A5YR AdoCGlyArg6 Investigative T08813 DRUGINFO D0F3XS AdoC(Aoc)Arg6 Investigative T08813 DRUGINFO D0I4MQ AdcAhxArg6 Investigative T08813 DRUGINFO D0KZ2I AdoC(betaAsp)2AlaArg6 Investigative T08813 DRUGINFO D0QS6O AdoC(Ahx)Arg6 Investigative T08813 DRUGINFO D0RC8H AdoC(beta-Ala)2AlaArg6 Investigative T08813 DRUGINFO D0V3TE AdoC(beta-Ala)Arg6 Investigative T08813 DRUGINFO D07MMG AdoC(Dpr)2AlaArg6 Investigative T08813 DRUGINFO D0UB2J [3H]cAMP Investigative T08813 DRUGINFO D0L8HO RO-316233 Investigative T12817 TARGETID T12817 T12817 FORMERID TTDS00234 T12817 UNIPROID HSP7C_HUMAN T12817 TARGNAME Lipopolysaccharide-associated protein 1 (HSPA8) T12817 GENENAME HSPA8 T12817 TARGTYPE Literature-reported T12817 SYNONYMS LPS-associated protein 1; LAP-1; Heat shock protein 73; Heat shock cognate 71 kDa protein; Heat shock 70 kDa protein 8; HSPA10; HSP73; HSC70 T12817 FUNCTION Plays a pivotal role in the protein quality control system, ensuring the correct folding of proteins, the re-folding of misfolded proteins and controlling the targeting of proteins for subsequent degradation. This is achieved through cycles of ATP binding, ATP hydrolysis and ADP release, mediated by co-chaperones. The co-chaperones have been shown to not only regulate different steps of the ATPase cycle of HSP70, but they also have an individual specificity such that one co-chaperone may promote folding of a substrate while another may promote degradation. The affinity of HSP70 for polypeptides is regulated by its nucleotide bound state. In the ATP-bound form, it has a low affinity for substrate proteins. However, upon hydrolysis of the ATP to ADP, it undergoes a conformational change that increases its affinity for substrate proteins. HSP70 goes through repeated cycles of ATP hydrolysis and nucleotide exchange, which permits cycles of substrate binding and release. The HSP70-associated co-chaperones are of three types: J-domain co-chaperones HSP40s (stimulate ATPase hydrolysis by HSP70), the nucleotide exchange factors (NEF) such as BAG1/2/3 (facilitate conversion of HSP70 from the ADP-bound to the ATP-bound state thereby promoting substrate release), and the TPR domain chaperones such as HOPX and STUB1. Acts as a repressor of transcriptional activation. Inhibits the transcriptional coactivator activity of CITED1 on Smad-mediated transcription. Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core complex. Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Participates in the ER-associated degradation (ERAD) quality control pathway in conjunction with J domain-containing co-chaperones and the E3 ligase STUB1. Interacts with VGF-derived peptide TLQP-21. Molecular chaperone implicated in a wide variety of cellular processes, including protection of the proteome from stress, folding and transport of newly synthesized polypeptides, activation of proteolysis of misfolded proteins and the formation and dissociation of protein complexes. T12817 PDBSTRUC 6B1N; 6B1M; 6B1I; 5AQV; 5AQU T12817 BIOCLASS Heat shock protein T12817 SEQUENCE MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTAAAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD T12817 DRUGINFO D0GP7D NSC-119911 Investigative T12817 DRUGINFO D0Z5LU NSC-119913 Investigative T15851 TARGETID T15851 T15851 FORMERID TTDR00231 T15851 UNIPROID UMPS_HUMAN T15851 TARGNAME Orotidine 5'-monophosphate decarboxylase (UMPS) T15851 GENENAME UMPS T15851 TARGTYPE Literature-reported T15851 SYNONYMS Uridine 5'-monophosphate synthase; UMP synthase T15851 FUNCTION Catalyses the formation of uridine monophosphate (UMP), an energy-carrying molecule in many important biosynthetic pathways. T15851 PDBSTRUC 4HKP; 4HIB; 3MW7; 3MO7; 3MI2 T15851 BIOCLASS Pentosyltransferase T15851 SEQUENCE MAVARAALGPLVTGLYDVQAFKFGDFVLKSGLSSPIYIDLRGIVSRPRLLSQVADILFQTAQNAGISFDTVCGVPYTALPLATVICSTNQIPMLIRRKETKDYGTKRLVEGTINPGETCLIIEDVVTSGSSVLETVEVLQKEGLKVTDAIVLLDREQGGKDKLQAHGIRLHSVCTLSKMLEILEQQKKVDAETVGRVKRFIQENVFVAANHNGSPLSIKEAPKELSFGARAELPRIHPVASKLLRLMQKKETNLCLSADVSLARELLQLADALGPSICMLKTHVDILNDFTLDVMKELITLAKCHEFLIFEDRKFADIGNTVKKQYEGGIFKIASWADLVNAHVVPGSGVVKGLQEVGLPLHRGCLLIAEMSSTGSLATGDYTRAAVRMAEEHSEFVVGFISGSRVSMKPEFLHLTPGVQLEAGGDNLGQQYNSPQEVIGKRGSDIIIVGRGIISAADRLEAAEMYRKAAWEAYLSRLGV T15851 DRUGINFO D00GOC Pyrazofurin Investigative T15851 DRUGINFO D08OFS 5-fluoro-6-azido-UMP Investigative T15851 DRUGINFO D0C7PT 5-fluoro-6-amino-UMP Investigative T15851 DRUGINFO D0DW2F 5-fluoro-6-iodo-UMP Investigative T15851 DRUGINFO D0P7AS 5-Fluoro-6-ethyluridine-5'-O-monophosphate Investigative T15851 DRUGINFO D08NFH Alpha-Phosphoribosylpyrophosphoric Acid Investigative T15851 DRUGINFO D0P0EP 6-Hydroxyuridine-5'-Phosphate Investigative T70310 TARGETID T70310 T70310 FORMERID TTDR00898 T70310 UNIPROID DNLJ_ECOLI T70310 TARGNAME Bacterial DNA ligase (Bact ligA) T70310 GENENAME Bact ligA T70310 TARGTYPE Literature-reported T70310 SYNONYMS ligA; Polydeoxyribonucleotide synthase [NAD+]; NAD+-dependent DNA ligase T70310 FUNCTION DNA ligase that catalyzes the formation of phosphodiester linkages between 5'-phosphoryl and 3'-hydroxyl groups in double-stranded DNA using NAD as a coenzyme and as the energy source for the reaction. It is essential for DNA replication and repair of damaged DNA. T70310 PDBSTRUC 5TT5; 4GLX; 2OWO T70310 BIOCLASS Phosphoric ester ligase T70310 ECNUMBER EC 6.5.1.2 T70310 SEQUENCE MESIEQQLTELRTTLRHHEYLYHVMDAPEIPDAEYDRLMRELRELETKHPELITPDSPTQRVGAAPLAAFSQIRHEVPMLSLDNVFDEESFLAFNKRVQDRLKNNEKVTWCCELKLDGLAVSILYENGVLVSAATRGDGTTGEDITSNVRTIRAIPLKLHGENIPARLEVRGEVFLPQAGFEKINEDARRTGGKVFANPRNAAAGSLRQLDPRITAKRPLTFFCYGVGVLEGGELPDTHLGRLLQFKKWGLPVSDRVTLCESAEEVLAFYHKVEEDRPTLGFDIDGVVIKVNSLAQQEQLGFVARAPRWAVAFKFPAQEQMTFVRDVEFQVGRTGAITPVARLEPVHVAGVLVSNATLHNADEIERLGLRIGDKVVIRRAGDVIPQVVNVVLSERPEDTREVVFPTHCPVCGSDVERVEGEAVARCTGGLICGAQRKESLKHFVSRRAMDVDGMGDKIIDQLVEKEYVHTPADLFKLTAGKLTGLERMGPKSAQNVVNALEKAKETTFARFLYALGIREVGEATAAGLAAYFGTLEALEAASIEELQKVPDVGIVVASHVHNFFAEESNRNVISELLAEGVHWPAPIVINAEEIDSPFAGKTVVLTGSLSQMSRDDAKARLVELGAKVAGSVSKKTDLVIAGEAAGSKLAKAQELGIEVIDEAEMLRLLGS T70310 DRUGINFO D04NGC 5-(methylthio)thiophene-2-carboxylic acid Investigative T70310 DRUGINFO D07MKJ 7-(4-methoxyphenyl)pteridine-2,4-diol Investigative T70310 DRUGINFO D07YPS (2-hydroxyphenyl)(4-hydroxyphenyl)methanone Investigative T70310 DRUGINFO D0C0FK 3-amino-2-(benzylideneamino)-5-mercaptophenol Investigative T70310 DRUGINFO D0Y0XQ 2,3-dioxoindoline-7-carboxylic acid Investigative T33966 TARGETID T33966 T33966 FORMERID TTDR01204 T33966 UNIPROID CBPA1_HUMAN T33966 TARGNAME Carboxypeptidase A1 (CPA1) T33966 GENENAME CPA1 T33966 TARGTYPE Literature-reported T33966 SYNONYMS CPA T33966 FUNCTION Carboxypeptidase that catalyzes the release of a C-terminal amino acid, but has little or no action with -Asp, -Glu, -Arg, -Lys or -Pro. T33966 PDBSTRUC 6I6Z; 5OM9; 4UF4; 4UEZ; 4UEF T33966 BIOCLASS Peptidase T33966 ECNUMBER EC 3.4.17.1 T33966 SEQUENCE MRGLLVLSVLLGAVFGKEDFVGHQVLRISVADEAQVQKVKELEDLEHLQLDFWRGPAHPGSPIDVRVPFPSIQAVKIFLESHGISYETMIEDVQSLLDEEQEQMFAFRSRARSTDTFNYATYHTLEEIYDFLDLLVAENPHLVSKIQIGNTYEGRPIYVLKFSTGGSKRPAIWIDTGIHSREWVTQASGVWFAKKITQDYGQDAAFTAILDTLDIFLEIVTNPDGFAFTHSTNRMWRKTRSHTAGSLCIGVDPNRNWDAGFGLSGASSNPCSETYHGKFANSEVEVKSIVDFVKDHGNIKAFISIHSYSQLLMYPYGYKTEPVPDQDELDQLSKAAVTALASLYGTKFNYGSIIKAIYQASGSTIDWTYSQGIKYSFTFELRDTGRYGFLLPASQIIPTAKETWLALLTIMEHTLNHPY T33966 DRUGINFO D07CVG SQ-14603 Investigative T33966 DRUGINFO D06LNX DL-benzylsuccinic acid Investigative T33966 DRUGINFO D0N4RO PMID18078750C1b Investigative T33966 DRUGINFO D0W3UL 2-Thiomethyl-3-Phenylpropanoic Acid Investigative T97749 TARGETID T97749 T97749 FORMERID TTDR00825 T97749 UNIPROID NEC2_HUMAN T97749 TARGNAME Neuroendocrine convertase 2 (PCSK2) T97749 GENENAME PCSK2 T97749 TARGTYPE Literature-reported T97749 SYNONYMS Proprotein convertase 2; Prohormone convertase 2; PCSK2; PC2; NEC 2; KEX2-like endoprotease 2 T97749 FUNCTION Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. T97749 BIOCLASS Peptidase T97749 ECNUMBER EC 3.4.21.94 T97749 SEQUENCE MKGGCVSQWKAAAGFLFCVMVFASAERPVFTNHFLVELHKGGEDKARQVAAEHGFGVRKLPFAEGLYHFYHNGLAKAKRRRSLHHKQQLERDPRVKMALQQEGFDRKKRGYRDINEIDINMNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASNYNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYNSKVAGIRMLDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGKGSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRKRNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRNQLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIPSTGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRPRDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGVLKEWTLMLHGTQSAPYIDQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILNKN T97749 DRUGINFO D0Y9PH Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide Investigative T97749 DRUGINFO D0A6FZ peptide 18 Investigative T62815 TARGETID T62815 T62815 FORMERID TTDR00561 T62815 UNIPROID UD2B7_HUMAN T62815 TARGNAME UDP-glucuronosyltransferase 2B7 (UGT2B7) T62815 GENENAME ugt3 T62815 TARGTYPE Literature-reported T62815 SYNONYMS ugt3; Uridine diphosphate glucuronosyltransferase; UDPGT T62815 FUNCTION UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. T62815 PDBSTRUC 2O6L T62815 BIOCLASS Hexosyltransferase T62815 ECNUMBER EC 2.4.1.17 T62815 SEQUENCE MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRGHEVTVLASSASILFDPNNSSALKIEIYPTSLTKTELENFIMQQIKRWSDLPKDTFWLYFSQVQEIMSIFGDITRKFCKDVVSNKKFMKKVQESRFDVIFADAIFPCSELLAELFNIPFVYSLSFSPGYTFEKHSGGFIFPPSYVPVVMSELTDQMTFMERVKNMIYVLYFDFWFEIFDMKKWDQFYSEVLGRPTTLSETMGKADVWLIRNSWNFQFPYPLLPNVDFVGGLHCKPAKPLPKEMEDFVQSSGENGVVVFSLGSMVSNMTEERANVIASALAQIPQKVLWRFDGNKPDTLGLNTRLYKWIPQNDLLGHPKTRAFITHGGANGIYEAIYHGIPMVGIPLFADQPDNIAHMKARGAAVRVDFNTMSSTDLLNALKRVINDPSYKENVMKLSRIQHDQPVKPLDRAVFWIEFVMRHKGAKHLRVAAHDLTWFQYHSLDVIGFLLVCVATVIFIVTKCCLFCFWKFARKAKKGKND T62815 DRUGINFO D0HP6W Autoantibody LKM-3 Investigative T62815 DRUGINFO D0M7YB ISOLONGIFOLOL Investigative T33367 TARGETID T33367 T33367 FORMERID TTDR00222 T33367 UNIPROID AATC_HUMAN T33367 TARGNAME Cytoplasmic aspartate aminotransferase (GOT1) T33367 GENENAME GOT1 T33367 TARGTYPE Literature-reported T33367 SYNONYMS Glutamate oxaloacetate transaminase-1; GOT1 T33367 FUNCTION Biosynthesis of L-glutamate from L-aspartate or L- cysteine. Important regulator of levels of glutamate, the major excitatory neurotransmitter of the vertebrate central nervous system. Acts as a scavenger of glutamate in brain neuroprotection. The aspartate aminotransferase activity is involved in hepatic glucose synthesis during development and in adipocyte glyceroneogenesis. Using L-cysteine as substrate, regulates levels of mercaptopyruvate, an important source of hydrogen sulfide. Mercaptopyruvate is converted into H(2)S via the action of 3- mercaptopyruvate sulfurtransferase (3MST). Hydrogen sulfide is an important synaptic modulator and neuroprotectant in the brain. T33367 PDBSTRUC 6DND; 6DNB; 6DNA; 3WZF; 3II0 T33367 BIOCLASS Transaminase T33367 ECNUMBER EC 2.6.1.1 T33367 SEQUENCE MAPPSVFAEVPQAQPVLVFKLTADFREDPDPRKVNLGVGAYRTDDCHPWVLPVVKKVEQKIANDNSLNHEYLPILGLAEFRSCASRLALGDDSPALKEKRVGGVQSLGGTGALRIGADFLARWYNGTNNKNTPVYVSSPTWENHNAVFSAAGFKDIRSYRYWDAEKRGLDLQGFLNDLENAPEFSIVVLHACAHNPTGIDPTPEQWKQIASVMKHRFLFPFFDSAYQGFASGNLERDAWAIRYFVSEGFEFFCAQSFSKNFGLYNERVGNLTVVGKEPESILQVLSQMEKIVRITWSNPPAQGARIVASTLSNPELFEEWTGNVKTMADRILTMRSELRARLEALKTPGTWNHITDQIGMFSFTGLNPKQVEYLVNEKHIYLLPSGRINVSGLTTKNLDYVATSIHEAVTKIQ T33367 DRUGINFO D01BTV aminooxyacetic acid Investigative T33367 DRUGINFO D0E7UH Maleic Acid Investigative T07466 TARGETID T07466 T07466 FORMERID TTDR00030 T07466 UNIPROID MURG_ECOLI T07466 TARGNAME Bacterial Glycosyltransferase MurG (Bact murG) T07466 GENENAME Bact murG T07466 TARGTYPE Literature-reported T07466 SYNONYMS Undecaprenyl-PP-MurNAc-pentapeptide-UDPGlcNAc GlcNAc transferase; MurG T07466 FUNCTION Cell wall formation. Catalyzes the transfer of a GlcNAc subunit on undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide (lipid intermediate I) to form undecaprenyl-pyrophosphoryl-MurNAc- (pentapeptide)GlcNAc (lipid intermediate II). T07466 PDBSTRUC 1NLM; 1F0K T07466 BIOCLASS Hexosyltransferase T07466 ECNUMBER EC 2.4.1.227 T07466 SEQUENCE MSGQGKRLMVMAGGTGGHVFPGLAVAHHLMAQGWQVRWLGTADRMEADLVPKHGIEIDFIRISGLRGKGIKALIAAPLRIFNAWRQARAIMKAYKPDVVLGMGGYVSGPGGLAAWSLGIPVVLHEQNGIAGLTNKWLAKIATKVMQAFPGAFPNAEVVGNPVRTDVLALPLPQQRLAGREGPVRVLVVGGSQGARILNQTMPQVAAKLGDSVTIWHQSGKGSQQSVEQAYAEAGQPQHKVTEFIDDMAAAYAWADVVVCRSGALTVSEIAAAGLPALFVPFQHKDRQQYWNALPLEKAGAAKIIEQPQLSVDAVANTLAGWSRETLLTMAERARAASIPDATERVANEVSRVARA T07466 DRUGINFO D06UGK Uridine-Diphosphate-N-Acetylgalactosamine Investigative T77546 TARGETID T77546 T77546 FORMERID TTDR00010 T77546 UNIPROID AOC1_HUMAN T77546 TARGNAME Diamine oxidase (AOC1) T77546 GENENAME AOC1 T77546 TARGTYPE Literature-reported T77546 SYNONYMS Kidney amine oxidase; KAO; Histaminase; Amiloride-binding protein; AOC1; ABP T77546 FUNCTION Catalyzes the degradation of compounds such as putrescine, histamine, spermine, and spermidine, substances involved in allergic and immune responses, cell proliferation, tissue differentiation, tumor formation, and possibly apoptosis. Placental DAO is thought to play a role in the regulation of the female reproductive function. T77546 PDBSTRUC 3MPH; 3K5T; 3HII; 3HIG; 3HI7 T77546 BIOCLASS CH-NH(2) donor oxidoreductase T77546 ECNUMBER EC 1.4.3.22 T77546 SEQUENCE MPALGWAVAAILMLQTAMAEPSPGTLPRKAGVFSDLSNQELKAVHSFLWSKKELRLQPSSTTTMAKNTVFLIEMLLPKKYHVLRFLDKGERHPVREARAVIFFGDQEHPNVTEFAVGPLPGPCYMRALSPRPGYQSSWASRPISTAEYALLYHTLQEATKPLHQFFLNTTGFSFQDCHDRCLAFTDVAPRGVASGQRRSWLIIQRYVEGYFLHPTGLELLVDHGSTDAGHWAVEQVWYNGKFYGSPEELARKYADGEVDVVVLEDPLPGGKGHDSTEEPPLFSSHKPRGDFPSPIHVSGPRLVQPHGPRFRLEGNAVLYGGWSFAFRLRSSSGLQVLNVHFGGERIAYEVSVQEAVALYGGHTPAGMQTKYLDVGWGLGSVTHELAPGIDCPETATFLDTFHYYDADDPVHYPRALCLFEMPTGVPLRRHFNSNFKGGFNFYAGLKGQVLVLRTTSTVYNYDYIWDFIFYPNGVMEAKMHATGYVHATFYTPEGLRHGTRLHTHLIGNIHTHLVHYRVDLDVAGTKNSFQTLQMKLENITNPWSPRHRVVQPTLEQTQYSWERQAAFRFKRKLPKYLLFTSPQENPWGHKRTYRLQIHSMADQVLPPGWQEEQAITWARYPLAVTKYRESELCSSSIYHQNDPWHPPVVFEQFLHNNENIENEDLVAWVTVGFLHIPHSEDIPNTATPGNSVGFLLRPFNFFPEDPSLASRDTVIVWPRDNGPNYVQRWIPEDRDCSMPPPFSYNGTYRPV T77546 DRUGINFO D0B8TJ Diminazene Investigative T11793 TARGETID T11793 T11793 FORMERID TTDR01444 T11793 UNIPROID CP2B6_HUMAN T11793 TARGNAME Cytochrome P450 2B6 (CYP2B6) T11793 GENENAME CYP2B6 T11793 TARGTYPE Literature-reported T11793 SYNONYMS Cytochrome P450 IIB1; CYPIIB6; 1,4-cineole 2-exo-monooxygenase T11793 FUNCTION In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase. Cytochromes P450 are a group of heme-thiolate monooxygenases. T11793 PDBSTRUC 5WBG; 5UFG; 5UEC; 5UDA; 5UAP T11793 BIOCLASS Paired donor oxygen oxidoreductase T11793 ECNUMBER EC 1.14.13.- T11793 SEQUENCE MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFREKYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNRWKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIICSIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQEINAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGTETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFSDLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGALKKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKIPPTYQIRFLPR T06365 TARGETID T06365 T06365 FORMERID TTDI02368 T06365 UNIPROID SPYA_HUMAN T06365 TARGNAME Alanine glyoxylate aminotransferase (AGXT) T06365 GENENAME AGXT T06365 TARGTYPE Literature-reported T06365 SYNONYMS Serine--pyruvate aminotransferase; SPAT; Alanine--glyoxylate aminotransferase; AGT1; AGT T06365 FUNCTION Catalyzes L-alanine and glyoxylate to pyruvate and glycine. Participates in alanine and aspartate metabolism and glycine, serine and threonine metabolism. T06365 PDBSTRUC 5OG0; 5OFY; 5LUC; 5HHY; 5F9S T06365 BIOCLASS Transaminase T06365 ECNUMBER EC 2.6.1.51 T06365 SEQUENCE MASHKLLVTPPKALLKPLSIPNQLLLGPGPSNLPPRIMAAGGLQMIGSMSKDMYQIMDEIKEGIQYVFQTRNPLTLVISGSGHCALEAALVNVLEPGDSFLVGANGIWGQRAVDIGERIGARVHPMTKDPGGHYTLQEVEEGLAQHKPVLLFLTHGESSTGVLQPLDGFGELCHRYKCLLLVDSVASLGGTPLYMDRQGIDILYSGSQKALNAPPGTSLISFSDKAKKKMYSRKTKPFSFYLDIKWLANFWGCDDQPRMYHHTIPVISLYSLRESLALIAEQGLENSWRQHREAAAYLHGRLQALGLQLFVKDPALRLPTVTTVAVPAGYDWRDIVSYVIDHFDIEIMGGLGPSTGKVLRIGLLGCNATRENVDRVTEALRAALQHCPKKKL T06365 DRUGINFO D0M9WX AMT-030 Terminated T98089 TARGETID T98089 T98089 FORMERID TTDI01948 T98089 UNIPROID DCK_HUMAN T98089 TARGNAME Deoxycytidine kinase (DCK) T98089 GENENAME DCK T98089 TARGTYPE Literature-reported T98089 SYNONYMS dCK T98089 FUNCTION Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents. T98089 PDBSTRUC 5MQT; 5MQL; 5MQJ; 4Q1F; 4Q1E T98089 BIOCLASS Kinase T98089 ECNUMBER EC 2.7.1.74 T98089 SEQUENCE MATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEVVPEPVARWCNVQSTQDEFEELTMSQKNGGNVLQMMYEKPERWSFTFQTYACLSRIRAQLASLNGKLKDAEKPVLFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHDWMNNQFGQSLELDGIIYLQATPETCLHRIYLRGRNEEQGIPLEYLEKLHYKHESWLLHRTLKTNFDYLQEVPILTLDVNEDFKDKYESLVEKVKEFLSTL T98089 DRUGINFO D06CYQ LP-661438 Investigative T36445 TARGETID T36445 T36445 FORMERID TTDR00824 T36445 UNIPROID NEC1_HUMAN T36445 TARGNAME Neuroendocrine convertase 1 (PCSK1) T36445 GENENAME PCSK1 T36445 TARGTYPE Literature-reported T36445 SYNONYMS Proprotein convertase 1; Prohormone convertase 1; PCSK1; PC1; NEC 1 T36445 FUNCTION Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin and insulin. T36445 BIOCLASS Peptidase T36445 ECNUMBER EC 3.4.21.93 T36445 SEQUENCE MERRAWSLQCTAFVLFCAWCALNSAKAKRQFVNEWAAEIPGGPEAASAIAEELGYDLLGQIGSLENHYLFKHKNHPRRSRRSAFHITKRLSDDDRVIWAEQQYEKERSKRSALRDSALNLFNDPMWNQQWYLQDTRMTAALPKLDLHVIPVWQKGITGKGVVITVLDDGLEWNHTDIYANYDPEASYDFNDNDHDPFPRYDPTNENKHGTRCAGEIAMQANNHKCGVGVAYNSKVGGIRMLDGIVTDAIEASSIGFNPGHVDIYSASWGPNDDGKTVEGPGRLAQKAFEYGVKQGRQGKGSIFVWASGNGGRQGDNCDCDGYTDSIYTISISSASQQGLSPWYAEKCSSTLATSYSSGDYTDQRITSADLHNDCTETHTGTSASAPLAAGIFALALEANPNLTWRDMQHLVVWTSEYDPLANNPGWKKNGAGLMVNSRFGFGLLNAKALVDLADPRTWRSVPEKKECVVKDNDFEPRALKANGEVIIEIPTRACEGQENAIKSLEHVQFEATIEYSRRGDLHVTLTSAAGTSTVLLAERERDTSPNGFKNWDFMSVHTWGENPIGTWTLRITDMSGRIQNEGRIVNWKLILHGTSSQPEHMKQPRVYTSYNTVQNDRRGVEKMVDPGEEQPTQENPKENTLVSKSPSSSSVGGRRDELEEGAPSQAMLRLLQSAFSKNSPPKQSPKKSPSAKLNIPYENFYEALEKLNKPSQLKDSEDSLYNDYVDVFYNTKPYKHRDDRLLQALVDILNEEN T36445 DRUGINFO D0Y9PH Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide Investigative T67754 TARGETID T67754 T67754 FORMERID TTDR00094 T67754 UNIPROID TKT_HUMAN T67754 TARGNAME Transketolase (TK) T67754 GENENAME TKT T67754 TARGTYPE Literature-reported T67754 SYNONYMS TKT1; SDDHD; HEL107; HEL-S-48 T67754 FUNCTION Catalyzes the transfer of a two-carbon ketol group from a ketose donor to an aldose acceptor, via a covalent intermediate with the cofactor thiamine pyrophosphate. T67754 PDBSTRUC 4KXY; 4KXX; 4KXW; 4KXV; 4KXU T67754 BIOCLASS Transketolase T67754 ECNUMBER EC 2.2.1.1 T67754 SEQUENCE MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA T67754 DRUGINFO D0OD8N 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane Investigative T62450 TARGETID T62450 T62450 FORMERID TTDR00592 T62450 UNIPROID NMT_CANAL T62450 TARGNAME Candida Peptide N-myristoyltransferase (Candi NMT1) T62450 GENENAME Candi NMT1 T62450 TARGTYPE Literature-reported T62450 SYNONYMS Peptide N-myristoyltransferase; NMT1; NMT; Myristoyl-CoA:protein N-myristoyltransferase T62450 FUNCTION Adds a myristoyl group to the N-terminal glycine residue of certain cellular proteins. Substrate specificity requires an N- terminal glycine in the nascent polypeptide substrates. Ser is presentat position 5 in almost all known N-myristoyl proteins and Lys is commonly encountered at postion 6. Basic residues are preferred at positions 7 and 8. T62450 PDBSTRUC 1NMT; 1IYL; 1IYK T62450 BIOCLASS Acyltransferase T62450 ECNUMBER EC 2.3.1.97 T62450 SEQUENCE MSGDNTGNKSNSAPSKSIEELLKLLAMGQELSPAQQKEMKDYKFWKTQPVPSLSETVTEEGPIDKLKTPEDVPNDPLPLISDFEWSTLDIDDNLQLDELYKLLYDNYVEDIDATFRFKYSHEFFQWALKPPGWRKDWHVGVRVKSTGKLVAFIAATPVTFKLNKSNKVIDSVEINFLCIHKKLRNKRLAPVLIKEITRRVNKQNIWQALYTGGSILPTPLTTCRYQHRPINWSKLHDVGFSHLPPNQTKSSMVASYTLPNNPKLKGLRPMTGKDVSTVLSLLYKYQERFDIVQLFTEEEFKHWMLGHDENSDSNVVKSYVVEDENGVITDYFSYYLLPFTVLDNAQHDELGIAYLFYYASDSFEKPNYKKRLNELITDALITSKKFGVDVFNCLTCQDNTYFLKDCKFGSGDGFLNYYLFNYRTFPMDGGIDKKTKEVVEDQTSGIGVVLL T62450 DRUGINFO D08TSK SC-58272 Investigative T62450 DRUGINFO D0N3CC (S-(2-oxo)pentadecyl-CoA) Investigative T62450 DRUGINFO D0QD8P Myristoyl-Coa Investigative T94621 TARGETID T94621 T94621 FORMERID TTDI00101 T94621 UNIPROID AKT2_HUMAN T94621 TARGNAME RAC-beta serine/threonine-protein kinase (AKT2) T94621 GENENAME AKT2 T94621 TARGTYPE Literature-reported T94621 SYNONYMS RAC-PK-beta; Protein kinase B beta; Protein kinase Akt-2; PKB beta T94621 FUNCTION AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. T94621 PDBSTRUC 3E8D; 3D0E; 3.00E+88; 3.00E+87; 2XH5 T94621 BIOCLASS Kinase T94621 ECNUMBER EC 2.7.11.1 T94621 SEQUENCE MNEVSVIKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTLPPLNNFSVAECQLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREEWMRAIQMVANSLKQRAPGEDPMDYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLGKGTFGKVILVREKATGRYYAMKILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFHLSRERVFTEERARFYGAEIVSALEYLHSRDVVYRDIKLENLMLDKDGHIKITDFGLCKEGISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHERLFELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSDAKEVMEHRFFLSINWQDVVQKKLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDRYDSLGLLELDQRTHFPQFSYSASIRE T94621 DRUGINFO D0M9QJ PHT-427 Investigative T94621 DRUGINFO D05APZ Akt inhibitor VIII Investigative T94621 DRUGINFO D0L2WP PMID20005102C1 Investigative T90358 TARGETID T90358 T90358 FORMERID TTDNC00400 T90358 UNIPROID PIK1_YEAST T90358 TARGNAME Fungal Phosphatidylinositol 4-kinase PIK1 (Fung PIK1) T90358 GENENAME Fung PIK1 T90358 TARGTYPE Literature-reported T90358 SYNONYMS PtdIns4kinase; Phosphatidylinositol 4kinase PIK1; PIK1; PI4kinase T90358 FUNCTION Acts on phosphatidylinositol (PI) in the first committed step in the production of the second messenger inositol 1,4,5,- trisphosphate. PIK1 is part of a nuclear phosphoinositide cycle and could control cytokinesis through the actin cytoskeleton. T90358 PDBSTRUC 2JU0 T90358 BIOCLASS Kinase T90358 ECNUMBER EC 2.7.1.67 T90358 SEQUENCE MHKASSSKKSFDDTIELKKNEQLLKLINSSEFTLHNCVELLCKHSENIGIHYYLCQKLATFPHSELQFYIPQLVQVLVTMETESMALEDLLLRLRAENPHFALLTFWQLQALLTDLSTDPASYGFQVARRVLNNLQTNLFNTSSGSDKNVKIHENVAPALVLSSMIMSAIAFPQLSEVTKPLVESQGRRQKAFVFKLARSAMKDFTKNMTLKNTLLNKKTSRSKRVSSNRSSTPTSPIDLIDPIKTKEDASFRKSRHSEVKLDFDIVDDIGNQVFEERISSSIKLPKRKPKYLDNSYVHRTYDGKNINRDGSISNTAKALDGNKGDYISPKGRNDENNEIGNNEDETGGETEEDADALNSDHFTSSMPDLHNIQPRTSSASSASLEGTPKLNRTNSQPLSRQAFKNSKKANSSLSQEIDLSQLSTTSKIKMLKANYFRCETQFAIALETISQRLARVPTEARLSALRAELFLLNRDLPAEVDIPTLLPPNKKGKLHKLVTITANEAQVLNSAEKVPYLLLIEYLRDEFDFDPTSETNERLLKKISGNQGGLIFDLNYMNRKENNENRNESTLTSNNTRSSVYDSNSFNNGASRNEGLSSTSRSDSASTAHVRTEVNKEEDLGDMSMVKVRNRTDDEAYRNALVIQSAANVPILPDDSQDRSPELNFGSNLDEVLIENGINSKNIHSQTDALADQMRVSAVMLAQLDKSPQQLSESTKQIRAQIISSMKEVQDKFGYHDLEALHGMAGERKLENDLMTGGIDTSYLGEDWATKKERIRKTSEYGHFENWDLCSVIAKTGDDLRQEAFAYQMIQAMANIWVKEKVDVWVKRMKILITSANTGLVETITNAMSVHSIKKALTKKMIEDAELDDKGGIASLNDHFLRAFGNPNGFKYRRAQDNFASSLAAYSVICYLLQVKDRHNGNIMIDNEGHVSHIDFGFMLSNSPGSVGFEAAPFKLTYEYIELLGGVEGEAFKKFVELTKSSFKALRKYADQIVSMCEIMQKDNMQPCFDAGEQTSVQLRQRFQLDLSEKEVDDFVENFLIGKSLGSIYTRIYDQFQLITQGIYS T83174 TARGETID T83174 T83174 FORMERID TTDI01949 T83174 UNIPROID KPCI_HUMAN T83174 TARGNAME Protein kinase C iota (PRKCI) T83174 GENENAME PRKCI T83174 TARGTYPE Literature-reported T83174 SYNONYMS nPKC-iota; aPKC-lambda/iota; Protein kinase C iota type; PRKC-lambda/iota; DXS1179E; Atypical protein kinase C-lambda/iota T83174 FUNCTION Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor (NGF), acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters (VTCs). In human coronary artery endothelial cells (HCAEC), is activated by saturated fatty acids and mediates lipid-induced apoptosis. Involved in early synaptic long term potentiation phase in CA1 hippocampal cells and short term memory formation. Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway. T83174 PDBSTRUC 5LIH; 5LI9; 5LI1; 3ZH8; 3A8X T83174 BIOCLASS Kinase T83174 ECNUMBER EC 2.7.11.13 T83174 SEQUENCE MPTQRDSSTMSHTVAGGGSGDHSHQVRVKAYYRGDIMITHFEPSISFEGLCNEVRDMCSFDNEQLFTMKWIDEEGDPCTVSSQLELEEAFRLYELNKDSELLIHVFPCVPERPGMPCPGEDKSIYRRGARRWRKLYCANGHTFQAKRFNRRAHCAICTDRIWGLGRQGYKCINCKLLVHKKCHKLVTIECGRHSLPQEPVMPMDQSSMHSDHAQTVIPYNPSSHESLDQVGEEKEAMNTRESGKASSSLGLQDFDLLRVIGRGSYAKVLLVRLKKTDRIYAMKVVKKELVNDDEDIDWVQTEKHVFEQASNHPFLVGLHSCFQTESRLFFVIEYVNGGDLMFHMQRQRKLPEEHARFYSAEISLALNYLHERGIIYRDLKLDNVLLDSEGHIKLTDYGMCKEGLRPGDTTSTFCGTPNYIAPEILRGEDYGFSVDWWALGVLMFEMMAGRSPFDIVGSSDNPDQNTEDYLFQVILEKQIRIPRSLSVKAASVLKSFLNKDPKERLGCHPQTGFADIQGHPFFRNVDWDMMEQKQVVPPFKPNISGEFGLDNFDSQFTNEPVQLTPDDDDIVRKIDQSEFEGFEYINPLLMSAEECV T83174 DRUGINFO D0B8NW ICA-1 Terminated T83174 DRUGINFO D0K6ES CRT-0004592 Investigative T67818 TARGETID T67818 T67818 FORMERID TTDR00081 T67818 UNIPROID P2RY1_HUMAN T67818 TARGNAME P2Y purinoceptor 1 (P2RY1) T67818 GENENAME P2RY1 T67818 TARGTYPE Literature-reported T67818 SYNONYMS P2Y1; P2Y(1) receptor; P2RY1; Adenosine P2Y1 receptor T67818 FUNCTION Receptor for extracellular adenine nucleotides such as ATP and ADP. In platelets binding to ADP leads to mobilization of intracellular calcium ions via activation of phospholipase C, a change in platelet shape, and probably to platelet aggregation. T67818 PDBSTRUC 4XNW; 4XNV; 1Y36 T67818 BIOCLASS GPCR rhodopsin T67818 SEQUENCE MTEVLWPAVPNGTDAAFLAGPGSSWGNSTVASTAAVSSSFKCALTKTGFQFYYLPAVYILVFIIGFLGNSVAIWMFVFHMKPWSGISVYMFNLALADFLYVLTLPALIFYYFNKTDWIFGDAMCKLQRFIFHVNLYGSILFLTCISAHRYSGVVYPLKSLGRLKKKNAICISVLVWLIVVVAISPILFYSGTGVRKNKTITCYDTTSDEYLRSYFIYSMCTTVAMFCVPLVLILGCYGLIVRALIYKDLDNSPLRRKSIYLVIIVLTVFAVSYIPFHVMKTMNLRARLDFQTPAMCAFNDRVYATYQVTRGLASLNSCVDPILYFLAGDTFRRRLSRATRKASRRSEANLQSKSEDMTLNILPEFKQNGDTSL T67818 DRUGINFO D00PAG [35S]ADPbetaS Investigative T67818 DRUGINFO D00PRR MRS2298 Investigative T67818 DRUGINFO D03ERS MRS2500 Investigative T67818 DRUGINFO D04DBR 2,2'-pyridylisatogen tosylate Investigative T67818 DRUGINFO D07MTB PMID23368907C16 Investigative T67818 DRUGINFO D08BXO MRS2950 Investigative T67818 DRUGINFO D08FOV MRS2279 Investigative T67818 DRUGINFO D09DLY 1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea Investigative T67818 DRUGINFO D09POE N-(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate Investigative T67818 DRUGINFO D0D4TY PMID22873688C3a Investigative T67818 DRUGINFO D0D5NP MRS2496 Investigative T67818 DRUGINFO D0E9DE BMS compound 4c Investigative T67818 DRUGINFO D0G8KA PMID18445527C11 Investigative T67818 DRUGINFO D0I5TV dATPalphaS Investigative T67818 DRUGINFO D0L5BW GlaxoSmithKline compound 6i Investigative T67818 DRUGINFO D0M0GV [32P]MRS2500 Investigative T67818 DRUGINFO D0NH6Q MRS2365 Investigative T67818 DRUGINFO D0NJ7Y GlaxoSmithKline compound 5h Investigative T67818 DRUGINFO D0O5ZY MRS-2179 Investigative T67818 DRUGINFO D0U4ZV 2-Cl-ADP(alpha-BH3) Investigative T67818 DRUGINFO D0U8HD 2-chloroadenosine-5-triphosphate Investigative T67818 DRUGINFO D0VY2Z adenosine-3'-5'-bisphosphate Investigative T67818 DRUGINFO D0W8WZ PMID18445527C67 Investigative T67818 DRUGINFO D0WG9Y A2P5P Investigative T67818 DRUGINFO D0BK8V 2',3'-ddATP Investigative T67818 DRUGINFO D07QYU PPADS Investigative T67818 DRUGINFO D0BB0O 2MeSADP Investigative T67818 DRUGINFO D0S3WN ATPgammaS Investigative T67818 DRUGINFO D0U1OJ 2MeSATP Investigative T67818 DRUGINFO D05NWF adenosine diphosphate Investigative T75517 TARGETID T75517 T75517 FORMERID TTDR00774 T75517 UNIPROID GUAA_HUMAN T75517 TARGNAME Glutamine amidotransferase (GMPS) T75517 GENENAME GMPS T75517 TARGTYPE Literature-reported T75517 SYNONYMS GMP synthetase; GMP synthase [glutamine-hydrolyzing] T75517 FUNCTION Involved in the de novo synthesis of guanine nucleotides which are not only essential for DNA and RNA synthesis, but also provide GTP, which is involved in a number of cellular processes important for cell division. T75517 PDBSTRUC 2VXO; 2VPI T75517 BIOCLASS Carbon-nitrogen ligase T75517 ECNUMBER EC 6.3.5.2 T75517 SEQUENCE MALCNGDSKLENAGGDLKDGHHHYEGAVVILDAGAQYGKVIDRRVRELFVQSEIFPLETPAFAIKEQGFRAIIISGGPNSVYAEDAPWFDPAIFTIGKPVLGICYGMQMMNKVFGGTVHKKSVREDGVFNISVDNTCSLFRGLQKEEVVLLTHGDSVDKVADGFKVVARSGNIVAGIANESKKLYGAQFHPEVGLTENGKVILKNFLYDIAGCSGTFTVQNRELECIREIKERVGTSKVLVLLSGGVDSTVCTALLNRALNQEQVIAVHIDNGFMRKRESQSVEEALKKLGIQVKVINAAHSFYNGTTTLPISDEDRTPRKRISKTLNMTTSPEEKRKIIGDTFVKIANEVIGEMNLKPEEVFLAQGTLRPDLIESASLVASGKAELIKTHHNDTELIRKLREEGKVIEPLKDFHKDEVRILGRELGLPEELVSRHPFPGPGLAIRVICAEEPYICKDFPETNNILKIVADFSASVKKPHTLLQRVKACTTEEDQEKLMQITSLHSLNAFLLPIKTVGVQGDCRSYSYVCGISSKDEPDWESLIFLARLIPRMCHNVNRVVYIFGPPVKEPPTDVTPTFLTTGVLSTLRQADFEAHNILRESGYAGKISQMPVILTPLHFDRDPLQKQPSCQRSVVIRTFITSDFMTGIPATPGNEIPVEVVLKMVTEIKKIPGISRIMYDLTSKPPGTTEWE T75517 DRUGINFO D0C3AG 2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol Investigative T75517 DRUGINFO D0L6RV 3,5-dibromo-2-(2,4-dibromophenoxy)phenol Investigative T75517 DRUGINFO D0L9WG Decoyinine Investigative T75517 DRUGINFO D0V1DW 3,4,5-tribromo-2-(2', 4'-dibromo-phenoxy)phenol Investigative T75517 DRUGINFO D0A1DU Pyrophosphate 2- Investigative T96862 TARGETID T96862 T96862 FORMERID TTDR00413 T96862 UNIPROID MVD1_HUMAN T96862 TARGNAME Diphosphomevalonate decarboxylase (MVD) T96862 GENENAME MVD T96862 TARGTYPE Literature-reported T96862 SYNONYMS Mevalonate pyrophosphate decarboxylase; Mevalonate (diphospho)decarboxylase; Mevalonate (diphospho)Diphosphomevalonate decarboxylasedecarboxylase; MVD T96862 FUNCTION Performs the first committed step in the biosynthesis of isoprenes. T96862 PDBSTRUC 3D4J T96862 BIOCLASS Carbon-carbon lyase T96862 ECNUMBER EC 4.1.1.33 T96862 SEQUENCE MASEKPLAAVTCTAPVNIAVIKYWGKRDEELVLPINSSLSVTLHQDQLKTTTTAVISKDFTEDRIWLNGREEDVGQPRLQACLREIRCLARKRRNSRDGDPLPSSLSCKVHVASVNNFPTAAGLASSAAGYACLAYTLARVYGVESDLSEVARRGSGSACRSLYGGFVEWQMGEQADGKDSIARQVAPESHWPELRVLILVVSAEKKLTGSTVGMRASVETSPLLRFRAESVVPARMAEMARCIRERDFPSFAQLTMKDSNQFHATCLDTFPPISYLNAISWRIIHLVHRFNAHHGDTKVAYTFDAGPNAVIFTLDDTVAEFVAAVWHGFPPGSNGDTFLKGLQVRPAPLSAELQAALAMEPTPGGVKYIIVTQVGPGPQILDDPCAHLLGPDGLPKPAA T96862 DRUGINFO D00KPR PMID17888661C18 Investigative T96862 DRUGINFO D00ZWA P'-geranyl 3,5,8-trihydroxy-3-methyloctanate 8-diphosphate Investigative T96862 DRUGINFO D01ENO P'-geranyl 3,5,9-trihydroxy-3-methylnonanate 9-diphosphate Investigative T96862 DRUGINFO D01JCH P'-geranyl 3,5,7-trihydroxy-3-methylheptanate 7-diphosphate Investigative T96862 DRUGINFO D01SPH diphosphoglycolyl proline Investigative T96862 DRUGINFO D03LRN PMID17888661C19 Investigative T96862 DRUGINFO D07GAU analog 3 (Vlattas et al., 1996) Investigative T96862 DRUGINFO D0G7HQ 2,2-difluoromevalonate 5-diphosphate Investigative T96862 DRUGINFO D0I0QH 6-fluoromevalonate pyrophosphate Investigative T96862 DRUGINFO D0P6GH P'-geranyl 2-fluoromevalonate 5-diphosphate Investigative T96862 DRUGINFO D0S4YV 2-fluoromevalonate 5-diphosphate Investigative T96862 DRUGINFO D0U7OO 6-fluoromevalonate 5-diphosphate Investigative T92557 TARGETID T92557 T92557 UNIPROID BCAT1_HUMAN T92557 TARGNAME Branched-chain-amino-acid transaminase 1 (BCAT1) T92557 GENENAME BCAT1 T92557 TARGTYPE Literature-reported T92557 SYNONYMS Protein ECA39; ECA39; Branched-chain-amino-acid aminotransferase, cytosolic; BCT1; BCAT(c) T92557 FUNCTION Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. T92557 PDBSTRUC 2COJ; 2COI; 2COG; 2ABJ T92557 BIOCLASS Transaminase T92557 ECNUMBER EC 2.6.1.42 T92557 SEQUENCE MKDCSNGCSAECTGEGGSKEVVGTFKAKDLIVTPATILKEKPDPNNLVFGTVFTDHMLTVEWSSEFGWEKPHIKPLQNLSLHPGSSALHYAVELFEGLKAFRGVDNKIRLFQPNLNMDRMYRSAVRATLPVFDKEELLECIQQLVKLDQEWVPYSTSASLYIRPTFIGTEPSLGVKKPTKALLFVLLSPVGPYFSSGTFNPVSLWANPKYVRAWKGGTGDCKMGGNYGSSLFAQCEAVDNGCQQVLWLYGEDHQITEVGTMNLFLYWINEDGEEELATPPLDGIILPGVTRRCILDLAHQWGEFKVSERYLTMDDLTTALEGNRVREMFGSGTACVVCPVSDILYKGETIHIPTMENGPKLASRILSKLTDIQYGREESDWTIVLS T70234 TARGETID T70234 T70234 FORMERID TTDI02377 T70234 UNIPROID EPHA4_HUMAN T70234 TARGNAME Ephrin type-A receptor 4 (EPHA4) T70234 GENENAME EPHA4 T70234 TARGTYPE Literature-reported T70234 SYNONYMS hEK8; Tyrosineprotein kinase receptor SEK; Tyrosineprotein kinase TYRO1; Tyrosine-protein kinase receptor SEK; Tyrosine-protein kinase TYRO1; TYRO1; SEK; Ephrin typeA receptor 4; EPHlike kinase 8; EPH-like kinase 8; EK8 T70234 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous, it has the unique property among Eph receptors to bind and to be physiologically activated by both GPI-anchored ephrin-A and transmembrane ephrin-B ligands including EFNA1 and EFNB3. Upon activation by ephrin ligands, modulates cell morphology and integrin-dependent cell adhesion through regulation of the Rac, Rap and Rho GTPases activity. Plays an important role in the development of the nervous system controlling different steps of axonal guidance including the establishment of the corticospinal projections. May also control the segregation of motor and sensory axons during neuromuscular circuit development. In addition to its role in axonal guidance plays a role in synaptic plasticity. Activated by EFNA1 phosphorylates CDK5 at 'Tyr-15' which in turn phosphorylates NGEF regulating RHOA and dendritic spine morphogenesis. In the nervous system, plays also a role in repair after injury preventing axonal regeneration and in angiogenesis playing a role in central nervous system vascular formation. Additionally, its promiscuity makes it available to participate in a variety of cell-cell signaling regulating for instance the development of the thymic epithelium. Receptor tyrosine kinase which binds membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T70234 PDBSTRUC 5JR2; 4W50; 4W4Z; 4M4R; 4M4P T70234 BIOCLASS Kinase T70234 ECNUMBER EC 2.7.10.1 T70234 SEQUENCE MAGIFYFALFSCLFGICDAVTGSRVYPANEVTLLDSRSVQGELGWIASPLEGGWEEVSIMDEKNTPIRTYQVCNVMEPSQNNWLRTDWITREGAQRVYIEIKFTLRDCNSLPGVMGTCKETFNLYYYESDNDKERFIRENQFVKIDTIAADESFTQVDIGDRIMKLNTEIRDVGPLSKKGFYLAFQDVGACIALVSVRVFYKKCPLTVRNLAQFPDTITGADTSSLVEVRGSCVNNSEEKDVPKMYCGADGEWLVPIGNCLCNAGHEERSGECQACKIGYYKALSTDATCAKCPPHSYSVWEGATSCTCDRGFFRADNDAASMPCTRPPSAPLNLISNVNETSVNLEWSSPQNTGGRQDISYNVVCKKCGAGDPSKCRPCGSGVHYTPQQNGLKTTKVSITDLLAHTNYTFEIWAVNGVSKYNPNPDQSVSVTVTTNQAAPSSIALVQAKEVTRYSVALAWLEPDRPNGVILEYEVKYYEKDQNERSYRIVRTAARNTDIKGLNPLTSYVFHVRARTAAGYGDFSEPLEVTTNTVPSRIIGDGANSTVLLVSVSGSVVLVVILIAAFVISRRRSKYSKAKQEADEEKHLNQGVRTYVDPFTYEDPNQAVREFAKEIDASCIKIEKVIGVGEFGEVCSGRLKVPGKREICVAIKTLKAGYTDKQRRDFLSEASIMGQFDHPNIIHLEGVVTKCKPVMIITEYMENGSLDAFLRKNDGRFTVIQLVGMLRGIGSGMKYLSDMSYVHRDLAARNILVNSNLVCKVSDFGMSRVLEDDPEAAYTTRGGKIPIRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSYGERPYWDMSNQDVIKAIEEGYRLPPPMDCPIALHQLMLDCWQKERSDRPKFGQIVNMLDKLIRNPNSLKRTGTESSRPNTALLDPSSPEFSAVVSVGDWLQAIKMDRYKDNFTAAGYTTLEAVVHVNQEDLARIGITAITHQNKILSSVQAMRTQMQQMHGRMVPV T70234 DRUGINFO D0I0SY MEDI-542 Terminated T70234 DRUGINFO D05FXD PMID19788238C66 Investigative T70234 DRUGINFO D0X8BU PMID23489211C20 Investigative T89082 TARGETID T89082 T89082 FORMERID TTDR00381 T89082 UNIPROID HMCS2_HUMAN T89082 TARGNAME Hydroxymethylglutaryl-CoA synthase 2 (HMGCS2) T89082 GENENAME HMGCS2 T89082 TARGTYPE Literature-reported T89082 SYNONYMS HMGCS2; HMG-CoAsynthase; 3-hydroxy-3-methylglutaryl coenzyme A synthase 2 T89082 FUNCTION This enzyme condenses acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, which is the substrate for HMG-CoA reductase. T89082 PDBSTRUC 2WYA T89082 BIOCLASS Acyltransferase T89082 ECNUMBER EC 2.3.3.10 T89082 SEQUENCE MQRLLTPVKRILQLTRAVQETSLTPARLLPVAHQRFSTASAVPLAKTDTWPKDVGILALEVYFPAQYVDQTDLEKYNNVEAGKYTVGLGQTRMGFCSVQEDINSLCLTVVQRLMERIQLPWDSVGRLEVGTETIIDKSKAVKTVLMELFQDSGNTDIEGIDTTNACYGGTASLFNAANWMESSSWDGRYAMVVCGDIAVYPSGNARPTGGAGAVAMLIGPKAPLALERGLRGTHMENVYDFYKPNLASEYPIVDGKLSIQCYLRALDRCYTSYRKKIQNQWKQAGSDRPFTLDDLQYMIFHTPFCKMVQKSLARLMFNDFLSASSDTQTSLYKGLEAFGGLKLEDTYTNKDLDKALLKASQDMFDKKTKASLYLSTHNGNMYTSSLYGCLASLLSHHSAQELAGSRIGAFSYGSGLAASFFSFRVSQDAAPGSPLDKLVSSTSDLPKRLASRKCVSPEEFTEIMNQREQFYHKVNFSPPGDTNSLFPGTWYLERVDEQHRRKYARRPV T89082 DRUGINFO D06CGD Acetoacetyl-Coenzyme A Investigative T89082 DRUGINFO D0E8JM 3-Sulfinoalanine Investigative T86829 TARGETID T86829 T86829 FORMERID TTDR00037 T86829 UNIPROID SCYD_MAGO7 T86829 TARGNAME Fungal Scytalone dehydratase (Fung SDH1) T86829 GENENAME Fung SDH1 T86829 TARGTYPE Literature-reported T86829 SYNONYMS SDH1 T86829 FUNCTION Catalyzes two steps in melanin biosynthesis. From scytalone they are two dehydration steps and one reduction step to yield melanin. T86829 PDBSTRUC 7STD; 6STD; 5STD; 4STD; 3STD T86829 BIOCLASS Alpha-carbonic anhydrase T86829 ECNUMBER EC 4.2.1.94 T86829 SEQUENCE MGSQVQKSDEITFSDYLGLMTCVYEWADSYDSKDWDRLRKVIAPTLRIDYRSFLDKLWEAMPAEEFVGMVSSKQVLGDPTLRTQHFIGGTRWEKVSEDEVIGYHQLRVPHQRYKDTTMKEVTMKGHAHSANLHWYKKIDGVWKFAGLKPDIRWGEFDFDRIFEDGRETFGDK T86829 DRUGINFO D05OPY (3-Phenyl-propyl)-quinazolin-4-yl-amine Investigative T86829 DRUGINFO D07CEB Isoquinolin-1-yl-(3-phenyl-propyl)-amine Investigative T86829 DRUGINFO D09FJW Carpropamid Investigative T86829 DRUGINFO D09XXN 2-Hydroxy-N-(3-phenyl-propyl)-benzamide Investigative T86829 DRUGINFO D0N7RW 5-Fluoro-2-hydroxy-N-isopropyl-benzamide Investigative T38257 TARGETID T38257 T38257 FORMERID TTDI00078 T38257 UNIPROID PTEN_HUMAN T38257 TARGNAME Phosphatase and tensin homolog (PTEN) T38257 GENENAME PTEN T38257 TARGTYPE Literature-reported T38257 SYNONYMS TEP1; Phosphatidylinositol 3,4,5trisphosphate 3phosphatase and dualspecificity protein phosphatase PTEN; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; Mutated in multiple advanced cancers 1; MMAC1 T38257 FUNCTION Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement. Tumor suppressor. T38257 PDBSTRUC 5BZZ; 5BZX; 5BUG; 4O1V; 2KYL T38257 BIOCLASS Phosphoric monoester hydrolase T38257 ECNUMBER EC 3.1.3.16 T38257 SEQUENCE MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV T88752 TARGETID T88752 T88752 FORMERID TTDI02365 T88752 UNIPROID RAC1_HUMAN T88752 TARGNAME Ras-related C3 botulinum toxin substrate 1 (RAC1) T88752 GENENAME RAC1 T88752 TARGTYPE Literature-reported T88752 SYNONYMS Cell migration-inducing gene5 protein T88752 FUNCTION In its active state, binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization, neurons adhesion, migration and differentiation, and growth-factor induced formation of membrane ruffles. Rac1 p21/rho GDI heterodimer is the active component of the cytosolic factor sigma 1, which is involved in stimulation of the NADPH oxidase activity in macrophages. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. Stimulates PKN2 kinase activity. In concert with RAB7A, plays a role in regulating the formation of RBs (ruffled borders) in osteoclasts. In podocytes, promotes nuclear shuttling of NR3C2; this modulation is required for a proper kidney functioning. Required for atypical chemokine receptor ACKR2-induced LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1) and for up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. In synapses, seems to mediate the regulation of F-actin cluster formation performed by SHANK3. Plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. T88752 PDBSTRUC 6BC1; 6AGP; 5O33; 5N6O; 5HZH T88752 BIOCLASS Small GTPase T88752 ECNUMBER EC 3.6.5.2 T88752 SEQUENCE MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDTAGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWYPEVRHHCPNTPIILVGTKLDLRDDKDTIEKLKEKKLTPITYPQGLAMAKEIGAVKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL T88752 DRUGINFO D0M9ER EHT-1864 Terminated T52617 TARGETID T52617 T52617 FORMERID TTDR01245 T52617 UNIPROID FAB1_MYCTU T52617 TARGNAME Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA) T52617 GENENAME MycB kasA T52617 TARGTYPE Literature-reported T52617 SYNONYMS kasA; KAS 1; Beta-ketoacyl-ACP synthase 1 T52617 FUNCTION Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-acp. T52617 PDBSTRUC 5LD8; 2WGG; 2WGF; 2WGE; 2WGD T52617 BIOCLASS Acyltransferase T52617 ECNUMBER EC 2.3.1.41 T52617 SEQUENCE MSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAVKIGGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVVGTGLGGAERIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAHAWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFGEAGALMLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADIDHVNAHGTATPIGDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVLTLRDGVIPPTLNYETPDPEIDLDVVAGEPRYGDYRYAVNNSFGFGGHNVALAFGRY T52617 DRUGINFO D0E7NO Decanoic Acid Investigative T52617 DRUGINFO D0V1EK 2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE Investigative T52617 DRUGINFO D0XS4G Caprylic acid Investigative T52617 DRUGINFO D0N0UC Lauric Acid Investigative T59445 TARGETID T59445 T59445 FORMERID TTDR00879 T59445 UNIPROID DHSO_HUMAN T59445 TARGNAME Sorbitoldehydrogenase (SORD) T59445 GENENAME SORD T59445 TARGTYPE Literature-reported T59445 SYNONYMS SORD; SDH; L-iditol2-dehydrogenase T59445 FUNCTION Convertssorbitol to fructose. Part of the polyol pathway that plays an important role in sperm physiology. May play a role in the sperm motility by providing an energetic source for sperm. T59445 PDBSTRUC 1PL8; 1PL7; 1PL6 T59445 BIOCLASS Short-chain dehydrogenases reductase T59445 ECNUMBER EC 1.1.1.- T59445 SEQUENCE MAAAAKPNNLSLVVHGPGDLRLENYPIPEPGPNEVLLRMHSVGICGSDVHYWEYGRIGNFIVKKPMVLGHEASGTVEKVGSSVKHLKPGDRVAIEPGAPRENDEFCKMGRYNLSPSIFFCATPPDDGNLCRFYKHNAAFCYKLPDNVTFEEGALIEPLSVGIHACRRGGVTLGHKVLVCGAGPIGMVTLLVAKAMGAAQVVVTDLSATRLSKAKEIGADLVLQISKESPQEIARKVEGQLGCKPEVTIECTGAEASIQAGIYATRSGGNLVLVGLGSEMTTVPLLHAAIREVDIKGVFRYCNTWPVAISMLASKSVNVKPLVTHRFPLEKALEAFETFKKGLGLKIMLKCDPSDQNP T59445 DRUGINFO D05DAN CP-470,711 Investigative T59445 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T48330 TARGETID T48330 T48330 FORMERID TTDR00626 T48330 UNIPROID LAT1_HUMAN T48330 TARGNAME Large neutral amino acids transporter 1 (SLC7A5) T48330 GENENAME SLC7A5 T48330 TARGTYPE Literature-reported T48330 SYNONYMS y+ system cationic amino acid transporter; Solute carrier family 7 member 5; MPE16; Large neutral amino acids transporter small subunit 1; LAT1; L-type amino acid transporter LAT1; L-type amino acid transporter 1; Integral membrane protein E16; HLAT1; CD98LC; CD98 light chain; 4F2LC; 4F2 light chain; 4F2 LC T48330 FUNCTION Involved in cellular amino acid uptake. Acts as an amino acid exchanger. Involved in the transport of L-DOPA across the blood-brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell membrane in tissues such as placenta. Plays a role in neuronal cell proliferation (neurogenesis) in brain. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the transmembrane. May play an important role in high-grade gliomas. Mediates blood-to-retina L-leucine transport across the inner blood-retinal barrier which in turn may play a key role in maintaining large neutral amino acids as well as neurotransmitters in the neural retina. Acts as the major transporter of tyrosine in fibroblasts. When associated with LAPTM4B, recruits SLC3A2 and SLC7A5 to lysosomes to promote leucine uptake into these organelles and is required for mTORC1 activation. Sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. T48330 PDBSTRUC 6IRT; 6IRS T48330 BIOCLASS Amino acid-polyamine-organocation T48330 SEQUENCE MAGAGPKRRALAAPAAEEKEEAREKMLAAKSADGSAPAGEGEGVTLQRNITLLNGVAIIVGTIIGSGIFVTPTGVLKEAGSPGLALVVWAACGVFSIVGALCYAELGTTISKSGGDYAYMLEVYGSLPAFLKLWIELLIIRPSSQYIVALVFATYLLKPLFPTCPVPEEAAKLVACLCVLLLTAVNCYSVKAATRVQDAFAAAKLLALALIILLGFVQIGKGDVSNLDPNFSFEGTKLDVGNIVLALYSGLFAYGGWNYLNFVTEEMINPYRNLPLAIIISLPIVTLVYVLTNLAYFTTLSTEQMLSSEAVAVDFGNYHLGVMSWIIPVFVGLSCFGSVNGSLFTSSRLFFVGSREGHLPSILSMIHPQLLTPVPSLVFTCVMTLLYAFSKDIFSVINFFSFFNWLCVALAIIGMIWLRHRKPELERPIKVNLALPVFFILACLFLIAVSFWKTPVECGIGFTIILSGLPVYFFGVWWKNKPKWLLQGIFSTTVLCQKLMQVVPQET T48330 DRUGINFO D01BCL (+/-)-2-Amino-1,2,3,4-tetrahydro-2-naphthoic acid Investigative T48330 DRUGINFO D05BOD BCH Investigative T48330 DRUGINFO D0SC5V (+/-)-2-Aminoindane-2-carboxylic acid Investigative T78326 TARGETID T78326 T78326 FORMERID TTDI00195 T78326 UNIPROID NAAA_HUMAN T78326 TARGNAME N-acylethanolamine-hydrolyzing acidamidase (NAAA) T78326 GENENAME NAAA T78326 TARGTYPE Literature-reported T78326 SYNONYMS Nacylsphingosine amidohydrolaselike; Nacylethanolaminehydrolyzing acid amidase subunit beta; NAAA; Acid ceramidaselike protein; ASAHlike protein T78326 FUNCTION Degrades bioactive fatty acid amides to their corresponding acids, with the following preference: N- palmitoylethanolamine > N-myristoylethanolamine > N- lauroylethanolamine = N-stearoylethanolamine > N- arachidonoylethanolamine > N-oleoylethanolamine. Also exhibits weak hydrolytic activity against the ceramides N- lauroylsphingosine and N-palmitoylsphingosine. T78326 PDBSTRUC 6DXX; 6DXW T78326 BIOCLASS Carbon-nitrogen hydrolase T78326 ECNUMBER EC 3.5.1.- T78326 SEQUENCE MRTADREARPGLPSLLLLLLAGAGLSAASPPAAPRFNVSLDSVPELRWLPVLRHYDLDLVRAAMAQVIGDRVPKWVHVLIGKVVLELERFLPQPFTGEIRGMCDFMNLSLADCLLVNLAYESSVFCTSIVAQDSRGHIYHGRNLDYPFGNVLRKLTVDVQFLKNGQIAFTGTTFIGYVGLWTGQSPHKFTVSGDERDKGWWWENAIAALFRRHIPVSWLIRATLSESENFEAAVGKLAKTPLIADVYYIVGGTSPREGVVITRNRDGPADIWPLDPLNGAWFRVETNYDHWKPAPKEDDRRTSAIKALNATGQANLSLEALFQILSVVPVYNNFTIYTTVMSAGSPDKYMTRIRNPSRK T78326 DRUGINFO D0G6RN S-OOPP Investigative T78326 DRUGINFO D0X3AT CCP Investigative T14945 TARGETID T14945 T14945 FORMERID TTDC00064 T14945 UNIPROID CENPE_HUMAN T14945 TARGNAME Centromeric protein E (CENPE) T14945 GENENAME CENPE T14945 TARGTYPE Literature-reported T14945 SYNONYMS Centromere-associated protein E; CENPE; CENP-E T14945 FUNCTION Essential for the maintenance of chromosomal stability through efficient stabilization of microtubule capture at kinetochores. Plays a key role in the movement of chromosomes toward the metaphase plate during mitosis. Is a slow plus end- directed motor whose activity is essential for metaphase chromosome alignment. Couples chromosome position to microtubule depolymerizing activity. The highly processive microtubule- dependent motor activity of CENPE servesto power chromosome congression and provides a flexible, motile tether linking kinetochores to dynamic spindle microtubules. Necessary for the mitotic checkpoint signal at individual kinetochores to prevent aneuploidy due to single chromosome loss. Required for the efficient recruitment of BUBR1, MAD1 and MAD2 to attached and newly unattached kinetochores. Stimulates mammalian BUBR1 kinase activity. Accumulates just before mitosis at the G2 phase of the cell cycle. T14945 PDBSTRUC 5JVP; 1T5C T14945 BIOCLASS TRAFAC class myosin-kinesin ATPase T14945 SEQUENCE MAEEGAVAVCVRVRPLNSREESLGETAQVYWKTDNNVIYQVDGSKSFNFDRVFHGNETTKNVYEEIAAPIIDSAIQGYNGTIFAYGQTASGKTYTMMGSEDHLGVIPRAIHDIFQKIKKFPDREFLLRVSYMEIYNETITDLLCGTQKMKPLIIREDVNRNVYVADLTEEVVYTSEMALKWITKGEKSRHYGETKMNQRSSRSHTIFRMILESREKGEPSNCEGSVKVSHLNLVDLAGSERAAQTGAAGVRLKEGCNINRSLFILGQVIKKLSDGQVGGFINYRDSKLTRILQNSLGGNAKTRIICTITPVSFDETLTALQFASTAKYMKNTPYVNEVSTDEALLKRYRKEIMDLKKQLEEVSLETRAQAMEKDQLAQLLEEKDLLQKVQNEKIENLTRMLVTSSSLTLQQELKAKRKRRVTWCLGKINKMKNSNYADQFNIPTNITTKTHKLSINLLREIDESVCSESDVFSNTLDTLSEIEWNPATKLLNQENIESELNSLRADYDNLVLDYEQLRTEKEEMELKLKEKNDLDEFEALERKTKKDQEMQLIHEISNLKNLVKHAEVYNQDLENELSSKVELLREKEDQIKKLQEYIDSQKLENIKMDLSYSLESIEDPKQMKQTLFDAETVALDAKRESAFLRSENLELKEKMKELATTYKQMENDIQLYQSQLEAKKKMQVDLEKELQSAFNEITKLTSLIDGKVPKDLLCNLELEGKITDLQKELNKEVEENEALREEVILLSELKSLPSEVERLRKEIQDKSEELHIITSEKDKLFSEVVHKESRVQGLLEEIGKTKDDLATTQSNYKSTDQEFQNFKTLHMDFEQKYKMVLEENERMNQEIVNLSKEAQKFDSSLGALKTELSYKTQELQEKTREVQERLNEMEQLKEQLENRDSTLQTVEREKTLITEKLQQTLEEVKTLTQEKDDLKQLQESLQIERDQLKSDIHDTVNMNIDTQEQLRNALESLKQHQETINTLKSKISEEVSRNLHMEENTGETKDEFQQKMVGIDKKQDLEAKNTQTLTADVKDNEIIEQQRKIFSLIQEKNELQQMLESVIAEKEQLKTDLKENIEMTIENQEELRLLGDELKKQQEIVAQEKNHAIKKEGELSRTCDRLAEVEEKLKEKSQQLQEKQQQLLNVQEEMSEMQKKINEIENLKNELKNKELTLEHMETERLELAQKLNENYEEVKSITKERKVLKELQKSFETERDHLRGYIREIEATGLQTKEELKIAHIHLKEHQETIDELRRSVSEKTAQIINTQDLEKSHTKLQEEIPVLHEEQELLPNVKEVSETQETMNELELLTEQSTTKDSTTLARIEMERLRLNEKFQESQEEIKSLTKERDNLKTIKEALEVKHDQLKEHIRETLAKIQESQSKQEQSLNMKEKDNETTKIVSEMEQFKPKDSALLRIEIEMLGLSKRLQESHDEMKSVAKEKDDLQRLQEVLQSESDQLKENIKEIVAKHLETEEELKVAHCCLKEQEETINELRVNLSEKETEISTIQKQLEAINDKLQNKIQEIYEKEEQFNIKQISEVQEKVNELKQFKEHRKAKDSALQSIESKMLELTNRLQESQEEIQIMIKEKEEMKRVQEALQIERDQLKENTKEIVAKMKESQEKEYQFLKMTAVNETQEKMCEIEHLKEQFETQKLNLENIETENIRLTQILHENLEEMRSVTKERDDLRSVEETLKVERDQLKENLRETITRDLEKQEELKIVHMHLKEHQETIDKLRGIVSEKTNEISNMQKDLEHSNDALKAQDLKIQEELRIAHMHLKEQQETIDKLRGIVSEKTDKLSNMQKDLENSNAKLQEKIQELKANEHQLITLKKDVNETQKKVSEMEQLKKQIKDQSLTLSKLEIENLNLAQKLHENLEEMKSVMKERDNLRRVEETLKLERDQLKESLQETKARDLEIQQELKTARMLSKEHKETVDKLREKISEKTIQISDIQKDLDKSKDELQKKIQELQKKELQLLRVKEDVNMSHKKINEMEQLKKQFEAQNLSMQSVRMDNFQLTKKLHESLEEIRIVAKERDELRRIKESLKMERDQFIATLREMIARDRQNHQVKPEKRLLSDGQQHLTESLREKCSRIKELLKRYSEMDDHYECLNRLSLDLEKEIEFQKELSMRVKANLSLPYLQTKHIEKLFTANQRCSMEFHRIMKKLKYVLSYVTKIKEEQHESINKFEMDFIDEVEKQKELLIKIQHLQQDCDVPSRELRDLKLNQNMDLHIEEILKDFSESEFPSIKTEFQQVLSNRKEMTQFLEEWLNTRFDIEKLKNGIQKENDRICQVNNFFNNRIIAIMNESTEFEERSATISKEWEQDLKSLKEKNEKLFKNYQTLKTSLASGAQVNPTTQDNKNPHVTSRATQLTTEKIRELENSLHEAKESAMHKESKIIKMQKELEVTNDIIAKLQAKVHESNKCLEKTKETIQVLQDKVALGAKPYKEEIEDLKMKLVKIDLEKMKNAKEFEKEISATKATVEYQKEVIRLLRENLRRSQQAQDTSVISEHTDPQPSNKPLTCGGGSGIVQNTKALILKSEHIRLEKEISKLKQQNEQLIKQKNELLSNNQHLSNEVKTWKERTLKREAHKQVTCENSPKSPKVTGTASKKKQITPSQCKERNLQDPVPKESPKSCFFDSRSKSLPSPHPVRYFDNSSLGLCPEVQNAGAESVDSQPGPWHASSGKDVPECKTQ T14945 DRUGINFO D00XEU GSK-923295 Terminated T47164 TARGETID T47164 T47164 FORMERID TTDI02447 T47164 UNIPROID STK4_HUMAN T47164 TARGNAME MST-1 protein kinase (STK4) T47164 GENENAME STK4 T47164 TARGTYPE Literature-reported T47164 SYNONYMS Serine/threonine-protein kinase Krs-2; Serine/threonine-protein kinase 4 18kDa subunit; Serine/threonine-protein kinase 4; STE20-like kinase MST1; Mammalian STE20-like protein kinase 1; MST1/N; MST1/C; MST1; MST-1; KRS2 T47164 FUNCTION Key component of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. STK3/MST2 and STK4/MST1 are required to repress proliferation of mature hepatocytes, to prevent activation of facultative adult liver stem cells (oval cells), and to inhibit tumor formation. Phosphorylates 'Ser-14' of histone H2B (H2BS14ph) during apoptosis. Phosphorylates FOXO3 upon oxidative stress, which results in its nuclear translocation and cell death initiation. Phosphorylates MOBKL1A, MOBKL1B and RASSF2. Phosphorylates TNNI3 (cardiac Tn-I) and alters its binding affinity to TNNC1 (cardiac Tn-C) and TNNT2 (cardiac Tn-T). Phosphorylates FOXO1 on 'Ser-212' and regulates its activation and stimulates transcription of PMAIP1 in a FOXO1-dependent manner. Phosphorylates SIRT1 and inhibits SIRT1-mediated p53/TP53 deacetylation, thereby promoting p53/TP53 dependent transcription and apoptosis upon DNA damage. Acts as an inhibitor of PKB/AKT1. Phosphorylates AR on 'Ser-650' and suppresses its activity by intersecting with PKB/AKT1 signaling and antagonizing formation of AR-chromatin complexes. Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation. T47164 PDBSTRUC 5TWH; 5TWG; 4OH8; 4NR2; 3COM T47164 BIOCLASS Kinase T47164 ECNUMBER EC 2.7.11.1 T47164 SEQUENCE METVQLRNPPRRQLKKLDEDSLTKQPEEVFDVLEKLGEGSYGSVYKAIHKETGQIVAIKQVPVESDLQEIIKEISIMQQCDSPHVVKYYGSYFKNTDLWIVMEYCGAGSVSDIIRLRNKTLTEDEIATILQSTLKGLEYLHFMRKIHRDIKAGNILLNTEGHAKLADFGVAGQLTDTMAKRNTVIGTPFWMAPEVIQEIGYNCVADIWSLGITAIEMAEGKPPYADIHPMRAIFMIPTNPPPTFRKPELWSDNFTDFVKQCLVKSPEQRATATQLLQHPFVRSAKGVSILRDLINEAMDVKLKRQESQQREVDQDDEENSEEDEMDSGTMVRAVGDEMGTVRVASTMTDGANTMIEHDDTLPSQLGTMVINAEDEEEEGTMKRRDETMQPAKPSFLEYFEQKEKENQINSFGKSVPGPLKNSSDWKIPQDGDYEFLKSWTVEDLQKRLLALDPMMEQEIEEIRQKYQSKRQPILDAIEAKKRRQQNF T47164 DRUGINFO D0A7HY TAT-120 Investigative T40787 TARGETID T40787 T40787 FORMERID TTDR00959 T40787 UNIPROID MTAP_HUMAN T40787 TARGNAME S-methyl-5'-thioadenosine phosphorylase (MTAP) T40787 GENENAME MTAP T40787 TARGTYPE Literature-reported T40787 SYNONYMS Methylthioadenosine phosphorylase; MTAPase; MTA phosphorylase; MSAP; 5'-methylthioadenosine phosphorylase T40787 FUNCTION Involved in the breakdown of MTA, a major by-product of polyamine biosynthesis. Responsible for the first step in the methionine salvage pathway after MTA has been generated from S-adenosylmethionine. Has broad substrate specificity with 6-aminopurine nucleosides as preferred substrates. Catalyzes the reversible phosphorylation of S-methyl-5'-thioadenosine (MTA) to adenine and 5-methylthioribose-1-phosphate. T40787 PDBSTRUC 6DZ3; 6DZ2; 6DZ0; 6DYZ; 5TC8 T40787 BIOCLASS Glycosyltransferases T40787 ECNUMBER EC 2.4.2.28 T40787 SEQUENCE MASGTTTTAVKIGIIGGTGLDDPEILEGRTEKYVDTPFGKPSDALILGKIKNVDCVLLARHGRQHTIMPSKVNYQANIWALKEEGCTHVIVTTACGSLREEIQPGDIVIIDQFIDRTTMRPQSFYDGSHSCARGVCHIPMAEPFCPKTREVLIETAKKLGLRCHSKGTMVTIEGPRFSSRAESFMFRTWGADVINMTTVPEVVLAKEAGICYASIAMATDYDCWKEHEEAVSVDRVLKTLKENANKAKSLLLTTIPQIGSTEWSETLHNLKNMAQFSVLLPRH T40787 DRUGINFO D0E4WF METHYLTHIOADENOSINE Terminated T40787 DRUGINFO D02JUP 5'-Deoxy-5'-(Methylthio)-Tubercidin Investigative T40787 DRUGINFO D0NH1Y Formycin Investigative T17143 TARGETID T17143 T17143 FORMERID TTDR00149 T17143 UNIPROID MP2K5_HUMAN T17143 TARGNAME ERK activator kinase 5 (MAP2K5) T17143 GENENAME MAP2K5 T17143 TARGTYPE Literature-reported T17143 SYNONYMS PRKMK5; Mitogen-activatedprotein kinase kinase 5; MKK5; MEK5; MEK 5; MAPKK 5; MAPK/ERK kinase 5; MAP kinase kinase5; MAP kinase kinase 5; Dual specificity mitogen-activated protein kinase kinase 5 T17143 FUNCTION Activation of this pathway appears to play a critical role in protecting cells from stress-induced apoptosis, neuronal survival and cardiac development and angiogenesis. Acts as a scaffold for the formation of a ternary MAP3K2/MAP3K3-MAP3K5-MAPK7 signaling complex. T17143 PDBSTRUC 4IC7; 2O2V; 2NPT T17143 BIOCLASS Kinase T17143 ECNUMBER EC 2.7.12.2 T17143 SEQUENCE MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEATTTAFEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACKPPGERNIHGLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDIRYRDTLGHGNGGTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSSYIIGFYGAFFVENRISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSLKILHRDVKPSNMLVNTRGQVKLCDFGVSTQLVNSIAKTYVGTNAYMAPERISGEQYGIHSDVWSLGISFMELALGRFPYPQIQKNQGSLMPLQLLQCIVDEDSPVLPVGEFSEPFVHFITQCMRKQPKERPAPEELMGHPFIVQFNDGNAAVVSMWVCRALEERRSQQGPP T17143 DRUGINFO D0R6JG BIX 02188 Investigative T91681 TARGETID T91681 T91681 UNIPROID TDG_HUMAN T91681 TARGNAME Thymine-DNA glycosylase (TDG) T91681 GENENAME TDG T91681 TARGTYPE Literature-reported T91681 SYNONYMS hTDG T91681 FUNCTION DNA glycosylase that plays a key role in active DNA demethylation: specifically recognizes and binds 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) in the context of CpG sites and mediates their excision through base-excision repair (BER) to install an unmethylated cytosine. Cannot remove 5-hydroxymethylcytosine (5hmC). According to an alternative model, involved in DNA demethylation by mediating DNA glycolase activity toward 5-hydroxymethyluracil (5hmU) produced by deamination of 5hmC. Also involved in DNA repair by acting as a thymine-DNA glycosylase that mediates correction of G/T mispairs to G/C pairs: in the DNA of higher eukaryotes, hydrolytic deamination of 5-methylcytosine to thymine leads to the formation of G/T mismatches. Its role in the repair of canonical base damage is however minor compared to its role in DNA demethylation. It is capable of hydrolyzing the carbon-nitrogen bond between the sugar-phosphate backbone of the DNA and a mispaired thymine. In addition to the G/T, it can remove thymine also from C/T and T/T mispairs in the order G/T >> C/T > T/T. It has no detectable activity on apyrimidinic sites and does not catalyze the removal of thymine from A/T pairs or from single-stranded DNA. It can also remove uracil and 5-bromouracil from mispairs with guanine. T91681 PDBSTRUC 5T2W; 5JXY; 5HF7; 5FF8; 5CYS T91681 BIOCLASS Uracil-DNA glycosylase (UDG) superfamily. TDG/mug family T91681 ECNUMBER EC 3.2.2.29 T91681 SEQUENCE MEAENAGSYSLQQAQAFYTFPFQQLMAEAPNMAVVNEQQMPEEVPAPAPAQEPVQEAPKGRKRKPRTTEPKQPVEPKKPVESKKSGKSAKSKEKQEKITDTFKVKRKVDRFNGVSEAELLTKTLPDILTFNLDIVIIGINPGLMAAYKGHHYPGPGNHFWKCLFMSGLSEVQLNHMDDHTLPGKYGIGFTNMVERTTPGSKDLSSKEFREGGRILVQKLQKYQPRIAVFNGKCIYEIFSKEVFGVKVKNLEFGLQPHKIPDTETLCYVMPSSSARCAQFPRAQDKVHYYIKLKDLRDQLKGIERNMDVQEVQYTFDLQLAQEDAKKMAVKEEKYDPGYEAAYGGAYGENPCSSEPCGFSSNGLIESVELRGESAFSGIPNGQWMTQSFTDQIPSFSNHCGTQEQEEESHA T80338 TARGETID T80338 T80338 FORMERID TTDI02445 T80338 UNIPROID AVR2B_HUMAN T80338 TARGNAME Activin receptor type IIB (ACVR2B) T80338 GENENAME ACVR2B T80338 TARGTYPE Literature-reported T80338 SYNONYMS Activin receptor type2B; Activin receptor type-2B; ACTRIIB; ACTR-IIB T80338 FUNCTION Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, the type-2 receptors act as a primary activin receptors (binds activin-A/INHBA, activin-B/INHBB as well as inhibin-A/INHA-INHBA). The type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor. Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c). T80338 PDBSTRUC 5NHR; 5NGV; 4FAO; 2QLU; 2H62 T80338 BIOCLASS Kinase T80338 ECNUMBER EC 2.7.11.30 T80338 SEQUENCE MTAPWVALALLWGSLCAGSGRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPTLLTVLAYSLLPIGGLSLIVLLAFWMYRHRKPPYGHVDIHEDPGPPPPSPLVGLKPLQLLEIKARGRFGCVWKAQLMNDFVAVKIFPLQDKQSWQSEREIFSTPGMKHENLLQFIAAEKRGSNLEVELWLITAFHDKGSLTDYLKGNIITWNELCHVAETMSRGLSYLHEDVPWCRGEGHKPSIAHRDFKSKNVLLKSDLTAVLADFGLAVRFEPGKPPGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWELVSRCKAADGPVDEYMLPFEEEIGQHPSLEELQEVVVHKKMRPTIKDHWLKHPGLAQLCVTIEECWDHDAEARLSAGCVEERVSLIRRSVNGTTSDCLVSLVTSVTNVDLPPKESSI T80338 DRUGINFO D0GK9J ACVR2B Investigative T60213 TARGETID T60213 T60213 FORMERID TTDI01817 T60213 UNIPROID BMPR2_HUMAN T60213 TARGNAME Bone morphogenetic protein receptor (BMPR2) T60213 GENENAME BMPR2 T60213 TARGTYPE Literature-reported T60213 SYNONYMS PPH1; Bone morphogenetic protein receptor type-2; Bone morphogenetic protein receptor type II; BMPR-II; BMPR-2; BMP type-2 receptor; BMP type II receptor T60213 FUNCTION Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is weak but enhanced by the presence of type I receptors for BMPs. Mediates induction of adipogenesis by GDF6. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. T60213 PDBSTRUC 3G2F; 2HLQ T60213 BIOCLASS Kinase T60213 ECNUMBER EC 2.7.11.30 T60213 SEQUENCE MTSSLQRPWRVPWLPWTILLVSTAAASQNQERLCAFKDPYQQDLGIGESRISHENGTILCSKGSTCYGLWEKSKGDINLVKQGCWSHIGDPQECHYEECVVTTTPPSIQNGTYRFCCCSTDLCNVNFTENFPPPDTTPLSPPHSFNRDETIIIALASVSVLAVLIVALCFGYRMLTGDRKQGLHSMNMMEAAASEPSLDLDNLKLLELIGRGRYGAVYKGSLDERPVAVKVFSFANRQNFINEKNIYRVPLMEHDNIARFIVGDERVTADGRMEYLLVMEYYPNGSLCKYLSLHTSDWVSSCRLAHSVTRGLAYLHTELPRGDHYKPAISHRDLNSRNVLVKNDGTCVISDFGLSMRLTGNRLVRPGEEDNAAISEVGTIRYMAPEVLEGAVNLRDCESALKQVDMYALGLIYWEIFMRCTDLFPGESVPEYQMAFQTEVGNHPTFEDMQVLVSREKQRPKFPEAWKENSLAVRSLKETIEDCWDQDAEARLTAQCAEERMAELMMIWERNKSVSPTVNPMSTAMQNERNLSHNRRVPKIGPYPDYSSSSYIEDSIHHTDSIVKNISSEHSMSSTPLTIGEKNRNSINYERQQAQARIPSPETSVTSLSTNTTTTNTTGLTPSTGMTTISEMPYPDETNLHTTNVAQSIGPTPVCLQLTEEDLETNKLDPKEVDKNLKESSDENLMEHSLKQFSGPDPLSSTSSSLLYPLIKLAVEATGQQDFTQTANGQACLIPDVLPTQIYPLPKQQNLPKRPTSLPLNTKNSTKEPRLKFGSKHKSNLKQVETGVAKMNTINAAEPHVVTVTMNGVAGRNHSVNSHAATTQYANGTVLSGQTTNIVTHRAQEMLQNQFIGEDTRLNINSSPDEHEPLLRREQQAGHDEGVLDRLVDRRERPLEGGRTNSNNNNSNPCSEQDVLAQGVPSTAADPGPSKPRRAQRPNSLDLSATNVLDGSSIQIGESTQDGKSGSGEKIKKRVKTPYSLKRWRPSTWVISTESLDCEVNNNGSNRAVHSKSSTAVYLAEGGTATTMVSKDIGMNCL T60213 DRUGINFO D00LZY AA-184 Investigative T60213 DRUGINFO D04JCT AA-204 Investigative T60213 DRUGINFO D0B8ES AA-123 Investigative T60213 DRUGINFO D0F8VH AA-166 Investigative T60213 DRUGINFO D0RF7O ML347 Investigative T60213 DRUGINFO D06CMG LDN-214117 Investigative T60213 DRUGINFO D05NEC PMID23639540C13r Investigative T60213 DRUGINFO D0F2MP PMID23639540C13d Investigative T60213 DRUGINFO D0PP6Y PMID23639540C13a Investigative T07087 TARGETID T07087 T07087 FORMERID TTDI02472 T07087 UNIPROID FAK2_HUMAN T07087 TARGNAME Focal adhesion kinase 2 (PTK2B) T07087 GENENAME PTK2B T07087 TARGTYPE Literature-reported T07087 SYNONYMS Related adhesion focal tyrosine kinase; RAFTK; Protein-tyrosine kinase 2-beta; Proline-rich tyrosine kinase 2; PYK2; FAK2; FADK 2; Cell adhesion kinase beta; Calcium-regulated non-receptor proline-rich tyrosine kinase; Calcium-dependent tyrosine kinase; CAKB; CAK-beta; CADTK T07087 FUNCTION Plays a role in the regulation of the humoral immune response, and is required for normal levels of marginal B-cells in the spleen and normal migration of splenic B-cells. Required for normal macrophage polarization and migration towards sites of inflammation. Regulates cytoskeleton rearrangement and cell spreading in T-cells, and contributes to the regulation of T-cell responses. Promotes osteoclastic bone resorption; this requires both PTK2B/PYK2 and SRC. May inhibit differentiation and activity of osteoprogenitor cells. Functions in signaling downstream of integrin and collagen receptors, immune receptors, G-protein coupled receptors (GPCR), cytokine, chemokine and growth factor receptors, and mediates responses to cellular stress. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and of the AKT1 signaling cascade. Promotes activation of NOS3. Regulates production of the cellular messenger cGMP. Promotes activation of the MAP kinase signaling cascade, including activation of MAPK1/ERK2, MAPK3/ERK1 and MAPK8/JNK1. Promotes activation of Rho family GTPases, such as RHOA and RAC1. Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Acts as a scaffold, binding to both PDPK1 and SRC, thereby allowing SRC to phosphorylate PDPK1 at 'Tyr-9, 'Tyr-373', and 'Tyr-376'. Promotes phosphorylation of NMDA receptors by SRC family members, and thereby contributes to the regulation of NMDA receptor ion channel activity and intracellular Ca(2+) levels. May also regulate potassium ion transport by phosphorylation of potassium channel subunits. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ASAP1, NPHP1, KCNA2 and SHC1. Promotes phosphorylation of ASAP2, RHOU and PXN; this requires both SRC and PTK2/PYK2. Non-receptor protein-tyrosine kinase that regulates reorganization of the actin cytoskeleton, cell polarization, cell migration, adhesion, spreading and bone remodeling. T07087 PDBSTRUC 5TOB; 5TO8; 4XEV; 4XEK; 4XEF T07087 BIOCLASS Kinase T07087 ECNUMBER EC 2.7.10.2 T07087 SEQUENCE MSGVSEPLSRVKLGTLRRPEGPAEPMVVVPVDVEKEDVRILKVCFYSNSFNPGKNFKLVKCTVQTEIREIITSILLSGRIGPNIRLAECYGLRLKHMKSDEIHWLHPQMTVGEVQDKYECLHVEAEWRYDLQIRYLPEDFMESLKEDRTTLLYFYQQLRNDYMQRYASKVSEGMALQLGCLELRRFFKDMPHNALDKKSNFELLEKEVGLDLFFPKQMQENLKPKQFRKMIQQTFQQYASLREEECVMKFFNTLAGFANIDQETYRCELIQGWNITVDLVIGPKGIRQLTSQDAKPTCLAEFKQIRSIRCLPLEEGQAVLQLGIEGAPQALSIKTSSLAEAENMADLIDGYCRLQGEHQGSLIIHPRKDGEKRNSLPQIPMLNLEARRSHLSESCSIESDIYAEIPDETLRRPGGPQYGIAREDVVLNRILGEGFFGEVYEGVYTNHKGEKINVAVKTCKKDCTLDNKEKFMSEAVIMKNLDHPHIVKLIGIIEEEPTWIIMELYPYGELGHYLERNKNSLKVLTLVLYSLQICKAMAYLESINCVHRDIAVRNILVASPECVKLGDFGLSRYIEDEDYYKASVTRLPIKWMSPESINFRRFTTASDVWMFAVCMWEILSFGKQPFFWLENKDVIGVLEKGDRLPKPDLCPPVLYTLMTRCWDYDPSDRPRFTELVCSLSDVYQMEKDIAMEQERNARYRTPKILEPTAFQEPPPKPSRPKYRPPPQTNLLAPKLQFQVPEGLCASSPTLTSPMEYPSPVNSLHTPPLHRHNVFKRHSMREEDFIQPSSREEAQQLWEAEKVKMRQILDKQQKQMVEDYQWLRQEEKSLDPMVYMNDKSPLTPEKEVGYLEFTGPPQKPPRLGAQSIQPTANLDRTDDLVYLNVMELVRAVLELKNELCQLPPEGYVVVVKNVGLTLRKLIGSVDDLLPSLPSSSRTEIEGTQKLLNKDLAELINKMRLAQQNAVTSLSEECKRQMLTASHTLAVDAKNLLDAVDQAKVLANLAHPPAE T07087 DRUGINFO D00SEC aloisine Investigative T67231 TARGETID T67231 T67231 FORMERID TTDR00712 T67231 UNIPROID MBTP1_HUMAN T67231 TARGNAME Endopeptidase S1P (MBTPS1) T67231 GENENAME MBTPS1 T67231 TARGTYPE Literature-reported T67231 SYNONYMS Subtilisin/kexin-isozyme-1; Subtilisin/kexin-isozyme 1; Site-1 protease; SKI1; SKI-1; S1P; Membrane-bound transcription factor site-1 protease; KIAA0091 T67231 FUNCTION Other known substrates are BDNF, GNPTAB and ATF6. Cleaves after hydrophobic or small residues, provided that Arg or Lys is in position P4. Cleaves known substrates after Arg-Ser-Val-Leu (SERBP-2), Arg-His-Leu-Leu (ATF6), Arg-Gly-Leu-Thr (BDNF) and its own propeptide after Arg-Arg-Leu-Leu. Mediates the protein cleavage of GNPTAB into subunit alpha and beta, thereby participating in biogenesis of lysosomes. Serine protease that catalyzes the first step in the proteolytic activation of the sterol regulatory element-binding proteins (SREBPs). T67231 BIOCLASS Peptidase T67231 ECNUMBER EC 3.4.21.112 T67231 SEQUENCE MKLVNIWLLLLVVLLCGKKHLGDRLEKKSFEKAPCPGCSHLTLKVEFSSTVVEYEYIVAFNGYFTAKARNSFISSALKSSEVDNWRIIPRNNPSSDYPSDFEVIQIKEKQKAGLLTLEDHPNIKRVTPQRKVFRSLKYAESDPTVPCNETRWSQKWQSSRPLRRASLSLGSGFWHATGRHSSRRLLRAIPRQVAQTLQADVLWQMGYTGANVRVAVFDTGLSEKHPHFKNVKERTNWTNERTLDDGLGHGTFVAGVIASMRECQGFAPDAELHIFRVFTNNQVSYTSWFLDAFNYAILKKIDVLNLSIGGPDFMDHPFVDKVWELTANNVIMVSAIGNDGPLYGTLNNPADQMDVIGVGGIDFEDNIARFSSRGMTTWELPGGYGRMKPDIVTYGAGVRGSGVKGGCRALSGTSVASPVVAGAVTLLVSTVQKRELVNPASMKQALIASARRLPGVNMFEQGHGKLDLLRAYQILNSYKPQASLSPSYIDLTECPYMWPYCSQPIYYGGMPTVVNVTILNGMGVTGRIVDKPDWQPYLPQNGDNIEVAFSYSSVLWPWSGYLAISISVTKKAASWEGIAQGHVMITVASPAETESKNGAEQTSTVKLPIKVKIIPTPPRSKRVLWDQYHNLRYPPGYFPRDNLRMKNDPLDWNGDHIHTNFRDMYQHLRSMGYFVEVLGAPFTCFDASQYGTLLMVDSEEEYFPEEIAKLRRDVDNGLSLVIFSDWYNTSVMRKVKFYDENTRQWWMPDTGGANIPALNELLSVWNMGFSDGLYEGEFTLANHDMYYASGCSIAKFPEDGVVITQTFKDQGLEVLKQETAVVENVPILGLYQIPAEGGGRIVLYGDSNCLDDSHRQKDCFWLLDALLQYTSYGVTPPSLSHSGNRQRPPSGAGSVTPERMEGNHLHRYSKVLEAHLGDPKPRPLPACPRLSWAKPQPLNETAPSNLWKHQKLLSIDLDKVVLPNFRSNRPQVRPLSPGESGAWDIPGGIMPGRYNQEVGQTIPVFAFLGAMVVLAFFVVQINKAKSRPKRRKPRVKRPQLMQQVHPPKTPSV T67231 DRUGINFO D0P7NY PF-429242 Investigative T61243 TARGETID T61243 T61243 FORMERID TTDR00821 T61243 UNIPROID GRM7_HUMAN T61243 TARGNAME Metabotropic glutamate receptor 7 (mGluR7) T61243 GENENAME GRM7 T61243 TARGTYPE Literature-reported T61243 SYNONYMS mGluR7; GPRC1G T61243 FUNCTION Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for glutamate. T61243 PDBSTRUC 5C5C; 3MQ4 T61243 BIOCLASS GPCR glutamate T61243 SEQUENCE MVQLRKLLRVLTLMKFPCCVLEVLLCALAAAARGQEMYAPHSIRIEGDVTLGGLFPVHAKGPSGVPCGDIKRENGIHRLEAMLYALDQINSDPNLLPNVTLGARILDTCSRDTYALEQSLTFVQALIQKDTSDVRCTNGEPPVFVKPEKVVGVIGASGSSVSIMVANILRLFQIPQISYASTAPELSDDRRYDFFSRVVPPDSFQAQAMVDIVKALGWNYVSTLASEGSYGEKGVESFTQISKEAGGLCIAQSVRIPQERKDRTIDFDRIIKQLLDTPNSRAVVIFANDEDIKQILAAAKRADQVGHFLWVGSDSWGSKINPLHQHEDIAEGAITIQPKRATVEGFDAYFTSRTLENNRRNVWFAEYWEENFNCKLTISGSKKEDTDRKCTGQERIGKDSNYEQEGKVQFVIDAVYAMAHALHHMNKDLCADYRGVCPEMEQAGGKKLLKYIRNVNFNGSAGTPVMFNKNGDAPGRYDIFQYQTTNTSNPGYRLIGQWTDELQLNIEDMQWGKGVREIPASVCTLPCKPGQRKKTQKGTPCCWTCEPCDGYQYQFDEMTCQHCPYDQRPNENRTGCQDIPIIKLEWHSPWAVIPVFLAMLGIIATIFVMATFIRYNDTPIVRASGRELSYVLLTGIFLCYIITFLMIAKPDVAVCSFRRVFLGLGMCISYAALLTKTNRIYRIFEQGKKSVTAPRLISPTSQLAITSSLISVQLLGVFIWFGVDPPNIIIDYDEHKTMNPEQARGVLKCDITDLQIICSLGYSILLMVTCTVYAIKTRGVPENFNEAKPIGFTMYTTCIVWLAFIPIFFGTAQSAEKLYIQTTTLTISMNLSASVALGMLYMPKVYIIIFHPELNVQKRKRSFKAVVTAATMSSRLSHKPSDRPNGEAKTELCENVDPNSPAAKKKYVSYNNLVI T61243 DRUGINFO D02ETA AMN082 Investigative T61243 DRUGINFO D08UOW MMPIP Investigative T61243 DRUGINFO D0K2XD ADX71743 Investigative T61243 DRUGINFO D0R2DP XAP044 Investigative T61243 DRUGINFO D0S8HE MSOPPE Investigative T61243 DRUGINFO D0W2TQ PPG Investigative T61243 DRUGINFO D0YO8B MCCG Investigative T61243 DRUGINFO D0KL4K LSP4-2022 Investigative T61243 DRUGINFO D0XG6U LSP1-2111 Investigative T61243 DRUGINFO D09SXN MAP4 Investigative T61243 DRUGINFO D0D2GL MPPG Investigative T61243 DRUGINFO D0N9UZ [3H]LY341495 Investigative T61243 DRUGINFO D0O8AK alpha-methylserine-O-phosphate Investigative T61243 DRUGINFO D0PN6Z L-AP4 Investigative T61243 DRUGINFO D0J8OW (+)-MCPG Investigative T61243 DRUGINFO D04DKM (1S,3R)-ACPD Investigative T61243 DRUGINFO D06DUE [3H]quisqualate Investigative T61243 DRUGINFO D0Z7CZ L-CCG-I Investigative T61243 DRUGINFO D07PZQ L-serine-O-phosphate Investigative T17967 TARGETID T17967 T17967 FORMERID TTDI02231 T17967 UNIPROID PDK2_HUMAN T17967 TARGNAME Pyruvate dehydrogenase kinase 2 (PDHK2) T17967 GENENAME PDK2 T17967 TARGTYPE Literature-reported T17967 SYNONYMS PDKII; PDK2; PDH kinase 2; [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial T17967 FUNCTION Kinase that plays a key role in the regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate. Inhibition of pyruvate dehydrogenase decreases glucose utilization and increases fat metabolism. Mediates cellular responses to insulin. Plays an important role in maintaining normal blood glucose levels and in metabolic adaptation to nutrient availability. Via its regulation of pyruvate dehydrogenase activity, plays an important role in maintaining normal blood pH and in preventing the accumulation of ketone bodies under starvation. Plays a role in the regulation of cell proliferation and in resistance to apoptosis under oxidative stress. Plays a role in p53/TP53-mediated apoptosis. T17967 PDBSTRUC 5M4P; 5M4N; 5M4M; 5M4K; 5J71 T17967 BIOCLASS Kinase T17967 ECNUMBER EC 2.7.11.2 T17967 SEQUENCE MRWVWALLKNASLAGAPKYIEHFSKFSPSPLSMKQFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLDIMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYFLDRFYLSRISIRMLINQHTLIFDGSTNPAHPKHIGSIDPNCNVSEVVKDAYDMAKLLCDKYYMASPDLEIQEINAANSKQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLILPPIKVMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPGTGGTPLAGFGYGLPISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS T17967 DRUGINFO D03GFC AZD-7545 Terminated T55826 TARGETID T55826 T55826 FORMERID TTDR00226 T55826 UNIPROID Q8I566_PLAF7 T55826 TARGNAME Plasmodium Serine hydroxymethyltransferase (Malaria SHMT) T55826 GENENAME Malaria SHMT T55826 TARGTYPE Literature-reported T55826 SYNONYMS Serine methylase; SHMT; Glycine hydroxymethyltransferase T55826 FUNCTION Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Required to prevent uracil accumulation in mtDNA. Interconversion of serine and glycine. Associates with mitochondrial DNA. T55826 PDBSTRUC 4O6Z T55826 BIOCLASS Methyltransferase T55826 ECNUMBER EC 2.1.2.1 T55826 SEQUENCE MFNNDPLQKYDKELFDLLEKEKNRQIETINLIASENLTNTAVRECLGDRISNKYSEGYPHKRYYGGNDYVDKIEELCYKRALEAFNVSEEEWGVNVQPLSGSAANVQALYALVGVKGKIMGMHLCSGGHLTHGFFDEKKKVSITSDLFESKLYKCNSEGYVDMESVRNLALSFQPKVIICGYTSYPRDIDYKGFREICDEVNAYLFADISHISSFVACNLLNNPFTYADVVTTTTHKILRGPRSALIFFNKKRNPGIDQKINSSVFPSFQGGPHNNKIAAVACQLKEVNTPFFKEYTKQVLLNSKALAECLLKRNLDLVTNGTDNHLIVVDLRKYNITGSKLQETCNAINIALNKNTIPSDVDCVSPSGIRIGTPALTTRGCKEKDMEFIADMLLKAILLTDELQQKYGKKLVDFKKGLVNNPKIDELKKEVVQWAKNLPFA T55826 DRUGINFO D04ZWL Mimosine Terminated T98275 TARGETID T98275 T98275 FORMERID TTDI01825 T98275 UNIPROID KAT6B_HUMAN T98275 TARGNAME Histone acetyltransferase KAT6B (KAT6B) T98275 GENENAME KAT6B T98275 TARGTYPE Literature-reported T98275 SYNONYMS KAT6B T98275 FUNCTION Functions as histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Mediates acetylation of histone H3 at 'Lys-122' (H3K122ac), a modification that localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Mediates acetylation of histone H3 at 'Lys-27' (H3K27ac). Also functions as acetyltransferase for nonhistone targets. Acetylates 'Lys-131' of ALX1 and acts as its coactivator in the presence of CREBBP. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation ofSIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Acetylates FOXO1 and enhances its transcriptional activity. Acetylates BCL6 wich disrupts its ability to recruit histone deacetylases and hinders its transcriptional repressor activity. Participates in CLOCK or NPAS2-regulated rhythmic gene transcription; exhibits a circadian association with CLOCKor NPAS2, correlating with increase in PER1/2 mRNA and histone H3 acetylation on the PER1/2 promoter. Acetylates MTA1 at 'Lys-626' which is essential for its transcriptional coactivator activity (PubMed:10733570, PubMed:11430825, PubMed:11701890, PubMed:12402037, PubMed:12586840, PubMed:12929931, PubMed:14645221, PubMed:15186775, PubMed:15890677, PubMed:16617102, PubMed:16762839, PubMed:18722353,PubMed:18995842, PubMed:23415232, PubMed:23911289, PubMed:23934153, PubMed:8945521). Acetylates XBP1 isoform 2; acetylation increases protein stability of XBP1 isoform 2 and enhances its transcriptional activity. T98275 PDBSTRUC 5U2J T98275 BIOCLASS Acyltransferase T98275 ECNUMBER EC 2.3.1.48 T98275 SEQUENCE MVKLANPLYTEWILEAIQKIKKQKQRPSEERICHAVSTSHGLDKKTVSEQLELSVQDGSVLKVTNKGLASYKDPDNPGRFSSVKPGTFPKSAKGSRGSCNDLRNVDWNKLLRRAIEGLEEPNGSSLKNIEKYLRSQSDLTSTTNNPAFQQRLRLGAKRAVNNGRLLKDGPQYRVNYGSLDGKGAPQYPSAFPSSLPPVSLLPHEKDQPRADPIPICSFCLGTKESNREKKPEELLSCADCGSSGHPSCLKFCPELTTNVKALRWQCIECKTCSACRVQGRNADNMLFCDSCDRGFHMECCDPPLSRMPKGMWICQVCRPKKKGRKLLHEKAAQIKRRYAKPIGRPKNKLKQRLLSVTSDEGSMNAFTGRGSPGRGQKTKVCTTPSSGHAASGKDSSSRLAVTDPTRPGATTKITTTSTYISASTLKVNKKTKGLIDGLTKFFTPSPDGRRSRGEIIDFSKHYRPRKKVSQKQSCTSHVLATGTTQKLKPPPSSLPPPTPISGQSPSSQKSSTATSSPSPQSSSSQCSVPSLSSLTTNSQLKALFDGLSHIYTTQGQSRKKGHPSYAPPKRMRRKTELSSTAKSKAHFFGKRDIRSRFISHSSSSSWGMARGSIFKAIAHFKRTTFLKKHRMLGRLKYKVTPQMGTPSPGKGSLTDGRIKPDQDDDTEIKINIKQESADVNVIGNKDVVTEEDLDVFKQAQELSWEKIECESGVEDCGRYPSVIEFGKYEIQTWYSSPYPQEYARLPKLYLCEFCLKYMKSKNILLRHSKKCGWFHPPANEIYRRKDLSVFEVDGNMSKIYCQNLCLLAKLFLDHKTLYYDVEPFLFYVLTKNDEKGCHLVGYFSKEKLCQQKYNVSCIMIMPQHQRQGFGRFLIDFSYLLSRREGQAGSPEKPLSDLGRLSYLAYWKSVILEYLYHHHERHISIKAISRATGMCPHDIATTLQHLHMIDKRDGRFVIIRREKLILSHMEKLKTCSRANELDPDSLRWTPILISNAAVSEEEREAEKEAERLMEQASCWEKEEQEILSTRANSRQSPAKVQSKNKYLHSPESRPVTGERGQLLELSKESSEEEEEEEDEEEEEEEEEEEEDEEEEEEEEEEEEEENIQSSPPRLTKPQSVAIKRKRPFVLKKKRGRKRRRINSSVTTETISETTEVLNEPFDNSDEERPMPQLEPTCEIEVEEDGRKPVLRKAFQHQPGKKRQTEEEEGKDNHCFKNADPCRNNMNDDSSNLKEGSKDNPEPLKCKQVWPKGTKRGLSKWRQNKERKTGFKLNLYTPPETPMEPDEQVTVEEQKETSEGKTSPSPIRIEEEVKETGEALLPQEENRREETCAPVSPNTSPGEKPEDDLIKPEEEEEEEEEEEEEEEEEEGEEEEGGGNVEKDPDGAKSQEKEEPEISTEKEDSARLDDHEEEEEEDEEPSHNEDHDADDEDDSHMESAEVEKEELPRESFKEVLENQETFLDLNVQPGHSNPEVLMDCGVDLTASCNSEPKELAGDPEAVPESDEEPPPGEQAQKQDQKNSKEVDTEFKEGNPATMEIDSETVQAVQSLTQESSEQDDTFQDCAETQEACRSLQNYTRADQSPQIATTLDDCQQSDHSSPVSSVHSHPGQSVRSVNSPSVPALENSYAQISPDQSAISVPSLQNMETSPMMDVPSVSDHSQQVVDSGFSDLGSIESTTENYENPSSYDSTMGGSICGNGSSQNSCSYSNLTSSSLTQSSCAVTQQMSNISGSCSMLQQTSISSPPTCSVKSPQGCVVERPPSSSQQLAQCSMAANFTPPMQLAEIPETSNANIGLYERMGQSDFGAGHYPQPSATFSLAKLQQLTNTLIDHSLPYSHSAAVTSYANSASLSTPLSNTGLVQLSQSPHSVPGGPQAQATMTPPPNLTPPPMNLPPPLLQRNMAASNIGISHSQRLQTQIASKGHISMRTKSASLSPAAATHQSQIYGRSQTVAMQGPARTLTMQRGMNMSVNLMPAPAYNVNSVNMNMNTLNAMNGYSMSQPMMNSGYHSNHGYMNQTPQYPMQMQMGMMGTQPYAQQPMQTPPHGNMMYTAPGHHGYMNTGMSKQSLNGSYMRR T98275 DRUGINFO D0YL8Z C646 Investigative T98275 DRUGINFO D0Z3MT MG149 Investigative T98275 DRUGINFO D03JNC garcinol Investigative T98275 DRUGINFO D03XXT SGC-CBP30 Investigative T98275 DRUGINFO D0E6JS anacardic acid Investigative T98275 DRUGINFO D0J3JI I-CBP112 Investigative T16902 TARGETID T16902 T16902 FORMERID TTDI00174 T16902 UNIPROID KAT2B_HUMAN T16902 TARGNAME Histone acetyltransferase KAT2B (KAT2B) T16902 GENENAME KAT2B T16902 TARGTYPE Literature-reported T16902 SYNONYMS Spermidine acetyltransferase KAT2B; PCAF; P300/CBP-associated factor; P/CAF; Lysine acetyltransferase 2B; Histone acetyltransferase PCAF; Histone acetylase PCAF T16902 FUNCTION Has significant histone acetyltransferase activity with core histones (H3 and H4), and also with nucleosome core particles. Also acetylates non-histone proteins, such as ACLY, PLK4 and TBX5. Inhibits cell-cycle progression and counteracts the mitogenic activity of the adenoviral oncoprotein E1A. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers. Involved in heart and limb development by mediating acetylation of TBX5, acetylation regulating nucleocytoplasmic shuttling of TBX5. Acts as a negative regulator of centrosome amplification by mediating acetylation of PLK4. Also acetylates spermidine. Functions as a histone acetyltransferase (HAT) to promote transcriptional activation. T16902 PDBSTRUC 6J3O; 5MKX; 5LVR; 5LVQ; 5FE9 T16902 BIOCLASS Acyltransferase T16902 ECNUMBER EC 2.3.1.48 T16902 SEQUENCE MSEAGGAGPGGCGAGAGAGAGPGALPPQPAALPPAPPQGSPCAAAAGGSGACGPATAVAAAGTAEGPGGGGSARIAVKKAQLRSAPRAKKLEKLGVYSACKAEESCKCNGWKNPNPSPTPPRADLQQIIVSLTESCRSCSHALAAHVSHLENVSEEEMNRLLGIVLDVEYLFTCVHKEEDADTKQVYFYLFKLLRKSILQRGKPVVEGSLEKKPPFEKPSIEQGVNNFVQYKFSHLPAKERQTIVELAKMFLNRINYWHLEAPSQRRLRSPNDDISGYKENYTRWLCYCNVPQFCDSLPRYETTQVFGRTLLRSVFTVMRRQLLEQARQEKDKLPLEKRTLILTHFPKFLSMLEEEVYSQNSPIWDQDFLSASSRTSQLGIQTVINPPPVAGTISYNSTSSSLEQPNAGSSSPACKASSGLEANPGEKRKMTDSHVLEEAKKPRVMGDIPMELINEVMSTITDPAAMLGPETNFLSAHSARDEAARLEERRGVIEFHVVGNSLNQKPNKKILMWLVGLQNVFSHQLPRMPKEYITRLVFDPKHKTLALIKDGRVIGGICFRMFPSQGFTEIVFCAVTSNEQVKGYGTHLMNHLKEYHIKHDILNFLTYADEYAIGYFKKQGFSKEIKIPKTKYVGYIKDYEGATLMGCELNPRIPYTEFSVIIKKQKEIIKKLIERKQAQIRKVYPGLSCFKDGVRQIPIESIPGIRETGWKPSGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLIDK T16902 DRUGINFO D07JMJ PMID15724976C1 Investigative T16902 DRUGINFO D0G4ET MB-3 Investigative T16902 DRUGINFO D0M6YZ LTK-14 Investigative T16902 DRUGINFO D03JNC garcinol Investigative T16902 DRUGINFO D0E6JS anacardic acid Investigative T53612 TARGETID T53612 T53612 FORMERID TTDR01120 T53612 UNIPROID KLK6_HUMAN T53612 TARGNAME Kallikrein-6 (KLK6) T53612 GENENAME KLK6 T53612 TARGTYPE Literature-reported T53612 SYNONYMS Zyme; Serine protease 9; Serine protease 18; SP59; Protease M; PRSS9; PRSS18; Neurosin; MSP; K6 T53612 FUNCTION Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis. Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. T53612 PDBSTRUC 6QHC; 6QHB; 6QHA; 6QH9; 6QFH T53612 BIOCLASS Peptidase T53612 ECNUMBER EC 3.4.21.- T53612 SEQUENCE MKKLMVVLSLIAAAWAEEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTAAHCKKPNLQVFLGKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHILGWGKTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNMLCAGDEKYGKDSCQGDSGGPLVCGDHLRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQKTIQAK T53612 DRUGINFO D00HWJ PMID24900446C5 Investigative T53612 DRUGINFO D07SFI Benzamidine Investigative T61792 TARGETID T61792 T61792 FORMERID TTDR00020 T61792 UNIPROID MRP2_HUMAN T61792 TARGNAME Multidrug resistance-associated protein 2 (ABCC2) T61792 GENENAME ABCC2 T61792 TARGTYPE Literature-reported T61792 SYNONYMS MRP2; Canalicular multispecific organic anion transporter 1; Canalicular multidrug resistance protein; CMRP; CMOAT1; CMOAT; ATP-binding cassette, sub-family C, member 2; ATP-binding cassette sub-family C member 2 T61792 FUNCTION May function as a cellular cisplatin transporter. Mediates hepatobiliary excretion of numerous organic anions. T61792 BIOCLASS ABC transporter T61792 ECNUMBER EC 7.6.2.2 T61792 SEQUENCE MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLHVYKSRTKRSSTTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYSRQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILIFSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVSKFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSGTKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIGYLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGETVNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAILSTKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFSQLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMISSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLDIMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNILFGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLDIYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIVEKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAASITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETGKVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQRDMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRIVNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMFYVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSWITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTSEIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGITCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTIIPQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIGQRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMDSDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF T30414 TARGETID T30414 T30414 FORMERID TTDR00111 T30414 UNIPROID PAR4_HUMAN T30414 TARGNAME Proteinase activated receptor 4 (F2RL3) T30414 GENENAME F2RL3 T30414 TARGTYPE Literature-reported T30414 SYNONYMS Thrombin receptor-like 3; Protease activated receptor 4; F2RL3; Coagulation factor II receptor-like3 T30414 FUNCTION Receptor for activated thrombin or trypsin coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelets activation. T30414 PDBSTRUC 3QDZ; 2ZPK T30414 BIOCLASS GPCR rhodopsin T30414 SEQUENCE MWGRLLLWPLVLGFSLSGGTQTPSVYDESGSTGGGDDSTPSILPAPRGYPGQVCANDSDTLELPDSSRALLLGWVPTRLVPALYGLVLVVGLPANGLALWVLATQAPRLPSTMLLMNLAAADLLLALALPPRIAYHLRGQRWPFGEAACRLATAALYGHMYGSVLLLAAVSLDRYLALVHPLRARALRGRRLALGLCMAAWLMAAALALPLTLQRQTFRLARSDRVLCHDALPLDAQASHWQPAFTCLALLGCFLPLLAMLLCYGATLHTLAASGRRYGHALRLTAVVLASAVAFFVPSNLLLLLHYSDPSPSAWGNLYGAYVPSLALSTLNSCVDPFIYYYVSAEFRDKVRAGLFQRSPGDTVASKASAEGGSRGMGTHSSLLQ T30414 DRUGINFO D0G9BX SC-47643 Terminated T30414 DRUGINFO D00KRL Ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate Investigative T84359 TARGETID T84359 T84359 FORMERID TTDR00972 T84359 UNIPROID KCY_STRPN T84359 TARGNAME Streptococcus Cytidylate kinase (Stre-coc cmk) T84359 GENENAME Stre-coc cmk T84359 TARGTYPE Literature-reported T84359 SYNONYMS cmk; TIGR4; MssA protein; Cytidine monophosphate kinase; CMP kinase T84359 FUNCTION Atp, datp, and gtp are equally effective as phosphate donors. Cmp and dcmp are the best phosphate acceptors. T84359 PDBSTRUC 1Q3T T84359 BIOCLASS Kinase T84359 ECNUMBER EC 2.7.4.25 T84359 SEQUENCE MKTIQIAIDGPASSGKSTVAKIIAKDFGFTYLDTGAMYRAATYMALKNQLGVEEVEALLALLDQHPISFGRSETGDQLVFVGDVDITHPIRENEVTNHVSAIAAIPQVREKLVSLQQEIAQQGGIVMDGRDIGTVVLPQAELKIFLVASVDERAERRYKENIAKGIETDLETLKKEIAARDYKDSHRETSPLKQAEDAVYLDTTGLNIQEVVEKIKAEAEKRM T84359 DRUGINFO D03SAZ Cytosine Arabinose-5'-Phosphate Investigative T84359 DRUGINFO D09ZMS 2',3'-Dideoxycytidine-5'-Monophosphate Investigative T84359 DRUGINFO D07XZT Cytidine-5'-Diphosphate Investigative T84359 DRUGINFO D0S2QZ Cytidine-5'-Monophosphate Investigative T77139 TARGETID T77139 T77139 FORMERID TTDR01005 T77139 UNIPROID M3K3_HUMAN T77139 TARGNAME MAPK/ERK kinase kinase 3 (MAP3K3) T77139 GENENAME MAP3K3 T77139 TARGTYPE Literature-reported T77139 SYNONYMS Mitogen-activated protein kinase kinase kinase 3; MEKK3; MEKK 3; MEK kinase 3; MAPKKK3 T77139 FUNCTION Mediates activation of the NF-kappa-B, AP1 and DDIT3 transcriptional regulators. Component of a protein kinase signal transduction cascade. T77139 PDBSTRUC 4YL6; 4Y5O; 2PPH; 2O2V; 2JRH T77139 BIOCLASS Kinase T77139 ECNUMBER EC 2.7.11.25 T77139 SEQUENCE MDEQEALNSIMNDLVALQMNRRHRMPGYETMKNKDTGHSNRQSDVRIKFEHNGERRIIAFSRPVKYEDVEHKVTTVFGQPLDLHYMNNELSILLKNQDDLDKAIDILDRSSSMKSLRILLLSQDRNHNSSSPHSGVSRQVRIKASQSAGDINTIYQPPEPRSRHLSVSSQNPGRSSPPPGYVPERQQHIARQGSYTSINSEGEFIPETSEQCMLDPLSSAENSLSGSCQSLDRSADSPSFRKSRMSRAQSFPDNRQEYSDRETQLYDKGVKGGTYPRRYHVSVHHKDYSDGRRTFPRIRRHQGNLFTLVPSSRSLSTNGENMGLAVQYLDPRGRLRSADSENALSVQERNVPTKSPSAPINWRRGKLLGQGAFGRVYLCYDVDTGRELASKQVQFDPDSPETSKEVSALECEIQLLKNLQHERIVQYYGCLRDRAEKTLTIFMEYMPGGSVKDQLKAYGALTESVTRKYTRQILEGMSYLHSNMIVHRDIKGANILRDSAGNVKLGDFGASKRLQTICMSGTGMRSVTGTPYWMSPEVISGEGYGRKADVWSLGCTVVEMLTEKPPWAEYEAMAAIFKIATQPTNPQLPSHISEHGRDFLRRIFVEARQRPSAEELLTHHFAQLMY T77139 DRUGINFO D08TVU PMID20483621C5n Investigative T94594 TARGETID T94594 T94594 FORMERID TTDR01157 T94594 UNIPROID NADD_PSEAE T94594 TARGNAME Pseudomonas Nicotinate-nucleotide adenylyltransferase (Pseudo nadD) T94594 GENENAME Pseudo nadD T94594 TARGTYPE Literature-reported T94594 SYNONYMS nadD of Pseudomonas aeruginosa; Nicotinic acid mononucleotide adenylyltransferase of Pseudomonas aeruginosa; Nicotinatemononucleotide adenylyltransferase of Pseudomonas aeruginosa; Nicotinate-nucleotide adenylyltransferase of Pseudomonas aeruginosa; NaMN-Atase; NaMN adenylyltransferase of Pseudomonas aeruginosa; NaMN AT of Pseudomonas aeruginosa; Deamido-NAD(+) pyrophosphorylase of Pseudomonas aeruginosa; Deamido-NAD(+) diphosphorylase of Pseudomonas aeruginosa T94594 FUNCTION Catalyzes the reversible adenylation of nicotinate mononucleotide (NaMN) to nicotinic acid adenine dinucleotide (NaAD). T94594 PDBSTRUC 1YUN; 1YUM; 1YUL T94594 BIOCLASS Kinase T94594 ECNUMBER EC 2.7.7.18 T94594 SEQUENCE MGKRIGLFGGTFDPVHIGHMRSAVEMAEQFALDELRLLPNARPPHRETPQVSAAQRLAMVERAVAGVERLTVDPRELQRDKPSYTIDTLESVRAELAADDQLFMLIGWDAFCGLPTWHRWEALLDHCHIVVLQRPDADSEPPESLRDLLAARSVADPQALKGPGGQITFVWQTPLAVSATQIRALLGAGRSVRFLVPDAVLNYIEAHHLYRAPH T94594 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T44614 TARGETID T44614 T44614 FORMERID TTDR00606 T44614 UNIPROID Q9N6S8_PLAFA T44614 TARGNAME Plasmodium Cysteine protease falcipain-2 (Malaria CPF2) T44614 GENENAME Malaria CPF2 T44614 TARGTYPE Literature-reported T44614 SYNONYMS Falcipain 2; Cysteine proteinase falcipain 2a T44614 FUNCTION A papain family cysteine protease and important hemoglobinase of erythrocytic Plasmodium falciparum parasites. T44614 PDBSTRUC 3PNR; 3BPF; 2GHU; 1YVB T44614 BIOCLASS Protease T44614 ECNUMBER EC 3.4.22.- T44614 SEQUENCE MDYNMDYAPHEVISQQGERFVDKYVDRKILKNKKSLLVIISLSVLSVVGFVLFYFTPNSRKSDLFKNSSVENNNDDYIINSLLKSPNGKKFIVSKIDEALSFYDSKKNDINKYNEGNNNNNADFKGLSLFKENTPSNNFIHNKDYFINFFDNKFLMNNAEHINQFYMFIKTNNKQYNSPNEMKERFQVFLQNAHKVNMHNNNKNSLYKKELNRFADLTYHEFKNKYLSLRSSKPLKNSKYLLDQMNYEEVIKKYRGEENFDHAAYDWRLHSGVTPVKDQKNCGSCWAFSSIGSVESQYAIRKNKLITLSEQELVDCSFKNYGCNGGLINNAFEDMIELGGICPDGDYPYVSDAPNLCNIDRCTEKYGIKNYLSVPDNKLKEALRFLGPISISVAVSDDFAFYKEGIFDGECGDQLNHAVMLVGFGMKEIVNPLTKKGEKHYYYIIKNSWGQQWGERGFINIETDESGLMRKCGLGTDAFIPLIE T44614 DRUGINFO D04ZIJ Pepstatin Terminated T44614 DRUGINFO D05TNI FITC-LMNNAEHINQFYMFI Investigative T44614 DRUGINFO D0PB3X Vinylsulphones Investigative T44614 DRUGINFO D08KCA Leupeptin Investigative T18390 TARGETID T18390 T18390 FORMERID TTDI00083 T18390 UNIPROID LATS2_HUMAN T18390 TARGNAME Large tumor suppressor homolog 2 (LATS2) T18390 GENENAME LATS2 T18390 TARGTYPE Literature-reported T18390 SYNONYMS Warts-like kinase; Serine/threonine-protein kinase kpm; Serine/threonine-protein kinase LATS2; Kinase phosphorylated during mitosis protein; KPM T18390 FUNCTION The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor. Phosphorylates SNAI1 in the nucleus leading to its nuclear retention and stabilization, which enhances its epithelial-mesenchymal transition and tumor cell invasion/migration activities. This tumor-promoting activity is independent of its effects upon YAP1 or WWTR1/TAZ. Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. T18390 PDBSTRUC 4ZRI T18390 BIOCLASS Kinase T18390 ECNUMBER EC 2.7.11.1 T18390 SEQUENCE MRPKTFPATTYSGNSRQRLQEIREGLKQPSKSSVQGLPAGPNSDTSLDAKVLGSKDATRQQQQMRATPKFGPYQKALREIRYSLLPFANESGTSAAAEVNRQMLQELVNAGCDQEMAGRALKQTGSRSIEAALEYISKMGYLDPRNEQIVRVIKQTSPGKGLMPTPVTRRPSFEGTGDSFASYHQLSGTPYEGPSFGADGPTALEEMPRPYVDYLFPGVGPHGPGHQHQHPPKGYGASVEAAGAHFPLQGAHYGRPHLLVPGEPLGYGVQRSPSFQSKTPPETGGYASLPTKGQGGPPGAGLAFPPPAAGLYVPHPHHKQAGPAAHQLHVLGSRSQVFASDSPPQSLLTPSRNSLNVDLYELGSTSVQQWPAATLARRDSLQKPGLEAPPRAHVAFRPDCPVPSRTNSFNSHQPRPGPPGKAEPSLPAPNTVTAVTAAHILHPVKSVRVLRPEPQTAVGPSHPAWVPAPAPAPAPAPAPAAEGLDAKEEHALALGGAGAFPLDVEYGGPDRRCPPPPYPKHLLLRSKSEQYDLDSLCAGMEQSLRAGPNEPEGGDKSRKSAKGDKGGKDKKQIQTSPVPVRKNSRDEEKRESRIKSYSPYAFKFFMEQHVENVIKTYQQKVNRRLQLEQEMAKAGLCEAEQEQMRKILYQKESNYNRLKRAKMDKSMFVKIKTLGIGAFGEVCLACKVDTHALYAMKTLRKKDVLNRNQVAHVKAERDILAEADNEWVVKLYYSFQDKDSLYFVMDYIPGGDMMSLLIRMEVFPEHLARFYIAELTLAIESVHKMGFIHRDIKPDNILIDLDGHIKLTDFGLCTGFRWTHNSKYYQKGSHVRQDSMEPSDLWDDVSNCRCGDRLKTLEQRARKQHQRCLAHSLVGTPNYIAPEVLLRKGYTQLCDWWSVGVILFEMLVGQPPFLAPTPTETQLKVINWENTLHIPAQVKLSPEARDLITKLCCSADHRLGRNGADDLKAHPFFSAIDFSSDIRKQPAPYVPTISHPMDTSNFDPVDEESPWNDASEGSTKAWDTLTSPNNKHPEHAFYEFTFRRFFDDNGYPFRCPKPSGAEASQAESSDLESSDLVDQTEGCQPVYV T18390 DRUGINFO D0R3MO PMID20684608C35 Investigative T91959 TARGETID T91959 T91959 UNIPROID SIR3_HUMAN T91959 TARGNAME NAD-dependent deacetylase sirtuin-3 (SIRT3) T91959 GENENAME SIRT3 T91959 TARGTYPE Literature-reported T91959 SYNONYMS hSIRT3; SIR2L3; SIR2-like protein 3; Regulatory protein SIR2 homolog 3 T91959 FUNCTION NAD-dependent protein deacetylase (PubMed:12186850, PubMed:12374852, PubMed:16788062, PubMed:18680753, PubMed:18794531, PubMed:23283301, PubMed:24121500, PubMed:24252090, PubMed:19535340). Activates or deactivates mitochondrial target proteins by deacetylating key lysine residues (PubMed:12186850, PubMed:12374852, PubMed:16788062, PubMed:18680753, PubMed:18794531, PubMed:23283301, PubMed:24121500, PubMed:24252090). Known targets include ACSS1, IDH, GDH, SOD2, PDHA1, LCAD, SDHA and the ATP synthase subunit ATP5PO (PubMed:16788062, PubMed:18680753, PubMed:24121500, PubMed:24252090, PubMed:19535340). Contributes to the regulation of the cellular energy metabolism (PubMed:24252090). Important for regulating tissue-specific ATP levels (PubMed:18794531). In response to metabolic stress, deacetylates transcription factor FOXO3 and recruits FOXO3 and mitochondrial RNA polymerase POLRMT to mtDNA to promote mtDNA transcription (PubMed:23283301). T91959 PDBSTRUC 6ISO; 5ZGC; 5Z94; 5Z93; 5YTK T91959 BIOCLASS Sirtuin family. Class I subfamily T91959 ECNUMBER EC 3.5.1.- T91959 SEQUENCE MAFWGWRAAAALRLWGRVVERVEAGGGVGPFQACGCRLVLGGRDDVSAGLRGSHGARGEPLDPARPLQRPPRPEVPRAFRRQPRAAAPSFFFSSIKGGRRSISFSVGASSVVGSGGSSDKGKLSLQDVAELIRARACQRVVVMVGAGISTPSGIPDFRSPGSGLYSNLQQYDLPYPEAIFELPFFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIPASKLVEAHGTFASATCTVCQRPFPGEDIRADVMADRVPRCPVCTGVVKPDIVFFGEPLPQRFLLHVVDFPMADLLLILGTSLEVEPFASLTEAVRSSVPRLLINRDLVGPLAWHPRSRDVAQLGDVVHGVESLVELLGWTEEMRDLVQRETGKLDGPDK T13795 TARGETID T13795 T13795 FORMERID TTDC00239 T13795 UNIPROID ACHA9_HUMAN T13795 TARGNAME Neuronal acetylcholine receptor alpha-9 (CHRNA9) T13795 GENENAME CHRNA9 T13795 TARGTYPE Literature-reported T13795 SYNONYMS Nicotinic acetylcholine receptor subunit alpha 9; NACHR alpha 9; CHRNA9 T13795 FUNCTION Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane (PubMed:11752216, PubMed:25282151). In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma. May also regulate keratinocyte adhesion (PubMed:11021840). T13795 PDBSTRUC 6HY7; 4UY2; 4UXU; 4D01 T13795 BIOCLASS Neurotransmitter receptor T13795 SEQUENCE MNWSHSCISFCWIYFAASRLRAAETADGKYAQKLFNDLFEDYSNALRPVEDTDKVLNVTLQITLSQIKDMDERNQILTAYLWIRQIWHDAYLTWDRDQYDGLDSIRIPSDLVWRPDIVLYNKADDESSEPVNTNVVLRYDGLITWDAPAITKSSCVVDVTYFPFDNQQCNLTFGSWTYNGNQVDIFNALDSGDLSDFIEDVEWEVHGMPAVKNVISYGCCSEPYPDVTFTLLLKRRSSFYIVNLLIPCVLISFLAPLSFYLPAASGEKVSLGVTILLAMTVFQLMVAEIMPASENVPLIGKYYIATMALITASTALTIMVMNIHFCGAEARPVPHWARVVILKYMSRVLFVYDVGESCLSPHHSRERDHLTKVYSKLPESNLKAARNKDLSRKKDMNKRLKNDLGCQGKNPQEAESYCAQYKVLTRNIEYIAKCLKDHKATNSKGSEWKKVAKVIDRFFMWIFFIMVFVMTILIIARAD T13795 DRUGINFO D09VJI [3H]methyllycaconitine Investigative T92460 TARGETID T92460 T92460 UNIPROID GUAD_HUMAN T92460 TARGNAME Guanine deaminase (GDA) T92460 GENENAME GDA T92460 TARGTYPE Literature-reported T92460 SYNONYMS p51-nedasin; KIAA1258; Guanine aminohydrolase; Guanase; GAH T92460 FUNCTION Catalyzes the hydrolytic deamination of guanine, producing xanthine and ammonia. T92460 PDBSTRUC 4AQL; 3E0L; 2UZ9 T92460 BIOCLASS Metallo-dependent hydrolase superfamily. ATZ/TRZ family T92460 ECNUMBER EC 3.5.4.3 T92460 SEQUENCE MCAAQMPPLAHIFRGTFVHSTWTCPMEVLRDHLLGVSDSGKIVFLEEASQQEKLAKEWCFKPCEIRELSHHEFFMPGLVDTHIHASQYSFAGSSIDLPLLEWLTKYTFPAEHRFQNIDFAEEVYTRVVRRTLKNGTTTACYFATIHTDSSLLLADITDKFGQRAFVGKVCMDLNDTFPEYKETTEESIKETERFVSEMLQKNYSRVKPIVTPRFSLSCSETLMGELGNIAKTRDLHIQSHISENRDEVEAVKNLYPSYKNYTSVYDKNNLLTNKTVMAHGCYLSAEELNVFHERGASIAHCPNSNLSLSSGFLNVLEVLKHEVKIGLGTDVAGGYSYSMLDAIRRAVMVSNILLINKVNEKSLTLKEVFRLATLGGSQALGLDGEIGNFEVGKEFDAILINPKASDSPIDLFYGDFFGDISEAVIQKFLYLGDDRNIEEVYVGGKQVVPFSSSV T73502 TARGETID T73502 T73502 FORMERID TTDR01340 T73502 UNIPROID WWP2_HUMAN T73502 TARGNAME WWP2 messenger RNA (WWP2 mRNA) T73502 GENENAME WWP2 T73502 TARGTYPE Literature-reported T73502 SYNONYMS WW domaincontaining protein 2 (mRNA); WW domain-containing protein 2 (mRNA); NEDD4like E3 ubiquitinprotein ligaseWWP2 (mRNA); HECT-type E3 ubiquitin transferase WWP2 (mRNA); Atrophin1interacting protein 2 (mRNA); Atrophin-1-interacting protein 2 (mRNA); AIP2 (mRNA) T73502 FUNCTION Polyubiquitinates POU5F1 by 'Lys-63'-linked conjugation and promotes it to proteasomal degradation; in embryonic stem cells (ESCs) the ubiquitination is proposed to regulate POU5F1 protein level. Ubiquitinates EGR2 and promotes it to proteasomal degradation; in T-cells the ubiquitination inhibits activation-induced cell death. Ubiquitinates SLC11A2; the ubiquitination is enhanced by presence of NDFIP1 and NDFIP2. Ubiquitinates RPB1 and promotes it to proteasomal degradation. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. T73502 PDBSTRUC 5TJQ; 5TJ8; 5TJ7; 4Y07 T73502 BIOCLASS mRNA target T73502 ECNUMBER EC 2.3.2.26 T73502 SEQUENCE MASASSSRAGVALPFEKSQLTLKVVSAKPKVHNRQPRINSYVEVAVDGLPSETKKTGKRIGSSELLWNEIIILNVTAQSHLDLKVWSCHTLRNELLGTASVNLSNVLKNNGGKMENMQLTLNLQTENKGSVVSGGELTIFLDGPTVDLGNVPNGSALTDGSQLPSRDSSGTAVAPENRHQPPSTNCFGGRSRTHRHSGASARTTPATGEQSPGARSRHRQPVKNSGHSGLANGTVNDEPTTATDPEEPSVVGVTSPPAAPLSVTPNPNTTSLPAPATPAEGEEPSTSGTQQLPAAAQAPDALPAGWEQRELPNGRVYYVDHNTKTTTWERPLPPGWEKRTDPRGRFYYVDHNTRTTTWQRPTAEYVRNYEQWQSQRNQLQGAMQHFSQRFLYQSSSASTDHDPLGPLPPGWEKRQDNGRVYYVNHNTRTTQWEDPRTQGMIQEPALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRPGFESGTKQGSPGAYDRSFRWKYHQFRFLCHSNALPSHVKISVSRQTLFEDSFQQIMNMKPYDLRRRLYIIMRGEEGLDYGGIAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQINPASSINPDHLTYFRFIGRFIAMALYHGKFIDTGFTLPFYKRMLNKRPTLKDLESIDPEFYNSIVWIKENNLEECGLELYFIQDMEILGKVTTHELKEGGESIRVTEENKEEYIMLLTDWRFTRGVEEQTKAFLDGFNEVAPLEWLRYFDEKELELMLCGMQEIDMSDWQKSTIYRHYTKNSKQIQWFWQVVKEMDNEKRIRLLQFVTGTCRLPVGGFAELIGSNGPQKFCIDKVGKETWLPRSHTCFNRLDLPPYKSYEQLREKLLYAIEETEGFGQE T73502 DRUGINFO D02LZA ISIS 103669 Investigative T73502 DRUGINFO D03IWY ISIS 103806 Investigative T73502 DRUGINFO D04WJM ISIS 103803 Investigative T73502 DRUGINFO D07WFF ISIS 103708 Investigative T73502 DRUGINFO D08CQR ISIS 103771 Investigative T73502 DRUGINFO D08CYT ISIS 103701 Investigative T73502 DRUGINFO D0DR3J ISIS 103752 Investigative T73502 DRUGINFO D0F5YL ISIS 103736 Investigative T73502 DRUGINFO D0F8GZ ISIS 103819 Investigative T73502 DRUGINFO D0J2ZI ISIS 103747 Investigative T73502 DRUGINFO D0M4LN ISIS 103671 Investigative T57292 TARGETID T57292 T57292 FORMERID TTDC00284 T57292 UNIPROID POL_HV1B1 T57292 TARGNAME Human immunodeficiency virus RT messenger RNA (HIV RT mRNA) T57292 GENENAME HIV RT mRNA T57292 TARGTYPE Literature-reported T57292 SYNONYMS gag-pol (588-1147) (mRNA); Pr160Gag-Pol (588-1147) (mRNA); Gag-Pol polyprotein (588-1147) (mRNA) T57292 FUNCTION Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation. Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). T57292 PDBSTRUC 6OE3; 6HAK; 6ELI; 6DUH; 6DUG T57292 BIOCLASS mRNA target T57292 ECNUMBER EC 2.7.7.49 T57292 SEQUENCE PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKIL T68227 TARGETID T68227 T68227 FORMERID TTDR01363 T68227 UNIPROID JUN_HUMAN T68227 TARGNAME c-Jun messenger RNA (c-Jun mRNA) T68227 GENENAME JUN T68227 TARGTYPE Literature-reported T68227 SYNONYMS V-jun avian sarcoma virus 17 oncogene homolog (mRNA); Transcription factor AP-1 (mRNA); Proto-oncogene c-jun (mRNA); P39 (mRNA); C-jun proto-oncogene (mRNA); Activator protein-1 (mRNA); Activator protein 1 (mRNA); AP1 (mRNA); AP-1 transcription factor (mRNA) T68227 FUNCTION Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. Binds to the USP28 promoter in colorectal cancer (CRC) cells. Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. T68227 PDBSTRUC 5T01; 5FV8; 1T2K; 1S9K; 1JNM T68227 BIOCLASS mRNA target T68227 SEQUENCE MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAELHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGALSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHVNSGCQLMLTQQLQTF T68227 DRUGINFO D04HFC [(R)-(+)-deoxytylophorinidine Investigative T68227 DRUGINFO D0B0PX ISIS 10582 Investigative T68227 DRUGINFO D0Y9AQ DCB-3503 Investigative T68227 DRUGINFO D0T1XE Pergularinine Investigative T64977 TARGETID T64977 T64977 FORMERID TTDI02245 T64977 UNIPROID IGF1R_HUMAN T64977 TARGNAME IGF1R messenger RNA (IGF1R mRNA) T64977 GENENAME IGF1R T64977 TARGTYPE Literature-reported T64977 SYNONYMS Type 1 insulin-like growth factor receptor (mRNA); Insulin-like growth factor 1 receptor (mRNA); IGF-IR (mRNA); IGF-I receptor (mRNA); IGF-1R (mRNA); IGF-1 receptor (mRNA); CD221 antigen (mRNA); CD221 (mRNA) T64977 FUNCTION Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R. Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). T64977 PDBSTRUC 5U8R; 5U8Q; 5HZN; 5FXS; 5FXR T64977 BIOCLASS mRNA target T64977 ECNUMBER EC 2.7.10.1 T64977 SEQUENCE MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLHILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGDLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCSAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHDGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTRNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDGQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSEILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRHNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFESRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTWEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGNYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHRKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRHSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC T64977 DRUGINFO D01QKD ATL-1101 Preclinical T64977 DRUGINFO D01ODR AG 1024 Investigative T64977 DRUGINFO D0B4SU PQ401 Investigative T64977 DRUGINFO D0E4LC GSK1511931 Investigative T64977 DRUGINFO D0O7LU AZD3463 Investigative T64977 DRUGINFO D06PJW GSK-1838705A Investigative T58074 TARGETID T58074 T58074 FORMERID TTDI02659 T58074 UNIPROID MMP2_HUMAN T58074 TARGNAME MMP2 messenger RNA (MMP2 mRNA) T58074 GENENAME MMP2 T58074 TARGTYPE Literature-reported T58074 SYNONYMS TBE-1 (mRNA); Matrix metalloproteinase 2 (mRNA); Gelatinase A (mRNA); CLG4A (mRNA); 72 kDa type IV collagenase (mRNA); 72 kDa gelatinase (mRNA) T58074 FUNCTION As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14. Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. T58074 PDBSTRUC 3AYU; 1RTG; 1QIB; 1KS0; 1J7M T58074 BIOCLASS mRNA target T58074 ECNUMBER EC 3.4.24.24 T58074 SEQUENCE MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGCPKESCNLFVLKDTLKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWDKNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGDGYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFNGKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGTSYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKYESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGALMAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQIRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEYWIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYIFAGDKFWRYNEVKKKMDPGFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLENQSLKSVKFGSIKSDWLGC T93690 TARGETID T93690 T93690 FORMERID TTDI02660 T93690 UNIPROID MMP9_HUMAN T93690 TARGNAME MMP9 messenger RNA (MMP9 mRNA) T93690 GENENAME MMP9 T93690 TARGTYPE Literature-reported T93690 SYNONYMS Matrix metalloproteinase 9 (mRNA); Gelatinase B (mRNA); GELB (mRNA); CLG4B (mRNA); 92 kDa type IV collagenase (mRNA); 92 kDa gelatinase (mRNA) T93690 FUNCTION Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide. May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. T93690 PDBSTRUC 6ESM; 5UE4; 5UE3; 5TH9; 5TH6 T93690 BIOCLASS mRNA target T93690 ECNUMBER EC 3.4.24.35 T93690 SEQUENCE MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTQDGNADGKPCQFPFIFQGQSYSACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFPFTFLGKEYSTCTSEGRGDGRLWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYRFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSERPTAGPTGPPSAGPTGPPTAGPSTATTVPLSPVDDACNVNIFDAIAEIGNQLYLFKDGKYWRFSEGRGSRPQGPFLIADKWPALPRKLDSVFEERLSKKLFFFSGRQVWVYTGASVLGPRRLDKLGLGADVAQVTGALRSGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLDTHDVFQYREKAYFCQDRFYWRVSSRSELNQVDQVGYVTYDILQCPED T06413 TARGETID T06413 T06413 FORMERID TTDC00287 T06413 UNIPROID KPCA_HUMAN T06413 TARGNAME PKC-alpha messenger RNA (PRKCA mRNA) T06413 GENENAME PRKCA T06413 TARGTYPE Literature-reported T06413 SYNONYMS Protein kinase C alpha type (mRNA); Protein Kinase C alpha (mRNA); PRKACA (mRNA); PKCalpha (mRNA); PKCA (mRNA); PKC-alpha (mRNA); PKC-A (mRNA) T06413 FUNCTION Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. During chemokine-induced CD4(+) T cell migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting in its dissociation from LRCH1 and the activation of GTPase CDC42. Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. T06413 PDBSTRUC 4RA4; 4DNL; 3IW4; 2ELI T06413 BIOCLASS mRNA target T06413 ECNUMBER EC 2.7.11.13 T06413 SEQUENCE MADVFPGNDSTASQDVANRFARKGALRQKNVHEVKDHKFIARFFKQPTFCSHCTDFIWGFGKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPDTDDPRSKHKFKIHTYGSPTFCDHCGSLLYGLIHQGMKCDTCDMNVHKQCVINVPSLCGMDHTEKRGRIYLKAEVADEKLHVTVRDAKNLIPMDPNGLSDPYVKLKLIPDPKNESKQKTKTIRSTLNPQWNESFTFKLKPSDKDRRLSVEIWDWDRTTRNDFMGSLSFGVSELMKMPASGWYKLLNQEEGEYYNVPIPEGDEEGNMELRQKFEKAKLGPAGNKVISPSEDRKQPSNNLDRVKLTDFNFLMVLGKGSFGKVMLADRKGTEELYAIKILKKDVVIQDDDVECTMVEKRVLALLDKPPFLTQLHSCFQTVDRLYFVMEYVNGGDLMYHIQQVGKFKEPQAVFYAAEISIGLFFLHKRGIIYRDLKLDNVMLDSEGHIKIADFGMCKEHMMDGVTTRTFCGTPDYIAPEIIAYQPYGKSVDWWAYGVLLYEMLAGQPPFDGEDEDELFQSIMEHNVSYPKSLSKEAVSVCKGLMTKHPAKRLGCGPEGERDVREHAFFRRIDWEKLENREIQPPFKPKVCGKGAENFDKFFTRGQPVLTPPDQLVIANIDQSDFEGFSYVNPQFVHPILQSAV T06413 DRUGINFO D00SIC ISIS 4189 Investigative T06413 DRUGINFO D02MFK Affinitak + Cisplatin Investigative T06413 DRUGINFO D0A2PN ISIS 9606 Investigative T06413 DRUGINFO D0K4GI Affinitak + Gemcitabine Investigative T04084 TARGETID T04084 T04084 FORMERID TTDI02685 T04084 UNIPROID ERBB3_HUMAN T04084 TARGNAME ERBB3 messenger RNA (ERBB3 mRNA) T04084 GENENAME ERBB3 T04084 TARGTYPE Literature-reported T04084 SYNONYMS Tyrosine kinase-type cell surface receptor HER3 (mRNA); Receptor tyrosine-protein kinase erbB-3 (mRNA); Proto-oncogene-like protein c-ErbB-3 (mRNA); HER3 (mRNA); C-erbB3 (mRNA); C-erbB-3 protein (mRNA) T04084 FUNCTION Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase. May also be activated by CSPG5. Involved in the regulation of myeloid cell differentiation. Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. T04084 PDBSTRUC 5O7P; 5O4O; 5CUS; 4RIY; 4RIX T04084 BIOCLASS mRNA target T04084 ECNUMBER EC 2.7.10.1 T04084 SEQUENCE MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGAEPYAGLRLAEVPDLLEKGERLAQPQICTIDVYMVMVKCWMIDENIRPTFKELANEFTRMARDPPRYLVIKRESGPGIAPGPEPHGLTNKKLEEVELEPELDLDLDLEAEEDNLATTTLGSALSLPVGTLNRPRGSQSLLSPSSGYMPMNQGNLGESCQESAVSGSSERCPRPVSLHPMPRGCLASESSEGHVTGSEAELQEKVSMCRSRSRSRSPRPRGDSAYHSQRHSLLTPVTPLSPPGLEEEDVNGYVMPDTHLKGTPSSREGTLSSVGLSSVLGTEEEDEDEEYEYMNRRRRHSPPHPPRPSSLEELGYEYMDVGSDLSASLGSTQSCPLHPVPIMPTAGTTPDEDYEYMNRQRDGGGPGGDYAAMGACPASEQGYEEMRAFQGPGHQAPHVHYARLKTLRSLEATDSAFDNPDYWHSRLFPKANAQRT T04084 DRUGINFO D0VV5X EZN-3920 Investigative T95594 TARGETID T95594 T95594 FORMERID TTDR01390 T95594 UNIPROID PK3CB_HUMAN T95594 TARGNAME PI3K p110 beta messenger RNA (PIK3CB mRNA) T95594 GENENAME PIK3CB T95594 TARGTYPE Literature-reported T95594 SYNONYMS p110beta (mRNA); PtdIns3kinase subunit p110beta (mRNA); PtdIns3kinase subunit beta (mRNA); PtdIns-3-kinase subunit p110-beta (mRNA); PtdIns-3-kinase subunit beta (mRNA); Phosphatidylinositol 4,5bisphosphate 3kinase catalytic subunitbeta isoform (mRNA); Phosphatidylinositol 4,5bisphosphate 3kinase 110 kDa catalyticsubunit beta (mRNA); Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (mRNA); Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit beta (mRNA); PIK3C1 (mRNA); PI3kinase subunit beta (mRNA); PI3Kbeta (mRNA); PI3K-beta (mRNA); PI3-kinase subunit beta (mRNA) T95594 FUNCTION Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors. T95594 BIOCLASS mRNA target T95594 ECNUMBER EC 2.7.1.153 T95594 SEQUENCE MCFSFIMPPAMADILDIWAVDSQIASDGSIPVDFLLPTGIYIQLEVPREATISYIKQMLWKQVHNYPMFNLLMDIDSYMFACVNQTAVYEELEDETRRLCDVRPFLPVLKLVTRSCDPGEKLDSKIGVLIGKGLHEFDSLKDPEVNEFRRKMRKFSEEKILSLVGLSWMDWLKQTYPPEHEPSIPENLEDKLYGGKLIVAVHFENCQDVFSFQVSPNMNPIKVNELAIQKRLTIHGKEDEVSPYDYVLQVSGRVEYVFGDHPLIQFQYIRNCVMNRALPHFILVECCKIKKMYEQEMIAIEAAINRNSSNLPLPLPPKKTRIISHVWENNNPFQIVLVKGNKLNTEETVKVHVRAGLFHGTELLCKTIVSSEVSGKNDHIWNEPLEFDINICDLPRMARLCFAVYAVLDKVKTKKSTKTINPSKYQTIRKAGKVHYPVAWVNTMVFDFKGQLRTGDIILHSWSSFPDELEEMLNPMGTVQTNPYTENATALHVKFPENKKQPYYYPPFDKIIEKAAEIASSDSANVSSRGGKKFLPVLKEILDRDPLSQLCENEMDLIWTLRQDCREIFPQSLPKLLLSIKWNKLEDVAQLQALLQIWPKLPPREALELLDFNYPDQYVREYAVGCLRQMSDEELSQYLLQLVQVLKYEPFLDCALSRFLLERALGNRRIGQFLFWHLRSEVHIPAVSVQFGVILEAYCRGSVGHMKVLSKQVEALNKLKTLNSLIKLNAVKLNRAKGKEAMHTCLKQSAYREALSDLQSPLNPCVILSELYVEKCKYMDSKMKPLWLVYNNKVFGEDSVGVIFKNGDDLRQDMLTLQMLRLMDLLWKEAGLDLRMLPYGCLATGDRSGLIEVVSTSETIADIQLNSSNVAAAAAFNKDALLNWLKEYNSGDDLDRAIEEFTLSCAGYCVASYVLGIGDRHSDNIMVKKTGQLFHIDFGHILGNFKSKFGIKRERVPFILTYDFIHVIQQGKTGNTEKFGRFRQCCEDAYLILRRHGNLFITLFALMLTAGLPELTSVKDIQYLKDSLALGKSEEEALKQFKQKFDEALRESWTTKVNWMAHTVRKDYRS T95594 DRUGINFO D00TQI ISIS 32014 Investigative T95594 DRUGINFO D01DFK ISIS 32024 Investigative T95594 DRUGINFO D02IBE ISIS 32035 Investigative T95594 DRUGINFO D04PYV ISIS 32000 Investigative T95594 DRUGINFO D05YJU ISIS 32021 Investigative T95594 DRUGINFO D06FJE ISIS 32003 Investigative T95594 DRUGINFO D06IZU ISIS 32028 Investigative T95594 DRUGINFO D07NAT ISIS 32039 Investigative T95594 DRUGINFO D08SMF ISIS 32005 Investigative T95594 DRUGINFO D09WIW ISIS 32008 Investigative T95594 DRUGINFO D0A5LZ ISIS 32006 Investigative T95594 DRUGINFO D0C1NA ISIS 31982 Investigative T95594 DRUGINFO D0D9PL ISIS 31963 Investigative T95594 DRUGINFO D0H7CG ISIS 32020 Investigative T95594 DRUGINFO D0QH9X ISIS 32004 Investigative T95594 DRUGINFO D0U8DY ISIS 32002 Investigative T95594 DRUGINFO D0V9MH ISIS 32015 Investigative T95594 DRUGINFO D0W3RP ISIS 32010 Investigative T95594 DRUGINFO D0Z4LP ISIS 31996 Investigative T95594 DRUGINFO D05BPX 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol Investigative T95594 DRUGINFO D07APP LY-292223 Investigative T95594 DRUGINFO D0W1ST Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate Investigative T91292 TARGETID T91292 T91292 FORMERID TTDR00989 T91292 UNIPROID MTHR_HUMAN T91292 TARGNAME MTHFR messenger RNA (MTHFR mRNA) T91292 GENENAME MTHFR T91292 TARGTYPE Literature-reported T91292 SYNONYMS Methylenetetrahydrofolate reductase (mRNA) T91292 FUNCTION Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine. T91292 PDBSTRUC 6FCX T91292 BIOCLASS mRNA target T91292 ECNUMBER EC 1.5.1.20 T91292 SEQUENCE MVNEARGNSSLNPCLEGSASSGSESSKDSSRCSTPGLDPERHERLREKMRRRLESGDKWFSLEFFPPRTAEGAVNLISRFDRMAAGGPLYIDVTWHPAGDPGSDKETSSMMIASTAVNYCGLETILHMTCCRQRLEEITGHLHKAKQLGLKNIMALRGDPIGDQWEEEEGGFNYAVDLVKHIRSEFGDYFDICVAGYPKGHPEAGSFEADLKHLKEKVSAGADFIITQLFFEADTFFRFVKACTDMGITCPIVPGIFPIQGYHSLRQLVKLSKLEVPQEIKDVIEPIKDNDAAIRNYGIELAVSLCQELLASGLVPGLHFYTLNREMATTEVLKRLGMWTEDPRRPLPWALSAHPKRREEDVRPIFWASRPKSYIYRTQEWDEFPNGRWGNSSSPAFGELKDYYLFYLKSKSPKEELLKMWGEELTSEESVFEVFVLYLSGEPNRNGHKVTCLPWNDEPLAAETSLLKEELLRVNRQGILTINSQPNINGKPSSDPIVGWGPSGGYVFQKAYLEFFTSRETAEALLQVLKKYELRVNYHLVNVKGENITNAPELQPNAVTWGIFPGREIIQPTVVDPVSFMFWKDEAFALWIERWGKLYEEESPSRTIIQYIHDNYFLVNLVDNDFPLDNCLWQVVEDTLELLNRPTQNARETEAP T91292 DRUGINFO D08VKT EX5 Investigative T91292 DRUGINFO D0L0AI 677T Investigative T58474 TARGETID T58474 T58474 FORMERID TTDR01398 T58474 UNIPROID RHOA_HUMAN T58474 TARGNAME RhoA messenger RNA (RHOA mRNA) T58474 GENENAME RHOA T58474 TARGTYPE Literature-reported T58474 SYNONYMS h12 (mRNA); Transforming protein RhoA (mRNA); Rho cDNA clone 12 (mRNA); RHO12 (mRNA); ARHA (mRNA); ARH12 (mRNA) T58474 FUNCTION Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. Stimulates PKN2 kinase activity. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Regulates KCNA2 potassium channel activity by reducing its location at the cell surface in response to CHRM1 activation; promotes KCNA2 endocytosis. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. T58474 PDBSTRUC 6R3V; 6BCB; 6BCA; 6BC0; 5ZHX T58474 BIOCLASS mRNA target T58474 ECNUMBER EC 3.6.5.2 T58474 SEQUENCE MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKDLRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQARRGKKKSGCLVL T58474 DRUGINFO D00CWJ ISIS 25565 Investigative T58474 DRUGINFO D09LKZ ISIS 25554 Investigative T58474 DRUGINFO D0A5LC ISIS 25563 Investigative T58474 DRUGINFO D0BJ0W ISIS 25566 Investigative T58474 DRUGINFO D0L0UV ISIS 25551 Investigative T58474 DRUGINFO D0L6LC ISIS 25567 Investigative T58474 DRUGINFO D0NH5A ISIS 25547 Investigative T58474 DRUGINFO D0NV8X ISIS 25552 Investigative T58474 DRUGINFO D0R3CV ISIS 25564 Investigative T58474 DRUGINFO D0XV1M ISIS 25549 Investigative T58474 DRUGINFO D0Z5NN ISIS 25544 Investigative T74258 TARGETID T74258 T74258 FORMERID TTDR01403 T74258 UNIPROID KPCZ_HUMAN T74258 TARGNAME PKC-zeta messenger RNA (PRKCZ mRNA) T74258 GENENAME PRKCZ T74258 TARGTYPE Literature-reported T74258 SYNONYMS Protein kinase C zeta type (mRNA); PKC2 (mRNA); NPKC-zeta (mRNA) T74258 FUNCTION Upon lipopolysaccharide (LPS) treatment in macrophages, or following mitogenic stimuli, functions downstream of PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently of RAF1 activation. Required for insulin-dependent activation of AKT3, but may function as an adapter rather than a direct activator. Upon insulin treatment may act as a downstream effector of PI3K and contribute to the activation of translocation of the glucose transporter SLC2A4/GLUT4 and subsequent glucose transport in adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity and can activate JUN promoter through MEF2C. Through binding with SQSTM1/p62, functions in interleukin-1 signaling and activation of NF-kappa-B with the specific adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in turn leads to the degradation of NF-kappa-B inhibitors. In migrating astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CDC42 to function in the establishment of cell polarity along with the microtubule motor and dynein. In association with FEZ1, stimulates neuronal differentiation in PC12 cells. In the inflammatory response, is required for the T-helper 2 (Th2) differentiation process, including interleukin production, efficient activation of JAK1 and the subsequent phosphorylation and nuclear translocation of STAT6. May be involved in development of allergic airway inflammation (asthma), a process dependent on Th2 immune response. In the NF-kappa-B-mediated inflammatory response, can relieve SETD6-dependent repression of NF-kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. In vein endothelial cells treated with the oxidant peroxynitrite, phosphorylates STK11 leading to nuclear export of STK11, subsequent inhibition of PI3K/Akt signaling, and increased apoptosis. Phosphorylates VAMP2 in vitro. Calcium- and diacylglycerol-independent serine/threonine-protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated protein (MAP) kinase cascade, and is involved in NF-kappa-B activation, mitogenic signaling, cell proliferation, cell polarity, inflammatory response and maintenance of long-term potentiation (LTP). T74258 BIOCLASS mRNA target T74258 ECNUMBER EC 2.7.11.13 T74258 SEQUENCE MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQQHPLTLKWVDSEGDPCTVSSQMELEEAFRLARQCRDEGLIIHVFPSTPEQPGLPCPGEDKSIYRRGARRWRKLYRANGHLFQAKRFNRRAYCGQCSERIWGLARQGYRCINCKLLVHKRCHGLVPLTCRKHMDSVMPSQEPPVDDKNEDADLPSEETDGIAYISSSRKHDSIKDDSEDLKPVIDGMDGIKISQGLGLQDFDLIRVIGRGSYAKVLLVRLKKNDQIYAMKVVKKELVHDDEDIDWVQTEKHVFEQASSNPFLVGLHSCFQTTSRLFLVIEYVNGGDLMFHMQRQRKLPEEHARFYAAEICIALNFLHERGIIYRDLKLDNVLLDADGHIKLTDYGMCKEGLGPGDTTSTFCGTPNYIAPEILRGEEYGFSVDWWALGVLMFEMMAGRSPFDIITDNPDMNTEDYLFQVILEKPIRIPRFLSVKASHVLKGFLNKDPKERLGCRPQTGFSDIKSHAFFRSIDWDLLEKKQALPPFQPQITDDYGLDNFDTQFTSEPVQLTPDDEDAIKRIDQSEFEGFEYINPLLLSTEESV T74258 DRUGINFO D0R2TM BALANOL Terminated T74258 DRUGINFO D05WAM ISIS 9008 Investigative T74258 DRUGINFO D06EPV ISIS 9022 Investigative T74258 DRUGINFO D07AUV ISIS 9023 Investigative T74258 DRUGINFO D0C1CA ISIS 9007 Investigative T74258 DRUGINFO D0M2SC ISIS 9025 Investigative T74258 DRUGINFO D06TLL Go 6983 Investigative T74258 DRUGINFO D06ZCX LY-326449 Investigative T28444 TARGETID T28444 T28444 FORMERID TTDR01408 T28444 UNIPROID DUS8_HUMAN T28444 TARGNAME DUSP8 messenger RNA (DUSP8 mRNA) T28444 GENENAME DUSP8 T28444 TARGTYPE Literature-reported T28444 SYNONYMS VH5 (mRNA); Dual specificity protein phosphatase hVH-5 (mRNA); Dual specificity protein phosphatase 8 (mRNA); C11orf81 (mRNA) T28444 FUNCTION Expected to display protein phosphatase activity toward phosphotyrosine, phosphoserine and phosphothreonine residues. Has phosphatase activity with synthetic phosphatase substrates and negatively regulates mitogen-activated protein kinase activity, presumably by catalysing their dephosphorylation. T28444 PDBSTRUC 4JMK T28444 BIOCLASS mRNA target T28444 ECNUMBER EC 3.1.3.16 T28444 SEQUENCE MAGDRLPRKVMDAKKLASLLRGGPGGPLVIDSRSFVEYNSWHVLSSVNICCSKLVKRRLQQGKVTIAELIQPAARSQVEATEPQDVVVYDQSTRDASVLAADSFLSILLSKLDGCFDSVAILTGGFATFSSCFPGLCEGKPAALLPMSLSQPCLPVPSVGLTRILPHLYLGSQKDVLNKDLMTQNGISYVLNASNSCPKPDFICESRFMRVPINDNYCEKLLPWLDKSIEFIDKAKLSSCQVIVHCLAGISRSATIAIAYIMKTMGMSSDDAYRFVKDRRPSISPNFNFLGQLLEYERSLKLLAALQGDPGTPSGTPEPPPSPAAGAPLPRLPPPTSESAATGNAAAREGGLSAGGEPPAPPTPPATSALQQGLRGLHLSSDRLQDTNRLKRSFSLDIKSAYAPSRRPDGPGPPDPGEAPKLCKLDSPSGAALGLSSPSPDSPDAAPEARPRPRRRPRPPAGSPARSPAHSLGLNFGDAARQTPRHGLSALSAPGLPGPGQPAGPGAWAPPLDSPGTPSPDGPWCFSPEGAQGAGGVLFAPFGRAGAPGPGGGSDLRRREAARAEPRDARTGWPEEPAPETQFKRRSCQMEFEEGMVEGRARGEELAALGKQASFSGSVEVIEVS T28444 DRUGINFO D01GLR ISIS 103387 Investigative T28444 DRUGINFO D0O3WF ISIS 103386 Investigative T28444 DRUGINFO D0XO0T ISIS 103375 Investigative T83398 TARGETID T83398 T83398 FORMERID TTDR01417 T83398 UNIPROID DUS5_HUMAN T83398 TARGNAME DUSP5 messenger RNA (DUSP5 mRNA) T83398 GENENAME DUSP5 T83398 TARGTYPE Literature-reported T83398 SYNONYMS VH3 (mRNA); Dual specificity protein phosphatase hVH3 (mRNA); Dual specificity protein phosphatase 5 (mRNA) T83398 FUNCTION The highest relative activity is toward ERK1. Dual specificity protein phosphatase; active with phosphotyrosine, phosphoserine and phosphothreonine residues. T83398 PDBSTRUC 2G6Z T83398 BIOCLASS mRNA target T83398 ECNUMBER EC 3.1.3.16 T83398 SEQUENCE MKVTSLDGRQLRKMLRKEAAARCVVLDCRPYLAFAASNVRGSLNVNLNSVVLRRARGGAVSARYVLPDEAARARLLQEGGGGVAAVVVLDQGSRHWQKLREESAARVVLTSLLACLPAGPRVYFLKGGYETFYSEYPECCVDVKPISQEKIESERALISQCGKPVVNVSYRPAYDQGGPVEILPFLYLGSAYHASKCEFLANLHITALLNVSRRTSEACATHLHYKWIPVEDSHTADISSHFQEAIDFIDCVREKGGKVLVHCEAGISRSPTICMAYLMKTKQFRLKEAFDYIKQRRSMVSPNFGFMGQLLQYESEILPSTPNPQPPSCQGEAAGSSLIGHLQTLSPDMQGAYCTFPASVLAPVPTHSTVSELSRSPVATATSC T83398 DRUGINFO D01EAV ISIS 133244 Investigative T83398 DRUGINFO D02DHS ISIS 133245 Investigative T83398 DRUGINFO D03PCV ISIS 133207 Investigative T83398 DRUGINFO D05PDW ISIS 133206 Investigative T83398 DRUGINFO D09PFL ISIS 133208 Investigative T83398 DRUGINFO D0C8WA ISIS 133242 Investigative T83398 DRUGINFO D0ND6Y ISIS 133211 Investigative T83398 DRUGINFO D0W5FH ISIS 133243 Investigative T11747 TARGETID T11747 T11747 FORMERID TTDR01422 T11747 UNIPROID M3K3_HUMAN T11747 TARGNAME MEKK3 messenger RNA (MAP3K3 mRNA) T11747 GENENAME MAP3K3 T11747 TARGTYPE Literature-reported T11747 SYNONYMS Mitogen-activated protein kinase kinase kinase 3 (mRNA); MEKK3 (mRNA); MEKK 3 (mRNA); MEK kinase 3 (mRNA); MAPKKK3 (mRNA) T11747 FUNCTION Mediates activation of the NF-kappa-B, AP1 and DDIT3 transcriptional regulators. Component of a protein kinase signal transduction cascade. T11747 PDBSTRUC 4YL6; 4Y5O; 2PPH; 2O2V; 2JRH T11747 BIOCLASS mRNA target T11747 ECNUMBER EC 2.7.11.25 T11747 SEQUENCE MDEQEALNSIMNDLVALQMNRRHRMPGYETMKNKDTGHSNRQSDVRIKFEHNGERRIIAFSRPVKYEDVEHKVTTVFGQPLDLHYMNNELSILLKNQDDLDKAIDILDRSSSMKSLRILLLSQDRNHNSSSPHSGVSRQVRIKASQSAGDINTIYQPPEPRSRHLSVSSQNPGRSSPPPGYVPERQQHIARQGSYTSINSEGEFIPETSEQCMLDPLSSAENSLSGSCQSLDRSADSPSFRKSRMSRAQSFPDNRQEYSDRETQLYDKGVKGGTYPRRYHVSVHHKDYSDGRRTFPRIRRHQGNLFTLVPSSRSLSTNGENMGLAVQYLDPRGRLRSADSENALSVQERNVPTKSPSAPINWRRGKLLGQGAFGRVYLCYDVDTGRELASKQVQFDPDSPETSKEVSALECEIQLLKNLQHERIVQYYGCLRDRAEKTLTIFMEYMPGGSVKDQLKAYGALTESVTRKYTRQILEGMSYLHSNMIVHRDIKGANILRDSAGNVKLGDFGASKRLQTICMSGTGMRSVTGTPYWMSPEVISGEGYGRKADVWSLGCTVVEMLTEKPPWAEYEAMAAIFKIATQPTNPQLPSHISEHGRDFLRRIFVEARQRPSAEELLTHHFAQLMY T11747 DRUGINFO D05QQI ISIS 122971 Investigative T11747 DRUGINFO D05RDM ISIS 122976 Investigative T11747 DRUGINFO D08SHY ISIS 122985 Investigative T11747 DRUGINFO D09TIM ISIS 122991 Investigative T11747 DRUGINFO D0F7AP ISIS 122974 Investigative T11747 DRUGINFO D0H8BJ ISIS 122975 Investigative T11747 DRUGINFO D0JZ4R ISIS 122970 Investigative T11747 DRUGINFO D0M5OL ISIS 122984 Investigative T11747 DRUGINFO D0N9VK ISIS 122986 Investigative T11747 DRUGINFO D0Z4CC ISIS 122990 Investigative T00564 TARGETID T00564 T00564 FORMERID TTDR01424 T00564 UNIPROID DUS9_HUMAN T00564 TARGNAME DUSP9 messenger RNA (DUSP9 mRNA) T00564 GENENAME DUSP9 T00564 TARGTYPE Literature-reported T00564 SYNONYMS Mitogen-activated protein kinase phosphatase 4 (mRNA); MKP4 (mRNA); MKP-4 (mRNA); MAP kinase phosphatase 4 (mRNA); Dual specificity protein phosphatase 9 (mRNA) T00564 FUNCTION Has a specificity for the ERK family. Inactivates MAP kinases. T00564 PDBSTRUC 3LJ8; 2HXP T00564 BIOCLASS mRNA target T00564 ECNUMBER EC 3.1.3.16 T00564 SEQUENCE MEGLGRSCLWLRRELSPPRPRLLLLDCRSRELYESARIGGALSVALPALLLRRLRRGSLSVRALLPGPPLQPPPPAPVLLYDQGGGRRRRGEAEAEAEEWEAESVLGTLLQKLREEGYLAYYLQGGFSRFQAECPHLCETSLAGRAGSSMAPVPGPVPVVGLGSLCLGSDCSDAESEADRDSMSCGLDSEGATPPPVGLRASFPVQILPNLYLGSARDSANLESLAKLGIRYILNVTPNLPNFFEKNGDFHYKQIPISDHWSQNLSRFFPEAIEFIDEALSQNCGVLVHCLAGVSRSVTVTVAYLMQKLHLSLNDAYDLVKRKKSNISPNFNFMGQLLDFERSLRLEERHSQEQGSGGQASAASNPPSFFTTPTSDGAFELAPT T00564 DRUGINFO D07HIJ ISIS 103473 Investigative T00564 DRUGINFO D07RVX ISIS 103471 Investigative T00564 DRUGINFO D0Q3KN ISIS 103489 Investigative T00564 DRUGINFO D0S4BJ ISIS 103486 Investigative T91154 TARGETID T91154 T91154 FORMERID TTDR01425 T91154 UNIPROID WWP1_HUMAN T91154 TARGNAME WWP1 messenger RNA (WWP1 mRNA) T91154 GENENAME WWP1 T91154 TARGTYPE Literature-reported T91154 SYNONYMS WW domain-containing protein 1 (mRNA); Tiul1 (mRNA); TGIF-interacting ubiquitin ligase 1 (mRNA); NEDD4-like E3 ubiquitin-protein ligase WWP1 (mRNA); HECT-type E3 ubiquitin transferase WWP1 (mRNA); Atrophin-1-interacting protein 5 (mRNA); AIP5 (mRNA) T91154 FUNCTION Ubiquitinates ERBB4 isoforms JM-A CYT-1 and JM-B CYT-1, KLF2, KLF5 and TP63 and promotes their proteasomal degradation. Ubiquitinates RNF11 without targeting it for degradation. Ubiquitinates and promotes degradation of TGFBR1; the ubiquitination is enhanced by SMAD7. Ubiquitinates SMAD6 and SMAD7. Ubiquitinates and promotes degradation of SMAD2 in response to TGF-beta signaling, which requires interaction with TGIF. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. T91154 PDBSTRUC 5HPT; 5HPS; 2OP7; 1ND7 T91154 BIOCLASS mRNA target T91154 ECNUMBER EC 2.3.2.26 T91154 SEQUENCE MATASPRSDTSNNHSGRLQLQVTVSSAKLKRKKNWFGTAIYTEVVVDGEITKTAKSSSSSNPKWDEQLTVNVTPQTTLEFQVWSHRTLKADALLGKATIDLKQALLIHNRKLERVKEQLKLSLENKNGIAQTGELTVVLDGLVIEQENITNCSSSPTIEIQENGDALHENGEPSARTTARLAVEGTNGIDNHVPTSTLVQNSCCSYVVNGDNTPSSPSQVAARPKNTPAPKPLASEPADDTVNGESSSFAPTDNASVTGTPVVSEENALSPNCTSTTVEDPPVQEILTSSENNECIPSTSAELESEARSILEPDTSNSRSSSAFEAAKSRQPDGCMDPVRQQSGNANTETLPSGWEQRKDPHGRTYYVDHNTRTTTWERPQPLPPGWERRVDDRRRVYYVDHNTRTTTWQRPTMESVRNFEQWQSQRNQLQGAMQQFNQRYLYSASMLAAENDPYGPLPPGWEKRVDSTDRVYFVNHNTKTTQWEDPRTQGLQNEEPLPEGWEIRYTREGVRYFVDHNTRTTTFKDPRNGKSSVTKGGPQIAYERGFRWKLAHFRYLCQSNALPSHVKINVSRQTLFEDSFQQIMALKPYDLRRRLYVIFRGEEGLDYGGLAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQINPASTINPDHLSYFCFIGRFIAMALFHGKFIDTGFSLPFYKRMLSKKLTIKDLESIDTEFYNSLIWIRDNNIEECGLEMYFSVDMEILGKVTSHDLKLGGSNILVTEENKDEYIGLMTEWRFSRGVQEQTKAFLDGFNEVVPLQWLQYFDEKELEVMLCGMQEVDLADWQRNTVYRHYTRNSKQIIWFWQFVKETDNEVRMRLLQFVTGTCRLPLGGFAELMGSNGPQKFCIEKVGKDTWLPRSHTCFNRLDLPPYKSYEQLKEKLLFAIEETEGFGQE T91154 DRUGINFO D01NSO ISIS 103616 Investigative T91154 DRUGINFO D04CLQ ISIS 103615 Investigative T91154 DRUGINFO D06GOO ISIS 103624 Investigative T91154 DRUGINFO D08IBR ISIS 103619 Investigative T91154 DRUGINFO D09GRF ISIS 103582 Investigative T91154 DRUGINFO D0AD7L ISIS 103631 Investigative T91154 DRUGINFO D0I8BN ISIS 103612 Investigative T91154 DRUGINFO D0K8XK ISIS 103621 Investigative T91154 DRUGINFO D0M2PZ ISIS 103613 Investigative T91154 DRUGINFO D0P2AR ISIS 103629 Investigative T91154 DRUGINFO D0T5RJ ISIS 103620 Investigative T91154 DRUGINFO D0TS6S ISIS 103622 Investigative T91154 DRUGINFO D0V8KZ ISIS 103601 Investigative T91154 DRUGINFO D0Y9ZR ISIS 103635 Investigative T25386 TARGETID T25386 T25386 FORMERID TTDR01427 T25386 UNIPROID DICER_HUMAN T25386 TARGNAME Helicase-moi messenger RNA (DICER1 mRNA) T25386 GENENAME DICER1 T25386 TARGTYPE Literature-reported T25386 SYNONYMS KIAA0928 (mRNA); Helicase with RNase motif (mRNA); Helicase MOI (mRNA); HERNA (mRNA); Endoribonuclease Dicer (mRNA); DICER (mRNA) T25386 FUNCTION Cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two nucleotides, producing respectively short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA-induced silencing complex (RISC) to complementary RNAs to degrade them or prevent their translation. Gene silencing mediated by siRNAs, also called RNA interference, controls the elimination of transcripts from mobile and repetitive DNA elements of the genome but also the degradation of exogenous RNA of viral origin for instance. The miRNA pathway on the other side is a mean to specifically regulate the expression of target genes. Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing. T25386 PDBSTRUC 5ZAM; 5ZAL; 5ZAK; 4WYQ; 4NHA T25386 BIOCLASS mRNA target T25386 ECNUMBER EC 3.1.26.3 T25386 SEQUENCE MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS T25386 DRUGINFO D07NRU ISIS 138649 Investigative T25386 DRUGINFO D0D7NA ISIS 138647 Investigative T25386 DRUGINFO D0DH8B ISIS 138616 Investigative T25386 DRUGINFO D0LF3W ISIS 138678 Investigative T25386 DRUGINFO D0O2ZR ISIS 138612 Investigative T25386 DRUGINFO D0O4MI ISIS 138648 Investigative T25386 DRUGINFO D0OV0E ISIS 138613 Investigative T52501 TARGETID T52501 T52501 FORMERID TTDR01432 T52501 UNIPROID M3K2_HUMAN T52501 TARGNAME MEKK2 messenger RNA (MAP3K2 mRNA) T52501 GENENAME MAP3K2 T52501 TARGTYPE Literature-reported T52501 SYNONYMS Mitogen-activated protein kinase kinase kinase 2 (mRNA); MEKK2 (mRNA); MEKK 2 (mRNA); MEK kinase 2 (mRNA); MAPKKK2 (mRNA) T52501 FUNCTION Regulates the JNK and ERK5 pathways by phosphorylating and activating MAP2K5 and MAP2K7. Plays a role in caveolae kiss-and-run dynamics. Component of a protein kinase signal transduction cascade. T52501 PDBSTRUC 5HQ8; 5EX0; 2NPT; 2CU1 T52501 BIOCLASS mRNA target T52501 ECNUMBER EC 2.7.11.25 T52501 SEQUENCE MDDQQALNSIMQDLAVLHKASRPALSLQETRKAKSSSPKKQNDVRVKFEHRGEKRILQFPRPVKLEDLRSKAKIAFGQSMDLHYTNNELVIPLTTQDDLDKAVELLDRSIHMKSLKILLVINGSTQATNLEPLPSLEDLDNTVFGAERKKRLSIIGPTSRDRSSPPPGYIPDELHQVARNGSFTSINSEGEFIPESMDQMLDPLSLSSPENSGSGSCPSLDSPLDGESYPKSRMPRAQSYPDNHQEFSDYDNPIFEKFGKGGTYPRRYHVSYHHQEYNDGRKTFPRARRTQGTSLRSPVSFSPTDHSLSTSSGSSIFTPEYDDSRIRRRGSDIDNPTLTVMDISPPSRSPRAPTNWRLGKLLGQGAFGRVYLCYDVDTGRELAVKQVQFDPDSPETSKEVNALECEIQLLKNLLHERIVQYYGCLRDPQEKTLSIFMEYMPGGSIKDQLKAYGALTENVTRKYTRQILEGVHYLHSNMIVHRDIKGANILRDSTGNVKLGDFGASKRLQTICLSGTGMKSVTGTPYWMSPEVISGEGYGRKADIWSVACTVVEMLTEKPPWAEFEAMAAIFKIATQPTNPKLPPHVSDYTRDFLKRIFVEAKLRPSADELLRHMFVHYH T52501 DRUGINFO D00GKE ISIS 113909 Investigative T52501 DRUGINFO D04LHI ISIS 113871 Investigative T52501 DRUGINFO D05AYU ISIS 113874 Investigative T52501 DRUGINFO D05HUP ISIS 113908 Investigative T52501 DRUGINFO D07EFO ISIS 113902 Investigative T52501 DRUGINFO D0D5HE ISIS 113906 Investigative T52501 DRUGINFO D0E3AR ISIS 113904 Investigative T52501 DRUGINFO D0F9AI ISIS 113907 Investigative T52501 DRUGINFO D0M9JK ISIS 113903 Investigative T52501 DRUGINFO D0QP0H ISIS 113858 Investigative T52501 DRUGINFO D0V7SZ ISIS 113905 Investigative T52501 DRUGINFO D0X7DN ISIS 113872 Investigative T52501 DRUGINFO D0Y3OV ISIS 113873 Investigative T01054 TARGETID T01054 T01054 FORMERID TTDI00139 T01054 UNIPROID WWP2_HUMAN T01054 TARGNAME NEDD4-like E3 ubiquitin-protein ligase WWP2 (WWP2) T01054 GENENAME WWP2 T01054 TARGTYPE Literature-reported T01054 SYNONYMS WW domaincontaining protein 2; WW domain-containing protein 2; NEDD4like E3 ubiquitinprotein ligaseWWP2; HECT-type E3 ubiquitin transferase WWP2; Atrophin1interacting protein 2; Atrophin-1-interacting protein 2; AIP2 T01054 FUNCTION Polyubiquitinates POU5F1 by 'Lys-63'-linked conjugation and promotes it to proteasomal degradation; in embryonic stem cells (ESCs) the ubiquitination is proposed to regulate POU5F1 protein level. Ubiquitinates EGR2 and promotes it to proteasomal degradation; in T-cells the ubiquitination inhibits activation-induced cell death. Ubiquitinates SLC11A2; the ubiquitination is enhanced by presence of NDFIP1 and NDFIP2. Ubiquitinates RPB1 and promotes it to proteasomal degradation. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. T01054 PDBSTRUC 5TJQ; 5TJ8; 5TJ7; 4Y07 T01054 BIOCLASS Acyltransferase T01054 ECNUMBER EC 2.3.2.26 T01054 SEQUENCE MASASSSRAGVALPFEKSQLTLKVVSAKPKVHNRQPRINSYVEVAVDGLPSETKKTGKRIGSSELLWNEIIILNVTAQSHLDLKVWSCHTLRNELLGTASVNLSNVLKNNGGKMENMQLTLNLQTENKGSVVSGGELTIFLDGPTVDLGNVPNGSALTDGSQLPSRDSSGTAVAPENRHQPPSTNCFGGRSRTHRHSGASARTTPATGEQSPGARSRHRQPVKNSGHSGLANGTVNDEPTTATDPEEPSVVGVTSPPAAPLSVTPNPNTTSLPAPATPAEGEEPSTSGTQQLPAAAQAPDALPAGWEQRELPNGRVYYVDHNTKTTTWERPLPPGWEKRTDPRGRFYYVDHNTRTTTWQRPTAEYVRNYEQWQSQRNQLQGAMQHFSQRFLYQSSSASTDHDPLGPLPPGWEKRQDNGRVYYVNHNTRTTQWEDPRTQGMIQEPALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRPGFESGTKQGSPGAYDRSFRWKYHQFRFLCHSNALPSHVKISVSRQTLFEDSFQQIMNMKPYDLRRRLYIIMRGEEGLDYGGIAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQINPASSINPDHLTYFRFIGRFIAMALYHGKFIDTGFTLPFYKRMLNKRPTLKDLESIDPEFYNSIVWIKENNLEECGLELYFIQDMEILGKVTTHELKEGGESIRVTEENKEEYIMLLTDWRFTRGVEEQTKAFLDGFNEVAPLEWLRYFDEKELELMLCGMQEIDMSDWQKSTIYRHYTKNSKQIQWFWQVVKEMDNEKRIRLLQFVTGTCRLPVGGFAELIGSNGPQKFCIDKVGKETWLPRSHTCFNRLDLPPYKSYEQLREKLLYAIEETEGFGQE T71374 TARGETID T71374 T71374 FORMERID TTDI03470 T71374 UNIPROID PLK4_HUMAN T71374 TARGNAME Polo-like kinase 4 (PLK4) T71374 GENENAME PLK4 T71374 TARGTYPE Literature-reported T71374 SYNONYMS Serine/threonine-protein kinase Sak; Serine/threonine-protein kinase PLK4; Serine/threonine-protein kinase 18; STK18; SAK; PLK-4 T71374 FUNCTION Able to trigger procentriole formation on the surface of the parental centriole cylinder, leading to the recruitment of centriole biogenesis proteins such as SASS6, CENPJ/CPAP, CCP110, CEP135 and gamma-tubulin. When overexpressed, it is able to induce centrosome amplification through the simultaneous generation of multiple procentrioles adjoining each parental centriole during S phase. Phosphorylates 'Ser-151' of FBXW5 during the G1/S transition, leading to inhibit FBXW5 ability to ubiquitinate SASS6. Its central role in centriole replication suggests a possible role in tumorigenesis, centrosome aberrations being frequently observed in tumors. Also involved in deuterosome-mediated centriole amplification in multiciliated that can generate more than 100 centrioles. Also involved in trophoblast differentiation by phosphorylating HAND1, leading to disrupt the interaction between HAND1 and MDFIC and activate HAND1. Phosphorylates CDC25C and CHEK2. Required for the recruitment of STIL to the centriole and for STIL-mediated centriole amplification. Serine/threonine-protein kinase that plays a central role in centriole duplication. T71374 PDBSTRUC 5LHZ; 5LHY; 4YYP; 4YUR; 4N9J T71374 BIOCLASS Kinase T71374 ECNUMBER EC 2.7.11.21 T71374 SEQUENCE MATCIGEKIEDFKVGNLLGKGSFAGVYRAESIHTGLEVAIKMIDKKAMYKAGMVQRVQNEVKIHCQLKHPSILELYNYFEDSNYVYLVLEMCHNGEMNRYLKNRVKPFSENEARHFMHQIITGMLYLHSHGILHRDLTLSNLLLTRNMNIKIADFGLATQLKMPHEKHYTLCGTPNYISPEIATRSAHGLESDVWSLGCMFYTLLIGRPPFDTDTVKNTLNKVVLADYEMPSFLSIEAKDLIHQLLRRNPADRLSLSSVLDHPFMSRNSSTKSKDLGTVEDSIDSGHATISTAITASSSTSISGSLFDKRRLLIGQPLPNKMTVFPKNKSSTDFSSSGDGNSFYTQWGNQETSNSGRGRVIQDAEERPHSRYLRRAYSSDRSGTSNSQSQAKTYTMERCHSAEMLSVSKRSGGGENEERYSPTDNNANIFNFFKEKTSSSSGSFERPDNNQALSNHLCPGKTPFPFADPTPQTETVQQWFGNLQINAHLRKTTEYDSISPNRDFQGHPDLQKDTSKNAWTDTKVKKNSDASDNAHSVKQQNTMKYMTALHSKPEIIQQECVFGSDPLSEQSKTRGMEPPWGYQNRTLRSITSPLVAHRLKPIRQKTKKAVVSILDSEEVCVELVKEYASQEYVKEVLQISSDGNTITIYYPNGGRGFPLADRPPSPTDNISRYSFDNLPEKYWRKYQYASRFVQLVRSKSPKITYFTRYAKCILMENSPGADFEVWFYDGVKIHKTEDFIQVIEKTGKSYTLKSESEVNSLKEEIKMYMDHANEGHRICLALESIISEEERKTRSAPFFPIIIGRKPGSTSSPKALSPPPSVDSNYPTRERASFNRMVMHSAASPTQAPILNPSMVTNEGLGLTTTASGTDISSNSLKDCLPKSAQLLKSVFVKNVGWATQLTSGAVWVQFNDGSQLVVQAGVSSISYTSPNGQTTRYGENEKLPDYIKQKLQCLSSILLMFSNPTPNFH T71374 DRUGINFO D0X2XZ CFI-400945 Phase 2 T71374 DRUGINFO D0M0QQ XMD8-92 Investigative T70027 TARGETID T70027 T70027 FORMERID TTDI02631 T70027 UNIPROID TOR1A_HUMAN T70027 TARGNAME Torsin-1A (TOR1A) T70027 GENENAME TOR1A T70027 TARGTYPE Literature-reported T70027 SYNONYMS Torsin family 1 member A; Torsin ATPase-1A; TORA; TA; Dystonia 1 protein; DYT1; DQ2 T70027 FUNCTION Involved in the regulation of synaptic vesicle recycling, controls STON2 protein stability in collaboration with the COP9 signalosome complex (CSN). In the nucleus, may link the cytoskeleton with the nuclear envelope, this mechanism seems to be crucial for the control of nuclear polarity, cell movement and, specifically in neurons, nuclear envelope integrity. Participates in the cellular trafficking and may regulate the subcellular location of multipass membrane proteins such as the dopamine transporter SLC6A3, leading to the modulation of dopamine neurotransmission. In the endoplasmic reticulum, plays a role in the quality control of protein folding by increasing clearance of misfolded proteins such as SGCE variants or holding them in an intermediate state for proper refolding. May have a redundant function with TOR1B in non-neural tissues. Protein with chaperone functions important for the control of protein folding, processing, stability and localization as well as for the reduction of misfolded protein aggregates. T70027 PDBSTRUC 5J1T; 5J1S T70027 BIOCLASS Acid anhydride hydrolase T70027 ECNUMBER EC 3.6.4.- T70027 SEQUENCE MKLGRAVLGLLLLAPSVVQAVEPISLGLALAGVLTGYIYPRLYCLFAECCGQKRSLSREALQKDLDDNLFGQHLAKKIILNAVFGFINNPKPKKPLTLSLHGWTGTGKNFVSKIIAENIYEGGLNSDYVHLFVATLHFPHASNITLYKDQLQLWIRGNVSACARSIFIFDEMDKMHAGLIDAIKPFLDYYDLVDGVSYQKAMFIFLSNAGAERITDVALDFWRSGKQREDIKLKDIEHALSVSVFNNKNSGFWHSSLIDRNLIDYFVPFLPLEYKHLKMCIRVEMQSRGYEIDEDIVSRVAEEMTFFPKEERVFSDKGCKTVFTKLDYYYDD T59537 TARGETID T59537 T59537 FORMERID TTDR01062 T59537 UNIPROID PMYT1_HUMAN T59537 TARGNAME Membrane-associated kinase (PKMYT1) T59537 GENENAME PKMYT1 T59537 TARGTYPE Literature-reported T59537 SYNONYMS Myt1 kinase; Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase; MYT1 T59537 FUNCTION Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation. May be involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree, however tyrosine kinase activity is unclear and may be indirect. May be a downstream target of Notch signaling pathway during eye development. Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins. T59537 PDBSTRUC 5VD3; 5VD1; 5VD0; 5VCZ; 5VCY T59537 BIOCLASS Kinase T59537 ECNUMBER EC 2.7.11.1 T59537 SEQUENCE MLERPPALAMPMPTEGTPPPLSGTPIPVPAYFRHAEPGFSLKRPRGLSRSLPPPPPAKGSIPISRLFPPRTPGWHQLQPRRVSFRGEASETLQSPGYDPSRPESFFQQSFQRLSRLGHGSYGEVFKVRSKEDGRLYAVKRSMSPFRGPKDRARKLAEVGSHEKVGQHPCCVRLEQAWEEGGILYLQTELCGPSLQQHCEAWGASLPEAQVWGYLRDTLLALAHLHSQGLVHLDVKPANIFLGPRGRCKLGDFGLLVELGTAGAGEVQEGDPRYMAPELLQGSYGTAADVFSLGLTILEVACNMELPHGGEGWQQLRQGYLPPEFTAGLSSELRSVLVMMLEPDPKLRATAEALLALPVLRQPRAWGVLWCMAAEALSRGWALWQALLALLCWLWHGLAHPASWLQPLGPPATPPGSPPCSLLLDSSLSSNWDDDSLGPSLSPEAVLARTVGSTSTPRSRCTPRDALDLSDINSEPPRGSFPSFEPRNLLSLFEDTLDPT T53159 TARGETID T53159 T53159 FORMERID TTDR00147 T53159 UNIPROID MP2K7_HUMAN T53159 TARGNAME ERK activator kinase 7 (MAP2K7) T53159 GENENAME MAP2K7 T53159 TARGTYPE Literature-reported T53159 SYNONYMS Stress-activated protein kinase kinase 4; SKK4; SAPKK4; SAPKK-4; SAPK kinase 4; PRKMK7; Mitogen-activated protein kinase kinase 7; MKK7; MEK7; MEK 7; MAPKK 7; MAPK/ERK kinase7; MAPK/ERK kinase 7; MAP kinase kinase 7; JNKK2; JNKK 2; JNK-activating kinase 2; JNK kinase 2; JNK activating kinase 2; Dual specificity mitogen-activated protein kinase kinase 7; C-Jun N-terminal kinase kinase 2 T53159 FUNCTION Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific role in JNK signal transduction pathway activated by proinflammatory cytokines. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Part of a non-canonical MAPK signaling pathway, composed of the upstream MAP3K12 kinase and downstream MAP kinases MAPK1/ERK2 and MAPK3/ERK1, that enhances the AP-1-mediated transcription of APP in response to APOE. Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. T53159 PDBSTRUC 6QHR; 6QHO; 6QG7; 6QG4; 6QFT T53159 BIOCLASS Kinase T53159 ECNUMBER EC 2.7.12.2 T53159 SEQUENCE MAASSLEQKLSRLEAKLKQENREARRRIDLNLDISPQRPRPTLQLPLANDGGSRSPSSESSPQHPTPPARPRHMLGLPSTLFTPRSMESIEIDQKLQEIMKQTGYLTIGGQRYQAEINDLENLGEMGSGTCGQVWKMRFRKTGHVIAVKQMRRSGNKEENKRILMDLDVVLKSHDCPYIVQCFGTFITNTDVFIAMELMGTCAEKLKKRMQGPIPERILGKMTVAIVKALYYLKEKHGVIHRDVKPSNILLDERGQIKLCDFGISGRLVDSKAKTRSAGCAAYMAPERIDPPDPTKPDYDIRADVWSLGISLVELATGQFPYKNCKTDFEVLTKVLQEEPPLLPGHMGFSGDFQSFVKDCLTKDHRKRPKYNKLLEHSFIKRYETLEVDVASWFKDVMAKTESPRTSGVLSQPHLPFFR T42447 TARGETID T42447 T42447 FORMERID TTDI03159 T42447 UNIPROID DCLK1_HUMAN T42447 TARGNAME Doublecortin-like kinase 1 (DCLK1) T42447 GENENAME DCLK1 T42447 TARGTYPE Literature-reported T42447 SYNONYMS Serine/threonine-protein kinase DCLK1; KIAA0369; Doublecortin-like and CAM kinase-like 1; Doublecortin domain-containing protein 3A; DCDC3A; DCAMKL1 T42447 FUNCTION May also participate in functions of the mature nervous system. Probable kinase that may be involved in a calcium-signaling pathway controlling neuronal migration in the developing brain. T42447 PDBSTRUC 5JZN; 5JZJ; 1UF0; 1MG4; 1MFW T42447 BIOCLASS Kinase T42447 ECNUMBER EC 2.7.11.1 T42447 SEQUENCE MSFGRDMELEHFDERDKAQRYSRGSRVNGLPSPTHSAHCSFYRTRTLQTLSSEKKAKKVRFYRNGDRYFKGIVYAISPDRFRSFEALLADLTRTLSDNVNLPQGVRTIYTIDGLKKISSLDQLVEGESYVCGSIEPFKKLEYTKNVNPNWSVNVKTTSASRAVSSLATAKGSPSEVRENKDFIRPKLVTIIRSGVKPRKAVRILLNKKTAHSFEQVLTDITDAIKLDSGVVKRLYTLDGKQVMCLQDFFGDDDIFIACGPEKFRYQDDFLLDESECRVVKSTSYTKIASSSRRSTTKSPGPSRRSKSPASTSSVNGTPGSQLSTPRSGKSPSPSPTSPGSLRKQRSSQHGGSSTSLASTKVCSSMDENDGPGEEVSEEGFQIPATITERYKVGRTIGDGNFAVVKECVERSTAREYALKIIKKSKCRGKEHMIQNEVSILRRVKHPNIVLLIEEMDVPTELYLVMELVKGGDLFDAITSTNKYTERDASGMLYNLASAIKYLHSLNIVHRDIKPENLLVYEHQDGSKSLKLGDFGLATIVDGPLYTVCGTPTYVAPEIIAETGYGLKVDIWAAGVITYILLCGFPPFRGSGDDQEVLFDQILMGQVDFPSPYWDNVSDSAKELITMMLLVDVDQRFSAVQVLEHPWVNDDGLPENEHQLSVAGKIKKHFNTGPKPNSTAAGVSVIATTALDKERQVFRRRRNQDVRSRYKAQPAPPELNSESEDYSPSSSETVRSPNSPF T42447 DRUGINFO D0H0LP PMID20483621C5g Investigative T56108 TARGETID T56108 T56108 FORMERID TTDI03589 T56108 UNIPROID TIF1A_HUMAN T56108 TARGNAME Tripartite motif-containing 24 (TRIM24) T56108 GENENAME TRIM24 T56108 TARGTYPE Literature-reported T56108 SYNONYMS Tripartite motif-containing protein 24; Transcription intermediary factor 1-alpha; TIF1A; TIF1-alpha; TIF1; RNF82; RING-type E3 ubiquitin transferase TIF1-alpha; RING finger protein 82; E3 ubiquitin-protein ligase TRIM24 T56108 FUNCTION Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity. Promotes ubiquitination and proteasomal degradation of p53/TP53. Plays a role in the regulation of cell proliferation and apoptosis, at least in part via its effects on p53/TP53 levels. Up-regulates ligand-dependent transcription activation by AR, GCR/NR3C1, thyroid hormone receptor (TR) and ESR1. Modulates transcription activation by retinoic acid (RA) receptors, including RARA. Plays a role in regulating retinoic acid-dependent proliferation of hepatocytes. Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes. T56108 PDBSTRUC 5H1V; 5H1U; 5H1T; 4ZQL; 4YC9 T56108 BIOCLASS Acyltransferase T56108 ECNUMBER EC 2.3.2.27 T56108 SEQUENCE MEVAVEKAVAAAAAASAAASGGPSAAPSGENEAESRQGPDSERGGEAARLNLLDTCAVCHQNIQSRAPKLLPCLHSFCQRCLPAPQRYLMLPAPMLGSAETPPPVPAPGSPVSGSSPFATQVGVIRCPVCSQECAERHIIDNFFVKDTTEVPSSTVEKSNQVCTSCEDNAEANGFCVECVEWLCKTCIRAHQRVKFTKDHTVRQKEEVSPEAVGVTSQRPVFCPFHKKEQLKLYCETCDKLTCRDCQLLEHKEHRYQFIEEAFQNQKVIIDTLITKLMEKTKYIKFTGNQIQNRIIEVNQNQKQVEQDIKVAIFTLMVEINKKGKALLHQLESLAKDHRMKLMQQQQEVAGLSKQLEHVMHFSKWAVSSGSSTALLYSKRLITYRLRHLLRARCDASPVTNNTIQFHCDPSFWAQNIINLGSLVIEDKESQPQMPKQNPVVEQNSQPPSGLSSNQLSKFPTQISLAQLRLQHMQQQVMAQRQQVQRRPAPVGLPNPRMQGPIQQPSISHQQPPPRLINFQNHSPKPNGPVLPPHPQQLRYPPNQNIPRQAIKPNPLQMAFLAQQAIKQWQISSGQGTPSTTNSTSSTPSSPTITSAAGYDGKAFGSPMIDLSSPVGGSYNLPSLPDIDCSSTIMLDNIVRKDTNIDHGQPRPPSNRTVQSPNSSVPSPGLAGPVTMTSVHPPIRSPSASSVGSRGSSGSSSKPAGADSTHKVPVVMLEPIRIKQENSGPPENYDFPVVIVKQESDEESRPQNANYPRSILTSLLLNSSQSSTSEETVLRSDAPDSTGDQPGLHQDNSSNGKSEWLDPSQKSPLHVGETRKEDDPNEDWCAVCQNGGELLCCEKCPKVFHLSCHVPTLTNFPSGEWICTFCRDLSKPEVEYDCDAPSHNSEKKKTEGLVKLTPIDKRKCERLLLFLYCHEMSLAFQDPVPLTVPDYYKIIKNPMDLSTIKKRLQEDYSMYSKPEDFVADFRLIFQNCAEFNEPDSEVANAGIKLENYFEELLKNLYPEKRFPKPEFRNESEDNKFSDDSDDDFVQPRKKRLKSIEERQLLK T56108 DRUGINFO D0C2PD PMID25974391C34 Investigative T01282 TARGETID T01282 T01282 FORMERID TTDR00733 T01282 UNIPROID TMPS2_HUMAN T01282 TARGNAME Transmembrane protease serine 2 (TMPRSS2) T01282 GENENAME TMPRSS2 T01282 TARGTYPE Literature-reported T01282 SYNONYMS TMPRSS2 protease; TMPRSS2 T01282 FUNCTION Serine protease that proteolytically cleaves and activates the viral spike glycoproteins which facilitate virus- cell membrane fusions; spike proteins are synthesized and maintained in precursor intermediate folding states and proteolysis permits the refolding and energy release required to create stable virus-cell linkages and membrane coalescence. Facilitates human SARS coronavirus (SARS-CoV) infection via two independent mechanisms, proteolytic cleavage of ACE2, which might promote viral uptake, and cleavage of coronavirus spike glycoprotein which activates the glycoprotein for cathepsin L- independent host cell entry. Proteolytically cleaves and activates the spike glycoproteins of human coronavirus 229E (HCoV-229E) and human coronavirus EMC (HCoV-EMC) and the fusion glycoproteins F0 of Sendai virus (SeV), human metapneumovirus (HMPV), human parainfluenza 1, 2, 3, 4a and 4b viruses (HPIV). Essential for spread and pathogenesis of influenza A virus (strains H1N1, H3N2 and H7N9); involved in proteolytic cleavage and activation of hemagglutinin (HA) protein which is essential for viral infectivity. T01282 BIOCLASS Peptidase T01282 ECNUMBER EC 3.4.21.- T01282 SEQUENCE MALNSGSPPAIGPYYENHGYQPENPYPAQPTVVPTVYEVHPAQYYPSPVPQYAPRVLTQASNPVVCTQPKSPSGTVCTSKTKKALCITLTLGTFLVGAALAAGLLWKFMGSKCSNSGIECDSSGTCINPSNWCDGVSHCPGGEDENRCVRLYGPNFILQVYSSQRKSWHPVCQDDWNENYGRAACRDMGYKNNFYSSQGIVDDSGSTSFMKLNTSAGNVDIYKKLYHSDACSSKAVVSLRCIACGVNLNSSRQSRIVGGESALPGAWPWQVSLHVQNVHVCGGSIITPEWIVTAAHCVEKPLNNPWHWTAFAGILRQSFMFYGAGYQVEKVISHPNYDSKTKNNDIALMKLQKPLTFNDLVKPVCLPNPGMMLQPEQLCWISGWGATEEKGKTSEVLNAAKVLLIETQRCNSRYVYDNLITPAMICAGFLQGNVDSCQGDSGGPLVTSKNNIWWLIGDTSWGSGCAKAYRPGVYGNVMVFTDWIYRQMRADG T01282 DRUGINFO D07ZRG PMID21741839C5 Investigative T92189 TARGETID T92189 T92189 UNIPROID OGG1_HUMAN T92189 TARGNAME N-glycosylase/DNA lyase (OGG1) T92189 GENENAME OGG1 T92189 TARGTYPE Literature-reported T92189 SYNONYMS OGH1; MUTM; MMH T92189 FUNCTION DNA repair enzyme that incises DNA at 8-oxoG residues. Excises 7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine (FAPY) from damaged DNA. Has a beta-lyase activity that nicks DNA 3' to the lesion. T92189 PDBSTRUC 5AN4; 3KTU; 3IH7; 2XHI; 2NOZ T92189 BIOCLASS Type-1 OGG1 family T92189 SEQUENCE MPARALLPRRMGHRTLASTPALWASIPCPRSELRLDLVLPSGQSFRWREQSPAHWSGVLADQVWTLTQTEEQLHCTVYRGDKSQASRPTPDELEAVRKYFQLDVTLAQLYHHWGSVDSHFQEVAQKFQGVRLLRQDPIECLFSFICSSNNNIARITGMVERLCQAFGPRLIQLDDVTYHGFPSLQALAGPEVEAHLRKLGLGYRARYVSASARAILEEQGGLAWLQQLRESSYEEAHKALCILPGVGTKVADCICLMALDKPQAVPVDVHMWHIAQRDYSWHPTTSQAKGPSPQTNKELGNFFRSLWGPYAGWAQAVLFSADLRQSRHAQEPPAKRRKGSKGPEG T15139 TARGETID T15139 T15139 FORMERID TTDI00155 T15139 UNIPROID SERA_HUMAN T15139 TARGNAME Phosphoglycerate dehydrogenase (PHGDH) T15139 GENENAME PHGDH T15139 TARGTYPE Literature-reported T15139 SYNONYMS PGDH3; Malate dehydrogenase; D-3-phosphoglycerate dehydrogenase; 3-PGDH; 2-oxoglutarate reductase T15139 FUNCTION Catalyzes the reversible oxidation of 3-phospho-D-glycerate to 3-phosphonooxypyruvate, the first step of the phosphorylated L-serine biosynthesis pathway. Also catalyzes the reversible oxidation of 2-hydroxyglutarate to 2-oxoglutarate and the reversible oxidation of (S)-malate to oxaloacetate. T15139 PDBSTRUC 5OFW; 5OFV; 5OFM; 5NZQ; 5NZP T15139 BIOCLASS Short-chain dehydrogenases reductase T15139 ECNUMBER EC 1.1.1.95 T15139 SEQUENCE MAFANLRKVLISDSLDPCCRKILQDGGLQVVEKQNLSKEELIAELQDCEGLIVRSATKVTADVINAAEKLQVVGRAGTGVDNVDLEAATRKGILVMNTPNGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSRCGEEIAVQFVDMVKGKSLTGVVNAQALTSAFSPHTKPWIGLAEALGTLMRAWAGSPKGTIQVITQGTSLKNAGNCLSPAVIVGLLKEASKQADVNLVNAKLLVKEAGLNVTTSHSPAAPGEQGFGECLLAVALAGAPYQAVGLVQGTTPVLQGLNGAVFRPEVPLRRDLPLLLFRTQTSDPAMLPTMIGLLAEAGVRLLSYQTSLVSDGETWHVMGISSLLPSLEAWKQHVTEAFQFHF T81623 TARGETID T81623 T81623 FORMERID TTDI03152 T81623 UNIPROID DAPK3_HUMAN T81623 TARGNAME Death-associated protein kinase 3 (DAPK3) T81623 GENENAME DAPK3 T81623 TARGTYPE Literature-reported T81623 SYNONYMS Zipper-interacting protein kinase; ZIPK; ZIP-kinase; MYPT1 kinase; DAP-like kinase; DAP kinase 3 T81623 FUNCTION Involved in the regulation of smooth muscle contraction. Regulates both type I (caspase-dependent) apoptotic and type II (caspase-independent) autophagic cell deaths signal, depending on the cellular setting. Involved in regulation of starvation-induced autophagy. Regulates myosin phosphorylation in both smooth muscle and non-muscle cells. In smooth muscle, regulates myosin either directly by phosphorylating MYL12B and MYL9 or through inhibition of smooth muscle myosin phosphatase (SMPP1M) via phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to enhance muscle responsiveness to Ca(2+) and promote a contractile state. Phosphorylates MYL12B in non-muscle cells leading to reorganization of actin cytoskeleton. Isoform 2 can phosphorylate myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of actin stress fibers into thick bundles. Involved in actin filament focal adhesion dynamics. The function in both reorganization of actin cytoskeleton and focal adhesion dissolution is modulated by RhoD. Positively regulates canonical Wnt/beta-catenin signaling through interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon interferon-gamma activation which is causing RPL13A release from the ribosome, RPL13A association with the GAIT complex and its subsequent involvement in transcript-selective translation inhibition. Enhances transcription from AR-responsive promoters in a hormone- and kinase-dependent manner. Involved in regulation of cell cycle progression and cell proliferation. May be a tumor suppressor. Serine/threonine kinase which is involved in the regulation of apoptosis, autophagy, transcription, translation and actin cytoskeleton reorganization. T81623 PDBSTRUC 5VJA; 5A6O; 5A6N; 3BQR; 3BHY T81623 BIOCLASS Kinase T81623 ECNUMBER EC 2.7.11.1 T81623 SEQUENCE MSTFRQEDVEDHYEMGEELGSGQFAIVRKCRQKGTGKEYAAKFIKKRRLSSSRRGVSREEIEREVNILREIRHPNIITLHDIFENKTDVVLILELVSGGELFDFLAEKESLTEDEATQFLKQILDGVHYLHSKRIAHFDLKPENIMLLDKNVPNPRIKLIDFGIAHKIEAGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGETKQETLTNISAVNYDFDEEYFSNTSELAKDFIRRLLVKDPKRRMTIAQSLEHSWIKAIRRRNVRGEDSGRKPERRRLKTTRLKEYTIKSHSSLPPNNSYADFERFSKVLEEAAAAEEGLRELQRSRRLCHEDVEALAAIYEEKEAWYREESDSLGQDLRRLRQELLKTEALKRQAQEEAKGALLGTSGLKRRFSRLENRYEALAKQVASEMRFVQDLVRALEQEKLQGVECGLR T81623 DRUGINFO D07ADX URMC-099 Investigative T39519 TARGETID T39519 T39519 FORMERID TTDI03565 T39519 UNIPROID SUV91_HUMAN T39519 TARGNAME Lysine N-methyltransferase 1A (SUV39H1) T39519 GENENAME SUV39H1 T39519 TARGTYPE Literature-reported T39519 SYNONYMS Suppressor of variegation 3-9 homolog 1; Su(var)3-9 homolog 1; SUV39H; Position-effect variegation 3-9 homolog; KMT1A; Histone-lysine N-methyltransferase SUV39H1; Histone H3-K9 methyltransferase 1; H3-K9-HMTase 1 T39519 FUNCTION Weakly methylates histone H1 (in vitro). H3 'Lys-9' trimethylation represents a specific tag for epigenetic transcriptional repression by recruiting HP1 (CBX1, CBX3 and/or CBX5) proteins to methylated histones. Mainly functions in heterochromatin regions, thereby playing a central role in the establishment of constitutive heterochromatin at pericentric and telomere regions. H3 'Lys-9' trimethylation is also required to direct DNA methylation at pericentric repeats. SUV39H1 is targeted to histone H3 via its interaction with RB1 and is involved in many processes, such as repression of MYOD1-stimulated differentiation, regulation of the control switch for exiting the cell cycle and entering differentiation, repression by the PML-RARA fusion protein, BMP-induced repression, repression of switch recombination to IgA and regulation of telomere length. Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. Recruited by the large PER complex to the E-box elements of the circadian target genes such as PER2 itself or PER1, contributes to the conversion of local chromatin to a heterochromatin-like repressive state through H3 'Lys-9' trimethylation. Histone methyltransferase that specifically trimethylates 'Lys-9' of histone H3 using monomethylated H3 'Lys-9' as substrate. T39519 PDBSTRUC 3MTS T39519 BIOCLASS Methyltransferase T39519 ECNUMBER EC 2.1.1.43 T39519 SEQUENCE MAENLKGCSVCCKSSWNQLQDLCRLAKLSCPALGISKRNLYDFEVEYLCDYKKIREQEYYLVKWRGYPDSESTWEPRQNLKCVRILKQFHKDLERELLRRHHRSKTPRHLDPSLANYLVQKAKQRRALRRWEQELNAKRSHLGRITVENEVDLDGPPRAFVYINEYRVGEGITLNQVAVGCECQDCLWAPTGGCCPGASLHKFAYNDQGQVRLRAGLPIYECNSRCRCGYDCPNRVVQKGIRYDLCIFRTDDGRGWGVRTLEKIRKNSFVMEYVGEIITSEEAERRGQIYDRQGATYLFDLDYVEDVYTVDAAYYGNISHFVNHSCDPNLQVYNVFIDNLDERLPRIAFFATRTIRAGEELTFDYNMQVDPVDMESTRMDSNFGLAGLPGSPKKRVRIECKCGTESCRKYLF T39519 DRUGINFO D04FNI chaetocin Investigative T74483 TARGETID T74483 T74483 FORMERID TTDR00544 T74483 UNIPROID KCNQ2_HUMAN T74483 TARGNAME Voltage-gated potassium channel Kv7.2 (KCNQ2) T74483 GENENAME KCNQ2 T74483 TARGTYPE Literature-reported T74483 SYNONYMS Voltage-gated potassium channel subunit Kv7.2; Neuroblastoma-specific potassium channel alpha subunit KvLQT2; Neuroblastoma-specific potassium channel KQT-like 2; KQT-like 2; KCNQ2; K+ channel KCNQ2 T74483 FUNCTION Probably importantin the regulation of neuronal excitability. Associates with kcnq3 to form a potassium channel with essentially identical properties to the channel underlying the native m-current. T74483 PDBSTRUC 6FEH; 6FEG; 5J03 T74483 BIOCLASS Voltage-gated ion channel T74483 SEQUENCE MVQKSRNGGVYPGPSGEKKLKVGFVGLDPGAPDSTRDGALLIAGSEAPKRGSILSKPRAGGAGAGKPPKRNAFYRKLQNFLYNVLERPRGWAFIYHAYVFLLVFSCLVLSVFSTIKEYEKSSEGALYILEIVTIVVFGVEYFVRIWAAGCCCRYRGWRGRLKFARKPFCVIDIMVLIASIAVLAAGSQGNVFATSALRSLRFLQILRMIRMDRRGGTWKLLGSVVYAHSKELVTAWYIGFLCLILASFLVYLAEKGENDHFDTYADALWWGLITLTTIGYGDKYPQTWNGRLLAATFTLIGVSFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAAGLIQSAWRFYATNLSRTDLHSTWQYYERTVTVPMYSSQTQTYGASRLIPPLNQLELLRNLKSKSGLAFRKDPPPEPSPSKGSPCRGPLCGCCPGRSSQKVSLKDRVFSSPRGVAAKGKGSPQAQTVRRSPSADQSLEDSPSKVPKSWSFGDRSRARQAFRIKGAASRQNSEEASLPGEDIVDDKSCPCEFVTEDLTPGLKVSIRAVCVMRFLVSKRKFKESLRPYDVMDVIEQYSAGHLDMLSRIKSLQSRVDQIVGRGPAITDKDRTKGPAEAELPEDPSMMGRLGKVEKQVLSMEKKLDFLVNIYMQRMGIPPTETEAYFGAKEPEPAPPYHSPEDSREHVDRHGCIVKIVRSSSSTGQKNFSAPPAAPPVQCPPSTSWQPQSHPRQGHGTSPVGDHGSLVRIPPPPAHERSLSAYGGGNRASMEFLRQEDTPGCRPPEGNLRDSDTSISIPSVDHEELERSFSGFSISQSKENLDALNSCYAAVAPCAKVRPYIAEGESDTDSDLCTPCGPPPRSATGEGPFGDVGWAGPRK T74483 DRUGINFO D0E2FZ ICA-69673 Preclinical T74483 DRUGINFO D08ATZ QO-58 Investigative T74483 DRUGINFO D0N5CH ICA-27243 Investigative T74483 DRUGINFO D0O4IO ztz240 Investigative T74483 DRUGINFO D02BGR (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide Investigative T74483 DRUGINFO D07FTI zinc pyrithione Investigative T74483 DRUGINFO D0P8PH XE991 Investigative T74483 DRUGINFO D08RJC PD-32577 Investigative T74483 DRUGINFO D07ZAJ PIP2 Investigative T74483 DRUGINFO D06PZZ [14C]TEA Investigative T13453 TARGETID T13453 T13453 FORMERID TTDR01044 T13453 UNIPROID GALR2_HUMAN T13453 TARGNAME Galanin receptor type 2 (GAL2-R) T13453 GENENAME GALR2 T13453 TARGTYPE Literature-reported T13453 SYNONYMS GALR2; GALR-2; GALNR2; GAL2-R T13453 FUNCTION The activity of this receptor is mediated by G proteins that activate the phospholipase C/protein kinase C pathway (via G(q)) and that inhibit adenylyl cyclase (via G(i)). Receptor for the hormone galanin and GALP. Receptor for the hormone spexin-1. T13453 BIOCLASS GPCR rhodopsin T13453 SEQUENCE MNVSGCPGAGNASQAGGGGGWHPEAVIVPLLFALIFLVGTVGNTLVLAVLLRGGQAVSTTNLFILNLGVADLCFILCCVPFQATIYTLDGWVFGSLLCKAVHFLIFLTMHASSFTLAAVSLDRYLAIRYPLHSRELRTPRNALAAIGLIWGLSLLFSGPYLSYYRQSQLANLTVCHPAWSAPRRRAMDICTFVFSYLLPVLVLGLTYARTLRYLWRAVDPVAAGSGARRAKRKVTRMILIVAALFCLCWMPHHALILCVWFGQFPLTRATYALRILSHLVSYANSCVNPIVYALVSKHFRKGFRTICAGLLGRAPGRASGRVCAAARGTHSGSVLERESSDLLHMSEAAGALRPCPGASQPCILEPCPGPSWQGPKAGDSILTVDVA T13453 DRUGINFO D00RWP GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2 Investigative T13453 DRUGINFO D01LMH [Sar1Gly]GAL-B2 Investigative T13453 DRUGINFO D02GOE (Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K Investigative T13453 DRUGINFO D02JQP GalB2 Investigative T13453 DRUGINFO D03ECE (Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K Investigative T13453 DRUGINFO D05GFD (Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K Investigative T13453 DRUGINFO D06DWA (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K Investigative T13453 DRUGINFO D07NOJ [Sar1Ala]GAL-B2 Investigative T13453 DRUGINFO D09SDZ GWTLNSAGYLLGPHAV-NH2 Investigative T13453 DRUGINFO D0D3CG GWTLNSAGYLLGPrPKPQQwFwLL-CONH2 Investigative T13453 DRUGINFO D0DD3F (Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K Investigative T13453 DRUGINFO D0EO5F (Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K Investigative T13453 DRUGINFO D0H4DF GALANTIDE Investigative T13453 DRUGINFO D0H9QA Gal-B5 Investigative T13453 DRUGINFO D0NJ4R GALANIN Investigative T13453 DRUGINFO D0PY7O WTLNSAGYLL-CONH2 Investigative T13453 DRUGINFO D0Q3CB GWTLNSAGYLLGPPPALALA-CONH2 Investigative T13453 DRUGINFO D0S4VO [N-Me,des-Sar]Gal-B2 Investigative T13453 DRUGINFO D0SV5D GWTLNSAGYLLGPPPGFSPFR-CONH2 Investigative T13453 DRUGINFO D0T6CU WTLNSAGYLLGPHAVGNHPSFSDKNGLTS-CONH2 Investigative T13453 DRUGINFO D0TF7R (Sar)WTLNSAGYLLGPKKKK Investigative T13453 DRUGINFO D0V7UG [N-Ac,des-Sar]Gal-B2 Investigative T13453 DRUGINFO D0Z3QG (Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K Investigative T13453 DRUGINFO D0Z7QU GWTLNSAGYLLGPRHYINLITRQRY-CONH2 Investigative T43289 TARGETID T43289 T43289 FORMERID TTDR00461 T43289 UNIPROID KLK8_HUMAN T43289 TARGNAME Neuropsin (KLK8) T43289 GENENAME KLK8 T43289 TARGTYPE Literature-reported T43289 SYNONYMS hK8; UNQ283/PRO322; Tumor-associated differentially expressed gene-14 protein; Tumor-associated differentially expressed gene 14 protein; TADG14; Serine protease TADG-14; Serine protease 19; PRSS19; Ovasin; Neuropsin (M(r) 25032); NRPN; NP; Kallikrein-8; Kallikrein 8; KLK8 (neuropsin/ovasin) T43289 FUNCTION Cleaves L1CAM in response to increased neural activity. Induces neurite outgrowth and fasciculation of cultured hippocampal neurons. Plays a role in the formation and maturation of orphan and small synaptic boutons in the Schaffer-collateral pathway, regulates Schaffer-collateral long-term potentiation in the hippocampus and is required for memory acquisition and synaptic plasticity. Involved in skin desquamation and keratinocyte proliferation. Plays a role in the secondary phase of pathogenesis following spinal cord injury. Serine protease which is capable of degrading a number of proteins such as casein, fibrinogen, kininogen, fibronectin and collagen type IV. T43289 PDBSTRUC 5MS4; 5MS3 T43289 BIOCLASS Peptidase T43289 ECNUMBER EC 3.4.21.118 T43289 SEQUENCE MGRPRPRAAKTWMFLLLLGGAWAGHSRAQEDKVLGGHECQPHSQPWQAALFQGQQLLCGGVLVGGNWVLTAAHCKKPKYTVRLGDHSLQNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSKVKPISLADHCTQPGQKCTVSGWGTVTSPRENFPDTLNCAEVKIFPQKKCEDAYPGQITDGMVCAGSSKGADTCQGDSGGPLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIKKIIGSKG T78019 TARGETID T78019 T78019 FORMERID TTDI00244 T78019 UNIPROID TP4A3_HUMAN T78019 TARGNAME Protein tyrosine phosphatase IVA 3 (PRL-3) T78019 GENENAME PTP4A3 T78019 TARGTYPE Literature-reported T78019 SYNONYMS Protein-tyrosine phosphatase of regenerating liver 3; Protein-tyrosine phosphatase 4a3; Protein tyrosine phosphatase type IVA 3; PRL3; PRL-3 T78019 FUNCTION Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis. Enhances cell proliferation, cell motility and invasive activity, and promotes cancer metastasis. May be involved in the progression of cardiac hypertrophy by inhibiting intracellular calcium mobilization in response to angiotensin II. T78019 PDBSTRUC 5TSR; 2MBC; 1V3A; 1R6H T78019 BIOCLASS Phosphoric monoester hydrolase T78019 ECNUMBER EC 3.1.3.48 T78019 SEQUENCE MARMNRPAPVEVSYKHMRFLITHNPTNATLSTFIEDLKKYGATTVVRVCEVTYDKTPLEKDGITVVDWPFDDGAPPPGKVVEDWLSLVKAKFCEAPGSCVAVHCVAGLGRAPVLVALALIESGMKYEDAIQFIRQKRRGAINSKQLTYLEKYRPKQRLRFKDPHTHKTRCCVM T78019 DRUGINFO D0C6RO Sodium orthovanadate Investigative T79307 TARGETID T79307 T79307 FORMERID TTDI03612 T79307 UNIPROID ULK1_HUMAN T79307 TARGNAME Serine/threonine-protein kinase ULK1 (ULK1) T79307 GENENAME ULK1 T79307 TARGTYPE Literature-reported T79307 SYNONYMS hATG1; Unc-51-like kinase 1; KIAA0722; Autophagy-related protein 1 homolog; ATG1 T79307 FUNCTION Acts upstream of phosphatidylinositol 3-kinase PIK3C3 to regulate the formation of autophagophores, the precursors of autophagosomes. Part of regulatory feedback loops in autophagy: acts both as a downstream effector and negative regulator of mammalian target of rapamycin complex 1 (mTORC1) via interaction with RPTOR. Activated via phosphorylation by AMPK and also acts as a regulator of AMPK by mediating phosphorylation of AMPK subunits PRKAA1, PRKAB2 and PRKAG1, leading to negatively regulate AMPK activity. May phosphorylate ATG13/KIAA0652 and RPTOR; however such data need additional evidences. Plays a role early in neuronal differentiation and is required for granule cell axon formation. May also phosphorylate SESN2 and SQSTM1 to regulate autophagy. Serine/threonine-protein kinase involved in autophagy in response to starvation. T79307 PDBSTRUC 6QAS; 6MNH; 6HYO; 5CI7; 4WNP T79307 BIOCLASS Kinase T79307 ECNUMBER EC 2.7.11.1 T79307 SEQUENCE MEPGRGGTETVGKFEFSRKDLIGHGAFAVVFKGRHREKHDLEVAVKCINKKNLAKSQTLLGKEIKILKELKHENIVALYDFQEMANSVYLVMEYCNGGDLADYLHAMRTLSEDTIRLFLQQIAGAMRLLHSKGIIHRDLKPQNILLSNPAGRRANPNSIRVKIADFGFARYLQSNMMAATLCGSPMYMAPEVIMSQHYDGKADLWSIGTIVYQCLTGKAPFQASSPQDLRLFYEKNKTLVPTIPRETSAPLRQLLLALLQRNHKDRMDFDEFFHHPFLDASPSVRKSPPVPVPSYPSSGSGSSSSSSSTSHLASPPSLGEMQQLQKTLASPADTAGFLHSSRDSGGSKDSSCDTDDFVMVPAQFPGDLVAEAPSAKPPPDSLMCSGSSLVASAGLESHGRTPSPSPPCSSSPSPSGRAGPFSSSRCGASVPIPVPTQVQNYQRIERNLQSPTQFQTPRSSAIRRSGSTSPLGFARASPSPPAHAEHGGVLARKMSLGGGRPYTPSPQVGTIPERPGWSGTPSPQGAEMRGGRSPRPGSSAPEHSPRTSGLGCRLHSAPNLSDLHVVRPKLPKPPTDPLGAVFSPPQASPPQPSHGLQSCRNLRGSPKLPDFLQRNPLPPILGSPTKAVPSFDFPKTPSSQNLLALLARQGVVMTPPRNRTLPDLSEVGPFHGQPLGPGLRPGEDPKGPFGRSFSTSRLTDLLLKAAFGTQAPDPGSTESLQEKPMEIAPSAGFGGSLHPGARAGGTSSPSPVVFTVGSPPSGSTPPQGPRTRMFSAGPTGSASSSARHLVPGPCSEAPAPELPAPGHGCSFADPITANLEGAVTFEAPDLPEETLMEQEHTEILRGLRFTLLFVQHVLEIAALKGSASEAAGGPEYQLQESVVADQISLLSREWGFAEQLVLYLKVAELLSSGLQSAIDQIRAGKLCLSSTVKQVVRRLNELYKASVVSCQGLSLRLQRFFLDKQRLLDRIHSITAERLIFSHAVQMVQSAALDEMFQHREGCVPRYHKALLLLEGLQHMLSDQADIENVTKCKLCIERRLSALLTGICA T79307 DRUGINFO D00EMH PMID21967808CR-16 Investigative T25690 TARGETID T25690 T25690 FORMERID TTDI00166 T25690 UNIPROID CISY_HUMAN T25690 TARGNAME Citrate synthase (CS) T25690 GENENAME CS T25690 TARGTYPE Literature-reported T25690 SYNONYMS Citrate synthase, mitochondrial; Citrate (Si)-synthase T25690 FUNCTION extracellular exosome, mitochondrial matrix, mitochondrion, nucleus, citrate (Si)-synthase activity, RNA binding, carbohydrate metabolic process, tricarboxylic acid cycle. T25690 PDBSTRUC 5UZR; 5UZQ; 5UZP T25690 BIOCLASS Acyltransferase T25690 ECNUMBER EC 2.3.3.1 T25690 SEQUENCE MALLTAAARLLGTKNASCLVLAARHASASSTNLKDILADLIPKEQARIKTFRQQHGKTVVGQITVDMMYGGMRGMKGLVYETSVLDPDEGIRFRGFSIPECQKLLPKAKGGEEPLPEGLFWLLVTGHIPTEEQVSWLSKEWAKRAALPSHVVTMLDNFPTNLHPMSQLSAAVTALNSESNFARAYAQGISRTKYWELIYEDSMDLIAKLPCVAAKIYRNLYREGSGIGAIDSNLDWSHNFTNMLGYTDHQFTELTRLYLTIHSDHEGGNVSAHTSHLVGSALSDPYLSFAAAMNGLAGPLHGLANQEVLVWLTQLQKEVGKDVSDEKLRDYIWNTLNSGRVVPGYGHAVLRKTDPRYTCQREFALKHLPNDPMFKLVAQLYKIVPNVLLEQGKAKNPWPNVDAHSGVLLQYYGMTEMNYYTVLFGVSRALGVLAQLIWSRALGFPLERPKSMSTEGLMKFVDSKSG T78205 TARGETID T78205 T78205 FORMERID TTDR00987 T78205 UNIPROID TRPM2_HUMAN T78205 TARGNAME Long transient receptor potential channel 2 (TRPM2) T78205 GENENAME TRPM2 T78205 TARGTYPE Literature-reported T78205 SYNONYMS TrpC7; Transient receptor potential melastatin 2; Transient receptor potential channel 7; Transient receptor potential cation channel subfamily M member 2; LTrpC2; LTrpC-2; Estrogen-responsive element-associated gene 1 protein; EREG1 T78205 FUNCTION Isoform 1: Nonselective, voltage-independent cation channel that mediates Na(+) and Ca(2+) influx, leading to increased cytoplasmic Ca(2+) levels. Functions as ligand-gated ion channel. Binding of ADP-ribose to the cytoplasmic Nudix domain causes a conformation change; the channel is primed but still requires Ca(2+) binding to trigger channel opening. Extracellular calcium passes through the channel and increases channel activity. Contributes to Ca(2+) release from intracellular stores in response to ADP-ribose. Plays a role in numerous processes that involve signaling via intracellular Ca(2+) levels (Probable). Besides, mediates the release of lysosomal Zn(2+) stores in response to reactive oxygen species, leading to increased cytosolic Zn(2+) levels. Activated by moderate heat (35 to 40 degrees Celsius). Activated by intracellular ADP-ribose, beta-NAD (NAD(+)) and similar compounds, and by oxidative stress caused by reactive oxygen or nitrogen species. The precise physiological activators are under debate; the true, physiological activators may be ADP-ribose and ADP-ribose-2'-phosphate. Activation by ADP-ribose and beta-NAD is strongly increased by moderate heat (35 to 40 degrees Celsius). Likewise, reactive oxygen species lower the threshold for activation by moderate heat (37 degrees Celsius). Plays a role in mediating behavorial and physiological responses to moderate heat and thereby contributes to body temperature homeostasis. Plays a role in insulin secretion, a process that requires increased cytoplasmic Ca(2+) levels (By similarity). Required for normal IFNG and cytokine secretion and normal innate immune immunity in response to bacterial infection. Required for normal phagocytosis and cytokine release by macrophages exposed to zymosan (in vitro). Plays a role in dendritic cell differentiation and maturation, and in dendritic cell chemotaxis via its role in regulating cytoplasmic Ca(2+) levels (By similarity). Plays a role in the regulation of the reorganization of the actin cytoskeleton and filopodia formation in response to reactive oxygen species via its role in increasing cytoplasmic Ca(2+) and Zn(2+) levels. Confers susceptibility to cell death following oxidative stress. T78205 PDBSTRUC 6MJ2; 6MIZ; 6MIX T78205 BIOCLASS Transient receptor potential catioin channel T78205 SEQUENCE MEPSALRKAGSEQEEGFEGLPRRVTDLGMVSNLRRSNSSLFKSWRLQCPFGNNDKQESLSSWIPENIKKKECVYFVESSKLSDAGKVVCQCGYTHEQHLEEATKPHTFQGTQWDPKKHVQEMPTDAFGDIVFTGLSQKVKKYVRVSQDTPSSVIYHLMTQHWGLDVPNLLISVTGGAKNFNMKPRLKSIFRRGLVKVAQTTGAWIITGGSHTGVMKQVGEAVRDFSLSSSYKEGELITIGVATWGTVHRREGLIHPTGSFPAEYILDEDGQGNLTCLDSNHSHFILVDDGTHGQYGVEIPLRTRLEKFISEQTKERGGVAIKIPIVCVVLEGGPGTLHTIDNATTNGTPCVVVEGSGRVADVIAQVANLPVSDITISLIQQKLSVFFQEMFETFTESRIVEWTKKIQDIVRRRQLLTVFREGKDGQQDVDVAILQALLKASRSQDHFGHENWDHQLKLAVAWNRVDIARSEIFMDEWQWKPSDLHPTMTAALISNKPEFVKLFLENGVQLKEFVTWDTLLYLYENLDPSCLFHSKLQKVLVEDPERPACAPAAPRLQMHHVAQVLRELLGDFTQPLYPRPRHNDRLRLLLPVPHVKLNVQGVSLRSLYKRSSGHVTFTMDPIRDLLIWAIVQNRRELAGIIWAQSQDCIAAALACSKILKELSKEEEDTDSSEEMLALAEEYEHRAIGVFTECYRKDEERAQKLLTRVSEAWGKTTCLQLALEAKDMKFVSHGGIQAFLTKVWWGQLSVDNGLWRVTLCMLAFPLLLTGLISFREKRLQDVGTPAARARAFFTAPVVVFHLNILSYFAFLCLFAYVLMVDFQPVPSWCECAIYLWLFSLVCEEMRQLFYDPDECGLMKKAALYFSDFWNKLDVGAILLFVAGLTCRLIPATLYPGRVILSLDFILFCLRLMHIFTISKTLGPKIIIVKRMMKDVFFFLFLLAVWVVSFGVAKQAILIHNERRVDWLFRGAVYHSYLTIFGQIPGYIDGVNFNPEHCSPNGTDPYKPKCPESDATQQRPAFPEWLTVLLLCLYLLFTNILLLNLLIAMFNYTFQQVQEHTDQIWKFQRHDLIEEYHGRPAAPPPFILLSHLQLFIKRVVLKTPAKRHKQLKNKLEKNEEAALLSWEIYLKENYLQNRQFQQKQRPEQKIEDISNKVDAMVDLLDLDPLKRSGSMEQRLASLEEQVAQTAQALHWIVRTLRASGFSSEADVPTLASQKAAEEPDAEPGGRKKTEEPGDSYHVNARHLLYPNCPVTRFPVPNEKVPWETEFLIYDPPFYTAERKDAAAMDPMGDTLEPLSTIQYNVVDGLRDRRSFHGPYTVQAGLPLNPMGRTGLRGRGSLSCFGPNHTLYPMVTRWRRNEDGAICRKSIKKMLEVLVVKLPLSEHWALPGGSREPGEMLPRKLKRILRQEHWPSFENLLKCGMEVYKGYMDDPRNTDNAWIETVAVSVHFQDQNDVELNRLNSNLHACDSGASIRWQVVDRRIPLYANHKTLLQKAAAEFGAHY T78205 DRUGINFO D01CNF OAADPR Investigative T78205 DRUGINFO D0E9LJ ADP ribose Investigative T78205 DRUGINFO D0Q1HN GEA 3162 Investigative T78205 DRUGINFO D0YO2D cADPR Investigative T78205 DRUGINFO D07RTQ NAADP Investigative T78205 DRUGINFO D0N7MS ACAA Investigative T78205 DRUGINFO D00HCI 2-APB Investigative T68470 TARGETID T68470 T68470 FORMERID TTDI03610 T68470 UNIPROID UBP1_HUMAN T68470 TARGNAME Deubiquitinating enzyme 1 (USP1) T68470 GENENAME USP1 T68470 TARGTYPE Literature-reported T68470 SYNONYMS hUBP; Ubiquitin-specific-processing protease 1; Ubiquitin thioesterase 1; Ubiquitin carboxyl-terminal hydrolase 1 T68470 FUNCTION Involved in PCNA-mediated translesion synthesis (TLS) by deubiquitinating monoubiquitinated PCNA. Has almost no deubiquitinating activity by itself and requires the interaction with WDR48 to have a high activity. Negative regulator of DNA damage repair which specifically deubiquitinates monoubiquitinated FANCD2. T68470 PDBSTRUC 6DO5 T68470 BIOCLASS Peptidase T68470 ECNUMBER EC 3.4.19.12 T68470 SEQUENCE MPGVIPSESNGLSRGSPSKKNRLSLKFFQKKETKRALDFTDSQENEEKASEYRASEIDQVVPAAQSSPINCEKRENLLPFVGLNNLGNTCYLNSILQVLYFCPGFKSGVKHLFNIISRKKEALKDEANQKDKGNCKEDSLASYELICSLQSLIISVEQLQASFLLNPEKYTDELATQPRRLLNTLRELNPMYEGYLQHDAQEVLQCILGNIQETCQLLKKEEVKNVAELPTKVEEIPHPKEEMNGINSIEMDSMRHSEDFKEKLPKGNGKRKSDTEFGNMKKKVKLSKEHQSLEENQRQTRSKRKATSDTLESPPKIIPKYISENESPRPSQKKSRVKINWLKSATKQPSILSKFCSLGKITTNQGVKGQSKENECDPEEDLGKCESDNTTNGCGLESPGNTVTPVNVNEVKPINKGEEQIGFELVEKLFQGQLVLRTRCLECESLTERREDFQDISVPVQEDELSKVEESSEISPEPKTEMKTLRWAISQFASVERIVGEDKYFCENCHHYTEAERSLLFDKMPEVITIHLKCFAASGLEFDCYGGGLSKINTPLLTPLKLSLEEWSTKPTNDSYGLFAVVMHSGITISSGHYTASVKVTDLNSLELDKGNFVVDQMCEIGKPEPLNEEEARGVVENYNDEEVSIRVGGNTQPSKVLNKKNVEAIGLLGGQKSKADYELYNKASNPDKVASTAFAENRNSETSDTTGTHESDRNKESSDQTGINISGFENKISYVVQSLKEYEGKWLLFDDSEVKVTEEKDFLNSLSPSTSPTSTPYLLFYKKL T68470 DRUGINFO D0M5FO ML323 Preclinical T33969 TARGETID T33969 T33969 FORMERID TTDS00278 T33969 UNIPROID ABCBB_HUMAN T33969 TARGNAME ATP-binding cassette transporter B11 (ABCB11) T33969 GENENAME ABCB11 T33969 TARGTYPE Literature-reported T33969 SYNONYMS BSEP; ATP-binding cassette, sub-family B, member 11; ATP-binding cassette sub-family B member 11 T33969 FUNCTION Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes. T33969 BIOCLASS ABC transporter T33969 SEQUENCE MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIWLMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLNQNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFRRIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWKLTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKREVERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYALAFWYGSTLVLDEGEYTPGTLVQIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEIEFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVTVDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNFIMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEVLSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQGNQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKSTYEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQILGTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAMLGQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKLSLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFIEALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRVISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDFVDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMIDGHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDFVMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVALDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPIS T04696 TARGETID T04696 T04696 FORMERID TTDNR00765 T04696 UNIPROID TYDP2_HUMAN T04696 TARGNAME Tyrosyl-DNA phosphodiesterase 2 (TDP2) T04696 GENENAME TDP2 T04696 TARGTYPE Literature-reported T04696 SYNONYMS hTDP2; VPg unlinkase; Tyrosyl-RNA phosphodiesterase; Tyr-DNA phosphodiesterase 2; TRAF and TNF receptor-associated protein; TDP2; ETS1-associated protein II; ETS1-associated protein 2; EAPII; 5'-tyrosyl-DNA phosphodiesterase; 5'-Tyr-DNA phosphodiesterase T04696 FUNCTION DNA repair enzyme that can remove a variety of covalent adducts from DNA through hydrolysis of a 5'-phosphodiester bond, giving rise to DNA with a free 5' phosphate. Catalyzes the hydrolysis of dead-end complexes between DNA and the topoisomerase 2 (TOP2) active site tyrosine residue. Hydrolyzes 5'- phosphoglycolates on protruding 5' ends on DNA double-strand breaks (DSBs) due to DNA damage by radiation and free radicals. The 5'-tyrosyl DNA phosphodiesterase activity can enable the repair of TOP2-induced DSBs without the need for nuclease activity, creating a 'clean' DSB with 5'-phosphate termini that are ready for ligation. Has preference for single-stranded DNA or duplex DNA with a 4 base pair overhang as substrate. Has also 3'- tyrosyl DNA phosphodiesterase activity, but less efficiently and much slower than TDP1. Constitutes the major if not only 5'- tyrosyl-DNA phosphodiesterase in cells. Also acts as a 5'-tyrosyl- RNA phosphodiesterase following picornavirus infection: its activity is hijacked by picornavirus and acts by specifically cleaving the protein-RNA covalent linkage generated during the viral genomic RNA replication steps of a picornavirus infection, without impairing the integrity of viral RNA. Also acts as an adapter by participating in the specific activation of MAP3K7/TAK1 in response to TGF-beta: associates with components of the TGF- beta receptor-TRAF6-TAK1 signaling module and promotes their ubiquitination dependent complex formation. Involved in non- canonical TGF-beta induced signaling routes. May also act as a negative regulator of ETS1 and may inhibit NF-kappa-B activation. Acts as a regulator of ribosome biogenesis following stress. T04696 PDBSTRUC 5J3S; 5J3P; 5INO T04696 BIOCLASS Phosphoric diester hydrolase T04696 ECNUMBER EC 3.1.4.- T04696 SEQUENCE MELGSCLEGGREAAEEEGEPEVKKRRLLCVEFASVASCDAAVAQCFLAENDWEMERALNSYFEPPVEESALERRPETISEPKTYVDLTNEETTDSTTSKISPSEDTQQENGSMFSLITWNIDGLDLNNLSERARGVCSYLALYSPDVIFLQEVIPPYYSYLKKRSSNYEIITGHEEGYFTAIMLKKSRVKLKSQEIIPFPSTKMMRNLLCVHVNVSGNELCLMTSHLESTRGHAAERMNQLKMVLKKMQEAPESATVIFAGDTNLRDREVTRCGGLPNNIVDVWEFLGKPKHCQYTWDTQMNSNLGITAACKLRFDRIFFRAAAEEGHIIPRSLDLLGLEKLDCGRFPSDHWGLLCNLDIIL T13086 TARGETID T13086 T13086 FORMERID TTDNR00709 T13086 UNIPROID NET1_HUMAN T13086 TARGNAME Netrin-1 (NTN1) T13086 GENENAME NTN1 T13086 TARGTYPE Literature-reported T13086 SYNONYMS NTN1; Epididymis tissue protein Li 131P T13086 FUNCTION Netrins control guidance of CNS commissural axons and peripheral motor axons. Its association with either Dor some UNC5 receptors will lead to axon attraction or repulsion, respectively. It also serve as a survival factor via its association with its receptors which prevent the initiation of apoptosis. Involved in tumorigenesis by regulating apoptosis. T13086 PDBSTRUC 6FKQ; 4URT T13086 SEQUENCE MMRAVWEALAALAAVACLVGAVRGGPGLSMFAGQAAQPDPCSDENGHPRRCIPDFVNAAFGKDVRVSSTCGRPPARYCVVSERGEERLRSCHLCNASDPKKAHPPAFLTDLNNPHNLTCWQSENYLQFPHNVTLTLSLGKKFEVTYVSLQFCSPRPESMAIYKSMDYGRTWVPFQFYSTQCRKMYNRPHRAPITKQNEQEAVCTDSHTDMRPLSGGLIAFSTLDGRPSAHDFDNSPVLQDWVTATDIRVAFSRLHTFGDENEDDSELARDSYFYAVSDLQVGGRCKCNGHAARCVRDRDDSLVCDCRHNTAGPECDRCKPFHYDRPWQRATAREANECVACNCNLHARRCRFNMELYKLSGRKSGGVCLNCRHNTAGRHCHYCKEGYYRDMGKPITHRKACKACDCHPVGAAGKTCNQTTGQCPCKDGVTGITCNRCAKGYQQSRSPIAPCIKIPVAPPTTAASSVEEPEDCDSYCKASKGKLKINMKKYCKKDYAVQIHILKADKAGDWWKFTVNIISVYKQGTSRIRRGDQSLWIRSRDIACKCPKIKPLKKYLLLGNAEDSPDQSGIVADKSSLVIQWRDTWARRLRKFQQREKKGKCKKA T26748 TARGETID T26748 T26748 FORMERID TTDR00710 T26748 UNIPROID NUDT3_HUMAN T26748 TARGNAME Diphosphoinositol polyphosphate phosphohydrolase 2 (NUDT3) T26748 GENENAME NUDT3 T26748 TARGTYPE Literature-reported T26748 SYNONYMS NUDT3; Diphosphoinositol polyphosphate phosphohydrolase; DIPP2 T26748 FUNCTION Cleaves a beta-phosphate from the diphosphate groups in PP-InsP5 (diphosphoinositol pentakisphosphate) and [PP]2-InsP4 (bisdiphosphoinositol tetrakisphosphate), suggesting that it may play a role in signal transduction. InsP6 (inositol hexakisphophate) is not a substrate. Acts as a negative regulator of the ERK1/2 pathway. Also able to catalyze the hydrolysis of dinucleoside oligophosphates, with Ap6A and Ap5A being the preferred substrates. The major reaction products are ADP and p4a from Ap6A and ADP and ATP from Ap5A. Also able to hydrolyze 5- phosphoribose 1-diphosphate. T26748 PDBSTRUC 2Q9P; 2FVV T26748 BIOCLASS Acid anhydrides hydrolase T26748 ECNUMBER EC 3.6.1.52 T26748 SEQUENCE MMKLKSNQTRTYDGDGYKKRAACLCFRSESEEEVLLVSSSRHPDRWIVPGGGMEPEEEPSVAAVREVCEEAGVKGTLGRLVGIFENQERKHRTYVYVLIVTEVLEDWEDSVNIGRKREWFKIEDAIKVLQYHKPVQASYFETLRQGYSANNGTPVVATTYSVSAQSSMSGIR T15053 TARGETID T15053 T15053 FORMERID TTDI00006 T15053 UNIPROID LDHA_HUMAN T15053 TARGNAME Lactate dehydrogenase A (LDHA) T15053 GENENAME LDHA T15053 TARGTYPE Literature-reported T15053 SYNONYMS Renal carcinoma antigen NYREN59; Renal carcinoma antigen NY-REN-59; PIG19; Llactate dehydrogenase A chain; LDHM; LDH-M; LDH-A; LDH muscle subunit; L-lactate dehydrogenase A chain; Cell proliferationinducing gene 19 protein; Cell proliferation-inducing gene 19 protein T15053 FUNCTION Cadherin binding, L-lactate dehydrogenase activity, glycolytic process, pyruvate metabolic process, substantia nigra development. T15053 PDBSTRUC 6BB3; 6BB2; 6BB1; 6BB0; 6BAZ T15053 BIOCLASS CH-OH donor oxidoreductase T15053 ECNUMBER EC 1.1.1.27 T15053 SEQUENCE MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF T95408 TARGETID T95408 T95408 FORMERID TTDR00739 T95408 UNIPROID SODM_ECOLI T95408 TARGNAME Bacterial Superoxide dismutase Mn (Bact sodA) T95408 GENENAME Bact sodA T95408 TARGTYPE Literature-reported T95408 SYNONYMS sodA; MnSOD; Mn-SOD; Manganese superoxide dismutase T95408 FUNCTION Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems. T95408 PDBSTRUC 3OT7; 3K9S; 1ZLZ; 1VEW; 1MMM T95408 BIOCLASS Superoxide acceptor oxidoreductase T95408 ECNUMBER EC 1.15.1.1 T95408 SEQUENCE MSYTLPSLPYAYDALEPHFDKQTMEIHHTKHHQTYVNNANAALESLPEFANLPVEELITKLDQLPADKKTVLRNNAGGHANHSLFWKGLKKGTTLQGDLKAAIERDFGSVDNFKAEFEKAAASRFGSGWAWLVLKGDKLAVVSTANQDSPLMGEAISGASGFPIMGLDVWEHAYYLKFQNRRPDYIKEFWNVVNWDEAAARFAAKK T67942 TARGETID T67942 T67942 FORMERID TTDR00871 T67942 UNIPROID METB_ECOLI T67942 TARGNAME Bacterial Cystathionine gamma-synthase (Bact metB) T67942 GENENAME Bact metB T67942 TARGTYPE Literature-reported T67942 SYNONYMS metB; O-succinylhomoserine (Thiol)-lyase; CGS T67942 FUNCTION Catalyzes the formation of L-cystathionine from O- succinyl-L-homoserine (OSHS) and L-cysteine, via a gamma- replacement reaction. In the absence of thiol, catalyzes gamma- elimination to form 2-oxobutanoate, succinate and ammonia. T67942 PDBSTRUC 1CS1 T67942 BIOCLASS Alkyl aryl transferase T67942 ECNUMBER EC 2.5.1.48 T67942 SEQUENCE MTRKQATIAVRSGLNDDEQYGCVVPPIHLSSTYNFTGFNEPRAHDYSRRGNPTRDVVQRALAELEGGAGAVLTNTGMSAIHLVTTVFLKPGDLLVAPHDCYGGSYRLFDSLAKRGCYRVLFVDQGDEQALRAALAEKPKLVLVESPSNPLLRVVDIAKICHLAREVGAVSVVDNTFLSPALQNPLALGADLVLHSCTKYLNGHSDVVAGVVIAKDPDVVTELAWWANNIGVTGGAFDSYLLLRGLRTLVPRMELAQRNAQAIVKYLQTQPLVKKLYHPSLPENQGHEIAARQQKGFGAMLSFELDGDEQTLRRFLGGLSLFTLAESLGGVESLISHAATMTHAGMAPEARAAAGISETLLRISTGIEDGEDLIADLENGFRAANKG T67942 DRUGINFO D03ESO GW-3333 Preclinical T67942 DRUGINFO D0I5PZ N'-Pyridoxyl-Lysine-5'-Monophosphate Investigative T16650 TARGETID T16650 T16650 FORMERID TTDR00389 T16650 UNIPROID GLHA_HUMAN T16650 TARGNAME Glycoprotein hormones alpha (CGA) T16650 GENENAME CGA T16650 TARGTYPE Literature-reported T16650 SYNONYMS Thyrotropin alpha chain; Thyroid-stimulating hormone alpha chain; TSH-alpha; Lutropin alpha chain; Luteinizing hormone alpha chain; LSH-alpha; Glycoprotein hormones alpha chain; Follitropin alpha chain; Follicle-stimulating hormone alpha chain; FSH-alpha; Chorionic gonadotrophin subunit alpha; Choriogonadotropin alpha chain; CG-alpha; Anterior pituitary glycoprotein hormones common subunit alpha T16650 FUNCTION Shared alpha chain of the active heterodimeric glycoprotein hormones thyrotropin/thyroid stimulating hormone/TSH, lutropin/luteinizing hormone/LH, follitropin/follicle stimulating hormone/FSH and choriogonadotropin/CG. These hormones bind specific receptors on target cells that in turn activate downstream signaling pathways. T16650 PDBSTRUC 4MQW; 4AY9; 1XWD; 1XUL; 1QFW T16650 BIOCLASS Glycoprotein hormone T16650 SEQUENCE MDYYRKYAAIFLVTLSVFLHVLHSAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS T16650 DRUGINFO D07LUR Alpha-D-Mannose Investigative T25136 TARGETID T25136 T25136 FORMERID TTDR00448 T25136 UNIPROID POL_HV1B1 T25136 TARGNAME Human immunodeficiency virus Ribonuclease H (HIV RNH) T25136 GENENAME HIV RNH T25136 TARGTYPE Literature-reported T25136 SYNONYMS Retroviral ribonuclease H; RNase H (600-1159); RNH1 T25136 FUNCTION Endonuclease that specifically degrades the RNA of RNA- DNA hybrids. T25136 PDBSTRUC 6OE3; 6HAK; 6ELI; 6DUH; 6DUG T25136 ECNUMBER EC 2.7.7.49 T25136 SEQUENCE PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKIL T25136 DRUGINFO D05SSB 2-hydroxyisoquinoline-1,3(2H,4H)-dione Investigative T25136 DRUGINFO D0NS0E 3-hydroxyquinazoline-2,4(1H,3H)-dione Investigative T36729 TARGETID T36729 T36729 FORMERID TTDI02469 T36729 UNIPROID CY24B_HUMAN T36729 TARGNAME NADPH oxidase 2 (CYBB) T36729 GENENAME CYBB T36729 TARGTYPE Literature-reported T36729 SYNONYMS p22 phagocyte Bcytochrome; p22 phagocyte B-cytochrome; gp91phox; gp911; gp91-phox; gp91-1; Superoxidegenerating NADPH oxidase heavy chain subunit; Superoxide-generating NADPH oxidase heavy chain subunit; Neutrophil cytochrome b 91 kDa polypeptide; NOX2; Hemebinding membrane glycoprotein gp91phox; Heme-binding membrane glycoprotein gp91phox; Cytochrome b558 subunit beta; Cytochrome b245 heavy chain; Cytochrome b-245 heavy chain; Cytochrome b(558) subunit beta; CGD91phox; CGD91-phox T36729 FUNCTION It is the terminal component of a respiratory chain that transfers single electrons from cytoplasmic NADPH across the plasma membrane to molecular oxygen on the exterior. Also functions as a voltage-gated proton channel that mediates the H(+) currents of resting phagocytes. It participates in the regulation of cellular pH and is blocked by zinc. Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. T36729 PDBSTRUC 3A1F T36729 BIOCLASS Phagocyte NADPH oxidase T36729 ECNUMBER EC 1.-.-.- T36729 SEQUENCE MGNWAVNEGLSIFVILVWLGLNVFLFVWYYRVYDIPPKFFYTRKLLGSALALARAPAACLNFNCMLILLPVCRNLLSFLRGSSACCSTRVRRQLDRNLTFHKMVAWMIALHSAIHTIAHLFNVEWCVNARVNNSDPYSVALSELGDRQNESYLNFARKRIKNPEGGLYLAVTLLAGITGVVITLCLILIITSSTKTIRRSYFEVFWYTHHLFVIFFIGLAIHGAERIVRGQTAESLAVHNITVCEQKISEWGKIKECPIPQFAGNPPMTWKWIVGPMFLYLCERLVRFWRSQQKVVITKVVTHPFKTIELQMKKKGFKMEVGQYIFVKCPKVSKLEWHPFTLTSAPEEDFFSIHIRIVGDWTEGLFNACGCDKQEFQDAWKLPKIAVDGPFGTASEDVFSYEVVMLVGAGIGVTPFASILKSVWYKYCNNATNLKLKKIYFYWLCRDTHAFEWFADLLQLLESQMQERNNAGFLSYNIYLTGWDESQANHFAVHHDEEKDVITGLKQKTLYGRPNWDNEFKTIASQHPNTRIGVFLCGPEALAETLSKQSISNSESGPRGVHFIFNKENF T79476 TARGETID T79476 T79476 FORMERID TTDR00137 T79476 UNIPROID ILVA_ECOLI T79476 TARGNAME Bacterial Threonine deaminase (Bact ilvA) T79476 GENENAME Bact ilvA T79476 TARGTYPE Literature-reported T79476 SYNONYMS ilvA; Putative threonine dehydratase T79476 FUNCTION Catalyzes the anaerobic formation of alpha-ketobutyrate and ammonia from threonine in a two-step reaction. The first step involved a dehydration of threonine and a production of enamine intermediates (aminocrotonate), which tautomerizes to its imine form(iminobutyrate). Both intermediates are unstable and short- lived. The second step is the nonenzymatic hydrolysis of the enamine/imine intermediates to form 2-ketobutyrate and free ammonia. In the low water environment of the cell, the second step is accelerated by RidA. T79476 PDBSTRUC 1TDJ T79476 BIOCLASS Carbon-nitrogen lyases T79476 ECNUMBER EC 4.3.1.19 T79476 SEQUENCE MADSQPLSGAPEGAEYLRAVLRAPVYEAAQVTPLQKMEKLSSRLDNVILVKREDRQPVHSFKLRGAYAMMAGLTEEQKAHGVITASAGNHAQGVAFSSARLGVKALIVMPTATADIKVDAVRGFGGEVLLHGANFDEAKAKAIELSQQQGFTWVPPFDHPMVIAGQGTLALELLQQDAHLDRVFVPVGGGGLAAGVAVLIKQLMPQIKVIAVEAEDSACLKAALDAGHPVDLPRVGLFAEGVAVKRIGDETFRLCQEYLDDIITVDSDAICAAMKDLFEDVRAVAEPSGALALAGMKKYIALHNIRGERLAHILSGANVNFHGLRYVSERCELGEQREALLAVTIPEEKGSFLKFCQLLGGRSVTEFNYRFADAKNACIFVGVRLSRGLEERKEILQMLNDGGYSVVDLSDDEMAKLHVRYMVGGRPSHPLQERLYSFEFPESPGALLRFLNTLGTYWNISLFHYRSHGTDYGRVLAAFELGDHEPDFETRLNELGYDCHDETNNPAFRFFLAG T67258 TARGETID T67258 T67258 FORMERID TTDS00378 T67258 UNIPROID HEP2_HUMAN T67258 TARGNAME Heparin cofactor II (SERPIND1) T67258 GENENAME SERPIND1 T67258 TARGTYPE Literature-reported T67258 SYNONYMS SERPIND1; Protease inhibitor leuserpin 2; HLS2; HC-II T67258 FUNCTION Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils. T67258 PDBSTRUC 6J12; 2NCW; 2NCV; 2NCU; 2NAT T67258 BIOCLASS Serpin protein T67258 SEQUENCE MKHSLNALLIFLIITSAWGGSKGPLDQLEKGGETAQSADPQWEQLNNKNLSMPLLPADFHKENTVTNDWIPEGEEDDDYLDLEKIFSEDDDYIDIVDSLSVSPTDSDVSAGNILQLFHGKSRIQRLNILNAKFAFNLYRVLKDQVNTFDNIFIAPVGISTAMGMISLGLKGETHEQVHSILHFKDFVNASSKYEITTIHNLFRKLTHRLFRRNFGYTLRSVNDLYIQKQFPILLDFKTKVREYYFAEAQIADFSDPAFISKTNNHIMKLTKGLIKDALENIDPATQMMILNCIYFKGSWVNKFPVEMTHNHNFRLNEREVVKVSMMQTKGNFLAANDQELDCDILQLEYVGGISMLIVVPHKMSGMKTLEAQLTPRVVERWQKSMTNRTREVLLPKFKLEKNYNLVESLKLMGIRMLFDKNGNMAGISDQRIAIDLFKHQGTITVNEEGTQATTVTTVGFMPLSTQVRFTVDRPFLFLIYEHRTSCLLFMGRVANPSRS T67258 DRUGINFO D07LUR Alpha-D-Mannose Investigative T49948 TARGETID T49948 T49948 FORMERID TTDR00104 T49948 UNIPROID METC_ECOLI T49948 TARGNAME Bacterial Cystathionine beta-lyase (Bact metC) T49948 GENENAME Bact metC T49948 TARGTYPE Literature-reported T49948 SYNONYMS Cysteine-S-conjugate beta-lyase MetC; Cysteine lyase MetC; Cysteine desulfhydrase MetC; Cystathionine beta-lyase MetC; CL; CBL; Beta-cystathionase MetC; Bacterial CD T49948 FUNCTION Primarily catalyzes the cleavage of cystathionine to homocysteine, pyruvate and ammonia during methionine biosynthesis. Also exhibits cysteine desulfhydrase activity, producing sulfide from cysteine. In addition, under certain growth conditions, exhibits significant alanine racemase coactivity. T49948 PDBSTRUC 4ITX; 4ITG; 2GQN; 2FQ6; 1CL2 T49948 BIOCLASS Carbon-sulfur lyases T49948 ECNUMBER EC 4.4.1.13 T49948 SEQUENCE MADKKLDTQLVNAGRSKKYTLGAVNSVIQRASSLVFDSVEAKKHATRNRANGELFYGRRGTLTHFSLQQAMCELEGGAGCVLFPCGAAAVANSILAFIEQGDHVLMTNTAYEPSQDFCSKILSKLGVTTSWFDPLIGADIVKHLQPNTKIVFLESPGSITMEVHDVPAIVAAVRSVVPDAIIMIDNTWAAGVLFKALDFGIDVSIQAATKYLVGHSDAMIGTAVCNARCWEQLRENAYLMGQMVDADTAYITSRGLRTLGVRLRQHHESSLKVAEWLAEHPQVARVNHPALPGSKGHEFWKRDFTGSSGLFSFVLKKKLNNEELANYLDNFSLFSMAYSWGGYESLILANQPEHIAAIRPQGEIDFSGTLIRLHIGLEDVDDLIADLDAGFARIV T54316 TARGETID T54316 T54316 FORMERID TTDNR00680 T54316 UNIPROID G6PI_HUMAN T54316 TARGNAME Glucose-6-phosphate isomerase (GPI) T54316 GENENAME GPI T54316 TARGTYPE Literature-reported T54316 SYNONYMS Sperm antigen 36; SA-36; Phosphohexose isomerase; Phosphoglucose isomerase; PHI; PGI; Neuroleukin; NLK; GPI; Autocrine motility factor; AMF T54316 FUNCTION Besides it's role as a glycolytic enzyme, mammalian GPI can function as a tumor-secreted cytokine and an angiogenic factor (AMF) that stimulates endothelial cell motility. GPI is also a neurotrophic factor (Neuroleukin) for spinal and sensory neurons. T54316 PDBSTRUC 1NUH; 1JLH; 1JIQ; 1IRI; 1IAT T54316 BIOCLASS Intramolecular oxidoreductases T54316 ECNUMBER EC 5.3.1.9 T54316 SEQUENCE MAALTRDPQFQKLQQWYREHRSELNLRRLFDANKDRFNHFSLTLNTNHGHILVDYSKNLVTEDVMRMLVDLAKSRGVEAARERMFNGEKINYTEGRAVLHVALRNRSNTPILVDGKDVMPEVNKVLDKMKSFCQRVRSGDWKGYTGKTITDVINIGIGGSDLGPLMVTEALKPYSSGGPRVWYVSNIDGTHIAKTLAQLNPESSLFIIASKTFTTQETITNAETAKEWFLQAAKDPSAVAKHFVALSTNTTKVKEFGIDPQNMFEFWDWVGGRYSLWSAIGLSIALHVGFDNFEQLLSGAHWMDQHFRTTPLEKNAPVLLALLGIWYINCFGCETHAMLPYDQYLHRFAAYFQQGDMESNGKYITKSGTRVDHQTGPIVWGEPGTNGQHAFYQLIHQGTKMIPCDFLIPVQTQHPIRKGLHHKILLANFLAQTEALMRGKSTEEARKELQAAGKSPEDLERLLPHKVFEGNRPTNSIVFTKLTPFMLGALVAMYEHKIFVQGIIWDINSFDQWGVELGKQLAKKIEPELDGSAQVTSHDASTNGLINFIKQQREARVQ T70654 TARGETID T70654 T70654 FORMERID TTDR00320 T70654 UNIPROID GPX1_HUMAN T70654 TARGNAME Glutathione peroxidase (GPX1) T70654 GENENAME GPX1 T70654 TARGTYPE Literature-reported T70654 SYNONYMS GSHPx-1; GPX1; Cellular glutathione peroxidase T70654 FUNCTION Protects the hemoglobin in erythrocytes from oxidative breakdown. T70654 PDBSTRUC 2F8A T70654 BIOCLASS Peroxidases T70654 ECNUMBER EC 1.11.1.9 T70654 SEQUENCE MCAARLAAAAAAAQSVYAFSARPLAGGEPVSLGSLRGKVLLIENVASLUGTTVRDYTQMNELQRRLGPRGLVVLGFPCNQFGHQENAKNEEILNSLKYVRPGGGFEPNFMLFEKCEVNGAGAHPLFAFLREALPAPSDDATALMTDPKLITWSPVCRNDVAWNFEKFLVGPDGVPLRRYSRRFQTIDIEPDIEALLSQGPSCA T29083 TARGETID T29083 T29083 FORMERID TTDI03196 T29083 UNIPROID FES_HUMAN T29083 TARGNAME Proto-oncogene c-Fes (FES) T29083 GENENAME FES T29083 TARGTYPE Literature-reported T29083 SYNONYMS p93c-fes; Tyrosine-protein kinase Fes/Fps; Proto-oncogene c-Fps; Feline sarcoma/Fujinami avian sarcoma oncogene homolog; FPS T29083 FUNCTION Plays a role in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Acts down-stream of the activated FCER1 receptor and the mast/stem cell growth factor receptor KIT. Plays a role in the regulation of mast cell degranulation. Plays a role in the regulation of cell differentiation and promotes neurite outgrowth in response to NGF signaling. Plays a role in cell scattering and cell migration in response to HGF-induced activation of EZR. Phosphorylates BCR and down-regulates BCR kinase activity. Phosphorylates HCLS1/HS1, PECAM1, STAT3 and TRIM28. Tyrosine-protein kinase that acts downstream of cell surface receptors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, cell attachment and cell spreading. T29083 PDBSTRUC 4DYL; 4.00E+93; 3CD3; 3CBL; 3BKB T29083 BIOCLASS Kinase T29083 ECNUMBER EC 2.7.10.2 T29083 SEQUENCE MGFSSELCSPQGHGVLQQMQEAELRLLEGMRKWMAQRVKSDREYAGLLHHMSLQDSGGQSRAISPDSPISQSWAEITSQTEGLSRLLRQHAEDLNSGPLSKLSLLIRERQQLRKTYSEQWQQLQQELTKTHSQDIEKLKSQYRALARDSAQAKRKYQEASKDKDRDKAKDKYVRSLWKLFAHHNRYVLGVRAAQLHHQHHHQLLLPGLLRSLQDLHEEMACILKEILQEYLEISSLVQDEVVAIHREMAAAAARIQPEAEYQGFLRQYGSAPDVPPCVTFDESLLEEGEPLEPGELQLNELTVESVQHTLTSVTDELAVATEMVFRRQEMVTQLQQELRNEEENTHPRERVQLLGKRQVLQEALQGLQVALCSQAKLQAQQELLQTKLEHLGPGEPPPVLLLQDDRHSTSSSEQEREGGRTPTLEILKSHISGIFRPKFSLPPPLQLIPEVQKPLHEQLWYHGAIPRAEVAELLVHSGDFLVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPSIPLLIDHLLSTQQPLTKKSGVVLHRAVPKDKWVLNHEDLVLGEQIGRGNFGEVFSGRLRADNTLVAVKSCRETLPPDLKAKFLQEARILKQYSHPNIVRLIGVCTQKQPIYIVMELVQGGDFLTFLRTEGARLRVKTLLQMVGDAAAGMEYLESKCCIHRDLAARNCLVTEKNVLKISDFGMSREEADGVYAASGGLRQVPVKWTAPEALNYGRYSSESDVWSFGILLWETFSLGASPYPNLSNQQTREFVEKGGRLPCPELCPDAVFRLMEQCWAYEPGQRPSFSTIYQELQSIRKRHR T29083 DRUGINFO D0K5UF PMID24432909C8e Investigative T29083 DRUGINFO D09AID PMID22564207C25b Investigative T51464 TARGETID T51464 T51464 FORMERID TTDR00680 T51464 UNIPROID CN37_HUMAN T51464 TARGNAME Cyclic nucleotide phosphodiesterase (CNP) T51464 GENENAME CNP T51464 TARGTYPE Literature-reported T51464 SYNONYMS CNPase; CNP; 2',3'-cyclic-nucleotide 3'-phosphodiesterase T51464 FUNCTION May participate in RNA metabolism in the myelinating cell, CNP is the third most abundant protein in central nervous system myelin. T51464 PDBSTRUC 1WOJ T51464 BIOCLASS Phosphoric diester hydrolase T51464 ECNUMBER EC 3.1.4.37 T51464 SEQUENCE MNRGFSRKSHTFLPKIFFRKMSSSGAKDKPELQFPFLQDEDTVATLLECKTLFILRGLPGSGKSTLARVIVDKYRDGTKMVSADAYKITPGARGAFSEEYKRLDEDLAAYCRRRDIRILVLDDTNHERERLEQLFEMADQYQYQVVLVEPKTAWRLDCAQLKEKNQWQLSADDLKKLKPGLEKDFLPLYFGWFLTKKSSETLRKAGQVFLEELGNHKAFKKELRQFVPGDEPREKMDLVTYFGKRPPGVLHCTTKFCDYGKAPGAEEYAQQDVLKKSYSKAFTLTISALFVTPKTTGARVELSEQQLQLWPSDVDKLSPTDNLPRGSRAHITLGCAADVEAVQTGLDLLEILRQEKGGSRGEEVGELSRGKLYSLGNGRWMLTLAKNMEVRAIFTGYYGKGKPVPTQGSRKGGALQSCTII T26617 TARGETID T26617 T26617 FORMERID TTDR00154 T26617 UNIPROID LPH_HUMAN T26617 TARGNAME Lactase-phlorizin hydrolase (LCT) T26617 GENENAME LCT T26617 TARGTYPE Literature-reported T26617 SYNONYMS Lactase-glycosylceramidase; LCT; Glycosyl-hydrolase T26617 FUNCTION LPH splits lactose in the small intestine. T26617 BIOCLASS Glycosylase T26617 SEQUENCE MELSWHVVFIALLSFSCWGSDWESDRNFISTAGPLTNDLLHNLSGLLGDQSSNFVAGDKDMYVCHQPLPTFLPEYFSSLHASQITHYKVFLSWAQLLPAGSTQNPDEKTVQCYRRLLKALKTARLQPMVILHHQTLPASTLRRTEAFADLFADYATFAFHSFGDLVGIWFTFSDLEEVIKELPHQESRASQLQTLSDAHRKAYEIYHESYAFQGGKLSVVLRAEDIPELLLEPPISALAQDTVDFLSLDLSYECQNEASLRQKLSKLQTIEPKVKVFIFNLKLPDCPSTMKNPASLLFSLFEAINKDQVLTIGFDINEFLSCSSSSKKSMSCSLTGSLALQPDQQQDHETTDSSPASAYQRIWEAFANQSRAERDAFLQDTFPEGFLWGASTGAFNVEGGWAEGGRGVSIWDPRRPLNTTEGQATLEVASDSYHKVASDVALLCGLRAQVYKFSISWSRIFPMGHGSSPSLPGVAYYNKLIDRLQDAGIEPMATLFHWDLPQALQDHGGWQNESVVDAFLDYAAFCFSTFGDRVKLWVTFHEPWVMSYAGYGTGQHPPGISDPGVASFKVAHLVLKAHARTWHHYNSHHRPQQQGHVGIVLNSDWAEPLSPERPEDLRASERFLHFMLGWFAHPVFVDGDYPATLRTQIQQMNRQCSHPVAQLPEFTEAEKQLLKGSADFLGLSHYTSRLISNAPQNTCIPSYDTIGGFSQHVNHVWPQTSSSWIRVVPWGIRRLLQFVSLEYTRGKVPIYLAGNGMPIGESENLFDDSLRVDYFNQYINEVLKAIKEDSVDVRSYIARSLIDGFEGPSGYSQRFGLHHVNFSDSSKSRTPRKSAYFFTSIIEKNGFLTKGAKRLLPPNTVNLPSKVRAFTFPSEVPSKAKVVWEKFSSQPKFERDLFYHGTFRDDFLWGVSSSAYQIEGAWDADGKGPSIWDNFTHTPGSNVKDNATGDIACDSYHQLDADLNMLRALKVKAYRFSISWSRIFPTGRNSSINSHGVDYYNRLINGLVASNIFPMVTLFHWDLPQALQDIGGWENPALIDLFDSYADFCFQTFGDRVKFWMTFNEPMYLAWLGYGSGEFPPGVKDPGWAPYRIAHAVIKAHARVYHTYDEKYRQEQKGVISLSLSTHWAEPKSPGVPRDVEAADRMLQFSLGWFAHPIFRNGDYPDTMKWKVGNRSELQHLATSRLPSFTEEEKRFIRATADVFCLNTYYSRIVQHKTPRLNPPSYEDDQEMAEEEDPSWPSTAMNRAAPWGTRRLLNWIKEEYGDIPIYITENGVGLTNPNTEDTDRIFYHKTYINEALKAYRLDGIDLRGYVAWSLMDNFEWLNGYTVKFGLYHVDFNNTNRPRTARASARYYTEVITNNGMPLAREDEFLYGRFPEGFIWSAASAAYQIEGAWRADGKGLSIWDTFSHTPLRVENDAIGDVACDSYHKIAEDLVTLQNLGVSHYRFSISWSRILPDGTTRYINEAGLNYYVRLIDTLLAASIQPQVTIYHWDLPQTLQDVGGWENETIVQRFKEYADVLFQRLGDKVKFWITLNEPFVIAYQGYGYGTAAPGVSNRPGTAPYIVGHNLIKAHAEAWHLYNDVYRASQGGVISITISSDWAEPRDPSNQEDVEAARRYVQFMGGWFAHPIFKNGDYNEVMKTRIRDRSLAAGLNKSRLPEFTESEKRRINGTYDFFGFNHYTTVLAYNLNYATAISSFDADRGVASIADRSWPDSGSFWLKMTPFGFRRILNWLKEEYNDPPIYVTENGVSQREETDLNDTARIYYLRTYINEALKAVQDKVDLRGYTVWSAMDNFEWATGFSERFGLHFVNYSDPSLPRIPKASAKFYASVVRCNGFPDPATGPHACLHQPDAGPTISPVRQEEVQFLGLMLGTTEAQTALYVLFSLVLLGVCGLAFLSYKYCKRSKQGKTQRSQQELSPVSSF T26617 DRUGINFO D04QWD Gluconolactone Investigative T26617 DRUGINFO D05RSP ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE Investigative T26617 DRUGINFO D07ATW Hyacinthacine B3 Investigative T26617 DRUGINFO D0R2BA D-Gluconhydroximo-1,5-Lactam Investigative T26617 DRUGINFO D0R5RE 2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol Investigative T26617 DRUGINFO D0X4EB 2-Deoxy-2fluoro-Glucose Investigative T26617 DRUGINFO D0E2BH Nojirimycine Tetrazole Investigative T26617 DRUGINFO D0SQ1T 2,5-dideoxy-2,5-imino-D-altritol Investigative T26617 DRUGINFO D0G6XS Fucose Investigative T26617 DRUGINFO D07LUR Alpha-D-Mannose Investigative T49627 TARGETID T49627 T49627 FORMERID TTDR01243 T49627 UNIPROID CP121_MYCBO T49627 TARGNAME Mycobacterium Cytochrome p450 121 (MycB cyp121) T49627 GENENAME MycB cyp121 T49627 TARGTYPE Literature-reported T49627 SYNONYMS Cytochrome P450 MT2; Cytochrome P450 121 T49627 FUNCTION Catalyzes the formation of an intramolecular C-C bond between two tyrosyl carbon atoms of Cyy. T49627 PDBSTRUC 5EDT T49627 BIOCLASS Paired donor oxygen oxidoreductase T49627 ECNUMBER EC 1.14.-.- T49627 SEQUENCE MTATVLLEVPFSARGDRIPDAVAELRTREPIRKVRTITGAEAWLVSSYALCTQVLEDRRFSMKETAAAGAPRLNALTVPPEVVNNMGNIADAGLRKAVMKAITPKAPGLEQFLRDTANSLLDNLITEGAPADLRNDFADPLATALHCKVLGIPQEDGPKLFRSLSIAFMSSADPIPAAKINWDRDIEYMAGILENPNITTGLMGELSRLRKDPAYSHVSDELFATIGVTFFGAGVISTGSFLTTALISLIQRPQLRNLLHEKPELIPAGVEELLRINLSFADGLPRLATADIQVGDVLVRKGELVLVLLEGANFDPEHFPNPGSIELDRPNPTSHLAFGRGQHFCPGSALGRRHAQIGIEALLKKMPGVDLAVPIDQLVWRTRFQRRIPERLPVLW T49627 DRUGINFO D0RM7D 4-Iodopyrazole Investigative T49627 DRUGINFO D0UU1I Heme Investigative T80855 TARGETID T80855 T80855 FORMERID TTDI02391 T80855 UNIPROID AAC2_MYCTU T80855 TARGNAME Mycobacterium Aminoglycoside 2'-N-acetyltransferase (MycB aac) T80855 GENENAME MycB aac T80855 TARGTYPE Literature-reported T80855 SYNONYMS Aminoglycoside 2'-N-acetyltransferase; AAC(2')-Ic T80855 FUNCTION May catalyze the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides and confer resistance to aminoglycosides (By similarity). In vitro assays show no significant increase of resistance to aminoglycosides, possibly due to low expression in a heterologous system. T80855 PDBSTRUC 1M4I; 1M4G; 1M4D; 1M44 T80855 BIOCLASS Acyltransferase T80855 ECNUMBER EC 2.3.1.- T80855 SEQUENCE MHTQVHTARLVHTADLDSETRQDIRQMVTGAFAGDFTETDWEHTLGGMHALIWHHGAIIAHAAVIQRRLIYRGNALRCGYVEGVAVRADWRGQRLVSALLDAVEQVMRGAYQLGALSSSARARRLYASRGWLPWHGPTSVLAPTGPVRTPDDDGTVFVLPIDISLDTSAELMCDWRAGDVW T54065 TARGETID T54065 T54065 FORMERID TTDR01019 T54065 UNIPROID AROA_ECOLI T54065 TARGNAME Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA) T54065 GENENAME Bact aroA T54065 TARGTYPE Literature-reported T54065 SYNONYMS aroA of Escherichia coli; EPSPS of Escherichia coli; EPSP synthase of Escherichia coli; 5-enolpyruvylshikimate-3-phosphate synthase of Escherichia coli T54065 FUNCTION Catalyzes the transfer of the enolpyruvyl moiety of phosphoenolpyruvate (PEP) to the 5-hydroxyl of shikimate-3- phosphate (S3P) to produce enolpyruvyl shikimate-3-phosphate and inorganic phosphate. T54065 PDBSTRUC 3FK1; 3FK0; 3FJZ; 3FJX; 2QFU T54065 BIOCLASS Alkyl aryl transferase T54065 ECNUMBER EC 2.5.1.19 T54065 SEQUENCE MESLTLQPIARVDGTINLPGSKSVSNRALLLAALAHGKTVLTNLLDSDDVRHMLNALTALGVSYTLSADRTRCEIIGNGGPLHAEGALELFLGNAGTAMRPLAAALCLGSNDIVLTGEPRMKERPIGHLVDALRLGGAKITYLEQENYPPLRLQGGFTGGNVDVDGSVSSQFLTALLMTAPLAPEDTVIRIKGDLVSKPYIDITLNLMKTFGVEIENQHYQQFVVKGGQSYQSPGTYLVEGDASSASYFLAAAAIKGGTVKVTGIGRNSMQGDIRFADVLEKMGATICWGDDYISCTRGELNAIDMDMNHIPDAAMTIATAALFAKGTTTLRNIYNWRVKETDRLFAMATELRKVGAEVEEGHDYIRITPPEKLNFAEIATYNDHRMAMCFSLVALSDTPVTILDPKCTAKTFPDYFEQLARISQAA T54065 DRUGINFO D0ZS5F Shikimate-3-Phosphate Investigative T54065 DRUGINFO D04HMD Glyphosate Investigative T54065 DRUGINFO D06EWG Formic Acid Investigative T91895 TARGETID T91895 T91895 FORMERID TTDR00354 T91895 UNIPROID COAA_ECOLI T91895 TARGNAME Bacterial Pantothenate kinase (Bact coaA) T91895 GENENAME Bact coaA T91895 TARGTYPE Literature-reported T91895 SYNONYMS Rts protein; Pantothenic acid kinase; Pantothenate kinase T91895 FUNCTION Phosphorylates pantothenate (vitamin B5) to form 4'-phosphopantothenate at the expense of a molecule of adenosine triphosphate (ATP). It is the rate-limiting step in the biosynthesis of CoA. T91895 PDBSTRUC 1SQ5; 1ESN; 1ESM T91895 BIOCLASS Kinase T91895 ECNUMBER EC 2.7.1.33 T91895 SEQUENCE MSIKEQTLMTPYLQFDRNQWAALRDSVPMTLSEDEIARLKGINEDLSLEEVAEIYLPLSRLLNFYISSNLRRQAVLEQFLGTNGQRIPYIISIAGSVAVGKSTTARVLQALLSRWPEHRRVELITTDGFLHPNQVLKERGLMKKKGFPESYDMHRLVKFVSDLKSGVPNVTAPVYSHLIYDVIPDGDKTVVQPDILILEGLNVLQSGMDYPHDPHHVFVSDFVDFSIYVDAPEDLLQTWYINRFLKFREGAFTDPDSYFHNYAKLTKEEAIKTAMTLWKEINWLNLKQNILPTRERASLILTKSANHAVEEVRLRK T91895 DRUGINFO D0W3NA Coenzyme A Investigative T91895 DRUGINFO D00ICA AMP-PNP Investigative T13236 TARGETID T13236 T13236 FORMERID TTDR00785 T13236 UNIPROID RIBB_ECOLI T13236 TARGNAME Bacterial Dihydroxy-2-butanone-4-phosphate synthase (Bact ribB) T13236 GENENAME Bact ribB T13236 TARGTYPE Literature-reported T13236 SYNONYMS RibB; DHBP synthase T13236 FUNCTION Catalyzes the conversion of D-ribulose 5-phosphate to formate and 3,4-dihydroxy-2-butanone 4-phosphate. T13236 PDBSTRUC 1IEZ; 1G58; 1G57 T13236 BIOCLASS DHBP synthase family T13236 ECNUMBER EC 4.1.99.12 T13236 SEQUENCE MNQTLLSSFGTPFERVENALAALREGRGVMVLDDEDRENEGDMIFPAETMTVEQMALTIRHGSGIVCLCITEDRRKQLDLPMMVENNTSAYGTGFTVTIEAAEGVTTGVSAADRITTVRAAIADGAKPSDLNRPGHVFPLRAQAGGVLTRGGHTEATIDLMTLAGFKPAGVLCELTNDDGTMARAPECIEFANKHNMALVTIEDLVAYRQAHERKAS T63890 TARGETID T63890 T63890 FORMERID TTDNR00665 T63890 UNIPROID YBEY_ECOLI T63890 TARGNAME Bacterial Endoribonuclease YbeY (Bact YbeY) T63890 GENENAME Bact YbeY T63890 TARGTYPE Literature-reported T63890 SYNONYMS ybeY; b0659; JW0656 T63890 FUNCTION Acts together with the RNase R to eliminate defective 70S ribosomes, but not properly matured 70S ribosomes or individual subunits, by a process mediated specifically by the 30S ribosomal subunit. Involved in the processing of 16S, 23S and 5S rRNAs, with a particularly strong effect on maturation at both the 5'-and 3'-ends of 16S rRNA as well as maturation of the 5'-end of 23S and 5S rRNAs. Single strand-specific metallo-endoribonuclease involved in late-stage 70S ribosome quality control and in maturation of the 3' terminus of the 16S rRNA. T63890 PDBSTRUC 1XM5 T63890 BIOCLASS Carboxylic ester hydrolase T63890 ECNUMBER EC 3.1.-.- T63890 SEQUENCE MSQVILDLQLACEDNSGLPEESQFQTWLNAVIPQFQEESEVTIRVVDTAESHSLNLTYRGKDKPTNVLSFPFEVPPGMEMSLLGDLVICRQVVEKEAQEQGKPLEAHWAHMVVHGSLHLLGYDHIEDDEAEEMEALETEIMLALGYEDPYIAEKE T54711 TARGETID T54711 T54711 FORMERID TTDR01087 T54711 UNIPROID SYK1_ECOLI T54711 TARGNAME Bacterial Lysyl-tRNA synthetase (Bact lysS) T54711 GENENAME Bact lysS T54711 TARGTYPE Literature-reported T54711 SYNONYMS Lysyl-tRNA synthetase; Lysine--tRNA ligase; LysRS T54711 FUNCTION Catalyses the formation of lysyl-transfer RNA, Lys-tRNA(Lys), which then is ready to insert lysine into proteins. T54711 PDBSTRUC 1KRT; 1KRS; 1BBW; 1BBU T54711 BIOCLASS Carbon-oxygen ligase T54711 ECNUMBER EC 6.1.1.6 T54711 SEQUENCE MSEQHAQGADAVVDLNNELKTRREKLANLREQGIAFPNDFRRDHTSDQLHAEFDGKENEELEALNIEVAVAGRMMTRRIMGKASFVTLQDVGGRIQLYVARDDLPEGVYNEQFKKWDLGDILGAKGKLFKTKTGELSIHCTELRLLTKALRPLPDKFHGLQDQEARYRQRYLDLISNDESRNTFKVRSQILSGIRQFMVNRGFMEVETPMMQVIPGGAAARPFITHHNALDLDMYLRIAPELYLKRLVVGGFERVFEINRNFRNEGISVRHNPEFTMMELYMAYADYKDLIELTESLFRTLAQDILGKTEVTYGDVTLDFGKPFEKLTMREAIKKYRPETDMADLDNFDSAKAIAESIGIHVEKSWGLGRIVTEIFEEVAEAHLIQPTFITEYPAEVSPLARRNDVNPEITDRFEFFIGGREIGNGFSELNDAEDQAQRFLDQVAAKDAGDDEAMFYDEDYVTALEHGLPPTAGLGIGIDRMVMLFTNSHTIRDVILFPAMRPVK T82723 TARGETID T82723 T82723 FORMERID TTDR00292 T82723 UNIPROID FABF_ECOLI T82723 TARGNAME Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF) T82723 GENENAME Bact fabF T82723 TARGTYPE Literature-reported T82723 SYNONYMS KASB; KAS II; KAS 2; FabF; Condensing enzyme FabF; Beta-ketoacyl-acyl carrier protein synthase B; Beta-ketoacyl-ACP synthase II; Beta-ketoacyl-ACP synthase 2; 3-oxoacyl-[acyl-carrier-protein] synthase 2 T82723 FUNCTION Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Has a preference for short chain acid substrates and may function to supply the octanoic substrates for lipoic acid biosynthesis. T82723 PDBSTRUC 3I8P; 3HO9; 3HO2; 3HNZ; 3G11 T82723 BIOCLASS Acyltransferase T82723 ECNUMBER EC 2.3.1.179 T82723 SEQUENCE MSKRRVVVTGLGMLSPVGNTVESTWKALLAGQSGISLIDHFDTSAYATKFAGLVKDFNCEDIISRKEQRKMDAFIQYGIVAGVQAMQDSGLEITEENATRIGAAIGSGIGGLGLIEENHTSLMNGGPRKISPFFVPSTIVNMVAGHLTIMYGLRGPSISIATACTSGVHNIGHAARIIAYGDADVMVAGGAEKASTPLGVGGFGAARALSTRNDNPQAASRPWDKERDGFVLGDGAGMLVLEEYEHAKKRGAKIYAELVGFGMSSDAYHMTSPPENGAGAALAMANALRDAGIEASQIGYVNAHGTSTPAGDKAEAQAVKTIFGEAASRVLVSSTKSMTGHLLGAAGAVESIYSILALRDQAVPPTINLDNPDEGCDLDFVPHEARQVSGMEYTLCNSFGFGGTNGSLIFKKI T82723 DRUGINFO D0D9YU PLATENSIMYCIN Investigative T82723 DRUGINFO D04JTY Thiolactomycin Investigative T82723 DRUGINFO D0N0UC Lauric Acid Investigative T91001 TARGETID T91001 T91001 FORMERID TTDNC00628 T91001 UNIPROID EFTU1_ECOLI T91001 TARGNAME Bacterial Elongation factor Tu (Bact EFTu) T91001 GENENAME Bact EFTu T91001 TARGTYPE Literature-reported T91001 SYNONYMS tufA; P43; Elongation factor Tu 1; EFTu 1 T91001 FUNCTION May play an important regulatory rolein cell growth and in the bacterial response to nutrient deprivation. T91001 PDBSTRUC 5UYQ; 5UYP; 5UYN; 5UYM; 5UYL T91001 BIOCLASS GTP-binding elongation factor family T91001 SEQUENCE MSKEKFERTKPHVNVGTIGHVDHGKTTLTAAITTVLAKTYGGAARAFDQIDNAPEEKARGITINTSHVEYDTPTRHYAHVDCPGHADYVKNMITGAAQMDGAILVVAATDGPMPQTREHILLGRQVGVPYIIVFLNKCDMVDDEELLELVEMEVRELLSQYDFPGDDTPIVRGSALKALEGDAEWEAKILELAGFLDSYIPEPERAIDKPFLLPIEDVFSISGRGTVVTGRVERGIIKVGEEVEIVGIKETQKSTCTGVEMFRKLLDEGRAGENVGVLLRGIKREEIERGQVLAKPGTIKPHTKFESEVYILSKDEGGRHTPFFKGYRPQFYFRTTDVTGTIELPEGVEMVMPGDNIKMVVTLIHPIAMDDGLRFAIREGGRTVGAGVVAKVLG T79001 TARGETID T79001 T79001 FORMERID TTDR00992 T79001 UNIPROID AROC_ECOLI T79001 TARGNAME Bacterial Chorismate synthase (Bact aroC) T79001 GENENAME Bact aroC T79001 TARGTYPE Literature-reported T79001 SYNONYMS aroC; Chorismate synthase; CS; 5enolpyruvylshikimate3phosphate phospholyase; 5-enolpyruvylshikimate-3-phosphate phospholyase T79001 FUNCTION Catalyzes the anti-1,4-elimination of the C-3 phosphate and the C-6 proR hydrogen from 5-enolpyruvylshikimate-3-phosphate (EPSP) to yield chorismate, which is the branch point compound that serves as the starting substrate for the three terminal pathways of aromatic amino acid biosynthesis. This reaction introduces a second double bond into the aromatic ring system. It uses NADPH to reduce FMN. T79001 BIOCLASS Alpha-carbonic anhydrase T79001 ECNUMBER EC 4.2.3.5 T79001 SEQUENCE MAGNTIGQLFRVTTFGESHGLALGCIVDGVPPGIPLTEADLQHDLDRRRPGTSRYTTQRREPDQVKILSGVFEGVTTGTSIGLLIENTDQRSQDYSAIKDVFRPGHADYTYEQKYGLRDYRGGGRSSARETAMRVAAGAIAKKYLAEKFGIEIRGCLTQMGDIPLDIKDWSQVEQNPFFCPDPDKIDALDELMRALKKEGDSIGAKVTVVASGVPAGLGEPVFDRLDADIAHALMSINAVKGVEIGDGFDVVALRGSQNRDEITKDGFQSNHAGGILGGISSGQQIIAHMALKPTSSITVPGRTINRFGEEVEMITKGRHDPCVGIRAVPIAEAMLAIVLMDHLLRQRAQNADVKTDIPRW T79001 DRUGINFO D0W0RT PTX-008313 Terminated T79001 DRUGINFO D0M1KX Cobalt Hexammine Ion Investigative T94823 TARGETID T94823 T94823 FORMERID TTDR00759 T94823 UNIPROID PEPD_HUMAN T94823 TARGNAME Xaa-Pro dipeptidase (PEPD) T94823 GENENAME PEPD T94823 TARGTYPE Literature-reported T94823 SYNONYMS X-Pro dipeptidase; Proline dipeptidase; Prolidase; PEPD; Imidodipeptidase T94823 FUNCTION Splits dipeptides with a prolyl or hydroxyprolyl residuein the carboxyl terminal position. Plays an important role in collagen metabolism because the high level of iminoacids in collagen. T94823 PDBSTRUC 6H2Q; 6H2P; 5MC5; 5MC4; 5MC3 T94823 BIOCLASS Peptidase T94823 ECNUMBER EC 3.4.13.9 T94823 SEQUENCE MAAATGPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTPFSGPK T53562 TARGETID T53562 T53562 FORMERID TTDI00081 T53562 UNIPROID XRCC5_HUMAN T53562 TARGNAME X-ray repair cross-complementing 5 (Ku80) T53562 GENENAME XRCC5 T53562 TARGTYPE Literature-reported T53562 SYNONYMS X-ray repair cross-complementing protein 5; X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining); Thyroid-lupus autoantigen; TLAA; Nuclear factor IV; Lupus Ku autoantigen protein p86; Ku86; G22P2; DNA repair protein XRCC5; CTCBF; CTC85; CTC box-binding factor 85 kDa subunit; ATP-dependent DNA helicase II 80 kDa subunit; ATP-dependent DNA helicase 2 subunit 2; 86 kDa subunit of Ku antigen T53562 FUNCTION Has a role in chromosome translocation. The DNA helicase II complex binds preferentially to fork-like ends of double-stranded DNA in a cell cycle-dependent manner. It works in the 3'-5' direction. Binding to DNA may be mediated by XRCC6. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break repair and V(D)J recombination. The XRCC5/6 dimer acts as regulatory subunit of the DNA-dependent protein kinase complex DNA-PK by increasing the affinity of the catalytic subunit PRKDC to DNA by 100-fold. The XRCC5/6 dimer is probably involved in stabilizing broken DNA ends and bringing them together. The assembly of the DNA-PK complex to DNA ends is required for the NHEJ ligation step. In association with NAA15, the XRCC5/6 dimer binds to the osteocalcin promoter and activates osteocalcin expression. The XRCC5/6 dimer probably also acts as a 5'-deoxyribose-5-phosphate lyase (5'-dRP lyase), by catalyzing the beta-elimination of the 5' deoxyribose-5-phosphate at an abasic site near double-strand breaks. XRCC5 probably acts as the catalytic subunit of 5'-dRP activity, and allows to 'clean' the termini of abasic sites, a class of nucleotide damage commonly associated with strand breaks, before such broken ends can be joined. The XRCC5/6 dimer together with APEX1 acts as a negative regulator of transcription. Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway. Single-stranded DNA-dependent ATP-dependent helicase. T53562 PDBSTRUC 6ERH; 6ERG; 6ERF; 5Y3R; 3RZ9 T53562 BIOCLASS Acid anhydride hydrolase T53562 ECNUMBER EC 3.6.4.- T53562 SEQUENCE MVRSGNKAAVVLCMDVGFTMSNSIPGIESPFEQAKKVITMFVQRQVFAENKDEIALVLFGTDGTDNPLSGGDQYQNITVHRHLMLPDFDLLEDIESKIQPGSQQADFLDALIVSMDVIQHETIGKKFEKRHIEIFTDLSSRFSKSQLDIIIHSLKKCDISLQFFLPFSLGKEDGSGDRGDGPFRLGGHGPSFPLKGITEQQKEGLEIVKMVMISLEGEDGLDEIYSFSESLRKLCVFKKIERHSIHWPCRLTIGSNLSIRIAAYKSILQERVKKTWTVVDAKTLKKEDIQKETVYCLNDDDETEVLKEDIIQGFRYGSDIVPFSKVDEEQMKYKSEGKCFSVLGFCKSSQVQRRFFMGNQVLKVFAARDDEAAAVALSSLIHALDDLDMVAIVRYAYDKRANPQVGVAFPHIKHNYECLVYVQLPFMEDLRQYMFSSLKNSKKYAPTEAQLNAVDALIDSMSLAKKDEKTDTLEDLFPTTKIPNPRFQRLFQCLLHRALHPREPLPPIQQHIWNMLNPPAEVTTKSQIPLSKIKTLFPLIEAKKKDQVTAQEIFQDNHEDGPTAKKLKTEQGGAHFSVSSLAEGSVTSVGSVNPAENFRVLVKQKKASFEEASNQLINHIEQFLDTNETPYFMKSIDCIRAFREEAIKFSEEQRFNNFLKALQEKVEIKQLNHFWEIVVQDGITLITKEEASGSSVTAEEAKKFLAPKDKPSGDTAAVFEEGGDVDDLLDMI T06397 TARGETID T06397 T06397 FORMERID TTDR00610 T06397 UNIPROID MEGL_PSEPU T06397 TARGNAME Pseudomonas Methionine gamma-lyase (Pseudo mdeA) T06397 GENENAME Pseudo mdeA T06397 TARGTYPE Literature-reported T06397 SYNONYMS Pseudo MGL; L-methionine gamma-lyase; L-methioninase; Homocysteine desulfhydrase T06397 FUNCTION Catalyzes the alpha,gamma-elimination of L-methionine to produce methanethiol, 2-oxobutanoate and ammonia. Is involved in L-methionine catabolism. In fact, shows a multicatalytic function since it also catalyzes gamma-replacement of L-methionine with thiol compounds, alpha,gamma-elimination and gamma-replacement reactions of L-homocysteine and its S-substituted derivatives, O-substituted-L-homoserines and DL-selenomethionine, and, to a lesser extent, alpha,beta-elimination and beta-replacement reactions of L-cysteine, S-methyl-L-cysteine, and O-acetyl-L-serine. Also catalyzes deamination and gamma-addition reactions of L-vinylglycine. Thus, the enzyme is able to cleave C-S, C-Se, and C-O bonds of sulfur, selenium, and oxygen amino acids, respectively. T06397 PDBSTRUC 5X30; 5X2Z; 5X2Y; 5X2X; 5X2W T06397 BIOCLASS Carbon-sulfur lyases T06397 ECNUMBER EC 4.4.1.11 T06397 SEQUENCE MHGSNKLPGFATRAIHHGYDPQDHGGALVPPVYQTATFTFPTVEYGAACFAGEQAGHFYSRISNPTLNLLEARMASLEGGEAGLALASGMGAITSTLWTLLRPGDEVLLGNTLYGCTFAFLHHGIGEFGVKLRHVDMADLQALEAAMTPATRVIYFESPANPNMHMADIAGVAKIARKHGATVVVDNTYCTPYLQRPLELGADLVVHSATKYLSGHGDITAGIVVGSQALVDRIRLQGLKDMTGAVLSPHDAALLMRGIKTLNLRMDRHCANAQVLAEFLARQPQVELIHYPGLASFPQYTLARQQMSQPGGMIAFELKGGIGAGRRFMNALQLFSRAVSLGDAESLAQHPASMTHSSYTPEERAHYGISEGLVRLSVGLEDIDDLLADVQQALKASA T06397 DRUGINFO D0ZU4S Trifluoromethionine Investigative T06397 DRUGINFO D0I5PZ N'-Pyridoxyl-Lysine-5'-Monophosphate Investigative T38877 TARGETID T38877 T38877 FORMERID TTDR01015 T38877 UNIPROID ARCA_PSEAE T38877 TARGNAME Pseudomonas Arginine deiminase (Pseudo arcA) T38877 GENENAME Pseudo arcA T38877 TARGTYPE Literature-reported T38877 SYNONYMS Arginine dihydrolase; Arginine deiminase; ADI; AD T38877 FUNCTION Catalyzes the irreversible hydrolysis of arginine to citrulline and ammonia. Involved in the first step of the most widespread anaerobic route of arginine degradation T38877 PDBSTRUC 2ACI; 2ABR; 2AAF; 2A9G; 1RXX T38877 BIOCLASS Carbon-nitrogen hydrolase T38877 ECNUMBER EC 3.5.3.6 T38877 SEQUENCE MSTEKTKLGVHSEAGKLRKVMVCSPGLAHQRLTPSNCDELLFDDVIWVNQAKRDHFDFVTKMRERGIDVLEMHNLLTETIQNPEALKWILDRKITADSVGLGLTSELRSWLESLEPRKLAEYLIGGVAADDLPASEGANILKMYREYLGHSSFLLPPLPNTQFTRDTTCWIYGGVTLNPMYWPARRQETLLTTAIYKFHPEFANAEFEIWYGDPDKDHGSSTLEGGDVMPIGNGVVLIGMGERSSRQAIGQVAQSLFAKGAAERVIVAGLPKSRAAMHLDTVFSFCDRDLVTVFPEVVKEIVPFSLRPDPSSPYGMNIRREEKTFLEVVAESLGLKKLRVVETGGNSFAAEREQWDDGNNVVCLEPGVVVGYDRNTYTNTLLRKAGVEVITISASELGRGRGGGHCMTCPIVRDPIDY T16891 TARGETID T16891 T16891 FORMERID TTDI03091 T16891 UNIPROID CATE_HUMAN T16891 TARGNAME Cathepsin E (CTSE) T16891 GENENAME CTSE T16891 TARGTYPE Literature-reported T16891 SYNONYMS Cathepsin E T16891 FUNCTION May have a role in immune function. Probably involved in the processing of antigenic peptides during MHC class II-mediated antigen presentation. May play a role in activation-induced lymphocyte depletion in the thymus, and in neuronal degeneration and glial cell activation in the brain. T16891 PDBSTRUC 1TZS; 1LCG T16891 BIOCLASS Peptidase T16891 ECNUMBER EC 3.4.23.34 T16891 SEQUENCE MKTLLLLLLVLLELGEAQGSLHRVPLRRHPSLKKKLRARSQLSEFWKSHNLDMIQFTESCSMDQSAKEPLINYLDMEYFGTISIGSPPQNFTVIFDTGSSNLWVPSVYCTSPACKTHSRFQPSQSSTYSQPGQSFSIQYGTGSLSGIIGADQVSVEGLTVVGQQFGESVTEPGQTFVDAEFDGILGLGYPSLAVGGVTPVFDNMMAQNLVDLPMFSVYMSSNPEGGAGSELIFGGYDHSHFSGSLNWVPVTKQAYWQIALDNIQVGGTVMFCSEGCQAIVDTGTSLITGPSDKIKQLQNAIGAAPVDGEYAVECANLNVMPDVTFTINGVPYTLSPTAYTLLDFVDGMQFCSSGFQGLDIHPPAGPLWILGDVFIRQFYSVFDRGNNRVGLAPAVP T16891 DRUGINFO D0KK6A PMID8410973C2 Investigative T16891 DRUGINFO D0P6RT PMID8410973C3 Investigative T31674 TARGETID T31674 T31674 FORMERID TTDR00640 T31674 UNIPROID ALF_PLAFA T31674 TARGNAME Plasmodium Fructose-bisphosphate aldolase (Malaria FBA) T31674 GENENAME Malaria FBA T31674 TARGTYPE Literature-reported T31674 SYNONYMS Fructose-bisphosphate aldolase; 41 kDa antigen T31674 FUNCTION Catalyzes carboncarbon bond formation (or cleavage). Participate in the metabolically important pathways of gluconeogenesis and glycolysis. T31674 PDBSTRUC 2PC4; 2EPH; 1A5C T31674 BIOCLASS Carbon-carbon lyase T31674 SEQUENCE MAHCTEYMNAPKKLPADVAEELATTAQKLVQAGKGILAADESTQTIKKRFDNIKLENTIENRASYRDLLFGTKGLGKFISGAILFEETLFQKNEAGVPMVNLLHNENIIPGIKVDKGLVNIPCTDEEKSTQGLDGLAERCKEYYKAGARFAKWRTVLVIDTAKGKPTDLSIHETAWGLARYASICQQNRLVPIVEPEILADGPHSIEVCAVVTQKVLSCVFKALQENGVLLEGALLKPNMVTAGYECTAKTTTQDVGFLTVRTLRRTVPPALPGVVFLSGGQSEEEASVNLNSINALGPHPWALTFSYGRALQASVLNTWQGKKENVAKAREVLLQRAEANSLATYGKYKGGAGGENAGASLYEKKYVY T31674 DRUGINFO D0RO6K PHOSPHOGLYCOLOHYDROXAMATE Investigative T65483 TARGETID T65483 T65483 FORMERID TTDI03077 T65483 UNIPROID CBPM_HUMAN T65483 TARGNAME Carboxypeptidase M (CPM) T65483 GENENAME CPM T65483 TARGTYPE Literature-reported T65483 SYNONYMS Human carboxypeptidase M T65483 FUNCTION It is believed to play important roles in the control of peptide hormone and growth factor activity at the cell surface, and in the membrane-localized degradation of extracellular proteins. Specifically removes C-terminal basic residues (Arg or Lys) from peptides and proteins. T65483 PDBSTRUC 1UWY T65483 BIOCLASS Peptidase T65483 ECNUMBER EC 3.4.17.12 T65483 SEQUENCE MDFPCLWLGLLLPLVAALDFNYHRQEGMEAFLKTVAQNYSSVTHLHSIGKSVKGRNLWVLVVGRFPKEHRIGIPEFKYVANMHGDETVGRELLLHLIDYLVTSDGKDPEITNLINSTRIHIMPSMNPDGFEAVKKPDCYYSIGRENYNQYDLNRNFPDAFEYNNVSRQPETVAVMKWLKTETFVLSANLHGGALVASYPFDNGVQATGALYSRSLTPDDDVFQYLAHTYASRNPNMKKGDECKNKMNFPNGVTNGYSWYPLQGGMQDYNYIWAQCFEITLELSCCKYPREEKLPSFWNNNKASLIEYIKQVHLGVKGQVFDQNGNPLPNVIVEVQDRKHICPYRTNKYGEYYLLLLPGSYIINVTVPGHDPHITKVIIPEKSQNFSALKKDILLPFQGQLDSIPVSNPSCPMIPLYRNLPDHSAATKPSLFLFLVSLLHIFFK T65483 DRUGINFO D0XA0N PMID14640538C3 Investigative T77181 TARGETID T77181 T77181 FORMERID TTDI03609 T77181 UNIPROID UCHL3_HUMAN T77181 TARGNAME Ubiquitin thioesterase L3 (UCHL3) T77181 GENENAME UCHL3 T77181 TARGTYPE Literature-reported T77181 SYNONYMS Ubiquitin carboxyl-terminal hydrolase isozyme L3; UCH-L3 T77181 FUNCTION Thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of either ubiquitin or NEDD8. Has a 10-fold preference for Arg and Lys at position P3", and exhibits a preference towards 'Lys-48'-linked ubiquitin chains. Deubiquitinates ENAC in apical compartments, thereby regulating apical membrane recycling. Indirectly increases the phosphorylation of IGFIR, AKT and FOXO1 and promotes insulin-signaling and insulin-induced adipogenesis. Required for stress-response retinal, skeletal muscle and germ cell maintenance. May be involved in working memory. Can hydrolyze UBB(+1), a mutated form of ubiquitin which is not effectively degraded by the proteasome and is associated with neurogenerative disorders. Deubiquitinating enzyme (DUB) that controls levels of cellular ubiquitin through processing of ubiquitin precursors and ubiquitinated proteins. T77181 PDBSTRUC 6ISU; 1XD3; 1UCH T77181 BIOCLASS Peptidase T77181 ECNUMBER EC 3.4.19.12 T77181 SEQUENCE MEGQRWLPLEANPEVTNQFLKQLGLHPNWQFVDVYGMDPELLSMVPRPVCAVLLLFPITEKYEVFRTEEEEKIKSQGQDVTSSVYFMKQTISNACGTIGLIHAIANNKDKMHFESGSTLKKFLEESVSMSPEERARYLENYDAIRVTHETSAHEGQTEAPSIDEKVDLHFIALVHVDGHLYELDGRKPFPINHGETSDETLLEDAIEVCKKFMERDPDELRFNAIALSAA T42533 TARGETID T42533 T42533 FORMERID TTDI00226 T42533 UNIPROID NDKA_HUMAN T42533 TARGNAME Nucleoside diphosphate kinase A (NM23-H1) T42533 GENENAME NME1 T42533 TARGTYPE Literature-reported T42533 SYNONYMS nm23H1; Tumor metastatic processassociated protein; Tumor metastatic process-associated protein; NM23; NDPKA; NDP kinase A; NDK A; Metastasis inhibition factor nm23; Granzyme Aactivated DNase; Granzyme A-activated DNase; GAAD T42533 FUNCTION The ATP gamma phosphate is transferred to the NDP beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate. Possesses nucleoside-diphosphate kinase, serine/threonine-specific protein kinase, geranyl and farnesyl pyrophosphate kinase, histidine protein kinase and 3'-5' exonuclease activities. Involved in cell proliferation, differentiation and development, signal transduction, G protein-coupled receptor endocytosis, and gene expression. Required for neural development including neural patterning and cell fate determination. During GZMA-mediated cell death, works in concert with TREX1. NME1 nicks one strand of DNA and TREX1 removes bases from the free 3' end to enhance DNA damage and prevent DNA end reannealing and rapid repair. Major role in the synthesis of nucleoside triphosphates other than ATP. T42533 PDBSTRUC 5UI4; 4ENO; 3L7U; 2HVE; 2HVD T42533 BIOCLASS Kinase T42533 ECNUMBER EC 2.7.4.6 T42533 SEQUENCE MANCERTFIAIKPDGVQRGLVGEIIKRFEQKGFRLVGLKFMQASEDLLKEHYVDLKDRPFFAGLVKYMHSGPVVAMVWEGLNVVKTGRVMLGETNPADSKPGTIRGDFCIQVGRNIIHGSDSVESAEKEIGLWFHPEELVDYTSCAQNWIYE T16993 TARGETID T16993 T16993 FORMERID TTDI03195 T16993 UNIPROID FER_HUMAN T16993 TARGNAME Proto-oncogene c-Fer (FER) T16993 GENENAME FER T16993 TARGTYPE Literature-reported T16993 SYNONYMS p94-Fer; Tyrosine-protein kinase Fer; Tyrosine kinase 3; TYK3; Fujinami poultry sarcoma/Feline sarcoma-related protein Fer; Feline encephalitis virus-related kinase FER T16993 FUNCTION Acts downstream of EGFR, KIT, PDGFRA and PDGFRB. Acts downstream of EGFR to promote activation of NF-kappa-B and cell proliferation. May play a role in the regulation of the mitotic cell cycle. Plays a role in the insulin receptor signaling pathway and in activation of phosphatidylinositol 3-kinase. Acts downstream of the activated FCER1 receptor and plays a role in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Plays a role in the regulation of mast cell degranulation. Plays a role in leukocyte recruitment and diapedesis in response to bacterial lipopolysaccharide (LPS). Plays a role in synapse organization, trafficking of synaptic vesicles, the generation of excitatory postsynaptic currents and neuron-neuron synaptic transmission. Plays a role in neuronal cell death after brain damage. Phosphorylates CTTN, CTNND1, PTK2/FAK1, GAB1, PECAM1 and PTPN11. May phosphorylate JUP and PTPN1. Can phosphorylate STAT3, but the biological relevance of this depends on cell type and stimulus. Tyrosine-protein kinase that acts downstream of cell surface receptors for growth factors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, lamellipodia formation, cell adhesion, cell migration and chemotaxis. T16993 PDBSTRUC 2KK6 T16993 BIOCLASS Kinase T16993 ECNUMBER EC 2.7.10.2 T16993 SEQUENCE MGFGSDLKNSHEAVLKLQDWELRLLETVKKFMALRIKSDKEYASTLQNLCNQVDKESTVQMNYVSNVSKSWLLMIQQTEQLSRIMKTHAEDLNSGPLHRLTMMIKDKQQVKKSYIGVHQQIEAEMIKVTKTELEKLKCSYRQLIKEMNSAKEKYKEALAKGKETEKAKERYDKATMKLHMLHNQYVLALKGAQLHQNQYYDITLPLLLDSLQKMQEEMIKALKGIFDEYSQITSLVTEEIVNVHKEIQMSVEQIDPSTEYNNFIDVHRTTAAKEQEIEFDTSLLEENENLQANEIMWNNLTAESLQVMLKTLAEELMQTQQMLLNKEEAVLELEKRIEESSETCEKKSDIVLLLSQKQALEELKQSVQQLRCTEAKFSAQKELLEQKVQENDGKEPPPVVNYEEDARSVTSMERKERLSKFESIRHSIAGIIRSPKSALGSSALSDMISISEKPLAEQDWYHGAIPRIEAQELLKKQGDFLVRESHGKPGEYVLSVYSDGQRRHFIIQYVDNMYRFEGTGFSNIPQLIDHHYTTKQVITKKSGVVLLNPIPKDKKWILSHEDVILGELLGKGNFGEVYKGTLKDKTSVAVKTCKEDLPQELKIKFLQEAKILKQYDHPNIVKLIGVCTQRQPVYIIMELVSGGDFLTFLRRKKDELKLKQLVKFSLDAAAGMLYLESKNCIHRDLAARNCLVGENNVLKISDFGMSRQEDGGVYSSSGLKQIPIKWTAPEALNYGRYSSESDVWSFGILLWETFSLGVCPYPGMTNQQAREQVERGYRMSAPQHCPEDISKIMMKCWDYKPENRPKFSELQKELTIIKRKLT T16993 DRUGINFO D0K5UF PMID24432909C8e Investigative T16993 DRUGINFO D09AID PMID22564207C25b Investigative T55302 TARGETID T55302 T55302 FORMERID TTDI02438 T55302 UNIPROID ANFB_HUMAN T55302 TARGNAME B-type natriuretic peptide (BNP) T55302 GENENAME NPPB T55302 TARGTYPE Literature-reported T55302 SYNONYMS Natriuretic peptides B; NPPB; Gammabrain natriuretic peptide; BNP32; BNP(529); BNP(132) T55302 FUNCTION Cardiac hormone which may function as a paracrine antifibrotic factor in the heart. Also plays a key role in cardiovascular homeostasis through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. Specifically binds and stimulates the cGMP production of the NPR1 receptor. Binds the clearance receptor NPR3. T55302 PDBSTRUC 3N56; 1YK1 T55302 BIOCLASS Natriuretic peptide family T55302 SEQUENCE MDPQTAPSRALLLLLFLHLAFLGGRSHPLGSPGSASDLETSGLQEQRNHLQGKLSELQVEQTSLEPLQESPRPTGVWKSREVATEGIRGHRKMVLYTLRAPRSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH T55302 DRUGINFO D06MPJ BD-NP Investigative T00329 TARGETID T00329 T00329 FORMERID TTDR00487 T00329 UNIPROID COLY_YERPE T00329 TARGNAME Bacterial Plasminogen activator (Bact pla) T00329 GENENAME Bact pla T00329 TARGTYPE Literature-reported T00329 SYNONYMS pla; Coagulase/fibrinolysin T00329 FUNCTION Seems to play an essential role in plague transmission by mediating flea blockage in a temperature-dependent fashion. Fibrinolytic activity prevails at 37 degrees Celsius whereas coagulase expression predominates at lower temperatures (<30 degrees Celsius). Activates plasminogen by cleaving it. T00329 PDBSTRUC 4DCB; 2X56; 2X55; 2X4M T00329 BIOCLASS Peptidase T00329 ECNUMBER EC 3.4.23.48 T00329 SEQUENCE MKKSSIVATIITILSGSANAASSQLIPNISPDSFTVAASTGMLSGKSHEMLYDAETGRKISQLDWKIKNVAILKGDISWDPYSFLTLNARGWTSLASGSGNMDDYDWMNENQSEWTDHSSHPATNVNHANEYDLNVKGWLLQDENYKAGITAGYQETRFSWTATGGSYSYNNGAYTGNFPKGVRVIGYNQRFSMPYIGLAGQYRINDFELNALFKFSDWVRAHDNDEHYMRDLTFREKTSGSRYYGTVINAGYYVTPNAKVFAEFTYSKYDEGKGGTQTIDKNSGDSVSIGGDAAGISNKNYTVTAGLQYRF T49995 TARGETID T49995 T49995 FORMERID TTDR01211 T49995 UNIPROID ARY1_HUMAN; ARY2_HUMAN T49995 TARGNAME Arylamine N-acetyltransferase (NAT) T49995 GENENAME NAT1; NAT2 T49995 TARGTYPE Literature-reported T49995 SYNONYMS NAT; N-acetyltransferase; Arylamide acetylase; AAC T49995 FUNCTION Could have a role in acetylating, and hence inactivating, the antitubercular drug isoniazid. T49995 BIOCLASS Acyltransferase T49995 SEQUENCE MDIEAYLERIGYKKSRNKLDLETLTDILQHQIRAVPFENLNIHCGDAMDLGLEAIFDQVVRRNRGGWCLQVNHLLYWALTTIGFETTMLGGYVYSTPAKKYSTGMIHLLLQVTIDGRNYIVDAGFGRSYQMWQPLELISGKDQPQVPCVFRLTEENGFWYLDQIRREQYIPNEEFLHSDLLEDSKYRKIYSFTLKPRTIEDFESMNTYLQTSPSSVFTSKSFCSLQTPDGVHCLVGFTLTHRRFNYKDNTDLIEFKTLSEEEIEKVLKNIFNISLQRKLVPKHGDRFFTI T49995 DRUGINFO D07VGG (Z)-5-Benzylidene-2-thioxothiazolidin-4-one Investigative T49995 DRUGINFO D08HQB (Z)-5-Octylidene-2-thioxothiazolidin-4-one Investigative T49995 DRUGINFO D0A5CN (Z)-5-Hexylidene-2-thioxothiazolidin-4-one Investigative T49995 DRUGINFO D0H9VW (Z)-5-Decylidene-2-thioxothiazolidin-4-one Investigative T49995 DRUGINFO D0W5ED (Z)-5-Butylidene-2-thioxothiazolidin-4-one Investigative T58470 TARGETID T58470 T58470 FORMERID TTDR00224 T58470 UNIPROID CCNA2_HUMAN T58470 TARGNAME Cyclin A2 (CCNA2) T58470 GENENAME CCNA2 T58470 TARGTYPE Literature-reported T58470 SYNONYMS Cyclin-A2; Cyclin-A; Cyclin A; CCNA T58470 FUNCTION Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2. The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 throughout the cell cycle. Cyclin which controls both the G1/S and the G2/M transition phases of the cell cycle. T58470 PDBSTRUC 6GVA; 6ATH; 5NEV; 5LMK; 5IF1 T58470 SEQUENCE MLGNSAPGPATREAGSALLALQQTALQEDQENINPEKAAPVQQPRTRAALAVLKSGNPRGLAQQQRPKTRRVAPLKDLPVNDEHVTVPPWKANSKQPAFTIHVDEAEKEAQKKPAESQKIEREDALAFNSAISLPGPRKPLVPLDYPMDGSFESPHTMDMSIILEDEKPVSVNEVPDYHEDIHTYLREMEVKCKPKVGYMKKQPDITNSMRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLRGKLQLVGTAAMLLASKFEEIYPPEVAEFVYITDDTYTKKQVLRMEHLVLKVLTFDLAAPTVNQFLTQYFLHQQPANCKVESLAMFLGELSLIDADPYLKYLPSVIAGAAFHLALYTVTGQSWPESLIRKTGYTLESLKPCLMDLHQTYLKAPQHAQQSIREKYKNSKYHGVSLLNPPETLNL T58470 DRUGINFO D0Z0KD PD-0183812 Terminated T58470 DRUGINFO D01FJB 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine Investigative T58470 DRUGINFO D02ZYA 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine Investigative T58470 DRUGINFO D03XKK 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine Investigative T58470 DRUGINFO D04RBG GW-8510 Investigative T58470 DRUGINFO D04UNQ 4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine Investigative T58470 DRUGINFO D07AEC RESCOVITINE Investigative T58470 DRUGINFO D07JHG 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine Investigative T58470 DRUGINFO D0E3FK MERIOLIN 7 Investigative T58470 DRUGINFO D0R1FT 6-O-Cyclohexylmethyl Guanine Investigative T58470 DRUGINFO D0U8YN NU-6027 Investigative T58470 DRUGINFO D01PEF MERIOLIN 8 Investigative T58470 DRUGINFO D06WUE 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide Investigative T58470 DRUGINFO D07OAT Purvalanol A Investigative T58470 DRUGINFO D08KSQ MERIOLIN 1 Investigative T58470 DRUGINFO D0B9YR MERIOLIN 4 Investigative T58470 DRUGINFO D0D0ZQ MERIOLIN 6 Investigative T58470 DRUGINFO D0H6CQ MERIOLIN 5 Investigative T58470 DRUGINFO D0S8VE MERIOLIN 3 Investigative T58470 DRUGINFO D0U1WL MERIOLIN 2 Investigative T58470 DRUGINFO D0W0BL 3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol Investigative T58470 DRUGINFO D02XHC aloisine A Investigative T58470 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T36657 TARGETID T36657 T36657 FORMERID TTDR01445 T36657 UNIPROID CP2A7_HUMAN T36657 TARGNAME Cytochrome P450 2A5 (CYP2A5) T36657 GENENAME Cyp2a5 T36657 TARGTYPE Literature-reported T36657 SYNONYMS Cytochrome P450-IIA3.2; Cytochrome P450-15-COH; Cyp2a5; Cyp2a-5; CYPIIA5 T36657 FUNCTION Exhibits a high coumarin 7-hydroxylase activity. T36657 BIOCLASS Paired donor oxygen oxidoreductase T36657 ECNUMBER EC 1.14.14.1 T36657 SEQUENCE MLASGLLLVALLACLTVMVLMSVWQQRKSRGKLPPGPTPLPFIGNYLQLNTEHICDSIMKFSECYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVAFSNGERAKQLLRFAIATLRDFGVGKRGIEERIQEESGFLIEAIRSTHGANIDPTFFLSRTVSNVISSIVFGDRFDYEDKEFLSLLSMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFKLLQGLEDFIAKKVEHNQRTLDPNSPQDFIDSFLIHMQEEEKNPNTEFYLKNLMMSTLNLFIAGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRTKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDPSFFSNPQDFNPQHFLDDKGQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVVFATIPRNYTMSFLPR T56474 TARGETID T56474 T56474 FORMERID TTDR00499 T56474 UNIPROID TNAP3_HUMAN T56474 TARGNAME Zinc finger protein A20 (TNFAIP3) T56474 GENENAME TNFAIP3 T56474 TARGTYPE Literature-reported T56474 SYNONYMS Tumor necrosis factor, alpha-induced protein3; Tumor necrosis factor alpha-induced protein 3; TNF alpha-induced protein 3; Putative DNA-binding protein A20; Putative DNA binding protein A20; OTUD7C; OTU domain-containing protein 7C; A20 T56474 FUNCTION Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages. Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. T56474 PDBSTRUC 5V3P; 5V3B; 5LRX; 3ZJG; 3ZJF T56474 BIOCLASS Acyltransferase T56474 ECNUMBER EC 2.3.2.- T56474 SEQUENCE MAEQVLPQALYLSNMRKAVKIRERTPEDIFKPTNGIIHHFKTMHRYTLEMFRTCQFCPQFREIIHKALIDRNIQATLESQKKLNWCREVRKLVALKTNGDGNCLMHATSQYMWGVQDTDLVLRKALFSTLKETDTRNFKFRWQLESLKSQEFVETGLCYDTRNWNDEWDNLIKMASTDTPMARSGLQYNSLEEIHIFVLCNILRRPIIVISDKMLRSLESGSNFAPLKVGGIYLPLHWPAQECYRYPIVLGYDSHHFVPLVTLKDSGPEIRAVPLVNRDRGRFEDLKVHFLTDPENEMKEKLLKEYLMVIEIPVQGWDHGTTHLINAAKLDEANLPKEINLVDDYFELVQHEYKKWQENSEQGRREGHAQNPMEPSVPQLSLMDVKCETPNCPFFMSVNTQPLCHECSERRQKNQNKLPKLNSKPGPEGLPGMALGASRGEAYEPLAWNPEESTGGPHSAPPTAPSPFLFSETTAMKCRSPGCPFTLNVQHNGFCERCHNARQLHASHAPDHTRHLDPGKCQACLQDVTRTFNGICSTCFKRTTAEASSSLSTSLPPSCHQRSKSDPSRLVRSPSPHSCHRAGNDAPAGCLSQAARTPGDRTGTSKCRKAGCVYFGTPENKGFCTLCFIEYRENKHFAAASGKVSPTASRFQNTIPCLGRECGTLGSTMFEGYCQKCFIEAQNQRFHEAKRTEEQLRSSQRRDVPRTTQSTSRPKCARASCKNILACRSEELCMECQHPNQRMGPGAHRGEPAPEDPPKQRCRAPACDHFGNAKCNGYCNECFQFKQMYG T77721 TARGETID T77721 T77721 FORMERID TTDR00623 T77721 UNIPROID GPDA_HUMAN T77721 TARGNAME Glycerol-3-phosphate dehydrogenase (GPD1) T77721 GENENAME GPD1 T77721 TARGTYPE Literature-reported T77721 SYNONYMS Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic; GPDH-C; GPD-C T77721 FUNCTION Catalyzes the reversible redox conversion of dihydroxyacetone phosphate (a.k.a. glycerone phosphate, outdated) to sn-glycerol 3-phosphate. serves as a major link between carbohydrate metabolism and lipid metabolism. A major contributor of electrons to the electron transport chain in the mitochondria. T77721 PDBSTRUC 6E8Z; 6E8Y; 6.00E+90; 1X0X; 1X0V T77721 BIOCLASS Short-chain dehydrogenases reductase T77721 ECNUMBER EC 1.1.1.8 T77721 SEQUENCE MASKKVCIVGSGNWGSAIAKIVGGNAAQLAQFDPRVTMWVFEEDIGGKKLTEIINTQHENVKYLPGHKLPPNVVAVPDVVQAAEDADILIFVVPHQFIGKICDQLKGHLKANATGISLIKGVDEGPNGLKLISEVIGERLGIPMSVLMGANIASEVADEKFCETTIGCKDPAQGQLLKELMQTPNFRITVVQEVDTVEICGALKNVVAVGAGFCDGLGFGDNTKAAVIRLGLMEMIAFAKLFCSGPVSSATFLESCGVADLITTCYGGRNRKVAEAFARTGKSIEQLEKELLNGQKLQGPETARELYSILQHKGLVDKFPLFMAVYKVCYEGQPVGEFIHCLQNHPEHM T28418 TARGETID T28418 T28418 FORMERID TTDI03175 T28418 UNIPROID EPHA1_HUMAN T28418 TARGNAME Ephrin type-A receptor 1 (EPHA1) T28418 GENENAME EPHA1 T28418 TARGTYPE Literature-reported T28418 SYNONYMS hEpha1; Tyrosine-protein kinase receptor EPH; Erythropoietin-producing hepatoma receptor; EPHT1; EPHT; EPH tyrosine kinase 1; EPH tyrosine kinase; EPH T28418 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Binds with a low affinity EFNA3 and EFNA4 and with a high affinity to EFNA1 which most probably constitutes its cognate/functional ligand. Upon activation by EFNA1 induces cell attachment to the extracellular matrix inhibiting cell spreading and motility through regulation of ILK and downstream RHOA and RAC. Plays also a role in angiogenesis and regulates cell proliferation. May play a role in apoptosis. Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T28418 PDBSTRUC 3KKA; 3HIL; 2K1L; 2K1K T28418 BIOCLASS Kinase T28418 ECNUMBER EC 2.7.10.1 T28418 SEQUENCE MERRWPLGLGLVLLLCAPLPPGARAKEVTLMDTSKAQGELGWLLDPPKDGWSEQQQILNGTPLYMYQDCPMQGRRDTDHWLRSNWIYRGEEASRVHVELQFTVRDCKSFPGGAGPLGCKETFNLLYMESDQDVGIQLRRPLFQKVTTVAADQSFTIRDLVSGSVKLNVERCSLGRLTRRGLYLAFHNPGACVALVSVRVFYQRCPETLNGLAQFPDTLPGPAGLVEVAGTCLPHARASPRPSGAPRMHCSPDGEWLVPVGRCHCEPGYEEGGSGEACVACPSGSYRMDMDTPHCLTCPQQSTAESEGATICTCESGHYRAPGEGPQVACTGPPSAPRNLSFSASGTQLSLRWEPPADTGGRQDVRYSVRCSQCQGTAQDGGPCQPCGVGVHFSPGARGLTTPAVHVNGLEPYANYTFNVEAQNGVSGLGSSGHASTSVSISMGHAESLSGLSLRLVKKEPRQLELTWAGSRPRSPGANLTYELHVLNQDEERYQMVLEPRVLLTELQPDTTYIVRVRMLTPLGPGPFSPDHEFRTSPPVSRGLTGGEIVAVIFGLLLGAALLLGILVFRSRRAQRQRQQRQRDRATDVDREDKLWLKPYVDLQAYEDPAQGALDFTRELDPAWLMVDTVIGEGEFGEVYRGTLRLPSQDCKTVAIKTLKDTSPGGQWWNFLREATIMGQFSHPHILHLEGVVTKRKPIMIITEFMENGALDAFLREREDQLVPGQLVAMLQGIASGMNYLSNHNYVHRDLAARNILVNQNLCCKVSDFGLTRLLDDFDGTYETQGGKIPIRWTAPEAIAHRIFTTASDVWSFGIVMWEVLSFGDKPYGEMSNQEVMKSIEDGYRLPPPVDCPAPLYELMKNCWAYDRARRPHFQKLQAHLEQLLANPHSLRTIANFDPRMTLRLPSLSGSDGIPYRTVSEWLESIRMKRYILHFHSAGLDTMECVLELTAEDLTQMGITLPGHQKRILCSIQGFKD T28418 DRUGINFO D05FXD PMID19788238C66 Investigative T28418 DRUGINFO D0X8BU PMID23489211C20 Investigative T04685 TARGETID T04685 T04685 FORMERID TTDI02012 T04685 UNIPROID ADRO_HUMAN T04685 TARGNAME NADPH:adrenodoxin oxidoreductase (FDXR) T04685 GENENAME FDXR T04685 TARGTYPE Literature-reported T04685 SYNONYMS NADPH:adrenodoxin oxidoreductase, mitochondrial; FerredoxinNADP(+) reductase; Ferredoxin reductase; FDXR; Adrenodoxin reductase T04685 FUNCTION Serves as the first electron transfer protein in all the mitochondrial P450 systems. Including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitaminD3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver. T04685 BIOCLASS Ferredoxin--NADP reductase type 1 T04685 ECNUMBER EC 1.18.1.6 T04685 SEQUENCE MASRCWRWWGWSAWPRTRLPPAGSTPSFCHHFSTQEKTPQICVVGSGPAGFYTAQHLLKHPQAHVDIYEKQPVPFGLVRFGVAPDHPEVKNVINTFTQTAHSGRCAFWGNVEVGRDVTVPELREAYHAVVLSYGAEDHRALEIPGEELPGVCSARAFVGWYNGLPENQELEPDLSCDTAVILGQGNVALDVARILLTPPEHLERTDITKAALGVLRQSRVKTVWLVGRRGPLQVAFTIKELREMIQLPGARPILDPVDFLGLQDKIKEVPRPRKRLTELLLRTATEKPGPAEAARQASASRAWGLRFFRSPQQVLPSPDGRRAAGVRLAVTRLEGVDEATRAVPTGDMEDLPCGLVLSSIGYKSRPVDPSVPFDSKLGVIPNVEGRVMDVPGLYCSGWVKRGPTGVIATTMTDSFLTGQMLLQDLKAGLLPSGPRPGYAAIQALLSSRGVRPVSFSDWEKLDAEEVARGQGTGKPREKLVDPQEMLRLLGH T25309 TARGETID T25309 T25309 FORMERID TTDR00741 T25309 UNIPROID CBL_HUMAN T25309 TARGNAME Signal transduction protein CBL (CBL) T25309 GENENAME CBL T25309 TARGTYPE Literature-reported T25309 SYNONYMS RNF55; RING-type E3 ubiquitin transferase CBL; RING finger protein 55; Proto-oncogene c-CBL; E3 ubiquitin-protein ligase CBL; Casitas B-lineage lymphoma proto-oncogene; CBL2; C-Cbl T25309 FUNCTION Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBLB, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA. Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. T25309 PDBSTRUC 5O76; 5J3X; 5HL0; 5HKZ; 5HKY T25309 BIOCLASS Acyltransferase T25309 ECNUMBER EC 2.3.2.27 T25309 SEQUENCE MAGNVKKSSGAGGGSGSGGSGSGGLIGLMKDAFQPHHHHHHHLSPHPPGTVDKKMVEKCWKLMDKVVRLCQNPKLALKNSPPYILDLLPDTYQHLRTILSRYEGKMETLGENEYFRVFMENLMKKTKQTISLFKEGKERMYEENSQPRRNLTKLSLIFSHMLAELKGIFPSGLFQGDTFRITKADAAEFWRKAFGEKTIVPWKSFRQALHEVHPISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWSSLLRNWNSLAVTHPGYMAFLTYDEVKARLQKFIHKPGSYIFRLSCTRLGQWAIGYVTADGNILQTIPHNKPLFQALIDGFREGFYLFPDGRNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQESEGQGCPFCRCEIKGTEPIVVDPFDPRGSGSLLRQGAEGAPSPNYDDDDDERADDTLFMMKELAGAKVERPPSPFSMAPQASLPPVPPRLDLLPQRVCVPSSASALGTASKAASGSLHKDKPLPVPPTLRDLPPPPPPDRPYSVGAESRPQRRPLPCTPGDCPSRDKLPPVPSSRLGDSWLPRPIPKVPVSAPSSSDPWTGRELTNRHSLPFSLPSQMEPRPDVPRLGSTFSLDTSMSMNSSPLVGPECDHPKIKPSSSANAIYSLAARPLPVPKLPPGEQCEGEEDTEYMTPSSRPLRPLDTSQSSRACDCDQQIDSCTYEAMYNIQSQAPSITESSTFGEGNLAAAHANTGPEESENEDDGYDVPKPPVPAVLARRTLSDISNASSSFGWLSLDGDPTTNVTEGSQVPERPPKPFPRRINSERKAGSCQQGSGPAASAATASPQLSSEIENLMSQGYSYQDIQKALVIAQNNIEMAKNILREFVSISSPAHVAT T59729 TARGETID T59729 T59729 FORMERID TTDR00862 T59729 UNIPROID DHAS2_VIBCH T59729 TARGNAME Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2) T59729 GENENAME Bact asd2 T59729 TARGTYPE Literature-reported T59729 SYNONYMS asd2; L-Aspartate-beta-semialdehyde dehydrogenase; ASADH; ASA dehydrogenase T59729 FUNCTION Catalyzes the NADPH-dependent formation of L-aspartate- semialdehyde (L-ASA) by the reductive dephosphorylation of L- aspartyl-4-phosphate. T59729 PDBSTRUC 2R00; 2QZ9 T59729 BIOCLASS Aldehyde/oxo donor oxidoreductase T59729 SEQUENCE MSQQFNVAIFGATGAVGETMLEVLQEREFPVDELFLLASERSEGKTYRFNGKTVRVQNVEEFDWSQVHIALFSAGGELSAKWAPIAAEAGVVVIDNTSHFRYDYDIPLVVPEVNPEAIAEFRNRNIIANPNCSTIQMLVALKPIYDAVGIERINVTTYQSVSGAGKAGIDELAGQTAKLLNGYPAETNTFSQQIAFNCIPQIDQFMDNGYTKEEMKMVWETQKIFNDPSIMVNPTCVRVPVFYGHAEAVHVETRAPIDAEQVMDMLEQTDGIELFRGADFPTQVRDAGGKDHVLVGRVRNDISHHSGINLWVVADNVRKGAATNAVQIAELLVRDYF T59729 DRUGINFO D00EUE S-sulpho-L-cysteine Investigative T59729 DRUGINFO D06SIH Aspartate Semialdehyde Investigative T59729 DRUGINFO D09TVP Cacodylate Ion Investigative T59729 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T72653 TARGETID T72653 T72653 FORMERID TTDR01166 T72653 UNIPROID CHS1_CANAX T72653 TARGNAME Candida Chitin synthase 1 (Candi CHS1) T72653 GENENAME Candi CHS1 T72653 TARGTYPE Literature-reported T72653 SYNONYMS Chitin-UDP acetyl-glucosaminyl transferase 1; CHS1 T72653 FUNCTION Formation and repair of the disk-shaped septumin yeast and the cross walls of the hyphal phase. T72653 BIOCLASS Hexosyltransferase T72653 ECNUMBER EC 2.4.1.16 T72653 SEQUENCE MHNINNGYVPNREKTITKRKVRLVGGKAGNLVLENPVPTELRKVLTRTESPFGEFTNMTYTACTSQPDTFSAEGFTLRAAKYGRETEIVICITMYNEDEVAFARTMHGVMKNIAHLCSRHKSKIWGKDSWKKVQVIIVADGRNKVQQSVLELLTATGCYQENLARPYVNNSKVNAHLFEYTTQISIDENLKFKGDEKNLAPVQVLFCLKESNQKKINSHRWLFNAFCPVLDPNVIVLLDVGTKPDNHAIYNLWKAFDRDSNVAGAAGEIKAMKGKGWINLTNPLVASQNFEYKLSNILDKPLESLFGYISVLPGALSAYRYIALKNHDDGTGPLASYFKGEDLLCSHDKDKENTKANFFEANMYLAEDRILCWELVSKRNDNWVLKFVKSATGETDVPETIAEFLSQRRRWINGAFFAALYSLYHFRKIWTTDHSYARKFWLHVEEFIYQLVSLLFSFFSLSNFYLTFYFLTGSLVSYKSLGKKGGFWIFTLFNYLCIGVLTSLFIVSIGNRPHASKNIFKTLIILLTICALYALVVGFVFVINTIATFGTGGTSTYVLVSIVVSLLSTYGLYTLMSILYLDPWHMLTCSVQYFLMIPSYTCTLQIFAFCNTHDVSWGTKGDNNPKEDLSNQYIIEKNASGEFEAVIVDTNIDEDYLETLYNIRSKRSNKKVALGHSEKTPLDGDDYAKDVRTRVVLFWMIANLVFIMTMVQVYEPGDTGRNIYLAFILWAVAVLALVRAIGSLGYLIQTYARFFVESKSKWMKRGYTAPSHNPLN T88415 TARGETID T88415 T88415 FORMERID TTDR01149 T88415 UNIPROID PTPRZ_HUMAN T88415 TARGNAME Receptor-type protein-tyrosine phosphatase zeta (PTPRZ1) T88415 GENENAME PTPRZ1 T88415 TARGTYPE Literature-reported T88415 SYNONYMS Receptor protein tyrosine phosphatase zeta; R-PTP-zeta; PTPRZ1 T88415 FUNCTION Protein tyrosine phosphatase that negatively regulates oligodendrocyte precursor proliferation in the embryonic spinal cord. Required for normal differentiation of the precursor cells into mature, fully myelinating oligodendrocytes. May play a role in protecting oligondendrocytes against apoptosis. May play a role in the establishment of contextual memory, probably via the dephosphorylation of proteins that are part of important signaling cascades. T88415 PDBSTRUC 5H08; 5AWX; 3S97; 3JXF T88415 BIOCLASS Phosphoric monoester hydrolase T88415 ECNUMBER EC 3.1.3.48 T88415 SEQUENCE MRILKRFLACIQLLCVCRLDWANGYYRQQRKLVEEIGWSYTGALNQKNWGKKYPTCNSPKQSPINIDEDLTQVNVNLKKLKFQGWDKTSLENTFIHNTGKTVEINLTNDYRVSGGVSEMVFKASKITFHWGKCNMSSDGSEHSLEGQKFPLEMQIYCFDADRFSSFEEAVKGKGKLRALSILFEVGTEENLDFKAIIDGVESVSRFGKQAALDPFILLNLLPNSTDKYYIYNGSLTSPPCTDTVDWIVFKDTVSISESQLAVFCEVLTMQQSGYVMLMDYLQNNFREQQYKFSRQVFSSYTGKEEIHEAVCSSEPENVQADPENYTSLLVTWERPRVVYDTMIEKFAVLYQQLDGEDQTKHEFLTDGYQDLGAILNNLLPNMSYVLQIVAICTNGLYGKYSDQLIVDMPTDNPELDLFPELIGTEEIIKEEEEGKDIEEGAIVNPGRDSATNQIRKKEPQISTTTHYNRIGTKYNEAKTNRSPTRGSEFSGKGDVPNTSLNSTSQPVTKLATEKDISLTSQTVTELPPHTVEGTSASLNDGSKTVLRSPHMNLSGTAESLNTVSITEYEEESLLTSFKLDTGAEDSSGSSPATSAIPFISENISQGYIFSSENPETITYDVLIPESARNASEDSTSSGSEESLKDPSMEGNVWFPSSTDITAQPDVGSGRESFLQTNYTEIRVDESEKTTKSFSAGPVMSQGPSVTDLEMPHYSTFAYFPTEVTPHAFTPSSRQQDLVSTVNVVYSQTTQPVYNGETPLQPSYSSEVFPLVTPLLLDNQILNTTPAASSSDSALHATPVFPSVDVSFESILSSYDGAPLLPFSSASFSSELFRHLHTVSQILPQVTSATESDKVPLHASLPVAGGDLLLEPSLAQYSDVLSTTHAASETLEFGSESGVLYKTLMFSQVEPPSSDAMMHARSSGPEPSYALSDNEGSQHIFTVSYSSAIPVHDSVGVTYQGSLFSGPSHIPIPKSSLITPTASLLQPTHALSGDGEWSGASSDSEFLLPDTDGLTALNISSPVSVAEFTYTTSVFGDDNKALSKSEIIYGNETELQIPSFNEMVYPSESTVMPNMYDNVNKLNASLQETSVSISSTKGMFPGSLAHTTTKVFDHEISQVPENNFSVQPTHTVSQASGDTSLKPVLSANSEPASSDPASSEMLSPSTQLLFYETSASFSTEVLLQPSFQASDVDTLLKTVLPAVPSDPILVETPKVDKISSTMLHLIVSNSASSENMLHSTSVPVFDVSPTSHMHSASLQGLTISYASEKYEPVLLKSESSHQVVPSLYSNDELFQTANLEINQAHPPKGRHVFATPVLSIDEPLNTLINKLIHSDEILTSTKSSVTGKVFAGIPTVASDTFVSTDHSVPIGNGHVAITAVSPHRDGSVTSTKLLFPSKATSELSHSAKSDAGLVGGGEDGDTDDDGDDDDDDRGSDGLSIHKCMSCSSYRESQEKVMNDSDTHENSLMDQNNPISYSLSENSEEDNRVTSVSSDSQTGMDRSPGKSPSANGLSQKHNDGKEENDIQTGSALLPLSPESKAWAVLTSDEESGSGQGTSDSLNENETSTDFSFADTNEKDADGILAAGDSEITPGFPQSPTSSVTSENSEVFHVSEAEASNSSHESRIGLAEGLESEKKAVIPLVIVSALTFICLVVLVGILIYWRKCFQTAHFYLEDSTSPRVISTPPTPIFPISDDVGAIPIKHFPKHVADLHASSGFTEEFETLKEFYQEVQSCTVDLGITADSSNHPDNKHKNRYINIVAYDHSRVKLAQLAEKDGKLTDYINANYVDGYNRPKAYIAAQGPLKSTAEDFWRMIWEHNVEVIVMITNLVEKGRRKCDQYWPADGSEEYGNFLVTQKSVQVLAYYTVRNFTLRNTKIKKGSQKGRPSGRVVTQYHYTQWPDMGVPEYSLPVLTFVRKAAYAKRHAVGPVVVHCSAGVGRTGTYIVLDSMLQQIQHEGTVNIFGFLKHIRSQRNYLVQTEEQYVFIHDTLVEAILSKETEVLDSHIHAYVNALLIPGPAGKTKLEKQFQLLSQSNIQQSDYSAALKQCNREKNRTSSIIPVERSRVGISSLSGEGTDYINASYIMGYYQSNEFIITQHPLLHTIKDFWRMIWDHNAQLVVMIPDGQNMAEDEFVYWPNKDEPINCESFKVTLMAEEHKCLSNEEKLIIQDFILEATQDDYVLEVRHFQCPKWPNPDSPISKTFELISVIKEEAANRDGPMIVHDEHGGVTAGTFCALTTLMHQLEKENSVDVYQVAKMINLMRPGVFADIEQYQFLYKVILSLVSTRQEENPSTSLDSNGAALPDGNIAESLESLV T25164 TARGETID T25164 T25164 FORMERID TTDR00747 T25164 UNIPROID HMP_ECOLI T25164 TARGNAME Bacterial Flavohemoglobin (Bact hmp) T25164 GENENAME Bact hmp T25164 TARGTYPE Literature-reported T25164 SYNONYMS Nitric oxide dioxygenase; NOD; NO oxygenase; Hemoglobin-like protein; HMP; Ferrisiderophore reductase B; Dihydropteridine reductase T25164 FUNCTION Various electron acceptors arealso reduced by HMP in vitro, including dihydropterine, ferrisiderophores, ferric citrate, cytochrome c, nitrite, S-nitrosoglutathione, and alkylhydroperoxides. However, it is unknown if these reactions are of any biological significance in vivo. T25164 PDBSTRUC 1GVH T25164 BIOCLASS Paired donor oxygen oxidoreductase T25164 ECNUMBER EC 1.14.12.17 T25164 SEQUENCE MLDAQTIATVKATIPLLVETGPKLTAHFYDRMFTHNPELKEIFNMSNQRNGDQREALFNAIAAYASNIENLPALLPAVEKIAQKHTSFQIKPEQYNIVGEHLLATLDEMFSPGQEVLDAWGKAYGVLANVFINREAEIYNENASKAGGWEGTRDFRIVAKTPRSALITSFELEPVDGGAVAEYRPGQYLGVWLKPEGFPHQEIRQYSLTRKPDGKGYRIAVKREEGGQVSNWLHNHANVGDVVKLVAPAGDFFMAVADDTPVTLISAGVGQTPMLAMLDTLAKAGHTAQVNWFHAAENGDVHAFADEVKELGQSLPRFTAHTWYRQPSEADRAKGQFDSEGLMDLSKLEGAFSDPTMQFYLCGPVGFMQFTAKQLVDLGVKQENIHYECFGPHKVL T25164 DRUGINFO D07KZA 2-(N-Morpholino)-Ethanesulfonic Acid Investigative T25164 DRUGINFO D0UU1I Heme Investigative T25164 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T25164 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T73180 TARGETID T73180 T73180 FORMERID TTDR01252 T73180 UNIPROID MMP11_HUMAN T73180 TARGNAME Matrix metalloproteinase-11 (MMP-11) T73180 GENENAME MMP11 T73180 TARGTYPE Literature-reported T73180 SYNONYMS Stromelysin-3 (ST3) gene; Stromelysin-3; STR-3; STMY3; ST3/MMP11; ST3; SL-3 T73180 FUNCTION May play an important role in the progression of epithelial malignancies. T73180 BIOCLASS Peptidase T73180 ECNUMBER EC 3.4.24.- T73180 SEQUENCE MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDAHHLHAERRGPQPWHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYWHGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDAQGHIWFFQGAQYWVYDGEKPVLGPAPLTELGLVRFPVHAALVWGPEKNKIYFFRGRDYWRFHPSTRRVDSPVPRRATDWRGVPSEIDAAFQDADGYAYFLRGRLYWKFDPVKVKALEGFPRLVGPDFFGCAEPANTFL T73180 DRUGINFO D01UNE PMID18790648C10 Investigative T85223 TARGETID T85223 T85223 FORMERID TTDR00828 T85223 UNIPROID DNAS1_HUMAN T85223 TARGNAME Deoxyribonuclease I (DNASE1) T85223 GENENAME DNASE1 T85223 TARGTYPE Literature-reported T85223 SYNONYMS Herpesvirus alkaline deoxyribonuclease; Herpesvirus alkaline DNase; Dornase alfa; DNase I; DNASE1; Alkaline deoxyribonuclease T85223 FUNCTION Among other functions, seems to be involved in cell death by apoptosis. Binds specifically to G-actin and blocks actin polymerization. T85223 PDBSTRUC 4AWN T85223 BIOCLASS Endodeoxyribonucleases T85223 ECNUMBER EC 3.1.21.1 T85223 SEQUENCE MRGMKLLGALLALAALLQGAVSLKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVMLK T85223 DRUGINFO D07LUR Alpha-D-Mannose Investigative T10052 TARGETID T10052 T10052 FORMERID TTDR00786 T10052 UNIPROID CCNE1_HUMAN T10052 TARGNAME G1/S-specific cyclin-E1 (CCNE1) T10052 GENENAME CCNE1 T10052 TARGTYPE Literature-reported T10052 SYNONYMS G1/S-specific cyclin E; Cyclin E; CCNE T10052 FUNCTION Essential for the control of the cell cycle at the G1/S (start) transition. T10052 PDBSTRUC 5L2W; 1W98 T10052 SEQUENCE MPRERRERDAKERDTMKEDGGAEFSARSRKRKANVTVFLQDPDEEMAKIDRTARDQCGSQPWDNNAVCADPCSLIPTPDKEDDDRVYPNSTCKPRIIAPSRGSPLPVLSWANREEVWKIMLNKEKTYLRDQHFLEQHPLLQPKMRAILLDWLMEVCEVYKLHRETFYLAQDFFDRYMATQENVVKTLLQLIGISSLFIAAKLEEIYPPKLHQFAYVTDGACSGDEILTMELMIMKALKWRLSPLTIVSWLNVYMQVAYLNDLHEVLLPQYPQQIFIQIAELLDLCVLDVDCLEFPYGILAASALYHFSSSELMQKVSGYQWCDIENCVKWMVPFAMVIRETGSSKLKHFRGVADEDAHNIQTHRDSLDLLDKARAKKAMLSEQNRASPLPSGLLTPPQSGKKQSSGPEMA T10052 DRUGINFO D0Z0KD PD-0183812 Terminated T10052 DRUGINFO D01PSU (2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime Investigative T10052 DRUGINFO D03KLM (2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime Investigative T10052 DRUGINFO D04AGE (2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime Investigative T10052 DRUGINFO D06GLV (2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime Investigative T10052 DRUGINFO D06XIW (2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime Investigative T10052 DRUGINFO D0B1LM (2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime Investigative T10052 DRUGINFO D0F3OM 2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol Investigative T10052 DRUGINFO D0GP3R 5-nitroindirubin-3'-oxime Investigative T10052 DRUGINFO D0H0EN (2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime Investigative T10052 DRUGINFO D0I6AE (2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime Investigative T10052 DRUGINFO D0J3RS (2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime Investigative T10052 DRUGINFO D0JR0G (2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime Investigative T10052 DRUGINFO D0L5PI (2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime Investigative T10052 DRUGINFO D0M4XD (2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime Investigative T10052 DRUGINFO D0W2FM (2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime Investigative T10052 DRUGINFO D0YZ9Y (2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime Investigative T10052 DRUGINFO D0W0BL 3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol Investigative T10052 DRUGINFO D02XHC aloisine A Investigative T10052 DRUGINFO D06AOY 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T10052 DRUGINFO D0M4SY BMS-536924 Investigative T10052 DRUGINFO D00NYT 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative T10052 DRUGINFO D0C3WY 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative T10052 DRUGINFO D0EK0G 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative T10052 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T35265 TARGETID T35265 T35265 FORMERID TTDI02166 T35265 UNIPROID S10A4_HUMAN T35265 TARGNAME S100 calcium-binding protein A4 (S100A4) T35265 GENENAME S100A4 T35265 TARGTYPE Literature-reported T35265 SYNONYMS Protein S100-A4; Protein Mts1; Placental calcium-binding protein; Metastasin; MTS1; Calvasculin; CAPL T35265 FUNCTION collagen-containing extracellular matrix, extracellular exosome, extracellular region, extracellular space, nucleus, perinuclear region of cytoplasm, calcium ion binding, identical protein binding, RAGE receptor binding, RNA binding T35265 PDBSTRUC 5LPU; 4HSZ; 4ETO; 4CFR; 4CFQ T35265 BIOCLASS S100 calcium-binding protein T35265 SEQUENCE MACPLEKALDVMVSTFHKYSGKEGDKFKLNKSELKELLTRELPSFLGKRTDEAAFQKLMSNLDSNRDNEVDFQEYCVFLSCIAMMCNEFFEGFPDKQPRKK T35265 DRUGINFO D0U7ZY SP-MET-1 Preclinical T34562 TARGETID T34562 T34562 FORMERID TTDR00684 T34562 UNIPROID PON1_HUMAN T34562 TARGNAME Serum paraoxonase/arylesterase 1 (PON1) T34562 GENENAME PON1 T34562 TARGTYPE Literature-reported T34562 SYNONYMS Serum paraoxonase; Serum aryldialkylphosphatase 1; Serum aryldiakylphosphatase 1; PON 1; PON; K-45; Aromatic esterase 1; A-esterase 1 T34562 FUNCTION Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation. Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. T34562 PDBSTRUC 1XHR; 1V04 T34562 BIOCLASS Carboxylic ester hydrolase T34562 ECNUMBER EC 3.1.1.2 T34562 SEQUENCE MAKLIALTLLGMGLALFRNHQSSYQTRLNALREVQPVELPNCNLVKGIETGSEDLEILPNGLAFISSGLKYPGIKSFNPNSPGKILLMDLNEEDPTVLELGITGSKFDVSSFNPHGISTFTDEDNAMYLLVVNHPDAKSTVELFKFQEEEKSLLHLKTIRHKLLPNLNDIVAVGPEHFYGTNDHYFLDPYLQSWEMYLGLAWSYVVYYSPSEVRVVAEGFDFANGINISPDGKYVYIAELLAHKIHVYEKHANWTLTPLKSLDFNTLVDNISVDPETGDLWVGCHPNGMKIFFYDSENPPASEVLRIQNILTEEPKVTQVYAENGTVLQGSTVASVYKGKLLIGTVFHKALYCEL T24548 TARGETID T24548 T24548 FORMERID TTDR00171 T24548 UNIPROID PYR1_HUMAN T24548 TARGNAME Aspartate carbamoyltransferase (CAD) T24548 GENENAME CAD T24548 TARGTYPE Literature-reported T24548 SYNONYMS CAD T24548 FUNCTION This protein is a "fusion" protein encoding four enzymatic activities of the pyrimidine pathway (GATase, CPSase, ATCase and DHOase). T24548 PDBSTRUC 6HG1; 6HFU; 6HFS; 6HFR; 6HFQ T24548 BIOCLASS Carbon-nitrogen ligase T24548 SEQUENCE MAALVLEDGSVLRGQPFGAAVSTAGEVVFQTGMVGYPEALTDPSYKAQILVLTYPLIGNYGIPPDEMDEFGLCKWFESSGIHVAALVVGECCPTPSHWSATRTLHEWLQQHGIPGLQGVDTRELTKKLREQGSLLGKLVQNGTEPSSLPFLDPNARPLVPEVSIKTPRVFNTGGAPRILALDCGLKYNQIRCLCQRGAEVTVVPWDHALDSQEYEGLFLSNGPGDPASYPSVVSTLSRVLSEPNPRPVFGICLGHQLLALAIGAKTYKMRYGNRGHNQPCLLVGSGRCFLTSQNHGFAVETDSLPADWAPLFTNANDGSNEGIVHNSLPFFSVQFHPEHQAGPSDMELLFDIFLETVKEATAGNPGGQTVRERLTERLCPPGIPTPGSGLPPPRKVLILGSGGLSIGQAGEFDYSGSQAIKALKEENIQTLLINPNIATVQTSQGLADKVYFLPITPHYVTQVIRNERPDGVLLTFGGQTALNCGVELTKAGVLARYGVRVLGTPVETIELTEDRRAFAARMAEIGEHVAPSEAANSLEQAQAAAERLGYPVLVRAAFALGGLGSGFASNREELSALVAPAFAHTSQVLVDKSLKGWKEIEYEVVRDAYGNCVTVCNMENLDPLGIHTGESIVVAPSQTLNDREYQLLRQTAIKVTQHLGIVGECNVQYALNPESEQYYIIEVNARLSRSSALASKATGYPLAYVAAKLALGIPLPELRNSVTGGTAAFEPSVDYCVVKIPRWDLSKFLRVSTKIGSCMKSVGEVMGIGRSFEEAFQKALRMVDENCVGFDHTVKPVSDMELETPTDKRIFVVAAALWAGYSVDRLYELTRIDRWFLHRMKRIIAHAQLLEQHRGQPLPPDLLQQAKCLGFSDKQIALAVLSTELAVRKLRQELGICPAVKQIDTVAAEWPAQTNYLYLTYWGTTHDLTFRTPHVLVLGSGVYRIGSSVEFDWCAVGCIQQLRKMGYKTIMVNYNPETVSTDYDMCDRLYFDEISFEVVMDIYELENPEGVILSMGGQLPNNMAMALHRQQCRVLGTSPEAIDSAENRFKFSRLLDTIGISQPQWRELSDLESARQFCQTVGYPCVVRPSYVLSGAAMNVAYTDGDLERFLSSAAAVSKEHPVVISKFIQEAKEIDVDAVASDGVVAAIAISEHVENAGVHSGDATLVTPPQDITAKTLERIKAIVHAVGQELQVTGPFNLQLIAKDDQLKVIECNVRVSRSFPFVSKTLGVDLVALATRVIMGEEVEPVGLMTGSGVVGVKVPQFSFSRLAGADVVLGVEMTSTGEVAGFGESRCEAYLKAMLSTGFKIPKKNILLTIGSYKNKSELLPTVRLLESLGYSLYASLGTADFYTEHGVKVTAVDWHFEEAVDGECPPQRSILEQLAEKNFELVINLSMRGAGGRRLSSFVTKGYRTRRLAADFSVPLIIDIKCTKLFVEALGQIGPAPPLKVHVDCMTSQKLVRLPGLIDVHVHLREPGGTHKEDFASGTAAALAGGITMVCAMPNTRPPIIDAPALALAQKLAEAGARCDFALFLGASSENAGTLGTVAGSAAGLKLYLNETFSELRLDSVVQWMEHFETWPSHLPIVAHAEQQTVAAVLMVAQLTQRSVHICHVARKEEILLIKAAKARGLPVTCEVAPHHLFLSHDDLERLGPGKGEVRPELGSRQDVEALWENMAVIDCFASDHAPHTLEEKCGSRPPPGFPGLETMLPLLLTAVSEGRLSLDDLLQRLHHNPRRIFHLPPQEDTYVEVDLEHEWTIPSHMPFSKAHWTPFEGQKVKGTVRRVVLRGEVAYIDGQVLVPPGYGQDVRKWPQGAVPQLPPSAPATSEMTTTPERPRRGIPGLPDGRFHLPPRIHRASDPGLPAEEPKEKSSRKVAEPELMGTPDGTCYPPPPVPRQASPQNLGTPGLLHPQTSPLLHSLVGQHILSVQQFTKDQMSHLFNVAHTLRMMVQKERSLDILKGKVMASMFYEVSTRTSSSFAAAMARLGGAVLSFSEATSSVQKGESLADSVQTMSCYADVVVLRHPQPGAVELAAKHCRRPVINAGDGVGEHPTQALLDIFTIREELGTVNGMTITMVGDLKHGRTVHSLACLLTQYRVSLRYVAPPSLRMPPTVRAFVASRGTKQEEFESIEEALPDTDVLYMTRIQKERFGSTQEYEACFGQFILTPHIMTRAKKKMVVMHPMPRVNEISVEVDSDPRAAYFRQAENGMYIRMALLATVLGRF T24548 DRUGINFO D0L6CN N-(phosphonacetyl)-L-aspartate Investigative T48543 TARGETID T48543 T48543 FORMERID TTDR00223 T48543 UNIPROID OAPT_PSEPU T48543 TARGNAME Pseudomonas Omega-amino acid:pyruvate aminotransferase (Pseudo Omega-APT) T48543 GENENAME Pseudo Omega-APT T48543 TARGTYPE Literature-reported T48543 SYNONYMS Omega-APT; Beta-alanine--pyruvate aminotransferase T48543 FUNCTION Catalyzes transamination between a variety of omega- amino acids, mono and diamines, and pyruvate. Plays a pivotal role in the metabolism of the omega amino acids. T48543 PDBSTRUC 3A8U T48543 BIOCLASS Transaminase T48543 ECNUMBER EC 2.6.1.18 T48543 SEQUENCE NMPEHAGASLASQLKLDAHWMPYTANRNFLRDPRLIVAAEGSWLVDDKGRKVYDSLSGLWTCGAGHTRKEIQEAVAKQLSTLDYSPGFQYGHPLSFQLAEKITDLTPGNLNHVFFTDSGSECALTAVKMVRAYWRLKGQATKTKMIGRARGYHGVNIAGTSLGGVNGNRKLFGQPMQDVDHLPHTLLASNAYSRGMPKEGGIALADELLKLIELHDASNIAAVFVEPLAGSAGVLVPPEGYLKRNREICNQHNILLVFDEVITGFGRTGSMFGADSFGVTPDLMCIAKQVTNGAIPMGAVIASTEIYQTFMNQPTPEYAVEFPHGYTYSAHPVACAAGLAALCLLQKENLVQSVAEVAPHFEKALHGIKGAKNVIDIRNFGLAGAIQIAPRDGDAIVRPFEAGMALWKAGFYVRFGGDTLQFGPTFNSKPQDLDRLFDAVGEVLNKLLD T58266 TARGETID T58266 T58266 FORMERID TTDI03179 T58266 UNIPROID EPHA8_HUMAN T58266 TARGNAME Ephrin type-A receptor 8 (EPHA8) T58266 GENENAME EPHA8 T58266 TARGTYPE Literature-reported T58266 SYNONYMS hEK3; Tyrosine-protein kinase receptor EEK; KIAA1459; EPH-like kinase 3; EPH- and ELK-related kinase; EK3; EEK T58266 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. The GPI-anchored ephrin-A EFNA2, EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation. With EFNA5 may regulate integrin-mediated cell adhesion and migration on fibronectin substrate but also neurite outgrowth. During development of the nervous system plays also a role in axon guidance. Downstream effectors of the EPHA8 signaling pathway include FYN which promotes cell adhesion upon activation by EPHA8 and the MAP kinases in the stimulation of neurite outgrowth. Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T58266 PDBSTRUC 3KUL; 1X5L; 1UCV T58266 BIOCLASS Kinase T58266 ECNUMBER EC 2.7.10.1 T58266 SEQUENCE MAPARGRLPPALWVVTAAAAAATCVSAARGEVNLLDTSTIHGDWGWLTYPAHGWDSINEVDESFQPIHTYQVCNVMSPNQNNWLRTSWVPRDGARRVYAEIKFTLRDCNSMPGVLGTCKETFNLYYLESDRDLGASTQESQFLKIDTIAADESFTGADLGVRRLKLNTEVRSVGPLSKRGFYLAFQDIGACLAILSLRIYYKKCPAMVRNLAAFSEAVTGADSSSLVEVRGQCVRHSEERDTPKMYCSAEGEWLVPIGKCVCSAGYEERRDACVACELGFYKSAPGDQLCARCPPHSHSAAPAAQACHCDLSYYRAALDPPSSACTRPPSAPVNLISSVNGTSVTLEWAPPLDPGGRSDITYNAVCRRCPWALSRCEACGSGTRFVPQQTSLVQASLLVANLLAHMNYSFWIEAVNGVSDLSPEPRRAAVVNITTNQAAPSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEKDKEMQSYSTLKAVTTRATVSGLKPGTRYVFQVRARTSAGCGRFSQAMEVETGKPRPRYDTRTIVWICLTLITGLVVLLLLLICKKRHCGYSKAFQDSDEEKMHYQNGQAPPPVFLPLHHPPGKLPEPQFYAEPHTYEEPGRAGRSFTREIEASRIHIEKIIGSGDSGEVCYGRLRVPGQRDVPVAIKALKAGYTERQRRDFLSEASIMGQFDHPNIIRLEGVVTRGRLAMIVTEYMENGSLDTFLRTHDGQFTIMQLVGMLRGVGAGMRYLSDLGYVHRDLAARNVLVDSNLVCKVSDFGLSRVLEDDPDAAYTTTGGKIPIRWTAPEAIAFRTFSSASDVWSFGVVMWEVLAYGERPYWNMTNRDVISSVEEGYRLPAPMGCPHALHQLMLDCWHKDRAQRPRFSQIVSVLDALIRSPESLRATATVSRCPPPAFVRSCFDLRGGSGGGGGLTVGDWLDSIRMGRYRDHFAAGGYSSLGMVLRMNAQDVRALGITLMGHQKKILGSIQTMRAQLTSTQGPRRHL T58266 DRUGINFO D05FXD PMID19788238C66 Investigative T58266 DRUGINFO D0X8BU PMID23489211C20 Investigative T62746 TARGETID T62746 T62746 FORMERID TTDI02437 T62746 UNIPROID PPIF_HUMAN T62746 TARGNAME Rotamase F (PPIF) T62746 GENENAME PPIF T62746 TARGTYPE Literature-reported T62746 SYNONYMS Peptidylprolyl cistrans isomerase F, mitochondrial; Peptidyl-prolyl cis-trans isomerase F, mitochondrial; PPIase F; Mitochondrial cyclophilin; Cyclophilin F; CyPM; CyP-M; CyP-D; CYP3 T62746 FUNCTION Involved in regulation of the mitochondrial permeability transition pore (mPTP). It is proposed that its association with the mPTP is masking a binding site for inhibiting inorganic phosphate (Pi) and promotes the open probability of the mPTP leading to apoptosis or necrosis; the requirement of the PPIase activity for this function is debated. In cooperation with mitochondrial TP53 is involved in activating oxidative stress-induced necrosis. Involved in modulation of mitochondrial membrane F(1)F(0) ATP synthase activity and regulation of mitochondrial matrix adenine nucleotide levels. Has anti-apoptotic activity independently of mPTP and in cooperation with BCL2 inhibits cytochrome c-dependent apoptosis. PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. T62746 PDBSTRUC 5NWO; 5CCS; 5CCR; 5CCQ; 5CCN T62746 BIOCLASS Cis-trans-isomerase T62746 ECNUMBER EC 5.2.1.8 T62746 SEQUENCE MLALRCGSRWLGLLSVPRSVPLRLPAARACSKGSGDPSSSSSSGNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVKEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS T86808 TARGETID T86808 T86808 FORMERID TTDI01793 T86808 UNIPROID HMOX2_HUMAN T86808 TARGNAME Heme oxygenase 2 (HMOX2) T86808 GENENAME HMOX2 T86808 TARGTYPE Literature-reported T86808 SYNONYMS HO2; HO-2 T86808 FUNCTION Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Heme oxygenase 2 could be implicated in the production of carbon monoxide in brain where it could act as a neurotransmitter. Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. T86808 PDBSTRUC 5UCA; 5UC9; 5UC8; 4WMH; 2RGZ T86808 BIOCLASS Paired donor oxygen oxidoreductase T86808 ECNUMBER EC 1.14.14.18 T86808 SEQUENCE MSAEVETSEGVDESEKKNSGALEKENQMRMADLSELLKEGTKEAHDRAENTQFVKDFLKGNIKKELFKLATTALYFTYSALEEEMERNKDHPAFAPLYFPMELHRKEALTKDMEYFFGENWEEQVQCPKAAQKYVERIHYIGQNEPELLVAHAYTRYMGDLSGGQVLKKVAQRALKLPSTGEGTQFYLFENVDNAQQFKQLYRARMNALDLNMKTKERIVEEANKAFEYNMQIFNELDQAGSTLARETLEDGFPVHDGKGDMRKCPFYAAEQDKGALEGSSCPFRTAMAVLRKPSLQFILAAGVALAAGLLAWYYM T74952 TARGETID T74952 T74952 FORMERID TTDR00978 T74952 UNIPROID KAP3_HUMAN T74952 TARGNAME cAMP protein kinase type II-beta (PRKAR2B) T74952 GENENAME PRKAR2B T74952 TARGTYPE Literature-reported T74952 SYNONYMS cAMP-dependent protein kinase type II-beta regulatory subunit; Type RIIbeta regulatory subunit of protein kinase A; RIIbeta subunit of cAMP-dependent protein kinase; PKA RIIbeta-subunit T74952 FUNCTION Type II regulatory chains mediate membrane association by binding to anchoring proteins, including the MAP2 kinase. Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. T74952 BIOCLASS Kinase T74952 SEQUENCE MSIEIPAGLTELLQGFTVEVLRHQPADLLEFALQHFTRLQQENERKGTARFGHEGRTWGDLGAAAGGGTPSKGVNFAEEPMQSDSEDGEEEEAAPADAGAFNAPVINRFTRRASVCAEAYNPDEEEDDAESRIIHPKTDDQRNRLQEACKDILLFKNLDPEQMSQVLDAMFEKLVKDGEHVIDQGDDGDNFYVIDRGTFDIYVKCDGVGRCVGNYDNRGSFGELALMYNTPRAATITATSPGALWGLDRVTFRRIIVKNNAKKRKMYESFIESLPFLKSLEFSERLKVVDVIGTKVYNDGEQIIAQGDSADSFFIVESGEVKITMKRKGKSEVEENGAVEIARCSRGQYFGELALVTNKPRAASAHAIGTVKCLAMDVQAFERLLGPCMEIMKRNIATYEEQLVALFGTNMDIVEPTA T74952 DRUGINFO D0R2TM BALANOL Terminated T74952 DRUGINFO D00OCS AdcAhxArg4NH(CH2)6NH2 Investigative T74952 DRUGINFO D02GEW AdcAhxArg4Lys-PEGOMe Investigative T74952 DRUGINFO D02ZWX AdoC(GABA)Arg6 Investigative T74952 DRUGINFO D03GNM AdcAhxArg4Lys(biotin)-PEG-OMe Investigative T74952 DRUGINFO D08GIG AdoC(Aun)Arg6 Investigative T74952 DRUGINFO D0A5YR AdoCGlyArg6 Investigative T74952 DRUGINFO D0F3XS AdoC(Aoc)Arg6 Investigative T74952 DRUGINFO D0I4MQ AdcAhxArg6 Investigative T74952 DRUGINFO D0KZ2I AdoC(betaAsp)2AlaArg6 Investigative T74952 DRUGINFO D0QS6O AdoC(Ahx)Arg6 Investigative T74952 DRUGINFO D0RC8H AdoC(beta-Ala)2AlaArg6 Investigative T74952 DRUGINFO D0V3TE AdoC(beta-Ala)Arg6 Investigative T74952 DRUGINFO D07MMG AdoC(Dpr)2AlaArg6 Investigative T74952 DRUGINFO D0UB2J [3H]cAMP Investigative T74952 DRUGINFO D09XIL Ro-4396686 Investigative T74952 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T04741 TARGETID T04741 T04741 FORMERID TTDR00945 T04741 UNIPROID PUR9_HUMAN T04741 TARGNAME Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) T04741 GENENAME ATIC T04741 TARGTYPE Literature-reported T04741 SYNONYMS PURH; OK/SW-cl.86; Bifunctional purine biosynthesis protein PURH T04741 FUNCTION Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis. T04741 PDBSTRUC 5UZ0; 5UY8; 1PL0; 1PKX; 1P4R T04741 BIOCLASS Methyltransferase T04741 SEQUENCE MAPGQLALFSVSDKTGLVEFARNLTALGLNLVASGGTAKALRDAGLAVRDVSELTGFPEMLGGRVKTLHPAVHAGILARNIPEDNADMARLDFNLIRVVACNLYPFVKTVASPGVTVEEAVEQIDIGGVTLLRAAAKNHARVTVVCEPEDYVVVSTEMQSSESKDTSLETRRQLALKAFTHTAQYDEAISDYFRKQYSKGVSQMPLRYGMNPHQTPAQLYTLQPKLPITVLNGAPGFINLCDALNAWQLVKELKEALGIPAAASFKHVSPAGAAVGIPLSEDEAKVCMVYDLYKTLTPISAAYARARGADRMSSFGDFVALSDVCDVPTAKIISREVSDGIIAPGYEEEALTILSKKKNGNYCVLQMDQSYKPDENEVRTLFGLHLSQKRNNGVVDKSLFSNVVTKNKDLPESALRDLIVATIAVKYTQSNSVCYAKNGQVIGIGAGQQSRIHCTRLAGDKANYWWLRHHPQVLSMKFKTGVKRAEISNAIDQYVTGTIGEDEDLIKWKALFEEVPELLTEAEKKEWVEKLTEVSISSDAFFPFRDNVDRAKRSGVAYIAAPSGSAADKVVIEACDELGIILAHTNLRLFHH T04741 DRUGINFO D02HXC NSC-30171 Investigative T04741 DRUGINFO D03NSJ NSC-45592 Investigative T04741 DRUGINFO D05YCQ NSC-47729 Investigative T04741 DRUGINFO D0A2JV NSC-26699 Investigative T04741 DRUGINFO D0B3XP NSC-37173 Investigative T04741 DRUGINFO D0D9NQ NSC-58046 Investigative T04741 DRUGINFO D0I2DB NSC-37031 Investigative T04741 DRUGINFO D0T4JD NSC-324572 Investigative T04741 DRUGINFO D0X2NH NSC-126445 Investigative T04741 DRUGINFO D0Z5WG FAICAR Investigative T04741 DRUGINFO D04JWS NSC-292213 Investigative T04741 DRUGINFO D09KUE NSC-88915 Investigative T00902 TARGETID T00902 T00902 FORMERID TTDI02363 T00902 UNIPROID NTF4_HUMAN T00902 TARGNAME Neurotrophin-4 (NTF4) T00902 GENENAME NTF4 T00902 TARGTYPE Literature-reported T00902 SYNONYMS Neutrophic factor 4; Neurotrophin5; Neurotrophin4; Neurotrophin-5; NTF5; NT4; NT-5; NT-4 T00902 FUNCTION Target-derived survival factor for peripheral sensory sympathetic neurons. T00902 PDBSTRUC 1HCF; 1B98; 1B8M T00902 BIOCLASS Growth factor T00902 SEQUENCE MLPLPSCSLPILLLFLLPSVPIESQPPPSTLPPFLAPEWDLLSPRVVLSRGAPAGPPLLFLLEAGAFRESAGAPANRSRRGVSETAPASRRGELAVCDAVSGWVTDRRTAVDLRGREVEVLGEVPAAGGSPLRQYFFETRCKADNAEEGGPGAGGGGCRGVDRRHWVSECKAKQSYVRALTADAQGRVGWRWIRIDTACVCTLLSRTGRA T00902 DRUGINFO D0P3SH ReN-1826 Terminated T76894 TARGETID T76894 T76894 FORMERID TTDR01138 T76894 UNIPROID RECO_HUMAN T76894 TARGNAME Recoverin (RCVRN) T76894 GENENAME RCVRN T76894 TARGTYPE Literature-reported T76894 SYNONYMS RCVRN; Cancer associated retinopathy protein; CAR protein T76894 FUNCTION Seems to be implicated in the pathway from retinal rod guanylatecyclase to rhodopsin. May be involved in the inhibition of the phosphorylation of rhodopsin in a calcium-dependent manner. The calcium-bound recoverin prolongs the photoresponse. T76894 PDBSTRUC 2D8N T76894 BIOCLASS Recoverin family T76894 SEQUENCE MGNSKSGALSKEILEELQLNTKFSEEELCSWYQSFLKDCPTGRITQQQFQSIYAKFFPDTDPKAYAQHVFRSFDSNLDGTLDFKEYVIALHMTTAGKTNQKLEWAFSLYDVDGNGTISKNEVLEIVMAIFKMITPEDVKLLPDDENTPEKRAEKIWKYFGKNDDDKLTEKEFIEGTLANKEILRLIQFEPQKVKEKMKNA T76894 DRUGINFO D08OBF MYRISTIC ACID Investigative T98539 TARGETID T98539 T98539 FORMERID TTDI02502 T98539 UNIPROID TIE1_HUMAN T98539 TARGNAME Tie-1 tyrosine kinase receptor (TIE1) T98539 GENENAME TIE1 T98539 TARGTYPE Literature-reported T98539 SYNONYMS Tyrosine-protein kinase receptor Tie-1; TIE1 T98539 FUNCTION Transmembrane tyrosine-protein kinase that may modulate TEK/TIE2 activity and contribute to the regulation of angiogenesis. T98539 PDBSTRUC 5N06 T98539 BIOCLASS Kinase T98539 ECNUMBER EC 2.7.10.1 T98539 SEQUENCE MVWRVPPFLLPILFLASHVGAAVDLTLLANLRLTDPQRFFLTCVSGEAGAGRGSDAWGPPLLLEKDDRIVRTPPGPPLRLARNGSHQVTLRGFSKPSDLVGVFSCVGGAGARRTRVIYVHNSPGAHLLPDKVTHTVNKGDTAVLSARVHKEKQTDVIWKSNGSYFYTLDWHEAQDGRFLLQLPNVQPPSSGIYSATYLEASPLGSAFFRLIVRGCGAGRWGPGCTKECPGCLHGGVCHDHDGECVCPPGFTGTRCEQACREGRFGQSCQEQCPGISGCRGLTFCLPDPYGCSCGSGWRGSQCQEACAPGHFGADCRLQCQCQNGGTCDRFSGCVCPSGWHGVHCEKSDRIPQILNMASELEFNLETMPRINCAAAGNPFPVRGSIELRKPDGTVLLSTKAIVEPEKTTAEFEVPRLVLADSGFWECRVSTSGGQDSRRFKVNVKVPPVPLAAPRLLTKQSRQLVVSPLVSFSGDGPISTVRLHYRPQDSTMDWSTIVVDPSENVTLMNLRPKTGYSVRVQLSRPGEGGEGAWGPPTLMTTDCPEPLLQPWLEGWHVEGTDRLRVSWSLPLVPGPLVGDGFLLRLWDGTRGQERRENVSSPQARTALLTGLTPGTHYQLDVQLYHCTLLGPASPPAHVLLPPSGPPAPRHLHAQALSDSEIQLTWKHPEALPGPISKYVVEVQVAGGAGDPLWIDVDRPEETSTIIRGLNASTRYLFRMRASIQGLGDWSNTVEESTLGNGLQAEGPVQESRAAEEGLDQQLILAVVGSVSATCLTILAALLTLVCIRRSCLHRRRTFTYQSGSGEETILQFSSGTLTLTRRPKLQPEPLSYPVLEWEDITFEDLIGEGNFGQVIRAMIKKDGLKMNAAIKMLKEYASENDHRDFAGELEVLCKLGHHPNIINLLGACKNRGYLYIAIEYAPYGNLLDFLRKSRVLETDPAFAREHGTASTLSSRQLLRFASDAANGMQYLSEKQFIHRDLAARNVLVGENLASKIADFGLSRGEEVYVKKTMGRLPVRWMAIESLNYSVYTTKSDVWSFGVLLWEIVSLGGTPYCGMTCAELYEKLPQGYRMEQPRNCDDEVYELMRQCWRDRPYERPPFAQIALQLGRMLEARKAYVNMSLFENFTYAGIDATAEEA T98539 DRUGINFO D00EMH PMID21967808CR-16 Investigative T86773 TARGETID T86773 T86773 FORMERID TTDNR00701 T86773 UNIPROID LONM_HUMAN T86773 TARGNAME ATP-dependent protease Lon (LONP1) T86773 GENENAME LONP1 T86773 TARGTYPE Literature-reported T86773 SYNONYMS Serine protease 15; Mitochondrial ATP-dependent protease Lon; Lon protease-like protein; LONP1; LONP; LONHs T86773 FUNCTION ATP-dependent serine protease that mediates the selective degradation of misfolded, unassembled or oxidatively damaged polypeptides as well as certain short-lived regulatory proteins in the mitochondrial matrix. May also have a chaperone function in the assembly of inner membrane protein complexes. Participates in the regulation of mitochondrial gene expression and in the maintenance of the integrity of the mitochondrial genome. Binds to mitochondrial promoters and RNA in a single- stranded, site-specific, and strand-specific manner. May regulate mitochondrial DNA replication and/or gene expression using site- specific, single-stranded DNA binding to target the degradation of regulatory proteins binding to adjacent sites in mitochondrial promoters. Endogenous substrates include mitochondrial steroidogenic acute regulatory (StAR) protein. T86773 PDBSTRUC 2X36 T86773 BIOCLASS Peptidase T86773 ECNUMBER EC 3.4.21.53 T86773 SEQUENCE MAASTGYVRLWGAARCWVLRRPMLAAAGGRVPTAAGAWLLRGQRTCDASPPWALWGRGPAIGGQWRGFWEASSRGGGAFSGGEDASEGGAEEGAGGAGGSAGAGEGPVITALTPMTIPDVFPHLPLIAITRNPVFPRFIKIIEVKNKKLVELLRRKVRLAQPYVGVFLKRDDSNESDVVESLDEIYHTGTFAQIHEMQDLGDKLRMIVMGHRRVHISRQLEVEPEEPEAENKHKPRRKSKRGKKEAEDELSARHPAELAMEPTPELPAEVLMVEVENVVHEDFQVTEEVKALTAEIVKTIRDIIALNPLYRESVLQMMQAGQRVVDNPIYLSDMGAALTGAESHELQDVLEETNIPKRLYKALSLLKKEFELSKLQQRLGREVEEKIKQTHRKYLLQEQLKIIKKELGLEKDDKDAIEEKFRERLKELVVPKHVMDVVDEELSKLGLLDNHSSEFNVTRNYLDWLTSIPWGKYSNENLDLARAQAVLEEDHYGMEDVKKRILEFIAVSQLRGSTQGKILCFYGPPGVGKTSIARSIARALNREYFRFSVGGMTDVAEIKGHRRTYVGAMPGKIIQCLKKTKTENPLILIDEVDKIGRGYQGDPSSALLELLDPEQNANFLDHYLDVPVDLSKVLFICTANVTDTIPEPLRDRMEMINVSGYVAQEKLAIAERYLVPQARALCGLDESKAKLSSDVLTLLIKQYCRESGVRNLQKQVEKVLRKSAYKIVSGEAESVEVTPENLQDFVGKPVFTVERMYDVTPPGVVMGLAWTAMGGSTLFVETSLRRPQDKDAKGDKDGSLEVTGQLGEVMKESARIAYTFARAFLMQHAPANDYLVTSHIHLHVPEGATPKDGPSAGCTIVTALLSLAMGRPVRQNLAMTGEVSLTGKILPVGGIKEKTIAAKRAGVTCIVLPAENKKDFYDLAAFITEGLEVHFVEHYREIFDIAFPDEQAEALAVER T72779 TARGETID T72779 T72779 FORMERID TTDR00983 T72779 UNIPROID SPB5_HUMAN T72779 TARGNAME Maspin (SERPINB5) T72779 GENENAME SERPINB5 T72779 TARGTYPE Literature-reported T72779 SYNONYMS Serpin B5; Protease inhibitor 5; Peptidase inhibitor 5; PI5; PI-5 T72779 FUNCTION It blocks the growth, invasion, and metastatic properties of mammary tumors. As it does not undergo the S (stressed) to R (relaxed) conformational transition characteristic of active serpins, it exhibits no serine protease inhibitory activity. Tumor suppressor. T72779 PDBSTRUC 1XU8; 1XQJ; 1XQG; 1WZ9 T72779 BIOCLASS Serpin protein T72779 SEQUENCE MDALQLANSAFAVDLFKQLCEKEPLGNVLFSPICLSTSLSLAQVGAKGDTANEIGQVLHFENVKDVPFGFQTVTSDVNKLSSFYSLKLIKRLYVDKSLNLSTEFISSTKRPYAKELETVDFKDKLEETKGQINNSIKDLTDGHFENILADNSVNDQTKILVVNAAYFVGKWMKKFSESETKECPFRVNKTDTKPVQMMNMEATFCMGNIDSINCKIIELPFQNKHLSMFILLPKDVEDESTGLEKIEKQLNSESLSQWTNPSTMANAKVKLSIPKFKVEKMIDPKACLENLGLKHIFSEDTSDFSGMSETKGVALSNVIHKVCLEITEDGGDSIEVPGARILQHKDELNADHPFIYIIRHNKTRNIIFFGKFCSP T72779 DRUGINFO D0P7JE S,S-(2-Hydroxyethyl)Thiocysteine Investigative T16731 TARGETID T16731 T16731 FORMERID TTDS00427 T16731 UNIPROID VATA_HUMAN T16731 TARGNAME Vacuolar-type proton ATPase catalytic A (v-ATPase-A) T16731 GENENAME ATP6V1A T16731 TARGTYPE Literature-reported T16731 SYNONYMS Vacuolar proton pump subunit alpha; Vacuolar ATPase isoform VA68; VPP2; V-ATPase subunit A; V-ATPase 69 kDa subunit; ATP6V1A1; ATP6V1A; ATP6A1 T16731 FUNCTION Catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase vacuolar ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells. T16731 BIOCLASS Acid anhydrides hydrolase T16731 ECNUMBER EC 7.1.2.2 T16731 SEQUENCE MDFSKLPKILDEDKESTFGYVHGVSGPVVTACDMAGAAMYELVRVGHSELVGEIIRLEGDMATIQVYEETSGVSVGDPVLRTGKPLSVELGPGIMGAIFDGIQRPLSDISSQTQSIYIPRGVNVSALSRDIKWDFTPCKNLRVGSHITGGDIYGIVSENSLIKHKIMLPPRNRGTVTYIAPPGNYDTSDVVLELEFEGVKEKFTMVQVWPVRQVRPVTEKLPANHPLLTGQRVLDALFPCVQGGTTAIPGAFGCGKTVISQSLSKYSNSDVIIYVGCGERGNEMSEVLRDFPELTMEVDGKVESIMKRTALVANTSNMPVAAREASIYTGITLSEYFRDMGYHVSMMADSTSRWAEALREISGRLAEMPADSGYPAYLGARLASFYERAGRVKCLGNPEREGSVSIVGAVSPPGGDFSDPVTSATLGIVQVFWGLDKKLAQRKHFPSVNWLISYSKYMRALDEYYDKHFTEFVPLRTKAKEILQEEEDLAEIVQLVGKASLAETDKITLEVAKLIKDDFLQQNGYTPYDRFCPFYKTVGMLSNMIAFYDMARRAVETTAQSDNKITWSIIREHMGDILYKLSSMKFKDPLKDGEAKIKSDYAQLLEDMQNAFRSLED T16731 DRUGINFO D09IFW Cruentaren Preclinical T50547 TARGETID T50547 T50547 FORMERID TTDR00107 T50547 UNIPROID PLM1_PLAFA T50547 TARGNAME Plasmodium Plasmepsin 1 (Malaria PLA1) T50547 GENENAME Malaria PLA1 T50547 TARGTYPE Literature-reported T50547 SYNONYMS Plasmepsin I; PFAPG; Aspartic hemoglobinase I T50547 FUNCTION Participates in the digestion of the host hemoglobin. Initial cleavage at the hinge region of hemoglobin, than cleaves at other sites, leading to denaturation of the molecule and to further degradation. T50547 PDBSTRUC 3QS1; 3QRV; 1LDU; 1LCR T50547 BIOCLASS Peptidase T50547 SEQUENCE MALSIKEDFSSAFAKNESAVNSSTFNNNMKTWKIQKRFQILYVFFFLLITGALFYYLIDNVLFPKNKKINEIMNTSKHVIIGFSIENSHDRIMKTVKQHRLKNYIKESLKFFKTGLTQKPHLGNAGDSVTLNDVANVMYYGEAQIGDNKQKFAFIFDTGSANLWVPSAQCNTIGCKTKNLYDSNKSKTYEKDGTKVEMNYVSGTVSGFFSKDIVTIANLSFPYKFIEVTDTNGFEPAYTLGQFDGIVGLGWKDLSIGSVDPVVVELKNQNKIEQAVFTFYLPFDDKHKGYLTIGGIEDRFYEGQLTYEKLNHDLYWQVDLDLHFGNLTVEKATAIVDSGTSSITAPTEFLNKFFEGLDVVKIPFLPLYITTCNNPKLPTLEFRSATNVYTLEPEYYLQQIFDFGISLCMVSIIPVDLNKNTFILGDPFMRKYFTVFDYDNHTVGFALAKKKL T50547 DRUGINFO D04ZIJ Pepstatin Terminated T50547 DRUGINFO D06BKP SC-5003 Investigative T50547 DRUGINFO D08AES L-mannitol derivative Investigative T50547 DRUGINFO D0ZU3S PS-777621 Investigative T50547 DRUGINFO D0S3BO KNI-10006 Investigative T50547 DRUGINFO D08KCA Leupeptin Investigative T50547 DRUGINFO D09FGQ E-64 Investigative T09770 TARGETID T09770 T09770 FORMERID TTDI02473 T09770 UNIPROID ADH7_HUMAN T09770 TARGNAME Gastric alcohol dehydrogenase (ADH7) T09770 GENENAME ADH7 T09770 TARGTYPE Literature-reported T09770 SYNONYMS Alcohol dehydrogenase class IV mu/sigma chain; Alcohol dehydrogenase class 4 mu/sigma chain; ADH7 T09770 FUNCTION Could function in retinol oxidation for the synthesis of retinoic acid, a hormone important for cellular differentiation. Medium-chain (octanol) and aromatic (m-nitrobenzaldehyde) compounds are the best substrates. Ethanol is not a good substrate but at the high ethanol concentrations reached in the digestive tract, it plays a role in the ethanol oxidation and contributes to the first pass ethanol metabolism. T09770 PDBSTRUC 1D1T; 1D1S; 1AGN T09770 BIOCLASS Short-chain dehydrogenases reductase T09770 ECNUMBER EC 1.1.1.1 T09770 SEQUENCE MFAEIQIQDKDRMGTAGKVIKCKAAVLWEQKQPFSIEEIEVAPPKTKEVRIKILATGICRTDDHVIKGTMVSKFPVIVGHEATGIVESIGEGVTTVKPGDKVIPLFLPQCRECNACRNPDGNLCIRSDITGRGVLADGTTRFTCKGKPVHHFMNTSTFTEYTVVDESSVAKIDDAAPPEKVCLIGCGFSTGYGAAVKTGKVKPGSTCVVFGLGGVGLSVIMGCKSAGASRIIGIDLNKDKFEKAMAVGATECISPKDSTKPISEVLSEMTGNNVGYTFEVIGHLETMIDALASCHMNYGTSVVVGVPPSAKMLTYDPMLLFTGRTWKGCVFGGLKSRDDVPKLVTEFLAKKFDLDQLITHVLPFKKISEGFELLNSGQSIRTVLTF T85540 TARGETID T85540 T85540 FORMERID TTDI03363 T85540 UNIPROID KDM5C_HUMAN T85540 TARGNAME Lysine-specific demethylase 5C (KDM5C) T85540 GENENAME KDM5C T85540 TARGTYPE Literature-reported T85540 SYNONYMS XE169; SMCX; Protein Xe169; Protein SmcX; Jumonji/ARID domain-containing protein 1C; JARID1C; Histone demethylase JARID1C; DXS1272E T85540 FUNCTION Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Participates in transcriptional repression of neuronal genes by recruiting histone deacetylases and REST at neuron-restrictive silencer elements. Represses the CLOCK-ARNTL/BMAL1 heterodimer-mediated transcriptional activation of the core clock component PER2. Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. T85540 PDBSTRUC 5FWJ; 2JRZ T85540 BIOCLASS Paired donor oxygen oxidoreductase T85540 ECNUMBER EC 1.14.11.- T85540 SEQUENCE MEPGSDDFLPPPECPVFEPSWAEFRDPLGYIAKIRPIAEKSGICKIRPPADWQPPFAVEVDNFRFTPRIQRLNELEAQTRVKLNYLDQIAKFWEIQGSSLKIPNVERRILDLYSLSKIVVEEGGYEAICKDRRWARVAQRLNYPPGKNIGSLLRSHYERIVYPYEMYQSGANLVQCNTRPFDNEEKDKEYKPHSIPLRQSVQPSKFNSYGRRAKRLQPDPEPTEEDIEKNPELKKLQIYGAGPKMMGLGLMAKDKTLRKKDKEGPECPPTVVVKEELGGDVKVESTSPKTFLESKEELSHSPEPCTKMTMRLRRNHSNAQFIESYVCRMCSRGDEDDKLLLCDGCDDNYHIFCLLPPLPEIPKGVWRCPKCVMAECKRPPEAFGFEQATREYTLQSFGEMADSFKADYFNMPVHMVPTELVEKEFWRLVNSIEEDVTVEYGADIHSKEFGSGFPVSDSKRHLTPEEEEYATSGWNLNVMPVLEQSVLCHINADISGMKVPWLYVGMVFSAFCWHIEDHWSYSINYLHWGEPKTWYGVPSLAAEHLEEVMKKLTPELFDSQPDLLHQLVTLMNPNTLMSHGVPVVRTNQCAGEFVITFPRAYHSGFNQGYNFAEAVNFCTADWLPAGRQCIEHYRRLRRYCVFSHEELICKMAACPEKLDLNLAAAVHKEMFIMVQEERRLRKALLEKGITEAEREAFELLPDDERQCIKCKTTCFLSALACYDCPDGLVCLSHINDLCKCSSSRQYLRYRYTLDELPAMLHKLKVRAESFDTWANKVRVALEVEDGRKRSLEELRALESEARERRFPNSELLQQLKNCLSEAEACVSRALGLVSGQEAGPHRVAGLQMTLTELRAFLDQMNNLPCAMHQIGDVKGVLEQVEAYQAEAREALASLPSSPGLLQSLLERGRQLGVEVPEAQQLQRQVEQARWLDEVKRTLAPSARRGTLAVMRGLLVAGASVAPSPAVDKAQAELQELLTIAERWEEKAHLCLEARQKHPPATLEAIIREAENIPVHLPNIQALKEALAKARAWIADVDEIQNGDHYPCLDDLEGLVAVGRDLPVGLEELRQLELQVLTAHSWREKASKTFLKKNSCYTLLEVLCPCADAGSDSTKRSRWMEKELGLYKSDTELLGLSAQDLRDPGSVIVAFKEGEQKEKEGILQLRRTNSAKPSPLASSSTASSTTSICVCGQVLAGAGALQCDLCQDWFHGRCVSVPRLLSSPRPNPTSSPLLAWWEWDTKFLCPLCMRSRRPRLETILALLVALQRLPVRLPEGEALQCLTERAISWQGRARQALASEDVTALLGRLAELRQRLQAEPRPEEPPNYPAAPASDPLREGSGKDMPKVQGLLENGDSVTSPEKVAPEEGSGKRDLELLSSLLPQLTGPVLELPEATRAPLEELMMEGDLLEVTLDENHSIWQLLQAGQPPDLERIRTLLELEKAERHGSRARGRALERRRRRKVDRGGEGDDPAREELEPKRVRSSGPEAEEVQEEEELEEETGGEGPPAPIPTTGSPSTQENQNGLEPAEGTTSGPSAPFSTLTPRLHLPCPQQPPQQQL T85540 DRUGINFO D0IQ7Y PBIT Investigative T85540 DRUGINFO D0WA3E IOX2 Investigative T15514 TARGETID T15514 T15514 FORMERID TTDR00269 T15514 UNIPROID HNF4A_HUMAN T15514 TARGNAME Hepatocyte nuclear factor 4-alpha (HNF4A) T15514 GENENAME HNF4A T15514 TARGTYPE Literature-reported T15514 SYNONYMS Transcription factor HNF-4; Transcription factor 14; TCF14; TCF-14; Nuclear receptor subfamily 2 group A member 1; NR2A1; HNF4; HNF-4-alpha T15514 FUNCTION Activates the transcription of CYP2C38. Represses the CLOCK-ARNTL/BMAL1 transcriptional activity and is essential for circadian rhythm maintenance and period regulation in the liver and colon cells. Transcriptional regulator which controls the expression of hepatic genes during the transition of endodermal cells to hepatic progenitor cells, facilitating the recruitment of RNA pol II to the promoters of target genes. T15514 PDBSTRUC 6CHT; 4IQR; 4B7W; 3FS1; 3CBB T15514 BIOCLASS Nuclear hormone receptor T15514 SEQUENCE MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI T15514 DRUGINFO D02RRY BI6015 Investigative T15514 DRUGINFO D0N0UC Lauric Acid Investigative T15514 DRUGINFO D08OBF MYRISTIC ACID Investigative T46515 TARGETID T46515 T46515 FORMERID TTDR00159 T46515 UNIPROID SYIC_HUMAN T46515 TARGNAME Isoleucyl-tRNA synthetase (IARS) T46515 GENENAME IARS T46515 TARGTYPE Literature-reported T46515 SYNONYMS Isoleucine--tRNA ligase, cytoplasmic; Isoleucine--tRNA ligase; IleRS; IRS T46515 FUNCTION Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. T46515 BIOCLASS Carbon-oxygen ligase T46515 ECNUMBER EC 6.1.1.5 T46515 SEQUENCE MLQQVPENINFPAEEEKILEFWTEFNCFQECLKQSKHKPKFTFYDGPPFATGLPHYGHILAGTIKDIVTRYAHQSGFHVDRRFGWDCHGLPVEYEIDKTLGIRGPEDVAKMGITEYNNQCRAIVMRYSAEWKSTVSRLGRWIDFDNDYKTLYPQFMESVWWVFKQLYDKGLVYRGVKVMPFSTACNTPLSNFESHQNYKDVQDPSVFVTFPLEEDETVSLVAWTTTPWTLPSNLAVCVNPEMQYVKIKDVARGRLLILMEARLSALYKLESDYEILERFPGAYLKGKKYRPLFDYFLKCKENGAFTVLVDNYVKEEEGTGVVHQAPYFGAEDYRVCMDFNIIRKDSLPVCPVDASGCFTTEVTDFAGQYVKDADKSIIRTLKEQGRLLVATTFTHSYPFCWRSDTPLIYKAVPSWFVRVENMVDQLLRNNDLCYWVPELVREKRFGNWLKDARDWTISRNRYWGTPIPLWVSDDFEEVVCIGSVAELEELSGAKISDLHRESVDHLTIPSRCGKGSLHRISEVFDCWFESGSMPYAQVHYPFENKREFEDAFPADFIAEGIDQTRGWFYTLLVLATALFGQPPFKNVIVNGLVLASDGQKMSKRKKNYPDPVSIIQKYGADALRLYLINSPVVRAENLRFKEEGVRDVLKDVLLPWYNAYRFLIQNVLRLQKEEEIEFLYNENTVRESPNITDRWILSFMQSLIGFFETEMAAYRLYTVVPRLVKFVDILTNWYVRMNRRRLKGENGMEDCVMALETLFSVLLSLCRLMAPYTPFLTELMYQNLKVLIDPVSVQDKDTLSIHYLMLPRVREELIDKKTESAVSQMQSVIELGRVIRDRKTIPIKYPLKEIVVIHQDPEALKDIKSLEKYIIEELNVRKVTLSTDKNKYGIRLRAEPDHMVLGKRLKGAFKAVMTSIKQLSSEELEQFQKTGTIVVEGHELHDEDIRLMYTFDQATGGTAQFEAHSDAQALVLLDVTPDQSMVDEGMAREVINRIQKLRKKCNLVPTDEITVYYKAKSEGTYLNSVIESHTEFIFTTIKAPLKPYPVSPSDKVLIQEKTQLKGSELEITLTRGSSLPGPACAYVNLNICANGSEQGGVLLLENPKGDNRLDLLKLKSVVTSIFGVKNTELAVFHDETEIQNQTDLLSLSGKTLCVTAGSAPSLINSSSTLLCQYINLQLLNAKPQECLMGTVGTLLLENPLGQNGLTHQGLLYEAAKVFGLRSRKLKLFLNETQTQEITEDIPVKTLNMKTVYVSVLPTTADF T46515 DRUGINFO D0N1BC Reveromycin A Terminated T76846 TARGETID T76846 T76846 FORMERID TTDR00375 T76846 UNIPROID MC3R_HUMAN T76846 TARGNAME Melanocortin receptor 3 (MC3R) T76846 GENENAME MC3R T76846 TARGTYPE Literature-reported T76846 SYNONYMS MC3-R T76846 FUNCTION Receptor for MSH (alpha, beta and gamma) and ACTH. This receptor is mediated by G proteins which activate adenylate cyclase. Required for expression of anticipatory patterns of activity and wakefulness during periods of limited nutrient availability and for the normal regulation of circadian clock activity in the brain. T76846 BIOCLASS GPCR rhodopsin T76846 SEQUENCE MNASCCLPSVQPTLPNGSEHLQAPFFSNQSSSAFCEQVFIKPEVFLSLGIVSLLENILVILAVVRNGNLHSPMYFFLCSLAVADMLVSVSNALETIMIAIVHSDYLTFEDQFIQHMDNIFDSMICISLVASICNLLAIAVDRYVTIFYALRYHSIMTVRKALTLIVAIWVCCGVCGVVFIVYSESKMVIVCLITMFFAMMLLMGTLYVHMFLFARLHVKRIAALPPADGVAPQQHSCMKGAVTITILLGVFIFCWAPFFLHLVLIITCPTNPYCICYTAHFNTYLVLIMCNSVIDPLIYAFRSLELRNTFREILCGCNGMNLG T76846 DRUGINFO D06SDP Melanotetan II Preclinical T76846 DRUGINFO D08XNQ SHU9119 Investigative T76846 DRUGINFO D0F0CP MK-9 Investigative T76846 DRUGINFO D01VMU C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2 Investigative T76846 DRUGINFO D0B9NH C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D0GN9K C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2 Investigative T76846 DRUGINFO D00NOG MK-11 Investigative T76846 DRUGINFO D00TSX C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D00VYC Ac-YR[CEHdFRWC]-NH2 Investigative T76846 DRUGINFO D01HTX C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D02MPZ C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D04YZZ C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T76846 DRUGINFO D05WNC C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D05XRI Ac-R[CEHdFRWC]-NH2 Investigative T76846 DRUGINFO D06PNU Tic-D-Phe-Arg-2-Nal-NHCH3 Investigative T76846 DRUGINFO D07DWH Ac-dR[CEHdFRWC]-NH2 Investigative T76846 DRUGINFO D07UXW C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D08DND C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2 Investigative T76846 DRUGINFO D09OMI Ac-YK[CEHdFRWC]-NH2 Investigative T76846 DRUGINFO D09UUC MK-10 Investigative T76846 DRUGINFO D0A8ME Ac-[CEHdFRWC]-NH2 Investigative T76846 DRUGINFO D0B8GR Ac-His-D-Phe-Arg-2-Nal-NHCH3 Investigative T76846 DRUGINFO D0C7VI Ac-YR[CEHdFRWC]SPPKD-NH2 Investigative T76846 DRUGINFO D0F6GX Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3 Investigative T76846 DRUGINFO D0M4EF C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D0P4GI C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D0VD7R C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D0W1SM C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D0XQ5U C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T76846 DRUGINFO D0ZD3M Ac-YCit[CEHdFRWC]-NH2 Investigative T76846 DRUGINFO D02JVA C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D03AZC Ac-YRMEHdFRWG-NH2 Investigative T76846 DRUGINFO D05LLI C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D06RTP C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D07SFD C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D07TBR Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 Investigative T76846 DRUGINFO D09PDT C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T76846 DRUGINFO D0AU4C AEKKDEGPYRMEHFRWGSPPKD Investigative T76846 DRUGINFO D0B4OL Ac-YRMEHdFRWGSPPKD-NH2 Investigative T76846 DRUGINFO D0CK0K Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 Investigative T76846 DRUGINFO D0I8SJ NDP-SYSMEHFRWGKPVG Investigative T76846 DRUGINFO D0ID5M GPYRMEHFRWGSPPKD-NH2 Investigative T76846 DRUGINFO D0L1MJ C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 Investigative T76846 DRUGINFO D0R0BY Ac-YR[CEH(pCl-dF)RWC]-NH2 Investigative T76846 DRUGINFO D0WG8P Ac-YR[CEH(pF-dF)RWC]-NH2 Investigative T76846 DRUGINFO D0WI8M C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 Investigative T76846 DRUGINFO D0X1YL Ac-YRC(Me)*EHdFRWC(Me)NH2 Investigative T76846 DRUGINFO D0YB7F MT-II Investigative T83009 TARGETID T83009 T83009 FORMERID TTDI03005 T83009 UNIPROID ABL2_HUMAN T83009 TARGNAME Tyrosine-protein kinase ABL2 (ABL2) T83009 GENENAME ABL2 T83009 TARGTYPE Literature-reported T83009 SYNONYMS Tyrosine-protein kinase ARG; Abelson-related gene protein; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; ARG; ABLL T83009 FUNCTION Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 acts also as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. T83009 PDBSTRUC 5NP5; 5NP3; 4EIH; 3ULR; 3HMI T83009 BIOCLASS Kinase T83009 ECNUMBER EC 2.7.10.2 T83009 SEQUENCE MGQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRTTETGFNIFTQHDHFASCVEDGFEGDKTGGSSPEALHRPYGCDVEPQALNEAIRWSSKENLLGATESDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNQNGEWSEVRSKNGQGWVPSNYITPVNSLEKHSWYHGPVSRSAAEYLLSSLINGSFLVRESESSPGQLSISLRYEGRVYHYRINTTADGKVYVTAESRFSTLAELVHHHSTVADGLVTTLHYPAPKCNKPTVYGVSPIHDKWEMERTDITMKHKLGGGQYGEVYVGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTLEPPFYIVTEYMPYGNLLDYLRECNREEVTAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHVVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNTFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYDLLEKGYRMEQPEGCPPKVYELMRACWKWSPADRPSFAETHQAFETMFHDSSISEEVAEELGRAASSSSVVPYLPRLPILPSKTRTLKKQVENKENIEGAQDATENSASSLAPGFIRGAQASSGSPALPRKQRDKSPSSLLEDAKETCFTRDRKGGFFSSFMKKRNAPTPPKRSSSFREMENQPHKKYELTGNFSSVASLQHADGFSFTPAQQEANLVPPKCYGGSFAQRNLCNDDGGGGGGSGTAGGGWSGITGFFTPRLIKKTLGLRAGKPTASDDTSKPFPRSNSTSSMSSGLPEQDRMAMTLPRNCQRSKLQLERTVSTSSQPEENVDRANDMLPKKSEESAAPSRERPKAKLLPRGATALPLRTPSGDLAITEKDPPGVGVAGVAAAPKGKEKNGGARLGMAGVPEDGEQPGWPSPAKAAPVLPTTHNHKVPVLISPTLKHTPADVQLIGTDSQGNKFKLLSEHQVTSSGDKDRPRRVKPKCAPPPPPVMRLLQHPSICSDPTEEPTALTAGQSTSETQEGGKKAALGAVPISGKAGRPVMPPPQVPLPTSSISPAKMANGTAGTKVALRKTKQAAEKISADKISKEALLECADLLSSALTEPVPNSQLVDTGHQLLDYCSGYVDCIPQTRNKFAFREAVSKLELSLQELQVSSAAAGVPGTNPVLNNLLSCVQEISDVVQR T83009 DRUGINFO D0JR3W PMID23441572C24 Investigative T06980 TARGETID T06980 T06980 FORMERID TTDR00958 T06980 UNIPROID XAPA_ECOLI T06980 TARGNAME Bacterial Purine nucleoside phosphorylase (Bact xapA) T06980 GENENAME Bact xapA T06980 TARGTYPE Literature-reported T06980 SYNONYMS Xanthosine phosphorylase; Purine nucleoside phosphorylase II; Purine nucleoside phosphorylase 2; PNP II; Bact Inosine-guanosine phosphorylase T06980 FUNCTION The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. This protein can degrade all purine nucleosides including xanthosine, inosine and guanosine, but cannot cleave adenosine, deoxyadenosine or hypoxanthine arabinoside. Has a preference for the neutral over the monoanionic form of xanthosine. T06980 PDBSTRUC 1YR3; 1YQU; 1YQQ T06980 BIOCLASS Kinase T06980 ECNUMBER EC 2.4.2.1 T06980 SEQUENCE MSQVQFSHNPLFCIDIIKTYKPDFTPRVAFILGSGLGALADQIENAVAISYEKLPGFPVSTVHGHAGELVLGHLQGVPVVCMKGRGHFYEGRGMTIMTDAIRTFKLLGCELLFCTNAAGSLRPEVGAGSLVALKDHINTMPGTPMVGLNDDRFGERFFSLANAYDAEYRALLQKVAKEEGFPLTEGVFVSYPGPNFETAAEIRMMQIIGGDVVGMSVVPEVISARHCDLKVVAVSAITNMAEGLSDVKLSHAQTLAAAELSKQNFINLICGFLRKIA T35158 TARGETID T35158 T35158 FORMERID TTDC00038 T35158 UNIPROID VDAC2_HUMAN T35158 TARGNAME Voltage-dependent anion-selective channel 2 (VDAC2) T35158 GENENAME VDAC2 T35158 TARGTYPE Literature-reported T35158 SYNONYMS hVDAC2; VDAC2; VDAC-2; Outer mitochondrial membrane protein porin 2 T35158 FUNCTION Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules. The channel adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV. The open state has a weak anion selectivity whereas the closed state is cation- selective. T35158 BIOCLASS Eukaryotic mitochondrial porin T35158 SEQUENCE MATHGQTCARPMCIPPSYADLGKAARDIFNKGFGFGLVKLDVKTKSCSGVEFSTSGSSNTDTGKVTGTLETKYKWCEYGLTFTEKWNTDNTLGTEIAIEDQICQGLKLTFDTTFSPNTGKKSGKIKSSYKRECINLGCDVDFDFAGPAIHGSAVFGYEGWLAGYQMTFDSAKSKLTRNNFAVGYRTGDFQLHTNVNDGTEFGGSIYQKVCEDLDTSVNLAWTSGTNCTRFGIAAKYQLDPTASISAKVNNSSLIGVGYTQTLRPGVKLTLSALVDGKSINAGGHKVGLALELEA T27297 TARGETID T27297 T27297 FORMERID TTDR00470 T27297 UNIPROID CRK_HUMAN T27297 TARGNAME Proto-oncogene c-Crk (c-Crk) T27297 GENENAME CRK T27297 TARGTYPE Literature-reported T27297 SYNONYMS P38; Adapter molecule crk T27297 FUNCTION Mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4. May regulate the EFNA5-EPHA3 signaling. Isoform Crk-II: Regulates cell adhesion, spreading and migration. T27297 PDBSTRUC 6ATV; 5UL6; 2MS4; 2EYZ; 2EYY T27297 SEQUENCE MAGNFDSEERSSWYWGRLSRQEAVALLQGQRHGVFLVRDSSTSPGDYVLSVSENSRVSHYIINSSGPRPPVPPSPAQPPPGVSPSRLRIGDQEFDSLPALLEFYKIHYLDTTTLIEPVSRSRQGSGVILRQEEAEYVRALFDFNGNDEEDLPFKKGDILRIRDKPEEQWWNAEDSEGKRGMIPVPYVEKYRPASASVSALIGGNQEGSHPQPLGGPEPGPYAQPSVNTPLPNLQNGPIYARVIQKRVPNAYDKTALALEVGELVKVTKINVSGQWEGECNGKRGHFPFTHVRLLDQQNPDEDFS T94980 TARGETID T94980 T94980 UNIPROID NEDD4_HUMAN T94980 TARGNAME E3 ubiquitin-protein ligase NEDD4 (NEDD4) T94980 GENENAME NEDD4 T94980 TARGTYPE Literature-reported T94980 SYNONYMS Neural precursor cell expressed developmentally down-regulated protein 4; NEDD4-1; NEDD-4; KIAA0093; HECT-type E3 ubiquitin transferase NEDD4; Cell proliferation-inducing gene 53 protein T94980 FUNCTION E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Specifically ubiquitinates 'Lys-63' in target proteins (PubMed:23644597). Involved in the pathway leading to the degradation of VEGFR-2/KDFR, independently of its ubiquitin-ligase activity. Monoubiquitinates IGF1R at multiple sites, thus leading to receptor internalization and degradation in lysosomes. Ubiquitinates FGFR1, leading to receptor internalization and degradation in lysosomes. Promotes ubiquitination of RAPGEF2. According to PubMed:18562292 the direct link between NEDD4 and PTEN regulation through polyubiquitination described in PubMed:17218260 is questionable. Involved in ubiquitination of ERBB4 intracellular domain E4ICD. Involved in the budding of many viruses. Part of a signaling complex composed of NEDD4, RAP2A and TNIK which regulates neuronal dendrite extension and arborization during development. Ubiquitinates TNK2 and regulates EGF-induced degradation of EGFR and TNF2. Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1 (PubMed:25631046). T94980 PDBSTRUC 5C91; 5C7J; 5AHT; 4N7H; 4N7F T94980 ECNUMBER EC 2.3.2.26 T94980 SEQUENCE MAQSLRLHFAARRSNTYPLSETSGDDLDSHVHMCFKRPTRISTSNVVQMKLTPRQTALAPLIKENVQSQERSSVPSSENVNKKSSCLQISLQPTRYSGYLQSSNVLADSDDASFTCILKDGIYSSAVVDNELNAVNDGHLVSSPAICSGSLSNFSTSDNGSYSSNGSDFGSCASITSGGSYTNSVISDSSSYTFPPSDDTFLGGNLPSDSTSNRSVPNRNTTPCEIFSRSTSTDPFVQDDLEHGLEIMKLPVSRNTKIPLKRYSSLVIFPRSPSTTRPTSPTSLCTLLSKGSYQTSHQFIISPSEIAHNEDGTSAKGFLSTAVNGLRLSKTICTPGEVRDIRPLHRKGSLQKKIVLSNNTPRQTVCEKSSEGYSCVSVHFTQRKAATLDCETTNGDCKPEMSEIKLNSDSEYIKLMHRTSACLPSSQNVDCQININGELERPHSQMNKNHGILRRSISLGGAYPNISCLSSLKHNCSKGGPSQLLIKFASGNEGKVDNLSRDSNRDCTNELSNSCKTRDDFLGQVDVPLYPLPTENPRLERPYTFKDFVLHPRSHKSRVKGYLRLKMTYLPKTSGSEDDNAEQAEELEPGWVVLDQPDAACHLQQQQEPSPLPPGWEERQDILGRTYYVNHESRRTQWKRPTPQDNLTDAENGNIQLQAQRAFTTRRQISEETESVDNRESSENWEIIREDEATMYSNQAFPSPPPSSNLDVPTHLAEELNARLTIFGNSAVSQPASSSNHSSRRGSLQAYTFEEQPTLPVLLPTSSGLPPGWEEKQDERGRSYYVDHNSRTTTWTKPTVQATVETSQLTSSQSSAGPQSQASTSDSGQQVTQPSEIEQGFLPKGWEVRHAPNGRPFFIDHNTKTTTWEDPRLKIPAHLRGKTSLDTSNDLGPLPPGWEERTHTDGRIFYINHNIKRTQWEDPRLENVAITGPAVPYSRDYKRKYEFFRRKLKKQNDIPNKFEMKLRRATVLEDSYRRIMGVKRADFLKARLWIEFDGEKGLDYGGVAREWFFLISKEMFNPYYGLFEYSATDNYTLQINPNSGLCNEDHLSYFKFIGRVAGMAVYHGKLLDGFFIRPFYKMMLHKPITLHDMESVDSEYYNSLRWILENDPTELDLRFIIDEELFGQTHQHELKNGGSEIVVTNKNKKEYIYLVIQWRFVNRIQKQMAAFKEGFFELIPQDLIKIFDENELELLMCGLGDVDVNDWREHTKYKNGYSANHQVIQWFWKAVLMMDSEKRIRLLQFVTGTSRVPMNGFAELYGSNGPQSFTVEQWGTPEKLPRAHTCFNRLDLPPYESFEELWDKLQMAIENTQGFDGVD T46527 TARGETID T46527 T46527 FORMERID TTDR01339 T46527 UNIPROID 3HAO_HUMAN T46527 TARGNAME 3-hydroxyanthranilate oxygenase (HAAO) T46527 GENENAME HAAO T46527 TARGTYPE Literature-reported T46527 SYNONYMS h3HAO; HAD; 3-hydroxyanthranilic acid dioxygenase; 3-hydroxyanthranilate 3,4-dioxygenase; 3-HAO T46527 FUNCTION Catalyzes the oxidative ring opening of 3-hydroxyanthranilate to 2-amino-3-carboxymuconate semialdehyde, which spontaneously cyclizes to quinolinate. T46527 PDBSTRUC 5TKQ; 5TK5; 2QNK T46527 ECNUMBER EC 1.13.11.6 T46527 SEQUENCE MERRLGVRAWVKENRGSFQPPVCNKLMHQEQLKVMFIGGPNTRKDYHIEEGEEVFYQLEGDMVLRVLEQGKHRDVVIRQGEIFLLPARVPHSPQRFANTVGLVVERRRLETELDGLRYYVGDTMDVLFEKWFYCKDLGTQLAPIIQEFFSSEQYRTGKPIPDQLLKEPPFPLSTRSIMEPMSLDAWLDSHHRELQAGTPLSLFGDTYETQVIAYGQGSSEGLRQNVDVWLWQLEGSSVVTMGGRRLSLAPDDSLLVLAGTSYAWERTQGSVALSVTQDPACKKPLG T78581 TARGETID T78581 T78581 FORMERID TTDR00184 T78581 UNIPROID GALR1_HUMAN T78581 TARGNAME Galanin receptor type 1 (GAL1-R) T78581 GENENAME GALR1 T78581 TARGTYPE Literature-reported T78581 SYNONYMS GALR1; GALR-1; GALNR1; GALN1R; GAL1-R T78581 FUNCTION The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity. Receptor for the hormone galanin. G protein-coupled peptide receptor activity. Neuropeptide binding. Peptide hormone binding. T78581 BIOCLASS GPCR rhodopsin T78581 SEQUENCE MELAVGNLSEGNASWPEPPAPEPGPLFGIGVENFVTLVVFGLIFALGVLGNSLVITVLARSKPGKPRSTTNLFILNLSIADLAYLLFCIPFQATVYALPTWVLGAFICKFIHYFFTVSMLVSIFTLAAMSVDRYVAIVHSRRSSSLRVSRNALLGVGCIWALSIAMASPVAYHQGLFHPRASNQTFCWEQWPDPRHKKAYVVCTFVFGYLLPLLLICFCYAKVLNHLHKKLKNMSKKSEASKKKTAQTVLVVVVVFGISWLPHHIIHLWAEFGVFPLTPASFLFRITAHCLAYSNSSVNPIIYAFLSENFRKAYKQVFKCHIRKDSHLSDTKESKSRIDTPPSTNCTHV T78581 DRUGINFO D0G9ME NAX-5055 Investigative T78581 DRUGINFO D0W6PP Galnon Investigative T78581 DRUGINFO D00RWP GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2 Investigative T78581 DRUGINFO D01LMH [Sar1Gly]GAL-B2 Investigative T78581 DRUGINFO D02GOE (Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K Investigative T78581 DRUGINFO D02JQP GalB2 Investigative T78581 DRUGINFO D03ECE (Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K Investigative T78581 DRUGINFO D05GFD (Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K Investigative T78581 DRUGINFO D06DWA (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K Investigative T78581 DRUGINFO D07NOJ [Sar1Ala]GAL-B2 Investigative T78581 DRUGINFO D09SDZ GWTLNSAGYLLGPHAV-NH2 Investigative T78581 DRUGINFO D0D3CG GWTLNSAGYLLGPrPKPQQwFwLL-CONH2 Investigative T78581 DRUGINFO D0DD3F (Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K Investigative T78581 DRUGINFO D0EO5F (Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K Investigative T78581 DRUGINFO D0H4DF GALANTIDE Investigative T78581 DRUGINFO D0H9QA Gal-B5 Investigative T78581 DRUGINFO D0NJ4R GALANIN Investigative T78581 DRUGINFO D0PY7O WTLNSAGYLL-CONH2 Investigative T78581 DRUGINFO D0Q3CB GWTLNSAGYLLGPPPALALA-CONH2 Investigative T78581 DRUGINFO D0S4VO [N-Me,des-Sar]Gal-B2 Investigative T78581 DRUGINFO D0SV5D GWTLNSAGYLLGPPPGFSPFR-CONH2 Investigative T78581 DRUGINFO D0T6CU WTLNSAGYLLGPHAVGNHPSFSDKNGLTS-CONH2 Investigative T78581 DRUGINFO D0TF7R (Sar)WTLNSAGYLLGPKKKK Investigative T78581 DRUGINFO D0V7UG [N-Ac,des-Sar]Gal-B2 Investigative T78581 DRUGINFO D0Z3QG (Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K Investigative T78581 DRUGINFO D0Z7QU GWTLNSAGYLLGPRHYINLITRQRY-CONH2 Investigative T30727 TARGETID T30727 T30727 FORMERID TTDR00455 T30727 UNIPROID CASP4_HUMAN T30727 TARGNAME Caspase-11 (CASP11) T30727 GENENAME Casp4 T30727 TARGTYPE Literature-reported T30727 SYNONYMS ICH-3 protease; Casp4 of Mus musculus T30727 FUNCTION Involved in ER-stress induced apoptosis. Cleaves caspase-1. Involved in the activation cascade of caspases responsible for apoptosis execution. Promotes IL-1 beta processing by ICE, so may also have a role in inflammatory responses. T30727 BIOCLASS Peptidase T30727 ECNUMBER EC 3.4.22.57 T30727 SEQUENCE MAEGNHRKKPLKVLESLGKDFLTGVLDNLVEQNVLNWKEEEKKKYYDAKTEDKVRVMADSMQEKQRMAGQMLLQTFFNIDQISPNKKAHPNMEAGPPESGESTDALKLCPHEEFLRLCKERAEEIYPIKERNNRTRLALIICNTEFDHLPPRNGADFDITGMKELLEGLDYSVDVEENLTARDMESALRAFATRPEHKSSDSTFLVLMSHGILEGICGTVHDEKKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGANRGELWVRDSPASLEVASSQSSENLEEDAVYKTHVEKDFIAFCSSTPHNVSWRDSTMGSIFITQLITCFQKYSWCCHLEEVFRKVQQSFETPRAKAQMPTIERLSMTRYFYLFPGN T30727 DRUGINFO D0Y5IQ Grassystatin a Investigative T21585 TARGETID T21585 T21585 FORMERID TTDI03104 T21585 UNIPROID CLK3_HUMAN T21585 TARGNAME CDC-like kinase 3 (CLK3) T21585 GENENAME CLK3 T21585 TARGTYPE Literature-reported T21585 SYNONYMS Dual specificity protein kinase CLK3 T21585 FUNCTION Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Phosphorylates SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. T21585 PDBSTRUC 6RCT; 6FYR; 6FYP; 6FT7; 3RAW T21585 BIOCLASS Kinase T21585 ECNUMBER EC 2.7.12.1 T21585 SEQUENCE MPVLSARRRELADHAGSGRRSGPSPTARSGPHLSALRAQPARAAHLSGRGTYVRRDTAGGGPGQARPLGPPGTSLLGRGARRSGEGWCPGAFESGARAARPPSRVEPRLATAASREGAGLPRAEVAAGSGRGARSGEWGLAAAGAWETMHHCKRYRSPEPDPYLSYRWKRRRSYSREHEGRLRYPSRREPPPRRSRSRSHDRLPYQRRYRERRDSDTYRCEERSPSFGEDYYGPSRSRHRRRSRERGPYRTRKHAHHCHKRRTRSCSSASSRSQQSSKRSSRSVEDDKEGHLVCRIGDWLQERYEIVGNLGEGTFGKVVECLDHARGKSQVALKIIRNVGKYREAARLEINVLKKIKEKDKENKFLCVLMSDWFNFHGHMCIAFELLGKNTFEFLKENNFQPYPLPHVRHMAYQLCHALRFLHENQLTHTDLKPENILFVNSEFETLYNEHKSCEEKSVKNTSIRVADFGSATFDHEHHTTIVATRHYRPPEVILELGWAQPCDVWSIGCILFEYYRGFTLFQTHENREHLVMMEKILGPIPSHMIHRTRKQKYFYKGGLVWDENSSDGRYVKENCKPLKSYMLQDSLEHVQLFDLMRRMLEFDPAQRITLAEALLHPFFAGLTPEERSFHTSRNPSR T21585 DRUGINFO D00BAJ KH-CB19 Investigative T21585 DRUGINFO D04IMY leucettine L41 Investigative T79326 TARGETID T79326 T79326 FORMERID TTDI02570 T79326 UNIPROID KHK_HUMAN T79326 TARGNAME Ketohexokinase (KHK) T79326 GENENAME KHK T79326 TARGTYPE Literature-reported T79326 SYNONYMS Hepatic fructokinase T79326 FUNCTION Catalyzes the phosphorylation of the ketose sugar fructose to fructose-1-phosphate. T79326 PDBSTRUC 5WBZ; 5WBR; 5WBQ; 5WBP; 5WBO T79326 BIOCLASS Kinase T79326 ECNUMBER EC 2.7.1.3 T79326 SEQUENCE MEEKQILCVGLVVLDVISLVDKYPKEDSEIRCLSQRWQRGGNASNSCTVLSLLGAPCAFMGSMAPGHVADFLVADFRRRGVDVSQVAWQSKGDTPSSCCIINNSNGNRTIVLHDTSLPDVSATDFEKVDLTQFKWIHIEGRNASEQVKMLQRIDAHNTRQPPEQKIRVSVEVEKPREELFQLFGYGDVVFVSKDVAKHLGFQSAEEALRGLYGRVRKGAVLVCAWAEEGADALGPDGKLLHSDAFPPPRVVDTLGAGDTFNASVIFSLSQGRSVQEALRFGCQVAGKKCGLQGFDGIV T35824 TARGETID T35824 T35824 FORMERID TTDI03390 T35824 UNIPROID MMP16_HUMAN T35824 TARGNAME Matrix metalloproteinase-16 (MMP-16) T35824 GENENAME MMP16 T35824 TARGTYPE Literature-reported T35824 SYNONYMS Membrane-type-3 matrix metalloproteinase; Membrane-type matrix metalloproteinase 3; MTMMP3; MT3MMP; MT3-MMP; MT-MMP 3; MMPX2; MMP-X2; C8orf57 T35824 FUNCTION Activates progelatinase A. Involved in the matrix remodeling of blood vessels. Isoform short cleaves fibronectin and also collagen type III, but at lower rate. It has no effect on type I, II, IV and V collagen. However, upon interaction with CSPG4, it may be involved in degradation and invasion of type I collagen by melanoma cells. Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin. T35824 PDBSTRUC 1RM8 T35824 BIOCLASS Peptidase T35824 ECNUMBER EC 3.4.24.- T35824 SEQUENCE MILLTFSTGRRLDFVHHSGVFFLQTLLWILCATVCGTEQYFNVEVWLQKYGYLPPTDPRMSVLRSAETMQSALAAMQQFYGINMTGKVDRNTIDWMKKPRCGVPDQTRGSSKFHIRRKRYALTGQKWQHKHITYSIKNVTPKVGDPETRKAIRRAFDVWQNVTPLTFEEVPYSELENGKRDVDITIIFASGFHGDSSPFDGEGGFLAHAYFPGPGIGGDTHFDSDEPWTLGNPNHDGNDLFLVAVHELGHALGLEHSNDPTAIMAPFYQYMETDNFKLPNDDLQGIQKIYGPPDKIPPPTRPLPTVPPHRSIPPADPRKNDRPKPPRPPTGRPSYPGAKPNICDGNFNTLAILRREMFVFKDQWFWRVRNNRVMDGYPMQITYFWRGLPPSIDAVYENSDGNFVFFKGNKYWVFKDTTLQPGYPHDLITLGSGIPPHGIDSAIWWEDVGKTYFFKGDRYWRYSEEMKTMDPGYPKPITVWKGIPESPQGAFVHKENGFTYFYKGKEYWKFNNQILKVEPGYPRSILKDFMGCDGPTDRVKEGHSPPDDVDIVIKLDNTASTVKAIAIVIPCILALCLLVLVYTVFQFKRKGTPRHILYCKRSMQEWV T35824 DRUGINFO D07GEL SL422 Investigative T69200 TARGETID T69200 T69200 FORMERID TTDI03566 T69200 UNIPROID SMCA4_HUMAN T69200 TARGNAME Mitotic growth and transcription activator (BAF190A) T69200 GENENAME SMARCA4 T69200 TARGTYPE Literature-reported T69200 SYNONYMS Transcription activator BRG1; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4; SNF2L4; SNF2B; SNF2-beta; Protein brahma homolog 1; Protein BRG-1; BRG1-associated factor 190A; BRG1; ATP-dependent helicase SMARCA4 T69200 FUNCTION Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating the calcium-dependent release of a repressor complex and the recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by SMARCA4-dependent recruitment of a phospho-RB1-HDAC repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves the release of HDAC1 and recruitment of CREBBP. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development, a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth. SMARCA4/BAF190A may promote neural stem cell self-renewal/proliferation by enhancing Notch-dependent proliferative signals, while concurrently making the neural stem cell insensitive to SHH-dependent differentiating cues. Acts as a corepressor of ZEB1 to regulate E-cadherin transcription and is required for induction of epithelial-mesenchymal transition (EMT) by ZEB1. Binds via DLX1 to enhancers located in the intergenic region between DLX5 and DLX6 and this binding is stabilized by the long non-coding RNA (lncRNA) Evf2. Binds to RNA in a promiscuous manner. Binding to RNAs including lncRNA Evf2 leads to inhibition of SMARCA4 ATPase and chromatin remodeling activities. Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). T69200 PDBSTRUC 6BGH; 5EA1; 5DKD; 3UVD; 2H60 T69200 BIOCLASS Acid anhydride hydrolase T69200 ECNUMBER EC 3.6.4.- T69200 SEQUENCE MSTPDPPLGGTPRPGPSPGPGPSPGAMLGPSPGPSPGSAHSMMGPSPGPPSAGHPIPTQGPGGYPQDNMHQMHKPMESMHEKGMSDDPRYNQMKGMGMRSGGHAGMGPPPSPMDQHSQGYPSPLGGSEHASSPVPASGPSSGPQMSSGPGGAPLDGADPQALGQQNRGPTPFNQNQLHQLRAQIMAYKMLARGQPLPDHLQMAVQGKRPMPGMQQQMPTLPPPSVSATGPGPGPGPGPGPGPGPAPPNYSRPHGMGGPNMPPPGPSGVPPGMPGQPPGGPPKPWPEGPMANAAAPTSTPQKLIPPQPTGRPSPAPPAVPPAASPVMPPQTQSPGQPAQPAPMVPLHQKQSRITPIQKPRGLDPVEILQEREYRLQARIAHRIQELENLPGSLAGDLRTKATIELKALRLLNFQRQLRQEVVVCMRRDTALETALNAKAYKRSKRQSLREARITEKLEKQQKIEQERKRRQKHQEYLNSILQHAKDFKEYHRSVTGKIQKLTKAVATYHANTEREQKKENERIEKERMRRLMAEDEEGYRKLIDQKKDKRLAYLLQQTDEYVANLTELVRQHKAAQVAKEKKKKKKKKKAENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTGTDAPKAGQLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEQPQAAQPPTLPVEEKKKIPDPDSDDVSEVDARHIIENAKQDVDDEYGVSQALARGLQSYYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVSLYNNNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPSVVKVSYKGSPAARRAFVPQLRSGKFNVLLTTYEYIIKDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRLLLTGTPLQNKLPELWALLNFLLPTIFKSCSTFEQWFNAPFAMTGEKVDLNEEETILIIRRLHKVLRPFLLRRLKKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAKGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPYMFQHIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRILPKLRATNHKVLLFCQMTSLMTIMEDYFAYRGFKYLRLDGTTKAEDRGMLLKTFNEPGSEYFIFLLSTRAGGLGLNLQSADTVIIFDSDWNPHQDLQAQDRAHRIGQQNEVRVLRLCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFLQAILEHEEQDESRHCSTGSGSASFAHTAPPPAGVNPDLEEPPLKEEDEVPDDETVNQMIARHEEEFDLFMRMDLDRRREEARNPKRKPRLMEEDELPSWIIKDDAEVERLTCEEEEEKMFGRGSRHRKEVDYSDSLTEKQWLKAIEEGTLEEIEEEVRQKKSSRKRKRDSDAGSSTPTTSTRSRDKDDESKKQKKRGRPPAEKLSPNPPNLTKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQTFNLEGSLIYEDSIVLQSVFTSVRQKIEKEDDSEGEESEEEEEGEEEGSESESRSVKVKIKLGRKEKAQDRLKGGRRRPSRGSRAKPVVSDDDSEEEQEEDRSGSGSEED T69200 DRUGINFO D09GNM PFI-3 Investigative T59230 TARGETID T59230 T59230 FORMERID TTDR00811 T59230 UNIPROID DHB4_HUMAN T59230 TARGNAME Estradiol 17 beta-dehydrogenase 4 (HSD17B4) T59230 GENENAME HSD17B4 T59230 TARGTYPE Literature-reported T59230 SYNONYMS MFE-2; HSD17B4; DBP; D-bifunctional protein; 17-beta-hydroxysteroid dehydrogenase 4; 17-beta-HSD 4; 17 beta-hydroxysteroid dehydrogenase type 4 T59230 FUNCTION Bifunctional enzymeacting on the peroxisomal beta- oxidation pathway for fatty acids. Catalyzes the formation of 3- ketoacyl-CoA intermediates from both straight-chain and 2-methyl- branched-chain fatty acids. T59230 PDBSTRUC 1ZBQ; 1S9C; 1IKT T59230 BIOCLASS Short-chain dehydrogenases reductase T59230 SEQUENCE MGSPLRFDGRVVLVTGAGAGLGRAYALAFAERGALVVVNDLGGDFKGVGKGSLAADKVVEEIRRRGGKAVANYDSVEEGEKVVKTALDAFGRIDVVVNNAGILRDRSFARISDEDWDIIHRVHLRGSFQVTRAAWEHMKKQKYGRIIMTSSASGIYGNFGQANYSAAKLGLLGLANSLAIEGRKSNIHCNTIAPNAGSRMTQTVMPEDLVEALKPEYVAPLVLWLCHESCEENGGLFEVGAGWIGKLRWERTLGAIVRQKNHPMTPEAVKANWKKICDFENASKPQSIQESTGSIIEVLSKIDSEGGVSANHTSRATSTATSGFAGAIGQKLPPFSYAYTELEAIMYALGVGASIKDPKDLKFIYEGSSDFSCLPTFGVIIGQKSMMGGGLAEIPGLSINFAKVLHGEQYLELYKPLPRAGKLKCEAVVADVLDKGSGVVIIMDVYSYSEKELICHNQFSLFLVGSGGFGGKRTSDKVKVAVAIPNRPPDAVLTDTTSLNQAALYRLSGDWNPLHIDPNFASLAGFDKPILHGLCTFGFSARRVLQQFADNDVSRFKAIKARFAKPVYPGQTLQTEMWKEGNRIHFQTKVQETGDIVISNAYVDLAPTSGTSAKTPSEGGKLQSTFVFEEIGRRLKDIGPEVVKKVNAVFEWHITKGGNIGAKWTIDLKSGSGKVYQGPAKGAADTTIILSDEDFMEVVLGKLDPQKAFFSGRLKARGNIMLSQKLQMILKDYAKL T59230 DRUGINFO D04TMV 3r-Hydroxydecanoyl-Coa Investigative T59230 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T91617 TARGETID T91617 T91617 UNIPROID TKTL1_HUMAN T91617 TARGNAME Transketolase-like protein 1 (TKTL1) T91617 GENENAME TKTL1 T91617 TARGTYPE Literature-reported T91617 SYNONYMS Transketolase-related protein; Transketolase 2; TKT2; TKR; TK 2 T91617 FUNCTION Catalyzes the transfer of a two-carbon ketol group from a ketose donor to an aldose acceptor, via a covalent intermediate with the cofactor thiamine pyrophosphate. T91617 BIOCLASS Transketolase family T91617 ECNUMBER EC 2.2.1.1 T91617 SEQUENCE MADAEARAEFPEEARPDRGTLQVLQDMASRLRIHSIRATCSTSSGHPTSCSSSSEIMSVLFFYIMRYKQSDPENPDNDRFVLAKRLSFVDVATGWLGQGLGVACGMAYTGKYFDRASYRVFCLMSDGESSEGSVWEAMAFASYYSLDNLVAIFDVNRLGHSGALPAEHCINIYQRRCEAFGWNTYVVDGRDVEALCQVFWQASQVKHKPTAVVAKTFKGRGTPSIEDAESWHAKPMPRERADAIIKLIESQIQTSRNLDPQPPIEDSPEVNITDVRMTSPPDYRVGDKIATRKACGLALAKLGYANNRVVVLDGDTRYSTFSEIFNKEYPERFIECFMAEQNMVSVALGCASRGRTIAFASTFAAFLTRAFDHIRIGGLAESNINIIGSHCGVSVGDDGASQMALEDIAMFRTIPKCTIFYPTDAVSTEHAVALAANAKGMCFIRTTRPETMVIYTPQERFEIGQAKVLRHCVSDKVTVIGAGITVYEALAAADELSKQDIFIRVIDLFTIKPLDVATIVSSAKATEGRIITVEDHYPQGGIGEAVCAAVSMDPDIQVHSLAVSGVPQSGKSEELLDMYGISARHIIVAVKCMLLN T49102 TARGETID T49102 T49102 FORMERID TTDI03401 T49102 UNIPROID NEK2_HUMAN T49102 TARGNAME NIMA-related kinase 2 (NEK2) T49102 GENENAME NEK2 T49102 TARGTYPE Literature-reported T49102 SYNONYMS Serine/threonine-protein kinase Nek2; NimA-related protein kinase 2; NimA-like protein kinase 1; Never in mitosis A-related kinase 2; NLK1; NEK2A; HSPK 21 T49102 FUNCTION Regulates centrosome separation (essential for the formation of bipolar spindles and high-fidelity chromosome separation) by phosphorylating centrosomal proteins such as CROCC, CEP250 and NINL, resulting in their displacement from the centrosomes. Regulates kinetochore microtubule attachment stability in mitosis via phosphorylation of NDC80. Involved in regulation of mitotic checkpoint protein complex via phosphorylation of CDC20 and MAD2L1. Plays an active role in chromatin condensation during the first meiotic division through phosphorylation of HMGA2. Phosphorylates: PPP1CC; SGO1; NECAB3 and NPM1. Essential for localization of MAD2L1 to kinetochore and MAPK1 and NPM1 to the centrosome. Phosphorylates CEP68 and CNTLN directly or indirectly. NEK2-mediated phosphorylation of CEP68 promotes CEP68 dissociation from the centrosome and its degradation at the onset of mitosis. Involved in the regulation of centrosome disjunction. Protein kinase which is involved in the control of centrosome separation and bipolar spindle formation in mitotic cells and chromatin condensation in meiotic cells. T49102 PDBSTRUC 6H0O; 5M57; 5M55; 5M53; 5M51 T49102 BIOCLASS Kinase T49102 ECNUMBER EC 2.7.11.1 T49102 SEQUENCE MPSRAEDYEVLYTIGTGSYGRCQKIRRKSDGKILVWKELDYGSMTEAEKQMLVSEVNLLRELKHPNIVRYYDRIIDRTNTTLYIVMEYCEGGDLASVITKGTKERQYLDEEFVLRVMTQLTLALKECHRRSDGGHTVLHRDLKPANVFLDGKQNVKLGDFGLARILNHDTSFAKTFVGTPYYMSPEQMNRMSYNEKSDIWSLGCLLYELCALMPPFTAFSQKELAGKIREGKFRRIPYRYSDELNEIITRMLNLKDYHRPSVEEILENPLIADLVADEQRRNLERRGRQLGEPEKSQDSSPVLSELKLKEIQLQERERALKAREERLEQKEQELCVRERLAEDKLARAENLLKNYSLLKERKFLSLASNPELLNLPSSVIKKKVHFSGESKENIMRSENSESQLTSKSKCKDLKKRLHAAQLRAQALSDIEKNYQLKSRQILGMR T49102 DRUGINFO D0C3KE PMID21627121C2 Investigative T49102 DRUGINFO D0K0UJ PMID20936789C31 Investigative T49102 DRUGINFO D0X1RH GSK579289A Investigative T70840 TARGETID T70840 T70840 FORMERID TTDI03352 T70840 UNIPROID LIMK1_HUMAN T70840 TARGNAME LIM domain kinase-1 (LIMK-1) T70840 GENENAME LIMK1 T70840 TARGTYPE Literature-reported T70840 SYNONYMS LIMK-1; LIMK T70840 FUNCTION Acts downstream of several Rho family GTPase signal transduction pathways. Activated by upstream kinases including ROCK1, PAK1 and PAK4, which phosphorylate LIMK1 on a threonine residue located in its activation loop. LIMK1 subsequently phosphorylates and inactivates the actin binding/depolymerizing factors cofilin-1/CFL1, cofilin-2/CFL2 and destrin/DSTN, thereby preventing the cleavage of filamentous actin (F-actin), and stabilizing the actin cytoskeleton. In this way LIMK1 regulates several actin-dependent biological processes including cell motility, cell cycle progression, and differentiation. Phosphorylates TPPP on serine residues, thereby promoting microtubule disassembly. Stimulates axonal outgrowth and may be involved in brain development. Isoform 3 has a dominant negative effect on actin cytoskeletal changes. Required for atypical chemokine receptor ACKR2-induced phosphorylation of cofilin (CFL1). Serine/threonine-protein kinase that plays an essential role in the regulation of actin filament dynamics. T70840 PDBSTRUC 5NXC; 5L6W; 5HVK; 5HVJ; 3S95 T70840 BIOCLASS Kinase T70840 ECNUMBER EC 2.7.11.1 T70840 SEQUENCE MRLTLLCCTWREERMGEEGSELPVCASCGQRIYDGQYLQALNADWHADCFRCCDCSASLSHQYYEKDGQLFCKKDYWARYGESCHGCSEQITKGLVMVAGELKYHPECFICLTCGTFIGDGDTYTLVEHSKLYCGHCYYQTVVTPVIEQILPDSPGSHLPHTVTLVSIPASSHGKRGLSVSIDPPHGPPGCGTEHSHTVRVQGVDPGCMSPDVKNSIHVGDRILEINGTPIRNVPLDEIDLLIQETSRLLQLTLEHDPHDTLGHGLGPETSPLSSPAYTPSGEAGSSARQKPVLRSCSIDRSPGAGSLGSPASQRKDLGRSESLRVVCRPHRIFRPSDLIHGEVLGKGCFGQAIKVTHRETGEVMVMKELIRFDEETQRTFLKEVKVMRCLEHPNVLKFIGVLYKDKRLNFITEYIKGGTLRGIIKSMDSQYPWSQRVSFAKDIASGMAYLHSMNIIHRDLNSHNCLVRENKNVVVADFGLARLMVDEKTQPEGLRSLKKPDRKKRYTVVGNPYWMAPEMINGRSYDEKVDVFSFGIVLCEIIGRVNADPDYLPRTMDFGLNVRGFLDRYCPPNCPPSFFPITVRCCDLDPEKRPSFVKLEHWLETLRMHLAGHLPLGPQLEQLDRGFWETYRRGESGLPAHPEVPD T70840 DRUGINFO D07XWC PMID19831390C14 Investigative T70840 DRUGINFO D0F6NZ PMID22902653C30 Investigative T70840 DRUGINFO D0FC4Y PMID22902653C31 Investigative T70840 DRUGINFO D0S0XD PMID22902653C35 Investigative T70840 DRUGINFO D03CPB RKI-1447 Investigative T09133 TARGETID T09133 T09133 FORMERID TTDI03353 T09133 UNIPROID LIMK2_HUMAN T09133 TARGNAME LIM domain kinase-2 (LIMK-2) T09133 GENENAME LIMK2 T09133 TARGTYPE Literature-reported T09133 SYNONYMS LIMK-2; LIM domain kinase 2 T09133 FUNCTION Displays serine/threonine-specific phosphorylation of myelin basic protein and histone (MBP) in vitro. T09133 PDBSTRUC 5NXD; 4TPT; 1X6A T09133 BIOCLASS Kinase T09133 ECNUMBER EC 2.7.11.1 T09133 SEQUENCE MSALAGEDVWRCPGCGDHIAPSQIWYRTVNETWHGSCFRCSECQDSLTNWYYEKDGKLYCPKDYWGKFGEFCHGCSLLMTGPFMVAGEFKYHPECFACMSCKVIIEDGDAYALVQHATLYCGKCHNEVVLAPMFERLSTESVQEQLPYSVTLISMPATTEGRRGFSVSVESACSNYATTVQVKEVNRMHISPNNRNAIHPGDRILEINGTPVRTLRVEEVEDAISQTSQTLQLLIEHDPVSQRLDQLRLEARLAPHMQNAGHPHALSTLDTKENLEGTLRRRSLRRSNSISKSPGPSSPKEPLLFSRDISRSESLRCSSSYSQQIFRPCDLIHGEVLGKGFFGQAIKVTHKATGKVMVMKELIRCDEETQKTFLTEVKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDPFPWQQKVRFAKGIASGMAYLHSMCIIHRDLNSHNCLIKLDKTVVVADFGLSRLIVEERKRAPMEKATTKKRTLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRTLDFGLNVKLFWEKFVPTDCPPAFFPLAAICCRLEPESRPAFSKLEDSFEALSLYLGELGIPLPAELEELDHTVSMQYGLTRDSPP T09133 DRUGINFO D0YI1Z PMID19831390C22m Investigative T09133 DRUGINFO D07XWC PMID19831390C14 Investigative T09133 DRUGINFO D0F6NZ PMID22902653C30 Investigative T09133 DRUGINFO D0FC4Y PMID22902653C31 Investigative T09133 DRUGINFO D0S0XD PMID22902653C35 Investigative T81637 TARGETID T81637 T81637 FORMERID TTDI03443 T81637 UNIPROID PDE1A_HUMAN T81637 TARGNAME Phosphodiesterase 1A (PDE1A) T81637 GENENAME PDE1A T81637 TARGTYPE Literature-reported T81637 SYNONYMS hCam-1; Cam-PDE 1A; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A; 61 kDa Cam-PDE T81637 FUNCTION Has a higher affinity for cGMP than for cAMP. Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. T81637 PDBSTRUC 1LXQ T81637 BIOCLASS Phosphoric diester hydrolase T81637 ECNUMBER EC 3.1.4.17 T81637 SEQUENCE MGSSATEIEELENTTFKYLTGEQTEKMWQRLKGILRCLVKQLERGDVNVVDLKKNIEYAASVLEAVYIDETRRLLDTEDELSDIQTDSVPSEVRDWLASTFTRKMGMTKKKPEEKPKFRSIVHAVQAGIFVERMYRKTYHMVGLAYPAAVIVTLKDVDKWSFDVFALNEASGEHSLKFMIYELFTRYDLINRFKIPVSCLITFAEALEVGYSKYKNPYHNLIHAADVTQTVHYIMLHTGIMHWLTELEILAMVFAAAIHDYEHTGTTNNFHIQTRSDVAILYNDRSVLENHHVSAAYRLMQEEEMNILINLSKDDWRDLRNLVIEMVLSTDMSGHFQQIKNIRNSLQQPEGIDRAKTMSLILHAADISHPAKSWKLHYRWTMALMEEFFLQGDKEAELGLPFSPLCDRKSTMVAQSQIGFIDFIVEPTFSLLTDSTEKIVIPLIEEASKAETSSYVASSSTTIVGLHIADALRRSNTKGSMSDGSYSPDYSLAAVDLKSFKNNLVDIIQQNKERWKELAAQEARTSSQKCEFIHQ T81637 DRUGINFO D02VHD SCH51866 Investigative T56121 TARGETID T56121 T56121 FORMERID TTDI03181 T56121 UNIPROID EPHB3_HUMAN T56121 TARGNAME Ephrin type-B receptor 3 (EPHB3) T56121 GENENAME EPHB3 T56121 TARGTYPE Literature-reported T56121 SYNONYMS hEK2; Tyrosine-protein kinase TYRO6; TYRO6; Embryonic kinase 2; ETK2; EPH-like tyrosine kinase 2; EPH-like kinase 2; EK2 T56121 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Generally has an overlapping and redundant function with EPHB2. Like EPHB2, functions in axon guidance during development regulating for instance the neurons forming the corpus callosum and the anterior commissure, 2 major interhemispheric connections between the temporal lobes of the cerebral cortex. In addition to its role in axon guidance plays also an important redundant role with other ephrin-B receptors in development and maturation of dendritic spines and the formation of excitatory synapses. Controls other aspects of development through regulation of cell migration and positioning. This includes angiogenesis, palate development and thymic epithelium development for instance. Forward and reverse signaling through the EFNB2/EPHB3 complex also regulate migration and adhesion of cells that tubularize the urethra and septate the cloaca. Finally, plays an important role in intestinal epithelium differentiation segregating progenitor from differentiated cells in the crypt. Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T56121 PDBSTRUC 5L6P; 5L6O; 3ZFY; 3P1I T56121 BIOCLASS Kinase T56121 ECNUMBER EC 2.7.10.1 T56121 SEQUENCE MARARPPPPPSPPPGLLPLLPPLLLLPLLLLPAGCRALEETLMDTKWVTSELAWTSHPESGWEEVSGYDEAMNPIRTYQVCNVRESSQNNWLRTGFIWRRDVQRVYVELKFTVRDCNSIPNIPGSCKETFNLFYYEADSDVASASSPFWMENPYVKVDTIAPDESFSRLDAGRVNTKVRSFGPLSKAGFYLAFQDQGACMSLISVRAFYKKCASTTAGFALFPETLTGAEPTSLVIAPGTCIPNAVEVSVPLKLYCNGDGEWMVPVGACTCATGHEPAAKESQCRPCPPGSYKAKQGEGPCLPCPPNSRTTSPAASICTCHNNFYRADSDSADSACTTVPSPPRGVISNVNETSLILEWSEPRDLGGRDDLLYNVICKKCHGAGGASACSRCDDNVEFVPRQLGLTERRVHISHLLAHTRYTFEVQAVNGVSGKSPLPPRYAAVNITTNQAAPSEVPTLRLHSSSGSSLTLSWAPPERPNGVILDYEMKYFEKSEGIASTVTSQMNSVQLDGLRPDARYVVQVRARTVAGYGQYSRPAEFETTSERGSGAQQLQEQLPLIVGSATAGLVFVVAVVVIAIVCLRKQRHGSDSEYTEKLQQYIAPGMKVYIDPFTYEDPNEAVREFAKEIDVSCVKIEEVIGAGEFGEVCRGRLKQPGRREVFVAIKTLKVGYTERQRRDFLSEASIMGQFDHPNIIRLEGVVTKSRPVMILTEFMENCALDSFLRLNDGQFTVIQLVGMLRGIAAGMKYLSEMNYVHRDLAARNILVNSNLVCKVSDFGLSRFLEDDPSDPTYTSSLGGKIPIRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSYGERPYWDMSNQDVINAVEQDYRLPPPMDCPTALHQLMLDCWVRDRNLRPKFSQIVNTLDKLIRNAASLKVIASAQSGMSQPLLDRTVPDYTTFTTVGDWLDAIKMGRYKESFVSAGFASFDLVAQMTAEDLLRIGVTLAGHQKKILSSIQDMRLQMNQTLPVQV T56121 DRUGINFO D05FXD PMID19788238C66 Investigative T56121 DRUGINFO D0X8BU PMID23489211C20 Investigative T18474 TARGETID T18474 T18474 FORMERID TTDI03176 T18474 UNIPROID EPHA5_HUMAN T18474 TARGNAME Ephrin type-A receptor 5 (EPHA5) T18474 GENENAME EPHA5 T18474 TARGTYPE Literature-reported T18474 SYNONYMS hEK7; EPH-like kinase 7; EPH homology kinase 1; EK7; EHK1; EHK-1; Brain-specific kinase; BSK T18474 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Among GPI-anchored ephrin-A ligands, EFNA5 most probably constitutes the cognate/functional ligand for EPHA5. Functions as an axon guidance molecule during development and may be involved in the development of the retinotectal, entorhino-hippocampal and hippocamposeptal pathways. Together with EFNA5 plays also a role in synaptic plasticity in adult brain through regulation of synaptogenesis. In addition to its function in the nervous system, the interaction of EPHA5 with EFNA5 mediates communication between pancreatic islet cells to regulate glucose-stimulated insulin secretion. Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T18474 PDBSTRUC 4ET7; 2R2P T18474 BIOCLASS Kinase T18474 ECNUMBER EC 2.7.10.1 T18474 SEQUENCE MRGSGPRGAGRRRPPSGGGDTPITPASLAGCYSAPRRAPLWTCLLLCAALRTLLASPSNEVNLLDSRTVMGDLGWIAFPKNGWEEIGEVDENYAPIHTYQVCKVMEQNQNNWLLTSWISNEGASRIFIELKFTLRDCNSLPGGLGTCKETFNMYYFESDDQNGRNIKENQYIKIDTIAADESFTELDLGDRVMKLNTEVRDVGPLSKKGFYLAFQDVGACIALVSVRVYYKKCPSVVRHLAVFPDTITGADSSQLLEVSGSCVNHSVTDEPPKMHCSAEGEWLVPIGKCMCKAGYEEKNGTCQVCRPGFFKASPHIQSCGKCPPHSYTHEEASTSCVCEKDYFRRESDPPTMACTRPPSAPRNAISNVNETSVFLEWIPPADTGGRKDVSYYIACKKCNSHAGVCEECGGHVRYLPRQSGLKNTSVMMVDLLAHTNYTFEIEAVNGVSDLSPGARQYVSVNVTTNQAAPSPVTNVKKGKIAKNSISLSWQEPDRPNGIILEYEIKYFEKDQETSYTIIKSKETTITAEGLKPASVYVFQIRARTAAGYGVFSRRFEFETTPVFAASSDQSQIPVIAVSVTVGVILLAVVIGVLLSGSCCECGCGRASSLCAVAHPSLIWRCGYSKAKQDPEEEKMHFHNGHIKLPGVRTYIDPHTYEDPNQAVHEFAKEIEASCITIERVIGAGEFGEVCSGRLKLPGKRELPVAIKTLKVGYTEKQRRDFLGEASIMGQFDHPNIIHLEGVVTKSKPVMIVTEYMENGSLDTFLKKNDGQFTVIQLVGMLRGISAGMKYLSDMGYVHRDLAARNILINSNLVCKVSDFGLSRVLEDDPEAAYTTRGGKIPIRWTAPEAIAFRKFTSASDVWSYGIVMWEVVSYGERPYWEMTNQDVIKAVEEGYRLPSPMDCPAALYQLMLDCWQKERNSRPKFDEIVNMLDKLIRNPSSLKTLVNASCRVSNLLAEHSPLGSGAYRSVGEWLEAIKMGRYTEIFMENGYSSMDAVAQVTLEDLRRLGVTLVGHQKKIMNSLQEMKVQLVNGMVPL T18474 DRUGINFO D05FXD PMID19788238C66 Investigative T18474 DRUGINFO D0X8BU PMID23489211C20 Investigative T02446 TARGETID T02446 T02446 FORMERID TTDI03180 T02446 UNIPROID EPHB1_HUMAN T02446 TARGNAME Ephrin type-B receptor 1 (EPHB1) T02446 GENENAME EPHB1 T02446 TARGTYPE Literature-reported T02446 SYNONYMS hEK6; Tyrosine-protein kinase receptor EPH-2; Neuronally-expressed EPH-related tyrosine kinase; EPHT2; EPH-like kinase 6; EPH tyrosine kinase 2; ELK; EK6 T02446 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Cognate/functional ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3. During nervous system development, regulates retinal axon guidance redirecting ipsilaterally ventrotemporal retinal ganglion cells axons at the optic chiasm midline. This probably requires repulsive interaction with EFNB2. In the adult nervous system together with EFNB3, regulates chemotaxis, proliferation and polarity of the hippocampus neural progenitors. In addition to its role in axon guidance plays also an important redundant role with other ephrin-B receptors in development and maturation of dendritic spines and synapse formation. May also regulate angiogenesis. More generally, may play a role in targeted cell migration and adhesion. Upon activation by EFNB1 and probably other ephrin-B ligands activates the MAPK/ERK and the JNK signaling cascades to regulate cell migration and adhesion respectively. Involved in the maintenance of the pool of satellite cells (muscle stem cells) by promoting their self-renewal and reducing their activation and differentiation. Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T02446 PDBSTRUC 5MJB; 5MJA; 3ZFX; 2EAO; 2DJS T02446 BIOCLASS Kinase T02446 ECNUMBER EC 2.7.10.1 T02446 SEQUENCE MALDYLLLLLLASAVAAMEETLMDTRTATAELGWTANPASGWEEVSGYDENLNTIRTYQVCNVFEPNQNNWLLTTFINRRGAHRIYTEMRFTVRDCSSLPNVPGSCKETFNLYYYETDSVIATKKSAFWSEAPYLKVDTIAADESFSQVDFGGRLMKVNTEVRSFGPLTRNGFYLAFQDYGACMSLLSVRVFFKKCPSIVQNFAVFPETMTGAESTSLVIARGTCIPNAEEVDVPIKLYCNGDGEWMVPIGRCTCKPGYEPENSVACKACPAGTFKASQEAEGCSHCPSNSRSPAEASPICTCRTGYYRADFDPPEVACTSVPSGPRNVISIVNETSIILEWHPPRETGGRDDVTYNIICKKCRADRRSCSRCDDNVEFVPRQLGLTECRVSISSLWAHTPYTFDIQAINGVSSKSPFPPQHVSVNITTNQAAPSTVPIMHQVSATMRSITLSWPQPEQPNGIILDYEIRYYEKEHNEFNSSMARSQTNTARIDGLRPGMVYVVQVRARTVAGYGKFSGKMCFQTLTDDDYKSELREQLPLIAGSAAAGVVFVVSLVAISIVCSRKRAYSKEAVYSDKLQHYSTGRGSPGMKIYIDPFTYEDPNEAVREFAKEIDVSFVKIEEVIGAGEFGEVYKGRLKLPGKREIYVAIKTLKAGYSEKQRRDFLSEASIMGQFDHPNIIRLEGVVTKSRPVMIITEFMENGALDSFLRQNDGQFTVIQLVGMLRGIAAGMKYLAEMNYVHRDLAARNILVNSNLVCKVSDFGLSRYLQDDTSDPTYTSSLGGKIPVRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSFGERPYWDMSNQDVINAIEQDYRLPPPMDCPAALHQLMLDCWQKDRNSRPRFAEIVNTLDKMIRNPASLKTVATITAVPSQPLLDRSIPDFTAFTTVDDWLSAIKMVQYRDSFLTAGFTSLQLVTQMTSEDLLRIGITLAGHQKKILNSIHSMRVQISQSPTAMA T02446 DRUGINFO D05FXD PMID19788238C66 Investigative T02446 DRUGINFO D0X8BU PMID23489211C20 Investigative T34337 TARGETID T34337 T34337 FORMERID TTDR01143 T34337 UNIPROID UPPS_ECOLI T34337 TARGNAME Bacterial Undecaprenyl pyrophosphate synthetase (Bact ispU) T34337 GENENAME Bact ispU T34337 TARGTYPE Literature-reported T34337 SYNONYMS ispU; Undecaprenyl diphosphate synthase; Undecaprenyl diphosphate synthase; UPP synthetase; UPP synthase; UDS; Di-trans-poly-cis-decaprenylcistransferase T34337 FUNCTION Generates ditrans,octacis-undecaprenyl pyrophosphate (UPP) from isopentenyl pyrophosphate (IPP) and farnesyl diphosphate (FPP). UPP is the precursor of glycosyl carrier lipid in the biosynthesis of bacterial cell wall polysaccharide components such as peptidoglycan and lipopolysaccharide. T34337 PDBSTRUC 5ZHE; 5CQJ; 5CQB; 4H3C; 4H3A T34337 BIOCLASS Alkyl aryl transferase T34337 ECNUMBER EC 2.5.1.31 T34337 SEQUENCE MMLSATQPLSEKLPAHGCRHVAIIMDGNGRWAKKQGKIRAFGHKAGAKSVRRAVSFAANNGIEALTLYAFSSENWNRPAQEVSALMELFVWALDSEVKSLHRHNVRLRIIGDTSRFNSRLQERIRKSEALTAGNTGLTLNIAANYGGRWDIVQGVRQLAEKVQQGNLQPDQIDEEMLNQHVCMHELAPVDLVIRTGGEHRISNFLLWQIAYAELYFTDVLWPDFDEQDFEGALNAFANRERRFGGTEPGDETA T34337 DRUGINFO D0Y1JB E-pentenylbutanedioic acid 32 Investigative T34337 DRUGINFO D0J8KR ISOPENTENYL PYROPHOSPHATE Investigative T10586 TARGETID T10586 T10586 FORMERID TTDI02118 T10586 UNIPROID LYSC_HUMAN T10586 TARGNAME Lysozyme (LYZ) T10586 GENENAME LYZ T10586 TARGTYPE Literature-reported T10586 SYNONYMS Lysozyme C; LYZ; 1,4betaNacetylmuramidase C T10586 FUNCTION Lysozymes have primarily a bacteriolytic function; those intissues and body fluids are associated with the monocyte- macrophage system and enhance the activity of immunoagents. T10586 PDBSTRUC 5LVK; 5LSH; 4R0P; 4ML7; 4I0C T10586 BIOCLASS Glycosylase T10586 ECNUMBER EC 3.2.1.17 T10586 SEQUENCE MKALIVLGLVLLSVTVQGKVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV T93712 TARGETID T93712 T93712 UNIPROID RACK1_HUMAN T93712 TARGNAME Receptor of activated protein C kinase 1 (RACK1) T93712 GENENAME RACK1 T93712 TARGTYPE Literature-reported T93712 SYNONYMS Small ribosomal subunit protein RACK1; Receptor of activated protein C kinase 1, N-terminally processed; Receptor for activated C kinase; Human lung cancer oncogene 7 protein; HLC-7; Guanine nucleotide-binding protein subunit beta-like protein 12.3; Guanine nucleotide-binding protein subunit beta-2-like 1, N-terminally processed; Guanine nucleotide-binding protein subunit beta-2-like 1; GNB2L1; Cell proliferation-inducing gene 21 protein T93712 FUNCTION Scaffolding protein involved in the recruitment, assembly and/or regulation of a variety of signaling molecules. Interacts with a wide variety of proteins and plays a role in many cellular processes. Component of the 40S ribosomal subunit involved in translational repression (PubMed:23636399). Involved in the initiation of the ribosome quality control (RQC), a pathway that takes place when a ribosome has stalled during translation, by promoting ubiquitination of a subset of 40S ribosomal subunits (PubMed:28132843). Binds to and stabilizes activated protein kinase C (PKC), increasing PKC-mediated phosphorylation. May recruit activated PKC to the ribosome, leading to phosphorylation of EIF6. Inhibits the activity of SRC kinases including SRC, LCK and YES1. Inhibits cell growth by prolonging the G0/G1 phase of the cell cycle. Enhances phosphorylation of BMAL1 by PRKCA and inhibits transcriptional activity of the BMAL1-CLOCK heterodimer. Facilitates ligand-independent nuclear translocation of AR following PKC activation, represses AR transactivation activity and is required for phosphorylation of AR by SRC. Modulates IGF1R-dependent integrin signaling and promotes cell spreading and contact with the extracellular matrix. Involved in PKC-dependent translocation of ADAM12 to the cell membrane. Promotes the ubiquitination and proteasome-mediated degradation of proteins such as CLEC1B and HIF1A. Required for VANGL2 membrane localization, inhibits Wnt signaling, and regulates cellular polarization and oriented cell division during gastrulation. Required for PTK2/FAK1 phosphorylation and dephosphorylation. Regulates internalization of the muscarinic receptor CHRM2. Promotes apoptosis by increasing oligomerization of BAX and disrupting the interaction of BAX with the anti-apoptotic factor BCL2L. Inhibits TRPM6 channel activity. Regulates cell surface expression of some GPCRs such as TBXA2R. Plays a role in regulation of FLT1-mediated cell migration. Involved in the transport of ABCB4 from the Golgi to the apical bile canalicular membrane (PubMed:19674157). Promotes migration of breast carcinoma cells by binding to and activating RHOA (PubMed:20499158). T93712 PDBSTRUC 6QZP; 6G5I; 6G5H; 6G53; 6G51 T93712 BIOCLASS WD repeat G protein beta family. Ribosomal protein RACK1 subfamily T93712 SEQUENCE MTEQMTLRGTLKGHNGWVTQIATTPQFPDMILSASRDKTIIMWKLTRDETNYGIPQRALRGHSHFVSDVVISSDGQFALSGSWDGTLRLWDLTTGTTTRRFVGHTKDVLSVAFSSDNRQIVSGSRDKTIKLWNTLGVCKYTVQDESHSEWVSCVRFSPNSSNPIIVSCGWDKLVKVWNLANCKLKTNHIGHTGYLNTVTVSPDGSLCASGGKDGQAMLWDLNEGKHLYTLDGGDIINALCFSPNRYWLCAATGPSIKIWDLEGKIIVDELKQEVISTSSKAEPPQCTSLAWSADGQTLFAGYTDNLVRVWQVTIGTR T95761 TARGETID T95761 T95761 FORMERID TTDR00920 T95761 UNIPROID ADAM8_HUMAN T95761 TARGNAME Cell surface antigen MS2 (ADAM8) T95761 GENENAME ADAM8 T95761 TARGTYPE Literature-reported T95761 SYNONYMS CD156a antigen; CD156; ADAM8; A disintegrin and metalloproteinase domain 8 T95761 FUNCTION Possible involvement in extravasation of leukocytes. T95761 PDBSTRUC 4DD8 T95761 BIOCLASS Peptidase T95761 ECNUMBER EC 3.4.24.- T95761 SEQUENCE MRGLGLWLLGAMMLPAIAPSRPWALMEQYEVVLPWRLPGPRVRRALPSHLGLHPERVSYVLGATGHNFTLHLRKNRDLLGSGYTETYTAANGSEVTEQPRGQDHCFYQGHVEGYPDSAASLSTCAGLRGFFQVGSDLHLIEPLDEGGEGGRHAVYQAEHLLQTAGTCGVSDDSLGSLLGPRTAAVFRPRPGDSLPSRETRYVELYVVVDNAEFQMLGSEAAVRHRVLEVVNHVDKLYQKLNFRVVLVGLEIWNSQDRFHVSPDPSVTLENLLTWQARQRTRRHLHDNVQLITGVDFTGTTVGFARVSAMCSHSSGAVNQDHSKNPVGVACTMAHEMGHNLGMDHDENVQGCRCQERFEAGRCIMAGSIGSSFPRMFSDCSQAYLESFLERPQSVCLANAPDLSHLVGGPVCGNLFVERGEQCDCGPPEDCRNRCCNSTTCQLAEGAQCAHGTCCQECKVKPAGELCRPKKDMCDLEEFCDGRHPECPEDAFQENGTPCSGGYCYNGACPTLAQQCQAFWGPGGQAAEESCFSYDILPGCKASRYRADMCGVLQCKGGQQPLGRAICIVDVCHALTTEDGTAYEPVPEGTRCGPEKVCWKGRCQDLHVYRSSNCSAQCHNHGVCNHKQECHCHAGWAPPHCAKLLTEVHAASGSLPVFVVVVLVLLAVVLVTLAGIIVYRKARSRILSRNVAPKTTMGRSNPLFHQAASRVPAKGGAPAPSRGPQELVPTTHPGQPARHPASSVALKRPPPAPPVTVSSPPFPVPVYTRQAPKQVIKPTFAPPVPPVKPGAGAANPGPAEGAVGPKVALKPPIQRKQGAGAPTAP T58924 TARGETID T58924 T58924 FORMERID TTDI03561 T58924 UNIPROID SRPK2_HUMAN T58924 TARGNAME SRSF protein kinase 2 (SRPK2) T58924 GENENAME SRPK2 T58924 TARGTYPE Literature-reported T58924 SYNONYMS Serine/arginine-rich protein-specific kinase 2; SR-protein-specific kinase 2; SFRS protein kinase 2 T58924 FUNCTION Promotes neuronal apoptosis by up-regulating cyclin-D1 (CCND1) expression. This is done by the phosphorylation of SRSF2, leading to the suppression of p53/TP53 phosphorylation thereby relieving the repressive effect of p53/TP53 on cyclin-D1 (CCND1) expression. Phosphorylates ACIN1, and redistributes it from the nuclear speckles to the nucleoplasm, resulting in cyclin A1 but not cyclin A2 up-regulation. Plays an essential role in spliceosomal B complex formation via the phosphorylation of DDX23/PRP28. Can mediate hepatitis B virus (HBV) core protein phosphorylation. Plays a negative role in the regulation of HBV replication through a mechanism not involving the phosphorylation of the core protein but by reducing the packaging efficiency of the pregenomic RNA (pgRNA) without affecting the formation of the viral core particles. Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is involved in the phosphorylation of SR splicing factors and the regulation of splicing. T58924 PDBSTRUC 5MYV; 2X7G T58924 BIOCLASS Kinase T58924 ECNUMBER EC 2.7.11.1 T58924 SEQUENCE MSVNSEKSSSSERPEPQQKAPLVPPPPPPPPPPPPPLPDPTPPEPEEEILGSDDEEQEDPADYCKGGYHPVKIGDLFNGRYHVIRKLGWGHFSTVWLCWDMQGKRFVAMKVVKSAQHYTETALDEIKLLKCVRESDPSDPNKDMVVQLIDDFKISGMNGIHVCMVFEVLGHHLLKWIIKSNYQGLPVRCVKSIIRQVLQGLDYLHSKCKIIHTDIKPENILMCVDDAYVRRMAAEATEWQKAGAPPPSGSAVSTAPQQKPIGKISKNKKKKLKKKQKRQAELLEKRLQEIEELEREAERKIIEENITSAAPSNDQDGEYCPEVKLKTTGLEEAAEAETAKDNGEAEDQEEKEDAEKENIEKDEDDVDQELANIDPTWIESPKTNGHIENGPFSLEQQLDDEDDDEEDCPNPEEYNLDEPNAESDYTYSSSYEQFNGELPNGRHKIPESQFPEFSTSLFSGSLEPVACGSVLSEGSPLTEQEESSPSHDRSRTVSASSTGDLPKAKTRAADLLVNPLDPRNADKIRVKIADLGNACWVHKHFTEDIQTRQYRSIEVLIGAGYSTPADIWSTACMAFELATGDYLFEPHSGEDYSRDEDHIAHIIELLGSIPRHFALSGKYSREFFNRRGELRHITKLKPWSLFDVLVEKYGWPHEDAAQFTDFLIPMLEMVPEKRASAGECLRHPWLNS T58924 DRUGINFO D07ADX URMC-099 Investigative T82773 TARGETID T82773 T82773 FORMERID TTDI03083 T82773 UNIPROID KC1G2_HUMAN T82773 TARGNAME Casein kinase I gamma-2 (CSNK1G2) T82773 GENENAME CSNK1G2 T82773 TARGTYPE Literature-reported T82773 SYNONYMS Casein kinase I isoform gamma-2; CKI-gamma 2; CK1G2 T82773 FUNCTION Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Phosphorylates COL4A3BP/CERT, MTA1 and SMAD3. Involved in brain development and vesicular trafficking and neurotransmitter releasing from small synaptic vesicles. Regulates fast synaptic transmission mediated by glutamate. SMAD3 phosphorylation promotes its ligand-dependent ubiquitination and subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF-beta responses. Hyperphosphorylation of the serine-repeat motif of COL4A3BP/CERT leads to its inactivation by dissociation from the Golgi complex, thus down-regulating ER-to-Golgi transport of ceramide and sphingomyelin synthesis. Triggers PER1 proteasomal degradation probably through phosphorylation. Serine/threonine-protein kinase. T82773 PDBSTRUC 2C47 T82773 BIOCLASS Kinase T82773 ECNUMBER EC 2.7.11.1 T82773 SEQUENCE MDFDKKGGKGETEEGRRMSKAGGGRSSHGIRSSGTSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEPIKSRAPQLHLEYRFYKQLSATEGVPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFTLKTVLMIAIQLITRMEYVHTKSLIYRDVKPENFLVGRPGTKRQHAIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEALGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRATPIEVLCENFPEEMATYLRYVRRLDFFEKPDYDYLRKLFTDLFDRSGFVFDYEYDWAGKPLPTPIGTVHTDLPSQPQLRDKTQPHSKNQALNSTNGELNADDPTAGHSNAPITAPAEVEVADETKCCCFFKRRKRKSLQRHK T82773 DRUGINFO D0H4VB PMID24900428C14 Investigative T08218 TARGETID T08218 T08218 FORMERID TTDR00023 T08218 UNIPROID RMLC_MYCTU T08218 TARGNAME Mycobacterium DTDP-dehydrorhamnose epimerase rmlC (MycB rmlC) T08218 GENENAME MycB rmlC T08218 TARGTYPE Literature-reported T08218 SYNONYMS dTDP-L-rhamnose synthase; dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase; dTDP-4-keto-6-deoxyglucose 3,5-epimerase; dTDP-4-dehydrorhamnose 3,5-epimerase; Thymidine diphospho-4-keto-rhamnose 3,5-epimerase T08218 FUNCTION Catalyzes the epimerization of the C3' and C5'positions of dTDP-6-deoxy-D-xylo-4-hexulose, forming dTDP-6-deoxy-L-lyxo-4-hexulose. Involved in the biosynthesis of the dTDP-L-rhamnose which is a component of the critical linker, D-N-acetylglucosamine-L-rhamnose disaccharide, which connects the galactan region of arabinogalactan to peptidoglycan via a phosphodiester linkage. T08218 PDBSTRUC 2IXC; 1UPI; 1PM7 T08218 BIOCLASS Racemases and epimerases T08218 ECNUMBER EC 5.1.3.13 T08218 SEQUENCE MKARELDVPGAWEITPTIHVDSRGLFFEWLTDHGFRAFAGHSLDVRQVNCSVSSAGVLRGLHFAQLPPSQAKYVTCVSGSVFDVVVDIREGSPTFGRWDSVLLDDQDRRTIYVSEGLAHGFLALQDNSTVMYLCSAEYNPQREHTICATDPTLAVDWPLVDGAAPSLSDRDAAAPSFEDVRASGLLPRWEQTQRFIGEMRGT T08218 DRUGINFO D0P7JE S,S-(2-Hydroxyethyl)Thiocysteine Investigative T81015 TARGETID T81015 T81015 FORMERID TTDR01089 T81015 UNIPROID PYRF_MYCTO T81015 TARGNAME Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF) T81015 GENENAME MycB pyrF T81015 TARGTYPE Literature-reported T81015 SYNONYMS Orotidine 5'-phosphate decarboxylase; OMPdecase; OMPDCase; OMP decarboxylase T81015 FUNCTION Catalyzes the decarboxylation of orotidine monophosphate (OMP), producing uridine monophosphate (UMP). T81015 BIOCLASS Carbon-carbon lyase T81015 ECNUMBER EC 4.1.1.23 T81015 SEQUENCE MTGFGLRLAEAKARRGPLCLGIDPHPELLRGWDLATTADGLAAFCDICVRAFADFAVVKPQVAFFESYGAAGFAVLERTIAELRAADVLVLADAKRGDIGATMSAYATAWVGDSPLAADAVTASPYLGFGSLRPLLEVAAAHGRGVFVLAATSNPEGAAVQNAAADGRSVAQLVVDQVGAANEAAGPGPGSIGVVVGATAPQAPDLSAFTGPVLVPGVGVQGGRPEALGGLGGAASSQLLPAVAREVLRAGPGVPELRAAGERMRDAVAYLAAV T81015 DRUGINFO D03GVL 6-aza-uridine monophosphate Investigative T81015 DRUGINFO D0ST0H Xanthosine-5'-monophosphate disodium salt Investigative T81015 DRUGINFO D0W3ZW 6-amino-uridine monophosphate Investigative T81015 DRUGINFO D0H9DJ Uridine-5'-Monophosphate Investigative T81015 DRUGINFO D0P0EP 6-Hydroxyuridine-5'-Phosphate Investigative T63851 TARGETID T63851 T63851 FORMERID TTDI03147 T63851 UNIPROID CDKL1_HUMAN T63851 TARGNAME Cyclin-dependent kinase-like 1 (CDKL1) T63851 GENENAME CDKL1 T63851 TARGTYPE Literature-reported T63851 SYNONYMS Serine/threonine-protein kinase KKIALRE; Protein kinase p42 KKIALRE T63851 FUNCTION Ciliary transition zone, extracellular exosome, intracellular membrane-bounded organelle, nucleoplasm, nucleus, cyclin-dependent protein serine/threonine kinase activity, protein phosphorylation, regulation of cilium assembly. T63851 PDBSTRUC 4AGU T63851 BIOCLASS Kinase T63851 ECNUMBER EC 2.7.11.22 T63851 SEQUENCE MMEKYEKIGKIGEGSYGVVFKCRNRDTGQIVAIKKFLESEDDPVIKKIALREIRMLKQLKHPNLVNLLEVFRRKRRLHLVFEYCDHTVLHELDRYQRGVPEHLVKSITWQTLQAVNFCHKHNCIHRDVKPENILITKHSVIKLCDFGFARLLAGPSDYYTDYVATRWYRSPELLVGDTQYGPPVDVWAIGCVFAELLSGVPLWPGKSDVDQLYLIRKTLGDLIPRHQQVFSTNQYFSGVKIPDPEDMEPLELKFPNISYPALGLLKGCLHMDPTQRLTCEQLLHHPYFENIREIEDLAKEHNKPTRKTLRKSRKHHCFTETSKLQYLPQLTGSSILPALDNKKYYCDTKKLNYRFPNI T63851 DRUGINFO D0P6JS PMID18986805C9b Investigative T53489 TARGETID T53489 T53489 FORMERID TTDR01230 T53489 UNIPROID CYB_PLAFA T53489 TARGNAME Plasmodium Cytochrome B (Malaria MT-CYB) T53489 GENENAME Malaria MT-CYB T53489 TARGTYPE Literature-reported T53489 SYNONYMS MT-CYB; Cyb T53489 FUNCTION Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis. T53489 BIOCLASS Cytochrome b family T53489 SEQUENCE MNFYSINLVKAHLINYPCPLNINFLWNYGFLLGIIFFIQIITGVFLASRYTPDVSYAYYSIQHILRELWSGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLPWGQMSYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMIFGARDYSVPIIWFMCAFYALLWIGCQLPQDIFILYGRLFIVLFFCSGLFVLVHYRRTHYDYSSQANI T53489 DRUGINFO D0C3YJ UBIQUINONE-2 Investigative T53489 DRUGINFO D0N7NB 5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole Investigative T53489 DRUGINFO D0O1FU FAMOXADONE Investigative T53489 DRUGINFO D0X4DY 2-NONYL-4-HYDROXYQUINOLINE N-OXIDE Investigative T53489 DRUGINFO D0YF6S 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione Investigative T53489 DRUGINFO D01ILH B-2-Octylglucoside Investigative T53489 DRUGINFO D02UVH B-Octylglucoside Investigative T87020 TARGETID T87020 T87020 FORMERID TTDR01039 T87020 UNIPROID FKBP4_HUMAN T87020 TARGNAME FK506-binding protein 4 (FKBP4) T87020 GENENAME FKBP4 T87020 TARGTYPE Literature-reported T87020 SYNONYMS p59; Peptidyl-prolyl cis-trans isomerase FKBP4; PPIase FKBP4; P59 protein; Immunophilin FKBP52; HSP-binding immunophilin; HSP binding immunophilin; HBI; FKBP59; FKBP52 protein; FKBP52; FKBP-52; FKBP-4; 59 kDa immunophilin; 52 kDa FKBP; 52 kDa FK506-binding protein; 52 kDa FK506 binding protein T87020 FUNCTION Component of steroid receptors heterocomplexes through interaction with heat-shock protein 90 (HSP90). May play a role in the intracellular trafficking of heterooligomeric forms of steroid hormone receptors between cytoplasm and nuclear compartments. The isomerase activity controls neuronal growth cones via regulation of TRPC1 channel opening. Acts also as a regulator of microtubule dynamics by inhibiting MAPT/TAU ability to promote microtubule assembly. May have a protective role against oxidative stress in mitochondria. Immunophilin protein with PPIase and co-chaperone activities. T87020 PDBSTRUC 4TW8; 4LAY; 4LAX; 4LAW; 4LAV T87020 BIOCLASS Cis-trans-isomerase T87020 ECNUMBER EC 5.2.1.8 T87020 SEQUENCE MTAEEMKATESGAQSAPLPMEGVDISPKQDEGVLKVIKREGTGTEMPMIGDRVFVHYTGWLLDGTKFDSSLDRKDKFSFDLGKGEVIKAWDIAIATMKVGEVCHITCKPEYAYGSAGSPPKIPPNATLVFEVELFEFKGEDLTEEEDGGIIRRIQTRGEGYAKPNEGAIVEVALEGYYKDKLFDQRELRFEIGEGENLDLPYGLERAIQRMEKGEHSIVYLKPSYAFGSVGKEKFQIPPNAELKYELHLKSFEKAKESWEMNSEEKLEQSTIVKERGTVYFKEGKYKQALLQYKKIVSWLEYESSFSNEEAQKAQALRLASHLNLAMCHLKLQAFSAAIESCNKALELDSNNEKGLFRRGEAHLAVNDFELARADFQKVLQLYPNNKAAKTQLAVCQQRIRRQLAREKKLYANMFERLAEEENKAKAEASSGDHPTDTEMKEEQKSNTAGSQSQVETEA T25462 TARGETID T25462 T25462 FORMERID TTDI00064 T25462 UNIPROID KMT2A_HUMAN T25462 TARGNAME Mixed-lineage leukemia protein (MLL) T25462 GENENAME KMT2A T25462 TARGTYPE Literature-reported T25462 SYNONYMS p320; p180; Zinc finger protein HRX; Trithoraxlike protein; Trithorax-like protein; Myeloid/lymphoid or mixed-lineage leukemia protein 1; Myeloid/lymphoid or mixed-lineage leukemia; MLL1; MLL cleavage product C180; Lysine Nmethyltransferase 2A; Lysine N-methyltransferase 2A; Histonelysine Nmethyltransferase MLL; Histone-lysine N-methyltransferase 2A; HTRX; HRX; CXXCtype zinc finger protein 7; CXXC7; CXXC-type zinc finger protein 7; ALL1; ALL-1 T25462 FUNCTION Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'. Binds to unmethylated CpG elements in the promoter of target genes and helps maintain them in the nonmethylated state. Required for transcriptional activation of HOXA9. Promotes PPP1R15A-induced apoptosis. Plays a critical role in the control of circadian gene expression and is essential for the transcriptional activation mediated by the CLOCK-ARNTL/BMAL1 heterodimer. Establishes a permissive chromatin state for circadian transcription by mediating a rhythmic methylation of 'Lys-4' of histone H3 (H3K4me) and this histone modification directs the circadian acetylation at H3K9 and H3K14 allowing the recruitment of CLOCK-ARNTL/BMAL1 to chromatin. Histone methyltransferase that plays an essential role in early development and hematopoiesis. T25462 PDBSTRUC 6EMQ; 5SVH; 5F6L; 5F5E; 4NW3 T25462 BIOCLASS Methyltransferase T25462 ECNUMBER EC 2.1.1.43 T25462 SEQUENCE MAHSCRWRFPARPGTTGGGGGGGRRGLGGAPRQRVPALLLPPGPPVGGGGPGAPPSPPAVAAAAAAAGSSGAGVPGGAAAASAASSSSASSSSSSSSSASSGPALLRVGPGFDAALQVSAAIGTNLRRFRAVFGESGGGGGSGEDEQFLGFGSDEEVRVRSPTRSPSVKTSPRKPRGRPRSGSDRNSAILSDPSVFSPLNKSETKSGDKIKKKDSKSIEKKRGRPPTFPGVKIKITHGKDISELPKGNKEDSLKKIKRTPSATFQQATKIKKLRAGKLSPLKSKFKTGKLQIGRKGVQIVRRRGRPPSTERIKTPSGLLINSELEKPQKVRKDKEGTPPLTKEDKTVVRQSPRRIKPVRIIPSSKRTDATIAKQLLQRAKKGAQKKIEKEAAQLQGRKVKTQVKNIRQFIMPVVSAISSRIIKTPRRFIEDEDYDPPIKIARLESTPNSRFSAPSCGSSEKSSAASQHSSQMSSDSSRSSSPSVDTSTDSQASEEIQVLPEERSDTPEVHPPLPISQSPENESNDRRSRRYSVSERSFGSRTTKKLSTLQSAPQQQTSSSPPPPLLTPPPPLQPASSISDHTPWLMPPTIPLASPFLPASTAPMQGKRKSILREPTFRWTSLKHSRSEPQYFSSAKYAKEGLIRKPIFDNFRPPPLTPEDVGFASGFSASGTAASARLFSPLHSGTRFDMHKRSPLLRAPRFTPSEAHSRIFESVTLPSNRTSAGTSSSGVSNRKRKRKVFSPIRSEPRSPSHSMRTRSGRLSSSELSPLTPPSSVSSSLSISVSPLATSALNPTFTFPSHSLTQSGESAEKNQRPRKQTSAPAEPFSSSSPTPLFPWFTPGSQTERGRNKDKAPEELSKDRDADKSVEKDKSRERDREREKENKRESRKEKRKKGSEIQSSSALYPVGRVSKEKVVGEDVATSSSAKKATGRKKSSSHDSGTDITSVTLGDTTAVKTKILIKKGRGNLEKTNLDLGPTAPSLEKEKTLCLSTPSSSTVKHSTSSIGSMLAQADKLPMTDKRVASLLKKAKAQLCKIEKSKSLKQTDQPKAQGQESDSSETSVRGPRIKHVCRRAAVALGRKRAVFPDDMPTLSALPWEEREKILSSMGNDDKSSIAGSEDAEPLAPPIKPIKPVTRNKAPQEPPVKKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCCKMRKCQNLQWMPSKAYLQKQAKAVKKKEKKSKTSEKKDSKESSVVKNVVDSSQKPTPSAREDPAPKKSSSEPPPRKPVEEKSEEGNVSAPGPESKQATTPASRKSSKQVSQPALVIPPQPPTTGPPRKEVPKTTPSEPKKKQPPPPESGPEQSKQKKVAPRPSIPVKQKPKEKEKPPPVNKQENAGTLNILSTLSNGNSSKQKIPADGVHRIRVDFKEDCEAENVWEMGGLGILTSVPITPRVVCFLCASSGHVEFVYCQVCCEPFHKFCLEENERPLEDQLENWCCRRCKFCHVCGRQHQATKQLLECNKCRNSYHPECLGPNYPTKPTKKKKVWICTKCVRCKSCGSTTPGKGWDAQWSHDFSLCHDCAKLFAKGNFCPLCDKCYDDDDYESKMMQCGKCDRWVHSKCENLSDEMYEILSNLPESVAYTCVNCTERHPAEWRLALEKELQISLKQVLTALLNSRTTSHLLRYRQAAKPPDLNPETEESIPSRSSPEGPDPPVLTEVSKQDDQQPLDLEGVKRKMDQGNYTSVLEFSDDIVKIIQAAINSDGGQPEIKKANSMVKSFFIRQMERVFPWFSVKKSRFWEPNKVSSNSGMLPNAVLPPSLDHNYAQWQEREENSHTEQPPLMKKIIPAPKPKGPGEPDSPTPLHPPTPPILSTDRSREDSPELNPPPGIEDNRQCALCLTYGDDSANDAGRLLYIGQNEWTHVNCALWSAEVFEDDDGSLKNVHMAVIRGKQLRCEFCQKPGATVGCCLTSCTSNYHFMCSRAKNCVFLDDKKVYCQRHRDLIKGEVVPENGFEVFRRVFVDFEGISLRRKFLNGLEPENIHMMIGSMTIDCLGILNDLSDCEDKLFPIGYQCSRVYWSTTDARKRCVYTCKIVECRPPVVEPDINSTVEHDENRTIAHSPTSFTESSSKESQNTAEIISPPSPDRPPHSQTSGSCYYHVISKVPRIRTPSYSPTQRSPGCRPLPSAGSPTPTTHEIVTVGDPLLSSGLRSIGSRRHSTSSLSPQRSKLRIMSPMRTGNTYSRNNVSSVSTTGTATDLESSAKVVDHVLGPLNSSTSLGQNTSTSSNLQRTVVTVGNKNSHLDGSSSSEMKQSSASDLVSKSSSLKGEKTKVLSSKSSEGSAHNVAYPGIPKLAPQVHNTTSRELNVSKIGSFAEPSSVSFSSKEALSFPHLHLRGQRNDRDQHTDSTQSANSSPDEDTEVKTLKLSGMSNRSSIINEHMGSSSRDRRQKGKKSCKETFKEKHSSKSFLEPGQVTTGEEGNLKPEFMDEVLTPEYMGQRPCNNVSSDKIGDKGLSMPGVPKAPPMQVEGSAKELQAPRKRTVKVTLTPLKMENESQSKNALKESSPASPLQIESTSPTEPISASENPGDGPVAQPSPNNTSCQDSQSNNYQNLPVQDRNLMLPDGPKPQEDGSFKRRYPRRSARARSNMFFGLTPLYGVRSYGEEDIPFYSSSTGKKRGKRSAEGQVDGADDLSTSDEDDLYYYNFTRTVISSGGEERLASHNLFREEEQCDLPKISQLDGVDDGTESDTSVTATTRKSSQIPKRNGKENGTENLKIDRPEDAGEKEHVTKSSVGHKNEPKMDNCHSVSRVKTQGQDSLEAQLSSLESSRRVHTSTPSDKNLLDTYNTELLKSDSDNNNSDDCGNILPSDIMDFVLKNTPSMQALGESPESSSSELLNLGEGLGLDSNREKDMGLFEVFSQQLPTTEPVDSSVSSSISAEEQFELPLELPSDLSVLTTRSPTVPSQNPSRLAVISDSGEKRVTITEKSVASSESDPALLSPGVDPTPEGHMTPDHFIQGHMDADHISSPPCGSVEQGHGNNQDLTRNSSTPGLQVPVSPTVPIQNQKYVPNSTDSPGPSQISNAAVQTTPPHLKPATEKLIVVNQNMQPLYVLQTLPNGVTQKIQLTSSVSSTPSVMETNTSVLGPMGGGLTLTTGLNPSLPTSQSLFPSASKGLLPMSHHQHLHSFPAATQSSFPPNISNPPSGLLIGVQPPPDPQLLVSESSQRTDLSTTVATPSSGLKKRPISRLQTRKNKKLAPSSTPSNIAPSDVVSNMTLINFTPSQLPNHPSLLDLGSLNTSSHRTVPNIIKRSKSSIMYFEPAPLLPQSVGGTAATAAGTSTISQDTSHLTSGSVSGLASSSSVLNVVSMQTTTTPTSSASVPGHVTLTNPRLLGTPDIGSISNLLIKASQQSLGIQDQPVALPPSSGMFPQLGTSQTPSTAAITAASSICVLPSTQTTGITAASPSGEADEHYQLQHVNQLLASKTGIHSSQRDLDSASGPQVSNFTQTVDAPNSMGLEQNKALSSAVQASPTSPGGSPSSPSSGQRSASPSVPGPTKPKPKTKRFQLPLDKGNGKKHKVSHLRTSSSEAHIPDQETTSLTSGTGTPGAEAEQQDTASVEQSSQKECGQPAGQVAVLPEVQVTQNPANEQESAEPKTVEEEESNFSSPLMLWLQQEQKRKESITEKKPKKGLVFEISSDDGFQICAESIEDAWKSLTDKVQEARSNARLKQLSFAGVNGLRMLGILHDAVVFLIEQLSGAKHCRNYKFRFHKPEEANEPPLNPHGSARAEVHLRKSAFDMFNFLASKHRQPPEYNPNDEEEEEVQLKSARRATSMDLPMPMRFRHLKKTSKEAVGVYRSPIHGRGLFCKRNIDAGEMVIEYAGNVIRSIQTDKREKYYDSKGIGCYMFRIDDSEVVDATMHGNAARFINHSCEPNCYSRVINIDGQKHIVIFAMRKIYRGEELTYDYKFPIEDASNKLPCNCGAKKCRKFLN T03453 TARGETID T03453 T03453 FORMERID TTDI03372 T03453 UNIPROID KIME_HUMAN T03453 TARGNAME Mevalonate kinase (MVK) T03453 GENENAME MVK T03453 TARGTYPE Literature-reported T03453 SYNONYMS POROK3; MVLK; LRBP T03453 FUNCTION Catalyzes the phosphorylation of mevalonate to mevalonate 5-phosphate, a key step in isoprenoid and cholesterol biosynthesis. T03453 PDBSTRUC 2R3V T03453 BIOCLASS Kinase T03453 ECNUMBER EC 2.7.1.36 T03453 SEQUENCE MLSEVLLVSAPGKVILHGEHAVVHGKVALAVSLNLRTFLRLQPHSNGKVDLSLPNIGIKRAWDVARLQSLDTSFLEQGDVTTPTSEQVEKLKEVAGLPDDCAVTERLAVLAFLYLYLSICRKQRALPSLDIVVWSELPPGAGLGSSAAYSVCLAAALLTVCEEIPNPLKDGDCVNRWTKEDLELINKWAFQGERMIHGNPSGVDNAVSTWGGALRYHQGKISSLKRSPALQILLTNTKVPRNTRALVAGVRNRLLKFPEIVAPLLTSIDAISLECERVLGEMGEAPAPEQYLVLEELIDMNQHHLNALGVGHASLDQLCQVTRARGLHSKLTGAGGGGCGITLLKPGLEQPEVEATKQALTSCGFDCLETSIGAPGVSIHSATSLDSRVQQALDGL T03453 DRUGINFO D0A5IX (RS)-5-diphosphomevalonate Investigative T03453 DRUGINFO D0P9IA dolichol phosphate Investigative T38584 TARGETID T38584 T38584 FORMERID TTDI02483 T38584 UNIPROID HGFA_HUMAN T38584 TARGNAME Hepatocyte growth factor activator (HGFAC) T38584 GENENAME HGFAC T38584 TARGTYPE Literature-reported T38584 SYNONYMS Hepatocyte growth factor activator long chain; HGFAC; HGFA; HGF activator T38584 FUNCTION Activates hepatocyte growth factor (HGF) by convertingit from a single chain to a heterodimeric form. T38584 PDBSTRUC 3K2U; 2WUC; 2WUB; 2R0L; 2R0K T38584 BIOCLASS Peptidase T38584 ECNUMBER EC 3.4.21.- T38584 SEQUENCE MGRWAWVPSPWPPPGLGPFLLLLLLLLLLPRGFQPQPGGNRTESPEPNATATPAIPTILVTSVTSETPATSAPEAEGPQSGGLPPPPRAVPSSSSPQAQALTEDGRPCRFPFRYGGRMLHACTSEGSAHRKWCATTHNYDRDRAWGYCVEATPPPGGPAALDPCASGPCLNGGSCSNTQDPQSYHCSCPRAFTGKDCGTEKCFDETRYEYLEGGDRWARVRQGHVEQCECFGGRTWCEGTRHTACLSSPCLNGGTCHLIVATGTTVCACPPGFAGRLCNIEPDERCFLGNGTGYRGVASTSASGLSCLAWNSDLLYQELHVDSVGAAALLGLGPHAYCRNPDNDERPWCYVVKDSALSWEYCRLEACESLTRVQLSPDLLATLPEPASPGRQACGRRHKKRTFLRPRIIGGSSSLPGSHPWLAAIYIGDSFCAGSLVHTCWVVSAAHCFSHSPPRDSVSVVLGQHFFNRTTDVTQTFGIEKYIPYTLYSVFNPSDHDLVLIRLKKKGDRCATRSQFVQPICLPEPGSTFPAGHKCQIAGWGHLDENVSGYSSSLREALVPLVADHKCSSPEVYGADISPNMLCAGYFDCKSDACQGDSGGPLACEKNGVAYLYGIISWGDGCGRLHKPGVYTRVANYVDWINDRIRPPRRLVAPS T87376 TARGETID T87376 T87376 FORMERID TTDR00905 T87376 UNIPROID UBE3A_HUMAN T87376 TARGNAME Renal carcinoma antigen NY-REN-54 (UBE3A) T87376 GENENAME UBE3A T87376 TARGTYPE Literature-reported T87376 SYNONYMS Ubiquitin-protein ligase E3A; Oncogenic protein-associated protein E6-AP; Human papillomavirus E6-associated protein; HPVE6A; HECT-type ubiquitin transferase E3A; EPVE6AP; E6AP ubiquitin-protein ligase; E6AP T87376 FUNCTION Several substrates have been identified including the ARNTL/BMAL1, ARC, RAD23A and RAD23B, MCM7 (which is involved in DNA replication), annexin A1, the PML tumor suppressor, and the cell cycle regulator CDKN1B. Additionally, may function as a cellular quality control ubiquitin ligase by helping the degradation of the cytoplasmic misfolded proteins. Finally, UBE3A also promotes its own degradation in vivo. Plays an important role in the regulation of the circadian clock: involved in the ubiquitination of the core clock component ARNTL/BMAL1, leading to its proteasomal degradation. Acts as transcriptional coactivator of progesterone receptor PGR upon progesterone hormone activation. Acts as a regulator of synaptic development by mediating ubiquitination and degradation of ARC. Synergizes with WBP2 in enhancing PGR activity. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and transfers it to its substrates. T87376 PDBSTRUC 4XR8; 4GIZ; 2KR1; 1EQX; 1D5F T87376 BIOCLASS Acyltransferase T87376 ECNUMBER EC 2.3.2.26 T87376 SEQUENCE MEKLHQCYWKSGEPQSDDIEASRMKRAAAKHLIERYYHQLTEGCGNEACTNEFCASCPTFLRMDNNAAAIKALELYKINAKLCDPHPSKKGASSAYLENSKGAPNNSCSEIKMNKKGARIDFKDVTYLTEEKVYEILELCREREDYSPLIRVIGRVFSSAEALVQSFRKVKQHTKEELKSLQAKDEDKDEDEKEKAACSAAAMEEDSEASSSRIGDSSQGDNNLQKLGPDDVSVDIDAIRRVYTRLLSNEKIETAFLNALVYLSPNVECDLTYHNVYSRDPNYLNLFIIVMENRNLHSPEYLEMALPLFCKAMSKLPLAAQGKLIRLWSKYNADQIRRMMETFQQLITYKVISNEFNSRNLVNDDDAIVAASKCLKMVYYANVVGGEVDTNHNEEDDEEPIPESSELTLQELLGEERRNKKGPRVDPLETELGVKTLDCRKPLIPFEEFINEPLNEVLEMDKDYTFFKVETENKFSFMTCPFILNAVTKNLGLYYDNRIRMYSERRITVLYSLVQGQQLNPYLRLKVRRDHIIDDALVRLEMIAMENPADLKKQLYVEFEGEQGVDEGGVSKEFFQLVVEEIFNPDIGMFTYDESTKLFWFNPSSFETEGQFTLIGIVLGLAIYNNCILDVHFPMVVYRKLMGKKGTFRDLGDSHPVLYQSLKDLLEYEGNVEDDMMITFQISQTDLFGNPMMYDLKENGDKIPITNENRKEFVNLYSDYILNKSVEKQFKAFRRGFHMVTNESPLKYLFRPEEIELLICGSRNLDFQALEETTEYDGGYTRDSVLIREFWEIVHSFTDEQKRLFLQFTTGTDRAPVGGLGKLKMIIAKNGPDTERLPTSHTCFNVLLLPEYSSKEKLKERLLKAITYAKGFGML T25200 TARGETID T25200 T25200 FORMERID TTDI02446 T25200 UNIPROID RN5A_HUMAN T25200 TARGNAME Ribonuclease L (RNASEL) T25200 GENENAME RNASEL T25200 TARGTYPE Literature-reported T25200 SYNONYMS Ribonuclease 4; RNase L; RNS4; 25Adependent ribonuclease; 25Adependent RNase; 2-5A-dependent ribonuclease; 2-5A-dependent RNase T25200 FUNCTION In INF treated and virus infected cells, RNASEL probably mediates its antiviral effects through a combination of direct cleavage of single-stranded viral RNAs, inhibition of protein synthesis through the degradation of rRNA, induction of apoptosis, and induction of other antiviral genes. RNASEL mediated apoptosis is the result of a JNK-dependent stress-response pathway leading to cytochrome c release from mitochondria and caspase-dependent apoptosis. Therefore, activation of RNASEL could lead to elimination of virus infected cells under some circumstances. In the crosstalk between autophagy and apoptosis proposed to induce autophagy as an early stress response to small double-stranded RNA and at later stages of prolonged stress to activate caspase-dependent proteolytic cleavage of BECN1 to terminate autophagy and promote apoptosis. Might play a central role in the regulation of mRNA turnover. Cleaves 3' of UpNp dimers, with preference for UU and UA sequences, to sets of discrete products ranging from between 4 and 22 nucleotides in length. Endoribonuclease that functions in the interferon (IFN) antiviral response. T25200 PDBSTRUC 4OAV; 4OAU; 4G8L; 4G8K; 1WDY T25200 BIOCLASS Endoribonucleases T25200 ECNUMBER EC 3.1.26.- T25200 SEQUENCE MESRDHNNPQEGPTSSSGRRAAVEDNHLLIKAVQNEDVDLVQQLLEGGANVNFQEEEGGWTPLHNAVQMSREDIVELLLRHGADPVLRKKNGATPFILAAIAGSVKLLKLFLSKGADVNECDFYGFTAFMEAAVYGKVKALKFLYKRGANVNLRRKTKEDQERLRKGGATALMDAAEKGHVEVLKILLDEMGADVNACDNMGRNALIHALLSSDDSDVEAITHLLLDHGADVNVRGERGKTPLILAVEKKHLGLVQRLLEQEHIEINDTDSDGKTALLLAVELKLKKIAELLCKRGASTDCGDLVMTARRNYDHSLVKVLLSHGAKEDFHPPAEDWKPQSSHWGAALKDLHRIYRPMIGKLKFFIDEKYKIADTSEGGIYLGFYEKQEVAVKTFCEGSPRAQREVSCLQSSRENSHLVTFYGSESHRGHLFVCVTLCEQTLEACLDVHRGEDVENEEDEFARNVLSSIFKAVQELHLSCGYTHQDLQPQNILIDSKKAAHLADFDKSIKWAGDPQEVKRDLEDLGRLVLYVVKKGSISFEDLKAQSNEEVVQLSPDEETKDLIHRLFHPGEHVRDCLSDLLGHPFFWTWESRYRTLRNVGNESDIKTRKSESEILRLLQPGPSEHSKSFDKWTTKINECVMKKMNKFYEKRGNFYQNTVGDLLKFIRNLGEHIDEEKHKKMKLKIGDPSLYFQKTFPDLVIYVYTKLQNTEYRKHFPQTHSPNKPQCDGAGGASGLASPGC T59130 TARGETID T59130 T59130 FORMERID TTDR00637 T59130 UNIPROID TPIS_PLAFA T59130 TARGNAME Bacterial Triosephosphate isomerase (Bact TPI) T59130 GENENAME Bact TPI T59130 TARGTYPE Literature-reported T59130 SYNONYMS Triose-phosphate isomerase; TPI; TIM T59130 FUNCTION identical protein binding, triose-phosphate isomerase activity. T59130 PDBSTRUC 5GZP; 5GV4; 5BRB; 5BNK; 5BMX T59130 BIOCLASS Intramolecular oxidoreductase T59130 ECNUMBER EC 5.3.1.1 T59130 SEQUENCE MARKYFVAANWKCNGTLESIKSLTNSFNNLDFDPSKLDVVVFPVSVHYDHTRKLLQSKFSTGIQNVSKFGNGSYTGEVSAEIAKDLNIEYVIIGHFERRKYFHETDEDVREKLQASLKNNLKAVVCFGESLEQREQNKTIEVITKQVKAFVDLIDNFDNVILAYEPLWAIGTGKTATPEQAQLVHKEIRKIVKDTCGEKQANQIRILYGGSVNTENCSSLIQQEDIDGFLVGNASLKESFVDIIKSAM T59130 DRUGINFO D08XXE 2-Phosphoglycolic Acid Investigative T59130 DRUGINFO D0MN3X Glycerol-2-Phosphate Investigative T59130 DRUGINFO D0Q7SY 3-Hydroxypyruvic Acid Investigative T59130 DRUGINFO D03MUW 3-Phosphoglycerol Investigative T59130 DRUGINFO D0WQ7U 3-Phosphoglyceric Acid Investigative T59130 DRUGINFO D03KBV 2-Phosphoglyceric Acid Investigative T83284 TARGETID T83284 T83284 FORMERID TTDI02224 T83284 UNIPROID QOR_HUMAN T83284 TARGNAME Quinone oxidoreductase (CRYZ) T83284 GENENAME CRYZ T83284 TARGTYPE Literature-reported T83284 SYNONYMS Zeta-crystallin; NADPH:quinone reductase; CRYZ T83284 FUNCTION Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones, such as 1,2-naphthoquinone or 9,10-phenanthrenequinone, are the best substrates (in vitro). May act in the detoxification of xenobiotics. Interacts with (AU)-rich elements (ARE) in the 3'-UTR of target mRNA species. Enhances the stability of mRNA coding for BCL2. NADPH binding interferes with mRNA binding. T83284 PDBSTRUC 1YB5 T83284 ECNUMBER EC 1.6.5.5 T83284 SEQUENCE MATGQKLMRAVRVFEFGGPEVLKLRSDIAVPIPKDHQVLIKVHACGVNPVETYIRSGTYSRKPLLPYTPGSDVAGVIEAVGDNASAFKKGDRVFTSSTISGGYAEYALAADHTVYKLPEKLDFKQGAAIGIPYFTAYRALIHSACVKAGESVLVHGASGGVGLAACQIARAYGLKILGTAGTEEGQKIVLQNGAHEVFNHREVNYIDKIKKYVGEKGIDIIIEMLANVNLSKDLSLLSHGGRVIVVGSRGTIEINPRDTMAKESSIIGVTLFSSTKEEFQQYAAALQAGMEIGWLKPVIGSQYPLEKVAEAHENIIHGSGATGKMILLL T14557 TARGETID T14557 T14557 FORMERID TTDI01973 T14557 UNIPROID I10R2_HUMAN T14557 TARGNAME Interleukin 10 receptor (IL10RB) T14557 GENENAME IL10RB T14557 TARGTYPE Literature-reported T14557 SYNONYMS Interleukin-10 receptor subunit beta; Interleukin-10 receptor subunit 2; IL-10RB; IL-10R2; IL-10R subunit beta; IL-10R subunit 2; IL-10 receptor subunit beta; D21S66; D21S58; Cytokine receptor family 2 member 4; Cytokine receptor class-II member 4; CRFB4; CRF2-4; CDw210b T14557 FUNCTION The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. The ligand/receptor complex stimulate the activation of the JAK/STAT signaling pathway leading to the expression of IFN-stimulated genes (ISG), which contribute to the antiviral state. Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1. T14557 PDBSTRUC 5T5W; 3LQM T14557 BIOCLASS Cytokine receptor T14557 SEQUENCE MAWSLGSWLGGCLLVSALGMVPPPENVRMNSVNFKNILQWESPAFAKGNLTFTAQYLSYRIFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDWVNITFCPVDDTIIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYNSWTYNVQYWKNGTDEKFQITPQYDFEVLRNLEPWTTYCVQVRGFLPDRNKAGEWSEPVCEQTTHDETVPSWMVAVILMASVFMVCLALLGCFALLWCVYKKTKYAFSPRNSLPQHLKEFLGHPHHNTLLFFSFPLSDENDVFDKLSVIAEDSESGKQNPGDSCSLGTPPGQGPQS T14557 DRUGINFO D02JRD VT-310 Investigative T14557 DRUGINFO D0A9TR XT-101 Investigative T14557 DRUGINFO D0I7VI EG-10 Investigative T97655 TARGETID T97655 T97655 FORMERID TTDR00173 T97655 UNIPROID ADCY2_HUMAN T97655 TARGNAME Adenylate cyclase type 2 (ADCY2) T97655 GENENAME ADCY2 T97655 TARGTYPE Literature-reported T97655 SYNONYMS ADCY2 T97655 FUNCTION This is a membrane-bound, calmodulin-insensitive adenylyl cyclase. T97655 BIOCLASS Phosphorus-oxygen lyase T97655 ECNUMBER EC 4.6.1.1 T97655 SEQUENCE MWQEAMRRRRYLRDRSEEAAGGGDGLPRSRDWLYESYYCMSQQHPLIVFLLLIVMGSCLALLAVFFALGLEVEDHVAFLITVPTALAIFFAIFILVCIESVFKKLLRLFSLVIWICLVAMGYLFMCFGGTVSPWDQVSFFLFIIFVVYTMLPFNMRDAIIASVLTSSSHTIVLSVCLSATPGGKEHLVWQILANVIIFICGNLAGAYHKHLMELALQQTYQDTCNCIKSRIKLEFEKRQQERLLLSLLPAHIAMEMKAEIIQRLQGPKAGQMENTNNFHNLYVKRHTNVSILYADIVGFTRLASDCSPGELVHMLNELFGKFDQIAKENECMRIKILGDCYYCVSGLPISLPNHAKNCVKMGLDMCEAIKKVRDATGVDINMRVGVHSGNVLCGVIGLQKWQYDVWSHDVTLANHMEAGGVPGRVHISSVTLEHLNGAYKVEEGDGDIRDPYLKQHLVKTYFVINPKGERRSPQHLFRPRHTLDGAKMRASVRMTRYLESWGAAKPFAHLHHRDSMTTENGKISTTDVPMGQHNFQNRTLRTKSQKKRFEEELNERMIQAIDGINAQKQWLKSEDIQRISLLFYNKVLEKEYRATALPAFKYYVTCACLIFFCIFIVQILVLPKTSVLGISFGAAFLLLAFILFVCFAGQLLQCSKKASPLLMWLLKSSGIIANRPWPRISLTIITTAIILMMAVFNMFFLSDSEETIPPTANTTNTSFSASNNQVAILRAQNLFFLPYFIYSCILGLISCSVFLRVNYELKMLIMMVALVGYNTILLHTHAHVLGDYSQVLFERPGIWKDLKTMGSVSLSIFFITLLVLGRQNEYYCRLDFLWKNKFKKEREEIETMENLNRVLLENVLPAHVAEHFLARSLKNEELYHQSYDCVCVMFASIPDFKEFYTESDVNKEGLECLRLLNEIIADFDDLLSKPKFSGVEKIKTIGSTYMAATGLSAVPSQEHSQEPERQYMHIGTMVEFAFALVGKLDAINKHSFNDFKLRVGINHGPVIAGVIGAQKPQYDIWGNTVNVASRMDSTGVLDKIQVTEETSLVLQTLGYTCTCRGIINVKGKGDLKTYFVNTEMSRSLSQSNVAS T97655 DRUGINFO D0K7HT 2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE Investigative T97655 DRUGINFO D0Y7VM Forskolin Investigative T85272 TARGETID T85272 T85272 FORMERID TTDI02460 T85272 UNIPROID KCNA1_HUMAN T85272 TARGNAME Voltage-gated potassium channel Kv1.1 (KCNA1) T85272 GENENAME KCNA1 T85272 TARGTYPE Literature-reported T85272 SYNONYMS Voltagegated potassium channel subunit Kv1.1; Voltagegated potassium channel HBK1; Voltagegated K(+) channel HuKI; Potassium voltagegated channel subfamily A member 1; KCNA1 T85272 FUNCTION Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium- selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:19912772). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, KCNA6, KCNA7, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (PubMed:12077175, PubMed:17156368). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation of delayed rectifier potassium channels (PubMed:12077175, PubMed:17156368). In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Homotetrameric KCNA1 forms a delayed-rectifier potassium channel that opens inresponse to membrane depolarization, followed by slow spontaneous channel closure (PubMed:19912772, PubMed:19968958, PubMed:19307729, PubMed:19903818). In contrast, a heterotetrameric channel formed by KCNA1 and KCNA4 shows rapid inactivation (PubMed:17156368). Regulates neuronal excitability in hippocampus, especially in mossy fibers and medial perforant path axons, preventing neuronal hyperexcitability. Response to toxins that are selective for KCNA1, respectively for KCNA2, suggests that heteromeric potassium channels composed of both KCNA1 and KCNA2 play a role in pacemaking and regulate the output of deep cerebellar nuclear neurons. May function as down- stream effector for G protein-coupled receptors and inhibit GABAergic inputs to basolateral amygdala neurons. May contribute to the regulation of neurotransmitter release, such as gamma-aminobutyric acid (GABA) release. Plays a role in regulating the generation of action potentials and preventing hyperexcitability in myelinated axons of the vagus nerve, and thereby contributes to the regulation of heart contraction. Required for normal neuromuscular responses (PubMed:11026449, PubMed:17136396). Regulates the frequency of neuronal action potential firing in response to mechanical stimuli, and plays a role in the perception of pain caused by mechanical stimuli,but does not play a role in the perception of pain due to heat stimuli. Required for normal responses to auditory stimuli and precise location of sound sources, but not for sound perception. The use of toxins that block specific channels suggest that it contributes to the regulation of the axonal release of the neurotransmitter dopamine. Required for normal postnatal brain development and normal proliferation of neuronal precursor cells in the brain. Plays a role in the reabsorption of Mg(2+) in the distal convoluted tubules in the kidney and in magnesium ion homeostasis, probably via its effect on the membrane potential (PubMed:23903368, PubMed:19307729). T85272 PDBSTRUC 2AFL T85272 BIOCLASS Voltage-gated ion channel T85272 SEQUENCE MTVMSGENVDEASAAPGHPQDGSYPRQADHDDHECCERVVINISGLRFETQLKTLAQFPNTLLGNPKKRMRYFDPLRNEYFFDRNRPSFDAILYYYQSGGRLRRPVNVPLDMFSEEIKFYELGEEAMEKFREDEGFIKEEERPLPEKEYQRQVWLLFEYPESSGPARVIAIVSVMVILISIVIFCLETLPELKDDKDFTGTVHRIDNTTVIYNSNIFTDPFFIVETLCIIWFSFELVVRFFACPSKTDFFKNIMNFIDIVAIIPYFITLGTEIAEQEGNQKGEQATSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEAEEAESHFSSIPDAFWWAVVSMTTVGYGDMYPVTIGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEGEEQAQLLHVSSPNLASDSDLSRRSSSTMSKSEYMEIEEDMNNSIAHYRQVNIRTANCTTANQNCVNKSKLLTDV T85272 DRUGINFO D02VKU mast cell degranulating peptide Investigative T85272 DRUGINFO D06PZZ [14C]TEA Investigative T52133 TARGETID T52133 T52133 FORMERID TTDI02424 T52133 UNIPROID ASPH_HUMAN T52133 TARGNAME Aspartate beta-hydroxylase (ASPH) T52133 GENENAME ASPH T52133 TARGTYPE Literature-reported T52133 SYNONYMS Peptideaspartate betadioxygenase; Aspartyl/asparaginyl betahydroxylase; ASPH; ASP betahydroxylase T52133 FUNCTION Isoform 8: membrane-bound Ca(2+)-sensing protein, which is a structural component of the ER-plasma membrane junctions. Isoform 8 regulates the activity of Ca(+2) released-activated Ca(+2) (CRAC) channels in T-cells. {ECO:0000269|PubMed:22586105}. T52133 PDBSTRUC 6RK9; 5JZU; 5JZA; 5JZ8; 5JZ6 T52133 BIOCLASS Paired donor oxygen oxidoreductase T52133 ECNUMBER EC 1.14.11.16 T52133 SEQUENCE MAQRKNAKSSGNSSSSGSGSGSTSAGSSSPGARRETKHGGHKNGRKGGLSGTSFFTWFMVIALLGVWTSVAVVWFDLVDYEEVLGKLGIYDADGDGDFDVDDAKVLLGLKERSTSEPAVPPEEAEPHTEPEEQVPVEAEPQNIEDEAKEQIQSLLHEMVHAEHVEGEDLQQEDGPTGEPQQEDDEFLMATDVDDRFETLEPEVSHEETEHSYHVEETVSQDCNQDMEEMMSEQENPDSSEPVVEDERLHHDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPEDNPVEDSQVIVEEVSIFPVEEQQEVPPETNRKTDDPEQKAKVKKKKPKLLNKFDKTIKAELDAAEKLRKRGKIEEAVNAFKELVRKYPQSPRARYGKAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLKLSLKRRSDRQQFLGHMRGSLLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEVLSVTPNDGFAKVHYGFILKAQNKIAESIPYLKEGIESGDPGTDDGRFYFHLGDAMQRVGNKEAYKWYELGHKRGHFASVWQRSLYNVNGLKAQPWWTPKETGYTELVKSLERNWKLIRDEGLAVMDKAKGLFLPEDENLREKGDWSQFTLWQQGRRNENACKGAPKTCTLLEKFPETTGCRRGQIKYSIMHPGTHVWPHTGPTNCRLRMHLGLVIPKEGCKIRCANETKTWEEGKVLIFDDSFEHEVWQDASSFRLIFIVDVWHPELTPQQRRSLPAI T60897 TARGETID T60897 T60897 FORMERID TTDI00242 T60897 UNIPROID TP4A2_HUMAN T60897 TARGNAME Protein tyrosine phosphatase IVA 2 (PRL-2) T60897 GENENAME PTP4A2 T60897 TARGTYPE Literature-reported T60897 SYNONYMS Protein-tyrosine phosphatase of regenerating liver 2; Protein-tyrosine phosphatase 4a2; Protein tyrosine phosphatase type IVA 2; PTPCAAX2; PTP(CAAXII); PRL2; OV-1; HU-PP-1; BM-008 T60897 FUNCTION Promotes tumors. Inhibits geranylgeranyl transferase type II activity by blocking the association between RABGGTA and RABGGTB. Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis. T60897 PDBSTRUC 5K25; 5K23; 5K22 T60897 BIOCLASS Phosphoric monoester hydrolase T60897 ECNUMBER EC 3.1.3.48 T60897 SEQUENCE MNRPAPVEISYENMRFLITHNPTNATLNKFTEELKKYGVTTLVRVCDATYDKAPVEKEGIHVLDWPFDDGAPPPNQIVDDWLNLLKTKFREEPGCCVAVHCVAGLGRAPVLVALALIECGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRFRDTNGHCCVQ T98179 TARGETID T98179 T98179 FORMERID TTDR01018 T98179 UNIPROID COASY_HUMAN T98179 TARGNAME Phosphopantetheine adenylyltransferase (PPAT) T98179 GENENAME COASY T98179 TARGTYPE Literature-reported T98179 SYNONYMS Pantetheine-phosphate adenylyltransferase; Dephospho-CoA pyrophosphorylase; COASY T98179 FUNCTION Bifunctional enzyme that catalyzes the fourth and fifth sequential steps of CoA biosynthetic pathway. The fourth reaction is catalyzed by the phosphopantetheine adenylyltransferase, coded by the coaD domain; the fifth reaction is catalyzed by the dephospho-CoA kinase, coded by the coaE domain. May act as a point of CoA biosynthesis regulation. T98179 BIOCLASS Kinase T98179 ECNUMBER EC 2.7.7.3 T98179 SEQUENCE VAGSPKQPVRGYYRGAVGGTFDRLHNAHKVLLSVACILAQEQLVVGVADKDLLKSKLLPELLQPYTERVEHLSEFLVDIKPSLTFDVIPLLDPYGPAGSDPSLEFLVVSEETYRGGMAINRFRLENDLEELALYQIQLLKDLRHTENEEDKVSSSSFRQRMLGNLLRPPYERPELPTCL T98179 DRUGINFO D03CIN PTX-007011 Terminated T98179 DRUGINFO D09HSI 4'-Phosphopantetheine Investigative T98179 DRUGINFO D0SK8U Dephospho Coenzyme A Investigative T98179 DRUGINFO D0W3NA Coenzyme A Investigative T98179 DRUGINFO D06GOK 2-Methyl-2,4-Pentanediol Investigative T37961 TARGETID T37961 T37961 FORMERID TTDI03430 T37961 UNIPROID PAK1_HUMAN T37961 TARGNAME PAK-1 protein kinase (PAK1) T37961 GENENAME PAK1 T37961 TARGTYPE Literature-reported T37961 SYNONYMS p65-PAK; p21-activated kinase 1; Serine/threonine-protein kinase PAK 1; PAK-1; Alpha-PAK T37961 FUNCTION Can directly phosphorylate BAD and protects cells against apoptosis. Activated by interaction with CDC42 and RAC1. Functions as GTPase effector that links the Rho-related GTPases CDC42 and RAC1 to the JNK MAP kinase pathway. Phosphorylates and activates MAP2K1, and thereby mediates activation of downstream MAP kinases. Involved in the reorganization of the actin cytoskeleton, actin stress fibers and of focal adhesion complexes. Phosphorylates the tubulin chaperone TBCB and thereby plays a role in the regulation of microtubule biogenesis and organization of the tubulin cytoskeleton. Plays a role in the regulation of insulin secretion in response to elevated glucose levels. Part of a ternary complex that contains PAK1, DVL1 and MUSK that is important for MUSK-dependent regulation of AChR clustering during the formation of the neuromuscular junction (NMJ). Activity is inhibited in cells undergoing apoptosis, potentially due to binding of CDC2L1 and CDC2L2. Phosphorylates MYL9/MLC2. Phosphorylates RAF1 at 'Ser-338' and 'Ser-339' resulting in: activation of RAF1, stimulation of RAF1 translocation to mitochondria, phosphorylation of BAD by RAF1, and RAF1 binding to BCL2. Phosphorylates SNAI1 at 'Ser-246' promoting its transcriptional repressor activity by increasing its accumulation in the nucleus. In podocytes, promotes NR3C2 nuclear localization. Required for atypical chemokine receptor ACKR2-induced phosphorylation of LIMK1 and cofilin (CFL1) and for the up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. In synapses, seems to mediate the regulation of F-actin cluster formation performed by SHANK3, maybe through CFL1 phosphorylation and inactivation. Plays a role in RUFY3-mediated facilitating gastric cancer cells migration and invasion. In response to DNA damage, phosphorylates MORC2 which activates its ATPase activity and facilitates chromatin remodeling. Protein kinase involved in intracellular signaling pathways downstream of integrins and receptor-type kinases that plays an important role in cytoskeleton dynamics, in cell adhesion, migration, proliferation, apoptosis, mitosis, and in vesicle-mediated transport processes. T37961 PDBSTRUC 6B16; 5KBR; 5KBQ; 5IME; 5DFP T37961 BIOCLASS Kinase T37961 ECNUMBER EC 2.7.11.1 T37961 SEQUENCE MSNNGLDIQDKPPAPPMRNTSTMIGAGSKDAGTLNHGSKPLPPNPEEKKKKDRFYRSILPGDKTNKKKEKERPEISLPSDFEHTIHVGFDAVTGEFTGMPEQWARLLQTSNITKSEQKKNPQAVLDVLEFYNSKKTSNSQKYMSFTDKSAEDYNSSNALNVKAVSETPAVPPVSEDEDDDDDDATPPPVIAPRPEHTKSVYTRSVIEPLPVTPTRDVATSPISPTENNTTPPDALTRNTEKQKKKPKMSDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRDIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNH T37961 DRUGINFO D07ORL Il-94 Investigative T37961 DRUGINFO D0L2WP PMID20005102C1 Investigative T37961 DRUGINFO D03CPB RKI-1447 Investigative T76888 TARGETID T76888 T76888 FORMERID TTDI02430 T76888 UNIPROID PRDX4_HUMAN T76888 TARGNAME Peroxiredoxin-4 (PRDX4) T76888 GENENAME PRDX4 T76888 TARGTYPE Literature-reported T76888 SYNONYMS Thioredoxindependent peroxide reductase A0372; Thioredoxin peroxidase AO372; PrxIV; Peroxiredoxin4; Peroxiredoxin IV; PRDX4; Antioxidant enzyme AOE372; AOE372 T76888 FUNCTION Probably involved in redox regulation of the cell. Regulates the activation of NF-kappa-B in the cytosol by a modulation of I-kappa-B-alpha phosphorylation. T76888 PDBSTRUC 5HQP; 4RQX; 3TKS; 3TKR; 3TKQ T76888 BIOCLASS Peroxidases T76888 ECNUMBER EC 1.11.1.15 T76888 SEQUENCE MEALPLLAATTPDHGRHRRLLLLPLLLFLLPAGAVQGWETEERPRTREEECHFYAGGQVYPGEASRVSVADHSLHLSKAKISKPAPYWEGTAVIDGEFKELKLTDYRGKYLVFFFYPLDFTFVCPTEIIAFGDRLEEFRSINTEVVACSVDSQFTHLAWINTPRRQGGLGPIRIPLLSDLTHQISKDYGVYLEDSGHTLRGLFIIDDKGILRQITLNDLPVGRSVDETLRLVQAFQYTDKHGEVCPAGWKPGSETIIPDPAGKLKYFDKLN T07766 TARGETID T07766 T07766 FORMERID TTDI03431 T07766 UNIPROID PAK2_HUMAN T07766 TARGNAME PAK-2 protein kinase (PAK2) T07766 GENENAME PAK2 T07766 TARGTYPE Literature-reported T07766 SYNONYMS p21-activated kinase 2; Serine/threonine-protein kinase PAK 2; S6/H4 kinase; PAK65; PAK-2; Gamma-PAK T07766 FUNCTION Acts as downstream effector of the small GTPases CDC42 and RAC1. Activation by the binding of active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Full-length PAK2 stimulates cell survival and cell growth. Phosphorylates MAPK4 and MAPK6 and activates the downstream target MAPKAPK5, a regulator of F-actin polymerization and cell migration. Phosphorylates JUN and plays an important role in EGF-induced cell proliferation. Phosphorylates many other substrates including histone H4 to promote assembly of H3. 3 and H4 into nucleosomes, BAD, ribosomal protein S6, or MBP. Additionally, associates with ARHGEF7 and GIT1 to perform kinase-independent functions such as spindle orientation control during mitosis. On the other hand, apoptotic stimuli such as DNA damage lead to caspase-mediated cleavage of PAK2, generating PAK-2p34, an active p34 fragment that translocates to the nucleus and promotes cellular apoptosis involving the JNK signaling pathway. Caspase-activated PAK2 phosphorylates MKNK1 and reduces cellular translation. Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell motility, cell cycle progression, apoptosis or proliferation. T07766 PDBSTRUC 3PCS T07766 BIOCLASS Kinase T07766 ECNUMBER EC 2.7.11.1 T07766 SEQUENCE MSDNGELEDKPPAPPVRMSSTIFSTGGKDPLSANHSLKPLPSVPEEKKPRHKIISIFSGTEKGSKKKEKERPEISPPSDFEHTIHVGFDAVTGEFTGMPEQWARLLQTSNITKLEQKKNPQAVLDVLKFYDSNTVKQKYLSFTPPEKDGFPSGTPALNAKGTEAPAVVTEEEDDDEETAPPVIAPRPDHTKSIYTRSVIDPVPAPVGDSHVDGAAKSLDKQKKKTKMTDEEIMEKLRTIVSIGDPKKKYTRYEKIGQGASGTVFTATDVALGQEVAIKQINLQKQPKKELIINEILVMKELKNPNIVNFLDSYLVGDELFVVMEYLAGGSLTDVVTETCMDEAQIAAVCRECLQALEFLHANQVIHRDIKSDNVLLGMEGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMVEGEPPYLNENPLRALYLIATNGTPELQNPEKLSPIFRDFLNRCLEMDVEKRGSAKELLQHPFLKLAKPLSSLTPLIMAAKEAMKSNR T07766 DRUGINFO D07ORL Il-94 Investigative T04393 TARGETID T04393 T04393 FORMERID TTDI02419 T04393 UNIPROID CBLB_HUMAN T04393 TARGNAME E3 ubiquitin protein ligase CBLB (CBLB) T04393 GENENAME CBLB T04393 TARGTYPE Literature-reported T04393 SYNONYMS Signal transduction protein CBLB; Signal transduction protein CBL-B; SH3binding protein CBLB; SH3-binding protein CBL-B; RNF56; RING-type E3 ubiquitin transferase CBL-B; RING finger protein 56; Nbla00127; E3 ubiquitinprotein ligase CBLB; E3 ubiquitin-protein ligase CBL-B; Casitas Blineage lymphoma protooncogene b; Casitas B-lineage lymphoma proto-oncogene b T04393 FUNCTION Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBL, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA. E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. T04393 PDBSTRUC 3ZNI; 3VGO; 3PFV; 2OOB; 2OOA T04393 BIOCLASS Acyltransferase T04393 ECNUMBER EC 2.3.2.27 T04393 SEQUENCE MANSMNGRNPGGRGGNPRKGRILGIIDAIQDAVGPPKQAAADRRTVEKTWKLMDKVVRLCQNPKLQLKNSPPYILDILPDTYQHLRLILSKYDDNQKLAQLSENEYFKIYIDSLMKKSKRAIRLFKEGKERMYEEQSQDRRNLTKLSLIFSHMLAEIKAIFPNGQFQGDNFRITKADAAEFWRKFFGDKTIVPWKVFRQCLHEVHQISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWGSILRNWNFLAVTHPGYMAFLTYDEVKARLQKYSTKPGSYIFRLSCTRLGQWAIGYVTGDGNILQTIPHNKPLFQALIDGSREGFYLYPDGRSYNPDLTGLCEPTPHDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTAWQESDGQGCPFCRCEIKGTEPIIVDPFDPRDEGSRCCSIIDPFGMPMLDLDDDDDREESLMMNRLANVRKCTDRQNSPVTSPGSSPLAQRRKPQPDPLQIPHLSLPPVPPRLDLIQKGIVRSPCGSPTGSPKSSPCMVRKQDKPLPAPPPPLRDPPPPPPERPPPIPPDNRLSRHIHHVESVPSRDPPMPLEAWCPRDVFGTNQLVGCRLLGEGSPKPGITASSNVNGRHSRVGSDPVLMRKHRRHDLPLEGAKVFSNGHLGSEEYDVPPRLSPPPPVTTLLPSIKCTGPLANSLSEKTRDPVEEDDDEYKIPSSHPVSLNSQPSHCHNVKPPVRSCDNGHCMLNGTHGPSSEKKSNIPDLSIYLKGDVFDSASDPVPLPPARPPTRDNPKHGSSLNRTPSDYDLLIPPLGEDAFDALPPSLPPPPPPARHSLIEHSKPPGSSSRPSSGQDLFLLPSDPFVDLASGQVPLPPARRLPGENVKTNRTSQDYDQLPSCSDGSQAPARPPKPRPRRTAPEIHHRKPHGPEAALENVDAKIAKLMGEGYAFEEVKRALEIAQNNVEVARSILREFAFPPPVSPRLNL T09395 TARGETID T09395 T09395 FORMERID TTDI02356 T09395 UNIPROID CHIT1_HUMAN T09395 TARGNAME Chitinase (CHIT1) T09395 GENENAME CHIT1 T09395 TARGTYPE Literature-reported T09395 SYNONYMS Chitotriosidase1; Chitinase1; CHIT1 T09395 FUNCTION Degrades chitin, chitotriose and chitobiose. May participate in the defense against nematodes and other pathogens. Isoform 3 has no enzymatic activity. {ECO:0000269|PubMed:7592832, ECO:0000269|PubMed:7836450}. T09395 PDBSTRUC 5NRF; 5NRA; 5NR8; 5HBF; 4WKH T09395 BIOCLASS Glycosylase T09395 ECNUMBER EC 3.2.1.14 T09395 SEQUENCE MVRSVAWAGFMVLLMIPWGSAAKLVCYFTNWAQYRQGEARFLPKDLDPSLCTHLIYAFAGMTNHQLSTTEWNDETLYQEFNGLKKMNPKLKTLLAIGGWNFGTQKFTDMVATANNRQTFVNSAIRFLRKYSFDGLDLDWEYPGSQGSPAVDKERFTTLVQDLANAFQQEAQTSGKERLLLSAAVPAGQTYVDAGYEVDKIAQNLDFVNLMAYDFHGSWEKVTGHNSPLYKRQEESGAAASLNVDAAVQQWLQKGTPASKLILGMPTYGRSFTLASSSDTRVGAPATGSGTPGPFTKEGGMLAYYEVCSWKGATKQRIQDQKVPYIFRDNQWVGFDDVESFKTKVSYLKQKGLGGAMVWALDLDDFAGFSCNQGRYPLIQTLRQELSLPYLPSGTPELEVPKPGQPSEPEHGPSPGQDTFCQGKADGLYPNPRERSSFYSCAAGRLFQQSCPTGLVFSNSCKCCTWN T91624 TARGETID T91624 T91624 UNIPROID TIF1B_HUMAN T91624 TARGNAME Transcription intermediary factor 1-beta (TRIM28) T91624 GENENAME TRIM28 T91624 TARGTYPE Literature-reported T91624 SYNONYMS Tripartite motif-containing protein 28; TIF1B; TIF1-beta; RNF96; RING-type E3 ubiquitin transferase TIF1-beta; RING finger protein 96; Nuclear corepressor KAP-1; KRIP-1; KRAB-interacting protein 1; KRAB-associated protein 1; KAP1; KAP-1; E3 SUMO-protein ligase TRIM28 T91624 FUNCTION Nuclear corepressor for KRAB domain-containing zinc finger proteins (KRAB-ZFPs). Mediates gene silencing by recruiting CHD3, a subunit of the nucleosome remodeling and deacetylation (NuRD) complex, and SETDB1 (which specifically methylates histone H3 at 'Lys-9' (H3K9me)) to the promoter regions of KRAB target genes. Enhances transcriptional repression by coordinating the increase in H3K9me, the decrease in histone H3 'Lys-9 and 'Lys-14' acetylation (H3K9ac and H3K14ac, respectively) and the disposition of HP1 proteins to silence gene expression. Recruitment of SETDB1 induces heterochromatinization. May play a role as a coactivator for CEBPB and NR3C1 in the transcriptional activation of ORM1. Also corepressor for ERBB4. Inhibits E2F1 activity by stimulating E2F1-HDAC1 complex formation and inhibiting E2F1 acetylation. May serve as a partial backup to prevent E2F1-mediated apoptosis in the absence of RB1. Important regulator of CDKN1A/p21(CIP1). Has E3 SUMO-protein ligase activity toward itself via its PHD-type zinc finger. Also specifically sumoylates IRF7, thereby inhibiting its transactivation activity. Ubiquitinates p53/TP53 leading to its proteosomal degradation; the function is enhanced by MAGEC2 and MAGEA2, and possibly MAGEA3 and MAGEA6. Mediates the nuclear localization of KOX1, ZNF268 and ZNF300 transcription factors. In association with isoform 2 of ZFP90, is required for the transcriptional repressor activity of FOXP3 and the suppressive function of regulatory T-cells (Treg) (PubMed:23543754). Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells (PubMed:24623306). Required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs) (PubMed:24623306). In ESCs, in collaboration with SETDB1, is also required for H3K9me3 and silencing of endogenous and introduced retroviruses in a DNA-methylation independent-pathway. Associates at promoter regions of tumor suppressor genes (TSGs) leading to their gene silencing (PubMed:24623306). The SETDB1-TRIM28-ZNF274 complex may play a role in recruiting ATRX to the 3'-exons of zinc-finger coding genes with atypical chromatin signatures to establish or maintain/protect H3K9me3 at these transcriptionally active regions (PubMed:27029610). Acts as a corepressor for ZFP568. T91624 PDBSTRUC 6I9H; 2YVR; 2RO1; 1FP0 T91624 BIOCLASS TRIM/RBCC family T91624 ECNUMBER EC 2.3.2.27 T91624 SEQUENCE MAASAAAASAAAASAASGSPGPGEGSAGGEKRSTAPSAAASASASAAASSPAGGGAEALELLEHCGVCRERLRPEREPRLLPCLHSACSACLGPAAPAAANSSGDGGAAGDGTVVDCPVCKQQCFSKDIVENYFMRDSGSKAATDAQDANQCCTSCEDNAPATSYCVECSEPLCETCVEAHQRVKYTKDHTVRSTGPAKSRDGERTVYCNVHKHEPLVLFCESCDTLTCRDCQLNAHKDHQYQFLEDAVRNQRKLLASLVKRLGDKHATLQKSTKEVRSSIRQVSDVQKRVQVDVKMAILQIMKELNKRGRVLVNDAQKVTEGQQERLERQHWTMTKIQKHQEHILRFASWALESDNNTALLLSKKLIYFQLHRALKMIVDPVEPHGEMKFQWDLNAWTKSAEAFGKIVAERPGTNSTGPAPMAPPRAPGPLSKQGSGSSQPMEVQEGYGFGSGDDPYSSAEPHVSGVKRSRSGEGEVSGLMRKVPRVSLERLDLDLTADSQPPVFKVFPGSTTEDYNLIVIERGAAAAATGQPGTAPAGTPGAPPLAGMAIVKEEETEAAIGAPPTATEGPETKPVLMALAEGPGAEGPRLASPSGSTSSGLEVVAPEGTSAPGGGPGTLDDSATICRVCQKPGDLVMCNQCEFCFHLDCHLPALQDVPGEEWSCSLCHVLPDLKEEDGSLSLDGADSTGVVAKLSPANQRKCERVLLALFCHEPCRPLHQLATDSTFSLDQPGGTLDLTLIRARLQEKLSPPYSSPQEFAQDVGRMFKQFNKLTEDKADVQSIIGLQRFFETRMNEAFGDTKFSAVLVEPPPMSLPGAGLSSQELSGGPGDGP T16886 TARGETID T16886 T16886 FORMERID TTDI00013 T16886 UNIPROID G3BP1_HUMAN T16886 TARGNAME GAP SH3 domain-binding protein 1 (G3BP1) T16886 GENENAME G3BP1 T16886 TARGTYPE Literature-reported T16886 SYNONYMS hDH VIII; Ras GTPase-activating protein-binding protein 1; G3BP-1; G3BP; ATP-dependent DNA helicase VIII T16886 FUNCTION Participates in the DNA-triggered cGAS/STING pathway by promoting the DNA binding and activation of CGAS. Enhances also DDX58-induced type I interferon production probably by helping DDX58 at sensing pathogenic RNA. In addition, plays an essential role in stress granule formation. Unwinds preferentially partial DNA and RNA duplexes having a 17 bp annealed portion and either a hanging 3' tail or hanging tails at both 5'- and 3'-ends. Unwinds DNA/DNA, RNA/DNA, and RNA/RNA substrates with comparable efficiency. Acts unidirectionally by moving in the 5' to 3' direction along the bound single-stranded DNA. Phosphorylation-dependent sequence-specific endoribonuclease in vitro. Cleaves exclusively between cytosine and adenine and cleaves MYC mRNA preferentially at the 3'-UTR. ATP- and magnesium-dependent helicase that plays an essential role in innate immunity. T16886 PDBSTRUC 5FW5; 4IIA; 4FCM; 4FCJ; 3Q90 T16886 BIOCLASS Acid anhydride hydrolase T16886 ECNUMBER EC 3.6.4.12 T16886 SEQUENCE MVMEKPSPLLVGREFVRQYYTLLNQAPDMLHRFYGKNSSYVHGGLDSNGKPADAVYGQKEIHRKVMSQNFTNCHTKIRHVDAHATLNDGVVVQVMGLLSNNNQALRRFMQTFVLAPEGSVANKFYVHNDIFRYQDEVFGGFVTEPQEESEEEVEEPEERQQTPEVVPDDSGTFYDQAVVSNDMEEHLEEPVAEPEPDPEPEPEQEPVSEIQEEKPEPVLEETAPEDAQKSSSPAPADIAQTVQEDLRTFSWASVTSKNLPPSGAVPVTGIPPHVVKVPASQPRPESKPESQIPPQRPQRDQRVREQRINIPPQRGPRPIREAGEQGDIEPRRMVRHPDSHQLFIGNLPHEVDKSELKDFFQSYGNVVELRINSGGKLPNFGFVVFDDSEPVQKVLSNRPIMFRGEVRLNVEEKKTRAAREGDRRDNRLRGPGGPRGGLGGGMRGPPRGGMVQKPGFGVGRGLAPRQ T98337 TARGETID T98337 T98337 FORMERID TTDNR00722 T98337 UNIPROID FKBP5_HUMAN T98337 TARGNAME FK506-binding protein 5 (FKBP5) T98337 GENENAME FKBP5 T98337 TARGTYPE Literature-reported T98337 SYNONYMS Peptidyl-prolyl cis-trans isomerase FKBP5; PPIase FKBP5; HSP90-binding immunophilin; FKBP54; FKBP51; FKBP-51; FKBP-5; FF1 antigen; Androgen-regulated protein 6; AIG6; 54 kDa progesterone receptor-associated immunophilin; 51 kDa FKBP; 51 kDa FK506-binding protein T98337 FUNCTION Component of unligated steroid receptors heterocomplexes through interaction with heat-shock protein 90 (HSP90). Plays a role in the intracellular trafficking of heterooligomeric forms of steroid hormone receptors maintaining the complex into the cytoplasm when unliganded. Immunophilin protein with PPIase and co-chaperone activities. T98337 PDBSTRUC 5OMP; 5OBK; 5NJX; 5DIV; 5DIU T98337 BIOCLASS Cis-trans-isomerase T98337 ECNUMBER EC 5.2.1.8 T98337 SEQUENCE MTTDEGAKNNEESPTATVAEQGEDITSKKDRGVLKIVKRVGNGEETPMIGDKVYVHYKGKLSNGKKFDSSHDRNEPFVFSLGKGQVIKAWDIGVATMKKGEICHLLCKPEYAYGSAGSLPKIPSNATLFFEIELLDFKGEDLFEDGGIIRRTKRKGEGYSNPNEGATVEIHLEGRCGGRMFDCRDVAFTVGEGEDHDIPIGIDKALEKMQREEQCILYLGPRYGFGEAGKPKFGIEPNAELIYEVTLKSFEKAKESWEMDTKEKLEQAAIVKEKGTVYFKGGKYMQAVIQYGKIVSWLEMEYGLSEKESKASESFLLAAFLNLAMCYLKLREYTKAVECCDKALGLDSANEKGLYRRGEAQLLMNEFESAKGDFEKVLEVNPQNKAARLQISMCQKKAKEHNERDRRIYANMFKKFAEQDAKEEANKAMGKKTSEGVTNEKGTDSQAMEEEKPEGHV T17367 TARGETID T17367 T17367 FORMERID TTDI02182 T17367 UNIPROID SQSTM_HUMAN T17367 TARGNAME Sequestosome-1 p62 (SQSTM1) T17367 GENENAME SQSTM1 T17367 TARGTYPE Literature-reported T17367 SYNONYMS Ubiquitin-binding protein p62; Sequestosome-1; Phosphotyrosine-independent ligand for the Lck SH2 domain of 62kDa; Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDa; OSIL; ORCA; EBIAP; EBI3-associated protein of 60 kDa T17367 FUNCTION Functions as a bridge between polyubiquitinated cargo and autophagosomes. Interacts directly with both the cargo to become degraded and an autophagy modifier of the MAP1 LC3 family. Along with WDFY3, involved in the formation and autophagic degradation of cytoplasmic ubiquitin-containing inclusions (p62 bodies, ALIS/aggresome-like induced structures). Along with WDFY3, required to recruit ubiquitinated proteins to PML bodies in the nucleus. May regulate the activation of NFKB1 by TNF-alpha, nerve growth factor (NGF) and interleukin-1. May play a role in titin/TTN downstream signaling in muscle cells. May regulate signaling cascades through ubiquitination. Adapter that mediates the interaction between TRAF6 and CYLD. May be involved in cell differentiation, apoptosis, immune response and regulation of K(+) channels. Involved in endosome organization by retaining vesicles in the perinuclear cloud: following ubiquitination by RNF26, attracts specific vesicle-associated adapters, forming a molecular bridge that restrains cognate vesicles in the perinuclear region and organizes the endosomal pathway for efficient cargo transport. Promotes relocalization of 'Lys-63'-linked ubiquitinated TMEM173/STING to autophagosomes. Autophagy receptor required for selective macroautophagy (aggrephagy). T17367 PDBSTRUC 6MJ7; 5YPH; 5YPG; 5YPF; 5YPE T17367 BIOCLASS Zinc-finger T17367 SEQUENCE MASLTVKAYLLGKEDAAREIRRFSFCCSPEPEAEAEAAAGPGPCERLLSRVAALFPALRPGGFQAHYRDEDGDLVAFSSDEELTMAMSYVKDDIFRIYIKEKKECRRDHRPPCAQEAPRNMVHPNVICDGCNGPVVGTRYKCSVCPDYDLCSVCEGKGLHRGHTKLAFPSPFGHLSEGFSHSRWLRKVKHGHFGWPGWEMGPPGNWSPRPPRAGEARPGPTAESASGPSEDPSVNFLKNVGESVAAALSPLGIEVDIDVEHGGKRSRLTPVSPESSSTEEKSSSQPSSCCSDPSKPGGNVEGATQSLAEQMRKIALESEGRPEEQMESDNCSGGDDDWTHLSSKEVDPSTGELQSLQMPESEGPSSLDPSQEGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQYSKHPPPL T17367 DRUGINFO D02NEZ IMX-942 Preclinical T25861 TARGETID T25861 T25861 FORMERID TTDR00902 T25861 UNIPROID TRPC3_HUMAN T25861 TARGNAME Short transient receptor potential channel 3 (TRPC3) T25861 GENENAME TRPC3 T25861 TARGTYPE Literature-reported T25861 SYNONYMS TrpC3; Htrp3; Htrp-3 T25861 FUNCTION Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Activated by diacylglycerol (DAG) in a membrane-delimited fashion, independently of protein kinase C, and by inositol 1,4,5- triphosphate receptors (ITPR) with bound IP3. May also be activated by internalcalcium store depletion. T25861 PDBSTRUC 6DJS; 6D7L; 6CUD; 5ZBG T25861 BIOCLASS Transient receptor potential catioin channel T25861 SEQUENCE MREKGRRQAVRGPAFMFNDRGTSLTAEEERFLDAAEYGNIPVVRKMLEESKTLNVNCVDYMGQNALQLAVGNEHLEVTELLLKKENLARIGDALLLAISKGYVRIVEAILNHPGFAASKRLTLSPCEQELQDDDFYAYDEDGTRFSPDITPIILAAHCQKYEVVHMLLMKGARIERPHDYFCKCGDCMEKQRHDSFSHSRSRINAYKGLASPAYLSLSSEDPVLTALELSNELAKLANIEKEFKNDYRKLSMQCKDFVVGVLDLCRDSEEVEAILNGDLESAEPLEVHRHKASLSRVKLAIKYEVKKFVAHPNCQQQLLTIWYENLSGLREQTIAIKCLVVLVVALGLPFLAIGYWIAPCSRLGKILRSPFMKFVAHAASFIIFLGLLVFNASDRFEGITTLPNITVTDYPKQIFRVKTTQFTWTEMLIMVWVLGMMWSECKELWLEGPREYILQLWNVLDFGMLSIFIAAFTARFLAFLQATKAQQYVDSYVQESDLSEVTLPPEIQYFTYARDKWLPSDPQIISEGLYAIAVVLSFSRIAYILPANESFGPLQISLGRTVKDIFKFMVLFIMVFFAFMIGMFILYSYYLGAKVNAAFTTVEESFKTLFWSIFGLSEVTSVVLKYDHKFIENIGYVLYGIYNVTMVVVLLNMLIAMINSSYQEIEDDSDVEWKFARSKLWLSYFDDGKTLPPPFSLVPSPKSFVYFIMRIVNFPKCRRRRLQKDIEMGMGNSKSRLNLFTQSNSRVFESHSFNSILNQPTRYQQIMKRLIKRYVLKAQVDKENDEVNEGELKEIKQDISSLRYELLEDKSQATEELAILIHKLSEKLNPSMLRCE T25861 DRUGINFO D0T7GC Pyr3 Investigative T25861 DRUGINFO D0F4FK KB-R7943 Investigative T25861 DRUGINFO D0JV2P BTP2 Investigative T25861 DRUGINFO D0N7MS ACAA Investigative T25861 DRUGINFO D0T6DU OAG Investigative T25861 DRUGINFO D00HCI 2-APB Investigative T53124 TARGETID T53124 T53124 FORMERID TTDR00812 T53124 UNIPROID MTMR1_HUMAN T53124 TARGNAME Myotubularin-related protein 1 (MTMR1) T53124 GENENAME MTMR1 T53124 TARGTYPE Literature-reported T53124 SYNONYMS MTMR1 T53124 FUNCTION Lipid phosphatase that has high specificity for phosphatidylinositol 3-phosphate and has no activity with phosphatidylinositol (3,5)-bisphosphate. T53124 PDBSTRUC 5C16 T53124 BIOCLASS Phosphoric monoester hydrolase T53124 ECNUMBER EC 3.1.3.95 T53124 SEQUENCE MDRPAAAAAAGCEGGGGPNPGPAGGRRPPRAAGGATAGSRQPSVETLDSPTGSHVEWCKQLIAATISSQISGSVTSENVSRDYKALRDGNKLAQMEEAPLFPGESIKAIVKDVMYICPFMGAVSGTLTVTDFKLYFKNVERDPHFILDVPLGVISRVEKIGAQSHGDNSCGIEIVCKDMRNLRLAYKQEEQSKLGIFENLNKHAFPLSNGQALFAFSYKEKFPINGWKVYDPVSEYKRQGLPNESWKISKINSNYEFCDTYPAIIVVPTSVKDDDLSKVAAFRAKGRVPVLSWIHPESQATITRCSQPLVGPNDKRCKEDEKYLQTIMDANAQSHKLIIFDARQNSVADTNKTKGGGYESESAYPNAELVFLEIHNIHVMRESLRKLKEIVYPSIDEARWLSNVDGTHWLEYIRMLLAGAVRIADKIESGKTSVVVHCSDGWDRTAQLTSLAMLMLDSYYRTIKGFETLVEKEWISFGHRFALRVGHGNDNHADADRSPIFLQFVDCVWQMTRQFPSAFEFNELFLITILDHLYSCLFGTFLCNCEQQRFKEDVYTKTISLWSYINSQLDEFSNPFFVNYENHVLYPVASLSHLELWVNYYVRWNPRMRPQMPIHQNLKELLAVRAELQKRVEGLQREVATRAVSSSSERGSSPSHSATSVHTSV T78543 TARGETID T78543 T78543 FORMERID TTDI03491 T78543 UNIPROID KGP1_HUMAN T78543 TARGNAME Protein kinase G1 (PRKG1) T78543 GENENAME PRKG1 T78543 TARGTYPE Literature-reported T78543 SYNONYMS cGMP-dependent protein kinase I; cGMP-dependent protein kinase 1; cGKI; cGK1; cGK 1; PRKGR1B; PRKGR1A; PRKG1B T78543 FUNCTION GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins. Numerous protein targets for PRKG1 phosphorylation are implicated in modulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 regulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the NO-signaling pathway, and other processes involved in several aspects of the CNS like axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception. Smooth muscle relaxation is mediated through lowering of intracellular free calcium, by desensitization of contractile proteins to calcium, and by decrease in the contractile state of smooth muscle or in platelet activation. Regulates intracellular calcium levels via several pathways: phosphorylates MRVI1/IRAG and inhibits IP3-induced Ca(2+) release from intracellular stores, phosphorylation of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels, which leads to increased opening of this channel. PRKG1 phosphorylates the canonical transient receptor potential channel (TRPC) family which inactivates the associated inward calcium current. Another mode of action of NO/cGMP/PKGI signaling involves PKGI-mediated inactivation of the Ras homolog gene family member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this protein in myriad processes: regulation of RHOA translocation; decreasing contraction; controlling vesicle trafficking, reduction of myosin light chain phosphorylation resulting in vasorelaxation. Activation of PRKG1 by NO signaling alters also gene expression in a number of tissues. In smooth muscle cells, increased cGMP and PRKG1 activity influence expression of smooth muscle-specific contractile proteins, levels of proteins in the NO/cGMP signaling pathway, down-regulation of the matrix proteins osteopontin and thrombospondin-1 to limit smooth muscle cell migration and phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP) functions in platelets and smooth muscle. Serine/threonine protein kinase that acts as key mediator of the nitric oxide (NO)/cGMP signaling pathway. T78543 PDBSTRUC 6C0T; 6BG2; 6BDL; 5L0N; 5JD7 T78543 BIOCLASS Kinase T78543 ECNUMBER EC 2.7.11.12 T78543 SEQUENCE MSELEEDFAKILMLKEERIKELEKRLSEKEEEIQELKRKLHKCQSVLPVPSTHIGPRTTRAQGISAEPQTYRSFHDLRQAFRKFTKSERSKDLIKEAILDNDFMKNLELSQIQEIVDCMYPVEYGKDSCIIKEGDVGSLVYVMEDGKVEVTKEGVKLCTMGPGKVFGELAILYNCTRTATVKTLVNVKLWAIDRQCFQTIMMRTGLIKHTEYMEFLKSVPTFQSLPEEILSKLADVLEETHYENGEYIIRQGARGDTFFIISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAYEDAEAKAKYEAEAAFFANLKLSDFNIIDTLGVGGFGRVELVQLKSEESKTFAMKILKKRHIVDTRQQEHIRSEKQIMQGAHSDFIVRLYRTFKDSKYLYMLMEACLGGELWTILRDRGSFEDSTTRFYTACVVEAFAYLHSKGIIYRDLKPENLILDHRGYAKLVDFGFAKKIGFGKKTWTFCGTPEYVAPEIILNKGHDISADYWSLGILMYELLTGSPPFSGPDPMKTYNIILRGIDMIEFPKKIAKNAANLIKKLCRDNPSERLGNLKNGVKDIQKHKWFEGFNWEGLRKGTLTPPIIPSVASPTDTSNFDSFPEDNDEPPPDDNSGWDIDF T78543 DRUGINFO D0T0CG Rp-8-CPT-cGMPS Investigative T92439 TARGETID T92439 T92439 FORMERID TTDI03444 T92439 UNIPROID PDE1C_HUMAN T92439 TARGNAME Phosphodiesterase 1C (PDE1C) T92439 GENENAME PDE1C T92439 TARGTYPE Literature-reported T92439 SYNONYMS Hcam3; Cam-PDE 1C; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C; 3',5'-cyclic-GMP phosphodiesterase; 3',5'-cyclic-AMP phosphodiesterase T92439 FUNCTION Has a high affinity for both cAMP and cGMP. Modulates the amplitude and duration of the cAMP signal in sensory cilia in response to odorant stimulation, hence contributing to the generation of action potentials. Regulates smooth muscle cell proliferation. Regulates the stability of growth factor receptors, including PDGFRB. Calmodulin-dependent cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. T92439 PDBSTRUC 1LXS T92439 BIOCLASS Phosphoric diester hydrolase T92439 ECNUMBER EC 3.1.4.- T92439 SEQUENCE MESPTKEIEEFESNSLKYLQPEQIEKIWLRLRGLRKYKKTSQRLRSLVKQLERGEASVVDLKKNLEYAATVLESVYIDETRRLLDTEDELSDIQSDAVPSEVRDWLASTFTRQMGMMLRRSDEKPRFKSIVHAVQAGIFVERMYRRTSNMVGLSYPPAVIEALKDVDKWSFDVFSLNEASGDHALKFIFYELLTRYDLISRFKIPISALVSFVEALEVGYSKHKNPYHNLMHAADVTQTVHYLLYKTGVANWLTELEIFAIIFSAAIHDYEHTGTTNNFHIQTRSDPAILYNDRSVLENHHLSAAYRLLQDDEEMNILINLSKDDWREFRTLVIEMVMATDMSCHFQQIKAMKTALQQPEAIEKPKALSLMLHTADISHPAKAWDLHHRWTMSLLEEFFRQGDREAELGLPFSPLCDRKSTMVAQSQVGFIDFIVEPTFTVLTDMTEKIVSPLIDETSQTGGTGQRRSSLNSISSSDAKRSGVKTSGSEGSAPINNSVISVDYKSFKATWTEVVHINRERWRAKVPKEEKAKKEAEEKARLAAEEQQKEMEAKSQAEEGASGKAEKKTSGETKNQVNGTRANKSDNPRGKNSKAEKSSGEQQQNGDFKDGKNKTDKKDHSNIGNDSKKTDGTKQRSHGSPAPSTSSTCRLTLPVIKPPLRHFKRPAYASSSYAPSVSKKTDEHPARYKMLDQRIKMKKIQNISHNWNRK T92439 DRUGINFO D02VHD SCH51866 Investigative T30502 TARGETID T30502 T30502 FORMERID TTDR00491 T30502 UNIPROID MCM6_HUMAN T30502 TARGNAME DNA replication licensing factor MCM6 (MCM6) T30502 GENENAME MCM6 T30502 TARGTYPE Literature-reported T30502 SYNONYMS p105MCM; Minichromosome maintenanceprotein 6 T30502 FUNCTION The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity. Acts as component of the MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. T30502 PDBSTRUC 2LE8; 2KLQ T30502 BIOCLASS Acid anhydride hydrolase T30502 ECNUMBER EC 3.6.4.12 T30502 SEQUENCE MDLAAAAEPGAGSQHLEVRDEVAEKCQKLFLDFLEEFQSSDGEIKYLQLAEELIRPERNTLVVSFVDLEQFNQQLSTTIQEEFYRVYPYLCRALKTFVKDRKEIPLAKDFYVAFQDLPTRHKIRELTSSRIGLLTRISGQVVRTHPVHPELVSGTFLCLDCQTVIRDVEQQFKYTQPNICRNPVCANRRRFLLDTNKSRFVDFQKVRIQETQAELPRGSIPRSLEVILRAEAVESAQAGDKCDFTGTLIVVPDVSKLSTPGARAETNSRVSGVDGYETEGIRGLRALGVRDLSYRLVFLACCVAPTNPRFGGKELRDEEQTAESIKNQMTVKEWEKVFEMSQDKNLYHNLCTSLFPTIHGNDEVKRGVLLMLFGGVPKTTGEGTSLRGDINVCIVGDPSTAKSQFLKHVEEFSPRAVYTSGKASSAAGLTAAVVRDEESHEFVIEAGALMLADNGVCCIDEFDKMDVRDQVAIHEAMEQQTISITKAGVKATLNARTSILAAANPISGHYDRSKSLKQNINLSAPIMSRFDLFFILVDECNEVTDYAIARRIVDLHSRIEESIDRVYSLDDIRRYLLFARQFKPKISKESEDFIVEQYKHLRQRDGSGVTKSSWRITVRQLESMIRLSEAMARMHCCDEVQPKHVKEAFRLLNKSIIRVETPDVNLDQEEEIQMEVDEGAGGINGHADSPAPVNGINGYNEDINQESAPKASLRLGFSEYCRISNLIVLHLRKVEEEEDESALKRSELVNWYLKEIESEIDSEEELINKKRIIEKVIHRLTHYDHVLIELTQAGLKGSTEGSESYEEDPYLVVNPNYLLED T99402 TARGETID T99402 T99402 FORMERID TTDR00965 T99402 UNIPROID GRM4_HUMAN T99402 TARGNAME Metabotropic glutamate receptor 4 (mGluR4) T99402 GENENAME GRM4 T99402 TARGTYPE Literature-reported T99402 SYNONYMS mGluR4; Group III metabotropic glutamate receptor 4; GPRC1D T99402 FUNCTION Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for glutamate. T99402 BIOCLASS GPCR glutamate T99402 SEQUENCE MPGKRGLGWWWARLPLCLLLSLYGPWMPSSLGKPKGHPHMNSIRIDGDITLGGLFPVHGRGSEGKPCGELKKEKGIHRLEAMLFALDRINNDPDLLPNITLGARILDTCSRDTHALEQSLTFVQALIEKDGTEVRCGSGGPPIITKPERVVGVIGASGSSVSIMVANILRLFKIPQISYASTAPDLSDNSRYDFFSRVVPSDTYQAQAMVDIVRALKWNYVSTVASEGSYGESGVEAFIQKSREDGGVCIAQSVKIPREPKAGEFDKIIRRLLETSNARAVIIFANEDDIRRVLEAARRANQTGHFFWMGSDSWGSKIAPVLHLEEVAEGAVTILPKRMSVRGFDRYFSSRTLDNNRRNIWFAEFWEDNFHCKLSRHALKKGSHVKKCTNRERIGQDSAYEQEGKVQFVIDAVYAMGHALHAMHRDLCPGRVGLCPRMDPVDGTQLLKYIRNVNFSGIAGNPVTFNENGDAPGRYDIYQYQLRNDSAEYKVIGSWTDHLHLRIERMHWPGSGQQLPRSICSLPCQPGERKKTVKGMPCCWHCEPCTGYQYQVDRYTCKTCPYDMRPTENRTGCRPIPIIKLEWGSPWAVLPLFLAVVGIAATLFVVITFVRYNDTPIVKASGRELSYVLLAGIFLCYATTFLMIAEPDLGTCSLRRIFLGLGMSISYAALLTKTNRIYRIFEQGKRSVSAPRFISPASQLAITFSLISLQLLGICVWFVVDPSHSVVDFQDQRTLDPRFARGVLKCDISDLSLICLLGYSMLLMVTCTVYAIKTRGVPETFNEAKPIGFTMYTTCIVWLAFIPIFFGTSQSADKLYIQTTTLTVSVSLSASVSLGMLYMPKVYIILFHPEQNVPKRKRSLKAVVTAATMSNKFTQKGNFRPNGEAKSELCENLEAPALATKQTYVTYTNHAI T99402 DRUGINFO D0L2YR DT-1687 Phase 2 T99402 DRUGINFO D00NCL PMID21688779C22a Investigative T99402 DRUGINFO D01JFF VU0361737 Investigative T99402 DRUGINFO D03PGL PMID20638279C11 Investigative T99402 DRUGINFO D05GQH ADX-88178 Investigative T99402 DRUGINFO D06DRY FP0429 Investigative T99402 DRUGINFO D07IOB VU0092145 Investigative T99402 DRUGINFO D09ONV VU0359516 Investigative T99402 DRUGINFO D0AY5T VU0400195 Investigative T99402 DRUGINFO D0GI1D Lu AF21934 Investigative T99402 DRUGINFO D0P2VP (2S,1'R,2'S)-2-(2'-phosphonocyclopropyl)glycine Investigative T99402 DRUGINFO D0T1SP PMID22465637C1 Investigative T99402 DRUGINFO D0V8KA PMID20638279C7 Investigative T99402 DRUGINFO D0W9VN VU0364770 Investigative T99402 DRUGINFO D0X3VM VU0155041 Investigative T99402 DRUGINFO D0Z5JT VU0001171 Investigative T99402 DRUGINFO D06PHE CPPG Investigative T99402 DRUGINFO D0H6BG PHCCC Investigative T99402 DRUGINFO D0IO8J 2-methyl-6-(phenylethynyl)pyridine Investigative T99402 DRUGINFO D0KL4K LSP4-2022 Investigative T99402 DRUGINFO D0LC5O (S)-3,4-DCPG Investigative T99402 DRUGINFO D0W3PY ACPT-I Investigative T99402 DRUGINFO D0XG6U LSP1-2111 Investigative T99402 DRUGINFO D09SXN MAP4 Investigative T99402 DRUGINFO D0D2GL MPPG Investigative T99402 DRUGINFO D0PN6Z L-AP4 Investigative T99402 DRUGINFO D0Z7CZ L-CCG-I Investigative T99402 DRUGINFO D07PZQ L-serine-O-phosphate Investigative T99029 TARGETID T99029 T99029 FORMERID TTDNR00633 T99029 UNIPROID PDK3_HUMAN T99029 TARGNAME Pyruvate dehydrogenase kinase 3 (PDHK3) T99029 GENENAME PDK3 T99029 TARGTYPE Literature-reported T99029 SYNONYMS Pyruvate dehydrogenase kinase isoform 3; PDK3 T99029 FUNCTION Inhibits pyruvatedehydrogenase activity by phosphorylation of the E1 subunit PDHA1, and thereby regulates glucose metabolism and aerobic respiration. Can also phosphorylate PDHA2. Decreases glucose utilization and increases fat metabolism in response to prolonged fasting, and as adaptation to a high-fat diet. Plays a role in glucose homeostasis and in maintaining normal blood glucose levels in function of nutrient levels and under starvation. Plays a role in the generation of reactive oxygen species. T99029 PDBSTRUC 2Q8I; 2PNR; 1Y8P; 1Y8O; 1Y8N T99029 BIOCLASS Kinase T99029 ECNUMBER EC 2.7.11.2 T99029 SEQUENCE MRLFRWLLKQPVPKQIERYSRFSPSPLSIKQFLDFGRDNACEKTSYMFLRKELPVRLANTMREVNLLPDNLLNRPSVGLVQSWYMQSFLELLEYENKSPEDPQVLDNFLQVLIKVRNRHNDVVPTMAQGVIEYKEKFGFDPFISTNIQYFLDRFYTNRISFRMLINQHTLLFGGDTNPVHPKHIGSIDPTCNVADVVKDAYETAKMLCEQYYLVAPELEVEEFNAKAPDKPIQVVYVPSHLFHMLFELFKNSMRATVELYEDRKEGYPAVKTLVTLGKEDLSIKISDLGGGVPLRKIDRLFNYMYSTAPRPSLEPTRAAPLAGFGYGLPISRLYARYFQGDLKLYSMEGVGTDAVIYLKALSSESFERLPVFNKSAWRHYKTTPEADDWSNPSSEPRDASKYKAKQ T47885 TARGETID T47885 T47885 FORMERID TTDR01317 T47885 UNIPROID KPCD1_HUMAN T47885 TARGNAME Protein kinase D (PRKD1) T47885 GENENAME PRKD1 T47885 TARGTYPE Literature-reported T47885 SYNONYMS nPKC-mu; nPKC-D1; Serine/threonine-protein kinase D1; Protein kinase C mu type; PRKCM; PKD1; PKD T47885 FUNCTION Phosphorylates the epidermal growth factor receptor (EGFR) on dual threonine residues, which leads to the suppression of epidermal growth factor (EGF)-induced MAPK8/JNK1 activation and subsequent JUN phosphorylation. Phosphorylates RIN1, inducing RIN1 binding to 14-3-3 proteins YWHAB, YWHAE and YWHAZ and increased competition with RAF1 for binding to GTP-bound form of Ras proteins (NRAS, HRAS and KRAS). Acts downstream of the heterotrimeric G-protein beta/gamma-subunit complex to maintain the structural integrity of the Golgi membranes, and is required for protein transport along the secretory pathway. In the trans-Golgi network (TGN), regulates the fission of transport vesicles that are on their way to the plasma membrane. May act by activating the lipid kinase phosphatidylinositol 4-kinase beta (PI4KB) at the TGN for the local synthesis of phosphorylated inositol lipids, which induces a sequential production of DAG, phosphatidic acid (PA) and lyso-PA (LPA) that are necessary for membrane fission and generation of specific transport carriers to the cell surface. Under oxidative stress, is phosphorylated at Tyr-463 via SRC-ABL1 and contributes to cell survival by activating IKK complex and subsequent nuclear translocation and activation of NFKB1. Involved in cell migration by regulating integrin alpha-5/beta-3 recycling and promoting its recruitment in newly forming focal adhesion. In osteoblast differentiation, mediates the bone morphogenetic protein 2 (BMP2)-induced nuclear export of HDAC7, which results in the inhibition of HDAC7 transcriptional repression of RUNX2. In neurons, plays an important role in neuronal polarity by regulating the biogenesis of TGN-derived dendritic vesicles, and is involved in the maintenance of dendritic arborization and Golgi structure in hippocampal cells. May potentiate mitogenesis induced by the neuropeptide bombesin or vasopressin by mediating an increase in the duration of MAPK1/3 (ERK1/2) signaling, which leads to accumulation of immediate-early gene products including FOS that stimulate cell cycle progression. Plays an important role in the proliferative response induced by low calcium in keratinocytes, through sustained activation of MAPK1/3 (ERK1/2) pathway. Downstream of novel PKC signaling, plays a role in cardiac hypertrophy by phosphorylating HDAC5, which in turn triggers XPO1/CRM1-dependent nuclear export of HDAC5, MEF2A transcriptional activation and induction of downstream target genes that promote myocyte hypertrophy and pathological cardiac remodeling. Mediates cardiac troponin I (TNNI3) phosphorylation at the PKA sites, which results in reduced myofilament calcium sensitivity, and accelerated crossbridge cycling kinetics. The PRKD1-HDAC5 pathway is also involved in angiogenesis by mediating VEGFA-induced specific subset of gene expression, cell migration, and tube formation. In response to VEGFA, is necessary and required for HDAC7 phosphorylation which induces HDAC7 nuclear export and endothelial cell proliferation and migration. During apoptosis induced by cytarabine and other genotoxic agents, PRKD1 is cleaved by caspase-3 at Asp-378, resulting in activation of its kinase function and increased sensitivity of cells to the cytotoxic effects of genotoxic agents. In epithelial cells, is required for transducing flagellin-stimulated inflammatory responses by binding and phosphorylating TLR5, which contributes to MAPK14/p38 activation and production of inflammatory cytokines. May play a role in inflammatory response by mediating activation of NF-kappa-B. May be involved in pain transmission by directly modulating TRPV1 receptor. Plays a role in activated KRAS-mediated stabilization of ZNF304 in colorectal cancer (CRC) cells. Regulates nuclear translocation of transcription factor TFEB in macrophages upon live S. enterica infection. Serine/threonine-protein kinase that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC, and is involved in the regulation of MAPK8/JNK1 and Ras signaling, Golgi membrane integrity and trafficking, cell survival through NF-kappa-B activation, cell migration, cell differentiation by mediating HDAC7 nuclear export, cell proliferation via MAPK1/3 (ERK1/2) signaling, and plays a role in cardiac hypertrophy, VEGFA-induced angiogenesis, genotoxic-induced apoptosis and flagellin-stimulated inflammatory response. T47885 BIOCLASS Kinase T47885 ECNUMBER EC 2.7.11.13 T47885 SEQUENCE MSAPPVLRPPSPLLPVAAAAAAAAAALVPGSGPGPAPFLAPVAAPVGGISFHLQIGLSREPVLLLQDSSGDYSLAHVREMACSIVDQKFPECGFYGMYDKILLFRHDPTSENILQLVKAASDIQEGDLIEVVLSASATFEDFQIRPHALFVHSYRAPAFCDHCGEMLWGLVRQGLKCEGCGLNYHKRCAFKIPNNCSGVRRRRLSNVSLTGVSTIRTSSAELSTSAPDEPLLQKSPSESFIGREKRSNSQSYIGRPIHLDKILMSKVKVPHTFVIHSYTRPTVCQYCKKLLKGLFRQGLQCKDCRFNCHKRCAPKVPNNCLGEVTINGDLLSPGAESDVVMEEGSDDNDSERNSGLMDDMEEAMVQDAEMAMAECQNDSGEMQDPDPDHEDANRTISPSTSNNIPLMRVVQSVKHTKRKSSTVMKEGWMVHYTSKDTLRKRHYWRLDSKCITLFQNDTGSRYYKEIPLSEILSLEPVKTSALIPNGANPHCFEITTANVVYYVGENVVNPSSPSPNNSVLTSGVGADVARMWEIAIQHALMPVIPKGSSVGTGTNLHRDISVSISVSNCQIQENVDISTVYQIFPDEVLGSGQFGIVYGGKHRKTGRDVAIKIIDKLRFPTKQESQLRNEVAILQNLHHPGVVNLECMFETPERVFVVMEKLHGDMLEMILSSEKGRLPEHITKFLITQILVALRHLHFKNIVHCDLKPENVLLASADPFPQVKLCDFGFARIIGEKSFRRSVVGTPAYLAPEVLRNKGYNRSLDMWSVGVIIYVSLSGTFPFNEDEDIHDQIQNAAFMYPPNPWKEISHEAIDLINNLLQVKMRKRYSVDKTLSHPWLQDYQTWLDLRELECKIGERYITHESDDLRWEKYAGEQGLQYPTHLINPSASHSDTPETEETEMKALGERVSIL T47885 DRUGINFO D03DYT K252a Investigative T47885 DRUGINFO D03HQE CRT0066101 Investigative T47885 DRUGINFO D0F2SA BPKDi Investigative T47885 DRUGINFO D0MC3K CID755673 Investigative T47885 DRUGINFO D0O8FN INDUS-815B Investigative T47885 DRUGINFO D08JPU G6976 Investigative T03581 TARGETID T03581 T03581 FORMERID TTDI03539 T03581 UNIPROID STK38_HUMAN T03581 TARGNAME NDR1 protein kinase (STK38) T03581 GENENAME STK38 T03581 TARGTYPE Literature-reported T03581 SYNONYMS Serine/threonine-protein kinase 38; Nuclear Dbf2-related kinase 1; NDR1 T03581 FUNCTION Converts MAP3K2 from its phosphorylated form to its non-phosphorylated form and inhibits autophosphorylation of MAP3K2. Negative regulator of MAP3K1/2 signaling. T03581 PDBSTRUC 6BXI; 1PSB T03581 BIOCLASS Kinase T03581 ECNUMBER EC 2.7.11.1 T03581 SEQUENCE MAMTGSTPCSSMSNHTKERVTMTKVTLENFYSNLIAQHEEREMRQKKLEKVMEEEGLKDEEKRLRRSAHARKETEFLRLKRTRLGLEDFESLKVIGRGAFGEVRLVQKKDTGHVYAMKILRKADMLEKEQVGHIRAERDILVEADSLWVVKMFYSFQDKLNLYLIMEFLPGGDMMTLLMKKDTLTEEETQFYIAETVLAIDSIHQLGFIHRDIKPDNLLLDSKGHVKLSDFGLCTGLKKAHRTEFYRNLNHSLPSDFTFQNMNSKRKAETWKRNRRQLAFSTVGTPDYIAPEVFMQTGYNKLCDWWSLGVIMYEMLIGYPPFCSETPQETYKKVMNWKETLTFPPEVPISEKAKDLILRFCCEWEHRIGAPGVEEIKSNSFFEGVDWEHIRERPAAISIEIKSIDDTSNFDEFPESDILKPTVATSNHPETDYKNKDWVFINYTYKRFEGLTARGAIPSYMKAAK T03581 DRUGINFO D0R3MO PMID20684608C35 Investigative T57006 TARGETID T57006 T57006 FORMERID TTDI03178 T57006 UNIPROID EPHA7_HUMAN T57006 TARGNAME Ephrin type-A receptor 7 (EPHA7) T57006 GENENAME EPHA7 T57006 TARGTYPE Literature-reported T57006 SYNONYMS hEK11; EPH-like kinase 11; EPH homology kinase 3; EK11; EHK3; EHK-3 T57006 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Among GPI-anchored ephrin-A ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their interaction regulates brain development modulating cell-cell adhesion and repulsion. Has a repellent activity on axons and is for instance involved in the guidance of corticothalamic axons and in the proper topographic mapping of retinal axons to the colliculus. May also regulate brain development through a caspase(CASP3)-dependent proapoptotic activity. Forward signaling may result in activation of components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1 AND MAPK3 which are phosphorylated upon activation of EPHA7. Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T57006 PDBSTRUC 3NRU; 3H8M; 3DKO; 2REI T57006 BIOCLASS Kinase T57006 ECNUMBER EC 2.7.10.1 T57006 SEQUENCE MVFQTRYPSWIILCYIWLLRFAHTGEAQAAKEVLLLDSKAQQTELEWISSPPNGWEEISGLDENYTPIRTYQVCQVMEPNQNNWLRTNWISKGNAQRIFVELKFTLRDCNSLPGVLGTCKETFNLYYYETDYDTGRNIRENLYVKIDTIAADESFTQGDLGERKMKLNTEVREIGPLSKKGFYLAFQDVGACIALVSVKVYYKKCWSIIENLAIFPDTVTGSEFSSLVEVRGTCVSSAEEEAENAPRMHCSAEGEWLVPIGKCICKAGYQQKGDTCEPCGRGFYKSSSQDLQCSRCPTHSFSDKEGSSRCECEDGYYRAPSDPPYVACTRPPSAPQNLIFNINQTTVSLEWSPPADNGGRNDVTYRILCKRCSWEQGECVPCGSNIGYMPQQTGLEDNYVTVMDLLAHANYTFEVEAVNGVSDLSRSQRLFAAVSITTGQAAPSQVSGVMKERVLQRSVELSWQEPEHPNGVITEYEIKYYEKDQRERTYSTVKTKSTSASINNLKPGTVYVFQIRAFTAAGYGNYSPRLDVATLEEATGKMFEATAVSSEQNPVIIIAVVAVAGTIILVFMVFGFIIGRRHCGYSKADQEGDEELYFHFKFPGTKTYIDPETYEDPNRAVHQFAKELDASCIKIERVIGAGEFGEVCSGRLKLPGKRDVAVAIKTLKVGYTEKQRRDFLCEASIMGQFDHPNVVHLEGVVTRGKPVMIVIEFMENGALDAFLRKHDGQFTVIQLVGMLRGIAAGMRYLADMGYVHRDLAARNILVNSNLVCKVSDFGLSRVIEDDPEAVYTTTGGKIPVRWTAPEAIQYRKFTSASDVWSYGIVMWEVMSYGERPYWDMSNQDVIKAIEEGYRLPAPMDCPAGLHQLMLDCWQKERAERPKFEQIVGILDKMIRNPNSLKTPLGTCSRPISPLLDQNTPDFTTFCSVGEWLQAIKMERYKDNFTAAGYNSLESVARMTIEDVMSLGITLVGHQKKIMSSIQTMRAQMLHLHGTGIQV T57006 DRUGINFO D02BXJ PMID21561767C8h Investigative T57006 DRUGINFO D05FXD PMID19788238C66 Investigative T57006 DRUGINFO D0X8BU PMID23489211C20 Investigative T90935 TARGETID T90935 T90935 FORMERID TTDR00018 T90935 UNIPROID DHC24_HUMAN T90935 TARGNAME Delta(24)-sterol reductase (DHCR24) T90935 GENENAME DHCR24 T90935 TARGTYPE Literature-reported T90935 SYNONYMS Seladin-1; Diminuto/dwarf1 homolog; DHCR24 T90935 FUNCTION Catalyzes the reduction of the delta-24 double bond of sterol intermediates. Protects cells from oxidative stress by reducing caspase 3 activity during apoptosis induced by oxidative stress. Also protects against amyloid-beta peptide-induced apoptosis. T90935 BIOCLASS CH-CH donor oxidoreductase T90935 ECNUMBER EC 1.3.1.72 T90935 SEQUENCE MEPAVSLAVCALLFLLWVRLKGLEFVLIHQRWVFVCLFLLPLSLIFDIYYYVRAWVVFKLSSAPRLHEQRVRDIQKQVREWKEQGSKTFMCTGRPGWLTVSLRVGKYKKTHKNIMINLMDILEVDTKKQIVRVEPLVTMGQVTALLTSIGWTLPVLPELDDLTVGGLIMGTGIESSSHKYGLFQHICTAYELVLADGSFVRCTPSENSDLFYAVPWSCGTLGFLVAAEIRIIPAKKYVKLRFEPVRGLEAICAKFTHESQRQENHFVEGLLYSLDEAVIMTGVMTDEAEPSKLNSIGNYYKPWFFKHVENYLKTNREGLEYIPLRHYYHRHTRSIFWELQDIIPFGNNPIFRYLFGWMVPPKISLLKLTQGETLRKLYEQHHVVQDMLVPMKCLQQALHTFQNDIHVYPIWLCPFILPSQPGLVHPKGNEAELYIDIGAYGEPRVKHFEARSCMRQLEKFVRSVHGFQMLYADCYMNREEFWEMFDGSLYHKLREKLGCQDAFPEVYDKICKAARH T90935 DRUGINFO D0K6NS T-226293 Preclinical T90935 DRUGINFO D06IAT Diazacholesterol Investigative T82848 TARGETID T82848 T82848 FORMERID TTDI00077 T82848 UNIPROID PTN14_HUMAN T82848 TARGNAME Protein-tyrosine phosphatase pez (PTPN14) T82848 GENENAME PTPN14 T82848 TARGTYPE Literature-reported T82848 SYNONYMS Tyrosine-protein phosphatase non-receptor type 14; PTPD2; PEZ T82848 FUNCTION Mediates beta-catenin dephosphorylation at adhesion junctions. Acts as a negative regulator of the oncogenic property of YAP, a downstream target of the hippo pathway, in a cell density-dependent manner. May function as a tumor suppressor. Protein tyrosine phosphatase which may play a role in the regulation of lymphangiogenesis, cell-cell adhesion, cell-matrix adhesion, cell migration, cell growth and also regulates TGF-beta gene expression, thereby modulating epithelial-mesenchymal transition. T82848 PDBSTRUC 2BZL T82848 BIOCLASS Phosphoric monoester hydrolase T82848 ECNUMBER EC 3.1.3.48 T82848 SEQUENCE MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELRETHYFGLWFLSKSQQARWVELEKPLKKHLDKFANEPLLFFGVMFYVPNVSWLQQEATRYQYYLQVKKDVLEGRLRCTLDQVIRLAGLAVQADFGDYNQFDSQDFLREYVLFPMDLALEEAVLEELTQKVAQEHKAHSGILPAEAELMYINEVERLDGFGQEIFPVKDNHGNCVHLGIFFMGIFVRNRIGRQAVIYRWNDMGNITHNKSTILVELINKEETALFHTDDIENAKYISRLFATRHKFYKQNKICTEQSNSPPPIRRQPTWSRSSLPRQQPYILPPVHVQCGEHYSETHTSQDSIFHGNEEALYCNSHNSLDLNYLNGTVTNGSVCSVHSVNSLNCSQSFIQASPVSSNLSIPGSDIMRADYIPSHRHSAIIVPSYRPTPDYETVMRQMKRGILHTDSQSQSLRNLNIINTHAYNQPEDLVYSQPEMRERHPYTVPYGPQGVYSNKLVSPSDQRNPKNNVVPSKPGASAISHTVSTPELANMQLQGSHNYSTAHMLKNYLFRPPPPYPRPRPATSTPDLASHRHKYVSGSSPDLVTRKVQLSVKTFQEDSSPVVHQSLQEVSEPLTATKHHGTVNKRHSLEVMNSMVRGMEAMTLKSLHLPMARRNTLREQGPPEEGSGSHEVPQLPQYHHKKTFSDATMLIHSSESEEEEEEAPESVPQIPMLREKMEYSAQLQAALARIPNKPPPEYPGPRKSVSNGALRQDQASLPPAMARARVLRHGPAKAISMSRTDPPAVNGASLGPSISEPDLTSVKERVKKEPVKERPVSEMFSLEDSIIEREMMIRNLEKQKMAGLEAQKRPLMLAALNGLSVARVSGREENRVDATRVPMDERFRTLKKKLEEGMVFTEYEQIPKKKANGIFSTAALPENAERSRIREVVPYEENRVELIPTKENNTGYINASHIKVVVGGAEWHYIATQGPLPHTCHDFWQMVWEQGVNVIAMVTAEEEGGRTKSHRYWPKLGSKHSSATYGKFKVTTKFRTDSVCYATTGLKVKHLLSGQERTVWHLQYTDWPDHGCPEDVQGFLSYLEEIQSVRRHTNSMLEGTKNRHPPIVVHCSAGVGRTGVLILSELMIYCLEHNEKVEVPMMLRLLREQRMFMIQTIAQYKFVYQVLIQFLQNSRLI T73977 TARGETID T73977 T73977 FORMERID TTDR00200 T73977 UNIPROID CAC1E_HUMAN T73977 TARGNAME Voltage-gated calcium channel alpha Cav2.3 (CACNA1E) T73977 GENENAME CACNA1E T73977 TARGTYPE Literature-reported T73977 SYNONYMS Voltage-gated calcium channel subunit alpha Cav2.3; Voltage-gated calcium channel alpha subunit Cav2.3; Voltage-dependent R-type calcium channel subunit alpha-1E; Voltage-dependent R-type calcium channel; R-type voltage-gated calcium channel; Class E voltage-gated calcium channel; Calcium channel, Ltype, alpha-1 polypeptide, isoform 6; Calcium channel, L type, alpha-1 polypeptide, isoform 6; CACNL1A6; CACH6; Brain calcium channel II; BII T73977 FUNCTION The isoform alpha-1E gives rise to R-type calcium currents. R-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by nickel. They are however insensitive to dihydropyridines (DHP). Calcium channels containing alpha-1E subunit could be involved in the modulation of firing patterns of neurons which is important for information processing. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. T73977 PDBSTRUC 3BXL T73977 BIOCLASS Voltage-gated ion channel T73977 SEQUENCE MARFGEAVVARPGSGDGDSDQSRNRQGTPVPASGQAAAYKQTKAQRARTMALYNPIPVRQNCFTVNRSLFIFGEDNIVRKYAKKLIDWPPFEYMILATIIANCIVLALEQHLPEDDKTPMSRRLEKTEPYFIGIFCFEAGIKIVALGFIFHKGSYLRNGWNVMDFIVVLSGILATAGTHFNTHVDLRTLRAVRVLRPLKLVSGIPSLQIVLKSIMKAMVPLLQIGLLLFFAILMFAIIGLEFYSGKLHRACFMNNSGILEGFDPPHPCGVQGCPAGYECKDWIGPNDGITQFDNILFAVLTVFQCITMEGWTTVLYNTNDALGATWNWLYFIPLIIIGSFFVLNLVLGVLSGEFAKERERVENRRAFMKLRRQQQIERELNGYRAWIDKAEEVMLAEENKNAGTSALEVLRRATIKRSRTEAMTRDSSDEHCVDISSVGTPLARASIKSAKVDGVSYFRHKERLLRISIRHMVKSQVFYWIVLSLVALNTACVAIVHHNQPQWLTHLLYYAEFLFLGLFLLEMSLKMYGMGPRLYFHSSFNCFDFGVTVGSIFEVVWAIFRPGTSFGISVLRALRLLRIFKITKYWASLRNLVVSLMSSMKSIISLLFLLFLFIVVFALLGMQLFGGRFNFNDGTPSANFDTFPAAIMTVFQILTGEDWNEVMYNGIRSQGGVSSGMWSAIYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTKDEQEEEEAFNQKHALQKAKEVSPMSAPNMPSIERDRRRRHHMSMWEPRSSHLRERRRRHHMSVWEQRTSQLRKHMQMSSQEALNREEAPTMNPLNPLNPLSSLNPLNAHPSLYRRPRAIEGLALGLALEKFEEERISRGGSLKGDGGDRSSALDNQRTPLSLGQREPPWLARPCHGNCDPTQQEAGGGEAVVTFEDRARHRQSQRRSRHRRVRTEGKESSSASRSRSASQERSLDEAMPTEGEKDHELRGNHGAKEPTIQEERAQDLRRTNSLMVSRGSGLAGGLDEADTPLVLPHPELEVGKHVVLTEQEPEGSSEQALLGNVQLDMGRVISQSEPDLSCITANTDKATTESTSVTVAIPDVDPLVDSTVVHISNKTDGEASPLKEAEIREDEEEVEKKKQKKEKRETGKAMVPHSSMFIFSTTNPIRRACHYIVNLRYFEMCILLVIAASSIALAAEDPVLTNSERNKVLRYFDYVFTGVFTFEMVIKMIDQGLILQDGSYFRDLWNILDFVVVVGALVAFALANALGTNKGRDIKTIKSLRVLRVLRPLKTIKRLPKLKAVFDCVVTSLKNVFNILIVYKLFMFIFAVIAVQLFKGKFFYCTDSSKDTEKECIGNYVDHEKNKMEVKGREWKRHEFHYDNIIWALLTLFTVSTGEGWPQVLQHSVDVTEEDRGPSRSNRMEMSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKMMEECSLEKNERACIDFAISAKPLTRYMPQNRHTFQYRVWHFVVSPSFEYTIMAMIALNTVVLMMKYYSAPCTYELALKYLNIAFTMVFSLECVLKVIAFGFLNYFRDTWNIFDFITVIGSITEIILTDSKLVNTSGFNMSFLKLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQVFGNIKLDEESHINRHNNFRSFFGSLMLLFRSATGEAWQEIMLSCLGEKGCEPDTTAPSGQNENERCGTDLAYVYFVSFIFFCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEFVRVWAEYDRAACGRIHYTEMYEMLTLMSPPLGLGKRCPSKVAYKRLVLMNMPVAEDMTVHFTSTLMALIRTALDIKIAKGGADRQQLDSELQKETLAIWPHLSQKMLDLLVPMPKASDLTVGKIYAAMMIMDYYKQSKVKKQRQQLEEQKNAPMFQRMEPSSLPQEIIANAKALPYLQQDPVSGLSGRSGYPSMSPLSPQDIFQLACMDPADDGQFQERQSLEPEVSELKSVQPSNHGIYLPSDTQEHAGSGRASSMPRLTVDPQVVTDPSSMRRSFSTIRDKRSNSSWLEEFSMERSSENTYKSRRRSYHSSLRLSAHRLNSDSGHKSDTHRSGGRERGRSKERKHLLSPDVSRCNSEERGTQADWESPERRQSRSPSEGRSQTPNRQGTGSLSESSIPSVSDTSTPRRSRRQLPPVPPKPRPLLSYSSLIRHAGSISPPADGSEEGSPLTSQALESNNACLTESSNSPHPQQSQHASPQRYISEPYLALHEDSHASDCGEEETLTFEAAVATSLGRSNTIGSAPPLRHSWQMPNGHYRRRRRGGPGPGMMCGAVNNLLSDTEEDDKC T73977 DRUGINFO D0QQ7N TH-9229 Terminated T73977 DRUGINFO D09YTH CPU-228 Investigative T60003 TARGETID T60003 T60003 FORMERID TTDI03493 T60003 UNIPROID PKN1_HUMAN T60003 TARGNAME Protein kinase N1 (PKN1) T60003 GENENAME PKN1 T60003 TARGTYPE Literature-reported T60003 SYNONYMS Serine/threonine-protein kinase N1; Serine-threonine protein kinase N; Protein-kinase C-related kinase 1; Protein kinase PKN-alpha; Protein kinase C-like PKN; Protein kinase C-like 1; Protease-activated kinase 1; PRKCL1; PRK1; PKN; PAK1 T60003 FUNCTION Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14. Regulates the cytoskeletal network by phosphorylating proteins such as VIM and neurofilament proteins NEFH, NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to bind to microtubules, resulting in disruption of tubulin assembly. Acts as a key coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and specifically mediating phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for epigenetic transcriptional activation that promotes demethylation of histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, HDAC7 and HDAC9, leading to impair their import in the nucleus. Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro. PKC-related serine/threonine-protein kinase involved in various processes such as regulation of the intermediate filaments of the actin cytoskeleton, cell migration, tumor cell invasion and transcription regulation. T60003 PDBSTRUC 4OTI; 4OTH; 4OTG; 4OTD; 4NKG T60003 BIOCLASS Kinase T60003 ECNUMBER EC 2.7.11.13 T60003 SEQUENCE MASDAVQSEPRSWSLLEQLGLAGADLAAPGVQQQLELERERLRREIRKELKLKEGAENLRRATTDLGRSLGPVELLLRGSSRRLDLLHQQLQELHAHVVLPDPAATHDGPQSPGAGGPTCSATNLSRVAGLEKQLAIELKVKQGAENMIQTYSNGSTKDRKLLLTAQQMLQDSKTKIDIIRMQLRRALQAGQLENQAAPDDTQGSPDLGAVELRIEELRHHFRVEHAVAEGAKNVLRLLSAAKAPDRKAVSEAQEKLTESNQKLGLLREALERRLGELPADHPKGRLLREELAAASSAAFSTRLAGPFPATHYSTLCKPAPLTGTLEVRVVGCRDLPETIPWNPTPSMGGPGTPDSRPPFLSRPARGLYSRSGSLSGRSSLKAEAENTSEVSTVLKLDNTVVGQTSWKPCGPNAWDQSFTLELERARELELAVFWRDQRGLCALKFLKLEDFLDNERHEVQLDMEPQGCLVAEVTFRNPVIERIPRLRRQKKIFSKQQGKAFQRARQMNIDVATWVRLLRRLIPNATGTGTFSPGASPGSEARTTGDISVEKLNLGTDSDSSPQKSSRDPPSSPSSLSSPIQESTAPELPSETQETPGPALCSPLRKSPLTLEDFKFLAVLGRGHFGKVLLSEFRPSGELFAIKALKKGDIVARDEVESLMCEKRILAAVTSAGHPFLVNLFGCFQTPEHVCFVMEYSAGGDLMLHIHSDVFSEPRAIFYSACVVLGLQFLHEHKIVYRDLKLDNLLLDTEGYVKIADFGLCKEGMGYGDRTSTFCGTPEFLAPEVLTDTSYTRAVDWWGLGVLLYEMLVGESPFPGDDEEEVFDSIVNDEVRYPRFLSAEAIGIMRRLLRRNPERRLGSSERDAEDVKKQPFFRTLGWEALLARRLPPPFVPTLSGRTDVSNFDEEFTGEAPTLSPPRDARPLTAAEQAAFLDFDFVAGGC T60003 DRUGINFO D06HVH PMID22136433C20 Investigative T60003 DRUGINFO D03CPB RKI-1447 Investigative T94197 TARGETID T94197 T94197 FORMERID TTDI03494 T94197 UNIPROID PKN2_HUMAN T94197 TARGNAME Protein kinase N2 (PKN2) T94197 GENENAME PKN2 T94197 TARGTYPE Literature-reported T94197 SYNONYMS Serine/threonine-protein kinase N2; Protein-kinase C-related kinase 2; Protein kinase C-like 2; PRKCL2; PRK2; PKN gamma T94197 FUNCTION Plays a role in the regulation of cell cycle progression, actin cytoskeleton assembly, cell migration, cell adhesion, tumor cell invasion and transcription activation signaling processes. Phosphorylates CTTN in hyaluronan-induced astrocytes and hence decreases CTTN ability to associate with filamentous actin. Phosphorylates HDAC5, therefore lead to impair HDAC5 import. Direct RhoA target required for the regulation of the maturation of primordial junctions into apical junction formation in bronchial epithelial cells. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Stimulates FYN kinase activity that is required for establishment of skin cell-cell adhesion during keratinocytes differentiation. Regulates epithelial bladder cells speed and direction of movement during cell migration and tumor cell invasion. Inhibits Akt pro-survival-induced kinase activity. Mediates Rho protein-induced transcriptional activation via the c-fos serum response factor (SRF). Involved in the negative regulation of ciliogenesis. PKC-related serine/threonine-protein kinase and Rho/Rac effector protein that participates in specific signal transduction responses in the cell. T94197 PDBSTRUC 6GBE; 6CCY; 4RRV; 4CRS T94197 BIOCLASS Kinase T94197 ECNUMBER EC 2.7.11.13 T94197 SEQUENCE MASNPERGEILLTELQGDSRSLPFSENVSAVQKLDFSDTMVQQKLDDIKDRIKREIRKELKIKEGAENLRKVTTDKKSLAYVDNILKKSNKKLEELHHKLQELNAHIVVSDPEDITDCPRTPDTPNNDPRCSTSNNRLKALQKQLDIELKVKQGAENMIQMYSNGSSKDRKLHGTAQQLLQDSKTKIEVIRMQILQAVQTNELAFDNAKPVISPLELRMEELRHHFRIEFAVAEGAKNVMKLLGSGKVTDRKALSEAQARFNESSQKLDLLKYSLEQRLNEVPKNHPKSRIIIEELSLVAASPTLSPRQSMISTQNQYSTLSKPAALTGTLEVRLMGCQDILENVPGRSKATSVALPGWSPSETRSSFMSRTSKSKSGSSRNLLKTDDLSNDVCAVLKLDNTVVGQTSWKPISNQSWDQKFTLELDRSRELEISVYWRDWRSLCAVKFLRLEDFLDNQRHGMCLYLEPQGTLFAEVTFFNPVIERRPKLQRQKKIFSKQQGKTFLRAPQMNINIATWGRLVRRAIPTVNHSGTFSPQAPVPTTVPVVDVRIPQLAPPASDSTVTKLDFDLEPEPPPAPPRASSLGEIDESSELRVLDIPGQDSETVFDIQNDRNSILPKSQSEYKPDTPQSGLEYSGIQELEDRRSQQRFQFNLQDFRCCAVLGRGHFGKVLLAEYKNTNEMFAIKALKKGDIVARDEVDSLMCEKRIFETVNSVRHPFLVNLFACFQTKEHVCFVMEYAAGGDLMMHIHTDVFSEPRAVFYAACVVLGLQYLHEHKIVYRDLKLDNLLLDTEGFVKIADFGLCKEGMGYGDRTSTFCGTPEFLAPEVLTETSYTRAVDWWGLGVLIYEMLVGESPFPGDDEEEVFDSIVNDEVRYPRFLSTEAISIMRRLLRRNPERRLGASEKDAEDVKKHPFFRLIDWSALMDKKVKPPFIPTIRGREDVSNFDDEFTSEAPILTPPREPRILSEEEQEMFRDFDYIADWC T94197 DRUGINFO D0N1UU PMID20471253C32 Investigative T83979 TARGETID T83979 T83979 FORMERID TTDI02539 T83979 UNIPROID PTGIS_HUMAN T83979 TARGNAME Prostacyclin synthase (PTGIS) T83979 GENENAME PTGIS T83979 TARGTYPE Literature-reported T83979 SYNONYMS Prostaglandin I2 synthase; PTGIS T83979 FUNCTION Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2). T83979 PDBSTRUC 3B6H; 2IAG T83979 BIOCLASS Intramolecular oxidoreductases T83979 ECNUMBER EC 5.3.99.4 T83979 SEQUENCE MAWAALLGLLAALLLLLLLSRRRTRRPGEPPLDLGSIPWLGYALDFGKDAASFLTRMKEKHGDIFTILVGGRYVTVLLDPHSYDAVVWEPRTRLDFHAYAIFLMERIFDVQLPHYSPSDEKARMKLTLLHRELQALTEAMYTNLHAVLLGDATEAGSGWHEMGLLDFSYSFLLRAGYLTLYGIEALPRTHESQAQDRVHSADVFHTFRQLDRLLPKLARGSLSVGDKDHMCSVKSRLWKLLSPARLARRAHRSKWLESYLLHLEEMGVSEEMQARALVLQLWATQGNMGPAAFWLLLFLLKNPEALAAVRGELESILWQAEQPVSQTTTLPQKVLDSTPVLDSVLSESLRLTAAPFITREVVVDLAMPMADGREFNLRRGDRLLLFPFLSPQRDPEIYTDPEVFKYNRFLNPDGSEKKDFYKDGKRLKNYNMPWGAGHNHCLGRSYAVNSIKQFVFLVLVHLDLELINADVEIPEFDLSRYGFGLMQPEHDVPVRYRIRP T72701 TARGETID T72701 T72701 FORMERID TTDI02304 T72701 UNIPROID RPOC_STAA8 T72701 TARGNAME Bacterial DNA-directed RNA polymerase beta' (Bact rpoC) T72701 GENENAME Bact rpoC T72701 TARGTYPE Literature-reported T72701 SYNONYMS rpoC; Transcriptase subunit beta'; RNAP subunit beta'; RNA polymerasesubunit beta'; DNAdirected RNA polymerase subunit beta' T72701 FUNCTION DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. T72701 BIOCLASS Nucleotidyltransferase T72701 ECNUMBER EC 2.7.7.6 T72701 SEQUENCE MIDVNNFHYMKIGLASPEKIRSWSFGEVKKPETINYRTLKPEKDGLFCERIFGPTKDWECSCGKYKRVRYKGMVCDRCGVEVTKSKVRRERMGHIELAAPVSHIWYFKGIPSRMGLLLDMSPRALEEVIYFASYVVVDPGPTGLEKKTLLSEAEFRDYYDKYPGQFVAKMGAEGIKDLLEEIDLDEELKLLRDELESATGQRLTRAIKRLEVVESFRNSGNKPSWMILDVLPIIPPEIRPMVQLDGGRFATSDLNDLYRRVINRNNRLKRLLDLGAPGIIVQNEKRMLQEAVDALIDNGRRGRPVTGPGNRPLKSLSHMLKGKQGRFRQNLLGKRVDYSGRSVIAVGPSLKMYQCGLPKEMALELFKPFVMKELVQREIATNIKNAKSKIERMDDEVWDVLEEVIREHPVLLNRAPTLHRLGIQAFEPTLVEGRAIRLHPLVTTAYNADFDGDQMAVHVPLSKEAQAEARMLMLAAQNILNPKDGKPVVTPSQDMVLGNYYLTLERKDAVNTGAIFNNTNEVLKAYANGFVHLHTRIGVHASSFNNPTFTEEQNKKILATSVGKIIFNEIIPDSFAYINEPTQENLERKTPNRYFIDPTTLGEGGLKEYFENEELIEPFNKKFLGNIIAEVFNRFSITDTSMMLDRMKDLGFKFSSKAGITVGVADIVVLPDKQQILDEHEKLVDRITKQFNRGLITEEERYNAVVEIWTDAKDQIQGELMQSLDKTNPIFMMSDSGARGNASNFTQLAGMRGLMAAPSGKIIELPITSSFREGLTVLEYFISTHGARKGLADTALKTADSGYLTRRLVDVAQDVIVREEDCGTDRGLLVSDIKEGTEMIEPFIERIEGRYSKETIRHPETDEIIIRPDELITPEIAKKITDAGIEQMYIRSAFTCNARHGVCEKCYGKNLATGEKVEVGEAVGTIAAQSIGEPGTQLTMRTFHTGGVAGSDITQGLPRIQEIFEARNPKGQAVITEIEGVVEDIKLAKDRQQEIVVKGANETRSYLASGTSRIIVEIGQPVQRGEVLTEGSIEPKNYLSVAGLNATESYLLKEVQKVYRMQGVEIDDKHVEVMVRQMLRKVRIIEAGDTKLLPGSLVDIHNFTDANREAFKHRKRPATAKPVLLGITKASLETESFLSAASFQETTRVLTDAAIKGKRDDLLGLKENVIIGKLIPAGTGMRRYSDVKYEKTAKPVAEVESQTEVTE T92639 TARGETID T92639 T92639 UNIPROID ATAT_HUMAN T92639 TARGNAME Alpha-tubulin N-acetyltransferase 1 (ATAT1) T92639 GENENAME ATAT1 T92639 TARGTYPE Literature-reported T92639 SYNONYMS MEC17; C6orf134; Alpha-TAT; Acetyltransferase mec-17 homolog T92639 FUNCTION Specifically acetylates 'Lys-40' in alpha-tubulin on the lumenal side of microtubules. Promotes microtubule destabilization and accelerates microtubule dynamics; this activity may be independent of acetylation activity. Acetylates alpha-tubulin with a slow enzymatic rate, due to a catalytic site that is not optimized for acetyl transfer. Enters the microtubule through each end and diffuses quickly throughout the lumen of microtubules. Acetylates only long/old microtubules because of its slow acetylation rate since it does not have time to act on dynamically unstable microtubules before the enzyme is released. Required for normal sperm flagellar function. Promotes directional cell locomotion and chemotaxis, through AP2A2-dependent acetylation of alpha-tubulin at clathrin-coated pits that are concentrated at the leading edge of migrating cells. May facilitate primary cilium assembly. T92639 PDBSTRUC 4U9Z; 4U9Y; 4PK3; 4PK2; 4IF5 T92639 BIOCLASS Acetyltransferase ATAT1 family T92639 ECNUMBER EC 2.3.1.108 T92639 SEQUENCE MEFPFDVDALFPERITVLDQHLRPPARRPGTTTPARVDLQQQIMTIIDELGKASAKAQNLSAPITSASRMQSNRHVVYILKDSSARPAGKGAIIGFIKVGYKKLFVLDDREAHNEVEPLCILDFYIHESVQRHGHGRELFQYMLQKERVEPHQLAIDRPSQKLLKFLNKHYNLETTVPQVNNFVIFEGFFAHQHRPPAPSLRATRHSRAAAVDPTPAAPARKLPPKRAEGDIKPYSSSDREFLKVAVEPPWPLNRAPRRATPPAHPPPRSSSLGNSPERGPLRPFVPEQELLRSLRLCPPHPTARLLLAADPGGSPAQRRRTRGTPPGLVAQSCCYSRHGGVNSSSPNTGNQDSKQGEQETKNRSASEEQALSQDGSGEKPMHTAPPQAPAPPAQSWTVGGDILNARFIRNLQERRSTRPW T92334 TARGETID T92334 T92334 UNIPROID M3K21_HUMAN T92334 TARGNAME Mixed lineage kinase 4 (MAP3K21) T92334 GENENAME MAP3K21 T92334 TARGTYPE Literature-reported T92334 SYNONYMS Mitogen-activated protein kinase kinase kinase MLK4; MLK4beta T92334 FUNCTION Negative regulator of TLR4 signaling. Does not activate JNK1/MAPK8 pathway, p38/MAPK14, nor ERK2/MAPK1 pathways. T92334 PDBSTRUC 4UYA T92334 BIOCLASS Protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase kinase subfamily T92334 ECNUMBER EC 2.7.11.25 T92334 SEQUENCE MALRGAAGATDTPVSSAGGAPGGSASSSSTSSGGSASAGAGLWAALYDYEARGEDELSLRRGQLVEVLSQDAAVSGDEGWWAGQVQRRLGIFPANYVAPCRPAASPAPPPSRPSSPVHVAFERLELKELIGAGGFGQVYRATWQGQEVAVKAARQDPEQDAAAAAESVRREARLFAMLRHPNIIELRGVCLQQPHLCLVLEFARGGALNRALAAANAAPDPRAPGPRRARRIPPHVLVNWAVQIARGMLYLHEEAFVPILHRDLKSSNILLLEKIEHDDICNKTLKITDFGLAREWHRTTKMSTAGTYAWMAPEVIKSSLFSKGSDIWSYGVLLWELLTGEVPYRGIDGLAVAYGVAVNKLTLPIPSTCPEPFAKLMKECWQQDPHIRPSFALILEQLTAIEGAVMTEMPQESFHSMQDDWKLEIQQMFDELRTKEKELRSREEELTRAALQQKSQEELLKRREQQLAEREIDVLERELNILIFQLNQEKPKVKKRKGKFKRSRLKLKDGHRISLPSDFQHKITVQASPNLDKRRSLNSSSSSPPSSPTMMPRLRAIQLTSDESNKTWGRNTVFRQEEFEDVKRNFKKKGCTWGPNSIQMKDRTDCKERIRPLSDGNSPWSTILIKNQKTMPLASLFVDQPGSCEEPKLSPDGLEHRKPKQIKLPSQAYIDLPLGKDAQRENPAEAESWEEAASANAATVSIEMTPTNSLSRSPQRKKTESALYGCTVLLASVALGLDLRELHKAQAAEEPLPKEEKKKREGIFQRASKSRRSASPPTSLPSTCGEASSPPSLPLSSALGILSTPSFSTKCLLQMDSEDPLVDSAPVTCDSEMLTPDFCPTAPGSGREPALMPRLDTDCSVSRNLPSSFLQQTCGNVPYCASSKHRPSHHRRTMSDGNPTPTGATIISATGASALPLCPSPAPHSHLPREVSPKKHSTVHIVPQRRPASLRSRSDLPQAYPQTAVSQLAQTACVVGRPGPHPTQFLAAKERTKSHVPSLLDADVEGQSRDYTVPLCRMRSKTSRPSIYELEKEFLS T15636 TARGETID T15636 T15636 FORMERID TTDR00588 T15636 UNIPROID TTBK1_HUMAN T15636 TARGNAME Tau-tubulin kinase (TTBK1) T15636 GENENAME TTBK1 T15636 TARGTYPE Literature-reported T15636 SYNONYMS Tau-tubulin kinase 1; KIAA1855; Brain-derived tau kinase; BDTK T15636 FUNCTION Serine/threonine kinase which is able to phosphorylate TAU on serine, threonine and tyrosine residues. Induces aggregation of TAU. T15636 PDBSTRUC 4NFN; 4NFM; 4BTM; 4BTK; 4BTJ T15636 BIOCLASS Kinase T15636 ECNUMBER EC 2.7.11.1 T15636 SEQUENCE MQCLAAALKDETNMSGGGEQADILPANYVVKDRWKVLKKIGGGGFGEIYEAMDLLTRENVALKVESAQQPKQVLKMEVAVLKKLQGKDHVCRFIGCGRNEKFNYVVMQLQGRNLADLRRSQPRGTFTLSTTLRLGKQILESIEAIHSVGFLHRDIKPSNFAMGRLPSTYRKCYMLDFGLARQYTNTTGDVRPPRNVAGFRGTVRYASVNAHKNREMGRHDDLWSLFYMLVEFAVGQLPWRKIKDKEQVGMIKEKYEHRMLLKHMPSEFHLFLDHIASLDYFTKPDYQLIMSVFENSMKERGIAENEAFDWEKAGTDALLSTSTSTPPQQNTRQTAAMFGVVNVTPVPGDLLRENTEDVLQGEHLSDQENAPPILPGRPSEGLGPSPHLVPHPGGPEAEVWEETDVNRNKLRINIGKSPCVEEEQSRGMGVPSSPVRAPPDSPTTPVRSLRYRRVNSPESERLSTADGRVELPERRSRMDLPGSPSRQACSSQPAQMLSVDTGHADRQASGRMDVSASVEQEALSNAFRSVPLAEEEDFDSKEWVIIDKETELKDFPPGAEPSTSGTTDEEPEELRPLPEEGEERRRLGAEPTVRPRGRSMQALAEEDLQHLPPQPLPPQLSQGDGRSETSQPPTPGSPSHSPLHSGPRPRRRESDPTGPQRQVFSVAPPFEVNGLPRAVPLSLPYQDFKRDLSDYRERARLLNRVRRVGFSHMLLTTPQVPLAPVQPQANGKEEEEEEEEDEEEEEEDEEEEEEEEEEEEEEEEEEEEEEEAAAAVALGEVLGPRSGSSSEGSERSTDRSQEGAPSTLLADDQKESRGRASMADGDLEPEEGSKTLVLVSPGDMKKSPVTAELAPDPDLGTLAALTPQHERPQPTGSQLDVSEPGTLSSVLKSEPKPPGPGAGLGAGTVTTGVGGVAVTSSPFTKVERTFVHIAEKTHLNVMSSGGQALRSEEFSAGGELGLELASDGGAVEEGARAPLENGLALSGLNGAEIEGSALSGAPRETPSEMATNSLPNGPALADGPAPVSPLEPSPEKVATISPRRHAMPGSRPRSRIPVLLSEEDTGSEPSGSLSAKERWSKRARPQQDLARLVMEKRQGRLLLRLASGASSSSSEEQRRASETLSGTGSEEDTPASEPAAALPRKSGRAAATRSRIPRPIGLRMPMPVAAQQPASRSHGAAPALDTAITSRLQLQTPPGSATAADLRPKQPPGRGLGPGRAQAGARPPAPRSPRLPASTSAARNASASPRSQSLSRRESPSPSHQARPGVPPPRGVPPARAQPDGTPSPGGSKKGPRGKLQAQRATTKGRAGGAEGRAGAR T65084 TARGETID T65084 T65084 FORMERID TTDI00096 T65084 UNIPROID OTU1_HUMAN T65084 TARGNAME Ubiquitin thioesterase OTU1 (YOD1) T65084 GENENAME YOD1 T65084 TARGTYPE Literature-reported T65084 SYNONYMS PRO0907; OTUD2; OTU domain-containing protein 2; HsHIN7; HIV-1-induced protease 7; HIN7; HIN-7; DUBA8; DUBA-8 T65084 FUNCTION May act by triming the ubiquitin chain on the associated substrate to facilitate their threading through the VCP/p97 pore. Ubiquitin moieties on substrates may present a steric impediment to the threading process when the substrate is transferred to the VCP pore and threaded through VCP's axial channel. Mediates deubiquitination of 'Lys-27'-, 'Lys-29'- and 'Lys-33'-linked polyubiquitin chains. Also able to hydrolyze 'Lys-11'-linked ubiquitin chains. Cleaves both polyubiquitin and di-ubiquitin. May play a role in macroautophagy, regulating for instance the clearance of damaged lysosomes. May recruit PLAA, UBXN6 and VCP to damaged lysosome membranes decorated with K48-linked ubiquitin chains and remove these chains allowing autophagosome formation. Hydrolase that can remove conjugated ubiquitin from proteins and participates in endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal proteins. T65084 PDBSTRUC 4BOZ; 4BOS; 4BOQ T65084 BIOCLASS Peptidase T65084 ECNUMBER EC 3.4.19.12 T65084 SEQUENCE MFGPAKGRHFGVHPAPGFPGGVSQQAAGTKAGPAGAWPVGSRTDTMWRLRCKAKDGTHVLQGLSSRTRVRELQGQIAAITGIAPGGQRILVGYPPECLDLSNGDTILEDLPIQSGDMLIIEEDQTRPRSSPAFTKRGASSYVRETLPVLTRTVVPADNSCLFTSVYYVVEGGVLNPACAPEMRRLIAQIVASDPDFYSEAILGKTNQEYCDWIKRDDTWGGAIEISILSKFYQCEICVVDTQTVRIDRFGEDAGYTKRVLLIYDGIHYDPLQRNFPDPDTPPLTIFSSNDDIVLVQALELADEARRRRQFTDVNRFTLRCMVCQKGLTGQAEAREHAKETGHTNFGEV T65818 TARGETID T65818 T65818 FORMERID TTDI03171 T65818 UNIPROID ERAP2_HUMAN T65818 TARGNAME Endoplasmic reticulum aminopeptidase 2 (ERAP2) T65818 GENENAME ERAP2 T65818 TARGTYPE Literature-reported T65818 SYNONYMS Leukocyte-derived arginine aminopeptidase; LRAP; L-RAP T65818 FUNCTION Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Preferentially hydrolyzes the basic residues Arg and Lys. Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. T65818 PDBSTRUC 5K1V; 5J6S; 5CU5; 5AB2; 5AB0 T65818 BIOCLASS Peptidase T65818 ECNUMBER EC 3.4.11.- T65818 SEQUENCE MFHSSAMVNSHRKPMFNIHRGFYCLTAILPQICICSQFSVPSSYHFTEDPGAFPVATNGERFPWQELRLPSVVIPLHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDSRYMKPGKELKVLSYPAHEQIALLVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNMPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWWNDIWLKEGFAKYMELIAVNATYPELQFDDYFLNVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNSCLESDFTSGGVCHSDPKMTSNMLAFLGENAEVKEMMTTWTLQKGIPLLVVKQDGCSLRLQQERFLQGVFQEDPEWRALQERYLWHIPLTYSTSSSNVIHRHILKSKTDTLDLPEKTSWVKFNVDSNGYYIVHYEGHGWDQLITQLNQNHTLLRPKDRVGLIHDVFQLVGAGRLTLDKALDMTYYLQHETSSPALLEGLSYLESFYHMMDRRNISDISENLKRYLLQYFKPVIDRQSWSDKGSVWDRMLRSALLKLACDLNHAPCIQKAAELFSQWMESSGKLNIPTDVLKIVYSVGAQTTAGWNYLLEQYELSMSSAEQNKILYALSTSKHQEKLLKLIELGMEGKVIKTQNLAALLHAIARRPKGQQLAWDFVRENWTHLLKKFDLGSYDIRMIISGTTAHFSSKDKLQEVKLFFESLEAQGSHLDIFQTVLETITKNIKWLEKNLPTLRTWLMVNT T65818 DRUGINFO D02MNM PMID23916253C17 Investigative T82467 TARGETID T82467 T82467 FORMERID TTDI03046 T82467 UNIPROID ATAD2_HUMAN T82467 TARGNAME ATPase family AAA domain containing 2 (ATAD2) T82467 GENENAME ATAD2 T82467 TARGTYPE Literature-reported T82467 SYNONYMS PRO2000; L16; ATPase family AAA domain-containing protein 2; ANCCA; AAA nuclear coregulator cancer-associated protein T82467 FUNCTION May play a role in the recruitment or occupancy of CREBBP at some ESR1 target gene promoters. May be required for histone hyperacetylation. Involved in the estrogen-induced cell proliferation and cell cycle progression of breast cancer cells. May be a transcriptional coactivator of the nuclear receptor ESR1 required to induce the expression of a subset of estradiol target genes, such as CCND1, MYC and E2F1. T82467 PDBSTRUC 6HIE; 6HID; 6HIC; 6HIB; 6HIA T82467 BIOCLASS Acid anhydride hydrolase T82467 ECNUMBER EC 3.6.1.3 T82467 SEQUENCE MVVLRSSLELHNHSAASATGSLDLSSDFLSLEHIGRRRLRSAGAAQKKPAATTAKAGDGSSVKEVETYHRTRALRSLRKDAQNSSDSSFEKNVEITEQLANGRHFTRQLARQQADKKKEEHREDKVIPVTRSLRARNIVQSTEHLHEDNGDVEVRRSCRIRSRYSGVNQSMLFDKLITNTAEAVLQKMDDMKKMRRQRMRELEDLGVFNETEESNLNMYTRGKQKDIQRTDEETTDNQEGSVESSEEGEDQEHEDDGEDEDDEDDDDDDDDDDDDDDEDDEDEEDGEEENQKRYYLRQRKATVYYQAPLEKPRHQRKPNIFYSGPASPARPRYRLSSAGPRSPYCKRMNRRRHAIHSSDSTSSSSSEDEQHFERRRKRSRNRAINRCLPLNFRKDELKGIYKDRMKIGASLADVDPMQLDSSVRFDSVGGLSNHIAALKEMVVFPLLYPEVFEKFKIQPPRGCLFYGPPGTGKTLVARALANECSQGDKRVAFFMRKGADCLSKWVGESERQLRLLFDQAYQMRPSIIFFDEIDGLAPVRSSRQDQIHSSIVSTLLALMDGLDSRGEIVVIGATNRLDSIDPALRRPGRFDREFLFSLPDKEARKEILKIHTRDWNPKPLDTFLEELAENCVGYCGADIKSICAEAALCALRRRYPQIYTTSEKLQLDLSSINISAKDFEVAMQKMIPASQRAVTSPGQALSTVVKPLLQNTVDKILEALQRVFPHAEFRTNKTLDSDISCPLLESDLAYSDDDVPSVYENGLSQKSSHKAKDNFNFLHLNRNACYQPMSFRPRILIVGEPGFGQGSHLAPAVIHALEKFTVYTLDIPVLFGVSTTSPEETCAQVIREAKRTAPSIVYVPHIHVWWEIVGPTLKATFTTLLQNIPSFAPVLLLATSDKPHSALPEEVQELFIRDYGEIFNVQLPDKEERTKFFEDLILKQAAKPPISKKKAVLQALEVLPVAPPPEPRSLTAEEVKRLEEQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESRKKRGCSSSKYAPSYYHVMPKQNSTLVGDKRSDPEQNEKLKTPSTPVACSTPAQLKRKIRKKSNWYLGTIKKRRKISQAKDDSQNAIDHKIESDTEETQDTSVDHNETGNTGESSVEENEKQQNASESKLELRNNSNTCNIENELEDSRKTTACTELRDKIACNGDASSSQIIHISDENEGKEMCVLRMTRARRSQVEQQQLITVEKALAILSQPTPSLVVDHERLKNLLKTVVKKSQNYNIFQLENLYAVISQCIYRHRKDHDKTSLIQKMEQEVENFSCSR T82467 DRUGINFO D00XRH PMID26155854C60 Investigative T82467 DRUGINFO D0F5TZ PMID26155854C57 Investigative T10899 TARGETID T10899 T10899 FORMERID TTDI00224 T10899 UNIPROID UBP37_HUMAN T10899 TARGNAME Ubiquitin carboxyl-terminal hydrolase 37 (USP37) T10899 GENENAME USP37 T10899 TARGTYPE Literature-reported T10899 SYNONYMS Ubiquitin-specific-processing protease 37; Ubiquitin thioesterase 37; KIAA1594; Deubiquitinating enzyme 37 T10899 FUNCTION Specifically mediates deubiquitination of 'Lys-11'-linked polyubiquitin chains, a specific ubiquitin-linkage type mediated by the APC/C complex. Also mediates deubiquitination of 'Lys-48'-linked polyubiquitin chains in vitro. Phosphorylation at Ser-628 during G1/S phase maximizes the deubiquitinase activity, leading to prevent degradation of cyclin-A (CCNA1 and CCNA2). Plays an important role in the regulation of DNA replication by stabilizing the licensing factor CDT1. Deubiquitinase that antagonizes the anaphase-promoting complex (APC/C) during G1/S transition by mediating deubiquitination of cyclin-A (CCNA1 and CCNA2), thereby promoting S phase entry. T10899 PDBSTRUC 3U12 T10899 BIOCLASS Peptidase T10899 ECNUMBER EC 3.4.19.12 T10899 SEQUENCE MSPLKIHGPIRIRSMQTGITKWKEGSFEIVEKENKVSLVVHYNTGGIPRIFQLSHNIKNVVLRPSGAKQSRLMLTLQDNSFLSIDKVPSKDAEEMRLFLDAVHQNRLPAAMKPSQGSGSFGAILGSRTSQKETSRQLSYSDNQASAKRGSLETKDDIPFRKVLGNPGRGSIKTVAGSGIARTIPSLTSTSTPLRSGLLENRTEKRKRMISTGSELNEDYPKENDSSSNNKAMTDPSRKYLTSSREKQLSLKQSEENRTSGLLPLQSSSFYGSRAGSKEHSSGGTNLDRTNVSSQTPSAKRSLGFLPQPVPLSVKKLRCNQDYTGWNKPRVPLSSHQQQQLQGFSNLGNTCYMNAILQSLFSLQSFANDLLKQGIPWKKIPLNALIRRFAHLLVKKDICNSETKKDLLKKVKNAISATAERFSGYMQNDAHEFLSQCLDQLKEDMEKLNKTWKTEPVSGEENSPDISATRAYTCPVITNLEFEVQHSIICKACGEIIPKREQFNDLSIDLPRRKKPLPPRSIQDSLDLFFRAEELEYSCEKCGGKCALVRHKFNRLPRVLILHLKRYSFNVALSLNNKIGQQVIIPRYLTLSSHCTENTKPPFTLGWSAHMAISRPLKASQMVNSCITSPSTPSKKFTFKSKSSLALCLDSDSEDELKRSVALSQRLCEMLGNEQQQEDLEKDSKLCPIEPDKSELENSGFDRMSEEELLAAVLEISKRDASPSLSHEDDDKPTSSPDTGFAEDDIQEMPENPDTMETEKPKTITELDPASFTEITKDCDENKENKTPEGSQGEVDWLQQYDMEREREEQELQQALAQSLQEQEAWEQKEDDDLKRATELSLQEFNNSFVDALGSDEDSGNEDVFDMEYTEAEAEELKRNAETGNLPHSYRLISVVSHIGSTSSSGHYISDVYDIKKQAWFTYNDLEVSKIQEAAVQSDRDRSGYIFFYMHKEIFDELLETEKNSQSLSTEVGKTTRQAL T89466 TARGETID T89466 T89466 FORMERID TTDI02412 T89466 UNIPROID TRXR3_HUMAN T89466 TARGNAME Thioredoxin glutathione reductase (TGR) T89466 GENENAME TXNRD3 T89466 TARGTYPE Literature-reported T89466 SYNONYMS Thioredoxin reductase TR2; Thioredoxin reductase 3; Thioredoxin and glutathione reductase; TGR T89466 FUNCTION Displays thioredoxin reductase, glutaredoxin and glutathione reductase activities. Catalyzes disulfide bond isomerization. Promotes disulfide bond formation between GPX4 and various sperm proteins and may play a role in sperm maturation by promoting formation of sperm structural components (By similarity). T89466 PDBSTRUC 3H8Q T89466 BIOCLASS Sulfur donor oxidoreductase T89466 ECNUMBER EC 1.8.1.9 T89466 SEQUENCE MERSPPQSPGPGKAGDAPNRRSGHVRGARVLSPPGRRARLSSPGPSRSSEAREELRRHLVGLIERSRVVIFSKSYCPHSTRVKELFSSLGVECNVLELDQVDDGARVQEVLSEITNQKTVPNIFVNKVHVGGCDQTFQAYQSGLLQKLLQEDLAYDYDLIIIGGGSGGLSCAKEAAILGKKVMVLDFVVPSPQGTSWGLGGTCVNVGCIPKKLMHQAALLGQALCDSRKFGWEYNQQVRHNWETMTKAIQNHISSLNWGYRLSLREKAVAYVNSYGEFVEHHKIKATNKKGQETYYTAAQFVIATGERPRYLGIQGDKEYCITSDDLFSLPYCPGKTLVVGASYVALECAGFLAGFGLDVTVMVRSILLRGFDQEMAEKVGSYMEQHGVKFLRKFIPVMVQQLEKGSPGKLKVLAKSTEGTETIEGVYNTVLLAIGRDSCTRKIGLEKIGVKINEKSGKIPVNDVEQTNVPYVYAVGDILEDKPELTPVAIQSGKLLAQRLFGASLEKCDYINVPTTVFTPLEYGCCGLSEEKAIEVYKKENLEIYHTLFWPLEWTVAGRENNTCYAKIICNKFDHDRVIGFHILGPNAGEVTQGFAAAMKCGLTKQLLDDTIGIHPTCGEVFTTLEITKSSGLDITQKGCUG T05806 TARGETID T05806 T05806 FORMERID TTDR00853 T05806 UNIPROID BPHL_HUMAN T05806 TARGNAME Valacyclovir hydrolase (BPHL) T05806 GENENAME BPHL T05806 TARGTYPE Literature-reported T05806 SYNONYMS VACVase; MCNAA; DJ40E16.6.1; Breast epithelial mucin-associated antigen; Bph-rp; Biphenyl hydrolase-like protein (Serine hydrolase) (Breast epithelial mucin-associated antigen, MCNAA, Bph-rp), variant 1; Biphenyl hydrolase-like protein; BPHL T05806 FUNCTION Serine hydrolase that catalyzes the hydrolytic activation of amino acid ester prodrugs of nucleoside analogs such as valacyclovir and valganciclovir. Activates valacyclovir to acyclovir. May play a role in detoxification processes. It is a specific alpha-amino acid ester hydrolase that prefers small, hydrophobic, and aromatic side chains and does not have a stringent requirement for the leaving group other than preferring aprimary alcohol. T05806 PDBSTRUC 2OCL; 2OCK; 2OCI; 2OCG T05806 BIOCLASS Carboxylic ester hydrolase T05806 ECNUMBER EC 3.1.-.- T05806 SEQUENCE MVAVLGGRGVLRLRLLLSALKPGIHVPRAGPAAAFGTSVTSAKVAVNGVQLHYQQTGEGDHAVLLLPGMLGSGETDFGPQLKNLNKKLFTVVAWDPRGYGHSRPPDRDFPADFFERDAKDAVDLMKALKFKKVSLLGWSDGGITALIAAAKYPSYIHKMVIWGANAYVTDEDSMIYEGIRDVSKWSERTRKPLEALYGYDYFARTCEKWVDGIRQFKHLPDGNICRHLLPRVQCPALIVHGEKDPLVPRFHADFIHKHVKGSRLHLMPEGKHNLHLRFADEFNKLAEDFLQ T05806 DRUGINFO D0DO9W L-Tyrosinamide Investigative T12837 TARGETID T12837 T12837 FORMERID TTDI02431 T12837 UNIPROID CARM1_HUMAN T12837 TARGNAME Histone-arginine methyltransferase CARM1 (CARM1) T12837 GENENAME CARM1 T12837 TARGTYPE Literature-reported T12837 SYNONYMS Protein arginine N-methyltransferase 4; PRMT4; Histonearginine methyltransferase CARM1; Coactivatorassociated arginine methyltransferase 1; Coactivator-associated arginine methyltransferase 1 T12837 FUNCTION Recruited to promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 families, methylates histone H3 at 'Arg-17' (H3R17me), forming mainly asymmetric dimethylarginine (H3R17me2a), leading to activate transcription via chromatin remodeling. During nuclear hormone receptor activation and TCF7L2/TCF4 activation, acts synergically with EP300/P300 and either one of the p160 histone acetyltransferases NCOA1/SRC1, NCOA2/GRIP1 and NCOA3/ACTR or CTNNB1/beta-catenin to activate transcription. During myogenic transcriptional activation, acts together with NCOA3/ACTR as a coactivator for MEF2C. During monocyte inflammatory stimulation, acts together with EP300/P300 as a coactivator for NF-kappa-B. Acts as coactivator for PPARG, promotes adipocyte differentiation and the accumulation of brown fat tissue. Plays a role in the regulation of pre-mRNA alternative splicing by methylation of splicing factors. Also seems to be involved in p53/TP53 transcriptional activation. Methylates EP300/P300, both at 'Arg-2142', which may loosen its interaction with NCOA2/GRIP1, and at 'Arg-580' and 'Arg-604' in the KIX domain, which impairs its interaction with CREB and inhibits CREB-dependent transcriptional activation. Also methylates arginine residues in RNA-binding proteins PABPC1, ELAVL1 and ELAV4, which may affect their mRNA-stabilizing properties and the half-life of their target mRNAs. Methylates (mono- and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in several proteins involved in DNA packaging, transcription regulation, pre-mRNA splicing, and mRNA stability. T12837 BIOCLASS Methyltransferase T12837 ECNUMBER EC 2.1.1.319 T12837 SEQUENCE MAAAAAAVGPGAGGAGSAVPGGAGPCATVSVFPGARLLTIGDANGEIQRHAEQQALRLEVRAGPDSAGIALYSHEDVCVFKCSVSRETECSRVGKQSFIITLGCNSVLIQFATPNDFCSFYNILKTCRGHTLERSVFSERTEESSAVQYFQFYGYLSQQQNMMQDYVRTGTYQRAILQNHTDFKDKIVLDVGCGSGILSFFAAQAGARKIYAVEASTMAQHAEVLVKSNNLTDRIVVIPGKVEEVSLPEQVDIIISEPMGYMLFNERMLESYLHAKKYLKPSGNMFPTIGDVHLAPFTDEQLYMEQFTKANFWYQPSFHGVDLSALRGAAVDEYFRQPVVDTFDIRILMAKSVKYTVNFLEAKEGDLHRIEIPFKFHMLHSGLVHGLAFWFDVAFIGSIMTVWLSTAPTEPLTHWYQVRCLFQSPLFAKAGDTLSGTCLLIANKRQSYDISIVAQVDQTGSKSSNLLDLKNPFFRYTGTTPSPPPGSHYTSPSENMWNTGSTYNLSSGMAVAGMPTAYDLSSVIASGSSVGHNNLIPLANTGIVNHTHSRMGSIMSTGIVQGSSGAQGSGGGSTSAHYAVNSQFTMGGPAISMASPMSIPTNTMHYGS T12837 DRUGINFO D0BU8W BMS pyrazole inhibitor 7f Investigative T12837 DRUGINFO D0Q3FY PMID19632837C17f Investigative T46000 TARGETID T46000 T46000 FORMERID TTDI03385 T46000 UNIPROID M4K3_HUMAN T46000 TARGNAME MEK kinase kinase 3 (MAP4K3) T46000 GENENAME MAP4K3 T46000 TARGTYPE Literature-reported T46000 SYNONYMS RAB8IPL1; Mitogen-activated protein kinase kinase kinase kinase 3; MEKKK 3; MAPK/ERK kinase kinase kinase 3; Germinal center kinase-related protein kinase; GLK T46000 FUNCTION Appears to act upstream of the JUN N-terminal pathway. May play a role in the response to environmental stress. T46000 PDBSTRUC 5J5T T46000 BIOCLASS Kinase T46000 ECNUMBER EC 2.7.11.1 T46000 SEQUENCE MNPGFDLSRRNPQEDFELIQRIGSGTYGDVYKARNVNTGELAAIKVIKLEPGEDFAVVQQEIIMMKDCKHPNIVAYFGSYLRRDKLWICMEFCGGGSLQDIYHVTGPLSELQIAYVSRETLQGLYYLHSKGKMHRDIKGANILLTDNGHVKLADFGVSAQITATIAKRKSFIGTPYWMAPEVAAVERKGGYNQLCDLWAVGITAIELAELQPPMFDLHPMRALFLMTKSNFQPPKLKDKMKWSNSFHHFVKMALTKNPKKRPTAEKLLQHPFVTQHLTRSLAIELLDKVNNPDHSTYHDFDDDDPEPLVAVPHRIHSTSRNVREEKTRSEITFGQVKFDPPLRKETEPHHELPDSDGFLDSSEEIYYTARSNLDLQLEYGQGHQGGYFLGANKSLLKSVEEELHQRGHVAHLEDDEGDDDESKHSTLKAKIPPPLPPKPKSIFIPQEMHSTEDENQGTIKRCPMSGSPAKPSQVPPRPPPPRLPPHKPVALGNGMSSFQLNGERDGSLCQQQNEHRGTNLSRKEKKDVPKPISNGLPPTPKVHMGACFSKVFNGCPLKIHCASSWINPDTRDQYLIFGAEEGIYTLNLNELHETSMEQLFPRRCTWLYVMNNCLLSISGKASQLYSHNLPGLFDYARQMQKLPVAIPAHKLPDRILPRKFSVSAKIPETKWCQKCCVVRNPYTGHKYLCGALQTSIVLLEWVEPMQKFMLIKHIDFPIPCPLRMFEMLVVPEQEYPLVCVGVSRGRDFNQVVRFETVNPNSTSSWFTESDTPQTNVTHVTQLERDTILVCLDCCIKIVNLQGRLKSSRKLSSELTFDFQIESIVCLQDSVLAFWKHGMQGRSFRSNEVTQEISDSTRIFRLLGSDRVVVLESRPTDNPTANSNLYILAGHENSY T46000 DRUGINFO D0C2GE PMID22765894C8h Investigative T27954 TARGETID T27954 T27954 FORMERID TTDR01253 T27954 UNIPROID CA2D3_HUMAN T27954 TARGNAME Voltage-gated calcium channel alpha-2/delta-3 (CACNA2D3) T27954 GENENAME CACNA2D3 T27954 TARGTYPE Literature-reported T27954 SYNONYMS Voltage-gated calcium channel subunit alpha-2/delta-3; Voltage-dependent calcium channel subunit delta-3; Voltage-dependent calcium channel subunit alpha-2-3; CACNA2D3 T27954 FUNCTION The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G). T27954 BIOCLASS Voltage-gated ion channel T27954 SEQUENCE MAGPGSPRRASRGASALLAAALLYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKYSGSQLLQKKYKEYEKDVAIEEIDGLQLVKKLAKNMEEMFHKKSEAVRRLVEAAEEAHLKHEFDADLQYEYFNAVLINERDKDGNFLELGKEFILAPNDHFNNLPVNISLSDVQVPTNMYNKDPAIVNGVYWSESLNKVFVDNFDRDPSLIWQYFGSAKGFFRQYPGIKWEPDENGVIAFDCRNRKWYIQAATSPKDVVILVDVSGSMKGLRLTIAKQTVSSILDTLGDDDFFNIIAYNEELHYVEPCLNGTLVQADRTNKEHFREHLDKLFAKGIGMLDIALNEAFNILSDFNHTGQGSICSQAIMLITDGAVDTYDTIFAKYNWPDRKVRIFTYLIGREAAFADNLKWMACANKGFFTQISTLADVQENVMEYLHVLSRPKVIDQEHDVVWTEAYIDSTLPQAQKLTDDQGPVLMTTVAMPVFSKQNETRSKGILLGVVGTDVPVKELLKTIPKYKLGIHGYAFAITNNGYILTHPELRLLYEEGKKRRKPNYSSVDLSEVEWEDRDDVLRNAMVNRKTGKFSMEVKKTVDKGKRVLVMTNDYYYTDIKGTPFSLGVALSRGHGKYFFRGNVTIEEGLHDLEHPDVSLADEWSYCNTDLHPEHRHLSQLEAIKLYLKGKEPLLQCDKELIQEVLFDAVVSAPIEAYWTSLALNKSENSDKGVEVAFLGTRTGLSRINLFVGAEQLTNQDFLKAGDKENIFNADHFPLWYRRAAEQIPGSFVYSIPFSTGPVNKSNVVTASTSIQLLDERKSPVVAAVGIQMKLEFFQRKFWTASRQCASLDGKCSISCDDETVNCYLIDNNGFILVSEDYTQTGDFFGEIEGAVMNKLLTMGSFKRITLYDYQAMCRANKESSDGAHGLLDPYNAFLSAVKWIMTELVLFLVEFNLCSWWHSDMTAKAQKLKQTLEPCDTEYPAFVSERTIKETTGNIACEDCSKSFVIQQIPSSNLFMVVVDSSCLCESVAPITMAPIEIRYNESLKCERLKAQKIRRRPESCHGFHPEENARECGGAPSLQAQTVLLLLPLLLMLFSR T27954 DRUGINFO D0D1EU PD-144550 Investigative T27954 DRUGINFO D0T6DR 3-Aminomethyl-5-methyl-hexanoic acid Investigative T68443 TARGETID T68443 T68443 FORMERID TTDR00338 T68443 UNIPROID MMP21_HUMAN T68443 TARGNAME Matrix metalloproteinase-21 (MMP-21) T68443 GENENAME MMP21 T68443 TARGTYPE Literature-reported T68443 SYNONYMS MMP T68443 FUNCTION May act as a negative regulator of the NOTCH-signaling pathway. Cleaves alpha-1-antitrypsin. Plays a specialized role in the generation of left-right asymmetry during embryogenesis. T68443 BIOCLASS Peptidase T68443 ECNUMBER EC 3.4.24.- T68443 SEQUENCE MLAASIFRPTLLLCWLAAPWPTQPESLFHSRDRSDLEPSPLRQAKPIADLHAAQRFLSRYGWSGVWAAWGPSPEGPPETPKGAALAEAVRRFQRANALPASGELDAATLAAMNRPRCGVPDMRPPPPSAPPSPPGPPPRARSRRSPRAPLSLSRRGWQPRGYPDGGAAQAFSKRTLSWRLLGEALSSQLSVADQRRIVALAFRMWSEVTPLDFREDLAAPGAAVDIKLGFGRGRHLGCPRAFDGSGQEFAHAWRLGDIHFDDDEHFTPPTSDTGISLLKVAVHEIGHVLGLPHTYRTGSIMQPNYIPQEPAFELDWSDRKAIQKLYGSCEGSFDTAFDWIRKERNQYGEVMVRFSTYFFRNSWYWLYENRNNRTRYGDPIQILTGWPGIPTHNIDAFVHIWTWKRDERYFFQGNQYWRYDSDKDQALTEDEQGKSYPKLISEGFPGIPSPLDTAFYDRRQKLIYFFKESLVFAFDVNRNRVLNSYPKRITEVFPAVIPQNHPFRNIDSAYYSYAYNSIFFFKGNAYWKVVNDKDKQQNSWLPANGLFPKKFISEKWFDVCDVHISTLNM T68443 DRUGINFO D0T9HG GM6001 Discontinued in Phase 2 T68443 DRUGINFO D07SPC N-hydroxy-2,3-bis(phenylsulfonamido)propanamide Investigative T68443 DRUGINFO D0L4EO 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid Investigative T68443 DRUGINFO D05THD 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide Investigative T68443 DRUGINFO D07MJD [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid Investigative T68443 DRUGINFO D0S9OL N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide Investigative T68443 DRUGINFO D03AMR SR-973 Investigative T68443 DRUGINFO D0W2UK IK-862 Investigative T38134 TARGETID T38134 T38134 FORMERID TTDI03070 T38134 UNIPROID KKCC1_HUMAN T38134 TARGNAME CaM-kinase IV kinase (CAMKK1) T38134 GENENAME CAMKK1 T38134 TARGTYPE Literature-reported T38134 SYNONYMS Calcium/calmodulin-dependent protein kinase kinase alpha; Calcium/calmodulin-dependent protein kinase kinase 1; CaMKK alpha; CaMKK 1; CaM-kinase kinase alpha; CaM-kinase kinase 1; CaM-KK alpha; CaM-KK 1; CAMKKA T38134 FUNCTION Calcium/calmodulin-dependent protein kinase that belongs to a proposed calcium-triggered signaling cascade involved in a number of cellular processes. Phosphorylates CAMK1, CAMK1D, CAMK1G and CAMK4. Involved in regulating cell apoptosis. Promotes cell survival by phosphorylating AKT1/PKB that inhibits pro-apoptotic BAD/Bcl2-antagonist of cell death. T38134 PDBSTRUC 6CD6; 6CCF T38134 BIOCLASS Kinase T38134 ECNUMBER EC 2.7.11.17 T38134 SEQUENCE MEGGPAVCCQDPRAELVERVAAIDVTHLEEADGGPEPTRNGVDPPPRARAASVIPGSTSRLLPARPSLSARKLSLQERPAGSYLEAQAGPYATGPASHISPRAWRRPTIESHHVAISDAEDCVQLNQYKLQSEIGKGAYGVVRLAYNESEDRHYAMKVLSKKKLLKQYGFPRRPPPRGSQAAQGGPAKQLLPLERVYQEIAILKKLDHVNVVKLIEVLDDPAEDNLYLVFDLLRKGPVMEVPCDKPFSEEQARLYLRDVILGLEYLHCQKIVHRDIKPSNLLLGDDGHVKIADFGVSNQFEGNDAQLSSTAGTPAFMAPEAISDSGQSFSGKALDVWATGVTLYCFVYGKCPFIDDFILALHRKIKNEPVVFPEEPEISEELKDLILKMLDKNPETRIGVPDIKLHPWVTKNGEEPLPSEEEHCSVVEVTEEEVKNSVRLIPSWTTVILVKSMLRKRSFGNPFEPQARREERSMSAPGNLLVKEGFGEGGKSPELPGVQEDEAAS T38134 DRUGINFO D0HZ8U STO609 Investigative T73184 TARGETID T73184 T73184 FORMERID TTDI03542 T73184 UNIPROID SETD7_HUMAN T73184 TARGNAME Histone-lysine N-methyltransferase SETD7 (SETD7) T73184 GENENAME SETD7 T73184 TARGTYPE Literature-reported T73184 SYNONYMS SET9; SET7/9; SET7; SET domain-containing protein 7; Lysine N-methyltransferase 7; KMT7; KIAA1717; Histone H3-K4 methyltransferase SETD7; H3-K4-HMTase SETD7 T73184 FUNCTION H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Plays a central role in the transcriptional activation of genes such as collagenase or insulin. Recruited by IPF1/PDX-1 to the insulin promoter, leading to activate transcription. Has also methyltransferase activity toward non-histone proteins such as p53/TP53, TAF10, and possibly TAF7 by recognizing and binding the [KR]-[STA]-K in substrate proteins. Monomethylates 'Lys-189' of TAF10, leading to increase the affinity of TAF10 for RNA polymerase II. Monomethylates 'Lys-372' of p53/TP53, stabilizing p53/TP53 and increasing p53/TP53-mediated transcriptional activation. Histone methyltransferase that specifically monomethylates 'Lys-4' of histone H3. T73184 PDBSTRUC 5YLT; 5EG2; 5AYF; 4JLG; 4JDS T73184 BIOCLASS Methyltransferase T73184 ECNUMBER EC 2.1.1.43 T73184 SEQUENCE MDSDDEMVEEAVEGHLDDDGLPHGFCTVTYSSTDRFEGNFVHGEKNGRGKFFFFDGSTLEGYYVDDALQGQGVYTYEDGGVLQGTYVDGELNGPAQEYDTDGRLIFKGQYKDNIRHGVCWIYYPDGGSLVGEVNEDGEMTGEKIAYVYPDERTALYGKFIDGEMIEGKLATLMSTEEGRPHFELMPGNSVYHFDKSTSSCISTNALLPDPYESERVYVAESLISSAGEGLFSKVAVGPNTVMSFYNGVRITHQEVDSRDWALNGNTLSLDEETVIDVPEPYNHVSKYCASLGHKANHSFTPNCIYDMFVHPRFGPIKCIRTLRAVEADEELTVAYGYDHSPPGKSGPEAPEWYQVELKAFQATQQK T73184 DRUGINFO D0J6OV (R)-PFI-2 Preclinical T03593 TARGETID T03593 T03593 FORMERID TTDNR00656 T03593 UNIPROID SIA8D_HUMAN T03593 TARGNAME Sialyltransferase 8D (ST8SIA4) T03593 GENENAME ST8SIA4 T03593 TARGTYPE Literature-reported T03593 SYNONYMS Sialyltransferase St8Sia IV; ST8SiaIV; SIAT8D; SIAT8-D; Polysialyltransferase-1; PST1; PST; CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase; Alpha-2,8-sialyltransferase 8D T03593 FUNCTION Catalyzes the polycondensation of alpha-2,8-linked sialic acid required for the synthesis of polysialic acid (PSA), which is present on the embryonic neural cell adhesion molecule (N-CAM), necessary for plasticity of neural cells. T03593 PDBSTRUC 6AHZ; 5Y3U; 5Y22 T03593 BIOCLASS Glycosyltransferases T03593 ECNUMBER EC 2.4.99.- T03593 SEQUENCE MRSIRKRWTICTISLLLIFYKTKEIARTEEHQETQLIGDGELSLSRSLVNSSDKIIRKAGSSIFQHNVEGWKINSSLVLEIRKNILRFLDAERDVSVVKSSFKPGDVIHYVLDRRRTLNISHDLHSLLPEVSPMKNRRFKTCAVVGNSGILLDSECGKEIDSHNFVIRCNLAPVVEFAADVGTKSDFITMNPSVVQRAFGGFRNESDREKFVHRLSMLNDSVLWIPAFMVKGGEKHVEWVNALILKNKLKVRTAYPSLRLIHAVRGYWLTNKVPIKRPSTGLLMYTLATRFCDEIHLYGFWPFPKDLNGKAVKYHYYDDLKYRYFSNASPHRMPLEFKTLNVLHNRGALKLTTGKCVKQ T17642 TARGETID T17642 T17642 FORMERID TTDI02462 T17642 UNIPROID HTRA1_HUMAN T17642 TARGNAME Serine protease HTRA1 (HTRA1) T17642 GENENAME HTRA1 T17642 TARGTYPE Literature-reported T17642 SYNONYMS Serine protease 11; L56; High-temperature requirement A serine peptidase 1; HTRA1 T17642 FUNCTION Serine protease with a variety of targets, including extracellular matrix proteins such as fibronectin. HTRA1-generated fibronectin fragments further induce synovial cells to up-regulate MMP1 and MMP3 production. May also degrade proteoglycans, such as aggrecan, decorin and fibromodulin. Through cleavage of proteoglycans, may release soluble FGF-glycosaminoglycan complexes that promote the range and intensity of FGF signals in the extracellular space. Regulates the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. Inhibits signaling mediated by TGF-beta family members. This activity requires the integrity of the catalytic site, although it is unclear whether TGF-beta proteins are themselves degraded. By acting on TGF-beta signaling, may regulate many physiological processes, including retinal angiogenesis and neuronal survival and maturation during development. Intracellularly, degrades TSC2, leading to the activation of TSC2 downstream targets. T17642 PDBSTRUC 3TJQ; 3TJO; 3TJN; 3NZI; 3NWU T17642 BIOCLASS Peptidase T17642 ECNUMBER EC 3.4.21.- T17642 SEQUENCE MQIPRAALLPLLLLLLAAPASAQLSRAGRSAPLAAGCPDRCEPARCPPQPEHCEGGRARDACGCCEVCGAPEGAACGLQEGPCGEGLQCVVPFGVPASATVRRRAQAGLCVCASSEPVCGSDANTYANLCQLRAASRRSERLHRPPVIVLQRGACGQGQEDPNSLRHKYNFIADVVEKIAPAVVHIELFRKLPFSKREVPVASGSGFIVSEDGLIVTNAHVVTNKHRVKVELKNGATYEAKIKDVDEKADIALIKIDHQGKLPVLLLGRSSELRPGEFVVAIGSPFSLQNTVTTGIVSTTQRGGKELGLRNSDMDYIQTDAIINYGNSGGPLVNLDGEVIGINTLKVTAGISFAIPSDKIKKFLTESHDRQAKGKAITKKKYIGIRMMSLTSSKAKELKDRHRDFPDVISGAYIIEVIPDTPAEAGGLKENDVIISINGQSVVSANDVSDVIKRESTLNMVVRRGNEDIMITVIPEEIDP T44341 TARGETID T44341 T44341 FORMERID TTDI03148 T44341 UNIPROID CDKL2_HUMAN T44341 TARGNAME Cyclin-dependent kinase-like 2 (CDKL2) T44341 GENENAME CDKL2 T44341 TARGTYPE Literature-reported T44341 SYNONYMS Serine/threonine-protein kinase KKIAMRE; Protein kinase p56 KKIAMRE T44341 FUNCTION centrosome, nucleus, cyclin-dependent protein serine/threonine kinase activity, protein kinase activity, protein phosphorylation, sex differentiation, signal transduction. T44341 PDBSTRUC 4BBM; 4AAA T44341 BIOCLASS Kinase T44341 ECNUMBER EC 2.7.11.22 T44341 SEQUENCE MEKYENLGLVGEGSYGMVMKCRNKDTGRIVAIKKFLESDDDKMVKKIAMREIKLLKQLRHENLVNLLEVCKKKKRWYLVFEFVDHTILDDLELFPNGLDYQVVQKYLFQIINGIGFCHSHNIIHRDIKPENILVSQSGVVKLCDFGFARTLAAPGEVYTDYVATRWYRAPELLVGDVKYGKAVDVWAIGCLVTEMFMGEPLFPGDSDIDQLYHIMMCLGNLIPRHQELFNKNPVFAGVRLPEIKEREPLERRYPKLSEVVIDLAKKCLHIDPDKRPFCAELLHHDFFQMDGFAERFSQELQLKVQKDARNVSLSKKSQNRKKEKEKDDSLVEERKTLVVQDTNADPKIKDYKLFKIKGSKIDGEKAEKGNRASNASCLHDSRTSHNKIVPSTSLKDCSNVSVDHTRNPSVAIPPLTHNLSAVAPSINSGMGTETIPIQGYRVDEKTKKCSIPFVKPNRHSPSGIYNINVTTLVSGPPLSDDSGADLPQMEHQH T44341 DRUGINFO D07ADX URMC-099 Investigative T71646 TARGETID T71646 T71646 FORMERID TTDR00572 T71646 UNIPROID GGH_HUMAN T71646 TARGNAME Gamma-glutamyl hydrolase (GGH) T71646 GENENAME GGH T71646 TARGTYPE Literature-reported T71646 SYNONYMS Human glutamyl hydrolase; Gamma-Glu-X carboxypeptidase; GGH; Conjugase T71646 FUNCTION Hydrolyzes the polyglutamate sidechains of pteroylpolyglutamates. Progressively removes gamma-glutamyl residues from pteroylpoly-gamma-glutamate to yield pteroyl-alpha- glutamate (folic acid) and free glutamate. May play an important role in the bioavailability ofdietary pteroylpolyglutamates and in the metabolism of pteroylpolyglutamates and antifolates. T71646 PDBSTRUC 1L9X T71646 BIOCLASS Peptidase T71646 ECNUMBER EC 3.4.19.9 T71646 SEQUENCE MASPGCLLCVLGLLLCGAASLELSRPHGDTAKKPIIGILMQKCRNKVMKNYGRYYIAASYVKYLESAGARVVPVRLDLTEKDYEILFKSINGILFPGGSVDLRRSDYAKVAKIFYNLSIQSFDDGDYFPVWGTCLGFEELSLLISGECLLTATDTVDVAMPLNFTGGQLHSRMFQNFPTELLLSLAVEPLTANFHKWSLSVKNFTMNEKLKKFFNVLTTNTDGKIEFISTMEGYKYPVYGVQWHPEKAPYEWKNLDGISHAPNAVKTAFYLAEFFVNEARKNNHHFKSESEEEKALIYQFSPIYTGNISSFQQCYIFD T38581 TARGETID T38581 T38581 FORMERID TTDI00205 T38581 UNIPROID PCSK5_HUMAN T38581 TARGNAME Proprotein convertase subtilisin/kexin type 5 (PCSK5) T38581 GENENAME PCSK5 T38581 TARGTYPE Literature-reported T38581 SYNONYMS hPC6; Subtilisin/kexin-like protease PC5; Proprotein convertase 6; Proprotein convertase 5; PCSK5; PC6; PC5 T38581 FUNCTION Likely to represent a widespread endoprotease activity within the constitutive and regulated secretory pathway. Capable of cleavage at the RX(K/R)R consensus motif. Plays an essential role in pregnancy establishment by proteolytic activation of a number of important factors such as BMP2, CALD1 and alpha- integrins. T38581 BIOCLASS Peptidase T38581 ECNUMBER EC 3.4.21.- T38581 SEQUENCE MGWGSRCCCPGRLDLLCVLALLGGCLLPVCRTRVYTNHWAVKIAGGFPEANRIASKYGFINIGQIGALKDYYHFYHSRTIKRSVISSRGTHSFISMEPKVEWIQQQVVKKRTKRDYDFSRAQSTYFNDPKWPSMWYMHCSDNTHPCQSDMNIEGAWKRGYTGKNIVVTILDDGIERTHPDLMQNYDALASCDVNGNDLDPMPRYDASNENKHGTRCAGEVAAAANNSHCTVGIAFNAKIGGVRMLDGDVTDMVEAKSVSFNPQHVHIYSASWGPDDDGKTVDGPAPLTRQAFENGVRMGRRGLGSVFVWASGNGGRSKDHCSCDGYTNSIYTISISSTAESGKKPWYLEECSSTLATTYSSGESYDKKIITTDLRQRCTDNHTGTSASAPMAAGIIALALEANPFLTWRDVQHVIVRTSRAGHLNANDWKTNAAGFKVSHLYGFGLMDAEAMVMEAEKWTTVPRQHVCVESTDRQIKTIRPNSAVRSIYKASGCSDNPNRHVNYLEHVVVRITITHPRRGDLAIYLTSPSGTRSQLLANRLFDHSMEGFKNWEFMTIHCWGERAAGDWVLEVYDTPSQLRNFKTPGKLKEWSLVLYGTSVQPYSPTNEFPKVERFRYSRVEDPTDDYGTEDYAGPCDPECSEVGCDGPGPDHCNDCLHYYYKLKNNTRICVSSCPPGHYHADKKRCRKCAPNCESCFGSHGDQCMSCKYGYFLNEETNSCVTHCPDGSYQDTKKNLCRKCSENCKTCTEFHNCTECRDGLSLQGSRCSVSCEDGRYFNGQDCQPCHRFCATCAGAGADGCINCTEGYFMEDGRCVQSCSISYYFDHSSENGYKSCKKCDISCLTCNGPGFKNCTSCPSGYLLDLGMCQMGAICKDGEYVDEHGHCQTCEASCAKCQGPTQEDCTTCPMTRIFDDGRCVSNCPSWKFEFENQCHPCHHTCQRCQGSGPTHCTSCGADNYGREHFLYQGECGDSCPEGHYATEGNTCLPCPDNCELCHSVHVCTRCMKGYFIAPTNHTCQKLECGQGEVQDPDYEECVPCEEGCLGCSLDDPGTCTSCAMGYYRFDHHCYKTCPEKTYSEEVECKACDSNCGSCDQNGCYWCEEGFFLLGGSCVRKCGPGFYGDQEMGECESCHRACETCTGPGHDECSSCQEGLQLLRGMCVHATKTQEEGKFWNDILRKLQPCHSSCKTCNGSATLCTSCPKGAYLLAQACVSSCPQGTWPSVRSGSCENCTEACAICSGADLCKKCQMQPGHPLFLHEGRCYSKCPEGSYAEDGICERCSSPCRTCEGNATNCHSCEGGHVLHHGVCQENCPERHVAVKGVCKHCPEMCQDCIHEKTCKECTPEFFLHDDMCHQSCPRGFYADSRHCVPCHKDCLECSGPKADDCELCLESSWVLYDGLCLEECPAGTYYEKETKECRDCHKSCLTCSSSGTCTTCQKGLIMNPRGSCMANEKCSPSEYWDEDAPGCKPCHVKCFHCMGPAEDQCQTCPMNSLLLNTTCVKDCPEGYYADEDSNRCAHCHSSCRTCEGRHSRQCHSCRPGWFQLGKECLLQCREGYYADNSTGRCERCNRSCKGCQGPRPTDCLSCDRFFFLLRSKGECHRSCPDHYYVEQSTQTCERCHPTCDQCKGKGALNCLSCVWSYHLMGGICTSDCLVGEYRVGEGEKFNCEKCHESCMECKGPGAKNCTLCPANLVLHMDDSHCLHCCNTSDPPSAQECCDCQDTTDECILRTSKVRPATEHFKTALFITSSMMLVLLLGAAVVVWKKSRGRVQPAAKAGYEKLADPNKSYSSYKSSYRESTSFEEDQVIEYRDRDYDEDDDDDIVYMGQDGTVYRKFKYGLLDDDDIDELEYDDESYSYYQ T38581 DRUGINFO D05JJL furin inhibitor peptide Investigative T84791 TARGETID T84791 T84791 FORMERID TTDR00901 T84791 UNIPROID CSN5_HUMAN T84791 TARGNAME JUN activation domain binding protein (COPS5) T84791 GENENAME COPS5 T84791 TARGTYPE Literature-reported T84791 SYNONYMS Signalosome subunit 5; SGN5; Jun activation domain-binding protein 1; JAB1; CSN5; COP9 signalosome complex subunit 5 T84791 FUNCTION The CSN complex is an essential regulator of the ubiquitin (Ubl) conjugation pathway by mediating the deneddylation of the cullin subunits of the SCF-type E3 ligase complexes, leading to decrease the Ubl ligase activity of SCF-type complexes such as SCF, CSA or DDB2. The complex is also involved in phosphorylation of p53/TP53, c-jun/JUN, IkappaBalpha/NFKBIA, ITPK1 and IRF8, possibly via its association with CK2 and PKD kinases. CSN-dependent phosphorylation of TP53 and JUN promotes and protects degradation by the Ubl system, respectively. In the complex, it probably acts as the catalytic center that mediates the cleavage of Nedd8 from cullins. It however has no metalloprotease activity by itself and requires the other subunits of the CSN complex. Interacts directly with a large number of proteins that are regulated by the CSN complex, confirming a key role in the complex. Promotes the proteasomal degradation of BRSK2. Probable protease subunit of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes. T84791 PDBSTRUC 5M5Q; 5JOH; 5JOG; 4WSN; 4F7O T84791 BIOCLASS Peptidase T84791 ECNUMBER EC 3.4.-.- T84791 SEQUENCE MAASGSGMAQKTWELANNMQEAQSIDEIYKYDKKQQQEILAAKPWTKDHHYFKYCKISALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYEYMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRTISAGKVNLGAFRTYPKGYKPPDEGPSEYQTIPLNKIEDFGVHCKQYYALEVSYFKSSLDRKLLELLWNKYWVNTLSSSSLLTNADYTTGQVFDLSEKLEQSEAQLGRGSFMLGLETHDRKSEDKLAKATRDSCKTTIEAIHGLMSQVIKDKLFNQINIS T85328 TARGETID T85328 T85328 FORMERID TTDI00240 T85328 UNIPROID TP4A1_HUMAN T85328 TARGNAME Protein tyrosine phosphatase IVA 1 (PRL-1) T85328 GENENAME PTP4A1 T85328 TARGTYPE Literature-reported T85328 SYNONYMS Protein-tyrosine phosphatase of regenerating liver 1; Protein-tyrosine phosphatase 4a1; Protein tyrosine phosphatase type IVA 1; PTPCAAX1; PTP(CAAXI); PRL1 T85328 FUNCTION May play a role in the development and maintenance of differentiating epithelial tissues. Enhances cell proliferation, cell motility and invasive activity, and promotes cancer metastasis. Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis. T85328 PDBSTRUC 5BX1; 1XM2; 1RXD T85328 BIOCLASS Phosphoric monoester hydrolase T85328 ECNUMBER EC 3.1.3.48 T85328 SEQUENCE MARMNRPAPVEVTYKNMRFLITHNPTNATLNKFIEELKKYGVTTIVRVCEATYDTTLVEKEGIHVLDWPFDDGAPPSNQIVDDWLSLVKIKFREEPGCCIAVHCVAGLGRAPVLVALALIEGGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRFKDSNGHRNNCCIQ T68265 TARGETID T68265 T68265 FORMERID TTDI02161 T68265 UNIPROID RNF34_HUMAN T68265 TARGNAME RING finger protein RIFF (RNF34) T68265 GENENAME RNF34 T68265 TARGTYPE Literature-reported T68265 SYNONYMS hRFI; RNF34; RING finger protein 34; Human RING finger homologous to inhibitor of apoptosis protein; FYVERING finger protein Momo; E3 ubiquitinprotein ligase RNF34; Caspases8 and 10associated RING finger protein 1; Caspase regulator CARP1; CARP1 T68265 FUNCTION E3 ubiquitin-protein ligase that regulates several biological processes through the ubiquitin-mediated proteasomal degradation of various target proteins. Ubiquitinates the caspases CASP8 and CASP10, promoting their proteasomal degradation, to negatively regulate cell death downstream of death domain receptors in the extrinsic pathway of apoptosis (PubMed:15069192). May mediate 'Lys-48'-linked polyubiquitination of RIPK1 and its subsequent proteasomal degradation thereby indirectly regulating the tumor necrosis factor-mediated signaling pathway (Ref.13). Negatively regulates p53/TP53 through its direct ubiquitination and targeting to proteasomal degradation (PubMed:17121812). Indirectly, may also negatively regulate p53/TP53 through ubiquitination and degradation of SFN (PubMed:18382127). Mediates PPARGC1A proteasomal degradation probably through ubiquitination thereby indirectly regulating the metabolism of brown fat cells (PubMed:22064484). Possibly involved in innate immunity, through 'Lys-48'-linked polyubiquitination of NOD1and its subsequent proteasomal degradation (PubMed:25012219). T68265 BIOCLASS Carbon-nitrogen ligase T68265 ECNUMBER EC 2.3.2.27 T68265 SEQUENCE MKAGATSMWASCCGLLNEVMGTGAVRGQQSAFAGATGPFRFTPNPEFSTYPPAATEGPNIVCKACGLSFSVFRKKHVCCDCKKDFCSVCSVLQENLRRCSTCHLLQETAFQRPQLMRLKVKDLRQYLILRNIPIDTCREKEDLVDLVLCHHGLGSEDDMDTSSLNSSRSQTSSFFTRSFFSNYTAPSATMSSFQGELMDGDQTSRSGVPAQVQSEITSANTEDDDDDDDEDDDDEEENAEDRNPGLSKERVRASLSDLSSLDDVEGMSVRQLKEILARNFVNYSGCCEKWELVEKVNRLYKENEENQKSYGERLQLQDEEDDSLCRICMDAVIDCVLLECGHMVTCTKCGKRMSECPICRQYVVRAVHVFKS T02587 TARGETID T02587 T02587 FORMERID TTDR01249 T02587 UNIPROID PLPP_HUMAN T02587 TARGNAME Pyridoxal phosphate phosphatase (PDXP) T02587 GENENAME PDXP T02587 TARGTYPE Literature-reported T02587 SYNONYMS PLPP; PLP phosphatase; PDXP T02587 FUNCTION Protein serine phosphatase that dephosphorylates 'Ser-3' in cofilin and probably also dephosphorylates phospho-serine residues in DSTN. Regulates cofilin-dependent actin cytoskeleton reorganization. Required for normal progress through mitosis and normal cytokinesis. Does not dephosphorylate phospho-threonines in LIMK1. Does not dephosphorylate peptides containing phospho- tyrosine. Pyridoxal phosphate phosphatase. Has some activity towards pyridoxal 5'-phosphate (PLP), pyridoxine 5'-phosphate (PMP) and pyridoxine 5'-phosphate (PNP), with a highest activity with PLP followed by PNP. T02587 PDBSTRUC 5GYN; 2P69; 2P27; 2OYC; 2CFT T02587 BIOCLASS Phosphoric monoester hydrolase T02587 ECNUMBER EC 3.1.3.3 T02587 SEQUENCE MARCERLRGAALRDVLGRAQGVLFDCDGVLWNGERAVPGAPELLERLARAGKAALFVSNNSRRARPELALRFARLGFGGLRAEQLFSSALCAARLLRQRLPGPPDAPGAVFVLGGEGLRAELRAAGLRLAGDPSAGDGAAPRVRAVLVGYDEHFSFAKLREACAHLRDPECLLVATDRDPWHPLSDGSRTPGTGSLAAAVETASGRQALVVGKPSPYMFECITENFSIDPARTLMVGDRLETDILFGHRCGMTTVLTLTGVSRLEEAQAYLAAGQHDLVPHYYVESIADLTEGLED T81240 TARGETID T81240 T81240 FORMERID TTDNR00663 T81240 UNIPROID ITCH_HUMAN T81240 TARGNAME E3 ubiquitin protein ligase Itchy (ITCH) T81240 GENENAME ITCH T81240 TARGTYPE Literature-reported T81240 SYNONYMS NFE2-associated polypeptide 1; NAPP1; Itch; HECT-type E3 ubiquitin transferase Itchy homolog; E3 ubiquitin-protein ligase Itchy homolog; Atrophin-1-interacting protein 4; AIP4 T81240 FUNCTION Catalyzes 'Lys-29'-, 'Lys-48'- and 'Lys-63'-linked ubiquitin conjugation. Involved in the control of inflammatory signaling pathways. Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, TAX1BP1 and RNF11, that ensures the transient nature of inflammatory signaling pathways. Promotes the association of the complex after TNF stimulation. Once the complex is formed, TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NFKB1. Ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences NOD2-dependent signal transduction pathways. Regulates the transcriptional activity of several transcription factors, and probably plays an important role in the regulation of immune response. Ubiquitinates NFE2 by 'Lys-63' linkages and is implicated in the control of the development of hematopoietic lineages. Mediates JUN ubiquitination and degradation. Mediates JUNB ubiquitination and degradation. Critical regulator of type 2 helper T (Th2) cell cytokine production by inducing JUNB ubiquitination and degradation. Involved in the negative regulation of MAVS-dependent cellular antiviral responses. Ubiquitinates MAVS through 'Lys-48'-linked conjugation resulting in MAVS proteasomal degradation. Following ligand stimulation, regulates sorting of Wnt receptor FZD4 to the degradative endocytic pathway probably by modulating PI42KA activity. Ubiquitinates PI4K2A and negatively regulates its catalytic activity. Ubiquitinates chemokine receptor CXCR4 and regulates sorting of CXCR4 to the degradative endocytic pathway following ligand stimulation by ubiquitinating endosomal sorting complex required for transport ESCRT-0 components HGS and STAM. Targets DTX1 for lysosomal degradation and controls NOTCH1 degradation, in the absence of ligand, through 'Lys-29'-linked polyubiquitination. Ubiquitinates SNX9. Ubiquitinates MAP3K7 through 'Lys-48'-linked conjugation. Involved in the regulation of apoptosis and reactive oxygen species levels through the ubiquitination and proteasomal degradation of TXNIP. Mediates the antiapoptotic activity of epidermal growth factor through the ubiquitination and proteasomal degradation of p15 BID. Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1. Acts as an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. T81240 PDBSTRUC 5SXP; 5DZD; 5DWS; 5CQ2; 5C7M T81240 BIOCLASS Acyltransferase T81240 ECNUMBER EC 2.3.2.26 T81240 SEQUENCE MSDSGSQLGSMGSLTMKSQLQITVISAKLKENKKNWFGPSPYVEVTVDGQSKKTEKCNNTNSPKWKQPLTVIVTPVSKLHFRVWSHQTLKSDVLLGTAALDIYETLKSNNMKLEEVVVTLQLGGDKEPTETIGDLSICLDGLQLESEVVTNGETTCSENGVSLCLPRLECNSAISAHCNLCLPGLSDSPISASRVAGFTGASQNDDGSRSKDETRVSTNGSDDPEDAGAGENRRVSGNNSPSLSNGGFKPSRPPRPSRPPPPTPRRPASVNGSPSATSESDGSSTGSLPPTNTNTNTSEGATSGLIIPLTISGGSGPRPLNPVTQAPLPPGWEQRVDQHGRVYYVDHVEKRTTWDRPEPLPPGWERRVDNMGRIYYVDHFTRTTTWQRPTLESVRNYEQWQLQRSQLQGAMQQFNQRFIYGNQDLFATSQSKEFDPLGPLPPGWEKRTDSNGRVYFVNHNTRITQWEDPRSQGQLNEKPLPEGWEMRFTVDGIPYFVDHNRRTTTYIDPRTGKSALDNGPQIAYVRDFKAKVQYFRFWCQQLAMPQHIKITVTRKTLFEDSFQQIMSFSPQDLRRRLWVIFPGEEGLDYGGVAREWFFLLSHEVLNPMYCLFEYAGKDNYCLQINPASYINPDHLKYFRFIGRFIAMALFHGKFIDTGFSLPFYKRILNKPVGLKDLESIDPEFYNSLIWVKENNIEECDLEMYFSVDKEILGEIKSHDLKPNGGNILVTEENKEEYIRMVAEWRLSRGVEEQTQAFFEGFNEILPQQYLQYFDAKELEVLLCGMQEIDLNDWQRHAIYRHYARTSKQIMWFWQFVKEIDNEKRMRLLQFVTGTCRLPVGGFADLMGSNGPQKFCIEKVGKENWLPRSHTCFNRLDLPPYKSYEQLKEKLLFAIEETEGFGQE T98642 TARGETID T98642 T98642 FORMERID TTDI03448 T98642 UNIPROID TOPK_HUMAN T98642 TARGNAME PDZ binding kinase (PBK) T98642 GENENAME PBK T98642 TARGTYPE Literature-reported T98642 SYNONYMS TOPK; T-LAK cell-originated protein kinase; Spermatogenesis-related protein kinase; SPK protein; PDZ-binding kinase; Nori-3; MAPKK-like protein kinase; Lymphokine-activated killer T-cell-originated protein kinase; Cancer/testis antigen 84; CT84 T98642 FUNCTION Seems to be active only in mitosis. May also play a role in the activation of lymphoid cells. When phosphorylated, forms a complex with TP53, leading to TP53 destabilization and attenuation of G2/M checkpoint during doxorubicin-induced DNA damage. Phosphorylates MAP kinase p38. T98642 PDBSTRUC 5J0A T98642 BIOCLASS Kinase T98642 ECNUMBER EC 2.7.12.2 T98642 SEQUENCE MEGISNFKTPSKLSEKKKSVLCSTPTINIPASPFMQKLGFGTGVNVYLMKRSPRGLSHSPWAVKKINPICNDHYRSVYQKRLMDEAKILKSLHHPNIVGYRAFTEANDGSLCLAMEYGGEKSLNDLIEERYKASQDPFPAAIILKVALNMARGLKYLHQEKKLLHGDIKSSNVVIKGDFETIKICDVGVSLPLDENMTVTDPEACYIGTEPWKPKEAVEENGVITDKADIFAFGLTLWEMMTLSIPHINLSNDDDDEDKTFDESDFDDEAYYAALGTRPPINMEELDESYQKVIELFSVCTNEDPKDRPSAAHIVEALETDV T98642 DRUGINFO D06DPJ HITOPK-032 Investigative T98642 DRUGINFO D0Y2WP OTS964 Investigative T68777 TARGETID T68777 T68777 FORMERID TTDR00391 T68777 UNIPROID NSD1_HUMAN T68777 TARGNAME Lysine N-methyltransferase 3B (NSD1) T68777 GENENAME NSD1 T68777 TARGTYPE Literature-reported T68777 SYNONYMS Nuclear receptor-binding SET domain-containing protein 1; NR-binding SET domain-containing protein; NR-binding SET domain containing protein; KMT3B; Hypothetical protein FLJ22263 similar to nuclear receptor-binding SET-domain protein 1; Histone-lysine N-methyltransferase, H3 lysine-36 and H4 lysine-20 specific; H4-K20-HMTase; H3-K36-HMTase; Androgen receptor-associated protein of 267 kDa; Androgen receptor-associated coregulator 267; Androgen receptor coactivator 267 kDa protein; Androgen receptor associated coregulator 267; ARA267 T68777 FUNCTION Preferentially methylates 'Lys-36' of histone H3 and 'Lys-20' of histone H4 (in vitro). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context. Histone methyltransferase. T68777 PDBSTRUC 3OOI T68777 BIOCLASS Methyltransferase T68777 ECNUMBER EC 2.1.1.43 T68777 SEQUENCE MDQTCELPRRNCLLPFSNPVNLDAPEDKDSPFGNGQSNFSEPLNGCTMQLSTVSGTSQNAYGQDSPSCYIPLRRLQDLASMINVEYLNGSADGSESFQDPEKSDSRAQTPIVCTSLSPGGPTALAMKQEPSCNNSPELQVKVTKTIKNGFLHFENFTCVDDADVDSEMDPEQPVTEDESIEEIFEETQTNATCNYETKSENGVKVAMGSEQDSTPESRHGAVKSPFLPLAPQTETQKNKQRNEVDGSNEKAALLPAPFSLGDTNITIEEQLNSINLSFQDDPDSSTSTLGNMLELPGTSSSSTSQELPFCQPKKKSTPLKYEVGDLIWAKFKRRPWWPCRICSDPLINTHSKMKVSNRRPYRQYYVEAFGDPSERAWVAGKAIVMFEGRHQFEELPVLRRRGKQKEKGYRHKVPQKILSKWEASVGLAEQYDVPKGSKNRKCIPGSIKLDSEEDMPFEDCTNDPESEHDLLLNGCLKSLAFDSEHSADEKEKPCAKSRARKSSDNPKRTSVKKGHIQFEAHKDERRGKIPENLGLNFISGDISDTQASNELSRIANSLTGSNTAPGSFLFSSCGKNTAKKEFETSNGDSLLGLPEGALISKCSREKNKPQRSLVCGSKVKLCYIGAGDEEKRSDSISICTTSDDGSSDLDPIEHSSESDNSVLEIPDAFDRTENMLSMQKNEKIKYSRFAATNTRVKAKQKPLISNSHTDHLMGCTKSAEPGTETSQVNLSDLKASTLVHKPQSDFTNDALSPKFNLSSSISSENSLIKGGAANQALLHSKSKQPKFRSIKCKHKENPVMAEPPVINEECSLKCCSSDTKGSPLASISKSGKVDGLKLLNNMHEKTRDSSDIETAVVKHVLSELKELSYRSLGEDVSDSGTSKPSKPLLFSSASSQNHIPIEPDYKFSTLLMMLKDMHDSKTKEQRLMTAQNLVSYRSPGRGDCSTNSPVGVSKVLVSGGSTHNSEKKGDGTQNSANPSPSGGDSALSGELSASLPGLLSDKRDLPASGKSRSDCVTRRNCGRSKPSSKLRDAFSAQMVKNTVNRKALKTERKRKLNQLPSVTLDAVLQGDRERGGSLRGGAEDPSKEDPLQIMGHLTSEDGDHFSDVHFDSKVKQSDPGKISEKGLSFENGKGPELDSVMNSENDELNGVNQVVPKKRWQRLNQRRTKPRKRMNRFKEKENSECAFRVLLPSDPVQEGRDEFPEHRTPSASILEEPLTEQNHADCLDSAGPRLNVCDKSSASIGDMEKEPGIPSLTPQAELPEPAVRSEKKRLRKPSKWLLEYTEEYDQIFAPKKKQKKVQEQVHKVSSRCEEESLLARGRSSAQNKQVDENSLISTKEEPPVLEREAPFLEGPLAQSELGGGHAELPQLTLSVPVAPEVSPRPALESEELLVKTPGNYESKRQRKPTKKLLESNDLDPGFMPKKGDLGLSKKCYEAGHLENGITESCATSYSKDFGGGTTKIFDKPRKRKRQRHAAAKMQCKKVKNDDSSKEIPGSEGELMPHRTATSPKETVEEGVEHDPGMPASKKMQGERGGGAALKENVCQNCEKLGELLLCEAQCCGAFHLECLGLTEMPRGKFICNECRTGIHTCFVCKQSGEDVKRCLLPLCGKFYHEECVQKYPPTVMQNKGFRCSLHICITCHAANPANVSASKGRLMRCVRCPVAYHANDFCLAAGSKILASNSIICPNHFTPRRGCRNHEHVNVSWCFVCSEGGSLLCCDSCPAAFHRECLNIDIPEGNWYCNDCKAGKKPHYREIVWVKVGRYRWWPAEICHPRAVPSNIDKMRHDVGEFPVLFFGSNDYLWTHQARVFPYMEGDVSSKDKMGKGVDGTYKKALQEAAARFEELKAQKELRQLQEDRKNDKKPPPYKHIKVNRPIGRVQIFTADLSEIPRCNCKATDENPCGIDSECINRMLLYECHPTVCPAGGRCQNQCFSKRQYPEVEIFRTLQRGWGLRTKTDIKKGEFVNEYVGELIDEEECRARIRYAQEHDITNFYMLTLDKDRIIDAGPKGNYARFMNHCCQPNCETQKWSVNGDTRVGLFALSDIKAGTELTFNYNLECLGNGKTVCKCGAPNCSGFLGVRPKNQPIATEEKSKKFKKKQQGKRRTQGEITKEREDECFSCGDAGQLVSCKKPGCPKVYHADCLNLTKRPAGKWECPWHQCDICGKEAASFCEMCPSSFCKQHREGMLFISKLDGRLSCTEHDPCGPNPLEPGEIREYVPPPVPLPPGPSTHLAEQSTGMAAQAPKMSDKPPADTNQMLSLSKKALAGTCQRPLLPERPLERTDSRPQPLDKVRDLAGSGTKSQSLVSSQRPLDRPPAVAGPRPQLSDKPSPVTSPSSSPSVRSQPLERPLGTADPRLDKSIGAASPRPQSLEKTSVPTGLRLPPPDRLLITSSPKPQTSDRPTDKPHASLSQRLPPPEKVLSAVVQTLVAKEKALRPVDQNTQSKNRAALVMDLIDLTPRQKERAASPHQVTPQADEKMPVLESSSWPASKGLGHMPRAVEKGCVSDPLQTSGKAAAPSEDPWQAVKSLTQARLLSQPPAKAFLYEPTTQASGRASAGAEQTPGPLSQSPGLVKQAKQMVGGQQLPALAAKSGQSFRSLGKAPASLPTEEKKLVTTEQSPWALGKASSRAGLWPIVAGQTLAQSCWSAGSTQTLAQTCWSLGRGQDPKPEQNTLPALNQAPSSHKCAESEQK T13928 TARGETID T13928 T13928 FORMERID TTDI03564 T13928 UNIPROID SENP8_HUMAN T13928 TARGNAME Deneddylase-1 (SENP8) T13928 GENENAME SENP8 T13928 TARGTYPE Literature-reported T13928 SYNONYMS Sentrin/SUMO-specific protease SENP8; Sentrin-specific protease 8; Protease, cysteine 2; PRSC2; NEDP1; NEDD8-specific protease 1; FKSG8; DEN1 T13928 FUNCTION Protease that catalyzes two essential functions in the NEDD8 pathway: processing of full-length NEDD8 to its mature form and deconjugation of NEDD8 from targeted proteins such as cullins or p53. T13928 PDBSTRUC 2BKR; 2BKQ; 1XT9 T13928 BIOCLASS Peptidase T13928 ECNUMBER EC 3.4.22.- T13928 SEQUENCE MDPVVLSYMDSLLRQSDVSLLDPPSWLNDHIIGFAFEYFANSQFHDCSDHVSFISPEVTQFIKCTSNPAEIAMFLEPLDLPNKRVVFLAINDNSNQAAGGTHWSLLVYLQDKNSFFHYDSHSRSNSVHAKQVAEKLEAFLGRKGDKLAFVEEKAPAQQNSYDCGMYVICNTEALCQNFFRQQTESLLQLLTPAYITKKRGEWKDLITTLAKK T13928 DRUGINFO D05TNT ST074946 Investigative T90113 TARGETID T90113 T90113 FORMERID TTDI02561 T90113 UNIPROID UB2E2_HUMAN T90113 TARGNAME Ubiquitin-protein ligase E2 (UBE2E2) T90113 GENENAME UBE2E2 T90113 TARGTYPE Literature-reported T90113 SYNONYMS Ubiquitin-conjugating enzyme E2 E2; Ubiquitin carrier protein E2; UbcH8; E2 ubiquitin-conjugating enzyme E2 T90113 FUNCTION In vitro catalyzes 'Lys-11'- and 'Lys-48'-, as well as 'Lys-63'-linked polyubiquitination. Catalyzes the ISGylation of influenza A virus NS1 protein. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. T90113 PDBSTRUC 1Y6L T90113 BIOCLASS Ubiquitin-conjugating enzyme T90113 ECNUMBER EC 2.3.2.23 T90113 SEQUENCE MSTEAQRVDDSPSTSGGSSDGDQRESVQQEPEREQVQPKKKEGKISSKTAAKLSTSAKRIQKELAEITLDPPPNCSAGPKGDNIYEWRSTILGPPGSVYEGGVFFLDITFSPDYPFKPPKVTFRTRIYHCNINSQGVICLDILKDNWSPALTISKVLLSICSLLTDCNPADPLVGSIATQYMTNRAEHDRMARQWTKRYAT T00037 TARGETID T00037 T00037 FORMERID TTDR00601 T00037 UNIPROID ERG6_PNEC8 T00037 TARGNAME Fungal Sterol 24-C-methyltransferase (Fung erg6) T00037 GENENAME Fung erg6 T00037 TARGTYPE Literature-reported T00037 SYNONYMS erg6; SAM:SMT; S-adenosyl-L-methionine:sterol C-24 methyl transferase; S-adenosyl-L-methionine-C-24-delta-sterol-methyltransferase T00037 FUNCTION Catalyzes the methyl transfer from S-adenosyl-methionine to the C-24 of zymosterol to form fecosterol. T00037 BIOCLASS Methyltransferase T00037 ECNUMBER EC 2.1.1.- T00037 SEQUENCE MSFELERIDIEKDREFSEIMHGKDAAKERGLLSSFRKDKEAQKIALDSYFGFWGDKCTSEKNDIHQQERFKFYATLTRHYYNLVTDFYEYGWSTSFHFCRFAKDESFSQAIARHEHYIALHAGIREGETVLDVGCGVGGPACQISVFTGANIVGLNNNDYQIQRAKYYSEKKGLSDKLKFIKGDFMQMPFPENSFDKIYSIEATIHAPSLEGVYSEIYRVLKPGGLYASYEWVMLNKYDENDPEHQQIVYGIEIGDSIPKISKIGEAEAALIKVGFEIIHSEELSTKNSPLPWYYYLDGDLRKVRSFRDFISIARMTTIGKWLISSFIGLMEFIGLLPKGSKKVNDILLVAADSLVKAGKKEIFTPMQLWVCRKPLV T00037 DRUGINFO D0M7DG 24-thiacycloartanol Investigative T95736 TARGETID T95736 T95736 FORMERID TTDI03381 T95736 UNIPROID M3K14_HUMAN T95736 TARGNAME Serine/threonine-protein kinase NIK (MAP3K14) T95736 GENENAME MAP3K14 T95736 TARGTYPE Literature-reported T95736 SYNONYMS NIK; NF-kappa-beta-inducing kinase; Mitogen-activated protein kinase kinase kinase 14; HsNIK T95736 FUNCTION Promotes proteolytic processing of NFKB2/P100, which leads to activation of NF-kappa-B via the non-canonical pathway. Could act in a receptor-selective manner. Lymphotoxin beta-activated kinase which seems to be exclusively involved in the activation of NF-kappa-B and its transcriptional activity. T95736 PDBSTRUC 4IDV; 4IDT; 4G3D; 4DN5 T95736 BIOCLASS Kinase T95736 ECNUMBER EC 2.7.11.25 T95736 SEQUENCE MAVMEMACPGAPGSAVGQQKELPKAKEKTPPLGKKQSSVYKLEAVEKSPVFCGKWEILNDVITKGTAKEGSEAGPAAISIIAQAECENSQEFSPTFSERIFIAGSKQYSQSESLDQIPNNVAHATEGKMARVCWKGKRRSKARKKRKKKSSKSLAHAGVALAKPLPRTPEQESCTIPVQEDESPLGAPYVRNTPQFTKPLKEPGLGQLCFKQLGEGLRPALPRSELHKLISPLQCLNHVWKLHHPQDGGPLPLPTHPFPYSRLPHPFPFHPLQPWKPHPLESFLGKLACVDSQKPLPDPHLSKLACVDSPKPLPGPHLEPSCLSRGAHEKFSVEEYLVHALQGSVSSGQAHSLTSLAKTWAARGSRSREPSPKTEDNEGVLLTEKLKPVDYEYREEVHWATHQLRLGRGSFGEVHRMEDKQTGFQCAVKKVRLEVFRAEELMACAGLTSPRIVPLYGAVREGPWVNIFMELLEGGSLGQLVKEQGCLPEDRALYYLGQALEGLEYLHSRRILHGDVKADNVLLSSDGSHAALCDFGHAVCLQPDGLGKSLLTGDYIPGTETHMAPEVVLGRSCDAKVDVWSSCCMMLHMLNGCHPWTQFFRGPLCLKIASEPPPVREIPPSCAPLTAQAIQEGLRKEPIHRVSAAELGGKVNRALQQVGGLKSPWRGEYKEPRHPPPNQANYHQTLHAQPRELSPRAPGPRPAEETTGRAPKLQPPLPPEPPEPNKSPPLTLSKEESGMWEPLPLSSLEPAPARNPSSPERKATVPEQELQQLEIELFLNSLSQPFSLEEQEQILSCLSIDSLSLSDDSEKNPSKASQSSRDTLSSGVHSWSSQAEARSSSWNMVLARGRPTDTPSYFNGVKVQIQSLNGEHLHIREFHRVKVGDIATGISSQIPAAAFSLVTKDGQPVRYDMEVPDSGIDLQCTLAPDGSFAWSWRVKHGQLENRP T95736 DRUGINFO D0LE7J PMID23374866C31 Investigative T21661 TARGETID T21661 T21661 FORMERID TTDR00247 T21661 UNIPROID METH_HUMAN T21661 TARGNAME Methionine synthase (MTR) T21661 GENENAME MTR T21661 TARGTYPE Literature-reported T21661 SYNONYMS Methionine synthase, vitamin-B12dependent; MTR; MS; Cobalamin-dependent methionine synthase; B12 dependent methionine synthetase; 5-methyltetrahydrofolate:homocysteine methyltransferase; 5-methyltetrahydrofolate-homocysteine methyltransferase; 5-methyltetrahydrofolate homocysteine methyltransferase T21661 FUNCTION Catalyzes the transfer of a methyl group from methyl- cobalamin to homocysteine, yielding enzyme-bound cob(I)alamin and methionine. Subsequently, remethylates the cofactor using methyltetrahydrofolate. T21661 PDBSTRUC 4CCZ; 2O2K T21661 BIOCLASS Methyltransferase T21661 ECNUMBER EC 2.1.1.13 T21661 SEQUENCE MSPALQDLSQPEGLKKTLRDEINAILQKRIMVLDGGMGTMIQREKLNEEHFRGQEFKDHARPLKGNNDILSITQPDVIYQIHKEYLLAGADIIETNTFSSTSIAQADYGLEHLAYRMNMCSAGVARKAAEEVTLQTGIKRFVAGALGPTNKTLSVSPSVERPDYRNITFDELVEAYQEQAKGLLDGGVDILLIETIFDTANAKAALFALQNLFEEKYAPRPIFISGTIVDKSGRTLSGQTGEGFVISVSHGEPLCIGLNCALGAAEMRPFIEIIGKCTTAYVLCYPNAGLPNTFGDYDETPSMMAKHLKDFAMDGLVNIVGGCCGSTPDHIREIAEAVKNCKPRVPPATAFEGHMLLSGLEPFRIGPYTNFVNIGERCNVAGSRKFAKLIMAGNYEEALCVAKVQVEMGAQVLDVNMDDGMLDGPSAMTRFCNLIASEPDIAKVPLCIDSSNFAVIEAGLKCCQGKCIVNSISLKEGEDDFLEKARKIKKYGAAMVVMAFDEEGQATETDTKIRVCTRAYHLLVKKLGFNPNDIIFDPNILTIGTGMEEHNLYAINFIHATKVIKETLPGARISGGLSNLSFSFRGMEAIREAMHGVFLYHAIKSGMDMGIVNAGNLPVYDDIHKELLQLCEDLIWNKDPEATEKLLRYAQTQGTGGKKVIQTDEWRNGPVEERLEYALVKGIEKHIIEDTEEARLNQKKYPRPLNIIEGPLMNGMKIVGDLFGAGKMFLPQVIKSARVMKKAVGHLIPFMEKEREETRVLNGTVEEEDPYQGTIVLATVKGDVHDIGKNIVGVVLGCNNFRVIDLGVMTPCDKILKAALDHKADIIGLSGLITPSLDEMIFVAKEMERLAIRIPLLIGGATTSKTHTAVKIAPRYSAPVIHVLDASKSVVVCSQLLDENLKDEYFEEIMEEYEDIRQDHYESLKERRYLPLSQARKSGFQMDWLSEPHPVKPTFIGTQVFEDYDLQKLVDYIDWKPFFDVWQLRGKYPNRGFPKIFNDKTVGGEARKVYDDAHNMLNTLISQKKLRARGVVGFWPAQSIQDDIHLYAEAAVPQAAEPIATFYGLRQQAEKDSASTEPYYCLSDFIAPLHSGIRDYLGLFAVACFGVEELSKAYEDDGDDYSSIMVKALGDRLAEAFAEELHERVRRELWAYCGSEQLDVADLRRLRYKGIRPAPGYPSQPDHTEKLTMWRLADIEQSTGIRLTESLAMAPASAVSGLYFSNLKSKYFAVGKISKDQVEDYALRKNISVAEVEKWLGPILGYDTD T12627 TARGETID T12627 T12627 FORMERID TTDR00661 T12627 UNIPROID ACON_HUMAN T12627 TARGNAME Citrate hydro-lyase (ACO2) T12627 GENENAME ACO2 T12627 TARGTYPE Literature-reported T12627 SYNONYMS Aconitase; ACO2 T12627 FUNCTION Catalyzes the isomerization of citrate to isocitrate via cis-aconitate. T12627 BIOCLASS Alpha-carbonic anhydrase T12627 ECNUMBER EC 4.2.1.3 T12627 SEQUENCE MAPYSLLVTRLQKALGVRQYHVASVLCQRAKVAMSHFEPNEYIHYDLLEKNINIVRKRLNRPLTLSEKIVYGHLDDPASQEIERGKSYLRLRPDRVAMQDATAQMAMLQFISSGLSKVAVPSTIHCDHLIEAQVGGEKDLRRAKDINQEVYNFLATAGAKYGVGFWKPGSGIIHQIILENYAYPGVLLIGTDSHTPNGGGLGGICIGVGGADAVDVMAGIPWELKCPKVIGVKLTGSLSGWSSPKDVILKVAGILTVKGGTGAIVEYHGPGVDSISCTGMATICNMGAEIGATTSVFPYNHRMKKYLSKTGREDIANLADEFKDHLVPDPGCHYDQLIEINLSELKPHINGPFTPDLAHPVAEVGKVAEKEGWPLDIRVGLIGSCTNSSYEDMGRSAAVAKQALAHGLKCKSQFTITPGSEQIRATIERDGYAQILRDLGGIVLANACGPCIGQWDRKDIKKGEKNTIVTSYNRNFTGRNDANPETHAFVTSPEIVTALAIAGTLKFNPETDYLTGTDGKKFRLEAPDADELPKGEFDPGQDTYQHPPKDSSGQHVDVSPTSQRLQLLEPFDKWDGKDLEDLQILIKVKGKCTTDHISAAGPWLKFRGHLDNISNNLLIGAINIENGKANSVRNAVTQEFGPVPDTARYYKKHGIRWVVIGDENYGEGSSREHAALEPRHLGGRAIITKSFARIHETNLKKQGLLPLTFADPADYNKIHPVDKLTIQGLKDFTPGKPLKCIIKHPNGTQETILLNHTFNETQIEWFRAGSALNRMKELQQ T12627 DRUGINFO D00UFR Aconitate Ion Investigative T12627 DRUGINFO D01EVI Alpha-Methylisocitric Acid Investigative T12627 DRUGINFO D02UII 4-Hydroxy-Aconitate Ion Investigative T12627 DRUGINFO D08ZAO Tricarballylic Acid Investigative T12627 DRUGINFO D0R6GQ Isocitric Acid Investigative T64716 TARGETID T64716 T64716 FORMERID TTDNR00737 T64716 UNIPROID Q9A1S9_STRP1 T64716 TARGNAME Streptococcus Pyrroline carboxylate reductase (Stre-coc proC) T64716 GENENAME Stre-coc proC T64716 TARGTYPE Literature-reported T64716 SYNONYMS Pyrroline-5-carboxylate reductase; PCA reductase; P5CR; P5C reductase T64716 FUNCTION Catalyzes the reduction of 1-pyrroline-5-carboxylate (PCA) to L-proline. T64716 PDBSTRUC 2AMF; 2AHR T64716 BIOCLASS CH-NH donor oxidoreductase T64716 ECNUMBER EC 1.5.1.2 T64716 SEQUENCE MKIGIIGVGKMASAIIKGLKQTPHELIISGSSLERSKEIAEQLALPYAMSHQDLIDQVDLVILGIKPQLFETVLKPLHFKQPIISMAAGISLQRLATFVGQDLPLLRIMPNMNAQILQSSTALTGNALVSQELQARVRDLTDSFGSTFDISEKDFDTFTALAGSSPAYIYLFIEALAKAGVKNGIPKAKALEIVTQTVLASASNLKTSSQSPHDFIDAICSPGGTTIAGLMELERLGLTATVSSAIDKTIDKAKSL T71055 TARGETID T71055 T71055 FORMERID TTDI00002 T71055 UNIPROID HOIL1_HUMAN T71055 TARGNAME Linear ubiquitin chain assembly complex (RBCK1) T71055 GENENAME RBCK1 T71055 TARGTYPE Literature-reported T71055 SYNONYMS XAP4; XAP3; Ubiquitin-conjugating enzyme 7-interacting protein 3; UBCE7IP3; RanBP-type and C3HC4-type zinc finger-containing protein 1; RNF54; RING-type E3 ubiquitin transferase HOIL-1; RING finger protein 54; Hepatitis B virus X-associated protein 4; Heme-oxidized IRP2 ubiquitin ligase 1; HOIL-1; HBV-associated factor 4; C20orf18 T71055 FUNCTION Functions as an E3 ligase for oxidized IREB2 and both heme and oxygen are necessary for IREB2 ubiquitination. Promotes ubiquitination of TAB2 and IRF3 and their degradation by the proteasome. Component of the LUBAC complex which conjugates linear ('Met-1'-linked) polyubiquitin chains to substrates and plays a key role in NF-kappa-B activation and regulation of inflammation. LUBAC conjugates linear polyubiquitin to IKBKG and RIPK1 and is involved in activation of the canonical NF-kappa-B and the JNK signaling pathways. Linear ubiquitination mediated by the LUBAC complex interferes with TNF-induced cell death and thereby prevents inflammation. LUBAC is recruited to the TNF-R1 signaling complex (TNF-RSC) following polyubiquitination of TNF-RSC components by BIRC2 and/or BIRC3 and to conjugate linear polyubiquitin to IKBKG and possibly other components contributing to the stability of the complex. Together with OTULIN, the LUBAC complex regulates the canonical Wnt signaling during angiogenesis. Binds polyubiquitin of different linkage types. E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, such as UBE2L3/UBCM4, and then transfers it to substrates. T71055 PDBSTRUC 4DBG; 2LGY; 2CRC T71055 BIOCLASS Acyltransferase T71055 ECNUMBER EC 2.3.2.31 T71055 SEQUENCE MDEKTKKAEEMALSLTRAVAGGDEQVAMKCAIWLAEQRVPLSVQLKPEVSPTQDIRLWVSVEDAQMHTVTIWLTVRPDMTVASLKDMVFLDYGFPPVLQQWVIGQRLARDQETLHSHGVRQNGDSAYLYLLSARNTSLNPQELQRERQLRMLEDLGFKDLTLQPRGPLEPGPPKPGVPQEPGRGQPDAVPEPPPVGWQCPGCTFINKPTRPGCEMCCRARPEAYQVPASYQPDEEERARLAGEEEALRQYQQRKQQQQEGNYLQHVQLDQRSLVLNTEPAECPVCYSVLAPGEAVVLRECLHTFCRECLQGTIRNSQEAEVSCPFIDNTYSCSGKLLEREIKALLTPEDYQRFLDLGISIAENRSAFSYHCKTPDCKGWCFFEDDVNEFTCPVCFHVNCLLCKAIHEQMNCKEYQEDLALRAQNDVAARQTTEMLKVMLQQGEAMRCPQCQIVVQKKDGCDWIRCTVCHTEICWVTKGPRWGPGGPGDTSGGCRCRVNGIPCHPSCQNCH T73551 TARGETID T73551 T73551 UNIPROID SETD2_HUMAN T73551 TARGNAME Lysine N-methyltransferase 3A (SETD2) T73551 GENENAME SETD2 T73551 TARGTYPE Literature-reported T73551 SYNONYMS p231HBP; hSET2; SET2; SET domain-containing protein 2; Protein-lysine N-methyltransferase SETD2; KMT3A; KIAA1732; Huntingtin-interacting protein B; Huntingtin-interacting protein 1; Huntingtin yeast partner B; Histone-lysine N-methyltransferase SETD2; HYPB; HSPC069; HIP-1; HIF1 T73551 FUNCTION Represents the main enzyme generating H3K36me3, a specific tag for epigenetic transcriptional activation. Plays a role in chromatin structure modulation during elongation by coordinating recruitment of the FACT complex and by interacting with hyperphosphorylated POLR2A. Acts as a key regulator of DNA mismatch repair in G1 and early S phase by generating H3K36me3, a mark required to recruit MSH6 subunit of the MutS alpha complex: early recruitment of the MutS alpha complex to chromatin to be replicated allows a quick identification of mismatch DNA to initiate the mismatch repair reaction. Required for DNA double-strand break repair in response to DNA damage: acts by mediating formation of H3K36me3, promoting recruitment of RAD51 and DNA repair via homologous recombination (HR). Acts as a tumor suppressor. H3K36me3 also plays an essential role in the maintenance of a heterochromatic state, by recruiting DNA methyltransferase DNMT3A. H3K36me3 is also enhanced in intron-containing genes, suggesting that SETD2 recruitment is enhanced by splicing and that splicing is coupled to recruitment of elongating RNA polymerase. Required during angiogenesis. Required for endoderm development by promoting embryonic stem cell differentiation toward endoderm: acts by mediating formation of H3K36me3 in distal promoter regions of FGFR3, leading to regulate transcription initiation of FGFR3. In addition to histones, also mediates methylation of other proteins, such as tubulins and STAT1. Trimethylates 'Lys-40' of alpha-tubulins such as TUBA1B (alpha-TubK40me3); alpha-TubK40me3 is required for normal mitosis and cytokinesis and may be a specific tag in cytoskeletal remodeling. Involved in interferon-alpha-induced antiviral defense by mediating both monomethylation of STAT1 at 'Lys-525' and catalyzing H3K36me3 on promoters of some interferon-stimulated genes (ISGs) to activate gene transcription. Histone methyltransferase that specifically trimethylates 'Lys-36' of histone H3 (H3K36me3) using dimethylated 'Lys-36' (H3K36me2) as substrate. T73551 PDBSTRUC 5V22; 5V21; 5LT8; 5LT7; 5LT6 T73551 BIOCLASS Methyltransferase T73551 ECNUMBER EC 2.1.1.43 T73551 SEQUENCE MKQLQPQPPPKMGDFYDPEHPTPEEEENEAKIENVQKTGFIKGPMFKGVASSRFLPKGTKTKVNLEEQGRQKVSFSFSLTKKTLQNRFLTALGNEKQSDTPNPPAVPLQVDSTPKMKMEIGDTLSTAEESSPPKSRVELGKIHFKKHLLHVTSRPLLATTTAVASPPTHAAPLPAVIAESTTVDSPPSSPPPPPPPAQATTLSSPAPVTEPVALPHTPITVLMAAPVPLPVDVAVRSLKEPPIIIVPESLEADTKQDTISNSLEEHVTQILNEQADISSKKEDSHIGKDEEIPDSSKISLSCKKTGSKKKSSQSEGIFLGSESDEDSVRTSSSQRSHDLKFSASIEKERDFKKSSAPLKSEDLGKPSRSKTDRDDKYFSYSKLERDTRYVSSRCRSERERRRSRSHSRSERGSRTNLSYSRSERSHYYDSDRRYHRSSPYRERTRYSRPYTDNRARESSDSEEEYKKTYSRRTSSHSSSYRDLRTSSYSKSDRDCKTETSYLEMERRGKYSSKLERESKRTSENEAIKRCCSPPNELGFRRGSSYSKHDSSASRYKSTLSKPIPKSDKFKNSFCCTELNEEIKQSHSFSLQTPCSKGSELRMINKNPEREKAGSPAPSNRLNDSPTLKKLDELPIFKSEFITHDSHDSIKELDSLSKVKNDQLRSFCPIELNINGSPGAESDLATFCTSKTDAVLMTSDDSVTGSELSPLVKACMLSSNGFQNISRCKEKDLDDTCMLHKKSESPFRETEPLVSPHQDKLMSMPVMTVDYSKTVVKEPVDTRVSCCKTKDSDIYCTLNDSNPSLCNSEAENIEPSVMKISSNSFMNVHLESKPVICDSRNLTDHSKFACEEYKQSIGSTSSASVNHFDDLYQPIGSSGIASSLQSLPPGIKVDSLTLLKCGENTSPVLDAVLKSKKSSEFLKHAGKETIVEVGSDLPDSGKGFASRENRRNNGLSGKCLQEAQEEGNSILPERRGRPEISLDERGEGGHVHTSDDSEVVFSSCDLNLTMEDSDGVTYALKCDSSGHAPEIVSTVHEDYSGSSESSNDESDSEDTDSDDSSIPRNRLQSVVVVPKNSTLPMEETSPCSSRSSQSYRHYSDHWEDERLESRRHLYEEKFESIASKACPQTDKFFLHKGTEKNPEISFTQSSRKQIDNRLPELSHPQSDGVDSTSHTDVKSDPLGHPNSEETVKAKIPSRQQEELPIYSSDFEDVPNKSWQQTTFQNRPDSRLGKTELSFSSSCEIPHVDGLHSSEELRNLGWDFSQEKPSTTYQQPDSSYGACGGHKYQQNAEQYGGTRDYWQGNGYWDPRSGRPPGTGVVYDRTQGQVPDSLTDDREEEENWDQQDGSHFSDQSDKFLLSLQKDKGSVQAPEISSNSIKDTLAVNEKKDFSKNLEKNDIKDRGPLKKRRQEIESDSESDGELQDRKKVRVEVEQGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRKKDSVDGELEALMENGEGLSDKNQVLSLSRLMVRIETLEQKLTCLELIQNTHSQSCLKSFLERHGLSLLWIWMAELGDGRESNQKLQEEIIKTLEHLPIPTKNMLEESKVLPIIQRWSQTKTAVPPLSEGDGYSSENTSRAHTPLNTPDPSTKLSTEADTDTPKKLMFRRLKIISENSMDSAISDATSELEGKDGKEDLDQLENVPVEEEEELQSQQLLPQQLPECKVDSETNIEASKLPTSEPEADAEIEPKESNGTKLEEPINEETPSQDEEEGVSDVESERSQEQPDKTVDISDLATKLLDSWKDLKEVYRIPKKSQTEKENTTTERGRDAVGFRDQTPAPKTPNRSRERDPDKQTQNKEKRKRRSSLSPPSSAYERGTKRPDDRYDTPTSKKKVRIKDRNKLSTEERRKLFEQEVAQREAQKQQQQMQNLGMTSPLPYDSLGYNAPHHPFAGYPPGYPMQAYVDPSNPNAGKVLLPTPSMDPVCSPAPYDHAQPLVGHSTEPLSAPPPVPVVPHVAAPVEVSSSQYVAQSDGVVHQDSSVAVLPVPAPGPVQGQNYSVWDSNQQSVSVQQQYSPAQSQATIYYQGQTCPTVYGVTSPYSQTTPPIVQSYAQPSLQYIQGQQIFTAHPQGVVVQPAAAVTTIVAPGQPQPLQPSEMVVTNNLLDLPPPSPPKPKTIVLPPNWKTARDPEGKIYYYHVITRQTQWDPPTWESPGDDASLEHEAEMDLGTPTYDENPMKASKKPKTAEADTSSELAKKSKEVFRKEMSQFIVQCLNPYRKPDCKVGRITTTEDFKHLARKLTHGVMNKELKYCKNPEDLECNENVKHKTKEYIKKYMQKFGAVYKPKEDTELE T67730 TARGETID T67730 T67730 FORMERID TTDR00170 T67730 UNIPROID TRYD_HUMAN T67730 TARGNAME Delta-tryptase (TPSD1) T67730 GENENAME TPSD1 T67730 TARGTYPE Literature-reported T67730 SYNONYMS TPSD1; Mast cell mMCP-7-like; HmMCP-3-like tryptase III; Delta tryptase T67730 FUNCTION Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type. T67730 BIOCLASS Peptidase T67730 ECNUMBER EC 3.4.21.59 T67730 SEQUENCE MLLLAPQMLSLLLLALPVLASPAYVAPAPGQALQQTGIVGGQEAPRSKWPWQVSLRVRGPYWMHFCGGSLIHPQWVLTAAHCVEPDIKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYIIQTGADIALLELEEPVNISSHIHTVTLPPASETFPPGMPCWVTGWGDVDNNVHLPPPYPLKEVEVPVVENHLCNAEYHTGLHTGHSFQIVRDDMLCAGSENHDSCQGDSGGPLVCKVNGT T67730 DRUGINFO D09YQM BMS-262084 Investigative T51597 TARGETID T51597 T51597 FORMERID TTDNR00634 T51597 UNIPROID CHIA_HUMAN T51597 TARGNAME Acidic mammalian chitinase (CHIA) T51597 GENENAME CHIA T51597 TARGTYPE Literature-reported T51597 SYNONYMS Lung-specific protein TSA1902; CHIA; AMCase T51597 FUNCTION Degrades chitin and chitotriose. May participate in the defense against nematodes, fungi and other pathogens. Plays a role in T-helper cell type 2 (Th2) immune response. Contributes to the response to IL-13 and inflammation in response to IL-13. Stimulates chemokine production by pulmonary epithelial cells. Protects lung epithelial cells against apoptosis and promotes phosphorylation of AKT1. Its function in the inflammatory response and in protecting cells against apoptosis is inhibited by allosamidin, suggesting that the function of this protein depends on carbohydrate binding. . T51597 PDBSTRUC 3RME; 3RM9; 3RM8; 3RM4; 3FY1 T51597 BIOCLASS Glycosylase T51597 ECNUMBER EC 3.2.1.14 T51597 SEQUENCE MTKLILLTGLVLILNLQLGSAYQLTCYFTNWAQYRPGLGRFMPDNIDPCLCTHLIYAFAGRQNNEITTIEWNDVTLYQAFNGLKNKNSQLKTLLAIGGWNFGTAPFTAMVSTPENRQTFITSVIKFLRQYEFDGLDFDWEYPGSRGSPPQDKHLFTVLVQEMREAFEQEAKQINKPRLMVTAAVAAGISNIQSGYEIPQLSQYLDYIHVMTYDLHGSWEGYTGENSPLYKYPTDTGSNAYLNVDYVMNYWKDNGAPAEKLIVGFPTYGHNFILSNPSNTGIGAPTSGAGPAGPYAKESGIWAYYEICTFLKNGATQGWDAPQEVPYAYQGNVWVGYDNIKSFDIKAQWLKHNKFGGAMVWAIDLDDFTGTFCNQGKFPLISTLKKALGLQSASCTAPAQPIEPITAAPSGSGNGSGSSSSGGSSGGSGFCAVRANGLYPVANNRNAFWHCVNGVTYQQNCQAGLVFDTSCDCCNWA T00477 TARGETID T00477 T00477 FORMERID TTDR01324 T00477 UNIPROID SRR_HUMAN T00477 TARGNAME Serine Racemase (SRR) T00477 GENENAME SRR T00477 TARGTYPE Literature-reported T00477 SYNONYMS L-serine dehydratase; L-serine ammonia-lyase; D-serine dehydratase; D-serine ammonia-lyase T00477 FUNCTION D-serine is a key coagonist with glutamate at NMDA receptors. Has dehydratase activity towards both L-serine and D-serine. Catalyzes the synthesis of D-serine from L-serine. T00477 PDBSTRUC 5X2L; 3L6R; 3L6B T00477 BIOCLASS Racemases and epimerase T00477 ECNUMBER EC 5.1.1.18 T00477 SEQUENCE MCAQYCISFADVEKAHINIRDSIHLTPVLTSSILNQLTGRNLFFKCELFQKTGSFKIRGALNAVRSLVPDALERKPKAVVTHSSGNHGQALTYAAKLEGIPAYIVVPQTAPDCKKLAIQAYGASIVYCEPSDESRENVAKRVTEETEGIMVHPNQEPAVIAGQGTIALEVLNQVPLVDALVVPVGGGGMLAGIAITVKALKPSVKVYAAEPSNADDCYQSKLKGKLMPNLYPPETIADGVKSSIGLNTWPIIRDLVDDIFTVTEDEIKCATQLVWERMKLLIEPTAGVGVAAVLSQHFQTVSPEVKNICIVLSGGNVDLTSSITWVKQAERPASYQSVSV T00477 DRUGINFO D08JNG Malonic acid Investigative T00477 DRUGINFO D0U6DZ L-erythro-3-hydroxyaspartate Investigative T98225 TARGETID T98225 T98225 FORMERID TTDI03105 T98225 UNIPROID CLK4_HUMAN T98225 TARGNAME CDC-like kinase 4 (CLK4) T98225 GENENAME CLK4 T98225 TARGTYPE Literature-reported T98225 SYNONYMS Dual specificity protein kinase CLK4 T98225 FUNCTION Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex and may be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing. Phosphorylates SRSF1 and SRSF3. Required for the regulation of alternative splicing of MAPT/TAU. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. T98225 PDBSTRUC 6FYV T98225 BIOCLASS Kinase T98225 ECNUMBER EC 2.7.12.1 T98225 SEQUENCE MRHSKRTHCPDWDSRESWGHESYRGSHKRKRRSHSSTQENRHCKPHHQFKESDCHYLEARSLNERDYRDRRYVDEYRNDYCEGYVPRHYHRDIESGYRIHCSKSSVRSRRSSPKRKRNRHCSSHQSRSKSHRRKRSRSIEDDEEGHLICQSGDVLRARYEIVDTLGEGAFGKVVECIDHGMDGMHVAVKIVKNVGRYREAARSEIQVLEHLNSTDPNSVFRCVQMLEWFDHHGHVCIVFELLGLSTYDFIKENSFLPFQIDHIRQMAYQICQSINFLHHNKLTHTDLKPENILFVKSDYVVKYNSKMKRDERTLKNTDIKVVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPCDVWSIGCILIEYYLGFTVFQTHDSKEHLAMMERILGPIPQHMIQKTRKRKYFHHNQLDWDEHSSAGRYVRRRCKPLKEFMLCHDEEHEKLFDLVRRMLEYDPTQRITLDEALQHPFFDLLKKK T98225 DRUGINFO D0UI7U ML315 Investigative T98225 DRUGINFO D06CXU PMID23642479C17 Investigative T90961 TARGETID T90961 T90961 FORMERID TTDI03054 T90961 UNIPROID BMP2K_HUMAN T90961 TARGNAME BMP-2-inducible protein kinase (BMP2K) T90961 GENENAME BMP2K T90961 TARGTYPE Literature-reported T90961 SYNONYMS HRIHFB2017; BIKe T90961 FUNCTION May be involved in osteoblast differentiation. T90961 PDBSTRUC 5IKW; 5I3R; 5I3O; 4W9X; 4W9W T90961 BIOCLASS Kinase T90961 ECNUMBER EC 2.7.11.1 T90961 SEQUENCE MKKFSRMPKSEGGSGGGAAGGGAGGAGAGAGCGSGGSSVGVRVFAVGRHQVTLEESLAEGGFSTVFLVRTHGGIRCALKRMYVNNMPDLNVCKREITIMKELSGHKNIVGYLDCAVNSISDNVWEVLILMEYCRAGQVVNQMNKKLQTGFTEPEVLQIFCDTCEAVARLHQCKTPIIHRDLKVENILLNDGGNYVLCDFGSATNKFLNPQKDGVNVVEEEIKKYTTLSYRAPEMINLYGGKPITTKADIWALGCLLYKLCFFTLPFGESQVAICDGNFTIPDNSRYSRNIHCLIRFMLEPDPEHRPDIFQVSYFAFKFAKKDCPVSNINNSSIPSALPEPMTASEAAARKSQIKARITDTIGPTETSIAPRQRPKANSATTATPSVLTIQSSATPVKVLAPGEFGNHRPKGALRPGNGPEILLGQGPPQQPPQQHRVLQQLQQGDWRLQQLHLQHRHPHQQQQQQQQQQQQQQQQQQQQQQQQQQQHHHHHHHHLLQDAYMQQYQHATQQQQMLQQQFLMHSVYQPQPSASQYPTMMPQYQQAFFQQQMLAQHQPSQQQASPEYLTSPQEFSPALVSYTSSLPAQVGTIMDSSYSANRSVADKEAIANFTNQKNISNPPDMSGWNPFGEDNFSKLTEEELLDREFDLLRSNRLEERASSDKNVDSLSAPHNHPPEDPFGSVPFISHSGSPEKKAEHSSINQENGTANPIKNGKTSPASKDQRTGKKTSVQGQVQKGNDESESDFESDPPSPKSSEEEEQDDEEVLQGEQGDFNDDDTEPENLGHRPLLMDSEDEEEEEKHSSDSDYEQAKAKYSDMSSVYRDRSGSGPTQDLNTILLTSAQLSSDVAVETPKQEFDVFGAVPFFAVRAQQPQQEKNEKNLPQHRFPAAGLEQEEFDVFTKAPFSKKVNVQECHAVGPEAHTIPGYPKSVDVFGSTPFQPFLTSTSKSESNEDLFGLVPFDEITGSQQQKVKQRSLQKLSSRQRRTKQDMSKSNGKRHHGTPTSTKKTLKPTYRTPERARRHKKVGRRDSQSSNEFLTISDSKENISVALTDGKDRGNVLQPEESLLDPFGAKPFHSPDLSWHPPHQGLSDIRADHNTVLPGRPRQNSLHGSFHSADVLKMDDFGAVPFTELVVQSITPHQSQQSQPVELDPFGAAPFPSKQ T90961 DRUGINFO D02NZE PMID20483621C5m Investigative T86454 TARGETID T86454 T86454 FORMERID TTDR00632 T86454 UNIPROID OXSM_HUMAN T86454 TARGNAME Beta-ketoacyl-ACP synthase (OXSM) T86454 GENENAME OXSM T86454 TARGTYPE Literature-reported T86454 SYNONYMS 3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial T86454 FUNCTION May play a role in the biosynthesis of lipoic acid as well as longer chain fatty acids required for optimal mitochondrial function. T86454 PDBSTRUC 2IWZ; 2IWY; 2C9H T86454 BIOCLASS Acyltransferase T86454 ECNUMBER EC 2.3.1.41 T86454 SEQUENCE MSNCLQNFLKITSTRLLCSRLCQQLRSKRKFFGTVPISRLHRRVVITGIGLVTPLGVGTHLVWDRLIGGESGIVSLVGEEYKSIPCSVAAYVPRGSDEGQFNEQNFVSKSDIKSMSSPTIMAIGAAELAMKDSGWHPQSEADQVATGVAIGMGMIPLEVVSETALNFQTKGYNKVSPFFVPKILVNMAAGQVSIRYKLKGPNHAVSTACTTGAHAVGDSFRFIAHGDADVMVAGGTDSCISPLSLAGFSRARALSTNSDPKLACRPFHPKRDGFVMGEGAAVLVLEEYEHAVQRRARIYAEVLGYGLSGDAGHITAPDPEGEGALRCMAAALKDAGVQPEEISYINAHATSTPLGDAAENKAIKHLFKDHAYALAVSSTKGATGHLLGAAGAVEAAFTTLACYYQKLPPTLNLDCSEPEFDLNYVPLKAQEWKTEKRFIGLTNSFGFGGTNATLCIAGL T91940 TARGETID T91940 T91940 UNIPROID SIR5_HUMAN T91940 TARGNAME NAD-dependent deacetylase sirtuin-5 (SIRT5) T91940 GENENAME SIRT5 T91940 TARGTYPE Literature-reported T91940 SYNONYMS SIR2L5; SIR2-like protein 5; Regulatory protein SIR2 homolog 5 T91940 FUNCTION NAD-dependent lysine demalonylase, desuccinylase and deglutarylase that specifically removes malonyl, succinyl and glutaryl groups on target proteins (PubMed:21908771, PubMed:22076378, PubMed:24703693, PubMed:29180469). Activates CPS1 and contributes to the regulation of blood ammonia levels during prolonged fasting: acts by mediating desuccinylation and deglutarylation of CPS1, thereby increasing CPS1 activity in response to elevated NAD levels during fasting (PubMed:22076378, PubMed:24703693). Activates SOD1 by mediating its desuccinylation, leading to reduced reactive oxygen species (PubMed:24140062). Activates SHMT2 by mediating its desuccinylation (PubMed:29180469). Modulates ketogenesis through the desuccinylation and activation of HMGCS2. Has weak NAD-dependent protein deacetylase activity; however this activity may not be physiologically relevant in vivo. Can deacetylate cytochrome c (CYCS) and a number of other proteins in vitro such as UOX. T91940 PDBSTRUC 6EQS; 5XHS; 5BWL; 4HDA; 4G1C T91940 BIOCLASS Sirtuin family. Class III subfamily T91940 ECNUMBER EC 3.5.1.- T91940 SEQUENCE MRPLQIVPSRLISQLYCGLKPPASTRNQICLKMARPSSSMADFRKFFAKAKHIVIISGAGVSAESGVPTFRGAGGYWRKWQAQDLATPLAFAHNPSRVWEFYHYRREVMGSKEPNAGHRAIAECETRLGKQGRRVVVITQNIDELHRKAGTKNLLEIHGSLFKTRCTSCGVVAENYKSPICPALSGKGAPEPGTQDASIPVEKLPRCEEAGCGGLLRPHVVWFGENLDPAILEEVDRELAHCDLCLVVGTSSVVYPAAMFAPQVAARGVPVAEFNTETTPATNRFRFHFQGPCGTTLPEALACHENETVS T28132 TARGETID T28132 T28132 FORMERID TTDC00240 T28132 UNIPROID CA2D2_HUMAN T28132 TARGNAME Voltage-gated calcium channel alpha-2/delta-2 (CACNA2D2) T28132 GENENAME CACNA2D2 T28132 TARGTYPE Literature-reported T28132 SYNONYMS Voltage-gated calcium channel subunit alpha-2/delta-2; Voltage-dependent calcium channel subunit delta-2; Voltage-dependent calcium channel subunit alpha-2-2; CACNA2D2 T28132 FUNCTION The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis. T28132 BIOCLASS Voltage-gated ion channel T28132 SEQUENCE MAVPARTCGASRPGPARTARPWPGCGPHPGPGTRRPTSGPPRPLWLLLPLLPLLAAPGASAYSFPQQHTMQHWARRLEQEVDGVMRIFGGVQQLREIYKDNRNLFEVQENEPQKLVEKVAGDIESLLDRKVQALKRLADAAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVERGSKASTLRLDFIEDPNFKNKVNYSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRRQDPTLLWQVFGSATGVTRYYPATPWRAPKKIDLYDVRRRPWYIQGASSPKDMVIIVDVSGSVSGLTLKLMKTSVCEMLDTLSDDDYVNVASFNEKAQPVSCFTHLVQANVRNKKVFKEAVQGMVAKGTTGYKAGFEYAFDQLQNSNITRANCNKMIMMFTDGGEDRVQDVFEKYNWPNRTVRVFTFSVGQHNYDVTPLQWMACANKGYYFEIPSIGAIRINTQEYLDVLGRPMVLAGKEAKQVQWTNVYEDALGLGLVVTGTLPVFNLTQDGPGEKKNQLILGVMGIDVALNDIKRLTPNYTLGANGYVFAIDLNGYVLLHPNLKPQTTNFREPVTLDFLDAELEDENKEEIRRSMIDGNKGHKQIRTLVKSLDERYIDEVTRNYTWVPIRSTNYSLGLVLPPYSTFYLQANLSDQILQVKLPISKLKDFEFLLPSSFESEGHVFIAPREYCKDLNASDNNTEFLKNFIELMEKVTPDSKQCNNFLLHNLILDTGITQQLVERVWRDQDLNTYSLLAVFAATDGGITRVFPNKAAEDWTENPEPFNASFYRRSLDNHGYVFKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLRPAVVGVKLDLEAWAEKFKVLASNRTHQDQPQKCGPNSHCEMDCEVNNEDLLCVLIDDGGFLVLSNQNHQWDQVGRFFSEVDANLMLALYNNSFYTRKESYDYQAACAPQPPGNLGAAPRGVFVPTVADFLNLAWWTSAAAWSLFQQLLYGLIYHSWFQADPAEAEGSPETRESSCVMKQTQYYFGSVNASYNAIIDCGNCSRLFHAQRLTNTNLLFVVAEKPLCSQCEAGRLLQKETHSDGPEQCELVQRPRYRRGPHICFDYNATEDTSDCGRGASFPPSLGVLVSLQLLLLLGLPPRPQPQVLVHASRRL T28132 DRUGINFO D0D1EU PD-144550 Investigative T28132 DRUGINFO D0T6DR 3-Aminomethyl-5-methyl-hexanoic acid Investigative T72849 TARGETID T72849 T72849 FORMERID TTDR00913 T72849 UNIPROID ERAP1_HUMAN T72849 TARGNAME Adipocyte-derived leucine aminopeptidase (ERAP1) T72849 GENENAME ERAP1 T72849 TARGTYPE Literature-reported T72849 SYNONYMS Type 1 tumor necrosis factor receptor shedding aminopeptidase regulator; Puromycin-insensitive leucyl-specific aminopeptidase; PILS-AP; ERAP1; Aminopeptidase PILS; ARTS-1; ALAP; A-LAP T72849 FUNCTION Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I- binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Strongly prefers substrates 9-16 residues long. Rapidly degrades 13-mer to a 9-mer and then stops. Preferentially hydrolyzes the residue Leu and peptides with a hydrophobic C-terminus, while it has weak activity toward peptides with charged C-terminus. May play a role in the inactivation of peptide hormones. May be involved in the regulationof blood pressure through the inactivation of angiotensin II and/or the generation of bradykinin in the kidney. T72849 PDBSTRUC 6Q4R; 5J5E; 3RJO; 3QNF; 3MDJ T72849 BIOCLASS Peptidase T72849 ECNUMBER EC 3.4.11.- T72849 SEQUENCE MVFLPLKWSLATMSFLLSSLLALLTVSTPSWCQSTEASPKRSDGTPFPWNKIRLPEYVIPVHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGAGERLSEEPLQVLEHPRQEQIALLAPEPLLVGLPYTVVIHYAGNLSETFHGFYKSTYRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMPLVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKFMEFVSVSVTHPELKVGDYFFGKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASICPTDGVKGMDGFCSRSQHSSSSSHWHQEGVDVKTMMNTWTLQKGFPLITITVRGRNVHMKQEHYMKGSDGAPDTGYLWHVPLTFITSKSDMVHRFLLKTKTDVLILPEEVEWIKFNVGMNGYYIVHYEDDGWDSLTGLLKGTHTAVSSNDRASLINNAFQLVSIGKLSIEKALDLSLYLKHETEIMPVFQGLNELIPMYKLMEKRDMNEVETQFKAFLIRLLRDLIDKQTWTDEGSVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKWKESNGNLSLPVDVTLAVFAVGAQSTEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKEKLQWLLDESFKGDKIKTQEFPQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFELGSSSIAHMVMGTTNQFSTRTRLEEVKGFFSSLKENGSQLRCVQQTIETIEENIGWMDKNFDKIRVWLQSEKLERM T72849 DRUGINFO D02MNM PMID23916253C17 Investigative T92288 TARGETID T92288 T92288 UNIPROID MSRB1_HUMAN T92288 TARGNAME Methionine-R-sulfoxide reductase B1 (MSRB1) T92288 GENENAME MSRB1 T92288 TARGTYPE Literature-reported T92288 SYNONYMS Selenoprotein X; SelX; SEPX1; MsrB1 T92288 FUNCTION Methionine-sulfoxide reductase that specifically reduces methionine (R)-sulfoxide back to methionine. While in many cases, methionine oxidation is the result of random oxidation following oxidative stress, methionine oxidation is also a post-translational modification that takes place on specific residue. Acts as a regulator of actin assembly by reducing methionine (R)-sulfoxide mediated by MICALs (MICAL1, MICAL2 or MICAL3) on actin, thereby promoting filament repolymerization. Plays a role in innate immunity by reducing oxidized actin, leading to actin repolymerization in macrophages. T92288 PDBSTRUC 3MAO T92288 BIOCLASS MsrB Met sulfoxide reductase family T92288 ECNUMBER EC 1.8.4.12 T92288 SEQUENCE MSFCSFFGGEVFQNHFEPGVYVCAKCGYELFSSRSKYAHSSPWPAFTETIHADSVAKRPEHNRSEALKVSCGKCGNGLGHEFLNDGPKPGQSRFUIFSSSLKFVPKGKETSASQGH T96435 TARGETID T96435 T96435 FORMERID TTDI02619 T96435 UNIPROID SENP1_HUMAN T96435 TARGNAME Sentrin specific protease-1 (SENP1) T96435 GENENAME SENP1 T96435 TARGTYPE Literature-reported T96435 SYNONYMS Sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1 T96435 FUNCTION The first is the hydrolysis of an alpha-linked peptide bond at the C-terminal end of the small ubiquitin-like modifier (SUMO) propeptides, SUMO1, SUMO2 and SUMO3 leading to the mature form of the proteins. The second is the deconjugation of SUMO1, SUMO2 and SUMO3 from targeted proteins, by cleaving an epsilon-linked peptide bond between the C-terminal glycine of the mature SUMO and the lysine epsilon-amino group of the target protein. Deconjugates SUMO1 from HIPK2. Deconjugates SUMO1 from HDAC1 and BHLHE40/DEC1, which decreases its transcriptional repression activity. Deconjugates SUMO1 from CLOCK, which decreases its transcriptional activation activity. Deconjugates SUMO2 from MTA1. Deconjugates SUMO1 from METTL3. Desumoylates CCAR2 which decreases its interaction with SIRT1. Deconjugates SUMO1 from GPS2. Protease that catalyzes two essential functions in the SUMO pathway. T96435 PDBSTRUC 6NNQ; 2XRE; 2XPH; 2IYD; 2IYC T96435 BIOCLASS Peptidase T96435 ECNUMBER EC 3.4.22.- T96435 SEQUENCE MDDIADRMRMDAGEVTLVNHNSVFKTHLLPQTGFPEDQLSLSDQQILSSRQGHLDRSFTCSTRSAAYNPSYYSDNPSSDSFLGSGDLRTFGQSANGQWRNSTPSSSSSLQKSRNSRSLYLETRKTSSGLSNSFAGKSNHHCHVSAYEKSFPIKPVPSPSWSGSCRRSLLSPKKTQRRHVSTAEETVQEEEREIYRQLLQMVTGKQFTIAKPTTHFPLHLSRCLSSSKNTLKDSLFKNGNSCASQIIGSDTSSSGSASILTNQEQLSHSVYSLSSYTPDVAFGSKDSGTLHHPHHHHSVPHQPDNLAASNTQSEGSDSVILLKVKDSQTPTPSSTFFQAELWIKELTSVYDSRARERLRQIEEQKALALQLQNQRLQEREHSVHDSVELHLRVPLEKEIPVTVVQETQKKGHKLTDSEDEFPEITEEMEKEIKNVFRNGNQDEVLSEAFRLTITRKDIQTLNHLNWLNDEIINFYMNMLMERSKEKGLPSVHAFNTFFFTKLKTAGYQAVKRWTKKVDVFSVDILLVPIHLGVHWCLAVVDFRKKNITYYDSMGGINNEACRILLQYLKQESIDKKRKEFDTNGWQLFSKKSQEIPQQMNGSDCGMFACKYADCITKDRPINFTQQHMPYFRKRMVWEILHRKLL T79694 TARGETID T79694 T79694 FORMERID TTDR00048 T79694 UNIPROID CAC1I_HUMAN T79694 TARGNAME Voltage-gated calcium channel alpha Cav3.3 (CACNA1I) T79694 GENENAME CACNA1I T79694 TARGTYPE Literature-reported T79694 SYNONYMS Voltage-gated calcium channel subunit alpha Cav3.3; Voltage-dependent T-type calcium channel subunit alpha-1I; KIAA1120; Ca(v)3.3 T79694 FUNCTION Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. This channel gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by nickel and mibefradil. A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes. Gates in voltage ranges similar to, but higher than alpha 1G or alpha 1H (By similarity). T79694 BIOCLASS Voltage-gated ion channel T79694 SEQUENCE MAESASPPSSSAAAPAAEPGVTTEQPGPRSPPSSPPGLEEPLDGADPHVPHPDLAPIAFFCLRQTTSPRNWCIKMVCNPWFECVSMLVILLNCVTLGMYQPCDDMDCLSDRCKILQVFDDFIFIFFAMEMVLKMVALGIFGKKCYLGDTWNRLDFFIVMAGMVEYSLDLQNINLSAIRTVRVLRPLKAINRVPSMRILVNLLLDTLPMLGNVLLLCFFVFFIFGIIGVQLWAGLLRNRCFLEENFTIQGDVALPPYYQPEEDDEMPFICSLSGDNGIMGCHEIPPLKEQGRECCLSKDDVYDFGAGRQDLNASGLCVNWNRYYNVCRTGSANPHKGAINFDNIGYAWIVIFQVITLEGWVEIMYYVMDAHSFYNFIYFILLIIVGSFFMINLCLVVIATQFSETKQREHRLMLEQRQRYLSSSTVASYAEPGDCYEEIFQYVCHILRKAKRRALGLYQALQSRRQALGPEAPAPAKPGPHAKEPRHYHGKTKGQGDEGRHLGSRHCQTLHGPASPGNDHSGRELCPQHSPLDATPHTLVQPIPATLASDPASCPCCQHEDGRRPSGLGSTDSGQEGSGSGSSAGGEDEADGDGARSSEDGASSELGKEEEEEEQADGAVWLCGDVWRETRAKLRGIVDSKYFNRGIMMAILVNTVSMGIEHHEQPEELTNILEICNVVFTSMFALEMILKLAAFGLFDYLRNPYNIFDSIIVIISIWEIVGQADGGLSVLRTFRLLRVLKLVRFMPALRRQLVVLMKTMDNVATFCMLLMLFIFIFSILGMHIFGCKFSLRTDTGDTVPDRKNFDSLLWAIVTVFQILTQEDWNVVLYNGMASTSPWASLYFVALMTFGNYVLFNLLVAILVEGFQAEGDANRSYSDEDQSSSNIEEFDKLQEGLDSSGDPKLCPIPMTPNGHLDPSLPLGGHLGPAGAAGPAPRLSLQPDPMLVALGSRKSSVMSLGRMSYDQRSLSSSRSSYYGPWGRSAAWASRRSSWNSLKHKPPSAEHESLLSAERGGGARVCEVAADEGPPRAAPLHTPHAHHIHHGPHLAHRHRHHRRTLSLDNRDSVDLAELVPAVGAHPRAAWRAAGPAPGHEDCNGRMPSIAKDVFTKMGDRGDRGEDEEEIDYTLCFRVRKMIDVYKPDWCEVREDWSVYLFSPENRFRVLCQTIIAHKLFDYVVLAFIFLNCITIALERPQIEAGSTERIFLTVSNYIFTAIFVGEMTLKVVSLGLYFGEQAYLRSSWNVLDGFLVFVSIIDIVVSLASAGGAKILGVLRVLRLLRTLRPLRVISRAPGLKLVVETLISSLKPIGNIVLICCAFFIIFGILGVQLFKGKFYHCLGVDTRNITNRSDCMAANYRWVHHKYNFDNLGQALMSLFVLASKDGWVNIMYNGLDAVAVDQQPVTNHNPWMLLYFISFLLIVSFFVLNMFVGVVVENFHKCRQHQEAEEARRREEKRLRRLEKKRRKAQRLPYYATYCHTRLLIHSMCTSHYLDIFITFIICLNVVTMSLEHYNQPTSLETALKYCNYMFTTVFVLEAVLKLVAFGLRRFFKDRWNQLDLAIVLLSVMGITLEEIEINAALPINPTIIRIMRVLRIARVLKLLKMATGMRALLDTVVQALPQVGNLGLLFMLLFFIYAALGVELFGKLVCNDENPCEGMSRHATFENFGMAFLTLFQVSTGDNWNGIMKDTLRDCTHDERSCLSSLQFVSPLYFVSFVLTAQFVLINVVVAVLMKHLDDSNKEAQEDAEMDAELELEMAHGLGPGPRLPTGSPGAPGRGPGGAGGGGDTEGGLCRRCYSPAQENLWLDSVSLIIKDSLEGELTIIDNLSGSIFHHYSSPAGCKKCHHDKQEVQLAETEAFSLNSDRSSSILLGDDLSLEDPTACPPGRKDSKGELDPPEPMRVGDLGECFFPLSSTAVSPDPENFLCEMEEIPFNPVRSWLKHDSSQAPPSPFSPDASSPLLPMPAEFFHPAVSASQKGPEKGTGTGTLPKIALQGSWASLRSPRVNCTLLRQATGSDTSLDASPSSSAGSLQTTLEDSLTLSDSPRRALGPPAPAPGPRAGLSPAARRRLSLRGRGLFSLRGLRAHQRSHSSGGSTSPGCTHHDSMDPSDEEGRGGAGGGGAGSEHSETLSSLSLTSLFCPPPPPPAPGLTPARKFSSTSSLAAPGRPHAAALAHGLARSPSWAADRSKDPPGRAPLPMGLGPLAPPPQPLPGELEPGDAASKRKR T79694 DRUGINFO D0OW2O U-92032 Terminated T79694 DRUGINFO D09PWJ ML218 Investigative T52188 TARGETID T52188 T52188 FORMERID TTDR00275 T52188 UNIPROID Q9U752_PLAFA T52188 TARGNAME Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1) T52188 GENENAME Malaria ACC1 T52188 TARGTYPE Literature-reported T52188 SYNONYMS Acetyl-CoA carboxylase; ACC1; ACC-alpha T52188 FUNCTION Catalyzes the rate-limiting reaction in the biogenesis of long-chain fatty acids. This protein carries three functions: biotin carboxyl carrier protein, biotin carboxylase, and carboxyltransferase. T52188 BIOCLASS Carbon-carbon ligase T52188 SEQUENCE SQGGGGKGIRKVENEYEIKKAYEQVQNELPNSPIFLMKVCNNVRHIEIQVVGDMYGNVCSLSGRDCTTQRRFQKIFEEGPPSVVPYPIFREMEKSSIRLTKMIKYRGAGTIEYLYDQINKKYFFLELNPRL T52188 DRUGINFO D04MKK Haloxyfop Investigative T52188 DRUGINFO D05RRI Clodinafop Investigative T52188 DRUGINFO D07DRJ Quizalofop Investigative T52188 DRUGINFO D07WIC CP-640186 Investigative T52188 DRUGINFO D0IY5Y A-80040 Investigative T52188 DRUGINFO D0P7HI AC-8632 Investigative T56871 TARGETID T56871 T56871 FORMERID TTDI00137 T56871 UNIPROID KDM5B_HUMAN T56871 TARGNAME Lysine-specific demethylase 5B (KDM5B) T56871 GENENAME KDM5B T56871 TARGTYPE Literature-reported T56871 SYNONYMS Retinoblastomabinding protein 2 homolog 1; Retinoblastoma-binding protein 2 homolog 1; RBP2H1; RBP2-H1; RBBP2H1; PLU1; PLU-1; Lysinespecific demethylase 5B; Jumonji/ARID domaincontaining protein 1B; Jumonji/ARID domain-containing protein 1B; JARID1B; Histone demethylase JARID1B; Cancer/testis antigen 31; CT31 T56871 FUNCTION Does not demethylate histone H3 'Lys-9' or H3 'Lys-27'. Demethylates trimethylated, dimethylated and monomethylated H3 'Lys-4'. Acts as a transcriptional corepressor for FOXG1B and PAX9. Favors the proliferation of breast cancer cells by repressing tumor suppressor genes such as BRCA1 and HOXA5. In contrast, may act as a tumor suppressor for melanoma. Represses the CLOCK-ARNTL/BMAL1 heterodimer-mediated transcriptional activation of the core clock component PER2. Histone demethylase that demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. T56871 PDBSTRUC 6EK6; 6EJ1; 6EJ0; 6EIY; 6EIU T56871 BIOCLASS Paired donor oxygen oxidoreductase T56871 ECNUMBER EC 1.14.11.- T56871 SEQUENCE MEAATTLHPGPRPALPLGGPGPLGEFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLNFLDQIAKYWELQGSTLKIPHVERKILDLFQLNKLVAEEGGFAVVCKDRKWTKIATKMGFAPGKAVGSHIRGHYERILNPYNLFLSGDSLRCLQKPNLTTDTKDKEYKPHDIPQRQSVQPSETCPPARRAKRMRAEAMNIKIEPEETTEARTHNLRRRMGCPTPKCENEKEMKSSIKQEPIERKDYIVENEKEKPKSRSKKATNAVDLYVCLLCGSGNDEDRLLLCDGCDDSYHTFCLIPPLHDVPKGDWRCPKCLAQECSKPQEAFGFEQAARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINKKKSLVSFKALIEESEMKKFPDNDLLRHLRLVTQDAEKCASVAQQLLNGKRQTRYRSGGGKSQNQLTVNELRQFVTQLYALPCVLSQTPLLKDLLNRVEDFQQHSQKLLSEETPSAAELQDLLDVSFEFDVELPQLAEMRIRLEQARWLEEVQQACLDPSSLTLDDMRRLIDLGVGLAPYSAVEKAMARLQELLTVSEHWDDKAKSLLKARPRHSLNSLATAVKEIEEIPAYLPNGAALKDSVQRARDWLQDVEGLQAGGRVPVLDTLIELVTRGRSIPVHLNSLPRLETLVAEVQAWKECAVNTFLTENSPYSLLEVLCPRCDIGLLGLKRKQRKLKEPLPNGKKKSTKLESLSDLERALTESKETASAMATLGEARLREMEALQSLRLANEGKLLSPLQDVDIKICLCQKAPAAPMIQCELCRDAFHTSCVAVPSISQGLRIWLCPHCRRSEKPPLEKILPLLASLQRIRVRLPEGDALRYMIERTVNWQHRAQQLLSSGNLKFVQDRVGSGLLYSRWQASAGQVSDTNKVSQPPGTTSFSLPDDWDNRTSYLHSPFSTGRSCIPLHGVSPEVNELLMEAQLLQVSLPEIQELYQTLLAKPSPAQQTDRSSPVRPSSEKNDCCRGKRDGINSLERKLKRRLEREGLSSERWERVKKMRTPKKKKIKLSHPKDMNNFKLERERSYELVRSAETHSLPSDTSYSEQEDSEDEDAICPAVSCLQPEGDEVDWVQCDGSCNQWFHQVCVGVSPEMAEKEDYICVRCTVKDAPSRK T56871 DRUGINFO D0IQ7Y PBIT Investigative T90987 TARGETID T90987 T90987 FORMERID TTDI03017 T90987 UNIPROID ATS1_HUMAN T90987 TARGNAME ADAM metallopeptidase with thrombospondin 1 (ADAMTS1) T90987 GENENAME ADAMTS1 T90987 TARGTYPE Literature-reported T90987 SYNONYMS METH1; METH-1; KIAA1346; ADAMTS-1; ADAM-TS1; ADAM-TS 1 T90987 FUNCTION Has angiogenic inhibitor activity. Active metalloprotease, which may be associated with various inflammatory processes as well as development of cancer cachexia. May play a critical role in follicular rupture. Cleaves aggrecan, a cartilage proteoglycan, at the '1938-Glu-|-Leu-1939' site (within the chondroitin sulfate attachment domain), and may be involved in its turnover. T90987 PDBSTRUC 3Q2H; 3Q2G; 2V4B; 2JIH T90987 BIOCLASS Peptidase T90987 ECNUMBER EC 3.4.24.- T90987 SEQUENCE MQRAVPEGFGRRKLGSDMGNAERAPGSRSFGPVPTLLLLAAALLAVSDALGRPSEEDEELVVPELERAPGHGTTRLRLHAFDQQLDLELRPDSSFLAPGFTLQNVGRKSGSETPLPETDLAHCFYSGTVNGDPSSAAALSLCEGVRGAFYLLGEAYFIQPLPAASERLATAAPGEKPPAPLQFHLLRRNRQGDVGGTCGVVDDEPRPTGKAETEDEDEGTEGEDEGAQWSPQDPALQGVGQPTGTGSIRKKRFVSSHRYVETMLVADQSMAEFHGSGLKHYLLTLFSVAARLYKHPSIRNSVSLVVVKILVIHDEQKGPEVTSNAALTLRNFCNWQKQHNPPSDRDAEHYDTAILFTRQDLCGSQTCDTLGMADVGTVCDPSRSCSVIEDDGLQAAFTTAHELGHVFNMPHDDAKQCASLNGVNQDSHMMASMLSNLDHSQPWSPCSAYMITSFLDNGHGECLMDKPQNPIQLPGDLPGTSYDANRQCQFTFGEDSKHCPDAASTCSTLWCTGTSGGVLVCQTKHFPWADGTSCGEGKWCINGKCVNKTDRKHFDTPFHGSWGMWGPWGDCSRTCGGGVQYTMRECDNPVPKNGGKYCEGKRVRYRSCNLEDCPDNNGKTFREEQCEAHNEFSKASFGSGPAVEWIPKYAGVSPKDRCKLICQAKGIGYFFVLQPKVVDGTPCSPDSTSVCVQGQCVKAGCDRIIDSKKKFDKCGVCGGNGSTCKKISGSVTSAKPGYHDIITIPTGATNIEVKQRNQRGSRNNGSFLAIKAADGTYILNGDYTLSTLEQDIMYKGVVLRYSGSSAALERIRSFSPLKEPLTIQVLTVGNALRPKIKYTYFVKKKKESFNAIPTFSAWVIEEWGECSKSCELGWQRRLVECRDINGQPASECAKEVKPASTRPCADHPCPQWQLGEWSSCSKTCGKGYKKRSLKCLSHDGGVLSHESCDPLKKPKHFIDFCTMAECS T90987 DRUGINFO D0H6CK PMID16516466C12c Investigative T50429 TARGETID T50429 T50429 FORMERID TTDI03455 T50429 UNIPROID PADI4_HUMAN T50429 TARGNAME Peptidyl arginine deiminase type IV (PADI4) T50429 GENENAME PADI4 T50429 TARGTYPE Literature-reported T50429 SYNONYMS Protein-arginine deiminase type-4; Protein-arginine deiminase type IV; Peptidylarginine deiminase IV; PDI5; PADI5; PAD4; HL-60 PAD T50429 FUNCTION Citrullinates histone H1 at 'Arg-54' (to form H1R54ci), histone H3 at 'Arg-2', 'Arg-8', 'Arg-17' and/or 'Arg-26' (to form H3R2ci, H3R8ci, H3R17ci, H3R26ci, respectively) and histone H4 at 'Arg-3' (to form H4R3ci). Acts as a key regulator of stem cell maintenance by mediating citrullination of histone H1: citrullination of 'Arg-54' of histone H1 (H1R54ci) results in H1 displacement from chromatin and global chromatin decondensation, thereby promoting pluripotency and stem cell maintenance. Promotes profound chromatin decondensation during the innate immune response to infection in neutrophils by mediating formation of H1R54ci. Citrullination of histone H3 prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1. Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance. T50429 PDBSTRUC 5N1B; 5N0Z; 5N0Y; 5N0M; 4X8G T50429 BIOCLASS Carbon-nitrogen hydrolase T50429 ECNUMBER EC 3.5.3.15 T50429 SEQUENCE MAQGTLIRVTPEQPTHAVCVLGTLTQLDICSSAPEDCTSFSINASPGVVVDIAHGPPAKKKSTGSSTWPLDPGVEVTLTMKVASGSTGDQKVQISYYGPKTPPVKALLYLTGVEISLCADITRTGKVKPTRAVKDQRTWTWGPCGQGAILLVNCDRDNLESSAMDCEDDEVLDSEDLQDMSLMTLSTKTPKDFFTNHTLVLHVARSEMDKVRVFQATRGKLSSKCSVVLGPKWPSHYLMVPGGKHNMDFYVEALAFPDTDFPGLITLTISLLDTSNLELPEAVVFQDSVVFRVAPWIMTPNTQPPQEVYACSIFENEDFLKSVTTLAMKAKCKLTICPEEENMDDQWMQDEMEIGYIQAPHKTLPVVFDSPRNRGLKEFPIKRVMGPDFGYVTRGPQTGGISGLDSFGNLEVSPPVTVRGKEYPLGRILFGDSCYPSNDSRQMHQALQDFLSAQQVQAPVKLYSDWLSVGHVDEFLSFVPAPDRKGFRLLLASPRSCYKLFQEQQNEGHGEALLFEGIKKKKQQKIKNILSNKTLREHNSFVERCIDWNRELLKRELGLAESDIIDIPQLFKLKEFSKAEAFFPNMVNMLVLGKHLGIPKPFGPVINGRCCLEEKVCSLLEPLGLQCTFINDFFTYHIRHGEVHCGTNVRRKPFSFKWWNMVP T50429 DRUGINFO D01FNC PMID24440480C3 Investigative T50429 DRUGINFO D02ZNQ streptonigrin Investigative T50429 DRUGINFO D0C4DE PMID25742366C14b Investigative T50429 DRUGINFO D0YP0A Cl-amidine Investigative T37271 TARGETID T37271 T37271 FORMERID TTDR00415 T37271 UNIPROID SIAT9_HUMAN T37271 TARGNAME Lactosylceramide alpha-2,3-sialyltransferase (ST3GAL5) T37271 GENENAME ST3GAL5 T37271 TARGTYPE Literature-reported T37271 SYNONYMS UNQ2510/PRO5998; Sialyltransferase 9; ST3Gal V; ST3GAL5; Ganglioside GM3 synthase; CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase T37271 FUNCTION Catalyzes the formation of ganglioside GM3 (alpha-N- acetylneuraminyl-2,3-beta-D-galactosyl-1, 4-beta-D- glucosylceramide). T37271 BIOCLASS Glycosyl transferase T37271 ECNUMBER EC 2.4.99.9 T37271 SEQUENCE MRTKAAGCAERRPLQPRTEAAAAPAGRAMPSEYTYVKLRSDCSRPSLQWYTRAQSKMRRPSLLLKDILKCTLLVFGVWILYILKLNYTTEECDMKKMHYVDPDHVKRAQKYAQQVLQKECRPKFAKTSMALLFEHRYSVDLLPFVQKAPKDSEAESKYDPPFGFRKFSSKVQTLLELLPEHDLPEHLKAKTCRRCVVIGSGGILHGLELGHTLNQFDVVIRLNSAPVEGYSEHVGNKTTIRMTYPEGAPLSDLEYYSNDLFVAVLFKSVDFNWLQAMVKKETLPFWVRLFFWKQVAEKIPLQPKHFRILNPVIIKETAFDILQYSEPQSRFWGRDKNVPTIGVIAVVLATHLCDEVSLAGFGYDLNQPRTPLHYFDSQCMAAMNFQTMHNVTTETKFLLKLVKEGVVKDLSGGIDREF T37271 DRUGINFO D0V2QF 5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine Investigative T00933 TARGETID T00933 T00933 FORMERID TTDI03456 T00933 UNIPROID PHF8_HUMAN T00933 TARGNAME Histone lysine demethylase PHF8 (PHF8) T00933 GENENAME PHF8 T00933 TARGTYPE Literature-reported T00933 SYNONYMS ZNF422; PHD finger protein 8; KIAA1111 T00933 FUNCTION Demethylates mono- and dimethylated histone H3 'Lys-9' residue (H3K9Me1 and H3K9Me2), dimethylated H3 'Lys-27' (H3K27Me2) and monomethylated histone H4 'Lys-20' residue (H4K20Me1). Acts as a transcription activator as H3K9Me1, H3K9Me2, H3K27Me2 and H4K20Me1 are epigenetic repressive marks. Involved in cell cycle progression by being required to control G1-S transition. Acts as a coactivator of rDNA transcription, by activating polymerase I (pol I) mediated transcription of rRNA genes. Required for brain development, probably by regulating expression of neuron-specific genes. Only has activity toward H4K20Me1 when nucleosome is used as a substrate and when not histone octamer is used as substrate. May also have weak activity toward dimethylated H3 'Lys-36' (H3K36Me2), however, the relevance of this result remains unsure in vivo. Specifically binds trimethylated 'Lys-4' of histone H3 (H3K4me3), affecting histone demethylase specificity: has weak activity toward H3K9Me2 in absence of H3K4me3, while it has high activity toward H3K9me2 when binding H3K4me3. Histone lysine demethylase with selectivity for the di- and monomethyl states that plays a key role cell cycle progression, rDNA transcription and brain development. T00933 PDBSTRUC 4DO0; 3KV4; 3K3O; 3K3N; 2WWU T00933 BIOCLASS Paired donor oxygen oxidoreductase T00933 ECNUMBER EC 1.14.11.27 T00933 SEQUENCE MNRSRAIVQRGRVLPPPAPLDTTNLAGRRTLQGRAKMASVPVYCLCRLPYDVTRFMIECDMCQDWFHGSCVGVEEEKAADIDLYHCPNCEVLHGPSIMKKRRGSSKGHDTHKGKPVKTGSPTFVRELRSRTFDSSDEVILKPTGNQLTVEFLEENSFSVPILVLKKDGLGMTLPSPSFTVRDVEHYVGSDKEIDVIDVTRQADCKMKLGDFVKYYYSGKREKVLNVISLEFSDTRLSNLVETPKIVRKLSWVENLWPEECVFERPNVQKYCLMSVRDSYTDFHIDFGGTSVWYHVLKGEKIFYLIRPTNANLTLFECWSSSSNQNEMFFGDQVDKCYKCSVKQGQTLFIPTGWIHAVLTPVDCLAFGGNFLHSLNIEMQLKAYEIEKRLSTADLFRFPNFETICWYVGKHILDIFRGLRENRRHPASYLVHGGKALNLAFRAWTRKEALPDHEDEIPETVRTVQLIKDLAREIRLVEDIFQQNVGKTSNIFGLQRIFPAGSIPLTRPAHSTSVSMSRLSLPSKNGSKKKGLKPKELFKKAERKGKESSALGPAGQLSYNLMDTYSHQALKTGSFQKAKFNITGACLNDSDDDSPDLDLDGNESPLALLMSNGSTKRVKSLSKSRRTKIAKKVDKARLMAEQVMEDEFDLDSDDELQIDERLGKEKATLIIRPKFPRKLPRAKPCSDPNRVREPGEVEFDIEEDYTTDEDMVEGVEGKLGNGSGAGGILDLLKASRQVGGPDYAALTEAPASPSTQEAIQGMLCMANLQSSSSSPATSSLQAWWTGGQDRSSGSSSSGLGTVSNSPASQRTPGKRPIKRPAYWRTESEEEEENASLDEQDSLGACFKDAEYIYPSLESDDDDPALKSRPKKKKNSDDAPWSPKARVTPTLPKQDRPVREGTRVASIETGLAAAAAKLAQQELQKAQKKKYIKKKPLLKEVEQPRPQDSNLSLTVPAPTVAATPQLVTSSSPLPPPEPKQEALSGSLADHEYTARPNAFGMAQANRSTTPMAPGVFLTQRRPSVGSQSNQAGQGKRPKKGLATAKQRLGRILKIHRNGKLLL T00933 DRUGINFO D0B2WZ daminozide Investigative T85924 TARGETID T85924 T85924 FORMERID TTDR01446 T85924 UNIPROID COLG_HATHI T85924 TARGNAME Clostridium histolyticum Collagenase (CH colG) T85924 GENENAME CH colG T85924 TARGTYPE Literature-reported T85924 SYNONYMS Microbial collagenase; Gelatinase ColG; Collagenase ColG; Class I collagenase T85924 FUNCTION Clostridial collagenases are among the most efficient degraders of eukaryotic collagen known; saprophytes use collagen as a carbon source while pathogens additionally digest collagen to aid in host colonization. Has both tripeptidylcarboxypeptidase on Gly-X-Y and endopeptidase activities; the endopeptidase cuts within the triple helix region of collagen while tripeptidylcarboxypeptidase successively digests the exposed ends, thus clostridial collagenases can digest large sections of collagen. Active on soluble type I collagen, insoluble collagen, azocoll, soluble PZ-peptide (all collagenase substrates) and gelatin. The full-length protein has collagenase activity, while the in vivo derived C-terminally truncated shorter versions only act on gelatin. In vitro digestion of soluble calf skin collagen fibrils requires both ColG and ColH; ColG forms missing the second collagen-binding domain are also synergistic with ColH, although their overall efficiency is decreased. The activator domain (residues 119-388) and catalytic subdomain (389-670) open and close around substrate using a Gly-rich hinge (387-397), allowing digestion when the protein is closed. Binding of collagen requires Ca(2+) and is inhibited by EGTA; the collagen-binding domain (CBD, S3a plus S3b) specifically recognizes the triple-helical conformation made by 3 collagen protein chains in the triple-helical region. Isolated CBD (S3a plus S3b) binds collagen fibrils and sheets of many tissues. T85924 PDBSTRUC 5IKU; 4TN9; 4JRW; 4HPK; 4ARE T85924 ECNUMBER EC 3.4.24.3 T85924 SEQUENCE MKKNILKILMDSYSKESKIQTVRRVTSVSLLAVYLTMNTSSLVLAKPIENTNDTSIKNVEKLRNAPNEENSKKVEDSKNDKVEHVKNIEEAKVEQVAPEVKSKSTLRSASIANTNSEKYDFEYLNGLSYTELTNLIKNIKWNQINGLFNYSTGSQKFFGDKNRVQAIINALQESGRTYTANDMKGIETFTEVLRAGFYLGYYNDGLSYLNDRNFQDKCIPAMIAIQKNPNFKLGTAVQDEVITSLGKLIGNASANAEVVNNCVPVLKQFRENLNQYAPDYVKGTAVNELIKGIEFDFSGAAYEKDVKTMPWYGKIDPFINELKALGLYGNITSATEWASDVGIYYLSKFGLYSTNRNDIVQSLEKAVDMYKYGKIAFVAMERITWDYDGIGSNGKKVDHDKFLDDAEKHYLPKTYTFDNGTFIIRAGDKVSEEKIKRLYWASREVKSQFHRVVGNDKALEVGNADDVLTMKIFNSPEEYKFNTNINGVSTDNGGLYIEPRGTFYTYERTPQQSIFSLEELFRHEYTHYLQARYLVDGLWGQGPFYEKNRLTWFDEGTAEFFAGSTRTSGVLPRKSILGYLAKDKVDHRYSLKKTLNSGYDDSDWMFYNYGFAVAHYLYEKDMPTFIKMNKAILNTDVKSYDEIIKKLSDDANKNTEYQNHIQELADKYQGAGIPLVSDDYLKDHGYKKASEVYSEISKAASLTNTSVTAEKSQYFNTFTLRGTYTGETSKGEFKDWDEMSKKLDGTLESLAKNSWSGYKTLTAYFTNYRVTSDNKVQYDVVFHGVLTDNADISNNKAPIAKVTGPSTGAVGRNIEFSGKDSKDEDGKIVSYDWDFGDGATSRGKNSVHAYKKAGTYNVTLKVTDDKGATATESFTIEIKNEDTTTPITKEMEPNDDIKEANGPIVEGVTVKGDLNGSDDADTFYFDVKEDGDVTIELPYSGSSNFTWLVYKEGDDQNHIASGIDKNNSKVGTFKSTKGRHYVFIYKHDSASNISYSLNIKGLGNEKLKEKENNDSSDKATVIPNFNTTMQGSLLGDDSRDYYSFEVKEEGEVNIELDKKDEFGVTWTLHPESNINDRITYGQVDGNKVSNKVKLRPGKYYLLVYKYSGSGNYELRVNK T80165 TARGETID T80165 T80165 FORMERID TTDR00988 T80165 UNIPROID TRPC6_HUMAN T80165 TARGNAME Short transient receptor potential channel 6 (TRPC6) T80165 GENENAME TRPC6 T80165 TARGTYPE Literature-reported T80165 SYNONYMS TRPC6; TRP6; STrpC6 T80165 FUNCTION Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Activated by diacylglycerol (DAG) in a membrane-delimited fashion, independently of protein kinase C. Seems not to be activated by intracellular calcium store depletion. T80165 PDBSTRUC 5YX9 T80165 BIOCLASS Transient receptor potential catioin channel T80165 SEQUENCE MSQSPAFGPRRGSSPRGAAGAAARRNESQDYLLMDSELGEDGCPQAPLPCYGYYPCFRGSDNRLAHRRQTVLREKGRRLANRGPAYMFSDRSTSLSIEEERFLDAAEYGNIPVVRKMLEECHSLNVNCVDYMGQNALQLAVANEHLEITELLLKKENLSRVGDALLLAISKGYVRIVEAILSHPAFAEGKRLATSPSQSELQQDDFYAYDEDGTRFSHDVTPIILAAHCQEYEIVHTLLRKGARIERPHDYFCKCNDCNQKQKHDSFSHSRSRINAYKGLASPAYLSLSSEDPVMTALELSNELAVLANIEKEFKNDYKKLSMQCKDFVVGLLDLCRNTEEVEAILNGDVETLQSGDHGRPNLSRLKLAIKYEVKKFVAHPNCQQQLLSIWYENLSGLRQQTMAVKFLVVLAVAIGLPFLALIYWFAPCSKMGKIMRGPFMKFVAHAASFTIFLGLLVMNAADRFEGTKLLPNETSTDNAKQLFRMKTSCFSWMEMLIISWVIGMIWAECKEIWTQGPKEYLFELWNMLDFGMLAIFAASFIARFMAFWHASKAQSIIDANDTLKDLTKVTLGDNVKYYNLARIKWDPSDPQIISEGLYAIAVVLSFSRIAYILPANESFGPLQISLGRTVKDIFKFMVIFIMVFVAFMIGMFNLYSYYIGAKQNEAFTTVEESFKTLFWAIFGLSEVKSVVINYNHKFIENIGYVLYGVYNVTMVIVLLNMLIAMINSSFQEIEDDADVEWKFARAKLWFSYFEEGRTLPVPFNLVPSPKSLFYLLLKLKKWISELFQGHKKGFQEDAEMNKINEEKKLGILGSHEDLSKLSLDKKQVGHNKQPSIRSSEDFHLNSFNNPPRQYQKIMKRLIKRYVLQAQIDKESDEVNEGELKEIKQDISSLRYELLEEKSQNTEDLAELIRELGEKLSMEPNQEETNR T80165 DRUGINFO D01SLS ML9 Investigative T80165 DRUGINFO D02DPK hyp 9 Investigative T80165 DRUGINFO D03LLM SLG Investigative T80165 DRUGINFO D07UFO 20-HETE Investigative T80165 DRUGINFO D0TV1R flufenamate Investigative T80165 DRUGINFO D0Y6ST SAG Investigative T80165 DRUGINFO D0F4FK KB-R7943 Investigative T80165 DRUGINFO D0KT5E lysophosphatidylcholine Investigative T80165 DRUGINFO D0N7MS ACAA Investigative T80165 DRUGINFO D0T6DU OAG Investigative T80165 DRUGINFO D00HCI 2-APB Investigative T37417 TARGETID T37417 T37417 FORMERID TTDI03540 T37417 UNIPROID ST38L_HUMAN T37417 TARGNAME NDR2 protein kinase (STK38L) T37417 GENENAME STK38L T37417 TARGTYPE Literature-reported T37417 SYNONYMS Serine/threonine-protein kinase 38-like; Nuclear Dbf2-related kinase 2; NDR2; KIAA0965 T37417 FUNCTION Involved in the regulation of structural processes in differentiating and mature neuronal cells. T37417 PDBSTRUC 5XQZ T37417 BIOCLASS Kinase T37417 ECNUMBER EC 2.7.11.1 T37417 SEQUENCE MAMTAGTTTTFPMSNHTRERVTVAKLTLENFYSNLILQHEERETRQKKLEVAMEEEGLADEEKKLRRSQHARKETEFLRLKRTRLGLDDFESLKVIGRGAFGEVRLVQKKDTGHIYAMKILRKSDMLEKEQVAHIRAERDILVEADGAWVVKMFYSFQDKRNLYLIMEFLPGGDMMTLLMKKDTLTEEETQFYISETVLAIDAIHQLGFIHRDIKPDNLLLDAKGHVKLSDFGLCTGLKKAHRTEFYRNLTHNPPSDFSFQNMNSKRKAETWKKNRRQLAYSTVGTPDYIAPEVFMQTGYNKLCDWWSLGVIMYEMLIGYPPFCSETPQETYRKVMNWKETLVFPPEVPISEKAKDLILRFCIDSENRIGNSGVEEIKGHPFFEGVDWEHIRERPAAIPIEIKSIDDTSNFDDFPESDILQPVPNTTEPDYKSKDWVFLNYTYKRFEGLTQRGSIPTYMKAGKL T37417 DRUGINFO D0RO9R PMID21123062C27 Investigative T70036 TARGETID T70036 T70036 FORMERID TTDR01065 T70036 UNIPROID NALD2_HUMAN T70036 TARGNAME Glutamate carboxypeptidase III (NAALAD2) T70036 GENENAME NAALAD2 T70036 TARGTYPE Literature-reported T70036 SYNONYMS NAALADase II; NAALAD2 T70036 FUNCTION Has N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Also exhibits a dipeptidyl-peptidase IV type activity. Inactivate the peptide neurotransmitter N- acetylaspartylglutamate. T70036 PDBSTRUC 3FF3; 3FEE; 3FED; 3FEC T70036 BIOCLASS Peptidase T70036 ECNUMBER EC 3.4.17.21 T70036 SEQUENCE MAESRGRLYLWMCLAAALASFLMGFMVGWFIKPLKETTTSVRYHQSIRWKLVSEMKAENIKSFLRSFTKLPHLAGTEQNFLLAKKIQTQWKKFGLDSAKLVHYDVLLSYPNETNANYISIVDEHETEIFKTSYLEPPPDGYENVTNIVPPYNAFSAQGMPEGDLVYVNYARTEDFFKLEREMGINCTGKIVIARYGKIFRGNKVKNAMLAGAIGIILYSDPADYFAPEVQPYPKGWNLPGTAAQRGNVLNLNGAGDPLTPGYPAKEYTFRLDVEEGVGIPRIPVHPIGYNDAEILLRYLGGIAPPDKSWKGALNVSYSIGPGFTGSDSFRKVRMHVYNINKITRIYNVVGTIRGSVEPDRYVILGGHRDSWVFGAIDPTSGVAVLQEIARSFGKLMSKGWRPRRTIIFASWDAEEFGLLGSTEWAEENVKILQERSIAYINSDSSIEGNYTLRVDCTPLLYQLVYKLTKEIPSPDDGFESKSLYESWLEKDPSPENKNLPRINKLGSGSDFEAYFQRLGIASGRARYTKNKKTDKYSSYPVYHTIYETFELVEKFYDPTFKKQLSVAQLRGALVYELVDSKIIPFNIQDYAEALKNYAASIYNLSKKHDQQLTDHGVSFDSLFSAVKNFSEAASDFHKRLIQVDLNNPIAVRMMNDQLMLLERAFIDPLGLPGKLFYRHIIFAPSSHNKYAGESFPGIYDAIFDIENKANSRLAWKEVKKHISIAAFTIQAAAGTLKEVL T15051 TARGETID T15051 T15051 FORMERID TTDI00232 T15051 UNIPROID TRAF6_HUMAN T15051 TARGNAME TNF receptor-associated factor 6 (TRAF6) T15051 GENENAME TRAF6 T15051 TARGTYPE Literature-reported T15051 SYNONYMS RNF85; RING-type E3 ubiquitin transferase TRAF6; RING finger protein 85; Interleukin-1 signal transducer; E3 ubiquitin-protein ligase TRAF6 T15051 FUNCTION Mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation. Leads to the activation of NF-kappa-B and JUN. May be essential for the formation of functional osteoclasts. Seems to also play a role in dendritic cells (DCs) maturation and/or activation. Represses c-Myb-mediated transactivation, in B-lymphocytes. Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor. Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation. Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as IKBKG, IRAK1, AKT1 and AKT2. T15051 PDBSTRUC 6A33; 5ZUJ; 4Z8M; 3HCU; 3HCT T15051 BIOCLASS Acyltransferase T15051 ECNUMBER EC 2.3.2.27 T15051 SEQUENCE MSLLNCENSCGSSQSESDCCVAMASSCSAVTKDDSVGGTASTGNLSSSFMEEIQGYDVEFDPPLESKYECPICLMALREAVQTPCGHRFCKACIIKSIRDAGHKCPVDNEILLENQLFPDNFAKREILSLMVKCPNEGCLHKMELRHLEDHQAHCEFALMDCPQCQRPFQKFHINIHILKDCPRRQVSCDNCAASMAFEDKEIHDQNCPLANVICEYCNTILIREQMPNHYDLDCPTAPIPCTFSTFGCHEKMQRNHLARHLQENTQSHMRMLAQAVHSLSVIPDSGYISEVRNFQETIHQLEGRLVRQDHQIRELTAKMETQSMYVSELKRTIRTLEDKVAEIEAQQCNGIYIWKIGNFGMHLKCQEEEKPVVIHSPGFYTGKPGYKLCMRLHLQLPTAQRCANYISLFVHTMQGEYDSHLPWPFQGTIRLTILDQSEAPVRQNHEEIMDAKPELLAFQRPTIPRNPKGFGYVTFMHLEALRQRTFIKDDTLLVRCEVSTRFDMGSLRREGFQPRSTDAGV T66935 TARGETID T66935 T66935 FORMERID TTDR00894 T66935 UNIPROID PARG_HUMAN T66935 TARGNAME Poly [ADP-ribose] glycohydrolase (PARG) T66935 GENENAME PARG T66935 TARGTYPE Literature-reported T66935 SYNONYMS Poly(ADP-ribose) glycohydrolase T66935 FUNCTION Poly(ADP-ribose) glycohydrolase that degrades poly(ADP-ribose) by hydrolyzing the ribose-ribose bonds present in poly(ADP-ribose). PARG acts both as an endo- and exoglycosidase, releasing poly(ADP-ribose) of different length as well as ADP-ribose monomers. It is however unable to cleave the ester bond between the terminal ADP-ribose and ADP-ribosylated residues, leaving proteins that are mono-ADP-ribosylated. Poly(ADP-ribose) is synthesized after DNA damage is only present transiently and is rapidly degraded by PARG. Required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress, while it is not required for recovery from transient replicative stress. Required for retinoid acid-dependent gene transactivation, probably by removing poly(ADP-ribose) from histone demethylase KDM4D, allowing chromatin derepression at RAR-dependent gene promoters. Involved in the synthesis of ATP in the nucleus, together with PARP1, NMNAT1 and NUDT5. Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming. T66935 PDBSTRUC 6HMN; 6HMM; 6HML; 6HMK; 6HH6 T66935 BIOCLASS Glycosylase T66935 ECNUMBER EC 3.2.1.143 T66935 SEQUENCE MNAGPGCEPCTKRPRWGAATTSPAASDARSFPSRQRRVLDPKDAHVQFRVPPSSPACVPGRAGQHRGSATSLVFKQKTITSWMDTKGIKTAESESLDSKENNNTRIESMMSSVQKDNFYQHNVEKLENVSQLSLDKSPTEKSTQYLNQHQTAAMCKWQNEGKHTEQLLESEPQTVTLVPEQFSNANIDRSPQNDDHSDTDSEENRDNQQFLTTVKLANAKQTTEDEQAREAKSHQKCSKSCDPGEDCASCQQDEIDVVPESPLSDVGSEDVGTGPKNDNKLTRQESCLGNSPPFEKESEPESPMDVDNSKNSCQDSEADEETSPGFDEQEDGSSSQTANKPSRFQARDADIEFRKRYSTKGGEVRLHFQFEGGESRTGMNDLNAKLPGNISSLNVECRNSKQHGKKDSKITDHFMRLPKAEDRRKEQWETKHQRTERKIPKYVPPHLSPDKKWLGTPIEEMRRMPRCGIRLPLLRPSANHTVTIRVDLLRAGEVPKPFPTHYKDLWDNKHVKMPCSEQNLYPVEDENGERTAGSRWELIQTALLNKFTRPQNLKDAILKYNVAYSKKWDFTALIDFWDKVLEEAEAQHLYQSILPDMVKIALCLPNICTQPIPLLKQKMNHSITMSQEQIASLLANAFFCTFPRRNAKMKSEYSSYPDINFNRLFEGRSSRKPEKLKTLFCYFRRVTEKKPTGLVTFTRQSLEDFPEWERCEKPLTRLHVTYEGTIEENGQGMLQVDFANRFVGGGVTSAGLVQEEIRFLINPELIISRLFTEVLDHNECLIITGTEQYSEYTGYAETYRWSRSHEDGSERDDWQRRCTEIVAIDALHFRRYLDQFVPEKMRRELNKAYCGFLRPGVSSENLSAVATGNWGCGAFGGDARLKALIQILAAAAAERDVVYFTFGDSELMRDIYSMHIFLTERKLTVGDVYKLLLRYYNEECRNCSTPGPDIKLYPFIYHAVESCAETADHSGQRTGT T66935 DRUGINFO D09XJJ N-bis-(3-phenyl-propyl)9-oxo-fluorene-2,7-diamide Investigative T66935 DRUGINFO D0YM5S GPI 18214 Investigative T87981 TARGETID T87981 T87981 FORMERID TTDI03278 T87981 UNIPROID IRAK3_HUMAN T87981 TARGNAME IL-1 receptor-associated kinase 3 (IRAK3) T87981 GENENAME IRAK3 T87981 TARGTYPE Literature-reported T87981 SYNONYMS Interleukin-1 receptor-associated kinase 3; IRAK-M; IRAK-3; IL-1 receptor-associated kinase M T87981 FUNCTION Inhibits dissociation of IRAK1 and IRAK4 from the Toll-like receptor signaling complex by either inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor complex. T87981 PDBSTRUC 5UKE T87981 BIOCLASS Kinase T87981 ECNUMBER EC 2.7.11.1 T87981 SEQUENCE MAGNCGARGALSAHTLLFDLPPALLGELCAVLDSCDGALGWRGLAERLSSSWLDVRHIEKYVDQGKSGTRELLWSWAQKNKTIGDLLQVLQEMGHRRAIHLITNYGAVLSPSEKSYQEGGFPNILFKETANVTVDNVLIPEHNEKGILLKSSISFQNIIEGTRNFHKDFLIGEGEIFEVYRVEIQNLTYAVKLFKQEKKMQCKKHWKRFLSELEVLLLFHHPNILELAAYFTETEKFCLIYPYMRNGTLFDRLQCVGDTAPLPWHIRIGILIGISKAIHYLHNVQPCSVICGSISSANILLDDQFQPKLTDFAMAHFRSHLEHQSCTINMTSSSSKHLWYMPEEYIRQGKLSIKTDVYSFGIVIMEVLTGCRVVLDDPKHIQLRDLLRELMEKRGLDSCLSFLDKKVPPCPRNFSAKLFCLAGRCAATRAKLRPSMDEVLNTLESTQASLYFAEDPPTSLKSFRCPSPLFLENVPSIPVEDDESQNNNLLPSDEGLRIDRMTQKTPFECSQSEVMFLSLDKKPESKRNEEACNMPSSSCEESWFPKYIVPSQDLRPYKVNIDPSSEAPGHSCRSRPVESSCSSKFSWDEYEQYKKE T87981 DRUGINFO D00EMH PMID21967808CR-16 Investigative T17339 TARGETID T17339 T17339 FORMERID TTDNR00662 T17339 UNIPROID DUS10_HUMAN T17339 TARGNAME Dual specificity protein phosphatase 10 (DUSP10) T17339 GENENAME DUSP10 T17339 TARGTYPE Literature-reported T17339 SYNONYMS Mitogen-activated protein kinase phosphatase 5; MKP5; MKP-5; MAP kinase phosphatase 5 T17339 FUNCTION Has a specificity for the MAPK11/MAPK12/MAPK13/MAPK14 subfamily. It preferably dephosphorylates p38. Protein phosphatase involved in the inactivation of MAP kinases. T17339 PDBSTRUC 3TG1; 2OUD; 2OUC; 1ZZW T17339 BIOCLASS Phosphoric monoester hydrolase T17339 ECNUMBER EC 3.1.3.16 T17339 SEQUENCE MPPSPLDDRVVVALSRPVRPQDLNLCLDSSYLGSANPGSNSHPPVIATTVVSLKAANLTYMPSSSGSARSLNCGCSSASCCTVATYDKDNQAQTQAIAAGTTTTAIGTSTTCPANQMVNNNENTGSLSPSSGVGSPVSGTPKQLASIKIIYPNDLAKKMTKCSKSHLPSQGPVIIDCRPFMEYNKSHIQGAVHINCADKISRRRLQQGKITVLDLISCREGKDSFKRIFSKEIIVYDENTNEPSRVMPSQPLHIVLESLKREGKEPLVLKGGLSSFKQNHENLCDNSLQLQECREVGGGASAASSLLPQPIPTTPDIENAELTPILPFLFLGNEQDAQDLDTMQRLNIGYVINVTTHLPLYHYEKGLFNYKRLPATDSNKQNLRQYFEEAFEFIEEAHQCGKGLLIHCQAGVSRSATIVIAYLMKHTRMTMTDAYKFVKGKRPIISPNLNFMGQLLEFEEDLNNGVTPRILTPKLMGVETVV T60688 TARGETID T60688 T60688 FORMERID TTDC00285 T60688 UNIPROID BIRC5_HUMAN T60688 TARGNAME Survivin messenger RNA (Survivin mRNA) T60688 GENENAME BIRC5 T60688 TARGTYPE Literature-reported T60688 SYNONYMS Survivin (mRNA); IAP4 (mRNA); Baculoviral IAP repeat-containing protein 5 (mRNA); Apoptosis inhibitor survivin (mRNA); Apoptosis inhibitor 4 (mRNA); API4 (mRNA) T60688 FUNCTION Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. The acetylated form represses STAT3 transactivation of target gene promoters. May play a role in neoplasia. Inhibitor of CASP3 and CASP7. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform. Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. T60688 PDBSTRUC 4A0N; 4A0J; 4A0I; 3UIK; 3UIJ T60688 BIOCLASS mRNA target T60688 SEQUENCE MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLAQCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD T60688 DRUGINFO D05FGY ISIS 343867 Investigative T60688 DRUGINFO D09KDC ISIS 341881 Investigative T60688 DRUGINFO D0F9EM ISIS 23707 Investigative T60688 DRUGINFO D0M3BA ISIS 23718 Investigative T60688 DRUGINFO D0U8JD ISIS 23705 Investigative T77174 TARGETID T77174 T77174 FORMERID TTDI02623 T77174 UNIPROID MCES_HUMAN T77174 TARGNAME mRNA cap guanine-N7 methyltransferase (RNMT) T77174 GENENAME RNMT T77174 TARGTYPE Literature-reported T77174 SYNONYMS hcm1p; hMet; hCMT1; RG7MT1; KIAA0398 T77174 FUNCTION Binds RNA containing 5'-terminal GpppC. Catalytic subunit of the mRNA-capping methyltransferase RNMT:RAMAC complex that methylates the N7 position of the added guanosine to the 5'-cap structure of mRNAs. T77174 PDBSTRUC 5E9W; 5E9J; 5E8J; 3EPP; 3BGV T77174 BIOCLASS Methyltransferase T77174 ECNUMBER EC 2.1.1.56 T77174 SEQUENCE MANSAKAEEYEKMSLEQAKASVNSETESSFNINENTTASGTGLSEKTSVCRQVDIARKRKEFEDDLVKESSSCGKDTPSKKRKLDPEIVPEEKDCGDAEGNSKKRKRETEDVPKDKSSTGDGTQNKRKIALEDVPEKQKNLEEGHSSTVAAHYNELQEVGLEKRSQSRIFYLRNFNNWMKSVLIGEFLEKVRQKKKRDITVLDLGCGKGGDLLKWKKGRINKLVCTDIADVSVKQCQQRYEDMKNRRDSEYIFSAEFITADSSKELLIDKFRDPQMCFDICSCQFVCHYSFESYEQADMMLRNACERLSPGGYFIGTTPNSFELIRRLEASETESFGNEIYTVKFQKKGDYPLFGCKYDFNLEGVVDVPEFLVYFPLLNEMAKKYNMKLVYKKTFLEFYEEKIKNNENKMLLKRMQALEPYPANESSKLVSEKVDDYEHAAKYMKNSQVRLPLGTLSKSEWEATSIYLVFAFEKQQ T35474 TARGETID T35474 T35474 FORMERID TTDI02684 T35474 UNIPROID RASK_HUMAN T35474 TARGNAME KRAS messenger RNA (KRAS mRNA) T35474 GENENAME KRAS T35474 TARGTYPE Literature-reported T35474 SYNONYMS c-Ki-ras (mRNA); c-K-ras (mRNA); RASK2 (mRNA); Ki-Ras (mRNA); KRAS2 (mRNA); K-Ras 2 (mRNA); GTPase KRas (mRNA) T35474 FUNCTION Plays an important role in the regulation of cell proliferation. Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. T35474 PDBSTRUC 6N2K; 6N2J; 6H47; 6H46; 6GQY T35474 BIOCLASS mRNA target T35474 SEQUENCE MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM T35474 DRUGINFO D04GPF ISIS 6958 Investigative T35474 DRUGINFO D09ENF PNT-300 Investigative T35474 DRUGINFO D0A4MW ISIS 7453 Investigative T35474 DRUGINFO D0O2LY ISIS 6957 Investigative T33529 TARGETID T33529 T33529 FORMERID TTDI02678 T33529 UNIPROID TGFB1_HUMAN T33529 TARGNAME TGFB1 messenger RNA (TGFB1 mRNA) T33529 GENENAME TGFB1 T33529 TARGTYPE Literature-reported T33529 SYNONYMS Transforming growth factor beta-1 proprotein (mRNA); Transforming growth factor beta-1 (mRNA); TGFB (mRNA); TGF-beta1 (mRNA); TGF-beta 1 (mRNA) T33529 FUNCTION Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively. T33529 PDBSTRUC 5VQP; 5FFO; 4KV5; 3KFD; 1KLD T33529 BIOCLASS mRNA target T33529 SEQUENCE MPPSGLRLLLLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS T90163 TARGETID T90163 T90163 FORMERID TTDR01357 T90163 UNIPROID APOA1_HUMAN T90163 TARGNAME APOA1 messenger RNA (APOA1 mRNA) T90163 GENENAME APOA1 T90163 TARGTYPE Literature-reported T90163 SYNONYMS Truncated apolipoprotein AI (mRNA); Apolipoprotein A1 (mRNA); Apolipoprotein A-I (mRNA); ApoAI (mRNA); ApoA-I (mRNA); Apo-AI (mRNA) T90163 FUNCTION As part of the SPAP complex, activates spermatozoa motility. Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). T90163 PDBSTRUC 6CM1; 6CLZ; 6CCX; 6CCH; 6CC9 T90163 BIOCLASS mRNA target T90163 SEQUENCE MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ T90163 DRUGINFO D09HDQ ISIS 144379 Investigative T90163 DRUGINFO D0I2VG ISIS 144396 Investigative T90163 DRUGINFO D0T5JP ISIS 144368 Investigative T73245 TARGETID T73245 T73245 FORMERID TTDI02248 T73245 UNIPROID TRFE_HUMAN T73245 TARGNAME Transferrin messenger RNA (TF mRNA) T73245 GENENAME TF T73245 TARGTYPE Literature-reported T73245 SYNONYMS Transferrin (mRNA); Siderophilin (mRNA); Serotransferrin (mRNA); PRO1400 (mRNA); Beta-1 metal-binding globulin (mRNA) T73245 FUNCTION It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation. Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. T73245 PDBSTRUC 6D05; 6D04; 6D03; 6CTC; 5Y6K T73245 BIOCLASS mRNA target T73245 SEQUENCE MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKCQSFRDHMKSVIPSDGPSVACVKKASYLDCIRAIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRDQYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARSMGGKEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAIAVVKKSASDLTWDNLKGKKSCHTAVGRTAGWNIPMGLLYNKINHCRFDEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAFRCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTRKPVEEYANCHLARAPNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKLHDRNTYEKYLGEEYVKAVGNLRKCSTSSLLEACTFRRP T77927 TARGETID T77927 T77927 FORMERID TTDI02386 T77927 UNIPROID GAG_HV1H2 T77927 TARGNAME Human immunodeficiency virus GAG messenger RNA (HIV gag mRNA) T77927 GENENAME HIV gag mRNA T77927 TARGTYPE Literature-reported T77927 SYNONYMS gag (mRNA); Pr55Gag (mRNA); Gag polyprotein (mRNA) T77927 FUNCTION Gag polyprotein: Mediates, with Gag-Pol polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). T77927 PDBSTRUC 6CQR; 6CQQ; 6CQN; 6CQL; 6CQJ T77927 BIOCLASS mRNA target T77927 SEQUENCE MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEGHQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPLTSLRSLFGNDPSSQ T33913 TARGETID T33913 T33913 FORMERID TTDR01162 T33913 UNIPROID PGFRB_HUMAN T33913 TARGNAME PDGFR beta messenger RNA (PDGFRB mRNA) T33913 GENENAME PDGFRB T33913 TARGTYPE Literature-reported T33913 SYNONYMS Platelet-derived growth factor receptor 1 (mRNA); PDGFR1 (mRNA); PDGFR-beta (mRNA); PDGFR-1 (mRNA); PDGFR (mRNA); PDGF-R-beta (mRNA); CD140b antigen (mRNA); CD140b (mRNA); CD140 antigen-like family member B (mRNA); Beta-type platelet-derived growth factor receptor (mRNA); Beta-PDGFR (mRNA); Beta platelet-derived growth factor receptor (mRNA) T33913 FUNCTION Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. T33913 PDBSTRUC 3MJG; 2PLE; 2PLD; 2L6W; 2IUI T33913 BIOCLASS mRNA target T33913 ECNUMBER EC 2.7.10.1 T33913 SEQUENCE MRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPVVWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFVPDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFSGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGNEVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDHQDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDSSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVLELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNVTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQVEPEPELEQLPDSGCPAPRAEAEDSFL T12052 TARGETID T12052 T12052 FORMERID TTDR01368 T12052 UNIPROID ROA1_HUMAN T12052 TARGNAME hnRNP A1 messenger RNA (HNRNPA1 mRNA) T12052 GENENAME HNRNPA1 T12052 TARGTYPE Literature-reported T12052 SYNONYMS hnRNP core protein A1 (mRNA); hnRNP A1 (mRNA); Single-strand RNA-binding protein (mRNA); Heterogeneous nuclear ribonucleoprotein A1 (mRNA); Helix-destabilizing protein (mRNA); HNRPA1 (mRNA) T12052 FUNCTION May bind to specific miRNA hairpins. Involved in the packaging of pre-mRNA into hnRNP particles, transport of poly(A) mRNA from the nucleus to the cytoplasm and may modulate splice site selection. T12052 PDBSTRUC 6DCL; 6BXX; 5ZGL; 5MPL; 5MPG T12052 BIOCLASS mRNA target T12052 SEQUENCE MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFVTYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHHLRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKALSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGSGDGYNGFGNDGGYGGGGPGYSGGSRGYGSGGQGYGNQGSGYGGSGSYDSYNNGGGGGFGGGSGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGYGGSSSSSSYGSGRRF T12052 DRUGINFO D00LSM ISIS 112000 Investigative T12052 DRUGINFO D00SQD ISIS 112022 Investigative T12052 DRUGINFO D04XOE ISIS 112019 Investigative T12052 DRUGINFO D06QZK ISIS 112005 Investigative T12052 DRUGINFO D07FSX ISIS 112002 Investigative T12052 DRUGINFO D07RUF ISIS 112023 Investigative T12052 DRUGINFO D0D9OL ISIS 111992 Investigative T12052 DRUGINFO D0GD1R ISIS 112003 Investigative T12052 DRUGINFO D0H0YU ISIS 111997 Investigative T12052 DRUGINFO D0H6OL ISIS 112004 Investigative T12052 DRUGINFO D0N7OK ISIS 112001 Investigative T12052 DRUGINFO D0QU6S ISIS 112024 Investigative T12052 DRUGINFO D0T0XZ ISIS 112020 Investigative T12052 DRUGINFO D0Y4TS ISIS 111993 Investigative T12052 DRUGINFO D0Z4RI ISIS 112021 Investigative T79690 TARGETID T79690 T79690 FORMERID TTDR00217 T79690 UNIPROID ITA4_HUMAN-ITB1_HUMAN T79690 TARGNAME VLA-4 messenger RNA (VLA-4 mRNA) T79690 GENENAME ITGA4-ITGB1 T79690 TARGTYPE Literature-reported T79690 SYNONYMS VLA-4 (mRNA); Integrin alpha-4/beta-1 (mRNA) T79690 FUNCTION Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha- 4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha- 4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. T79690 BIOCLASS mRNA target T79690 SEQUENCE MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD T44846 TARGETID T44846 T44846 FORMERID TTDC00289 T44846 UNIPROID VEGFA_HUMAN T44846 TARGNAME VEGF A165 messenger RNA (VEGF A165 mRNA) T44846 GENENAME VEGFA A165 T44846 TARGTYPE Literature-reported T44846 SYNONYMS Vascular permeability factor A165 (mRNA); Vascular endothelial growth factor A A165 (mRNA); VPF A165 (mRNA); VEGF-A A165 (mRNA); VEGF A165 (mRNA) T44846 FUNCTION Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. T44846 PDBSTRUC 6D3O; 6BFT; 5T89; 5O4E; 5HHD T44846 BIOCLASS mRNA target T44846 SEQUENCE MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGPHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR T58479 TARGETID T58479 T58479 FORMERID TTDI02235 T58479 UNIPROID VEGFA_HUMAN T58479 TARGNAME VEGF messenger RNA (VEGF mRNA) T58479 GENENAME VEGFA T58479 TARGTYPE Literature-reported T58479 SYNONYMS Vascular permeability factor (mRNA); Vascular endothelial growth factor A (mRNA); VPF (mRNA); VEGF-A (mRNA); VEGF (mRNA) T58479 FUNCTION Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. T58479 PDBSTRUC 6D3O; 6BFT; 5T89; 5O4E; 5HHD T58479 BIOCLASS mRNA target T58479 SEQUENCE MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGPHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR T58479 DRUGINFO D05ITS ALN-VEG01 Terminated T87916 TARGETID T87916 T87916 FORMERID TTDR01374 T87916 UNIPROID LYAM2_HUMAN T87916 TARGNAME E-selectin messenger RNA (SELE mRNA) T87916 GENENAME SELE T87916 TARGTYPE Literature-reported T87916 SYNONYMS Leukocyte-endothelial cell adhesion molecule 2 (mRNA); LECAM2 (mRNA); Endothelial leukocyte adhesion molecule 1 (mRNA); ELAM1 (mRNA); ELAM-1 (mRNA); E-selectin (mRNA); CD62E antigen (mRNA); CD62E (mRNA); CD62 antigen-like family member E (mRNA) T87916 FUNCTION Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with SELPLG/PSGL1. May have a role in capillary morphogenesis. Cell-surface glycoprotein having a role in immunoadhesion. T87916 PDBSTRUC 6EYK; 6EYJ; 6EYI; 4CSY; 4C16 T87916 BIOCLASS mRNA target T87916 SEQUENCE MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKCEQIVNCTALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACNVVECDAVTNPANGFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNWDNEKPTCKAVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECTTQGQWTQQIPVCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQGFVLKGSKRLQCGPTGEWDNEKPTCEAVRCDAVHQPPKGLVRCAHSPIGEFTYKSSCAFSCEEGFELHGSTQLECTSQGQWTEEVPSCQVVKCSSLAVPGKINMSCSGEPVFGTVCKFACPEGWTLNGSAARTCGATGHWSGLLPTCEAPTESNIPLVAGLSAAGLSLLTLAPFLLWLRKCLRKAKKFVPASSCQSLESDGSYQKPSYIL T87916 DRUGINFO D02MDK ISIS 2674 Investigative T87916 DRUGINFO D04KSX ISIS 9984 Investigative T87916 DRUGINFO D07BCS ISIS 2686 Investigative T87916 DRUGINFO D0E6KA ISIS 4730 Investigative T87916 DRUGINFO D0E8OO ISIS 4764 Investigative T87916 DRUGINFO D0L1ZC ISIS 4759 Investigative T87916 DRUGINFO D0N5AF ISIS 11929 Investigative T87916 DRUGINFO D0OQ2Q ISIS 2678 Investigative T87916 DRUGINFO D0QR1L ISIS 4756 Investigative T87916 DRUGINFO D0R4BK ISIS 4729 Investigative T87916 DRUGINFO D0Y4RS ISIS 4719 Investigative T10252 TARGETID T10252 T10252 FORMERID TTDR01376 T10252 UNIPROID CEBPB_HUMAN T10252 TARGNAME C/EBP beta messenger RNA (CEBPB mRNA) T10252 GENENAME CEBPB T10252 TARGTYPE Literature-reported T10252 SYNONYMS Transcription factor CCAAT/enhancer-binding protein beta (mRNA); Transcription factor 5 (mRNA); TCF5 (mRNA); TCF-5 (mRNA); PP9092 (mRNA); Nuclear factor NF-IL6 (mRNA); Liver-enriched inhibitory protein (mRNA); Liver activator protein (mRNA); LIP (mRNA); LAP (mRNA); CCAAT/enhancer-binding protein beta (mRNA); C/EBP beta (mRNA) T10252 FUNCTION Plays also a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. The consensus recognition site is 5'-T[TG]NNGNAA[TG]-3'. Its functional capacity is governed by protein interactions and post-translational protein modifications. During early embryogenesis, plays essential and redundant functions with CEBPA. Has a promitotic effect on many cell types such as hepatocytes and adipocytes but has an antiproliferative effect on T-cells by repressing MYC expression, facilitating differentiation along the T-helper 2 lineage. Binds to regulatory regions of several acute-phase and cytokines genes and plays a role in the regulation of acute-phase reaction and inflammation. Plays also a role in intracellular bacteria killing. During adipogenesis, is rapidly expressed and, after activation by phosphorylation, induces CEBPA and PPARG, which turn on the series of adipocyte genes that give rise to the adipocyte phenotype. The delayed transactivation of the CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic clonal expansion and thereby progression of terminal differentiation. Essential for female reproduction because of a critical role in ovarian follicle development. Restricts osteoclastogenesis: together with NFE2L1; represses expression of DSPP during odontoblast differentiation. Important transcription factor regulating the expression of genes involved in immune and inflammatory responses. T10252 PDBSTRUC 6MG3; 6MG2; 6MG1; 2.00E+43; 2.00E+42 T10252 BIOCLASS mRNA target T10252 SEQUENCE MQRLVAWDPACLPLPPPPPAFKSMEVANFYYEADCLAAAYGGKAAPAAPPAARPGPRPPAGELGSIGDHERAIDFSPYLEPLGAPQAPAPATATDTFEAAPPAPAPAPASSGQHHDFLSDLFSDDYGGKNCKKPAEYGYVSLGRLGAAKGALHPGCFAPLHPPPPPPPPPAELKAEPGFEPADCKRKEEAGAPGGGAGMAAGFPYALRAYLGYQAVPSGSSGSLSTSSSSSPPGTPSPADAKAPPTACYAGAAPAPSQVKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLFKQLPEPLLASSGHC T10252 DRUGINFO D0TC8O ISIS 116508 Investigative T10252 DRUGINFO D0TD0K ISIS 116507 Investigative T10252 DRUGINFO D0Z5SL ISIS 116505 Investigative T68026 TARGETID T68026 T68026 FORMERID TTDR01377 T68026 UNIPROID VCAM1_HUMAN T68026 TARGNAME VCAM-1 messenger RNA (VCAM1 mRNA) T68026 GENENAME VCAM1 T68026 TARGTYPE Literature-reported T68026 SYNONYMS Vascular cell adhesion protein 1 (mRNA); Vascular cell adhesion molecule 1 (mRNA); VCAM-1 (mRNA); V-CAM 1 (mRNA); INCAM-100 (mRNA); CD106 antigen (mRNA); CD106 (mRNA) T68026 FUNCTION Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and signal transduction. The VCAM1/ITGA4/ITGB1 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. Important in cell-cell recognition. T68026 PDBSTRUC 1VSC; 1VCA; 1IJ9 T68026 BIOCLASS mRNA target T68026 SEQUENCE MPGKMVVILGASNILWIMFAASQAFKIETTPESRYLAQIGDSVSLTCSTTGCESPFFSWRTQIDSPLNGKVTNEGTTSTLTMNPVSFGNEHSYLCTATCESRKLEKGIQVEIYSFPKDPEIHLSGPLEAGKPITVKCSVADVYPFDRLEIDLLKGDHLMKSQEFLEDADRKSLETKSLEVTFTPVIEDIGKVLVCRAKLHIDEMDSVPTVRQAVKELQVYISPKNTVISVNPSTKLQEGGSVTMTCSSEGLPAPEIFWSKKLDNGNLQHLSGNATLTLIAMRMEDSGIYVCEGVNLIGKNRKEVELIVQEKPFTVEISPGPRIAAQIGDSVMLTCSVMGCESPSFSWRTQIDSPLSGKVRSEGTNSTLTLSPVSFENEHSYLCTVTCGHKKLEKGIQVELYSFPRDPEIEMSGGLVNGSSVTVSCKVPSVYPLDRLEIELLKGETILENIEFLEDTDMKSLENKSLEMTFIPTIEDTGKALVCQAKLHIDDMEFEPKQRQSTQTLYVNVAPRDTTVLVSPSSILEEGSSVNMTCLSQGFPAPKILWSRQLPNGELQPLSENATLTLISTKMEDSGVYLCEGINQAGRSRKEVELIIQVTPKDIKLTAFPSESVKEGDTVIISCTCGNVPETWIILKKKAETGDTVLKSIDGAYTIRKAQLKDAGVYECESKNKVGSQLRSLTLDVQGRENNKDYFSPELLVLYFASSLIIPAIGMIIYFARKANMKGSYSLVEAQKSKV T68026 DRUGINFO D02TPS ISIS 3792 Investigative T68026 DRUGINFO D02WXX ISIS 3801 Investigative T68026 DRUGINFO D04RGN SYMBIOPOLYOL Investigative T68026 DRUGINFO D08YCI ISIS 5876 Investigative T68026 DRUGINFO D0A7AV ISIS 5875 Investigative T68026 DRUGINFO D0A7SE ISIS 3804 Investigative T68026 DRUGINFO D0J7IV ISIS 5884 Investigative T68026 DRUGINFO D0P3FU ISIS 3805 Investigative T68026 DRUGINFO D0R5NX ISIS 5874 Investigative T42004 TARGETID T42004 T42004 FORMERID TTDR01378 T42004 UNIPROID NUCL_HUMAN T42004 TARGNAME Nucleolin messenger RNA (NCL mRNA) T42004 GENENAME NCL T42004 TARGTYPE Literature-reported T42004 SYNONYMS Protein C23 (mRNA); Nucleolin (mRNA) T42004 FUNCTION It is found associated with intranucleolar chromatin and pre-ribosomal particles. It induces chromatin decondensation by binding to histone H1. It is thought to play a role in pre-rRNA transcription and ribosome assembly. May play a role in the process of transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats. Nucleolin is the major nucleolar protein of growing eukaryotic cells. T42004 PDBSTRUC 2KRR; 2FC9; 2FC8 T42004 BIOCLASS mRNA target T42004 SEQUENCE MVKLAKAGKNQGDPKKMAPPPKEVEEDSEDEEMSEDEEDDSSGEEVVIPQKKGKKAAATSAKKVVVSPTKKVAVATPAKKAAVTPGKKAAATPAKKTVTPAKAVTTPGKKGATPGKALVATPGKKGAAIPAKGAKNGKNAKKEDSDEEEDDDSEEDEEDDEDEDEDEDEIEPAAMKAAAAAPASEDEDDEDDEDDEDDDDDEEDDSEEEAMETTPAKGKKAAKVVPVKAKNVAEDEDEEEDDEDEDDDDDEDDEDDDDEDDEEEEEEEEEEPVKEAPGKRKKEMAKQKAAPEAKKQKVEGTEPTTAFNLFVGNLNFNKSAPELKTGISDVFAKNDLAVVDVRIGMTRKFGYVDFESAEDLEKALELTGLKVFGNEIKLEKPKGKDSKKERDARTLLAKNLPYKVTQDELKEVFEDAAEIRLVSKDGKSKGIAYIEFKTEADAEKTFEEKQGTEIDGRSISLYYTGEKGQNQDYRGGKNSTWSGESKTLVLSNLSYSATEETLQEVFEKATFIKVPQNQNGKSKGYAFIEFASFEDAKEALNSCNKREIEGRAIRLELQGPRGSPNARSQPSKTLFVKGLSEDTTEETLKESFDGSVRARIVTDRETGSSKGFGFVDFNSEEDAKAAKEAMEDGEIDGNKVTLDWAKPKGEGGFGGRGGGRGGFGGRGGGRGGRGGFGGRGRGGFGGRGGFRGGRGGGGDHKPQGKKTKFE T42004 DRUGINFO D00FEY ISIS 110074 Investigative T42004 DRUGINFO D02YVB ISIS 110065 Investigative T42004 DRUGINFO D07XNG ISIS 110067 Investigative T42004 DRUGINFO D0E5TD ISIS 110068 Investigative T42004 DRUGINFO D0KO1E ISIS 110073 Investigative T42004 DRUGINFO D0S6OP ISIS 110066 Investigative T42004 DRUGINFO D0W7DK ISIS 110064 Investigative T04945 TARGETID T04945 T04945 FORMERID TTDR01380 T04945 UNIPROID TNR6_HUMAN T04945 TARGNAME Fas messenger RNA (FAS mRNA) T04945 GENENAME FAS T04945 TARGTYPE Literature-reported T04945 SYNONYMS Tumor necrosis factor receptor superfamily member 6 (mRNA); TNFRSF6 (mRNA); FASLG receptor (mRNA); FAS1 (mRNA); CD95 (mRNA); Apoptosis-mediating surface antigen FAS (mRNA); Apo-1 antigen (mRNA); APT1 (mRNA) T04945 FUNCTION The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). Receptor for TNFSF6/FASLG. T04945 PDBSTRUC 3TJE; 3THM; 3EZQ; 3EWT; 2NA7 T04945 BIOCLASS mRNA target T04945 SEQUENCE MLGIWTLLPLVLTSVARLSSKSVNAQVTDINSKGLELRKTVTTVETQNLEGLHHDGQFCHKPCPPGERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRRCRLCDEGHGLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKCEHGIIKECTLTSNTKCKEEGSRSNLGWLCLLLLPIPLIVWVKRKEVQKTCRKHRKENQGSHESPTLNPETVAINLSDVDLSKYITTIAGVMTLSQVKGFVRKNGVNEAKIDEIKNDNVQDTAEQKVQLLRNWHQLHGKKEAYDTLIKDLKKANLCTLAEKIQTIILKDITSDSENSNFRNEIQSLV T04945 DRUGINFO D0J1SU ISIS 17020 Investigative T50678 TARGETID T50678 T50678 FORMERID TTDI02681 T50678 UNIPROID CD40L_HUMAN T50678 TARGNAME CD40LG messenger RNA (CD40LG mRNA) T50678 GENENAME CD40LG T50678 TARGTYPE Literature-reported T50678 SYNONYMS Tumor necrosis factor ligand superfamily member 5 (mRNA); TRAP (mRNA); TNFSF5 (mRNA); TNF-related activation protein (mRNA); T-cell antigen Gp39 (mRNA); T cell antigen Gp39 (mRNA); CD40L (mRNA); CD40-L (mRNA); CD40 ligand (mRNA); CD154 antigen (mRNA); CD154 (mRNA) T50678 FUNCTION Costimulates T-cell proliferation and cytokine production. Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation. Induces the activation of NF-kappa-B and kinases MAPK8 and PAK2 in T-cells. Induces tyrosine phosphorylation of isoform 3 of CD28. Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4. Involved in immunoglobulin class switching. Cytokine that binds to CD40/TNFRSF5. T50678 PDBSTRUC 6BRB; 3QD6; 3LKJ; 1I9R; 1ALY T50678 BIOCLASS mRNA target T50678 SEQUENCE MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL T79799 TARGETID T79799 T79799 FORMERID TTDR01383 T79799 UNIPROID GNA11_HUMAN T79799 TARGNAME G-alpha-11 messenger RNA (GNA11 mRNA) T79799 GENENAME GNA11 T79799 TARGTYPE Literature-reported T79799 SYNONYMS Guanine nucleotide-binding protein subunit alpha-11 (mRNA); Guanine nucleotide-binding protein G(y) subunit alpha (mRNA); GA11 (mRNA); G-protein subunit alpha-11 (mRNA); G alpha-11 (mRNA) T79799 FUNCTION Acts as an activator of phospholipase C. Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. T79799 PDBSTRUC 6OIJ T79799 BIOCLASS mRNA target T79799 SEQUENCE MTLESMMACCLSDEVKESKRINAEIEKQLRRDKRDARRELKLLLLGTGESGKSTFIKQMRIIHGAGYSEEDKRGFTKLVYQNIFTAMQAMIRAMETLKILYKYEQNKANALLIREVDVEKVTTFEHQYVSAIKTLWEDPGIQECYDRRREYQLSDSAKYYLTDVDRIATLGYLPTQQDVLRVRVPTTGIIEYPFDLENIIFRMVDVGGQRSERRKWIHCFENVTSIMFLVALSEYDQVLVESDNENRMEESKALFRTIITYPWFQNSSVILFLNKKDLLEDKILYSHLVDYFPEFDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATDTENIRFVFAAVKDTILQLNLKEYNLV T79799 DRUGINFO D02FVN ISIS 20585 Investigative T79799 DRUGINFO D02QWL ISIS 20995 Investigative T79799 DRUGINFO D0F4UV ISIS 20586 Investigative T79799 DRUGINFO D0KX4U ISIS 20579 Investigative T79799 DRUGINFO D0L8AJ ISIS 20994 Investigative T79799 DRUGINFO D0L9DW ISIS 20993 Investigative T79799 DRUGINFO D0M5GP ISIS 20990 Investigative T79799 DRUGINFO D0O4HL ISIS 20577 Investigative T10939 TARGETID T10939 T10939 FORMERID TTDI02666 T10939 UNIPROID WEE1_HUMAN T10939 TARGNAME WEE1 messenger RNA (WEE1 mRNA) T10939 GENENAME WEE1 T10939 TARGTYPE Literature-reported T10939 SYNONYMS Wee1A kinase (mRNA); WEE1hu (mRNA) T10939 FUNCTION Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation. Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. T10939 PDBSTRUC 5VDA; 5VD9; 5VD8; 5VD7; 5VD5 T10939 BIOCLASS mRNA target T10939 ECNUMBER EC 2.7.10.2 T10939 SEQUENCE MSFLSRQQPPPPRRAGAACTLRQKLIFSPCSDCEEEEEEEEEEGSGHSTGEDSAFQEPDSPLPPARSPTEPGPERRRSPGPAPGSPGELEEDLLLPGACPGADEAGGGAEGDSWEEEGFGSSSPVKSPAAPYFLGSSFSPVRCGGPGDASPRGCGARRAGEGRRSPRPDHPGTPPHKTFRKLRLFDTPHTPKSLLSKARGIDSSSVKLRGSSLFMDTEKSGKREFDVRQTPQVNINPFTPDSLLLHSSGQCRRRKRTYWNDSCGEDMEASDYELEDETRPAKRITITESNMKSRYTTEFHELEKIGSGEFGSVFKCVKRLDGCIYAIKRSKKPLAGSVDEQNALREVYAHAVLGQHSHVVRYFSAWAEDDHMLIQNEYCNGGSLADAISENYRIMSYFKEAELKDLLLQVGRGLRYIHSMSLVHMDIKPSNIFISRTSIPNAASEEGDEDDWASNKVMFKIGDLGHVTRISSPQVEEGDSRFLANEVLQENYTHLPKADIFALALTVVCAAGAEPLPRNGDQWHEIRQGRLPRIPQVLSQEFTELLKVMIHPDPERRPSAMALVKHSVLLSASRKSAEQLRIELNAEKFKNSLLQKELKKAQMAKAAAEERALFTDRMATRSTTQSNRTSRLIGKKMNRSVSLTIY T22306 TARGETID T22306 T22306 FORMERID TTDI02311 T22306 UNIPROID AKT1_HUMAN T22306 TARGNAME AKT1 messenger RNA (AKT1 mRNA) T22306 GENENAME AKT1 T22306 TARGTYPE Literature-reported T22306 SYNONYMS RAC-PK-alpha (mRNA); RAC (mRNA); Proto-oncogene c-Akt (mRNA); Protein kinase B alpha (mRNA); Protein kinase B (mRNA); PKB alpha (mRNA); PKB (mRNA) T22306 FUNCTION AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53. T22306 PDBSTRUC 6NPZ; 6HHJ; 6HHI; 6HHH; 6HHG T22306 BIOCLASS mRNA target T22306 ECNUMBER EC 2.7.11.1 T22306 SEQUENCE MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA T45433 TARGETID T45433 T45433 FORMERID TTDI02254 T45433 UNIPROID IL3RB_HUMAN T45433 TARGNAME GM-CSFR/IL-3R/IL-5R common beta messenger RNA (CSF2RB mRNA) T45433 GENENAME CSF2RB T45433 TARGTYPE Literature-reported T45433 SYNONYMS IL5RB (mRNA); IL3RB (mRNA); IL-5R (mRNA); GM-CSF/IL-3/IL-5 receptor common beta subunit (mRNA); Cytokine receptor common subunit beta (mRNA); CDw131 (mRNA); CD131 (mRNA) T45433 FUNCTION High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor. T45433 PDBSTRUC 5DWU; 4NKQ; 2NA9; 2NA8; 2GYS T45433 BIOCLASS mRNA target T45433 SEQUENCE MVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVTLIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLGTRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQDSWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPGDEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSLHTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWETMKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTGYNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPNPSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIEDPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSRSLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQGAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFTPNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSPRNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPSSPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC T29148 TARGETID T29148 T29148 FORMERID TTDR01384 T29148 UNIPROID CD80_HUMAN T29148 TARGNAME B7 translation initiation codon region messenger RNA (CD80 mRNA) T29148 GENENAME CD80 T29148 TARGTYPE Literature-reported T29148 SYNONYMS T-lymphocyte activation antigen CD80 (mRNA); LAB7 (mRNA); CTLA-4 counter-receptor B7.1 (mRNA); CD28LG1 (mRNA); CD28LG (mRNA); BB1 (mRNA); B7 (mRNA); Activation B7-1 antigen (mRNA) T29148 FUNCTION T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation. Involved in the costimulatory signal essential for T-lymphocyte activation. T29148 PDBSTRUC 1I8L; 1DR9 T29148 BIOCLASS mRNA target T29148 SEQUENCE MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV T29148 DRUGINFO D07QCW ISIS 13805 Investigative T29148 DRUGINFO D0LH7O ISIS 13812 Investigative T71268 TARGETID T71268 T71268 FORMERID TTDI02299 T71268 UNIPROID IRS1_HUMAN T71268 TARGNAME IRS1 messenger RNA (IRS1 mRNA) T71268 GENENAME IRS1 T71268 TARGTYPE Literature-reported T71268 SYNONYMS Insulin receptor substrate 1 (mRNA); IRS-1 (mRNA) T71268 FUNCTION When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit. May mediate the control of various cellular processes by insulin. T71268 PDBSTRUC 6BNT; 5U1M; 2Z8C; 1QQG; 1K3A T71268 BIOCLASS mRNA target T71268 SEQUENCE MASPPESDGFSDVRKVGYLRKPKSMHKRFFVLRAASEAGGPARLEYYENEKKWRHKSSAPKRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIAADSEAEQDSWYQALLQLHNRAKGHHDGAAALGAGGGGGSCSGSSGLGEAGEDLSYGDVPPGPAFKEVWQVILKPKGLGQTKNLIGIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHSENFFFIEVGRSAVTGPGEFWMQVDDSVVAQNMHETILEAMRAMSDEFRPRSKSQSSSNCSNPISVPLRRHHLNNPPPSQVGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGTMSRPASVDGSPVSPSTNRTHAHRHRGSARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHGSTSDCLFPRRSSASVSGSPSDGGFISSDEYGSSPCDFRSSFRSVTPDSLGHTPPARGEEELSNYICMGGKGPSTLTAPNGHYILSRGGNGHRCTPGTGLGTSPALAGDEAASAADLDNRFRKRTHSAGTSPTITHQKTPSQSSVASIEEYTEMMPAYPPGGGSGGRLPGHRHSAFVPTRSYPEEGLEMHPLERRGGHHRPDSSTLHTDDGYMPMSPGVAPVPSGRKGSGDYMPMSPKSVSAPQQIINPIRRHPQRVDPNGYMMMSPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGHHSHVLPHPKPPVESSGGKLLPCTGDYMNMSPVGDSNTSSPSDCYYGPEDPQHKPVLSYYSLPRSFKHTQRPGEPEEGARHQHLRLSTSSGRLLYAATADDSSSSTSSDSLGGGYCGARLEPSLPHPHHQVLQPHLPRKVDTAAQTNSRLARPTRLSLGDPKASTLPRAREQQQQQQPLLHPPEPKSPGEYVNIEFGSDQSGYLSGPVAFHSSPSVRCPSQLQPAPREEETGTEEYMKMDLGPGRRAAWQESTGVEMGRLGPAPPGAASICRPTRAVPSSRGDYMTMQMSCPRQSYVDTSPAAPVSYADMRTGIAAEEVSLPRATMAAASSSSAASASPTGPQGAAELAAHSSLLGGPQGPGGMSAFTRVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGNTVPFGAGAAVGGGGGSSSSSEDVKRHSSASFENVWLRPGELGGAPKEPAKLCGAAGGLENGLNYIDLDLVKDFKQCPQECTPEPQPPPPPPPHQPLGSGESSSTRRSSEDLSAYASISFQKQPEDRQ T97783 TARGETID T97783 T97783 FORMERID TTDR01389 T97783 UNIPROID CD86_HUMAN T97783 TARGNAME CD86 messenger RNA (CD86 mRNA) T97783 GENENAME CD86 T97783 TARGTYPE Literature-reported T97783 SYNONYMS T-lymphocyte activation antigen CD86 (mRNA); FUN-1 (mRNA); CTLA-4 counter-receptor B7.2 (mRNA); CD86 (mRNA); CD28LG2 (mRNA); BU63 (mRNA); B70 (mRNA); Activation B7-2 antigen (mRNA) T97783 FUNCTION May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation. Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. T97783 PDBSTRUC 5YXK; 1NCN; 1I85 T97783 BIOCLASS mRNA target T97783 SEQUENCE MDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGVMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQPPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTMEREESEQTKKREKIHIPERSDEAQRVFKSSKTSSCDKSDTCF T97783 DRUGINFO D07RML ISIS 9133 Investigative T97783 DRUGINFO D0N4CJ ISIS 9139 Investigative T97783 DRUGINFO D0O0BZ ISIS 10373 Investigative T97783 DRUGINFO D0V2AQ ISIS 113131 Investigative T97044 TARGETID T97044 T97044 FORMERID TTDR01392 T97044 UNIPROID NOP2_HUMAN T97044 TARGNAME P120 messenger RNA (NOP2 mRNA) T97044 GENENAME NOP2 T97044 TARGTYPE Literature-reported T97044 SYNONYMS Proliferation-associated nucleolar protein p120 (mRNA); Proliferating-cell nucleolar antigen p120 (mRNA); Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase (mRNA); Nucleolar protein 2 homolog (mRNA); Nucleolar protein 1 (mRNA); NSUN1 (mRNA); NOL1 (mRNA) T97044 FUNCTION S-adenosyl-L-methionine-dependent methyltransferase that specifically methylates the C(5) position of cytosine 4447 in 28S rRNA. May play a role in the regulation of the cell cycle and the increased nucleolar activity that is associated with the cell proliferation. Involved in ribosomal large subunit assembly. T97044 BIOCLASS mRNA target T97044 ECNUMBER EC 2.1.1.- T97044 SEQUENCE MGRKLDPTKEKRGPGRKARKQKGAETELVRFLPAVSDENSKRLSSRARKRAAKRRLGSVEAPKTNKSPEAKPLPGKLPKGISAGAVQTAGKKGPQSLFNAPRGKKRPAPGSDEEEEEEDSEEDGMVNHGDLWGSEDDADTVDDYGADSNSEDEEEGEALLPIERAARKQKAREAAAGIQWSEEETEDEEEEKEVTPESGPPKVEEADGGLQINVDEEPFVLPPAGEMEQDAQAPDLQRVHKRIQDIVGILRDFGAQREEGRSRSEYLNRLKKDLAIYYSYGDFLLGKLMDLFPLSELVEFLEANEVPRPVTLRTNTLKTRRRDLAQALINRGVNLDPLGKWSKTGLVVYDSSVPIGATPEYLAGHYMLQGASSMLPVMALAPQEHERILDMCCAPGGKTSYMAQLMKNTGVILANDANAERLKSVVGNLHRLGVTNTIISHYDGRQFPKVVGGFDRVLLDAPCSGTGVISKDPAVKTNKDEKDILRCAHLQKELLLSAIDSVNATSKTGGYLVYCTCSITVEENEWVVDYALKKRNVRLVPTGLDFGQEGFTRFRERRFHPSLRSTRRFYPHTHNMDGFFIAKFKKFSNSIPQSQTGNSETATPTNVDLPQVIPKSENSSQPAKKAKGAAKTKQQLQKQQHPKKASFQKLNGISKGADSELSTVPSVTKTQASSSFQDSSQPAGKAEGIREPKVTGKLKQRSPKLQSSKKVAFLRQNAPPKGTDTQTPAVLSPSKTQATLKPKDHHQPLGRAKGVEKQQLPEQPFEKAAFQKQNDTPKGPQPPTVSPIRSSRPPPAKRKKSQSRGNSQLLLS T97044 DRUGINFO D04AJS ISIS 6756 Investigative T97044 DRUGINFO D04NBZ ISIS 6755 Investigative T97044 DRUGINFO D08NLU ISIS 6748 Investigative T97044 DRUGINFO D09LXU ISIS 6739 Investigative T37077 TARGETID T37077 T37077 FORMERID TTDR01393 T37077 UNIPROID TNFL6_HUMAN T37077 TARGNAME FasL messenger RNA (FASLG mRNA) T37077 GENENAME FASLG T37077 TARGTYPE Literature-reported T37077 SYNONYMS Tumor necrosis factor ligand superfamily member 6 (mRNA); TNFSF6 (mRNA); FasL (mRNA); Fas ligand (mRNA); FAS antigen ligand (mRNA); CD95L (mRNA); CD95-L (mRNA); CD95 ligand (mRNA); CD178 antigen (mRNA); CD178 (mRNA); Apoptosis antigen ligand (mRNA); APTL (mRNA); APT1LG1 (mRNA) T37077 FUNCTION Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses. TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance. Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis. Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. T37077 PDBSTRUC 5L36; 5L19; 4MSV; 1BZI T37077 BIOCLASS mRNA target T37077 SEQUENCE MQQPFNYPYPQIYWVDSSASSPWAPPGTVLPCPTSVPRRPGQRRPPPPPPPPPLPPPPPPPPLPPLPLPPLKKRGNHSTGLCLLVMFFMVLVALVGLGLGMFQLFHLQKELAELRESTSQMHTASSLEKQIGHPSPPPEKKELRKVAHLTGKSNSRSMPLEWEDTYGIVLLSGVKYKKGGLVINETGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQDLVMMEGKMMSYCTTGQMWARSSYLGAVFNLTSADHLYVNVSELSLVNFEESQTFFGLYKL T37077 DRUGINFO D0BR7X ISIS 16179 Investigative T03551 TARGETID T03551 T03551 FORMERID TTDR01397 T03551 UNIPROID PTEN_HUMAN T03551 TARGNAME PTEN messenger RNA (PTEN mRNA) T03551 GENENAME PTEN T03551 TARGTYPE Literature-reported T03551 SYNONYMS TEP1 (mRNA); Phosphatidylinositol 3,4,5trisphosphate 3phosphatase and dualspecificity protein phosphatase PTEN (mRNA); Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (mRNA); Mutated in multiple advanced cancers 1 (mRNA); MMAC1 (mRNA) T03551 FUNCTION Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement. Tumor suppressor. T03551 PDBSTRUC 5BZZ; 5BZX; 5BUG; 4O1V; 2KYL T03551 BIOCLASS mRNA target T03551 ECNUMBER EC 3.1.3.16 T03551 SEQUENCE MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV T28729 TARGETID T28729 T28729 FORMERID TTDR01400 T28729 UNIPROID E2F1_HUMAN T28729 TARGNAME E2F1 messenger RNA (E2F1 mRNA) T28729 GENENAME E2F1 T28729 TARGTYPE Literature-reported T28729 SYNONYMS pRB-binding protein E2F-1 (mRNA); Transcription factor E2F1 (mRNA); Retinoblastoma-binding protein 3 (mRNA); Retinoblastoma-associated protein 1 (mRNA); RBBP3 (mRNA); RBBP-3 (mRNA); RBAP-1 (mRNA); PBR3 (mRNA); E2F-1 (mRNA) T28729 FUNCTION The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F1 binds preferentially RB1 in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis. Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters. Positively regulates transcription of RRP1B. Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. T28729 PDBSTRUC 6G0P; 5M9O; 5M9N; 2AZE; 1O9K T28729 BIOCLASS mRNA target T28729 SEQUENCE MALAGAPAGGPCAPALEALLGAGALRLLDSSQIVIISAAQDASAPPAPTGPAAPAAGPCDPDLLLFATPQAPRPTPSAPRPALGRPPVKRRLDLETDHQYLAESSGPARGRGRHPGKGVKSPGEKSRYETSLNLTTKRFLELLSHSADGVVDLNWAAEVLKVQKRRIYDITNVLEGIQLIAKKSKNHIQWLGSHTTVGVGGRLEGLTQDLRQLQESEQQLDHLMNICTTQLRLLSEDTDSQRLAYVTCQDLRSIADPAEQMVMVIKAPPETQLQAVDSSENFQISLKSKQGPIDVFLCPEETVGGISPGKTPSQEVTSEEENRATDSATIVSPPPSSPPSSLTTDPSQSLLSLEQEPLLSRMGSLRAPVDEDRLSPLVAADSLLEHVREDFSGLLPEEFISLSPPHEALDYHFGLEEGEGIRDLFDCDFGDLTPLDF T28729 DRUGINFO D01KTF ISIS 113048 Investigative T28729 DRUGINFO D08YXP ISIS 113020 Investigative T28729 DRUGINFO D09RTT ISIS 113022 Investigative T28729 DRUGINFO D0E4IZ ISIS 113019 Investigative T28729 DRUGINFO D0WM1A ISIS 113021 Investigative T09935 TARGETID T09935 T09935 FORMERID TTDR01406 T09935 UNIPROID FOXO1_HUMAN T09935 TARGNAME Forkhead box O1A messenger RNA (FOXO1 mRNA) T09935 GENENAME FOXO1 T09935 TARGTYPE Literature-reported T09935 SYNONYMS Forkhead in rhabdomyosarcoma (mRNA); Forkhead box protein O1A (mRNA); Forkhead box protein O1 (mRNA); FOXO1A (mRNA); FKHR (mRNA) T09935 FUNCTION Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'. Activity suppressed by insulin. Main regulator of redox balance and osteoblast numbers and controls bone mass. Orchestrates the endocrine function of the skeleton in regulating glucose metabolism. Acts synergistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity. Also suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP. In hepatocytes, promotes gluconeogenesis by acting together with PPARGC1A and CEBPA to activate the expression of genes such as IGFBP1, G6PC and PCK1. Important regulator of cell death acting downstream of CDK1, PKB/AKT1 and STK4/MST1. Promotes neural cell death. Mediates insulin action on adipose tissue. Regulates the expression of adipogenic genes such as PPARG during preadipocyte differentiation and, adipocyte size and adipose tissue-specific gene expression in response to excessive calorie intake. Regulates the transcriptional activity of GADD45A and repair of nitric oxide-damaged DNA in beta-cells. Required for the autophagic cell death induction in response to starvation or oxidative stress in a transcription-independent manner. Mediates the function of MLIP in cardiomyocytes hypertrophy and cardiac remodeling. Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress. T09935 PDBSTRUC 5DUI; 4LG0; 3COA; 3CO7; 3CO6 T09935 BIOCLASS mRNA target T09935 SEQUENCE MAEAPQVVEIDPDFEPLPRPRSCTWPLPRPEFSQSNSATSSPAPSGSAAANPDAAAGLPSASAAAVSADFMSNLSLLEESEDFPQAPGSVAAAVAAAAAAAATGGLCGDFQGPEAGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQIYEWMVKSVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQNEGTGKSSWWMLNPEGGKSGKSPRRRAASMDNNSKFAKSRSRAAKKKASLQSGQEGAGDSPGSQFSKWPASPGSHSNDDFDNWSTFRPRTSSNASTISGRLSPIMTEQDDLGEGDVHSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQSSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQTLQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSRVLGQNVMMGPNSVMSTYGSQASHNKMMNPSSHTHPGHAQQTSAVNGRPLPHTVSTMPHTSGMNRLTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYGRMGLLHQEKLPSDLDGMFIERLDCDMESIIRNDLMDGDTLDFNFDNVLPNQSFPHSVKTTTHSWVSG T09935 DRUGINFO D02DUM ISIS 188780 Investigative T09935 DRUGINFO D09NLT ISIS 188763 Investigative T09935 DRUGINFO D09XIQ ISIS 188761 Investigative T09935 DRUGINFO D0D6YO ISIS 188778 Investigative T09935 DRUGINFO D0L0JX ISIS 188782 Investigative T09935 DRUGINFO D0L0WC ISIS 188781 Investigative T09935 DRUGINFO D0N1RP ISIS 188759 Investigative T09935 DRUGINFO D0O3QM ISIS 188757 Investigative T09935 DRUGINFO D0U0OE ISIS 188755 Investigative T48791 TARGETID T48791 T48791 FORMERID TTDR01409 T48791 UNIPROID M3K1_HUMAN T48791 TARGNAME MEKK1 messenger RNA (MAP3K1 mRNA) T48791 GENENAME MAP3K1 T48791 TARGTYPE Literature-reported T48791 SYNONYMS Mitogenactivated protein kinase kinase kinase 1 (mRNA); Mitogen-activated protein kinase kinase kinase 1 (mRNA); MEKK1 (mRNA); MEKK 1 (mRNA); MEKK (mRNA); MEK kinase 1 (mRNA); MAPKKK1 (mRNA) T48791 FUNCTION Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4. May phosphorylate the MAPK8/JNK1 kinase. Activates CHUK and IKBKB, the central protein kinases of the NF-kappa-B pathway. Component of a protein kinase signal transduction cascade. T48791 BIOCLASS mRNA target T48791 ECNUMBER EC 2.7.11.25 T48791 SEQUENCE MAAAAGNRASSSGFPGARATSPEAGGGGGALKASSAPAAAAGLLREAGSGGRERADWRRRQLRKVRSVELDQLPEQPLFLAASPPASSTSPSPEPADAAGSGTGFQPVAVPPPHGAASRGGAHLTESVAAPDSGASSPAAAEPGEKRAPAAEPSPAAAPAGREMENKETLKGLHKMDDRPEERMIREKLKATCMPAWKHEWLERRNRRGPVVVKPIPVKGDGSEMNHLAAESPGEVQASAASPASKGRRSPSPGNSPSGRTVKSESPGVRRKRVSPVPFQSGRITPPRRAPSPDGFSPYSPEETNRRVNKVMRARLYLLQQIGPNSFLIGGDSPDNKYRVFIGPQNCSCARGTFCIHLLFVMLRVFQLEPSDPMLWRKTLKNFEVESLFQKYHSRRSSRIKAPSRNTIQKFVSRMSNSHTLSSSSTSTSSSENSIKDEEEQMCPICLLGMLDEESLTVCEDGCRNKLHHHCMSIWAEECRRNREPLICPLCRSKWRSHDFYSHELSSPVDSPSSLRAAQQQTVQQQPLAGSRRNQESNFNLTHYGTQQIPPAYKDLAEPWIQVFGMELVGCLFSRNWNVREMALRRLSHDVSGALLLANGESTGNSGGSSGSSPSGGATSGSSQTSISGDVVEACCSVLSMVCADPVYKVYVAALKTLRAMLVYTPCHSLAERIKLQRLLQPVVDTILVKCADANSRTSQLSISTLLELCKGQAGELAVGREILKAGSIGIGGVDYVLNCILGNQTESNNWQELLGRLCLIDRLLLEFPAEFYPHIVSTDVSQAEPVEIRYKKLLSLLTFALQSIDNSHSMVGKLSRRIYLSSARMVTTVPHVFSKLLEMLSVSSSTHFTRMRRRLMAIADEVEIAEAIQLGVEDTLDGQQDSFLQASVPNNYLETTENSSPECTVHLEKTGKGLCATKLSASSEDISERLASISVGPSSSTTTTTTTTEQPKPMVQTKGRPHSQCLNSSPLSHHSQLMFPALSTPSSSTPSVPAGTATDVSKHRLQGFIPCRIPSASPQTQRKFSLQFHRNCPENKDSDKLSPVFTQSRPLPSSNIHRPKPSRPTPGNTSKQGDPSKNSMTLDLNSSSKCDDSFGCSSNSSNAVIPSDETVFTPVEEKCRLDVNTELNSSIEDLLEASMPSSDTTVTFKSEVAVLSPEKAENDDTYKDDVNHNQKCKEKMEAEEEEALAIAMAMSASQDALPIVPQLQVENGEDIIIIQQDTPETLPGHTKAKQPYREDTEWLKGQQIGLGAFSSCYQAQDVGTGTLMAVKQVTYVRNTSSEQEEVVEALREEIRMMSHLNHPNIIRMLGATCEKSNYNLFIEWMAGGSVAHLLSKYGAFKESVVINYTEQLLRGLSYLHENQIIHRDVKGANLLIDSTGQRLRIADFGAAARLASKGTGAGEFQGQLLGTIAFMAPEVLRGQQYGRSCDVWSVGCAIIEMACAKPPWNAEKHSNHLALIFKIASATTAPSIPSHLSPGLRDVALRCLELQPQDRPPSRELLKHPVFRTTW T48791 DRUGINFO D00UDD ISIS 100913 Investigative T48791 DRUGINFO D01DVV ISIS 100939 Investigative T48791 DRUGINFO D09BIH ISIS 100935 Investigative T48791 DRUGINFO D0Q8XG ISIS 100929 Investigative T39134 TARGETID T39134 T39134 FORMERID TTDR01412 T39134 UNIPROID NCOA4_HUMAN T39134 TARGNAME ARA70 messenger RNA (NCOA4 mRNA) T39134 GENENAME NCOA4 T39134 TARGTYPE Literature-reported T39134 SYNONYMS Ret-activating protein ELE1 (mRNA); RFG (mRNA); Nuclear receptor coactivator 4 (mRNA); NCoA-4 (mRNA); ELE1 (mRNA); Androgen receptor-associated protein of 70 kDa (mRNA); Androgen receptor coactivator 70 kDa protein (mRNA); ARA70 (mRNA); ARA70 (dARA70N) (mRNA); 70 kDa androgen receptor coactivator (mRNA); 70 kDa AR-activator (mRNA) T39134 FUNCTION Ligand-independent coactivator of the peroxisome proliferator-activated receptor (PPAR) gamma. Enhances the androgen receptor transcriptional activity in prostate cancer cells. T39134 PDBSTRUC 1T5Z T39134 BIOCLASS mRNA target T39134 SEQUENCE MNTFQDQSGSSSNREPLLRCSDARRDLELAIGGVLRAEQQIKDNLREVKAQIHSCISRHLECLRSREVWLYEQVDLIYQLKEETLQQQAQQLYSLLGQFNCLTHQLECTQNKDLANQVSVCLERLGSLTLKPEDSTVLLFEADTITLRQTITTFGSLKTIQIPEHLMAHASSANIGPFLEKRGCISMPEQKSASGIVAVPFSEWLLGSKPASGYQAPYIPSTDPQDWLTQKQTLENSQTSSRACNFFNNVGGNLKGLENWLLKSEKSSYQKCNSHSTTSSFSIEMEKVGDQELPDQDEMDLSDWLVTPQESHKLRKPENGSRETSEKFKLLFQSYNVNDWLVKTDSCTNCQGNQPKGVEIENLGNLKCLNDHLEAKKPLSTPSMVTEDWLVQNHQDPCKVEEVCRANEPCTSFAECVCDENCEKEALYKWLLKKEGKDKNGMPVEPKPEPEKHKDSLNMWLCPRKEVIEQTKAPKAMTPSRIADSFQVIKNSPLSEWLIRPPYKEGSPKEVPGTEDRAGKQKFKSPMNTSWCSFNTADWVLPGKKMGNLSQLSSGEDKWLLRKKAQEVLLNSPLQEEHNFPPDHYGLPAVCDLFACMQLKVDKEKWLYRTPLQM T39134 DRUGINFO D00EPB ISIS 114397 Investigative T39134 DRUGINFO D01OOI ISIS 114399 Investigative T39134 DRUGINFO D03MWW ISIS 114372 Investigative T39134 DRUGINFO D03OGC ISIS 114388 Investigative T39134 DRUGINFO D08RDK ISIS 114371 Investigative T39134 DRUGINFO D0A2OL ISIS 114390 Investigative T39134 DRUGINFO D0A6GY ISIS 114442 Investigative T39134 DRUGINFO D0N7AB ISIS 114404 Investigative T78475 TARGETID T78475 T78475 FORMERID TTDR01415 T78475 UNIPROID SMAD1_HUMAN T78475 TARGNAME Smad1 messenger RNA (SMAD1 mRNA) T78475 GENENAME SMAD1 T78475 TARGTYPE Literature-reported T78475 SYNONYMS Transforming growth factor-beta-signaling protein 1 (mRNA); Smad1 (mRNA); SMAD family member 1 (mRNA); SMAD 1 (mRNA); Mothers against decapentaplegic homolog 1 (mRNA); Mothers against DPP homolog 1 (mRNA); Mad-related protein 1 (mRNA); MADR1 (mRNA); MADH1 (mRNA); MAD homolog 1 (mRNA); JV4-1 (mRNA); BSP1 (mRNA); BSP-1 (mRNA) T78475 FUNCTION SMAD1 is a receptor-regulated SMAD (R-SMAD). SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. May act synergistically with SMAD4 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase. T78475 PDBSTRUC 5ZOK; 3Q4A; 3Q47; 2LB1; 2LB0 T78475 BIOCLASS mRNA target T78475 SEQUENCE MNVTSLFSFTSPAVKRLLGWKQGDEEEKWAEKAVDALVKKLKKKKGAMEELEKALSCPGQPSNCVTIPRSLDGRLQVSHRKGLPHVIYCRVWRWPDLQSHHELKPLECCEFPFGSKQKEVCINPYHYKRVESPVLPPVLVPRHSEYNPQHSLLAQFRNLGQNEPHMPLNATFPDSFQQPNSHPFPHSPNSSYPNSPGSSSSTYPHSPTSSDPGSPFQMPADTPPPAYLPPEDPMTQDGSQPMDTNMMAPPLPSEINRGDVQAVAYEEPKHWCSIVYYELNNRVGEAFHASSTSVLVDGFTDPSNNKNRFCLGLLSNVNRNSTIENTRRHIGKGVHLYYVGGEVYAECLSDSSIFVQSRNCNYHHGFHPTTVCKIPSGCSLKIFNNQEFAQLLAQSVNHGFETVYELTKMCTIRMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVLTQMGSPHNPISSVS T78475 DRUGINFO D03IPJ ISIS 28425 Investigative T78475 DRUGINFO D0D9WM ISIS 28407 Investigative T78475 DRUGINFO D0X2HI ISIS 28405 Investigative T82372 TARGETID T82372 T82372 FORMERID TTDR01418 T82372 UNIPROID STXB4_HUMAN T82372 TARGNAME STXBP4 messenger RNA (STXBP4 mRNA) T82372 GENENAME STXBP4 T82372 TARGTYPE Literature-reported T82372 SYNONYMS Syntaxin-binding protein 4 (mRNA); Syntaxin 4-interacting protein (mRNA); Synip (mRNA); STX4-interacting protein (mRNA) T82372 FUNCTION Inhibits the translocation of SLC2A4 from intracellular vesicles to the plasma membrane by STX4A binding and preventing the interaction between STX4A and VAMP2. Stimulation with insulin disrupts the interaction with STX4A, leading to increased levels of SLC2A4 at the plasma membrane. May also play a role in the regulation of insulin release by pancreatic beta cells after stimulation by glucose. Plays a role in the translocation of transport vesicles from the cytoplasm to the plasma membrane. T82372 PDBSTRUC 2YSG T82372 BIOCLASS mRNA target T82372 SEQUENCE MNKNTSTVVSPSLLEKDPAFQMITIAKETGLGLKVLGGINRNEGPLVYIQEIIPGGDCYKDGRLKPGDQLVSVNKESMIGVSFEEAKSIITGAKLRLESAWEIAFIRQKSDNIQPENLSCTSLIEASGEYGPQASTLSLFSSPPEILIPKTSSTPKTNNDILSSCEIKTGYNKTVQIPITSENSTVGLSNTDVASAWTENYGLQEKISLNPSVRFKAEKLEMALNYLGIQPTKEQHQALRQQVQADSKGTVSFGDFVQVARNLFCLQLDEVNVGAHEISNILDSQLLPCDSSEADEMERLKCERDDALKEVNTLKEKLLESDKQRKQLTEELQNVKQEAKAVVEETRALRSRIHLAEAAQRQAHGMEMDYEEVIRLLEAKITELKAQLADYSDQNKESVQDLKKRIMVLDCQLRKSEMARKTFEASTEKLLHFVEAIQEVFSDNSTPLSNLSERRAVLASQTSLTPLGRNGRSIPATLALESKELVKSVRALLDMDCLPYGWEEAYTADGIKYFINHVTQTTSWIHPVMSVLNLSRSEENEEDCSRELPNQKS T82372 DRUGINFO D06DMI ISIS 119286 Investigative T82372 DRUGINFO D06LLJ ISIS 119283 Investigative T82372 DRUGINFO D07JFD ISIS 119263 Investigative T82372 DRUGINFO D0G0JO ISIS 119282 Investigative T82372 DRUGINFO D0G9WZ ISIS 119262 Investigative T82372 DRUGINFO D0L6SQ ISIS 119284 Investigative T82372 DRUGINFO D0M2JM ISIS 119285 Investigative T82372 DRUGINFO D0RD7X ISIS 119281 Investigative T82372 DRUGINFO D0Y5GA ISIS 119264 Investigative T53734 TARGETID T53734 T53734 FORMERID TTDI02661 T53734 UNIPROID COP1_HUMAN T53734 TARGNAME COP1 messenger RNA (COP1 mRNA) T53734 GENENAME RFWD2 T53734 TARGTYPE Literature-reported T53734 SYNONYMS hCOP1 (mRNA); RNF200 (mRNA); RING-type E3 ubiquitin transferase RFWD2 (mRNA); RING finger protein 200 (mRNA); RING finger and WD repeat domain protein 2 (mRNA); E3 ubiquitinprotein ligase RFWD2 (mRNA); Constitutive photomorphogenesis protein 1 homolog (mRNA); COP1 (mRNA) T53734 FUNCTION E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Involved in JUN ubiquitination and degradation. Directly involved in p53 (TP53) ubiquitination and degradation, thereby abolishing p53-dependent transcription and apoptosis. Ubiquitinates p53 independently of MDM2 or RCHY1. Probably mediates E3 ubiquitin ligase activity by functioning as the essential RING domain subunit of larger E3 complexes. In contrast, it does not constitute the catalytic RING subunit in the DCX DET1-COP1 complex that negatively regulates JUN, the ubiquitin ligase activity being mediated by RBX1. Involved in 14-3-3 protein sigma/SFN ubiquitination and proteasomal degradation, leading to AKT activation and promotion of cell survival. Ubiquitinates MTA1 leading to its proteasomal degradation. Upon binding to TRIB1, ubiquitinates CEBPA, which lacks a canonical COP1-binding motif. E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins. T53734 PDBSTRUC 5IGQ; 5HQG T53734 BIOCLASS mRNA target T53734 ECNUMBER EC 2.3.2.27 T53734 SEQUENCE MSGSRQAGSGSAGTSPGSSAASSVTSASSSLSSSPSPPSVAVSAAALVSGGVAQAAGSGGLGGPVRPVLVAPAVSGSGGGAVSTGLSRHSCAARPSAGVGGSSSSLGSGSRKRPLLAPLCNGLINSYEDKSNDFVCPICFDMIEEAYMTKCGHSFCYKCIHQSLEDNNRCPKCNYVVDNIDHLYPNFLVNELILKQKQRFEEKRFKLDHSVSSTNGHRWQIFQDWLGTDQDNLDLANVNLMLELLVQKKKQLEAESHAAQLQILMEFLKVARRNKREQLEQIQKELSVLEEDIKRVEEMSGLYSPVSEDSTVPQFEAPSPSHSSIIDSTEYSQPPGFSGSSQTKKQPWYNSTLASRRKRLTAHFEDLEQCYFSTRMSRISDDSRTASQLDEFQECLSKFTRYNSVRPLATLSYASDLYNGSSIVSSIEFDRDCDYFAIAGVTKKIKVYEYDTVIQDAVDIHYPENEMTCNSKISCISWSSYHKNLLASSDYEGTVILWDGFTGQRSKVYQEHEKRCWSVDFNLMDPKLLASGSDDAKVKLWSTNLDNSVASIEAKANVCCVKFSPSSRYHLAFGCADHCVHYYDLRNTKQPIMVFKGHRKAVSYAKFVSGEEIVSASTDSQLKLWNVGKPYCLRSFKGHINEKNFVGLASNGDYIACGSENNSLYLYYKGLSKTLLTFKFDTVKSVLDKDRKEDDTNEFVSAVCWRALPDGESNVLIAANSQGTIKVLELV T60004 TARGETID T60004 T60004 FORMERID TTDI02656 T60004 UNIPROID CSN5_HUMAN T60004 TARGNAME COPS5 messenger RNA (COPS5 mRNA) T60004 GENENAME COPS5 T60004 TARGTYPE Literature-reported T60004 SYNONYMS Signalosome subunit 5 (mRNA); SGN5 (mRNA); Jun activation domain-binding protein 1 (mRNA); JAB1 (mRNA); CSN5 (mRNA); COP9 signalosome complex subunit 5 (mRNA) T60004 FUNCTION The CSN complex is an essential regulator of the ubiquitin (Ubl) conjugation pathway by mediating the deneddylation of the cullin subunits of the SCF-type E3 ligase complexes, leading to decrease the Ubl ligase activity of SCF-type complexes such as SCF, CSA or DDB2. The complex is also involved in phosphorylation of p53/TP53, c-jun/JUN, IkappaBalpha/NFKBIA, ITPK1 and IRF8, possibly via its association with CK2 and PKD kinases. CSN-dependent phosphorylation of TP53 and JUN promotes and protects degradation by the Ubl system, respectively. In the complex, it probably acts as the catalytic center that mediates the cleavage of Nedd8 from cullins. It however has no metalloprotease activity by itself and requires the other subunits of the CSN complex. Interacts directly with a large number of proteins that are regulated by the CSN complex, confirming a key role in the complex. Promotes the proteasomal degradation of BRSK2. Probable protease subunit of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes. T60004 PDBSTRUC 5M5Q; 5JOH; 5JOG; 4WSN; 4F7O T60004 BIOCLASS mRNA target T60004 ECNUMBER EC 3.4.-.- T60004 SEQUENCE MAASGSGMAQKTWELANNMQEAQSIDEIYKYDKKQQQEILAAKPWTKDHHYFKYCKISALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYEYMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRTISAGKVNLGAFRTYPKGYKPPDEGPSEYQTIPLNKIEDFGVHCKQYYALEVSYFKSSLDRKLLELLWNKYWVNTLSSSSLLTNADYTTGQVFDLSEKLEQSEAQLGRGSFMLGLETHDRKSEDKLAKATRDSCKTTIEAIHGLMSQVIKDKLFNQINIS T85056 TARGETID T85056 T85056 FORMERID TTDR01421 T85056 UNIPROID CYH2_HUMAN T85056 TARGNAME Cytohesin-2 messenger RNA (CYTH2 mRNA) T85056 GENENAME CYTH2 T85056 TARGTYPE Literature-reported T85056 SYNONYMS Protein ARNO (mRNA); PSCD2L (mRNA); PSCD2 (mRNA); PH, SEC7 and coiled-coil domain-containing protein 2 (mRNA); Cytohesin-2 (mRNA); CYTH2 (mRNA); ARNO (mRNA); ARF nucleotide-binding site opener (mRNA); ARF exchange factor (mRNA) T85056 FUNCTION Promotes guanine-nucleotide exchange on ARF1, ARF3 and ARF6. Activates ARF factors through replacement of GDP with GTP. The cell membrane form, in association with ARL4 proteins, recruits ARF6 to the plasma membrane. Involved in neurite growth. Acts as a guanine-nucleotide exchange factor (GEF). T85056 PDBSTRUC 4Z21; 4L5M; 4JXH; 4JWL; 4JMO T85056 BIOCLASS mRNA target T85056 SEQUENCE MEDGVYEPPDLTPEERMELENIRRRKQELLVEIQRLREELSEAMSEVEGLEANEGSKTLQRNRKMAMGRKKFNMDPKKGIQFLVENELLQNTPEEIARFLYKGEGLNKTAIGDYLGEREELNLAVLHAFVDLHEFTDLNLVQALRQFLWSFRLPGEAQKIDRMMEAFAQRYCLCNPGVFQSTDTCYVLSFAVIMLNTSLHNPNVRDKPGLERFVAMNRGINEGGDLPEELLRNLYDSIRNEPFKIPEDDGNDLTHTFFNPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLENLSIREVDDPRKPNCFELYIPNNKGQLIKACKTEADGRVVEGNHMVYRISAPTQEEKDEWIKSIQAAVSVDPFYEMLAARKKRISVKKKQEQP T85056 DRUGINFO D01QNF ISIS 111117 Investigative T85056 DRUGINFO D02GIB ISIS 111119 Investigative T85056 DRUGINFO D05ZKG ISIS 111105 Investigative T85056 DRUGINFO D08JIG ISIS 111086 Investigative T85056 DRUGINFO D0A0VB ISIS 111118 Investigative T85056 DRUGINFO D0F3PC ISIS 111121 Investigative T85056 DRUGINFO D0F8HG ISIS 111120 Investigative T85056 DRUGINFO D0L7DD ISIS 111085 Investigative T85056 DRUGINFO D0Q6XR ISIS 111084 Investigative T14113 TARGETID T14113 T14113 FORMERID TTDR01429 T14113 UNIPROID RDRP_I97A1 T14113 TARGNAME Influenza PB1 messenger RNA (Influ PB1 mRNA) T14113 GENENAME Influ PB1 mRNA T14113 TARGTYPE Literature-reported T14113 SYNONYMS RNA-directed RNA polymerase subunit P1 (mRNA); RNA-directed RNA polymerase catalytic subunit (mRNA); Polymerase basic protein 1 (mRNA) T14113 FUNCTION The transcription of viral mRNAs occurs by a unique mechanism called cap-snatching. 5' methylated caps of cellular mRNAs are cleaved after 10-13 nucleotides by PA. In turn, these short capped RNAs are used as primers by PB1 for transcription of viral mRNAs. During virus replication, PB1 initiates RNA synthesis and copy vRNA into complementary RNA (cRNA) which in turn serves as a template for the production of more vRNAs. RNA-dependent RNA polymerase which is responsible for replication and transcription of virus RNA segments. T14113 PDBSTRUC 3CM8 T14113 BIOCLASS mRNA target T14113 ECNUMBER EC 2.7.7.48 T14113 SEQUENCE MDVNPTLLFLKVPAQNAISTTFPYTGDPPYSHGTGTGYTMDTVNRTHQYSEKGRWTTNTETGAPQLNPIDGPLPEDNEPSGYAQTDCVLEAMAFLEESHPGLFENSCLETMEVVQQTRMDKLTQGRQTYDWTLNRNQPAATALANTIEVFRSNGLTANESGRLIDFLKDVMESMDKEEMEITTHFQRKRRVRDNMTKKMVTQRTIGKKKQRLTKKSYLIRALTLNTMTKDAERGKLKRRAIATPGMQIRGFVHFVEALARSICEKLEQSGLPVGGNEKKAKLANVVRKMMTNSQDTELSFTVTGDNTKWNENQNPRIFLAMITYITRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFESKSMKLRTQIPAEMLANIDLKYFNESTRKKIEKIRPLLVEGTASLSPGMMMGMFNMLSTVLGVSILNLGQKRYTKTTYWWDGLQSSDDFALIVNAPNHEGIQAGVDRFYRTCKLVGINMSKKKSYINRTGTFEFTSFFYRYGFVANFSMELPSFGVSGINESADMSIGVTVIKNNMINNDLGPATAQMALQLFIKDYRYTYRCHRGDTQIQTRRSFELKKLWEQTRSKAGLLVSDGGPNLYNIRNLHIPEVGLKWELMDEDYQGRLCNPLNPFVSHKEVESVNNAVVMPAHGPAKSMEYDAVATTHSWIPKRNRSILNTSQRGILEDEQMYQKCCTLFEKFFPSSSYRRPVGISSMMEAMVSRARIDARIDFESGRIKKEEFAEILKICSTIEELGRQGK T14113 DRUGINFO D0EJ7Q ISIS 3304 Investigative T52796 TARGETID T52796 T52796 FORMERID TTDR01430 T52796 UNIPROID JAG2_HUMAN T52796 TARGNAME Jagged2 messenger RNA (JAG2 mRNA) T52796 GENENAME JAG2 T52796 TARGTYPE Literature-reported T52796 SYNONYMS hJ2 (mRNA); Protein jagged-2 (mRNA); Jagged2 (mRNA) T52796 FUNCTION Involved in limb development. Putative Notch ligand involved in the mediation of Notch signaling. T52796 PDBSTRUC 5MWF; 5MW7; 5MW5 T52796 BIOCLASS mRNA target T52796 SEQUENCE MRAQGRGRLPRRLLLLLALWVQAARPMGYFELQLSALRNVNGELLSGACCDGDGRTTRAGGCGHDECDTYVRVCLKEYQAKVTPTGPCSYGHGATPVLGGNSFYLPPAGAAGDRARARARAGGDQDPGLVVIPFQFAWPRSFTLIVEAWDWDNDTTPNEELLIERVSHAGMINPEDRWKSLHFSGHVAHLELQIRVRCDENYYSATCNKFCRPRNDFFGHYTCDQYGNKACMDGWMGKECKEAVCKQGCNLLHGGCTVPGECRCSYGWQGRFCDECVPYPGCVHGSCVEPWQCNCETNWGGLLCDKDLNYCGSHHPCTNGGTCINAEPDQYRCTCPDGYSGRNCEKAEHACTSNPCANGGSCHEVPSGFECHCPSGWSGPTCALDIDECASNPCAAGGTCVDQVDGFECICPEQWVGATCQLDANECEGKPCLNAFSCKNLIGGYYCDCIPGWKGINCHINVNDCRGQCQHGGTCKDLVNGYQCVCPRGFGGRHCELERDECASSPCHSGGLCEDLADGFHCHCPQGFSGPLCEVDVDLCEPSPCRNGARCYNLEGDYYCACPDDFGGKNCSVPREPCPGGACRVIDGCGSDAGPGMPGTAASGVCGPHGRCVSQPGGNFSCICDSGFTGTYCHENIDDCLGQPCRNGGTCIDEVDAFRCFCPSGWEGELCDTNPNDCLPDPCHSRGRCYDLVNDFYCACDDGWKGKTCHSREFQCDAYTCSNGGTCYDSGDTFRCACPPGWKGSTCAVAKNSSCLPNPCVNGGTCVGSGASFSCICRDGWEGRTCTHNTNDCNPLPCYNGGICVDGVNWFRCECAPGFAGPDCRINIDECQSSPCAYGATCVDEINGYRCSCPPGRAGPRCQEVIGFGRSCWSRGTPFPHGSSWVEDCNSCRCLDGRRDCSKVWCGWKPCLLAGQPEALSAQCPLGQRCLEKAPGQCLRPPCEAWGECGAEEPPSTPCLPRSGHLDNNCARLTLHFNRDHVPQGTTVGAICSGIRSLPATRAVARDRLLVLLCDRASSGASAVEVAVSFSPARDLPDSSLIQGAAHAIVAAITQRGNSSLLLAVTEVKVETVVTGGSSTGLLVPVLCGAFSVLWLACVVLCVWWTRKRRKERERSRLPREESANNQWAPLNPIRNPIERPGGHKDVLYQCKNFTPPPRRADEALPGPAGHAAVREDEEDEDLGRGEEDSLEAEKFLSHKFTKDPGRSPGRPAHWASGPKVDNRAVRSINEARYAGKE T52796 DRUGINFO D0T5NX ISIS 148715 Investigative T70367 TARGETID T70367 T70367 FORMERID TTDR01433 T70367 UNIPROID TLN1_HUMAN T70367 TARGNAME Talin messenger RNA (TLN1 mRNA) T70367 GENENAME TLN1 T70367 TARGTYPE Literature-reported T70367 SYNONYMS Talin-1 (mRNA); TLN (mRNA); KIAA1027 (mRNA) T70367 FUNCTION High molecular weight cytoskeletal protein concentrated at regions of cell-substratum contact and, in lymphocytes, at cell-cell contacts. Probably involved in connections of major cytoskeletal structures to the plasma membrane. T70367 PDBSTRUC 4DJ9; 2MWN; 1SYQ T70367 BIOCLASS mRNA target T70367 SEQUENCE MVALSLKISIGNVVKTMQFEPSTMVYDACRIIRERIPEAPAGPPSDFGLFLSDDDPKKGIWLEAGKALDYYMLRNGDTMEYRKKQRPLKIRMLDGTVKTIMVDDSKTVTDMLMTICARIGITNHDEYSLVRELMEEKKEEITGTLRKDKTLLRDEKKMEKLKQKLHTDDELNWLDHGRTLREQGVEEHETLLLRRKFFYSDQNVDSRDPVQLNLLYVQARDDILNGSHPVSFDKACEFAGFQCQIQFGPHNEQKHKAGFLDLKDFLPKEYVKQKGERKIFQAHKNCGQMSEIEAKVRYVKLARSLKTYGVSFFLVKEKMKGKNKLVPRLLGITKECVMRVDEKTKEVIQEWNLTNIKRWAASPKSFTLDFGDYQDGYYSVQTTEGEQIAQLIAGYIDIILKKKKSKDHFGLEGDEESTMLEDSVSPKKSTVLQQQYNRVGKVEHGSVALPAIMRSGASGPENFQVGSMPPAQQQITSGQMHRGHMPPLTSAQQALTGTINSSMQAVQAAQATLDDFDTLPPLGQDAASKAWRKNKMDESKHEIHSQVDAITAGTASVVNLTAGDPAETDYTAVGCAVTTISSNLTEMSRGVKLLAALLEDEGGSGRPLLQAAKGLAGAVSELLRSAQPASAEPRQNLLQAAGNVGQASGELLQQIGESDTDPHFQDALMQLAKAVASAAAALVLKAKSVAQRTEDSGLQTQVIAAATQCALSTSQLVACTKVVAPTISSPVCQEQLVEAGRLVAKAVEGCVSASQAATEDGQLLRGVGAAATAVTQALNELLQHVKAHATGAGPAGRYDQATDTILTVTENIFSSMGDAGEMVRQARILAQATSDLVNAIKADAEGESDLENSRKLLSAAKILADATAKMVEAAKGAAAHPDSEEQQQRLREAAEGLRMATNAAAQNAIKKKLVQRLEHAAKQAAASATQTIAAAQHAASTPKASAGPQPLLVQSCKAVAEQIPLLVQGVRGSQAQPDSPSAQLALIAASQSFLQPGGKMVAAAKASVPTIQDQASAMQLSQCAKNLGTALAELRTAAQKAQEACGPLEMDSALSVVQNLEKDLQEVKAAARDGKLKPLPGETMEKCTQDLGNSTKAVSSAIAQLLGEVAQGNENYAGIAARDVAGGLRSLAQAARGVAALTSDPAVQAIVLDTASDVLDKASSLIEEAKKAAGHPGDPESQQRLAQVAKAVTQALNRCVSCLPGQRDVDNALRAVGDASKRLLSDSLPPSTGTFQEAQSRLNEAAAGLNQAATELVQASRGTPQDLARASGRFGQDFSTFLEAGVEMAGQAPSQEDRAQVVSNLKGISMSSSKLLLAAKALSTDPAAPNLKSQLAAAARAVTDSINQLITMCTQQAPGQKECDNALRELETVRELLENPVQPINDMSYFGCLDSVMENSKVLGEAMTGISQNAKNGNLPEFGDAISTASKALCGFTEAAAQAAYLVGVSDPNSQAGQQGLVEPTQFARANQAIQMACQSLGEPGCTQAQVLSAATIVAKHTSALCNSCRLASARTTNPTAKRQFVQSAKEVANSTANLVKTIKALDGAFTEENRAQCRAATAPLLEAVDNLSAFASNPEFSSIPAQISPEGRAAMEPIVISAKTMLESAGGLIQTARALAVNPRDPPSWSVLAGHSRTVSDSIKKLITSMRDKAPGQLECETAIAALNSCLRDLDQASLAAVSQQLAPREGISQEALHTQMLTAVQEISHLIEPLANAARAEASQLGHKVSQMAQYFEPLTLAAVGAASKTLSHPQQMALLDQTKTLAESALQLLYTAKEAGGNPKQAAHTQEALEEAVQMMTEAVEDLTTTLNEAASAAGVVGGMVDSITQAINQLDEGPMGEPEGSFVDYQTTMVRTAKAIAVTVQEMVTKSNTSPEELGPLANQLTSDYGRLASEAKPAAVAAENEEIGSHIKHRVQELGHGCAALVTKAGALQCSPSDAYTKKELIECARRVSEKVSHVLAALQAGNRGTQACITAASAVSGIIADLDTTIMFATAGTLNREGTETFADHREGILKTAKVLVEDTKVLVQNAAGSQEKLAQAAQSSVATITRLADVVKLGAASLGAEDPETQVVLINAVKDVAKALGDLISATKAAAGKVGDDPAVWQLKNSAKVMVTNVTSLLKTVKAVEDEATKGTRALEATTEHIRQELAVFCSPEPPAKTSTPEDFIRMTKGITMATAKAVAAGNSCRQEDVIATANLSRRAIADMLRACKEAAYHPEVAPDVRLRALHYGRECANGYLELLDHVLLTLQKPSPELKQQLTGHSKRVAGSVTELIQAAEAMKGTEWVDPEDPTVIAENELLGAAAAIEAAAKKLEQLKPRAKPKEADESLNFEEQILEAAKSIAAATSALVKAASAAQRELVAQGKVGAIPANALDDGQWSQGLISAARMVAAATNNLCEAANAAVQGHASQEKLISSAKQVAASTAQLLVACKVKADQDSEAMKRLQAAGNAVKRASDNLVKAAQKAAAFEEQENETVVVKEKMVGGIAQIIAAQEEMLRKERELEEARKKLAQIRQQQYKFLPSELRDEH T70367 DRUGINFO D01XJR ISIS 109116 Investigative T70367 DRUGINFO D08IDM ISIS 109111 Investigative T70367 DRUGINFO D09JJF ISIS 109113 Investigative T70367 DRUGINFO D0A9EI ISIS 109114 Investigative T70367 DRUGINFO D0E8IK ISIS 109112 Investigative T70367 DRUGINFO D0V2QL ISIS 109110 Investigative T70367 DRUGINFO D0Z8DM ISIS 109115 Investigative T24800 TARGETID T24800 T24800 FORMERID TTDR01434 T24800 UNIPROID TNR11_HUMAN T24800 TARGNAME RANK messenger RNA (RANK mRNA) T24800 GENENAME TNFRSF11A T24800 TARGTYPE Literature-reported T24800 SYNONYMS Tumor necrosis factor receptor superfamily member 11A (mRNA); Receptor activator of NF-KB (mRNA); RANK (mRNA); Osteoclast differentiation factor receptor (mRNA); ODFR (mRNA); CD265 (mRNA) T24800 FUNCTION Involved in the regulation of interactions between T-cells and dendritic cells. Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. T24800 PDBSTRUC 1LB5 T24800 BIOCLASS mRNA target T24800 SEQUENCE MAPRARRRRPLFALLLLCALLARLQVALQIAPPCTSEKHYEHLGRCCNKCEPGKYMSSKCTTTSDSVCLPCGPDEYLDSWNEEDKCLLHKVCDTGKALVAVVAGNSTTPRRCACTAGYHWSQDCECCRRNTECAPGLGAQHPLQLNKDTVCKPCLAGYFSDAFSSTDKCRPWTNCTFLGKRVEHHGTEKSDAVCSSSLPARKPPNEPHVYLPGLIILLLFASVALVAAIIFGVCYRKKGKALTANLWHWINEACGRLSGDKESSGDSCVSTHTANFGQQGACEGVLLLTLEEKTFPEDMCYPDQGGVCQGTCVGGGPYAQGEDARMLSLVSKTEIEEDSFRQMPTEDEYMDRPSQPTDQLLFLTEPGSKSTPPFSEPLEVGENDSLSQCFTGTQSTVGSESCNCTEPLCRTDWTPMSSENYLQKEVDSGHCPHWAASPSPNWADVCTGCRNPPGEDCEPLVGSPKRGPLPQCAYGMGLPPEEEASRTEARDQPEDGADGRLPSSARAGAGSGSSPGGQSPASGNVTGNSNSTFISSGQVMNFKGDIIVVYVSQTSQEGAAAAAEPMGRPVQEETLARRDSFAGNGPRFPDPCGGPEGLREPEKASRPVQEQGGAKA T24800 DRUGINFO D01TAJ ISIS 109525 Investigative T24800 DRUGINFO D02VPR ISIS 109491 Investigative T24800 DRUGINFO D02ZTS ISIS 109526 Investigative T24800 DRUGINFO D07HSU ISIS 109524 Investigative T24800 DRUGINFO D0E8GT ISIS 109502 Investigative T24800 DRUGINFO D0U7AA ISIS 109490 Investigative T96816 TARGETID T96816 T96816 FORMERID TTDR00360 T96816 UNIPROID A0A1C3KAW3_PLAMA T96816 TARGNAME Plasmodium Enopyruvyl shikimate phosphate synthase (Malaria ESPS) T96816 GENENAME Malaria ESPS T96816 TARGTYPE Literature-reported T96816 SYNONYMS aroA of Aeropyrum pernix; Probable 3-phosphoshikimate 1-carboxyvinyltransferase of Aeropyrum pernix; EPSPS of Aeropyrum pernix; EPSP synthase of Aeropyrum pernix; 5-enolpyruvylshikimate-3-phosphate synthase of Aeropyrum pernix T96816 FUNCTION Catalyzes the transfer of the enolpyruvyl moiety of phosphoenolpyruvate (PEP) to the 5-hydroxyl of shikimate-3- phosphate (S3P) to produce enolpyruvyl shikimate-3-phosphate and inorganic phosphate. T96816 BIOCLASS Alkyl aryl transferase T96816 ECNUMBER EC 1.1.1.25 T96816 SEQUENCE MCNKKCGPKCNEKYSEGGRNKGRTTNSSVEMIKHKNILSENKKRNRSDVEKYVQEEYTISDKFKGIIKQMINNHGTGSFEIGNVLIIVLNMKKYHDKSEKCKEFGKMLQEISISSKNELICFADTNIMDLLHFTYHLYFKGAHGTVALHSIEVYILTSLFKTSNAKEHKRGLSEALRLAILNDKNMFIRIKKNDLNYFVKNLKYFLNKCILNIRDIIKKGENNAKYIHVLSFGNTIGNAIKNVIKNSPGCTYINDRDYINYGIFYELKIMYELDAIDMLLLLNIEEIMIKYKLKYKLDSNFVNYYTNDIITYLHKTHSSTTNEIPLVHILNINKIQKNVLVHTPLSIIIKVFYPFICLSPFHNISTTSAQEGEFIGIVNEDRDGMIHTSTTIDMVQKKKEHTIRKINYVYLQGVGNKSEIIRVIYVSTMGRQNVRIENMNLCFDVIVFIKILKDLNFQIFLKKKKSNDIYTNVNRTVIRNCLFINGNVEQTVFLFKNFIFQKKIILNIYNSGTVCRFLLPLLCLYICKQNLKAKEEKKQLLKYIILKGDEQMESHRVINPLVNVVLKCFKYVKIKYLKKKNYLPICIYVKREIHESYTLFCSNDVAIDNYHSSQFVSSMLLISVYSETDTCIRLKFKKIHNCLNRSKKIKVKKEQKKKKITIFRKYIKRKEVSRFKCSYYTMLSICWSCNGKKCNSINKGSTLCCKCSSSPDFNFDENYRHPRKRYNWYNFGYPINEIRNRMNSSNFSTTSKAFIDLTVRVMKLWGVRVKMKRNNYTIKKNEKYLLYSNNNDSTSIRGIAGNRSSIKSRTSNRICRSGGNKNERFNNVHYKYASMINRKHHFNDSRHILFPGIHNKKEKMLVYSLHGRGEKSSKGSCDTCKQKGVDEVKKEVHNNPHEEYNFVMLKQKEKVDQINNKEKEEDKNISNDVTNDGGYTLVKNILRYEINNDLGLYFYFIIGSLIKRQNCVIFLKLNINRMKLKNVGKGYYKIETIDFQKNVLNYFLLNILLLLGINMYINMNDEIRKIYLLTSKRMNIKKKKIIRHLEKAIRNKWKRKNGYYKKRHRNIYTTACYGVNNSTCEHLSQGECTFKYYIFEKIYMKYKIMHFRNVLLKIVVDAEYFSDDFFSICVLFCYYLLTHERENNTELLFKIKNIHNQNIKESIRILNAVLILKICFHNILFIFCDNNSIYITKTHHQIQNCLFFKCKREHWALLCTSSDNNERKNNSSSIGSNSNNGNNNRRSRCKKKLFFNNSKYVINDDQELYLYIDAKKDHRIIFMATILSLIFKNIIIDNSYEVEKSYPHFYEQARKYLEININYVNSDNVKFHNFEEVNNYNILNEQDSKSCVEVISSSIESHESTYSCTDASRSDVDMLKNYKSPTMSTEGNYSINTRSKKLINKHTNCNSLNRPMENNTCTEKNFYKTNGAHIIHKKEANRTHRSTRGNLYFMNHEYWKTSNLNLKNVVMKKTKKCIHRKRAPKGIINLCNLTNPMLQLHTCGSTGSIASEENELTVMRCGERKGIISRKGIFTVSNSGGSDSYSDSYSDSYSDSFMKCNEDPSNERSNECNKDHSNERSNGSSKWFERRGGTEEGYQTKLRLNLRERLRSGKSSSFLNKVKNQLNGDKTNLFLPSDTNYMRTYKYEEVKVNNGNVFYLLKEINNLNVHIICGIRNVGKSYLGHRIENSLVIDIDEYILNGQISFDKLTIDDFRFYEYITFVSALYLSYCLLTLKNYLWANISGSISCNDRGDVWSNIQSSMHGNDDKKDVFLCRAENSKVCINRSCVAVHAYFDNIFFCMGNDIIFYNKKINDLYYNLKNKLLTCKNYDINSITIVLGGGIIEFYKSRQVLKKLKNVVLIKRNKRELCDICINDNVKPKLSGNIKEIINRRTVLFDELNSFHFSIPSEIKISNHIKNLKESRNKLIVSSFINFFNYKFFVKPTILDWGAIRTLSIHLKFFHSFDYELLRSSYDVVEIVYEHIGSTKDGQSEQKDGSGQRGCVEQRGCNERRCRGEELDMGGQHDQRGKNRKYAKNEEKLLALAIFIIRSYTTKPIAVKLHTSIFHAQFFKIKNRCTKLKKDGKKNVAHLFCNNLLNVLYKYKINIVEVDIKFLKVVKYFLAHKKKKANIFFIISKHRNKVNKLKIKSDLNKLNIFHADLIKLTYNYASKSDKEFLSKTINAYNSHRLINTKLSRIKNVYNNTNEEISLYSCYVNNSFVFLYNNVTHLEYQKTNLRNLETGKNSKNIENHNYDENKKNRDFYHNNFMYGFYYQKVKSIISYVPTEGDK T96816 DRUGINFO D04HMD Glyphosate Investigative T10063 TARGETID T10063 T10063 FORMERID TTDNR00723 T10063 UNIPROID GLMM_MYCTA T10063 TARGNAME Mycobacterium Phosphoglucosamine mutase (MycB glmM) T10063 GENENAME MycB glmM T10063 TARGTYPE Literature-reported T10063 SYNONYMS glmM of Mycobacterium tuberculosis T10063 FUNCTION Catalyzes the conversion of glucosamine-6-phosphate to glucosamine-1-phosphate. T10063 BIOCLASS Intramolecular transferases T10063 ECNUMBER EC 5.4.2.10 T10063 SEQUENCE MGRLFGTDGVRGVANRELTAELALALGAAAARRLSRSGAPGRRVAVLGRDPRASGEMLEAAVIAGLTSEGVDALRVGVLPTPAVAYLTGAYDADFGVMISASHNPMPDNGIKIFGPGGHKLDDDTEDQIEDLVLGVSRGPGLRPAGAGIGRVIDAEDATERYLRHVAKAATARLDDLAVVVDCAHGAASSAAPRAYRAAGARVIAINAEPNGRNINDGCGSTHLDPLRAAVLAHRADLGLAHDGDADRCLAVDANGDLVDGDAIMVVLALAMKEAGELACNTLVATVMSNLGLHLAMRSAGVTVRTTAVGDRYVLEELRAGDYSLGGEQSGHIVMPALGSTGDGIVTGLRLMTRMVQTGSSLSDLASAMRTLPQVLINVEVVDKATAAAAPSVRTAVEQAAAELGDTGRILLRPSGTEPMIRVMVEAADEGVAQRLAATVADAVSTAR T47995 TARGETID T47995 T47995 FORMERID TTDR00495 T47995 UNIPROID CLCA1_HUMAN T47995 TARGNAME Calcium-activated chloride channel protein 1 (CaCC-1) T47995 GENENAME CLCA1 T47995 TARGTYPE Literature-reported T47995 SYNONYMS hCaCC-1; hCLCA1; Calcium-activated chloride channel regulator 1; Calcium-activated chloride channel family member 1; CaCC-1; CACC1 T47995 FUNCTION May be involved in mediating calcium-activated chloride conductance. May play critical roles in goblet cell metaplasia, mucus hypersecretion, cystic fibrosis and AHR. May be involved in the regulation of mucus production and/or secretion by goblet cells. Involved in the regulation of tissue inflammation in the innate immune response. May play a role as a tumor suppressor. Induces MUC5AC. T47995 BIOCLASS Voltage-gated ion channel T47995 ECNUMBER EC 3.4.-.- T47995 SEQUENCE MGPFKSSVFILILHLLEGALSNSLIQLNNNGYEGIVVAIDPNVPEDETLIQQIKDMVTQASLYLLEATGKRFYFKNVAILIPETWKTKADYVRPKLETYKNADVLVAESTPPGNDEPYTEQMGNCGEKGERIHLTPDFIAGKKLAEYGPQGRAFVHEWAHLRWGVFDEYNNDEKFYLSNGRIQAVRCSAGITGTNVVKKCQGGSCYTKRCTFNKVTGLYEKGCEFVLQSRQTEKASIMFAQHVDSIVEFCTEQNHNKEAPNKQNQKCNLRSTWEVIRDSEDFKKTTPMTTQPPNPTFSLLQIGQRIVCLVLDKSGSMATGNRLNRLNQAGQLFLLQTVELGSWVGMVTFDSAAHVQNELIQINSGSDRDTLAKRLPAAASGGTSICSGLRSAFTVIRKKYPTDGSEIVLLTDGEDNTISGCFNEVKQSGAIIHTVALGPSAAQELEELSKMTGGLQTYASDQVQNNGLIDAFGALSSGNGAVSQRSIQLESKGLTLQNSQWMNGTVIVDSTVGKDTLFLITWTMQPPQILLWDPSGQKQGGFVVDKNTKMAYLQIPGIAKVGTWKYSLQASSQTLTLTVTSRASNATLPPITVTSKTNKDTSKFPSPLVVYANIRQGASPILRASVTALIESVNGKTVTLELLDNGAGADATKDDGVYSRYFTTYDTNGRYSVKVRALGGVNAARRRVIPQQSGALYIPGWIENDEIQWNPPRPEINKDDVQHKQVCFSRTSSGGSFVASDVPNAPIPDLFPPGQITDLKAEIHGGSLINLTWTAPGDDYDHGTAHKYIIRISTSILDLRDKFNESLQVNTTALIPKEANSEEVFLFKPENITFENGTDLFIAIQAVDKVDLKSEISNIARVSLFIPPQTPPETPSPDETSAPCPNIHINSTIPGIHILKIMWKWIGELQLSIA T36292 TARGETID T36292 T36292 FORMERID TTDI03311 T36292 UNIPROID KCNU1_HUMAN T36292 TARGNAME Calcium-activated potassium channel KCa5.1 (KCNU1) T36292 GENENAME KCNU1 T36292 TARGTYPE Literature-reported T36292 SYNONYMS Slowpoke homolog 3; SLO3; Potassium channel subfamily U member 1; KCa5; KCNMC1; KCNMA3; Calcium-activated potassium channel, subfamily M subunit alpha-3; Calcium-activated potassium channel subunit alpha-3 T36292 FUNCTION Testis-specific potassium channel activated by both intracellular pH and membrane voltage that mediates export of K(+). May represent the primary spermatozoan K(+) current. In contrast to KCNMA1/SLO1, it is not activated by Ca(2+) or Mg(2+). Critical for fertility. May play an important role in sperm osmoregulation required for the acquisition of normal morphology and motility when faced with osmotic challenges, such as those experienced after mixing with seminal fluid and entry into the vagina. T36292 PDBSTRUC 4HPF T36292 BIOCLASS Voltage-gated ion channel T36292 SEQUENCE MFQTKLRNETWEDLPKMSCTTEIQAAFILSSFVTFFSGLIILLIFRLIWRSVKKWQIIKGTGIILELFTSGTIARSHVRSLHFQGQFRDHIEMLLSAQTFVGQVLVILVFVLSIGSLIIYFINSADPVGSCSSYEDKTIPIDLVFNAFFSFYFGLRFMAADDKIKFWLEMNSIVDIFTIPPTFISYYLKSNWLGLRFLRALRLLELPQILQILRAIKTSNSVKFSKLLSIILSTWFTAAGFIHLVENSGDPWLKGRNSQNISYFESIYLVMATTSTVGFGDVVAKTSLGRTFIMFFTLGSLILFANYIPEMVELFANKRKYTSSYEALKGKKFIVVCGNITVDSVTAFLRNFLRDKSGEINTEIVFLGETPPSLELETIFKCYLAYTTFISGSAMKWEDLRRVAVESAEACLIIANPLCSDSHAEDISNIMRVLSIKNYDSTTRIIIQILQSHNKVYLPKIPSWNWDTGDNIICFAELKLGFIAQGCLVPGLCTFLTSLFVEQNKKVMPKQTWKKHFLNSMKNKILTQRLSDDFAGMSFPEVARLCFLKMHLLLIAIEYKSLFTDGFCGLILNPPPQVRIRKNTLGFFIAETPKDVRRALFYCSVCHDDVFIPELITNCGCKSRSRQHITVPSVKRMKKCLKGISSRISGQDSPPRVSASTSSISNFTTRTLQHDVEQDSDQLDSSGMFHWCKPTSLDKVTLKRTGKSKYKFRNHIVACVFGDAHSAPMGLRNFVMPLRASNYTRKELKDIVFIGSLDYLQREWRFLWNFPQIYILPGCALYSGDLHAANIEQCSMCAVLSPPPQPSSNQTLVDTEAIMATLTIGSLQIDSSSDPSPSVSEETPGYTNGHNEKSNCRKVPILTELKNPSNIHFIEQLGGLEGSLQETNLHLSTAFSTGTVFSGSFLDSLLATAFYNYHVLELLQMLVTGGVSSQLEQHLDKDKVYGVADSCTSLLSGRNRCKLGLLSLHETILSDVNPRNTFGQLFCGSLDLFGILCVGLYRIIDEEELNPENKRFVITRPANEFKLLPSDLVFCAIPFSTACYKRNEEFSLQKSYEIVNKASQTTETHSDTNCPPTIDSVTETLYSPVYSYQPRTNSLSFPKQIAWNQSRTNSIISSQIPLGDNAKENERKTSDEVYDEDPFAYSEPL T36292 DRUGINFO D0O2TC iberiotoxin Investigative T36292 DRUGINFO D06PZZ [14C]TEA Investigative T70065 TARGETID T70065 T70065 FORMERID TTDR00167 T70065 UNIPROID A9CSR1_PLAFA T70065 TARGNAME Plasmodium Dihydroorotase (Malaria dho) T70065 GENENAME Malaria dho T70065 TARGTYPE Literature-reported T70065 SYNONYMS Dihydroorotase T70065 FUNCTION A Zn2+ amidohydrolase superfamily that catalyzes reversible cyclization of N-carbamoyl-L-aspartate (L-CA) to form L-dihydroorotate (L-DHO). T70065 BIOCLASS Carbon-nitrogen hydrolase T70065 ECNUMBER EC 3.5.2.3 T70065 SEQUENCE MKNYFYIPIADDMHCHLRQGDMLDFTVNSIRRGGCNRVLVMPNTHPIISTCSDAQKYLYQLKSRDDDIEYLMTLYLNKNTDENDILSNYYKCNLQGVKIYPSNVTTNSSDGITSLEPYYKVFHALEKLNKSIHIHCEEPNINPLYAEEKYLPHIHDLAIKFPGLNIVLEHISSSESINVIKEFRNVAGSITPHHLYLTIDDVVNMDIYDHAIDNTYIEKYIKNTYHYCKPLPKLLEDKIALQDVIKDDFPRVFLGSDSAPHYKVMKRKPYYKPGIYTQPFLINYVAHILNKFDALDKMENFTSKNASLFLNLAEKKKLAKYYICVEKHPFKLPREYNGVVPFLAGKTLDYDIHYVSKF T70065 DRUGINFO D0DN4W 5-bromo orotate Investigative T70065 DRUGINFO D0E1IO N-Carbamoyl-L-Aspartate Investigative T70065 DRUGINFO D0J2FJ 5-iodo orotate Investigative T70065 DRUGINFO D0S7BE 5-methyl orotate Investigative T70065 DRUGINFO D0AZ4T Dihydroorotate Investigative T70065 DRUGINFO D0B1TS Orotate Investigative T70065 DRUGINFO D0E2WX 5-Fluoro orotate Investigative T70065 DRUGINFO D0CC0B Lysine Nz-Carboxylic Acid Investigative T17814 TARGETID T17814 T17814 FORMERID TTDI02150 T17814 UNIPROID PGRC1_HUMAN T17814 TARGNAME Opioid receptor sigma 2 (PGRMC1) T17814 GENENAME PGRMC1 T17814 TARGTYPE Literature-reported T17814 SYNONYMS mPR; PGRMC; Membraneassociated progesterone receptor component 1; Membrane-associated progesterone receptor component 1; IZA; HPR6.6; Dap1 T17814 FUNCTION Binds progesterone. Has many reported cellular functions (heme homeostasis, interaction with CYPs). Component of a progesterone-binding protein complex. T17814 PDBSTRUC 4X8Y T17814 BIOCLASS GPCR rhodopsin T17814 SEQUENCE MAAEDVVATGADPSDLESGGLLHEIFTSPLNLLLLGLCIFLLYKIVRGDQPAASGDSDDDEPPPLPRLKRRDFTPAELRRFDGVQDPRILMAINGKVFDVTKGRKFYGPEGPYGVFAGRDASRGLATFCLDKEALKDEYDDLSDLTAAQQETLSDWESQFTFKYHHVGKLLKEGEEPTVYSDEEEPKDESARKND T13902 TARGETID T13902 T13902 FORMERID TTDI00024 T13902 UNIPROID NR5A2_HUMAN T13902 TARGNAME Liver receptor homolog-1 (NR5A2) T13902 GENENAME NR5A2 T13902 TARGTYPE Literature-reported T13902 SYNONYMS LRH1; CYP7A promoterbinding factor; B1binding factor; Alpha1fetoprotein transcription factor T13902 FUNCTION Together with the oxysterol receptors NR1H3/LXR-alpha and NR1H2/LXR-beta, acts as an essential transcriptional regulator of lipid metabolism. Plays an anti-inflammatory role during the hepatic acute phase response by acting as a corepressor: inhibits the hepatic acute phase response by preventing dissociation of the N-Cor corepressor complex. Binds to the sequence element 5'-AACGACCGACCTTGAG-3' of the enhancer II of hepatitis B virus genes, a critical cis-element of their expression and regulation. May be responsible for the liver-specific activity of enhancer II, probably in combination with other hepatocyte transcription factors. Key regulator of cholesterol 7-alpha-hydroxylase gene (CYP7A) expression in liver. May also contribute to the regulation of pancreas-specific genes and play important roles in embryonic development. Activates the transcription of CYP2C38. Nuclear receptor that acts as a key metabolic sensor by regulating the expression of genes involved in bile acid synthesis, cholesterol homeostasis and triglyceride synthesis. T13902 PDBSTRUC 5UNJ; 5SYZ; 5L11; 5L0M; 4RWV T13902 BIOCLASS Nuclear hormone receptor T13902 SEQUENCE MSSNSDTGDLQESLKHGLTPIGAGLPDRHGSPIPARGRLVMLPKVETEALGLARSHGEQGQMPENMQVSQFKMVNYSYDEDLEELCPVCGDKVSGYHYGLLTCESCKGFFKRTVQNNKRYTCIENQNCQIDKTQRKRCPYCRFQKCLSVGMKLEAVRADRMRGGRNKFGPMYKRDRALKQQKKALIRANGLKLEAMSQVIQAMPSDLTISSAIQNIHSASKGLPLNHAALPPTDYDRSPFVTSPISMTMPPHGSLQGYQTYGHFPSRAIKSEYPDPYTSSPESIMGYSYMDSYQTSSPASIPHLILELLKCEPDEPQVQAKIMAYLQQEQANRSKHEKLSTFGLMCKMADQTLFSIVEWARSSIFFRELKVDDQMKLLQNCWSELLILDHIYRQVVHGKEGSIFLVTGQQVDYSIIASQAGATLNNLMSHAQELVAKLRSLQFDQREFVCLKFLVLFSLDVKNLENFQLVEGVQEQVNAALLDYTMCNYPQQTEKFGQLLLRLPEIRAISMQAEEYLYYKHLNGDVPYNNLLIEMLHAKRA T53975 TARGETID T53975 T53975 FORMERID TTDR00534 T53975 UNIPROID CXCR6_HUMAN T53975 TARGNAME C-X-C chemokine receptor type 6 (CXCR6) T53975 GENENAME CXCR6 T53975 TARGTYPE Literature-reported T53975 SYNONYMS TYMSTR; STRL33; G-protein coupled receptor bonzo; G-protein coupled receptor STRL33; G protein-coupled receptor bonzo; G protein-coupled receptor STRL33; Chemokine receptor CXCR6; CXCR-6; CXC-R6; CDw186; CD186; BONZO T53975 FUNCTION Used as a coreceptor by SIVs and by strains of HIV-2 and m-tropic HIV-1. Receptor for the C-X-C chemokine CXCL16. T53975 BIOCLASS GPCR rhodopsin T53975 SEQUENCE MAEHDYHEDYGFSSFNDSSQEEHQDFLQFSKVFLPCMYLVVFVCGLVGNSLVLVISIFYHKLQSLTDVFLVNLPLADLVFVCTLPFWAYAGIHEWVFGQVMCKSLLGIYTINFYTSMLILTCITVDRFIVVVKATKAYNQQAKRMTWGKVTSLLIWVISLLVSLPQIIYGNVFNLDKLICGYHDEAISTVVLATQMTLGFFLPLLTMIVCYSVIIKTLLHAGGFQKHRSLKIIFLVMAVFLLTQMPFNLMKFIRSTHWEYYAMTSFHYTIMVTEAIAYLRACLNPVLYAFVSLKFRKNFWKLVKDIGCLPYLGVSHQWKSSEDNSKTFSASHNVEATSMFQL T53975 DRUGINFO D00RXS AMD3101 Investigative T93237 TARGETID T93237 T93237 FORMERID TTDNR00654 T93237 UNIPROID CCL21_HUMAN T93237 TARGNAME Secondary lymphoid-tissue chemokine (CCL21) T93237 GENENAME CCL21 T93237 TARGTYPE Literature-reported T93237 SYNONYMS UNQ784/PRO1600; Small-inducible cytokine A21; SLC; SCYA21; C-C motif chemokine 21; Beta-chemokine exodus-2; 6Ckine T93237 FUNCTION Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4. Inhibits hemopoiesis and stimulates chemotaxis. T93237 PDBSTRUC 5EKI; 2L4N T93237 BIOCLASS Cytokine: CC chemokine T93237 SEQUENCE MAQSLALSLLILVLAFGIPRTQGSDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSKGCKRTERSQTPKGP T82183 TARGETID T82183 T82183 FORMERID TTDR00726 T82183 UNIPROID LEP_STRPN T82183 TARGNAME Streptococcus Signal peptidase I (Stre-coc lepB) T82183 GENENAME Stre-coc lepB T82183 TARGTYPE Literature-reported T82183 SYNONYMS Signal peptidase I; SPase I; Leader peptidase I T82183 FUNCTION Cleavage of hydrophobic, N-terminal signal or leader sequences from secreted and periplasmic proteins. T82183 BIOCLASS Peptidase T82183 ECNUMBER EC 3.4.21.89 T82183 SEQUENCE MNSFKNFLKEWGLFLLILSLLALSRIFFWSNVRVEGHSMDPTLADGEILFVVKHLPIDRFDIVVAHEEDGNKDIVKRVIGMPGDTIRYENDKLYINDKETDEPYLADYIKRFKDDKLQSTYSGKGFEGNKGTFFRSIAQKAQAFTVDVNYNTNFSFTVPEGEYLLLGDDRLVSSDSRHVGTFKAKDITGEAKFRLWPITRIGTF T22604 TARGETID T22604 T22604 FORMERID TTDR00609 T22604 UNIPROID CET1_YEAST T22604 TARGNAME Fungal RNA triphosphatase (Fung CET1) T22604 GENENAME Fung CET1 T22604 TARGTYPE Literature-reported T22604 SYNONYMS TPase; Polynucleotide 5'-triphosphatase; MRNA capping enzyme beta subunit; MRNA 5'-triphosphatase; CET1 T22604 FUNCTION First step of mRNA capping. Converts the 5'-triphosphate end of a nascent mRNA chain into a diphosphate end. T22604 PDBSTRUC 3KYH; 1D8I; 1D8H T22604 BIOCLASS Phosphoric monoester hydrolase T22604 SEQUENCE MSYTDNPPQTKRALSLDDLVNHDENEKVKLQKLSEAANGSRPFAENLESDINQTETGQAAPIDNYKESTGHGSHSQKPKSRKSSNDDEETDTDDEMGASGEINFDSEMDFDYDKQHRNLLSNGSPPMNDGSDANAKLEKPSDDSIHQNSKSDEEQRIPKQGNEGNIASNYITQVPLQKQKQTEKKIAGNAVGSVVKKEEEANAAVDNIFEEKATLQSKKNNIKRDLEVLNEISASSKPSKYRNVPIWAQKWKPTIKALQSINVKDLKIDPSFLNIIPDDDLTKSVQDWVYATIYSIAPELRSFIELEMKFGVIIDAKGPDRVNPPVSSQCVFTELDAHLTPNIDASLFKELSKYIRGISEVTENTGKFSIIESQTRDSVYRVGLSTQRPRFLRMSTDIKTGRVGQFIEKRHVAQLLLYSPKDSYDVKISLNLELPVPDNDPPEKYKSQSPISERTKDRVSYIHNDSCTRIDITKVENHNQNSKSRQSETTHEVELEINTPALLNAFDNITNDSKEYASLIRTFLNNGTIIRRKLSSLSYEIFEGSKKVM T94438 TARGETID T94438 T94438 UNIPROID AQP7_HUMAN T94438 TARGNAME Aquaporin-7 (AQP7) T94438 GENENAME AQP7 T94438 TARGTYPE Literature-reported T94438 SYNONYMS Aquaporin-7-like; Aquaporin adipose; Aquaglyceroporin-7; AQPap; AQP7L; AQP-7 T94438 FUNCTION Forms a channel for water and glycerol. T94438 BIOCLASS Major intrinsic protein T94438 SEQUENCE MVQASGHRRSTRGSKMVSWSVIAKIQEILQRKMVREFLAEFMSTYVMMVFGLGSVAHMVLNKKYGSYLGVNLGFGFGVTMGVHVAGRISGAHMNAAVTFANCALGRVPWRKFPVYVLGQFLGSFLAAATIYSLFYTAILHFSGGQLMVTGPVATAGIFATYLPDHMTLWRGFLNEAWLTGMLQLCLFAITDQENNPALPGTEALVIGILVVIIGVSLGMNTGYAINPSRDLPPRIFTFIAGWGKQVFSNGENWWWVPVVAPLLGAYLGGIIYLVFIGSTIPREPLKLEDSVAYEDHGITVLPKMGSHEPTISPLTPVSVSPANRSSVHPAPPLHESMALEHF T68465 TARGETID T68465 T68465 FORMERID TTDI01444 T68465 UNIPROID CXL11_HUMAN T68465 TARGNAME C-X-C motif chemokine 11 (CXCL11) T68465 GENENAME CXCL11 T68465 TARGTYPE Literature-reported T68465 SYNONYMS Small-inducible cytokine B11; SCYB9B; SCYB11; Interferon-inducible T-cell alpha chemoattractant; Interferon gamma-inducible protein 9; ITAC; IP-9; I-TAC; H174; Beta-R1 T68465 FUNCTION Induces calcium release in activated T-cells. Binds to CXCR3. May play an important role in CNS diseases which involve T-cell recruitment. May play a role in skin immune responses. Chemotactic for interleukin-activated T-cells but not unstimulated T-cells, neutrophils or monocytes. T68465 PDBSTRUC 1RJT T68465 BIOCLASS Cytokine: CXC chemokine T68465 SEQUENCE MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVADIEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKNF T56057 TARGETID T56057 T56057 FORMERID TTDI03364 T56057 UNIPROID KDM6B_HUMAN T56057 TARGNAME Lysine-specific demethylase 6B (KDM6B) T56057 GENENAME KDM6B T56057 TARGTYPE Literature-reported T56057 SYNONYMS Lysine demethylase 6B; KIAA0346; Jumonji domain-containing protein 3; JmjC domain-containing protein 3; JMJD3 T56057 FUNCTION Histone demethylase that specifically demethylates 'Lys-27' of histone H3, thereby playing a central role in histone code. Demethylates trimethylated and dimethylated H3 'Lys-27'. Plays a central role in regulation of posterior development, by regulating HOX gene expression. Involved in inflammatory response by participating in macrophage differentiation in case of inflammation by regulating gene expression and macrophage differentiation. Plays a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression by acting as a link between T-box factors and the SMARCA4-containing SWI/SNF remodeling complex (By similarity). T56057 PDBSTRUC 6F6D; 5OY3; 5FP3; 4ASK; 2XXZ T56057 ECNUMBER EC 1.14.11.- T56057 SEQUENCE MHRAVDPPGARAAREAFALGGLSCAGAWSSCPPHPPPRSAWLPGGRCSASIGQPPLPAPLPPSHGSSSGHPSKPYYAPGAPTPRPLHGKLESLHGCVQALLREPAQPGLWEQLGQLYESEHDSEEATRCYHSALRYGGSFAELGPRIGRLQQAQLWNFHTGSCQHRAKVLPPLEQVWNLLHLEHKRNYGAKRGGPPVKRAAEPPVVQPVPPAALSGPSGEEGLSPGGKRRRGCNSEQTGLPPGLPLPPPPLPPPPPPPPPPPPPLPGLATSPPFQLTKPGLWSTLHGDAWGPERKGSAPPERQEQRHSLPHPYPYPAPAYTAHPPGHRLVPAAPPGPGPRPPGAESHGCLPATRPPGSDLRESRVQRSRMDSSVSPAATTACVPYAPSRPPGLPGTTTSSSSSSSSNTGLRGVEPNPGIPGADHYQTPALEVSHHGRLGPSAHSSRKPFLGAPAATPHLSLPPGPSSPPPPPCPRLLRPPPPPAWLKGPACRAAREDGEILEELFFGTEGPPRPAPPPLPHREGFLGPPASRFSVGTQDSHTPPTPPTPTTSSSNSNSGSHSSSPAGPVSFPPPPYLARSIDPLPRPPSPAQNPQDPPLVPLTLALPPAPPSSCHQNTSGSFRRPESPRPRVSFPKTPEVGPGPPPGPLSKAPQPVPPGVGELPARGPRLFDFPPTPLEDQFEEPAEFKILPDGLANIMKMLDESIRKEEEQQQHEAGVAPQPPLKEPFASLQSPFPTDTAPTTTAPAVAVTTTTTTTTTTTATQEEEKKPPPALPPPPPLAKFPPPSQPQPPPPPPPSPASLLKSLASVLEGQKYCYRGTGAAVSTRPGPLPTTQYSPGPPSGATALPPTSAAPSAQGSPQPSASSSSQFSTSGGPWARERRAGEEPVPGPMTPTQPPPPLSLPPARSESEVLEEISRACETLVERVGRSATDPADPVDTAEPADSGTERLLPPAQAKEEAGGVAAVSGSCKRRQKEHQKEHRRHRRACKDSVGRRPREGRAKAKAKVPKEKSRRVLGNLDLQSEEIQGREKSRPDLGGASKAKPPTAPAPPSAPAPSAQPTPPSASVPGKKAREEAPGPPGVSRADMLKLRSLSEGPPKELKIRLIKVESGDKETFIASEVEERRLRMADLTISHCAADVVRASRNAKVKGKFRESYLSPAQSVKPKINTEEKLPREKLNPPTPSIYLESKRDAFSPVLLQFCTDPRNPITVIRGLAGSLRLNLGLFSTKTLVEASGEHTVEVRTQVQQPSDENWDLTGTRQIWPCESSRSHTTIAKYAQYQASSFQESLQEEKESEDEESEEPDSTTGTPPSSAPDPKNHHIIKFGTNIDLSDAKRWKPQLQELLKLPAFMRVTSTGNMLSHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFAVHEHYWETISAFCDRHGVDYLTGSWWPILDDLYASNIPVYRFVQRPGDLVWINAGTVHWVQATGWCNNIAWNVGPLTAYQYQLALERYEWNEVKNVKSIVPMIHVSWNVARTVKISDPDLFKMIKFCLLQSMKHCQVQRESLVRAGKKIAYQGRVKDEPAYYCNECDVEVFNILFVTSENGSRNTYLVHCEGCARRRSAGLQGVVVLEQYRTEELAQAYDAFTLAPASTSR T56057 DRUGINFO D0S3DD GSK-J1 Investigative T56057 DRUGINFO D0X5US IOX1 Investigative T32821 TARGETID T32821 T32821 FORMERID TTDR00924 T32821 UNIPROID PLCB_HUMAN T32821 TARGNAME Lysophosphatidic acid acyltransferase beta (LPAATB) T32821 GENENAME AGPAT2 T32821 TARGTYPE Literature-reported T32821 SYNONYMS Lysophosphatidic acid acyltransferase-beta; LPAAT-beta; AGPAT2; 1-acylglycerol-3-phosphate O-acyltransferase 2; 1-AGPAT 2; 1-AGP acyltransferase 2 T32821 FUNCTION Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. T32821 BIOCLASS Acyltransferase T32821 ECNUMBER EC 2.3.1.51 T32821 SEQUENCE MELWPCLAAALLLLLLLVQLSRAAEFYAKVALYCALCFTVSAVASLVCLLRHGGRTVENMSIIGWFVRSFKYFYGLRFEVRDPRRLQEARPCVIVSNHQSILDMMGLMEVLPERCVQIAKRELLFLGPVGLIMYLGGVFFINRQRSSTAMTVMADLGERMVRENLKVWIYPEGTRNDNGDLLPFKKGAFYLAVQAQVPIVPVVYSSFSSFYNTKKKFFTSGTVTVQVLEAIPTSGLTAADVPALVDTCHRAMRTTFLHISKTPQENGATAGSGVQPAQ T50914 TARGETID T50914 T50914 FORMERID TTDI02578 T50914 UNIPROID PPM1D_HUMAN T50914 TARGNAME Protein phosphatase 1D (PPM1D) T50914 GENENAME PPM1D T50914 TARGTYPE Literature-reported T50914 SYNONYMS p53-induced protein phosphatase 1; WIP1; Protein phosphatase magnesium-dependent 1 delta; Protein phosphatase 2C isoform delta; PP2C-delta T50914 FUNCTION Required for the relief of p53-dependent checkpoint mediated cell cycle arrest. Binds to and dephosphorylates 'Ser-15' of TP53 and 'Ser-345' of CHEK1 which contributes to the functional inactivation of these proteins. Mediates MAPK14 dephosphorylation and inactivation. Is also an important regulator of global heterochromatin silencing and critical in maintaining genome integrity. Involved in the negative regulation of p53 expression. T50914 BIOCLASS Phosphoric monoester hydrolase T50914 ECNUMBER EC 3.1.3.16 T50914 SEQUENCE MAGLYSLGVSVFSDQGGRKYMEDVTQIVVEPEPTAEEKPSPRRSLSQPLPPRPSPAALPGGEVSGKGPAVAAREARDPLPDAGASPAPSRCCRRRSSVAFFAVCDGHGGREAAQFAREHLWGFIKKQKGFTSSEPAKVCAAIRKGFLACHLAMWKKLAEWPKTMTGLPSTSGTTASVVIIRGMKMYVAHVGDSGVVLGIQDDPKDDFVRAVEVTQDHKPELPKERERIEGLGGSVMNKSGVNRVVWKRPRLTHNGPVRRSTVIDQIPFLAVARALGDLWSYDFFSGEFVVSPEPDTSVHTLDPQKHKYIILGSDGLWNMIPPQDAISMCQDQEEKKYLMGEHGQSCAKMLVNRALGRWRQRMLRADNTSAIVICISPEVDNQGNFTNEDELYLNLTDSPSYNSQETCVMTPSPCSTPPVKSLEEDPWPRVNSKDHIPALVRSNAFSENFLEVSAEIARENVQGVVIPSKDPEPLEENCAKALTLRIHDSLNNSLPIGLVPTNSTNTVMDQKNLKMSTPGQMKAQEIERTPPTNFKRTLEESNSGPLMKKHRRNGLSRSSGAQPASLPTTSQRKNSVKLTMRRRLRGQKKIGNPLLHQHRKTVCVC T14306 TARGETID T14306 T14306 FORMERID TTDI02464 T14306 UNIPROID CFLAR_HUMAN T14306 TARGNAME CASP8-FADD-like regulator (CFLAR) T14306 GENENAME CFLAR T14306 TARGTYPE Literature-reported T14306 SYNONYMS cFLIP; c-FLIP; Usurpin; MRIT; MACHrelated inducer of toxicity; MACH-related inducer of toxicity; Inhibitor of FLICE; IFLICE; I-FLICE; FLAME1; FLAME-1; FADDlike antiapoptotic molecule 1; FADD-like antiapoptotic molecule 1; Cellular FLICElike inhibitory protein; Cellular FLICE-like inhibitory protein; Casper; Caspaselike apoptosis regulatory protein; Caspaseeightrelated protein; Caspase-like apoptosis regulatory protein; Caspase-eight-related protein; Caspase homolog; CLARP; CASP8AP1; CASP8 and FADDlike apoptosis regulator subunit p12; CASP8 and FADDlike apoptosis regulator; CASP8 and FADD-like apoptosis regulator; CASH T14306 FUNCTION Acts as an inhibitor of TNFRSF6 mediated apoptosis. A proteolytic fragment (p43) is likely retained in the death-inducing signaling complex (DISC) thereby blocking further recruitment and processing of caspase-8 at the complex. Full length and shorter isoforms have been shown either to induce apoptosis or to reduce TNFRSF-triggered apoptosis. Lacks enzymatic (caspase) activity. Apoptosis regulator protein which may function as a crucial link between cell survival and cell death pathways in mammalian cells. T14306 PDBSTRUC 3H13; 3H11; 2N5R T14306 BIOCLASS Peptidase T14306 SEQUENCE MSAEVIHQVEEALDTDEKEMLLFLCRDVAIDVVPPNVRDLLDILRERGKLSVGDLAELLYRVRRFDLLKRILKMDRKAVETHLLRNPHLVSDYRVLMAEIGEDLDKSDVSSLIFLMKDYMGRGKISKEKSFLDLVVELEKLNLVAPDQLDLLEKCLKNIHRIDLKTKIQKYKQSVQGAGTSYRNVLQAAIQKSLKDPSNNFRLHNGRSKEQRLKEQLGAQQEPVKKSIQESEAFLPQSIPEERYKMKSKPLGICLIIDCIGNETELLRDTFTSLGYEVQKFLHLSMHGISQILGQFACMPEHRDYDSFVCVLVSRGGSQSVYGVDQTHSGLPLHHIRRMFMGDSCPYLAGKPKMFFIQNYVVSEGQLEDSSLLEVDGPAMKNVEFKAQKRGLCTVHREADFFWSLCTADMSLLEQSHSSPSLYLQCLSQKLRQERKRPLLDLHIELNGYMYDWNSRVSAKEKYYVWLQHTLRKKLILSYT T88531 TARGETID T88531 T88531 FORMERID TTDI02513 T88531 UNIPROID GPR39_HUMAN T88531 TARGNAME G-protein coupled receptor 39 (GPR39) T88531 GENENAME GPR39 T88531 TARGTYPE Literature-reported T88531 SYNONYMS Gprotein coupled receptor 39; GPR39 T88531 FUNCTION Zn(2+) acts as a agonist. Thisreceptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated mainly through G(q)-alpha and G(12)/G(13) proteins. Involved in regulation of body weight, gastrointestinal mobility, hormone secretion and cell death. T88531 BIOCLASS GPCR rhodopsin T88531 SEQUENCE MASPSLPGSDCSQIIDHSHVPEFEVATWIKITLILVYLIIFVMGLLGNSATIRVTQVLQKKGYLQKEVTDHMVSLACSDILVFLIGMPMEFYSIIWNPLTTSSYTLSCKLHTFLFEACSYATLLHVLTLSFERYIAICHPFRYKAVSGPCQVKLLIGFVWVTSALVALPLLFAMGTEYPLVNVPSHRGLTCNRSSTRHHEQPETSNMSICTNLSSRWTVFQSSIFGAFVVYLVVLLSVAFMCWNMMQVLMKSQKGSLAGGTRPPQLRKSESEESRTARRQTIIFLRLIVVTLAVCWMPNQIRRIMAAAKPKHDWTRSYFRAYMILLPFSETFFYLSSVINPLLYTVSSQQFRRVFVQVLCCRLSLQHANHEKRLRVHAHSTTDSARFVQRPLLFASRRQSSARRTEKIFLSTFQSEAEPQSKSQSLSLESLEPNSGAKPANSAAENGFQEHEV T88531 DRUGINFO D0E1HY GPCR39 pepducins Investigative T88531 DRUGINFO D0H4UN PMID24900608C1 Investigative T88531 DRUGINFO D0V6KN PMID25313322C15 Investigative T60744 TARGETID T60744 T60744 FORMERID TTDR00119 T60744 UNIPROID OREX_HUMAN T60744 TARGNAME Orexin (HCRT) T60744 GENENAME HCRT T60744 TARGTYPE Literature-reported T60744 SYNONYMS Hypocretin; Hcrt T60744 FUNCTION Neuropeptides that play a significant role in the regulationof food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. A broader role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids, is also suggested. Orexin-A binds to both OX1R and OX2R with a high affinity, whereas orexin-B binds only to OX2R with a similar high affinity. T60744 PDBSTRUC 1WSO; 1UVQ; 1R02; 1CQ0 T60744 SEQUENCE MNLPSTKVSWAAVTLLLLLLLLPPALLSSGAAAQPLPDCCRQKTCSCRLYELLHGAGNHAAGILTLGKRRSGPPGLQGRLQRLLQASGNHAAGILTMGRRAGAEPAPRPCLGRRCSAPAAASVAPGGQSGI T60744 DRUGINFO D0U7QA Pyroglutamic Acid Investigative T97637 TARGETID T97637 T97637 UNIPROID LANC1_HUMAN T97637 TARGNAME Glutathione S-transferase LANCL1 (LANCL1) T97637 GENENAME LANCL1 T97637 TARGTYPE Literature-reported T97637 SYNONYMS p40; LanC-like protein 1; GPR69A; 40 kDa erythrocyte membrane protein T97637 FUNCTION Functions as glutathione transferase. Catalyzes conjugation of the glutathione (GSH) to artificial substrates 1-chloro-2,4-dinitrobenzene (CDNB) and p-nitrophenyl acetate. Mitigates neuronal oxidative stress during normal postnatal development and in response to oxidative stresses probably through GSH antioxidant defense mechanism (By similarity). May play a role in EPS8 signaling. Binds glutathione. T97637 PDBSTRUC 3E6U; 3.00E+73 T97637 ECNUMBER EC 2.5.1.18 T97637 SEQUENCE MAQRAFPNPYADYNKSLAEGYFDAAGRLTPEFSQRLTNKIRELLQQMERGLKSADPRDGTGYTGWAGIAVLYLHLYDVFGDPAYLQLAHGYVKQSLNCLTKRSITFLCGDAGPLAVAAVLYHKMNNEKQAEDCITRLIHLNKIDPHAPNEMLYGRIGYIYALLFVNKNFGVEKIPQSHIQQICETILTSGENLARKRNFTAKSPLMYEWYQEYYVGAAHGLAGIYYYLMQPSLQVSQGKLHSLVKPSVDYVCQLKFPSGNYPPCIGDNRDLLVHWCHGAPGVIYMLIQAYKVFREEKYLCDAYQCADVIWQYGLLKKGYGLCHGSAGNAYAFLTLYNLTQDMKYLYRACKFAEWCLEYGEHGCRTPDTPFSLFEGMAGTIYFLADLLVPTKARFPAFEL T47306 TARGETID T47306 T47306 FORMERID TTDR01132 T47306 UNIPROID G6PT1_HUMAN T47306 TARGNAME Glucose-6-phosphate translocase (SLC37A4) T47306 GENENAME SLC37A4 T47306 TARGTYPE Literature-reported T47306 SYNONYMS Transformation-related gene 19 protein; TRG19; TRG-19; Solute carrier family 37 member 4; PRO0685; Glucose-6-phosphate exchanger SLC37A4; Glucose-5-phosphate transporter; Glucose 5-phosphate transporter; G6PT1 T47306 FUNCTION Transports cytoplasmic glucose-6-phosphate into the lumen of the endoplasmic reticulum and translocates inorganic phosphate into the opposite direction. Forms with glucose-6-phosphatase the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it plays a central role in homeostatic regulation of blood glucose levels. Inorganic phosphate and glucose-6-phosphate antiporter of the endoplasmic reticulum. T47306 BIOCLASS Major facilitator T47306 SEQUENCE MAAQGYGYYRTVIFSAMFGGYSLYYFNRKTFSFVMPSLVEEIPLDKDDLGFITSSQSAAYAISKFVSGVLSDQMSARWLFSSGLLLVGLVNIFFAWSSTVPVFAALWFLNGLAQGLGWPPCGKVLRKWFEPSQFGTWWAILSTSMNLAGGLGPILATILAQSYSWRSTLALSGALCVVVSFLCLLLIHNEPADVGLRNLDPMPSEGKKGSLKEESTLQELLLSPYLWVLSTGYLVVFGVKTCCTDWGQFFLIQEKGQSALVGSSYMSALEVGGLVGSIAAGYLSDRAMAKAGLSNYGNPRHGLLLFMMAGMTVSMYLFRVTVTSDSPKLWILVLGAVFGFSSYGPIALFGVIANESAPPNLCGTSHAIVGLMANVGGFLAGLPFSTIAKHYSWSTAFWVAEVICAASTAAFFLLRNIRTKMGRVSKKAE T47306 DRUGINFO D00UCE S 0957 Investigative T47306 DRUGINFO D01NIJ S 1743 Investigative T47306 DRUGINFO D02HCQ Chlorogenic acid Investigative T47306 DRUGINFO D0A9CK S-4048 Investigative T47306 DRUGINFO D0GG6X Kodaistatin A Investigative T47306 DRUGINFO D0I3IR Kodaistatin C Investigative T47306 DRUGINFO D0S5RY S 3025 Investigative T47306 DRUGINFO D0Z6OT Mumbaistatin Investigative T27700 TARGETID T27700 T27700 FORMERID TTDI00003 T27700 UNIPROID CXL13_HUMAN T27700 TARGNAME C-X-C motif chemokine 13 (CXCL13) T27700 GENENAME CXCL13 T27700 TARGTYPE Literature-reported T27700 SYNONYMS Smallinducible cytokine B13; Small-inducible cytokine B13; SCYB13; CXC chemokine BLC; BLC; BCA1; BCA-1; B lymphocyte chemoattractant; B cellattracting chemokine 1; B cell-attracting chemokine 1; Angie T27700 FUNCTION Does not induce calcium release in B-lymphocytes. Binds to BLR1/CXCR5. Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils. T27700 PDBSTRUC 5CBE; 5CBA; 4ZAI T27700 BIOCLASS Cytokine: CXC chemokine T27700 SEQUENCE MKFISTSLLLMLLVSSLSPVQGVLEVYYTSLRCRCVQESSVFIPRRFIDRIQILPRGNGCPRKEIIVWKKNKSIVCVDPQAEWIQRMMEVLRKRSSSTLPVPVFKRKIP T00302 TARGETID T00302 T00302 FORMERID TTDR00876 T00302 UNIPROID TM11D_HUMAN T00302 TARGNAME Airway trypsin-like protease (TMPRSS11D) T00302 GENENAME TMPRSS11D T00302 TARGTYPE Literature-reported T00302 SYNONYMS TMPRSS11D; Human airway trypsin-like protease; HAT T00302 FUNCTION May play some biological role in the host defense system on the mucous membrane independently of or in cooperation with other substances in airway mucous or bronchial secretions. Plays a role in the proteolytic processing of ACE2. Proteolytically cleaves and activates the human coronavirus 229E (HCoV-229E) spike glycoprotein which facilitate virus-cell membrane fusions; spike proteins are synthesized andmaintained in precursor intermediate folding states and proteolysis permits the refolding and energy release required to create stable virus-cell linkages and membrane coalescence. T00302 BIOCLASS Peptidase T00302 ECNUMBER EC 3.4.21.- T00302 SEQUENCE MYRPARVTSTSRFLNPYVVCFIVVAGVVILAVTIALLVYFLAFDQKSYFYRSSFQLLNVEYNSQLNSPATQEYRTLSGRIESLITKTFKESNLRNQFIRAHVAKLRQDGSGVRADVVMKFQFTRNNNGASMKSRIESVLRQMLNNSGNLEINPSTEITSLTDQAAANWLINECGAGPDLITLSEQRILGGTEAEEGSWPWQVSLRLNNAHHCGGSLINNMWILTAAHCFRSNSNPRDWIATSGISTTFPKLRMRVRNILIHNNYKSATHENDIALVRLENSVTFTKDIHSVCLPAATQNIPPGSTAYVTGWGAQEYAGHTVPELRQGQVRIISNDVCNAPHSYNGAILSGMLCAGVPQGGVDACQGDSGGPLVQEDSRRLWFIVGIVSWGDQCGLPDKPGVYTRVTAYLDWIRQQTGI T00302 DRUGINFO D07ZRG PMID21741839C5 Investigative T00302 DRUGINFO D0W2SV Inhibitor 1 [Colombo et al., 2012] Investigative T21653 TARGETID T21653 T21653 FORMERID TTDI03413 T21653 UNIPROID NUAK1_HUMAN T21653 TARGNAME Omphalocele kinase 1 (NUAK1) T21653 GENENAME NUAK1 T21653 TARGTYPE Literature-reported T21653 SYNONYMS OMPHK1; NUAK family SNF1-like kinase 1; KIAA0537; ARK5; AMPK-related protein kinase 5 T21653 FUNCTION Phosphorylates ATM, CASP6, LATS1, PPP1R12A and p53/TP53. Acts as a regulator of cellular senescence and cellular ploidy by mediating phosphorylation of 'Ser-464' of LATS1, thereby controlling its stability. Controls cell adhesion by regulating activity of the myosin protein phosphatase 1 (PP1) complex. Acts by mediating phosphorylation of PPP1R12A subunit of myosin PP1: phosphorylated PPP1R12A then interacts with 14-3-3, leading to reduced dephosphorylation of myosin MLC2 by myosin PP1. May be involved in DNA damage response: phosphorylates p53/TP53 at 'Ser-15' and 'Ser-392' and is recruited to the CDKN1A/WAF1 promoter to participate to transcription activation by p53/TP53. May also act as a tumor malignancy-associated factor by promoting tumor invasion and metastasis under regulation and phosphorylation by AKT1. Suppresses Fas-induced apoptosis by mediating phosphorylation of CASP6, thereby suppressing the activation of the caspase and the subsequent cleavage of CFLAR. Regulates UV radiation-induced DNA damage response mediated by CDKN1A. In association with STK11, phosphorylates CDKN1A in response to UV radiation and contributes to its degradation which is necessary for optimal DNA repair. Serine/threonine-protein kinase involved in various processes such as cell adhesion, regulation of cell ploidy and senescence, cell proliferation and tumor progression. T21653 BIOCLASS Kinase T21653 ECNUMBER EC 2.7.11.1 T21653 SEQUENCE MEGAAAPVAGDRPDLGLGAPGSPREAVAGATAALEPRKPHGVKRHHHKHNLKHRYELQETLGKGTYGKVKRATERFSGRVVAIKSIRKDKIKDEQDMVHIRREIEIMSSLNHPHIISIYEVFENKDKIVIIMEYASKGELYDYISERRRLSERETRHFFRQIVSAVHYCHKNGVVHRDLKLENILLDDNCNIKIADFGLSNLYQKDKFLQTFCGSPLYASPEIVNGRPYRGPEVDSWALGVLLYTLVYGTMPFDGFDHKNLIRQISSGEYREPTQPSDARGLIRWMLMVNPDRRATIEDIANHWWVNWGYKSSVCDCDALHDSESPLLARIIDWHHRSTGLQADTEAKMKGLAKPTTSEVMLERQRSLKKSKKENDFAQSGQDAVPESPSKLSSKRPKGILKKRSNSEHRSHSTGFIEGVVGPALPSTFKMEQDLCRTGVLLPSSPEAEVPGKLSPKQSATMPKKGILKKTQQRESGYYSSPERSESSELLDSNDVMGSSIPSPSPPDPARVTSHSLSCRRKGILKHSSKYSAGTMDPALVSPEMPTLESLSEPGVPAEGLSRSYSRPSSVISDDSVLSSDSFDLLDLQENRPARQRIRSCVSAENFLQIQDFEGLQNRPRPQYLKRYRNRLADSSFSLLTDMDDVTQVYKQALEICSKLN T21653 DRUGINFO D00HLW WZ4003 Investigative T21653 DRUGINFO D09AID PMID22564207C25b Investigative T88404 TARGETID T88404 T88404 FORMERID TTDI00160 T88404 UNIPROID OPA1_HUMAN T88404 TARGNAME Optic atrophy protein 1 (OPA1) T88404 GENENAME OPA1 T88404 TARGTYPE Literature-reported T88404 SYNONYMS OPA1; Dynaminlike 120 kDa protein, mitochondrial; Dynaminlike 120 kDa protein, form S1 T88404 FUNCTION Dynamin-like 120 kDa protein, form S1: Inactive form produced by cleavage at S1 position by OMA1 following stress conditions that induce loss of mitochondrial membrane potential, leading to negative regulation of mitochondrial fusion. T88404 BIOCLASS Carbon-carbon hydrolase T88404 ECNUMBER EC 3.6.5.5 T88404 SEQUENCE MWRLRRAAVACEVCQSLVKHSSGIKGSLPLQKLHLVSRSIYHSHHPTLKLQRPQLRTSFQQFSSLTNLPLRKLKFSPIKYGYQPRRNFWPARLATRLLKLRYLILGSAVGGGYTAKKTFDQWKDMIPDLSEYKWIVPDIVWEIDEYIDFEKIRKALPSSEDLVKLAPDFDKIVESLSLLKDFFTSGSPEETAFRATDRGSESDKHFRKVSDKEKIDQLQEELLHTQLKYQRILERLEKENKELRKLVLQKDDKGIHHRKLKKSLIDMYSEVLDVLSDYDASYNTQDHLPRVVVVGDQSAGKTSVLEMIAQARIFPRGSGEMMTRSPVKVTLSEGPHHVALFKDSSREFDLTKEEDLAALRHEIELRMRKNVKEGCTVSPETISLNVKGPGLQRMVLVDLPGVINTVTSGMAPDTKETIFSISKAYMQNPNAIILCIQDGSVDAERSIVTDLVSQMDPHGRRTIFVLTKVDLAEKNVASPSRIQQIIEGKLFPMKALGYFAVVTGKGNSSESIEAIREYEEEFFQNSKLLKTSMLKAHQVTTRNLSLAVSDCFWKMVRESVEQQADSFKATRFNLETEWKNNYPRLRELDRNELFEKAKNEILDEVISLSQVTPKHWEEILQQSLWERVSTHVIENIYLPAAQTMNSGTFNTTVDIKLKQWTDKQLPNKAVEVAWETLQEEFSRFMTEPKGKEHDDIFDKLKEAVKEESIKRHKWNDFAEDSLRVIQHNALEDRSISDKQQWDAAIYFMEEALQARLKDTENAIENMVGPDWKKRWLYWKNRTQEQCVHNETKNELEKMLKCNEEHPAYLASDEITTVRKNLESRGVEVDPSLIKDTWHQVYRRHFLKTALNHCNLCRRGFYYYQRHFVDSELECNDVVLFWRIQRMLAITANTLRQQLTNTEVRRLEKNVKEVLEDFAEDGEKKIKLLTGKRVQLAEDLKKVREIQEKLDAFIEALHQEK T16799 TARGETID T16799 T16799 FORMERID TTDR00136 T16799 UNIPROID ECE2_HUMAN T16799 TARGNAME Endothelin-converting enzyme 2 (ECE2) T16799 GENENAME ECE2 T16799 TARGTYPE Literature-reported T16799 SYNONYMS UNQ403/PRO740; KIAA0604; ECE-2 T16799 FUNCTION Converts big endothelin-1 to endothelin-1. Also involved in the processing of various neuroendocrine peptides, including neurotensin, angiotensin I, substance P, proenkephalin-derived peptides, and prodynorphin-derived peptides. May limit beta- amyloid peptide accumulation in brain. May also have methyltransferase activity. T16799 ECNUMBER EC 3.4.24.71 T16799 SEQUENCE MNVALQELGAGSNMVEYKRATLRDEDAPETPVEGGASPDAMEVGKGASPFSPGPSPGMTPGTPRSSGLFWRVTCPHLRSISGLCSRTMVGFQKGTRQLLGSRTQLELVLAGASLLLAALLLGCLVALGVQYHRDPSHSTCLTEACIRVAGKILESLDRGVSPCEDFYQFSCGGWIRRNPLPDGRSRWNTFNSLWDQNQAILKHLLENTTFNSSSEAEQKTQRFYLSCLQVERIEELGAQPLRDLIEKIGGWNITGPWDQDNFMEVLKAVAGTYRATPFFTVYISADSKSSNSNVIQVDQSGLFLPSRDYYLNRTANEKVLTAYLDYMEELGMLLGGRPTSTREQMQQVLELEIQLANITVPQDQRRDEEKIYHKMSISELQALAPSMDWLEFLSFLLSPLELSDSEPVVVYGMDYLQQVSELINRTEPSILNNYLIWNLVQKTTSSLDRRFESAQEKLLETLYGTKKSCVPRWQTCISNTDDALGFALGSLFVKATFDRQSKEIAEGMISEIRTAFEEALGQLVWMDEKTRQAAKEKADAIYDMIGFPDFILEPKELDDVYDGYEISEDSFFQNMLNLYNFSAKVMADQLRKPPSRDQWSMTPQTVNAYYLPTKNEIVFPAGILQAPFYARNHPKALNFGGIGVVMGHELTHAFDDQGREYDKEGNLRPWWQNESLAAFRNHTACMEEQYNQYQVNGERLNGRQTLGENIADNGGLKAAYNAYKAWLRKHGEEQQLPAVGLTNHQLFFVGFAQVWCSVRTPESSHEGLVTDPHSPARFRVLGTLSNSRDFLRHFGCPVGSPMNPGQLCEVW T16799 DRUGINFO D0P4KL S136492 Investigative T16799 DRUGINFO D0G9UX CGS 35066 Investigative T47721 TARGETID T47721 T47721 FORMERID TTDR00535 T47721 UNIPROID CUBN_HUMAN T47721 TARGNAME Intrinsic factor-B12 receptor (CUBN) T47721 GENENAME CUBN T47721 TARGTYPE Literature-reported T47721 SYNONYMS Intrinsic factor-vitamin B12 receptor; Cubilin; CUBN T47721 FUNCTION Cotransporter which plays a role in lipoprotein, vitamin and iron metabolism, by facilitating their uptake. Binds to ALB, MB, Kappa and lambda-light chains, TF, hemoglobin, GC, SCGB1A1, APOA1, high density lipoprotein, and the GIF-cobalamin complex. The binding of all ligands requires calcium. Serves as important transporter in several absorptive epithelia, including intestine, renal proximal tubules and embryonic yolk sac. Interaction with LRP2 mediates its trafficking throughout vesicles and facilitates the uptake of specific ligands like GC, hemoglobin, ALB, TF and SCGB1A1. Interaction with AMN controls its trafficking to the plasma membrane and facilitates endocytosis of ligands. May play an important role in the development of the peri-implantation embryo through internalization of APOA1 and cholesterol. Binds to LGALS3 at the maternal-fetal interface. T47721 PDBSTRUC 6GJE; 3KQ4 T47721 BIOCLASS Growth factor T47721 SEQUENCE MMNMSLPFLWSLLTLLIFAEVNGEAGELELQRQKRSINLQQPRMATERGNLVFLTGSAQNIEFRTGSLGKIKLNDEDLSECLHQIQKNKEDIIELKGSAIGLPQNISSQIYQLNSKLVDLERKFQGLQQTVDKKVCSSNPCQNGGTCLNLHDSFFCICPPQWKGPLCSADVNECEIYSGTPLSCQNGGTCVNTMGSYSCHCPPETYGPQCASKYDDCEGGSVARCVHGICEDLMREQAGEPKYSCVCDAGWMFSPNSPACTLDRDECSFQPGPCSTLVQCFNTQGSFYCGACPTGWQGNGYICEDINECEINNGGCSVAPPVECVNTPGSSHCQACPPGYQGDGRVCTLTDICSVSNGGCHPDASCSSTLGSLPLCTCLPGYTGNGYGPNGCVQLSNICLSHPCLNGQCIDTVSGYFCKCDSGWTGVNCTENINECLSNPCLNGGTCVDGVDSFSCECTRLWTGALCQVPQQVCGESLSGINGSFSYRSPDVGYVHDVNCFWVIKTEMGKVLRITFTFFRLESMDNCPHEFLQVYDGDSSSAFQLGRFCGSSLPHELLSSDNALYFHLYSEHLRNGRGFTVRWETQQPECGGILTGPYGSIKSPGYPGNYPPGRDCVWIVVTSPDLLVTFTFGTLSLEHHDDCNKDYLEIRDGPLYQDPLLGKFCTTFSVPPLQTTGPFARIHFHSDSQISDQGFHITYLTSPSDLRCGGNYTDPEGELFLPELSGPFTHTRQCVYMMKQPQGEQIQINFTHVELQCQSDSSQNYIEVRDGETLLGKVCGNGTISHIKSITNSVWIRFKIDASVEKASFRAVYQVACGDELTGEGVIRSPFFPNVYPGERTCRWTIHQPQSQVILLNFTVFEIGSSAHCETDYVEIGSSSILGSPENKKYCGTDIPSFITSVYNFLYVTFVKSSSTENHGFMAKFSAEDLACGEILTESTGTIQSPGHPNVYPHGINCTWHILVQPNHLIHLMFETFHLEFHYNCTNDYLEVYDTDSETSLGRYCGKSIPPSLTSSGNSLMLVFVTDSDLAYEGFLINYEAISAATACLQDYTDDLGTFTSPNFPNNYPNNWECIYRITVRTGQLIAVHFTNFSLEEAIGNYYTDFLEIRDGGYEKSPLLGIFYGSNLPPTIISHSNKLWLKFKSDQIDTRSGFSAYWDGSSTGCGGNLTTSSGTFISPNYPMPYYHSSECYWWLKSSHGSAFELEFKDFHLEHHPNCTLDYLAVYDGPSSNSHLLTQLCGDEKPPLIRSSGDSMFIKLRTDEGQQGRGFKAEYRQTCENVVIVNQTYGILESIGYPNPYSENQHCNWTIRATTGNTVNYTFLAFDLEHHINCSTDYLELYDGPRQMGRYCGVDLPPPGSTTSSKLQVLLLTDGVGRREKGFQMQWFVYGCGGELSGATGSFSSPGFPNRYPPNKECIWYIRTDPGSSIQLTIHDFDVEYHSRCNFDVLEIYGGPDFHSPRIAQLCTQRSPENPMQVSSTGNELAIRFKTDLSINGRGFNASWQAVTGGCGGIFQAPSGEIHSPNYPSPYRSNTDCSWVIRVDRNHRVLLNFTDFDLEPQDSCIMAYDGLSSTMSRLARTCGREQLANPIVSSGNSLFLRFQSGPSRQNRGFRAQFRQACGGHILTSSFDTVSSPRFPANYPNNQNCSWIIQAQPPLNHITLSFTHFELERSTTCARDFVEILDGGHEDAPLRGRYCGTDMPHPITSFSSALTLRFVSDSSISAGGFHTTVTASVSACGGTFYMAEGIFNSPGYPDIYPPNVECVWNIVSSPGNRLQLSFISFQLEDSQDCSRDFVEIREGNATGHLVGRYCGNSFPLNYSSIVGHTLWVRFISDGSGSGTGFQATFMKIFGNDNIVGTHGKVASPFWPENYPHNSNYQWTVNVNASHVVHGRILEMDIEEIQNCYYDKLRIYDGPSIHARLIGAYCGTQTESFSSTGNSLTFHFYSDSSISGKGFLLEWFAVDAPDGVLPTIAPGACGGFLRTGDAPVFLFSPGWPDSYSNRVDCTWLIQAPDSTVELNILSLDIESHRTCAYDSLVIRDGDNNLAQQLAVLCGREIPGPIRSTGEYMFIRFTSDSSVTRAGFNASFHKSCGGYLHADRGIITSPKYPETYPSNLNCSWHVLVQSGLTIAVHFEQPFQIPNGDSSCNQGDYLVLRNGPDICSPPLGPPGGNGHFCGSHASSTLFTSDNQMFVQFISDHSNEGQGFKIKYEAKSLACGGNVYIHDADSAGYVTSPNHPHNYPPHADCIWILAAPPETRIQLQFEDRFDIEVTPNCTSNYLELRDGVDSDAPILSKFCGTSLPSSQWSSGEVMYLRFRSDNSPTHVGFKAKYSIAQCGGRVPGQSGVVESIGHPTLPYRDNLFCEWHLQGLSGHYLTISFEDFNLQNSSGCEKDFVEIWDNHTSGNILGRYCGNTIPDSIDTSSNTAVVRFVTDGSVTASGFRLRFESSMEECGGDLQGSIGTFTSPNYPNPNPHGRICEWRITAPEGRRITLMFNNLRLATHPSCNNEHVIVFNGIRSNSPQLEKLCSSVNVSNEIKSSGNTMKVIFFTDGSRPYGGFTASYTSSEDAVCGGSLPNTPEGNFTSPGYDGVRNYSRNLNCEWTLSNPNQGNSSISIHFEDFYLESHQDCQFDVLEFRVGDADGPLMWRLCGPSKPTLPLVIPYSQVWIHFVTNERVEHIGFHAKYSFTDCGGIQIGDSGVITSPNYPNAYDSLTHCSSLLEAPQGHTITLTFSDFDIEPHTTCAWDSVTVRNGGSPESPIIGQYCGNSNPRTIQSGSNQLVVTFNSDHSLQGGGFYATWNTQTLGCGGIFHSDNGTIRSPHWPQNFPENSRCSWTAITHKSKHLEISFDNNFLIPSGDGQCQNSFVKVWAGTEEVDKALLATGCGNVAPGPVITPSNTFTAVFQSQEAPAQGFSASFVSRCGSNFTGPSGYIISPNYPKQYDNNMNCTYVIEANPLSVVLLTFVSFHLEARSAVTGSCVNDGVHIIRGYSVMSTPFATVCGDEMPAPLTIAGPVLLNFYSNEQITDFGFKFSYRIISCGGVFNFSSGIITSPAYSYADYPNDMHCLYTITVSDDKVIELKFSDFDVVPSTSCSHDYLAIYDGANTSDPLLGKFCGSKRPPNVKSSNNSMLLVFKTDSFQTAKGWKMSFRQTLGPQQGCGGYLTGSNNTFASPDSDSNGMYDKNLNCVWIIIAPVNKVIHLTFNTFALEAASTRQRCLYDYVKLYDGDSENANLAGTFCGSTVPAPFISSGNFLTVQFISDLTLEREGFNATYTIMDMPCGGTYNATWTPQNISSPNSSDPDVPFSICTWVIDSPPHQQVKITVWALQLTSQDCTQNYLQLQDSPQGHGNSRFQFCGRNASAVPVFYSSMSTAMVIFKSGVVNRNSRMSFTYQIADCNRDYHKAFGNLRSPGWPDNYDNDKDCTVTLTAPQNHTISLFFHSLGIENSVECRNDFLEVRNGSNSNSPLLGKYCGTLLPNPVFSQNNELYLRFKSDSVTSDRGYEIIWTSSPSGCGGTLYGDRGSFTSPGYPGTYPNNTYCEWVLVAPAGRLVTINFYFISIDDPGDCVQNYLTLYDGPNASSPSSGPYCGGDTSIAPFVASSNQVFIKFHADYARRPSAFRLTWDS T76723 TARGETID T76723 T76723 FORMERID TTDI03485 T76723 UNIPROID ANM3_HUMAN T76723 TARGNAME Protein arginine methyltransferase 3 (PRMT3) T76723 GENENAME PRMT3 T76723 TARGTYPE Literature-reported T76723 SYNONYMS Protein arginine N-methyltransferase 3; Heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 3; HRMT1L3 T76723 FUNCTION Methylates (mono and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in some proteins. T76723 PDBSTRUC 4RYL; 4QQN; 4HSG; 3SMQ; 2FYT T76723 ECNUMBER EC 2.1.1.- T76723 SEQUENCE MCSLASGATGGRGAVENEEDLPELSDSGDEAAWEDEDDADLPHGKQQTPCLFCNRLFTSAEETFSHCKSEHQFNIDSMVHKHGLEFYGYIKLINFIRLKNPTVEYMNSIYNPVPWEKEEYLKPVLEDDLLLQFDVEDLYEPVSVPFSYPNGLSENTSVVEKLKHMEARALSAEAALARAREDLQKMKQFAQDFVMHTDVRTCSSSTSVIADLQEDEDGVYFSSYGHYGIHEEMLKDKIRTESYRDFIYQNPHIFKDKVVLDVGCGTGILSMFAAKAGAKKVLGVDQSEILYQAMDIIRLNKLEDTITLIKGKIEEVHLPVEKVDVIISEWMGYFLLFESMLDSVLYAKNKYLAKGGSVYPDICTISLVAVSDVNKHADRIAFWDDVYGFKMSCMKKAVIPEAVVEVLDPKTLISEPCGIKHIDCHTTSISDLEFSSDFTLKITRTSMCTAIAGYFDIYFEKNCHNRVVFSTGPQSTKTHWKQTVFLLEKPFSVKAGEALKGKVTVHKNKKDPRSLTVTLTLNNSTQTYGLQ T76723 DRUGINFO D00JWB SGC707 Investigative T76723 DRUGINFO D0AF1J PMID22795084C1 Investigative T93266 TARGETID T93266 T93266 FORMERID TTDI03255 T93266 UNIPROID HCN1_HUMAN T93266 TARGNAME Hyperpolarization cyclic nucleotide-gated channel 1 (HCN1) T93266 GENENAME HCN1 T93266 TARGTYPE Literature-reported T93266 SYNONYMS Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1; Brain cyclic nucleotide-gated channel 1; BCNG1; BCNG-1 T93266 FUNCTION Contributes to the native pacemaker currents in heart (If) and in neurons (Ih). May mediate responses to sour stimuli. Hyperpolarization-activated ion channel exhibiting weak selectivity for potassium over sodium ions. T93266 PDBSTRUC 5U6P; 5U6O T93266 BIOCLASS Voltage-gated ion channel T93266 SEQUENCE MEGGGKPNSSSNSRDDGNSVFPAKASATGAGPAAAEKRLGTPPGGGGAGAKEHGNSVCFKVDGGGGGGGGGGGGEEPAGGFEDAEGPRRQYGFMQRQFTSMLQPGVNKFSLRMFGSQKAVEKEQERVKTAGFWIIHPYSDFRFYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIFNVASDTVFLLDLIMNFRTGTVNEDSSEIILDPKVIKMNYLKSWFVVDFISSIPVDYIFLIVEKGMDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLCIGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLDSSRRQYQEKYKQVEQYMSFHKLPADMRQKIHDYYEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMPLFANADPNFVTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTDGSYFGEICLLTKGRRTASVRADTYCRLYSLSVDNFNEVLEEYPMMRRAFETVAIDRLDRIGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHDREMVQAIAPINYPQMTTLNSTSSTTTPTSRMRTQSPPVYTATSLSHSNLHSPSPSTQTPQPSAILSPCSYTTAVCSPPVQSPLAARTFHYASPTASQLSLMQQQPQQQVQQSQPPQTQPQQPSPQPQTPGSSTPKNEVHKSTQALHNTNLTREVRPLSASQPSLPHEVSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGVPPAPPPPAAALPRESSSVLNTDPDAEKPRFASNL T93266 DRUGINFO D0J0ZK MEL57A Investigative T20776 TARGETID T20776 T20776 FORMERID TTDR00737 T20776 UNIPROID F262_HUMAN T20776 TARGNAME Fru-2,6-P2ase 2/6PF-2-K (PFK/FBPase 2) T20776 GENENAME PFKFB2 T20776 TARGTYPE Literature-reported T20776 SYNONYMS PFKFB2; PFK-2/FBPase-2; 6PF-2-K/Fru-2,6-P2ASE heart-typeisozyme T20776 FUNCTION Synthesis and degradation of fructose 2,6-bisphosphate. T20776 PDBSTRUC 5HTK T20776 BIOCLASS Kinase T20776 SEQUENCE MSGASSSEQNNNSYETKTPNLRMSEKKCSWASYMTNSPTLIVMIGLPARGKTYVSKKLTRYLNWIGVPTKVFNLGVYRREAVKSYKSYDFFRHDNEEAMKIRKQCALVALEDVKAYLTEENGQIAVFDATNTTRERRDMILNFAEQNSFKVFFVESVCDDPDVIAANILEVKVSSPDYPERNRENVMEDFLKRIECYKVTYRPLDPDNYDKDLSFIKVINVGQRFLVNRVQDYIQSKIVYYLMNIHVQPRTIYLCRHGESEFNLLGKIGGDSGLSVRGKQFAQALRKFLEEQEITDLKVWTSQLKRTIQTAESLGVPYEQWKILNEIDAGVCEEMTYAEIEKRYPEEFALRDQEKYLYRYPGGESYQDLVQRLEPVIMELERQGNVLVISHQAVMRCLLAYFLDKGADELPYLRCPLHTIFKLTPVAYGCKVETIKLNVEAVNTHRDKPTNNFPKNQTPVRMRRNSFTPLSSSNTIRRPRNYSVGSRPLKPLSPLRAQDMQEGAD T57316 TARGETID T57316 T57316 FORMERID TTDR01067 T57316 UNIPROID NSMA_HUMAN T57316 TARGNAME Sphingomyelin phosphodiesterase 2 (SMPD2) T57316 GENENAME SMPD2 T57316 TARGTYPE Literature-reported T57316 SYNONYMS SMPD2; Neutral sphingomyelinase; NSMase; N-SMase; Lyso-platelet activating factor-phospholipase C; Lyso-PAF-PLC T57316 FUNCTION Converts sphingomyelin to ceramide. Hydrolyze 1-acyl-2- lyso-sn-glycero-3-phosphocholine (lyso-PC) and 1-O-alkyl-2-lyso- sn-glycero-3-phosphocholine (lyso-platelet-activating factor). The physiological substrate seems to be Lyso-PAF. T57316 BIOCLASS Phosphoric diester hydrolase T57316 ECNUMBER EC 3.1.4.12 T57316 SEQUENCE MKPNFSLRLRIFNLNCWGIPYLSKHRADRMRRLGDFLNQESFDLALLEEVWSEQDFQYLRQKLSPTYPAAHHFRSGIIGSGLCVFSKHPIQELTQHIYTLNGYPYMIHHGDWFSGKAVGLLVLHLSGMVLNAYVTHLHAEYNRQKDIYLAHRVAQAWELAQFIHHTSKKADVVLLCGDLNMHPEDLGCCLLKEWTGLHDAYLETRDFKGSEEGNTMVPKNCYVSQQELKPFPFGVRIDYVLYKAVSGFYISCKSFETTTGFDPHRGTPLSDHEALMATLFVRHSPPQQNPSSTHGPAERSPLMCVLKEAWTELGLGMAQARWWATFASYVIGLGLLLLALLCVLAAGGGAGEAAILLWTPSVGLVLWAGAFYLFHVQEVNGLYRAQAELQHVLGRAREAQDLGPEPQPALLLGQQEGDRTKEQ T04303 TARGETID T04303 T04303 FORMERID TTDI03534 T04303 UNIPROID STK16_HUMAN T04303 TARGNAME TGF-beta-stimulated factor 1 (STK16) T04303 GENENAME STK16 T04303 TARGTYPE Literature-reported T04303 SYNONYMS hPSK; Tyrosine-protein kinase STK16; TSF1; TSF-1; Serine/threonine-protein kinase 16; Protein kinase PKL12; PKL12; Myristoylated and palmitoylated serine/threonine-protein kinase; MPSK1; MPSK T04303 FUNCTION Membrane-associated protein kinase that phosphorylates on serine and threonine residues. In vitro substrates include DRG1, ENO1 and EIF4EBP1. Also autophosphorylates. May be involved in secretory vesicle trafficking or intracellular signaling. May have a role in regulating stromal-epithelial interactions that occur during ductal morphogenesis in the mammary gland. May be involved in TGF-beta signaling. Able to autophosphorylate on Tyr residue; it is however unclear whether it has tyrosine-protein kinase toward other proteins. T04303 PDBSTRUC 2BUJ T04303 ECNUMBER EC 2.7.11.1 T04303 SEQUENCE MGHALCVCSRGTVIIDNKRYLFIQKLGEGGFSYVDLVEGLHDGHFYALKRILCHEQQDREEAQREADMHRLFNHPNILRLVAYCLRERGAKHEAWLLLPFFKRGTLWNEIERLKDKGNFLTEDQILWLLLGICRGLEAIHAKGYAHRDLKPTNILLGDEGQPVLMDLGSMNQACIHVEGSRQALTLQDWAAQRCTISYRAPELFSVQSHCVIDERTDVWSLGCVLYAMMFGEGPYDMVFQKGDSVALAVQNQLSIPQSPRHSSALRQLLNSMMTVDPHQRPHIPLLLSQLEALQPPAPGQHTTQI T04303 DRUGINFO D0RO9R PMID21123062C27 Investigative T12084 TARGETID T12084 T12084 FORMERID TTDI03514 T12084 UNIPROID RBBP9_HUMAN T12084 TARGNAME Retinoblastoma-binding protein 9 (RBBP9) T12084 GENENAME RBBP9 T12084 TARGTYPE Literature-reported T12084 SYNONYMS Retinoblastoma-binding protein 10; RBBP10; RBBP-9; RBBP-10; Putative hydrolase RBBP9; Protein BOG; BOG; B5T-overexpressed gene protein T12084 FUNCTION May play a role in the transformation process due to its capacity to confer resistance to the growth-inhibitory effects of TGF-beta1 through interaction with retinoblastoma and the subsequent displacement of E2F-1. T12084 PDBSTRUC 2QS9 T12084 ECNUMBER EC 3.-.-.- T12084 SEQUENCE MASPSKAVIVPGNGGGDVTTHGWYGWVKKELEKIPGFQCLAKNMPDPITARESIWLPFMETELHCDEKTIIIGHSSGAIAAMRYAETHRVYAIVLVSAYTSDLGDENERASGYFTRPWQWEKIKANCPYIVQFGSTDDPFLPWKEQQEVADRLETKLHKFTDCGHFQNTEFHELITVVKSLLKVPA T12084 DRUGINFO D06WSN Ala(1-naph)-Pro-CN Investigative T91020 TARGETID T91020 T91020 FORMERID TTDR00700 T91020 UNIPROID DFFB_HUMAN T91020 TARGNAME Caspase-activated deoxyribonuclease (DFFB) T91020 GENENAME DFFB T91020 TARGTYPE Literature-reported T91020 SYNONYMS DFFB; DFF-40; Caspase-activated nuclease; Caspase-activated DNase; CPAN T91020 FUNCTION Nuclease that induces DNA fragmentation andchromatin condensation during apoptosis. Degrades naked DNA and induces apoptotic morphology. T91020 PDBSTRUC 1IBX T91020 ECNUMBER EC 3.-.-.- T91020 SEQUENCE MLQKPKSVKLRALRSPRKFGVAGRSCQEVLRKGCLRFQLPERGSRLCLYEDGTELTEDYFPSVPDNAELVLLTLGQAWQGYVSDIRRFLSAFHEPQVGLIQAAQQLLCDEQAPQRQRLLADLLHNVSQNIAAETRAEDPPWFEGLESRFQSKSGYLRYSCESRIRSYLREVSSYPSTVGAEAQEEFLRVLGSMCQRLRSMQYNGSYFDRGAKGGSRLCTPEGWFSCQGPFDMDSCLSRHSINPYSNRESRILFSTWNLDHIIEKKRTIIPTLVEAIKEQDGREVDWEYFYGLLFTSENLKLVHIVCHKKTTHKLNCDPSRIYKPQTRLKRKQPVRKRQ T35272 TARGETID T35272 T35272 FORMERID TTDR01090 T35272 UNIPROID FOLB_CHLTR T35272 TARGNAME Bacterial Dihydroneopterin aldolase (Bact folB) T35272 GENENAME Bact folB T35272 TARGTYPE Literature-reported T35272 SYNONYMS folB of Chlamydia trachomatis; DhnA-type aldolase; DHNA of Chlamydia trachomatis T35272 FUNCTION Catalyzes the conversion of 7,8-dihydroneopterin to 6- hydroxymethyl-7,8-dihydropterin. T35272 BIOCLASS Carbon-carbon lyase T35272 ECNUMBER EC 4.1.2.25 T35272 SEQUENCE MLLYRLDIADFRVWVSIGVSEQERHYPQPVLVSLSLFFKEEPKACSTDKVSDSVCYAELVSLIEEVATNNPCALIERLAKVLLEKIEKALAGQVSRIDLRVSKERPPIPDLLSPVSFSISREVP T30292 TARGETID T30292 T30292 FORMERID TTDR00769 T30292 UNIPROID CATV_GVCPM T30292 TARGNAME Virus Cysteine proteinase (Viru VCATH) T30292 GENENAME Viru VCATH T30292 TARGTYPE Literature-reported T30292 SYNONYMS Viral cathepsin; VCATH; V-cath; CP of Cydia pomonella granulosis virus T30292 FUNCTION Cysteine protease that plays an essential role in host liquefactionto facilitate horizontal transmission of the virus. May participate in the degradation of foreign protein expressed by the baculovirus system. T30292 BIOCLASS Peptidase T30292 ECNUMBER EC 3.4.22.50 T30292 SEQUENCE MTKLLNFVILASVLTVTAHALTYDLNNSDELFKNFAIKYNKTYVSDEERAIKLENFKNNLKMINEKNMASKYAVFDINEYSDLNKNALLRRTTGFRLGLKKNPSAFTMTECSVVVIKDEPQALLPETLDWRDKHGVTPVKNQMECGSCWAFSTIANIESLYNIKYDKALNLSEQHLVNCDNINNGCAGGLMHWALESILQEGGVVSAENEPYYGFDGVCKKSPFELSISGSRRYVLQNENKLRELLVVNGPISVAIDVSDLINYKAGIADICENNEGLNHAVLLVGYGVKNDVPYWILKNSWGAEWGEEGYFRVQRDKNSCGMMNEYASSAIL T30292 DRUGINFO D09FGQ E-64 Investigative T40545 TARGETID T40545 T40545 FORMERID TTDR00838 T40545 UNIPROID S27A4_HUMAN T40545 TARGNAME Solute carrier family 27 member 4 (SLC27A4) T40545 GENENAME SLC27A4 T40545 TARGTYPE Literature-reported T40545 SYNONYMS Long-chain fatty acid transport protein 4; Fatty acid transport protein 4; FATP4; FATP-4; ACSVL4 T40545 FUNCTION Involved in translocation of long-chain fatty acids (LFCA) across the plasma membrane. Appears to be the principal fatty acid transporter in small intestinal enterocytes. Plays a role in the formation of the epidermal barrier. Required for fat absorption in early embryogenesis. Has acyl-CoA ligase activity for long-chain and very-long-chain fatty acids (VLCFAs). Indirectly inhibits RPE65 via substrate competition and via production of VLCFA derivatives like lignoceroyl-CoA. Prevents light-induced degeneration of rods and cones (By similarity). T40545 BIOCLASS Carbon-sulfur ligase T40545 ECNUMBER EC 6.2.1.- T40545 SEQUENCE MLLGASLVGVLLFSKLVLKLPWTQVGFSLLFLYLGSGGWRFIRVFIKTIRRDIFGGLVLLKVKAKVRQCLQERRTVPILFASTVRRHPDKTALIFEGTDTHWTFRQLDEYSSSVANFLQARGLASGDVAAIFMENRNEFVGLWLGMAKLGVEAALINTNLRRDALLHCLTTSRARALVFGSEMASAICEVHASLDPSLSLFCSGSWEPGAVPPSTEHLDPLLKDAPKHLPSCPDKGFTDKLFYIYTSGTTGLPKAAIVVHSRYYRMAALVYYGFRMRPNDIVYDCLPLYHSAGNIVGIGQCLLHGMTVVIRKKFSASRFWDDCIKYNCTIVQYIGELCRYLLNQPPREAENQHQVRMALGNGLRQSIWTNFSSRFHIPQVAEFYGATECNCSLGNFDSQVGACGFNSRILSFVYPIRLVRVNEDTMELIRGPDGVCIPCQPGEPGQLVGRIIQKDPLRRFDGYLNQGANNKKIAKDVFKKGDQAYLTGDVLVMDELGYLYFRDRTGDTFRWKGENVSTTEVEGTLSRLLDMADVAVYGVEVPGTEGRAGMAAVASPTGNCDLERFAQVLEKELPLYARPIFLRLLPELHKTGTYKFQKTELRKEGFDPAIVKDPLFYLDAQKGRYVPLDQEAYSRIQAGEEKL T48518 TARGETID T48518 T48518 FORMERID TTDI02408 T48518 UNIPROID SPDEF_HUMAN T48518 TARGNAME Prostate derived ETS factor (SPDEF) T48518 GENENAME SPDEF T48518 TARGTYPE Literature-reported T48518 SYNONYMS SAM pointed domain-containing Ets transcription factor; Prostate-specific Ets; Prostate-derived Ets factor; Prostate epithelium-specific Ets transcription factor; PSE; PDEF T48518 FUNCTION Binds to 5'-GGAT-3' DNA sequences. May play a role in the regulation of the prostate gland and/or prostate cancer development. Acts as a transcriptional activator for SERPINB5 promoter. May function as an androgen-independent transactivator of the prostate-specific antigen (PSA) promoter. T48518 PDBSTRUC 2DKX; 1YO5 T48518 BIOCLASS E26 transformation-specific ETS T48518 SEQUENCE MGSASPGLSSVSPSHLLLPPDTVSRTGLEKAAAGAVGLERRDWSPSPPATPEQGLSAFYLSYFDMLYPEDSSWAAKAPGASSREEPPEEPEQCPVIDSQAPAGSLDLVPGGLTLEEHSLEQVQSMVVGEVLKDIETACKLLNITADPMDWSPSNVQKWLLWTEHQYRLPPMGKAFQELAGKELCAMSEEQFRQRSPLGGDVLHAHLDIWKSAAWMKERTSPGAIHYCASTSEESWTDSEVDSSCSGQPIHLWQFLKELLLKPHSYGRFIRWLNKEKGIFKIEDSAQVARLWGIRKNRPAMNYDKLSRSIRQYYKKGIIRKPDISQRLVYQFVHPI T71362 TARGETID T71362 T71362 FORMERID TTDI02610 T71362 UNIPROID I18RA_HUMAN T71362 TARGNAME Interleukin 18 receptor (IL18RAP) T71362 GENENAME IL18RAP T71362 TARGTYPE Literature-reported T71362 SYNONYMS Interleukin18 receptor beta; Interleukin18 receptor accessory proteinlike; Interleukin18 receptor accessory protein; Interleukin1 receptor 7; Interleukin-18 receptor beta; Interleukin-18 receptor accessory protein-like; Interleukin-18 receptor accessory protein; Interleukin-1 receptor 7; IL1RAcPL; IL1R7; IL1R accessory proteinlike; IL18Rbeta; IL18RAcP; IL18 receptor accessory protein; IL-1RAcPL; IL-1R7; IL-1R-7; IL-1R accessory protein-like; IL-18Rbeta; IL-18RAcP; IL-18R-beta; IL-18 receptor accessory protein; CDw218b; CD218b; CD218 antigenlike family member B; CD218 antigen-like family member B; Accessory proteinlike; Accessory protein-like; AcPL T71362 FUNCTION May play a role in IL18-mediated IFNG synthesis from T-helper 1 (Th1) cells. Within the IL18 receptor complex, does not mediate IL18-binding, but involved in IL18-dependent signal transduction, leading to NF-kappa-B and JNK activation. T71362 PDBSTRUC 3WO4 T71362 BIOCLASS Cytokine receptor T71362 SEQUENCE MLCLGWIFLWLVAGERIKGFNISGCSTKKLLWTYSTRSEEEFVLFCDLPEPQKSHFCHRNRLSPKQVPEHLPFMGSNDLSDVQWYQQPSNGDPLEDIRKSYPHIIQDKCTLHFLTPGVNNSGSYICRPKMIKSPYDVACCVKMILEVKPQTNASCEYSASHKQDLLLGSTGSISCPSLSCQSDAQSPAVTWYKNGKLLSVERSNRIVVDEVYDYHQGTYVCDYTQSDTVSSWTVRAVVQVRTIVGDTKLKPDILDPVEDTLEVELGKPLTISCKARFGFERVFNPVIKWYIKDSDLEWEVSVPEAKSIKSTLKDEIIERNIILEKVTQRDLRRKFVCFVQNSIGNTTQSVQLKEKRGVVLLYILLGTIGTLVAVLAASALLYRHWIEIVLLYRTYQSKDQTLGDKKDFDAFVSYAKWSSFPSEATSSLSEEHLALSLFPDVLENKYGYSLCLLERDVAPGGVYAEDIVSIIKRSRRGIFILSPNYVNGPSIFELQAAVNLALDDQTLKLILIKFCYFQEPESLPHLVKKALRVLPTVTWRGLKSVPPNSRFWAKMRYHMPVKNSQGFTWNQLRITSRIFQWKGLSRTETTGRSSQPKEW T60254 TARGETID T60254 T60254 FORMERID TTDI03331 T60254 UNIPROID KCNH1_HUMAN T60254 TARGNAME Voltage-gated potassium channel Kv10.1 (KCNH1) T60254 GENENAME KCNH1 T60254 TARGTYPE Literature-reported T60254 SYNONYMS hEAG1; h-eag; Voltage-gated potassium channel subunit Kv10.1; Potassium voltage-gated channel subfamily H member 1; EAG1; EAG channel 1; EAG T60254 FUNCTION Channel properties are modulated by subunit assembly. Mediates IK(NI) current in myoblasts. Involved in the regulation of cell proliferation and differentiation, in particular adipogenic and osteogenic differentiation in bone marrow-derived mesenchymal stem cells (MSCs). Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel. T60254 PDBSTRUC 5J7E T60254 BIOCLASS Voltage-gated ion channel T60254 SEQUENCE MTMAGGRRGLVAPQNTFLENIVRRSNDTNFVLGNAQIVDWPIVYSNDGFCKLSGYHRAEVMQKSSTCSFMYGELTDKDTIEKVRQTFENYEMNSFEILMYKKNRTPVWFFVKIAPIRNEQDKVVLFLCTFSDITAFKQPIEDDSCKGWGKFARLTRALTSSRGVLQQLAPSVQKGENVHKHSRLAEVLQLGSDILPQYKQEAPKTPPHIILHYCVFKTTWDWIILILTFYTAILVPYNVSFKTRQNNVAWLVVDSIVDVIFLVDIVLNFHTTFVGPAGEVISDPKLIRMNYLKTWFVIDLLSCLPYDVINAFENVDEVSAFMGDPGKIGFADQIPPPLEGRESQGISSLFSSLKVVRLLRLGRVARKLDHYIEYGAAVLVLLVCVFGLAAHWMACIWYSIGDYEIFDEDTKTIRNNSWLYQLAMDIGTPYQFNGSGSGKWEGGPSKNSVYISSLYFTMTSLTSVGFGNIAPSTDIEKIFAVAIMMIGSLLYATIFGNVTTIFQQMYANTNRYHEMLNSVRDFLKLYQVPKGLSERVMDYIVSTWSMSRGIDTEKVLQICPKDMRADICVHLNRKVFKEHPAFRLASDGCLRALAMEFQTVHCAPGDLIYHAGESVDSLCFVVSGSLEVIQDDEVVAILGKGDVFGDVFWKEATLAQSCANVRALTYCDLHVIKRDALQKVLEFYTAFSHSFSRNLILTYNLRKRIVFRKISDVKREEEERMKRKNEAPLILPPDHPVRRLFQRFRQQKEARLAAERGGRDLDDLDVEKGNVLTEHASANHSLVKASVVTVRESPATPVSFQAASTSGVPDHAKLQAPGSECLGPKGGGGDCAKRKSWARFKDACGKSEDWNKVSKAESMETLPERTKASGEATLKKTDSCDSGITKSDLRLDNVGEARSPQDRSPILAEVKHSFYPIPEQTLQATVLEVRHELKEDIKALNAKMTNIEKQLSEILRILTSRRSSQSPQELFEISRPQSPESERDIFGAS T60254 DRUGINFO D02QJW clofilium Investigative T60254 DRUGINFO D02WWM LY97241 Investigative T60254 DRUGINFO D0XH1N ICA-105574 Investigative T95154 TARGETID T95154 T95154 UNIPROID FMNL1_HUMAN T95154 TARGNAME Formin-like protein 1 (FMNL1) T95154 GENENAME FMNL1 T95154 TARGTYPE Literature-reported T95154 SYNONYMS Leukocyte formin; FRL1; FMNL; CLL-associated antigen KW-13; C17orf1B; C17orf1 T95154 FUNCTION May play a role in the control of cell motility and survival of macrophages. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the cortical actin filament dynamics and cell shape. T95154 PDBSTRUC 4YDH T95154 BIOCLASS Formin homology family T95154 SEQUENCE MGNAAGSAEQPAGPAAPPPKQPAPPKQPMPAAGELEERFNRALNCMNLPPDKVQLLSQYDNEKKWELICDQERFQVKNPPAAYIQKLKSYVDTGGVSRKVAADWMSNLGFKRRVQESTQVLRELETSLRTNHIGWVQEFLNEENRGLDVLLEYLAFAQCSVTYDMESTDNGASNSEKNKPLEQSVEDLSKGPPSSVPKSRHLTIKLTPAHSRKALRNSRIVSQKDDVHVCIMCLRAIMNYQSGFSLVMNHPACVNEIALSLNNKNPRTKALVLELLAAVCLVRGGHDIILAAFDNFKEVCGEQHRFEKLMEYFRNEDSNIDFMVACMQFINIVVHSVENMNFRVFLQYEFTHLGLDLYLERLRLTESDKLQVQIQAYLDNIFDVGALLEDTETKNAVLEHMEELQEQVALLTERLRDAENESMAKIAELEKQLSQARKELETLRERFSESTAMGPSRRPPEPEKAPPAAPTRPSALELKVEELEEKGLIRILRGPGDAVSIEILPVAVATPSGGDAPTPGVPTGSPSPDLAPAAEPAPGAAPPPPPPLPGLPSPQEAPPSAPPQAPPLPGSPEPPPAPPLPGDLPPPPPPPPPPPGTDGPVPPPPPPPPPPPGGPPDALGRRDSELGPGVKAKKPIQTKFRMPLLNWVALKPSQITGTVFTELNDEKVLQELDMSDFEEQFKTKSQGPSLDLSALKSKAAQKAPSKATLIEANRAKNLAITLRKGNLGAERICQAIEAYDLQALGLDFLELLMRFLPTEYERSLITRFEREQRPMEELSEEDRFMLCFSRIPRLPERMTTLTFLGNFPDTAQLLMPQLNAIIAASMSIKSSDKLRQILEIVLAFGNYMNSSKRGAAYGFRLQSLDALLEMKSTDRKQTLLHYLVKVIAEKYPQLTGFHSDLHFLDKAGSVSLDSVLADVRSLQRGLELTQREFVRQDDCMVLKEFLRANSPTMDKLLADSKTAQEAFESVVEYFGENPKTTSPGLFFSLFSRFIKAYKKAEQEVEQWKKEAAAQEAGADTPGKGEPPAPKSPPKARRPQMDLISELKRRQQKEPLIYESDRDGAIEDIITVIKTVPFTARTGKRTSRLLCEASLGEEMPL T19531 TARGETID T19531 T19531 FORMERID TTDI01386 T19531 UNIPROID ADCY5_HUMAN T19531 TARGNAME Adenylate cyclase type 5 (AC5) T19531 GENENAME ADCY5 T19531 TARGTYPE Literature-reported T19531 SYNONYMS Adenylyl cyclase 5; Adenylate cyclase type V; ATP pyrophosphate-lyase 5; AC5 T19531 FUNCTION Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling. Mediates signaling downstream of ADRB1. Regulates the increase of free cytosolic Ca(2+) in response to increased blood glucose levels and contributes to the regulation of Ca(2+)-dependent insulin secretion. T19531 BIOCLASS Phosphorus-oxygen lyase T19531 ECNUMBER EC 4.6.1.1 T19531 SEQUENCE MSGSKSVSPPGYAAQKTAAPAPRGGPEHRSAWGEADSRANGYPHAPGGSARGSTKKPGGAVTPQQQQRLASRWRSDDDDDPPLSGDDPLAGGFGFSFRSKSAWQERGGDDCGRGSRRQRRGAASGGSTRAPPAGGGGGSAAAAASAGGTEVRPRSVEVGLEERRGKGRAADELEAGAVEGGEGSGDGGSSADSGSGAGPGAVLSLGACCLALLQIFRSKKFPSDKLERLYQRYFFRLNQSSLTMLMAVLVLVCLVMLAFHAARPPLQLPYLAVLAAAVGVILIMAVLCNRAAFHQDHMGLACYALIAVVLAVQVVGLLLPQPRSASEGIWWTVFFIYTIYTLLPVRMRAAVLSGVLLSALHLAIALRTNAQDQFLLKQLVSNVLIFSCTNIVGVCTHYPAEVSQRQAFQETRECIQARLHSQRENQQQERLLLSVLPRHVAMEMKADINAKQEDMMFHKIYIQKHDNVSILFADIEGFTSLASQCTAQELVMTLNELFARFDKLAAENHCLRIKILGDCYYCVSGLPEARADHAHCCVEMGMDMIEAISLVREVTGVNVNMRVGIHSGRVHCGVLGLRKWQFDVWSNDVTLANHMEAGGKAGRIHITKATLNYLNGDYEVEPGCGGERNAYLKEHSIETFLILRCTQKRKEEKAMIAKMNRQRTNSIGHNPPHWGAERPFYNHLGGNQVSKEMKRMGFEDPKDKNAQESANPEDEVDEFLGRAIDARSIDRLRSEHVRKFLLTFREPDLEKKYSKQVDDRFGAYVACASLVFLFICFVQITIVPHSIFMLSFYLTCSLLLTLVVFVSVIYSCVKLFPSPLQTLSRKIVRSKMNSTLVGVFTITLVFLAAFVNMFTCNSRDLLGCLAQEHNISASQVNACHVAESAVNYSLGDEQGFCGSPWPNCNFPEYFTYSVLLSLLACSVFLQISCIGKLVLMLAIELIYVLIVEVPGVTLFDNADLLVTANAIDFFNNGTSQCPEHATKVALKVVTPIIISVFVLALYLHAQQVESTARLDFLWKLQATEEKEEMEELQAYNRRLLHNILPKDVAAHFLARERRNDELYYQSCECVAVMFASIANFSEFYVELEANNEGVECLRLLNEIIADFDEIISEDRFRQLEKIKTIGSTYMAASGLNDSTYDKVGKTHIKALADFAMKLMDQMKYINEHSFNNFQMKIGLNIGPVVAGVIGARKPQYDIWGNTVNVASRMDSTGVPDRIQVTTDMYQVLAANTYQLECRGVVKVKGKGEMMTYFLNGGPPLS T19531 DRUGINFO D03UXO NKY80 Investigative T35809 TARGETID T35809 T35809 FORMERID TTDI03063 T35809 UNIPROID BRD1_HUMAN T35809 TARGNAME Bromodomain-containing protein 1 (BRD1) T35809 GENENAME BRD1 T35809 TARGTYPE Literature-reported T35809 SYNONYMS Bromodomain and PHD finger-containing protein 2; BRPF2; BRL; BR140-like protein T35809 FUNCTION Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. T35809 PDBSTRUC 5PWB; 5PWA; 5PW9; 5PW8; 5PW7 T35809 BIOCLASS Bromodomain T35809 SEQUENCE MRRKGRCHRGSAARHPSSPCSVKHSPTRETLTYAQAQRMVEIEIEGRLHRISIFDPLEIILEDDLTAQEMSECNSNKENSERPPVCLRTKRHKNNRVKKKNEALPSAHGTPASASALPEPKVRIVEYSPPSAPRRPPVYYKFIEKSAEELDNEVEYDMDEEDYAWLEIVNEKRKGDCVPAVSQSMFEFLMDRFEKESHCENQKQGEQQSLIDEDAVCCICMDGECQNSNVILFCDMCNLAVHQECYGVPYIPEGQWLCRHCLQSRARPADCVLCPNKGGAFKKTDDDRWGHVVCALWIPEVGFANTVFIEPIDGVRNIPPARWKLTCYLCKQKGVGACIQCHKANCYTAFHVTCAQKAGLYMKMEPVKELTGGGTTFSVRKTAYCDVHTPPGCTRRPLNIYGDVEMKNGVCRKESSVKTVRSTSKVRKKAKKAKKALAEPCAVLPTVCAPYIPPQRLNRIANQVAIQRKKQFVERAHSYWLLKRLSRNGAPLLRRLQSSLQSQRSSQQRENDEEMKAAKEKLKYWQRLRHDLERARLLIELLRKREKLKREQVKVEQVAMELRLTPLTVLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPAAAPRRPFSWEDVDRLLDPANRAHLGLEEQLRELLDMLDLTCAMKSSGSRSKRAKLLKKEIALLRNKLSQQHSQPLPTGPGLEGFEEDGAALGPEAGEEVLPRLETLLQPRKRSRSTCGDSEVEEESPGKRLDAGLTNGFGGARSEQEPGGGLGRKATPRRRCASESSISSSNSPLCDSSFNAPKCGRGKPALVRRHTLEDRSELISCIENGNYAKAARIAAEVGQSSMWISTDAAASVLEPLKVVWAKCSGYPSYPALIIDPKMPRVPGHHNGVTIPAPPLDVLKIGEHMQTKSDEKLFLVLFFDNKRSWQWLPKSKMVPLGIDETIDKLKMMEGRNSSIRKAVRIAFDRAMNHLSRVHGEPTSDLSDID T35809 DRUGINFO D08RDI OF-1 Investigative T35809 DRUGINFO D0O6XT NI-57 Investigative T42025 TARGETID T42025 T42025 FORMERID TTDI03183 T42025 UNIPROID ERR2_HUMAN T42025 TARGNAME Estrogen-related receptor-beta (ESRRB) T42025 GENENAME ESRRB T42025 TARGTYPE Literature-reported T42025 SYNONYMS Steroid hormone receptor ERR2; Nuclear receptor subfamily 3 group B member 2; NR3B2; Estrogen-related receptor beta; Estrogen receptor-like 2; ESRL2; ERRB2; ERR-beta; ERR beta-2 T42025 FUNCTION Isoform 3: Transcription factor that binds a canonical ESRRB recognition (ERRE) sequence 5'TCAAGGTCA-3' localized on promoter and enhancer of targets genes regulating their expression or their transcription activity. Plays a role, in a LIF-independent manner, in maintainance of self-renewal and pluripotency of embryonic and trophoblast stem cells through different signaling pathways including FGF signaling pathway and Wnt signaling pathways. Upon FGF signaling pathway activation, interacts with KDM1A by directly binding to enhancer site of ELF5 and EOMES and activating their transcription leading to self-renewal of trophoblast stem cells. Also regulates expression of multiple rod-specific genes and is required for survival of this cell type (By similarity). Plays a role as transcription factor activator of GATA6, NR0B1, POU5F1 and PERM1. Plays a role as transcription factor repressor of NFE2L2 transcriptional activity and ESR1 transcriptional activity. During mitosis remains bound to a subset of interphase target genes, including pluripotency regulators, through the canonical ESRRB recognition (ERRE) sequence, leading to their transcriptional activation in early G1 phase. Can coassemble on structured DNA elements with other transcription factors like SOX2, POU5F1, KDM1A and NCOA3 to trigger ESRRB-dependent gene activation. This mechanism, in the case of SOX2 corecruitment prevents the embryonic stem cells (ESCs) to epiblast stem cells (EpiSC) transition through positive regulation of NR0B1 that inhibits the EpiSC transcriptional program. Also plays a role inner ear development by controlling expression of ion channels and transporters and in early placentation (By similarity). T42025 PDBSTRUC 1LO1 T42025 BIOCLASS Nuclear hormone receptor T42025 SEQUENCE MSSDDRHLGSSCGSFIKTEPSSPSSGIDALSHHSPSGSSDASGGFGLALGTHANGLDSPPMFAGAGLGGTPCRKSYEDCASGIMEDSAIKCEYMLNAIPKRLCLVCGDIASGYHYGVASCEACKAFFKRTIQGNIEYSCPATNECEITKRRRKSCQACRFMKCLKVGMLKEGVRLDRVRGGRQKYKRRLDSESSPYLSLQISPPAKKPLTKIVSYLLVAEPDKLYAMPPPGMPEGDIKALTTLCDLADRELVVIIGWAKHIPGFSSLSLGDQMSLLQSAWMEILILGIVYRSLPYDDKLVYAEDYIMDEEHSRLAGLLELYRAILQLVRRYKKLKVEKEEFVTLKALALANSDSMYIEDLEAVQKLQDLLHEALQDYELSQRHEEPWRTGKLLLTLPLLRQTAAKAVQHFYSVKLQGKVPMHKLFLEMLEAKV T42025 DRUGINFO D06JPQ DY131 Investigative T42025 DRUGINFO D0S9YX biochanin A Investigative T42025 DRUGINFO D0SY2M daidzein Investigative T08198 TARGETID T08198 T08198 FORMERID TTDI03428 T08198 UNIPROID OXSR1_HUMAN T08198 TARGNAME Oxidative stress responsive 1 (OXSR1) T08198 GENENAME OXSR1 T08198 TARGTYPE Literature-reported T08198 SYNONYMS Serine/threonine-protein kinase OSR1; Oxidative stress-responsive 1 protein; KIAA1101 T08198 FUNCTION Phosphorylates RELL1, RELL2 and RELT. Phosphorylates PAK1. Phosphorylates PLSCR1 in the presence of RELT. T08198 PDBSTRUC 3DAK; 2VWI; 2V3S T08198 ECNUMBER EC 2.7.11.1 T08198 SEQUENCE MSEDSSALPWSINRDDYELQEVIGSGATAVVQAAYCAPKKEKVAIKRINLEKCQTSMDELLKEIQAMSQCHHPNIVSYYTSFVVKDELWLVMKLLSGGSVLDIIKHIVAKGEHKSGVLDESTIATILREVLEGLEYLHKNGQIHRDVKAGNILLGEDGSVQIADFGVSAFLATGGDITRNKVRKTFVGTPCWMAPEVMEQVRGYDFKADIWSFGITAIELATGAAPYHKYPPMKVLMLTLQNDPPSLETGVQDKEMLKKYGKSFRKMISLCLQKDPEKRPTAAELLRHKFFQKAKNKEFLQEKTLQRAPTISERAKKVRRVPGSSGRLHKTEDGGWEWSDDEFDEESEEGKAAISQLRSPRVKESISNSELFPTTDPVGTLLQVPEQISAHLPQPAGQIATQPTQVSLPPTAEPAKTAQALSSGSGSQETKIPISLVLRLRNSKKELNDIRFEFTPGRDTAEGVSQELISAGLVDGRDLVIVAANLQKIVEEPQSNRSVTFKLASGVEGSDIPDDGKLIGFAQLSIS T08198 DRUGINFO D0RJ8J PMID24793884C74 Investigative T98078 TARGETID T98078 T98078 FORMERID TTDI01362 T98078 UNIPROID DCMC_HUMAN T98078 TARGNAME Malonyl-CoA decarboxylase (MLYCD) T98078 GENENAME MLYCD T98078 TARGTYPE Literature-reported T98078 SYNONYMS Malonyl-CoA decarboxylase, mitochondrial; MCD T98078 FUNCTION Catalyzes the conversion of malonyl-CoA to acetyl-CoA. In the fatty acid biosynthesis MCD selectively removes malonyl-CoA and thus assures that methyl-malonyl-CoA is the only chain elongating substrate for fatty acid synthase and that fatty acids with multiple methyl side chains are produced. In peroxisomes it may be involved in degrading intraperoxisomal malonyl-CoA, which is generated by the peroxisomal beta-oxidation of odd chain-length dicarboxylic fatty acids. Plays a role in the metabolic balance between glucose and lipid oxidation in muscle independent of alterations in insulin signaling. May play a role in controlling the extent of ischemic injury by promoting glucose oxidation. T98078 PDBSTRUC 4F0X; 2YGW T98078 ECNUMBER EC 4.1.1.9 T98078 SEQUENCE MRGFGPGLTARRLLPLRLPPRPPGPRLASGQAAGALERAMDELLRRAVPPTPAYELREKTPAPAEGQCADFVSFYGGLAETAQRAELLGRLARGFGVDHGQVAEQSAGVLHLRQQQREAAVLLQAEDRLRYALVPRYRGLFHHISKLDGGVRFLVQLRADLLEAQALKLVEGPDVREMNGVLKGMLSEWFSSGFLNLERVTWHSPCEVLQKISEAEAVHPVKNWMDMKRRVGPYRRCYFFSHCSTPGEPLVVLHVALTGDISSNIQAIVKEHPPSETEEKNKITAAIFYSISLTQQGLQGVELGTFLIKRVVKELQREFPHLGVFSSLSPIPGFTKWLLGLLNSQTKEHGRNELFTDSECKEISEITGGPINETLKLLLSSSEWVQSEKLVRALQTPLMRLCAWYLYGEKHRGYALNPVANFHLQNGAVLWRINWMADVSLRGITGSCGLMANYRYFLEETGPNSTSYLGSKIIKASEQVLSLVAQFQKNSKL T64725 TARGETID T64725 T64725 FORMERID TTDNR00674 T64725 UNIPROID FADS2_HUMAN T64725 TARGNAME Fatty acid desaturase 2 (FADS2) T64725 GENENAME FADS2 T64725 TARGTYPE Literature-reported T64725 SYNONYMS FADS2; Delta-6 desaturase; Delta(6) fatty acid desaturase; Delta(6) desaturase; D6D T64725 FUNCTION Component of a lipid metabolic pathway that catalyzes biosynthesis of highly unsaturated fatty acids (HUFA) from precursor essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3). Catalyzes the first andrate limiting step in this pathway which is the desaturation of LA (18:2n-6) and ALA (18:3n-3) into gamma- linoleic acid (GLA) (18:3n-6) and stearidonic acid (18:4n-3) respectively and other desaturation steps. Highly unsaturated fatty acids (HUFA) play pivotal roles in many biological functions. It catalizes as well the introduction of a cis double bond in palmitate to produce the mono-unsaturated fatty acid sapienate, the most abundant fatty acid in sebum. T64725 BIOCLASS Paired donor oxygen oxidoreductase T64725 ECNUMBER EC 1.14.19.3 T64725 SEQUENCE MGKGGNQGEGAAEREVSVPTFSWEEIQKHNLRTDRWLVIDRKVYNITKWSIQHPGGQRVIGHYAGEDATDAFRAFHPDLEFVGKFLKPLLIGELAPEEPSQDHGKNSKITEDFRALRKTAEDMNLFKTNHVFFLLLLAHIIALESIAWFTVFYFGNGWIPTLITAFVLATSQAQAGWLQHDYGHLSVYRKPKWNHLVHKFVIGHLKGASANWWNHRHFQHHAKPNIFHKDPDVNMLHVFVLGEWQPIEYGKKKLKYLPYNHQHEYFFLIGPPLLIPMYFQYQIIMTMIVHKNWVDLAWAVSYYIRFFITYIPFYGILGALLFLNFIRFLESHWFVWVTQMNHIVMEIDQEAYRDWFSSQLTATCNVEQSFFNDWFSGHLNFQIEHHLFPTMPRHNLHKIAPLVKSLCAKHGIEYQEKPLLRALLDIIRSLKKSGKLWLDAYLHK T36419 TARGETID T36419 T36419 FORMERID TTDI01445 T36419 UNIPROID TXD12_HUMAN T36419 TARGNAME Thioredoxin domain-contained protein 12 (TXNDC12) T36419 GENENAME TXNDC12 T36419 TARGTYPE Literature-reported T36419 SYNONYMS hTLP19; UNQ713/PRO1376; Thioredoxin-like protein p19; Thioredoxin domain-containing protein 12; TLP19; Endoplasmic reticulum resident protein 19; Endoplasmic reticulum resident protein 18; ERp19; ERp18; ER protein 19; ER protein 18 T36419 FUNCTION Possesses significant protein thiol-disulfide oxidase activity. T36419 PDBSTRUC 2K8V; 1SEN T36419 ECNUMBER EC 1.8.4.2 T36419 SEQUENCE METRPRLGATCLLGFSFLLLVISSDGHNGLGKGFGDHIHWRTLEDGKKEAAASGLPLMVIIHKSWCGACKALKPKFAESTEISELSHNFVMVNLEDEEEPKDEDFSPDGGYIPRILFLDPSGKVHPEIINENGNPSYKYFYVSAEQVVQGMKEAQERLTGDAFRKKHLEDEL T17523 TARGETID T17523 T17523 FORMERID TTDI03528 T17523 UNIPROID S1PR4_HUMAN T17523 TARGNAME Sphingosine-1-phosphate receptor 4 (S1PR4) T17523 GENENAME S1PR4 T17523 TARGTYPE Literature-reported T17523 SYNONYMS Sphingosine 1-phosphate receptor Edg-6; Sphingosine 1-phosphate receptor 4; S1P4; S1P receptor Edg-6; S1P receptor 4; Endothelial differentiation G-protein coupled receptor 6; EDG6 T17523 FUNCTION Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. May be involved in cell migration processes that are specific for lymphocytes. T17523 PDBSTRUC 2DCO T17523 BIOCLASS GPCR rhodopsin T17523 SEQUENCE MNATGTPVAPESCQQLAAGGHSRLIVLHYNHSGRLAGRGGPEDGGLGALRGLSVAASCLVVLENLLVLAAITSHMRSRRWVYYCLVNITLSDLLTGAAYLANVLLSGARTFRLAPAQWFLREGLLFTALAASTFSLLFTAGERFATMVRPVAESGATKTSRVYGFIGLCWLLAALLGMLPLLGWNCLCAFDRCSSLLPLYSKRYILFCLVIFAGVLATIMGLYGAIFRLVQASGQKAPRPAARRKARRLLKTVLMILLAFLVCWGPLFGLLLADVFGSNLWAQEYLRGMDWILALAVLNSAVNPIIYSFRSREVCRAVLSFLCCGCLRLGMRGPGDCLARAVEAHSGASTTDSSLRPRDSFRGSRSLSFRMREPLSSISSVRSI T17523 DRUGINFO D0L8NF phytosphingosine 1-phosphate Investigative T17523 DRUGINFO D02UUO dihydrosphingosine-1-phosphate Investigative T17523 DRUGINFO D0U7YK KRP 203-phosphate Investigative T17523 DRUGINFO D05KEE AFD(R) Investigative T17523 DRUGINFO D06DYN FTY720-phosphate Investigative T17523 DRUGINFO D0W1ZW VPC03090-P Investigative T17523 DRUGINFO D03BRM AUY954 Investigative T64485 TARGETID T64485 T64485 FORMERID TTDNR00643 T64485 UNIPROID ANGT_HUMAN T64485 TARGNAME Angiotensinogen (AGT) T64485 GENENAME AGT T64485 TARGTYPE Literature-reported T64485 SYNONYMS Serpin A8; SERPINA8 T64485 FUNCTION Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis. T64485 PDBSTRUC 6I3I; 6I3F; 5XJM; 5M3Y; 5M3X T64485 BIOCLASS Serpin protein T64485 SEQUENCE MRKRAPQSEMAPAGVSLRATILCLLAWAGLAAGDRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGALDHTADRLQAILGVPWKDKNCTSRLDAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGCSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDNSTSVSVPMLSGMGTFQHWSDIQDNFSVTQVPFTESACLLLIQPHYASDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIRVGEVLNSIFFELEADEREPTESTQQLNKPEVLEVTLNRPFLFAVYDQSATALHFLGRVANPLSTA T28025 TARGETID T28025 T28025 FORMERID TTDR00099 T28025 UNIPROID FOS_HUMAN T28025 TARGNAME Proto-oncogene c-Fos (c-Fos) T28025 GENENAME FOS T28025 TARGTYPE Literature-reported T28025 SYNONYMS G0S7; G0/G1 switch regulatory protein 7; Cellular oncogene fos; C-fos T28025 FUNCTION In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regulating the development of cells destined to form and maintain the skeleton. It is thought to have an important role in signal transduction, cell proliferation and differentiation. In growing cells, activates phospholipid synthesis, possibly by activating CDS1 and PI4K2A. This activity requires Tyr-dephosphorylation and association with the endoplasmic reticulum. Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor. T28025 PDBSTRUC 1S9K; 1FOS; 1A02 T28025 BIOCLASS Basic leucine zipper bZIP T28025 SEQUENCE MMFSGFNADYEASSSRCSSASPAGDSLSYYHSPADSFSSMGSPVNAQDFCTDLAVSSANFIPTVTAISTSPDLQWLVQPALVSSVAPSQTRAPHPFGVPAPSAGAYSRAGVVKTMTGGRAQSIGRRGKVEQLSPEEEEKRRIRRERNKMAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAHRPACKIPDDLGFPEEMSVASLDLTGGLPEVATPESEEAFTLPLLNDPEPKPSVEPVKSISSMELKTEPFDDFLFPASSRPSGSETARSVPDMDLSGSFYAADWEPLHSGSLGMGPMATELEPLCTPVVTCTPSCTAYTSSFVFTYPEADSFPSCAAAHRKGSSSNEPSSDSLSSPTLLAL T71081 TARGETID T71081 T71081 FORMERID TTDI02547 T71081 UNIPROID RASH_HUMAN T71081 TARGNAME GTPase HRas (HRAS) T71081 GENENAME HRAS T71081 TARGTYPE Literature-reported T71081 SYNONYMS p21ras; cHras; c-H-ras; Transforming protein p21; HaRas; Ha-Ras; H-Ras-1; GTPase HRas, Nterminally processed T71081 FUNCTION Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Involved in the activation of Ras protein signal transduction. T71081 PDBSTRUC 821P; 721P; 6Q21; 6D5W; 6D5V T71081 BIOCLASS Small GTPase T71081 SEQUENCE MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS T62912 TARGETID T62912 T62912 FORMERID TTDR00261 T62912 UNIPROID COLI_HUMAN T62912 TARGNAME Corticotropin-lipotropin (POMC) T62912 GENENAME POMC T62912 TARGTYPE Literature-reported T62912 SYNONYMS Pro-opiomelanocortin T62912 FUNCTION Corticotropin: Stimulates the adrenal glands to release cortisol. T62912 PDBSTRUC 4Y49; 4XPD; 4XNH T62912 SEQUENCE MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQDLTTESNLLECIRACKPDLSAETPMFPGNGDEQPLTENPRKYVMGHFRWDRFGRRNSSSSGSSGAGQKREDVSAGEDCGPLPEGGPEPRSDGAKPGPREGKRSYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEFKRELTGQRLREGDGPDGPADDGAGAQADLEHSLLVAAEKKDEGPYRMEHFRWGSPPKDKRYGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE T62912 DRUGINFO D0B7GU Dihydromorphine Investigative T51671 TARGETID T51671 T51671 FORMERID TTDR00777 T51671 UNIPROID NPY_HUMAN T51671 TARGNAME Neuropeptide Y (NPY) T51671 GENENAME NPY T51671 TARGTYPE Literature-reported T51671 SYNONYMS Pro-neuropeptide Y T51671 FUNCTION NPY is implicated in the control of feeding and in secretion of gonadotrophin-release hormone. T51671 PDBSTRUC 1RON; 1QFA T51671 SEQUENCE MLGNKRLGLSGLTLALSLLVCLGALAEAYPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRYGKRSSPETLISDLLMRESTENVPRTRLEDPAMW T51671 DRUGINFO D08JUG Alpha-Aminoisobutyric Acid Investigative T51671 DRUGINFO D0DO9W L-Tyrosinamide Investigative T50768 TARGETID T50768 T50768 FORMERID TTDI02055 T50768 UNIPROID DQA1_HUMAN T50768 TARGNAME HLA class II antigen DQ-2 alpha (HLA-DQA1) T50768 GENENAME HLA-DQA1 T50768 TARGTYPE Literature-reported T50768 SYNONYMS MHC class II DQA1; HLADQA1; HLADCA; HLA-DQA1; HLA class II histocompatibility antigen, DQ alpha 1 chain; DCalpha; DC1 alpha chain T50768 FUNCTION Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs,other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM andMHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. T50768 PDBSTRUC 6MFG; 6MFF; 5KSV; 5KSU; 5KSB T50768 BIOCLASS MHC class II T50768 SEQUENCE MILNKALMLGALALTTVMSPCGGEDIVADHVASYGVNLYQSYGPSGQYTHEFDGDEQFYVDLGRKETVWCLPVLRQFRFDPQFALTNIAVLKHNLNSLIKRSNSTAATNEVPEVTVFSKSPVTLGQPNILICLVDNIFPPVVNITWLSNGHSVTEGVSETSFLSKSDHSFFKISYLTLLPSAEESYDCKVEHWGLDKPLLKHWEPEIPAPMSELTETVVCALGLSVGLVGIVVGTVFIIRGLRSVGASRHQGPL T75655 TARGETID T75655 T75655 FORMERID TTDR00441 T75655 UNIPROID APOA2_HUMAN T75655 TARGNAME Apolipoprotein A-II (APOA2) T75655 GENENAME APOA2 T75655 TARGTYPE Literature-reported T75655 SYNONYMS Apolipoprotein A2; ApoA-II; Apo-AII T75655 FUNCTION May stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism. T75655 BIOCLASS Apolipoprotein T75655 SEQUENCE MKLLAATVLLLTICSLEGALVRRQAKEPCVESLVSQYFQTVTDYGKDLMEKVKSPELQAEAKSYFEKSKEQLTPLIKKAGTELVNFLSYFVELGTQPATQ T75655 DRUGINFO D02UVH B-Octylglucoside Investigative T26144 TARGETID T26144 T26144 FORMERID TTDI01765 T26144 UNIPROID FIBG_HUMAN T26144 TARGNAME Fibrinogen (FGG) T26144 GENENAME FGG T26144 TARGTYPE Literature-reported T26144 SYNONYMS PRO2061; Fibrinogen gamma chain T26144 FUNCTION Has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways. Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. T26144 PDBSTRUC 4B60; 3HUS; 3H32; 3GHG; 3FIB T26144 BIOCLASS Fibrinogen protein T26144 SEQUENCE MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQTKVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIMKYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQDIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEGFGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKYRLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGWWMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTIGEGQQHHLGGAKQVRPEHPAETEYDSLYPEDDL T66686 TARGETID T66686 T66686 FORMERID TTDR00666 T66686 UNIPROID PBPB_ECOLI T66686 TARGNAME Bacterial Penicillin-binding protein 1B (Bact mrcB) T66686 GENENAME Bact mrcB T66686 TARGTYPE Literature-reported T66686 SYNONYMS mrcB; PBP1b; PBP-1b; PBP 1b; Murein polymerase T66686 FUNCTION Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits). T66686 PDBSTRUC 6G5R; 6FZK; 5HLD; 5HLB; 5HLA T66686 BIOCLASS Acyltransferase T66686 SEQUENCE MAGNDREPIGRKGKPTRPVKQKVSRRRYEDDDDYDDYDDYEDEEPMPRKGKGKGKGRKPRGKRGWLWLLLKLAIVFAVLIAIYGVYLDQKIRSRIDGKVWQLPAAVYGRMVNLEPDMTISKNEMVKLLEATQYRQVSKMTRPGEFTVQANSIEMIRRPFDFPDSKEGQVRARLTFDGDHLATIVNMENNRQFGFFRLDPRLITMISSPNGEQRLFVPRSGFPDLLVDTLLATEDRHFYEHDGISLYSIGRAVLANLTAGRTVQGASTLTQQLVKNLFLSSERSYWRKANEAYMALIMDARYSKDRILELYMNEVYLGQSGDNEIRGFPLASLYYFGRPVEELSLDQQALLVGMVKGASIYNPWRNPKLALERRNLVLRLLQQQQIIDQELYDMLSARPLGVQPRGGVISPQPAFMQLVRQELQAKLGDKVKDLSGVKIFTTFDSVAQDAAEKAAVEGIPALKKQRKLSDLETAIVVVDRFSGEVRAMVGGSEPQFAGYNRAMQARRSIGSLAKPATYLTALSQPKIYRLNTWIADAPIALRQPNGQVWSPQNDDRRYSESGRVMLVDALTRSMNVPTVNLGMALGLPAVTETWIKLGVPKDQLHPVPAMLLGALNLTPIEVAQAFQTIASGGNRAPLSALRSVIAEDGKVLYQSFPQAERAVPAQAAYLTLWTMQQVVQRGTGRQLGAKYPNLHLAGKTGTTNNNVDTWFAGIDGSTVTITWVGRDNNQPTKLYGASGAMSIYQRYLANQTPTPLNLVPPEDIADMGVDYDGNFVCSGGMRILPVWTSDPQSLCQQSEMQQQPSGNPFDQSSQPQQQPQQQPAQQEQKDSDGVAGWIKDMFGSN T66686 DRUGINFO D08COD N-BENZOYL-D-ALANINE Investigative T66686 DRUGINFO D0O4TL Cephalosporin C Investigative T78338 TARGETID T78338 T78338 FORMERID TTDNR00676 T78338 UNIPROID POLG_YEFV1 T78338 TARGNAME Flavivirus RNA-directed RNA polymerase NS5 (FlaV NS5) T78338 GENENAME FlaV NS5 T78338 TARGTYPE Literature-reported T78338 SYNONYMS Flavivirus Non-structural protein 5 T78338 FUNCTION Capsid protein C: Plays a role in virus budding by binding to the cell membrane and gathering the viral RNA into a nucleocapsid that forms the core of a mature virus particle. During virus entry, may induce genome penetration into the host cytoplasm after hemifusion induced by the surface proteins. Can migrate to the cell nucleus where it modulates host functions. T78338 PDBSTRUC 6IW4; 6IW2; 6IW1; 6IW0; 6EPK T78338 ECNUMBER EC 2.1.1.56 T78338 SEQUENCE GSANGKTLGEVWKRELNLLDKRQFELYKRTDIVEVDRDTARRHLAEGKVDTGVAVSRGTAKLRWFHERGYVKLEGRVIDLGCGRGGWCYYAAAQKEVSGVKGFTLGRDGHEKPMNVQSLGWNIITFKDKTDIHRLEPVKCDTLLCDIGESSSSSVTEGERTVRVLDTVEKWLACGVDNFCVKVLAPYMPDVLEKLELLQRRFGGTVIRNPLSRNSTHEMYYVSGARSNVTFTVNQTSRLLMRRMRRPTGKVTLEADVILPIGTRSVETDKGPLDKEAIEERVERIKSEYMTSWFYDNDNPYRTWHYCGSYVTKTSGSAASMVNGVIKILTYPWDRIEEVTRMAMTDTTPFGQQRVFKEKVDTRAKDPPAGTRKIMKVVNRWLFRHLAREKNPRLCTKEEFIAKVRSHAAIGAYLEEQEQWKTANEAVQDPKFWELVDEERKLHQQGRCRTCVYNMMGKREKKLSEFGKAKGSRAIWYMWLGARYLEFEALGFLNEDHWASRENSGGGVEGIGLQYLGYVIRDLAAMDGGGFYADDTAGWDTRITEADLDDEQEILNYMSPHHKKLAQAVMEMTYKNKVVKVLRPAPGGKAYMDVISRRDQRGSGQVVTYALNTITNLKVQLIRMAEAEMVIHHQHVQDCDESVLTRLEAWLTEHGCDRLKRMAVSGDDCVVRPIDDRFGLALSHLNAMSKVRKDISEWQPSKGWNDWENVPFCSHHFHELQLKDGRRIVVPCREQDELIGRGRVSPGNGWMIKETACLSKAYANMWSLMYFHKRDMRLLSLAVSSAVPTSWVPQGRTTWSIHGKGEWMTTEDMLEVWNRVWITNNPHMQDKTMVKKWRDVPYLTKRQDKLCGSLIGMTNRATWASHIHLVIHRIRTLIGQEKYTDYLTVMDRYSVDADLQLGELI T26457 TARGETID T26457 T26457 FORMERID TTDI02427 T26457 UNIPROID ITB3_HUMAN T26457 TARGNAME Integrin beta-3 (ITGB3) T26457 GENENAME ITGB3 T26457 TARGTYPE Literature-reported T26457 SYNONYMS GPIIIa; GP3A; CD61 T26457 FUNCTION Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling. ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling. ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling. ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling. ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling. ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. T26457 PDBSTRUC 6CKB; 6BXJ; 6BXF; 6BXB; 6AVU T26457 BIOCLASS Integrin T26457 SEQUENCE MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT T27402 TARGETID T27402 T27402 FORMERID TTDR00789 T27402 UNIPROID S10A8_HUMAN T27402 TARGNAME Calgranulin A (S100A8) T27402 GENENAME S100A8 T27402 TARGTYPE Literature-reported T27402 SYNONYMS Urinary stone protein band A; S100 calcium-binding protein A8; Protein S100-A8; P8; Myeloid-related protein 8; Migration inhibitory factor-related protein 8; MRP8; MRP-8; Leukocyte L1 complex light chain; Cystic fibrosis antigen; Calprotectin L1L subunit; Calgranulin-A; CFAG; CAGA T27402 FUNCTION It can induce neutrophil chemotaxis and adhesion. Predominantly found as calprotectin (S100A8/A9) which has a wide plethora of intra- and extracellular functions. The intracellular functions include: facilitating leukocyte arachidonic acid trafficking and metabolism, modulation of the tubulin-dependent cytoskeleton during migration of phagocytes and activation of the neutrophilic NADPH-oxidase. Activates NADPH-oxidase by facilitating the enzyme complex assembly at the cell membrane, transferring arachidonic acid, an essential cofactor, to the enzyme complex and S100A8 contributes to the enzyme assembly by directly binding to NCF2/P67PHOX. The extracellular functions involve proinflammatory, antimicrobial, oxidant-scavenging and apoptosis-inducing activities. Its proinflammatory activity includes recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to pattern recognition receptors such as Toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (AGER). Binding to TLR4 and AGER activates the MAP-kinase and NF-kappa-B signaling pathways resulting in the amplification of the proinflammatory cascade. Has antimicrobial activity towards bacteria and fungi and exerts its antimicrobial activity probably via chelation of Zn(2+) which is essential for microbial growth. Can induce cell death via autophagy and apoptosis and this occurs through the cross-talk of mitochondria and lysosomes via reactive oxygen species (ROS) and the process involves BNIP3. Can regulate neutrophil number and apoptosis by an anti-apoptotic effect; regulates cell survival via ITGAM/ITGB and TLR4 and a signaling mechanism involving MEK-ERK. Its role as an oxidant scavenger has a protective role in preventing exaggerated tissue damage by scavenging oxidants. Can act as a potent amplifier of inflammation in autoimmunity as well as in cancer development and tumor spread. The iNOS-S100A8/A9 transnitrosylase complex directs selective inflammatory stimulus-dependent S-nitrosylation of GAPDH and probably multiple targets such as ANXA5, EZR, MSN and VIM by recognizing a [IL]-x-C-x-x-[DE] motif; S100A8 seems to contribute to S-nitrosylation site selectivity. S100A8 is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. T27402 PDBSTRUC 6DS2; 5W1F; 5HLV; 5HLO; 4XJK T27402 BIOCLASS S100 calcium-binding protein T27402 SEQUENCE MLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRKKGADVWFKELDINTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE T25076 TARGETID T25076 T25076 FORMERID TTDR00412 T25076 UNIPROID EDN1_HUMAN T25076 TARGNAME Endothelin-1 (EDN1) T25076 GENENAME EDN1 T25076 TARGTYPE Literature-reported T25076 SYNONYMS Preproendothelin-1; PPET1 T25076 FUNCTION Endothelins are endothelium-derived vasoconstrictor peptides. T25076 PDBSTRUC 6DK5; 5GLH; 1V6R; 1T7H; 1EDP T25076 BIOCLASS Endothelin/sarafotoxin T25076 SEQUENCE MDYLLMIFSLLFVACQGAPETAVLGAELSAVGENGGEKPTPSPPWRLRRSKRCSCSSLMDKECVYFCHLDIIWVNTPEHVVPYGLGSPRSKRALENLLPTKATDRENRCQCASQKDKKCWNFCQAGKELRAEDIMEKDWNNHKKGKDCSKLGKKCIYQQLVRGRKIRRSSEEHLRQTRSETMRNSVKSSFHDPKLKGKPSRERYVTHNRAHW T25076 DRUGINFO D09WFI Tetramethylpyrazine Discontinued in Phase 2 T28153 TARGETID T28153 T28153 FORMERID TTDR00570 T28153 UNIPROID ILVC_ECOLI T28153 TARGNAME Bacterial Ketol-acid reductoisomerase (Bact ilvC) T28153 GENENAME Bact ilvC T28153 TARGTYPE Literature-reported T28153 SYNONYMS Ketol-acid reductoisomerase type II; Ketol-acid reductoisomerase type 2; Ketol-acid reductoisomerase (NADP(+)); KARI; Alpha-keto-beta-hydroxylacyl reductoisomerase; Acetohydroxy-acid isomeroreductase; AHIR T28153 FUNCTION Involved in the biosynthesis of branched-chain amino acids (BCAA). Catalyzes an alkyl-migration followed by a ketol-acid reduction of (S)-2-acetolactate (S2AL) to yield (R)-2,3-dihydroxy-isovalerate. In the isomerase reaction, S2AL is rearranged via a Mg-dependent methyl migration to produce 3-hydroxy-3-methyl-2-ketobutyrate (HMKB). In the reductase reaction, this 2-ketoacid undergoes a metal-dependent reduction by NADPH to yield (R)-2,3-dihydroxy-isovalerate. Also able to use 2-ketopantoate, 2-ketoisovalerate, 2-ketovalerate, 2-ketobutyrate, 3-hydroxypyruvate, 3-hydroxy-2-ketobutyrate and pyruvate. T28153 PDBSTRUC 3ULK; 1YRL T28153 BIOCLASS Short-chain dehydrogenases reductase T28153 SEQUENCE MANYFNTLNLRQQLAQLGKCRFMGRDEFADGASYLQGKKVVIVGCGAQGLNQGLNMRDSGLDISYALRKEAIAEKRASWRKATENGFKVGTYEELIPQADLVINLTPDKQHSDVVRTVQPLMKDGAALGYSHGFNIVEVGEQIRKDITVVMVAPKCPGTEVREEYKRGFGVPTLIAVHPENDPKGEGMAIAKAWAAATGGHRAGVLESSFVAEVKSDLMGEQTILCGMLQAGSLLCFDKLVEEGTDPAYAEKLIQFGWETITEALKQGGITLMMDRLSNPAKLRAYALSEQLKEIMAPLFQKHMDDIISGEFSSGMMADWANDDKKLLTWREETGKTAFETAPQYEGKIGEQEYFDKGVLMIAMVKAGVELAFETMVDSGIIEESAYYESLHELPLIANTIARKRLYEMNVVISDTAEYGNYLFSYACVPLLKPFMAELQPGDLGKAIPEGAVDNGQLRDVNEAIRSHAIEQVGKKLRGYMTDMKRIAVAG T23000 TARGETID T23000 T23000 FORMERID TTDI02079 T23000 UNIPROID GELS_HUMAN T23000 TARGNAME Gelsolin (GSN) T23000 GENENAME GSN T23000 TARGTYPE Literature-reported T23000 SYNONYMS GSN; Brevin; Actindepolymerizing factor; AGEL T23000 FUNCTION Calcium-regulated, actin-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-blocking or capping). It can promote the assembly of monomers into filaments (nucleation) as well as sever filaments already formed. Plays a role in ciliogenesis. {ECO:0000269|PubMed:20393563}. T23000 PDBSTRUC 6H1F; 5UBO; 5O2Z; 5H3N; 5H3M T23000 SEQUENCE MAPHRPAPALLCALSLALCALSLPVRAATASRGASQAGAPQGRVPEARPNSMVVEHPEFLKAGKEPGLQIWRVEKFDLVPVPTNLYGDFFTGDAYVILKTVQLRNGNLQYDLHYWLGNECSQDESGAAAIFTVQLDDYLNGRAVQHREVQGFESATFLGYFKSGLKYKKGGVASGFKHVVPNEVVVQRLFQVKGRRVVRATEVPVSWESFNNGDCFILDLGNNIHQWCGSNSNRYERLKATQVSKGIRDNERSGRARVHVSEEGTEPEAMLQVLGPKPALPAGTEDTAKEDAANRKLAKLYKVSNGAGTMSVSLVADENPFAQGALKSEDCFILDHGKDGKIFVWKGKQANTEERKAALKTASDFITKMDYPKQTQVSVLPEGGETPLFKQFFKNWRDPDQTDGLGLSYLSSHIANVERVPFDAATLHTSTAMAAQHGMDDDGTGQKQIWRIEGSNKVPVDPATYGQFYGGDSYIILYNYRHGGRQGQIIYNWQGAQSTQDEVAASAILTAQLDEELGGTPVQSRVVQGKEPAHLMSLFGGKPMIIYKGGTSREGGQTAPASTRLFQVRANSAGATRAVEVLPKAGALNSNDAFVLKTPSAAYLWVGTGASEAEKTGAQELLRVLRAQPVQVAEGSEPDGFWEALGGKAAYRTSPRLKDKKMDAHPPRLFACSNKIGRFVIEEVPGELMQEDLATDDVMLLDTWDQVFVWVGKDSQEEEKTEALTSAKRYIETDPANRDRRTPITVVKQGFEPPSFVGWFLGWDDDYWSVDPLDRAMAELAA T68513 TARGETID T68513 T68513 FORMERID TTDI00080 T68513 UNIPROID S10A6_HUMAN T68513 TARGNAME S100 calcium-binding protein A6 (S100A6) T68513 GENENAME S100A6 T68513 TARGTYPE Literature-reported T68513 SYNONYMS Protein S100-A6; Prolactin receptor-associated protein; PRA; MLN 4; Growth factor-inducible protein 2A9; Calcyclin; CACY T68513 FUNCTION May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a role in many physiological processes such as the reorganization of the actin cytoskeleton and in cell motility. Binds 2 calcium ions. Calcium binding is cooperative. May function as calcium sensor and modulator, contributing to cellular calcium signaling. T68513 PDBSTRUC 4YBH; 2M1K; 1K9P; 1K9K; 1K96 T68513 BIOCLASS S100 calcium-binding protein T68513 SEQUENCE MACPLDQAIGLLVAIFHKYSGREGDKHTLSKKELKELIQKELTIGSKLQDAEIARLMEDLDRNKDQEVNFQEYVTFLGALALIYNEALKG T68829 TARGETID T68829 T68829 FORMERID TTDI02351 T68829 UNIPROID APOA4_HUMAN T68829 TARGNAME Apolipoprotein A-IV (APOA4) T68829 GENENAME APOA4 T68829 TARGTYPE Literature-reported T68829 SYNONYMS Apolipoprotein A4; ApoAIV; APOA4 T68829 FUNCTION May have a role in chylomicrons and VLDL secretion and catabolism. Required for efficient activation of lipoprotein lipase by ApoC-II; potent activator of LCAT. Apoa-IV is a major component of HDL and chylomicrons. T68829 PDBSTRUC 3S84 T68829 BIOCLASS Apolipoprotein T68829 SEQUENCE MFLKAVVLTLALVAVAGARAEVSADQVATVMWDYFSQLSNNAKEAVEHLQKSELTQQLNALFQDKLGEVNTYAGDLQKKLVPFATELHERLAKDSEKLKEEIGKELEELRARLLPHANEVSQKIGDNLRELQQRLEPYADQLRTQVSTQAEQLRRQLTPYAQRMERVLRENADSLQASLRPHADELKAKIDQNVEELKGRLTPYADEFKVKIDQTVEELRRSLAPYAQDTQEKLNHQLEGLTFQMKKNAEELKARISASAEELRQRLAPLAEDVRGNLRGNTEGLQKSLAELGGHLDQQVEEFRRRVEPYGENFNKALVQQMEQLRQKLGPHAGDVEGHLSFLEKDLRDKVNSFFSTFKEKESQDKTLSLPELEQQQEQQQEQQQEQVQMLAPLES T64137 TARGETID T64137 T64137 FORMERID TTDR00387 T64137 UNIPROID CRF_HUMAN T64137 TARGNAME Corticoliberin (CRH) T64137 GENENAME CRH T64137 TARGTYPE Literature-reported T64137 SYNONYMS Corticotropin-releasing hormone; Corticotropin-releasing factor; Corticotropin releasing hormone; Corticotropin; CRF; Adrenocorticotropic hormone T64137 FUNCTION Induces NLRP6 in intestinal epithelial cells, hence may influence gut microbiota profile. Hormone regulating the release of corticotropin from pituitary gland. T64137 PDBSTRUC 3EHU; 3EHT; 1GOE; 1GO9 T64137 SEQUENCE MRLPLLVSAGVLLVALLPCPPCRALLSRGPVPGARQAPQHPQPLDFFQPPPQSEQPQQPQARPVLLRMGEEYFLRLGNLNKSPAAPLSPASSLLAGGSGSRPSPEQATANFFRVLLQQLLLPRRSLDSPAALAERGARNALGGHQEAPERERRSEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEIIGK T64137 DRUGINFO D0B3LN D-Phenylalanine Investigative T64137 DRUGINFO D08JUG Alpha-Aminoisobutyric Acid Investigative T04386 TARGETID T04386 T04386 FORMERID TTDNR00644 T04386 UNIPROID ANXA2_HUMAN T04386 TARGNAME Annexin A2 (ANXA2) T04386 GENENAME ANXA2 T04386 TARGTYPE Literature-reported T04386 SYNONYMS p36; Protein I; Placental anticoagulant protein IV; PAP-IV; Lipocortin II; LPC2D; Chromobindin-8; Calpactin-1 heavy chain; Calpactin I heavy chain; CAL1H; Annexin-2; Annexin II; ANX2L4; ANX2 T04386 FUNCTION It binds two calcium ions with high affinity. May be involved in heat-stress response. Inhibits PCSK9-enhanced LDLR degradation, probably reduces PCSK9 protein levels via a translational mechanism but also competes with LDLR for binding with PCSK9. Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. T04386 PDBSTRUC 5N7G; 5N7F; 5N7D; 5LQ2; 5LQ0 T04386 BIOCLASS Annexin protein T04386 SEQUENCE MSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNILTNRSNAQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKGLGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRAEDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDMLESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDMLKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD T86717 TARGETID T86717 T86717 FORMERID TTDR00762 T86717 UNIPROID AROB_ECOLI T86717 TARGNAME Bacterial Dehydroquinate synthase (Bact aroB) T86717 GENENAME Bact aroB T86717 TARGTYPE Literature-reported T86717 SYNONYMS DHQS; 3-dehydroquinate synthase T86717 FUNCTION Catalyzes the conversion of 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) to dehydroquinate (DHQ). T86717 BIOCLASS Alpha-carbonic anhydrase T86717 SEQUENCE MERIVVTLGERSYPITIASGLFNEPASFLPLKSGEQVMLVTNETLAPLYLDKVRGVLEQAGVNVDSVILPDGEQYKSLAVLDTVFTALLQKPHGRDTTLVALGGGVVGDLTGFAAASYQRGVRFIQVPTTLLSQVDSSVGGKTAVNHPLGKNMIGAFYQPASVVVDLDCLKTLPPRELASGLAEVIKYGIILDGAFFNWLEENLDALLRLDGPAMAYCIRRCCELKAEVVAADERETGLRALLNLGHTFGHAIEAEMGYGNWLHGEAVAAGMVMAARTSERLGQFSSAETQRIITLLKRAGLPVNGPREMSAQAYLPHMLRDKKVLAGEMRLILPLAIGKSEVRSGVSHELVLNAIADCQSA T86717 DRUGINFO D02XNU Carbaphosphonate Investigative T86717 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T52936 TARGETID T52936 T52936 FORMERID TTDI03135 T52936 UNIPROID CXB1_HUMAN T52936 TARGNAME Connexin-32 (Cx32) T52936 GENENAME GJB1 T52936 TARGTYPE Literature-reported T52936 SYNONYMS Gap junction beta-1 protein; GAP junction 28 kDa liver protein; CX32 T52936 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T52936 PDBSTRUC 5KK9; 1TXH T52936 BIOCLASS Gap junction-forming connexin T52936 SEQUENCE MNWTGLYTLLSGVNRHSTAIGRVWLSVIFIFRIMVLVVAAESVWGDEKSSFICNTLQPGCNSVCYDQFFPISHVRLWSLQLILVSTPALLVAMHVAHQQHIEKKMLRLEGHGDPLHLEEVKRHKVHISGTLWWTYVISVVFRLLFEAVFMYVFYLLYPGYAMVRLVKCDVYPCPNTVDCFVSRPTEKTVFTVFMLAASGICIILNVAEVVYLIIRACARRAQRRSNPPSRKGSGFGHRLSPEYKQNEINKLLSEQDGSLKDILRRSPGTGAGLAEKSDRCSAC T52936 DRUGINFO D00VJY octanol Investigative T63179 TARGETID T63179 T63179 FORMERID TTDS00196 T63179 UNIPROID MCR_HUMAN T63179 TARGNAME Aldosterone receptor (NR3C2) T63179 GENENAME NR3C2 T63179 TARGTYPE Literature-reported T63179 SYNONYMS MR T63179 FUNCTION Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels. T63179 PDBSTRUC 6GGG; 6GG8; 6GEV; 5MWY; 5MWP T63179 SEQUENCE METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNSTQGSSKEKQELLPCLQQDNNRPGILTSDIKTELESKELSATVAESMGLYMDSVRDADYSYEQQNQQGSMSPAKIYQNVEQLVKFYKGNGHRPSTLSCVNTPLRSFMSDSGSSVNGGVMRAVVKSPIMCHEKSPSVCSPLNMTSSVCSPAGINSVSSTTASFGSFPVHSPITQGTPLTCSPNVENRGSRSHSPAHASNVGSPLSSPLSSMKSSISSPPSHCSVKSPVSSPNNVTLRSSVSSPANINNSRCSVSSPSNTNNRSTLSSPAASTVGSICSPVNNAFSYTASGTSAGSSTLRDVVPSPDTQEKGAQEVPFPKTEEVESAISNGVTGQLNIVQYIKPEPDGAFSSSCLGGNSKINSDSSFSVPIKQESTKHSCSGTSFKGNPTVNPFPFMDGSYFSFMDDKDYYSLSGILGPPVPGFDGNCEGSGFPVGIKQEPDDGSYYPEASIPSSAIVGVNSGGQSFHYRIGAQGTISLSRSARDQSFQHLSSFPPVNTLVESWKSHGDLSSRRSDGYPVLEYIPENVSSSTLRSVSTGSSRPSKICLVCGDEASGCHYGVVTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRLQKCLQAGMNLGARKSKKLGKLKGIHEEQPQQQQPPPPPPPPQSPEEGTTYIAPAKEPSVNTALVPQLSTISRALTPSPVMVLENIEPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQVVKWAKVLPGFKNLPLEDQITLIQYSWMCLSSFALSWRSYKHTNSQFLYFAPDLVFNEEKMHQSAMYELCQGMHQISLQFVRLQLTFEEYTIMKVLLLLSTIPKDGLKSQAAFEEMRTNYIKELRKMVTKCPNNSGQSWQRFYQLTKLLDSMHDLVSDLLEFCFYTFRESHALKVEFPAMLVEIISDQLPKVESGNAKPLYFHRK T17221 TARGETID T17221 T17221 UNIPROID GSTA1_HUMAN T17221 TARGNAME Glutathione S-transferase A1 (GSTA1) T17221 GENENAME GSTA1 T17221 TARGTYPE Literature-reported T17221 SYNONYMS GTH1; GSTA1-1; GST-epsilon; GST class-alpha member 1; GST HA subunit 1; Androst-5-ene-3,17-dione isomerase; 13-hydroperoxyoctadecadienoate peroxidase T17221 FUNCTION Glutathione S-transferase that catalyzes the nucleophilic attack of the sulfur atom of glutathione on the electrophilic groups of a wide range of exogenous and endogenous compounds (Probable). Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2). It also catalyzes the isomerization of D5-androstene-3,17-dione (AD) into D4-androstene-3,17-dione and may therefore play an important role in hormone biosynthesis. Through its glutathione-dependent peroxidase activity toward the fatty acid hydroperoxide (13S)-hydroperoxy-(9Z,11E)-octadecadienoate/13-HPODE it is also involved in the metabolism of oxidized linoleic acid. T17221 PDBSTRUC 6ATR; 6ATQ; 6ATP; 6ATO; 5LD0 T17221 ECNUMBER EC 2.5.1.18 T17221 SEQUENCE MAEKPKLHYFNARGRMESTRWLLAAAGVEFEEKFIKSAEDLDKLRNDGYLMFQQVPMVEIDGMKLVQTRAILNYIASKYNLYGKDIKERALIDMYIEGIADLGEMILLLPVCPPEEKDAKLALIKEKIKNRYFPAFEKVLKSHGQDYLVGNKLSRADIHLVELLYYVEELDSSLISSFPLLKALKTRISNLPTVKKFLQPGSPRKPPMDEKSLEEARKIFRF T63359 TARGETID T63359 T63359 FORMERID TTDR01102 T63359 UNIPROID MURB_ECOLI T63359 TARGNAME Bacterial UDP-N-acetylenolpyruvylglucosamine reductase (Bact murB) T63359 GENENAME Bact murB T63359 TARGTYPE Literature-reported T63359 SYNONYMS UDP-N-acetylmuramate dehydrogenase; MurB T63359 FUNCTION Cell wall formation. T63359 PDBSTRUC 2Q85; 2MBR; 1UXY; 1MBT; 1MBB T63359 BIOCLASS Short-chain dehydrogenases reductase T63359 SEQUENCE MNHSLKPWNTFGIDHNAQHIVCAEDEQQLLNAWQYATAEGQPVLILGEGSNVLFLEDYRGTVIINRIKGIEIHDEPDAWYLHVGAGENWHRLVKYTLQEGMPGLENLALIPGCVGSSPIQNIGAYGVELQRVCAYVDSVELATGKQVRLTAKECRFGYRDSIFKHEYQDRFAIVAVGLRLPKEWQPVLTYGDLTRLDPTTVTPQQVFNAVCHMRTTKLPDPKVNGNAGSFFKNPVVSAETAKALLSQFPTAPNYPQADGSVKLAAGWLIDQCQLKGMQIGGAAVHRQQALVLINEDNAKSEDVVQLAHHVRQKVGEKFNVWLEPEVRFIGASGEVSAVETIS T63359 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T78241 TARGETID T78241 T78241 FORMERID TTDI01453 T78241 UNIPROID ICP0_HHV11 T78241 TARGNAME Herpes simplex virus E3 ubiquitin-protein ligase ICP0 (HSV ICP0) T78241 GENENAME HSV ICP0 T78241 TARGTYPE Literature-reported T78241 SYNONYMS VMW110; Trans-acting transcriptional protein ICP0; RING-type E3 ubiquitin transferase ICP0; Immediate-early protein IE110; E3 ubiquitin-protein ligase ICP0; Alpha-0 protein T78241 FUNCTION Evades nuclear antiviral defenses triggered by dsDNA viruses. Acts during the initial stages of lytic infection and the reactivation of latent viral genome. Prevents the antiviral effect of nuclear bodies by degrading host PML and SP100. Prevents antiviral response to viral DNA induced by IFI16 by degrading it. Additionally, inhibits host IRF3 nuclear signaling to prevent interferon production by the infected cells. Interestingly, the E3 ubiquitin ligase activity associated with the RING finger domain does not seem to be directly required to inhibit the activation of IRF3 but instead plays a critical role in modulating the cellular localization of ICP0. Upon reactivation of latent genome, suppresses the silencing of viral DNA by dissociating either HDAC1 or HDAC2 from the HDAC-RCOR1-REST-KDM1A complex localized at the ND10 structures and causes their dispersal. Two cellular histone ubiquitin ligases RNF8 and RNF168 are also targeted by ICP0 for degradation, leading to a loss of ubiquitinated forms of H2A, a relief of transcriptional repression, and the activation of latent viral genomes. Enhances the localization of host CCND3 to ND10 bodies that serve as precursors of replication compartments to enable efficient viral replication. Like many RING-finger E3 ubiquitin ligases, ICP0 can induce its own ubiquitination, an activity that promotes its instability due to its targeting to the 26S proteasome for degradation. ICP0 restricts this process by recruiting the cellular ubiquitin-specific protease USP7 that cleaves the anchored ubiquitin chains from ICP0, thereby promoting its stabilization. T78241 PDBSTRUC 5C56; 4WPI; 4WPH T78241 ECNUMBER EC 2.3.2.27 T78241 SEQUENCE MEPRPGASTRRPEGRPQREPAPDVWVFPCDRDLPDSSDSEAETEVGGRGDADHHDDDSASEADSTDTELFETGLLGPQGVDGGAVSGGSPPREEDPGSCGGAPPREDGGSDEGDVCAVCTDEIAPHLRCDTFPCMHRFCIPCMKTWMQLRNTCPLCNAKLVYLIVGVTPSGSFSTIPIVNDPQTRMEAEEAVRAGTAVDFIWTGNQRFAPRYLTLGGHTVRALSPTHPEPTTDEDDDDLDDADYVPPAPRRTPRAPPRRGAAAPPVTGGASHAAPQPAAARTAPPSAPIGPHGSSNTNTTTNSSGGGGSRQSRAAAPRGASGPSGGVGVGVGVVEAEAGRPRGRTGPLVNRPAPLANNRDPIVISDSPPASPHRPPAAPMPGSAPRPGPPASAAASGPARPRAAVAPCVRAPPPGPGPRAPAPGAEPAARPADARRVPQSHSSLAQAANQEQSLCRARATVARGSGGPGVEGGHGPSRGAAPSGAAPLPSAASVEQEAAVRPRKRRGSGQENPSPQSTRPPLAPAGAKRAATHPPSDSGPGGRGQGGPGTPLTSSAASASSSSASSSSAPTPAGAASSAAGAASSSASASSGGAVGALGGRQEETSLGPRAASGPRGPRKCARKTRHAETSGAVPAGGLTRYLPISGVSSVVALSPYVNKTITGDCLPILDMETGNIGAYVVLVDQTGNMATRLRAAVPGWSRRTLLPETAGNHVMPPEYPTAPASEWNSLWMTPVGNMLFDQGTLVGALDFRSLRSRHPWSGEQGASTRDEGKQ T15048 TARGETID T15048 T15048 FORMERID TTDR00333 T15048 UNIPROID IBP1_HUMAN T15048 TARGNAME Insulin-like growth factor-binding protein 1 (IGFBP1) T15048 GENENAME IGFBP1 T15048 TARGTYPE Literature-reported T15048 SYNONYMS Placental protein 12; PP12; KITLG; IGFBP-1; IGF-binding protein 1; IBP1; IBP-1 T15048 FUNCTION IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Promotes cell migration. T15048 PDBSTRUC 2DSQ; 1ZT5; 1ZT3 T15048 BIOCLASS Insulin-like growth factor binding T15048 SEQUENCE MSEVPVARVWLVLLLLTVQVGVTAGAPWQCAPCSAEKLALCPPVSASCSEVTRSAGCGCCPMCALPLGAACGVATARCARGLSCRALPGEQQPLHALTRGQGACVQESDASAPHAAEAGSPESPESTEITEEELLDNFHLMAPSEEDHSILWDAISTYDGSKALHVTNIKKWKEPCRIELYRVVESLAKAQETSGEEISKFYLPNCNKNGFYHSRQCETSMDGEAGLCWCVYPWNGKRIPGSPEIRGDPNCQIYFNVQN T95409 TARGETID T95409 T95409 FORMERID TTDR00357 T95409 UNIPROID PT1_ECOLI T95409 TARGNAME Bacterial Phosphoenolpyruvate transferase (Bact ptsI) T95409 GENENAME Bact ptsI T95409 TARGTYPE Literature-reported T95409 SYNONYMS ptsI; Phosphotransferase system, enzyme I; Phosphoenolpyruvate-protein phosphotransferase T95409 FUNCTION General (non sugar-specific) component of the phosphoenolpyruvate-dependent sugar phosphotransferase system (sugar PTS). This major carbohydrate active-transport system catalyzes the phosphorylation of incoming sugar substrates concomitantly with their translocation across the cell membrane. Enzyme I transfers the phosphoryl group from phosphoenolpyruvate (PEP) to the phosphoryl carrier protein (HPr). T95409 PDBSTRUC 3EZE; 3EZB; 3EZA; 2XDF; 2N5T T95409 BIOCLASS Kinase T95409 SEQUENCE MISGILASPGIAFGKALLLKEDEIVIDRKKISADQVDQEVERFLSGRAKASAQLETIKTKAGETFGEEKEAIFEGHIMLLEDEELEQEIIALIKDKHMTADAAAHEVIEGQASALEELDDEYLKERAADVRDIGKRLLRNILGLKIIDLSAIQDEVILVAADLTPSETAQLNLKKVLGFITDAGGRTSHTSIMARSLELPAIVGTGSVTSQVKNDDYLILDAVNNQVYVNPTNEVIDKMRAVQEQVASEKAELAKLKDLPAITLDGHQVEVCANIGTVRDVEGAERNGAEGVGLYRTEFLFMDRDALPTEEEQFAAYKAVAEACGSQAVIVRTMDIGGDKELPYMNFPKEENPFLGWRAIRIAMDRREILRDQLRAILRASAFGKLRIMFPMIISVEEVRALRKEIEIYKQELRDEGKAFDESIEIGVMVETPAAATIARHLAKEVDFFSIGTNDLTQYTLAVDRGNDMISHLYQPMSPSVLNLIKQVIDASHAEGKWTGMCGELAGDERATLLLLGMGLDEFSMSAISIPRIKKIIRNTNFEDAKVLAEQALAQPTTDELMTLVNKFIEEKTIC T95409 DRUGINFO D0L3IS 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE Investigative T53510 TARGETID T53510 T53510 UNIPROID GSTA2_HUMAN T53510 TARGNAME Glutathione S-transferase A2 (GSTA2) T53510 GENENAME GSTA2 T53510 TARGTYPE Literature-reported T53510 SYNONYMS GTH2; GSTA2-2; GST2; GST-gamma; GST class-alpha member 2; GST HA subunit 2 T53510 FUNCTION Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. T53510 PDBSTRUC 4ACS; 2WJU; 2VCT; 1AGS T53510 ECNUMBER EC 2.5.1.18 T53510 SEQUENCE MAEKPKLHYSNIRGRMESIRWLLAAAGVEFEEKFIKSAEDLDKLRNDGYLMFQQVPMVEIDGMKLVQTRAILNYIASKYNLYGKDIKEKALIDMYIEGIADLGEMILLLPFSQPEEQDAKLALIQEKTKNRYFPAFEKVLKSHGQDYLVGNKLSRADIHLVELLYYVEELDSSLISSFPLLKALKTRISNLPTVKKFLQPGSPRKPPMDEKSLEESRKIFRF T96005 TARGETID T96005 T96005 FORMERID TTDR00743 T96005 UNIPROID GROA_HUMAN T96005 TARGNAME C-X-C motif chemokine 1 (CXCL1) T96005 GENENAME CXCL1 T96005 TARGTYPE Literature-reported T96005 SYNONYMS SCYB1; Neutrophil-activating protein 3; NAP-3; Melanoma growth stimulatory activity; MGSA; Growth-regulated alpha protein; Growth regulated protein; GROA; GRO1; GRO-alpha(1-73); GRO-alpha; GRO-a protein; GRO T96005 FUNCTION May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity. Has chemotactic activity for neutrophils. T96005 PDBSTRUC 1ROD; 1MSH; 1MSG; 1MGS T96005 BIOCLASS Cytokine: CXC chemokine T96005 SEQUENCE MARAALSAAPSNPRLLRVALLLLLLVAAGRRAAGASVATELRCQCLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPASPIVKKIIEKMLNSDKSN T63595 TARGETID T63595 T63595 FORMERID TTDR00518 T63595 UNIPROID HMGB1_HUMAN T63595 TARGNAME High mobility group protein B1 (HMGB1) T63595 GENENAME HMGB1 T63595 TARGTYPE Literature-reported T63595 SYNONYMS High mobility group protein 1; High mobility group box chromosomal protein 1; HMG1; HMG-1 T63595 FUNCTION In the nucleus is one of the major chromatin-associated non-histone proteins and acts as a DNA chaperone involved in replication, transcription, chromatin remodeling, V(D)J recombination, DNA repair and genome stability. Proposed to be an universal biosensor for nucleic acids. Promotes host inflammatory response to sterile and infectious signals and is involved in the coordination and integration of innate and adaptive immune responses. In the cytoplasm functions as sensor and/or chaperone for immunogenic nucleic acids implicating the activation of TLR9-mediated immune responses, and mediates autophagy. Acts as danger associated molecular pattern (DAMP) molecule that amplifies immune responses during tissue injury. Released to the extracellular environment can bind DNA, nucleosomes, IL-1 beta, CXCL12, AGER isoform 2/sRAGE, lipopolysaccharide (LPS) and lipoteichoic acid (LTA), and activates cells through engagement of multiple surface receptors. In the extracellular compartment fully reduced HMGB1 (released by necrosis) acts as a chemokine, disulfide HMGB1 (actively secreted) as a cytokine, and sulfonyl HMGB1 (released from apoptotic cells) promotes immunological tolerance. Has proangiogdenic activity. May be involved in platelet activation. Binds to phosphatidylserine and phosphatidylethanolamide. Bound to RAGE mediates signaling for neuronal outgrowth. May play a role in accumulation of expanded polyglutamine (polyQ) proteins such as huntingtin (HTT) or TBP. Multifunctional redox sensitive protein with various roles in different cellular compartments. T63595 PDBSTRUC 6CIM; 6CIL; 6CIK; 6CIJ; 6CG0 T63595 SEQUENCE MGKGDPKKPRGKMSSYAFFVQTCREEHKKKHPDASVNFSEFSKKCSERWKTMSAKEKGKFEDMAKADKARYEREMKTYIPPKGETKKKFKDPNAPKRPPSAFFLFCSEYRPKIKGEHPGLSIGDVAKKLGEMWNNTAADDKQPYEKKAAKLKEKYEKDIAAYRAKGKPDAAKKGVVKAEKSKKKKEEEEDEEDEEDEEEEEDEEDEDEEEDDDDE T63595 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T40103 TARGETID T40103 T40103 FORMERID TTDI03092 T40103 UNIPROID CATH_HUMAN T40103 TARGNAME Cathepsin H (CTSH) T40103 GENENAME CTSH T40103 TARGTYPE Literature-reported T40103 SYNONYMS Pro-cathepsin H T40103 FUNCTION Important for the overall degradation of proteins in lysosomes. T40103 PDBSTRUC 6CZS; 6CZK; 1BZN T40103 BIOCLASS Peptidase T40103 SEQUENCE MWATLPLLCAGAWLLGVPVCGAAELCVNSLEKFHFKSWMSKHRKTYSTEEYHHRLQTFASNWRKINAHNNGNHTFKMALNQFSDMSFAEIKHKYLWSEPQNCSATKSNYLRGTGPYPPSVDWRKKGNFVSPVKNQGACGSCWTFSTTGALESAIAIATGKMLSLAEQQLVDCAQDFNNHGCQGGLPSQAFEYILYNKGIMGEDTYPYQGKDGYCKFQPGKAIGFVKDVANITIYDEEAMVEAVALYNPVSFAFEVTQDFMMYRTGIYSSTSCHKTPDKVNHAVLAVGYGEKNGIPYWIVKNSWGPQWGMNGYFLIERGKNMCGLAACASYPIPLV T40103 DRUGINFO D0G2QG PMID16290936C1b Investigative T49925 TARGETID T49925 T49925 FORMERID TTDI03198 T49925 UNIPROID FGR_HUMAN T49925 TARGNAME Tyrosine-protein kinase Fgr (FGR) T49925 GENENAME FGR T49925 TARGTYPE Literature-reported T49925 SYNONYMS p58c-Fgr; p58-Fgr; p55-Fgr; SRC2; Proto-oncogene c-Fgr; Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog T49925 FUNCTION Promotes mast cell degranulation, release of inflammatory cytokines and IgE-mediated anaphylaxis. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as MS4A2/FCER1B, FCGR2A and/or FCGR2B. Acts downstream of ITGB1 and ITGB2, and regulates actin cytoskeleton reorganization, cell spreading and adhesion. Depending on the context, activates or inhibits cellular responses. Functions as negative regulator of ITGB2 signaling, phagocytosis and SYK activity in monocytes. Required for normal ITGB1 and ITGB2 signaling, normal cell spreading and adhesion in neutrophils and macrophages. Functions as positive regulator of cell migration and regulates cytoskeleton reorganization via RAC1 activation. Phosphorylates SYK (in vitro) and promotes SYK-dependent activation of AKT1 and MAP kinase signaling. Phosphorylates PLD2 in antigen-stimulated mast cells, leading to PLD2 activation and the production of the signaling molecules lysophosphatidic acid and diacylglycerol. Promotes activation of PIK3R1. Phosphorylates FASLG, and thereby regulates its ubiquitination and subsequent internalization. Phosphorylates ABL1. Promotes phosphorylation of CBL, CTTN, PIK3R1, PTK2/FAK1, PTK2B/PYK2 and VAV2. Phosphorylates HCLS1 that has already been phosphorylated by SYK, but not unphosphorylated HCLS1. Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration. T49925 BIOCLASS Kinase T49925 ECNUMBER EC 2.7.10.2 T49925 SEQUENCE MGCVFCKKLEPVATAKEDAGLEGDFRSYGAADHYGPDPTKARPASSFAHIPNYSNFSSQAINPGFLDSGTIRGVSGIGVTLFIALYDYEARTEDDLTFTKGEKFHILNNTEGDWWEARSLSSGKTGCIPSNYVAPVDSIQAEEWYFGKIGRKDAERQLLSPGNPQGAFLIRESETTKGAYSLSIRDWDQTRGDHVKHYKIRKLDMGGYYITTRVQFNSVQELVQHYMEVNDGLCNLLIAPCTIMKPQTLGLAKDAWEISRSSITLERRLGTGCFGDVWLGTWNGSTKVAVKTLKPGTMSPKAFLEEAQVMKLLRHDKLVQLYAVVSEEPIYIVTEFMCHGSLLDFLKNPEGQDLRLPQLVDMAAQVAEGMAYMERMNYIHRDLRAANILVGERLACKIADFGLARLIKDDEYNPCQGSKFPIKWTAPEAALFGRFTIKSDVWSFGILLTELITKGRIPYPGMNKREVLEQVEQGYHMPCPPGCPASLYEAMEQTWRLDPEERPTFEYLQSFLEDYFTSAEPQYQPGDQT T49925 DRUGINFO D08RZB PMID15546730C2 Investigative T49925 DRUGINFO D0E7VO PMID24900538C2c Investigative T70019 TARGETID T70019 T70019 FORMERID TTDR01441 T70019 UNIPROID NORA_STAAU T70019 TARGNAME Staphylococcus Quinolone resistance protein norA (Stap-coc norA) T70019 GENENAME Stap-coc norA T70019 TARGTYPE Literature-reported T70019 SYNONYMS norA T70019 FUNCTION Involved in quinolone resistance. May constitute a membrane-associated active efflux pump of hydrophilic quinolones. T70019 BIOCLASS Major facilitator superfamily T70019 SEQUENCE MNKQIFVLYFNIFLIFLGIGLVIPVLPVYLKDLGLTGSDLGLLVAAFALSQMIISPFGGTLADKLGKKLIICIGLILFSVSEFMFAVGHNFSVLMLSRVIGGMSAGMVMPGVTGLIADISPSHQKAKNFGYMSAIINSGFILGPGIGGFMAEVSHRMPFYFAGALGILAFIMSIVLIHDPKKSTTSGFQKLEPQLLTKINWKVFITPVILTLVLSFGLSAFETLYSLYTADKVNYSPKDISIAITGGGIFGALFQIYFFDKFMKYFSELTFIAWSLLYSVVVLILLVFANGYWSIMLISFVVFIGFDMIRPAITNYFSNIAGERQGFAGGLNSTFTSMGNFIGPLIAGALFDVHIEAPIYMAIGVSLAGVVIVLIEKQHRAKLKEQNM T23688 TARGETID T23688 T23688 FORMERID TTDR00022 T23688 UNIPROID KDSA_ECOLI T23688 TARGNAME Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA) T23688 GENENAME Bact kdsA T23688 TARGTYPE Literature-reported T23688 SYNONYMS kdsA; Phospho-2-dehydro-3-deoxyoctonate aldolase; KDOPS; KDOP synthase; KDO8PS; KDO8P synthase; KDO8-P synthase; KDO-8-phosphate synthetase; 3-deoxy-D-manno-octulosonic acid 8-phosphate synthetase; 3-Deoxy-d-manno-2-octulosonate-8-phosphate synthase; 2-dehydro-3-deoxyphosphooctonate aldolase T23688 FUNCTION Synthesis of KDO 8-P which is required for lipid A maturation and cellular growth. T23688 PDBSTRUC 1X8F; 1X6U; 1Q3N; 1PL9; 1PHW T23688 BIOCLASS Alkyl aryl transferase T23688 SEQUENCE MKQKVVSIGDINVANDLPFVLFGGMNVLESRDLAMRICEHYVTVTQKLGIPYVFKASFDKANRSSIHSYRGPGLEEGMKIFQELKQTFGVKIITDVHEPSQAQPVADVVDVIQLPAFLARQTDLVEAMAKTGAVINVKKPQFVSPGQMGNIVDKFKEGGNEKVILCDRGANFGYDNLVVDMLGFSIMKKVSGNSPVIFDVTHALQCRDPFGAASGGRRAQVAELARAGMAVGLAGLFIEAHPDPEHAKCDGPSALPLAKLEPFLKQMKAIDDLVKGFEELDTSK T23688 DRUGINFO D02KLU Ribose-5-Phosphate Investigative T23688 DRUGINFO D04OQZ Arabinose-5-Phosphate Investigative T23688 DRUGINFO D05FBL 1-Deoxy-Ribofuranose-5'-Phosphate Investigative T23688 DRUGINFO D0C1PC 3-Fluoro-2-(Phosphonooxy)Propanoic Acid Investigative T23688 DRUGINFO D0KT4N Erythose-4-Phosphate Investigative T23688 DRUGINFO D0RK2I 2-(Phosphonooxy)Butanoic Acid Investigative T23688 DRUGINFO D0T3AE Phosphoenolpyruvate Investigative T23688 DRUGINFO D03KBV 2-Phosphoglyceric Acid Investigative T51284 TARGETID T51284 T51284 FORMERID TTDR00655 T51284 UNIPROID PDXJ_ECOLI T51284 TARGNAME Bacterial Pyridoxal phosphate biosynthetic pdxJ (Bact pdxJ) T51284 GENENAME Bact pdxJ T51284 TARGTYPE Literature-reported T51284 SYNONYMS pdxJ; Pyridoxine 5'-phosphate synthase; PNP synthase T51284 FUNCTION Catalyzes the condensation of 1-deoxy-d-xylulose-5- phosphate (dxp) and 1-amino-3-(phosphohydroxy)propan-2-one to form pyridoxine 5'-phosphate (pnp). T51284 PDBSTRUC 1M5W; 1IXQ; 1IXP; 1IXO; 1IXN T51284 ECNUMBER EC 2.6.99.2 T51284 SEQUENCE MAELLLGVNIDHIATLRNARGTAYPDPVQAAFIAEQAGADGITVHLREDRRHITDRDVRILRQTLDTRMNLEMAVTEEMLAIAVETKPHFCCLVPEKRQEVTTEGGLDVAGQRDKMRDACKRLADAGIQVSLFIDADEEQIKAAAEVGAPFIEIHTGCYADAKTDAEQAQELARIAKAATFAASLGLKVNAGHGLTYHNVKAIAAIPEMHELNIGHAIIGRAVMTGLKDAVAEMKRLMLEARG T51284 DRUGINFO D09JAO 1-Deoxy-D-Xylulose-5-Phosphate Investigative T51284 DRUGINFO D03MUW 3-Phosphoglycerol Investigative T51284 DRUGINFO D0B8JD Pyridoxine-5'-Phosphate Investigative T32468 TARGETID T32468 T32468 FORMERID TTDR00291 T32468 UNIPROID FABB_ECOL6 T32468 TARGNAME Bacterial Beta-ketoacyl-ACP synthase I (Bact fabB) T32468 GENENAME Bact fabB T32468 TARGTYPE Literature-reported T32468 SYNONYMS fabB; KAS I; Condensing enzyme FabB; 3-oxoacyl-[acyl-carrier-protein] synthase I T32468 FUNCTION Catalyzes the condensation reactionof fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-acp. Specific for elongation from c-10 to unsaturated c-16 and c-18 fatty acids. T32468 BIOCLASS Acyltransferase T32468 ECNUMBER EC 2.3.1.41 T32468 SEQUENCE MKRAVITGLGIVSSIGNNQQEVLASLREGRSGITFSQELKDSGMRSHVWGNVKLDTTGLIDRKVVRFMSDASIYAFLSMEQAIADAGLSPEAYQNNPRVGLIAGSGGGSPRFQVFGADAMRGPRGLKAVGPYVVTKAMASGVSACLATPFKIHGVNYSISSACATSAHCIGNAVEQIQLGKQDIVFAGGGEELCWEMACEFDAMGALSTKYNDTPEKASRTYDAHRDGFVIAGGGGMVVVEELEHALARGAHIYAEIVGYGATSDGADMVAPSGEGAVRCMKMAMHGVDTPIDYLNSHGTSTPVGDVKELAAIREVFGDKSPAISATKAMTGHSLGAAGVQEAIYSLLMLEHGFIAPSINIEELDEQAAGLNIVTETTDRELTTVMSNSFGFGGTNATLVMRKLKD T32468 DRUGINFO D04JTY Thiolactomycin Investigative T66964 TARGETID T66964 T66964 FORMERID TTDR00218 T66964 UNIPROID CYSK_ECOLI T66964 TARGNAME Bacterial O-acetylserine sulfhydrylase A (Bact cysK) T66964 GENENAME Bact cysK T66964 TARGTYPE Literature-reported T66964 SYNONYMS Sulfate starvation-induced protein 5; SSI5; S-carboxymethylcysteine synthase; OAS-TL A; O-acetylserine sulfhydrylase A; O-acetylserine (thiol)-lyase A; Cysteine synthase A; CSase A T66964 FUNCTION In addition to its role in cysteine synthesis, stimulates the tRNase activity of CdiA-CT from E.coli strain 536 / UPEC in microbial infection; stimulation does not require O-acetylserine sulfhydrylase activity. CdiA is the toxic component of a toxin-immunity protein module, which functions as a cellular contact-dependent growth inhibition (CDI) system. CDI modules allow bacteria to communicate with and inhibit the growth of closely related neighboring bacteria in a contact-dependent fashion (experiments done in strains BW25113 and X90, both K12 derivatives). This protein is not required for CDI of strain EC93, whose toxin may function by forming inner cell membrane pores. CysK stabilizes CdiA-CT, allowing it to bind tRNA substrate; neither CdiA-CT nor CysK bind tRNA alone in vitro. T66964 PDBSTRUC 5J5V; 5J43 T66964 BIOCLASS Alkyl aryl transferase T66964 SEQUENCE MSKIFEDNSLTIGHTPLVRLNRIGNGRILAKVESRNPSFSVKCRIGANMIWDAEKRGVLKPGVELVEPTSGNTGIALAYVAAARGYKLTLTMPETMSIERRKLLKALGANLVLTEGAKGMKGAIQKAEEIVASNPEKYLLLQQFSNPANPEIHEKTTGPEIWEDTDGQVDVFIAGVGTGGTLTGVSRYIKGTKGKTDLISVAVEPTDSPVIAQALAGEEIKPGPHKIQGIGAGFIPANLDLKLVDKVIGITNEEAISTARRLMEEEGILAGISSGAAVAAALKLQEDESFTNKNIVVILPSSGERYLSTALFADLFTEKELQQ T53588 TARGETID T53588 T53588 FORMERID TTDI02066 T53588 UNIPROID FABI_ECOLI T53588 TARGNAME Bacterial NADH-dependent enoyl-ACP reductase (Bact fabI) T53588 GENENAME Bact fabI T53588 TARGTYPE Literature-reported T53588 SYNONYMS Enoyl[acylcarrierprotein] reductase [NADH] FabI; ENR of Mycobacterium tuberculosis T53588 FUNCTION Catalyzes the reduction of a carbon-carbon double bond in an enoyl moiety that is covalently linked to an acyl carrier protein (ACP). Involved in the elongation cycle of fatty acid which are used in the lipid metabolism and in the biotin biosynthesis. T53588 PDBSTRUC 5CG2; 5CG1; 5CFZ; 4JX8; 4JQC T53588 BIOCLASS Short-chain dehydrogenases reductase T53588 SEQUENCE MGFLSGKRILVTGVASKLSIAYGIAQAMHREGAELAFTYQNDKLKGRVEEFAAQLGSDIVLQCDVAEDASIDTMFAELGKVWPKFDGFVHSIGFAPGDQLDGDYVNAVTREGFKIAHDISSYSFVAMAKACRSMLNPGSALLTLSYLGAERAIPNYNVMGLAKASLEANVRYMANAMGPEGVRVNAISAGPIRTLAASGIKDFRKMLAHCEAVTPIRRTVTIEDVGNSAAFLCSDLSAGISGEVVHVDGGFSIAAMNELELK T53588 DRUGINFO D00KJO MUT-056399 Preclinical T70521 TARGETID T70521 T70521 FORMERID TTDR00591 T70521 UNIPROID MTNN_ECOLI T70521 TARGNAME Bacterial MTA/SAH nucleosidase (Bact mtnN) T70521 GENENAME Bact mtnN T70521 TARGTYPE Literature-reported T70521 SYNONYMS mtnN; S-adenosylhomocysteine nucleosidase; P46; 5'-methylthioadenosine nucleosidase; 5'-Methylthioadenosine/S-adenosylhomocysteine (MTA/AdoHcy) nucleosidase T70521 FUNCTION Catalyzes the irreversible cleavage of the glycosidic bond in both 5'-methylthioadenosine (MTA) and S- adenosylhomocysteine (SAH/AdoHcy) to adenine and the corresponding thioribose, 5'-methylthioribose and S-ribosylhomocysteine, respectively. Can also use 5'-isobutylthioadenosine, 5'-n- butylthioadenosine, S-adenosyl-D-homocysteine, decarboxylated adenosylhomocysteine, deaminated adenosylhomocysteine and S-2-aza- adenosylhomocysteine as substrates. T70521 PDBSTRUC 4YML; 4WKC; 3O4V; 1Z5P; 1Z5O T70521 BIOCLASS Glycosylase T70521 SEQUENCE MKIGIIGAMEEEVTLLRDKIENRQTISLGGCEIYTGQLNGTEVALLKSGIGKVAAALGATLLLEHCKPDVIINTGSAGGLAPTLKVGDIVVSDEARYHDADVTAFGYEYGQLPGCPAGFKADDKLIAAAEACIAELNLNAVRGLIVSGDAFINGSVGLAKIRHNFPQAIAVEMEATAIAHVCHNFNVPFVVVRAISDVADQQSHLSFDEFLAVAAKQSSLMVESLVQKLAHG T70521 DRUGINFO D02JUP 5'-Deoxy-5'-(Methylthio)-Tubercidin Investigative T70521 DRUGINFO D0NH1Y Formycin Investigative T92724 TARGETID T92724 T92724 FORMERID TTDNR00744 T92724 UNIPROID R1AB_CVHSA T92724 TARGNAME Virus Replicase polyprotein 1ab (Viru rep) T92724 GENENAME Viru rep T92724 TARGTYPE Literature-reported T92724 SYNONYMS rep of Human SARS coronavirus; pp1ab; ORF1ab polyprotein T92724 FUNCTION O-methyltransferase: Methyltransferase that mediates mRNAcap 2'-O-ribose methylation to the 5'-cap structure of viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16. Therefore plays an essential role in viral mRNAs cap methylation which is essential to evade immune system. T92724 PDBSTRUC 5NFY; 5N5O; 5N19; 5F22; 5E6J T92724 BIOCLASS Viral RNA helicase T92724 SEQUENCE MESLVLGVNEKTHVQLSLPVLQVRDVLVRGFGDSVEEALSEAREHLKNGTCGLVELEKGVLPQLEQPYVFIKRSDALSTNHGHKVVELVAEMDGIQYGRSGITLGVLVPHVGETPIAYRNVLLRKNGNKGAGGHSYGIDLKSYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGGAVTRYVDNNFCGPDGYPLDCIKDFLARAGKSMCTLSEQLDYIESKRGVYCCRDHEHEIAWFTERSDKSYEHQTPFEIKSAKKFDTFKGECPKFVFPLNSKVKVIQPRVEKKKTEGFMGRIRSVYPVASPQECNNMHLSTLMKCNHCDEVSWQTCDFLKATCEHCGTENLVIEGPTTCGYLPTNAVVKMPCPACQDPEIGPEHSVADYHNHSNIETRLRKGGRTRCFGGCVFAYVGCYNKRAYWVPRASADIGSGHTGITGDNVETLNEDLLEILSRERVNINIVGDFHLNEEVAIILASFSASTSAFIDTIKSLDYKSFKTIVESCGNYKVTKGKPVKGAWNIGQQRSVLTPLCGFPSQAAGVIRSIFARTLDAANHSIPDLQRAAVTILDGISEQSLRLVDAMVYTSDLLTNSVIIMAYVTGGLVQQTSQWLSNLLGTTVEKLRPIFEWIEAKLSAGVEFLKDAWEILKFLITGVFDIVKGQIQVASDNIKDCVKCFIDVVNKALEMCIDQVTIAGAKLRSLNLGEVFIAQSKGLYRQCIRGKEQLQLLMPLKAPKEVTFLEGDSHDTVLTSEEVVLKNGELEALETPVDSFTNGAIVGTPVCVNGLMLLEIKDKEQYCALSPGLLATNNVFRLKGGAPIKGVTFGEDTVWEVQGYKNVRITFELDERVDKVLNEKCSVYTVESGTEVTEFACVVAEAVVKTLQPVSDLLTNMGIDLDEWSVATFYLFDDAGEENFSSRMYCSFYPPDEEEEDDAECEEEEIDETCEHEYGTEDDYQGLPLEFGASAETVRVEEEEEEDWLDDTTEQSEIEPEPEPTPEEPVNQFTGYLKLTDNVAIKCVDIVKEAQSANPMVIVNAANIHLKHGGGVAGALNKATNGAMQKESDDYIKLNGPLTVGGSCLLSGHNLAKKCLHVVGPNLNAGEDIQLLKAAYENFNSQDILLAPLLSAGIFGAKPLQSLQVCVQTVRTQVYIAVNDKALYEQVVMDYLDNLKPRVEAPKQEEPPNTEDSKTEEKSVVQKPVDVKPKIKACIDEVTTTLEETKFLTNKLLLFADINGKLYHDSQNMLRGEDMSFLEKDAPYMVGDVITSGDITCVVIPSKKAGGTTEMLSRALKKVPVDEYITTYPGQGCAGYTLEEAKTALKKCKSAFYVLPSEAPNAKEEILGTVSWNLREMLAHAEETRKLMPICMDVRAIMATIQRKYKGIKIQEGIVDYGVRFFFYTSKEPVASIITKLNSLNEPLVTMPIGYVTHGFNLEEAARCMRSLKAPAVVSVSSPDAVTTYNGYLTSSSKTSEEHFVETVSLAGSYRDWSYSGQRTELGVEFLKRGDKIVYHTLESPVEFHLDGEVLSLDKLKSLLSLREVKTIKVFTTVDNTNLHTQLVDMSMTYGQQFGPTYLDGADVTKIKPHVNHEGKTFFVLPSDDTLRSEAFEYYHTLDESFLGRYMSALNHTKKWKFPQVGGLTSIKWADNNCYLSSVLLALQQLEVKFNAPALQEAYYRARAGDAANFCALILAYSNKTVGELGDVRETMTHLLQHANLESAKRVLNVVCKHCGQKTTTLTGVEAVMYMGTLSYDNLKTGVSIPCVCGRDATQYLVQQESSFVMMSAPPAEYKLQQGTFLCANEYTGNYQCGHYTHITAKETLYRIDGAHLTKMSEYKGPVTDVFYKETSYTTTIKPVSYKLDGVTYTEIEPKLDGYYKKDNAYYTEQPIDLVPTQPLPNASFDNFKLTCSNTKFADDLNQMTGFTKPASRELSVTFFPDLNGDVVAIDYRHYSASFKKGAKLLHKPIVWHINQATTKTTFKPNTWCLRCLWSTKPVDTSNSFEVLAVEDTQGMDNLACESQQPTSEEVVENPTIQKEVIECDVKTTEVVGNVILKPSDEGVKVTQELGHEDLMAAYVENTSITIKKPNELSLALGLKTIATHGIAAINSVPWSKILAYVKPFLGQAAITTSNCAKRLAQRVFNNYMPYVFTLLFQLCTFTKSTNSRIRASLPTTIAKNSVKSVAKLCLDAGINYVKSPKFSKLFTIAMWLLLLSICLGSLICVTAAFGVLLSNFGAPSYCNGVRELYLNSSNVTTMDFCEGSFPCSICLSGLDSLDSYPALETIQVTISSYKLDLTILGLAAEWVLAYMLFTKFFYLLGLSAIMQVFFGYFASHFISNSWLMWFIISIVQMAPVSAMVRMYIFFASFYYIWKSYVHIMDGCTSSTCMMCYKRNRATRVECTTIVNGMKRSFYVYANGGRGFCKTHNWNCLNCDTFCTGSTFISDEVARDLSLQFKRPINPTDQSSYIVDSVAVKNGALHLYFDKAGQKTYERHPLSHFVNLDNLRANNTKGSLPINVIVFDGKSKCDESASKSASVYYSQLMCQPILLLDQALVSDVGDSTEVSVKMFDAYVDTFSATFSVPMEKLKALVATAHSELAKGVALDGVLSTFVSAARQGVVDTDVDTKDVIECLKLSHHSDLEVTGDSCNNFMLTYNKVENMTPRDLGACIDCNARHINAQVAKSHNVSLIWNVKDYMSLSEQLRKQIRSAAKKNNIPFRLTCATTRQVVNVITTKISLKGGKIVSTCFKLMLKATLLCVLAALVCYIVMPVHTLSIHDGYTNEIIGYKAIQDGVTRDIISTDDCFANKHAGFDAWFSQRGGSYKNDKSCPVVAAIITREIGFIVPGLPGTVLRAINGDFLHFLPRVFSAVGNICYTPSKLIEYSDFATSACVLAAECTIFKDAMGKPVPYCYDTNLLEGSISYSELRPDTRYVLMDGSIIQFPNTYLEGSVRVVTTFDAEYCRHGTCERSEVGICLSTSGRWVLNNEHYRALSGVFCGVDAMNLIANIFTPLVQPVGALDVSASVVAGGIIAILVTCAAYYFMKFRRVFGEYNHVVAANALLFLMSFTILCLVPAYSFLPGVYSVFYLYLTFYFTNDVSFLAHLQWFAMFSPIVPFWITAIYVFCISLKHCHWFFNNYLRKRVMFNGVTFSTFEEAALCTFLLNKEMYLKLRSETLLPLTQYNRYLALYNKYKYFSGALDTTSYREAACCHLAKALNDFSNSGADVLYQPPQTSITSAVLQSGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPRHVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGHSMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTITLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRTILGSTILEDEFTPFDVVRQCSGVTFQGKFKKIVKGTHHWMLLTFLTSLLILVQSTQWSLFFFVYENAFLPFTLGIMAIAACAMLLVKHKHAFLCLFLLPSLATVAYFNMVYMPASWVMRIMTWLELADTSLSGYRLKDCVMYASALVLLILMTARTVYDDAARRVWTLMNVITLVYKVYYGNALDQAISMWALVISVTSNYSGVVTTIMFLARAIVFVCVEYYPLLFITGNTLQCIMLVYCFLGYCCCCYFGLFCLLNRYFRLTLGVYDYLVSTQEFRYMNSQGLLPPKSSIDAFKLNIKLLGIGGKPCIKVATVQSKMSDVKCTSVVLLSVLQQLRVESSSKLWAQCVQLHNDILLAKDTTEAFEKMVSLLSVLLSMQGAVDINRLCEEMLDNRATLQAIASEFSSLPSYAAYATAQEAYEQAVANGDSEVVLKKLKKSLNVAKSEFDRDAAMQRKLEKMADQAMTQMYKQARSEDKRAKVTSAMQTMLFTMLRKLDNDALNNIINNARDGCVPLNIIPLTTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPNLAWPLIVTALRANSAVKLQNNELSPVALRQMSCAAGTTQTACTDDNALAYYNNSKGGRFVLALLSDHQDLKWARFPKSDGTGTIYTELEPPCRFVTDTPKGPKVKYLYFIKGLNNLNRGMVLGSLAATVRLQAGNATEVPANSTVLSFCAFAVDPAKAYKDYLASGGQPITNCVKMLCTHTGTGQAITVTPEANMDQESFGGASCCLYCRCHIDHPNPKGFCDLKGKYVQIPTTCANDPVGFTLRNTVCTVCGMWKGYGCSCDQLREPLMQSADASTFLNRVCGVSAARLTPCGTGTSTDVVYRAFDIYNEKVAGFAKFLKTNCCRFQEKDEEGNLLDSYFVVKRHTMSNYQHEETIYNLVKDCPAVAVHDFFKFRVDGDMVPHISRQRLTKYTMADLVYALRHFDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYANLGERVRQSLLKTVQFCDAMRDAGIVGVLTLDNQDLNGNWYDFGDFVQVAPGCGVPIVDSYYSLLMPILTLTRALAAESHMDADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYHPNCINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQDVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNKDFYDFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIRQLLFVVEVVDKYFDCYDGGCINANQVIVNNLDKSAGFPFNKWGKARLYYDSMSYEDQDALFAYTKRNVIPTITQMNLKYAISAKNRARTVAGVSICSTMTNRQFHQKLLKSIAATRGATVVIGTSKFYGGWHNMLKTVYSDVETPHLMGWDYPKCDRAMPNMLRIMASLVLARKHNTCCNLSHRFYRLANECAQVLSEMVMCGGSLYVKPGGTSSGDATTAYANSVFNICQAVTANVNALLSTDGNKIADKYVRNLQHRLYECLYRNRDVDHEFVDEFYAYLRKHFSMMILSDDAVVCYNSNYAAQGLVASIKNFKAVLYYQNNVFMSEAKCWTETDLTKGPHEFCSQHTMLVKQGDDYVYLPYPDPSRILGAGCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTGHMLDMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQAVGACVLCNSQTSLRCGACIRRPFLCCKCCYDHVISTSHKLVLSVNPYVCNAPGCDVTDVTQLYLGGMSYYCKSHKPPISFPLCANGQVFGLYKNTCVGSDNVTDFNAIATCDWTNAGDYILANTCTERLKLFAAETLKATEETFKLSYGIATVREVLSDRELHLSWEVGKPRPPLNRNYVFTGYRVTKNSKVQIGEYTFEKGDYGDAVVYRGTTTYKLNVGDYFVLTSHTVMPLSAPTLVPQEHYVRITGLYPTLNISDEFSSNVANYQKVGMQKYSTLQGPPGTGKSHFAIGLALYYPSARIVYTACSHAAVDALCEKALKYLPIDKCSRIIPARARVECFDKFKVNSTLEQYVFCTVNALPETTADIVVFDEISMATNYDLSVVNARLRAKHYVYIGDPAQLPAPRTLLTKGTLEPEYFNSVCRLMKTIGPDMFLGTCRRCPAEIVDTVSALVYDNKLKAHKDKSAQCFKMFYKGVITHDVSSAINRPQIGVVREFLTRNPAWRKAVFISPYNSQNAVASKILGLPTQTVDSSQGSEYDYVIFTQTTETAHSCNVNRFNVAITRAKIGILCIMSDRDLYDKLQFTSLEIPRRNVATLQAENVTGLFKDCSKIITGLHPTQAPTHLSVDIKFKTEGLCVDIPGIPKDMTYRRLISMMGFKMNYQVNGYPNMFITREEAIRHVRAWIGFDVEGCHATRDAVGTNLPLQLGFSTGVNLVAVPTGYVDTENNTEFTRVNAKPPPGDQFKHLIPLMYKGLPWNVVRIKIVQMLSDTLKGLSDRVVFVLWAHGFELTSMKYFVKIGPERTCCLCDKRATCFSTSSDTYACWNHSVGFDYVYNPFMIDVQQWGFTGNLQSNHDQHCQVHGNAHVASCDAIMTRCLAVHECFVKRVDWSVEYPIIGDELRVNSACRKVQHMVVKSALLADKFPVLHDIGNPKAIKCVPQAEVEWKFYDAQPCSDKAYKIEELFYSYATHHDKFTDGVCLFWNCNVDRYPANAIVCRFDTRVLSNLNLPGCDGGSLYVNKHAFHTPAFDKSAFTNLKQLPFFYYSDSPCESHGKQVVSDIDYVPLKSATCITRCNLGGAVCRHHANEYRQYLDAYNMMISAGFSLWIYKQFDTYNLWNTFTRLQSLENVAYNVVNKGHFDGHAGEAPVSIINNAVYTKVDGIDVEIFENKTTLPVNVAFELWAKRNIKPVPEIKILNNLGVDIAANTVIWDYKREAPAHVSTIGVCTMTDIAKKPTESACSSLTVLFDGRVEGQVDLFRNARNGVLITEGSVKGLTPSKGPAQASVNGVTLIGESVKTQFNYFKKVDGIIQQLPETYFTQSRDLEDFKPRSQMETDFLELAMDEFIQRYKLEGYAFEHIVYGDFSHGQLGGLHLMIGLAKRSQDSPLKLEDFIPMDSTVKNYFITDAQTGSSKCVCSVIDLLLDDFVEIIKSQDLSVISKVVKVTIDYAEISFMLWCKDGHVETFYPKLQASQAWQPGVAMPNLYKMQRMLLEKCDLQNYGENAVIPKGIMMNVAKYTQLCQYLNTLTLAVPYNMRVIHFGAGSDKGVAPGTAVLRQWLPTGTLLVDSDLNDFVSDADSTLIGDCATVHTANKWDLIISDMYDPRTKHVTKENDSKEGFFTYLCGFIKQKLALGGSIAVKITEHSWNADLYKLMGHFSWWTAFVTNVNASSSEAFLIGANYLGKPKEQIDGYTMHANYIFWRNTNPIQLSSYSLFDMSKFPLKLRGTAVMSLKENQINDMIYSLLEKGRLIIRENNRVVVSSDILVNN T78540 TARGETID T78540 T78540 FORMERID TTDR00638 T78540 UNIPROID PAP_HHV11 T78540 TARGNAME Herpes simplex virus DNA polymerase processivity factor (HSV UL42) T78540 GENENAME HSV UL42 T78540 TARGTYPE Literature-reported T78540 SYNONYMS UL42; Protein UL42; Polymerase accessory protein; HSV PAP; DNA-binding protein UL42 T78540 FUNCTION Plays an essential role in viral DNA replication by acting as the polymerase accessory subunit. Associates with the viral polymerase to increase its processivity and forms high- affinity direct interactions with DNA. Facilitates the origin- binding protein UL9 loading onto DNA thus increasing its ability to assemble into a functional complex capable of unwinding duplex DNA. T78540 PDBSTRUC 1DML T78540 BIOCLASS Herpesviridae DNA polymerase T78540 SEQUENCE MTDSPGGVAPASPVEDASDASLGQPEEGAPCQVVLQGAELNGILQAFAPLRTSLLDSLLVMGDRGILIHNTIFGEQVFLPLEHSQFSRYRWRGPTAAFLSLVDQKRSLLSVFRANQYPDLRRVELAITGQAPFRTLVQRIWTTTSDGEAVELASETLMKRELTSFVVLVPQGTPDVQLRLTRPQLTKVLNATGADSATPTTFELGVNGKFSVFTTSTCVTFAAREEGVSSSTSTQVQILSNALTKAGQAAANAKTVYGENTHRTFSVVVDDCSMRAVLRRLQVGGGTLKFFLTTPVPSLCVTATGPNAVSAVFLLKPQKICLDWLGHSQGSPSAGSSASRASGSEPTDSQDSASDAVSHGDPEDLDGAARAGEAGALHACPMPSSTTRVTPTTKRGRSGGEDARADTALKKPKTGSPTAPPPADPVPLDTEDDSDAADGTAARPAAPDARSGSRYACYFRDLPTGEASPGAFSAFRGGPQTPYGFGFP T35565 TARGETID T35565 T35565 FORMERID TTDI01826 T35565 UNIPROID PPBN_HUMAN T35565 TARGNAME Alkaline phosphatase (ALPPL2) T35565 GENENAME ALPPL2 T35565 TARGTYPE Literature-reported T35565 SYNONYMS Placental alkaline phosphatase-like; PLAP-like; Germ cell alkaline phosphatase; GCAP; Alkaline phosphatase, placental-like; Alkaline phosphatase, germ cell type; Alkaline phosphatase Nagao isozyme; ALPPL; ALPG; ALP-1 T35565 FUNCTION extracellular region, plasma membrane, alkaline phosphatase activity. T35565 BIOCLASS Phosphoric monoester hydrolase T35565 ECNUMBER EC 3.1.3.1 T35565 SEQUENCE MQGPWVLLLLGLRLQLSLGIIPVEEENPDFWNRQAAEALGAAKKLQPAQTAAKNLIIFLGDGMGVSTVTAARILKGQKKDKLGPETFLAMDRFPYVALSKTYSVDKHVPDSGATATAYLCGVKGNFQTIGLSAAARFNQCNTTRGNEVISVMNRAKKAGKSVGVVTTTRVQHASPAGAYAHTVNRNWYSDADVPASARQEGCQDIATQLISNMDIDVILGGGRKYMFPMGTPDPEYPDDYSQGGTRLDGKNLVQEWLAKHQGARYVWNRTELLQASLDPSVTHLMGLFEPGDMKYEIHRDSTLDPSLMEMTEAALLLLSRNPRGFFLFVEGGRIDHGHHESRAYRALTETIMFDDAIERAGQLTSEEDTLSLVTADHSHVFSFGGYPLRGSSIFGLAPGKARDRKAYTVLLYGNGPGYVLKDGARPDVTESESGSPEYRQQSAVPLDGETHAGEDVAVFARGPQAHLVHGVQEQTFIAHVMAFAACLEPYTACDLAPRAGTTDAAHPGPSVVPALLPLLAGTLLLLGTATAP T04233 TARGETID T04233 T04233 FORMERID TTDI02417 T04233 UNIPROID BXB_CLOBO T04233 TARGNAME Bacterial Botulinum toxin B (Bact botB) T04233 GENENAME Bact botB T04233 TARGTYPE Literature-reported T04233 SYNONYMS botB; Botulinum neurotoxin type B; Botulinum neurotoxin B heavy chain; BontoxilysinB; BoNT/B T04233 FUNCTION Botulinum toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-2. T04233 PDBSTRUC 6G5K; 6G5G; 6G5F; 5VMR; 5VID T04233 BIOCLASS Peptidase T04233 SEQUENCE MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSYSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE T56496 TARGETID T56496 T56496 FORMERID TTDI03457 T56496 UNIPROID PNMT_HUMAN T56496 TARGNAME Phenylethanolamine N-methyltransferase (PNMT) T56496 GENENAME PNMT T56496 TARGTYPE Literature-reported T56496 SYNONYMS PNMTase; PENT; Noradrenaline N-methyltransferase T56496 FUNCTION Converts noradrenaline to adrenaline. T56496 PDBSTRUC 4MQ4; 4MIK; 4DM3; 3KR2; 3KR1 T56496 ECNUMBER EC 2.1.1.28 T56496 SEQUENCE MSGADRSPNAGAAPDSAPGQAAVASAYQRFEPRAYLRNNYAPPRGDLCNPNGVGPWKLRCLAQTFATGEVSGRTLIDIGSGPTVYQLLSACSHFEDITMTDFLEVNRQELGRWLQEEPGAFNWSMYSQHACLIEGKGECWQDKERQLRARVKRVLPIDVHQPQPLGAGSPAPLPADALVSAFCLEAVSPDLASFQRALDHITTLLRPGGHLLLIGALEESWYLAGEARLTVVPVSEEEVREALVRSGYKVRDLRTYIMPAHLQTGVDDVKGVFFAWAQKVGL T56496 DRUGINFO D05ZKW LY134046 Investigative T42319 TARGETID T42319 T42319 FORMERID TTDR00423 T42319 UNIPROID PERE_HUMAN T42319 TARGNAME Eosinophil peroxidase (EPX) T42319 GENENAME EPX T42319 TARGTYPE Literature-reported T42319 SYNONYMS EPX T42319 FUNCTION Mediates tyrosine nitration of secondary granule proteins in mature resting eosinophils. Shows significant inhibitory activity towards Mycobacterium tuberculosis H37Rv by inducing bacterial fragmentation and lysis. T42319 BIOCLASS Peroxidases T42319 ECNUMBER EC 1.11.1.7 T42319 SEQUENCE MHLLPALAGVLATLVLAQPCEGTDPASPGAVETSVLRDCIAEAKLLVDAAYNWTQKSIKQRLRSGSASPMDLLSYFKQPVAATRTVVRAADYMHVALGLLEEKLQPQRSGPFNVTDVLTEPQLRLLSQASGCALRDQAERCSDKYRTITGRCNNKRRPLLGASNQALARWLPAEYEDGLSLPFGWTPSRRRNGFLLPLVRAVSNQIVRFPNERLTSDRGRALMFMQWGQFIDHDLDFSPESPARVAFTAGVDCERTCAQLPPCFPIKIPPNDPRIKNQRDCIPFFRSAPSCPQNKNRVRNQINALTSFVDASMVYGSEVSLSLRLRNRTNYLGLLAINQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSTETPKLAAMHTLFMREHNRLATELRRLNPRWNGDKLYNEARKIMGAMVQIITYRDFLPLVLGKARARRTLGHYRGYCSNVDPRVANVFTLAFRFGHTMLQPFMFRLDSQYRASAPNSHVPLSSAFFASWRIVYEGGIDPILRGLMATPAKLNRQDAMLVDELRDRLFRQVRRIGLDLAALNMQRSRDHGLPGYNAWRRFCGLSQPRNLAQLSRVLKNQDLARKFLNLYGTPDNIDIWIGAIAEPLLPGARVGPLLACLFENQFRRARDGDRFWWQKRGVFTKRQRKALSRISLSRIICDNTGITTVSRDIFRANIYPRGFVNCSRIPRLNLSAWRGT T10844 TARGETID T10844 T10844 FORMERID TTDR00311 T10844 UNIPROID FCGR1_HUMAN T10844 TARGNAME Immunoglobulin gamma Fc receptor I (FCGR1) T10844 GENENAME FCGR1A T10844 TARGTYPE Literature-reported T10844 SYNONYMS IgG Fc receptor I; FcRI; Fc-gamma RI; FCGR1A; CD64 antigen; CD64 T10844 FUNCTION High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses. T10844 PDBSTRUC 4ZNE; 4X4M; 4W4O; 3RJD T10844 BIOCLASS Immunoglobulin T10844 SEQUENCE MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNGTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAGISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGAT T37986 TARGETID T37986 T37986 FORMERID TTDR00027 T37986 UNIPROID CARB_STRTH T37986 TARGNAME Streptomyces RNA methyltransferase (Stre-myc carB) T37986 GENENAME Stre-myc carB T37986 TARGTYPE Literature-reported T37986 SYNONYMS carB; RNA methyltransferase T37986 FUNCTION Probable RNA methylase. Confers resistance to carbomycin and several other macrolides, lincomycin and vernamycin B, but not to all macrolide-lincosamide-streptogramin B antibiotics. T37986 BIOCLASS Methyltransferase T37986 ECNUMBER EC 2.1.1.- T37986 SEQUENCE MAALLKRILRRRMAEKRSGRGRMAAARTTGAQSRKTAQRSGRSEADRRRRVHGQNFLVDRETVQRFVRFADPDPGEVVLEVGAGNGAITRELARLCRRVVAYEIDRHFADRLREATAEDPRIEVVAGDFLKTSQPKVPFSVVGNIPFGNTADIVDWCLNARRLRTTTLVTQLEYARKRTGGYRRWSRLTVATWPEVEWRMGERISRRWFRPVPAVDSAVLRLERRPVPLIPPGLMHDFRDLVETGFTGKGGSLDASLRRRFPARRVAAGFRRARLEQGVVVAYVTPGQWITLFEELHGR T37986 DRUGINFO D00FLT Sinefungin Investigative T57421 TARGETID T57421 T57421 FORMERID TTDR00740 T57421 UNIPROID ACPH_HUMAN T57421 TARGNAME Acylamino-acid-releasing enzyme (APEH) T57421 GENENAME APEH T57421 TARGTYPE Literature-reported T57421 SYNONYMS Oxidized protein hydrolase; OPH; DNF15S2 protein; Acylpeptide hydrolase; Acylaminoacyl-peptidase; Acyl-peptide hydrolase; APH; APEH; AARE T57421 FUNCTION This enzyme catalyzes the hydrolysis of the N-terminal peptide bond of an N-acetylated peptide to generate an N- acetylated amino acid and a peptide with a free N-terminus. It preferentially cleaves off Ac-Ala, Ac-Met and Ac-Ser. T57421 BIOCLASS Peptidase T57421 ECNUMBER EC 3.4.19.1 T57421 SEQUENCE MERQVLLSEPEEAAALYRGLSRQPALSAACLGPEVTTQYGGQYRTVHTEWTQRDLERMENIRFCRQYLVFHDGDSVVFAGPAGNSVETRGELLSRESPSGTMKAVLRKAGGTGPGEEKQFLEVWEKNRKLKSFNLSALEKHGPVYEDDCFGCLSWSHSETHLLYVAEKKRPKAESFFQTKALDVSASDDEIARLKKPDQAIKGDQFVFYEDWGENMVSKSIPVLCVLDVESGNISVLEGVPENVSPGQAFWAPGDAGVVFVGWWHEPFRLGIRFCTNRRSALYYVDLIGGKCELLSDDSLAVSSPRLSPDQCRIVYLQYPSLIPHHQCSQLCLYDWYTKVTSVVVDVVPRQLGENFSGIYCSLLPLGCWSADSQRVVFDSAQRSRQDLFAVDTQVGTVTSLTAGGSGGSWKLLTIDQDLMVAQFSTPSLPPTLKVGFLPSAGKEQSVLWVSLEEAEPIPDIHWGIRVLQPPPEQENVQYAGLDFEAILLQPGSPPDKTQVPMVVMPHGGPHSSFVTAWMLFPAMLCKMGFAVLLVNYRGSTGFGQDSILSLPGNVGHQDVKDVQFAVEQVLQEEHFDASHVALMGGSHGGFISCHLIGQYPETYRACVARNPVINIASMLGSTDIPDWCVVEAGFPFSSDCLPDLSVWAEMLDKSPIRYIPQVKTPLLLMLGQEDRRVPFKQGMEYYRALKTRNVPVRLLLYPKSTHALSEVEVESDSFMNAVLWLRTHLGS T57421 DRUGINFO D03DNV ARI-3099 Investigative T16578 TARGETID T16578 T16578 FORMERID TTDI00229 T16578 UNIPROID ANXA8_HUMAN T16578 TARGNAME Annexin A8 (ANXA8) T16578 GENENAME ANXA8 T16578 TARGTYPE Literature-reported T16578 SYNONYMS Vascular anticoagulant-beta; VAC-beta; Annexin-8; Annexin VIII; ANX8 T16578 FUNCTION This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade. T16578 PDBSTRUC 1W45; 1W3W T16578 BIOCLASS Annexin protein T16578 SEQUENCE MAWWKSWIEQEGVTVKSSSHFNPDPDAETLYKAMKGIGTNEQAIIDVLTKRSNTQRQQIAKSFKAQFGKDLTETLKSELSGKFERLIVALMYPPYRYEAKELHDAMKGLGTKEGVIIEILASRTKNQLREIMKAYEEDYGSSLEEDIQADTSGYLERILVCLLQGSRDDVSSFVDPGLALQDAQDLYAAGEKIRGTDEMKFITILCTRSATHLLRVFEEYEKIANKSIEDSIKSETHGSLEEAMLTVVKCTQNLHSYFAERLYYAMKGAGTRDGTLIRNIVSRSEIDLNLIKCHFKKMYGKTLSSMIMEDTSGDYKNALLSLVGSDP T40628 TARGETID T40628 T40628 FORMERID TTDS00055 T40628 UNIPROID 3BHS1_HUMAN; 3BHS2_HUMAN T40628 TARGNAME Hydroxysteroid dehydrogenase 3-beta (HSD3B) T40628 GENENAME HSD3B1; HSD3B2 T40628 TARGTYPE Literature-reported T40628 SYNONYMS 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase T40628 FUNCTION Catalyzes the biosynthesis of the steroid progesterone from pregnenolone, 17-hydroxyprogesterone from 17-hydroxypregnenolone, and androstenedione from dehydroepiandrosterone (DHEA) in the adrenal gland. Also catalyzes the oxidative conversion of 5-3-hydroxysteroids to the 4-3-keto configuration and is, therefore, essential for the biosynthesis of all classes of hormonal steroids, namely progesterone, glucocorticoids, mineralocorticoids, androgens, and estrogens. T40628 BIOCLASS Short-chain dehydrogenases reductase T40628 SEQUENCE MTGWSCLVTGAGGFLGQRIIRLLVKEKELKEIRVLDKAFGPELREEFSKLQNKTKLTVLEGDILDEPFLKRACQDVSVIIHTACIIDVFGVTHRESIMNVNVKGTQLLLEACVQASVPVFIYTSSIEVAGPNSYKEIIQNGHEEEPLENTWPAPYPHSKKLAEKAVLAANGWNLKNGGTLYTCALRPMYIYGEGSRFLSASINEALNNNGILSSVGKFSTVNPVYVGNVAWAHILALRALQDPKKAPSIRGQFYYISDDTPHQSYDNLNYTLSKEFGLRLDSRWSFPLSLMYWIGFLLEIVSFLLRPIYTYRPPFNRHIVTLSNSVFTFSYKKAQRDLAYKPLYSWEEAKQKTVEWVGSLVDRHKETLKSKTQ T40628 DRUGINFO D05ZPJ 4-MA Investigative T40628 DRUGINFO D06LVG 17 beta-N,N-diethylcarbamoyl-4-aza-5 alpha-androstan-3-one (4MA) Investigative T40628 DRUGINFO D08WDY Equilenin Investigative T40628 DRUGINFO D09SWM Epostane Investigative T40628 DRUGINFO D0T5MO 5alpha-Androstan-3,17-Dione Investigative T40628 DRUGINFO D0M8RO 4-ANDROSTENE-3-17-DIONE Investigative T40628 DRUGINFO D0Q5FV 2-Sulfhydryl-Ethanol Investigative T82297 TARGETID T82297 T82297 FORMERID TTDR00687 T82297 UNIPROID FOLR2_HUMAN T82297 TARGNAME Folate receptor beta (FOLR2) T82297 GENENAME FOLR2 T82297 TARGTYPE Literature-reported T82297 SYNONYMS Placental folate-binding protein; Folate receptor, fetal/placental; Folate receptor type-beta; Folate receptor 2; FR-beta; FOLR2 T82297 FUNCTION Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. T82297 PDBSTRUC 4KN2; 4KN1; 4KN0; 4KMZ; 4KMY T82297 BIOCLASS Folate receptor T82297 SEQUENCE MVWKWMPLLLLLVCVATMCSAQDRTDLLNVCMDAKHHKTKPGPEDKLHDQCSPWKKNACCTASTSQELHKDTSRLYNFNWDHCGKMEPACKRHFIQDTCLYECSPNLGPWIQQVNQSWRKERFLDVPLCKEDCQRWWEDCHTSHTCKSNWHRGWDWTSGVNKCPAGALCRTFESYFPTPAALCEGLWSHSYKVSNYSRGSGRCIQMWFDSAQGNPNEEVARFYAAAMHVNAGEMLHGTGGLLLSLALMLQLWLLG T91614 TARGETID T91614 T91614 UNIPROID TRI27_HUMAN T91614 TARGNAME Zinc finger protein RFP (TRIM27) T91614 GENENAME TRIM27 T91614 TARGTYPE Literature-reported T91614 SYNONYMS Tripartite motif-containing protein 27; Ret finger protein; RNF76; RING-type E3 ubiquitin transferase TRIM27; RING finger protein 76 T91614 FUNCTION E3 ubiquitin-protein ligase that mediates ubiquitination of PIK3C2B and inhibits its activity; mediates the formation of 'Lys-48'-linked polyubiquitin chains; the function inhibits CD4 T-cell activation. Acts as a regulator of retrograde transport: together with MAGEL2, mediates the formation of 'Lys-63'-linked polyubiquitin chains at 'Lys-220' of WASHC1, leading to promote endosomal F-actin assembly (PubMed:23452853). Has a transcriptional repressor activity by cooperating with EPC1. Induces apoptosis by activating Jun N-terminal kinase and p38 kinase and also increases caspase-3-like activity independently of mitochondrial events. May function in male germ cell development. Has DNA-binding activity and preferentially bound to double-stranded DNA. T91614 BIOCLASS TRIM/RBCC family T91614 ECNUMBER EC 2.3.2.27 T91614 SEQUENCE MASGSVAECLQQETTCPVCLQYFAEPMMLDCGHNICCACLARCWGTAETNVSCPQCRETFPQRHMRPNRHLANVTQLVKQLRTERPSGPGGEMGVCEKHREPLKLYCEEDQMPICVVCDRSREHRGHSVLPLEEAVEGFKEQIQNQLDHLKRVKDLKKRRRAQGEQARAELLSLTQMEREKIVWEFEQLYHSLKEHEYRLLARLEELDLAIYNSINGAITQFSCNISHLSSLIAQLEEKQQQPTRELLQDIGDTLSRAERIRIPEPWITPPDLQEKIHIFAQKCLFLTESLKQFTEKMQSDMEKIQELREAQLYSVDVTLDPDTAYPSLILSDNLRQVRYSYLQQDLPDNPERFNLFPCVLGSPCFIAGRHYWEVEVGDKAKWTIGVCEDSVCRKGGVTSAPQNGFWAVSLWYGKEYWALTSPMTALPLRTPLQRVGIFLDYDAGEVSFYNVTERCHTFTFSHATFCGPVRPYFSLSYSGGKSAAPLIICPMSGIDGFSGHVGNHGHSMETSP T38983 TARGETID T38983 T38983 FORMERID TTDR00198 T38983 UNIPROID ETS1_HUMAN T38983 TARGNAME Protein C-ets-1 (ETS1) T38983 GENENAME ETS1 T38983 TARGTYPE Literature-reported T38983 SYNONYMS P54; EWSR2 T38983 FUNCTION Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts. May control the differentiation, survival and proliferation of lymphoid cells. May also regulate angiogenesis through regulation of expression of genes controlling endothelial cell migration and invasion. Transcription factor. T38983 PDBSTRUC 5ZMC; 4LG0; 4L18; 4L0Z; 4L0Y T38983 BIOCLASS E26 transformation-specific ETS T38983 SEQUENCE MKAAVDLKPTLTIIKTEKVDLELFPSPDMECADVPLLTPSSKEMMSQALKATFSGFTKEQQRLGIPKDPRQWTETHVRDWVMWAVNEFSLKGVDFQKFCMNGAALCALGKDCFLELAPDFVGDILWEHLEILQKEDVKPYQVNGVNPAYPESRYTSDYFISYGIEHAQCVPPSEFSEPSFITESYQTLHPISSEELLSLKYENDYPSVILRDPLQTDTLQNDYFAIKQEVVTPDNMCMGRTSRGKLGGQDSFESIESYDSCDRLTQSWSSQSSFNSLQRVPSYDSFDSEDYPAALPNHKPKGTFKDYVRDRADLNKDKPVIPAAALAGYTGSGPIQLWQFLLELLTDKSCQSFISWTGDGWEFKLSDPDEVARRWGKRKNKPKMNYEKLSRGLRYYYDKNIIHKTAGKRYVYRFVCDLQSLLGYTPEELHAMLDVKPDADE T82685 TARGETID T82685 T82685 FORMERID TTDR01007 T82685 UNIPROID PLAK_HUMAN T82685 TARGNAME Junction plakoglobin (JUP) T82685 GENENAME JUP T82685 TARGTYPE Literature-reported T82685 SYNONYMS Plakoglobin; Desmoplakin-3; Desmoplakin III; DP3; Catenin gamma; CTNNG T82685 FUNCTION The membrane-associated plaques are architectural elements in an important strategic position to influence the arrangement and function of both the cytoskeleton and the cells within the tissue. The presence of plakoglobin in both the desmosomes and in the intermediate junctions suggests that it plays a central role in the structure and function of submembranous plaques. Acts as a substrate for VE-PTP and is required by it to stimulate VE-cadherin function in endothelial cells. Can replace beta-catenin in E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton. Common junctional plaque protein. T82685 PDBSTRUC 3IFQ T82685 BIOCLASS Beta-catenin T82685 SEQUENCE MEVMNLMEQPIKVTEWQQTYTYDSGIHSGANTCVPSVSSKGIMEEDEACGRQYTLKKTTTYTQGVPPSQGDLEYQMSTTARAKRVREAMCPGVSGEDSSLLLATQVEGQATNLQRLAEPSQLLKSAIVHLINYQDDAELATRALPELTKLLNDEDPVVVTKAAMIVNQLSKKEASRRALMGSPQLVAAVVRTMQNTSDLDTARCTTSILHNLSHHREGLLAIFKSGGIPALVRMLSSPVESVLFYAITTLHNLLLYQEGAKMAVRLADGLQKMVPLLNKNNPKFLAITTDCLQLLAYGNQESKLIILANGGPQALVQIMRNYSYEKLLWTTSRVLKVLSVCPSNKPAIVEAGGMQALGKHLTSNSPRLVQNCLWTLRNLSDVATKQEGLESVLKILVNQLSVDDVNVLTCATGTLSNLTCNNSKNKTLVTQNSGVEALIHAILRAGDKDDITEPAVCALRHLTSRHPEAEMAQNSVRLNYGIPAIVKLLNQPNQWPLVKATIGLIRNLALCPANHAPLQEAAVIPRLVQLLVKAHQDAQRHVAAGTQQPYTDGVRMEEIVEGCTGALHILARDPMNRMEIFRLNTIPLFVQLLYSSVENIQRVAAGVLCELAQDKEAADAIDAEGASAPLMELLHSRNEGTATYAAAVLFRISEDKNPDYRKRVSVELTNSLFKHDPAAWEAAQSMIPINEPYGDDMDATYRPMYSSDVPLDPLEMHMDMDGDYPIDTYSDGLRPPYPTADHMLA T73557 TARGETID T73557 T73557 FORMERID TTDR01279 T73557 UNIPROID GLNA_HUMAN T73557 TARGNAME Astrocyte glutamine synthetase (GLUL) T73557 GENENAME GLUL T73557 TARGTYPE Literature-reported T73557 SYNONYMS Palmitoyltransferase GLUL; Glutamine synthetase; Glutamate--ammonia ligase; GS; GLNS T73557 FUNCTION Glutamine synthetase that catalyzes the ATP-dependent conversion of glutamate and ammonia to glutamine. Its role depends on tissue localization: in the brain, it regulates the levels of toxic ammonia and converts neurotoxic glutamate to harmless glutamine, whereas in the liver, it is one of the enzymes responsible for the removal of ammonia (By similarity). Essential for proliferation of fetal skin fibroblasts. Independently of its glutamine synthetase activity, required for endothelial cell migration during vascular development: acts by regulating membrane localization and activation of the GTPase RHOJ, possibly by promoting RHOJ palmitoylation. May act as a palmitoyltransferase for RHOJ: able to autopalmitoylate and then transfer the palmitoyl group to RHOJ. Plays a role in ribosomal 40S subunit biogenesis. T73557 PDBSTRUC 2QC8; 2OJW T73557 ECNUMBER EC 6.3.1.2 T73557 SEQUENCE MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELPEWNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHTCKRIMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRDIVEAHYRACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIATFDPKPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGLDNARRLTGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRTCLLNETGDEPFQYKN T34471 TARGETID T34471 T34471 FORMERID TTDI03078 T34471 UNIPROID CBPN_HUMAN T34471 TARGNAME Arginine carboxypeptidase (CPN1) T34471 GENENAME CPN1 T34471 TARGTYPE Literature-reported T34471 SYNONYMS Serum carboxypeptidase N; SCPN; Plasma carboxypeptidase N; Lysine carboxypeptidase; Kininase-1; Carboxypeptidase N small subunit; Carboxypeptidase N polypeptide 1; Carboxypeptidase N catalytic chain; CPN; Anaphylatoxin inactivator; ACBP T34471 FUNCTION Protects the body from potent vasoactive and inflammatory peptides containing C-terminal Arg or Lys (such as kinins or anaphylatoxins) which are released into the circulation. T34471 PDBSTRUC 2NSM T34471 ECNUMBER EC 3.4.17.3 T34471 SEQUENCE MSDLLSVFLHLLLLFKLVAPVTFRHHRYDDLVRTLYKVQNECPGITRVYSIGRSVEGRHLYVLEFSDHPGIHEPLEPEVKYVGNMHGNEALGRELMLQLSEFLCEEFRNRNQRIVQLIQDTRIHILPSMNPDGYEVAAAQGPNKPGYLVGRNNANGVDLNRNFPDLNTYIYYNEKYGGPNHHLPLPDNWKSQVEPETRAVIRWMHSFNFVLSANLHGGAVVANYPYDKSFEHRVRGVRRTASTPTPDDKLFQKLAKVYSYAHGWMFQGWNCGDYFPDGITNGASWYSLSKGMQDFNYLHTNCFEITLELSCDKFPPEEELQREWLGNREALIQFLEQVHQGIKGMVLDENYNNLANAVISVSGINHDVTSGDHGDYFRLLLPGIYTVSATAPGYDPETVTVTVGPAEPTLVNFHLKRSIPQVSPVRRAPSRRHGVRAKVQPQARKKEMEMRQLQRGPA T34471 DRUGINFO D0XA0N PMID14640538C3 Investigative T96256 TARGETID T96256 T96256 UNIPROID EZRI_HUMAN T96256 TARGNAME Cytovillin (EZR) T96256 GENENAME EZR T96256 TARGTYPE Literature-reported T96256 SYNONYMS p81; Villin-2; VIL2 T96256 FUNCTION Probably involved in connections of major cytoskeletal structures to the plasma membrane. In epithelial cells, required for the formation of microvilli and membrane ruffles on the apical pole. Along with PLEKHG6, required for normal macropinocytosis. T96256 PDBSTRUC 4RMA; 4RM9; 4RM8; 1NI2 T96256 SEQUENCE MPKPINVRVTTMDAELEFAIQPNTTGKQLFDQVVKTIGLREVWYFGLHYVDNKGFPTWLKLDKKVSAQEVRKENPLQFKFRAKFYPEDVAEELIQDITQKLFFLQVKEGILSDEIYCPPETAVLLGSYAVQAKFGDYNKEVHKSGYLSSERLIPQRVMDQHKLTRDQWEDRIQVWHAEHRGMLKDNAMLEYLKIAQDLEMYGINYFEIKNKKGTDLWLGVDALGLNIYEKDDKLTPKIGFPWSEIRNISFNDKKFVIKPIDKKAPDFVFYAPRLRINKRILQLCMGNHELYMRRRKPDTIEVQQMKAQAREEKHQKQLERQQLETEKKRRETVEREKEQMMREKEELMLRLQDYEEKTKKAERELSEQIQRALQLEEERKRAQEEAERLEADRMAALRAKEELERQAVDQIKSQEQLAAELAEYTAKIALLEEARRRKEDEVEEWQHRAKEAQDDLVKTKEELHLVMTAPPPPPPPVYEPVSYHVQESLQDEGAEPTGYSAELSSEGIRDDRNEEKRITEAEKNERVQRQLLTLSSELSQARDENKRTHNDIIHNENMRQGRDKYKTLRQIRQGNTKQRIDEFEAL T69208 TARGETID T69208 T69208 FORMERID TTDI03465 T69208 UNIPROID PHKG2_HUMAN T69208 TARGNAME Phosphorylase kinase testis gamma 2 (PHKG2) T69208 GENENAME PHKG2 T69208 TARGTYPE Literature-reported T69208 SYNONYMS Phosphorylase kinase subunit gamma-2; Phosphorylase b kinase gamma catalytic chain, liver/testis isoform; PSK-C3; PHK-gamma-T; PHK-gamma-LT T69208 FUNCTION Catalytic subunit of the phosphorylase b kinase (PHK), which mediates the neural and hormonal regulation of glycogen breakdown (glycogenolysis) by phosphorylating and thereby activating glycogen phosphorylase. May regulate glycogeneolysis in the testis. In vitro, phosphorylates PYGM (By similarity). T69208 PDBSTRUC 2Y7J T69208 ECNUMBER EC 2.7.11.19 T69208 SEQUENCE MTLDVGPEDELPDWAAAKEFYQKYDPKDVIGRGVSSVVRRCVHRATGHEFAVKIMEVTAERLSPEQLEEVREATRRETHILRQVAGHPHIITLIDSYESSSFMFLVFDLMRKGELFDYLTEKVALSEKETRSIMRSLLEAVSFLHANNIVHRDLKPENILLDDNMQIRLSDFGFSCHLEPGEKLRELCGTPGYLAPEILKCSMDETHPGYGKEVDLWACGVILFTLLAGSPPFWHRRQILMLRMIMEGQYQFSSPEWDDRSSTVKDLISRLLQVDPEARLTAEQALQHPFFERCEGSQPWNLTPRQRFRVAVWTVLAAGRVALSTHRVRPLTKNALLRDPYALRSVRHLIDNCAFRLYGHWVKKGEQQNRAALFQHRPPGPFPIMGPEEEGDSAAITEDEAVLVLG T69208 DRUGINFO D0E7VO PMID24900538C2c Investigative T95715 TARGETID T95715 T95715 UNIPROID TFE2_HUMAN T95715 TARGNAME Transcription factor E2-alpha (TCF3) T95715 GENENAME TCF3 T95715 TARGTYPE Literature-reported T95715 SYNONYMS bHLHb21; Transcription factor ITF-1; Transcription factor 3; TCF-3; Kappa-E2-binding factor; Immunoglobulin transcription factor 1; Immunoglobulin enhancer-binding factor E12/E47; ITF1; E2A; Class B basic helix-loop-helix protein 21 T95715 FUNCTION Transcriptional regulator. Involved in the initiation of neuronal differentiation. Heterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E-box motifs: 5'-CANNTG-3'. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region. T95715 PDBSTRUC 3U5V; 2YPB; 2YPA; 2MH0; 1HLH T95715 SEQUENCE MNQPQRMAPVGTDKELSDLLDFSMMFPLPVTNGKGRPASLAGAQFGGSGLEDRPSSGSWGSGDQSSSSFDPSRTFSEGTHFTESHSSLSSSTFLGPGLGGKSGERGAYASFGRDAGVGGLTQAGFLSGELALNSPGPLSPSGMKGTSQYYPSYSGSSRRRAADGSLDTQPKKVRKVPPGLPSSVYPPSSGEDYGRDATAYPSAKTPSSTYPAPFYVADGSLHPSAELWSPPGQAGFGPMLGGGSSPLPLPPGSGPVGSSGSSSTFGGLHQHERMGYQLHGAEVNGGLPSASSFSSAPGATYGGVSSHTPPVSGADSLLGSRGTTAGSSGDALGKALASIYSPDHSSNNFSSSPSTPVGSPQGLAGTSQWPRAGAPGALSPSYDGGLHGLQSKIEDHLDEAIHVLRSHAVGTAGDMHTLLPGHGALASGFTGPMSLGGRHAGLVGGSHPEDGLAGSTSLMHNHAALPSQPGTLPDLSRPPDSYSGLGRAGATAAASEIKREEKEDEENTSAADHSEEEKKELKAPRARTSPDEDEDDLLPPEQKAEREKERRVANNARERLRVRDINEAFKELGRMCQLHLNSEKPQTKLLILHQAVSVILNLEQQVRERNLNPKAACLKRREEEKVSGVVGDPQMVLSAPHPGLSEAHNPAGHM T92098 TARGETID T92098 T92098 FORMERID TTDI00219 T92098 UNIPROID CREB1_HUMAN T92098 TARGNAME Cyclic AMP-responsive element-binding protein (CREB1) T92098 GENENAME CREB1 T92098 TARGTYPE Literature-reported T92098 SYNONYMS cAMP-responsive element-binding protein 1; Cyclic AMP-responsive element-binding protein 1; Cyclic AMP responseelement-binding protein; CREB-1; CREB; CAMP-response element binding protein T92098 FUNCTION Transcription activation is enhanced by the TORC coactivators which act independently of Ser-133 phosphorylation. Involved in different cellular processes including the synchronization of circadian rhythmicity and the differentiation of adipose cells. Phosphorylation-dependent transcription factor that stimulates transcription upon binding to the DNA cAMP response element (CRE), a sequence present in many viral and cellular promoters. T92098 PDBSTRUC 5ZKO; 5ZK1; 2LXT T92098 BIOCLASS Basic leucine zipper bZIP T92098 SEQUENCE MTMESGAENQQSGDAAVTEAENQQMTVQAQPQIATLAQVSMPAAHATSSAPTVTLVQLPNGQTVQVHGVIQAAQPSVIQSPQVQTVQISTIAESEDSQESVDSVTDSQKRREILSRRPSYRKILNDLSSDAPGVPRIEEEKSEEETSAPAITTVTVPTPIYQTSSGQYIAITQGGAIQLANNGTDGVQGLQTLTMTNAAATQPGTTILQYAQTTDGQQILVPSNQVVVQAASGDVQTYQIRTAPTSTIAPGVVMASSPALPTQPAEEAARKREVRLMKNREAARECRRKKKEYVKCLENRVAVLENQNKTLIEELKALKDLYCHKSD T33491 TARGETID T33491 T33491 FORMERID TTDR00329 T33491 UNIPROID KINA_BACSU T33491 TARGNAME Bacterial Sporulation kinase A (Bact kinA) T33491 GENENAME Bact kinA T33491 TARGTYPE Literature-reported T33491 SYNONYMS Stage II sporulation protein J; Stage II sporulation protein F; Sporulation kinase A T33491 FUNCTION Phosphorylates the sporulation-regulatory proteins spo0A and spo0F. It also autophosphorylates in the presence of ATP. T33491 PDBSTRUC 2VLG T33491 ECNUMBER EC 2.7.13.3 T33491 SEQUENCE MEQDTQHVKPLQTKTDIHAVLASNGRIIYISANSKLHLGYLQGEMIGSFLKTFLHEEDQFLVESYFYNEHHLMPCTFRFIKKDHTIVWVEAAVEIVTTRAERTEREIILKMKVLEEETGHQSLNCEKHEIEPASPESTTYITDDYERLVENLPSPLCISVKGKIVYVNSAMLSMLGAKSKDAIIGKSSYEFIEEEYHDIVKNRIIRMQKGMEVGMIEQTWKRLDGTPVHLEVKASPTVYKNQQAELLLLIDISSRKKFQTILQKSRERYQLLIQNSIDTIAVIHNGKWVFMNESGISLFEAATYEDLIGKNIYDQLHPCDHEDVKERIQNIAEQKTESEIVKQSWFTFQNRVIYTEMVCIPTTFFGEAAVQVILRDISERKQTEELMLKSEKLSIAGQLAAGIAHEIRNPLTAIKGFLQLMKPTMEGNEHYFDIVFSELSRIELILSELLMLAKPQQNAVKEYLNLKKLIGEVSALLETQANLNGIFIRTSYEKDSIYINGDQNQLKQVFINLIKNAVESMPDGGTVDIIITEDEHSVHVTVKDEGEGIPEKVLNRIGEPFLTTKEKGTGLGLMVTFNIIENHQGVIHVDSHPEKGTAFKISFPKK T33491 DRUGINFO D05ALG RWJ-49815 Terminated T33491 DRUGINFO D00VFM RWJ-49968 Investigative T33491 DRUGINFO D02MQL RWJ-61907 Investigative T33491 DRUGINFO D00MZS SK509 Investigative T76286 TARGETID T76286 T76286 FORMERID TTDNR00726 T76286 UNIPROID CD36_HUMAN T76286 TARGNAME Platelet glycoprotein 4 (CD36) T76286 GENENAME CD36 T76286 TARGTYPE Literature-reported T76286 SYNONYMS Thrombospondin receptor; Platelet glycoprotein IV; Platelet collagen receptor; PAS-4; PAS IV; Leukocyte differentiation antigen CD36; Glycoprotein IIIb; GPIV; GPIIIB; GP4; GP3B; Fatty acid translocase; FAT T76286 FUNCTION Ligands can be of proteinaceous nature like thrombospondin, fibronectin, collagen or amyloid-beta as well as of lipidic nature such as oxidized low-density lipoprotein (oxLDL), anionic phospholipids, long-chain fatty acids and bacterial diacylated lipopeptides. They are generally multivalent and can therefore engage multiple receptors simultaneously, the resulting formation of CD36 clusters initiates signal transduction and internalization of receptor-ligand complexes. The dependency on coreceptor signaling is strongly ligand specific. Cellular responses to these ligands are involved in angiogenesis, inflammatory response, fatty acid metabolism, taste and dietary fat processing in the intestine. Binds long-chain fatty acids and facilitates their transport into cells, thus participating in muscle lipid utilization, adipose energy storage, and gut fat absorption. In the small intestine, plays a role in proximal absorption of dietary fatty acid and cholesterol for optimal chylomicron formation, possibly through the activation of MAPK1/3 (ERK1/2) signaling pathway. Involved in oral fat perception and preferences. Detection into the tongue of long-chain fatty acids leads to a rapid and sustained rise in flux and protein content of pancreatobiliary secretions. In taste receptor cells, mediates the induction of an increase in intracellular calcium levels by long-chain fatty acids, leading to the activation of the gustatory neurons in the nucleus of the solitary tract. Important factor in both ventromedial hypothalamus neuronal sensing of long-chain fatty acid and the regulation of energy and glucose homeostasis. Receptor for thombospondins, THBS1 and THBS2, mediating their antiangiogenic effects. As a coreceptor for TLR4:TLR6 heterodimer, promotes inflammation in monocytes/macrophages. Upon ligand binding, such as oxLDL or amyloid-beta 42, interacts with the heterodimer TLR4:TLR6, the complex is internalized and triggers inflammatory response, leading to NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion, through the priming and activation of the NLRP3 inflammasome. Selective and nonredundant sensor of microbial diacylated lipopeptide that signal via TLR2:TLR6 heterodimer, this cluster triggers signaling from the cell surface, leading to the NF-kappa-B-dependent production of TNF, via MYD88 signaling pathway and subsequently is targeted to the Golgi in a lipid-raft dependent pathway. Multifunctional glycoprotein that acts as receptor for a broad range of ligands. T76286 PDBSTRUC 5LGD T76286 BIOCLASS Long chain fatty acid translocase T76286 SEQUENCE MGCDRNCGLIAGAVIGAVLAVFGGILMPVGDLLIQKTIKKQVVLEEGTIAFKNWVKTGTEVYRQFWIFDVQNPQEVMMNSSNIQVKQRGPYTYRVRFLAKENVTQDAEDNTVSFLQPNGAIFEPSLSVGTEADNFTVLNLAVAAASHIYQNQFVQMILNSLINKSKSSMFQVRTLRELLWGYRDPFLSLVPYPVTTTVGLFYPYNNTADGVYKVFNGKDNISKVAIIDTYKGKRNLSYWESHCDMINGTDAASFPPFVEKSQVLQFFSSDICRSIYAVFESDVNLKGIPVYRFVLPSKAFASPVENPDNYCFCTEKIISKNCTSYGVLDISKCKEGRPVYISLPHFLYASPDVSEPIDGLNPNEEEHRTYLDIEPITGFTLQFAKRLQVNLLVKPSEKIQVLKNLKRNYIVPILWLNETGTIGDEKANMFRSQVTGKINLLGLIEMILLSVGVVMFVAFMISYCACRSKTIK T45888 TARGETID T45888 T45888 FORMERID TTDR00218 T45888 UNIPROID CYSM_ECOLI T45888 TARGNAME Bacterial O-acetylserine sulfhydrylase B (Bact cysM) T45888 GENENAME Bact cysM T45888 TARGTYPE Literature-reported T45888 SYNONYMS OAS-TL B; O-acetylserine sulfhydrylase B; O-acetylserine (thiol)-lyase B; Cysteine synthase B; CSase B T45888 FUNCTION Two cysteine synthase enzymes are found. Both catalyze the same reaction. Cysteine synthase B can also use thiosulfate in place of sulfide to give cysteine thiosulfonate as a product. T45888 PDBSTRUC 2V03; 2BHT; 2BHS T45888 BIOCLASS Alkyl aryl transferase T45888 SEQUENCE MSTLEQTIGNTPLVKLQRMGPDNGSEVWLKLEGNNPAGSVKDRAALSMIVEAEKRGEIKPGDVLIEATSGNTGIALAMIAALKGYRMKLLMPDNMSQERRAAMRAYGAELILVTKEQGMEGARDLALEMANRGEGKLLDQFNNPDNPYAHYTTTGPEIWQQTGGRITHFVSSMGTTGTITGVSRFMREQSKPVTIVGLQPEEGSSIPGIRRWPTEYLPGIFNASLVDEVLDIHQRDAENTMRELAVREGIFCGVSSGGAVAGALRVAKANPDAVVVAIICDRGDRYLSTGVFGEEHFSQGAGI T46546 TARGETID T46546 T46546 FORMERID TTDR01030 T46546 UNIPROID CBPE_HUMAN T46546 TARGNAME Carboxypeptidase E (CPE) T46546 GENENAME CPE T46546 TARGTYPE Literature-reported T46546 SYNONYMS Prohormone processing carboxypeptidase; Enkephalin convertase; CPH; CPE T46546 FUNCTION Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin. T46546 BIOCLASS Peptidase T46546 ECNUMBER EC 3.4.17.10 T46546 SEQUENCE MAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELREALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVGRELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRSNAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIPFVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPCRKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWEDNKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYKLTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF T06767 TARGETID T06767 T06767 FORMERID TTDR01186 T06767 UNIPROID BETB_ECOLI T06767 TARGNAME Bacterial Betaine aldehyde dehydrogenase (Bact betB) T06767 GENENAME Bact betB T06767 TARGTYPE Literature-reported T06767 SYNONYMS betB; BADH T06767 FUNCTION Involved in the biosynthesis of the osmoprotectant glycine betaine. Catalyzes the reversible oxidation of betaine aldehyde to the corresponding acid. It is highly specific for betaine and has a significantly higher affinity for NAD than for NADP. T06767 BIOCLASS Aldehyde/oxo donor oxidoreductase T06767 ECNUMBER EC 1.2.1.8 T06767 SEQUENCE MSRMAEQQLYIHGGYTSATSGRTFETINPANGNVLATVQAAGREDVDRAVKSAQQGQKIWASMTAMERSRILRRAVDILRERNDELAKLETLDTGKAYSETSTVDIVTGADVLEYYAGLIPALEGSQIPLRETSFVYTRREPLGVVAGIGAWNYPIQIALWKSAPALAAGNAMIFKPSEVTPLTALKLAEIYSEAGLPDGVFNVLPGVGAETGQYLTEHPGIAKVSFTGGVASGKKVMANSAASSLKEVTMELGGKSPLIVFDDADLDLAADIAMMANFFSSGQVCTNGTRVFVPAKCKAAFEQKILARVERIRAGDVFDPQTNFGPLVSFPHRDNVLRYIAKGKEEGARVLCGGDVLKGDGFDNGAWVAPTVFTDCSDDMTIVREEIFGPVMSILTYESEDEVIRRANDTDYGLAAGIVTADLNRAHRVIHQLEAGICWINTWGESPAEMPVGGYKHSGIGRENGVMTLQSYTQVKSIQVEMAKFQSIF T51734 TARGETID T51734 T51734 FORMERID TTDR00419 T51734 UNIPROID CEBPB_HUMAN T51734 TARGNAME CCAAT/enhancer binding protein beta (CEBPB) T51734 GENENAME CEBPB T51734 TARGTYPE Literature-reported T51734 SYNONYMS Transcription factor CCAAT/enhancer-binding protein beta; Transcription factor 5; TCF5; TCF-5; PP9092; Nuclear factor NF-IL6; Liver-enriched inhibitory protein; Liver activator protein; LIP; LAP; CCAAT/enhancer-binding protein beta; C/EBP beta T51734 FUNCTION Plays also a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. The consensus recognition site is 5'-T[TG]NNGNAA[TG]-3'. Its functional capacity is governed by protein interactions and post-translational protein modifications. During early embryogenesis, plays essential and redundant functions with CEBPA. Has a promitotic effect on many cell types such as hepatocytes and adipocytes but has an antiproliferative effect on T-cells by repressing MYC expression, facilitating differentiation along the T-helper 2 lineage. Binds to regulatory regions of several acute-phase and cytokines genes and plays a role in the regulation of acute-phase reaction and inflammation. Plays also a role in intracellular bacteria killing. During adipogenesis, is rapidly expressed and, after activation by phosphorylation, induces CEBPA and PPARG, which turn on the series of adipocyte genes that give rise to the adipocyte phenotype. The delayed transactivation of the CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic clonal expansion and thereby progression of terminal differentiation. Essential for female reproduction because of a critical role in ovarian follicle development. Restricts osteoclastogenesis: together with NFE2L1; represses expression of DSPP during odontoblast differentiation. Important transcription factor regulating the expression of genes involved in immune and inflammatory responses. T51734 PDBSTRUC 6MG3; 6MG2; 6MG1; 2.00E+43; 2.00E+42 T51734 BIOCLASS Basic leucine zipper bZIP T51734 SEQUENCE MQRLVAWDPACLPLPPPPPAFKSMEVANFYYEADCLAAAYGGKAAPAAPPAARPGPRPPAGELGSIGDHERAIDFSPYLEPLGAPQAPAPATATDTFEAAPPAPAPAPASSGQHHDFLSDLFSDDYGGKNCKKPAEYGYVSLGRLGAAKGALHPGCFAPLHPPPPPPPPPAELKAEPGFEPADCKRKEEAGAPGGGAGMAAGFPYALRAYLGYQAVPSGSSGSLSTSSSSSPPGTPSPADAKAPPTACYAGAAPAPSQVKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLFKQLPEPLLASSGHC T64268 TARGETID T64268 T64268 FORMERID TTDI02449 T64268 UNIPROID IBP2_HUMAN T64268 TARGNAME Insulin-like growth factor-binding protein 2 (IGFBP2) T64268 GENENAME IGFBP2 T64268 TARGTYPE Literature-reported T64268 SYNONYMS IGFBP-2; IGF-binding protein 2; IBP2; IBP-2; BP2 T64268 FUNCTION Inhibits IGF-mediated growth and developmental rates. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. T64268 PDBSTRUC 2H7T T64268 BIOCLASS Insulin-like growth factor binding T64268 SEQUENCE MLPRVGCPALPLPPPPLLPLLLLLLGASGGGGGARAEVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ T86152 TARGETID T86152 T86152 FORMERID TTDR00895 T86152 UNIPROID NADE_ECOLI T86152 TARGNAME Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE) T86152 GENENAME Bact nadE T86152 TARGTYPE Literature-reported T86152 SYNONYMS efg; Nitrogen-regulatory protein; Nicotinamide adenine dinucleotide synthetase; NadE; NAD+ synthetase; NAD+ synthase; NAD(+)-synthetase; NAD synthetase; NAD synthase; Diphosphopyridine nucleotide synthetase T86152 FUNCTION Catalyzes a keystep in NAD biosynthesis, transforming deamido-NAD into NAD by a two-step reaction. T86152 PDBSTRUC 1WXI; 1WXH; 1WXG; 1WXF; 1WXE T86152 BIOCLASS Carbon-nitrogen ligase T86152 SEQUENCE MTLQQQIIKALGAKPQINAEEEIRRSVDFLKSYLQTYPFIKSLVLGISGGQDSTLAGKLCQMAINELRLETGNESLQFIAVRLPYGVQADEQDCQDAIAFIQPDRVLTVNIKGAVLASEQALREAGIELSDFVRGNEKARERMKAQYSIAGMTSGVVVGTDHAAEAITGFFTKYGDGGTDINPLYRLNKRQGKQLLAALACPEHLYKKAPTADLEDDRPSLPDEVALGVTYDNIDDYLEGKNVPQQVARTIENWYLKTEHKRRPPITVFDDFWKK T86152 DRUGINFO D00QLM [3H]alphabeta-meATP Investigative T86152 DRUGINFO D0R4PI Diphosphate Investigative T86152 DRUGINFO D0A1DU Pyrophosphate 2- Investigative T86152 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T53270 TARGETID T53270 T53270 FORMERID TTDI00061 T53270 UNIPROID ATF4_HUMAN T53270 TARGNAME Activating transcription factor 4 (ATF-4) T53270 GENENAME ATF4 T53270 TARGTYPE Literature-reported T53270 SYNONYMS cAMPresponsive elementbinding protein 2; cAMPdependent transcription factor ATF4; cAMP-responsive element-binding protein 2; cAMP-dependent transcription factor ATF-4; Taxresponsive enhancer elementbinding protein 67; TaxREB67; Tax-responsive enhancer element-binding protein 67; TXREB; DNAbinding protein TAXREB67; DNA-binding protein TAXREB67; Cyclic AMPresponsive elementbinding protein 2; Cyclic AMPdependent transcription factor ATF4; Cyclic AMP-responsive element-binding protein 2; Cyclic AMP-dependent transcription factor ATF-4; CREB2; CREB-2 T53270 FUNCTION Binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Cooperates with FOXO1 in osteoblasts to regulate glucose homeostasis through suppression of beta-cell production and decrease in insulin production. It binds to a Tax-responsive enhancer element in the long terminal repeat of HTLV-I. Regulates the induction of DDIT3/CHOP and asparagine synthetase (ASNS) in response to endoplasmic reticulum (ER) stress. In concert with DDIT3/CHOP, activates the transcription of TRIB3 and promotes ER stress-induced neuronal apoptosis by regulating the transcriptional induction of BBC3/PUMA. Activates transcription of SIRT4. Regulates the circadian expression of the core clock component PER2 and the serotonin transporter SLC6A4. Binds in a circadian time-dependent manner to the cAMP response elements (CRE) in the SLC6A4 and PER2 promoters and periodically activates the transcription of these genes. During ER stress response, activates the transcription of NLRP1, possibly in concert with other factors. Transcriptional activator. T53270 PDBSTRUC 1CI6 T53270 BIOCLASS Basic leucine zipper bZIP T53270 SEQUENCE MTEMSFLSSEVLVGDLMSPFDQSGLGAEESLGLLDDYLEVAKHFKPHGFSSDKAKAGSSEWLAVDGLVSPSNNSKEDAFSGTDWMLEKMDLKEFDLDALLGIDDLETMPDDLLTTLDDTCDLFAPLVQETNKQPPQTVNPIGHLPESLTKPDQVAPFTFLQPLPLSPGVLSSTPDHSFSLELGSEVDITEGDRKPDYTAYVAMIPQCIKEEDTPSDNDSGICMSPESYLGSPQHSPSTRGSPNRSLPSPGVLCGSARPKPYDPPGEKMVAAKVKGEKLDKKLKKMEQNKTAATRYRQKKRAEQEALTGECKELEKKNEALKERADSLAKEIQYLKDLIEEVRKARGKKRVP T44991 TARGETID T44991 T44991 FORMERID TTDR00453 T44991 UNIPROID VCAM1_HUMAN T44991 TARGNAME Vascular cell adhesion protein 1 (VCAM1) T44991 GENENAME VCAM1 T44991 TARGTYPE Literature-reported T44991 SYNONYMS Vascular cell adhesion molecule 1; VCAM-1; V-CAM 1; INCAM-100; CD106 antigen; CD106 T44991 FUNCTION Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and signal transduction. The VCAM1/ITGA4/ITGB1 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. Important in cell-cell recognition. T44991 PDBSTRUC 1VSC; 1VCA; 1IJ9 T44991 SEQUENCE MPGKMVVILGASNILWIMFAASQAFKIETTPESRYLAQIGDSVSLTCSTTGCESPFFSWRTQIDSPLNGKVTNEGTTSTLTMNPVSFGNEHSYLCTATCESRKLEKGIQVEIYSFPKDPEIHLSGPLEAGKPITVKCSVADVYPFDRLEIDLLKGDHLMKSQEFLEDADRKSLETKSLEVTFTPVIEDIGKVLVCRAKLHIDEMDSVPTVRQAVKELQVYISPKNTVISVNPSTKLQEGGSVTMTCSSEGLPAPEIFWSKKLDNGNLQHLSGNATLTLIAMRMEDSGIYVCEGVNLIGKNRKEVELIVQEKPFTVEISPGPRIAAQIGDSVMLTCSVMGCESPSFSWRTQIDSPLSGKVRSEGTNSTLTLSPVSFENEHSYLCTVTCGHKKLEKGIQVELYSFPRDPEIEMSGGLVNGSSVTVSCKVPSVYPLDRLEIELLKGETILENIEFLEDTDMKSLENKSLEMTFIPTIEDTGKALVCQAKLHIDDMEFEPKQRQSTQTLYVNVAPRDTTVLVSPSSILEEGSSVNMTCLSQGFPAPKILWSRQLPNGELQPLSENATLTLISTKMEDSGVYLCEGINQAGRSRKEVELIIQVTPKDIKLTAFPSESVKEGDTVIISCTCGNVPETWIILKKKAETGDTVLKSIDGAYTIRKAQLKDAGVYECESKNKVGSQLRSLTLDVQGRENNKDYFSPELLVLYFASSLIIPAIGMIIYFARKANMKGSYSLVEAQKSKV T20186 TARGETID T20186 T20186 FORMERID TTDR00670 T20186 UNIPROID TNNI3_HUMAN T20186 TARGNAME Cardiac troponin I (TNNI3) T20186 GENENAME TNNI3 T20186 TARGTYPE Literature-reported T20186 SYNONYMS TNNI3 T20186 FUNCTION Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. T20186 PDBSTRUC 6MV3; 5WCL; 5W88; 5VLN; 4Y99 T20186 BIOCLASS Troponin T20186 SEQUENCE MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKTLLLQIAKQELEREAEERRGEKGRALSTRCQPLELAGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRVRISADAMMQALLGARAKESLDLRAHLKQVKKEDTEKENREVGDWRKNIDALSGMEGRKKKFES T51102 TARGETID T51102 T51102 FORMERID TTDI01524 T51102 UNIPROID E2AK2_HUMAN T51102 TARGNAME Protein kinase R (PKR) T51102 GENENAME EIF2AK2 T51102 TARGTYPE Literature-reported T51102 SYNONYMS eIF-2A protein kinase 2; Protein kinase RNA-activated; PRKR; PKR; P1/eIF-2A protein kinase; Interferon-inducible RNA-dependent protein kinase; Interferon-induced, double-stranded RNA-activated protein kinase; Eukaryotic translation initiation factor 2-alpha kinase 2 T51102 FUNCTION IFN-induced dsRNA-dependent serine/threonine-protein kinase which plays a key role in the innate immune response to viral infection and is also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation. Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1). Inhibits viral replication via phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (EIF2S1), this phosphorylation impairs the recycling of EIF2S1 between successive rounds of initiation leading to inhibition of translation which eventually results in shutdown of cellular and viral protein synthesis. Also phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein US11. In addition to serine/threonine-protein kinase activity, also has tyrosine-protein kinase activity and phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and proteosomal degradation. Either as an adapter protein and/or via its kinase activity, can regulate various signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in the expression of genes encoding proinflammatory cytokines and IFNs. Activates the NF-kappa-B pathway via interaction with IKBKB and TRAF family of proteins and activates the p38 MAP kinase pathway via interaction with MAP2K6. Can act as both a positive and negative regulator of the insulin signaling pathway (ISP). Negatively regulates ISP by inducing the inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A which activates FOXO1, which in turn up-regulates the expression of insulin receptor substrate 2 (IRS2). Can regulate NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 and NLRC4 inflammasomes. Can trigger apoptosis via FADD-mediated activation of CASP8. Plays a role in the regulation of the cytoskeleton by binding to gelsolin (GSN), sequestering the protein in an inactive conformation away from actin. T51102 PDBSTRUC 3UIU; 2A1A; 2A19; 1QU6 T51102 ECNUMBER EC 2.7.11.1 T51102 SEQUENCE MAGDLSAGFFMEELNTYRQKQGVVLKYQELPNSGPPHDRRFTFQVIIDGREFPEGEGRSKKEAKNAAAKLAVEILNKEKKAVSPLLLTTTNSSEGLSMGNYIGLINRIAQKKRLTVNYEQCASGVHGPEGFHYKCKMGQKEYSIGTGSTKQEAKQLAAKLAYLQILSEETSVKSDYLSSGSFATTCESQSNSLVTSTLASESSSEGDFSADTSEINSNSDSLNSSSLLMNGLRNNQRKAKRSLAPRFDLPDMKETKYTVDKRFGMDFKEIELIGSGGFGQVFKAKHRIDGKTYVIKRVKYNNEKAEREVKALAKLDHVNIVHYNGCWDGFDYDPETSDDSLESSDYDPENSKNSSRSKTKCLFIQMEFCDKGTLEQWIEKRRGEKLDKVLALELFEQITKGVDYIHSKKLIHRDLKPSNIFLVDTKQVKIGDFGLVTSLKNDGKRTRSKGTLRYMSPEQISSQDYGKEVDLYALGLILAELLHVCDTAFETSKFFTDLRDGIISDIFDKKEKTLLQKLLSKKPEDRPNTSEILRTLTVWKKSPEKNERHTC T11861 TARGETID T11861 T11861 FORMERID TTDR00625 T11861 UNIPROID DHOM_BACSU T11861 TARGNAME Bacterial Homoserine dehydrogenase (Bact hom) T11861 GENENAME Bact hom T11861 TARGTYPE Literature-reported T11861 SYNONYMS Homoserine dehydrogenase; HDH T11861 FUNCTION A dimer enzyme, with each monomer composed of three regions, the nucleotide-binding region, the dimerization region and the catalytic region. Required for the biosynthesis of the three essential amino acids, methionine, isoleucine and threonine from aspartate. Participates in this aspartate pathway of the NAD(P)H-dependent reduction of L-aspartate semialdehyde (L-ASA) to L-homoserine (L-Hse). T11861 BIOCLASS Short-chain dehydrogenases reductase T11861 ECNUMBER EC 1.1.1.3 T11861 SEQUENCE MKAIRVGLLGLGTVGSGVVKIIQDHQDKLMHQVGCPVTIKKVLVKDLEKKREVDLPKEVLTTEVYDVIDDPDVDVVIEVIGGVEQTKQYLVDALRSKKHVVTANKDLMAVYGSELLAEAKENGCDIYFEASVAGGIPILRTLEEGLSSDRITKMMGIVNGTTNFILTKMIKEKSPYEEVLKEAQDLGFAEADPTSDVEGLDAARKMAILARLGFSMNVDLEDVKVKGISQITDEDISFSKRLGYTMKLIGIAQRDGSKIEVSVQPTLLPDHHPLSAVHNEFNAVYVYGEAVGETMFYGPGAGSMPTATSVVSDLVAVMKNMRLGVTGNSFVGPQYEKNMKSPSDIYAQQFLRIHVKDEVGSFSKITSVFSERGVSFEKILQLPIKGHDELAEIVIVTHHTSEADFSDILQNLNDLEVVQEVKSTYRVEGNGWS T45601 TARGETID T45601 T45601 FORMERID TTDI03474 T45601 UNIPROID PEPC_HUMAN T45601 TARGNAME Progastricsin pepsinogen C (PGC) T45601 GENENAME PGC T45601 TARGTYPE Literature-reported T45601 SYNONYMS Pepsinogen C; Gastricsin T45601 FUNCTION Hydrolyzes a variety of proteins. T45601 PDBSTRUC 1HTR; 1AVF T45601 ECNUMBER EC 3.4.23.3 T45601 SEQUENCE MKWMVVVLVCLQLLEAAVVKVPLKKFKSIRETMKEKGLLGEFLRTHKYDPAWKYRFGDLSVTYEPMAYMDAAYFGEISIGTPPQNFLVLFDTGSSNLWVPSVYCQSQACTSHSRFNPSESSTYSTNGQTFSLQYGSGSLTGFFGYDTLTVQSIQVPNQEFGLSENEPGTNFVYAQFDGIMGLAYPALSVDEATTAMQGMVQEGALTSPVFSVYLSNQQGSSGGAVVFGGVDSSLYTGQIYWAPVTQELYWQIGIEEFLIGGQASGWCSEGCQAIVDTGTSLLTVPQQYMSALLQATGAQEDEYGQFLVNCNSIQNLPSLTFIINGVEFPLPPSSYILSNNGYCTVGVEPTYLSSQNGQPLWILGDVFLRSYYSVYDLGNNRVGFATAA T45601 DRUGINFO D0P6RT PMID8410973C3 Investigative T15722 TARGETID T15722 T15722 FORMERID TTDI02540 T15722 UNIPROID CD11B_HUMAN T15722 TARGNAME Cyclin-dependent kinase 11B (CDK11B) T15722 GENENAME CDK11B T15722 TARGTYPE Literature-reported T15722 SYNONYMS p58 CLK1; p58 CLK-1; PK58; PITSLREA; PITSLRE serine/threonineprotein kinase CDC2L1; PITSLRE serine/threonine-protein kinase CDC2L1; Galactosyltransferaseassociated protein kinase p58/GTA; Galactosyltransferase-associated protein kinase p58/GTA; Cyclindependent kinase 11B; Cell division protein kinase 11B; Cell division cycle 2-like protein kinase 1; CLK-1; CDK11; CDC2L1 T15722 FUNCTION Involved in pre-mRNA splicing in a kinase activity-dependent manner. Isoform 7 may act as a negative regulator of normal cell cycle progression. Plays multiple roles in cell cycle progression, cytokinesis and apoptosis. T15722 BIOCLASS Kinase T15722 ECNUMBER EC 2.7.11.22 T15722 SEQUENCE MGDEKDSWKVKTLDEILQEKKRRKEQEEKAEIKRLKNSDDRDSKRDSLEEGELRDHRMEITIRNSPYRREDSMEDRGEEDDSLAIKPPQQMSRKEKAHHRKDEKRKEKRRHRSHSAEGGKHARVKEKEREHERRKRHREEQDKARREWERQKRREMAREHSRRERDRLEQLERKRERERKMREQQKEQREQKERERRAEERRKEREARREVSAHHRTMREDYSDKVKASHWSRSPPRPPRERFELGDGRKPGEARPAPAQKPAQLKEEKMEERDLLSDLQDISDSERKTSSAESSSAESGSGSEEEEEEEEEEEEEGSTSEESEEEEEEEEEEEEETGSNSEEASEQSAEEVSEEEMSEDEERENENHLLVVPESRFDRDSGESEEAEEEVGEGTPQSSALTEGDYVPDSPALSPIELKQELPKYLPALQGCRSVEEFQCLNRIEEGTYGVVYRAKDKKTDEIVALKRLKMEKEKEGFPITSLREINTILKAQHPNIVTVREIVVGSNMDKIYIVMNYVEHDLKSLMETMKQPFLPGEVKTLMIQLLRGVKHLHDNWILHRDLKTSNLLLSHAGILKVGDFGLAREYGSPLKAYTPVVVTLWYRAPELLLGAKEYSTAVDMWSVGCIFGELLTQKPLFPGKSEIDQINKVFKDLGTPSEKIWPGYSELPAVKKMTFSEHPYNNLRKRFGALLSDQGFDLMNKFLTYFPGRRISAEDGLKHEYFRETPLPIDPSMFPTWPAKSEQQRVKRGTSPRPPEGGLGYSQLGDDDLKETGFHLTTTNQGASAAGPGFSLKF T41119 TARGETID T41119 T41119 FORMERID TTDNR00715 T41119 UNIPROID NR4A1_HUMAN T41119 TARGNAME Early response protein NAK1 (NR4A1) T41119 GENENAME NR4A1 T41119 TARGTYPE Literature-reported T41119 SYNONYMS Testicular receptor 3; ST-59; Orphan nuclear receptor TR3; Orphan nuclear receptor HMR; Nur77; Nuclear receptor subfamily 4 group A member 1; Nuclear hormone receptor NUR/77; NAK1; GFRP1 T41119 FUNCTION May act concomitantly with NURR1 in regulating the expression of delayed-early genes during liver regeneration. Binds the NGFI-B response element (NBRE) 5'-AAAAGGTCA-3'. May inhibit NF-kappa-B transactivation of IL2. Participates in energy homeostasis by sequestrating the kinase STK11 in the nucleus, thereby attenuating cytoplasmic AMPK activation. Plays a role in the vascular response to injury. Orphan nuclear receptor. T41119 PDBSTRUC 4WHG; 4WHF; 4RZG; 4RZF; 4RZE T41119 BIOCLASS Nuclear hormone receptor T41119 SEQUENCE MPCIQAQYGTPAPSPGPRDHLASDPLTPEFIKPTMDLASPEAAPAAPTALPSFSTFMDGYTGEFDTFLYQLPGTVQPCSSASSSASSTSSSSATSPASASFKFEDFQVYGCYPGPLSGPVDEALSSSGSDYYGSPCSAPSPSTPSFQPPQLSPWDGSFGHFSPSQTYEGLRAWTEQLPKASGPPQPPAFFSFSPPTGPSPSLAQSPLKLFPSQATHQLGEGESYSMPTAFPGLAPTSPHLEGSGILDTPVTSTKARSGAPGGSEGRCAVCGDNASCQHYGVRTCEGCKGFFKRTVQKNAKYICLANKDCPVDKRRRNRCQFCRFQKCLAVGMVKEVVRTDSLKGRRGRLPSKPKQPPDASPANLLTSLVRAHLDSGPSTAKLDYSKFQELVLPHFGKEDAGDVQQFYDLLSGSLEVIRKWAEKIPGFAELSPADQDLLLESAFLELFILRLAYRSKPGEGKLIFCSGLVLHRLQCARGFGDWIDSILAFSRSLHSLLVDVPAFACLSALVLITDRHGLQEPRRVEELQNRIASCLKEHVAAVAGEPQPASCLSRLLGKLPELRTLCTQGLQRIFYLKLEDLVPPPPIIDKIFMDTLPF T93278 TARGETID T93278 T93278 FORMERID TTDI02434 T93278 UNIPROID MRC1_HUMAN T93278 TARGNAME Mannose receptor (MRC1) T93278 GENENAME MRC1 T93278 TARGTYPE Literature-reported T93278 SYNONYMS Macrophage mannose receptor 1like protein 1; Macrophage mannose receptor 1-like protein 1; Macrophage mannose receptor 1; MRC1L1; MMR; Human mannose receptor; Ctype lectin domain family 13 member Dlike; Ctype lectin domain family 13 member D; CLEC13DL; CLEC13D; CD206; C-type lectin domain family 13 member D-like; C-type lectin domain family 13 member D T93278 FUNCTION Binds both sulfated and non-sulfated polysaccharide chains. Mediates the endocytosis of glycoproteins by macrophages. T93278 PDBSTRUC 5XTW; 5XTS; 1EGI; 1EGG T93278 BIOCLASS Fibronectin protein T93278 SEQUENCE MRLPLLLVFASVIPGAVLLLDTRQFLIYNEDHKRCVDAVSPSAVQTAACNQDAESQKFRWVSESQIMSVAFKLCLGVPSKTDWVAITLYACDSKSEFQKWECKNDTLLGIKGEDLFFNYGNRQEKNIMLYKGSGLWSRWKIYGTTDNLCSRGYEAMYTLLGNANGATCAFPFKFENKWYADCTSAGRSDGWLWCGTTTDYDTDKLFGYCPLKFEGSESLWNKDPLTSVSYQINSKSALTWHQARKSCQQQNAELLSITEIHEQTYLTGLTSSLTSGLWIGLNSLSFNSGWQWSDRSPFRYLNWLPGSPSAEPGKSCVSLNPGKNAKWENLECVQKLGYICKKGNTTLNSFVIPSESDVPTHCPSQWWPYAGHCYKIHRDEKKIQRDALTTCRKEGGDLTSIHTIEELDFIISQLGYEPNDELWIGLNDIKIQMYFEWSDGTPVTFTKWLRGEPSHENNRQEDCVVMKGKDGYWADRGCEWPLGYICKMKSRSQGPEIVEVEKGCRKGWKKHHFYCYMIGHTLSTFAEANQTCNNENAYLTTIEDRYEQAFLTSFVGLRPEKYFWTGLSDIQTKGTFQWTIEEEVRFTHWNSDMPGRKPGCVAMRTGIAGGLWDVLKCDEKAKFVCKHWAEGVTHPPKPTTTPEPKCPEDWGASSRTSLCFKLYAKGKHEKKTWFESRDFCRALGGDLASINNKEEQQTIWRLITASGSYHKLFWLGLTYGSPSEGFTWSDGSPVSYENWAYGEPNNYQNVEYCGELKGDPTMSWNDINCEHLNNWICQIQKGQTPKPEPTPAPQDNPPVTEDGWVIYKDYQYYFSKEKETMDNARAFCKRNFGDLVSIQSESEKKFLWKYVNRNDAQSAYFIGLLISLDKKFAWMDGSKVDYVSWATGEPNFANEDENCVTMYSNSGFWNDINCGYPNAFICQRHNSSINATTVMPTMPSVPSGCKEGWNFYSNKCFKIFGFMEEERKNWQEARKACIGFGGNLVSIQNEKEQAFLTYHMKDSTFSAWTGLNDVNSEHTFLWTDGRGVHYTNWGKGYPGGRRSSLSYEDADCVVIIGGASNEAGKWMDDTCDSKRGYICQTRSDPSLTNPPATIQTDGFVKYGKSSYSLMRQKFQWHEAETYCKLHNSLIASILDPYSNAFAWLQMETSNERVWIALNSNLTDNQYTWTDKWRVRYTNWAADEPKLKSACVYLDLDGYWKTAHCNESFYFLCKRSDEIPATEPPQLPGRCPESDHTAWIPFHGHCYYIESSYTRNWGQASLECLRMGSSLVSIESAAESSFLSYRVEPLKSKTNFWIGLFRNVEGTWLWINNSPVSFVNWNTGDPSGERNDCVALHASSGFWSNIHCSSYKGYICKRPKIIDAKPTHELLTTKADTRKMDPSKPSSNVAGVVIIVILLILTGAGLAAYFFYKKRRVHLPQEGAFENTLYFNSQSSPGTSDMKDLVGNIEQNEHSVI T92635 TARGETID T92635 T92635 FORMERID TTDR00744 T92635 UNIPROID GATA3_HUMAN T92635 TARGNAME GATA-binding factor 3 (GATA3) T92635 GENENAME GATA3 T92635 TARGTYPE Literature-reported T92635 SYNONYMS Trans-acting T-cell-specific transcription factor GATA-3 T92635 FUNCTION Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process following immune and inflammatory responses. T92635 PDBSTRUC 4HCA; 4HC9; 4HC7 T92635 BIOCLASS Zinc-finger T92635 SEQUENCE MEVTADQPRWVSHHHPAVLNGQHPDTHHPGLSHSYMDAAQYPLPEEVDVLFNIDGQGNHVPPYYGNSVRATVQRYPPTHHGSQVCRPPLLHGSLPWLDGGKALGSHHTASPWNLSPFSKTSIHHGSPGPLSVYPPASSSSLSGGHASPHLFTFPPTPPKDVSPDPSLSTPGSAGSARQDEKECLKYQVPLPDSMKLESSHSRGSMTALGGASSSTHHPITTYPPYVPEYSSGLFPPSSLLGGSPTGFGCKSRPKARSSTGRECVNCGATSTPLWRRDGTGHYLCNACGLYHKMNGQNRPLIKPKRRLSAARRAGTSCANCQTTTTTLWRRNANGDPVCNACGLYYKLHNINRPLTMKKEGIQTRNRKMSSKSKKCKKVHDSLEDFPKNSSFNPAALSRHMSSLSHISPFSHSSHMLTTPTPMHPPSSLSFGPHHPSSMVTAMG T87542 TARGETID T87542 T87542 FORMERID TTDR00166 T87542 UNIPROID GSA_ECOLI T87542 TARGNAME Bacterial Glutamate-1-semialdehyde aminomutase (Bact hemL) T87542 GENENAME Bact hemL T87542 TARGTYPE Literature-reported T87542 SYNONYMS Glutamate-1-semialdehyde aminotransferase; Glutamate-1-semialdehyde 2,1-aminomutase; GSA-AT; GSA T87542 FUNCTION Catalyses the formation of this key precursor of tetrapyrroles. T87542 BIOCLASS Intramolecular transferases T87542 SEQUENCE MSKSENLYSAARELIPGGVNSPVRAFTGVGGTPLFIEKADGAYLYDVDGKAYIDYVGSWGPMVLGHNHPAIRNAVIEAAERGLSFGAPTEMEVKMAQLVTELVPTMDMVRMVNSGTEATMSAIRLARGFTGRDKIIKFEGCYHGHADCLLVKAGSGALTLGQPNSPGVPADFAKYTLTCTYNDLASVRAAFEQYPQEIACIIVEPVAGNMNCVPPLPEFLPGLRALCDEFGALLIIDEVMTGFRVALAGAQDYYGVVPDLTCLGKIIGGGMPVGAFGGRRDVMDALAPTGPVYQAGTLSGNPIAMAAGFACLNEVAQPGVHETLDELTTRLAEGLLEAAEEAGIPLVVNHVGGMFGIFFTDAESVTCYQDVMACDVERFKRFFHMMLDEGVYLAPSAFEAGFMSVAHSMEDINNTIDAARRVFAKL T87542 DRUGINFO D03DVF Gabaculine Investigative T87542 DRUGINFO D0VF4Q Diaminopropyl sulfate Investigative T96028 TARGETID T96028 T96028 UNIPROID IL32_HUMAN T96028 TARGNAME Interleukin-32 (IL32) T96028 GENENAME IL32 T96028 TARGTYPE Literature-reported T96028 SYNONYMS Tumor necrosis factor alpha-inducing factor; TAIF; Natural killer cells protein 4; NK4; IL-32 T96028 FUNCTION It induces various cytokines such as TNFA/TNF-alpha and IL8. It activates typical cytokine signal pathways of NF-kappa-B and p38 MAPK. Cytokine that may play a role in innate and adaptive immune responses. T96028 BIOCLASS Cytokine: interleukin T96028 SEQUENCE MCFPKVLSDDMKKLKARMVMLLPTSAQGLGAWVSACDTEDTVGHLGPWRDKDPALWCQLCLSSQHQAIERFYDKMQNAESGRGQVMSSLAELEDDFKEGYLETVAAYYEEQHPELTPLLEKERDGLRCRGNRSPVPDVEDPATEEPGESFCDKVMRWFQAMLQRLQTWWHGVLAWVKEKVVALVHAVQALWKQFQSFCCSLSELFMSSFQSYGAPRGDKEELTPQKCSEPQSSK T94083 TARGETID T94083 T94083 FORMERID TTDR00331 T94083 UNIPROID ACPS_ECOLI T94083 TARGNAME Bacterial Holo-ACP synthase (Bact acpS) T94083 GENENAME Bact acpS T94083 TARGTYPE Literature-reported T94083 SYNONYMS acpS; Holo-[acyl-carrier protein] synthase; 4'-phosphopantetheinyl transferase acpS T94083 FUNCTION Transfers the 4'-phosphopantetheine moiety from coenzyme A to the 'Ser-36' of acyl-carrier-protein. T94083 PDBSTRUC 5XUH; 5XU7; 5VCB; 5VBX T94083 BIOCLASS Kinase T94083 SEQUENCE MAILGLGTDIVEIARIEAVIARSGDRLARRVLSDNEWAIWKTHHQPVRFLAKRFAVKEAAAKAFGTGIRNGLAFNQFEVFNDELGKPRLRLWGEALKLAEKLGVANMHVTLADERHYACATVIIES T67540 TARGETID T67540 T67540 FORMERID TTDR00816 T67540 UNIPROID PTRB_ECOLI T67540 TARGNAME Bacterial Protease II (Bact ptrB) T67540 GENENAME Bact ptrB T67540 TARGTYPE Literature-reported T67540 SYNONYMS ptrB; Oligopeptidase B T67540 FUNCTION Cleaves peptide bonds on the C-terminal side of lysyl and argininyl residues. T67540 BIOCLASS Peptidase T67540 ECNUMBER EC 3.4.21.83 T67540 SEQUENCE MLPKAARIPHAMTLHGDTRIDNYYWLRDDTRSQPEVLDYLQQENSYGHRVMASQQALQDRILKEIIDRIPQREVSAPYIKNGYRYRHIYEPGCEYAIYQRQSAFSEEWDEWETLLDANKRAAHSEFYSMGGMAITPDNTIMALAEDFLSRRQYGIRFRNLETGNWYPELLDNVEPSFVWANDSWIFYYVRKHPVTLLPYQVWRHAIGTPASQDKLIYEEKDDTYYVSLHKTTSKHYVVIHLASATTSEVRLLDAEMADAEPFVFLPRRKDHEYSLDHYQHRFYLRSNRHGKNFGLYRTRMRDEQQWEELIPPRENIMLEGFTLFTDWLVVEERQRGLTSLRQINRKTREVIGIAFDDPAYVTWIAYNPEPETARLRYGYSSMTTPDTLFELDMDTGERRVLKQTEVPGFYAANYRSEHLWIVARDGVEVPVSLVYHRKHFRKGHNPLLVYGYGSYGASIDADFSFSRLSLLDRGFVYAIVHVRGGGELGQQWYEDGKFLKKKNTFNDYLDACDALLKLGYGSPSLCYAMGGSAGGMLMGVAINQRPELFHGVIAQVPFVDVVTTMLDESIPLTTGEFEEWGNPQDPQYYEYMKSYSPYDNVTAQAYPHLLVTTGLHDSQVQYWEPAKWVAKLRELKTDDHLLLLCTDMDSGHGGKSGRFKSYEGVAMEYAFLVALAQGTLPATPAD T61800 TARGETID T61800 T61800 FORMERID TTDR00586 T61800 UNIPROID IBP6_HUMAN T61800 TARGNAME Insulin-like growth factor-binding protein 6 (IGFBP6) T61800 GENENAME IGFBP6 T61800 TARGTYPE Literature-reported T61800 SYNONYMS IGFBP-6; IGF-binding protein 6; IBP6; IBP-6 T61800 FUNCTION IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. T61800 PDBSTRUC 1RMJ T61800 BIOCLASS Insulin-like growth factor binding T61800 SEQUENCE MTPHRLLPPLLLLLALLLAASPGGALARCPGCGQGVQAGCPGGCVEEEDGGSPAEGCAEAEGCLRREGQECGVYTPNCAPGLQCHPPKDDEAPLRALLLGRGRCLPARAPAVAEENPKESKPQAGTARPQDVNRRDQQRNPGTSTTPSQPNSAGVQDTEMGPCRRHLDSVLQQLQTEVYRGAQTLYVPNCDHRGFYRKRQCRSSQGQRRGPCWCVDRMGKSLPGSPDGNGSSSCPTGSSG T97917 TARGETID T97917 T97917 FORMERID TTDR00540 T97917 UNIPROID FPR2_HUMAN T97917 TARGNAME FMLP-related receptor I (FPR2) T97917 GENENAME FPR2 T97917 TARGTYPE Literature-reported T97917 SYNONYMS RFP; Lipoxin A4 receptor; LXA4 receptor; HM63; G-protein-coupled receptor FPR-Like-1; Formyl peptide receptor-like 1; FPRL1; FPR2; FMLP-R-I T97917 FUNCTION Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophils chemotactic factors. Binding of FMLP to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The activation of LXA4R could result in an anti-inflammatory outcome counteracting the actions of proinflammatory signals such as LTB4 (leukotrieneB4). T97917 BIOCLASS GPCR rhodopsin T97917 SEQUENCE METNFSTPLNEYEEVSYESAGYTVLRILPLVVLGVTFVLGVLGNGLVIWVAGFRMTRTVTTICYLNLALADFSFTATLPFLIVSMAMGEKWPFGWFLCKLIHIVVDINLFGSVFLIGFIALDRCICVLHPVWAQNHRTVSLAMKVIVGPWILALVLTLPVFLFLTTVTIPNGDTYCTFNFASWGGTPEERLKVAITMLTARGIIRFVIGFSLPMSIVAICYGLIAAKIHKKGMIKSSRPLRVLTAVVASFFICWFPFQLVALLGTVWLKEMLFYGKYKIIDILVNPTSSLAFFNSCLNPMLYVFVGQDFRERLIHSLPTSLERALSEDSAPTNDTAANSASPPAETELQAM T97917 DRUGINFO D09TXO humanin Preclinical T97917 DRUGINFO D04NBD quin-C7 Investigative T97917 DRUGINFO D07PSF aspirin triggered lipoxin A4 Investigative T97917 DRUGINFO D0C3HQ quin-C1 Investigative T97917 DRUGINFO D0H1EB ATLa2 Investigative T97917 DRUGINFO D0MU1V AG-26 Investigative T97917 DRUGINFO D0NL4R PMID23788657C1754-31 Investigative T97917 DRUGINFO D01EOQ PMID22607879CR-(-)-5f Investigative T97917 DRUGINFO D05PYO aspirin-triggered resolvin D1 Investigative T97917 DRUGINFO D0M0YH fMet-Leu-Phe Investigative T97917 DRUGINFO D0V8YH RvD1-ME Investigative T97917 DRUGINFO D0WB8E pyrazolone, 1 Investigative T97917 DRUGINFO D0P0KG [3H]resolvin D1 Investigative T97917 DRUGINFO D0R1FZ LXA4 Investigative T89215 TARGETID T89215 T89215 FORMERID TTDR00706 T89215 UNIPROID RS12_HUMAN T89215 TARGNAME Small ribosomal subunit protein eS12 (RPS12) T89215 GENENAME RPS12 T89215 TARGTYPE Literature-reported T89215 SYNONYMS 40S ribosomal protein S12 T89215 FUNCTION A component of the 40S ribosome subunit. Ribosome, the organelle that catalyzes protein synthesis, consists of a small 40S subunit and a large 60S subunit. Increased expression in colorectal cancers compared to matched normal colonic mucosa. T89215 PDBSTRUC 6QZP; 6G5I; 6G5H; 6G53; 6G51 T89215 BIOCLASS Ribosomal protein T89215 SEQUENCE MAEEGIAAGGVMDVNTALQEVLKTALIHDGLARGIREAAKALDKRQAHLCVLASNCDEPMYVKLVEALCAEHQINLIKVDDNKKLGEWVGLCKIDREGKPRKVVGCSCVVVKDYGKESQAKDVIEEYFKCKK T96704 TARGETID T96704 T96704 FORMERID TTDR00986 T96704 UNIPROID DNJB1_HUMAN T96704 TARGNAME Heat shock protein 40 (HSP40) T96704 GENENAME DNAJB1 T96704 TARGTYPE Literature-reported T96704 SYNONYMS Heat shock 40 kDa protein 1; HSP40; HDJ-1; DnaJ protein homolog 1; DnaJ homolog subfamily B member 1; DNAJB1 T96704 FUNCTION Interacts with HSP70 and can stimulate its ATPase activity. Stimulates the association between HSC70 and HIP. T96704 PDBSTRUC 6BYR; 4WB7; 3AGZ; 3AGY; 3AGX T96704 BIOCLASS Heat shock protein T96704 SEQUENCE MGKDYYQTLGLARGASDEEIKRAYRRQALRYHPDKNKEPGAEEKFKEIAEAYDVLSDPRKREIFDRYGEEGLKGSGPSGGSGGGANGTSFSYTFHGDPHAMFAEFFGGRNPFDTFFGQRNGEEGMDIDDPFSGFPMGMGGFTNVNFGRSRSAQEPARKKQDPPVTHDLRVSLEEIYSGCTKKMKISHKRLNPDGKSIRNEDKILTIEVKKGWKEGTKITFPKEGDQTSNNIPADIVFVLKDKPHNIFKRDGSDVIYPARISLREALCGCTVNVPTLDGRTIPVVFKDVIRPGMRRKVPGEGLPLPKTPEKRGDLIIEFEVIFPERIPQTSRTVLEQVLPI T70850 TARGETID T70850 T70850 FORMERID TTDR00558 T70850 UNIPROID END1_ECOLI T70850 TARGNAME Bacterial RNA endonuclease (Bact endA) T70850 GENENAME Bact endA T70850 TARGTYPE Literature-reported T70850 SYNONYMS endA; Endonuclease I; Endo I T70850 FUNCTION Has double-strand break activity. T70850 BIOCLASS Endodeoxyribonucleases T70850 ECNUMBER EC 3.1.21.1 T70850 SEQUENCE MYRYLSIAAVVLSAAFSGPALAEGINSFSQAKAAAVKVHADAPGTFYCGCKINWQGKKGVVDLQSCGYQVRKNENRASRVEWEHVVPAWQFGHQRQCWQDGGRKNCAKDPVYRKMESDMHNLQPSVGEVNGDRGNFMYSQWNGGEGQYGQCAMKVDFKEKAAEPPARARGAIARTYFYMRDQYNLTLSRQQTQLFNAWNKMYPVTDWECERDERIAKVQGNHNPYVQRACQARKS T85801 TARGETID T85801 T85801 FORMERID TTDR00746 T85801 UNIPROID ALGC_PSEAE T85801 TARGNAME Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC) T85801 GENENAME Pseudo algC T85801 TARGTYPE Literature-reported T85801 SYNONYMS algC; PMM/PGM; PMM / PGM T85801 FUNCTION Highly reversible phosphoryltransferase. The phosphomannomutase activity produces a precursor for alginate polymerization, the alginate layer causes a mucoid phenotype and provides a protective barrier against host immune defenses and antibiotics. Also involved in core lipopolysaccaride (LPS) biosynthesis due to its phosphoglucomutase activity. Essential for rhamnolipid production, an exoproduct correlated with pathogenicity (PubMed:10481091). Required for biofilm production. The reaction proceeds via 2 processive phosphoryl transferase reactions; first from enzyme-phospho-Ser-108 to the substrate (generatinga bisphosphorylated substrate intermediate and a dephosphorylated enzyme), a 180 degree rotation of the intermediate (probably aided by movement of domain 4), and subsequent transfer of phosphate back to the enzyme (PubMed:11716469, PubMed:16880541, PubMed:16595672, PubMed:22242625). T85801 PDBSTRUC 4MRQ; 4IL8; 3RSM; 3C04; 3BKQ T85801 BIOCLASS Intramolecular transferases T85801 SEQUENCE MSTAKAPTLPASIFRAYDIRGVVGDTLTAETAYWIGRAIGSESLARGEPCVAVGRDGRLSGPELVKQLIQGLVDCGCQVSDVGMVPTPVLYYAANVLEGKSGVMLTGSHNPPDYNGFKIVVAGETLANEQIQALRERIEKNDLASGVGSVEQVDILPRYFKQIRDDIAMAKPMKVVVDCGNGVAGVIAPQLIEALGCSVIPLYCEVDGNFPNHHPDPGKPENLKDLIAKVKAENADLGLAFDGDGDRVGVVTNTGTIIYPDRLLMLFAKDVVSRNPGADIIFDVKCTRRLIALISGYGGRPVMWKTGHSLIKKKMKETGALLAGEMSGHVFFKERWFGFDDGIYSAARLLEILSQDQRDSEHVFSAFPSDISTPEINITVTEDSKFAIIEALQRDAQWGEGNITTLDGVRVDYPKGWGLVRASNTTPVLVLRFEADTEEELERIKTVFRNQLKAVDSSLPVPF T85801 DRUGINFO D03AZI D-Mannose 1-Phosphate Investigative T85801 DRUGINFO D0Q0OH Alpha-D-Mannose-6-Phosphate Investigative T85801 DRUGINFO D0S5WE Alpha-D-Glucose-1-Phosphate Investigative T85801 DRUGINFO D01AWD Alpha-D-Glucose-6-Phosphate Investigative T85801 DRUGINFO D07PZQ L-serine-O-phosphate Investigative T79724 TARGETID T79724 T79724 FORMERID TTDR00748 T79724 UNIPROID HPPK_ECOLI T79724 TARGNAME Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK) T79724 GENENAME Bact folK T79724 TARGTYPE Literature-reported T79724 SYNONYMS PPPK; HPPK; 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase; 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase; 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase T79724 FUNCTION 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase activity, magnesium ion binding T79724 PDBSTRUC 6AN6; 6AN4; 5ETP; 5ETO; 5ETN T79724 BIOCLASS Kinase T79724 SEQUENCE MTVAYIAIGSNLASPLEQVNAALKALGDIPESHILTVSSFYRTPPLGPQDQPDYLNAAVALETSLAPEELLNHTQRIELQQGRVRKAERWGPRTLDLDIMLFGNEVINTERLTVPHYDMKNRGFMLWPLFEIAPELVFPDGEMLRQILHTRAFDKLNKW T79724 DRUGINFO D0F6WV PD-157695 Preclinical T79724 DRUGINFO D02UKY 6-Hydroxymethylpterin Investigative T79724 DRUGINFO D05BQE P(1)-(6-Hydroxymethylpterin)-P(4)-(5'-adenosyl)tetraphosphate Investigative T79724 DRUGINFO D03BIT [Pterin-6-Yl Methanyl]-Phosphonophosphate Investigative T79724 DRUGINFO D0W0NE 6-Hydroxymethyl-7,8-Dihydropterin Investigative T79724 DRUGINFO D00QLM [3H]alphabeta-meATP Investigative T79724 DRUGINFO D0F2ME Acetate Ion Investigative T43773 TARGETID T43773 T43773 FORMERID TTDI01927 T43773 UNIPROID POLG_HCV1 T43773 TARGNAME Hepatitis C virus Protease NS2-3/3 (HCV NS2-3/3) T43773 GENENAME HCV NS2-3/3 T43773 TARGTYPE Literature-reported T43773 SYNONYMS HCV p23/p70 T43773 FUNCTION NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication. T43773 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T43773 ECNUMBER EC 3.4.-.- T43773 SEQUENCE LDTEVAASCGGVVLVGLMALTLSPYYKRYISWCLWWLQYFLTRVEAQLHVWIPPLNVRGGRDAVILLMCAVHPTLVFDITKLLLAVFGPLWILQASLLKVPYFVRVQGLLRFCALARKMIGGHYVQMVIIKLGALTGTYVYNHLTPLRDWAHNGLRDLAVAVEPVVFSQMETKLITWGADTAACGDIINGLPVSARRGREILLGPADGMVSKGWRLLAPITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVV T46318 TARGETID T46318 T46318 FORMERID TTDI03014 T46318 UNIPROID AOAH_HUMAN T46318 TARGNAME Acyloxyacyl hydrolase (neutrophil) T46318 GENENAME AOAH T46318 TARGTYPE Literature-reported T46318 SYNONYMS Acyloxyacyl hydrolase T46318 FUNCTION Removes the secondary (acyloxyacyl-linked) fatty acyl chains from the lipid A region of bacterial lipopolysaccharides. By breaking down LPS, terminates the host response to bacterial infection and prevents prolonged and damaging inflammatory responses (By similarity). In peritoneal macrophages, seems to be important for recovery from a state of immune tolerance following infection by Gram-negative bacteria (By similarity). T46318 PDBSTRUC 5W7C; 5W78 T46318 ECNUMBER EC 3.1.1.77 T46318 SEQUENCE MQSPWKILTVAPLFLLLSLQSSASPANDDQSRPSLSNGHTCVGCVLVVSVIEQLAQVHNSTVQASMERLCSYLPEKLFLKTTCYLVIDKFGSDIIKLLSADMNADVVCHTLEFCKQNTGQPLCHLYPLPKETWKFTLQKARQIVKKSPILKYSRSGSDICSLPVLAKICQKIKLAMEQSVPFKDVDSDKYSVFPTLRGYHWRGRDCNDSDESVYPGRRPNNWDVHQDSNCNGIWGVDPKDGVPYEKKFCEGSQPRGIILLGDSAGAHFHISPEWITASQMSLNSFINLPTALTNELDWPQLSGATGFLDSTVGIKEKSIYLRLWKRNHCNHRDYQNISRNGASSRNLKKFIESLSRNKVLDYPAIVIYAMIGNDVCSGKSDPVPAMTTPEKLYSNVMQTLKHLNSHLPNGSHVILYGLPDGTFLWDNLHNRYHPLGQLNKDMTYAQLYSFLNCLQVSPCHGWMSSNKTLRTLTSERAEQLSNTLKKIAASEKFTNFNLFYMDFAFHEIIQEWQKRGGQPWQLIEPVDGFHPNEVALLLLADHFWKKVQLQWPQILGKENPFNPQIKQVFGDQGGH T46318 DRUGINFO D06UDN JZL195 Investigative T75152 TARGETID T75152 T75152 FORMERID TTDR00512 T75152 UNIPROID LYOX_HUMAN T75152 TARGNAME Lysyl oxidase (LOX) T75152 GENENAME LOX T75152 TARGTYPE Literature-reported T75152 SYNONYMS Protein-lysine 6-oxidase T75152 FUNCTION Regulator of Ras expression. May play a role in tumor suppression. Plays a role in the aortic wall architecture. Responsible for the post-translational oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. T75152 BIOCLASS CH-NH(2) donor oxidoreductase T75152 ECNUMBER EC 1.4.3.13 T75152 SEQUENCE MRFAWTVLLLGPLQLCALVHCAPPAAGQQQPPREPPAAPGAWRQQIQWENNGQVFSLLSLGSQYQPQRRRDPGAAVPGAANASAQQPRTPILLIRDNRTAAARTRTAGSSGVTAGRPRPTARHWFQAGYSTSRAREAGASRAENQTAPGEVPALSNLRPPSRVDGMVGDDPYNPYKYSDDNPYYNYYDTYERPRPGGRYRPGYGTGYFQYGLPDLVADPYYIQASTYVQKMSMYNLRCAAEENCLASTAYRADVRDYDHRVLLRFPQRVKNQGTSDFLPSRPRYSWEWHSCHQHYHSMDEFSHYDLLDANTQRRVAEGHKASFCLEDTSCDYGYHRRFACTAHTQGLSPGCYDTYGADIDCQWIDITDVKPGNYILKVSVNPSYLVPESDYTNNVVRCDIRYTGHHAYASGCTISPY T88947 TARGETID T88947 T88947 FORMERID TTDI03128 T88947 UNIPROID CXB2_HUMAN T88947 TARGNAME Gap junction beta-2 protein (Cx26) T88947 GENENAME GJB2 T88947 TARGTYPE Literature-reported T88947 SYNONYMS Connexin-26 T88947 FUNCTION Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. They are formed by the docking of two hexameric hemichannels, one from each cell membrane. Small molecules and ions diffuse from one cell to a neighboring cell via the central pore. Structural component of gap junctions. T88947 PDBSTRUC 5KJG; 5KJ3; 5ERA; 5ER7; 3IZ2 T88947 BIOCLASS Gap junction-forming connexin T88947 SEQUENCE MDWGTLQTILGGVNKHSTSIGKIWLTVLFIFRIMILVVAAKEVWGDEQADFVCNTLQPGCKNVCYDHYFPISHIRLWALQLIFVSTPALLVAMHVAYRRHEKKRKFIKGEIKSEFKDIEEIKTQKVRIEGSLWWTYTSSIFFRVIFEAAFMYVFYVMYDGFSMQRLVKCNAWPCPNTVDCFVSRPTEKTVFTVFMIAVSGICILLNVTELCYLLIRYCSGKSKKPV T88947 DRUGINFO D00VJY octanol Investigative T47657 TARGETID T47657 T47657 FORMERID TTDI03349 T47657 UNIPROID LTK_HUMAN T47657 TARGNAME Leukocyte receptor tyrosine kinase (LTK) T47657 GENENAME LTK T47657 TARGTYPE Literature-reported T47657 SYNONYMS TYK1; Protein tyrosine kinase 1; Leukocyte tyrosine kinase receptor T47657 FUNCTION The exact function of this protein is not known. Studies with chimeric proteins (replacing its extracellular region with that of several known growth factor receptors, such as EGFR and CSFIR) demonstrate its ability to promote growth and specifically neurite outgrowth, and cell survival. Signaling appears to involve the PI3 kinase pathway. Involved in regulation of the secretory pathway involving endoplasmic reticulum (ER) export sites (ERESs) and ER to Golgi transport. Receptor with a tyrosine-protein kinase activity. T47657 BIOCLASS Kinase T47657 ECNUMBER EC 2.7.10.1 T47657 SEQUENCE MGCWGQLLVWFGAAGAILCSSPGSQETFLRSSPLPLASPSPRDPKVSAPPSILEPASPLNSPGTEGSWLFSTCGASGRHGPTQTQCDGAYAGTSVVVTVGAAGQLRGVQLWRVPGPGQYLISAYGAAGGKGAKNHLSRAHGVFVSAIFSLGLGESLYILVGQQGEDACPGGSPESQLVCLGESRAVEEHAAMDGSEGVPGSRRWAGGGGGGGGATYVFRVRAGELEPLLVAAGGGGRAYLRPRDRGRTQASPEKLENRSEAPGSGGRGGAAGGGGGWTSRAPSPQAGRSLQEGAEGGQGCSEAWATLGWAAAGGFGGGGGACTAGGGGGGYRGGDASETDNLWADGEDGVSFIHPSSELFLQPLAVTENHGEVEIRRHLNCSHCPLRDCQWQAELQLAECLCPEGMELAVDNVTCMDLHKPPGPLVLMVAVVATSTLSLLMVCGVLILVKQKKWQGLQEMRLPSPELELSKLRTSAIRTAPNPYYCQVGLGPAQSWPLPPGVTEVSPANVTLLRALGHGAFGEVYEGLVIGLPGDSSPLQVAIKTLPELCSPQDELDFLMEALIISKFRHQNIVRCVGLSLRATPRLILLELMSGGDMKSFLRHSRPHLGQPSPLVMRDLLQLAQDIAQGCHYLEENHFIHRDIAARNCLLSCAGPSRVAKIGDFGMARDIYRASYYRRGDRALLPVKWMPPEAFLEGIFTSKTDSWSFGVLLWEIFSLGYMPYPGRTNQEVLDFVVGGGRMDPPRGCPGPVYRIMTQCWQHEPELRPSFASILERLQYCTQDPDVLNSLLPMELGPTPEEEGTSGLGNRSLECLRPPQPQELSPEKLKSWGGSPLGPWLSSGLKPLKSRGLQPQNLWNPTYRS T47657 DRUGINFO D0K5UF PMID24432909C8e Investigative T93904 TARGETID T93904 T93904 UNIPROID PEBP1_HUMAN T93904 TARGNAME Phosphatidylethanolamine-binding protein 1 (PEBP1) T93904 GENENAME PEBP1 T93904 TARGTYPE Literature-reported T93904 SYNONYMS Raf kinase inhibitor protein; RKIP; Prostatic-binding protein; PEBP-1; PEBP; PBP; Neuropolypeptide h3; Hippocampal cholinergic neurostimulating peptide; HCNPpp; HCNP T93904 FUNCTION Binds ATP, opioids and phosphatidylethanolamine. Has lower affinity for phosphatidylinositol and phosphatidylcholine. Serine protease inhibitor which inhibits thrombin, neuropsin and chymotrypsin but not trypsin, tissue type plasminogen activator and elastase. Inhibits the kinase activity of RAF1 by inhibiting its activation and by dissociating the RAF1/MEK complex and acting as a competitive inhibitor of MEK phosphorylation. T93904 PDBSTRUC 2QYQ; 2L7W; 1BEH; 1BD9 T93904 BIOCLASS Phosphatidylethanolamine-binding protein family T93904 SEQUENCE MPVDLSKWSGPLSLQEVDEQPQHPLHVTYAGAAVDELGKVLTPTQVKNRPTSISWDGLDSGKLYTLVLTDPDAPSRKDPKYREWHHFLVVNMKGNDISSGTVLSDYVGSGPPKGTGLHRYVWLVYEQDRPLKCDEPILSNRSGDHRGKFKVASFRKKYELRAPVAGTCYQAEWDDYVPKLYEQLSGK T00299 TARGETID T00299 T00299 FORMERID TTDR01260 T00299 UNIPROID ACHA5_HUMAN T00299 TARGNAME Neuronal acetylcholine receptor alpha-5 (CHRNA5) T00299 GENENAME CHRNA5 T00299 TARGTYPE Literature-reported T00299 SYNONYMS NACHRA5; CHRNA5 T00299 FUNCTION After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. T00299 BIOCLASS Neurotransmitter receptor T00299 SEQUENCE MAARGSGPRALRLLLLVQLVAGRCGLAGAAGGAQRGLSEPSSIAKHEDSLLKDLFQDYERWVRPVEHLNDKIKIKFGLAISQLVDVDEKNQLMTTNVWLKQEWIDVKLRWNPDDYGGIKVIRVPSDSVWTPDIVLFDNADGRFEGTSTKTVIRYNGTVTWTPPANYKSSCTIDVTFFPFDLQNCSMKFGSWTYDGSQVDIILEDQDVDKRDFFDNGEWEIVSATGSKGNRTDSCCWYPYVTYSFVIKRLPLFYTLFLIIPCIGLSFLTVLVFYLPSNEGEKICLCTSVLVSLTVFLLVIEEIIPSSSKVIPLIGEYLVFTMIFVTLSIMVTVFAINIHHRSSSTHNAMAPLVRKIFLHTLPKLLCMRSHVDRYFTQKEETESGSGPKSSRNTLEAALDSIRYITRHIMKENDVREVVEDWKFIAQVLDRMFLWTFLFVSIVGSLGLFVPVIYKWANILIPVHIGNANK T00299 DRUGINFO D00YUX alpha-conotoxin PnIA Investigative T31297 TARGETID T31297 T31297 FORMERID TTDR00613 T31297 UNIPROID A85B_MYCTU T31297 TARGNAME Mycobacterium 30kDa major secretory protein (MycB fbpB) T31297 GENENAME MycB fbpB T31297 TARGTYPE Literature-reported T31297 SYNONYMS Mycolyl transferase 85B; Fibronectin-binding protein B; Extracellular alpha-antigen; Antigen 85B; Antigen 85 complex B; Ag85B; 85B; 30 kDa extracellular protein T31297 FUNCTION Proteins of the antigen 85 complex are responsible for the high affinity of mycobacteria to fibronectin. Possesses a mycolyltransferase activity required for the biogenesis of trehalose dimycolate (cord factor). T31297 PDBSTRUC 5TS1; 5TRZ; 1F0P; 1F0N T31297 BIOCLASS Acyltransferase T31297 SEQUENCE MTDVSRKIRAWGRRLMIGTAAAVVLPGLVGLAGGAATAGAFSRPGLPVEYLQVPSPSMGRDIKVQFQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIVMPVGGQSSFYSDWYSPACGKAGCQTYKWETFLTSELPQWLSANRAVKPTGSAAIGLSMAGSSAMILAAYHPQQFIYAGSLSALLDPSQGMGPSLIGLAMGDAGGYKAADMWGPSSDPAWERNDPTQQIPKLVANNTRLWVYCGNGTPNELGGANIPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFPPNGTHSWEYWGAQLNAMKGDLQSSLGAG T93537 TARGETID T93537 T93537 UNIPROID S10A3_HUMAN T93537 TARGNAME S100 calcium-binding protein A3 (S100A3) T93537 GENENAME S100A3 T93537 TARGTYPE Literature-reported T93537 SYNONYMS S100E; Protein S-100E T93537 FUNCTION Binds both calcium and zinc. May be involved in calcium-dependent cuticle cell differentiation, hair shaft and hair cuticular barrier formation. T93537 PDBSTRUC 3NSO; 3NSL; 3NSK; 3NSI; 1KSO T93537 BIOCLASS S100 calcium-binding protein T93537 SEQUENCE MARPLEQAVAAIVCTFQEYAGRCGDKYKLCQAELKELLQKELATWTPTEFRECDYNKFMSVLDTNKDCEVDFVEYVRSLACLCLYCHEYFKDCPSEPPCSQ T96972 TARGETID T96972 T96972 FORMERID TTDR00492 T96972 UNIPROID MCM7_HUMAN T96972 TARGNAME DNA replication licensing factor MCM7 (MCM7) T96972 GENENAME MCM7 T96972 TARGTYPE Literature-reported T96972 SYNONYMS P1.1-MCM3; Minichromosome maintenanceprotein 7; MCM2; CDC47 homolog; CDC47 T96972 FUNCTION The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity. Required for S-phase checkpoint activation upon UV-induced damage. Acts as component of the MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. T96972 BIOCLASS Acid anhydride hydrolase T96972 ECNUMBER EC 3.6.4.12 T96972 SEQUENCE MALKDYALEKEKVKKFLQEFYQDDELGKKQFKYGNQLVRLAHREQVALYVDLDDVAEDDPELVDSICENARRYAKLFADAVQELLPQYKEREVVNKDVLDVYIEHRLMMEQRSRDPGMVRSPQNQYPAELMRRFELYFQGPSSNKPRVIREVRADSVGKLVTVRGIVTRVSEVKPKMVVATYTCDQCGAETYQPIQSPTFMPLIMCPSQECQTNRSGGRLYLQTRGSRFIKFQEMKMQEHSDQVPVGNIPRSITVLVEGENTRIAQPGDHVSVTGIFLPILRTGFRQVVQGLLSETYLEAHRIVKMNKSEDDESGAGELTREELRQIAEEDFYEKLAASIAPEIYGHEDVKKALLLLLVGGVDQSPRGMKIRGNINICLMGDPGVAKSQLLSYIDRLAPRSQYTTGRGSSGVGLTAAVLRDSVSGELTLEGGALVLADQGVCCIDEFDKMAEADRTAIHEVMEQQTISIAKAGILTTLNARCSILAAANPAYGRYNPRRSLEQNIQLPAALLSRFDLLWLIQDRPDRDNDLRLAQHITYVHQHSRQPPSQFEPLDMKLMRRYIAMCREKQPMVPESLADYITAAYVEMRREAWASKDATYTSARTLLAILRLSTALARLRMVDVVEKEDVNEAIRLMEMSKDSLLGDKGQTARTQRPADVIFATVRELVSGGRSVRFSEAEQRCVSRGFTPAQFQAALDEYEELNVWQVNASRTRITFV T80848 TARGETID T80848 T80848 FORMERID TTDNR00757 T80848 UNIPROID SDC2_HUMAN T80848 TARGNAME Syndecan-2 (SDC2) T80848 GENENAME SDC2 T80848 TARGTYPE Literature-reported T80848 SYNONYMS SYND2; Heparan sulfate proteoglycan core protein; HSPG1; HSPG; Fibroglycan; CD362 T80848 FUNCTION Cell surface proteoglycan that bears heparan sulfate. Regulates dendritic arbor morphogenesis (By similarity). T80848 PDBSTRUC 6ITH T80848 BIOCLASS Peptide translocating syndecan T80848 SEQUENCE MRRAWILLTLGLVACVSAESRAELTSDKDMYLDNSSIEEASGVYPIDDDDYASASGSGADEDVESPELTTSRPLPKILLTSAAPKVETTTLNIQNKIPAQTKSPEETDKEKVHLSDSERKMDPAEEDTNVYTEKHSDSLFKRTEVLAAVIAGGVIGFLFAIFLILLLVYRMRKKDEGSYDLGERKPSSAAYQKAPTKEFYA T72467 TARGETID T72467 T72467 FORMERID TTDI03113 T72467 UNIPROID CLCN1_HUMAN T72467 TARGNAME Chloride channel protein 1 (ClC-1) T72467 GENENAME CLCN1 T72467 TARGTYPE Literature-reported T72467 SYNONYMS ClC-1; Chloride channel protein, skeletal muscle; CLC1 T72467 FUNCTION Voltage-gated chloride channel. Plays an important role in membrane repolarization in skeletal muscle cells after muscle contraction. T72467 PDBSTRUC 6QVU; 6QVD; 6QVC; 6QVB; 6QV6 T72467 BIOCLASS Chloride channel T72467 SEQUENCE MEQSRSQQRGGEQSWWGSDPQYQYMPFEHCTSYGLPSENGGLQHRLRKDAGPRHNVHPTQIYGHHKEQFSDREQDIGMPKKTGSSSTVDSKDEDHYSKCQDCIHRLGQVVRRKLGEDGIFLVLLGLLMALVSWSMDYVSAKSLQAYKWSYAQMQPSLPLQFLVWVTFPLVLILFSALFCHLISPQAVGSGIPEMKTILRGVVLKEYLTMKAFVAKVVALTAGLGSGIPVGKEGPFVHIASICAAVLSKFMSVFCGVYEQPYYYSDILTVGCAVGVGCCFGTPLGGVLFSIEVTSTYFAVRNYWRGFFAATFSAFVFRVLAVWNKDAVTITALFRTNFRMDFPFDLKELPAFAAIGICCGLLGAVFVYLHRQVMLGVRKHKALSQFLAKHRLLYPGIVTFVIASFTFPPGMGQFMAGELMPREAISTLFDNNTWVKHAGDPESLGQSAVWIHPRVNVVIIIFLFFVMKFWMSIVATTMPIPCGGFMPVFVLGAAFGRLVGEIMAMLFPDGILFDDIIYKILPGGYAVIGAAALTGAVSHTVSTAVICFELTGQIAHILPMMVAVILANMVAQSLQPSLYDSIIQVKKLPYLPDLGWNQLSKYTIFVEDIMVRDVKFVSASYTYGELRTLLQTTTVKTLPLVDSKDSMILLGSVERSELQALLQRHLCPERRLRAAQEMARKLSELPYDGKARLAGEGLPGAPPGRPESFAFVDEDEDEDLSGKSELPPSLALHPSTTAPLSPEEPNGPLPGHKQQPEAPEPAGQRPSIFQSLLHCLLGRARPTKKKTTQDSTDLVDNMSPEEIEAWEQEQLSQPVCFDSCCIDQSPFQLVEQTTLHKTHTLFSLLGLHLAYVTSMGKLRGVLALEELQKAIEGHTKSGVQLRPPLASFRNTTSTRKSTGAPPSSAENWNLPEDRPGATGTGDVIAASPETPVPSPSPEPPLSLAPGKVEGELEELELVESPGLEEELADILQGPSLRSTDEEDEDELIL T72467 DRUGINFO D02FUG S-(-)CPP Investigative T72467 DRUGINFO D0YK1E S-(-)CPB Investigative T72467 DRUGINFO D0O6KR 9-anthroic acid Investigative T96387 TARGETID T96387 T96387 FORMERID TTDR00766 T96387 UNIPROID FBPA_HAEIN T96387 TARGNAME Haemophilus influenzae Iron-transporter ferric ion-binding (Hae-influ fbpA) T96387 GENENAME Hae-influ fbpA T96387 TARGTYPE Literature-reported T96387 SYNONYMS Major ferric iron binding protein; MIRP; Iron-regulated 40 kDa protein; Fe(3+)-binding protein; Fe(+3)Iron-utilization periplasmic protein precursor-binding protein T96387 FUNCTION Part of the ABC transporter complex FbpABC (TC 3.A.1.10.1) involved in Fe(3+) ions import. This protein specifically binds Fe(3+) and is involved in its transmembrane transport. T96387 PDBSTRUC 3ODB; 3OD7; 3KN8; 3KN7; 2O6A T96387 BIOCLASS ABC transporter T96387 SEQUENCE MQFKHFKLATLAAALAFSANSFADITVYNGQHKEAATAVAKAFEQETGIKVTLNSGKSEQLAGQLKEEGDKTPADVFYTEQTATFADLSEAGLLAPISEQTIQQTAQKGVPLAPKKDWIALSGRSRVVVYDHTKLSEKDMEKSVLDYATPKWKGKIGYVSTSGAFLEQVVALSKMKGDKVALNWLKGLKENGKLYAKNSVALQAVENGEVPAALINNYYWYNLAKEKGVENLKSRLYFVRHQDPGALVSYSGAAVLKASKNQAEAQKFVDFLASKKGQEALVAARAEYPLRADVVSPFNLEPYEKLEAPVVSATTAQDKEHAIKLIEEAGLK T05828 TARGETID T05828 T05828 FORMERID TTDI03140 T05828 UNIPROID CXG1_HUMAN T05828 TARGNAME Connexin-45 (Cx45) T05828 GENENAME GJC1 T05828 TARGTYPE Literature-reported T05828 SYNONYMS Gap junction gamma-1 protein; Gap junction alpha-7 protein; GJA7 T05828 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T05828 PDBSTRUC 3SHW T05828 BIOCLASS Gap junction-forming connexin T05828 SEQUENCE MSWSFLTRLLEEIHNHSTFVGKIWLTVLIVFRIVLTAVGGESIYYDEQSKFVCNTEQPGCENVCYDAFAPLSHVRFWVFQIILVATPSVMYLGYAIHKIAKMEHGEADKKAARSKPYAMRWKQHRALEETEEDNEEDPMMYPEMELESDKENKEQSQPKPKHDGRRRIREDGLMKIYVLQLLARTVFEVGFLIGQYFLYGFQVHPFYVCSRLPCPHKIDCFISRPTEKTIFLLIMYGVTGLCLLLNIWEMLHLGFGTIRDSLNSKRRELEDPGAYNYPFTWNTPSAPPGYNIAVKPDQIQYTELSNAKIAYKQNKANTAQEQQYGSHEENLPADLEALQREIRMAQERLDLAVQAYSHQNNPHGPREKKAKVGSKAGSNKSTASSKSGDGKTSVWI T05828 DRUGINFO D00VJY octanol Investigative T95553 TARGETID T95553 T95553 FORMERID TTDI00140 T95553 UNIPROID ARL2_HUMAN T95553 TARGNAME ADP-ribosylation factor-like protein 2 (ARL2) T95553 GENENAME ARL2 T95553 TARGTYPE Literature-reported T95553 SYNONYMS ARFL2 T95553 FUNCTION GTP-binding protein that does not act as an allosteric activator of the cholera toxin catalytic subunit. Regulates formation of new microtubules and centrosome integrity. Prevents the TBCD-induced microtubule destruction. Participates in association with TBCD, in the disassembly of the apical junction complexes. Antagonizes the effect of TBCD on epithelial cell detachment and tight and adherens junctions disassembly. Together with ARL2, plays a role in the nuclear translocation, retention and transcriptional activity of STAT3. Component of a regulated secretory pathway involved in Ca(2+)-dependent release of acetylcholine. Required for normal progress through the cell cycle. Small GTP-binding protein which cycles between an inactive GDP-bound and an active GTP-bound form, and the rate of cycling is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP). T95553 PDBSTRUC 3DOF; 3DOE T95553 BIOCLASS Small GTPase T95553 SEQUENCE MGLLTILKKMKQKERELRLLMLGLDNAGKTTILKKFNGEDIDTISPTLGFNIKTLEHRGFKLNIWDVGGQKSLRSYWRNYFESTDGLIWVVDSADRQRMQDCQRELQSLLVEERLAGATLLIFANKQDLPGALSSNAIREVLELDSIRSHHWCIQGCSAVTGENLLPGIDWLLDDISSRIFTAD T93147 TARGETID T93147 T93147 UNIPROID TAGL2_HUMAN T93147 TARGNAME Transgelin-2 (TAGLN2) T93147 GENENAME TAGLN2 T93147 TARGTYPE Literature-reported T93147 SYNONYMS SM22-alpha homolog; KIAA0120; Epididymis tissue protein Li 7e T93147 FUNCTION cytosol, extracellular exosome, extracellular region, vesicle, cadherin binding, epithelial cell differentiation, platelet degranulation. T93147 PDBSTRUC 1WYM T93147 BIOCLASS Calponin family T93147 SEQUENCE MANRGPAYGLSREVQQKIEKQYDADLEQILIQWITTQCRKDVGRPQPGRENFQNWLKDGTVLCELINALYPEGQAPVKKIQASTMAFKQMEQISQFLQAAERYGINTTDIFQTVDLWEGKNMACVQRTLMNLGGLAVARDDGLFSGDPNWFPKKSKENPRNFSDNQLQEGKNVIGLQMGTNRGASQAGMTGYGMPRQIL T90122 TARGETID T90122 T90122 FORMERID TTDI01359 T90122 UNIPROID QSEC_ECOLI T90122 TARGNAME Bacterial Sensor protein QseC (Bact QseC) T90122 GENENAME Bact QseC T90122 TARGTYPE Literature-reported T90122 SYNONYMS Sensor protein QseC T90122 FUNCTION Member of a two-component regulatory system QseB/QseC. Activates the flagella regulon by activating transcription of FlhDC. May activate QseB by phosphorylation. T90122 PDBSTRUC 3JZ3; 2KSE T90122 ECNUMBER EC 2.7.13.3 T90122 SEQUENCE MKFTQRLSLRVRLTLIFLILASVTWLLSSFVAWKQTTDNVDELFDTQLMLFAKRLSTLDLNEINAADRMAQTPNRLKHGHVDDDALTFAIFTHDGRMVLNDGDNGEDIPYSYQREGFADGQLVGEDDPWRFVWMTSPDGKYRIVVGQEWEYREDMALAIVAGQLIPWLVALPIMLIIMMVLLGRELAPLNKLALALRMRDPDSEKPLNATGVPSEVRPLVESLNQLFARTHAMMVRERRFTSDAAHELRSPLTALKVQTEVAQLSDDDPQARKKALLQLHSGIDRATRLVDQLLTLSRLDSLDNLQDVAEIPLEDLLQSSVMDIYHTAQQAKIDVRLTLNAHSIKRTGQPLLLSLLVRNLLDNAVRYSPQGSVVDVTLNADNFIVRDNGPGVTPEALARIGERFYRPPGQTATGSGLGLSIVQRIAKLHGMNVEFGNAEQGGFEAKVSW T20585 TARGETID T20585 T20585 FORMERID TTDNR00750 T20585 UNIPROID STAT6_HUMAN T20585 TARGNAME Signal transducer and activator of transcription 6 (STAT6) T20585 GENENAME STAT6 T20585 TARGTYPE Literature-reported T20585 SYNONYMS IL-4 Stat T20585 FUNCTION Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signaling. Carries out a dual function: signal transduction and activation of transcription. T20585 PDBSTRUC 5NWX; 5NWM; 5D39; 4Y5W; 4Y5U T20585 BIOCLASS Transcription factor T20585 SEQUENCE MSLWGLVSKMPPEKVQRLYVDFPQHLRHLLGDWLESQPWEFLVGSDAFCCNLASALLSDTVQHLQASVGEQGEGSTILQHISTLESIYQRDPLKLVATFRQILQGEKKAVMEQFRHLPMPFHWKQEELKFKTGLRRLQHRVGEIHLLREALQKGAEAGQVSLHSLIETPANGTGPSEALAMLLQETTGELEAAKALVLKRIQIWKRQQQLAGNGAPFEESLAPLQERCESLVDIYSQLQQEVGAAGGELEPKTRASLTGRLDEVLRTLVTSCFLVEKQPPQVLKTQTKFQAGVRFLLGLRFLGAPAKPPLVRADMVTEKQARELSVPQGPGAGAESTGEIINNTVPLENSIPGNCCSALFKNLLLKKIKRCERKGTESVTEEKCAVLFSASFTLGPGKLPIQLQALSLPLVVIVHGNQDNNAKATILWDNAFSEMDRVPFVVAERVPWEKMCETLNLKFMAEVGTNRGLLPEHFLFLAQKIFNDNSLSMEAFQHRSVSWSQFNKEILLGRGFTFWQWFDGVLDLTKRCLRSYWSDRLIIGFISKQYVTSLLLNEPDGTFLLRFSDSEIGGITIAHVIRGQDGSPQIENIQPFSAKDLSIRSLGDRIRDLAQLKNLYPKKPKDEAFRSHYKPEQMGKDGRGYVPATIKMTVERDQPLPTPELQMPTMVPSYDLGMAPDSSMSMQLGPDMVPQVYPPHSHSIPPYQGLSPEESVNVLSAFQEPHLQMPPSLGQMSLPFDQPHPQGLLPCQPQEHAVSSPDPLLCSDVTMVEDSCLSQPVTAFPQGTWIGEDIFPPLLPPTEQDLTKLLLEGQGESGGGSLGAQPLLQPSHYGQSGISMSHMDLRANPSW T36456 TARGETID T36456 T36456 FORMERID TTDI02563 T36456 UNIPROID HUTH_HUMAN T36456 TARGNAME Histidine ammonia-lyase (HAL) T36456 GENENAME HAL T36456 TARGTYPE Literature-reported T36456 SYNONYMS Histidine ammonialyase; Histidase; HIS T36456 FUNCTION Histidine ammonia-lyase activity, histidine catabolic process. T36456 BIOCLASS Carbon-nitrogen lyase T36456 ECNUMBER EC 4.3.1.3 T36456 SEQUENCE MPRYTVHVRGEWLAVPCQDAQLTVGWLGREAVRRYIKNKPDNGGFTSVDDAHFLVRRCKGLGLLDNEDRLEVALENNEFVEVVIEGDAMSPDFIPSQPEGVYLYSKYREPEKYIELDGDRLTTEDLVNLGKGRYKIKLTPTAEKRVQKSREVIDSIIKEKTVVYGITTGFGKFARTVIPINKLQELQVNLVRSHSSGVGKPLSPERCRMLLALRINVLAKGYSGISLETLKQVIEMFNASCLPYVPEKGTVGASGDLAPLSHLALGLVGEGKMWSPKSGWADAKYVLEAHGLKPVILKPKEGLALINGTQMITSLGCEAVERASAIARQADIVAALTLEVLKGTTKAFDTDIHALRPHRGQIEVAFRFRSLLDSDHHPSEIAESHRFCDRVQDAYTLRCCPQVHGVVNDTIAFVKNIITTELNSATDNPMVFANRGETVSGGNFHGEYPAKALDYLAIGIHELAAISERRIERLCNPSLSELPAFLVAEGGLNSGFMIAHCTAAALVSENKALCHPSSVDSLSTSAATEDHVSMGGWAARKALRVIEHVEQVLAIELLAACQGIEFLRPLKTTTPLEKVYDLVRSVVRPWIKDRFMAPDIEAAHRLLLEQKVWEVAAPYIEKYRMEHIPESRPLSPTAFSLQFLHKKSTKIPESEDL T32590 TARGETID T32590 T32590 FORMERID TTDI03606 T32590 UNIPROID TXK_HUMAN T32590 TARGNAME Tyrosine-protein kinase TXK (TXK) T32590 GENENAME TXK T32590 TARGTYPE Literature-reported T32590 SYNONYMS Resting lymphocyte kinase; RLK; Protein-tyrosine kinase 4; PTK4 T32590 FUNCTION Non-receptor tyrosine kinase that plays a redundant role with ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of TXK to the cell membrane, where it is phosphorylated at Tyr-420. Phosphorylation leads to TXK full activation. Contributes also to signaling from many receptors and participates in multiple downstream pathways, including regulation of the actin cytoskeleton. Like ITK, can phosphorylate PLCG1, leading to its localization in lipid rafts and activation, followed by subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. With PARP1 and EEF1A1, TXK forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFNG to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production. Phosphorylates both PARP1 and EEF1A1. Phosphorylates also key sites in LCP2 leading to the up-regulation of Th1 preferred cytokine IL-2. Phosphorylates 'Tyr-201' of CTLA4 which leads to the association of PI-3 kinase with the CTLA4 receptor. T32590 PDBSTRUC 2DM0 T32590 ECNUMBER EC 2.7.10.2 T32590 SEQUENCE MILSSYNTIQSVFCCCCCCSVQKRQMRTQISLSTDEELPEKYTQRRRPWLSQLSNKKQSNTGRVQPSKRKPLPPLPPSEVAEEKIQVKALYDFLPREPCNLALRRAEEYLILEKYNPHWWKARDRLGNEGLIPSNYVTENKITNLEIYEWYHRNITRNQAEHLLRQESKEGAFIVRDSRHLGSYTISVFMGARRSTEAAIKHYQIKKNDSGQWYVAERHAFQSIPELIWYHQHNAAGLMTRLRYPVGLMGSCLPATAGFSYEKWEIDPSELAFIKEIGSGQFGVVHLGEWRSHIQVAIKAINEGSMSEEDFIEEAKVMMKLSHSKLVQLYGVCIQRKPLYIVTEFMENGCLLNYLRENKGKLRKEMLLSVCQDICEGMEYLERNGYIHRDLAARNCLVSSTCIVKISDFGMTRYVLDDEYVSSFGAKFPIKWSPPEVFLFNKYSSKSDVWSFGVLMWEVFTEGKMPFENKSNLQVVEAISEGFRLYRPHLAPMSIYEVMYSCWHEKPEGRPTFAELLRAVTEIAETW T32590 DRUGINFO D04TLI PMID17600705C23 Investigative T32590 DRUGINFO D01RHR PMID24915291C31 Investigative T32590 DRUGINFO D06BJG PMID24915291C38 Investigative T87756 TARGETID T87756 T87756 FORMERID TTDR00701 T87756 UNIPROID IGA1_HAEIF T87756 TARGNAME Haemophilus influenzae Immunoglobulin A1 protease (Hae-influ iga) T87756 GENENAME Hae-influ iga T87756 TARGTYPE Literature-reported T87756 SYNONYMS iga; IGA1 protease T87756 FUNCTION Virulence factor; cleaves host immunoglobulin A producing intact Fc and Fab fragments. T87756 BIOCLASS Peptidase T87756 ECNUMBER EC 3.4.21.72 T87756 SEQUENCE MLNKKFKLNFIALTVAYALTPYTEAALVRDDVDYQIFRDFAENKGKFSVGATNVLVKDKNNKDLGTALPNGIPMIDFSVVDVDKRIATLINPQYVVGVKHVSNGVSELHFGNLNGNMNNGNAKAHRDVSSEENRYFSVEKNEYPTKLNGKTVTTEDQTQKRREDYYMPRLDKFVTEVAPIEASTASSDAGTYNDQNKYPAFVRLGSGSQFIYKKGDNYSLILNNHEVGGNNLKLVGDAYTYGIAGTPYKVNHENNGLIGFGNSKEEHSDPKGILSQDPLTNYAVLGDSGSPLFVYDREKGKWLFLGSYDFWAGYNKKSWQEWNIYKSQFTKDVLNKDSAGSLIGSKTDYSWSSNGKTSTITGGEKSLNVDLADGKDKPNHGKSVTFEGSGTLTLNNNIDQGAGGLFFEGDYEVKGTSDNTTWKGAGVSVAEGKTVTWKVHNPQYDRLAKIGKGTLIVEGTGDNKGSLKVGDGTVILKQQTNGSGQHAFASVGIVSGRSTLVLNDDKQVDPNSIYFGFRGGRLDLNGNSLTFDHIRNIDDGARLVNHNMTNASNITITGESLITDPNTITPYNIDAPDEDNPYAFRRIKDGGQLYLNLENYTYYALRKGASTRSELPKNSGESNENWLYMGKTSDEAKRNVMNHINNERMNGFNGYFGEEEGKNNGNLNVTFKGKSEQNRFLLTGGTNLNGDLTVEKGTLFLSGRPTPHARDIAGISSTKKDPHFAENNEVVVEDDWINRNFKATTMNVTGNASLYSGRNVANITSNITASNKAQVHIGYKTGDTVCVRSDYTGYVTCTTDKLSDKALNSFNPTNLRGNVNLTESANFVLGKANLFGTIQSRGNSQVRLTENSHWHLTGNSDVHQLDLANGHIHLNSADNSNNVTKYNTLTVNSLSGNGSFYYLTDLSNKQGDKVVVTKSATGNFTLQVADKTGEPNHNELTLFDASKAQRDHLNVSLVGNTVDLGAWKYKLRNVNGRYDLYNPEVEKRNQTVDTTNITTPNNIQADVPSVPSNNEEIARVDEAPVPPPAPATPSETTETVAENSKQESKTVEKNEQDATETTAQNREVAKEAKSNVKANTQTNEVAQSGSETKETQTTETKETATVEKEEKAKVETEKTQEVPKVTSQVSPKQEQSETVQPQAEPARENDPTVNIKEPQSQTNTTADTEQPAKETSSNVEQPVTESTTVNTGNSVVENPENTTPATTQPTVNSESSNKPKNRHRRSVRSVPHNVEPATTSSNDRSTVALCDLTSTNTNAVLSDARAKAQFVALNVGKAVSQHISQLEMNNEGQYNVWVSNTSMNKNYSSSQYRRFSSKSTQTQLGWDQTISNNVQLGGVFTYVRNSNNFDKATSKNTLAQVNFYSKYYADNHWYLGIDLGYGKFQSKLQTNHNAKFARHTAQFGLTAGKAFNLGNFGITPIVGVRYSYLSNADFALDQARIKVNPISVKTAFAQVDLSYTYHLGEFSVTPILSARYDANQGSGKINVNGYDFAYNVENQQQYNAGLKLKYHNVKLSLIGGLTKAKQAEKQKTAELKLSFSF T95438 TARGETID T95438 T95438 FORMERID TTDNR00670 T95438 UNIPROID EAA2_HUMAN T95438 TARGNAME Excitatory amino acid transporter 2 (SLC1A2) T95438 GENENAME SLC1A2 T95438 TARGTYPE Literature-reported T95438 SYNONYMS Solute carrier family 1 member 2; Sodium-dependent glutamate/aspartate transporter 2; Glutamate/aspartatetransporter II; Glutamate/aspartate transporter II; GLT1; EAAT2 T95438 FUNCTION Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport. Essential for the rapid removal of released glutamate from the synaptic cleft, and for terminating the postsynaptic action of glutamate. Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. T95438 BIOCLASS Dicarboxylate/amino acid:cation symporter T95438 SEQUENCE MASTEGANNMPKQVEVRMHDSHLGSEEPKHRHLGLRLCDKLGKNLLLTLTVFGVILGAVCGGLLRLASPIHPDVVMLIAFPGDILMRMLKMLILPLIISSLITGLSGLDAKASGRLGTRAMVYYMSTTIIAAVLGVILVLAIHPGNPKLKKQLGPGKKNDEVSSLDAFLDLIRNLFPENLVQACFQQIQTVTKKVLVAPPPDEEANATSAVVSLLNETVTEVPEETKMVIKKGLEFKDGMNVLGLIGFFIAFGIAMGKMGDQAKLMVDFFNILNEIVMKLVIMIMWYSPLGIACLICGKIIAIKDLEVVARQLGMYMVTVIIGLIIHGGIFLPLIYFVVTRKNPFSFFAGIFQAWITALGTASSAGTLPVTFRCLEENLGIDKRVTRFVLPVGATINMDGTALYEAVAAIFIAQMNGVVLDGGQIVTVSLTATLASVGAASIPSAGLVTMLLILTAVGLPTEDISLLVAVDWLLDRMRTSVNVVGDSFGAGIVYHLSKSELDTIDSQHRVHEDIEMTKTQSIYDDMKNHRESNSNQCVYAAHNSVIVDECKVTLAANGKSADCSVEEEPWKREK T95438 DRUGINFO D02JJX WAY-213613 Investigative T95438 DRUGINFO D04MSI threo-3-methylglutamate Investigative T95438 DRUGINFO D07CIW [3H]ETB-TBOA Investigative T95438 DRUGINFO D07GUB DL-TBOA Investigative T95438 DRUGINFO D0S8AN SYM2081 Investigative T95438 DRUGINFO D08CAB D-aspartic acid Investigative T67163 TARGETID T67163 T67163 FORMERID TTDR00554 T67163 UNIPROID NR4A2_HUMAN T67163 TARGNAME Orphan nuclear receptor NURR1 (NR4A2) T67163 GENENAME NR4A2 T67163 TARGTYPE Literature-reported T67163 SYNONYMS Transcriptionally-inducible nuclear receptor; Transcriptionally inducible nuclear receptor; TINUR; Nuclear receptor subfamily 4 group A member 2; NURR1; NOT; Immediate-early response protein NOT T67163 FUNCTION It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons. Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development. T67163 PDBSTRUC 6DDA; 5YD6; 5Y41; 1OVL T67163 BIOCLASS Nuclear hormone receptor T67163 SEQUENCE MPCVQAQYGSSPQGASPASQSYSYHSSGEYSSDFLTPEFVKFSMDLTNTEITATTSLPSFSTFMDNYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMHNYQQHSHLPPQSEEMMPHSGSVYYKPSSPPTPTTPGFQVQHSPMWDDPGSLHNFHQNYVATTHMIEQRKTPVSRLSLFSFKQSPPGTPVSSCQMRFDGPLHVPMNPEPAGSHHVVDGQTFAVPNPIRKPASMGFPGLQIGHASQLLDTQVPSPPSRGSPSNEGLCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQKCLAVGMVKEVVRTDSLKGRRGRLPSKPKSPQEPSPPSPPVSLISALVRAHVDSNPAMTSLDYSRFQANPDYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQDLLFESAFLELFVLRLAYRSNPVEGKLIFCNGVVLHRLQCVRGFGEWIDSIVEFSSNLQNMNIDISAFSCIAALAMVTERHGLKEPKRVEELQNKIVNCLKDHVTFNNGGLNRPNYLSKLLGKLPELRTLCTQGLQRIFYLKLEDLVPPPAIIDKLFLDTLPF T51817 TARGETID T51817 T51817 FORMERID TTDR00488 T51817 UNIPROID GATA4_HUMAN T51817 TARGNAME GATA-binding factor 4 (GATA4) T51817 GENENAME GATA4 T51817 TARGTYPE Literature-reported T51817 SYNONYMS Transcription factor GATA-4; GATA-4; GATA binding factor-4 T51817 FUNCTION In cooperation with TBX5, it binds to cardiac super-enhancers and promotes cardiomyocyte gene expression, while it downregulates endocardial and endothelial gene expression. Involved in bone morphogenetic protein (BMP)-mediated induction of cardiac-specific gene expression. Binds to BMP response element (BMPRE) DNA sequences within cardiac activating regions. Acts as a transcriptional activator of ANF in cooperation with NKX2-5. Promotes cardiac myocyte enlargement. Required during testicular development. May play a role in sphingolipid signaling by regulating the expression of sphingosine-1-phosphate degrading enzyme, spingosine-1-phosphate lyase. Transcriptional activator that binds to the consensus sequence 5'-AGATAG-3' and plays a key role in cardiac development and function. T51817 PDBSTRUC 2M9W T51817 BIOCLASS Zinc-finger T51817 SEQUENCE MYQSLAMAANHGPPPGAYEAGGPGAFMHGAGAASSPVYVPTPRVPSSVLGLSYLQGGGAGSASGGASGGSSGGAASGAGPGTQQGSPGWSQAGADGAAYTPPPVSPRFSFPGTTGSLAAAAAAAAAREAAAYSSGGGAAGAGLAGREQYGRAGFAGSYSSPYPAYMADVGASWAAAAAASAGPFDSPVLHSLPGRANPAARHPNLDMFDDFSEGRECVNCGAMSTPLWRRDGTGHYLCNACGLYHKMNGINRPLIKPQRRLSASRRVGLSCANCQTTTTTLWRRNAEGEPVCNACGLYMKLHGVPRPLAMRKEGIQTRKRKPKNLNKSKTPAAPSGSESLPPASGASSNSSNATTSSSEEMRPIKTEPGLSSHYGHSSSVSQTFSVSAMSGHGPSIHPVLSALKLSPQGYASPVSQSPQTSSKQDSWNSLVLADSHGDIITA T23831 TARGETID T23831 T23831 FORMERID TTDR00602 T23831 UNIPROID NADR_HAEIN T23831 TARGNAME Haemophilus influenzae NadR protein (Hae-influ nadR) T23831 GENENAME Hae-influ nadR T23831 TARGTYPE Literature-reported T23831 SYNONYMS nadR; Transcriptional regulator nadR T23831 FUNCTION This enzyme has twoactivities: nicotinamide mononucleotide (NMN) adenylyltransferase and ribosylnicotinamide (RN) kinase. The RN kinase activity catalyzes the phosphorylation of RN to form nicotinamide ribonucleotide. The NMN adenylyltransferase activity catalyzes the transfer of the AMP moiety of ATP to nicotinamide ribonucleotide to form NAD(+). T23831 PDBSTRUC 1LW7 T23831 BIOCLASS Nicotinamide ribonucleoside uptake permease T23831 SEQUENCE MGFTTGREFHPALRMRAKYNAKYLGTKSEREKYFHLAYNKHTQFLRYQEQIMSKTKEKKVGVIFGKFYPVHTGHINMIYEAFSKVDELHVIVCSDTVRDLKLFYDSKMKRMPTVQDRLRWMQQIFKYQKNQIFIHHLVEDGIPSYPNGWQSWSEAVKTLFHEKHFEPSIVFSSEPQDKAPYEKYLGLEVSLVDPDRTFFNVSATKIRTTPFQYWKFIPKEARPFFAKTVAILGGESSGKSVLVNKLAAVFNTTSAWEYGREFVFEKLGGDEQAMQYSDYPQMALGHQRYIDYAVRHSHKIAFIDTDFITTQAFCIQYEGKAHPFLDSMIKEYPFDVTILLKNNTEWVDDGLRSLGSQKQRQQFQQLLKKLLDKYKVPYIEIESPSYLDRYNQVKAVIEKVLNEEEISELQNTTFPIKGTSQ T23831 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T05887 TARGETID T05887 T05887 FORMERID TTDR00689 T05887 UNIPROID TNNT2_HUMAN T05887 TARGNAME Cardiac muscle troponin T (TNNT2) T05887 GENENAME TNNT2 T05887 TARGTYPE Literature-reported T05887 SYNONYMS TnTC; TNNT2; Cardiac troponin C (cTnC); CTnT T05887 FUNCTION Troponin T is the tropomyosin-binding subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. T05887 PDBSTRUC 4Y99; 1J1E; 1J1D T05887 BIOCLASS Troponin T05887 SEQUENCE MSDIEEVVEEYEEEEQEEAAVEEEEDWREDEDEQEEAAEEDAEAEAETEETRAEEDEEEEEAKEAEDGPMEESKPKPRSFMPNLVPPKIPDGERVDFDDIHRKRMEKDLNELQALIEAHFENRKKEEEELVSLKDRIERRRAERAEQQRIRNEREKERQNRLAEERARREEEENRRKAEDEARKKKALSNMMHFGGYIQKQAQTERKSGKRQTEREKKKKILAERRKVLAIDHLNEDQLREKAKELWQSIYNLEAEKFDLQEKFKQQKYEINVLRNRINDNQKVSKTRGKAKVTGRWK T54526 TARGETID T54526 T54526 FORMERID TTDR01085 T54526 UNIPROID GPMI_MYCGE T54526 TARGNAME Mycobacterium Bisphosphoglycerate phosphoglycerate mutase (MycB gpmI) T54526 GENENAME MycB gpmI T54526 TARGTYPE Literature-reported T54526 SYNONYMS gpmI; Phosphoglyceromutase; Phosphoglycerate mutase; IPGM; BPG-independent PGAM T54526 FUNCTION Catalyzes the interconversion of 2-phosphoglycerate and 3-phosphoglycerate. T54526 BIOCLASS Intramolecular transferases T54526 SEQUENCE MHKKVLLAILDGYGISNAIYGNAVQNANTPMLDELINSYPCVLLDASGEAVGLPMGQIGNSEVGHLNIGAGRVVYTGLSLINQHIKDRSFFANKAFLKTIEHVEKNHSKIHLIGLFSNGGVHSHNEHLLALIELFSKHAKVVLHLFGDGRDVAPCSLKQDLEKLMIFLKNYPNVVIGTIGGRYYGMDRDQRWDREMIAYKALLGVSKNKFNDPIGYIETQYQNQITDEFIYPAINANLNSDQFALNNNDGVIFFNFRPDRARQMSHLIFNSNYYNYQPELKRKENLFFVTMMNYEGIVPSEFAFPPQTIKNSLGEVIANNNLKQLRIAETEKYAHVTFFFDGGFEVNLSNETKTLIPSLKVATYDLAPEMSCKAITDALLEKLNNFDFTVLNFANPDMVGHTGNYQACIKALEALDVQIKRIVDFCKANQITMFLTADHGNAEVMIDNNNNPVTKHTINPVPFVCTDKNVNFNQTGILANIAPTILEYLNLSKPKEMTAKSLLKNNN T54526 DRUGINFO D0V6EH Clorsulon Investigative T54526 DRUGINFO D0WQ7U 3-Phosphoglyceric Acid Investigative T54526 DRUGINFO D03KBV 2-Phosphoglyceric Acid Investigative T64245 TARGETID T64245 T64245 FORMERID TTDR00462 T64245 UNIPROID TNFL6_HUMAN T64245 TARGNAME Apoptosis antigen ligand (CD178) T64245 GENENAME FASLG T64245 TARGTYPE Literature-reported T64245 SYNONYMS Tumor necrosis factor ligand superfamily member 6; TNFSF6; FasL; Fas ligand; FAS antigen ligand; CD95L; CD95-L; CD95 ligand; CD178 antigen; CD178; APTL; APT1LG1 T64245 FUNCTION Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses. TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance. Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis. Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. T64245 PDBSTRUC 5L36; 5L19; 4MSV; 1BZI T64245 BIOCLASS Cytokine: tumor necrosis factor T64245 SEQUENCE MQQPFNYPYPQIYWVDSSASSPWAPPGTVLPCPTSVPRRPGQRRPPPPPPPPPLPPPPPPPPLPPLPLPPLKKRGNHSTGLCLLVMFFMVLVALVGLGLGMFQLFHLQKELAELRESTSQMHTASSLEKQIGHPSPPPEKKELRKVAHLTGKSNSRSMPLEWEDTYGIVLLSGVKYKKGGLVINETGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQDLVMMEGKMMSYCTTGQMWARSSYLGAVFNLTSADHLYVNVSELSLVNFEESQTFFGLYKL T07740 TARGETID T07740 T07740 FORMERID TTDI03317 T07740 UNIPROID KCNJ4_HUMAN T07740 TARGNAME Inward rectifier potassium channel Kir2.3 (KCNJ4) T07740 GENENAME KCNJ4 T07740 TARGTYPE Literature-reported T07740 SYNONYMS Potassium channel, inwardly rectifying subfamily J member 4; Inward rectifier potassium channel 4; Inward rectifier K(+) channel Kir2.3; IRK3; IRK-3; Hippocampal inward rectifier; HRK1; HIRK2; HIR T07740 FUNCTION Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium and cesium (By similarity). T07740 PDBSTRUC 3GJ9 T07740 BIOCLASS Inward rectifier potassium channel T07740 SEQUENCE MHGHSRNGQAHVPRRKRRNRFVKKNGQCNVYFANLSNKSQRYMADIFTTCVDTRWRYMLMIFSAAFLVSWLFFGLLFWCIAFFHGDLEASPGVPAAGGPAAGGGGAAPVAPKPCIMHVNGFLGAFLFSVETQTTIGYGFRCVTEECPLAVIAVVVQSIVGCVIDSFMIGTIMAKMARPKKRAQTLLFSHHAVISVRDGKLCLMWRVGNLRKSHIVEAHVRAQLIKPYMTQEGEYLPLDQRDLNVGYDIGLDRIFLVSPIIIVHEIDEDSPLYGMGKEELESEDFEIVVILEGMVEATAMTTQARSSYLASEILWGHRFEPVVFEEKSHYKVDYSRFHKTYEVAGTPCCSARELQESKITVLPAPPPPPSAFCYENELALMSQEEEEMEEEAAAAAAVAAGLGLEAGSKEEAGIIRMLEFGSHLDLERMQASLPLDNISYRRESAI T07740 DRUGINFO D07LZY rose bengal (photoactivated) Investigative T07740 DRUGINFO D06PZZ [14C]TEA Investigative T38012 TARGETID T38012 T38012 FORMERID TTDI02593 T38012 UNIPROID KCNJ3_HUMAN T38012 TARGNAME Inward rectifier potassium channel Kir3.1 (KCNJ3) T38012 GENENAME KCNJ3 T38012 TARGTYPE Literature-reported T38012 SYNONYMS Potassium channel, inwardly rectifying subfamily J member 3; KCNJ3; Inward rectifier K(+) channel Kir3.1; GIRK1; G proteinactivated inward rectifier potassium channel 1 T38012 FUNCTION This potassium channel is controlled byG proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This receptor plays a crucial role in regulating the heartbeat. T38012 BIOCLASS Inward rectifier potassium channel T38012 SEQUENCE MSALRRKFGDDYQVVTTSSSGSGLQPQGPGQDPQQQLVPKKKRQRFVDKNGRCNVQHGNLGSETSRYLSDLFTTLVDLKWRWNLFIFILTYTVAWLFMASMWWVIAYTRGDLNKAHVGNYTPCVANVYNFPSAFLFFIETEATIGYGYRYITDKCPEGIILFLFQSILGSIVDAFLIGCMFIKMSQPKKRAETLMFSEHAVISMRDGKLTLMFRVGNLRNSHMVSAQIRCKLLKSRQTPEGEFLPLDQLELDVGFSTGADQLFLVSPLTICHVIDAKSPFYDLSQRSMQTEQFEIVVILEGIVETTGMTCQARTSYTEDEVLWGHRFFPVISLEEGFFKVDYSQFHATFEVPTPPYSVKEQEEMLLMSSPLIAPAITNSKERHNSVECLDGLDDITTKLPSKLQKITGREDFPKKLLRMSSTTSEKAYSLGDLPMKLQRISSVPGNSEEKLVSKTTKMLSDPMSQSVADLPPKLQKMAGGAARMEGNLPAKLRKMNSDRFT T38012 DRUGINFO D0E3FR ML297 Investigative T38012 DRUGINFO D07ZAJ PIP2 Investigative T69420 TARGETID T69420 T69420 UNIPROID GSHB_HUMAN T69420 TARGNAME Glutathione synthetase (GSS) T69420 GENENAME GSS T69420 TARGTYPE Literature-reported T69420 SYNONYMS Glutathione synthase; GSH-S; GSH synthetase T69420 FUNCTION Catalyzes the oxidation of GSH to glutathione disulfide (GSSG) by reducing free radicals and reactive oxygen species such as hydrogen peroxide. Uses GSH to clean up various metabolites, xenobiotics, and electrophiles to mercapturates for excretion. T69420 PDBSTRUC 2HGS T69420 ECNUMBER EC 6.3.2.3 T69420 SEQUENCE MATNWGSLLQDKQQLEELARQAVDRALAEGVLLRTSQEPTSSEVVSYAPFTLFPSLVPSALLEQAYAVQMDFNLLVDAVSQNAAFLEQTLSSTIKQDDFTARLFDIHKQVLKEGIAQTVFLGLNRSDYMFQRSADGSPALKQIEINTISASFGGLASRTPAVHRHVLSVLSKTKEAGKILSNNPSKGLALGIAKAWELYGSPNALVLLIAQEKERNIFDQRAIENELLARNIHVIRRTFEDISEKGSLDQDRRLFVDGQEIAVVYFRDGYMPRQYSLQNWEARLLLERSHAAKCPDIATQLAGTKKVQQELSRPGMLEMLLPGQPEAVARLRATFAGLYSLDVGEEGDQAIAEALAAPSRFVLKPQREGGGNNLYGEEMVQALKQLKDSEERASYILMEKIEPEPFENCLLRPGSPARVVQCISELGIFGVYVRQEKTLVMNKHVGHLLRTKAIEHADGGVAAGVAVLDNPYPV T74448 TARGETID T74448 T74448 FORMERID TTDI02441 T74448 UNIPROID CD97_HUMAN T74448 TARGNAME Leukocyte antigen CD97 (CD97) T74448 GENENAME CD97 T74448 TARGTYPE Literature-reported T74448 SYNONYMS CD97 antigen subunit beta; CD97 antigen T74448 FUNCTION Plays an essential role in leukocyte migration. Receptor potentially involved in both adhesion and signaling processes early after leukocyte activation. T74448 PDBSTRUC 2BOU T74448 BIOCLASS GPCR secretin T74448 SEQUENCE MGGRVFLAFCVWLTLPGAETQDSRGCARWCPQNSSCVNATACRCNPGFSSFSEIITTPTETCDDINECATPSKVSCGKFSDCWNTEGSYDCVCSPGYEPVSGAKTFKNESENTCQDVDECQQNPRLCKSYGTCVNTLGSYTCQCLPGFKFIPEDPKVCTDVNECTSGQNPCHSSTHCLNNVGSYQCRCRPGWQPIPGSPNGPNNTVCEDVDECSSGQHQCDSSTVCFNTVGSYSCRCRPGWKPRHGIPNNQKDTVCEDMTFSTWTPPPGVHSQTLSRFFDKVQDLGRDSKTSSAEVTIQNVIKLVDELMEAPGDVEALAPPVRHLIATQLLSNLEDIMRILAKSLPKGPFTYISPSNTELTLMIQERGDKNVTMGQSSARMKLNWAVAAGAEDPGPAVAGILSIQNMTTLLANASLNLHSKKQAELEEIYESSIRGVQLRRLSAVNSIFLSHNNTKELNSPILFAFSHLESSDGEAGRDPPAKDVMPGPRQELLCAFWKSDSDRGGHWATEGCQVLGSKNGSTTCQCSHLSSFAILMAHYDVEDWKLTLITRVGLALSLFCLLLCILTFLLVRPIQGSRTTIHLHLCICLFVGSTIFLAGIENEGGQVGLRCRLVAGLLHYCFLAAFCWMSLEGLELYFLVVRVFQGQGLSTRWLCLIGYGVPLLIVGVSAAIYSKGYGRPRYCWLDFEQGFLWSFLGPVTFIILCNAVIFVTTVWKLTQKFSEINPDMKKLKKARALTITAIAQLFLLGCTWVFGLFIFDDRSLVLTYVFTILNCLQGAFLYLLHCLLNKKVREEYRKWACLVAGGSKYSEFTSTTSGTGHNQTRALRASESGI T33586 TARGETID T33586 T33586 FORMERID TTDNR00748 T33586 UNIPROID TRPC1_HUMAN T33586 TARGNAME Short transient receptor potential channel 1 (TRPC1) T33586 GENENAME TRPC1 T33586 TARGTYPE Literature-reported T33586 SYNONYMS TrpC1; Transient receptor protein 1; TRP-1 T33586 FUNCTION Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Seems to be also activated by intracellular calcium store depletion. T33586 BIOCLASS Transient receptor potential catioin channel T33586 SEQUENCE MMAALYPSTDLSGASSSSLPSSPSSSSPNEVMALKDVREVKEENTLNEKLFLLACDKGDYYMVKKILEENSSGDLNINCVDVLGRNAVTITIENENLDILQLLLDYGCQSADALLVAIDSEVVGAVDILLNHRPKRSSRPTIVKLMERIQNPEYSTTMDVAPVILAAHRNNYEILTMLLKQDVSLPKPHAVGCECTLCSAKNKKDSLRHSRFRLDIYRCLASPALIMLTEEDPILRAFELSADLKELSLVEVEFRNDYEELARQCKMFAKDLLAQARNSRELEVILNHTSSDEPLDKRGLLEERMNLSRLKLAIKYNQKEFVSQSNCQQFLNTVWFGQMSGYRRKPTCKKIMTVLTVGIFWPVLSLCYLIAPKSQFGRIIHTPFMKFIIHGASYFTFLLLLNLYSLVYNEDKKNTMGPALERIDYLLILWIIGMIWSDIKRLWYEGLEDFLEESRNQLSFVMNSLYLATFALKVVAHNKFHDFADRKDWDAFHPTLVAEGLFAFANVLSYLRLFFMYTTSSILGPLQISMGQMLQDFGKFLGMFLLVLFSFTIGLTQLYDKGYTSKEQKDCVGIFCEQQSNDTFHSFIGTCFALFWYIFSLAHVAIFVTRFSYGEELQSFVGAVIVGTYNVVVVIVLTKLLVAMLHKSFQLIANHEDKEWKFARAKLWLSYFDDKCTLPPPFNIIPSPKTICYMISSLSKWICSHTSKGKVKRQNSLKEWRNLKQKRDENYQKVMCCLVHRYLTSMRQKMQSTDQATVENLNELRQDLSKFRNEIRDLLGFRTSKYAMFYPRN T33586 DRUGINFO D00HCI 2-APB Investigative T22717 TARGETID T22717 T22717 FORMERID TTDI02607 T22717 UNIPROID NRAM2_HUMAN T22717 TARGNAME Divalent metal transporter 1 (SLC11A2) T22717 GENENAME SLC11A2 T22717 TARGTYPE Literature-reported T22717 SYNONYMS Solute carrier family 11 member 2; OK/SW-cl.20; Natural resistanceassociated macrophage protein 2; Natural resistance-associated macrophage protein 2; NRAMP2; NRAMP 2; Divalent cation transporter 1; DMT1; DMT-1; DCT1 T22717 FUNCTION Can also transport manganese, cobalt, cadmium, nickel, vanadium and lead. Involved in apical iron uptake into duodenal enterocytes. Involved in iron transport from acidified endosomes into the cytoplasm of erythroid precursor cells. May play an important role in hepatic iron accumulation and tissue iron distribution. May serve to import iron into the mitochondria. Important in metal transport, in particular iron. T22717 PDBSTRUC 5F0P; 5F0M; 5F0L T22717 BIOCLASS Natural resistance-associated macrophage protein T22717 SEQUENCE MVLGPEQKMSDDSVSGDHGESASLGNINPAYSNPSLSQSPGDSEEYFATYFNEKISIPEEEYSCFSFRKLWAFTGPGFLMSIAYLDPGNIESDLQSGAVAGFKLLWILLLATLVGLLLQRLAARLGVVTGLHLAEVCHRQYPKVPRVILWLMVELAIIGSDMQEVIGSAIAINLLSVGRIPLWGGVLITIADTFVFLFLDKYGLRKLEAFFGFLITIMALTFGYEYVTVKPSQSQVLKGMFVPSCSGCRTPQIEQAVGIVGAVIMPHNMYLHSALVKSRQVNRNNKQEVREANKYFFIESCIALFVSFIINVFVVSVFAEAFFGKTNEQVVEVCTNTSSPHAGLFPKDNSTLAVDIYKGGVVLGCYFGPAALYIWAVGILAAGQSSTMTGTYSGQFVMEGFLNLKWSRFARVVLTRSIAIIPTLLVAVFQDVEHLTGMNDFLNVLQSLQLPFALIPILTFTSLRPVMSDFANGLGWRIAGGILVLIICSINMYFVVVYVRDLGHVALYVVAAVVSVAYLGFVFYLGWQCLIALGMSFLDCGHTCHLGLTAQPELYLLNTMDADSLVSR T41646 TARGETID T41646 T41646 FORMERID TTDI00183 T41646 UNIPROID ARRB1_HUMAN T41646 TARGNAME Beta-arrestin-1 (ARRB1) T41646 GENENAME ARRB1 T41646 TARGTYPE Literature-reported T41646 SYNONYMS Non-visual arrestin-2; Betaarrestin1; Arrestin beta1; Arrestin beta-1; ARR1 T41646 FUNCTION During homologous desensitization, beta-arrestins bind to the GPRK-phosphorylated receptor and sterically preclude its coupling to the cognate G-protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adapter protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G-proteins. Two different modes of arrestin-mediated internalization occur. Class A receptors, like ADRB2, OPRM1, ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the plasma membrane and undergo rapid recycling. Class B receptors, like AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptors, for extended periods of time. Receptor resensitization then requires that receptor-bound arrestin is removed so that the receptor can be dephosphorylated and returned to the plasma membrane. Involved in internalization of P2RY4 and UTP-stimulated internalization of P2RY2. Involved in phosphorylation-dependent internalization of OPRD1 ands subsequent recycling. Involved in the degradation of cAMP by recruiting cAMP phosphodiesterases to ligand-activated receptors. Beta-arrestins function as multivalent adapter proteins that can switch the GPCR from a G-protein signaling mode that transmits short-lived signals from the plasma membrane via small molecule second messengers and ion channels to a beta-arrestin signaling mode that transmits a distinct set of signals that are initiated as the receptor internalizes and transits the intracellular compartment. Acts as signaling scaffold for MAPK pathways such as MAPK1/3 (ERK1/2). ERK1/2 activated by the beta-arrestin scaffold is largely excluded from the nucleus and confined to cytoplasmic locations such as endocytic vesicles, also called beta-arrestin signalosomes. Recruits c-Src/SRC to ADRB2 resulting in ERK activation. GPCRs for which the beta-arrestin-mediated signaling relies on both ARRB1 and ARRB2 (codependent regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is inhibited by the other respective beta-arrestin form (reciprocal regulation). Inhibits ERK1/2 signaling in AGTR1- and AVPR2-mediated activation (reciprocal regulation). Is required for SP-stimulated endocytosis of NK1R and recruits c-Src/SRC to internalized NK1R resulting in ERK1/2 activation, which is required for the antiapoptotic effects of SP. Is involved in proteinase-activated F2RL1-mediated ERK activity. Acts as signaling scaffold for the AKT1 pathway. Is involved in alpha-thrombin-stimulated AKT1 signaling. Is involved in IGF1-stimulated AKT1 signaling leading to increased protection from apoptosis. Involved in activation of the p38 MAPK signaling pathway and in actin bundle formation. Involved in F2RL1-mediated cytoskeletal rearrangement and chemotaxis. Involved in AGTR1-mediated stress fiber formation by acting together with GNAQ to activate RHOA. Appears to function as signaling scaffold involved in regulation of MIP-1-beta-stimulated CCR5-dependent chemotaxis. Involved in attenuation of NF-kappa-B-dependent transcription in response to GPCR or cytokine stimulation by interacting with and stabilizing CHUK. May serve as nuclear messenger for GPCRs. Involved in OPRD1-stimulated transcriptional regulation by translocating to CDKN1B and FOS promoter regions and recruiting EP300 resulting in acetylation of histone H4. Involved in regulation of LEF1 transcriptional activity via interaction with DVL1 and/or DVL2 Also involved in regulation of receptors other than GPCRs. Involved in Toll-like receptor and IL-1 receptor signaling through the interaction with TRAF6 which prevents TRAF6 autoubiquitination and oligomerization required for activation of NF-kappa-B and JUN. Binds phosphoinositides. Binds inositolhexakisphosphate (InsP6). Involved in IL8-mediated granule release in neutrophils. Required for atypical chemokine receptor ACKR2-induced RAC1-LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1) and for the up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. Involved in the internalization of the atypical chemokine receptor ACKR3. Negatively regulates the NOTCH signaling pathway by mediating the ubiquitination and degradation of NOTCH1 by ITCH. Participates to the recruitment of the ubiquitin-protein ligase to the receptor. Functions in regulating agonist-mediated G-protein coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes. T41646 PDBSTRUC 2IV8 T41646 BIOCLASS Arrestin protein T41646 SEQUENCE MGDKGTRVFKKASPNGKLTVYLGKRDFVDHIDLVDPVDGVVLVDPEYLKERRVYVTLTCAFRYGREDLDVLGLTFRKDLFVANVQSFPPAPEDKKPLTRLQERLIKKLGEHAYPFTFEIPPNLPCSVTLQPGPEDTGKACGVDYEVKAFCAENLEEKIHKRNSVRLVIRKVQYAPERPGPQPTAETTRQFLMSDKPLHLEASLDKEIYYHGEPISVNVHVTNNTNKTVKKIKISVRQYADICLFNTAQYKCPVAMEEADDTVAPSSTFCKVYTLTPFLANNREKRGLALDGKLKHEDTNLASSTLLREGANREILGIIVSYKVKVKLVVSRGGLLGDLASSDVAVELPFTLMHPKPKEEPPHREVPENETPVDTNLIELDTNDDDIVFEDFARQRLKGMKDDKEEEEDGTGSPQLNNR T92095 TARGETID T92095 T92095 FORMERID TTDR00709 T92095 UNIPROID INPP_HUMAN T92095 TARGNAME Inositol polyphosphate 1-phosphatase (INPP1) T92095 GENENAME INPP1 T92095 TARGTYPE Literature-reported T92095 SYNONYMS IPPase; IPP T92095 FUNCTION Removes the phosphate group at position 1 of the inositol ring from the polyphosphates inositol 1,4-bisphosphate and inositol 1,3,4-trisphophosphate. T92095 BIOCLASS Phosphoric monoester hydrolase T92095 ECNUMBER EC 3.1.3.57 T92095 SEQUENCE MSDILRELLCVSEKAANIARACRQQEALFQLLIEEKKEGEKNKKFAVDFKTLADVLVQEVIKQNMENKFPGLEKNIFGEESNEFTNDWGEKITLRLCSTEEETAELLSKVLNGNKVASEALARVVHQDVAFTDPTLDSTEINVPQDILGIWVDPIDSTYQYIKGSADIKSNQGIFPCGLQCVTILIGVYDIQTGVPLMGVINQPFVSRDPNTLRWKGQCYWGLSYMGTNMHSLQLTISRRNGSETHTGNTGSEAAFSPSFSAVISTSEKETIKAALSRVCGDRIFGAAGAGYKSLCVVQGLVDIYIFSEDTTFKWDSCAAHAILRAMGGGIVDLKECLERNPETGLDLPQLVYHVENEGAAGVDRWANKGGLIAYRSRKRLETFLSLLVQNLAPAETHT T86731 TARGETID T86731 T86731 FORMERID TTDR00214 T86731 UNIPROID AT1A2_HUMAN T86731 TARGNAME Sodium pump alpha-2 (ATP1A2) T86731 GENENAME ATP1A2 T86731 TARGTYPE Literature-reported T86731 SYNONYMS Sodium/potassium-transporting ATPase subunit alpha-2; Sodium/potassium-transporting ATPase alpha2; Sodium pump 2; Na+/K+ ATPase 2; Na(+)/K(+) ATPase alpha-2 subunit; KIAA0778; Alpha(+)Sodium/potassium-transporting ATPase alpha-2 chain T86731 FUNCTION This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium, providing the energy for active transport of various nutrients. T86731 BIOCLASS Cation transporting ATPase T86731 ECNUMBER EC 7.2.2.13 T86731 SEQUENCE MGRGAGREYSPAATTAENGGGKKKQKEKELDELKKEVAMDDHKLSLDELGRKYQVDLSKGLTNQRAQDVLARDGPNALTPPPTTPEWVKFCRQLFGGFSILLWIGAILCFLAYGIQAAMEDEPSNDNLYLGVVLAAVVIVTGCFSYYQEAKSSKIMDSFKNMVPQQALVIREGEKMQINAEEVVVGDLVEVKGGDRVPADLRIISSHGCKVDNSSLTGESEPQTRSPEFTHENPLETRNICFFSTNCVEGTARGIVIATGDRTVMGRIATLASGLEVGRTPIAMEIEHFIQLITGVAVFLGVSFFVLSLILGYSWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKNLEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTEDQSGATFDKRSPTWTALSRIAGLCNRAVFKAGQENISVSKRDTAGDASESALLKCIELSCGSVRKMRDRNPKVAEIPFNSTNKYQLSIHEREDSPQSHVLVMKGAPERILDRCSTILVQGKEIPLDKEMQDAFQNAYMELGGLGERVLGFCQLNLPSGKFPRGFKFDTDELNFPTEKLCFVGLMSMIDPPRAAVPDAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPMSQVNPREAKACVVHGSDLKDMTSEQLDEILKNHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKKADIGIAMGISGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTLTSNIPEITPFLLFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEAAESDIMKRQPRNSQTDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPSRLLGIRLDWDDRTMNDLEDSYGQEWTYEQRKVVEFTCHTAFFASIVVVQWADLIICKTRRNSVFQQGMKNKILIFGLLEETALAAFLSYCPGMGVALRMYPLKVTWWFCAFPYSLLIFIYDEVRKLILRRYPGGWVEKETYY T14030 TARGETID T14030 T14030 FORMERID TTDNR00740 T14030 UNIPROID RAB7A_HUMAN T14030 TARGNAME Ras-related protein Rab-7a (RAB7A) T14030 GENENAME RAB7A T14030 TARGTYPE Literature-reported T14030 SYNONYMS RAB7 T14030 FUNCTION Governs early-to-late endosomal maturation, microtubule minus-end as well as plus-end directed endosomal migration and positioning, and endosome-lysosome transport through different protein-protein interaction cascades. Plays a central role, not only in endosomal traffic, but also in many other cellular and physiological events, such as growth-factor-mediated cell signaling, nutrient-transportor mediated nutrient uptake, neurotrophin transport in the axons of neurons and lipid metabolism. Also involved in regulation of some specialized endosomal membrane trafficking, such as maturation of melanosomes, pathogen-induced phagosomes (or vacuoles) and autophagosomes. Plays a role in the maturation and acidification of phagosomes that engulf pathogens, such as S. aureus and M. tuberculosis. Plays a role in the fusion of phagosomes with lysosomes. Plays important roles in microbial pathogen infection and survival, as well as in participating in the life cycle of viruses. Microbial pathogens possess survival strategies governed by RAB7A, sometimes by employing RAB7A function (e. g. Salmonella) and sometimes by excluding RAB7A function (e. g. Mycobacterium). In concert with RAC1, plays a role in regulating the formation of RBs (ruffled borders) in osteoclasts. Controls the endosomal trafficking and neurite outgrowth signaling of NTRK1/TRKA. Regulates the endocytic trafficking of the EGF-EGFR complex by regulating its lysosomal degradation. Involved in the ADRB2-stimulated lipolysis through lipophagy, a cytosolic lipase-independent autophagic pathway. Required for the exosomal release of SDCBP, CD63 and syndecan. Key regulator in endo-lysosomal trafficking. T14030 PDBSTRUC 6IYB; 3LAW; 1YHN; 1T91 T14030 BIOCLASS Small GTPase T14030 SEQUENCE MTSRKKVLLKVIILGDSGVGKTSLMNQYVNKKFSNQYKATIGADFLTKEVMVDDRLVTMQIWDTAGQERFQSLGVAFYRGADCCVLVFDVTAPNTFKTLDSWRDEFLIQASPRDPENFPFVVLGNKIDLENRQVATKRAQAWCYSKNNIPYFETSAKEAINVEQAFQTIARNALKQETEVELYNEFPEPIKLDKNDRAKASAESCSC T81658 TARGETID T81658 T81658 FORMERID TTDI03389 T81658 UNIPROID MMP15_HUMAN T81658 TARGNAME Matrix metalloproteinase-15 (MMP-15) T81658 GENENAME MMP15 T81658 TARGTYPE Literature-reported T81658 SYNONYMS SMCP-2; Membrane-type-2 matrix metalloproteinase; Membrane-type matrix metalloproteinase 2; MTMMP2; MT2MMP; MT2-MMP; MT-MMP 2 T81658 FUNCTION May activate progelatinase A. Endopeptidase that degrades various components of the extracellular matrix. T81658 BIOCLASS Peptidase T81658 ECNUMBER EC 3.4.24.- T81658 SEQUENCE MGSDPSAPGRPGWTGSLLGDREEAARPRLLPLLLVLLGCLGLGVAAEDAEVHAENWLRLYGYLPQPSRHMSTMRSAQILASALAEMQRFYGIPVTGVLDEETKEWMKRPRCGVPDQFGVRVKANLRRRRKRYALTGRKWNNHHLTFSIQNYTEKLGWYHSMEAVRRAFRVWEQATPLVFQEVPYEDIRLRRQKEADIMVLFASGFHGDSSPFDGTGGFLAHAYFPGPGLGGDTHFDADEPWTFSSTDLHGNNLFLVAVHELGHALGLEHSSNPNAIMAPFYQWKDVDNFKLPEDDLRGIQQLYGTPDGQPQPTQPLPTVTPRRPGRPDHRPPRPPQPPPPGGKPERPPKPGPPVQPRATERPDQYGPNICDGDFDTVAMLRGEMFVFKGRWFWRVRHNRVLDNYPMPIGHFWRGLPGDISAAYERQDGRFVFFKGDRYWLFREANLEPGYPQPLTSYGLGIPYDRIDTAIWWEPTGHTFFFQEDRYWRFNEETQRGDPGYPKPISVWQGIPASPKGAFLSNDAAYTYFYKGTKYWKFDNERLRMEPGYPKSILRDFMGCQEHVEPGPRWPDVARPPFNPHGGAEPGADSAEGDVGDGDGDFGAGVNKDGGSRVVVQMEEVARTVNVVMVLVPLLLLLCVLGLTYALVQMQRKGAPRVLLYCKRSLQEWV T81658 DRUGINFO D07GEL SL422 Investigative T08165 TARGETID T08165 T08165 FORMERID TTDR00909 T08165 UNIPROID BLI4_CAEEL T08165 TARGNAME Elegans Endoprotease bli-4 (Elegans bli-4) T08165 GENENAME Elegans bli-4 T08165 TARGTYPE Literature-reported T08165 SYNONYMS kpc-4; bli-4; K04F10.4; Endoprotease bli-4; Blistered cuticle protein 4; Blisterase T08165 FUNCTION Involved in cuticle biosynthesis probably by cleaving pro-collagen into its mature form. Acts in ASEL sensory neurons to regulate high salt chemotaxis responses probably by cleaving insulin-like protein ins-6 into its mature and active form. Essential for embryonic and larval development. isoform a, isoform e, isoform f, isoform g and isoform h are involved in cuticle biosynthesis but are dispensable for larval development. Serine endoprotease which cleaves proproteins at paired basic amino acids. T08165 BIOCLASS Peptidase T08165 ECNUMBER EC 3.4.21.- T08165 SEQUENCE MRISIGRIAWQILAVLIAVAFTIEHDSICDESIGACGEPIHTVIRLAKRDDELARRIAADHDMHVKGDPFLDTHYFLYHSETTRTRRHKRAIVERLDSHPAVEWVEEQRPKKRVKRDYILLDNDVHHSNPFRRSVLNRDGTRRAQRQQPQSPREIPSLPFPDPLYKDQWYLHGGAVGGYDMNVRQAWLQGYAGRNVSVSILDDGIQRDHPDLAANYDPLASTDINDHDDDPTPQNNGDNKHGTRCAGEVAALAGNNQCGVGVAFKAKIGGVRMLDGAVSDSVEAASLSLNQDHIDIYSASWGPEDDGKTFDGPGPLAREAFYRGIKNGRGGKGNIFVWASGNGGSRQDSCSADGYTTSVYTLSISSATYDNHRPWYLEECPSSIATTYSSADFRQPAIVTVDVPGGCTDKHTGTSASAPLAAGIIALALEANPELTWRDMQHLVLRTANWKPLENNPGWSRNGVGRMVSNKFGYGLIDGGALVNMAKTWKTVPEQHICTYEYRLANPNPRPIVGRFQLNFTLDVNGCESGTPVLYLEHVQVHATVRYLKRGDLKLTLFSPSGTRSVLLPPRPQDFNANGFHKWPFLSVQQWGEDPRGTWLLMVESVTTNPAATGTFHDWTLLLYGTADPAQSGDPVYSATPATSQGVLSRVHQLTSQVEESAPISFPDLTSAGNCHDECNGGCTESSSATSCFACKHLTQTLRNKGGSGFKCVQKCDDTYYLDGDKCKMCSSHCHTCTKAEVCETCPGSLLLIDVDNMPHYDHGKCVESCPPGLVADYESNLVQAKCIWRKDLCGDGYYINAVGKCDLCDSSCETCTAPGPMSCEKCSKGYGKGSIGYCRPCCPEGSTKSWQCEDCSKPDPTLLIDSNKSSGFGLMFWIVVSLIAACGICACKKCASETKSSNVEYAPLAQYNATNGAINLGAHTDDEDDDEDEVFVNPQIV T08165 DRUGINFO D00KEP Edetic acid Investigative T15823 TARGETID T15823 T15823 FORMERID TTDR01106 T15823 UNIPROID BRCA2_HUMAN T15823 TARGNAME Breast cancer type 2 susceptibility protein (BRCA2) T15823 GENENAME BRCA2 T15823 TARGTYPE Literature-reported T15823 SYNONYMS Fanconi anemia group D1 protein; FANCD1; FACD T15823 FUNCTION Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity. In concert with NPM1, regulates centrosome duplication. Interacts with the TREX-2 complex (transcription and export complex 2) subunits PCID2 and SEM1, and is required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability. Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination. Involved in double-strand break repair and/or homologous recombination. T15823 PDBSTRUC 3EU7; 1N0W T15823 SEQUENCE MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAAAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI T24588 TARGETID T24588 T24588 FORMERID TTDR01248 T24588 UNIPROID RENBP_HUMAN T24588 TARGNAME N-acylglucosamine 2-epimerase (RENBP) T24588 GENENAME RENBP T24588 TARGTYPE Literature-reported T24588 SYNONYMS RnBP; Renin-binding protein; RENBP; N-acetyl-D-glucosamine 2-epimerase; GlcNAc 2-epimerase; AGE T24588 FUNCTION Catalyzes the interconversion of N-acetylglucosamine to N-acetylmannosamine. Binds to renin forming a protein complex called high molecular weight (HMW) renin and inhibits renin activity. Involved in the N-glycolylneuraminic acid (Neu5Gc) degradation pathway: although human is not able to catalyze formation of Neu5Gc due to the inactive CMAHP enzyme, Neu5Gc is present in food and must be degraded. T24588 BIOCLASS Racemases and epimerases T24588 ECNUMBER EC 5.1.3.8 T24588 SEQUENCE MSKGLPARQDMEKERETLQAWKERVGQELDRVVAFWMEHSHDQEHGGFFTCLGREGRVYDDLKYVWLQGRQVWMYCRLYRTFERFRHAQLLDAAKAGGEFLLRYARVAPPGKKCAFVLTRDGRPVKVQRTIFSECFYTMAMNELWRATGEVRYQTEAVEMMDQIVHWVQEDASGLGRPQLQGAPAAEPMAVPMMLLNLVEQLGEADEELAGKYAELGDWCARRILQHVQRDGQAVLENVSEGGKELPGCLGRQQNPGHTLEAGWFLLRHCIRKGDPELRAHVIDKFLLLPFHSGWDPDHGGLFYFQDADNFCPTQLEWAMKLWWPHSEAMIAFLMGYSDSGDPVLLRLFYQVAEYTFRQFRDPEYGEWFGYLSREGKVALSIKGGPFKGCFHVPRCLAMCEEMLGALLSRPAPAPSPAPTPACRGAE T04149 TARGETID T04149 T04149 FORMERID TTDI03118 T04149 UNIPROID CLCKA_HUMAN T04149 TARGNAME Chloride channel protein ClC-Ka (ClC-K1) T04149 GENENAME CLCNKA T04149 TARGTYPE Literature-reported T04149 SYNONYMS ClC-K1; Chloride channel Ka T04149 FUNCTION Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms. T04149 PDBSTRUC 2PFI T04149 BIOCLASS Chloride channel T04149 SEQUENCE MEELVGLREGFSGDPVTLQELWGPCPHIRRAIQGGLEWLKQKVFRLGEDWYFLMTLGVLMALVSYAMNFAIGCVVRAHQWLYREIGDSHLLRYLSWTVYPVALVSFSSGFSQSITPSSGGSGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTLFLGKVGPFVHLSVMIAAYLGRVRTTTIGEPENKSKQNEMLVAAAAVGVATVFAAPFSGVLFSIEVMSSHFSVRDYWRGFFAATCGAFIFRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGGICGVLSCAYLFCQRTFLSFIKTNRYSSKLLATSKPVYSALATLLLASITYPPGVGHFLASRLSMKQHLDSLFDNHSWALMTQNSSPPWPEELDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIPMPAGYFMPIFILGAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTHTISTALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIIVKKLPYLPRILGRNIGSHHVRVEHFMNHSITTLAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLVQALQAEPPSRAPGHQQCLQDILARGCPTEPVTLTLFSETTLHQAQNLFKLLNLQSLFVTSRGRAVGCVSWVEMKKAISNLTNPPAPK T04149 DRUGINFO D0S2HQ 3-phenyl-CPP Investigative T04149 DRUGINFO D0PW7B DIDS Investigative T23191 TARGETID T23191 T23191 FORMERID TTDR00271 T23191 UNIPROID NR0B1_HUMAN T23191 TARGNAME Orphan nuclear receptor DAX-1 (NR0B1) T23191 GENENAME NR0B1 T23191 TARGTYPE Literature-reported T23191 SYNONYMS Nuclear receptor subfamily 0 group B member 1; Nuclear receptor DAX-1; DSS-AHC critical region on the X chromosome protein 1; DAX1; AHC T23191 FUNCTION Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions. May also have a role in the development of the embryo and in the maintenance of embryonic stem cell pluripotency. Orphan nuclear receptor. T23191 PDBSTRUC 4RWV T23191 BIOCLASS Nuclear hormone receptor T23191 SEQUENCE MAGENHQWQGSILYNMLMSAKQTRAAPEAPETRLVDQCWGCSCGDEPGVGREGLLGGRNVALLYRCCFCGKDHPRQGSILYSMLTSAKQTYAAPKAPEATLGPCWGCSCGSDPGVGRAGLPGGRPVALLYRCCFCGEDHPRQGSILYSLLTSSKQTHVAPAAPEARPGGAWWDRSYFAQRPGGKEALPGGRATALLYRCCFCGEDHPQQGSTLYCVPTSTNQAQAAPEERPRAPWWDTSSGALRPVALKSPQVVCEAASAGLLKTLRFVKYLPCFQVLPLDQQLVLVRNCWASLLMLELAQDRLQFETVEVSEPSMLQKILTTRRRETGGNEPLPVPTLQHHLAPPAEARKVPSASQVQAIKCFLSKCWSLNISTKEYAYLKGTVLFNPDVPGLQCVKYIQGLQWGTQQILSEHTRMTHQGPHDRFIELNSTLFLLRFINANVIAELFFRPIIGTVSMDDMMLEMLCTKI T52566 TARGETID T52566 T52566 FORMERID TTDR00846 T52566 UNIPROID CHIO_HUMAN T52566 TARGNAME Beta-chimaerin (CHN2) T52566 GENENAME CHN2 T52566 TARGTYPE Literature-reported T52566 SYNONYMS Rho-GTPase-activating protein 3; CHN2; Beta2-chimaerin; Beta-chimerin T52566 FUNCTION Gtpase activating protein for p21-rac. Insufficient expression of beta-2 chimaerin is expected to lead to higher rac activity and could therefore play a role in the progression from low-grade to high-grade tumors. T52566 PDBSTRUC 1XA6 T52566 BIOCLASS Zinc-finger T52566 SEQUENCE MAASSNSSLSGSSVSSDAEEYQPPIWKSYLYQLQQEAPRPKRIICPREVENRPKYYGREFHGIISREQADELLGGVEGAYILRESQRQPGCYTLALRFGNQTLNYRLFHDGKHFVGEKRFESIHDLVTDGLITLYIETKAAEYISKMTTNPIYEHIGYATLLREKVSRRLSRSKNEPRKTNVTHEEHTAVEKISSLVRRAALTHNDNHFNYEKTHNFKVHTFRGPHWCEYCANFMWGLIAQGVRCSDCGLNVHKQCSKHVPNDCQPDLKRIKKVYCCDLTTLVKAHNTQRPMVVDICIREIEARGLKSEGLYRVSGFTEHIEDVKMAFDRDGEKADISANVYPDINIITGALKLYFRDLPIPVITYDTYSKFIDAAKISNADERLEAVHEVLMLLPPAHYETLRYLMIHLKKVTMNEKDNFMNAENLGIVFGPTLMRPPEDSTLTTLHDMRYQKLIVQILIENEDVLF T42337 TARGETID T42337 T42337 FORMERID TTDI03371 T42337 UNIPROID MAP11_HUMAN T42337 TARGNAME Methionyl aminopeptidase 1 (METAP1) T42337 GENENAME METAP1 T42337 TARGTYPE Literature-reported T42337 SYNONYMS Peptidase M 1; Methionine aminopeptidase 1; MetAP 1; MAP 1; KIAA0094 T42337 FUNCTION Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). Required for normal progression through the cell cycle. T42337 PDBSTRUC 5YR7; 5YR6; 5YR5; 5YR4; 5YKP T42337 ECNUMBER EC 3.4.11.18 T42337 SEQUENCE MAAVETRVCETDGCSSEAKLQCPTCIKLGIQGSYFCSQECFKGSWATHKLLHKKAKDEKAKREVSSWTVEGDINTDPWAGYRYTGKLRPHYPLMPTRPVPSYIQRPDYADHPLGMSESEQALKGTSQIKLLSSEDIEGMRLVCRLAREVLDVAAGMIKPGVTTEEIDHAVHLACIARNCYPSPLNYYNFPKSCCTSVNEVICHGIPDRRPLQEGDIVNVDITLYRNGYHGDLNETFFVGEVDDGARKLVQTTYECLMQAIDAVKPGVRYRELGNIIQKHAQANGFSVVRSYCGHGIHKLFHTAPNVPHYAKNKAVGVMKSGHVFTIEPMICEGGWQDETWPDGWTAVTRDGKRSAQFEHTLLVTDTGCEILTRRLDSARPHFMSQF T42337 DRUGINFO D0Z7RB PMID23634668C14 Investigative T34563 TARGETID T34563 T34563 FORMERID TTDR00089 T34563 UNIPROID DAAA_STAHA T34563 TARGNAME Staphylococcus D-amino acid aminotransferase (Stap-coc dat) T34563 GENENAME Stap-coc dat T34563 TARGTYPE Literature-reported T34563 SYNONYMS Stap-coc dat; DAAT; D-aspartate aminotransferase; D-amino acid transaminase; D-alanine aminotransferase T34563 FUNCTION Acts on the D-isomers of alanine, leucine, aspartate, glutamate, aminobutyrate, norvaline and asparagine. The enzyme transfers an amino group from a substrate D-amino acid to the pyridoxal phosphate cofactor to form pyridoxamine andan alpha- keto acid in the first half-reaction. The second half-reaction is the reverse of the first, transferring the amino group from the pyridoxamine to a second alpha-keto acid to form the product D- amino acid via a ping-pong mechanism. This is an important process in the formation of D-alanine and D-glutamate, which are essential bacterial cell wall components. T34563 BIOCLASS Transaminase T34563 ECNUMBER EC 2.6.1.21 T34563 SEQUENCE MTKVFINGEFIDQNEAKVSYEDRGYVFGDGIYEYIRAYDGKLFTVTEHFERFIRSASEIQLDLGYTVEELIDVVRELLKVNNIQNGGIYIQATRGVAPRNHSFPTPEVKPVIMAFAKSYDRPYDDLENGINAATVEDIRWLRCDIKSLNLLGNVLAKEYAVKYNAGEAIQHRGETVTEGASSNVYAIKDGAIYTHPVNNYILNGITRKVIKWISEDEDIPFKEETFTVEFLKNADEVIVSSTSAEVTPVVKIDGEQVGDGKVGPVTRQLQEGFNKYIESRSS T34563 DRUGINFO D01NBK Pyridoxamine-5'-Phosphate Investigative T34563 DRUGINFO D0F2ME Acetate Ion Investigative T69580 TARGETID T69580 T69580 FORMERID TTDR01105 T69580 UNIPROID FGF8_HUMAN T69580 TARGNAME Fibroblast growth factor-8 (FGF8) T69580 GENENAME FGF8 T69580 TARGTYPE Literature-reported T69580 SYNONYMS Heparin-binding growth factor 8; HBGF-8; Fibroblast growth factor 8; FGF-8; Androgen-induced growth factor; AIGF T69580 FUNCTION Required for normal brain, eye, ear and limb development during embryogenesis. Required for normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Plays a role in neurite outgrowth in hippocampal cells. Plays an important role in the regulation of embryonic development, cell proliferation, cell differentiation and cell migration. T69580 PDBSTRUC 2FDB T69580 BIOCLASS Growth factor T69580 SEQUENCE MGSPRSALSCLLLHLLVLCLQAQEGPGRGPALGRELASLFRAGREPQGVSQQHVREQSLVTDQLSRRLIRTYQLYSRTSGKHVQVLANKRINAMAEDGDPFAKLIVETDTFGSRVRVRGAETGLYICMNKKGKLIAKSNGKGKDCVFTEIVLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQHQREVHFMKRLPRGHHTTEQSLRFEFLNYPPFTRSLRGSQRTWAPEPR T23934 TARGETID T23934 T23934 FORMERID TTDI01443 T23934 UNIPROID CCL23_HUMAN T23934 TARGNAME C-C motif chemokine 23 (CCL23) T23934 GENENAME CCL23 T23934 TARGTYPE Literature-reported T23934 SYNONYMS Small-inducible cytokine A23; SCYA23; Myeloid progenitor inhibitory factor 1; Macrophage inflammatory protein 3; MPIF1; MPIF-1; MIP3; MIP-3; CKB-8; CK-beta-8 T23934 FUNCTION Inhibits proliferation of myeloid progenitor cells in colony formation assays. This protein can bind heparin. Binds CCR1. CCL23(19-99), CCL23(22-99), CCL23(27-99), CCL23(30-99) are more potent chemoattractants than the small-inducible cytokine A23. Shows chemotactic activity for monocytes, resting T-lymphocytes, and neutrophils, but not for activated lymphocytes. T23934 PDBSTRUC 1G91 T23934 BIOCLASS Cytokine: CC chemokine T23934 SEQUENCE MKVSVAALSCLMLVTALGSQARVTKDAETEFMMSKLPLENPVLLDRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQVQVCVRMLKLDTRIKTRKN T97731 TARGETID T97731 T97731 FORMERID TTDI02485 T97731 UNIPROID NETR_HUMAN T97731 TARGNAME Neurotrypsin (PRSS12) T97731 GENENAME PRSS12 T97731 TARGTYPE Literature-reported T97731 SYNONYMS Serine protease 12; PRSS12; Motopsin; Leydin T97731 FUNCTION Plays a role in neuronal plasticity and the proteolytic action may subserve structural reorganizations associated with learning and memory operations. T97731 BIOCLASS Peptidase T97731 ECNUMBER EC 3.4.21.- T97731 SEQUENCE MTLARFVLALMLGALPEVVGFDSVLNDSLHHSHRHSPPAGPHYPYYLPTQQRPPRTRPPPPLPRFPRPPRALPAQRPHALQAGHTPRPHPWGCPAGEPWVSVTDFGAPCLRWAEVPPFLERSPPASWAQLRGQRHNFCRSPDGAGRPWCFYGDARGKVDWGYCDCRHGSVRLRGGKNEFEGTVEVYASGVWGTVCSSHWDDSDASVICHQLQLGGKGIAKQTPFSGLGLIPIYWSNVRCRGDEENILLCEKDIWQGGVCPQKMAAAVTCSFSHGPTFPIIRLAGGSSVHEGRVELYHAGQWGTVCDDQWDDADAEVICRQLGLSGIAKAWHQAYFGEGSGPVMLDEVRCTGNELSIEQCPKSSWGEHNCGHKEDAGVSCTPLTDGVIRLAGGKGSHEGRLEVYYRGQWGTVCDDGWTELNTYVVCRQLGFKYGKQASANHFEESTGPIWLDDVSCSGKETRFLQCSRRQWGRHDCSHREDVSIACYPGGEGHRLSLGFPVRLMDGENKKEGRVEVFINGQWGTICDDGWTDKDAAVICRQLGYKGPARARTMAYFGEGKGPIHVDNVKCTGNERSLADCIKQDIGRHNCRHSEDAGVICDYFGKKASGNSNKESLSSVCGLRLLHRRQKRIIGGKNSLRGGWPWQVSLRLKSSHGDGRLLCGATLLSSCWVLTAAHCFKRYGNSTRSYAVRVGDYHTLVPEEFEEEIGVQQIVIHREYRPDRSDYDIALVRLQGPEEQCARFSSHVLPACLPLWRERPQKTASNCYITGWGDTGRAYSRTLQQAAIPLLPKRFCEERYKGRFTGRMLCAGNLHEHKRVDSCQGDSGGPLMCERPGESWVVYGVTSWGYGCGVKDSPGVYTKVSAFVPWIKSVTKL T11317 TARGETID T11317 T11317 FORMERID TTDI03529 T11317 UNIPROID SIK1_HUMAN T11317 TARGNAME Salt-inducible kinase 1 (SIK1) T11317 GENENAME SIK1 T11317 TARGTYPE Literature-reported T11317 SYNONYMS Serine/threonine-protein kinase SNF1LK; Serine/threonine-protein kinase SNF1-like kinase 1; Serine/threonine-protein kinase SIK1; SNF1LK; SIK-1; SIK T11317 FUNCTION Phosphorylates HDAC4, HDAC5, PPME1, SREBF1, CRTC1/TORC1. Inhibits CREB activity by phosphorylating and inhibiting activity of TORCs, the CREB-specific coactivators, like CRTC2/TORC2 and CRTC3/TORC3 in response to cAMP signaling. Acts as a tumor suppressor and plays a key role in p53/TP53-dependent anoikis, a type of apoptosis triggered by cell detachment: required for phosphorylation of p53/TP53 in response to loss of adhesion and is able to suppress metastasis. Part of a sodium-sensing signaling network, probably by mediating phosphorylation of PPME1: following increases in intracellular sodium, SIK1 is activated by CaMK1 and phosphorylates PPME1 subunit of protein phosphatase 2A (PP2A), leading to dephosphorylation of sodium/potassium-transporting ATPase ATP1A1 and subsequent increase activity of ATP1A1. Acts as a regulator of muscle cells by phosphorylating and inhibiting class II histone deacetylases HDAC4 and HDAC5, leading to promote expression of MEF2 target genes in myocytes. Also required during cardiomyogenesis by regulating the exit of cardiomyoblasts from the cell cycle via down-regulation of CDKN1C/p57Kip2. Acts as a regulator of hepatic gluconeogenesis by phosphorylating and repressing the CREB-specific coactivators CRTC1/TORC1 and CRTC2/TORC2, leading to inhibit CREB activity. Also regulates hepatic lipogenesis by phosphorylating and inhibiting SREBF1. In concert with CRTC1/TORC1, regulates the light-induced entrainment of the circadian clock by attenuating PER1 induction; represses CREB-mediated transcription of PER1 by phosphorylating and deactivating CRTC1/TORC1. Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, gluconeogenesis and lipogenesis regulation, muscle growth and differentiation and tumor suppression. T11317 BIOCLASS Kinase T11317 ECNUMBER EC 2.7.11.1 T11317 SEQUENCE MVIMSEFSADPAGQGQGQQKPLRVGFYDIERTLGKGNFAVVKLARHRVTKTQVAIKIIDKTRLDSSNLEKIYREVQLMKLLNHPHIIKLYQVMETKDMLYIVTEFAKNGEMFDYLTSNGHLSENEARKKFWQILSAVEYCHDHHIVHRDLKTENLLLDGNMDIKLADFGFGNFYKSGEPLSTWCGSPPYAAPEVFEGKEYEGPQLDIWSLGVVLYVLVCGSLPFDGPNLPTLRQRVLEGRFRIPFFMSQDCESLIRRMLVVDPARRITIAQIRQHRWMRAEPCLPGPACPAFSAHSYTSNLGDYDEQALGIMQTLGVDRQRTVESLQNSSYNHFAAIYYLLLERLKEYRNAQCARPGPARQPRPRSSDLSGLEVPQEGLSTDPFRPALLCPQPQTLVQSVLQAEMDCELQSSLQWPLFFPVDASCSGVFRPRPVSPSSLLDTAISEEARQGPGLEEEQDTQESLPSSTGRRHTLAEVSTRLSPLTAPCIVVSPSTTASPAEGTSSDSCLTFSASKSPAGLSGTPATQGLLGACSPVRLASPFLGSQSATPVLQAQGGLGGAVLLPVSFQEGRRASDTSLTQGLKAFRQQLRKTTRTKGFLGLNKIKGLARQVCQAPASRASRGGLSPFHAPAQSPGLHGGAAGSREGWSLLEEVLEQQRLLQLQHHPAAAPGCSQAPQPAPAPFVIAPCDGPGAAPLPSTLLTSGLPLLPPPLLQTGASPVASAAQLLDTHLHIGTGPTALPAVPPPRLARLAPGCEPLGLLQGDCEMEDLMPCSLGTFVLVQ T11317 DRUGINFO D03YVB HG-9-91-01 Investigative T11317 DRUGINFO D0E7VO PMID24900538C2c Investigative T93594 TARGETID T93594 T93594 UNIPROID RIPK4_HUMAN T93594 TARGNAME PKC-delta-interacting protein kinase (RIPK4) T93594 GENENAME RIPK4 T93594 TARGTYPE Literature-reported T93594 SYNONYMS DIK; Ankyrin repeat domain-containing protein 3; ANKRD3 T93594 FUNCTION Involved in stratified epithelial development. It is a direct transcriptional target of TP63. Plays a role in NF-kappa-B activation. T93594 BIOCLASS Protein kinase superfamily. TKL Ser/Thr protein kinase family T93594 ECNUMBER EC 2.7.11.1 T93594 SEQUENCE MEGDGGTPWALALLRTFDAGEFTGWEKVGSGGFGQVYKVRHVHWKTWLAIKCSPSLHVDDRERMELLEEAKKMEMAKFRYILPVYGICREPVGLVMEYMETGSLEKLLASEPLPWDLRFRIIHETAVGMNFLHCMAPPLLHLDLKPANILLDAHYHVKISDFGLAKCNGLSHSHDLSMDGLFGTIAYLPPERIREKSRLFDTKHDVYSFAIVIWGVLTQKKPFADEKNILHIMVKVVKGHRPELPPVCRARPRACSHLIRLMQRCWQGDPRVRPTFQGNGLNGELIRQVLAALLPVTGRWRSPGEGFRLESEVIIRVTCPLSSPQEITSETEDLCEKPDDEVKETAHDLDVKSPPEPRSEVVPARLKRASAPTFDNDYSLSELLSQLDSGVSQAVEGPEELSRSSSESKLPSSGSGKRLSGVSSVDSAFSSRGSLSLSFEREPSTSDLGTTDVQKKKLVDAIVSGDTSKLMKILQPQDVDLALDSGASLLHLAVEAGQEECAKWLLLNNANPNLSNRRGSTPLHMAVERRVRGVVELLLARKISVNAKDEDQWTALHFAAQNGDESSTRLLLEKNASVNEVDFEGRTPMHVACQHGQENIVRILLRRGVDVSLQGKDAWLPLHYAAWQGHLPIVKLLAKQPGVSVNAQTLDGRTPLHLAAQRGHYRVARILIDLCSDVNVCSLLAQTPLHVAAETGHTSTARLLLHRGAGKEAMTSDGYTALHLAARNGHLATVKLLVEEKADVLARGPLNQTALHLAAAHGHSEVVEELVSADVIDLFDEQGLSALHLAAQGRHAQTVETLLRHGAHINLQSLKFQGGHGPAATLLRRSKT T53578 TARGETID T53578 T53578 FORMERID TTDR00303 T53578 UNIPROID FABI1_RHIME T53578 TARGNAME Bacterial NADH-dependent enoyl-ACP reductase 1 (Bact fabI1) T53578 GENENAME Bact fabI1 T53578 TARGTYPE Literature-reported T53578 SYNONYMS NADH-dependent enoyl-ACP reductase 1; Enoyl-[acyl-carrier-protein] reductase [NADH] 1 T53578 FUNCTION A key enzyme of the type II fatty acid synthesis (FAS) system. Essential for bacterial metabolism and its sequence conservation across many bacterial species but distinctly different from those of mammalian fatty acid biosynthesis enzymes. T53578 BIOCLASS CH-CH donor oxidoreductase T53578 SEQUENCE MAQASGLMNGKRGVIMGVANNRSIAWGIAKALAEAGAEIALTWQGDALKKRVEPLAQELGAFMAGHCDVTDLATIDAVFSALEEKWGKIDFVVHAIAFSDKDELTGRYLDTSRDNFARTMDISVYSFTAVAARADRVMNDGGSILTLTYYGAEKVMPHYNVMGVAKAALEASVRYLAVDLGNRGIRVNAISAGPIKTLAASGIGDFRYILKWNEYNAPLKRTVSIEEVGNSALYLLSDLSSGVTGEVHHVDSGYHTVGMKAVDAPDISVLKD T53578 DRUGINFO D08ZHT Diazaborines Investigative T79589 TARGETID T79589 T79589 FORMERID TTDR00304 T79589 UNIPROID FABI2_RHIME T79589 TARGNAME Bacterial NADH-dependent enoyl-ACP reductase 2 (Bact fabI2) T79589 GENENAME Bact fabI2 T79589 TARGTYPE Literature-reported T79589 SYNONYMS NADH-dependent enoyl-ACP reductase 2; Enoyl-[acyl-carrier-protein] reductase [NADH] 2 T79589 FUNCTION Identified as the FabI protein, which is the target of a group of antibacterial compounds, the diazaborines. T79589 BIOCLASS CH-CH donor oxidoreductase T79589 SEQUENCE MNGLMNGKRGLIMGVANSHSIAWGIAKSLAAQGAELAFTYQGEALGKRVKPLAAEVNSDFLLPCDVEDIGSVDAVVDAIKERWGKLDFVVHAIGFSDKNELKGLYADTTRDNFSRTMVISCFSFTEIAKRAAELMSEGGTMLTLTYGGSMRVMPNYNVMGVAKAALEASVRYLAADYGSRGIRVNAISAGPIRTLAGAGISDARAMLSWQQKNSPLRRTVTIEDVGSSALYLLSDLSRGVTGEIHYVDSGYNITSMPTLEALRVADAD T79589 DRUGINFO D08ZHT Diazaborines Investigative T32445 TARGETID T32445 T32445 FORMERID TTDI01414 T32445 UNIPROID CABC1_PROVU T32445 TARGNAME Proteus vulgaris Chondroitin ABC endolyase 1 (PROVU cABC1) T32445 GENENAME PROVU cABC1 T32445 TARGTYPE Literature-reported T32445 SYNONYMS cABC I; INN=Condoliase; Endochondroitinase ABC; Chondroitinase ABC I; Chondroitin sulfate ABC lyase I; Chondroitin sulfate ABC endolyase; Chondroitin ABC lyase I; Chondroitin ABC endoeliminase; ChS ABC lyase I T32445 FUNCTION Endolytic, broad-specificity glycosaminoglycan lyase, which degrades the polysaccharides chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate and to a lesser extent hyaluronan, by beta-elimination of 1,4-hexosaminidic bond to unsaturated tetrasaccharides and disaccharides. Is not active against keratan sulfate, heparan sulfate, and heparin. Is able to promote functional recovery in the injured central nervous system (CNS), via its role in the disruption of the normal organization of the extracellular matrix (ECM). T32445 PDBSTRUC 1HN0 T32445 ECNUMBER EC 4.2.2.20 T32445 SEQUENCE MPIFRFTALAMTLGLLSAPYNAMAATSNPAFDPKNLMQSEIYHFAQNNPLADFSSDKNSILTLSDKRSIMGNQSLLWKWKGGSSFTLHKKLIVPTDKEASKAWGRSSTPVFSFWLYNEKPIDGYLTIDFGEKLISTSEAQAGFKVKLDFTGWRAVGVSLNNDLENREMTLNATNTSSDGTQDSIGRSLGAKVDSIRFKAPSNVSQGEIYIDRIMFSVDDARYQWSDYQVKTRLSEPEIQFHNVKPQLPVTPENLAAIDLIRQRLINEFVGGEKETNLALEENISKLKSDFDALNIHTLANGGTQGRHLITDKQIIIYQPENLNSQDKQLFDNYVILGNYTTLMFNISRAYVLEKDPTQKAQLKQMYLLMTKHLLDQGFVKGSALVTTHHWGYSSRWWYISTLLMSDALKEANLQTQVYDSLLWYSREFKSSFDMKVSADSSDLDYFNTLSRQHLALLLLEPDDQKRINLVNTFSHYITGALTQVPPGGKDGLRPDGTAWRHEGNYPGYSFPAFKNASQLIYLLRDTPFSVGESGWNNLKKAMVSAWIYSNPEVGLPLAGRHPFNSPSLKSVAQGYYWLAMSAKSSPDKTLASIYLAISDKTQNESTAIFGETITPASLPQGFYAFNGGAFGIHRWQDKMVTLKAYNTNVWSSEIYNKDNRYGRYQSHGVAQIVSNGSQLSQGYQQEGWDWNRMQGATTIHLPLKDLDSPKPHTLMQRGERGFSGTSSLEGQYGMMAFDLIYPANLERFDPNFTAKKSVLAADNHLIFIGSNINSSDKNKNVETTLFQHAITPTLNTLWINGQKIENMPYQTTLQQGDWLIDSNGNGYLITQAEKVNVSRQHQVSAENKNRQPTEGNFSSAWIDHSTRPKDASYEYMVFLDATPEKMGEMAQKFRENNGLYQVLRKDKDVHIILDKLSNVTGYAFYQPASIEDKWIKKVNKPAIVMTHRQKDTLIVSAVTPDLNMTRQKAATPVTINVTINGKWQSADKNSEVKYQVSGDNTELTFTSYFGIPQEIKLSPLP T85005 TARGETID T85005 T85005 FORMERID TTDNR00760 T85005 UNIPROID TYB4_HUMAN T85005 TARGNAME Thymosin beta-4 (TMSB4X) T85005 GENENAME TMSB4X T85005 TARGTYPE Literature-reported T85005 SYNONYMS TMSB4X; T beta-4; Fx T85005 FUNCTION Seraspenide inhibits the entry of hematopoietic pluripotent stem cellsinto the S-phase. T85005 PDBSTRUC 4PL8; 4PL7; 3TU5; 1UY5 T85005 BIOCLASS Thymosin family T85005 SEQUENCE MSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES T24255 TARGETID T24255 T24255 FORMERID TTDR00723 T24255 UNIPROID ISPF_PLAF7 T24255 TARGNAME Plasmodium MECDP-synthase (Malaria ISPF) T24255 GENENAME Malaria ISPF T24255 TARGTYPE Literature-reported T24255 SYNONYMS MECPS; MECDP-synthase; ISPF T24255 FUNCTION Converts 4-diphosphocytidyl-2C-methyl-D-erythritol 2- phosphate into 2C-methyl-D-erythritol 2,4-cyclodiphosphate and CMP. T24255 PDBSTRUC 4C82; 4C81 T24255 BIOCLASS Phosphorus-oxygen lyase T24255 SEQUENCE MFLKGYTSNVVLIILTFFILLTKEEKNIKNNISGYCFLNFGLKKNAIIKKREKQNLKLFCYNGIRIGQGYDIHKIKVLDEEYNTYANNDFNKNEQSFKTLTLGGVKINNVLVLSHSDGDIIYHSIVDSILGALGSLDIGTLFPDKDEKNKNKNSAIFLRYARLLIYKKNYDIGNVDINVIAQVPKISNIRKNIIKNISTVLNIDESQISVKGKTHEKLGVIGEKKAIECFANILLIPKNS T07607 TARGETID T07607 T07607 FORMERID TTDR00897 T07607 UNIPROID RPB7_HUMAN T07607 TARGNAME DNA-directed RNA polymerase II RPB7 (hsRPB7) T07607 GENENAME POLR2G T07607 TARGTYPE Literature-reported T07607 SYNONYMS RPB7; Human RNA polymerase II seventh subunit; HsRPB7 T07607 FUNCTION Dna-dependent rna polymerase catalyzes the transcription of dna into rna using the four ribonucleoside triphosphates as substrates. It is suggested that rpb7 contributes to the function of rna polymerase ii in the absence of rpb4. T07607 PDBSTRUC 5IYD; 5IYC; 5IYB; 5IYA; 5IY9 T07607 BIOCLASS Kinase T07607 SEQUENCE MFYHISLEHEILLHPRYFGPNLLNTVKQKLFTEVEGTCTGKYGFVIAVTTIDNIGAGVIQPGRGFVLYPVKYKAIVFRPFKGEVVDAVVTQVNKVGLFTEIGPMSCFISRHSIPSEMEFDPNSNPPCYKTMDEDIVIQQDDEIRLKIVGTRVDKNDIFAIGSLMDDYLGLVS T59875 TARGETID T59875 T59875 FORMERID TTDI03184 T59875 UNIPROID ERR3_HUMAN T59875 TARGNAME Estrogen-related receptor-gamma (ESRRG) T59875 GENENAME ESRRG T59875 TARGTYPE Literature-reported T59875 SYNONYMS Nuclear receptor subfamily 3 group B member 3; NR3B3; KIAA0832; Estrogen-related receptor gamma; Estrogen receptor-related protein 3; ERRG2; ERR3; ERR gamma-2 T59875 FUNCTION Binds specifically to an estrogen response element and activates reporter genes controlled by estrogen response elements. Induces the expression of PERM1 in the skeletal muscle. Orphan receptor that acts as transcription activator in the absence of bound ligand. T59875 PDBSTRUC 6A6K; 5YSO; 2ZKC; 2ZBS; 2ZAS T59875 BIOCLASS Nuclear hormone receptor T59875 SEQUENCE MDSVELCLPESFSLHYEEELLCRMSNKDRHIDSSCSSFIKTEPSSPASLTDSVNHHSPGGSSDASGSYSSTMNGHQNGLDSPPLYPSAPILGGSGPVRKLYDDCSSTIVEDPQTKCEYMLNSMPKRLCLVCGDIASGYHYGVASCEACKAFFKRTIQGNIEYSCPATNECEITKRRRKSCQACRFMKCLKVGMLKEGVRLDRVRGGRQKYKRRIDAENSPYLNPQLVQPAKKPYNKIVSHLLVAEPEKIYAMPDPTVPDSDIKALTTLCDLADRELVVIIGWAKHIPGFSTLSLADQMSLLQSAWMEILILGVVYRSLSFEDELVYADDYIMDEDQSKLAGLLDLNNAILQLVKKYKSMKLEKEEFVTLKAIALANSDSMHIEDVEAVQKLQDVLHEALQDYEAGQHMEDPRRAGKMLMTLPLLRQTSTKAVQHFYNIKLEGKVPMHKLFLEMLEAKV T59875 DRUGINFO D0DX8T GSK4716 Investigative T59875 DRUGINFO D06JPQ DY131 Investigative T59875 DRUGINFO D0S9YX biochanin A Investigative T59875 DRUGINFO D0SY2M daidzein Investigative T65721 TARGETID T65721 T65721 FORMERID TTDI01371 T65721 UNIPROID RAC1_HUMAN T65721 TARGNAME Ras-like protein TC25 (RAC1) T65721 GENENAME RAC1 T65721 TARGTYPE Literature-reported T65721 SYNONYMS p21-Rac1; TC25; MIG5; Cell migration-inducing gene 5 protein T65721 FUNCTION Plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization, neurons adhesion, migration and differentiation, and growth-factor induced formation of membrane ruffles. Rac1 p21/rho GDI heterodimer is the active component of the cytosolic factor sigma 1, which is involved in stimulation of the NADPH oxidase activity in macrophages. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. Stimulates PKN2 kinase activity. In concert with RAB7A, plays a role in regulating the formation of RBs (ruffled borders) in osteoclasts. In podocytes, promotes nuclear shuttling of NR3C2; this modulation is required for a proper kidney functioning. Required for atypical chemokine receptor ACKR2-induced LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1) and for up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. In neurons, is involved in dendritic spine formation and synaptic plasticity (By similarity). In synapses, seems to mediate the regulation of F-actin cluster formation performed by SHANK3. T65721 PDBSTRUC 6BC1; 6AGP; 5O33; 5N6O; 5HZH T65721 ECNUMBER EC 3.6.5.2 T65721 SEQUENCE MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDTAGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWYPEVRHHCPNTPIILVGTKLDLRDDKDTIEKLKEKKLTPITYPQGLAMAKEIGAVKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL T16398 TARGETID T16398 T16398 FORMERID TTDR01212 T16398 UNIPROID FABD_MYCBO T16398 TARGNAME Mycobacterium Malonyl-CoA:acyl carrier transacylase (MycB fabD) T16398 GENENAME MycB fabD T16398 TARGTYPE Literature-reported T16398 SYNONYMS Malonyl CoA-acyl carrier protein transacylase; MCT T16398 FUNCTION Essential for the biosynthesis of fatty acids in all bacteria. Catalyzes the transacylation of malonate from malonyl-CoA to activated holo-ACP, to generate malonyl-ACP, which is an elongation substrate in fatty acid biosynthesis. T16398 BIOCLASS Acyltransferase T16398 ECNUMBER EC 2.3.1.39 T16398 SEQUENCE MIALLAPGQGSQTEGMLSPWLQLPGAADQIAAWSKAADLDLARLGTTASTEEITDTAVAQPLIVAATLLAHQELARRCVLAGKDVIVAGHSVGEIAAYAIAGVIAADDAVALAATRGAEMAKACATEPTGMSAVLGGDETEVLSRLEQLDLVPANRNAAGQIVAAGRLTALEKLAEDPPAKARVRALGVAGAFHTEFMAPALDGFAAAAANIATADPTATLLSNRDGKPVTSAAAAMDTLVSQLTQPVRWDLCTATLREHTVTAIVEFPPAGTLSGIAKRELRGVPARAVKSPADLDELANL T91449 TARGETID T91449 T91449 FORMERID TTDI01416 T91449 UNIPROID CLPP_STAAW T91449 TARGNAME Staphylococcus ATP-dependent protease ClpP (Stap-coc CLPP) T91449 GENENAME Stap-coc CLPP T91449 TARGTYPE Literature-reported T91449 SYNONYMS Stap-coc Endopeptidase Clp; ATP-dependent Clp protease proteolytic subunit T91449 FUNCTION Cleaves peptides in various proteins in a process that requires ATP hydrolysis. Has a chymotrypsin-like activity. Plays a major role in the degradation of misfolded proteins. T91449 PDBSTRUC 4EMP; 4EMM; 3STA; 3ST9 T91449 ECNUMBER EC 3.4.21.92 T91449 SEQUENCE MNLIPTVIETTNRGERAYDIYSRLLKDRIIMLGSQIDDNVANSIVSQLLFLQAQDSEKDIYLYINSPGGSVTAGFAIYDTIQHIKPDVQTICIGMAASMGSFLLAAGAKGKRFALPNAEVMIHQPLGGAQGQATEIEIAANHILKTREKLNRILSERTGQSIEKIQKDTDRDNFLTAEEAKEYGLIDEVMVPETK T15526 TARGETID T15526 T15526 FORMERID TTDR00678 T15526 UNIPROID US28_HCMVT T15526 TARGNAME Cytomegalovirus Glycoprotein coupled receptor (CMV US28) T15526 GENENAME CMV US28 T15526 TARGTYPE Literature-reported T15526 SYNONYMS HHRF3; G-protein coupled receptor homolog US28 T15526 FUNCTION Receptor for a C-C type chemokine. Binds to MIP-1 alpha, RANTES, and MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. May regulate viral latency or reactivation; potential pathway for virally transformed cell proliferation. T15526 PDBSTRUC 5WB2; 5WB1 T15526 BIOCLASS GPCR rhodopsin T15526 SEQUENCE MTPTTTTAELTTEFDYDEDATPCVFTDVLNQSKPVTLFLYGVVFLFGSIGNFLVIFTITWRRRIQCSGDVYFINLAAADLLFVCTLPLWMQYLLDHNSLASVPCTLLTACFYVAMFASLCFITEIALDRYYAIVYMRYRPVKQACLFSIFWWIFAVIIAIPHFMVVTKKDNQCMTDYDYLEVSYPIILNVELMLGAFVIPLSVISYCYYRISRIVAVSQSRHKGRIVRVLIAVVLVFIIFWLPYHLTLFVDTLKLLKWISSSCEFERSLKRALILTESLAFCHCCLNPLLYVFVGTKFRQELHCLLAEFRQRLFSRDVSWYHSMSFSRRSSPSRRETSSDTLSDEVCRVSQIIP T95961 TARGETID T95961 T95961 FORMERID TTDR01264 T95961 UNIPROID I13R1_HUMAN T95961 TARGNAME Interleukin 13 receptor alpha-1 (IL13RA1) T95961 GENENAME IL13RA1 T95961 TARGTYPE Literature-reported T95961 SYNONYMS Interleukin-13 receptor subunit alpha-1; IL13RA; IL13R; IL-13RA1; IL-13RA-1; IL-13R-alpha-1; IL-13R subunit alpha-1; IL-13R alpha-1 chain; IL-13 receptor subunit alpha-1; Cancer/testis antigen 19; CT19; CD213a1 antigen; CD213a1 T95961 FUNCTION Together with IL4RA can form a functional receptor for IL13. Also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling, but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity. Binds with low affinity to interleukin-13 (IL13). T95961 PDBSTRUC 5E4E; 4HWB; 3BPO; 3BPN T95961 BIOCLASS Cytokine receptor T95961 SEQUENCE MEWPARLCGLWALLLCAGGGGGGGGAAPTETQPPVTNLSVSVENLCTVIWTWNPPEGASSNCSLWYFSHFGDKQDKKIAPETRRSIEVPLNERICLQVGSQCSTNESEKPSILVEKCISPPEGDPESAVTELQCIWHNLSYMKCSWLPGRNTSPDTNYTLYYWHRSLEKIHQCENIFREGQYFGCSFDLTKVKDSSFEQHSVQIMVKDNAGKIKPSFNIVPLTSRVKPDPPHIKNLSFHNDDLYVQWENPQNFISRCLFYEVEVNNSQTETHNVFYVQEAKCENPEFERNVENTSCFMVPGVLPDTLNTVRIRVKTNKLCYEDDKLWSNWSQEMSIGKKRNSTLYITMLLIVPVIVAGAIIVLLLYLKRLKIIIFPPIPDPGKIFKEMFGDQNDDTLHWKKYDIYEKQTKEETDSVVLIENLKKASQ T72010 TARGETID T72010 T72010 FORMERID TTDNR00711 T72010 UNIPROID NGAL_HUMAN T72010 TARGNAME Neutrophil gelatinase-associated lipocalin (LCN2) T72010 GENENAME LCN2 T72010 TARGTYPE Literature-reported T72010 SYNONYMS p25; Siderocalin LCN2; Oncogene 24p3; NGAL; Lipocalin-2; LCN2; 25 kDa alpha-2-microglobulin-related subunit of MMP-9 T72010 FUNCTION Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal development. Binds iron through association with 2,5-dihydroxybenzoic acid (2,5- DHBA), a siderophore that shares structural similarities withbacterial enterobactin, and delivers or removes iron from the cell, depending on the context. Iron-bound form (holo-24p3) is internalized following binding to the SLC22A17 (24p3R) receptor, leading to release of iron and subsequent increase of intracellular iron concentration. In contrast, association of the iron-free form (apo-24p3) with the SLC22A17 (24p3R) receptor is followed by association with an intracellular siderophore, iron chelation and iron transfer to the extracellular medium, thereby reducing intracellular iron concentration. Involved in apoptosis due to interleukin-3 (IL3) deprivation: iron-loaded form increases intracellular iron concentration without promoting apoptosis, while iron-free form decreases intracellular iron levels, inducing expression of the proapoptotic protein BCL2L11/BIM, resulting in apoptosis. Involved in innate immunity, possibly by sequestrating iron, leading to limit bacterial growth. . T72010 PDBSTRUC 6GR0; 6GQZ; 5NKN; 5N48; 5N47 T72010 BIOCLASS Calycin family T72010 SEQUENCE MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG T38093 TARGETID T38093 T38093 FORMERID TTDI02538 T38093 UNIPROID RET5_HUMAN T38093 TARGNAME Cellular retinol binding protein III (RBP5) T38093 GENENAME RBP5 T38093 TARGTYPE Literature-reported T38093 SYNONYMS Retinol-binding protein 5; RBP5; HRBPiso; CRBP-III T38093 FUNCTION Intracellular transport of retinol. T38093 PDBSTRUC 6E5W; 1GGL T38093 BIOCLASS Calycin family T38093 SEQUENCE MPPNLTGYYRFVSQKNMEDYLQALNISLAVRKIALLLKPDKEIEHQGNHMTVRTLSTFRNYTVQFDVGVEFEEDLRSVDGRKCQTIVTWEEEHLVCVQKGEVPNRGWRHWLEGEMLYLELTARDAVCEQVFRKVR T47351 TARGETID T47351 T47351 FORMERID TTDNR00636 T47351 UNIPROID ARF1_HUMAN T47351 TARGNAME ADP-ribosylation factor 1 (ARF1) T47351 GENENAME ARF1 T47351 TARGTYPE Literature-reported T47351 SYNONYMS PVNH8 T47351 FUNCTION Modulates vesicle budding and uncoating within the Golgi complex. Deactivation induces the redistribution of the entire Golgi complex to the endoplasmic reticulum, suggesting a crucial role in protein trafficking. In its GTP-bound form, its triggers the association with coat proteins with the Golgi membrane. The hydrolysis of ARF1-bound GTP, which is mediated by ARFGAPs proteins, is required for dissociation of coat proteins from Golgi membranes and vesicles. The GTP-bound form interacts with PICK1 to limit PICK1-mediated inhibition of Arp2/3 complex activity; the function is linked to AMPA receptor (AMPAR) trafficking, regulation of synaptic plasicity of excitatory synapses and spine shrinkage during long-term depression (LTD). GTP-binding protein involved in protein trafficking among different compartments. T47351 PDBSTRUC 6FAE; 6DFF; 6D84; 6D83; 6CRI T47351 BIOCLASS Small GTPase T47351 SEQUENCE MGNIFANLFKGLFGKKEMRILMVGLDAAGKTTILYKLKLGEIVTTIPTIGFNVETVEYKNISFTVWDVGGQDKIRPLWRHYFQNTQGLIFVVDSNDRERVNEAREELMRMLAEDELRDAVLLVFANKQDLPNAMNAAEITDKLGLHSLRHRNWYIQATCATSGDGLYEGLDWLSNQLRNQK T80175 TARGETID T80175 T80175 FORMERID TTDR00955 T80175 UNIPROID DLDH_TRYCR T80175 TARGNAME Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD) T80175 GENENAME Trypano LPD T80175 TARGTYPE Literature-reported T80175 SYNONYMS Lipoamide dehydrogenase; LipDH; LPD; Glycine cleavage system L protein; Dihydrolipoamide dehydrogenase T80175 FUNCTION Lipoamide dehydrogenase is a component of the glycine cleavage system as well as of the alpha-ketoacid dehydrogenase complexes. T80175 PDBSTRUC 2QAE T80175 BIOCLASS Sulfur donor oxidoreductase T80175 SEQUENCE MFRRCAVKLNPYDVVVIGGGPGGYVASIKAAQLGMKTACVEKRGALGGTCLNVGCIPSKALLHATHVYHDAHANFARYGLMGGEGVTMDSAKMQQQKERAVKGLTGGVEYLFKKNKVTYYKGEGSFETAHSIRVNGLDGKQEMFETKKTIIATGSEPTELPFLPFDEKVVLSSTGALALPRVPKTMVVIGGGVIGLELGSVWARLGAKVTVVEFAPRCAPTLDEDVTNALVGALAKNEKMKFMTSTKVVGGTNNGDSVSLEVEGKNGKRETVTCEALLVSVGRRPFTGGLGLDKINVAKNERGFVKIGDHFETSIPDVYAIGDVVDKGPMLAHKAEDEGVACAEILAGKPGHVNYGVIPAVIYTMPEVASVGKSEEELKKEGVAYKVGKFPFNANSRAKAVSTEDGFVKVLVDKATDRILGVHIVCTTAGELIGEACLAMEYGASSEDVGRTCHAHPTMSEALKEACMALVAKTINF T80175 DRUGINFO D00IMW Flavin-Adenine Dinucleotide Investigative T80175 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T75210 TARGETID T75210 T75210 FORMERID TTDR00546 T75210 UNIPROID LRP2_HUMAN T75210 TARGNAME LDL receptor related protein-2 (LRP-2) T75210 GENENAME LRP2 T75210 TARGTYPE Literature-reported T75210 SYNONYMS Megalin; Lowdensity lipoprotein receptorrelated protein 2; Low-density lipoprotein receptor-related protein 2; Gp330; Glycoprotein 330 T75210 FUNCTION Acts together with CUBN to mediate endocytosis of high-density lipoproteins. Mediates receptor-mediated uptake of polybasic drugs such as aprotinin, aminoglycosides and polymyxin B. In the kidney, mediates the tubular uptake and clearance of leptin. Also mediates transport of leptin across the blood-brain barrier through endocytosis at the choroid plexus epithelium. Endocytosis of leptin in neuronal cells is required for hypothalamic leptin signaling and leptin-mediated regulation of feeding and body weight. Mediates endocytosis and subsequent lysosomal degradation of CST3 in kidney proximal tubule cells. Mediates renal uptake of 25-hydroxyvitamin D3 in complex with the vitamin D3 transporter GC/DBP. Mediates renal uptake of metallothionein-bound heavy metals. Together with CUBN, mediates renal reabsorption of myoglobin. Mediates renal uptake and subsequent lysosomal degradation of APOM. Plays a role in kidney selenium homeostasis by mediating renal endocytosis of selenoprotein SEPP1. Mediates renal uptake of the antiapoptotic protein BIRC5/survivin which may be important for functional integrity of the kidney. Mediates renal uptake of matrix metalloproteinase MMP2 in complex with metalloproteinase inhibitor TIMP1. Mediates endocytosis of Sonic hedgehog protein N-product (ShhN), the active product of SHH. Also mediates ShhN transcytosis. In the embryonic neuroepithelium, mediates endocytic uptake and degradation of BMP4, is required for correct SHH localization in the ventral neural tube and plays a role in patterning of the ventral telencephalon. Required at the onset of neurulation to sequester SHH on the apical surface of neuroepithelial cells of the rostral diencephalon ventral midline and to control PTCH1-dependent uptake and intracellular trafficking of SHH. During neurulation, required in neuroepithelial cells for uptake of folate bound to the folate receptor FOLR1 which is necessary for neural tube closure. In the adult brain, negatively regulates BMP signaling in the subependymal zone which enables neurogenesis to proceed. In astrocytes, mediates endocytosis of ALB which is required for the synthesis of the neurotrophic factor oleic acid. Involved in neurite branching. During optic nerve development, required for SHH-mediated migration and proliferation of oligodendrocyte precursor cells. Mediates endocytic uptake and clearance of SHH in the retinal margin which protects retinal progenitor cells from mitogenic stimuli and keeps them quiescent. Plays a role in reproductive organ development by mediating uptake in reproductive tissues of androgen and estrogen bound to the sex hormone binding protein SHBG. Mediates endocytosis of angiotensin-2. Also mediates endocytosis of angiotensis 1-7. Binds to the complex composed of beta-amyloid protein 40 and CLU/APOJ and mediates its endocytosis and lysosomal degradation. Required for embryonic heart development. Required for normal hearing, possibly through interaction with estrogen in the inner ear. Multiligand endocytic receptor. T75210 PDBSTRUC 2M0P T75210 BIOCLASS Low density lipoprotein receptor T75210 SEQUENCE MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEIGCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQCIPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCTEICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWVCDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENNTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQKCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVESQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNKIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLERAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSLIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYATNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIRGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAANRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYLFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFDGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHLKSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNEPPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECIPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDEKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKCIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGSDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCLGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFLLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLVASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDRRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALDPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLDYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVMYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNCLRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGEIHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTLIANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEHLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQYEVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGLFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHVDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLYFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFLDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTPYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAEVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRSLHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTVIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGYLYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTLTGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGINTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERCGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRCDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDRTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQHWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKRHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTCGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDGSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSISGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAPGYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKRLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLNGGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVIISTKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTIYWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLCLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSDGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDCGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCHPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDHYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGAYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSHEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDELGCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQHCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQDEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKYVMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMFWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYDGTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRIFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPPCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGALAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAIDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSEIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLPAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV T23489 TARGETID T23489 T23489 UNIPROID SMASE_MYCTU T23489 TARGNAME Mycobacterium Sphingomyelinase (MycB spmT) T23489 GENENAME MycB spmT T23489 TARGTYPE Literature-reported T23489 SYNONYMS SMase T23489 FUNCTION Catalyzes the cleavage of sphingomyelin, a major lipid in eukaryotic cells, into ceramide and phosphocholine, which are then utilized by M.tuberculosis as carbon, nitrogen and phosphorus sources, respectively. Thus, enables M.tuberculosis to utilize sphingomyelin as a source of several essential nutrients for intracellular growth during infection. Furthermore, lyses erythrocytes and constitutes the main hemolytic factor of M.tuberculosis. T23489 BIOCLASS SpmT family T23489 ECNUMBER EC 3.1.4.12 T23489 SEQUENCE MDYAKRIGQVGALAVVLGVGAAVTTHAIGSAAPTDPSSSSTDSPVDACSPLGGSASSLAAIPGASVPQVGVRQVDPGSIPDDLLNALIDFLAAVRNGLVPIIENRTPVANPQQVSVPEGGTVGPVRFDACDPDGNRMTFAVRERGAPGGPQHGIVTVDQRTASFIYTADPGFVGTDTFSVNVSDDTSLHVHGLAGYLGPFHGHDDVATVTVFVGNTPTDTISGDFSMLTYNIAGLPFPLSSAILPRFFYTKEIGKRLNAYYVANVQEDFAYHQFLIKKSKMPSQTPPEPPTLLWPIGVPFSDGLNTLSEFKVQRLDRQTWYECTSDNCLTLKGFTYSQMRLPGGDTVDVYNLHTNTGGGPTTNANLAQVANYIQQNSAGRAVIVTGDFNARYSDDQSALLQFAQVNGLTDAWVQVEHGPTTPPFAPTCMVGNECELLDKIFYRSGQGVTLQAVSYGNEAPKFFNSKGEPLSDHSPAVVGFHYVADNVAVR T90808 TARGETID T90808 T90808 UNIPROID HSAD_MYCTU T90808 TARGNAME Mycobacterium Meta-cleavage product hydrolase (MycB HsaD) T90808 GENENAME MycB HsaD T90808 TARGTYPE Literature-reported T90808 SYNONYMS Meta-cleavage product hydrolase; MCP hydrolase; HOPDA hydrolase; 4,5:9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate hydrolase; 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase T90808 FUNCTION Catalyzes the hydrolysis of a carbon-carbon bond in 4,5: 9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate (4,9-DSHA) to yield 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate (DOHNAA) and 2-hydroxy-hexa-2,4-dienoate (HHD). Is also able to catalyze the hydrolysis of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid (HOPDA) and the synthetic analog 8-(2-chlorophenyl)-2-hydroxy-5-methyl-6-oxoocta-2,4-dienoic acid (HOPODA). T90808 PDBSTRUC 5JZS; 5JZB; 2WUG; 2WUF; 2WUE T90808 ECNUMBER EC 3.7.1.17 T90808 SEQUENCE MTATEELTFESTSRFAEVDVDGPLKLHYHEAGVGNDQTVVLLHGGGPGAASWTNFSRNIAVLARHFHVLAVDQPGYGHSDKRAEHGQFNRYAAMALKGLFDQLGLGRVPLVGNSLGGGTAVRFALDYPARAGRLVLMGPGGLSINLFAPDPTEGVKRLSKFSVAPTRENLEAFLRVMVYDKNLITPELVDQRFALASTPESLTATRAMGKSFAGADFEAGMMWREVYRLRQPVLLIWGREDRVNPLDGALVALKTIPRAQLHVFGQCGHWVQVEKFDEFNKLTIEFLGGGR T90800 TARGETID T90800 T90800 FORMERID TTDI02634 T90800 UNIPROID CD83_HUMAN T90800 TARGNAME Cell surface protein HB15 (CD83) T90800 GENENAME CD83 T90800 TARGTYPE Literature-reported T90800 SYNONYMS hCD83; CD83 antigen; Bcell activation protein; B-cell activation protein T90800 FUNCTION May play a significant role in antigen presentation or the cellular interactions that follow lymphocyte activation. T90800 PDBSTRUC 5MJ2; 5MJ1; 5MJ0; 5MIX T90800 BIOCLASS Immunoglobulin T90800 SEQUENCE MSRGLQLLLLSCAYSLAPATPEVKVACSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNGSFDAPNERPYSLKIRNTTSCNSGTYRCTLQDPDGQRNLSGKVILRVTGCPAQRKEETFKKYRAEIVLLLALVIFYLTLIIFTCKFARLQSIFPDFSKAGMERAFLPVTSPNKHLGLVTPHKTELV T41195 TARGETID T41195 T41195 FORMERID TTDI03267 T41195 UNIPROID HMCS1_HUMAN T41195 TARGNAME Hydroxymethylglutaryl-CoA synthase 1 (HMGCS1) T41195 GENENAME HMGCS1 T41195 TARGTYPE Literature-reported T41195 SYNONYMS Hydroxymethylglutaryl-CoA synthase, cytoplasmic; HMGCS; HMG-CoA synthase; 3-hydroxy-3-methylglutaryl coenzyme A synthase 1 T41195 FUNCTION This enzyme condenses acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, which is the substrate for HMG-CoA reductase. T41195 PDBSTRUC 2P8U T41195 ECNUMBER EC 2.3.3.10 T41195 SEQUENCE MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINSLCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTAAVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHAYDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYCKLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQKTKASLLVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKITASLCDLKSRLDSRTGVAPDVFAENMKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARRPTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH T41195 DRUGINFO D06XQX (S)-3-hydroxy-3-methylglutaryl-CoA Investigative T41195 DRUGINFO D07SEU L-659,699 Investigative T93331 TARGETID T93331 T93331 UNIPROID SATB1_HUMAN T93331 TARGNAME DNA-binding protein SATB1 (SATB1) T93331 GENENAME SATB1 T93331 TARGTYPE Literature-reported T93331 SYNONYMS Special AT-rich sequence-binding protein 1 T93331 FUNCTION Crucial silencing factor contributing to the initiation of X inactivation mediated by Xist RNA that occurs during embryogenesis and in lymphoma. Binds to DNA at special AT-rich sequences, the consensus SATB1-binding sequence (CSBS), at nuclear matrix- or scaffold-associated regions. Thought to recognize the sugar-phosphate structure of double-stranded DNA. Transcriptional repressor controlling nuclear and viral gene expression in a phosphorylated and acetylated status-dependent manner, by binding to matrix attachment regions (MARs) of DNA and inducing a local chromatin-loop remodeling. Acts as a docking site for several chromatin remodeling enzymes (e.g. PML at the MHC-I locus) and also by recruiting corepressors (HDACs) or coactivators (HATs) directly to promoters and enhancers. Modulates genes that are essential in the maturation of the immune T-cell CD8SP from thymocytes. Required for the switching of fetal globin species, and beta- and gamma-globin genes regulation during erythroid differentiation. Plays a role in chromatin organization and nuclear architecture during apoptosis. Interacts with the unique region (UR) of cytomegalovirus (CMV). Alu-like motifs and SATB1-binding sites provide a unique chromatin context which seems preferentially targeted by the HIV-1 integration machinery. Moreover, HIV-1 Tat may overcome SATB1-mediated repression of IL2 and IL2RA (interleukin) in T-cells by binding to the same domain than HDAC1. Delineates specific epigenetic modifications at target gene loci, directly up-regulating metastasis-associated genes while down-regulating tumor-suppressor genes. Reprograms chromatin organization and the transcription profiles of breast tumors to promote growth and metastasis. T93331 PDBSTRUC 3TUO; 3NZL; 2O4A; 2O49; 2MW8 T93331 BIOCLASS CUT homeobox family T93331 SEQUENCE MDHLNEATQGKEHSEMSNNVSDPKGPPAKIARLEQNGSPLGRGRLGSTGAKMQGVPLKHSGHLMKTNLRKGTMLPVFCVVEHYENAIEYDCKEEHAEFVLVRKDMLFNQLIEMALLSLGYSHSSAAQAKGLIQVGKWNPVPLSYVTDAPDATVADMLQDVYHVVTLKIQLHSCPKLEDLPPEQWSHTTVRNALKDLLKDMNQSSLAKECPLSQSMISSIVNSTYYANVSAAKCQEFGRWYKHFKKTKDMMVEMDSLSELSQQGANHVNFGQQPVPGNTAEQPPSPAQLSHGSQPSVRTPLPNLHPGLVSTPISPQLVNQQLVMAQLLNQQYAVNRLLAQQSLNQQYLNHPPPVSRSMNKPLEQQVSTNTEVSSEIYQWVRDELKRAGISQAVFARVAFNRTQGLLSEILRKEEDPKTASQSLLVNLRAMQNFLQLPEAERDRIYQDERERSLNAASAMGPAPLISTPPSRPPQVKTATIATERNGKPENNTMNINASIYDEIQQEMKRAKVSQALFAKVAATKSQGWLCELLRWKEDPSPENRTLWENLSMIRRFLSLPQPERDAIYEQESNAVHHHGDRPPHIIHVPAEQIQQQQQQQQQQQQQQQAPPPPQPQQQPQTGPRLPPRQPTVASPAESDEENRQKTRPRTKISVEALGILQSFIQDVGLYPDEEAIQTLSAQLDLPKYTIIKFFQNQRYYLKHHGKLKDNSGLEVDVAEYKEEELLKDLEESVQDKNTNTLFSVKLEEELSVEGNTDINTDLKD T57582 TARGETID T57582 T57582 FORMERID TTDR00728 T57582 UNIPROID CNTN2_HUMAN T57582 TARGNAME Contactin-2 (CNTN2) T57582 GENENAME CNTN2 T57582 TARGTYPE Literature-reported T57582 SYNONYMS Transient axonal glycoprotein 1; TAX-1 gene; TAX-1; CNTN2; Axonin-1; Axonal glycoprotein TAG-1 T57582 FUNCTION In conjunction with another transmembrane protein, CNTNAP2, contributes to the organization of axonal domains at nodes of Ranvier by maintaining voltage-gated potassium channels at the juxtaparanodal region. May be involved in cell adhesion. T57582 PDBSTRUC 2OM5 T57582 BIOCLASS Basigin family T57582 SEQUENCE MGTATRRKPHLLLVAAVALVSSSAWSSALGSQTTFGPVFEDQPLSVLFPEESTEEQVLLACRARASPPATYRWKMNGTEMKLEPGSRHQLVGGNLVIMNPTKAQDAGVYQCLASNPVGTVVSREAILRFGFLQEFSKEERDPVKAHEGWGVMLPCNPPAHYPGLSYRWLLNEFPNFIPTDGRHFVSQTTGNLYIARTNASDLGNYSCLATSHMDFSTKSVFSKFAQLNLAAEDTRLFAPSIKARFPAETYALVGQQVTLECFAFGNPVPRIKWRKVDGSLSPQWTTAEPTLQIPSVSFEDEGTYECEAENSKGRDTVQGRIIVQAQPEWLKVISDTEADIGSNLRWGCAAAGKPRPTVRWLRNGEPLASQNRVEVLAGDLRFSKLSLEDSGMYQCVAENKHGTIYASAELAVQALAPDFRLNPVRRLIPAARGGEILIPCQPRAAPKAVVLWSKGTEILVNSSRVTVTPDGTLIIRNISRSDEGKYTCFAENFMGKANSTGILSVRDATKITLAPSSADINLGDNLTLQCHASHDPTMDLTFTWTLDDFPIDFDKPGGHYRRTNVKETIGDLTILNAQLRHGGKYTCMAQTVVDSASKEATVLVRGPPGPPGGVVVRDIGDTTIQLSWSRGFDNHSPIAKYTLQARTPPAGKWKQVRTNPANIEGNAETAQVLGLTPWMDYEFRVIASNILGTGEPSGPSSKIRTREAAPSVAPSGLSGGGGAPGELIVNWTPMSREYQNGDGFGYLLSFRRQGSTHWQTARVPGADAQYFVYSNESVRPYTPFEVKIRSYNRRGDGPESLTALVYSAEEEPRVAPTKVWAKGVSSSEMNVTWEPVQQDMNGILLGYEIRYWKAGDKEAAADRVRTAGLDTSARVSGLHPNTKYHVTVRAYNRAGTGPASPSANATTMKPPPRRPPGNISWTFSSSSLSIKWDPVVPFRNESAVTGYKMLYQNDLHLTPTLHLTGKNWIEIPVPEDIGHALVQIRTTGPGGDGIPAEVHIVRNGGTSMMVENMAVRPAPHPGTVISHSVAMLILIGSLEL T64053 TARGETID T64053 T64053 FORMERID TTDR00077 T64053 UNIPROID COX1_PLAFA T64053 TARGNAME Plasmodium Cytochrome C oxidoreductase (Malaria MT-CO1) T64053 GENENAME Malaria MT-CO1 T64053 TARGTYPE Literature-reported T64053 SYNONYMS MT-CO1; Cytochrome c oxidase subunit 1; Cytochrome c oxidase polypeptide I T64053 FUNCTION Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Subunits 1- 3 form the functional core of the enzyme complex. CO I is the catalytic subunit of the enzyme. Electrons originating in cytochrome c aretransferred via the copper A center of subunit 2 and heme A of subunit 1 to the bimetallic center formed by heme A3 and copper B. T64053 BIOCLASS Heme-copper respiratory oxidase family T64053 ECNUMBER EC 1.9.3.1 T64053 SEQUENCE MVLNRYSLITNCNHKTLGLYYLWFSFLFGSYGFLLSVILRTELYSSSLRIIAQENVNLYNMIFTIHGIIMIFFNIMPGLFGGFGNYFLPILCGSPELAYPRINSISLLLQPIAFVLVILSTAAEFGGGTGWTLYPPLSTSLMSLSPVAVDVIIFGLLVSGVASIMSSLNFITTVMHLRAKGLTLGILSVSTWSLIITSGMLLLTLPVLTGGVLMLLSDLHFNTLFFDPTFAGDPILYQHLFWFFGHPEVYILILPAFGVISHVISTNYCRNLFGNQSMILAMGCIAVLGSLVWVHHMYTTGLEVDTRAYFTSTTILISIPTGTKVFNWICTYMSSNFGMIHSSSLLSLLFICTFTFGGTTGVILGNAAIDVALHDTYYVIAHFHFVLSIGAIIGLFTTVSAFQDNFFGKNLRENSIVILWSMLFFVGVILTFLPMHFLGFNVMPRRIPDYPDALNGWNMICSIGSTMTLFGLLIFK T45158 TARGETID T45158 T45158 FORMERID TTDR01084 T45158 UNIPROID SNZ1_YEAST T45158 TARGNAME Fungal Pyridoxin biosynthesis protein SNZ1 (Fung SNZ1) T45158 GENENAME Fung SNZ1 T45158 TARGTYPE Literature-reported T45158 SYNONYMS SNZ1; PDX1 homolog 1; Fung P35 T45158 FUNCTION Catalyzes the formation of pyridoxal 5'-phosphate from ribose 5-phosphate (RBP), glyceraldehyde 3-phosphate (G3P) and ammonia. The ammonia is provided by a SNO isoform. Can also use ribulose 5-phosphate and dihydroxyacetone phosphate as substrates, resulting from enzyme-catalyzed isomerization of RBP and G3P, respectively. T45158 PDBSTRUC 3O07; 3O06; 3O05; 3FEM T45158 ECNUMBER EC 4.3.3.6 T45158 SEQUENCE MTGEDFKIKSGLAQMLKGGVIMDVVTPEQAKIAEKSGACAVMALESIPADMRKSGKVCRMSDPKMIKDIMNSVSIPVMAKVRIGHFVEAQIIEALEVDYIDESEVLTPADWTHHIEKDKFKVPFVCGAKDLGEALRRINEGAAMIRTKGEAGTGDVSEAVKHIRRITEEIKACQQLKSEDDIAKVAEEMRVPVSLLKDVLEKGKLPVVNFAAGGVATPADAALLMQLGCDGVFVGSGIFKSSNPVRLATAVVEATTHFDNPSKLLEVSSDLGELMGGVSIESISHASNGVRLSEIGW T29635 TARGETID T29635 T29635 FORMERID TTDI03341 T29635 UNIPROID KCNC4_HUMAN T29635 TARGNAME Voltage-gated potassium channel Kv3.4 (KCNC4) T29635 GENENAME KCNC4 T29635 TARGTYPE Literature-reported T29635 SYNONYMS Voltage-gated potassium channel subunit Kv3.4; Potassium voltage-gated channel subfamily C member 4; KSHIIIC; C1orf30 T29635 FUNCTION This protein mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient. T29635 PDBSTRUC 1ZTN; 1B4I; 1B4G T29635 BIOCLASS Voltage-gated ion channel T29635 SEQUENCE MISSVCVSSYRGRKSGNKPPSKTCLKEEMAKGEASEKIIINVGGTRHETYRSTLRTLPGTRLAWLADPDGGGRPETDGGGVGSSGSSGGGGCEFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELTFWGIDETDVEPCCWMTYRQHRDAEEALDIFESPDGGGSGAGPSDEAGDDERELALQRLGPHEGGAGHGAGSGGCRGWQPRMWALFEDPYSSRAARVVAFASLFFILVSITTFCLETHEAFNIDRNVTEILRVGNITSVHFRREVETEPILTYIEGVCVLWFTLEFLVRIVCCPDTLDFVKNLLNIIDFVAILPFYLEVGLSGLSSKAARDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERIGARPSDPRGNDHTDFKNIPIGFWWAVVTMTTLGYGDMYPKTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPKKRKKHVPRPAQLESPMYCKSEETSPRDSTCSDTSPPAREEGMIERKRADSKQNGDANAVLSDEEGAGLTQPLASSPTPEERRALRRSTTRDRNKKAAACFLLSTGDYACADGSVRKGTFVLRDLPLQHSPEAACPPTAGTLFLPH T29635 DRUGINFO D0Y4AS DABCO Investigative T29635 DRUGINFO D0A1IR DABCO-C16 Investigative T29635 DRUGINFO D06PZZ [14C]TEA Investigative T20221 TARGETID T20221 T20221 FORMERID TTDR00508 T20221 UNIPROID TNFC_HUMAN T20221 TARGNAME Lymphotoxin-beta (LTB) T20221 GENENAME LTB T20221 TARGTYPE Literature-reported T20221 SYNONYMS Tumor necrosis factor ligand superfamily member 3; Tumor necrosis factor C; TNF-C; LTB; LT-beta T20221 FUNCTION Cytokine that binds to LTBR/TNFRSF3. May play a specific role in immune response regulation. Provides the membrane anchor for the attachment of the heterotrimeric complex to the cell surface. Isoform 2 is probably non-functional. T20221 PDBSTRUC 4MXW T20221 BIOCLASS Cytokine: tumor necrosis factor T20221 SEQUENCE MGALGLEGRGGRLQGRGSLLLAVAGATSLVTLLLAVPITVLAVLALVPQDQGGLVTETADPGAQAQQGLGFQKLPEEEPETDLSPGLPAAHLIGAPLKGQGLGWETTKEQAFLTSGTQFSDAEGLALPQDGLYYLYCLVGYRGRAPPGGGDPQGRSVTLRSSLYRAGGAYGPGTPELLLEGAETVTPVLDPARRQGYGPLWYTSVGFGGLVQLRRGERVYVNISHPDMVDFARGKTFFGAVMVG T27577 TARGETID T27577 T27577 FORMERID TTDI03146 T27577 UNIPROID CDK18_HUMAN T27577 TARGNAME Cyclin-dependent kinase 18 (CDK18) T27577 GENENAME CDK18 T27577 TARGTYPE Literature-reported T27577 SYNONYMS Serine/threonine-protein kinase PCTAIRE-3; PCTK3; PCTAIRE3; PCTAIRE-motif protein kinase 3; Cell division protein kinase 18 T27577 FUNCTION May play a role in signal transduction cascades in terminally differentiated cells. T27577 BIOCLASS Kinase T27577 ECNUMBER EC 2.7.11.22 T27577 SEQUENCE MIMNKMKNFKRRFSLSVPRTETIEESLAEFTEQFNQLHNRRNENLQLGPLGRDPPQECSTFSPTDSGEEPGQLSPGVQFQRRQNQRRFSMEDVSKRLSLPMDIRLPQEFLQKLQMESPDLPKPLSRMSRRASLSDIGFGKLETYVKLDKLGEGTYATVFKGRSKLTENLVALKEIRLEHEEGAPCTAIREVSLLKNLKHANIVTLHDLIHTDRSLTLVFEYLDSDLKQYLDHCGNLMSMHNVKIFMFQLLRGLAYCHHRKILHRDLKPQNLLINERGELKLADFGLARAKSVPTKTYSNEVVTLWYRPPDVLLGSTEYSTPIDMWGVGCIHYEMATGRPLFPGSTVKEELHLIFRLLGTPTEETWPGVTAFSEFRTYSFPCYLPQPLINHAPRLDTDGIHLLSSLLLYESKSRMSAEAALSHSYFRSLGERVHQLEDTASIFSLKEIQLQKDPGYRGLAFQQPGRGKNRRQSIF T27577 DRUGINFO D0N3LC PMID24793884C77 Investigative T54472 TARGETID T54472 T54472 FORMERID TTDR00299 T54472 UNIPROID CDC2H_PLAFK T54472 TARGNAME Plasmodium CDK PfPK5 (Malaria PfPK5) T54472 GENENAME Malaria PfPK5 T54472 TARGTYPE Literature-reported T54472 SYNONYMS PfPK5; PK5; Cell division control protein 2 homolog; CRK2 T54472 FUNCTION It is required in higher cells for entry into S-phase and mitosis. Component of the kinase complex that phosphorylates the repetitive C-terminus of RNA polymerase II. Plays a key role in the control of the eukaryotic cell cycle. T54472 PDBSTRUC 1V0P; 1V0O; 1V0B; 1OB3; 1LCH T54472 BIOCLASS Kinase T54472 SEQUENCE MEKYHGLEKIGEGTYGVVYKAQNNYGETFALKKIRLEKEDEGIPSTTIREISILKELKHSNIVKLYDVIHTKKRLVLVFEHLDQDLKKLLDVCEGGLESVTAKSFLLQLLNGIAYCHDRRVLHRDLKPQNLLINREGELKIADFGLARAFGIPVRKYTHEVVTLWYRAPDVLMGSKKYSTTIDIWSVGCIFAEMVNGTPLFPGVSEADQLMRIFRILGTPNSKNWPNVTELPKYDPNFTVYEPLPWESFLKGLDESGIDLLSKMLKLDPNQRITAKQALEHAYFKENN T54472 DRUGINFO D0G2CT Indirubin-5-sulfonate Investigative T91130 TARGETID T91130 T91130 FORMERID TTDR01159 T91130 UNIPROID LRP1_HUMAN T91130 TARGNAME LDL receptor related protein-1 (LRP-1) T91130 GENENAME LRP1 T91130 TARGTYPE Literature-reported T91130 SYNONYMS Alpha-2-macroglobulin receptor; A2MR T91130 FUNCTION Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission. Acts as an alpha-2-macroglobulin receptor. Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. T91130 PDBSTRUC 2KNY; 2KNX; 2FYL; 2FYJ; 1J8E T91130 BIOCLASS Low density lipoprotein receptor T91130 SEQUENCE MLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEAPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGCQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYLLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANETVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDIDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTKLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFENYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACENDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRGMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDGIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNGWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFYDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVTLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGVTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRFKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDDCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQFKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRWRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENCESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAPGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGESCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDKIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTTLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLTVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNTLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRTVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVLDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTNKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSGQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLWWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQLCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSGTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIYWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDGTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFSVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCAVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNLNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVENVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLDECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDKIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDIPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAVNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVSNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCSATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNYFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCGDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDDREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDGENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCHINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTHGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAVALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCDKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSRSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLFEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGGCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCGDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKCTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCVDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDCADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTDNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDPKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNNTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESVRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMPRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDWGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPIVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYHQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTCNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPTGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQMAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGHCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGVVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPTNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA T85273 TARGETID T85273 T85273 FORMERID TTDR01130 T85273 UNIPROID FOXM1_HUMAN T85273 TARGNAME Forkhead box protein M1 (FOXM1) T85273 GENENAME FOXM1 T85273 TARGTYPE Literature-reported T85273 SYNONYMS Winged-helix factor from INS-1 cells; Winged helix factor from INS-1 cells; WIN; Transcription factor Trident; MPP2; MPM-2 reactive phosphoprotein 2; M-phase phosphoprotein 2; Hepatocyte nuclear factor 3 forkhead homolog 11; HNF-3/fork-head homolog-11; HNF-3/fork-head homolog 11; HFH11; HFH-11; Foxm1b; Foxm1; Forkhead-related protein FKHL16; Forkhead Box (Fox) m1b; FKHL16 T85273 FUNCTION Plays a role in the control of cell proliferation. Plays also a role in DNA breaks repair participating in the DNA damage checkpoint response. Transcriptional factor regulating the expression of cell cycle genes essential for DNA replication and mitosis. T85273 PDBSTRUC 3G73 T85273 SEQUENCE MKTSPRRPLILKRRRLPLPVQNAPSETSEEEPKRSPAQQESNQAEASKEVAESNSCKFPAGIKIINHPTMPNTQVVAIPNNANIHSIITALTAKGKESGSSGPNKFILISCGGAPTQPPGLRPQTQTSYDAKRTEVTLETLGPKPAARDVNLPRPPGALCEQKRETCADGEAAGCTINNSLSNIQWLRKMSSDGLGSRSIKQEMEEKENCHLEQRQVKVEEPSRPSASWQNSVSERPPYSYMAMIQFAINSTERKRMTLKDIYTWIEDHFPYFKHIAKPGWKNSIRHNLSLHDMFVRETSANGKVSFWTIHPSANRYLTLDQVFKPLDPGSPQLPEHLESQQKRPNPELRRNMTIKTELPLGARRKMKPLLPRVSSYLVPIQFPVNQSLVLQPSVKVPLPLAASLMSSELARHSKRVRIAPKVLLAEEGIAPLSSAGPGKEEKLLFGEGFSPLLPVQTIKEEEIQPGEEMPHLARPIKVESPPLEEWPSPAPSFKEESSHSWEDSSQSPTPRPKKSYSGLRSPTRCVSEMLVIQHRERRERSRSRRKQHLLPPCVDEPELLFSEGPSTSRWAAELPFPADSSDPASQLSYSQEVGGPFKTPIKETLPISSTPSKSVLPRTPESWRLTPPAKVGGLDFSPVQTSQGASDPLPDPLGLMDLSTTPLQSAPPLESPQRLLSSEPLDLISVPFGNSSPSDIDVPKPGSPEPQVSGLAANRSLTEGLVLDTMNDSLSKILLDISFPGLDEDPLGPDNINWSQFIPELQ T85273 DRUGINFO D01FSW (D-Arg)(9)-p19(ARF) 26-44 peptide Investigative T77537 TARGETID T77537 T77537 FORMERID TTDI01356 T77537 UNIPROID ITK_HUMAN T77537 TARGNAME Tyrosine-protein kinase ITK (ITK) T77537 GENENAME ITK T77537 TARGTYPE Literature-reported T77537 SYNONYMS Tyrosine-protein kinase Lyk; Tyrosine-protein kinase ITK/TSK; LYK; Kinase EMT; Interleukin-2-inducible T-cell kinase; IL-2-inducible T-cell kinase T77537 FUNCTION Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. Once activated, phosphorylates PLCG1, leading to the activation of this lipase and subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. Phosphorylates 2 essential adapter proteins: the linker for activation of T-cells/LAT protein and LCP2. Then, a large number of signaling molecules such as VAV1 are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Phosphorylates TBX21 at 'Tyr-530' and mediates its interaction with GATA3 (By similarity). T77537 PDBSTRUC 4RFM; 4QD6; 4PQN; 4PPC; 4PPB T77537 ECNUMBER EC 2.7.10.2 T77537 SEQUENCE MNNFILLEEQLIKKSQQKRRTSPSNFKVRFFVLTKASLAYFEDRHGKKRTLKGSIELSRIKCVEIVKSDISIPCHYKYPFQVVHDNYLLYVFAPDRESRQRWVLALKEETRNNNSLVPKYHPNFWMDGKWRCCSQLEKLATGCAQYDPTKNASKKPLPPTPEDNRRPLWEPEETVVIALYDYQTNDPQELALRRNEEYCLLDSSEIHWWRVQDRNGHEGYVPSSYLVEKSPNNLETYEWYNKSISRDKAEKLLLDTGKEGAFMVRDSRTAGTYTVSVFTKAVVSENNPCIKHYHIKETNDNPKRYYVAEKYVFDSIPLLINYHQHNGGGLVTRLRYPVCFGRQKAPVTAGLRYGKWVIDPSELTFVQEIGSGQFGLVHLGYWLNKDKVAIKTIREGAMSEEDFIEEAEVMMKLSHPKLVQLYGVCLEQAPICLVFEFMEHGCLSDYLRTQRGLFAAETLLGMCLDVCEGMAYLEEACVIHRDLAARNCLVGENQVIKVSDFGMTRFVLDDQYTSSTGTKFPVKWASPEVFSFSRYSSKSDVWSFGVLMWEVFSEGKIPYENRSNSEVVEDISTGFRLYKPRLASTHVYQIMNHCWKERPEDRPAFSRLLRQLAEIAESGL T77745 TARGETID T77745 T77745 FORMERID TTDI02401 T77745 UNIPROID BST2_HUMAN T77745 TARGNAME Bone marrow stromal antigen 2 (BST2) T77745 GENENAME BST2 T77745 TARGTYPE Literature-reported T77745 SYNONYMS Tetherin; HM1.24 antigen; CD317; BST2 T77745 FUNCTION IFN-induced antiviral host restriction factor which efficiently blocks the release of diverse mammalian enveloped viruses by directly tethering nascent virions to the membranes of infected cells. Acts as a direct physical tether, holding virions to the cell membrane and linking virions to each other. The tethered virions can be internalized by endocytosis and subsequently degraded or they can remain on the cell surface. In either case, their spread as cell-free virions is restricted. Its target viruses belong to diverse families, including retroviridae: human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), simian immunodeficiency viruses (SIVs), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), prototype foamy virus (PFV), Mason- Pfizer monkey virus (MPMV), human T-cell leukemia virus type 1 (HTLV-1), Rous sarcoma virus (RSV) and murine leukemia virus (MLV), flavivirideae: hepatitis C virus (HCV), filoviridae: ebola virus (EBOV) and marburg virus (MARV), arenaviridae: lassa virus (LASV) and machupo virus (MACV), herpesviridae: kaposis sarcoma- associated herpesvirus (KSHV), rhabdoviridae: vesicular stomatitis virus (VSV), orthomyxoviridae: influenza A virus, and paramyxoviridae: nipah virus. Can inhibit cell surface proteolytic activity of MMP14 causing decreased activation of MMP15 which results in inhibition of cell growth and migration. Can stimulate signaling by LILRA4/ILT7 and consequently provide negative feedback to the production of IFN by plasmacytoid dendritic cells in response to viral infection. Plays a role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. Isoform 1 and isoform 2 are both effective viral restriction factors but have differing antiviral and signaling activities. Isoform 2 is resistant to HIV-1 Vpu-mediated degradation and restricts HIV-1 viral budding in the presence of Vpu. Isoform 1 acts as an activator of NF-kappa-B and this activity is inhibited by isoform 2. T77745 PDBSTRUC 6DFF; 6D84; 6D83; 6CRI; 6CM9 T77745 BIOCLASS Tetherin family T77745 SEQUENCE MASTSYDYCRVPMEDGDKRCKLLLGIGILVLLIIVILGVPLIIFTIKANSEACRDGLRAVMECRNVTHLLQQELTEAQKGFQDVEAQAATCNHTVMALMASLDAEKAQGQKKVEELEGEITTLNHKLQDASAEVERLRRENQVLSVRIADKKYYPSSQDSSSAAAPQLLIVLLGLSALLQ T49649 TARGETID T49649 T49649 FORMERID TTDR00636 T49649 UNIPROID LAC1_BOTFU T49649 TARGNAME Fungal Laccase (Fung lcc1) T49649 GENENAME Fung lcc1 T49649 TARGTYPE Literature-reported T49649 SYNONYMS lcc1; Urishiol oxidase; Fragment; Diphenol oxidase; Benzenediol:oxygen oxidoreductase T49649 FUNCTION Lignin degradation and detoxification of lignin-derived products. T49649 BIOCLASS Diphenol donor oxidoreductase T49649 ECNUMBER EC 1.10.3.2 T49649 SEQUENCE MKNSFFSSLAKFASLSLAFALPTAEVIPSALEERQSCANTATTRSCWGQYSASTNSYTTVPKTGYWLVVQNTTLSADGVSRPTLNFNGTIPGPQITADWGDDVIVHVTNKLTSNGTSIHWHGIRQLNNAQYDGVPGITQCPIAPGGTLTYKFHADNYGSSWYHSHFILQYGDGLFGPLVINGPATANYDVDLGMLFLNDWNHVPVQSLWDKAKTGAPPTLLTGLMNGTNTYNGAGKKFQTTFTPGLKYRIRVVNTAVDGHFQFSIDGHSFQVIAMDFVPIVPYNATSILVSIAQRYDIIVTANAAVGNYWIRAGWQTACSGNTNAANITGILRYTGSSSTADPTTTSTVTASTSCLDEPLASLVPFVPINPVASSIMKTTLTTGGGQWLFNGSSLLLNWTDPTLLTVLNSGNIWPTEYNVIPIESTTANKGWAVLAISGPNGPNHPIHLHGHDFWTLSQGTGAYTATTALNLVNPPRRDVMTLPTGGHLVIAFQIDNPGSWLMHCHIAWHASEGLALQFVESESSILPTIGTADVSTFQNTCAAWKAWTPTEPFPQDDSGI T72850 TARGETID T72850 T72850 FORMERID TTDR00040 T72850 UNIPROID FOXO1_HUMAN T72850 TARGNAME Forkhead box protein O1A (FOXO1) T72850 GENENAME FOXO1 T72850 TARGTYPE Literature-reported T72850 SYNONYMS Forkhead in rhabdomyosarcoma; Forkhead box protein O1; FOXO1A; FKHR T72850 FUNCTION Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress. Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'. Activity suppressed by insulin. Main regulator of redox balance and osteoblast numbers and controls bone mass. Orchestrates the endocrine function of the skeleton in regulating glucose metabolism. Acts synergistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity. Also suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP. In hepatocytes, promotes gluconeogenesis by acting together with PPARGC1A and CEBPA to activate the expression of genes such as IGFBP1, G6PC and PCK1. Important regulator of cell death acting downstream of CDK1, PKB/AKT1 and STK4/MST1. Promotes neural cell death. Mediates insulin action on adipose tissue. Regulates the expression of adipogenic genes such as PPARG during preadipocyte differentiation and, adipocyte size and adipose tissue-specific gene expression in response to excessive calorie intake. Regulates the transcriptional activity of GADD45A and repair of nitric oxide-damaged DNA in beta-cells. Required for the autophagic cell death induction in response to starvation or oxidative stress in a transcription-independent manner. Mediates the function of MLIP in cardiomyocytes hypertrophy and cardiac remodeling (By similarity). T72850 PDBSTRUC 5DUI; 4LG0; 3COA; 3CO7; 3CO6 T72850 SEQUENCE MAEAPQVVEIDPDFEPLPRPRSCTWPLPRPEFSQSNSATSSPAPSGSAAANPDAAAGLPSASAAAVSADFMSNLSLLEESEDFPQAPGSVAAAVAAAAAAAATGGLCGDFQGPEAGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQIYEWMVKSVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQNEGTGKSSWWMLNPEGGKSGKSPRRRAASMDNNSKFAKSRSRAAKKKASLQSGQEGAGDSPGSQFSKWPASPGSHSNDDFDNWSTFRPRTSSNASTISGRLSPIMTEQDDLGEGDVHSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQSSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQTLQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSRVLGQNVMMGPNSVMSTYGSQASHNKMMNPSSHTHPGHAQQTSAVNGRPLPHTVSTMPHTSGMNRLTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYGRMGLLHQEKLPSDLDGMFIERLDCDMESIIRNDLMDGDTLDFNFDNVLPNQSFPHSVKTTTHSWVSG T72850 DRUGINFO D0W9KE AS-1708727 Investigative T93716 TARGETID T93716 T93716 FORMERID TTDR00207 T93716 UNIPROID KIF5A_HUMAN T93716 TARGNAME Kinesin heavy chain neuron-specific 1 (KIF5A) T93716 GENENAME KIF5A T93716 TARGTYPE Literature-reported T93716 SYNONYMS NKHC; Kinesin heavy chain isoform 5A; KIF5A T93716 FUNCTION Microtubule-dependent motor required for slow axonal transport of neurofilament proteins (NFH, NFM and NFL). T93716 PDBSTRUC 4UY0; 4UXY; 4UXT T93716 BIOCLASS Kinesin-like protein family T93716 SEQUENCE MAETNNECSIKVLCRFRPLNQAEILRGDKFIPIFQGDDSVVIGGKPYVFDRVFPPNTTQEQVYHACAMQIVKDVLAGYNGTIFAYGQTSSGKTHTMEGKLHDPQLMGIIPRIARDIFNHIYSMDENLEFHIKVSYFEIYLDKIRDLLDVTKTNLSVHEDKNRVPFVKGCTERFVSSPEEILDVIDEGKSNRHVAVTNMNEHSSRSHSIFLINIKQENMETEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGTKSYVPYRDSKMTRILQDSLGGNCRTTMFICCSPSSYNDAETKSTLMFGQRAKTIKNTASVNLELTAEQWKKKYEKEKEKTKAQKETIAKLEAELSRWRNGENVPETERLAGEEAALGAELCEETPVNDNSSIVVRIAPEERQKYEEEIRRLYKQLDDKDDEINQQSQLIEKLKQQMLDQEELLVSTRGDNEKVQRELSHLQSENDAAKDEVKEVLQALEELAVNYDQKSQEVEEKSQQNQLLVDELSQKVATMLSLESELQRLQEVSGHQRKRIAEVLNGLMKDLSEFSVIVGNGEIKLPVEISGAIEEEFTVARLYISKIKSEVKSVVKRCRQLENLQVECHRKMEVTGRELSSCQLLISQHEAKIRSLTEYMQSVELKKRHLEESYDSLSDELAKLQAQETVHEVALKDKEPDTQDADEVKKALELQMESHREAHHRQLARLRDEINEKQKTIDELKDLNQKLQLELEKLQADYEKLKSEEHEKSTKLQELTFLYERHEQSKQDLKGLEETVARELQTLHNLRKLFVQDVTTRVKKSAEMEPEDSGGIHSQKQKISFLENNLEQLTKVHKQLVRDNADLRCELPKLEKRLRATAERVKALEGALKEAKEGAMKDKRRYQQEVDRIKEAVRYKSSGKRGHSAQIAKPVRPGHYPASSPTNPYGTRSPECISYTNSLFQNYQNLYLQATPSSTSDMYFANSCTSSGATSSGGPLASYQKANMDNGNATDINDNRSDLPCGYEAEDQAKLFPLHQETAAS T58393 TARGETID T58393 T58393 FORMERID TTDI00023 T58393 UNIPROID CNTN1_HUMAN T58393 TARGNAME Contactin-1 (CNTN1) T58393 GENENAME CNTN1 T58393 TARGTYPE Literature-reported T58393 SYNONYMS Neural cell surface protein F3; Glycoprotein gp135; CNTN1 T58393 FUNCTION Contactins mediate cell surface interactions during nervous system development. Involved in the formation of paranodal axo-glial junctions in myelinated peripheral nerves and in the signaling between axons and myelinating glial cells via its association with CNTNAP1. Participates in oligodendrocytes generation by acting as a ligand of NOTCH1. Its association with NOTCH1 promotes NOTCH1 activation through the released notch intracellular domain (NICD) and subsequent translocation to the nucleus. Interaction with TNR induces a repulsion of neurons and an inhibition of neurite outgrowth. T58393 PDBSTRUC 3S97; 2EE2 T58393 BIOCLASS Immunoglobulin T58393 SEQUENCE MKMWLLVSHLVIISITTCLAEFTWYRRYGHGVSEEDKGFGPIFEEQPINTIYPEESLEGKVSLNCRARASPFPVYKWRMNNGDVDLTSDRYSMVGGNLVINNPDKQKDAGIYYCLASNNYGMVRSTEATLSFGYLDPFPPEERPEVRVKEGKGMVLLCDPPYHFPDDLSYRWLLNEFPVFITMDKRRFVSQTNGNLYIANVEASDKGNYSCFVSSPSITKSVFSKFIPLIPIPERTTKPYPADIVVQFKDVYALMGQNVTLECFALGNPVPDIRWRKVLEPMPSTAEISTSGAVLKIFNIQLEDEGIYECEAENIRGKDKHQARIYVQAFPEWVEHINDTEVDIGSDLYWPCVATGKPIPTIRWLKNGYAYHKGELRLYDVTFENAGMYQCIAENTYGAIYANAELKILALAPTFEMNPMKKKILAAKGGRVIIECKPKAAPKPKFSWSKGTEWLVNSSRILIWEDGSLEINNITRNDGGIYTCFAENNRGKANSTGTLVITDPTRIILAPINADITVGENATMQCAASFDPALDLTFVWSFNGYVIDFNKENIHYQRNFMLDSNGELLIRNAQLKHAGRYTCTAQTIVDNSSASADLVVRGPPGPPGGLRIEDIRATSVALTWSRGSDNHSPISKYTIQTKTILSDDWKDAKTDPPIIEGNMEAARAVDLIPWMEYEFRVVATNTLGRGEPSIPSNRIKTDGAAPNVAPSDVGGGGGRNRELTITWAPLSREYHYGNNFGYIVAFKPFDGEEWKKVTVTNPDTGRYVHKDETMSPSTAFQVKVKAFNNKGDGPYSLVAVINSAQDAPSEAPTEVGVKVLSSSEISVHWEHVLEKIVESYQIRYWAAHDKEEAANRVQVTSQEYSARLENLLPDTQYFIEVGACNSAGCGPPSDMIEAFTKKAPPSQPPRIISSVRSGSRYIITWDHVVALSNESTVTGYKVLYRPDGQHDGKLYSTHKHSIEVPIPRDGEYVVEVRAHSDGGDGVVSQVKISGAPTLSPSLLGLLLPAFGILVYLEF T58178 TARGETID T58178 T58178 FORMERID TTDI03220 T58178 UNIPROID GRIK2_HUMAN T58178 TARGNAME Glutamate receptor ionotropic kainate 2 (GRIK2) T58178 GENENAME GRIK2 T58178 TARGTYPE Literature-reported T58178 SYNONYMS Glutamate receptor ionotropic, kainate 2; Glutamate receptor 6; GluR6; GluR-6; GluK2; Excitatory amino acid receptor 4; EAA4 T58178 FUNCTION L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. May be involved in the transmission of light information from the retina to the hypothalamus. Modulates cell surface expression of NETO2. Ionotropic glutamate receptor. T58178 PDBSTRUC 5CMM; 3QXM T58178 BIOCLASS Glutamate-gated ion channel T58178 SEQUENCE MKIIFPILSNPVFRRTVKLLLCLLWIGYSQGTTHVLRFGGIFEYVESGPMGAEELAFRFAVNTINRNRTLLPNTTLTYDTQKINLYDSFEASKKACDQLSLGVAAIFGPSHSSSANAVQSICNALGVPHIQTRWKHQVSDNKDSFYVSLYPDFSSLSRAILDLVQFFKWKTVTVVYDDSTGLIRLQELIKAPSRYNLRLKIRQLPADTKDAKPLLKEMKRGKEFHVIFDCSHEMAAGILKQALAMGMMTEYYHYIFTTLDLFALDVEPYRYSGVNMTGFRILNTENTQVSSIIEKWSMERLQAPPKPDSGLLDGFMTTDAALMYDAVHVVSVAVQQFPQMTVSSLQCNRHKPWRFGTRFMSLIKEAHWEGLTGRITFNKTNGLRTDFDLDVISLKEEGLEKIGTWDPASGLNMTESQKGKPANITDSLSNRSLIVTTILEEPYVLFKKSDKPLYGNDRFEGYCIDLLRELSTILGFTYEIRLVEDGKYGAQDDANGQWNGMVRELIDHKADLAVAPLAITYVREKVIDFSKPFMTLGISILYRKPNGTNPGVFSFLNPLSPDIWMYILLAYLGVSCVLFVIARFSPYEWYNPHPCNPDSDVVENNFTLLNSFWFGVGALMQQGSELMPKALSTRIVGGIWWFFTLIIISSYTANLAAFLTVERMESPIDSADDLAKQTKIEYGAVEDGATMTFFKKSKISTYDKMWAFMSSRRQSVLVKSNEEGIQRVLTSDYAFLMESTTIEFVTQRNCNLTQIGGLIDSKGYGVGTPMGSPYRDKITIAILQLQEEGKLHMMKEKWWRGNGCPEEESKEASALGVQNIGGIFIVLAAGLVLSVFVAVGEFLYKSKKNAQLEKRSFCSAMVEELRMSLKCQRRLKHKPQAPVIVKTEEVINMHTFNDRRLPGKETMA T58178 DRUGINFO D00VEZ 2,4-epi-neodysiherbaine Investigative T58178 DRUGINFO D09KRH domoic acid Investigative T58178 DRUGINFO D0K6AF dysiherbaine Investigative T58178 DRUGINFO D0S8AN SYM2081 Investigative T58178 DRUGINFO D04PFN [3H]kainate Investigative T23606 TARGETID T23606 T23606 FORMERID TTDI03492 T23606 UNIPROID KGP2_HUMAN T23606 TARGNAME Protein kinase G2 (PRKG2) T23606 GENENAME PRKG2 T23606 TARGTYPE Literature-reported T23606 SYNONYMS cGMP-dependent protein kinase II; cGMP-dependent protein kinase 2; cGKII; cGK2; cGK 2; PRKGR2 T23606 FUNCTION Crucial regulator of intestinal secretion and bone growth (By similarity). Phosphorylates and activates CFTR on the plasma membrane. Plays a key role in intestinal secretion by regulating cGMP-dependent translocation of CFTR in jejunum (By similarity). Acts downstream of NMDAR to activate the plasma membrane accumulation of GRIA1/GLUR1 in synapse and increase synaptic plasticity. Phosphorylates GRIA1/GLUR1 at Ser-863 (By similarity). Acts as regulator of gene expression and activator of the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2 in mechanically stimulated osteoblasts. Under fluid shear stress, mediates ERK activation and subsequent induction of FOS, FOSL1/FRA1, FOSL2/FRA2 and FOSB that play a key role in the osteoblast anabolic response to mechanical stimulation (By similarity). T23606 PDBSTRUC 6BQ8; 5JIZ; 5JIX; 5C8W; 5C6C T23606 ECNUMBER EC 2.7.11.12 T23606 SEQUENCE MGNGSVKPKHSKHPDGHSGNLTTDALRNKVTELERELRRKDAEIQEREYHLKELREQLSKQTVAIAELTEELQNKCIQLNKLQDVVHMQGGSPLQASPDKVPLEVHRKTSGLVSLHSRRGAKAGVSAEPTTRTYDLNKPPEFSFEKARVRKDSSEKKLITDALNKNQFLKRLDPQQIKDMVECMYGRNYQQGSYIIKQGEPGNHIFVLAEGRLEVFQGEKLLSSIPMWTTFGELAILYNCTRTASVKAITNVKTWALDREVFQNIMRRTAQARDEQYRNFLRSVSLLKNLPEDKLTKIIDCLEVEYYDKGDYIIREGEEGSTFFILAKGKVKVTQSTEGHDQPQLIKTLQKGEYFGEKALISDDVRSANIIAEENDVACLVIDRETFNQTVGTFEELQKYLEGYVANLNRDDEKRHAKRSMSNWKLSKALSLEMIQLKEKVARFSSSSPFQNLEIIATLGVGGFGRVELVKVKNENVAFAMKCIRKKHIVDTKQQEHVYSEKRILEELCSPFIVKLYRTFKDNKYVYMLLEACLGGELWSILRDRGSFDEPTSKFCVACVTEAFDYLHRLGIIYRDLKPENLILDAEGYLKLVDFGFAKKIGSGQKTWTFCGTPEYVAPEVILNKGHDFSVDFWSLGILVYELLTGNPPFSGVDQMMTYNLILKGIEKMDFPRKITRRPEDLIRRLCRQNPTERLGNLKNGINDIKKHRWLNGFNWEGLKARSLPSPLQRELKGPIDHSYFDKYPPEKGMPPDELSGWDKDF T23606 DRUGINFO D0N1UU PMID20471253C32 Investigative T23619 TARGETID T23619 T23619 FORMERID TTDI00007 T23619 UNIPROID MTA1_HUMAN T23619 TARGNAME Metastasis associated gene-1 (MTA1) T23619 GENENAME MTA1 T23619 TARGTYPE Literature-reported T23619 SYNONYMS Metastasisassociated protein MTA1; Metastasis-associated protein MTA1 T23619 FUNCTION As a part of the histone-deacetylase multiprotein complex (NuRD), regulates transcription of its targets by modifying the acetylation status of the target chromatin and cofactor accessibility to the target DNA. In conjunction with other components of NuRD, acts as a transcriptional corepressor of BRCA1, ESR1, TFF1 and CDKN1A. Acts as a transcriptional coactivator of BCAS3, PAX5 and SUMO2, independent of the NuRD complex. Stimulates the expression of WNT1 by inhibiting the expression of its transcriptional corepressor SIX3. Regulates p53-dependent and -independent DNA repair processes following genotoxic stress. Regulates the stability and function of p53/TP53 by inhibiting its ubiquitination by COP1 and MDM2 thereby regulating the p53-dependent DNA repair. Plays an important role in tumorigenesis, tumor invasion, and metastasis. Involved in the epigenetic regulation of ESR1 expression in breast cancer in a TFAP2C, IFI16 and HDAC4/5/6-dependent manner. Plays a role in the regulation of the circadian clock and is essential for the generation and maintenance of circadian rhythms under constant light and for normal entrainment of behavior to light-dark (LD) cycles. Positively regulates the CLOCK-ARNTL/BMAL1 heterodimer mediated transcriptional activation of its own transcription and the transcription of CRY1. Regulates deacetylation of ARNTL/BMAL1 by regulating SIRT1 expression, resulting in derepressing CRY1-mediated transcription repression. Isoform Short binds to ESR1 and sequesters it in the cytoplasm and enhances its non-genomic responses. With TFCP2L1, promotes establishment and maintenance of pluripotency in embryonic stem cells (ESCs) and inhibits endoderm differentiation. Transcriptional coregulator which can act as both a transcriptional corepressor and coactivator. T23619 PDBSTRUC 6G16; 5ICN; 5FXY; 4PC0; 4PBZ T23619 SEQUENCE MAANMYRVGDYVYFENSSSNPYLIRRIEELNKTANGNVEAKVVCFYRRRDISSTLIALADKHATLSVCYKAGPGADNGEEGEIEEEMENPEMVDLPEKLKHQLRHRELFLSRQLESLPATHIRGKCSVTLLNETESLKSYLEREDFFFYSLVYDPQQKTLLADKGEIRVGNRYQADITDLLKEGEEDGRDQSRLETQVWEAHNPLTDKQIDQFLVVARSVGTFARALDCSSSVRQPSLHMSAAAASRDITLFHAMDTLHKNIYDISKAISALVPQGGPVLCRDEMEEWSASEANLFEEALEKYGKDFTDIQQDFLPWKSLTSIIEYYYMWKTTDRYVQQKRLKAAEAESKLKQVYIPNYNKPNPNQISVNNVKAGVVNGTGAPGQSPGAGRACESCYTTQSYQWYSWGPPNMQCRLCASCWTYWKKYGGLKMPTRLDGERPGPNRSNMSPHGLPARSSGSPKFAMKTRQAFYLHTTKLTRIARRLCREILRPWHAARHPYLPINSAAIKAECTARLPEASQSPLVLKQAVRKPLEAVLRYLETHPRPPKPDPVKSVSSVLSSLTPAKVAPVINNGSPTILGKRSYEQHNGVDGNMKKRLLMPSRGLANHGQARHMGPSRNLLLNGKSYPTKVRLIRGGSLPPVKRRRMNWIDAPDDVFYMATEETRKIRKLLSSSETKRAARRPYKPIALRQSQALPPRPPPPAPVNDEPIVIED T92794 TARGETID T92794 T92794 UNIPROID UT1_HUMAN T92794 TARGNAME Urea transporter 1 (SLC14A1) T92794 GENENAME SLC14A1 T92794 TARGTYPE Literature-reported T92794 SYNONYMS Urea transporter, erythrocyte; UTE; UT1; Solute carrier family 14 member 1; RACH1; JK; HUT11 T92794 FUNCTION Urea channel that facilitates transmembrane urea transport down a concentration gradient. A constriction of the transmembrane channel functions as selectivity filter through which urea is expected to pass in dehydrated form. The rate of urea conduction is increased by hypotonic stress. Plays an important role in the kidney medulla collecting ducts, where it allows rapid equilibration between the lumen of the collecting ducts and the interstitium, and thereby prevents water loss driven by the high concentration of urea in the urine. Facilitates urea transport across erythrocyte membranes. May also play a role in transmembrane water transport, possibly by indirect means. T92794 PDBSTRUC 6QD5 T92794 BIOCLASS Urea transporter family T92794 SEQUENCE MEDSPTMVRVDSPTMVRGENQVSPCQGRRCFPKALGYVTGDMKELANQLKDKPVVLQFIDWILRGISQVVFVNNPVSGILILVGLLVQNPWWALTGWLGTVVSTLMALLLSQDRSLIASGLYGYNATLVGVLMAVFSDKGDYFWWLLLPVCAMSMTCPIFSSALNSMLSKWDLPVFTLPFNMALSMYLSATGHYNPFFPAKLVIPITTAPNISWSDLSALELLKSIPVGVGQIYGCDNPWTGGIFLGAILLSSPLMCLHAAIGSLLGIAAGLSLSAPFEDIYFGLWGFNSSLACIAMGGMFMALTWQTHLLALGCALFTAYLGVGMANFMAEVGLPACTWPFCLATLLFLIMTTKNSNIYKMPLSKVTYPEENRIFYLQAKKRMVESPL T02484 TARGETID T02484 T02484 FORMERID TTDI01479 T02484 UNIPROID NNTM_HUMAN T02484 TARGNAME Pyridine nucleotide transhydrogenase (NNT) T02484 GENENAME NNT T02484 TARGTYPE Literature-reported T02484 SYNONYMS Nicotinamide nucleotide transhydrogenase; NAD(P) transhydrogenase, mitochondrial T02484 FUNCTION The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane. May play a role in reactive oxygen species (ROS) detoxification in the adrenal gland. T02484 PDBSTRUC 1U31; 1PT9; 1DJL T02484 ECNUMBER EC 7.1.1.1 T02484 SEQUENCE MANLLKTVVTGCSCPLLSNLGSCKGLRVKKDFLRTFYTHQELWCKAPVKPGIPYKQLTVGVPKEIFQNEKRVALSPAGVQNLVKQGFNVVVESGAGEASKFSDDHYRVAGAQIQGAKEVLASDLVVKVRAPMVNPTLGVHEADLLKTSGTLISFIYPAQNPELLNKLSQRKTTVLAMDQVPRVTIAQGYDALSSMANIAGYKAVVLAANHFGRFFTGQITAAGKVPPAKILIVGGGVAGLASAGAAKSMGAIVRGFDTRAAALEQFKSLGAEPLEVDLKESGEGQGGYAKEMSKEFIEAEMKLFAQQCKEVDILISTALIPGKKAPVLFNKEMIESMKEGSVVVDLAAEAGGNFETTKPGELYIHKGITHIGYTDLPSRMATQASTLYSNNITKLLKAISPDKDNFYFDVKDDFDFGTMGHVIRGTVVMKDGKVIFPAPTPKNIPQGAPVKQKTVAELEAEKAATITPFRKTMSTASAYTAGLTGILGLGIAAPNLAFSQMVTTFGLAGIVGYHTVWGVTPALHSPLMSVTNAISGLTAVGGLALMGGHLYPSTTSQGLAALAAFISSVNIAGGFLVTQRMLDMFKRPTDPPEYNYLYLLPAGTFVGGYLAALYSGYNIEQIMYLGSGLCCVGALAGLSTQGTARLGNALGMIGVAGGLAATLGVLKPGPELLAQMSGAMALGGTIGLTIAKRIQISDLPQLVAAFHSLVGLAAVLTCIAEYIIEYPHFATDAAANLTKIVAYLGTYIGGVTFSGSLIAYGKLQGLLKSAPLLLPGRHLLNAGLLAASVGGIIPFMVDPSFTTGITCLGSVSALSAVMGVTLTAAIGGADMPVVITVLNSYSGWALCAEGFLLNNNLLTIVGALIGSSGAILSYIMCVAMNRSLANVILGGYGTTSTAGGKPMEISGTHTEINLDNAIDMIREANSIIITPGYGLCAAKAQYPIADLVKMLTEQGKKVRFGIHPVAGRMPGQLNVLLAEAGVPYDIVLEMDEINHDFPDTDLVLVIGANDTVNSAAQEDPNSIIAGMPVLEVWKSKQVIVMKRSLGVGYAAVDNPIFYKPNTAMLLGDAKKTCDALQAKVRESYQK T04499 TARGETID T04499 T04499 FORMERID TTDR00891 T04499 UNIPROID KSR1_HUMAN T04499 TARGNAME Kinase suppressor of Ras-1 (KSR1) T04499 GENENAME KSR1 T04499 TARGTYPE Literature-reported T04499 SYNONYMS Kinase suppressor of Ras 1; KSR T04499 FUNCTION Promotes phosphorylation of Raf family members and activation of downstream MAP kinases. Promotes activation of MAPK1 and/or MAPK3, both in response to EGF and to cAMP. Does not have kinase activity by itself. Scaffolding protein that is part of a multiprotein signaling complex. T04499 PDBSTRUC 5VYK T04499 BIOCLASS Kinase T04499 SEQUENCE MDRAALRAAAMGEKKEGGGGGDAAAAEGGAGAAASRALQQCGQLQKLIDISIGSLRGLRTKCAVSNDLTQQEIRTLEAKLVRYICKQRQCKLSVAPGERTPELNSYPRFSDWLYTFNVRPEVVQEIPRDLTLDALLEMNEAKVKETLRRCGASGDECGRLQYALTCLRKVTGLGGEHKEDSSWSSLDARRESGSGPSTDTLSAASLPWPPGSSQLGRAGNSAQGPRSISVSALPASDSPTPSFSEGLSDTCIPLHASGRLTPRALHSFITPPTTPQLRRHTKLKPPRTPPPPSRKVFQLLPSFPTLTRSKSHESQLGNRIDDVSSMRFDLSHGSPQMVRRDIGLSVTHRFSTKSWLSQVCHVCQKSMIFGVKCKHCRLKCHNKCTKEAPACRISFLPLTRLRRTESVPSDINNPVDRAAEPHFGTLPKALTKKEHPPAMNHLDSSSNPSSTTSSTPSSPAPFPTSSNPSSATTPPNPSPGQRDSRFNFPAAYFIHHRQQFIFPVPSAGHCWKCLLIAESLKENAFNISAFAHAAPLPEAADGTRLDDQPKADVLEAHEAEAEEPEAGKSEAEDDEDEVDDLPSSRRPWRGPISRKASQTSVYLQEWDIPFEQVELGEPIGQGRWGRVHRGRWHGEVAIRLLEMDGHNQDHLKLFKKEVMNYRQTRHENVVLFMGACMNPPHLAIITSFCKGRTLHSFVRDPKTSLDINKTRQIAQEIIKGMGYLHAKGIVHKDLKSKNVFYDNGKVVITDFGLFGISGVVREGRRENQLKLSHDWLCYLAPEIVREMTPGKDEDQLPFSKAADVYAFGTVWYELQARDWPLKNQAAEASIWQIGSGEGMKRVLTSVSLGKEVSEILSACWAFDLQERPSFSLLMDMLEKLPKLNRRLSHPGHFWKSADINSSKVVPRFERFGLGVLESSNPKM T52409 TARGETID T52409 T52409 FORMERID TTDI02420 T52409 UNIPROID MTM1_HUMAN T52409 TARGNAME Myotubularin (MTM1) T52409 GENENAME MTM1 T52409 TARGTYPE Literature-reported T52409 SYNONYMS MTM1 T52409 FUNCTION Lipid phosphatase which dephosphorylates phosphatidylinositol 3-monophosphate (PI3P) and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2). Has also been shown to dephosphorylate phosphotyrosine- and phosphoserine- containing peptides. Negatively regulates EGFR degradation through regulation of EGFR trafficking from the late endosome to the lysosome. Plays a role in vacuolar formation and morphology. Regulates desmin intermediate filament assembly and architecture. Plays a role in mitochondrial morphology and positioning. Required for skeletal muscle maintenance but not for myogenesis. T52409 BIOCLASS Phosphoric monoester hydrolase T52409 ECNUMBER EC 3.1.3.95 T52409 SEQUENCE MASASTSKYNSHSLENESIKRTSRDGVNRDLTEAVPRLPGETLITDKEVIYICPFNGPIKGRVYITNYRLYLRSLETDSSLILDVPLGVISRIEKMGGATSRGENSYGLDITCKDMRNLRFALKQEGHSRRDMFEILTRYAFPLAHSLPLFAFLNEEKFNVDGWTVYNPVEEYRRQGLPNHHWRITFINKCYELCDTYPALLVVPYRASDDDLRRVATFRSRNRIPVLSWIHPENKTVIVRCSQPLVGMSGKRNKDDEKYLDVIRETNKQISKLTIYDARPSVNAVANKATGGGYESDDAYHNAELFFLDIHNIHVMRESLKKVKDIVYPNVEESHWLSSLESTHWLEHIKLVLTGAIQVADKVSSGKSSVLVHCSDGWDRTAQLTSLAMLMLDSFYRSIEGFEILVQKEWISFGHKFASRIGHGDKNHTDADRSPIFLQFIDCVWQMSKQFPTAFEFNEQFLIIILDHLYSCRFGTFLFNCESARERQKVTERTVSLWSLINSNKEKFKNPFYTKEINRVLYPVASMRHLELWVNYYIRWNPRIKQQQPNPVEQRYMELLALRDEYIKRLEELQLANSAKLSDPPTSPSSPSQMMPHVQTHF T24965 TARGETID T24965 T24965 FORMERID TTDI03097 T24965 UNIPROID CAC1S_HUMAN T24965 TARGNAME Voltage-gated calcium channel alpha Cav1.1 (CACNA1S) T24965 GENENAME CACNA1S T24965 TARGTYPE Literature-reported T24965 SYNONYMS Voltage-gated calcium channel subunit alpha Cav1.1; Voltage-dependent L-type calcium channel subunit alpha-1S; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; CACNL1A3; CACN1; CACH1 T24965 FUNCTION Pore-forming, alpha-1S subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents in skeletal muscle. Calcium channels containing the alpha-1S subunit play an important role in excitation-contraction coupling in skeletal muscle via their interaction with RYR1, which triggers Ca(2+) release from the sarcplasmic reticulum and ultimately results in muscle contraction. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. T24965 PDBSTRUC 6B27; 2VAY T24965 BIOCLASS Voltage-gated ion channel T24965 SEQUENCE MEPSSPQDEGLRKKQPKKPVPEILPRPPRALFCLTLENPLRKACISIVEWKPFETIILLTIFANCVALAVYLPMPEDDNNSLNLGLEKLEYFFLIVFSIEAAMKIIAYGFLFHQDAYLRSGWNVLDFTIVFLGVFTVILEQVNVIQSHTAPMSSKGAGLDVKALRAFRVLRPLRLVSGVPSLQVVLNSIFKAMLPLFHIALLVLFMVIIYAIIGLELFKGKMHKTCYFIGTDIVATVENEEPSPCARTGSGRRCTINGSECRGGWPGPNHGITHFDNFGFSMLTVYQCITMEGWTDVLYWVNDAIGNEWPWIYFVTLILLGSFFILNLVLGVLSGEFTKEREKAKSRGTFQKLREKQQLDEDLRGYMSWITQGEVMDVEDFREGKLSLDEGGSDTESLYEIAGLNKIIQFIRHWRQWNRIFRWKCHDIVKSKVFYWLVILIVALNTLSIASEHHNQPLWLTRLQDIANRVLLSLFTTEMLMKMYGLGLRQYFMSIFNRFDCFVVCSGILEILLVESGAMTPLGISVLRCIRLLRIFKITKYWTSLSNLVASLLNSIRSIASLLLLLFLFIVIFALLGMQLFGGRYDFEDTEVRRSNFDNFPQALISVFQVLTGEDWTSMMYNGIMAYGGPSYPGMLVCIYFIILFVCGNYILLNVFLAIAVDNLAEAESLTSAQKAKAEEKKRRKMSKGLPDKSEEEKSTMAKKLEQKPKGEGIPTTAKLKIDEFESNVNEVKDPYPSADFPGDDEEDEPEIPLSPRPRPLAELQLKEKAVPIPEASSFFIFSPTNKIRVLCHRIVNATWFTNFILLFILLSSAALAAEDPIRADSMRNQILKHFDIGFTSVFTVEIVLKMTTYGAFLHKGSFCRNYFNMLDLLVVAVSLISMGLESSAISVVKILRVLRVLRPLRAINRAKGLKHVVQCMFVAISTIGNIVLVTTLLQFMFACIGVQLFKGKFFRCTDLSKMTEEECRGYYYVYKDGDPMQIELRHREWVHSDFHFDNVLSAMMSLFTVSTFEGWPQLLYKAIDSNAEDVGPIYNNRVEMAIFFIIYIILIAFFMMNIFVGFVIVTFQEQGETEYKNCELDKNQRQCVQYALKARPLRCYIPKNPYQYQVWYIVTSSYFEYLMFALIMLNTICLGMQHYNQSEQMNHISDILNVAFTIIFTLEMILKLMAFKARGYFGDPWNVFDFLIVIGSIIDVILSEIDTFLASSGGLYCLGGGCGNVDPDESARISSAFFRLFRVMRLIKLLSRAEGVRTLLWTFIKSFQALPYVALLIVMLFFIYAVIGMQMFGKIALVDGTQINRNNNFQTFPQAVLLLFRCATGEAWQEILLACSYGKLCDPESDYAPGEEYTCGTNFAYYYFISFYMLCAFLVINLFVAVIMDNFDYLTRDWSILGPHHLDEFKAIWAEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKFCPHRVACKRLVGMNMPLNSDGTVTFNATLFALVRTALKIKTEGNFEQANEELRAIIKKIWKRTSMKLLDQVIPPIGDDEVTVGKFYATFLIQEHFRKFMKRQEEYYGYRPKKDIVQIQAGLRTIEEEAAPEICRTVSGDLAAEEELERAMVEAAMEEGIFRRTGGLFGQVDNFLERTNSLPPVMANQRPLQFAEIEMEEMESPVFLEDFPQDPRTNPLARANTNNANANVAYGNSNHSNSHVFSSVHYEREFPEETETPATRGRALGQPCRVLGPHSKPCVEMLKGLLTQRAMPRGQAPPAPCQCPRVESSMPEDRKSSTPGSLHEETPHSRSTRENTSRCSAPATALLIQKALVRGGLGTLAADANFIMATGQALADACQMEPEEVEIMATELLKGREAPEGMASSLGCLNLGSSLGSLDQHQGSQETLIPPRL T24965 DRUGINFO D04ALU [3H](+)-cis-diltiazem Investigative T24965 DRUGINFO D06XTT FPL64176 Investigative T24965 DRUGINFO D0U7BI SZ(+)-(S)-202-791 Investigative T24965 DRUGINFO D03UJT [3H](-)devapamil Investigative T24965 DRUGINFO D0S3YP [3H](+)-isradipine Investigative T24965 DRUGINFO D02RIH (-)-(S)-BayK8644 Investigative T56035 TARGETID T56035 T56035 FORMERID TTDR00051 T56035 UNIPROID KGP1_HUMAN; KGP2_HUMAN T56035 TARGNAME cGMP-dependent protein kinase (cGK) T56035 GENENAME PRKG1; PRKG2 T56035 TARGTYPE Literature-reported T56035 SYNONYMS cGK; PRKGR T56035 FUNCTION Activated by cGMP. Phosphorylates a number of biologically important targets and is implicated in the regulation of smooth muscle relaxation, platelet function, sperm metabolism, cell division, and nucleic acid synthesis. T56035 BIOCLASS Kinase T56035 SEQUENCE MSELEEDFAKILMLKEERIKELEKRLSEKEEEIQELKRKLHKCQSVLPVPSTHIGPRTTRAQGISAEPQTYRSFHDLRQAFRKFTKSERSKDLIKEAILDNDFMKNLELSQIQEIVDCMYPVEYGKDSCIIKEGDVGSLVYVMEDGKVEVTKEGVKLCTMGPGKVFGELAILYNCTRTATVKTLVNVKLWAIDRQCFQTIMMRTGLIKHTEYMEFLKSVPTFQSLPEEILSKLADVLEETHYENGEYIIRQGARGDTFFIISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAYEDAEAKAKYEAEAAFFANLKLSDFNIIDTLGVGGFGRVELVQLKSEESKTFAMKILKKRHIVDTRQQEHIRSEKQIMQGAHSDFIVRLYRTFKDSKYLYMLMEACLGGELWTILRDRGSFEDSTTRFYTACVVEAFAYLHSKGIIYRDLKPENLILDHRGYAKLVDFGFAKKIGFGKKTWTFCGTPEYVAPEIILNKGHDISADYWSLGILMYELLTGSPPFSGPDPMKTYNIILRGIDMIEFPKKIAKNAANLIKKLCRDNPSERLGNLKNGVKDIQKHKWFEGFNWEGLRKGTLTPPIIPSVASPTDTSNFDSFPEDNDEPPPDDNSGWDIDF T56035 DRUGINFO D01MMM TENELLONE A Investigative T56035 DRUGINFO D04KSU TENELLONE B Investigative T56035 DRUGINFO D05JRA ARC-1028 Investigative T56035 DRUGINFO D0GB4V STAUROSPORINONE Investigative T51698 TARGETID T51698 T51698 FORMERID TTDI00558 T51698 UNIPROID IL16_HUMAN T51698 TARGNAME Interleukin-16 (IL16) T51698 GENENAME IL16 T51698 TARGTYPE Literature-reported T51698 SYNONYMS Prointerleukin16; Pro-interleukin-16; LCF; Interleukin16 T51698 FUNCTION Primes CD4+ T-cells for IL-2 and IL-15 responsiveness. Also induces T-lymphocyte expression of interleukin 2 receptor. Ligand for CD4. Interleukin-16 stimulates a migratory response in CD4+ lymphocytes, monocytes, and eosinophils. T51698 PDBSTRUC 5FB8; 1X6D; 1I16 T51698 BIOCLASS Cytokine: interleukin T51698 SEQUENCE MESHSRAGKSRKSAKFRSISRSLMLCNAKTSDDGSSPDEKYPDPFEISLAQGKEGIFHSSVQLADTSEAGPSSVPDLALASEAAQLQAAGNDRGKTCRRIFFMKESSTASSREKPGKLEAQSSNFLFPKACHQRARSNSTSVNPYCTREIDFPMTKKSAAPTDRQPYSLCSNRKSLSQQLDCPAGKAAGTSRPTRSLSTAQLVQPSGGLQASVISNIVLMKGQAKGLGFSIVGGKDSIYGPIGIYVKTIFAGGAAAADGRLQEGDEILELNGESMAGLTHQDALQKFKQAKKGLLTLTVRTRLTAPPSLCSHLSPPLCRSLSSSTCITKDSSSFALESPSAPISTAKPNYRIMVEVSLQKEAGVGLGIGLCSVPYFQCISGIFVHTLSPGSVAHLDGRLRCGDEIVEISDSPVHCLTLNEVYTILSHCDPGPVPIIVSRHPDPQVSEQQLKEAVAQAVENTKFGKERHQWSLEGVKRLESSWHGRPTLEKEREKNSAPPHRRAQKVMIRSSSDSSYMSGSPGGSPGSGSAEKPSSDVDISTHSPSLPLAREPVVLSIASSRLPQESPPLPESRDSHPPLRLKKSFEILVRKPMSSKPKPPPRKYFKSDSDPQKSLEERENSSCSSGHTPPTCGQEARELLPLLLPQEDTAGRSPSASAGCPGPGIGPQTKSSTEGEPGWRRASPVTQTSPIKHPLLKRQARMDYSFDTTAEDPWVRISDCIKNLFSPIMSENHGHMPLQPNASLNEEEGTQGHPDGTPPKLDTANGTPKVYKSADSSTVKKGPPVAPKPAWFRQSLKGLRNRASDPRGLPDPALSTQPAPASREHLGSHIRASSSSSSIRQRISSFETFGSSQLPDKGAQRLSLQPSSGEAAKPLGKHEEGRFSGLLGRGAAPTLVPQQPEQVLSSGSPAASEARDPGVSESPPPGRQPNQKTLPPGPDPLLRLLSTQAEESQGPVLKMPSQRARSFPLTRSQSCETKLLDEKTSKLYSISSQVSSAVMKSLLCLPSSISCAQTPCIPKEGASPTSSSNEDSAANGSAETSALDTGFSLNLSELREYTEGLTEAKEDDDGDHSSLQSGQSVISLLSSEELKKLIEEVKVLDEATLKQLDGIHVTILHKEEGAGLGFSLAGGADLENKVITVHRVFPNGLASQEGTIQKGNEVLSINGKSLKGTTHHDALAILRQAREPRQAVIVTRKLTPEAMPDLNSSTDSAASASAASDVSVESTAEATVCTVTLEKMSAGLGFSLEGGKGSLHGDKPLTINRIFKGAASEQSETVQPGDEILQLGGTAMQGLTRFEAWNIIKALPDGPVTIVIRRKSLQSKETTAAGDS T63883 TARGETID T63883 T63883 FORMERID TTDR00705 T63883 UNIPROID DAG1_HUMAN T63883 TARGNAME Dystroglycan (DAG1) T63883 GENENAME DAG1 T63883 TARGTYPE Literature-reported T63883 SYNONYMS Dystrophin-associated glycoprotein 1; Alpha-dystroglycan T63883 FUNCTION The dystroglycan complex is involved in a number of processes including laminin and basement membrane assembly, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, and epithelial polarization. T63883 PDBSTRUC 5LLK; 5GGP; 2MK7; 1EG4 T63883 BIOCLASS Dystroglycan protein T63883 SEQUENCE MRMSVGLSLLLPLSGRTFLLLLSVVMAQSHWPSEPSEAVRDWENQLEASMHSVLSDLHEAVPTVVGIPDGTAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSWLHWDSQSHTLEGLPLDTDKGVHYISVSATRLGANGSHIPQTSSVFSIEVYPEDHSELQSVRTASPDPGEVVSSACAADEPVTVLTVILDADLTKMTPKQRIDLLHRMRSFSEVELHNMKLVPVVNNRLFDMSAFMAGPGNAKKVVENGALLSWKLGCSLNQNSVPDIHGVEAPAREGAMSAQLGYPVVGWHIANKKPPLPKRVRRQIHATPTPVTAIGPPTTAIQEPPSRIVPTPTSPAIAPPTETMAPPVRDPVPGKPTVTIRTRGAIIQTPTLGPIQPTRVSEAGTTVPGQIRPTMTIPGYVEPTAVATPPTTTTKKPRVSTPKPATPSTDSTTTTTRRPTKKPRTPRPVPRVTTKVSITRLETASPPTRIRTTTSGVPRGGEPNQRPELKNHIDRVDAWVGTYFEVKIPSDTFYDHEDTTTDKLKLTLKLREQQLVGEKSWVQFNSNSQLMYGLPDSSHVGKHEYFMHATDKGGLSAVDAFEIHVHRRPQGDRAPARFKAKFVGDPALVLNDIHKKIALVKKLAFAFGDRNCSTITLQNITRGSIVVEWTNNTLPLEPCPKEQIAGLSRRIAEDDGKPRPAFSNALEPDFKATSITVTGSGSCRHLQFIPVVPPRRVPSEAPPTEVPDRDPEKSSEDDVYLHTVIPAVVVAAILLIAGIIAMICYRKKRKGKLTLEDQATFIKKGVPIIFADELDDSKPPPSSSMPLILQEEKAPLPPPEYPNQSVPETTPLNQDTMGEYTPLRDEDPNAPPYQPPPPFTAPMEGKGSRPKNMTPYRSPPPYVPP T12581 TARGETID T12581 T12581 FORMERID TTDI03296 T12581 UNIPROID ITPR3_HUMAN T12581 TARGNAME IP3 receptor isoform 3 (ITPR3) T12581 GENENAME ITPR3 T12581 TARGTYPE Literature-reported T12581 SYNONYMS Type 3 inositol 1,4,5-trisphosphate receptor; Type 3 InsP3 receptor; InsP3R3; Inositol 1,4,5-trisphosphate receptor type 3; IP3R 3 T12581 FUNCTION Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium. T12581 PDBSTRUC 6DRC; 6DRA; 6DR2; 6DR0; 6DQZ T12581 BIOCLASS Ryanodine-inositol triphosphate calcium channel T12581 SEQUENCE MSEMSSFLHIGDIVSLYAEGSVNGFISTLGLVDDRCVVEPAAGDLDNPPKKFRDCLFKVCPMNRYSAQKQYWKAKQTKQDKEKIADVVLLQKLQHAAQMEQKQNDTENKKVHGDVVKYGSVIQLLHMKSNKYLTVNKRLPALLEKNAMRVTLDATGNEGSWLFIQPFWKLRSNGDNVVVGDKVILNPVNAGQPLHASNYELSDNAGCKEVNSVNCNTSWKINLFMQFRDHLEEVLKGGDVVRLFHAEQEKFLTCDEYKGKLQVFLRTTLRQSATSATSSNALWEVEVVHHDPCRGGAGHWNGLYRFKHLATGNYLAAEENPSYKGDASDPKAAGMGAQGRTGRRNAGEKIKYCLVAVPHGNDIASLFELDPTTLQKTDSFVPRNSYVRLRHLCTNTWIQSTNVPIDIEEERPIRLMLGTCPTKEDKEAFAIVSVPVSEIRDLDFANDASSMLASAVEKLNEGFISQNDRRFVIQLLEDLVFFVSDVPNNGQNVLDIMVTKPNRERQKLMREQNILKQVFGILKAPFREKGGEGPLVRLEELSDQKNAPYQHMFRLCYRVLRHSQEDYRKNQEHIAKQFGMMQSQIGYDILAEDTITALLHNNRKLLEKHITKTEVETFVSLVRKNREPRFLDYLSDLCVSNHIAIPVTQELICKCVLDPKNSDILIRTELRPVKEMAQSHEYLSIEYSEEEVWLTWTDKNNEHHEKSVRQLAQEARAGNAHDENVLSYYRYQLKLFARMCLDRQYLAIDEISQQLGVDLIFLCMADEMLPFDLRASFCHLMLHVHVDRDPQELVTPVKFARLWTEIPTAITIKDYDSNLNASRDDKKNKFANTMEFVEDYLNNVVSEAVPFANEEKNKLTFEVVSLAHNLIYFGFYSFSELLRLTRTLLGIIDCVQGPPAMLQAYEDPGGKNVRRSIQGVGHMMSTMVLSRKQSVFSAPSLSAGASAAEPLDRSKFEENEDIVVMETKLKILEILQFILNVRLDYRISYLLSVFKKEFVEVFPMQDSGADGTAPAFDSTTANMNLDRIGEQAEAMFGVGKTSSMLEVDDEGGRMFLRVLIHLTMHDYAPLVSGALQLLFKHFSQRQEAMHTFKQVQLLISAQDVENYKVIKSELDRLRTMVEKSELWVDKKGSGKGEEVEAGAAKDKKERPTDEEGFLHPPGEKSSENYQIVKGILERLNKMCGVGEQMRKKQQRLLKNMDAHKVMLDLLQIPYDKGDAKMMEILRYTHQFLQKFCAGNPGNQALLHKHLHLFLTPGLLEAETMQHIFLNNYQLCSEISEPVLQHFVHLLATHGRHVQYLDFLHTVIKAEGKYVKKCQDMIMTELTNAGDDVVVFYNDKASLAHLLDMMKAARDGVEDHSPLMYHISLVDLLAACAEGKNVYTEIKCTSLLPLEDVVSVVTHEDCITEVKMAYVNFVNHCYVDTEVEMKEIYTSNHIWTLFENFTLDMARVCSKREKRVADPTLEKYVLSVVLDTINAFFSSPFSENSTSLQTHQTIVVQLLQSTTRLLECPWLQQQHKGSVEACIRTLAMVAKGRAILLPMDLDAHISSMLSSGASCAAAAQRNASSYKATTRAFPRVTPTANQWDYKNIIEKLQDIITALEERLKPLVQAELSVLVDVLHWPELLFLEGSEAYQRCESGGFLSKLIQHTKDLMESEEKLCIKVLRTLQQMLLKKTKYGDRGNQLRKMLLQNYLQNRKSTSRGDLPDPIGTGLDPDWSAIAATQCRLDKEGATKLVCDLITSTKNEKIFQESIGLAIHLLDGGNTEIQKSFHNLMMSDKKSERFFKVLHDRMKRAQQETKSTVAVNMNDLGSQPHEDREPVDPTTKGRVASFSIPGSSSRYSLGPSLRRGHEVSERVQSSEMGTSVLIMQPILRFLQLLCENHNRDLQNFLRCQNNKTNYNLVCETLQFLDIMCGSTTGGLGLLGLYINEDNVGLVIQTLETLTEYCQGPCHENQTCIVTHESNGIDIITALILNDISPLCKYRMDLVLQLKDNASKLLLALMESRHDSENAERILISLRPQELVDVIKKAYLQEEERENSEVSPREVGHNIYILALQLSRHNKQLQHLLKPVKRIQEEEAEGISSMLSLNNKQLSQMLKSSAPAQEEEEDPLAYYENHTSQIEIVRQDRSMEQIVFPVPGICQFLTEETKHRLFTTTEQDEQGSKVSDFFDQSSFLHNEMEWQRKLRSMPLIYWFSRRMTLWGSISFNLAVFINIIIAFFYPYMEGASTGVLDSPLISLLFWILICFSIAALFTKRYSIRPLIVALILRSIYYLGIGPTLNILGALNLTNKIVFVVSFVGNRGTFIRGYKAMVMDMEFLYHVGYILTSVLGLFAHELFYSILLFDLIYREETLFNVIKSVTRNGRSILLTALLALILVYLFSIVGFLFLKDDFILEVDRLPNNHSTASPLGMPHGAAAFVDTCSGDKMDCVSGLSVPEVLEEDRELDSTERACDTLLMCIVTVMNHGLRNGGGVGDILRKPSKDESLFPARVVYDLLFFFIVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVSFEEHIKLEHNMWNYLYFIVLVRVKNKTDYTGPESYVAQMIKNKNLDWFPRMRAMSLVSNEGEGEQNEIRILQDKLNSTMKLVSHLTAQLNELKEQMTEQRKRRQRLGFVDVQNCISR T12581 DRUGINFO D06KHR decavanadate Investigative T38017 TARGETID T38017 T38017 FORMERID TTDR01134 T38017 UNIPROID IRF3_HUMAN T38017 TARGNAME Interferon regulatory factor 3 (IRF3) T38017 GENENAME IRF3 T38017 TARGTYPE Literature-reported T38017 SYNONYMS IRF-3 T38017 FUNCTION Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters. Acts as a more potent activator of the IFN-beta (IFNB) gene than the IFN-alpha (IFNA) gene and plays a critical role in both the early and late phases of the IFNA/B gene induction. Found in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, is phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization and association with CREB binding protein (CREBBP) to form dsRNA-activated factor 1 (DRAF1), a complex which activates the transcription of the type I IFN and ISG genes. Can activate distinct gene expression programs in macrophages and can induce significant apoptosis in primary macrophages. Key transcriptional regulator of type I interferon (IFN)-dependent immune responses which plays a critical role in the innate immune response against DNA and RNA viruses. T38017 PDBSTRUC 5JER; 5JEO; 5JEM; 5JEL; 5JEK T38017 SEQUENCE MGTPKPRILPWLVSQLDLGQLEGVAWVNKSRTRFRIPWKHGLRQDAQQEDFGIFQAWAEATGAYVPGRDKPDLPTWKRNFRSALNRKEGLRLAEDRSKDPHDPHKIYEFVNSGVGDFSQPDTSPDTNGGGSTSDTQEDILDELLGNMVLAPLPDPGPPSLAVAPEPCPQPLRSPSLDNPTPFPNLGPSENPLKRLLVPGEEWEFEVTAFYRGRQVFQQTISCPEGLRLVGSEVGDRTLPGWPVTLPDPGMSLTDRGVMSYVRHVLSCLGGGLALWRAGQWLWAQRLGHCHTYWAVSEELLPNSGHGPDGEVPKDKEGGVFDLGPFIVDLITFTEGSGRSPRYALWFCVGESWPQDQPWTKRLVMVKVVPTCLRALVEMARVGGASSLENTVDLHISNSHPLSLTSDQYKAYLQDLVEGMDFQGPGES T38017 DRUGINFO D0O0VZ Piceatannol Investigative T24714 TARGETID T24714 T24714 FORMERID TTDI00159 T24714 UNIPROID TRIPC_HUMAN T24714 TARGNAME E3 ubiquitin-protein ligase TRIP12 (TRIP12) T24714 GENENAME TRIP12 T24714 TARGTYPE Literature-reported T24714 SYNONYMS ULF; Thyroid receptorinteracting protein 12; TRinteracting protein 12; TRIP12; E3 ubiquitinprotein ligase for Arf; E3 ubiquitinprotein ligase TRIP12 T24714 FUNCTION E3 ubiquitin-protein ligase involved inubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus,regardeless of the presence of lysine residues in target proteins. In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress. In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation. Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation. Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins. Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes. T24714 BIOCLASS Carbon-nitrogen ligase T24714 ECNUMBER EC 2.3.2.26 T24714 SEQUENCE MSNRPNNNPGGSLRRSQRNTAGAQPQDDSIGGRSCSSSSAVIVPQPEDPDRANTSERQKTGQVPKKDNSRGVKRSASPDYNRTNSPSSAKKPKALQHTESPSETNKPHSKSKKRHLDQEQQLKSAQSPSTSKAHTRKSGATGGSRSQKRKRTESSCVKSGSGSESTGAEERSAKPTKLASKSATSAKAGCSTITDSSSAASTSSSSSAVASASSTVPPGARVKQGKDQNKARRSRSASSPSPRRSSREKEQSKTGGSSKFDWAARFSPKVSLPKTKLSLPGSSKSETSKPGPSGLQAKLASLRKSTKKRSESPPAELPSLRRSTRQKTTGSCASTSRRGSGLGKRGAAEARRQEKMADPESNQEAVNSSAARTDEAPQGAAGAVGMTTSGESESDDSEMGRLQALLEARGLPPHLFGPLGPRMSQLFHRTIGSGASSKAQQLLQGLQASDESQQLQAVIEMCQLLVMGNEETLGGFPVKSVVPALITLLQMEHNFDIMNHACRALTYMMEALPRSSAVVVDAIPVFLEKLQVIQCIDVAEQALTALEMLSRRHSKAILQAGGLADCLLYLEFFSINAQRNALAIAANCCQSITPDEFHFVADSLPLLTQRLTHQDKKSVESTCLCFARLVDNFQHEENLLQQVASKDLLTNVQQLLVVTPPILSSGMFIMVVRMFSLMCSNCPTLAVQLMKQNIAETLHFLLCGASNGSCQEQIDLVPRSPQELYELTSLICELMPCLPKEGIFAVDTMLKKGNAQNTDGAIWQWRDDRGLWHPYNRIDSRIIEQINEDTGTARAIQRKPNPLANSNTSGYSESKKDDARAQLMKEDPELAKSFIKTLFGVLYEVYSSSAGPAVRHKCLRAILRIIYFADAELLKDVLKNHAVSSHIASMLSSQDLKIVVGALQMAEILMQKLPDIFSVYFRREGVMHQVKHLAESESLLTSPPKACTNGSGSMGSTTSVSSGTATAATHAAADLGSPSLQHSRDDSLDLSPQGRLSDVLKRKRLPKRGPRRPKYSPPRDDDKVDNQAKSPTTTQSPKSSFLASLNPKTWGRLSTQSNSNNIEPARTAGGSGLARAASKDTISNNREKIKGWIKEQAHKFVERYFSSENMDGSNPALNVLQRLCAATEQLNLQVDGGAECLVEIRSIVSESDVSSFEIQHSGFVKQLLLYLTSKSEKDAVSREIRLKRFLHVFFSSPLPGEEPIGRVEPVGNAPLLALVHKMNNCLSQMEQFPVKVHDFPSGNGTGGSFSLNRGSQALKFFNTHQLKCQLQRHPDCANVKQWKGGPVKIDPLALVQAIERYLVVRGYGRVREDDEDSDDDGSDEEIDESLAAQFLNSGNVRHRLQFYIGEHLLPYNMTVYQAVRQFSIQAEDERESTDDESNPLGRAGIWTKTHTIWYKPVREDEESNKDCVGGKRGRAQTAPTKTSPRNAKKHDELWHDGVCPSVSNPLEVYLIPTPPENITFEDPSLDVILLLRVLHAISRYWYYLYDNAMCKEIIPTSEFINSKLTAKANRQLQDPLVIMTGNIPTWLTELGKTCPFFFPFDTRQMLFYVTAFDRDRAMQRLLDTNPEINQSDSQDSRVAPRLDRKKRTVNREELLKQAESVMQDLGSSRAMLEIQYENEVGTGLGPTLEFYALVSQELQRADLGLWRGEEVTLSNPKGSQEGTKYIQNLQGLFALPFGRTAKPAHIAKVKMKFRFLGKLMAKAIMDFRLVDLPLGLPFYKWMLRQETSLTSHDLFDIDPVVARSVYHLEDIVRQKKRLEQDKSQTKESLQYALETLTMNGCSVEDLGLDFTLPGFPNIELKKGGKDIPVTIHNLEEYLRLVIFWALNEGVSRQFDSFRDGFESVFPLSHLQYFYPEELDQLLCGSKADTWDAKTLMECCRPDHGYTHDSRAVKFLFEILSSFDNEQQRLFLQFVTGSPRLPVGGFRSLNPPLTIVRKTFESTENPDDFLPSVMTCVNYLKLPDYSSIEIMREKLLIAAREGQQSFHLS T44516 TARGETID T44516 T44516 FORMERID TTDR00071 T44516 UNIPROID KCNB1_HUMAN T44516 TARGNAME Voltage-gated potassium channel Kv2.1 (KCNB1) T44516 GENENAME KCNB1 T44516 TARGTYPE Literature-reported T44516 SYNONYMS Voltage-gated potassium channel subunit Kv2.1; Rectifier potassium channel Kv2.1; Potassium voltage-gated channel subfamily B member 1; Potassium channel Kv2.1; H-DRK1; DRK1 T44516 FUNCTION Contributes to the regulation of the action potential (AP) repolarization, duration and frequency of repetitive AP firing in neurons, muscle cells and endocrine cells and plays a role in homeostatic attenuation of electrical excitability throughout the brain. Plays also a role in the regulation of exocytosis independently of its electrical function. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarization. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB2; channel properties depend on the type of alpha subunits that are part of the channel. Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNF1, KCNG1, KCNG3, KCNG4, KCNH1, KCNH2, KCNS1, KCNS2, KCNS3 and KCNV1, creating a functionally diverse range of channel complexes. Heterotetrameric channel activity formed with KCNS3 show increased current amplitude with the threshold for action potential activation shifted towards more negative values in hypoxic-treated pulmonary artery smooth muscle cells. Channel properties are also modulated by cytoplasmic ancillary beta subunits such as AMIGO1, KCNE1, KCNE2 and KCNE3, slowing activation and inactivation rate of the delayed rectifier potassium channels. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Major contributor to the slowly inactivating delayed-rectifier voltage-gated potassium current in neurons of the central nervous system, sympathetic ganglion neurons, neuroendocrine cells, pancreatic beta cells, cardiomyocytes and smooth muscle cells. Mediates the major part of the somatodendritic delayed-rectifier potassium current in hippocampal and cortical pyramidal neurons and sympathetic superior cervical ganglion (CGC) neurons that acts to slow down periods of firing, especially during high frequency stimulation. Plays a role in the induction of long-term potentiation (LTP) of neuron excitability in the CA3 layer of the hippocampus. Contributes to the regulation of glucose-induced action potential amplitude and duration in pancreatic beta cells, hence limiting calcium influx and insulin secretion. Plays a role in the regulation of resting membrane potential and contraction in hypoxia-treated pulmonary artery smooth muscle cells. May contribute to the regulation of the duration of both the action potential of cardiomyocytes and the heart ventricular repolarization QT interval. Contributes to the pronounced pro-apoptotic potassium current surge during neuronal apoptotic cell death in response to oxidative injury. May confer neuroprotection in response to hypoxia/ischemic insults by suppressing pyramidal neurons hyperexcitability in hippocampal and cortical regions. Promotes trafficking of KCNG3, KCNH1 and KCNH2 to the cell surface membrane, presumably by forming heterotetrameric channels with these subunits. Plays a role in the calcium-dependent recruitment and release of fusion-competent vesicles from the soma of neurons, neuroendocrine and glucose-induced pancreatic beta cells by binding key components of the fusion machinery in a pore-independent manner. Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain, but also in the pancreas and cardiovascular system. T44516 BIOCLASS Voltage-gated ion channel T44516 SEQUENCE MPAGMTKHGSRSTSSLPPEPMEIVRSKACSRRVRLNVGGLAHEVLWRTLDRLPRTRLGKLRDCNTHDSLLEVCDDYSLDDNEYFFDRHPGAFTSILNFYRTGRLHMMEEMCALSFSQELDYWGIDEIYLESCCQARYHQKKEQMNEELKREAETLREREGEEFDNTCCAEKRKKLWDLLEKPNSSVAAKILAIISIMFIVLSTIALSLNTLPELQSLDEFGQSTDNPQLAHVEAVCIAWFTMEYLLRFLSSPKKWKFFKGPLNAIDLLAILPYYVTIFLTESNKSVLQFQNVRRVVQIFRIMRILRILKLARHSTGLQSLGFTLRRSYNELGLLILFLAMGIMIFSSLVFFAEKDEDDTKFKSIPASFWWATITMTTVGYGDIYPKTLLGKIVGGLCCIAGVLVIALPIPIIVNNFSEFYKEQKRQEKAIKRREALERAKRNGSIVSMNMKDAFARSIEMMDIVVEKNGENMGKKDKVQDNHLSPNKWKWTKRTLSETSSSKSFETKEQGSPEKARSSSSPQHLNVQQLEDMYNKMAKTQSQPILNTKESAAQSKPKEELEMESIPSPVAPLPTRTEGVIDMRSMSSIDSFISCATDFPEATRFSHSPLTSLPSKTGGSTAPEVGWRGALGASGGRFVEANPSPDASQHSSFFIESPKSSMKTNNPLKLRALKVNFMEGDPSPLLPVLGMYHDPLRNRGSAAAAVAGLECATLLDKAVLSPESSIYTTASAKTPPRSPEKHTAIAFNFEAGVHQYIDADTDDEGQLLYSVDSSPPKSLPGSTSPKFSTGTRSEKNHFESSPLPTSPKFLRQNCIYSTEALTGKGPSGQEKCKLENHISPDVRVLPGGGAHGSTRDQSI T44516 DRUGINFO D0O8MU 3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol Investigative T44516 DRUGINFO D0A1IR DABCO-C16 Investigative T44516 DRUGINFO D0I7VY RY796 Investigative T44516 DRUGINFO D06PZZ [14C]TEA Investigative T64022 TARGETID T64022 T64022 FORMERID TTDI02102 T64022 UNIPROID IMB1_HUMAN T64022 TARGNAME Importin beta (KPNB1) T64022 GENENAME KPNB1 T64022 TARGTYPE Literature-reported T64022 SYNONYMS Pore targeting complex 97 kDa subunit; PTAC97; Nuclear factor p97; NTF97; Karyopherin subunit beta1; Karyopherin subunit beta-1; Importin90; Importin-90; Importin subunit beta1; Importin subunit beta-1 T64022 FUNCTION Acting autonomously, serves itself as NLS receptor. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Mediates autonomously the nuclear import of ribosomal proteins RPL23A, RPS7 and RPL5. Binds to a beta-like import receptor binding (BIB) domain of RPL23A. In association with IPO7 mediates the nuclear import of H1 histone. In vitro, mediates nuclear import of H2A, H2B, H3 and H4 histones. In case of HIV-1 infection, binds and mediates the nuclear import of HIV-1 Rev. Imports SNAI1 and PRKCI into the nucleus. Functions in nuclear protein import, either in association with an adapter protein, like an importin-alpha subunit, which binds to nuclear localization signals (NLS) in cargo substrates, or by acting as autonomous nuclear transport receptor. T64022 PDBSTRUC 6N89; 6N88; 3W5K; 3LWW; 2QNA T64022 BIOCLASS Eukaryotic nuclear pore complex T64022 SEQUENCE MELITILEKTVSPDRLELEAAQKFLERAAVENLPTFLVELSRVLANPGNSQVARVAAGLQIKNSLTSKDPDIKAQYQQRWLAIDANARREVKNYVLQTLGTETYRPSSASQCVAGIACAEIPVNQWPELIPQLVANVTNPNSTEHMKESTLEAIGYICQDIDPEQLQDKSNEILTAIIQGMRKEEPSNNVKLAATNALLNSLEFTKANFDKESERHFIMQVVCEATQCPDTRVRVAALQNLVKIMSLYYQYMETYMGPALFAITIEAMKSDIDEVALQGIEFWSNVCDEEMDLAIEASEAAEQGRPPEHTSKFYAKGALQYLVPILTQTLTKQDENDDDDDWNPCKAAGVCLMLLATCCEDDIVPHVLPFIKEHIKNPDWRYRDAAVMAFGCILEGPEPSQLKPLVIQAMPTLIELMKDPSVVVRDTAAWTVGRICELLPEAAINDVYLAPLLQCLIEGLSAEPRVASNVCWAFSSLAEAAYEAADVADDQEEPATYCLSSSFELIVQKLLETTDRPDGHQNNLRSSAYESLMEIVKNSAKDCYPAVQKTTLVIMERLQQVLQMESHIQSTSDRIQFNDLQSLLCATLQNVLRKVQHQDALQISDVVMASLLRMFQSTAGSGGVQEDALMAVSTLVEVLGGEFLKYMEAFKPFLGIGLKNYAEYQVCLAAVGLVGDLCRALQSNIIPFCDEVMQLLLENLGNENVHRSVKPQILSVFGDIALAIGGEFKKYLEVVLNTLQQASQAQVDKSDYDMVDYLNELRESCLEAYTGIVQGLKGDQENVHPDVMLVQPRVEFILSFIDHIAGDEDHTDGVVACAAGLIGDLCTAFGKDVLKLVEARPMIHELLTEGRRSKTNKAKTLATWATKELRKLKNQA T53892 TARGETID T53892 T53892 FORMERID TTDI03463 T53892 UNIPROID PMVK_HUMAN T53892 TARGNAME Phosphomevalonate kinase (PMVK) T53892 GENENAME PMVK T53892 TARGTYPE Literature-reported T53892 SYNONYMS hPMK; PMKase; PMKI T53892 FUNCTION Regulated in response to dietary sterol levels and that this regulation is coordinate with 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme of cholesterol biosynthesis. T53892 PDBSTRUC 3CH4 T53892 ECNUMBER EC 2.7.4.2 T53892 SEQUENCE MAPLGGAPRLVLLFSGKRKSGKDFVTEALQSRLGADVCAVLRLSGPLKEQYAQEHGLNFQRLLDTSTYKEAFRKDMIRWGEEKRQADPGFFCRKIVEGISQPIWLVSDTRRVSDIQWFREAYGAVTQTVRVVALEQSRQQRGWVFTPGVDDAESECGLDNFGDFDWVIENHGVEQRLEEQLENLIEFIRSRL T53892 DRUGINFO D04EWW isoferulic acid Investigative T53892 DRUGINFO D08ERD (R)-5-diphosphomevalonate Investigative T53892 DRUGINFO D08QCI 3-hydroxy-3-methyl-6-phosphohexanoic acid Investigative T53892 DRUGINFO D0T2QL cinnamic acid Investigative T20498 TARGETID T20498 T20498 FORMERID TTDI02583 T20498 UNIPROID RBP1_HUMAN T20498 TARGNAME RalA binding protein 1 (RALBP1) T20498 GENENAME RALBP1 T20498 TARGTYPE Literature-reported T20498 SYNONYMS RalBP1; RalA-binding protein 1; Ral-interacting protein 1; RLIP76; RLIP1; Dinitrophenyl S-glutathione ATPase; DNP-SG ATPase; 76 kDa Ral-interacting protein T20498 FUNCTION Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the major ATP-dependent transporter of glutathione conjugates of electrophiles (GS-E) and DOX in erythrocytes. Can catalyze transport of glutathione conjugates and xenobiotics, and may contribute to the multidrug resistance phenomenon. Serves as a scaffold protein that brings together proteins forming an endocytotic complex during interphase and also with CDK1 to switch off endocytosis, One of its substrates would be EPN1/Epsin. Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. T20498 PDBSTRUC 2MBG; 2KWI; 2KWH T20498 BIOCLASS Non ABC multidrug exporter T20498 SEQUENCE MTECFLPPTSSPSEHRRVEHGSGLTRTPSSEEISPTKFPGLYRTGEPSPPHDILHEPPDVVSDDEKDHGKKKGKFKKKEKRTEGYAAFQEDSSGDEAESPSKMKRSKGIHVFKKPSFSKKKEKDFKIKEKPKEEKHKEEKHKEEKHKEKKSKDLTAADVVKQWKEKKKKKKPIQEPEVPQIDVPNLKPIFGIPLADAVERTMMYDGIRLPAVFRECIDYVEKYGMKCEGIYRVSGIKSKVDELKAAYDREESTNLEDYEPNTVASLLKQYLRDLPENLLTKELMPRFEEACGRTTETEKVQEFQRLLKELPECNYLLISWLIVHMDHVIAKELETKMNIQNISIVLSPTVQISNRVLYVFFTHVQELFGNVVLKQVMKPLRWSNMATMPTLPETQAGIKEEIRRQEFLLNCLHRDLQGGIKDLSKEERLWEVQRILTALKRKLREAKRQECETKIAQEIASLSKEDVSKEEMNENEEVINILLAQENEILTEQEELLAMEQFLRRQIASEKEEIERLRAEIAEIQSRQQHGRSETEEYSSESESESEDEEELQIILEDLQRQNEELEIKNNHLNQAIHEEREAIIELRVQLRLLQMQRAKAEQQAQEDEEPEWRGGAVQPPRDGVLEPKAAKEQPKAGKEPAKPSPSRDRKETSI T12075 TARGETID T12075 T12075 FORMERID TTDI02226 T12075 UNIPROID SHH_HUMAN T12075 TARGNAME Hedgehog protein (SHH) T12075 GENENAME SHH T12075 TARGTYPE Literature-reported T12075 SYNONYMS Sonic hedgehog protein C-product; Sonic hedgehog protein; SHH; HHG-1 T12075 FUNCTION Intercellular signal essential for a variety of patterning events duringdevelopment: signal produced by the notochord that induces ventral cell fate in the neural tube and somites, and the polarizing signal for patterning of the anterior- posterior axis of the developinglimb bud. Displays both floor plate- and motor neuron-inducing activity. The threshold concentration of N-product required for motor neuron induction is 5-fold lower than that required for floor plate induction. Activates the transcription of target genes by interacting with its receptor PTCH1 to prevent normal inhibition by PTCH1 on the constitutive signaling activity of SMO. T12075 PDBSTRUC 6OEV; 6E1H; 6DMY; 3MXW; 3M1N T12075 BIOCLASS Hedgehog T12075 SEQUENCE MLLLARCLLLVLVSSLLVCSGLACGPGRGFGKRRHPKKLTPLAYKQFIPNVAEKTLGASGRYEGKISRNSERFKELTPNYNPDIIFKDEENTGADRLMTQRCKDKLNALAISVMNQWPGVKLRVTEGWDEDGHHSEESLHYEGRAVDITTSDRDRSKYGMLARLAVEAGFDWVYYESKAHIHCSVKAENSVAAKSGGCFPGSATVHLEQGGTKLVKDLSPGDRVLAADDQGRLLYSDFLTFLDRDDGAKKVFYVIETREPRERLLLTAAHLLFVAPHNDSATGEPEASSGSGPPSGGALGPRALFASRVRPGQRVYVVAERDGDRRLLPAAVHSVTLSEEAAGAYAPLTAQGTILINRVLASCYAVIEEHSWAHRAFAPFRLAHALLAALAPARTDRGGDSGGGDRGGGGGRVALTAPGAADAPGAGATAGIHWYSQLLYQIGTWLLDSEALHPLGMAVKSS T89859 TARGETID T89859 T89859 FORMERID TTDR00817 T89859 UNIPROID NR0B2_HUMAN T89859 TARGNAME Orphan nuclear receptor SHP (NR0B2) T89859 GENENAME NR0B2 T89859 TARGTYPE Literature-reported T89859 SYNONYMS Small heterodimer partner; Short heterodimer partner; SHP; Nuclear receptor subfamily 0 group B member 2 T89859 FUNCTION Specifically inhibits transactivation of the nuclear receptor with which it interacts. Inhibits transcriptional activity of NEUROD1 on E-box-containing promoter by interfering with the coactivation function of the p300/CBP-mediated transcription complex for NEUROD1. Essential component of the liver circadian clock which via its interaction with NR1D1 and RORG regulates NPAS2-mediated hepatic lipid metabolism. Regulates the circadian expression of cytochrome P450 (CYP) enzymes. Represses: NR5A2 and HNF4A to down-regulate CYP2C38, NFLI3 to up-regulate CYP2A5, BHLHE41/HNF1A axis to up-regulate CYP1A2, CYP2E1 and CYP3A11, and NR1D1 to up-regulate CYP2B10, CYP4A10 and CYP4A14. Transcriptional regulator that acts as a negative regulator of receptor-dependent signaling pathways. T89859 PDBSTRUC 5UFS; 4ONI; 4DOR; 2Z4J; 2Q3Y T89859 BIOCLASS Nuclear hormone receptor T89859 SEQUENCE MSTSQPGACPCQGAASRPAILYALLSSSLKAVPRPRSRCLCRQHRPVQLCAPHRTCREALDVLAKTVAFLRNLPSFWQLPPQDQRRLLQGCWGPLFLLGLAQDAVTFEVAEAPVPSILKKILLEEPSSSGGSGQLPDRPQPSLAAVQWLQCCLESFWSLELSPKEYACLKGTILFNPDVPGLQAASHIGHLQQEAHWVLCEVLEPWCPAAQGRLTRVLLTASTLKSIPTSLLGDLFFRPIIGDVDIAGLLGDMLLLR T94364 TARGETID T94364 T94364 UNIPROID CIP4_HUMAN T94364 TARGNAME Thyroid receptor-interacting protein 10 (TRIP10) T94364 GENENAME TRIP10 T94364 TARGTYPE Literature-reported T94364 SYNONYMS hSTP; TRIP-10; TR-interacting protein 10; Salt tolerant protein; STP; STOT; Protein Felic; Cdc42-interacting protein 4; CIP4 T94364 FUNCTION Required to coordinate membrane tubulation with reorganization of the actin cytoskeleton during endocytosis. Binds to lipids such as phosphatidylinositol 4,5-bisphosphate and phosphatidylserine and promotes membrane invagination and the formation of tubules. Also promotes CDC42-induced actin polymerization by recruiting WASL/N-WASP which in turn activates the Arp2/3 complex. Actin polymerization may promote the fission of membrane tubules to form endocytic vesicles. Required for the formation of podosomes, actin-rich adhesion structures specific to monocyte-derived cells. May be required for the lysosomal retention of FASLG/FASL. Required for translocation of GLUT4 to the plasma membrane in response to insulin signaling. T94364 PDBSTRUC 2KE4; 2EFK; 2CT4 T94364 SEQUENCE MDWGTELWDQFEVLERHTQWGLDLLDRYVKFVKERTEVEQAYAKQLRSLVKKYLPKRPAKDDPESKFSQQQSFVQILQEVNDFAGQRELVAENLSVRVCLELTKYSQEMKQERKMHFQEGRRAQQQLENGFKQLENSKRKFERDCREAEKAAQTAERLDQDINATKADVEKAKQQAHLRSHMAEESKNEYAAQLQRFNRDQAHFYFSQMPQIFDKLQDMDERRATRLGAGYGLLSEAELEVVPIIAKCLEGMKVAANAVDPKNDSHVLIELHKSGFARPGDVEFEDFSQPMNRAPSDSSLGTPSDGRPELRGPGRSRTKRWPFGKKNKPRPPPLSPLGGPVPSALPNGPPSPRSGRDPLAILSEISKSVKPRLASFRSLRGSRGTVVTEDFSHLPPEQQRKRLQQQLEERSRELQKEVDQREALKKMKDVYEKTPQMGDPASLEPQIAETLSNIERLKLEVQKYEAWLAEAESRVLSNRGDSLSRHARPPDPPASAPPDSSSNSASQDTKESSEEPPSEESQDTPIYTEFDEDFEEEPTSPIGHCVAIYHFEGSSEGTISMAEGEDLSLMEEDKGDGWTRVRRKEGGEGYVPTSYLRVTLN T75792 TARGETID T75792 T75792 FORMERID TTDI01449 T75792 UNIPROID JHD2C_HUMAN T75792 TARGNAME Jumonji domain-containing protein 1C (JMJD1C) T75792 GENENAME JMJD1C T75792 TARGTYPE Literature-reported T75792 SYNONYMS Thyroid receptor-interacting protein 8; TRIP8; TRIP-8; TR-interacting protein 8; Probable JmjC domain-containing histone demethylation protein 2C; KIAA1380; JHDM2C T75792 FUNCTION Probable histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code. Demethylation of Lys residue generates formaldehyde and succinate. May be involved in hormone-dependent transcriptional activation, by participating in recruitment to androgen-receptor target genes (By similarity). T75792 PDBSTRUC 5FZO; 2YPD T75792 ECNUMBER EC 1.14.11.- T75792 SEQUENCE MAVETRAELVGKRFLCVAVGDEARSERWESGRGWRSWRAGVIRAVSHRDSRNPDLAVYVEFDDLEWDKREWVKVYEDFSTFLVEYHLIWAKRNDPSQTQGSKSKQIQWPALTFKPLVERNIPSSVTAVEFLVDKQLDFLTEDSAFQPYQDDIDSLNPVLRDNPQLHEEVKVWVKEQKVQEIFMQGPYSLNGYRVRVYRQDSATQWFTGIITHHDLFTRTMIVMNDQVLEPQNVDPSMVQMTFLDDVVHSLLKGENIGITSRRRSRANQNVNAVHSHYTRAQANSPRPAMNSQAAVPKQNTHQQQQQRSIRPNKRKGSDSSIPDEEKMKEEKYDYISRGENPKGKNKHLMNKRRKPEEDEKKLNMKRLRTDNVSDFSESSDSENSNKRIIDNSSEQKPENELKNKNTSKINGEEGKPHNNEKAGEETLKNSQPPWDQIQEDKKHEEAEKRKSVDTQLQEDMIIHSSEQSTVSDHNSNDLLPQECNMDKTHTMELLPKEKFVSRPPTPKCVIDITNDTNLEKVAQENSSTFGLQTLQKMDPNVSDSKHSIANAKFLETAKKDSDQSWVSDVVKVDLTQSSVTNASSGNDHLNMEKEKYVSYISPLSAVSVMEDKLHKRSPPPETIKSKLNTSVDTHKIKSSPSPEVVKPKITHSPDSVKSKATYVNSQATGERRLANKIEHELSRCSFHPIPTRSSTLETTKSPLIIDKNEHFTVYRDPALIGSETGANHISPFLSQHPFPLHSSSHRTCLNPGTHHPALTPAPHLLAGSSSQTPLPTINTHPLTSGPHHAVHHPHLLPTVLPGVPTASLLGGHPRLESAHASSLSHLALAHQQQQQLLQHQSPHLLGQAHPSASYNQLGLYPIIWQYPNGTHAYSGLGLPSSKWVHPENAVNAEASLRRNSPSPWLHQPTPVTSADGIGLLSHIPVRPSSAEPHRPLKITAHSSPPLTKTLVDHHKEELERKAFMEPLRSVASTSAKNDLDLNRSQTGKDCHLHRHFVDPVLNQLQRPPQETGERLNKYKEEHRRILQESIDVAPFTTKIKGLEGERENYSRVASSSSSPKSHIIKQDMDVERSVSDLYKMKHSVPQSLPQSNYFTTLSNSVVNEPPRSYPSKEVSNIYGDKQSNALAAAAANPQTLTSFITSLSKPPPLIKHQPESEGLVGKIPEHLPHQIASHSVTTFRNDCRSPTHLTVSSTNTLRSMPALHRAPVFHPPIHHSLERKEGSYSSLSPPTLTPVMPVNAGGKVQESQKPPTLIPEPKDSQANFKSSSEQSLTEMWRPNNNLSKEKTEWHVEKSSGKLQAAMASVIVRPSSSTKTDSMPAMQLASKDRVSERSSAGAHKTDCLKLAEAGETGRIILPNVNSDSVHTKSEKNFQAVSQGSVPSSVMSAVNTMCNTKTDVITSAADTTSVSSWGGSEVISSLSNTILASTSSECVSSKSVSQPVAQKQECKVSTTAPVTLASSKTGSVVQPSSGFSGTTDFIHLKKHKAALAAAQYKSSNASETEPNAIKNQTLSASLPLDSTVICSTINKANSVGNGQASQTSQPNYHTKLKKAWLTRHSEEDKNTNKMENSGNSVSEIIKPCSVNLIASTSSDIQNSVDSKIIVDKYVKDDKVNRRKAKRTYESGSESGDSDESESKSEQRTKRQPKPTYKKKQNDLQKRKGEIEEDLKPNGVLSRSAKERSKLKLQSNSNTGIPRSVLKDWRKVKKLKQTGESFLQDDSCCEIGPNLQKCRECRLIRSKKGEEPAHSPVFCRFYYFRRLSFSKNGVVRIDGFSSPDQYDDEAMSLWTHENFEDDELDIETSKYILDIIGDKFCQLVTSEKTALSWVKKDAKIAWKRAVRGVREMCDACEATLFNIHWVCQKCGFVVCLDCYKAKERKSSRDKELYAWMKCVKGQPHDHKHLMPTQIIPGSVLTDLLDAMHTLREKYGIKSHCHCTNKQNLQVGNFPTMNGVSQVLQNVLNHSNKISLCMPESQQQNTPPKSEKNGGSSPESDVGTDNKLTPPESQSPLHWLADLAEQKAREEKKENKELTLENQIKEEREQDNSESPNGRTSPLVSQNNEQGSTLRDLLTTTAGKLRVGSTDAGIAFAPVYSMGAPSSKSGRTMPNILDDIIASVVENKIPPSKTSKINVKPELKEEPEESIISAVDENNKLYSDIPHSWICEKHILWLKDYKNSSNWKLFKECWKQGQPAVVSGVHKKMNISLWKAESISLDFGDHQADLLNCKDSIISNANVKEFWDGFEEVSKRQKNKSGETVVLKLKDWPSGEDFKTMMPARYEDLLKSLPLPEYCNPEGKFNLASHLPGFFVRPDLGPRLCSAYGVVAAKDHDIGTTNLHIEVSDVVNILVYVGIAKGNGILSKAGILKKFEEEDLDDILRKRLKDSSEIPGALWHIYAGKDVDKIREFLQKISKEQGLEVLPEHDPIRDQSWYVNKKLRQRLLEEYGVRTCTLIQFLGDAIVLPAGALHQVQNFHSCIQVTEDFVSPEHLVESFHLTQELRLLKEEINYDDKLQVKNILYHAVKEMVRALKIHEDEVEDMEEN T95660 TARGETID T95660 T95660 UNIPROID TWST1_HUMAN T95660 TARGNAME Twist-related protein 1 (TWIST1) T95660 GENENAME TWIST1 T95660 TARGTYPE Literature-reported T95660 SYNONYMS bHLHa38; TWIST; H-twist; Class A basic helix-loop-helix protein 38 T95660 FUNCTION Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of proinflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation. Represses the activity of the circadian transcriptional activator: NPAS2-ARNTL/BMAL1 heterodimer. T95660 PDBSTRUC 2MJV T95660 SEQUENCE MMQDVSSSPVSPADDSLSNSEEEPDRQQPPSGKRGGRKRRSSRRSAGGGAGPGGAAGGGVGGGDEPGSPAQGKRGKKSAGCGGGGGAGGGGGSSSGGGSPQSYEELQTQRVMANVRERQRTQSLNEAFAALRKIIPTLPSDKLSKIQTLKLAARYIDFLYQVLQSDELDSKMASCSYVAHERLSYAFSVWRMEGAWSMSASH T15572 TARGETID T15572 T15572 FORMERID TTDR00799 T15572 UNIPROID ADIPO_HUMAN T15572 TARGNAME Adiponectin (ADIPOQ) T15572 GENENAME ADIPOQ T15572 TARGTYPE Literature-reported T15572 SYNONYMS Gelatin-binding protein; GBP28; ApM-1; Adipose most abundant gene transcript 1 protein; Adipose most abundant gene transcript 1; Adipocyte, C1q and collagen domain-containing protein; Adipocyte, C1q and collagen domain containingprotein; Adipocyte complement-related 30 kDa protein; APM1; ACRP30; ACDC; 30 kDa adipocyte complement-related protein T15572 FUNCTION Stimulates AMPK phosphorylation and activation in the liver and the skeletal muscle, enhancing glucose utilization and fatty-acid combustion. Antagonizes TNF-alpha by negatively regulating its expression in various tissues such as liver and macrophages, and also by counteracting its effects. Inhibits endothelial NF-kappa-B signaling through a cAMP-dependent pathway. May play a role in cell growth, angiogenesis and tissue remodeling by binding and sequestering various growth factors with distinct binding affinities, depending on the type of complex, LMW, MMW or HMW. Important adipokine involved in the control of fat metabolism and insulin sensitivity, with direct anti-diabetic, anti-atherogenic and anti-inflammatory activities. T15572 PDBSTRUC 4DOU T15572 BIOCLASS Adiponectin protein T15572 SEQUENCE MLLLGAVLLLLALPGHDQETTTQGPGVLLPLPKGACTGWMAGIPGHPGHNGAPGRDGRDGTPGEKGEKGDPGLIGPKGDIGETGVPGAEGPRGFPGIQGRKGEPGEGAYVYRSAFSVGLETYVTIPNMPIRFTKIFYNQQNHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSLFKKDKAMLFTYDQYQENNVDQASGSVLLHLEVGDQVWLQVYGEGERNGLYADNDNDSTFTGFLLYHDTN T86541 TARGETID T86541 T86541 FORMERID TTDI02591 T86541 UNIPROID ASIC2_HUMAN T86541 TARGNAME Acid-sensing ion channel 2 (ASIC2) T86541 GENENAME ASIC2 T86541 TARGTYPE Literature-reported T86541 SYNONYMS Mammalian degenerin homolog; Brain sodium channel 1; BNaC1; BNC1; Amiloridesensitive cation channelneuronal 1; Amiloridesensitive cation channel1, neuronal; Amiloridesensitive brain sodium channel; Acidsensing ion channel 2; ASIC2 T86541 FUNCTION Cation channel with high affinityfor sodium, which is gated by extracellular protons and inhibited by the diuretic amiloride. Also permeable for Li(+) and K(+). Generates a biphasic current with a fast inactivating and a slow sustained phase. Heteromeric channel assembly seems to modulate. T86541 BIOCLASS Amiloride-sensitive sodium channel T86541 SEQUENCE MDLKESPSEGSLQPSSIQIFANTSTLHGIRHIFVYGPLTIRRVLWAVAFVGSLGLLLVESSERVSYYFSYQHVTKVDEVVAQSLVFPAVTLCNLNGFRFSRLTTNDLYHAGELLALLDVNLQIPDPHLADPSVLEALRQKANFKHYKPKQFSMLEFLHRVGHDLKDMMLYCKFKGQECGHQDFTTVFTKYGKCYMFNSGEDGKPLLTTVKGGTGNGLEIMLDIQQDEYLPIWGETEETTFEAGVKVQIHSQSEPPFIQELGFGVAPGFQTFVATQEQRLTYLPPPWGECRSSEMGLDFFPVYSITACRIDCETRYIVENCNCRMVHMPGDAPFCTPEQHKECAEPALGLLAEKDSNYCLCRTPCNLTRYNKELSMVKIPSKTSAKYLEKKFNKSEKYISENILVLDIFFEALNYETIEQKKAYEVAALLGDIGGQMGLFIGASILTILELFDYIYELIKEKLLDLLGKEEDEGSHDENVSTCDTMPNHSETISHTVNVPLQTTLGTLEEIAC T86541 DRUGINFO D07VOF THA-904 Investigative T86541 DRUGINFO D06AVE A-317567 Investigative T94366 TARGETID T94366 T94366 UNIPROID CDC37_HUMAN T94366 TARGNAME Hsp90 co-chaperone Cdc37 (CDC37) T94366 GENENAME CDC37 T94366 TARGTYPE Literature-reported T94366 SYNONYMS p50Cdc37; Hsp90 co-chaperone Cdc37, N-terminally processed; Hsp90 chaperone protein kinase-targeting subunit; CDC37A T94366 FUNCTION Inhibits HSP90AA1 ATPase activity. Co-chaperone that binds to numerous kinases and promotes their interaction with the Hsp90 complex, resulting in stabilization and promotion of their activity. T94366 PDBSTRUC 5HPE; 5FWP; 5FWM; 5FWL; 5FWK T94366 SEQUENCE MVDYSVWDHIEVSDDEDETHPNIDTASLFRWRHQARVERMEQFQKEKEELDRGCRECKRKVAECQRKLKELEVAEGGKAELERLQAEAQQLRKEERSWEQKLEEMRKKEKSMPWNVDTLSKDGFSKSMVNTKPEKTEEDSEEVREQKHKTFVEKYEKQIKHFGMLRRWDDSQKYLSDNVHLVCEETANYLVIWCIDLEVEEKCALMEQVAHQTIVMQFILELAKSLKVDPRACFRQFFTKIKTADRQYMEGFNDELEAFKERVRGRAKLRIEKAMKEYEEEERKKRLGPGGLDPVEVYESLPEELQKCFDVKDVQMLQDAISKMDPTDAKYHMQRCIDSGLWVPNSKASEAKEGEEAGPGDPLLEAVPKTGDEKDVSV T82254 TARGETID T82254 T82254 FORMERID TTDI02372 T82254 UNIPROID BAK_HUMAN T82254 TARGNAME Apoptosis regulator BAK (BAK) T82254 GENENAME BAK1 T82254 TARGTYPE Literature-reported T82254 SYNONYMS CDN1; Bcl2like protein 7; Bcl2L7; Bcl2-L-7; Bcl2 homologous antagonist/killer; Bcl-2-like protein 7; Bcl-2 homologous antagonist/killer T82254 FUNCTION Upon arrival of cell death signals, promotes mitochondrial outer membrane (MOM) permeabilization by oligomerizing to form pores within the MOM. This releases apoptogenic factors into the cytosol, including cytochrome c, promoting the activation of caspase 9 which in turn processes and activates the effector caspases. Plays a role in the mitochondrial apoptosic process. T82254 PDBSTRUC 5VX1; 5VX0; 5VWZ; 5VWY; 5VWX T82254 BIOCLASS B-cell lymphoma Bcl-2 T82254 SEQUENCE MASGQGPGPPRQECGEPALPSASEEQVAQDTEEVFRSYVFYRHQQEQEAEGVAAPADPEMVTLPLQPSSTMGQVGRQLAIIGDDINRRYDSEFQTMLQHLQPTAENAYEYFTKIATSLFESGINWGRVVALLGFGYRLALHVYQHGLTGFLGQVTRFVVDFMLHHCIARWIAQRGGWVAALNLGNGPILNVLVVLGVVLLGQFVVRRFFKS T36581 TARGETID T36581 T36581 FORMERID TTDI03387 T36581 UNIPROID MAPK3_HUMAN T36581 TARGNAME MAPK-activated protein kinase 3 (MAPKAPK3) T36581 GENENAME MAPKAPK3 T36581 TARGTYPE Literature-reported T36581 SYNONYMS MAPKAPK3 T36581 FUNCTION Stress-activated serine/threonine-protein kinase involved in cytokines production, endocytosis, cell migration, chromatin remodeling and transcriptional regulation. Following stress, it is phosphorylated and activated by MAP kinase p38-alpha/MAPK14, leading to phosphorylation of substrates. Phosphorylates serine in the peptide sequence, Hyd-X-R-X2-S, where Hyd is a large hydrophobic residue. MAPKAPK2 and MAPKAPK3, share the same function and substrate specificity, but MAPKAPK3 kinase activity and level in protein expression are lower compared to MAPKAPK2. Phosphorylates HSP27/HSPB1, KRT18, KRT20, RCSD1, RPS6KA3, TAB3 and TTP/ZFP36. Mediates phosphorylation of HSP27/HSPB1 in response to stress, leading to dissociate HSP27/HSPB1 from large small heat-shock protein (sHsps) oligomers and impair their chaperone activities and ability to protect against oxidative stress effectively. Involved in inflammatory response by regulating tumor necrosis factor (TNF) and IL6 production post-transcriptionally: acts by phosphorylating AU-rich elements (AREs)-binding proteins, such as TTP/ZFP36, leading to regulate the stability and translation of TNF and IL6 mRNAs. Phosphorylation of TTP/ZFP36, a major post-transcriptional regulator of TNF, promotes its binding to 14-3-3 proteins and reduces its ARE mRNA affinity leading to inhibition of dependent degradation of ARE-containing transcript. Involved in toll-like receptor signaling pathway (TLR) in dendritic cells: required for acute TLR-induced macropinocytosis by phosphorylating and activating RPS6KA3. Also acts as a modulator of Polycomb-mediated repression. T36581 PDBSTRUC 3SHE; 3R1N; 3FXW; 3FHR T36581 ECNUMBER EC 2.7.11.1 T36581 SEQUENCE MDGETAEEQGGPVPPPVAPGGPGLGGAPGGRREPKKYAVTDDYQLSKQVLGLGVNGKVLECFHRRTGQKCALKLLYDSPKARQEVDHHWQASGGPHIVCILDVYENMHHGKRCLLIIMECMEGGELFSRIQERGDQAFTEREAAEIMRDIGTAIQFLHSHNIAHRDVKPENLLYTSKEKDAVLKLTDFGFAKETTQNALQTPCYTPYYVAPEVLGPEKYDKSCDMWSLGVIMYILLCGFPPFYSNTGQAISPGMKRRIRLGQYGFPNPEWSEVSEDAKQLIRLLLKTDPTERLTITQFMNHPWINQSMVVPQTPLHTARVLQEDKDHWDEVKEEMTSALATMRVDYDQVKIKDLKTSNNRLLNKRRKKQAGSSSASQGCNNQ T36581 DRUGINFO D0EW9J PMID17480064C16 Investigative T67339 TARGETID T67339 T67339 FORMERID TTDI03481 T67339 UNIPROID PRSS8_HUMAN T67339 TARGNAME Channel-activating protease 1 (CAP1) T67339 GENENAME PRSS8 T67339 TARGTYPE Literature-reported T67339 SYNONYMS Serine protease 8; Prostasin; CAP1 T67339 FUNCTION Possesses a trypsin-like cleavage specificity with a preference for poly-basic substrates. Stimulates epithelial sodium channel (ENaC) activity through activating cleavage of the gamma subunits (SCNN1G). T67339 PDBSTRUC 3GYM; 3GYL; 3FVF; 3E1X; 3E0P T67339 ECNUMBER EC 3.4.21.- T67339 SEQUENCE MAQKGVLGPGQLGAVAILLYLGLLRSGTGAEGAEAPCGVAPQARITGGSSAVAGQWPWQVSITYEGVHVCGGSLVSEQWVLSAAHCFPSEHHKEAYEVKLGAHQLDSYSEDAKVSTLKDIIPHPSYLQEGSQGDIALLQLSRPITFSRYIRPICLPAANASFPNGLHCTVTGWGHVAPSVSLLTPKPLQQLEVPLISRETCNCLYNIDAKPEEPHFVQEDMVCAGYVEGGKDACQGDSGGPLSCPVEGLWYLTGIVSWGDACGARNRPGVYTLASSYASWIQSKVTELQPRVVPQTQESQPDSNLCGSHLAFSSAPAQGLLRPILFLPLGLALGLLSPWLSEH T67339 DRUGINFO D00XOV B3C Investigative T00295 TARGETID T00295 T00295 FORMERID TTDR00656 T00295 UNIPROID MOG_HUMAN T00295 TARGNAME Myelin-oligodendrocyte glycoprotein (MOG) T00295 GENENAME MOG T00295 TARGTYPE Literature-reported T00295 SYNONYMS Myelinoligodendrocyte glycoprotein; MOG T00295 FUNCTION Mediates homophilic cell-cell adhesion. Minor component of the myelin sheath. May be involved in completion and/or maintenance of the myelin sheath and in cell- cell communication. {ECO:0000250}. T00295 PDBSTRUC 1Q70 T00295 BIOCLASS Immunoglobulin T00295 SEQUENCE MASLSRPSLPSCLCSFLLLLLLQVSSSYAGQFRVIGPRHPIRALVGDEVELPCRISPGKNATGMEVGWYRPPFSRVVHLYRNGKDQDGDQAPEYRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTCFFRDHSYQEEAAMELKVEDPFYWVSPGVLVLLAVLPVLLLQITVGLIFLCLQYRLRGKLRAEIENLHRTFDPHFLRVPCWKITLFVIVPVLGPLVALIICYNWLHRRLAGQFLEELRNPF T42976 TARGETID T42976 T42976 UNIPROID GSTA3_HUMAN T42976 TARGNAME Glutathione S-transferase A3 (GSTA3) T42976 GENENAME GSTA3 T42976 TARGTYPE Literature-reported T42976 SYNONYMS Glutathione S-transferase A3-3; GST class-alpha member 3 T42976 FUNCTION Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Catalyzes isomerization reactions that contribute to the biosynthesis of steroid hormones. Efficiently catalyze obligatory double-bond isomerizations of delta(5)-androstene-3,17-dione and delta(5)-pregnene-3,20-dione, precursors to testosterone and progesterone, respectively. T42976 PDBSTRUC 2VCV; 1TDI T42976 ECNUMBER EC 2.5.1.18 T42976 SEQUENCE MAGKPKLHYFNGRGRMEPIRWLLAAAGVEFEEKFIGSAEDLGKLRNDGSLMFQQVPMVEIDGMKLVQTRAILNYIASKYNLYGKDIKERALIDMYTEGMADLNEMILLLPLCRPEEKDAKIALIKEKTKSRYFPAFEKVLQSHGQDYLVGNKLSRADISLVELLYYVEELDSSLISNFPLLKALKTRISNLPTVKKFLQPGSPRKPPADAKALEEARKIFRF T05722 TARGETID T05722 T05722 FORMERID TTDR00019 T05722 UNIPROID ADH2_ENTHI T05722 TARGNAME Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2) T05722 GENENAME Entamo ADH2 T05722 TARGTYPE Literature-reported T05722 SYNONYMS Aldehydealcohol dehydrogenase 2; Aldehyde-alcohol dehydrogenase 2; Alcohol dehydrogenase; ADH; ACDH T05722 FUNCTION May be a critical enzyme in the fermentative pathway. This enzyme has two NAD(+)-dependent activities: ADH and ACDH. T05722 BIOCLASS CH-OH donor oxidoreductase T05722 SEQUENCE MSTQQTMTVDEHINQLVRKAQVALKEYLKPEYTQEKIDYIVKKASVAALDQHCALAAAAVEETGRGIFEDKATKNIFACEHVTHEMRHAKTVGIINVDPLYGITEIAEPVGVVCGVTPVTNPTSTAIFKSLISIKTRNPIVFSFHPSALKCSIMAAKIVRDAAIAAGAPENCIQWIEFGGIEASNKLMNHPGVATILATGGNAMVKAAYSSGKPALGVGAGNVPTYIEKTCNIKQAANDVVMSKSFDNGMICASEQAAIIDKEIYDQVVEEMKTLGAYFINEEEKAKLEKFMFGVNAYSADVNNARLNPKCPGMSPQWFAEQVGIKVPEDCNIICAVCKEVGPNEPLTREKLSPVLAILKAENTQDGIDKAEAMVEFNGRGHSAAIHSNDKAVVEKYALTMKACRILHNTPSSQGGIGSIYNYIWPSFTLGCGSYGGNSVSANVTYHNLLNIKRLADRRNNLQWFRVPPKIFFEPHSIRYLAELKELSKIFIVSDRMMYKLGYVDRVMDVLKRRSNEVEIEIFIDVEPDPSIQTVQKGLAVMNTFGPDNIIAIGGGSAMDAAKIMWLLYEHPEADFFAMKQKFIDLRKRAFKFPTMGKKARLICIPTTSGTGSEVTPFAVISDHETGKKYPLADYSLTPSVAIVDPMFTMSLPKRAIADTGLDVLVHATEAYVSVMANEYTDGLAREAVKLVFENLLKSYNGDLEAREKMHNAATIAGMAFASAFLGMDHSMAHKVGAAFHLPHGRCVAVLLPHVIRYNGQKPRKLAMWPKYNFYKADQRYMELAQMVGLKCNTPAEGVEAFAKACEELMKATETITGFKKANIDEAAWMSKVPEMALLAFEDQCSPANPRVPMVKDMEKILKAAYYPIA T05722 DRUGINFO D08NRK Cyclopropyl Investigative T05722 DRUGINFO D09NJF Trifluoroethanol Investigative T05722 DRUGINFO D0R5AJ Cyclobutyl Investigative T05722 DRUGINFO D06SPO 3,5-dichlorosalicylic acid Investigative T05722 DRUGINFO D0J2FY 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative T05722 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T27020 TARGETID T27020 T27020 FORMERID TTDR00600 T27020 UNIPROID Q27733_PLAFA T27020 TARGNAME Plasmodium Delta-aminolevulinic acid synthetase (Malaria DAAS) T27020 GENENAME Malaria DAAS T27020 TARGTYPE Literature-reported T27020 SYNONYMS Delta-aminolevulinic acid synthetase T27020 FUNCTION Vital for parasite haem synthesis and parasite survival. T27020 BIOCLASS Acyltransferase T27020 ECNUMBER EC 2.3.1.37 T27020 SEQUENCE MRKKRTLKVSINEIKKYCPFVKNIQFLYNTNEKKNNLVLSVMSDLCPVGKAINEKHFIIIDNKSKINIIKILKQANMQSKVLVQCIKNKNIEKENMSNDDLLKSGKRNNNVLFYDILEKNKNDHSFQINDNTIQKNNIIYKYINSLDEYKLFKNNCNNNLKDLLNKLYTDKRYRIFTILNKYRINYPNVYIENNKLMLPSFYEFYQKYGYKPCIGNIRYQLSASFEDNNKNICSFSHKNKENYLFNFWNLHIDNVSNEKTVVWCSNDYLCLSNNEKIIEVGIETLKKIGNSSGGTRNISGSLLNHTHLEYIIAKWYNKESSLLFTSGYIANVGALETLGKLLNLIYISDEMNHASIINGIRESRCEKFIFKHNDMNDLERILYNLRINKQYENRKIMIVFESIYSMSGHISNIEYIVQLAKKYNALTYVDEVHAVGLYGNKGSGYLEELHLCNHIDIINGTLSKAIGSLGGFICANKYYIDVIRSYSSHFIFTTSLTPVNINTSAEAIHIIQNDMSLRKKLTQVVNKTKQKLQERGIQVLHNNSHIVVLMINSAEKCKQICDDLLKEYNIYIQPINYPTVPMGMERIRITPSPFHTDEQIFKLVNSLYTLFKKYQVNMFDKKNKHTLMKL T92770 TARGETID T92770 T92770 UNIPROID ZIK1_HUMAN T92770 TARGNAME Zinc finger protein 762 (ZIK1) T92770 GENENAME ZIK1 T92770 TARGTYPE Literature-reported T92770 SYNONYMS ZNF762 T92770 FUNCTION May be a transcriptional repressor. T92770 BIOCLASS Krueppel C2H2-type zinc-finger protein family T92770 SEQUENCE MAAAALRAPTQVTVSPETHMDLTKGCVTFEDIAIYFSQDEWGLLDEAQRLLYLEVMLENFALVASLGCGHGTEDEETPSDQNVSVGVSQSKAGSSTQKTQSCEMCVPVLKDILHLADLPGQKPYLVGECTNHHQHQKHHSAKKSLKRDMDRASYVKCCLFCMSLKPFRKWEVGKDLPAMLRLLRSLVFPGGKKPGTITECGEDIRSQKSHYKSGECGKASRHKHTPVYHPRVYTGKKLYECSKCGKAFRGKYSLVQHQRVHTGERPWECNECGKFFSQTSHLNDHRRIHTGERPYECSECGKLFRQNSSLVDHQKIHTGARPYECSQCGKSFSQKATLVKHQRVHTGERPYKCGECGNSFSQSAILNQHRRIHTGAKPYECGQCGKSFSQKATLIKHQRVHTGERPYKCGDCGKSFSQSSILIQHRRIHTGARPYECGQCGKSFSQKSGLIQHQVVHTGERPYECNKCGNSFSQCSSLIHHQKCHNT T91842 TARGETID T91842 T91842 FORMERID TTDNC00393 T91842 UNIPROID CRTC2_HUMAN T91842 TARGNAME CREB-regulated transcription coactivator 2 (TORC2) T91842 GENENAME CRTC2 T91842 TARGTYPE Literature-reported T91842 SYNONYMS Transducer of regulated cAMP response elementbinding protein 2; Transducer of CREB protein 2; CRTC2; CREBregulated transcription coactivator 2 T91842 FUNCTION Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133'phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates gluconeogenesis as a component of the LKB1/AMPK/TORC2 signaling pathway. Regulates the expression of specific genes such as thesteroidogenic gene, StAR. Potent coactivator of PPARGC1A and inducer of mitochondrial biogenesis in muscle cells. Also coactivator for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeats (LTR). T91842 PDBSTRUC 4HTM T91842 BIOCLASS Transducer of regulated CREB T91842 SEQUENCE MATSGANGPGSATASASNPRKFSEKIALQKQRQAEETAAFEEVMMDIGSTRLQAQKLRLAYTRSSHYGGSLPNVNQIGSGLAEFQSPLHSPLDSSRSTRHHGLVERVQRDPRRMVSPLRRYTRHIDSSPYSPAYLSPPPESSWRRTMAWGNFPAEKGQLFRLPSALNRTSSDSALHTSVMNPSPQDTYPGPTPPSILPSRRGGILDGEMDPKVPAIEENLLDDKHLLKPWDAKKLSSSSSRPRSCEVPGINIFPSPDQPANVPVLPPAMNTGGSLPDLTNLHFPPPLPTPLDPEETAYPSLSGGNSTSNLTHTMTHLGISRGMGLGPGYDAPGLHSPLSHPSLQSSLSNPNLQASLSSPQPQLQGSHSHPSLPASSLARHVLPTTSLGHPSLSAPALSSSSSSSSTSSPVLGAPSYPASTPGASPHHRRVPLSPLSLLAGPADARRSQQQLPKQFSPTMSPTLSSITQGVPLDTSKLSTDQRLPPYPYSSPSLVLPTQPHTPKSLQQPGLPSQSCSVQSSGGQPPGRQSHYGTPYPPGPSGHGQQSYHRPMSDFNLGNLEQFSMESPSASLVLDPPGFSEGPGFLGGEGPMGGPQDPHTFNHQNLTHCSRHGSGPNIILTGDSSPGFSKEIAAALAGVPGFEVSAAGLELGLGLEDELRMEPLGLEGLNMLSDPCALLPDPAVEESFRSDRLQ T77616 TARGETID T77616 T77616 FORMERID TTDI00017 T77616 UNIPROID AGK_HUMAN T77616 TARGNAME Acylglycerol kinase (AGK) T77616 GENENAME AGK T77616 TARGTYPE Literature-reported T77616 SYNONYMS hAGK; Multisubstrate lipid kinase; Multiple substrate lipid kinase; MuLK; HsMuLK; Acylglycerol kinase, mitochondrial; AGK T77616 FUNCTION Lipid kinase that can phosphorylate both monoacylglycerol and diacylglycerol to form lysophosphatidic acid (LPA) and phosphatidic acid (PA), respectively. Does not phosphorylate sphingosine. Overexpression increases the formation and secretion of LPA, resulting in transactivation of EGFR and activation of the downstream MAPK signaling pathway, leading to increased cell growth. T77616 BIOCLASS Kinase T77616 ECNUMBER EC 2.7.1.107 T77616 SEQUENCE MTVFFKTLRNHWKKTTAGLCLLTWGGHWLYGKHCDNLLRRAACQEAQVFGNQLIPPNAQVKKATVFLNPAACKGKARTLFEKNAAPILHLSGMDVTIVKTDYEGQAKKLLELMENTDVIIVAGGDGTLQEVVTGVLRRTDEATFSKIPIGFIPLGETSSLSHTLFAESGNKVQHITDATLAIVKGETVPLDVLQIKGEKEQPVFAMTGLRWGSFRDAGVKVSKYWYLGPLKIKAAHFFSTLKEWPQTHQASISYTGPTERPPNEPEETPVQRPSLYRRILRRLASYWAQPQDALSQEVSPEVWKDVQLSTIELSITTRNNQLDPTSKEDFLNICIEPDTISKGDFITIGSRKVRNPKLHVEGTECLQASQCTLLIPEGAGGSFSIDSEEYEAMPVEVKLLPRKLQFFCDPRKREQMLTSPTQ T87463 TARGETID T87463 T87463 FORMERID TTDR00260 T87463 UNIPROID Q56921_YEREN T87463 TARGNAME Fungal Protein kinase A (Fung ypkA) T87463 GENENAME Fung ypkA T87463 TARGTYPE Literature-reported T87463 SYNONYMS Protein kinase A T87463 FUNCTION Exists as a heterotetramer consisting of two regulatory subunits that bind and inactivate two catalytic subunits. T87463 BIOCLASS Kinase T87463 SEQUENCE MKIMGTMSPSISLAKAHERISKHWQNPVGELNIEGKRYRIIDNQVVRLNPHSGFSLFREGVGKIFSGKMFSFSIARNLTDTLHAAQKTTSQELRSDIPNALSNLFGAKPQTELPLGWKGKPLSGAPDLEGMRVAETDKFAEGESHISIIETKDKQRLVAKIERSIAEGHLFAELEAYKHIYKTAGKHPNLANVHGMAVVPYGNRKEEALLMDEVDGWRCSDTLRSLADSWKQGKINSEAYWGTIKFIAHRLLDVTNHLAKAGIVHNDIKPGNVVFDRASGEPVVIDLGLHSRSGEQPKGFTESFKAPELGVGNLGASEKSDVFLVVSSLLHGIEGFEKDPEIKPNQGLRFITSEPAHVMDENGYPIHRPGIAGVETAYTRFITDILGVSADSRPDSNEARLHEFLSDGTIDEESAKQILKDTLTGEMSPLPTDVRRITPKKLRELSDLLRTHLSSAATKQLDMGVVLSDLDTMLVALDKAEREGGVDKDQLKSFNSLILKTYSVIGAYIKGREGDTKSSSTEVSPYHRSNFMLSIVEPSLQRIQKHLDQTHSSDIGSLMRAHKHLETLLEVLVTLSQQGQPVTSETYSFLNRLAEAKVTLSQQLNTLQQQQESAKAQLSILINRSGSWADVARQSLLRFDSTRPVVKFGTEQYTAIHRQMMAAHAAITLQEVSEFTDDMRNFTADSIPLLIQLGRSSLMDEHLVEQREKLRELTTIAERLNRLEREWM T87463 DRUGINFO D0R2TM BALANOL Terminated T87463 DRUGINFO D06NOJ Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS) Investigative T87463 DRUGINFO D08OBO Rp-cAMPS Investigative T87463 DRUGINFO D0M5NU N6 benzyl-cAMP Investigative T87463 DRUGINFO D01TDV PMID21742770C1 Investigative T87463 DRUGINFO D0T9ZL chelerythrine Investigative T87463 DRUGINFO D0UB2J [3H]cAMP Investigative T87463 DRUGINFO D01YWE PMID19364658C33 Investigative T87463 DRUGINFO D0IX7Y BX-912 Investigative T87463 DRUGINFO D0RG0Z BX-795 Investigative T87463 DRUGINFO D0L2WP PMID20005102C1 Investigative T87463 DRUGINFO D09XIL Ro-4396686 Investigative T87463 DRUGINFO D0A5RM 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative T26357 TARGETID T26357 T26357 FORMERID TTDR00254 T26357 UNIPROID PYRB_PSEPU T26357 TARGNAME Pseudomonas Aspartate carbamoyltransferase (Pseudo pyrB) T26357 GENENAME Pseudo pyrB T26357 TARGTYPE Literature-reported T26357 SYNONYMS PYRB; L-aspartic acid transcarbamylase; L-aspartate transcarbamoylase; Aspartate transcarbamylase; ATCase; ACTase T26357 FUNCTION Involved in allosteric regulation of aspartate carbamoyltransferase. T26357 BIOCLASS Methyltransferase T26357 ECNUMBER EC 2.1.3.2 T26357 SEQUENCE MTPIDAKRPLQLNDQGQLRHFLSLDGLPRELLTEILDTADSFLEVGARAVKKVPLLRGKTVCNVFFENSTRTRTTFELAAQRLSADVISLNVSTSSTSKGETLFDTLRNLEAMAADMFVVRHSDSGAAHFIAEHVCPDVAVINGGDGRHAHPTQGMLDMLTIRRHKGSFENLSVAIVGDILHSRVARSDMLALKALGCPDIRVIGPKTLIPIGIEQYGVKVYTDLAEGLKDVDVVIMLRLQRERMAGGLLPSEGEFYRLFGLTTARLACAKPDAIVMHPGPINRGVEIESAVADGKHSVILNQVTYGIAVRMAVLSMAMSGQNAQRQFDQENAQ T26357 DRUGINFO D0L6CN N-(phosphonacetyl)-L-aspartate Investigative T85161 TARGETID T85161 T85161 FORMERID TTDNR00645 T85161 UNIPROID CLPP_WOLTR T85161 TARGNAME Bacterial ATP-dependent Clp proteolytic protease (Bact clpP) T85161 GENENAME Bact clpP T85161 TARGTYPE Literature-reported T85161 SYNONYMS clpP; Bact Endopeptidase Clp T85161 FUNCTION Cleaves peptides in various proteins ina process that requires ATP hydrolysis. Has a chymotrypsin-like activity. Plays a major role in the degradation of misfolded proteins. T85161 BIOCLASS Peptidase T85161 ECNUMBER EC 3.4.21.92 T85161 SEQUENCE MTLIPIVIEQTSRGERAYDIYSRLVKERIIFVTGPVEDNMASVIVAQLLFLESENPDKDIYMYINSPGGVVTAGLSIYDTMQYIKPDVSTLCIGQAASMGSLLLAAGTEGKRYSLPHSRIMIHQPSGGYQGQATDIEIHANEILRVKRKLNQIYEKHTGNSLKKIEGMMERDKFMDPEEARRIGLIDRVIAERKDIKVENIKVEQKVG T57750 TARGETID T57750 T57750 FORMERID TTDR00024 T57750 UNIPROID MENB_STAAC T57750 TARGNAME Staphylococcus DHNA-CoA synthase (Stap-coc menB) T57750 GENENAME Stap-coc menB T57750 TARGTYPE Literature-reported T57750 SYNONYMS DHNA-CoA synthase; 1,4-dihydroxy-2-naphthoyl-CoA synthase T57750 FUNCTION Converts o-succinylbenzoyl-CoA (OSB-CoA) to 1,4-dihydroxy-2-naphthoyl-CoA (DHNA-CoA). T57750 PDBSTRUC 2UZF T57750 BIOCLASS Carbon-carbon lyase T57750 SEQUENCE MTNRQWETLREYDEIKYEFYEGIAKVTINRPEVRNAFTPKTVAEMIDAFSRARDDQNVSVIVLTGEGDLAFCSGGDQKKRGHGGYVGEDQIPRLNVLDLQRLIRIIPKPVIAMVKGYAVGGGNVLNVVCDLTIAADNAIFGQTGPKVGSFDAGYGSGYLARIVGHKKAREIWYLCRQYNAQEALDMGLVNTVVPLEKVEDETVQWCKEIMKHSPTALRFLKAAMNADTDGLAGLQQMAGDATLLYYTTDEAKEGRDAFKEKRDPDFDQFPKFP T57750 DRUGINFO D06CGD Acetoacetyl-Coenzyme A Investigative T57750 DRUGINFO D0W3NA Coenzyme A Investigative T00075 TARGETID T00075 T00075 FORMERID TTDI03101 T00075 UNIPROID MRCKA_HUMAN T00075 TARGNAME CDC42 binding protein kinase alpha (DMPK-like alpha) T00075 GENENAME CDC42BPA T00075 TARGTYPE Literature-reported T00075 SYNONYMS Serine/threonine-protein kinase MRCK alpha; Myotonic dystrophy protein kinase-like alpha; Myotonic dystrophy kinase-related CDC42-binding kinase alpha; MRCK alpha; KIAA0451; CDC42-binding protein kinase alpha T00075 FUNCTION Regulates actin cytoskeletal reorganization via phosphorylation of PPP1R12C and MYL9/MLC2. In concert with MYO18A and LURAP1, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration. Phosphorylates: PPP1R12A, LIMK1 and LIMK2. May play a role in TFRC-mediated iron uptake. In concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the lamellipodium resulting in its activation and subsequent phosphorylation of CFL1 which is important for lamellipodial F-actin regulation. Serine/threonine-protein kinase which is an important downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization and cell migration. T00075 BIOCLASS Kinase T00075 ECNUMBER EC 2.7.11.1 T00075 SEQUENCE MSGEVRLRQLEQFILDGPAQTNGQCFSVETLLDILICLYDECNNSPLRREKNILEYLEWAKPFTSKVKQMRLHREDFEILKVIGRGAFGEVAVVKLKNADKVFAMKILNKWEMLKRAETACFREERDVLVNGDNKWITTLHYAFQDDNNLYLVMDYYVGGDLLTLLSKFEDRLPEDMARFYLAEMVIAIDSVHQLHYVHRDIKPDNILMDMNGHIRLADFGSCLKLMEDGTVQSSVAVGTPDYISPEILQAMEDGKGRYGPECDWWSLGVCMYEMLYGETPFYAESLVETYGKIMNHKERFQFPAQVTDVSENAKDLIRRLICSREHRLGQNGIEDFKKHPFFSGIDWDNIRNCEAPYIPEVSSPTDTSNFDVDDDCLKNSETMPPPTHTAFSGHHLPFVGFTYTSSCVLSDRSCLRVTAGPTSLDLDVNVQRTLDNNLATEAYERRIKRLEQEKLELSRKLQESTQTVQALQYSTVDGPLTASKDLEIKNLKEEIEKLRKQVTESSHLEQQLEEANAVRQELDDAFRQIKAYEKQIKTLQQEREDLNKELVQASERLKNQSKELKDAHCQRKLAMQEFMEINERLTELHTQKQKLARHVRDKEEEVDLVMQKVESLRQELRRTERAKKELEVHTEALAAEASKDRKLREQSEHYSKQLENELEGLKQKQISYSPGVCSIEHQQEITKLKTDLEKKSIFYEEELSKREGIHANEIKNLKKELHDSEGQQLALNKEIMILKDKLEKTRRESQSEREEFESEFKQQYEREKVLLTEENKKLTSELDKLTTLYENLSIHNQQLEEEVKDLADKKESVAHWEAQITEIIQWVSDEKDARGYLQALASKMTEELEALRNSSLGTRATDMPWKMRRFAKLDMSARLELQSALDAEIRAKQAIQEELNKVKASNIITECKLKDSEKKNLELLSEIEQLIKDTEELRSEKGIEHQDSQHSFLAFLNTPTDALDQFERSPSCTPASKGRRTVDSTPLSVHTPTLRKKGCPGSTGFPPKRKTHQFFVKSFTTPTKCHQCTSLMVGLIRQGCSCEVCGFSCHITCVNKAPTTCPVPPEQTKGPLGIDPQKGIGTAYEGHVRIPKPAGVKKGWQRALAIVCDFKLFLYDIAEGKASQPSVVISQVIDMRDEEFSVSSVLASDVIHASRKDIPCIFRVTASQLSASNNKCSILMLADTENEKNKWVGVLSELHKILKKNKFRDRSVYVPKEAYDSTLPLIKTTQAAAIIDHERIALGNEEGLFVVHVTKDEIIRVGDNKKIHQIELIPNDQLVAVISGRNRHVRLFPMSALDGRETDFYKLSETKGCQTVTSGKVRHGALTCLCVAMKRQVLCYELFQSKTRHRKFKEIQVPYNVQWMAIFSEQLCVGFQSGFLRYPLNGEGNPYSMLHSNDHTLSFIAHQPMDAICAVEISSKEYLLCFNSIGIYTDCQGRRSRQQELMWPANPSSCCYNAPYLSVYSENAVDIFDVNSMEWIQTLPLKKVRPLNNEGSLNLLGLETIRLIYFKNKMAEGDELVVPETSDNSRKQMVRNINNKRRYSFRVPEEERMQQRREMLRDPEMRNKLISNPTNFNHIAHMGPGDGIQILKDLPMNPRPQESRTVFSGSVSIPSITKSRPEPGRSMSASSGLSARSSAQNGSALKREFSGGSYSAKRQPMPSPSEGSLSSGGMDQGSDAPARDFDGEDSDSPRHSTASNSSNLSSPPSPASPRKTKSLSLESTDRGSWDP T00075 DRUGINFO D03CPB RKI-1447 Investigative T01725 TARGETID T01725 T01725 FORMERID TTDNR00736 T01725 UNIPROID HHAT_HUMAN T01725 TARGNAME Protein-cysteine N-palmitoyltransferase HHAT (HHAT) T01725 GENENAME HHAT T01725 TARGTYPE Literature-reported T01725 SYNONYMS Skinny hedgehog protein 1; Melanoma antigen recognized by T-cells 2; MART-2; Hedgehog acyltransferase; HHAT T01725 FUNCTION Catalyzes N-terminal palmitoylation of SHH; which is required for SHH signaling. May bind GTP. . T01725 BIOCLASS Acyltransferase T01725 ECNUMBER EC 2.3.1.- T01725 SEQUENCE MLPRWELALYLLASLGFHFYSFYEVYKVSREHEEELDQEFELETDTLFGGLKKDATDFEWSFWMEWGKQWLVWLLLGHMVVSQMATLLARKHRPWILMLYGMWACWCVLGTPGVAMVLLHTTISFCVAQFRSQLLTWLCSLLLLSTLRLQGVEEVKRRWYKTENEYYLLQFTLTVRCLYYTSFSLELCWQQLPAASTSYSFPWMLAYVFYYPVLHNGPILSFSEFIKQMQQQEHDSLKASLCVLALGLGRLLCWWWLAELMAHLMYMHAIYSSIPLLETVSCWTLGGLALAQVLFFYVKYLVLFGVPALLMRLDGLTPPALPRCVSTMFSFTGMWRYFDVGLHNFLIRYVYIPVGGSQHGLLGTLFSTAMTFAFVSYWHGGYDYLWCWAALNWLGVTVENGVRRLVETPCIQDSLARYFSPQARRRFHAALASCSTSMLILSNLVFLGGNEVGKTYWNRIFIQGWPWVTLSVLGFLYCYSHVGIAWAQTYATD T79332 TARGETID T79332 T79332 FORMERID TTDNR00675 T79332 UNIPROID FAAH2_HUMAN T79332 TARGNAME Fatty-acid amide hydrolase 2 (FAAH2) T79332 GENENAME FAAH2 T79332 TARGTYPE Literature-reported T79332 SYNONYMS Oleamide hydrolase 2; Anandamide amidohydrolase 2; Amidase domain-containing protein; AMDD T79332 FUNCTION Hydrolyzes monounsaturated substrate anandamide preferentially as compared to polyunsaturated substrates. Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. T79332 BIOCLASS Carbon-nitrogen hydrolase T79332 ECNUMBER EC 3.5.1.99 T79332 SEQUENCE MAPSFTARIQLFLLRALGFLIGLVGRAALVLGGPKFASKTPRPVTEPLLLLSGMQLAKLIRQRKVKCIDVVQAYINRIKDVNPMINGIVKYRFEEAMKEAHAVDQKLAEKQEDEATLENKWPFLGVPLTVKEAFQLQGMPNSSGLMNRRDAIAKTDATVVALLKGAGAIPLGITNCSELCMWYESSNKIYGRSNNPYDLQHIVGGSSGGEGCTLAAACSVIGVGSDIGGSIRMPAFFNGIFGHKPSPGVVPNKGQFPLAVGAQELFLCTGPMCRYAEDLAPMLKVMAGPGIKRLKLDTKVHLKDLKFYWMEHDGGSFLMSKVDQDLIMTQKKVVVHLETILGASVQHVKLKKMKYSFQLWIAMMSAKGHDGKEPVKFVDLLGDHGKHVSPLWELIKWCLGLSVYTIPSIGLALLEEKLRYSNEKYQKFKAVEESLRKELVDMLGDDGVFLYPSHPTVAPKHHVPLTRPFNFAYTGVFSALGLPVTQCPLGLNAKGLPLGIQVVAGPFNDHLTLAVAQYLEKTFGGWVCPGKF T90787 TARGETID T90787 T90787 UNIPROID NAPEP_HUMAN T90787 TARGNAME NAPE-hydrolyzing phospholipase D (NAPE-PLD) T90787 GENENAME NAPEPLD T90787 TARGTYPE Literature-reported T90787 SYNONYMS NAPE-PLD; N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D; N-acyl phosphatidylethanolamine phospholipase D; C7orf18 T90787 FUNCTION Hydrolyzes N-acyl-phosphatidylethanolamines (NAPEs) to produce N-acylethanolamines (NAEs) and phosphatidic acid. Responsible for the generation of these bioactive fatty acid ethanolamides (FAEs), including anandamide (N-arachidonoylethanolamine), the ligand of cannabinoid and vanilloid receptors. As a regulator of lipid metabolism in the adipose tissue, mediates the crosstalk between adipocytes, gut microbiota and immune cells to control body temperature and weight. In particular, regulates energy homeostasis by promoting cold-induced brown or beige adipocyte differentiation program to generate heat from fatty acids and glucose (By similarity). T90787 PDBSTRUC 4QN9 T90787 ECNUMBER EC 3.1.4.54 T90787 SEQUENCE MDENESNQSLMTSSQYPKEAVRKRQNSARNSGASDSSRFSRKSFKLDYRLEEDVTKSKKGKDGRFVNPWPTWKNPSIPNVLRWLIMEKDHSSVPSSKEELDKELPVLKPYFITNPEEAGVREAGLRVTWLGHATVMVEMDELIFLTDPIFSSRASPSQYMGPKRFRRSPCTISELPPIDAVLISHNHYDHLDYNSVIALNERFGNELRWFVPLGLLDWMQKCGCENVIELDWWEENCVPGHDKVTFVFTPSQHWCKRTLMDDNKVLWGSWSVLGPWNRFFFAGDTGYCPAFEEIGKRFGPFDLAAIPIGAYEPRWFMKYQHVDPEEAVRIHTDVQTKKSMAIHWGTFALANEHYLEPPVKLNEALERYGLNAEDFFVLKHGESRYLNNDDENF T91786 TARGETID T91786 T91786 UNIPROID STYK1_HUMAN T91786 TARGNAME Tyrosine-protein kinase STYK1 (STYK1) T91786 GENENAME STYK1 T91786 TARGTYPE Literature-reported T91786 SYNONYMS Serine/threonine/tyrosine kinase 1; Protein PK-unique; Novel oncogene with kinase domain; NOK T91786 FUNCTION Probable tyrosine protein-kinase, which has strong transforming capabilities on a variety of cell lines. When overexpressed, it can also induce tumor cell invasion as well as metastasis in distant organs. May act by activating both MAP kinase and phosphatidylinositol 3'-kinases (PI3K) pathways. T91786 BIOCLASS Protein kinase superfamily. Tyr protein kinase family T91786 ECNUMBER EC 2.7.10.2 T91786 SEQUENCE MGMTRMLLECSLSDKLCVIQEKQYEVIIVPTLLVTIFLILLGVILWLFIREQRTQQQRSGPQGIAPVPPPRDLSWEAGHGGNVALPLKETSVENFLGATTPALAKLQVPREQLSEVLEQICSGSCGPIFRANMNTGDPSKPKSVILKALKEPAGLHEVQDFLGRIQFHQYLGKHKNLVQLEGCCTEKLPLYMVLEDVAQGDLLSFLWTCRRDVMTMDGLLYDLTEKQVYHIGKQVLLALEFLQEKHLFHGDVAARNILMQSDLTAKLCGLGLAYEVYTRGAISSTQTIPLKWLAPERLLLRPASIRADVWSFGILLYEMVTLGAPPYPEVPPTSILEHLQRRKIMKRPSSCTHTMYSIMKSCWRWREADRPSPRELRLRLEAAIKTADDEAVLQVPELVVPELYAAVAGIRVESLFYNYSML T16188 TARGETID T16188 T16188 FORMERID TTDI03613 T16188 UNIPROID ULK3_HUMAN T16188 TARGNAME Unc-51 like kinase 3 (ULK3) T16188 GENENAME ULK3 T16188 TARGTYPE Literature-reported T16188 SYNONYMS Unc-51-like kinase 3; Serine/threonine-protein kinase ULK3 T16188 FUNCTION Serine/threonine protein kinase that acts as a regulator of Sonic hedgehog (SHH) signaling and autophagy. Acts as a negative regulator of SHH signaling in the absence of SHH ligand: interacts with SUFU, thereby inactivating the protein kinase activity and preventing phosphorylation of GLI proteins (GLI1, GLI2 and/or GLI3). Positively regulates SHH signaling in the presence of SHH: dissociates from SUFU, autophosphorylates and mediates phosphorylation of GLI2, activating it and promoting its nuclear translocation. Phosphorylates in vitro GLI2, as well as GLI1 and GLI3, although less efficiently. Also acts as a regulator of autophagy: following cellular senescence, able to induce autophagy. T16188 PDBSTRUC 6FDZ; 6FDY; 4WZX T16188 ECNUMBER EC 2.7.11.1 T16188 SEQUENCE MAGPGWGPPRLDGFILTERLGSGTYATVYKAYAKKDTREVVAIKCVAKKSLNKASVENLLTEIEILKGIRHPHIVQLKDFQWDSDNIYLIMEFCAGGDLSRFIHTRRILPEKVARVFMQQLASALQFLHERNISHLDLKPQNILLSSLEKPHLKLADFGFAQHMSPWDEKHVLRGSPLYMAPEMVCQRQYDARVDLWSMGVILYEALFGQPPFASRSFSELEEKIRSNRVIELPLRPLLSRDCRDLLQRLLERDPSRRISFQDFFAHPWVDLEHMPSGESLGRATALVVQAVKKDQEGDSAAALSLYCKALDFFVPALHYEVDAQRKEAIKAKVGQYVSRAEELKAIVSSSNQALLRQGTSARDLLREMARDKPRLLAALEVASAAMAKEEAAGGEQDALDLYQHSLGELLLLLAAEPPGRRRELLHTEVQNLMARAEYLKEQVKMRESRWEADTLDKEGLSESVRSSCTLQ T16188 DRUGINFO D0G4CS PMID24900237C15 Investigative T88699 TARGETID T88699 T88699 FORMERID TTDI02611 T88699 UNIPROID PAOX_HUMAN T88699 TARGNAME Polyamine oxidase (PAOX) T88699 GENENAME PAOX T88699 TARGTYPE Literature-reported T88699 SYNONYMS Peroxisomal N(1)acetylspermine/spermidine oxidase; PAOX T88699 FUNCTION Flavoenzyme which catalyzes the oxidation of N(1)- acetylspermine to spermidine and is thus involved in the polyamine back-conversion. Can also oxidize N(1)-acetylspermidine to putrescine. Substrate specificity: N(1)-acetylspermine = N(1)- acetylspermidine > N(1),N(12)-diacylspermine >> spermine. Does not oxidize spermidine. Plays an important role in the regulation of polyamine intracellular concentration and has the potential to act as a determinant of cellular sensitivity to the antitumor polyamine analogs. T88699 BIOCLASS CH-NH donor oxidoreductase T88699 ECNUMBER EC 1.5.3.13 T88699 SEQUENCE MESTGSVGEAPGGPRVLVVGGGIAGLGAAQRLCGHSAFPHLRVLEATARAGGRIRSERCFGGVVEVGAHWIHGPSRGNPVFQLAAEYGLLGEKELSQENQLVETGGHVGLPSVSYASSGASVSLQLVAEMATLFYGLIDQTREFLHAAETPVPSVGEYLKKEIGQHVAGWTEDEETRKLKLAVLNSFFNLECCVSGTHSMDLVALAPFGEYTVLPGLDCTFSKGYQGLTNCMMAALPEDTVVFEKPVKTIHWNGSFQEAAFPGETFPVSVECEDGDRFPAHHVIVTVPLGFLREHLDTFFDPPLPAEKAEAIRKIGFGTNNKIFLEFEEPFWEPDCQLIQLVWEDTSPLEDAAPELQDAWFRKLIGFVVLPAFASVHVLCGFIAGLESEFMETLSDEEVLLCLTQVLRRVTGNPRLPAPKSVLRSRWHSAPYTRGSYSYVAVGSTGGDLDLLAQPLPADGAGAQLQILFAGEATHRTFYSTTHGALLSGWREADRLLSLWAPQVQQPRPRL T18784 TARGETID T18784 T18784 FORMERID TTDI03365 T18784 UNIPROID KDM7A_HUMAN T18784 TARGNAME Lysine-specific demethylase 7A (KDM7A) T18784 GENENAME KDM7A T18784 TARGTYPE Literature-reported T18784 SYNONYMS Lysine-specific demethylase 7; KIAA1718; KDM7; JmjC domain-containing histone demethylation protein 1D; JHDM1D T18784 FUNCTION Histone demethylase required for brain development. Specifically demethylates dimethylated 'Lys-9' and 'Lys-27' (H3K9me2 and H3K27me2, respectively) of histone H3 and monomethylated histone H4 'Lys-20' residue (H4K20Me1), thereby playing a central role in histone code. Specifically binds trimethylated 'Lys-4' of histone H3 (H3K4me3), affecting histone demethylase specificity: in presence of H3K4me3, it has no demethylase activity toward H3K9me2, while it has high activity toward H3K27me2. Demethylates H3K9me2 in absence of H3K4me3. Has activity toward H4K20Me1 only when nucleosome is used as a substrate and when not histone octamer is used as substrate. T18784 PDBSTRUC 3U78; 3KVB; 3KVA; 3KV9; 3KV6 T18784 ECNUMBER EC 1.14.11.- T18784 SEQUENCE MAGAAAAVAAGAAAGAAAAAVSVAAPGRASAPPPPPPVYCVCRQPYDVNRFMIECDICKDWFHGSCVGVEEHHAVDIDLYHCPNCAVLHGSSLMKKRRNWHRHDYTEIDDGSKPVQAGTRTFIKELRSRVFPSADEIIIKMHGSQLTQRYLEKHGFDVPIMVPKLDDLGLRLPSPTFSVMDVERYVGGDKVIDVIDVARQADSKMTLHNYVKYFMNPNRPKVLNVISLEFSDTKMSELVEVPDIAKKLSWVENYWPDDSVFPKPFVQKYCLMGVQDSYTDFHIDFGGTSVWYHVLWGEKIFYLIKPTDENLARYESWSSSVTQSEVFFGDKVDKCYKCVVKQGHTLFVPTGWIHAVLTSQDCMAFGGNFLHNLNIGMQLRCYEMEKRLKTPDLFKFPFFEAICWFVAKNLLETLKELREDGFQPQTYLVQGVKALHTALKLWMKKELVSEHAFEIPDNVRPGHLIKELSKVIRAIEEENGKPVKSQGIPIVCPVSRSSNEATSPYHSRRKMRKLRDHNVRTPSNLDILELHTREVLKRLEMCPWEEDILSSKLNGKFNKHLQPSSTVPEWRAKDNDLRLLLTNGRIIKDERQPFADQSLYTADSENEEDKRRTKKAKMKIEESSGVEGVEHEESQKPLNGFFTRVKSELRSRSSGYSDISESEDSGPECTALKSIFTTEESESSGDEKKQEITSNFKEESNVMRNFLQKSQKPSRSEIPIKRECPTSTSTEEEAIQGMLSMAGLHYSTCLQRQIQSTDCSGERNSLQDPSSCHGSNHEVRQLYRYDKPVECGYHVKTEDPDLRTSSWIKQFDTSRFHPQDLSRSQKCIRKEGSSEISQRVQSRNYVDSSGSSLQNGKYMQNSNLTSGACQISNGSLSPERPVGETSFSVPLHPTKRPASNPPPISNQATKGKRPKKGMATAKQRLGKILKLNRNGHARFFV T18784 DRUGINFO D0B2WZ daminozide Investigative T68208 TARGETID T68208 T68208 FORMERID TTDNR00635 T68208 UNIPROID ADM2_HUMAN T68208 TARGNAME Adrenomedullin 2 (ADM2) T68208 GENENAME ADM2 T68208 TARGTYPE Literature-reported T68208 SYNONYMS Intermedin; ADM2 T68208 FUNCTION IMDL and IMDS may play a role as physiological regulators of gastrointestinal, cardiovascular bioactivities mediated by the CALCRL/RAMPs receptor complexes. Activates the cAMP-dependent pathway. T68208 PDBSTRUC 6D1U T68208 BIOCLASS Adrenomedullin T68208 SEQUENCE MARIPTAALGCISLLCLQLPGSLSRSLGGDPRPVKPREPPARSPSSSLQPRHPAPRPVVWKLHRALQAQRGAGLAPVMGQPLRDGGRQHSGPRRHSGPRRTQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSYG T92208 TARGETID T92208 T92208 UNIPROID NEK8_HUMAN T92208 TARGNAME Serine/threonine-protein kinase Nek8 (NEK8) T92208 GENENAME NEK8 T92208 TARGTYPE Literature-reported T92208 SYNONYMS Nima-related protein kinase 12a; NimA-related protein kinase 8; Never in mitosis A-related kinase 8; NEK12A; JCK T92208 FUNCTION Required for renal tubular integrity. May regulate local cytoskeletal structure in kidney tubule epithelial cells. May regulate ciliary biogenesis through targeting of proteins to the cilia. Plays a role in organogenesis and is involved in the regulation of the Hippo signaling pathway. T92208 BIOCLASS Protein kinase superfamily. NEK Ser/Thr protein kinase family T92208 ECNUMBER EC 2.7.11.1 T92208 SEQUENCE MEKYERIRVVGRGAFGIVHLCLRKADQKLVIIKQIPVEQMTKEERQAAQNECQVLKLLNHPNVIEYYENFLEDKALMIAMEYAPGGTLAEFIQKRCNSLLEEETILHFFVQILLALHHVHTHLILHRDLKTQNILLDKHRMVVKIGDFGISKILSSKSKAYTVVGTPCYISPELCEGKPYNQKSDIWALGCVLYELASLKRAFEAANLPALVLKIMSGTFAPISDRYSPELRQLVLSLLSLEPAQRPPLSHIMAQPLCIRALLNLHTDVGSVRMRRAEKSVAPSNTGSRTTSVRCRGIPRGPVRPAIPPPLSSVYAWGGGLGTPLRLPMLNTEVVQVAAGRTQKAGVTRSGRLILWEAPPLGAGGGSLLPGAVEQPQPQFISRFLEGQSGVTIKHVACGDFFTACLTDRGIIMTFGSGSNGCLGHGSLTDISQPTIVEALLGYEMVQVACGASHVLALSTERELFAWGRGDSGRLGLGTRESHSCPQQVPMPPGQEAQRVVCGIDSSMILTVPGQALACGSNRFNKLGLDHLSLGEEPVPHQQVEEALSFTLLGSAPLDQEPLLSIDLGTAHSAAVTASGDCYTFGSNQHGQLGTNTRRGSRAPCKVQGLEGIKMAMVACGDAFTVAIGAESEVYSWGKGARGRLGRRDEDAGLPRPVQLDETHPYTVTSVSCCHGNTLLAVRSVTDEPVPP T01441 TARGETID T01441 T01441 FORMERID TTDI00111 T01441 UNIPROID SYVN1_HUMAN T01441 TARGNAME Synovial apoptosis inhibitor 1 (SYVN1) T01441 GENENAME SYVN1 T01441 TARGTYPE Literature-reported T01441 SYNONYMS RING-type E3 ubiquitin transferase synoviolin; KIAA1810; HRD1; E3 ubiquitinprotein ligase synoviolin; E3 ubiquitin-protein ligase synoviolin T01441 FUNCTION Component of the endoplasmic reticulum quality control (ERQC) system also called ER-associated degradation (ERAD) involved in ubiquitin-dependent degradation of misfolded endoplasmic reticulum proteins. Also promotes the degradation of normal but naturally short-lived proteins such as SGK. Protects cells from ER stress-induced apoptosis. Protects neurons from apoptosis induced by polyglutamine-expanded huntingtin (HTT) or unfolded GPR37 by promoting their degradation. Sequesters p53/TP53 in the cytoplasm and promotes its degradation, thereby negatively regulating its biological function in transcription, cell cycle regulation and apoptosis. Mediates the ubiquitination and subsequent degradation of cytoplasmic NFE2L1. Acts as an E3 ubiquitin-protein ligase which accepts ubiquitin specifically from endoplasmic reticulum-associated UBC7 E2 ligase and transfers it to substrates, promoting their degradation. T01441 BIOCLASS Acyltransferase T01441 ECNUMBER EC 2.3.2.27 T01441 SEQUENCE MFRTAVMMAASLALTGAVVAHAYYLKHQFYPTVVYLTKSSPSMAVLYIQAFVLVFLLGKVMGKVFFGQLRAAEMEHLLERSWYAVTETCLAFTVFRDDFSPRFVALFTLLLFLKCFHWLAEDRVDFMERSPNISWLFHCRIVSLMFLLGILDFLFVSHAYHSILTRGASVQLVFGFEYAILMTMVLTIFIKYVLHSVDLQSENPWDNKAVYMLYTELFTGFIKVLLYMAFMTIMIKVHTFPLFAIRPMYLAMRQFKKAVTDAIMSRRAIRNMNTLYPDATPEELQAMDNVCIICREEMVTGAKRLPCNHIFHTSCLRSWFQRQQTCPTCRMDVLRASLPAQSPPPPEPADQGPPPAPHPPPLLPQPPNFPQGLLPPFPPGMFPLWPPMGPFPPVPPPPSSGEAVAPPSTSAAALSRPSGAATTTAAGTSATAASATASGPGSGSAPEAGPAPGFPFPPPWMGMPLPPPFAFPPMPVPPAGFAGLTPEELRALEGHERQHLEARLQSLRNIHTLLDAAMLQINQYLTVLASLGPPRPATSVNSTEETATTVVAAASSTSIPSSEATTPTPGASPPAPEMERPPAPESVGTEEMPEDGEPDAAELRRRRLQKLESPVAH T98395 TARGETID T98395 T98395 FORMERID TTDI00112 T98395 UNIPROID PRGC2_HUMAN T98395 TARGNAME PPAR-gamma coactivator 1-beta (PPARGC1B) T98395 GENENAME PPARGC1B T98395 TARGTYPE Literature-reported T98395 SYNONYMS Peroxisome proliferator-activated receptor gamma coactivator 1-beta; PPARGC1; PPARGC-1-beta; PGC1B; PGC1; PGC-1-related estrogen receptor alpha coactivator; PGC-1-beta; PERC T98395 FUNCTION Plays a role of stimulator of transcription factors and nuclear receptors activities. Activates transcriptional activity of estrogen receptor alpha, nuclear respiratory factor 1 (NRF1) and glucocorticoid receptor in the presence of glucocorticoids. May play a role in constitutive non-adrenergic-mediated mitochondrial biogenesis as suggested by increased basal oxygen consumption and mitochondrial number when overexpressed. May be involved in fat oxidation and non-oxidative glucose metabolism and in the regulation of energy expenditure. Induces the expression of PERM1 in the skeletal muscle in an ESRRA-dependent manner. T98395 PDBSTRUC 6D0Y; 3SP6 T98395 BIOCLASS RNA recognition motif T98395 SEQUENCE MAGNDCGALLDEELSSFFLNYLADTQGGGSGEEQLYADFPELDLSQLDASDFDSATCFGELQWCPENSETEPNQYSPDDSELFQIDSENEALLAELTKTLDDIPEDDVGLAAFPALDGGDALSCTSASPAPSSAPPSPAPEKPSAPAPEVDELSLLQKLLLATSYPTSSSDTQKEGTAWRQAGLRSKSQRPCVKADSTQDKKAPMMQSQSRSCTELHKHLTSAQCCLQDRGLQPPCLQSPRLPAKEDKEPGEDCPSPQPAPASPRDSLALGRADPGAPVSQEDMQAMVQLIRYMHTYCLPQRKLPPQTPEPLPKACSNPSQQVRSRPWSRHHSKASWAEFSILRELLAQDVLCDVSKPYRLATPVYASLTPRSRPRPPKDSQASPGRPSSVEEVRIAASPKSTGPRPSLRPLRLEVKREVRRPARLQQQEEEDEEEEEEEEEEEKEEEEEWGRKRPGRGLPWTKLGRKLESSVCPVRRSRRLNPELGPWLTFADEPLVPSEPQGALPSLCLAPKAYDVERELGSPTDEDSGQDQQLLRGPQIPALESPCESGCGDMDEDPSCPQLPPRDSPRCLMLALSQSDPTFGKKSFEQTLTVELCGTAGLTPPTTPPYKPTEEDPFKPDIKHSLGKEIALSLPSPEGLSLKATPGAAHKLPKKHPERSELLSHLRHATAQPASQAGQKRPFSCSFGDHDYCQVLRPEGVLQRKVLRSWEPSGVHLEDWPQQGAPWAEAQAPGREEDRSCDAGAPPKDSTLLRDHEIRASLTKHFGLLETALEEEDLASCKSPEYDTVFEDSSSSSGESSFLPEEEEEEGEEEEEDDEEEDSGVSPTCSDHCPYQSPPSKANRQLCSRSRSSSGSSPCHSWSPATRRNFRCESRGPCSDRTPSIRHARKRREKAIGEGRVVYIQNLSSDMSSRELKRRFEVFGEIEECEVLTRNRRGEKYGFITYRCSEHAALSLTKGAALRKRNEPSFQLSYGGLRHFCWPRYTDYDSNSEEALPASGKSKYEAMDFDSLLKEAQQSLH T92858 TARGETID T92858 T92858 FORMERID TTDR01139 T92858 UNIPROID Q8IDQ9_PLAF7 T92858 TARGNAME Plasmodium Phosphoethanolamine N-methyltransferase (Malaria PNM) T92858 GENENAME Malaria PNM T92858 TARGTYPE Literature-reported T92858 SYNONYMS Phosphoethanolamine N-methyltransferase T92858 FUNCTION Golgi apparatus, phosphoethanolamine N-methyltransferase activity, phosphatidylcholine biosynthetic process T92858 BIOCLASS Transferases of one-carbon groups T92858 ECNUMBER EC 2.1.1.103 T92858 SEQUENCE MTLIENLNSDKTFLENNQYTDEGVKVYEFIFGENYISSGGLEATKKILSDIELNENSKVLDIGSGLGGGCMYINEKYGAHTHGIDICSNIVNMANERVSGNNKIIFEANDILTKEFPENNFDLIYSRDAILHLSLENKNKLFQKCYKWLKPTGTLLITDYCATEKENWDDEFKEYVKQRKYTLITVEEYADILTACNFKNVVSKDLSDYWNQLLEVEHKYLHENKEEFLKLFSEKKFISLDDGWSRKIKDSKRKMQRWGYFKATKN T47543 TARGETID T47543 T47543 FORMERID TTDR00300 T47543 UNIPROID Q8IDW1_PLAF7 T47543 TARGNAME Plasmodium CDK PfPK6 (Malaria PfPK6) T47543 GENENAME Malaria PfPK6 T47543 TARGTYPE Literature-reported T47543 SYNONYMS Protein kinase 6; PF3D7_1337100; CDK-related protein kinase 6 T47543 FUNCTION Cyclin-dependent protein serine/threonine kinase activity, protein phosphorylation. T47543 BIOCLASS Kinase T47543 ECNUMBER EC 2.7.11.22 T47543 SEQUENCE MNRIDISNFDFLYVIGKGTYGIVYKALDKKENNFVAIKKIINLCDENYGISKCILRELTILQKIKHKNIINLKYVFYGKDIEDKLKGENLENSCLYLAFEYCDIDLFNLIKKHNLNIKEIKYIIFELLLALSYFHSNNYIHRDIKPENIFITSEGEIKLGDLGMSVEKSDHMTPTVVTLWYRAPEILLKSTNYDQKVDIWSLGCLFMELIQGRPLFPGKNDCTQLELIYLLLGDKDKLTTVDKERKDMFPYFEINMLKDAIDDEHTLDLISKMLIYDPNYRISSKEALKHPCFQDIEQVKFSYNF T34816 TARGETID T34816 T34816 FORMERID TTDR00704 T34816 UNIPROID Q8IM16_PLAF7 T34816 TARGNAME Plasmodium Plasmepsin 4 (Malaria PLA4) T34816 GENENAME Malaria PLA4 T34816 TARGTYPE Literature-reported T34816 SYNONYMS Plasmepsin IV T34816 FUNCTION Plays a crucial role in this critical process which yields nutrients for parasite growth. T34816 PDBSTRUC 1LS5 T34816 ECNUMBER EC 3.4.23.- T34816 SEQUENCE MALTVKEEEFSNTLIKNASAFDRLKLGNLKNLKIQKKLQFLYLILFVLITGVFFFFLIGNFYSHRKLYQVIKNTKHTTIGFKIDRPHDKVLSSVLKNKLSTYVKESFKFFKSGYAQKGYLGSENDSIELDDVANLMFYGEGQIGTNKQPFMFIFDTGSANLWVPSVNCDSIGCSTKHLYDASASKSYEKDGTKVEISYGSGTVRGYFSKDVISLGDLSLPYKFIEVTDADDLEPIYSGSEFDGILGLGWKDLSIGSIDPVVVELKKQNKIDNALFTFYLPVHDKHVGYLTIGGIESDFYEGPLTYEKLNHDLYWQIDLDIHFGKYVMQKANAVVDSGTSTITAPTSFLNKFFRDMNVIKVPFLPLYVTTCDNDDLPTLEFHSRNNKYTLEPEFYMDPLSDIDPALCMLYILPVDIDDNTFILGDPFMRKYFTVFDYEKESVGFAVAKNL T85915 TARGETID T85915 T85915 FORMERID TTDI03359 T85915 UNIPROID TPH2_HUMAN T85915 TARGNAME L-Tryptophan hydroxylase 2 (TPH2) T85915 GENENAME TPH2 T85915 TARGTYPE Literature-reported T85915 SYNONYMS Tryptophan 5-monooxygenase 2; Tryptophan 5-hydroxylase 2; Neuronal tryptophan hydroxylase; NTPH T85915 FUNCTION Rate-limiting enzyme in the synthesis of serotonin (5-hydroxytryptamine, or 5HT). Has functions in peripheral tissues, including the maintenance of vascular tone and gut motility. T85915 PDBSTRUC 4V06 T85915 ECNUMBER EC 1.14.16.4 T85915 SEQUENCE MQPAMMMFSSKYWARRGFSLDSAVPEEHQLLGSSTLNKPNSGKNDDKGNKGSSKREAATESGKTAVVFSLKNEVGGLVKALRLFQEKRVNMVHIESRKSRRRSSEVEIFVDCECGKTEFNELIQLLKFQTTIVTLNPPENIWTEEEELEDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPEPDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKDTRSIENVVQDLRSDLNTVCDALNKMNQYLGI T85915 DRUGINFO D0U9QD 6-fluorotryptophan Investigative T85915 DRUGINFO D0F2GG fenclonine Investigative T85915 DRUGINFO D0IT5D alpha-propyldopacetamide Investigative T38166 TARGETID T38166 T38166 FORMERID TTDI00153 T38166 UNIPROID PLPL6_HUMAN T38166 TARGNAME Neuropathy target esterase (PNPLA6) T38166 GENENAME PNPLA6 T38166 TARGTYPE Literature-reported T38166 SYNONYMS Patatin-like phospholipase domain-containing protein 6; NTE T38166 FUNCTION Phospholipase B that deacylates intracellular phosphatidylcholine (PtdCho), generating glycerophosphocholine (GroPtdCho). This deacylation occurs at both sn-2 and sn-1 positions of PtdCho. Its specific chemical modification by certain organophosphorus (OP) compounds leads to distal axonopathy. T38166 BIOCLASS Carboxylic ester hydrolase T38166 ECNUMBER EC 3.1.1.5 T38166 SEQUENCE MEAPLQTGMMGTSSHGLATNSSGAKVAERDGFQDVLAPGEGSAGRICGAQPVPFVPQVLGVMIGAGVAVVVTAVLILLVVRRLRVPKTPAPDGPRYRFRKRDKVLFYGRKIMRKVSQSTSSLVDTSVSATSRPRMRKKLKMLNIAKKILRIQKETPTLQRKEPPPAVLEADLTEGDLANSHLPSEVLYMLKNVRVLGHFEKPLFLELCRHMVFQRLGQGDYVFRPGQPDASIYVVQDGLLELCLPGPDGKECVVKEVVPGDSVNSLLSILDVITGHQHPQRTVSARAARDSTVLRLPVEAFSAVFTKYPESLVRVVQIIMVRLQRVTFLALHNYLGLTNELFSHEIQPLRLFPSPGLPTRTSPVRGSKRMVSTSATDEPRETPGRPPDPTGAPLPGPTGDPVKPTSLETPSAPLLSRCVSMPGDISGLQGGPRSDFDMAYERGRISVSLQEEASGGSLAAPARTPTQEPREQPAGACEYSYCEDESATGGCPFGPYQGRQTSSIFEAAKQELAKLMRIEDPSLLNSRVLLHHAKAGTIIARQGDQDVSLHFVLWGCLHVYQRMIDKAEDVCLFVAQPGELVGQLAVLTGEPLIFTLRAQRDCTFLRISKSDFYEIMRAQPSVVLSAAHTVAARMSPFVRQMDFAIDWTAVEAGRALYRQGDRSDCTYIVLNGRLRSVIQRGSGKKELVGEYGRGDLIGVVEALTRQPRATTVHAVRDTELAKLPEGTLGHIKRRYPQVVTRLIHLLSQKILGNLQQLQGPFPAGSGLGVPPHSELTNPASNLATVAILPVCAEVPMVAFTLELQHALQAIGPTLLLNSDIIRARLGASALDSIQEFRLSGWLAQQEDAHRIVLYQTDASLTPWTVRCLRQADCILIVGLGDQEPTLGQLEQMLENTAVRALKQLVLLHREEGAGPTRTVEWLNMRSWCSGHLHLRCPRRLFSRRSPAKLHELYEKVFSRRADRHSDFSRLARVLTGNTIALVLGGGGARGCSHIGVLKALEEAGVPVDLVGGTSIGSFIGALYAEERSASRTKQRAREWAKSMTSVLEPVLDLTYPVTSMFTGSAFNRSIHRVFQDKQIEDLWLPYFNVTTDITASAMRVHKDGSLWRYVRASMTLSGYLPPLCDPKDGHLLMDGGYINNLPADIARSMGAKTVIAIDVGSQDETDLSTYGDSLSGWWLLWKRLNPWADKVKVPDMAEIQSRLAYVSCVRQLEVVKSSSYCEYLRPPIDCFKTMDFGKFDQIYDVGYQYGKAVFGGWSRGNVIEKMLTDRRSTDLNESRRADVLAFPSSGFTDLAEIVSRIEPPTSYVSDGCADGEESDCLTEYEEDAGPDCSRDEGGSPEGASPSTASEMEEEKSILRQRRCLPQEPPGSATDA T81903 TARGETID T81903 T81903 FORMERID TTDI00105 T81903 UNIPROID OSCAR_HUMAN T81903 TARGNAME Osteoclast-associated receptor (OSCAR) T81903 GENENAME OSCAR T81903 TARGTYPE Literature-reported T81903 SYNONYMS hOSCAR; Polymeric immunoglobulin receptor 3; PolyIg receptor 3; PIgR3; Osteoclastassociated immunoglobulinlike receptor; OSCAR T81903 FUNCTION Regulator of osteoclastogenesis which plays an importantbone-specific function in osteoclast differentiation. T81903 PDBSTRUC 5EIV; 5EIQ; 5CJB; 5CJ8 T81903 BIOCLASS Leukocyte receptor complex T81903 SEQUENCE MALVLILQLLTLWPLCHTDITPSVPPASYHPKPWLGAQPATVVTPGVNVTLRCRAPQPAWRFGLFKPGEIAPLLFRDVSSELAEFFLEEVTPAQGGIYRCCYRRPDWGPGVWSQPSDVLELLVTEELPRPSLVALPGPVVGPGANVSLRCAGRLRNMSFVLYREGVAAPLQYRHSAQPWADFTLLGARAPGTYSCYYHTPSAPYVLSQRSEVLVISWEGEGPEARPASSAPGMQAPGPPPSDPGAQAPSLSSFRPRGLVLQPLLPQTQDSWDPAPPPSDPGV T78865 TARGETID T78865 T78865 FORMERID TTDI02627 T78865 UNIPROID CHSS2_HUMAN T78865 TARGNAME N-acetylgalactosaminyltransferase 2 (CHPF) T78865 GENENAME CHPF T78865 TARGTYPE Literature-reported T78865 SYNONYMS Nacetylgalactosaminylproteoglycan 3betaglucuronosyltransferase II; GlucuronosylNacetylgalactosaminylproteoglycan 4betaNacetylgalactosaminyltransferase II; Chondroitinpolymerizing factor; Chondroitin sulfate synthase 2; Chondroitin glucuronyltransferase 2; ChPF T78865 FUNCTION Has both beta-1,3-glucuronic acid and beta-1,4-N- acetylgalactosamine transferase activity. Transfers glucuronic acid (GlcUA) from UDP-GlcUA and N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of the elongating chondroitin polymer. Isoform 2 may facilitate PARK2 transport into the mitochondria. In collaboration with PARK2, isoform 2 may enhance cell viability and protect cells from oxidative stress. T78865 BIOCLASS Hexosyltransferase T78865 ECNUMBER EC 2.4.1.175 T78865 SEQUENCE MRASLLLSVLRPAGPVAVGISLGFTLSLLSVTWVEEPCGPGPPQPGDSELPPRGNTNAARRPNSVQPGAEREKPGAGEGAGENWEPRVLPYHPAQPGQAAKKAVRTRYISTELGIRQRLLVAVLTSQTTLPTLGVAVNRTLGHRLERVVFLTGARGRRAPPGMAVVTLGEERPIGHLHLALRHLLEQHGDDFDWFFLVPDTTYTEAHGLARLTGHLSLASAAHLYLGRPQDFIGGEPTPGRYCHGGFGVLLSRMLLQQLRPHLEGCRNDIVSARPDEWLGRCILDATGVGCTGDHEGVHYSHLELSPGEPVQEGDPHFRSALTAHPVRDPVHMYQLHKAFARAELERTYQEIQELQWEIQNTSHLAVDGDQAAAWPVGIPAPSRPASRFEVLRWDYFTEQHAFSCADGSPRCPLRGADRADVADVLGTALEELNRRYHPALRLQKQQLVNGYRRFDPARGMEYTLDLQLEALTPQGGRRPLTRRVQLLRPLSRVEILPVPYVTEASRLTVLLPLAAAERDLAPGFLEAFATAALEPGDAAAALTLLLLYEPRQAQRVAHADVFAPVKAHVAELERRFPGARVPWLSVQTAAPSPLRLMDLLSKKHPLDTLFLLAGPDTVLTPDFLNRCRMHAISGWQAFFPMHFQAFHPAVAPPQGPGPPELGRDTGRFDRQAASEACFYNSDYVAARGRLAAASEQEEELLESLDVYELFLHFSSLHVLRAVEPALLQRYRAQTCSARLSEDLYHRCLQSVLEGLGSRTQLAMLLFEQEQGNST T55242 TARGETID T55242 T55242 FORMERID TTDI02649 T55242 UNIPROID IFNL3_HUMAN T55242 TARGNAME Interferon-lambda 3 (IFNL3) T55242 GENENAME IFNL3 T55242 TARGTYPE Literature-reported T55242 SYNONYMS ZCYTO22; Interleukin28C; Interleukin28B; Interleukin-28C; Interleukin-28B; Interferon lambda3; Interferon lambda-3; IL28C; IL28B; IL-28C; IL-28B; IFNlambda3; IFN-lambda-3; Cytokine Zcyto22 T55242 FUNCTION Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression. Cytokine with antiviral, antitumour and immunomodulatory activities. T55242 PDBSTRUC 5T5W; 3HHC T55242 BIOCLASS Cytokine: interferon T55242 SEQUENCE MTGDCMPVLVLMAAVLTVTGAVPVARLRGALPDARGCHIAQFKSLSPQELQAFKRAKDALEESLLLKDCKCRSRLFPRTWDLRQLQVRERPVALEAELALTLKVLEATADTDPALGDVLDQPLHTLHHILSQLRACIQPQPTAGPRTRGRLHHWLHRLQEAPKKESPGCLEASVTFNLFRLLTRDLNCVASGDLCV T63298 TARGETID T63298 T63298 FORMERID TTDI03160 T63298 UNIPROID DCLK2_HUMAN T63298 TARGNAME Doublecortin-like kinase 2 (DCLK2) T63298 GENENAME DCLK2 T63298 TARGTYPE Literature-reported T63298 SYNONYMS Serine/threonine-protein kinase DCLK2; Doublecortin-like and CAM kinase-like 2; Doublecortin domain-containing protein 3B; DCK2; DCDC3B; DCAMKL2; CaMK-like CREB regulatory kinase 2; CLICK2; CLICK-II; CL2 T63298 FUNCTION May play a role in the down-regulation of CRE-dependent gene activation probably by phosphorylation of the CREB coactivator CRTC2/TORC2 and the resulting retention of TORC2 in the cytoplasm. Protein kinase with a significantly reduced C(a2+)/CAM affinity and dependence compared to other members of the CaMK family. T63298 BIOCLASS Kinase T63298 ECNUMBER EC 2.7.11.1 T63298 SEQUENCE MASTRSIELEHFEERDKRPRPGSRRGAPSSSGGSSSSGPKGNGLIPSPAHSAHCSFYRTRTLQALSSEKKAKKARFYRNGDRYFKGLVFAISSDRFRSFDALLIELTRSLSDNVNLPQGVRTIYTIDGSRKVTSLDELLEGESYVCASNEPFRKVDYTKNINPNWSVNIKGGTSRALAAASSVKSEVKESKDFIKPKLVTVIRSGVKPRKAVRILLNKKTAHSFEQVLTDITEAIKLDSGVVKRLCTLDGKQVTCLQDFFGDDDVFIACGPEKFRYAQDDFVLDHSECRVLKSSYSRSSAVKYSGSKSPGPSRRSKSPASVNGTPSSQLSTPKSTKSSSSSPTSPGSFRGLKQISAHGRSSSNVNGGPELDRCISPEGVNGNRCSESSTLLEKYKIGKVIGDGNFAVVKECIDRSTGKEFALKIIDKAKCCGKEHLIENEVSILRRVKHPNIIMLVEEMETATELFLVMELVKGGDLFDAITSSTKYTERDGSAMVYNLANALRYLHGLSIVHRDIKPENLLVCEYPDGTKSLKLGDFGLATVVEGPLYTVCGTPTYVAPEIIAETGYGLKVDIWAAGVITYILLCGFPPFRSENNLQEDLFDQILAGKLEFPAPYWDNITDSAKELISQMLQVNVEARCTAGQILSHPWVSDDASQENNMQAEVTGKLKQHFNNALPKQNSTTTGVSVIMNTALDKEGQIFCSKHCQDSGRPGMEPISPVPPSVEEIPVPGEAVPAPTPPESPTPHPPPAAPGGERAGTWRRHRD T63298 DRUGINFO D0M0QQ XMD8-92 Investigative T43102 TARGETID T43102 T43102 FORMERID TTDR00971 T43102 UNIPROID DPP10_HUMAN T43102 TARGNAME Similar to dipeptidyl aminopeptidase-like protein (DPP10) T43102 GENENAME DPP10 T43102 TARGTYPE Literature-reported T43102 SYNONYMS KIAA1492; Inactive dipeptidyl peptidase 10; Dipeptidyl peptidase-like protein 2; Dipeptidyl peptidase X; Dipeptidyl peptidase IV-related protein 3; DPRP3; DPRP-3; DPP X; DPL2 T43102 FUNCTION Promotes cell surface expression of the potassium channel KCND2. Modulates the activity and gating characteristics of the potassium channel KCND2. Has no dipeptidyl aminopeptidase activity. T43102 PDBSTRUC 4WJL T43102 BIOCLASS Prolyl oligopeptidase family T43102 SEQUENCE MNQTASVSHHIKCQPSKTIKELGSNSPPQRNWKGIAIALLVILVVCSLITMSVILLTPDELTNSSETRLSLEDLFRKDFVLHDPEARWINDTDVVYKSENGHVIKLNIETNATTLLLENTTFVTFKASRHSVSPDLKYVLLAYDVKQIFHYSYTASYVIYNIHTREVWELNPPEVEDSVLQYAAWGVQGQQLIYIFENNIYYQPDIKSSSLRLTSSGKEEIIFNGIADWLYEEELLHSHIAHWWSPDGERLAFLMINDSLVPTMVIPRFTGALYPKGKQYPYPKAGQVNPTIKLYVVNLYGPTHTLELMPPDSFKSREYYITMVKWVSNTKTVVRWLNRAQNISILTVCETTTGACSKKYEMTSDTWLSQQNEEPVFSRDGSKFFMTVPVKQGGRGEFHHVAMFLIQSKSEQITVRHLTSGNWEVIKILAYDETTQKIYFLSTESSPRGRQLYSASTEGLLNRQCISCNFMKEQCTYFDASFSPMNQHFLLFCEGPRVPVVSLHSTDNPAKYFILESNSMLKEAILKKKIGKPEIKILHIDDYELPLQLSLPKDFMDRNQYALLLIMDEEPGGQLVTDKFHIDWDSVLIDMDNVIVARFDGRGSGFQGLKILQEIHRRLGSVEVKDQITAVKFLLKLPYIDSKRLSIFGKGYGGYIASMILKSDEKLFKCGSVVAPITDLKLYASAFSERYLGMPSKEESTYQAASVLHNVHGLKEENILIIHGTADTKVHFQHSAELIKHLIKAGVNYTMQVYPDEGHNVSEKSKYHLYSTILKFFSDCLKEEISVLPQEPEEDE T95238 TARGETID T95238 T95238 UNIPROID ENAH_HUMAN T95238 TARGNAME Protein enabled homolog MENA (ENAH) T95238 GENENAME ENAH T95238 TARGTYPE Literature-reported T95238 SYNONYMS MENA T95238 FUNCTION Ena/VASP proteins are actin-associated proteins involved in a range of processes dependent on cytoskeleton remodeling and cell polarity such as axon guidance and lamellipodial and filopodial dynamics in migrating cells. ENAH induces the formation of F-actin rich outgrowths in fibroblasts. Acts synergistically with BAIAP2-alpha and downstream of NTN1 to promote filipodia formation. T95238 PDBSTRUC 5NEG; 5NDU; 5ND0; 5NCP; 5NCG T95238 SEQUENCE MSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVLNSQETGPTLPRQNSQLPAQVQNGPSQEELEIQRRQLQEQQRQKELERERLERERMERERLERERLERERLERERLEQEQLERERQERERQERLERQERLERQERLERQERLDRERQERQERERLERLERERQERERQEQLEREQLEWERERRISSAAAPASVETPLNSVLGDSSASEPGLQAASQPAETPSQQGIVLGPLAPPPPPPLPPGPAQASVALPPPPGPPPPPPLPSTGPPPPPPPPPLPNQVPPPPPPPPAPPLPASGFFLASMSEDNRPLTGLAAAIAGAKLRKVSRMEDTSFPSGGNAIGVNSASSKTDTGRGNGPLPLGGSGLMEEMSALLARRRRIAEKGSTIETEQKEDKGEDSEPVTSKASSTSTPEPTRKPWERTNTMNGSKSPVISRRDSPRKNQIVFDNRSYDSLHRPKSTPLSQPSANGVQTEGLDYDRLKQDILDEMRKELTKLKEELIDAIRQELSKSNTA T23485 TARGETID T23485 T23485 FORMERID TTDR00450 T23485 UNIPROID STEA2_HUMAN T23485 TARGNAME Metalloreductase STEAP2 (STEAP2) T23485 GENENAME STEAP2 T23485 TARGTYPE Literature-reported T23485 SYNONYMS STEAP2 T23485 FUNCTION Metalloreductase that hasthe ability to reduce both Fe(3+) to Fe(2+) and Cu(2+) to Cu(1+). Uses NAD(+) as acceptor. T23485 BIOCLASS Metal ion oxidoreductase T23485 ECNUMBER EC 1.16.1.- T23485 SEQUENCE MESISMMGSPKSLSETFLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGSRNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNMRINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIELARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYARNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQCRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMYISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFEEEYYRFYTPPNFVLALVLPSIVILGKIILFLPCISRKLKRIKKGWEKSQFLEEGMGGTIPHVSPERVTVM T39698 TARGETID T39698 T39698 FORMERID TTDI03403 T39698 UNIPROID NEK7_HUMAN T39698 TARGNAME NIMA-related kinase 7 (NEK7) T39698 GENENAME NEK7 T39698 TARGTYPE Literature-reported T39698 SYNONYMS Serine/threonine-protein kinase Nek7; NimA-related protein kinase 7; Never in mitosis A-related kinase 7 T39698 FUNCTION Protein kinase which plays an important role in mitotic cell cycle progression. Required for microtubule nucleation activity of the centrosome, robust mitotic spindle formation and cytokinesis. Phosphorylates RPS6KB1. T39698 PDBSTRUC 6GT1; 5DE2; 2WQN; 2WQM T39698 ECNUMBER EC 2.7.11.1 T39698 SEQUENCE MDEQSQGMQGPPVPQFQPQKALRPDMGYNTLANFRIEKKIGRGQFSEVYRAACLLDGVPVALKKVQIFDLMDAKARADCIKEIDLLKQLNHPNVIKYYASFIEDNELNIVLELADAGDLSRMIKHFKKQKRLIPERTVWKYFVQLCSALEHMHSRRVMHRDIKPANVFITATGVVKLGDLGLGRFFSSKTTAAHSLVGTPYYMSPERIHENGYNFKSDIWSLGCLLYEMAALQSPFYGDKMNLYSLCKKIEQCDYPPLPSDHYSEELRQLVNMCINPDPEKRPDVTYVYDVAKRMHACTASS T39698 DRUGINFO D0V0KA PMID20462760C22 Investigative T52604 TARGETID T52604 T52604 FORMERID TTDR00827 T52604 UNIPROID PUR6_CANAL T52604 TARGNAME Candida AIR carboxylase (Candi ADE2) T52604 GENENAME Candi ADE2 T52604 TARGTYPE Literature-reported T52604 SYNONYMS Phosphoribosylaminoimidazole carboxylase; AIRC; AIR carboxylase T52604 FUNCTION Catalyzes the sixth step of the de novo purine biosynthesis pathway. T52604 BIOCLASS Carbon-carbon lyase T52604 ECNUMBER EC 4.1.1.21 T52604 SEQUENCE MDSKTVGILGGGQLGRMIVEAAHRLNIKTVILDAAKSPAKQINALDDHVDGSFTNYDSIVKLAEKADVLTVEIEHVDVDALIKVQEKFPKVEIYPLPETIRLIQDKYLQKNHLIKHDVAVTESVAVETNTVDDLLHIGEKFGYPYMLKSRTLAYDGRGNFVVKDKSYCEKALEFLKDRPLYAEKWCPFTKELAVMVVRSLEGEVFAYPTVETIHENNICHLVYAPARIPDTLAKKASILAKNAVKSFLGCGIFGVEMFLLENNELLINEIAPRPHNSGHYTIDACVTSQFEAHVRAVTGLPMPKGFTEFSTSITNAIMLNVLGDKATPNKELEICRRALETPHASVYLYGKTTRPERKMGHINVVTSSMQDAESRLSYILGDTTEIPKSLATDKESPLVGIIMGSDSDLPVMAVGARILKQFGVPFELTIVSAHRTPHRMSEYAIEAPKRGLKCIIAGAGGAAHLPGMVAAMTPLPVIGVPVKGSTLDGVDSLHSIVQMPRGIPVATVAINNSTNAALLAIRILGAYDSKWLTEMNQYMLNMETEVLGKAETLEEIGYEDYLTDKLKK T30661 TARGETID T30661 T30661 FORMERID TTDR00735 T30661 UNIPROID VPS34_CANAX T30661 TARGNAME Candida PtdIns-3-kinase VPS34 (Candi VPS34) T30661 GENENAME Candi VPS34 T30661 TARGTYPE Literature-reported T30661 SYNONYMS Vacuolar sorting protein 34; VPS34; PtdIns-3-kinase; Phosphatidylinositol 3-kinase VPS34 T30661 FUNCTION Phosphatidylinositol 3-kinase homolog required for vacuolar sorting and segregation. T30661 BIOCLASS Kinase T30661 ECNUMBER EC 2.7.1.137 T30661 SEQUENCE MATLSQPQSALPKTKIATTFGLSKDLKSPISVKVCYLECTRNNVSLVPLSTKFEDPTVFKKLSQIYKNSDLFVEIRVYDGKNNNLISTPVRTSYKAFNNKGRTWNQQLKLNIDYNQISIDAYLKFSICEIIDTKPSVFGVSYLSLFSHDSSTLRSGSHKIPVFMEDDPQYSKNIQYGTLIGLTDLEKRLIDYENGKYPRLNWLDKMVLPKVDATFLKTNNKDHDYYLYIELPQFEFPIVYSDIIYQIPTIEPITETTSKIPPDDTLNSNIIINSIDIPMATSHDPSIMKVYDPDFHITANNHLNPNATTFDPVELKYRKLERNIDNNTILDKELKPTPQLRDELLRIMIKPSNAESTDNEKNLIWKFRYYFSKNNSGNDPSNKSVKSFLPKFLRSINWENDYELDHTFKEIIPFYWNVDKLQIGDALELLGDYFNPYTLGKPTYQDDSMTSKSSKMKSDEKRFIKIYNNVCFLRKLAVERLKLANSEELLLYLLQLVQALKYEALIYEKSPPFCERSDQIEDNASSTLKSPLADFLIERAVENEKLGNFFYWYVKVENEDQLNNPHIDGPIKIYMDILNRYIELLKAHCHENRLPYYKHLKHQIWFIKKLTSLVELLRASFKKNEATAKKVEYLREYLANSGNELLKFPEPFPLPLDPSVMICGCYPEESSVFKSSLAPLKITLKTIEKKKHGHATSQLFGKRSRYGKYPLMFKIGDDLRQDQLVIQIIDLMDQLLKNENLDLKLTPYKILATSPISGLIQFVPNETLDSILSKTYPTSVTYSGGGETSDGPPSVSNNGILNYLRLHSQEQQSEEPISKSILSTNTSQSNTEIPVLPRQPKPTITSDLGVSPILMDNYVKSCAGYCVITYILGVGDRHLDNLLLSPNGKFWHADFGYILGRDPKPFPPLMKLPIQVIDGMGGLHHENYNVFKSYCFITYTTLRKNSNLILNLFQLMLDANIPDIQFDPSRVIEKVQEKFCLQMTEEEAILHFQNLINDSVNAFLPVVIDRLHSLAQYWRA T92628 TARGETID T92628 T92628 UNIPROID BAP1_HUMAN T92628 TARGNAME Ubiquitin carboxyl-terminal hydrolase BAP1 (BAP1) T92628 GENENAME BAP1 T92628 TARGTYPE Literature-reported T92628 SYNONYMS KIAA0272; Cerebral protein 6; BRCA1-associated protein 1 T92628 FUNCTION Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B. Acts as a regulator of cell growth by mediating deubiquitination of HCFC1 N-terminal and C-terminal chains, with some specificity toward 'Lys-48'-linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin chains. Deubiquitination of HCFC1 does not lead to increase stability of HCFC1. Interferes with the BRCA1 and BARD1 heterodimer activity by inhibiting their ability to mediate ubiquitination and autoubiquitination. It however does not mediate deubiquitination of BRCA1 and BARD1. Able to mediate autodeubiquitination via intramolecular interactions to couteract monoubiquitination at the nuclear localization signal (NLS), thereby protecting it from cytoplasmic sequestration (PubMed:24703950). Acts as a tumor suppressor. T92628 BIOCLASS Peptidase C12 family. BAP1 subfamily T92628 ECNUMBER EC 3.4.19.12 T92628 SEQUENCE MNKGWLELESDPGLFTLLVEDFGVKGVQVEEIYDLQSKCQGPVYGFIFLFKWIEERRSRRKVSTLVDDTSVIDDDIVNNMFFAHQLIPNSCATHALLSVLLNCSSVDLGPTLSRMKDFTKGFSPESKGYAIGNAPELAKAHNSHARPEPRHLPEKQNGLSAVRTMEAFHFVSYVPITGRLFELDGLKVYPIDHGPWGEDEEWTDKARRVIMERIGLATAGEPYHDIRFNLMAVVPDRRIKYEARLHVLKVNRQTVLEALQQLIRVTQPELIQTHKSQESQLPEESKSASNKSPLVLEANRAPAASEGNHTDGAEEAAGSCAQAPSHSPPNKPKLVVKPPGSSLNGVHPNPTPIVQRLPAFLDNHNYAKSPMQEEEDLAAGVGRSRVPVRPPQQYSDDEDDYEDDEEDDVQNTNSALRYKGKGTGKPGALSGSADGQLSVLQPNTINVLAEKLKESQKDLSIPLSIKTSSGAGSPAVAVPTHSQPSPTPSNESTDTASEIGSAFNSPLRSPIRSANPTRPSSPVTSHISKVLFGEDDSLLRVDCIRYNRAVRDLGPVISTGLLHLAEDGVLSPLALTEGGKGSSPSIRPIQGSQGSSSPVEKEVVEATDSREKTGMVRPGEPLSGEKYSPKELLALLKCVEAEIANYEACLKEEVEKRKKFKIDDQRRTHNYDEFICTFISMLAQEGMLANLVEQNISVRRRQGVSIGRLHKQRKPDRRKRSRPYKAKRQ T93949 TARGETID T93949 T93949 UNIPROID NR4A3_HUMAN T93949 TARGNAME Nuclear hormone receptor NOR-1 (NR4A3) T93949 GENENAME NR4A3 T93949 TARGTYPE Literature-reported T93949 SYNONYMS Neuron-derived orphan receptor 1; NOR1; Mitogen-induced nuclear orphan receptor; MINOR; CSMF; CHN T93949 FUNCTION Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes. Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and inflammation. Mediates proliferation of vascular smooth muscle, myeloid progenitor cell and type B pancreatic cells; promotes mitogen-induced vascular smooth muscle cell proliferation through transactivation of SKP2 promoter by binding a NBRE site. Upon PDGF stimulation, stimulates vascular smooth muscle cell proliferation by regulating CCND1 and CCND2 expression. In islets, induces type B pancreatic cell proliferation through up-regulation of genes that activate cell cycle, as well as genes that cause degradation of the CDKN1A. Negatively regulates myeloid progenitor cell proliferation by repressing RUNX1 in a NBRE site-independent manner. During inner ear, plays a role as a key mediator of the proliferative growth phase of semicircular canal development. Mediates also survival of neuron and smooth muscle cells; mediates CREB-induced neuronal survival, and during hippocampus development, plays a critical role in pyramidal cell survival and axonal guidance. Is required for S phase entry of the cell cycle and survival of smooth muscle cells by inducing CCND1, resulting in RB1 phosphorylation. Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription. Plays also a role in inflammation; upon TNF stimulation, mediates monocyte adhesion by inducing the expression of VCAM1 and ICAM1 by binding to the NBRE consensus site. In mast cells activated by Fc-epsilon receptor cross-linking, promotes the synthesis and release of cytokines but impairs events leading to degranulation. Plays also a role in metabolism; by modulating feeding behavior; and by playing a role in energy balance by inhibiting the glucocorticoid-induced orexigenic neuropeptides AGRP expression, at least in part by forming a complex with activated NR3C1 on the AGRP- glucocorticoid response element (GRE), and thus weakening the DNA binding activity of NR3C1. Upon catecholamines stimulation, regulates gene expression that controls oxidative metabolism in skeletal muscle. Plays a role in glucose transport by regulating translocation of the SLC2A4 glucose transporter to the cell surface (PubMed:24022864). Finally, during gastrulation plays a crucial role in the formation of anterior mesoderm by controlling cell migration. Inhibits adipogenesis. Also participates in cardiac hypertrophy by activating PARP1. T93949 BIOCLASS Nuclear hormone receptor family. NR4 subfamily T93949 SEQUENCE MPCVQAQYSPSPPGSSYAAQTYSSEYTTEIMNPDYTKLTMDLGSTEITATATTSLPSISTFVEGYSSNYELKPSCVYQMQRPLIKVEEGRAPSYHHHHHHHHHHHHHHQQQHQQPSIPPASSPEDEVLPSTSMYFKQSPPSTPTTPAFPPQAGALWDEALPSAPGCIAPGPLLDPPMKAVPTVAGARFPLFHFKPSPPHPPAPSPAGGHHLGYDPTAAAALSLPLGAAAAAGSQAAALESHPYGLPLAKRAAPLAFPPLGLTPSPTASSLLGESPSLPSPPSRSSSSGEGTCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQKCLSVGMVKEVVRTDSLKGRRGRLPSKPKSPLQQEPSQPSPPSPPICMMNALVRALTDSTPRDLDYSRYCPTDQAAAGTDAEHVQQFYNLLTASIDVSRSWAEKIPGFTDLPKEDQTLLIESAFLELFVLRLSIRSNTAEDKFVFCNGLVLHRLQCLRGFGEWLDSIKDFSLNLQSLNLDIQALACLSALSMITERHGLKEPKRVEELCNKITSSLKDHQSKGQALEPTESKVLGALVELRKICTLGLQRIFYLKLEDLVSPPSIIDKLFLDTLPF T03772 TARGETID T03772 T03772 FORMERID TTDI00095 T03772 UNIPROID TNR14_HUMAN T03772 TARGNAME Herpesvirus entry mediator (CD270) T03772 GENENAME TNFRSF14 T03772 TARGTYPE Literature-reported T03772 SYNONYMS UNQ329/PRO509; Tumor necrosis factor receptor-like 2; Tumor necrosis factor receptor superfamily member 14; TR2; HveA; Herpesvirus entry mediator A; Herpes virus entry mediator A; HVEM T03772 FUNCTION Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation. Participates in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions. Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumor immune response. In the context of bacterial infection, acts as a signaling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and proinflammatory cytokines. Upon binding to CD160 on activated CD4+ T cells, downregulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response. May interact in cis (on the same cell) or in trans (on other cells) with BTLA. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells. Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signaling network. T03772 PDBSTRUC 5T2R; 5T2Q; 4RSU; 4FHQ; 2AW2 T03772 BIOCLASS Cytokine receptor T03772 SEQUENCE MEPPGDWGPPPWRSTPKTDVLRLVLYLTFLGAPCYAPALPSCKEDEYPVGSECCPKCSPGYRVKEACGELTGTVCEPCPPGTYIAHLNGLSKCLQCQMCDPAMGLRASRNCSRTENAVCGCSPGHFCIVQDGDHCAACRAYATSSPGQRVQKGGTESQDTLCQNCPPGTFSPNGTLEECQHQTKCSWLVTKAGAGTSSSHWVWWFLSGSLVIVIVCSTVGLIICVKRRKPRGDVVKVIVSVQRKRQEAEGEATVIEALQAPPDVTTVAVEETIPSFTGRSPNH T00455 TARGETID T00455 T00455 FORMERID TTDR00043 T00455 UNIPROID Q937U6_BORHE T00455 TARGNAME Bacterial Class 1 lysyl-tRNA synthetase (Bact lysK) T00455 GENENAME Bact lysK T00455 TARGTYPE Literature-reported T00455 SYNONYMS Class 1 lysyl-tRNA synthetase T00455 FUNCTION Catalyses the formation of lysyl-transfer RNA, Lys-tRNA(Lys), which then is ready to insert lysine into proteins. Only found in a few bacteria such as -proteobacteria. Functionally equivalent but structurally unrelated compared with class II LysRS. Requires tRNALys binding prior to aminoacyl-adenylate synthesis. T00455 BIOCLASS Carbon-oxygen ligase T00455 ECNUMBER EC 6.1.1.6 T00455 SEQUENCE DFYAKKIIEEKGEKEQYTVASGITPSGTVHIGNFREVISVDLVARALKDAGRNVRFIYSWDNYDVFRKVPKNMPNQELLTTHLRQAITRVPDTQTNQSSYARANEVEFEKYLPIVGIKPEFIDQSLKYMSSDYSSQIKFALDHKDEIEKVLNKYRTTKLADNWYPISIFCTKCNRDTTTIKNYNHCYSIEYCCECGNKESLDLRKTWAVKLPWRIDWPMRWKYENVDFEPAGKDHHSSGGSFDTSIEIVKIFGGTPPITFQYDFISIKGRGGKISSSSGDVGSLKDVLEIYTPEVTRFLFASTKPNTEFSISFDLDVIKIYEDYDKFERVYYGIDDIKENKKEAFKRIYELSQPKLPDKEIPYQIGFRHLSTICQIFEGDKDKIFKLLNDVKESQKAKLINKIECAINWIKKFAPEDFKFSLRYTFDNIEPLKDNNKQGVTQLLDFLKKDFNNITEKEIQDEIYNIARNNNIEPPLFFKQLYNILINKDKGPKLAGFIKIIGIKKFEEIVKHYI T70539 TARGETID T70539 T70539 FORMERID TTDR00612 T70539 UNIPROID MCHR2_HUMAN T70539 TARGNAME Melanin-concentrating hormone receptor 2 (MCHR2) T70539 GENENAME MCHR2 T70539 TARGTYPE Literature-reported T70539 SYNONYMS SLT; MCHR-2; MCH2R; MCH2 protein; MCH-R2; MCH-2R; MCH(2) receptor; MCH receptor 2; GPRv17; GPR145; G-protein coupled receptor 145; G protein coupled receptor 145 T70539 FUNCTION Receptor for melanin-concentrating hormone, coupled to G proteins that activate phosphoinositide hydrolysis. T70539 BIOCLASS GPCR rhodopsin T70539 SEQUENCE MNPFHASCWNTSAELLNKSWNKEFAYQTASVVDTVILPSMIGIICSTGLVGNILIVFTIIRSRKKTVPDIYICNLAVADLVHIVGMPFLIHQWARGGEWVFGGPLCTIITSLDTCNQFACSAIMTVMSVDRYFALVQPFRLTRWRTRYKTIRINLGLWAASFILALPVWVYSKVIKFKDGVESCAFDLTSPDDVLWYTLYLTITTFFFPLPLILVCYILILCYTWEMYQQNKDARCCNPSVPKQRVMKLTKMVLVLVVVFILSAAPYHVIQLVNLQMEQPTLAFYVGYYLSICLSYASSSINPFLYILLSGNFQKRLPQIQRRATEKEINNMGNTLKSHF T70539 DRUGINFO D04BDL PMID22123324C38 Investigative T70539 DRUGINFO D01BTF melanin-concentrating hormone Investigative T70539 DRUGINFO D0V5ZP ATC0065 Investigative T54460 TARGETID T54460 T54460 FORMERID TTDI02637 T54460 UNIPROID SLAF6_HUMAN T54460 TARGNAME SLAM family member 6 (SLAMF6) T54460 GENENAME SLAMF6 T54460 TARGTYPE Literature-reported T54460 SYNONYMS SLAMF6; NTB-A; NK-T-B-antigen; CD352; Activating NK receptor T54460 FUNCTION Triggers cytolytic activity only in natural killer cells (NK) expressing high surface densities of natural cytotoxicity receptors. T54460 PDBSTRUC 2IF7 T54460 BIOCLASS Immunoglobulin T54460 SEQUENCE MLWLFQSLLFVFCFGPGNVVSQSSLTPLMVNGILGESVTLPLEFPAGEKVNFITWLFNETSLAFIVPHETKSPEIHVTNPKQGKRLNFTQSYSLQLSNLKMEDTGSYRAQISTKTSAKLSSYTLRILRQLRNIQVTNHSQLFQNMTCELHLTCSVEDADDNVSFRWEALGNTLSSQPNLTVSWDPRISSEQDYTCIAENAVSNLSFSVSAQKLCEDVKIQYTDTKMILFMVSGICIVFGFIILLLLVLRKRRDSLSLSTQRTQGPAESARNLEYVSVSPTNNTVYASVTHSNRETEIWTPRENDTITIYSTINHSKESKPTFSRATALDNVV T38187 TARGETID T38187 T38187 FORMERID TTDI02127 T38187 UNIPROID MRGX2_HUMAN T38187 TARGNAME Mas-related gene 2 (MRGX2) T38187 GENENAME MRGPRX2 T38187 TARGTYPE Literature-reported T38187 SYNONYMS Masrelated Gprotein coupled receptormember X2; MRGPRX2 T38187 FUNCTION Mast cell-specific receptor for basic secretagogues (PubMed:25517090). Basic secretagogues are a set of cationic amphiphilic drugs, as well as endo- and exogenous peptides, which share basic head group combined with a hydrophobic core of the molecule. Recognizes and binds small molecules containing a cyclized a tetrahydroisoquinoline (THIQ), such as non-steroidal neuromuscular blocking drugs (NMBDs), including tubocurarine and atracurium. Mediates mast cell responsiveness and side effects of small-molecule therapeutic drugs by acting as a specific receptor for basic secretagogues drugs in mast cells: binding to drugs induces pseudo-allergic reactions characterized by histamine release, inflammation and airway contraction. Acts as a receptor for a number of ligands, including peptides: acts as a receptor of cortistatin-14, a regulator of sleep regulation locomotor activity, and cortical function (PubMed:12915402). Acts as a receptor for proadrenomedullin N- terminal peptides PAMP-12, and atlower extent PAMP-20 (PubMed:15823563). Acts as a receptor for antibacterial protein LL-37, promoting chemotaxis, degranulation and chemokine production in mast cells (PubMed:22069323). Acts as a receptor for PMX-53 peptide, a potent antagonist of C5AR1/CD88 (PubMed:21441599). Acts as a receptor for beta-defensins (PubMed:23698749). Acts as a receptor for complanadine A, an alkaloid (PubMed:24930830). {ECO:0000250|UniProtKB:Q3UG50, ECO:0000269|PubMed:15823563, ECO:0000269|PubMed:21441599, ECO:0000269|PubMed:22069323, ECO:0000269|PubMed:23698749, ECO:0000269|PubMed:24930830, ECO:0000269|PubMed:25517090, ECO:0000305|PubMed:12915402}. T38187 BIOCLASS GPCR rhodopsin T38187 SEQUENCE MDPTTPAWGTESTTVNGNDQALLLLCGKETLIPVFLILFIALVGLVGNGFVLWLLGFRMRRNAFSVYVLSLAGADFLFLCFQIINCLVYLSNFFCSISINFPSFFTTVMTCAYLAGLSMLSTVSTERCLSVLWPIWYRCRRPRHLSAVVCVLLWALSLLLSILEGKFCGFLFSDGDSGWCQTFDFITAAWLIFLFMVLCGSSLALLVRILCGSRGLPLTRLYLTILLTVLVFLLCGLPFGIQWFLILWIWKDSDVLFCHIHPVSVVLSSLNSSANPIIYFFVGSFRKQWRLQQPILKLALQRALQDIAEVDHSEGCFRQGTPEMSRSSLV T43031 TARGETID T43031 T43031 FORMERID TTDI03400 T43031 UNIPROID NEK1_HUMAN T43031 TARGNAME NIMA-related kinase 1 (NEK1) T43031 GENENAME NEK1 T43031 TARGTYPE Literature-reported T43031 SYNONYMS Serine/threonine-protein kinase Nek1; Renal carcinoma antigen NY-REN-55; NimA-related protein kinase 1; Never in mitosis A-related kinase 1; KIAA1901 T43031 FUNCTION Phosphorylates serines and threonines, but also appears to possess tyrosine kinase activity. Involved in DNA damage checkpoint control and for proper DNA damage repair. In response to injury that includes DNA damage, NEK1 phosphorylates VDAC1 to limit mitochondrial cell death. May be implicated in the control of meiosis (By similarity). Involved in cilium assembly. T43031 PDBSTRUC 4B9D; 4APC T43031 ECNUMBER EC 2.7.11.1 T43031 SEQUENCE MEKYVRLQKIGEGSFGKAILVKSTEDGRQYVIKEINISRMSSKEREESRREVAVLANMKHPNIVQYRESFEENGSLYIVMDYCEGGDLFKRINAQKGVLFQEDQILDWFVQICLALKHVHDRKILHRDIKSQNIFLTKDGTVQLGDFGIARVLNSTVELARTCIGTPYYLSPEICENKPYNNKSDIWALGCVLYELCTLKHAFEAGSMKNLVLKIISGSFPPVSLHYSYDLRSLVSQLFKRNPRDRPSVNSILEKGFIAKRIEKFLSPQLIAEEFCLKTFSKFGSQPIPAKRPASGQNSISVMPAQKITKPAAKYGIPLAYKKYGDKKLHEKKPLQKHKQAHQTPEKRVNTGEERRKISEEAARKRRLEFIEKEKKQKDQIISLMKAEQMKRQEKERLERINRAREQGWRNVLSAGGSGEVKAPFLGSGGTIAPSSFSSRGQYEHYHAIFDQMQQQRAEDNEAKWKREIYGRGLPERGILPGVRPGFPYGAAGHHHFPDADDIRKTLKRLKAVSKQANANRQKGQLAVERAKQVEEFLQRKREAMQNKARAEGHMVYLARLRQIRLQNFNERQQIKAKLRGEKKEANHSEGQEGSEEADMRRKKIESLKAHANARAAVLKEQLERKRKEAYEREKKVWEEHLVAKGVKSSDVSPPLGQHETGGSPSKQQMRSVISVTSALKEVGVDSSLTDTRETSEEMQKTNNAISSKREILRRLNENLKAQEDEKGKQNLSDTFEINVHEDAKEHEKEKSVSSDRKKWEAGGQLVIPLDELTLDTSFSTTERHTVGEVIKLGPNGSPRRAWGKSPTDSVLKILGEAELQLQTELLENTTIRSEISPEGEKYKPLITGEKKVQCISHEINPSAIVDSPVETKSPEFSEASPQMSLKLEGNLEEPDDLETEILQEPSGTNKDESLPCTITDVWISEEKETKETQSADRITIQENEVSEDGVSSTVDQLSDIHIEPGTNDSQHSKCDVDKSVQPEPFFHKVVHSEHLNLVPQVQSVQCSPEESFAFRSHSHLPPKNKNKNSLLIGLSTGLFDANNPKMLRTCSLPDLSKLFRTLMDVPTVGDVRQDNLEIDEIEDENIKEGPSDSEDIVFEETDTDLQELQASMEQLLREQPGEEYSEEEESVLKNSDVEPTANGTDVADEDDNPSSESALNEEWHSDNSDGEIASECECDSVFNHLEELRLHLEQEMGFEKFFEVYEKIKAIHEDEDENIEICSKIVQNILGNEHQHLYAKILHLVMADGAYQEDNDE T43031 DRUGINFO D0K0UJ PMID20936789C31 Investigative T11906 TARGETID T11906 T11906 FORMERID TTDI03597 T11906 UNIPROID TRPM7_HUMAN T11906 TARGNAME Long transient receptor potential channel 7 (TRPM7) T11906 GENENAME TRPM7 T11906 TARGTYPE Literature-reported T11906 SYNONYMS Transient receptor potential cation channel subfamily M member 7; LTrpC-7; LTRPC7; Channel-kinase 1; CHAK1 T11906 FUNCTION Essential ion channel and serine/threonine-protein kinase. Divalent cation channel permeable to calcium and magnesium. Has a central role in magnesium ion homeostasis and in the regulation of anoxic neuronal cell death. Involved in TNF-induced necroptosis downstream of MLKL by mediating calcium influx. The kinase activity is essential for the channel function. May be involved in a fundamental process that adjusts plasma membrane divalent cation fluxes according to the metabolic state of the cell. Phosphorylates annexin A1 (ANXA1). T11906 BIOCLASS Transient receptor potential catioin channel T11906 ECNUMBER EC 2.7.11.1 T11906 SEQUENCE MSQKSWIESTLTKRECVYIIPSSKDPHRCLPGCQICQQLVRCFCGRLVKQHACFTASLAMKYSDVKLGDHFNQAIEEWSVEKHTEQSPTDAYGVINFQGGSHSYRAKYVRLSYDTKPEVILQLLLKEWQMELPKLVISVHGGMQKFELHPRIKQLLGKGLIKAAVTTGAWILTGGVNTGVAKHVGDALKEHASRSSRKICTIGIAPWGVIENRNDLVGRDVVAPYQTLLNPLSKLNVLNNLHSHFILVDDGTVGKYGAEVRLRRELEKTINQQRIHARIGQGVPVVALIFEGGPNVILTVLEYLQESPPVPVVVCEGTGRAADLLAYIHKQTEEGGNLPDAAEPDIISTIKKTFNFGQNEALHLFQTLMECMKRKELITVFHIGSDEHQDIDVAILTALLKGTNASAFDQLILTLAWDRVDIAKNHVFVYGQQWLVGSLEQAMLDALVMDRVAFVKLLIENGVSMHKFLTIPRLEELYNTKQGPTNPMLFHLVRDVKQGNLPPGYKITLIDIGLVIEYLMGGTYRCTYTRKRFRLIYNSLGGNNRRSGRNTSSSTPQLRKSHESFGNRADKKEKMRHNHFIKTAQPYRPKIDTVMEEGKKKRTKDEIVDIDDPETKRFPYPLNELLIWACLMKRQVMARFLWQHGEESMAKALVACKIYRSMAYEAKQSDLVDDTSEELKQYSNDFGQLAVELLEQSFRQDETMAMKLLTYELKNWSNSTCLKLAVSSRLRPFVAHTCTQMLLSDMWMGRLNMRKNSWYKVILSILVPPAILLLEYKTKAEMSHIPQSQDAHQMTMDDSENNFQNITEEIPMEVFKEVRILDSNEGKNEMEIQMKSKKLPITRKFYAFYHAPIVKFWFNTLAYLGFLMLYTFVVLVQMEQLPSVQEWIVIAYIFTYAIEKVREIFMSEAGKVNQKIKVWFSDYFNISDTIAIISFFIGFGLRFGAKWNFANAYDNHVFVAGRLIYCLNIIFWYVRLLDFLAVNQQAGPYVMMIGKMVANMFYIVVIMALVLLSFGVPRKAILYPHEAPSWTLAKDIVFHPYWMIFGEVYAYEIDVCANDSVIPQICGPGTWLTPFLQAVYLFVQYIIMVNLLIAFFNNVYLQVKAISNIVWKYQRYHFIMAYHEKPVLPPPLIILSHIVSLFCCICKRRKKDKTSDGPKLFLTEEDQKKLHDFEEQCVEMYFNEKDDKFHSGSEERIRVTFERVEQMCIQIKEVGDRVNYIKRSLQSLDSQIGHLQDLSALTVDTLKTLTAQKASEASKVHNEITRELSISKHLAQNLIDDGPVRPSVWKKHGVVNTLSSSLPQGDLESNNPFHCNILMKDDKDPQCNIFGQDLPAVPQRKEFNFPEAGSSSGALFPSAVSPPELRQRLHGVELLKIFNKNQKLGSSSTSIPHLSSPPTKFFVSTPSQPSCKSHLETGTKDQETVCSKATEGDNTEFGAFVGHRDSMDLQRFKETSNKIKILSNNNTSENTLKRVSSLAGFTDCHRTSIPVHSKQAEKISRRPSTEDTHEVDSKAALIPDWLQDRPSNREMPSEEGTLNGLTSPFKPAMDTNYYYSAVERNNLMRLSQSIPFTPVPPRGEPVTVYRLEESSPNILNNSMSSWSQLGLCAKIEFLSKEEMGGGLRRAVKVQCTWSEHDILKSGHLYIIKSFLPEVVNTWSSIYKEDTVLHLCLREIQQQRAAQKLTFAFNQMKPKSIPYSPRFLEVFLLYCHSAGQWFAVEECMTGEFRKYNNNNGDEIIPTNTLEEIMLAFSHWTYEYTRGELLVLDLQGVGENLTDPSVIKAEEKRSCDMVFGPANLGEDAIKNFRAKHHCNSCCRKLKLPDLKRNDYTPDKIIFPQDEPSDLNLQPGNSTKESESTNSVRLML T11906 DRUGINFO D0T0JU waixenicin A Investigative T11906 DRUGINFO D07JDC carvacrol Investigative T11906 DRUGINFO D07ZAJ PIP2 Investigative T11906 DRUGINFO D00HCI 2-APB Investigative T37371 TARGETID T37371 T37371 FORMERID TTDI03441 T37371 UNIPROID PASK_HUMAN T37371 TARGNAME PAS domain-containing serine/threonine-protein kinase (PASK) T37371 GENENAME PASK T37371 TARGTYPE Literature-reported T37371 SYNONYMS hPASK; PASKIN; PAS-kinase; KIAA0135 T37371 FUNCTION Serine/threonine-protein kinase involved in energy homeostasis and protein translation. Phosphorylates EEF1A1, GYS1, PDX1 and RPS6. Probably plays a role under changing environmental conditions (oxygen, glucose, nutrition), rather than under standard conditions. Acts as a sensor involved in energy homeostasis: regulates glycogen synthase synthesis by mediating phosphorylation of GYS1, leading to GYS1 inactivation. May be involved in glucose-stimulated insulin production in pancreas and regulation of glucagon secretion by glucose in alpha cells; however such data require additional evidences. May play a role in regulation of protein translation by phosphorylating EEF1A1, leading to increase translation efficiency. May also participate to respiratory regulation. T37371 PDBSTRUC 3DLS; 1LL8 T37371 ECNUMBER EC 2.7.11.1 T37371 SEQUENCE MEDGGLTAFEEDQRCLSQSLPLPVSAEGPAAQTTAEPSRSFSSAHRHLSRRNGLSRLCQSRTALSEDRWSSYCLSSLAAQNICTSKLHCPAAPEHTDPSEPRGSVSCCSLLRGLSSGWSSPLLPAPVCNPNKAIFTVDAKTTEILVANDKACGLLGYSSQDLIGQKLTQFFLRSDSDVVEALSEEHMEADGHAAVVFGTVVDIISRSGEKIPVSVWMKRMRQERRLCCVVVLEPVERVSTWVAFQSDGTVTSCDSLFAHLHGYVSGEDVAGQHITDLIPSVQLPPSGQHIPKNLKIQRSVGRARDGTTFPLSLKLKSQPSSEEATTGEAAPVSGYRASVWVFCTISGLITLLPDGTIHGINHSFALTLFGYGKTELLGKNITFLIPGFYSYMDLAYNSSLQLPDLASCLDVGNESGCGERTLDPWQGQDPAEGGQDPRINVVLAGGHVVPRDEIRKLMESQDIFTGTQTELIAGGQLLSCLSPQPAPGVDNVPEGSLPVHGEQALPKDQQITALGREEPVAIESPGQDLLGESRSEPVDVKPFASCEDSEAPVPAEDGGSDAGMCGLCQKAQLERMGVSGPSGSDLWAGAAVAKPQAKGQLAGGSLLMHCPCYGSEWGLWWRSQDLAPSPSGMAGLSFGTPTLDEPWLGVENDREELQTCLIKEQLSQLSLAGALDVPHAELVPTECQAVTAPVSSCDLGGRDLCGGCTGSSSACYALATDLPGGLEAVEAQEVDVNSFSWNLKELFFSDQTDQTSSNCSCATSELRETPSSLAVGSDPDVGSLQEQGSCVLDDRELLLLTGTCVDLGQGRRFRESCVGHDPTEPLEVCLVSSEHYAASDRESPGHVPSTLDAGPEDTCPSAEEPRLNVQVTSTPVIVMRGAAGLQREIQEGAYSGSCYHRDGLRLSIQFEVRRVELQGPTPLFCCWLVKDLLHSQRDSAARTRLFLASLPGSTHSTAAELTGPSLVEVLRARPWFEEPPKAVELEGLAACEGEYSQKYSTMSPLGSGAFGFVWTAVDKEKNKEVVVKFIKKEKVLEDCWIEDPKLGKVTLEIAILSRVEHANIIKVLDIFENQGFFQLVMEKHGSGLDLFAFIDRHPRLDEPLASYIFRQLVSAVGYLRLKDIIHRDIKDENIVIAEDFTIKLIDFGSAAYLERGKLFYTFCGTIEYCAPEVLMGNPYRGPELEMWSLGVTLYTLVFEENPFCELEETVEAAIHPPYLVSKELMSLVSGLLQPVPERRTTLEKLVTDPWVTQPVNLADYTWEEVFRVNKPESGVLSAASLEMGNRSLSDVAQAQELCGGPVPGEAPNGQGCLHPGDPRLLTS T37371 DRUGINFO D0H2CM PP-242 Investigative T87448 TARGETID T87448 T87448 FORMERID TTDI02478 T87448 UNIPROID NODAL_HUMAN T87448 TARGNAME Nodal homolog (NODAL) T87448 GENENAME NODAL T87448 TARGTYPE Literature-reported T87448 SYNONYMS nodal growth differentiation factor; HTX5 T87448 FUNCTION Essential for mesoderm formation and axial patterning during embryonic development. T87448 PDBSTRUC 4N1D T87448 BIOCLASS Growth factor T87448 SEQUENCE MHAHCLPFLLHAWWALLQAGAATVATALLRTRGQPSSPSPLAYMLSLYRDPLPRADIIRSLQAEDVAVDGQNWTFAFDFSFLSQQEDLAWAELRLQLSSPVDLPTEGSLAIEIFHQPKPDTEQASDSCLERFQMDLFTVTLSQVTFSLGSMVLEVTRPLSKWLKHPGALEKQMSRVAGECWPRPPTPPATNVLLMLYSNLSQEQRQLGGSTLLWEAESSWRAQEGQLSWEWGKRHRRHHLPDRSQLCRKVKFQVDFNLIGWGSWIIYPKQYNAYRCEGECPNPVGEEFHPTNHAYIQSLLKRYQPHRVPSTCCAPVKTKPLSMLYVDNGRVLLDHHKDMIVEECGCL T29678 TARGETID T29678 T29678 FORMERID TTDI01968 T29678 UNIPROID SCN2A_HUMAN T29678 TARGNAME Voltage-gated sodium channel alpha Nav1.2 (SCN2A) T29678 GENENAME SCN2A T29678 TARGTYPE Literature-reported T29678 SYNONYMS Voltage-gated sodium channelsubunit alpha Nav1.2; Sodium channel protein type II subunit alpha; Sodium channel protein brainII subunit alpha; SCN2A; HBSC II T29678 FUNCTION Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. T29678 PDBSTRUC 6J8E; 4RLY; 4JPZ; 2KAV T29678 BIOCLASS Voltage-gated ion channel T29678 SEQUENCE MAQSVLVPPGPDSFRFFTRESLAAIEQRIAEEKAKRPKQERKDEDDENGPKPNSDLEAGKSLPFIYGDIPPEMVSVPLEDLDPYYINKKTFIVLNKGKAISRFSATPALYILTPFNPIRKLAIKILVHSLFNMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKILARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCLQWPPDNSSFEINITSFFNNSLDGNGTTFNRTVSIFNWDEYIEDKSHFYFLEGQNDALLCGNSSDAGQCPEGYICVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTLRAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMLEQLKKQQEEAQAAAAAASAESRDFSGAGGIGVFSESSSVASKLSSKSEKELKNRRKKKKQKEQSGEEEKNDRVRKSESEDSIRRKGFRFSLEGSRLTYEKRFSSPHQSLLSIRGSLFSPRRNSRASLFSFRGRAKDIGSENDFADDEHSTFEDNDSRRDSLFVPHRHGERRHSNVSQASRASRVLPILPMNGKMHSAVDCNGVVSLVGGPSTLTSAGQLLPEGTTTETEIRKRRSSSYHVSMDLLEDPTSRQRAMSIASILTNTMEELEESRQKCPPCWYKFANMCLIWDCCKPWLKVKHLVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTEQFSSVLSVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVSLSLMELGLANVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKISNDCELPRWHMHDFFHSFLIVFRVLCGEWIETMWDCMEVAGQTMCLTVFMMVMVIGNLVVLNLFLALLLSSFSSDNLAATDDDNEMNNLQIAVGRMQKGIDFVKRKIREFIQKAFVRKQKALDEIKPLEDLNNKKDSCISNHTTIEIGKDLNYLKDGNGTTSGIGSSVEKYVVDESDYMSFINNPSLTVTVPIAVGESDFENLNTEEFSSESDMEESKEKLNATSSSEGSTVDIGAPAEGEQPEVEPEESLEPEACFTEDCVRKFKCCQISIEEGKGKLWWNLRKTCYKIVEHNWFETFIVFMILLSSGALAFEDIYIEQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGFQVYFTNAWCWLDFLIVDVSLVSLTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYHCINYTTGEMFDVSVVNNYSECKALIESNQTARWKNVKVNFDNVGLGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEDNLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPANKFQGMVFDFVTKQVFDISIMILICLNMVTMMVETDDQSQEMTNILYWINLVFIVLFTGECVLKLISLRYYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSGPPDCDPDKDHPGSSVKGDCGNPSVGIFFFVSYIIISFLVVVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFIEFAKLSDFADALDPPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMASNPSKVSYEPITTTLKRKQEEVSAIIIQRAYRRYLLKQKVKKVSSIYKKDKGKECDGTPIKEDTLIDKLNENSTPEKTDMTPSTTSPPSYDSVTKPEKEKFEKDKSEKEDKGKDIRESKK T29678 DRUGINFO D0A1MW aconitine Investigative T29678 DRUGINFO D0G9WE batrachotoxin Investigative T29678 DRUGINFO D0S4MN veratridine Investigative T05739 TARGETID T05739 T05739 FORMERID TTDNC00444 T05739 UNIPROID PLCA_HUMAN T05739 TARGNAME Lysophosphatidic acid transferase (AGPAT1) T05739 GENENAME AGPAT1 T05739 TARGTYPE Literature-reported T05739 SYNONYMS Protein G15; AGPAT1; 1acylsnglycerol3phosphate acyltransferase alpha; 1acylglycerol3phosphate Oacyltransferase 1; 1AGPAT 1; 1AGP acyltransferase 1 T05739 FUNCTION Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. T05739 BIOCLASS Acyltransferase T05739 ECNUMBER EC 2.3.1.51 T05739 SEQUENCE MDLWPGAWMLLLLLFLLLLFLLPTLWFCSPSAKYFFKMAFYNGWILFLAVLAIPVCAVRGRNVENMKILRLMLLHIKYLYGIRVEVRGAHHFPPSQPYVVVSNHQSSLDLLGMMEVLPGRCVPIAKRELLWAGSAGLACWLAGVIFIDRKRTGDAISVMSEVAQTLLTQDVRVWVFPEGTRNHNGSMLPFKRGAFHLAVQAQVPIVPIVMSSYQDFYCKKERRFTSGQCQVRVLPPVPTEGLTPDDVPALADRVRHSMLTVFREISTDGRGGGDYLKKPGGGG T93263 TARGETID T93263 T93263 UNIPROID SH3G1_HUMAN T93263 TARGNAME Endophilin-A2 (SH3GL1) T93263 GENENAME SH3GL1 T93263 TARGTYPE Literature-reported T93263 SYNONYMS SH3D2B; SH3 domain-containing GRB2-like protein 1; SH3 domain protein 2B; Extra eleven-nineteen leukemia fusion gene protein; Endophilin-2; EEN fusion partner of MLL; EEN; CNSA1 T93263 FUNCTION Implicated in endocytosis. May recruit other proteins to membranes with high curvature. T93263 BIOCLASS Endophilin family T93263 SEQUENCE MSVAGLKKQFYKASQLVSEKVGGAEGTKLDDDFKEMEKKVDVTSKAVTEVLARTIEYLQPNPASRAKLTMLNTVSKIRGQVKNPGYPQSEGLLGECMIRHGKELGGESNFGDALLDAGESMKRLAEVKDSLDIEVKQNFIDPLQNLCEKDLKEIQHHLKKLEGRRLDFDYKKKRQGKIPDEELRQALEKFEESKEVAETSMHNLLETDIEQVSQLSALVDAQLDYHRQAVQILDELAEKLKRRMREASSRPKREYKPKPREPFDLGEPEQSNGGFPCTTAPKIAASSSFRSSDKPIRTPSRSMPPLDQPSCKALYDFEPENDGELGFHEGDVITLTNQIDENWYEGMLDGQSGFFPLSYVEVLVPLPQ T22769 TARGETID T22769 T22769 FORMERID TTDC00055 T22769 UNIPROID TEP1_HUMAN T22769 TARGNAME Telomerase protein component 1 (TEP1) T22769 GENENAME TEP1 T22769 TARGTYPE Literature-reported T22769 SYNONYMS p80 telomerase homolog; p240; Telomerase-associated protein 1; Telomerase protein 1; TP1; TLP1 T22769 FUNCTION Component of the ribonucleoprotein vaults particle, a multi-subunit structure involved in nucleo-cytoplasmic transport. Responsible for the localizing and stabilizing vault RNA (vRNA) association in the vault ribonucleoprotein particle. Binds to TERC. Component of the telomerase ribonucleoprotein complex that is essential for the replication of chromosome termini. T22769 SEQUENCE MEKLHGHVSAHPDILSLENRCLAMLPDLQPLEKLHQHVSTHSDILSLKNQCLATLPDLKTMEKPHGYVSAHPDILSLENQCLATLSDLKTMEKPHGHVSAHPDILSLENRCLATLSSLKSTVSASPLFQSLQISHMTQADLYRVNNSNCLLSEPPSWRAQHFSKGLDLSTCPIALKSISATETAQEATLGRWFDSEEKKGAETQMPSYSLSLGEEEEVEDLAVKLTSGDSESHPEPTDHVLQEKKMALLSLLCSTLVSEVNMNNTSDPTLAAIFEICRELALLEPEFILKASLYARQQLNVRNVANNILAIAAFLPACRPHLRRYFCAIVQLPSDWIQVAELYQSLAEGDKNKLVPLPACLRTAMTDKFAQFDEYQLAKYNPRKHRAKRHPRRPPRSPGMEPPFSHRCFPRYIGFLREEQRKFEKAGDTVSEKKNPPRFTLKKLVQRLHIHKPAQHVQALLGYRYPSNLQLFSRSRLPGPWDSSRAGKRMKLSRPETWERELSLRGNKASVWEELIENGKLPFMAMLRNLCNLLRVGISSRHHELILQRLQHAKSVIHSRQFPFRFLNAHDAIDALEAQLRNQALPFPSNITLMRRILTRNEKNRPRRRFLCHLSRQQLRMAMRIPVLYEQLKREKLRVHKARQWKYDGEMLNRYRQALETAVNLSVKHSLPLLPGRTVLVYLTDANADRLCPKSNPQGPPLNYALLLIGMMITRAEQVDVVLCGGDTLKTAVLKAEEGILKTAIKLQAQVQEFDENDGWSLNTFGKYLLSLAGQRVPVDRVILLGQSMDDGMINVAKQLYWQRVNSKCLFVGILLRRVQYLSTDLNPNDVTLSGCTDAILKFIAEHGASHLLEHVGQMDKIFKIPPPPGKTGVQSLRPLEEDTPSPLAPVSQQGWRSIRLFISSTFRDMHGERDLLLRSVLPALQARAAPHRISLHGIDLRWGVTEEETRRNRQLEVCLGEVENAQLFVGILGSRYGYIPPSYNLPDHPHFHWAQQYPSGRSVTEMEVMQFLNRNQRLQPSAQALIYFRDSSFLSSVPDAWKSDFVSESEEAARRISELKSYLSRQKGITCRRYPCEWGGVAAGRPYVGGLEEFGQLVLQDVWNMIQKLYLQPGALLEQPVSIPDDDLVQATFQQLQKPPSPARPRLLQDTVQRLMLPHGRLSLVTGQSGQGKTAFLASLVSALQAPDGAKVASLVFFHFSGARPDQGLALTLLRRLCTYLRGQLKEPGALPSTYRSLVWELQQRLLPKSAESLHPGQTQVLIIDGADRLVDQNGQLISDWIPKKLPRCVHLVLSVSSDAGLGETLEQSQGAHVLALGPLEASARARLVREELALYGKRLEESPFNNQMRLLLVKRESGRPLYLRLVTDHLRLFTLYEQVSERLRTLPATVPLLLQHILSTLEKEHGPDVLPQALTALEVTRSGLTVDQLHGVLSVWRTLPKGTKSWEEAVAAGNSGDPYPMGPFACLVQSLRSLLGEGPLERPGARLCLPDGPLRTAAKRCYGKRPGLEDTAHILIAAQLWKTCDADASGTFRSCPPEALGDLPYHLLQSGNRGLLSKFLTNLHVVAAHLELGLVSRLLEAHALYASSVPKEEQKLPEADVAVFRTFLRQQASILSQYPRLLPQQAANQPLDSPLCHQASLLSRRWHLQHTLRWLNKPRTMKNQQSSSLSLAVSSSPTAVAFSTNGQRAAVGTANGTVYLLDLRTWQEEKSVVSGCDGISACLFLSDDTLFLTAFDGLLELWDLQHGCRVLQTKAHQYQITGCCLSPDCRLLATVCLGGCLKLWDTVRGQLAFQHTYPKSLNCVAFHPEGQVIATGSWAGSISFFQVDGLKVTKDLGAPGASIRTLAFNVPGGVVAVGRLDSMVELWAWREGARLAAFPAHHGFVAAALFLHAGCQLLTAGEDGKVQVWSGSLGRPRGHLGSLSLSPALSVALSPDGDRVAVGYRADGIRIYKISSGSQGAQGQALDVAVSALAWLSPKVLVSGAEDGSLQGWALKECSLQSLWLLSRFQKPVLGLATSQELLASASEDFTVQLWPRQLLTRPHKAEDFPCGTELRGHEGPVSCCSFSTDGGSLATGGRDRSLLCWDVRTPKTPVLIHSFPACHRDWVTGCAWTKDNLLISCSSDGSVGLWDPESGQRLGQFLGHQSAVSAVAAVEEHVVSVSRDGTLKVWDHQGVELTSIPAHSGPISHCAAAMEPRAAGQPGSELLVVTVGLDGATRLWHPLLVCQTHTLLGHSGPVRAAAVSETSGLMLTASEDGSVRLWQVPKEADDTCIPRSSAAVTAVAWAPDGSMAVSGNQAGELILWQEAKAVATAQAPGHIGALIWSSAHTFFVLSADEKISEWQVKLRKGSAPGNLSLHLNRILQEDLGVLTSLDWAPDGHFLILAKADLKLLCMKPGDAPSEIWSSYTENPMILSTHKEYGIFVLQPKDPGVLSFLRQKESGEFEERLNFDINLENPSRTLISITQAKPESESSFLCASSDGILWNLAKCSPEGEWTTGNMWQKKANTPETQTPGTDPSTCRESDASMDSDASMDSEPTPHLKTRQRRKIHSGSVTALHVLPELLVTASKDRDVKLWERPSMQLLGLFRCEGSVSCLEPWLGANSTLQLAVGDVQGNVYFLNWE T32498 TARGETID T32498 T32498 FORMERID TTDR00044 T32498 UNIPROID Q9BLW4_LEIME T32498 TARGNAME Leishmania GDP-mannose pyrophosphorylase (Leishm exgmp) T32498 GENENAME Leishm exgmp T32498 TARGTYPE Literature-reported T32498 SYNONYMS GDP-mannose pyrophosphorylase T32498 FUNCTION Assembles as a hexamer of 240 kDa in several Leishmania species. Critical for cell integrity and survival. T32498 BIOCLASS Transferases of phosphorus-containing groups T32498 ECNUMBER EC 2.7.7.22 T32498 SEQUENCE MSASDGQGMRAVILVGGFGTRLRPLTLTTPKPLVPFCNKPMIIHQIEALKAVGVTEVILAVAYRPEAMKEQMDEWSRKLGVSFVFSVEEDPLGTAGPLALARDILMQDDKPFFVLNSDVTCMFPLQELLDFHKARGGEGTIMVSQVTQWEKYGVVVYSQQSYQIERFVEKPSSFLGDRVNAGIYIFNKSILDRIPPCRTSIEKEIFPAMAAEGELYAFNLEGFWMDVGQPKDYILGMTKFIPSLLDGDRKTEQLHTEATEHQHGGRFTVVGASLIDPSAKIGDGAVIGPCASIGANCVIGESCRIDNAAILENSKVGKGTMVSRSIVGWNNRIGSWCHIEDISVLGDDVEVKDGVVLIGTKVLPNKDVGEHHFQAGIIM T95033 TARGETID T95033 T95033 UNIPROID HTAI2_HUMAN T95033 TARGNAME Oxidoreductase HTATIP2 (HTATIP2) T95033 GENENAME HTATIP2 T95033 TARGTYPE Literature-reported T95033 SYNONYMS HIV-1 TAT-interactive protein 2; 30 kDa HIV-1 TAT-interacting protein T95033 FUNCTION Oxidoreductase required for tumor suppression. NAPDH-bound form inhibits nuclear import by competing with nuclear import substrates for binding to a subset of nuclear transport receptors. May act as a redox sensor linked to transcription through regulation of nuclear import. Isoform 1 is a metastasis suppressor with proapoptotic as well as antiangiogenic properties. Isoform 2 has an antiapoptotic effect. T95033 PDBSTRUC 2BKA T95033 ECNUMBER EC 1.1.1.- T95033 SEQUENCE MAETEALSKLREDFRMQNKSVFILGASGETGRVLLKEILEQGLFSKVTLIGRRKLTFDEEAYKNVNQEVVDFEKLDDYASAFQGHDVGFCCLGTTRGKAGAEGFVRVDRDYVLKSAELAKAGGCKHFNLLSSKGADKSSNFLYLQVKGEVEAKVEELKFDRYSVFRPGVLLCDRQESRPGEWLVRKFFGSLPDSWASGHSVPVVTVVRAMLNNVVRPRDKQMELLENKAIHDLGKAHGSLKP T22335 TARGETID T22335 T22335 FORMERID TTDR01213 T22335 UNIPROID FANCJ_HUMAN T22335 TARGNAME BRCA1-associated C-terminal helicase 1 (FANCJ) T22335 GENENAME BRIP1 T22335 TARGTYPE Literature-reported T22335 SYNONYMS Protein FACJ; Fanconi anemia group J protein; FANCJ; BRCA1-interacting protein C-terminal helicase 1; BRCA1-interacting protein 1; BACH1; ATP-dependent RNA helicase BRIP1 T22335 FUNCTION DNA-dependent ATPase and 5' to 3' DNA helicase required for the maintenance of chromosomal stability. Acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination. Involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1. T22335 PDBSTRUC 3AL3; 1T29; 1T15 T22335 ECNUMBER EC 3.6.4.13 T22335 SEQUENCE MSSMWSEYTIGGVKIYFPYKAYPSQLAMMNSILRGLNSKQHCLLESPTGSGKSLALLCSALAWQQSLSGKPADEGVSEKAEVQLSCCCACHSKDFTNNDMNQGTSRHFNYPSTPPSERNGTSSTCQDSPEKTTLAAKLSAKKQASIYRDENDDFQVEKKRIRPLETTQQIRKRHCFGTEVHNLDAKVDSGKTVKLNSPLEKINSFSPQKPPGHCSRCCCSTKQGNSQESSNTIKKDHTGKSKIPKIYFGTRTHKQIAQITRELRRTAYSGVPMTILSSRDHTCVHPEVVGNFNRNEKCMELLDGKNGKSCYFYHGVHKISDQHTLQTFQGMCKAWDIEELVSLGKKLKACPYYTARELIQDADIIFCPYNYLLDAQIRESMDLNLKEQVVILDEAHNIEDCARESASYSVTEVQLRFARDELDSMVNNNIRKKDHEPLRAVCCSLINWLEANAEYLVERDYESACKIWSGNEMLLTLHKMGITTATFPILQGHFSAVLQKEEKISPIYGKEEAREVPVISASTQIMLKGLFMVLDYLFRQNSRFADDYKIAIQQTYSWTNQIDISDKNGLLVLPKNKKRSRQKTAVHVLNFWCLNPAVAFSDINGKVQTIVLTSGTLSPMKSFSSELGVTFTIQLEANHIIKNSQVWVGTIGSGPKGRNLCATFQNTETFEFQDEVGALLLSVCQTVSQGILCFLPSYKLLEKLKERWLSTGLWHNLELVKTVIVEPQGGEKTNFDELLQVYYDAIKYKGEKDGALLVAVCRGKVSEGLDFSDDNARAVITIGIPFPNVKDLQVELKRQYNDHHSKLRGLLPGRQWYEIQAYRALNQALGRCIRHRNDWGALILVDDRFRNNPSRYISGLSKWVRQQIQHHSTFESALESLAEFSKKHQKVLNVSIKDRTNIQDNESTLEVTSLKYSTSPYLLEAASHLSPENFVEDEAKICVQELQCPKIITKNSPLPSSIISRKEKNDPVFLEEAGKAEKIVISRSTSPTFNKQTKRVSWSSFNSLGQYFTGKIPKATPELGSSENSASSPPRFKTEKMESKTVLPFTDKCESSNLTVNTSFGSCPQSETIISSLKIDATLTRKNHSEHPLCSEEALDPDIELSLVSEEDKQSTSNRDFETEAEDESIYFTPELYDPEDTDEEKNDLAETDRGNRLANNSDCILAKDLFEIRTIKEVDSAREVKAEDCIDTKLNGILHIEESKIDDIDGNVKTTWINELELGKTHEIEIKNFKPSPSKNKGMFPGFK T61029 TARGETID T61029 T61029 FORMERID TTDI03596 T61029 UNIPROID TRPM6_HUMAN T61029 TARGNAME Long transient receptor potential channel 6 (TRPM6) T61029 GENENAME TRPM6 T61029 TARGTYPE Literature-reported T61029 SYNONYMS Transient receptor potential cation channel subfamily M member 6; Melastatin-related TRP cation channel 6; Channel kinase 2; CHAK2 T61029 FUNCTION Essential ion channel and serine/threonine-protein kinase. Crucial for magnesium homeostasis. Has an important role in epithelial magnesium transport and in the active magnesium absorption in the gut and kidney. Isoforms of the type M6-kinase lack the ion channel region. T61029 BIOCLASS Transient receptor potential catioin channel T61029 ECNUMBER EC 2.7.11.1 T61029 SEQUENCE MKEQPVLERLQSQKSWIKGVFDKRECSTIIPSSKNPHRCTPVCQVCQNLIRCYCGRLIGDHAGIDYSWTISAAKGKESEQWSVEKHTTKSPTDTFGTINFQDGEHTHHAKYIRTSYDTKLDHLLHLMLKEWKMELPKLVISVHGGIQNFTMPSKFKEIFSQGLVKAAETTGAWIITEGINTGVSKHVGDALKSHSSHSLRKIWTVGIPPWGVIENQRDLIGKDVVCLYQTLDNPLSKLTTLNSMHSHFILSDDGTVGKYGNEMKLRRNLEKYLSLQKIHCRSRQGVPVVGLVVEGGPNVILSVWETVKDKDPVVVCEGTGRAADLLAFTHKHLADEGMLRPQVKEEIICMIQNTFNFSLKQSKHLFQILMECMVHRDCITIFDADSEEQQDLDLAILTALLKGTNLSASEQLNLAMAWDRVDIAKKHILIYEQHWKPDALEQAMSDALVMDRVDFVKLLIEYGVNLHRFLTIPRLEELYNTKQGPTNTLLHHLVQDVKQHTLLSGYRITLIDIGLVVEYLIGRAYRSNYTRKHFRALYNNLYRKYKHQRHSSGNRNESAESTLHSQFIRTAQPYKFKEKSIVLHKSRKKSKEQNVSDDPESTGFLYPYNDLLVWAVLMKRQKMAMFFWQHGEEATVKAVIACILYRAMAHEAKESHMVDDASEELKNYSKQFGQLALDLLEKAFKQNERMAMTLLTYELRNWSNSTCLKLAVSGGLRPFVSHTCTQMLLTDMWMGRLKMRKNSWLKIIISIILPPTILTLEFKSKAEMSHVPQSQDFQFMWYYSDQNASSSKESASVKEYDLERGHDEKLDENQHFGLESGHQHLPWTRKVYEFYSAPIVKFWFYTMAYLAFLMLFTYTVLVEMQPQPSVQEWLVSIYIFTNAIEVVREICISEPGKFTQKVKVWISEYWNLTETVAIGLFSAGFVLRWGDPPFHTAGRLIYCIDIIFWFSRLLDFFAVNQHAGPYVTMIAKMTANMFYIVIIMAIVLLSFGVARKAILSPKEPPSWSLARDIVFEPYWMIYGEVYAGEIDVCSSQPSCPPGSFLTPFLQAVYLFVQYIIMVNLLIAFFNNVYLDMESISNNLWKYNRYRYIMTYHEKPWLPPPLILLSHVGLLLRRLCCHRAPHDQEEGDVGLKLYLSKEDLKKLHDFEEQCVEKYFHEKMEDVNCSCEERIRVTSERVTEMYFQLKEMNEKVSFIKDSLLSLDSQVGHLQDLSALTVDTLKVLSAVDTLQEDEALLAKRKHSTCKKLPHSWSNVICAEVLGSMEIAGEKKYQYYSMPSSLLRSLAGGRHPPRVQRGALLEITNSKREATNVRNDQERQETQSSIVVSGVSPNRQAHSKYGQFLLVPSNLKRVPFSAETVLPLSRPSVPDVLATEQDIQTEVLVHLTGQTPVVSDWASVDEPKEKHEPIAHLLDGQDKAEQVLPTLSCTPEPMTMSSPLSQAKIMQTGGGYVNWAFSEGDETGVFSIKKKWQTCLPSTCDSDSSRSEQHQKQAQDSSLSDNSTRSAQSSECSEVGPWLQPNTSFWINPLRRYRPFARSHSFRFHKEEKLMKICKIKNLSGSSEIGQGAWVKAKMLTKDRRLSKKKKNTQGLQVPIITVNACSQSDQLNPEPGENSISEEEYSKNWFTVSKFSHTGVEPYIHQKMKTKEIGQCAIQISDYLKQSQEDLSKNSLWNSRSTNLNRNSLLKSSIGVDKISASLKSPQEPHHHYSAIERNNLMRLSQTIPFTPVQLFAGEEITVYRLEESSPLNLDKSMSSWSQRGRAAMIQVLSREEMDGGLRKAMRVVSTWSEDDILKPGQVFIVKSFLPEVVRTWHKIFQESTVLHLCLREIQQQRAAQKLIYTFNQVKPQTIPYTPRFLEVFLIYCHSANQWLTIEKYMTGEFRKYNNNNGDEITPTNTLEELMLAFSHWTYEYTRGELLVLDLQGVGENLTDPSVIKPEVKQSRGMVFGPANLGEDAIRNFIAKHHCNSCCRKLKLPDLKRNDYSPERINSTFGLEIKIESAEEPPARETGRNSPEDDMQL T61029 DRUGINFO D00HCI 2-APB Investigative T42014 TARGETID T42014 T42014 FORMERID TTDI02608 T42014 UNIPROID SGPP1_HUMAN T42014 TARGNAME Sphingosine-1-phosphate phosphatase 1 (SGPP1) T42014 GENENAME SGPP1 T42014 TARGTYPE Literature-reported T42014 SYNONYMS hSPPase1; hSPP1; Spp1; Sphingosine-1-phosphatase 1; SPPase1; SGPP1 T42014 FUNCTION Has enzymatic activity against both sphingosine 1- phosphate (S1P) and dihydro-S1P. Regulates intracellular and extracellular S1P levels. T42014 BIOCLASS Phosphoric monoester hydrolase T42014 ECNUMBER EC 3.1.3.- T42014 SEQUENCE MSLRQRLAQLVGRLQDPQKVARFQRLCGVEAPPRRSADRREDEKAEAPLAGDPRLRGRQPGAPGGPQPPGSDRNQCPAKPDGGGAPNGVRNGLAAELGPASPRRAGALRRNSLTGEEGQLARVSNWPLYCLFCFGTELGNELFYILFFPFWIWNLDPLVGRRLVVIWVLVMYLGQCTKDIIRWPRPASPPVVKLEVFYNSEYSMPSTHAMSGTAIPISMVLLTYGRWQYPLIYGLILIPCWCSLVCLSRIYMGMHSILDIIAGFLYTILILAVFYPFVDLIDNFNQTHKYAPFIIIGLHLALGIFSFTLDTWSTSRGDTAEILGSGAGIACGSHVTYNMGLVLDPSLDTLPLAGPPITVTLFGKAILRILIGMVFVLIIRDVMKKITIPLACKIFNIPCDDIRKARQHMEVELPYRYITYGMVGFSITFFVPYIFFFIGIS T56272 TARGETID T56272 T56272 FORMERID TTDI02516 T56272 UNIPROID HCAR1_HUMAN T56272 TARGNAME G protein coupled receptor 81 (HCAR1) T56272 GENENAME HCAR1 T56272 TARGTYPE Literature-reported T56272 SYNONYMS Hydroxycarboxylic acid receptor 1; HCAR1; Gprotein coupled receptor 81; Gprotein coupled receptor 104 T56272 FUNCTION Acts as a receptor for L-lactate and mediates its anti- lipolytic effect through a G(i)-protein-mediated pathway. T56272 BIOCLASS GPCR rhodopsin T56272 SEQUENCE MYNGSCCRIEGDTISQVMPPLLIVAFVLGALGNGVALCGFCFHMKTWKPSTVYLFNLAVADFLLMICLPFRTDYYLRRRHWAFGDIPCRVGLFTLAMNRAGSIVFLTVVAADRYFKVVHPHHAVNTISTRVAAGIVCTLWALVILGTVYLLLENHLCVQETAVSCESFIMESANGWHDIMFQLEFFMPLGIILFCSFKIVWSLRRRQQLARQARMKKATRFIMVVAIVFITCYLPSVSARLYFLWTVPSSACDPSVHGALHITLSFTYMNSMLDPLVYYFSSPSFPKFYNKLKICSLKPKQPGHSKTQRPEEMPISNLGRRSCISVANSFQSQSDGQWDPHIVEWH T56272 DRUGINFO D06FZS L-lactic acid Investigative T56272 DRUGINFO D0DA9T D-lactic acid Investigative T56272 DRUGINFO D0W1OR 3,5-dihydroxybenzoic acid Investigative T21460 TARGETID T21460 T21460 FORMERID TTDI02392 T21460 UNIPROID BBC3_HUMAN T21460 TARGNAME Bcl-2-binding component 3 (BBC3) T21460 GENENAME BBC3 T21460 TARGTYPE Literature-reported T21460 SYNONYMS p53 upregulated modulator of apoptosis; p53 up-regulated modulator of apoptosis; PUMA; JFY1; JFY-1; Bcl2binding component 3 T21460 FUNCTION Functions by promoting partial unfolding of BCL2L1 and dissociation of BCL2L1 from p53/TP53. Regulates ER stress-induced neuronal apoptosis. Essential mediator of p53/TP53-dependent and p53/TP53-independent apoptosis. T21460 PDBSTRUC 5UUL; 4HNJ; 4BPK; 4BPJ; 4BPI T21460 BIOCLASS B-cell lymphoma Bcl-2 T21460 SEQUENCE MARARQEGSSPEPVEGLARDGPRPFPLGRLVPSAVSCGLCEPGLAAAPAAPTLLPAAYLCAPTAPPAVTAALGGSRWPGGPRSRPRGPRPDGPQPSLSLAEQHLESPVPSAPGALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNAQYERRRQEEQQRHRPSPWRVLYNLIMGLLPLPRGHRAPEMEPN T26073 TARGETID T26073 T26073 FORMERID TTDI02515 T26073 UNIPROID GPR87_HUMAN T26073 TARGNAME G protein coupled receptor 87 (GPR87) T26073 GENENAME GPR87 T26073 TARGTYPE Literature-reported T26073 SYNONYMS GPR87; G-protein coupled receptor 95; G-protein coupled receptor 87 T26073 FUNCTION Receptor for lysophosphatidic acid (LPA). Necessary for p53/TP53-dependent survival in response to DNA damage. T26073 BIOCLASS GPCR rhodopsin T26073 SEQUENCE MGFNLTLAKLPNNELHGQESHNSGNRSDGPGKNTTLHNEFDTIVLPVLYLIIFVASILLNGLAVWIFFHIRNKTSFIFYLKNIVVADLIMTLTFPFRIVHDAGFGPWYFKFILCRYTSVLFYANMYTSIVFLGLISIDRYLKVVKPFGDSRMYSITFTKVLSVCVWVIMAVLSLPNIILTNGQPTEDNIHDCSKLKSPLGVKWHTAVTYVNSCLFVAVLVILIGCYIAISRYIHKSSRQFISQSSRKRKHNQSIRVVVAVFFTCFLPYHLCRIPFTFSHLDRLLDESAQKILYYCKEITLFLSACNVCLDPIIYFFMCRSFSRRLFKKSNIRTRSESIRSLQSVRRSEVRIYYDYTDV T26073 DRUGINFO D02LXI Ki16425 Investigative T26073 DRUGINFO D0G6XT dioctanoylglycerol pyrophosphate Investigative T26073 DRUGINFO D0X0UR LPA Investigative T98635 TARGETID T98635 T98635 FORMERID TTDR00795 T98635 UNIPROID ANGL4_HUMAN T98635 TARGNAME Angiopoietin-related protein 4 (ANGPTL4) T98635 GENENAME ANGPTL4 T98635 TARGTYPE Literature-reported T98635 SYNONYMS UNQ171/PRO197; PSEC0166; PP1158; PGAR; Hepatic fibrinogen/angiopoietin-related protein; HFARP; Angiopoietin-like protein PP1158; Angiopoietin-like protein 4; Angiopoietin-like 4; ARP4 T98635 FUNCTION May also play a role in regulating glucose homeostasis and insulin sensitivity. Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro). Depending on context, may modulate tumor-related angiogenesis. Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism. T98635 PDBSTRUC 6EUB T98635 BIOCLASS Fibrinogen protein T98635 SEQUENCE MSGAPTAGAALMLCAATAVLLSAQGGPVQSKSPRFASWDEMNVLAHGLLQLGQGLREHAERTRSQLSALERRLSACGSACQGTEGSTDLPLAPESRVDPEVLHSLQTQLKAQNSRIQQLFHKVAQQQRHLEKQHLRIQHLQSQFGLLDHKHLDHEVAKPARRKRLPEMAQPVDPAHNVSRLHRLPRDCQELFQVGERQSGLFEIQPQGSPPFLVNCKMTSDGGWTVIQRRHDGSVDFNRPWEAYKAGFGDPHGEFWLGLEKVHSITGDRNSRLAVQLRDWDGNAELLQFSVHLGGEDTAYSLQLTAPVAGQLGATTVPPSGLSVPFSTWDQDHDLRRDKNCAKSLSGGWWFGTCSHSNLNGQYFRSIPQQRQKLKKGIFWKTWRGRYYPLQATTMLIQPMAAEAAS T53468 TARGETID T53468 T53468 FORMERID TTDI03619 T53468 UNIPROID WNK3_HUMAN T53468 TARGNAME WNK lysine-deficient protein kinase 3 (WNK3) T53468 GENENAME WNK3 T53468 TARGTYPE Literature-reported T53468 SYNONYMS Serine/threonine-protein kinase WNK3; Protein kinase with no lysine 3; Protein kinase lysine-deficient 3; KIAA1566 T53468 FUNCTION Serine/threonine kinase which plays an important role in the regulation of electrolyte homeostasis, cell signaling, survival and proliferation. Acts as an activator and inhibitor of sodium-coupled chloride cotransporters and potassium-coupled chloride cotransporters respectively. Phosphorylates WNK4. Regulates the phosphorylation of SLC12A1 and SLC12A2. Increases Ca(2+) influx mediated by TRPV5 and TRPV6 by enhancing their membrane expression level via a kinase-dependent pathway. Inhibits the activity of KCNJ1 by decreasing its expression at the cell membrane in a non-catalytic manner. T53468 PDBSTRUC 5O2C; 5O2B; 5O26; 5O23; 5O21 T53468 ECNUMBER EC 2.7.11.1 T53468 SEQUENCE MATDSGDPASTEDSEKPDGISFENRVPQVAATLTVEARLKEKNSTFSASGETVERKRFFRKSVEMTEDDKVAESSPKDERIKAAMNIPRVDKLPSNVLRGGQEVKYEQCSKSTSEISKDCFKEKNEKEMEEEAEMKAVATSPSGRFLKFDIELGRGAFKTVYKGLDTETWVEVAWCELQDRKLTKAEQQRFKEEAEMLKGLQHPNIVRFYDSWESILKGKKCIVLVTELMTSGTLKTYLKRFKVMKPKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLMRTSFAKSVIGTPEFMAPEMYEEHYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGIKPASFNKVTDPEVKEIIEGCIRQNKSERLSIRDLLNHAFFAEDTGLRVELAEEDDCSNSSLALRLWVEDPKKLKGKHKDNEAIEFSFNLETDTPEEVAYEMVKSGFFHESDSKAVAKSIRDRVTPIKKTREKKPAGCLEERRDSQCKSMGNVFPQPQNTTLPLAPAQQTGAECEETEVDQHVRQQLLQRKPQQHCSSVTGDNLSEAGAASVIHSDTSSQPSVAYSSNQTMGSQMVSNIPQAEVNVPGQIYSSQQLVGHYQQVSGLQKHSKLTQPQILPLVQGQSTVLPVHVLGPTVVSQPQVSPLTVQKVPQIKPVSQPVGAEQQAALLKPDLVRSLNQDVATTKENVSSPDNPSGNGKQDRIKQRRASCPRPEKGTKFQLTVLQVSTSGDNMVECQLETHNNKMVTFKFDVDGDAPEDIADYMVEDNFVLESEKEKFVEELRAIVGQAQEILHVHFATERATGVDSITVDSNSSQTGSSEQVQINSTSTQTSNESAPQSSPVGRWRFCINQTIRNRETQSPPSLQHSMSAVPGRHPLPSPKNTSNKEISRDTLLTIENNPCHRALFTSKSEHKDVVDGKISECASVETKQPAILYQVEDNRQIMAPVTNSSSYSTTSVRAVPAECEGLTKQASIFIPVYPCHQTASQADALMSHPGESTQTSGNSLTTLAFDQKPQTLSVQQPAMDAEFISQEGETTVNTEASSPKTVIPTQTPGLEPTTLQPTTVLESDGERPPKLEFADNRIKTLDEKLRNLLYQEHSISSIYPESQKDTQSIDSPFSSSAEDTLSCPVTEVIAISHCGIKDSPVQSPNFQQTGSKLLSNVAASQPANISVFKRDLNVITSVPSELCLHEMSSDASLPGDPEAYPAAVSSGGAIHLQTGGGYFGLSFTCPSLKNPISKKSWTRKLKSWAYRLRQSTSFFKRSKVRQVETEEMRSAIAPDPIPLTRESTADTRALNRCKAMSGSFQRGRFQVITIPQQQSAKMTSFGIEHISVFSETNHSSEEAFIKTAKSQLVEIEPATQNPKTSFSYEKLQALQETCKENKGVPKQGDNFLSFSAACETDVSSVTPEKEFEETSATGSSMQSGSELLLKEREILTAGKQPSSDSEFSASLAGSGKSVAKTGPESNQCLPHHEEQAYAQTQSSLFYSPSSPMSSDDESEIEDEDLKVELQRLREKHIQEVVNLQTQQNKELQELYERLRSIKDSKTQSTEIPLPPASPRRPRSFKSKLRSRPQSLTHVDNGIVATGKSCLINELENPLCVESNAASCQQSPASKKGMFTDDLHKLVDDWTKEAVGNSLIKPSLNQLKQSQHKLETENWNKVSENTPSTMGYTSTWISSLSQIRGAVPTSLPQGLSLPSFPGPLSSYGMPHVCQYNAVAGAGYPVQWVGISGTTQQSVVIPAQSGGPFQPGMNMQAFPTSSVQNPATIPPGPK T53468 DRUGINFO D0E7VO PMID24900538C2c Investigative T17552 TARGETID T17552 T17552 FORMERID TTDI00194 T17552 UNIPROID STK33_HUMAN T17552 TARGNAME Serine/threonine-protein kinase 33 (STK33) T17552 GENENAME STK33 T17552 TARGTYPE Literature-reported T17552 SYNONYMS STK33 T17552 FUNCTION Serine/threonine protein kinase which phosphorylates VIME. May play a specific role in the dynamic behavior of the intermediate filament cytoskeleton by phosphorylation of VIME. Not essential for the survival of KRAS-dependent AML cell lines. T17552 BIOCLASS Kinase T17552 ECNUMBER EC 2.7.11.1 T17552 SEQUENCE MADSGLDKKSTKCPDCSSASQKDVLCVCSSKTRVPPVLVVEMSQTSSIGSAESLISLERKKEKNINRDITSRKDLPSRTSNVERKASQQQWGRGNFTEGKVPHIRIENGAAIEEIYTFGRILGKGSFGIVIEATDKETETKWAIKKVNKEKAGSSAVKLLEREVNILKSVKHEHIIHLEQVFETPKKMYLVMELCEDGELKEILDRKGHFSENETRWIIQSLASAIAYLHNNDIVHRDLKLENIMVKSSLIDDNNEINLNIKVTDFGLAVKKQSRSEAMLQATCGTPIYMAPEVISAHDYSQQCDIWSIGVVMYMLLRGEPPFLASSEEKLFELIRKGELHFENAVWNSISDCAKSVLKQLMKVDPAHRITAKELLDNQWLTGNKLSSVRPTNVLEMMKEWKNNPESVEENTTEEKNKPSTEEKLKSYQPWGNVPDANYTSDEEEEKQSTAYEKQFPATSKDNFDMCSSSFTSSKLLPAEIKGEMEKTPVTPSQGTATKYPAKSGALSRTKKKL T17552 DRUGINFO D01TDV PMID21742770C1 Investigative T85188 TARGETID T85188 T85188 FORMERID TTDR00349 T85188 UNIPROID RTN4R_HUMAN T85188 TARGNAME Reticulon-4 receptor (RTN4R) T85188 GENENAME RTN4R T85188 TARGTYPE Literature-reported T85188 SYNONYMS UNQ330/PRO526; RTN4R; Nogo-66 receptor; Nogo receptor; NgR T85188 FUNCTION Receptor for RTN4, OMG and MAG. Mediates axonal growth inhibition and may play a role in regulating axonal regeneration and plasticity in the adult central nervous system. Acts in conjunction with RTN4 and LIGO1 in regulating neuronal precursor cell motility during cortical development. T85188 PDBSTRUC 1P8T; 1OZN T85188 SEQUENCE MKRASAGGSRLLAWVLWLQAWQVAAPCPGACVCYNEPKVTTSCPQQGLQAVPVGIPAASQRIFLHGNRISHVPAASFRACRNLTILWLHSNVLARIDAAAFTGLALLEQLDLSDNAQLRSVDPATFHGLGRLHTLHLDRCGLQELGPGLFRGLAALQYLYLQDNALQALPDDTFRDLGNLTHLFLHGNRISSVPERAFRGLHSLDRLLLHQNRVAHVHPHAFRDLGRLMTLYLFANNLSALPTEALAPLRALQYLRLNDNPWVCDCRARPLWAWLQKFRGSSSEVPCSLPQRLAGRDLKRLAANDLQGCAVATGPYHPIWTGRATDEEPLGLPKCCQPDAADKASVLEPGRPASAGNALKGRVPPGDSPPGNGSGPRHINDSPFGTLPGSAEPPLTAVRPEGSEPPGFPTSGPRRRPGCSRKNRTRSHCRLGQAGSGGGGTGDSEGSGALPSLTCSLTPLGLALVLWTVLGPC T85188 DRUGINFO D07LUR Alpha-D-Mannose Investigative T77061 TARGETID T77061 T77061 FORMERID TTDI03161 T77061 UNIPROID DCLK3_HUMAN T77061 TARGNAME Doublecortin-like kinase 3 (DCLK3) T77061 GENENAME DCLK3 T77061 TARGTYPE Literature-reported T77061 SYNONYMS Serine/threonine-protein kinase DCLK3; KIAA1765; Doublecortin-like and CAM kinase-like 3; Doublecortin domain-containing protein 3C; DCDC3C; DCAMKL3 T77061 FUNCTION Protein kinase activity, peptidyl-serine phosphorylation. T77061 BIOCLASS Kinase T77061 ECNUMBER EC 2.7.11.1 T77061 SEQUENCE MGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVS T77061 DRUGINFO D08TVU PMID20483621C5n Investigative T63753 TARGETID T63753 T63753 FORMERID TTDR00797 T63753 UNIPROID TRYS_TRYCC T63753 TARGNAME Trypanosoma Trypanothione synthetase (Trypano TRS) T63753 GENENAME Trypano TRS T63753 TARGTYPE Literature-reported T63753 SYNONYMS TRS; Cf-TS T63753 FUNCTION Bifunctional enzyme which catalyzes the formation oftrypanothione (N(1),N(8)-bis(glutathionyl)spermidine) from glutathione and spermidine. Converts spermidine or glutathionylspermidine into trypanothione. Can also convert aminopropylcadaverine into glutothionylaminopropylcadaverine and homotrypanothione. Also has low amidase activity, hydrolyzing trypanothione, homotrypanothione or glutathionylspermidine to form glutathione and the corresponding polyamine. T63753 BIOCLASS Carbon-nitrogen ligase T63753 ECNUMBER EC 6.3.1.9 T63753 SEQUENCE MPTLQSLAVPFGCVQGYAPGGIPAYSNKHESYFSGERSIDGNLFCGFKYQCVEFARRWLFERKSLVLPDVDWAVHIFNLKEVSDARTGKPVRCVAIRNGTAAKPVVDSLLIYPSDDYSPVGHVAAITEVGDKWVRIADQNHRFHKWDANYAAELPLIHEKGVWTILDPLEDEVLKPLGWVTFPDTPDRNPNEPLVLHESLHFKRGELPTLRRLTFTPTSREKDWLDLTNEAEAYFADVCGIDVKNPKLEKASYYQMNRELYLDCAKYGNQLHQMFLEATKFVLGSDELLRLFCIPEEYWPRLRHSWETQPHAITGRFDFAFDEDTQQFKCFEYNADSASTLLECGVIQQKWARSVGLDDGTTYSSGSLVSSRLQLAWEMAEVTGRVHFLIDNDDEEHYTALYVMQHASAAGLETKLCVLFDEFHFDENGVVVDSDGVAVTTVWKTWMWETAIADHQKARVQRGNDWRPTPKDEVRLCDILLGPNWDLRVFEPMWKIIPSNKAILPIIYNKHPDHPALLRASYELTVELQRTGYVRKPIVGRVGRNVTVTEASGDIAAKSDGDFSDRDMVYQELFRLPERDGYYAILGGWVIGDVYCGTGVREDKTIITGLESPFSALRVYQGAQRRPLTHEDLDKAEAAAVGGGLKT T03404 TARGETID T03404 T03404 FORMERID TTDR00533 T03404 UNIPROID CHST5_HUMAN T03404 TARGNAME Intestinal GlcNAc-6-sulfotransferase (CHST5) T03404 GENENAME CHST5 T03404 TARGTYPE Literature-reported T03404 SYNONYMS N-acetylglucosamine-6-O-sulfotransferase; N-acetylglucosamine 6-O-sulfotransferase; LSST; L-selectin ligand sulfotransferase GST-3; L-selectin ligand sulfotransferase; Intestinal N-acetylglucosamine-6-O-sulfotransferase; High endothelial cell GlcNAc 6-O-sulfotransferase; HEC-GlcNAc6ST; GlcNAc 6-O-sulfotransferase; Carbohydrate sulfotransferase GST-3; CHST5 T03404 FUNCTION Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc) residues and O-linked sugars of mucin-type acceptors. Acts on the non-reducing terminal GlcNAc of short carbohydrate substrates. However, it does not transfer sulfate to longer carbohydrate substrates that have poly-N-acetyllactosamine structures. Has no activitytoward keratan. Not involved in generating HEV-expressed ligands for SELL. Its substrate specificity may be influenced by its subcellular location. T03404 BIOCLASS Transferases of sulfur-containing groups T03404 ECNUMBER EC 2.8.2.- T03404 SEQUENCE MGMRARVPKVAHSTRRPPAARMWLPRFSSKTVTVLLLAQTTCLLLFIISRPGPSSPAGGEDRVHVLVLSSWRSGSSFLGQLFSQHPDVFYLMEPAWHVWTTLSQGSAATLHMAVRDLMRSIFLCDMDVFDAYMPQSRNLSAFFNWATSRALCSPPACSAFPRGTISKQDVCKTLCTRQPFSLAREACRSYSHVVLKEVRFFNLQVLYPLLSDPALNLRIVHLVRDPRAVLRSREAAGPILARDNGIVLGTNGKWVEADPHLRLIREVCRSHVRIAEAATLKPPPFLRGRYRLVRFEDLAREPLAEIRALYAFTGLTLTPQLEAWIHNITHGSGIGKPIEAFHTSSRNARNVSQAWRHALPFTKILRVQEVCAGALQLLGYRPVYSADQQRDLTLDLVLPRGPDHFSWASPD T98352 TARGETID T98352 T98352 UNIPROID UBP44_HUMAN T98352 TARGNAME Ubiquitin carboxyl-terminal hydrolase 44 (USP44) T98352 GENENAME USP44 T98352 TARGTYPE Literature-reported T98352 SYNONYMS Ubiquitin-specific-processing protease 44; Ubiquitin thioesterase 44; Deubiquitinating enzyme 44 T98352 FUNCTION Deubiquitinase that plays a key regulatory role in the spindle assembly checkpoint or mitotic checkpoint by preventing premature anaphase onset. Acts by specifically mediating deubiquitination of CDC20, a negative regulator of the anaphase promoting complex/cyclosome (APC/C). Deubiquitination of CDC20 leads to stabilize the MAD2L1-CDC20-APC/C ternary complex (also named mitotic checkpoint complex), thereby preventing premature activation of the APC/C. Promotes association of MAD2L1 with CDC20 and reinforces the spindle assembly checkpoint. Acts as a negative regulator of histone H2B (H2BK120ub1) ubiquitination. T98352 BIOCLASS Peptidase C19 family. USP44 subfamily T98352 ECNUMBER EC 3.4.19.12 T98352 SEQUENCE MLAMDTCKHVGQLQLAQDHSSLNPQKWHCVDCNTTESIWACLSCSHVACGRYIEEHALKHFQESSHPVALEVNEMYVFCYLCDDYVLNDNTTGDLKLLRRTLSAIKSQNYHCTTRSGRFLRSMGTGDDSYFLHDGAQSLLQSEDQLYTALWHRRRILMGKIFRTWFEQSPIGRKKQEEPFQEKIVVKREVKKRRQELEYQVKAELESMPPRKSLRLQGLAQSTIIEIVSVQVPAQTPASPAKDKVLSTSENEISQKVSDSSVKRRPIVTPGVTGLRNLGNTCYMNSVLQVLSHLLIFRQCFLKLDLNQWLAMTASEKTRSCKHPPVTDTVVYQMNECQEKDTGFVCSRQSSLSSGLSGGASKGRKMELIQPKEPTSQYISLCHELHTLFQVMWSGKWALVSPFAMLHSVWRLIPAFRGYAQQDAQEFLCELLDKIQRELETTGTSLPALIPTSQRKLIKQVLNVVNNIFHGQLLSQVTCLACDNKSNTIEPFWDLSLEFPERYQCSGKDIASQPCLVTEMLAKFTETEALEGKIYVCDQCNSKRRRFSSKPVVLTEAQKQLMICHLPQVLRLHLKRFRWSGRNNREKIGVHVGFEEILNMEPYCCRETLKSLRPECFIYDLSAVVMHHGKGFGSGHYTAYCYNSEGGFWVHCNDSKLSMCTMDEVCKAQAYILFYTQRVTENGHSKLLPPELLLGSQHPNEDADTSSNEILS T98198 TARGETID T98198 T98198 FORMERID TTDI03397 T98198 UNIPROID MYLK2_HUMAN T98198 TARGNAME Myosin light chain kinase 2 (MYLK2) T98198 GENENAME MYLK2 T98198 TARGTYPE Literature-reported T98198 SYNONYMS MYLK2 T98198 FUNCTION Implicated in the level of global muscle contraction and cardiac function. Phosphorylates a specific serine in the N-terminus of a myosin light chain. T98198 PDBSTRUC 3KF9; 2LV6 T98198 ECNUMBER EC 2.7.11.18 T98198 SEQUENCE MATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGV T98198 DRUGINFO D0N4LR GSK2606414 Investigative T14200 TARGETID T14200 T14200 FORMERID TTDI00034 T14200 UNIPROID ABCG5_HUMAN T14200 TARGNAME ATP-binding cassette transporter G5 (ABCG5) T14200 GENENAME ABCG5 T14200 TARGTYPE Literature-reported T14200 SYNONYMS Sterolin1; ATPbinding cassette subfamily G member 5; ABCG5 T14200 FUNCTION Transporter that appears to play an indispensable role in the selective transportof the dietary cholesterol in and out of the enterocytes and in the selective sterol excretion by the liver into bile. T14200 PDBSTRUC 5DO7 T14200 BIOCLASS ABC transporter T14200 SEQUENCE MGDLSSLTPGGSMGLQVNRGSQSSLEGAPATAPEPHSLGILHASYSVSHRVRPWWDITSCRQQWTRQILKDVSLYVESGQIMCILGSSGSGKTTLLDAMSGRLGRAGTFLGEVYVNGRALRREQFQDCFSYVLQSDTLLSSLTVRETLHYTALLAIRRGNPGSFQKKVEAVMAELSLSHVADRLIGNYSLGGISTGERRRVSIAAQLLQDPKVMLFDEPTTGLDCMTANQIVVLLVELARRNRIVVLTIHQPRSELFQLFDKIAILSFGELIFCGTPAEMLDFFNDCGYPCPEHSNPFDFYMDLTSVDTQSKEREIETSKRVQMIESAYKKSAICHKTLKNIERMKHLKTLPMVPFKTKDSPGVFSKLGVLLRRVTRNLVRNKLAVITRLLQNLIMGLFLLFFVLRVRSNVLKGAIQDRVGLLYQFVGATPYTGMLNAVNLFPVLRAVSDQESQDGLYQKWQMMLAYALHVLPFSVVATMIFSSVCYWTLGLHPEVARFGYFSAALLAPHLIGEFLTLVLLGIVQNPNIVNSVVALLSIAGVLVGSGFLRNIQEMPIPFKIISYFTFQKYCSEILVVNEFYGLNFTCGSSNVSVTTNPMCAFTQGIQFIEKTCPGATSRFTMNFLILYSFIPALVILGIVVFKIRDHLISR T57307 TARGETID T57307 T57307 FORMERID TTDI03000 T57307 UNIPROID SLK_HUMAN T57307 TARGNAME STE20-related serine/threonine-protein kinase (SLK) T57307 GENENAME SLK T57307 TARGTYPE Literature-reported T57307 SYNONYMS hSLK; STE20-related kinase; STE20-like kinase T57307 FUNCTION Mediates apoptosis and actin stress fiber dissolution. T57307 PDBSTRUC 6HVD; 4USF; 2UV2; 2JFM; 2JFL T57307 ECNUMBER EC 2.7.11.1 T57307 SEQUENCE MSFFNFRKIFKLGSEKKKKQYEHVKRDLNPEDFWEIIGELGDGAFGKVYKAQNKETSVLAAAKVIDTKSEEELEDYMVEIDILASCDHPNIVKLLDAFYYENNLWILIEFCAGGAVDAVMLELERPLTESQIQVVCKQTLDALNYLHDNKIIHRDLKAGNILFTLDGDIKLADFGVSAKNTRTIQRRDSFIGTPYWMAPEVVMCETSKDRPYDYKADVWSLGITLIEMAEIEPPHHELNPMRVLLKIAKSEPPTLAQPSRWSSNFKDFLKKCLEKNVDARWTTSQLLQHPFVTVDSNKPIRELIAEAKAEVTEEVEDGKEEDEEEETENSLPIPASKRASSDLSIASSEEDKLSQNACILESVSEKTERSNSEDKLNSKILNEKPTTDEPEKAVEDINEHITDAQLEAMTELHDRTAVIKENEREKRPKLENLPDTEDQETVDINSVSEGKENNIMITLETNIEHNLKSEEEKDQEKQQMFENKLIKSEEIKDTILQTVDLVSQETGEKEANIQAVDSEVGLTKEDTQEKLGEDDKTQKDVISNTSDVIGTCEAADVAQKVDEDSAEDTQSNDGKEVVEVGQKLINKPMVGPEAGGTKEVPIKEIVEMNEIEEGKNKEQAINSSENIMDINEEPGTTEGEEITESSSTEEMEVRSVVADTDQKALGSEVQDASKVTTQIDKEKKEIPVSIKKEPEVTVVSQPTEPQPVLIPSININSDSGENKEEIGSLSKTETILPPESENPKENDNDSGTGSTADTSSIDLNLSISSFLSKTKDSGSISLQETRRQKKTLKKTRKFIVDGVEVSVTTSKIVTDSDSKTEELRFLRRQELRELRFLQKEEQRAQQQLNSKLQQQREQIFRRFEQEMMSKKRQYDQEIENLEKQQKQTIERLEQEHTNRLRDEAKRIKGEQEKELSKFQNMLKNRKKEVINEVEKAPKELRKELMKRRKEELAQSQHAQEQEFVQKQQQELDGSLKKIIQQQKAELANIERECLNNKQQLMRAREAAIWELEERHLQEKHQLLKQQLKDQYFMQRHQLLKRHEKETEQMQRYNQRLIEELKNRQTQERARLPKIQRSEAKTRMAMFKKSLRINSTATPDQDRDKIKQFAAQEEKRQKNERMAQHQKHENQMRDLQLQCEANVRELHQLQNEKCHLLVEHETQKLKELDEEHSQELKEWREKLRPRKKTLEEEFARKLQEQEVFFKMTGESECLNPSTQSRISKFYPIPSLHSTGS T57307 DRUGINFO D0N0LN RN486 Investigative T63682 TARGETID T63682 T63682 FORMERID TTDI03572 T63682 UNIPROID TAOK3_HUMAN T63682 TARGNAME TAO kinase 3 (TAOK3) T63682 GENENAME TAOK3 T63682 TARGTYPE Literature-reported T63682 SYNONYMS hKFC-A; Thousand and one amino acid protein 3; Serine/threonine-protein kinase TAO3; MAP3K18; Kinase from chicken homolog A; KDS; Jun kinase-inhibitory kinase; JNK/SAPK-inhibitory kinase; JIK; Dendritic cell-derived protein kinase; DPK; Cutaneous T-cell lymphoma-associated antigen HD-CL-09; CTCL-associated antigen HD-CL-09 T63682 FUNCTION Serine/threonine-protein kinase that acts as a regulator of the p38/MAPK14 stress-activated MAPK cascade and of the MAPK8/JNK cascade. Acts as an activator of the p38/MAPK14 stress-activated MAPK cascade. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of upstream MAP2K3 and MAP2K6 kinases. Inhibits basal activity of MAPK8/JNK cascade and diminishes its activation in response epidermal growth factor (EGF). T63682 PDBSTRUC 6BDN T63682 ECNUMBER EC 2.7.11.1 T63682 SEQUENCE MRKGVLKDPEIADLFYKDDPEELFIGLHEIGHGSFGAVYFATNAHTSEVVAIKKMSYSGKQTHEKWQDILKEVKFLRQLKHPNTIEYKGCYLKEHTAWLVMEYCLGSASDLLEVHKKPLQEVEIAAITHGALHGLAYLHSHALIHRDIKAGNILLTEPGQVKLADFGSASMASPANSFVGTPYWMAPEVILAMDEGQYDGKVDIWSLGITCIELAERKPPLFNMNAMSALYHIAQNDSPTLQSNEWTDSFRRFVDYCLQKIPQERPTSAELLRHDFVRRDRPLRVLIDLIQRTKDAVRELDNLQYRKMKKILFQETRNGPLNESQEDEEDSEHGTSLNREMDSLGSNHSIPSMSVSTGSQSSSVNSMQEVMDESSSELVMMHDDESTINSSSSVVHKKDHVFIRDEAGHGDPRPEPRPTQSVQSQALHYRNRERFATIKSASLVTRQIHEHEQENELREQMSGYKRMRRQHQKQLIALENKLKAEMDEHRLKLQKEVETHANNSSIELEKLAKKQVAIIEKEAKVAAADEKKFQQQILAQQKKDLTTFLESQKKQYKICKEKIKEEMNEDHSTPKKEKQERISKHKENLQHTQAEEEAHLLTQQRLYYDKNCRFFKRKIMIKRHEVEQQNIREELNKKRTQKEMEHAMLIRHDESTRELEYRQLHTLQKLRMDLIRLQHQTELENQLEYNKRRERELHRKHVMELRQQPKNLKAMEMQIKKQFQDTCKVQTKQYKALKNHQLEVTPKNEHKTILKTLKDEQTRKLAILAEQYEQSINEMMASQALRLDEAQEAECQALRLQLQQEMELLNAYQSKIKMQTEAQHERELQKLEQRVSLRRAHLEQKIEEELAALQKERSERIKNLLERQEREIETFDMESLRMGFGNLVTLDFPKEDYR T63682 DRUGINFO D0T8NU PMID19115845C89S Investigative T53952 TARGETID T53952 T53952 FORMERID TTDI03263 T53952 UNIPROID HIPK2_HUMAN T53952 TARGNAME Homeodomain interacting protein kinase 2 (HIPK2) T53952 GENENAME HIPK2 T53952 TARGTYPE Literature-reported T53952 SYNONYMS hHIPk2; Homeodomain-interacting protein kinase 2 T53952 FUNCTION Acts as a corepressor of several transcription factors, including SMAD1 and POU4F1/Brn3a and probably NK homeodomain transcription factors. Phosphorylates PDX1, ATF1, PML, p53/TP53, CREB1, CTBP1, CBX4, RUNX1, EP300, CTNNB1, HMGA1 and ZBTB4. Inhibits cell growth and promotes apoptosis through the activation of p53/TP53 both at the transcription level and at the protein level (by phosphorylation and indirect acetylation). The phosphorylation of p53/TP53 may be mediated by a p53/TP53-HIPK2-AXIN1 complex. Involved in the response to hypoxia by acting as a transcriptional co-suppressor of HIF1A. Mediates transcriptional activation of TP73. In response to TGFB, cooperates with DAXX to activate JNK. Negative regulator through phosphorylation and subsequent proteasomal degradation of CTNNB1 and the antiapoptotic factor CTBP1. In the Wnt/beta-catenin signaling pathway acts as an intermediate kinase between MAP3K7/TAK1 and NLK to promote the proteasomal degradation of MYB. Phosphorylates CBX4 upon DNA damage and promotes its E3 SUMO-protein ligase activity. Activates CREB1 and ATF1 transcription factors by phosphorylation in response to genotoxic stress. In response to DNA damage, stabilizes PML by phosphorylation. PML, HIPK2 and FBXO3 may act synergically to activate p53/TP53-dependent transactivation. Promotes angiogenesis, and is involved in erythroid differentiation, especially during fetal liver erythropoiesis. Phosphorylation of RUNX1 and EP300 stimulates EP300 transcription regulation activity. Triggers ZBTB4 protein degradation in response to DNA damage. Modulates HMGA1 DNA-binding affinity. In response to high glucose, triggers phosphorylation-mediated subnuclear localization shifting of PDX1. Involved in the regulation of eye size, lens formation and retinal lamination during late embryogenesis. Serine/threonine-protein kinase involved in transcription regulation, p53/TP53-mediated cellular apoptosis and regulation of the cell cycle. T53952 BIOCLASS Kinase T53952 ECNUMBER EC 2.7.11.1 T53952 SEQUENCE MAPVYEGMASHVQVFSPHTLQSSAFCSVKKLKIEPSSNWDMTGYGSHSKVYSQSKNIPLSQPATTTVSTSLPVPNPSLPYEQTIVFPGSTGHIVVTSASSTSVTGQVLGGPHNLMRRSTVSLLDTYQKCGLKRKSEEIENTSSVQIIEEHPPMIQNNASGATVATATTSTATSKNSGSNSEGDYQLVQHEVLCSMTNTYEVLEFLGRGTFGQVVKCWKRGTNEIVAIKILKNHPSYARQGQIEVSILARLSTESADDYNFVRAYECFQHKNHTCLVFEMLEQNLYDFLKQNKFSPLPLKYIRPVLQQVATALMKLKSLGLIHADLKPENIMLVDPSRQPYRVKVIDFGSASHVSKAVCSTYLQSRYYRAPEIILGLPFCEAIDMWSLGCVIAELFLGWPLYPGASEYDQIRYISQTQGLPAEYLLSAGTKTTRFFNRDTDSPYPLWRLKTPDDHEAETGIKSKEARKYIFNCLDDMAQVNMTTDLEGSDMLVEKADRREFIDLLKKMLTIDADKRITPIETLNHPFVTMTHLLDFPHSTHVKSCFQNMEICKRRVNMYDTVNQSKTPFITHVAPSTSTNLTMTFNNQLTTVHNQAPSSTSATISLANPEVSILNYPSTLYQPSAASMAAVAQRSMPLQTGTAQICARPDPFQQALIVCPPGFQGLQASPSKHAGYSVRMENAVPIVTQAPGAQPLQIQPGLLAQQAWPSGTQQILLPPAWQQLTGVATHTSVQHATVIPETMAGTQQLADWRNTHAHGSHYNPIMQQPALLTGHVTLPAAQPLNVGVAHVMRQQPTSTTSSRKSKQHQSSVRNVSTCEVSSSQAISSPQRSKRVKENTPPRCAMVHSSPACSTSVTCGWGDVASSTTRERQRQTIVIPDTPSPTVSVITISSDTDEEEEQKHAPTSTVSKQRKNVISCVTVHDSPYSDSSSNTSPYSVQQRAGHNNANAFDTKGSLENHCTGNPRTIIVPPLKTQASEVLVECDSLVPVNTSHHSSSYKSKSSSNVTSTSGHSSGSSSGAITYRQQRPGPHFQQQQPLNLSQAQQHITTDRTGSHRRQQAYITPTMAQAPYSFPHNSPSHGTVHPHLAAAAAAAHLPTQPHLYTYTAPAALGSTGTVAHLVASQGSARHTVQHTAYPASIVHQVPVSMGPRVLPSPTIHPSQYPAQFAHQTYISASPASTVYTGYPLSPAKVNQYPYI T53952 DRUGINFO D04TPA PMID24900749C1a Investigative T22302 TARGETID T22302 T22302 FORMERID TTDI02571 T22302 UNIPROID S12A5_HUMAN T22302 TARGNAME Solute carrier family 12 member 5 (SLC12A5) T22302 GENENAME SLC12A5 T22302 TARGTYPE Literature-reported T22302 SYNONYMS hKCC2; SLC12A5; Neuronal K-Cl cotransporter; K-Cl cotransporter 2; Electroneutral potassium-chloride cotransporter 2 T22302 FUNCTION Mediates electroneutral potassium-chloride cotransportin mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in neurons. T22302 BIOCLASS Cation-chloride cotransporter T22302 SEQUENCE MSRRFTVTSLPPAGPARSPDPESRRHSVADPRHLPGEDVKGDGNPKESSPFINSTDTEKGKEYDGKNMALFEEEMDTSPMVSSLLSGLANYTNLPQGSREHEEAENNEGGKKKPVQAPRMGTFMGVYLPCLQNIFGVILFLRLTWVVGIAGIMESFCMVFICCSCTMLTAISMSAIATNGVVPAGGSYYMISRSLGPEFGGAVGLCFYLGTTFAGAMYILGTIEILLAYLFPAMAIFKAEDASGEAAAMLNNMRVYGTCVLTCMATVVFVGVKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPNFPICLLGNRTLSRHGFDVCAKLAWEGNETVTTRLWGLFCSSRFLNATCDEYFTRNNVTEIQGIPGAASGLIKENLWSSYLTKGVIVERSGMTSVGLADGTPIDMDHPYVFSDMTSYFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYISSVVLFGACIEGVVLRDKFGEAVNGNLVVGTLAWPSPWVIVIGSFFSTCGAGLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIGILIASLDEVAPILSMFFLMCYMFVNLACAVQTLLRTPNWRPRFRYYHWTLSFLGMSLCLALMFICSWYYALVAMLIAGLIYKYIEYRGAEKEWGDGIRGLSLSAARYALLRLEEGPPHTKNWRPQLLVLVRVDQDQNVVHPQLLSLTSQLKAGKGLTIVGSVLEGTFLENHPQAQRAEESIRRLMEAEKVKGFCQVVISSNLRDGVSHLIQSGGLGGLQHNTVLVGWPRNWRQKEDHQTWRNFIELVRETTAGHLALLVTKNVSMFPGNPERFSEGSIDVWWIVHDGGMLMLLPFLLRHHKVWRKCKMRIFTVAQMDDNSIQMKKDLTTFLYHLRITAEVEVVEMHESDISAYTYEKTLVMEQRSQILKQMHLTKNEREREIQSITDESRGSIRRKNPANTRLRLNVPEETAGDSEEKPEEEVQLIHDQSAPSCPSSSPSPGEEPEGEGETDPEKVHLTWTKDKSVAEKNKGPSPVSSEGIKDFFSMKPEWENLNQSNVRRMHTAVRLNEVIVKKSRDAKLVLLNMPGPPRNRNGDENYMEFLEVLTEHLDRVMLVRGGGREVITIYS T22302 DRUGINFO D0M2PP VU0240551 Investigative T22302 DRUGINFO D0V6KL CLP-635 Investigative T22302 DRUGINFO D0K9KZ DIOA Investigative T96232 TARGETID T96232 T96232 UNIPROID FOXP1_HUMAN T96232 TARGNAME Forkhead box protein P1 (FOXP1) T96232 GENENAME FOXP1 T96232 TARGTYPE Literature-reported T96232 SYNONYMS Mac-1-regulated forkhead; MFH; FOXP1-ES T96232 FUNCTION Transcriptional repressor (PubMed:18347093, PubMed:26647308). Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential. Plays an important role in the specification and differentiation of lung epithelium. Acts cooperatively with FOXP4 to regulate lung secretory epithelial cell fate and regeneration by restricting the goblet cell lineage program; the function may involve regulation of AGR2. Essential transcriptional regulator of B-cell development. Involved in regulation of cardiac muscle cell proliferation. Involved in the columnar organization of spinal motor neurons. Promotes the formation of the lateral motor neuron column (LMC) and the preganglionic motor column (PGC) and is required for respective appropriate motor axon projections. The segment-appropriate generation of spinal chord motor columns requires cooperation with other Hox proteins. Can regulate PITX3 promoter activity; may promote midbrain identity in embryonic stem cell-derived dopamine neurons by regulating PITX3. Negatively regulates the differentiation of T follicular helper cells T(FH)s. Involved in maintenance of hair follicle stem cell quiescence; the function probably involves regulation of FGF18. Represses transcription of various pro-apoptotic genes and cooperates with NF-kappa B-signaling in promoting B-cell expansion by inhibition of caspase-dependent apoptosis (PubMed:25267198). Binds to CSF1R promoter elements and is involved in regulation of monocyte differentiation and macrophage functions; repression of CSF1R in monocytes seems to involve NCOR2 as corepressor (PubMed:15286807, PubMed:18799727, PubMed:18347093). Involved in endothelial cell proliferation, tube formation and migration indicative for a role in angiogenesis; the role in neovascularization seems to implicate suppression of SEMA5B (PubMed:24023716). Can negatively regulate androgen receptor signaling (PubMed:18640093). T96232 PDBSTRUC 2KIU T96232 SEQUENCE MMQESGTETKSNGSAIQNGSGGSNHLLECGGLREGRSNGETPAVDIGAADLAHAQQQQQQALQVARQLLLQQQQQQQVSGLKSPKRNDKQPALQVPVSVAMMTPQVITPQQMQQILQQQVLSPQQLQVLLQQQQALMLQQQQLQEFYKKQQEQLQLQLLQQQHAGKQPKEQQQVATQQLAFQQQLLQMQQLQQQHLLSLQRQGLLTIQPGQPALPLQPLAQGMIPTELQQLWKEVTSAHTAEETTGNNHSSLDLTTTCVSSSAPSKTSLIMNPHASTNGQLSVHTPKRESLSHEEHPHSHPLYGHGVCKWPGCEAVCEDFQSFLKHLNSEHALDDRSTAQCRVQMQVVQQLELQLAKDKERLQAMMTHLHVKSTEPKAAPQPLNLVSSVTLSKSASEASPQSLPHTPTTPTAPLTPVTQGPSVITTTSMHTVGPIRRRYSDKYNVPISSADIAQNQEFYKNAEVRPPFTYASLIRQAILESPEKQLTLNEIYNWFTRMFAYFRRNAATWKNAVRHNLSLHKCFVRVENVKGAVWTVDEVEFQKRRPQKISGNPSLIKNMQSSHAYCTPLNAALQASMAENSIPLYTTASMGNPTLGNLASAIREELNGAMEHTNSNESDSSPGRSPMQAVHPVHVKEEPLDPEEAEGPLSLVTTANHSPDFDHDRDYEDEPVNEDME T77127 TARGETID T77127 T77127 FORMERID TTDR00796 T77127 UNIPROID TXNIP_HUMAN T77127 TARGNAME Vitamin D3 up-regulated protein 1 (VDUP1) T77127 GENENAME TXNIP T77127 TARGTYPE Literature-reported T77127 SYNONYMS Vitamin D(3) up-regulating protein-1; Thioredoxin-interacting protein; Thioredoxin-binding protein 2 T77127 FUNCTION Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm. Functions as a transcriptional repressor, possibly by acting as a bridge molecule between transcription factors and corepressor complexes, and over-expression will induce G0/G1 cell cycle arrest. Required for the maturation of natural killer cells. Acts as a suppressor of tumor cell growth. Inhibits the proteasomal degradation of DDIT4, and thereby contributes to the inhibition of the mammalian target of rapamycin complex 1 (mTORC1). May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability. T77127 PDBSTRUC 5DZD; 5DWS; 5DF6; 5CQ2; 4ROJ T77127 BIOCLASS Arrestin protein T77127 SEQUENCE MVMFKKIKSFEVVFNDPEKVYGSGEKVAGRVIVEVCEVTRVKAVRILACGVAKVLWMQGSQQCKQTSEYLRYEDTLLLEDQPTGENEMVIMRPGNKYEYKFGFELPQGPLGTSFKGKYGCVDYWVKAFLDRPSQPTQETKKNFEVVDLVDVNTPDLMAPVSAKKEKKVSCMFIPDGRVSVSARIDRKGFCEGDEISIHADFENTCSRIVVPKAAIVARHTYLANGQTKVLTQKLSSVRGNHIISGTCASWRGKSLRVQKIRPSILGCNILRVEYSLLIYVSVPGSKKVILDLPLVIGSRSGLSSRTSSMASRTSSEMSWVDLNIPDTPEAPPCYMDVIPEDHRLESPTTPLLDDMDGSQDSPIFMYAPEFKFMPPPTYTEVDPCILNNNVQ T92296 TARGETID T92296 T92296 FORMERID TTDI02624 T92296 UNIPROID FN3K_HUMAN T92296 TARGNAME Fructosamine-3-kinase (FN3K) T92296 GENENAME FN3K T92296 TARGTYPE Literature-reported T92296 SYNONYMS Fructosamine 3 kinase; FN3K; F3K T92296 FUNCTION May initiate a process leading to the deglycation of fructoselysine and of glycated proteins. May play a role in the phosphorylation of 1-deoxy-1-morpholinofructose (DMF), fructoselysine, fructoseglycine, fructose and glycated lysozyme. T92296 BIOCLASS Kinase T92296 ECNUMBER EC 2.7.1.- T92296 SEQUENCE MEQLLRAELRTATLRAFGGPGAGCISEGRAYDTDAGPVFVKVNRRTQARQMFEGEVASLEALRSTGLVRVPRPMKVIDLPGGGAAFVMEHLKMKSLSSQASKLGEQMADLHLYNQKLREKLKEEENTVGRRGEGAEPQYVDKFGFHTVTCCGFIPQVNEWQDDWPTFFARHRLQAQLDLIEKDYADREARELWSRLQVKIPDLFCGLEIVPALLHGDLWSGNVAEDDVGPIIYDPASFYGHSEFELAIALMFGGFPRSFFTAYHRKIPKAPGFDQRLLLYQLFNYLNHWNHFGREYRSPSLGTMRRLLK T52638 TARGETID T52638 T52638 FORMERID TTDI01530 T52638 UNIPROID WNK1_HUMAN T52638 TARGNAME Serine/threonine-protein kinase WNK1 (WNK1) T52638 GENENAME WNK1 T52638 TARGTYPE Literature-reported T52638 SYNONYMS p65; hWNK1; Protein kinase with no lysine 1; Protein kinase lysine-deficient 1; Kinase deficient protein; KDP; HSN2; Erythrocyte 65 kDa protein T52638 FUNCTION Serine/threonine kinase which plays an important role in the regulation of electrolyte homeostasis, cell signaling, survival, and proliferation. Acts as an activator and inhibitor of sodium-coupled chloride cotransporters and potassium-coupled chloride cotransporters respectively. Activates SCNN1A, SCNN1B, SCNN1D and SGK1. Controls sodium and chloride ion transport by inhibiting the activity of WNK4, by either phosphorylating the kinase or via an interaction between WNK4 and the autoinhibitory domain of WNK1. WNK4 regulates the activity of the thiazide-sensitive Na-Cl cotransporter, SLC12A3, by phosphorylation. WNK1 may also play a role in actin cytoskeletal reorganization. Phosphorylates NEDD4L. Acts as a scaffold to inhibit SLC4A4, SLC26A6 as well as CFTR activities and surface expression, recruits STK39 which mediates the inhibition (By similarity). T52638 PDBSTRUC 6FBK; 5WE8; 5WDY; 5TF9; 4PWN T52638 ECNUMBER EC 2.7.11.1 T52638 SEQUENCE MSGGAAEKQSSTPGSLFLSPPAPAPKNGSSSDSSVGEKLGAAAADAVTGRTEEYRRRRHTMDKDSRGAAATTTTTEHRFFRRSVICDSNATALELPGLPLSLPQPSIPAAVPQSAPPEPHREETVTATATSQVAQQPPAAAAPGEQAVAGPAPSTVPSSTSKDRPVSQPSLVGSKEEPPPARSGSGGGSAKEPQEERSQQQDDIEELETKAVGMSNDGRFLKFDIEIGRGSFKTVYKGLDTETTVEVAWCELQDRKLTKSERQRFKEEAEMLKGLQHPNIVRFYDSWESTVKGKKCIVLVTELMTSGTLKTYLKRFKVMKIKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLKRASFAKSVIGTPEFMAPEMYEEKYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRRVTSGVKPASFDKVAIPEVKEIIEGCIRQNKDERYSIKDLLNHAFFQEETGVRVELAEEDDGEKIAIKLWLRIEDIKKLKGKYKDNEAIEFSFDLERDVPEDVAQEMVESGYVCEGDHKTMAKAIKDRVSLIKRKREQRQLVREEQEKKKQEESSLKQQVEQSSASQTGIKQLPSASTGIPTASTTSASVSTQVEPEEPEADQHQQLQYQQPSISVLSDGTVDSGQGSSVFTESRVSSQQTVSYGSQHEQAHSTGTVPGHIPSTVQAQSQPHGVYPPSSVAQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTSSEATTAQPVSQPQAPQVLPQVSAGKQLPVSQPVPTIQGEPQIPVATQPSVVPVHSGAHFLPVGQPLPTPLLPQYPVSQIPISTPHVSTAQTGFSSLPITMAAGITQPLLTLASSATTAAIPGVSTVVPSQLPTLLQPVTQLPSQVHPQLLQPAVQSMGIPANLGQAAEVPLSSGDVLYQGFPPRLPPQYPGDSNIAPSSNVASVCIHSTVLSPPMPTEVLATPGYFPTVVQPYVESNLLVPMGGVGGQVQVSQPGGSLAQAPTTSSQQAVLESTQGVSQVAPAEPVAVAQTQATQPTTLASSVDSAHSDVASGMSDGNENVPSSSGRHEGRTTKRHYRKSVRSRSRHEKTSRPKLRILNVSNKGDRVVECQLETHNRKMVTFKFDLDGDNPEEIATIMVNNDFILAIERESFVDQVREIIEKADEMLSEDVSVEPEGDQGLESLQGKDDYGFSGSQKLEGEFKQPIPASSMPQQIGIPTSSLTQVVHSAGRRFIVSPVPESRLRESKVFPSEITDTVAASTAQSPGMNLSHSASSLSLQQAFSELRRAQMTEGPNTAPPNFSHTGPTFPVVPPFLSSIAGVPTTAAATAPVPATSSPPNDISTSVIQSEVTVPTEEGIAGVATSTGVVTSGGLPIPPVSESPVLSSVVSSITIPAVVSISTTSPSLQVPTSTSEIVVSSTALYPSVTVSATSASAGGSTATPGPKPPAVVSQQAAGSTTVGATLTSVSTTTSFPSTASQLCIQLSSSTSTPTLAETVVVSAHSLDKTSHSSTTGLAFSLSAPSSSSSPGAGVSSYISQPGGLHPLVIPSVIASTPILPQAAGPTSTPLLPQVPSIPPLVQPVANVPAVQQTLIHSQPQPALLPNQPHTHCPEVDSDTQPKAPGIDDIKTLEEKLRSLFSEHSSSGAQHASVSLETSLVIESTVTPGIPTTAVAPSKLLTSTTSTCLPPTNLPLGTVALPVTPVVTPGQVSTPVSTTTSGVKPGTAPSKPPLTKAPVLPVGTELPAGTLPSEQLPPFPGPSLTQSQQPLEDLDAQLRRTLSPEMITVTSAVGPVSMAAPTAITEAGTQPQKGVSQVKEGPVLATSSGAGVFKMGRFQVSVAADGAQKEGKNKSEDAKSVHFESSTSESSVLSSSSPESTLVKPEPNGITIPGISSDVPESAHKTTASEAKSDTGQPTKVGRFQVTTTANKVGRFSVSKTEDKITDTKKEGPVASPPFMDLEQAVLPAVIPKKEKPELSEPSHLNGPSSDPEAAFLSRDVDDGSGSPHSPHQLSSKSLPSQNLSQSLSNSFNSSYMSSDNESDIEDEDLKLELRRLRDKHLKEIQDLQSRQKHEIESLYTKLGKVPPAVIIPPAAPLSGRRRRPTKSKGSKSSRSSSLGNKSPQLSGNLSGQSAASVLHPQQTLHPPGNIPESGQNQLLQPLKPSPSSDNLYSAFTSDGAISVPSLSAPGQGTSSTNTVGATVNSQAAQAQPPAMTSSRKGTFTDDLHKLVDNWARDAMNLSGRRGSKGHMNYEGPGMARKFSAPGQLCISMTSNLGGSAPISAASATSLGHFTKSMCPPQQYGFPATPFGAQWSGTGGPAPQPLGQFQPVGTASLQNFNISNLQKSISNPPGSNLRTT T46216 TARGETID T46216 T46216 FORMERID TTDI03065 T46216 UNIPROID BRD9_HUMAN T46216 TARGNAME Bromodomain-containing protein 9 (BRD9) T46216 GENENAME BRD9 T46216 TARGTYPE Literature-reported T46216 SYNONYMS Rhabdomyosarcoma antigen MU-RMS-40.8 T46216 FUNCTION Plays a role in chromatin remodeling and regulation of transcription. Acts as a chromatin reader that recognizes and binds acylated histones: binds histones that are acetylated and/or butyrylated. Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. T46216 PDBSTRUC 6HM0; 6BQA; 5TWX; 5MKY; 5JI8 T46216 BIOCLASS Bromodomain T46216 SEQUENCE MGKKHKKHKAEWRSSYEDYADKPLEKPLKLVLKVGGSEVTELSGSGHDSSYYDDRSDHERERHKEKKKKKKKKSEKEKHLDDEERRKRKEEKKRKREREHCDTEGEADDFDPGKKVEVEPPPDRPVRACRTQPAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKQAALLGNEDTAVEEPVPEVVPVQVETAKKSKKPSREVISCMFEPEGNACSLTDSTAEEHVLALVEHAADEARDRINRFLPGGKMGYLKRNGDGSLLYSVVNTAEPDADEEETHPVDLSSLSSKLLPGFTTLGFKDERRNKVTFLSSATTALSMQNNSVFGDLKSDEMELLYSAYGDETGVQCALSLQEFVKDAGSYSKKVVDDLLDQITGGDHSRTLFQLKQRRNVPMKPPDEAKVGDTLGDSSSSVLEFMSMKSYPDVSVDISMLSSLGKVKKELDPDDSHLNLDETTKLLQDLHEAQAERGGSRPSSNLSSLSNASERDQHHLGSPSRLSVGEQPDVTHDPYEFLQSPEPAASAKT T46216 DRUGINFO D0N5BI I-BRD9 Investigative T46216 DRUGINFO DVZ6M1 BI 7273 Investigative T46216 DRUGINFO D08LXU LP99 Investigative T39996 TARGETID T39996 T39996 FORMERID TTDI03185 T39996 UNIPROID EHMT1_HUMAN T39996 TARGNAME Euchromatic histone-lysine N-methyltransferase 1 (EHMT1) T39996 GENENAME EHMT1 T39996 TARGTYPE Literature-reported T39996 SYNONYMS EHMT1 T39996 FUNCTION Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones. Also weakly methylates 'Lys-27' of histone H3 (H3K27me). Also required for DNA methylation, the histone methyltransferase activity is not required for DNA methylation, suggesting that these 2 activities function independently. Probably targeted to histone H3 by different DNA-binding proteins like E2F6, MGA, MAX and/or DP1. During G0 phase, it probably contributes to silencing of MYC- and E2F-responsive genes, suggesting a role in G0/G1 transition in cell cycle. In addition to the histone methyltransferase activity, also methylates non-histone proteins: mediates dimethylation of 'Lys-373' of p53/TP53. T39996 PDBSTRUC 6MBP; 6MBO; 6BY9; 5VSF; 5VSD T39996 ECNUMBER EC 2.1.1.- T39996 SEQUENCE MAAADAEAVPARGEPQQDCCVKTELLGEETPMAADEGSAEKQAGEAHMAADGETNGSCENSDASSHANAAKHTQDSARVNPQDGTNTLTRIAENGVSERDSEAAKQNHVTADDFVQTSVIGSNGYILNKPALQAQPLRTTSTLASSLPGHAAKTLPGGAGKGRTPSAFPQTPAAPPATLGEGSADTEDRKLPAPGADVKVHRARKTMPKSVVGLHAASKDPREVREARDHKEPKEEINKNISDFGRQQLLPPFPSLHQSLPQNQCYMATTKSQTACLPFVLAAAVSRKKKRRMGTYSLVPKKKTKVLKQRTVIEMFKSITHSTVGSKGEKDLGASSLHVNGESLEMDSDEDDSEELEEDDGHGAEQAAAFPTEDSRTSKESMSEADRAQKMDGESEEEQESVDTGEEEEGGDESDLSSESSIKKKFLKRKGKTDSPWIKPARKRRRRSRKKPSGALGSESYKSSAGSAEQTAPGDSTGYMEVSLDSLDLRVKGILSSQAEGLANGPDVLETDGLQEVPLCSCRMETPKSREITTLANNQCMATESVDHELGRCTNSVVKYELMRPSNKAPLLVLCEDHRGRMVKHQCCPGCGYFCTAGNFMECQPESSISHRFHKDCASRVNNASYCPHCGEESSKAKEVTIAKADTTSTVTPVPGQEKGSALEGRADTTTGSAAGPPLSEDDKLQGAASHVPEGFDPTGPAGLGRPTPGLSQGPGKETLESALIALDSEKPKKLRFHPKQLYFSARQGELQKVLLMLVDGIDPNFKMEHQNKRSPLHAAAEAGHVDICHMLVQAGANIDTCSEDQRTPLMEAAENNHLEAVKYLIKAGALVDPKDAEGSTCLHLAAKKGHYEVVQYLLSNGQMDVNCQDDGGWTPMIWATEYKHVDLVKLLLSKGSDINIRDNEENICLHWAAFSGCVDIAEILLAAKCDLHAVNIHGDSPLHIAARENRYDCVVLFLSRDSDVTLKNKEGETPLQCASLNSQVWSALQMSKALQDSAPDRPSPVERIVSRDIARGYERIPIPCVNAVDSEPCPSNYKYVSQNCVTSPMNIDRNITHLQYCVCIDDCSSSNCMCGQLSMRCWYDKDGRLLPEFNMAEPPLIFECNHACSCWRNCRNRVVQNGLRARLQLYRTRDMGWGVRSLQDIPPGTFVCEYVGELISDSEADVREEDSYLFDLDNKDGEVYCIDARFYGNVSRFINHHCEPNLVPVRVFMAHQDLRFPRIAFFSTRLIEAGEQLGFDYGERFWDIKGKLFSCRCGSPKCRHSSAALAQRQASAAQEAQEDGLPDTSSAAAADPL T39996 DRUGINFO D06PPL BIX-01294 Preclinical T39996 DRUGINFO D0C5EG A-366 Preclinical T39996 DRUGINFO D0BI4T UNC0642 Investigative T39996 DRUGINFO D0GK7A UNC0638 Investigative T52946 TARGETID T52946 T52946 FORMERID TTDS00512 T52946 UNIPROID S52A2_HUMAN T52946 TARGNAME Gamma-hydroxybutyrate receptor (SLC52A2) T52946 GENENAME SLC52A2 T52946 TARGTYPE Literature-reported T52946 SYNONYMS SLC52A2; Protein GPR172A; PERV-A receptor 1; GPR172A T52946 FUNCTION Riboflavintransporter. Riboflavin transport is Na(+)- independent but moderately pH-sensitive. Activity is strongly inhibited by riboflavin analogs, such as lumiflavin. Weakly inhibited by flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN). In case of infection by retroviruses, acts as a cell receptor to retroviral envelopes similar to the porcine endogenous retrovirus (PERV-A). T52946 BIOCLASS Eukaryoticriboflavin transporter T52946 SEQUENCE MAAPTPARPVLTHLLVALFGMGSWAAVNGIWVELPVVVKELPEGWSLPSYVSVLVALGNLGLLVVTLWRRLAPGKDEQVPIRVVQVLGMVGTALLASLWHHVAPVAGQLHSVAFLALAFVLALACCASNVTFLPFLSHLPPRFLRSFFLGQGLSALLPCVLALVQGVGRLECPPAPINGTPGPPLDFLERFPASTFFWALTALLVASAAAFQGLLLLLPPPPSVPTGELGSGLQVGAPGAEEEVEESSPLQEPPSQAAGTTPGPDPKAYQLLSARSACLLGLLAATNALTNGVLPAVQSFSCLPYGRLAYHLAVVLGSAANPLACFLAMGVLCRSLAGLGGLSLLGVFCGGYLMALAVLSPCPPLVGTSAGVVLVVLSWVLCLGVFSYVKVAASSLLHGGGRPALLAAGVAIQVGSLLGAVAMFPPTSIYHVFHSRKDCADPCDS T52946 DRUGINFO D00ENC 4-Hydroxy-pent-2-enoic acid Investigative T52946 DRUGINFO D00FPB 4-Hydroxy-3-methyl-butyric acid Investigative T52946 DRUGINFO D00XKM 4-Hydroxy-4-phenyl-butyric acid Investigative T52946 DRUGINFO D01TPW 4-hydroxy-but-2-enoate Investigative T52946 DRUGINFO D05SGJ 5-hydroxy-pentanoate Investigative T52946 DRUGINFO D06CQQ 4-Hydroxy-4-phenyl-but-2-enoic acid Investigative T52946 DRUGINFO D06VNT 4-Hydroxy-3-methyl-but-2-enoic acid Investigative T52946 DRUGINFO D07QSV 4-Hydroxy-pentanoic acid Investigative T52946 DRUGINFO D0V0FG 4-Cyclohexyl-4-hydroxy-but-2-enoic acid Investigative T39380 TARGETID T39380 T39380 FORMERID TTDI03355 T39380 UNIPROID LPAR2_HUMAN T39380 TARGNAME Lysophosphatidic acid receptor 2 (LPAR2) T39380 GENENAME LPAR2 T39380 TARGTYPE Literature-reported T39380 SYNONYMS Lysophosphatidic acid receptor Edg-4; LPA2; LPA-2; LPA receptor 2; EDG4 T39380 FUNCTION Seems to be coupled to the G(i)/G(o), G(12)/G(13), and G(q) families of heteromeric G proteins. Plays a key role in phospholipase C-beta (PLC-beta) signaling pathway. Stimulates phospholipase C (PLC) activity in a manner that is independent of RALA activation. Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. T39380 PDBSTRUC 4P0C T39380 BIOCLASS GPCR rhodopsin T39380 SEQUENCE MVIMGQCYYNETIGFFYNNSGKELSSHWRPKDVVVVALGLTVSVLVLLTNLLVIAAIASNRRFHQPIYYLLGNLAAADLFAGVAYLFLMFHTGPRTARLSLEGWFLRQGLLDTSLTASVATLLAIAVERHRSVMAVQLHSRLPRGRVVMLIVGVWVAALGLGLLPAHSWHCLCALDRCSRMAPLLSRSYLAVWALSSLLVFLLMVAVYTRIFFYVRRRVQRMAEHVSCHPRYRETTLSLVKTVVIILGAFVVCWTPGQVVLLLDGLGCESCNVLAVEKYFLLLAEANSLVNAAVYSCRDAEMRRTFRRLLCCACLRQSTRESVHYTSSAQGGASTRIMLPENGHPLMDSTL T39380 DRUGINFO D01PKC PMID18178086C15 Investigative T39380 DRUGINFO D0E0DY decyl dihydrogen phosphate Investigative T39380 DRUGINFO D0G8FF GRI977143 Investigative T39380 DRUGINFO D06IXI BrP-LPA Investigative T39380 DRUGINFO D0FZ6A dodecylphosphate Investigative T39380 DRUGINFO D04KQT dodecyl-thiophosphate Investigative T39380 DRUGINFO D0K3GQ oleoyl-thiophosphate Investigative T39380 DRUGINFO D0R8LB NAEPA Investigative T39380 DRUGINFO D02LXI Ki16425 Investigative T39380 DRUGINFO D0R2VH 2-oleoyl-LPA Investigative T39380 DRUGINFO D0X0UR LPA Investigative T56143 TARGETID T56143 T56143 FORMERID TTDI00075 T56143 UNIPROID GPR35_HUMAN T56143 TARGNAME Kynurenic acid receptor (GPR35) T56143 GENENAME GPR35 T56143 TARGTYPE Literature-reported T56143 SYNONYMS KYNA receptor; Gprotein coupled receptor 35; GPR35 T56143 FUNCTION Acts as a receptor for kynurenic acid, an intermediate in the tryptophan metabolic pathway. The activity of this receptor is mediated by G-proteins that elicit calcium mobilization and inositol phosphate production through G(qi/o) proteins. T56143 BIOCLASS GPCR rhodopsin T56143 SEQUENCE MNGTYNTCGSSDLTWPPAIKLGFYAYLGVLLVLGLLLNSLALWVFCCRMQQWTETRIYMTNLAVADLCLLCTLPFVLHSLRDTSDTPLCQLSQGIYLTNRYMSISLVTAIAVDRYVAVRHPLRARGLRSPRQAAAVCAVLWVLVIGSLVARWLLGIQEGGFCFRSTRHNFNSMAFPLLGFYLPLAVVVFCSLKVVTALAQRPPTDVGQAEATRKAARMVWANLLVFVVCFLPLHVGLTVRLAVGWNACALLETIRRALYITSKLSDANCCLDAICYYYMAKEFQEASALAVAPSAKAHKSQDSLCVTLA T56143 DRUGINFO D04BYU pamoic acid Investigative T56143 DRUGINFO D0R2VH 2-oleoyl-LPA Investigative T30829 TARGETID T30829 T30829 FORMERID TTDI03402 T30829 UNIPROID NEK6_HUMAN T30829 TARGNAME NIMA-related kinase 6 (NEK6) T30829 GENENAME NEK6 T30829 TARGTYPE Literature-reported T30829 SYNONYMS Serine/threonine-protein kinase Nek6; Protein kinase SID6-1512; NimA-related protein kinase 6; Never in mitosis A-related kinase 6 T30829 FUNCTION Required for chromosome segregation at metaphase-anaphase transition, robust mitotic spindle formation and cytokinesis. Phosphorylates ATF4, CIR1, PTN, RAD26L, RBBP6, RPS7, RPS6KB1, TRIP4, STAT3 and histones H1 and H3. Phosphorylates KIF11 to promote mitotic spindle formation. Involved in G2/M phase cell cycle arrest induced by DNA damage. Inhibition of activity results in apoptosis. May contribute to tumorigenesis by suppressing p53/TP53-induced cancer cell senescence. Protein kinase which plays an important role in mitotic cell cycle progression. T30829 BIOCLASS Kinase T30829 ECNUMBER EC 2.7.11.1 T30829 SEQUENCE MAGQPGHMPHGGSSNNLCHTLGPVHPPDPQRHPNTLSFRCSLADFQIEKKIGRGQFSEVYKATCLLDRKTVALKKVQIFEMMDAKARQDCVKEIGLLKQLNHPNIIKYLDSFIEDNELNIVLELADAGDLSQMIKYFKKQKRLIPERTVWKYFVQLCSAVEHMHSRRVMHRDIKPANVFITATGVVKLGDLGLGRFFSSETTAAHSLVGTPYYMSPERIHENGYNFKSDIWSLGCLLYEMAALQSPFYGDKMNLFSLCQKIEQCDYPPLPGEHYSEKLRELVSMCICPDPHQRPDIGYVHQVAKQMHIWMSST T30829 DRUGINFO D0V0KA PMID20462760C22 Investigative T41702 TARGETID T41702 T41702 FORMERID TTDI03082 T41702 UNIPROID KC1G1_HUMAN T41702 TARGNAME Casein kinase I gamma-1 (CSNK1G1) T41702 GENENAME CSNK1G1 T41702 TARGTYPE Literature-reported T41702 SYNONYMS Casein kinase I isoform gamma-1; CKI-gamma 1 T41702 FUNCTION Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate (By similarity). Phosphorylates CLSPN. T41702 PDBSTRUC 2CMW T41702 ECNUMBER EC 2.7.11.1 T41702 SEQUENCE MDHPSREKDERQRTTKPMAQRSAHCSRPSGSSSSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEPIKSRAPQLHLEYRFYKQLGSAGEGLPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFTLKTVLMIAIQLLSRMEYVHSKNLIYRDVKPENFLIGRQGNKKEHVIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEALGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRNTPIEALCENFPEEMATYLRYVRRLDFFEKPDYEYLRTLFTDLFEKKGYTFDYAYDWVGRPIPTPVGSVHVDSGASAITRESHTHRDRPSQQQPLRNQVVSSTNGELNVDDPTGAHSNAPITAHAEVEVVEEAKCCCFFKRKRKKTAQRHK T41702 DRUGINFO D01YWE PMID19364658C33 Investigative T99802 TARGETID T99802 T99802 FORMERID TTDI03442 T99802 UNIPROID PDE11_HUMAN T99802 TARGNAME Phosphodiesterase 11A (PDE11A) T99802 GENENAME PDE11A T99802 TARGTYPE Literature-reported T99802 SYNONYMS cAMP and cGMP phosphodiesterase 11A; Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A T99802 FUNCTION Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively. Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP. T99802 BIOCLASS Phosphoric diester hydrolase T99802 ECNUMBER EC 3.1.4.35 T99802 SEQUENCE MAASRLDFGEVETFLDRHPELFEDYLMRKGKQEMVEKWLQRHSQGQGALGPRPSLAGTSSLAHSTCRGGSSVGGGTGPNGSAHSQPLPGGGDCGGVPLSPSWAGGSRGDGNLQRRASQKELRKSFARSKAIHVNRTYDEQVTSRAQEPLSSVRRRALLRKASSLPPTTAHILSALLESRVNLPRYPPTAIDYKCHLKKHNERQFFLELVKDISNDLDLTSLSYKILIFVCLMVDADRCSLFLVEGAAAGKKTLVSKFFDVHAGTPLLPCSSTENSNEVQVPWGKGIIGYVGEHGETVNIPDAYQDRRFNDEIDKLTGYKTKSLLCMPIRSSDGEIIGVAQAINKIPEGAPFTEDDEKVMQMYLPFCGIAISNAQLFAASRKEYERSRALLEVVNDLFEEQTDLEKIVKKIMHRAQTLLKCERCSVLLLEDIESPVVKFTKSFELMSPKCSADAENSFKESMEKSSYSDWLINNSIAELVASTGLPVNISDAYQDPRFDAEADQISGFHIRSVLCVPIWNSNHQIIGVAQVLNRLDGKPFDDADQRLFEAFVIFCGLGINNTIMYDQVKKSWAKQSVALDVLSYHATCSKAEVDKFKAANIPLVSELAIDDIHFDDFSLDVDAMITAALRMFMELGMVQKFKIDYETLCRWLLTVRKNYRMVLYHNWRHAFNVCQLMFAMLTTAGFQDILTEVEILAVIVGCLCHDLDHRGTNNAFQAKSGSALAQLYGTSATLEHHHFNHAVMILQSEGHNIFANLSSKEYSDLMQLLKQSILATDLTLYFERRTEFFELVSKGEYDWNIKNHRDIFRSMLMTACDLGAVTKPWEISRQVAELVTSEFFEQGDRERLELKLTPSAIFDRNRKDELPRLQLEWIDSICMPLYQALVKVNVKLKPMLDSVATNRSKWEELHQKRLLASTASSSPASVMVAKEDRN T99802 DRUGINFO D03QTH BC11-38 Investigative T59082 TARGETID T59082 T59082 FORMERID TTDR00854 T59082 UNIPROID CD209_HUMAN T59082 TARGNAME Membrane-associated lectin type-C (CD209) T59082 GENENAME CD209 T59082 TARGTYPE Literature-reported T59082 SYNONYMS Surface C-type lectin DC-SIGN; Probable mannose-binding C-type lectin DC-SIGN; MDC-SIGN1A type I isoform; Dendritic cell-specific ICAM-3-grabbing nonintegrin 1; Dendritic cell-specific ICAM-3-grabbing non-integrin 1; DC-specific ICAM-3 grabbing nonintegrin; DC-SIGN1; DC-SIGN; CLEC4L; CD209 antigen; CD 209; C-type lectin domain family 4 member L T59082 FUNCTION Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The receptor returns to the cell membrane surface and the pathogen-derived antigens are presented to resting T-cells via MHC class II proteins to initiate the adaptive immune response. T59082 PDBSTRUC 2XR6; 2XR5; 2IT6; 2IT5; 2B6B T59082 SEQUENCE MSDSKEPRLQQLGLLEEEQLRGLGFRQTRGYKSLAGCLGHGPLVLQLLSFTLLAGLLVQVSKVPSSISQEQSRQDAIYQNLTQLKAAVGELSEKSKLQEIYQELTQLKAAVGELPEKSKLQEIYQELTRLKAAVGELPEKSKLQEIYQELTWLKAAVGELPEKSKMQEIYQELTRLKAAVGELPEKSKQQEIYQELTRLKAAVGELPEKSKQQEIYQELTRLKAAVGELPEKSKQQEIYQELTQLKAAVERLCHPCPWEWTFFQGNCYFMSNSQRNWHDSITACKEVGAQLVVIKSAEEQNFLQLQSSRSNRFTWMGLSDLNQEGTWQWVDGSPLLPSFKQYWNRGEPNNVGEEDCAEFSGNGWNDDKCNLAKFWICKKSAASCSRDEEQFLSPAPATPNPPPA T59082 DRUGINFO D0G6XS Fucose Investigative T59082 DRUGINFO D07LUR Alpha-D-Mannose Investigative T23984 TARGETID T23984 T23984 FORMERID TTDI03064 T23984 UNIPROID BRD7_HUMAN T23984 TARGNAME Bromodomain-containing protein 7 (BRD7) T23984 GENENAME BRD7 T23984 TARGTYPE Literature-reported T23984 SYNONYMS Protein CELTIX-1; CELTIX1; BP75; 75 kDa bromodomain protein T23984 FUNCTION May play a role in chromatin remodeling. Activator of the Wnt signaling pathway in a DVL1-dependent manner by negatively regulating the GSK3B phosphotransferase activity. Induces dephosphorylation of GSK3B at 'Tyr-216'. Down-regulates TRIM24-mediated activation of transcriptional activation by AR. Transcriptional corepressor that down-regulates the expression of target genes. Binds to target promoters, leading to increased histone H3 acetylation at 'Lys-9' (H3K9ac). Binds to the ESR1 promoter. Recruits BRCA1 and POU2F1 to the ESR1 promoter. Coactivator for TP53-mediated activation of transcription of a set of target genes. Required for TP53-mediated cell-cycle arrest in response to oncogene activation. Promotes acetylation of TP53 at 'Lys-382', and thereby promotes efficient recruitment of TP53 to target promoters. Inhibits cell cycle progression from G1 to S phase. Acts both as coactivator and as corepressor. T23984 PDBSTRUC 5MQ1; 2I7K T23984 BIOCLASS Bromodomain T23984 SEQUENCE MGKKHKKHKSDKHLYEEYVEKPLKLVLKVGGNEVTELSTGSSGHDSSLFEDKNDHDKHKDRKRKKRKKGEKQIPGEEKGRKRRRVKEDKKKRDRDRVENEAEKDLQCHAPVRLDLPPEKPLTSSLAKQEEVEQTPLQEALNQLMRQLQRKDPSAFFSFPVTDFIAPGYSMIIKHPMDFSTMKEKIKNNDYQSIEELKDNFKLMCTNAMIYNKPETIYYKAAKKLLHSGMKILSQERIQSLKQSIDFMADLQKTRKQKDGTDTSQSGEDGGCWQREREDSGDAEAHAFKSPSKENKKKDKDMLEDKFKSNNLEREQEQLDRIVKESGGKLTRRLVNSQCEFERRKPDGTTTLGLLHPVDPIVGEPGYCPVRLGMTTGRLQSGVNTLQGFKEDKRNKVTPVLYLNYGPYSSYAPHYDSTFANISKDDSDLIYSTYGEDSDLPSDFSIHEFLATCQDYPYVMADSLLDVLTKGGHSRTLQEMEMSLPEDEGHTRTLDTAKEMEITEVEPPGRLDSSTQDRLIALKAVTNFGVPVEVFDSEEAEIFQKKLDETTRLLRELQEAQNERLSTRPPPNMICLLGPSYREMHLAEQVTNNLKELAQQVTPGDIVSTYGVRKAMGISIPSPVMENNFVDLTEDTEEPKKTDVAECGPGGS T23984 DRUGINFO D08LXU LP99 Investigative T26846 TARGETID T26846 T26846 FORMERID TTDR00883 T26846 UNIPROID PLCB1_HUMAN T26846 TARGNAME Phospholipase C-beta-1 (PLCB1) T26846 GENENAME PLCB1 T26846 TARGTYPE Literature-reported T26846 SYNONYMS Phospholipase C-beta1; Phospholipase C-I; Phosphoinositide phospholipase C-beta-1; Phosphoinositide phospholipase C; PLC-beta-1; PLC-I; PLC-154; KIAA0581; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 T26846 FUNCTION The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. T26846 BIOCLASS Phosphoric diester hydrolase T26846 ECNUMBER EC 3.1.4.11 T26846 SEQUENCE MAGAQPGVHALQLKPVCVSDSLKKGTKFVKWDDDSTIVTPIILRTDPQGFFFYWTDQNKETELLDLSLVKDARCGRHAKAPKDPKLRELLDVGNIGRLEQRMITVVYGPDLVNISHLNLVAFQEEVAKEWTNEVFSLATNLLAQNMSRDAFLEKAYTKLKLQVTPEGRIPLKNIYRLFSADRKRVETALEACSLPSSRNDSIPQEDFTPEVYRVFLNNLCPRPEIDNIFSEFGAKSKPYLTVDQMMDFINLKQRDPRLNEILYPPLKQEQVQVLIEKYEPNNSLARKGQISVDGFMRYLSGEENGVVSPEKLDLNEDMSQPLSHYFINSSHNTYLTAGQLAGNSSVEMYRQVLLSGCRCVELDCWKGRTAEEEPVITHGFTMTTEISFKEVIEAIAECAFKTSPFPILLSFENHVDSPKQQAKMAEYCRLIFGDALLMEPLEKYPLESGVPLPSPMDLMYKILVKNKKKSHKSSEGSGKKKLSEQASNTYSDSSSMFEPSSPGAGEADTESDDDDDDDDCKKSSMDEGTAGSEAMATEEMSNLVNYIQPVKFESFEISKKRNKSFEMSSFVETKGLEQLTKSPVEFVEYNKMQLSRIYPKGTRVDSSNYMPQLFWNAGCQMVALNFQTMDLAMQINMGMYEYNGKSGYRLKPEFMRRPDKHFDPFTEGIVDGIVANTLSVKIISGQFLSDKKVGTYVEVDMFGLPVDTRRKAFKTKTSQGNAVNPVWEEEPIVFKKVVLPTLACLRIAVYEEGGKFIGHRILPVQAIRPGYHYICLRNERNQPLTLPAVFVYIEVKDYVPDTYADVIEALSNPIRYVNLMEQRAKQLAALTLEDEEEVKKEADPGETPSEAPSEARTTPAENGVNHTTTLTPKPPSQALHSQPAPGSVKAPAKTEDLIQSVLTEVEAQTIEELKQQKSFVKLQKKHYKEMKDLVKRHHKKTTDLIKEHTTKYNEIQNDYLRRRAALEKSAKKDSKKKSEPSSPDHGSSTIEQDLAALDAEMTQKLIDLKDKQQQQLLNLRQEQYYSEKYQKREHIKLLIQKLTDVAEECQNNQLKKLKEICEKEKKELKKKMDKKRQEKITEAKSKDKSQMEEEKTEMIRSYIQEVVQYIKRLEEAQSKRQEKLVEKHKEIRQQILDEKPKLQVELEQEYQDKFKRLPLEILEFVQEAMKGKISEDSNHGSAPLSLSSDPGKVNHKTPSSEELGGDIPGKEFDTPL T79726 TARGETID T79726 T79726 FORMERID TTDR00918 T79726 UNIPROID G6PC2_HUMAN T79726 TARGNAME Glucose-6-phosphatase 2 (G6PC2) T79726 GENENAME G6PC2 T79726 TARGTYPE Literature-reported T79726 SYNONYMS IGRP; G6PC2 T79726 FUNCTION May hydrolyze glucose-6-phosphate to glucose in the endoplasmic reticulum. May be responsible for glucose production through glycogenolysis and gluconeogenesis. T79726 BIOCLASS Phosphoric monoester hydrolase T79726 ECNUMBER EC 3.1.3.9 T79726 SEQUENCE MDFLHRNGVLIIQHLQKDYRAYYTFLNFMSNVGDPRNIFFIYFPLCFQFNQTVGTKMIWVAVIGDWLNLIFKWILFGHRPYWWVQETQIYPNHSSPCLEQFPTTCETGPGSPSGHAMGASCVWYVMVTAALSHTVCGMDKFSITLHRLTWSFLWSVFWLIQISVCISRVFIATHFPHQVILGVIGGMLVAEAFEHTPGIQTASLGTYLKTNLFLFLFAVGFYLLLRVLNIDLLWSVPIAKKWCANPDWIHIDTTPFAGLVRNLGVLFGLGFAINSEMFLLSCRGGNNYTLSFRLLCALTSLTILQLYHFLQIPTHEEHLFYVLSFCKSASIPLTVVAFIPYSVHMLMKQSGKKSQ T20542 TARGETID T20542 T20542 FORMERID TTDI03166 T20542 UNIPROID DYRK4_HUMAN T20542 TARGNAME Dual-specificity tyrosine-phosphorylation regulated kinase 4 (DYRK4) T20542 GENENAME DYRK4 T20542 TARGTYPE Literature-reported T20542 SYNONYMS Dual specificity tyrosine-phosphorylation-regulated kinase 4 T20542 FUNCTION Possible non-essential role in spermiogenesis. T20542 BIOCLASS Kinase T20542 ECNUMBER EC 2.7.12.1 T20542 SEQUENCE MPASELKASEIPFHPSIKTQDPKAEEKSPKKQKVTLTAAEALKLFKNQLSPYEQSEILGYAELWFLGLEAKKLDTAPEKFSKTSFDDEHGFYLKVLHDHIAYRYEVLETIGKGSFGQVAKCLDHKNNELVALKIIRNKKRFHQQALMELKILEALRKKDKDNTYNVVHMKDFFYFRNHFCITFELLGINLYELMKNNNFQGFSLSIVRRFTLSVLKCLQMLSVEKIIHCDLKPENIVLYQKGQASVKVIDFGSSCYEHQKVYTYIQSRFYRSPEVILGHPYDVAIDMWSLGCITAELYTGYPLFPGENEVEQLACIMEVLGLPPAGFIQTASRRQTFFDSKGFPKNITNNRGKKRYPDSKDLTMVLKTYDTSFLDFLRRCLVWEPSLRMTPDQALKHAWIHQSRNLKPQPRPQTLRKSNSFFPSETRKDKVQGCHHSSRKADEITKETTEKTKDSPTKHVQHSGDQQDCLQHGADTVQLPQLVDAPKKSEAAVGAEVSMTSPGQSKNFSLKNTNVLPPIV T20542 DRUGINFO D04IMY leucettine L41 Investigative T55068 TARGETID T55068 T55068 FORMERID TTDI03344 T55068 UNIPROID KCNQ5_HUMAN T55068 TARGNAME Voltage-gated potassium channel Kv7.5 (KCNQ5) T55068 GENENAME KCNQ5 T55068 TARGTYPE Literature-reported T55068 SYNONYMS Voltage-gated potassium channel subunit Kv7.5; Potassium voltage-gated channel subfamily KQT member 5; Potassium channel subunit alpha KvLQT5; KQT-like 5 T55068 FUNCTION Therefore, it is important in the regulation of neuronal excitability. May contribute, with other potassium channels, to the molecular diversity of a heterogeneous population of M-channels, varying in kinetic and pharmacological properties, which underlie this physiologically important current. Insensitive to tetraethylammonium, but inhibited by barium, linopirdine and XE991. Activated by niflumic acid and the anticonvulsant retigabine. As the native M-channel, the potassium channel composed of KCNQ3 and KCNQ5 is also suppressed by activation of the muscarinic acetylcholine receptor CHRM1. Associates with KCNQ3 to form a potassium channel which contributes to M-type current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons. T55068 PDBSTRUC 6B8Q T55068 BIOCLASS Voltage-gated ion channel T55068 SEQUENCE MPRHHAGGEEGGAAGLWVKSGAAAAAAGGGRLGSGMKDVESGRGRVLLNSAAARGDGLLLLGTRAATLGGGGGGLRESRRGKQGARMSLLGKPLSYTSSQSCRRNVKYRRVQNYLYNVLERPRGWAFIYHAFVFLLVFGCLILSVFSTIPEHTKLASSCLLILEFVMIVVFGLEFIIRIWSAGCCCRYRGWQGRLRFARKPFCVIDTIVLIASIAVVSAKTQGNIFATSALRSLRFLQILRMVRMDRRGGTWKLLGSVVYAHSKELITAWYIGFLVLIFSSFLVYLVEKDANKEFSTYADALWWGTITLTTIGYGDKTPLTWLGRLLSAGFALLGISFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAANLIQCVWRSYAADEKSVSIATWKPHLKALHTCSPTKKEQGEASSSQKLSFKERVRMASPRGQSIKSRQASVGDRRSPSTDITAEGSPTKVQKSWSFNDRTRFRPSLRLKSSQPKPVIDADTALGTDDVYDEKGCQCDVSVEDLTPPLKTVIRAIRIMKFHVAKRKFKETLRPYDVKDVIEQYSAGHLDMLCRIKSLQTRVDQILGKGQITSDKKSREKITAEHETTDDLSMLGRVVKVEKQVQSIESKLDCLLDIYQQVLRKGSASALALASFQIPPFECEQTSDYQSPVDSKDLSGSAQNSGCLSRSTSANISRGLQFILTPNEFSAQTFYALSPTMHSQATQVPISQSDGSAVAATNTIANQINTAPKPAAPTTLQIPPPLPAIKHLPRPETLHPNPAGLQESISDVTTCLVASKENVQVAQSNLTKDRSMRKSFDMGGETLLSVCPMVPKDLGKSLSVQNLIRSTEELNIQLSGSESSGSRGSQDFYPKWRESKLFITDEEVGPEETETDTFDAAPQPAREAAFASDSLRTGRSRSSQSICKAGESTDALSLPHVKLK T55068 DRUGINFO D02BGR (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide Investigative T55068 DRUGINFO D07FTI zinc pyrithione Investigative T55068 DRUGINFO D0P8PH XE991 Investigative T55068 DRUGINFO D06PZZ [14C]TEA Investigative T79824 TARGETID T79824 T79824 FORMERID TTDI03538 T79824 UNIPROID STK36_HUMAN T79824 TARGNAME Fused homolog (STK36) T79824 GENENAME STK36 T79824 TARGTYPE Literature-reported T79824 SYNONYMS Serine/threonine-protein kinase 36; KIAA1278 T79824 FUNCTION Controls the activity of the transcriptional regulators GLI1, GLI2 and GLI3 by opposing the effect of SUFU and promoting their nuclear localization. GLI2 requires an additional function of STK36 to become transcriptionally active, but the enzyme does not need to possess an active kinase catalytic site for this to occur. Required for postnatal development, possibly by regulating the homeostasis of cerebral spinal fluid or ciliary function. Essential for construction of the central pair apparatus of motile cilia. Serine/threonine protein kinase which plays an important role in the sonic hedgehog (Shh) pathway by regulating the activity of GLI transcription factors. T79824 BIOCLASS Kinase T79824 ECNUMBER EC 2.7.11.1 T79824 SEQUENCE MEKYHVLEMIGEGSFGRVYKGRRKYSAQVVALKFIPKLGRSEKELRNLQREIEIMRGLRHPNIVHMLDSFETDKEVVVVTDYAEGELFQILEDDGKLPEDQVQAIAAQLVSALYYLHSHRILHRDMKPQNILLAKGGGIKLCDFGFARAMSTNTMVLTSIKGTPLYMSPELVEERPYDHTADLWSVGCILYELAVGTPPFYATSIFQLVSLILKDPVRWPSTISPCFKNFLQGLLTKDPRQRLSWPDLLYHPFIAGHVTIITEPAGPDLGTPFTSRLPPELQVLKDEQAHRLAPKGNQSRILTQAYKRMAEEAMQKKHQNTGPALEQEDKTSKVAPGTAPLPRLGATPQESSLLAGILASELKSSWAKSGTGEVPSAPRENRTTPDCERAFPEERPEVLGQRSTDVVDLENEEPDSDNEWQHLLETTEPVPIQLKAPLTLLCNPDFCQRIQSQLHEAGGQILKGILEGASHILPAFRVLSSLLSSCSDSVALYSFCREAGLPGLLLSLLRHSQESNSLQQQSWYGTFLQDLMAVIQAYFACTFNLERSQTSDSLQVFQEAANLFLDLLGKLLAQPDDSEQTLRRDSLMCFTVLCEAMDGNSRAISKAFYSSLLTTQQVVLDGLLHGLTVPQLPVHTPQGAPQVSQPLREQSEDIPGAISSALAAICTAPVGLPDCWDAKEQVCWHLANQLTEDSSQLRPSLISGLQHPILCLHLLKVLYSCCLVSEGLCRLLGQEPLALESLFMLIQGKVKVVDWEESTEVTLYFLSLLVFRLQNLPCGMEKLGSDVATLFTHSHVVSLVSAAACLLGQLGQQGVTFDLQPMEWMAAATHALSAPAEVRLTPPGSCGFYDGLLILLLQLLTEQGKASLIRDMSSSEMWTVLWHRFSMVLRLPEEASAQEGELSLSSPPSPEPDWTLISPQGMAALLSLAMATFTQEPQLCLSCLSQHGSILMSILKHLLCPSFLNQLRQAPHGSEFLPVVVLSVCQLLCFPFALDMDADLLIGVLADLRDSEVAAHLLQVCCYHLPLMQVELPISLLTRLALMDPTSLNQFVNTVSASPRTIVSFLSVALLSDQPLLTSDLLSLLAHTARVLSPSHLSFIQELLAGSDESYRPLRSLLGHPENSVRAHTYRLLGHLLQHSMALRGALQSQSGLLSLLLLGLGDKDPVVRCSASFAVGNAAYQAGPLGPALAAAVPSMTQLLGDPQAGIRRNVASALGNLGPEGLGEELLQCEVPQRLLEMACGDPQPNVKEAALIALRSLQQEPGIHQVLVSLGASEKLSLLSLGNQSLPHSSPRPASAKHCRKLIHLLRPAHSM T79824 DRUGINFO D09RYV Ro-0505124 Investigative T97821 TARGETID T97821 T97821 FORMERID TTDI03623 T97821 UNIPROID M3K20_HUMAN T97821 TARGNAME MLK-related kinase (MLTK) T97821 GENENAME MAP3K20 T97821 TARGTYPE Literature-reported T97821 SYNONYMS ZAK; Sterile alpha motif- and leucine zipper-containing kinase AZK; Mixed lineage kinase-related kinase; Mitogen-activated protein kinase kinase kinase MLT; Mitogen-activated protein kinase kinase kinase 20; MRK; MLTK; MLK-like mitogen-activated protein triple kinase; Leucine zipper- and sterile alpha motif-containing kinase; Human cervical cancer suppressor gene 4 protein; HCCS4; HCCS-4 T97821 FUNCTION Stress-activated component of a protein kinase signal transduction cascade. Regulates the JNK and p38 pathways. Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14. Pro-apoptotic. Role in regulation of S and G2 cell cycle checkpoint by direct phosphorylation of CHEK2. Involved in limb development. T97821 PDBSTRUC 5X5O; 5HES T97821 ECNUMBER EC 2.7.11.25 T97821 SEQUENCE MSSLGASFVQIKFDDLQFFENCGGGSFGSVYRAKWISQDKEVAVKKLLKIEKEAEILSVLSHRNIIQFYGVILEPPNYGIVTEYASLGSLYDYINSNRSEEMDMDHIMTWATDVAKGMHYLHMEAPVKVIHRDLKSRNVVIAADGVLKICDFGASRFHNHTTHMSLVGTFPWMAPEVIQSLPVSETCDTYSYGVVLWEMLTREVPFKGLEGLQVAWLVVEKNERLTIPSSCPRSFAELLHQCWEADAKKRPSFKQIISILESMSNDTSLPDKCNSFLHNKAEWRCEIEATLERLKKLERDLSFKEQELKERERRLKMWEQKLTEQSNTPLLPSFEIGAWTEDDVYCWVQQLVRKGDSSAEMSVYASLFKENNITGKRLLLLEEEDLKDMGIVSKGHIIHFKSAIEKLTHDYINLFHFPPLIKDSGGEPEENEEKIVNLELVFGFHLKPGTGPQDCKWKMYMEMDGDEIAITYIKDVTFNTNLPDAEILKMTKPPFVMEKWIVGIAKSQTVECTVTYESDVRTPKSTKHVHSIQWSRTKPQDEVKAVQLAIQTLFTNSDGNPGSRSDSSADCQWLDTLRMRQIASNTSLQRSQSNPILGSPFFSHFDGQDSYAAAVRRPQVPIKYQQITPVNQSRSSSPTQYGLTKNFSSLHLNSRDSGFSSGNTDTSSERGRYSDRSRNKYGRGSISLNSSPRGRYSGKSQHSTPSRGRYPGKFYRVSQSALNPHQSPDFKRSPRDLHQPNTIPGMPLHPETDSRASEEDSKVSEGGWTKVEYRKKPHRPSPAKTNKERARGDHRGWRNF T97821 DRUGINFO D06BDC PMID16539403C15b Investigative T75015 TARGETID T75015 T75015 FORMERID TTDI01485 T75015 UNIPROID E2AK3_HUMAN T75015 TARGNAME Pancreatic eIF2-alpha kinase (HsPEK) T75015 GENENAME EIF2AK3 T75015 TARGTYPE Literature-reported T75015 SYNONYMS PERK; HsPEK; Eukaryotic translation initiation factor 2-alpha kinase 3 T75015 FUNCTION Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the unfolded protein response (UPR) and in response to low amino acid availability. Converts phosphorylated eIF-2-alpha/EIF2S1 either in a global protein synthesis inhibitor, leading to a reduced overall utilization of amino acids, or to a translation initiation activator of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function. T75015 PDBSTRUC 5SV7; 4YZS; 4X7O; 4X7N; 4X7L T75015 ECNUMBER EC 2.7.11.1 T75015 SEQUENCE MERAISPGLLVRALLLLLLLLGLAARTVAAGRARGLPAPTAEAAFGLGAAAAPTSATRVPAAGAVAAAEVTVEDAEALPAAAGEQEPRGPEPDDETELRPRGRSLVIISTLDGRIAALDPENHGKKQWDLDVGSGSLVSSSLSKPEVFGNKMIIPSLDGALFQWDQDRESMETVPFTVESLLESSYKFGDDVVLVGGKSLTTYGLSAYSGKVRYICSALGCRQWDSDEMEQEEDILLLQRTQKTVRAVGPRSGNEKWNFSVGHFELRYIPDMETRAGFIESTFKPNENTEESKIISDVEEQEAAIMDIVIKVSVADWKVMAFSKKGGHLEWEYQFCTPIASAWLLKDGKVIPISLFDDTSYTSNDDVLEDEEDIVEAARGATENSVYLGMYRGQLYLQSSVRISEKFPSSPKALESVTNENAIIPLPTIKWKPLIHSPSRTPVLVGSDEFDKCLSNDKFSHEEYSNGALSILQYPYDNGYYLPYYKRERNKRSTQITVRFLDNPHYNKNIRKKDPVLLLHWWKEIVATILFCIIATTFIVRRLFHPHPHRQRKESETQCQTENKYDSVSGEANDSSWNDIKNSGYISRYLTDFEPIQCLGRGGFGVVFEAKNKVDDCNYAIKRIRLPNRELAREKVMREVKALAKLEHPGIVRYFNAWLEAPPEKWQEKMDEIWLKDESTDWPLSSPSPMDAPSVKIRRMDPFATKEHIEIIAPSPQRSRSFSVGISCDQTSSSESQFSPLEFSGMDHEDISESVDAAYNLQDSCLTDCDVEDGTMDGNDEGHSFELCPSEASPYVRSRERTSSSIVFEDSGCDNASSKEEPKTNRLHIGNHCANKLTAFKPTSSKSSSEATLSISPPRPTTLSLDLTKNTTEKLQPSSPKVYLYIQMQLCRKENLKDWMNGRCTIEERERSVCLHIFLQIAEAVEFLHSKGLMHRDLKPSNIFFTMDDVVKVGDFGLVTAMDQDEEEQTVLTPMPAYARHTGQVGTKLYMSPEQIHGNSYSHKVDIFSLGLILFELLYPFSTQMERVRTLTDVRNLKFPPLFTQKYPCEYVMVQDMLSPSPMERPEAINIIENAVFEDLDFPGKTVLRQRSRSLSSSGTKHSRQSNNSHSPLPSN T02134 TARGETID T02134 T02134 FORMERID TTDR00615 T02134 UNIPROID GSH0_HUMAN T02134 TARGNAME Glutamate--cysteine ligase modifier (GCLM) T02134 GENENAME GCLM T02134 TARGTYPE Literature-reported T02134 SYNONYMS Glutamate--cysteine ligase modifier subunit; Gamma-glutamylcysteine synthetase regulatory subunit; Gamma-ECS regulatory subunit; GCS light chain T02134 FUNCTION cytosol, glutamate-cysteine ligase complex, enzyme regulator activity, glutamate-cysteine ligase catalytic subunit binding, glutamate metabolic process, glutathione biosynthetic process, positive regulation of glutamate-cysteine ligase activity, regulation of blood vessel size, response to drug, response to oxidative stress. T02134 BIOCLASS Aldo/keto reductase family T02134 SEQUENCE MGTDSRAAKALLARARTLHLQTGNLLNWGRLRKKCPSTHSEELHDCIQKTLNEWSSQINPDLVREFPDVLECTVSHAVEKINPDEREEMKVSAKLFIVESNSSSSTRSAVDMACSVLGVAQLDSVIIASPPIEDGVNLSLEHLQPYWEELENLVQSKKIVAIGTSDLDKTQLEQLYQWAQVKPNSNQVNLASCCVMPPDLTAFAKQFDIQLLTHNDPKELLSEASFQEALQESIPDIQAHEWVPLWLLRYSVIVKSRGIIKSKGYILQAKRRGS T02134 DRUGINFO D0WI3W Cystamine Investigative T02134 DRUGINFO D0Z6VR Buthionine sulfoximine Investigative T02134 DRUGINFO D0GV9Q N-Formylmethionine Investigative T37428 TARGETID T37428 T37428 FORMERID TTDR00046 T37428 UNIPROID RBX2_HUMAN T37428 TARGNAME RING-box protein 2 (RNF7) T37428 GENENAME RNF7 T37428 TARGTYPE Literature-reported T37428 SYNONYMS Sensitive to apoptosis gene protein; SAG; Regulator of cullins 2; Rbx2; ROC2; RING finger protein 7; CKII beta-binding protein 1; CKBBP1 T37428 FUNCTION CRLs complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins, ARIH1 mediating addition of the first ubiquitin on CRLs targets. Through the RING-type zinc finger, seems to recruit the E2 ubiquitination enzyme to the complex and brings it into close proximity to the substrate. Promotes the neddylation of CUL5 via its interaction with UBE2F. May play a role in protecting cells from apoptosis induced by redox agents. Probable component of the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription. T37428 PDBSTRUC 2ECL T37428 BIOCLASS Zinc-finger T37428 SEQUENCE MADVEDGEETCALASHSGSSGSKSGGDKMFSLKKWNAVAMWSWDVECDTCAICRVQVMDACLRCQAENKQEDCVVVWGECNHSFHNCCMSLWVKQNNRCPLCQQDWVVQRIGK T66206 TARGETID T66206 T66206 FORMERID TTDR00506 T66206 UNIPROID PEMT_HUMAN T66206 TARGNAME Phosphatidylethanolamine N-methyltransferase (PEMT) T66206 GENENAME PEMT T66206 TARGTYPE Literature-reported T66206 SYNONYMS PEMT2; PEAMT T66206 FUNCTION Catalyzes three sequential methylation of phosphatidylethanolamine (pe) by adomet, thus producing phosphatidylcholine (pc). T66206 BIOCLASS Methyltransferase T66206 ECNUMBER EC 2.1.1.17 T66206 SEQUENCE MTRLLGYVDPLDPSFVAAVITITFNPLYWNVVARWEHKTRKLSRAFGSPYLACYSLSVTILLLNFLRSHCFTQAMLSQPRMESLDTPAAYSLGLALLGLGVVLVLSSFFALGFAGTFLGDYFGILKEARVTVFPFNILDNPMYWGSTANYLGWAIMHASPTGLLLTVLVALTYIVALLYEEPFTAEIYRQKASGSHKRS T91323 TARGETID T91323 T91323 FORMERID TTDI00169 T91323 UNIPROID ST17A_HUMAN T91323 TARGNAME Cytoplasmic DRAK1 (STK17A) T91323 GENENAME STK17A T91323 TARGTYPE Literature-reported T91323 SYNONYMS Serine/threonine-protein kinase 17A; STK17A; DAP kinase-related apoptosis-inducing protein kinase 1 T91323 FUNCTION Acts as a positive regulator of apoptosis. Also acts as a regulator of cellular reactive oxygen species. T91323 BIOCLASS Kinase T91323 ECNUMBER EC 2.7.11.1 T91323 SEQUENCE MIPLEKPGSGGSSPGATSGSGRAGRGLSGPCRPPPPPQARGLLTEIRAVVRTEPFQDGYSLCPGRELGRGKFAVVRKCIKKDSGKEFAAKFMRKRRKGQDCRMEIIHEIAVLELAQDNPWVINLHEVYETASEMILVLEYAAGGEIFDQCVADREEAFKEKDVQRLMRQILEGVHFLHTRDVVHLDLKPQNILLTSESPLGDIKIVDFGLSRILKNSEELREIMGTPEYVAPEILSYDPISMATDMWSIGVLTYVMLTGISPFLGNDKQETFLNISQMNLSYSEEEFDVLSESAVDFIRTLLVKKPEDRATAEECLKHPWLTQSSIQEPSFRMEKALEEANALQEGHSVPEINSDTDKSETKESIVTEELIVVTSYTLGQCRQSEKEKMEQKAISKRFKFEEPLLQEIPGEFIY T08647 TARGETID T08647 T08647 FORMERID TTDI03177 T08647 UNIPROID EPHA6_HUMAN T08647 TARGNAME Ephrin type-A receptor 6 (EPHA6) T08647 GENENAME EPHA6 T08647 TARGTYPE Literature-reported T08647 SYNONYMS HEK12; EPH-like kinase 12; EPH homology kinase 2; EK12; EHK2; EHK-2 T08647 FUNCTION The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. T08647 BIOCLASS Kinase T08647 ECNUMBER EC 2.7.10.1 T08647 SEQUENCE MGGCEVREFLLQFGFFLPLLTAWPGDCSHVSNNQVVLLDTTTVLGELGWKTYPLNGWDAITEMDEHNRPIHTYQVCNVMEPNQNNWLRTNWISRDAAQKIYVEMKFTLRDCNSIPWVLGTCKETFNLFYMESDESHGIKFKPNQYTKIDTIAADESFTQMDLGDRILKLNTEIREVGPIERKGFYLAFQDIGACIALVSVRVFYKKCPFTVRNLAMFPDTIPRVDSSSLVEVRGSCVKSAEERDTPKLYCGADGDWLVPLGRCICSTGYEEIEGSCHACRPGFYKAFAGNTKCSKCPPHSLTYMEATSVCQCEKGYFRAEKDPPSMACTRPPSAPRNVVFNINETALILEWSPPSDTGGRKDLTYSVICKKCGLDTSQCEDCGGGLRFIPRHTGLINNSVIVLDFVSHVNYTFEIEAMNGVSELSFSPKPFTAITVTTDQDAPSLIGVVRKDWASQNSIALSWQAPAFSNGAILDYEIKYYEKEHEQLTYSSTRSKAPSVIITGLKPATKYVFHIRVRTATGYSGYSQKFEFETGDETSDMAAEQGQILVIATAAVGGFTLLVILTLFFLITGRCQWYIKAKMKSEEKRRNHLQNGHLRFPGIKTYIDPDTYEDPSLAVHEFAKEIDPSRIRIERVIGAGEFGEVCSGRLKTPGKREIPVAIKTLKGGHMDRQRRDFLREASIMGQFDHPNIIRLEGVVTKRSFPAIGVEAFCPSFLRAGFLNSIQAPHPVPGGGSLPPRIPAGRPVMIVVEYMENGSLDSFLRKHDGHFTVIQLVGMLRGIASGMKYLSDMGYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEAAYTTTGGKIPIRWTAPEAIAYRKFSSASDAWSYGIVMWEVMSYGERPYWEMSNQDVILSIEEGYRLPAPMGCPASLHQLMLHCWQKERNHRPKFTDIVSFLDKLIRNPSALHTLVEDILVMPESPGEVPEYPLFVTVGDWLDSIKMGQYKNNFVAAGFTTFDLISRMSIDDIRRIGVILIGHQRRIVSSIQTLRLHMMHIQEKGFHV T08647 DRUGINFO D0X8BU PMID23489211C20 Investigative T95947 TARGETID T95947 T95947 FORMERID TTDR01257 T95947 UNIPROID ASIC3_HUMAN T95947 TARGNAME Acid-sensing ion channel 3 (ASIC3) T95947 GENENAME ASIC3 T95947 TARGTYPE Literature-reported T95947 SYNONYMS hTNaC1; hASIC3; Testis sodium channel 1; TNAC1; SLNAC1; Neuronal amiloride-sensitive cation channel 3; Amiloride-sensitive cation channel 3; ASIC3; ACCN3 T95947 FUNCTION Cation channel with high affinity for sodium, whichis gated by extracellular protons and inhibited by the diuretic amiloride. Generates a biphasic current with a fast inactivating and a slow sustained phase. In sensory neurons is proposed to mediate the pain induced by acidosis that occurs in ischemic, damaged or inflamed tissue. May be involved in hyperalgesia. May play a role in mechanoreception. Heteromeric channel assembly seems to modulate channel properties. T95947 BIOCLASS Amiloride-sensitive sodium channel T95947 SEQUENCE MKPTSGPEEARRPASDIRVFASNCSMHGLGHVFGPGSLSLRRGMWAAAVVLSVATFLYQVAERVRYYREFHHQTALDERESHRLIFPAVTLCNINPLRRSRLTPNDLHWAGSALLGLDPAEHAAFLRALGRPPAPPGFMPSPTFDMAQLYARAGHSLDDMLLDCRFRGQPCGPENFTTIFTRMGKCYTFNSGADGAELLTTTRGGMGNGLDIMLDVQQEEYLPVWRDNEETPFEVGIRVQIHSQEEPPIIDQLGLGVSPGYQTFVSCQQQQLSFLPPPWGDCSSASLNPNYEPEPSDPLGSPSPSPSPPYTLMGCRLACETRYVARKCGCRMVYMPGDVPVCSPQQYKNCAHPAIDAMLRKDSCACPNPCASTRYAKELSMVRIPSRAAARFLARKLNRSEAYIAENVLALDIFFEALNYETVEQKKAYEMSELLGDIGGQMGLFIGASLLTILEILDYLCEVFRDKVLGYFWNRQHSQRHSSTNLLQEGLGSHRTQVPHLSLGPRPPTPPCAVTKTLSASHRTCYLVTQL T95947 DRUGINFO D0BL6W THA-902 Investigative T95947 DRUGINFO D0K7CV agmatine Investigative T95947 DRUGINFO D0S6HI arcaine Investigative T95947 DRUGINFO D0S9UQ GMQ Investigative T95947 DRUGINFO D0T7GQ APETX2 Investigative T95947 DRUGINFO D06AVE A-317567 Investigative T95947 DRUGINFO D02ACL benzamil Investigative T86877 TARGETID T86877 T86877 FORMERID TTDR00878 T86877 UNIPROID MKRN1_HUMAN T86877 TARGNAME E3 ubiquitin-protein ligase makorin-1 (MKRN1) T86877 GENENAME MKRN1 T86877 TARGTYPE Literature-reported T86877 SYNONYMS RNF61; RING-type E3 ubiquitin transferase makorin-1; RING finger protein 61 T86877 FUNCTION E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include FILIP1, p53/TP53, CDKN1A and TERT. Keeps cells alive by suppressing p53/TP53 under normal conditions, but stimulates apoptosis by repressing CDKN1A under stress conditions. Acts as a negative regulator of telomerase. Has negative and positive effects on RNA polymerase II-dependent transcription. T86877 BIOCLASS Carbon-nitrogen ligase T86877 ECNUMBER EC 2.3.2.27 T86877 SEQUENCE MAEAATPGTTATTSGAGAAAATAAAASPTPIPTVTAPSLGAGGGGGGSDGSGGGWTKQVTCRYFMHGVCKEGDNCRYSHDLSDSPYSVVCKYFQRGYCIYGDRCRYEHSKPLKQEEATATELTTKSSLAASSSLSSIVGPLVEMNTGEAESRNSNFATVGAGSEDWVNAIEFVPGQPYCGRTAPSCTEAPLQGSVTKEESEKEQTAVETKKQLCPYAAVGECRYGENCVYLHGDSCDMCGLQVLHPMDAAQRSQHIKSCIEAHEKDMELSFAVQRSKDMVCGICMEVVYEKANPSERRFGILSNCNHTYCLKCIRKWRSAKQFESKIIKSCPECRITSNFVIPSEYWVEEKEEKQKLILKYKEAMSNKACRYFDEGRGSCPFGGNCFYKHAYPDGRREEPQRQKVGTSSRYRAQRRNHFWELIEERENSNPFDNDEEEVVTFELGEMLLMLLAAGGDDELTDSEDEWDLFHDELEDFYDLDL T44584 TARGETID T44584 T44584 FORMERID TTDNR00696 T44584 UNIPROID IL19_HUMAN T44584 TARGNAME Interleukin-19 (IL19) T44584 GENENAME IL19 T44584 TARGTYPE Literature-reported T44584 SYNONYMS ZMDA1; NG.1; Melanoma differentiation-associated protein-like protein; IL-19 T44584 FUNCTION Up-regulates IL-6 and TNF-alpha and induces apoptosis. May play some important roles in inflammatory responses. T44584 PDBSTRUC 1N1F T44584 BIOCLASS Cytokine: interleukin T44584 SEQUENCE MKLQCVSLWLLGTILILCSVDNHGLRRCLISTDMHHIEESFQEIKRAIQAKDTFPNVTILSTLETLQIIKPLDVCCVTKNLLAFYVDRVFKDHQEPNPKILRKISSIANSFLYMQKTLRQCQEQRQCHCRQEATNATRVIHDNYDQLEVHAAAIKSLGELDVFLAWINKNHEVMFSA T92768 TARGETID T92768 T92768 UNIPROID AMACR_HUMAN T92768 TARGNAME Alpha-methylacyl-CoA racemase (AMACR) T92768 GENENAME AMACR T92768 TARGTYPE Literature-reported T92768 SYNONYMS IBLi; 2-methylacyl-CoA racemase T92768 FUNCTION Racemization of 2-methyl-branched fatty acid CoA esters. Responsible for the conversion of pristanoyl-CoA and C27-bile acyl-CoAs to their (S)-stereoisomers. T92768 BIOCLASS CaiB/BaiF CoA-transferase family T92768 ECNUMBER EC 5.1.99.4 T92768 SEQUENCE MALQGISVVELSGLAPGPFCAMVLADFGARVVRVDRPGSRYDVSRLGRGKRSLVLDLKQPRGAAVLRRLCKRSDVLLEPFRRGVMEKLQLGPEILQRENPRLIYARLSGFGQSGSFCRLAGHDINYLALSGVLSKIGRSGENPYAPLNLLADFAGGGLMCALGIIMALFDRTRTGKGQVIDANMVEGTAYLSSFLWKTQKLSLWEAPRGQNMLDGGAPFYTTYRTADGEFMAVGAIEPQFYELLIKGLGLKSDELPNQMSMDDWPEMKKKFADVFAEKTKAEWCQIFDGTDACVTPVLTFEEVVHHDHNKERGSFITSEEQDVSPRPAPLLLNTPAIPSFKRDPFIGEHTEEILEEFGFSREEIYQLNSDKIIESNKVKASL T75545 TARGETID T75545 T75545 FORMERID TTDR01199 T75545 UNIPROID S12A6_HUMAN T75545 TARGNAME Solute carrier family 12 member 6 (SLC12A6) T75545 GENENAME SLC12A6 T75545 TARGTYPE Literature-reported T75545 SYNONYMS SLC12A6; Electroneutral potassium-chloride cotransporter 3 T75545 FUNCTION Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells. T75545 BIOCLASS Cation-chloride cotransporter T75545 SEQUENCE MHPPETTTKMASVRFMVTPTKIDDIPGLSDTSPDLSSRSSSRVRFSSRESVPETSRSEPMSEMSGATTSLATVALDPPSDRTSHPQDVIEDLSQNSITGEHSQLLDDGHKKARNAYLNNSNYEEGDEYFDKNLALFEEEMDTRPKVSSLLNRMANYTNLTQGAKEHEEAENITEGKKKPTKTPQMGTFMGVYLPCLQNIFGVILFLRLTWVVGTAGVLQAFAIVLICCCCTMLTAISMSAIATNGVVPAGGSYFMISRALGPEFGGAVGLCFYLGTTFAAAMYILGAIEIFLVYIVPRAAIFHSDDALKESAAMLNNMRVYGTAFLVLMVLVVFIGVRYVNKFASLFLACVIVSILAIYAGAIKSSFAPPHFPVCMLGNRTLSSRHIDVCSKTKEINNMTVPSKLWGFFCNSSQFFNATCDEYFVHNNVTSIQGIPGLASGIITENLWSNYLPKGEIIEKPSAKSSDVLGSLNHEYVLVDITTSFTLLVGIFFPSVTGIMAGSNRSGDLKDAQKSIPIGTILAILTTSFVYLSNVVLFGACIEGVVLRDKFGDAVKGNLVVGTLSWPSPWVIVIGSFFSTCGAGLQSLTGAPRLLQAIAKDNIIPFLRVFGHSKANGEPTWALLLTAAIAELGILIASLDLVAPILSMFFLMCYLFVNLACALQTLLRTPNWRPRFRYYHWALSFMGMSICLALMFISSWYYAIVAMVIAGMIYKYIEYQGAEKEWGDGIRGLSLSAARFALLRLEEGPPHTKNWRPQLLVLLKLDEDLHVKHPRLLTFASQLKAGKGLTIVGSVIVGNFLENYGEALAAEQTIKHLMEAEKVKGFCQLVVAAKLREGISHLIQSCGLGGMKHNTVVMGWPNGWRQSEDARAWKTFIGTVRVTTAAHLALLVAKNISFFPSNVEQFSEGNIDVWWIVHDGGMLMLLPFLLKQHKVWRKCSIRIFTVAQLEDNSIQMKKDLATFLYHLRIEAEVEVVEMHDSDISAYTYERTLMMEQRSQMLRHMRLSKTERDREAQLVKDRNSMLRLTSIGSDEDEETETYQEKVHMTWTKDKYMASRGQKAKSMEGFQDLLNMRPDQSNVRRMHTAVKLNEVIVNKSHEAKLVLLNMPGPPRNPEGDENYMEFLEVLTEGLERVLLVRGGGSEVITIYS T75545 DRUGINFO D0K9KZ DIOA Investigative T66743 TARGETID T66743 T66743 FORMERID TTDI01439 T66743 UNIPROID MUTYH_HUMAN T66743 TARGNAME Adenine DNA glycosylase (MUTYH) T66743 GENENAME MUTYH T66743 TARGTYPE Literature-reported T66743 SYNONYMS hMYH; MutY homolog; MYH T66743 FUNCTION Involved in oxidative DNA damage repair. Initiates repair of A*oxoG to C*G by removing the inappropriately paired adenine base from the DNA backbone. Possesses both adenine and 2-OH-A DNA glycosylase activities. T66743 PDBSTRUC 3N5N; 1X51 T66743 ECNUMBER EC 3.2.2.31 T66743 SEQUENCE MTPLVSRLSRLWAIMRKPRAAVGSGHRKQAASQEGRQKHAKNNSQAKPSACDGMIAECPGAPAGLARQPEEVVLQASVSSYHLFRDVAEVTAFRGSLLSWYDQEKRDLPWRRRAEDEMDLDRRAYAVWVSEVMLQQTQVATVINYYTGWMQKWPTLQDLASASLEEVNQLWAGLGYYSRGRRLQEGARKVVEELGGHMPRTAETLQQLLPGVGRYTAGAIASIAFGQATGVVDGNVARVLCRVRAIGADPSSTLVSQQLWGLAQQLVDPARPGDFNQAAMELGATVCTPQRPLCSQCPVESLCRARQRVEQEQLLASGSLSGSPDVEECAPNTGQCHLCLPPSEPWDQTLGVVNFPRKASRKPPREESSATCVLEQPGALGAQILLVQRPNSGLLAGLWEFPSVTWEPSEQLQRKALLQELQRWAGPLPATHLRHLGEVVHTFSHIKLTYQVYGLALEGQTPVTTVPPGARWLTQEEFHTAAVSTAMKKVFRVYQGQQPGTCMGSKRSQVSSPCSRKKPRMGQQVLDNFFRSHISTDAHSLNSAAQ T25122 TARGETID T25122 T25122 FORMERID TTDI00042 T25122 UNIPROID GGT7_HUMAN T25122 TARGNAME Gamma-glutamyl transferase 7 (GGT7) T25122 GENENAME GGT7 T25122 TARGTYPE Literature-reported T25122 SYNONYMS Glutathione hydrolase 7; Gamma-glutamyltranspeptidase 7; Gamma-glutamyltransferase-like 5; Gamma-glutamyltransferase-like 3; Gamma-glutamyltransferase 7 light chain; Gamma-glutamyltransferase 7; GGTL5; GGTL3; GGT7; GGT 7 T25122 FUNCTION Involved in the pathway glutathione metabolism, which is part of Sulfur metabolism. Cleaves glutathione conjugates. Glutathione hydrolase activity. Hypoglycin A gamma-glutamyl transpeptidase activity. Leukotriene C4 gamma-glutamyl transferase activity. Peptidyltransferase activity. T25122 BIOCLASS Peptidase T25122 ECNUMBER EC 3.4.19.13 T25122 SEQUENCE MAAENEASQESALGAYSPVDYMSITSFPRLPEDEPAPAAPLRGRKDEDAFLGDPDTDPDSFLKSARLQRLPSSSSEMGSQDGSPLRETRKDPFSAAAAECSCRQDGLTVIVTACLTFATGVTVALVMQIYFGDPQIFQQGAVVTDAARCTSLGIEVLSKQGSSVDAAVAAALCLGIVAPHSSGLGGGGVMLVHDIRRNESHLIDFRESAPGALREETLQRSWETKPGLLVGVPGMVKGLHEAHQLYGRLPWSQVLAFAAAVAQDGFNVTHDLARALAEQLPPNMSERFRETFLPSGRPPLPGSLLHRPDLAEVLDVLGTSGPAAFYAGGNLTLEMVAEAQHAGGVITEEDFSNYSALVEKPVCGVYRGHLVLSPPPPHTGPALISALNILEGFNLTSLVSREQALHWVAETLKIALALASRLGDPVYDSTITESMDDMLSKVEAAYLRGHINDSQAAPAPLLPVYELDGAPTAAQVLIMGPDDFIVAMVSSLNQPFGSGLITPSGILLNSQMLDFSWPNRTANHSAPSLENSVQPGKRPLSFLLPTVVRPAEGLCGTYLALGANGAARGLSGLTQVLLNVLTLNRNLSDSLARGRLHPDLQSNLLQVDSEFTEEEIEFLEARGHHVEKVDVLSWVHGSRRTNNFIIAVKDPRSPDAAGATIL T72534 TARGETID T72534 T72534 FORMERID TTDI03585 T72534 UNIPROID TNIK_HUMAN T72534 TARGNAME TRAF2 and NCK interacting kinase (TNIK) T72534 GENENAME TNIK T72534 TARGTYPE Literature-reported T72534 SYNONYMS TRAF2 and NCK-interacting protein kinase; KIAA0551 T72534 FUNCTION Serine/threonine kinase that acts as an essential activator of the Wnt signaling pathway. Recruited to promoters of Wnt target genes and required to activate their expression. May act by phosphorylating TCF4/TCF7L2. Appears to act upstream of the JUN N-terminal pathway. May play a role in the response to environmental stress. Part of a signaling complex composed of NEDD4, RAP2A and TNIK which regulates neuronal dendrite extension and arborization during development. More generally, it may play a role in cytoskeletal rearrangements and regulate cell spreading. Phosphorylates SMAD1 on Thr-322. T72534 PDBSTRUC 5D7A; 5CWZ; 5AX9; 2X7F T72534 ECNUMBER EC 2.7.11.1 T72534 SEQUENCE MASDSPARSLDEIDLSALRDPAGIFELVELVGNGTYGQVYKGRHVKTGQLAAIKVMDVTGDEEEEIKQEINMLKKYSHHRNIATYYGAFIKKNPPGMDDQLWLVMEFCGAGSVTDLIKNTKGNTLKEEWIAYICREILRGLSHLHQHKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDFKSDLWSLGITAIEMAEGAPPLCDMHPMRALFLIPRNPAPRLKSKKWSKKFQSFIESCLVKNHSQRPATEQLMKHPFIRDQPNERQVRIQLKDHIDRTKKKRGEKDETEYEYSGSEEEEEENDSGEPSSILNLPGESTLRRDFLRLQLANKERSEALRRQQLEQQQRENEEHKRQLLAERQKRIEEQKEQRRRLEEQQRREKELRKQQEREQRRHYEEQMRREEERRRAEHEQEYIRRQLEEEQRQLEILQQQLLHEQALLLEYKRKQLEEQRQAERLQRQLKQERDYLVSLQHQRQEQRPVEKKPLYHYKEGMSPSEKPAWAKEVEERSRLNRQSSPAMPHKVANRISDPNLPPRSESFSISGVQPARTPPMLRPVDPQIPHLVAVKSQGPALTASQSVHEQPTKGLSGFQEALNVTSHRVEMPRQNSDPTSENPPLPTRIEKFDRSSWLRQEEDIPPKVPQRTTSISPALARKNSPGNGSALGPRLGSQPIRASNPDLRRTEPILESPLQRTSSGSSSSSSTPSSQPSSQGGSQPGSQAGSSERTRVRANSKSEGSPVLPHEPAKVKPEESRDITRPSRPASYKKAIDEDLTALAKELRELRIEETNRPMKKVTDYSSSSEESESSEEEEEDGESETHDGTVAVSDIPRLIPTGAPGSNEQYNVGMVGTHGLETSHADSFSGSISREGTLMIRETSGEKKRSGHSDSNGFAGHINLPDLVQQSHSPAGTPTEGLGRVSTHSQEMDSGTEYGMGSSTKASFTPFVDPRVYQTSPTDEDEEDEESSAAALFTSELLRQEQAKLNEARKISVVNVNPTNIRPHSDTPEIRKYKKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQGKVYNLINRRRFQQMDVLEGLNVLVTISGKKNKLRVYYLSWLRNRILHNDPEVEKKQGWITVGDLEGCIHYKVVKYERIKFLVIALKNAVEIYAWAPKPYHKFMAFKSFADLQHKPLLVDLTVEEGQRLKVIFGSHTGFHVIDVDSGNSYDIYIPSHIQGNITPHAIVILPKTDGMEMLVCYEDEGVYVNTYGRITKDVVLQWGEMPTSVAYIHSNQIMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVFFMTLNRNSMMNW T72534 DRUGINFO D0K0UM PMID23232060C5 Investigative T87381 TARGETID T87381 T87381 FORMERID TTDI02426 T87381 UNIPROID ADA30_HUMAN T87381 TARGNAME ADAM metallopeptidase 30 (ADAM30) T87381 GENENAME ADAM30 T87381 TARGTYPE Literature-reported T87381 SYNONYMS Disintegrin and metalloproteinase domaincontaining protein 30; ADAM30 T87381 FUNCTION May be involved in spermatogenesis and fertilization. T87381 BIOCLASS Peptidase T87381 ECNUMBER EC 3.4.24.- T87381 SEQUENCE MRSVQIFLSQCRLLLLLVPTMLLKSLGEDVIFHPEGEFDSYEVTIPEKLSFRGEVQGVVSPVSYLLQLKGKKHVLHLWPKRLLLPRHLRVFSFTEHGELLEDHPYIPKDCNYMGSVKESLDSKATISTCMGGLRGVFNIDAKHYQIEPLKASPSFEHVVYLLKKEQFGNQVCGLSDDEIEWQMAPYENKARLRDFPGSYKHPKYLELILLFDQSRYRFVNNNLSQVIHDAILLTGIMDTYFQDVRMRIHLKALEVWTDFNKIRVGYPELAEVLGRFVIYKKSVLNARLSSDWAHLYLQRKYNDALAWSFGKVCSLEYAGSVSTLLDTNILAPATWSAHELGHAVGMSHDEQYCQCRGRLNCIMGSGRTGFSNCSYISFFKHISSGATCLNNIPGLGYVLKRCGNKIVEDNEECDCGSTEECQKDRCCQSNCKLQPGANCSIGLCCHDCRFRPSGYVCRQEGNECDLAEYCDGNSSSCPNDVYKQDGTPCKYEGRCFRKGCRSRYMQCQSIFGPDAMEAPSECYDAVNLIGDQFGNCEITGIRNFKKCESANSICGRLQCINVETIPDLPEHTTIISTHLQAENLMCWGTGYHLSMKPMGIPDLGMINDGTSCGEGRVCFKKNCVNSSVLQFDCLPEKCNTRGVCNNRKNCHCMYGWAPPFCEEVGYGGSIDSGPPGLLRGAIPSSIWVVSIIMFRLILLILSVVFVFFRQVIGNHLKPKQEKMPLSKAKTEQEESKTKTVQEESKTKTGQEESEAKTGQEESKAKTGQEESKANIESKRPKAKSVKKQKK T88104 TARGETID T88104 T88104 FORMERID TTDI03136 T88104 UNIPROID CXD2_HUMAN T88104 TARGNAME Gap junction delta-2 protein (Cx36) T88104 GENENAME GJD2 T88104 TARGTYPE Literature-reported T88104 SYNONYMS GJA9; Connexin-36 T88104 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T88104 PDBSTRUC 2N6A T88104 BIOCLASS Gap junction-forming connexin T88104 SEQUENCE MGEWTILERLLEAAVQQHSTMIGRILLTVVVIFRILIVAIVGETVYDDEQTMFVCNTLQPGCNQACYDRAFPISHIRYWVFQIIMVCTPSLCFITYSVHQSAKQRERRYSTVFLALDRDPPESIGGPGGTGGGGSGGGKREDKKLQNAIVNGVLQNTENTSKETEPDCLEVKELTPHPSGLRTASKSKLRRQEGISRFYIIQVVFRNALEIGFLVGQYFLYGFSVPGLYECNRYPCIKEVECYVSRPTEKTVFLVFMFAVSGICVVLNLAELNHLGWRKIKLAVRGAQAKRKSIYEIRNKDLPRVSVPNFGRTQSSDSAYV T88104 DRUGINFO D00VJY octanol Investigative T65005 TARGETID T65005 T65005 FORMERID TTDI03256 T65005 UNIPROID HCN2_HUMAN T65005 TARGNAME Hyperpolarization cyclic nucleotide-gated channel 2 (HCN2) T65005 GENENAME HCN2 T65005 TARGTYPE Literature-reported T65005 SYNONYMS Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2; Brain cyclic nucleotide-gated channel 2; BCNG2; BCNG-2 T65005 FUNCTION Contributes to the native pacemaker currents in heart (If) and in neurons (Ih). Can also transport ammonium in the distal nephron. Produces a large instantaneous current. Modulated by intracellular chloride ions and pH; acidic pH shifts the activation to more negative voltages. Hyperpolarization-activated ion channel exhibiting weak selectivity for potassium over sodium ions. T65005 PDBSTRUC 3U10; 2MPF T65005 BIOCLASS Voltage-gated ion channel T65005 SEQUENCE MDARGGGGRPGESPGATPAPGPPPPPPPAPPQQQPPPPPPPAPPPGPGPAPPQHPPRAEALPPEAADEGGPRGRLRSRDSSCGRPGTPGAASTAKGSPNGECGRGEPQCSPAGPEGPARGPKVSFSCRGAASGPAPGPGPAEEAGSEEAGPAGEPRGSQASFMQRQFGALLQPGVNKFSLRMFGSQKAVEREQERVKSAGAWIIHPYSDFRFYWDFTMLLFMVGNLIIIPVGITFFKDETTAPWIVFNVVSDTFFLMDLVLNFRTGIVIEDNTEIILDPEKIKKKYLRTWFVVDFVSSIPVDYIFLIVEKGIDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVMRICNLISMMLLLCHWDGCLQFLVPMLQDFPRNCWVSINGMVNHSWSELYSFALFKAMSHMLCIGYGRQAPESMTDIWLTMLSMIVGATCYAMFIGHATALIQSLDSSRRQYQEKYKQVEQYMSFHKLPADFRQKIHDYYEHRYQGKMFDEDSILGELNGPLREEIVNFNCRKLVASMPLFANADPNFVTAMLTKLKFEVFQPGDYIIREGTIGKKMYFIQHGVVSVLTKGNKEMKLSDGSYFGEICLLTRGRRTASVRADTYCRLYSLSVDNFNEVLEEYPMMRRAFETVAIDRLDRIGKKNSILLHKVQHDLNSGVFNNQENAIIQEIVKYDREMVQQAELGQRVGLFPPPPPPPQVTSAIATLQQAAAMSFCPQVARPLVGPLALGSPRLVRRPPPGPAPAAASPGPPPPASPPGAPASPRAPRTSPYGGLPAAPLAGPALPARRLSRASRPLSASQPSLPHGAPGPAASTRPASSSTPRLGPTPAARAAAPSPDRRDSASPGAAGGLDPQDSARSRLSSNL T65005 DRUGINFO D0T8LP cyclic CMP Investigative T65005 DRUGINFO D07ZAJ PIP2 Investigative T92966 TARGETID T92966 T92966 UNIPROID TPX2_HUMAN T92966 TARGNAME Hepatocellular carcinoma-associated antigen 90 (TPX2) T92966 GENENAME TPX2 T92966 TARGTYPE Literature-reported T92966 SYNONYMS Restricted expression proliferation-associated protein 100; Protein fls353; Hepatocellular carcinoma-associated antigen 519; HCA519; Differentially expressed in cancerous and non-cancerous lung cells 2; DIL2; DIL-2; C20orf2; C20orf1 T92966 FUNCTION Spindle assembly factor required for normal assembly of mitotic spindles. Required for normal assembly of microtubules during apoptosis. Required for chromatin and/or kinetochore dependent microtubule nucleation. Mediates AURKA localization to spindle microtubules (PubMed:18663142, PubMed:19208764). Activates AURKA by promoting its autophosphorylation at 'Thr-288' and protects this residue against dephosphorylation (PubMed:18663142, PubMed:19208764). TPX2 is inactivated upon binding to importin-alpha (PubMed:26165940). At the onset of mitosis, GOLGA2 interacts with importin-alpha, liberating TPX2 from importin-alpha, allowing TPX2 to activates AURKA kinase and stimulates local microtubule nucleation (PubMed:26165940). T92966 PDBSTRUC 6BJC; 5LXM; 4C3P; 3HA6; 3E5A T92966 BIOCLASS TPX2 family T92966 SEQUENCE MSQVKSSYSYDAPSDFINFSSLDDEGDTQNIDSWFEEKANLENKLLGKNGTGGLFQGKTPLRKANLQQAIVTPLKPVDNTYYKEAEKENLVEQSIPSNACSSLEVEAAISRKTPAQPQRRSLRLSAQKDLEQKEKHHVKMKAKRCATPVIIDEILPSKKMKVSNNKKKPEEEGSAHQDTAEKNASSPEKAKGRHTVPCMPPAKQKFLKSTEEQELEKSMKMQQEVVEMRKKNEEFKKLALAGIGQPVKKSVSQVTKSVDFHFRTDERIKQHPKNQEEYKEVNFTSELRKHPSSPARVTKGCTIVKPFNLSQGKKRTFDETVSTYVPLAQQVEDFHKRTPNRYHLRSKKDDINLLPSKSSVTKICRDPQTPVLQTKHRARAVTCKSTAELEAEELEKLQQYKFKARELDPRILEGGPILPKKPPVKPPTEPIGFDLEIEKRIQERESKKKTEDEHFEFHSRPCPTKILEDVVGVPEKKVLPITVPKSPAFALKNRIRMPTKEDEEEDEPVVIKAQPVPHYGVPFKPQIPEARTVEICPFSFDSRDKERQLQKEKKIKELQKGEVPKFKALPLPHFDTINLPEKKVKNVTQIEPFCLETDRRGALKAQTWKHQLEEELRQQKEAACFKARPNTVISQEPFVPKKEKKSVAEGLSGSLVQEPFQLATEKRAKERQELEKRMAEVEAQKAQQLEEARLQEEEQKKEELARLRRELVHKANPIRKYQGLEIKSSDQPLTVPVSPKFSTRFHC T36612 TARGETID T36612 T36612 FORMERID TTDI03454 T36612 UNIPROID PADI3_HUMAN T36612 TARGNAME Peptidyl arginine deiminase type III (PADI3) T36612 GENENAME PADI3 T36612 TARGTYPE Literature-reported T36612 SYNONYMS Protein-arginine deiminase type-3; Protein-arginine deiminase type III; Peptidylarginine deiminase III; PDI3; PAD3 T36612 FUNCTION Catalyzes the deimination of arginine residues of proteins. T36612 PDBSTRUC 6CE1 T36612 ECNUMBER EC 3.5.3.15 T36612 SEQUENCE MSLQRIVRVSLEHPTSAVCVAGVETLVDIYGSVPEGTEMFEVYGTPGVDIYISPNMERGRERADTRRWRFDATLEIIVVMNSPSNDLNDSHVQISYHSSHEPLPLAYAVLYLTCVDISLDCDLNCEGRQDRNFVDKRQWVWGPSGYGGILLVNCDRDDPSCDVQDNCDQHVHCLQDLEDMSVMVLRTQGPAALFDDHKLVLHTSSYDAKRAQVFHICGPEDVCEAYRHVLGQDKVSYEVPRLHGDEERFFVEGLSFPDAGFTGLISFHVTLLDDSNEDFSASPIFTDTVVFRVAPWIMTPSTLPPLEVYVCRVRNNTCFVDAVAELARKAGCKLTICPQAENRNDRWIQDEMELGYVQAPHKTLPVVFDSPRNGELQDFPYKRILGPDFGYVTREPRDRSVSGLDSFGNLEVSPPVVANGKEYPLGRILIGGNLPGSSGRRVTQVVRDFLHAQKVQPPVELFVDWLAVGHVDEFLSFVPAPDGKGFRMLLASPGACFKLFQEKQKCGHGRALLFQGVVDDEQVKTISINQVLSNKDLINYNKFVQSCIDWNREVLKRELGLAECDIIDIPQLFKTERKKATAFFPDLVNMLVLGKHLGIPKPFGPIINGCCCLEEKVRSLLEPLGLHCTFIDDFTPYHMLHGEVHCGTNVCRKPFSFKWWNMVP T36612 DRUGINFO D01FNC PMID24440480C3 Investigative T36612 DRUGINFO D02ZNQ streptonigrin Investigative T36612 DRUGINFO D0C4DE PMID25742366C14b Investigative T36612 DRUGINFO D0YP0A Cl-amidine Investigative T55616 TARGETID T55616 T55616 FORMERID TTDR00072 T55616 UNIPROID MMP17_HUMAN T55616 TARGNAME Matrix metalloproteinase-17 (MMP17) T55616 GENENAME MMP17 T55616 TARGTYPE Literature-reported T55616 SYNONYMS Membrane-type-4 matrix metalloproteinase; Membrane-type matrix metalloproteinase 4; MTMMP4; MT4MMP; MT4-MMP; MT-MMP 4; MMP-17 T55616 FUNCTION Endopeptidase that degrades various components of the extracellular matrix, such as fibrin. May be involved in the activation of membrane-bound precursors of growth factors or inflammatory mediators, such as tumor necrosis factor-alpha. May also be involved in tumoral process. Cleaves pro-TNF-alpha at the '74-Ala-|-Gln-75' site. Not obvious if able to proteolytically activate progelatinase A. Does not hydrolyze collagen types I, II, III, IV and V, gelatin, fibronectin, laminin, decorin nor alpha1-antitrypsin. T55616 BIOCLASS Peptidase T55616 ECNUMBER EC 3.4.24.- T55616 SEQUENCE MRRRAARGPGPPPPGPGLSRLPLPLLLLLALGTRGGCAAPAPAPRAEDLSLGVEWLSRFGYLPPADPTTGQLQTQEELSKAITAMQQFGGLEATGILDEATLALMKTPRCSLPDLPVLTQARRRRQAPAPTKWNKRNLSWRVRTFPRDSPLGHDTVRALMYYALKVWSDIAPLNFHEVAGSAADIQIDFSKADHNDGYPFDGPGGTVAHAFFPGHHHTAGDTHFDDDEAWTFRSSDAHGMDLFAVAVHEFGHAIGLSHVAAAHSIMRPYYQGPVGDPLRYGLPYEDKVRVWQLYGVRESVSPTAQPEEPPLLPEPPDNRSSAPPRKDVPHRCSTHFDAVAQIRGEAFFFKGKYFWRLTRDRHLVSLQPAQMHRFWRGLPLHLDSVDAVYERTSDHKIVFFKGDRYWVFKDNNVEEGYPRPVSDFSLPPGGIDAAFSWAHNDRTYFFKDQLYWRYDDHTRHMDPGYPAQSPLWRGVPSTLDDAMRWSDGASYFFRGQEYWKVLDGELEVAPGYPQSTARDWLVCGDSQADGSVAAGVDAAEGPRAPPGQHDQSRSEDGYEVCSCTSGASSPPGAPGPLVAATMLLLLPPLSPGALWTAAQALTL T91113 TARGETID T91113 T91113 FORMERID TTDNR00660 T91113 UNIPROID PA24C_HUMAN T91113 TARGNAME Phospholipase A2 group IVC (PLA2G4C) T91113 GENENAME PLA2G4C T91113 TARGTYPE Literature-reported T91113 SYNONYMS cPLA2-gamma; PLA2G4C T91113 FUNCTION Has a preference for arachidonic acid at the sn-2 position of phosphatidylcholine as compared with palmitic acid. T91113 BIOCLASS Carboxylic ester hydrolase T91113 ECNUMBER EC 3.1.1.4 T91113 SEQUENCE MGSSEVSIIPGLQKEEKAAVERRRLHVLKALKKLRIEADEAPVVAVLGSGGGLRAHIACLGVLSEMKEQGLLDAVTYLAGVSGSTWAISSLYTNDGDMEALEADLKHRFTRQEWDLAKSLQKTIQAARSENYSLTDFWAYMVISKQTRELPESHLSNMKKPVEEGTLPYPIFAAIDNDLQPSWQEARAPETWFEFTPHHAGFSALGAFVSITHFGSKFKKGRLVRTHPERDLTFLRGLWGSALGNTEVIREYIFDQLRNLTLKGLWRRAVANAKSIGHLIFARLLRLQESSQGEHPPPEDEGGEPEHTWLTEMLENWTRTSLEKQEQPHEDPERKGSLSNLMDFVKKTGICASKWEWGTTHNFLYKHGGIRDKIMSSRKHLHLVDAGLAINTPFPLVLPPTREVHLILSFDFSAGDPFETIRATTDYCRRHKIPFPQVEEAELDLWSKAPASCYILKGETGPVVMHFPLFNIDACGGDIEAWSDTYDTFKLADTYTLDVVVLLLALAKKNVRENKKKILRELMNVAGLYYPKDSARSCCLA T92105 TARGETID T92105 T92105 UNIPROID RNF6_HUMAN T92105 TARGNAME E3 ubiquitin-protein ligase RNF6 (RNF6) T92105 GENENAME RNF6 T92105 TARGTYPE Literature-reported T92105 SYNONYMS SPG2; RING-type E3 ubiquitin transferase RNF6 T92105 FUNCTION E3 ubiquitin-protein ligase mediating 'Lys-48'-linked polyubiquitination of LIMK1 and its subsequent targeting to the proteasome for degradation. Negatively regulates axonal outgrowth through regulation of the LIMK1 turnover. Mediates 'Lys-6' and 'Lys-27'-linked polyubiquitination of AR/androgen receptor thereby modulating its transcriptional activity. May also bind DNA and function as a transcriptional regulator. T92105 BIOCLASS RNF12 family T92105 ECNUMBER EC 2.3.2.27 T92105 SEQUENCE MNQSRSRSDGGSEETLPQDHNHHENERRWQQERLHREEAYYQFINELNDEDYRLMRDHNLLGTPGEITSEELQQRLDGVKEQLASQPDLRDGTNYRDSEVPRESSHEDSLLEWLNTFRRTGNATRSGQNGNQTWRAVSRTNPNNGEFRFSLEIHVNHENRGFEIHGEDYTDIPLSDSNRDHTANRQQRSTSPVARRTRSQTSVNFNGSSSNIPRTRLASRGQNPAEGSFSTLGRLRNGIGGAAGIPRANASRTNFSSHTNQSGGSELRQREGQRFGAAHVWENGARSNVTVRNTNQRLEPIRLRSTSNSRSRSPIQRQSGTVYHNSQRESRPVQQTTRRSVRRRGRTRVFLEQDRERERRGTAYTPFSNSRLVSRITVEEGEESSRSSTAVRRHPTITLDLQVRRIRPGENRDRDSIANRTRSRVGLAENTVTIESNSGGFRRTISRLERSGIRTYVSTITVPLRRISENELVEPSSVALRSILRQIMTGFGELSSLMEADSESELQRNGQHLPDMHSELSNLGTDNNRSQHREGSSQDRQAQGDSTEMHGENETTQPHTRNSDSRGGRQLRNPNNLVETGTLPILRLAHFFLLNESDDDDRIRGLTKEQIDNLSTRHYEHNSIDSELGKICSVCISDYVTGNKLRQLPCMHEFHIHCIDRWLSENCTCPICRQPVLGSNIANNG T70332 TARGETID T70332 T70332 FORMERID TTDR00646 T70332 UNIPROID RXLT1_HUMAN T70332 TARGNAME Beta-1,2-xylosyltransferase (RXYLT1) T70332 GENENAME XYLT T70332 TARGTYPE Literature-reported T70332 SYNONYMS XYLT; Beta-(1,2)-xylosyltransferase T70332 FUNCTION Catalyzes beta-1,2 glycosidic linkages. T70332 BIOCLASS Pentosyltransferase T70332 ECNUMBER EC 2.4.2.- T70332 SEQUENCE MRLTRKRLCSFLIALYCLFSLYAAYHVFFGRRRQAPAGSPRGLRKGAAPARERRGREQSTLESEEWNPWEGDEKNEQQHRFKTSLQILDKSTKGKTDLSVQIWGKAAIGLYLWEHIFEGLLDPSDVTAQWREGKSIVGRTQYSFITGPAVIPGYFSVDVNNVVLILNGREKAKIFYATQWLLYAQNLVQIQKLQHLAVVLLGNEHCDNEWINPFLKRNGGFVELLFIIYDSPWINDVDVFQWPLGVATYRNFPVVEASWSMLHDERPYLCNFLGTIYENSSRQALMNILKKDGNDKLCWVSAREHWQPQETNESLKNYQDALLQSDLTLCPVGVNTECYRIYEACSYGSIPVVEDVMTAGNCGNTSVHHGAPLQLLKSMGAPFIFIKNWKELPAVLEKEKTIILQEKIERRKMLLQWYQHFKTELKMKFTNILESSFLMNNKS T27747 TARGETID T27747 T27747 FORMERID TTDR00597 T27747 UNIPROID PIGL_HUMAN T27747 TARGNAME N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase (PIGL) T27747 GENENAME PIGL T27747 TARGTYPE Literature-reported T27747 SYNONYMS Phosphatidylinositol-glycan biosynthesis, class L protein; PIGL; PIG-L; GlcNAc-PI de-N-acetylase T27747 FUNCTION Involved in thesecond step of GPI biosynthesis. De-N- acetylation of N-acetylglucosaminyl-phosphatidylinositol. T27747 BIOCLASS Carbon-nitrogen hydrolase T27747 ECNUMBER EC 3.5.1.89 T27747 SEQUENCE MEAMWLLCVALAVLAWGFLWVWDSSERMKSREQGGRLGAESRTLLVIAHPDDEAMFFAPTVLGLARLRHWVYLLCFSAGNYYNQGETRKKELLQSCDVLGIPLSSVMIIDNRDFPDDPGMQWDTEHVARVLLQHIEVNGINLVVTFDAGGVSGHSNHIALYAAVRALHSEGKLPKGCSVLTLQSVNVLRKYISLLDLPLSLLHTQDVLFVLNSKEVAQAKKAMSCHRSQLLWFRRLYIIFSRYMRINSLSFL T71949 TARGETID T71949 T71949 FORMERID TTDI03360 T71949 UNIPROID KDM2A_HUMAN T71949 TARGNAME Lysine-specific demethylase 2A (KDM2A) T71949 GENENAME KDM2A T71949 TARGTYPE Literature-reported T71949 SYNONYMS FBXL11; FBL7; F-box/LRR-repeat protein 11; F-box protein Lilina; F-box protein FBL7; F-box and leucine-rich repeat protein 11; CXXC8; CXXC-type zinc finger protein 8; [Histone-H3]-lysine-36 demethylase 1A; KIAA1004; JmjC domain-containing histone demethylation protein 1A; JHDM1A T71949 FUNCTION Histone demethylase that specifically demethylates 'Lys-36' of histone H3, thereby playing a central role in histone code. Preferentially demethylates dimethylated H3 'Lys-36' residue while it has weak or no activity for mono- and tri-methylated H3 'Lys-36'. May also recognize and bind to some phosphorylated proteins and promote their ubiquitination and degradation. Required to maintain the heterochromatic state. Associates with centromeres and represses transcription of small non-coding RNAs that are encoded by the clusters of satellite repeats at the centromere. Required to sustain centromeric integrity and genomic stability, particularly during mitosis. Regulates circadian gene expression by repressing the transcriptional activator activity of CLOCK-ARNTL/BMAL1 heterodimer and RORA in a catalytically-independent manner. T71949 PDBSTRUC 6C16; 6BYH; 4BBQ; 2YU2; 2YU1 T71949 ECNUMBER EC 1.14.11.27 T71949 SEQUENCE MEPEEERIRYSQRLRGTMRRRYEDDGISDDEIEGKRTFDLEEKLHTNKYNANFVTFMEGKDFNVEYIQRGGLRDPLIFKNSDGLGIKMPDPDFTVNDVKMCVGSRRMVDVMDVNTQKGIEMTMAQWTRYYETPEEEREKLYNVISLEFSHTRLENMVQRPSTVDFIDWVDNMWPRHLKESQTESTNAILEMQYPKVQKYCLMSVRGCYTDFHVDFGGTSVWYHIHQGGKVFWLIPPTAHNLELYENWLLSGKQGDIFLGDRVSDCQRIELKQGYTFVIPSGWIHAVYTPTDTLVFGGNFLHSFNIPMQLKIYNIEDRTRVPNKFRYPFYYEMCWYVLERYVYCITNRSHLTKEFQKESLSMDLELNGLESGNGDEEAVDREPRRLSSRRSVLTSPVANGVNLDYDGLGKTCRSLPSLKKTLAGDSSSDCSRGSHNGQVWDPQCAPRKDRQVHLTHFELEGLRCLVDKLESLPLHKKCVPTGIEDEDALIADVKILLEELANSDPKLALTGVPIVQWPKRDKLKFPTRPKVRVPTIPITKPHTMKPAPRLTPVRPAAASPIVSGARRRRVRCRKCKACVQGECGVCHYCRDMKKFGGPGRMKQSCVLRQCLAPRLPHSVTCSLCGEVDQNEETQDFEKKLMECCICNEIVHPGCLQMDGEGLLNEELPNCWECPKCYQEDSSEKAQKRKMEESDEEAVQAKVLRPLRSCDEPLTPPPHSPTSMLQLIHDPVSPRGMVTRSSPGAGPSDHHSASRDERFKRRQLLRLQATERTMVREKENNPSGKKELSEVEKAKIRGSYLTVTLQRPTKELHGTSIVPKLQAITASSANLRHSPRVLVQHCPARTPQRGDEEGLGGEEEEEEEEEEEDDSAEEGGAARLNGRGSWAQDGDESWMQREVWMSVFRYLSRRELCECMRVCKTWYKWCCDKRLWTKIDLSRCKAIVPQALSGIIKRQPVSLDLSWTNISKKQLTWLVNRLPGLKDLLLAGCSWSAVSALSTSSCPLLRTLDLRWAVGIKDPQIRDLLTPPADKPGQDNRSKLRNMTDFRLAGLDITDATLRLIIRHMPLLSRLDLSHCSHLTDQSSNLLTAVGSSTRYSLTELNMAGCNKLTDQTLIYLRRIANVTLIDLRGCKQITRKACEHFISDLSINSLYCLSDEKLIQKIS T71949 DRUGINFO D0B2WZ daminozide Investigative T71949 DRUGINFO D0WA3E IOX2 Investigative T58937 TARGETID T58937 T58937 FORMERID TTDI02367 T58937 UNIPROID SC6A5_HUMAN T58937 TARGNAME Glycine transporter-2 (SLC6A5) T58937 GENENAME SLC6A5 T58937 TARGTYPE Literature-reported T58937 SYNONYMS Solute carrier family 6 member 5; Sodium-and chloride-dependent glycine transporter 2; SLC6A5; GlyT2; GlyT-2 T58937 FUNCTION Terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. May be responsible for the termination of neurotransmission at strychnine-sensitive glycinergic synapses. T58937 BIOCLASS Neurotransmitter:sodium symporter T58937 SEQUENCE MDCSAPKEMNKLPANSPEAAAAQGHPDGPCAPRTSPEQELPAAAAPPPPRVPRSASTGAQTFQSADARACEAERPGVGSCKLSSPRAQAASAALRDLREAQGAQASPPPGSSGPGNALHCKIPFLRGPEGDANVSVGKGTLERNNTPVVGWVNMSQSTVVLATDGITSVLPGSVATVATQEDEQGDENKARGNWSSKLDFILSMVGYAVGLGNVWRFPYLAFQNGGGAFLIPYLMMLALAGLPIFFLEVSLGQFASQGPVSVWKAIPALQGCGIAMLIISVLIAIYYNVIICYTLFYLFASFVSVLPWGSCNNPWNTPECKDKTKLLLDSCVISDHPKIQIKNSTFCMTAYPNVTMVNFTSQANKTFVSGSEEYFKYFVLKISAGIEYPGEIRWPLALCLFLAWVIVYASLAKGIKTSGKVVYFTATFPYVVLVILLIRGVTLPGAGAGIWYFITPKWEKLTDATVWKDAATQIFFSLSAAWGGLITLSSYNKFHNNCYRDTLIVTCTNSATSIFAGFVIFSVIGFMANERKVNIENVADQGPGIAFVVYPEALTRLPLSPFWAIIFFLMLLTLGLDTMFATIETIVTSISDEFPKYLRTHKPVFTLGCCICFFIMGFPMITQGGIYMFQLVDTYAASYALVIIAIFELVGISYVYGLQRFCEDIEMMIGFQPNIFWKVCWAFVTPTILTFILCFSFYQWEPMTYGSYRYPNWSMVLGWLMLACSVIWIPIMFVIKMHLAPGRFIERLKLVCSPQPDWGPFLAQHRGERYKNMIDPLGTSSLGLKLPVKDLELGTQC T58937 DRUGINFO D0E1OC ALX 1393 Investigative T93177 TARGETID T93177 T93177 UNIPROID STRAP_HUMAN T93177 TARGNAME UNR-interacting protein (STRAP) T93177 GENENAME STRAP T93177 TARGTYPE Literature-reported T93177 SYNONYMS WD-40 repeat protein PT-WD; UNRIP; MAWD; MAP activator with WD repeats T93177 FUNCTION The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. Thereby, plays an important role in the splicing of cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP. Dissociation by the SMN complex of CLNS1A from the trapped Sm proteins and their transfer to an SMN-Sm complex triggers the assembly of core snRNPs and their transport to the nucleus. STRAP plays a role in the cellular distribution of the SMN complex. Negatively regulates TGF-beta signaling but positively regulates the PDPK1 kinase activity by enhancing its autophosphorylation and by significantly reducing the association of PDPK1 with 14-3-3 protein. T93177 BIOCLASS WD repeat STRAP family T93177 SEQUENCE MAMRQTPLTCSGHTRPVVDLAFSGITPYGYFLISACKDGKPMLRQGDTGDWIGTFLGHKGAVWGATLNKDATKAATAAADFTAKVWDAVSGDELMTLAHKHIVKTVDFTQDSNYLLTGGQDKLLRIYDLNKPEAEPKEISGHTSGIKKALWCSEDKQILSADDKTVRLWDHATMTEVKSLNFNMSVSSMEYIPEGEILVITYGRSIAFHSAVSLDPIKSFEAPATINSASLHPEKEFLVAGGEDFKLYKYDYNSGEELESYKGHFGPIHCVRFSPDGELYASGSEDGTLRLWQTVVGKTYGLWKCVLPEEDSGELAKPKIGFPETTEEELEEIASENSDCIFPSAPDVKA T30286 TARGETID T30286 T30286 FORMERID TTDI03258 T30286 UNIPROID HCN4_HUMAN T30286 TARGNAME Hyperpolarization cyclic nucleotide-gated channel 4 (HCN4) T30286 GENENAME HCN4 T30286 TARGTYPE Literature-reported T30286 SYNONYMS Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 T30286 FUNCTION Contributes to the native pacemaker currents in heart (If) that regulate the rhythm of heart beat. May contribute to the native pacemaker currents in neurons (Ih). May mediate responses to sour stimuli. Hyperpolarization-activated ion channel with very slow activation and inactivation exhibiting weak selectivity for potassium over sodium ions. T30286 PDBSTRUC 6GYO; 6GYN; 4NVP; 4KL1; 4HBN T30286 BIOCLASS Voltage-gated ion channel T30286 SEQUENCE MDKLPPSMRKRLYSLPQQVGAKAWIMDEEEDAEEEGAGGRQDPSRRSIRLRPLPSPSPSAAAGGTESRSSALGAADSEGPARGAGKSSTNGDCRRFRGSLASLGSRGGGSGGTGSGSSHGHLHDSAEERRLIAEGDASPGEDRTPPGLAAEPERPGASAQPAASPPPPQQPPQPASASCEQPSVDTAIKVEGGAAAGDQILPEAEVRLGQAGFMQRQFGAMLQPGVNKFSLRMFGSQKAVEREQERVKSAGFWIIHPYSDFRFYWDLTMLLLMVGNLIIIPVGITFFKDENTTPWIVFNVVSDTFFLIDLVLNFRTGIVVEDNTEIILDPQRIKMKYLKSWFMVDFISSIPVDYIFLIVETRIDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIVNLIGMMLLLCHWDGCLQFLVPMLQDFPDDCWVSINNMVNNSWGKQYSYALFKAMSHMLCIGYGRQAPVGMSDVWLTMLSMIVGATCYAMFIGHATALIQSLDSSRRQYQEKYKQVEQYMSFHKLPPDTRQRIHDYYEHRYQGKMFDEESILGELSEPLREEIINFNCRKLVASMPLFANADPNFVTSMLTKLRFEVFQPGDYIIREGTIGKKMYFIQHGVVSVLTKGNKETKLADGSYFGEICLLTRGRRTASVRADTYCRLYSLSVDNFNEVLEEYPMMRRAFETVALDRLDRIGKKNSILLHKVQHDLNSGVFNYQENEIIQQIVQHDREMAHCAHRVQAAASATPTPTPVIWTPLIQAPLQAAAATTSVAIALTHHPRLPAAIFRPPPGSGLGNLGAGQTPRHLKRLQSLIPSALGSASPASSPSQVDTPSSSSFHIQQLAGFSAPAGLSPLLPSSSSSPPPGACGSPSAPTPSAGVAATTIAGFGHFHKALGGSLSSSDSPLLTPLQPGARSPQAAQPSPAPPGARGGLGLPEHFLPPPPSSRSPSSSPGQLGQPPGELSLGLATGPLSTPETPPRQPEPPSLVAGASGGASPVGFTPRGGLSPPGHSPGPPRTFPSAPPRASGSHGSLLLPPASSPPPPQVPQRRGTPPLTPGRLTQDLKLISASQPALPQDGAQTLRRASPHSSGESMAAFPLFPRAGGGSGGSGSSGGLGPPGRPYGAIPGQHVTLPRKTSSGSLPPPLSLFGARATSSGGPPLTAGPQREPGARPEPVRSKLPSNL T30286 DRUGINFO D0W5XD EC18 Investigative T25362 TARGETID T25362 T25362 FORMERID TTDI03361 T25362 UNIPROID KDM3A_HUMAN T25362 TARGNAME Lysine-specific demethylase 3A (KDM3A) T25362 GENENAME KDM3A T25362 TARGTYPE Literature-reported T25362 SYNONYMS TSGA; KIAA0742; Jumonji domain-containing protein 1A; JmjC domain-containing histone demethylation protein 2A; JMJD1A; JMJD1; JHDM2A T25362 FUNCTION Preferentially demethylates mono- and dimethylated H3 'Lys-9' residue, with a preference for dimethylated residue, while it has weak or no activity on trimethylated H3 'Lys-9'. Demethylation of Lys residue generates formaldehyde and succinate. Involved in hormone-dependent transcriptional activation, by participating in recruitment to androgen-receptor target genes, resulting in H3 'Lys-9' demethylation and transcriptional activation. Involved in spermatogenesis by regulating expression of target genes such as PRM1 and TNP1 which are required for packaging and condensation of sperm chromatin. Involved in obesity resistance through regulation of metabolic genes such as PPARA and UCP1. Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code. T25362 BIOCLASS Paired donor oxygen oxidoreductase T25362 ECNUMBER EC 1.14.11.- T25362 SEQUENCE MVLTLGESWPVLVGRRFLSLSAADGSDGSHDSWDVERVAEWPWLSGTIRAVSHTDVTKKDLKVCVEFDGESWRKRRWIEVYSLLRRAFLVEHNLVLAERKSPEISERIVQWPAITYKPLLDKAGLGSITSVRFLGDQQRVFLSKDLLKPIQDVNSLRLSLTDNQIVSKEFQALIVKHLDESHLLKGDKNLVGSEVKIYSLDPSTQWFSATVINGNPASKTLQVNCEEIPALKIVDPSLIHVEVVHDNLVTCGNSARIGAVKRKSSENNGTLVSKQAKSCSEASPSMCPVQSVPTTVFKEILLGCTAATPPSKDPRQQSTPQAANSPPNLGAKIPQGCHKQSLPEEISSCLNTKSEALRTKPDVCKAGLLSKSSQIGTGDLKILTEPKGSCTQPKTNTDQENRLESVPQALTGLPKECLPTKASSKAELEIANPPELQKHLEHAPSPSDVSNAPEVKAGVNSDSPNNCSGKKVEPSALACRSQNLKESSVKVDNESCCSRSNNKIQNAPSRKSVLTDPAKLKKLQQSGEAFVQDDSCVNIVAQLPKCRECRLDSLRKDKEQQKDSPVFCRFFHFRRLQFNKHGVLRVEGFLTPNKYDNEAIGLWLPLTKNVVGIDLDTAKYILANIGDHFCQMVISEKEAMSTIEPHRQVAWKRAVKGVREMCDVCDTTIFNLHWVCPRCGFGVCVDCYRMKRKNCQQGAAYKTFSWLKCVKSQIHEPENLMPTQIIPGKALYDVGDIVHSVRAKWGIKANCPCSNRQFKLFSKPASKEDLKQTSLAGEKPTLGAVLQQNPSVLEPAAVGGEAASKPAGSMKPACPASTSPLNWLADLTSGNVNKENKEKQPTMPILKNEIKCLPPLPPLSKSSTVLHTFNSTILTPVSNNNSGFLRNLLNSSTGKTENGLKNTPKILDDIFASLVQNKTTSDLSKRPQGLTIKPSILGFDTPHYWLCDNRLLCLQDPNNKSNWNVFRECWKQGQPVMVSGVHHKLNSELWKPESFRKEFGEQEVDLVNCRTNEIITGATVGDFWDGFEDVPNRLKNEKEPMVLKLKDWPPGEDFRDMMPSRFDDLMANIPLPEYTRRDGKLNLASRLPNYFVRPDLGPKMYNAYGLITPEDRKYGTTNLHLDVSDAANVMVYVGIPKGQCEQEEEVLKTIQDGDSDELTIKRFIEGKEKPGALWHIYAAKDTEKIREFLKKVSEEQGQENPADHDPIHDQSWYLDRSLRKRLHQEYGVQGWAIVQFLGDVVFIPAGAPHQVHNLYSCIKVAEDFVSPEHVKHCFWLTQEFRYLSQTHTNHEDKLQVKNVIYHAVKDAVAMLKASESSFGKP T25362 DRUGINFO D0X5US IOX1 Investigative T82267 TARGETID T82267 T82267 FORMERID TTDI03602 T82267 UNIPROID TRPV2_HUMAN T82267 TARGNAME Transient receptor potential cation channel V2 (TRPV2) T82267 GENENAME TRPV2 T82267 TARGTYPE Literature-reported T82267 SYNONYMS Vanilloid receptor-like protein 1; VRL-1; VRL; TrpV2; Transient receptor potential cation channel subfamily V member 2; Osm-9-like TRP channel 2; OTRPC2 T82267 FUNCTION Calcium-permeable, non-selective cation channel with an outward rectification. Seems to be regulated, at least in part, by IGF-I, PDGF and neuropeptide head activator. May transduce physical stimuli in mast cells. Activated by temperatures higher than 52 degrees Celsius; is not activated by vanilloids and acidic pH. T82267 PDBSTRUC 2F37 T82267 BIOCLASS Transient receptor potential catioin channel T82267 SEQUENCE MTSPSSSPVFRLETLDGGQEDGSEADRGKLDFGSGLPPMESQFQGEDRKFAPQIRVNLNYRKGTGASQPDPNRFDRDRLFNAVSRGVPEDLAGLPEYLSKTSKYLTDSEYTEGSTGKTCLMKAVLNLKDGVNACILPLLQIDRDSGNPQPLVNAQCTDDYYRGHSALHIAIEKRSLQCVKLLVENGANVHARACGRFFQKGQGTCFYFGELPLSLAACTKQWDVVSYLLENPHQPASLQATDSQGNTVLHALVMISDNSAENIALVTSMYDGLLQAGARLCPTVQLEDIRNLQDLTPLKLAAKEGKIEIFRHILQREFSGLSHLSRKFTEWCYGPVRVSLYDLASVDSCEENSVLEIIAFHCKSPHRHRMVVLEPLNKLLQAKWDLLIPKFFLNFLCNLIYMFIFTAVAYHQPTLKKQAAPHLKAEVGNSMLLTGHILILLGGIYLLVGQLWYFWRRHVFIWISFIDSYFEILFLFQALLTVVSQVLCFLAIEWYLPLLVSALVLGWLNLLYYTRGFQHTGIYSVMIQKVILRDLLRFLLIYLVFLFGFAVALVSLSQEAWRPEAPTGPNATESVQPMEGQEDEGNGAQYRGILEASLELFKFTIGMGELAFQEQLHFRGMVLLLLLAYVLLTYILLLNMLIALMSETVNSVATDSWSIWKLQKAISVLEMENGYWWCRKKQRAGVMLTVGTKPDGSPDERWCFRVEEVNWASWEQTLPTLCEDPSGAGVPRTLENPVLASPPKEDEDGASEENYVPVQLLQSN T82267 DRUGINFO D0B3AR TRIM Investigative T82267 DRUGINFO D00VWN citral Investigative T82267 DRUGINFO D0U5LL cannabinol Investigative T82267 DRUGINFO D03TWR diphenylboronic anhydride Investigative T82267 DRUGINFO D0KT5E lysophosphatidylcholine Investigative T82267 DRUGINFO D0M1UA lysophosphatidylinositol Investigative T82267 DRUGINFO D00HCI 2-APB Investigative T82267 DRUGINFO D06PZZ [14C]TEA Investigative T15438 TARGETID T15438 T15438 FORMERID TTDI02635 T15438 UNIPROID JAM1_HUMAN T15438 TARGNAME Junctional adhesion molecule A (F11R) T15438 GENENAME F11R T15438 TARGTYPE Literature-reported T15438 SYNONYMS Platelet adhesion molecule 1; Platelet F11 receptor; PAM-1; Junctional adhesion molecule 1; JCAM; JAM1; JAM-A; JAM-1; CD321 T15438 FUNCTION Seems to play a role in epithelial tight junction formation. Appears early in primordial forms of cell junctions and recruits PARD3. The association of the PARD6-PARD3 complex may prevent the interaction of PARD3 with JAM1, thereby preventing tight junction assembly (By similarity). Plays a role in regulating monocyte transmigration involved in integrity of epithelial barrier (By similarity). Ligand for integrin alpha-L/beta-2 involved in memory T-cell and neutrophil transmigration. Involved in platelet activation. T15438 PDBSTRUC 4ODB; 3TSZ; 3EOY; 1NBQ T15438 BIOCLASS Immunoglobulin T15438 SEQUENCE MGTKAQVERKLLCLFILAILLCSLALGSVTVHSSEPEVRIPENNPVKLSCAYSGFSSPRVEWKFDQGDTTRLVCYNNKITASYEDRVTFLPTGITFKSVTREDTGTYTCMVSEEGGNSYGEVKVKLIVLVPPSKPTVNIPSSATIGNRAVLTCSEQDGSPPSEYTWFKDGIVMPTNPKSTRAFSNSSYVLNPTTGELVFDPLSASDTGEYSCEARNGYGTPMTSNAVRMEAVERNVGVIVAAVLVTLILLGILVFGIWFAYSRGHFDRTKKGTSSKKVIYSQPSARSEGEFKQTSSFLV T29728 TARGETID T29728 T29728 FORMERID TTDI03084 T29728 UNIPROID KC1G3_HUMAN T29728 TARGNAME Casein kinase I gamma-3 (CSNK1G3) T29728 GENENAME CSNK1G3 T29728 TARGTYPE Literature-reported T29728 SYNONYMS Casein kinase I isoform gamma-3; CKI-gamma 3 T29728 FUNCTION Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate (By similarity). T29728 PDBSTRUC 6GRO; 4HGS; 4HGL; 4G17; 4G16 T29728 ECNUMBER EC 2.7.11.1 T29728 SEQUENCE MENKKKDKDKSDDRMARPSGRSGHNTRGTGSSSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEPMKSRAPQLHLEYRFYKQLGSGDGIPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFSLKTVLMIAIQLISRMEYVHSKNLIYRDVKPENFLIGRPGNKTQQVIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEALGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRATPIEVLCENFPEMATYLRYVRRLDFFEKPDYDYLRKLFTDLFDRKGYMFDYEYDWIGKQLPTPVGAVQQDPALSSNREAHQHRDKMQQSKNQSADHRAAWDSQQANPHHLRAHLAADRHGGSVQVVSSTNGELNTDDPTAGRSNAPITAPTEVEVMDETKCCCFFKRRKRKTIQRHK T29728 DRUGINFO D06UKS PMID21982499C14k Investigative T78492 TARGETID T78492 T78492 FORMERID TTDR00146 T78492 UNIPROID M3K4_HUMAN T78492 TARGNAME MAPK/ERK kinase kinase 4 (MAP3K4) T78492 GENENAME MAP3K4 T78492 TARGTYPE Literature-reported T78492 SYNONYMS Mitogen-activated protein kinase kinase kinase 4; MTK1; MEKK4; MEKK 4; MEK kinase 4; MAPKKK4; MAP three kinase 1; KIAA0213 T78492 FUNCTION Activates the CSBP2, P38 and JNK MAPK pathways, but not the ERK pathway. Specifically phosphorylates and activates MAP2K4 and MAP2K6. Component of a protein kinase signal transduction cascade. T78492 BIOCLASS Kinase T78492 ECNUMBER EC 2.7.11.25 T78492 SEQUENCE MREAAAALVPPPAFAVTPAAAMEEPPPPPPPPPPPPEPETESEPECCLAARQEGTLGDSACKSPESDLEDFSDETNTENLYGTSPPSTPRQMKRMSTKHQRNNVGRPASRSNLKEKMNAPNQPPHKDTGKTVENVEEYSYKQEKKIRAALRTTERDRKKNVQCSFMLDSVGGSLPKKSIPDVDLNKPYLSLGCSNAKLPVSVPMPIARPARQTSRTDCPADRLKFFETLRLLLKLTSVSKKKDREQRGQENTSGFWLNRSNELIWLELQAWHAGRTINDQDFFLYTARQAIPDIINEILTFKVDYGSFAFVRDRAGFNGTSVEGQCKATPGTKIVGYSTHHEHLQRQRVSFEQVKRIMELLEYIEALYPSLQALQKDYEKYAAKDFQDRVQALCLWLNITKDLNQKLRIMGTVLGIKNLSDIGWPVFEIPSPRPSKGNEPEYEGDDTEGELKELESSTDESEEEQISDPRVPEIRQPIDNSFDIQSRDCISKKLERLESEDDSLGWGAPDWSTEAGFSRHCLTSIYRPFVDKALKQMGLRKLILRLHKLMDGSLQRARIALVKNDRPVEFSEFPDPMWGSDYVQLSRTPPSSEEKCSAVSWEELKAMDLPSFEPAFLVLCRVLLNVIHECLKLRLEQRPAGEPSLLSIKQLVRECKEVLKGGLLMKQYYQFMLQEVLEDLEKPDCNIDAFEEDLHKMLMVYFDYMRSWIQMLQQLPQASHSLKNLLEEEWNFTKEITHYIRGGEAQAGKLFCDIAGMLLKSTGSFLEFGLQESCAEFWTSADDSSASDEIRRSVIEISRALKELFHEARERASKALGFAKMLRKDLEIAAEFRLSAPVRDLLDVLKSKQYVKVQIPGLENLQMFVPDTLAEEKSIILQLLNAAAGKDCSKDSDDVLIDAYLLLTKHGDRARDSEDSWGTWEAQPVKVVPQVETVDTLRSMQVDNLLLVVMQSAHLTIQRKAFQQSIEGLMTLCQEQTSSQPVIAKALQQLKNDALELCNRISNAIDRVDHMFTSEFDAEVDESESVTLQQYYREAMIQGYNFGFEYHKEVVRLMSGEFRQKIGDKYISFARKWMNYVLTKCESGRGTRPRWATQGFDFLQAIEPAFISALPEDDFLSLQALMNECIGHVIGKPHSPVTGLYLAIHRNSPRPMKVPRCHSDPPNPHLIIPTPEGFSTRSMPSDARSHGSPAAAAAAAAAAVAASRPSPSGGDSVLPKSISSAHDTRGSSVPENDRLASIAAELQFRSLSRHSSPTEERDEPAYPRGDSSGSTRRSWELRTLISQSKDTASKLGPIEAIQKSVRLFEEKRYREMRRKNIIGQVCDTPKSYDNVMHVGLRKVTFKWQRGNKIGEGQYGKVYTCISVDTGELMAMKEIRFQPNDHKTIKETADELKIFEGIKHPNLVRYFGVELHREEMYIFMEYCDEGTLEEVSRLGLQEHVIRLYSKQITIAINVLHEHGIVHRDIKGANIFLTSSGLIKLGDFGCSVKLKNNAQTMPGEVNSTLGTAAYMAPEVITRAKGEGHGRAADIWSLGCVVIEMVTGKRPWHEYEHNFQIMYKVGMGHKPPIPERLSPEGKDFLSHCLESDPKMRWTASQLLDHSFVKVCTDEE T52382 TARGETID T52382 T52382 FORMERID TTDR00927 T52382 UNIPROID LY96_HUMAN T52382 TARGNAME Lymphocyte antigen 96 (LY96) T52382 GENENAME LY96 T52382 TARGTYPE Literature-reported T52382 SYNONYMS MD-2 protein; MD-2; LY96; ESOP-1 T52382 FUNCTION Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria. Enhances TLR4-dependent activation of NF-kappa-B. Cells expressing both MD2 and TLR4, but not TLR4 alone, respond to LPS. T52382 PDBSTRUC 4G8A; 3ULA; 3FXI; 2Z65; 2.00E+59 T52382 SEQUENCE MLPFLFFSTLFSSIFTEAQKQYWVCNSSDASISYTYCDKMQYPISINVNPCIELKRSKGLLHIFYIPRRDLKQLYFNLYITVNTMNLPKRKEVICRGSDDDYSFCRALKGETVNTTISFSFKGIKFSKGKYKCVVEAISGSPEEMLFCLEFVILHQPNSN T52382 DRUGINFO D0A0GD 3-Hydroxy-Myristic Acid Investigative T52382 DRUGINFO D0N0UC Lauric Acid Investigative T52382 DRUGINFO D08OBF MYRISTIC ACID Investigative T69986 TARGETID T69986 T69986 FORMERID TTDR00066 T69986 UNIPROID W8U2K6_STAAU T69986 TARGNAME Staphylococcus Replicative DNA helicase (Stap-coc dnaC) T69986 GENENAME Stap-coc dnaC T69986 TARGTYPE Literature-reported T69986 SYNONYMS Replicative DNA helicase T69986 FUNCTION Participates in initiation and elongation during chromosome replication; it exhibits DNA-dependent ATPase activity. T69986 BIOCLASS Acid anhydride hydrolase T69986 ECNUMBER EC 3.6.4.12 T69986 SEQUENCE MDRMYEQNQMPHNNEAEQSVLGSIIIDPELINTTQEVLLPESFYRGAHQHIFRAMMHLNEDNKEIDVVTLMDQLSTEGTLNEAGGPQYLAELSTNVPTTRNVQYYTDIVSKHALKRRLIQTADSIANDGYNDELELDAILSDAERRILELSSSRESDGFKDIRDVLGQVYETAEELDQNSGQTPGIPTGYRDLDQMTAGFNRNDLIILAARPSVGKTAFALNIAQKVATHEDMYTVGIFSLEMGADQLATRMICSSGNVDSNRLRTGTMTEEDWSRFTIAVGKLSRTKIFIDDTPGIRINDLRSKCRRLKQEHGLDMIVIDYLQLIQGSGSRASDNRQQEVSEISRTLKALARELECPVIALSQLSRGVEQRQDKRPMMSDIRESGSIEQDADIVAFLYRDDYYNRGGDEDDDDDGGFEPQTNDENGEIEIIIAKQRNGPTGTVKLHFMKQYNKFTDIDYAHADMM T28343 TARGETID T28343 T28343 FORMERID TTDR01341 T28343 UNIPROID E2F3_HUMAN T28343 TARGNAME E2F3 messenger RNA (E2F3 mRNA) T28343 GENENAME E2F3 T28343 TARGTYPE Literature-reported T28343 SYNONYMS Transcription factor E2F3 (mRNA); KIAA0075 (mRNA); E2F-3 (mRNA) T28343 FUNCTION The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F3 binds specifically to RB1 in a cell-cycle dependent manner. Inhibits adipogenesis, probably through the repression of CEBPA binding to its target gene promoters. Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. T28343 BIOCLASS mRNA target T28343 SEQUENCE MRKGIQPALEQYLVTAGGGEGAAVVAAAAAASMDKRALLASPGFAAAAAAAAAPGAYIQILTTNTSTTSCSSSLQSGAVAAGPLLPSAPGAEQTAGSLLYTTPHGPSSRAGLLQQPPALGRGGSGGGGGPPAKRRLELGESGHQYLSDGLKTPKGKGRAALRSPDSPKTPKSPSEKTRYDTSLGLLTKKFIQLLSQSPDGVLDLNKAAEVLKVQKRRIYDITNVLEGIHLIKKKSKNNVQWMGCSLSEDGGMLAQCQGLSKEVTELSQEEKKLDELIQSCTLDLKLLTEDSENQRLAYVTYQDIRKISGLKDQTVIVVKAPPETRLEVPDSIESLQIHLASTQGPIEVYLCPEETETHSPMKTNNQDHNGNIPKPASKDLASTNSGHSDCSVSMGNLSPLASPANLLQQTEDQIPSNLEGPFVNLLPPLLQEDYLLSLGEEEGISDLFDAYDLEKLPLVEDFMCS T28343 DRUGINFO D04FHQ ISIS 114197 Investigative T28343 DRUGINFO D05FIN ISIS 114184 Investigative T28343 DRUGINFO D08ZWA ISIS 114232 Investigative T28343 DRUGINFO D0G8CN ISIS 114170 Investigative T92714 TARGETID T92714 T92714 FORMERID TTDR01347 T92714 UNIPROID SMAD6_HUMAN T92714 TARGNAME MADH6 messenger RNA (MADH6 mRNA) T92714 GENENAME SMAD6 T92714 TARGTYPE Literature-reported T92714 SYNONYMS hSMAD6 (mRNA); Smad6 (mRNA); SMAD family member 6 (mRNA); SMAD 6 (mRNA); Mothers against decapentaplegic homolog 6 (mRNA); Mothers against DPP homolog 6 (mRNA); MADH6 (mRNA); MAD homolog 6 (mRNA) T92714 FUNCTION Suppresses IL1R-TLR signaling through its direct interaction with PEL1, preventing NF-kappa-B activation, nuclear transport and NF-kappa-B-mediated expression of proinflammatory genes. May block the BMP-SMAD1 signaling pathway by competing with SMAD4 for receptor-activated SMAD1-binding. Binds to regulatory elements in target promoter regions. Acts as a mediator of TGF-beta and BMP antiflammatory activity. T92714 BIOCLASS mRNA target T92714 SEQUENCE MFRSKRSGLVRRLWRSRVVPDREEGGSGGGGGGDEDGSLGSRAEPAPRAREGGGCGRSEVRPVAPRRPRDAVGQRGAQGAGRRRRAGGPPRPMSEPGAGAGSSLLDVAEPGGPGWLPESDCETVTCCLFSERDAAGAPRDASDPLAGAALEPAGGGRSREARSRLLLLEQELKTVTYSLLKRLKERSLDTLLEAVESRGGVPGGCVLVPRADLRLGGQPAPPQLLLGRLFRWPDLQHAVELKPLCGCHSFAAAADGPTVCCNPYHFSRLCGPESPPPPYSRLSPRDEYKPLDLSDSTLSYTETEATNSLITAPGEFSDASMSPDATKPSHWCSVAYWEHRTRVGRLYAVYDQAVSIFYDLPQGSGFCLGQLNLEQRSESVRRTRSKIGFGILLSKEPDGVWAYNRGEHPIFVNSPTLDAPGGRALVVRKVPPGYSIKVFDFERSGLQHAPEPDAADGPYDPNSVRISFAKGWGPCYSRQFITSCPCWLEILLNNPR T92714 DRUGINFO D03HVU ISIS 101987 Investigative T92714 DRUGINFO D06RHG ISIS 101952 Investigative T92714 DRUGINFO D0P2EY ISIS 101983 Investigative T92714 DRUGINFO D0P6AS ISIS 101985 Investigative T92714 DRUGINFO D0U5PS ISIS 101986 Investigative T92714 DRUGINFO D0W0SS ISIS 101996 Investigative T92714 DRUGINFO D0X1NL ISIS 101998 Investigative T92714 DRUGINFO D0X3FC ISIS 101995 Investigative T92714 DRUGINFO D0Y7VA ISIS 101984 Investigative T92714 DRUGINFO D0Z2RM ISIS 101997 Investigative T92714 DRUGINFO D0Z6ZA ISIS 101960 Investigative T30397 TARGETID T30397 T30397 FORMERID TTDR01350 T30397 UNIPROID M2_I97A1 T30397 TARGNAME Influenza M messenger RNA (Influenza M mRNA) T30397 GENENAME Influenza M mRNA T30397 TARGTYPE Literature-reported T30397 SYNONYMS Proton channel protein M2 (mRNA); Matrix protein 2 (mRNA); M (mRNA) T30397 FUNCTION After attaching to the cell surface, the virion enters the cell by endocytosis. Acidification of the endosome triggers M2 ion channel activity. The influx of protons into virion interior is believed to disrupt interactions between the viral ribonucleoprotein (RNP), matrix protein 1 (M1), and lipid bilayers, thereby freeing the viral genome from interaction with viral proteins and enabling RNA segments to migrate to the host cell nucleus, where influenza virus RNA transcription and replication occur. Also plays a role in viral proteins secretory pathway. Elevates the intravesicular pH of normally acidic compartments, such as trans-Golgi network, preventing newly formed hemagglutinin from premature switching to the fusion-active conformation. Forms a proton-selective ion channel that is necessary for the efficient release of the viral genome during virus entry. T30397 PDBSTRUC 6MPN; 6MPM; 6MPL; 4RWC; 4RWB T30397 BIOCLASS mRNA target T30397 SEQUENCE MSLLTEVETLTRNGWGCRCSDSSDPLVVAASIIGILHLILWILDRLFFKCIYRRFKYGLKRGPSTEGVPESMREEYRQEQQNAVDVDDGHFVNIELE T30397 DRUGINFO D0O8FS ISIS 3309 Investigative T70278 TARGETID T70278 T70278 FORMERID TTDR01351 T70278 UNIPROID ZN217_HUMAN T70278 TARGNAME ZNF217 messenger RNA (ZNF217 mRNA) T70278 GENENAME ZNF217 T70278 TARGTYPE Literature-reported T70278 SYNONYMS Zinc finger protein 217 (mRNA); ZABC1 (mRNA) T70278 FUNCTION Promotes cell proliferation and antagonizes cell death. Promotes phosphorylation of AKT1 at 'Ser-473'. Binds to the promoters of target genes and functions as repressor. T70278 PDBSTRUC 4IS1; 4F2J; 3UK3; 2HU2 T70278 BIOCLASS mRNA target T70278 SEQUENCE MQSKVTGNMPTQSLLMYMDGPEVIGSSLGSPMEMEDALSMKGTAVVPFRATQEKNVIQIEGYMPLDCMFCSQTFTHSEDLNKHVLMQHRPTLCEPAVLRVEAEYLSPLDKSQVRTEPPKEKNCKENEFSCEVCGQTFRVAFDVEIHMRTHKDSFTYGCNMCGRRFKEPWFLKNHMRTHNGKSGARSKLQQGLESSPATINEVVQVHAAESISSPYKICMVCGFLFPNKESLIEHRKVHTKKTAFGTSSAQTDSPQGGMPSSREDFLQLFNLRPKSHPETGKKPVRCIPQLDPFTTFQAWQLATKGKVAICQEVKESGQEGSTDNDDSSSEKELGETNKGSCAGLSQEKEKCKHSHGEAPSVDADPKLPSSKEKPTHCSECGKAFRTYHQLVLHSRVHKKDRRAGAESPTMSVDGRQPGTCSPDLAAPLDENGAVDRGEGGSEDGSEDGLPEGIHLDKNDDGGKIKHLTSSRECSYCGKFFRSNYYLNIHLRTHTGEKPYKCEFCEYAAAQKTSLRYHLERHHKEKQTDVAAEVKNDGKNQDTEDALLTADSAQTKNLKRFFDGAKDVTGSPPAKQLKEMPSVFQNVLGSAVLSPAHKDTQDFHKNAADDSADKVNKNPTPAYLDLLKKRSAVETQANNLICRTKADVTPPPDGSTTHNLEVSPKEKQTETAADCRYRPSVDCHEKPLNLSVGALHNCPAISLSKSLIPSITCPFCTFKTFYPEVLMMHQRLEHKYNPDVHKNCRNKSLLRSRRTGCPPALLGKDVPPLSSFCKPKPKSAFPAQSKSLPSAKGKQSPPGPGKAPLTSGIDSSTLAPSNLKSHRPQQNVGVQGAATRQQQSEMFPKTSVSPAPDKTKRPETKLKPLPVAPSQPTLGSSNINGSIDYPAKNDSPWAPPGRDYFCNRSASNTAAEFGEPLPKRLKSSVVALDVDQPGANYRRGYDLPKYHMVRGITSLLPQDCVYPSQALPPKPRFLSSSEVDSPNVLTVQKPYGGSGPLYTCVPAGSPASSSTLEGKRPVSYQHLSNSMAQKRNYENFIGNAHYRPNDKKT T70278 DRUGINFO D01KCM ISIS 114563 Investigative T70278 DRUGINFO D03NEA ISIS 114559 Investigative T70278 DRUGINFO D08WJY ISIS 114531 Investigative T70278 DRUGINFO D0AJ0H ISIS 114527 Investigative T70278 DRUGINFO D0E5FG ISIS 114537 Investigative T70278 DRUGINFO D0L3NU ISIS 14548 Investigative T70278 DRUGINFO D0LY0E ISIS 114532 Investigative T70278 DRUGINFO D0N5CF ISIS 114530 Investigative T58495 TARGETID T58495 T58495 FORMERID TTDR01094 T58495 UNIPROID FOS_HUMAN T58495 TARGNAME c-Fos messenger RNA (c-Fos mRNA) T58495 GENENAME FOS T58495 TARGTYPE Literature-reported T58495 SYNONYMS Proto-oncogene c-Fos (mRNA); G0S7 (mRNA); G0/G1 switch regulatory protein 7 (mRNA); Cellular oncogene fos (mRNA); C-fos (mRNA) T58495 FUNCTION In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regulating the development of cells destined to form and maintain the skeleton. It is thought to have an important role in signal transduction, cell proliferation and differentiation. In growing cells, activates phospholipid synthesis, possibly by activating CDS1 and PI4K2A. This activity requires Tyr-dephosphorylation and association with the endoplasmic reticulum. Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor. T58495 PDBSTRUC 1S9K; 1FOS; 1A02 T58495 BIOCLASS mRNA target T58495 SEQUENCE MMFSGFNADYEASSSRCSSASPAGDSLSYYHSPADSFSSMGSPVNAQDFCTDLAVSSANFIPTVTAISTSPDLQWLVQPALVSSVAPSQTRAPHPFGVPAPSAGAYSRAGVVKTMTGGRAQSIGRRGKVEQLSPEEEEKRRIRRERNKMAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAHRPACKIPDDLGFPEEMSVASLDLTGGLPEVATPESEEAFTLPLLNDPEPKPSVEPVKSISSMELKTEPFDDFLFPASSRPSGSETARSVPDMDLSGSFYAADWEPLHSGSLGMGPMATELEPLCTPVVTCTPSCTAYTSSFVFTYPEADSFPSCAAAHRKGSSSNEPSSDSLSSPTLLAL T58495 DRUGINFO D0Z2OW ISIS 10639 Investigative T40516 TARGETID T40516 T40516 FORMERID TTDI02388 T40516 UNIPROID TGFA_HUMAN T40516 TARGNAME TGFA messenger RNA (TGFA mRNA) T40516 GENENAME TGFA T40516 TARGTYPE Literature-reported T40516 SYNONYMS TGF-alpha (40-89) (mRNA); TGF type 1 (40-89) (mRNA); Protransforming growth factor alpha (40-89) (mRNA); ETGF (40-89) (mRNA); EGF-like TGF (40-89) (mRNA) T40516 FUNCTION TGF alpha is a mitogenic polypeptide that is able to bind to the EGF receptor/EGFR and to act synergistically with TGF beta to promote anchorage-independent cell proliferation in soft agar. T40516 PDBSTRUC 5KN5; 4TGF; 3TGF; 3.00E+50; 2TGF T40516 BIOCLASS mRNA target T40516 SEQUENCE MVPSAGQLALFALGIVLAACQALENSTSPLSADPPVAAAVVSHFNDCPDSHTQFCFHGTCRFLVQEDKPACVCHSGYVGARCEHADLLAVVAASQKKQAITALVVVSIVALAVLIITCVLIHCCQVRKHCEWCRALICRHEKPSALLKGRTACCHSETVV T85810 TARGETID T85810 T85810 FORMERID TTDR01359 T85810 UNIPROID VE2_BPV1 T85810 TARGNAME Human papillomavirus E2 region messenger RNA (HPV E2 mRNA) T85810 GENENAME HPV E2 mRNA T85810 TARGTYPE Literature-reported T85810 SYNONYMS BPV regulatory protein E2 (mRNA) T85810 FUNCTION A dimer of E2 interacts with a dimer of E1 in order to improve specificity of E1 DNA binding activity. Once the complex recognizes and binds DNA at specific sites, the E2 dimer is removed from DNA. E2 also regulates viral transcription through binding to the E2RE response element (5'-ACCNNNNNNGGT-3') present in multiple copies in the regulatory regions of the viral genome. Activates or represses transcription depending on E2RE's position with regards to proximal promoter elements including the TATA-box. Repression occurs by sterically hindering the assembly of the transcription initiation complex. Plays a role in the initiation of viral DNA replication. T85810 PDBSTRUC 6BUS; 2JEX; 2JEU; 2BOP; 1JJH T85810 BIOCLASS mRNA target T85810 SEQUENCE METACERLHVAQETQMQLIEKSSDKLQDHILYWTAVRTENTLLYAARKKGVTVLGHCRVPHSVVCQERAKQAIEMQLSLQELSKTEFGDEPWSLLDTSWDRYMSEPKRCFKKGARVVEVEFDGNASNTNWYTVYSNLYMRTEDGWQLAKAGADGTGLYYCTMAGAGRIYYSRFGDEAARFSTTGHYSVRDQDRVYAGVSSTSSDFRDRPDGVWVASEGPEGDPAGKEAEPAQPVSSLLGSPACGPIRAGLGWVRDGPRSHPYNFPAGSGGSILRSSSTPVQGTVPVDLASRQEEEEQSPDSTEEEPVTLPRRTTNDGFHLLKAGGSCFALISGTANQVKCYRFRVKKNHRHRYENCTTTWFTVADNGAERQGQAQILITFGSPSQRQDFLKHVPLPPGMNISGFTASLDF T85810 DRUGINFO D02ZPT ISIS 2324 Investigative T85810 DRUGINFO D08LZK ISIS 1753 Investigative T85810 DRUGINFO D0WM8R ISIS 1751 Investigative T81018 TARGETID T81018 T81018 FORMERID TTDI02658 T81018 UNIPROID HG2A_HUMAN T81018 TARGNAME CD74 messenger RNA (CD74 mRNA) T81018 GENENAME CD74 T81018 TARGTYPE Literature-reported T81018 SYNONYMS p33 (mRNA); Ii (mRNA); Ia antigenassociated invariant chain (mRNA); Ia antigen-associated invariant chain (mRNA); HLADR antigensassociated invariant chain (mRNA); HLA-DR antigens-associated invariant chain (mRNA); HLA class II histocompatibility antigen gamma chain (mRNA); DHLAG (mRNA) T81018 FUNCTION Serves as cell surface receptor for the cytokine MIF. Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. T81018 PDBSTRUC 5KSV; 5KSU; 4X5W; 4AH2; 4AEN T81018 BIOCLASS mRNA target T81018 SEQUENCE MHRRRSRSCREDQKPVMDDQRDLISNNEQLPMLGRRPGAPESKCSRGALYTGFSILVTLLLAGQATTAYFLYQQQGRLDKLTVTSQNLQLENLRMKLPKPPKPVSKMRMATPLLMQALPMGALPQGPMQNATKYGNMTEDHVMHLLQNADPLKVYPPLKGSFPENLRHLKNTMETIDWKVFESWMHHWLLFEMSRHSLEQKPTDAPPKVLTKCQEEVSHIPAVHPGSFRPKCDENGNYLPLQCYGSIGYCWCVFPNGTEVPNTRSRGHHNCSESLELEDPSSGLGVTKQDLGPVPM T46790 TARGETID T46790 T46790 FORMERID TTDR01068 T46790 UNIPROID PAI1_HUMAN T46790 TARGNAME PAI-1 messenger RNA (PAI-1 mRNA) T46790 GENENAME SERPINE1 T46790 TARGTYPE Literature-reported T46790 SYNONYMS Serpin E1 (mRNA); Plasminogen activator inhibitor type 1 (mRNA); Plasminogen activator inhibitor 1 (mRNA); PLANH1 (mRNA); PAI1 (mRNA); PAI-1 (mRNA); PAI (mRNA); Endothelial plasminogen activator inhibitor (mRNA) T46790 FUNCTION Inhibits TMPRSS7. Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots. As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading. Acts as a regulator of cell migration, independently of its role as protease inhibitor. It is required for stimulation of keratinocyte migration during cutaneous injury repair. It is involved in cellular and replicative senescence. Plays a role in alveolar type 2 cells senescence in the lung. Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis. Serine protease inhibitor. T46790 PDBSTRUC 9PAI; 6I8S; 5ZLZ; 5BRR; 4IC0 T46790 BIOCLASS mRNA target T46790 SEQUENCE MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP T68498 TARGETID T68498 T68498 FORMERID TTDI02655 T68498 UNIPROID ISG15_HUMAN T68498 TARGNAME ISG15 messenger RNA (ISG15 mRNA) T68498 GENENAME ISG15 T68498 TARGTYPE Literature-reported T68498 SYNONYMS hUCRP (mRNA); Ubiquitin-like protein ISG15 (mRNA); Ubiquitin cross-reactive protein (mRNA); UCRP (mRNA); Interferon-induced 17 kDa protein (mRNA); Interferon-induced 15 kDa protein (mRNA); IP17 (mRNA); G1P2 (mRNA) T68498 FUNCTION ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation-inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA-induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity. The secreted form acts through the integrin ITGAL/ITGB2 receptor to initiate activation of SRC family tyrosine kinases including LYN, HCK and FGR which leads to secretion of IFNG and IL10; the interaction is mediated by ITGAL. Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. T68498 PDBSTRUC 6FFA; 6BI8; 5W8U; 5W8T; 5TL6 T68498 BIOCLASS mRNA target T68498 SEQUENCE MGWDLTVKMLAGNEFQVSLSSSMSVSELKAQITQKIGVHAFQQRLAVHPSGVALQDRVPLASQGLGPGSTVLLVVDKCDEPLSILVRNNKGRSSTYEVRLTQTVAHLKQQVSGLEGVQDDLFWLTFEGKPLEDQLPLGEYGLKPLSTVFMNLRLRGGGTEPGGRS T43303 TARGETID T43303 T43303 FORMERID TTDR01364 T43303 UNIPROID VE6_HPV18 T43303 TARGNAME Human papillomavirus-18 E6 region messenger RNA (HPV-18 E6 mRNA) T43303 GENENAME HPV-18 E6 mRNA T43303 TARGTYPE Literature-reported T43303 SYNONYMS HPV-18 protein E6 (mRNA); HPV-18 E6 (mRNA) T43303 FUNCTION Acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. E6 associates with host UBE3A/E6-AP ubiquitin-protein ligase, and inactivates tumor suppressors TP53 and TP73 by targeting them to the 26S proteasome for degradation. In turn, DNA damage and chromosomal instabilities increase and lead to cell proliferation and cancer development. The complex E6/E6AP targets several other substrates to degradation via the proteasome including host DLG1 or NFX1, a repressor of human telomerase reverse transcriptase (hTERT). The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization. Other cellular targets including BAK1, Fas-associated death domain-containing protein (FADD) and procaspase 8, are degraded by E6/E6AP causing inhibition of apoptosis. E6 also inhibits immune response by interacting with host IRF3 and TYK2. These interactions prevent IRF3 transcriptional activities and inhibit TYK2-mediated JAK-STAT activation by interferon alpha resulting in inhibition of the interferon signaling pathway. Plays a major role in the induction and maintenance of cellular transformation. T43303 PDBSTRUC 5K4F; 5IC3; 4JOR; 2I0L; 2I0I T43303 BIOCLASS mRNA target T43303 SEQUENCE MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDLFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNLLIRCLRCQKPLNPAEKLRHLNEKRRFHNIAGHYRGQCHSCCNRARQERLQRRRETQV T43303 DRUGINFO D07AMO ISIS 2490 Investigative T27984 TARGETID T27984 T27984 FORMERID TTDR01097 T27984 UNIPROID CXB1_HUMAN T27984 TARGNAME Connexin 32 messenger RNA (GJB1 mRNA) T27984 GENENAME GJB1 T27984 TARGTYPE Literature-reported T27984 SYNONYMS Gap junction beta-1 protein (mRNA); GAP junction 28 kDa liver protein (mRNA); CX32 (mRNA) T27984 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T27984 PDBSTRUC 5KK9; 1TXH T27984 BIOCLASS mRNA target T27984 SEQUENCE MNWTGLYTLLSGVNRHSTAIGRVWLSVIFIFRIMVLVVAAESVWGDEKSSFICNTLQPGCNSVCYDQFFPISHVRLWSLQLILVSTPALLVAMHVAHQQHIEKKMLRLEGHGDPLHLEEVKRHKVHISGTLWWTYVISVVFRLLFEAVFMYVFYLLYPGYAMVRLVKCDVYPCPNTVDCFVSRPTEKTVFTVFMLAASGICIILNVAEVVYLIIRACARRAQRRSNPPSRKGSGFGHRLSPEYKQNEINKLLSEQDGSLKDILRRSPGTGAGLAEKSDRCSAC T27984 DRUGINFO D00LEN Sc-43077 Investigative T27984 DRUGINFO D02VNG Sc-43076 Investigative T12354 TARGETID T12354 T12354 FORMERID TTDNR00708 T12354 UNIPROID TAU_HUMAN T12354 TARGNAME Tau messenger RNA (TAU mRNA) T12354 GENENAME MAPT T12354 TARGTYPE Literature-reported T12354 SYNONYMS tau phosphorylation (mRNA); TAU (mRNA); Paired helical filamenttau (mRNA); Paired helical filament-tau (mRNA); PHFtau (mRNA); PHF-tau (mRNA); Neurofibrillary tangle protein (mRNA); Microtubule-associated protein tau (mRNA); MTBT1 (mRNA); MAPTL (mRNA) T12354 FUNCTION The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. T12354 PDBSTRUC 6QJQ; 6QJP; 6QJM; 6QJH; 6NWQ T12354 BIOCLASS mRNA target T12354 SEQUENCE MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL T36651 TARGETID T36651 T36651 FORMERID TTDI02378 T36651 UNIPROID KAP0_HUMAN T36651 TARGNAME PRKAR1A messenger RNA (PRKAR1A mRNA) T36651 GENENAME PRKAR1A T36651 TARGTYPE Literature-reported T36651 SYNONYMS cAMP-dependent protein kinase type I-alpha regulatory subunit (mRNA); Tissue-specific extinguisher-1 (mRNA); Tissue-specific extinguisher 1 (mRNA); TSE1 (mRNA); RIalpha subunit of cAMP-dependent protein kinase (mRNA); PRKAR1 (mRNA); PKR1 (mRNA); PKA RIalpha-subunit (mRNA); CAMP-dependent protein kinase (PKA) (mRNA) T36651 FUNCTION Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. T36651 PDBSTRUC 5KJZ; 5KJY; 5KJX T36651 BIOCLASS mRNA target T36651 SEQUENCE MESGSTAASEEARSLRECELYVQKHNIQALLKDSIVQLCTARPERPMAFLREYFERLEKEEAKQIQNLQKAGTRTDSREDEISPPPPNPVVKGRRRRGAISAEVYTEEDAASYVRKVIPKDYKTMAALAKAIEKNVLFSHLDDNERSDIFDAMFSVSFIAGETVIQQGDEGDNFYVIDQGETDVYVNNEWATSVGEGGSFGELALIYGTPRAATVKAKTNVKLWGIDRDSYRRILMGSTLRKRKMYEEFLSKVSILESLDKWERLTVADALEPVQFEDGQKIVVQGEPGDEFFIILEGSAAVLQRRSENEEFVEVGRLGPSDYFGEIALLMNRPRAATVVARGPLKCVKLDRPRFERVLGPCSDILKRNIQQYNSFVSLSV T18601 TARGETID T18601 T18601 FORMERID TTDC00279 T18601 UNIPROID NCAP_CVH22 T18601 TARGNAME Coronavirus Nucleocapsid messenger RNA (HCoV Nucleoprotein mRNA) T18601 GENENAME HCoV Nucleoprotein mRNA T18601 TARGTYPE Literature-reported T18601 SYNONYMS Nc of HCoV (mRNA); N of HCoV (mRNA) T18601 FUNCTION Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. Packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. T18601 BIOCLASS mRNA target T18601 SEQUENCE MATVKWADASEPQRGRQGRIPYSLYSPLLVDSEQPWKVIPRNLVPINKKDKNKLIGYWNVQKRFRTRKGKRVDLSPKLHFYYLGTGPHKDAKFRERVEGVVWVAVDGAKTEPTGYGVRRKNSEPEIPHFNQKLPNGVTVVEEPDSRAPSRSQSRSQSRGRGESKPQSRNPSSDRNHNSQDDIMKAVAAALKSLGFDKPQEKDKKSAKTGTPKPSRNQSPASSQTSAKSLARSQSSETKEQKHEMQKPRWKRQPNDDVTSNVTQCFGPRDLDHNFGSAGVVANGVKAKGYPQFAELVPSTAAMLFDSHIVSKESGNTVVLTFTTRVTVPKDHPHLGKFLEELNAFTREMQQHPLLNPSALEFNPSQTSPATAEPVRDEVSIETDIIDEVN T22298 TARGETID T22298 T22298 FORMERID TTDI02683 T22298 UNIPROID ANPRA_HUMAN T22298 TARGNAME NPR1 messenger RNA (NPR1 mRNA) T22298 GENENAME NPR1 T22298 TARGTYPE Literature-reported T22298 SYNONYMS NPR-A (mRNA); Guanylate cyclase A (mRNA); GC-A (mRNA); Atrial natriuretic peptide receptor type A (mRNA); Atrial natriuretic peptide receptor 1 (mRNA); ANPRA (mRNA); ANPR-A (mRNA); ANP-A (mRNA) T22298 FUNCTION Has guanylate cyclase activity upon binding of the ligand. Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. T22298 BIOCLASS mRNA target T22298 ECNUMBER EC 4.6.1.2 T22298 SEQUENCE MPGPRRPAGSRLRLLLLLLLPPLLLLLRGSHAGNLTVAVVLPLANTSYPWSWARVGPAVELALAQVKARPDLLPGWTVRTVLGSSENALGVCSDTAAPLAAVDLKWEHNPAVFLGPGCVYAAAPVGRFTAHWRVPLLTAGAPALGFGVKDEYALTTRAGPSYAKLGDFVAALHRRLGWERQALMLYAYRPGDEEHCFFLVEGLFMRVRDRLNITVDHLEFAEDDLSHYTRLLRTMPRKGRVIYICSSPDAFRTLMLLALEAGLCGEDYVFFHLDIFGQSLQGGQGPAPRRPWERGDGQDVSARQAFQAAKIITYKDPDNPEYLEFLKQLKHLAYEQFNFTMEDGLVNTIPASFHDGLLLYIQAVTETLAHGGTVTDGENITQRMWNRSFQGVTGYLKIDSSGDRETDFSLWDMDPENGAFRVVLNYNGTSQELVAVSGRKLNWPLGYPPPDIPKCGFDNEDPACNQDHLSTLEVLALVGSLSLLGILIVSFFIYRKMQLEKELASELWRVRWEDVEPSSLERHLRSAGSRLTLSGRGSNYGSLLTTEGQFQVFAKTAYYKGNLVAVKRVNRKRIELTRKVLFELKHMRDVQNEHLTRFVGACTDPPNICILTEYCPRGSLQDILENESITLDWMFRYSLTNDIVKGMLFLHNGAICSHGNLKSSNCVVDGRFVLKITDYGLESFRDLDPEQGHTVYAKKLWTAPELLRMASPPVRGSQAGDVYSFGIILQEIALRSGVFHVEGLDLSPKEIIERVTRGEQPPFRPSLALQSHLEELGLLMQRCWAEDPQERPPFQQIRLTLRKFNRENSSNILDNLLSRMEQYANNLEELVEERTQAYLEEKRKAEALLYQILPHSVAEQLKRGETVQAEAFDSVTIYFSDIVGFTALSAESTPMQVVTLLNDLYTCFDAVIDNFDVYKVETIGDAYMVVSGLPVRNGRLHACEVARMALALLDAVRSFRIRHRPQEQLRLRIGIHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGEALKIHLSSETKAVLEEFGGFELELRGDVEMKGKGKVRTYWLLGERGSSTRG T79598 TARGETID T79598 T79598 FORMERID TTDI02675 T79598 UNIPROID IBP2_HUMAN T79598 TARGNAME IGFBP2 messenger RNA (IGFBP2 mRNA) T79598 GENENAME IGFBP2 T79598 TARGTYPE Literature-reported T79598 SYNONYMS Insulinlike growth factorbinding protein 2 (mRNA); Insulin-like growth factor-binding protein 2 (mRNA); IGFbinding protein 2 (mRNA); IGFBP-2 (mRNA); IGF-binding protein 2 (mRNA); IBP2 (mRNA); IBP-2 (mRNA); BP2 (mRNA) T79598 FUNCTION IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Inhibits IGF-mediated growth and developmental rates. T79598 PDBSTRUC 2H7T T79598 BIOCLASS mRNA target T79598 SEQUENCE MLPRVGCPALPLPPPPLLPLLLLLLGASGGGGGARAEVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ T29095 TARGETID T29095 T29095 FORMERID TTDI02653 T29095 UNIPROID ROA2_HUMAN T29095 TARGNAME hnRNP A2/B1 messenger RNA (HNRNPA2B1 mRNA) T29095 GENENAME HNRNPA2B1 T29095 TARGTYPE Literature-reported T29095 SYNONYMS hnRNP A2/B1 (mRNA); Heterogeneous nuclear ribonucleoproteins A2/B1 (mRNA); HNRPA2B1 (mRNA) T29095 FUNCTION The hnRNP particle arrangement on nascent hnRNA is non-random and sequence-dependent and serves to condense and stabilize the transcripts and minimize tangling and knotting. Packaging plays a role in various processes such as transcription, pre-mRNA processing, RNA nuclear export, subcellular location, mRNA translation and stability of mature mRNAs. Forms hnRNP particles with at least 20 other different hnRNP and heterogeneous nuclear RNA in the nucleus. Involved in transport of specific mRNAs to the cytoplasm in oligodendrocytes and neurons: acts by specifically recognizing and binding the A2RE (21 nucleotide hnRNP A2 response element) or the A2RE11 (derivative 11 nucleotide oligonucleotide) sequence motifs present on some mRNAs, and promotes their transport to the cytoplasm. Specifically binds single-stranded telomeric DNA sequences, protecting telomeric DNA repeat against endonuclease digestion. Also binds other RNA molecules, such as primary miRNA (pri-miRNAs): acts as a nuclear 'reader' of the N6-methyladenosine (m6A) mark by specifically recognizing and binding a subset of nuclear m6A-containing pri-miRNAs. Binding to m6A-containing pri-miRNAs promotes pri-miRNA processing by enhancing binding of DGCR8 to pri-miRNA transcripts. Involved in miRNA sorting into exosomes following sumoylation, possibly by binding (m6A)-containing pre-miRNAs. Acts as a regulator of efficiency of mRNA splicing, possibly by binding to m6A-containing pre-mRNAs. Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-mRNAs, packaging them into hnRNP particles. T29095 PDBSTRUC 5WWG; 5WWF; 5WWE; 5HO4; 5EN1 T29095 BIOCLASS mRNA target T29095 SEQUENCE MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKRSRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIKEDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGHNAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGFGDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNYNDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY T57428 TARGETID T57428 T57428 FORMERID TTDI02686 T57428 UNIPROID IL4RA_HUMAN T57428 TARGNAME IL4R messenger RNA (IL4R mRNA) T57428 GENENAME IL4R T57428 TARGTYPE Literature-reported T57428 SYNONYMS Interleukin-4 receptor subunit alpha (mRNA); IL4RA (mRNA); IL-4RA (mRNA); IL-4R-alpha (mRNA); IL-4R subunit alpha (mRNA); IL-4 receptor subunit alpha (mRNA); CD124 antigen (mRNA); CD124 (mRNA); 582J2.1 (mRNA) T57428 FUNCTION Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2. Receptor for both interleukin 4 and interleukin 13. T57428 PDBSTRUC 5E4E; 3BPO; 3BPN; 3BPL; 1ITE T57428 BIOCLASS mRNA target T57428 SEQUENCE MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPDNYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRARVRAWAQCYNTTWSEWSPSTKWHNSYREPFEQHLLLGVSVSCIVILAVCLLCYVSITKIKKEWWDQIPNPARSRLVAIIIQDAQGSQWEKRSRGQEPAKCPHWKNCLTKLLPCFLEHNMKRDEDPHKAAKEMPFQGSGKSAWCPVEISKTVLWPESISVVRCVELFEAPVECEEEEEVEEEKGSFCASPESSRDDFQEGREGIVARLTESLFLDLLGEENGGFCQQDMGESCLLPPSGSTSAHMPWDEFPSAGPKEAPPWGKEQPLHLEPSPPASPTQSPDNLTCTETPLVIAGNPAYRSFSNSLSQSPCPRELGPDPLLARHLEEVEPEMPCVPQLSEPTTVPQPEPETWEQILRRNVLQHGAAAAPVSAPTSGYQEFVHAVEQGGTQASAVVGLGPPGEAGYKAFSSLLASSAVSPEKCGFGASSGEEGYKPFQDLIPGCPGDPAPVPVPLFTFGLDREPPRSPQSSHLPSSSPEHLGLEPGEKVEDMPKPPLPQEQATDPLVDSLGSGIVYSALTCHLCGHLKQCHGQEDGGQTPVMASPCCGCCCGDRSSPPTTPLRAPDPSPGGVPLEASLCPASLAPSGISEKSKSSSSFHPAPGNAQSSSQTPKIVNFVSVGPTYMRVS T17008 TARGETID T17008 T17008 FORMERID TTDI02676 T17008 UNIPROID IBP5_HUMAN T17008 TARGNAME IGFBP5 messenger RNA (IGFBP5 mRNA) T17008 GENENAME IGFBP5 T17008 TARGTYPE Literature-reported T17008 SYNONYMS Insulin-like growth factor-binding protein 5 (mRNA); IGFBP-5 (mRNA); IGF-binding protein 5 (mRNA); IBP5 (mRNA); IBP-5 (mRNA) T17008 FUNCTION IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. T17008 PDBSTRUC 1H59; 1BOE T17008 BIOCLASS mRNA target T17008 SEQUENCE MVLLTAVLLLLAAYAGPAQSLGSFVHCEPCDEKALSMCPPSPLGCELVKEPGCGCCMTCALAEGQSCGVYTERCAQGLRCLPRQDEEKPLHALLHGRGVCLNEKSYREQVKIERDSREHEEPTTSEMAEETYSPKIFRPKHTRISELKAEAVKKDRRKKLTQSKFVGGAENTAHPRIISAPEMRQESEQGPCRRHMEASLQELKASPRMVPRAVYLPNCDRKGFYKRKQCKPSRGRKRGICWCVDKYGMKLPGMEYVDGDFQCHTFDSSNVE T21679 TARGETID T21679 T21679 FORMERID TTDR01268 T21679 UNIPROID HD_HUMAN T21679 TARGNAME Huntingtin messenger RNA (HTT mRNA) T21679 GENENAME HTT T21679 TARGTYPE Literature-reported T21679 SYNONYMS IT15 (mRNA); Huntington disease protein (mRNA); Huntingtin (mRNA); HD protein (mRNA); HD (mRNA) T21679 FUNCTION May play a role in microtubule-mediated transport or vesicle function. T21679 PDBSTRUC 6N8C; 6EZ8; 4RAV; 4FED; 4FEC T21679 BIOCLASS mRNA target T21679 SEQUENCE MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQPPPPPPPPPPPQLPQPPPQAQPLLPQPQPPPPPPPPPPGPAVAEEPLHRPKKELSATKKDRVNHCLTICENIVAQSVRNSPEFQKLLGIAMELFLLCSDDAESDVRMVADECLNKVIKALMDSNLPRLQLELYKEIKKNGAPRSLRAALWRFAELAHLVRPQKCRPYLVNLLPCLTRTSKRPEESVQETLAAAVPKIMASFGNFANDNEIKVLLKAFIANLKSSSPTIRRTAAGSAVSICQHSRRTQYFYSWLLNVLLGLLVPVEDEHSTLLILGVLLTLRYLVPLLQQQVKDTSLKGSFGVTRKEMEVSPSAEQLVQVYELTLHHTQHQDHNVVTGALELLQQLFRTPPPELLQTLTAVGGIGQLTAAKEESGGRSRSGSIVELIAGGGSSCSPVLSRKQKGKVLLGEEEALEDDSESRSDVSSSALTASVKDEISGELAASSGVSTPGSAGHDIITEQPRSQHTLQADSVDLASCDLTSSATDGDEEDILSHSSSQVSAVPSDPAMDLNDGTQASSPISDSSQTTTEGPDSAVTPSDSSEIVLDGTDNQYLGLQIGQPQDEDEEATGILPDEASEAFRNSSMALQQAHLLKNMSHCRQPSDSSVDKFVLRDEATEPGDQENKPCRIKGDIGQSTDDDSAPLVHCVRLLSASFLLTGGKNVLVPDRDVRVSVKALALSCVGAAVALHPESFFSKLYKVPLDTTEYPEEQYVSDILNYIDHGDPQVRGATAILCGTLICSILSRSRFHVGDWMGTIRTLTGNTFSLADCIPLLRKTLKDESSVTCKLACTAVRNCVMSLCSSSYSELGLQLIIDVLTLRNSSYWLVRTELLETLAEIDFRLVSFLEAKAENLHRGAHHYTGLLKLQERVLNNVVIHLLGDEDPRVRHVAAASLIRLVPKLFYKCDQGQADPVVAVARDQSSVYLKLLMHETQPPSHFSVSTITRIYRGYNLLPSITDVTMENNLSRVIAAVSHELITSTTRALTFGCCEALCLLSTAFPVCIWSLGWHCGVPPLSASDESRKSCTVGMATMILTLLSSAWFPLDLSAHQDALILAGNLLAASAPKSLRSSWASEEEANPAATKQEEVWPALGDRALVPMVEQLFSHLLKVINICAHVLDDVAPGPAIKAALPSLTNPPSLSPIRRKGKEKEPGEQASVPLSPKKGSEASAASRQSDTSGPVTTSKSSSLGSFYHLPSYLKLHDVLKATHANYKVTLDLQNSTEKFGGFLRSALDVLSQILELATLQDIGKCVEEILGYLKSCFSREPMMATVCVQQLLKTLFGTNLASQFDGLSSNPSKSQGRAQRLGSSSVRPGLYHYCFMAPYTHFTQALADASLRNMVQAEQENDTSGWFDVLQKVSTQLKTNLTSVTKNRADKNAIHNHIRLFEPLVIKALKQYTTTTCVQLQKQVLDLLAQLVQLRVNYCLLDSDQVFIGFVLKQFEYIEVGQFRESEAIIPNIFFFLVLLSYERYHSKQIIGIPKIIQLCDGIMASGRKAVTHAIPALQPIVHDLFVLRGTNKADAGKELETQKEVVVSMLLRLIQYHQVLEMFILVLQQCHKENEDKWKRLSRQIADIILPMLAKQQMHIDSHEALGVLNTLFEILAPSSLRPVDMLLRSMFVTPNTMASVSTVQLWISGILAILRVLISQSTEDIVLSRIQELSFSPYLISCTVINRLRDGDSTSTLEEHSEGKQIKNLPEETFSRFLLQLVGILLEDIVTKQLKVEMSEQQHTFYCQELGTLLMCLIHIFKSGMFRRITAAATRLFRSDGCGGSFYTLDSLNLRARSMITTHPALVLLWCQILLLVNHTDYRWWAEVQQTPKRHSLSSTKLLSPQMSGEEEDSDLAAKLGMCNREIVRRGALILFCDYVCQNLHDSEHLTWLIVNHIQDLISLSHEPPVQDFISAVHRNSAASGLFIQAIQSRCENLSTPTMLKKTLQCLEGIHLSQSGAVLTLYVDRLLCTPFRVLARMVDILACRRVEMLLAANLQSSMAQLPMEELNRIQEYLQSSGLAQRHQRLYSLLDRFRLSTMQDSLSPSPPVSSHPLDGDGHVSLETVSPDKDWYVHLVKSQCWTRSDSALLEGAELVNRIPAEDMNAFMMNSEFNLSLLAPCLSLGMSEISGGQKSALFEAAREVTLARVSGTVQQLPAVHHVFQPELPAEPAAYWSKLNDLFGDAALYQSLPTLARALAQYLVVVSKLPSHLHLPPEKEKDIVKFVVATLEALSWHLIHEQIPLSLDLQAGLDCCCLALQLPGLWSVVSSTEFVTHACSLIYCVHFILEAVAVQPGEQLLSPERRTNTPKAISEEEEEVDPNTQNPKYITAACEMVAEMVESLQSVLALGHKRNSGVPAFLTPLLRNIIISLARLPLVNSYTRVPPLVWKLGWSPKPGGDFGTAFPEIPVEFLQEKEVFKEFIYRINTLGWTSRTQFEETWATLLGVLVTQPLVMEQEESPPEEDTERTQINVLAVQAITSLVLSAMTVPVAGNPAVSCLEQQPRNKPLKALDTRFGRKLSIIRGIVEQEIQAMVSKRENIATHHLYQAWDPVPSLSPATTGALISHEKLLLQINPERELGSMSYKLGQVSIHSVWLGNSITPLREEEWDEEEEEEADAPAPSSPPTSPVNSRKHRAGVDIHSCSQFLLELYSRWILPSSSARRTPAILISEVVRSLLVVSDLFTERNQFELMYVTLTELRRVHPSEDEILAQYLVPATCKAAAVLGMDKAVAEPVSRLLESTLRSSHLPSRVGALHGVLYVLECDLLDDTAKQLIPVISDYLLSNLKGIAHCVNIHSQQHVLVMCATAFYLIENYPLDVGPEFSASIIQMCGVMLSGSEESTPSIIYHCALRGLERLLLSEQLSRLDAESLVKLSVDRVNVHSPHRAMAALGLMLTCMYTGKEKVSPGRTSDPNPAAPDSESVIVAMERVSVLFDRIRKGFPCEARVVARILPQFLDDFFPPQDIMNKVIGEFLSNQQPYPQFMATVVYKVFQTLHSTGQSSMVRDWVMLSLSNFTQRAPVAMATWSLSCFFVSASTSPWVAAILPHVISRMGKLEQVDVNLFCLVATDFYRHQIEEELDRRAFQSVLEVVAAPGSPYHRLLTCLRNVHKVTTC T21679 DRUGINFO D00QIJ Huntingtin gene antisense Preclinical T21679 DRUGINFO D0V7VX ALN-HTT Preclinical T61586 TARGETID T61586 T61586 FORMERID TTDI02384 T61586 UNIPROID KI67_HUMAN T61586 TARGNAME Antigen KI-67 messenger RNA (MKI67 mRNA) T61586 GENENAME MKI67 T61586 TARGTYPE Literature-reported T61586 SYNONYMS Proliferation marker protein Ki-67 (mRNA); Antigen identified by monoclonal antibody Ki-67 (mRNA); Antigen Ki67 (mRNA); Antigen KI-67 (mRNA) T61586 FUNCTION Associates with the surface of the mitotic chromosome, the perichromosomal layer, and covers a substantial fraction of the chromosome surface. Prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility. Binds DNA, with a preference for supercoiled DNA and AT-rich DNA. Does not contribute to the internal structure of mitotic chromosomes. May play a role in chromatin organization. It is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in maintaining mitotic chromosomes dispersed. Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly. T61586 PDBSTRUC 5J28; 2AFF; 1R21 T61586 BIOCLASS mRNA target T61586 SEQUENCE MWPTRRLVTIKRSGVDGPHFPLSLSTCLFGRGIECDIRIQLPVVSKQHCKIEIHEQEAILHNFSSTNPTQVNGSVIDEPVRLKHGDVITIIDRSFRYENESLQNGRKSTEFPRKIREQEPARRVSRSSFSSDPDEKAQDSKAYSKITEGKVSGNPQVHIKNVKEDSTADDSKDSVAQGTTNVHSSEHAGRNGRNAADPISGDFKEISSVKLVSRYGELKSVPTTQCLDNSKKNESPFWKLYESVKKELDVKSQKENVLQYCRKSGLQTDYATEKESADGLQGETQLLVSRKSRPKSGGSGHAVAEPASPEQELDQNKGKGRDVESVQTPSKAVGASFPLYEPAKMKTPVQYSQQQNSPQKHKNKDLYTTGRRESVNLGKSEGFKAGDKTLTPRKLSTRNRTPAKVEDAADSATKPENLSSKTRGSIPTDVEVLPTETEIHNEPFLTLWLTQVERKIQKDSLSKPEKLGTTAGQMCSGLPGLSSVDINNFGDSINESEGIPLKRRRVSFGGHLRPELFDENLPPNTPLKRGEAPTKRKSLVMHTPPVLKKIIKEQPQPSGKQESGSEIHVEVKAQSLVISPPAPSPRKTPVASDQRRRSCKTAPASSSKSQTEVPKRGGRKSGNLPSKRVSISRSQHDILQMICSKRRSGASEANLIVAKSWADVVKLGAKQTQTKVIKHGPQRSMNKRQRRPATPKKPVGEVHSQFSTGHANSPCTIIIGKAHTEKVHVPARPYRVLNNFISNQKMDFKEDLSGIAEMFKTPVKEQPQLTSTCHIAISNSENLLGKQFQGTDSGEEPLLPTSESFGGNVFFSAQNAAKQPSDKCSASPPLRRQCIRENGNVAKTPRNTYKMTSLETKTSDTETEPSKTVSTANRSGRSTEFRNIQKLPVESKSEETNTEIVECILKRGQKATLLQQRREGEMKEIERPFETYKENIELKENDEKMKAMKRSRTWGQKCAPMSDLTDLKSLPDTELMKDTARGQNLLQTQDHAKAPKSEKGKITKMPCQSLQPEPINTPTHTKQQLKASLGKVGVKEELLAVGKFTRTSGETTHTHREPAGDGKSIRTFKESPKQILDPAARVTGMKKWPRTPKEEAQSLEDLAGFKELFQTPGPSEESMTDEKTTKIACKSPPPESVDTPTSTKQWPKRSLRKADVEEEFLALRKLTPSAGKAMLTPKPAGGDEKDIKAFMGTPVQKLDLAGTLPGSKRQLQTPKEKAQALEDLAGFKELFQTPGHTEELVAAGKTTKIPCDSPQSDPVDTPTSTKQRPKRSIRKADVEGELLACRNLMPSAGKAMHTPKPSVGEEKDIIIFVGTPVQKLDLTENLTGSKRRPQTPKEEAQALEDLTGFKELFQTPGHTEEAVAAGKTTKMPCESSPPESADTPTSTRRQPKTPLEKRDVQKELSALKKLTQTSGETTHTDKVPGGEDKSINAFRETAKQKLDPAASVTGSKRHPKTKEKAQPLEDLAGLKELFQTPVCTDKPTTHEKTTKIACRSQPDPVDTPTSSKPQSKRSLRKVDVEEEFFALRKRTPSAGKAMHTPKPAVSGEKNIYAFMGTPVQKLDLTENLTGSKRRLQTPKEKAQALEDLAGFKELFQTRGHTEESMTNDKTAKVACKSSQPDPDKNPASSKRRLKTSLGKVGVKEELLAVGKLTQTSGETTHTHTEPTGDGKSMKAFMESPKQILDSAASLTGSKRQLRTPKGKSEVPEDLAGFIELFQTPSHTKESMTNEKTTKVSYRASQPDLVDTPTSSKPQPKRSLRKADTEEEFLAFRKQTPSAGKAMHTPKPAVGEEKDINTFLGTPVQKLDQPGNLPGSNRRLQTRKEKAQALEELTGFRELFQTPCTDNPTTDEKTTKKILCKSPQSDPADTPTNTKQRPKRSLKKADVEEEFLAFRKLTPSAGKAMHTPKAAVGEEKDINTFVGTPVEKLDLLGNLPGSKRRPQTPKEKAKALEDLAGFKELFQTPGHTEESMTDDKITEVSCKSPQPDPVKTPTSSKQRLKISLGKVGVKEEVLPVGKLTQTSGKTTQTHRETAGDGKSIKAFKESAKQMLDPANYGTGMERWPRTPKEEAQSLEDLAGFKELFQTPDHTEESTTDDKTTKIACKSPPPESMDTPTSTRRRPKTPLGKRDIVEELSALKQLTQTTHTDKVPGDEDKGINVFRETAKQKLDPAASVTGSKRQPRTPKGKAQPLEDLAGLKELFQTPICTDKPTTHEKTTKIACRSPQPDPVGTPTIFKPQSKRSLRKADVEEESLALRKRTPSVGKAMDTPKPAGGDEKDMKAFMGTPVQKLDLPGNLPGSKRWPQTPKEKAQALEDLAGFKELFQTPGTDKPTTDEKTTKIACKSPQPDPVDTPASTKQRPKRNLRKADVEEEFLALRKRTPSAGKAMDTPKPAVSDEKNINTFVETPVQKLDLLGNLPGSKRQPQTPKEKAEALEDLVGFKELFQTPGHTEESMTDDKITEVSCKSPQPESFKTSRSSKQRLKIPLVKVDMKEEPLAVSKLTRTSGETTQTHTEPTGDSKSIKAFKESPKQILDPAASVTGSRRQLRTRKEKARALEDLVDFKELFSAPGHTEESMTIDKNTKIPCKSPPPELTDTATSTKRCPKTRPRKEVKEELSAVERLTQTSGQSTHTHKEPASGDEGIKVLKQRAKKKPNPVEEEPSRRRPRAPKEKAQPLEDLAGFTELSETSGHTQESLTAGKATKIPCESPPLEVVDTTASTKRHLRTRVQKVQVKEEPSAVKFTQTSGETTDADKEPAGEDKGIKALKESAKQTPAPAASVTGSRRRPRAPRESAQAIEDLAGFKDPAAGHTEESMTDDKTTKIPCKSSPELEDTATSSKRRPRTRAQKVEVKEELLAVGKLTQTSGETTHTDKEPVGEGKGTKAFKQPAKRKLDAEDVIGSRRQPRAPKEKAQPLEDLASFQELSQTPGHTEELANGAADSFTSAPKQTPDSGKPLKISRRVLRAPKVEPVGDVVSTRDPVKSQSKSNTSLPPLPFKRGGGKDGSVTGTKRLRCMPAPEEIVEELPASKKQRVAPRARGKSSEPVVIMKRSLRTSAKRIEPAEELNSNDMKTNKEEHKLQDSVPENKGISLRSRRQNKTEAEQQITEVFVLAERIEINRNEKKPMKTSPEMDIQNPDDGARKPIPRDKVTENKRCLRSARQNESSQPKVAEESGGQKSAKVLMQNQKGKGEAGNSDSMCLRSRKTKSQPAASTLESKSVQRVTRSVKRCAENPKKAEDNVCVKKIRTRSHRDSEDI T42440 TARGETID T42440 T42440 FORMERID TTDI02667 T42440 UNIPROID HEPC_HUMAN T42440 TARGNAME Hepcidin messenger RNA (HAMP mRNA) T42440 GENENAME HAMP T42440 TARGTYPE Literature-reported T42440 SYNONYMS UNQ487/PRO1003 (mRNA); Putative liver tumor regressor (mRNA); PLTR (mRNA); Liver-expressed antimicrobial peptide 1 (mRNA); LEAP1 (mRNA); LEAP-1 (mRNA); Hepcidin (mRNA); HEPC (mRNA) T42440 FUNCTION Acts by promoting endocytosis and degradation of ferroportin, leading to the retention of iron in iron-exporting cells and decreased flow of iron into plasma. Controls the major flows of iron into plasma: absorption of dietary iron in the intestine, recycling of iron by macrophages, which phagocytose old erythrocytes and other cells, and mobilization of stored iron from hepatocytes. Liver-produced hormone that constitutes the main circulating regulator of iron absorption and distribution across tissues. T42440 PDBSTRUC 4QAE; 3H0T; 2KEF; 1M4F; 1M4E T42440 BIOCLASS mRNA target T42440 SEQUENCE MALSSQIWAACLLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGARASWMPMFQRRRRRDTHFPICIFCCGCCHRSKCGMCCKT T12486 TARGETID T12486 T12486 FORMERID TTDI02234 T12486 UNIPROID HSPB3_HUMAN T12486 TARGNAME HSP27 messenger RNA (HSPB3 mRNA) T12486 GENENAME HSPB3 T12486 TARGTYPE Literature-reported T12486 SYNONYMS Protein 3 (mRNA); HspB3 (mRNA); Heat shock protein beta-3 (mRNA); Heat shock 17 kDa protein (mRNA); HSPL27 (mRNA); HSP 17 (mRNA) T12486 FUNCTION Inhibitor of actin polymerization. T12486 PDBSTRUC 6F2R T12486 BIOCLASS mRNA target T12486 SEQUENCE MAKIILRHLIEIPVRYQEEFEARGLEDCRLDHALYALPGPTIVDLRKTRAAQSPPVDSAAETPPREGKSHFQILLDVVQFLPEDIIIQTFEGWLLIKAQHGTRMDEHGFISRSFTRQYKLPDGVEIKDLSAVLCHDGILVVEVKDPVGTK T77125 TARGETID T77125 T77125 FORMERID TTDR01096 T77125 UNIPROID AGRL3_HUMAN T77125 TARGNAME CIRL-3 messenger RNA (CIRL-3 mRNA) T77125 GENENAME ADGRL3 T77125 TARGTYPE Literature-reported T77125 SYNONYMS Lectomedin-3 (mRNA); Latrophilin-3 (mRNA); LPHN3 (mRNA); LEC3 (mRNA); KIAA0768 (mRNA); Calcium-independent alpha-latrotoxin receptor 3 (mRNA); CIRL-3 (mRNA); Adhesion G protein-coupled receptor L3 (mRNA) T77125 FUNCTION Plays a role in the development of glutamatergic synapses in the cortex. Important in determining the connectivity rates between the principal neurons in the cortex. Plays a role in cell-cell adhesion and neuron guidance via its interactions with FLRT2 and FLRT3 that are expressed at the surface of adjacent cells. T77125 PDBSTRUC 5CMN T77125 BIOCLASS mRNA target T77125 SEQUENCE MWPSQLLIFMMLLAPIIHAFSRAPIPMAVVRRELSCESYPIELRCPGTDVIMIESANYGRTDDKICDSDPAQMENIRCYLPDAYKIMSQRCNNRTQCAVVAGPDVFPDPCPGTYKYLEVQYECVPYKVEQKVFLCPGLLKGVYQSEHLFESDHQSGAWCKDPLQASDKIYYMPWTPYRTDTLTEYSSKDDFIAGRPTTTYKLPHRVDGTGFVVYDGALFFNKERTRNIVKFDLRTRIKSGEAIIANANYHDTSPYRWGGKSDIDLAVDENGLWVIYATEQNNGKIVISQLNPYTLRIEGTWDTAYDKRSASNAFMICGILYVVKSVYEDDDNEATGNKIDYIYNTDQSKDSLVDVPFPNSYQYIAAVDYNPRDNLLYVWNNYHVVKYSLDFGPLDSRSGQAHHGQVSYISPPIHLDSELERPSVKDISTTGPLGMGSTTTSTTLRTTTLSPGRSTTPSVSGRRNRSTSTPSPAVEVLDDMTTHLPSASSQIPALEESCEAVEAREIMWFKTRQGQIAKQPCPAGTIGVSTYLCLAPDGIWDPQGPDLSNCSSPWVNHITQKLKSGETAANIARELAEQTRNHLNAGDITYSVRAMDQLVGLLDVQLRNLTPGGKDSAARSLNKAMVETVNNLLQPQALNAWRDLTTSDQLRAATMLLHTVEESAFVLADNLLKTDIVRENTDNIKLEVARLSTEGNLEDLKFPENMGHGSTIQLSANTLKQNGRNGEIRVAFVLYNNLGPYLSTENASMKLGTEALSTNHSVIVNSPVITAAINKEFSNKVYLADPVVFTVKHIKQSEENFNPNCSFWSYSKRTMTGYWSTQGCRLLTTNKTHTTCSCNHLTNFAVLMAHVEVKHSDAVHDLLLDVITWVGILLSLVCLLICIFTFCFFRGLQSDRNTIHKNLCISLFVAELLFLIGINRTDQPIACAVFAALLHFFFLAAFTWMFLEGVQLYIMLVEVFESEHSRRKYFYLVGYGMPALIVAVSAAVDYRSYGTDKVCWLRLDTYFIWSFIGPATLIIMLNVIFLGIALYKMFHHTAILKPESGCLDNIKSWVIGAIALLCLLGLTWAFGLMYINESTVIMAYLFTIFNSLQGMFIFIFHCVLQKKVRKEYGKCLRTHCCSGKSTESSIGSGKTSGSRTPGRYSTGSQSRIRRMWNDTVRKQSESSFITGDINSSASLNREGLLNNARDTSVMDTLPLNGNHGNSYSIASGEYLSNCVQIIDRGYNHNETALEKKILKELTSNYIPSYLNNHERSSEQNRNLMNKLVNNLGSGREDDAIVLDDATSFNHEESLGLELIHEESDAPLLPPRVYSTENHQPHHYTRRRIPQDHSESFFPLLTNEHTEDLQSPHRDSLYTSMPTLAGVAATESVTTSTQTEPPPAKCGDAEDVYYKSMPNLGSRNHVHQLHTYYQLGRGSSDGFIVPPNKDGTPPEGSSKGPAHLVTSL T85419 TARGETID T85419 T85419 FORMERID TTDR01428 T85419 UNIPROID NRAM_I97A1 T85419 TARGNAME Influenza NA messenger RNA (Influenza NA mRNA) T85419 GENENAME Influenza NA mRNA T85419 TARGTYPE Literature-reported T85419 SYNONYMS Neuraminidase (mRNA); NA of influenza (mRNA) T85419 FUNCTION Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication. Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. T85419 BIOCLASS mRNA target T85419 ECNUMBER EC 3.2.1.18 T85419 SEQUENCE MNPNQKIITIGSICMVVGIISLMLQIGNIISVWVSHIIQTWHPNQPEPCNQSINFYTEQAAASVTLAGNSSLCPISGWAIYSKDNSIRIGSKGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRTLMSCPVGEAPSPYNSRFESVAWSASACHDGISWLTIGISGPDNGAVAVLKYNGIITDTIKSWRNNILRTQESECACVNGSCFTVMTDGPSNEQASYKIFKIEKGRVVKSVELNAPNYHYEECSCYPDAGEITCVCRDNWHGSNRPWVSFNQNLEYQIGYICSGVFGDSPRPNDGTGSCGPVSLNGAYGVKGFSFKYGNGVWIGRTKSTSSRSGFEMIWDPNGWTETDSSFSLKQDIIAITDWSGYSGSFIQHPELTGLNCMRPCFWVELIRGRPKEKTIWTSGSSISFCGVNSDTVGWSWPDGADLPFTIDK T85419 DRUGINFO D04DNL ALN-FLU01 Preclinical T85419 DRUGINFO D0N0MY ISIS 3308 Investigative T42120 TARGETID T42120 T42120 FORMERID TTDR01145 T42120 UNIPROID A0A072ZJB2_PSEAI T42120 TARGNAME Pseudomonas Amidotransferase (Pseudo yafJ) T42120 GENENAME Pseudo yafJ T42120 TARGTYPE Literature-reported T42120 SYNONYMS Putative glutamine amidotransferase yafJ; Putative glutamine amidotransferase; Glutamine amidotransferases class-II; Class II glutamine amidotransferase T42120 FUNCTION Catalyses the removal of the ammonia group from a glutamine molecule and its subsequent transfer to a specific substrate, thus creating a new carbon-nitrogen group on the substrate. T42120 ECNUMBER EC 2.4.2.- T42120 SEQUENCE MCELLGMSANVPTDIVFSFTGLMQRGGGTGPHRDGWGIAFYEGRGVRLFQDPLASVDSEVARLVQRFPIKSETVIGHIRQANVGKVGLSNTHPFIRELGGRYWTFAHNGQLADFQPKPGFYRPVGETDSEAAFCDLLNRVRRAFPEPVPVEVLLPVLISACDEYRKKGVFNALISDGDWLFTFCSSKLAYITRRAPFGPARLKDADLTVDFHAETTPDDVVTVIATEPLTDNENWTLQQSGEWVLWWGGEVLAKGRV T46060 TARGETID T46060 T46060 FORMERID TTDI01367 T46060 UNIPROID A0A0F7UUA6_TOXGV T46060 TARGNAME Toxoplasma Calcium-dependent protein kinase 1 (Tg CDPK1) T46060 GENENAME Tg CDPK1 T46060 TARGTYPE Literature-reported T46060 SYNONYMS CAM kinase, CDPK family TgCDPK1 T46060 FUNCTION Provides the mechanistic link between calcium signalling and motility, differentiation and invasion. Required for the microneme secretion at the apical complex and parasite proliferation. T46060 PDBSTRUC 6BFA T46060 SEQUENCE MGQQESTLGGAAGEPRSRGHAAGTSGGPGDHLHATPGMFVQHSTAIFSDRYKGQRVLGKGSFGEVILCKDKITGQECAVKVISKRQVKQKTDKESLLREVQLLKQLDHPNIMKLYEFFEDKGYFYLVGEVYTGGELFDEIISRKRFSEVDAARIIRQVLSGITYMHKNKIVHRDLKPENLLLESKSKDANIRIIDFGLSTHFEASKKMKDKIGTAYYIAPEVLHGTYDEKCDVWSTGVILYILLSGCPPFNGANEYDILKKVEKGKYTFELPQWKKVSESAKDLIRKMLTYVPSMRISARDALDHEWIQTYTKEQISVDVPSLDNAILNIRQFQGTQKLAQAALLYMGSKLTSQDETKELTAIFHKMDKNGDGQLDRAELIEGYKELMRMKGQDASMLDASAVEHEVDQVLDAVDFDKNGYIEYSEFVTVAMDRKTLLSRERLERAFRMFDSDNSGKISSTELATIFGVSDVDSETWKSVLSEVDKNNDGEVDFDEFQQMLLKLCGN T27334 TARGETID T27334 T27334 FORMERID TTDS00455 T27334 UNIPROID A0A0M4UFG9_CAMJU T27334 TARGNAME Campylobacter Flavodoxin:quinone reductase (CAMJU FqrB) T27334 GENENAME CAMJU FqrB T27334 TARGTYPE Literature-reported T27334 SYNONYMS NADPH oxidoreductase, putative flavodoxin quinone reductase FqrB T27334 FUNCTION Exhibited NADPH quinone reductase activity with menadione or benzoquinone. Reduced flavodoxin (FldA), the electron carrier of PFOR. T27334 BIOCLASS Iron-sulfur protein donor oxidoreductase T27334 SEQUENCE MKKIDLIVVGAGPTGIGCAVEAKLKNKEVLILEKSNNICQTLMQFYKDGKRVDKAYKGCEGTNHGHVPFEDGTKESTIETFQNALKEHNIEVEFGSEVESVKNENGVFLVSTAKGVYGCKNIIVAIGRMGKPNKPDYKLPMTLTKIINFNANSVLGNEKILVVGGGNSAAEYAVDLANSNQVSLCYRKKEFTRLNDINLKDIHEAGNSGEVELKLGIDINEVEDDNGKAKVNFTDGTSDIYDRIIYAIGGSTPLDFLQKCGINVDDKGVPLMDENKQSNVKGIFVAGDITTKNGASIVTGLNDAVKILSVL T79181 TARGETID T79181 T79181 FORMERID TTDI01334 T79181 UNIPROID A0A151C7Z8_BIFBI T79181 TARGNAME Bifidobacterium Exo-alpha sialidase (BB sialidase) T79181 GENENAME BB sialidase T79181 TARGTYPE Literature-reported T79181 SYNONYMS Exo-alpha-sialidase; BB Sialidase T79181 FUNCTION Involved in the degradation of sialyloligosaccharides in human milk and intestinal glycoconjugates. T79181 ECNUMBER EC 3.2.1.18 T79181 SEQUENCE MVRSTKPSLLRRFGALVAAAAMLVVLPAGVSTASAASDDADMLTVTMTRTDALGDEVYVGDTLTYSFTNTNNTSSAFTAFPAESNLSGVLTTGTPNCRYENLAGGASYPCSTASHTITADDLTAGSFTPRTVWKATSDRGGTQVLQDNIVSTGDTVTVKEGKRPDPATIPTDRADGEAVRLATARQNLGTECYRIPALAEAPNGWILAAFDQRPNTAMANGSGVKCWDAPQPNSIVQRISKDGGKSWTPIQYVAQGKNAPERYGYSDPSYVVDKETGEIFLFFVHSYNKGFADSQLGVDESNRNVLHAVVVSSKDNGETWSKPRDITADITKGYENEWKSRFATSGAGIQLKYGKYKGRLIQQYAVGRTTGSNAAVSVYSDDHGKTWQAGNPVTGMLMDENKVVELSDGRVMLNSRPGNGSGYRRVAISEDGGVNYGTVKNETQLPDPNNNAHITRAFPNAPEGSAKAKVLLYSSPRANNEGRANGVVRISLDDGTTWSSGKLYKEGSMAYSVITALSGAAGGGYGLLYEGAWVTGGGIDSHDIMYTHISMDWLGYLSATADDVTASVEEGASTVDVTVPVSNVGSVDYTGVTVTPADLPTGWSASPVNVGALASGTSKDVTVTVNVPATAKKDDVAKIVLRVTGTSAANADATTGFDGSITVNVTEKSEPDPEPEPTITGVSAVTSQAGVKVGDVFDASKVSVTAAMSDGSSKALAAGEYSLSAVDADGKAVDLAEPFAAAGVVTVTVSVPVEGAGPLTASFTIDVAEKSVDPEPKPEPEPKPEPEKPAGPKVDVPTEQPGLSKTGASTAGMSIVFVLLALSGVAALSLRRRSAH T46395 TARGETID T46395 T46395 FORMERID TTDI03126 T46395 UNIPROID CXE1_HUMAN T46395 TARGNAME Connexin-23 (Cx23) T46395 GENENAME GJE1 T46395 TARGTYPE Literature-reported T46395 SYNONYMS Putative gap junction epsilon-1 protein T46395 FUNCTION Does not form functional gap junctions. Mediates calcium-independent ATP release, suggesting activity as a hemichannel. T46395 BIOCLASS Gap junction-forming connexin T46395 SEQUENCE MSLNYIKNFYEGCVKPPTVIGQFHTLFFGSIRIFFLGVLGFAVYGNEALHFICDPDKREVNLFCYNQFRPITPQVSFSALQLVIVLVPGALFHLYAACKSINQECILQKPIYTIIYILSVLLRISLAAIAFWLQIYLFGFQVKSLYLCDARSLGENMIIRCMVPEHFEKTIFLIAINTFTTITILLFVAEIFEIIFRRLYFPFRQ T46395 DRUGINFO D00VJY octanol Investigative T10490 TARGETID T10490 T10490 FORMERID TTDI01348 T10490 UNIPROID B4EEM8_BURCJ T10490 TARGNAME Burkholderia Glutamate racemase (BURCJ murI) T10490 GENENAME BURCJ murI T10490 TARGTYPE Literature-reported T10490 SYNONYMS Glutamate racemase T10490 FUNCTION Provides the (R)-glutamate required for cell wall biosynthesis. T10490 ECNUMBER EC 5.1.1.3 T10490 SEQUENCE MTNPSDATALRAAAPVGIFDSGLGGLSVLRAARAHLPDESFVYVADSHHAPYGPRDEAFITERTLAIGEWLAREGAKALVIACNTATARAIAAIRERLSIPLVGVEPGIKPAAALSATGVAGVLATQSTLNSPRFQALLDRYGAGRRFICQPGHGLVEAIERGDTNSPALRALLERYIQPMLDDGADTLVLGCTHYPFFTETIRDLVGERLTIVDTSDAIARQLARVLDERGLRAPAGTHAAPPRFCSTSDGLQLRALASTLLGLDAPVESVTISSPNARACATA T82584 TARGETID T82584 T82584 FORMERID TTDI02466 T82584 UNIPROID KCJ18_HUMAN T82584 TARGNAME Inward rectifier potassium channel Kir2.6 (KCNJ18) T82584 GENENAME KCNJ18 T82584 TARGTYPE Literature-reported T82584 SYNONYMS Potassium channel, inwardly rectifying subfamily J member 18; KCNJ18; Inward rectifier potassium channel 18; Inward rectifier K(+) channel Kir2.6 T82584 FUNCTION Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised,the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. T82584 BIOCLASS Inward rectifier potassium channel T82584 SEQUENCE MTAASRANPYSIVSLEEDGLHLVTMSGANGFGNGKVHTRRRCRNRFVKKNGQCNIAFANMDEKSQRYLADMFTTCVDIRWRYMLLIFSLAFLASWLLFGVIFWVIAVAHGDLEPAEGHGRTPCVMQVHGFMAAFLFSIETQTTIGYGLRCVTEECLVAVFMVVAQSIVGCIIDSFMIGAIMAKMARPKKRAQTLLFSHNAVVALRDGKLCLMWRVGNLRKSHIVEAHVRAQLIKPRVTEEGEYIPLDQIDIDVGFDKGLDRIFLVSPITILHEIDEASPLFGISRQDLETDDFEIVVILEGMVEATAMTTQARSSYLANEILWGHRFEPVLFEEKNQYKIDYSHFHKTYEVPSTPRCSAKDLVENKFLLPSANSFCYENELAFLSRDEEDEADGDQDGRSRDGLSPQARHDFDRLQAGGGVLEQRPYRRGSEI T92184 TARGETID T92184 T92184 FORMERID TTDI01696 T92184 UNIPROID D2Y0P7_EIMTE T92184 TARGNAME Eimeria tenella Telomerase reverse transcriptase (EIMTE TERT) T92184 GENENAME EIMTE TERT T92184 TARGTYPE Literature-reported T92184 SYNONYMS EIMTE Telomerase reverse transcriptase; EIMTE Telomerase catalytic subunit T92184 FUNCTION Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. It elongates telomeres. It is a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. T92184 ECNUMBER EC 2.7.7.49 T92184 SEQUENCE MVLSKAGLVALKQMELVTGELYLEKQRKRIVKFEELGYNDSSGLERRLEELLITLDPSEPKAILEGFKLGRELLFNTSLDNLSDNGIDRKLRLINGEKLILWSSIELQNGYSSFPNQRSMSSSGRSRKNEYNTELSPTSFITDQIKNIIPDSEKDSLTYQVQDFELLLRKHFPRIRIFHSGSYSGLRTSFDTIKPKKYSFCNSTLYKFQNLHAWNTLLSKIGPIEILFLFVCCIIFRILGDHSEILIQQAGRMLTNDFLEELARLYETGPKTKNKFVSSSSVLTSPLTTIIEKEEVKPELDETERQVNKREPGGIIKSEDRLSKSIYILDIKPYLSTRFLCDHFYSRGGLPCKSLVRLLPPLLLGANRTLRFILQTDHIFIDHNRQSKLGLLGISEMTKYSRVFKKLASACMEEFQMNLLLIRNTNSPVNFLDQICPIEPKLIDDLSLQFNNKLPPCFEITSTRVVNFLSRYLIKVLPKNILLGTFKNFKTFINKKIPIIVNLHIRETFKIQHAMNGIEVSNWVNRLEIESYQFKIKSKNELNESINRSKKQPNNVTRSKSKKSLISLGIKYLATRENIYFLIYLVFPVILRRHYATEIEGFSKVRYFNRPVWIKIVHRQADKWYLESLKGIIQLKDSYMLNLSISQIISKELDKNISFSEENIPKIRWVPKSKGLRPLINSKLVSGQIGLVQNLQEDHTVREEKKCKGFCDICSVWCTNGDCLPTGSCINNNWYYNYYFSYNGNNNGIVNNHYNYGHIYNNGGGIKFTSFSNSQCTQIMTNPPGRGVGLGFGNLNIGIGYISGSSVPTNTPINVMRRPSSNRKIIDIRPSTNNRMLFYPSILRSFKLLRMGKNHTLASLVGQGDIYKFIIKNWIKNWRDKQQFRQMNEFYQNDKQGKMSHVIYIIKADLVNCKFENINKSKIFEFLDVISLPNIESLSLYLSRALKTTSIPPFDNMNRDSYIQDELRSCGITSKGKLNMIVIFEKDHDPEDQKVVKSKIKIIGPRDLDELWNLKLNSCLSKDLSINLGQKAEIFTFKLSRRVINNWLVKEIIKIHKLNTSFRLRTCSFKSLRLISKQLGNSKIKFGRFLSLFKQDFGIKPQGSSSYILCICLYYNFLDLNPEIQNLLGHSFSSSYFISSFLNPIKLQEVQLLDKPTEDLFSQHKDLEGLSRTYPEKENEIFNIYNTSSKTRRLEISEYNINAKSVKLLQPEEFNNNSINQNCQNIRANLSYDQESPKSSNKQQESLLRWVDDLFLLTSDLESFAKKFLKLYIQLLWGSNVKSKDKINSNPWIDHNNEIIFILEDDVLLSSPSSSECSSSCSSSSSSSSSSSSSSSSSSSFPPSTECSSPVTEKRNTNKISEKDCNEKEMINKQAKIASQFHKQVSWTGMKFKSSEYSYNCMVSLPWKNEFICVMLDTVTLTKHQFTTSNYNFHRFKSSTISENLQTKSNYWSVLGMIKLIRYDFRIKFNGLLYCKINSLFTDVSFYNSTNNTEIKN T32909 TARGETID T32909 T32909 FORMERID TTDR00864 T32909 UNIPROID E9BI04_LEIDB T32909 TARGNAME Leishmania Glutathionylspermidine synthase (Leishm GSP) T32909 GENENAME Leishm GSP T32909 TARGTYPE Literature-reported T32909 SYNONYMS GspS; Glutathionylspermidine synthetase; Glutathione:spermidine ligase [ADP-forming]; GSP synthetase; GSP T32909 FUNCTION Conjugates glutathione (gamma-Glu-Cys-Gly) and spermidine to form glutathionylspermidine in the biosynthesis trypanothione (N(1),N(8)-bis(glutathionyl)spermidine), which is involved in maintaining intracellular thiol redox and in defense againstoxidants. T32909 BIOCLASS Carbon-nitrogen ligase T32909 SEQUENCE MLSLPRDHHYHTHHRGTELVPFDQVIGITPDGVPVISNGNEFHFTNLESVTPFYQALCSFDRKAPVTVSYKKLGVKWQCVEFARRYLASRKAVWTASMPIAADMWRAETPFVRVQDGTPVEFTRIANRSHGPAPAMSDIIVWGQSEETPFGHVAVVTEVLPEAVRVAEQNQGFERWPQGMLYSREIPVQRSSAGTVELVDEDPVLGWVTLHCPYYDFRDGDLADKFRIVTGPGCIVRQPFPKHVELPWLQPEERCDFYLKRSLAIGGNVGDDARAKECDVPSAFYFLDYNIWCRLGRAAHSLHRIAMTATAQVLDDADSAYLLEHYFGLPPEIHPLLRRSWEMMPPMSGRFDFGYDGNKVAMLEYNCDSSGALLECCNTQEKMANYYGVSQGMSTGSFLGAKCVSHFARLMSNEKVCPKHKLIHFMIDDDDEERYTAMCMMNFAEKAGFRTKLCVKLIDFRYRDGAPANAAPLSVTCDHPIIVDSDGDEVLLVWKTWSWDTVLREYHRQCSATDSVSSPTLSDILLNNNICVIEPLWKAVTGSKALLPFMHALAPDHEHLLAADFVPTKDIISHHYVSKPINGRAGQNIMMFDPVTDAAELNAAPQEMLSESSSQLFSIKPPAASCSALQSQSIDRTNECSTGTFFDSAVVYQKRFFLKKFEGKYFPIFCGWMIDDEFGGVVVREDTSKITKLDSIVIPARVVRENVSLGGAYTDEGET T93136 TARGETID T93136 T93136 UNIPROID M4Q7H6_PSEAI T93136 TARGNAME Pseudomonas Type III secretion system protein PcrV (Pseudo pcrV) T93136 GENENAME Pseudo pcrV T93136 TARGTYPE Literature-reported T93136 SYNONYMS Type III secretion system protein T93136 FUNCTION Essential for cytotoxicity. Found both within the bacterial cytoplasm and localized extracellularly. T93136 PDBSTRUC 6CYF T93136 SEQUENCE MEVRNLNAARELFLDELLAASAAPASAEQEELLALLRSERIVLAHAGQPLSEAQVLKALAWLLAANPSAPPGQGLEVLREVLQARRQPGAQWDLREFLVSAYFSLHGRLDEDVIGVYKDVLQTQDGKRKALLDELKALTAELKVYSVIQSQINAALSARQGIRIDAGGIDLVDPTLYGYAVGDPRWKDSPEYALLSNLDTFSGKLSIKDFLSGSPKQSGELKGLSDEYPFEKDNNPVGNFATTVSDRSRPLNDKVNEKTTLLNDTSSRYNSAVEALNRFIQKYDSVLSDILSAI T64102 TARGETID T64102 T64102 FORMERID TTDNR00747 T64102 UNIPROID SGK1_HUMAN; SGK2_HUMAN; SGK3_HUMAN T64102 TARGNAME Serum-and glucocorticoid-inducible kinase SGK (SGK) T64102 GENENAME SGK1; SGK2; SGK3 T64102 TARGTYPE Literature-reported T64102 SYNONYMS Serum/glucocorticoid-regulated kinase; Serine/threonine-protein kinase Sgk; SGK T64102 FUNCTION Invovled in ion channel and transporter regulation, regulation of cell volume, cell proliferation and apoptosis, memory formation, transcription and metabolism. T64102 BIOCLASS Kinase T64102 SEQUENCE MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLGFSYAPPTDSFL T24542 TARGETID T24542 T24542 FORMERID TTDR00110 T24542 UNIPROID PAR3_HUMAN T24542 TARGNAME Proteinase activated receptor 3 (F2RL2) T24542 GENENAME F2RL2 T24542 TARGTYPE Literature-reported T24542 SYNONYMS Thrombin receptor-like 2; Protease activated receptor 3; PAR-3; F2RL2; Coagulation factor II receptor-like 2 T24542 FUNCTION Receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. T24542 BIOCLASS GPCR rhodopsin T24542 SEQUENCE MKALIFAAAGLLLLLPTFCQSGMENDTNNLAKPTLPIKTFRGAPPNSFEEFPFSALEGWTGATITVKIKCPEESASHLHVKNATMGYLTSSLSTKLIPAIYLLVFVVGVPANAVTLWMLFFRTRSICTTVFYTNLAIADFLFCVTLPFKIAYHLNGNNWVFGEVLCRATTVIFYGNMYCSILLLACISINRYLAIVHPFTYRGLPKHTYALVTCGLVWATVFLYMLPFFILKQEYYLVQPDITTCHDVHNTCESSSPFQLYYFISLAFFGFLIPFVLIIYCYAAIIRTLNAYDHRWLWYVKASLLILVIFTICFAPSNIILIIHHANYYYNNTDGLYFIYLIALCLGSLNSCLDPFLYFLMSKTRNHSTAYLTK T38745 TARGETID T38745 T38745 FORMERID TTDR00953 T38745 UNIPROID DFFA_HUMAN T38745 TARGNAME DNA fragmentation factor alpha (DFFA) T38745 GENENAME DFFA T38745 TARGTYPE Literature-reported T38745 SYNONYMS Inhibitor of caspase-3-activated Dnase; Inhibitor of CAD; ICAD; H13; DNA fragmentation factor subunit alpha; DNA fragmentation factor 45 kDa subunit; DFF45; DFF1; DFF-45 T38745 FUNCTION Inhibitor of the caspase-activated DNase (DFF40). T38745 PDBSTRUC 1KOY; 1IYR; 1IBX T38745 SEQUENCE MEVTGDAGVPESGEIRTLKPCLLRRNYSREQHGVAASCLEDLRSKACDILAIDKSLTPVTLVLAEDGTIVDDDDYFLCLPSNTKFVALASNEKWAYNNSDGGTAWISQESFDVDETDSGAGLKWKNVARQLKEDLSSIILLSEEDLQMLVDAPCSDLAQELRQSCATVQRLQHTLQQVLDQREEVRQSKQLLQLYLQALEKEGSLLSKQEESKAAFGEEVDAVDTGISRETSSDVALASHILTALREKQAPELSLSSQDLELVTKEDPKALAVALNWDIKKTETVQEACERELALRLQQTQSLHSLRSISASKASPPGDLQNPKRARQDPT T99092 TARGETID T99092 T99092 UNIPROID CLIC1_HUMAN T99092 TARGNAME Chloride intracellular channel protein 1 (CLIC1) T99092 GENENAME CLIC1 T99092 TARGTYPE Literature-reported T99092 SYNONYMS hRNCC; Regulatory nuclear chloride ion channel protein; Nuclear chloride ion channel 27; NCC27; G6; Chloride channel ABP T99092 FUNCTION Can insert into membranes and form chloride ion channels. Channel activity depends on the pH. Membrane insertion seems to be redox-regulated and may occur only under oxydizing conditions. Involved in regulation of the cell cycle. T99092 PDBSTRUC 4K0N; 4K0G; 4JZQ; 4IQA; 3UVH T99092 SEQUENCE MAEEQPQVELFVKAGSDGAKIGNCPFSQRLFMVLWLKGVTFNVTTVDTKRRTETVQKLCPGGQLPFLLYGTEVHTDTNKIEEFLEAVLCPPRYPKLAALNPESNTAGLDIFAKFSAYIKNSNPALNDNLEKGLLKALKVLDNYLTSPLPEEVDETSAEDEGVSQRKFLDGNELTLADCNLLPKLHIVQVVCKKYRGFTIPEAFRGVHRYLSNAYAREEFASTCPDDEEIELAYEQVAKALK T43928 TARGETID T43928 T43928 FORMERID TTDR00193 T43928 UNIPROID TR11B_HUMAN T43928 TARGNAME Osteoclastogenesis inhibitory factor (TNFRSF11B) T43928 GENENAME TNFRSF11B T43928 TARGTYPE Literature-reported T43928 SYNONYMS Tumor necrosis factor receptor superfamily member 11B; Osteoprotegerin; Osteoclastogenesis inhibitoryfactor; OPG; OCIF T43928 FUNCTION Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. T43928 PDBSTRUC 3URF T43928 SEQUENCE MNNLLCCALVFLDISIKWTTQETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYYTDSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGLLLTQKGNATHDNICSGNSESTQKCGIDVTLCEEAFFRFAVPTKFTPNWLSVLVDNLPGTKVNAESVERIKRQHSSQEQTFQLLKLWKHQNKDQDIVKKIIQDIDLCENSVQRHIGHANLTFEQLRSLMESLPGKKVGAEDIEKTIKACKPSDQILKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPKTVTQSLKKTIRFLHSFTMYKLYQKLFLEMIGNQVQSVKISCL T75136 TARGETID T75136 T75136 FORMERID TTDR01303 T75136 UNIPROID NR5A2_HUMAN T75136 TARGNAME Alpha-1-fetoprotein transcription factor (NR5A2) T75136 GENENAME NR5A2 T75136 TARGTYPE Literature-reported T75136 SYNONYMS hB1F; Nuclear receptor subfamily 5 group A member 2; Liver receptor homolog 1; LRH-1; Hepatocytic transcription factor; FTF; CYP7A promoter-binding factor; CPF; B1F; B1-binding factor T75136 FUNCTION Nuclear receptor that acts as a key metabolic sensor by regulating the expression of genes involved in bile acid synthesis, cholesterol homeostasis and triglyceride synthesis. Together with the oxysterol receptors NR1H3/LXR-alpha and NR1H2/LXR-beta, acts as an essential transcriptional regulator of lipid metabolism. Plays an anti-inflammatory role during the hepatic acute phase response by acting as a corepressor: inhibits the hepatic acute phase response by preventing dissociation of the N-Cor corepressor complex. Binds to the sequence element 5'-AACGACCGACCTTGAG-3' of the enhancer II of hepatitis B virus genes, a critical cis-element of their expression and regulation. May be responsible for the liver-specific activity of enhancer II, probably in combination with other hepatocyte transcription factors. Key regulator of cholesterol 7-alpha-hydroxylase gene (CYP7A) expression in liver. May also contribute to the regulation of pancreas-specific genes and play important roles in embryonic development. Activates the transcription of CYP2C38 (By similarity). T75136 PDBSTRUC 5UNJ; 5SYZ; 5L11; 5L0M; 4RWV T75136 SEQUENCE MSSNSDTGDLQESLKHGLTPIGAGLPDRHGSPIPARGRLVMLPKVETEALGLARSHGEQGQMPENMQVSQFKMVNYSYDEDLEELCPVCGDKVSGYHYGLLTCESCKGFFKRTVQNNKRYTCIENQNCQIDKTQRKRCPYCRFQKCLSVGMKLEAVRADRMRGGRNKFGPMYKRDRALKQQKKALIRANGLKLEAMSQVIQAMPSDLTISSAIQNIHSASKGLPLNHAALPPTDYDRSPFVTSPISMTMPPHGSLQGYQTYGHFPSRAIKSEYPDPYTSSPESIMGYSYMDSYQTSSPASIPHLILELLKCEPDEPQVQAKIMAYLQQEQANRSKHEKLSTFGLMCKMADQTLFSIVEWARSSIFFRELKVDDQMKLLQNCWSELLILDHIYRQVVHGKEGSIFLVTGQQVDYSIIASQAGATLNNLMSHAQELVAKLRSLQFDQREFVCLKFLVLFSLDVKNLENFQLVEGVQEQVNAALLDYTMCNYPQQTEKFGQLLLRLPEIRAISMQAEEYLYYKHLNGDVPYNNLLIEMLHAKRA T72274 TARGETID T72274 T72274 FORMERID TTDI01466 T72274 UNIPROID DLL1_HUMAN T72274 TARGNAME Delta-like protein 1 (DLL1) T72274 GENENAME DLL1 T72274 TARGTYPE Literature-reported T72274 SYNONYMS H-Delta-1; Drosophila Delta homolog 1; Delta1 T72274 FUNCTION Transmembrane ligand protein of NOTCH1, NOTCH2 and NOTCH3 receptors that binds the extracellular domain (ECD) of Notch receptor in a cis and trans fashion manner. Following transinteraction, ligand cells produce mechanical force that depends of a clathrin-mediated endocytosis, requiring ligand ubiquitination, EPN1 interaction, and actin polymerisation; these events promote Notch receptor extracellular domain (NECD) transendocytosis and triggers Notch signaling through induction of cleavage, hyperphosphorylation, and nuclear accumulation of the intracellular domain of Notch receptors (NICD) (By similarity). Is required for embryonic development and maintenance of adult stem cells in many different tissues and immune systeme; the DLL1-induced Notch signaling is mediated through an intercellular communication that regulates cell lineage, cell specification, cell patterning and morphogenesis through effects on differentiation and proliferation. Plays a role in brain development at different level, namely by regulating neuronal differentiation of neural precursor cells via cell-cell interaction, most likely through the lateral inhibitory system in an endogenous level dependent-manner. During neocortex development, Dll1-Notch signaling transmission is mediated by dynamic interactions between intermediate neurogenic progenitors and radial glia; the cell-cell interactions are mediated via dynamic and transient elongation processes, likely to reactivate/maintain Notch activity in neighboring progenitors, and coordinate progenitor cell division and differentiation across radial and zonal boundaries. During cerebellar development, regulates Bergmann glial monolayer formation and its morphological maturation through a Notch signaling pathway. At the retina and spinal cord level, regulates neurogenesis by preventing the premature differentiation of neural progenitors and also by maintaining progenitors in spinal cord through Notch signaling pathway. Also controls neurogenesis of the neural tube in a progenitor domain-specific fashion along the dorsoventral axis. Maintains quiescence of neural stem cells and plays a role as a fate determinant that segregates asymmetrically to one daughter cell during neural stem cells mitosis, resulting in neuronal differentiation in Dll1-inheriting cell. Plays a role in immune systeme development, namely the development of all T-cells and marginal zone (MZ) B-cells (By similarity). Blocks the differentiation of progenitor cells into the B-cell lineage while promoting the emergence of a population of cells with the characteristics of a T-cell/NK-cell precursor. Also plays a role during muscle development. During early development, inhibits myoblasts differentiation from the medial dermomyotomal lip and later regulates progenitor cell differentiation. Directly modulates cell adhesion and basal lamina formation in satellite cells through Notch signaling. Maintains myogenic progenitors pool by suppressing differentiation through down-regulation of MYOD1 and is required for satellite cell homing and PAX7 expression. During craniofacial and trunk myogenesis suppresses differentiation of cranial mesoderm-derived and somite-derived muscle via MYOD1 regulation but in cranial mesoderm-derived progenitors, is neither required for satellite cell homing nor for PAX7 expression. Also plays a role during pancreatic cell development. During type B pancreatic cell development, may be involved in the initiation of proximodistal patterning in the early pancreatic epithelium. Stimulates multipotent pancreatic progenitor cells proliferation and pancreatic growth by maintaining HES1 expression and PTF1A protein levels. During fetal stages of development, is required to maintain arterial identity and the responsiveness of arterial endothelial cells for VEGFA through regulation of KDR activation and NRP1 expression. Controls sprouting angiogenesis and subsequent vertical branch formation througth regulation on tip cell differentiation. Negatively regulates goblet cell differentiation in intestine and controls secretory fat commitment through lateral inhibition in small intestine. Plays a role during inner ear development; negatively regulates auditory hair cell differentiation. Plays a role during nephron development through Notch signaling pathway. Regulates growth, blood pressure and energy homeostasis (By similarity). T72274 PDBSTRUC 4XBM T72274 SEQUENCE MGSRCALALAVLSALLCQVWSSGVFELKLQEFVNKKGLLGNRNCCRGGAGPPPCACRTFFRVCLKHYQASVSPEPPCTYGSAVTPVLGVDSFSLPDGGGADSAFSNPIRFPFGFTWPGTFSLIIEALHTDSPDDLATENPERLISRLATQRHLTVGEEWSQDLHSSGRTDLKYSYRFVCDEHYYGEGCSVFCRPRDDAFGHFTCGERGEKVCNPGWKGPYCTEPICLPGCDEQHGFCDKPGECKCRVGWQGRYCDECIRYPGCLHGTCQQPWQCNCQEGWGGLFCNQDLNYCTHHKPCKNGATCTNTGQGSYTCSCRPGYTGATCELGIDECDPSPCKNGGSCTDLENSYSCTCPPGFYGKICELSAMTCADGPCFNGGRCSDSPDGGYSCRCPVGYSGFNCEKKIDYCSSSPCSNGAKCVDLGDAYLCRCQAGFSGRHCDDNVDDCASSPCANGGTCRDGVNDFSCTCPPGYTGRNCSAPVSRCEHAPCHNGATCHERGHRYVCECARGYGGPNCQFLLPELPPGPAVVDLTEKLEGQGGPFPWVAVCAGVILVLMLLLGCAAVVVCVRLRLQKHRPPADPCRGETETMNNLANCQREKDISVSIIGATQIKNTNKKADFHGDHSADKNGFKARYPAVDYNLVQDLKGDDTAVRDAHSKRDTKCQPQGSSGEEKGTPTTLRGGEASERKRPDSGCSTSKDTKYQSVYVISEEKDECVIATEV T56505 TARGETID T56505 T56505 FORMERID TTDR01282 T56505 UNIPROID CCN1_HUMAN T56505 TARGNAME Cellular communication network factor 1 (CCN1) T56505 GENENAME CCN1 T56505 TARGTYPE Literature-reported T56505 SYNONYMS Protein GIG1; Protein CYR61; Insulin-like growth factor-binding protein 10; IGFBP10; IGFBP-10; IGF-binding protein 10; IBP-10; GIG1; CYR61; CCN family member 1 T56505 FUNCTION Promotes cell proliferation, chemotaxis, angiogenesis and cell adhesion. Appears to play a role in wound healing by up-regulating, in skin fibroblasts, the expression of a number of genes involved in angiogenesis, inflammation and matrix remodeling including VEGA-A, VEGA-C, MMP1, MMP3, TIMP1, uPA, PAI-1 and integrins alpha-3 and alpha-5. CCN1-mediated gene regulation is dependent on heparin-binding. Down-regulates the expression of alpha-1 and alpha-2 subunits of collagen type-1. Promotes cell adhesion and adhesive signaling through integrin alpha-6/beta-1, cell migration through integrin alpha-v/beta-5 and cell proliferation through integrin alpha-v/beta-3. T56505 PDBSTRUC 4D11; 4D0Z T56505 SEQUENCE MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRD T85289 TARGETID T85289 T85289 FORMERID TTDNR00731 T85289 UNIPROID CYR61_HUMAN T85289 TARGNAME Cysteine-rich angiogenic inducer 61 (CYR61) T85289 GENENAME CYR61 T85289 TARGTYPE Literature-reported T85289 SYNONYMS CCN1 T85289 FUNCTION Appears to play a role in wound healing by up-regulating, in skin fibroblasts, the expression of a number of genes involved in angiogenesis, inflammation and matrix remodeling including VEGA-A, VEGA-C, MMP1, MMP3, TIMP1, uPA, PAI-1 and integrins alpha-3 and alpha-5. CYR61-mediated gene regulation is dependent on heparin-binding. Down-regulates the expression of alpha-1 and alpha-2 subunits of collagen type-1. Promotes cell adhesion and adhesive signaling through integrin alpha-6/beta-1, cell migration through integrin alpha-v/beta-5 and cell proliferation through integrin alpha-v/beta-3. Promotes cell proliferation, chemotaxis, angiogenesis and cell adhesion. T85289 PDBSTRUC 4D11; 4D0Z T85289 SEQUENCE MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRD T22117 TARGETID T22117 T22117 FORMERID TTDR00584 T22117 UNIPROID CCL22_HUMAN T22117 TARGNAME Macrophage-derived chemokine (MDC) T22117 GENENAME CCL22 T22117 TARGTYPE Literature-reported T22117 SYNONYMS Stimulated T-cell chemotactic protein 1; Stimulated T cell chemotactic protein1; Small-inducible cytokine A22; SCYA22; MDC(1-69); CC chemokine STCP-1; C-C motif chemokine 22; A-152E5.1 T22117 FUNCTION Chemotactic for monocytes, dendritic cells and natural killer cells. Mild chemoattractant for primary activated T-lymphocytes and a potent chemoattractant for chronically activated T-lymphocytes but has no chemoattractant activity for neutrophils, eosinophils, and resting T-lymphocytes. Binds to CCR4. Processed forms MDC(3-69), MDC(5-69) and MDC(7-69) seem not be active. May play a role in the trafficking of activated/effector T-lymphocytes to inflammatory sites and other aspects of activated T-lymphocyte physiology. T22117 BIOCLASS Cytokine: CC chemokine T22117 SEQUENCE MDRLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYRLPLRVVKHFYWTSDSCPRPGVVLLTFRDKEICADPRVPWVKMILNKLSQ T73908 TARGETID T73908 T73908 FORMERID TTDI02557 T73908 UNIPROID WNT7A_HUMAN T73908 TARGNAME Wnt-7a protein (WNT7A) T73908 GENENAME WNT7A T73908 TARGTYPE Literature-reported T73908 SYNONYMS Protein Wnt-7a T73908 FUNCTION Plays an important role in embryonic development, including dorsal versus ventral patterning during limb development, skeleton development and urogenital tract development. Required for central nervous system (CNS) angiogenesis and blood-brain barrier regulation. Required for normal, sexually dimorphic development of the Mullerian ducts, and for normal fertility in both sexes. Required for normal neural stem cell proliferation in the hippocampus dentate gyrus. Required for normal progress through the cell cycle in neural progenitor cells, for self-renewal of neural stem cells, and for normal neuronal differentiation and maturation. Promotes formation of synapses via its interaction with FZD5. Ligand for members of the frizzled family of seven transmembrane receptors that functions in the canonical Wnt/beta-catenin signaling pathway. T73908 PDBSTRUC 4UZQ T73908 SEQUENCE MNRKARRCLGHLFLSLGMVYLRIGGFSSVVALGASIICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREAAFTYAIIAAGVAHAITAACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK T91390 TARGETID T91390 T91390 UNIPROID CRTN_STAAE T91390 TARGNAME Staphylococcus Dehydrosqualene desaturase (Stap-coc crtN) T91390 GENENAME Stap-coc crtN T91390 TARGTYPE Literature-reported T91390 SYNONYMS Dehydrosqualene desaturase; 4,4'-diapophytoene desaturase (4,4'-diaponeurosporene-forming) T91390 FUNCTION Involved in the biosynthesis of the yellow-orange carotenoid staphyloxanthin, which plays a role in the virulence via its protective function against oxidative stress. Catalyzes three successive dehydrogenation reactions that lead to the introduction of three double bonds into 4,4'-diapophytoene (dehydrosqualene), with 4,4'-diapophytofluene and 4,4'-diapo-zeta-carotene as intermediates, and 4,4'-diaponeurosporene (the major deep-yellow pigment in staphylococci strains) as the end product. T91390 ECNUMBER EC 1.3.8.- T91390 SEQUENCE MKIAVIGAGVTGLAAAARIASQGHEVTIFEKNNNVGGRMNQLKKDGFTFDMGPTIVMMPDVYKDVFTACGKNYEDYIELRQLRYIYDVYFDHDDRITVPTDLAELQQMLESIEPGSTHGFMSFLTDVYKKYEIARRYFLERTYRKPSDFYNMTSLVQGAKLKTLNHADQLIEHYIDNEKIQKLLAFQTLYIGIDPKRGPSLYSIIPMIEMMFGVHFIKGGMYGMAQGLAQLNKDLGVNIELNAEIEQIIIDPKFKRADAIKVNGDIRKFDKILCTADFPSVAESLMPDFAPIKKYPPHKIADLDYSCSAFLMYIGIDIDVTDQVRLHNVIFSDDFRGNIEEIFEGRLSYDPSIYVYVPAVADKSLAPEGKTGIYVLMPTPELKTGSGIDWSDEALTQQIKEIIYRKLATIEVFEDIKSHIVSETIFTPNDFEQTYHAKFGSAFGLMPTLAQSNYYRPQNVSRDYKDLYFAGASTHPGAGVPIVLTSAKITVDEMIKDIERGV T91390 DRUGINFO D09HYG NP16 Investigative T51270 TARGETID T51270 T51270 FORMERID TTDI02589 T51270 UNIPROID CLD4_HUMAN T51270 TARGNAME Claudin-4 (CLDN4) T51270 GENENAME CLDN4 T51270 TARGTYPE Literature-reported T51270 SYNONYMS WilliamsBeuren syndrome chromosomal region 8 protein; Clostridium perfringens enterotoxin receptor; Claudin4; CPEreceptor; CPER; CLDN4 T51270 FUNCTION Plays a major role in tight junction-specific obliteration of the intercellularspace. T51270 PDBSTRUC 5B2G T51270 SEQUENCE MASMGLQVMGIALAVLGWLAVMLCCALPMWRVTAFIGSNIVTSQTIWEGLWMNCVVQSTGQMQCKVYDSLLALPQDLQAARALVIISIIVAALGVLLSVVGGKCTNCLEDESAKAKTMIVAGVVFLLAGLMVIVPVSWTAHNIIQDFYNPLVASGQKREMGASLYVGWAASGLLLLGGGLLCCNCPPRTDKPYSAKYSAARSAAASNYV T41036 TARGETID T41036 T41036 FORMERID TTDI03018 T41036 UNIPROID AGRB1_HUMAN T41036 TARGNAME Adhesion G protein-coupled receptor B1 (BAI1) T41036 GENENAME BAI1 T41036 TARGTYPE Literature-reported T41036 SYNONYMS Brain-specific angiogenesis inhibitor 1; ADGRB1 T41036 FUNCTION Mediates the binding and engulfment of Gram-negative bacteria. Stimulates production of reactive oxygen species by macrophages in response to Gram-negative bacteria, resulting in enhanced microbicidal macrophage activity. In the gastric mucosa, required for recognition and engulfment of apoptotic gastric epithelial cells. Promotes myoblast fusion. Activates the Rho pathway in a G-protein-dependent manner. Inhibits MDM2-mediated ubiquitination and degradation of DLG4/PSD95, promoting DLG4 stability and regulating synaptic plasticity. Required for the formation of dendritic spines by ensuring the correct localization of PARD3 and TIAM1. Potent inhibitor of angiogenesis in brain and may play a significant role as a mediator of the p53/TP53 signal in suppression of glioblastoma. Phosphatidylserine receptor which enhances the engulfment of apoptotic cells. T41036 BIOCLASS GPCR secretin T41036 SEQUENCE MRGQAAAPGPVWILAPLLLLLLLLGRRARAAAGADAGPGPEPCATLVQGKFFGYFSAAAVFPANASRCSWTLRNPDPRRYTLYMKVAKAPVPCSGPGRVRTYQFDSFLESTRTYLGVESFDEVLRLCDPSAPLAFLQASKQFLQMRRQQPPQHDGLRPRAGPPGPTDDFSVEYLVVGNRNPSRAACQMLCRWLDACLAGSRSSHPCGIMQTPCACLGGEAGGPAAGPLAPRGDVCLRDAVAGGPENCLTSLTQDRGGHGATGGWKLWSLWGECTRDCGGGLQTRTRTCLPAPGVEGGGCEGVLEEGRQCNREACGPAGRTSSRSQSLRSTDARRREELGDELQQFGFPAPQTGDPAAEEWSPWSVCSSTCGEGWQTRTRFCVSSSYSTQCSGPLREQRLCNNSAVCPVHGAWDEWSPWSLCSSTCGRGFRDRTRTCRPPQFGGNPCEGPEKQTKFCNIALCPGRAVDGNWNEWSSWSACSASCSQGRQQRTRECNGPSYGGAECQGHWVETRDCFLQQCPVDGKWQAWASWGSCSVTCGAGSQRRERVCSGPFFGGAACQGPQDEYRQCGTQRCPEPHEICDEDNFGAVIWKETPAGEVAAVRCPRNATGLILRRCELDEEGIAYWEPPTYIRCVSIDYRNIQMMTREHLAKAQRGLPGEGVSEVIQTLVEISQDGTSYSGDLLSTIDVLRNMTEIFRRAYYSPTPGDVQNFVQILSNLLAEENRDKWEEAQLAGPNAKELFRLVEDFVDVIGFRMKDLRDAYQVTDNLVLSIHKLPASGATDISFPMKGWRATGDWAKVPEDRVTVSKSVFSTGLTEADEASVFVVGTVLYRNLGSFLALQRNTTVLNSKVISVTVKPPPRSLRTPLEIEFAHMYNGTTNQTCILWDETDVPSSSAPPQLGPWSWRGCRTVPLDALRTRCLCDRLSTFAILAQLSADANMEKATLPSVTLIVGCGVSSLTLLMLVIIYVSVWRYIRSERSVILINFCLSIISSNALILIGQTQTRNKVVCTLVAAFLHFFFLSSFCWVLTEAWQSYMAVTGHLRNRLIRKRFLCLGWGLPALVVAISVGFTKAKGYSTMNYCWLSLEGGLLYAFVGPAAAVVLVNMVIGILVFNKLVSKDGITDKKLKERAGASLWSSCVVLPLLALTWMSAVLAVTDRRSALFQILFAVFDSLEGFVIVMVHCILRREVQDAVKCRVVDRQEEGNGDSGGSFQNGHAQLMTDFEKDVDLACRSVLNKDIAACRTATITGTLKRPSLPEEEKLKLAHAKGPPTNFNSLPANVSKLHLHGSPRYPGGPLPDFPNHSLTLKRDKAPKSSFVGDGDIFKKLDSELSRAQEKALDTSYVILPTATATLRPKPKEEPKYSIHIDQMPQTRLIHLSTAPEASLPARSPPSRQPPSGGPPEAPPAQPPPPPPPPPPPPQQPLPPPPNLEPAPPSLGDPGEPAAHPGPSTGPSTKNENVATLSVSSLERRKSRYAELDFEKIMHTRKRHQDMFQDLNRKLQHAAEKDKEVLGPDSKPEKQQTPNKRPWESLRKAHGTPTWVKKELEPLQPSPLELRSVEWERSGATIPLVGQDIIDLQTEV T41036 DRUGINFO D0K4SL phosphatidylserine Investigative T91397 TARGETID T91397 T91397 UNIPROID CTRO_HUMAN T91397 TARGNAME Citron Rho-interacting kinase (CIT) T91397 GENENAME CIT T91397 TARGTYPE Literature-reported T91397 SYNONYMS Serine/threonine-protein kinase 21; STK21; KIAA0949; CRIK T91397 FUNCTION Plays a role in cytokinesis. Required for KIF14 localization to the central spindle and midbody. Putative RHO/RAC effector that binds to the GTP-bound forms of RHO and RAC1. It probably binds p21 with a tighter specificity in vivo. Displays serine/threonine protein kinase activity. Plays an important role in the regulation of cytokinesis and the development of the central nervous system. Phosphorylates MYL9/MLC2. T91397 ECNUMBER EC 2.7.11.1 T91397 SEQUENCE MLKFKYGARNPLDAGAAEPIASRASRLNLFFQGKPPFMTQQQMSPLSREGILDALFVLFEECSQPALMKIKHVSNFVRKYSDTIAELQELQPSAKDFEVRSLVGCGHFAEVQVVREKATGDIYAMKVMKKKALLAQEQVSFFEEERNILSRSTSPWIPQLQYAFQDKNHLYLVMEYQPGGDLLSLLNRYEDQLDENLIQFYLAELILAVHSVHLMGYVHRDIKPENILVDRTGHIKLVDFGSAAKMNSNKMVNAKLPIGTPDYMAPEVLTVMNGDGKGTYGLDCDWWSVGVIAYEMIYGRSPFAEGTSARTFNNIMNFQRFLKFPDDPKVSSDFLDLIQSLLCGQKERLKFEGLCCHPFFSKIDWNNIRNSPPPFVPTLKSDDDTSNFDEPEKNSWVSSSPCQLSPSGFSGEELPFVGFSYSKALGILGRSESVVSGLDSPAKTSSMEKKLLIKSKELQDSQDKCHKMEQEMTRLHRRVSEVEAVLSQKEVELKASETQRSLLEQDLATYITECSSLKRSLEQARMEVSQEDDKALQLLHDIREQSRKLQEIKEQEYQAQVEEMRLMMNQLEEDLVSARRRSDLYESELRESRLAAEEFKRKATECQHKLLKAKDQGKPEVGEYAKLEKINAEQQLKIQELQEKLEKAVKASTEATELLQNIRQAKERAERELEKLQNREDSSEGIRKKLVEAEELEEKHREAQVSAQHLEVHLKQKEQHYEEKIKVLDNQIKKDLADKETLENMMQRHEEEAHEKGKILSEQKAMINAMDSKIRSLEQRIVELSEANKLAANSSLFTQRNMKAQEEMISELRQQKFYLETQAGKLEAQNRKLEEQLEKISHQDHSDKNRLLELETRLREVSLEHEEQKLELKRQLTELQLSLQERESQLTALQAARAALESQLRQAKTELEETTAEAEEEIQALTAHRDEIQRKFDALRNSCTVITDLEEQLNQLTEDNAELNNQNFYLSKQLDEASGANDEIVQLRSEVDHLRREITEREMQLTSQKQTMEALKTTCTMLEEQVMDLEALNDELLEKERQWEAWRSVLGDEKSQFECRVRELQRMLDTEKQSRARADQRITESRQVVELAVKEHKAEILALQQALKEQKLKAESLSDKLNDLEKKHAMLEMNARSLQQKLETERELKQRLLEEQAKLQQQMDLQKNHIFRLTQGLQEALDRADLLKTERSDLEYQLENIQVLYSHEKVKMEGTISQQTKLIDFLQAKMDQPAKKKKGLFSRRKEDPALPTQVPLQYNELKLALEKEKARCAELEEALQKTRIELRSAREEAAHRKATDHPHPSTPATARQQIAMSAIVRSPEHQPSAMSLLAPPSSRRKESSTPEEFSRRLKERMHHNIPHRFNVGLNMRATKCAVCLDTVHFGRQASKCLECQVMCHPKCSTCLPATCGLPAEYATHFTEAFCRDKMNSPGLQTKEPSSSLHLEGWMKVPRNNKRGQQGWDRKYIVLEGSKVLIYDNEAREAGQRPVEEFELCLPDGDVSIHGAVGASELANTAKADVPYILKMESHPHTTCWPGRTLYLLAPSFPDKQRWVTALESVVAGGRVSREKAEADAKLLGNSLLKLEGDDRLDMNCTLPFSDQVVLVGTEEGLYALNVLKNSLTHVPGIGAVFQIYIIKDLEKLLMIAGEERALCLVDVKKVKQSLAQSHLPAQPDISPNIFEAVKGCHLFGAGKIENGLCICAAMPSKVVILRYNENLSKYCIRKEIETSEPCSCIHFTNYSILIGTNKFYEIDMKQYTLEEFLDKNDHSLAPAVFAASSNSFPVSIVQVNSAGQREEYLLCFHEFGVFVDSYGRRSRTDDLKWSRLPLAFAYREPYLFVTHFNSLEVIEIQARSSAGTPARAYLDIPNPRYLGPAISSGAIYLASSYQDKLRVICCKGNLVKESGTEHHRGPSTSRSSPNKRGPPTYNEHITKRVASSPAPPEGPSHPREPSTPHRYREGRTELRRDKSPGRPLEREKSPGRMLSTRRERSPGRLFEDSSRGRLPAGAVRTPLSQVNKVWDQSSV T80513 TARGETID T80513 T80513 FORMERID TTDI03197 T80513 UNIPROID FFAR3_HUMAN T80513 TARGNAME Free fatty acid receptor 3 (FFAR3) T80513 GENENAME FFAR3 T80513 TARGTYPE Literature-reported T80513 SYNONYMS GPR41; G-protein coupled receptor 41 T80513 FUNCTION G protein-coupled receptor that is activated by a major product of dietary fiber digestion, the short chain fatty acids (SCFAs), and that plays a role in the regulation of whole-body energy homeostasis and in intestinal immunity. In omnivorous mammals, the short chain fatty acids acetate, propionate and butyrate are produced primarily by the gut microbiome that metabolizes dietary fibers. SCFAs serve as a source of energy but also act as signaling molecules. That G protein-coupled receptor is probably coupled to the pertussis toxin-sensitive, G(i/o)-alpha family of G proteins. Its activation results in the formation of inositol 1,4,5-trisphosphate, the mobilization of intracellular calcium, the phosphorylation of the MAPK3/ERK1 and MAPK1/ERK2 kinases and the inhibition of intracellular cAMP accumulation. Activated by SCFAs and by beta-hydroxybutyrate, a ketone body produced by the liver upon starvation, it inhibits N-type calcium channels and modulates the activity of sympathetic neurons through a signaling cascade involving the beta and gamma subunits of its coupled G protein, phospholipase C and MAP kinases. Thereby, it may regulate energy expenditure through the control of the sympathetic nervous system that controls for instance heart rate. Upon activation by SCFAs accumulating in the intestine, it may also signal to the brain via neural circuits which in turn would regulate intestinal gluconeogenesis. May also control the production of hormones involved in whole-body energy homeostasis. May for instance, regulate blood pressure through renin secretion. May also regulate secretion of the PYY peptide by enteroendocrine cells and control gut motility, intestinal transit rate, and the harvesting of energy from SCFAs produced by gut microbiota. May also indirectly regulate the production of LEP/Leptin, a hormone acting on the CNS to inhibit food intake, in response to the presence of short-chain fatty acids in the intestine. Finally, may also play a role in glucose homeostasis. Besides its role in energy homeostasis, may play a role in intestinal immunity. May mediate the activation of the inflammatory and immune response by SCFAs in the gut, regulating the rapid production of chemokines and cytokines by intestinal epithelial cells. Among SCFAs, the fatty acids containing less than 6 carbons, the most potent activators are probably propionate, butyrate and pentanoate while acetate is a poor activator. T80513 BIOCLASS GPCR rhodopsin T80513 SEQUENCE MDTGPDQSYFSGNHWFVFSVYLLTFLVGLPLNLLALVVFVGKLQRRPVAVDVLLLNLTASDLLLLLFLPFRMVEAANGMHWPLPFILCPLSGFIFFTTIYLTALFLAAVSIERFLSVAHPLWYKTRPRLGQAGLVSVACWLLASAHCSVVYVIEFSGDISHSQGTNGTCYLEFRKDQLAILLPVRLEMAVVLFVVPLIITSYCYSRLVWILGRGGSHRRQRRVAGLLAATLLNFLVCFGPYNVSHVVGYICGESPAWRIYVTLLSTLNSCVDPFVYYFSSSGFQADFHELLRRLCGLWGQWQQESSMELKEQKGGEEQRADRPAERKTSEHSQGCGTGGQVACAES T80513 DRUGINFO D05UBB (S)-4-CMTB Investigative T80513 DRUGINFO D06ZVB isobutyric acid Investigative T80513 DRUGINFO D07FPQ 1-methylcyclopropanecarboxylic acid Investigative T80513 DRUGINFO D0V6IE pentanoic acid Investigative T06146 TARGETID T06146 T06146 FORMERID TTDI00028 T06146 UNIPROID RGS12_HUMAN T06146 TARGNAME Regulator of G-protein signaling 12 (RGS12) T06146 GENENAME RGS12 T06146 TARGTYPE Literature-reported T06146 SYNONYMS RGS12 T06146 FUNCTION Regulates G protein-coupled receptor signaling cascades. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. T06146 PDBSTRUC 2KV8; 2EBZ T06146 SEQUENCE MFRAGEASKRPLPGPSPPRVRSVEVARGRAGYGFTLSGQAPCVLSCVMRGSPADFVGLRAGDQILAVNEINVKKASHEDVVKLIGKCSGVLHMVIAEGVGRFESCSSDEEGGLYEGKGWLKPKLDSKALGINRAERVVEEMQSGGIFNMIFENPSLCASNSEPLKLKQRSLSESAATRFDVGHESINNPNPNMLSKEEISKVIHDDSVFSIGLESHDDFALDASILNVAMIVGYLGSIELPSTSSNLESDSLQAIRGCMRRLRAEQKIHSLVTMKIMHDCVQLSTDKAGVVAEYPAEKLAFSAVCPDDRRFFGLVTMQTNDDGSLAQEEEGALRTSCHVFMVDPDLFNHKIHQGIARRFGFECTADPDTNGCLEFPASSLPVLQFISVLYRDMGELIEGMRARAFLDGDADAHQNNSTSSNSDSGIGNFHQEEKSNRVLVVDLGGSSSRHGPGGSAWDGVGGRGAQPWGAPWTGPFCPDPEGSPPFEAAHQTDRFWDLNKHLGPASPVEVPPASLRSSVPPSKRGTVGAGCGFNQRWLPVHVLREWQCGHTSDQDSYTDSTDGWSSINCGTLPPPMSKIPADRYRVEGSFAQPPLNAPKREWSRKAFGMQSIFGPHRNVRKTKEDKKGSKFGRGTGLTQPSQRTSARRSFGRSKRFSITRSLDDLESATVSDGELTGADLKDCVSNNSLSSNASLPSVQSCRRLRERRVASWAVSFERLLQDPVGVRYFSDFLRKEFSEENILFWQACEYFNHVPAHDKKELSYRAREIFSKFLCSKATTPVNIDSQAQLADDVLRAPHPDMFKEQQLQIFNLMKFDSYTRFLKSPLYQECILAEVEGRALPDSQQVPSSPASKHSLGSDHSSVSTPKKLSGKSKSGRSLNEELGDEDSEKKRKGAFFSWSRTRSTGRSQKKREHGDHADDALHANGGLCRRESQGSVSSAGSLDLSEACRTLAPEKDKATKHCCIHLPDGTSCVVAVKAGFSIKDILSGLCERHGINGAAADLFLVGGDKPLVLHQDSSILESRDLRLEKRTLFRLDLVPINRSVGLKAKPTKPVTEVLRPVVARYGLDLSGLLVRLSGEKEPLDLGAPISSLDGQRVVLEEKDPSRGKASADKQKGVPVKQNTAVNSSSRNHSATGEERTLGKSNSIKIKGENGKNARDPRLSKREESIAKIGKKKYQKINLDEAEEFFELISKAQSNRADDQRGLLRKEDLVLPEFLRLPPGSTELTLPTPAAVAKGFSKRSATGNGRESASQPGEQWEPVQESSDSPSTSPGSASSPPGPPGTTPPGQKSPSGPFCTPQSPVSLAQEGTAQIWKRQSQEVEAGGIQTVEDEHVAELTLMGEGDISSPNSTLLPPPSTPQEVPGPSRPGSGTHGSRDLPVNRIIDVDLVTGSAPGRDGGIAGAQAGPGRSQASGGPPTSDLPGLGPVPGEPAKPKTSAHHATFV T44387 TARGETID T44387 T44387 FORMERID TTDI03396 T44387 UNIPROID MUSK_HUMAN T44387 TARGNAME Muscle-specific kinase receptor (MUSK) T44387 GENENAME MUSK T44387 TARGTYPE Literature-reported T44387 SYNONYMS Muscle-specific tyrosine-protein kinase receptor; Muscle, skeletal receptor tyrosine-protein kinase; MuSK T44387 FUNCTION Receptor tyrosine kinase which plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between the motor neuron and the skeletal muscle. Recruitment of AGRIN by LRP4 to the MUSK signaling complex induces phosphorylation and activation of MUSK, the kinase of the complex. The activation of MUSK in myotubes regulates the formation of NMJs through the regulation of different processes including the specific expression of genes in subsynaptic nuclei, the reorganization of the actin cytoskeleton and the clustering of the acetylcholine receptors (AChR) in the postsynaptic membrane. May regulate AChR phosphorylation and clustering through activation of ABL1 and Src family kinases which in turn regulate MUSK. DVL1 and PAK1 that form a ternary complex with MUSK are also important for MUSK-dependent regulation of AChR clustering. May positively regulate Rho family GTPases through FNTA. Mediates the phosphorylation of FNTA which promotes prenylation, recruitment to membranes and activation of RAC1 a regulator of the actin cytoskeleton and of gene expression. Other effectors of the MUSK signaling include DNAJA3 which functions downstream of MUSK. May also play a role within the central nervous system by mediating cholinergic responses, synaptic plasticity and memory formation (By similarity). T44387 ECNUMBER EC 2.7.10.1 T44387 SEQUENCE MRELVNIPLVHILTLVAFSGTEKLPKAPVITTPLETVDALVEEVATFMCAVESYPQPEISWTRNKILIKLFDTRYSIRENGQLLTILSVEDSDDGIYCCTANNGVGGAVESCGALQVKMKPKITRPPINVKIIEGLKAVLPCTTMGNPKPSVSWIKGDSPLRENSRIAVLESGSLRIHNVQKEDAGQYRCVAKNSLGTAYSKVVKLEVEVFARILRAPESHNVTFGSFVTLHCTATGIPVPTITWIENGNAVSSGSIQESVKDRVIDSRLQLFITKPGLYTCIATNKHGEKFSTAKAAATISIAEWSKPQKDNKGYCAQYRGEVCNAVLAKDALVFLNTSYADPEEAQELLVHTAWNELKVVSPVCRPAAEALLCNHIFQECSPGVVPTPIPICREYCLAVKELFCAKEWLVMEEKTHRGLYRSEMHLLSVPECSKLPSMHWDPTACARLPHLDYNKENLKTFPPMTSSKPSVDIPNLPSSSSSSFSVSPTYSMTVIISIMSSFAIFVLLTITTLYCCRRRKQWKNKKRESAAVTLTTLPSELLLDRLHPNPMYQRMPLLLNPKLLSLEYPRNNIEYVRDIGEGAFGRVFQARAPGLLPYEPFTMVAVKMLKEEASADMQADFQREAALMAEFDNPNIVKLLGVCAVGKPMCLLFEYMAYGDLNEFLRSMSPHTVCSLSHSDLSMRAQVSSPGPPPLSCAEQLCIARQVAAGMAYLSERKFVHRDLATRNCLVGENMVVKIADFGLSRNIYSADYYKANENDAIPIRWMPPESIFYNRYTTESDVWAYGVVLWEIFSYGLQPYYGMAHEEVIYYVRDGNILSCPENCPVELYNLMRLCWSKLPADRPSFTSIHRILERMCERAEGTVSV T44387 DRUGINFO D00ERW PMID17935989C25 Investigative T44387 DRUGINFO D02NNT PMID21493067C1d Investigative T72732 TARGETID T72732 T72732 FORMERID TTDI03182 T72732 UNIPROID EPHB6_HUMAN T72732 TARGNAME Ephrin type-B receptor 6 (EPHB6) T72732 GENENAME EPHB6 T72732 TARGTYPE Literature-reported T72732 SYNONYMS Tyrosine-protein kinase-defective receptor EPH-6; HEP T72732 FUNCTION Binds to ephrin-B1 and ephrin-B2. Modulates cell adhesion and migration by exerting both positive and negative effects upon stimulation with ephrin-B2. Inhibits JNK activation, T-cell receptor-induced IL-2 secretion and CD25 expression upon stimulation with ephrin-B2. Kinase-defective receptor for members of the ephrin-B family. T72732 BIOCLASS Kinase T72732 SEQUENCE MATEGAAQLGNRVAGMVCSLWVLLLVSSVLALEEVLLDTTGETSEIGWLTYPPGGWDEVSVLDDQRRLTRTFEACHVAGAPPGTGQDNWLQTHFVERRGAQRAHIRLHFSVRACSSLGVSGGTCRETFTLYYRQAEEPDSPDSVSSWHLKRWTKVDTIAADESFPSSSSSSSSSSSAAWAVGPHGAGQRAGLQLNVKERSFGPLTQRGFYVAFQDTGACLALVAVRLFSYTCPAVLRSFASFPETQASGAGGASLVAAVGTCVAHAEPEEDGVGGQAGGSPPRLHCNGEGKWMVAVGGCRCQPGYQPARGDKACQACPRGLYKSSAGNAPCSPCPARSHAPNPAAPVCPCLEGFYRASSDPPEAPCTGPPSAPQELWFEVQGSALMLHWRLPRELGGRGDLLFNVVCKECEGRQEPASGGGGTCHRCRDEVHFDPRQRGLTESRVLVGGLRAHVPYILEVQAVNGVSELSPDPPQAAAINVSTSHEVPSAVPVVHQVSRASNSITVSWPQPDQTNGNILDYQLRYYDQAEDESHSFTLTSETNTATVTQLSPGHIYGFQVRARTAAGHGPYGGKVYFQTLPQGELSSQLPERLSLVIGSILGALAFLLLAAITVLAVVFQRKRRGTGYTEQLQQYSSPGLGVKYYIDPSTYEDPCQAIRELAREVDPAYIKIEEVIGTGSFGEVRQGRLQPRGRREQTVAIQALWAGGAESLQMTFLGRAAVLGQFQHPNILRLEGVVTKSRPLMVLTEFMELGPLDSFLRQREGQFSSLQLVAMQRGVAAAMQYLSSFAFVHRSLSAHSVLVNSHLVCKVARLGHSPQGPSCLLRWAAPEVIAHGKHTTSSDVWSFGILMWEVMSYGERPYWDMSEQEVLNAIEQEFRLPPPPGCPPGLHLLMLDTWQKDRARRPHFDQLVAAFDKMIRKPDTLQAGGDPGERPSQALLTPVALDFPCLDSPQAWLSAIGLECYQDNFSKFGLCTFSDVAQLSLEDLPALGITLAGHQKKLLHHIQLLQQHLRQQGSVEV T72732 DRUGINFO D0X8BU PMID23489211C20 Investigative T75077 TARGETID T75077 T75077 FORMERID TTDR01122 T75077 UNIPROID SMAD9_HUMAN T75077 TARGNAME Mothers against decapentaplegic homolog 9 (SMAD9) T75077 GENENAME Smad9 T75077 TARGTYPE Literature-reported T75077 SYNONYMS Smad9; Smad8; SMAD 9; SMAD 8; Mothers against DPP homolog 9 T75077 FUNCTION Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase. SMAD9 is a receptor-regulated SMAD (R-SMAD). Has been shown to be activated by activin type I receptor-like kinases (ALK-2, ALK-3, ALK-6) which stimulate heteromerization between SMAD9 and SMAD4. May play a role in osteoblast differentiation and maturation. T75077 BIOCLASS Dwarfin SMAD family T75077 SEQUENCE MHSTTPISSLFSFTSPAVKRLLGWKQGDEEEKWAEKAVDSLVKKLKKKKGAMDELERALSCPGQPSKCVTIPRSLDGRLQVSHRKGLPHVIYCRVWRWPDLQSHHELKPLECCEFPFGSKQKEVCINPYHYRRVETPVLPPVLVPRHSEYNPQLSLLAKFRSASLHSEPLMPHNATYPDSFQQPPCSALPPSPSHAFSQSPCTASYPHSPGSPSEPESPYQHSVDTPPLPYHATEASETQSGQPVDATADRHVVLSIPNGDFRPVCYEEPQHWCSVAYYELNNRVGETFQASSRSVLIDGFTDPSNNRNRFCLGLLSNVNRNSTIENTRRHIGKGVHLYYVGGEVYAECVSDSSIFVQSRNCNYQHGFHPATVCKIPSGCSLKVFNNQLFAQLLAQSVHHGFEVVYELTKMCTIRMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVLTQMGSPHNPISSVS T96302 TARGETID T96302 T96302 FORMERID TTDI02512 T96302 UNIPROID GP182_HUMAN T96302 TARGNAME G protein coupled receptor 182 (GPR182) T96302 GENENAME GPR182 T96302 TARGTYPE Literature-reported T96302 SYNONYMS Gprotein coupled receptor 182; GPR182 T96302 FUNCTION Orphan receptor. T96302 BIOCLASS GPCR rhodopsin T96302 SEQUENCE MSVKPSWGPGPSEGVTAVPTSDLGEIHNWTELLDLFNHTLSECHVELSQSTKRVVLFALYLAMFVVGLVENLLVICVNWRGSGRAGLMNLYILNMAIADLGIVLSLPVWMLEVTLDYTWLWGSFSCRFTHYFYFVNMYSSIFFLVCLSVDRYVTLTSASPSWQRYQHRVRRAMCAGIWVLSAIIPLPEVVHIQLVEGPEPMCLFMAPFETYSTWALAVALSTTILGFLLPFPLITVFNVLTACRLRQPGQPKSRRHCLLLCAYVAVFVMCWLPYHVTLLLLTLHGTHISLHCHLVHLLYFFYDVIDCFSMLHCVINPILYNFLSPHFRGRLLNAVVHYLPKDQTKAGTCASSSSCSTQHSIIITKGDSQPAAAAPHPEPSLSFQAHHLLPNTSPISPTQPLTPS T43881 TARGETID T43881 T43881 FORMERID TTDI02052 T43881 UNIPROID DFB4A_HUMAN T43881 TARGNAME Beta-defensin 4A (DEFB4A) T43881 GENENAME DEFB4A T43881 TARGTYPE Literature-reported T43881 SYNONYMS hBD2; Skinantimicrobial peptide 1; SAP1; Defensin, beta 2; DEFB4B; DEFB4A; Betadefensin 4A; Betadefensin 2; BD2 T43881 FUNCTION Has antibacterial activity. T43881 PDBSTRUC 6CS9; 1FQQ; 1FD4; 1FD3; 1E4Q T43881 SEQUENCE MRVLYLLFSFLFIFLMPLPGVFGGIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP T43881 DRUGINFO D00XSL rHuB-D2 Investigative T30817 TARGETID T30817 T30817 FORMERID TTDI02349 T30817 UNIPROID SPTC1_HUMAN; SPTC2_HUMAN; SPTC3_HUMAN T30817 TARGNAME Serine palmitoyltransferase (SPTC) T30817 GENENAME SPTLC1; SPTLC2; SPTLC3 T30817 TARGTYPE Literature-reported T30817 SYNONYMS Serine-palmitoyl-CoA transferase; SPT; Long chain base biosynthesis protein; LCB T30817 FUNCTION Serine palmitoyltransferase (SPT). The heterodimer formed with SPTLC2 or SPTLC3 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16-CoA as substrates, with a slight preference for C14-CoA. The SPTLC1- SPTLC2-SPTSSB complex shows a strong preference for C18-CoA substrate, while the SPTLC1-SPTLC3-SPTSSB isozyme displays an ability to use a broader range of acyl-CoAs, without apparent preference. T30817 BIOCLASS Acyltransferase T30817 SEQUENCE MATATEQWVLVEMVQALYEAPAYHLILEGILILWIIRLLFSKTYKLQERSDLTVKEKEELIEEWQPEPLVPPVPKDHPALNYNIVSGPPSHKTVVNGKECINFASFNFLGLLDNPRVKAAALASLKKYGVGTCGPRGFYGTFDVHLDLEDRLAKFMKTEEAIIYSYGFATIASAIPAYSKRGDIVFVDRAACFAIQKGLQASRSDIKLFKHNDMADLERLLKEQEIEDQKNPRKARVTRRFIVVEGLYMNTGTICPLPELVKLKYKYKARIFLEESLSFGVLGEHGRGVTEHYGINIDDIDLISANMENALASIGGFCCGRSFVIDHQRLSGQGYCFSASLPPLLAAAAIEALNIMEENPGIFAVLKEKCGQIHKALQGISGLKVVGESLSPAFHLQLEESTGSREQDVRLLQEIVDQCMNRSIALTQARYLEKEEKCLPPPSIRVVVTVEQTEEELERAASTIKEVAQAVLL T30817 DRUGINFO D0Q7JJ NA-808 Preclinical T55956 TARGETID T55956 T55956 FORMERID TTDI03373 T55956 UNIPROID GRM6_HUMAN T55956 TARGNAME Metabotropic glutamate receptor 6 (mGluR6) T55956 GENENAME GRM6 T55956 TARGTYPE Literature-reported T55956 SYNONYMS MGLUR6; GPRC1F T55956 FUNCTION G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity (By similarity). Signaling stimulates TRPM1 channel activity and Ca(2+) uptake. Required for normal vision. T55956 BIOCLASS GPCR glutamate T55956 SEQUENCE MARPRRAREPLLVALLPLAWLAQAGLARAAGSVRLAGGLTLGGLFPVHARGAAGRACGQLKKEQGVHRLEAMLYALDRVNADPELLPGVRLGARLLDTCSRDTYALEQALSFVQALIRGRGDGDEVGVRCPGGVPPLRPAPPERVVAVVGASASSVSIMVANVLRLFAIPQISYASTAPELSDSTRYDFFSRVVPPDSYQAQAMVDIVRALGWNYVSTLASEGNYGESGVEAFVQISREAGGVCIAQSIKIPREPKPGEFSKVIRRLMETPNARGIIIFANEDDIRRVLEAARQANLTGHFLWVGSDSWGAKTSPILSLEDVAVGAITILPKRASIDGFDQYFMTRSLENNRRNIWFAEFWEENFNCKLTSSGTQSDDSTRKCTGEERIGRDSTYEQEGKVQFVIDAVYAIAHALHSMHQALCPGHTGLCPAMEPTDGRMLLQYIRAVRFNGSAGTPVMFNENGDAPGRYDIFQYQATNGSASSGGYQAVGQWAETLRLDVEALQWSGDPHEVPSSLCSLPCGPGERKKMVKGVPCCWHCEACDGYRFQVDEFTCEACPGDMRPTPNHTGCRPTPVVRLSWSSPWAAPPLLLAVLGIVATTTVVATFVRYNNTPIVRASGRELSYVLLTGIFLIYAITFLMVAEPGAAVCAARRLFLGLGTTLSYSALLTKTNRIYRIFEQGKRSVTPPPFISPTSQLVITFSLTSLQVVGMIAWLGARPPHSVIDYEEQRTVDPEQARGVLKCDMSDLSLIGCLGYSLLLMVTCTVYAIKARGVPETFNEAKPIGFTMYTTCIIWLAFVPIFFGTAQSAEKIYIQTTTLTVSLSLSASVSLGMLYVPKTYVILFHPEQNVQKRKRSLKATSTVAAPPKGEDAEAHK T55956 DRUGINFO D0L0YF homo-AMPA Investigative T55956 DRUGINFO D0N0NJ 1-benzyl-APDC Investigative T55956 DRUGINFO D0ZS8N THPG Investigative T55956 DRUGINFO D0H6BG PHCCC Investigative T55956 DRUGINFO D0KL4K LSP4-2022 Investigative T55956 DRUGINFO D0LC5O (S)-3,4-DCPG Investigative T55956 DRUGINFO D0W3PY ACPT-I Investigative T55956 DRUGINFO D0XG6U LSP1-2111 Investigative T55956 DRUGINFO D09SXN MAP4 Investigative T55956 DRUGINFO D0D2GL MPPG Investigative T55956 DRUGINFO D0N9UZ [3H]LY341495 Investigative T55956 DRUGINFO D0O8AK alpha-methylserine-O-phosphate Investigative T55956 DRUGINFO D0PN6Z L-AP4 Investigative T55956 DRUGINFO D04DKM (1S,3R)-ACPD Investigative T55956 DRUGINFO D0Z7CZ L-CCG-I Investigative T55956 DRUGINFO D07PZQ L-serine-O-phosphate Investigative T31788 TARGETID T31788 T31788 FORMERID TTDI00011 T31788 UNIPROID MOT4_HUMAN T31788 TARGNAME Monocarboxylate transporter 4 (SLC16A3) T31788 GENENAME SLC16A3 T31788 TARGTYPE Literature-reported T31788 SYNONYMS Solute carrier family 16 member 3; MCT4; MCT 4 T31788 FUNCTION Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Proton-linked monocarboxylate transporter. T31788 BIOCLASS Major facilitator T31788 SEQUENCE MGGAVVDEGPTGVKAPDGGWGWAVLFGCFVITGFSYAFPKAVSVFFKELIQEFGIGYSDTAWISSILLAMLYGTGPLCSVCVNRFGCRPVMLVGGLFASLGMVAASFCRSIIQVYLTTGVITGLGLALNFQPSLIMLNRYFSKRRPMANGLAAAGSPVFLCALSPLGQLLQDRYGWRGGFLILGGLLLNCCVCAALMRPLVVTAQPGSGPPRPSRRLLDLSVFRDRGFVLYAVAASVMVLGLFVPPVFVVSYAKDLGVPDTKAAFLLTILGFIDIFARPAAGFVAGLGKVRPYSVYLFSFSMFFNGLADLAGSTAGDYGGLVVFCIFFGISYGMVGALQFEVLMAIVGTHKFSSAIGLVLLMEAVAVLVGPPSGGKLLDATHVYMYVFILAGAEVLTSSLILLLGNFFCIRKKPKEPQPEVAAAEEEKLHKPPADSGVDLREVEHFLKAEPEKNGEVVHTPETSV T39919 TARGETID T39919 T39919 FORMERID TTDI00222 T39919 UNIPROID MRP4_HUMAN T39919 TARGNAME Multidrug resistance protein 4 (ABCC4) T39919 GENENAME ABCC4 T39919 TARGTYPE Literature-reported T39919 SYNONYMS Multispecific organic anion transporter B; Multidrug resistanceassociated protein 4; MRP/cMOATrelated ABC transporter; MOATB; ATPbinding cassette subfamily C member 4; ABCC4 T39919 FUNCTION May be an organic anion pump relevant to cellular detoxification. T39919 BIOCLASS ABC transporter T39919 SEQUENCE MLPVYQEVKPNPLQDANLCSRVFFWWLNPLFKIGHKRRLEEDDMYSVLPEDRSQHLGEELQGFWDKEVLRAENDAQKPSLTRAIIKCYWKSYLVLGIFTLIEESAKVIQPIFLGKIINYFENYDPMDSVALNTAYAYATVLTFCTLILAILHHLYFYHVQCAGMRLRVAMCHMIYRKALRLSNMAMGKTTTGQIVNLLSNDVNKFDQVTVFLHFLWAGPLQAIAVTALLWMEIGISCLAGMAVLIILLPLQSCFGKLFSSLRSKTATFTDARIRTMNEVITGIRIIKMYAWEKSFSNLITNLRKKEISKILRSSCLRGMNLASFFSASKIIVFVTFTTYVLLGSVITASRVFVAVTLYGAVRLTVTLFFPSAIERVSEAIVSIRRIQTFLLLDEISQRNRQLPSDGKKMVHVQDFTAFWDKASETPTLQGLSFTVRPGELLAVVGPVGAGKSSLLSAVLGELAPSHGLVSVHGRIAYVSQQPWVFSGTLRSNILFGKKYEKERYEKVIKACALKKDLQLLEDGDLTVIGDRGTTLSGGQKARVNLARAVYQDADIYLLDDPLSAVDAEVSRHLFELCICQILHEKITILVTHQLQYLKAASQILILKDGKMVQKGTYTEFLKSGIDFGSLLKKDNEESEQPPVPGTPTLRNRTFSESSVWSQQSSRPSLKDGALESQDTENVPVTLSEENRSEGKVGFQAYKNYFRAGAHWIVFIFLILLNTAAQVAYVLQDWWLSYWANKQSMLNVTVNGGGNVTEKLDLNWYLGIYSGLTVATVLFGIARSLLVFYVLVNSSQTLHNKMFESILKAPVLFFDRNPIGRILNRFSKDIGHLDDLLPLTFLDFIQTLLQVVGVVSVAVAVIPWIAIPLVPLGIIFIFLRRYFLETSRDVKRLESTTRSPVFSHLSSSLQGLWTIRAYKAEERCQELFDAHQDLHSEAWFLFLTTSRWFAVRLDAICAMFVIIVAFGSLILAKTLDAGQVGLALSYALTLMGMFQWCVRQSAEVENMMISVERVIEYTDLEKEAPWEYQKRPPPAWPHEGVIIFDNVNFMYSPGGPLVLKHLTALIKSQEKVGIVGRTGAGKSSLISALFRLSEPEGKIWIDKILTTEIGLHDLRKKMSIIPQEPVLFTGTMRKNLDPFNEHTDEELWNALQEVQLKETIEDLPGKMDTELAESGSNFSVGQRQLVCLARAILRKNQILIIDEATANVDPRTDELIQKKIREKFAHCTVLTIAHRLNTIIDSDKIMVLDSGRLKEYDEPYVLLQNKESLFYKMVQQLGKAEAAALTETAKQVYFKRNYPHIGHTDHMVTNTSNGQPSTLTIFETAL T95411 TARGETID T95411 T95411 FORMERID TTDR00025 T95411 UNIPROID O15851_LEIME T95411 TARGNAME Leishmania Cdc2-related kinase 3 (Leishmania CRK3) T95411 GENENAME Leishmania CRK3 T95411 TARGTYPE Literature-reported T95411 SYNONYMS Cdc2-related kinase 3; CRK3 cyclin-dependent kinase; CRK3 T95411 FUNCTION Form an active protein kinase complex with Leishmania cyclins CYCA and CYC6. T95411 BIOCLASS Kinase T95411 SEQUENCE MSSFGRVTARSGDAGTRDSLDRYNRLDVLGEGTYGVVYRAVDKITGQYVALKKVRLDRTEEGIPQTALREVSILQEFDHPNIVNLLDVICSDGKLYLVFEYVEADLKKAIEKQEGGYSGMDLKRLIYQLLDGLYFCHRHRIIHRDLKPANILLTSGNVLKLADFGLARAFQVPMHTYTHEVVTLWYRAPEILLGEKHYTPAVDMWSVGCIFAELARRKVLFRGDSEIGQLFEIFQVLGTPTDTEGSWPGVSRLPDYRDVFPKWTAKRLGQVLPELHPDAIDLLSKMLKYDPRERISAKEALQHPWFSDLRW T21829 TARGETID T21829 T21829 FORMERID TTDR00026 T21829 UNIPROID RIR2_TRYBB T21829 TARGNAME Trypanosoma Ribonucleotide reductase R2 (Trypano RNR2) T21829 GENENAME Trypano RNR2 T21829 TARGTYPE Literature-reported T21829 SYNONYMS Ribonucleotide reductase R2 subunit; RNR2 T21829 FUNCTION Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. T21829 BIOCLASS CH/CH(2) oxidoreductase T21829 SEQUENCE MPPKSHKCSRKEGEVEEPLLTENPDRYVIFPIKYPDIWQKYKEAESSIWTVEEIDLGNDMTDWEKLDDGERHFIKHVLAFFAASDGIVLENLAERFMCEVQVPEVRCFYGFQIAMENIHSETYSVLIDTYVVDPDEKQRLLHAIRTIPCIEKKAKWAIEWIGSQTSFPTRLVAFAAVEGIFFSGSFCAIFWLKKRGLMPGLTFSNELISRDEGLHTDFACLLYEKYIVNKLPRDRVLEIICNAVSIEREFICDALPVRLIGMNSQLMTQYIEFVADRLLVSLGYDRHYNSKNPFDFMDMISLQGKTNFFEKKVGEYQKAGVMSSERSSKVFSLDADF T94335 TARGETID T94335 T94335 FORMERID TTDI01474 T94335 UNIPROID MQMTN_HELPY T94335 TARGNAME Helicobacter pylori Methylthioadenosine nucleosidase (HELPY mtnN) T94335 GENENAME HELPY mtnN T94335 TARGTYPE Literature-reported T94335 SYNONYMS MTAN; MTA/SAH nucleosidase; Aminofutalosine nucleosidase; Aminodeoxyfutalosine nucleosidase; AFL nucleosidase; 6-amino-6-deoxyfutalosine N-ribosylhydrolase; 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase T94335 FUNCTION Catalyzes the direct conversion of aminodeoxyfutalosine (AFL) into dehypoxanthine futalosine (DHFL) and adenine via the hydrolysis of the N-glycosidic bond; this reaction seems to represent an essential step in the menaquinone biosynthesis pathway in Helicobacter species. Can also probably catalyzes the hydrolysis of 5'-methylthioadenosine (MTA) and S-adenosylhomocysteine (SAH) to adenine and the corresponding thioribose, 5'-methylthioribose and S-ribosylhomocysteine, respectively. These other activities highlight the tremendous versatility of the enzyme, which also plays key roles in S-adenosylmethionine recycling and in the biosynthesis of the quorum-sensing molecule autoinducer-2. Does not act on futalosine (FL) as substrate. T94335 PDBSTRUC 4BN0; 4BMZ; 4BMY; 4BMX T94335 SEQUENCE MVQKIGILGAMREEITPILELFGVDFEEIPLGGNVFHKGVYHNKEIIVAYSKIGKVHSTLTTTSMILAFGVQKVLFSGVAGSLVKDLKINDLLVAIQLVQHDVDLSAFDHPLGFIPESAIFIETSESLNALAKEVANEQHIVLKEGVIASGDQFVHSKERKEFLVSEFKASAVEMEGASVAFVCQKFGVPCCVLRSISDNADEEANMSFDAFLEKSAQTSAKFLKSMVDEL T78670 TARGETID T78670 T78670 FORMERID TTDR00800 T78670 UNIPROID PPK1_MYCLE T78670 TARGNAME Mycobacterium Polyphosphate kinase (MycB ppk) T78670 GENENAME MycB ppk T78670 TARGTYPE Literature-reported T78670 SYNONYMS Polyphosphoric acid kinase; PPK; ATP-polyphosphate phosphotransferase T78670 FUNCTION Catalyzes the reversible transfer of the terminal phosphate of ATP to form a long-chain polyphosphate (polyP). T78670 BIOCLASS Kinase T78670 SEQUENCE MMSNDLLVTDIEAEARTEENIWHSDNSALAAPPAATTSASQDQLPDDRYLNRESSWLDFNARVLALAADNSLPLLERAKFLAIFASNLDEFYMVRVAGLKRRDEMDLSVRSADGLTPREQLSRIGEQTQWIASRHARVFLDSVLPALGEEGIYIVTWTDLDQAERDQLSTYFNEQVFPVLTPLAVDPAHPFPFVSGLSLNLAVTVKQPEDGTQHFARVKVPNNVDRFVELANRGAVRDTSAGDEGQLIHRFLPMEELIAAFLPVLFPGTEIVEHHAFRITRNADFEVEEDRDEDLLQALERELARRRFGSPVRLEIADDMTESMLELLLRELDVHPSDVIEVPGLLDLSSLWQIYGLDRPALKDRAFIPDTHPAFAERETPKSIFATLREGDVLVHHPYHSFATSVQRFIEQATADPDVLAIKQTLYRTSGDSPIVLALIEAAEAGKQVVALVEIKARFDEQANIRWARALEHAGVHVVYGIVGLKTHCKTCLVVRREGPTIRRYCHIGTGNYNSKTARLYEDVGLLTAAPDIGADLTDLFNSLTGYSRKLAYRNLLVAPYGIRRGIIERVEREVAAHRESGPQTGKGLIRLKMNALVDEQVIDALYRASQAGVRVEVVVRGICALRPGTEGFSENIFVRSILGRFLEHSRIIHFRAIDEFWIGSADMMHRNLDRRVEVLAQVKDSRLTAQLDELLKSALDPFTRCWELRPDGQWTASPQKGQQVRDHQESLMERHRSR T94369 TARGETID T94369 T94369 FORMERID TTDNR00724 T94369 UNIPROID O33336_MYCTU T94369 TARGNAME Mycobacterium Phosphopantetheinyl transferase (MycB pptT) T94369 GENENAME MycB pptT T94369 TARGTYPE Literature-reported T94369 SYNONYMS Phosphopantetheinyl transferase PptT (CoA:APO-[ACP]pantetheinephosphotransferase) (CoA:APO-[acyl-carrier protein]pantetheinephosphotransferase) T94369 FUNCTION Invovled in the assembly-line production of complex molecules such as fatty acids, polyketides and polypeptides, where they activate acyl or peptidyl carrier proteins, transferring a 4'-phosphopantetheinyl moiety from coenzyme A (CoA) to a reactive serine residue on the carrier protein. T94369 PDBSTRUC 4U89; 4QVH; 4QJK T94369 SEQUENCE MTVGTLVASVLPATVFEDLAYAELYSDPPGLTPLPEEAPLIARSVAKRRNEFITVRHCARIALDQLGVPPAPILKGDKGEPCWPDGMVGSLTHCAGYRGAVVGRRDAVRSVGIDAEPHDVLPNGVLDAISLPAERADMPRTMPAALHWDRILFCAKEATYKAWFPLTKRWLGFEDAHITFETDSTGWTGRFVSRILIDGSTLSGPPLTTLRGRWSVERGLVLTAIVL T79566 TARGETID T79566 T79566 FORMERID TTDI03042 T79566 UNIPROID AQP9_HUMAN T79566 TARGNAME Aquaporin-9 (AQP9) T79566 GENENAME AQP9 T79566 TARGTYPE Literature-reported T79566 SYNONYMS Small solute channel 1; SSC1; Aquaglyceroporin-9; AQP-9 T79566 FUNCTION Forms a water channel with a broad specificity. Also permeable glycerol and urea. Mediates passage of a wide variety of small, non-charged solutes including carbamides, polyols, purines, and pyrimidines. T79566 BIOCLASS Major intrinsic protein T79566 SEQUENCE MQPEGAEKGKSFKQRLVLKSSLAKETLSEFLGTFILIVLGCGCVAQAILSRGRFGGVITINVGFSMAVAMAIYVAGGVSGGHINPAVSLAMCLFGRMKWFKLPFYVGAQFLGAFVGAATVFGIYYDGLMSFAGGKLLIVGENATAHIFATYPAPYLSLANAFADQVVATMILLIIVFAIFDSRNLGAPRGLEPIAIGLLIIVIASSLGLNSGCAMNPARDLSPRLFTALAGWGFEVFRAGNNFWWIPVVGPLVGAVIGGLIYVLVIEIHHPEPDSVFKTEQSEDKPEKYELSVIM T79566 DRUGINFO D0HD2G phloretin Investigative T77099 TARGETID T77099 T77099 FORMERID TTDNR00721 T77099 UNIPROID S26A4_HUMAN T77099 TARGNAME Solute carrier family 26 member 4 (SLC26A4) T77099 GENENAME SLC26A4 T77099 TARGTYPE Literature-reported T77099 SYNONYMS Sodium-independent chloride/iodide transporter; SLC26A4 T77099 FUNCTION Sodium-independent transporter of chloride and iodide. T77099 BIOCLASS Sulfate permease T77099 SEQUENCE MAAPGGRSEPPQLPEYSCSYMVSRPVYSELAFQQQHERRLQERKTLRESLAKCCSCSRKRAFGVLKTLVPILEWLPKYRVKEWLLSDVISGVSTGLVATLQGMAYALLAAVPVGYGLYSAFFPILTYFIFGTSRHISVGPFPVVSLMVGSVVLSMAPDEHFLVSSSNGTVLNTTMIDTAARDTARVLIASALTLLVGIIQLIFGGLQIGFIVRYLADPLVGGFTTAAAFQVLVSQLKIVLNVSTKNYNGVLSIIYTLVEIFQNIGDTNLADFTAGLLTIVVCMAVKELNDRFRHKIPVPIPIEVIVTIIATAISYGANLEKNYNAGIVKSIPRGFLPPELPPVSLFSEMLAASFSIAVVAYAIAVSVGKVYATKYDYTIDGNQEFIAFGISNIFSGFFSCFVATTALSRTAVQESTGGKTQVAGIISAAIVMIAILALGKLLEPLQKSVLAAVVIANLKGMFMQLCDIPRLWRQNKIDAVIWVFTCIVSIILGLDLGLLAGLIFGLLTVVLRVQFPSWNGLGSIPSTDIYKSTKNYKNIEEPQGVKILRFSSPIFYGNVDGFKKCIKSTVGFDAIRVYNKRLKALRKIQKLIKSGQLRATKNGIISDAVSTNNAFEPDEDIEDLEELDIPTKEIEIQVDWNSELPVKVNVPKVPIHSLVLDCGAISFLDVVGVRSLRVIVKEFQRIDVNVYFASLQDYVIEKLEQCGFFDDNIRKDTFFLTVHDAILYLQNQVKSQEGQGSILETITLIQDCKDTLELIETELTEEELDVQDEAMRTLAS T58460 TARGETID T58460 T58460 FORMERID TTDR00608 T58460 UNIPROID ENSA_HUMAN T58460 TARGNAME Alpha-endosulfine (ENSA) T58460 GENENAME ENSA T58460 TARGTYPE Literature-reported T58460 SYNONYMS ENSA; ARPP19e T58460 FUNCTION Endogenous ligand for sulfonylurea receptor. By inhibitingsulfonylurea from binding to the receptor, it reduces k(atp) channel currents and thereby stimulates insulin secretion. T58460 BIOCLASS Endosulfine family T58460 SEQUENCE MSQKQEEENPAEETGEEKQDTQEKEGILPERAEEAKLKAKYPSLGQKPGGSDFLMKRLQKGQKYFDSGDYNMAKAKMKNKQLPSAGPDKNLVTGDHIPTPQDLPQRKSSLVTSKLAGGQVE T68320 TARGETID T68320 T68320 FORMERID TTDI03621 T68320 UNIPROID XPP2_HUMAN T68320 TARGNAME X-prolyl aminopeptidase 2 (XPNPEP2) T68320 GENENAME XPNPEP2 T68320 TARGTYPE Literature-reported T68320 SYNONYMS mAmP; Xaa-Pro aminopeptidase 2; X-Pro aminopeptidase 2; Membrane-bound aminopeptidase P; Membrane-bound AmP; Membrane-bound APP; Aminoacylproline aminopeptidase T68320 FUNCTION Membrane-bound metalloprotease which catalyzes the removal of a penultimate prolyl residue from the N-termini of peptides, such as Arg-Pro-Pro. May play a role in the metabolism of the vasodilator bradykinin. T68320 ECNUMBER EC 3.4.11.9 T68320 SEQUENCE MARAHWGCCPWLVLLCACAWGHTKPVDLGGQDVRNCSTNPPYLPVTVVNTTMSLTALRQQMQTQNLSAYIIPGTDAHMNEYIGQHDERRAWITGFTGSAGTAVVTMKKAAVWTDSRYWTQAERQMDCNWELHKEVGTTPIVTWLLTEIPAGGRVGFDPFLLSIDTWESYDLALQGSNRQLVSITTNLVDLVWGSERPPVPNQPIYALQEAFTGSTWQEKVSGVRSQMQKHQKVPTAVLLSALEETAWLFNLRASDIPYNPFFYSYTLLTDSSIRLFANKSRFSSETLSYLNSSCTGPMCVQIEDYSQVRDSIQAYSLGDVRIWIGTSYTMYGIYEMIPKEKLVTDTYSPVMMTKAVKNSKEQALLKASHVRDAVAVIRYLVWLEKNVPKGTVDEFSGAEIVDKFRGEEQFSSGPSFETISASGLNAALAHYSPTKELNRKLSSDEMYLLDSGGQYWDGTTDITRTVHWGTPSAFQKEAYTRVLIGNIDLSRLIFPAATSGRMVEAFARRALWDAGLNYGHGTGHGIGNFLCVHEWPVGFQSNNIAMAKGMFTSIEPGYYKDGEFGIRLEDVALVVEAKTKYPGSYLTFEVVSFVPYDRNLIDVSLLSPEHLQYLNRYYQTIREKVGPELQRRQLLEEFEWLQQHTEPLAARAPDTASWASVLVVSTLAILGWSV T68320 DRUGINFO D0CG7Q PMID10395480C6 Investigative T74965 TARGETID T74965 T74965 FORMERID TTDR01020 T74965 UNIPROID CF30_MYCTU T74965 TARGNAME Mycobacterium 27kDa antigen Cfp30B (MycB cfp32) T74965 GENENAME MycB cfp32 T74965 TARGTYPE Literature-reported T74965 SYNONYMS MycB Putative glyoxylase CF30 T74965 FUNCTION May function as a glyoxylase involved in the methylglyoxal detoxification pathway. Induces maturation of dendritic cells in a TLR2-dependent manner, causing increased expression of cell-surface molecules (CD80, CD86, MHC class I and II) and proinflammatory cytokines (TNF-alpha, IL-6, IL-1 beta and IL-12p70). Acts via both the NF-kappa-B and MAPK signaling pathways. Induces Th1-polarized immune responses. T74965 PDBSTRUC 3OXH T74965 SEQUENCE MPKRSEYRQGTPNWVDLQTTDQSAAKKFYTSLFGWGYDDNPVPGGGGVYSMATLNGEAVAAIAPMPPGAPEGMPPIWNTYIAVDDVDAVVDKVVPGGGQVMMPAFDIGDAGRMSFITDPTGAAVGLWQANRHIGATLVNETGTLIWNELLTDKPDLALAFYEAVVGLTHSSMEIAAGQNYRVLKAGDAEVGGCMEPPMPGVPNHWHVYFAVDDADATAAKAAAAGGQVIAEPADIPSVGRFAVLSDPQGAIFSVLKPAPQQ T38453 TARGETID T38453 T38453 FORMERID TTDI00033 T38453 UNIPROID ZEB2_HUMAN T38453 TARGNAME Zinc finger E-box-binding homeobox 2 (ZEB2) T38453 GENENAME ZEB2 T38453 TARGTYPE Literature-reported T38453 SYNONYMS Zinc finger homeobox protein 1b; ZFX1B; ZFHX1B; Smad-interacting protein 1; SMADIP1; SIP1; KIAA0569; HRIHFB2411 T38453 FUNCTION Represses transcription of E-cadherin. Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters. T38453 PDBSTRUC 2DA7 T38453 SEQUENCE MKQPIMADGPRCKRRKQANPRRKNVVNYDNVVDTGSETDEEDKLHIAEDDGIANPLDQETSPASVPNHESSPHVSQALLPREEEEDEIREGGVEHPWHNNEILQASVDGPEEMKEDYDTMGPEATIQTAINNGTVKNANCTSDFEEYFAKRKLEERDGHAVSIEEYLQRSDTAIIYPEAPEELSRLGTPEANGQEENDLPPGTPDAFAQLLTCPYCDRGYKRLTSLKEHIKYRHEKNEENFSCPLCSYTFAYRTQLERHMVTHKPGTDQHQMLTQGAGNRKFKCTECGKAFKYKHHLKEHLRIHSGEKPYECPNCKKRFSHSGSYSSHISSKKCIGLISVNGRMRNNIKTGSSPNSVSSSPTNSAITQLRNKLENGKPLSMSEQTGLLKIKTEPLDFNDYKVLMATHGFSGTSPFMNGGLGATSPLGVHPSAQSPMQHLGVGMEAPLLGFPTMNSNLSEVQKVLQIVDNTVSRQKMDCKAEEISKLKGYHMKDPCSQPEEQGVTSPNIPPVGLPVVSHNGATKSIIDYTLEKVNEAKACLQSLTTDSRRQISNIKKEKLRTLIDLVTDDKMIENHNISTPFSCQFCKESFPGPIPLHQHERYLCKMNEEIKAVLQPHENIVPNKAGVFVDNKALLLSSVLSEKGMTSPINPYKDHMSVLKAYYAMNMEPNSDELLKISIAVGLPQEFVKEWFEQRKVYQYSNSRSPSLERSSKPLAPNSNPPTKDSLLPRSPVKPMDSITSPSIAELHNSVTNCDPPLRLTKPSHFTNIKPVEKLDHSRSNTPSPLNLSSTSSKNSHSSSYTPNSFSSEELQAEPLDLSLPKQMKEPKSIIATKNKTKASSISLDHNSVSSSSENSDEPLNLTFIKKEFSNSNNLDNKSTNPVFSMNPFSAKPLYTALPPQSAFPPATFMPPVQTSIPGLRPYPGLDQMSFLPHMAYTYPTGAATFADMQQRRKYQRKQGFQGELLDGAQDYMSGLDDMTDSDSCLSRKKIKKTESGMYACDLCDKTFQKSSSLLRHKYEHTGKRPHQCQICKKAFKHKHHLIEHSRLHSGEKPYQCDKCGKRFSHSGSYSQHMNHRYSYCKREAEEREAAEREAREKGHLEPTELLMNRAYLQSITPQGYSDSEERESMPRDGESEKEHEKEGEDGYGKLGRQDGDEEFEEEEEESENKSMDTDPETIRDEEETGDHSMDDSSEDGKMETKSDHEEDNMEDGM T71492 TARGETID T71492 T71492 FORMERID TTDR01013 T71492 UNIPROID NHRF3_HUMAN T71492 TARGNAME PDZ domain containing-protein (PDZK1) T71492 GENENAME PDZK1 T71492 TARGTYPE Literature-reported T71492 SYNONYMS Sodium-hydrogen exchanger regulatory factor 3; PDZD1; PDZ domain-containing protein 1; NaPi-Cap1; Na/Pi cotransporter C-terminal-associated protein 1; Na(+)/H(+) exchanger regulatory factor 3; Na(+)/H(+) exchange regulatory cofactor NHE-RF3; NHERF3; NHERF-3; Multi-PDZ domain containing adaptor protein; CFTR-associated protein of 70 kDa; CAP70 T71492 FUNCTION May be involved in the coordination of a diverse range of regulatory processes for ion transport and second messenger cascades. In complex with SLC9A3R1, may cluster proteins that are functionally dependent in a mutual fashion and modulate the trafficking and the activity of the associated membrane proteins. May play a role in the cellular mechanisms associated with multidrug resistance through its interaction with ABCC2 and PDZK1IP1. May potentiate the CFTR chloride channel activity. Required for normal cell-surface expression of SCARB1. Plays a role in maintaining normal plasma cholesterol levels via its effects on SCARB1. Plays a role in the normal localization and function of the chloride-anion exchanger SLC26A6 to the plasma membrane in the brush border of the proximal tubule of the kidney. May be involved in the regulation of proximal tubular Na(+)-dependent inorganic phosphate cotransport therefore playing an important role in tubule function. A scaffold protein that connects plasma membrane proteins and regulatory components, regulating their surface expression in epithelial cells apical domains. T71492 PDBSTRUC 6EZI; 4Q2P; 3TMH; 2VSP; 2EEJ T71492 SEQUENCE MTSTFNPRECKLSKQEGQNYGFFLRIEKDTEGHLVRVVEKCSPAEKAGLQDGDRVLRINGVFVDKEEHMQVVDLVRKSGNSVTLLVLDGDSYEKAVKTRVDLKELGQSQKEQGLSDNILSPVMNGGVQTWTQPRLCYLVKEGGSYGFSLKTVQGKKGVYMTDITPQGVAMRAGVLADDHLIEVNGENVEDASHEEVVEKVKKSGSRVMFLLVDKETDKRHVEQKIQFKRETASLKLLPHQPRIVEMKKGSNGYGFYLRAGSEQKGQIIKDIDSGSPAEEAGLKNNDLVVAVNGESVETLDHDSVVEMIRKGGDQTSLLVVDKETDNMYRLAHFSPFLYYQSQELPNGSVKEAPAPTPTSLEVSSPPDTTEEVDHKPKLCRLAKGENGYGFHLNAIRGLPGSFIKEVQKGGPADLAGLEDEDVIIEVNGVNVLDEPYEKVVDRIQSSGKNVTLLVCGKKAYDYFQAKKIPIVSSLADPLDTPPDSKEGIVVESNHDSHMAKERAHSTASHSSSNSEDTEM T99333 TARGETID T99333 T99333 FORMERID TTDI03098 T99333 UNIPROID CAC1F_HUMAN T99333 TARGNAME Voltage-gated calcium channel alpha Cav1.4 (CACNA1F) T99333 GENENAME CACNA1F T99333 TARGTYPE Literature-reported T99333 SYNONYMS Voltage-gated calcium channel subunit alpha Cav1.4; Voltage-dependent L-type calcium channel subunit alpha-1F; CACNAF1 T99333 FUNCTION Isoform 1: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, and by benzothiazepines. Activates at more negative voltages and does not undergo calcium-dependent inactivation (CDI), due to incoming calcium ions, during depolarization. T99333 BIOCLASS Voltage-gated ion channel T99333 SEQUENCE MSESEGGKDTTPEPSPANGAGPGPEWGLCPGPPAVEGESSGASGLGTPKRRNQHSKHKTVAVASAQRSPRALFCLTLANPLRRSCISIVEWKPFDILILLTIFANCVALGVYIPFPEDDSNTANHNLEQVEYVFLVIFTVETVLKIVAYGLVLHPSAYIRNGWNLLDFIIVVVGLFSVLLEQGPGRPGDAPHTGGKPGGFDVKALRAFRVLRPLRLVSGVPSLHIVLNSIMKALVPLLHIALLVLFVIIIYAIIGLELFLGRMHKTCYFLGSDMEAEEDPSPCASSGSGRACTLNQTECRGRWPGPNGGITNFDNFFFAMLTVFQCVTMEGWTDVLYWMQDAMGYELPWVYFVSLVIFGSFFVLNLVLGVLSGEFSKEREKAKARGDFQKQREKQQMEEDLRGYLDWITQAEELDMEDPSADDNLGSMAEEGRAGHRPQLAELTNRRRGRLRWFSHSTRSTHSTSSHASLPASDTGSMTETQGDEDEEEGALASCTRCLNKIMKTRVCRRLRRANRVLRARCRRAVKSNACYWAVLLLVFLNTLTIASEHHGQPVWLTQIQEYANKVLLCLFTVEMLLKLYGLGPSAYVSSFFNRFDCFVVCGGILETTLVEVGAMQPLGISVLRCVRLLRIFKVTRHWASLSNLVASLLNSMKSIASLLLLLFLFIIIFSLLGMQLFGGKFNFDQTHTKRSTFDTFPQALLTVFQILTGEDWNVVMYDGIMAYGGPFFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLASGDAGTAKDKGGEKSNEKDLPQENEGLVPGVEKEEEEGARREGADMEEEEEEEEEEEEEEEEEGAGGVELLQEVVPKEKVVPIPEGSAFFCLSQTNPLRKGCHTLIHHHVFTNLILVFIILSSVSLAAEDPIRAHSFRNHILGYFDYAFTSIFTVEILLKMTVFGAFLHRGSFCRSWFNMLDLLVVSVSLISFGIHSSAISVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIMIVTTLLQFMFACIGVQLFKGKFYTCTDEAKHTPQECKGSFLVYPDGDVSRPLVRERLWVNSDFNFDNVLSAMMALFTVSTFEGWPALLYKAIDAYAEDHGPIYNYRVEISVFFIVYIIIIAFFMMNIFVGFVIITFRAQGEQEYQNCELDKNQRQCVEYALKAQPLRRYIPKNPHQYRVWATVNSAAFEYLMFLLILLNTVALAMQHYEQTAPFNYAMDILNMVFTGLFTIEMVLKIIAFKPKHYFTDAWNTFDALIVVGSIVDIAVTEVNNGGHLGESSEDSSRISITFFRLFRVMRLVKLLSKGEGIRTLLWTFIKSFQALPYVALLIAMIFFIYAVIGMQMFGKVALQDGTQINRNNNFQTFPQAVLLLFRCATGEAWQEIMLASLPGNRCDPESDFGPGEEFTCGSNFAIAYFISFFMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWSEYDPGAKGRIKHLDVVALLRRIQPPLGFGKLCPHRVACKRLVAMNMPLNSDGTVTFNATLFALVRTSLKIKTEGNLEQANQELRIVIKKIWKRMKQKLLDEVIPPPDEEEVTVGKFYATFLIQDYFRKFRRRKEKGLLGNDAAPSTSSALQAGLRSLQDLGPEMRQALTCDTEEEEEEGQEGVEEEDEKDLETNKATMVSQPSARRGSGISVSLPVGDRLPDSLSFGPSDDDRGTPTSSQPSVPQAGSNTHRRGSGALIFTIPEEGNSQPKGTKGQNKQDEDEEVPDRLSYLDEQAGTPPCSVLLPPHRAQRYMDGHLVPRRRLLPPTPAGRKPSFTIQCLQRQGSCEDLPIPGTYHRGRNSGPNRAQGSWATPPQRGRLLYAPLLLVEEGAAGEGYLGRSSGPLRTFTCLHVPGTHSDPSHGKRGSADSLVEAVLISEGLGLFARDPRFVALAKQEIADACRLTLDEMDNAASDLLAQGTSSLYSDEESILSRFDEEDLGDEMACVHAL T99333 DRUGINFO D02RIH (-)-(S)-BayK8644 Investigative T99333 DRUGINFO D00YNI L-(cis)-diltiazem Investigative T78587 TARGETID T78587 T78587 FORMERID TTDR00761 T78587 UNIPROID O61142_PLAFA T78587 TARGNAME Plasmodium Subtilisin-like protease (Malaria sub-1) T78587 GENENAME Malaria sub-1 T78587 TARGTYPE Literature-reported T78587 SYNONYMS Subtilisin-like protease T78587 FUNCTION Plays a dual role at the blood stage by enabling egress of the progeny merozoites from the infected erythrocyte and priming merozoites for subsequent erythrocyte invasion. T78587 BIOCLASS Protease T78587 SEQUENCE MMLNKKVVALCTLTLHLFCIFLCLGKEVRSEENGKIQDDAKKIVSELRFLEKVEDVIEKSNIGGNEVDADENSFNPDTEVPIEEIEEIKMRELKDVKEEKNKNDNHNNNNNNNNISSSSSSSSNTFGEEKEEVSKKKKKLRLIVSENHATTPSFFQESLLEPDVLSFLESKGNLSNLKNINSMIIELKEDTTDDELISYIKILEEKGALIESDKLVSADNIDISGIKDAIRRGEENIDVNDYKSMLEVENDAEDYDKMFGMFNESHAATSKRKRHSTNERGYDTFSSPSYKTYSKSDYLYDDDNNNNNYYYSHSSNGHNSSSRNSSSSRSRPGKYHFNDEFRNLQWGLDLSRLDETQELINEHQVMSTRICVIDSGIDYNHPDLKDNIELNLKELHGRKGFDDDNNGIVDDIYGANFVNNSGNPMDDNYHGTHVSGIISAIGNNNIGVVGVDVNSKLIICKALDEHKLGRLGDMFKCLDYCISRNAHMINGSFSFDEYSGIFNSSVEYLQRKGILFFVSASNCSHPKSSTPDIRKCDLSINAKYPPILSTVYDNVISVANLKKNDNNNHYSLSINSFYSNKYCQLAAPGTNIYSTAPHNSYRKLNGTSMAAPHVAAIASLIFSINPDLSYKKVIQILKDSIVYLPSLKNMVAWAGYADINKAVNLAIKSKKTYINSNISNKWKKKSRYLH T76126 TARGETID T76126 T76126 FORMERID TTDR00826 T76126 UNIPROID O74271_CANAX T76126 TARGNAME Candida Histidine kinase (Candi chik1) T76126 GENENAME Candi chik1 T76126 TARGTYPE Literature-reported T76126 SYNONYMS Histidine kinase T76126 FUNCTION Catalyses the phosphorylation of a histidine residue in response to detection of an extracellular signal such as a chemical ligand or change in environment, to initiate a change in cell state or activity. T76126 BIOCLASS Kinase T76126 SEQUENCE MNPTKKPRLSPMQPSVFEILNDPELYSQHCHSLRETLLDHFNHQATLIDTYEHELEKSKNANKAFQQALSEIGTVVISVAMGDLSKKVEIHTVENDPEILKVKITINTMMDQLQTFANEVTKVATEVANGELGGQAKNDGSVGIWRSLTDNVNIMALNLTNQVREIADVTRAVAKGDLSRKINVHAQGEILQLQRTINTMVDQLRTFAFEVSKVARDVGVLGILGGQALIENVEGIWEELTDNVNAMALNLTTQVRNIANVTTAVAKGDLSKKVTADCKGEILDLKLTINQMVDRLQNFALAVTTLSREVGTLGIWGGQANVQDVEGAWKQVTENVNLMATNLTNQVRSIATVTTAVAHGDLSQKIDVHAQGEILQLKNTINKMVDSLQLFASEVSKVAQDVGINGKLGIQAQVSDVDGLWKEITSNVNTMASNLTSQVRAFAQITAAATDGDFTRFITVEASGEMDALKTKINQMVFNLRESLQRNTAAREAAELANSAKSEFLANMSHEIRTPLNGIIGMTQLSLDTELTQYQREMLSIVHNLANSLLTIIDDILDISKIEANRMTVEQIDFSLRGTVFGALKTLAVKAIEKNLDLTYQCDSSFPDNLIGDSFRLRQVILNLAGNAIKFTKEGKVSVSVKKSDKMVLDSKLLLEVCVSDTGIGIEKDKLGLIFDTFCQADGSTTRKFGGTGLGLSISKQLIHLMGGEIWVTSEYGSGSNFYFTVCVSPSNIRYTRQTEQLLPFSSHYVLFVSTEHTQEELDVLRDGIIELGLIPIIVRNIEDATLTEPVKYDIIMIDSIEIAKKLRLLSEVKYIPLVLVHHSIPQLNMRVCIDLGISSYANTPCSITDLASAIIPALESRSISQNSDESVRYKILLAEDNLVNQKLAVRILEKQGHSVEVVENGLEAYEAIKRNKYDVVLMDVQMPVMGGFEATEKIRQWEKKSNPIDSLTFRTPIIALTAHAMLGDREKSLAKGMDDYVSKPLKPKLLMQTINKCIHNINQLKELSRNSRGSDFAKKMTRNTPGSTTRQGSDEGSVEDMIGDTPRQGSVEGGGTSSRPVQRRSATEGSITTISEQIDR T70797 TARGETID T70797 T70797 FORMERID TTDR00792 T70797 UNIPROID GA45B_HUMAN T70797 TARGNAME Negative growth-regulatory protein MyD118 (GADD45B) T70797 GENENAME GADD45B T70797 TARGTYPE Literature-reported T70797 SYNONYMS Myeloid differentiation primary response protein MyD118; GADD45beta; GADD45B; DNA damage-inducible gene 45beta T70797 FUNCTION Involved in the regulation of growth and apoptosis. Mediates activation of stress-responsive MTK1/MEKK4 MAPKKK. T70797 BIOCLASS Ribosomal protein T70797 SEQUENCE MTLEELVACDNAAQKMQTVTAAVEELLVAAQRQDRLTVGVYESAKLMNVDPDSVVLCLLAIDEEEEDDIALQIHFTLIQSFCCDNDINIVRVSGMQRLAQLLGEPAETQGTTEARDLHCLLVTNPHTDAWKSHGLVEVASYCEESRGNNQWVPYISLQER T17656 TARGETID T17656 T17656 FORMERID TTDI01473 T17656 UNIPROID ERN1_HUMAN T17656 TARGNAME Inositol-requiring protein 1 (IRE1a) T17656 GENENAME ERN1 T17656 TARGTYPE Literature-reported T17656 SYNONYMS hIRE1p; Serine/threonine-protein kinase/endoribonuclease IRE1; Ire1-alpha; IRE1a; IRE1; Endoplasmic reticulum-to-nucleus signaling 1 T17656 FUNCTION Serine/threonine-protein kinase and endoribonuclease that acts as a key sensor for the endoplasmic reticulum unfolded protein response (UPR). In unstressed cells, the endoplasmic reticulum luminal domain is maintained in its inactive monomeric state by binding to the endoplasmic reticulum chaperone HSPA5/BiP. Accumulation of misfolded protein in the endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal domain to homodimerize, promoting autophosphorylation of the kinase domain and subsequent activation of the endoribonuclease activity. The endoribonuclease activity is specific for XBP1 mRNA and excises 26 nucleotides from XBP1 mRNA. The resulting spliced transcript of XBP1 encodes a transcriptional activator protein that up-regulates expression of UPR target genes. Acts as an upstream signal for ER stress-induced GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of CFTR to cell membrane by modulating the expression and localization of SEC16A. T17656 PDBSTRUC 6HX1; 6HV0; 5HGI; 4Z7H; 4Z7G T17656 SEQUENCE MPARRLLLLLTLLLPGLGIFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEEPAFLPDPNDGSLYTLGSKNNEGLTKLPFTIPELVQASPCRSSDGILYMGKKQDIWYVIDLLTGEKQQTLSSAFADSLCPSTSLLYLGRTEYTITMYDTKTRELRWNATYFDYAASLPEDDVDYKMSHFVSNGDGLVVTVDSESGDVLWIQNYASPVVAFYVWQREGLRKVMHINVAVETLRYLTFMSGEVGRITKWKYPFPKETEAKSKLTPTLYVGKYSTSLYASPSMVHEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDVKFDPGLKSKNKLNYLRNYWLLIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKKSFEEVINLVDQTSENAPTTVSRDVEEKPAHAPARPEAPVDSMLKDMATIILSTFLLIGWVAFIITYPLSMHQQQQLQHQQFQKELEKIQLLQQQQQQLPFHPPGDTAQDGELLDTSGPYSESSGTSSPSTSPRASNHSLCSGSSASKAGSSPSLEQDDGDEETSVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPPEPQPPVTPDAL T94313 TARGETID T94313 T94313 UNIPROID CRLF1_HUMAN T94313 TARGNAME Cytokine receptor-like factor 1 (CRLF1) T94313 GENENAME CRLF1 T94313 TARGTYPE Literature-reported T94313 SYNONYMS ZcytoR5; Cytokine-like factor 1; CLF-1 T94313 FUNCTION Cytokine receptor subunit, possibly playing a regulatory role in the immune system and during fetal development. May be involved in nervous system development. T94313 BIOCLASS Type I cytokine receptor family. Type 3 subfamily T94313 SEQUENCE MPAGRRGPAAQSARRPPPLLPLLLLLCVLGAPRAGSGAHTAVISPQDPTLLIGSSLLATCSVHGDPPGATAEGLYWTLNGRRLPPELSRVLNASTLALALANLNGSRQRSGDNLVCHARDGSILAGSCLYVGLPPEKPVNISCWSKNMKDLTCRWTPGAHGETFLHTNYSLKYKLRWYGQDNTCEEYHTVGPHSCHIPKDLALFTPYEIWVEATNRLGSARSDVLTLDILDVVTTDPPPDVHVSRVGGLEDQLSVRWVSPPALKDFLFQAKYQIRYRVEDSVDWKVVDDVSNQTSCRLAGLKPGTVYFVQVRCNPFGIYGSKKAGIWSEWSHPTAASTPRSERPGPGGGACEPRGGEPSSGPVRRELKQFLGWLKKHAYCSNLSFRLYDQWRAWMQKSHKTRNQDEGILPSGRRGTARGPAR T57387 TARGETID T57387 T57387 FORMERID TTDR01117 T57387 UNIPROID GEMI_HUMAN T57387 TARGNAME Geminin (GMNN) T57387 GENENAME GMNN T57387 TARGTYPE Literature-reported T57387 SYNONYMS geminin DNA replication inhibitor; MGORS6 T57387 FUNCTION It is degraded during the mitotic phase of the cell cycle. Its destruction at the metaphase-anaphase transition permits replication in the succeeding cell cycle. Inhibits DNA replication by preventing the incorporation of MCM complex into pre-replication complex (pre-RC). T57387 PDBSTRUC 4BRY; 2WVR; 2LP0; 1UII; 1T6F T57387 SEQUENCE MNPSMKQKQEEIKENIKNSSVPRRTLKMIQPSASGSLVGRENELSAGLSKRKHRNDHLTSTTSSPGVIVPESSENKNLGGVTQESFDLMIKENPSSQYWKEVAEKRRKALYEALKENEKLHKEIEQKDNEIARLKKENKELAEVAEHVQYMAELIERLNGEPLDNFESLDNQEFDSEEETVEDSLVEDSEIGTCAEGTVSSSTDAKPCI T64744 TARGETID T64744 T64744 FORMERID TTDI01422 T64744 UNIPROID TNR21_HUMAN T64744 TARGNAME Death receptor 6 (CD358) T64744 GENENAME TNFRSF21 T64744 TARGTYPE Literature-reported T64744 SYNONYMS UNQ437/PRO868; Tumor necrosis factor receptor superfamily member 21; DR6 T64744 FUNCTION Can also promote apoptosis mediated by BAX and by the release of cytochrome c from the mitochondria into the cytoplasm. Plays a role in neuronal apoptosis, including apoptosis in response to amyloid peptides derived from APP, and is required for both normal cell body death and axonal pruning. Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP). N-APP binds TNFRSF21; this triggers caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6). Negatively regulates oligodendrocyte survival, maturation and myelination. Plays a role in signaling cascades triggered by stimulation of T-cell receptors, in the adaptive immune response and in the regulation of T-cell differentiation and proliferation. Negatively regulates T-cell responses and the release of cytokines such as IL4, IL5, IL10, IL13 and IFNG by Th2 cells. Negatively regulates the production of IgG, IgM and IgM in response to antigens. May inhibit the activation of JNK in response to T-cell stimulation. Promotes apoptosis, possibly via a pathway that involves the activation of NF-kappa-B. T64744 PDBSTRUC 3U3V; 3U3T; 3U3S; 3U3Q; 3U3P T64744 SEQUENCE MGTSPSSSTALASCSRIARRATATMIAGSLLLLGFLSTTTAQPEQKASNLIGTYRHVDRATGQVLTCDKCPAGTYVSEHCTNTSLRVCSSCPVGTFTRHENGIEKCHDCSQPCPWPMIEKLPCAALTDRECTCPPGMFQSNATCAPHTVCPVGWGVRKKGTETEDVRCKQCARGTFSDVPSSVMKCKAYTDCLSQNLVVIKPGTKETDNVCGTLPSFSSSTSPSPGTAIFPRPEHMETHEVPSSTYVPKGMNSTESNSSASVRPKVLSSIQEGTVPDNTSSARGKEDVNKTLPNLQVVNHQQGPHHRHILKLLPSMEATGGEKSSTPIKGPKRGHPRQNLHKHFDINEHLPWMIVLFLLLVLVVIVVCSIRKSSRTLKKGPRQDPSAIVEKAGLKKSMTPTQNREKWIYYCNGHGIDILKLVAAQVGSQWKDIYQFLCNASEREVAAFSNGYTADHERAYAALQHWTIRGPEASLAQLISALRQHRRNDVVEKIRGLMEDTTQLETDKLALPMSPSPLSPSPIPSPNAKLENSALLTVEPSPQDKNKGFFVDESEPLLRCDSTSSGSSALSRNGSFITKEKKDTVLRQVRLDPCDLQPIFDDMLHFLNPEELRVIEEIPQAEDKLDRLFEIIGVKSQEASQTLLDSVYSHLPDLL T16326 TARGETID T16326 T16326 FORMERID TTDI03132 T16326 UNIPROID CXB3_HUMAN T16326 TARGNAME Gap junction beta-3 protein (Cx31) T16326 GENENAME GJB3 T16326 TARGTYPE Literature-reported T16326 SYNONYMS Connexin-31; CX31 T16326 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T16326 BIOCLASS Gap junction-forming connexin T16326 SEQUENCE MDWKTLQALLSGVNKYSTAFGRIWLSVVFVFRVLVYVVAAERVWGDEQKDFDCNTKQPGCTNVCYDNYFPISNIRLWALQLIFVTCPSLLVILHVAYREERERRHRQKHGDQCAKLYDNAGKKHGGLWWTYLFSLIFKLIIEFLFLYLLHTLWHGFNMPRLVQCANVAPCPNIVDCYIARPTEKKIFTYFMVGASAVCIVLTICELCYLICHRVLRGLHKDKPRGGCSPSSSASRASTCRCHHKLVEAGEVDPDPGNNKLQASAPNLTPI T16326 DRUGINFO D00VJY octanol Investigative T99351 TARGETID T99351 T99351 FORMERID TTDI02549 T99351 UNIPROID SPI2_HUMAN T99351 TARGNAME Serpin I2 (SERPINI2) T99351 GENENAME SERPINI2 T99351 TARGTYPE Literature-reported T99351 SYNONYMS Peptidase inhibitor 14; Pancreas-specific protein TSA2004; Pancpin; PI14; PI-14; Myoepithelium-derived serine protease inhibitor; MEPI T99351 FUNCTION A member of the plasminogen activator inhibitor-1 family, a subset of the serpin superfamily whose members act as tissue-specific tPA inhibitors.Plays central roles in the regulation of a wide variety of physiological processes, including coagulation, fibrinolysis, development, malignancy and inflammation. T99351 BIOCLASS Serpin protein T99351 SEQUENCE MDTIFLWSLLLLFFGSQASRCSAQKNTEFAVDLYQEVSLSHKDNIIFSPLGITLVLEMVQLGAKGKAQQQIRQTLKQQETSAGEEFFVLKSFFSAISEKKQEFTFNLANALYLQEGFTVKEQYLHGNKEFFQSAIKLVDFQDAKACAEMISTWVERKTDGKIKDMFSGEEFGPLTRLVLVNAIYFKGDWKQKFRKEDTQLINFTKKNGSTVKIPMMKALLRTKYGYFSESSLNYQVLELSYKGDEFSLIIILPAEGMDIEEVEKLITAQQILKWLSEMQEEEVEISLPRFKVEQKVDFKDVLYSLNITEIFSGGCDLSGITDSSEVYVSQVTQKVFFEINEDGSEAATSTGIHIPVIMSLAQSQFIANHPFLFIMKHNPTESILFMGRVTNPDTQEIKGRDLDSL T53890 TARGETID T53890 T53890 FORMERID TTDR01136 T53890 UNIPROID PSD10_HUMAN T53890 TARGNAME Gankyrin (PSMD10) T53890 GENENAME PSMD10 T53890 TARGTYPE Literature-reported T53890 SYNONYMS p28(GANK); 26S proteasome regulatory subunit p28; 26S proteasome non-ATPase regulatory subunit 10 T53890 FUNCTION In the initial step of the base subcomplex assembly is part of an intermediate PSMD10:PSMC4:PSMC5:PAAF1 module which probably assembles with a PSMD5:PSMC2:PSMC1:PSMD2 module. Independently of the proteasome, regulates EGF-induced AKT activation through inhibition of the RHOA/ROCK/PTEN pathway, leading to prolonged AKT activation. Plays an important role in RAS-induced tumorigenesis. Acts as a chaperone during the assembly of the 26S proteasome, specifically of the PA700/19S regulatory complex (RC). T53890 PDBSTRUC 5VHR; 5VHQ; 5VHP; 5VHO; 5VHN T53890 SEQUENCE MEGCVSNLMVCNLAYSGKLEELKESILADKSLATRTDQDSRTALHWACSAGHTEIVEFLLQLGVPVNDKDDAGWSPLHIAASAGRDEIVKALLGKGAQVNAVNQNGCTPLHYAASKNRHEIAVMLLEGGANPDAKDHYEATAMHRAAAKGNLKMIHILLYYKASTNIQDTEGNTPLHLACDEERVEEAKLLVSQGASIYIENKEEKTPLQVAKGGLGLILKRMVEG T90360 TARGETID T90360 T90360 FORMERID TTDR00912 T90360 UNIPROID SYUG_HUMAN T90360 TARGNAME Gamma-synuclein (SNCG) T90360 GENENAME SNCG T90360 TARGTYPE Literature-reported T90360 SYNONYMS Synoretin; Persyn; PRSN; Breast cancer-specific gene 1 protein; BCSG1 T90360 FUNCTION May be involved in modulating axonal architecture during development and in the adult. In vitro, increases the susceptibility of neurofilament-H to calcium-dependent proteases. May also function in modulating the keratin network in skin. Activates the MAPK and Elk-1 signal transduction pathway. Plays a role in neurofilament network integrity. T90360 BIOCLASS Synuclein T90360 SEQUENCE MDVFKKGFSIAKEGVVGAVEKTKQGVTEAAEKTKEGVMYVGAKTKENVVQSVTSVAEKTKEQANAVSEAVVSSVNTVATKTVEEAENIAVTSGVVRKEDLRPSAPQQEGEASKEKEEVAEEAQSGGD T59486 TARGETID T59486 T59486 FORMERID TTDNR00641 T59486 UNIPROID ZFAN5_HUMAN T59486 TARGNAME AN1-type zinc finger protein 5 (ZFAND5) T59486 GENENAME ZFAND5 T59486 TARGTYPE Literature-reported T59486 SYNONYMS Zinc finger protein 216; Zinc finger A20 domain-containing protein 2; ZNF216; ZA20D2 T59486 FUNCTION May act by anchoring ubiquitinated proteins to the proteasome. Plays a role in ubiquitin-mediated protein degradation during muscle atrophy. Plays a role in the regulation of NF-kappa-B activation and apoptosis. Inhibits NF-kappa-B activation triggered by overexpression of RIPK1 and TRAF6 but not of RELA. Inhibits also tumor necrosis factor (TNF), IL-1 and TLR4-induced NF-kappa-B activation in a dose-dependent manner. Overexpression sensitizes cells to TNF-induced apoptosis. Is a potent inhibitory factor for osteoclast differentiation. Involved in protein degradation via the ubiquitin-proteasome system. T59486 BIOCLASS Zinc-finger T59486 SEQUENCE MAQETNQTPGPMLCSTGCGFYGNPRTNGMCSVCYKEHLQRQQNSGRMSPMGTASGSNSPTSDSASVQRADTSLNNCEGAAGSTSEKSRNVPVAALPVTQQMTEMSISREDKITTPKTEVSEPVVTQPSPSVSQPSTSQSEEKAPELPKPKKNRCFMCRKKVGLTGFDCRCGNLFCGLHRYSDKHNCPYDYKAEAAAKIRKENPVVVAEKIQRI T53600 TARGETID T53600 T53600 FORMERID TTDR00614 T53600 UNIPROID EF3_CANGA T53600 TARGNAME Candida Elongation factor 3 (Candi TEF3) T53600 GENENAME Candi TEF3 T53600 TARGTYPE Literature-reported T53600 SYNONYMS TEF3; EF-3 T53600 FUNCTION The main role of EF-3 may be to transduce nucleoside triphosphate energy into mechanical energy for translocation during translation. EF-3 stimulates EF-1-alpha-dependent binding of aminoacyl-tRNA to the ribosome. T53600 BIOCLASS ABC transporter T53600 SEQUENCE MTDSDQSLKVLEELFKNLSVATADNRVEAAQEVASFLNGNIIEHDIPEKFFEELAKAVKDKKTSANFLEAVAHIANEANLSPSVEPFVITLVPEICAKAGDKDKDVQAVASKTLVAISKAINPVAIKAYLPHLTKSLETTNKWQEKVSVLAAISALVDAAKEQVALRMPELIPVLSETMWDTKKEVKEAATATMTKATETVDNKDIERFIPQLISCIADPKQVPETVHLLGATTFVAEVTPATLSIMVPLLSRGLAERETSIKRKAAVIIDNMCKLVEDPQVVAPFLDKLLPGLKNNYATIADPEAREVTLRGLKTLRRVGNVTEDDVLPEISHAGDIETTLGVINELLKGENVAPRFKIVVEYIAAMAGDLIDERVIDQQAWFTHITPYMTIFMHERNAKDVLDEFRKRAVDNIPVGPNFDDEEDEGEDLCNCEFSLAYGAKILLNKTQLRLKRGRRYGLCGPNGAGKSTLMRAIANGQVDGFPTPEECMTVYVEHDIDGTHADTSVLDFVVSSEVGTKEAITAKLVEFGFTEEMINMPISSLSGGWKMKLALARAVLKNADILLLDEPTNHLDTVNVAWLVNYLNTCGITSVIVSHDSGFLDNVCQYIIHYEGLKLRKYKGNLSEFVKKCPTAQSYYELGASDLEFKFPEPGYLEGVKTKQKAIVKVSNMTFQYPGTSKPQISDISFQCSLSSRIAVIGPNGAGKSTLINVLTGELLPTSGEVYTHENCRIAYIKQHAFAHIESHLDKTPSEYIQWRFQTGEDRETMDRANRQINENDAEAMNKIFKIEGTPRRIAGIHARRKFKNTYEYECSFLLGENIGMKSERWVPMMSVDNAWIPRGELVESHSKMVAEVDMKEALASGQFRPLTRKEIEEHCAMLGLDAELVSHSRIRGLSGGQKVKLVLAACSWQRPHLIVLDEPTNYLDRDSLGALSKALKAFEGGVIIITHSAEFTKNLTEEVWAVKDGKMTPSGHNWVSGQGAGPRIEKKEDEEDKFDAMGNKIAGGKKKKKLSSAELRKKKKERMKKKKELGDAYVSSDDEDF T71525 TARGETID T71525 T71525 FORMERID TTDR00494 T71525 UNIPROID HEXI1_HUMAN T71525 TARGNAME Hexamethylene bis-acetamide-inducible protein 1 (HEXIM1) T71525 GENENAME HEXIM1 T71525 TARGTYPE Literature-reported T71525 SYNONYMS Protein HEXIM1; Menage a quatre protein 1; MAQ1; HIS1; Estrogen down-regulated gene 1 protein; EDG1; Cardiac lineage protein 1; CLP1 T71525 FUNCTION Transcriptional regulator which functions as a general RNA polymerase II transcription inhibitor. In cooperation with 7SK snRNA sequesters P-TEFb in a large inactive 7SK snRNP complex preventing RNA polymerase II phosphorylation and subsequent transcriptional elongation. May also regulate NF-kappa-B, ESR1, NR3C1 and CIITA-dependent transcriptional activity. Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway. T71525 PDBSTRUC 3S9G; 2GD7 T71525 SEQUENCE MAEPFLSEYQHQPQTSNCTGAAAVQEELNPERPPGAEERVPEEDSRWQSRAFPQLGGRPGPEGEGSLESQPPPLQTQACPESSCLREGEKGQNGDDSSAGGDFPPPAEVEPTPEAELLAQPCHDSEASKLGAPAAGGEEEWGQQQRQLGKKKHRRRPSKKKRHWKPYYKLTWEEKKKFDEKQSLRASRIRAEMFAKGQPVAPYNTTQFLMDDHDQEEPDLKTGLYSKRAAAKSDDTSDDDFMEEGGEEDGGSDGMGGDGSEFLQRDFSETYERYHTESLQNMSKQELIKEYLELEKCLSRMEDENNRLRLESKRLGGDDARVRELELELDRLRAENLQLLTENELHRQQERAPLSKFGD T15914 TARGETID T15914 T15914 FORMERID TTDR01121 T15914 UNIPROID ZN202_HUMAN T15914 TARGNAME Zinc finger protein 202 (ZNF202) T15914 GENENAME ZNF202 T15914 TARGTYPE Literature-reported T15914 SYNONYMS Zinc finger protein ZNF202; ZNF202 T15914 FUNCTION Transcriptional repressor that binds to elements found predominantly in genes that participate in lipid metabolism. Among its targets are structural components of lipoprotein particles (apolipoproteins AIV, CIII, and E), enzymes involved in lipidprocessing (lipoprotein lipase, lecithin cholesteryl ester transferase), transporters involved in lipid homeostasis (ABCA1, ABCG1), and several genes involved in processes related to energy metabolism and vascular disease. T15914 BIOCLASS Zinc-finger T15914 SEQUENCE MATAVEPEDQDLWEEEGILMVKLEDDFTCRPESVLQRDDPVLETSHQNFRRFRYQEAASPREALIRLRELCHQWLRPERRTKEQILELLVLEQFLTVLPGELQSWVRGQRPESGEEAVTLVEGLQKQPRRPRRWVTVHVHGQEVLSEETVHLGVEPESPNELQDPVQSSTPEQSPEETTQSPDLGAPAEQRPHQEEELQTLQESEVPVPEDPDLPAERSSGDSEMVALLTALSQGLVTFKDVAVCFSQDQWSDLDPTQKEFYGEYVLEEDCGIVVSLSFPIPRPDEISQVREEEPWVPDIQEPQETQEPEILSFTYTGDRSKDEEECLEQEDLSLEDIHRPVLGEPEIHQTPDWEIVFEDNPGRLNERRFGTNISQVNSFVNLRETTPVHPLLGRHHDCSVCGKSFTCNSHLVRHLRTHTGEKPYKCMECGKSYTRSSHLARHQKVHKMNAPYKYPLNRKNLEETSPVTQAERTPSVEKPYRCDDCGKHFRWTSDLVRHQRTHTGEKPFFCTICGKSFSQKSVLTTHQRIHLGGKPYLCGECGEDFSEHRRYLAHRKTHAAEELYLCSECGRCFTHSAAFAKHLRGHASVRPCRCNECGKSFSRRDHLVRHQRTHTGEKPFTCPTCGKSFSRGYHLIRHQRTHSEKTS T49888 TARGETID T49888 T49888 FORMERID TTDI02625 T49888 UNIPROID ELP1_HUMAN T49888 TARGNAME IKK complex-associated protein (IKBKAP) T49888 GENENAME IKBKAP T49888 TARGTYPE Literature-reported T49888 SYNONYMS IkappaB kinase complexassociated protein; IkappaB kinase complex-associated protein; IKK complexassociated protein; IKAP; Elongator complex protein 1; ELP1 T49888 FUNCTION May act as a scaffold protein that may assemble active IKK-MAP3K14 complexes (IKKA, IKKB and MAP3K14/NIK). T49888 PDBSTRUC 5CQR T49888 SEQUENCE MRNLKLFRTLEFRDIQGPGNPQCFSLRTEQGTVLIGSEHGLIEVDPVSREVKNEVSLVAEGFLPEDGSGRIVGVQDLLDQESVCVATASGDVILCSLSTQQLECVGSVASGISVMSWSPDQELVLLATGQQTLIMMTKDFEPILEQQIHQDDFGESKFITVGWGRKETQFHGSEGRQAAFQMQMHESALPWDDHRPQVTWRGDGQFFAVSVVCPETGARKVRVWNREFALQSTSEPVAGLGPALAWKPSGSLIASTQDKPNQQDIVFFEKNGLLHGHFTLPFLKDEVKVNDLLWNADSSVLAVWLEDLQREESSIPKTCVQLWTVGNYHWYLKQSLSFSTCGKSKIVSLMWDPVTPYRLHVLCQGWHYLAYDWHWTTDRSVGDNSSDLSNVAVIDGNRVLVTVFRQTVVPPPMCTYQLLFPHPVNQVTFLAHPQKSNDLAVLDASNQISVYKCGDCPSADPTVKLGAVGGSGFKVCLRTPHLEKRYKIQFENNEDQDVNPLKLGLLTWIEEDVFLAVSHSEFSPRSVIHHLTAASSEMDEEHGQLNVSSSAAVDGVIISLCCNSKTKSVVLQLADGQIFKYLWESPSLAIKPWKNSGGFPVRFPYPCTQTELAMIGEEECVLGLTDRCRFFINDIEVASNITSFAVYDEFLLLTTHSHTCQCFCLRDASFKTLQAGLSSNHVSHGEVLRKVERGSRIVTVVPQDTKLVLQMPRGNLEVVHHRALVLAQIRKWLDKLMFKEAFECMRKLRINLNLIYDHNPKVFLGNVETFIKQIDSVNHINLFFTELKEEDVTKTMYPAPVTSSVYLSRDPDGNKIDLVCDAMRAVMESINPHKYCLSILTSHVKKTTPELEIVLQKVHELQGNAPSDPDAVSAEEALKYLLHLVDVNELYDHSLGTYDFDLVLMVAEKSQKDPKEYLPFLNTLKKMETNYQRFTIDKYLKRYEKAIGHLSKCGPEYFPECLNLIKDKNLYNEALKLYSPSSQQYQDISIAYGEHLMQEHMYEPAGLMFARCGAHEKALSAFLTCGNWKQALCVAAQLNFTKDQLVGLGRTLAGKLVEQRKHIDAAMVLEECAQDYEEAVLLLLEGAAWEEALRLVYKYNRLDIIETNVKPSILEAQKNYMAFLDSQTATFSRHKKRLLVVRELKEQAQQAGLDDEVPHGQESDLFSETSSVVSGSEMSGKYSHSNSRISARSSKNRRKAERKKHSLKEGSPLEDLALLEALSEVVQNTENLKDEVYHILKVLFLFEFDEQGRELQKAFEDTLQLMERSLPEIWTLTYQQNSATPVLGPNSTANSIMASYQQQKTSVPVLDAELFIPPKINRRTQWKLSLLD T63743 TARGETID T63743 T63743 FORMERID TTDNR00756 T63743 UNIPROID SMC2_HUMAN T63743 TARGNAME Structural maintenance of chromosomes protein 2 (SMC2) T63743 GENENAME SMC2 T63743 TARGTYPE Literature-reported T63743 SYNONYMS hCAP-E; XCAP-E homolog; SMC2L1; SMC-2; SMC protein 2; PRO0324; Chromosome-associated protein E; CAPE T63743 FUNCTION The condensin complex probably introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases. Central component of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes. T63743 PDBSTRUC 4U4P T63743 SEQUENCE MHIKSIILEGFKSYAQRTEVNGFDPLFNAITGLNGSGKSNILDSICFLLGISNLSQVRASNLQDLVYKNGQAGITKASVSITFDNSDKKQSPLGFEVHDEITVTRQVVIGGRNKYLINGVNANNTRVQDLFCSVGLNVNNPHFLIMQGRITKVLNMKPPEILSMIEEAAGTRMYEYKKIAAQKTIEKKEAKLKEIKTILEEEITPTIQKLKEERSSYLEYQKVMREIEHLSRLYIAYQFLLAEDTKVRSAEELKEMQDKVIKLQEELSENDKKIKALNHEIEELEKRKDKETGGILRSLEDALAEAQRVNTKSQSAFDLKKKNLACEESKRKELEKNMVEDSKTLAAKEKEVKKITDGLHALQEASNKDAEALAAAQQHFNAVSAGLSSNEDGAEATLAGQMMACKNDISKAQTEAKQAQMKLKHAQQELKNKQAEVKKMDSGYRKDQEALEAVKRLKEKLEAEMKKLNYEENKEESLLEKRRQLSRDIGRLKETYEALLARFPNLRFAYKDPEKNWNRNCVKGLVASLISVKDTSATTALELVAGERLYNVVVDTEVTGKKLLERGELKRRYTIIPLNKISARCIAPETLRVAQNLVGPDNVHVALSLVEYKPELQKAMEFVFGTTFVCDNMDNAKKVAFDKRIMTRTVTLGGDVFDPHGTLSGGARSQAASILTKFQELKDVQDELRIKENELRALEEELAGLKNTAEKYRQLKQQWEMKTEEADLLQTKLQQSSYHKQQEELDALKKTIEESEETLKNTKEIQRKAEEKYEVLENKMKNAEAERERELKDAQKKLDCAKTKADASSKKMKEKQQEVEAITLELEELKREHTSYKQQLEAVNEAIKSYESQIEVMAAEVAKNKESVNKAQEEVTKQKEVITAQDTVIKAKYAEVAKHKEQNNDSQLKIKELDHNISKHKREAEDGAAKVSKMLKDYDWINAERHLFGQPNSAYDFKTNNPKEAGQRLQKLQEMKEKLGRNVNMRAMNVLTEAEERYNDLMKKKRIVENDKSKILTTIEDLDQKKNQALNIAWQKVNKDFGSIFSTLLPGANAMLAPPEGQTVLDGLEFKVALGNTWKENLTELSGGQRSLVALSLILSMLLFKPAPIYILDEVDAALDLSHTQNIGQMLRTHFTHSQFIVVSLKEGMFNNANVLFKTKFVDGVSTVARFTQCQNGKISKEAKSKAKPPKGAHVEV T20302 TARGETID T20302 T20302 FORMERID TTDI00170 T20302 UNIPROID ATG7_HUMAN T20302 TARGNAME Autophagy-related protein 7 (ATG7) T20302 GENENAME ATG7 T20302 TARGTYPE Literature-reported T20302 SYNONYMS hAGP7; Ubiquitin-like modifier-activating enzyme ATG7; Ubiquitin-activating enzyme E1-like protein; ATG12-activating enzyme E1 ATG7; APG7L; APG7-like T20302 FUNCTION Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes. Required for autophagic death induced by caspase-8 inhibition. Required for mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. Modulates p53/TP53 activity to regulate cell cycle and survival during metabolic stress. Plays also a key role in the maintenance of axonal homeostasis, the prevention of axonal degeneration, the maintenance of hematopoietic stem cells, the formation of Paneth cell granules, as well as in adipose differentiation. Plays a role in regulating the liver clock and glucose metabolism by mediating the autophagic degradation of CRY1 (clock repressor) in a time-dependent manner. E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy. T20302 BIOCLASS Autophagy phagophore-formation transporter T20302 SEQUENCE MAAATGDPGLSKLQFAPFSSALDVGFWHELTQKKLNEYRLDEAPKDIKGYYYNGDSAGLPARLTLEFSAFDMSAPTPARCCPAIGTLYNTNTLESFKTADKKLLLEQAANEIWESIKSGTALENPVLLNKFLLLTFADLKKYHFYYWFCYPALCLPESLPLIQGPVGLDQRFSLKQIEALECAYDNLCQTEGVTALPYFLIKYDENMVLVSLLKHYSDFFQGQRTKITIGVYDPCNLAQYPGWPLRNFLVLAAHRWSSSFQSVEVVCFRDRTMQGARDVAHSIIFEVKLPEMAFSPDCPKAVGWEKNQKGGMGPRMVNLSECMDPKRLAESSVDLNLKLMCWRLVPTLDLDKVVSVKCLLLGAGTLGCNVARTLMGWGVRHITFVDNAKISYSNPVRQPLYEFEDCLGGGKPKALAAADRLQKIFPGVNARGFNMSIPMPGHPVNFSSVTLEQARRDVEQLEQLIESHDVVFLLMDTRESRWLPAVIAASKRKLVINAALGFDTFVVMRHGLKKPKQQGAGDLCPNHPVASADLLGSSLFANIPGYKLGCYFCNDVVAPGDSTRDRTLDQQCTVSRPGLAVIAGALAVELMVSVLQHPEGGYAIASSSDDRMNEPPTSLGLVPHQIRGFLSRFDNVLPVSLAFDKCTACSSKVLDQYEREGFNFLAKVFNSSHSFLEDLTGLTLLHQETQAAEIWDMSDDETI T76062 TARGETID T76062 T76062 FORMERID TTDI03133 T76062 UNIPROID CXB5_HUMAN T76062 TARGNAME Gap junction beta-5 protein (Cx31.1) T76062 GENENAME GJB5 T76062 TARGTYPE Literature-reported T76062 SYNONYMS Connexin-31.1 T76062 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T76062 BIOCLASS Gap junction-forming connexin T76062 SEQUENCE MNWSIFEGLLSGVNKYSTAFGRIWLSLVFIFRVLVYLVTAERVWSDDHKDFDCNTRQPGCSNVCFDEFFPVSHVRLWALQLILVTCPSLLVVMHVAYREVQEKRHREAHGENSGRLYLNPGKKRGGLWWTYVCSLVFKASVDIAFLYVFHSFYPKYILPPVVKCHADPCPNIVDCFISKPSEKNIFTLFMVATAAICILLNLVELIYLVSKRCHECLAARKAQAMCTGHHPHGTTSSCKQDDLLSGDLIFLGSDSHPPLLPDRPRDHVKKTIL T76062 DRUGINFO D00VJY octanol Investigative T35283 TARGETID T35283 T35283 FORMERID TTDI03383 T35283 UNIPROID M3K6_HUMAN T35283 TARGNAME Apoptosis signal-regulating kinase 2 (MAP3K6) T35283 GENENAME MAP3K6 T35283 TARGTYPE Literature-reported T35283 SYNONYMS MAP3K6 T35283 FUNCTION Component of a protein kinase signal transduction cascade. Activates the JNK, but not ERK or p38 kinase pathways. T35283 ECNUMBER EC 2.7.11.25 T35283 SEQUENCE MAGPCPRSGAERAGSCWQDPLAVALSRGRQLAAPPGRGCARSRPLSVVYVLTREPQPGLEPREGTEAEPLPLRCLREACAQVPRPRPPPQLRSLPFGTLELGDTAALDAFYNADVVVLEVSSSLVQPSLFYHLGVRESFSMTNNVLLCSQADLPDLQALREDVFQKNSDCVGSYTLIPYVVTATGRVLCGDAGLLRGLADGLVQAGVGTEALLTPLVGRLARLLEATPTDSCGYFRETIRRDIRQARERFSGPQLRQELARLQRRLDSVELLSPDIIMNLLLSYRDVQDYSAIIELVETLQALPTCDVAEQHNVCFHYTFALNRRNRPGDRAKALSVLLPLVQLEGSVAPDLYCMCGRIYKDMFFSSGFQDAGHREQAYHWYRKAFDVEPSLHSGINAAVLLIAAGQHFEDSKELRLIGMKLGCLLARKGCVEKMQYYWDVGFYLGAQILANDPTQVVLAAEQLYKLNAPIWYLVSVMETFLLYQHFRPTPEPPGGPPRRAHFWLHFLLQSCQPFKTACAQGDQCLVLVLEMNKVLLPAKLEVRGTDPVSTVTLSLLEPETQDIPSSWTFPVASICGVSASKRDERCCFLYALPPAQDVQLCFPSVGHCQWFCGLIQAWVTNPDSTAPAEEAEGAGEMLEFDYEYTETGERLVLGKGTYGVVYAGRDRHTRVRIAIKEIPERDSRFSQPLHEEIALHRRLRHKNIVRYLGSASQGGYLKIFMEEVPGGSLSSLLRSVWGPLKDNESTISFYTRQILQGLGYLHDNHIVHRDIKGDNVLINTFSGLLKISDFGTSKRLAGITPCTETFTGTLQYMAPEIIDQGPRGYGKAADIWSLGCTVIEMATGRPPFHELGSPQAAMFQVGMYKVHPPMPSSLSAEAQAFLLRTFEPDPRLRASAQTLLGDPFLQPGKRSRSPSSPRHAPRPSDAPSASPTPSANSTTQSQTFPCPQAPSQHPPSPPKRCLSYGGTSQLRVPEEPAAEEPASPEESSGLSLLHQESKRRAMLAAVLEQELPALAENLHQEQKQEQGARLGRNHVEELLRCLGAHIHTPNRRQLAQELRALQGRLRAQGLGPALLHRPLFAFPDAVKQILRKRQIRPHWMFVLDSLLSRAVRAALGVLGPEVEKEAVSPRSEELSNEGDSQQSPGQQSPLPVEPEQGPAPLMVQLSLLRAETDRLREILAGKEREYQALVQRALQRLNEEARTYVLAPEPPTALSTDQGLVQWLQELNVDSGTIQMLLNHSFTLHTLLTYATRDDLIYTRIRGGMVCRIWRAILAQRAGSTPVTSGP T35283 DRUGINFO D0Q0YV PMID23147077C10 Investigative T23655 TARGETID T23655 T23655 FORMERID TTDR00820 T23655 UNIPROID WISP3_HUMAN T23655 TARGNAME Cellular communication network factor 6 (CCN6) T23655 GENENAME WISP3 T23655 TARGTYPE Literature-reported T23655 SYNONYMS WNT1 inducible signaling pathway protein 3; WISP3; WISP-3; UNQ462/PRO790 T23655 FUNCTION Appears to be required for normal postnatal skeletal growth and cartilage homeostasis. T23655 BIOCLASS Growth factor T23655 SEQUENCE MQGLLFSTLLLAGLAQFCCRVQGTGPLDTTPEGRPGEVSDAPQRKQFCHWPCKCPQQKPRCPPGVSLVRDGCGCCKICAKQPGEICNEADLCDPHKGLYCDYSVDRPRYETGVCAYLVAVGCEFNQVHYHNGQVFQPNPLFSCLCVSGAIGCTPLFIPKLAGSHCSGAKGGKKSDQSNCSLEPLLQQLSTSYKTMPAYRNLPLIWKKKCLVQATKWTPCSRTCGMGISNRVTNENSNCEMRKEKRLCYIQPCDSNILKTIKIPKGKTCQPTFQLSKAEKFVFSGCSSTQSYKPTFCGICLDKRCCIPNKSKMITIQFDCPNEGSFKWKMLWITSCVCQRNCREPGDIFSELKIL T19110 TARGETID T19110 T19110 FORMERID TTDI02027 T19110 UNIPROID BMP10_HUMAN T19110 TARGNAME Bone morphogenetic protein 10 (BMP10) T19110 GENENAME BMP10 T19110 TARGTYPE Literature-reported T19110 SYNONYMS BMP10 T19110 FUNCTION Required for maintaining the proliferative activity of embryonic cardiomyocytes by preventing premature activation of the negative cell cycle regulator CDKN1C/p57KIP and maintaining the required expression levels of cardiogenic factors such as MEF2C and NKX2-5. Acts as a ligand for ACVRL1/ALK1, BMPR1A/ALK3 and BMPR1B/ALK6, leading to activation of SMAD1, SMAD5 and SMAD8 transcription factors. Inhibits endothelial cell migration and growth. May reduce cell migration and cell matrix adhesion in breast cancer cell lines. T19110 BIOCLASS Growth factor T19110 SEQUENCE MGSLVLTLCALFCLAAYLVSGSPIMNLEQSPLEEDMSLFGDVFSEQDGVDFNTLLQSMKDEFLKTLNLSDIPTQDSAKVDPPEYMLELYNKFATDRTSMPSANIIRSFKNEDLFSQPVSFNGLRKYPLLFNVSIPHHEEVIMAELRLYTLVQRDRMIYDGVDRKITIFEVLESKGDNEGERNMLVLVSGEIYGTNSEWETFDVTDAIRRWQKSGSSTHQLEVHIESKHDEAEDASSGRLEIDTSAQNKHNPLLIVFSDDQSSDKERKEELNEMISHEQLPELDNLGLDSFSSGPGEEALLQMRSNIIYDSTARIRRNAKGNYCKRTPLYIDFKEIGWDSWIIAPPGYEAYECRGVCNYPLAEHLTPTKHAIIQALVHLKNSQKASKACCVPTKLEPISILYLDKGVVTYKFKYEGMAVSECGCR T02346 TARGETID T02346 T02346 FORMERID TTDR00574 T02346 UNIPROID UTS2_HUMAN T02346 TARGNAME Urotensin II (UTS2) T02346 GENENAME UTS2 T02346 TARGTYPE Literature-reported T02346 SYNONYMS Urotensin-II; UTS2; UII; U-II; HU-II T02346 FUNCTION Highly potent vasoconstrictor. T02346 PDBSTRUC 6HVC; 6HVB T02346 SEQUENCE MYKLASCCLLFIGFLNPLLSLPLLDSREISFQLSAPHEDARLTPEELERASLLQILPEMLGAERGDILRKADSSTNIFNPRGNLRKFQDFSGQDPNILLSHLLARIWKPYKKRETPDCFWKYCV T24820 TARGETID T24820 T24820 FORMERID TTDI03129 T24820 UNIPROID CXB6_HUMAN T24820 TARGNAME Connexin-30 (Cx30) T24820 GENENAME GJB6 T24820 TARGTYPE Literature-reported T24820 SYNONYMS Gap junction beta-6 protein T24820 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T24820 BIOCLASS Gap junction-forming connexin T24820 SEQUENCE MDWGTLHTFIGGVNKHSTSIGKVWITVIFIFRVMILVVAAQEVWGDEQEDFVCNTLQPGCKNVCYDHFFPVSHIRLWALQLIFVSTPALLVAMHVAYYRHETTRKFRRGEKRNDFKDIEDIKKQKVRIEGSLWWTYTSSIFFRIIFEAAFMYVFYFLYNGYHLPWVLKCGIDPCPNLVDCFISRPTEKTVFTIFMISASVICMLLNVAELCYLLLKVCFRRSKRAQTQKNHPNHALKESKQNEMNELISDSGQNAITGFPS T24820 DRUGINFO D00VJY octanol Investigative T89359 TARGETID T89359 T89359 FORMERID TTDR00856 T89359 UNIPROID FSTL3_HUMAN T89359 TARGNAME Follistatin-related protein 3 (FSTL3) T89359 GENENAME FSTL3 T89359 TARGTYPE Literature-reported T89359 SYNONYMS UNQ674/PRO1308; Follistatin-related gene protein; Follistatin-related gene; Follistatin-like 3; FSTL3; FLRG T89359 FUNCTION Isoform 1 or the secreted form is a binding and antagonizing protein for members of the TGF-beta family, such us activin, BMP2 and MSTN. Inhibits activin A-, activin B-, BMP2- and MSDT-induced cellular signaling; more effective on activin Athan on activin B. Involved in bone formation; inhibits osteoclast differentiationc. Involved in hematopoiesis; involved in differentiation of hemopoietic progenitor cells, increases hematopoietic cell adhesion to fibronectin and seems to contribute to the adhesion of hematopoietic precursor cells to the bone marrow stroma. Isoform 2 or the nuclear form is probably involved in transcriptional regulation via interaction with MLLT10. T89359 PDBSTRUC 3SEK; 3B4V; 2KCX T89359 SEQUENCE MRPGAPGPLWPLPWGALAWAVGFVSSMGSGNPAPGGVCWLQQGQEATCSLVLQTDVTRAECCASGNIDTAWSNLTHPGNKINLLGFLGLVHCLPCKDSCDGVECGPGKACRMLGGRPRCECAPDCSGLPARLQVCGSDGATYRDECELRAARCRGHPDLSVMYRGRCRKSCEHVVCPRPQSCVVDQTGSAHCVVCRAAPCPVPSSPGQELCGNNNVTYISSCHMRQATCFLGRSIGVRHAGSCAGTPEEPPGGESAEEEENFV T72319 TARGETID T72319 T72319 FORMERID TTDI00148 T72319 UNIPROID CBX7_HUMAN T72319 TARGNAME Chromobox protein homolog 7 (CBX7) T72319 GENENAME CBX7 T72319 TARGTYPE Literature-reported T72319 SYNONYMS Chromobox 7 T72319 FUNCTION PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility. Promotes histone H3 trimethylation at 'Lys-9' (H3K9me3). Binds to trimethylated lysine residues in histones, and possibly also other proteins. Regulator of cellular lifespan by maintaining the repression of CDKN2A, but not by inducing telomerase activity. Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. T72319 PDBSTRUC 5EPJ; 4MN3; 3GS2; 2L1B; 2L12 T72319 SEQUENCE MELSAIGEQVFAVESIRKKRVRKGKVEYLVKWKGWPPKYSTWEPEEHILDPRLVMAYEEKEERDRASGYRKRGPKPKRLLLQRLYSMDLRSSHKAKGKEKLCFSLTCPLGSGSPEGVVKAGAPELVDKGPLVPTLPFPLRKPRKAHKYLRLSRKKFPPRGPNLESHSHRRELFLQEPPAPDVLQAAGEWEPAAQPPEEEADADLAEGPPPWTPALPSSEVTVTDITANSITVTFREAQAAEGFFRDRSGKF T46824 TARGETID T46824 T46824 FORMERID TTDI02597 T46824 UNIPROID SG1D2_HUMAN T46824 TARGNAME Lipophilin-B (SCGB1D2) T46824 GENENAME SCGB1D2 T46824 TARGTYPE Literature-reported T46824 SYNONYMS Secretoglobin family 1D member 2; SCGB1D2 T46824 FUNCTION May bind androgens and other steroids, may also bind estramustine, a chemotherapeutic agent used for prostate cancer. May be under transcriptional regulation of steroid hormones. T46824 BIOCLASS Secretoglobin family T46824 SEQUENCE MKLSVCLLLVTLALCCYQANAEFCPALVSELLDFFFISEPLFKLSLAKFDAPPEAVAAKLGVKRCTDQMSLQKRSLIAEVLVKILKKCSV T34352 TARGETID T34352 T34352 FORMERID TTDI02400 T34352 UNIPROID AGR2_HUMAN T34352 TARGNAME Anterior gradient protein 2 (AG-2) T34352 GENENAME AGR2 T34352 TARGTYPE Literature-reported T34352 SYNONYMS hAG2; Secreted cement gland protein XAG2 homolog; AGR2; AG2 T34352 FUNCTION Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells. Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth. T34352 PDBSTRUC 2LNT; 2LNS T34352 SEQUENCE MEKIPVSAFLLLVALSYTLARDTTVKPGAKKDTKDSRPKLPQTLSRGWGDQLIWTQTYEEALYKSKTSNKPLMIIHHLDECPHSQALKKVFAENKEIQKLAEQFVLLNLVYETTDKHLSPDGQYVPRIMFVDPSLTVRADITGRYSNRLYAYEPADTALLLDNMKKALKLLKTEL T88991 TARGETID T88991 T88991 FORMERID TTDR00767 T88991 UNIPROID O96438_CRIFA T88991 TARGNAME Crithidia Tryparedoxin (Crithi TryX) T88991 GENENAME Crithi TryX T88991 TARGTYPE Literature-reported T88991 SYNONYMS Tryparedoxin I T88991 FUNCTION Mediates the flux of reduction equivalents from the unique redox metabolite trypanothione T88991 PDBSTRUC 1QK8; 1OKD; 1O8X; 1O8W; 1O85 T88991 SEQUENCE MSGLDKYLPGIEKLRRGDGEVEVKSLAGKLVFFYFSASWCPPCRGFTPQLIEFYDKFHESKNFEVVFCTWDEEEDGFAGYFAKMPWLAVPFAQSEAVQKLSKHFNVESIPTLIGVDADSGDVVTTRARATLVKDPEGEQFPWKDAP T88057 TARGETID T88057 T88057 FORMERID TTDR00133 T88057 UNIPROID LDHA_HUMAN; LDHB_HUMAN; LDHC_HUMAN T88057 TARGNAME L-lactate dehydrogenase (LDH) T88057 GENENAME LDHA; LDHB; LDHC T88057 TARGTYPE Literature-reported T88057 SYNONYMS Renal carcinoma antigen NY-REN; LDH T88057 FUNCTION Catalyzes the conversion of lactate to pyruvate and back, as it converts NAD+ to NADH and back. Expressed extensively in body tissues, such as blood cells and heart muscle. Functions asa marker of common injuries and disease such as heart failure because it is released during tissue damage T88057 BIOCLASS Short-chain dehydrogenases reductase T88057 SEQUENCE MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF T88057 DRUGINFO D01PLP 3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID Investigative T88057 DRUGINFO D03IMZ 4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid Investigative T88057 DRUGINFO D09EDP 3-Hydroxyisoxazole-4-Carboxylic Acid Investigative T88057 DRUGINFO D0M6CB Naphthalene-2,6-disulfonic acid Investigative T88057 DRUGINFO D0T3PV 4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid Investigative T88057 DRUGINFO D0LP2H OXAMATE Investigative T88057 DRUGINFO D0R6JE Nicotinamide-Adenine-Dinucleotide Investigative T37384 TARGETID T37384 T37384 FORMERID TTDR00028 T37384 UNIPROID CDK1_YEAST T37384 TARGNAME Saccharomyces Cell division control protein 28 (Saccha CDC28) T37384 GENENAME Saccha CDC28 T37384 TARGTYPE Literature-reported T37384 SYNONYMS YBR160W; YBR1211; SRM5; HSL5; Cyclindependent kinase 1 of Saccharomyces cerevisiae; Cell division protein kinase 1; Cell division control protein 28; CDK1 of Saccharomyces cerevisiae; CDK1; CDC28 T37384 FUNCTION More than 200 substrates have been identified. This protein is essential for the completion of the start, the controlling event, in the cell cycle. T37384 BIOCLASS Kinase T37384 SEQUENCE MSGELANYKRLEKVGEGTYGVVYKALDLRPGQGQRVVALKKIRLESEDEGVPSTAIREISLLKELKDDNIVRLYDIVHSDAHKLYLVFEFLDLDLKRYMEGIPKDQPLGADIVKKFMMQLCKGIAYCHSHRILHRDLKPQNLLINKDGNLKLGDFGLARAFGVPLRAYTHEIVTLWYRAPEVLLGGKQYSTGVDTWSIGCIFAEMCNRKPIFSGDSEIDQIFKIFRVLGTPNEAIWPDIVYLPDFKPSFPQWRRKDLSQVVPSLDPRGIDLLDKLLAYDPINRISARRAAIHPYFQES T37384 DRUGINFO D03EIM Borrelidin Investigative T12938 TARGETID T12938 T12938 FORMERID TTDI01392 T12938 UNIPROID LALBA_HUMAN T12938 TARGNAME Lactalbumin alpha (LALBA) T12938 GENENAME LALBA T12938 TARGTYPE Literature-reported T12938 SYNONYMS Lysozyme-like protein 7; Lactose synthase B protein; LYZL7; Alpha-lactalbumin T12938 FUNCTION Regulatory subunit of lactose synthase, changes the substrate specificity of galactosyltransferase in the mammary gland making glucose a good acceptor substrate for this enzyme. This enables LS to synthesize lactose, the major carbohydrate component of milk. In other tissues, galactosyltransferase transfers galactose onto the N-acetylglucosamine of the oligosaccharide chains in glycoproteins. T12938 PDBSTRUC 4L41; 3B0O; 3B0I; 1HML; 1CB3 T12938 SEQUENCE MRFFVPLFLVGILFPAILAKQFTKCELSQLLKDIDGYGGIALPELICTMFHTSGYDTQAIVENNESTEYGLFQISNKLWCKSSQVPQSRNICDISCDKFLDDDITDDIMCAKKILDIKGIDYWLAHKALCTEKLEQWLCEKL T20975 TARGETID T20975 T20975 FORMERID TTDR00262 T20975 UNIPROID NEU2_HUMAN T20975 TARGNAME Arginine vasopressin (AVP) T20975 GENENAME AVP T20975 TARGTYPE Literature-reported T20975 SYNONYMS Vasopressin-neurophysin 2-copeptin; VP; Copeptin; AVP-NPII; ARVP T20975 FUNCTION Neurophysin 2 specifically binds vasopressin. T20975 SEQUENCE MPDTMLPACFLGLLAFSSACYFQNCPRGGKRAMSDLELRQCLPCGPGGKGRCFGPSICCADELGCFVGTAEALRCQEENYLPSPCQSGQKACGSGGRCAAFGVCCNDESCVTEPECREGFHRRARASDRSNATQLDGPAGALLLRLVQLAGAPEPFEPAQPDAY T88213 TARGETID T88213 T88213 FORMERID TTDI02558 T88213 UNIPROID VIP_HUMAN T88213 TARGNAME Vasoactive intestinal polypeptide (VIP) T88213 GENENAME VIP T88213 TARGTYPE Literature-reported T88213 SYNONYMS Vasoactive intestinal peptide; VIP peptides; Peptide histidine valine 42; Intestinal peptide PHV-42 T88213 FUNCTION VIP causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis and relaxes the smooth muscle of trachea, stomach and gall bladder. T88213 PDBSTRUC 2RRI; 2RRH T88213 SEQUENCE MDTRNKAQLLVLLTLLSVLFSQTSAWPLYRAPSALRLGDRIPFEGANEPDQVSLKEDIDMLQNALAENDTPYYDVSRNARHADGVFTSDFSKLLGQLSAKKYLESLMGKRVSSNISEDPVPVKRHSDAVFTDNYTRLRKQMAVKKYLNSILNGKRSSEGESPDFPEELEK T29827 TARGETID T29827 T29827 FORMERID TTDI01398 T29827 UNIPROID ETXB_STAAU T29827 TARGNAME Staphylococcus Enterotoxin B (Stap-coc entB) T29827 GENENAME Stap-coc entB T29827 TARGTYPE Literature-reported T29827 SYNONYMS SEB; Enterotoxin type B T29827 FUNCTION Staphylococcal enterotoxins cause the intoxication staphylococcal food poisoning syndrome. The illness characterized by high fever, hypotension, diarrhea, shock, and in some cases death. T29827 PDBSTRUC 4RGO; 4RGN; 4RGM; 4C56; 3W2D T29827 SEQUENCE MYKRLFISHVILIFALILVISTPNVLAESQPDPKPDELHKSSKFTGLMENMKVLYDDNHVSAINVKSIDQFLYFDLIYSIKDTKLGNYDNVRVEFKNKDLADKYKDKYVDVFGANYYYQCYFSKKTNDINSHQTDKRKTCMYGGVTEHNGNQLDKYRSITVRVFEDGKNLLSFDVQTNKKKVTAQELDYLTRHYLVKNKKLYEFNNSPYETGYIKFIENENSFWYDMMPAPGDKFDQSKYLMMYNDNKMVDSKDVKIEVYLTTKKK T38610 TARGETID T38610 T38610 FORMERID TTDNR00640 T38610 UNIPROID CRYAA_HUMAN T38610 TARGNAME Alpha-crystallin A chain (CRYAA) T38610 GENENAME CRYAA T38610 TARGTYPE Literature-reported T38610 SYNONYMS HspB4; Heat shock protein beta-4; CRYA1 T38610 FUNCTION Has chaperone-like activity, preventing aggregation of various proteins under a wide range of stress conditions. Contributes to the transparency and refractive index of the lens. T38610 BIOCLASS Heat shock protein T38610 SEQUENCE MDVTIQHPWFKRTLGPFYPSRLFDQFFGEGLFEYDLLPFLSSTISPYYRQSLFRTVLDSGISEVRSDRDKFVIFLDVKHFSPEDLTVKVQDDFVEIHGKHNERQDDHGYISREFHRRYRLPSNVDQSALSCSLSADGMLTFCGPKIQTGLDATHAERAIPVSREEKPTSAPSS T43793 TARGETID T43793 T43793 FORMERID TTDI02348 T43793 UNIPROID C1QB_HUMAN T43793 TARGNAME Complement C1q component (C1Q) T43793 GENENAME C1QB T43793 TARGTYPE Literature-reported T43793 SYNONYMS C1QB T43793 FUNCTION C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takesplace on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes. T43793 PDBSTRUC 6FCZ; 5HZF; 5HKJ; 2WNV; 2WNU T43793 SEQUENCE MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIFSGFLLFPDMEA T45289 TARGETID T45289 T45289 FORMERID TTDR00471 T45289 UNIPROID FETUA_HUMAN T45289 TARGNAME Alpha-2-HS-glycoprotein (AHSG) T45289 GENENAME AHSG T45289 TARGTYPE Literature-reported T45289 SYNONYMS PRO2743; Ba-alpha-2-glycoprotein; Alpha2-HS glycoprotein T45289 FUNCTION Promotes endocytosis, possesses opsonic properties and influences the mineral phase of bone. Shows affinity for calcium and barium ions. T45289 BIOCLASS Fetuin family T45289 SEQUENCE MKSLVLLLCLAQLWGCHSAPHGPGLIYRQPNCDDPETEEAALVAIDYINQNLPWGYKHTLNQIDEVKVWPQQPSGELFEIEIDTLETTCHVLDPTPVARCSVRQLKEHAVEGDCDFQLLKLDGKFSVVYAKCDSSPDSAEDVRKVCQDCPLLAPLNDTRVVHAAKAALAAFNAQNNGSNFQLEEISRAQLVPLPPSTYVEFTVSGTDCVAKEATEAAKCNLLAEKQYGFCKATLSEKLGGAEVAVTCMVFQTQPVSSQPQPEGANEAVPTPVVDPDAPPSPPLGAPGLPPAGSPPDSHVLLAAPPGHQLHRAHYDLRHTFMGVVSLGSPSGEVSHPRKTRTVVQPSVGAAAGPVVPPCPGRIRHFKV T10577 TARGETID T10577 T10577 FORMERID TTDI01421 T10577 UNIPROID DNAA_ECOLI T10577 TARGNAME Bacterial Initiator protein DnaA (Bact dnaA) T10577 GENENAME Bact dnaA T10577 TARGTYPE Literature-reported T10577 SYNONYMS Chromosomal replication initiator protein DnaA T10577 FUNCTION Plays a key role in the initiation and regulation of chromosomal replication. Binds in an ATP-dependent fashion to the origin of replication (oriC) to initiate formation of the DNA replication initiation complex exactly once per cell cycle. Binds the DnaA box (consensus sequence 5'-TTATC[CA]A[CA]A-3'); subsequent binding of DNA polymerase III subunits leads to replisome formation. The DnaA-ATP form converts to DnaA-ADP; once converted to ADP the protein cannot initiate replication, ensuring only 1 round of replication per cell cycle. DnaA can inhibit its own gene expression as well as that of other genes such as dam, rpoH, ftsA and mioC. T10577 PDBSTRUC 2E0G; 1J1V T10577 SEQUENCE MSLSLWQQCLARLQDELPATEFSMWIRPLQAELSDNTLALYAPNRFVLDWVRDKYLNNINGLLTSFCGADAPQLRFEVGTKPVTQTPQAAVTSNVAAPAQVAQTQPQRAAPSTRSGWDNVPAPAEPTYRSNVNVKHTFDNFVEGKSNQLARAAARQVADNPGGAYNPLFLYGGTGLGKTHLLHAVGNGIMARKPNAKVVYMHSERFVQDMVKALQNNAIEEFKRYYRSVDALLIDDIQFFANKERSQEEFFHTFNALLEGNQQIILTSDRYPKEINGVEDRLKSRFGWGLTVAIEPPELETRVAILMKKADENDIRLPGEVAFFIAKRLRSNVRELEGALNRVIANANFTGRAITIDFVREALRDLLALQEKLVTIDNIQKTVAEYYKIKVADLLSKRRSRSVARPRQMAMALAKELTNHSLPEIGDAFGGRDHTTVLHACRKIEQLREESHDIKEDFSNLIRTLSS T33869 TARGETID T33869 T33869 FORMERID TTDR00316 T33869 UNIPROID POLG_FMDVO T33869 TARGNAME Foot-and-mouth disease virus Capsid VP2 (FMDV VP2) T33869 GENENAME FMDV VP2 T33869 TARGTYPE Literature-reported T33869 SYNONYMS Foot-and-mouth disease virus P1B; Foot-and-mouth disease virus Virion protein 2 T33869 FUNCTION Leader protease: Autocatalytically cleaves itself from the polyprotein at the L/VP0 junction. Cleaves also the host translation initiation factors EIF4G1 and EIF4G3, in order to shutoff the capped cellular mRNA transcription. Plays a role in counteracting host innate antiviral response using diverse mechanisms. Possesses a deubiquitinase activity acting on both 'Lys'-48 and 'Lys'-63-linked polyubiquitin chains. In turn, inhibits the ubiquitination and subsequent activation of key signaling molecules of type I IFN response such as host DDX58, TBK1, TRAF3 and TRAF6. Inhibits host NF-kappa-B activity by inducing a decrease in RELA mRNA levels. Cleaves a peptide bond in the C-terminus of host ISG15, resulting in the damaging of this mofidier that can no longer be attached to target proteins. Cleaves also host G3BP1 and G3BP2 in order to inhibit cytoplasmic stress granules assembly. T33869 PDBSTRUC 6FFA; 4QBB; 2JQG; 2JQF; 1QQP T33869 SEQUENCE DKKTEETTLLEDRILTTRNGHTTSTTQSSVGVTYGYATAEDFVSGPNTSGLETRVVQAERFFKTHLFDWVTSDSFGRCHLLELPTDHKGVYGSLTDSYAYMRNGWDVEVTAVGNQFNGGCLLVAMVPELYSIQKRELYQLTLFPHQFINPRTNMTAHITVPFVGVNRYDQYKVHKPWTLVVMVVAPLTVNTEGAPQIKVYANIAPTNVHVAGEFPSKE T69204 TARGETID T69204 T69204 FORMERID TTDR00317 T69204 UNIPROID POLG_FMDVO T69204 TARGNAME Foot-and-mouth disease virus Capsid VP3 (FMDV VP3) T69204 GENENAME FMDV VP3 T69204 TARGTYPE Literature-reported T69204 SYNONYMS Foot-and-mouth disease virus P1C; Foot-and-mouth disease virus Virion protein 3 T69204 FUNCTION Leader protease: Autocatalytically cleaves itself from the polyprotein at the L/VP0 junction. Cleaves also the host translation initiation factors EIF4G1 and EIF4G3, in order to shutoff the capped cellular mRNA transcription. Plays a role in counteracting host innate antiviral response using diverse mechanisms. Possesses a deubiquitinase activity acting on both 'Lys'-48 and 'Lys'-63-linked polyubiquitin chains. In turn, inhibits the ubiquitination and subsequent activation of key signaling molecules of type I IFN response such as host DDX58, TBK1, TRAF3 and TRAF6. Inhibits host NF-kappa-B activity by inducing a decrease in RELA mRNA levels. Cleaves a peptide bond in the C-terminus of host ISG15, resulting in the damaging of this mofidier that can no longer be attached to target proteins. Cleaves also host G3BP1 and G3BP2 in order to inhibit cytoplasmic stress granules assembly. T69204 PDBSTRUC 6FFA; 4QBB; 2JQG; 2JQF; 1QQP T69204 SEQUENCE GIFPVACSDGYGGLVTTDPKTADPVYGKVFNPPRNQLPGRFTNLLDVAEACPTFLRFEGGVPYVTTKTDSDRVLAQFDMSLAAKQMSNTFLAGLAQYYTQYSGTINLHFMFTGPTDAKARYMVAYAPPGMEPPKTPEAAAHCIHAEWDTGLNSKFTFSIPYLSAADYAYTASGVAETTNVQGWVCLFQITHGKADGDALVVLASAGKDFELRLPVDA T20556 TARGETID T20556 T20556 FORMERID TTDR00315 T20556 UNIPROID POLG_FMDVO T20556 TARGNAME Foot-and-mouth disease virus Capsid VP1 (FMDV VP1) T20556 GENENAME FMDV VP1 T20556 TARGTYPE Literature-reported T20556 SYNONYMS Foot-and-mouth disease virus P1D; Foot-and-mouth disease virus Virion protein 1 T20556 FUNCTION Leader protease: Autocatalytically cleaves itself from the polyprotein at the L/VP0 junction. Cleaves also the host translation initiation factors EIF4G1 and EIF4G3, in order to shutoff the capped cellular mRNA transcription. Plays a role in counteracting host innate antiviral response using diverse mechanisms. Possesses a deubiquitinase activity acting on both 'Lys'-48 and 'Lys'-63-linked polyubiquitin chains. In turn, inhibits the ubiquitination and subsequent activation of key signaling molecules of type I IFN response such as host DDX58, TBK1, TRAF3 and TRAF6. Inhibits host NF-kappa-B activity by inducing a decrease in RELA mRNA levels. Cleaves a peptide bond in the C-terminus of host ISG15, resulting in the damaging of this mofidier that can no longer be attached to target proteins. Cleaves also host G3BP1 and G3BP2 in order to inhibit cytoplasmic stress granules assembly. T20556 PDBSTRUC 6FFA; 4QBB; 2JQG; 2JQF; 1QQP T20556 SEQUENCE TTSAGESADPVTTTVENYGGETQIQRRQHTDVSFIMDRFVKVTPQNQINILDLMQIPSHTLVGALLRASTYYFSDLEIAVKHEGDLTWVPNGAPEKALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGECRYNRNAVPNLRGDLQVLAQKVARTLPTSFNYGAIKATRVTELLYRMKRAETYCPRPLLAIHPTEARHKQKIVAPVKQ T81210 TARGETID T81210 T81210 FORMERID TTDI01481 T81210 UNIPROID POLG_YEFV1 T81210 TARGNAME Flavivirus Serine protease NS2B-NS3 (FlaV NS2B-NS3) T81210 GENENAME FlaV NS2B-NS3 T81210 TARGTYPE Literature-reported T81210 SYNONYMS FlavivirusNon-structural protein 2B-Non-structural protein 3; Flavivirus Flavivirin protease NS2B regulatory subunit-Flavivirin protease NS3 catalytic subunit Non-structural protein 3 T81210 FUNCTION Capsid protein C: Plays a role in virus budding by binding to the cell membrane and gathering the viral RNA into a nucleocapsid that forms the core of a mature virus particle. During virus entry, may induce genome penetration into the host cytoplasm after hemifusion induced by the surface proteins. Can migrate to the cell nucleus where it modulates host functions. T81210 PDBSTRUC 6IW4; 6IW2; 6IW1; 6IW0; 6EPK T81210 SEQUENCE SIPVNEALAAAGLVGVLAGLAFQEMENFLGPIAVGGLLMMLVSVAGRVDGLELKKLGEVSWEEEAEISGSSARYDVALSEQGEFKLLSEEKVPWDQVVMTSLALVGAALHPFALLLVLAGWLFHVRGARRSGDVLWDIPTPKIIEECEHLEDGIYGIFQSTFLGASQRGVGVAQGGVFHTMWHVTRGAFLVRNGKKLIPSWASVKEDLVAYGGSWKLEGRWDGEEEVQLIAAVPGKNVVNVQTKPSLFKVRNGGEIGAVALDYPSGTSGSPIVNRNGEVIGLYGNGILVGDNSFVSAISQTEVKEEGKEELQEIPTMLKKGMTTVLDFHPGAGKTRRFLPQILAECARRRLRTLVLAPTRVVLSEMKEAFHGLDVKFHTQAFSAHGSGREVIDAMCHATLTYRMLEPTRVVNWEVIIMDEAHFLDPASIAARGWAAHRARANESATILMTATPPGTSDEFPHSNGEIEDVQTDIPSEPWNTGHDWILADKRPTAWFLPSIRAANVMAASLRKAGKSVVVLNRKTFEREYPTIKQKKPDFILATDIAEMGANLCVERVLDCRTAFKPVLVDEGRKVAIKGPLRISASSAAQRRGRIGRNPNRDGDSYYYSEPTSENNAHHVCWLEASMLLDNMEVRGGMVAPLYGVEGTKTPVSPGEMRLRDDQRKVFRELVRNCDLPVWLSWQVAKAGLKTNDRKWCFEGPEEHEILNDSGETVKCRAPGGAKKPLRPRWCDERVSSDQSALSEFIKFAEGRR T42838 TARGETID T42838 T42838 FORMERID TTDR00456 T42838 UNIPROID VIF_HV1A2 T42838 TARGNAME Human immunodeficiency virus Virion infectivity factor (HIV vif) T42838 GENENAME HIV vif T42838 TARGTYPE Literature-reported T42838 SYNONYMS Virion infectivity factor; Vif; SOR protein T42838 FUNCTION Counteracts the innate antiviral activity of host APOBEC3F and APOBEC3G. Forms a complex with host APOBEC3F and APOBEC3G thus preventing the entry of these lethally hypermutating enzymes into progeny virions. Recruits an active E3 ubiquitin ligase complex composed of elongin BC, CUL5, and RBX2 to induce polyubiquitination of APOBEC3G and APOBEC3F. In turn, they are directed to the 26S proteasome for degradation. Vif interaction with APOBEC3G also blocks its cytidine deaminase activity in a proteasome-independent manner, suggesting a dual inhibitory mechanism. May interact directly with APOBEC3G mRNA in order to inhibit its translation. Seems to play a role in viral morphology by affecting the stability of the viral nucleoprotein core. Finally, Vif also contributes to the G2 cell cycle arrest observed in HIV infected cells. T42838 BIOCLASS Primate lentivirus group Vif protein T42838 SEQUENCE MENRWQVMIVWQVDRMRIRTWKSLVKHHMYISKKAKGWFYRHHYESTHPRVSSEVHIPLGDAKLVITTYWGLHTGEREWHLGQGVAIEWRKKKYSTQVDPGLADQLIHLHYFDCFSESAIKNAILGYRVSPRCEYQAGHNKVGSLQYLALAALITPKKTKPPLPSVKKLTEDRWNKPQKTKGHRGSHTMNGH T55863 TARGETID T55863 T55863 FORMERID TTDNR00691 T55863 UNIPROID NCAP_I34A1 T55863 TARGNAME Influenza Nucleoprotein (Influ NP) T55863 GENENAME Influ NP T55863 TARGTYPE Literature-reported T55863 SYNONYMS Influ Protein N; Influ Nucleoprotein; Influ Nucleocapsid protein T55863 FUNCTION Encapsidates the negative strand viral RNA, protecting it from nucleases. The encapsidated genomic RNA is termed the ribonucleoprotein (RNP) and serves as template for transcription and replication. The RNP needs to be localized in the host nucleus to start an infectious cycle, but is too large to diffuse through the nuclear pore complex. NP comprises at least 2 nuclear localization signals that are responsible for the active RNP import into the nucleus through cellular importin alpha/beta pathway. Later in the infection, nclear export of RNPs are mediated through viral proteins NEP interacting with M1 which binds nucleoproteins. It is possible that nucleoprotein binds directly host exportin-1/XPO1 and plays an active role in RNPs nuclear export. M1 interaction with RNP seems to hide nucleoprotein's nuclear localization signals. Soon after a virion infects a new cell, M1 dissociates from the RNP under acidification of the virion driven by M2 protein. Dissociation of M1 from RNP unmasks nucleoprotein's nuclear localization signals, targeting the RNP to the nucleus. T55863 PDBSTRUC 5V5O; 5NQ3; 5NPZ; 4ZDU; 4NQV T55863 SEQUENCE MASQGTKRSYEQMETDGERQNATEIRASVGKMIGGIGRFYIQMCTELKLSDYEGRLIQNSLTIERMVLSAFDERRNKYLEEHPSAGKDPKKTGGPIYRRVNGKWMRELILYDKEEIRRIWRQANNGDDATAGLTHMMIWHSNLNDATYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGVGTMVMELVRMIKRGINDRNFWRGENGRKTRIAYERMCNILKGKFQTAAQKAMMDQVRESRNPGNAEFEDLTFLARSALILRGSVAHKSCLPACVYGPAVASGYDFEREGYSLVGIDPFRLLQNSQVYSLIRPNENPAHKSQLVWMACHSAAFEDLRVLSFIKGTKVLPRGKLSTRGVQIASNENMETMESSTLELRSRYWAIRTRSGGNTNQQRASAGQISIQPTFSVQRNLPFDRTTIMAAFNGNTEGRTSDMRTEIIRMMESARPEDVSFQGRGVFELSDEKAASPIVPSFDMSNEGSYFFGDNAEEYDN T43842 TARGETID T43842 T43842 FORMERID TTDNR00730 T43842 UNIPROID GLYC_PIARV T43842 TARGNAME Virus Pre-glycoprotein GP complex (Viru GPC) T43842 GENENAME Viru GPC T43842 TARGTYPE Literature-reported T43842 SYNONYMS Pre-GP-C; GPC T43842 FUNCTION Glycoprotein G2 is a viral fusion protein. Membrane fusion is mediated by conformational changes induced upon acidification in the endosome (Potential). T43842 BIOCLASS Arenaviridae GPC protein T43842 SEQUENCE MGQIVTLIQSIPEVLQEVFNVALIIVSVLCIVKGFVNLMRCGLFQLVTFLILSGRSCDSMMIDRRHNLTHVEFNLTRMFDNLPQSCSKNNTHHYYKGPSNTTWGIELTLTNTSIANETSGNFSNIGSLGYGNISNCDRTREAGHTLKWLLNELHFNVLHVTRHIGARCKTVEGAGVLIQYNLTVGDRGGEVGRHLIASLAQIIGDPKIAWVGKCFNNCSGDTCRLTNCEGGTHYNFLIIQNTTWENHCTYTPMATIRMALQRTAYSSVSRKLLGFFTWDLSDSSGQHVPGGYCLEQWAIIWAGIKCFDNTVMAKCNKDHNEEFCDTMRLFDFNQNAIKTLQLNVENSLNLFKKTINGLISDSLVIRNSLKQLAKIPYCNYTKFWYINDTITGRHSLPQCWLVHNGSYLNETHFKNDWLWESQNLYNEMLMKEYEERQGKTPLALTDICFWSLVFYTITVFLHIVGIPTHRHIIGDGCPKPHRITRNSLCSCGYYKYQRNLTNG T08722 TARGETID T08722 T08722 FORMERID TTDR01237 T08722 UNIPROID PRIO_HUMAN T08722 TARGNAME Major prion protein (PRNP) T08722 GENENAME PRNP T08722 TARGTYPE Literature-reported T08722 SYNONYMS Prion protein PrP(C); Prion protein; PrP33-35C; PrP27-30; PrP; PRNP; CD230 antigen; ASCR T08722 FUNCTION The physiological function of prp is not known. T08722 PDBSTRUC 5YJ5; 5YJ4; 5L6R; 4N9O; 4KML T08722 SEQUENCE MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERVVEQMCITQYERESQAYYQRGSSMVLFSSPPVILLISFLIFLIVG T88786 TARGETID T88786 T88786 FORMERID TTDR00185 T88786 UNIPROID MYCN_HUMAN T88786 TARGNAME N-myc proto-oncogene protein (MYCN) T88786 GENENAME MYCN T88786 TARGTYPE Literature-reported T88786 SYNONYMS bHLHe37; NMYC; N-myc; Class E basic helix-loop-helix protein 37 T88786 FUNCTION Positively regulates the transcription of MYCNOS in neuroblastoma cells. T88786 PDBSTRUC 5G1X T88786 SEQUENCE MPSCSTSTMPGMICKNPDLEFDSLQPCFYPDEDDFYFGGPDSTPPGEDIWKKFELLPTPPLSPSRGFAEHSSEPPSWVTEMLLENELWGSPAEEDAFGLGGLGGLTPNPVILQDCMWSGFSAREKLERAVSEKLQHGRGPPTAGSTAQSPGAGAASPAGRGHGGAAGAGRAGAALPAELAHPAAECVDPAVVFPFPVNKREPAPVPAAPASAPAAGPAVASGAGIAAPAGAPGVAPPRPGGRQTSGGDHKALSTSGEDTLSDSDDEDDEEEDEEEEIDVVTVEKRRSSSNTKAVTTFTITVRPKNAALGPGRAQSSELILKRCLPIHQQHNYAAPSPYVESEDAPPQKKIKSEASPRPLKSVIPPKAKSLSPRNSDSEDSERRRNHNILERQRRNDLRSSFLTLRDHVPELVKNEKAAKVVILKKATEYVHSLQAEEHQLLLEKEKLQARQQQLLKKIEHARTC T45518 TARGETID T45518 T45518 UNIPROID DPOL_HHV21-PAP_HHV11 T45518 TARGNAME Herpes simplex virus DNA polymerase POL (HSV POL) T45518 GENENAME HSV POL T45518 TARGTYPE Literature-reported T45518 SYNONYMS Complex of DNA polymerase processivity factor and DNA polymerase catalytic subunit T45518 FUNCTION Synthesize herpes simplex virus DNA from deoxyribonucleotides, the building blocks of DNA. T45518 BIOCLASS DNA polymerase type-B family T45518 SEQUENCE MTDSPGGVAPASPVEDASDASLGQPEEGAPCQVVLQGAELNGILQAFAPLRTSLLDSLLVMGDRGILIHNTIFGEQVFLPLEHSQFSRYRWRGPTAAFLSLVDQKRSLLSVFRANQYPDLRRVELAITGQAPFRTLVQRIWTTTSDGEAVELASETLMKRELTSFVVLVPQGTPDVQLRLTRPQLTKVLNATGADSATPTTFELGVNGKFSVFTTSTCVTFAAREEGVSSSTSTQVQILSNALTKAGQAAANAKTVYGENTHRTFSVVVDDCSMRAVLRRLQVGGGTLKFFLTTPVPSLCVTATGPNAVSAVFLLKPQKICLDWLGHSQGSPSAGSSASRASGSEPTDSQDSASDAVSHGDPEDLDGAARAGEAGALHACPMPSSTTRVTPTTKRGRSGGEDARADTALKKPKTGSPTAPPPADPVPLDTEDDSDAADGTAARPAAPDARSGSRYACYFRDLPTGEASPGAFSAFRGGPQTPYGFGFPMFCAAGGPASPGGKSAARAASGFFAPHNPRGATQTAPPPCRRQNFYNPHLAQTGTQPKAPGPAQRHTYYSECDEFRFIAPRSLDEDAPAEQRTGVHDGRLRRAPKVYCGGDERDVLRVGPEGFWPRRLRLWGGADHAPEGFDPTVTVFHVYDILEHVEHAYSMRAAQLHERFMDAITPAGTVITLLGLTPEGHRVAVHVYGTRQYFYMNKAEVDRHLQCRAPRDLCERLAAALRESPGASFRGISADHFEAEVVERADVYYYETRPTLYYRVFVRSGRALAYLCDNFCPAIRKYEGGVDATTRFILDNPGFVTFGWYRLKPGRGNAPAQPRPPTAFGTSSDVEFNCTADNLAVEGAMCDLPAYKLMCFDIECKAGGEDELAFPVAERPEDLVIQISCLLYDLSTTALEHILLFSLGSCDLPESHLSDLASRGLPAPVVLEFDSEFEMLLAFMTFVKQYGPEFVTGYNIINFDWPFVLTKLTEIYKVPLDGYGRMNGRGVFRVWDIGQSHFQKRSKIKVNGMVNIDMYGIITDKVKLSSYKLNAVAEAVLKDKKKDLSYRDIPAYYASGPAQRGVIGEYCVQDSLLVGQLFFKFLPHLELSAVARLAGINITRTIYDGQQIRVFTCLLRLAGQKGFILPDTQGRFRGLDKEAPKRPAVPRGEGERPGDGNGDEDKDDDEDGDEDGDEREEVARETGGRHVGYQGARVLDPTSGFHVDPVVVFDFASLYPSIIQAHNLCFSTLSLRPEAVAHLEADRDYLEIEVGGRRLFFVKAHVRESLLSILLRDWLAMRKQIRSRIPQSPPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTIGREMLLATRAYVHARWAEFDQLLADFPEAAGMRAPGPYSMRIIYGDTDSIFVLCRGLTGEALVAMGDKMASHISRALFLPPIKLECEKTFTKLLLIAKKKYIGVICGGKMLIKGVDLVRKNNCAFINRTSRALVDLLFYDDTVSGAAAALAERPAEEWLARPLPEGLQAFGAVLVDAHRRITDPERDIQDFVLTAELSRHPRAYTNKRLAHLTVYYKLMARRAQVPSIKDRIPYVIVAQTREVEETVARLAALRELDAAAPGDEPAPPAALPSPAKRPRETPSHADPPGGASKPRKLLVSELAEDPGYAIARGVPLNTDYYFSHLLGAACVTFKALFGNNAKITESLLKRFIPETWHPPDDVAARLRAAGFGPAGAGATAEETRRMLHRAFDTLA T45518 DRUGINFO D08VKN CP 4010 Investigative T59432 TARGETID T59432 T59432 FORMERID TTDR00182 T59432 UNIPROID TVB79_HUMAN T59432 TARGNAME T-cell receptor beta chain V region CTL-L17 (TCRB) T59432 GENENAME TCRB T59432 TARGTYPE Literature-reported T59432 SYNONYMS V beta 17 T-cell receptor; TRBV7-9; T cell receptor beta variable 7-9 T59432 FUNCTION Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens. Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation. The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity. V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition. T59432 BIOCLASS Immunoglobulin T59432 SEQUENCE MGTSLLCWMALCLLGADHADTGVSQNPRHKITKRGQNVTFRCDPISEHNRLYWYRQTLGQGPEFLTYFQNEAQLEKSRLLSDRFSAERPKGSFSTLEIQRTEQGDSAMYLCASSL T39701 TARGETID T39701 T39701 FORMERID TTDI01262 T39701 UNIPROID NSP4_ROTS1 T39701 TARGNAME Rotavirus Toxin (Rota TOX) T39701 GENENAME Rota TOX T39701 TARGTYPE Literature-reported T39701 SYNONYMS Non-structural glycoprotein 4; NSP4; NS28; NCVP5 T39701 FUNCTION Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca(2+) in the cytoplasm of infected cell. In turn, high levels of cytoplasmic calcium trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication and immature particle assembly. T39701 PDBSTRUC 2O1K; 1G1J; 1G1I T39701 SEQUENCE MEKLTDLNYTLSVITLMNNTLHTILEDPGMAYFPYIASVLTGLFALNKASIPTMKIALKTSKCSYKVVKYCIVTIFNTLLKLAGYKEQITTKDEIEKQMDRVVKEMRRQLEMIDKLTTREIEQVELLKRIYDKLTVQTTGEIDMTKEINQKNVRTLEEWESGKNPYEPREVTAAM T40728 TARGETID T40728 T40728 FORMERID TTDI02574 T40728 UNIPROID LEG2_HUMAN T40728 TARGNAME Galectin-2 (LGALS2) T40728 GENENAME LGALS2 T40728 TARGTYPE Literature-reported T40728 SYNONYMS SLac lectin 2; Lactosebinding lectin 2; LGALS2; HL14; Gal2; Betagalactosidebinding lectin L14II T40728 FUNCTION This protein binds beta-galactoside. Its physiological function is not yet known. T40728 PDBSTRUC 5EWS; 5DG2; 5DG1; 1HLC T40728 SEQUENCE MTGELEVKNMDMKPGSTLKITGSIADGTDGFVINLGQGTDKLNLHFNPRFSESTIVCNSLDGSNWGQEQREDHLCFSPGSEVKFTVTFESDKFKVKLPDGHELTFPNRLGHSHLSYLSVRGGFNMSSFKLKE T85715 TARGETID T85715 T85715 FORMERID TTDI02582 T85715 UNIPROID CD5_HUMAN T85715 TARGNAME T-cell surface glycoprotein CD5 (CD5) T85715 GENENAME CD5 T85715 TARGTYPE Literature-reported T85715 SYNONYMS Lymphocyte antigen T1/Leu-1; LEU1 T85715 FUNCTION May act as a receptor in regulating T-cell proliferation. T85715 PDBSTRUC 2OTT; 2JP0; 2JOP; 2JA4 T85715 SEQUENCE MPMGSLQPLATLYLLGMLVASCLGRLSWYDPDFQARLTRSNSKCQGQLEVYLKDGWHMVCSQSWGRSSKQWEDPSQASKVCQRLNCGVPLSLGPFLVTYTPQSSIICYGQLGSFSNCSHSRNDMCHSLGLTCLEPQKTTPPTTRPPPTTTPEPTAPPRLQLVAQSGGQHCAGVVEFYSGSLGGTISYEAQDKTQDLENFLCNNLQCGSFLKHLPETEAGRAQDPGEPREHQPLPIQWKIQNSSCTSLEHCFRKIKPQKSGRVLALLCSGFQPKVQSRLVGGSSICEGTVEVRQGAQWAALCDSSSARSSLRWEEVCREQQCGSVNSYRVLDAGDPTSRGLFCPHQKLSQCHELWERNSYCKKVFVTCQDPNPAGLAAGTVASIILALVLLVVLLVVCGPLAYKKLVKKFRQKKQRQWIGPTGMNQNMSFHRNHTATVRSHAENPTASHVDNEYSQPPRNSHLSAYPALEGALHRSSMQPDNSSDSDYDLHGAQRL T24089 TARGETID T24089 T24089 FORMERID TTDR00377 T24089 UNIPROID CCKN_HUMAN T24089 TARGNAME Cholecystokinin (CCK) T24089 GENENAME CCK T24089 TARGTYPE Literature-reported T24089 SYNONYMS Procholecystokinin; CCK T24089 FUNCTION This peptide hormone induces gall bladder contraction and therelease of pancreatic enzymes in the gut. Its function in the brain is not clear. Binding to CCK-A receptors stimulates amylase release from the pancreas, binding to CCK-B receptors stimulates gastric acid secretion. T24089 BIOCLASS Gastrin cholecystokinin T24089 SEQUENCE MNSGVCLCVLMAVLAAGALTQPVPPADPAGSGLQRAEEAPRRQLRVSQRTDGESRAHLGALLARYIQQARKAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDFGRRSAEEYEYPS T31186 TARGETID T31186 T31186 FORMERID TTDI00074 T31186 UNIPROID IF4E_HUMAN T31186 TARGNAME Eukaryotic initiation factor 4E (EIF4E) T31186 GENENAME EIF4E T31186 TARGTYPE Literature-reported T31186 SYNONYMS eIF4F 25 kDa subunit; eIF4E; eIF-4F 25 kDa subunit; eIF-4E; Eukaryotic translation initiation factor 4E; EIF4F; EIF4EL1 T31186 FUNCTION Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap. Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures. T31186 PDBSTRUC 5ZML; 5ZK9; 5ZK7; 5ZK5; 5ZJZ T31186 SEQUENCE MATVEPETTPTPNPPTTEEEKTESNQEVANPEHYIKHPLQNRWALWFFKNDKSKTWQANLRLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLFKDGIEPMWEDEKNKRGGRWLITLNKQQRRSDLDRFWLETLLCLIGESFDDYSDDVCGAVVNVRAKGDKIAIWTTECENREAVTHIGRVYKERLGLPPKIVIGYQSHADTATKSGSTTKNRFVV T99314 TARGETID T99314 T99314 FORMERID TTDI01522 T99314 UNIPROID TSST_STAAU T99314 TARGNAME Staphylococcus Toxic shock syndrome toxin-1 (Stap-coc tst) T99314 GENENAME Stap-coc tst T99314 TARGTYPE Literature-reported T99314 SYNONYMS Toxic shock syndrome toxin-1; TSST-1 T99314 FUNCTION Responsible for the symptoms of toxic shock syndrome. T99314 PDBSTRUC 5TSS; 4TSS; 4OHJ; 3TSS; 2TSS T99314 SEQUENCE MNKKLLMNFFIVSPLLLATTATDFTPVPLSSNQIIKTAKASTNDNIKDLLDWYSSGSDTFTNSEVLDNSLGSMRIKNTDGSISLIIFPSPYYSPAFTKGEKVDLNTKRTKKSQHTSEGTYIHFQISGVTNTEKLPTPIELPLKVKVHGKDSPLKYGPKFDKKQLAISTLDFEIRHQLTQIHGLYRSSDKTGGYWKITMNDGSTYQSDLSKKFEYNTEKPPINIDEIKTIEAEIN T80070 TARGETID T80070 T80070 FORMERID TTDR00618 T80070 UNIPROID HGXR_PLAFK T80070 TARGNAME Plasmodium Hypoxanthine-guanine-xanthine phosphoribosyltransferase (Malaria LACZ) T80070 GENENAME Malaria LACZ T80070 TARGTYPE Literature-reported T80070 SYNONYMS LACZ of Plasmodium falciparum (isolate K1 / Thailand); HGXPRTase; HGXPRT; HGPRT of Plasmodium falciparum (isolate K1 / Thailand) T80070 FUNCTION Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5- phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Works with guanine, hypoxanthine and xanthine. Plays a central role in the generation of purine nucleotides through the purine salvage pathway. T80070 BIOCLASS Pentosyltransferase T80070 SEQUENCE MPIPNNPGAGENAFDPVFVKDDDGYDLDSFMIPAHYKKYLTKVLVPNGVIKNRIEKLAYDIKKVYNNEEFHILCLLKGSRGFFTALLKHLSRIHNYSAVEMSKPLFGEHYVRVKSYCNDQSTGTLEIVSEDLSCLKGKHVLIVEDIIDTGKTLVKFCEYLKKFEIKTVAIACLFIKRTPLWNGFKADFVGFSIPDHFVVGYSLDYNEIFRDLDHCCLVNDEGKKKYKATSL T80070 DRUGINFO D0A1DU Pyrophosphate 2- Investigative T69541 TARGETID T69541 T69541 FORMERID TTDR01189 T69541 UNIPROID MCR_HUMAN T69541 TARGNAME Corticosteroid receptor type I (NR3C2) T69541 GENENAME NR3C2 T69541 TARGTYPE Literature-reported T69541 SYNONYMS MCR; MLR; MR; Mineralocorticoid receptor; Nuclear receptor subfamily 3 group C member 2 T69541 FUNCTION Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels. T69541 PDBSTRUC 6GGG; 6GG8; 6GEV; 5MWY; 5MWP T69541 SEQUENCE METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNSTQGSSKEKQELLPCLQQDNNRPGILTSDIKTELESKELSATVAESMGLYMDSVRDADYSYEQQNQQGSMSPAKIYQNVEQLVKFYKGNGHRPSTLSCVNTPLRSFMSDSGSSVNGGVMRAVVKSPIMCHEKSPSVCSPLNMTSSVCSPAGINSVSSTTASFGSFPVHSPITQGTPLTCSPNVENRGSRSHSPAHASNVGSPLSSPLSSMKSSISSPPSHCSVKSPVSSPNNVTLRSSVSSPANINNSRCSVSSPSNTNNRSTLSSPAASTVGSICSPVNNAFSYTASGTSAGSSTLRDVVPSPDTQEKGAQEVPFPKTEEVESAISNGVTGQLNIVQYIKPEPDGAFSSSCLGGNSKINSDSSFSVPIKQESTKHSCSGTSFKGNPTVNPFPFMDGSYFSFMDDKDYYSLSGILGPPVPGFDGNCEGSGFPVGIKQEPDDGSYYPEASIPSSAIVGVNSGGQSFHYRIGAQGTISLSRSARDQSFQHLSSFPPVNTLVESWKSHGDLSSRRSDGYPVLEYIPENVSSSTLRSVSTGSSRPSKICLVCGDEASGCHYGVVTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRLQKCLQAGMNLGARKSKKLGKLKGIHEEQPQQQQPPPPPPPPQSPEEGTTYIAPAKEPSVNTALVPQLSTISRALTPSPVMVLENIEPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQVVKWAKVLPGFKNLPLEDQITLIQYSWMCLSSFALSWRSYKHTNSQFLYFAPDLVFNEEKMHQSAMYELCQGMHQISLQFVRLQLTFEEYTIMKVLLLLSTIPKDGLKSQAAFEEMRTNYIKELRKMVTKCPNNSGQSWQRFYQLTKLLDSMHDLVSDLLEFCFYTFRESHALKVEFPAMLVEIISDQLPKVESGNAKPLYFHRK T66016 TARGETID T66016 T66016 FORMERID TTDR00069 T66016 UNIPROID MMP3_HUMAN; MMP10_HUMAN; MMP11_HUMAN T66016 TARGNAME Stromelysin (SL) T66016 GENENAME MMP3; MMP10; MMP11 T66016 TARGTYPE Literature-reported T66016 SYNONYMS Transin; STMY; SL; Matrix metalloproteinase SL T66016 FUNCTION Plays an important role in tissue remodeling associated with various physiological or pathological processes such as morphogenesis, angiogenesis, tissue repair, cirrhosis, arthritis, and metastasis. Excess MMPs degrade the structural proteins of the aortic wall. Disregulation of the balance between MMPs and TIMPs is also a characteristic of acute and chronic cardiovascular diseases. T66016 BIOCLASS Peptidase T66016 SEQUENCE MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNC T54461 TARGETID T54461 T54461 FORMERID TTDI02531 T54461 UNIPROID K1C19_HUMAN T54461 TARGNAME Keratin type I cytoskeletal 19 (KRT19) T54461 GENENAME KRT19 T54461 TARGTYPE Literature-reported T54461 SYNONYMS Keratin19; Keratin, type I cytoskeletal 19; KRT19; K19; Cytokeratin19; CK19 T54461 FUNCTION Involved in the organization of myofibers. Together with KRT8, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle. {ECO:0000269|PubMed:16000376}. T54461 BIOCLASS Intermediate filament family T54461 SEQUENCE MTSYSYRQSSATSSFGGLGGGSVRFGPGVAFRAPSIHGGSGGRGVSVSSARFVSSSSSGAYGGGYGGVLTASDGLLAGNEKLTMQNLNDRLASYLDKVRALEAANGELEVKIRDWYQKQGPGPSRDYSHYYTTIQDLRDKILGATIENSRIVLQIDNARLAADDFRTKFETEQALRMSVEADINGLRRVLDELTLARTDLEMQIEGLKEELAYLKKNHEEEISTLRGQVGGQVSVEVDSAPGTDLAKILSDMRSQYEVMAEQNRKDAEAWFTSRTEELNREVAGHTEQLQMSRSEVTDLRRTLQGLEIELQSQLSMKAALEDTLAETEARFGAQLAHIQALISGIEAQLGDVRADSERQNQEYQRLMDIKSRLEQEIATYRSLLEGQEDHYNNLSASKVL T09439 TARGETID T09439 T09439 FORMERID TTDR00504 T09439 UNIPROID SPRC_HUMAN T09439 TARGNAME Osteonectin (SPARC) T09439 GENENAME SPARC T09439 TARGTYPE Literature-reported T09439 SYNONYMS Secreted protein acidic and rich in cysteine; ON; Basement-membrane protein 40; Basement membrane protein BM-40; BM-40 T09439 FUNCTION Binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. There are two calcium binding sites; an acidic domain that binds 5 to 8 Ca(2+) with a low affinity and an EF-hand loop that binds a Ca(2+) ion with a high affinity. Appears to regulate cell growth through interactions with the extracellular matrix and cytokines. T09439 PDBSTRUC 2V53; 1SRA; 1NUB; 1BMO T09439 SEQUENCE MRAWIFFLLCLAGRALAAPQQEALPDETEVVEETVAEVTEVSVGANPVQVEVGEFDDGAEETEEEVVAENPCQNHHCKHGKVCELDENNTPMCVCQDPTSCPAPIGEFEKVCSNDNKTFDSSCHFFATKCTLEGTKKGHKLHLDYIGPCKYIPPCLDSELTEFPLRMRDWLKNVLVTLYERDEDNNLLTEKQKLRVKKIHENEKRLEAGDHPVELLARDFEKNYNMYIFPVHWQFGQLDQHPIDGYLSHTELAPLRAPLIPMEHCTTRFFETCDLDNDKYIALDEWAGCFGIKQKDIDKDLVI T01697 TARGETID T01697 T01697 FORMERID TTDR00307 T01697 UNIPROID FEMB_STAAM T01697 TARGNAME Staphylococcus Aminoacyltransferase FemB (Stap-coc femB) T01697 GENENAME Stap-coc femB T01697 TARGTYPE Literature-reported T01697 SYNONYMS Possible protein femB; ORF 419 T01697 FUNCTION Its function is unknown but its expression is needed for attaining the full level of resistance to the antibiotic methicillin. T01697 ECNUMBER EC 2.3.2.18 T01697 SEQUENCE MKFTELTVTEFDNFVQNPSLESHYFQVKENIVTRENDGFEVVLLGIKDDNNKVIAASLFSKIPTMGSYVYYSNRGPVMDFSDLGLVDYYLKELDKYLQQHQCLYVKLDPYWLYHLYDKDIVPFEGREKNDALVNLFKSHGYEHHGFTTEYDTSSQVRWMGVLNLEGKTPETLKKTFDSQRKRNINKAINYGVKVRFLERDEFNLFLDLYRETEERAGFVSKTDDYFYNFIDTYGDKVLVPLAYIDLDEYVLKLQQELNDKENRRDQMMAKENKSDKQMKKIAELDKQIDHDQHELLNASELSKTDGPILNLASGVYFANAYEVNYFSGGSSEKYNQFMGPYMMHWFMINYCFDNGYDRYNFYGLSGDFTENSEDYGVYRFKRGFNVQIEELIGDFYKPIHKVKYWLFTTLDKLRKKLKK T24718 TARGETID T24718 T24718 FORMERID TTDR00038 T24718 UNIPROID MTSA1_STRPN T24718 TARGNAME Streptococcus Pneumococcal surface adhesin A (Stre-coc psaA) T24718 GENENAME Stre-coc psaA T24718 TARGTYPE Literature-reported T24718 SYNONYMS PsaA T24718 FUNCTION Part of an atp-driven transport system for manganese. Also act as an adhesin which is involved on adherence to extracellular matrix. It is an important factor in pathogenesis and infection. T24718 PDBSTRUC 4UTP; 4UTO; 3ZTT; 3ZKA; 3ZK9 T24718 SEQUENCE MKKLGTLLVLFLSAIILVACASGKKDTTSGQKLKVVATNSIIADITKNIAGDKIDLHSIVPIGQDPHEYEPLPEDVKKTSEADLIFYNGINLETGGNAWFTKLVENAKKTENKDYFAVSDGVDVIYLEGQNEKGKEDPHAWLNLENGIIFAKNIAKQLSAKDPNNKEFYEKNLKEYTDKLDKLDKESKDKFNKIPAEKKLIVTSEGAFKYFSKAYGVPSAYIWEINTEEEGTPEQIKTLVEKLRQTKVPSLFVESSVDDRPMKTVSQDTNIPIYAQIFTDSIAEQGKEGDSYYSMMKYNLDKIAEGLAK T88125 TARGETID T88125 T88125 FORMERID TTDR00932 T88125 UNIPROID ENGB_ECOLI T88125 TARGNAME Bacterial GTP-binding protein YihA (Bact engB) T88125 GENENAME Bact engB T88125 TARGTYPE Literature-reported T88125 SYNONYMS engB; Probable GTP-binding protein engB T88125 FUNCTION Necessary for normal cell division and for the maintenance of normal septation. Depletion of this protein leads to a severe reduction in growth rate and to extensive filamentation, with a block beyond the stage of segregation. Essential for bacteria survivial. T88125 PDBSTRUC 1PUI T88125 SEQUENCE MTNLNYQQTHFVMSAPDIRHLPSDTGIEVAFAGRSNAGKSSALNTLTNQKSLARTSKTPGRTQLINLFEVADGKRLVDLPGYGYAEVPEEMKRKWQRALGEYLEKRQSLQGLVVLMDIRHPLKDLDQQMIEWAVDSNIAVLVLLTKADKLASGARKAQLNMVREAVLAFNGDVQVETFSSLKKQGVDKLRQKLDTWFSEMQPVEETQDGE T88125 DRUGINFO D0EQ4T Guanosine-5'-Triphosphate Investigative T88125 DRUGINFO D0C7LS Guanosine-5'-Diphosphate Investigative T41371 TARGETID T41371 T41371 FORMERID TTDI01340 T41371 UNIPROID MRAY_ECOLI T41371 TARGNAME Bacterial Phospho-MurNAc-pentapeptide translocase (Bact MraY) T41371 GENENAME Bact MraY T41371 TARGTYPE Literature-reported T41371 SYNONYMS UDP-MurNAc-pentapeptide phosphotransferase; Phospho-N-acetylmuramoyl-pentapeptide-transferase T41371 FUNCTION First step of the lipid cycle reactions in the biosynthesis of the cell wall peptidoglycan. T41371 ECNUMBER EC 2.7.8.13 T41371 SEQUENCE MLVWLAEHLVKYYSGFNVFSYLTFRAIVSLLTALFISLWMGPRMIAHLQKLSFGQVVRNDGPESHFSKRGTPTMGGIMILTAIVISVLLWAYPSNPYVWCVLVVLVGYGVIGFVDDYRKVVRKDTKGLIARWKYFWMSVIALGVAFALYLAGKDTPATQLVVPFFKDVMPQLGLFYILLAYFVIVGTGNAVNLTDGLDGLAIMPTVFVAGGFALVAWATGNMNFASYLHIPYLRHAGELVIVCTAIVGAGLGFLWFNTYPAQVFMGDVGSLALGGALGIIAVLLRQEFLLVIMGGVFVVETLSVILQVGSFKLRGQRIFRMAPIHHHYELKGWPEPRVIVRFWIISLMLVLIGLATLKVR T53766 TARGETID T53766 T53766 FORMERID TTDR01301 T53766 UNIPROID H2AZ_HUMAN T53766 TARGNAME Histone variant H2A.Z (H2AFZ) T53766 GENENAME H2AFZ T53766 TARGTYPE Literature-reported T53766 SYNONYMS Histone H2A.Z; H2AZ; H2A/z T53766 FUNCTION Variant histone H2A which replaces conventional H2A in a subset of nucleosomes. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. May be involved in the formation of constitutive heterochromatin. May be required for chromosome segregation during cell division. T53766 PDBSTRUC 5Z30; 5FUG; 5CHL; 5B33; 5B32 T53766 SEQUENCE MAGGKAGKDSGKAKTKAVSRSQRAGLQFPVGRIHRHLKSRTTSHGRVGATAAVYSAAILEYLTAEVLELAGNASKDLKVKRITPRHLQLAIRGDEELDSLIKATIAGGGVIPHIHKSLIGKKGQQKTV T89752 TARGETID T89752 T89752 FORMERID TTDI03563 T89752 UNIPROID SBK3_HUMAN T89752 TARGNAME Sugen kinase 110 (SBK3) T89752 GENENAME SBK3 T89752 TARGTYPE Literature-reported T89752 SYNONYMS Uncharacterized serine/threonine-protein kinase SBK3; SH3-binding domain kinase family member 3; SGK110 T89752 FUNCTION A serine/threonine protein kinase that does not have an activating compound and are either non-specific or their specificity has not been analyzed to date. T89752 ECNUMBER EC 2.7.11.1 T89752 SEQUENCE MERRASETPEDGDPEEDTATALQRLVELTTSRVTPVRSLRDQYHLIRKLGSGSYGRVLLAQPHQGGPAVALKLLRRDLVLRSTFLREFCVGRCVSAHPGLLQTLAGPLQTPRYFAFAQEYAPCGDLSGMLQERGLPELLVKRVVAQLAGALDFLHSRGLVHADVKPDNVLVFDPVCSRVALGDLGLTRPEGSPTPAPPVPLPTAPPELCLLLPPDTLPLRPAVDSWGLGVLLFCAATACFPWDVALAPNPEFEAFAGWVTTKPQPPQPPPPWDQFAPPALALLQGLLDLDPETRSPPLAVLDFLGDDWGLQGNREGPGVLGSAVSYEDREEGGSSLEEWTDEGDDSKSGGRTGTDGGAP T89752 DRUGINFO D00EMH PMID21967808CR-16 Investigative T12005 TARGETID T12005 T12005 FORMERID TTDR00857 T12005 UNIPROID R1A_CVHSA T12005 TARGNAME Coronavirus Main proteinase (CoV 1a) T12005 GENENAME CoV 1a T12005 TARGTYPE Literature-reported T12005 SYNONYMS pp1a; Replicase polyprotein 1a; ORF1a polyprotein T12005 FUNCTION The papain-like proteinase (PL-PRO) is responsible for the cleavages located at the N-terminus of replicase polyprotein. In addition, PL-PRO possesses a deubiquitinating/deISGylating activity and processes both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular substrates. Antagonizes innate immune induction of type I interferon by blocking the phosphorylation, dimerization and subsequent nuclear translocation of host IRF-3. T12005 PDBSTRUC 5Y3Q; 5Y3E; 5F22; 4OW0; 4OVZ T12005 SEQUENCE MESLVLGVNEKTHVQLSLPVLQVRDVLVRGFGDSVEEALSEAREHLKNGTCGLVELEKGVLPQLEQPYVFIKRSDALSTNHGHKVVELVAEMDGIQYGRSGITLGVLVPHVGETPIAYRNVLLRKNGNKGAGGHSYGIDLKSYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGGAVTRYVDNNFCGPDGYPLDCIKDFLARAGKSMCTLSEQLDYIESKRGVYCCRDHEHEIAWFTERSDKSYEHQTPFEIKSAKKFDTFKGECPKFVFPLNSKVKVIQPRVEKKKTEGFMGRIRSVYPVASPQECNNMHLSTLMKCNHCDEVSWQTCDFLKATCEHCGTENLVIEGPTTCGYLPTNAVVKMPCPACQDPEIGPEHSVADYHNHSNIETRLRKGGRTRCFGGCVFAYVGCYNKRAYWVPRASADIGSGHTGITGDNVETLNEDLLEILSRERVNINIVGDFHLNEEVAIILASFSASTSAFIDTIKSLDYKSFKTIVESCGNYKVTKGKPVKGAWNIGQQRSVLTPLCGFPSQAAGVIRSIFARTLDAANHSIPDLQRAAVTILDGISEQSLRLVDAMVYTSDLLTNSVIIMAYVTGGLVQQTSQWLSNLLGTTVEKLRPIFEWIEAKLSAGVEFLKDAWEILKFLITGVFDIVKGQIQVASDNIKDCVKCFIDVVNKALEMCIDQVTIAGAKLRSLNLGEVFIAQSKGLYRQCIRGKEQLQLLMPLKAPKEVTFLEGDSHDTVLTSEEVVLKNGELEALETPVDSFTNGAIVGTPVCVNGLMLLEIKDKEQYCALSPGLLATNNVFRLKGGAPIKGVTFGEDTVWEVQGYKNVRITFELDERVDKVLNEKCSVYTVESGTEVTEFACVVAEAVVKTLQPVSDLLTNMGIDLDEWSVATFYLFDDAGEENFSSRMYCSFYPPDEEEEDDAECEEEEIDETCEHEYGTEDDYQGLPLEFGASAETVRVEEEEEEDWLDDTTEQSEIEPEPEPTPEEPVNQFTGYLKLTDNVAIKCVDIVKEAQSANPMVIVNAANIHLKHGGGVAGALNKATNGAMQKESDDYIKLNGPLTVGGSCLLSGHNLAKKCLHVVGPNLNAGEDIQLLKAAYENFNSQDILLAPLLSAGIFGAKPLQSLQVCVQTVRTQVYIAVNDKALYEQVVMDYLDNLKPRVEAPKQEEPPNTEDSKTEEKSVVQKPVDVKPKIKACIDEVTTTLEETKFLTNKLLLFADINGKLYHDSQNMLRGEDMSFLEKDAPYMVGDVITSGDITCVVIPSKKAGGTTEMLSRALKKVPVDEYITTYPGQGCAGYTLEEAKTALKKCKSAFYVLPSEAPNAKEEILGTVSWNLREMLAHAEETRKLMPICMDVRAIMATIQRKYKGIKIQEGIVDYGVRFFFYTSKEPVASIITKLNSLNEPLVTMPIGYVTHGFNLEEAARCMRSLKAPAVVSVSSPDAVTTYNGYLTSSSKTSEEHFVETVSLAGSYRDWSYSGQRTELGVEFLKRGDKIVYHTLESPVEFHLDGEVLSLDKLKSLLSLREVKTIKVFTTVDNTNLHTQLVDMSMTYGQQFGPTYLDGADVTKIKPHVNHEGKTFFVLPSDDTLRSEAFEYYHTLDESFLGRYMSALNHTKKWKFPQVGGLTSIKWADNNCYLSSVLLALQQLEVKFNAPALQEAYYRARAGDAANFCALILAYSNKTVGELGDVRETMTHLLQHANLESAKRVLNVVCKHCGQKTTTLTGVEAVMYMGTLSYDNLKTGVSIPCVCGRDATQYLVQQESSFVMMSAPPAEYKLQQGTFLCANEYTGNYQCGHYTHITAKETLYRIDGAHLTKMSEYKGPVTDVFYKETSYTTTIKPVSYKLDGVTYTEIEPKLDGYYKKDNAYYTEQPIDLVPTQPLPNASFDNFKLTCSNTKFADDLNQMTGFTKPASRELSVTFFPDLNGDVVAIDYRHYSASFKKGAKLLHKPIVWHINQATTKTTFKPNTWCLRCLWSTKPVDTSNSFEVLAVEDTQGMDNLACESQQPTSEEVVENPTIQKEVIECDVKTTEVVGNVILKPSDEGVKVTQELGHEDLMAAYVENTSITIKKPNELSLALGLKTIATHGIAAINSVPWSKILAYVKPFLGQAAITTSNCAKRLAQRVFNNYMPYVFTLLFQLCTFTKSTNSRIRASLPTTIAKNSVKSVAKLCLDAGINYVKSPKFSKLFTIAMWLLLLSICLGSLICVTAAFGVLLSNFGAPSYCNGVRELYLNSSNVTTMDFCEGSFPCSICLSGLDSLDSYPALETIQVTISSYKLDLTILGLAAEWVLAYMLFTKFFYLLGLSAIMQVFFGYFASHFISNSWLMWFIISIVQMAPVSAMVRMYIFFASFYYIWKSYVHIMDGCTSSTCMMCYKRNRATRVECTTIVNGMKRSFYVYANGGRGFCKTHNWNCLNCDTFCTGSTFISDEVARDLSLQFKRPINPTDQSSYIVDSVAVKNGALHLYFDKAGQKTYERHPLSHFVNLDNLRANNTKGSLPINVIVFDGKSKCDESASKSASVYYSQLMCQPILLLDQALVSDVGDSTEVSVKMFDAYVDTFSATFSVPMEKLKALVATAHSELAKGVALDGVLSTFVSAARQGVVDTDVDTKDVIECLKLSHHSDLEVTGDSCNNFMLTYNKVENMTPRDLGACIDCNARHINAQVAKSHNVSLIWNVKDYMSLSEQLRKQIRSAAKKNNIPFRLTCATTRQVVNVITTKISLKGGKIVSTCFKLMLKATLLCVLAALVCYIVMPVHTLSIHDGYTNEIIGYKAIQDGVTRDIISTDDCFANKHAGFDAWFSQRGGSYKNDKSCPVVAAIITREIGFIVPGLPGTVLRAINGDFLHFLPRVFSAVGNICYTPSKLIEYSDFATSACVLAAECTIFKDAMGKPVPYCYDTNLLEGSISYSELRPDTRYVLMDGSIIQFPNTYLEGSVRVVTTFDAEYCRHGTCERSEVGICLSTSGRWVLNNEHYRALSGVFCGVDAMNLIANIFTPLVQPVGALDVSASVVAGGIIAILVTCAAYYFMKFRRVFGEYNHVVAANALLFLMSFTILCLVPAYSFLPGVYSVFYLYLTFYFTNDVSFLAHLQWFAMFSPIVPFWITAIYVFCISLKHCHWFFNNYLRKRVMFNGVTFSTFEEAALCTFLLNKEMYLKLRSETLLPLTQYNRYLALYNKYKYFSGALDTTSYREAACCHLAKALNDFSNSGADVLYQPPQTSITSAVLQSGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPRHVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGHSMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTITLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRTILGSTILEDEFTPFDVVRQCSGVTFQGKFKKIVKGTHHWMLLTFLTSLLILVQSTQWSLFFFVYENAFLPFTLGIMAIAACAMLLVKHKHAFLCLFLLPSLATVAYFNMVYMPASWVMRIMTWLELADTSLSGYRLKDCVMYASALVLLILMTARTVYDDAARRVWTLMNVITLVYKVYYGNALDQAISMWALVISVTSNYSGVVTTIMFLARAIVFVCVEYYPLLFITGNTLQCIMLVYCFLGYCCCCYFGLFCLLNRYFRLTLGVYDYLVSTQEFRYMNSQGLLPPKSSIDAFKLNIKLLGIGGKPCIKVATVQSKMSDVKCTSVVLLSVLQQLRVESSSKLWAQCVQLHNDILLAKDTTEAFEKMVSLLSVLLSMQGAVDINRLCEEMLDNRATLQAIASEFSSLPSYAAYATAQEAYEQAVANGDSEVVLKKLKKSLNVAKSEFDRDAAMQRKLEKMADQAMTQMYKQARSEDKRAKVTSAMQTMLFTMLRKLDNDALNNIINNARDGCVPLNIIPLTTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPNLAWPLIVTALRANSAVKLQNNELSPVALRQMSCAAGTTQTACTDDNALAYYNNSKGGRFVLALLSDHQDLKWARFPKSDGTGTIYTELEPPCRFVTDTPKGPKVKYLYFIKGLNNLNRGMVLGSLAATVRLQAGNATEVPANSTVLSFCAFAVDPAKAYKDYLASGGQPITNCVKMLCTHTGTGQAITVTPEANMDQESFGGASCCLYCRCHIDHPNPKGFCDLKGKYVQIPTTCANDPVGFTLRNTVCTVCGMWKGYGCSCDQLREPLMQSADASTFLNGFAV T12005 DRUGINFO D08ACB Sabadinine Investigative T42335 TARGETID T42335 T42335 FORMERID TTDI02112 T42335 UNIPROID LCRV_YERPE T42335 TARGNAME Yersinia pestis Virulence associated V antigen (YP lcrV) T42335 GENENAME YP lcrV T42335 TARGTYPE Literature-reported T42335 SYNONYMS lcrV; YP Virulence-associated V antigen; YP Low calcium response locus protein V T42335 FUNCTION Possibly involved in calcium regulation of YOP expression, which includes the export process. T42335 PDBSTRUC 4JBU; 1R6F T42335 SEQUENCE MIRAYEQNPQHFIEDLEKVRVEQLTGHGSSVLEELVQLVKDKNIDISIKYDPRKDSEVFANRVITDDIELLKKILAYFLPEDAILKGGHYDNQLQNGIKRVKEFLESSPNTQWELRAFMAVMHFSLTADRIDDDILKVIVDSMNHHGDARSKLREELAELTAELKIYSVIQAEINKHLSSSGTINIHDKSINLMDKNLYGYTDEEIFKASAEYKILEKMPQTTIQVDGSEKKIVSIKDFLGSENKRTGALGNLKNSYSYNKDNNELSHFATTCSDKSRPLNDLVSQKTTQLSDITSRFNSAIEALNRFIQKYDSVMQRLLDDTSGK T17863 TARGETID T17863 T17863 FORMERID TTDI03449 T17863 UNIPROID PEPA5_HUMAN T17863 TARGNAME Pepsinogen-5 (PGA5) T17863 GENENAME PGA5 T17863 TARGTYPE Literature-reported T17863 SYNONYMS Pepsin A-5 T17863 FUNCTION Shows particularly broad specificity; although bonds involving phenylalanine and leucine are preferred, many others are also cleaved to some extent. T17863 ECNUMBER EC 3.4.23.1 T17863 SEQUENCE MKWLLLLGLVALSECIMYKVPLIRKKSLRRTLSERGLLKDFLKKHNLNPARKYFPQWEAPTLVDEQPLENYLDMEYFGTIGIGTPAQDFTVVFDTGSSNLWVPSVYCSSLACTNHNRFNPEDSSTYQSTSETVSITYGTGSMTGILGYDTVQVGGISDTNQIFGLSETEPGSFLYYAPFDGILGLAYPSISSSGATPVFDNIWNQGLVSQDLFSVYLSADDKSGSVVIFGGIDSSYYTGSLNWVPVTVEGYWQITVDSITMNGETIACAEGCQAIVDTGTSLLTGPTSPIANIQSDIGASENSDGDMVVSCSAISSLPDIVFTINGVQYPVPPSAYILQSEGSCISGFQGMNVPTESGELWILGDVFIRQYFTVFDRANNQVGLAPVA T17863 DRUGINFO D0P6RT PMID8410973C3 Investigative T55447 TARGETID T55447 T55447 FORMERID TTDI01681 T55447 UNIPROID SAA1_HUMAN T55447 TARGNAME Serum amyloid A-1 protein (SAA1) T55447 GENENAME SAA1 T55447 TARGTYPE Literature-reported T55447 SYNONYMS SAA T55447 FUNCTION Major acute phase protein. T55447 PDBSTRUC 6MST; 4IP9; 4IP8 T55447 SEQUENCE MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYIGSDKYFHARGNYDAAKRGPGGVWAAEAISDARENIQRFFGHGAEDSLADQAANEWGRSGKDPNHFRPAGLPEKY T68596 TARGETID T68596 T68596 FORMERID TTDR00990 T68596 UNIPROID TRBR1_HUMAN T68596 TARGNAME M1-specific T cell receptor beta chain (TRB) T68596 GENENAME TRB T68596 TARGTYPE Literature-reported T68596 SYNONYMS TR beta chain TRBV19*01J2S7*01C*02 T68596 FUNCTION The beta chain of TRAV27*01J42*01C*01/TRBV19*01J2S7*01C*02 alpha-beta T cell receptor (TR) clonotype that is specific for HLA-A*02:01-restricted M/matrix protein 1 immunodominant epitope GILGFVFTL of influenza A virus (IAV). Classified as a public TCR clonotype, it is preferentially selected in effector memory CD8-positive T cells among multiple HLA-A*02:01 carriers/individuals and confers long-lived immunity against IAV infection. Can cross-recognize sporadically emerging IAV variants by molecular mimicry, inducing immunity toward different influenza strains. Antigen recognition initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn, ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell differentiation into effector/memory T cells (By similarity). T68596 PDBSTRUC 5HHO; 5HHM; 2VLR; 2VLK; 2VLJ T68596 SEQUENCE MSNQVLCCVVLCLLGANTVDGGITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLIYYSQIVNDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSIRSSYEQYFGPGTRLTVTEDLKNVFPPKVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG T93223 TARGETID T93223 T93223 UNIPROID SRGN_HUMAN T93223 TARGNAME Serglycin (SRGN) T93223 GENENAME SRGN T93223 TARGTYPE Literature-reported T93223 SYNONYMS Secretory granule proteoglycan core protein; Platelet proteoglycan core protein; PRG1; PRG; P.PG; Hematopoietic proteoglycan core protein T93223 FUNCTION Plays a role in formation of mast cell secretory granules and mediates storage of various compounds in secretory vesicles. Required for storage of some proteases in both connective tissue and mucosal mast cells and for storage of granzyme B in T-lymphocytes. Plays a role in localizing neutrophil elastase in azurophil granules of neutrophils. Mediates processing of MMP2. Plays a role in cytotoxic cell granule-mediated apoptosis by forming a complex with granzyme B which is delivered to cells by perforin to induce apoptosis. Regulates the secretion of TNF-alpha and may also regulate protease secretion. Inhibits bone mineralization. T93223 BIOCLASS Serglycin family T93223 SEQUENCE MMQKLLKCSRLVLALALILVLESSVQGYPTRRARYQWVRCNPDSNSANCLEEKGPMFELLPGESNKIPRLRTDLFPKTRIQDLNRIFPLSEDYSGSGFGSGSGSGSGSGSGFLTEMEQDYQLVDESDAFHDNLRSLDRNLPSDSQDLGQHGLEEDFML T24595 TARGETID T24595 T24595 FORMERID TTDI03009 T24595 UNIPROID ACRO_HUMAN T24595 TARGNAME Acrosin (ACR) T24595 GENENAME ACR T24595 TARGTYPE Literature-reported T24595 SYNONYMS ACRS T24595 FUNCTION Acrosin is the major protease of mammalian spermatozoa. It is a serine protease of trypsin-like cleavage specificity, it is synthesized in a zymogen form, proacrosin and stored in the acrosome. T24595 ECNUMBER EC 3.4.21.10 T24595 SEQUENCE MVEMLPTAILLVLAVSVVAKDNATCDGPCGLRFRQNPQGGVRIVGGKAAQHGAWPWMVSLQIFTYNSHRYHTCGGSLLNSRWVLTAAHCFVGKNNVHDWRLVFGAKEITYGNNKPVKAPLQERYVEKIIIHEKYNSATEGNDIALVEITPPISCGRFIGPGCLPHFKAGLPRGSQSCWVAGWGYIEEKAPRPSSILMEARVDLIDLDLCNSTQWYNGRVQPTNVCAGYPVGKIDTCQGDSGGPLMCKDSKESAYVVVGITSWGVGCARAKRPGIYTATWPYLNWIASKIGSNALRMIQSATPPPPTTRPPPIRPPFSHPISAHLPWYFQPPPRPLPPRPPAAQPRPPPSPPPPPPPPASPLPPPPPPPPPTPSSTTKLPQGLSFAKRLQQLIEVLKGKTYSDGKNHYDMETTELPELTSTS T24595 DRUGINFO D0F9YV PMID3514912C9 Investigative T00032 TARGETID T00032 T00032 FORMERID TTDR00484 T00032 UNIPROID OSTP_HUMAN T00032 TARGNAME Osteopontin (SPP1) T00032 GENENAME SPP1 T00032 TARGTYPE Literature-reported T00032 SYNONYMS Uropontin; Urinary stone protein; Secreted phosphoprotein 1; SPP-1; PSEC0156; OPN; Nephropontin; Bone sialoprotein 1; BNSP T00032 FUNCTION Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction. Binds tightly to hydroxyapatite. T00032 PDBSTRUC 3DSF; 3CXD T00032 SEQUENCE MRIAVICFCLLGITCAIPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQKQNLLAPQNAVSSEETNDFKQETLPSKSNESHDHMDDMDDEDDDDHVDSQDSIDSNDSDDVDDTDDSHQSDESHHSDESDELVTDFPTDLPATEVFTPVVPTVDTYDGRGDSVVYGLRSKSKKFRRPDIQYPDATDEDITSHMESEELNGAYKAIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSHKQSRLYKRKANDESNEHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDKHLKFRISHELDSASSEVN T60443 TARGETID T60443 T60443 FORMERID TTDI01493 T60443 UNIPROID LSTP_STAST T60443 TARGNAME Staphylococcus Lysostaphin (Stap-coc lss) T60443 GENENAME Stap-coc lss T60443 TARGTYPE Literature-reported T60443 SYNONYMS Lysostaphin; Glycyl-glycine endopeptidase T60443 FUNCTION Lyses staphylococcal cells by hydrolyzing the polyglycine interpeptide bridges of the peptidoglycan. T60443 ECNUMBER EC 3.4.24.75 T60443 SEQUENCE MKKTKNNYYTTPLAIGLSTFALASIVYGGIQNETHASEKSNMDVSKKVAEVETSKPPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKALVQNRTALRAATHEHSAQWLNNYKKGYGYGPYPLGINGGIHYGVDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSAGYGKAGGTVTPTPNTGWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQDGHVWVGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIK T32699 TARGETID T32699 T32699 FORMERID TTDI02122 T32699 UNIPROID MBL2_HUMAN T32699 TARGNAME Mannose binding protein (MBL2) T32699 GENENAME MBL2 T32699 TARGTYPE Literature-reported T32699 SYNONYMS Mannosebinding protein C; Mannosebinding lectin; Mannanbinding protein; MBPC; MBP1; MBL2; Collectin1 T32699 FUNCTION Calcium-dependent lectin involved in innate immune defense. Binds mannose, fucose and N-acetylglucosamine on different microorganisms and activates the lectin complement pathway. Binds to late apoptotic cells, as well as to apoptotic blebs and to necrotic cells, but not to early apoptotic cells, facilitating their uptake by macrophages. May bind DNA. {ECO:0000269|PubMed:14515269}. T32699 PDBSTRUC 1HUP T32699 SEQUENCE MSLFPSLPLLLLSMVAASYSETVTCEDAQKTCPAVIACSSPGINGFPGKDGRDGTKGEKGEPGQGLRGLQGPPGKLGPPGNPGPSGSPGPKGQKGDPGKSPDGDSSLAASERKALQTEMARIKKWLTFSLGKQVGNKFFLTNGEIMTFEKVKALCVKFQASVATPRNAAENGAIQNLIKEEAFLGITDEKTEGQFVDLTGNRLTYTNWNEGEPNNAGSDEDCVLLLKNGQWNDVPCSTSHLAVCEFPI T31145 TARGETID T31145 T31145 FORMERID TTDI02604 T31145 UNIPROID LAMP1_HUMAN T31145 TARGNAME Lysosome-associated membrane glycoprotein 1 (CD107a) T31145 GENENAME LAMP1 T31145 TARGTYPE Literature-reported T31145 SYNONYMS Lysosomeassociated membrane protein 1; Lysosomeassociated membrane glycoprotein 1; Lysosome-associated membrane protein 1; LAMP-1; CD107 antigenlike family member A; CD107 antigen-like family member A T31145 FUNCTION Implicated in tumor cell metastasis. Presents carbohydrate ligands to selectins. T31145 BIOCLASS Lysosomal protein import T31145 SEQUENCE MAAPGSARRPLLLLLLLLLLGLMHCASAAMFMVKNGNGTACIMANFSAAFSVNYDTKSGPKNMTFDLPSDATVVLNRSSCGKENTSDPSLVIAFGRGHTLTLNFTRNATRYSVQLMSFVYNLSDTHLFPNASSKEIKTVESITDIRADIDKKYRCVSGTQVHMNNVTVTLHDATIQAYLSNSSFSRGETRCEQDRPSPTTAPPAPPSPSPSPVPKSPSVDKYNVSGTNGTCLLASMGLQLNLTYERKDNTTVTRLLNINPNKTSASGSCGAHLVTLELHSEGTTVLLFQFGMNASSSRFFLQGIQLNTILPDARDPAFKAANGSLRALQATVGNSYKCNAEEHVRVTKAFSVNIFKVWVQAFKVEGGQFGSVEECLLDENSMLIPIAVGGALAGLVLIVLIAYLVGRKRSHAGYQTI T93484 TARGETID T93484 T93484 FORMERID TTDI02204 T93484 UNIPROID UTER_HUMAN T93484 TARGNAME Uteroglobin (SCGB1A1) T93484 GENENAME SCGB1A1 T93484 TARGTYPE Literature-reported T93484 SYNONYMS Urine protein 1; Urinary protein 1; UP-1; Secretoglobin family 1A member 1; SCGB1A1; Clara cells 10 kDa secretory protein; Clara cell phospholipid-binding protein; CCPBP; CC10 T93484 FUNCTION Binds phosphatidylcholine, phosphatidylinositol, polychlorinated biphenyls (PCB) and weakly progesterone, potent inhibitor of phospholipase A2. T93484 BIOCLASS Secretoglobin family T93484 SEQUENCE MKLAVTLTLVTLALCCSSASAEICPSFQRVIETLLMDTPSSYEAAMELFSPDQDMREAGAQLKKLVDTLPQKPRESIIKLMEKIAQSSLCN T83450 TARGETID T83450 T83450 FORMERID TTDI00004 T83450 UNIPROID CO6A3_HUMAN T83450 TARGNAME Collagen VI (COL6A3) T83450 GENENAME COL6A3 T83450 TARGTYPE Literature-reported T83450 SYNONYMS COL6A3 T83450 FUNCTION Collagen VI acts as a cell-binding protein. T83450 PDBSTRUC 2KNT; 1KUN; 1KTH; 1KNT T83450 SEQUENCE MRKHRHLPLVAVFCLFLSGFPTTHAQQQQADVKNGAAADIIFLVDSSWTIGEEHFQLVREFLYDVVKSLAVGENDFHFALVQFNGNPHTEFLLNTYRTKQEVLSHISNMSYIGGTNQTGKGLEYIMQSHLTKAAGSRAGDGVPQVIVVLTDGHSKDGLALPSAELKSADVNVFAIGVEDADEGALKEIASEPLNMHMFNLENFTSLHDIVGNLVSCVHSSVSPERAGDTETLKDITAQDSADIIFLIDGSNNTGSVNFAVILDFLVNLLEKLPIGTQQIRVGVVQFSDEPRTMFSLDTYSTKAQVLGAVKALGFAGGELANIGLALDFVVENHFTRAGGSRVEEGVPQVLVLISAGPSSDEIRYGVVALKQASVFSFGLGAQAASRAELQHIATDDNLVFTVPEFRSFGDLQEKLLPYIVGVAQRHIVLKPPTIVTQVIEVNKRDIVFLVDGSSALGLANFNAIRDFIAKVIQRLEIGQDLIQVAVAQYADTVRPEFYFNTHPTKREVITAVRKMKPLDGSALYTGSALDFVRNNLFTSSAGYRAAEGIPKLLVLITGGKSLDEISQPAQELKRSSIMAFAIGNKGADQAELEEIAFDSSLVFIPAEFRAAPLQGMLPGLLAPLRTLSGTPEVHSNKRDIIFLLDGSANVGKTNFPYVRDFVMNLVNSLDIGNDNIRVGLVQFSDTPVTEFSLNTYQTKSDILGHLRQLQLQGGSGLNTGSALSYVYANHFTEAGGSRIREHVPQLLLLLTAGQSEDSYLQAANALTRAGILTFCVGASQANKAELEQIAFNPSLVYLMDDFSSLPALPQQLIQPLTTYVSGGVEEVPLAQPESKRDILFLFDGSANLVGQFPVVRDFLYKIIDELNVKPEGTRIAVAQYSDDVKVESRFDEHQSKPEILNLVKRMKIKTGKALNLGYALDYAQRYIFVKSAGSRIEDGVLQFLVLLVAGRSSDRVDGPASNLKQSGVVPFIFQAKNADPAELEQIVLSPAFILAAESLPKIGDLHPQIVNLLKSVHNGAPAPVSGEKDVVFLLDGSEGVRSGFPLLKEFVQRVVESLDVGQDRVRVAVVQYSDRTRPEFYLNSYMNKQDVVNAVRQLTLLGGPTPNTGAALEFVLRNILVSSAGSRITEGVPQLLIVLTADRSGDDVRNPSVVVKRGGAVPIGIGIGNADITEMQTISFIPDFAVAIPTFRQLGTVQQVISERVTQLTREELSRLQPVLQPLPSPGVGGKRDVVFLIDGSQSAGPEFQYVRTLIERLVDYLDVGFDTTRVAVIQFSDDPKVEFLLNAHSSKDEVQNAVQRLRPKGGRQINVGNALEYVSRNIFKRPLGSRIEEGVPQFLVLISSGKSDDEVDDPAVELKQFGVAPFTIARNADQEELVKISLSPEYVFSVSTFRELPSLEQKLLTPITTLTSEQIQKLLASTRYPPPAVESDAADIVFLIDSSEGVRPDGFAHIRDFVSRIVRRLNIGPSKVRVGVVQFSNDVFPEFYLKTYRSQAPVLDAIRRLRLRGGSPLNTGKALEFVARNLFVKSAGSRIEDGVPQHLVLVLGGKSQDDVSRFAQVIRSSGIVSLGVGDRNIDRTELQTITNDPRLVFTVREFRELPNIEERIMNSFGPSAATPAPPGVDTPPPSRPEKKKADIVFLLDGSINFRRDSFQEVLRFVSEIVDTVYEDGDSIQVGLVQYNSDPTDEFFLKDFSTKRQIIDAINKVVYKGGRHANTKVGLEHLRVNHFVPEAGSRLDQRVPQIAFVITGGKSVEDAQDVSLALTQRGVKVFAVGVRNIDSEEVGKIASNSATAFRVGNVQELSELSEQVLETLHDAMHETLCPGVTDAAKACNLDVILGFDGSRDQNVFVAQKGFESKVDAILNRISQMHRVSCSGGRSPTVRVSVVANTPSGPVEAFDFDEYQPEMLEKFRNMRSQHPYVLTEDTLKVYLNKFRQSSPDSVKVVIHFTDGADGDLADLHRASENLRQEGVRALILVGLERVVNLERLMHLEFGRGFMYDRPLRLNLLDLDYELAEQLDNIAEKACCGVPCKCSGQRGDRGPIGSIGPKGIPGEDGYRGYPGDEGGPGERGPPGVNGTQGFQGCPGQRGVKGSRGFPGEKGEVGEIGLDGLDGEDGDKGLPGSSGEKGNPGRRGDKGPRGEKGERGDVGIRGDPGNPGQDSQERGPKGETGDLGPMGVPGRDGVPGGPGETGKNGGFGRRGPPGAKGNKGGPGQPGFEGEQGTRGAQGPAGPAGPPGLIGEQGISGPRGSGGAAGAPGERGRTGPLGRKGEPGEPGPKGGIGNRGPRGETGDDGRDGVGSEGRRGKKGERGFPGYPGPKGNPGEPGLNGTTGPKGIRGRRGNSGPPGIVGQKGDPGYPGPAGPKGNRGDSIDQCALIQSIKDKCPCCYGPLECPVFPTELAFALDTSEGVNQDTFGRMRDVVLSIVNDLTIAESNCPRGARVAVVTYNNEVTTEIRFADSKRKSVLLDKIKNLQVALTSKQQSLETAMSFVARNTFKRVRNGFLMRKVAVFFSNTPTRASPQLREAVLKLSDAGITPLFLTRQEDRQLINALQINNTAVGHALVLPAGRDLTDFLENVLTCHVCLDICNIDPSCGFGSWRPSFRDRRAAGSDVDIDMAFILDSAETTTLFQFNEMKKYIAYLVRQLDMSPDPKASQHFARVAVVQHAPSESVDNASMPPVKVEFSLTDYGSKEKLVDFLSRGMTQLQGTRALGSAIEYTIENVFESAPNPRDLKIVVLMLTGEVPEQQLEEAQRVILQAKCKGYFFVVLGIGRKVNIKEVYTFASEPNDVFFKLVDKSTELNEEPLMRFGRLLPSFVSSENAFYLSPDIRKQCDWFQGDQPTKNLVKFGHKQVNVPNNVTSSPTSNPVTTTKPVTTTKPVTTTTKPVTTTTKPVTIINQPSVKPAAAKPAPAKPVAAKPVATKMATVRPPVAVKPATAAKPVAAKPAAVRPPAAAAAKPVATKPEVPRPQAAKPAATKPATTKPMVKMSREVQVFEITENSAKLHWERAEPPGPYFYDLTVTSAHDQSLVLKQNLTVTDRVIGGLLAGQTYHVAVVCYLRSQVRATYHGSFSTKKSQPPPPQPARSASSSTINLMVSTEPLALTETDICKLPKDEGTCRDFILKWYYDPNTKSCARFWYGGCGGNENKFGSQKECEKVCAPVLAKPGVISVMGT T98090 TARGETID T98090 T98090 FORMERID TTDR01036 T98090 UNIPROID KCRB_HUMAN; KCRS_HUMAN; KCRU_HUMAN; KCRM_HUMAN T98090 TARGNAME Creatine kinase (CK) T98090 GENENAME CKB; CKMT2; CKMT1A; CKM T98090 TARGTYPE Literature-reported T98090 SYNONYMS Creatine kinase T98090 FUNCTION Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa. T98090 BIOCLASS Kinase T98090 SEQUENCE MPFSNSHNALKLRFPAEDEFPDLSAHNNHMAKVLTPELYAELRAKSTPSGFTLDDVIQTGVDNPGHPYIMTVGCVAGDEESYEVFKDLFDPIIEDRHGGYKPSDEHKTDLNPDNLQGGDDLDPNYVLSSRVRTGRSIRGFCLPPHCSRGERRAIEKLAVEALSSLDGDLAGRYYALKSMTEAEQQQLIDDHFLFDKPVSPLLLASGMARDWPDARGIWHNDNKTFLVWVNEEDHLRVISMQKGGNMKEVFTRFCTGLTQIETLFKSKDYEFMWNPHLGYILTCPSNLGTGLRAGVHIKLPNLGKHEKFSEVLKRLRLQKRGTGGVDTAAVGGVFDVSNADRLGFSEVELVQMVVDGVKLLIEMEQRLEQGQAIDDLMPAQK T98090 DRUGINFO D03GXQ Iodoacetamide Investigative T98090 DRUGINFO D0B1XN 5-(4'-benzoylbiphenyl-4-yl)-2-furoic acid Investigative T52629 TARGETID T52629 T52629 FORMERID TTDI01452 T52629 UNIPROID FCG2A_HUMAN; FCG2B_HUMAN; FCG2C_HUMAN T52629 TARGNAME Immunoglobulin gamma Fc receptor II (FCGR2) T52629 GENENAME FCGR2A; FCGR2B; FCGR2C T52629 TARGTYPE Literature-reported T52629 SYNONYMS Low affinity immunoglobulin gamma Fc region receptor II; IgG Fc receptor II; IGFR2; FcRII; Fc-gamma-RII; Fc-gamma RII; FCG2; CDw32; CD32 T52629 FUNCTION Inhibits the functions of activating FcRs, such as phagocytosis and pro-inflammatory cytokine release, mainly by clustering of FCGR2B with different activating FCGR receptors or with the BCR by immune complexes. T52629 BIOCLASS Immunoglobulin T52629 SEQUENCE MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTLTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDDKNIYLTLPPNDHVNSNN T77410 TARGETID T77410 T77410 FORMERID TTDI02477 T77410 UNIPROID BMP4_HUMAN T77410 TARGNAME Bone morphogenetic protein 4 (BMP4) T77410 GENENAME BMP4 T77410 TARGTYPE Literature-reported T77410 SYNONYMS DVR4; Bone morphogenetic protein 2B; BMP2B; BMP-4; BMP-2B T77410 FUNCTION Acts in mesoderm induction, tooth development, limb formation and fracture repair. Acts in concert with PTHLH/PTHRP to stimulate ductal outgrowth during embryonic mammary development and to inhibit hair follicle induction. Induces cartilage and bone formation. T77410 BIOCLASS Growth factor T77410 SEQUENCE MIPGNRMLMVVLLCQVLLGGASHASLIPETGKKKVAEIQGHAGGRRSGQSHELLRDFEATLLQMFGLRRRPQPSKSAVIPDYMRDLYRLQSGEEEEEQIHSTGLEYPERPASRANTVRSFHHEEHLENIPGTSENSAFRFLFNLSSIPENEVISSAELRLFREQVDQGPDWERGFHRINIYEVMKPPAEVVPGHLITRLLDTRLVHHNVTRWETFDVSPAVLRWTREKQPNYGLAIEVTHLHQTRTHQGQHVRISRSLPQGSGNWAQLRPLLVTFGHDGRGHALTRRRRAKRSPKHHSQRARKKNKNCRRHSLYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFPLADHLNSTNHAIVQTLVNSVNSSIPKACCVPTELSAISMLYLDEYDKVVLKNYQEMVVEGCGCR T08919 TARGETID T08919 T08919 FORMERID TTDR01008 T08919 UNIPROID CADH1_HUMAN T08919 TARGNAME Epithelial cadherin (CDH1) T08919 GENENAME CDH1 T08919 TARGTYPE Literature-reported T08919 SYNONYMS Uvomorulin; UVO; E-cadherin gene; E-cadherin; Cadherin-1; CDHE; CD324; CAM 120/80 T08919 FUNCTION Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7. T08919 PDBSTRUC 6CXY; 4ZTE; 4ZT1; 3L6Y; 3L6X T08919 SEQUENCE MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD T99686 TARGETID T99686 T99686 FORMERID TTDI01745 T99686 UNIPROID ITA4_HUMAN-ITB4_HUMAN T99686 TARGNAME Integrin alpha-4/beta-4 (ITGA4/B4) T99686 GENENAME ITGA4-ITGB4 T99686 TARGTYPE Literature-reported T99686 SYNONYMS alpha(4)beta(4) integrin; Alpha 4 beta 4 integrin T99686 FUNCTION Heterodimeric integral membrane proteins composed of an alpha chain and a beta chain that function in cell surface adhesion and signaling. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha 4 subunit. T99686 BIOCLASS Integrin T99686 SEQUENCE MAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDDMAGPRPSPWARLLLAALISVSLSGTLANRCKKAPVKSCTECVRVDKDCAYCTDEMFRDRRCNTQAELLAAGCQRESIVVMESSFQITEETQIDTTLRRSQMSPQGLRVRLRPGEERHFELEVFEPLESPVDLYILMDFSNSMSDDLDNLKKMGQNLARVLSQLTSDYTIGFGKFVDKVSVPQTDMRPEKLKEPWPNSDPPFSFKNVISLTEDVDEFRNKLQGERISGNLDAPEGGFDAILQTAVCTRDIGWRPDSTHLLVFSTESAFHYEADGANVLAGIMSRNDERCHLDTTGTYTQYRTQDYPSVPTLVRLLAKHNIIPIFAVTNYSYSYYEKLHTYFPVSSLGVLQEDSSNIVELLEEAFNRIRSNLDIRALDSPRGLRTEVTSKMFQKTRTGSFHIRRGEVGIYQVQLRALEHVDGTHVCQLPEDQKGNIHLKPSFSDGLKMDAGIICDVCTCELQKEVRSARCSFNGDFVCGQCVCSEGWSGQTCNCSTGSLSDIQPCLREGEDKPCSGRGECQCGHCVCYGEGRYEGQFCEYDNFQCPRTSGFLCNDRGRCSMGQCVCEPGWTGPSCDCPLSNATCIDSNGGICNGRGHCECGRCHCHQQSLYTDTICEINYSAIHPGLCEDLRSCVQCQAWGTGEKKGRTCEECNFKVKMVDELKRAEEVVVRCSFRDEDDDCTYSYTMEGDGAPGPNSTVLVHKKKDCPPGSFWWLIPLLLLLLPLLALLLLLCWKYCACCKACLALLPCCNRGHMVGFKEDHYMLRENLMASDHLDTPMLRSGNLKGRDVVRWKVTNNMQRPGFATHAASINPTELVPYGLSLRLARLCTENLLKPDTRECAQLRQEVEENLNEVYRQISGVHKLQQTKFRQQPNAGKKQDHTIVDTVLMAPRSAKPALLKLTEKQVEQRAFHDLKVAPGYYTLTADQDARGMVEFQEGVELVDVRVPLFIRPEDDDEKQLLVEAIDVPAGTATLGRRLVNITIIKEQARDVVSFEQPEFSVSRGDQVARIPVIRRVLDGGKSQVSYRTQDGTAQGNRDYIPVEGELLFQPGEAWKELQVKLLELQEVDSLLRGRQVRRFHVQLSNPKFGAHLGQPHSTTIIIRDPDELDRSFTSQMLSSQPPPHGDLGAPQNPNAKAAGSRKIHFNWLPPSGKPMGYRVKYWIQGDSESEAHLLDSKVPSVELTNLYPYCDYEMKVCAYGAQGEGPYSSLVSCRTHQEVPSEPGRLAFNVVSSTVTQLSWAEPAETNGEITAYEVCYGLVNDDNRPIGPMKKVLVDNPKNRMLLIENLRESQPYRYTVKARNGAGWGPEREAIINLATQPKRPMSIPIIPDIPIVDAQSGEDYDSFLMYSDDVLRSPSGSQRPSVSDDTGCGWKFEPLLGEELDLRRVTWRLPPELIPRLSASSGRSSDAEAPHGPPDDGGAGGKGGSLPRSATPGPPGEHLVNGRMDFAFPGSTNSLHRMTTTSAAAYGTHLSPHVPHRVLSTSSTLTRDYNSLTRSEHSHSTTLPRDYSTLTSVSSHDSRLTAGVPDTPTRLVFSALGPTSLRVSWQEPRCERPLQGYSVEYQLLNGGELHRLNIPNPAQTSVVVEDLLPNHSYVFRVRAQSQEGWGREREGVITIESQVHPQSPLCPLPGSAFTLSTPSAPGPLVFTALSPDSLQLSWERPRRPNGDIVGYLVTCEMAQGGGPATAFRVDGDSPESRLTVPGLSENVPYKFKVQARTTEGFGPEREGIITIESQDGGPFPQLGSRAGLFQHPLQSEYSSITTTHTSATEPFLVDGLTLGAQHLEAGGSLTRHVTQEFVSRTLTTSGTLSTHMDQQFFQT T25093 TARGETID T25093 T25093 FORMERID TTDR00306 T25093 UNIPROID FEMA_STAAW T25093 TARGNAME Staphylococcus Aminoacyltransferase FemA (Stap-coc femA) T25093 GENENAME Stap-coc femA T25093 TARGTYPE Literature-reported T25093 SYNONYMS Factor essential for expression of methicillin resistance T25093 FUNCTION May be involved in cell wall or membrane metabolism, or it might be a control element acting on expression of genes involved in cell wall or membrane biosynthesis. It is involved in resistance to the antibiotic methicillin. T25093 ECNUMBER EC 2.3.2.17 T25093 SEQUENCE MKFTNLTAKEFGAFTDSMPYSHFTQTVGHYELKLAEGYETHLVGIKNNNNEVIAACLLTAVPVMKVFKYFYSNRGPVIDYENQELVHFFFNELSKYVKKHRCLYLHIDPYLPYQYLNHDGEITGNAGNDWFFDKMSNLGFEHTGFHKGFDPVLQIRYHSVLDLKDKTADDIIKNMDGLRKRNTKKVKKNGVKVRFLSEEELPIFRSFMEDTSESKAFADRDDKFYYNRLKYYKDRVLVPLAYINFDEYIKELNEERDILNKDLNKALKDIEKRPENKKAHNKRDNLQQQLDANEQKIEEGKRLQEEHGNELPISAGFFFINPFEVVYYAGGTSNAFRHFAGSYAVQWEMINYALNHGIDRYNFYGVSGKFTEDAEDAGVVKFKKGYNAEIIEYVGDFIKPINKPVYAAYTALKKVKDRIF T47492 TARGETID T47492 T47492 FORMERID TTDR00938 T47492 UNIPROID NCF1_HUMAN T47492 TARGNAME Neutrophil cytosol factor 1 (NCF1) T47492 GENENAME NCF1 T47492 TARGTYPE Literature-reported T47492 SYNONYMS SH3PXD1A; SH3 and PX domain-containing protein 1A; P47-phox; P47(phox) NAD(P)H oxidase; Nox-organizing protein 2; Nox organizer 2; Neutrophil NADPH oxidase factor 1; NOXO2; NCF-47K; NCF-1; 47 kDa neutrophil oxidase factor; 47 kDa autosomal chronic granulomatous disease protein T47492 FUNCTION NCF2, NCF1, and a membrane bound cytochrome b558 are required for activation of the latent NADPH oxidase (necessary for superoxide production). T47492 PDBSTRUC 1WLP; 1W70; 1UEC; 1OV3; 1O7K T47492 SEQUENCE MGDTFIRHIALLGFEKRFVPSQHYVYMFLVKWQDLSEKVVYRRFTEIYEFHKTLKEMFPIEAGAINPENRIIPHLPAPKWFDGQRAAENRQGTLTEYCSTLMSLPTKISRCPHLLDFFKVRPDDLKLPTDNQTKKPETYLMPKDGKSTATDITGPIILQTYRAIANYEKTSGSEMALSTGDVVEVVEKSESGWWFCQMKAKRGWIPASFLEPLDSPDETEDPEPNYAGEPYVAIKAYTAVEGDEVSLLEGEAVEVIHKLLDGWWVIRKDDVTGYFPSMYLQKSGQDVSQAQRQIKRGAPPRRSSIRNAHSIHQRSRKRLSQDAYRRNSVRFLQQRRRQARPGPQSPGSPLEEERQTQRSKPQPAVPPRPSADLILNRCSESTKRKLASAV T30215 TARGETID T30215 T30215 FORMERID TTDR00328 T30215 UNIPROID ALGQ_PSEAE T30215 TARGNAME Pseudomonas Histidine kinase AlgR2 (Pseudo algQ) T30215 GENENAME Pseudo algQ T30215 TARGTYPE Literature-reported T30215 SYNONYMS algQ; Transcriptional regulatory protein AlgQ (mRNA); Alginate regulatory protein AlgR2 (mRNA) T30215 FUNCTION The promoter for a critical alginate biosynthetic gene, AlgD, encoding GDP-mannose dehydrogenase, is activated only under conditions reminiscent of the cystic fibrosis lung (i.e. under high osmolarity), and at least two regulatory genes, AlgP and AlgQ, have been implicated in this activation process. T30215 BIOCLASS Kinase T30215 SEQUENCE MLESCRNAQERWGGVHQLIDRWLHERQQLVQAFDALSGIQAPAPNAEELQHFCQLLLDYVSAGHFEVYEQLTAEGKAFGDQRGLELAKQIFPRLEAITESALNFNDRCDNGDCREGACLIAELKVLRQQLHERFELEDCLIEVLHNAHSQSGAEGSAVPV T30215 DRUGINFO D07UCF LY266500 Investigative T89299 TARGETID T89299 T89299 FORMERID TTDR00840 T89299 UNIPROID FOSL1_HUMAN T89299 TARGNAME Fos-related antigen 1 (FOSL1) T89299 GENENAME FOSL1 T89299 TARGTYPE Literature-reported T89299 SYNONYMS Fra-1; FRA1 T89299 FUNCTION DNA-binding transcription factor activity, DNA-binding transcription factor activity, RNA polymerase II-specific, RNA polymerase II proximal promoter sequence-specific DNA binding, cellular defense response, chemotaxis, positive regulation of cell population proliferation, positive regulation of DNA-templated transcription, initiation, pri-miRNA transcription by RNA polymerase II. T89299 BIOCLASS Basic leucine zipper bZIP T89299 SEQUENCE MFRDFGEPGPSSGNGGGYGGPAQPPAAAQAAQQKFHLVPSINTMSGSQELQWMVQPHFLGPSSYPRPLTYPQYSPPQPRPGVIRALGPPPGVRRRPCEQISPEEEERRRVRRERNKLAAAKCRNRRKELTDFLQAETDKLEDEKSGLQREIEELQKQKERLELVLEAHRPICKIPEGAKEGDTGSTSGTSSPPAPCRPVPCISLSPGPVLEPEALHTPTLMTTPSLTPFTPSLVFTYPSTPEPCASAHRKSSSSSGDPSSDPLGSPTLLAL T32600 TARGETID T32600 T32600 FORMERID TTDI00198 T32600 UNIPROID FOSL2_HUMAN T32600 TARGNAME Fos-related antigen 2 (FOSL2) T32600 GENENAME FOSL2 T32600 TARGTYPE Literature-reported T32600 SYNONYMS FRA2; FRA-2 T32600 FUNCTION As a dimer with JUN, activates LIF transcription. Activates CEBPB transcription in PGE2-activated osteoblasts. Controls osteoclast survival and size. T32600 BIOCLASS Basic leucine zipper bZIP T32600 SEQUENCE MYQDYPGNFDTSSRGSSGSPAHAESYSSGGGGQQKFRVDMPGSGSAFIPTINAITTSQDLQWMVQPTVITSMSNPYPRSHPYSPLPGLASVPGHMALPRPGVIKTIGTTVGRRRRDEQLSPEEEEKRRIRRERNKLAAAKCRNRRRELTEKLQAETEELEEEKSGLQKEIAELQKEKEKLEFMLVAHGPVCKISPEERRSPPAPGLQPMRSGGGSVGAVVVKQEPLEEDSPSSSSAGLDKAQRSVIKPISIAGGFYGEEPLHTPIVVTSTPAVTPGTSNLVFTYPSVLEQESPASPSESCSKAHRRSSSSGDQSSDSLNSPTLLAL T92834 TARGETID T92834 T92834 FORMERID TTDI02393 T92834 UNIPROID AREG_HUMAN T92834 TARGNAME Amphiregulin (AREG) T92834 GENENAME AREG T92834 TARGTYPE Literature-reported T92834 SYNONYMS SDGF; Colorectum cellderived growth factor; Colorectum cell-derived growth factor; CRDGF; AREGB; AR T92834 FUNCTION Autocrine growth factor as well as a mitogen for a broad range of target cells including astrocytes, Schwann cells and fibroblasts. Ligand of the EGF receptor/EGFR. T92834 PDBSTRUC 2RNL T92834 SEQUENCE MRAPLLPPAPVVLSLLILGSGHYAAGLDLNDTYSGKREPFSGDHSADGFEVTSRSEMSSGSEISPVSEMPSSSEPSSGADYDYSEEYDNEPQIPGYIVDDSVRVEQVVKPPQNKTESENTSDKPKRKKKGGKNGKNRRNRKKKNPCNAEFQNFCIHGECKYIEHLEAVTCKCQQEYFGERCGEKSMKTHSMIDSSLSKIALAAIAAFMSAVILTAVAVITVQLRRQYVRKYEGEAEERKKLRQENGNVHAIA T48269 TARGETID T48269 T48269 FORMERID TTDR00718 T48269 UNIPROID HN_PI1HW T48269 TARGNAME Parainfluenza Hemagglutinin-neuraminidase glycoprotein (HPIV HN) T48269 GENENAME HPIV HN T48269 TARGTYPE Literature-reported T48269 SYNONYMS Hemagglutinin-neuraminidase T48269 FUNCTION Attaches the virus to sialic acid-containing cell receptors and thereby initiating infection. Binding of HN protein to the receptor induces a conformational change that allows the F protein to trigger virion/cell membranes fusion (By similarity). T48269 ECNUMBER EC 3.2.1.18 T48269 SEQUENCE MAEKGKTNSSYWSTTRNDNSTVNTYIDTPAGKTHIWLLIATTMHTILSFIIMILCIDLIIKQDTCMKTNIMTVSSMNESAKTIKETITELIRQEVISRTINIQSSVQSGIPILLNKQSRDLTQLIEKSCNRQELAQICENTIAIHHADGISPLDPHDFWRCPVGEPLLSNNPNISLLPGPSLLSGSTTISGCVRLPSLSIGDAIYAYSSNLITQGCADIGKSYQVLQLGYISLNSDMYPDLKPVISHTYDINDNRKSCSVIAAGTRGYQLCSLPTVNETTDYSSEGIEDLVFDILDLKGKTKSHRYKNEDITFDHPFSAMYPSVGSGIKIENTLIFLGYGGLTTPLQGDTKCVTNRCANVNQSVCNDALKITWLKKRQVVNVLIRINNYLSDRPKIVVETIPITQNYLGAEGRLLKLGKKIYIYTRSSGWHSHLQIGSLDINNPMTIKWAPHEVLSRPGNQDCNWYNRCPRECISGVYTDAYPLSPDAVNVATTTLYANTSRVNPTIMYSNTSEIINMLRLKNVQLEAAYTTTSCITHFGKGYCFHIVEINQTSLNTLQPMLFKTSIPKICKITS T55244 TARGETID T55244 T55244 FORMERID TTDI00168 T55244 UNIPROID H2AX_HUMAN T55244 TARGNAME Gamma-Histone H2AX (H2AFX) T55244 GENENAME H2AFX T55244 TARGTYPE Literature-reported T55244 SYNONYMS Phosphorylation of H2AX; Histone H2AX; Histone H2A.x; H2a/x; H2AX T55244 FUNCTION Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Required for checkpoint-mediated arrest of cell cycle progression in response to low doses of ionizing radiation and for efficient repair of DNA double strand breaks (DSBs) specifically when modified by C-terminal phosphorylation. Variant histone H2A which replaces conventional H2A in a subset of nucleosomes. T55244 PDBSTRUC 3U3Z; 3SZM; 3SQD; 3SHV; 2DYP T55244 SEQUENCE MSGRGKTGGKARAKAKSRSSRAGLQFPVGRVHRLLRKGHYAERVGAGAPVYLAAVLEYLTAEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGGVTIAQGGVLPNIQAVLLPKKTSATVGPKAPSGGKKATQASQEY T88920 TARGETID T88920 T88920 FORMERID TTDI01419 T88920 UNIPROID ANK1_HUMAN T88920 TARGNAME Ankyrin (ANK) T88920 GENENAME ANK1 T88920 TARGTYPE Literature-reported T88920 SYNONYMS Erythrocyte ankyrin; Ankyrin-R; Ankyrin-1; ANK-1; ANK T88920 FUNCTION Attaches integral membrane proteins to cytoskeletal elements; binds to the erythrocyte membrane protein band 4.2, to Na-K ATPase, to the lymphocyte membrane protein GP85, and to the cytoskeletal proteins fodrin, tubulin, vimentin and desmin. Erythrocyte ankyrins also link spectrin (beta chain) to the cytoplasmic domain of the erythrocytes anion exchange protein; they retain most or all of these binding functions. T88920 PDBSTRUC 3UD2; 3UD1; 3KBU; 3KBT; 3F59 T88920 SEQUENCE MPYSVGFREADAATSFLRAARSGNLDKALDHLRNGVDINTCNQNGLNGLHLASKEGHVKMVVELLHKEIILETTTKKGNTALHIAALAGQDEVVRELVNYGANVNAQSQKGFTPLYMAAQENHLEVVKFLLENGANQNVATEDGFTPLAVALQQGHENVVAHLINYGTKGKVRLPALHIAARNDDTRTAAVLLQNDPNPDVLSKTGFTPLHIAAHYENLNVAQLLLNRGASVNFTPQNGITPLHIASRRGNVIMVRLLLDRGAQIETKTKDELTPLHCAARNGHVRISEILLDHGAPIQAKTKNGLSPIHMAAQGDHLDCVRLLLQYDAEIDDITLDHLTPLHVAAHCGHHRVAKVLLDKGAKPNSRALNGFTPLHIACKKNHVRVMELLLKTGASIDAVTESGLTPLHVASFMGHLPIVKNLLQRGASPNVSNVKVETPLHMAARAGHTEVAKYLLQNKAKVNAKAKDDQTPLHCAARIGHTNMVKLLLENNANPNLATTAGHTPLHIAAREGHVETVLALLEKEASQACMTKKGFTPLHVAAKYGKVRVAELLLERDAHPNAAGKNGLTPLHVAVHHNNLDIVKLLLPRGGSPHSPAWNGYTPLHIAAKQNQVEVARSLLQYGGSANAESVQGVTPLHLAAQEGHAEMVALLLSKQANGNLGNKSGLTPLHLVAQEGHVPVADVLIKHGVMVDATTRMGYTPLHVASHYGNIKLVKFLLQHQADVNAKTKLGYSPLHQAAQQGHTDIVTLLLKNGASPNEVSSDGTTPLAIAKRLGYISVTDVLKVVTDETSFVLVSDKHRMSFPETVDEILDVSEDEGEELISFKAERRDSRDVDEEKELLDFVPKLDQVVESPAIPRIPCAMPETVVIRSEEQEQASKEYDEDSLIPSSPATETSDNISPVASPVHTGFLVSFMVDARGGSMRGSRHNGLRVVIPPRTCAAPTRITCRLVKPQKLSTPPPLAEEEGLASRIIALGPTGAQFLSPVIVEIPHFASHGRGDRELVVLRSENGSVWKEHRSRYGESYLDQILNGMDEELGSLEELEKKRVCRIITTDFPLYFVIMSRLCQDYDTIGPEGGSLKSKLVPLVQATFPENAVTKRVKLALQAQPVPDELVTKLLGNQATFSPIVTVEPRRRKFHRPIGLRIPLPPSWTDNPRDSGEGDTTSLRLLCSVIGGTDQAQWEDITGTTKLVYANECANFTTNVSARFWLSDCPRTAEAVNFATLLYKELTAVPYMAKFVIFAKMNDPREGRLRCYCMTDDKVDKTLEQHENFVEVARSRDIEVLEGMSLFAELSGNLVPVKKAAQQRSFHFQSFRENRLAMPVKVRDSSREPGGSLSFLRKAMKYEDTQHILCHLNITMPPCAKGSGAEDRRRTPTPLALRYSILSESTPGSLSGTEQAEMKMAVISEHLGLSWAELARELQFSVEDINRIRVENPNSLLEQSVALLNLWVIREGQNANMENLYTALQSIDRGEIVNMLEGSGRQSRNLKPDRRHTDRDYSLSPSQMNGYSSLQDELLSPASLGCALSSPLRADQYWNEVAVLDAIPLAATEHDTMLEMSDMQVWSAGLTPSLVTAEDSSLECSKAEDSDATGHEWKLEGALSEEPRGPELGSLELVEDDTVDSDATNGLIDLLEQEEGQRSEEKLPGSKRQDDATGAGQDSENEVSLVSGHQRGQARITHSPTVSQVTERSQDRLQDWDADGSIVSYLQDAAQGSWQEEVTQGPHSFQGTSTMTEGLEPGGSQEYEKVLVSVSEHTWTEQPEAESSQADRDRRQQGQEEQVQEAKNTFTQVVQGNEFQNIPGEQVTEEQFTDEQGNIVTKKIIRKVVRQIDLSSADAAQEHEEVTVEGPLEDPSELEVDIDYFMKHSKDHTSTPNP T08985 TARGETID T08985 T08985 FORMERID TTDI02499 T08985 UNIPROID 1A33_HUMAN T08985 TARGNAME MHC class I antigen A*33 (HLA-A) T08985 GENENAME HLA-A T08985 TARGTYPE Literature-reported T08985 SYNONYMS HLAA; HLA-A; HLA class I histocompatibility antigen, A33 alpha chain; Aw33; Aw19 T08985 FUNCTION Involved in the presentation of foreign antigens to the immune system. T08985 BIOCLASS MHC class I T08985 SEQUENCE MAVMAPRTLLLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYGCDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQLRAYLDGTCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPIVGIIAGLVLLGAVITGAVVAAVMWRRKSSDRKGGSYTQAASSDSAQGSDVSLTACKV T89056 TARGETID T89056 T89056 FORMERID TTDI02394 T89056 UNIPROID PECA1_HUMAN T89056 TARGNAME Platelet endothelial cell adhesion molecule (PECAM1) T89056 GENENAME PECAM1 T89056 TARGTYPE Literature-reported T89056 SYNONYMS PECAM-1; PECA1; GPIIA'; EndoCAM; ECAM; CD31 antigen; CD31 T89056 FUNCTION Tyr-690 plays a critical role in TEM and is required for efficient trafficking of PECAM1 to and from the lateral border recycling compartment (LBRC) and is also essential for the LBRC membrane to be targeted around migrating leukocytes. Trans-homophilic interaction may play a role in endothelial cell-cell adhesion via cell junctions. Heterophilic interaction with CD177 plays a role in transendothelial migration of neutrophils. Homophilic ligation of PECAM1 prevents macrophage-mediated phagocytosis of neighboring viable leukocytes by transmitting a detachment signal. Promotes macrophage-mediated phagocytosis of apoptotic leukocytes by tethering them to the phagocytic cells; PECAM1-mediated detachment signal appears to be disabled in apoptotic leukocytes. Modulates bradykinin receptor BDKRB2 activation. Regulates bradykinin- and hyperosmotic shock-induced ERK1/2 activation in endothelial cells. Induces susceptibility to atherosclerosis. Cell adhesion molecule which is required for leukocyte transendothelial migration (TEM) under most inflammatory conditions. T89056 PDBSTRUC 5GNI; 5C14; 2KY5 T89056 SEQUENCE MQPRWAQGATMWLGVLLTLLLCSSLEGQENSFTINSVDMKSLPDWTVQNGKNLTLQCFADVSTTSHVKPQHQMLFYKDDVLFYNISSMKSTESYFIPEVRIYDSGTYKCTVIVNNKEKTTAEYQVLVEGVPSPRVTLDKKEAIQGGIVRVNCSVPEEKAPIHFTIEKLELNEKMVKLKREKNSRDQNFVILEFPVEEQDRVLSFRCQARIISGIHMQTSESTKSELVTVTESFSTPKFHISPTGMIMEGAQLHIKCTIQVTHLAQEFPEIIIQKDKAIVAHNRHGNKAVYSVMAMVEHSGNYTCKVESSRISKVSSIVVNITELFSKPELESSFTHLDQGERLNLSCSIPGAPPANFTIQKEDTIVSQTQDFTKIASKSDSGTYICTAGIDKVVKKSNTVQIVVCEMLSQPRISYDAQFEVIKGQTIEVRCESISGTLPISYQLLKTSKVLENSTKNSNDPAVFKDNPTEDVEYQCVADNCHSHAKMLSEVLRVKVIAPVDEVQISILSSKVVESGEDIVLQCAVNEGSGPITYKFYREKEGKPFYQMTSNATQAFWTKQKASKEQEGEYYCTAFNRANHASSVPRSKILTVRVILAPWKKGLIAVVIIGVIIALLIIAAKCYFLRKAKAKQMPVEMSRPAVPLLNSNNEKMSDPNMEANSHYGHNDDVRNHAMKPINDNKEPLNSDVQYTEVQVSSAESHKDLGKKDTETVYSEVRKAVPDAVESRYSRTEGSLDGT T19492 TARGETID T19492 T19492 FORMERID TTDI03326 T19492 UNIPROID KCNA2_HUMAN T19492 TARGNAME Voltage-gated potassium channel Kv1.2 (KCNA2) T19492 GENENAME KCNA2 T19492 TARGTYPE Literature-reported T19492 SYNONYMS Voltage-gated potassium channel subunit Kv1.2; Voltage-gated potassium channel HBK5; Voltage-gated K(+) channel HuKIV; Potassium voltage-gated channel subfamily A member 2; NGK1 T19492 FUNCTION Prevents aberrant action potential firing and regulates neuronal output. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, KCNA6, KCNA7, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation of delayed rectifier potassium channels. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Homotetrameric KCNA2 forms a delayed-rectifier potassium channel that opens in response to membrane depolarization, followed by slow spontaneous channel closure. In contrast, a heteromultimer formed by KCNA2 and KCNA4 shows rapid inactivation. Regulates neuronal excitability and plays a role as pacemaker in the regulation of neuronal action potentials. KCNA2-containing channels play a presynaptic role and prevent hyperexcitability and aberrant action potential firing. Response to toxins that are selective for KCNA2-containing potassium channels suggests that in Purkinje cells, dendritic subthreshold KCNA2-containing potassium channels prevent random spontaneous calcium spikes, suppressing dendritic hyperexcitability without hindering the generation of somatic action potentials, and thereby play an important role in motor coordination. Plays a role in the induction of long-term potentiation of neuron excitability in the CA3 layer of the hippocampus. May function as down-stream effector for G protein-coupled receptors and inhibit GABAergic inputs to basolateral amygdala neurons. May contribute to the regulation of neurotransmitter release, such as gamma-aminobutyric acid (GABA). Contributes to the regulation of the axonal release of the neurotransmitter dopamine. Reduced KCNA2 expression plays a role in the perception of neuropathic pain after peripheral nerve injury, but not acute pain. Plays a role in the regulation of the time spent in non-rapid eye movement (NREM) sleep. Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the cardiovascular system. T19492 BIOCLASS Voltage-gated ion channel T19492 SEQUENCE MTVATGDPADEAAALPGHPQDTYDPEADHECCERVVINISGLRFETQLKTLAQFPETLLGDPKKRMRYFDPLRNEYFFDRNRPSFDAILYYYQSGGRLRRPVNVPLDIFSEEIRFYELGEEAMEMFREDEGYIKEEERPLPENEFQRQVWLLFEYPESSGPARIIAIVSVMVILISIVSFCLETLPIFRDENEDMHGSGVTFHTYSNSTIGYQQSTSFTDPFFIVETLCIIWFSFEFLVRFFACPSKAGFFTNIMNIIDIVAIIPYFITLGTELAEKPEDAQQGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEADERESQFPSIPDAFWWAVVSMTTVGYGDMVPTTIGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEGEEQAQYLQVTSCPKIPSSPDLKKSRSASTISKSDYMEIQEGVNNSNEDFREENLKTANCTLANTNYVNITKMLTDV T19492 DRUGINFO D02VKU mast cell degranulating peptide Investigative T19492 DRUGINFO D06PZZ [14C]TEA Investigative T68211 TARGETID T68211 T68211 FORMERID TTDNR00688 T68211 UNIPROID HMGA1_HUMAN T68211 TARGNAME High mobility group protein HMG-I/Y (HMGA1) T68211 GENENAME HMGA1 T68211 TARGTYPE Literature-reported T68211 SYNONYMS High mobility group protein R; High mobility group protein HMG-I/HMG-Y; High mobility group protein A1; High mobility group AT-hook protein 1; HMGIY; HMG-I(Y) T68211 FUNCTION It is suggested that these proteins could function in nucleosome phasing and in the 3'-end processing of mRNA transcripts. They are also involved in the transcription regulation of genes containing, or in close proximity to A+T-rich regions. HMG-I/Y bind preferentially to the minor groove of A+T rich regions in double-stranded DNA. T68211 PDBSTRUC 2EZG; 2EZF; 2EZE; 2EZD T68211 SEQUENCE MSESSSKSSQPLASKQEKDGTEKRGRGRPRKQPPVSPGTALVGSQKEPSEVPTPKRPRGRPKGSKNKGAAKTRKTTTTPGRKPRGRPKKLEKEEEEGISQESSEEEQ T65561 TARGETID T65561 T65561 FORMERID TTDI03328 T65561 UNIPROID KCNA6_HUMAN T65561 TARGNAME Voltage-gated potassium channel Kv1.6 (KCNA6) T65561 GENENAME KCNA6 T65561 TARGTYPE Literature-reported T65561 SYNONYMS Voltage-gated potassium channel subunit Kv1.6; Voltage-gated potassium channel HBK2; Potassium voltage-gated channel subfamily A member 6 T65561 FUNCTION Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA6, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (By similarity). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation (By similarity). Homotetrameric channels display rapid activation and slow inactivation. T65561 BIOCLASS Voltage-gated ion channel T65561 SEQUENCE MRSEKSLTLAAPGEVRGPEGEQQDAGDFPEAGGGGGCCSSERLVINISGLRFETQLRTLSLFPDTLLGDPGRRVRFFDPLRNEYFFDRNRPSFDAILYYYQSGGRLRRPVNVPLDIFLEEIRFYQLGDEALAAFREDEGCLPEGGEDEKPLPSQPFQRQVWLLFEYPESSGPARGIAIVSVLVILISIVIFCLETLPQFRVDGRGGNNGGVSRVSPVSRGSQEEEEDEDDSYTFHHGITPGEMGTGGSSSLSTLGGSFFTDPFFLVETLCIVWFTFELLVRFSACPSKPAFFRNIMNIIDLVAIFPYFITLGTELVQQQEQQPASGGGGQNGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGKTLQASMRELGLLIFFLFIGVILFSSAVYFAEADDDDSLFPSIPDAFWWAVVTMTTVGYGDMYPMTVGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEQEEQGQYTHVTCGQPAPDLRATDNGLGKPDFPEANRERRPSYLPTPHRAYAEKRMLTEV T65561 DRUGINFO D02VKU mast cell degranulating peptide Investigative T65561 DRUGINFO D06PZZ [14C]TEA Investigative T93966 TARGETID T93966 T93966 UNIPROID NEUM_HUMAN T93966 TARGNAME Neuromodulin (GAP43) T93966 GENENAME GAP43 T93966 TARGTYPE Literature-reported T93966 SYNONYMS pp46; Neural phosphoprotein B-50; Growth-associated protein 43; Axonal membrane protein GAP-43 T93966 FUNCTION This protein is associated with nerve growth. It is a major component of the motile "growth cones" that form the tips of elongating axons. Plays a role in axonal and dendritic filopodia induction. T93966 BIOCLASS Neuromodulin family T93966 SEQUENCE MLCCMRRTKQVEKNDDDQKIEQDGIKPEDKAHKAATKIQASFRGHITRKKLKGEKKDDVQAAEAEANKKDEAPVADGVEKKGEGTTTAEAAPATGSKPDEPGKAGETPSEEKKGEGDAATEQAAPQAPASSEEKAGSAETESATKASTDNSPSSKAEDAPAKEEPKQADVPAAVTAAAATTPAAEDAAAKATAQPPTETGESSQAEENIEAVDETKPKESARQDEGKEEEPEADQEHA T52110 TARGETID T52110 T52110 FORMERID TTDR01109 T52110 UNIPROID LBP_HUMAN T52110 TARGNAME Lipopolysaccharide-binding protein (LBP) T52110 GENENAME LBP T52110 TARGTYPE Literature-reported T52110 SYNONYMS LBP T52110 FUNCTION Plays a role in the innate immune response. Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer membrane of all Gram-negative bacteria. Acts as an affinity enhancer for CD14, facilitating its association with LPS. Promotes the release of cytokines in response to bacterial lipopolysaccharide. T52110 BIOCLASS Bactericidal permeability increasing protein T52110 SEQUENCE MGALARALPSILLALLLTSTPEALGANPGLVARITDKGLQYAAQEGLLALQSELLRITLPDFTGDLRIPHVGRGRYEFHSLNIHSCELLHSALRPVPGQGLSLSISDSSIRVQGRWKVRKSFFKLQGSFDVSVKGISISVNLLLGSESSGRPTVTASSCSSDIADVEVDMSGDLGWLLNLFHNQIESKFQKVLESRICEMIQKSVSSDLQPYLQTLPVTTEIDSFADIDYSLVEAPRATAQMLEVMFKGEIFHRNHRSPVTLLAAVMSLPEEHNKMVYFAISDYVFNTASLVYHEEGYLNFSITDDMIPPDSNIRLTTKSFRPFVPRLARLYPNMNLELQGSVPSAPLLNFSPGNLSVDPYMEIDAFVLLPSSSKEPVFRLSVATNVSATLTFNTSKITGFLKPGKVKVELKESKVGLFNAELLEALLNYYILNTFYPKFNDKLAEGFPLPLLKRVQLYDLGLQIHKDFLFLGANVQYMRV T52110 DRUGINFO D0X0EU E-5531 Discontinued in Phase 2 T11966 TARGETID T11966 T11966 FORMERID TTDR00517 T11966 UNIPROID ATF3_HUMAN T11966 TARGNAME Cyclic-AMP-dependent transcription factor ATF-3 (ATF3) T11966 GENENAME ATF3 T11966 TARGTYPE Literature-reported T11966 SYNONYMS cAMP-dependent transcription factor ATF-3; Cyclic AMP-dependent transcription factor ATF-3; Activating transcription factor 3 T11966 FUNCTION Represses transcription from promoters with ATF sites. It may repress transcription by stabilizing the binding of inhibitory cofactors at the promoter. Isoform 2 activates transcription presumably by sequestering inhibitory cofactors away from the promoters. This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. T11966 BIOCLASS Basic leucine zipper bZIP T11966 SEQUENCE MMLQHPGQVSASEVSASAIVPCLSPPGSLVFEDFANLTPFVKEELRFAIQNKHLCHRMSSALESVTVSDRPLGVSITKAEVAPEEDERKKRRRERNKIAAAKCRNKKKEKTECLQKESEKLESVNAELKAQIEELKNEKQHLIYMLNLHRPTCIVRAQNGRTPEDERNLFIQQIKEGTLQS T93922 TARGETID T93922 T93922 FORMERID TTDR00647 T93922 UNIPROID PLCG1_HUMAN; PLCG2_HUMAN T93922 TARGNAME Phospholipase C-gamma (PPCG) T93922 GENENAME PLCG1; PLCG2 T93922 TARGTYPE Literature-reported T93922 SYNONYMS Phospholipase C gamma; Phosphoinositide phospholipase C-gamma; PLC-gamma; PLC; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma T93922 FUNCTION Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an important role in the regulation of intracellular signaling cascades. Becomes activated in response to ligand-mediated activation of receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, FGFR1, FGFR2, FGFR3 and FGFR4. Plays a role in actin reorganization and cell migration. T93922 BIOCLASS Phosphoric diester hydrolase T93922 SEQUENCE MAGAASPCANGCGPGAPSDAEVLHLCRSLEVGTVMTLFYSKKSQRPERKTFQVKLETRQITWSRGADKIEGAIDIREIKEIRPGKTSRDFDRYQEDPAFRPDQSHCFVILYGMEFRLKTLSLQATSEDEVNMWIKGLTWLMEDTLQAPTPLQIERWLRKQFYSVDRNREDRISAKDLKNMLSQVNYRVPNMRFLRERLTDLEQRSGDITYGQFAQLYRSLMYSAQKTMDLPFLEASTLRAGERPELCRVSLPEFQQFLLDYQGELWAVDRLQVQEFMLSFLRDPLREIEEPYFFLDEFVTFLFSKENSVWNSQLDAVCPDTMNNPLSHYWISSSHNTYLTGDQFSSESSLEAYARCLRMGCRCIELDCWDGPDGMPVIYHGHTLTTKIKFSDVLHTIKEHAFVASEYPVILSIEDHCSIAQQRNMAQYFKKVLGDTLLTKPVEISADGLPSPNQLKRKILIKHKKLAEGSAYEEVPTSMMYSENDISNSIKNGILYLEDPVNHEWYPHYFVLTSSKIYYSEETSSDQGNEDEEEPKEVSSSTELHSNEKWFHGKLGAGRDGRHIAERLLTEYCIETGAPDGSFLVRESETFVGDYTLSFWRNGKVQHCRIHSRQDAGTPKFFLTDNLVFDSLYDLITHYQQVPLRCNEFEMRLSEPVPQTNAHESKEWYHASLTRAQAEHMLMRVPRDGAFLVRKRNEPNSYAISFRAEGKIKHCRVQQEGQTVMLGNSEFDSLVDLISYYEKHPLYRKMKLRYPINEEALEKIGTAEPDYGALYEGRNPGFYVEANPMPTFKCAVKALFDYKAQREDELTFIKSAIIQNVEKQEGGWWRGDYGGKKQLWFPSNYVEEMVNPVALEPEREHLDENSPLGDLLRGVLDVPACQIAIRPEGKNNRLFVFSISMASVAHWSLDVAADSQEELQDWVKKIREVAQTADARLTEGKIMERRKKIALELSELVVYCRPVPFDEEKIGTERACYRDMSSFPETKAEKYVNKAKGKKFLQYNRLQLSRIYPKGQRLDSSNYDPLPMWICGSQLVALNFQTPDKPMQMNQALFMTGRHCGYVLQPSTMRDEAFDPFDKSSLRGLEPCAISIEVLGARHLPKNGRGIVCPFVEIEVAGAEYDSTKQKTEFVVDNGLNPVWPAKPFHFQISNPEFAFLRFVVYEEDMFSDQNFLAQATFPVKGLKTGYRAVPLKNNYSEDLELASLLIKIDIFPAKENGDLSPFSGTSLRERGSDASGQLFHGRAREGSFESRYQQPFEDFRISQEHLADHFDSRERRAPRRTRVNGDNRL T43901 TARGETID T43901 T43901 FORMERID TTDI02429 T43901 UNIPROID FST_HUMAN T43901 TARGNAME Follistatin (FST) T43901 GENENAME FST T43901 TARGTYPE Literature-reported T43901 SYNONYMS FST; FS; Activinbinding protein T43901 FUNCTION Binds directly to activin and functions as an activin antagonist. Specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH). T43901 PDBSTRUC 5JHW; 3HH2; 2P6A; 2B0U T43901 SEQUENCE MVRARHQPGGLCLLLLLLCQFMEDRSAQAGNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGKKCRMNKKNKPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCNSISEDTEEEEEDEDQDYSFPISSILEW T53033 TARGETID T53033 T53033 FORMERID TTDR01238 T53033 UNIPROID TNR1B_HUMAN T53033 TARGNAME Tumor necrosis factor receptor type II (TNF-R2) T53033 GENENAME TNFRSF1B T53033 TARGTYPE Literature-reported T53033 SYNONYMS p80 TNF-alpha receptor; p75; Tumor necrosis factor receptor superfamily member 1B; Tumor necrosis factor receptor 2; TNFR2; TNFR-II; TNFBR; TNF-RII; TNF-R2; Etanercept; CD120b T53033 FUNCTION Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity. T53033 PDBSTRUC 3ALQ; 1CA9 T53033 SEQUENCE MAPVAVWAALAVGLELWAAAHALPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDFALPVGLIVGVTALGLLIIGVVNCVIMTQVKKKPLCLQREAKVPHLPADKARGTQGPEQQHLLITAPSSSSSSLESSASALDRRAPTRNQPQAPGVEASGAGEARASTGSSDSSPGGHGTQVNVTCIVNVCSSSDHSSQCSSQASSTMGDTDSSPSESPKDEQVPFSKEECAFRSQLETPETLLGSTEEKPLPLGVPDAGMKPS T88356 TARGETID T88356 T88356 FORMERID TTDNR00690 T88356 UNIPROID TRPC_PSEAE T88356 TARGNAME Pseudomonas Indole-3-glycerol phosphate synthase (Pseudo trpC) T88356 GENENAME Pseudo trpC T88356 TARGTYPE Literature-reported T88356 SYNONYMS Indole-3-glycerol phosphate synthase; IGPS T88356 FUNCTION Catalyzes the fifth reaction in the synthesis of tryptophan from chorismate--a reaction that is absent in mammals. T88356 BIOCLASS Carbon-carbon lyase T88356 SEQUENCE MSVPTVLQKILARKAEEVAERRARVNLAEVERLARSADAPRGFANALLERAKRKEPAVIAEIKKASPSKGVLREHFVPAEIARSYEAGGAACLSVLTDVDFFQGADAYLKEARAACALPVIRKDFMIDPYQIVEARAIGADCILLIVSALDDVLMAELAATAKSVGLDVLVEVHDGTELERALKTLDTPLVGINNRNLHTFEVSLETTLDLLPEIPRDRLVVTESGILNRADVELMEVSEVYAFLVGEAFMRADDPGLELKRLFFQERGAVVLGADPD T08379 TARGETID T08379 T08379 FORMERID TTDI00116 T08379 UNIPROID HXA5_HUMAN T08379 TARGNAME Homeobox protein Hox-A5 (HOXA5) T08379 GENENAME HOXA5 T08379 TARGTYPE Literature-reported T08379 SYNONYMS Homeobox protein HoxA5; Homeobox protein Hox1C; Homeobox protein Hox-1C; HOX1C T08379 FUNCTION Binds to its own promoter. Binds specifically to the motif 5'-CYYNATTA[TG]Y-3'. Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. T08379 BIOCLASS Antp homeobox T08379 SEQUENCE MSSYFVNSFCGRYPNGPDYQLHNYGDHSSVSEQFRDSASMHSGRYGYGYNGMDLSVGRSGSGHFGSGERARSYAASASAAPAEPRYSQPATSTHSPQPDPLPCSAVAPSPGSDSHHGGKNSLSNSSGASADAGSTHISSREGVGTASGAEEDAPASSEQASAQSEPSPAPPAQPQIYPWMRKLHISHDNIGGPEGKRARTAYTRYQTLELEKEFHFNRYLTRRRRIEIAHALCLSERQIKIWFQNRRMKWKKDNKLKSMSMAAAGGAFRP T48358 TARGETID T48358 T48358 FORMERID TTDR00573 T48358 UNIPROID EDN2_HUMAN T48358 TARGNAME Endothelin (EDN) T48358 GENENAME EDN2 T48358 TARGTYPE Literature-reported T48358 SYNONYMS Preproendothelin-2; PPET2; Endothelin-2; ET-2 T48358 FUNCTION Endothelins are endothelium-derived vasoconstrictor peptides. T48358 BIOCLASS Endothelin/sarafotoxin T48358 SEQUENCE MVSVPTTWCSVALALLVALHEGKGQAAATLEQPASSSHAQGTHLRLRRCSCSSWLDKECVYFCHLDIIWVNTPEQTAPYGLGNPPRRRRRSLPRRCQCSSARDPACATFCLRRPWTEAGAVPSRKSPADVFQTGKTGATTGELLQRLRDISTVKSLFAKRQQEAMREPRSTHSRWRKR T21580 TARGETID T21580 T21580 FORMERID TTDI02476 T21580 UNIPROID RASA1_HUMAN T21580 TARGNAME GTPase activating protein (RASA1) T21580 GENENAME RASA1 T21580 TARGTYPE Literature-reported T21580 SYNONYMS p120GAP; RasGAP; Ras p21 protein activator; Ras GTPase-activating protein 1; RASA; GTPase-activating protein; GAP T21580 FUNCTION Stimulates the GTPase of normal but not oncogenic Ras p21; this stimulation may be further increased in the presence of NCK1. Inhibitory regulator of the Ras-cyclic AMP pathway. T21580 PDBSTRUC 4FSS; 2M51; 2J06; 2J05; 2GSB T21580 SEQUENCE MMAAEAGSEEGGPVTAGAGGGGAAAGSSAYPAVCRVKIPAALPVAAAPYPGLVETGVAGTLGGGAALGSEFLGAGSVAGALGGAGLTGGGTAAGVAGAAAGVAGAAVAGPSGDMALTKLPTSLLAETLGPGGGFPPLPPPPYLPPLGAGLGTVDEGDSLDGPEYEEEEVAIPLTAPPTNQWYHGKLDRTIAEERLRQAGKSGSYLIRESDRRPGSFVLSFLSQMNVVNHFRIIAMCGDYYIGGRRFSSLSDLIGYYSHVSCLLKGEKLLYPVAPPEPVEDRRRVRAILPYTKVPDTDEISFLKGDMFIVHNELEDGWMWVTNLRTDEQGLIVEDLVEEVGREEDPHEGKIWFHGKISKQEAYNLLMTVGQVCSFLVRPSDNTPGDYSLYFRTNENIQRFKICPTPNNQFMMGGRYYNSIGDIIDHYRKEQIVEGYYLKEPVPMQDQEQVLNDTVDGKEIYNTIRRKTKDAFYKNIVKKGYLLKKGKGKRWKNLYFILEGSDAQLIYFESEKRATKPKGLIDLSVCSVYVVHDSLFGRPNCFQIVVQHFSEEHYIFYFAGETPEQAEDWMKGLQAFCNLRKSSPGTSNKRLRQVSSLVLHIEEAHKLPVKHFTNPYCNIYLNSVQVAKTHAREGQNPVWSEEFVFDDLPPDINRFEITLSNKTKKSKDPDILFMRCQLSRLQKGHATDEWFLLSSHIPLKGIEPGSLRVRARYSMEKIMPEEEYSEFKELILQKELHVVYALSHVCGQDRTLLASILLRIFLHEKLESLLLCTLNDREISMEDEATTLFRATTLASTLMEQYMKATATQFVHHALKDSILKIMESKQSCELSPSKLEKNEDVNTNLTHLLNILSELVEKIFMASEILPPTLRYIYGCLQKSVQHKWPTNTTMRTRVVSGFVFLRLICPAILNPRMFNIISDSPSPIAARTLILVAKSVQNLANLVEFGAKEPYMEGVNPFIKSNKHRMIMFLDELGNVPELPDTTEHSRTDLSRDLAALHEICVAHSDELRTLSNERGAQQHVLKKLLAITELLQQKQNQYTKTNDVR T49522 TARGETID T49522 T49522 FORMERID TTDR00108 T49522 UNIPROID PTN_HUMAN T49522 TARGNAME Pleiotrophin (PTN) T49522 GENENAME PTN T49522 TARGTYPE Literature-reported T49522 SYNONYMS Osteoblast-specific factor 1; Osteoblast specific factor 1; OSF-1; NEGF1; Heparin-binding neurite outgrowth-promoting factor 1; Heparin-binding neurite outgrowth-promoting factor; Heparin-binding neurite outgrowth promoting factor 1; Heparin-binding growth-associated molecule; Heparin-binding brain mitogen; HBNF1; HBNF-1; HBNF; HBBM; HB-GAM T49522 FUNCTION Binds cell-surface proteoglycan receptor via their chondroitin sulfate (CS) groups. Thereby regulates many processes like cell proliferation, cell survival, cell growth, cell differentiation and cell migration in several tissues namely neuron and bone. Also plays a role in synaptic plasticity and learning-related behavior by inhibiting long-term synaptic potentiation. Binds PTPRZ1, leading to neutralization of the negative charges of the CS chains of PTPRZ1, inducing PTPRZ1 clustering, thereby causing the dimerization and inactivation of its phosphatase activity leading to increased tyrosine phosphorylation of each of the PTPRZ1 substrates like ALK, CTNNB1 or AFAP1L2 in order to activate the PI3K-AKT pathway. Through PTPRZ1 binding controls oligodendrocyte precursor cell differentiation by enhancing the phosphorylation of AFAP1L2 in order to activate the PI3K-AKT pathway. Forms a complex with PTPRZ1 and integrin alpha-V/beta-3 (ITGAV:ITGB3) that stimulates endothelial cell migration through SRC dephosphorylation and activation that consequently leads to ITGB3 'Tyr-773' phosphorylation. In adult hippocampus promotes dendritic arborization, spine development, and functional integration and connectivity of newborn granule neurons through ALK by activating AKT signaling pathway. Binds GPC2 and chondroitin sulfate proteoglycans (CSPGs) at the neuron surface, leading to abrogation of binding between PTPRS and CSPGs and neurite outgrowth promotion. Binds SDC3 and mediates bone formation by recruiting and attaching osteoblasts/osteoblast precursors to the sites for new bone deposition. Binds ALK and promotes cell survival and cell proliferation through MAPK pathway activation. Inhibits proliferation and enhances differentiation of neural stem cells by inhibiting FGF2-induced fibroblast growth factor receptor signaling pathway. Mediates regulatory mechanisms in normal hemostasis and in hematopoietic regeneration and in maintaining the balance of myeloid and lymphoid regeneration. In addition may play a role in the female reproductive system, auditory response and the progesterone-induced decidualization pathway. Secreted growth factor that mediates its signal through cell-surface proteoglycan and non-proteoglycan receptors. T49522 PDBSTRUC 2N6F T49522 SEQUENCE MQAQQYQQQRRKFAAAFLAFIFILAAVDTAEAGKKEKPEKKVKKSDCGEWQWSVCVPTSGDCGLGTREGTRTGAECKQTMKTQRCKIPCNWKKQFGAECKYQFQAWGECDLNTALKTRTGSLKRALHNAECQKTVTISKPCGKLTKPKPQAESKKKKKEGKKQEKMLD T90089 TARGETID T90089 T90089 FORMERID TTDI01993 T90089 UNIPROID SCF_HUMAN T90089 TARGNAME Mast cell growth factor (MGF) T90089 GENENAME KITLG T90089 TARGTYPE Literature-reported T90089 SYNONYMS sKITLG; cKit ligand; c-Kit ligand; Stem cell factor; Soluble KIT ligand; SCF; Kit ligand T90089 FUNCTION Plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KITLG/SCF binding can activate several signaling pathways. Promotes phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and subsequent activation of the kinase AKT1. KITLG/SCF and KIT also transmit signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT promote activation of PLCG1, leading to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KITLG/SCF acts synergistically with other cytokines, probably interleukins. Ligand for the receptor-type protein-tyrosine kinase KIT. T90089 PDBSTRUC 2E9W; 1SCF; 1EXZ T90089 SEQUENCE MKKTQTWILTCIYLQLLLFNPLVKTEGICRNRVTNNVKDVTKLVANLPKDYMITLKYVPGMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKENSSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKDSRVSVTKPFMLPPVAASSLRNDSSSSNRKAKNPPGDSSLHWAAMALPALFSLIIGFAFGALYWKKRQPSLTRAVENIQINEEDNEISMLQEKEREFQEV T03878 TARGETID T03878 T03878 FORMERID TTDR00404 T03878 UNIPROID MK_HUMAN T03878 TARGNAME Midgestation and kidney protein (Midkine) T03878 GENENAME MDK T03878 TARGTYPE Literature-reported T03878 SYNONYMS Neurite outgrowth-promoting protein; Neurite outgrowth-promoting factor 2; NEGF2; MK1; MK; Amphiregulin-associated protein; ARAP T03878 FUNCTION Binds cell-surface proteoglycan receptors via their chondroitin sulfate (CS) groups. Thereby regulates many processes like inflammatory response, cell proliferation, cell adhesion, cell growth, cell survival, tissue regeneration, cell differentiation and cell migration. Participates in inflammatory processes by exerting two different activities. Firstly, mediates neutrophils and macrophages recruitment to the sites of inflammation both by direct action by cooperating namely with ITGB2 via LRP1 and by inducing chemokine expression. This inflammation can be accompanied by epithelial cell survival and smooth muscle cell migration after renal and vessel damage, respectively. Secondly, suppresses the development of tolerogenic dendric cells thereby inhibiting the differentiation of regulatory T cells and also promote T cell expansion through NFAT signaling and Th1 cell differentiation. Promotes tissue regeneration after injury or trauma. After heart damage negatively regulates the recruitment of inflammatory cells and mediates cell survival through activation of anti-apoptotic signaling pathways via MAPKs and AKT pathways through the activation of angiogenesis. Also facilites liver regeneration as well as bone repair by recruiting macrophage at trauma site and by promoting cartilage development by facilitating chondrocyte differentiation. Plays a role in brain by promoting neural precursor cells survival and growth through interaction with heparan sulfate proteoglycans. Binds PTPRZ1 and promotes neuronal migration and embryonic neurons survival. Binds SDC3 or GPC2 and mediates neurite outgrowth and cell adhesion. Binds chondroitin sulfate E and heparin leading to inhibition of neuronal cell adhesion induced by binding with GPC2. Binds CSPG5 and promotes elongation of oligodendroglial precursor-like cells. Also binds ITGA6:ITGB1 complex; this interaction mediates MDK-induced neurite outgrowth. Binds LRP1; promotes neuronal survival. Binds ITGA4:ITGB1 complex; this interaction mediates MDK-induced osteoblast cells migration through PXN phosphorylation. Binds anaplastic lymphoma kinase (ALK) which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate (IRS1), followed by the activation of mitogen-activated protein kinase (MAPK) and PI3-kinase, and the induction of cell proliferation. Promotes epithelial to mesenchymal transition through interaction with NOTCH2. During arteriogenesis, plays a role in vascular endothelial cell proliferation by inducing VEGFA expression and release which in turn induces nitric oxide synthase expression. Moreover activates vasodilation through nitric oxide synthase activation. Negatively regulates bone formation in response to mechanical load by inhibiting Wnt/beta-catenin signaling in osteoblasts. In addition plays a role in hippocampal development, working memory, auditory response, early fetal adrenal gland development and the female reproductive system. Secreted protein that functions as cytokine and growth factor and mediates its signal through cell-surface proteoglycan and non-proteoglycan receptors. T03878 PDBSTRUC 1MKN; 1MKC T03878 SEQUENCE MQHRGFLLLTLLALLALTSAVAKKKDKVKKGGPGSECAEWAWGPCTPSSKDCGVGFREGTCGAQTQRIRCRVPCNWKKEFGADCKYKFENWGACDGGTGTKVRQGTLKKARYNAQCQETIRVTKPCTPKTKAKAKAKKGKGKD T50007 TARGETID T50007 T50007 FORMERID TTDR01059 T50007 UNIPROID MSRE_HUMAN T50007 TARGNAME Scavenger receptor A1 (MSR1) T50007 GENENAME MSR1 T50007 TARGTYPE Literature-reported T50007 SYNONYMS Macrophage scavenger receptor; Macrophage acetylated LDL receptor I and II; MSR1; CD204 antigen T50007 FUNCTION Membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis. Two types of receptor subunits exist. These receptors mediate the endocytosis of a diverse group of macromolecules, including modified low density lipoproteins (LDL). Isoform III does not internalize acetylated LDL. T50007 SEQUENCE MEQWDHFHNQQEDTDSCSESVKFDARSMTALLPPNPKNSPSLQEKLKSFKAALIALYLLVFAVLIPLIGIVAAQLLKWETKNCSVSSTNANDITQSLTGKGNDSEEEMRFQEVFMEHMSNMEKRIQHILDMEANLMDTEHFQNFSMTTDQRFNDILLQLSTLFSSVQGHGNAIDEISKSLISLNTTLLDLQLNIENLNGKIQENTFKQQEEISKLEERVYNVSAEIMAMKEEQVHLEQEIKGEVKVLNNITNDLRLKDWEHSQTLRNITLIQGPPGPPGEKGDRGPTGESGPRGFPGPIGPPGLKGDRGAIGFPGSRGLPGYAGRPGNSGPKGQKGEKGSGNTLTPFTKVRLVGGSGPHEGRVEILHSGQWGTICDDRWEVRVGQVVCRSLGYPGVQAVHKAAHFGQGTGPIWLNEVFCFGRESSIEECKIRQWGTRACSHSEDAGVTCTL T50007 DRUGINFO D0ML3S 2,4-bis-docosanoylamino-benzenesulfonate Investigative T26304 TARGETID T26304 T26304 FORMERID TTDI02504 T26304 UNIPROID PGS1_HUMAN T26304 TARGNAME Bone/cartilage proteoglycan I (BGN) T26304 GENENAME BGN T26304 TARGTYPE Literature-reported T26304 SYNONYMS PGS1; BGN T26304 FUNCTION May be involved in collagen fiber assembly. T26304 BIOCLASS Small leucine-rich proteoglycan T26304 SEQUENCE MWPLWRLVSLLALSQALPFEQRGFWDFTLDDGPFMMNDEEASGADTSGVLDPDSVTPTYSAMCPFGCHCHLRVVQCSDLGLKSVPKEISPDTTLLDLQNNDISELRKDDFKGLQHLYALVLVNNKISKIHEKAFSPLRKLQKLYISKNHLVEIPPNLPSSLVELRIHDNRIRKVPKGVFSGLRNMNCIEMGGNPLENSGFEPGAFDGLKLNYLRISEAKLTGIPKDLPETLNELHLDHNKIQAIELEDLLRYSKLYRLGLGHNQIRMIENGSLSFLPTLRELHLDNNKLARVPSGLPDLKLLQVVYLHSNNITKVGVNDFCPMGFGVKRAYYNGISLFNNPVPYWEVQPATFRCVTDRLAIQFGNYKK T50574 TARGETID T50574 T50574 FORMERID TTDI02572 T50574 UNIPROID CD9_HUMAN T50574 TARGNAME Leukocyte antigen MIC3 (CD9) T50574 GENENAME CD9 T50574 TARGTYPE Literature-reported T50574 SYNONYMS p24; Tspan29; Tspan-29; Tetraspanin29; Tetraspanin-29; Motilityrelated protein; Motility-related protein; MRP-1; MIC3; GIG2; Cell growthinhibiting gene 2 protein; Cell growth-inhibiting gene 2 protein; CD9 antigen; 5H9 antigen T50574 FUNCTION Present at the cell surface of oocytes and plays a key role in sperm-egg fusion, possibly by organizing multiprotein complexes and the morphology of the membrane required for the fusion. In myoblasts, associates with CD81 and PTGFRN and inhibits myotube fusion during muscle regeneration. In macrophages, associates with CD81 and beta-1 and beta-2 integrins, and prevents macrophage fusion into multinucleated giant cells specialized in ingesting complement-opsonized large particles. Also prevents the fusion between mononuclear cell progenitors into osteoclasts in charge of bone resorption. Acts as a receptor for PSG17. Involved in platelet activation and aggregation. Regulates paranodal junction formation. Involved in cell adhesion, cell motility and tumor metastasis. Integral membrane protein associated with integrins, which regulates different processes, such as sperm-egg fusion, platelet activation and aggregation, and cell adhesion. T50574 BIOCLASS Tetraspanin T50574 SEQUENCE MPVKGGTKCIKYLLFGFNFIFWLAGIAVLAIGLWLRFDSQTKSIFEQETNNNNSSFYTGVYILIGAGALMMLVGFLGCCGAVQESQCMLGLFFGFLLVIFAIEIAAAIWGYSHKDEVIKEVQEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVEQFISDICPKKDVLETFTVKSCPDAIKEVFDNKFHIIGAVGIGIAVVMIFGMIFSMILCCAIRRNREMV T15665 TARGETID T15665 T15665 FORMERID TTDNR00646 T15665 UNIPROID KCNA4_HUMAN; KCNC4_HUMAN; KCND1_HUMAN; KCND2_HUMAN; KCND3_HUMAN T15665 TARGNAME Voltage-gated A-type potassium channel (A-KC) T15665 GENENAME KCNA4; KCNC4; KCND1; KCND2; KCND3 T15665 TARGTYPE Literature-reported T15665 SYNONYMS Potassium voltage-gated channel T15665 FUNCTION Regulatory subunit of Kv4/D (Shal)-type voltage-gated rapidly inactivating A-type potassium channels. Regulates channel density, inactivation kinetics and rate of recovery from inactivation in a calcium-dependent and isoform-specific manner. In vitro, modulates KCND1/Kv4.1 and KCND2/Kv4.2 currents. Increases the presence of KCND2 at the cell surface. T15665 BIOCLASS Voltage-gated ion channel T15665 SEQUENCE MEVAMVSAESSGCNSHMPYGYAAQARARERERLAHSRAAAAAAVAAATAAVEGSGGSGGGSHHHHQSRGACTSHDPQSSRGSRRRRRQRSEKKKAHYRQSSFPHCSDLMPSGSEEKILRELSEEEEDEEEEEEEEEEGRFYYSEDDHGDECSYTDLLPQDEGGGGYSSVRYSDCCERVVINVSGLRFETQMKTLAQFPETLLGDPEKRTQYFDPLRNEYFFDRNRPSFDAILYYYQSGGRLKRPVNVPFDIFTEEVKFYQLGEEALLKFREDEGFVREEEDRALPENEFKKQIWLLFEYPESSSPARGIAIVSVLVILISIVIFCLETLPEFRDDRDLVMALSAGGHGGLLNDTSAPHLENSGHTIFNDPFFIVETVCIVWFSFEFVVRCFACPSQALFFKNIMNIIDIVSILPYFITLGTDLAQQQGGGNGQQQQAMSFAILRIIRLVRVFRIFKLSRHSKGLQILGHTLRASMRELGLLIFFLFIGVILFSSAVYFAEADEPTTHFQSIPDAFWWAVVTMTTVGYGDMKPITVGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETENEEQTQLTQNAVSCPYLPSNLLKKFRSSTSSSLGDKSEYLEMEEGVKESLCAKEEKCQGKGDDSETDKNNCSNAKAVETDV T67877 TARGETID T67877 T67877 FORMERID TTDR00867 T67877 UNIPROID GALA_HUMAN T67877 TARGNAME Galanin (GAL) T67877 GENENAME GAL T67877 TARGTYPE Literature-reported T67877 SYNONYMS Galanin peptides; Galanin messageassociated peptide; GMAP; GAL T67877 FUNCTION Contracts smooth muscle of the gastrointestinal and genitourinary tract, regulates growth hormone release, modulates insulin release, and may be involved in the control of adrenal secretion. T67877 BIOCLASS Galanin family T67877 SEQUENCE MARGSALLLASLLLAAALSASAGLWSPAKEKRGWTLNSAGYLLGPHAVGNHRSFSDKNGLTSKRELRPEDDMKPGSFDRSIPENNIMRTIIEFLSFLHLKEAGALDRLLDLPAAASSEDIERS T77909 TARGETID T77909 T77909 FORMERID TTDR00236 T77909 UNIPROID POLG_HRV1A T77909 TARGNAME Virus Genome polyprotein (Viru POL) T77909 GENENAME Viru POL T77909 TARGTYPE Literature-reported T77909 SYNONYMS Protein VP1; Genome polyprotein of Human rhinovirus 1A T77909 FUNCTION RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to- tail interaction called interface-I.Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomicreplication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated. T77909 PDBSTRUC 2HWF; 2HWE; 2HWD; 1R1A; 1AYN T77909 SEQUENCE MGAQVSRQNVGTHSTQNSVSNGSSLNYFNINYFKDAASSGASRLDFSQDPSKFTDPVKDVLEKGIPTLQSPSVEACGYSDRIMQITRGDSTITSQDVANAVVGYGVWPHYLTPQDATAIDKPTQPDTSSNRFYTLESKHWNGSSKGWWWKLPDALKDMGIFGENMYYHFLGRSGYTVHVQCNASKFHQGTLLVAMIPEHQLASAKHGSVTAGYKLTHPGEAGRDVSQERDASLRQPSDDSWLNFDGTLLGNLLIFPHQFINLRSNNSATLIVPYVNAVPMDSMLRHNNWSLVIIPISPLRSETTSSNIVPITVSISPMCAEFSGARAKNIKQGLPVYITPGSGQFMTTDDMQSPCALPWYHPTKEISIPGEVKNLIEMCQVDTLIPVNNVGNNVGNVSMYTVQLGNQTGMAQKVFSIKVDITSQPLATTLIGEIASYYTHWTGSLRFSFMFCGTANTTLKLLLAYTPPGIDEPTTRKDAMLGTHVVWDVGLQSTISLVVPWVSASHFRLTADNKYSMAGYITCWYQTNLVVPPSTPQTADMLCFVSACKDFCLRMARDTDLHIQSGPIEQNPVENYIDEVLNEVLVVPNIKESHHTTSNSAPLLDAAETGHTSNVQPEDAIETRYVITSQTRDEMSIESFLGRSGCVHISRIKVDYTDYNGQDINFTKWKITLQEMAQIRRKFELFTYVRFDSEITLVPCIAGRGDDIGHIVMQYMYVPPGAPIPSKRNDFSWQSGTNMSIFWQHGQPFPRFSLPFLSIASAYYMFYDGYDGDNTSSKYGSVVTNDMGTICSRIVTEKQKHSVVITTHIYHKAKHTKAWCPRPPRAVPYTHSHVTNYMPETGDVTTAIVRRNTITTAGPSDLYVHVGNLIYRNLHLFNSEMHDSILISYSSDLIIYRTNTIGDDYIPNCNCTEATYYCRHKNRYYPIKVTPHDWYEIQESEYYPKHIQYNLLIGEGPCEPGDCGGKLLCRHGVIGIITAGGEGHVAFIDLRQFHCAEEQGITDYIHMLGEAFGNGFVDSVKEQINAINPINNISKKVIKWLLRIISAMVIIIRNSSDPQTIIATLTLIGCNGSPWRFLKEKFCKWTQLTYIHKESDSWLKKFTEMCNAARGLEWIGNKISKFIDWMKSMLPQAQLKVKYLNEIKKLSLLEKQIENLRAADSATQEKIKCEIDTLHDLSCKFLPLYAHEAKRIKVLYNKCSNIIKQRKRSEPVAVMIHGPPGTGKSITTNFLARMITNESDVYSLPPDPKYFDGYDNQSVVIMDDIMQNPDGEDMTLFCQMVSSVTFIPPMADLPDKGKPFDSRFILCSTNHSLLAPPTISSLPAMNRRFFFDLDIVVHDNYKDTQGKLDVSKAFRPCNVNTKIGNAKCCPFVCGKAVXFKDRSTCSTYTLAQVYNHILEEDKRRRQVVDVMSAIFQGPISLDXPPPPAIXDLLQSVRTPEVIKYCQDNKWVIPAECQVERDLNIANSIIAIIANIISIAGIIFVIYKLFCSLQGPYSGEPKPKTKVPERRVVAQGPEEEFGRSILKNNTCVITTGNGKFTGLGIHDRILIIPTHADPGREVQVNGVHTKVLDSYDLYNRDGVKLEITVIQLDRNEKFRDIRKYIPETEDDYPECNLALSANQDEPTIIKVGDVVSYGNILLSGNQTARMLKYNYPTKSGYCGGVLYKIGQILGIHVGGNGRDGFSAMLLRSYFTDTQGQIKVNKHATECGLPTIHTPSKTKLQPSVFYDVFPGSKEPAVLTDNDPRLEVNFKEALFSKYKGNVECNLNEHMEIAIAHYSAQLMTLDIDSRPIALEDSVFGIEGLEALDLNTSAGFPYVTMGIKKRDLINNKTKDISRLKEALDKYGVDLPMITFLKDELRKKEKISTGKTRVIEASSINDTILFRTTFGNLFSKFHLNPGVVTGSAVGCDPETFWSKIPVMLDGDCIMAFDYTNYDGSIHPVWFQALKKVLENLSFQSNLIDRLCYSKHLFKSTYYEVAGGVPSGCSGTSIFNTMINNIIIRTLVLDAYKNIDLDKLKIIAYGDDVIFSYKYTLDMEAIANEGKKYGLTITPADKSNEFKKLDYSNVTFLKRGFKQDERHTFLIHPTFPVEEIHESIRWTKKPSQMQEHVLSLCHLMWHNGRKVYEDFSSKIRSVSAGRALYIPPYDLLKHEWYEKF T77909 DRUGINFO D0N0UC Lauric Acid Investigative T77909 DRUGINFO D08OBF MYRISTIC ACID Investigative T48040 TARGETID T48040 T48040 FORMERID TTDR00873 T48040 UNIPROID XPA_HUMAN T48040 TARGNAME DNA repair protein complementing XP-A cells (XPA) T48040 GENENAME XPA T48040 TARGTYPE Literature-reported T48040 SYNONYMS Xeroderma pigmentosum group A-complementing protein; XPAC; XPA protein T48040 FUNCTION Initiates repair by binding to damaged sites with various affinities, depending on the photoproduct and the transcriptional state of the region. Required for UV-induced CHEK1 phosphorylation and the recruitment of CEP164 to cyclobutane pyrimidine dimmers (CPD), sites of DNA damage after UV irradiation. Involved in DNA excision repair. T48040 PDBSTRUC 2JNW; 1XPA; 1D4U T48040 SEQUENCE MAAADGALPEAAALEQPAELPASVRASIERKRQRALMLRQARLAARPYSATAAAATGGMANVKAAPKIIDTGGGFILEEEEEEEQKIGKVVHQPGPVMEFDYVICEECGKEFMDSYLMNHFDLPTCDNCRDADDKHKLITKTEAKQEYLLKDCDLEKREPPLKFIVKKNPHHSQWGDMKLYLKLQIVKRSLEVWGSQEALEEAKEVRQENREKMKQKKFDKKVKELRRAVRSSVWKRETIVHQHEYGPEENLEDDMYRKTCTMCGHELTYEKM T84553 TARGETID T84553 T84553 FORMERID TTDR01022 T84553 UNIPROID AMPD1_HUMAN; AMPD2_HUMAN; AMPD3_HUMAN T84553 TARGNAME Adenosine monophosphate deaminase (AMPD) T84553 GENENAME AMPD1; AMPD2; AMPD3 T84553 TARGTYPE Literature-reported T84553 SYNONYMS AMP deaminase T84553 FUNCTION AMP deaminase plays a critical role in energy metabolism. Catalyzes the deamination of AMP to IMP and plays an important role in the purine nucleotide cycle. T84553 BIOCLASS Carbon-nitrogen hydrolase T84553 SEQUENCE MNVRIFYSVSQSPHSLLSLLFYCAILESRISATMPLFKLPAEEKQIDDAMRNFAEKVFASEVKDEGGRQEISPFDVDEICPISHHEMQAHIFHLETLSTSTEARRKKRFQGRKTVNLSIPLSETSSTKLSHIDEYISSSPTYQTVPDFQRVQITGDYASGVTVEDFEIVCKGLYRALCIREKYMQKSFQRFPKTPSKYLRNIDGEAWVANESFYPVFTPPVKKGEDPFRTDNLPENLGYHLKMKDGVVYVYPNEAAVSKDEPKPLPYPNLDTFLDDMNFLLALIAQGPVKTYTHRRLKFLSSKFQVHQMLNEMDELKELKNNPHRDFYNCRKVDTHIHAAACMNQKHLLRFIKKSYQIDADRVVYSTKEKNLTLKELFAKLKMHPYDLTVDSLDVHAGRQTFQRFDKFNDKYNPVGASELRDLYLKTDNYINGEYFATIIKEVGADLVEAKYQHAEPRLSIYGRSPDEWSKLSSWFVCNRIHCPNMTWMIQVPRIYDVFRSKNFLPHFGKMLENIFMPVFEATINPQADPELSVFLKHITGFDSVDDESKHSGHMFSSKSPKPQEWTLEKNPSYTYYAYYMYANIMVLNSLRKERGMNTFLFRPHCGEAGALTHLMTAFMIADDISHGLNLKKSPVLQYLFFLAQIPIAMSPLSNNSLFLEYAKNPFLDFLQKGLMISLSTDDPMQFHFTKEPLMEEYAIAAQVFKLSTCDMCEVARNSVLQCGISHEEKVKFLGDNYLEEGPAGNDIRRTNVAQIRMAYRYETWCYELNLIAEGLKSTE T84553 DRUGINFO D0T0OW Coformycin Investigative T69121 TARGETID T69121 T69121 FORMERID TTDR00651 T69121 UNIPROID ITA6_HUMAN T69121 TARGNAME Integrin alpha-6 (ITGA6) T69121 GENENAME ITGA6 T69121 TARGTYPE Literature-reported T69121 SYNONYMS VLA-6 integrin; VLA-6; CD49f; CD49 antigen-like family member F; Alpha6 beta1 integrin T69121 FUNCTION Integrin alpha-6/beta-1 (ITGA6:ITGB1) is present in oocytes and is involved in sperm-egg fusion. Integrin alpha-6/beta-4 (ITGA6:ITGB4) is a receptor for laminin in epithelial cells and it plays a critical structural role in the hemidesmosome. ITGA6:ITGB4 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGA6:ITGB4 binds to IGF1 and this binding is essential for IGF1 signaling. ITGA6:ITGB4 binds to IGF2 and this binding is essential for IGF2 signaling. Integrin alpha-6/beta-1 (ITGA6:ITGB1) is a receptor for laminin on platelets. T69121 BIOCLASS Integrin T69121 SEQUENCE MAAAGQLCLLYLSAGLLSRLGAAFNLDTREDNVIRKYGDPGSLFGFSLAMHWQLQPEDKRLLLVGAPRAEALPLQRANRTGGLYSCDITARGPCTRIEFDNDADPTSESKEDQWMGVTVQSQGPGGKVVTCAHRYEKRQHVNTKQESRDIFGRCYVLSQNLRIEDDMDGGDWSFCDGRLRGHEKFGSCQQGVAATFTKDFHYIVFGAPGTYNWKGIVRVEQKNNTFFDMNIFEDGPYEVGGETEHDESLVPVPANSYLGLLFLTSVSYTDPDQFVYKTRPPREQPDTFPDVMMNSYLGFSLDSGKGIVSKDEITFVSGAPRANHSGAVVLLKRDMKSAHLLPEHIFDGEGLASSFGYDVAVVDLNKDGWQDIVIGAPQYFDRDGEVGGAVYVYMNQQGRWNNVKPIRLNGTKDSMFGIAVKNIGDINQDGYPDIAVGAPYDDLGKVFIYHGSANGINTKPTQVLKGISPYFGYSIAGNMDLDRNSYPDVAVGSLSDSVTIFRSRPVINIQKTITVTPNRIDLRQKTACGAPSGICLQVKSCFEYTANPAGYNPSISIVGTLEAEKERRKSGLSSRVQFRNQGSEPKYTQELTLKRQKQKVCMEETLWLQDNIRDKLRPIPITASVEIQEPSSRRRVNSLPEVLPILNSDEPKTAHIDVHFLKEGCGDDNVCNSNLKLEYKFCTREGNQDKFSYLPIQKGVPELVLKDQKDIALEITVTNSPSNPRNPTKDGDDAHEAKLIATFPDTLTYSAYRELRAFPEKQLSCVANQNGSQADCELGNPFKRNSNVTFYLVLSTTEVTFDTPDLDINLKLETTSNQDNLAPITAKAKVVIELLLSVSGVAKPSQVYFGGTVVGEQAMKSEDEVGSLIEYEFRVINLGKPLTNLGTATLNIQWPKEISNGKWLLYLVKVESKGLEKVTCEPQKEINSLNLTESHNSRKKREITEKQIDDNRKFSLFAERKYQTLNCSVNVNCVNIRCPLRGLDSKASLILRSRLWNSTFLEEYSKLNYLDILMRAFIDVTAAAENIRLPNAGTQVRVTVFPSKTVAQYSGVPWWIILVAILAGILMLALLVFILWKCGFFKRSRYDDSVPRYHAVRIRKEEREIKDEKYIDNLEKKQWITKWNENESYS T48195 TARGETID T48195 T48195 FORMERID TTDR00780 T48195 UNIPROID CXCR1_HUMAN; CXCR2_HUMAN T48195 TARGNAME Interleukin 8 receptor (IL8R) T48195 GENENAME CXCR1; CXCR2 T48195 TARGTYPE Literature-reported T48195 SYNONYMS IL8R; IL-8R; IL-8 receptor; High affinity interleukin-8 receptor; CXCR; CXC-R; CDw128 T48195 FUNCTION This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity. Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activate a phosphatidylinositol-calcium second messenger system. T48195 BIOCLASS Cytokine receptor T48195 SEQUENCE MSNITDPQMWDFDDLNFTGMPPADEDYSPCMLETETLNKYVVIIAYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALTLPIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLLACISVDRYLAIVHATRTLTQKRHLVKFVCLGCWGLSMNLSLPFFLFRQAYHPNNSSPVCYEVLGNDTAKWRMVLRILPHTFGFIVPLFVMLFCYGFTLRTLFKAHMGQKHRAMRVIFAVVLIFLLCWLPYNLVLLADTLMRTQVIQESCERRNNIGRALDATEILGFLHSCLNPIIYAFIGQNFRHGFLKILAMHGLVSKEFLARHRVTSYTSSSVNVSSNL T05249 TARGETID T05249 T05249 FORMERID TTDI01504 T05249 UNIPROID ZA2G_HUMAN T05249 TARGNAME Zinc alpha-2 glycoprotein (AZGP1) T05249 GENENAME AZGP1 T05249 TARGTYPE Literature-reported T05249 SYNONYMS Zn-alpha-2-glycoprotein; Zn-alpha-2-GP; Zinc-alpha-2-glycoprotein; ZNGP1; ZAG T05249 FUNCTION Stimulates lipid degradation in adipocytes and causes the extensive fat losses associated with some advanced cancers. May bind polyunsaturated fatty acids. T05249 PDBSTRUC 3ES6; 1ZAG; 1T80; 1T7Z; 1T7Y T05249 SEQUENCE MVRMVPVLLSLLLLLGPAVPQENQDGRYSLTYIYTGLSKHVEDVPAFQALGSLNDLQFFRYNSKDRKSQPMGLWRQVEGMEDWKQDSQLQKAREDIFMETLKDIVEYYNDSNGSHVLQGRFGCEIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDPAAQITKQKWEAEPVYVQRAKAYLEEECPATLRKYLKYSKNILDRQDPPSVVVTSHQAPGEKKKLKCLAYDFYPGKIDVHWTRAGEVQEPELRGDVLHNGNGTYQSWVVVAVPPQDTAPYSCHVQHSSLAQPLVVPWEAS T88321 TARGETID T88321 T88321 FORMERID TTDR00335 T88321 UNIPROID RBTN2_HUMAN T88321 TARGNAME Rhombotin-2 (LMO2) T88321 GENENAME LMO2 T88321 TARGTYPE Literature-reported T88321 SYNONYMS TTG2; T-cell translocation protein 2; RHOM2; RBTNL1; RBTN2; LMO-2; LIM-only protein 2; LIM-domain protein Lmo2; LIM domain only protein 2; Cysteine-rich protein TTG-2; Cysteine rich protein TTG-2 T88321 FUNCTION Acts with LDB1 to maintain erythroid precursors in an immature state. Acts with TAL1/SCL to regulate red blood cell development. T88321 PDBSTRUC 4KFZ; 2YPA; 2XJZ; 2XJY T88321 SEQUENCE MSSAIERKSLDPSEEPVDEVLQIPPSLLTCGGCQQNIGDRYFLKAIDQYWHEDCLSCDLCGCRLGEVGRRLYYKLGRKLCRRDYLRLFGQDGLCASCDKRIRAYEMTMRVKDKVYHLECFKCAACQKHFCVGDRYLLINSDIVCEQDIYEWTKINGMI T62410 TARGETID T62410 T62410 FORMERID TTDR00980 T62410 UNIPROID CYSP_PLAFA T62410 TARGNAME Plasmodium Trophozoite cysteine proteinase (Malaria TCP) T62410 GENENAME Malaria TCP T62410 TARGTYPE Literature-reported T62410 SYNONYMS Trophozoite cysteine proteinase; TCP T62410 FUNCTION Probably degrades erythrocyte hemoglobin. T62410 ECNUMBER EC 3.4.22.- T62410 SEQUENCE MVAIKEMKELAFARPSLVETLNKKKKFLKKKEKRTFVLSIYAFITFIIFCIGILYFTNKSSAHNNNNNKNEHSLKKEEIELLRVLLEKYKKQKDGILNESSNEEDEEKYTLNSETYNNKNNVSNIKNDSIKSKKEEYINLERILLEKYKKFINENNEENRKELSNILHKLLEINKLILREEKDDKKVYLINDNYDEKGALEIGMNEEMKYKKEDPINNIKYASKFFKFMKEHNKVYKNIDEQMRKFEIFKINYISIKNHNKLNKNAMYKKKVNQFSDYSEEELKEYFKTLLHVPNHMIEKYSKPFENHLKDNILISEFYTNGKRNEKDIFSKVPEILDYREKGIVHEPKDQGLCGSCWAFASVGNIESVFAKKNKNILSFSEQEVVDCSKDNFGCDGGHPFYSFLYVLQNELCLGDEYKYKAKDDMFCLNYRCKRKVSLSSIGAVKENQLILALNEVGPLSVNVGVNNDFVAYSEGVYNGTCSEELNHSVLLVGYGQVEKTKLNYNNKIQTYNTKENSNQPDDNIIYYWIIKNSWSKKWGENGFMRLSRNKNGDNVFCGIGEEVFYPIL T24609 TARGETID T24609 T24609 FORMERID TTDI00031 T24609 UNIPROID PTBP1_HUMAN T24609 TARGNAME Polypyrimidine tract-binding protein (PTBP1) T24609 GENENAME PTBP1 T24609 TARGTYPE Literature-reported T24609 SYNONYMS hnRNP I; Polypyrimidine tractbinding protein 1; Polypyrimidine tract-binding protein 1; PTB; Heterogeneous nuclear ribonucleoprotein I; 57 kDa RNAbinding protein PPTB1; 57 kDa RNA-binding protein PPTB-1 T24609 FUNCTION Activates exon skipping of its own pre-mRNA during muscle cell differentiation. Binds to the polypyrimidine tract of introns. May promote RNA looping when bound to two separate polypyrimidine tracts in the same pre-mRNA. May promote the binding of U2 snRNP to pre-mRNA. Cooperates with RAVER1 to modulate switching between mutually exclusive exons during maturation of the TPM1 pre-mRNA. Represses the splicing of MAPT/Tau exon 10. In case of infection by picornaviruses, binds to the viral internal ribosome entry site (IRES) and stimulates the IRES-mediated translation. Plays a role in pre-mRNA splicing and in the regulation of alternative splicing events. T24609 PDBSTRUC 3ZZZ; 3ZZY; 2N3O; 2EVZ; 2ADC T24609 SEQUENCE MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRVIHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPVLRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQSPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLSLDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLSVPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGVYGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREGQEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGVVKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI T65266 TARGETID T65266 T65266 FORMERID TTDNR00687 T65266 UNIPROID POLG_HCV1 T65266 TARGNAME Hepatitis C virus Protein p7 (HCV p7) T65266 GENENAME HCV p7 T65266 TARGTYPE Literature-reported T65266 SYNONYMS HCV p7 T65266 FUNCTION Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity). T65266 PDBSTRUC 3SU4; 3RC5; 3RC4; 3QGI; 3QGH T65266 SEQUENCE ALENLVILNAASLAGTHGLVSFLVFFCFAWYLKGKWVPGAVYTFYGMWPLLLLLLALPQRAYA T94593 TARGETID T94593 T94593 FORMERID TTDR00627 T94593 UNIPROID PPLA_HUMAN T94593 TARGNAME Cardiac phospholamban (PLN) T94593 GENENAME PLN T94593 TARGTYPE Literature-reported T94593 SYNONYMS Phospholamban; PLN; PLB T94593 FUNCTION Reversibly inhibits the activity of ATP2A2 in cardiac sarcoplasmic reticulum by decreasing the apparent affinity of the ATPase for Ca(2+). Modulates the contractility of the heart muscle in response to physiological stimuli via its effects on ATP2A2. Modulatescalcium re-uptake during muscle relaxation and plays an important role in calcium homeostasis in the heart muscle. The degree of ATP2A2 inhibition depends on the oligomeric state of PLN. ATP2A2 inhibition is alleviated by PLN phosphorylation. T94593 PDBSTRUC 2HYN; 1ZLL; 1PSL; 1PLP; 1PLN T94593 SEQUENCE MEKVQYLTRSAIRRASTIEMPQQARQKLQNLFINFCLILICLLLICIIVMLL T09341 TARGETID T09341 T09341 FORMERID TTDNR00735 T09341 UNIPROID VP16_BPPRD T09341 TARGNAME Virus Protein P16 (Viru GpS) T09341 GENENAME Viru GpS T09341 TARGTYPE Literature-reported T09341 SYNONYMS XVI; Protein S; GpS T09341 FUNCTION protein of the infection vertex complex, which increases the vertex stability. Anchors the vertex structure to the viral membrane. Essential for viral infectivity. T09341 PDBSTRUC 1W8X T09341 SEQUENCE MDKKKLLYWVGGGLVLILIWLWFRNRPAAQVASNWEGPPYMTYNQPQAGSVTLPVAGYTSPSPTLPNRNRSCGCNPAVSAAMAQGADLASKLTDSITSQLNDYASSLNDYLASQAGV T79821 TARGETID T79821 T79821 FORMERID TTDNR00664 T79821 UNIPROID CALR_HUMAN T79821 TARGNAME Calreticulin (CALR) T79821 GENENAME CALR T79821 TARGTYPE Literature-reported T79821 SYNONYMS grp60; HACBP; Endoplasmic reticulum resident protein 60; ERp60; ERC; Calregulin; CRTC; CRP55 T79821 FUNCTION Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity). T79821 PDBSTRUC 6ENY; 5V90; 5LK5; 3POW; 3POS T79821 SEQUENCE MLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDEEKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQTDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDNTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPEHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYSPDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL T93830 TARGETID T93830 T93830 FORMERID TTDR01125 T93830 UNIPROID GRN_HUMAN T93830 TARGNAME Granulin (GRN) T93830 GENENAME GRN T93830 TARGTYPE Literature-reported T93830 SYNONYMS Progranulin (58-573); Proepithelin (58-573); PGRN (58-573); PEPI (58-573); PCDGF (58-573); PC cell-derived growth factor (58-573); Granulin-epithelin; Granulin precursor (58-573); Glycoprotein of 88 Kda (58-573); Glycoprotein 88 (58-573); GP88 (58-573); Epithelin precursor (58-573); Acrogranin (58-573) T93830 FUNCTION Functions as regulator of proteins trafficking to lysosome and activity of lysosomal enzymes. Facilitates also the acidification of lysosomes, causing degradation of mature CTSD by CTSB. In addition, functions as wound-related growth factor that acts directly on dermal fibroblasts and endothelial cells to promote division, migration and the formation of capillary-like tubule structure. Also promotes epithelial cell proliferation by blocking TNF-mediated neutrophil activation preventing release of oxidants and proteases. Moreover, modulates inflammation in neuron by preserving neuron survival, axonal outgrowth and neuronal integrity. Secreted proteins that act as key regulator of lysosomal function and as a growth factor involved in inflammation, wound healing and cell proliferation. T93830 PDBSTRUC 2JYV; 2JYU; 2JYT; 2JYE; 1G26 T93830 SEQUENCE GGPCQVDAHCSAGHSCIFTVSGTSSCCPFPEAVACGDGHHCCPRGFHCSADGRSCFQRSGNNSVGAIQCPDSQFECPDFSTCCVMVDGSWGCCPMPQASCCEDRVHCCPHGAFCDLVHTRCITPTGTHPLAKKLPAQRTNRAVALSSSVMCPDARSRCPDGSTCCELPSGKYGCCPMPNATCCSDHLHCCPQDTVCDLIQSKCLSKENATTDLLTKLPAHTVGDVKCDMEVSCPDGYTCCRLQSGAWGCCPFTQAVCCEDHIHCCPAGFTCDTQKGTCEQGPHQVPWMEKAPAHLSLPDPQALKRDVPCDNVSSCPSSDTCCQLTSGEWGCCPIPEAVCCSDHQHCCPQGYTCVAEGQCQRGSEIVAGLEKMPARRASLSHPRDIGCDQHTSCPVGQTCCPSLGGSWACCQLPHAVCCEDRQHCCPAGYTCNVKARSCEKEVVSAQPATFLARSPHVGVKDVECGEGHFCHDNQTCCRDNRQGWACCPYRQGVCCADRRHCCPAGFRCAARGTKCL T86503 TARGETID T86503 T86503 FORMERID TTDI03478 T86503 UNIPROID PCSK6_HUMAN T86503 TARGNAME Proprotein convertase subtilisin/kexin type 6 (PCSK6) T86503 GENENAME PCSK6 T86503 TARGTYPE Literature-reported T86503 SYNONYMS Subtilisin/kexin-like protease PACE4; Subtilisin-like proprotein convertase 4; SPC4; Paired basic amino acid cleaving enzyme 4; PACE4 T86503 FUNCTION Serine endoprotease that processes various proproteins by cleavage at paired basic amino acids, recognizing the RXXX[KR]R consensus motif. Likely functions in the constitutive secretory pathway, with unique restricted distribution in both neuroendocrine and non-neuroendocrine tissues. T86503 ECNUMBER EC 3.4.21.- T86503 SEQUENCE MPPRAPPAPGPRPPPRAAAATDTAAGAGGAGGAGGAGGPGFRPLAPRPWRWLLLLALPAACSAPPPRPVYTNHWAVQVLGGPAEADRVAAAHGYLNLGQIGNLEDYYHFYHSKTFKRSTLSSRGPHTFLRMDPQVKWLQQQEVKRRVKRQVRSDPQALYFNDPIWSNMWYLHCGDKNSRCRSEMNVQAAWKRGYTGKNVVVTILDDGIERNHPDLAPNYDSYASYDVNGNDYDPSPRYDASNENKHGTRCAGEVAASANNSYCIVGIAYNAKIGGIRMLDGDVTDVVEAKSLGIRPNYIDIYSASWGPDDDGKTVDGPGRLAKQAFEYGIKKGRQGLGSIFVWASGNGGREGDYCSCDGYTNSIYTISVSSATENGYKPWYLEECASTLATTYSSGAFYERKIVTTDLRQRCTDGHTGTSVSAPMVAGIIALALEANSQLTWRDVQHLLVKTSRPAHLKASDWKVNGAGHKVSHFYGFGLVDAEALVVEAKKWTAVPSQHMCVAASDKRPRSIPLVQVLRTTALTSACAEHSDQRVVYLEHVVVRTSISHPRRGDLQIYLVSPSGTKSQLLAKRLLDLSNEGFTNWEFMTVHCWGEKAEGQWTLEIQDLPSQVRNPEKQGKLKEWSLILYGTAEHPYHTFSAHQSRSRMLELSAPELEPPKAALSPSQVEVPEDEEDYTAQSTPGSANILQTSVCHPECGDKGCDGPNADQCLNCVHFSLGSVKTSRKCVSVCPLGYFGDTAARRCRRCHKGCETCSSRAATQCLSCRRGFYHHQEMNTCVTLCPAGFYADESQKNCLKCHPSCKKCVDEPEKCTVCKEGFSLARGSCIPDCEPGTYFDSELIRCGECHHTCGTCVGPGREECIHCAKNFHFHDWKCVPACGEGFYPEEMPGLPHKVCRRCDENCLSCAGSSRNCSRCKTGFTQLGTSCITNHTCSNADETFCEMVKSNRLCERKLFIQFCCRTCLLAG T86503 DRUGINFO D0A6FZ peptide 18 Investigative T86503 DRUGINFO D05JJL furin inhibitor peptide Investigative T31641 TARGETID T31641 T31641 FORMERID TTDI01412 T31641 UNIPROID HRR25_YEAST T31641 TARGNAME Saccharomyces Casein Kinase I Isoform Hrr25 (Saccha HRR25) T31641 GENENAME Saccha HRR25 T31641 TARGTYPE Literature-reported T31641 SYNONYMS Casein kinase I homolog HRR25 T31641 FUNCTION Associated with repair of damaged DNA and meiosis. Phosphorylates serine and threonine. Can use casein as a substrate. T31641 PDBSTRUC 5CZO; 5CYZ; 4XHL T31641 SEQUENCE MDLRVGRKFRIGRKIGSGSFGDIYHGTNLISGEEVAIKLESIRSRHPQLDYESRVYRYLSGGVGIPFIRWFGREGEYNAMVIDLLGPSLEDLFNYCHRRFSFKTVIMLALQMFCRIQYIHGRSFIHRDIKPDNFLMGVGRRGSTVHVIDFGLSKKYRDFNTHRHIPYRENKSLTGTARYASVNTHLGIEQSRRDDLESLGYVLIYFCKGSLPWQGLKATTKKQKYDRIMEKKLNVSVETLCSGLPLEFQEYMAYCKNLKFDEKPDYLFLARLFKDLSIKLEYHNDHLFDWTMLRYTKAMVEKQRDLLIEKGDLNANSNAASASNSTDNKSETFNKIKLLAMKKFPTHFHYYKNEDKHNPSPEEIKQQTILNNNAASSLPEELLNALDKGMENLRQQQPQQQVQSSQPQPQPQQLQQQPNGQRPNYYPEPLLQQQQRDSQEQQQQVPMATTRATQYPPQINSNNFNTNQASVPPQMRSNPQQPPQDKPAGQSIWL T06819 TARGETID T06819 T06819 FORMERID TTDI01458 T06819 UNIPROID S100G_HUMAN T06819 TARGNAME S100 calcium-binding protein G (S100G) T06819 GENENAME S100G T06819 TARGTYPE Literature-reported T06819 SYNONYMS Vitamin D-dependent calcium-binding protein, intestinal; S100D; Protein S100-G; Calbindin-D9k; CALB3; CABP9K; CABP T06819 FUNCTION Vitamin D-dependent. Its expression correlates with calcium transport activity. May increase Ca2+ absorption by buffering Ca2+ in the cytoplasm and increase ATP-dependent Ca2+ transport in duodenal basolateral membrane vesicles. T06819 BIOCLASS S100 calcium-binding protein T06819 SEQUENCE MSTKKSPEELKRIFEKYAAKEGDPDQLSKDELKLLIQAEFPSLLKGPNTLDDLFQELDKNGDGEVSFEEFQVLVKKISQ T45034 TARGETID T45034 T45034 FORMERID TTDR00729 T45034 UNIPROID SPB3_HUMAN T45034 TARGNAME Squamous cell carcinoma antigen 1 (SCCA-1) T45034 GENENAME SERPINB3 T45034 TARGTYPE Literature-reported T45034 SYNONYMS Serpin B3; SCCA1; SCCA-1; SCCA; Protein T4-A T45034 FUNCTION May act as a papain-like cysteine protease inhibitor to modulate the host immune response against tumor cells. Also functions as an inhibitor of UV-induced apoptosis via suppression of the activity of c-Jun NH(2)-terminal kinase (JNK1). T45034 PDBSTRUC 4ZK3; 4ZK0; 2ZV6 T45034 SEQUENCE MNSLSEANTKFMFDLFQQFRKSKENNIFYSPISITSALGMVLLGAKDNTAQQIKKVLHFDQVTENTTGKAATYHVDRSGNVHHQFQKLLTEFNKSTDAYELKIANKLFGEKTYLFLQEYLDAIKKFYQTSVESVDFANAPEESRKKINSWVESQTNEKIKNLIPEGNIGSNTTLVLVNAIYFKGQWEKKFNKEDTKEEKFWPNKNTYKSIQMMRQYTSFHFASLEDVQAKVLEIPYKGKDLSMIVLLPNEIDGLQKLEEKLTAEKLMEWTSLQNMRETRVDLHLPRFKVEESYDLKDTLRTMGMVDIFNGDADLSGMTGSRGLVLSGVLHKAFVEVTEEGAEAAAATAVVGFGSSPTSTNEEFHCNHPFLFFIRQNKTNSILFYGRFSSP T01683 TARGETID T01683 T01683 FORMERID TTDI01867 T01683 UNIPROID PML_HUMAN T01683 TARGNAME Promyelocytic leukemia protein (PML) T01683 GENENAME PML T01683 TARGTYPE Literature-reported T01683 SYNONYMS Tripartite motif-containing protein 19; TRIM19; RNF71; RING finger protein 71; Protein PML; PP8675; MYL T01683 FUNCTION Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Isoform PML-4 has a multifaceted role in the regulation of apoptosis and growth suppression: activates RB1 and inhibits AKT1 via interactions with PP1 and PP2A phosphatases respectively, negatively affects the PI3K pathway by inhibiting MTOR and activating PTEN, and positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Isoform PML-4 also: acts as a transcriptional repressor of TBX2 during cellular senescence and the repression is dependent on a functional RBL2/E2F4 repressor complex, regulates double-strand break repair in gamma-irradiation-induced DNA damage responses via its interaction with WRN, acts as a negative regulator of telomerase by interacting with TERT, and regulates PER2 nuclear localization and circadian function. Isoform PML-6 inhibits specifically the activity of the tetrameric form of PKM. The nuclear isoforms (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5) in concert with SATB1 are involved in local chromatin-loop remodeling and gene expression regulation at the MHC-I locus. Isoform PML-2 is required for efficient IFN-gamma induced MHC II gene transcription via regulation of CIITA. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. PML also regulates transcription activity of ELF4 and can act as an important mediator for TNF-alpha- and IFN-alpha-mediated inhibition of endothelial cell network formation and migration. T01683 PDBSTRUC 5YUF; 4WJO; 4WJN; 2MWX; 2MVW T01683 SEQUENCE MEPAPARSPRPQQDPARPQEPTMPPPETPSEGRQPSPSPSPTERAPASEEEFQFLRCQQCQAEAKCPKLLPCLHTLCSGCLEASGMQCPICQAPWPLGADTPALDNVFFESLQRRLSVYRQIVDAQAVCTRCKESADFWCFECEQLLCAKCFEAHQWFLKHEARPLAELRNQSVREFLDGTRKTNNIFCSNPNHRTPTLTSIYCRGCSKPLCCSCALLDSSHSELKCDISAEIQQRQEELDAMTQALQEQDSAFGAVHAQMHAAVGQLGRARAETEELIRERVRQVVAHVRAQERELLEAVDARYQRDYEEMASRLGRLDAVLQRIRTGSALVQRMKCYASDQEVLDMHGFLRQALCRLRQEEPQSLQAAVRTDGFDEFKVRLQDLSSCITQGKDAAVSKKASPEAASTPRDPIDVDLPEEAERVKAQVQALGLAEAQPMAVVQSVPGAHPVPVYAFSIKGPSYGEDVSNTTTAQKRKCSQTQCPRKVIKMESEEGKEARLARSSPEQPRPSTSKAVSPPHLDGPPSPRSPVIGSEVFLPNSNHVASGAGEAEERVVVISSSEDSDAENSSSRELDDSSSESSDLQLEGPSTLRVLDENLADPQAEDRPLVFFDLKIDNETQKISQLAAVNRESKFRVVIQPEAFFSIYSKAVSLEVGLQHFLSFLSSMRRPILACYKLWGPGLPNFFRALEDINRLWEFQEAISGFLAALPLIRERVPGASSFKLKNLAQTYLARNMSERSAMAAVLAMRDLCRLLEVSPGPQLAQHVYPFSSLQCFASLQPLVQAAVLPRAEARLLALHNVSFMELLSAHRRDRQGGLKKYSRYLSLQTTTLPPAQPAFNLQALGTYFEGLLEGPALARAEGVSTPLAGRGLAERASQQS T34099 TARGETID T34099 T34099 FORMERID TTDI01482 T34099 UNIPROID POLG_DEN26 T34099 TARGNAME Dengue virus NS2B/NS3 protease (DENV NS2B/NS3) T34099 GENENAME DENV NS2B/NS3 T34099 TARGTYPE Literature-reported T34099 SYNONYMS Genome polyprotein T34099 FUNCTION Capsid protein C: Plays a role in virus budding by binding to the cell membrane and gathering the viral RNA into a nucleocapsid that forms the core of a mature virus particle. During virus entry, may induce genome penetration into the host cytoplasm after hemifusion induced by the surface proteins. Can migrate to the cell nucleus where it modulates host functions. Overcomes the anti-viral effects of host EXOC1 by sequestering and degrading the latter through the proteasome degradation pathway. T34099 PDBSTRUC 4O6B; 2R69 T34099 SEQUENCE MNDQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLYMALVAFLRFLTIPPTAGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRRSAGMIIMLIPTVMAFHLTTRNGEPHMIVSRQEKGKSLLFKTEDGVNMCTLMAMDLGELCEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMGEHRRQKRSVALVPHVGMGLETRTETWMSSEGAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCAMFRCKKNMEGKVVQPENLEYTIVITPHSGEEHAVGNDTGKHGKEIKITPQSSTTEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQMSSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQADSGCVVSWKNKELKCGSGIFITDNVHTWTEQYKFQPESPSKLASAIQKAHEEGICGIRSVTRLENLMWKQITPELNHILSENEVKLTIMTGDIKGIMQAGKRSLRPQPTELKYSWKTWGKAKMLSTESHNQTFLIDGPETAECPNTNRAWNSLEVEDYGFGVFTTNIWLKLKEKQDVFCDSKLMSAAIKDNRAVHADMGYWIESALNDTWKIEKASFIEVKNCHWPKSHTLWSNGVLESEMIIPKNLAGPVSQHNYRPGYHTQITGPWHLGKLEMDFDFCDGTTVVVTEDCGNRGPSLRTTTASGKLITEWCCRSCTLPPLRYRGEDGCWYGMEIRPLKEKEENLVNSLVTAGHGQVDNFSLGVLGMALFLEEMLRTRVGTKHAILLVAVSFVTLIIGNMSFRDLGRVMVMVGATMTDDIGMGVTYLALLAAFKVRPTFAAGLLLRKLTSKALMMTTIGIVLSSQSTTPETILELTDALALGMMVLKMVRNMEKYQLAVTIMAILCVPNAVILQNAWKVSCTILAVVSVSPLFLTSSQQKTDWIPLALTIKGLNPTAIFLTTLSRTSKKRSWPLNEAIMAVGMVSILASSLLKNDIPMTGPLVAGGPLTVCYVLTGRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLTILIRTGLLVISGLFPVSIPITAAAWYLWEVKKQRAGVLWDVPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPSWADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFSPGTSGSPIIDKKGKVVGLYGNGVVTRSGAYVSAIAQTEKSIEDNPEIEDDIFRKRRLTIMDLHPGAGKTKRYLPAIVREAIKRGLRTLILAPTRVVAAEMEEALRGLPIRYQTPAIRAEHTGREIVDLMCHATFTMRLLSPVRVPNYNLIIMDEAHFTDPASIAARGYISTRVEMGEAAGIFMTATPPGSRDPFPQSNAPIIDEEREIPERSWNSGHEWVTDFKGKTVWFVPSIKAGNDIAACLSKNGKKVIQLSRKTFDSEYAKTRTNDWDFVVTTDISEMGANFKAERVIDPRRCMKPVILTDGEERVILAGPMPVTHSSAAQRRGRIGRNPKNENDQYIYMGEPLENDEDCAHWKEAKMLLDNINTPEGIIPSMFEPEREKVDAIDGEYRLRGEARTTFVDLMRRGDLPVWLAYRVAAEGINYADRRWCFDGVKNNQILEENVEVEIWTKEGERKKLKPRWLDARIYSDPLALKEFKEFAAGRKSLTLNLITEMGRLPTFMTQKARDALDNLAVLHTAEAGGRAYNHALSELPETLETLLLLTLLATVTGGILLFLMSGRGIGKMTLGMCCIITASILLWYAQIQPHWIAASIILEFFLIVLLIPEPEKQRTPQDNQLTYVVIAILTVVAATMANEMGFLEKTKKDLGLGSIATQQPESNILDIDLRPASAWTLYAVATTFVTPMLRHSIENSSVNVSLTAIANQATVLMGLGKGWPLSKMDIGVPLLAIGCYSQVNPTTLTAALFLLVAHYAIIGPALQAKASREAQKRAAAGIMKNPTVDGITVIDLDPIPYDPKFEKQLGQVMLLVLCVTQVLMMRTTWALCEVLTLATGPISTLWEGNPGRFWNTTIAVSMANIFRGSYLAGAGLLFSIMKNTTNARRGTGNIGETLGEKWKSRLNALGKSEFQIYKKSGIQEVDRTLAKEGIKRGETDHHAVSRGSAKLRWFVERNMVTPEGKVVDLGCGRGGWSYYCGGLKNVREVKGLTKGGPGHEEPIPMSTYGWNLVRLQSGVDVFFIPPEKCDTLLCDIGESSPNPTVEAGRTLRVLNLVENWLNNNTQFCIKVLNPYMPSVIEKMEALQRKYGGALVRNPLSRNSTHEMYWVSNASGNIVSSVNMISRMLINRFTMRYKKATYEPDVDLGSGTRNIGIESEIPNLDIIGKRIEKIKQEHETSWHYDQDHPYKTWAYHGSYETKQTGSASSMVNGVFRLLTKPWDVVPMVTQMAMTDTTPFGQQRVFKEKVDTRTQEPKEGTKKLMKITAEWLWKELGKKKTPRMCTREEFTRKVRSNAALGAIFTDENKWKSAREAVEDSRFWELVDKERNLHLEGKCETCVYNIMGKREKKLGEFGKAKGSRAIWYMWLGARFLEFEALGFLNEDHWFSRENSLSGVEGEGLHKLGYILRDVSKKEGGAMYADDTAGWDTRITLEDLKNEAMVTNHMEGEHKKLAEAIFKLTYQNKVVRVQRPTPRGTVMDIISRRDQRGSGQVGTYGLNTFTNMEAQLIRQMEGEGVFKSIQHLTITEEIAVQNWLARVGRERLSRMAISGDDCVVKPLDDRLPSALTALNDTGKIRKDIQQWEPSRGWNDWTQVPFCSHHFHELIMKDGRVLVVPCRNQDELIGRARISQGAGWSLRETACLGKSYDQMWSLMYFHRRDLRLAANAICSAVPSHWVPTSRTTWSIHAKHEWMTTEDMLTVWNRVWIQENPWMEDKTPVESWEEIPYLGKREDQWCGSLIGLTSRATWAKNIQAAINQVRSLIGNEEYTDYMPSMKRFRREEEEAGVLW T72507 TARGETID T72507 T72507 FORMERID TTDI01801 T72507 UNIPROID CCND3_HUMAN T72507 TARGNAME Cyclin D (CCND3) T72507 GENENAME CCND3 T72507 TARGTYPE Literature-reported T72507 SYNONYMS G1/S-specific cyclin-D3 T72507 FUNCTION Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. T72507 PDBSTRUC 3G33 T72507 SEQUENCE MELLCCEGTRHAPRAGPDPRLLGDQRVLQSLLRLEERYVPRASYFQCVQREIKPHMRKMLAYWMLEVCEEQRCEEEVFPLAMNYLDRYLSCVPTRKAQLQLLGAVCMLLASKLRETTPLTIEKLCIYTDHAVSPRQLRDWEVLVLGKLKWDLAAVIAHDFLAFILHRLSLPRDRQALVKKHAQTFLALCATDYTFAMYPPSMIATGSIGAAVQGLGACSMSGDELTELLAGITGTEVDCLRACQEQIEAALRESLREASQTSSSPAPKAPRGSSSQGPSQTSTPTDVTAIHL T43589 TARGETID T43589 T43589 FORMERID TTDR00394 T43589 UNIPROID CTR1_HUMAN T43589 TARGNAME High-affinity cationic amino acid transporter-1 (SLC7A1) T43589 GENENAME SLC7A1 T43589 TARGTYPE Literature-reported T43589 SYNONYMS System Y+ basic amino acid transporter; Solute carrier family 7 member 1; REC1L; High affinity cationic amino acid transporter 1; Ecotropic retrovirus receptor homolog; Ecotropic retroviral leukemia receptor homolog; CAT-1; ATRC1 T43589 FUNCTION High-affinity, low capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine) in non-hepatic tissues. T43589 BIOCLASS Amino acid-polyamine-organocation T43589 SEQUENCE MGCKVLLNIGQQMLRRKVVDCSREETRLSRCLNTFDLVALGVGSTLGAGVYVLAGAVARENAGPAIVISFLIAALASVLAGLCYGEFGARVPKTGSAYLYSYVTVGELWAFITGWNLILSYIIGTSSVARAWSATFDELIGRPIGEFSRTHMTLNAPGVLAENPDIFAVIIILILTGLLTLGVKESAMVNKIFTCINVLVLGFIMVSGFVKGSVKNWQLTEEDFGNTSGRLCLNNDTKEGKPGVGGFMPFGFSGVLSGAATCFYAFVGFDCIATTGEEVKNPQKAIPVGIVASLLICFIAYFGVSAALTLMMPYFCLDNNSPLPDAFKHVGWEGAKYAVAVGSLCALSASLLGSMFPMPRVIYAMAEDGLLFKFLANVNDRTKTPIIATLASGAVAAVMAFLFDLKDLVDLMSIGTLLAYSLVAACVLVLRYQPEQPNLVYQMASTSDELDPADQNELASTNDSQLGFLPEAEMFSLKTILSPKNMEPSKISGLIVNISTSLIAVLIITFCIVTVLGREALTKGALWAVFLLAGSALLCAVVTGVIWRQPESKTKLSFKVPFLPVLPILSIFVNVYLMMQLDQGTWVRFAVWMLIGFIIYFGYGLWHSEEASLDADQARTPDGNLDQCK T64520 TARGETID T64520 T64520 FORMERID TTDR00849 T64520 UNIPROID GLMM_ECOLI T64520 TARGNAME Bacterial Lantibiotic mersacidin (Bact glmM) T64520 GENENAME Bact glmM T64520 TARGTYPE Literature-reported T64520 SYNONYMS glmM of Escherichia coli; Protein mrsA; Mersacidin T64520 FUNCTION Catalyzes the conversion of glucosamine-6-phosphate to glucosamine-1-phosphate. Can also catalyze the formation of glucose-6-P from glucose-1-P, although at a 1400-fold lower rate. T64520 ECNUMBER EC 5.4.2.10 T64520 SEQUENCE MSNRKYFGTDGIRGRVGDAPITPDFVLKLGWAAGKVLARHGSRKIIIGKDTRISGYMLESALEAGLAAAGLSALFTGPMPTPAVAYLTRTFRAEAGIVISASHNPFYDNGIKFFSIDGTKLPDAVEEAIEAEMEKEISCVDSAELGKASRIVDAAGRYIEFCKATFPNELSLSELKIVVDCANGATYHIAPNVLRELGANVIAIGCEPNGVNINAEVGATDVRALQARVLAEKADLGIAFDGDGDRVIMVDHEGNKVDGDQIMYIIAREGLRQGQLRGGAVGTLMSNMGLELALKQLGIPFARAKVGDRYVLEKMQEKGWRIGAENSGHVILLDKTTTGDGIVAGLQVLAAMARNHMSLHDLCSGMKMFPQILVNVRYTAGSGDPLEHESVKAVTAEVEAALGNRGRVLLRKSGTEPLIRVMVEGEDEAQVTEFAHRIADAVKAV T64520 DRUGINFO D02DXP Alpha-Aminobutyric Acid Investigative T64520 DRUGINFO D03HHP 2,3-Didehydroalanine Investigative T64520 DRUGINFO D0W8FQ 2-Thioethenamine Investigative T26338 TARGETID T26338 T26338 FORMERID TTDR01158 T26338 UNIPROID HXA7_HUMAN T26338 TARGNAME Homeobox protein Hox-A7 (HOXA7) T26338 GENENAME HOXA7 T26338 TARGTYPE Literature-reported T26338 SYNONYMS HoxA7; Hox-1A; Hox 1.1; Homeobox protein Hox-1A; Homeobox protein Hox 1.1; HOX1A T26338 FUNCTION Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. T26338 BIOCLASS Antp homeobox T26338 SEQUENCE MSSSYYVNALFSKYTAGASLFQNAEPTSCSFAPNSQRSGYGAGAGAFASTVPGLYNVNSPLYQSPFASGYGLGADAYGNLPCASYDQNIPGLCSDLAKGACDKTDEGALHGAAEANFRIYPWMRSSGPDRKRGRQTYTRYQTLELEKEFHFNRYLTRRRRIEIAHALCLTERQIKIWFQNRRMKWKKEHKDEGPTAAAAPEGAVPSAAATAAADKADEEDDDEEEEDEEE T25675 TARGETID T25675 T25675 FORMERID TTDI00040 T25675 UNIPROID HXA13_HUMAN T25675 TARGNAME Homeobox protein Hox-A13 (HOXA13) T25675 GENENAME HOXA13 T25675 TARGTYPE Literature-reported T25675 SYNONYMS Homeobox protein HoxA13; Homeobox protein Hox1J; HOXA13 T25675 FUNCTION Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. T25675 PDBSTRUC 2L7Z T25675 SEQUENCE MTASVLLHPRWIEPTVMFLYDNGGGLVADELNKNMEGAAAAAAAAAAAAAAGAGGGGFPHPAAAAAGGNFSVAAAAAAAAAAAANQCRNLMAHPAPLAPGAASAYSSAPGEAPPSAAAAAAAAAAAAAAAAAASSSGGPGPAGPAGAEAAKQCSPCSAAAQSSSGPAALPYGYFGSGYYPCARMGPHPNAIKSCAQPASAAAAAAFADKYMDTAGPAAEEFSSRAKEFAFYHQGYAAGPYHHHQPMPGYLDMPVVPGLGGPGESRHEPLGLPMESYQPWALPNGWNGQMYCPKEQAQPPHLWKSTLPDVVSHPSDASSYRRGRKKRVPYTKVQLKELEREYATNKFITKDKRRRISATTNLSERQVTIWFQNRRVKEKKVINKLKTTS T90940 TARGETID T90940 T90940 FORMERID TTDR00399 T90940 UNIPROID OTSB_ECOLI T90940 TARGNAME Bacterial Trehalose-phosphatase (Bact otsB) T90940 GENENAME Bact otsB T90940 TARGTYPE Literature-reported T90940 SYNONYMS otsB; Trehalose-6-phosphate phosphatase; Trehalose 6-phosphate phosphatase; TPP T90940 FUNCTION Removes the phosphate from trehalose 6-phosphate (Tre6P) to produce free trehalose. Also catalyzes the dephosphorylation of glucose-6-phosphate (Glu6P) and 2-deoxyglucose-6-phosphate (2dGlu6P). T90940 BIOCLASS Phosphoric monoester hydrolase T90940 SEQUENCE MTEPLTETPELSAKYAWFFDLDGTLAEIKPHPDQVVVPDNILQGLQLLATASDGALALISGRSMVELDALAKPYRFPLAGVHGAERRDINGKTHIVHLPDAIARDISVQLHTVIAQYPGAELEAKGMAFALHYRQAPQHEDALMTLAQRITQIWPQMALQQGKCVVEIKPRGTSKGEAIAAFMQEAPFIGRTPVFLGDDLTDESGFAVVNRLGGMSVKIGTGATQASWRLAGVPDVWSWLEMITTALQQKRENNRSDDYESFSRSI T16243 TARGETID T16243 T16243 FORMERID TTDI00204 T16243 UNIPROID ARRB2_HUMAN T16243 TARGNAME Beta-arrestin-2 (ARRB2) T16243 GENENAME ARRB2 T16243 TARGTYPE Literature-reported T16243 SYNONYMS Non-visual arrestin-3; Betaarrestin2; Arrestin beta2; Arrestin beta-2; ARR2; ARB2 T16243 FUNCTION During homologous desensitization, beta-arrestins bind to the GPRK-phosphorylated receptor and sterically preclude its coupling to the cognate G-protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adapter protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G-proteins. Two different modes of arrestin-mediated internalization occur. Class A receptors, like ADRB2, OPRM1, ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the plasma membrane and undergo rapid recycling. Class B receptors, like AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptors, for extended periods of time. Receptor resensitization then requires that receptor-bound arrestin is removed so that the receptor can be dephosphorylated and returned to the plasma membrane. Mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21. Involved in internalization of P2RY1, P2RY4, P2RY6 and P2RY11 and ATP-stimulated internalization of P2RY2. Involved in phosphorylation-dependent internalization of OPRD1 and subsequent recycling or degradation. Involved in ubiquitination of IGF1R. Beta-arrestins function as multivalent adapter proteins that can switch the GPCR from a G-protein signaling mode that transmits short-lived signals from the plasma membrane via small molecule second messengers and ion channels to a beta-arrestin signaling mode that transmits a distinct set of signals that are initiated as the receptor internalizes and transits the intracellular compartment. Acts as signaling scaffold for MAPK pathways such as MAPK1/3 (ERK1/2) and MAPK10 (JNK3). ERK1/2 and JNK3 activated by the beta-arrestin scaffold are largely excluded from the nucleus and confined to cytoplasmic locations such as endocytic vesicles, also called beta-arrestin signalosomes. Acts as signaling scaffold for the AKT1 pathway. GPCRs for which the beta-arrestin-mediated signaling relies on both ARRB1 and ARRB2 (codependent regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is inhibited by the other respective beta-arrestin form (reciprocal regulation). Increases ERK1/2 signaling in AGTR1- and AVPR2-mediated activation (reciprocal regulation). Involved in CCR7-mediated ERK1/2 signaling involving ligand CCL19. Is involved in type-1A angiotensin II receptor/AGTR1-mediated ERK activity. Is involved in type-1A angiotensin II receptor/AGTR1-mediated MAPK10 activity. Is involved in dopamine-stimulated AKT1 activity in the striatum by disrupting the association of AKT1 with its negative regulator PP2A. Involved in AGTR1-mediated chemotaxis. Appears to function as signaling scaffold involved in regulation of MIP-1-beta-stimulated CCR5-dependent chemotaxis. Involved in attenuation of NF-kappa-B-dependent transcription in response to GPCR or cytokine stimulation by interacting with and stabilizing CHUK. Suppresses UV-induced NF-kappa-B-dependent activation by interacting with CHUK. The function is promoted by stimulation of ADRB2 and dephosphorylation of ARRB2. Involved in p53/TP53-mediated apoptosis by regulating MDM2 and reducing the MDM2-mediated degradation of p53/TP53. May serve as nuclear messenger for GPCRs. Upon stimulation of OR1D2, may be involved in regulation of gene expression during the early processes of fertilization. Also involved in regulation of receptors other than GPCRs. Involved in endocytosis of TGFBR2 and TGFBR3 and down-regulates TGF-beta signaling such as NF-kappa-B activation. Involved in endocytosis of low-density lipoprotein receptor/LDLR. Involved in endocytosis of smoothened homolog/Smo, which also requires GRK2. Involved in endocytosis of SLC9A5. Involved in endocytosis of ENG and subsequent TGF-beta-mediated ERK activation and migration of epithelial cells. Involved in Toll-like receptor and IL-1 receptor signaling through the interaction with TRAF6 which prevents TRAF6 autoubiquitination and oligomerization required for activation of NF-kappa-B and JUN. Involved in insulin resistance by acting as insulin-induced signaling scaffold for SRC, AKT1 and INSR. Involved in regulation of inhibitory signaling of natural killer cells by recruiting PTPN6 and PTPN11 to KIR2DL1. Involved in IL8-mediated granule release in neutrophils. Involved in the internalization of the atypical chemokine receptor ACKR3. Functions in regulating agonist-mediated G-protein coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes. T16243 BIOCLASS Arrestin protein T16243 SEQUENCE MGEKPGTRVFKKSSPNCKLTVYLGKRDFVDHLDKVDPVDGVVLVDPDYLKDRKVFVTLTCAFRYGREDLDVLGLSFRKDLFIATYQAFPPVPNPPRPPTRLQDRLLRKLGQHAHPFFFTIPQNLPCSVTLQPGPEDTGKACGVDFEIRAFCAKSLEEKSHKRNSVRLVIRKVQFAPEKPGPQPSAETTRHFLMSDRSLHLEASLDKELYYHGEPLNVNVHVTNNSTKTVKKIKVSVRQYADICLFSTAQYKCPVAQLEQDDQVSPSSTFCKVYTITPLLSDNREKRGLALDGKLKHEDTNLASSTIVKEGANKEVLGILVSYRVKVKLVVSRGGDVSVELPFVLMHPKPHDHIPLPRPQSAAPETDVPVDTNLIEFDTNYATDDDIVFEDFARLRLKGMKDDDYDDQLC T07775 TARGETID T07775 T07775 FORMERID TTDI02421 T07775 UNIPROID NAC1_HUMAN T07775 TARGNAME Sodium calcium exchanger 1 (SLC8A1) T07775 GENENAME SLC8A1 T07775 TARGTYPE Literature-reported T07775 SYNONYMS Solute carrier family 8 member 1; Sodium/calcium exchanger 1; Na(+)/Ca(2+)-exchange protein 1; NCX1; CNC T07775 FUNCTION Contributes to Ca(2+) transport during excitation-contraction coupling in muscle. In a first phase, voltage-gated channels mediate the rapid increase of cytoplasmic Ca(2+) levels due to release of Ca(2+) stores from the endoplasmic reticulum. SLC8A1 mediates the export of Ca(2+) from the cell during the next phase, so that cytoplasmic Ca(2+) levels rapidly return to baseline. Required for normal embryonic heart development and the onset of heart contractions. Mediates the exchange of one Ca(2+) ion against three to four Na(+) ions across the cell membrane, and thereby contributes to the regulation of cytoplasmic Ca(2+) levels and Ca(2+)-dependent cellular processes. T07775 BIOCLASS Calcium:cation antiporter T07775 SEQUENCE MYNMRRLSLSPTFSMGFHLLVTVSLLFSHVDHVIAETEMEGEGNETGECTGSYYCKKGVILPIWEPQDPSFGDKIARATVYFVAMVYMFLGVSIIADRFMSSIEVITSQEKEITIKKPNGETTKTTVRIWNETVSNLTLMALGSSAPEILLSVIEVCGHNFTAGDLGPSTIVGSAAFNMFIIIALCVYVVPDGETRKIKHLRVFFVTAAWSIFAYTWLYIILSVISPGVVEVWEGLLTFFFFPICVVFAWVADRRLLFYKYVYKRYRAGKQRGMIIEHEGDRPSSKTEIEMDGKVVNSHVENFLDGALVLEVDERDQDDEEARREMARILKELKQKHPDKEIEQLIELANYQVLSQQQKSRAFYRIQATRLMTGAGNILKRHAADQARKAVSMHEVNTEVTENDPVSKIFFEQGTYQCLENCGTVALTIIRRGGDLTNTVFVDFRTEDGTANAGSDYEFTEGTVVFKPGDTQKEIRVGIIDDDIFEEDENFLVHLSNVKVSSEASEDGILEANHVSTLACLGSPSTATVTIFDDDHAGIFTFEEPVTHVSESIGIMEVKVLRTSGARGNVIVPYKTIEGTARGGGEDFEDTCGELEFQNDEIVKTISVKVIDDEEYEKNKTFFLEIGEPRLVEMSEKKALLLNELGGFTITGKYLFGQPVFRKVHAREHPILSTVITIADEYDDKQPLTSKEEEERRIAEMGRPILGEHTKLEVIIEESYEFKSTVDKLIKKTNLALVVGTNSWREQFIEAITVSAGEDDDDDECGEEKLPSCFDYVMHFLTVFWKVLFAFVPPTEYWNGWACFIVSILMIGLLTAFIGDLASHFGCTIGLKDSVTAVVFVALGTSVPDTFASKVAATQDQYADASIGNVTGSNAVNVFLGIGVAWSIAAIYHAANGEQFKVSPGTLAFSVTLFTIFAFINVGVLLYRRRPEIGGELGGPRTAKLLTSCLFVLLWLLYIFFSSLEAYCHIKGF T68009 TARGETID T68009 T68009 FORMERID TTDR00830 T68009 UNIPROID CADH5_HUMAN T68009 TARGNAME Vascular endothelial cadherin (CDH5) T68009 GENENAME CDH5 T68009 TARGTYPE Literature-reported T68009 SYNONYMS VE-cadherin; VE-cad; Cadherin-5; CD144 antigen; CD144; 7B4 antigen T68009 FUNCTION Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction. T68009 BIOCLASS Cadherin protein T68009 SEQUENCE MQRLMMLLATSGACLGLLAVAAVAAAGANPAQRDTHSLLPTHRRQKRDWIWNQMHIDEEKNTSLPHHVGKIKSSVSRKNAKYLLKGEYVGKVFRVDAETGDVFAIERLDRENISEYHLTAVIVDKDTGENLETPSSFTIKVHDVNDNWPVFTHRLFNASVPESSAVGTSVISVTAVDADDPTVGDHASVMYQILKGKEYFAIDNSGRIITITKSLDREKQARYEIVVEARDAQGLRGDSGTATVLVTLQDINDNFPFFTQTKYTFVVPEDTRVGTSVGSLFVEDPDEPQNRMTKYSILRGDYQDAFTIETNPAHNEGIIKPMKPLDYEYIQQYSFIVEATDPTIDLRYMSPPAGNRAQVIINITDVDEPPIFQQPFYHFQLKENQKKPLIGTVLAMDPDAARHSIGYSIRRTSDKGQFFRVTKKGDIYNEKELDREVYPWYNLTVEAKELDSTGTPTGKESIVQVHIEVLDENDNAPEFAKPYQPKVCENAVHGQLVLQISAIDKDITPRNVKFKFILNTENNFTLTDNHDNTANITVKYGQFDREHTKVHFLPVVISDNGMPSRTGTSTLTVAVCKCNEQGEFTFCEDMAAQVGVSIQAVVAILLCILTITVITLLIFLRRRLRKQARAHGKSVPEIHEQLVTYDEEGGGEMDTTSYDVSVLNSVRRGGAKPPRPALDARPSLYAQVQKPPRHAPGAHGGPGEMAAMIEVKKDEADHDGDGPPYDTLHIYGYEGSESIAESLSSLGTDSSDSDVDYDFLNDWGPRFKMLAELYGSDPREELLY T18796 TARGETID T18796 T18796 FORMERID TTDI03137 T18796 UNIPROID CXA4_HUMAN T18796 TARGNAME Gap junction alpha-4 protein (Cx37) T18796 GENENAME GJA4 T18796 TARGTYPE Literature-reported T18796 SYNONYMS Connexin-37 T18796 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T18796 BIOCLASS Gap junction-forming connexin T18796 SEQUENCE MGDWGFLEKLLDQVQEHSTVVGKIWLTVLFIFRILILGLAGESVWGDEQSDFECNTAQPGCTNVCYDQAFPISHIRYWVLQFLFVSTPTLVYLGHVIYLSRREERLRQKEGELRALPAKDPQVERALAAVERQMAKISVAEDGRLRIRGALMGTYVASVLCKSVLEAGFLYGQWRLYGWTMEPVFVCQRAPCPYLVDCFVSRPTEKTIFIIFMLVVGLISLVLNLLELVHLLCRCLSRGMRARQGQDAPPTQGTSSDPYTDQVFFYLPVGQGPSSPPCPTYNGLSSSEQNWANLTTEERLASSRPPLFLDPPPQNGQKPPSRPSSSASKKQYV T18796 DRUGINFO D00VJY octanol Investigative T96396 TARGETID T96396 T96396 FORMERID TTDI02601 T96396 UNIPROID PHB_HUMAN T96396 TARGNAME Prohibitin (PHB) T96396 GENENAME PHB T96396 TARGTYPE Literature-reported T96396 SYNONYMS PHB1; HEL-S-54e; HEL-215 T96396 FUNCTION It has a role in regulating proliferation. As yet it is unclear if the protein or the mRNA exhibits this effect. May play a role in regulating mitochondrial respiration activity and in aging. Prohibitin inhibits DNA synthesis. T96396 PDBSTRUC 1LU7 T96396 SEQUENCE MAAKVFESIGKFGLALAVAGGVVNSALYNVDAGHRAVIFDRFRGVQDIVVGEGTHFLIPWVQKPIIFDCRSRPRNVPVITGSKDLQNVNITLRILFRPVASQLPRIFTSIGEDYDERVLPSITTEILKSVVARFDAGELITQRELVSRQVSDDLTERAATFGLILDDVSLTHLTFGKEFTEAVEAKQVAQQEAERARFVVEKAEQQKKAAIISAEGDSKAAELIANSLATAGDGLIELRKLEAAEDIAYQLSRSRNITYLPAGQSVLLQLPQ T95742 TARGETID T95742 T95742 FORMERID TTDR00725 T95742 UNIPROID MERL_HUMAN T95742 TARGNAME Neurofibromin-2 (NF2) T95742 GENENAME NF2 T95742 TARGTYPE Literature-reported T95742 SYNONYMS Schwannomin; Schwannomerlin; SCH; Moesin-ezrin-radixin-like protein; Merlin T95742 FUNCTION Probable regulator of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway, a signaling pathway that plays a pivotal role in tumor suppression by restricting proliferation and promoting apoptosis. Along with WWC1 can synergistically induce the phosphorylation of LATS1 and LATS2 and can probably function in the regulation of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway. May act as a membrane stabilizing protein. May inhibit PI3 kinase by binding to AGAP2 and impairing its stimulating activity. Suppresses cell proliferation and tumorigenesis by inhibiting the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex. T95742 PDBSTRUC 6CDS; 4ZRJ; 4ZRI; 3U8Z; 1H4R T95742 SEQUENCE MAGAIASRMSFSSLKRKQPKTFTVRIVTMDAEMEFNCEMKWKGKDLFDLVCRTLGLRETWFFGLQYTIKDTVAWLKMDKKVLDHDVSKEEPVTFHFLAKFYPENAEEELVQEITQHLFFLQVKKQILDEKIYCPPEASVLLASYAVQAKYGDYDPSVHKRGFLAQEELLPKRVINLYQMTPEMWEERITAWYAEHRGRARDEAEMEYLKIAQDLEMYGVNYFAIRNKKGTELLLGVDALGLHIYDPENRLTPKISFPWNEIRNISYSDKEFTIKPLDKKIDVFKFNSSKLRVNKLILQLCIGNHDLFMRRRKADSLEVQQMKAQAREEKARKQMERQRLAREKQMREEAERTRDELERRLLQMKEEATMANEALMRSEETADLLAEKAQITEEEAKLLAQKAAEAEQEMQRIKATAIRTEEEKRLMEQKVLEAEVLALKMAEESERRAKEADQLKQDLQEAREAERRAKQKLLEIATKPTYPPMNPIPAPLPPDIPSFNLIGDSLSFDFKDTDMKRLSMEIEKEKVEYMEKSKHLQEQLNELKTEIEALKLKERETALDILHNENSDRGGSSKHNTIKKLTLQSAKSRVAFFEEL T35862 TARGETID T35862 T35862 FORMERID TTDI00104 T35862 UNIPROID SFTPD_HUMAN T35862 TARGNAME Lung surfactant protein D (SFTPD) T35862 GENENAME SFTPD T35862 TARGTYPE Literature-reported T35862 SYNONYMS SP-D; SFTP4; Pulmonary surfactant-associated protein D; PSPD; PSP-D; Collectin-7; COLEC7 T35862 FUNCTION Contributes to the lung's defense against inhaled microorganisms, organic antigens and toxins. Interacts with compounds such as bacterial lipopolysaccharides, oligosaccharides and fatty acids and modulates leukocyte action in immune response. May participate in the extracellular reorganization or turnover of pulmonary surfactant. Binds strongly maltose residues and to a lesser extent other alpha-glucosyl moieties. T35862 PDBSTRUC 5OXS; 5OXR; 4M18; 4M17; 4.00E+52 T35862 SEQUENCE MLLFLLSALVLLTQPLGYLEAEMKTYSHRTMPSACTLVMCSSVESGLPGRDGRDGREGPRGEKGDPGLPGAAGQAGMPGQAGPVGPKGDNGSVGEPGPKGDTGPSGPPGPPGVPGPAGREGPLGKQGNIGPQGKPGPKGEAGPKGEVGAPGMQGSAGARGLAGPKGERGVPGERGVPGNTGAAGSAGAMGPQGSPGARGPPGLKGDKGIPGDKGAKGESGLPDVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEAQLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDSKTEGKFTYPTGESLVYSNWAPGEPNDDGGSEDCVEIFTNGKWNDRACGEKRLVVCEF T57174 TARGETID T57174 T57174 FORMERID TTDI03050 T57174 UNIPROID ARBK2_HUMAN T57174 TARGNAME Beta-adrenergic receptor kinase 2 (ADRBK2) T57174 GENENAME GRK3 T57174 TARGTYPE Literature-reported T57174 SYNONYMS G-protein-coupled receptor kinase 3; Beta-ARK-2; BARK2; ADRBK2 T57174 FUNCTION Specifically phosphorylates the agonist-occupied form of the beta-adrenergic and closely related receptors. T57174 ECNUMBER EC 2.7.11.15 T57174 SEQUENCE MADLEAVLADVSYLMAMEKSKATPAARASKRIVLPEPSIRSVMQKYLAERNEITFDKIFNQKIGFLLFKDFCLNEINEAVPQVKFYEEIKEYEKLDNEEDRLCRSRQIYDAYIMKELLSCSHPFSKQAVEHVQSHLSKKQVTSTLFQPYIEEICESLRGDIFQKFMESDKFTRFCQWKNVELNIHLTMNEFSVHRIIGRGGFGEVYGCRKADTGKMYAMKCLDKKRIKMKQGETLALNERIMLSLVSTGDCPFIVCMTYAFHTPDKLCFILDLMNGGDLHYHLSQHGVFSEKEMRFYATEIILGLEHMHNRFVVYRDLKPANILLDEHGHARISDLGLACDFSKKKPHASVGTHGYMAPEVLQKGTAYDSSADWFSLGCMLFKLLRGHSPFRQHKTKDKHEIDRMTLTVNVELPDTFSPELKSLLEGLLQRDVSKRLGCHGGGSQEVKEHSFFKGVDWQHVYLQKYPPPLIPPRGEVNAADAFDIGSFDEEDTKGIKLLDCDQELYKNFPLVISERWQQEVTETVYEAVNADTDKIEARKRAKNKQLGHEEDYALGKDCIMHGYMLKLGNPFLTQWQRRYFYLFPNRLEWRGEGESRQNLLTMEQILSVEETQIKDKKCILFRIKGGKQFVLQCESDPEFVQWKKELNETFKEAQRLLRRAPKFLNKPRSGTVELPKPSLCHRNSNGL T57174 DRUGINFO D0U8UK PMID21596927C101 Investigative T28758 TARGETID T28758 T28758 FORMERID TTDI00165 T28758 UNIPROID DEK_HUMAN T28758 TARGNAME DEK protein (DEK) T28758 GENENAME DEK T28758 TARGTYPE Literature-reported T28758 SYNONYMS Protein DEK T28758 FUNCTION Involved in chromatin organization. T28758 PDBSTRUC 2JX3; 1Q1V T28758 SEQUENCE MSASAPAAEGEGTPTQPASEKEPEMPGPREESEEEEDEDDEEEEEEEKEKSLIVEGKREKKKVERLTMQVSSLQREPFTIAQGKGQKLCEIERIHFFLSKKKTDELRNLHKLLYNRPGTVSSLKKNVGQFSGFPFEKGSVQYKKKEEMLKKFRNAMLKSICEVLDLERSGVNSELVKRILNFLMHPKPSGKPLPKSKKTCSKGSKKERNSSGMARKAKRTKCPEILSDESSSDEDEKKNKEESSDDEDKESEEEPPKKTAKREKPKQKATSKSKKSVKSANVKKADSSTTKKNQNSSKKESESEDSSDDEPLIKKLKKPPTDEELKETIKKLLASANLEEVTMKQICKKVYENYPTYDLTERKDFIKTTVKELIS T72405 TARGETID T72405 T72405 UNIPROID GLRX1_HUMAN T72405 TARGNAME Glutaredoxin-1 (GLRX) T72405 GENENAME GLRX T72405 TARGTYPE Literature-reported T72405 SYNONYMS Thioltransferase-1; TTase-1; GRX T72405 FUNCTION Has a glutathione-disulfide oxidoreductase activity in the presence of NADPH and glutathione reductase. Reduces low molecular weight disulfides and proteins. T72405 PDBSTRUC 4RQR; 1JHB; 1B4Q T72405 SEQUENCE MAQEFVNCKIQPGKVVVFIKPTCPYCRRAQEILSQLPIKQGLLEFVDITATNHTNEIQDYLQQLTGARTVPRVFIGKDCIGGCSDLVSLQQSGELLTRLKQIGALQ T47988 TARGETID T47988 T47988 FORMERID TTDI03138 T47988 UNIPROID CXA5_HUMAN T47988 TARGNAME Gap junction alpha-5 protein (Cx40) T47988 GENENAME GJA5 T47988 TARGTYPE Literature-reported T47988 SYNONYMS Connexin-40 T47988 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T47988 BIOCLASS Gap junction-forming connexin T47988 SEQUENCE MGDWSFLGNFLEEVHKHSTVVGKVWLTVLFIFRMLVLGTAAESSWGDEQADFRCDTIQPGCQNVCYDQAFPISHIRYWVLQIIFVSTPSLVYMGHAMHTVRMQEKRKLREAERAKEVRGSGSYEYPVAEKAELSCWEEGNGRIALQGTLLNTYVCSILIRTTMEVGFIVGQYFIYGIFLTTLHVCRRSPCPHPVNCYVSRPTEKNVFIVFMLAVAALSLLLSLAELYHLGWKKIRQRFVKPRQHMAKCQLSGPSVGIVQSCTPPPDFNQCLENGPGGKFFNPFSNNMASQQNTDNLVTEQVRGQEQTPGEGFIQVRYGQKPEVPNGVSPGHRLPHGYHSDKRRLSKASSKARSDDLSV T47988 DRUGINFO D00VJY octanol Investigative T29652 TARGETID T29652 T29652 FORMERID TTDR00555 T29652 UNIPROID SURE_ECOLI T29652 TARGNAME Bacterial Acid phosphatase surE (Bact surE) T29652 GENENAME Bact surE T29652 TARGTYPE Literature-reported T29652 SYNONYMS Stationary-phase survival protein surE; Phosphomonoesterase; Glycerophosphatase; Acid Phosphomonoesterase; Acid Phosphatase T29652 FUNCTION This protein is essential for the survival of e.coli in stationary phase and for survival of heat and osmotic stresses. T29652 BIOCLASS Phosphoric monoester hydrolase T29652 SEQUENCE MRILLSNDDGVHAPGIQTLAKALREFADVQVVAPDRNRSGASNSLTLESSLRTFTFENGDIAVQMGTPTDCVYLGVNALMRPRPDIVVSGINAGPNLGDDVIYSGTVAAAMEGRHLGFPALAVSLDGHKHYDTAAAVTCSILRALCKEPLRTGRILNINVPDLPLDQIKGIRVTRCGTRHPADQVIPQQDPRGNTLYWIGPPGGKCDAGPGTDFAAVDEGYVSITPLHVDLTAHSAQDVVSDWLNSVGVGTQW T47236 TARGETID T47236 T47236 FORMERID TTDR00852 T47236 UNIPROID SRBP1_HUMAN T47236 TARGNAME Sterol regulatory element binding protein-1 (SREBF1) T47236 GENENAME SREBF1 T47236 TARGTYPE Literature-reported T47236 SYNONYMS bHLHd1; Sterol regulatory element-binding transcription factor 1; Sterol regulatory element-binding protein 1; SREBP1; SREBP-1; SREBP 1; Class D basic helix-loop-helix protein 1 T47236 FUNCTION Regulates transcription of the LDL receptor gene as well as the fatty acid and to a lesser degree the cholesterol synthesis pathway. Binds to the sterol regulatory element 1 (SRE-1) (5'-ATCACCCCAC-3'). Has dual sequence specificity binding to both an E-box motif (5'-ATCACGTGA-3') and to SRE-1 (5'-ATCACCCCAC-3'). Transcriptional activator required for lipid homeostasis. T47236 PDBSTRUC 1AM9 T47236 SEQUENCE MDEPPFSEAALEQALGEPCDLDAALLTDIEDMLQLINNQDSDFPGLFDPPYAGSGAGGTDPASPDTSSPGSLSPPPATLSSSLEAFLSGPQAAPSPLSPPQPAPTPLKMYPSMPAFSPGPGIKEESVPLSILQTPTPQPLPGALLPQSFPAPAPPQFSSTPVLGYPSPPGGFSTGSPPGNTQQPLPGLPLASPPGVPPVSLHTQVQSVVPQQLLTVTAAPTAAPVTTTVTSQIQQVPVLLQPHFIKADSLLLTAMKTDGATVKAAGLSPLVSGTTVQTGPLPTLVSGGTILATVPLVVDAEKLPINRLAAGSKAPASAQSRGEKRTAHNAIEKRYRSSINDKIIELKDLVVGTEAKLNKSAVLRKAIDYIRFLQHSNQKLKQENLSLRTAVHKSKSLKDLVSACGSGGNTDVLMEGVKTEVEDTLTPPPSDAGSPFQSSPLSLGSRGSGSGGSGSDSEPDSPVFEDSKAKPEQRPSLHSRGMLDRSRLALCTLVFLCLSCNPLASLLGARGLPSPSDTTSVYHSPGRNVLGTESRDGPGWAQWLLPPVVWLLNGLLVLVSLVLLFVYGEPVTRPHSGPAVYFWRHRKQADLDLARGDFAQAAQQLWLALRALGRPLPTSHLDLACSLLWNLIRHLLQRLWVGRWLAGRAGGLQQDCALRVDASASARDAALVYHKLHQLHTMGKHTGGHLTATNLALSALNLAECAGDAVSVATLAEIYVAAALRVKTSLPRALHFLTRFFLSSARQACLAQSGSVPPAMQWLCHPVGHRFFVDGDWSVLSTPWESLYSLAGNPVDPLAQVTQLFREHLLERALNCVTQPNPSPGSADGDKEFSDALGYLQLLNSCSDAAGAPAYSFSISSSMATTTGVDPVAKWWASLTAVVIHWLRRDEEAAERLCPLVEHLPRVLQESERPLPRAALHSFKAARALLGCAKAESGPASLTICEKASGYLQDSLATTPASSSIDKAVQLFLCDLLLVVRTSLWRQQQPPAPAPAAQGTSSRPQASALELRGFQRDLSSLRRLAQSFRPAMRRVFLHEATARLMAGASPTRTHQLLDRSLRRRAGPGGKGGAVAELEPRPTRREHAEALLLASCYLPPGFLSAPGQRVGMLAEAARTLEKLGDRRLLHDCQQMLMRLGGGTTVTSS T17122 TARGETID T17122 T17122 FORMERID TTDI02450 T17122 UNIPROID ITAE_HUMAN T17122 TARGNAME Integrin alpha-E (ITGAE) T17122 GENENAME ITGAE T17122 TARGTYPE Literature-reported T17122 SYNONYMS Mucosal lymphocyte 1 antigen; Integrin alphaIEL; Integrin alphaE heavy chain; Integrin alpha-IEL; HML1 antigen; HML-1 antigen; CD103 T17122 FUNCTION It mediates adhesion of intra-epithelial T-lymphocytes to epithelial cell monolayers. Integrin alpha-E/beta-7 is a receptor for E-cadherin. T17122 BIOCLASS Integrin T17122 SEQUENCE MWLFHTLLCIASLALLAAFNVDVARPWLTPKGGAPFVLSSLLHQDPSTNQTWLLVTSPRTKRTPGPLHRCSLVQDEILCHPVEHVPIPKGRHRGVTVVRSHHGVLICIQVLVRRPHSLSSELTGTCSLLGPDLRPQAQANFFDLENLLDPDARVDTGDCYSNKEGGGEDDVNTARQRRALEKEEEEDKEEEEDEEEEEAGTEIAIILDGSGSIDPPDFQRAKDFISNMMRNFYEKCFECNFALVQYGGVIQTEFDLRDSQDVMASLARVQNITQVGSVTKTASAMQHVLDSIFTSSHGSRRKASKVMVVLTDGGIFEDPLNLTTVINSPKMQGVERFAIGVGEEFKSARTARELNLIASDPDETHAFKVTNYMALDGLLSKLRYNIISMEGTVGDALHYQLAQIGFSAQILDERQVLLGAVGAFDWSGGALLYDTRSRRGRFLNQTAAAAADAEAAQYSYLGYAVAVLHKTCSLSYIAGAPRYKHHGAVFELQKEGREASFLPVLEGEQMGSYFGSELCPVDIDMDGSTDFLLVAAPFYHVHGEEGRVYVYRLSEQDGSFSLARILSGHPGFTNARFGFAMAAMGDLSQDKLTDVAIGAPLEGFGADDGASFGSVYIYNGHWDGLSASPSQRIRASTVAPGLQYFGMSMAGGFDISGDGLADITVGTLGQAVVFRSRPVVRLKVSMAFTPSALPIGFNGVVNVRLCFEISSVTTASESGLREALLNFTLDVDVGKQRRRLQCSDVRSCLGCLREWSSGSQLCEDLLLMPTEGELCEEDCFSNASVKVSYQLQTPEGQTDHPQPILDRYTEPFAIFQLPYEKACKNKLFCVAELQLATTVSQQELVVGLTKELTLNINLTNSGEDSYMTSMALNYPRNLQLKRMQKPPSPNIQCDDPQPVASVLIMNCRIGHPVLKRSSAHVSVVWQLEENAFPNRTADITVTVTNSNERRSLANETHTLQFRHGFVAVLSKPSIMYVNTGQGLSHHKEFLFHVHGENLFGAEYQLQICVPTKLRGLQVVAVKKLTRTQASTVCTWSQERACAYSSVQHVEEWHSVSCVIASDKENVTVAAEISWDHSEELLKDVTELQILGEISFNKSLYEGLNAENHRTKITVVFLKDEKYHSLPIIIKGSVGGLLVLIVILVILFKCGFFKRKYQQLNLESIRKAQLKSENLLEEEN T39855 TARGETID T39855 T39855 FORMERID TTDR00667 T39855 UNIPROID CDN1A_HUMAN T39855 TARGNAME Melanoma differentiation-associated protein 6 (CDKN1A) T39855 GENENAME CDKN1A T39855 TARGTYPE Literature-reported T39855 SYNONYMS WAF1; SDI1; PIC1; P21(WAF1); P21; Melanoma differentiation associated protein 6; MDA6; MDA-6; Cyclin-dependent kinase inhibitor 1; CIP1; CDK-interacting protein 1; CAP20 T39855 FUNCTION Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding. May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. T39855 PDBSTRUC 6CIX; 6CIV; 6CEJ; 6CBI; 5E0U T39855 SEQUENCE MSEPAGDVRQNPCGSKACRRLFGPVDSEQLSRDCDALMAGCIQEARERWNFDFVTETPLEGDFAWERVRGLGLPKLYLPTGPRRGRDELGGGRRPGTSPALLQGTAEEDHVDLSLSCTLVPRSGEQAEGSPGGPGDSQGRKRRQTSMTDFYHSKRRLIFSKRKP T81179 TARGETID T81179 T81179 FORMERID TTDR00870 T81179 UNIPROID GMT1_YEAST T81179 TARGNAME Fungal GDP-mannose transporter (Fung VRG4) T81179 GENENAME Fung VRG4 T81179 TARGTYPE Literature-reported T81179 SYNONYMS VRG4 gene; VRG4; Golgi GDP-mannose transporter T81179 FUNCTION Involved in the import of GDP-mannose from the cytoplasminto the Golgi lumen. Defective copy causes severe glycosylation defect and abnormal retention of soluble endoplasmic reticulum proteins. Involved in vanadate sensitivity. T81179 PDBSTRUC 5OGK; 5OGE T81179 SEQUENCE MSELKTGHAGHNPWASVANSGPISILSYCGSSILMTVTNKFVVNLKDFNMNFVMLFVQSLVCTITLIILRILGYAKFRSLNKTDAKNWFPISFLLVLMIYTSSKALQYLAVPIYTIFKNLTIILIAYGEVLFFGGSVTSMELSSFLLMVLSSVVATWGDQQAVAAKAASLAEGAAGAVASFNPGYFWMFTNCITSALFVLIMRKRIKLTNFKDFDTMFYNNVLALPILLLFSFCVEDWSSVNLTNNFSNDSLTAMIISGVASVGISYCSGWCVRVTSSTTYSMVGALNKLPIALSGLIFFDAPRNFLSILSIFIGFLSGIIYAVAKQKKQQAQPLRK T75918 TARGETID T75918 T75918 FORMERID TTDR00976 T75918 UNIPROID KAPB_SCHPO T75918 TARGNAME Fungal cAMP-dependent protein kinase (Fung pka1) T75918 GENENAME Fung pka1 T75918 TARGTYPE Literature-reported T75918 SYNONYMS cAMP-dependent protein kinase catalytic subunit T75918 FUNCTION Has cAMP-dependent protein kinase and protein serine/threonine kinase activity. T75918 BIOCLASS Kinase T75918 SEQUENCE MDTTAVASKGSTNVGSSTDTLSTSASLHPSMNAGSVNEYSEQQRHGTNSFNGKPSVHDSVGSDASVSNGHNNHNESSLWTSGIPKALEEATKSKKPDSLVSTSTSGCASAHSVGYQNIDNLIPSPLPESASRSSSQSSHQRHSRDGRGELGSEHGERRSAMDGLRDRHIRKVRVSQLLDLQRRRIRPADHTTKDRYGIQDFNFLQTLGTGSFGRVHLVQSNHNRLYYAIKVLEKKKIVDMKQIEHTCDERYILSRVQHPFITILWGTFQDAKNLFMVMDFAEGGELFSLLRKCHRFPEKVAKFYAAEVILALDYLHHNQIVYRDLKPENLLLDRFGHLKIVDFGFAKRVSTSNCCTLCGTPDYLAPEIISLKPYNKAADWWSLGILIFEMLAGYPPFYSENPMKLYENILEGKVNYPSYFSPASIDLLSHLLQRDITCRYGNLKDGSMDIIMHPWFRDISWDKILTRKIEVPYVPPIQAGMGDSSQFDAYADVATDYGTSEDPEFTSIFKDF T35799 TARGETID T35799 T35799 FORMERID TTDI02598 T35799 UNIPROID MLH1_HUMAN T35799 TARGNAME DNA mismatch repair protein Mlh1 (MLH1) T35799 GENENAME MLH1 T35799 TARGTYPE Literature-reported T35799 SYNONYMS MutL protein homolog 1; COCA2 T35799 FUNCTION DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis. Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). T35799 PDBSTRUC 5U5P; 4P7A; 3RBN T35799 SEQUENCE MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVKEGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRGEALASISHVAHVTITTKTADGKCAYRASYSDGKLKAPPKPCAGNQGTQITVEDLFYNIATRRKALKNPSEEYGKILEVVGRYSVHNAGISFSVKKQGETVADVRTLPNASTVDNIRSIFGNAVSRELIEIGCEDKTLAFKMNGYISNANYSVKKCIFLLFINHRLVESTSLRKAIETVYAAYLPKNTHPFLYLSLEISPQNVDVNVHPTKHEVHFLHEESILERVQQHIESKLLGSNSSRMYFTQTLLPGLAGPSGEMVKSTTSLTSSSTSGSSDKVYAHQMVRTDSREQKLDAFLQPLSKPLSSQPQAIVTEDKTDISSGRARQQDEEMLELPAPAEVAAKNQSLEGDTTKGTSEMSEKRGPTSSNPRKRHREDSDVEMVEDDSRKEMTAACTPRRRIINLTSVLSLQEEINEQGHEVLREMLHNHSFVGCVNPQWALAQHQTKLYLLNTTKLSEELFYQILIYDFANFGVLRLSEPAPLFDLAMLALDSPESGWTEEDGPKEGLAEYIVEFLKKKAEMLADYFSLEIDEEGNLIGLPLLIDNYVPPLEGLPIFILRLATEVNWDEEKECFESLSKECAMFYSIRKQYISEESTLSGQQSEVPGSIPNSWKWTVEHIVYKALRSHILPPKHFTEDGNILQLANLPDLYKVFERC T46208 TARGETID T46208 T46208 UNIPROID PMEL_HUMAN T46208 TARGNAME Gp100[209-217] peptide (PMEL) T46208 GENENAME PMEL T46208 TARGTYPE Literature-reported T46208 SYNONYMS Silver locus protein homolog (209-217); SILV (209-217); Premelanosome protein (209-217); PMEL17 (209-217); P100 (209-217); P1 (209-217); Melanomaassociated ME20 antigen (209-217); Melanoma-associated ME20 antigen (209-217); Melanocyte protein Pmel 17 (209-217); Melanocyte protein PMEL (209-217); Mbeta (209-217); ME20S (209-217); ME20M (209-217); ME20-M (209-217); D12S53E (209-217) T46208 FUNCTION Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. Plays a central role in the biogenesis of melanosomes. T46208 PDBSTRUC 5EU6; 5EU5; 5EU4; 5EU3; 4IS6 T46208 SEQUENCE MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAMLGTHTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQPLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAIPLTSCGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVLYRYGSFSVTLDIVQGIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQLVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIMPGQEAGLGQVPLIVGILLVLMAVVLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPRIFCSCPIGENSPLLSGQQV T46208 DRUGINFO D0YU0L GPA-TriMAR-T cells Phase 1 T79485 TARGETID T79485 T79485 FORMERID TTDR00468 T79485 UNIPROID LEP_HUMAN T79485 TARGNAME Leptin (LEP) T79485 GENENAME LEP T79485 TARGTYPE Literature-reported T79485 SYNONYMS Obesity factor; Obese protein; LEP T79485 FUNCTION May function as part of a signaling pathway that acts to regulate the size of the body fat depot. An increase in the level of LEP may act directly or indirectly on the CNS to inhibit food intake and/or regulate energy expenditure as part of a homeostatic mechanism to maintain constancy of the adipose mass. T79485 PDBSTRUC 1AX8 T79485 SEQUENCE MHWGTLCGFLWLWPYLFYVQAVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPGC T43548 TARGETID T43548 T43548 FORMERID TTDI01407 T43548 UNIPROID BCL6_HUMAN T43548 TARGNAME B-cell lymphoma 6 protein (BCL-6) T43548 GENENAME BCL6 T43548 TARGTYPE Literature-reported T43548 SYNONYMS Zinc finger protein 51; Zinc finger and BTB domain-containing protein 27; ZNF51; ZBTB27; Protein LAZ-3; LAZ3; BCL5; BCL-6; BCL-5; B-cell lymphoma 5 protein T43548 FUNCTION Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4(+) T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation. T43548 PDBSTRUC 6EW8; 6EW7; 6EW6; 6CQ1; 6C3N T43548 SEQUENCE MASPADSCIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKCNLSVINLDPEINPEGFCILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTCRKFIKASEAEMVSAIKPPREEFLNSRMLMPQDIMAYRGREVVENNLPLRSAPGCESRAFAPSLYSGLSTPPASYSMYSHLPVSSLLFSDEEFRDVRMPVANPFPKERALPCDSARPVPGEYSRPTLEVSPNVCHSNIYSPKETIPEEARSDMHYSVAEGLKPAAPSARNAPYFPCDKASKEEERPSSEDEIALHFEPPNAPLNRKGLVSPQSPQKSDCQPNSPTESCSSKNACILQASGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAELGRLSPRAYTAPPACQPPMEPENLDLQSPTKLSASGEDSTIPQASRLNNIVNRSMTGSPRSSSESHSPLYMHPPKCTSCGSQSPQHAEMCLHTAGPTFPEEMGETQSEYSDSSCENGAFFCNECDCRFSEEASLKRHTLQTHSDKPYKCDRCQASFRYKGNLASHKTVHTGEKPYRCNICGAQFNRPANLKTHTRIHSGEKPYKCETCGARFVQVAHLRAHVLIHTGEKPYPCEICGTRFRHLQTLKSHLRIHTGEKPYHCEKCNLHFRHKSQLRLHLRQKHGAITNTKVQYRVSATDLPPELPKAC T38325 TARGETID T38325 T38325 FORMERID TTDNR00742 T38325 UNIPROID RGS2_HUMAN T38325 TARGNAME G0/G1 switch regulatory protein 8 (RGS2) T38325 GENENAME RGS2 T38325 TARGTYPE Literature-reported T38325 SYNONYMS Regulator of G-protein signaling 2; GIG31; G0S8; Cell growth-inhibiting gene 31 protein T38325 FUNCTION Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. It is involved in the negative regulation of the angiotensin-activated signaling pathway. Plays a role in the regulation of blood pressure in response to signaling via G protein-coupled receptors and GNAQ. Plays a role in regulating the constriction and relaxation of vascular smooth muscle. Binds EIF2B5 and blocks its activity, thereby inhibiting the translation of mRNA into protein. Regulates G protein-coupled receptor signaling cascades. T38325 PDBSTRUC 4EKD; 4EKC; 2V4Z; 2AF0 T38325 SEQUENCE MQSAMFLAVQHDCRPMDKSAGSGHKSEEKREKMKRTLLKDWKTRLSYFLQNSSTPGKPKTGKKSKQQAFIKPSPEEAQLWSEAFDELLASKYGLAAFRAFLKSEFCEENIEFWLACEDFKKTKSPQKLSSKARKIYTDFIEKEAPKEINIDFQTKTLIAQNIQEATSGCFTTAQKRVYSLMENNSYPRFLESEFYQDLCKKPQITTEPHAT T78332 TARGETID T78332 T78332 FORMERID TTDI02073 T78332 UNIPROID FOLR3_HUMAN T78332 TARGNAME Folate receptor gamma (FOLR3) T78332 GENENAME FOLR3 T78332 TARGTYPE Literature-reported T78332 SYNONYMS Folate receptor 3; FRgamma; FOLR3 T78332 FUNCTION Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells. Isoform Short does not bind folate. T78332 BIOCLASS Folate receptor T78332 SEQUENCE MDMAWQMMQLLLLALVTAAGSAQPRSARARTDLLNVCMNAKHHKTQPSPEDELYGQCSPWKKNACCTASTSQELHKDTSRLYNFNWDHCGKMEPTCKRHFIQDSCLYECSPNLGPWIRQVNQSWRKERILNVPLCKEDCERWWEDCRTSYTCKSNWHKGWNWTSGINECPAGALCSTFESYFPTPAALCEGLWSHSFKVSNYSRGSGRCIQMWFDSAQGNPNEEVAKFYAAAMNAGAPSRGIIDS T65161 TARGETID T65161 T65161 FORMERID TTDR00996 T65161 UNIPROID TSN7_HUMAN T65161 TARGNAME Tetraspanin-7 (TSPAN7) T65161 GENENAME TSPAN7 T65161 TARGTYPE Literature-reported T65161 SYNONYMS TSPAN7; TALLA-1; T-cell acute lymphoblastic leukemia-associated antigen 1; T-cell acute lymphoblastic leukemia associated antigen 1; Membrane component, X chromosome, surface marker 1; Cell surface glycoprotein A15; CD231 antigen T65161 FUNCTION May be involved in cell proliferation and cell motility. T65161 BIOCLASS Tetraspanin family T65161 SEQUENCE MASRRMETKPVITCLKTLLIIYSFVFWITGVILLAVGVWGKLTLGTYISLIAENSTNAPYVLIGTGTTIVVFGLFGCFATCRGSPWMLKLYAMFLSLVFLAELVAGISGFVFRHEIKDTFLRTYTDAMQTYNGNDERSRAVDHVQRSLSCCGVQNYTNWSTSPYFLEHGIPPSCCMNETDCNPQDLHNLTVAATKVNQKGCYDLVTSFMETNMGIIAGVAFGIAFSQLIGMLLACCLSRFITANQYEMV T91906 TARGETID T91906 T91906 FORMERID TTDR00842 T91906 UNIPROID ELK3_HUMAN T91906 TARGNAME ETS domain-containing protein Elk-3 (ELK3) T91906 GENENAME ELK3 T91906 TARGTYPE Literature-reported T91906 SYNONYMS Serum response factor accessory protein 2; SRF accessory protein 2; SAP2; SAP-2; ETS-related protein NET; ETS-related protein ERP T91906 FUNCTION Forms a ternary complex with the serum response factor and the ETS and SRF motifs of the Fos serum response element. May be a negative regulator of transcription, but can activate transcription when coexpressed with Ras, Src or Mos. T91906 BIOCLASS E26 transformation-specific ETS T91906 SEQUENCE MESAITLWQFLLQLLLDQKHEHLICWTSNDGEFKLLKAEEVAKLWGLRKNKTNMNYDKLSRALRYYYDKNIIKKVIGQKFVYKFVSFPEILKMDPHAVEISRESLLLQDSDCKASPEGREAHKHGLAALRSTSRNEYIHSGLYSSFTINSLQNPPDAFKAIKTEKLEEPPEDSPPVEEVRTVIRFVTNKTDKHVTRPVVSLPSTSEAAAASAFLASSVSAKISSLMLPNAASISSASPFSSRSPSLSPNSPLPSEHRSLFLEAACHDSDSLEPLNLSSGSKTKSPSLPPKAKKPKGLEISAPPLVLSGTDIGSIALNSPALPSGSLTPAFFTAQTPNGLLLTPSPLLSSIHFWSSLSPVAPLSPARLQGPSTLFQFPTLLNGHMPVPIPSLDRAASPVLLSSNSQKS T90897 TARGETID T90897 T90897 UNIPROID GRIA2_HUMAN T90897 TARGNAME Phosphorylated GluA2 (pGluA2) T90897 GENENAME GRIA2 T90897 TARGTYPE Literature-reported T90897 SYNONYMS Glutamate receptor ionotropic, AMPA 2 (phosphorylated); Glutamate receptor 2 (phosphorylated); GluR-K2 (phosphorylated); GluR-B (phosphorylated); GluR-2 (phosphorylated); GluA2 (phosphorylated); GLUR2 (phosphorylated); AMPA-selective glutamate receptor 2 (phosphorylated) T90897 FUNCTION Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate. Through complex formation with NSG1, GRIP1 and STX12 controls the intracellular fate of AMPAR and the endosomal sorting of the GRIA2 subunit toward recycling and membrane targeting (By similarity). T90897 PDBSTRUC 5ZG3; 5ZG2; 5ZG1; 5ZG0; 5YBG T90897 SEQUENCE MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFGFYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINVGNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNIKFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRNAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKEKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSRAEAKRMKVAKNAQNINPSSSQNSQNFATYKEGYNVYGIESVKI T26765 TARGETID T26765 T26765 FORMERID TTDR00703 T26765 UNIPROID BCRA_BACLI T26765 TARGNAME Bacterial Bacitracin transport ATP-binding bcrA (Bact bcrA) T26765 GENENAME Bact bcrA T26765 TARGTYPE Literature-reported T26765 SYNONYMS BCRA T26765 FUNCTION Part of the binding-protein-dependent transport system for bacitracin that confer resistance to this antibiotic. Probably responsible for energy coupling to the transport system. T26765 BIOCLASS ABC transporter T26765 SEQUENCE MSTIIKTTDLTKMYGSQKSVDHLNINVKQGDIYGFLGRNGAGKTTTIRMLLGLIKPTSGQIEIFGENFFKNKKEILRRIGSIVEVPGFYANLTARENLLINAKIIGIHKKNAIDEVLEIVGLQHETKKLVGKFSLGMKQRLGIARALLHYPELLILDEPTNGLDPIGIKEMRRLIHSLAKERNITIFISSHILSEIEQLVDHVGIIHEGKLLEEIPFDHLKKRNRKYLEFQLSDQNKAVVLMEQHFDIHDYEVHQDGIIRVYSHLGQQGKLNKLFVENGIDVLKITMSEDSLEDYFVKLIGGGTIG T16452 TARGETID T16452 T16452 FORMERID TTDR00604 T16452 UNIPROID CDN2A_HUMAN T16452 TARGNAME Multiple tumor suppressor 1 (CDKN2A) T16452 GENENAME CDKN2A T16452 TARGTYPE Literature-reported T16452 SYNONYMS p16INK4A; Tumour suppressor gene p16; P16-INK4a; P16-INK4; P16 gene; MTS-1; Cyclin-dependent kinase inhibitor 2A; Cyclin-dependent kinase 4 inhibitor A; CDK4I T16452 FUNCTION Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. T16452 PDBSTRUC 2A5E; 1DC2; 1BI7; 1A5E T16452 SEQUENCE MEPAAGSSMEPSADWLATAAARGRVEEVRALLEAGALPNAPNSYGRRPIQVMMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGARLDVRDAWGRLPVDLAEELGHRDVARYLRAAAGGTRGSNHARIDAAEGPSDIPD T45755 TARGETID T45755 T45755 FORMERID TTDR00822 T45755 UNIPROID CDN2C_HUMAN T45755 TARGNAME CDK inhibitor 4C p18-INK4c (CDKN2C) T45755 GENENAME CDKN2C T45755 TARGTYPE Literature-reported T45755 SYNONYMS P18-INK6; P18-INK4c; P18(INK4c) protein; P18(INK4c); P18 INK4c protein; Cyclin-dependent kinase 6 inhibitor; Cyclin-dependent kinase 4 inhibitor C T45755 FUNCTION Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB. Interacts strongly with CDK6, weakly with CDK4. T45755 PDBSTRUC 1MX6; 1MX4; 1MX2; 1IHB; 1G3N T45755 SEQUENCE MAEPWGNELASAAARGDLEQLTSLLQNNVNVNAQNGFGRTALQVMKLGNPEIARRLLLRGANPDLKDRTGFAVIHDAARAGFLDTLQTLLEFQADVNIEDNEGNLPLHLAAKEGHLRVVEFLVKHTASNVGHRNHKGDTACDLARLYGRNEVVSLMQANGAGGATNLQ T86582 TARGETID T86582 T86582 FORMERID TTDI03190 T86582 UNIPROID EAA1_HUMAN T86582 TARGNAME Excitatory amino acid transporter 1 (SLC1A3) T86582 GENENAME SLC1A3 T86582 TARGTYPE Literature-reported T86582 SYNONYMS Solute carrier family 1 member 3; Sodium-dependent glutamate/aspartate transporter 1; GLAST-1; EAAT1 T86582 FUNCTION Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport. Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate (By similarity). T86582 PDBSTRUC 5MJU; 5LM4; 5LLU; 5LLM T86582 SEQUENCE MTKSNGEEPKMGGRMERFQQGVRKRTLLAKKKVQNITKEDVKSYLFRNAFVLLTVTAVIVGTILGFTLRPYRMSYREVKYFSFPGELLMRMLQMLVLPLIISSLVTGMAALDSKASGKMGMRAVVYYMTTTIIAVVIGIIIVIIIHPGKGTKENMHREGKIVRVTAADAFLDLIRNMFPPNLVEACFKQFKTNYEKRSFKVPIQANETLVGAVINNVSEAMETLTRITEELVPVPGSVNGVNALGLVVFSMCFGFVIGNMKEQGQALREFFDSLNEAIMRLVAVIMWYAPVGILFLIAGKIVEMEDMGVIGGQLAMYTVTVIVGLLIHAVIVLPLLYFLVTRKNPWVFIGGLLQALITALGTSSSSATLPITFKCLEENNGVDKRVTRFVLPVGATINMDGTALYEALAAIFIAQVNNFELNFGQIITISITATAASIGAAGIPQAGLVTMVIVLTSVGLPTDDITLIIAVDWFLDRLRTTTNVLGDSLGAGIVEHLSRHELKNRDVEMGNSVIEENEMKKPYQLIAQDNETEKPIDSETKM T86582 DRUGINFO D0I3EE UCPH-101 Investigative T86582 DRUGINFO D07CIW [3H]ETB-TBOA Investigative T86582 DRUGINFO D07GUB DL-TBOA Investigative T86582 DRUGINFO D0S8AN SYM2081 Investigative T86582 DRUGINFO D08CAB D-aspartic acid Investigative T31721 TARGETID T31721 T31721 FORMERID TTDI03191 T31721 UNIPROID EAA3_HUMAN T31721 TARGNAME Excitatory amino acid transporter 3 (SLC1A1) T31721 GENENAME SLC1A1 T31721 TARGTYPE Literature-reported T31721 SYNONYMS Solute carrier family 1 member 1; Sodium-dependent glutamate/aspartate transporter 3; Neuronal and epithelial glutamate transporter; Excitatory amino-acid carrier 1; EAAT3; EAAC1 T31721 FUNCTION Can also transport L-cysteine. Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport. Plays an important role in L-glutamate and L-aspartate reabsorption in renal tubuli. Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate. Negatively regulated by ARL6IP5. Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. T31721 BIOCLASS Dicarboxylate/amino acid:cation symporter T31721 SEQUENCE MGKPARKGCEWKRFLKNNWVLLSTVAAVVLGITTGVLVREHSNLSTLEKFYFAFPGEILMRMLKLIILPLIISSMITGVAALDSNVSGKIGLRAVVYYFCTTLIAVILGIVLVVSIKPGVTQKVGEIARTGSTPEVSTVDAMLDLIRNMFPENLVQACFQQYKTKREEVKPPSDPEMNMTEESFTAVMTTAISKNKTKEYKIVGMYSDGINVLGLIVFCLVFGLVIGKMGEKGQILVDFFNALSDATMKIVQIIMCYMPLGILFLIAGKIIEVEDWEIFRKLGLYMATVLTGLAIHSIVILPLIYFIVVRKNPFRFAMGMAQALLTALMISSSSATLPVTFRCAEENNQVDKRITRFVLPVGATINMDGTALYEAVAAVFIAQLNDLDLGIGQIITISITATSASIGAAGVPQAGLVTMVIVLSAVGLPAEDVTLIIAVDWLLDRFRTMVNVLGDAFGTGIVEKLSKKELEQMDVSSEVNIVNPFALESTILDNEDSDTKKSYVNGGFAVDKSDTISFTQTSQF T31721 DRUGINFO D09HET L-beta-BA Investigative T31721 DRUGINFO D0F5SO NBI-59159 Investigative T31721 DRUGINFO D07CIW [3H]ETB-TBOA Investigative T31721 DRUGINFO D07GUB DL-TBOA Investigative T31721 DRUGINFO D08CAB D-aspartic acid Investigative T46849 TARGETID T46849 T46849 FORMERID TTDR00809 T46849 UNIPROID MSH2_HUMAN T46849 TARGNAME DNA mismatch repair protein MSH2 (MSH2) T46849 GENENAME MSH2 T46849 TARGTYPE Literature-reported T46849 SYNONYMS hMSH2; MutS protein homolog 2; Mismatch repair gene Msh2 T46849 FUNCTION Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. Recruits DNA helicase MCM9 to chromatin which unwinds the mismatch containg DNA strand. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis. Component of the post-replicative DNA mismatch repair system (MMR). T46849 PDBSTRUC 3THZ; 3THY; 3THX; 3THW; 2O8F T46849 SEQUENCE MAVQPKETLQLESAAEVGFVRFFQGMPEKPTTTVRLFDRGDFYTAHGEDALLAAREVFKTQGVIKYMGPAGAKNLQSVVLSKMNFESFVKDLLLVRQYRVEVYKNRAGNKASKENDWYLAYKASPGNLSQFEDILFGNNDMSASIGVVGVKMSAVDGQRQVGVGYVDSIQRKLGLCEFPDNDQFSNLEALLIQIGPKECVLPGGETAGDMGKLRQIIQRGGILITERKKADFSTKDIYQDLNRLLKGKKGEQMNSAVLPEMENQVAVSSLSAVIKFLELLSDDSNFGQFELTTFDFSQYMKLDIAAVRALNLFQGSVEDTTGSQSLAALLNKCKTPQGQRLVNQWIKQPLMDKNRIEERLNLVEAFVEDAELRQTLQEDLLRRFPDLNRLAKKFQRQAANLQDCYRLYQGINQLPNVIQALEKHEGKHQKLLLAVFVTPLTDLRSDFSKFQEMIETTLDMDQVENHEFLVKPSFDPNLSELREIMNDLEKKMQSTLISAARDLGLDPGKQIKLDSSAQFGYYFRVTCKEEKVLRNNKNFSTVDIQKNGVKFTNSKLTSLNEEYTKNKTEYEEAQDAIVKEIVNISSGYVEPMQTLNDVLAQLDAVVSFAHVSNGAPVPYVRPAILEKGQGRIILKASRHACVEVQDEIAFIPNDVYFEKDKQMFHIITGPNMGGKSTYIRQTGVIVLMAQIGCFVPCESAEVSIVDCILARVGAGDSQLKGVSTFMAEMLETASILRSATKDSLIIIDELGRGTSTYDGFGLAWAISEYIATKIGAFCMFATHFHELTALANQIPTVNNLHVTALTTEETLTMLYQVKKGVCDQSFGIHVAELANFPKHVIECAKQKALELEEFQYIGESQGYDIMEPAAKKCYLEREQGEKIIQEFLSKVKQMPFTEMSEENITIKLKQLKAEVIAKNNSFVNEIISRIKVTT T47098 TARGETID T47098 T47098 FORMERID TTDI00233 T47098 UNIPROID ABCG1_HUMAN T47098 TARGNAME ATP-binding cassette transporter G1 (ABCG1) T47098 GENENAME ABCG1 T47098 TARGTYPE Literature-reported T47098 SYNONYMS White protein homolog; WHT1; ATP-binding cassette transporter 8; ATP-binding cassette sub-family G member 1; ABC8 T47098 FUNCTION Catalyzes the efflux of phospholipids such as sphingomyelin, cholesterol and its oxygenated derivatives like 7beta-hydroxycholesterol and this transport is coupled to hydrlysis of ATP. The lipid efflux is ALB-dependent. Is an active component of the macrophage lipid export complex. Could also be involved in intracellular lipid transport processes. The role in cellular lipid homeostasis may not be limited to macrophages. Prevents cell death by transporting cytotoxic 7beta-hydroxycholesterol. T47098 BIOCLASS ABC transporter T47098 SEQUENCE MACLMAAFSVGTAMNASSYSAEMTEPKSVCVSVDEVVSSNMEATETDLLNGHLKKVDNNLTEAQRFSSLPRRAAVNIEFRDLSYSVPEGPWWRKKGYKTLLKGISGKFNSGELVAIMGPSGAGKSTLMNILAGYRETGMKGAVLINGLPRDLRCFRKVSCYIMQDDMLLPHLTVQEAMMVSAHLKLQEKDEGRREMVKEILTALGLLSCANTRTGSLSGGQRKRLAIALELVNNPPVMFFDEPTSGLDSASCFQVVSLMKGLAQGGRSIICTIHQPSAKLFELFDQLYVLSQGQCVYRGKVCNLVPYLRDLGLNCPTYHNPADFVMEVASGEYGDQNSRLVRAVREGMCDSDHKRDLGGDAEVNPFLWHRPSEEVKQTKRLKGLRKDSSSMEGCHSFSASCLTQFCILFKRTFLSIMRDSVLTHLRITSHIGIGLLIGLLYLGIGNEAKKVLSNSGFLFFSMLFLMFAALMPTVLTFPLEMGVFLREHLNYWYSLKAYYLAKTMADVPFQIMFPVAYCSIVYWMTSQPSDAVRFVLFAALGTMTSLVAQSLGLLIGAASTSLQVATFVGPVTAIPVLLFSGFFVSFDTIPTYLQWMSYISYVRYGFEGVILSIYGLDREDLHCDIDETCHFQKSEAILRELDVENAKLYLDFIVLGIFFISLRLIAYFVLRYKIRAER T73414 TARGETID T73414 T73414 FORMERID TTDI02108 T73414 UNIPROID KI67_HUMAN T73414 TARGNAME Proliferation marker protein Ki-67 (MKI67) T73414 GENENAME MKI67 T73414 TARGTYPE Literature-reported T73414 SYNONYMS Antigen identified by monoclonal antibody Ki-67; Antigen Ki67; Antigen KI-67 T73414 FUNCTION Associates with the surface of the mitotic chromosome, the perichromosomal layer, and covers a substantial fraction of the chromosome surface. Prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility. Binds DNA, with a preference for supercoiled DNA and AT-rich DNA. Does not contribute to the internal structure of mitotic chromosomes. May play a role in chromatin organization. It is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in maintaining mitotic chromosomes dispersed. Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly. T73414 PDBSTRUC 5J28; 2AFF; 1R21 T73414 SEQUENCE MWPTRRLVTIKRSGVDGPHFPLSLSTCLFGRGIECDIRIQLPVVSKQHCKIEIHEQEAILHNFSSTNPTQVNGSVIDEPVRLKHGDVITIIDRSFRYENESLQNGRKSTEFPRKIREQEPARRVSRSSFSSDPDEKAQDSKAYSKITEGKVSGNPQVHIKNVKEDSTADDSKDSVAQGTTNVHSSEHAGRNGRNAADPISGDFKEISSVKLVSRYGELKSVPTTQCLDNSKKNESPFWKLYESVKKELDVKSQKENVLQYCRKSGLQTDYATEKESADGLQGETQLLVSRKSRPKSGGSGHAVAEPASPEQELDQNKGKGRDVESVQTPSKAVGASFPLYEPAKMKTPVQYSQQQNSPQKHKNKDLYTTGRRESVNLGKSEGFKAGDKTLTPRKLSTRNRTPAKVEDAADSATKPENLSSKTRGSIPTDVEVLPTETEIHNEPFLTLWLTQVERKIQKDSLSKPEKLGTTAGQMCSGLPGLSSVDINNFGDSINESEGIPLKRRRVSFGGHLRPELFDENLPPNTPLKRGEAPTKRKSLVMHTPPVLKKIIKEQPQPSGKQESGSEIHVEVKAQSLVISPPAPSPRKTPVASDQRRRSCKTAPASSSKSQTEVPKRGGRKSGNLPSKRVSISRSQHDILQMICSKRRSGASEANLIVAKSWADVVKLGAKQTQTKVIKHGPQRSMNKRQRRPATPKKPVGEVHSQFSTGHANSPCTIIIGKAHTEKVHVPARPYRVLNNFISNQKMDFKEDLSGIAEMFKTPVKEQPQLTSTCHIAISNSENLLGKQFQGTDSGEEPLLPTSESFGGNVFFSAQNAAKQPSDKCSASPPLRRQCIRENGNVAKTPRNTYKMTSLETKTSDTETEPSKTVSTANRSGRSTEFRNIQKLPVESKSEETNTEIVECILKRGQKATLLQQRREGEMKEIERPFETYKENIELKENDEKMKAMKRSRTWGQKCAPMSDLTDLKSLPDTELMKDTARGQNLLQTQDHAKAPKSEKGKITKMPCQSLQPEPINTPTHTKQQLKASLGKVGVKEELLAVGKFTRTSGETTHTHREPAGDGKSIRTFKESPKQILDPAARVTGMKKWPRTPKEEAQSLEDLAGFKELFQTPGPSEESMTDEKTTKIACKSPPPESVDTPTSTKQWPKRSLRKADVEEEFLALRKLTPSAGKAMLTPKPAGGDEKDIKAFMGTPVQKLDLAGTLPGSKRQLQTPKEKAQALEDLAGFKELFQTPGHTEELVAAGKTTKIPCDSPQSDPVDTPTSTKQRPKRSIRKADVEGELLACRNLMPSAGKAMHTPKPSVGEEKDIIIFVGTPVQKLDLTENLTGSKRRPQTPKEEAQALEDLTGFKELFQTPGHTEEAVAAGKTTKMPCESSPPESADTPTSTRRQPKTPLEKRDVQKELSALKKLTQTSGETTHTDKVPGGEDKSINAFRETAKQKLDPAASVTGSKRHPKTKEKAQPLEDLAGLKELFQTPVCTDKPTTHEKTTKIACRSQPDPVDTPTSSKPQSKRSLRKVDVEEEFFALRKRTPSAGKAMHTPKPAVSGEKNIYAFMGTPVQKLDLTENLTGSKRRLQTPKEKAQALEDLAGFKELFQTRGHTEESMTNDKTAKVACKSSQPDPDKNPASSKRRLKTSLGKVGVKEELLAVGKLTQTSGETTHTHTEPTGDGKSMKAFMESPKQILDSAASLTGSKRQLRTPKGKSEVPEDLAGFIELFQTPSHTKESMTNEKTTKVSYRASQPDLVDTPTSSKPQPKRSLRKADTEEEFLAFRKQTPSAGKAMHTPKPAVGEEKDINTFLGTPVQKLDQPGNLPGSNRRLQTRKEKAQALEELTGFRELFQTPCTDNPTTDEKTTKKILCKSPQSDPADTPTNTKQRPKRSLKKADVEEEFLAFRKLTPSAGKAMHTPKAAVGEEKDINTFVGTPVEKLDLLGNLPGSKRRPQTPKEKAKALEDLAGFKELFQTPGHTEESMTDDKITEVSCKSPQPDPVKTPTSSKQRLKISLGKVGVKEEVLPVGKLTQTSGKTTQTHRETAGDGKSIKAFKESAKQMLDPANYGTGMERWPRTPKEEAQSLEDLAGFKELFQTPDHTEESTTDDKTTKIACKSPPPESMDTPTSTRRRPKTPLGKRDIVEELSALKQLTQTTHTDKVPGDEDKGINVFRETAKQKLDPAASVTGSKRQPRTPKGKAQPLEDLAGLKELFQTPICTDKPTTHEKTTKIACRSPQPDPVGTPTIFKPQSKRSLRKADVEEESLALRKRTPSVGKAMDTPKPAGGDEKDMKAFMGTPVQKLDLPGNLPGSKRWPQTPKEKAQALEDLAGFKELFQTPGTDKPTTDEKTTKIACKSPQPDPVDTPASTKQRPKRNLRKADVEEEFLALRKRTPSAGKAMDTPKPAVSDEKNINTFVETPVQKLDLLGNLPGSKRQPQTPKEKAEALEDLVGFKELFQTPGHTEESMTDDKITEVSCKSPQPESFKTSRSSKQRLKIPLVKVDMKEEPLAVSKLTRTSGETTQTHTEPTGDSKSIKAFKESPKQILDPAASVTGSRRQLRTRKEKARALEDLVDFKELFSAPGHTEESMTIDKNTKIPCKSPPPELTDTATSTKRCPKTRPRKEVKEELSAVERLTQTSGQSTHTHKEPASGDEGIKVLKQRAKKKPNPVEEEPSRRRPRAPKEKAQPLEDLAGFTELSETSGHTQESLTAGKATKIPCESPPLEVVDTTASTKRHLRTRVQKVQVKEEPSAVKFTQTSGETTDADKEPAGEDKGIKALKESAKQTPAPAASVTGSRRRPRAPRESAQAIEDLAGFKDPAAGHTEESMTDDKTTKIPCKSSPELEDTATSSKRRPRTRAQKVEVKEELLAVGKLTQTSGETTHTDKEPVGEGKGTKAFKQPAKRKLDAEDVIGSRRQPRAPKEKAQPLEDLASFQELSQTPGHTEELANGAADSFTSAPKQTPDSGKPLKISRRVLRAPKVEPVGDVVSTRDPVKSQSKSNTSLPPLPFKRGGGKDGSVTGTKRLRCMPAPEEIVEELPASKKQRVAPRARGKSSEPVVIMKRSLRTSAKRIEPAEELNSNDMKTNKEEHKLQDSVPENKGISLRSRRQNKTEAEQQITEVFVLAERIEINRNEKKPMKTSPEMDIQNPDDGARKPIPRDKVTENKRCLRSARQNESSQPKVAEESGGQKSAKVLMQNQKGKGEAGNSDSMCLRSRKTKSQPAASTLESKSVQRVTRSVKRCAENPKKAEDNVCVKKIRTRSHRDSEDI T91180 TARGETID T91180 T91180 FORMERID TTDI03450 T91180 UNIPROID S15A1_HUMAN T91180 TARGNAME Solute carrier family 15 member 1 (SLC15A1) T91180 GENENAME SLC15A1 T91180 TARGTYPE Literature-reported T91180 SYNONYMS PEPT1; Oligopeptide transporter, small intestine isoform; Intestinal H(+)/peptide cotransporter T91180 FUNCTION May constitute a major route for the absorption of protein digestion end-products. Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. T91180 BIOCLASS Proton-dependent oligopeptide transporter T91180 SEQUENCE MGMSKSHSFFGYPLSIFFIVVNEFCERFSYYGMRAILILYFTNFISWDDNLSTAIYHTFVALCYLTPILGALIADSWLGKFKTIVSLSIVYTIGQAVTSVSSINDLTDHNHDGTPDSLPVHVVLSLIGLALIALGTGGIKPCVSAFGGDQFEEGQEKQRNRFFSIFYLAINAGSLLSTIITPMLRVQQCGIHSKQACYPLAFGVPAALMAVALIVFVLGSGMYKKFKPQGNIMGKVAKCIGFAIKNRFRHRSKAFPKREHWLDWAKEKYDERLISQIKMVTRVMFLYIPLPMFWALFDQQGSRWTLQATTMSGKIGALEIQPDQMQTVNAILIVIMVPIFDAVLYPLIAKCGFNFTSLKKMAVGMVLASMAFVVAAIVQVEIDKTLPVFPKGNEVQIKVLNIGNNTMNISLPGEMVTLGPMSQTNAFMTFDVNKLTRINISSPGSPVTAVTDDFKQGQRHTLLVWAPNHYQVVKDGLNQKPEKGENGIRFVNTFNELITITMSGKVYANISSYNASTYQFFPSGIKGFTISSTEIPPQCQPNFNTFYLEFGSAYTYIVQRKNDSCPEVKVFEDISANTVNMALQIPQYFLLTCGEVVFSVTGLEFSYSQAPSNMKSVLQAGWLLTVAVGNIIVLIVAGAGQFSKQWAEYILFAALLLVVCVIFAIMARFYTYINPAEIEAQFDEDEKKNRLEKSNPYFMSGANSQKQM T91180 DRUGINFO D0S3VV 4-AMBA Investigative T91180 DRUGINFO D02FZM Lys[Z(NO2)]-Pro Investigative T91180 DRUGINFO D06PWQ [14C]GlySar Investigative T91180 DRUGINFO D08QDL [11C]GlySar Investigative T91180 DRUGINFO D0Q3VU [3H]GlySar Investigative T14006 TARGETID T14006 T14006 FORMERID TTDI02616 T14006 UNIPROID CDN1B_HUMAN T14006 TARGNAME CDK inhibitor 1B p27Kip1 (CDKN1B) T14006 GENENAME CDKN1B T14006 TARGTYPE Literature-reported T14006 SYNONYMS p27Kip1; KIP1; Cyclindependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor 1B T14006 FUNCTION Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry. Important regulator of cell cycle progression. T14006 PDBSTRUC 6ATH; 5UQ3; 2AST; 1JSU; 1H27 T14006 SEQUENCE MSNVRVSNGSPSLERMDARQAEHPKPSACRNLFGPVDHEELTRDLEKHCRDMEEASQRKWNFDFQNHKPLEGKYEWQEVEKGSLPEFYYRPPRPPKGACKVPAQESQDVSGSRPAAPLIGAPANSEDTHLVDPKTDPSDSQTGLAEQCAGIRKRPATDDSSTQNKRANRTEENVSDGSPNAGSVEQTPKKPGLRRRQT T94048 TARGETID T94048 T94048 FORMERID TTDI00223 T94048 UNIPROID YAP1_HUMAN T94048 TARGNAME Yes-associated protein 1 (YAP1) T94048 GENENAME YAP1 T94048 TARGTYPE Literature-reported T94048 SYNONYMS Yorkie homolog; Yes-associated protein YAP65 homolog; YAP65; Transcriptional coactivator YAP1; Protein yorkie homolog; 65 kDa Yes-associated protein T94048 FUNCTION The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Plays a key role in tissue tension and 3D tissue shape by regulating cortical actomyosin network formation. Acts via ARHGAP18, a Rho GTPase activating protein that suppresses F-actin polymerization. Plays a key role to control cell proliferation in response to cell contact. Phosphorylation of YAP1 by LATS1/2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. The presence of TEAD transcription factors are required for it to stimulate gene expression, cell growth, anchorage-independent growth, and epithelial mesenchymal transition (EMT) induction. Transcriptional regulator which can act both as a coactivator and a corepressor and is the critical downstream regulatory target in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. T94048 PDBSTRUC 6HIL; 6HIK; 6GEK; 6GEI; 6GEG T94048 SEQUENCE MDPGQQPPPQPAPQGQGQPPSQPPQGQGPPSGPGQPAPAATQAAPQAPPAGHQIVHVRGDSETDLEALFNAVMNPKTANVPQTVPMRLRKLPDSFFKPPEPKSHSRQASTDAGTAGALTPQHVRAHSSPASLQLGAVSPGTLTPTGVVSGPAATPTAQHLRQSSFEIPDDVPLPAGWEMAKTSSGQRYFLNHIDQTTTWQDPRKAMLSQMNVTAPTSPPVQQNMMNSASGPLPDGWEQAMTQDGEIYYINHKNKTTSWLDPRLDPRFAMNQRISQSAPVKQPPPLAPQSPQGGVMGGSNSNQQQQMRLQQLQMEKERLRLKQQELLRQAMRNINPSTANSPKCQELALRSQLPTLEQDGGTQNPVSSPGMSQELRTMTTNSSDPFLNSGTYHSRDESTDSGLSMSSYSVPRTPDDFLNSVDEMDTGDTINQSTLPSQQNRFPDYLEAIPGTNVDLGTLEGDGMNIEGEELMPSLQEALSSDILNDMESVLAATKLDKESFLTWL T17721 TARGETID T17721 T17721 FORMERID TTDI03319 T17721 UNIPROID KCNJ6_HUMAN T17721 TARGNAME Inward rectifier potassium channel Kir3.2 (KCNJ6) T17721 GENENAME KCNJ6 T17721 TARGTYPE Literature-reported T17721 SYNONYMS Potassium channel, inwardly rectifying subfamily J member 6; KCNJ7; KATP2; KATP-2; Inward rectifier K(+) channel Kir3.2; GIRK2; GIRK-2; G protein-activated inward rectifier potassium channel 2; BIR1 T17721 FUNCTION This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. T17721 BIOCLASS Inward rectifier potassium channel T17721 SEQUENCE MAKLTESMTNVLEGDSMDQDVESPVAIHQPKLPKQARDDLPRHISRDRTKRKIQRYVRKDGKCNVHHGNVRETYRYLTDIFTTLVDLKWRFNLLIFVMVYTVTWLFFGMIWWLIAYIRGDMDHIEDPSWTPCVTNLNGFVSAFLFSIETETTIGYGYRVITDKCPEGIILLLIQSVLGSIVNAFMVGCMFVKISQPKKRAETLVFSTHAVISMRDGKLCLMFRVGDLRNSHIVEASIRAKLIKSKQTSEGEFIPLNQTDINVGYYTGDDRLFLVSPLIISHEINQQSPFWEISKAQLPKEELEIVVILEGMVEATGMTCQARSSYITSEILWGYRFTPVLTLEDGFYEVDYNSFHETYETSTPSLSAKELAELASRAELPLSWSVSSKLNQHAELETEEEEKNLEEQTERNGDVANLENESKV T17721 DRUGINFO D0P0ZB F3 Investigative T17721 DRUGINFO D07ZAJ PIP2 Investigative T14252 TARGETID T14252 T14252 FORMERID TTDR00201 T14252 UNIPROID S6A11_HUMAN T14252 TARGNAME Gamma-aminobutyric acid transporter 4 (SLC6A11) T14252 GENENAME Slc6a11 T14252 TARGTYPE Literature-reported T14252 SYNONYMS Sodium- and chloride-dependent GABA transporter 4; Slc6a11; GAT4; GABA transporter 4 T14252 FUNCTION Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals. Can also transport beta-alanine and taurine. T14252 BIOCLASS Neurotransmitter:sodium symporter T14252 SEQUENCE MTAEKALPLGNGKAAEEARESEAPGGGCSSGGAAPARHPRVKRDKAVHERGHWNNKVEFVLSVAGEIIGLGNVWRFPYLCYKNGGGAFLIPYVVFFICCGIPVFFLETALGQFTSEGGITCWRKVCPLFEGIGYATQVIEAHLNVYYIIILAWAIFYLSNCFTTELPWATCGHEWNTENCVEFQKLNVSNYSHVSLQNATSPVMEFWEHRVLAISDGIEHIGNLRWELALCLLAAWTICYFCIWKGTKSTGKVVYVTATFPYIMLLILLIRGVTLPGASEGIKFYLYPDLSRLSDPQVWVDAGTQIFFSYAICLGCLTALGSYNNYNNNCYRDCIMLCCLNSGTSFVAGFAIFSVLGFMAYEQGVPIAEVAESGPGLAFIAYPKAVTMMPLSPLWATLFFMMLIFLGLDSQFVCVESLVTAVVDMYPKVFRRGYRRELLILALSVISYFLGLVMLTEGGMYIFQLFDSYAASGMCLLFVAIFECICIGWVYGSNRFYDNIEDMIGYRPPSLIKWCWMIMTPGICAGIFIFFLIKYKPLKYNNIYTYPAWGYGIGWLMALSSMLCIPLWICITVWKTEGTLPEKLQKLTTPSTDLKMRGKLGVSPRMVTVNDCDAKLKSDGTIAAITEKETHF T14252 DRUGINFO D0H7WK SNAP-5114 Investigative T16353 TARGETID T16353 T16353 FORMERID TTDI02404 T16353 UNIPROID CXA8_HUMAN T16353 TARGNAME Gap junction alpha-8 protein (Cx50) T16353 GENENAME GJA8 T16353 TARGTYPE Literature-reported T16353 SYNONYMS Lens fiber protein MP70; GJA8; Cx50; Connexin50 T16353 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T16353 BIOCLASS Gap junction-forming connexin T16353 SEQUENCE MGDWSFLGNILEEVNEHSTVIGRVWLTVLFIFRILILGTAAEFVWGDEQSDFVCNTQQPGCENVCYDEAFPISHIRLWVLQIIFVSTPSLMYVGHAVHYVRMEEKRKSREAEELGQQAGTNGGPDQGSVKKSSGSKGTKKFRLEGTLLRTYICHIIFKTLFEVGFIVGHYFLYGFRILPLYRCSRWPCPNVVDCFVSRPTEKTIFILFMLSVASVSLFLNVMELGHLGLKGIRSALKRPVEQPLGEIPEKSLHSIAVSSIQKAKGYQLLEEEKIVSHYFPLTEVGMVETSPLPAKPFNQFEEKISTGPLGDLSRGYQETLPSYAQVGAQEVEGEGPPAEEGAEPEVGEKKEEAERLTTEEQEKVAVPEGEKVETPGVDKEGEKEEPQSEKVSKQGLPAEKTPSLCPELTTDDARPLSRLSKASSRARSDDLTV T16353 DRUGINFO D05QML PQ-1 Investigative T16353 DRUGINFO D00VJY octanol Investigative T00724 TARGETID T00724 T00724 FORMERID TTDNR00762 T00724 UNIPROID SOX2_HUMAN T00724 TARGNAME Transcription factor SOX-2 (SOX2) T00724 GENENAME SOX2 T00724 TARGTYPE Literature-reported T00724 SYNONYMS SRY-box 2; MCOPS3; ANOP3 T00724 FUNCTION Critical for early embryogenesis and for embryonic stem cell pluripotency. May function as a switch in neuronal development. Downstream SRRT target that mediates the promotion of neural stem cell self-renewal. Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation. Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206. T00724 PDBSTRUC 2LE4; 1O4X T00724 SEQUENCE MYNMMETELKPPGPQQTSGGGGGNSTAAAAGGNQKNSPDRVKRPMNAFMVWSRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRLRALHMKEHPDYKYRPRRKTKTLMKKDKYTLPGGLLAPGGNSMASGVGVGAGLGAGVNQRMDSYAHMNGWSNGSYSMMQDQLGYPQHPGLNAHGAAQMQPMHRYDVSALQYNSMTSSQTYMNGSPTYSMSYSQQGTPGMALGSMGSVVKSEASSSPPVVTSSSHSRAPCQAGDLRDMISMYLPGAEVPEPAAPSRLHMSQHYQSGPVPGTAINGTLPLSHM T49080 TARGETID T49080 T49080 FORMERID TTDI03338 T49080 UNIPROID KCNC1_HUMAN T49080 TARGNAME Voltage-gated potassium channel Kv3.1 (KCNC1) T49080 GENENAME KCNC1 T49080 TARGTYPE Literature-reported T49080 SYNONYMS Voltage-gated potassium channel subunit Kv4; Voltage-gated potassium channel subunit Kv3.1; Potassium voltage-gated channel subfamily C member 1; NGK2 T49080 FUNCTION The channel opens in response to the voltage difference across the membrane, forming a potassium-selective channel through which potassium ions pass in accordance with their electrochemical gradient. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNC2, and possibly other family members as well. Contributes to fire sustained trains of very brief action potentials at high frequency in pallidal neurons. Voltage-gated potassium channel that plays an important role in the rapid repolarization of fast-firing brain neurons. T49080 BIOCLASS Voltage-gated ion channel T49080 SEQUENCE MGQGDESERIVINVGGTRHQTYRSTLRTLPGTRLAWLAEPDAHSHFDYDPRADEFFFDRHPGVFAHILNYYRTGKLHCPADVCGPLYEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDSFGGAPLDNSADDADADGPGDSGDGEDELEMTKRLALSDSPDGRPGGFWRRWQPRIWALFEDPYSSRYARYVAFASLFFILVSITTFCLETHERFNPIVNKTEIENVRNGTQVRYYREAETEAFLTYIEGVCVVWFTFEFLMRVIFCPNKVEFIKNSLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERIGAQPNDPSASEHTHFKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPKKKKKHIPRPPQLGSPNYCKSVVNSPHHSTQSDTCPLAQEEILEINRAGRKPLRGMSI T49080 DRUGINFO D0C2NK norfluoxetine Investigative T49080 DRUGINFO D06PZZ [14C]TEA Investigative T15033 TARGETID T15033 T15033 FORMERID TTDR00629 T15033 UNIPROID CX3C1_HUMAN T15033 TARGNAME C-X3-C chemokine receptor 1 (CX3CR1) T15033 GENENAME CX3CR1 T15033 TARGTYPE Literature-reported T15033 SYNONYMS V28; GPR13; G-protein coupled receptor 13; Fractalkine receptor CX3CR1; Fractalkine receptor; CX3C chemokine receptor 1; CMKBRL1; CMKBLR1; CMK-BRL1; CMK-BRL-1; C-X3-C CKR-1; Beta chemokine receptor-like1; Beta chemokine receptor-like 1 T15033 FUNCTION Acts as coreceptor with CD4 for HIV-1 virus envelope protein (in vitro). Isoform 2 and isoform 3 seem to be more potent HIV-1 coreceptors than isoform 1. Receptor for the CX3C chemokine fractalkine (CX3CL1); binds to CX3CL1 and mediates both its adhesive and migratory functions. T15033 BIOCLASS GPCR rhodopsin T15033 SEQUENCE MDQFPESVTENFEYDDLAEACYIGDIVVFGTVFLSIFYSVIFAIGLVGNLLVVFALTNSKKPKSVTDIYLLNLALSDLLFVATLPFWTHYLINEKGLHNAMCKFTTAFFFIGFFGSIFFITVISIDRYLAIVLAANSMNNRTVQHGVTISLGVWAAAILVAAPQFMFTKQKENECLGDYPEVLQEIWPVLRNVETNFLGFLLPLLIMSYCYFRIIQTLFSCKNHKKAKAIKLILLVVIVFFLFWTPYNVMIFLETLKLYDFFPSCDMRKDLRLALSVTETVAFSHCCLNPLIYAFAGEKFRRYLYHLYGKCLAVLCGRSVHVDFSSSESQRSRHGSVLSSNFTYHTSDGDALLLL T33063 TARGETID T33063 T33063 FORMERID TTDI01535 T33063 UNIPROID STAR_HUMAN T33063 TARGNAME Steroidogenic acute regulatory protein (STAR) T33063 GENENAME STAR T33063 TARGTYPE Literature-reported T33063 SYNONYMS Steroidogenic acute regulatory protein, mitochondrial; StARD1; START domain-containing protein 1 T33063 FUNCTION Plays a key role in steroid hormone synthesis by enhancing the metabolism of cholesterol into pregnenolone. Mediates the transfer of cholesterol from the outer mitochondrial membrane to the inner mitochondrial membrane where it is cleaved to pregnenolone. T33063 PDBSTRUC 5OMA; 3P0L; 2I93; 1IMG T33063 SEQUENCE MLLATFKLCAGSSYRHMRNMKGLRQQAVMAISQELNRRALGGPTPSTWINQVRRRSSLLGSRLEETLYSDQELAYLQQGEEAMQKALGILSNQEGWKKESQQDNGDKVMSKVVPDVGKVFRLEVVVDQPMERLYEELVERMEAMGEWNPNVKEIKVLQKIGKDTFITHELAAEAAGNLVGPRDFVSVRCAKRRGSTCVLAGMATDFGNMPEQKGVIRAEHGPTCMVLHPLAGSPSKTKLTWLLSIDLKGWLPKSIINQVLSQTQVDFANHLRKRLESHPASEARC T33909 TARGETID T33909 T33909 FORMERID TTDNR00743 T33909 UNIPROID RGS6_HUMAN T33909 TARGNAME Regulator of G-protein signaling 6 (RGS6) T33909 GENENAME RGS6 T33909 TARGTYPE Literature-reported T33909 SYNONYMS S914 T33909 FUNCTION Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. The RGS6/GNB5 dimer enhances GNAO1 GTPase activity. Regulates G protein-coupled receptor signaling cascades. T33909 PDBSTRUC 2ES0 T33909 SEQUENCE MAQGSGDQRAVGVADPEESSPNMIVYCKIEDIITKMQDDKTGGVPIRTVKSFLSKIPSVVTGTDIVQWLMKNLSIEDPVEAIHLGSLIAAQGYIFPISDHVLTMKDDGTFYRFQAPYFWPSNCWEPENTDYAIYLCKRTMQNKARLELADYEAENLARLQRAFARKWEFIFMQAEAQVKIDRKKDKTERKILDSQERAFWDVHRPVPGCVNTTEMDIRKCRRLKNPQKVKKSVYGVTEESQAQSPVHVLSQPIRKTTKEDIRKQITFLNAQIDRHCLKMSKVAESLIAYTEQYVEYDPLITPAEPSNPWISDDVALWDIEMSKEPSQQRVKRWGFSFDEILKDQVGRDQFLRFLESEFSSENLRFWLAVQDLKKQPLQDVAKRVEEIWQEFLAPGAPSAINLDSHSYEITSQNVKDGGRYTFEDAQEHIYKLMKSDSYARFLRSNAYQDLLLAKKKGKSLAGKRLTGLMQSS T11561 TARGETID T11561 T11561 FORMERID TTDR00497 T11561 UNIPROID ERF_HUMAN T11561 TARGNAME ETS-domain transcription factor ERF (ERF) T11561 GENENAME ERF T11561 TARGTYPE Literature-reported T11561 SYNONYMS Transcription factor Ets2; PE-2; Ets2 repressor factor; ETS domain-containing transcription factor ERF T11561 FUNCTION May regulate other genes involved in cellular proliferation. Required for extraembryonic ectoderm differentiation, ectoplacental cone cavity closure, and chorioallantoic attachment. May be important for regulating trophoblast stem cell differentiation. Potent transcriptional repressor that binds to the H1 element of the Ets2 promoter. T11561 BIOCLASS E26 transformation-specific ETS T11561 SEQUENCE MKTPADTGFAFPDWAYKPESSPGSRQIQLWHFILELLRKEEYQGVIAWQGDYGEFVIKDPDEVARLWGVRKCKPQMNYDKLSRALRYYYNKRILHKTKGKRFTYKFNFNKLVLVNYPFIDVGLAGGAVPQSAPPVPSGGSHFRFPPSTPSEVLSPTEDPRSPPACSSSSSSLFSAVVARRLGRGSVSDCSDGTSELEEPLGEDPRARPPGPPDLGAFRGPPLARLPHDPGVFRVYPRPRGGPEPLSPFPVSPLAGPGSLLPPQLSPALPMTPTHLAYTPSPTLSPMYPSGGGGPSGSGGGSHFSFSPEDMKRYLQAHTQSVYNYHLSPRAFLHYPGLVVPQPQRPDKCPLPPMAPETPPVPSSASSSSSSSSSPFKFKLQPPPLGRRQRAAGEKAVAGADKSGGSAGGLAEGAGALAPPPPPPQIKVEPISEGESEEVEVTDISDEDEEDGEVFKTPRAPPAPPKPEPGEAPGASQCMPLKLRFKRRWSEDCRLEGGGGPAGGFEDEGEDKKVRGEGPGEAGGPLTPRRVSSDLQHATAQLSLEHRDS T60671 TARGETID T60671 T60671 FORMERID TTDI03114 T60671 UNIPROID CLCN3_HUMAN T60671 TARGNAME Chloride channel protein 3 (CLC-3) T60671 GENENAME CLCN3 T60671 TARGTYPE Literature-reported T60671 SYNONYMS H(+)/Cl(-) exchange transporter 3; ClC-3 T60671 FUNCTION Functions as antiporter and contributes to the acidification of the endosome and synaptic vesicle lumen, and may thereby affect vesicle trafficking and exocytosis. May play an important role in neuronal cell function through regulation of membrane excitability by protein kinase C. It could help neuronal cells to establish short-term memory. Mediates the exchange of chloride ions against protons. T60671 BIOCLASS Chloride channel T60671 SEQUENCE MESEQLFHRGYYRNSYNSITSASSDEELLDGAGVIMDFQTSEDDNLLDGDTAVGTHYTMTNGGSINSSTHLLDLLDEPIPGVGTYDDFHTIDWVREKCKDRERHRRINSKKKESAWEMTKSLYDAWSGWLVVTLTGLASGALAGLIDIAADWMTDLKEGICLSALWYNHEQCCWGSNETTFEERDKCPQWKTWAELIIGQAEGPGSYIMNYIMYIFWALSFAFLAVSLVKVFAPYACGSGIPEIKTILSGFIIRGYLGKWTLMIKTITLVLAVASGLSLGKEGPLVHVACCCGNIFSYLFPKYSTNEAKKREVLSAASAAGVSVAFGAPIGGVLFSLEEVSYYFPLKTLWRSFFAALVAAFVLRSINPFGNSRLVLFYVEYHTPWYLFELFPFILLGVFGGLWGAFFIRANIAWCRRRKSTKFGKYPVLEVIIVAAITAVIAFPNPYTRLNTSELIKELFTDCGPLESSSLCDYRNDMNASKIVDDIPDRPAGIGVYSAIWQLCLALIFKIIMTVFTFGIKVPSGLFIPSMAIGAIAGRIVGIAVEQLAYYHHDWFIFKEWCEVGADCITPGLYAMVGAAACLGGVTRMTVSLVVIVFELTGGLEYIVPLMAAVMTSKWVGDAFGREGIYEAHIRLNGYPFLDAKEEFTHTTLAADVMRPRRNDPPLAVLTQDNMTVDDIENMINETSYNGFPVIMSKESQRLVGFALRRDLTIAIESARKKQEGIVGSSRVCFAQHTPSLPAESPRPLKLRSILDMSPFTVTDHTPMEIVVDIFRKLGLRQCLVTHNGRLLGIITKKDILRHMAQTANQDPASIMFN T60671 DRUGINFO D0HD2G phloretin Investigative T20455 TARGETID T20455 T20455 FORMERID TTDI03116 T20455 UNIPROID CLCN6_HUMAN T20455 TARGNAME Chloride channel protein 6 (ClC-6) T20455 GENENAME CLCN6 T20455 TARGTYPE Literature-reported T20455 SYNONYMS KIAA0046; ClC-6; Chloride transport protein 6 T20455 FUNCTION Chloride transport protein, initially identified as voltage-gated chloride channel. The presence of the conserved gating glutamate residues suggests that is functions as antiporter. T20455 BIOCLASS Chloride channel T20455 SEQUENCE MAGCRGSLCCCCRWCCCCGERETRTPEELTILGETQEEEDEILPRKDYESLDYDRCINDPYLEVLETMDNKKGRRYEAVKWMVVFAIGVCTGLVGLFVDFFVRLFTQLKFGVVQTSVEECSQKGCLALSLLELLGFNLTFVFLASLLVLIEPVAAGSGIPEVKCYLNGVKVPGIVRLRTLLCKVLGVLFSVAGGLFVEKEGPMIHSGSVVGAGLPQFQSISLRKIQFNFPYFRSDRDKRDFVSAGAAAGVAAAFGAPIGGTLFSLEEGSSFWNQGLTWKVLFCSMSATFTLNFFRSGIQFGSWGSFQLPGLLNFGEFKCSDSDKKCHLWTAMDLGFFVVMGVIGGLLGATFNCLNKRLAKYRMRNVHPKPKLVRVLESLLVSLVTTVVVFVASMVLGECRQMSSSSQIGNDSFQLQVTEDVNSSIKTFFCPNDTYNDMATLFFNPQESAILQLFHQDGTFSPVTLALFFVLYFLLACWTYGISVPSGLFVPSLLCGAAFGRLVANVLKSYIGLGHIYSGTFALIGAAAFLGGVVRMTISLTVILIESTNEITYGLPIMVTLMVAKWTGDFFNKGIYDIHVGLRGVPLLEWETEVEMDKLRASDIMEPNLTYVYPHTRIQSLVSILRTTVHHAFPVVTENRGNEKEFMKGNQLISNNIKFKKSSILTRAGEQRKRSQSMKSYPSSELRNMCDEHIASEEPAEKEDLLQQMLERRYTPYPNLYPDQSPSEDWTMEERFRPLTFHGLILRSQLVTLLVRGVCYSESQSSASQPRLSYAEMAEDYPRYPDIHDLDLTLLNPRMIVDVTPYMNPSPFTVSPNTHVSQVFNLFRTMGLRHLPVVNAVGEIVGIITRHNLTYEFLQARLRQHYQTI T20455 DRUGINFO D0PW7B DIDS Investigative T43531 TARGETID T43531 T43531 FORMERID TTDI03370 T43531 UNIPROID CLCN7_HUMAN T43531 TARGNAME Chloride channel protein 7 (ClC-7) T43531 GENENAME CLCN7 T43531 TARGTYPE Literature-reported T43531 SYNONYMS H(+)/Cl(-) exchange transporter 7; ClC-7; Chloride channel 7 alpha subunit T43531 FUNCTION Slowly voltage-gated channel mediating the exchange of chloride ions against protons. Functions as antiporter and contributes to the acidification of the lysosome lumen. T43531 BIOCLASS Chloride channel T43531 SEQUENCE MANVSKKVSWSGRDRDDEEAAPLLRRTARPGGGTPLLNGAGPGAARQSPRSALFRVGHMSSVELDDELLDPDMDPPHPFPKEIPHNEKLLSLKYESLDYDNSENQLFLEEERRINHTAFRTVEIKRWVICALIGILTGLVACFIDIVVENLAGLKYRVIKGNIDKFTEKGGLSFSLLLWATLNAAFVLVGSVIVAFIEPVAAGSGIPQIKCFLNGVKIPHVVRLKTLVIKVSGVILSVVGGLAVGKEGPMIHSGSVIAAGISQGRSTSLKRDFKIFEYFRRDTEKRDFVSAGAAAGVSAAFGAPVGGVLFSLEEGASFWNQFLTWRIFFASMISTFTLNFVLSIYHGNMWDLSSPGLINFGRFDSEKMAYTIHEIPVFIAMGVVGGVLGAVFNALNYWLTMFRIRYIHRPCLQVIEAVLVAAVTATVAFVLIYSSRDCQPLQGGSMSYPLQLFCADGEYNSMAAAFFNTPEKSVVSLFHDPPGSYNPLTLGLFTLVYFFLACWTYGLTVSAGVFIPSLLIGAAWGRLFGISLSYLTGAAIWADPGKYALMGAAAQLGGIVRMTLSLTVIMMEATSNVTYGFPIMLVLMTAKIVGDVFIEGLYDMHIQLQSVPFLHWEAPVTSHSLTAREVMSTPVTCLRRREKVGVIVDVLSDTASNHNGFPVVEHADDTQPARLQGLILRSQLIVLLKHKVFVERSNLGLVQRRLRLKDFRDAYPRFPPIQSIHVSQDERECTMDLSEFMNPSPYTVPQEASLPRVFKLFRALGLRHLVVVDNRNQVVGLVTRKDLARYRLGKRGLEELSLAQT T43531 DRUGINFO D00UTF NS5818 Investigative T43531 DRUGINFO D03APP diphenylamine-2-carboxylic acid Investigative T43531 DRUGINFO D0A2UX SITS Investigative T43531 DRUGINFO D0Z4AU GTPgammaS Investigative T43531 DRUGINFO D08DQL NPPB Investigative T43531 DRUGINFO D0PW7B DIDS Investigative T78758 TARGETID T78758 T78758 FORMERID TTDI03119 T78758 UNIPROID CLCKB_HUMAN T78758 TARGNAME Chloride channel protein ClC-Kb (ClC-K2) T78758 GENENAME CLCNKB T78758 TARGTYPE Literature-reported T78758 SYNONYMS ClC-K2; Chloride channel Kb T78758 FUNCTION Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms. T78758 BIOCLASS Chloride channel T78758 SEQUENCE MEEFVGLREGSSGNPVTLQELWGPCPRIRRGIRGGLEWLKQKLFRLGEDWYFLMTLGVLMALVSCAMDLAVESVVRAHQWLYREIGDSHLLRYLSWTVYPVALVSFSSGFSQSITPSSGGSGIPEVKTMLAGVVLEDYLDIKNFGAKVVGLSCTLACGSTLFLGKVGPFVHLSVMMAAYLGRVRTTTIGEPENKSKQNEMLVAAAAVGVATVFAAPFSGVLFSIEVMSSHFSVWDYWRGFFAATCGAFMFRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGGLCGILGSAYLFCQRIFFGFIRNNRFSSKLLATSKPVYSALATLVLASITYPPSAGRFLASRLSMKQHLDSLFDNHSWALMTQNSSPPWPEELDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIPMPAGYFMPIFVYGAAIGRLFGETLSFIFPEGIVAGGITNPIMPGGYALAGAAAFSGAVTHTISTALLAFEVTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTVIVKKLPYLPRILGRNIGSHRVRVEHFMNHSITTLAKDMPLEEVVKVVTSTDVAKYPLVESTESQILVGIVRRAQLVQALKAEPPSWAPGHQQCLQDILAAGCPTEPVTLKLSPETSLHEAHNLFELLNLHSLFVTSRGRAVGCVSWVEMKKAISNLTNPPAPK T78758 DRUGINFO D0S2HQ 3-phenyl-CPP Investigative T78758 DRUGINFO D0PW7B DIDS Investigative T84341 TARGETID T84341 T84341 FORMERID TTDR00875 T84341 UNIPROID HDGF_HUMAN T84341 TARGNAME Hepatoma-derived growth factor (HDGF) T84341 GENENAME HDGF T84341 TARGTYPE Literature-reported T84341 SYNONYMS High-mobility group protein 1-like 2; High mobility group protein 1-like 2; HMG1L2; HMG-1L2 T84341 FUNCTION Acts as a transcriptional repressor. Heparin-binding protein, with mitogenic activity for fibroblasts. T84341 PDBSTRUC 2NLU; 1RI0 T84341 SEQUENCE MSRSNRQKEYKCGDLVFAKMKGYPHWPARIDEMPEAAVKSTANKYQVFFFGTHETAFLGPKDLFPYEESKEKFGKPNKRKGFSEGLWEIENNPTVKASGYQSSQKKSCVEEPEPEPEAAEGDGDKKGNAEGSSDEEGKLVIDEPAKEKNEKGALKRRAGDLLEDSPKRPKEAENPEGEEKEAATLEVERPLPMEVEKNSTPSEPGSGRGPPQEEEEEEDEEEEATKEDAEAPGIRDHESL T30035 TARGETID T30035 T30035 FORMERID TTDR01114 T30035 UNIPROID STC1_HUMAN T30035 TARGNAME Stanniocalcin 1 (STC1) T30035 GENENAME STC1 T30035 TARGTYPE Literature-reported T30035 SYNONYMS Stanniocalcin-1; STC1 T30035 FUNCTION Stimulates renal phosphate reabsorption, and could therefore prevent hypercalcemia. T30035 BIOCLASS Stanniocalcin family T30035 SEQUENCE MLQNSAVLLVLVISASATHEAEQNDSVSPRKSRVAAQNSAEVVRCLNSALQVGCGAFACLENSTCDTDGMYDICKSFLYSAAKFDTQGKAFVKESLKCIANGVTSKVFLAIRRCSTFQRMIAEVQEECYSKLNVCSIAKRNPEAITEVVQLPNHFSNRYYNRLVRSLLECDEDTVSTIRDSLMEKIGPNMASLFHILQTDHCAQTHPRADFNRRRTNEPQKLKVLLRNLRGEEDSPSHIKRTSHESA T35983 TARGETID T35983 T35983 FORMERID TTDI01489 T35983 UNIPROID PDX1_HUMAN T35983 TARGNAME Pancreas duodenum homeobox 1 (PDX1) T35983 GENENAME PDX1 T35983 TARGTYPE Literature-reported T35983 SYNONYMS Somatostatin-transactivating factor 1; STF1; STF-1; Pancreas/duodenum homeobox protein 1; PDX-1; Islet/duodenum homeobox-1; Insulin upstream factor 1; Insulin promoter factor 1; IUF-1; IPF1; IPF-1; IDX-1; Glucose-sensitive factor; GSF T35983 FUNCTION Activates insulin, somatostatin, glucokinase, islet amyloid polypeptide and glucose transporter type 2 gene transcription. Particularly involved in glucose-dependent regulation of insulin gene transcription. As part of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells is involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element. Binds preferentially the DNA motif 5'-[CT]TAAT[TG]-3'. During development, specifies the early pancreatic epithelium, permitting its proliferation, branching and subsequent differentiation. At adult stage, required for maintaining the hormone-producing phenotype of the beta-cell. T35983 PDBSTRUC 6F8F T35983 SEQUENCE MNGEEQYYAATQLYKDPCAFQRGPAPEFSASPPACLYMGRQPPPPPPHPFPGALGALEQGSPPDISPYEVPPLADDPAVAHLHHHLPAQLALPHPPAGPFPEGAEPGVLEEPNRVQLPFPWMKSTKAHAWKGQWAGGAYAAEPEENKRTRTAYTRAQLLELEKEFLFNKYISRPRRVELAVMLNLTERHIKIWFQNRRMKWKKEEDKKRGGGTAVGGGGVAEPEQDCAVTSGEELLALPPPPPPGGAVPPAAPVAAREGRLPPGLSASPQPSSVAPRRPQEPR T10704 TARGETID T10704 T10704 FORMERID TTDR00442 T10704 UNIPROID MKC7_YEAST T10704 TARGNAME Fungal Glycosylphosphatidylinositol-aspartyl-protease (Fung MKC7) T10704 GENENAME Fung MKC7 T10704 TARGTYPE Literature-reported T10704 SYNONYMS Yapsin 2; MKC7; Glycosylphosphatidylinositol-anchored protein; GPI-anchored aspartyl protease T10704 FUNCTION Cleaves proteins C-terminally to the most C-terminal basic residue. Can process the alpha-mating factor precursor. Required for cell wall integrity. T10704 BIOCLASS Peptidase T10704 SEQUENCE MKLSVLTFVVDALLVCSSIVDAGVTDFPSLPSNEVYVKMNFQKKYGSSFENALDDTKGRTRLMTRDDDYELVELTNQNSFYSVELDIGTPPQKVTVLVDTGSSDLWVTGSDNPYCSTKKKDTTGSSFKQVNKDALASVVESVFTEISYDTTIVTSEATATFDSTASTSQLIDCATYGTFNTSKSSTFNSNNTEFSIAYGDTTFASGTWGHDQLSLNDLNITGLSFAVANETNSTVGVLGIGLPGLESTYSGVSLSSVQKSYTYNNFPMVLKNSGVIKSTAYSLFANDSDSKHGTILFGAVDHGKYAGDLYTIPIINTLQHRGYKDPIQFQVTLQGLGTSKGDKEDNLTTLTTTKIPVLLDSGTTISYMPTELVKMLADQVGATYSSAYGYYIMDCIKEMEEESSIIFDFGGFYLSNWLSDFQLVTDSRSNICILGIAPQSDPTIILGDNFLANTYVVYDLDNMEISMAQANFSDDGEYIEIIESAVPSALKAPGYSSTWSTYESIVSGGNMFSTAANSSISYFASTSHSATSSSSSKGQKTQTSTTALSISKSTSSTSSTGMLSPTSSSSTRKENGGHNLNPPFFARFITAIFHHI T38622 TARGETID T38622 T38622 FORMERID TTDR00674 T38622 UNIPROID CRBB1_HUMAN T38622 TARGNAME Beta-crystallin B1 (CRYBB1) T38622 GENENAME CRYBB1 T38622 TARGTYPE Literature-reported T38622 SYNONYMS CRYBB1; Beta B1-crystallin T38622 FUNCTION Crystallins are the dominant structural components of the vertebrate eye lens. T38622 PDBSTRUC 1OKI T38622 SEQUENCE MSQAAKASASATVAVNPGPDTKGKGAPPAGTSPSPGTTLAPTTVPITSAKAAELPPGNYRLVVFELENFQGRRAEFSGECSNLADRGFDRVRSIIVSAGPWVAFEQSNFRGEMFILEKGEYPRWNTWSSSYRSDRLMSFRPIKMDAQEHKISLFEGANFKGNTIEIQGDDAPSLWVYGFSDRVGSVKVSSGTWVGYQYPGYRGYQYLLEPGDFRHWNEWGAFQPQMQSLRRLRDKQWHLEGSFPVLATEPPK T38622 DRUGINFO D0H1GU Double Oxidized Cysteine Investigative T93033 TARGETID T93033 T93033 FORMERID TTDNR00692 T93033 UNIPROID ITA8_HUMAN T93033 TARGNAME Integrin alpha-8 (ITGA8) T93033 GENENAME ITGA8 T93033 TARGTYPE Literature-reported T93033 SYNONYMS Integrin alpha-8 light chain; Integrin alpha-8 heavy chain T93033 FUNCTION It recognizes the sequence R-G-D in a wide array of ligands including TNC, FN1, SPP1 TGFB1, TGFB3 and VTN. NPNT is probably its functional ligand in kidney genesis. Neuronal receptor for TNC it mediates cell-cell interactions and regulates neurite outgrowth of sensory and motor neurons. Integrin alpha-8/beta-1 functions in the genesis of kidney and probably of other organs by regulating the recruitment of mesenchymal cells into epithelial structures. T93033 BIOCLASS Integrin T93033 SEQUENCE MSPGASRGPRGSQAPLIAPLCCAAAALGMLLWSPACQAFNLDVEKLTVYSGPKGSYFGYAVDFHIPDARTASVLVGAPKANTSQPDIVEGGAVYYCPWPAEGSAQCRQIPFDTTNNRKIRVNGTKEPIEFKSNQWFGATVKAHKGKVVACAPLYHWRTLKPTPEKDPVGTCYVAIQNFSAYAEFSPCRNSNADPEGQGYCQAGFSLDFYKNGDLIVGGPGSFYWQGQVITASVADIIANYSFKDILRKLAGEKQTEVAPASYDDSYLGYSVAAGEFTGDSQQELVAGIPRGAQNFGYVSIINSTDMTFIQNFTGEQMASYFGYTVVVSDVNSDGLDDVLVGAPLFMEREFESNPREVGQIYLYLQVSSLLFRDPQILTGTETFGRFGSAMAHLGDLNQDGYNDIAIGVPFAGKDQRGKVLIYNGNKDGLNTKPSQVLQGVWASHAVPSGFGFTLRGDSDIDKNDYPDLIVGAFGTGKVAVYRARPVVTVDAQLLLHPMIINLENKTCQVPDSMTSAACFSLRVCASVTGQSIANTIVLMAEVQLDSLKQKGAIKRTLFLDNHQAHRVFPLVIKRQKSHQCQDFIVYLRDETEFRDKLSPINISLNYSLDESTFKEGLEVKPILNYYRENIVSEQAHILVDCGEDNLCVPDLKLSARPDKHQVIIGDENHLMLIINARNEGEGAYEAELFVMIPEEADYVGIERNNKGFRPLSCEYKMENVTRMVVCDLGNPMVSGTNYSLGLRFAVPRLEKTNMSINFDLQIRSSNKDNPDSNFVSLQINITAVAQVEIRGVSHPPQIVLPIHNWEPEEEPHKEEEVGPLVEHIYELHNIGPSTISDTILEVGWPFSARDEFLLYIFHIQTLGPLQCQPNPNINPQDIKPAASPEDTPELSAFLRNSTIPHLVRKRDVHVVEFHRQSPAKILNCTNIECLQISCAVGRLEGGESAVLKVRSRLWAHTFLQRKNDPYALASLVSFEVKKMPYTDQPAKLPEGSIVIKTSVIWATPNVSFSIPLWVIILAILLGLLVLAILTLALWKCGFFDRARPPQEDMTDREQLTNDKTPEA T95842 TARGETID T95842 T95842 FORMERID TTDR00653 T95842 UNIPROID MOT1_HUMAN T95842 TARGNAME Monocarboxylate transporter 1 (SLC16A1) T95842 GENENAME SLC16A1 T95842 TARGTYPE Literature-reported T95842 SYNONYMS Solute carrier family 16 member 1; MCT1; MCT 1 T95842 FUNCTION Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bodies. Required for normal nutrient assimilation, increase of white adipose tissue and body weight gain when on a high-fat diet. Plays a role in cellular responses to a high-fat diet by modulating the cellular levels of lactate and pyruvate, small molecules that contribute to the regulation of central metabolic pathways and insulin secretion, with concomitant effects on plasma insulin levels and blood glucose homeostasis. Proton-coupled monocarboxylate transporter. T95842 BIOCLASS Major facilitator T95842 SEQUENCE MPPAVGGPVGYTPPDGGWGWAVVIGAFISIGFSYAFPKSITVFFKEIEGIFHATTSEVSWISSIMLAVMYGGGPISSILVNKYGSRIVMIVGGCLSGCGLIAASFCNTVQQLYVCIGVIGGLGLAFNLNPALTMIGKYFYKRRPLANGLAMAGSPVFLCTLAPLNQVFFGIFGWRGSFLILGGLLLNCCVAGALMRPIGPKPTKAGKDKSKASLEKAGKSGVKKDLHDANTDLIGRHPKQEKRSVFQTINQFLDLTLFTHRGFLLYLSGNVIMFFGLFAPLVFLSSYGKSQHYSSEKSAFLLSILAFVDMVARPSMGLVANTKPIRPRIQYFFAASVVANGVCHMLAPLSTTYVGFCVYAGFFGFAFGWLSSVLFETLMDLVGPQRFSSAVGLVTIVECCPVLLGPPLLGRLNDMYGDYKYTYWACGVVLIISGIYLFIGMGINYRLLAKEQKANEQKKESKEEETSIDVAGKPNEVTKAAESPDQKDTDGGPKEEESPV T80042 TARGETID T80042 T80042 FORMERID TTDI00102 T80042 UNIPROID TERF1_HUMAN T80042 TARGNAME Telomeric repeat-binding factor 1 (TERF1) T80042 GENENAME TERF1 T80042 TARGTYPE Literature-reported T80042 SYNONYMS Telomeric protein Pin2/TRF1; TTAGGG repeat-binding factor 1; TRF1; TRF; TRBF1; PIN2; NIMA-interacting protein 2 T80042 FUNCTION Involved in the regulation of the mitotic spindle. Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection. Shelterin associates with arrays of double-stranded 5'-TTAGGG-3' repeats added by telomerase and protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage surveillance and chromosome ends are inappropriately processed by DNA repair pathways. Binds the telomeric double-stranded 5'-TTAGGG-3' repeat and negatively regulates telomere length. T80042 PDBSTRUC 5XUP; 5WIR; 5HKP; 3L82; 3BQO T80042 SEQUENCE MAEDVSSAAPSPRGCADGRDADPTEEQMAETERNDEEQFECQELLECQVQVGAPEEEEEEEEDAGLVAEAEAVAAGWMLDFLCLSLCRAFRDGRSEDFRRTRNSAEAIIHGLSSLTACQLRTIYICQFLTRIAAGKTLDAQFENDERITPLESALMIWGSIEKEHDKLHEEIQNLIKIQAIAVCMENGNFKEAEEVFERIFGDPNSHMPFKSKLLMIISQKDTFHSFFQHFSYNHMMEKIKSYVNYVLSEKSSTFLMKAAAKVVESKRTRTITSQDKPSGNDVEMETEANLDTRKSVSDKQSAVTESSEGTVSLLRSHKNLFLSKLQHGTQQQDLNKKERRVGTPQSTKKKKESRRATESRIPVSKSQPVTPEKHRARKRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSVMLKDRWRTMKKLKLISSDSED T45779 TARGETID T45779 T45779 FORMERID TTDI02467 T45779 UNIPROID PMS1_HUMAN T45779 TARGNAME DNA mismatch repair protein PMS1 (PMS1) T45779 GENENAME PMS1 T45779 TARGTYPE Literature-reported T45779 SYNONYMS PMSL1; PMS1 protein homolog 1 T45779 FUNCTION Probably involved in the repair of mismatches in DNA. T45779 PDBSTRUC 2CS1 T45779 SEQUENCE MKQLPAATVRLLSSSQIITSVVSVVKELIENSLDAGATSVDVKLENYGFDKIEVRDNGEGIKAVDAPVMAMKYYTSKINSHEDLENLTTYGFRGEALGSICCIAEVLITTRTAADNFSTQYVLDGSGHILSQKPSHLGQGTTVTALRLFKNLPVRKQFYSTAKKCKDEIKKIQDLLMSFGILKPDLRIVFVHNKAVIWQKSRVSDHKMALMSVLGTAVMNNMESFQYHSEESQIYLSGFLPKCDADHSFTSLSTPERSFIFINSRPVHQKDILKLIRHHYNLKCLKESTRLYPVFFLKIDVPTADVDVNLTPDKSQVLLQNKESVLIALENLMTTCYGPLPSTNSYENNKTDVSAADIVLSKTAETDVLFNKVESSGKNYSNVDTSVIPFQNDMHNDESGKNTDDCLNHQISIGDFGYGHCSSEISNIDKNTKNAFQDISMSNVSWENSQTEYSKTCFISSVKHTQSENGNKDHIDESGENEEEAGLENSSEISADEWSRGNILKNSVGENIEPVKILVPEKSLPCKVSNNNYPIPEQMNLNEDSCNKKSNVIDNKSGKVTAYDLLSNRVIKKPMSASALFVQDHRPQFLIENPKTSLEDATLQIEELWKTLSEEEKLKYEEKATKDLERYNSQMKRAIEQESQMSLKDGRKKIKPTSAWNLAQKHKLKTSLSNQPKLDELLQSQIEKRRSQNIKMVQIPFSMKNLKINFKKQNKVDLEEKDEPCLIHNLRFPDAWLMTSKTEVMLLNPYRVEEALLFKRLLENHKLPAEPLEKPIMLTESLFNGSHYLDVLYKMTADDQRYSGSTYLSDPRLTANGFKIKLIPGVSITENYLEIEGMANCLPFYGVADLKEILNAILNRNAKEVYECRPRKVISYLEGEAVRLSRQLPMYLSKEDIQDIIYRMKHQFGNEIKECVHGRPFFHHLTYLPETT T30777 TARGETID T30777 T30777 FORMERID TTDI00157 T30777 UNIPROID AIF1_HUMAN T30777 TARGNAME Allograft inflammatory factor-1 (AIF1) T30777 GENENAME AIF1 T30777 TARGTYPE Literature-reported T30777 SYNONYMS Protein G1; Ionized calciumbinding adapter molecule 1; Allograft inflammatory factor 1; AIF1 T30777 FUNCTION Actin-binding protein that enhances membrane ruffling and RAC activation. Enhances the actin-bundling activity of LCP1. Binds calcium. Plays a role in RAC signaling and in phagocytosis. May play a role in macrophage activation and function. Promotes the proliferation of vascular smooth muscle cells and of T- lymphocytes. Enhances lymphocyte migration. Plays a role in vascular inflammation. T30777 PDBSTRUC 2G2B; 2D58 T30777 SEQUENCE MSQTRDLQGGKAFGLLKAQQEERLDEINKQFLDDPKYSSDEDLPSKLEGFKEKYMEFDLNGNGDIDIMSLKRMLEKLGVPKTHLELKKLIGEVSSGSGETFSYPDFLRMMLGKRSAILKMILMYEEKAREKEKPTGPPAKKAISELP T78650 TARGETID T78650 T78650 FORMERID TTDR00336 T78650 UNIPROID PLTP_HUMAN T78650 TARGNAME Phospholipid transfer protein (PLTP) T78650 GENENAME PLTP T78650 TARGTYPE Literature-reported T78650 SYNONYMS Plasma phospholipid transfer protein; Lipid transfer protein II; Lipid II precursor T78650 FUNCTION Essential for the transfer of excess surface lipids from triglyceride-rich lipoproteins to HDL, thereby facilitating the formation of smaller lipoprotein remnants, contributing to the formation of LDL, and assisting in the maturation of HDL particles. PLTP also plays a key role in the uptake of cholesterol from peripheral cells and tissues that is subsequently transported to the liver for degradation and excretion. Two distinct forms of PLTP exist in plasma: an active form that can transfer PC from phospholipid vesicles to high-density lipoproteins (HDL), and an inactive form that lacks this capability. Facilitates the transfer of a spectrum of different lipid molecules, including diacylglycerol, phosphatidic acid, sphingomyelin, phosphatidylcholine, phosphatidylglycerol, cerebroside and phosphatidyl ethanolamine. T78650 BIOCLASS Bactericidal permeability increasing protein T78650 SEQUENCE MALFGALFLALLAGAHAEFPGCKIRVTSKALELVKQEGLRFLEQELETITIPDLRGKEGHFYYNISEVKVTELQLTSSELDFQPQQELMLQITNASLGLRFRRQLLYWFFYDGGYINASAEGVSIRTGLELSRDPAGRMKVSNVSCQASVSRMHAAFGGTFKKVYDFLSTFITSGMRFLLNQQICPVLYHAGTVLLNSLLDTVPVRSSVDELVGIDYSLMKDPVASTSNLDMDFRGAFFPLTERNWSLPNRAVEPQLQEEERMVYVAFSEFFFDSAMESYFRAGALQLLLVGDKVPHDLDMLLRATYFGSIVLLSPAVIDSPLKLELRVLAPPRCTIKPSGTTISVTASVTIALVPPDQPEVQLSSMTMDARLSAKMALRGKALRTQLDLRRFRIYSNHSALESLALIPLQAPLKTMLQIGVMPMLNERTWRGVQIPLPEGINFVHEVVTNHAGFLTIGADLHFAKGLREVIEKNRPADVRASTAPTPSTAAV T62415 TARGETID T62415 T62415 FORMERID TTDI02643 T62415 UNIPROID MANF_HUMAN T62415 TARGNAME Mesencephalic astrocyte-derived neurotrophic factor (ARMET) T62415 GENENAME MANF T62415 TARGTYPE Literature-reported T62415 SYNONYMS Mesencephalic astrocytederived neurotrophic factor; MANF; Argininerich protein T62415 FUNCTION Selectively promotes the survival of dopaminergic neurons of the ventral mid-brain. Modulates GABAergic transmission to the dopaminergic neurons of the substantia nigra. Enhances spontaneous, as well as evoked, GABAergic inhibitory postsynaptic currents in dopaminergic neurons. Inhibits cell proliferation and endoplasmic reticulum (ER) stress-induced cell death. T62415 PDBSTRUC 2W51; 2KVE; 2KVD T62415 SEQUENCE MRRMWATQGLAVALALSVLPGSRALRPGDCEVCISYLGRFYQDLKDRDVTFSPATIENELIKFCREARGKENRLCYYIGATDDAATKIINEVSKPLAHHIPVEKICEKLKKKDSQICELKYDKQIDLSTVDLKKLRVKELKKILDDWGETCKGCAEKSDYIRKINELMPKYAPKAASARTDL T41145 TARGETID T41145 T41145 FORMERID TTDI03061 T41145 UNIPROID BRPF1_HUMAN T41145 TARGNAME Bromodomain and PHD finger containing 1 (BRPF1) T41145 GENENAME BRPF1 T41145 TARGTYPE Literature-reported T41145 SYNONYMS Protein Br140; Peregrin; Bromodomain and PHD finger-containing protein 1; BR140 T41145 FUNCTION Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. Preferentially mediates histone H3-K23 acetylation. Positively regulates the transcription of RUNX1 and RUNX2. T41145 PDBSTRUC 6EKQ; 5T4V; 5T4U; 5OWE; 5OWB T41145 SEQUENCE MGVDFDVKTFCHNLRATKPPYECPVETCRKVYKSYSGIEYHLYHYDHDNPPPPQQTPLRKHKKKGRQSRPANKQSPSPSEVSQSPGREVMSYAQAQRMVEVDLHGRVHRISIFDNLDVVSEDEEAPEEAPENGSNKENTETPAATPKSGKHKNKEKRKDSNHHHHHNVSASTTPKLPEVVYRELEQDTPDAPPRPTSYYRYIEKSAEELDEEVEYDMDEEDYIWLDIMNERRKTEGVSPIPQEIFEYLMDRLEKESYFESHNKGDPNALVDEDAVCCICNDGECQNSNVILFCDMCNLAVHQECYGVPYIPEGQWLCRRCLQSPSRAVDCALCPNKGGAFKQTDDGRWAHVVCALWIPEVCFANTVFLEPIDSIEHIPPARWKLTCYICKQRGSGACIQCHKANCYTAFHVTCAQQAGLYMKMEPVRETGANGTSFSVRKTAYCDIHTPPGSARRLPALSHSEGEEDEDEEEDEGKGWSSEKVKKAKAKSRIKMKKARKILAEKRAAAPVVSVPCIPPHRLSKITNRLTIQRKSQFMQRLHSYWTLKRQSRNGVPLLRRLQTHLQSQRNCDQVGRDSEDKNWALKEQLKSWQRLRHDLERARLLVELIRKREKLKRETIKVQQIAMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMGIDFETGMHIPHSLAGDEATHHTEDAAEEERLVLLENQKHLPVEEQLKLLLERLDEVNASKQSVGRSRRAKMIKKEMTALRRKLAHQRETGRDGPERHGPSSRGSLTPHPAACDKDGQTDSAAEESSSQETSKGLGPNMSSTPAHEVGRRTSVLFSKKNPKTAGPPKRPGRPPKNRESQMTPSHGGSPVGPPQLPIMSSLRQRKRGRSPRPSSSSDSDSDKSTEDPPMDLPANGFSGGNQPVKKSFLVYRNDCSLPRSSSDSESSSSSSSSAASDRTSTTPSKQGRGKPSFSRGTFPEDSSEDTSGTENEAYSVGTGRGVGHSMVRKSLGRGAGWLSEDEDSPLDALDLVWAKCRGYPSYPALIIDPKMPREGMFHHGVPIPVPPLEVLKLGEQMTQEAREHLYLVLFFDNKRTWQWLPRTKLVPLGVNQDLDKEKMLEGRKSNIRKSVQIAYHRALQHRSKVQGEQSSETSDSD T41145 DRUGINFO D0Q7IU PFI-4 Investigative T41145 DRUGINFO D03BTJ PMID25408830C3 Investigative T41145 DRUGINFO D08RDI OF-1 Investigative T41145 DRUGINFO D09ZPM PMID25408830C1 Investigative T41145 DRUGINFO D0C2PD PMID25974391C34 Investigative T41145 DRUGINFO D0J6XI PMID25408830C2 Investigative T41145 DRUGINFO D0O6XT NI-57 Investigative T91529 TARGETID T91529 T91529 FORMERID TTDR00900 T91529 UNIPROID PRP1_ECOLI T91529 TARGNAME Bacterial Serine/threonine protein phosphatase 1 (Bact pphA) T91529 GENENAME Bact pphA T91529 TARGTYPE Literature-reported T91529 SYNONYMS pphA; Nuclear PP1 T91529 FUNCTION Plays a key role in signaling protein misfolding via the CpxR/CPXA transducing system. It also modulates the phosphorylated status of many phosphoproteins in E.coli, some of which acting as major chaperones. Has been shown, in vitro, to act on Ser, Thr and Tyr-phosphorylated substrates. T91529 BIOCLASS Phosphoric monoester hydrolase T91529 SEQUENCE MKQPAPVYQRIAGHQWRHIWLSGDIHGCLEQLRRKLWHCRFDPWRDLLISVGDVIDRGPQSLRCLQLLEQHWVCAVRGNHEQMAMDALASQQMSLWLMNGGDWFIALADNQQKQAKTALEKCQHLPFILEVHSRTGKHVIAHADYPDDVYEWQKDVDLHQVLWSRSRLGERQKGQGITGADHFWFGHTPLRHRVDIGNLHYIDTGAVFGGELTLVQLQ T02937 TARGETID T02937 T02937 FORMERID TTDR01086 T02937 UNIPROID PPSA_HELPY T02937 TARGNAME Bacterial Phosphoenolpyruvate synthase (Bact ppsA) T02937 GENENAME Bact ppsA T02937 TARGTYPE Literature-reported T02937 SYNONYMS ppsA; Pyruvate,water dikinase; Pyruvate, water dikinase; PEP synthase T02937 FUNCTION Catalyzes the phosphorylation of pyruvate to phosphoenolpyruvate. T02937 BIOCLASS Kinase T02937 SEQUENCE MRYIKFFKELNNKNVNLVGGKNASIGEMFQELVPIGIKVPDGFAITSEAYWYLLEQGGAKQKIIELLENVDATEIDVLKIRSKQIRELIFGTPFPSDLRDEIFQAYEILSQQYHMKEADVAVRSSATAEDLPDASFAGQQDTYLNIKGKTELIHYIKSCLASLFTDRAISYRASRGFDHLKVALSVGVQKMVRADKGSAGVMFSIDTETGFKDAVFITSAWGLGENVVGGTINPDEFYVFKPTLEQNKRPIIKRQLGNKTQKMVYAPRGSEHPTRNIKTTKKEWQSFSLSDEDVLILAKYAIEIEKHYSKEAKQYRPMDIEWAKDGESGEIFIVQARPETVQSQKSKEESQVFEKFKFKNPNEKKEIILQGRAIGSKIGSGKVRIINDLEHMNSFKEGEILVTDNTDPDWEPCMKKASAVITNRGGRTCHAAIVAREIGVPAIVGVSGATDSLYTGMEITVSCAEGEEGYVYAGIYEHEIERVELSNMQETQTKIYINIGNPEKAFGFSQLPNHGVGLARMEMIILNQIKAHPLALVDLHHKKSVKEKNEIENLMAGYANPKDFFVKKIAEGIGMISAAFYPKPVIVRTSDFKSNEYMRMLGGSSYEPNEENPMLGYRGASRYYSESYNEAFSWECEALALVREEMGLTNMKVMIPFLRTIEEGKKVLEILRKNNLESGKNGLEIYIMCELPVNVILADDFLSLFDGFSIGSNDLTQLTLGVDRDSELVSHVFDERNEAMLKMFKKAIEACKRHNKYCGICGQAPSDYPEVTEFLVKEGITSISLNPDSVIPTWNAVAKLEKELKEHGLTEH T74109 TARGETID T74109 T74109 FORMERID TTDI01809 T74109 UNIPROID ITA1_HUMAN-ITB3_HUMAN T74109 TARGNAME Integrin alpha-1/beta-3 (ITGA1/B3) T74109 GENENAME ITGA1-ITGB3 T74109 TARGTYPE Literature-reported T74109 SYNONYMS alpha(1)beta(3) integrin; Alpha 1 beta 3 integrin T74109 FUNCTION The heterodimeric receptor is involved in cell-cell adhesion and may play a role in inflammation and fibrosis. The alpha 1 subunit contains an inserted (I) von Willebrand factor type I domain which is thought to be involved in collagen binding. T74109 BIOCLASS Integrin T74109 SEQUENCE MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGTMAPRPRARPGVAVACCWLLTVVLRCCVSFNVDVKNSMTFSGPVEDMFGYTVQQYENEEGKWVLIGSPLVGQPKNRTGDVYKCPVGRGESLPCVKLDLPVNTSIPNVTEVKENMTFGSTLVTNPNGGFLACGPLYAYRCGHLHYTTGICSDVSPTFQVVNSIAPVQECSTQLDIVIVLDGSNSIYPWDSVTAFLNDLLERMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEVLVAAKKIVQRGGRQTMTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNHRLKKVIQDCEDENIQRFSIAILGSYNRGNLSTEKFVEEIKSIASEPTEKHFFNVSDELALVTIVKTLGERIFALEATADQSAASFEMEMSQTGFSAHYSQDWVMLGAVGAYDWNGTVVMQKASQIIIPRNTTFNVESTKKNEPLASYLGYTVNSATASSGDVLYIAGQPRYNHTGQVIIYRMEDGNIKILQTLSGEQIGSYFGSILTTTDIDKDSNTDILLVGAPMYMGTEKEEQGKVYVYALNQTRFEYQMSLEPIKQTCCSSRQHNSCTTENKNEPCGARFGTAIAAVKDLNLDGFNDIVIGAPLEDDHGGAVYIYHGSGKTIRKEYAQRIPSGGDGKTLKFFGQSIHGEMDLNGDGLTDVTIGGLGGAALFWSRDVAVVKVTMNFEPNKVNIQKKNCHMEGKETVCINATVCFDVKLKSKEDTIYEADLQYRVTLDSLRQISRSFFSGTQERKVQRNITVRKSECTKHSFYMLDKHDFQDSVRITLDFNLTDPENGPVLDDSLPNSVHEYIPFAKDCGNKEKCISDLSLHVATTEKDLLIVRSQNDKFNVSLTVKNTKDSAYNTRTIVHYSPNLVFSGIEAIQKDSCESNHNITCKVGYPFLRRGEMVTFKILFQFNTSYLMENVTIYLSATSDSEEPPETLSDNVVNISIPVKYEVGLQFYSSASEYHISIAANETVPEVINSTEDIGNEINIFYLIRKSGSFPMPELKLSISFPNMTSNGYPVLYPTGLSSSENANCRPHIFEDPFSINSGKKMTTSTDHLKRGTILDCNTCKFATITCNLTSSDISQVNVSLILWKPTFIKSYFSSLNLTIRGELRSENASLVLSSSNQKRELAIQISKDGLPGRVPLWVILLSAFAGLLLLMLLILALWKIGFFKRPLKKKMEK T06717 TARGETID T06717 T06717 FORMERID TTDI01805 T06717 UNIPROID ITA1_HUMAN-ITB1_HUMAN T06717 TARGNAME Integrin alpha-1/beta-1 (ITGA1/B1) T06717 GENENAME ITGA1-ITGB1 T06717 TARGTYPE Literature-reported T06717 SYNONYMS alpha(1)beta(1) integrin; Alpha 1 beta 1 integrin T06717 FUNCTION Integrin alpha-1/beta-1 is a receptor for laminin and collagen. It recognizes the proline-hydroxylated sequence G-F-P-G- E-R in collagen. Involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth. T06717 BIOCLASS Integrin T06717 SEQUENCE MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMAPRPRARPGVAVACCWLLTVVLRCCVSFNVDVKNSMTFSGPVEDMFGYTVQQYENEEGKWVLIGSPLVGQPKNRTGDVYKCPVGRGESLPCVKLDLPVNTSIPNVTEVKENMTFGSTLVTNPNGGFLACGPLYAYRCGHLHYTTGICSDVSPTFQVVNSIAPVQECSTQLDIVIVLDGSNSIYPWDSVTAFLNDLLERMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEVLVAAKKIVQRGGRQTMTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNHRLKKVIQDCEDENIQRFSIAILGSYNRGNLSTEKFVEEIKSIASEPTEKHFFNVSDELALVTIVKTLGERIFALEATADQSAASFEMEMSQTGFSAHYSQDWVMLGAVGAYDWNGTVVMQKASQIIIPRNTTFNVESTKKNEPLASYLGYTVNSATASSGDVLYIAGQPRYNHTGQVIIYRMEDGNIKILQTLSGEQIGSYFGSILTTTDIDKDSNTDILLVGAPMYMGTEKEEQGKVYVYALNQTRFEYQMSLEPIKQTCCSSRQHNSCTTENKNEPCGARFGTAIAAVKDLNLDGFNDIVIGAPLEDDHGGAVYIYHGSGKTIRKEYAQRIPSGGDGKTLKFFGQSIHGEMDLNGDGLTDVTIGGLGGAALFWSRDVAVVKVTMNFEPNKVNIQKKNCHMEGKETVCINATVCFDVKLKSKEDTIYEADLQYRVTLDSLRQISRSFFSGTQERKVQRNITVRKSECTKHSFYMLDKHDFQDSVRITLDFNLTDPENGPVLDDSLPNSVHEYIPFAKDCGNKEKCISDLSLHVATTEKDLLIVRSQNDKFNVSLTVKNTKDSAYNTRTIVHYSPNLVFSGIEAIQKDSCESNHNITCKVGYPFLRRGEMVTFKILFQFNTSYLMENVTIYLSATSDSEEPPETLSDNVVNISIPVKYEVGLQFYSSASEYHISIAANETVPEVINSTEDIGNEINIFYLIRKSGSFPMPELKLSISFPNMTSNGYPVLYPTGLSSSENANCRPHIFEDPFSINSGKKMTTSTDHLKRGTILDCNTCKFATITCNLTSSDISQVNVSLILWKPTFIKSYFSSLNLTIRGELRSENASLVLSSSNQKRELAIQISKDGLPGRVPLWVILLSAFAGLLLLMLLILALWKIGFFKRPLKKKMEK T84671 TARGETID T84671 T84671 FORMERID TTDR00999 T84671 UNIPROID TCL1A_HUMAN T84671 TARGNAME T-cell leukemia/lymphoma protein 1A (TCL1A) T84671 GENENAME TCL1A T84671 TARGTYPE Literature-reported T84671 SYNONYMS TCL1 oncogene; TCL1; TCL-1 protein; T-cell leukemia/lymphoma 1 oncogene; Protein p14 TCL1; P14 TCL1 protein; Oncogene TCL1; Oncogene TCL-1 T84671 FUNCTION Promotes nuclear translocation of AKT1. Enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell survival. Enhances the phosphorylation and activation of AKT1, AKT2 and AKT3. T84671 PDBSTRUC 1JSG T84671 SEQUENCE MAECPTLGEAVTDHPDRLWAWEKFVYLDEKQHAWLPLTIEIKDRLQLRVLLRREDVVLGRPMTPTQIGPSLLPIMWQLYPDGRYRSSDSSFWRLVYHIKIDGVEDMLLELLPDD T01529 TARGETID T01529 T01529 FORMERID TTDI03143 T01529 UNIPROID CXA9_HUMAN T01529 TARGNAME Connexin-59 (Cx59) T01529 GENENAME GJA9 T01529 TARGTYPE Literature-reported T01529 SYNONYMS Gap junction alpha-9 protein; GJA10; Cx58; Connexin-58 T01529 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T01529 BIOCLASS Gap junction-forming connexin T01529 SEQUENCE MGDWNLLGDTLEEVHIHSTMIGKIWLTILFIFRMLVLGVAAEDVWNDEQSGFICNTEQPGCRNVCYDQAFPISLIRYWVLQVIFVSSPSLVYMGHALYRLRVLEEERQRMKAQLRVELEEVEFEMPRDRRRLEQELCQLEKRKLNKAPLRGTLLCTYVIHIFTRSVVEVGFMIGQYLLYGFHLEPLFKCHGHPCPNIIDCFVSRPTEKTIFLLFMQSIATISLFLNILEIFHLGFKKIKRGLWGKYKLKKEHNEFHANKAKQNVAKYQSTSANSLKRLPSAPDYNLLVEKQTHTAVYPSLNSSSVFQPNPDNHSVNDEKCILDEQETVLSNEISTLSTSCSHFQHISSNNNKDTHKIFGKELNGNQLMEKRETEGKDSKRNYYSRGHRSIPGVAIDGENNMRQSPQTVFSLPANCDWKPRWLRATWGSSTEHENRGSPPKGNLKGQFRKGTVRTLPPSQGDSQSLDIPNTADSLGGLSFEPGLVRTCNNPVCPPNHVVSLTNNLIGRRVPTDLQI T01529 DRUGINFO D00VJY octanol Investigative T06525 TARGETID T06525 T06525 FORMERID TTDI01491 T06525 UNIPROID RAC3_HUMAN T06525 TARGNAME Rac family small GTPase 3 (RAC3) T06525 GENENAME RAC3 T06525 TARGTYPE Literature-reported T06525 SYNONYMS p21-Rac3; Ras-related C3 botulinum toxin substrate 3 T06525 FUNCTION Plasma membrane-associated small GTPase which cycles between an active GTP-bound and inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses, such as cell spreading and the formation of actin-based protusions including lamellipodia and membrane ruffles. Promotes cell adhesion and spreading on fibrinogen in a CIB1 and alpha-IIb/beta3 integrin-mediated manner. T06525 PDBSTRUC 2QME; 2OV2; 2IC5; 2G0N; 2C2H T06525 SEQUENCE MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDTAGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWYPEVRHHCPHTPILLVGTKLDLRDDKDTIERLRDKKLAPITYPQGLAMAREIGSVKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKPGKKCTVF T10864 TARGETID T10864 T10864 FORMERID TTDI02514 T10864 UNIPROID GPR85_HUMAN T10864 TARGNAME Super conserved receptor brain 2 (GPR85) T10864 GENENAME GPR85 T10864 TARGTYPE Literature-reported T10864 SYNONYMS Super conserved receptor expressed in brain 2; SREB2; Probable Gprotein coupled receptor 85; Probable G-protein coupled receptor 85 T10864 FUNCTION Orphan receptor. T10864 BIOCLASS GPCR rhodopsin T10864 SEQUENCE MANYSHAADNILQNLSPLTAFLKLTSLGFIIGVSVVGNLLISILLVKDKTLHRAPYYFLLDLCCSDILRSAICFPFVFNSVKNGSTWTYGTLTCKVIAFLGVLSCFHTAFMLFCISVTRYLAIAHHRFYTKRLTFWTCLAVICMVWTLSVAMAFPPVLDVGTYSFIREEDQCTFQHRSFRANDSLGFMLLLALILLATQLVYLKLIFFVHDRRKMKPVQFVAAVSQNWTFHGPGASGQAAANWLAGFGRGPTPPTLLGIRQNANTTGRRRLLVLDEFKMEKRISRMFYIMTFLFLTLWGPYLVACYWRVFARGPVVPGGFLTAAVWMSFAQAGINPFVCIFSNRELRRCFSTTLLYCRKSRLPREPYCVI T73230 TARGETID T73230 T73230 FORMERID TTDI01512 T73230 UNIPROID RL15_HUMAN T73230 TARGNAME Large ribosomal subunit protein eL15 (RPL15) T73230 GENENAME RPL15 T73230 TARGTYPE Literature-reported T73230 SYNONYMS TCBAP0781; EC45; 60S ribosomal protein L15 T73230 FUNCTION Up-regulated in gastric cancer tissues. Also highly expressed in gastric cancer cell lines AGS, MKN45, MKN28, SGC7901 and KATOIII. T73230 PDBSTRUC 6QZP; 6EK0; 5T2C; 5LKS; 5AJ0 T73230 SEQUENCE MGAYKYIQELWRKKQSDVMRFLLRVRCWQYRQLSALHRAPRPTRPDKARRLGYKAKQGYVIYRIRVRRGGRKRPVPKGATYGKPVHHGVNQLKFARSLQSVAEERAGRHCGALRVLNSYWVGEDSTYKFFEVILIDPFHKAIRRNPDTQWITKPVHKHREMRGLTSAGRKSRGLGKGHKFHHTIGGSRRAAWRRRNTLQLHRYR T58080 TARGETID T58080 T58080 FORMERID TTDR01280 T58080 UNIPROID B2MG_HUMAN T58080 TARGNAME Beta-2-microglobulin (B2M) T58080 GENENAME B2M T58080 TARGTYPE Literature-reported T58080 SYNONYMS Beta-2-microglobulin T58080 FUNCTION Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Exogenously applied M.tuberculosis EsxA or EsxA-EsxB (or EsxA expressed in host) binds B2M and decreases its export to the cell surface (total protein levels do not change), probably leading to defects in class I antigen presentation. T58080 PDBSTRUC 6MTM; 6MTL; 6MT6; 6MT5; 6MT4 T58080 SEQUENCE MSRSVALAVLALLSLSGLEAIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM T77393 TARGETID T77393 T77393 FORMERID TTDI03618 T77393 UNIPROID WDR5_HUMAN T77393 TARGNAME WD repeat-containing protein 5 (WDR5) T77393 GENENAME WDR5 T77393 TARGTYPE Literature-reported T77393 SYNONYMS BMP2-induced 3-kb gene protein; BIG3 T77393 FUNCTION May position the N-terminus of histone H3 for efficient trimethylation at 'Lys-4'. As part of the MLL1/MLL complex it is involved in methylation and dimethylation at 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. As part of the NSL complex it may be involved in acetylation of nucleosomal histone H4 on several lysine residues. May regulate osteoblasts differentiation. Contributes to histone modification. T77393 PDBSTRUC 6IAM; 6E1Z; 6E1Y; 6DYA; 6DY7 T77393 SEQUENCE MATEEKKPETEAARAQPTPSSSATQSKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPTENIIASAALENDKTIKLWKSDC T77393 DRUGINFO D0XI3W OICR-9429 Investigative T58361 TARGETID T58361 T58361 FORMERID TTDR00964 T58361 UNIPROID RHOB_HUMAN T58361 TARGNAME Transforming protein RhoB (RHOB) T58361 GENENAME RHOB T58361 TARGTYPE Literature-reported T58361 SYNONYMS RhoB T58361 FUNCTION Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. T58361 PDBSTRUC 2FV8 T58361 SEQUENCE MAAIRKKLVVVGDGACGKTCLLIVFSKDEFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSVDSPDSLENIPEKWVPEVKHFCPNVPIILVANKKDLRSDEHVRTELARMKQEPVRTDDGRAMAVRIQAYDYLECSAKTKEGVREVFETATRAALQKRYGSQNGCINCCKVL T46929 TARGETID T46929 T46929 FORMERID TTDR01292 T46929 UNIPROID IF5A1_HUMAN T46929 TARGNAME Eukaryotic translation initiation factor 5A-1 (EIF5A) T46929 GENENAME EIF5A T46929 TARGTYPE Literature-reported T46929 SYNONYMS eIF-5A1; eIF-5A-1; eIF-5A; eIF-4D; Rev-binding factor; Eukaryotic initiation factor 5A isoform 1 T46929 FUNCTION A GTPase-activating protein, which helps the large ribosomal subunit associate with the small subunit. Involved in the initiation phase of eukaryotic translation. Stabilize the formation of ribosomal preinitiation complexes around the start codon and are an important input for post-transcription gene regulation. Helps with elongation and also plays a role in termination. T46929 PDBSTRUC 5DLQ; 3CPF; 1FH4 T46929 SEQUENCE MADDLDFETGDAGASATFPMQCSALRKNGFVVLKGRPCKIVEMSTSKTGKHGHAKVHLVGIDIFTGKKYEDICPSTHNMDVPNIKRNDFQLIGIQDGYLSLLQDSGEVREDLRLPEGDLGKEIEQKYDCGEEILITVLSAMTEEAAVAIKAMAK T74570 TARGETID T74570 T74570 FORMERID TTDI03315 T74570 UNIPROID KCNJ2_HUMAN T74570 TARGNAME Inward rectifier potassium channel Kir2.1 (KCNJ2) T74570 GENENAME KCNJ2 T74570 TARGTYPE Literature-reported T74570 SYNONYMS hIRK1; Potassium channel, inwardly rectifying subfamily J member 2; Inward rectifier K(+) channel Kir2.1; IRK1; IRK-1; Cardiac inward rectifier potassium channel T74570 FUNCTION Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium or cesium. Probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues. T74570 BIOCLASS Inward rectifier potassium channel T74570 SEQUENCE MGSVRTNRYSIVSSEEDGMKLATMAVANGFGNGKSKVHTRQQCRSRFVKKDGHCNVQFINVGEKGQRYLADIFTTCVDIRWRWMLVIFCLAFVLSWLFFGCVFWLIALLHGDLDASKEGKACVSEVNSFTAAFLFSIETQTTIGYGFRCVTDECPIAVFMVVFQSIVGCIIDAFIIGAVMAKMAKPKKRNETLVFSHNAVIAMRDGKLCLMWRVGNLRKSHLVEAHVRAQLLKSRITSEGEYIPLDQIDINVGFDSGIDRIFLVSPITIVHEIDEDSPLYDLSKQDIDNADFEIVVILEGMVEATAMTTQCRSSYLANEILWGHRYEPVLFEEKHYYKVDYSRFHKTYEVPNTPLCSARDLAEKKYILSNANSFCYENEVALTSKEEDDSENGVPESTSTDTPPDIDLHNQASVPLEPRPLRRESEI T74570 DRUGINFO D05HXE oleoyl-CoA Investigative T74570 DRUGINFO D07ZAJ PIP2 Investigative T27457 TARGETID T27457 T27457 FORMERID TTDI01880 T27457 UNIPROID ACTG_HUMAN T27457 TARGNAME Gamma-actin (ACTG) T27457 GENENAME ACTG1 T27457 TARGTYPE Literature-reported T27457 SYNONYMS Actin, cytoplasmic 2; ACTG T27457 FUNCTION Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. T27457 PDBSTRUC 6G2T; 6CXJ; 6CXI; 5JLH T27457 SEQUENCE MEEEIAALVIDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREKMTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRLDLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEKSYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQEYDESGPSIVHRKCF T31442 TARGETID T31442 T31442 FORMERID TTDR01209 T31442 UNIPROID EMBA_MYCAV T31442 TARGNAME Mycobacterium Arabinosyltransferase A (MycB embA) T31442 GENENAME MycB embA T31442 TARGTYPE Literature-reported T31442 SYNONYMS Probable arabinosyltransferase A T31442 FUNCTION Arabinosyl transferase responsible for the polymerization of arabinose into the arabinan of arabinogalactan. T31442 ECNUMBER EC 2.4.2.- T31442 SEQUENCE MPHDGKQRSQRIPRSVAAVAGIAGLLLCLAVPLLPVRQTTATVLWPQGTVDGHVSQITAPLVSGAPRALDISIPCPAVATLPADGGLVVSTLPPGGMDAGKNGLFVRANKDVVVVAFRDTVAAVAQRPAVAAGACSVLHAWADAGAAGAEFVGIPGAAGTLPAEKKPQVGGIFTDLKVPAGPGLSARVDIDTRFITAPTVLKQIVMVLGTLAVLTAIVALAVLDRRSRGGGTLINWRSPIAWLSRYRPGTHLANWRRVGLATWIADAAVLATLLLWHVVGATSSDDGYNLTIARVAPKAGYLVDYYRYFGTTDAPFDWYLGLLSRLASVSTAGVWMRLPATLAGIGCWLIISHWVLRRLGPGRGGLAANRVAVFTAGAVFVAAWLPFNNGLRPEPLIALGVLVTWMLVERAIALQRLAPAAVAVVVALLTATLAPQGLIAVAALLTGARAVAQAIRRRRASDGLLAPLAVLAAALSLILVVVFRSQTVATVLESARIKYKVGPTIAWYQDWLRYYFLTVESNPDGSMARRFAVLVMLLCLFGMLVILLRRGHVPGVASGPRWRLIGTTAVGLLLLTFTPTKWAVQFGAFAGLAGALGALTAFACSRIGLHNRRNLTLYVTALLFVLAWATSGINGWFYVGNYGVPWYDIQPVIASHPVTSMFLTLSIITGLLAAWQHFRMDYAGHTEVKDSRRNRVLASTPLLVVATIMVVGEVASLTKGAVFRYPLYTTGKANLAAIASGLSPTSCAMADDVLAEPDANAGMLQPLPGQTFGPDGPLGGVNPVGFKPDGVGDDLQSDPVVTKPGLVNSDASPNKPNVAYSDSAGTAGGKGPVGVNGSHAALPFGLDPARTPVMGSYGENSLAATATSAWYQLPPRTPDRPLVVVSAAGAIWSYKEDGTFTYGQSLKLQWGVARPDGSTVPLAEVQPIDIGPQPAWRNLRFPLAWAPPEANVARIVAYDPNLSSEQWFAFTPPRVPVTETLQQLIGSQTPVMMDIATAANFPCQRPFSEHLGVAELPAYRILPDRKQTAASSNLWQSSEAGGPFLFLQALLRTSTIPTYLRGDWYRDWGSVEQYFRLVPADQAPDAAIEQGVMTVHGWSRQGPIRALP T68114 TARGETID T68114 T68114 FORMERID TTDR01210 T68114 UNIPROID EMBB_MYCAV T68114 TARGNAME Mycobacterium Arabinosyltransferase B (MycB embB) T68114 GENENAME MycB embB T68114 TARGTYPE Literature-reported T68114 SYNONYMS Probable arabinosyltransferase B T68114 FUNCTION Arabinosyl transferase responsible for the polymerization of arabinose into the arabinan of arabinogalactan. T68114 ECNUMBER EC 2.4.2.- T68114 SEQUENCE MSVSTVGGDVRVTRWVATIAGLIGFVLSVATPLLPVVQTTATLNWPQGGQLNSVTAPLISLTPVDLTATVPCSLVRDLPPGGGVILSTGPKKGKDAALNALFVVAHGKRVDVTDRNVVIASASRDQVAGAGCSRIEIASTRAGTFATFVGLTDPAGKPLGGGFPDPNLRPQIVGVFTDLTGPAPAGLKLSATIDTRFSTTPTTLKLAAMVTAILATIVALVALWRLDQLDGHRMRRLIPANWRTFTLADVAVIFGFVLWHVIGANSSDDGYILGMARVADRAGYMSNYFRWFGSPEDPFGWYYNLLALMTHVSDASLWMRLPDLFAGIVCWLLLSREVLPRLGPAVAASRPANWAAGMVLLTAWMPFDNGLRPEPIIALGSLVTYVLIERSMRYSRLTPAALAVITAAFTLGVQPTGLIAVAALVAGGRPILRILVRRHRVVGTWPLVAPMLAAGTVILTVVFADQTLATVLEATRIRTAIGPSQAWYTENLRYYYLILPTVDGSLSRRFGFLITALCLFTAVFIMLRRKRIPGVARGPAWRLMGVIFGTMFFLMFTPTKWVHHFGLFAAVGAAMAALTTVLVSPAVLGWSRNRMAFLAALLFMMALCFATTNGWWYVSSYGVPFNSTMPKIGGITVSTVFFSMFVAAALYAIWLHFASREHGEGRLARALTAAPVPLAAGFMALVFIASMVAGIVRQYPTYSNAWDNLREFSGGCGLADDVLVEPDSNVGYMTPLGGDYGPLGPLGGQHPVGFSPNGVPEHTVAEAIRITPNQPGTDYDWDAPTKLSAPGINGSTVPLPYGLDAARVPLAGSYTTGAQQQSRLTSAWYRLPAPDDGHPLVVVTAAGKIAGNSVLHHHTDGQTVVLEYGRPGPGGDIVPAGRLVPYDLYGEQPKAWRNLRFARSDMPADTVAVRVVAEDLSLTPEDWIAVTPPRVPEMRSLQEYVGSTQPVLMDWAVGLAFPCQQPMLHVNGVTEIPKFRITPDYTAKKMDTDTWEDGTNGGLLGITDLLLRAHVMSTYLSHDWGRDWGSLRRFETIADAHPAQLDLGTATRTGWWSPGPIRIKP T82604 TARGETID T82604 T82604 FORMERID TTDNR00659 T82604 UNIPROID CP4F2_HUMAN; CP4F3_HUMAN T82604 TARGNAME Cytochrome P450 4f (P450-4F) T82604 GENENAME CYP4F2; CYP4F3 T82604 TARGTYPE Literature-reported T82604 SYNONYMS Leukotriene-B(4) omega-hydroxylase; Leukotriene-B(4) 20-monooxygenase; Cytochrome P450-LTB-omega; CYPIVF; 20-hydroxyeicosatetraenoic acid synthase; 20-HETE synthase T82604 FUNCTION Hydroxylates arachidonic acid (20:4n-6) to (18R)- hydroxyarachidonate. Shows little activity against prostaglandin (PG) D2, PGE1, PGE2, PGF2alpha, and leukotriene B4. Catalyzes omega-2 and omega-3-hydroxylation of PGH1 and PGH2. Catalyzes epoxidation of 4,7,10,13,16,19-(Z)-docosahexaenoic acid (22:6n-3) and 7,10,13,16,19-(Z)-docosapentaenoic acid (22:5n-3) and omega-3- hydroxylation of 4,7,10,13,16-(Z)-docosapentaenoic acid (22:5n-6). Catalyzes hydroxylation of PGI2 and carbaprostacyclin. T82604 BIOCLASS Paired donor oxygen oxidoreductase T82604 SEQUENCE MSQLSLSWLGLWPVAASPWLLLLLVGASWLLAHVLAWTYAFYDNCRRLRCFPQPPRRNWFWGHQGMVNPTEEGMRVLTQLVATYPQGFKVWMGPISPLLSLCHPDIIRSVINASAAIAPKDKFFYSFLEPWLGDGLLLSAGDKWSRHRRMLTPAFHFNILKPYMKIFNESVNIMHAKWQLLASEGSACLDMFEHISLMTLDSLQKCVFSFDSHCQEKPSEYIAAILELSALVSKRHHEILLHIDFLYYLTPDGQRFRRACRLVHDFTDAVIQERRRTLPSQGVDDFLQAKAKSKTLDFIDVLLLSKDEDGKKLSDEDIRAEADTFMFEGHDTTASGLSWVLYHLAKHPEYQERCRQEVQELLKDREPKEIEWDDLAHLPFLTMCMKESLRLHPPVPVISRHVTQDIVLPDGRVIPKGIICLISVFGTHHNPAVWPDPEVYDPFRFDPENIKERSPLAFIPFSAGPRNCIGQTFAMAEMKVVLALTLLRFRVLPDHTEPRRKPELVLRAEGGLWLRVEPLS T34405 TARGETID T34405 T34405 FORMERID TTDR00524 T34405 UNIPROID X3CL1_HUMAN T34405 TARGNAME Fractalkine (CX3CL1) T34405 GENENAME CX3CL1 T34405 TARGTYPE Literature-reported T34405 SYNONYMS Small-inducible cytokine D1; Small inducible cytokine D1; SCYD1; Neurotactin; NTT; FKN; CX3C membrane-anchored chemokine; C-X3-C motif chemokine 1; A-152E5.2 T34405 FUNCTION Binds to CX3CR1. Binds to integrins ITGAV:ITGB3 and ITGA4:ITGB1. Can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner. In the presence of CX3CR1, activates integrins by binding to the classical ligand-binding site (site 1) in integrins. In the absence of CX3CR1, binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1. The soluble form is chemotactic for T-cells and monocytes and not for neutrophils. The membrane-bound form promotes adhesion of those leukocytes to endothelial cells. May play a role in regulating leukocyte adhesion and migration processes at the endothelium. Acts as a ligand for both CX3CR1 and integrins. T34405 PDBSTRUC 5WB2; 4XT3; 4XT1; 3ONA; 1F2L T34405 SEQUENCE MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIPVALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGTFEKQIGEVKPRTTPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTGVTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEAPSTQDPSTQASTASSPAPEENAPSEGQRVWGQGQSPRPENSLEREEMGPVPAHTDAFQDWGPGSMAHVSVVPVSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDAQAATRRQAVGLLAFLGLLFCLGVAMFTYQSLQGCPRKMAGEMAEGLRYIPRSCGSNSYVLVPV T90766 TARGETID T90766 T90766 UNIPROID H33_HUMAN T90766 TARGNAME Mutated Histone H3.3 (H3F3A) T90766 GENENAME H3F3A T90766 TARGTYPE Literature-reported T90766 SYNONYMS PP781; Histone H3.3; H3F3; H3.3B; H3.3A T90766 FUNCTION Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis. Deposited at sites of nucleosomal displacement throughout transcribed genes, suggesting that it represents an epigenetic imprint of transcriptionally active chromatin. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. T90766 PDBSTRUC 6J51; 6J50; 6J4Z; 6J4Y; 6J4X T90766 SEQUENCE MARTKQTARKSTGGKAPRKQLATKAARKSAPSTGGVKKPHRYRPGTVALREIRRYQKSTELLIRKLPFQRLVREIAQDFKTDLRFQSAAIGALQEASEAYLVGLFEDTNLCAIHAKRVTIMPKDIQLARRIRGERA T73675 TARGETID T73675 T73675 FORMERID TTDR00595 T73675 UNIPROID P96966_PORGN T73675 TARGNAME Bacterial Kgp protease (Bact kgp-381) T73675 GENENAME Bact kgp-381 T73675 TARGTYPE Literature-reported T73675 SYNONYMS Cysteine protease T73675 FUNCTION Important for both nutrition and virulence of P. gingivalis T73675 BIOCLASS Protease T73675 SEQUENCE MRKLLLLIAASLLGVGLYAQSAKIKLDAPTTRTTCTNNSFKQFDASFSFNEVELTKVETKGGTFASVSIPGAFPTGEVGSPEVPAVRKLIAVPVGATPVVRVKSFTEQVYSLNQYGSEKLMPHQPSMSKSDDPEKVPFVYNAAAYARKGFVGQELTQVEMLGTMRGVRIAALTINPVQYDVVANQLKVRNNIEIEVSFQGADEVATQRLYDASFSPYFETAYKQLFNRDVYTDHGDLYNTPVRMLVVAGAKFKEALKPWLTWKAQKGFYLDVHYTDEAEVGTTNASIKAFIHKKYNDGLAASAAPVFLALVGDTDVISGEKGKKTKKVTDLYYSAVDGDYFPEMYTFRMSASSPEELTNIIDKY T33755 TARGETID T33755 T33755 FORMERID TTDR00594 T33755 UNIPROID MP63_MYCTU T33755 TARGNAME Mycobacterium Immunogenic protein MPT63/MPB63 (MycB mpt63) T33755 GENENAME MycB mpt63 T33755 TARGTYPE Literature-reported T33755 SYNONYMS Immunogenic protein MPT63; Antigen MPT63; 16 kDa immunoprotective extracellular protein T33755 FUNCTION A secreted protein of unknown function that is specific to mycobacteria. T33755 PDBSTRUC 1LMI T33755 SEQUENCE MKLTTMIKTAVAVVAMAAIATFAAPVALAAYPITGKLGSELTMTDTVGQVVLGWKVSDLKSSTAVIPGYPVAGQVWEATATVNAIRGSVTPAVSQFNARTADGINYRVLWQAAGPDTISGATIPQGEQSTGKIYFDVTGPSPTIVAMNNGMEDLLIWEP T16285 TARGETID T16285 T16285 FORMERID TTDI02428 T16285 UNIPROID MUC5A_HUMAN T16285 TARGNAME Tracheobronchial mucin 5A (MUC5AC) T16285 GENENAME MUC5AC T16285 TARGTYPE Literature-reported T16285 SYNONYMS Tracheobronchial mucin; TBM; Mucin5AC; Mucin5 subtype AC, tracheobronchial; Mucin-5AC; Mucin-5 subtype AC, tracheobronchial; Major airway glycoprotein; MUC5; MUC-5AC; Lewis B blood group antigen; LeB; Gastric mucin T16285 FUNCTION Gel-forming glycoprotein of gastric and respiratoy tract epithelia that protects the mucosa from infection and chemical damage by binding to inhaled microrganisms and particles that are subsequently removed by the mucocilary system. T16285 PDBSTRUC 5AJP; 5AJO; 5AJN T16285 SEQUENCE MSVGRRKLALLWALALALACTRHTGHAQDGSSESSYKHHPALSPIARGPSGVPLRGATVFPSLRTIPVVRASNPAHNGRVCSTWGSFHYKTFDGDVFRFPGLCNYVFSEHCGAAYEDFNIQLRRSQESAAPTLSRVLMKVDGVVIQLTKGSVLVNGHPVLLPFSQSGVLIQQSSSYTKVEARLGLVLMWNHDDSLLLELDTKYANKTCGLCGDFNGMPVVSELLSHNTKLTPMEFGNLQKMDDPTDQCQDPVPEPPRNCSTGFGICEELLHGQLFSGCVALVDVGSYLEACRQDLCFCEDTDLLSCVCHTLAEYSRQCTHAGGLPQDWRGPDFCPQKCPNNMQYHECRSPCADTCSNQEHSRACEDHCVAGCFCPEGTVLDDIGQTGCVPVSKCACVYNGAAYAPGATYSTDCTNCTCSGGRWSCQEVPCPGTCSVLGGAHFSTFDGKQYTVHGDCSYVLTKPCDSSAFTVLAELRRCGLTDSETCLKSVTLSLDGAQTVVVIKASGEVFLNQIYTQLPISAANVTIFRPSTFFIIAQTSLGLQLNLQLVPTMQLFMQLAPKLRGQTCGLCGNFNSIQADDFRTLSGVVEATAAAFFNTFKTQAACPNIRNSFEDPCSLSVENEKYAQHWCSQLTDADGPFGRCHAAVKPGTYYSNCMFDTCNCERSEDCLCAALSSYVHACAAKGVQLGGWRDGVCTKPMTTCPKSMTYHYHVSTCQPTCRSLSEGDITCSVGFIPVDGCICPKGTFLDDTGKCVQASNCPCYHRGSMIPNGESVHDSGAICTCTHGKLSCIGGQAPAPVCAAPMVFFDCRNATPGDTGAGCQKSCHTLDMTCYSPQCVPGCVCPDGLVADGEGGCITAEDCPCVHNEASYRAGQTIRVGCNTCTCDSRMWRCTDDPCLATCAVYGDGHYLTFDGQSYSFNGDCEYTLVQNHCGGKDSTQDSFRVVTENVPCGTTGTTCSKAIKIFLGGFELKLSHGKVEVIGTDESQEVPYTIRQMGIYLVVDTDIGLVLLWDKKTSIFINLSPEFKGRVCGLCGNFDDIAVNDFATRSRSVVGDVLEFGNSWKLSPSCPDALAPKDPCTANPFRKSWAQKQCSILHGPTFAACHAHVEPARYYEACVNDACACDSGGDCECFCTAVAAYAQACHEVGLCVSWRTPSICPLFCDYYNPEGQCEWHYQPCGVPCLRTCRNPRGDCLRDVRGLEGCYPKCPPEAPIFDEDKMQCVATCPTPPLPPRCHVHGKSYRPGAVVPSDKNCQSCLCTERGVECTYKAEACVCTYNGQRFHPGDVIYHTTDGTGGCISARCGANGTIERRVYPCSPTTPVPPTTFSFSTPPLVVSSTHTPSNGPSSAHTGPPSSAWPTTAGTSPRTRLPTASASLPPVCGEKCLWSPWMDVSRPGRGTDSGDFDTLENLRAHGYRVCESPRSVECRAEDAPGVPLRALGQRVQCSPDVGLTCRNREQASGLCYNYQIRVQCCTPLPCSTSSSPAQTTPPTTSKTTETRASGSSAPSSTPGTVSLSTARTTPAPGTATSVKKTFSTPSPPPVPATSTSSMSTTAPGTSVVSSKPTPTEPSTSSCLQELCTWTEWIDGSYPAPGINGGDFDTFQNLRDEGYTFCESPRSVQCRAESFPNTPLADLGQDVICSHTEGLICLNKNQLPPICYNYEIRIQCCETVNVCRDITRLPKTVATTRPTPHPTGAQTQTTFTTHMPSASTEQPTATSRGGPTATSVTQGTHTTLVTRNCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPRGCHMTSTPGSTSSSPAQTTPSTTSKTTETQASGSSAPSSTPGTVSLSTARTTPAPGTATSVKKTFSTPSPPPVPATSTSSMSTTAPGTSVVSSKPTPTEPSTSSCLQELCTWTEWIDGSYPAPGINGGDFDTFQNLRDEGYTFCESPRSVQCRAESFPNTPLADLGQDVICSHTEGLICLNKNQLPPICYNYEIRIQCCETVNVCRDITRPPKTVATTRPTPHPTGAQTQTTFTTHMPSASTEQPTATSRGGPTATSVTQGTHTTPVTRNCHPRCTWTTWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTYAHTTSTTSAPTARTTSAPTTRTTSASPASTTSGPGNTPSPVPTTSTISAPTTSITSAPTTSTTSAPTSSTTSGPGTTPSPVPTTSITSAPTTSTTSAPTTSTTSARTSSTTSATTTSRISGPETTPSPVPTTSTTSATTTSTTSAPTTSTTSAPTSSTTSSPQTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPTTRTTSAPKSSTTSAATTSTTSGPETTPRPVPTTSTTSSPTTSTTSAPTTSTTSASTTSTTSGAGTTPSPVPTTSTTSAPTTSTTSAPISSTTSATTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSAVPTTSITSAPTTSTNSAPISSTTSATTTSRISGPETTPSPVPTASTTSASTTSTTSGPGTTPSPVPTTSTISVPTTSTTSASTTSTTSASTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSAPTTSTISAPTTSTTSATTTSTTSAPTPRRTSAPTTSTISASTTSTTSATTTSTTSATTTSTISAPTTSTTLSPTTSTTSTTITSTTSAPISSTTSTPQTSTTSAPTTSTTSGPGTTSSPVPTTSTTSAPTTSTTSAPTTRTTSVPTSSTTSTATTSTTSGPGTTPSPVPTTSTTSAPTTRTTSAPTTSTTSAPTTSTTSAPTSSTTSATTTSTISVPTTSTTSVPGTTPSPVPTTSTISVPTTSTTSASTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSAPTTSTISAPTTSTPSAPTTSTTLAPTTSTTSAPTTSTTSTPTSSTTSSPQTSTTSASTTSITSGPGTTPSPVPTTSTTSAPTTSTTSAATTSTISAPTTSTTSAPTTSTTSASTASKTSGLGTTPSPIPTTSTTSPPTTSTTSASTASKTSGPGTTPSPVPTTSTIFAPRTSTTSASTTSTTPGPGTTPSPVPTTSTASVSKTSTSHVSISKTTHSQPVTRDCHLRCTWTKWFDIDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTSAPTTSTTSAPTTSTTSAPTTSTTSTPQTSISSAPTSSTTSAPTSSTISARTTSIISAPTTSTTSSPTTSTTSATTTSTTSAPTSSTTSTPQTSKTSAATSSTTSGSGTTPSPVTTTSTASVSKTSTSHVSVSKTTHSQPVTRDCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTSVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTSSITSTTQTSTTSAPTTSTTPASIPSTTSAPTTSTTSAPTTSTTSAPTTSTTSTPQTTTSSAPTSSTTSAPTTSTISAPTTSTISAPTTSTTSAPTASTTSAPTSTSSAPTTNTTSAPTTSTTSAPITSTISAPTTSTTSTPQTSTISSPTTSTTSTPQTSTTSSPTTSTTSAPTTSTTSAPTTSTTSTPQTSISSAPTSSTTSAPTASTISAPTTSTTSFHTTSTTSPPTSSTSSTPQTSKTSAATSSTTSGSGTTPSPVPTTSTASVSKTSTSHVSVSKTTHSQPVTRDCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTSAPTTSTIPASTPSTTSAPTTSTTSAPTTSTTSAPTHRTTSGPTTSTTLAPTTSTTSAPTTSTNSAPTTSTISASTTSTISAPTTSTISSPTSSTTSTPQTSKTSAATSSTTSGSGTTPSPVPTTSTTSASTTSTTSAPTTSTTSGPGTTPSPVPSTSTTSAATTSTTSAPTTRTTSAPTSSMTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPITSTTSGPGSTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTTPSPVPTTSTTSAPTTRTTSASTASTTSGPGSTPSPVPTTSTTSAPTTRTTPASTASTTSGPGTTPSPVPTTSTTSASTTSTISLPTTSTTSAPITSMTSGPGTTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTSLSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTPVSKTSTSHLSVSKTTHSQPVTSDCHPLCAWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVNIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPRGCPVTSVTPYGTSPTNALYPSLSTSMVSASVASTSVASSSVASSSVAYSTQTCFCNVADRLYPAGSTIYRHRDLAGHCYYALCSQDCQVVRGVDSDCPSTTLPPAPATSPSISTSEPVTELGCPNAVPPRKKGETWATPNCSEATCEGNNVISLRPRTCPRVEKPTCANGYPAVKVADQDGCCHHYQCQCVCSGWGDPHYITFDGTYYTFLDNCTYVLVQQIVPVYGHFRVLVDNYFCGAEDGLSCPRSIILEYHQDRVVLTRKPVHGVMTNEIIFNNKVVSPGFRKNGIVVSRIGVKMYATIPELGVQVMFSGLIFSVEVPFSKFANNTEGQCGTCTNDRKDECRTPRGTVVASCSEMSGLWNVSIPDQPACHRPHPTPTTVGPTTVGSTTVGPTTVGSTTVGPTTPPAPCLPSPICQLILSKVFEPCHTVIPPLLFYEGCVFDRCHMTDLDVVCSSLELYAALCASHDICIDWRGRTGHMCPFTCPADKVYQPCGPSNPSYCYGNDSASLGALPEAGPITEGCFCPEGMTLFSTSAQVCVPTGCPRCLGPHGEPVKVGHTVGMDCQECTCEAATWTLTCRPKLCPLPPACPLPGFVPVPAAPQAGQCCPQYSCACNTSRCPAPVGCPEGARAIPTYQEGACCPVQNCSWTVCSINGTLYQPGAVVSSSLCETCRCELPGGPPSDAFVVSCETQICNTHCPVGFEYQEQSGQCCGTCVQVACVTNTSKSPAHLFYPGETWSDAGNHCVTHQCEKHQDGLVVVTTKKACPPLSCSLDEARMSKDGCCRFCPPPPPPYQNQSTCAVYHRSLIIQQQGCSSSEPVRLAYCRGNCGDSSSMYSLEGNTVEHRCQCCQELRTSLRNVTLHCTDGSSRAFSYTEVEECGCMGRRCPAPGDTQHSEEAEPEPSQEAESGSWERGVPVSPMH T28516 TARGETID T28516 T28516 FORMERID TTDNC00588 T28516 UNIPROID FABG_MYCTU T28516 TARGNAME Mycobacterium Beta-ketoacyl-ACP reductase (MycB fabG1) T28516 GENENAME MycB fabG1 T28516 TARGTYPE Literature-reported T28516 SYNONYMS Beta-ketoacyl-acyl carrier protein reductase; Beta-ketoacyl-ACP reductase; 3-oxoacyl-[acyl-carrier-protein] reductase FabG1; 3-ketoacyl-acyl carrier protein reductase T28516 FUNCTION Catalyzes the NADPH-dependent reduction of beta-ketoacyl-ACP substrates to beta-hydroxyacyl-ACP products, the first reductive step in the elongation cycle of fatty acid biosynthesis. MabA preferentially metabolizes long-chain substrates (C8-C20) and has a poor affinity for the C4 substrate. T28516 PDBSTRUC 2NTN; 1UZN; 1UZM; 1UZL T28516 SEQUENCE MTATATEGAKPPFVSRSVLVTGGNRGIGLAIAQRLAADGHKVAVTHRGSGAPKGLFGVECDVTDSDAVDRAFTAVEEHQGPVEVLVSNAGLSADAFLMRMTEEKFEKVINANLTGAFRVAQRASRSMQRNKFGRMIFIGSVSGSWGIGNQANYAASKAGVIGMARSIARELSKANVTANVVAPGYIDTDMTRALDERIQQGALQFIPAKRVGTPAEVAGVVSFLASEDASYISGAVIPVDGGMGMGH T55435 TARGETID T55435 T55435 FORMERID TTDI02545 T55435 UNIPROID PKNB_MYCTU T55435 TARGNAME Mycobacterium Serine/threonine-protein kinase PknB (MycB pknB) T55435 GENENAME MycB pknB T55435 TARGTYPE Literature-reported T55435 SYNONYMS pknB; Serine/threonineprotein kinase PknB T55435 FUNCTION Key component of a signal transduction pathway that regulates cell growth and cell division via phosphorylation of target proteins such as GarA, GlmU, PapA5, PbpA, FhaB (Rv0019c), FhaA(Rv0020c), MviN, PstP, EmbR, Rv1422, Rv1747 and RseA. Shows a strong preference for Thr versus Ser as the phosphoacceptor. T55435 PDBSTRUC 6I2P; 6B2P; 5U94; 5E0Z; 5E0Y T55435 SEQUENCE MTTPSHLSDRYELGEILGFGGMSEVHLARDLRLHRDVAVKVLRADLARDPSFYLRFRREAQNAAALNHPAIVAVYDTGEAETPAGPLPYIVMEYVDGVTLRDIVHTEGPMTPKRAIEVIADACQALNFSHQNGIIHRDVKPANIMISATNAVKVMDFGIARAIADSGNSVTQTAAVIGTAQYLSPEQARGDSVDARSDVYSLGCVLYEVLTGEPPFTGDSPVSVAYQHVREDPIPPSARHEGLSADLDAVVLKALAKNPENRYQTAAEMRADLVRVHNGEPPEAPKVLTDAERTSLLSSAAGNLSGPRTDPLPRQDLDDTDRDRSIGSVGRWVAVVAVLAVLTVVVTIAINTFGGITRDVQVPDVRGQSSADAIATLQNRGFKIRTLQKPDSTIPPDHVIGTDPAANTSVSAGDEITVNVSTGPEQREIPDVSTLTYAEAVKKLTAAGFGRFKQANSPSTPELVGKVIGTNPPANQTSAITNVVIIIVGSGPATKDIPDVAGQTVDVAQKNLNVYGFTKFSQASVDSPRPAGEVTGTNPPAGTTVPVDSVIELQVSKGNQFVMPDLSGMFWVDAEPRLRALGWTGMLDKGADVDAGGSQHNRVVYQNPPAGTGVNRDGIITLRFGQ T04369 TARGETID T04369 T04369 FORMERID TTDR01000 T04369 UNIPROID CFP32_MYCTU T04369 TARGNAME Mycobacterium Glyoxylase CFP32 (MycB cfp32) T04369 GENENAME MycB cfp32 T04369 TARGTYPE Literature-reported T04369 SYNONYMS MycB Putative glyoxylase CFP32; 27 kDa antigen Cfp30B T04369 FUNCTION May function as a glyoxylase involved in the methylglyoxal detoxification pathway. Induces maturation of dendritic cells in a TLR2-dependent manner, causing increased expression of cell-surface molecules (CD80, CD86, MHC class I and II) and proinflammatory cytokines (TNF-alpha, IL-6, IL-1 beta and IL-12p70). Acts via both the NF-kappa-B and MAPK signaling pathways. Induces Th1-polarized immune responses. T04369 PDBSTRUC 3OXH T04369 SEQUENCE MPKRSEYRQGTPNWVDLQTTDQSAAKKFYTSLFGWGYDDNPVPGGGGVYSMATLNGEAVAAIAPMPPGAPEGMPPIWNTYIAVDDVDAVVDKVVPGGGQVMMPAFDIGDAGRMSFITDPTGAAVGLWQANRHIGATLVNETGTLIWNELLTDKPDLALAFYEAVVGLTHSSMEIAAGQNYRVLKAGDAEVGGCMEPPMPGVPNHWHVYFAVDDADATAAKAAAAGGQVIAEPADIPSVGRFAVLSDPQGAIFSVLKPAPQQ T89162 TARGETID T89162 T89162 FORMERID TTDI01467 T89162 UNIPROID GLMU_MYCTU T89162 TARGNAME Mycobacterium Bifunctional protein GlmU (MycB glmU) T89162 GENENAME MycB glmU T89162 TARGTYPE Literature-reported T89162 SYNONYMS Bifunctional protein GlmU T89162 FUNCTION Catalyzes the last two sequential reactions in the de novo biosynthetic pathway for UDP-N-acetylglucosamine (UDP-GlcNAc). The C-terminal domain catalyzes the transfer of acetyl group from acetyl coenzyme A to glucosamine-1-phosphate (GlcN-1-P) to produce N-acetylglucosamine-1-phosphate (GlcNAc-1-P), which is converted into UDP-GlcNAc by the transfer of uridine 5-monophosphate (from uridine 5-triphosphate), a reaction catalyzed by the N-terminal domain. T89162 PDBSTRUC 4HCQ; 4G87; 4G3S; 4G3Q; 4G3P T89162 SEQUENCE MTFPGDTAVLVLAAGPGTRMRSDTPKVLHTLAGRSMLSHVLHAIAKLAPQRLIVVLGHDHQRIAPLVGELADTLGRTIDVALQDRPLGTGHAVLCGLSALPDDYAGNVVVTSGDTPLLDADTLADLIATHRAVSAAVTVLTTTLDDPFGYGRILRTQDHEVMAIVEQTDATPSQREIREVNAGVYAFDIAALRSALSRLSSNNAQQELYLTDVIAILRSDGQTVHASHVDDSALVAGVNNRVQLAELASELNRRVVAAHQLAGVTVVDPATTWIDVDVTIGRDTVIHPGTQLLGRTQIGGRCVVGPDTTLTDVAVGDGASVVRTHGSSSSIGDGAAVGPFTYLRPGTALGADGKLGAFVEVKNSTIGTGTKVPHLTYVGDADIGEYSNIGASSVFVNYDGTSKRRTTVGSHVRTGSDTMFVAPVTIGDGAYTGAGTVVREDVPPGALAVSAGPQRNIENWVQRKRPGSPAAQASKRASEMACQQPTQPPDADQTP T50583 TARGETID T50583 T50583 FORMERID TTDI01525 T50583 UNIPROID ESXA_MYCTU T50583 TARGNAME Mycobacterium 6kDa early secretory antigenic target (MycB esxA) T50583 GENENAME MycB esxA T50583 TARGTYPE Literature-reported T50583 SYNONYMS ESAT-6; 6 kDa early secretory antigenic target T50583 FUNCTION A secreted protein that plays a number of roles in modulating the host's immune response to infection as well as being responsible for bacterial escape into the host cytoplasm. Acts as a strong host (human) T-cell antigen. Inhibits IL-12 p40 (IL12B) and TNF-alpha expression by infected host (mouse) macrophages, reduces the nitric oxide response by about 75%. In mice previously exposed to the bacterium, elicits high level of IFN-gamma production by T-cells upon subsequent challenge by M.tuberculosis, in the first phase of a protective immune response. Higher levels (1.6-3.3 uM) of recombinant protein inhibit IFN-gamma production by host (human) T-cells and also IL-17 and TNF-alpha production but not IL-2; decreases expression of host ATF-2 and JUN transcription factors by affecting T-cell receptors signaling downstream of ZAP70, without cytotoxicity or apoptosis. EsxA inhibits IFN-gamma production in human T-cells by activating p38 MAPK (MAPK14), p38 MAPK is not responsible for IL-17 decrease. Binds host (mouse) Toll-like receptor 2 (TLR2) and decreases host MYD88-dependent signaling; binding to TLR2 activates host kinase AKT and subsequently inhibits downstream activation of NF-kappa-B; the C-terminal 20 residues (76-95) are necessary and sufficient for the TLR2 inhibitory effect. Required for induction of host (human) IL-1B maturation and release by activating the host NLRP3/ASC inflammasome; may also promote access of other tuberculosis proteins to the host cells cytoplasm. Induces IL-8 (CXCL8) expression in host (human) lung epithelial cells. Exogenously applied protein, or protein expressed in host (human and mouse), binds beta-2-microglobulin (B2M) and decreases its export to the cell surface, probably leading to defects in class I antigen presentation by the host cell. Responsible for mitochondrial fragmention, redistribution around the cell nucleus and decreased mitochondrial mass; this effect is not seen until 48 hours post-infection. Able to disrupt artificial planar bilayers in the absence of EsxB (CFP-10). Native protein binds artificial liposomes in the absence but not presence of EsxB and is able to rigidify and lyse them; the EsxA-EsxB complex dissociates at acidic pH, EsxB might serve as a chaperone to prevent membrane lysis. Recombinant protein induces leakage of phosphocholine liposomes at acidic pH in the absence of ExsB, undergoes conformational change, becoming more alpha-helical at acidic pH. The study using recombinant protein did not find dissociation of EsxA-EsxB complex at acidic pH. Involved in translocation of bacteria from the host (human) phagolysosome to the host cytoplasm. Translocation into host cytoplasm is visible 3 days post-infection using cultured human cells and precedes host cell death. Recombinant protein induces apoptosis in host (human) differentiated cell lines, which is cell-line dependent; bacteria missing the ESX-1 locus do not induce apoptosis. Host (human) cells treated with EsxA become permeable to extracellular dye. EsxA and EsxA-EsxB are cytotoxic to pneumocytes. ESX-1 secretion system-induced host (mouse) cell apoptosis, which is probably responsible for infection of new host cells, might be due to EsxA. EsxA induces necrosis in aged neutrophils. May help regulate assembly and function of the type VII secretion system (T7SS) (By similarity). EsxA disassembles pre-formed EccC-EsxB multimers, possibly by making EccC-EsxA-EsxB trimers instead of EccC-EsxB-EsxB-EccC tetramers (By similarity). T50583 PDBSTRUC 3FAV; 1WA8 T50583 SEQUENCE MTEQQWNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQGVQQKWDATATELNNALQNLARTISEAGQAMASTEGNVTGMFA T26109 TARGETID T26109 T26109 FORMERID TTDR00004 T26109 UNIPROID LIGD_MYCTU T26109 TARGNAME Mycobacterium Primase (MycB ligD) T26109 GENENAME MycB ligD T26109 TARGTYPE Literature-reported T26109 SYNONYMS NHEJ DNA repair protein D; NHEJ DNA polymerase; Multifunctional non-homologous end joining DNA repair protein LigD; Mt-Lig T26109 FUNCTION With Ku forms a non-homologous end joining (NHEJ) repair enzyme which repairs DNA double-strand breaks (DSB) with reduced fidelity. Recognizes, processes and reseals DSBs, including repairs on incompatible DSB which require 3'-resection, gap filling and ligation. Anneals the 3' overhanging strands from opposing breaks to form a gapped intermediate, which then can be extended in trans by using the termini as primers for extension of the annealed break. Binds to the recessed 5'-phosphate moiety of the downstream DNA strand forming a stable synaptic complex even when the 3'-protruding ends of the template DNA strands are not complementary. Has numerous activites; gap filling copies the template strand, and prefers a 5'-phosphate in the gap and rNTPS, DNA-directed DNA or RNA polymerase on 5'-overhangs, terminal transferase (extending ssDNA or blunt dsDNA in a non-templated fashion, preferentially with rNTPs), DNA-dependent RNA primase (synthesizes short RNAs on unprimed closed ssDNA) and 3'- to 5'-exonuclease on ssDNA. Isolated Pol domain (and presumably the holoenzyme) is able to form complexes between 2 noncompatible protruding 3'-ends DNA ends via microhomologous DNA strands, in a end-bridging function to which it adds a templated nucleotide. Minimal primer length is 2 nucleotides. T26109 PDBSTRUC 4MKY; 3PKY; 2R9L; 2IRY; 2IRX T26109 SEQUENCE MGSASEQRVTLTNADKVLYPATGTTKSDIFDYYAGVAEVMLGHIAGRPATRKRWPNGVDQPAFFEKQLALSAPPWLSRATVAHRSGTTTYPIIDSATGLAWIAQQAALEVHVPQWRFVAEPGSGELNPGPATRLVFDLDPGEGVMMAQLAEVARAVRDLLADIGLVTFPVTSGSKGLHLYTPLDEPVSSRGATVLAKRVAQRLEQAMPALVTSTMTKSLRAGKVFVDWSQNSGSKTTIAPYSLRGRTHPTVAAPRTWAELDDPALRQLSYDEVLTRIARDGDLLERLDADAPVADRLTRYRRMRDASKTPEPIPTAKPVTGDGNTFVIQEHHARRPHYDFRLECDGVLVSWAVPKNLPDNTSVNHLAIHTEDHPLEYATFEGAIPSGEYGAGKVIIWDSGTYDTEKFHDDPHTGEVIVNLHGGRISGRYALIRTNGDRWLAHRLKNQKDQKVFEFDNLAPMLATHGTVAGLKASQWAFEGKWDGYRLLVEADHGAVRLRSRSGRDVTAEYPQLRALAEDLADHHVVLDGEAVVLDSSGVPSFSQMQNRGRDTRVEFWAFDLLYLDGRALLGTRYQDRRKLLETLANATSLTVPELLPGDGAQAFACSRKHGWEGVIAKRRDSRYQPGRRCASWVKDKHWNTQEVVIGGWRAGEGGRSSGVGSLLMGIPGPGGLQFAGRVGTGLSERELANLKEMLAPLHTDESPFDVPLPARDAKGITYVKPALVAEVRYSEWTPEGRLRQSSWRGLRPDKKPSEVVRE T61765 TARGETID T61765 T61765 FORMERID TTDR01297 T61765 UNIPROID GLGE_MYCTU T61765 TARGNAME Mycobacterium Alpha-glucan:maltose-phosphate maltosyltransferase (MycB glgE) T61765 GENENAME MycB glgE T61765 TARGTYPE Literature-reported T61765 SYNONYMS GMPMT; Alpha-1,4-glucan:maltose-1-phosphate maltosyltransferase; (1->4)-alpha-D-glucan:phosphate alpha-D-maltosyltransferase; (1->4)-alpha-D-glucan:maltose-1-phosphate alpha-D-maltosyltransferase T61765 FUNCTION Essential maltosyltransferase that uses maltose 1-phosphate (M1P) as the sugar donor to elongate linear or branched alpha-(1->4)-glucans. Maltooligosaccharides with a degree of polymerization (DP) superior or equal to 4 are efficient acceptors, with DP5 being optimal in the GlgE-catalyzed polymerization with M1P. Is specific for the alpha-anomer of M1P as substrate, since the beta-anomer of M1P gives no activity. Exhibits an alpha-retaining catalytic mechanism. Is also able to catalyze the reverse reaction in vitro, releasing M1P from glycogen in the presence of inorganic phosphate. Also catalyzes disproportionation reactions through maltosyl transfer between maltooligosaccharides. Is involved in a branched alpha-glucan biosynthetic pathway from trehalose, together with TreS, Mak and GlgB. T61765 BIOCLASS Glycosyl transferase T61765 SEQUENCE MSGRAIGTETEWWVPGRVEIDDVAPVVSCGVYPAKAVVGEVVPVSAAVWREGHEAVAATLVVRYLGVRYPHLTDRPRARVLPTPSEPQQRVKPLLIPMTSGQEPFVFHGQFTPDRVGLWTFRVDGWGDPIHTWRHGLIAKLDAGQGETELSNDLLVGAVLLERAATGVPRGLRDPLLAAAAALRTPGDPVTRTALALTPEIEELLADYPLRDLVTRGEQFGVWVDRPLARFGAWYEMFPRSTGGWDDDGNPVHGTFATAAAELPRIAGMGFDVVYLPPIHPIGKVHRKGRNNSPTAAPTDVGSPWAIGSDEGGHDTVHPSLGTIDDFDDFVSAARDLGMEVALDLALQCAPDHPWAREHRQWFTELPDGTIAYAENPPKKYQDIYPLNFDNDPEGLYDEVLRVVQHWVNHGVKFFRVDNPHTKPPNFWAWLIAQVKTVDPDVLFLSEAFTPPARQYGLAKLGFTQSYSYFTWRTTKWELTEFGNQIAELADYRRPNLFVNTPDILHAVLQHNGPGMFAIRAVLAATMSPAWGMYCGYELFEHRAVREGSEEYLDSEKYELRPRDFASALDQGRSLQPFITRLNIIRRLHPAFQQLRTIHFHHVDNDALLAYSKFDPATGDCVLVVVTLNAFGPEEATLWLDMAALGMEDYDRFWVRDEITGEEYQWGQANYIRIDPARAVAHIINMPAVPYESRNTLLRRR T51032 TARGETID T51032 T51032 FORMERID TTDR01012 T51032 UNIPROID PHAS_MYCTU T51032 TARGNAME Mycobacterium Polyketide synthase (MycB pks2) T51032 GENENAME MycB pks2 T51032 TARGTYPE Literature-reported T51032 SYNONYMS Polyketide synthase pks2; Phthioceranic/hydroxyphthioceranic acid synthase T51032 FUNCTION Catalyzes the synthesis of the hepta- and octamethyl phthioceranic acids and/or hydroxyphthioceranic acids that are the major acyl constituents of sulfolipids. T51032 ECNUMBER EC 2.3.1.- T51032 SEQUENCE MGLGSAASGTGADRGAWTLAEPRVTPVAVIGMACRLPGGIDSPELLWKALLRGDDLITEVPPDRWDCDEFYDPQPGVPGRTVCKWGGFLDNPADFDCEFFGIGEREAIAIDPQQRLLLETSWEAMEHAGLTQQTLAGSATGVFAGVTHGDYTMVAADAKQLEEPYGYLGNSFSMASGRVAYAMRLHGPAITVDTACSSGLTAVHMACRSLHEGESDVALAGGVALMLEPRKAAAGSALGMLSPTGRCRAFDVAADGFVSGEGCAVVVLKRLPDALADGDRILAVIRGTSANQDGHTVNIATPSQPAQVAAYRAALAAGGVDAATVGMVEAHGPGTPIGDPIEYASVSEVYGVDGPCALASVKTNFGHTQSTAGVLGLIKVVLALKHGVVPRNLHFTRLPDEIAGITTNLFVPEVTTPWPTNGRQVPRRAAVSSYGFSGTNVHAVVEQAPQTEAQPHAASTPPTGTPALFTLSASSADALRQTAQRLTDWIQQHADSLVLSDLAYTLARRRTHRSVRTAVIASSVDELIAGLGEVADGDTVYQPAVGQDDRGPVWLFSGQGSQWAAMGADLLTNESVFAATVAELEPLIAAESGFSVTEAMTAPETVTGIDRVQPTIFAMQVALAATMAAYGVRPGAVIGHSMGESAAAVVAGVLSAEDGVRVICRRSKLMATIAGSAAMASVELPALAVQSELTALGIDDVVVAVVTAPQSTVIAGGTESVRKLVDIWERRDVLARAVAVDVASHSPQVDPILDELIAALADLNPKAPEIPYYSATLFDPREAPACDARYWADNLRHTVRFSAAVRSALDDGYRVFAELSPHPLLTHAVDQIAGSVGMPVAALAGMRREQPLPLGLRRLLTDLHNAGAAVDFSVLCPQGRLVDAPLPAWSHRFLFYDREGVDNRSPGGSTVAVHPLLGAHVRLPEEPERHAWQADVGTATLPWLGDHRIHNVAALPGAAYCEMALSAARAVLGEQSEVRDMRFEAMLLLDDQTPVSTVATVTSPGVVDFAVEALQEGVGHHLRRASAVLQQVSGECEPPAYDMASLLEAHPCRVDGEDLRRQFDKHGVQYGPAFTGLAVAYVAEDATATMLAEVALPGSIRSQQGLYAIHPALLDACFQSVGAHPDSQSVGSGLLVPLGVRRVRAYAPVRTARYCYTRVTKVELVGVEADIDVLDAHGTVLLAVCGLRIGTGVSERDKHNRVLNERLLTIEWHQRELPEMDPSGAGKWLLISDCAASDVTATRLADAFREHSAACTTMRWPLHDDQLAAADQLRDQVGSDEFSGVVVLTGSNTGTPHQGSADRGAEYVRRLVGIARELSDLPGAVPRMYVVTRGAQRVLADDCVNLEQGGLRGLLRTIGAEHPHLRATQIDVDEQTGVEQLARQLLATSEEDETAWRDNEWYVARLCPTPLRPQERRTIVADHQQSGMRLQIRTPGDMQTIELAAFHRVPPGPGQIEVAVRASSVNFADVLIAFGRYPSFEGHLPQLGTDFAGVVTAVGPGVTDHKVGDHVGGMSPNGCWGTFVTCDARLAATLPPGLGDAQAAAVTTAHATAWYGLHELARIRAGDTVLIHSGTGGVGQAAIAIARAAGAEIFATAGTPQRRELLRNMGIEHVYDSRSIEFAEQIRRDTNGRGVDVVLNSVTGAAQLAGLKLLAFRGRFVEIGKRDIYGDTKLGLFPFRRNLSFYAVDLGLLSATHPEELRDLLGTVYRLTAAGELPMPQSTHYPLVEAATAIRVMGNAEHTGKLVLHIPQTGKSLVTLPPEQAQVFRPDGSYIITGGLGGLGLFLAEKMAAAGCGRIVLNSRTQPTQKMRETIEAIAAMGSEVVVECGDIAQPGTAERLVATAVATGLPVRGVLHAAAVVEDATLANITDELLARDWAPKVHGAWELHEATSGQPLDWFCLFSSAAALTGSPGQSAYSAANSWLDAFAHWRQAQGLPATAIAWGAWSDIGQLGWWSASPARASALEESNYTAITPDEGAYAFEALLRHNRVYTGYAPVIGAPWLVAFAERSRFFEVFSSSNGSGTSKFRVELNELPRDEWPARLRQLVAEQVSLILRRTVDPDRPLPEYGLDSLGALELRTRIETETGIRLAPKNVSATVRGLADHLYEQLAPDDAPAAALSSQ T43711 TARGETID T43711 T43711 FORMERID TTDI01725 T43711 UNIPROID RUNX1_HUMAN T43711 TARGNAME Runt-related transcription factor 1 (RUNX1) T43711 GENENAME RUNX1 T43711 TARGTYPE Literature-reported T43711 SYNONYMS SL3/AKV core-binding factor alpha B subunit; SL3-3 enhancer factor 1 alpha B subunit; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEBP2-alpha B; PEA2-alpha B; Oncogene AML-1; Core-binding factor subunit alpha-2; CBFA2; CBF-alpha-2; Acute myeloid leukemia 1 protein; AML1 T43711 FUNCTION Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter. Inhibits KAT6B-dependent transcriptional activation (By similarity). Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells. Positively regulates the expression of RORC in T-helper 17 cells (By similarity). T43711 PDBSTRUC 1LJM; 1H9D; 1CO1; 1CMO; 1.00E+50 T43711 SEQUENCE MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY T93292 TARGETID T93292 T93292 FORMERID TTDI00217 T93292 UNIPROID TAGL_HUMAN T93292 TARGNAME Transgelin (TAGLN) T93292 GENENAME TAGLN T93292 TARGTYPE Literature-reported T93292 SYNONYMS TAGLN; Smooth muscle protein 22-alpha; SM22-alpha; Protein WS3-10; 22 kDa actin-binding protein T93292 FUNCTION Actin cross-linking/gelling protein. Involved in calcium interactions and contractile properties of the cell that may contribute to replicative senescence. T93292 BIOCLASS Calponin family T93292 SEQUENCE MANKGPSYGMSREVQSKIEKKYDEELEERLVEWIIVQCGPDVGRPDRGRLGFQVWLKNGVILSKLVNSLYPDGSKPVKVPENPPSMVFKQMEQVAQFLKAAEDYGVIKTDMFQTVDLFEGKDMAAVQRTLMALGSLAVTKNDGHYRGDPNWFMKKAQEHKREFTESQLQEGKHVIGLQMGSNRGASQAGMTGYGRPRQIIS T68877 TARGETID T68877 T68877 FORMERID TTDR00810 T68877 UNIPROID ID2_HUMAN T68877 TARGNAME DNA-binding protein inhibitor ID-2 (ID2) T68877 GENENAME ID2 T68877 TARGTYPE Literature-reported T68877 SYNONYMS bHLHb26; Inhibitor of differentiation 2; Inhibitor of DNA binding 2; Id2; Class B basic helix-loop-helix protein 26 T68877 FUNCTION Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Inhibits skeletal muscle and cardiac myocyte differentiation. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. Restricts the CLOCK and ARNTL/BMAL1 localization to the cytoplasm. Plays a role in both the input and output pathways of the circadian clock: in the input component, is involved in modulating the magnitude of photic entrainment and in the output component, contributes to the regulation of a variety of liver clock-controlled genes involved in lipid metabolism. Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. T68877 PDBSTRUC 4AYA T68877 SEQUENCE MKAFSPVRSVRKNSLSDHSLGISRSKTPVDDPMSLLYNMNDCYSKLKELVPSIPQNKKVSKMEILQHVIDYILDLQIALDSHPTIVSLHHQRPGQNQASRTPLTTLNTDISILSLQASEFPSELMSNDSKALCG T29818 TARGETID T29818 T29818 FORMERID TTDR00464 T29818 UNIPROID PAX5_HUMAN T29818 TARGNAME Paired box protein Pax-5 (PAX5) T29818 GENENAME PAX5 T29818 TARGTYPE Literature-reported T29818 SYNONYMS PAX5; BSAP; B-cell specific transcription factor T29818 FUNCTION May play an important role in b-cell differentiation as well as neural development and spermatogenesis. Involved in the regulation of the cd19 gene, a b-lymphoid-specific target gene. T29818 PDBSTRUC 1MDM; 1K78 T29818 SEQUENCE MDLEKNYPTPRTSRTGHGGVNQLGGVFVNGRPLPDVVRQRIVELAHQGVRPCDISRQLRVSHGCVSKILGRYYETGSIKPGVIGGSKPKVATPKVVEKIAEYKRQNPTMFAWEIRDRLLAERVCDNDTVPSVSSINRIIRTKVQQPPNQPVPASSHSIVSTGSVTQVSSVSTDSAGSSYSISGILGITSPSADTNKRKRDEGIQESPVPNGHSLPGRDFLRKQMRGDLFTQQQLEVLDRVFERQHYSDIFTTTEPIKPEQTTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPIVTGRDLASTTLPGYPPHVPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSWRFPNPGLLGSPYYYSAAARGAAPPAAATAYDRH T93945 TARGETID T93945 T93945 FORMERID TTDI02602 T93945 UNIPROID CAV1_HUMAN T93945 TARGNAME Caveolin 1 (CAV1) T93945 GENENAME CAV1 T93945 TARGTYPE Literature-reported T93945 SYNONYMS Caveolin1; Caveolin-1; Cav-1 T93945 FUNCTION Forms a stable heterooligomeric complex with CAV2 that targets to lipid rafts and drives caveolae formation. Mediates the recruitment of CAVIN proteins (CAVIN1/2/3/4) to the caveolae. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Recruits CTNNB1 to caveolar membranes and may regulate CTNNB1-mediated signaling through the Wnt pathway. Negatively regulates TGFB1-mediated activation of SMAD2/3 by mediating the internalization of TGFBR1 from membrane rafts leading to its subsequent degradation. May act as a scaffolding protein within caveolar membranes. T93945 BIOCLASS Caveolin protein T93945 SEQUENCE MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLNDDVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAILSFLHIWAVVPCIKSFLIEIQCISRVYSIYVHTVCDPLFEAVGKIFSNVRINLQKEI T36147 TARGETID T36147 T36147 FORMERID TTDI01383 T36147 UNIPROID UPAR_HUMAN T36147 TARGNAME Urokinase plasminogen receptor (PLAUR) T36147 GENENAME PLAUR T36147 TARGTYPE Literature-reported T36147 SYNONYMS UPAR; U-PAR; Monocyte activation antigen Mo3; MO3 T36147 FUNCTION Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form. T36147 PDBSTRUC 4QTI; 4K24; 3U74; 3U73; 3BT2 T36147 SEQUENCE MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT T22945 TARGETID T22945 T22945 FORMERID TTDI01517 T22945 UNIPROID TAP1_HUMAN T22945 TARGNAME Antigen peptide transporter 1 (TAP1) T22945 GENENAME TAP1 T22945 TARGTYPE Literature-reported T22945 SYNONYMS Y3; Really interesting new gene 4 protein; RING4; Peptide transporter involved in antigen processing 1; Peptide transporter TAP1; Peptide transporter PSF1; Peptide supply factor 1; PSF1; PSF-1; ATP-binding cassette sub-family B member 2; ABCB2 T22945 FUNCTION Involved in the transport of antigens from the cytoplasm to the endoplasmic reticulum for association with MHC class I molecules. Also acts as a molecular scaffold for the final stage of MHC class I folding, namely the binding of peptide. Nascent MHC class I molecules associate with TAP via tapasin. Inhibited by the covalent attachment of herpes simplex virus ICP47 protein, which blocks the peptide-binding site of TAP. Inhibited by human cytomegalovirus US6 glycoprotein, which binds to the lumenal side of the TAP complex and inhibits peptide translocation by specifically blocking ATP-binding to TAP1 and prevents the conformational rearrangement of TAP induced by peptide binding. Inhibited by human adenovirus E3-19K glycoprotein, which binds the TAP complex and acts as a tapasin inhibitor, preventing MHC class I/TAP association. Expression of TAP1 is down-regulated by human Epstein-Barr virus vIL-10 protein, thereby affecting the transport of peptides into the endoplasmic reticulum and subsequent peptide loading by MHC class I molecules. T22945 PDBSTRUC 5U1D; 1JJ7 T22945 SEQUENCE MAELLASAGSACSWDFPRAPPSFPPPAASRGGLGGTRSFRPHRGAESPRPGRDRDGVRVPMASSRCPAPRGCRCLPGASLAWLGTVLLLLADWVLLRTALPRIFSLLVPTALPLLRVWAVGLSRWAVLWLGACGVLRATVGSKSENAGAQGWLAALKPLAAALGLALPGLALFRELISWGAPGSADSTRLLHWGSHPTAFVVSYAAALPAAALWHKLGSLWVPGGQGGSGNPVRRLLGCLGSETRRLSLFLVLVVLSSLGEMAIPFFTGRLTDWILQDGSADTFTRNLTLMSILTIASAVLEFVGDGIYNNTMGHVHSHLQGEVFGAVLRQETEFFQQNQTGNIMSRVTEDTSTLSDSLSENLSLFLWYLVRGLCLLGIMLWGSVSLTMVTLITLPLLFLLPKKVGKWYQLLEVQVRESLAKSSQVAIEALSAMPTVRSFANEEGEAQKFREKLQEIKTLNQKEAVAYAVNSWTTSISGMLLKVGILYIGGQLVTSGAVSSGNLVTFVLYQMQFTQAVEVLLSIYPRVQKAVGSSEKIFEYLDRTPRCPPSGLLTPLHLEGLVQFQDVSFAYPNRPDVLVLQGLTFTLRPGEVTALVGPNGSGKSTVAALLQNLYQPTGGQLLLDGKPLPQYEHRYLHRQVAAVGQEPQVFGRSLQENIAYGLTQKPTMEEITAAAVKSGAHSFISGLPQGYDTEVDEAGSQLSGGQRQAVALARALIRKPCVLILDDATSALDANSQLQVEQLLYESPERYSRSVLLITQHLSLVEQADHILFLEGGAIREGGTHQQLMEKKGCYWAMVQAPADAPE T07591 TARGETID T07591 T07591 FORMERID TTDNR00699 T07591 UNIPROID K1C17_HUMAN T07591 TARGNAME Keratin type I cytoskeletal 17 (KRT17) T07591 GENENAME KRT17 T07591 TARGTYPE Literature-reported T07591 SYNONYMS Keratin-17; KRT17; K17; Cytokeratin-17; CK-17 T07591 FUNCTION May play a role in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair. May be a marker of basal cell differentiation in complex epithelia and therefore indicative of a certain type of epithelial stem cells". May act as an autoantigen in the immunopathogenesis of psoriasis with certain peptide regions being a major target for autoreactive T-cells and hence causing their proliferation. Required for the correct growth of hair follicles in particular for the persistence of the anagen (growth) state. Modulates the function of TNF-alpha in the specific context of hair cycling. Regulates protein synthesis and epithelial cell growth through binding to the adapter protein SFN and by stimulating Akt/mTOR pathway. Involved in tissue repair. T07591 BIOCLASS Intermediate filament family T07591 SEQUENCE MTTSIRQFTSSSSIKGSSGLGGGSSRTSCRLSGGLGAGSCRLGSAGGLGSTLGGSSYSSCYSFGSGGGYGSSFGGVDGLLAGGEKATMQNLNDRLASYLDKVRALEEANTELEVKIRDWYQRQAPGPARDYSQYYRTIEELQNKILTATVDNANILLQIDNARLAADDFRTKFETEQALRLSVEADINGLRRVLDELTLARADLEMQIENLKEELAYLKKNHEEEMNALRGQVGGEINVEMDAAPGVDLSRILNEMRDQYEKMAEKNRKDAEDWFFSKTEELNREVATNSELVQSGKSEISELRRTMQALEIELQSQLSMKASLEGNLAETENRYCVQLSQIQGLIGSVEEQLAQLRCEMEQQNQEYKILLDVKTRLEQEIATYRRLLEGEDAHLTQYKKEPVTTRQVRTIVEEVQDGKVISSREQVHQTTR T52886 TARGETID T52886 T52886 FORMERID TTDI02566 T52886 UNIPROID 1433F_HUMAN T52886 TARGNAME AS1 14-3-3 protein eta (YWHAH) T52886 GENENAME YWHAH T52886 TARGTYPE Literature-reported T52886 SYNONYMS YWHA1; Protein AS1; 14-3-3 protein eta T52886 FUNCTION Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negatively regulates the kinase activity of PDPK1. Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. T52886 PDBSTRUC 2C74; 2C63 T52886 SEQUENCE MGDREQLLQRARLAEQAERYDDMASAMKAVTELNEPLSNEDRNLLSVAYKNVVGARRSSWRVISSIEQKTMADGNEKKLEKVKAYREKIEKELETVCNDVLSLLDKFLIKNCNDFQYESKVFYLKMKGDYYRYLAEVASGEKKNSVVEASEAAYKEAFEISKEQMQPTHPIRLGLALNFSVFYYEIQNAPEQACLLAKQAFDDAIAELDTLNEDSYKDSTLIMQLLRDNLTLWTSDQQDEEAGEGN T50072 TARGETID T50072 T50072 FORMERID TTDI00100 T50072 UNIPROID PLP2_HUMAN T50072 TARGNAME Proteolipid protein 2 (PLP2) T50072 GENENAME PLP2 T50072 TARGTYPE Literature-reported T50072 SYNONYMS PLP2; Intestinal membrane A4 protein; Differentiation-dependent protein A4 T50072 FUNCTION May play a role in cell differentiation in the intestinal epithelium. T50072 BIOCLASS Plasmolipin family T50072 SEQUENCE MADSERLSAPGCWAACTNFSRTRKGILLFAEIILCLVILICFSASTPGYSSLSVIEMILAAIFFVVYMCDLHTKIPFINWPWSDFFRTLIAAILYLITSIVVLVERGNHSKIVAGVLGLIATCLFGYDAYVTFPVRQPRHTAAPTDPADGPV T04827 TARGETID T04827 T04827 FORMERID TTDNR00741 T04827 UNIPROID SUH_HUMAN T04827 TARGNAME Recombining binding protein suppressor of hairless (RBPJ) T04827 GENENAME RBPJ T04827 TARGTYPE Literature-reported T04827 SYNONYMS Renal carcinoma antigen NY-REN-30; RBPSUH; RBPJK; RBP-JK; RBP-J kappa; RBP-J; J kappa-recombination signal-binding protein; IGKJRB1; IGKJRB; CBF-1 T04827 FUNCTION Acts as a transcriptional repressor when it is not associated with Notch proteins. When associated with some NICD product of Notch proteins (Notch intracellular domain), it acts as a transcriptional activator that activates transcription of Notch target genes. Probably represses or activates transcription via the recruitment of chromatin remodeling complexes containing histone deacetylase or histone acetylase proteins, respectively. Specifically binds to the immunoglobulin kappa-type J segment recombination signal sequence. Binds specifically to methylated DNA. Binds to the oxygen responsive element of COX4I2 and activates its transcription under hypoxia conditions (4% oxygen). Negatively regulates the phagocyte oxidative burst in response to bacterial infection by repressing transcription of NADPH oxidase subunits. Transcriptional regulator that plays a central role in Notch signaling, a signaling pathway involved in cell-cell communication that regulates a broad spectrum of cell-fate determinations. T04827 PDBSTRUC 3V79; 3NBN; 2F8X T04827 SEQUENCE MDHTEGSPAEEPPAHAPSPGKFGERPPPKRLTREAMRNYLKERGDQTVLILHAKVAQKSYGNEKRFFCPPPCVYLMGSGWKKKKEQMERDGCSEQESQPCAFIGIGNSDQEMQQLNLEGKNYCTAKTLYISDSDKRKHFMLSVKMFYGNSDDIGVFLSKRIKVISKPSKKKQSLKNADLCIASGTKVALFNRLRSQTVSTRYLHVEGGNFHASSQQWGAFFIHLLDDDESEGEEFTVRDGYIHYGQTVKLVCSVTGMALPRLIIRKVDKQTALLDADDPVSQLHKCAFYLKDTERMYLCLSQERIIQFQATPCPKEPNKEMINDGASWTIISTDKAEYTFYEGMGPVLAPVTPVPVVESLQLNGGGDVAMLELTGQNFTPNLRVWFGDVEAETMYRCGESMLCVVPDISAFREGWRWVRQPVQVPVTLVRNDGIIYSTSLTFTYTPEPGPRPHCSAAGAILRANSSQVPPNESNTNSEGSYTNASTNSTSVTSSTATVVS T69192 TARGETID T69192 T69192 FORMERID TTDR01306 T69192 UNIPROID C1QBP_HUMAN T69192 TARGNAME ASF/SF2-associated protein p32 (C1QBP) T69192 GENENAME C1QBP T69192 TARGTYPE Literature-reported T69192 SYNONYMS p33; gC1q-R protein; SF2P32; SF2AP32; Mitochondrial matrix protein p32; Hyaluronan-binding protein 1; HABP1; Glycoprotein gC1qBP; GC1QBP; Complement component 1 Q subcomponent-binding protein, mitochondrial; C1qBP T69192 FUNCTION Is believed to be a multifunctional and multicompartmental protein involved in inflammation and infection processes, ribosome biogenesis, protein synthesis in mitochondria, regulation of apoptosis, transcriptional regulation and pre-mRNA splicing. At the cell surface is thought to act as an endothelial receptor for plasma proteins of the complement and kallikrein-kinin cascades. Putative receptor for C1q; specifically binds to the globular "heads" of C1q thus inhibiting C1; may perform the receptor function through a complex with C1qR/CD93. In complex with cytokeratin-1/KRT1 is a high affinity receptor for kininogen-1/HMWK. Can also bind other plasma proteins, such as coagulation factor XII leading to its autoactivation. May function to bind initially fluid kininogen-1 to the cell membrane. The secreted form may enhance both extrinsic and intrinsic coagulation pathways. It is postulated that the cell surface form requires docking with transmembrane proteins for downstream signaling which might be specific for a cell-type or response. By acting as C1q receptor is involved in chemotaxis of immature dendritic cells and neutrophils and is proposed to signal through CD209/DC-SIGN on immature dendritic cells, through integrin alpha-4/beta-1 during trophoblast invasion of the decidua, and through integrin beta-1 during endothelial cell adhesion and spreading. Signaling involved in inhibition of innate immune response is implicating the PI3K-AKT/PKB pathway. Required for protein synthesis in mitochondria. In mitochondrial translation may be involved in formation of functional 55S mitoribosomes; the function seems to involve its RNA-binding activity. May be involved in the nucleolar ribosome maturation process; the function may involve the exchange of FBL for RRP1 in the association with pre-ribosome particles. Involved in regulation of RNA splicing by inhibiting the RNA-binding capacity of SRSF1 and its phosphorylation. Is required for the nuclear translocation of splicing factor U2AF1L4. Involved in regulation of CDKN2A- and HRK-mediated apoptosis. Stabilizes mitochondrial CDKN2A isoform smARF. May be involved in regulation of FOXC1 transcriptional activity and NFY/CCAAT-binding factor complex-mediated transcription. May play a role in antibacterial defense as it can bind to cell surface hyaluronan and inhibit Streptococcus pneumoniae hyaluronate lyase. May be involved in modulation of the immune response; ligation by HCV core protein is resulting in suppression of interleukin-12 production in monocyte-derived dendritic cells. Involved in regulation of antiviral response by inhibiting DDX58- and IFIH1-mediated signaling pathways probably involving its association with MAVS after viral infection. T69192 PDBSTRUC 3RPX; 1P32 T69192 SEQUENCE MLPLLRCVPRVLGSSVAGLRAAAPASPFRQLLQPAPRLCTRPFGLLSVRAGSERRPGLLRPRGPCACGCGCGSLHTDGDKAFVDFLSDEIKEERKIQKHKTLPKMSGGWELELNGTEAKLVRKVAGEKITVTFNINNSIPPTFDGEEEPSQGQKVEEQEPELTSTPNFVVEVIKNDDGKKALVLDCHYPEDEVGQEDEAESDIFSIREVSFQSTGESEWKDTNYTLNTDSLDWALYDHLMDFLADRGVDNTFADELVELSTALEHQEYITFLEDLKSFVKSQ T48780 TARGETID T48780 T48780 FORMERID TTDI02536 T48780 UNIPROID CD69_HUMAN T48780 TARGNAME Early activation antigen CD69 (CD69) T48780 GENENAME CD69 T48780 TARGTYPE Literature-reported T48780 SYNONYMS MLR3; Leukocyte surface antigen Leu23; GP32/28; Early Tcell activation antigen p60; EA1; Ctype lectin domain family 2 member C; CD69; BLAC/P26; Activation inducer molecule T48780 FUNCTION Involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets. T48780 PDBSTRUC 3HUP; 3CCK; 1FM5; 1E8I; 1.00E+87 T48780 SEQUENCE MSSENCFVAENSSLHPESGQENDATSPHFSTRHEGSFQVPVLCAVMNVVFITILIIALIALSVGQYNCPGQYTFSMPSDSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDSEKDMNFLKRYAGREEHWVGLKKEPGHPWKWSNGKEFNNWFNVTGSDKCVFLKNTEVSSMECEKNLYWICNKPYK T44658 TARGETID T44658 T44658 FORMERID TTDR01281 T44658 UNIPROID TISB_HUMAN T44658 TARGNAME CCCH tandem zinc finger protein ZFP36L1 (ERF-1) T44658 GENENAME ZFP36L1 T44658 TARGTYPE Literature-reported T44658 SYNONYMS mRNA decay activator protein ZFP36L1; Zinc finger protein 36, C3H1 type-like 1; ZFP36-like 1; TPA-induced sequence 11b; ERF-1; EGF-response factor 1; Butyrate response factor 1; BERG36 T44658 FUNCTION Zinc-finger RNA-binding protein that destabilizes several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis. Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signaling events to the mRNA decay machinery. Functions by recruiting the CCR4-NOT deadenylase complex and components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes. Induces also the degradation of ARE-containing mRNAs even in absence of poly(A) tail (By similarity). Binds to 3'-UTR ARE of numerous mRNAs. Positively regulates early adipogenesis by promoting ARE-mediated mRNA decay of immediate early genes (IEGs) (By similarity). Promotes ARE-mediated mRNA decay of mineralocorticoid receptor NR3C2 mRNA in response to hypertonic stress. Negatively regulates hematopoietic/erythroid cell differentiation by promoting ARE-mediated mRNA decay of the transcription factor STAT5B mRNA. Positively regulates monocyte/macrophage cell differentiation by promoting ARE-mediated mRNA decay of the cyclin-dependent kinase CDK6 mRNA. Promotes degradation of ARE-containing pluripotency-associated mRNAs in embryonic stem cells (ESCs), such as NANOG, through a fibroblast growth factor (FGF)-induced MAPK-dependent signaling pathway, and hence attenuates ESC self-renewal and positively regulates mesendoderm differentiation (By similarity). May play a role in mediating pro-apoptotic effects in malignant B-cells by promoting ARE-mediated mRNA decay of BCL2 mRNA. In association with ZFP36L2 maintains quiescence on developing B lymphocytes by promoting ARE-mediated decay of several mRNAs encoding cell cycle regulators that help B cells progress through the cell cycle, and hence ensuring accurate variable-diversity-joining (VDJ) recombination and functional immune cell formation (By similarity). Together with ZFP36L2 is also necessary for thymocyte development and prevention of T-cell acute lymphoblastic leukemia (T-ALL) transformation by promoting ARE-mediated mRNA decay of the oncogenic transcription factor NOTCH1 mRNA (By similarity). Participates in the delivery of target ARE-mRNAs to processing bodies (PBs). In addition to its cytosolic mRNA-decay function, plays a role in the regulation of nuclear mRNA 3'-end processing; modulates mRNA 3'-end maturation efficiency of the DLL4 mRNA through binding with an ARE embedded in a weak noncanonical polyadenylation (poly(A)) signal in endothelial cells. Also involved in the regulation of stress granule (SG) and P-body (PB) formation and fusion. Plays a role in vasculogenesis and endocardial development (By similarity). Plays a role in the regulation of keratinocyte proliferation, differentiation and apoptosis. Plays a role in myoblast cell differentiation (By similarity). T44658 PDBSTRUC 1W0W; 1W0V T44658 SEQUENCE MTTTLVSATIFDLSEVLCKGNKMLNYSAPSAGGCLLDRKAVGTPAGGGFPRRHSVTLPSSKFHQNQLLSSLKGEPAPALSSRDSRFRDRSFSEGGERLLPTQKQPGGGQVNSSRYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEERRALAGARDLSADRPRLQHSFSFAGFPSAAATAAATGLLDSPTSITPPPILSADDLLGSPTLPDGTNNPFAFSSQELASLFAPSMGLPGGGSPTTFLFRPMSESPHMFDSPPSPQDSLSDQEGYLSSSSSSHSGSDSPTLDNSRRLPIFSRLSISDD T80395 TARGETID T80395 T80395 FORMERID TTDI00045 T80395 UNIPROID KHDR1_HUMAN T80395 TARGNAME GAP-associated tyrosine phosphoprotein p62 (KHDRBS1) T80395 GENENAME KHDRBS1 T80395 TARGTYPE Literature-reported T80395 SYNONYMS p68; p21 Ras GTPaseactivating proteinassociated p62; p21 Ras GTPase-activating protein-associated p62; Srcassociated in mitosis 68 kDa protein; Src-associated in mitosis 68 kDa protein; Sam68; KH domaincontaining, RNAbinding, signal transductionassociated protein 1; KH domain-containing, RNA-binding, signal transduction-associated protein 1; GAPassociated tyrosine phosphoprotein p62 T80395 FUNCTION Once phosphorylated, functions as an adapter protein in signal transduction cascades by binding to SH2 and SH3 domain-containing proteins. Role in G2-M progression in the cell cycle. Represses CBP-dependent transcriptional activation apparently by competing with other nuclear factors for binding to CBP. Also acts as a putative regulator of mRNA stability and/or translation rates and mediates mRNA nuclear export. Positively regulates the association of constitutive transport element (CTE)-containing mRNA with large polyribosomes and translation initiation. According to some authors, is not involved in the nucleocytoplasmic export of unspliced (CTE)-containing RNA species according to. RNA-binding protein that plays a role in the regulation of alternative splicing and influences mRNA splice site selection and exon inclusion. Binds to RNA containing 5'-[AU]UAA-3' as a bipartite motif spaced by more than 15 nucleotides. Binds poly(A). Can regulate CD44 alternative splicing in a Ras pathway-dependent manner. In cooperation with HNRNPA1 modulates alternative splicing of BCL2L1 by promoting splicing toward isoform Bcl-X(S), and of SMN1. Can regulate alternative splicing of NRXN1 and NRXN3 in the laminin G-like domain 6 containing the evolutionary conserved neurexin alternative spliced segment 4 (AS4) involved in neurexin selective targeting to postsynaptic partners. In a neuronal activity-dependent manner cooperates synergistically with KHDRBS2/SLIM-1 in regulation of NRXN1 exon skipping at AS4. The cooperation with KHDRBS2/SLIM-1 is antagonistic for regulation of NXRN3 alternative splicing at AS4. Recruited and tyrosine phosphorylated by several receptor systems, for example the T-cell, leptin and insulin receptors. T80395 PDBSTRUC 3QHE; 2XA6 T80395 SEQUENCE MQRRDDPAARMSRSSGRSGSMDPSGAHPSVRQTPSRQPPLPHRSRGGGGGSRGGARASPATQPPPLLPPSATGPDATVGGPAPTPLLPPSATASVKMEPENKYLPELMAEKDSLDPSFTHAMQLLTAEIEKIQKGDSKKDDEENYLDLFSHKNMKLKERVLIPVKQYPKFNFVGKILGPQGNTIKRLQEETGAKISVLGKGSMRDKAKEEELRKGGDPKYAHLNMDLHVFIEVFGPPCEAYALMAHAMEEVKKFLVPDMMDDICQEQFLELSYLNGVPEPSRGRGVPVRGRGAAPPPPPVPRGRGVGPPRGALVRGTPVRGAITRGATVTRGVPPPPTVRGAPAPRARTAGIQRIPLPPPPAPETYEEYGYDDTYAEQSYEGYEGYYSQSQGDSEYYDYGHGEVQDSYEAYGQDDWNGTRPSLKAPPARPVKGAYREHPYGRY T13510 TARGETID T13510 T13510 FORMERID TTDR00383 T13510 UNIPROID LRP1_HUMAN T13510 TARGNAME Apolipoprotein E receptor (LRP1) T13510 GENENAME LRP1 T13510 TARGTYPE Literature-reported T13510 SYNONYMS Prolow-density lipoprotein receptor-related protein 1; LRP-1; CD91; APR; APOER T13510 FUNCTION Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission. Acts as an alpha-2-macroglobulin receptor. T13510 PDBSTRUC 2KNY; 2KNX; 2FYL; 2FYJ; 1J8E T13510 SEQUENCE MLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEAPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGCQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYLLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANETVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDIDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTKLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFENYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACENDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRGMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDGIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNGWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFYDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVTLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGVTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRFKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDDCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQFKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRWRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENCESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAPGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGESCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDKIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTTLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLTVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNTLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRTVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVLDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTNKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSGQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLWWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQLCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSGTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIYWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDGTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFSVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCAVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNLNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVENVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLDECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDKIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDIPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAVNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVSNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCSATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNYFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCGDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDDREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDGENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCHINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTHGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAVALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCDKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSRSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLFEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGGCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCGDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKCTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCVDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDCADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTDNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDPKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNNTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESVRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMPRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDWGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPIVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYHQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTCNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPTGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQMAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGHCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGVVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPTNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA T22538 TARGETID T22538 T22538 FORMERID TTDR00682 T22538 UNIPROID MFGM_HUMAN T22538 TARGNAME Lactadherin (MFGE8) T22538 GENENAME MFGE8 T22538 TARGTYPE Literature-reported T22538 SYNONYMS Milk fat globule-EGF factor 8; MFGM; MFGE8; MFG-E8; Human milk fat globule membrane protein BA46; HMFG; Breast epithelial antigen BA46 T22538 FUNCTION Medin is the main constituent of aortic medial amyloid. T22538 BIOCLASS Growth factor T22538 SEQUENCE MPRPRLLAALCGALLCAPSLLVALDICSKNPCHNGGLCEEISQEVRGDVFPSYTCTCLKGYAGNHCETKCVEPLGLENGNIANSQIAASSVRVTFLGLQHWVPELARLNRAGMVNAWTPSSNDDNPWIQVNLLRRMWVTGVVTQGASRLASHEYLKAFKVAYSLNGHEFDFIHDVNKKHKEFVGNWNKNAVHVNLFETPVEAQYVRLYPTSCHTACTLRFELLGCELNGCANPLGLKNNSIPDKQITASSSYKTWGLHLFSWNPSYARLDKQGNFNAWVAGSYGNDQWLQVDLGSSKEVTGIITQGARNFGSVQFVASYKVAYSNDSANWTEYQDPRTGSSKIFPGNWDNHSHKKNLFETPILARYVRILPVAWHNRIALRLELLGC T73616 TARGETID T73616 T73616 FORMERID TTDR00039 T73616 UNIPROID SENX3_MYCTU T73616 TARGNAME Mycobacterium Sensor-like histidine kinase senX3 (MycB senX3) T73616 GENENAME MycB senX3 T73616 TARGTYPE Literature-reported T73616 SYNONYMS SenX3; Rv0490; MTCY20G9.16 T73616 FUNCTION Probably forms part of a two-component regulatory system senx3/regx3. Phosphorylates regx3. T73616 ECNUMBER EC 2.7.13.3 T73616 SEQUENCE MTVFSALLLAGVLSALALAVGGAVGMRLTSRVVEQRQRVATEWSGITVSQMLQCIVTLMPLGAAVVDTHRDVVYLNERAKELGLVRDRQLDDQAWRAARQALGGEDVEFDLSPRKRSATGRSGLSVHGHARLLSEEDRRFAVVFVHDQSDYARMEAARRDFVANVSHELKTPVGAMALLAEALLASADDSETVRRFAEKVLIEANRLGDMVAELIELSRLQGAERLPNMTDVDVDTIVSEAISRHKVAADNADIEVRTDAPSNLRVLGDQTLLVTALANLVSNAIAYSPRGSLVSISRRRRGANIEIAVTDRGIGIAPEDQERVFERFFRGDKARSRATGGSGLGLAIVKHVAANHDGTIRVWSKPGTGSTFTLALPALIEAYHDDERPEQAREPELRSNRSQREEELSR T03385 TARGETID T03385 T03385 FORMERID TTDI01456 T03385 UNIPROID SRBP2_HUMAN T03385 TARGNAME SREBP transcription factor 2 (SREBF2) T03385 GENENAME SREBF2 T03385 TARGTYPE Literature-reported T03385 SYNONYMS Sterol regulatory element-binding transcription factor 2; Sterol regulatory element-binding protein 2; SREBP2; SREBP-2; Class D basic helix-loop-helix protein 2; BHLHD2 T03385 FUNCTION Transcriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the cholesterol and to a lesser degree the fatty acid synthesis pathway (By similarity). Binds the sterol regulatory element 1 (SRE-1) (5'-ATCACCCCAC-3') found in the flanking region of the LDRL and HMG-CoA synthase genes. T03385 PDBSTRUC 1UKL T03385 SEQUENCE MDDSGELGGLETMETLTELGDELTLGDIDEMLQFVSNQVGEFPDLFSEQLCSSFPGSGGSGSSSGSSGSSSSSSNGRGSSSGAVDPSVQRSFTQVTLPSFSPSAASPQAPTLQVKVSPTSVPTTPRATPILQPRPQPQPQPQTQLQQQTVMITPTFSTTPQTRIIQQPLIYQNAATSFQVLQPQVQSLVTSSQVQPVTIQQQVQTVQAQRVLTQTANGTLQTLAPATVQTVAAPQVQQVPVLVQPQIIKTDSLVLTTLKTDGSPVMAAVQNPALTALTTPIQTAALQVPTLVGSSGTILTTMPVMMGQEKVPIKQVPGGVKQLEPPKEGERRTTHNIIEKRYRSSINDKIIELKDLVMGTDAKMHKSGVLRKAIDYIKYLQQVNHKLRQENMVLKLANQKNKLLKGIDLGSLVDNEVDLKIEDFNQNVLLMSPPASDSGSQAGFSPYSIDSEPGSPLLDDAKVKDEPDSPPVALGMVDRSRILLCVLTFLCLSFNPLTSLLQWGGAHDSDQHPHSGSGRSVLSFESGSGGWFDWMMPTLLLWLVNGVIVLSVFVKLLVHGEPVIRPHSRSSVTFWRHRKQADLDLARGDFAAAAGNLQTCLAVLGRALPTSRLDLACSLSWNVIRYSLQKLRLVRWLLKKVFQCRRATPATEAGFEDEAKTSARDAALAYHRLHQLHITGKLPAGSACSDVHMALCAVNLAECAEEKIPPSTLVEIHLTAAMGLKTRCGGKLGFLASYFLSRAQSLCGPEHSAVPDSLRWLCHPLGQKFFMERSWSVKSAAKESLYCAQRNPADPIAQVHQAFCKNLLERAIESLVKPQAKKKAGDQEEESCEFSSALEYLKLLHSFVDSVGVMSPPLSRSSVLKSALGPDIICRWWTSAITVAISWLQGDDAAVRSHFTKVERIPKALEVTESPLVKAIFHACRAMHASLPGKADGQQSSFCHCERASGHLWSSLNVSGATSDPALNHVVQLLTCDLLLSLRTALWQKQASASQAVGETYHASGAELAGFQRDLGSLRRLAHSFRPAYRKVFLHEATVRLMAGASPTRTHQLLEHSLRRRTTQSTKHGEVDAWPGQRERATAILLACRHLPLSFLSSPGQRAVLLAEAARTLEKVGDRRSCNDCQQMIVKLGGGTAIAAS T26983 TARGETID T26983 T26983 FORMERID TTDNR00763 T26983 UNIPROID TP53B_HUMAN T26983 TARGNAME Tumor suppressor p53-binding protein 1 (TP53BP1) T26983 GENENAME TP53BP1 T26983 TARGTYPE Literature-reported T26983 SYNONYMS p53BP1; p53-binding protein 1; TP53-binding protein 1; 53BP1 T26983 FUNCTION Plays a key role in the repair of double-strand DNA breaks (DSBs) in response to DNA damage by promoting non-homologous end joining (NHEJ)-mediated repair of DSBs and specifically counteracting the function of the homologous recombination (HR) repair protein BRCA1. In response to DSBs, phosphorylation by ATM promotes interaction with RIF1 and dissociation from NUDT16L1/TIRR, leading to recruitment to DSBs sites. Recruited to DSBs sites by recognizing and binding histone H2A monoubiquitinated at 'Lys-15' (H2AK15Ub) and histone H4 dimethylated at 'Lys-20' (H4K20me2), two histone marks that are present at DSBs sites. Required for immunoglobulin class-switch recombination (CSR) during antibody genesis, a process that involves the generation of DNA DSBs. Participates to the repair and the orientation of the broken DNA ends during CSR. In contrast, it is not required for classic NHEJ and V(D)J recombination. Promotes NHEJ of dysfunctional telomeres via interaction with PAXIP1. Double-strand break (DSB) repair protein involved in response to DNA damage, telomere dynamics and class-switch recombination (CSR) during antibody genesis. T26983 PDBSTRUC 6IUA; 6IU7; 6CO2; 6CO1; 5ZCJ T26983 SEQUENCE MDPTGSQLDSDFSQQDTPCLIIEDSQPESQVLEDDSGSHFSMLSRHLPNLQTHKENPVLDVVSNPEQTAGEERGDGNSGFNEHLKENKVADPVDSSNLDTCGSISQVIEQLPQPNRTSSVLGMSVESAPAVEEEKGEELEQKEKEKEEDTSGNTTHSLGAEDTASSQLGFGVLELSQSQDVEENTVPYEVDKEQLQSVTTNSGYTRLSDVDANTAIKHEEQSNEDIPIAEQSSKDIPVTAQPSKDVHVVKEQNPPPARSEDMPFSPKASVAAMEAKEQLSAQELMESGLQIQKSPEPEVLSTQEDLFDQSNKTVSSDGCSTPSREEGGCSLASTPATTLHLLQLSGQRSLVQDSLSTNSSDLVAPSPDAFRSTPFIVPSSPTEQEGRQDKPMDTSVLSEEGGEPFQKKLQSGEPVELENPPLLPESTVSPQASTPISQSTPVFPPGSLPIPSQPQFSHDIFIPSPSLEEQSNDGKKDGDMHSSSLTVECSKTSEIEPKNSPEDLGLSLTGDSCKLMLSTSEYSQSPKMESLSSHRIDEDGENTQIEDTEPMSPVLNSKFVPAENDSILMNPAQDGEVQLSQNDDKTKGDDTDTRDDISILATGCKGREETVAEDVCIDLTCDSGSQAVPSPATRSEALSSVLDQEEAMEIKEHHPEEGSSGSEVEEIPETPCESQGEELKEENMESVPLHLSLTETQSQGLCLQKEMPKKECSEAMEVETSVISIDSPQKLAILDQELEHKEQEAWEEATSEDSSVVIVDVKEPSPRVDVSCEPLEGVEKCSDSQSWEDIAPEIEPCAENRLDTKEEKSVEYEGDLKSGTAETEPVEQDSSQPSLPLVRADDPLRLDQELQQPQTQEKTSNSLTEDSKMANAKQLSSDAEAQKLGKPSAHASQSFCESSSETPFHFTLPKEGDIIPPLTGATPPLIGHLKLEPKRHSTPIGISNYPESTIATSDVMSESMVETHDPILGSGKGDSGAAPDVDDKLCLRMKLVSPETEASEESLQFNLEKPATGERKNGSTAVAESVASPQKTMSVLSCICEARQENEARSEDPPTTPIRGNLLHFPSSQGEEEKEKLEGDHTIRQSQQPMKPISPVKDPVSPASQKMVIQGPSSPQGEAMVTDVLEDQKEGRSTNKENPSKALIERPSQNNIGIQTMECSLRVPETVSAATQTIKNVCEQGTSTVDQNFGKQDATVQTERGSGEKPVSAPGDDTESLHSQGEEEFDMPQPPHGHVLHRHMRTIREVRTLVTRVITDVYYVDGTEVERKVTEETEEPIVECQECETEVSPSQTGGSSGDLGDISSFSSKASSLHRTSSGTSLSAMHSSGSSGKGAGPLRGKTSGTEPADFALPSSRGGPGKLSPRKGVSQTGTPVCEEDGDAGLGIRQGGKAPVTPRGRGRRGRPPSRTTGTRETAVPGPLGIEDISPNLSPDDKSFSRVVPRVPDSTRRTDVGAGALRRSDSPEIPFQAAAGPSDGLDASSPGNSFVGLRVVAKWSSNGYFYSGKITRDVGAGKYKLLFDDGYECDVLGKDILLCDPIPLDTEVTALSEDEYFSAGVVKGHRKESGELYYSIEKEGQRKWYKRMAVILSLEQGNRLREQYGLGPYEAVTPLTKAADISLDNLVEGKRKRRSNVSSPATPTASSSSSTTPTRKITESPRASMGVLSGKRKLITSEEERSPAKRGRKSATVKPGAVGAGEFVSPCESGDNTGEPSALEEQRGPLPLNKTLFLGYAFLLTMATTSDKLASRSKLPDGPTGSSEEEEEFLEIPPFNKQYTESQLRAGAGYILEDFNEAQCNTAYQCLLIADQHCRTRKYFLCLASGIPCVSHVWVHDSCHANQLQNYRNYLLPAGYSLEEQRILDWQPRENPFQNLKVLLVSDQQQNFLELWSEILMTGGAASVKQHHSSAHNKDIALGVFDVVVTDPSCPASVLKCAEALQLPVVSQEWVIQCLIVGERIGFKQHPKYKHDYVSH T80454 TARGETID T80454 T80454 FORMERID TTDI00126 T80454 UNIPROID TIAM1_HUMAN T80454 TARGNAME T-lymphoma invasion and metastasis 1 (TIAM1) T80454 GENENAME TIAM1 T80454 TARGTYPE Literature-reported T80454 SYNONYMS TIAM-1; T-lymphoma invasion and metastasis-inducing protein 1 T80454 FUNCTION Acts as a GDP-dissociation stimulator protein that stimulates the GDP-GTP exchange activity of RHO-like GTPases and activates them. Activates RAC1, CDC42, and to a lesser extent RHOA. Required for normal cell adhesion and cell migration. Modulates the activity of RHO-like proteins and connects extracellular signals to cytoskeletal activities. T80454 PDBSTRUC 4NXR; 4NXQ; 4NXP; 4K2P; 4K2O T80454 SEQUENCE MGNAESQHVEHEFYGEKHASLGRKHTSRSLRLSHKTRRTRHASSGKVIHRNSEVSTRSSSTPSIPQSLAENGLEPFSQDGTLEDFGSPIWVDRVDMGLRPVSYTDSSVTPSVDSSIVLTAASVQSMPDTEESRLYGDDATYLAEGGRRQHSYTSNGPTFMETASFKKKRSKSADIWREDSLEFSLSDLSQEHLTSNEEILGSAEEKDCEEARGMETRASPRQLSTCQRANSLGDLYAQKNSGVTANGGPGSKFAGYCRNLVSDIPNLANHKMPPAAAEETPPYSNYNTLPCRKSHCLSEGATNPQISHSNSMQGRRAKTTQDVNAGEGSEFADSGIEGATTDTDLLSRRSNATNSSYSPTTGRAFVGSDSGSSSTGDAARQGVYENFRRELEMSTTNSESLEEAGSAHSDEQSSGTLSSPGQSDILLTAAQGTVRKAGALAVKNFLVHKKNKKVESATRRKWKHYWVSLKGCTLFFYESDGRSGIDHNSIPKHAVWVENSIVQAVPEHPKKDFVFCLSNSLGDAFLFQTTSQTELENWITAIHSACATAVARHHHKEDTLRLLKSEIKKLEQKIDMDEKMKKMGEMQLSSVTDSKKKKTILDQIFVWEQNLEQFQMDLFRFRCYLASLQGGELPNPKRLLAFASRPTKVAMGRLGIFSVSSFHALVAARTGETGVRRRTQAMSRSASKRRSRFSSLWGLDTTSKKKQGRPSINQVFGEGTEAVKKSLEGIFDDIVPDGKREKEVVLPNVHQHNPDCDIWVHEYFTPSWFCLPNNQPALTVVRPGDTARDTLELICKTHQLDHSAHYLRLKFLIENKMQLYVPQPEEDIYELLYKEIEICPKVTQSIHIEKSDTAADTYGFSLSSVEEDGIRRLYVNSVKETGLASKKGLKAGDEILEINNRAADALNSSMLKDFLSQPSLGLLVRTYPELEEGVELLESPPHRVDGPADLGESPLAFLTSNPGHSLCSEQGSSAETAPEETEGPDLESSDETDHSSKSTEQVAAFCRSLHEMNPSDQSPSPQDSTGPQLATMRQLSDADKLRKVICELLETERTYVKDLNCLMERYLKPLQKETFLTQDELDVLFGNLTEMVEFQVEFLKTLEDGVRLVPDLEKLEKVDQFKKVLFSLGGSFLYYADRFKLYSAFCASHTKVPKVLVKAKTDTAFKAFLDAQNPKQQHSSTLESYLIKPIQRILKYPLLLRELFALTDAESEEHYHLDVAIKTMNKVASHINEMQKIHEEFGAVFDQLIAEQTGEKKEVADLSMGDLLLHTTVIWLNPPASLGKWKKEPELAAFVFKTAVVLVYKDGSKQKKKLVGSHRLSIYEDWDPFRFRHMIPTEALQVRALASADAEANAVCEIVHVKSESEGRPERVFHLCCSSPESRKDFLKAVHSILRDKHRRQLLKTESLPSSQQYVPFGGKRLCALKGARPAMSRAVSAPSKSLGRRRRRLARNRFTIDSDAVSASSPEKESQQPPGGGDTDRWVEEQFDLAQYEEQDDIKETDILSDDDEFCESVKGASVDRDLQERLQATSISQRERGRKTLDSHASRMAQLKKQAALSGINGGLESASEEVIWVRREDFAPSRKLNTEI T98569 TARGETID T98569 T98569 FORMERID TTDI01389 T98569 UNIPROID AIMP2_HUMAN T98569 TARGNAME AIMP multisynthetase complex protein 2 (AIMP2) T98569 GENENAME AIMP2 T98569 TARGTYPE Literature-reported T98569 SYNONYMS Protein JTV-1; PRO0992; Multisynthase complex auxiliary component p38; JTV1; Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 T98569 FUNCTION Required for assembly and stability of the aminoacyl-tRNA synthase complex. Mediates ubiquitination and degradation of FUBP1, a transcriptional activator of MYC, leading to MYC down-regulation which is required for aveolar type II cell differentiation. Blocks MDM2-mediated ubiquitination and degradation of p53/TP53. Functions as a proapoptotic factor. T98569 PDBSTRUC 6ILD; 5Y6L; 5A5H; 5A34; 5A1N T98569 SEQUENCE MPMYQVKPYHGGGAPLRVELPTCMYRLPNVHGRSYGPAPGAGHVQEESNLSLQALESRQDDILKRLYELKAAVDGLSKMIQTPDADLDVTNIIQADEPTTLTTNALDLNSVLGKDYGALKDIVINANPASPPLSLLVLHRLLCEHFRVLSTVHTHSSVKSVPENLLKCFGEQNKKQPRQDYQLGFTLIWKNVPKTQMKFSIQTMCPIEGEGNIARFLFSLFGQKHNAVNATLIDSWVDIAIFQLKEGSSKEKAAVFRSMNSALGKSPWLAGNELTVADVVLWSVLQQIGGCSVTVPANVQRWMRSCENLAPFNTALKLLK T31577 TARGETID T31577 T31577 FORMERID TTDR00860 T31577 UNIPROID SG2A2_HUMAN T31577 TARGNAME Mammaglobin A (SCGB2A2) T31577 GENENAME SCGB2A2 T31577 TARGTYPE Literature-reported T31577 SYNONYMS UGB2; Secretoglobin family 2A member 2; Mammaglobin-A; Mammaglobin-1; MGB1 T31577 FUNCTION Expressed mainly in mucosa. Involved in cell signalling, immune response, and chemotaxis, and may also serve as transporters for steroid hormones in humans. T31577 BIOCLASS Secretoglobin family T31577 SEQUENCE MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF T80306 TARGETID T80306 T80306 FORMERID TTDR00814 T80306 UNIPROID SKP2_HUMAN T80306 TARGNAME S-phase kinase-associated protein 2 (SKP2) T80306 GENENAME SKP2 T80306 TARGTYPE Literature-reported T80306 SYNONYMS Skp2; P45skp2; FBXL1; F-box/LRR-repeat protein 1; F-box protein Skp2; Cyclin-A/CDK2-associated protein p45; Cyclin A/CDK2-associated protein p45; Cyclin A/CDK2-associated p45 T80306 FUNCTION Specifically recognizes phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition. Degradation of CDKN1B/p27kip also requires CKS1. Recognizes target proteins ORC1, CDT1, RBL2, KMT2A/MLL1, CDK9, RAG2, FOXO1, UBP43, and probably MYC, TOB1 and TAL1. Degradation of TAL1 also requires STUB1. Recognizes CDKN1A in association with CCNE1 or CCNE2 and CDK2. Promotes ubiquitination and destruction of CDH1 in a CK1-Dependent Manner, thereby regulating cell migration. Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription. T80306 PDBSTRUC 2AST; 2ASS; 1LDK; 1FS2; 1FS1 T80306 SEQUENCE MHRKHLQEIPDLSSNVATSFTWGWDSSKTSELLSGMGVSALEKEEPDSENIPQELLSNLGHPESPPRKRLKSKGSDKDFVIVRRPKLNRENFPGVSWDSLPDELLLGIFSCLCLPELLKVSGVCKRWYRLASDESLWQTLDLTGKNLHPDVTGRLLSQGVIAFRCPRSFMDQPLAEHFSPFRVQHMDLSNSVIEVSTLHGILSQCSKLQNLSLEGLRLSDPIVNTLAKNSNLVRLNLSGCSGFSEFALQTLLSSCSRLDELNLSWCFDFTEKHVQVAVAHVSETITQLNLSGYRKNLQKSDLSTLVRRCPNLVHLDLSDSVMLKNDCFQEFFQLNYLQHLSLSRCYDIIPETLLELGEIPTLKTLQVFGIVPDGTLQLLKEALPHLQINCSHFTTIARPTIGNKKNQEIWGIKCRLTLQKPSCL T16401 TARGETID T16401 T16401 FORMERID TTDI02172 T16401 UNIPROID SGCG_HUMAN T16401 TARGNAME Sarcoglycan gamma (SGCG) T16401 GENENAME SGCG T16401 TARGTYPE Literature-reported T16401 SYNONYMS SGCG; Gammasarcoglycan; GammaSG; 35DAG; 35 kDa dystrophinassociated glycoprotein T16401 FUNCTION Component of the sarcoglycan complex, a subcomplexof the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix. T16401 BIOCLASS Sarcoglycan T16401 SEQUENCE MVREQYTTATEGICIERPENQYVYKIGIYGWRKRCLYLFVLLLLIILVVNLALTIWILKVMWFSPAGMGHLCVTKDGLRLEGESEFLFPLYAKEIHSRVDSSLLLQSTQNVTVNARNSEGEVTGRLKVGPKMVEVQNQQFQINSNDGKPLFTVDEKEVVVGTDKLRVTGPEGALFEHSVETPLVRADPFQDLRLESPTRSLSMDAPRGVHIQAHAGKIEALSQMDILFHSSDGMLVLDAETVCLPKLVQGTWGPSGSSQSLYEICVCPDGKLYLSVAGVSTTCQEHNHICL T91598 TARGETID T91598 T91598 FORMERID TTDI03608 T91598 UNIPROID TNK1_HUMAN T91598 TARGNAME Non-receptor tyrosine-protein kinase TNK1 (TNK1) T91598 GENENAME TNK1 T91598 TARGTYPE Literature-reported T91598 SYNONYMS CD38 negative kinase 1 T91598 FUNCTION Involved in negative regulation of cell growth. Has tumor suppressor properties. Plays a negative regulatory role in the Ras-MAPK pathway. May function in signaling pathways utilized broadly during fetal development and more selectively in adult tissues and in cells of the lymphohematopoietic system. Could specifically be involved in phospholipid signal transduction. T91598 ECNUMBER EC 2.7.10.2 T91598 SEQUENCE MLPEAGSLWLLKLLRDIQLAQFYWPILEELNVTRPEHFDFVKPEDLDGIGMGRPAQRRLSEALKRLRSGPKSKNWVYKILGGFAPEHKEPTLPSDSPRHLPEPEGGLKCLIPEGAVCRGELLGSGCFGVVHRGLWTLPSGKSVPVAVKSLRVGPEGPMGTELGDFLREVSVMMNLEHPHVLRLHGLVLGQPLQMVMELAPLGSLHARLTAPAPTPPLLVALLCLFLRQLAGAMAYLGARGLVHRDLATRNLLLASPRTIKVADFGLVRPLGGARGRYVMGGPRPIPYAWCAPESLRHGAFSSASDVWMFGVTLWEMFSGGEEPWAGVPPYLILQRLEDRARLPRPPLCSRALYSLALRCWAPHPADRPSFSHLEGLLQEAGPSEACCVRDVTEPGALRMETGDPITVIEGSSSFHSPDSTIWKGQNGRTFKVGSFPASAVTLADAGGLPATRPVHRGTPARGDQHPGSIDGDRKKANLWDAPPARGQRRNMPLERMKGISRSLESVLSLGPRPTGGGSSPPEIRQARAVPQGPPGLPPRPPLSSSSPQPSQPSRERLPWPKRKPPHNHPMGMPGARKAAALSGGLLSDPELQRKIMEVELSVHGVTHQECQTALGATGGDVVSAIRNLKVDQLFHLSSRSRADCWRILEHYQWDLSAASRYVLARP T91598 DRUGINFO D0M0QQ XMD8-92 Investigative T84941 TARGETID T84941 T84941 FORMERID TTDNR00669 T84941 UNIPROID 4EBP1_HUMAN T84941 TARGNAME Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) T84941 GENENAME EIF4EBP1 T84941 TARGTYPE Literature-reported T84941 SYNONYMS eIF4E-binding protein 1; Phosphorylated heat- andacid-stable protein regulated by insulin 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I; 4E-BP1 T84941 FUNCTION In contrast, hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation. Mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways. Repressor of translation initiation that regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress translation. T84941 PDBSTRUC 6BCX; 6BCU; 5WBJ; 5NVN; 5EKV T84941 SEQUENCE MSGGSSCSQTPSRAIPATRRVVLGDGVQLPPGDYSTTPGGTLFSTTPGGTRIIYDRKFLMECRNSPVTKTPPRDLPTIPGVTSPSSDEPPMEASQSHLRNSPEDKRAGGEESQFEMDI T04364 TARGETID T04364 T04364 FORMERID TTDI00246 T04364 UNIPROID CUL3_HUMAN T04364 TARGNAME Cullin-3 (CUL-3) T04364 GENENAME CUL3 T04364 TARGTYPE Literature-reported T04364 SYNONYMS KIAA0617; Cullin3 T04364 FUNCTION BCR complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins. As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1. The functional specificity of the BCR complex depends on the BTB domain-containing protein as the substrate recognition component. BCR(KLHL42) is involved in ubiquitination of KATNA1. BCR(SPOP) is involved in ubiquitination of BMI1/PCGF4, BRMS1, H2AFY and DAXX, GLI2 and GLI3. Can also form a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex containing homodimeric SPOPL or the heterodimer formed by SPOP and SPOPL; these complexes have lower ubiquitin ligase activity. BCR(KLHL9-KLHL13) controls the dynamic behavior of AURKB on mitotic chromosomes and thereby coordinates faithful mitotic progression and completion of cytokinesis. BCR(KLHL12) is involved in ER-Golgi transport by regulating the size of COPII coats, thereby playing a key role in collagen export, which is required for embryonic stem (ES) cells division: BCR(KLHL12) acts by mediating monoubiquitination of SEC31 (SEC31A or SEC31B). BCR(KLHL3) acts as a regulator of ion transport in the distal nephron; by mediating ubiquitination of WNK4. The BCR(KLHL20) E3 ubiquitin ligase complex is involved in interferon response and anterograde Golgi to endosome transport: it mediates both ubiquitination leading to degradation and 'Lys-33'-linked ubiquitination. The BCR(KLHL21) E3 ubiquitin ligase complex regulates localization of the chromosomal passenger complex (CPC) from chromosomes to the spindle midzone in anaphase and mediates the ubiquitination of AURKB. The BCR(KLHL22) ubiquitin ligase complex mediates monoubiquitination of PLK1, leading to PLK1 dissociation from phosphoreceptor proteins and subsequent removal from kinetochores, allowing silencing of the spindle assembly checkpoint (SAC) and chromosome segregation. The BCR(KLHL22) ubiquitin ligase complex is also responsible for the amino acid-stimulated 'Lys-48' polyubiquitination and proteasomal degradation of DEPDC5. Through the degradation of DEPDC5, releases the GATOR1 complex-mediated inhibition of the TORC1 pathway. The BCR(KLHL25) ubiquitin ligase complex is involved in translational homeostasis by mediating ubiquitination and subsequent degradation of hypophosphorylated EIF4EBP1 (4E-BP1). The BCR(KBTBD8) complex acts by mediating monoubiquitination of NOLC1 and TCOF1, leading to remodel the translational program of differentiating cells in favor of neural crest specification. Involved in ubiquitination of cyclin E and of cyclin D1 (in vitro) thus involved in regulation of G1/S transition. Involved in the ubiquitination of KEAP1, ENC1 and KLHL41. In concert with ATF2 and RBX1, promotes degradation of KAT5 thereby attenuating its ability to acetylate and activate ATM. The BCR(KCTD17) E3 ubiquitin ligase complex mediates ubiquitination and degradation of TCHP, a down-regulator of cilium assembly, thereby inducing ciliogenesis. The BCR(KLHL24) E3 ubiquitin ligase complex mediates ubiquitination of KRT14, controls KRT14 levels during keratinocytes differentiation, and is essential for skin integrity. Core component of multiple cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. T04364 PDBSTRUC 6I2M; 5NLB; 4HXI; 4EOZ; 4APF T04364 SEQUENCE MSNLSKGTGSRKDTKMRIRAFPMTMDEKYVNSIWDLLKNAIQEIQRKNNSGLSFEELYRNAYTMVLHKHGEKLYTGLREVVTEHLINKVREDVLNSLNNNFLQTLNQAWNDHQTAMVMIRDILMYMDRVYVQQNNVENVYNLGLIIFRDQVVRYGCIRDHLRQTLLDMIARERKGEVVDRGAIRNACQMLMILGLEGRSVYEEDFEAPFLEMSAEFFQMESQKFLAENSASVYIKKVEARINEEIERVMHCLDKSTEEPIVKVVERELISKHMKTIVEMENSGLVHMLKNGKTEDLGCMYKLFSRVPNGLKTMCECMSSYLREQGKALVSEEGEGKNPVDYIQGLLDLKSRFDRFLLESFNNDRLFKQTIAGDFEYFLNLNSRSPEYLSLFIDDKLKKGVKGLTEQEVETILDKAMVLFRFMQEKDVFERYYKQHLARRLLTNKSVSDDSEKNMISKLKTECGCQFTSKLEGMFRDMSISNTTMDEFRQHLQATGVSLGGVDLTVRVLTTGYWPTQSATPKCNIPPAPRHAFEIFRRFYLAKHSGRQLTLQHHMGSADLNATFYGPVKKEDGSEVGVGGAQVTGSNTRKHILQVSTFQMTILMLFNNREKYTFEEIQQETDIPERELVRALQSLACGKPTQRVLTKEPKSKEIENGHIFTVNDQFTSKLHRVKIQTVAAKQGESDPERKETRQKVDDDRKHEIEAAIVRIMKSRKKMQHNVLVAEVTQQLKARFLPSPVVIKKRIEGLIEREYLARTPEDRKVYTYVA T81135 TARGETID T81135 T81135 FORMERID TTDI00008 T81135 UNIPROID FHL1_HUMAN T81135 TARGNAME Skeletal muscle LIM-protein 1 (FHL1) T81135 GENENAME FHL1 T81135 TARGTYPE Literature-reported T81135 SYNONYMS Skeletal muscle LIMprotein 1; SLIM1; SLIM; Four and a half LIM domains protein 1; FHL1 T81135 FUNCTION May have an involvement in muscle development or hypertrophy. T81135 PDBSTRUC 2EGQ; 2CUR; 2CUP; 1X63 T81135 SEQUENCE MAEKFDCHYCRDPLQGKKYVQKDGHHCCLKCFDKFCANTCVECRKPIGADSKEVHYKNRFWHDTCFRCAKCLHPLANETFVAKDNKILCNKCTTREDSPKCKGCFKAIVAGDQNVEYKGTVWHKDCFTCSNCKQVIGTGSFFPKGEDFYCVTCHETKFAKHCVKCNKAITSGGITYQDQPWHADCFVCVTCSKKLAGQRFTAVEDQYYCVDCYKNFVAKKCAGCKNPITGKRTVSRVSHPVSKARKPPVCHGKRLPLTLFPSANLRGRHPGGERTCPSWVVVLYRKNRSLAAPRGPGLVKAPVWWPMKDNPGTTTASTAKNAP T75613 TARGETID T75613 T75613 FORMERID TTDI02360 T75613 UNIPROID LAMC2_HUMAN T75613 TARGNAME Laminin gamma-2 subunit (LAMC2) T75613 GENENAME LAMC2 T75613 TARGTYPE Literature-reported T75613 SYNONYMS Nicein subunit gamma; Large adhesive scatter factor 140 kDa subunit; Laminin5 subunit gamma; Laminin-5 subunit gamma; Laminin subunit gamma2; Laminin subunit gamma-2; Laminin B2t chain; Ladsin 140 kDa subunit; LAMNB2; LAMB2T; Kalinin/nicein/epiligrin 100 kDa subunit; Kalinin subunit gamma; Epiligrin subunit gamma; Cellscattering factor 140 kDa subunit; Cell-scattering factor 140 kDa subunit; CSF 140 kDa subunit T75613 FUNCTION Ladsin exerts cell-scattering activity toward a wide variety of cells, including epithelial, endothelial, and fibroblastic cells. Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. T75613 SEQUENCE MPALWLGCCLCFSLLLPAARATSRREVCDCNGKSRQCIFDRELHRQTGNGFRCLNCNDNTDGIHCEKCKNGFYRHRERDRCLPCNCNSKGSLSARCDNSGRCSCKPGVTGARCDRCLPGFHMLTDAGCTQDQRLLDSKCDCDPAGIAGPCDAGRCVCKPAVTGERCDRCRSGYYNLDGGNPEGCTQCFCYGHSASCRSSAEYSVHKITSTFHQDVDGWKAVQRNGSPAKLQWSQRHQDVFSSAQRLDPVYFVAPAKFLGNQQVSYGQSLSFDYRVDRGGRHPSAHDVILEGAGLRITAPLMPLGKTLPCGLTKTYTFRLNEHPSNNWSPQLSYFEYRRLLRNLTALRIRATYGEYSTGYIDNVTLISARPVSGAPAPWVEQCICPVGYKGQFCQDCASGYKRDSARLGPFGTCIPCNCQGGGACDPDTGDCYSGDENPDIECADCPIGFYNDPHDPRSCKPCPCHNGFSCSVMPETEEVVCNNCPPGVTGARCELCADGYFGDPFGEHGPVRPCQPCQCNNNVDPSASGNCDRLTGRCLKCIHNTAGIYCDQCKAGYFGDPLAPNPADKCRACNCNPMGSEPVGCRSDGTCVCKPGFGGPNCEHGAFSCPACYNQVKIQMDQFMQQLQRMEALISKAQGGDGVVPDTELEGRMQQAEQALQDILRDAQISEGASRSLGLQLAKVRSQENSYQSRLDDLKMTVERVRALGSQYQNRVRDTHRLITQMQLSLAESEASLGNTNIPASDHYVGPNGFKSLAQEATRLAESHVESASNMEQLTRETEDYSKQALSLVRKALHEGVGSGSGSPDGAVVQGLVEKLEKTKSLAQQLTREATQAEIEADRSYQHSLRLLDSVSRLQGVSDQSFQVEEAKRIKQKADSLSSLVTRHMDEFKRTQKNLGNWKEEAQQLLQNGKSGREKSDQLLSRANLAKSRAQEALSMGNATFYEVESILKNLREFDLQVDNRKAEAEEAMKRLSYISQKVSDASDKTQQAERALGSAAADAQRAKNGAGEALEISSEIEQEIGSLNLEANVTADGALAMEKGLASLKSEMREVEGELERKELEFDTNMDAVQMVITEAQKVDTRAKNAGVTIQDTLNTLDGLLHLMDQPLSVDEEGLVLLEQKLSRAKTQINSQLRPMMSELEERARQQRGHLHLLETSIDGILADVKNLENIRDNLPPGCYNTQALEQQ T75613 DRUGINFO D08DSC BST-1005 Preclinical T29630 TARGETID T29630 T29630 FORMERID TTDI02414 T29630 UNIPROID RUNX3_HUMAN T29630 TARGNAME Runt-related transcription factor 3 (RUNX3) T29630 GENENAME RUNX3 T29630 TARGTYPE Literature-reported T29630 SYNONYMS SL3/AKV core-binding factor alpha C subunit; SL3-3 enhancer factor 1 alpha C subunit; Polyomavirus enhancer-binding protein 2 alpha C subunit; PEBP2A3; PEBP2-alpha C; PEA2-alpha C; Oncogene AML-2; Core-binding factor subunit alpha-3; CBFA3; CBF-alpha-3; Acute myeloid leukemia 2 protein; AML2 T29630 FUNCTION RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. May be involved in the control of cellular proliferation and/or differentiation. In association with ZFHX3, upregulates CDKN1A promoter activity following TGF-beta stimulation. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing. Forms the heterodimeric complex core-binding factor (CBF) with CBFB. T29630 PDBSTRUC 5W69 T29630 SEQUENCE MRIPVDPSTSRRFTPPSPAFPCGGGGGKMGENSGALSAQAAVGPGGRARPEVRSMVDVLADHAGELVRTDSPNFLCSVLPSHWRCNKTLPVAFKVVALGDVPDGTVVTVMAGNDENYSAELRNASAVMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPTQVATYHRAIKVTVDGPREPRRHRQKLEDQTKPFPDRFGDLERLRMRVTPSTPSPRGSLSTTSHFSSQPQTPIQGTSELNPFSDPRQFDRSFPTLPTLTESRFPDPRMHYPGAMSAAFPYSATPSGTSISSLSVAGMPATSRFHHTYLPPPYPGAPQNQSGPFQANPSPYHLYYGTSSGSYQFSMVAGSSSGGDRSPTRMLASCTSSAASVAAGNLMNPSLGGQSDGVEADGSHSNSPTALSTPGRMDEAVWRPY T45794 TARGETID T45794 T45794 FORMERID TTDR00388 T45794 UNIPROID NCOA4_HUMAN T45794 TARGNAME Nuclear receptor coactivator 4 (NCOA4) T45794 GENENAME NCOA4 T45794 TARGTYPE Literature-reported T45794 SYNONYMS Ret-activating protein ELE1; RFG; NCoA-4; ELE1; Androgen receptor-associated protein of 70 kDa; Androgen receptor coactivator 70 kDa protein; ARA70 (dARA70N); ARA70; 70 kDa androgen receptor coactivator; 70 kDa AR-activator T45794 FUNCTION Ligand-independent coactivator of the peroxisome proliferator-activated receptor (PPAR) gamma. Enhances the androgen receptor transcriptional activity in prostate cancer cells. T45794 PDBSTRUC 1T5Z T45794 SEQUENCE MNTFQDQSGSSSNREPLLRCSDARRDLELAIGGVLRAEQQIKDNLREVKAQIHSCISRHLECLRSREVWLYEQVDLIYQLKEETLQQQAQQLYSLLGQFNCLTHQLECTQNKDLANQVSVCLERLGSLTLKPEDSTVLLFEADTITLRQTITTFGSLKTIQIPEHLMAHASSANIGPFLEKRGCISMPEQKSASGIVAVPFSEWLLGSKPASGYQAPYIPSTDPQDWLTQKQTLENSQTSSRACNFFNNVGGNLKGLENWLLKSEKSSYQKCNSHSTTSSFSIEMEKVGDQELPDQDEMDLSDWLVTPQESHKLRKPENGSRETSEKFKLLFQSYNVNDWLVKTDSCTNCQGNQPKGVEIENLGNLKCLNDHLEAKKPLSTPSMVTEDWLVQNHQDPCKVEEVCRANEPCTSFAECVCDENCEKEALYKWLLKKEGKDKNGMPVEPKPEPEKHKDSLNMWLCPRKEVIEQTKAPKAMTPSRIADSFQVIKNSPLSEWLIRPPYKEGSPKEVPGTEDRAGKQKFKSPMNTSWCSFNTADWVLPGKKMGNLSQLSSGEDKWLLRKKAQEVLLNSPLQEEHNFPPDHYGLPAVCDLFACMQLKVDKEKWLYRTPLQM T28858 TARGETID T28858 T28858 FORMERID TTDI03340 T28858 UNIPROID KCNC3_HUMAN T28858 TARGNAME Voltage-gated potassium channel Kv3.3 (KCNC3) T28858 GENENAME KCNC3 T28858 TARGTYPE Literature-reported T28858 SYNONYMS Voltage-gated potassium channel subunit Kv3.3; Potassium voltage-gated channel subfamily C member 3; KSHIIID T28858 FUNCTION Voltage-gated potassium channel that plays an important role in the rapid repolarization of fast-firing brain neurons. The channel opens in response to the voltage difference across the membrane, forming a potassium-selective channel through which potassium ions pass in accordance with their electrochemical gradient. The channel displays rapid activation and inactivation kinetics. It plays a role in the regulation of the frequency, shape and duration of action potentials in Purkinje cells. Required for normal survival of cerebellar neurons, probably via its role in regulating the duration and frequency of action potentials that in turn regulate the activity of voltage-gated Ca(2+) channels and cellular Ca(2+) homeostasis (By similarity). Required for normal motor function. Plays a role in the reorganization of the cortical actin cytoskeleton and the formation of actin veil structures in neuronal growth cones via its interaction with HAX1 and the Arp2/3 complex. T28858 BIOCLASS Voltage-gated ion channel T28858 SEQUENCE MLSSVCVSSFRGRQGASKQQPAPPPQPPESPPPPPLPPQQQQPAQPGPAASPAGPPAPRGPGDRRAEPCPGLPAAAMGRHGGGGGDSGKIVINVGGVRHETYRSTLRTLPGTRLAGLTEPEAAARFDYDPGADEFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELGFWGIDETDVEACCWMTYRQHRDAEEALDSFEAPDPAGAANAANAAGAHDGGLDDEAGAGGGGLDGAGGELKRLCFQDAGGGAGGPPGGAGGAGGTWWRRWQPRVWALFEDPYSSRAARYVAFASLFFILISITTFCLETHEGFIHISNKTVTQASPIPGAPPENITNVEVETEPFLTYVEGVCVVWFTFEFLMRITFCPDKVEFLKSSLNIIDCVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERIGADPDDILGSNHTYFKNIPIGFWWAVVTMTTLGYGDMYPKTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPKKKNKHIPRPPQPGSPNYCKPDPPPPPPPHPHHGSGGISPPPPITPPSMGVTVAGAYPAGPHTHPGLLRGGAGGLGIMGLPPLPAPGEPCPLAQEEVIEINRADPRPNGDPAAAALAHEDCPAIDQPAMSPEDKSPITPGSRGRYSRDRACFLLTDYAPSPDGSIRKATGAPPLPPQDWRKPGPPSFLPDLNANAAAWISP T28858 DRUGINFO D06PZZ [14C]TEA Investigative T03409 TARGETID T03409 T03409 FORMERID TTDR00962 T03409 UNIPROID COX17_HUMAN T03409 TARGNAME Cytochrome c oxidase copper chaperone (COX17) T03409 GENENAME COX17 T03409 TARGTYPE Literature-reported T03409 SYNONYMS Cytochrome c oxidase assembly protein COX17; COX17; CCO assembly protein COX17 T03409 FUNCTION Copper chaperone for cytochromec oxidase (COX). Binds two copper ions and deliver them to the Cu(A) site of COX. T03409 PDBSTRUC 2RNB; 2RN9; 2LGQ; 2L0Y T03409 SEQUENCE MPGLVDSNPAPPESQEKKPLKPCCACPETKKARDACIIEKGEEHCGHLIEAHKECMRALGFKI T81409 TARGETID T81409 T81409 FORMERID TTDI00173 T81409 UNIPROID SEPT6_HUMAN T81409 TARGNAME Septin-6 (SEPT6) T81409 GENENAME SEPTIN6 T81409 TARGTYPE Literature-reported T81409 SYNONYMS KIAA0128 T81409 FUNCTION Filament-forming cytoskeletal GTPase. Required for normal organization of the actin cytoskeleton. Involved in cytokinesis. May play a role in HCV RNA replication. T81409 PDBSTRUC 2QAG T81409 SEQUENCE MAATDIARQVGEGCRTVPLAGHVGFDSLPDQLVNKSVSQGFCFNILCVGETGLGKSTLMDTLFNTKFEGEPATHTQPGVQLQSNTYDLQESNVRLKLTIVSTVGFGDQINKEDSYKPIVEFIDAQFEAYLQEELKIRRVLHTYHDSRIHVCLYFIAPTGHSLKSLDLVTMKKLDSKVNIIPIIAKADAISKSELTKFKIKITSELVSNGVQIYQFPTDDESVAEINGTMNAHLPFAVIGSTEELKIGNKMMRARQYPWGTVQVENEAHCDFVKLREMLIRVNMEDLREQTHTRHYELYRRCKLEEMGFKDTDPDSKPFSLQETYEAKRNEFLGELQKKEEEMRQMFVQRVKEKEAELKEAEKELHEKFDRLKKLHQDEKKKLEDKKKSLDDEVNAFKQRKTAAELLQSQGSQAGGSQTLKRDKEKKNNPWLCTE T16180 TARGETID T16180 T16180 FORMERID TTDR00885 T16180 UNIPROID E2F2_HUMAN T16180 TARGNAME Transcription factor E2F2 (E2F2) T16180 GENENAME E2F2 T16180 TARGTYPE Literature-reported T16180 SYNONYMS E2F-2 T16180 FUNCTION The DRTF1/E2F complex functions in the control of cell-cycle progression from g1 to s phase. E2F2 binds specifically to RB1 in a cell-cycle dependent manner. Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. T16180 PDBSTRUC 1N4M T16180 SEQUENCE MLQGPRALASAAGQTPKVVPAMSPTELWPSGLSSPQLCPATATYYTPLYPQTAPPAAAPGTCLDATPHGPEGQVVRCLPAGRLPAKRKLDLEGIGRPVVPEFPTPKGKCIRVDGLPSPKTPKSPGEKTRYDTSLGLLTKKFIYLLSESEDGVLDLNWAAEVLDVQKRRIYDITNVLEGIQLIRKKAKNNIQWVGRGMFEDPTRPGKQQQLGQELKELMNTEQALDQLIQSCSLSFKHLTEDKANKRLAYVTYQDIRAVGNFKEQTVIAVKAPPQTRLEVPDRTEDNLQIYLKSTQGPIEVYLCPEEVQEPDSPSEEPLPSTSTLCPSPDSAQPSSSTDPSIMEPTASSVPAPAPTPQQAPPPPSLVPLEATDSLLELPHPLLQQTEDQFLSPTLACSSPLISFSPSLDQDDYLWGLEAGEGISDLFDSYDLGDLLIN T02231 TARGETID T02231 T02231 FORMERID TTDI00176 T02231 UNIPROID IL27B_HUMAN T02231 TARGNAME Interleukin-35 (IL35) T02231 GENENAME EBI3 T02231 TARGTYPE Literature-reported T02231 SYNONYMS Interleukin-27 subunit beta; IL27B; IL-27B; IL-27 subunit beta; Epstein-Barr virus-induced gene 3 protein; EBV-induced gene 3 protein T02231 FUNCTION IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines. Associates with IL27 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. T02231 BIOCLASS Cytokine: interleukin T02231 SEQUENCE MTPQLLLALVLWASCPPCSGRKGPPAALTLPRVQCRASRYPIAVDCSWTLPPAPNSTSPVSFIATYRLGMAARGHSWPCLQQTPTSTSCTITDVQLFSMAPYVLNVTAVHPWGSSSSFVPFITEHIIKPDPPEGVRLSPLAERQLQVQWEPPGSWPFPEIFSLKYWIRYKRQGAARFHRVGPIEATSFILRAVRPRARYYVQVAAQDLTDYGELSDWSLPATATMSLGK T85835 TARGETID T85835 T85835 FORMERID TTDR01131 T85835 UNIPROID FGL2_HUMAN T85835 TARGNAME Fibroleukin (FGL2) T85835 GENENAME FGL2 T85835 TARGTYPE Literature-reported T85835 SYNONYMS PT49; Hfgl2; Fibrinogen-like protein 2; FGL2 T85835 FUNCTION May play a role in physiologic lymphocyte functions at mucosal sites. T85835 BIOCLASS Fibrinogen T85835 SEQUENCE MKLANWYWLSSAVLATYGFLVVANNETEEIKDERAKDVCPVRLESRGKCEEAGECPYQVSLPPLTIQLPKQFSRIEEVFKEVQNLKEIVNSLKKSCQDCKLQADDNGDPGRNGLLLPSTGAPGEVGDNRVRELESEVNKLSSELKNAKEEINVLHGRLEKLNLVNMNNIENYVDSKVANLTFVVNSLDGKCSKCPSQEQIQSRPVQHLIYKDCSDYYAIGKRSSETYRVTPDPKNSSFEVYCDMETMGGGWTVLQARLDGSTNFTRTWQDYKAGFGNLRREFWLGNDKIHLLTKSKEMILRIDLEDFNGVELYALYDQFYVANEFLKYRLHVGNYNGTAGDALRFNKHYNHDLKFFTTPDKDNDRYPSGNCGLYYSSGWWFDACLSANLNGKYYHQKYRGVRNGIFWGTWPGVSEAHPGGYKSSFKEAKMMIRPKHFKP T84616 TARGETID T84616 T84616 FORMERID TTDI00108 T84616 UNIPROID BECN1_HUMAN T84616 TARGNAME Beclin-1 (BECN1) T84616 GENENAME BECN1 T84616 TARGTYPE Literature-reported T84616 SYNONYMS Protein GT197; GT197; Coiledcoil myosinlike BCL2interacting protein; Coiled-coil myosin-like BCL2-interacting protein T84616 FUNCTION Acts as core subunit of the PI3K complex that mediates formation of phosphatidylinositol 3-phosphate; different complex forms are believed to play a role in multiple membrane trafficking pathways: PI3KC3-C1 is involved in initiation of autophagosomes and PI3KC3-C2 in maturation of autophagosomes and endocytosis. Involved in regulation of degradative endocytic trafficking and required for the abcission step in cytokinesis, probably in the context of PI3KC3-C2. Essential for the formation of PI3KC3-C2 but not PI3KC3-C1 PI3K complex forms. Involved in endocytosis. Protects against infection by a neurovirulent strain of Sindbis virus. May play a role in antiviral host defense. Plays a central role in autophagy. T84616 PDBSTRUC 6HOK; 6HOJ; 6HOI; 6DCO; 6DCN T84616 SEQUENCE MEGSKTSNNSTMQVSFVCQRCSQPLKLDTSFKILDRVTIQELTAPLLTTAQAKPGETQEEETNSGEEPFIETPRQDGVSRRFIPPARMMSTESANSFTLIGEASDGGTMENLSRRLKVTGDLFDIMSGQTDVDHPLCEECTDTLLDQLDTQLNVTENECQNYKRCLEILEQMNEDDSEQLQMELKELALEEERLIQELEDVEKNRKIVAENLEKVQAEAERLDQEEAQYQREYSEFKRQQLELDDELKSVENQMRYAQTQLDKLKKTNVFNATFHIWHSGQFGTINNFRLGRLPSVPVEWNEINAAWGQTVLLLHALANKMGLKFQRYRLVPYGNHSYLESLTDKSKELPLYCSGGLRFFWDNKFDHAMVAFLDCVQQFKEEVEKGETRFCLPYRMDVEKGKIEDTGGSGGSYSIKTQFNSEEQWTKALKFMLTNLKWGLAWVSSQFYNK T42890 TARGETID T42890 T42890 FORMERID TTDNR00666 T42890 UNIPROID CASL_HUMAN T42890 TARGNAME Enhancer of filamentation 1 (NEDD9) T42890 GENENAME NEDD9 T42890 TARGTYPE Literature-reported T42890 SYNONYMS p105; hEF1; Renal carcinoma antigen NY-REN-12; Neural precursor cell expressed developmentally down-regulated protein 9; NEDD-9; CasL; Cas scaffolding protein family member 2; CRK-associated substrate-related protein; CASS2; CAS-L T42890 FUNCTION May function in transmitting growth control signals between focal adhesions at the cell periphery and the mitotic spindle in response to adhesion or growth factor signals initiating cell proliferation. May play an important role in integrin beta-1 or B cell antigen receptor (BCR) mediated signaling in B- and T-cells. Integrin beta-1 stimulation leads to recruitment of various proteins including CRK, NCK and SHPTP2 to the tyrosine phosphorylated form. Docking protein which plays a central coordinating role for tyrosine-kinase-based signaling related to cell adhesion. T42890 PDBSTRUC 5X3S; 2L81 T42890 SEQUENCE MKYKNLMARALYDNVPECAEELAFRKGDILTVIEQNTGGLEGWWLCSLHGRQGIVPGNRVKLLIGPMQETASSHEQPASGLMQQTFGQQKLYQVPNPQAAPRDTIYQVPPSYQNQGIYQVPTGHGTQEQEVYQVPPSVQRSIGGTSGPHVGKKVITPVRTGHGYVYEYPSRYQKDVYDIPPSHTTQGVYDIPPSSAKGPVFSVPVGEIKPQGVYDIPPTKGVYAIPPSACRDEAGLREKDYDFPPPMRQAGRPDLRPEGVYDIPPTCTKPAGKDLHVKYNCDIPGAAEPVARRHQSLSPNHPPPQLGQSVGSQNDAYDVPRGVQFLEPPAETSEKANPQERDGVYDVPLHNPPDAKGSRDLVDGINRLSFSSTGSTRSNMSTSSTSSKESSLSASPAQDKRLFLDPDTAIERLQRLQQALEMGVSSLMALVTTDWRCYGYMERHINEIRTAVDKVELFLKEYLHFVKGAVANAACLPELILHNKMKRELQRVEDSHQILSQTSHDLNECSWSLNILAINKPQNKCDDLDRFVMVAKTVPDDAKQLTTTINTNAEALFRPGPGSLHLKNGPESIMNSTEYPHGGSQGQLLHPGDHKAQAHNKALPPGLSKEQAPDCSSSDGSERSWMDDYDYVHLQGKEEFERQQKELLEKENIMKQNKMQLEHHQLSQFQLLEQEITKPVENDISKWKPSQSLPTTNSGVSAQDRQLLCFYYDQCETHFISLLNAIDALFSCVSSAQPPRIFVAHSKFVILSAHKLVFIGDTLTRQVTAQDIRNKVMNSSNQLCEQLKTIVMATKMAALHYPSTTALQEMVHQVTDLSRNAQLFKRSLLEMATF T43605 TARGETID T43605 T43605 FORMERID TTDR00313 T43605 UNIPROID FGFP1_HUMAN T43605 TARGNAME Heparin binding protein (FGFBP1) T43605 GENENAME FGFBP1 T43605 TARGTYPE Literature-reported T43605 SYNONYMS HBp17; HBP17 heparin-binding and FGF-binding protein; Fibroblast growth factor binding protein 1; FGFBP1; FGF-binding protein HBp17; FGF-BP T43605 FUNCTION Acts as a carrier protein that release fibroblast- binding factors (FGFs) from the extracellular matrix (EM) storage and thus enhance the mitogenic activity of FGFs. Enhances FGF2 signaling during tissue repair, angiogenesis and in tumor growth. T43605 BIOCLASS Fibroblast growth factor-binding T43605 SEQUENCE MKICSLTLLSFLLLAAQVLLVEGKKKVKNGLHSKVVSEQKDTLGNTQIKQKSRPGNKGKFVTKDQANCRWAATEQEEGISLKVECTQLDHEFSCVFAGNPTSCLKLKDERVYWKQVARNLRSQKDICRYSKTAVKTRVCRKDFPESSLKLVSSTLFGNTKPRKEKTEMSPREHIKGKETTPSSLAVTQTMATKAPECVEDPDMANQRKTALEFCGETWSSLCTFFLSIVQDTSC T61227 TARGETID T61227 T61227 FORMERID TTDI03294 T61227 UNIPROID ITPR1_HUMAN T61227 TARGNAME IP3 receptor isoform 1 (ITPR1) T61227 GENENAME ITPR1 T61227 TARGTYPE Literature-reported T61227 SYNONYMS Type 1 inositol 1,4,5-trisphosphate receptor; Type 1 InsP3 receptor; InsP3R1; Inositol 1,4,5-trisphosphate receptor type 1; IP3R 1 T61227 FUNCTION Involved in the regulation of epithelial secretion of electrolytes and fluid through the interaction with AHCYL1. Plays a role in ER stress-induced apoptosis. Cytoplasmic calcium released from the ER triggers apoptosis by the activation of CaM kinase II, eventually leading to the activation of downstream apoptosis pathways. Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate. T61227 BIOCLASS Ryanodine-inositol triphosphate calcium channel T61227 SEQUENCE MSDKMSSFLHIGDICSLYAEGSTNGFISTLGLVDDRCVVQPETGDLNNPPKKFRDCLFKLCPMNRYSAQKQFWKAAKPGANSTTDAVLLNKLHHAADLEKKQNETENRKLLGTVIQYGNVIQLLHLKSNKYLTVNKRLPALLEKNAMRVTLDEAGNEGSWFYIQPFYKLRSIGDSVVIGDKVVLNPVNAGQPLHASSHQLVDNPGCNEVNSVNCNTSWKIVLFMKWSDNKDDILKGGDVVRLFHAEQEKFLTCDEHRKKQHVFLRTTGRQSATSATSSKALWEVEVVQHDPCRGGAGYWNSLFRFKHLATGHYLAAEVDPDFEEECLEFQPSVDPDQDASRSRLRNAQEKMVYSLVSVPEGNDISSIFELDPTTLRGGDSLVPRNSYVRLRHLCTNTWVHSTNIPIDKEEEKPVMLKIGTSPVKEDKEAFAIVPVSPAEVRDLDFANDASKVLGSIAGKLEKGTITQNERRSVTKLLEDLVYFVTGGTNSGQDVLEVVFSKPNRERQKLMREQNILKQIFKLLQAPFTDCGDGPMLRLEELGDQRHAPFRHICRLCYRVLRHSQQDYRKNQEYIAKQFGFMQKQIGYDVLAEDTITALLHNNRKLLEKHITAAEIDTFVSLVRKNREPRFLDYLSDLCVSMNKSIPVTQELICKAVLNPTNADILIETKLVLSRFEFEGVSSTGENALEAGEDEEEVWLFWRDSNKEIRSKSVRELAQDAKEGQKEDRDVLSYYRYQLNLFARMCLDRQYLAINEISGQLDVDLILRCMSDENLPYDLRASFCRLMLHMHVDRDPQEQVTPVKYARLWSEIPSEIAIDDYDSSGASKDEIKERFAQTMEFVEEYLRDVVCQRFPFSDKEKNKLTFEVVNLARNLIYFGFYNFSDLLRLTKILLAILDCVHVTTIFPISKMAKGEENKGNNDVEKLKSSNVMRSIHGVGELMTQVVLRGGGFLPMTPMAAAPEGNVKQAEPEKEDIMVMDTKLKIIEILQFILNVRLDYRISCLLCIFKREFDESNSQTSETSSGNSSQEGPSNVPGALDFEHIEEQAEGIFGGSEENTPLDLDDHGGRTFLRVLLHLTMHDYPPLVSGALQLLFRHFSQRQEVLQAFKQVQLLVTSQDVDNYKQIKQDLDQLRSIVEKSELWVYKGQGPDETMDGASGENEHKKTEEGNNKPQKHESTSSYNYRVVKEILIRLSKLCVQESASVRKSRKQQQRLLRNMGAHAVVLELLQIPYEKAEDTKMQEIMRLAHEFLQNFCAGNQQNQALLHKHINLFLNPGILEAVTMQHIFMNNFQLCSEINERVVQHFVHCIETHGRNVQYIKFLQTIVKAEGKFIKKCQDMVMAELVNSGEDVLVFYNDRASFQTLIQMMRSERDRMDENSPLMYHIHLVELLAVCTEGKNVYTEIKCNSLLPLDDIVRVVTHEDCIPEVKIAYINFLNHCYVDTEVEMKEIYTSNHMWKLFENFLVDICRACNNTSDRKHADSILEKYVTEIVMSIVTTFFSSPFSDQSTTLQTRQPVFVQLLQGVFRVYHCNWLMPSQKASVESCIRVLSDVAKSRAIAIPVDLDSQVNNLFLKSHSIVQKTAMNWRLSARNAARRDSVLAASRDYRNIIERLQDIVSALEDRLRPLVQAELSVLVDVLHRPELLFPENTDARRKCESGGFICKLIKHTKQLLEENEEKLCIKVLQTLREMMTKDRGYGEKLISIDELDNAELPPAPDSENATEELEPSPPLRQLEDHKRGEALRQVLVNRYYGNVRPSGRRESLTSFGNGPLSAGGPGKPGGGGGGSGSSSMSRGEMSLAEVQCHLDKEGASNLVIDLIMNASSDRVFHESILLAIALLEGGNTTIQHSFFCRLTEDKKSEKFFKVFYDRMKVAQQEIKATVTVNTSDLGNKKKDDEVDRDAPSRKKAKEPTTQITEEVRDQLLEASAATRKAFTTFRREADPDDHYQPGEGTQATADKAKDDLEMSAVITIMQPILRFLQLLCENHNRDLQNFLRCQNNKTNYNLVCETLQFLDCICGSTTGGLGLLGLYINEKNVALINQTLESLTEYCQGPCHENQNCIATHESNGIDIITALILNDINPLGKKRMDLVLELKNNASKLLLAIMESRHDSENAERILYNMRPKELVEVIKKAYMQGEVEFEDGENGEDGAASPRNVGHNIYILAHQLARHNKELQSMLKPGGQVDGDEALEFYAKHTAQIEIVRLDRTMEQIVFPVPSICEFLTKESKLRIYYTTERDEQGSKINDFFLRSEDLFNEMNWQKKLRAQPVLYWCARNMSFWSSISFNLAVLMNLLVAFFYPFKGVRGGTLEPHWSGLLWTAMLISLAIVIALPKPHGIRALIASTILRLIFSVGLQPTLFLLGAFNVCNKIIFLMSFVGNCGTFTRGYRAMVLDVEFLYHLLYLVICAMGLFVHEFFYSLLLFDLVYREETLLNVIKSVTRNGRSIILTAVLALILVYLFSIVGYLFFKDDFILEVDRLPNETAVPETGESLASEFLFSDVCRVESGENCSSPAPREELVPAEETEQDKEHTCETLLMCIVTVLSHGLRSGGGVGDVLRKPSKEEPLFAARVIYDLLFFFMVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVTFEEHIKEEHNMWHYLCFIVLVKVKDSTEYTGPESYVAEMIKERNLDWFPRMRAMSLVSSDSEGEQNELRNLQEKLESTMKLVTNLSGQLSELKDQMTEQRKQKQRIGLLGHPPHMNVNPQQPA T61227 DRUGINFO D0MY2Y xestospongin C Investigative T61227 DRUGINFO D06YZB inositol 2,4,5-trisphosphate Investigative T61227 DRUGINFO D06KHR decavanadate Investigative T61227 DRUGINFO D07ZAJ PIP2 Investigative T95992 TARGETID T95992 T95992 UNIPROID LASP1_HUMAN T95992 TARGNAME LIM and SH3 domain protein 1 (LASP1) T95992 GENENAME LASP1 T95992 TARGTYPE Literature-reported T95992 SYNONYMS Metastatic lymph node gene 50 protein; MLN50; MLN 50; LASP-1 T95992 FUNCTION Plays an important role in the regulation of dynamic actin-based, cytoskeletal activities. Agonist-dependent changes in LASP1 phosphorylation may also serve to regulate actin-associated ion transport activities, not only in the parietal cell but also in certain other F-actin-rich secretory epithelial cell types. T95992 PDBSTRUC 3I35 T95992 SEQUENCE MNPNCARCGKIVYPTEKVNCLDKFWHKACFHCETCKMTLNMKNYKGYEKKPYCNAHYPKQSFTMVADTPENLRLKQQSELQSQVRYKEEFEKNKGKGFSVVADTPELQRIKKTQDQISNIKYHEEFEKSRMGPSGGEGMEPERRDSQDGSSYRRPLEQQQPHHIPTSAPVYQQPQQQPVAQSYGGYKEPAAPVSIQRSAPGGGGKRYRAVYDYSAADEDEVSFQDGDTIVNVQQIDDGWMYGTVERTGDTGMLPANYVEAI T52595 TARGETID T52595 T52595 FORMERID TTDNC00408 T52595 UNIPROID MTF1_HUMAN T52595 TARGNAME Metal regulatory transcription factor 1 (MTF1) T52595 GENENAME MTF1 T52595 TARGTYPE Literature-reported T52595 SYNONYMS Transcription factor MTF1; MTF1; MREbinding transcription factor T52595 FUNCTION Activates the metallothionein I promoter. Binds to the metal responsive element (MRE). T52595 BIOCLASS Zinc-finger T52595 SEQUENCE MGEHSPDNNIIYFEAEEDELTPDDKMLRFVDKNGLVPSSSGTVYDRTTVLIEQDPGTLEDEDDDGQCGEHLPFLVGGEEGFHLIDHEAMSQGYVQHIISPDQIHLTINPGSTPMPRNIEGATLTLQSECPETKRKEVKRYQCTFEGCPRTYSTAGNLRTHQKTHRGEYTFVCNQEGCGKAFLTSYSLRIHVRVHTKEKPFECDVQGCEKAFNTLYRLKAHQRLHTGKTFNCESEGCSKYFTTLSDLRKHIRTHTGEKPFRCDHDGCGKAFAASHHLKTHVRTHTGERPFFCPSNGCEKTFSTQYSLKSHMKGHDNKGHSYNALPQHNGSEDTNHSLCLSDLSLLSTDSELRENSSTTQGQDLSTISPAIIFESMFQNSDDTAIQEDPQQTASLTESFNGDAESVSDVPPSTGNSASLSLPLVLQPGLSEPPQPLLPASAPSAPPPAPSLGPGSQQAAFGNPPALLQPPEVPVPHSTQFAANHQEFLPHPQAPQPIVPGLSVVAGASASAAAVASAVAAPAPPQSTTEPLPAMVQTLPLGANSVLTNNPTITITPTPNTAILQSSLVMGEQNLQWILNGATSSPQNQEQIQQASKVEKVFFTTAVPVASSPGSSVQQIGLSVPVIIIKQEEACQCQCACRDSAKERASSRRKGCSSPPPPEPSPQAPDGPSLQLPAQTFSSAPVPGSSSSTLPSSCEQSRQAETPSDPQTETLSAMDVSEFLSLQSLDTPSNLIPIEALLQGEEEMGLTSSFSK T39738 TARGETID T39738 T39738 FORMERID TTDI00109 T39738 UNIPROID CUL7_HUMAN T39738 TARGNAME Cullin-7 (CUL-7) T39738 GENENAME CUL7 T39738 TARGTYPE Literature-reported T39738 SYNONYMS KIAA0076 T39738 FUNCTION Core component of the 3M complex, a complex required to regulate microtubule dynamics and genome integrity. It is unclear how the 3M complex regulates microtubules, it could act by controlling the level of a microtubule stabilizer. Interaction with CUL9 is required to inhibit CUL9 activity and ubiquitination of BIRC5. Core component of a Cul7-RING ubiquitin-protein ligase with FBXW8, which mediates ubiquitination and consequent degradation of target proteins such as GORASP1, IRS1 and MAP4K1/HPK1. Ubiquitination of GORASP1 regulates Golgi morphogenesis and dendrite patterning in brain. Mediates ubiquitination and degradation of IRS1 in a mTOR-dependent manner: the Cul7-RING(FBXW8) complex recognizes and binds IRS1 previously phosphorylated by S6 kinase (RPS6KB1 or RPS6KB2). The Cul7-RING(FBXW8) complex also mediates ubiquitination of MAP4K1/HPK1: recognizes and binds autophosphorylated MAP4K1/HPK1, leading to its degradation, thereby affecting cell proliferation and differentiation. Acts as a regulator in trophoblast cell epithelial-mesenchymal transition and placental development. Does not promote polyubiquitination and proteasomal degradation of p53/TP53. While the Cul7-RING(FBXW8) and the 3M complexes are associated and involved in common processes, CUL7 and the Cul7-RING(FBXW8) complex may be have additional functions. Core component of the 3M and Cul7-RING(FBXW8) complexes, which mediates the ubiquitination of target proteins. T39738 PDBSTRUC 2JNG T39738 SEQUENCE MVGELRYREFRVPLGPGLHAYPDELIRQRVGHDGHPEYQIRWLILRRGDEGDGGSGQVDCKAEHILLWMSKDEIYANCHKMLGEDGQVIGPSQESAGEVGALDKSVLEEMETDVKSLIQRALRQLEECVGTIPPAPLLHTVHVLSAYASIEPLTGVFKDPRVLDLLMHMLSSPDYQIRWSAGRMIQALSSHDAGTRTQILLSLSQQEAIEKHLDFDSRCALLALFAQATLSEHPMSFEGIQLPQVPGRVLFSLVKRYLHVTSLLDQLNDSAAEPGAQNTSAPEELSGERGQLELEFSMAMGTLISELVQAMRWDQASDRPRSSARSPGSIFQPQLADVSPGLPAAQAQPSFRRSRRFRPRSEFASGNTYALYVRDTLQPGMRVRMLDDYEEISAGDEGEFRQSNNGVPPVQVFWESTGRTYWVHWHMLEILGFEEDIEDMVEADEYQGAVASRVLGRALPAWRWRPMTELYAVPYVLPEDEDTEECEHLTLAEWWELLFFIKKLDGPDHQEVLQILQENLDGEILDDEILAELAVPIELAQDLLLTLPQRLNDSALRDLINCHVYKKYGPEALAGNQAYPSLLEAQEDVLLLDAQAQAKDSEDAAKVEAKEPPSQSPNTPLQRLVEGYGPAGKILLDLEQALSSEGTQENKVKPLLLQLQRQPQPFLALMQSLDTPETNRTLHLTVLRILKQLVDFPEALLLPWHEAVDACMACLRSPNTDREVLQELIFFLHRLTSVSRDYAVVLNQLGARDAISKALEKHLGKLELAQELRDMVFKCEKHAHLYRKLITNILGGCIQMVLGQIEDHRRTHQPINIPFFDVFLRYLCQGSSVEVKEDKCWEKVEVSSNPHRASKLTDHNPKTYWESNGSAGSHYITLHMRRGILIRQLTLLVASEDSSYMPARVVVCGGDSTSSLHTELNSVNVMPSASRVILLENLTRFWPIIQIRIKRCQQGGIDTRIRGLEILGPKPTFWPVFREQLCRHTRLFYMVRAQAWSQDMAEDRRSLLHLSSRLNGALRQEQNFADRFLPDDEAAQALGKTCWEALVSPVVQNITSPDEDGISPLGWLLDQYLECQEAVFNPQSRGPAFFSRVRRLTHLLVHVEPCEAPPPVVATPRPKGRNRSHDWSSLATRGLPSSIMRNLTRCWRAVVEKQVNNFLTSSWRDDDFVPRYCEHFNILQNSSSELFGPRAAFLLALQNGCAGALLKLPFLKAAHVSEQFARHIDQQIQGSRIGGAQEMERLAQLQQCLQAVLIFSGLEIATTFEHYYQHYMADRLLGVVSSWLEGAVLEQIGPCFPNRLPQQMLQSLSTSKELQRQFHVYQLQQLDQELLKLEDTEKKIQVGLGASGKEHKSEKEEEAGAAAVVDVAEGEEEEEENEDLYYEGAMPEVSVLVLSRHSWPVASICHTLNPRTCLPSYLRGTLNRYSNFYNKSQSHPALERGSQRRLQWTWLGWAELQFGNQTLHVSTVQMWLLLYLNDLKAVSVESLLAFSGLSADMLNQAIGPLTSSRGPLDLHEQKDIPGGVLKIRDGSKEPRSRWDIVRLIPPQTYLQAEGEDGQNLEKRRNLLNCLIVRILKAHGDEGLHIDQLVCLVLEAWQKGPCPPRGLVSSLGKGSACSSTDVLSCILHLLGKGTLRRHDDRPQVLSYAVPVTVMEPHTESLNPGSSGPNPPLTFHTLQIRSRGVPYASCTATQSFSTFR T29187 TARGETID T29187 T29187 FORMERID TTDI02618 T29187 UNIPROID POSTN_HUMAN T29187 TARGNAME Periostin (POSTN) T29187 GENENAME POSTN T29187 TARGTYPE Literature-reported T29187 SYNONYMS POSTN; PN; Osteoblastspecific factor 2 T29187 FUNCTION Enhances incorporation of BMP1 in the fibronectin matrix ofconnective tissues, and subsequent proteolytic activation of lysyl oxidase LOX. Induces cell attachment and spreading and plays a role in cell adhesion. May play a role in extracellular matrix mineralization. {ECO:0000250, ECO:0000269|PubMed:12235007, ECO:0000269|PubMed:18450759}. T29187 PDBSTRUC 5YJH; 5YJG; 5WT7 T29187 SEQUENCE MIPFLPMFSLLLLLIVNPINANNHYDKILAHSRIRGRDQGPNVCALQQILGTKKKYFSTCKNWYKKSICGQKTTVLYECCPGYMRMEGMKGCPAVLPIDHVYGTLGIVGATTTQRYSDASKLREEIEGKGSFTYFAPSNEAWDNLDSDIRRGLESNVNVELLNALHSHMINKRMLTKDLKNGMIIPSMYNNLGLFINHYPNGVVTVNCARIIHGNQIATNGVVHVIDRVLTQIGTSIQDFIEAEDDLSSFRAAAITSDILEALGRDGHFTLFAPTNEAFEKLPRGVLERIMGDKVASEALMKYHILNTLQCSESIMGGAVFETLEGNTIEIGCDGDSITVNGIKMVNKKDIVTNNGVIHLIDQVLIPDSAKQVIELAGKQQTTFTDLVAQLGLASALRPDGEYTLLAPVNNAFSDDTLSMDQRLLKLILQNHILKVKVGLNELYNGQILETIGGKQLRVFVYRTAVCIENSCMEKGSKQGRNGAIHIFREIIKPAEKSLHEKLKQDKRFSTFLSLLEAADLKELLTQPGDWTLFVPTNDAFKGMTSEEKEILIRDKNALQNIILYHLTPGVFIGKGFEPGVTNILKTTQGSKIFLKEVNDTLLVNELKSKESDIMTTNGVIHVVDKLLYPADTPVGNDQLLEILNKLIKYIQIKFVRGSTFKEIPVTVYTTKIITKVVEPKIKVIEGSLQPIIKTEGPTLTKVKIEGEPEFRLIKEGETITEVIHGEPIIKKYTKIIDGVPVEITEKETREERIITGPEIKYTRISTGGGETEETLKKLLQEEVTKVTKFIEGGDGHLFEDEEIKRLLQGDTPVRKLQANKKVQGSRRRLREGRSQ T86587 TARGETID T86587 T86587 FORMERID TTDR00793 T86587 UNIPROID OZF_HUMAN T86587 TARGNAME Zinc finger protein OZF (ZNF146) T86587 GENENAME ZNF146 T86587 TARGTYPE Literature-reported T86587 SYNONYMS Zinc finger protein 146; Only zinc finger protein; OZF T86587 FUNCTION A nuclear zinc finger protein consisting of a single domain of 10 zinc finger motifs of the Kruppel type, preceded by 10 amino acids. Involved in gene regulation and tumorigenesis. T86587 BIOCLASS Zinc-finger T86587 SEQUENCE MSHLSQQRIYSGENPFACKVCGKVFSHKSNLTEHEHFHTREKPFECNECGKAFSQKQYVIKHQNTHTGEKLFECNECGKSFSQKENLLTHQKIHTGEKPFECKDCGKAFIQKSNLIRHQRTHTGEKPFVCKECGKTFSGKSNLTEHEKIHIGEKPFKCSECGTAFGQKKYLIKHQNIHTGEKPYECNECGKAFSQRTSLIVHVRIHSGDKPYECNVCGKAFSQSSSLTVHVRSHTGEKPYGCNECGKAFSQFSTLALHLRIHTGKKPYQCSECGKAFSQKSHHIRHQKIHTH T09513 TARGETID T09513 T09513 FORMERID TTDI02622 T09513 UNIPROID CD5R1_HUMAN T09513 TARGNAME CDK5 activator 1 (CDK5R1) T09513 GENENAME CDK5R1 T09513 TARGTYPE Literature-reported T09513 SYNONYMS TPKII regulatory subunit; NCK5A; Cyclindependent kinase 5 regulatory subunit 1; Cyclindependent kinase 5 activator 1, p25; Cyclindependent kinase 5 activator 1; Cyclin-dependent kinase 5 regulatory subunit 1; Cyclin-dependent kinase 5 activator 1; CDK5R T09513 FUNCTION The complex p35/CDK5 is required for neurite outgrowth and cortical lamination. Involved in dendritic spine morphogenesis by mediating the EFNA1-EPHA4 signaling. Activator of TPKII. The complex p35/CDK5 participates in the regulation of the circadian clock by modulating the function of CLOCK protein: phosphorylates CLOCK at 'Thr-451' and 'Thr-461' and regulates the transcriptional activity of the CLOCK-ARNTL/BMAL1 heterodimer in association with altered stability and subcellular distribution. p35 is a neuron specific activator of CDK5. T09513 PDBSTRUC 3O0G; 1UNL; 1UNH; 1UNG; 1H4L T09513 SEQUENCE MGTVLSLSPSYRKATLFEDGAATVGHYTAVQNSKNAKDKNLKRHSIISVLPWKRIVAVSAKKKNSKKVQPNSSYQNNITHLNNENLKKSLSCANLSTFAQPPPAQPPAPPASQLSGSQTGGSSSVKKAPHPAVTSAGTPKRVIVQASTSELLRCLGEFLCRRCYRLKHLSPTDPVLWLRSVDRSLLLQGWQDQGFITPANVVFLYMLCRDVISSEVGSDHELQAVLLTCLYLSYSYMGNEISYPLKPFLVESCKEAFWDRCLSVINLMSSKMLQINADPHYFTQVFSDLKNESGQEDKKRLLLGLDR T57291 TARGETID T57291 T57291 FORMERID TTDR00363 T57291 UNIPROID 2A5A_HUMAN T57291 TARGNAME PP2A B subunit isoform R5-alpha (PPP2R5A) T57291 GENENAME PPP2R5A T57291 TARGTYPE Literature-reported T57291 SYNONYMS Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform; Protein phosphatase-2A; PR61alpha; PP2A, B subunit, R5 alpha isoform; PP2A, B subunit, PR61 alpha isoform; PP2A, B subunit, B56 alpha isoform; PP2A, B subunit, B' alpha isoform; PP2A B subunit isoform PR61-alpha; PP2A B subunit isoform B56-alpha; PP2A B subunit isoform B'-alpha T57291 FUNCTION The B regulatory subunit might modulate substrate selectivity and catalytic activity, and also might direct the localization of the catalytic enzyme to a particular subcellular compartment. T57291 SEQUENCE MSSSSPPAGAASAAISASEKVDGFTRKSVRKAQRQKRSQGSSQFRSQGSQAELHPLPQLKDATSNEQQELFCQKLQQCCILFDFMDSVSDLKSKEIKRATLNELVEYVSTNRGVIVESAYSDIVKMISANIFRTLPPSDNPDFDPEEDEPTLEASWPHIQLVYEFFLRFLESPDFQPSIAKRYIDQKFVQQLLELFDSEDPRERDFLKTVLHRIYGKFLGLRAFIRKQINNIFLRFIYETEHFNGVAELLEILGSIINGFALPLKAEHKQFLMKVLIPMHTAKGLALFHAQLAYCVVQFLEKDTTLTEPVIRGLLKFWPKTCSQKEVMFLGEIEEILDVIEPTQFKKIEEPLFKQISKCVSSSHFQVAERALYFWNNEYILSLIEENIDKILPIMFASLYKISKEHWNPTIVALVYNVLKTLMEMNGKLFDDLTSSYKAERQREKKKELEREELWKKLEELKLKKALEKQNSAYNMHSILSNTSAE T57291 DRUGINFO D0W4IL NORCANTHARIDIN Investigative T16555 TARGETID T16555 T16555 FORMERID TTDI03438 T16555 UNIPROID P2Y14_HUMAN T16555 TARGNAME P2Y purinoceptor 14 (P2RY14) T16555 GENENAME P2RY14 T16555 TARGTYPE Literature-reported T16555 SYNONYMS UDP-glucose receptor; P2Y14; KIAA0001; GPR105; G-protein coupled receptor 105 T16555 FUNCTION Receptor for UDP-glucose and other UDP-sugar coupled to G-proteins. Not activated by ATP, ADP, UTP or ATP. T16555 PDBSTRUC 2B6V T16555 SEQUENCE MINSTSTQPPDESCSQNLLITQQIIPVLYCMVFIAGILLNGVSGWIFFYVPSSKSFIIYLKNIVIADFVMSLTFPFKILGDSGLGPWQLNVFVCRVSAVLFYVNMYVSIVFFGLISFDRYYKIVKPLWTSFIQSVSYSKLLSVIVWMLMLLLAVPNIILTNQSVREVTQIKCIELKSELGRKWHKASNYIFVAIFWIVFLLLIVFYTAITKKIFKSHLKSSRNSTSVKKKSSRNIFSIVFVFFVCFVPYHIARIPYTKSQTEAHYSCQSKEILRYMKEFTLLLSAANVCLDPIIYFFLCQPFREILCKKLHIPLKAQNDLDISRIKRGNTTLESTDTL T16555 DRUGINFO D05MXI PPTN Investigative T16555 DRUGINFO D07TSE 2-thio-UDP Investigative T16555 DRUGINFO D09EGQ MRS2905 Investigative T16555 DRUGINFO D0E8TW MRS2690 Investigative T16555 DRUGINFO D0O8AN UDP-glucuronic acid Investigative T16555 DRUGINFO D0Q5SV alpha.beta-methylene-2-thio-UDP Investigative T16555 DRUGINFO D0V9TZ MRS2802 Investigative T16555 DRUGINFO D07MIE UDP-glucose Investigative T14181 TARGETID T14181 T14181 FORMERID TTDI00103 T14181 UNIPROID TERF2_HUMAN T14181 TARGNAME Telomeric repeat-binding factor 2 (TERF2) T14181 GENENAME TERF2 T14181 TARGTYPE Literature-reported T14181 SYNONYMS Telomeric DNA-binding protein; TTAGGG repeat-binding factor 2; TRF2; TRBF2 T14181 FUNCTION Binds the telomeric double-stranded 5'-TTAGGG-3' repeat and plays a central role in telomere maintenance and protection against end-to-end fusion of chromosomes. In addition to its telomeric DNA-binding role, required to recruit a number of factors and enzymes required for telomere protection, including the shelterin complex, TERF2IP/RAP1 and DCLRE1B/Apollo. Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection. Shelterin associates with arrays of double-stranded 5'-TTAGGG-3' repeats added by telomerase and protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage surveillance and chromosome ends are inappropriately processed by DNA repair pathways. Together with DCLRE1B/Apollo, plays a key role in telomeric loop (T loop) formation by generating 3' single-stranded overhang at the leading end telomeres: T loops have been proposed to protect chromosome ends from degradation and repair. Required both to recruit DCLRE1B/Apollo to telomeres and activate the exonuclease activity of DCLRE1B/Apollo. Preferentially binds to positive supercoiled DNA. Together with DCLRE1B/Apollo, required to control the amount of DNA topoisomerase (TOP1, TOP2A and TOP2B) needed for telomere replication during fork passage and prevent aberrant telomere topology. Recruits TERF2IP/RAP1 to telomeres, thereby participating in to repressing homology-directed repair (HDR), which can affect telomere length. T14181 PDBSTRUC 6J67; 5XYF; 5WQD; 4RQI; 4M7C T14181 SEQUENCE MAAGAGTAGPASGPGVVRDPAASQPRKRPGREGGEGARRSDTMAGGGGSSDGSGRAAGRRASRSSGRARRGRHEPGLGGPAERGAGEARLEEAVNRWVLKFYFHEALRAFRGSRYGDFRQIRDIMQALLVRPLGKEHTVSRLLRVMQCLSRIEEGENLDCSFDMEAELTPLESAINVLEMIKTEFTLTEAVVESSRKLVKEAAVIICIKNKEFEKASKILKKHMSKDPTTQKLRNDLLNIIREKNLAHPVIQNFSYETFQQKMLRFLESHLDDAEPYLLTMAKKALKSESAASSTGKEDKQPAPGPVEKPPREPARQLRNPPTTIGMMTLKAAFKTLSGAQDSEAAFAKLDQKDLVLPTQALPASPALKNKRPRKDENESSAPADGEGGSELQPKNKRMTISRLVLEEDSQSTEPSAGLNSSQEAASAPPSKPTVLNQPLPGEKNPKVPKGKWNSSNGVEEKETWVEEDELFQVQAAPDEDSTTNITKKQKWTVEESEWVKAGVQKYGEGNWAAISKNYPFVNRTAVMIKDRWRTMKRLGMN T49542 TARGETID T49542 T49542 FORMERID TTDI03575 T49542 UNIPROID TESK1_HUMAN T49542 TARGNAME Testis-specific kinase 1 (TESK1) T49542 GENENAME TESK1 T49542 TARGTYPE Literature-reported T49542 SYNONYMS Testicular protein kinase 1; Dual specificity testis-specific protein kinase 1 T49542 FUNCTION Dual specificity protein kinase activity catalyzing autophosphorylation and phosphorylation of exogenous substrates on both serine/threonine and tyrosine residues. Probably plays a central role at and after the meiotic phase of spermatogenesis (By similarity). T49542 ECNUMBER EC 2.7.12.1 T49542 SEQUENCE MAGERPPLRGPGPGPGEVPGEGPPGPGGTGGGPGRGRPSSYRALRSAVSSLARVDDFHCAEKIGAGFFSEVYKVRHRQSGQVMVLKMNKLPSNRGNTLREVQLMNRLRHPNILRFMGVCVHQGQLHALTEYMNGGTLEQLLSSPEPLSWPVRLHLALDIARGLRYLHSKGVFHRDLTSKNCLVRREDRGFTAVVGDFGLAEKIPVYREGARKEPLAVVGSPYWMAPEVLRGELYDEKADVFAFGIVLCELIARVPADPDYLPRTEDFGLDVPAFRTLVGDDCPLPFLLLAIHCCNLEPSTRAPFTEITQHLEWILEQLPEPAPLTRTALTHNQGSVARGGPSATLPRPDPRLSRSRSDLFLPPSPESPPNWGDNLTRVNPFSLREDLRGGKIKLLDTPSKPVLPLVPPSPFPSTQLPLVTTPETLVQPGTPARRCRSLPSSPELPRRMETALPGPGPPAVGPSAEEKMECEGSSPEPEPPGPAPQLPLAVATDNFISTCSSASQPWSPRSGPVLNNNPPAVVVNSPQGWAGEPWNRAQHSLPRAAALERTEPSPPPSAPREPDEGLPCPGCCLGPFSFGFLSMCPRPTPAVARYRNLNCEAGSLLCHRGHHAKPPTPSLQLPGARS T49542 DRUGINFO D0F6NZ PMID22902653C30 Investigative T49542 DRUGINFO D0FC4Y PMID22902653C31 Investigative T49542 DRUGINFO D0S0XD PMID22902653C35 Investigative T78349 TARGETID T78349 T78349 FORMERID TTDR00841 T78349 UNIPROID ELAV1_HUMAN T78349 TARGNAME ELAV-like protein 1 (ELAVL1) T78349 GENENAME ELAVL1 T78349 TARGTYPE Literature-reported T78349 SYNONYMS HuR; Hu-antigen R T78349 FUNCTION Involved in embryonic stem cells (ESCs) differentiation: preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), stabilizing them, promoting ESCs differentiation. Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs. Binds avidly to the AU-rich element in FOS and IL3/interleukin-3 mRNAs. In the case of the FOS AU-rich element, binds to a core element of 27 nucleotides that contain AUUUA, AUUUUA, and AUUUUUA motifs. Binds preferentially to the 5'-UUUU[AG]UUU-3' motif in vitro. With ZNF385A, binds the 3'-UTR of p53/TP53 mRNA to control their nuclear export induced by CDKN2A. Hence, may regulate p53/TP53 expression and mediate in part the CDKN2A anti-proliferative activity. May also bind with ZNF385A the CCNB1 mRNA. Increases the stability of the leptin mRNA harboring an AU-rich element (ARE) in its 3' UTR. RNA-binding protein that binds to the 3'-UTR region of mRNAs and increases their stability. T78349 PDBSTRUC 6GD3; 6GD2; 6GD1; 6GC5; 6G2K T78349 SEQUENCE MSNGYEDHMAEDCRGDIGRTNLIVNYLPQNMTQDELRSLFSSIGEVESAKLIRDKVAGHSLGYGFVNYVTAKDAERAINTLNGLRLQSKTIKVSYARPSSEVIKDANLYISGLPRTMTQKDVEDMFSRFGRIINSRVLVDQTTGLSRGVAFIRFDKRSEAEEAITSFNGHKPPGSSEPITVKFAANPNQNKNVALLSQLYHSPARRFGGPVHHQAQRFRFSPMGVDHMSGLSGVNVPGNASSGWCIFIYNLGQDADEGILWQMFGPFGAVTNVKVIRDFNTNKCKGFGFVTMTNYEEAAMAIASLNGYRLGDKILQVSFKTNKSHK T59493 TARGETID T59493 T59493 FORMERID TTDI03023 T59493 UNIPROID AAAT_HUMAN T59493 TARGNAME Alanine/serine/cysteine transporter 2 (SLC1A5) T59493 GENENAME SLC1A5 T59493 TARGTYPE Literature-reported T59493 SYNONYMS Solute carrier family 1 member 5; Sodium-dependent neutral amino acid transporter type 2; RDRC; RDR; RD114/simian type D retrovirus receptor; Neutral amino acid transporter B(0); M7V1; Baboon M7 virus receptor; ATB(0); ASCT2 T59493 FUNCTION Sodium-dependent amino acids transporter that has a broad substrate specificity, with a preference for zwitterionic amino acids. It accepts as substrates all neutral amino acids, including glutamine, asparagine, and branched-chain and aromatic amino acids, and excludes methylated, anionic, and cationic amino acids. Through binding of the fusogenic protein syncytin-1/ERVW-1 may mediate trophoblasts syncytialization, the spontaneous fusion of their plasma membranes, an essential process in placental development. T59493 PDBSTRUC 6GCT; 5MJU; 5LM4; 5LLU; 5LLM T59493 SEQUENCE MVADPPRDSKGLAAAEPTANGGLALASIEDQGAAAGGYCGSRDQVRRCLRANLLVLLTVVAVVAGVALGLGVSGAGGALALGPERLSAFVFPGELLLRLLRMIILPLVVCSLIGGAASLDPGALGRLGAWALLFFLVTTLLASALGVGLALALQPGAASAAINASVGAAGSAENAPSKEVLDSFLDLARNIFPSNLVSAAFRSYSTTYEERNITGTRVKVPVGQEVEGMNILGLVVFAIVFGVALRKLGPEGELLIRFFNSFNEATMVLVSWIMWYAPVGIMFLVAGKIVEMEDVGLLFARLGKYILCCLLGHAIHGLLVLPLIYFLFTRKNPYRFLWGIVTPLATAFGTSSSSATLPLMMKCVEENNGVAKHISRFILPIGATVNMDGAALFQCVAAVFIAQLSQQSLDFVKIITILVTATASSVGAAGIPAGGVLTLAIILEAVNLPVDHISLILAVDWLVDRSCTVLNVEGDALGAGLLQNYVDRTESRSTEPELIQVKSELPLDPLPVPTEEGNPLLKHYRGPAGDATVASEKESVM T59493 DRUGINFO D00IWH p-nitrophenyl glutamyl anilide Investigative T59493 DRUGINFO D0VX9R benzylserine Investigative T69271 TARGETID T69271 T69271 FORMERID TTDI00066 T69271 UNIPROID IBP7_HUMAN T69271 TARGNAME Insulin-like growth factor-binding protein 7 (IGFBP7) T69271 GENENAME IGFBP7 T69271 TARGTYPE Literature-reported T69271 SYNONYMS Tumorderived adhesion factor; Tumor-derived adhesion factor; TAF; Prostacyclinstimulating factor; Prostacyclin-stimulating factor; PSF; PGI2stimulating factor; PGI2-stimulating factor; MAC25 protein; MAC25; Insulinlike growth factorbinding protein 7; IGFbinding protein 7; IGFBPrP1; IGFBP-rP1; IGFBP-7; IGF-binding protein 7; IBP7; IBP-7 T69271 FUNCTION Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion. Binds IGF-I and IGF-II with a relatively low affinity. T69271 BIOCLASS Immunoglobulin T69271 SEQUENCE MERPSLRALLLGAAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPLGCLLGETRDACGCCPMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAGGPGVSGVCVCKSRYPVCGSDGTTYPSGCQLRAASQRAESRGEKAITQVSKGTCEQGPSIVTPPKDIWNVTGAQVYLSCEVIGIPTPVLIWNKVKRGHYGVQRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSKEDAGEYECHASNSQGQASASAKITVVDALHEIPVKKGEGAEL T31882 TARGETID T31882 T31882 FORMERID TTDI03330 T31882 UNIPROID KCA10_HUMAN T31882 TARGNAME Voltage-gated potassium channel Kv1.8 (KCNA10) T31882 GENENAME KCNA10 T31882 TARGTYPE Literature-reported T31882 SYNONYMS Voltage-gated potassium channel subunit Kv1.8; Potassium voltage-gated channel subfamily A member 10 T31882 FUNCTION Mediates voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient. The channel activity is up-regulated by cAMP. T31882 BIOCLASS Voltage-gated ion channel T31882 SEQUENCE MDVCGWKEMEVALVNFDNSDEIQEEPGYATDFDSTSPKGRPGGSSFSNGKILISESTNHETAFSKLPGDYADPPGPEPVVLNEGNQRVIINIAGLRFETQLRTLSQFPETLLGDREKRMQFFDSMRNEYFFDRNRPSFDGILYYYQSGGKIRRPANVPIDIFADEISFYELGSEAMDQFREDEGFIKDPETLLPTNDIHRQFWLLFEYPESSSAARAVAVVSVLVVVISITIFCLETLPEFREDRELKVVRDPNLNMSKTVLSQTMFTDPFFMVESTCIVWFTFELVLRFVVCPSKTDFFRNIMNIIDIISIIPYFATLITELVQETEPSAQQNMSLAILRIIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEVDEPESHFSSIPDGFWWAVVTMTTVGYGDMCPTTPGGKIVGTLCAIAGVLTIALPVPVIVSNFNYFYHRETENEEKQNIPGEIERILNSVGSRMGSTDSLNKTNGGCSTEKSRK T31882 DRUGINFO D06PZZ [14C]TEA Investigative T52067 TARGETID T52067 T52067 FORMERID TTDI03451 T52067 UNIPROID S15A2_HUMAN T52067 TARGNAME Solute carrier family 15 member 2 (SLC15A2) T52067 GENENAME SLC15A2 T52067 TARGTYPE Literature-reported T52067 SYNONYMS Peptide transporter 2; PEPT2; Oligopeptide transporter, kidney isoform; Kidney H(+)/peptide cotransporter T52067 FUNCTION Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. Transports the dipeptide-like aminopeptidase inhibitor bestatin (By similarity). Can also transport the aminocephalosporin antibiotic cefadroxil (By similarity). T52067 PDBSTRUC 6EZI T52067 SEQUENCE MNPFQKNESKETLFSPVSIEEVPPRPPSPPKKPSPTICGSNYPLSIAFIVVNEFCERFSYYGMKAVLILYFLYFLHWNEDTSTSIYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLVYVLGHVIKSLGALPILGGQVVHTVLSLIGLSLIALGTGGIKPCVAAFGGDQFEEKHAEERTRYFSVFYLSINAGSLISTFITPMLRGDVQCFGEDCYALAFGVPGLLMVIALVVFAMGSKIYNKPPPEGNIVAQVFKCIWFAISNRFKNRSGDIPKRQHWLDWAAEKYPKQLIMDVKALTRVLFLYIPLPMFWALLDQQGSRWTLQAIRMNRNLGFFVLQPDQMQVLNPLLVLIFIPLFDFVIYRLVSKCGINFSSLRKMAVGMILACLAFAVAAAVEIKINEMAPAQPGPQEVFLQVLNLADDEVKVTVVGNENNSLLIESIKSFQKTPHYSKLHLKTKSQDFHFHLKYHNLSLYTEHSVQEKNWYSLVIREDGNSISSMMVKDTESRTTNGMTTVRFVNTLHKDVNISLSTDTSLNVGEDYGVSAYRTVQRGEYPAVHCRTEDKNFSLNLGLLDFGAAYLFVITNNTNQGLQAWKIEDIPANKMSIAWQLPQYALVTAGEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTIAVGNIIVLVVAQFSGLVQWAEFILFSCLLLVICLIFSIMGYYYVPVKTEDMRGPADKHIPHIQGNMIKLETKKTKL T52067 DRUGINFO D0E1YE Lys[Z(NO2)]-Lys[Z(NO2)] Investigative T52067 DRUGINFO D02FZM Lys[Z(NO2)]-Pro Investigative T52067 DRUGINFO D06PWQ [14C]GlySar Investigative T52067 DRUGINFO D08QDL [11C]GlySar Investigative T52067 DRUGINFO D0Q3VU [3H]GlySar Investigative T87930 TARGETID T87930 T87930 FORMERID TTDI03223 T87930 UNIPROID GRIK5_HUMAN T87930 TARGNAME Glutamate receptor ionotropic kainate 5 (GRIK5) T87930 GENENAME GRIK5 T87930 TARGTYPE Literature-reported T87930 SYNONYMS KA2; Glutamate receptor ionotropic, kainate 5; Glutamate receptor KA-2; GluK5; GRIK2; Excitatory amino acid receptor 2; EAA2 T87930 FUNCTION L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds kainate > quisqualate > domoate > L-glutamate >> AMPA >> NMDA = 1S,3R-ACPD. Receptor for glutamate. T87930 BIOCLASS Glutamate-gated ion channel T87930 SEQUENCE MPAELLLLLIVAFASPSCQVLSSLRMAAILDDQTVCGRGERLALALAREQINGIIEVPAKARVEVDIFELQRDSQYETTDTMCQILPKGVVSVLGPSSSPASASTVSHICGEKEIPHIKVGPEETPRLQYLRFASVSLYPSNEDVSLAVSRILKSFNYPSASLICAKAECLLRLEELVRGFLISKETLSVRMLDDSRDPTPLLKEIRDDKVSTIIIDANASISHLILRKASELGMTSAFYKYILTTMDFPILHLDGIVEDSSNILGFSMFNTSHPFYPEFVRSLNMSWRENCEASTYLGPALSAALMFDAVHVVVSAVRELNRSQEIGVKPLACTSANIWPHGTSLMNYLRMVEYDGLTGRVEFNSKGQRTNYTLRILEKSRQGHREIGVWYSNRTLAMNATTLDINLSQTLANKTLVVTTILENPYVMRRPNFQALSGNERFEGFCVDMLRELAELLRFRYRLRLVEDGLYGAPEPNGSWTGMVGELINRKADLAVAAFTITAEREKVIDFSKPFMTLGISILYRVHMGRKPGYFSFLDPFSPAVWLFMLLAYLAVSCVLFLAARLSPYEWYNPHPCLRARPHILENQYTLGNSLWFPVGGFMQQGSEIMPRALSTRCVSGVWWAFTLIIISSYTANLAAFLTVQRMEVPVESADDLADQTNIEYGTIHAGSTMTFFQNSRYQTYQRMWNYMQSKQPSVFVKSTEEGIARVLNSRYAFLLESTMNEYHRRLNCNLTQIGGLLDTKGYGIGMPLGSPFRDEITLAILQLQENNRLEILKRKWWEGGRCPKEEDHRAKGLGMENIGGIFIVLICGLIIAVFVAVMEFIWSTRRSAESEEVSVCQEMLQELRHAVSCRKTSRSRRRRRPGGPSRALLSLRAVREMRLSNGKLYSAGAGGDAGSAHGGPQRLLDDPGPPSGARPAAPTPCTHVRVCQECRRIQALRASGAGAPPRGLGVPAEATSPPRPRPGPAGPRELAEHE T87930 DRUGINFO D09KRH domoic acid Investigative T87930 DRUGINFO D0K6AF dysiherbaine Investigative T87930 DRUGINFO D0S8AN SYM2081 Investigative T87930 DRUGINFO D04PFN [3H]kainate Investigative T33211 TARGETID T33211 T33211 FORMERID TTDI03479 T33211 UNIPROID PCSK7_HUMAN T33211 TARGNAME Proprotein convertase subtilisin/kexin type 7 (PCSK7) T33211 GENENAME PCSK7 T33211 TARGTYPE Literature-reported T33211 SYNONYMS Subtilisin/kexin-like protease PC7; SPC7; Proprotein convertase 8; Proprotein convertase 7; Prohormone convertase 7; PC8; PC7; Lymphoma proprotein convertase; LPC T33211 FUNCTION Serine endoprotease that processes various proproteins by cleavage at paired basic amino acids, recognizing the RXXX[KR]R consensus motif. Likely functions in the constitutive secretory pathway. T33211 ECNUMBER EC 3.4.21.- T33211 SEQUENCE MPKGRQKVPHLDAPLGLPTCLWLELAGLFLLVPWVMGLAGTGGPDGQGTGGPSWAVHLESLEGDGEEETLEQQADALAQAAGLVNAGRIGELQGHYLFVQPAGHRPALEVEAIRQQVEAVLAGHEAVRWHSEQRLLRRAKRSVHFNDPKYPQQWHLNNRRSPGRDINVTGVWERNVTGRGVTVVVVDDGVEHTIQDIAPNYSPEGSYDLNSNDPDPMPHPDVENGNHHGTRCAGEIAAVPNNSFCAVGVAYGSRIAGIRVLDGPLTDSMEAVAFNKHYQINDIYSCSWGPDDDGKTVDGPHQLGKAALQHGVIAGRQGFGSIFVVASGNGGQHNDNCNYDGYANSIYTVTIGAVDEEGRMPFYAEECASMLAVTFSGGDKMLRSIVTTDWDLQKGTGCTEGHTGTSAAAPLAAGMIALMLQVRPCLTWRDVQHIIVFTATRYEDRRAEWVTNEAGFSHSHQHGFGLLNAWRLVNAAKIWTSVPYLASYVSPVLKENKAIPQSPRSLEVLWNVSRMDLEMSGLKTLEHVAVTVSITHPRRGSLELKLFCPSGMMSLIGAPRSMDSDPNGFNDWTFSTVRCWGERARGTYRLVIRDVGDESFQVGILRQWQLTLYGSVWSAVDIRDRQRLLESAMSGKYLHDDFALPCPPGLKIPEEDGYTITPNTLKTLVLVGCFTVFWTVYYMLEVYLSQRNVASNQVCRSGPCHWPHRSRKAKEEGTELESVPLCSSKDPDEVETESRGPPTTSDLLAPDLLEQGDWSLSQNKSALDCPHQHLDVPHGKEEQIC T33211 DRUGINFO D0A6FZ peptide 18 Investigative T33211 DRUGINFO D05JJL furin inhibitor peptide Investigative T36440 TARGETID T36440 T36440 FORMERID TTDI01382 T36440 UNIPROID AMHR2_HUMAN T36440 TARGNAME Anti-mullerian hormone II receptor (AMHR2) T36440 GENENAME AMHR2 T36440 TARGTYPE Literature-reported T36440 SYNONYMS MRII; MISRII; MISR2; MIS type II receptor; Anti-Muellerian hormone type-2 receptor; Anti-Muellerian hormone type II receptor; AMHR; AMH type II receptor T36440 FUNCTION On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for anti-Muellerian hormone. T36440 ECNUMBER EC 2.7.11.30 T36440 SEQUENCE MLGSLGLWALLPTAVEAPPNRRTCVFFEAPGVRGSTKTLGELLDTGTELPRAIRCLYSRCCFGIWNLTQDRAQVEMQGCRDSDEPGCESLHCDPSPRAHPSPGSTLFTCSCGTDFCNANYSHLPPPGSPGTPGSQGPQAAPGESIWMALVLLGLFLLLLLLLGSIILALLQRKNYRVRGEPVPEPRPDSGRDWSVELQELPELCFSQVIREGGHAVVWAGQLQGKLVAIKAFPPRSVAQFQAERALYELPGLQHDHIVRFITASRGGPGRLLSGPLLVLELHPKGSLCHYLTQYTSDWGSSLRMALSLAQGLAFLHEERWQNGQYKPGIAHRDLSSQNVLIREDGSCAIGDLGLALVLPGLTQPPAWTPTQPQGPAAIMEAGTQRYMAPELLDKTLDLQDWGMALRRADIYSLALLLWEILSRCPDLRPDSSPPPFQLAYEAELGNTPTSDELWALAVQERRRPYIPSTWRCFATDPDGLRELLEDCWDADPEARLTAECVQQRLAALAHPQESHPFPESCPRGCPPLCPEDCTSIPAPTILPCRPQRSACHFSVQQGPCSRNPQPACTLSPV T78350 TARGETID T78350 T78350 FORMERID TTDI01503 T78350 UNIPROID MIA_HUMAN T78350 TARGNAME Melanoma derived growth regulator (MIA) T78350 GENENAME MIA T78350 TARGTYPE Literature-reported T78350 SYNONYMS Melanoma-derived growth regulatory protein; Melanoma inhibitory activity protein T78350 FUNCTION Elicits growth inhibition on melanoma cells in vitro as well as some other neuroectodermal tumors, including gliomas. T78350 PDBSTRUC 5IXB; 1K0X; 1I1J; 1HJD T78350 SEQUENCE MARSLVCLGVIILLSAFSGPGVRGGPMPKLADRKLCADQECSHPISMAVALQDYMAPDCRFLTIHRGQVVYVFSKLKGRGRLFWGGSVQGDYYGDLAARLGYFPSSIVREDQTLKPGKVDVKTDKWDFYCQ T97388 TARGETID T97388 T97388 FORMERID TTDI02007 T97388 UNIPROID UPP1_HUMAN; UPP2_HUMAN T97388 TARGNAME Uridine phosphorylase (UPP) T97388 GENENAME UPP1; UPP2 T97388 TARGTYPE Literature-reported T97388 SYNONYMS UrdPase; UPase T97388 FUNCTION Catalyzes the reversible phosphorylytic cleavage ofuridine and deoxyuridine to uracil and ribose- or deoxyribose-1- phosphate. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis. T97388 BIOCLASS Pentosyltransferase T97388 SEQUENCE MAATGANAEKAESHNDCPVRLLNPNIAKMKEDILYHFNLTTSRHNFPALFGDVKFVCVGGSPSRMKAFIRCVGAELGLDCPGRDYPNICAGTDRYAMYKVGPVLSVSHGMGIPSISIMLHELIKLLYYARCSNVTIIRIGTSGGIGLEPGTVVITEQAVDTCFKAEFEQIVLGKRVIRKTDLNKKLVQELLLCSAELSEFTTVVGNTMCTLDFYEGQGRLDGALCSYTEKDKQAYLEAAYAAGVRNIEMESSVFAAMCSACGLQAAVVCVTLLNRLEGDQISSPRNVLSEYQQRPQRLVSYFIKKKLSKA T97388 DRUGINFO D03LNM TK-112690 Investigative T74891 TARGETID T74891 T74891 FORMERID TTDR01291 T74891 UNIPROID Q27641_ENTDI T74891 TARGNAME Entamoeba Cysteine proteinase CP4 (Eh CP4) T74891 GENENAME Eh CP4 T74891 TARGTYPE Literature-reported T74891 SYNONYMS Entamoeba Cysteine proteinase CP4; Cysteine proteinase T74891 FUNCTION Plays a key role in disrupting the colonic epithelial barrier and the innate host immune response during invasion of E. histolytica, the protozoan cause of human amebiasis. T74891 ECNUMBER EC 3.4.22.35 T74891 SEQUENCE FVAAATAIDFKSWAAKNNKHFTAVEALRRRAIFNMNAKFVAKFNKANSFELSVDGPFAAMTNEEYNHLLRVHETEAAADSVYDNTIITASSKDWRAEGKVTPVRDQGNCGSCYSFSSLAVLESRLLIAGSKYNQNNQDLSEQQIVDCSTANNGCNGGSLSATYLYVKNNGVTDEASYPYTATKGTCKAFTPKVQTTGLTHVTPNEDALTSALEQGPVAVCIDAGKASFQLYKSGVYDEPKCSKTVNHGVAAVGYGTQDGKDYYIVKNSWGTSWGDKGYILMSRNKNNQCAIASVAYFPNGAHDAN T74891 DRUGINFO D0J6WV WRR605 Investigative T74371 TARGETID T74371 T74371 FORMERID TTDI00128 T74371 UNIPROID KI26B_HUMAN T74371 TARGNAME Kinesin-like protein KIF26B (KIF26B) T74371 GENENAME KIF26B T74371 TARGTYPE Literature-reported T74371 SYNONYMS Kinesinlike protein KIF26B T74371 FUNCTION Plays an important role in the compact adhesion between mesenchymal cells adjacent to the ureteric buds, possibly by interacting with MYH10. This could lead to the establishment of the basolateral integrity of the mesenchyme and the polarized expression of ITGA8, which maintains the GDNF expression required for further ureteric bud attraction. Although it seems to lack ATPase activity it is constitutively associated with microtubules. Essential for embryonic kidney development. T74371 BIOCLASS Myosin-kinesin ATPase T74371 SEQUENCE MNSVAGNKERLAVSTRGKKYGVNEVCSPTKPAAPFSPESWYRKAYEESRAGSRPTPEGAGSALGSSGTPSPGSGTSSPSSFTGSPGPASPGIGTSSPGSLGGSPGFGTGSPGSGSGGGSSPGSDRGVWCENCNARLVELKRQALRLLLPGPFPGKDPAFSAVIHDKLQVPNTIRKAWNDRDNRCDICATHLNQLKQEAIQMVLTLEQAAGSEHYDASPCSPPPLSNIPTLVGSRHVGGLQQPRDWAFVPAPCATSNYTGFANKHGSKPSSLGVSNGAEKKSGSPTHQAKVSLQMATSPSNGNILNSVAIQAHQYLDGTWSLSRTNGVTLYPYQISQLMTESSREGLTEAVLNRYNADKPSACSVPASQGSCVASETSTGTSVAASFFARAAQKLNLSSKKKKHRPSTSSAAEPPLFATSFSGILQTSPPPAPPCLLRAVNKVKDTPGLGKVKVMLRICSTLARDTSESSSFLKVDPRKKQITLYDPLTCGGQNAFQKRGNQVPPKMFAFDAVFPQDASQAEVCAGTVAEVIQSVVNGADGCVFCFGHAKLGKSYTMIGKDDSMQNLGIIPCAISWLFKLINERKEKTGARFSVRVSAVEVWGKEENLRDLLSEVATGSLQDGQSPGVYLCEDPICGTQLQNQSELRAPTAEKAAFFLDAAIASRRSHQQDCDEDDHRNSHVFFTLHIYQYRMEKSGKGGMSGGRSRLHLIDLGSCVKALSKNREGGSGLCLSLSALGNVILALVNGSKHIPYKESKLAMLLRESLGNMNCRTTMIAHISAAVGSYAETLSTIQIASRVLRMKKKKTKYTSSSSGGESSCEEGRMRRPTQLRPFHTRATVDPDFPIAHLSSDPDYSSSSEQSCDTVIYIGPNGTALSDKELTDNEGPPDFVPIVPALQKTRGDSRPAEAGEAAAGKSERDCLKCNTFAELQERLDCIDGSEEPSSFPFEELPAQFGPEQASRGPRLSQAAGASPLSESDKEDNGSEGQLTNREGPELPASKMQRSHSPVPAAAPAHSPSPASPRSVPGSSSQHSASPLVQSPSLQSSRESLNSCGFVEGKPRPMGSPRLGIASLSKTSEYKPPSSPSQRCKVYTQKGVLPSPAPLPPSSKDSGVASRESLLQPEVRTPPVGMSPQVLKKSMSAGSEGFPETPVDDEQQAATPSESKKEILSTTMVTVQQPLELNGEDELVFTLVEELTISGVLDSGRPTSIISFNSDCSARALASGSRPVSIISSISEDLECYSSTAPVSEVSITQFLPLPKMSLDEKAQDAGSRRSSISSWLSEMSAGSEGEQSCHSFIAQTCFGHGEAMAEPVASEFVSSLQNTAVVCREKPKASPDNLLILSEMGDDSFNKAAPIKGCKISTVSKAMVTISNTANLSSCEGYIPMKTNITVYPCIAMSPRNIQEPEAPTATPKAGPTLAQSRESKENSAKKEMKFEDPWLKREEEVKKETAHPNEEGMMRCETATGPSNAETRAEQEQDGKPSPGDRLSSSSGEVSASPVTDNFRRVVDGCEMALPGLATQSPVHPNKSVKSSSLPRAFQKASRQEEPDSLSYYCAAETNGVGAASGTPPSKATLEGKVASPKHCVLARPKGTPPLPPVRKSSLDQKNRASPQHSASGSGTSSPLNQPAAFPAGLPDEPSGKTKDASSSSKLFSAKLEQLASRSNSLGRATVSHYECLSLERAESLSSVSSRLHAGKDGTMPRAGRSLGRSAGTSPPSSGASPKAGQSKISAVSRLLLASPRARGPSASTTKTLSFSTKSLPQAVGQGSSSPPGGKHTPWSTQSLSRNRSSGLASKLPLRAVSGRISELLQGGAGARGLQLRAGPEAEARGGALAEDEPAAAHLLPSPYSKITPPRRPHRCSSGHGSDNSSVLSGELPPAMGKTALFYHSGGSSGYESVMRDSEATGSASSAQDSTSENSSSVGGRCRSLKTPKKRSNPGSQRRRLIPALSLDTSSPVRKPPNSTGVRWVDGPLRSSPRGLGEPFEIKVYEIDDVERLQRRRGGASKEAMCFNAKLKILEHRQQRIAEVRAKYEWLMKELEATKQYLMLDPNKWLSEFDLEQVWELDSLEYLEALECVTERLESRVNFCKAHLMMITCFDITSRRR T16240 TARGETID T16240 T16240 FORMERID TTDI03590 T16240 UNIPROID Q3C1U7_HUMAN T16240 TARGNAME Short transient receptor potential channel 2 (TRPC2) T16240 GENENAME TRPC2 T16240 TARGTYPE Literature-reported T16240 SYNONYMS Uncharacterized protein T16240 FUNCTION Has calcium channel activity. T16240 BIOCLASS Transient receptor potential catioin channel T16240 SEQUENCE SCACLECSNARRYDLLKLSLSRINTYLGIASRAHLSLASEDAMLAAFQLSRELRRLARKEPEFKPEYIALESLSQDYGFQLLGMCWNQSEVTAVLNDLAEDSETEPEAEGLGLAFEEGIPSLVRPRLAVNYNQKRFVAHLICQQVLSSI T16240 DRUGINFO D0Y6ST SAG Investigative T16240 DRUGINFO D0T6DU OAG Investigative T16240 DRUGINFO D00HCI 2-APB Investigative T78575 TARGETID T78575 T78575 FORMERID TTDI03475 T78575 UNIPROID PPCEL_HUMAN T78575 TARGNAME Prolyl endopeptidase-like (PREPL) T78575 GENENAME PREPL T78575 TARGTYPE Literature-reported T78575 SYNONYMS Prolylendopeptidase-like; KIAA0436 T78575 FUNCTION Probable serine peptidase whose precise substrate specificity remains unclear. Does not cleave peptides after a arginine or lysine residue. May play a role in the regulation of synaptic vesiscle exocytosis. T78575 ECNUMBER EC 3.4.21.- T78575 SEQUENCE MQQKTKLFLQALKYSIPHLGKCMQKQHLNHYNFADHCYNRIKLKKYHLTKCLQNKPKISELARNIPSRSFSCKDLQPVKQENEKPLPENMDAFEKVRTKLETQPQEEYEIINVEVKHGGFVYYQEGCCLVRSKDEEADNDNYEVLFNLEELKLDQPFIDCIRVAPDEKYVAAKIRTEDSEASTCVIIKLSDQPVMEASFPNVSSFEWVKDEEDEDVLFYTFQRNLRCHDVYRATFGDNKRNERFYTEKDPSYFVFLYLTKDSRFLTINIMNKTTSEVWLIDGLSPWDPPVLIQKRIHGVLYYVEHRDDELYILTNVGEPTEFKLMRTAADTPAIMNWDLFFTMKRNTKVIDLDMFKDHCVLFLKHSNLLYVNVIGLADDSVRSLKLPPWACGFIMDTNSDPKNCPFQLCSPIRPPKYYTYKFAEGKLFEETGHEDPITKTSRVLRLEAKSKDGKLVPMTVFHKTDSEDLQKKPLLVHVYGAYGMDLKMNFRPERRVLVDDGWILAYCHVRGGGELGLQWHADGRLTKKLNGLADLEACIKTLHGQGFSQPSLTTLTAFSAGGVLAGALCNSNPELVRAVTLEAPFLDVLNTMMDTTLPLTLEELEEWGNPSSDEKHKNYIKRYCPYQNIKPQHYPSIHITAYENDERVPLKGIVSYTEKLKEAIAEHAKDTGEGYQTPNIILDIQPGGNHVIEDSHKKITAQIKFLYEELGLDSTSVFEDLKKYLKF T78575 DRUGINFO D05OLW PMID21692504C8 Investigative T46541 TARGETID T46541 T46541 FORMERID TTDI00230 T46541 UNIPROID BOREA_HUMAN T46541 TARGNAME Borealin (CDCA8) T46541 GENENAME CDCA8 T46541 TARGTYPE Literature-reported T46541 SYNONYMS hDasraB; hDasra-B; Pluripotent embryonic stem cellrelated gene 3 protein; Pluripotent embryonic stem cell-related gene 3 protein; PESCRG3; DasraB; Dasra-B; Dasra B; Cell division cycleassociated protein 8; Cell division cycle-associated protein 8 T46541 FUNCTION The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Major effector of the TTK kinase in the control of attachment-error-correction and chromosome alignment. Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. T46541 PDBSTRUC 2RAX; 2RAW; 2QFA; 2KDD T46541 SEQUENCE MAPRKGSSRVAKTNSLRRRKLASFLKDFDREVEIRIKQIESDRQNLLKEVDNLYNIEILRLPKALREMNWLDYFALGGNKQALEEAATADLDITEINKLTAEAIQTPLKSAKTRKVIQVDEMIVEEEEEEENERKNLQTARVKRCPPSKKRTQSIQGKGKGKRSSRANTVTPAVGRLEVSMVKPTPGLTPRFDSRVFKTPGLRTPAAGERIYNISGNGSPLADSKEIFLTVPVGGGESLRLLASDLQRHSIAQLDPEALGNIKKLSNRLAQICSSIRTHK T74685 TARGETID T74685 T74685 FORMERID TTDR00702 T74685 UNIPROID AHPD_MYCTU T74685 TARGNAME Mycobacterium Alkylhydroperoxidase AhpD (MycB ahpD) T74685 GENENAME MycB ahpD T74685 TARGTYPE Literature-reported T74685 SYNONYMS Alkylhydroperoxidase AhpD; Alkyl hydroperoxide reductase AhpD T74685 FUNCTION Antioxidant protein with alkyl hydroperoxidase activity. Required for the reduction of the AhpC active site cysteine residues and for the regeneration of the AhpC enzyme activity. T74685 PDBSTRUC 1ME5; 1LW1; 1KNC; 1GU9 T74685 SEQUENCE MSIEKLKAALPEYAKDIKLNLSSITRSSVLDQEQLWGTLLASAAATRNPQVLADIGAEATDHLSAAARHAALGAAAIMGMNNVFYRGRGFLEGRYDDLRPGLRMNIIANPGIPKANFELWSFAVSAINGCSHCLVAHEHTLRTVGVDREAIFEALKAAAIVSGVAQALATIEALSPS T20033 TARGETID T20033 T20033 FORMERID TTDR00843 T20033 UNIPROID EF2_CANAL T20033 TARGNAME Candida Elongation factor 2 (Candi EFT2) T20033 GENENAME Candi EFT2 T20033 TARGTYPE Literature-reported T20033 SYNONYMS EFT2; EF2 T20033 FUNCTION Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post- translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome. T20033 BIOCLASS Acid anhydrides hydrolase T20033 SEQUENCE MVAFTIEQIRGLMDKVTNVRNMSVIAHVDHGKSTLSDSLVQKAGIISAAKAGDARFMDTRKDEQERGITIKSTAISLYASMTDEDVKDIKQKTDGNSFLVNLIDSPGHVDFSSEVTAALRVTDGALVVVDTVEGVCVQTETVLRQALGERIKPVVVINKVDRALLELQTTKEDLYQTFARTVESVNVIISTYCDPVLGDVQVYPQKGTVAFASGLHGWAFTVRQFANKYSKKFGVDKEKMMERLWGDSYFNPKTKKWTNKDKDADGKPLERAFNMFILDPIFRLFAAIMNFKKDEIPVLLEKLEIQLKGDEKDLEGKALLKVVMRKFLPAADALLEMIVLHLPSPVTAQAYRAETLYEGPSDDPFCTAIRNCDPNADLMLYVSKMVPTSDKGRFYAFGRVFAGTVKSGQKVRIQGPNYQVGKKEDLFLKSIQRTVLMMGRSVEQIDDCPAGNIIGLVGIDQFLLKSGTITTNEAAHNMKVMKFSVSPVVQVAVEVKNANDLPKLVEGLKRLSKSDPCVLTYMSESGEHIVAGTGELHLEICLQDLENDHAGVPLRISPPVVSYRETVEGESSMVALSKSPNKHNRIYVKAQPIDEEVSLDIENGVINPRDDFKARARILADKHGWDVVDARKIWCFGPDGNGPNLVVDQTKAVQYLNEIKDSVVAAFQWATKEGPIFGENCRSVRVNILDVTLHADAIHRGGGQIIPTMRRVTYASMLLAEPAIQEPVFLVEIQCPENAIGGIYSVLNKKRGQVISEEQRPGTPLFTVKAYLPVNESFGFTGELRQATGGQAFPQLIFDHWQVMSGDVTDENSKPGAIVKEKRVRAGLKPEVPEYTEYYDKL T20033 DRUGINFO D09IVQ Adenosine-5-Diphosphoribose Investigative T20033 DRUGINFO D0OY0X Diphthamide Investigative T20033 DRUGINFO D0C7LS Guanosine-5'-Diphosphate Investigative T86265 TARGETID T86265 T86265 FORMERID TTDI00132 T86265 UNIPROID SGO1_HUMAN T86265 TARGNAME Shugoshin-like protein 1 (SGO1) T86265 GENENAME SGO1 T86265 TARGTYPE Literature-reported T86265 SYNONYMS hSgo1; Serologically defined breast cancer antigen NY-BR-85; SGOL1; SGO1 T86265 FUNCTION Plays a central role in chromosome cohesion during mitosis by preventing premature dissociation of cohesin complex from centromeres after prophase, when most of cohesin complex dissociates from chromosomes arms. May act by preventing phosphorylation of the STAG2 subunit of cohesin complex at the centromere, ensuring cohesin persistence at centromere until cohesin cleavage by ESPL1/separase at anaphase. Essential for proper chromosome segregation during mitosis and this function requires interaction with PPP2R1A. Its phosphorylated form is necessary for chromosome congression and for the proper attachment of spindle microtubule to the kinetochore. Necessary for kinetochore localization of PLK1 and CENPF. May play a role in the tension sensing mechanism of the spindle-assembly checkpoint by regulating PLK1 kinetochore affinity. Isoform 3 plays a role in maintaining centriole cohesion involved in controlling spindle pole integrity. Involved in centromeric enrichment of AUKRB in prometaphase. T86265 PDBSTRUC 4A0I; 3Q6S; 3FGA T86265 SEQUENCE MAKERCLKKSFQDSLEDIKKRMKEKRNKNLAEIGKRRSFIAAPCQIITNTSTLLKNYQDNNKMLVLALENEKSKVKEAQDIILQLRKECYYLTCQLYALKGKLTSQQTVEPAQNQEICSSGMDPNSDDSSRNLFVKDLPQIPLEETELPGQGESFQIEDQIPTIPQDTLGVDFDSGEAKSTDNVLPRTVSVRSSLKKHCNSICQFDSLDDFETSHLAGKSFEFERVGFLDPLVNMHIPENVQHNACQWSKDQVNLSPKLIQPGTFTKTKEDILESKSEQTKSKQRDTQERKREEKRKANRRKSKRMSKYKENKSENKKTVPQKKMHKSVSSNDAYNFNLEEGVHLTPFRQKVSNDSNREENNESEVSLCESSGSGDDSDDLYLPTCKYIQNPTSNSDRPVTRPLAKRALKYTDEKETEGSKPTKTPTTTPPETQQSPHLSLKDITNVSLYPVVKIRRLSLSPKKNKASPAVALPKRRCTASVNYKEPTLASKLRRGDPFTDLCFLNSPIFKQKKDLRRSKKRALEVSPAKEAIFILYYVREFVSRFPDCRKCKLETHICLR T14928 TARGETID T14928 T14928 FORMERID TTDNR00733 T14928 UNIPROID FA83B_HUMAN T14928 TARGNAME Protein FAM83B (FA83B) T14928 GENENAME FAM83B T14928 TARGTYPE Literature-reported T14928 SYNONYMS C6orf143 T14928 FUNCTION Probable proto-oncogene that functions in the epidermal growth factor receptor/EGFR signaling pathway. May activate both the EGFR itself and downstream RAS/MAPK and PI3K/AKT/TOR signaling cascades. T14928 PDBSTRUC 5QHS; 5QHR; 5QHQ; 5QHP; 5QHO T14928 SEQUENCE METSSMLSSLNDECKSDNYIEPHYKEWYRVAIDILIEHGLEAYQEFLVQERVSDFLAEEEINYILKNVQKVAQSTAHGTDDSCDDTLSSGTYWPVESDVEAPNLDLGWPYVMPGLLGGTHIDLLFHPPRAHLLTIKETIRKMIKEARKVIALVMDIFTDVDIFKEIVEASTRGVSVYILLDESNFNHFLNMTEKQGCSVQRLRNIRVRTVKGQDYLSKTGAKFHGKMEQKFLLVDCQKVMYGSYSYMWSFEKAHLSMVQIITGQLVESFDEEFRTLYARSCVPSSFAQEESARVKHGKALWENGTYQHSVSSLASVSSQRNLFGRQDKIHKLDSSYFKNRGIYTLNEHDKYNIRSHGYKPHFVPNFNGPNAIRQFQPNQINENWKRHSYAGEQPETVPYLLLNRALNRTNNPPGNWKKPSDSLSVASSSREGYVSHHNTPAQSFANRLAQRKTTNLADRNSNVRRSFNGTDNHIRFLQQRMPTLEHTTKSFLRNWRIESYLNDHSEATPDSNGSALGDRFEGYDNPENLKANALYTHSRLRSSLVFKPTLPEQKEVNSCTTGSSNSTIIGSQGSETPKEVPDTPTNVQHLTDKPLPESIPKLPLQSEAPKMHTLQVPENHSVALNQTTNGHTESNNYIYKTLGVNKQTENLKNQQTENLLKRRSFPLFDNSKANLDPGNSKHYVYSTLTRNRVRQPEKPKEDLLKSSKSMHNVTHNLEEDEEEVTKRNSPSGTTTKSVSIAALLDVNKEESNKELASKKEVKGSPSFLKKGSQKLRSLLSLTPDKKENLSKNKAPAFYRLCSSSDTLVSEGEENQKPKKSDTKVDSSPRRKHSSSSNSQGSIHKSKEDVTVSPSQEINAPPDENKRTPSPGPVESKFLERAGDASAPRFNTEQIQYRDSREINAVVTPERRPTSSPRPTSSELLRSHSTDRRVYSRFEPFCKIESSIQPTSNMPNTSINRPEIKSATMGNSYGRSSPLLNYNTGVYRSYQPNENKFRGFMQKFGNFIHKNK T65626 TARGETID T65626 T65626 FORMERID TTDI03142 T65626 UNIPROID CXG2_HUMAN T65626 TARGNAME Gap junction gamma-2 protein (Cx47) T65626 GENENAME GJC2 T65626 TARGTYPE Literature-reported T65626 SYNONYMS Gap junction alpha-12 protein; GJA12; Cx46.6; Connexin-47; Connexin-46.6 T65626 FUNCTION May play a role in myelination in central and peripheral nervous systems. One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T65626 BIOCLASS Gap junction-forming connexin T65626 SEQUENCE MTNMSWSFLTRLLEEIHNHSTFVGKVWLTVLVVFRIVLTAVGGEAIYSDEQAKFTCNTRQPGCDNVCYDAFAPLSHVRFWVFQIVVISTPSVMYLGYAVHRLARASEQERRRALRRRPGPRRAPRAHLPPPHAGWPEPADLGEEEPMLGLGEEEEEEETGAAEGAGEEAEEAGAEEACTKAVGADGKAAGTPGPTGQHDGRRRIQREGLMRVYVAQLVARAAFEVAFLVGQYLLYGFEVRPFFPCSRQPCPHVVDCFVSRPTEKTVFLLVMYVVSCLCLLLNLCEMAHLGLGSAQDAVRGRRGPPASAPAPAPRPPPCAFPAAAAGLACPPDYSLVVRAAERARAHDQNLANLALQALRDGAAAGDRDRDSSPCVGLPAASRGPPRAGAPASRTGSATSAGTVGEQGRPGTHERPGAKPRAGSEKGSASSRDGKTTVWI T65626 DRUGINFO D00VJY octanol Investigative T96365 TARGETID T96365 T96365 UNIPROID DEP1A_HUMAN T96365 TARGNAME DEP domain-containing protein 1A (DEPDC1) T96365 GENENAME DEPDC1 T96365 TARGTYPE Literature-reported T96365 SYNONYMS DEPDC1A T96365 FUNCTION May be involved in transcriptional regulation as a transcriptional corepressor. The DEPDC1A-ZNF224 complex may play a critical role in bladder carcinogenesis by repressing the transcription of the A20 gene, leading to transport of NF-KB protein into the nucleus, resulting in suppression of apoptosis of bladder cancer cells. T96365 PDBSTRUC 2YSR T96365 SEQUENCE MESQGVPPGPYRATKLWNEVTTSFRAGMPLRKHRQHFKKYGNCFTAGEAVDWLYDLLRNNSNFGPEVTRQQTIQLLRKFLKNHVIEDIKGRWGSENVDDNNQLFRFPATSPLKTLPRRYPELRKNNIENFSKDKDSIFKLRNLSRRTPKRHGLHLSQENGEKIKHEIINEDQENAIDNRELSQEDVEEVWRYVILIYLQTILGVPSLEEVINPKQVIPQYIMYNMANTSKRGVVILQNKSDDLPHWVLSAMKCLANWPRSNDMNNPTYVGFERDVFRTIADYFLDLPEPLLTFEYYELFVNILVVCGYITVSDRSSGIHKIQDDPQSSKFLHLNNLNSFKSTECLLLSLLHREKNKEESDSTERLQISNPGFQERCAKKMQLVNLRNRRVSANDIMGGSCHNLIGLSNMHDLSSNSKPRCCSLEGIVDVPGNSSKEASSVFHQSFPNIEGQNNKLFLESKPKQEFLLNLHSEENIQKPFSAGFKRTSTLTVQDQEELCNGKCKSKQLCRSQSLLLRSSTRRNSYINTPVAEIIMKPNVGQGSTSVQTAMESELGESSATINKRLCKSTIELSENSLLPASSMLTGTQSLLQPHLERVAIDALQLCCLLLPPPNRRKLQLLMRMISRMSQNVDMPKLHDAMGTRSLMIHTFSRCVLCCAEEVDLDELLAGRLVSFLMDHHQEILQVPSYLQTAVEKHLDYLKKGHIENPGDGLFAPLPTYSYCKQISAQEFDEQKVSTSQAAIAELLENIIKNRSLPLKEKRKKLKQFQKEYPLIYQKRFPTTESEAALFGDKPTIKQPMLILRKPKFRSLR T34708 TARGETID T34708 T34708 FORMERID TTDI02584 T34708 UNIPROID MBNL2_HUMAN T34708 TARGNAME Muscleblind-like protein 1 (MBNL2) T34708 GENENAME MBNL2 T34708 TARGTYPE Literature-reported T34708 SYNONYMS Muscleblindlike proteinlike 39; Muscleblindlike proteinlike; Muscleblindlike protein 2; Muscleblindlike protein 1; Muscleblind-like protein-like 39; Muscleblind-like protein-like; Muscleblind-like protein 2; MLP1; MBLL39; MBLL T34708 FUNCTION Acts either as activator or repressor of splicing on specific pre-mRNA targets. Inhibits cardiac troponin-T (TNNT2) pre-mRNA exon inclusion but induces insulin receptor (IR) pre-mRNA exon inclusion in muscle. Antagonizes the alternative splicing activity pattern of CELF proteins. RNA-binding protein that binds to 5'ACACCC-3' core sequence, termed zipcode, within the 3'UTR of ITGA3. Binds to CUG triplet repeat expansion in myotonic dystrophy muscle cells by sequestering the target RNAs. Seems to regulate expression and localization of ITGA3 by transporting it from the nucleus to cytoplasm at adhesion plaques. May play a role in myotonic dystrophy pathophysiology (DM). Mediates pre-mRNA alternative splicing regulation. T34708 PDBSTRUC 2RPP; 2E5S T34708 SEQUENCE MALNVAPVRDTKWLTLEVCRQFQRGTCSRSDEECKFAHPPKSCQVENGRVIACFDSLKGRCSRENCKYLHPPTHLKTQLEINGRNNLIQQKTAAAMLAQQMQFMFPGTPLHPVPTFPVGPAIGTNTAISFAPYLAPVTPGVGLVPTEILPTTPVIVPGSPPVTVPGSTATQKLLRTDKLEVCREFQRGNCARGETDCRFAHPADSTMIDTSDNTVTVCMDYIKGRCMREKCKYFHPPAHLQAKIKAAQHQANQAAVAAQAAAAAATVMAFPPGALHPLPKRQALEKSNGTSAVFNPSVLHYQQALTSAQLQQHAAFIPTGSVLCMTPATSIDNSEIISRNGMECQESALRITKHCYCTYYPVSSSIELPQTAC T87719 TARGETID T87719 T87719 FORMERID TTDI01500 T87719 UNIPROID CLC6A_HUMAN T87719 TARGNAME Dendritic cell-associated C-type lectin 2 (CLEC6A) T87719 GENENAME CLEC6A T87719 TARGTYPE Literature-reported T87719 SYNONYMS Dectin-2; DECTIN2; DC-associated C-type lectin 2; CLECSF10; C-type lectin superfamily member 10; C-type lectin domain family 6 member A T87719 FUNCTION Binds high-mannose carbohydrates in a Ca(2+)-dependent manner. Functional receptor for alpha-mannans on C.albicans hypheas. Plays an important role in the host defense against C.albicans infection by inducing TH17 cell differentiation. Recognizes also, in a mannose-dependent manner, allergens from house dust mite and fungi, by promoting cysteinyl leukotriene production. Recognizes soluble elements from the eggs of Shistosoma mansoni altering adaptive immune responses. Transduces signals through an Fc receptor gamma chain /FCER1G and Syk-CARD9-NF-kappa-B-dependent pathway (By similarity). T87719 PDBSTRUC 5VYB T87719 SEQUENCE MMQEQQPQSTEKRGWLSLRLWSVAGISIALLSACFIVSCVVTYHFTYGETGKRLSELHSYHSSLTCFSEGTKVPAWGCCPASWKSFGSSCYFISSEEKVWSKSEQNCVEMGAHLVVFNTEAEQNFIVQQLNESFSYFLGLSDPQGNNNWQWIDKTPYEKNVRFWHLGEPNHSAEQCASIVFWKPTGWGWNDVICETRRNSICEMNKIYL T51996 TARGETID T51996 T51996 FORMERID TTDR00308 T51996 UNIPROID FEMX_STAAR T51996 TARGNAME Staphylococcus Lipid II:glycine glycyltransferase (Stap-coc femX) T51996 GENENAME Stap-coc femX T51996 TARGTYPE Literature-reported T51996 SYNONYMS femX; Lipid II:glycine glycyltransferase; Factor essential for expression of methicillin resistance X T51996 FUNCTION Catalyzes the incorporation of the first glycine of the pentaglycine interpeptide bridge, which is characteristic of the S.aureus peptidoglycan. This glycine is added to the epsilon-amino group of the L-lysine of the membrane-bound lipid II intermediate (GlcNAc-(beta-1,4)-N-acetylmuramic acid(-L-Ala-D-iGln-L-Lys-D-Ala- D-Ala)-pyrophosphoryl-undecaprenol), using glycyl-tRNA(Gly) as donor, in a ribosome-independent mechanism. Involved in methicillin resistance. T51996 ECNUMBER EC 2.3.2.16 T51996 SEQUENCE MEKMHITNQEHDAFVKSNPNGDLLQLTKWAETKKLTGWYARRIAVGRDGEIQGVAQLLFKKVPKLPYTLCYISRGFVVDYSNKEALNALLDSAKEIAKAEKAYAIKIDPDVEVDKGTDALQNLKALGFKHKGFKEGLSKDYIQPRMTMITPIDKNDDELLNSFERRNRSKVRLALKRGTTVERSDREGLKTFAELMKITGERDGFLTRDISYFENIYDALHEDGDAELFLVKLDPKENIAKVNQELNELHAEIAKWQQKMETSEKQAKKAQNMINDAQNKIAKNEDLKRDLEALEKEHPEGIYLSGALLMFAGSKSYYLYGASSNEFRDFLPNHHMQYTMMKYAREHGATTYDFGGTDNDPDKDSEHYGLWAFKKVWGTYLSEKIGEFDYVLNQPLYQLIEQVKPRLTKAKIKISRKLKRK T25924 TARGETID T25924 T25924 FORMERID TTDI00089 T25924 UNIPROID GRHL2_HUMAN T25924 TARGNAME Grainyhead-like 2 (GRHL2) T25924 GENENAME GRHL2 T25924 TARGTYPE Literature-reported T25924 SYNONYMS Transcription factor CP2like 3; Grainyheadlike protein 2 homolog; GRHL2; Brother of mammalian grainyhead T25924 FUNCTION Transcription factor playing an important role in primary neurulationand in epithelial development (PubMed:25152456). Binds directly to the consensus DNA sequence 5'-AACCGGTT-3' acting as an activator and repressor on distinct target genes. During embryogenesis, plays unique and cooperative roles with GRHL3 in establishing distinct zones of primary neurulation. Essential for closure 3 (rostral end of the forebrain), functions cooperatively with GRHL3 in closure 2 (forebrain/midbrain boundary) and posterior neuropore closure. Regulates epithelial morphogenesis acting as a target gene-associated transcriptional activator of apicaljunctional complex components. Up-regulates of CLDN3 and CLDN4, as well as of RAB25, which increases the CLDN4 protein and its localization at tight junctions. Comprises an essential component of the transcriptional machinery that establishes appropriate expression levels of CLDN4 and CDH1 in different types of epithelia. Exhibits functional redundancy with GRHL3 in epidermal morphogenetic events and epidermal wound repair. In lung, forms a regulatory loop with NKX2-1 that coordinates lung epithelial cell morphogenesis and differentiation. In keratinocytes, plays a role in telomerase activation during cellular proliferation, regulates TERT expression by binding to TERT promoter region and inhibiting DNA methylation at the 5'-CpG island, possibly by interfering with DNMT1 enzyme activity (PubMed:19015635, PubMed:20938050). In addition, impairs keratinocyte differentiation and epidermal function by inhibiting the expression of genes clustered at the epidermal differentiation complex (EDC) as well as GRHL1 and GRHL3 through epigenetic mechanisms (PubMed:23254293). T25924 PDBSTRUC 5MR7 T25924 SEQUENCE MSQESDNNKRLVALVPMPSDPPFNTRRAYTSEDEAWKSYLENPLTAATKAMMSINGDEDSAAALGLLYDYYKVPRDKRLLSVSKASDSQEDQEKRNCLGTSEAQSNLSGGENRVQVLKTVPVNLSLNQDHLENSKREQYSISFPESSAIIPVSGITVVKAEDFTPVFMAPPVHYPRGDGEEQRVVIFEQTQYDVPSLATHSAYLKDDQRSTPDSTYSESFKDAATEKFRSASVGAEEYMYDQTSSGTFQYTLEATKSLRQKQGEGPMTYLNKGQFYAITLSETGDNKCFRHPISKVRSVVMVVFSEDKNRDEQLKYWKYWHSRQHTAKQRVLDIADYKESFNTIGNIEEIAYNAVSFTWDVNEEAKIFITVNCLSTDFSSQKGVKGLPLMIQIDTYSYNNRSNKPIHRAYCQIKVFCDKGAERKIRDEERKQNRKKGKGQASQTQCNSSSDGKLAAIPLQKKSDITYFKTMPDLHSQPVLFIPDVHFANLQRTGQVYYNTDDEREGGSVLVKRMFRPMEEEFGPVPSKQMKEEGTKRVLLYVRKETDDVFDALMLKSPTVKGLMEAISEKYGLPVEKIAKLYKKSKKGILVNMDDNIIEHYSNEDTFILNMESMVEGFKVTLMEI T35828 TARGETID T35828 T35828 FORMERID TTDR00075 T35828 UNIPROID RK18_PLAF7 T35828 TARGNAME Plasmodium Apicoplast ribosome (Malaria RPL18) T35828 GENENAME Malaria RPL18 T35828 TARGTYPE Literature-reported T35828 SYNONYMS Putative 50S ribosomal protein L18, apicoplastic T35828 FUNCTION Has a unique composition, resulting from the loss of several large and small subunit proteins accompanied by significant sequence and size divergences in parasite orthologues of ribosomal proteins. Many more ribosomal proteins with apicoplast and mitochondrial targeting sequences that are post-translationally processed for targeting to organelles. T35828 BIOCLASS Ribosomal protein T35828 SEQUENCE MYISFILFSIIFIFLGVIENFIINKRVLYKPNFLLYSEKKNKKKSTPEQVTTRVNKDLKEKKRKRPRSKILECLLKEKVEKVEKVEKNSDENQCSNVDKEIREGKRVPRLRVRNTNNHIYASIIDDYKKYVLCSTCSRDATLSKILGTYRRKATNRVINNGRTIKSAWEIGKIIGKKALSKGIFKVRFDRARHPYAGKVEALAEGARAVGLLL T95865 TARGETID T95865 T95865 FORMERID TTDNC00437 T95865 UNIPROID TAF2_HUMAN T95865 TARGNAME Cofactor of initiator function (CIF) T95865 GENENAME TAF2 T95865 TARGTYPE Literature-reported T95865 SYNONYMS Transcription initiation factor TFIID subunit 2; Transcription initiation factor TFIID 150 kDa subunit; TBP-associated factor 150 kDa; TAFII150; TAFII-150; TAF2; TAF(II)150; RNA polymerase II TBP-associated factor subunit B; 150 kDa cofactor of initiator function T95865 FUNCTION Transcription factor TFIID is one of the general factors required for accurate and regulated initiation by RNA polymerase II. TFIID is a multimeric protein complex that plays a central role in mediating promoter responses to various activators and repressors. It requires core promoter-specific cofactors for productive transcription stimulation. TAF2 stabilizes TFIID binding to core promoter. T95865 PDBSTRUC 6MZM; 6MZL; 6MZC; 5FUR T95865 SEQUENCE MPLTGVEPARMNRKKGDKGFESPRPYKLTHQVVCINNINFQRKSVVGFVELTIFPTVANLNRIKLNSKQCRIYRVRINDLEAAFIYNDPTLEVCHSESKQRNLNYFSNAYAAAVSAVDPDAGNGELCIKVPSELWKHVDELKVLKIHINFSLDQPKGGLHFVVPSVEGSMAERGAHVFSCGYQNSTRFWFPCVDSYSELCTWKLEFTVDAAMVAVSNGDLVETVYTHDMRKKTFHYMLTIPTAASNISLAIGPFEILVDPYMHEVTHFCLPQLLPLLKHTTSYLHEVFEFYEEILTCRYPYSCFKTVFIDEAYVEVAAYASMSIFSTNLLHSAMIIDETPLTRRCLAQSLAQQFFGCFISRMSWSDEWVLKGISGYIYGLWMKKTFGVNEYRHWIKEELDKIVAYELKTGGVLLHPIFGGGKEKDNPASHLHFSIKHPHTLSWEYYSMFQCKAHLVMRLIENRISMEFMLQVFNKLLSLASTASSQKFQSHMWSQMLVSTSGFLKSISNVSGKDIQPLIKQWVDQSGVVKFYGSFAFNRKRNVLELEIKQDYTSPGTQKYVGPLKVTVQELDGSFNHTLQIEENSLKHDIPCHSKSRRNKKKKIPLMNGEEVDMDLSAMDADSPLLWIRIDPDMSVLRKVEFEQADFMWQYQLRYERDVVAQQESILALEKFPTPASRLALTDILEQEQCFYRVRMSACFCLAKIANSMVSTWTGPPAMKSLFTRMFCCKSCPNIVKTNNFMSFQSYFLQKTMPVAMALLRDVHNLCPKEVLTFILDLIKYNDNRKNKFSDNYYRAEMIDALANSVTPAVSVNNEVRTLDNLNPDVRLILEEITRFLNMEKLLPSYRHTITVSCLRAIRVLQKNGHVPSDPALFKSYAEYGHFVDIRIAALEAVVDYTKVDRSYEELQWLLNMIQNDPVPYVRHKILNMLTKNPPFTKNMESPLCNEALVDQLWKLMNSGTSHDWRLRCGAVDLYFTLFGLSRPSCLPLPELGLVLNLKEKKAVLNPTIIPESVAGNQEAANNPSSHPQLVGFQNPFSSSQDEEEIDMDTVHDSQAFISHHLNMLERPSTPGLSKYRPASSRSALIPQHSAGCDSTPTTKPQWSLELARKGTGKEQAPLEMSMHPAASAPLSVFTKESTASKHSDHHHHHHHEHKKKKKKHKHKHKHKHKHDSKEKDKEPFTFSSPASGRSIRSPSLSD T38772 TARGETID T38772 T38772 FORMERID TTDI03127 T38772 UNIPROID CXB7_HUMAN T38772 TARGNAME Connexin-25 (Cx25) T38772 GENENAME GJB7 T38772 TARGTYPE Literature-reported T38772 SYNONYMS Gap junction beta-7 protein; CX25 T38772 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T38772 BIOCLASS Gap junction-forming connexin T38772 SEQUENCE MSWMFLRDLLSGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHVWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSV T38772 DRUGINFO D00VJY octanol Investigative T93711 TARGETID T93711 T93711 UNIPROID RHDF2_HUMAN T93711 TARGNAME Inactive rhomboid protein 2 (RHBDF2) T93711 GENENAME RHBDF2 T93711 TARGTYPE Literature-reported T93711 SYNONYMS iRhom2; Rhomboid veinlet-like protein 6; Rhomboid veinlet-like protein 5; Rhomboid family member 2; Rhomboid 5 homolog 2; RHBDL6; RHBDL5 T93711 FUNCTION Rhomboid protease-like protein which has no protease activity but regulates the secretion of several ligands of the epidermal growth factor receptor. Indirectly activates the epidermal growth factor receptor signaling pathway and may thereby regulate sleep, cell survival, proliferation and migration. T93711 BIOCLASS Peptidase S54 family T93711 SEQUENCE MASADKNGGSVSSVSSSRLQSRKPPNLSITIPPPEKETQAPGEQDSMLPEGFQNRRLKKSQPRTWAAHTTACPPSFLPKRKNPAYLKSVSLQEPRSRWQESSEKRPGFRRQASLSQSIRKGAAQWFGVSGDWEGQRQQWQRRSLHHCSMRYGRLKASCQRDLELPSQEAPSFQGTESPKPCKMPKIVDPLARGRAFRHPEEMDRPHAPHPPLTPGVLSLTSFTSVRSGYSHLPRRKRMSVAHMSLQAAAALLKGRSVLDATGQRCRVVKRSFAFPSFLEEDVVDGADTFDSSFFSKEEMSSMPDDVFESPPLSASYFRGIPHSASPVSPDGVQIPLKEYGRAPVPGPRRGKRIASKVKHFAFDRKKRHYGLGVVGNWLNRSYRRSISSTVQRQLESFDSHRPYFTYWLTFVHVIITLLVICTYGIAPVGFAQHVTTQLVLRNKGVYESVKYIQQENFWVGPSSIDLIHLGAKFSPCIRKDGQIEQLVLRERDLERDSGCCVQNDHSGCIQTQRKDCSETLATFVKWQDDTGPPMDKSDLGQKRTSGAVCHQDPRTCEEPASSGAHIWPDDITKWPICTEQARSNHTGFLHMDCEIKGRPCCIGTKGSCEITTREYCEFMHGYFHEEATLCSQVHCLDKVCGLLPFLNPEVPDQFYRLWLSLFLHAGVVHCLVSVVFQMTILRDLEKLAGWHRIAIIFILSGITGNLASAIFLPYRAEVGPAGSQFGLLACLFVELFQSWPLLERPWKAFLNLSAIVLFLFICGLLPWIDNIAHIFGFLSGLLLAFAFLPYITFGTSDKYRKRALILVSLLAFAGLFAALVLWLYIYPINWPWIEHLTCFPFTSRFCEKYELDQVLH T93711 DRUGINFO D0X4IO Sulforaphane Investigative T78181 TARGETID T78181 T78181 FORMERID TTDI00094 T78181 UNIPROID RICTR_HUMAN T78181 TARGNAME MTOR complex 2 (RICTOR) T78181 GENENAME RICTOR T78181 TARGTYPE Literature-reported T78181 SYNONYMS hAVO3; Rapamycin-insensitive companion of mTOR; KIAA1999; AVO3 homolog T78181 FUNCTION mTORC2 is activated by growth factors, but, in contrast to mTORC1, seems to be nutrient-insensitive. mTORC2 seems to function upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation of stress-fibers or F-actin. mTORC2 plays a critical role in AKT1 'Ser-473' phosphorylation, which may facilitate the phosphorylation of the activation loop of AKT1 on 'Thr-308' by PDK1 which is a prerequisite for full activation. mTORC2 regulates the phosphorylation of SGK1 at 'Ser-422'. mTORC2 also modulates the phosphorylation of PRKCA on 'Ser-657'. Plays an essential role in embryonic growth and development. Subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals. T78181 PDBSTRUC 5ZCS T78181 SEQUENCE MAAIGRGRSLKNLRVRGRNDSGEENVPLDLTREPSDNLREILQNVARLQGVSNMRKLGHLNNFTKLLCDIGHSEEKLGFHYEDIIICLRLALLNEAKEVRAAGLRALRYLIQDSSILQKVLKLKVDYLIARCIDIQQSNEVERTQALRLVRKMITVNASLFPSSVTNSLIAVGNDGLQERDRMVRACIAIICELALQNPEVVALRGGLNTILKNVIDCQLSRINEALITTILHLLNHPKTRQYVRADVELERILAPYTDFHYRHSPDTAEGQLKEDREARFLASKMGIIATFRSWAGIINLCKPGNSGIQSLIGVLCIPNMEIRRGLLEVLYDIFRLPLPVVTEEFIEALLSVDPGRFQDSWRLSDGFVAAEAKTILPHRARSRPDLMDNYLALILSAFIRNGLLEGLVEVITNSDDHISVRATILLGELLHMANTILPHSHSHHLHCLPTLMNMAASFDIPKEKRLRASAALNCLKRFHEMKKRGPKPYSLHLDHIIQKAIATHQKRDQYLRVQKDIFILKDTEEALLINLRDSQVLQHKENLEWNWNLIGTILKWPNVNLRNYKDEQLHRFVRRLLYFYKPSSKLYANLDLDFAKAKQLTVVGCQFTEFLLESEEDGQGYLEDLVKDIVQWLNASSGMKPERSLQNNGLLTTLSQHYFLFIGTLSCHPHGVKMLEKCSVFQCLLNLCSLKNQDHLLKLTVSSLDYSRDGLARVILSKILTAATDACRLYATKHLRVLLRANVEFFNNWGIELLVTQLHDKNKTISSEALDILDEACEDKANLHALIQMKPALSHLGDKGLLLLLRFLSIPKGFSYLNERGYVAKQLEKWHREYNSKYVDLIEEQLNEALTTYRKPVDGDNYVRRSNQRLQRPHVYLPIHLYGQLVHHKTGCHLLEVQNIITELCRNVRTPDLDKWEEIKKLKASLWALGNIGSSNWGLNLLQEENVIPDILKLAKQCEVLSIRGTCVYVLGLIAKTKQGCDILKCHNWDAVRHSRKHLWPVVPDDVEQLCNELSSIPSTLSLNSESTSSRHNSESESVPSSMFILEDDRFGSSSTSTFFLDINEDTEPTFYDRSGPIKDKNSFPFFASSKLVKNRILNSLTLPNKKHRSSSDPKGGKLSSESKTSNRRIRTLTEPSVDFNHSDDFTPISTVQKTLQLETSFMGNKHIEDTGSTPSIGENDLKFTKNFGTENHRENTSRERLVVESSTSSHMKIRSQSFNTDTTTSGISSMSSSPSRETVGVDATTMDTDCGSMSTVVSTKTIKTSHYLTPQSNHLSLSKSNSVSLVPPGSSHTLPRRAQSLKAPSIATIKSLADCNFSYTSSRDAFGYATLKRLQQQRMHPSLSHSEALASPAKDVLFTDTITMKANSFESRLTPSRFMKALSYASLDKEDLLSPINQNTLQRSSSVRSMVSSATYGGSDDYIGLALPVDINDIFQVKDIPYFQTKNIPPHDDRGARAFAHDAGGLPSGTGGLVKNSFHLLRQQMSLTEIMNSIHSDASLFLESTEDTGLQEHTDDNCLYCVCIEILGFQPSNQLSAICSHSDFQDIPYSDWCEQTIHNPLEVVPSKFSGISGCSDGVSQEGSASSTKSTELLLGVKTIPDDTPMCRILLRKEVLRLVINLSSSVSTKCHETGLLTIKEKYPQTFDDICLYSEVSHLLSHCTFRLPCRRFIQELFQDVQFLQMHEEAEAVLATPPKQPIVDTSAES T77063 TARGETID T77063 T77063 FORMERID TTDI03477 T77063 UNIPROID PCSK4_HUMAN T77063 TARGNAME Proprotein convertase subtilisin/kexin type 4 (PCSK4) T77063 GENENAME PCSK4 T77063 TARGTYPE Literature-reported T77063 SYNONYMS UNQ2757/PRO6496; Proprotein convertase 4; PC4 T77063 FUNCTION Proprotein convertase involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues (By similarity). In males, important for ADAM2 processing as well as other acrosomal proteins with roles in fertilization and critical for normal fertilization events such as sperm capacitation, acrosome reaction and binding of sperm to zona pellucida (By similarity). Plays also a role in female fertility, involved in the regulation of trophoblast migration and placental development, may be through the proteolytical processing and activation of proteins such as IGF2. May also participate in folliculogenesis in the ovaries (By similarity). T77063 ECNUMBER EC 3.4.21.- T77063 SEQUENCE MRPAPIALWLRLVLALALVRPRAVGWAPVRAPIYVSSWAVQVSQGNREVERLARKFGFVNLGPIFPDGQYFHLRHRGVVQQSLTPHWGHRLHLKKNPKVQWFQQQTLQRRVKRSVVVPTDPWFSKQWYMNSEAQPDLSILQAWSQGLSGQGIVVSVLDDGIEKDHPDLWANYDPLASYDFNDYDPDPQPRYTPSKENRHGTRCAGEVAAMANNGFCGVGVAFNARIGGVRMLDGTITDVIEAQSLSLQPQHIHIYSASWGPEDDGRTVDGPGILTREAFRRGVTKGRGGLGTLFIWASGNGGLHYDNCNCDGYTNSIHTLSVGSTTQQGRVPWYSEACASTLTTTYSSGVATDPQIVTTDLHHGCTDQHTGTSASAPLAAGMIALALEANPFLTWRDMQHLVVRASKPAHLQAEDWRTNGVGRQVSHHYGYGLLDAGLLVDTARTWLPTQPQRKCAVRVQSRPTPILPLIYIRENVSACAGLHNSIRSLEHVQAQLTLSYSRRGDLEISLTSPMGTRSTLVAIRPLDVSTEGYNNWVFMSTHFWDENPQGVWTLGLENKGYYFNTGTLYRYTLLLYGTAEDMTARPTGPQVTSSACVQRDTEGLCQACDGPAYILGQLCLAYCPPRFFNHTRLVTAGPGHTAAPALRVCSSCHASCYTCRGGSPRDCTSCPPSSTLDQQQGSCMGPTTPDSRPRLRAAACPHHRCPASAMVLSLLAVTLGGPVLCGMSMDLPLYAWLSRARATPTKPQVWLPAGT T77063 DRUGINFO D05JJL furin inhibitor peptide Investigative T68206 TARGETID T68206 T68206 FORMERID TTDI02470 T68206 UNIPROID BTNL3_HUMAN T68206 TARGNAME Butyrophilin-like protein 3 (BTNL3) T68206 GENENAME BTNL3 T68206 TARGTYPE Literature-reported T68206 SYNONYMS UNQ744/PRO1472; COLF4100; Butyrophilin-like receptor; BTNLR T68206 FUNCTION Regulate the homing and maturation of V7+ and V4+ T cells to the gut epithelium. T68206 BIOCLASS Immunoglobulin T68206 SEQUENCE MAFVLILVLSFYELVSGQWQVTGPGKFVQALVGEDAVFSCSLFPETSAEAMEVRFFRNQFHAVVHLYRDGEDWESKQMPQYRGRTEFVKDSIAGGRVSLRLKNITPSDIGLYGCWFSSQIYDEEATWELRVAALGSLPLISIVGYVDGGIQLLCLSSGWFPQPTAKWKGPQGQDLSSDSRANADGYSLYDVEISIIVQENAGSILCSIHLAEQSHEVESKVLIGETFFQPSPWRLASILLGLLCGALCGVVMGMIIVFFKSKGKIQAELDWRRKHGQAELRDARKHAVEVTLDPETAHPKLCVSDLKTVTHRKAPQEVPHSEKRFTRKSVVASQGFQAGKHYWEVDVGQNVGWYVGVCRDDVDRGKNNVTLSPNNGYWVLRLTTEHLYFTFNPHFISLPPSTPPTRVGVFLDYEGGTISFFNTNDQSLIYTLLTCQFEGLLRPYIQHAMYDEEKGTPIFICPVSWG T70513 TARGETID T70513 T70513 FORMERID TTDI02537 T70513 UNIPROID CLC9A_HUMAN T70513 TARGNAME C-type lectin domain containing 9A (CLEC9A) T70513 GENENAME CLEC9A T70513 TARGTYPE Literature-reported T70513 SYNONYMS CLEC9A T70513 FUNCTION Functions as an endocytic receptor on a small subset of myeloid cells specialized for the uptake and processing of material from dead cells. Recognizes filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged, and mediate the cross-presentation of dead-cell associated antigens in a Syk-dependent manner. T70513 PDBSTRUC 3VPP T70513 SEQUENCE MHEEEIYTSLQWDSPAPDTYQKCLSSNKCSGACCLVMVISCVFCMGLLTASIFLGVKLLQVSTIAMQQQEKLIQQERALLNFTEWKRSCALQMKYCQAFMQNSLSSAHNSSPCPNNWIQNRESCYYVSEIWSIWHTSQENCLKEGSTLLQIESKEEMDFITGSLRKIKGSYDYWVGLSQDGHSGRWLWQDGSSPSPGLLPAERSQSANQVCGYVKSNSLLSSNCSTWKYFICEKYALRSSV T97016 TARGETID T97016 T97016 FORMERID TTDI03571 T97016 UNIPROID TAOK1_HUMAN T97016 TARGNAME TAO kinase 1 (TAOK1) T97016 GENENAME TAOK1 T97016 TARGTYPE Literature-reported T97016 SYNONYMS hTAOK1; hKFC-B; Thousand and one amino acid protein kinase 1; TAOK1; Serine/threonine-protein kinase TAO1; Prostate-derived sterile 20-like kinase 2; Prostate-derived STE20-like kinase 2; PSK2; PSK-2; MARKK; MARK Kinase; MAP3K16; Kinase from chicken homolog B; KIAA1361 T97016 FUNCTION Serine/threonine-protein kinase involved in various processes such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response and regulation of cytoskeleton stability. Phosphorylates MAP2K3, MAP2K6 and MARK2. Acts as an activator of the p38/MAPK14 stress-activated MAPK cascade by mediating phosphorylation and subsequent activation of the upstream MAP2K3 and MAP2K6 kinases. Involved in G-protein coupled receptor signaling to p38/MAPK14. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of MAP2K3 and MAP2K6. Acts as a regulator of cytoskeleton stability by phosphorylating 'Thr-208' of MARK2, leading to activate MARK2 kinase activity and subsequent phosphorylation and detachment of MAPT/TAU from microtubules. Also acts as a regulator of apoptosis: regulates apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation via activation of the MAPK8/JNK cascade. T97016 ECNUMBER EC 2.7.11.1 T97016 SEQUENCE MPSTNRAGSLKDPEIAELFFKEDPEKLFTDLREIGHGSFGAVYFARDVRTNEVVAIKKMSYSGKQSTEKWQDIIKEVKFLQRIKHPNSIEYKGCYLREHTAWLVMEYCLGSASDLLEVHKKPLQEVEIAAITHGALQGLAYLHSHTMIHRDIKAGNILLTEPGQVKLADFGSASMASPANSFVGTPYWMAPEVILAMDEGQYDGKVDVWSLGITCIELAERKPPLFNMNAMSALYHIAQNESPTLQSNEWSDYFRNFVDSCLQKIPQDRPTSEELLKHIFVLRERPETVLIDLIQRTKDAVRELDNLQYRKMKKLLFQEAHNGPAVEAQEEEEEQDHGVGRTGTVNSVGSNQSIPSMSISASSQSSSVNSLPDVSDDKSELDMMEGDHTVMSNSSVIHLKPEEENYREEGDPRTRASDPQSPPQVSRHKSHYRNREHFATIRTASLVTRQMQEHEQDSELREQMSGYKRMRRQHQKQLMTLENKLKAEMDEHRLRLDKDLETQRNNFAAEMEKLIKKHQAAMEKEAKVMSNEEKKFQQHIQAQQKKELNSFLESQKREYKLRKEQLKEELNENQSTPKKEKQEWLSKQKENIQHFQAEEEANLLRRQRQYLELECRRFKRRMLLGRHNLEQDLVREELNKRQTQKDLEHAMLLRQHESMQELEFRHLNTIQKMRCELIRLQHQTELTNQLEYNKRRERELRRKHVMEVRQQPKSLKSKELQIKKQFQDTCKIQTRQYKALRNHLLETTPKSEHKAVLKRLKEEQTRKLAILAEQYDHSINEMLSTQALRLDEAQEAECQVLKMQLQQELELLNAYQSKIKMQAEAQHDRELRELEQRVSLRRALLEQKIEEEMLALQNERTERIRSLLERQAREIEAFDSESMRLGFSNMVLSNLSPEAFSHSYPGASGWSHNPTGGPGPHWGHPMGGPPQAWGHPMQGGPQPWGHPSGPMQGVPRGSSMGVRNSPQALRRTASGGRTEQGMSRSTSVTSQISNGSHMSYT T97016 DRUGINFO D08HFG PMID20873740C18 Investigative T52116 TARGETID T52116 T52116 FORMERID TTDI00087 T52116 UNIPROID S26A9_HUMAN T52116 TARGNAME Solute carrier family 26 member 9 (SLC26A9) T52116 GENENAME SLC26A9 T52116 TARGTYPE Literature-reported T52116 SYNONYMS SLC26A9; Anion transporter/exchanger protein 9 T52116 FUNCTION DIDS- and thiosulfate- sensitive anion exchanger mediating chloride, sulfate and oxalate transport. Mediates chloride/bicarbonate exchange or chloride-independent bicarbonate extrusion thus assuring bicarbonate secretion. Inhibited by ammonium and thiosulfate. T52116 BIOCLASS Sulfate permease T52116 SEQUENCE MSQPRPRYVVDRAAYSLTLFDDEFEKKDRTYPVGEKLRNAFRCSSAKIKAVVFGLLPVLSWLPKYKIKDYIIPDLLGGLSGGSIQVPQGMAFALLANLPAVNGLYSSFFPLLTYFFLGGVHQMVPGTFAVISILVGNICLQLAPESKFQVFNNATNESYVDTAAMEAERLHVSATLACLTAIIQMGLGFMQFGFVAIYLSESFIRGFMTAAGLQILISVLKYIFGLTIPSYTGPGSIVFTFIDICKNLPHTNIASLIFALISGAFLVLVKELNARYMHKIRFPIPTEMIVVVVATAISGGCKMPKKYHMQIVGEIQRGFPTPVSPVVSQWKDMIGTAFSLAIVSYVINLAMGRTLANKHGYDVDSNQEMIALGCSNFFGSFFKIHVICCALSVTLAVDGAGGKSQVASLCVSLVVMITMLVLGIYLYPLPKSVLGALIAVNLKNSLKQLTDPYYLWRKSKLDCCIWVVSFLSSFFLSLPYGVAVGVAFSVLVVVFQTQFRNGYALAQVMDTDIYVNPKTYNRAQDIQGIKIITYCSPLYFANSEIFRQKVIAKTGMDPQKVLLAKQKYLKKQEKRRMRPTQQRRSLFMKTKTVSLQELQQDFENAPPTDPNNNQTPANGTSVSYITFSPDSSSPAQSEPPASAEAPGEPSDMLASVPPFVTFHTLILDMSGVSFVDLMGIKALAKLSSTYGKIGVKVFLVNIHAQVYNDISHGGVFEDGSLECKHVFPSIHDAVLFAQANARDVTPGHNFQGAPGDAELSLYDSEEDIRSYWDLEQEMFGSMFHAETLTAL T91259 TARGETID T91259 T91259 FORMERID TTDI00146 T91259 UNIPROID CXXC5_HUMAN T91259 TARGNAME Retinoid-inducible nuclear factor (CXXC5) T91259 GENENAME CXXC5 T91259 TARGTYPE Literature-reported T91259 SYNONYMS TCCCIA00297; Retinoidinducible nuclear factor; RINF; Putative NFkappaBactivating protein 102; Putative NF-kappa-B-activating protein 102; Putative MAPKactivating protein PM08; Putative MAPK-activating protein PM08; HSPC195; CXXCtype zinc finger protein 5; CXXC-type zinc finger protein 5; CF5 T91259 FUNCTION Acts as a mediator of BMP4-mediated modulation of canonical Wnt signaling activity in neural stem cells. Required for DNA damage-induced ATM phosphorylation, p53 activation and cell cycle arrest. Involved in myelopoiesis. Transcription factor. Binds to the oxygen responsive element of COX4I2 and represses its transcription under hypoxia conditions (4% oxygen), as well as normoxia conditions (20% oxygen). May repress COX4I2 transactivation induced by CHCHD2 and RBPJ. May indirectly participate in activation of the NF-kappa-B and MAPK pathways. T91259 PDBSTRUC 5W9S T91259 SEQUENCE MSSLGGGSQDAGGSSSSSTNGSGGSGSSGPKAGAADKSAVVAAAAPASVADDTPPPERRNKSGIISEPLNKSLRRSRPLSHYSSFGSSGGSGGGSMMGGESADKATAAAAAASLLANGHDLAAAMAVDKSNPTSKHKSGAVASLLSKAERATELAAEGQLTLQQFAQSTEMLKRVVQEHLPLMSEAGAGLPDMEAVAGAEALNGQSDFPYLGAFPINPGLFIMTPAGVFLAESALHMAGLAEYPMQGELASAISSGKKKRKRCGMCAPCRRRINCEQCSSCRNRKTGHQICKFRKCEELKKKPSAALEKVMLPTGAAFRWFQ T07944 TARGETID T07944 T07944 FORMERID TTDI01516 T07944 UNIPROID CHSTF_HUMAN T07944 TARGNAME Carbohydrate sulfotransferase 15 (CHST15) T07944 GENENAME CHST15 T07944 TARGTYPE Literature-reported T07944 SYNONYMS hBRAG; N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase; KIAA0598; GalNAc4S-6ST; GALNAC4S6ST; BRAG; B-cell RAG-associated gene protein T07944 FUNCTION Sulfotransferase that transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the C-6 hydroxyl group of the GalNAc 4-sulfate residue of chondroitin sulfate A and forms chondroitin sulfate E containing GlcA-GalNAc(4,6-SO(4)) repeating units. It also transfers sulfate to a unique non-reducing terminal sequence, GalNAc(4SO4)-GlcA(2SO4)-GalNAc(6SO4), to yield a highly sulfated structure similar to the structure found in thrombomodulin chondroitin sulfate. May also act as a B-cell receptor involved in BCR ligation-mediated early activation that mediate regulatory signals key to B-cell development and/or regulation of B-cell-specific RAG expression; however such results are unclear in vivo. T07944 ECNUMBER EC 2.8.2.33 T07944 SEQUENCE MRHCINCCIQLLPDGAHKQQVNCQGGPHHGHQACPTCKGENKILFRVDSKQMNLLAVLEVRTEGNENWGGFLRFKKGKRCSLVFGLIIMTLVMASYILSGAHQELLISSPFHYGGFPSNPSLMDSENPSDTKEHHHQSSVNNISYMKDYPSIKLIINSITTRIEFTTRQLPDLEDLKKQELHMFSVIPNKFLPNSKSPCWYEEFSGQNTTDPYLTNSYVLYSKRFRSTFDALRKAFWGHLAHAHGKHFRLRCLPHFYIIGQPKCGTTDLYDRLRLHPEVKFSAIKEPHWWTRKRFGIVRLRDGLRDRYPVEDYLDLFDLAAHQIHQGLQASSAKEQSKMNTIIIGEASASTMWDNNAWTFFYDNSTDGEPPFLTQDFIHAFQPNARLIVMLRDPVERLYSDYLYFASSNKSADDFHEKVTEALQLFENCMLDYSLRACVYNNTLNNAMPVRLQVGLYAVYLLDWLSVFDKQQFLILRLEDHASNVKYTMHKVFQFLNLGPLSEKQEALMTKSPASNARRPEDRNLGPMWPITQKILRDFYRPFNARLAQVLADEAFAWKTT T16614 TARGETID T16614 T16614 FORMERID TTDI03593 T16614 UNIPROID TRPM1_HUMAN T16614 TARGNAME Long transient receptor potential channel 1 (TRPM1) T16614 GENENAME TRPM1 T16614 TARGTYPE Literature-reported T16614 SYNONYMS Transient receptor potential cation channel subfamily M member 1; Melastatin-1; MLSN; LTRPC1 T16614 FUNCTION Cation channel essential for the depolarizing photoresponse of retinal ON bipolar cells. It is part of the GRM6 signaling cascade. May play a role in metastasis suppression (By similarity). May act as a spontaneously active, calcium-permeable plasma membrane channel. T16614 BIOCLASS Transient receptor potential catioin channel T16614 SEQUENCE MKDSNRCCCGQFTNQHIPPLPSATPSKNEEESKQVETQPEKWSVAKHTQSYPTDSYGVLEFQGGGYSNKAMYIRVSYDTKPDSLLHLMVKDWQLELPKLLISVHGGLQNFEMQPKLKQVFGKGLIKAAMTTGAWIFTGGVSTGVISHVGDALKDHSSKSRGRVCAIGIAPWGIVENKEDLVGKDVTRVYQTMSNPLSKLSVLNNSHTHFILADNGTLGKYGAEVKLRRLLEKHISLQKINTRLGQGVPLVGLVVEGGPNVVSIVLEYLQEEPPIPVVICDGSGRASDILSFAHKYCEEGGIINESLREQLLVTIQKTFNYNKAQSHQLFAIIMECMKKKELVTVFRMGSEGQQDIEMAILTALLKGTNVSAPDQLSLALAWNRVDIARSQIFVFGPHWPPLGSLAPPTDSKATEKEKKPPMATTKGGRGKGKGKKKGKVKEEVEEETDPRKIELLNWVNALEQAMLDALVLDRVDFVKLLIENGVNMQHFLTIPRLEELYNTRLGPPNTLHLLVRDVKKSNLPPDYHISLIDIGLVLEYLMGGAYRCNYTRKNFRTLYNNLFGPKRPKALKLLGMEDDEPPAKGKKKKKKKKEEEIDIDVDDPAVSRFQYPFHELMVWAVLMKRQKMAVFLWQRGEESMAKALVACKLYKAMAHESSESDLVDDISQDLDNNSKDFGQLALELLDQSYKHDEQIAMKLLTYELKNWSNSTCLKLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNPGLKVIMGILLPPTILFLEFRTYDDFSYQTSKENEDGKEKEEENTDANADAGSRKGDEENEHKKQRSIPIGTKICEFYNAPIVKFWFYTISYLGYLLLFNYVILVRMDGWPSLQEWIVISYIVSLALEKIREILMSEPGKLSQKIKVWLQEYWNITDLVAISTFMIGAILRLQNQPYMGYGRVIYCVDIIFWYIRVLDIFGVNKYLGPYVMMIGKMMIDMLYFVVIMLVVLMSFGVARQAILHPEEKPSWKLARNIFYMPYWMIYGEVFADQIDLYAMEINPPCGENLYDEEGKRLPPCIPGAWLTPALMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHDRPVLPPPMIILSHIYIIIMRLSGRCRKKREGDQEERDRGLKLFLSDEELKRLHEFEEQCVQEHFREKEDEQQSSSDERIRVTSERVENMSMRLEEINERETFMKTSLQTVDLRLAQLEELSNRMVNALENLAGIDRSDLIQARSRASSECEATYLLRQSSINSADGYSLYRYHFNGEELLFEDTSLSTSPGTGVRKKTCSFRIKEEKDVKTHLVPECQNSLHLSLGTSTSATPDGSHLAVDDLKNAEESKLGPDIGISKEDDERQTDSKKEETISPSLNKTDVIHGQDKSDVQNTQLTVETTNIEGTISYPLEETKITRYFPDETINACKTMKSRSFVYSRGRKLVGGVNQDVEYSSITDQQLTTEWQCQVQKITRSHSTDIPYIVSEAAVQAEHKEQFADMQDEHHVAEAIPRIPRLSLTITDRNGMENLLSVKPDQTLGFPSLRSKSLHGHPRNVKSIQGKLDRSGHASSVSSLVIVSGMTAEEKKVKKEKASTETEC T51314 TARGETID T51314 T51314 FORMERID TTDR00738 T51314 UNIPROID Q82443_9DELA T51314 TARGNAME T-cell leukemia virus Type-1 proteinase (TLV pro) T51314 GENENAME TLV pro T51314 TARGTYPE Literature-reported T51314 SYNONYMS Protease T51314 FUNCTION Critical for virion replication. T51314 BIOCLASS Protease T51314 SEQUENCE KEFNMGGGLTSPPTLQQVLLNQDPASILPVIPLDPARRPVIKAQVDTQTSHPKTIEALLDTGADMTVLPIALFSSNTPLKNTSVLGAGGQTQDHFKLTSLPVLIRLPFRTTPIVLTSCLVDTKNNWAIIGRDALQQCQGVLYLPEAKGPPVILPIQAPAVLGLEHLPRPPEISQFPLNQNASRPCNTWSERPWRQAISNPTPDQEITQYSQLKRPMEPGDSSTTCGPLTL T00973 TARGETID T00973 T00973 FORMERID TTDI03473 T00973 UNIPROID PB1_HUMAN T00973 TARGNAME Polybromo-1 (PBRM1) T00973 GENENAME PBRM1 T00973 TARGTYPE Literature-reported T00973 SYNONYMS hPB1; Protein polybromo-1; Polybromo-1D; PB1; BRG1-associated factor 180; BAF180 T00973 FUNCTION Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). Acts as a negative regulator of cell proliferation. Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). T00973 PDBSTRUC 5IID; 5II2; 5II1; 5HRX; 5HRW T00973 SEQUENCE MGSKRRRATSPSSSVSGDFDDGHHSVSTPGPSRKRRRLSNLPTVDPIAVCHELYNTIRDYKDEQGRLLCELFIRAPKRRNQPDYYEVVSQPIDLMKIQQKLKMEEYDDVNLLTADFQLLFNNAKSYYKPDSPEYKAACKLWDLYLRTRNEFVQKGEADDEDDDEDGQDNQGTVTEGSSPAYLKEILEQLLEAIVVATNPSGRLISELFQKLPSKVQYPDYYAIIKEPIDLKTIAQRIQNGSYKSIHAMAKDIDLLAKNAKTYNEPGSQVFKDANSIKKIFYMKKAEIEHHEMAKSSLRMRTPSNLAAARLTGPSHSKGSLGEERNPTSKYYRNKRAVQGGRLSAITMALQYGSESEEDAALAAARYEEGESEAESITSFMDVSNPFYQLYDTVRSCRNNQGQLIAEPFYHLPSKKKYPDYYQQIKMPISLQQIRTKLKNQEYETLDHLECDLNLMFENAKRYNVPNSAIYKRVLKLQQVMQAKKKELARRDDIEDGDSMISSATSDTGSAKRKSKKNIRKQRMKILFNVVLEAREPGSGRRLCDLFMVKPSKKDYPDYYKIILEPMDLKIIEHNIRNDKYAGEEGMIEDMKLMFRNARHYNEEGSQVYNDAHILEKLLKEKRKELGPLPDDDDMASPKLKLSRKSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGDEDSHVPNVTLLIQELIHNLFVSVMSHQDDEGRCYSDSLAEIPAVDPNFPNKPPLTFDIIRKNVENNRYRRLDLFQEHMFEVLERARRMNRTDSEIYEDAVELQQFFIKIRDELCKNGEILLSPALSYTTKHLHNDVEKERKEKLPKEIEEDKLKREEEKREAEKSEDSSGAAGLSGLHRTYSQDCSFKNSMYHVGDYVYVEPAEANLQPHIVCIERLWEDSAGEKWLYGCWFYRPNETFHLATRKFLEKEVFKSDYYNKVPVSKILGKCVVMFVKEYFKLCPENFRDEDVFVCESRYSAKTKSFKKIKLWTMPISSVRFVPRDVPLPVVRVASVFANADKGDDEKNTDNSEDSRAEDNFNLEKEKEDVPVEMSNGEPGCHYFEQLHYNDMWLKVGDCVFIKSHGLVRPRVGRIEKVWVRDGAAYFYGPIFIHPEETEHEPTKMFYKKEVFLSNLEETCPMTCILGKCAVLSFKDFLSCRPTEIPENDILLCESRYNESDKQMKKFKGLKRFSLSAKVVDDEIYYFRKPIVPQKEPSPLLEKKIQLLEAKFAELEGGDDDIEEMGEEDSEVIEPPSLPQLQTPLASELDLMPYTPPQSTPKSAKGSAKKEGSKRKINMSGYILFSSEMRAVIKAQHPDYSFGELSRLVGTEWRNLETAKKAEYEERAAKVAEQQERERAAQQQQPSASPRAGTPVGALMGVVPPPTPMGMLNQQLTPVAGMMGGYPPGLPPLQGPVDGLVSMGSMQPLHPGGPPPHHLPPGVPGLPGIPPPGVMNQGVAPMVGTPAPGGSPYGQQVGVLGPPGQQAPPPYPGPHPAGPPVIQQPTTPMFVAPPPKTQRLLHSEAYLKYIEGLSAESNSISKWDQTLAARRRDVHLSKEQESRLPSHWLKSKGAHTTMADALWRLRDLMLRDTLNIRQAYNLENV T00973 DRUGINFO D09GNM PFI-3 Investigative T52547 TARGETID T52547 T52547 FORMERID TTDNR00734 T52547 UNIPROID LYRIC_HUMAN T52547 TARGNAME Metastasis adhesion protein (MTDH) T52547 GENENAME MTDH T52547 TARGTYPE Literature-reported T52547 SYNONYMS Protein LYRIC; Metadherin; Lysine-rich CEACAM1 co-isolated protein; LYRIC; Astrocyte elevated gene-1 protein; AEG1; AEG-1; 3D3/LYRIC T52547 FUNCTION Activates the nuclear factor kappa-B (NF-kappa-B) transcription factor. Promotes anchorage-independent growth of immortalized melanocytes and astrocytes which is a key component in tumor cell expansion. Promotes lung metastasis and also has an effect on bone and brain metastasis, possibly by enhancing the seeding of tumor cells to the target organ endothelium. Induces chemoresistance. Downregulates SLC1A2/EAAT2 promoter activity when expressed ectopically. T52547 PDBSTRUC 4QMG T52547 SEQUENCE MAARSWQDELAQQAEEGSARLREMLSVGLGFLRTELGLDLGLEPKRYPGWVILVGTGALGLLLLFLLGYGWAAACAGARKKRRSPPRKREEAAAVPAAAPDDLALLKNLRSEEQKKKNRKKLSEKPKPNGRTVEVAEGEAVRTPQSVTAKQPPEIDKKNEKSKKNKKKSKSDAKAVQNSSRHDGKEVDEGAWETKISHREKRQQRKRDKVLTDSGSLDSTIPGIENTITVTTEQLTTASFPVGSKKNKGDSHLNVQVSNFKSGKGDSTLQVSSGLNENLTVNGGGWNEKSVKLSSQISAGEEKWNSVSPASAGKRKTEPSAWSQDTGDANTNGKDWGRSWSDRSIFSGIGSTAEPVSQSTTSDYQWDVSRNQPYIDDEWSGLNGLSSADPNSDWNAPAEEWGNWVDEERASLLKSQEPIPDDQKVSDDDKEKGEGALPTGKSKKKKKKKKKQGEDNSTAQDTEELEKEIREDLPVNTSKTRPKQEKAFSLKTISTSDPAEVLVKNSQPIKTLPPATSTEPSVILSKSDSDKSSSQVPPILQETDKSKSNTKQNSVPPSQTKSETSWESPKQIKKKKKARRET T91643 TARGETID T91643 T91643 FORMERID TTDI02519 T91643 UNIPROID P2RY8_HUMAN T91643 TARGNAME P2Y purinoceptor 8 (P2RY8) T91643 GENENAME P2RY8 T91643 TARGTYPE Literature-reported T91643 SYNONYMS P2Y8; P2RY8 T91643 FUNCTION Probable receptor for purines coupled to G-proteins. T91643 BIOCLASS GPCR rhodopsin T91643 SEQUENCE MQVPNSTGPDNATLQMLRNPAIAVALPVVYSLVAAVSIPGNLFSLWVLCRRMGPRSPSVIFMINLSVTDLMLASVLPFQIYYHCNRHHWVFGVLLCNVVTVAFYANMYSSILTMTCISVERFLGVLYPLSSKRWRRRRYAVAACAGTWLLLLTALSPLARTDLTYPVHALGIITCFDVLKWTMLPSVAMWAVFLFTIFILLFLIPFVITVACYTATILKLLRTEEAHGREQRRRAVGLAAVVLLAFVTCFAPNNFVLLAHIVSRLFYGKSYYHVYKLTLCLSCLNNCLDPFVYYFASREFQLRLREYLGCRRVPRDTLDTRRESLFSARTTSVRSEAGAHPEGMEGATRPGLQRQESVF T93951 TARGETID T93951 T93951 UNIPROID NLRC5_HUMAN T93951 TARGNAME Caterpiller protein 16.1 (NLRC5) T93951 GENENAME NLRC5 T93951 TARGTYPE Literature-reported T93951 SYNONYMS Nucleotide-binding oligomerization domain protein 4; Nucleotide-binding oligomerization domain protein 27; NOD4; NOD27; CLR16.1 T93951 FUNCTION Probable regulator of the NF-kappa-B and type I interferon signaling pathways. May also regulate the type II interferon signaling pathway. Plays a role in homeostatic control of innate immunity and in antiviral defense mechanisms. T93951 BIOCLASS NLRP family T93951 SEQUENCE MDPVGLQLGNKNLWSCLVRLLTKDPEWLNAKMKFFLPNTDLDSRNETLDPEQRVILQLNKLHVQGSDTWQSFIHCVCMQLEVPLDLEVLLLSTFGYDDGFTSQLGAEGKSQPESQLHHGLKRPHQSCGSSPRRKQCKKQQLELAKKYLQLLRTSAQQRYRSQIPGSGQPHAFHQVYVPPILRRATASLDTPEGAIMGDVKVEDGADVSISDLFNTRVNKGPRVTVLLGKAGMGKTTLAHRLCQKWAEGHLNCFQALFLFEFRQLNLITRFLTPSELLFDLYLSPESDHDTVFQYLEKNADQVLLIFDGLDEALQPMGPDGPGPVLTLFSHLCNGTLLPGCRVMATSRPGKLPACLPAEAAMVHMLGFDGPRVEEYVNHFFSAQPSREGALVELQTNGRLRSLCAVPALCQVACLCLHHLLPDHAPGQSVALLPNMTQLYMQMVLALSPPGHLPTSSLLDLGEVALRGLETGKVIFYAKDIAPPLIAFGATHSLLTSFCVCTGPGHQQTGYAFTHLSLQEFLAALHLMASPKVNKDTLTQYVTLHSRWVQRTKARLGLSDHLPTFLAGLASCTCRPFLSHLAQGNEDCVGAKQAAVVQVLKKLATRKLTGPKVVELCHCVDETQEPELASLTAQSLPYQLPFHNFPLTCTDLATLTNILEHREAPIHLDFDGCPLEPHCPEALVGCGQIENLSFKSRKCGDAFAEALSRSLPTMGRLQMLGLAGSKITARGISHLVKALPLCPQLKEVSFRDNQLSDQVVLNIVEVLPHLPRLRKLDLSSNSICVSTLLCLARVAVTCPTVRMLQAREADLIFLLSPPTETTAELQRAPDLQESDGQRKGAQSRSLTLRLQKCQLQVHDAEALIALLQEGPHLEEVDLSGNQLEDEGCRLMAEAASQLHIARKLDLSNNGLSVAGVHCVLRAVSACWTLAELHISLQHKTVIFMFAQEPEEQKGPQERAAFLDSLMLQMPSELPLSSRRMRLTHCGLQEKHLEQLCKALGGSCHLGHLHLDFSGNALGDEGAARLAQLLPGLGALQSLNLSENGLSLDAVLGLVRCFSTLQWLFRLDISFESQHILLRGDKTSRDMWATGSLPDFPAAAKFLGFRQRCIPRSLCLSECPLEPPSLTRLCATLKDCPGPLELQLSCEFLSDQSLETLLDCLPQLPQLSLLQLSQTGLSPKSPFLLANTLSLCPRVKKVDLRSLHHATLHFRSNEEEEGVCCGRFTGCSLSQEHVESLCWLLSKCKDLSQVDLSANLLGDSGLRCLLECLPQVPISGLLDLSHNSISQESALYLLETLPSCPRVREASVNLGSEQSFRIHFSREDQAGKTLRLSECSFRPEHVSRLATGLSKSLQLTELTLTQCCLGQKQLAILLSLVGRPAGLFSLRVQEPWADRARVLSLLEVCAQASGSVTEISISETQQQLCVQLEFPRQEENPEAVALRLAHCDLGAHHSLLVGQLMETCARLQQLSLSQVNLCEDDDASSLLLQSLLLSLSELKTFRLTSSCVSTEGLAHLASGLGHCHHLEELDLSNNQFDEEGTKALMRALEGKWMLKRLDLSHLLLNSSTLALLTHRLSQMTCLQSLRLNRNSIGDVGCCHLSEALRAATSLEELDLSHNQIGDAGVQHLATILPGLPELRKIDLSGNSISSAGGVQLAESLVLCRRLEELMLGCNALGDPTALGLAQELPQHLRVLHLPFSHLGPGGALSLAQALDGSPHLEEISLAENNLAGGVLRFCMELPLLRQIDLVSCKIDNQTAKLLTSSFTSCPALEVILLSWNLLGDEAAAELAQVLPQMGRLKRVDLEKNQITALGAWLLAEGLAQGSSIQVIRLWNNPIPCDMAQHLKSQEPRLDFAFFDNQPQAPWGT T11203 TARGETID T11203 T11203 FORMERID TTDI00052 T11203 UNIPROID FBX11_HUMAN T11203 TARGNAME Vitiligo-associated protein 1 (FBXO11) T11203 GENENAME FBXO11 T11203 TARGTYPE Literature-reported T11203 SYNONYMS Vitiligoassociated protein 1; VIT1; VIT-1; UG063H01; Protein arginine N-methyltransferase 9; PRMT9; Fbox only protein 11; FBX11; F-box only protein 11 T11203 FUNCTION The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal center B-cells terminal differentiation toward memory B-cells and plasma cells. The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF-beta signaling, cell migration and the timing of the cell-cycle progression and exit. Binds to and neddylates phosphorylated p53/TP53, inhibiting its transcriptional activity. SCF(FBXO11) does not seem to direct ubiquitination of p53/TP53. Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6 and PRDM1/BLIMP1. T11203 PDBSTRUC 5VMD T11203 SEQUENCE MNSVRAANRRPRRVSRPRPVQQQQQQPPQQPPPQPPQQQPPQQQPPPPPQQQQQQQPPPPPPPPPPLPQERNNVGERDDDVPADMVAEESGPGAQNSPYQLRRKTLLPKRTACPTKNSMEGASTSTTENFGHRAKRARVSGKSQDLSAAPAEQYLQEKLPDEVVLKIFSYLLEQDLCRAACVCKRFSELANDPILWKRLYMEVFEYTRPMMHPEPGKFYQINPEEYEHPNPWKESFQQLYKGAHVKPGFAEHFYSNPARYKGRENMLYYDTIEDALGGVQEAHFDGLIFVHSGIYTDEWIYIESPITMIGAAPGKVADKVIIENTRDSTFVFMEGSEDAYVGYMTIRFNPDDKSAQHHNAHHCLEITVNCSPIIDHCIIRSTCTVGSAVCVSGQGACPTIKHCNISDCENVGLYITDHAQGIYEDNEISNNALAGIWVKNHGNPIIRRNHIHHGRDVGVFTFDHGMGYFESCNIHRNRIAGFEVKAYANPTVVRCEIHHGQTGGIYVHEKGRGQFIENKIYANNFAGVWITSNSDPTIRGNSIFNGNQGGVYIFGDGRGLIEGNDIYGNALAGIQIRTNSCPIVRHNKIHDGQHGGIYVHEKGQGVIEENEVYSNTLAGVWVTTGSTPVLRRNRIHSGKQVGVYFYDNGHGVLEDNDIYNHMYSGVQIRTGSNPKIRRNKIWGGQNGGILVYNSGLGCIEDNEIFDNAMAGVWIKTDSNPTLRRNKIHDGRDGGICIFNGGRGLLEENDIFRNAQAGVLISTNSHPILRKNRIFDGFAAGIEITNHATATLEGNQIFNNRFGGLFLASGVNVTMKDNKIMNNQDAIEKAVSRGQCLYKISSYTSYPMHDFYRCHTCNTTDRNAICVNCIKKCHQGHDVEFIRHDRFFCDCGAGTLSNPCTLAGEPTHDTDTLYDSAPPIESNTLQHN T83794 TARGETID T83794 T83794 FORMERID TTDR00074 T83794 UNIPROID Q8I5S7_PLAF7 T83794 TARGNAME Plasmodium Choline transporter (Malaria CT) T83794 GENENAME Malaria CT T83794 TARGTYPE Literature-reported T83794 SYNONYMS Glycerol-3-phosphate 1-O-acyltransferase T83794 FUNCTION Mediates the delivery of these compounds to the intracellular parasite T83794 ECNUMBER EC 2.3.1.15 T83794 SEQUENCE MPDFYFLIRWLCKVIVKSVFRDVNVINPENVPLYGSVIFVGNHNNQFIDACVLIANIPRQVKFIVAEKSMRRAVIGKLASVIGCISVKRPQDLKFKGIGHICWNEGDVKITGINTRFRLDVQIGDKLLIQNKMFPVVKIESETELLIQEVINIECEDKMNGVPFKIIPKINQTEVYNLVTNSLKNGDTIGIFPEGGSHDRTNLLPLKPGVAIMTLCALADGIEDVSIIPVGLSYSKLYQLQGCATLFYGNAIIISQDLCKEYNNNNREAISKLLSKIEEGMRSCMLTSKDHETSRCIELCVSLYTPERMTISKNKIYNNLQLFCKMFWKFGNSKVIENLSYELKCYEKLLQANKIKDDEVWMLKQSTSAATLKFIEHICTFIFCVIFGMTFSLLWLPLVLISIYLAERHRKAALRNSTIKIQGGDVVSSYKVLVLIVLLPTFNIVYGLLFSIYLYHSWLKRILFVFLSMCILPICYYINLNYAVQIPSLLRQMKILLKVICGKINVWRDNERELISTRHELQLKVRDLVSTLGPDVSDDFLEQLYRNIPKFVVDVDTKRLIRGKDEFLPILQRSQLEYKEEIL T83794 DRUGINFO D0Z8GS G-25 Investigative T14380 TARGETID T14380 T14380 FORMERID TTDI01494 T14380 UNIPROID Q8I6Z5_PLAF7 T14380 TARGNAME Plasmodium Plasmepsin 5 (Malaria PLA5) T14380 GENENAME Malaria PLA5 T14380 TARGTYPE Literature-reported T14380 SYNONYMS Plasmepsin V T14380 FUNCTION endoplasmic reticulum, integral component of membrane, aspartic-type endopeptidase activity, protein catabolic process, proteolysis T14380 ECNUMBER EC 3.4.23.- T14380 SEQUENCE MNNYFLRKENFFILFCFVFVSIFFVSNVTIIKCNNVENKIDNVGKKIENVGKKIGDMENKNDNVENKNDNVGNKNDNVKNASSDLYKYKLYGDIDEYAYYFLDIDIGKPSQRISLILDTGSSSLSFPCNGCKDCGIHMEKPYNLNYSKTSSILYCNKSNCPYGLKCVGNKCEYLQSYCEGSQIYGFYFSDIVTLPSYNNKNKISFEKLMGCHMHEESLFLHQQATGVLGFSLTKPNGVPTFVDLLFKHTPSLKPIYSICVSEHGGELIIGGYEPDYFLSNQKEKQKMDKSDNNSSNKGNVSIKLKNNDKNDDEENNSKDVIVSNNVEDIVWQAITRKYYYYIKIYGLDLYGTNIMDKKELDMLVDSGSTFTHIPENIYNQINYYLDILCIHDMTNIYEINKRLKLTNESLNKPLVYFEDFKTALKNIIQNENLCIKIVDGVQCWKSLENLPNLYITLSNNYKMIWKPSSYLYKKESFWCKGLEKQVNNKPILGLTFFKNKQVIFDLQQNQIAFIESKCPSNLTSSRPRTFNEYREKENIFLKVSYINLYCLWLLLALTILLSLILYVRKMFYMDYFPLSDQNKSPIQEST T73077 TARGETID T73077 T73077 FORMERID TTDR00708 T73077 UNIPROID Q8ITL2_9TRYP T73077 TARGNAME Leishmania 65kD membrane-associated NADH-fumarate reductase (Leishm nfr65) T73077 GENENAME Leishm nfr65 T73077 TARGTYPE Literature-reported T73077 SYNONYMS NADH-dependent fumarate reductase T73077 FUNCTION An obligatory component of the respiratory chain of the parasite. Important in the intermediate metabolism in the Leishmania parasite and is absent in mammalian cells. T73077 BIOCLASS CH-CH donor oxidoreductase T73077 SEQUENCE MVDGRSSASIVAVDPERAARERDAAARALLQDSPLHTTMQYATSGLELTVPYALKVVASADTFDRAKEVADEVLRCAWQLADTVLNSFNPNSEVSLVGRLPVGQKHQMSAPLKRVMACCQRVYNSSAGCFDPSTAPVAKALREIALGKERNNACLEALTQACTLPNSFVIDFEAGTISRKHEHASLDLGGVSKGYIVDYVIDNINAAGFQNVFFDWGGDCRASGMNARNTPWVVGITRPPSLDMLPNPPKEASYISVISLDNEALATSGDYENLIYTADDKPLTCTYDWKGKELMKPSQSNIAQVSVKCYSAMYADALATACFIKRDPAKVRQLLDGWRYVRDTVRDYRVYVRENERVAKMFEIATEDAEMRKRRISNTLPARVIVVGGGLAGLSAAIEAAGCGAQVVLMEKEAKLGGNSAKATSGINGWGTRAQAKASIVDGGKYFERDTYKSGIGGNTDPALVKTLSMKSADAIGWLTSLGVPLTVLSQLGGHSRKRTHRAPDKKDGTPLPIGFTIMKTLEDHVRGNLSGRITIMENCSVTSLLSETKERPDGTKQIRVTGVEFTQAGSGKTTILADAVILATGGFSNDKTADSLLREHAPHLVNFPTTNGPWATGDGVKLAQRLGAQLVDMDKVQLHPTGLINPKDPANPTKFLGPEALRGSGGVLLNKQGKRFVNELDLRSVVSKAIMEQGAEYPGSGGSMFAYCVLNAAAQKLFGVSSHEFYWKKMGLFVKADTMRDLAALIGCPVESVQQTLEEYERLSISQRSCPITRKSVYPCVLGTKGPYYVAFVTPSIHYTMGGCLISPSAEIQMKNTSSRAPLSHSNPILGLFGAGEVTGGVHGGNRLGGNSLLECVVFGRIAGDRASTILQRKSSALSFKVWTTVVLREVREGGVYGAGSRVLRFNLPGALQRSGLSLGQFIAIRGDWDGQQLIGYYSPITLPDDLGMIDILARSDKGTLREWISALEPGDAVEMKACGGLVIERRLSDKHFVFMGHIINKLCLIAGGTGVAPMLQIIKAAFMKPFIDTLESVHLIYAAEDVTELTYREVLEERRRESRGKFKKTFVLNRPPPLWTDGVGFIDRGILTNHVQPPSDNLLVAICGPPVMQRIVKATLKTLGYNMNLVRTVDETEPSGSSKI T13863 TARGETID T13863 T13863 FORMERID TTDI03587 T13863 UNIPROID TMPS6_HUMAN T13863 TARGNAME Transmembrane protease serine 6 (TMPRSS6) T13863 GENENAME TMPRSS6 T13863 TARGTYPE Literature-reported T13863 SYNONYMS Matriptase-2 T13863 FUNCTION Serine protease which hydrolyzes a range of proteins including type I collagen, fibronectin and fibrinogen. Can also activate urokinase-type plasminogen activator with low efficiency. May play a specialized role in matrix remodeling processes in liver. Through the cleavage of HJV, a regulator of the expression of the iron absorption-regulating hormone hepicidin/HAMP, plays a role in iron homeostasis. T13863 ECNUMBER EC 3.4.21.- T13863 SEQUENCE MLLLFHSKRMPVAEAPQVAGGQGDGGDGEEAEPEGMFKACEDSKRKARGYLRLVPLFVLLALLVLASAGVLLWYFLGYKAEVMVSQVYSGSLRVLNRHFSQDLTRRESSAFRSETAKAQKMLKELITSTRLGTYYNSSSVYSFGEGPLTCFFWFILQIPEHRRLMLSPEVVQALLVEELLSTVNSSAAVPYRAEYEVDPEGLVILEASVKDIAALNSTLGCYRYSYVGQGQVLRLKGPDHLASSCLWHLQGPKDLMLKLRLEWTLAECRDRLAMYDVAGPLEKRLITSVYGCSRQEPVVEVLASGAIMAVVWKKGLHSYYDPFVLSVQPVVFQACEVNLTLDNRLDSQGVLSTPYFPSYYSPQTHCSWHLTVPSLDYGLALWFDAYALRRQKYDLPCTQGQWTIQNRRLCGLRILQPYAERIPVVATAGITINFTSQISLTGPGVRVHYGLYNQSDPCPGEFLCSVNGLCVPACDGVKDCPNGLDERNCVCRATFQCKEDSTCISLPKVCDGQPDCLNGSDEEQCQEGVPCGTFTFQCEDRSCVKKPNPQCDGRPDCRDGSDEEHCDCGLQGPSSRIVGGAVSSEGEWPWQASLQVRGRHICGGALIADRWVITAAHCFQEDSMASTVLWTVFLGKVWQNSRWPGEVSFKVSRLLLHPYHEEDSHDYDVALLQLDHPVVRSAAVRPVCLPARSHFFEPGLHCWITGWGALREGGPISNALQKVDVQLIPQDLCSEVYRYQVTPRMLCAGYRKGKKDACQGDSGGPLVCKALSGRWFLAGLVSWGLGCGRPNYFGVYTRITGVISWIQQVVT T13863 DRUGINFO D0W2SV Inhibitor 1 [Colombo et al., 2012] Investigative T63580 TARGETID T63580 T63580 FORMERID TTDNR00727 T63580 UNIPROID PLDX1_HUMAN T63580 TARGNAME Plexin domain-containing protein 1 (PLXDC1) T63580 GENENAME PLXDC1 T63580 TARGTYPE Literature-reported T63580 SYNONYMS Tumor endothelial marker 7; Tumor endothelial marker 3; PLXDC1 T63580 FUNCTION Plays a critical role in endothelial cell capillarymorphogenesis. T63580 BIOCLASS Plexin family T63580 SEQUENCE MRGELWLLVLVLREAARALSPQPGAGHDEGPGSGWAAKGTVRGWNRRARESPGHVSEPDRTQLSQDLGGGTLAMDTLPDNRTRVVEDNHSYYVSRLYGPSEPHSRELWVDVAEANRSQVKIHTILSNTHRQASRVVLSFDFPFYGHPLRQITIATGGFIFMGDVIHRMLTATQYVAPLMANFNPGYSDNSTVVYFDNGTVFVVQWDHVYLQGWEDKGSFTFQAALHHDGRIVFAYKEIPMSVPEISSSQHPVKTGLSDAFMILNPSPDVPESRRRSIFEYHRIELDPSKVTSMSAVEFTPLPTCLQHRSCDACMSSDLTFNCSWCHVLQRCSSGFDRYRQEWMDYGCAQEAEGRMCEDFQDEDHDSASPDTSFSPYDGDLTTTSSSLFIDSLTTEDDTKLNPYAGGDGLQNNLSPKTKGTPVHLGTIVGIVLAVLLVAAIILAGIYINGHPTSNAALFFIERRPHHWPAMKFRSHPDHSTYAEVEPSGHEKEGFMEAEQC T28620 TARGETID T28620 T28620 FORMERID TTDNR00668 T28620 UNIPROID EGFL6_HUMAN T28620 TARGNAME Epidermal growth factor-like protein 6 (EGFL6) T28620 GENENAME EGFL6 T28620 TARGTYPE Literature-reported T28620 SYNONYMS MAM and EGF domains-containing gene protein; EGFL6; EGF-like protein 6 T28620 FUNCTION May bind integrin alpha-8/beta-1 and play a role in hair follicle morphogenesis. Promotes matrix assembly. T28620 BIOCLASS Growth factor T28620 SEQUENCE MPLPWSLALPLLLSWVAGGFGNAASARHHGLLASARQPGVCHYGTKLACCYGWRRNSKGVCEATCEPGCKFGECVGPNKCRCFPGYTGKTCSQDVNECGMKPRPCQHRCVNTHGSYKCFCLSGHMLMPDATCVNSRTCAMINCQYSCEDTEEGPQCLCPSSGLRLAPNGRDCLDIDECASGKVICPYNRRCVNTFGSYYCKCHIGFELQYISGRYDCIDINECTMDSHTCSHHANCFNTQGSFKCKCKQGYKGNGLRCSAIPENSVKEVLRAPGTIKDRIKKLLAHKNSMKKKAKIKNVTPEPTRTPTPKVNLQPFNYEEIVSRGGNSHGGKKGNEEKMKEGLEDEKREEKALKNDIEERSLRGDVFFPKVNEAGEFGLILVQRKALTSKLEHKDLNISVDCSFNHGICDWKQDREDDFDWNPADRDNAIGFYMAVPALAGHKKDIGRLKLLLPDLQPQSNFCLLFDYRLAGDKVGKLRVFVKNSNNALAWEKTTSEDEKWKTGKIQLYQGTDATKSIIFEAERGKGKTGEIAVDGVLLVSGLCPDSLLSVDD T10375 TARGETID T10375 T10375 FORMERID TTDI03058 T10375 UNIPROID BRSK2_HUMAN T10375 TARGNAME BR serine/threonine kinase 2 (BRSK2) T10375 GENENAME BRSK2 T10375 TARGTYPE Literature-reported T10375 SYNONYMS Serine/threonine-protein kinase SAD-A; Serine/threonine-protein kinase BRSK2; Serine/threonine-protein kinase 29; STK29; SADA; PEN11B; HUSSY-12; C11orf7; Brain-specific serine/threonine-protein kinase 2; Brain-selective kinase 2; BR serine/threonine-protein kinase 2 T10375 FUNCTION Serine/threonine-protein kinase that plays a key role in polarization of neurons and axonogenesis, cell cycle progress and insulin secretion. Phosphorylates CDK16, CDC25C, MAPT/TAU, PAK1 and WEE1. Following phosphorylation and activation by STK11/LKB1, acts as a key regulator of polarization of cortical neurons, probably by mediating phosphorylation of microtubule-associated proteins such as MAPT/TAU at 'Thr-529' and 'Ser-579'. Also regulates neuron polarization by mediating phosphorylation of WEE1 at 'Ser-642' in postmitotic neurons, leading to down-regulate WEE1 activity in polarized neurons. Plays a role in the regulation of the mitotic cell cycle progress and the onset of mitosis. Plays a role in the regulation of insulin secretion in response to elevated glucose levels, probably via phosphorylation of CDK16 and PAK1. While BRSK2 phosphorylated at Thr-174 can inhibit insulin secretion, BRSK2 phosphorylated at Thr-260 can promote insulin secretion. Regulates reorganization of the actin cytoskeleton. May play a role in the apoptotic response triggered by endoplasmic reticulum (ER) stress. T10375 ECNUMBER EC 2.7.11.1 T10375 SEQUENCE MTSTGKDGGAQHAQYVGPYRLEKTLGKGQTGLVKLGVHCVTCQKVAIKIVNREKLSESVLMKVEREIAILKLIEHPHVLKLHDVYENKKYLYLVLEHVSGGELFDYLVKKGRLTPKEARKFFRQIISALDFCHSHSICHRDLKPENLLLDEKNNIRIADFGMASLQVGDSLLETSCGSPHYACPEVIRGEKYDGRKADVWSCGVILFALLVGALPFDDDNLRQLLEKVKRGVFHMPHFIPPDCQSLLRGMIEVDAARRLTLEHIQKHIWYIGGKNEPEPEQPIPRKVQIRSLPSLEDIDPDVLDSMHSLGCFRDRNKLLQDLLSEEENQEKMIYFLLLDRKERYPSQEDEDLPPRNEIDPPRKRVDSPMLNRHGKRRPERKSMEVLSVTDGGSPVPARRAIEMAQHGQRSRSISGASSGLSTSPLSSPRVTPHPSPRGSPLPTPKGTPVHTPKESPAGTPNPTPPSSPSVGGVPWRARLNSIKNSFLGSPRFHRRKLQVPTPEEMSNLTPESSPELAKKSWFGNFISLEKEEQIFVVIKDKPLSSIKADIVHAFLSIPSLSHSVISQTSFRAEYKATGGPAVFQKPVKFQVDITYTEGGEAQKENGIYSVTFTLLSGPSRRFKRVVETIQAQLLSTHDPPAAQHLSDTTNCMEMMTGRLSKCGSPLSNFFDVIKQLFSDEKNGQAAQAPSTPAKRSAHGPLGDSAAAGPGPGGDAEYPTGKDTAKMGPPTARREQP T10375 DRUGINFO D0Z8PT CCT244747 Investigative T92902 TARGETID T92902 T92902 UNIPROID TRI59_HUMAN T92902 TARGNAME Tripartite motif-containing 59 (TRIM59) T92902 GENENAME TRIM59 T92902 TARGTYPE Literature-reported T92902 SYNONYMS Tumor suppressor TSBF-1; TSBF1; TRIM57; RNF104; RING finger protein 104 T92902 FUNCTION May serve as a multifunctional regulator for innate immune signaling pathways. T92902 BIOCLASS TRIM/RBCC family T92902 SEQUENCE MHNFEEELTCPICYSIFEDPRVLPCSHTFCRNCLENILQASGNFYIWRPLRIPLKCPNCRSITEIAPTGIESLPVNFALRAIIEKYQQEDHPDIVTCPEHYRQPLNVYCLLDKKLVCGHCLTIGQHHGHPIDDLQSAYLKEKDTPQKLLEQLTDTHWTDLTHLIEKLKEQKSHSEKMIQGDKEAVLQYFKELNDTLEQKKKSFLTALCDVGNLINQEYTPQIERMKEIREQQLELMALTISLQEESPLKFLEKVDDVRQHVQILKQRPLPEVQPVEIYPRVSKILKEEWSRTEIGQIKNVLIPKMKISPKRMSCSWPGKDEKEVEFLKILNIVVVTLISVILMSILFFNQHIITFLSEITLIWFSEASLSVYQSLSNSLHKVKNILCHIFYLLKEFVWKIVSH T12714 TARGETID T12714 T12714 FORMERID TTDI02606 T12714 UNIPROID ZNT8_HUMAN T12714 TARGNAME Zinc transporter 8 (SLC30A8) T12714 GENENAME SLC30A8 T12714 TARGTYPE Literature-reported T12714 SYNONYMS ZnT-8; Solute carrier family 30 member 8; SLC30A8 T12714 FUNCTION Facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles, being a zinc-efflux transporter. May be a major component for providing zinc to insulin maturation and/or storage processes in insulin-secreting pancreatic beta-cells. T12714 BIOCLASS Cation diffusion facilitator T12714 SEQUENCE MEFLERTYLVNDKAAKMYAFTLESVELQQKPVNKDQCPRERPEELESGGMYHCHSGSKPTEKGANEYAYAKWKLCSASAICFIFMIAEVVGGHIAGSLAVVTDAAHLLIDLTSFLLSLFSLWLSSKPPSKRLTFGWHRAEILGALLSILCIWVVTGVLVYLACERLLYPDYQIQATVMIIVSSCAVAANIVLTVVLHQRCLGHNHKEVQANASVRAAFVHALGDLFQSISVLISALIIYFKPEYKIADPICTFIFSILVLASTITILKDFSILLMEGVPKSLNYSGVKELILAVDGVLSVHSLHIWSLTMNQVILSAHVATAASRDSQVVRREIAKALSKSFTMHSLTIQMESPVDQDPDCLFCEDPCD T69651 TARGETID T69651 T69651 FORMERID TTDR01161 T69651 UNIPROID Q8MTU2_TOXGO T69651 TARGNAME Toxoplasma Toxopain-1 (Tg cp1) T69651 GENENAME Tg cp1 T69651 TARGTYPE Literature-reported T69651 SYNONYMS Toxoplasma Cysteine proteinase T69651 FUNCTION A cathepsin B, play a critical role in the pathogenesis of toxoplasmosis. Secreted in the parasitophorous vacuole, where it may be involved in the degradation of host cell peptides, a process extensively studied in the related apicomplexan Plasmodium falciparum T69651 BIOCLASS Protease T69651 SEQUENCE MEGRKSFRVLGTPLPFAALAAILLLGCMYTRAAGTPDDSLFPLSEDTSVDPRESFSAEDVLNAFVSPESVESLFDSIVAEQVVATSGNLTESAPRDRDSAPERRSDGGTLRGHPEDAGELLRLLLADSEDMELWKANFFRHLTHSMRHIVRDSVLVSEKAFPSEQAGEAGRDPGDLKKALEETGEDVFWESRPASSNAAVALIKKKMEKQAGKTGEGAGHTWEPEVSLRFRYLSLKDAKKLMGTFLVNTKVEGFPTPKGMPLPAKEFENATEPVPAHFDARTAFPACKDVVGHVRDQGDCGSCWAFASTEAFNDRLCIRSQGKRLMPLSAQHTTSCCNAIHCASFGCNGGQPGMAWRWFERKGVVTGGDFDALGKGTTCWPYEVPFCAHHAKAPFPDCDATLVPRKTPKCRKDCEEQAYADNVHPFDQDTHKATSAYSLRSRDDVKRDMMTHGPVSGAFMVYEDFLSYKSGVYKHVSGLPVGGHAIKIIGWGTENGEEYWHAVNSWNTYWGDGGQFKIAMGQCGIDGEMVAGEAAWQETEGVVNGEEELPGQRAAGARAGAHAEEEREM T10336 TARGETID T10336 T10336 FORMERID TTDI03134 T10336 UNIPROID CXD3_HUMAN T10336 TARGNAME Gap junction delta-3 protein (Cx31.9) T10336 GENENAME GJD3 T10336 TARGTYPE Literature-reported T10336 SYNONYMS Gap junction chi-1 protein; Gap junction alpha-11 protein; GJC1; GJA11; Connexin-31.9 T10336 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T10336 BIOCLASS Gap junction-forming connexin T10336 SEQUENCE MGEWAFLGSLLDAVQLQSPLVGRLWLVVMLIFRILVLATVGGAVFEDEQEEFVCNTLQPGCRQTCYDRAFPVSHYRFWLFHILLLSAPPVLFVVYSMHRAGKEAGGAEAAAQCAPGLPEAQCAPCALRARRARRCYLLSVALRLLAELTFLGGQALLYGFRVAPHFACAGPPCPHTVDCFVSRPTEKTVFVLFYFAVGLLSALLSVAELGHLLWKGRPRAGERDNRCNRAHEEAQKLLPPPPPPPPPPALPSRRPGPEPCAPPAYAHPAPASLRECGSGRGKASPATGRRDLAI T10336 DRUGINFO D00VJY octanol Investigative T58216 TARGETID T58216 T58216 FORMERID TTDI02130 T58216 UNIPROID MUC15_HUMAN T58216 TARGNAME Mucin-15 (MUC15) T58216 GENENAME MUC15 T58216 TARGTYPE Literature-reported T58216 SYNONYMS Mucin15; MUC15 T58216 FUNCTION May play a role in the cell adhesion to the extracellular matrix. T58216 BIOCLASS Mucin T58216 SEQUENCE MLALAKILLISTLFYSLLSGSHGKENQDINTTQNIAEVFKTMENKPISLESEANLNSDKENITTSNLKASHSPPLNLPNNSHGITDFSSNSSAEHSLGSLKPTSTISTSPPLIHSFVSKVPWNAPIADEDLLPISAHPNATPALSSENFTWSLVNDTVKTPDNSSITVSILSSEPTSPSVTPLIVEPSGWLTTNSDSFTGFTPYQEKTTLQPTLKFTNNSKLFPNTSDPQKENRNTGIVFGAILGAILGVSLLTLVGYLLCGKRKTDSFSHRRLYDDRNEPVLRLDNAPEPYDVSFGNSSYYNPTLNDSAMPESEENARDGIPMDDIPPLRTSV T15509 TARGETID T15509 T15509 FORMERID TTDI03154 T15509 UNIPROID DGLB_HUMAN T15509 TARGNAME Diacylglycerol lipase beta (DAGLB) T15509 GENENAME DAGLB T15509 TARGTYPE Literature-reported T15509 SYNONYMS Sn1-specific diacylglycerol lipase beta; KCCR13L; DGL-beta T15509 FUNCTION Catalyzes the hydrolysis of diacylglycerol (DAG) to 2-arachidonoyl-glycerol (2-AG), the most abundant endocannabinoid in tissues. Required for axonal growth during development and for retrograde synaptic signaling at mature synapses. T15509 ECNUMBER EC 3.1.1.- T15509 SEQUENCE MPGMVLFGRRWAIASDDLVFPGFFELVVRVLWWIGILTLYLMHRGKLDCAGGALLSSYLIVLMILLAVVICTVSAIMCVSMRGTICNPGPRKSMSKLLYIRLALFFPEMVWASLGAAWVADGVQCDRTVVNGIIATVVVSWIIIAATVVSIIIVFDPLGGKMAPYSSAGPSHLDSHDSSQLLNGLKTAATSVWETRIKLLCCCIGKDDHTRVAFSSTAELFSTYFSDTDLVPSDIAAGLALLHQQQDNIRNNQEPAQVVCHAPGSSQEADLDAELENCHHYMQFAAAAYGWPLYIYRNPLTGLCRIGGDCCRSRTTDYDLVGGDQLNCHFGSILHTTGLQYRDFIHVSFHDKVYELPFLVALDHRKESVVVAVRGTMSLQDVLTDLSAESEVLDVECEVQDRLAHKGISQAARYVYQRLINDGILSQAFSIAPEYRLVIVGHSLGGGAAALLATMLRAAYPQVRCYAFSPPRGLWSKALQEYSQSFIVSLVLGKDVIPRLSVTNLEDLKRRILRVVAHCNKPKYKILLHGLWYELFGGNPNNLPTELDGGDQEVLTQPLLGEQSLLTRWSPAYSFSSDSPLDSSPKYPPLYPPGRIIHLQEEGASGRFGCCSAAHYSAKWSHEAEFSKILIGPKMLTDHMPDILMRALDSVVSDRAACVSCPAQGVSSVDVA T15509 DRUGINFO D05LXG RHC80267 Investigative T89345 TARGETID T89345 T89345 FORMERID TTDI03332 T89345 UNIPROID KCNH5_HUMAN T89345 TARGNAME Voltage-gated potassium channel Kv10.2 (KCNH5) T89345 GENENAME KCNH5 T89345 TARGTYPE Literature-reported T89345 SYNONYMS hEAG2; Voltage-gated potassium channel subunit Kv10.2; Potassium voltage-gated channel subfamily H member 5; Ether-a-go-go potassium channel 2; EAG2 T89345 FUNCTION Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a non-inactivating outward rectifying current. Channel properties may be modulated by cAMP and subunit assembly. T89345 BIOCLASS Voltage-gated ion channel T89345 SEQUENCE MPGGKRGLVAPQNTFLENIVRRSSESSFLLGNAQIVDWPVVYSNDGFCKLSGYHRADVMQKSSTCSFMYGELTDKKTIEKVRQTFDNYESNCFEVLLYKKNRTPVWFYMQIAPIRNEHEKVVLFLCTFKDITLFKQPIEDDSTKGWTKFARLTRALTNSRSVLQQLTPMNKTEVVHKHSRLAEVLQLGSDILPQYKQEAPKTPPHIILHYCAFKTTWDWVILILTFYTAIMVPYNVSFKTKQNNIAWLVLDSVVDVIFLVDIVLNFHTTFVGPGGEVISDPKLIRMNYLKTWFVIDLLSCLPYDIINAFENVDEGISSLFSSLKVVRLLRLGRVARKLDHYLEYGAAVLVLLVCVFGLVAHWLACIWYSIGDYEVIDEVTNTIQIDSWLYQLALSIGTPYRYNTSAGIWEGGPSKDSLYVSSLYFTMTSLTTIGFGNIAPTTDVEKMFSVAMMMVGSLLYATIFGNVTTIFQQMYANTNRYHEMLNNVRDFLKLYQVPKGLSERVMDYIVSTWSMSKGIDTEKVLSICPKDMRADICVHLNRKVFNEHPAFRLASDGCLRALAVEFQTIHCAPGDLIYHAGESVDALCFVVSGSLEVIQDDEVVAILGKGDVFGDIFWKETTLAHACANVRALTYCDLHIIKREALLKVLDFYTAFANSFSRNLTLTCNLRKRIIFRKISDVKKEEEERLRQKNEVTLSIPVDHPVRKLFQKFKQQKELRNQGSTQGDPERNQLQVESRSLQNGASITGTSVVTVSQITPIQTSLAYVKTSESLKQNNRDAMELKPNGGADQKCLKVNSPIRMKNGNGKGWLRLKNNMGAHEEKKEDWNNVTKAESMGLLSEDPKSSDSENSVTKNPLRKTDSCDSGITKSDLRLDKAGEARSPLEHSPIQADAKHPFYPIPEQALQTTLQEVKHELKEDIQLLSCRMTALEKQVAEILKILSEKSVPQASSPKSQMPLQVPPQIPCQDIFSVSRPESPESDKDEIHF T89345 DRUGINFO D02WWM LY97241 Investigative T98633 TARGETID T98633 T98633 FORMERID TTDI03130 T98633 UNIPROID CXG3_HUMAN T98633 TARGNAME Gap junction gamma-3 protein (Cx30.2) T98633 GENENAME GJC3 T98633 TARGTYPE Literature-reported T98633 SYNONYMS Gap junction epsilon-1 protein; GJE1; Cx31.3; Connexin-31.3; Connexin-30.2 T98633 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T98633 BIOCLASS Gap junction-forming connexin T98633 SEQUENCE MCGRFLRRLLAEESRRSTPVGRLLLPVLLGFRLVLLAASGPGVYGDEQSEFVCHTQQPGCKAACFDAFHPLSPLRFWVFQVILVAVPSALYMGFTLYHVIWHWELSGKGKEEETLIQGREGNTDVPGAGSLRLLWAYVAQLGARLVLEGAALGLQYHLYGFQMPSSFACRREPCLGSITCNLSRPSEKTIFLKTMFGVSGFCLLFTFLELVLLGLGRWWRTWKHKSSSSKYFLTSESTRRHKKATDSLPVVETKEQFQEAVPGRSLAQEKQRPVGPRDA T98633 DRUGINFO D00VJY octanol Investigative T97754 TARGETID T97754 T97754 FORMERID TTDI03584 T97754 UNIPROID TPC2_HUMAN T97754 TARGNAME Two pore calcium channel protein 2 (TPC2) T97754 GENENAME TPCN2 T97754 TARGTYPE Literature-reported T97754 SYNONYMS Voltage-dependent calcium channel protein TPC2; TPC2 T97754 FUNCTION Nicotinic acid adenine dinucleotide phosphate (NAADP) receptor that may function as one of the major voltage-gated Ca(2+) channels (VDCC) across the lysosomal membrane. May be involved in smooth muscle contraction. T97754 PDBSTRUC 6NQ2; 6NQ1; 6NQ0 T97754 SEQUENCE MAEPQAESEPLLGGARGGGGDWPAGLTTYRSIQVGPGAAARWDLCIDQAVVFIEDAIQYRSINHRVDASSMWLYRRYYSNVCQRTLSFTIFLILFLAFIETPSSLTSTADVRYRAAPWEPPCGLTESVEVLCLLVFAADLSVKGYLFGWAHFQKNLWLLGYLVVLVVSLVDWTVSLSLVCHEPLRIRRLLRPFFLLQNSSMMKKTLKCIRWSLPEMASVGLLLAIHLCLFTMFGMLLFAGGKQDDGQDRERLTYFQNLPESLTSLLVLLTTANNPDVMIPAYSKNRAYAIFFIVFTVIGSLFLMNLLTAIIYSQFRGYLMKSLQTSLFRRRLGTRAAFEVLSSMVGEGGAFPQAVGVKPQNLLQVLQKVQLDSSHKQAMMEKVRSYGSVLLSAEEFQKLFNELDRSVVKEHPPRPEYQSPFLQSAQFLFGHYYFDYLGNLIALANLVSICVFLVLDADVLPAERDDFILGILNCVFIVYYLLEMLLKVFALGLRGYLSYPSNVFDGLLTVVLLVLEISTLAVYRLPHPGWRPEMVGLLSLWDMTRMLNMLIVFRFLRIIPSMKLMAVVASTVLGLVQNMRAFGGILVVVYYVFAIIGINLFRGVIVALPGNSSLAPANGSAPCGSFEQLEYWANNFDDFAAALVTLWNLMVVNNWQVFLDAYRRYSGPWSKIYFVLWWLVSSVIWVNLFLALILENFLHKWDPRSHLQPLAGTPEATYQMTVELLFRDILEEPGEDELTERLSQHPHLWLCR T97754 DRUGINFO D01ZCI phosphatidyl (3,5) inositol biphosphate Investigative T63747 TARGETID T63747 T63747 FORMERID TTDI01465 T63747 UNIPROID PAFA_CORGL T63747 TARGNAME Corynebacterium Pup-protein ligase (Cory pafA) T63747 GENENAME Cory pafA T63747 TARGTYPE Literature-reported T63747 SYNONYMS Pup-conjugating enzyme; Pup--protein ligase; Proteasome accessory factor A T63747 FUNCTION Catalyzes the covalent attachment of the prokaryotic ubiquitin-like protein modifier Pup to the proteasomal substrate proteins, thereby targeting them for proteasomal degradation. This tagging system is termed pupylation. The ligation reaction involves the side-chain carboxylate of the C-terminal glutamate of Pup and the side-chain amino group of a substrate lysine. T63747 PDBSTRUC 4BJR; 4B0T T63747 SEQUENCE MSTVESALTRRIMGIETEYGLTFVDGDSKKLRPDEIARRMFRPIVEKYSSSNIFIPNGSRLYLDVGSHPEYATAECDNLTQLINFEKAGDVIADRMAVDAEESLAKEDIAGQVYLFKNNVDSVGNSYGCHENYLVGRSMPLKALGKRLMPFLITRQLICGAGRIHHPNPLDKGESFPLGYCISQRSDHVWEGVSSATTRSRPIINTRDEPHADSHSYRRLHVIVGDANMAEPSIALKVGSTLLVLEMIEADFGLPSLELANDIASIREISRDATGSTLLSLKDGTTMTALQIQQVVFEHASKWLEQRPEPEFSGTSNTEMARVLDLWGRMLKAIESGDFSEVDTEIDWVIKKKLIDRFIQRGNLGLDDPKLAQVDLTYHDIRPGRGLFSVLQSRGMIKRWTTDEAILAAVDTAPDTTRAHLRGRILKAADTLGVPVTVDWMRHKVNRPEPQSVELGDPFSAVNSEVDQLIEYMTVHAESYRS T96301 TARGETID T96301 T96301 UNIPROID DPTOR_HUMAN T96301 TARGNAME DEP domain-containing protein 6 (DEPTOR) T96301 GENENAME DEPTOR T96301 TARGTYPE Literature-reported T96301 SYNONYMS DEPDC6 T96301 FUNCTION Negative regulator of the mTORC1 and mTORC2 signaling pathways. Inhibits the kinase activity of both complexes. T96301 SEQUENCE MEEGGSTGSAGSDSSTSGSGGAQQRELERMAEVLVTGEQLRLRLHEEKVIKDRRHHLKTYPNCFVAKELIDWLIEHKEASDRETAIKLMQKLADRGIIHHVCDEHKEFKDVKLFYRFRKDDGTFPLDNEVKAFMRGQRLYEKLMSPENTLLQPREEEGVKYERTFMASEFLDWLVQEGEATTRKEAEQLCHRLMEHGIIQHVSNKHPFVDSNLLYQFRMNFRRRRRLMELLNEKSPSSQETHDSPFCLRKQSHDNRKSTSFMSVSPSKEIKIVSAVRRSSMSSCGSSGYFSSSPTLSSSPPVLCNPKSVLKRPVTSEELLTPGAPYARKTFTIVGDAVGWGFVVRGSKPCHIQAVDPSGPAAAAGMKVCQFVVSVNGLNVLHVDYRTVSNLILTGPRTIVMEVMEELEC T40243 TARGETID T40243 T40243 FORMERID TTDI03106 T40243 UNIPROID CERK1_HUMAN T40243 TARGNAME Ceramide kinase (CERK) T40243 GENENAME CERK T40243 TARGTYPE Literature-reported T40243 SYNONYMS hCERK; Lipid kinase 4; LK4; KIAA1646; Acylsphingosine kinase T40243 FUNCTION Catalyzes specifically the phosphorylation of ceramide to form ceramide 1-phosphate. Acts efficiently on natural and analog ceramides (C6, C8, C16 ceramides, and C8-dihydroceramide), to a lesser extent on C2-ceramide and C6-dihydroceramide, but not on other lipids, such as various sphingosines. Shows a greater preference for D-erythro isomer of ceramides. Binds phosphoinositides. T40243 ECNUMBER EC 2.7.1.138 T40243 SEQUENCE MGATGAAEPLQSVLWVKQQRCAVSLEPARALLRWWRSPGPGAGAPGADACSVPVSEIIAVEETDVHGKHQGSGKWQKMEKPYAFTVHCVKRARRHRWKWAQVTFWCPEEQLCHLWLQTLREMLEKLTSRPKHLLVFINPFGGKGQGKRIYERKVAPLFTLASITTDIIVTEHANQAKETLYEINIDKYDGIVCVGGDGMFSEVLHGLIGRTQRSAGVDQNHPRAVLVPSSLRIGIIPAGSTDCVCYSTVGTSDAETSALHIVVGDSLAMDVSSVHHNSTLLRYSVSLLGYGFYGDIIKDSEKKRWLGLARYDFSGLKTFLSHHCYEGTVSFLPAQHTVGSPRDRKPCRAGCFVCRQSKQQLEEEQKKALYGLEAAEDVEEWQVVCGKFLAINATNMSCACRRSPRGLSPAAHLGDGSSDLILIRKCSRFNFLRFLIRHTNQQDQFDFTFVEVYRVKKFQFTSKHMEDEDSDLKEGGKKRFGHICSSHPSCCCTVSNSSWNCDGEVLHSPAIEVRVHCQLVRLFARGIEENPKPDSHS T40243 DRUGINFO D0S9JG NVP 231 Investigative T60156 TARGETID T60156 T60156 FORMERID TTDI00158 T60156 UNIPROID GTR12_HUMAN T60156 TARGNAME Glucose transporter type 12 (GLUT12) T60156 GENENAME SLC2A12 T60156 TARGTYPE Literature-reported T60156 SYNONYMS Solute carrier family 2, facilitated glucose transporter member 12; SLC2A12 T60156 FUNCTION Facilitative glucose transporter. T60156 BIOCLASS Major facilitator superfamily T60156 SEQUENCE MVPVENTEGPSLLNQKGTAVETEGSGSRHPPWARGCGMFTFLSSVTAAVSGLLVGYELGIISGALLQIKTLLALSCHEQEMVVSSLVIGALLASLTGGVLIDRYGRRTAIILSSCLLGLGSLVLILSLSYTVLIVGRIAIGVSISLSSIATCVYIAEIAPQHRRGLLVSLNELMIVIGILSAYISNYAFANVFHGWKYMFGLVIPLGVLQAIAMYFLPPSPRFLVMKGQEGAASKVLGRLRALSDTTEELTVIKSSLKDEYQYSFWDLFRSKDNMRTRIMIGLTLVFFVQITGQPNILFYASTVLKSVGFQSNEAASLASTGVGVVKVISTIPATLLVDHVGSKTFLCIGSSVMAASLVTMGIVNLNIHMNFTHICRSHNSINQSLDESVIYGPGNLSTNNNTLRDHFKGISSHSRSSLMPLRNDVDKRGETTSASLLNAGLSHTEYQIVTDPGDVPAFLKWLSLASLLVYVAAFSIGLGPMPWLVLSEIFPGGIRGRAMALTSSMNWGINLLISLTFLTVTDLIGLPWVCFIYTIMSLASLLFVVMFIPETKGCSLEQISMELAKVNYVKNNICFMSHHQEELVPKQPQKRKPQEQLLECNKLCGRGQSRQLSPET T20053 TARGETID T20053 T20053 FORMERID TTDI03057 T20053 UNIPROID BRSK1_HUMAN T20053 TARGNAME BR serine/threonine kinase 1 (BRSK1) T20053 GENENAME BRSK1 T20053 TARGTYPE Literature-reported T20053 SYNONYMS hSAD1; Synapses of Amphids Defective homolog 1; Serine/threonine-protein kinase SAD-B; Serine/threonine-protein kinase BRSK1; SADB; SAD1 homolog; SAD1; KIAA1811; Brain-specific serine/threonine-protein kinase 1; Brain-selective kinase 1; BR serine/threonine-protein kinase 1 T20053 FUNCTION Serine/threonine-protein kinase that plays a key role in polarization of neurons and centrosome duplication. Phosphorylates CDC25B, CDC25C, MAPT/TAU, RIMS1, TUBG1, TUBG2 and WEE1. Following phosphorylation and activation by STK11/LKB1, acts as a key regulator of polarization of cortical neurons, probably by mediating phosphorylation of microtubule-associated proteins such as MAPT/TAU at 'Thr-529' and 'Ser-579'. Also regulates neuron polarization by mediating phosphorylation of WEE1 at 'Ser-642' in post-mitotic neurons, leading to down-regulate WEE1 activity in polarized neurons. In neurons, localizes to synaptic vesicles and plays a role in neurotransmitter release, possibly by phosphorylating RIMS1. Also acts as a positive regulator of centrosome duplication by mediating phosphorylation of gamma-tubulin (TUBG1 and TUBG2) at 'Ser-131', leading to translocation of gamma-tubulin and its associated proteins to the centrosome. Involved in the UV-induced DNA damage checkpoint response, probably by inhibiting CDK1 activity through phosphorylation and activation of WEE1, and inhibition of CDC25B and CDC25C. T20053 ECNUMBER EC 2.7.11.1 T20053 SEQUENCE MSSGAKEGGGGSPAYHLPHPHPHPPQHAQYVGPYRLEKTLGKGQTGLVKLGVHCITGQKVAIKIVNREKLSESVLMKVEREIAILKLIEHPHVLKLHDVYENKKYLYLVLEHVSGGELFDYLVKKGRLTPKEARKFFRQIVSALDFCHSYSICHRDLKPENLLLDEKNNIRIADFGMASLQVGDSLLETSCGSPHYACPEVIKGEKYDGRRADMWSCGVILFALLVGALPFDDDNLRQLLEKVKRGVFHMPHFIPPDCQSLLRGMIEVEPEKRLSLEQIQKHPWYLGGKHEPDPCLEPAPGRRVAMRSLPSNGELDPDVLESMASLGCFRDRERLHRELRSEEENQEKMIYYLLLDRKERYPSCEDQDLPPRNDVDPPRKRVDSPMLSRHGKRRPERKSMEVLSITDAGGGGSPVPTRRALEMAQHSQRSRSVSGASTGLSSSPLSSPRSPVFSFSPEPGAGDEARGGGSPTSKTQTLPSRGPRGGGAGEQPPPPSARSTPLPGPPGSPRSSGGTPLHSPLHTPRASPTGTPGTTPPPSPGGGVGGAAWRSRLNSIRNSFLGSPRFHRRKMQVPTAEEMSSLTPESSPELAKRSWFGNFISLDKEEQIFLVLKDKPLSSIKADIVHAFLSIPSLSHSVLSQTSFRAEYKASGGPSVFQKPVRFQVDISSSEGPEPSPRRDGSGGGGIYSVTFTLISGPSRRFKRVVETIQAQLLSTHDQPSVQALADEKNGAQTRPAGAPPRSLQPPPGRPDPELSSSPRRGPPKDKKLLATNGTPLP T20053 DRUGINFO D0Z8PT CCT244747 Investigative T14241 TARGETID T14241 T14241 FORMERID TTDI03599 T14241 UNIPROID MCLN3_HUMAN T14241 TARGNAME Mucolipin-3 (TRPML3) T14241 GENENAME MCOLN3 T14241 TARGTYPE Literature-reported T14241 SYNONYMS Transient receptor potential channel mucolipin 3; TRPML3 T14241 FUNCTION Nonselective ligand-gated cation channel probably playing a role in the regulation of membrane trafficking events. Acts as Ca(2+)-permeable cation channel with inwardly rectifying activity. Mediates release of Ca(2+) from endosomes to the cytoplasm, contributes to endosomal acidification and is involved in the regulation of membrane trafficking and fusion in the endosomal pathway. Does not seem to act as mechanosensory transduction channel in inner ear sensory hair cells. Proposed to play a critical role at the cochlear stereocilia ankle-link region during hair-bundle growth (By similarity). Involved in the regulation of autophagy. Through association with GABARAPL2 may be involved in autophagosome formation possibly providing Ca(2+) for the fusion process (By similarity). Through a possible and probably tissue-specific heteromerization with MCOLN1 may be at least in part involved in many lysosome-dependent cellular events. Possible heteromeric ion channel assemblies with TRPV5 show pharmacological similarity with TRPML3. T14241 PDBSTRUC 6AYG; 6AYF; 6AYE T14241 SEQUENCE MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRKPWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYTQSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFDIDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPDCYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVSLILCIRSVIRGLQLQQEFVNFFLLHYKKEVSVSDQMEFVNGWYIMIIISDILTIIGSILKMEIQAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYLGYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFISLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVSLFCCCKK T14241 DRUGINFO D04OPE SF-11 Investigative T14241 DRUGINFO D0BK2Y SF-21 Investigative T14241 DRUGINFO D0E9FD SN-1 Investigative T14241 DRUGINFO D0G1LN SN-2 Investigative T56207 TARGETID T56207 T56207 FORMERID TTDR01017 T56207 UNIPROID ASAP3_HUMAN T56207 TARGNAME Development and differentiation-enhancing factor-like 1 (DDEFL1) T56207 GENENAME ASAP3 T56207 TARGTYPE Literature-reported T56207 SYNONYMS UPLC1; Protein up-regulated in liver cancer 1; DDEFL1; Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 3 T56207 FUNCTION Promotes cell proliferation. T56207 PDBSTRUC 3LVR; 3LVQ; 2B0O T56207 SEQUENCE MPEQFSVAEFLAVTAEDLSSPAGAAAFAAKMPRYRGAALAREEILEGDQAILQRIKKAVRAIHSSGLGHVENEEQYREAVESLGNSHLSQNSHELSTGFLNLAVFTREVAALFKNLIQNLNNIVSFPLDSLMKGQLRDGRQDSKKQLEKAWKDYEAKMAKLEKERDRARVTGGIPGEVAQDMQRERRIFQLHMCEYLLKAGESQMKQGPDFLQSLIKFFHAQHNFFQDGWKAAQSLFPFIEKLAASVHALHQAQEDELQKLTQLRDSLRGTLQLESREEHLSRKNSGCGYSIHQHQGNKQFGTEKVGFLYKKSDGIRRVWQKRKCGVKYGCLTISHSTINRPPVKLTLLTCQVRPNPEEKKCFDLVTHNRTYHFQAEDEHECEAWVSVLQNSKDEALSSAFLGEPSAGPGSWGSAGHDGEPHDLTKLLIAEVKSRPGNSQCCDCGAADPTWLSTNLGVLTCIQCSGVHRELGVRFSRMQSLTLDLLGPSELLLALNMGNTSFNEVMEAQLPSHGGPKPSAESDMGTRRDYIMAKYVEHRFARRCTPEPQRLWTAICNRDLLSVLEAFANGQDFGQPLPGPDAQAPEELVLHLAVKVANQASLPLVDFIIQNGGHLDAKAADGNTALHYAALYNQPDCLKLLLKGRALVGTVNEAGETALDIARKKHHKECEELLEQAQAGTFAFPLHVDYSWVISTEPGSDSEEDEEEKRCLLKLPAQAHWASGRLDISNKTYETVASLGAATPQGESEDCPPPLPVKNSSRTLVQGCARHASGDRSEVSSLSSEAPETPESLGSPASSSSLMSPLEPGDPSQAPPNSEEGLREPPGTSRPSLTSGTTPSEMYLPVRFSSESTRSYRRGARSPEDGPSARQPLPRRNVPVGITEGDGSRTGSLPASSVQLLQD T62998 TARGETID T62998 T62998 FORMERID TTDR00384 T62998 UNIPROID SCRB1_HUMAN T62998 TARGNAME Scavenger receptor class B member 1 (SCARB1) T62998 GENENAME SCARB1 T62998 TARGTYPE Literature-reported T62998 SYNONYMS SRB1; SR-BI; Collagen type I receptor, thrombospondin receptor-like 1; CLA1; CLA-1; CD36L1; CD36 antigen-like 1; CD36 and LIMPII analogous 1; CD36 T62998 FUNCTION Receptor for different ligands such as phospholipids, cholesterol ester, lipoproteins, phosphatidylserine and apoptotic cells. Receptor for HDL, mediating selective uptake of cholesteryl ether and HDL-dependent cholesterol efflux. Also facilitates the flux of free and esterified cholesterol between the cell surface and apoB-containing lipoproteins and modified lipoproteins, although less efficiently than HDL. May be involved in the phagocytosis of apoptotic cells, via its phosphatidylserine binding activity. T62998 BIOCLASS Long chain fatty acid translocase T62998 SEQUENCE MGCSAKARWAAGALGVAGLLCAVLGAVMIVMVPSLIKQQVLKNVRIDPSSLSFNMWKEIPIPFYLSVYFFDVMNPSEILKGEKPQVRERGPYVYREFRHKSNITFNNNDTVSFLEYRTFQFQPSKSHGSESDYIVMPNILVLGAAVMMENKPMTLKLIMTLAFTTLGERAFMNRTVGEIMWGYKDPLVNLINKYFPGMFPFKDKFGLFAELNNSDSGLFTVFTGVQNISRIHLVDKWNGLSKVDFWHSDQCNMINGTSGQMWPPFMTPESSLEFYSPEACRSMKLMYKESGVFEGIPTYRFVAPKTLFANGSIYPPNEGFCPCLESGIQNVSTCRFSAPLFLSHPHFLNADPVLAEAVTGLHPNQEAHSLFLDIHPVTGIPMNCSVKLQLSLYMKSVAGIGQTGKIEPVVLPLLWFAESGAMEGETLHTFYTQLVLMPKVMHYAQYVLLALGCVLLLVPVICQIRSQVGAGQRAARADSHSLACWGKGASDRTLWPTAAWSPPPAAVLRLCRSGSGHCWGLRSTLASFACRVATTLPVLEGLGPSLGGGTGS T89560 TARGETID T89560 T89560 FORMERID TTDNR00753 T89560 UNIPROID STAB2_HUMAN T89560 TARGNAME Stabilin-2 (STAB2) T89560 GENENAME STAB2 T89560 TARGTYPE Literature-reported T89560 SYNONYMS STAB2; Hyaluronan receptor for endocytosis; Fasciclin, EGF-like, laminin-type EGF-like and link domain-containing scavenger receptor 2; FEEL-2; FAS1 EGF-like and X-link domain-containing adhesion molecule 2 T89560 FUNCTION Phosphatidylserine receptor that enhances the engulfment of apoptotic cells. Hyaluronan receptor that binds to and mediates endocytosis of hyaluronic acid (HA). Acts also, in different species, as a primary systemic scavenger receptor for heparin (Hep), chondroitin sulfate (CS), dermatan sulfate (DS), nonglycosaminoglycan (GAG), acetylated low-density lipoprotein (AcLDL), pro-collagen propeptides and advanced glycation end products (AGE). May serve to maintain tissue integrity by supporting extracellular matrix turnover or it may contribute to maintaining fluidity of bodily liquids by resorption of hyaluronan. Counter receptor which plays an important role in lymphocyte recruitment in the hepatic vasculature. Binds to both Gram-positive and Gram-negative bacteria and may play a role in defense against bacterial infection. The proteolytically processed 190 kDa form also functions as an endocytosis receptor for heparin internalisation as well as HA and CS. T89560 PDBSTRUC 5N86 T89560 SEQUENCE MMLQHLVIFCLGLVVQNFCSPAETTGQARRCDRKSLLTIRTECRSCALNLGVKCPDGYTMITSGSVGVRDCRYTFEVRTYSLSLPGCRHICRKDYLQPRCCPGRWGPDCIECPGGAGSPCNGRGSCAEGMEGNGTCSCQEGFGGTACETCADDNLFGPSCSSVCNCVHGVCNSGLDGDGTCECYSAYTGPKCDKPIPECAALLCPENSRCSPSTEDENKLECKCLPNYRGDGKYCDPINPCLRKICHPHAHCTYLGPNRHSCTCQEGYRGDGQVCLPVDPCQINFGNCPTKSTVCKYDGPGQSHCECKEHYQNFVPGVGCSMTDICKSDNPCHRNANCTTVAPGRTECICQKGYVGDGLTCYGNIMERLRELNTEPRGKWQGRLTSFISLLDKAYAWPLSKLGPFTVLLPTDKGLKGFNVNELLVDNKAAQYFVKLHIIAGQMNIEYMNNTDMFYTLTGKSGEIFNSDKDNQIKLKLHGGKKKVKIIQGDIIASNGLLHILDRAMDKLEPTFESNNEQTIMTMLQPRYSKFRSLLEETNLGHALDEDGVGGPYTIFVPNNEALNNMKDGTLDYLLSPEGSRKLLELVRYHIVPFTQLEVATLISTPHIRSMANQLIQFNTTDNGQILANDVAMEEIEITAKNGRIYTLTGVLIPPSIVPILPHRCDETKREMKLGTCVSCSLVYWSRCPANSEPTALFTHRCVYSGRFGSLKSGCARYCNATVKIPKCCKGFYGPDCNQCPGGFSNPCSGNGQCADSLGGNGTCICEEGFQGSQCQFCSDPNKYGPRCNKKCLCVHGTCNNRIDSDGACLTGTCRDGSAGRLCDKQTSACGPYVQFCHIHATCEYSNGTASCICKAGYEGDGTLCSEMDPCTGLTPGGCSRNAECIKTGTGTHTCVCQQGWTGNGRDCSEINNCLLPSAGGCHDNASCLYVGPGQNECECKKGFRGNGIDCEPITSCLEQTGKCHPLASCQSTSSGVWSCVCQEGYEGDGFLCYGNAAVELSFLSEAAIFNRWINNASLQPTLSATSNLTVLVPSQQATEDMDQDEKSFWLSQSNIPALIKYHMLLGTYRVADLQTLSSSDMLATSLQGNFLHLAKVDGNITIEGASIVDGDNAATNGVIHIINKVLVPQRRLTGSLPNLLMRLEQMPDYSIFRGYIIQYNLANAIEAADAYTVFAPNNNAIENYIREKKVLSLEEDVLRYHVVLEEKLLKNDLHNGMHRETMLGFSYFLSFFLHNDQLYVNEAPINYTNVATDKGVIHGLGKVLEIQKNRCDNNDTTIIRGRCRTCSSELTCPFGTKSLGNEKRRCIYTSYFMGRRTLFIGCQPKCVRTVITRECCAGFFGPQCQPCPGNAQNVCFGNGICLDGVNGTGVCECGEGFSGTACETCTEGKYGIHCDQACSCVHGRCNQGPLGDGSCDCDVGWRGVHCDNATTEDNCNGTCHTSANCLTNSDGTASCKCAAGFQGNGTICTAINACEISNGGCSAKADCKRTTPGRRVCTCKAGYTGDGIVCLEINPCLENHGGCDKNAECTQTGPNQAACNCLPAYTGDGKVCTLINVCLTKNGGCSEFAICNHTGQVERTCTCKPNYIGDGFTCRGSIYQELPKNPKTSQYFFQLQEHFVKDLVGPGPFTVFAPLSAAFDEEARVKDWDKYGLMPQVLRYHVVACHQLLLENLKLISNATSLQGEPIVISVSQSTVYINNKAKIISSDIISTNGIVHIIDKLLSPKNLLITPKDNSGRILQNLTTLATNNGYIKFSNLIQDSGLLSVITDPIHTPVTLFWPTDQALHALPAEQQDFLFNQDNKDKLKEYLKFHVIRDAKVLAVDLPTSTAWKTLQGSELSVKCGAGRDIGDLFLNGQTCRIVQRELLFDLGVAYGIDCLLIDPTLGGRCDTFTTFDASGECGSCVNTPSCPRWSKPKGVKQKCLYNLPFKRNLEGCRERCSLVIQIPRCCKGYFGRDCQACPGGPDAPCNNRGVCLDQYSATGECKCNTGFNGTACEMCWPGRFGPDCLPCGCSDHGQCDDGITGSGQCLCETGWTGPSCDTQAVLPAVCTPPCSAHATCKENNTCECNLDYEGDGITCTVVDFCKQDNGGCAKVARCSQKGTKVSCSCQKGYKGDGHSCTEIDPCADGLNGGCHEHATCKMTGPGKHKCECKSHYVGDGLNCEPEQLPIDRCLQDNGQCHADAKCVDLHFQDTTVGVFHLRSPLGQYKLTFDKAREACANEAATMATYNQLSYAQKAKYHLCSAGWLETGRVAYPTAFASQNCGSGVVGIVDYGPRPNKSEMWDVFCYRMKDVNCTCKVGYVGDGFSCSGNLLQVLMSFPSLTNFLTEVLAYSNSSARGRAFLEHLTDLSIRGTLFVPQNSGLGENETLSGRDIEHHLANVSMFFYNDLVNGTTLQTRLGSKLLITASQDPLQPTETRFVDGRAILQWDIFASNGIIHVISRPLKAPPAPVTLTHTGLGAGIFFAIILVTGAVALAAYSYFRINRRTIGFQHFESEEDINVAALGKQQPENISNPLYESTTSAPPEPSYDPFTDSEERQLEGNDPLRTL T11578 TARGETID T11578 T11578 FORMERID TTDI00149 T11578 UNIPROID SRS12_HUMAN T11578 TARGNAME Serine/arginine-rich splicing factor 12 (Srrp35) T11578 GENENAME SRSF12 T11578 TARGTYPE Literature-reported T11578 SYNONYMS Splicing factor, arginine/serine-rich 19; Splicing factor, arginine/serine-rich 13B; SRSF12; 35 kDa SR repressor protein T11578 FUNCTION Splicing factor that seems to antagonize SR proteins in pre-mRNA splicing regulation. T11578 BIOCLASS Splicing factor SR family T11578 SEQUENCE MSRYTRPPNTSLFIRNVADATRPEDLRREFGRYGPIVDVYIPLDFYTRRPRGFAYVQFEDVRDAEDALYNLNRKWVCGRQIEIQFAQGDRKTPGQMKSKERHPCSPSDHRRSRSPSQRRTRSRSSSWGRNRRRSDSLKESRHRRFSYSQSKSRSKSLPRRSTSARQSRTPRRNFGSRGRSRSKSLQKRSKSIGKSQSSSPQKQTSSGTKSRSHGRHSDSIARSPCKSPKGYTNSETKVQTAKHSHFRSHSRSRSYRHKNSW T23763 TARGETID T23763 T23763 FORMERID TTDI02480 T23763 UNIPROID ROBO4_HUMAN T23763 TARGNAME Roundabout homolog 4 (ROBO4) T23763 GENENAME ROBO4 T23763 TARGTYPE Literature-reported T23763 SYNONYMS ROBO4; Magic roundabout T23763 FUNCTION Receptor for Slit proteins, at least for SLIT2, and seemsto be involved in angiogenesis and vascular patterning. May mediate the inhibition of primary endothelial cell migration by Slit proteins. T23763 BIOCLASS Immunoglobulin T23763 SEQUENCE MGSGGDSLLGGRGSLPLLLLLIMGGMAQDSPPQILVHPQDQLFQGPGPARMSCQASGQPPPTIRWLLNGQPLSMVPPDPHHLLPDGTLLLLQPPARGHAHDGQALSTDLGVYTCEASNRLGTAVSRGARLSVAVLREDFQIQPRDMVAVVGEQFTLECGPPWGHPEPTVSWWKDGKPLALQPGRHTVSGGSLLMARAEKSDEGTYMCVATNSAGHRESRAARVSIQEPQDYTEPVELLAVRIQLENVTLLNPDPAEGPKPRPAVWLSWKVSGPAAPAQSYTALFRTQTAPGGQGAPWAEELLAGWQSAELGGLHWGQDYEFKVRPSSGRARGPDSNVLLLRLPEKVPSAPPQEVTLKPGNGTVFVSWVPPPAENHNGIIRGYQVWSLGNTSLPPANWTVVGEQTQLEIATHMPGSYCVQVAAVTGAGAGEPSRPVCLLLEQAMERATQEPSEHGPWTLEQLRATLKRPEVIATCGVALWLLLLGTAVCIHRRRRARVHLGPGLYRYTSEDAILKHRMDHSDSQWLADTWRSTSGSRDLSSSSSLSSRLGADARDPLDCRRSLLSWDSRSPGVPLLPDTSTFYGSLIAELPSSTPARPSPQVPAVRRLPPQLAQLSSPCSSSDSLCSRRGLSSPRLSLAPAEAWKAKKKQELQHANSSPLLRGSHSLELRACELGNRGSKNLSQSPGAVPQALVAWRALGPKLLSSSNELVTRHLPPAPLFPHETPPTQSQQTQPPVAPQAPSSILLPAAPIPILSPCSPPSPQASSLSGPSPASSRLSSSSLSSLGEDQDSVLTPEEVALCLELSEGEETPRNSVSPMPRAPSPPTTYGYISVPTASEFTDMGRTGGGVGPKGGVLLCPPRPCLTPTPSEGSLANGWGSASEDNAASARASLVSSSDGSFLADAHFARALAVAVDSFGFGLEPREADCVFIDASSPPSPRDEIFLTPNLSLPLWEWRPDWLEDMEVSHTQRLGRGMPPWPPDSQISSQRSQLHCRMPKAGASPVDYS T69984 TARGETID T69984 T69984 FORMERID TTDR00695 T69984 UNIPROID PGTA_HUMAN; PGTB2_HUMAN T69984 TARGNAME Geranylgeranyl transferase II (GGTase-II) T69984 GENENAME RABGGTA; RABGGTB T69984 TARGTYPE Literature-reported T69984 SYNONYMS Rab geranylgeranyltransferase; Rab geranyl-geranyltransferase; Rab GGTase; Rab GG transferase; Geranylgeranyl transferase type-2; Geranylgeranyl transferase type II T69984 FUNCTION Catalyzes the transfer of a geranylgeranyl moiety from geranylgeranyl diphosphate to both cysteines of Rab proteins with the C-terminal sequence -XXCC, -XCXC and -CCXX, such as RAB1A, RAB3A, RAB5A and RAB7A. T69984 BIOCLASS Alkyl aryl transferase T69984 SEQUENCE MHGRLKVKTSEEQAEAKRLEREQKLKLYQSATQAVFQKRQAGELDESVLELTSQILGANPDFATLWNCRREVLQQLETQKSPEELAALVKAELGFLESCLRVNPKSYGTWHHRCWLLGRLPEPNWTRELELCARFLEVDERNFHCWDYRRFVATQAAVPPAEELAFTDSLITRNFSNYSSWHYRSCLLPQLHPQPDSGPQGRLPEDVLLKELELVQNAFFTDPNDQSAWFYHRWLLGRADPQDALRCLHVSRDEACLTVSFSRPLLVGSRMEILLLMVDDSPLIVEWRTPDGRNRPSHVWLCDLPAASLNDQLPQHTFRVIWTAGDVQKECVLLKGRQEGWCRDSTTDEQLFRCELSVEKSTVLQSELESCKELQELEPENKWCLLTIILLMRALDPLLYEKETLQYFQTLKAVDPMRATYLDDLRSKFLLENSVLKMEYAEVRVLHLAHKDLTVLCHLEQLLLVTHLDLSHNRLRTLPPALAALRCLEVLQASDNAIESLDGVTNLPRLQELLLCNNRLQQPAVLQPLASCPRLVLLNLQGNPLCQAVGILEQLAELLPSVSSVLT T53186 TARGETID T53186 T53186 FORMERID TTDI03320 T53186 UNIPROID KCNJ9_HUMAN T53186 TARGNAME Inward rectifier potassium channel Kir3.3 (KCNJ9) T53186 GENENAME KCNJ9 T53186 TARGTYPE Literature-reported T53186 SYNONYMS Potassium channel, inwardly rectifying subfamily J member 9; Inward rectifier K(+) channel Kir3.3; GIRK3; GIRK-3; G protein-activated inward rectifier potassium channel 3 T53186 FUNCTION This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium (By similarity). T53186 BIOCLASS Inward rectifier potassium channel T53186 SEQUENCE MAQENAAFSPGQEEPPRRRGRQRYVEKDGRCNVQQGNVRETYRYLTDLFTTLVDLQWRLSLLFFVLAYALTWLFFGAIWWLIAYGRGDLEHLEDTAWTPCVNNLNGFVAAFLFSIETETTIGYGHRVITDQCPEGIVLLLLQAILGSMVNAFMVGCMFVKISQPNKRAATLVFSSHAVVSLRDGRLCLMFRVGDLRSSHIVEASIRAKLIRSRQTLEGEFIPLHQTDLSVGFDTGDDRLFLVSPLVISHEIDAASPFWEASRRALERDDFEIVVILEGMVEATGMTCQARSSYLVDEVLWGHRFTSVLTLEDGFYEVDYASFHETFEVPTPSCSARELAEAAARLDAHLYWSIPSRLDEKVEEEGAGEGAGGEAGADKEQNGCLPPPESESKV T53186 DRUGINFO D07ZAJ PIP2 Investigative T84032 TARGETID T84032 T84032 FORMERID TTDR00756 T84032 UNIPROID HXB13_HUMAN T84032 TARGNAME Homeobox protein Hox-B13 (HOXB13) T84032 GENENAME HOXB13 T84032 TARGTYPE Literature-reported T84032 SYNONYMS Hoxb-13; HOXB13 T84032 FUNCTION Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. T84032 PDBSTRUC 5NO6; 5EGO; 5EG0; 5EF6; 5EEA T84032 SEQUENCE MEPGNYATLDGAKDIEGLLGAGGGRNLVAHSPLTSHPAAPTLMPAVNYAPLDLPGSAEPPKQCHPCPGVPQGTSPAPVPYGYFGGGYYSCRVSRSSLKPCAQAATLAAYPAETPTAGEEYPSRPTEFAFYPGYPGTYQPMASYLDVSVVQTLGAPGEPRHDSLLPVDSYQSWALAGGWNSQMCCQGEQNPPGPFWKAAFADSSGQHPPDACAFRRGRKKRIPYSKGQLRELEREYAANKFITKDKRRKISAATSLSERQITIWFQNRRVKEKKVLAKVKNSATP T29481 TARGETID T29481 T29481 FORMERID TTDI02395 T29481 UNIPROID FGF14_HUMAN T29481 TARGNAME Fibroblast growth factor-14 (FGF14) T29481 GENENAME FGF14 T29481 TARGTYPE Literature-reported T29481 SYNONYMS Fibroblast growth factor homologous factor 4; Fibroblast growth factor 14; FHF4; FGF14 T29481 FUNCTION Probably involved in nervous system development and function. T29481 BIOCLASS Growth factor T29481 SEQUENCE MAAAIASGLIRQKRQAREQHWDRPSASRRRSSPSKNRGLCNGNLVDIFSKVRIFGLKKRRLRRQDPQLKGIVTRLYCRQGYYLQMHPDGALDGTKDDSTNSTLFNLIPVGLRVVAIQGVKTGLYIAMNGEGYLYPSELFTPECKFKESVFENYYVIYSSMLYRQQESGRAWFLGLNKEGQAMKGNRVKKTKPAAHFLPKPLEVAMYREPSLHDVGETVPKPGVTPSKSTSASAIMNGGKPVNKSKTT T65932 TARGETID T65932 T65932 FORMERID TTDI03337 T65932 UNIPROID KCNB2_HUMAN T65932 TARGNAME Voltage-gated potassium channel Kv2.2 (KCNB2) T65932 GENENAME KCNB2 T65932 TARGTYPE Literature-reported T65932 SYNONYMS Voltage-gated potassium channel subunit Kv2.2; Potassium voltage-gated channel subfamily B member 2 T65932 FUNCTION Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and smooth muscle cells. Channels open or close in response to the voltage difference across the membrane, letting potassium ions pass in accordance with their electrochemical gradient. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarization. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB1; channel properties depend on the type of alpha subunits that are part of the channel. Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNS1 and KCNS2, creating a functionally diverse range of channel complexes. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Contributes to the delayed-rectifier voltage-gated potassium current in cortical pyramidal neurons and smooth muscle cells. T65932 BIOCLASS Voltage-gated ion channel T65932 SEQUENCE MAEKAPPGLNRKTSRSTLSLPPEPVDIIRSKTCSRRVKINVGGLNHEVLWRTLDRLPRTRLGKLRDCNTHESLLEVCDDYNLNENEYFFDRHPGAFTSILNFYRTGKLHMMEEMCALSFGQELDYWGIDEIYLESCCQARYHQKKEQMNEELRREAETMREREGEEFDNTCCPDKRKKLWDLLEKPNSSVAAKILAIVSILFIVLSTIALSLNTLPELQETDEFGQLNDNRQLAHVEAVCIAWFTMEYLLRFLSSPNKWKFFKGPLNVIDLLAILPYYVTIFLTESNKSVLQFQNVRRVVQIFRIMRILRILKLARHSTGLQSLGFTLRRSYNELGLLILFLAMGIMIFSSLVFFAEKDEDATKFTSIPASFWWATITMTTVGYGDIYPKTLLGKIVGGLCCIAGVLVIALPIPIIVNNFSEFYKEQKRQEKAIKRREALERAKRNGSIVSMNLKDAFARSMELIDVAVEKAGESANTKDSADDNHLSPSRWKWARKALSETSSNKSFENKYQEVSQKDSHEQLNNTSSSSPQHLSAQKLEMLYNEITKTQPHSHPNPDCQEKPERPSAYEEEIEMEEVVCPQEQLAVAQTEVIVDMKSTSSIDSFTSCATDFTETERSPLPPPSASHLQMKFPTDLPGTEEHQRARGPPFLTLSREKGPAARDGTLEYAPVDITVNLDASGSQCGLHSPLQSDNATDSPKSSLKGSNPLKSRSLKVNFKENRGSAPQTPPSTARPLPVTTADFSLTTPQHISTILLEETPSQGDRPLLGTEVSAPCQGPSKGLSPRFPKQKLFPFSSRERRSFTEIDTGDDEDFLELPGAREEKQVDSSPNCFADKPSDGRDPLREEGSVGSSSPQDTGHNCRQDIYHAVSEVKKDSSQEGCKMENHLFAPEIHSNPGDTGYCPTRETSM T65932 DRUGINFO D0I7VY RY796 Investigative T65932 DRUGINFO D06PZZ [14C]TEA Investigative T43817 TARGETID T43817 T43817 FORMERID TTDNR00673 T43817 UNIPROID GLMN_HUMAN T43817 TARGNAME FKBP-associated protein (FAP48) T43817 GENENAME GLMN T43817 TARGTYPE Literature-reported T43817 SYNONYMS Glomulin; FK506-binding protein-associated protein; FAP48 T43817 FUNCTION Isoform 1: Regulatory component of cullin-RING-based SCF (SKP1-Cullin-F-box protein) E3 ubiquitin-protein ligase complexes. Inhibits E3 ubiquitin ligase activity by binding to RBX1 (via RING domain) and inhibiting its interaction with the E2 ubiquitin-conjugating enzyme CDC34. Inhibits RBX1-mediated neddylation of CUL1. Required for normal stability and normal cellular levels of key components of SCF ubiquitin ligase complexes, including FBXW7, RBX1, CUL1, CUL2, CUL3, CUL4A, and thereby contributes to the regulation of CCNE1 and MYC levels (By similarity). Essential for normal development of the vasculature. Contributes to the regulation of RPS6KB1 phosphorylation. T43817 PDBSTRUC 4F52 T43817 SEQUENCE MAVEELQSIIKRCQILEEQDFKEEDFGLFQLAGQRCIEEGHTDQLLEIIQNEKNKVIIKNMGWNLVGPVVRCLLCKDKEDSKRKVYFLIFDLLVKLCNPKELLLGLLELIEEPSGKQISQSILLLLQPLQTVIQKLHNKAYSIGLALSTLWNQLSLLPVPYSKEQIQMDDYGLCQCCKALIEFTKPFVEEVIDNKENSLENEKLKDELLKFCFKSLKCPLLTAQFFEQSEEGGNDPFRYFASEIIGFLSAIGHPFPKMIFNHGRKKRTWNYLEFEEEENKQLADSMASLAYLVFVQGIHIDQLPMVLSPLYLLQFNMGHIEVFLQRTEESVISKGLELLENSLLRIEDNSLLYQYLEIKSFLTVPQGLVKVMTLCPIETLRKKSLAMLQLYINKLDSQGKYTLFRCLLNTSNHSGVEAFIIQNIKNQIDMSLKRTRNNKWFTGPQLISLLDLVLFLPEGAETDLLQNSDRIMASLNLLRYLVIKDNENDNQTGLWTELGNIENNFLKPLHIGLNMSKAHYEAEIKNSQEAQKSKDLCSITVSGEEIPNMPPEMQLKVLHSALFTFDLIESVLARVEELIEIKTKSTSEENIGIK T21705 TARGETID T21705 T21705 FORMERID TTDR00937 T21705 UNIPROID FBXW7_HUMAN T21705 TARGNAME F-box and WD-40 domain protein 7 (Fbxw7) T21705 GENENAME FBXW7 T21705 TARGTYPE Literature-reported T21705 SYNONYMS hCdc4; hAgo; SEL10; SEL-10; FBX30; FBW7; F-box/WD repeat-containing protein 7; F-box-WD40 repeat protein 6; F-box protein Fbxw6; F-box protein FBX30; F-box protein FBW7; F-box and WD-40 domain-containing protein 7; Archipelago homolog T21705 FUNCTION Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E (CCNE1 or CCNE2), DISC1, JUN, MYC, NOTCH1 released notch intracellular domain (NICD), NOTCH2, MCL1, and probably PSEN1. Acts as a negative regulator of JNK signaling by binding to phosphorylated JUN and promoting its ubiquitination and subsequent degradation. SCF(FBXW7) complex mediates the ubiquitination and subsequent degradation of NFE2L1. Involved in bone homeostasis and negative regulation of osteoclast differentiation. Regulates the amplitude of the cyclic expression of hepatic core clock genes and genes involved in lipid and glucose metabolism via ubiquitination and proteasomal degradation of their transcriptional repressor NR1D1; CDK1-dependent phosphorylation of NR1D1 is necessary for SCF(FBXW7)-mediated ubiquitination. Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. T21705 PDBSTRUC 5V4B; 5IBK; 2OVR; 2OVQ; 2OVP T21705 SEQUENCE MNQELLSVGSKRRRTGGSLRGNPSSSQVDEEQMNRVVEEEQQQQLRQQEEEHTARNGEVVGVEPRPGGQNDSQQGQLEENNNRFISVDEDSSGNQEEQEEDEEHAGEQDEEDEEEEEMDQESDDFDQSDDSSREDEHTHTNSVTNSSSIVDLPVHQLSSPFYTKTTKMKRKLDHGSEVRSFSLGKKPCKVSEYTSTTGLVPCSATPTTFGDLRAANGQGQQRRRITSVQPPTGLQEWLKMFQSWSGPEKLLALDELIDSCEPTQVKHMMQVIEPQFQRDFISLLPKELALYVLSFLEPKDLLQAAQTCRYWRILAEDNLLWREKCKEEGIDEPLHIKRRKVIKPGFIHSPWKSAYIRQHRIDTNWRRGELKSPKVLKGHDDHVITCLQFCGNRIVSGSDDNTLKVWSAVTGKCLRTLVGHTGGVWSSQMRDNIIISGSTDRTLKVWNAETGECIHTLYGHTSTVRCMHLHEKRVVSGSRDATLRVWDIETGQCLHVLMGHVAAVRCVQYDGRRVVSGAYDFMVKVWDPETETCLHTLQGHTNRVYSLQFDGIHVVSGSLDTSIRVWDVETGNCIHTLTGHQSLTSGMELKDNILVSGNADSTVKIWDIKTGQCLQTLQGPNKHQSAVTCLQFNKNFVITSSDDGTVKLWDLKTGEFIRNLVTLESGGSGGVVWRIRASNTKLVCAVGSRNGTEETKLLVLDFDVDMK T70012 TARGETID T70012 T70012 FORMERID TTDI03144 T70012 UNIPROID CXA10_HUMAN T70012 TARGNAME Connexin-62 (Cx62) T70012 GENENAME GJA10 T70012 TARGTYPE Literature-reported T70012 SYNONYMS Gap junction alpha-10 protein; CX62 T70012 FUNCTION Involved in tracer coupling between horizontal cells of the retina. May play a role in the regulation of horizontal cell patterning. One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T70012 BIOCLASS Gap junction-forming connexin T70012 SEQUENCE MGDWNLLGGILEEVHSHSTIVGKIWLTILFIFRMLVLRVAAEDVWDDEQSAFACNTRQPGCNNICYDDAFPISLIRFWVLQIIFVSSPSLVYMGHALYRLRAFEKDRQRKKSHLRAQMENPDLDLEEQQRIDRELRRLEEQKRIHKVPLKGCLLRTYVLHILTRSVLEVGFMIGQYILYGFQMHPLYKCTQPPCPNAVDCFVSRPTEKTIFMLFMHSIAAISLLLNILEIFHLGIRKIMRTLYKKSSSEGIEDETGPPFHLKKYSVAQQCMICSSLPERISPLQANNQQQVIRVNVPKSKTMWQIPQPRQLEVDPSNGKKDWSEKDQHSGQLHVHSPCPWAGSAGNQHLGQQSDHSSFGLQNTMSQSWLGTTTAPRNCPSFAVGTWEQSQDPEPSGEPLTDLHSHCRDSEGSMRESGVWIDRSRPGSRKASFLSRLLSEKRHLHSDSGSSGSRNSSCLDFPHWENSPSPLPSVTGHRTSMVRQAALPIMELSQELFHSGCFLFPFFLPGVCMYVCVDREADGGGDYLWRDKIIHSIHSVKFNS T70012 DRUGINFO D00VJY octanol Investigative T40299 TARGETID T40299 T40299 FORMERID TTDI00212 T40299 UNIPROID ATG2B_HUMAN T40299 TARGNAME Autophagy-related 2B (ATG2B) T40299 GENENAME ATG2B T40299 TARGTYPE Literature-reported T40299 SYNONYMS C14orf103; Autophagyrelated protein 2 homolog B; Autophagy-related protein 2 homolog B T40299 FUNCTION Required for both autophagosome formation and regulation of lipid droplet morphology and dispersion. T40299 BIOCLASS Autophagy phagophore-formation transporter T40299 SEQUENCE MPWPFSESIKKRACRYLLQRYLGHFLQEKLSLEQLSLDLYQGTGSLAQVPLDKWCLNEILESADAPLEVTEGFIQSISLSVPWGSLLQDNCALEVRGLEMVFRPRPRPATGSEPMYWSSFMTSSMQLAKECLSQKLTDEQGEGSQPFEGLEKFAETIETVLRRVKVTFIDTVLRIEHVPENSKTGTALEIRIERTVYCDETADESSGINVHQPTAFAHKLLQLSGVSLFWDEFSASAKSSPVCSTAPVETEPKLSPSWNPKIIYEPHPQLTRNLPEIAPSDPVQIGRLIGRLELSLTLKQNEVLPGAKLDVDGQIDSIHLLLSPRQVHLLLDMLAAIAGPENSSKIGLANKDRKNRPMQQEDEYRIQMELNRYYLRKDSLSVGVSSEQSFYETETARTPSSREEEVFFSMADMDMSHSLSSLPPLGDPPNMDLELSLTSTYTNTPAGSPLSATVLQPTWGEFLDHHKEQPVRGSTFPSNLVHPTPLQKTSLPSRSVSVDESRPELIFRLAVGTFSISVLHIDPLSPPETSQNLNPLTPMAVAFFTCIEKIDPARFSTEDFKSFRAVFAEACSHDHLRFIGTGIKVSYEQRQRSASRYFSTDMSIGQMEFLECLFPTDFHSVPPHYTELLTFHSKEETGSHSPVCLQLHYKHSENRGPQGNQARLSSVPHKAELQIKLNPVCCELDISIVDRLNSLLQPQKLATVEMMASHMYTSYNKHISLHKAFTEVFLDDSHSPANCRISVQVATPALNLSVRFPIPDLRSDQERGPWFKKSLQKEILYLAFTDLEFKTEFIGGSTPEQIKLELTFRELIGSFQEEKGDPSIKFFHVSSGVDGDTTSSDDFDWPRIVLKINPPAMHSILERIAAEEEEENDGHYQEEEEGGAHSLKDVCDLRRPAPSPFSSRRVMFENEQMVMPGDPVEMTEFQDKAISNSHYVLELTLPNIYVTLPNKSFYEKLYNRIFNDLLLWEPTAPSPVETFENISYGIGLSVASQLINTFNKDSFSAFKSAVHYDEESGSEEETLQYFSTVDPNYRSRRKKKLDSQNKNSQSFLSVLLNINHGLIAVFTDVKQDNGDLLENKHGEFWLEFNSGSLFCVTKYEGFDDKHYICLHSSSFSLYHKGIVNGVILPTETRLPSSTRPHWLEPTIYSSEEDGLSKTSSDGVGGDSLNMLSVAVKILSDKSESNTKEFLIAVGLKGATLQHRMLPSGLSWHEQILYFLNIADEPVLGYNPPTSFTTFHVHLWSCALDYRPLYLPIRSLLTVETFSVSSSVALDKSSSTLRIILDEAALHLSDKCNTVTINLSRDYVRVMDMGLLELTITAVKSDSDGEQTEPRFELHCSSDVVHIRTCSDSCAALMNLIQYIASYGDLQTPNKADMKPGAFQRRSKVDSSGRSSSRGPVLPEADQQMLRDLMSDAMEEIDMQQGTSSVKPQANGVLDEKSQIQEPCCSDLFLFPDESGNVSQESGPTYASFSHHFISDAMTGVPTENDDFCILFAPKAAMQEKEEEPVIKIMVDDAIVIRDNYFSLPVNKTDTSKAPLHFPIPVIRYVVKEVSLVWHLYGGKDFGIVPPTSPAKSYISPHSSPSHTPTRHGRNTVCGGKGRNHDFLMEIQLSKVKFQHEVYPPCKPDCDSSLSEHPVSRQVFIVQDLEIRDRLATSQMNKFLYLYCSKEMPRKAHSNMLTVKALHVCPESGRSPQECCLRVSLMPLRLNIDQDALFFLKDFFTSLSAEVELQMTPDPEVKKSPGADVTCSLPRHLSTSKEPNLVISFSGPKQPSQNDSANSVEVVNGMEEKNFSAEEASFRDQPVFFREFRFTSEVPIRLDYHGKHVSMDQGTLAGILIGLAQLNCSELKLKRLSYRHGLLGVDKLFSYAITEWLNDIKKNQLPGILGGVGPMHSLVQLVQGLKDLVWLPIEQYRKDGRIVRGFQRGAASFGTSTAMAALELTNRMVQTIQAAAETAYDMVSPGTLSIEPKKTKRFPHHRLAHQPVDLREGVAKAYSVVKEGITDTAQTIYETAAREHESRGVTGAVGEVLRQIPPAVVKPLIVATEATSNVLGGMRNQIRPDVRQDESQKWRHGDD T33931 TARGETID T33931 T33931 FORMERID TTDI03345 T33931 UNIPROID LMBL3_HUMAN T33931 TARGNAME Lethal(3)malignant brain tumor-like 3 (L3MBTL3) T33931 GENENAME L3MBTL3 T33931 TARGTYPE Literature-reported T33931 SYNONYMS MBT1; MBT-1; Lethal(3)malignant brain tumor-like protein 3; L(3)mbt-like protein 3; KIAA1798; H-l(3)mbt-like protein 3 T33931 FUNCTION Putative Polycomb group (PcG) protein. PcG proteins maintain the transcriptionally repressive state of genes, probably via a modification of chromatin, rendering it heritably changed in its expressibility. Required for normal maturation of myeloid progenitor cells (By similarity). T33931 PDBSTRUC 4L59; 4FL6; 3UT1; 1WJS; 1WJQ T33931 SEQUENCE MTESASSTSGQEFDVFSVMDWKDGVGTLPGSDLKFRVNEFGALEVITDENEMENVKKATATTTWMVPTAQEAPTSPPSSRPVFPPAYWTSPPGCPTVFSEKTGMPFRLKDPVKVEGLQFCENCCQYGNVDECLSGGNYCSQNCARHIKDKDQKEERDVEEDNEEEDPKCSRKKKPKLSLKADTKEDGEERDDEMENKQDVRILRGSQRARRKRRGDSAVLKQGLPPKGKKAWCWASYLEEEKAVAVPAKLFKEHQSFPYNKNGFKVGMKLEGVDPEHQSVYCVLTVAEVCGYRIKLHFDGYSDCYDFWVNADALDIHPVGWCEKTGHKLHPPKGYKEEEFNWQTYLKTCKAQAAPKSLFENQNITVIPSGFRVGMKLEAVDKKNPSFICVATVTDMVDNRFLVHFDNWDESYDYWCEASSPHIHPVGWCKEHRRTLITPPGYPNVKHFSWDKYLEETNSLPAPARAFKVKPPHGFQKKMKLEVVDKRNPMFIRVATVADTDDHRVKVHFDGWNNCYDYWIDADSPDIHPVGWCSKTGHPLQPPLSPLELMEASEHGGCSTPGCKGIGHFKRARHLGPHSAANCPYSEINLNKDRIFPDRLSGEMPPASPSFPRNKRTDANESSSSPEIRDQHADDVKEDFEERTESEMRTSHEARGAREEPTVQQAQRRSAVFLSFKSPIPCLPLRWEQQSKLLPTVAGIPASKVSKWSTDEVSEFIQSLPGCEEHGKVFKDEQIDGEAFLLMTQTDIVKIMSIKLGPALKIFNSILMFKAAEKNSHNEL T33931 DRUGINFO D0W9RR UNC1215 Investigative T78355 TARGETID T78355 T78355 FORMERID TTDI03139 T78355 UNIPROID CXD4_HUMAN T78355 TARGNAME Gap junction delta-4 protein (Cx40.1) T78355 GENENAME GJD4 T78355 TARGTYPE Literature-reported T78355 SYNONYMS Connexin-40.1; CX40.1 T78355 FUNCTION One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. T78355 BIOCLASS Gap junction-forming connexin T78355 SEQUENCE MEGVDLLGFLIITLNCNVTMVGKLWFVLTMLLRMLVIVLAGRPVYQDEQERFVCNTLQPGCANVCYDVFSPVSHLRFWLIQGVCVLLPSAVFSVYVLHRGATLAALGPRRCPDPREPASGQRRCPRPFGERGGLQVPDFSAGYIIHLLLRTLLEAAFGALHYFLFGFLAPKKFPCTRPPCTGVVDCYVSRPTEKSLLMLFLWAVSALSFLLGLADLVCSLRRRMRRRPGPPTSPSIRKQSGASGHAEGRRTDEEGGREEEGAPAPPGARAGGEGAGSPRRTSRVSGHTKIPDEDESEVTSSASEKLGRQPRGRPHREAAQDPRGSGSEEQPSAAPSRLAAPPSCSSLQPPDPPASSSGAPHLRARKSEWV T78355 DRUGINFO D00VJY octanol Investigative T14071 TARGETID T14071 T14071 FORMERID TTDI00029 T14071 UNIPROID HS12B_HUMAN T14071 TARGNAME Heat shock protein A 12B (HSPA12B) T14071 GENENAME HSPA12B T14071 TARGTYPE Literature-reported T14071 SYNONYMS Heat shock 70 kDa protein 12B; C20orf60 T14071 FUNCTION Interacts with extended peptide segments of proteins as well as partially folded proteins to prevent aggregation, remodel folding pathways, and regulate activity. When not interacting with a substrate peptide, usually in an ATP bound state. Hsp70 by itself is characterized by a very weak ATPase activity. As newly synthesized proteins emerge from the ribosomes, the substrate binding domain of Hsp70 recognizes sequences of hydrophobic amino acid residues, and interacts with them. This spontaneous interaction is reversible, and in the ATP bound state Hsp70 may relatively freely bind and release peptides. T14071 BIOCLASS Heat shock protein T14071 SEQUENCE MLAVPEMGLQGLYIGSSPERSPVPSPPGSPRTQESCGIAPLTPSQSPKPEVRAPQQASFSVVVAIDFGTTSSGYAFSFASDPEAIHMMRKWEGGDPGVAHQKTPTCLLLTPEGAFHSFGYTARDYYHDLDPEEARDWLYFEKFKMKIHSATDLTLKTQLEAVNGKTMPALEVFAHALRFFREHALQELREQSPSLPEKDTVRWVLTVPAIWKQPAKQFMREAAYLAGLVSRENAEQLLIALEPEAASVYCRKLRLHQLLDLSGRAPGGGRLGERRSIDSSFRQAREQLRRSRHSRTFLVESGVGELWAEMQAGDRYVVADCGGGTVDLTVHQLEQPHGTLKELYKASGGPYGAVGVDLAFEQLLCRIFGEDFIATFKRQRPAAWVDLTIAFEARKRTAGPHRAGALNISLPFSFIDFYRKQRGHNVETALRRSSVNFVKWSSQGMLRMSCEAMNELFQPTVSGIIQHIEALLARPEVQGVKLLFLVGGFAESAVLQHAVQAALGARGLRVVVPHDVGLTILKGAVLFGQAPGVVRVRRSPLTYGVGVLNRFVPGRHPPEKLLVRDGRRWCTDVFERFVAAEQSVALGEEVRRSYCPARPGQRRVLINLYCCAAEDARFITDPGVRKCGALSLELEPADCGQDTAGAPPGRREIRAAMQFGDTEIKVTAVDVSTNRSVRASIDFLSN T86026 TARGETID T86026 T86026 FORMERID TTDI01532 T86026 UNIPROID H6ST2_HUMAN T86026 TARGNAME Heparan sulfate 6-O-sulfotransferase-2 (HS6ST2) T86026 GENENAME HS6ST2 T86026 TARGTYPE Literature-reported T86026 SYNONYMS Heparan-sulfate 6-O-sulfotransferase 2; HS6ST-2 T86026 FUNCTION 6-O-sulfation enzyme which catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to position 6 of the N-sulfoglucosamine residue (GlcNS) of heparan sulfate. T86026 ECNUMBER EC 2.8.2.- T86026 SEQUENCE MALPACAVREFEPPRQPERGAPVRTTCPRRHSRVEAELAASRPGSVAASVRAGPPRGVSHGFHTRPLLDKPRKASSSLAGAACAPLFALLSRGRRRRMHVLRRRWDLGSLCRALLTRGLAALGHSLKHVLGAIFSKIFGPMASVGNMDEKSNKLLLALVMLFLFAVIVLQYVCPGTECQLLRLQAFSSPVPDPYRSEDESSARFVPRYNFTRGDLLRKVDFDIKGDDLIVFLHIQKTGGTTFGRHLVRNIQLEQPCECRVGQKKCTCHRPGKRETWLFSRFSTGWSCGLHADWTELTSCVPSVVDGKRDARLRPSRNFHYITILRDPVSRYLSEWRHVQRGATWKASLHVCDGRPPTSEELPSCYTGDDWSGCPLKEFMDCPYNLANNRQVRMLSDLTLVGCYNLSVMPEKQRNKVLLESAKSNLKHMAFFGLTEFQRKTQYLFEKTFNMNFISPFTQYNTTRASSVEINEEIQKRIEGLNFLDMELYSYAKDLFLQRYQFMRQKEHQEARRKRQEQRKFLKGRLLQTHFQSQGQGQSQNPNQNQSQNPNPNANQNLTQNLMQNLTQSLSQKENRESPKQNSGKEQNDNTSNGTNDYIGSVEKWR T42884 TARGETID T42884 T42884 FORMERID TTDI02511 T42884 UNIPROID GP101_HUMAN T42884 TARGNAME G protein coupled receptor 101 (GPR101) T42884 GENENAME GPR101 T42884 TARGTYPE Literature-reported T42884 SYNONYMS Probable Gprotein coupled receptor 101; GPR101 T42884 FUNCTION Orphan receptor. T42884 BIOCLASS GPCR rhodopsin T42884 SEQUENCE MTSTCTNSTRESNSSHTCMPLSKMPISLAHGIIRSTVLVIFLAASFVGNIVLALVLQRKPQLLQVTNRFIFNLLVTDLLQISLVAPWVVATSVPLFWPLNSHFCTALVSLTHLFAFASVNTIVVVSVDRYLSIIHPLSYPSKMTQRRGYLLLYGTWIVAILQSTPPLYGWGQAAFDERNALCSMIWGASPSYTILSVVSFIVIPLIVMIACYSVVFCAARRQHALLYNVKRHSLEVRVKDCVENEDEEGAEKKEEFQDESEFRRQHEGEVKAKEGRMEAKDGSLKAKEGSTGTSESSVEARGSEEVRESSTVASDGSMEGKEGSTKVEENSMKADKGRTEVNQCSIDLGEDDMEFGEDDINFSEDDVEAVNIPESLPPSRRNSNSNPPLPRCYQCKAAKVIFIIIFSYVLSLGPYCFLAVLAVWVDVETQVPQWVITIIIWLFFLQCCIHPYVYGYMHKTIKKEIQDMLKKFFCKEKPPKEDSHPDLPGTEGGTEGKIVPSYDSATFP T04413 TARGETID T04413 T04413 FORMERID TTDI03578 T04413 UNIPROID TSSK2_HUMAN T04413 TARGNAME Testis-specific serine kinase 2 (TSSK2) T04413 GENENAME TSSK2 T04413 TARGTYPE Literature-reported T04413 SYNONYMS Testis-specific serine/threonine-protein kinase 2; TSSK-2; TSK2; TSK-2; Serine/threonine-protein kinase 22B; STK22B; SPOGA2; DiGeorge syndrome protein G; DGSG; DGS-G T04413 FUNCTION Testis-specific serine/threonine-protein kinase required during spermatid development. Phosphorylates TSKS at 'Ser-288' and SPAG16. Involved in the late stages of spermatogenesis, during the reconstruction of the cytoplasm. During spermatogenesis, required for the transformation of a ring-shaped structure around the base of the flagellum originating from the chromatoid body. T04413 ECNUMBER EC 2.7.11.1 T04413 SEQUENCE MDDATVLRKKGYIVGINLGKGSYAKVKSAYSERLKFNVAVKIIDRKKTPTDFVERFLPREMDILATVNHGSIIKTYEIFETSDGRIYIIMELGVQGDLLEFIKCQGALHEDVARKMFRQLSSAVKYCHDLDIVHRDLKCENLLLDKDFNIKLSDFGFSKRCLRDSNGRIILSKTFCGSAAYAAPEVLQSIPYQPKVYDIWSLGVILYIMVCGSMPYDDSDIRKMLRIQKEHRVDFPRSKNLTCECKDLIYRMLQPDVSQRLHIDEILSHSWLQPPKPKATSSASFKREGEGKYRAECKLDTKTGLRPDHRPDHKLGAKTQHRLLVVPENENRMEDRLAETSRAKDHHISGAEVGKAST T04413 DRUGINFO D0E7VO PMID24900538C2c Investigative T13394 TARGETID T13394 T13394 FORMERID TTDI03339 T13394 UNIPROID KCNC2_HUMAN T13394 TARGNAME Voltage-gated potassium channel Kv3.2 (KCNC2) T13394 GENENAME KCNC2 T13394 TARGTYPE Literature-reported T13394 SYNONYMS Shaw-like potassium channel; Potassium voltage-gated channel subfamily C member 2 T13394 FUNCTION Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Contributes to the regulation of the fast action potential repolarization and in sustained high-frequency firing in neurons of the central nervous system. Homotetramer channels mediate delayed-rectifier voltage-dependent potassium currents that activate rapidly at high-threshold voltages and inactivate slowly. Forms tetrameric channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNC1, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties may be modulated either by the association with ancillary subunits, such as KCNE1, KCNE2 or KCNE3 or indirectly by nitric oxide (NO) through a cGMP- and PKG-mediated signaling cascade, slowing channel activation and deactivation of delayed rectifier potassium channels (By similarity). Contributes to fire sustained trains of very brief action potentials at high frequency in retinal ganglion cells, thalamocortical and suprachiasmatic nucleus (SCN) neurons and in hippocampal and neocortical interneurons. Sustained maximal action potential firing frequency in inhibitory hippocampal interneurons is negatively modulated by histamine H2 receptor activation in a cAMP- and protein kinase (PKA) phosphorylation-dependent manner. Plays a role in maintaining the fidelity of synaptic transmission in neocortical GABAergic interneurons by generating action potential (AP) repolarization at nerve terminals, thus reducing spike-evoked calcium influx and GABA neurotransmitter release. Required for long-range synchronization of gamma oscillations over distance in the neocortex. Contributes to the modulation of the circadian rhythm of spontaneous action potential firing in suprachiasmatic nucleus (SCN) neurons in a light-dependent manner (By similarity). T13394 BIOCLASS Voltage-gated ion channel T13394 SEQUENCE MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPSPPPLSPPPRAPPLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQFKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYEKSRSLNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSIL T13394 DRUGINFO D06PZZ [14C]TEA Investigative T92865 TARGETID T92865 T92865 FORMERID TTDI00228 T92865 UNIPROID KI20B_HUMAN T92865 TARGNAME Kinesin-like protein KIF20B (MPHOSPH1) T92865 GENENAME KIF20B T92865 TARGTYPE Literature-reported T92865 SYNONYMS Mphase phosphoprotein 1; MPP1; M-phase phosphoprotein 1; Kinesinrelated motor interacting with PIN1; Kinesinlike protein KIF20B; Kinesin-related motor interacting with PIN1; Kinesin family member 20B; KRMP1; Cancer/testis antigen 90; CT90 T92865 FUNCTION Required for proper midbody organization and abscission in polarized cortical stem cells. Plays a role in the regulation of neuronal polarization by mediating the transport of specific cargos. Participates in the mobilization of SHTN1 and in the accumulation of PIP3 in the growth cone of primary hippocampal neurons in a tubulin and actin-dependent manner. In the developing telencephalon, cooperates with SHTN1 to promote both the transition from the multipolar to the bipolar stage and the radial migration of cortical neurons from the ventricular zone toward the superficial layer of the neocortex. Involved in cerebral cortex growth. Acts as an oncogene for promoting bladder cancer cells proliferation, apoptosis inhibition and carcinogenic progression. Plus-end-directed motor enzyme that is required for completion of cytokinesis. T92865 BIOCLASS Myosin-kinesin ATPase T92865 SEQUENCE MESNFNQEGVPRPSYVFSADPIARPSEINFDGIKLDLSHEFSLVAPNTEANSFESKDYLQVCLRIRPFTQSEKELESEGCVHILDSQTVVLKEPQCILGRLSEKSSGQMAQKFSFSKVFGPATTQKEFFQGCIMQPVKDLLKGQSRLIFTYGLTNSGKTYTFQGTEENIGILPRTLNVLFDSLQERLYTKMNLKPHRSREYLRLSSEQEKEEIASKSALLRQIKEVTVHNDSDDTLYGSLTNSLNISEFEESIKDYEQANLNMANSIKFSVWVSFFEIYNEYIYDLFVPVSSKFQKRKMLRLSQDVKGYSFIKDLQWIQVSDSKEAYRLLKLGIKHQSVAFTKLNNASSRSHSIFTVKILQIEDSEMSRVIRVSELSLCDLAGSERTMKTQNEGERLRETGNINTSLLTLGKCINVLKNSEKSKFQQHVPFRESKLTHYFQSFFNGKGKICMIVNISQCYLAYDETLNVLKFSAIAQKVCVPDTLNSSQEKLFGPVKSSQDVSLDSNSNSKILNVKRATISWENSLEDLMEDEDLVEELENAEETQNVETKLLDEDLDKTLEENKAFISHEEKRKLLDLIEDLKKKLINEKKEKLTLEFKIREEVTQEFTQYWAQREADFKETLLQEREILEENAERRLAIFKDLVGKCDTREEAAKDICATKVETEETHNYVGFEDIIDSLQDNVADIKKQAEIAHLYIASLPDPQEATACLELKFNQIKAELAKTKGELIKTKEELKKRENESDSLIQELETSNKKIITQNQRIKELINIIDQKEDTINEFQNLKSHMENTFKCNDKADTSSLIINNKLICNETVEVPKDSKSKICSERKRVNENELQQDEPPAKKGSIHVSSAITEDQKKSEEVRPNIAEIEDIRVLQENNEGLRAFLLTIENELKNEKEEKAELNKQIVHFQQELSLSEKKNLTLSKEVQQIQSNYDIAIAELHVQKSKNQEQEEKIMKLSNEIETATRSITNNVSQIKLMHTKIDELRTLDSVSQISNIDLLNLRDLSNGSEEDNLPNTQLDLLGNDYLVSKQVKEYRIQEPNRENSFHSSIEAIWEECKEIVKASSKKSHQIEELEQQIEKLQAEVKGYKDENNRLKEKEHKNQDDLLKEKETLIQQLKEELQEKNVTLDVQIQHVVEGKRALSELTQGVTCYKAKIKELETILETQKVECSHSAKLEQDILEKESIILKLERNLKEFQEHLQDSVKNTKDLNVKELKLKEEITQLTNNLQDMKHLLQLKEEEEETNRQETEKLKEELSASSARTQNLKADLQRKEEDYADLKEKLTDAKKQIKQVQKEVSVMRDEDKLLRIKINELEKKKNQCSQELDMKQRTIQQLKEQLNNQKVEEAIQQYERACKDLNVKEKIIEDMRMTLEEQEQTQVEQDQVLEAKLEEVERLATELEKWKEKCNDLETKNNQRSNKEHENNTDVLGKLTNLQDELQESEQKYNADRKKWLEEKMMLITQAKEAENIRNKEMKKYAEDRERFFKQQNEMEILTAQLTEKDSDLQKWREERDQLVAALEIQLKALISSNVQKDNEIEQLKRIISETSKIETQIMDIKPKRISSADPDKLQTEPLSTSFEISRNKIEDGSVVLDSCEVSTENDQSTRFPKPELEIQFTPLQPNKMAVKHPGCTTPVTVKIPKARKRKSNEMEEDLVKCENKKNATPRTNLKFPISDDRNSSVKKEQKVAIRPSSKKTYSLRSQASIIGVNLATKKKEGTLQKFGDFLQHSPSILQSKAKKIIETMSSSKLSNVEASKENVSQPKRAKRKLYTSEISSPIDISGQVILMDQKMKESDHQIIKRRLRTKTAK T78311 TARGETID T78311 T78311 FORMERID TTDNR00716 T78311 UNIPROID NACC1_HUMAN T78311 TARGNAME Nucleus accumbens-associated protein 1 (NACC1) T78311 GENENAME NACC1 T78311 TARGTYPE Literature-reported T78311 SYNONYMS NAC1; NAC-1; BTBD14B; BTB/POZ domain-containing protein 14B T78311 FUNCTION Seems to function as a transcriptional corepressor in neuronal cells through recruitment of HDAC3 and HDAC4. Contributes to tumor progression, and tumor cell proliferation and survival. This may be mediated at least in part through repressing transcriptional activity of GADD45GIP1. Required for recruiting the proteasome from the nucleus to the cytoplasm and dendritic spines. Functions as a transcriptional repressor. T78311 PDBSTRUC 4U2N; 3GA1 T78311 SEQUENCE MAQTLQMEIPNFGNSILECLNEQRLQGLYCDVSVVVKGHAFKAHRAVLAASSSYFRDLFNNSRSAVVELPAAVQPQSFQQILSFCYTGRLSMNVGDQFLLMYTAGFLQIQEIMEKGTEFFLKVSSPSCDSQGLHAEEAPSSEPQSPVAQTSGWPACSTPLPLVSRVKTEQQESDSVQCMPVAKRLWDSGQKEAGGGGNGSRKMAKFSTPDLAANRPHQPPPPQQAPVVAAAQPAVAAGAGQPAGGVAAAGGVVSGPSTSERTSPGTSSAYTSDSPGSYHNEEDEEEDGGEEGMDEQYRQICNMYTMYSMMNVGQTAEKVEALPEQVAPESRNRIRVRQDLASLPAELINQIGNRCHPKLYDEGDPSEKLELVTGTNVYITRAQLMNCHVSAGTRHKVLLRRLLASFFDRNTLANSCGTGIRSSTNDPRRKPLDSRVLHAVKYYCQNFAPNFKESEMNAIAADMCTNARRVVRKSWMPKVKVLKAEDDAYTTFISETGKIEPDMMGVEHGFETASHEGEAGPSAEALQ T84737 TARGETID T84737 T84737 FORMERID TTDI03329 T84737 UNIPROID KCNA7_HUMAN T84737 TARGNAME Voltage-gated potassium channel Kv1.7 (KCNA7) T84737 GENENAME KCNA7 T84737 TARGTYPE Literature-reported T84737 SYNONYMS Voltage-gated potassium channel subunit Kv1.7; Potassium voltage-gated channel subfamily A member 7 T84737 FUNCTION Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient (By similarity). T84737 BIOCLASS Voltage-gated ion channel T84737 SEQUENCE MEPRCPPPCGCCERLVLNVAGLRFETRARTLGRFPDTLLGDPARRGRFYDDARREYFFDRHRPSFDAVLYYYQSGGRLRRPAHVPLDVFLEEVAFYGLGAAALARLREDEGCPVPPERPLPRRAFARQLWLLFEFPESSQAARVLAVVSVLVILVSIVVFCLETLPDFRDDRDGTGLAAAAAAGPFPAPLNGSSQMPGNPPRLPFNDPFFVVETLCICWFSFELLVRLLVCPSKAIFFKNVMNLIDFVAILPYFVALGTELARQRGVGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLRASMRELGLLIFFLFIGVVLFSSAVYFAEVDRVDSHFTSIPESFWWAVVTMTTVGYGDMAPVTVGGKIVGSLCAIAGVLTISLPVPVIVSNFSYFYHRETEGEEAGMFSHVDMQPCGPLEGKANGGLVDGEVPELPPPLWAPPGKHLVTEV T84737 DRUGINFO D0G4SU tedisamil Investigative T84737 DRUGINFO D06PZZ [14C]TEA Investigative T23785 TARGETID T23785 T23785 FORMERID TTDI03576 T23785 UNIPROID TESK2_HUMAN T23785 TARGNAME Testis-specific kinase 2 (TESK2) T23785 GENENAME TESK2 T23785 TARGTYPE Literature-reported T23785 SYNONYMS Testicular protein kinase 2; Dual specificity testis-specific protein kinase 2 T23785 FUNCTION Dual specificity protein kinase activity catalyzing autophosphorylation and phosphorylation of exogenous substrates on both serine/threonine and tyrosine residues. Phosphorylates cofilin at 'Ser-3'. May play an important role in spermatogenesis. T23785 ECNUMBER EC 2.7.12.1 T23785 SEQUENCE MDRSKRNSIAGFPPRVERLEEFEGGGGGEGNVSQVGRVWPSSYRALISAFSRLTRLDDFTCEKIGSGFFSEVFKVRHRASGQVMALKMNTLSSNRANMLKEVQLMNRLSHPNILRFMGVCVHQGQLHALTEYINSGNLEQLLDSNLHLPWTVRVKLAYDIAVGLSYLHFKGIFHRDLTSKNCLIKRDENGYSAVVADFGLAEKIPDVSMGSEKLAVVGSPFWMAPEVLRDEPYNEKADVFSYGIILCEIIARIQADPDYLPRTENFGLDYDAFQHMVGDCPPDFLQLTFNCCNMDPKLRPSFVEIGKTLEEILSRLQEEEQERDRKLQPTARGLLEKAPGVKRLSSLDDKIPHKSPCPRRTIWLSRSQSDIFSRKPPRTVSVLDPYYRPRDGAARTPKVNPFSARQDLMGGKIKFFDLPSKSVISLVFDLDAPGPGTMPLADWQEPLAPPIRRWRSLPGSPEFLHQEACPFVGREESLSDGPPPRLSSLKYRVKEIPPFRASALPAAQAHEAMDCSILQEENGFGSRPQGTSPCPAGASEEMEVEERPAGSTPATFSTSGIGLQTQGKQDG T23785 DRUGINFO D0F6NZ PMID22902653C30 Investigative T23785 DRUGINFO D0FC4Y PMID22902653C31 Investigative T23785 DRUGINFO D0S0XD PMID22902653C35 Investigative T13319 TARGETID T13319 T13319 FORMERID TTDI01496 T13319 UNIPROID PNKP_HUMAN T13319 TARGNAME Polynucleotide kinase-3'-phosphatase (PNKP) T13319 GENENAME PNKP T13319 TARGTYPE Literature-reported T13319 SYNONYMS DNA 5'-kinase/3'-phosphatase; Bifunctional polynucleotide phosphatase/kinase T13319 FUNCTION Plays a key role in the repair of DNA damage, functioning as part of both the non-homologous end-joining (NHEJ) and base excision repair (BER) pathways. Through its two catalytic activities, PNK ensures that DNA termini are compatible with extension and ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups on, the ribose sugar of the DNA backbone. T13319 PDBSTRUC 2W3O; 2BRF T13319 SEQUENCE MGEVEAPGRLWLESPPGGAPPIFLPSDGQALVLGRGPLTQVTDRKCSRTQVELVADPETRTVAVKQLGVNPSTTGTQELKPGLEGSLGVGDTLYLVNGLHPLTLRWEETRTPESQPDTPPGTPLVSQDEKRDAELPKKRMRKSNPGWENLEKLLVFTAAGVKPQGKVAGFDLDGTLITTRSGKVFPTGPSDWRILYPEIPRKLRELEAEGYKLVIFTNQMSIGRGKLPAEEFKAKVEAVVEKLGVPFQVLVATHAGLYRKPVTGMWDHLQEQANDGTPISIGDSIFVGDAAGRPANWAPGRKKKDFSCADRLFALNLGLPFATPEEFFLKWPAAGFELPAFDPRTVSRSGPLCLPESRALLSASPEVVVAVGFPGAGKSTFLKKHLVSAGYVHVNRDTLGSWQRCVTTCETALKQGKRVAIDNTNPDAASRARYVQCARAAGVPCRCFLFTATLEQARHNNRFREMTDSSHIPVSDMVMYGYRKQFEAPTLAEGFSAILEIPFRLWVEPRLGRLYCQFSEG T95817 TARGETID T95817 T95817 FORMERID TTDR00720 T95817 UNIPROID RIMP_STRPN T95817 TARGNAME Streptococcus UPF0090 protein SP0552 (Stre-coc rimP) T95817 GENENAME Stre-coc rimP T95817 TARGTYPE Literature-reported T95817 SYNONYMS rimP; SP14.3; Hypothetical protein SP14.3 T95817 FUNCTION Required for maturation of 30S ribosomal subunits. T95817 PDBSTRUC 1IB8 T95817 SEQUENCE MDAIATIVELVREVVEPVIEAPFELVDIEYGKIGSDMILSIFVDKPEGITLNDTADLTEIISPVLDTIKPDPFPEQYFLEITSPGLERPLKTKDAVAGAVGKYIHVGLYQAIDKQKVFEGTLLAFEEDELTMEYMDKTRKKTVQIPYSLVSKARLAVKL T78567 TARGETID T78567 T78567 FORMERID TTDNR00717 T78567 UNIPROID OSMR_HUMAN T78567 TARGNAME Oncostatin-M-specific receptor beta (OSMR) T78567 GENENAME OSMR T78567 TARGTYPE Literature-reported T78567 SYNONYMS Oncostatin-M-specific receptor subunit beta; OSMRB; Interleukin-31 receptor subunit beta; IL-31RB; IL-31R-beta; IL-31R subunit beta; IL-31 receptor subunit beta T78567 FUNCTION Binds IL31 to activate STAT3 and possibly STAT1 and STAT5. Capable of transducing OSM-specific signaling events. Associates with IL31RA to form the IL31 receptor. T78567 BIOCLASS Cytokine receptor T78567 SEQUENCE MALFAVFQTTFFLTLLSLRTYQSEVLAERLPLTPVSLKVSTNSTRQSLHLQWTVHNLPYHQELKMVFQIQISRIETSNVIWVGNYSTTVKWNQVLHWSWESELPLECATHFVRIKSLVDDAKFPEPNFWSNWSSWEEVSVQDSTGQDILFVFPKDKLVEEGTNVTICYVSRNIQNNVSCYLEGKQIHGEQLDPHVTAFNLNSVPFIRNKGTNIYCEASQGNVSEGMKGIVLFVSKVLEEPKDFSCETEDFKTLHCTWDPGTDTALGWSKQPSQSYTLFESFSGEKKLCTHKNWCNWQITQDSQETYNFTLIAENYLRKRSVNILFNLTHRVYLMNPFSVNFENVNATNAIMTWKVHSIRNNFTYLCQIELHGEGKMMQYNVSIKVNGEYFLSELEPATEYMARVRCADASHFWKWSEWSGQNFTTLEAAPSEAPDVWRIVSLEPGNHTVTLFWKPLSKLHANGKILFYNVVVENLDKPSSSELHSIPAPANSTKLILDRCSYQICVIANNSVGASPASVIVISADPENKEVEEERIAGTEGGFSLSWKPQPGDVIGYVVDWCDHTQDVLGDFQWKNVGPNTTSTVISTDAFRPGVRYDFRIYGLSTKRIACLLEKKTGYSQELAPSDNPHVLVDTLTSHSFTLSWKDYSTESQPGFIQGYHVYLKSKARQCHPRFEKAVLSDGSECCKYKIDNPEEKALIVDNLKPESFYEFFITPFTSAGEGPSATFTKVTTPDEHSSMLIHILLPMVFCVLLIMVMCYLKSQWIKETCYPDIPDPYKSSILSLIKFKENPHLIIMNVSDCIPDAIEVVSKPEGTKIQFLGTRKSLTETELTKPNYLYLLPTEKNHSGPGPCICFENLTYNQAASDSGSCGHVPVSPKAPSMLGLMTSPENVLKALEKNYMNSLGEIPAGETSLNYVSQLASPMFGDKDSLPTNPVEAPHCSEYKMQMAVSLRLALPPPTENSSLSSITLLDPGEHYC T78567 DRUGINFO D4XL6Z Vixarelimab Phase 1 T43524 TARGETID T43524 T43524 FORMERID TTDR01104 T43524 UNIPROID I12R2_HUMAN T43524 TARGNAME Interleukin 12 receptor beta-2 (IL12RB2) T43524 GENENAME IL12RB2 T43524 TARGTYPE Literature-reported T43524 SYNONYMS Interleukin-12 receptor subunit beta-2; IL-12RB2; IL-12R-beta2; IL-12R-beta-2; IL-12R subunit beta-2; IL-12R beta 2; IL-12 receptor subunit beta-2; IL-12 receptor beta-2 T43524 FUNCTION Receptor for interleukin-12. This subunit is the signaling component coupling to the JAK2/STAT4 pathway. Promotes the proliferation of T-cells as well as NK cells. Induces the promotion of T-cells towards the Th1 phenotype by strongly enhancing IFN-gamma production. T43524 BIOCLASS Cytokine receptor T43524 SEQUENCE MAHTFRGCSLAFMFIITWLLIKAKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRRINFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPESPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRCTLYWRDEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGSWSDWSESLRAQTPEEEPTGMLDVWYMKRHIDYSRQQISLFWKNLSVSEARGKILHYQVTLQELTGGKAMTQNITGHTSWTTVIPRTGNWAVAVSAANSKGSSLPTRINIMNLCEAGLLAPRQVSANSEGMDNILVTWQPPRKDPSAVQEYVVEWRELHPGGDTQVPLNWLRSRPYNVSALISENIKSYICYEIRVYALSGDQGGCSSILGNSKHKAPLSGPHINAITEEKGSILISWNSIPVQEQMGCLLHYRIYWKERDSNSQPQLCEIPYRVSQNSHPINSLQPRVTYVLWMTALTAAGESSHGNEREFCLQGKANWMAFVAPSICIAIIMVGIFSTHYFQQKVFVLLAALRPQWCSREIPDPANSTCAKKYPIAEEKTQLPLDRLLIDWPTPEDPEPLVISEVLHQVTPVFRHPPCSNWPQREKGIQGHQASEKDMMHSASSPPPPRALQAESRQLVDLYKVLESRGSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQHISLSVFPSSSLHPLTFSCGDKLTLDQLKMRCDSLML T14630 TARGETID T14630 T14630 FORMERID TTDI03462 T14630 UNIPROID PI51A_HUMAN T14630 TARGNAME PtdIns(4)P-5-kinase 1 alpha (PIP5K1A) T14630 GENENAME PIP5K1A T14630 TARGTYPE Literature-reported T14630 SYNONYMS Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha; Phosphatidylinositol 4-phosphate 5-kinase type I alpha; PIP5KIalpha; PIP5K1-alpha; 68 kDa type I phosphatidylinositol 4-phosphate 5-kinase alpha T14630 FUNCTION Catalyzes the phosphorylation of phosphatidylinositol 4-phosphate (PtdIns4P) to form phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). PtdIns(4,5)P2 is involved in a variety of cellular processes and is the substrate to form phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), another second messenger. The majority of PtdIns(4,5)P2 is thought to occur via type I phosphatidylinositol 4-phosphate 5-kinases given the abundance of PtdIns4P. Participates in a variety of cellular processes such as actin cytoskeleton organization, cell adhesion, migration and phagocytosis. Required for membrane ruffling formation, actin organization and focal adhesion formation during directional cell migration by controlling integrin-induced translocation of RAC1 to the plasma membrane. Together with PIP5K1C is required for phagocytosis, but they regulate different types of actin remodeling at sequential steps. Promotes particle ingestion by activating WAS that induces Arp2/3 dependent actin polymerization at the nascent phagocytic cup. Together with PIP5K1B is required after stimulation of G-protein coupled receptors for stable platelet adhesion. Plays a role during calcium-induced keratinocyte differentiation. Recruited to the plasma membrane by the E-cadherin/beta-catenin complex where it provides the substrate PtdIns(4,5)P2 for the production of PtdIns(3,4,5)P3, diacylglycerol and inositol 1,4,5-trisphosphate that mobilize internal calcium and drive keratinocyte differentiation. Together with PIP5K1C have a role during embryogenesis. Functions also in the nucleus where acts as an activator of TUT1 adenylyltransferase activity in nuclear speckles, thereby regulating mRNA polyadenylation of a select set of mRNAs. Positively regulates insulin-induced translocation of SLC2A4 to the cell membrane in adipocytes (By similarity). T14630 ECNUMBER EC 2.7.1.68 T14630 SEQUENCE MASASSGPSSSVGFSSFDPAVPSCTLSSAASGIKRPMASEVLEARQDSYISLVPYASGMPIKKIGHRSVDSSGETTYKKTTSSALKGAIQLGITHTVGSLSTKPERDVLMQDFYVVESIFFPSEGSNLTPAHHYNDFRFKTYAPVAFRYFRELFGIRPDDYLYSLCSEPLIELCSSGASGSLFYVSSDDEFIIKTVQHKEAEFLQKLLPGYYMNLNQNPRTLLPKFYGLYCVQAGGKNIRIVVMNNLLPRSVKMHIKYDLKGSTYKRRASQKEREKPLPTFKDLDFLQDIPDGLFLDADMYNALCKTLQRDCLVLQSFKIMDYSLLMSIHNIDHAQREPLSSETQYSVDTRRPAPQKALYSTAMESIQGEARRGGTMETDDHMGGIPARNSKGERLLLYIGIIDILQSYRFVKKLEHSWKALVHDGDTVSVHRPGFYAERFQRFMCNTVFKKIPLKPSPSKKFRSGSSFSRRAGSSGNSCITYQPSVSGEHKAQVTTKAEVEPGVHLGRPDVLPQTPPLEEISEGSPIPDPSFSPLVGETLQMLTTSTTLEKLEVAESEFTH T14630 DRUGINFO D0GG9W ISA-2011B Investigative T41988 TARGETID T41988 T41988 FORMERID TTDI02533 T41988 UNIPROID NKX31_HUMAN T41988 TARGNAME Homeobox protein Nkx-3.1 (NKX3-1) T41988 GENENAME NKX3-1 T41988 TARGTYPE Literature-reported T41988 SYNONYMS NKX3A; NKX31; NKX3.1; Homeobox protein Nkx3.1; Homeobox protein NK3 homolog A; Homeobox protein NK-3 homolog A T41988 FUNCTION Plays an important role in normal prostate development, regulating proliferation of glandular epithelium and in the formation of ducts in prostate. Acts as a tumor suppressor controlling prostate carcinogenesis, as shown by the ability to inhibit proliferation and invasion activities of PC-3 prostate cancer cells. Transcription factor, which binds preferentially the consensus sequence 5'-TAAGT[AG]-3' and can behave as a transcriptional repressor. T41988 PDBSTRUC 2L9R T41988 SEQUENCE MLRVPEPRPGEAKAEGAAPPTPSKPLTSFLIQDILRDGAQRQGGRTSSQRQRDPEPEPEPEPEGGRSRAGAQNDQLSTGPRAAPEEAETLAETEPERHLGSYLLDSENTSGALPRLPQTPKQPQKRSRAAFSHTQVIELERKFSHQKYLSAPERAHLAKNLKLTETQVKIWFQNRRYKTKRKQLSSELGDLEKHSSLPALKEEAFSRASLVSVYNSYPYYPYLYCVGSWSPAFW T46092 TARGETID T46092 T46092 FORMERID TTDI00196 T46092 UNIPROID FOXC2_HUMAN T46092 TARGNAME Forkhead box protein C2 (FOXC2) T46092 GENENAME FOXC2 T46092 TARGTYPE Literature-reported T46092 SYNONYMS Transcription factor FKH14; Mesenchyme fork head protein 1; MFH1 protein; Forkheadrelated protein FKHL14; FOXC2 T46092 FUNCTION Transcriptional activator. Might be involved in the formation of special mesenchymal tissues. T46092 PDBSTRUC 6AKP; 6AKO; 1D5V T46092 SEQUENCE MQARYSVSDPNALGVVPYLSEQNYYRAAGSYGGMASPMGVYSGHPEQYSAGMGRSYAPYHHHQPAAPKDLVKPPYSYIALITMAIQNAPEKKITLNGIYQFIMDRFPFYRENKQGWQNSIRHNLSLNECFVKVPRDDKKPGKGSYWTLDPDSYNMFENGSFLRRRRRFKKKDVSKEKEERAHLKEPPPAASKGAPATPHLADAPKEAEKKVVIKSEAASPALPVITKVETLSPESALQGSPRSAASTPAGSPDGSLPEHHAAAPNGLPGFSVENIMTLRTSPPGGELSPGAGRAGLVVPPLALPYAAAPPAAYGQPCAQGLEAGAAGGYQCSMRAMSLYTGAERPAHMCVPPALDEALSDHPSGPTSPLSALNLAAGQEGALAATGHHHQHHGHHHPQAPPPPPAPQPQPTPQPGAAAAQAASWYLNHSGDLNHLPGHTFAAQQQTFPNVREMFNSHRLGIENSTLGESQVSGNASCQLPYRSTPPLYRHAAPYSYDCTKY T31808 TARGETID T31808 T31808 FORMERID TTDI01387 T31808 UNIPROID ADAM2_HUMAN; ADAM7_HUMAN T31808 TARGNAME A disintegrin and metalloproteinase (ADAM) T31808 GENENAME ADAM2; ADAM7 T31808 TARGTYPE Literature-reported T31808 SYNONYMS Disintegrin and metalloproteinase domain-containing protein; ADAM T31808 FUNCTION Sperm surface membrane protein that may be involved in sperm-egg plasma membrane adhesion and fusion during fertilization. Could have a direct role in sperm-zona binding or migration of sperm from the uterus into the oviduct. Interactions with egg membrane could be mediated via binding between its disintegrin-like domain to one or more integrins receptors on the egg. This is a non catalytic metalloprotease-like protein. T31808 BIOCLASS Peptidase T31808 SEQUENCE MWRVLFLLSGLGGLRMDSNFDSLPVQITVPEKIRSIIKEGIESQASYKIVIEGKPYTVNLMQKNFLPHNFRVYSYSGTGIMKPLDQDFQNFCHYQGYIEGYPKSVVMVSTCTGLRGVLQFENVSYGIEPLESSVGFEHVIYQVKHKKADVSLYNEKDIESRDLSFKLQSVEPQQDFAKYIEMHVIVEKQLYNHMGSDTTVVAQKVFQLIGLTNAIFVSFNITIILSSLELWIDENKIATTGEANELLHTFLRWKTSYLVLRPHDVAFLLVYREKSNYVGATFQGKMCDANYAGGVVLHPRTISLESLAVILAQLLSLSMGITYDDINKCQCSGAVCIMNPEAIHFSGVKIFSNCSFEDFAHFISKQKSQCLHNQPRLDPFFKQQAVCGNAKLEAGEECDCGTEQDCALIGETCCDIATCRFKAGSNCAEGPCCENCLFMSKERMCRPSFEECDLPEYCNGSSASCPENHYVQTGHPCGLNQWICIDGVCMSGDKQCTDTFGKEVEFGPSECYSHLNSKTDVSGNCGISDSGYTQCEADNLQCGKLICKYVGKFLLQIPRATIIYANISGHLCIAVEFASDHADSQKMWIKDGTSCGSNKVCRNQRCVSSSYLGYDCTTDKCNDRGVCNNKKHCHCSASYLPPDCSVQSDLWPGGSIDSGNFPPVAIPARLPERRYIENIYHSKPMRWPFFLFIPFFIIFCVLIAIMVKVNFQRKKWRTEDYSSDEQPESESEPKG T98158 TARGETID T98158 T98158 FORMERID TTDR00021 T98158 UNIPROID GLPO_STRP1 T98158 TARGNAME Streptococcus Glycerol-3-phosphate oxidase (Stre-coc glpO) T98158 GENENAME Stre-coc glpO T98158 TARGTYPE Literature-reported T98158 SYNONYMS Glycerol-3-phosphate oxidase; Alpha-glycerophosphate oxidase T98158 FUNCTION A FAD-dependent -glycerophosphate oxidase and catalyzes the formation of dihydroxyacetonephosphate. Used in the kinetic assay to study gluconeogenesis in liver and in immobilization studies on pencil graphite (PG) electrode. T98158 BIOCLASS Short-chain dehydrogenases reductase T98158 SEQUENCE MEFSRETRRLALQKMQERDLDLLIIGGGITGAGVALQAAASGLDTGLIEMQDFAQGTSSRSTKLVHGGLRYLKQFDVEVVSDTVSERAVVQQIAPHIPKPDPMLLPVYDEPGSTFSMFRLKVAMDLYDLLAGVSNTPAANKVLTKEEVLKREPDLKQEGLLGGGVYLDFRNNDARLVIENIKRANRDGALIASHVKAEDFLLDDNGKIIGVKARDLLSDQEIIIKAKLVINTTGPWSDEIRQFSHKGQPIHQMRPTKGVHLVVDRQKLPVSQPVYVDTGLNDGRMVFVLPREEKTYFGTTDTDYTGDLEHPQVTQEDVDYLLGVVNNRFPNANVTIDDIESSWAGLRPLLSGNSASDYNGGNSGKVSDDSFDHLVDTVKAYINHEDSREAVEKAIKQVETSTSEKELDPSAVSRGSSFERDENGLFTLAGGKITDYRKMAEGALTGIIQILKEEFGKSFKLINSKTYPVSGGEINPANVDSEIEAYAQLGTLSGLSMDDARYLANLYGSNAPKVFALTRQLTAAEGLSLAETLSLHYAMDYEMALKPTDYFLRRTNHLLFMRDSLDALIDPVINEMAKHFEWSDQERVAQEDDLRRVIADNDLSALKGHQEG T35664 TARGETID T35664 T35664 FORMERID TTDI03437 T35664 UNIPROID P2Y13_HUMAN T35664 TARGNAME P2Y purinoceptor 13 (P2RY13) T35664 GENENAME P2RY13 T35664 TARGTYPE Literature-reported T35664 SYNONYMS P2Y13; GPR94; GPR86; G-protein coupled receptor 94; G-protein coupled receptor 86; FKSG77 T35664 FUNCTION Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system. T35664 PDBSTRUC 2B6U T35664 SEQUENCE MTAAIRRQRELSILPKVTLEAMNTTVMQGFNRSERCPRDTRIVQLVFPALYTVVFLTGILLNTLALWVFVHIPSSSTFIIYLKNTLVADLIMTLMLPFKILSDSHLAPWQLRAFVCRFSSVIFYETMYVGIVLLGLIAFDRFLKIIRPLRNIFLKKPVFAKTVSIFIWFFLFFISLPNTILSNKEATPSSVKKCASLKGPLGLKWHQMVNNICQFIFWTVFILMLVFYVVIAKKVYDSYRKSKSKDRKNNKKLEGKVFVVVAVFFVCFAPFHFARVPYTHSQTNNKTDCRLQNQLFIAKETTLFLAATNICMDPLIYIFLCKKFTEKLPCMQGRKTTASSQENHSSQTDNITLG T35664 DRUGINFO D08MPL MRS2211 Investigative T35664 DRUGINFO D08WNN [33P]2MeSADP Investigative T35664 DRUGINFO D0V7WT MRS2603 Investigative T35664 DRUGINFO D01GRB 2MeSAMP Investigative T35664 DRUGINFO D07QYU PPADS Investigative T35664 DRUGINFO D0BB0O 2MeSADP Investigative T35664 DRUGINFO D0S3WN ATPgammaS Investigative T35664 DRUGINFO D0U1OJ 2MeSATP Investigative T35664 DRUGINFO D05NWF adenosine diphosphate Investigative T02439 TARGETID T02439 T02439 FORMERID TTDI03188 T02439 UNIPROID E2AK1_HUMAN T02439 TARGNAME Eukaryotic translation initiation factor 2-alpha kinase 1 (EIF2AK1) T02439 GENENAME EIF2AK1 T02439 TARGTYPE Literature-reported T02439 SYNONYMS PRO1362; KIAA1369; Hemin-sensitive initiation factor 2-alpha kinase; Heme-regulated inhibitor; Heme-regulated eukaryotic initiation factor eIF-2-alpha kinase; HRI T02439 FUNCTION Inhibits protein synthesis at the translation initiation level, in response to various stress conditions, including oxidative stress, heme deficiency, osmotic shock and heat shock. Exerts its function through the phosphorylation of EIF2S1 at 'Ser-48' and 'Ser-51', thus preventing its recycling. Binds hemin forming a 1:1 complex through a cysteine thiolate and histidine nitrogenous coordination. This binding occurs with moderate affinity, allowing it to sense the heme concentration within the cell. Thanks to this unique heme-sensing capacity, plays a crucial role to shut off protein synthesis during acute heme-deficient conditions. In red blood cells (RBCs), controls hemoglobin synthesis ensuring a coordinated regulation of the synthesis of its heme and globin moieties. Thus plays an essential protective role for RBC survival in anemias of iron deficiency. Similarly, in hepatocytes, involved in heme-mediated translational control of CYP2B and CYP3A and possibly other hepatic P450 cytochromes. May also contain ER stress during acute heme-deficient conditions (By similarity). T02439 ECNUMBER EC 2.7.11.1 T02439 SEQUENCE MQGGNSGVRKREEEGDGAGAVAAPPAIDFPAEGPDPEYDESDVPAEIQVLKEPLQQPTFPFAVANQLLLVSLLEHLSHVHEPNPLRSRQVFKLLCQTFIKMGLLSSFTCSDEFSSLRLHHNRAITHLMRSAKERVRQDPCEDISRIQKIRSREVALEAQTSRYLNEFEELAILGKGGYGRVYKVRNKLDGQYYAIKKILIKGATKTVCMKVLREVKVLAGLQHPNIVGYHTAWIEHVHVIQPRADRAAIELPSLEVLSDQEEDREQCGVKNDESSSSSIIFAEPTPEKEKRFGESDTENQNNKSVKYTTNLVIRESGELESTLELQENGLAGLSASSIVEQQLPLRRNSHLEESFTSTEESSEENVNFLGQTEAQYHLMLHIQMQLCELSLWDWIVERNKRGREYVDESACPYVMANVATKIFQELVEGVFYIHNMGIVHRDLKPRNIFLHGPDQQVKIGDFGLACTDILQKNTDWTNRNGKRTPTHTSRVGTCLYASPEQLEGSEYDAKSDMYSLGVVLLELFQPFGTEMERAEVLTGLRTGQLPESLRKRCPVQAKYIQHLTRRNSSQRPSAIQLLQSELFQNSGNVNLTLQMKIIEQEKEIAELKKQLNLLSQDKGVRDDGKDGGVG T02439 DRUGINFO D02LIR PMID19854648C27 Investigative T81482 TARGETID T81482 T81482 FORMERID TTDI01353 T81482 UNIPROID E2AK1_HUMAN T81482 TARGNAME Heme-controlled repressor (HCR) T81482 GENENAME EIF2AK1 T81482 TARGTYPE Literature-reported T81482 SYNONYMS HCR T81482 FUNCTION Inhibits protein synthesis at the translation initiation level, in response to various stress conditions, including oxidative stress, heme deficiency, osmotic shock and heat shock. Exerts its function through the phosphorylation of EIF2S1 at 'Ser-48' and 'Ser-51', thus preventing its recycling. Binds hemin forming a 1:1 complex through a cysteine thiolate and histidine nitrogenous coordination. This binding occurs with moderate affinity, allowing it to sense the heme concentration within the cell. Thanks to this unique heme-sensing capacity, plays a crucial role to shut off protein synthesis during acute heme-deficient conditions. In red blood cells (RBCs), controls hemoglobin synthesis ensuring a coordinated regulation of the synthesis of its heme and globin moieties. Thus plays an essential protective role for RBC survival in anemias of iron deficiency. Similarly, in hepatocytes, involved in heme-mediated translational control of CYP2B and CYP3A and possibly other hepatic P450 cytochromes. May also contain ER stress during acute heme-deficient conditions (By similarity). T81482 ECNUMBER EC 2.7.11.1 T81482 SEQUENCE MQGGNSGVRKREEEGDGAGAVAAPPAIDFPAEGPDPEYDESDVPAEIQVLKEPLQQPTFPFAVANQLLLVSLLEHLSHVHEPNPLRSRQVFKLLCQTFIKMGLLSSFTCSDEFSSLRLHHNRAITHLMRSAKERVRQDPCEDISRIQKIRSREVALEAQTSRYLNEFEELAILGKGGYGRVYKVRNKLDGQYYAIKKILIKGATKTVCMKVLREVKVLAGLQHPNIVGYHTAWIEHVHVIQPRADRAAIELPSLEVLSDQEEDREQCGVKNDESSSSSIIFAEPTPEKEKRFGESDTENQNNKSVKYTTNLVIRESGELESTLELQENGLAGLSASSIVEQQLPLRRNSHLEESFTSTEESSEENVNFLGQTEAQYHLMLHIQMQLCELSLWDWIVERNKRGREYVDESACPYVMANVATKIFQELVEGVFYIHNMGIVHRDLKPRNIFLHGPDQQVKIGDFGLACTDILQKNTDWTNRNGKRTPTHTSRVGTCLYASPEQLEGSEYDAKSDMYSLGVVLLELFQPFGTEMERAEVLTGLRTGQLPESLRKRCPVQAKYIQHLTRRNSSQRPSAIQLLQSELFQNSGNVNLTLQMKIIEQEKEIAELKKQLNLLSQDKGVRDDGKDGGVG T94532 TARGETID T94532 T94532 FORMERID TTDR01150 T94532 UNIPROID REG4_HUMAN T94532 TARGNAME Regenerating islet-derived protein IV (REG4) T94532 GENENAME REG4 T94532 TARGTYPE Literature-reported T94532 SYNONYMS Regenerating islet-derived protein 4; Regenerating islet-derived family, member 4; Reg IV; RELP; REGIV; REG-like protein; REG-4; Gastrointestinal secretory protein GISP; Gastrointestinal secretory protein; GISP T94532 FUNCTION May be involved in inflammatory and metaplastic responses of the gastrointestinal epithelium. Calcium-independent lectin displaying mannose-binding specificity and able to maintain carbohydrate recognition activity in an acidic environment. T94532 PDBSTRUC 2KV3 T94532 SEQUENCE MASRSMRLLLLLSCLAKTGVLGDIIMRPSCAPGWFYHKSNCYGYFRKLRNWSDAELECQSYGNGAHLASILSLKEASTIAEYISGYQRSQPIWIGLHDPQKRQQWQWIDGAMYLYRSWSGKSMGGNKHCAEMSSNNNFLTWSSNECNKRQHFLCKYRP T15126 TARGETID T15126 T15126 FORMERID TTDI02223 T15126 UNIPROID NUF2_HUMAN T15126 TARGNAME Kinetochore protein Nuf2 (NUF2) T15126 GENENAME NUF2 T15126 TARGTYPE Literature-reported T15126 SYNONYMS hsNuf2; hNuf2R; hNuf2; NUF2R; Cell division cycleassociated protein 1; Cell division cycle-associated protein 1; CDCA1 T15126 FUNCTION Required for kinetochore integrity and the organization of stable microtubule binding sites in the outer plate of the kinetochore. The NDC80 complex synergistically enhances the affinity of the SKA1 complex for microtubules and may allow the NDC80 complex to track depolymerizing microtubules. Acts as a component of the essential kinetochore-associated NDC80 complex, which is required for chromosome segregation and spindle checkpoint activity. T15126 PDBSTRUC 3IZ0; 2VE7 T15126 SEQUENCE METLSFPRYNVAEIVIHIRNKILTGADGKNLTKNDLYPNPKPEVLHMIYMRALQIVYGIRLEHFYMMPVNSEVMYPHLMEGFLPFSNLVTHLDSFLPICRVNDFETADILCPKAKRTSRFLSGIINFIHFREACRETYMEFLWQYKSSADKMQQLNAAHQEALMKLERLDSVPVEEQEEFKQLSDGIQELQQSLNQDFHQKTIVLQEGNSQKKSNISEKTKRLNELKLSVVSLKEIQESLKTKIVDSPEKLKNYKEKMKDTVQKLKNARQEVVEKYEIYGDSVDCLPSCQLEVQLYQKKIQDLSDNREKLASILKESLNLEDQIESDESELKKLKTEENSFKRLMIVKKEKLATAQFKINKKHEDVKQYKRTVIEDCNKVQEKRGAVYERVTTINQEIQKIKLGIQQLKDAAEREKLKSQEIFLNLKTALEKYHDGIEKAAEDSYAKIDEKTAELKRKMFKMST T89793 TARGETID T89793 T89793 FORMERID TTDI00208 T89793 UNIPROID TBL1R_HUMAN T89793 TARGNAME Transducin beta-like 1X-related protein 1 (TBL1XR1) T89793 GENENAME TBL1XR1 T89793 TARGTYPE Literature-reported T89793 SYNONYMS Transducin betalike 1Xrelated protein 1; TBLR1; TBL1related protein 1; TBL1-related protein 1; Nuclear receptor corepressor/HDAC3 complexsubunit TBLR1; Nuclear receptor corepressor/HDAC3 complex subunit TBLR1; IRA1; Fboxlike/WD repeatcontaining protein TBL1XR1; F-box-like/WD repeat-containing protein TBL1XR1 T89793 FUNCTION Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of the N-Cor corepressor complex that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of N-Cor complex, thereby allowing cofactor exchange, and transcription activation. F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units. T89793 PDBSTRUC 4LG9 T89793 SEQUENCE MSISSDEVNFLVYRYLQESGFSHSAFTFGIESHISQSNINGALVPPAALISIIQKGLQYVEAEVSINEDGTLFDGRPIESLSLIDAVMPDVVQTRQQAYRDKLAQQQAAAAAAAAAAASQQGSAKNGENTANGEENGAHTIANNHTDMMEVDGDVEIPPNKAVVLRGHESEVFICAWNPVSDLLASGSGDSTARIWNLSENSTSGSTQLVLRHCIREGGQDVPSNKDVTSLDWNSEGTLLATGSYDGFARIWTKDGNLASTLGQHKGPIFALKWNKKGNFILSAGVDKTTIIWDAHTGEAKQQFPFHSAPALDVDWQSNNTFASCSTDMCIHVCKLGQDRPIKTFQGHTNEVNAIKWDPTGNLLASCSDDMTLKIWSMKQDNCVHDLQAHNKEIYTIKWSPTGPGTNNPNANLMLASASFDSTVRLWDVDRGICIHTLTKHQEPVYSVAFSPDGRYLASGSFDKCVHIWNTQTGALVHSYRGTGGIFEVCWNAAGDKVGASASDGSVCVLDLRK T95661 TARGETID T95661 T95661 UNIPROID TM6S2_HUMAN T95661 TARGNAME Transmembrane 6 superfamily member 2 (TM6SF2) T95661 GENENAME TM6SF2 T95661 TARGTYPE Literature-reported T95661 SYNONYMS KIAA1926 T95661 FUNCTION Regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content (PubMed:24531328, PubMed:24927523). May function as sterol isomerase (PubMed:25566323). T95661 BIOCLASS TM6SF family T95661 SEQUENCE MDIPPLAGKIAALSLSALPVSYALNHVSALSHPLWVALMSALILGLLFVAVYSLSHGEVSYDPLYAVFAVFAFTSVVDLIIALQEDSYVVGFMEFYTKEGEPYLRTAHGVFICYWDGTVHYLLYLAMAGAICRRKRYRNFGLYWLGSFAMSILVFLTGNILGKYSSEIRPAFFLTIPYLLVPCWAGMKVFSQPRALTRCTANMVQEEQRKGLLQRPADLALVIYLILAGFFTLFRGLVVLDCPTDACFVYIYQYEPYLRDPVAYPKVQMLMYMFYVLPFCGLAAYALTFPGCSWLPDWALVFAGGIGQAQFSHMGASMHLRTPFTYRVPEDTWGCFFVCNLLYALGPHLLAYRCLQWPAFFHQPPPSDPLALHKKQH T86910 TARGETID T86910 T86910 FORMERID TTDI03404 T86910 UNIPROID NLRP1_HUMAN T86910 TARGNAME NLR pyrin domain containing 1 (NLRP1) T86910 GENENAME NLRP1 T86910 TARGTYPE Literature-reported T86910 SYNONYMS Nucleotide-binding domain and caspase recruitment domain; NACHT, LRR and PYD domains-containing protein 1; NAC; KIAA0926; Death effector filament-forming ced-4-like apoptosis protein; DEFCAP; Caspase recruitment domain-containing protein 7; CARD7 T86910 FUNCTION As the sensor component of the NLRP1 inflammasome, plays a crucial role in innate immunity and inflammation. In response to pathogens and other damage-associated signals, initiates the formation of the inflammasome polymeric complex, made of NLRP1, CASP1, and possibly PYCARD. Recruitment of proCASP1 to the inflammasome promotes its activation and CASP1-catalyzed IL1B and IL18 maturation and secretion in the extracellular milieu. Activation of NLRP1 inflammasome is also required for HMGB1 secretion. The active cytokines and HMGB1 stimulate inflammatory responses. Inflammasomes can also induce pyroptosis, an inflammatory form of programmed cell death. May be activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, in a NOD2-dependent manner. Contrary to its mouse ortholog, not activated by Bacillus anthracis lethal toxin. It is unclear whether isoform 2 is involved in inflammasome formation. It is not cleaved within the FIIND domain, does not assemble into specks, nor promote IL1B release. However, in an vitro cell-free system, it has been shown to be activated by MDP. Binds ATP. T86910 PDBSTRUC 5Y3S; 4IM6; 4IFP; 3KAT; 1PN5 T86910 SEQUENCE MAGGAWGRLACYLEFLKKEELKEFQLLLANKAHSRSSSGETPAQPEKTSGMEVASYLVAQYGEQRAWDLALHTWEQMGLRSLCAQAQEGAGHSPSFPYSPSEPHLGSPSQPTSTAVLMPWIHELPAGCTQGSERRVLRQLPDTSGRRWREISASLLYQALPSSPDHESPSQESPNAPTSTAVLGSWGSPPQPSLAPREQEAPGTQWPLDETSGIYYTEIREREREKSEKGRPPWAAVVGTPPQAHTSLQPHHHPWEPSVRESLCSTWPWKNEDFNQKFTQLLLLQRPHPRSQDPLVKRSWPDYVEENRGHLIEIRDLFGPGLDTQEPRIVILQGAAGIGKSTLARQVKEAWGRGQLYGDRFQHVFYFSCRELAQSKVVSLAELIGKDGTATPAPIRQILSRPERLLFILDGVDEPGWVLQEPSSELCLHWSQPQPADALLGSLLGKTILPEASFLITARTTALQNLIPSLEQARWVEVLGFSESSRKEYFYRYFTDERQAIRAFRLVKSNKELWALCLVPWVSWLACTCLMQQMKRKEKLTLTSKTTTTLCLHYLAQALQAQPLGPQLRDLCSLAAEGIWQKKTLFSPDDLRKHGLDGAIISTFLKMGILQEHPIPLSYSFIHLCFQEFFAAMSYVLEDEKGRGKHSNCIIDLEKTLEAYGIHGLFGASTTRFLLGLLSDEGEREMENIFHCRLSQGRNLMQWVPSLQLLLQPHSLESLHCLYETRNKTFLTQVMAHFEEMGMCVETDMELLVCTFCIKFSRHVKKLQLIEGRQHRSTWSPTMVVLFRWVPVTDAYWQILFSVLKVTRNLKELDLSGNSLSHSAVKSLCKTLRRPRCLLETLRLAGCGLTAEDCKDLAFGLRANQTLTELDLSFNVLTDAGAKHLCQRLRQPSCKLQRLQLVSCGLTSDCCQDLASVLSASPSLKELDLQQNNLDDVGVRLLCEGLRHPACKLIRLGLDQTTLSDEMRQELRALEQEKPQLLIFSRRKPSVMTPTEGLDTGEMSNSTSSLKRQRLGSERAASHVAQANLKLLDVSKIFPIAEIAEESSPEVVPVELLCVPSPASQGDLHTKPLGTDDDFWGPTGPVATEVVDKEKNLYRVHFPVAGSYRWPNTGLCFVMREAVTVEIEFCVWDQFLGEINPQHSWMVAGPLLDIKAEPGAVEAVHLPHFVALQGGHVDTSLFQMAHFKEEGMLLEKPARVELHHIVLENPSFSPLGVLLKMIHNALRFIPVTSVVLLYHRVHPEEVTFHLYLIPSDCSIRKAIDDLEMKFQFVRIHKPPPLTPLYMGCRYTVSGSGSGMLEILPKELELCYRSPGEDQLFSEFYVGHLGSGIRLQVKDKKDETLVWEALVKPGDLMPATTLIPPARIAVPSPLDAPQLLHFVDQYREQLIARVTSVEVVLDKLHGQVLSQEQYERVLAENTRPSQMRKLFSLSQSWDRKCKDGLYQALKETHPHLIMELWEKGSKKGLLPLSS T86910 DRUGINFO D05UGC muramyl dipeptide Investigative T90464 TARGETID T90464 T90464 FORMERID TTDI02149 T90464 UNIPROID PDGFD_HUMAN T90464 TARGNAME Platelet-derived growth factor D (PDGFD) T90464 GENENAME PDGFD T90464 TARGTYPE Literature-reported T90464 SYNONYMS Spinal cordderived growth factor B; SCDGFB; Plateletderived growth factor D, receptorbinding form; PDGFD receptorbinding form; PDGFD latent form; PDGFD; Irisexpressed growth factor T90464 FUNCTION Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin. Plays an important role in wound healing. Induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Can initiate events that lead to a mesangial proliferative glomerulonephritis, including influx of monocytes and macrophages and production of extracellular matrix. T90464 BIOCLASS Growth factor T90464 SEQUENCE MHRLIFVYTLICANFCSCRDTSATPQSASIKALRNANLRRDESNHLTDLYRRDETIQVKGNGYVQSPRFPNSYPRNLLLTWRLHSQENTRIQLVFDNQFGLEEAENDICRYDFVEVEDISETSTIIRGRWCGHKEVPPRIKSRTNQIKITFKSDDYFVAKPGFKIYYSLLEDFQPAAASETNWESVTSSISGVSYNSPSVTDPTLIADALDKKIAEFDTVEDLLKYFNPESWQEDLENMYLDTPRYRGRSYHDRKSKVDLDRLNDDAKRYSCTPRNYSVNIREELKLANVVFFPRCLLVQRCGGNCGCGTVNWRSCTCNSGKTVKKYHEVLQFEPGHIKRRGRAKTMALVDIQLDHHERCDCICSSRPPR T13039 TARGETID T13039 T13039 FORMERID TTDI00082 T13039 UNIPROID IF5A2_HUMAN T13039 TARGNAME Eukaryotic initiation factor 5A2 (EIF5A2) T13039 GENENAME EIF5A2 T13039 TARGTYPE Literature-reported T13039 SYNONYMS eIF5A2; eIF-5A2; eIF-5A-2; Eukaryotic translation initiation factor 5A-2; Eukaryotic initiation factor 5A isoform 2 T13039 FUNCTION Has an important function at the level of mRNA turnover, probably acting downstream of decapping. Involved in actin dynamics and cell cycle progression, mRNA decay and probably in a pathway involved in stress response and maintenance of cell wall integrity. Functions as a regulator of apoptosis. Mediates effects of polyamines on neuronal process extension and survival. May play an important role in brain development and function, and in skeletal muscle stem cell differentiation. mRNA-binding protein involved in translation elongation. T13039 BIOCLASS Eukaryotic nuclear pore complex T13039 SEQUENCE MADEIDFTTGDAGASSTYPMQCSALRKNGFVVLKGRPCKIVEMSTSKTGKHGHAKVHLVGIDIFTGKKYEDICPSTHNMDVPNIKRNDYQLICIQDGYLSLLTETGEVREDLKLPEGELGKEIEGKYNAGEDVQVSVMCAMSEEYAVAIKPCK T55005 TARGETID T55005 T55005 FORMERID TTDI03414 T55005 UNIPROID NUAK2_HUMAN T55005 TARGNAME NUAK family SNF1-like kinase 2 (NUAK2) T55005 GENENAME NUAK2 T55005 TARGTYPE Literature-reported T55005 SYNONYMS SNF1/AMP kinase-related kinase; SNARK; Omphalocele kinase 2; OMPHK2 T55005 FUNCTION Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells. Able to phosphorylate 'Ser-464' of LATS1. T55005 ECNUMBER EC 2.7.11.1 T55005 SEQUENCE MESLVFARRSGPTPSAAELARPLAEGLIKSPKPLMKKQAVKRHHHKHNLRHRYEFLETLGKGTYGKVKKARESSGRLVAIKSIRKDKIKDEQDLMHIRREIEIMSSLNHPHIIAIHEVFENSSKIVIVMEYASRGDLYDYISERQQLSEREARHFFRQIVSAVHYCHQNRVVHRDLKLENILLDANGNIKIADFGLSNLYHQGKFLQTFCGSPLYASPEIVNGKPYTGPEVDSWSLGVLLYILVHGTMPFDGHDHKILVKQISNGAYREPPKPSDACGLIRWLLMVNPTRRATLEDVASHWWVNWGYATRVGEQEAPHEGGHPGSDSARASMADWLRRSSRPLLENGAKVCSFFKQHAPGGGSTTPGLERQHSLKKSRKENDMAQSLHSDTADDTAHRPGKSNLKLPKGILKKKVSASAEGVQEDPPELSPIPASPGQAAPLLPKKGILKKPRQRESGYYSSPEPSESGELLDAGDVFVSGDPKEQKPPQASGLLLHRKGILKLNGKFSQTALELAAPTTFGSLDELAPPRPLARASRPSGAVSEDSILSSESFDQLDLPERLPEPPLRGCVSVDNLTGLEEPPSEGPGSCLRRWRQDPLGDSCFSLTDCQEVTATYRQALRVCSKLT T55005 DRUGINFO D00HLW WZ4003 Investigative T85823 TARGETID T85823 T85823 FORMERID TTDR00390 T85823 UNIPROID SVIL_HUMAN T85823 TARGNAME Supervillin (SVIL) T85823 GENENAME SVIL T85823 TARGTYPE Literature-reported T85823 SYNONYMS p205/p250; Archvillin T85823 FUNCTION Isoform 1: Forms a high-affinity link between the actin cytoskeleton and the membrane. Is among the first costameric proteins to assemble during myogenesis and it contributes to myogenic membrane structure and differentiation. Appears to be involved in myosin II assembly. May modulate myosin II regulation through MLCK during cell spreading, an initial step in cell migration. May play a role in invadopodial function. T85823 PDBSTRUC 2K6N; 2K6M T85823 SEQUENCE MKRKERIARRLEGIENDTQPILLQSCTGLVTHRLLEEDTPRYMRASDPASPHIGRSNEEEETSDSSLEKQTRSKYCTETSGVHGDSPYGSGTMDTHSLESKAERIARYKAERRRQLAEKYGLTLDPEADSEYLSRYTKSRKEPDAVEKRGGKSDKQEESSRDASSLYPGTETMGLRTCAGESKDYALHVGDGSSDPEVLLNIENQRRGQELSATRQAHDLSPAAESSSTFSFSGRDSSFTEVPRSPKHAHSSSLQQAASRSPSFGDPQLSPEARPSTGKPKHEWFLQKDSEGDTPSLINWPSRVKVREKLVKEESARNSPELASESVTQRRHQPAPVHYVSFQSEHSAFDRVPSKAAGSTRQPIRGYVQPADTGHTAKLVTPETPENASECSWVASATQNVPKPPSLTVLEGDGRDSPVLHVCESKAEEEEGEGEGEEKEEDVCFTEALEQSKKTLLALEGDGLVRSPEDPSRNEDFGKPAVSTVTLEHQKELENVAQPPQAPHQPTERTGRSEMVLYIQSEPVSQDAKPTGHNREASKKRKVRTRSLSDFTGPPQLQALKYKDPASRRELELPSSKTEGPYGEISMLDTKVSVAQLRSAFLASANACRRPELKSRVERSAEGPGLPTGVERERGSRKPRRYFSPGESRKTSERFRTQPITSAERKESDRCTSHSETPTVDDEEKVDERAKLSVAAKRLLFREMEKSFDEQNVPKRRSRNTAVEQRLRRLQDRSLTQPITTEEVVIAATEPIPASCSGGTHPVMARLPSPTVARSAVQPARLQASAHQKALAKDQTNEGKELAEQGEPDSSTLSLAEKLALFNKLSQPVSKAISTRNRIDTRQRRMNARYQTQPVTLGEVEQVQSGKLIPFSPAVNTSVSTVASTVAPMYAGDLRTKPPLDHNASATDYKFSSSIENSDSPVRSILKSQAWQPLVEGSENKGMLREYGETESKRALTGRDSGMEKYGSFEEAEASYPILNRAREGDSHKESKYAVPRRGSLERANPPITHLGDEPKEFSMAKMNAQGNLDLRDRLPFEEKVEVENVMKRKFSLRAAEFGEPTSEQTGTAAGKTIAQTTAPVSWKPQDSSEQPQEKLCKNPCAMFAAGEIKTPTGEGLLDSPSKTMSIKERLALLKKSGEEDWRNRLSRRQEGGKAPASSLHTQEAGRSLIKKRVTESRESQMTIEERKQLITVREEAWKTRGRGAANDSTQFTVAGRMVKKGLASPTAITPVASPICGKTRGTTPVSKPLEDIEARPDMQLESDLKLDRLETFLRRLNNKVGGMHETVLTVTGKSVKEVMKPDDDETFAKFYRSVDYNMPRSPVEMDEDFDVIFDPYAPKLTSSVAEHKRAVRPKRRVQASKNPLKMLAAREDLLQEYTEQRLNVAFMESKRMKVEKMSSNSNFSEVTLAGLASKENFSNVSLRSVNLTEQNSNNSAVPYKRLMLLQIKGRRHVQTRLVEPRASALNSGDCFLLLSPHCCFLWVGEFANVIEKAKASELATLIQTKRELGCRATYIQTIEEGINTHTHAAKDFWKLLGGQTSYQSAGDPKEDELYEAAIIETNCIYRLMDDKLVPDDDYWGKIPKCSLLQPKEVLVFDFGSEVYVWHGKEVTLAQRKIAFQLAKHLWNGTFDYENCDINPLDPGECNPLIPRKGQGRPDWAIFGRLTEHNETILFKEKFLDWTELKRSNEKNPGELAQHKEDPRTDVKAYDVTRMVSMPQTTAGTILDGVNVGRGYGLVEGHDRRQFEITSVSVDVWHILEFDYSRLPKQSIGQFHEGDAYVVKWKFMVSTAVGSRQKGEHSVRAAGKEKCVYFFWQGRHSTVSEKGTSALMTVELDEERGAQVQVLQGKEPPCFLQCFQGGMVVHSGRREEEEENVQSEWRLYCVRGEVPVEGNLLEVACHCSSLRSRTSMVVLNVNKALIYLWHGCKAQAHTKEVGRTAANKIKEQCPLEAGLHSSSKVTIHECDEGSEPLGFWDALGRRDRKAYDCMLQDPGSFNFAPRLFILSSSSGDFAATEFVYPARAPSVVSSMPFLQEDLYSAPQPALFLVDNHHEVYLWQGWWPIENKITGSARIRWASDRKSAMETVLQYCKGKNLKKPAPKSYLIHAGLEPLTFTNMFPSWEHREDIAEITEMDTEVSNQITLVEDVLAKLCKTIYPLADLLARPLPEGVDPLKLEIYLTDEDFEFALDMTRDEYNALPAWKQVNLKKAKGLF T31060 TARGETID T31060 T31060 FORMERID TTDR00832 T31060 UNIPROID O51E2_HUMAN T31060 TARGNAME Olfactory receptor 51E2 (OR51E2) T31060 GENENAME OR51E2 T31060 TARGTYPE Literature-reported T31060 SYNONYMS Prostate specific G-protein coupled receptor; PSGR; OR51E2; HPRAJ T31060 FUNCTION Probable G protein-coupled receptor that is activated bythe short chain fatty acids (SCFA) acetate and propionate. In response to SCFA, may positively regulate renin secretion and increase blood pressure (PubMed:23401498). May also be activated by steroidhormones and regulate cell proliferation (PubMed:19389702). May also function as an olfactory receptor being activated by beta-ionone (PubMed:19389702). T31060 BIOCLASS GPCR rhodopsin T31060 SEQUENCE MSSCNFTHATFVLIGIPGLEKAHFWVGFPLLSMYVVAMFGNCIVVFIVRTERSLHAPMYLFLCMLAAIDLALSTSTMPKILALFWFDSREISFEACLTQMFFIHALSAIESTILLAMAFDRYVAICHPLRHAAVLNNTVTAQIGIVAVVRGSLFFFPLPLLIKRLAFCHSNVLSHSYCVHQDVMKLAYADTLPNVVYGLTAILLVMGVDVMFISLSYFLIIRTVLQLPSKSERAKAFGTCVSHIGVVLAFYVPLIGLSVVHRFGNSLHPIVRVVMGDIYLLLPPVINPIIYGAKTKQIRTRVLAMFKISCDKDLQAVGGK T03023 TARGETID T03023 T03023 FORMERID TTDI03559 T03023 UNIPROID SRMS_HUMAN T03023 TARGNAME Tyrosine-protein kinase Srms (SRMS) T03023 GENENAME SRMS T03023 TARGTYPE Literature-reported T03023 SYNONYMS C20orf148 T03023 FUNCTION Non-receptor tyrosine-protein kinase which phosphorylates DOK1 on tyrosine residues. Also phosphorylates KHDRBS1/SAM68 and VIM on tyrosine residues. Phosphorylation of KHDRBS1 is EGF-dependent. T03023 ECNUMBER EC 2.7.10.2 T03023 SEQUENCE MEPFLRRRLAFLSFFWDKIWPAGGEPDHGTPGSLDPNTDPVPTLPAEPCSPFPQLFLALYDFTARCGGELSVRRGDRLCALEEGGGYIFARRLSGQPSAGLVPITHVAKASPETLSDQPWYFSGVSRTQAQQLLLSPPNEPGAFLIRPSESSLGGYSLSVRAQAKVCHYRVSMAADGSLYLQKGRLFPGLEELLTYYKANWKLIQNPLLQPCMPQKAPRQDVWERPHSEFALGRKLGEGYFGEVWEGLWLGSLPVAIKVIKSANMKLTDLAKEIQTLKGLRHERLIRLHAVCSGGEPVYIVTELMRKGNLQAFLGTPEGRALRLPPLLGFACQVAEGMSYLEEQRVVHRDLAARNVLVDDGLACKVADFGLARLLKDDIYSPSSSSKIPVKWTAPEAANYRVFSQKSDVWSFGVLLHEVFTYGQCPYEGMTNHETLQQIMRGYRLPRPAACPAEVYVLMLECWRSSPEERPSFATLREKLHAIHRCHP T03023 DRUGINFO D09ADW PMID21802293C66 Investigative T47731 TARGETID T47731 T47731 FORMERID TTDI00046 T47731 UNIPROID CHM4B_HUMAN T47731 TARGNAME Charged multivesicular body protein 4B (CHMP4B) T47731 GENENAME CHMP4B T47731 TARGTYPE Literature-reported T47731 SYNONYMS hVps322; hVps32-2; hSnf72; hSnf7-2; Vps322; Vps32-2; Vacuolar protein sortingassociated protein 322; Vacuolar protein sorting-associated protein 32-2; SNF72; SNF7-2; SNF7 homolog associated with Alix 1; SHAX1; Chromatinmodifying protein 4b; Chromatin-modifying protein 4b; CHMP4b; C20orf178 T47731 FUNCTION MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis. Together with SPAST, the ESCRT-III complex promotes nuclear envelope sealing and mitotic spindle disassembly during late anaphase. Plays a role in the endosomal sorting pathway. ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. When overexpressed, membrane-assembled circular arrays of CHMP4B filaments can promote or stabilize negative curvature and outward budding. CHMP4A/B/C are required for the exosomal release of SDCBP, CD63 and syndecan. Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. T47731 PDBSTRUC 5MK2; 4ABM; 3UM3; 3C3Q T47731 SEQUENCE MSVFGKLFGAGGGKAGKGGPTPQEAIQRLRDTEEMLSKKQEFLEKKIEQELTAAKKHGTKNKRAALQALKRKKRYEKQLAQIDGTLSTIEFQREALENANTNTEVLKNMGYAAKAMKAAHDNMDIDKVDELMQDIADQQELAEEISTAISKPVGFGEEFDEDELMAELEELEQEELDKNLLEISGPETVPLPNVPSIALPSKPAKKKEEEDDDMKELENWAGSM T57818 TARGETID T57818 T57818 FORMERID TTDI03043 T57818 UNIPROID AMPB_HUMAN T57818 TARGNAME Arginyl aminopeptidase (RNPEP) T57818 GENENAME RNPEP T57818 TARGTYPE Literature-reported T57818 SYNONYMS Arginine aminopeptidase; Aminopeptidase B; APB; AP-B T57818 FUNCTION Exopeptidase which selectively removes arginine and/or lysine residues from the N-terminus of several peptide substrates including Arg(0)-Leu-enkephalin, Arg(0)-Met-enkephalin and Arg(-1)-Lys(0)-somatostatin-14. Can hydrolyze leukotriene A4 (LTA-4) into leukotriene B4 (LTB-4) (By similarity). T57818 ECNUMBER EC 3.4.11.6 T57818 SEQUENCE MASGEHSPGSGAARRPLHSAQAVDVASASNFRAFELLHLHLDLRAEFGPPGPGAGSRGLSGTAVLDLRCLEPEGAAELRLDSHPCLEVTAAALRRERPGSEEPPAEPVSFYTQPFSHYGQALCVSFPQPCRAAERLQVLLTYRVGEGPGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPCFDTPAVKYKYSALIEVPDGFTAVMSASTWEKRGPNKFFFQMCQPIPSYLIALAIGDLVSAEVGPRSRVWAEPCLIDAAKEEYNGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNKLRVKIEPGVDPDDTYNETPYEKGFCFVSYLAHLVGDQDQFDSFLKAYVHEFKFRSILADDFLDFYLEYFPELKKKRVDIIPGFEFDRWLNTPGWPPYLPDLSPGDSLMKPAEELAQLWAAEELDMKAIEAVAISPWKTYQLVYFLDKILQKSPLPPGNVKKLGDTYPSISNARNAELRLRWGQIVLKNDHQEDFWKVKEFLHNQGKQKYTLPLYHAMMGGSEVAQTLAKETFASTASQLHSNVVNYVQQIVAPKGS T57818 DRUGINFO D02BLC Lys-thiol Investigative T40698 TARGETID T40698 T40698 FORMERID TTDI00130 T40698 UNIPROID FA83D_HUMAN T40698 TARGNAME Spindle protein CHICA (FAM83D) T40698 GENENAME FAM83D T40698 TARGTYPE Literature-reported T40698 SYNONYMS Protein FAM83D; FAM83D T40698 FUNCTION Probable proto-oncogene that regulates cell proliferation, growth, migration and epithelial to mesenchymal transition. Through the degradation of FBXW7, may act indirectly on the expression and downstream signaling of MTOR, JUN and MYC. May play also a role in cell proliferation through activation of the ERK1/ERK2 signaling cascade. May also be important for proper chromosome congression and alignment during mitosis through its interaction with KIF22. T40698 PDBSTRUC 5E0M; 5E0L T40698 SEQUENCE MALLSEGLDEVPAACLSPCGPPNPTELFSESRRLALEELVAGGPEAFAAFLRRERLARFLNPDEVHAILRAAERPGEEGAAAAAAAEDSFGSSHDCSSGTYFPEQSDLEPPLLELGWPAFYQGAYRGATRVETHFQPRGAGEGGPYGCKDALRQQLRSAREVIAVVMDVFTDIDIFRDLQEICRKQGVAVYILLDQALLSQFLDMCMDLKVHPEQEKLMTVRTITGNIYYARSGTKIIGKVHEKFTLIDGIRVATGSYSFTWTDGKLNSSNLVILSGQVVEHFDLEFRILYAQSKPISPKLLSHFQSSNKFDHLTNRKPQSKELTLGNLLRMRLARLSSTPRKADLDPEMPAEGKAERKPHDCESSTVSEEDYFSSHRDELQSRKAIDAATQTEPGEEMPGLSVSEVGTQTSITTACAGTQTAVITRIASSQTTIWSRSTTTQTDMDENILFPRGTQSTEGSPVSKMSVSRSSSLKSSSSVSSQGSVASSTGSPASIRTTDFHNPGYPKYLGTPHLELYLSDSLRNLNKERQFHFAGIRSRLNHMLAMLSRRTLFTENHLGLHSGNFSRVNLLAVRDVALYPSYQ T49593 TARGETID T49593 T49593 FORMERID TTDI01397 T49593 UNIPROID LN28A_HUMAN T49593 TARGNAME Zinc finger CCHC domain-containing 1 (Lin-28A) T49593 GENENAME LIN28A T49593 TARGTYPE Literature-reported T49593 SYNONYMS Zinc finger CCHC domain-containing protein 1; ZCCHC1; Protein lin-28 homolog A; Lin-28A; LIN28; CSDD1 T49593 FUNCTION RNA-binding protein that inhibits processing of pre-let-7 miRNAs and regulates translation of mRNAs that control developmental timing, pluripotency and metabolism. Seems to recognize a common structural G-quartet (G4) feature in its miRNA and mRNA targets (Probable). 'Translational enhancer' that drives specific mRNAs to polysomes and increases the efficiency of protein synthesis. Its association with the translational machinery and target mRNAs results in an increased number of initiation events per molecule of mRNA and, indirectly, in mRNA stabilization. Binds IGF2 mRNA, MYOD1 mRNA, ARBP/36B4 ribosomal protein mRNA and its own mRNA. Essential for skeletal muscle differentiation program through the translational up-regulation of IGF2 expression. Suppressor of microRNA (miRNA) biogenesis, including that of let-7, miR107, miR-143 and miR-200c. Specifically binds the miRNA precursors (pre-miRNAs), recognizing an 5'-GGAG-3' motif found in pre-miRNA terminal loop, and recruits TUT4 AND tut7 uridylyltransferaseS. This results in the terminal uridylation of target pre-miRNAs. Uridylated pre-miRNAs fail to be processed by Dicer and undergo degradation. The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state by preventing let-7-mediated differentiation of embryonic stem cells. Localized to the periendoplasmic reticulum area, binds to a large number of spliced mRNAs and inhibits the translation of mRNAs destined for the ER, reducing the synthesis of transmembrane proteins, ER or Golgi lumen proteins, and secretory proteins. Binds to and enhances the translation of mRNAs for several metabolic enzymes, such as PFKP, PDHA1 or SDHA, increasing glycolysis and oxidative phosphorylation. Which, with the let-7 repression may enhance tissue repair in adult tissue (By similarity). T49593 PDBSTRUC 5UDZ; 2LI8; 2CQF T49593 SEQUENCE MGSVSNQQFAGGCAKAAEEAPEEAPEDAARAADEPQLLHGAGICKWFNVRMGFGFLSMTARAGVALDPPVDVFVHQSKLHMEGFRSLKEGEAVEFTFKKSAKGLESIRVTGPGGVFCIGSERRPKGKSMQKRRSKGDRCYNCGGLDHHAKECKLPPQPKKCHFCQSISHMVASCPLKAQQGPSAQGKPTYFREEEEEIHSPTLLPEAQN T55667 TARGETID T55667 T55667 FORMERID TTDI00084 T55667 UNIPROID PKHA5_HUMAN T55667 TARGNAME Pleckstrin homology domain-containing A5 (PLEKHA5) T55667 GENENAME PLEKHA5 T55667 TARGTYPE Literature-reported T55667 SYNONYMS Pleckstrin homology domain-containing family A member 5; Phosphoinositol 3-phosphate-binding protein 2; PH domain-containing family A member 5; PEPP2; PEPP-2; KIAA1686 T55667 FUNCTION Involved in the mechanism of CNS homing of metastatic disease. Functions as a regulator of brain metastasis in melanoma. T55667 PDBSTRUC 2DKP T55667 SEQUENCE MAADLNLEWISLPRSWTYGITRGGRVFFINEEAKSTTWLHPVTGEAVVTGHRRQSTDLPTGWEEAYTFEGARYYINHNERKVTCKHPVTGQPSQDNCIFVVNEQTVATMTSEEKKERPISMINEASNYNVTSDYAVHPMSPVGRTSRASKKVHNFGKRSNSIKRNPNAPVVRRGWLYKQDSTGMKLWKKRWFVLSDLCLFYYRDEKEEGILGSILLPSFQIALLTSEDHINRKYAFKAAHPNMRTYYFCTDTGKEMELWMKAMLDAALVQTEPVKRVDKITSENAPTKETNNIPNHRVLIKPEIQNNQKNKEMSKIEEKKALEAEKYGFQKDGQDRPLTKINSVKLNSLPSEYESGSACPAQTVHYRPINLSSSENKIVNVSLADLRGGNRPNTGPLYTEADRVIQRTNSMQQLEQWIKIQKGRGHEEETRGVISYQTLPRNMPSHRAQIMARYPEGYRTLPRNSKTRPESICSVTPSTHDKTLGPGAEEKRRSMRDDTMWQLYEWQQRQFYNKQSTLPRHSTLSSPKTMVNISDQTMHSIPTSPSHGSIAAYQGYSPQRTYRSEVSSPIQRGDVTIDRRHRAHHPKHVYVPDRRSVPAGLTLQSVSPQSLQGKTLSQDEGRGTLYKYRPEEVDIDAKLSRLCEQDKVVHALEEKLQQLHKEKYTLEQALLSASQEIEMHADNPAAIQTVVLQRDDLQNGLLSTCRELSRATAELERAWREYDKLEYDVTVTRNQMQEQLDHLGEVQTESAGIQRAQIQKELWRIQDVMEGLSKHKQQRGTTEIGMIGSKPFSTVKYKNEGPDYRLYKSEPELTTVAEVDESNGEEKSEPVSEIETSVVKGSHFPVGVVPPRAKSPTPESSTIASYVTLRKTKKMMDLRTERPRSAVEQLCLAESTRPRMTVEEQMERIRRHQQACLREKKKGLNVIGASDQSPLQSPSNLRDNPFRTTQTRRRDDKELDTAIRENDVKPDHETPATEIVQLKETEPQNVDFSKELKKTENISYEMLFEPEPNGVNSVEMMDKERNKDKMPEDVTFSPQDETQTANHKPEEHPEENTKNSVDEQEETVISYESTPEVSRGNQTMAVKSLSPSPESSASPVPSTQPQLTEGSHFMCV T20296 TARGETID T20296 T20296 FORMERID TTDR01289 T20296 UNIPROID EMAL4_HUMAN T20296 TARGNAME Echinoderm microtubule-associated protein-like 4 (EMAP-4) T20296 GENENAME EML4 T20296 TARGTYPE Literature-reported T20296 SYNONYMS Ropp 120; Restrictedly overexpressed proliferation-associated protein; EMAPL4; EMAP-4; C2orf2 T20296 FUNCTION May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic. T20296 PDBSTRUC 4CGC T20296 SEQUENCE MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGANRKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEKSHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGKDCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLGTFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIFGKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDLNPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTRLVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIDGTFLAVGSHDNFIYLYVVSENGRKYSRYGRCTGHSSYITHLDWSPDNKYIMSNSGDYEILYWDIPNGCKLIRNRSDCKDIDWTTYTCVLGFQVFGVWPEGSDGTDINALVRSHNRKVIAVADDFCKVHLFQYPCSKAKAPSHKYSAHSSHVTNVSFTHNDSHLISTGGKDMSIIQWKLVEKLSLPQNETVADTTLTKAPVSSTESVIQSNTPTPPPSQPLNETAEEESRISSSPTLLENSLEQTVEPSEDHSEEESEEGSGDLGEPLYEEPCNEISKEQAKATLLEDQQDPSPSS T78992 TARGETID T78992 T78992 FORMERID TTDR01325 T78992 UNIPROID NEK6_HUMAN T78992 TARGNAME Serine/threonine-protein kinase Nek6 (NEK6) T78992 GENENAME NEK6 T78992 TARGTYPE Literature-reported T78992 SYNONYMS Protein kinase SID6-1512; NimA-related protein kinase 6; Never in mitosis A-related kinase 6 T78992 FUNCTION Protein kinase which plays an important role in mitotic cell cycle progression. Required for chromosome segregation at metaphase-anaphase transition, robust mitotic spindle formation and cytokinesis. Phosphorylates ATF4, CIR1, PTN, RAD26L, RBBP6, RPS7, RPS6KB1, TRIP4, STAT3 and histones H1 and H3. Phosphorylates KIF11 to promote mitotic spindle formation. Involved in G2/M phase cell cycle arrest induced by DNA damage. Inhibition of activity results in apoptosis. May contribute to tumorigenesis by suppressing p53/TP53-induced cancer cell senescence. T78992 ECNUMBER EC 2.7.11.1 T78992 SEQUENCE MAGQPGHMPHGGSSNNLCHTLGPVHPPDPQRHPNTLSFRCSLADFQIEKKIGRGQFSEVYKATCLLDRKTVALKKVQIFEMMDAKARQDCVKEIGLLKQLNHPNIIKYLDSFIEDNELNIVLELADAGDLSQMIKYFKKQKRLIPERTVWKYFVQLCSAVEHMHSRRVMHRDIKPANVFITATGVVKLGDLGLGRFFSSETTAAHSLVGTPYYMSPERIHENGYNFKSDIWSLGCLLYEMAALQSPFYGDKMNLFSLCQKIEQCDYPPLPGEHYSEKLRELVSMCICPDPHQRPDIGYVHQVAKQMHIWMSST T69184 TARGETID T69184 T69184 FORMERID TTDI03594 T69184 UNIPROID TRPM3_HUMAN T69184 TARGNAME Long transient receptor potential channel 3 (TRPM3) T69184 GENENAME TRPM3 T69184 TARGTYPE Literature-reported T69184 SYNONYMS Transient receptor potential cation channel subfamily M member 3; Melastatin-2; MLSN2; LTrpC3; LTrpC-3; KIAA1616 T69184 FUNCTION Its activity is increased by reduction in extracellular osmolarity, by store depletion and muscarinic receptor activation. Calcium channel mediating constitutive calcium ion entry. T69184 BIOCLASS Transient receptor potential catioin channel T69184 SEQUENCE MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRECVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGGHSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGKYGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPVVALIVEGGPNVISIVLEYLRDTPPVPVVVCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLVVLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN T69184 DRUGINFO D06ATM sphinganine Investigative T69184 DRUGINFO D0A5RA epipregnanolone sulphate Investigative T69184 DRUGINFO D0OS7U NN-dimethyl-D-erythrosphingosine Investigative T69184 DRUGINFO D00HCI 2-APB Investigative T10918 TARGETID T10918 T10918 FORMERID TTDI03592 T10918 UNIPROID TRPC7_HUMAN T10918 TARGNAME Short transient receptor potential channel 7 (TRPC7) T10918 GENENAME TRPC7 T10918 TARGTYPE Literature-reported T10918 SYNONYMS hTRP7; Transient receptor protein 7; TRP7; TRP-7 T10918 FUNCTION Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Activated by diacylglycerol (DAG) (By similarity). May also be activated by intracellular calcium store depletion. T10918 BIOCLASS Transient receptor potential catioin channel T10918 SEQUENCE MLRNSTFKNMQRRHTTLREKGRRQAIRGPAYMFNEKGTSLTPEEERFLDSAEYGNIPVVRKMLEESKTLNFNCVDYMGQNALQLAVGNEHLEVTELLLKKENLARVGDALLLAISKGYVRIVEAILNHPAFAQGQRLTLSPLEQELRDDDFYAYDEDGTRFSHDITPIILAAHCQEYEIVHILLLKGARIERPHDYFCKCNECTEKQRKDSFSHSRSRMNAYKGLASAAYLSLSSEDPVLTALELSNELARLANIETEFKNDYRKLSMQCKDFVVGVLDLCRDTEEVEAILNGDVNFQVWSDHHRPSLSRIKLAIKYEVKKFVAHPNCQQQLLTMWYENLSGLRQQSIAVKFLAVFGVSIGLPFLAIAYWIAPCSKLGRTLRSPFMKFVAHAVSFTIFLGLLVVNASDRFEGVKTLPNETFTDYPKQIFRVKTTQFSWTEMLIMKWVLGMIWSECKEIWEEGPREYVLHLWNLLDFGMLSIFVASFTARFMAFLKATEAQLYVDQHVQDDTLHNVSLPPEVAYFTYARDKWWPSDPQIISEGLYAIAVVLSFSRIAYILPANESFGPLQISLGRTVKDIFKFMVIFIMVFVAFMIGMFNLYSYYRGAKYNPAFTTVEESFKTLFWSIFGLSEVISVVLKYDHKFIENIGYVLYGVYNVTMVVVLLNMLIAMINNSYQEIEEDADVEWKFARAKLWLSYFDEGRTLPAPFNLVPSPKSFYYLIMRIKMCLIKLCKSKAKSCENDLEMGMLNSKFKKTRYQAGMRNSENLTANNTLSKPTRYQKIMKRLIKRYVLKAQVDRENDEVNEGELKEIKQDISSLRYELLEEKSQATGELADLIQQLSEKFGKNLNKDHLRVNKGKDI T10918 DRUGINFO D0T6DU OAG Investigative T10918 DRUGINFO D00HCI 2-APB Investigative T98320 TARGETID T98320 T98320 UNIPROID Q9I1N2_PSEAE T98320 TARGNAME Pseudomonas Aeruginosa Psl (Pseudo pslG) T98320 GENENAME Pseudo pslG T98320 TARGTYPE Literature-reported T98320 SYNONYMS Pseudo PslG T98320 FUNCTION Involved in the synthesis of a key biofilm matrix exopolysaccharide Psl in Pseudomonas aeruginosa. Prevents biofilm formation and disassembles existing biofilms within minutes at nanomolar concentrations when supplied exogenously. T98320 PDBSTRUC 5BXA; 5BX9; 4ZN2 T98320 SEQUENCE MARKGLYLGGSALLLAVVLLLVFWGRPADAEIQVLKAPRAVVWKDFLGVNAQFLWFSPERYNKQIDRLQDLGLEWVRLDLHWDRLETAEDQYQLASLDQLVKDLEARQLKSVFYLVGSARFITTAPFYSPFQDQYPPRDPEVFARRMAMLSQRYPSVAAWQVWNEPNLIGFWRPKADPEGYAKLLQASTIALRMVDPEKPVVSAGMAFFSEMPDGRTMFDALGHLGVESLGTIATYHPYTQLPEGNYPWNLDFVSHANQINRALRNAGVPAIWSTEWGWSAYKGPKELQDIIGVEGQADYVLRRLALMSALDYDRIFLFTLSDLDQRASVRDRDYGLLDLDANPKPVYLALQRFLKVTGPKLRPADPPVTEDLPDGSFSIGWTREDGRNVWLFWSARGGNVRLPKLKEATLHDPLSGKVTPLSGSDGLEVPVKSSLQMLVWE T32306 TARGETID T32306 T32306 FORMERID TTDR01016 T32306 UNIPROID Q9NG20_PLABE T32306 TARGNAME Plasmodium Subtilisin-like protease 2 (Malaria sub2) T32306 GENENAME Malaria sub2 T32306 TARGTYPE Literature-reported T32306 SYNONYMS Subtilisin-like protease 2 T32306 FUNCTION Essential for red cell invasion. T32306 BIOCLASS Protease T32306 SEQUENCE MLRTFYVLSLMLIEFILHNGQYNKHICSKNSKKYNFVGKKHRILVSDIEDRENHIEGIADIYKPIFNIYEISAEFHKKKNIADKKKKRKYGINQSIEKRRIAEENERRQLNKTEGTQFLELSNRYPNIGKQNSQQNKVNEINNQNAASNSNDNIGNDNIGNDNIGNDEDDDEDDDEDLIEGRKDNLEEDDLIEKNDSNLPRGKMHEKEEKNKNINTTPGNESSNKNVNDKKKNGISLKDKIDNKQNNGGLKEKGNNLDDNIKTYTFDHYKIITNSDNILNDIKVDASDISKLSINSINIEYNEKNKAEYTHQRHIVLSNNGNRRYKIFLMTKNPKFTKTEDIEEPGMSFIQTETGENEDEKEDEENYLNENLYSGFGTIDYENDYSKKKKKIESEHASGLNDKISNSQNIEKSGSHENEKYNHGYIEKIRSFFSFLSMPSSKKDDSIGSEKKTEERSNTDSKAKLNKKTNDMAKKNNSNAFLSVDKIIDQYLLNLKNKNMKEQELIFIFHGNLDLHSKEMKTVINEANAKFTKYINMHFKDVKNIRYDISSPINFVCFFIPIIFDMSNLKILKEALIILNNELKDYIDNWNFSNTYVAFDNNYENEDIDNVMNKLNENMEKYIKKPKKLYNIKYSFLRKIWGLKSIISLSKNQDKKDAEIEEKILSALPKELKEYSTWNLSFIRVFNAWLLSGYGNKNVKICVIDSGIDKNHIDLANNIYTPKYSDRYEMTDELFDFMVKNPIDTSGHGTHVSGIAAASANSLGMVGVAPNINLISLRFIDGDNYGGSFHVIKAINICILNKSPIINASWGSRNYDTNMFLAIERLKYTFKGKGTVFIAAAGNENKNNDLYPIYPASYKLQNVYSVGSINKFLQISPFSNYGANSVHILAPGHHIYSTTPMNTYKMNTGTSMAAPHVSGVAGLIYSVCYKQGFIPDADEVLEIITRTSIKIVSKDKKTIHNSLINAEAAVLTTLLGGLWIQMDCHFAKFYLNENKQKSVPIVFSAYKDGVYESDIIIGIQPEDANSKEYGEIVIPIKILTNPKLKDFSLSPRVGKKIRIDENESNDDILSYICENALYNLYEHDNSFLISSLILFFIGIILIVLASIVFFLKHHQSKQRDGEKYMHQKMVDRTYNVKYNFKDSGTDGIKRINTLDDNINNHRNTQRFTIVQNEDNMYVLKKKSSIQAKYEPRNELVKRSLVKRPIVKHADINVNFSNVDVLYEPKNNSSE T93909 TARGETID T93909 T93909 UNIPROID PALMD_HUMAN T93909 TARGNAME Palmdelphin (PALMD) T93909 GENENAME PALMD T93909 TARGTYPE Literature-reported T93909 SYNONYMS Paralemmin-like protein; PALML; C1orf11 T93909 FUNCTION cytoplasm. T93909 BIOCLASS Paralemmin family T93909 SEQUENCE MEEAELVKGRLQAITDKRKIQEEISQKRLKIEEDKLKHQHLKKKALREKWLLDGISSGKEQEEMKKQNQQDQHQIQVLEQSILRLEKEIQDLEKAELQISTKEEAILKKLKSIERTTEDIIRSVKVEREERAEESIEDIYANIPDLPKSYIPSRLRKEINEEKEDDEQNRKALYAMEIKVEKDLKTGESTVLSSIPLPSDDFKGTGIKVYDDGQKSVYAVSSNHSAAYNGTDGLAPVEVEELLRQASERNSKSPTEYHEPVYANPFYRPTTPQRETVTPGPNFQERIKIKTNGLGIGVNESIHNMGNGLSEERGNNFNHISPIPPVPHPRSVIQQAEEKLHTPQKRLMTPWEESNVMQDKDAPSPKPRLSPRETIFGKSEHQNSSPTCQEDEEDVRYNIVHSLPPDINDTEPVTMIFMGYQQAEDSEEDKKFLTGYDGIIHAELVVIDDEEEEDEGEAEKPSYHPIAPHSQVYQPAKPTPLPRKRSEASPHENTNHKSPHKNSISLKEQEESLGSPVHHSPFDAQTTGDGTEDPSLTALRMRMAKLGKKVI T89780 TARGETID T89780 T89780 FORMERID TTDR00452 T89780 UNIPROID TREM1_HUMAN T89780 TARGNAME Triggering receptor expressed on monocytes 1 (TREM1) T89780 GENENAME Trem1 T89780 TARGTYPE Literature-reported T89780 SYNONYMS Trem1; TREM-1 T89780 FUNCTION Stimulates neutrophil and monocyte-mediated inflammatory responses. Triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock. T89780 PDBSTRUC 1SMO; 1Q8M T89780 SEQUENCE MRKTRLWGLLWMLFVSELRAATKLTEEKYELKEGQTLDVKCDYTLEKFASSQKAWQIIRDGEMPKTLACTERPSKNSHPVQVGRIILEDYHDHGLLRVRMVNLQVEDSGLYQCVIYQPPKEPHMLFDRIRLVVTKGFSGTPGSNENSTQNVYKIPPTTTKALCPLYTSPRTVTQAPPKSTADVSTPDSEINLTNVTDIIRVPVFNIVILLAGGFLSKSLVFSVLFAVTLRSFVP T89780 DRUGINFO D0K2BZ D-tartaric acid Investigative T57613 TARGETID T57613 T57613 FORMERID TTDR01198 T57613 UNIPROID KCNK9_HUMAN T57613 TARGNAME TWIK-related acid-sensitive potassium channel 3 (TASK3) T57613 GENENAME KCNK9 T57613 TARGTYPE Literature-reported T57613 SYNONYMS Two pore potassium channel KT3.2; TWIK-related acid-sensitive K+ channel 3; KCNK9; Acid-sensitive potassium channel protein TASK-3 T57613 FUNCTION pH-dependent, voltage-insensitive, background potassium channel protein. T57613 PDBSTRUC 6GHP; 4FR3; 3UX0; 3SPR; 3SP5 T57613 SEQUENCE MKRQNVRTLSLIVCTFTYLLVGAAVFDALESDHEMREEEKLKAEEIRIKGKYNISSEDYRQLELVILQSEPHRAGVQWKFAGSFYFAITVITTIGYGHAAPGTDAGKAFCMFYAVLGIPLTLVMFQSLGERMNTFVRYLLKRIKKCCGMRNTDVSMENMVTVGFFSCMGTLCIGAAAFSQCEEWSFFHAYYYCFITLTTIGFGDYVALQTKGALQKKPLYVAFSFMYILVGLTVIGAFLNLVVLRFLTMNSEDERRDAEERASLAGNRNSMVIHIPEEPRPSRPRYKADVPDLQSVCSCTCYRSQDYGGRSVAPQNSFSAKLAPHYFHSISYKIEEISPSTLKNSLFPSPISSISPGLHSFTDHQRLMKRRKSV T84706 TARGETID T84706 T84706 FORMERID TTDI02534 T84706 UNIPROID CD320_HUMAN T84706 TARGNAME Transcobalamin receptor (CD320) T84706 GENENAME CD320 T84706 TARGTYPE Literature-reported T84706 SYNONYMS UNQ198/PRO224; TCblR; FDCsignaling molecule 8D6; FDCSM8D6; FDC-signaling molecule 8D6; FDC-SM-8D6; CD320 antigen; 8D6A; 8D6 antigen T84706 FUNCTION Plays an important role in cobalamin uptake. Plasma membrane protein that is expressed on follicular dendritic cells (FDC) and mediates interaction with germinal center B cells. Functions as costimulator to promote B cell responses to antigenic stimuli; promotes B cell differentiation and proliferation. Germinal center-B (GC-B) cells differentiate into memory B-cells and plasma cells (PC) through interaction with T-cells and follicular dendritic cells (FDC). CD320 augments the proliferation of PC precursors generated by IL-10. Receptor for transcobalamin saturated with cobalamin (TCbl). T84706 PDBSTRUC 4ZRQ; 4ZRP T84706 SEQUENCE MSGGWMAQVGAWRTGALGLALLLLLGLGLGLEAAASPLSTPTSAQAAGPSSGSCPPTKFQCRTSGLCVPLTWRCDRDLDCSDGSDEEECRIEPCTQKGQCPPPPGLPCPCTGVSDCSGGTDKKLRNCSRLACLAGELRCTLSDDCIPLTWRCDGHPDCPDSSDELGCGTNEILPEGDATTMGPPVTLESVTSLRNATTMGPPVTLESVPSVGNATSSSAGDQSGSPTAYGVIAAAAVLSASLVTATLLLLSWLRAQERLRPLGLLVAMKESLLLSEQKTSLP T75419 TARGETID T75419 T75419 FORMERID TTDR01107 T75419 UNIPROID FANCF_HUMAN T75419 TARGNAME Fanconi anemia group F protein (FANCF) T75419 GENENAME FANCF T75419 TARGTYPE Literature-reported T75419 SYNONYMS Protein FACF T75419 FUNCTION May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. T75419 PDBSTRUC 2IQC T75419 SEQUENCE MESLLQHLDRFSELLAVSSTTYVSTWDPATVRRALQWARYLRHIHRRFGRHGPIRTALERRLHNQWRQEGGFGRGPVPGLANFQALGHCDVLLSLRLLENRALGDAARYHLVQQLFPGPGVRDADEETLQESLARLARRRSAVHMLRFNGYRENPNLQEDSLMKTQAELLLERLQEVGKAEAERPARFLSSLWERLPQNNFLKVIAVALLQPPLSRRPQEELEPGIHKSPGEGSQVLVHWLLGNSEVFAAFCRALPAGLLTLVTSRHPALSPVYLGLLTDWGQRLHYDLQKGIWVGTESQDVPWEELHNRFQSLCQAPPPLKDKVLTALETCKAQDGDFEVPGLSIWTDLLLALRSGAFRKRQVLGLSAGLSSV T14196 TARGETID T14196 T14196 FORMERID TTDI00214 T14196 UNIPROID RIC8A_HUMAN T14196 TARGNAME Synembryn-A (RIC8A) T14196 GENENAME RIC8A T14196 TARGTYPE Literature-reported T14196 SYNONYMS Protein Ric-8A T14196 FUNCTION Able to activate GNAI1, GNAO1 and GNAQ, but not GNAS by exchanging bound GDP for free GTP. Involved in regulation of microtubule pulling forces during mitotic movement of chromosomes by stimulating G(i)-alpha protein, possibly leading to release G(i)-alpha-GTP and NuMA proteins from the NuMA-GPSM2-G(i)-alpha-GDP complex. Also acts as an activator for G(q)-alpha (GNAQ) protein by enhancing the G(q)-coupled receptor-mediated ERK activation. Guanine nucleotide exchange factor (GEF), which can activate some, but not all, G-alpha proteins. T14196 BIOCLASS Synembryn T14196 SEQUENCE MEPRAVAEAVETGEEDVIMEALRSYNQEHSQSFTFDDAQQEDRKRLAELLVSVLEQGLPPSHRVIWLQSVRILSRDRNCLDPFTSRQSLQALACYADISVSEGSVPESADMDVVLESLKCLCNLVLSSPVAQMLAAEARLVVKLTERVGLYRERSFPHDVQFFDLRLLFLLTALRTDVRQQLFQELKGVRLLTDTLELTLGVTPEGNPPPTLLPSQETERAMEILKVLFNITLDSIKGEVDEEDAALYRHLGTLLRHCVMIATAGDRTEEFHGHAVNLLGNLPLKCLDVLLTLEPHGDSTEFMGVNMDVIRALLIFLEKRLHKTHRLKESVAPVLSVLTECARMHRPARKFLKAQVLPPLRDVRTRPEVGEMLRNKLVRLMTHLDTDVKRVAAEFLFVLCSESVPRFIKYTGYGNAAGLLAARGLMAGGRPEGQYSEDEDTDTDEYKEAKASINPVTGRVEEKPPNPMEGMTEEQKEHEAMKLVTMFDKLSRNRVIQPMGMSPRGHLTSLQDAMCETMEQQLSSDPDSDPD T54646 TARGETID T54646 T54646 FORMERID TTDR01118 T54646 UNIPROID TF7L2_HUMAN T54646 TARGNAME Transcription factor 7-like 2 (TCF7L2) T54646 GENENAME TCF7L2 T54646 TARGTYPE Literature-reported T54646 SYNONYMS TCF4; TCF-4; T-cell-specific transcription factor 4; T-cell transcription factor-4; T-cell factor 4; HTCF-4; HMG box transcription factor 4 T54646 FUNCTION Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine. Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. T54646 PDBSTRUC 2GL7; 1JPW; 1JDH T54646 SEQUENCE MPQLNGGGGDDLGANDELISFKDEGEQEEKSSENSSAERDLADVKSSLVNESETNQNSSSDSEAERRPPPRSESFRDKSRESLEEAAKRQDGGLFKGPPYPGYPFIMIPDLTSPYLPNGSLSPTARTLHFQSGSTHYSAYKTIEHQIAVQYLQMKWPLLDVQAGSLQSRQALKDARSPSPAHIVSNKVPVVQHPHHVHPLTPLITYSNEHFTPGNPPPHLPADVDPKTGIPRPPHPPDISPYYPLSPGTVGQIPHPLGWLVPQQGQPVYPITTGGFRHPYPTALTVNASMSRFPPHMVPPHHTLHTTGIPHPAIVTPTVKQESSQSDVGSLHSSKHQDSKKEEEKKKPHIKKPLNAFMLYMKEMRAKVVAECTLKESAAINQILGRRWHALSREEQAKYYELARKERQLHMQLYPGWSARDNYGKKKKRKRDKQPGETNEHSECFLNPCLSLPPITDLSAPKKCRARFGLDQQNNWCGPCRRKKKCVRYIQGEGSCLSPPSSDGSLLDSPPPSPNLLGSPPRDAKSQTEQTQPLSLSLKPDPLAHLSMMPPPPALLLAEATHKASALCPNGALDLPPAALQPAAPSSSIAQPSTSSLHSHSSLAGTQPQPLSLVTKSLE T72236 TARGETID T72236 T72236 FORMERID TTDNC00605 T72236 UNIPROID RTN4_HUMAN T72236 TARGNAME Neurite outgrowth inhibitor NOGO-A (RTN4) T72236 GENENAME RTN4 T72236 TARGTYPE Literature-reported T72236 SYNONYMS Reticulon-5; RTN-x; Nogo protein; Neuroendocrine-specific protein C homolog; Neuroendocrine-specific protein; Neurite outgrowth inhibitor; NSP; NOGO; KIAA0886; Foocen T72236 FUNCTION Required to induce the formation and stabilization of endoplasmic reticulum (ER) tubules. They regulate membrane morphogenesis in the ER by promoting tubular ER production. They influence nuclear envelope expansion, nuclear pore complex formation and proper localization of inner nuclear membrane proteins. However each isoform have specific functions mainly depending on their tissue expression specificities (Probable). T72236 PDBSTRUC 2JV5; 2G31 T72236 SEQUENCE MEDLDQSPLVSSSDSPPRPQPAFKYQFVREPEDEEEEEEEEEEDEDEDLEELEVLERKPAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVPAPSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKRRGSSGSVDETLFALPAASEPVIRSSAENMDLKEQPGNTISAGQEDFPSVLLETAASLPSLSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEYSEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKEDEVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDSDMLAAGGKIESNLESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIATNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLTKVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEASSVNYESIKHEPENPPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDFSDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETSFESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEELSTAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVSHKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDVSALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE T78150 TARGETID T78150 T78150 FORMERID TTDR01113 T78150 UNIPROID DBLOH_HUMAN T78150 TARGNAME Direct IAP-binding protein with low pI (DIABLO) T78150 GENENAME DIABLO T78150 TARGTYPE Literature-reported T78150 SYNONYMS Smac protein; Smac; Second mitochondria-derived activator of caspase; Direct IAP binding protein with low pI; Diablo homolog, mitochondrial T78150 FUNCTION Acts by opposing the inhibitory activity of inhibitor of apoptosis proteins (IAP). Inhibits the activity of BIRC6/bruce by inhibiting its binding to caspases. Isoform 3 attenuates the stability and apoptosis-inhibiting activity of XIAP/BIRC4 by promoting XIAP/BIRC4 ubiquitination and degradation through the ubiquitin-proteasome pathway. Isoform 3 also disrupts XIAP/BIRC4 interacting with processed caspase-9 and promotes caspase-3 activation. Isoform 1 is defective in the capacity to down-regulate the XIAP/BIRC4 abundance. Promotes apoptosis by activating caspases in the cytochrome c/Apaf-1/caspase-9 pathway. T78150 PDBSTRUC 4TX5; 3UIJ; 3UIH; 3D9U; 1XB1 T78150 SEQUENCE MAALKSWLSRSVTSFFRYRQCLCVPVVANFKKRCFSELIRPWHKTVTIGFGVTLCAVPIAQKSEPHSLSSEALMRRAVSLVTDSTSTFLSQTTYALIEAITEYTKAVYTLTSLYRQYTSLLGKMNSEEEDEVWQVIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEEVHQLSRKAETKLAEAQIEELRQKTQEEGEERAESEQEAYLRED T59510 TARGETID T59510 T59510 UNIPROID PDGFC_HUMAN T59510 TARGNAME Platelet-derived growth factor C (PDGFC) T59510 GENENAME PDGFC T59510 TARGTYPE Literature-reported T59510 SYNONYMS VEGF-E; UNQ174/PRO200; Spinal cord-derived growth factor; SCDGF; PDGF-C; Fallotein T59510 FUNCTION Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen and chemoattractant for cells of mesenchymal origin. Required for normal skeleton formation during embryonic development, especially for normal development of the craniofacial skeleton and for normal development of the palate. Required for normal skin morphogenesis during embryonic development. Plays an important role in wound healing, where it appears to be involved in three stages: inflammation, proliferation and remodeling. Plays an important role in angiogenesis and blood vessel development. Involved in fibrotic processes, in which transformation of interstitial fibroblasts into myofibroblasts plus collagen deposition occurs. The CUB domain has mitogenic activity in coronary artery smooth muscle cells, suggesting a role beyond the maintenance of the latency of the PDGF domain. In the nucleus, PDGFC seems to have additional function. T59510 BIOCLASS Growth factor T59510 SEQUENCE MSLFGLLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHSPRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTILGRWCGSGTVPGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPPSALPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGRKSRVVDLNLLTEEVRLYSCTPRNFSVSIREELKRTDTIFWPGCLLVKRCGGNCACCLHNCNECQCVPSKVTKKYHEVLQLRPKTGVRGLHKSLTDVALEHHEECDCVCRGSTGG T44305 TARGETID T44305 T44305 FORMERID TTDR00605 T44305 UNIPROID S17A5_HUMAN T44305 TARGNAME Vesicular H(+)/Aspartate-glutamate cotransporter (HP59) T44305 GENENAME SLC17A5 T44305 TARGTYPE Literature-reported T44305 SYNONYMS Solute carrier family 17 member 5; Sodium/sialic acid cotransporter; SLC17A5; Membrane glycoprotein HP59; AST T44305 FUNCTION Transports glucuronic acid and free sialic acid out of the lysosome after it is cleaved from sialoglycoconjugates undergoing degradation, this is required for normal CNS myelination. Mediates aspartate and glutamate membrane potential- dependent uptake into synaptic vesicles and synaptic-like microvesicles. Also functions as an electrogenic 2NO(3)(-)/H(+) cotransporter in the plasma membrane of salivary gland acinar cells, mediating the physiological nitrate efflux, 25% of the circulating nitrate ions is typically removed and secreted in saliva. T44305 BIOCLASS Major facilitator superfamily T44305 SEQUENCE MRSPVRDLARNDGEESTDRTPLLPGAPRAEAAPVCCSARYNLAILAFFGFFIVYALRVNLSVALVDMVDSNTTLEDNRTSKACPEHSAPIKVHHNQTGKKYQWDAETQGWILGSFFYGYIITQIPGGYVASKIGGKMLLGFGILGTAVLTLFTPIAADLGVGPLIVLRALEGLGEGVTFPAMHAMWSSWAPPLERSKLLSISYAGAQLGTVISLPLSGIICYYMNWTYVFYFFGTIGIFWFLLWIWLVSDTPQKHKRISHYEKEYILSSLRNQLSSQKSVPWVPILKSLPLWAIVVAHFSYNWTFYTLLTLLPTYMKEILRFNVQENGFLSSLPYLGSWLCMILSGQAADNLRAKWNFSTLCVRRIFSLIGMIGPAVFLVAAGFIGCDYSLAVAFLTISTTLGGFCSSGFSINHLDIAPSYAGILLGITNTFATIPGMVGPVIAKSLTPDNTVGEWQTVFYIAAAINVFGAIFFTLFAKGEVQNWALNDHHGHRH T74425 TARGETID T74425 T74425 UNIPROID GLRX2_HUMAN T74425 TARGNAME Glutaredoxin-2 (GLRX2) T74425 GENENAME GLRX2 T74425 TARGTYPE Literature-reported T74425 SYNONYMS Glutaredoxin-2, mitochondrial; GRX2; CGI-133 T74425 FUNCTION Glutathione-dependent oxidoreductase that facilitates the maintenance of mitochondrial redox homeostasis upon induction of apoptosis by oxidative stress. Involved in response to hydrogen peroxide and regulation of apoptosis caused by oxidative stress. Acts as a very efficient catalyst of monothiol reactions because of its high affinity for protein glutathione-mixed disulfides. Can receive electrons not only from glutathione (GSH), but also from thioredoxin reductase supporting both monothiol and dithiol reactions. Efficiently catalyzes both glutathionylation and deglutathionylation of mitochondrial complex I, which in turn regulates the superoxide production by the complex. Overexpression decreases the susceptibility to apoptosis and prevents loss of cardiolipin and cytochrome c release. T74425 PDBSTRUC 2HT9; 2FLS; 2CQ9 T74425 SEQUENCE MIWRRAALAGTRLVWSRSGSAGWLDRAAGAAGAAAAAASGMESNTSSSLENLATAPVNQIQETISDNCVVIFSKTSCSYCTMAKKLFHDMNVNYKVVELDLLEYGNQFQDALYKMTGERTVPRIFVNGTFIGGATDTHRLHKEGKLLPLVHQCYLKKSKRKEFQ T90905 TARGETID T90905 T90905 FORMERID TTDI03342 T90905 UNIPROID KCND1_HUMAN T90905 TARGNAME Voltage-gated potassium channel Kv4.1 (KCND1) T90905 GENENAME KCND1 T90905 TARGTYPE Literature-reported T90905 SYNONYMS Voltage-gated potassium channel subunit Kv4.1; Potassium voltage-gated channel subfamily D member 1 T90905 FUNCTION Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits. T90905 BIOCLASS Voltage-gated ion channel T90905 SEQUENCE MAAGLATWLPFARAAAVGWLPLAQQPLPPAPGVKASRGDEVLVVNVSGRRFETWKNTLDRYPDTLLGSSEKEFFYDADSGEYFFDRDPDMFRHVLNFYRTGRLHCPRQECIQAFDEELAFYGLVPELVGDCCLEEYRDRKKENAERLAEDEEAEQAGDGPALPAGSSLRQRLWRAFENPHTSTAALVFYYVTGFFIAVSVIANVVETIPCRGSARRSSREQPCGERFPQAFFCMDTACVLIFTGEYLLRLFAAPSRCRFLRSVMSLIDVVAILPYYIGLLVPKNDDVSGAFVTLRVFRVFRIFKFSRHSQGLRILGYTLKSCASELGFLLFSLTMAIIIFATVMFYAEKGTNKTNFTSIPAAFWYTIVTMTTLGYGDMVPSTIAGKIFGSICSLSGVLVIALPVPVIVSNFSRIYHQNQRADKRRAQQKVRLARIRLAKSGTTNAFLQYKQNGGLEDSGSGEEQALCVRNRSAFEQQHHHLLHCLEKTTCHEFTDELTFSEALGAVSPGGRTSRSTSVSSQPVGPGSLLSSCCPRRAKRRAIRLANSTASVSRGSMQELDMLAGLRRSHAPQSRSSLNAKPHDSLDLNCDSRDFVAAIISIPTPPANTPDESQPSSPGGGGRAGSTLRNSSLGTPCLFPETVKISSL T90905 DRUGINFO D06PZZ [14C]TEA Investigative T61316 TARGETID T61316 T61316 FORMERID TTDI03131 T61316 UNIPROID CXB4_HUMAN T61316 TARGNAME Gap junction beta-4 protein (Cx30.3) T61316 GENENAME GJB4 T61316 TARGTYPE Literature-reported T61316 SYNONYMS Connexin-30.3 T61316 FUNCTION Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. They are formed by the docking of two hexameric hemichannels, one from each cell membrane. Small molecules and ions diffuse from one cell to a neighboring cell via the central pore. Structural component of gap junctions. T61316 BIOCLASS Gap junction-forming connexin T61316 SEQUENCE MNWAFLQGLLSGVNKYSTVLSRIWLSVVFIFRVLVYVVAAEEVWDDEQKDFVCNTKQPGCPNVCYDEFFPVSHVRLWALQLILVTCPSLLVVMHVAYREERERKHHLKHGPNAPSLYDNLSKKRGGLWWTYLLSLIFKAAVDAGFLYIFHRLYKDYDMPRVVACSVEPCPHTVDCYISRPTEKKVFTYFMVTTAAICILLNLSEVFYLVGKRCMEIFGPRHRRPRCRECLPDTCPPYVLSQGGHPEDGNSVLMKAGSAPVDAGGYP T61316 DRUGINFO D00VJY octanol Investigative T64642 TARGETID T64642 T64642 FORMERID TTDR00483 T64642 UNIPROID IMP3_HUMAN T64642 TARGNAME U3 snoRNP protein IMP3 (IMP3) T64642 GENENAME IMP3 T64642 TARGTYPE Literature-reported T64642 SYNONYMS U3 small nucleolar ribonucleoprotein protein IMP3; MRPS4; C15orf12; BRMS2 T64642 FUNCTION Component of the 60-80S U3 small nucleolar ribonucleoprotein (U3 snoRNP). Required for the early cleavages during pre-18S ribosomal RNA processing. T64642 PDBSTRUC 2CQJ T64642 SEQUENCE MVRKLKFHEQKLLKQVDFLNWEVTDHNLHELRVLRRYRLQRREDYTRYNQLSRAVRELARRLRDLPERDQFRVRASAALLDKLYALGLVPTRGSLELCDFVTASSFCRRRLPTVLLKLRMAQHLQAAVAFVEQGHVRVGPDVVTDPAFLVTRSMEDFVTWVDSSKIKRHVLEYNEERDDFDLEA T93337 TARGETID T93337 T93337 UNIPROID S38A7_HUMAN T93337 TARGNAME Solute carrier family 38 member 7 (SLC38A7) T93337 GENENAME SLC38A7 T93337 TARGTYPE Literature-reported T93337 SYNONYMS SNAT7 T93337 FUNCTION Mediates sodium-dependent transport of amino acids, preferentially L-glutamine. T93337 BIOCLASS Amino acid/polyamine transporter 2 family T93337 SEQUENCE MAQVSINNDYSEWDLSTDAGERARLLQSPCVDTAPKSEWEASPGGLDRGTTSTLGAIFIVVNACLGAGLLNFPAAFSTAGGVAAGIALQMGMLVFIISGLVILAYCSQASNERTYQEVVWAVCGKLTGVLCEVAIAVYTFGTCIAFLIIIGDQQDKIIAVMAKEPEGASGPWYTDRKFTISLTAFLFILPLSIPREIGFQKYASFLSVVGTWYVTAIVIIKYIWPDKEMTPGNILTRPASWMAVFNAMPTICFGFQCHVSSVPVFNSMQQPEVKTWGGVVTAAMVIALAVYMGTGICGFLTFGAAVDPDVLLSYPSEDMAVAVARAFIILSVLTSYPILHFCGRAVVEGLWLRYQGVPVEEDVGRERRRRVLQTLVWFLLTLLLALFIPDIGKVISVIGGLAACFIFVFPGLCLIQAKLSEMEEVKPASWWVLVSYGVLLVTLGAFIFGQTTANAIFVDLLA T79501 TARGETID T79501 T79501 FORMERID TTDI03488 T79501 UNIPROID ANM7_HUMAN T79501 TARGNAME Protein arginine methyltransferase 7 (PRMT7) T79501 GENENAME PRMT7 T79501 TARGTYPE Literature-reported T79501 SYNONYMS Protein arginine N-methyltransferase 7; KIAA1933; Histone-arginine N-methyltransferase PRMT7; [Myelin basic protein]-arginine N-methyltransferase PRMT7 T79501 FUNCTION Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles. Specifically mediates the symmetric dimethylation of histone H4 'Arg-3' to form H4R3me2s. Plays a role in gene imprinting by being recruited by CTCFL at the H19 imprinted control region (ICR) and methylating histone H4 to form H4R3me2s, possibly leading to recruit DNA methyltransferases at these sites. May also play a role in embryonic stem cell (ESC) pluripotency. Also able to mediate the arginine methylation of histone H2A and myelin basic protein (MBP) in vitro; the relevance of such results is however unclear in vivo. T79501 ECNUMBER EC 2.1.1.321 T79501 SEQUENCE MKIFCSRANPTTGSVEWLEEDEHYDYHQEIARSSYADMLHDKDRNVKYYQGIRAAVSRVKDRGQKALVLDIGTGTGLLSMMAVTAGADFCYAIEVFKPMADAAVKIVEKNGFSDKIKVINKHSTEVTVGPEGDMPCRANILVTELFDTELIGEGALPSYEHAHRHLVEENCEAVPHRATVYAQLVESGRMWSWNKLFPIHVQTSLGEQVIVPPVDVESCPGAPSVCDIQLNQVSPADFTVLSDVLPMFSIDFSKQVSSSAACHSRRFEPLTSGRAQVVLSWWDIEMDPEGKIKCTMAPFWAHSDPEEMQWRDHWMQCVYFLPQEEPVVQGSALYLVAHHDDYCVWYSLQRTSPEKNERVRQMRPVCDCQAHLLWNRPRFGEINDQDRTDRYVQALRTVLKPDSVCLCVSDGSLLSVLAHHLGVEQVFTVESSAASHKLLRKIFKANHLEDKINIIEKRPELLTNEDLQGRKVSLLLGEPFFTTSLLPWHNLYFWYVRTAVDQHLGPGAMVMPQAASLHAVVVEFRDLWRIRSPCGDCEGFDVHIMDDMIKRALDFRESREAEPHPLWEYPCRSLSEPWQILTFDFQQPVPLQPLCAEGTVELRRPGQSHAAVLWMEYHLTPECTLSTGLLEPADPEGGCCWNPHCKQAVYFFSPAPDPRALLGGPRTVSYAVEFHPDTGDIIMEFRHADTPD T79501 DRUGINFO D00QZA DS-437 Investigative T44961 TARGETID T44961 T44961 FORMERID TTDI00215 T44961 UNIPROID RIC8B_HUMAN T44961 TARGNAME Synembryn-B (RIC8B) T44961 GENENAME RIC8B T44961 TARGTYPE Literature-reported T44961 SYNONYMS hSyn; Protein Ric-8B; Brain synembryn T44961 FUNCTION Able to potentiate G(olf)-alpha-dependent cAMP accumulation suggesting that it may be an important component for odorant signal transduction. Guanine nucleotide exchange factor (GEF), which can activate some, but not all, G-alpha proteins by exchanging bound GDP for free GTP. T44961 BIOCLASS Synembryn T44961 SEQUENCE MDEERALYIVRAGEAGAIERVLRDYSDKHRATFKFESTDEDKRKKLCEGIFKVLIKDIPTTCQVSCLEVLRILSRDKKVLVPVTTKENMQILLRLAKLNELDDSLEKVSEFPVIVESLKCLCNIVFNSQMAQQLSLELNLAAKLCNLLRKCKDRKFINDIKCFDLRLLFLLSLLHTDIRSQLRYELQGLPLLTQILESAFSIKWTDEYESAIDHNGPPLSPQETDCAIEALKALFNVTVDSWKVHKESDSHQFRVMAAVLRHCLLIVGPTEDKTEELHSNAVNLLSNVPVSCLDVLICPLTHEETAQEATTLDELPSNKTAEKETVLKNNTMVYNGMNMEAIHVLLNFMEKRIDKGSSYREGLTPVLSLLTECSRAHRNIRKFLKDQVLPPLRDVTNRPEVGSTVRNKLVRLMTHVDLGVKQIAAEFLFVLCKERVDSLLKYTGYGNAAGLLAARGLLAGGRGDNWYSEDEDTDTEEYKNAKPKEELLKPMGLKPDGTITPLEEALNQYSVIEETSSDTD T01255 TARGETID T01255 T01255 FORMERID TTDI03537 T01255 UNIPROID ST32B_HUMAN T01255 TARGNAME Yet another novel kinase 2 (STK32B) T01255 GENENAME STK32B T01255 TARGTYPE Literature-reported T01255 SYNONYMS YANK2; Serine/threonine-protein kinase 32B T01255 FUNCTION Catalyzes the conversion of L-seryl-protein into O-phospho-L-seryl-protein. T01255 ECNUMBER EC 2.7.11.1 T01255 SEQUENCE MGGNHSHKPPVFDENEEVNFDHFQILRAIGKGSFGKVCIVQKRDTKKMYAMKYMNKQKCIERDEVRNVFRELQIMQGLEHPFLVNLWYSFQDEEDMFMVVDLLLGGDLRYHLQQNVHFTEGTVKLYICELALALEYLQRYHIIHRDIKPDNILLDEHGHVHITDFNIATVVKGAERASSMAGTKPYMAPEVFQVYMDRGPGYSYPVDWWSLGITAYELLRGWRPYEIHSVTPIDEILNMFKVERVHYSSTWCKGMVALLRKLLTKDPESRVSSLHDIQSVPYLADMNWDAVFKKALMPGFVPNKGRLNCDPTFELEEMILESKPLHKKKKRLAKNRSRDGTKDSCPLNGHLQHCLETVREEFIIFNREKLRRQQGQGSQLLDTDSRGGGQAQSKLQDGCNNNLLTHTCTRGCSS T01255 DRUGINFO D0RJ8J PMID24793884C74 Investigative T89521 TARGETID T89521 T89521 UNIPROID DTL_HUMAN T89521 TARGNAME DDB1- and CUL4-associated factor 2 (DTL) T89521 GENENAME DTL T89521 TARGTYPE Literature-reported T89521 SYNONYMS Retinoic acid-regulated nuclear matrix-associated protein; RAMP; Lethal(2) denticleless protein homolog; L2DTL; Denticleless protein homolog; DCAF2; CDW1; CDT2 T89521 FUNCTION Substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle control, DNA damage response and translesion DNA synthesis. The DCX(DTL) complex, also named CRL4(CDT2) complex, mediates the polyubiquitination and subsequent degradation of CDT1, CDKN1A/p21(CIP1), FBH1, KMT5A and SDE2. CDT1 degradation in response to DNA damage is necessary to ensure proper cell cycle regulation of DNA replication. CDKN1A/p21(CIP1) degradation during S phase or following UV irradiation is essential to control replication licensing. KMT5A degradation is also important for a proper regulation of mechanisms such as TGF-beta signaling, cell cycle progression, DNA repair and cell migration. Most substrates require their interaction with PCNA for their polyubiquitination: substrates interact with PCNA via their PIP-box, and those containing the 'K+4' motif in the PIP box, recruit the DCX(DTL) complex, leading to their degradation. In undamaged proliferating cells, the DCX(DTL) complex also promotes the 'Lys-164' monoubiquitination of PCNA, thereby being involved in PCNA-dependent translesion DNA synthesis. The DDB1-CUL4A-DTL E3 ligase complex regulates the circadian clock function by mediating the ubiquitination and degradation of CRY1. T89521 PDBSTRUC 6QC0 T89521 SEQUENCE MLFNSVLRQPQLGVLRNGWSSQYPLQSLLTGYQCSGNDEHTSYGETGVPVPPFGCTFSSAPNMEHVLAVANEEGFVRLYNTESQSFRKKCFKEWMAHWNAVFDLAWVPGELKLVTAAGDQTAKFWDVKAGELIGTCKGHQCSLKSVAFSKFEKAVFCTGGRDGNIMVWDTRCNKKDGFYRQVNQISGAHNTSDKQTPSKPKKKQNSKGLAPSVDFQQSVTVVLFQDENTLVSAGAVDGIIKVWDLRKNYTAYRQEPIASKSFLYPGSSTRKLGYSSLILDSTGSTLFANCTDDNIYMFNMTGLKTSPVAIFNGHQNSTFYVKSSLSPDDQFLVSGSSDEAAYIWKVSTPWQPPTVLLGHSQEVTSVCWCPSDFTKIATCSDDNTLKIWRLNRGLEEKPGGDKLSTVGWASQKKKESRPGLVTVTSSQSTPAKAPRAKCNPSNSSPSSAACAPSCAGDLPLPSNTPTFSIKTSPAKARSPINRRGSVSSVSPKPPSSFKMSIRNWVTRTPSSSPPITPPASETKIMSPRKALIPVSQKSSQAEACSESRNRVKRRLDSSCLESVKQKCVKSCNCVTELDGQVENLHLDLCCLAGNQEDLSKDSLGPTKSSKIEGAGTSISEPPSPISPYASESCGTLPLPLRPCGEGSEMVGKENSSPENKNWLLAMAAKRKAENPSPRSPSSQTPNSRRQSGKKLPSPVTITPSSMRKICTYFHRKSQEDFCGPEHSTEL T85545 TARGETID T85545 T85545 FORMERID TTDI02402 T85545 UNIPROID TRPM5_HUMAN T85545 TARGNAME Long transient receptor potential channel 5 (TRPM5) T85545 GENENAME TRPM5 T85545 TARGTYPE Literature-reported T85545 SYNONYMS Transient receptor potential cation channelsubfamily M member 5; TRPM5; MLSN1- and TRP-related gene 1 protein; LTrpC5; LTrpC-5 T85545 FUNCTION Voltage-modulated Ca(2+)-activated, monovalent cation channel (VCAM) that mediates a transient membrane depolarization and plays a central role in taste transduction. Monovalent- specific, non-selective cation channel that mediates the transport of Na(+), K(+) and Cs(+) ions equally well. Activated directly by increases in intracellular Ca(2+), but is impermeable to it. Gating is voltage-dependent and displays rapid activation and deactivation kinetics upon channel stimulation even during sustained elevations in Ca(2+). Also activated by a fast intracellular Ca(2+) increase in response to inositol 1,4,5- triphosphate-producing receptoragonists. The channel is blocked by extracellular acidification. External acidification has 2 effects, a fast reversible block of the current and a slower irreversible enhancement of current inactivation. Is a highly temperature-sensitive, heat activated channel showing a steep increase of inward currents at temperatures between 15 and 35 degrees Celsius. Heat activation is due to a shift of the voltage- dependent activation curve to negative potentials. Activated by arachidonic acid in vitro. May be involved in perception of bitter, sweet and umami tastes. May also be involved in sensing semiochemicals. T85545 BIOCLASS Transient receptor potential catioin channel T85545 SEQUENCE MQDVQGPRPGSPGDAEDRRELGLHRGEVNFGGSGKKRGKFVRVPSGVAPSVLFDLLLAEWHLPAPNLVVSLVGEEQPFAMKSWLRDVLRKGLVKAAQSTGAWILTSALRVGLARHVGQAVRDHSLASTSTKVRVVAVGMASLGRVLHRRILEEAQEDFPVHYPEDDGGSQGPLCSLDSNLSHFILVEPGPPGKGDGLTELRLRLEKHISEQRAGYGGTGSIEIPVLCLLVNGDPNTLERISRAVEQAAPWLILVGSGGIADVLAALVNQPHLLVPKVAEKQFKEKFPSKHFSWEDIVRWTKLLQNITSHQHLLTVYDFEQEGSEELDTVILKALVKACKSHSQEPQDYLDELKLAVAWDRVDIAKSEIFNGDVEWKSCDLEEVMVDALVSNKPEFVRLFVDNGADVADFLTYGRLQELYRSVSRKSLLFDLLQRKQEEARLTLAGLGTQQAREPPAGPPAFSLHEVSRVLKDFLQDACRGFYQDGRPGDRRRAEKGPAKRPTGQKWLLDLNQKSENPWRDLFLWAVLQNRHEMATYFWAMGQEGVAAALAACKILKEMSHLETEAEAARATREAKYERLALDLFSECYSNSEARAFALLVRRNRCWSKTTCLHLATEADAKAFFAHDGVQAFLTRIWWGDMAAGTPILRLLGAFLCPALVYTNLITFSEEAPLRTGLEDLQDLDSLDTEKSPLYGLQSRVEELVEAPRAQGDRGPRAVFLLTRWRKFWGAPVTVFLGNVVMYFAFLFLFTYVLLVDFRPPPQGPSGPEVTLYFWVFTLVLEEIRQGFFTDEDTHLVKKFTLYVGDNWNKCDMVAIFLFIVGVTCRMLPSAFEAGRTVLAMDFMVFTLRLIHIFAIHKQLGPKIIVVERMMKDVFFFLFFLSVWLVAYGVTTQALLHPHDGRLEWIFRRVLYRPYLQIFGQIPLDEIDEARVNCSTHPLLLEDSPSCPSLYANWLVILLLVTFLLVTNVLLMNLLIAMFSYTFQVVQGNADMFWKFQRYNLIVEYHERPALAPPFILLSHLSLTLRRVFKKEAEHKREHLERDLPDPLDQKVVTWETVQKENFLSKMEKRRRDSEGEVLRKTAHRVDFIAKYLGGLREQEKRIKCLESQINYCSVLVSSVADVLAQGGGPRSSQHCGEGSQLVAADHRGGLDGWEQPGAGQPPSDT T18978 TARGETID T18978 T18978 FORMERID TTDI03601 T18978 UNIPROID PK2L1_HUMAN T18978 TARGNAME Polycystic kidney disease 2-like 1 (TRPP2) T18978 GENENAME PKD2L1 T18978 TARGTYPE Literature-reported T18978 SYNONYMS Polycystin-L1; Polycystin-L; Polycystin-2L1; Polycystin-2 homolog; Polycystic kidney disease 2-like 1 protein; PKDL; PKD2L T18978 FUNCTION Pore-forming subunit of a heterotetrameric, non-selective cation channel that is permeable to Ca(2+). Pore-forming subunit of a calcium-permeant ion channel formed by PKD1L2 and PKD1L1 in primary cilia, where it controls cilium calcium concentration, but does not affect cytoplasmic calcium concentration. The channel formed by PKD1L2 and PKD1L1 in primary cilia regulates sonic hedgehog/SHH signaling and GLI2 transcription. Pore-forming subunit of a channel formed by PKD1L2 and PKD1L3 that contributes to sour taste perception in gustatory cells. The heteromeric channel formed by PKD1L2 and PKD1L3 is activated by low pH, but opens only when the extracellular pH rises again. May play a role in the perception of carbonation taste (By similarity). May play a role in the sensory perception of water, via a mechanism that activates the channel in response to dilution of salivary bicarbonate and changes in salivary pH (By similarity). T18978 PDBSTRUC 6DU8; 4GIF; 3TE3 T18978 SEQUENCE MNAVGSPEGQELQKLGSGAWDNPAYSGPPSPHGTLRVCTISSTGPLQPQPKKPEDEPQETAYRTQVSSCCLHICQGIRGLWGTTLTENTAENRELYIKTTLRELLVYIVFLVDICLLTYGMTSSSAYYYTKVMSELFLHTPSDTGVSFQAISSMADFWDFAQGPLLDSLYWTKWYNNQSLGHGSHSFIYYENMLLGVPRLRQLKVRNDSCVVHEDFREDILSCYDVYSPDKEEQLPFGPFNGTAWTYHSQDELGGFSHWGRLTSYSGGGYYLDLPGSRQGSAEALRALQEGLWLDRGTRVVFIDFSVYNANINLFCVLRLVVEFPATGGAIPSWQIRTVKLIRYVSNWDFFIVGCEVIFCVFIFYYVVEEILELHIHRLRYLSSIWNILDLVVILLSIVAVGFHIFRTLEVNRLMGKLLQQPNTYADFEFLAFWQTQYNNMNAVNLFFAWIKIFKYISFNKTMTQLSSTLARCAKDILGFAVMFFIVFFAYAQLGYLLFGTQVENFSTFIKCIFTQFRIILGDFDYNAIDNANRILGPAYFVTYVFFVFFVLLNMFLAIINDTYSEVKEELAGQKDELQLSDLLKQGYNKTLLRLRLRKERVSDVQKVLQGGEQEIQFEDFTNTLRELGHAEHEITELTATFTKFDRDGNRILDEKEQEKMRQDLEEERVALNTEIEKLGRSIVSSPQGKSGPEAARAGGWVSGEEFYMLTRRVLQLETVLEGVVSQIDAVGSKLKMLERKGWLAPSPGVKEQAIWKHPQPAPAVTPDPWGVQGGQESEVPYKREEEALEERRLSRGEIPTLQRS T18978 DRUGINFO D03WNI malic acid Investigative T18978 DRUGINFO D05OEV phenamil Investigative T18978 DRUGINFO D0TV1R flufenamate Investigative T18978 DRUGINFO D02ACL benzamil Investigative T18978 DRUGINFO D02RTS citric acid Investigative T02891 TARGETID T02891 T02891 FORMERID TTDI03004 T02891 UNIPROID HTR5B_HUMAN T02891 TARGNAME 5-HT 5B receptor (HTR5B) T02891 GENENAME HTR5B T02891 TARGTYPE Literature-reported T02891 SYNONYMS KIAA1414; HEATR5B; HEAT repeat-containing protein 5B T02891 FUNCTION endocytic vesicle, membrane, endocytosis, protein localization, retrograde transport, endosome to Golgi. T02891 BIOCLASS GPCR rhodopsin T02891 SEQUENCE MELAHSLLLNEEALAQITEAKRPVFIFEWLRFLDKVLVAANKTDVKEKQKKLVEQLTGLISSSPGPPTRKLLAKNLAALYSIGDTFTVFQTLDKCNDIIRNKDDTAAYLPTKLAAVACVGAFYEKMGRMLGSAFPETVNNLLKSLKSAESQGRSEILMSLQKVLSGLGGAAASSHRDIYKNARSLLTDRSMAVRCAVAKCLLELQNEAVFMWTAELENIATLCFKALENSNYGVRVAVSKLLGTVMATALMPKQATVMRQNVKRATFDEVLELMATGFLRGGSGFLKSGGEMLKVGGSVNREVRVGVTQAYVVFVTTLGGQWLERSFATFLSHVLDLVSHPRATQTHVEAVYSRRCVSFILRATVGSLLGEKAQIAAAKEICQAIGKQMKAVEAVVNDTSGENKSGAADIAASQHVMVCALQELGSLVQSLNATASPLIQEASIGLLEIVTSVLLHPSMAARLAAAWCLRCVAVALPFQLTPFLDRCAERLNNLKTSPEAVSGYSFAMAALLGGVHQCPLGIPHAKGKMVVSIAEDLLRTAAQNSRLSLQRTQAGWLLLGALMTLGPSVVRYHLPKMLLLWRNVFPRSLKELEAEKARGDSFTWQVTLEGRAGALCAMRSFVAHCPELLTEDVIRKLMTPIECAMTMMSHIPSVMKAHGAHLKASAAMVRLRLYDILALLPPKTYEGSFNALLRELVAEFTLTDNSANTTTSLLRSLCHYDDSVLLGSWLQETDHKSIEDQLQPNSASGSGALEHDPSSIYLRIPAGEAVPGPLPLGVSVIDASVALFGVVFPHVSYKHRLQMLDHFAECVKQAKGVRQQAVQLNIFTAVLSALKGLAENKSTLGPEEVRKSALTLVMGPLDNPNPILRCAAGEALGRMAQVVGEATFIARMAQYSFDKLKSARDVVSRTGHSLALGCLHRYVGGIGSGQHLKTSVSILLALAQDGTSPEVQTWSLHSLALIVDSSGPMYRGYVEPTLSLVLTLLLTVPPSHTEVHQCLGRCLGAIITTVGPELQGNGATTSTIRSSCLVGCAITQDHSDSLVQAAAISCLQQLHMFAPRHVNLSSLVPSLCVHLCSSHLLLRRAAVACLRQLAQREAAEVCEYAMSLAKNTGDKESSSANVSPFAPGVSSRTDIHCRHQGVNITETGLEGLLFGMLDRETDRKLCSDIHDTLGHMLSSLAVEKLSHWLMLCKDVLAASSDMSTATLLSSGKDEEAEKKDEMDDDTMFTTLGEEDKSKPFVAPRWATRVFAADCLCRIINLCENADQAHFDLALARSAKLRNPTNDLLVLHLSDLIRMAFMAATDHSNQLRMAGLQALEDIIKKFASVPEPEFPGHVILEQYQANVGAALRPAFSQDTPSDIIAKACQVCSTWIGSGVVSDLNDLRRVHNLLVSSLDKVQAGKGSSSQLYRESATTMEKLAVLKAWAEVYVVAMNIKKEAESKPKRAIKNTDDDDDDCGTIDELPPDSLITLVQPELPTLSRLWLAALKDYALLTLPAEFSSQLPPDGGAFYTPETIDTARLHYRNSWAPILHAVALWLNSTGFTCSESTEAAAISGLQKRSTSVNLNQASGAVGSAKSLPEINKDRMHLILGVSIQFLCSPRPEEPIEHVTACLQALHTLLDSPYARVHIAEDQLIGVELLSVLHRLLLTWNPSSVQLLVTGVVQQIVRAAQDYLQEKRNTLNEDDMEKEACTVLGEGGDSGGLIPGKSLVFATMELLMFILVRHMPHLSTKVSDSPSHIATKTRLSEESARLVAATVTILSDLPSLCSPAGCMTILPTILFLIARILKDTAIKSADNQVPPPVSAALQGIKSIVTLSMAKTEAGVQKQWTALIRSTLACILEYSQPEDSVPTPDEVSMLTAIALFLWSASNEIIGVQSLQNGCMNRFKNALNSCDPWVQAKCYQLLLSVFQHSNRALSTPYIHSLAPIVVEKLKAVERNRPASNIELLAVQEGIKVLETLVALGEEQNRVQLLALLVPTLISYLLDENSFASASSASKDLHEFALQNLMHIGPLYPHAFKTVMGAAPELKVRLETAVRASQASKAKAAARQPAPAIHSAPTIKLKTSFF T02891 DRUGINFO D0BW9V [125I]LSD Investigative T02891 DRUGINFO D08PJK [3H]5-CT Investigative T66396 TARGETID T66396 T66396 FORMERID TTDI03187 T66396 UNIPROID E2AK4_HUMAN T66396 TARGNAME Eukaryotic translation initiation factor 2-alpha kinase 4 (EIF2AK4) T66396 GENENAME EIF2AK4 T66396 TARGTYPE Literature-reported T66396 SYNONYMS eIF-2-alpha kinase GCN2; KIAA1338; GCN2-like protein; GCN2 T66396 FUNCTION Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' in response to low amino acid availability. Plays a role as an activator of the integrated stress response (ISR) required for adapatation to amino acid starvation. Converts phosphorylated eIF-2-alpha/EIF2S1 either to a competitive inhibitor of the translation initiation factor eIF-2B, leading to a global protein synthesis repression, and thus to a reduced overall utilization of amino acids, or to a translational initiation activation of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Binds uncharged tRNAs (By similarity). Involved in cell cycle arrest by promoting cyclin D1 mRNA translation repression after the unfolded protein response pathway (UPR) activation or cell cycle inhibitor CDKN1A/p21 mRNA translation activation in response to amino acid deprivation. Plays a role in the consolidation of synaptic plasticity, learning as well as formation of long-term memory. Plays a role in neurite outgrowth inhibition. Plays a proapoptotic role in response to glucose deprivation. Promotes global cellular protein synthesis repression in response to UV irradiation independently of the stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) and p38 MAPK signaling pathways (By similarity). Plays a role in the antiviral response against alphavirus infection; impairs early viral mRNA translation of the incoming genomic virus RNA, thus preventing alphavirus replication (By similarity). T66396 ECNUMBER EC 2.7.11.1 T66396 SEQUENCE MAGGRGAPGRGRDEPPESYPQRQDHELQALEAIYGADFQDLRPDACGPVKEPPEINLVLYPQGLTGEEVYVKVDLRVKCPPTYPDVVPEIELKNAKGLSNESVNLLKSRLEELAKKHCGEVMIFELAYHVQSFLSEHNKPPPKSFHEEMLERRAQEEQQRLLEAKRKEEQEQREILHEIQRRKEEIKEEKKRKEMAKQERLEIASLSNQDHTSKKDPGGHRTAAILHGGSPDFVGNGKHRANSSGRSRRERQYSVCNSEDSPGSCEILYFNMGSPDQLMVHKGKCIGSDEQLGKLVYNALETATGGFVLLYEWVLQWQKKMGPFLTSQEKEKIDKCKKQIQGTETEFNSLVKLSHPNVVRYLAMNLKEQDDSIVVDILVEHISGVSLAAHLSHSGPIPVHQLRRYTAQLLSGLDYLHSNSVVHKVLSASNVLVDAEGTVKITDYSISKRLADICKEDVFEQTRVRFSDNALPYKTGKKGDVWRLGLLLLSLSQGQECGEYPVTIPSDLPADFQDFLKKCVCLDDKERWSPQQLLKHSFINPQPKMPLVEQSPEDSEGQDYVETVIPSNRLPSAAFFSETQRQFSRYFIEFEELQLLGKGAFGAVIKVQNKLDGCCYAVKRIPINPASRQFRRIKGEVTLLSRLHHENIVRYYNAWIERHERPAGPGTPPPDSGPLAKDDRAARGQPASDTDGLDSVEAAAPPPILSSSVEWSTSGERSASARFPATGPGSSDDEDDDEDEHGGVFSQSFLPASDSESDIIFDNEDENSKSQNQDEDCNEKNGCHESEPSVTTEAVHYLYIQMEYCEKSTLRDTIDQGLYRDTVRLWRLFREILDGLAYIHEKGMIHRDLKPVNIFLDSDDHVKIGDFGLATDHLAFSADSKQDDQTGDLIKSDPSGHLTGMVGTALYVSPEVQGSTKSAYNQKVDLFSLGIIFFEMSYHPMVTASERIFVLNQLRDPTSPKFPEDFDDGEHAKQKSVISWLLNHDPAKRPTATELLKSELLPPPQMEESELHEVLHHTLTNVDGKAYRTMMAQIFSQRISPAIDYTYDSDILKGNFSIRTAKMQQHVCETIIRIFKRHGAVQLCTPLLLPRNRQIYEHNEAALFMDHSGMLVMLPFDLRIPFARYVARNNILNLKRYCIERVFRPRKLDRFHPKELLECAFDIVTSTTNSFLPTAEIIYTIYEIIQEFPALQERNYSIYLNHTMLLKAILLHCGIPEDKLSQVYIILYDAVTEKLTRREVEAKFCNLSLSSNSLCRLYKFIEQKGDLQDLMPTINSLIKQKTGIAQLVKYGLKDLEEVVGLLKKLGIKLQVLINLGLVYKVQQHNGIIFQFVAFIKRRQRAVPEILAAGGRYDLLIPQFRGPQALGPVPTAIGVSIAIDKISAAVLNMEESVTISSCDLLVVSVGQMSMSRAINLTQKLWTAGITAEIMYDWSQSQEELQEYCRHHEITYVALVSDKEGSHVKVKSFEKERQTEKRVLETELVDHVLQKLRTKVTDERNGREASDNLAVQNLKGSFSNASGLFEIHGATVVPIVSVLAPEKLSASTRRRYETQVQTRLQTSLANLHQKSSEIEILAVDLPKETILQFLSLEWDADEQAFNTTVKQLLSRLPKQRYLKLVCDEIYNIKVEKKVSVLFLYSYRDDYYRILF T66396 DRUGINFO D0T5VB WO2013110309CA127 Investigative T93511 TARGETID T93511 T93511 FORMERID TTDR00984 T93511 UNIPROID PHLN_BURPS T93511 TARGNAME Bacterial Phosphatidylcholine-specificphospholipase C (Bact plcN) T93511 GENENAME Bact plcN T93511 TARGTYPE Literature-reported T93511 SYNONYMS plcN; Phosphatidylcholine-hydrolyzing phospholipase C; Phosphatidylcholine cholinephosphohydrolase; PLC-N; PC-PLC; Non-hemolytic phospholipase C; Lecithinase T93511 FUNCTION Hydrolyzes phosphatidylserine as well as phosphatidylcholine. T93511 BIOCLASS Phosphoric diester hydrolase T93511 SEQUENCE MTNQNRRDFLRLAAGTAGAAALQLFPPVIREALAIPANRRTGTIRDVEHIVILMQENRSFDHYFGKLRGVRGFGDPRPLALQNGKSVFHQPVLLGPAELLPFHPDASNLGMQFLQDLPHGWQDMHGAWNKGRYDRWIANKGTTTMAYLERDDIPFHYQLADAFTICDAYHCSIPSSTDPNRYYMWTGYVGNDGAGGGPVLGNEEAGYGWSTYPETLEQAGVSWKIYQDIGTGLDAAGSWGWTQNPYIGNYGDNSLLYFNQYRNAQPGSPLYDKARTGTNVSAGGTLFDVLQQDVKNGTLPQVSWICAPEAYSEHPNWPANYGAWYVEQVLKALTSNPDVWSKTALFITYDENDGFFDHVAPPFAPQSRENGLSTVSTAGEIFAGDATHMAGPYGLGPRVPMLVVSPWTKGGWVCSQTFDHTSLLQFIEARFNDRYSVRAPNVTPWRRAVCGDLTSAFNFSSPDGSWPQLPDTSGYAPPDRNRHPSYVPVPPAAQSMPKQEAGLRAARALPYELFVLGRIDQSTGKFKLTFANTGRAGAAFQVTAGNRLDGPWAYTVEARKRLSDEWSTALTLSIYDLTVYGPNGFLCQFRGSTAAALGLSANPEVIYGYDVANGNITLRLSNRGRAAVRLTVTNAYGNAAPRVYELKPGQRINDYWDLRDSHSWYDLSVSDGAPNGFLRRFAGHVETGRPSTSDPLIATA T93511 DRUGINFO D0W1AW D609 Investigative T25740 TARGETID T25740 T25740 FORMERID TTDR00539 T25740 UNIPROID Q9U738_PLAFA T25740 TARGNAME Plasmodium Folylpolyglutamate synthase (Malaria dhfs-fpgs) T25740 GENENAME Malaria dhfs-fpgs T25740 TARGTYPE Literature-reported T25740 SYNONYMS dhfs-fpgs; Folylpolyglutamate synthetase; Folylpoly-gamma-glutamate synthetase; FPGS T25740 FUNCTION Catalyzes conversion of folates to polyglutamate derivatives allowing concentration of folate compounds in the cell and the intracellular retention of these cofactors, which are important substrates for most of the folate-dependent enzymes that are involved in one-carbon transfer reactions involved in purine, pyrimidine and amino acid synthesis. Unsubstitued reduced folates are the preferred substrates. Metabolizes methotrexate (MTX) to polyglutamates. T25740 BIOCLASS Carbon-nitrogen ligase T25740 SEQUENCE MEKNQNDKSNKNDIIHMNDKSGNYDKNNINNFIDKNDEHDMSDILHKINNEEKKYEEIKSYSECLELLYKTHALKLGLDNPKKLNESFGHPCDKYKTIHIAGTNGKGSVCYKIYTCLKIKKFKVGLFSSPHIFSLRERIIVNDEPISEKELIHLVNEVLNKAKKLYINPSFFEIITLVAFLHFLNKKVDYAIIETGIGGRLDATNILTKPEVIVITSIGYDHLNILGDNLPIICNEKIGIFKKDANVVIGPSVAIYKNVFDKAKELNCTIHTVVPEPRGERYNEENSRIALRTLEILNISIDYFLKSIIPIKPPLRIQYLATEQIQHIKKKFSPDNLEHNVQYPLAVILDVGHNETAIDRLCTDINYFHKGQNIRICISITKPRNLSVFHPFIAQFGDTLKDIFYLPSLNERTYDFEEIVEMLNNEEEIKNEIKELILSSSKKVGKWLAHEKQGNINEEDALKLYKRGCIPLIIKNAFLECCKDNSILLVCGTFFVFDEVLNVFDIHSDMQDTIFMNEPSLV T17291 TARGETID T17291 T17291 FORMERID TTDI03028 T17291 UNIPROID RHCG_HUMAN T17291 TARGNAME Ammonium transporter Rh type C (RHCG) T17291 GENENAME RHCG T17291 TARGTYPE Literature-reported T17291 SYNONYMS Tumor-related protein DRC2; Rhesus blood group family type C glycoprotein; Rh type C glycoprotein; Rh glycoprotein kidney; Rh family type C glycoprotein; RHGK; PDRC2; CDRC2; C15orf6 T17291 FUNCTION Functions as an electroneutral and bidirectional ammonium transporter. May regulate transepithelial ammonia secretion. T17291 PDBSTRUC 3HD6 T17291 SEQUENCE MAWNTNLRWRLPLTCLLLQVIMVILFGVFVRYDFEADAHWWSERTHKNLSDMENEFYYRYPSFQDVHVMVFVGFGFLMTFLQRYGFSAVGFNFLLAAFGIQWALLMQGWFHFLQDRYIVVGVENLINADFCVASVCVAFGAVLGKVSPIQLLIMTFFQVTLFAVNEFILLNLLKVKDAGGSMTIHTFGAYFGLTVTRILYRRNLEQSKERQNSVYQSDLFAMIGTLFLWMYWPSFNSAISYHGDSQHRAAINTYCSLAACVLTSVAISSALHKKGKLDMVHIQNATLAGGVAVGTAAEMMLMPYGALIIGFVCGIISTLGFVYLTPFLESRLHIQDTCGINNLHGIPGIIGGIVGAVTAASASLEVYGKEGLVHSFDFQGFNGDWTARTQGKFQIYGLLVTLAMALMGGIIVGLILRLPFWGQPSDENCFEDAVYWEMPEGNSTVYIPEDPTFKPSGPSVPSVPMVSPLPMASSVPLVP T17291 DRUGINFO D0JS4B [14C]methylamine Investigative T10125 TARGETID T10125 T10125 FORMERID TTDNC00497 T10125 UNIPROID DKK2_HUMAN T10125 TARGNAME Dickkopf-related protein 2 (DKK2) T10125 GENENAME DKK2 T10125 TARGTYPE Literature-reported T10125 SYNONYMS hDkk2; hDkk-2; UNQ682/PRO1316; Dkk2; Dkk-2; Dickkopfrelated protein 2; Dickkopf2; Dickkopf-2 T10125 FUNCTION DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease. Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6. T10125 BIOCLASS Dickkopf protein T10125 SEQUENCE MAALMRSKDSSCCLLLLAAVLMVESSQIGSSRAKLNSIKSSLGGETPGQAANRSAGMYQGLAFGGSKKGKNLGQAYPCSSDKECEVGRYCHSPHQGSSACMVCRRKKKRCHRDGMCCPSTRCNNGICIPVTESILTPHIPALDGTRHRDRNHGHYSNHDLGWQNLGRPHTKMSHIKGHEGDPCLRSSDCIEGFCCARHFWTKICKPVLHQGEVCTKQRKKGSHGLEIFQRCDCAKGLSCKVWKDATYSSKARLHVCQKI T67837 TARGETID T67837 T67837 FORMERID TTDR01328 T67837 UNIPROID STK39_HUMAN T67837 TARGNAME Ste-20-related kinase (STK39) T67837 GENENAME STK39 T67837 TARGTYPE Literature-reported T67837 SYNONYMS Serine/threonine-protein kinase 39; STE20/SPS1-related proline-alanine-rich protein kinase; SPAK; DCHT T67837 FUNCTION May act as a mediator of stress-activated signals. Mediates the inhibition of SLC4A4, SLC26A6 as well as CFTR activities by the WNK scaffolds, probably through phosphorylation. Phosphorylates RELT. T67837 ECNUMBER EC 2.7.11.1 T67837 SEQUENCE MAEPSGSPVHVQLPQQAAPVTAAAAAAPAAATAAPAPAAPAAPAPAPAPAAQAVGWPICRDAYELQEVIGSGATAVVQAALCKPRQERVAIKRINLEKCQTSMDELLKEIQAMSQCSHPNVVTYYTSFVVKDELWLVMKLLSGGSMLDIIKYIVNRGEHKNGVLEEAIIATILKEVLEGLDYLHRNGQIHRDLKAGNILLGEDGSVQIADFGVSAFLATGGDVTRNKVRKTFVGTPCWMAPEVMEQVRGYDFKADMWSFGITAIELATGAAPYHKYPPMKVLMLTLQNDPPTLETGVEDKEMMKKYGKSFRKLLSLCLQKDPSKRPTAAELLKCKFFQKAKNREYLIEKLLTRTPDIAQRAKKVRRVPGSSGHLHKTEDGDWEWSDDEMDEKSEEGKAAFSQEKSRRVKEENPEIAVSASTIPEQIQSLSVHDSQGPPNANEDYREASSCAVNLVLRLRNSRKELNDIRFEFTPGRDTADGVSQELFSAGLVDGHDVVIVAANLQKIVDDPKALKTLTFKLASGCDGSEIPDEVKLIGFAQLSVS T88567 TARGETID T88567 T88567 FORMERID TTDNR00657 T88567 UNIPROID CLM8_HUMAN T88567 TARGNAME CMRF35-like molecule 8 (CD300A) T88567 GENENAME CD300A T88567 TARGTYPE Literature-reported T88567 SYNONYMS NK inhibitory receptor; Inhibitory receptor protein 60; Immunoglobulin superfamily member 12; IgSF12; IRp60; IRC1/IRC2; HSPC083; CMRF35H; CMRF35-H9; CMRF35-H; CMRF-35-H9; CLM-8; CD300a; CD300 antigen-like family member A T88567 FUNCTION Negatively regulates the Toll-like receptor (TLR) signaling mediated by MYD88 but not TRIF through activation of PTPN6. Inhibitory receptor which may contribute to the down-regulation of cytolytic activity in natural killer (NK) cells, and to the down-regulation of mast cell degranulation. T88567 PDBSTRUC 2Q87 T88567 SEQUENCE MWLPWALLLLWVPGCFALSKCRTVAGPVGGSLSVQCPYEKEHRTLNKYWCRPPQIFLCDKIVETKGSAGKRNGRVSIRDSPANLSFTVTLENLTEEDAGTYWCGVDTPWLRDFHDPVVEVEVSVFPASTSMTPASITAAKTSTITTAFPPVSSTTLFAVGATHSASIQEETEEVVNSQLPLLLSLLALLLLLLVGASLLAWRMFQKWIKAGDHSELSQNPKQAATQSELHYANLELLMWPLQEKPAPPREVEVEYSTVASPREELHYASVVFDSNTNRIAAQRPREEEPDSDYSVIRKT T15745 TARGETID T15745 T15745 FORMERID TTDI03060 T15745 UNIPROID BAZ2B_HUMAN T15745 TARGNAME Bromodomain adjacent to zinc finger 2B (BAZ2B) T15745 GENENAME BAZ2B T15745 TARGTYPE Literature-reported T15745 SYNONYMS hWALp4; KIAA1476; Bromodomain adjacent to zinc finger domain protein 2B T15745 FUNCTION May play a role in transcriptional regulation interacting with ISWI. T15745 PDBSTRUC 6FI1; 6FHQ; 6FH7; 6FH6; 6FGU T15745 SEQUENCE MESGERLPSSAASSTTPTSSSTPSVASVVSKGGLSTGVASLSSTINPCGHLFRTAGDQPFNLSTVSSAFPMVSHPVFGLHSASSGHSEFGGLGTLGTPTALAAHPQLASFPGAEWWRTTDAHTRTGATFFPPLLGIPPLFAPPAQNHDSSSFHSRTSGKSNRNGPEKGVNGSINGSNTSSVIGINTSVLSTTASSSMGQTKSTSSGGGNRKCNQEQSKNQPLDARVDKIKDKKPRKKAMESSSNSDSDSGTSSDTSSEGISSSDSDDLEEDEEEEDQSIEESEDDDSDSESEAQHKSNNQVLLHGISDPKADGQKATEKAQEKRIHQPLPLASESQTHSFQSQQKQPQVLSQQLPFIFQSSQAKEESVNKHTSVIQSTGLVSNVKPLSLVNQAKKETYMKLIVPSPDVLKAGNKNTSEESSLLTSELRSKREQYKQAFPSQLKKQESSKSLKKVIAALSNPKATSSSPAHPKQTLENNHPNPFLTNALLGNHQPNGVIQSVIQEAPLALTTKTKMQSKINENIAAASSTPFSSPVNLSTSGRRTPGNQTPVMPSASPILHSQGKEKAVSNNVNPVKTQHHSHPAKSLVEQFRGTDSDIPSSKDSEDSNEDEEEDDEEEDEEDDEDDESDDSQSESDSNSESDTEGSEEEDDDDKDQDESDSDTEGEKTSMKLNKTTSSVKSPSMSLTGHSTPRNLHIAKAPGSAPAALCSESQSPAFLGTSSSTLTSSPHSGTSKRRRVTDERELRIPLEYGWQRETRIRNFGGRLQGEVAYYAPCGKKLRQYPEVIKYLSRNGIMDISRDNFSFSAKIRVGDFYEARDGPQGMQWCLLKEEDVIPRIRAMEGRRGRPPNPDRQRAREESRMRRRKGRPPNVGNAEFLDNADAKLLRKLQAQEIARQAAQIKLLRKLQKQEQARVAKEAKKQQAIMAAEEKRKQKEQIKIMKQQEKIKRIQQIRMEKELRAQQILEAKKKKKEEAANAKLLEAEKRIKEKEMRRQQAVLLKHQERERRRQHMMLMKAMEARKKAEEKERLKQEKRDEKRLNKERKLEQRRLELEMAKELKKPNEDMCLADQKPLPELPRIPGLVLSGSTFSDCLMVVQFLRNFGKVLGFDVNIDVPNLSVLQEGLLNIGDSMGEVQDLLVRLLSAAVCDPGLITGYKAKTALGEHLLNVGVNRDNVSEILQIFMEAHCGQTELTESLKTKAFQAHTPAQKASVLAFLINELACSKSVVSEIDKNIDYMSNLRRDKWVVEGKLRKLRIIHAKKTGKRDTSGGIDLGEEQHPLGTPTPGRKRRRKGGDSDYDDDDDDDSDDQGDEDDEDEEDKEDKKGKKTDICEDEDEGDQAASVEELEKQIEKLSKQQSQYRRKLFDASHSLRSVMFGQDRYRRRYWILPQCGGIFVEGMESGEGLEEIAKEREKLKKAESVQIKEEMFETSGDSLNCSNTDHCEQKEDLKEKDNTNLFLQKPGSFSKLSKLLEVAKMPPESEVMTPKPNAGANGCTLSYQNSGKHSLGSVQSTATQSNVEKADSNNLFNTGSSGPGKFYSPLPNDQLLKTLTEKNRQWFSLLPRTPCDDTSLTHADMSTASLVTPQSQPPSKSPSPTPAPLGSSAQNPVGLNPFALSPLQVKGGVSMMGLQFCGWPTGVVTSNIPFTSSVPSLGSGLGLSEGNGNSFLTSNVASSKSESPVPQNEKATSAQPAAVEVAKPVDFPSPKPIPEEMQFGWWRIIDPEDLKALLKVLHLRGIREKALQKQIQKHLDYITQACLKNKDVAIIELNENEENQVTRDIVENWSVEEQAMEMDLSVLQQVEDLERRVASASLQVKGWMCPEPASEREDLVYFEHKSFTKLCKEHDGEFTGEDESSAHALERKSDNPLDIAVTRLADLERNIERRIEEDIAPGLRVWRRALSEARSAAQVALCIQQLQKSIAWEKSIMKVYCQICRKGDNEELLLLCDGCDKGCHTYCHRPKITTIPDGDWFCPACIAKASGQTLKIKKLHVKGKKTNESKKGKKVTLTGDTEDEDSASTSSSLKRGNKDLKKRKMEENTSINLSKQESFTSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS T15745 DRUGINFO D02KSN PMID25719566C7 Investigative T15745 DRUGINFO D07HET PMID25719566C1 Investigative T15745 DRUGINFO D0I4FP BAZ2-ICR Investigative T15745 DRUGINFO D0T3WL GSK2801 Investigative T95682 TARGETID T95682 T95682 FORMERID TTDI03059 T95682 UNIPROID BAZ2A_HUMAN T95682 TARGNAME Bromodomain adjacent to zinc finger 2A (BAZ2A) T95682 GENENAME BAZ2A T95682 TARGTYPE Literature-reported T95682 SYNONYMS hWALp3; Transcription termination factor I-interacting protein 5; Tip5; TTF-I-interacting protein 5; KIAA0314; Bromodomain adjacent to zinc finger domain protein 2A T95682 FUNCTION In the complex, it plays a central role by being recruited to rDNA and by targeting chromatin modifying enzymes such as HDAC1, leading to repress RNA polymerase I transcription. Recruited to rDNA via its interaction with TTF1 and its ability to recognize and bind histone H4 acetylated on 'Lys-16' (H4K16ac), leading to deacetylation of H4K5ac, H4K8ac, H4K12ac but not H4K16ac. Specifically binds pRNAs, 150-250 nucleotide RNAs that are complementary in sequence to the rDNA promoter; pRNA-binding is required for heterochromatin formation and rDNA silencing. Essential component of the NoRC (nucleolar remodeling complex) complex, a complex that mediates silencing of a fraction of rDNA by recruiting histone-modifying enzymes and DNA methyltransferases, leading to heterochromatin formation and transcriptional silencing. T95682 PDBSTRUC 6FKP; 6FI0; 6FHU; 6FGW; 6FGV T95682 SEQUENCE MEMEANDHFNFTGLPPAPAASGLKPSPSSGEGLYTNGSPMNFPQQGKSLNGDVNVNGLSTVSHTTTSGILNSAPHSSSTSHLHHPSVAYDCLWNYSQYPSANPGSNLKDPPLLSQFSGGQYPLNGILGGSRQPSSPSHNTNLRAGSQEFWANGTQSPMGLNFDSQELYDSFPDQNFEVMPNGPPSFFTSPQTSPMLGSSIQTFAPSQEVGSGIHPDEAAEKEMTSVVAENGTGLVGSLELEEEQPELKMCGYNGSVPSVESLHQEVSVLVPDPTVSCLDDPSHLPDQLEDTPILSEDSLEPFNSLAPEPVSGGLYGIDDTELMGAEDKLPLEDSPVISALDCPSLNNATAFSLLADDSQTSTSIFASPTSPPVLGESVLQDNSFDLNNGSDAEQEEMETQSSDFPPSLTQPAPDQSSTIQLHPATSPAVSPTTSPAVSLVVSPAASPEISPEVCPAASTVVSPAVFSVVSPASSAVLPAVSLEVPLTASVTSPKASPVTSPAAAFPTASPANKDVSSFLETTADVEEITGEGLTASGSGDVMRRRIATPEEVRLPLQHGWRREVRIKKGSHRWQGETWYYGPCGKRMKQFPEVIKYLSRNVVHSVRREHFSFSPRMPVGDFFEERDTPEGLQWVQLSAEEIPSRIQAITGKRGRPRNTEKAKTKEVPKVKRGRGRPPKVKITELLNKTDNRPLKKLEAQETLNEEDKAKIAKSKKKMRQKVQRGECQTTIQGQARNKRKQETKSLKQKEAKKKSKAEKEKGKTKQEKLKEKVKREKKEKVKMKEKEEVTKAKPACKADKTLATQRRLEERQRQQMILEEMKKPTEDMCLTDHQPLPDFSRVPGLTLPSGAFSDCLTIVEFLHSFGKVLGFDPAKDVPSLGVLQEGLLCQGDSLGEVQDLLVRLLKAALHDPGFPSYCQSLKILGEKVSEIPLTRDNVSEILRCFLMAYGVEPALCDRLRTQPFQAQPPQQKAAVLAFLVHELNGSTLIINEIDKTLESMSSYRKNKWIVEGRLRRLKTVLAKRTGRSEVEMEGPEECLGRRRSSRIMEETSGMEEEEEEESIAAVPGRRGRRDGEVDATASSIPELERQIEKLSKRQLFFRKKLLHSSQMLRAVSLGQDRYRRRYWVLPYLAGIFVEGTEGNLVPEEVIKKETDSLKVAAHASLNPALFSMKMELAGSNTTASSPARARGRPRKTKPGSMQPRHLKSPVRGQDSEQPQAQLQPEAQLHAPAQPQPQLQLQLQSHKGFLEQEGSPLSLGQSQHDLSQSAFLSWLSQTQSHSSLLSSSVLTPDSSPGKLDPAPSQPPEEPEPDEAESSPDPQALWFNISAQMPCNAAPTPPPAVSEDQPTPSPQQLASSKPMNRPSAANPCSPVQFSSTPLAGLAPKRRAGDPGEMPQSPTGLGQPKRRGRPPSKFFKQMEQRYLTQLTAQPVPPEMCSGWWWIRDPEMLDAMLKALHPRGIREKALHKHLNKHRDFLQEVCLRPSADPIFEPRQLPAFQEGIMSWSPKEKTYETDLAVLQWVEELEQRVIMSDLQIRGWTCPSPDSTREDLAYCEHLSDSQEDITWRGRGREGLAPQRKTTNPLDLAVMRLAALEQNVERRYLREPLWPTHEVVLEKALLSTPNGAPEGTTTEISYEITPRIRVWRQTLERCRSAAQVCLCLGQLERSIAWEKSVNKVTCLVCRKGDNDEFLLLCDGCDRGCHIYCHRPKMEAVPEGDWFCTVCLAQQVEGEFTQKPGFPKRGQKRKSGYSLNFSEGDGRRRRVLLRGRESPAAGPRYSEEGLSPSKRRRLSMRNHHSDLTFCEIILMEMESHDAAWPFLEPVNPRLVSGYRRIIKNPMDFSTMRERLLRGGYTSSEEFAADALLVFDNCQTFNEDDSEVGKAGHIMRRFFESRWEEFYQGKQANL T95682 DRUGINFO D0I4FP BAZ2-ICR Investigative T95682 DRUGINFO D0T3WL GSK2801 Investigative T86025 TARGETID T86025 T86025 FORMERID TTDR00693 T86025 UNIPROID ANX10_HUMAN T86025 TARGNAME Annexin A10 (ANXA10) T86025 GENENAME ANXA10 T86025 TARGTYPE Literature-reported T86025 SYNONYMS Annexin-14; Annexin-10; ANX14 T86025 FUNCTION The expression of the tissue- and tumor-restricted ANXA10 is a marker of liver cell differentiation and growth arrest, and its down-regulation associated with malignant phenotype of hepatocytes, vascular invasion, and progression of HCC, leading to poor prognosis. T86025 BIOCLASS Annexin protein T86025 SEQUENCE MFCGDYVQGTIFPAPNFNPIMDAQMLGGALQGFDCDKDMLINILTQRCNAQRMMIAEAYQSMYGRDLIGDMREQLSDHFKDVMAGLMYPPPLYDAHELWHAMKGVGTDENCLIEILASRTNGEIFQMREAYCLQYSNNLQEDIYSETSGHFRDTLMNLVQGTREEGYTDPAMAAQDAMVLWEACQQKTGEHKTMLQMILCNKSYQQLRLVFQEFQNISGQDMVDAINECYDGYFQELLVAIVLCVRDKPAYFAYRLYSAIHDFGFHNKTVIRILIARSEIDLLTIRKRYKERYGKSLFHDIRNFASGHYKKALLAICAGDAEDY T35161 TARGETID T35161 T35161 FORMERID TTDI02525 T35161 UNIPROID HSPB8_HUMAN T35161 TARGNAME Heat shock protein beta-8 (HSPB8) T35161 GENENAME HSPB8 T35161 TARGTYPE Literature-reported T35161 SYNONYMS Small stress proteinlike protein HSP22; Small stress protein-like protein HSP22; Protein kinase H11; PP1629; HspB8; Heat shock protein beta8; HSP22; E2induced gene 1 protein; E2IG1; E2-induced gene 1 protein; CRYAC; Alphacrystallin C chain; Alpha-crystallin C chain T35161 FUNCTION Displays temperature-dependent chaperone activity. T35161 BIOCLASS Heat shock protein T35161 SEQUENCE MADGQMPFSCHYPSRLRRDPFRDSPLSSRLLDDGFGMDPFPDDLTASWPDWALPRLSSAWPGTLRSGMVPRGPTATARFGVPAEGRTPPPFPGEPWKVCVNVHSFKPEELMVKTKDGYVEVSGKHEEKQQEGGIVSKNFTKKIQLPAEVDPVTVFASLSPEGLLIIEAPQVPPYSTFGESSFNNELPQDSQEVTCT T90071 TARGETID T90071 T90071 FORMERID TTDI02405 T90071 UNIPROID MYH2_HUMAN T90071 TARGNAME Myosin-2 (MYH2) T90071 GENENAME MYH2 T90071 TARGTYPE Literature-reported T90071 SYNONYMS Myosin heavy chain, skeletal muscle, adult 2; Myosin heavy chain IIa; Myosin heavy chain 2a; Myosin heavy chain 2; MyHCIIa; MyHC2a; MyHC-IIa; MyHC-2a; MYHSA2 T90071 FUNCTION Required for cytoskeleton organization. Muscle contraction. T90071 BIOCLASS Myosin-kinesin ATPase T90071 SEQUENCE MSSDSELAVFGEAAPFLRKSERERIEAQNRPFDAKTSVFVAEPKESFVKGTIQSREGGKVTVKTEGGATLTVKDDQVFPMNPPKYDKIEDMAMMTHLHEPAVLYNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYKPEVVTAYRGKKRQEAPPHIFSISDNAYQFMLTDRENQSILITGESGAGKTVNTKRVIQYFATIAVTGEKKKEEITSGKIQGTLEDQIISANPLLEAFGNAKTVRNDNSSRFGKFIRIHFGTTGKLASADIETYLLEKSRVVFQLKAERSYHIFYQITSNKKPELIEMLLITTNPYDYPFVSQGEISVASIDDQEELMATDSAIDILGFTNEEKVSIYKLTGAVMHYGNLKFKQKQREEQAEPDGTEVADKAAYLQSLNSADLLKALCYPRVKVGNEYVTKGQTVEQVSNAVGALAKAVYEKMFLWMVARINQQLDTKQPRQYFIGVLDIAGFEIFDFNSLEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLAACIELIEKPMGIFSILEEECMFPKATDTSFKNKLYDQHLGKSANFQKPKVVKGKAEAHFALIHYAGVVDYNITGWLEKNKDPLNETVVGLYQKSAMKTLAQLFSGAQTAEGEGAGGGAKKGGKKKGSSFQTVSALFRENLNKLMTNLRSTHPHFVRCIIPNETKTPGAMEHELVLHQLRCNGVLEGIRICRKGFPSRILYADFKQRYKVLNASAIPEGQFIDSKKASEKLLASIDIDHTQYKFGHTKVFFKAGLLGLLEEMRDDKLAQLITRTQARCRGFLARVEYQRMVERREAIFCIQYNIRSFMNVKHWPWMKLFFKIKPLLKSAETEKEMATMKEEFQKIKDELAKSEAKRKELEEKMVTLLKEKNDLQLQVQAEAEGLADAEERCDQLIKTKIQLEAKIKEVTERAEDEEEINAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDETIAKLTKEKKALQEAHQQTLDDLQAEEDKVNTLTKAKIKLEQQVDDLEGSLEQEKKLRMDLERAKRKLEGDLKLAQESIMDIENEKQQLDEKLKKKEFEISNLQSKIEDEQALGIQLQKKIKELQARIEELEEEIEAERASRAKAEKQRSDLSRELEEISERLEEAGGATSAQIEMNKKREAEFQKMRRDLEEATLQHEATAATLRKKHADSVAELGEQIDNLQRVKQKLEKEKSEMKMEIDDLASNVETVSKAKGNLEKMCRTLEDQLSELKSKEEEQQRLINDLTAQRGRLQTESGEFSRQLDEKEALVSQLSRGKQAFTQQIEELKRQLEEEIKAKNALAHALQSSRHDCDLLREQYEEEQESKAELQRALSKANTEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQAAEEHVEAVNAKCASLEKTKQRLQNEVEDLMLDVERTNAACAALDKKQRNFDKILAEWKQKCEETHAELEASQKEARSLGTELFKIKNAYEESLDQLETLKRENKNLQQEISDLTEQIAEGGKRIHELEKIKKQVEQEKCELQAALEEAEASLEHEEGKILRIQLELNQVKSEVDRKIAEKDEEIDQLKRNHIRIVESMQSTLDAEIRSRNDAIRLKKKMEGDLNEMEIQLNHANRMAAEALRNYRNTQGILKDTQIHLDDALRSQEDLKEQLAMVERRANLLQAEIEELRATLEQTERSRKIAEQELLDASERVQLLHTQNTSLINTKKKLETDISQMQGEMEDILQEARNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTVKDLQLRLDEAEQLALKGGKKQIQKLEARVRELEGEVESEQKRNAEAVKGLRKHERRVKELTYQTEEDRKNILRLQDLVDKLQAKVKSYKRQAEEAEEQSNTNLAKFRKLQHELEEAEERADIAESQVNKLRVKSREVHTKVISEE T98577 TARGETID T98577 T98577 FORMERID TTDI02498 T98577 UNIPROID ITA11_HUMAN T98577 TARGNAME Integrin alpha-11 (ITGA11) T98577 GENENAME ITGA11 T98577 TARGTYPE Literature-reported T98577 SYNONYMS MSTP018 T98577 FUNCTION Integrin alpha-11/beta-1 is a receptor for collagen. T98577 BIOCLASS Integrin T98577 SEQUENCE MDLPRGLVVAWALSLWPGFTDTFNMDTRKPRVIPGSRTAFFGYTVQQHDISGNKWLVVGAPLETNGYQKTGDVYKCPVIHGNCTKLNLGRVTLSNVSERKDNMRLGLSLATNPKDNSFLACSPLWSHECGSSYYTTGMCSRVNSNFRFSKTVAPALQRCQTYMDIVIVLDGSNSIYPWVEVQHFLINILKKFYIGPGQIQVGVVQYGEDVVHEFHLNDYRSVKDVVEAASHIEQRGGTETRTAFGIEFARSEAFQKGGRKGAKKVMIVITDGESHDSPDLEKVIQQSERDNVTRYAVAVLGYYNRRGINPETFLNEIKYIASDPDDKHFFNVTDEAALKDIVDALGDRIFSLEGTNKNETSFGLEMSQTGFSSHVVEDGVLLGAVGAYDWNGAVLKETSAGKVIPLRESYLKEFPEELKNHGAYLGYTVTSVVSSRQGRVYVAGAPRFNHTGKVILFTMHNNRSLTIHQAMRGQQIGSYFGSEITSVDIDGDGVTDVLLVGAPMYFNEGRERGKVYVYELRQNLFVYNGTLKDSHSYQNARFGSSIASVRDLNQDSYNDVVVGAPLEDNHAGAIYIFHGFRGSILKTPKQRITASELATGLQYFGCSIHGQLDLNEDGLIDLAVGALGNAVILWSRPVVQINASLHFEPSKINIFHRDCKRSGRDATCLAAFLCFTPIFLAPHFQTTTVGIRYNATMDERRYTPRAHLDEGGDRFTNRAVLLSSGQELCERINFHVLDTADYVKPVTFSVEYSLEDPDHGPMLDDGWPTTLRVSVPFWNGCNEDEHCVPDLVLDARSDLPTAMEYCQRVLRKPAQDCSAYTLSFDTTVFIIESTRQRVAVEATLENRGENAYSTVLNISQSANLQFASLIQKEDSDGSIECVNEERRLQKQVCNVSYPFFRAKAKVAFRLDFEFSKSIFLHHLEIELAAGSDSNERDSTKEDNVAPLRFHLKYEADVLFTRSSSLSHYEVKPNSSLERYDGIGPPFSCIFRIQNLGLFPIHGMMMKITIPIATRSGNRLLKLRDFLTDEANTSCNIWGNSTEYRPTPVEEDLRRAPQLNHSNSDVVSINCNIRLVPNQEINFHLLGNLWLRSLKALKYKSMKIMVNAALQRQFHSPFIFREEDPSRQIVFEISKQEDWQVPIWIIVGSTLGGLLLLALLVLALWKLGFFRSARRRREPGLDPTPKVLE T82955 TARGETID T82955 T82955 FORMERID TTDI00181 T82955 UNIPROID RB22A_HUMAN T82955 TARGNAME Ras-related protein Rab-22A (Rab22a) T82955 GENENAME RAB22A T82955 TARGTYPE Literature-reported T82955 SYNONYMS Rab-22; RAB22 T82955 FUNCTION Mediates trafficking of TF from early endosomes to recycling endosomes. Required for NGF-mediated endocytosis of NTRK1, and subsequent neurite outgrowth. Binds GTP and GDP and has low GTPase activity. Alternates between a GTP-bound active form and a GDP-bound inactive form. Plays a role in endocytosis and intracellular protein transport. T82955 BIOCLASS Small GTPase T82955 SEQUENCE MALRELKVCLLGDTGVGKSSIVWRFVEDSFDPNINPTIGASFMTKTVQYQNELHKFLIWDTAGQERFRALAPMYYRGSAAAIIVYDITKEETFSTLKNWVKELRQHGPPNIVVAIAGNKCDLIDVREVMERDAKDYADSIHAIFVETSAKNAININELFIEISRRIPSTDANLPSGGKGFKLRRQPSEPKRSCC T27466 TARGETID T27466 T27466 FORMERID TTDI03062 T27466 UNIPROID BRPF3_HUMAN T27466 TARGNAME Bromodomain and PHD finger containing 3 (BRPF3) T27466 GENENAME BRPF3 T27466 TARGTYPE Literature-reported T27466 SYNONYMS KIAA1286; Bromodomain and PHD finger-containing protein 3 T27466 FUNCTION Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. T27466 PDBSTRUC 3PFS T27466 SEQUENCE MRKPRRKSRQNAEGRRSPSPYSLKCSPTRETLTYAQAQRIVEVDIDGRLHRISIYDPLKIITEDELTAQDITECNSNKENSEQPQFPGKSKKPSSKGKKKESCSKHASGTSFHLPQPSFRMVDSGIQPEAPPLPAAYYRYIEKPPEDLDAEVEYDMDEEDLAWLDMVNEKRRVDGHSLVSADTFELLVDRLEKESYLESRSSGAQQSLIDEDAFCCVCLDDECHNSNVILFCDICNLAVHQECYGVPYIPEGQWLCRCCLQSPSRPVDCILCPNKGGAFKQTSDGHWAHVVCAIWIPEVCFANTVFLEPIEGIDNIPPARWKLTCYICKQKGLGAAIQCHKVNCYTAFHVTCAQRAGLFMKIEPMRETSLNGTIFTVRKTAYCEAHSPPGAATARRKGDSPRSISETGDEEGLKEGDGEEEEEEEVEEEEQEAQGGVSGSLKGVPKKSKMSLKQKIKKEPEEAGQDTPSTLPMLAVPQIPSYRLNKICSGLSFQRKNQFMQRLHNYWLLKRQARNGVPLIRRLHSHLQSQRNAEQREQDEKTSAVKEELKYWQKLRHDLERARLLIELIRKREKLKREQVKVQQAAMELELMPFNVLLRTTLDLLQEKDPAHIFAEPVNLSEVPDYLEFISKPMDFSTMRRKLESHLYRTLEEFEEDFNLIVTNCMKYNAKDTIFHRAAVRLRDLGGAILRHARRQAENIGYDPERGTHLPESPKLEDFYRFSWEDVDNILIPENRAHLSPEVQLKELLEKLDLVSAMRSSGARTRRVRLLRREINALRQKLAQPPPPQPPSLNKTVSNGELPAGPQGDAAVLEQALQEEPEDDGDRDDSKLPPPPTLEPTGPAPSLSEQESPPEPPTLKPINDSKPPSRFLKPRKVEEDELLEKSPLQLGNEPLQRLLSDNGINRLSLMAPDTPAGTPLSGVGRRTSVLFKKAKNGVKLQRSPDRVLENGEDHGVAGSPASPASIEEERHSRKRPRSRSCSESEGERSPQQEEETGMTNGFGKHTESGSDSECSLGLSGGLAFEACSGLTPPKRSRGKPALSRVPFLEGVNGDSDYNGSGRSLLLPFEDRGDLEPLELVWAKCRGYPSYPALIIDPKMPREGLLHNGVPIPVPPLDVLKLGEQKQAEAGEKLFLVLFFDNKRTWQWLPRDKVLPLGVEDTVDKLKMLEGRKTSIRKSVQVAYDRAMIHLSRVRGPHSFVTSSYL T27466 DRUGINFO D0O6XT NI-57 Investigative T62643 TARGETID T62643 T62643 FORMERID TTDI03336 T62643 UNIPROID KCNH3_HUMAN T62643 TARGNAME Voltage-gated potassium channel Kv12.2 (KCNH3) T62643 GENENAME KCNH3 T62643 TARGTYPE Literature-reported T62643 SYNONYMS Voltage-gated potassium channel subunit Kv12.2; Potassium voltage-gated channel subfamily H member 3; KIAA1282; Ether-a-go-go-like potassium channel 2; ELK2; ELK channel 2; Brain-specific eag-like channel 1; BEC1 T62643 FUNCTION Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits an outward current with fast inactivation. Channel properties may be modulated by cAMP and subunit assembly. T62643 BIOCLASS Voltage-gated ion channel T62643 SEQUENCE MPAMRGLLAPQNTFLDTIATRFDGTHSNFVLGNAQVAGLFPVVYCSDGFCDLTGFSRAEVMQRGCACSFLYGPDTSELVRQQIRKALDEHKEFKAELILYRKSGLPFWCLLDVIPIKNEKGEVALFLVSHKDISETKNRGGPDRWKETGGGRRRYGRARSKGFNANRRRSRAVLYHLSGHLQKQPKGKHKLNKGVFGEKPNLPEYKVAAIRKSPFILLHCGALRATWDGFILLATLYVAVTVPYSVCVSTAREPSAARGPPSVCDLAVEVLFILDIVLNFRTTFVSKSGQVVFAPKSICLHYVTTWFLLDVIAALPFDLLHAFKVNVYFGAHLLKTVRLLRLLRLLPRLDRYSQYSAVVLTLLMAVFALLAHWVACVWFYIGQREIESSESELPEIGWLQELARRLETPYYLVGRRPAGGNSSGQSDNCSSSSEANGTGLELLGGPSLRSAYITSLYFALSSLTSVGFGNVSANTDTEKIFSICTMLIGALMHAVVFGNVTAIIQRMYARRFLYHSRTRDLRDYIRIHRIPKPLKQRMLEYFQATWAVNNGIDTTELLQSLPDELRADIAMHLHKEVLQLPLFEAASRGCLRALSLALRPAFCTPGEYLIHQGDALQALYFVCSGSMEVLKGGTVLAILGKGDLIGCELPRREQVVKANADVKGLTYCVLQCLQLAGLHDSLALYPEFAPRFSRGLRGELSYNLGAGGGSAEVDTSSLSGDNTLMSTLEEKETDGEQGPTVSPAPADEPSSPLLSPGCTSSSSAAKLLSPRRTAPRPRLGGRGRPGRAGALKAEAGPSAPPRALEGLRLPPMPWNVPPDLSPRVVDGIEDGCGSDQPKFSFRVGQSGPECSSSPSPGPESGLLTVPHGPSEARNTDTLDKLRQAVTELSEQVLQMREGLQSLRQAVQLVLAPHREGPCPRASGEGPCPASTSGLLQPLCVDTGASSYCLQPPAGSVLSGTWPHPRPGPPPLMAPWPWGPPASQSSPWPRATAFWTSTSDSEPPASGDLCSEPSTPASPPPSEEGARTGPAEPVSQAEATSTGEPPPGSGGLALPWDPHSLEMVLIGCHGSGTVQWTQEEGTGV T62643 DRUGINFO D0F5KY CX4 Investigative T27819 TARGETID T27819 T27819 FORMERID TTDR00754 T27819 UNIPROID MD1L1_HUMAN T27819 TARGNAME Mitotic checkpoint protein (MAD1L1) T27819 GENENAME MAD1L1 T27819 TARGTYPE Literature-reported T27819 SYNONYMS hMAD1; Tax-binding protein 181; TXBP181; Mitotic spindle assembly checkpoint protein MAD1; Mitotic checkpoint gene hMAD1; Mitotic checkpoint MAD1 protein homolog; Mitotic arrest deficient 1-like protein 1; MAD1-like protein 1; MAD1 (Mitotic arrest deficient, yeast, homolog)-like 1; MAD1; HsMAD1 T27819 FUNCTION May recruit MAD2L1 to unattached kinetochores. Has a role in the correct positioning of the septum. Required for anchoring MAD2L1 to the nuclear periphery. Binds to the TERT promoter and represses telomerase expression, possibly by interfering with MYC binding. Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate. T27819 PDBSTRUC 4DZO; 1GO4 T27819 SEQUENCE MEDLGENTMVLSTLRSLNNFISQRVEGGSGLDISTSAPGSLQMQYQQSMQLEERAEQIRSKSHLIQVEREKMQMELSHKRARVELERAASTSARNYEREVDRNQELLTRIRQLQEREAGAEEKMQEQLERNRQCQQNLDAASKRLREKEDSLAQAGETINALKGRISELQWSVMDQEMRVKRLESEKQELQEQLDLQHKKCQEANQKIQELQASQEARADHEQQIKDLEQKLSLQEQDAAIVKNMKSELVRLPRLERELKQLREESAHLREMRETNGLLQEELEGLQRKLGRQEKMQETLVGLELENERLLAKLQSWERLDQTMGLSIRTPEDLSRFVVELQQRELALKDKNSAVTSSARGLEKARQQLQEELRQVSGQLLEERKKRETHEALARRLQKRVLLLTKERDGMRAILGSYDSELTPAEYSPQLTRRMREAEDMVQKVHSHSAEMEAQLSQALEELGGQKQRADMLEMELKMLKSQSSSAEQSFLFSREEADTLRLKVEELEGERSRLEEEKRMLEAQLERRALQGDYDQSRTKVLHMSLNPTSVARQRLREDHSQLQAECERLRGLLRAMERGGTVPADLEAAAASLPSSKEVAELKKQVESAELKNQRLKEVFQTKIQEFRKACYTLTGYQIDITTENQYRLTSLYAEHPGDCLIFKATSPSGSKMQLLETEFSHTVGELIEVHLRRQDSIPAFLSSLTLELFSRQTVA T44585 TARGETID T44585 T44585 FORMERID TTDI00122 T44585 UNIPROID SH2B3_HUMAN T44585 TARGNAME Signal transduction protein Lnk (SH2B3) T44585 GENENAME SH2B3 T44585 TARGTYPE Literature-reported T44585 SYNONYMS SH2B3; SH2B adapter protein 3; Lymphocyte-specific adapter protein Lnk; Lymphocyte adapter protein T44585 FUNCTION Links T-cell receptor activation signal to phospholipaseC-gamma-1, GRB2 and phosphatidylinositol 3-kinase. T44585 BIOCLASS SH2B adapter family T44585 SEQUENCE MNGPALQPSSPSSAPSASPAAAPRGWSEFCELHAVAAARELARQYWLFAREHPQHAPLRAELVSLQFTDLFQRYFCREVRDGRAPGRDYRDTGRGPPAKAEASPEPGPGPAAPGLPKARSSEELAPPRPPGPCSFQHFRRSLRHIFRRRSAGELPAAHTAAAPGTPGEAAETPARPGLAKKFLPWSLAREPPPEALKEAVLRYSLADEASMDSGARWQRGRLALRRAPGPDGPDRVLELFDPPKSSRPKLQAACSSIQEVRWCTRLEMPDNLYTFVLKVKDRTDIIFEVGDEQQLNSWMAELSECTGRGLESTEAEMHIPSALEPSTSSSPRGSTDSLNQGASPGGLLDPACQKTDHFLSCYPWFHGPISRVKAAQLVQLQGPDAHGVFLVRQSETRRGEYVLTFNFQGIAKHLRLSLTERGQCRVQHLHFPSVVDMLHHFQRSPIPLECGAACDVRLSSYVVVVSQPPGSCNTVLFPFSLPHWDSESLPHWGSELGLPHLSSSGCPRGLSPEGLPGRSSPPEQIFHLVPSPEELANSLQHLEHEPVNRARDSDYEMDSSSRSHLRAIDNQYTPL T34408 TARGETID T34408 T34408 FORMERID TTDR00839 T34408 UNIPROID Q9UVD0_PNECA T34408 TARGNAME Fungal Kexin-like serine endoprotease (Fung klse) T34408 GENENAME Fung klse T34408 TARGTYPE Literature-reported T34408 SYNONYMS Kexin-like serine endoprotease T34408 FUNCTION Cleave secretory proproteins to their active forms. Required for N-Glycan processing, morphogenesis and virulence T34408 BIOCLASS Peptidase T34408 SEQUENCE EPPAPPSQPEPPAPQPQPEPPAPPPQPEPPAPPPQPEPPAPPPQPEPPAPPSQPEPPAPPPQPEPPAPPPQPEPPAPPPKPQPEQKPTSITSSTFTTSSSKTKISTIRKASSTKTSSTTKTSTRPSPTEGTFTGSSASYLSFFEKRHLLLQMILLLFFFLFLSYSF T83701 TARGETID T83701 T83701 FORMERID TTDR01083 T83701 UNIPROID PDX1_EMENI T83701 TARGNAME Fungal Pyridoxin biosynthesis pyroA (Fung pyroA) T83701 GENENAME Fung pyroA T83701 TARGTYPE Literature-reported T83701 SYNONYMS pyroA; Pdx1 homolog T83701 FUNCTION Catalyzes the formation of pyridoxal 5'-phosphate from ribose 5-phosphate (RBP), glyceraldehyde 3-phosphate (G3P) and ammonia. The ammonia is provided by PDX2. Can also use ribulose 5- phosphate and dihydroxyacetone phosphate as substrates, resulting from enzyme-catalyzed isomerization of RBP and G3P, respectively. Also plays an indirect role in resistance to singlet oxygen- generating photosensitizers. T83701 ECNUMBER EC 4.3.3.6 T83701 SEQUENCE MAATNGASNDFTVKAGLAQMLKGGVIMDVVNAEQARIAEEAGAAAVMALERVPADIRAQGGVARMSDPSMIKEIMEAVTIPVMAKARIGHFVECQILEAIGVDYIDESEVLTPADNLYHVTKHNFKAPFVCGCRNLGEALRRISEGAAMIRTKGEAGTGDVVEAVKHMRTVNAEIARARAILQSSPDPEPELRAYARELEAPYELLREAAEKGRLPVVNFAAGGVATPADAALMMQLGCDGVFVGSGIFKSGDAKKRAKAIVQAVTHYKDPKVLAEVSQGLGEAMVGINVSHMKDEDKLAKRGW T52513 TARGETID T52513 T52513 FORMERID TTDR00047 T52513 UNIPROID RPOA_PRRSR T52513 TARGNAME Virus Papain-like cysteine protease (Viru pcp) T52513 GENENAME Viru pcp T52513 TARGTYPE Literature-reported T52513 SYNONYMS rep of Porcine reproductive and respiratory syndrome virus; Pol; ORF1ab polyprotein of Porcine reproductive and respiratory syndrome virus; Nsp8; Nsp5-6-7; Nsp3; Nsp12; Nsp11; Non-structural protein 12; Hel; CP of Porcine reproductive and respiratory syndrome virus; 3CLSP T52513 FUNCTION The helicase chain, which contains a zinc finger structure,displays RNA and DNA duplex-unwinding activities with 5' to 3' polarity. T52513 BIOCLASS Arteriviridae polyprotein family T52513 SEQUENCE MSGILDRCTCTPNARVFMAEGQVYCTRCLSARSLLPLNLQVSELGVLGLFYRPEEPLRWTLPRAFPTVECSPAGACWLSAIFPIARMTSGNLNFQQRMVRVAAELYRAGQLTPAVLKALQVYERGCRWYPIVGPVPGVAVFANSLHVSDKPFPGATHVLTNLPLPQRPKPEDFCPFECAMATVYDIGHDAVMYVAERKVSWAPRGGDEVKFEAVPGELKLIANRLRTSFPPHHTVDMSKFAFTAPGCGVSMRVERQHGCLPADTVPEGNCWWSLFDLLPLEVQNKEIRHANQFGYQTKHGVSGKYLQRRLQVNGLRAVTDLNGPIVVQYFSVKESWIRHLKLAGEPSYSGFEDLLRIRVEPNTSPLADKEEKIFRFGSHKWYGAGKRARKARSCATATVAGRALSVRETRQAKEHEVAGANKAEHLKHYSPPAEGNCGWHCISAIANRMVNSKFETTLPERVRPPDDWATDEDLVNAIQILRLPAALDRNGACTSAKYVLKLEGEHWTVTVTPGMSPSLLPLECVQGCCGHKGGLGSPDAVEVSGFDPACLDRLAEVMHLPSSAIPAALAEMSGDSDRSASPVTTVWTVSQFFARHSGGNHPDQVRLGKIISLCQVIEDCCCSQNKTNRVTPEEVAAKIDLYLRGATNLEECLARLEKARPPRVIDTSFDWDVVLPGVEAATQTIKLPQVNQCRALVPVVTQKSLDNNSVPLTAFSLANYYYRAQGDEVRHRERLTAVLSKLEKVVREEYGLMPTEPGPRPTLPRGLDELKDQMEEDLLKLANAQTTSDMMAWAVEQVDLKTWVKNYPRWTPPPPPPKVQPRKTKPVKSLPERKPVPAPRRKVGSDCGSPVSLGGDVPNSWEDLAVSSPFDLPTPPEPATPSSELVIVSSPQCIFRPATPLSEPAPIPAPRGTVSRPVTPLSEPIPVPAPRRKFQQVKRLSSAAAIPPYQDEPLDLSASSQTEYEASPPAPPQSGGVLGVEGHEAEETLSEISDMSGNIKPASVSSSSSLSSVRITRPKYSAQAIIDSGGPCSGHLQEVKETCLSVMREACDATKLDDPATQEWLSRMWDRVDMLTWRNTSVYQAICTLDGRLKFLPKMILETPPPYPCEFVMMPHTPAPSVGAESDLTIGSVATEDVPRILEKIENVGEMANQGPLAFSEDKPVDDQLVNDPRISSRRPDESTSAPSAGTGGAGSFTDLPPSDGADADGGGPFRTVKRKAERLFDQLSRQVFDLVSHLPVFFSRLFYPGGGYSPGDWGFAAFTLLCLFLCYSYPAFGIAPLLGVFSGSSRRVRMGVFGCWLAFAVGLFKPVSDPVGAACEFDSPECRNILHSFELLKPWDPVRSLVVGPVGLGLAILGRLLGGARCIWHFLLRLGIVADCILAGAYVLSQGRCKKCWGSCIRTAPNEVAFNVFPFTRATRSSLIDLCDRFCAPKGMDPIFLATGWRGCWAGRSPIEQPSEKPIAFAQLDEKKITARTVVAQPYDPNQAVKCLRVLQSGGAMVAKAVPKVVKVSAVPFRAPFFPTGVKVDPDCRVVVDPDTFTAALRSGYSTTNLVLGVGDFAQLNGLKIRQISKPSGGGPHLMAALHVACSMALHMLAGIYVTAVGSCGTGTNDPWCANPFAVPGYGPGSLCTSRLCISQHGLTLPLTALVAGFGIQEIALVVLIFVSIGGMAHRLSCKADMLCVLLAIASYVWVPLTWLLCVFPCWLRCFSLHPLTILWLVFFLISVNMPSGILAMVLLVSLWLLGRYTNVAGLVTPYDIHHYTSGPRGVAALATAPDGTYLAAVRRAALTGRTMLFTPSQLGSLLEGAFRTRKPSLNTVNVIGSSMGSGGVFTIDGKVKCVTAAHVLTGNSARVSGVGFNQMLDFDVKGDFAIADCPNWQGAAPKTQFCTDGWTGRAYWLTSSGVEPGVIGKGFAFCFTACGDSGSPVITEAGELVGVHTGSNKQGGGIVTRPSGQFCNVAPIKLSELSEFFAGPKVPLGDVKVGSHIIKDISEVPSDLCALLAAKPELEGGLSTVQLLCVFFLLWRMMGHAWTPLVAVSFFILNEVLPAVLVRSVFSFGMFVLSWLTPWSAQVLMIRLLTAALNRNRWSLAFFSLGAVTGFVADLAATQGHPLQAVMNLSTYAFLPRMMVVTSPVPVITCGVVHLLAIILYLFKYRGPHHILVGDGVFSAAFFLRYFAEGKLREGVSQSCGMNHESLTGALAMRLNDEDLDFLMKWTDFKCFVSASNMRNAAGQFIEAAYAKALRVELAQLVQVDKVRGTLAKLEAFADTVAPQLSPGDIVVALGHTPVGSIFDLKVGSTKHTLQAIETRVLAGSKMTVARVVDPTPTPPPAPVPIPLPPKVLENGPNAWGDEDRLNKKKRRRMEALGIYVMGGKKYQKFWDKNSGDVFYEEVHNNTDEWECLRVGDPADFDPEKGTLCGHVTIENKAYHVYTSPSGKKFLVPVNPENGRVQWEAAKLSVEQALGMMNVDGELTAKELEKLKRIIDKLQGLTKEQCLNCLAASDLTRCGRGGLVVTETAVKIVKFHNRTFTLGPVNLKVASEVELKDAVEHNQHPVARPIDGGVVLLRSAVPSLIDVLISGADASPKLLAHHGPGNTGIDGTLWDFESEATKEEVALSAQIIQACDIRRGDAPEIGLPYKLYPVRGNPERVKGVLQNTRFGDIPYKTPSDTGSPVHAAACLTPNATPVTDGRSVLATTMPPGFELYVPTIPASVLDYLDSRPDCPKQLTEHGCEDAALKDLSKYDLSTQGFVLPGVLRLVRKYLFAHVGKCPPVHRPSTYPAKNSMAGINGNRFPTKDIQSVPEIDVLCAQAVRENWQTVTPCTLKKQYCGKKKTRTILGTNNFIALAHRAVLSGVTQGFMKKAFNSPIALGKNKFKELQTPVLGRCLEADLASCDRSTPAIVRWFAANLLYELACAEEHLPSYVLNCCHDLLVTQSGAVTKRGGLSSGDPITSVSNTIYSLVIYAQHMVLSYFKSGHPHGLLFLQDQLKFEDMLKVQPLIVYSDDLVLYAESPTMPNYHWWVEHLNLMLGFQTDPKKTAITDSPSFLGCRIINGRQLVPNRDRILAALAYHMKASNVSEYYASAAAILMDSCACLEYDPEWFEELVVGIAQCARKDGYSFPGTPFFMSMWEKLRSNYEGKKSRVCGYCGAPAPYATACGLDVCIYHTHFHQHCPVTIWCGHPAGSGSCSECKSPVGKGTSPLDEVLEQVPYKPPRTVIMHVEQGLTPLDPGRYQTRRGLVSVRRGIRGNEVGLPDGDYASTALLPTCKEINMVAVASNVLRSRFIIGPPGAGKTYWLLQQVQDGDVIYTPTHQTMLDMIRALGTCRFNVPAGTTLQFPVPSRTGPWVRILAGGWCPGKNSFLDEAAYCNHLDVLRLLSKTTLTCLGDFKQLHPVGFDSHCYVFDIMPQTQLKTIWRFGQNICDAIQPDYRDKLMSMVNTTRVTYVEKPVRYGQVLTPYHRDREDDAITIDSSQGATFDVVTLHLPTKDSLNRQRALVAITRARHAIFVYDPHRQLQGLFDLPAKGTPVNLAVHCDGQLIVLDRNNKECTVAQALGNGDKFRATDKRVVDSLRAICADLEGSSSPLPKVAHNLGFYFSPDLTQFAKLPVELAPHWPVVSTQNNEKWPDRLVASLRPIHKYSRACIGAGYMVGPSVFLGTPGVVSYYLTKFVKGGAQVLPETVFSTGRIEVDCREYLDDREREVAASLPHGFIGDVKGTTVGGCHHVTSRYLPRVLPKESVAVVGVSSPGKAAKALCTLTDVYLPDLEAYLHPETQSKCWKMMLDFKEVRLMVWKDKTAYFQLEGRYFTWYQLASYASYIRVPVNSTVYLDPCMGPALCNRRVVGSTHWGADLAVTPYDYGAKIILSSAYHGEMPPGYKILACAEFSLDDPVKYKHTWGFESDTAYLYEFTGNGEDWEDYNDAFRARQEGKIYKATATSLKFYFPPGPVIEPTLGLN T68237 TARGETID T68237 T68237 FORMERID TTDR00327 T68237 UNIPROID Q9WWI2_PSESY T68237 TARGNAME Pseudomonas Histidine kinase AlgR1 (Pseudo algR1) T68237 GENENAME Pseudo algR1 T68237 TARGTYPE Literature-reported T68237 SYNONYMS Response regulator transcription factor; Alginate biosynthesis regulatory protein T68237 FUNCTION Plays an important role in essential signal transduction for adapting to bacterial stress. T68237 BIOCLASS Kinase T68237 SEQUENCE MNVLIVDDEPLARERLSRMVNEIEGYRVLEPSASNGEEALALIETHKPDVVLLDIRMPGLDGLQVAARLCEREAPPAVVFCTAHDEFALEAFQVSAVGYLVKPVRPEHLVEALRKAERPNRVQLAALTRPAAESGSGPRSHISARTRKGIELIPLDQVIYFIADHKYVTLRHEGGEVLLDEPLKALEDEFGDRFVRIHRNALVARERIERLQRTPLGHFQLFLRGLNGDALIVSRRHVAGVRKMMQQL T90439 TARGETID T90439 T90439 FORMERID TTDI00151 T90439 UNIPROID JAG2_HUMAN T90439 TARGNAME Jagged-2 protein (JAG2) T90439 GENENAME JAG2 T90439 TARGTYPE Literature-reported T90439 SYNONYMS hJ2; Protein jagged-2; Jagged2 T90439 FUNCTION Involved in limb development. Putative Notch ligand involved in the mediation of Notch signaling. T90439 PDBSTRUC 5MWF; 5MW7; 5MW5 T90439 SEQUENCE MRAQGRGRLPRRLLLLLALWVQAARPMGYFELQLSALRNVNGELLSGACCDGDGRTTRAGGCGHDECDTYVRVCLKEYQAKVTPTGPCSYGHGATPVLGGNSFYLPPAGAAGDRARARARAGGDQDPGLVVIPFQFAWPRSFTLIVEAWDWDNDTTPNEELLIERVSHAGMINPEDRWKSLHFSGHVAHLELQIRVRCDENYYSATCNKFCRPRNDFFGHYTCDQYGNKACMDGWMGKECKEAVCKQGCNLLHGGCTVPGECRCSYGWQGRFCDECVPYPGCVHGSCVEPWQCNCETNWGGLLCDKDLNYCGSHHPCTNGGTCINAEPDQYRCTCPDGYSGRNCEKAEHACTSNPCANGGSCHEVPSGFECHCPSGWSGPTCALDIDECASNPCAAGGTCVDQVDGFECICPEQWVGATCQLDANECEGKPCLNAFSCKNLIGGYYCDCIPGWKGINCHINVNDCRGQCQHGGTCKDLVNGYQCVCPRGFGGRHCELERDECASSPCHSGGLCEDLADGFHCHCPQGFSGPLCEVDVDLCEPSPCRNGARCYNLEGDYYCACPDDFGGKNCSVPREPCPGGACRVIDGCGSDAGPGMPGTAASGVCGPHGRCVSQPGGNFSCICDSGFTGTYCHENIDDCLGQPCRNGGTCIDEVDAFRCFCPSGWEGELCDTNPNDCLPDPCHSRGRCYDLVNDFYCACDDGWKGKTCHSREFQCDAYTCSNGGTCYDSGDTFRCACPPGWKGSTCAVAKNSSCLPNPCVNGGTCVGSGASFSCICRDGWEGRTCTHNTNDCNPLPCYNGGICVDGVNWFRCECAPGFAGPDCRINIDECQSSPCAYGATCVDEINGYRCSCPPGRAGPRCQEVIGFGRSCWSRGTPFPHGSSWVEDCNSCRCLDGRRDCSKVWCGWKPCLLAGQPEALSAQCPLGQRCLEKAPGQCLRPPCEAWGECGAEEPPSTPCLPRSGHLDNNCARLTLHFNRDHVPQGTTVGAICSGIRSLPATRAVARDRLLVLLCDRASSGASAVEVAVSFSPARDLPDSSLIQGAAHAIVAAITQRGNSSLLLAVTEVKVETVVTGGSSTGLLVPVLCGAFSVLWLACVVLCVWWTRKRRKERERSRLPREESANNQWAPLNPIRNPIERPGGHKDVLYQCKNFTPPPRRADEALPGPAGHAAVREDEEDEDLGRGEEDSLEAEKFLSHKFTKDPGRSPGRPAHWASGPKVDNRAVRSINEARYAGKE T21038 TARGETID T21038 T21038 FORMERID TTDI03416 T21038 UNIPROID NOD1_HUMAN T21038 TARGNAME Pattern recognition receptor NOD1 (NOD1) T21038 GENENAME NOD1 T21038 TARGTYPE Literature-reported T21038 SYNONYMS Nucleotide-binding oligomerization domain-containing protein 1; Caspase recruitment domain-containing protein 4; CARD4 T21038 FUNCTION Induces NF-kappa-B activity via RIPK2 and IKK-gamma. Confers responsiveness to intracellular bacterial lipopolysaccharides (LPS). Forms an intracellular sensing system along with ARHGEF2 for the detection of microbial effectors during cell invasion by pathogens. Required for RHOA and RIPK2 dependent NF-kappa-B signaling pathway activation upon S. flexneri cell invasion. Involved not only in sensing peptidoglycan (PGN)-derived muropeptides but also in the activation of NF-kappa-B by Shigella effector proteins IpgB2 and OspB. Recruits NLRP10 to the cell membrane following bacterial infection. Enhances caspase-9-mediated apoptosis. T21038 PDBSTRUC 4JQW; 4E9M; 2NZ7; 2NSN; 2DBD T21038 SEQUENCE MEEQGHSEMEIIPSESHPHIQLLKSNRELLVTHIRNTQCLVDNLLKNDYFSAEDAEIVCACPTQPDKVRKILDLVQSKGEEVSEFFLYLLQQLADAYVDLRPWLLEIGFSPSLLTQSKVVVNTDPVSRYTQQLRHHLGRDSKFVLCYAQKEELLLEEIYMDTIMELVGFSNESLGSLNSLACLLDHTTGILNEQGETIFILGDAGVGKSMLLQRLQSLWATGRLDAGVKFFFHFRCRMFSCFKESDRLCLQDLLFKHYCYPERDPEEVFAFLLRFPHVALFTFDGLDELHSDLDLSRVPDSSCPWEPAHPLVLLANLLSGKLLKGASKLLTARTGIEVPRQFLRKKVLLRGFSPSHLRAYARRMFPERALQDRLLSQLEANPNLCSLCSVPLFCWIIFRCFQHFRAAFEGSPQLPDCTMTLTDVFLLVTEVHLNRMQPSSLVQRNTRSPVETLHAGRDTLCSLGQVAHRGMEKSLFVFTQEEVQASGLQERDMQLGFLRALPELGPGGDQQSYEFFHLTLQAFFTAFFLVLDDRVGTQELLRFFQEWMPPAGAATTSCYPPFLPFQCLQGSGPAREDLFKNKDHFQFTNLFLCGLLSKAKQKLLRHLVPAAALRRKRKALWAHLFSSLRGYLKSLPRVQVESFNQVQAMPTFIWMLRCIYETQSQKVGQLAARGICANYLKLTYCNACSADCSALSFVLHHFPKRLALDLDNNNLNDYGVRELQPCFSRLTVLRLSVNQITDGGVKVLSEELTKYKIVTYLGLYNNQITDVGARYVTKILDECKGLTHLKLGKNKITSEGGKYLALAVKNSKSISEVGMWGNQVGDEGAKAFAEALRNHPSLTTLSLASNGISTEGGKSLARALQQNTSLEILWLTQNELNDEVAESLAEMLKVNQTLKHLWLIQNQITAKGTAQLADALQSNTGITEICLNGNLIKPEEAKVYEDEKRIICF T21038 DRUGINFO D0A1GQ meso-DAP Investigative T10756 TARGETID T10756 T10756 FORMERID TTDI03509 T10756 UNIPROID FACE2_HUMAN T10756 TARGNAME Ras converting CAAX endopeptidase 1 (RCE1) T10756 GENENAME RCE1 T10756 TARGTYPE Literature-reported T10756 SYNONYMS hRCE1; RCE1B; RCE1A; RCE1 homolog; Prenyl protein-specific endoprotease 2; Farnesylated proteins-converting enzyme 2; FACE2; FACE-2; CAAX prenyl protease 2 T10756 FUNCTION Proteolytically removes the C-terminal three residues of farnesylated and geranylated proteins. Seems to be able to process K-Ras, N-Ras, H-Ras, RAP1B and G-gamma-1. T10756 ECNUMBER EC 3.4.22.- T10756 SEQUENCE MAALGGDGLRLLSVSRPERPPESAALGGLGPGLCCWVSVFSCLSLACSYVGSLYVWKSELPRDHPAVIKRRFTSVLVVSSLSPLCVLLWRELTGIQPGTSLLTLMGFRLEGIFPAALLPLLLTMILFLGPLMQLSMDCPCDLADGLKVVLAPRSWARCLTDMRWLRNQVIAPLTEELVFRACMLPMLAPCMGLGPAVFTCPLFFGVAHFHHIIEQLRFRQSSVGNIFLSAAFQFSYTAVFGAYTAFLFIRTGHLIGPVLCHSFCNYMGFPAVCAALEHPQRRPLLAGYALGVGLFLLLLQPLTDPKLYGSLPLCVLLERAGDSEAPLCS T10756 DRUGINFO D0E2SI CID16197121 Investigative T10756 DRUGINFO D0F3TM PMID17942791C3 Investigative T78943 TARGETID T78943 T78943 FORMERID TTDR00479 T78943 UNIPROID NISCH_HUMAN T78943 TARGNAME Imidazoline receptor 1 (IR1) T78943 GENENAME NISCH T78943 TARGTYPE Literature-reported T78943 SYNONYMS hIRAS; KIAA0975; Imidazoline-1 receptor candidate protein; Imidazoline-1 receptor; Imidazoline receptor antisera-selected protein; IRAS; IR1; I1R candidate protein; I-1 receptor candidate protein; I-1 T78943 FUNCTION Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension (By similarity). Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons (By similarity). Acts as a modulator of Rac-regulated signal transduction pathways (By similarity). Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity (By similarity). Also blocks Pak-independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation (By similarity). Inhibits also LIMK1 kinase activity by reducing LIMK1 'Tyr-508' phosphorylation (By similarity). Inhibits Rac-induced cell migration and invasion in breast and colon epithelial cells (By similarity). Inhibits lamellipodia formation, when overexpressed (By similarity). Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement of insulin activation of MAPK1 and MAPK3. When overexpressed, induces a redistribution of cell surface ITGA5 integrin to intracellular endosomal structures. T78943 PDBSTRUC 3P0C T78943 SEQUENCE MATARTFGPEREAEPAKEARVVGSELVDTYTVYIIQVTDGSHEWTVKHRYSDFHDLHEKLVAERKIDKNLLPPKKIIGKNSRSLVEKREKDLEVYLQKLLAAFPGVTPRVLAHFLHFHFYEINGITAALAEELFEKGEQLLGAGEVFAIGPLQLYAVTEQLQQGKPTCASGDAKTDLGHILDFTCRLKYLKVSGTEGPFGTSNIQEQLLPFDLSIFKSLHQVEISHCDAKHIRGLVASKPTLATLSVRFSATSMKEVLVPEASEFDEWEPEGTTLEGPVTAVIPTWQALTTLDLSHNSVSEIDESVKLIPKIEFLDLSHNGLLVVDNLQHLYNLVHLDLSYNKLSSLEGLHTKLGNIKTLNLAGNLLESLSGLHKLYSLVNLDLRDNRIEQMEEVRSIGSLPCLEHVSLLNNPLSIIPDYRTKVLAQFGERASEVCLDDTVTTEKELDTVEVLKAIQKAKEVKSKLSNPEKKGGEDSRLSAAPCIRPSSSPPTVAPASASLPQPILSNQGIMFVQEEALASSLSSTDSLTPEHQPIAQGCSDSLESIPAGQAASDDLRDVPGAVGGASPEHAEPEVQVVPGSGQIIFLPFTCIGYTATNQDFIQRLSTLIRQAIERQLPAWIEAANQREEGQGEQGEEEDEEEEEEEDVAENRYFEMGPPDVEEEEGGGQGEEEEEEEEDEEAEEERLALEWALGADEDFLLEHIRILKVLWCFLIHVQGSIRQFAACLVLTDFGIAVFEIPHQESRGSSQHILSSLRFVFCFPHGDLTEFGFLMPELCLVLKVRHSENTLFIISDAANLHEFHADLRSCFAPQHMAMLCSPILYGSHTSLQEFLRQLLTFYKVAGGCQERSQGCFPVYLVYSDKRMVQTAAGDYSGNIEWASCTLCSAVRRSCCAPSEAVKSAAIPYWLLLTPQHLNVIKADFNPMPNRGTHNCRNRNSFKLSRVPLSTVLLDPTRSCTQPRGAFADGHVLELLVGYRFVTAIFVLPHEKFHFLRVYNQLRASLQDLKTVVIAKTPGTGGSPQGSFADGQPAERRASNDQRPQEVPAEALAPAPAEVPAPAPAAASASGPAKTPAPAEASTSALVPEETPVEAPAPPPAEAPAQYPSEHLIQATSEENQIPSHLPACPSLRHVASLRGSAIIELFHSSIAEVENEELRHLMWSSVVFYQTPGLEVTACVLLSTKAVYFVLHDGLRRYFSEPLQDFWHQKNTDYNNSPFHISQCFVLKLSDLQSVNVGLFDQHFRLTGSTPMQVVTCLTRDSYLTHCFLQHLMVVLSSLERTPSPEPVDKDFYSEFGNKTTGKMENYELIHSSRVKFTYPSEEEIGDLTFTVAQKMAEPEKAPALSILLYVQAFQVGMPPPGCCRGPLRPKTLLLTSSEIFLLDEDCVHYPLPEFAKEPPQRDRYRLDDGRRVRDLDRVLMGYQTYPQALTLVFDDVQGHDLMGSVTLDHFGEVPGGPARASQGREVQWQVFVPSAESREKLISLLARQWEALCGRELPVELTG T65689 TARGETID T65689 T65689 FORMERID TTDNR00712 T65689 UNIPROID NISCH_HUMAN T65689 TARGNAME Nischarin (NISCH) T65689 GENENAME NISCH T65689 TARGTYPE Literature-reported T65689 SYNONYMS NISCH; I1R T65689 FUNCTION Acts either as the functional imidazoline-1 receptor (I1R) candidate or as amembrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension. Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons. Acts as a modulator of Rac-regulated signal transduction pathways. Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity. Also blocks Pak-independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation. Inhibits also LIMK1 kinase activity by reducing LIMK1 'Tyr-508' phosphorylation. Inhibits Rac-induced cell migration and invasion in breast and colon epithelial cells. Inhibits lamellipodia formation, when overexpressed. Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement of insulin activation of MAPK1 and MAPK3. When overexpressed, induces a redistribution of cell surface ITGA5 integrin to intracellular endosomal structures. . T65689 PDBSTRUC 3P0C T65689 SEQUENCE MATARTFGPEREAEPAKEARVVGSELVDTYTVYIIQVTDGSHEWTVKHRYSDFHDLHEKLVAERKIDKNLLPPKKIIGKNSRSLVEKREKDLEVYLQKLLAAFPGVTPRVLAHFLHFHFYEINGITAALAEELFEKGEQLLGAGEVFAIGPLQLYAVTEQLQQGKPTCASGDAKTDLGHILDFTCRLKYLKVSGTEGPFGTSNIQEQLLPFDLSIFKSLHQVEISHCDAKHIRGLVASKPTLATLSVRFSATSMKEVLVPEASEFDEWEPEGTTLEGPVTAVIPTWQALTTLDLSHNSVSEIDESVKLIPKIEFLDLSHNGLLVVDNLQHLYNLVHLDLSYNKLSSLEGLHTKLGNIKTLNLAGNLLESLSGLHKLYSLVNLDLRDNRIEQMEEVRSIGSLPCLEHVSLLNNPLSIIPDYRTKVLAQFGERASEVCLDDTVTTEKELDTVEVLKAIQKAKEVKSKLSNPEKKGGEDSRLSAAPCIRPSSSPPTVAPASASLPQPILSNQGIMFVQEEALASSLSSTDSLTPEHQPIAQGCSDSLESIPAGQAASDDLRDVPGAVGGASPEHAEPEVQVVPGSGQIIFLPFTCIGYTATNQDFIQRLSTLIRQAIERQLPAWIEAANQREEGQGEQGEEEDEEEEEEEDVAENRYFEMGPPDVEEEEGGGQGEEEEEEEEDEEAEEERLALEWALGADEDFLLEHIRILKVLWCFLIHVQGSIRQFAACLVLTDFGIAVFEIPHQESRGSSQHILSSLRFVFCFPHGDLTEFGFLMPELCLVLKVRHSENTLFIISDAANLHEFHADLRSCFAPQHMAMLCSPILYGSHTSLQEFLRQLLTFYKVAGGCQERSQGCFPVYLVYSDKRMVQTAAGDYSGNIEWASCTLCSAVRRSCCAPSEAVKSAAIPYWLLLTPQHLNVIKADFNPMPNRGTHNCRNRNSFKLSRVPLSTVLLDPTRSCTQPRGAFADGHVLELLVGYRFVTAIFVLPHEKFHFLRVYNQLRASLQDLKTVVIAKTPGTGGSPQGSFADGQPAERRASNDQRPQEVPAEALAPAPAEVPAPAPAAASASGPAKTPAPAEASTSALVPEETPVEAPAPPPAEAPAQYPSEHLIQATSEENQIPSHLPACPSLRHVASLRGSAIIELFHSSIAEVENEELRHLMWSSVVFYQTPGLEVTACVLLSTKAVYFVLHDGLRRYFSEPLQDFWHQKNTDYNNSPFHISQCFVLKLSDLQSVNVGLFDQHFRLTGSTPMQVVTCLTRDSYLTHCFLQHLMVVLSSLERTPSPEPVDKDFYSEFGNKTTGKMENYELIHSSRVKFTYPSEEEIGDLTFTVAQKMAEPEKAPALSILLYVQAFQVGMPPPGCCRGPLRPKTLLLTSSEIFLLDEDCVHYPLPEFAKEPPQRDRYRLDDGRRVRDLDRVLMGYQTYPQALTLVFDDVQGHDLMGSVTLDHFGEVPGGPARASQGREVQWQVFVPSAESREKLISLLARQWEALCGRELPVELTG T75644 TARGETID T75644 T75644 FORMERID TTDI00005 T75644 UNIPROID SGT1_HUMAN T75644 TARGNAME Suppressor of G2 allele of SKP1 homolog (Sgt1) T75644 GENENAME SUGT1 T75644 TARGTYPE Literature-reported T75644 SYNONYMS Protein SGT1 homolog; Protein 40-6-3 T75644 FUNCTION May play a role in ubiquitination and subsequent proteasomal degradation of target proteins. T75644 PDBSTRUC 1RL1 T75644 SEQUENCE MAAAAAGTATSQRFFQSFSDALIDEDPQAALEELTKALEQKPDDAQYYCQRAYCHILLGNYCVAVADAKKSLELNPNNSTAMLRKGICEYHEKNYAAALETFTEGQKLDIETGFHRVGQAGLQLLTSSDPPALDSQSAGITGADANFSVWIKRCQEAQNGSESEVWTHQSKIKYDWYQTESQVVITLMIKNVQKNDVNVEFSEKELSALVKLPSGEDYNLKLELLHPIIPEQSTFKVLSTKIEIKLKKPEAVRWEKLEGQGDVPTPKQFVADVKNLYPSSSPYTRNWDKLVGEIKEEEKNEKLEGDAALNRLFQQIYSDGSDEVKRAMNKSFMESGGTVLSTNWSDVGKRKVEINPPDDMEWKKY T32386 TARGETID T32386 T32386 FORMERID TTDR00582 T32386 UNIPROID MRC2_HUMAN T32386 TARGNAME Endocytic receptor Endo180 (MRC2) T32386 GENENAME MRC2 T32386 TARGTYPE Literature-reported T32386 SYNONYMS Urokinase-type plasminogen activator receptor-associated protein; Urokinase receptor-associated protein; UPARAP; UPAR-associated protein; Macrophage mannose receptor 2; KIAA0709; Endocytic receptor 180; ENDO180; CLEC13E; CD280; C-type mannose receptor 2; C-type lectin domain family 13 member E T32386 FUNCTION May play a role as endocytotic lectin receptor displaying calcium-dependent lectin activity. Internalizes glycosylated ligands from the extracellular space for release in an endosomal compartment via clathrin-mediated endocytosis. May be involved in plasminogen activation system controlling the extracellular level of PLAUR/PLAU, and thus may regulate protease activity at the cell surface. May contribute to cellular uptake, remodeling and degradation of extracellular collagen matrices. May play a role during cancer progression as well as in other chronic tissue destructive diseases acting on collagen turnover. May participate in remodeling of extracellular matrix cooperating with the matrix metalloproteinases (MMPs). T32386 PDBSTRUC 5EW6; 5E4L; 5E4K; 5AO6; 5AO5 T32386 SEQUENCE MGPGRPAPAPWPRHLLRCVLLLGCLHLGRPGAPGDAALPEPNVFLIFSHGLQGCLEAQGGQVRVTPACNTSLPAQRWKWVSRNRLFNLGTMQCLGTGWPGTNTTASLGMYECDREALNLRWHCRTLGDQLSLLLGARTSNISKPGTLERGDQTRSGQWRIYGSEEDLCALPYHEVYTIQGNSHGKPCTIPFKYDNQWFHGCTSTGREDGHLWCATTQDYGKDERWGFCPIKSNDCETFWDKDQLTDSCYQFNFQSTLSWREAWASCEQQGADLLSITEIHEQTYINGLLTGYSSTLWIGLNDLDTSGGWQWSDNSPLKYLNWESDQPDNPSEENCGVIRTESSGGWQNRDCSIALPYVCKKKPNATAEPTPPDRWANVKVECEPSWQPFQGHCYRLQAEKRSWQESKKACLRGGGDLVSIHSMAELEFITKQIKQEVEELWIGLNDLKLQMNFEWSDGSLVSFTHWHPFEPNNFRDSLEDCVTIWGPEGRWNDSPCNQSLPSICKKAGQLSQGAAEEDHGCRKGWTWHSPSCYWLGEDQVTYSEARRLCTDHGSQLVTITNRFEQAFVSSLIYNWEGEYFWTALQDLNSTGSFFWLSGDEVMYTHWNRDQPGYSRGGCVALATGSAMGLWEVKNCTSFRARYICRQSLGTPVTPELPGPDPTPSLTGSCPQGWASDTKLRYCYKVFSSERLQDKKSWVQAQGACQELGAQLLSLASYEEEHFVANMLNKIFGESEPEIHEQHWFWIGLNRRDPRGGQSWRWSDGVGFSYHNFDRSRHDDDDIRGCAVLDLASLQWVAMQCDTQLDWICKIPRGTDVREPDDSPQGRREWLRFQEAEYKFFEHHSTWAQAQRICTWFQAELTSVHSQAELDFLSHNLQKFSRAQEQHWWIGLHTSESDGRFRWTDGSIINFISWAPGKPRPVGKDKKCVYMTASREDWGDQRCLTALPYICKRSNVTKETQPPDLPTTALGGCPSDWIQFLNKCFQVQGQEPQSRVKWSEAQFSCEQQEAQLVTITNPLEQAFITASLPNVTFDLWIGLHASQRDFQWVEQEPLMYANWAPGEPSGPSPAPSGNKPTSCAVVLHSPSAHFTGRWDDRSCTEETHGFICQKGTDPSLSPSPAALPPAPGTELSYLNGTFRLLQKPLRWHDALLLCESRNASLAYVPDPYTQAFLTQAARGLRTPLWIGLAGEEGSRRYSWVSEEPLNYVGWQDGEPQQPGGCTYVDVDGAWRTTSCDTKLQGAVCGVSSGPPPPRRISYHGSCPQGLADSAWIPFREHCYSFHMELLLGHKEARQRCQRAGGAVLSILDEMENVFVWEHLQSYEGQSRGAWLGMNFNPKGGTLVWQDNTAVNYSNWGPPGLGPSMLSHNSCYWIQSNSGLWRPGACTNITMGVVCKLPRAEQSSFSPSALPENPAALVVVLMAVLLLLALLTAALILYRRRQSIERGAFEGARYSRSSSSPTEATEKNILVSDMEMNEQQE T27600 TARGETID T27600 T27600 FORMERID TTDI00091 T27600 UNIPROID TACC3_HUMAN T27600 TARGNAME Transforming acidic coiled-coil protein 3 (TACC3) T27600 GENENAME TACC3 T27600 TARGTYPE Literature-reported T27600 SYNONYMS Transforming acidic coiled-coil-containing protein 3; ERIC1; ERIC-1 T27600 FUNCTION Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors. Acts as component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter-microtubule bridge. The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fiber tension. May be involved in the control of cell growth and differentiation. May contribute to cancer. Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome. T27600 PDBSTRUC 5ODT; 5ODS; 5LXO; 5LXN T27600 SEQUENCE MSLQVLNDKNVSNEKNTENCDFLFSPPEVTGRSSVLRVSQKENVPPKNLAKAMKVTFQTPLRDPQTHRILSPSMASKLEAPFTQDDTLGLENSHPVWTQKENQQLIKEVDAKTTHGILQKPVEADTDLLGDASPAFGSGSSSESGPGALADLDCSSSSQSPGSSENQMVSPGKVSGSPEQAVEENLSSYSLDRRVTPASETLEDPCRTESQHKAETPHGAEEECKAETPHGAEEECRHGGVCAPAAVATSPPGAIPKEACGGAPLQGLPGEALGCPAGVGTPVPADGTQTLTCAHTSAPESTAPTNHLVAGRAMTLSPQEEVAAGQMASSSRSGPVKLEFDVSDGATSKRAPPPRRLGERSGLKPPLRKAAVRQQKAPQEVEEDDGRSGAGEDPPMPASRGSYHLDWDKMDDPNFIPFGGDTKSGCSEAQPPESPETRLGQPAAEQLHAGPATEEPGPCLSQQLHSASAEDTPVVQLAAETPTAESKERALNSASTSLPTSCPGSEPVPTHQQGQPALELKEESFRDPAEVLGTGAEVDYLEQFGTSSFKESALRKQSLYLKFDPLLRDSPGRPVPVATETSSMHGANETPSGRPREAKLVEFDFLGALDIPVPGPPPGVPAPGGPPLSTGPIVDLLQYSQKDLDAVVKATQEENRELRSRCEELHGKNLELGKIMDRFEEVVYQAMEEVQKQKELSKAEIQKVLKEKDQLTTDLNSMEKSFSDLFKRFEKQKEVIEGYRKNEESLKKCVEDYLARITQEGQRYQALKAHAEEKLQLANEEIAQVRSKAQAEALALQASLRKEQMRIQSLEKTVEQKTKENEELTRICDDLISKMEKI T30614 TARGETID T30614 T30614 FORMERID TTDI03141 T30614 UNIPROID CXA3_HUMAN T30614 TARGNAME Gap junction alpha-3 protein (Cx46) T30614 GENENAME GJA3 T30614 TARGTYPE Literature-reported T30614 SYNONYMS Connexin-46 T30614 FUNCTION Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. They are formed by the docking of two hexameric hemichannels, one from each cell membrane. Small molecules and ions diffuse from one cell to a neighboring cell via the central pore. Structural component of lens fiber gap junctions. T30614 BIOCLASS Gap junction-forming connexin T30614 SEQUENCE MGDWSFLGRLLENAQEHSTVIGKVWLTVLFIFRILVLGAAAEDVWGDEQSDFTCNTQQPGCENVCYDRAFPISHIRFWALQIIFVSTPTLIYLGHVLHIVRMEEKKKEREEEEQLKRESPSPKEPPQDNPSSRDDRGRVRMAGALLRTYVFNIIFKTLFEVGFIAGQYFLYGFELKPLYRCDRWPCPNTVDCFISRPTEKTIFIIFMLAVACASLLLNMLEIYHLGWKKLKQGVTSRLGPDASEAPLGTADPPPLPPSSRPPAVAIGFPPYYAHTAAPLGQARAVGYPGAPPPAADFKLLALTEARGKGQSAKLYNGHHHLLMTEQNWANQAAERQPPALKAYPAASTPAAPSPVGSSSPPLAHEAEAGAAPLLLDGSGSSLEGSALAGTPEEEEQAVTTAAQMHQPPLPLGDPGRASKASRASSGRARPEDLAI T30614 DRUGINFO D00VJY octanol Investigative T46814 TARGETID T46814 T46814 FORMERID TTDI03418 T46814 UNIPROID SO1B1_HUMAN T46814 TARGNAME Liver organic anion transporter 1 (SLCO1B1) T46814 GENENAME SLCO1B1 T46814 TARGTYPE Literature-reported T46814 SYNONYMS Solute carrier organic anion transporter family member 1B1; Solute carrier family 21 member 6; Sodium-independent organic anion-transporting polypeptide 2; SLC21A6; OATPC; OATP2; OATP-C; OATP-2; Liver-specific organic anion transporter 1; LST1; LST-1 T46814 FUNCTION Involved in the clearance of bile acids and organic anions from the liver. Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. T46814 BIOCLASS Organo anion transporter T46814 SEQUENCE MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKSSIIHIERRFEISSSLVGFIDGSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCFIMGIGGVLTALPHFFMGYYRYSKETNINSSENSTSTLSTCLINQILSLNRASPEIVGKGCLKESGSYMWIYVFMGNMLRGIGETPIVPLGLSYIDDFAKEGHSSLYLGILNAIAMIGPIIGFTLGSLFSKMYVDIGYVDLSTIRITPTDSRWVGAWWLNFLVSGLFSIISSIPFFFLPQTPNKPQKERKASLSLHVLETNDEKDQTANLTNQGKNITKNVTGFFQSFKSILTNPLYVMFVLLTLLQVSSYIGAFTYVFKYVEQQYGQPSSKANILLGVITIPIFASGMFLGGYIIKKFKLNTVGIAKFSCFTAVMSLSFYLLYFFILCENKSVAGLTMTYDGNNPVTSHRDVPLSYCNSDCNCDESQWEPVCGNNGITYISPCLAGCKSSSGNKKPIVFYNCSCLEVTGLQNRNYSAHLGECPRDDACTRKFYFFVAIQVLNLFFSALGGTSHVMLIVKIVQPELKSLALGFHSMVIRALGGILAPIYFGALIDTTCIKWSTNNCGTRGSCRTYNSTSFSRVYLGLSSMLRVSSLVLYIILIYAMKKKYQEKDINASENGSVMDEANLESLNKNKHFVPSAGADSETHC T46814 DRUGINFO D0I3LQ [3H]estradiol-17beta-glucuronide Investigative T46814 DRUGINFO D04AXP [3H]estrone-3-sulphate Investigative T72944 TARGETID T72944 T72944 FORMERID TTDR01321 T72944 UNIPROID ROBO1_HUMAN T72944 TARGNAME Roundabout homolog 1 (ROBO1) T72944 GENENAME ROBO1 T72944 TARGTYPE Literature-reported T72944 SYNONYMS H-Robo-1; Deleted in U twenty twenty; DUTT1 T72944 FUNCTION Receptor for SLIT1 and SLIT2 that mediates cellular responses to molecular guidance cues in cellular migration, including axonal navigation at the ventral midline of the neural tube and projection of axons to different regions during neuronal development. Interaction with the intracellular domain of FLRT3 mediates axon attraction towards cells expressing NTN1. In axon growth cones, the silencing of the attractive effect of NTN1 by SLIT2 may require the formation of a ROBO1-DCC complex (By similarity). Plays a role in the regulation of cell migration via its interaction with MYO9B; inhibits MYO9B-mediated stimulation of RHOA GTPase activity, and thereby leads to increased levels of active, GTP-bound RHOA. May be required for lung development (By similarity). T72944 PDBSTRUC 6A79; 6A78; 6A77; 5OPE; 5O5I T72944 SEQUENCE MKWKHVPFLVMISLLSLSPNHLFLAQLIPDPEDVERGNDHGTPIPTSDNDDNSLGYTGSRLRQEDFPPRIVEHPSDLIVSKGEPATLNCKAEGRPTPTIEWYKGGERVETDKDDPRSHRMLLPSGSLFFLRIVHGRKSRPDEGVYVCVARNYLGEAVSHNASLEVAILRDDFRQNPSDVMVAVGEPAVMECQPPRGHPEPTISWKKDGSPLDDKDERITIRGGKLMITYTRKSDAGKYVCVGTNMVGERESEVAELTVLERPSFVKRPSNLAVTVDDSAEFKCEARGDPVPTVRWRKDDGELPKSRYEIRDDHTLKIRKVTAGDMGSYTCVAENMVGKAEASATLTVQEPPHFVVKPRDQVVALGRTVTFQCEATGNPQPAIFWRREGSQNLLFSYQPPQSSSRFSVSQTGDLTITNVQRSDVGYYICQTLNVAGSIITKAYLEVTDVIADRPPPVIRQGPVNQTVAVDGTFVLSCVATGSPVPTILWRKDGVLVSTQDSRIKQLENGVLQIRYAKLGDTGRYTCIASTPSGEATWSAYIEVQEFGVPVQPPRPTDPNLIPSAPSKPEVTDVSRNTVTLSWQPNLNSGATPTSYIIEAFSHASGSSWQTVAENVKTETSAIKGLKPNAIYLFLVRAANAYGISDPSQISDPVKTQDVLPTSQGVDHKQVQRELGNAVLHLHNPTVLSSSSIEVHWTVDQQSQYIQGYKILYRPSGANHGESDWLVFEVRTPAKNSVVIPDLRKGVNYEIKARPFFNEFQGADSEIKFAKTLEEAPSAPPQGVTVSKNDGNGTAILVSWQPPPEDTQNGMVQEYKVWCLGNETRYHINKTVDGSTFSVVIPFLVPGIRYSVEVAASTGAGSGVKSEPQFIQLDAHGNPVSPEDQVSLAQQISDVVKQPAFIAGIGAACWIILMVFSIWLYRHRKKRNGLTSTYAGIRKVPSFTFTPTVTYQRGGEAVSSGGRPGLLNISEPAAQPWLADTWPNTGNNHNDCSISCCTAGNGNSDSNLTTYSRPADCIANYNNQLDNKQTNLMLPESTVYGDVDLSNKINEMKTFNSPNLKDGRFVNPSGQPTPYATTQLIQSNLSNNMNNGSGDSGEKHWKPLGQQKQEVAPVQYNIVEQNKLNKDYRANDTVPPTIPYNQSYDQNTGGSYNSSDRGSSTSGSQGHKKGARTPKVPKQGGMNWADLLPPPPAHPPPHSNSEEYNISVDESYDQEMPCPVPPARMYLQQDELEEEEDERGPTPPVRGAASSPAAVSYSHQSTATLTPSPQEELQPMLQDCPEETGHMQHQPDRRRQPVSPPPPPRPISPPHTYGYISGPLVSDMDTDAPEEEEDEADMEVAKMQTRRLLLRGLEQTPASSVGDLESSVTGSMINGWGSASEEDNISSGRSSVSSSDGSFFTDADFAQAVAAAAEYAGLKVARRQMQDAAGRRHFHASQCPRPTSPVSTDSNMSAAVMQKTRPAKKLKHQPGHLRRETYTDDLPPPPVPPPAIKSPTAQSKTQLEVRPVVVPKLPSMDARTDRSSDRKGSSYKGREVLDGRQVVDMRTNPGDPREAQEQQNDGKGRGNKAAKRDLPPAKTHLIQEDILPYCRPTFPTSNNPRDPSSSSSMSSRGSGSRQREQANVGRRNIAEMQVLGGYERGEDNNEELEETES T85746 TARGETID T85746 T85746 FORMERID TTDI02528 T85746 UNIPROID TNR11_HUMAN T85746 TARGNAME Osteoclast differentiation factor receptor (ODFR) T85746 GENENAME TNFRSF11A T85746 TARGTYPE Literature-reported T85746 SYNONYMS Tumor necrosis factor receptor superfamily member 11A; Receptor activator of NF-KB; RANK; ODFR; CD265 T85746 FUNCTION Involved in the regulation of interactions between T-cells and dendritic cells. Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. T85746 PDBSTRUC 1LB5 T85746 SEQUENCE MAPRARRRRPLFALLLLCALLARLQVALQIAPPCTSEKHYEHLGRCCNKCEPGKYMSSKCTTTSDSVCLPCGPDEYLDSWNEEDKCLLHKVCDTGKALVAVVAGNSTTPRRCACTAGYHWSQDCECCRRNTECAPGLGAQHPLQLNKDTVCKPCLAGYFSDAFSSTDKCRPWTNCTFLGKRVEHHGTEKSDAVCSSSLPARKPPNEPHVYLPGLIILLLFASVALVAAIIFGVCYRKKGKALTANLWHWINEACGRLSGDKESSGDSCVSTHTANFGQQGACEGVLLLTLEEKTFPEDMCYPDQGGVCQGTCVGGGPYAQGEDARMLSLVSKTEIEEDSFRQMPTEDEYMDRPSQPTDQLLFLTEPGSKSTPPFSEPLEVGENDSLSQCFTGTQSTVGSESCNCTEPLCRTDWTPMSSENYLQKEVDSGHCPHWAASPSPNWADVCTGCRNPPGEDCEPLVGSPKRGPLPQCAYGMGLPPEEEASRTEARDQPEDGADGRLPSSARAGAGSGSSPGGQSPASGNVTGNSNSTFISSGQVMNFKGDIIVVYVSQTSQEGAAAAAEPMGRPVQEETLARRDSFAGNGPRFPDPCGGPEGLREPEKASRPVQEQGGAKA T74777 TARGETID T74777 T74777 FORMERID TTDR01348 T74777 UNIPROID HEMA_I97A1 T74777 TARGNAME Influenza HA messenger RNA (Influ HA mRNA) T74777 GENENAME Influ HA mRNA T74777 TARGTYPE Literature-reported T74777 SYNONYMS Hemagglutinin (mRNA); HA of influenza (mRNA) T74777 FUNCTION Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. This attachment induces virion internalization of about two third of the virus particles through clathrin-dependent endocytosis and about one third through a clathrin- and caveolin-independent pathway. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induces an irreversible conformational change in HA2, releasing the fusion hydrophobic speptide. Several trimers are required to form a competent fusion pore. T74777 BIOCLASS mRNA target T74777 SEQUENCE MEKTVLLLATVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILERTHNGKLCDLNGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKASPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSNHDASSGVSSACPYLGRSSFFRNVVWLIKKNSAYPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPEIATRPKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSTIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECPKYVKSNRLVLATGLRNTPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGVTNKVNSIINKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVKNGTYDYPQYSEEARLNREEISGVKLESMGTYQILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI T74777 DRUGINFO D0Y4II ISIS 3306 Investigative T15381 TARGETID T15381 T15381 FORMERID TTDR01349 T15381 UNIPROID PB2_I97A1 T15381 TARGNAME Influenza PB2 messenger RNA (Influ PB2 mRNA) T15381 GENENAME Influ PB2 mRNA T15381 TARGTYPE Literature-reported T15381 SYNONYMS RNA-directed RNA polymerase subunit P3 (mRNA); Polymerase basic protein 2 (mRNA); PB2 (mRNA) T15381 FUNCTION Recognizes and binds the 7-methylguanosine-containing cap of the target pre-RNA which is subsequently cleaved after 10-13 nucleotides by the viral protein PA. Plays a role in the initiation of the viral genome replication and modulates the activity of the ribonucleoprotein (RNP) complex. Plays an essential role in transcription initiation and cap-stealing mechanism, in which cellular capped pre-mRNAs are used to generate primers for viral transcription. T15381 BIOCLASS mRNA target T15381 SEQUENCE MERIKELRDLMSQSRTREILTKTTVDHMAIIKKYTSGRQEKNPALRMKWMMAMKYPITADKRIMEMIPERNEQGQTLWSKTNDAGSDRVMVSPLAVTWWNRNGPTTSTVHYPKVYKTYFEKVERLKHGTFGPVHFRNQVKIRRRVDMNPGHADLSAKEAQDVIMEVVFPNEVGARILTSESQLTITKEKREELKNCNISPLMVAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQGTCWEQMYTPGGEVRNDDVDQSLIIAARNIVRRATVSADPLASLLEMCHSTQIGGVRMVDILKQNPTEEQAVDICKAAMGLRISSSFSFGGFTFKRTKGFSVKREEEVLTGNLQTLKIKVHEGYEEFTMVGRRATAILRKATRRMIQLIVSGRDEQSIAEAIIVAMVFSQEDCMIKAVRGDLNFVNRANQRLNPMHQLLRHFQKDAKVLFQNWGIEPIDNVMGMIGILPDMTPSTEMSLRGVRVSKMGVDEYSSTERVVVSIDRFLRVRDQQGNVLLSPEEVSETQGMEKLTITYSSSMMWEINGPESVLVNTYQWIIRNWETVKIQWSQEPTMLYNKMEFEPFQSLVPKAARSQYSGFVRTLFQQMRDVLGTFDTVQIIKLLPFAAAPPEQSRMQFSSLTVNVRGSGMRILVRGNSPAFNYNKTTKRLTILGKDAGALTEDPDEGTAGVESAVLRGFLILGKEDKRYGPALSINELSNLTKGEKANVLIRQGDVVLVMKRKRDSSILTDSQTATKRIRMAIN T15381 DRUGINFO D0ZF2W ISIS 3303 Investigative T19527 TARGETID T19527 T19527 FORMERID TTDI02233 T19527 UNIPROID ENV_HV190 T19527 TARGNAME Influenza Env messenger RNA (Influ Env mRNA) T19527 GENENAME Influ Env mRNA T19527 TARGTYPE Literature-reported T19527 SYNONYMS HIV-1 90CF056 envelope glycoprotein gp160 (mRNA); HIV-1 90CF056 env polyprotein (mRNA) T19527 FUNCTION Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41. T19527 BIOCLASS mRNA target T19527 SEQUENCE METQRNYPSLWRWGTLILGMLLICSAAQNLWVTVYYGVPVWKEAKTTLFCASDAKAYETEKHNVWATHACVPTDPNPQEMVMENVTESFNMWENNMVEQMHTDIISLWDQSLKPCVKLTPLCVTLNCTNVRNNTSNSTSSMEAGGELTNCSFNVTTVLRDKQQKVHALFYRLDVVPIDNNSTQYRLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGLCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEQIIIRTKNISDNTKNIIVQLKTPVNITCTRPNNNTRTSIHLGPGRAFYATGDIIGDIRQAHCNISRTDWNKTLHQVVTQLGIHLNNRTISFKPNSGGDMEVRTHSFNCRGEFFYCNTSGLFNSSWEMHTNYTSNDTKGNENITLPCRIKQIVNMWQRVGRAMYAPPIQGNIMCVSNITGLILTIDEGNASAENYTFRPGGGDMRDNWRSELYKYKVVKIEPLGIAPTKTRRRVVEREKRAVGMGASFLGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIQARQHMLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTNVPWNSSWSNKSQSEIWDNMTWMEWDKQISNYTEEIYRLLEVSQTQQEKNEQDLLALDKWASLWTWFDISHWLWYIKIFIMIVGGLIGLRIIFAVLSIVNRVRQGYSPLSFQTLVPNPRGPDRPEGTEEGGGEQDRDRSVRLVNGFLPVVWDDLRSLSLFSYRLLRDLLLIVVRTVELLGRRGREALKYLWNLLQYWGQELKNSAIDLLNTTAIAVAEGTDGIIVIVQRAWRAILHIPRRIRQGFERSLL T24979 TARGETID T24979 T24979 FORMERID TTDR01354 T24979 UNIPROID NCAP_I97A1 T24979 TARGNAME Influenza NP messenger RNA (Influ NP mRNA) T24979 GENENAME Influ NP mRNA T24979 TARGTYPE Literature-reported T24979 SYNONYMS Influenza nucleoprotein (mRNA); Influenza nucleocapsid protein (mRNA) T24979 FUNCTION The encapsidated genomic RNA is termed the ribonucleoprotein (RNP) and serves as template for transcription and replication. The RNP needs to be localized in the host nucleus to start an infectious cycle, but is too large to diffuse through the nuclear pore complex. NP comprises at least 2 nuclear localization signals that are responsible for the active RNP import into the nucleus through cellular importin alpha/beta pathway. Later in the infection, nclear export of RNPs are mediated through viral proteins NEP interacting with M1 which binds nucleoproteins. It is possible that nucleoprotein binds directly host exportin-1/XPO1 and plays an active role in RNPs nuclear export. M1 interaction with RNP seems to hide nucleoprotein's nuclear localization signals. Soon after a virion infects a new cell, M1 dissociates from the RNP under acidification of the virion driven by M2 protein. Dissociation of M1 from RNP unmasks nucleoprotein's nuclear localization signals, targeting the RNP to the nucleus. Encapsidates the negative strand viral RNA, protecting it from nucleases. T24979 BIOCLASS mRNA target T24979 SEQUENCE MASQGTKRSYEQMETGGERQNATEIRASVGRMVGGIGRFYIQMCTELKLSDQEGRLIQNSITIERMVLSAFDERRNRYLEEHPSAGKDPKKTGGPIYRRRDGKWVRELILYDKEEIRRIWRQANNGEDATAGLTHMMIWHSNLNDATYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAIKGVGTMVMELIRMIKRGINDRNFWRGENGRRTRIAYERMCNILKGKFQTAAQKAMMDQVRESRNPGNAEIEDLIFLARSALILRGSVAHKSCLPACVYGPAVASGYDFEREGYSLVGIDPFRLLQNSQVFSLIRPKENPAHKSQLVWMACHSAAFEDLRVSSFIRGTRVIPRGQLSTRGVQIASNENVEAMDSTTLELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFERVTIMAAFKGNTEGRTSDMRTEIIRMMESARPEDVSFQGRGVFELSDEKATNPIVPSFDMSNEGSYFFGDNAEEYDN T24979 DRUGINFO D0Y0EJ ISIS 3307 Investigative T72614 TARGETID T72614 T72614 FORMERID TTDR01095 T72614 UNIPROID AGRL1_HUMAN T72614 TARGNAME CIRL-1 messenger RNA (CIRL-1 mRNA) T72614 GENENAME ADGRL1 T72614 TARGTYPE Literature-reported T72614 SYNONYMS Lectomedin-2 (mRNA); Latrophilin-1 (mRNA); LPHN1 (mRNA); LEC2 (mRNA); KIAA0821 (mRNA); Calcium-independent alpha-latrotoxin receptor 1 (mRNA); CIRL-1 (mRNA); Adhesion G protein-coupled receptor L1 (mRNA) T72614 FUNCTION Receptor for TENM2 that mediates heterophilic synaptic cell-cell contact and postsynaptic specialization. Receptor probably implicated in the regulation of exocytosis. Calcium-independent receptor of high affinity for alpha-latrotoxin, an excitatory neurotoxin present in black widow spider venom which triggers massive exocytosis from neurons and neuroendocrine cells. T72614 BIOCLASS mRNA target T72614 SEQUENCE MARLAAVLWNLCVTAVLVTSATQGLSRAGLPFGLMRRELACEGYPIELRCPGSDVIMVENANYGRTDDKICDADPFQMENVQCYLPDAFKIMSQRCNNRTQCVVVAGSDAFPDPCPGTYKYLEVQYDCVPYKVEQKVFVCPGTLQKVLEPTSTHESEHQSGAWCKDPLQAGDRIYVMPWIPYRTDTLTEYASWEDYVAARHTTTYRLPNRVDGTGFVVYDGAVFYNKERTRNIVKYDLRTRIKSGETVINTANYHDTSPYRWGGKTDIDLAVDENGLWVIYATEGNNGRLVVSQLNPYTLRFEGTWETGYDKRSASNAFMVCGVLYVLRSVYVDDDSEAAGNRVDYAFNTNANREEPVSLTFPNPYQFISSVDYNPRDNQLYVWNNYFVVRYSLEFGPPDPSAGPATSPPLSTTTTARPTPLTSTASPAATTPLRRAPLTTHPVGAINQLGPDLPPATAPVPSTRRPPAPNLHVSPELFCEPREVRRVQWPATQQGMLVERPCPKGTRGIASFQCLPALGLWNPRGPDLSNCTSPWVNQVAQKIKSGENAANIASELARHTRGSIYAGDVSSSVKLMEQLLDILDAQLQALRPIERESAGKNYNKMHKRERTCKDYIKAVVETVDNLLRPEALESWKDMNATEQVHTATMLLDVLEEGAFLLADNVREPARFLAAKENVVLEVTVLNTEGQVQELVFPQEEYPRKNSIQLSAKTIKQNSRNGVVKVVFILYNNLGLFLSTENATVKLAGEAGPGGPGGASLVVNSQVIAASINKESSRVFLMDPVIFTVAHLEDKNHFNANCSFWNYSERSMLGYWSTQGCRLVESNKTHTTCACSHLTNFAVLMAHREIYQGRINELLLSVITWVGIVISLVCLAICISTFCFLRGLQTDRNTIHKNLCINLFLAELLFLVGIDKTQYEIACPIFAGLLHYFFLAAFSWLCLEGVHLYLLLVEVFESEYSRTKYYYLGGYCFPALVVGIAAAIDYRSYGTEKACWLRVDNYFIWSFIGPVSFVIVVNLVFLMVTLHKMIRSSSVLKPDSSRLDNIKSWALGAIALLFLLGLTWAFGLLFINKESVVMAYLFTTFNAFQGVFIFVFHCALQKKVHKEYSKCLRHSYCCIRSPPGGTHGSLKTSAMRSNTRYYTGTQSRIRRMWNDTVRKQTESSFMAGDINSTPTLNRGTMGNHLLTNPVLQPRGGTSPYNTLIAESVGFNPSSPPVFNSPGSYREPKHPLGGREACGMDTLPLNGNFNNSYSLRSGDFPPGDGGPEPPRGRNLADAAAFEKMIISELVHNNLRGSSSAAKGPPPPEPPVPPVPGGGGEEEAGGPGGADRAEIELLYKALEEPLLLPRAQSVLYQSDLDESESCTAEDGATSRPLSSPPGRDSLYASGANLRDSPSYPDSSPEGPSEALPPPPPAPPGPPEIYYTSRPPALVARNPLQGYYQVRRPSHEGYLAAPGLEGPGPDGDGQMQLVTSL T25220 TARGETID T25220 T25220 FORMERID TTDR00092 T25220 UNIPROID VIE1_HCMVT; VIE2_HCMVT; VIE3_HCMVT T25220 TARGNAME Cytomegalovirus Immediate-early protein messenger RNA (CMV IE mRNA) T25220 GENENAME CMV IE mRNA T25220 TARGTYPE Literature-reported T25220 SYNONYMS Human cytomegalovirus immediate-early protein (mRNA) T25220 FUNCTION Alters host cell cycle progression, probably through its interaction with host E2F1 or RB1 that overcomes the RB1-mediated repression of E2F-responsive promoters. Plays an important role in transactivating viral early genes as well as activating its own promoter. Targets and disrupts host PML/nuclear domain 10 (ND10). Promotes efficient viral growth by interacting with and directing host SP100 to degradation, leading to enhanced acetylation level of histones. In addition, functions in counteracting the host innate antiviral response. Inhibits the type I interferon pathway by directly interacting with and sequestrating host STAT2. T25220 BIOCLASS mRNA target T25220 SEQUENCE MESSAKRKMDPDNPDEGPSSKVPRPETPVTKATTFLQTMLRKEVNSQLSLGDPLFPELAEESLKTFERVTEDCNENPEKDVLAELVKQIKVRVDMVRHRIKEHMLKKYTQTEEKFTGAFNMMGGCLQNALDILDKVHEPFEEMKCIGLTMQSMYENYIVPEDKREMWMACIKELHDVSKGAANKLGGALQAKARAKKDELRRKMMYMCYRNIEFFTKNSAFPKTTNGCSQAMAALQNLPQCSPDEIMAYAQKIFKILDEERDKVLTHIDHIFMDILTTCVETMCNEYKVTSDACMMTMYGGISLLSEFCRVLSCYVLEETSVMLAKRPLITKPEVISVMKRRIEEICMKVFAQYILGADPLRVCSPSVDDLRAIAEESDEEEAIVAYTLATRGASSSDSLVSPPESPVPATIPLSSVIVAENSDQEESEQSDEEEEEGAQEEREDTVSVKSEPVSEIEEVAPEEEEDGAEEPTASGGKSTHPMVTRSKADQ T71342 TARGETID T71342 T71342 FORMERID TTDR01365 T71342 UNIPROID VE7_HPV18 T71342 TARGNAME Human papillomavirus-18 E7 region messenger RNA (HPV-18 E7 mRNA) T71342 GENENAME HPV-18 E7 mRNA T71342 TARGTYPE Literature-reported T71342 SYNONYMS HPV-18 protein E7 (mRNA); HPV-18 E7 (mRNA) T71342 FUNCTION Stimulation of progression from G1 to S phase allows the virus to efficiently use the cellular DNA replicating machinery to achieve viral genome replication. E7 protein has both transforming and trans-activating activities. Induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. Plays also a role in the inhibition of both antiviral and antiproliferative functions of host interferon alpha. Interaction with host TMEM173/STING impairs the ability of TMEM173/STING to sense cytosolic DNA and promote the production of type I interferon (IFN-alpha and IFN-beta). Plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. T71342 BIOCLASS mRNA target T71342 SEQUENCE MHGPKATLQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWCASQQ T71342 DRUGINFO D0X9EH ISIS 2491 Investigative T29672 TARGETID T29672 T29672 FORMERID TTDI02652 T29672 UNIPROID GLI2_HUMAN T29672 TARGNAME GLI2 messenger RNA (GLI2 mRNA) T29672 GENENAME GLI2 T29672 TARGTYPE Literature-reported T29672 SYNONYMS Zinc finger protein GLI2 (mRNA); Tax helper protein (mRNA); THP (mRNA); GLI family zinc finger protein 2 (mRNA) T29672 FUNCTION Functions as transcriptional activator. May also function as transcriptional repressor. Requires STK36 for full transcriptional activator activity. Required for normal embryonic development. Functions as transcription regulator in the hedgehog (Hh) pathway. T29672 BIOCLASS mRNA target T29672 SEQUENCE METSASATASEKQEAKSGILEAAGFPDPGKKASPLVVAAAAAAAVAAQGVPQHLLPPFHAPLPIDMRHQEGRYHYEPHSVHGVHGPPALSGSPVISDISLIRLSPHPAGPGESPFNAPHPYVNPHMEHYLRSVHSSPTLSMISAARGLSPADVAQEHLKERGLFGLPAPGTTPSDYYHQMTLVAGHPAPYGDLLMQSGGAASAPHLHDYLNPVDVSRFSSPRVTPRLSRKRALSISPLSDASLDLQRMIRTSPNSLVAYINNSRSSSAASGSYGHLSAGALSPAFTFPHPINPVAYQQILSQQRGLGSAFGHTPPLIQPSPTFLAQQPMALTSINATPTQLSSSSNCLSDTNQNKQSSESAVSSTVNPVAIHKRSKVKTEPEGLRPASPLALTQGQVSGHGSCGCALPLSQEQLADLKEDLDRDDCKQEAEVVIYETNCHWEDCTKEYDTQEQLVHHINNEHIHGEKKEFVCRWQACTREQKPFKAQYMLVVHMRRHTGEKPHKCTFEGCSKAYSRLENLKTHLRSHTGEKPYVCEHEGCNKAFSNASDRAKHQNRTHSNEKPYICKIPGCTKRYTDPSSLRKHVKTVHGPDAHVTKKQRNDVHLRTPLLKENGDSEAGTEPGGPESTEASSTSQAVEDCLHVRAIKTESSGLCQSSPGAQSSCSSEPSPLGSAPNNDSGVEMPGTGPGSLGDLTALDDTPPGADTSALAAPSAGGLQLRKHMTTMHRFEQLKKEKLKSLKDSCSWAGPTPHTRNTKLPPLPGSGSILENFSGSGGGGPAGLLPNPRLSELSASEVTMLSQLQERRDSSTSTVSSAYTVSRRSSGISPYFSSRRSSEASPLGAGRPHNASSADSYDPISTDASRRSSEASQCSGGSGLLNLTPAQQYSLRAKYAAATGGPPPTPLPGLERMSLRTRLALLDAPERTLPAGCPRPLGPRRGSDGPTYGHGHAGAAPAFPHEAPGGGARRASDPVRRPDALSLPRVQRFHSTHNVNPGPLPPCADRRGLRLQSHPSTDGGLARGAYSPRPPSISENVAMEAVAAGVDGAGPEADLGLPEDDLVLPDDVVQYIKAHASGALDEGTGQVYPTESTGFSDNPRLPSPGLHGQRRMVAADSNVGPSAPMLGGCQLGFGAPSSLNKNNMPVQWNEVSSGTVDALASQVKPPPFPQGNLAVVQQKPAFGQYPGYSPQGLQASPGGLDSTQPHLQPRSGAPSQGIPRVNYMQQLRQPVAGSQCPGMTTTMSPHACYGQVHPQLSPSTISGALNQFPQSCSNMPAKPGHLGHPQQTEVAPDPTTMGNRHRELGVPDSALAGVPPPHPVQSYPQQSHHLAASMSQEGYHQVPSLLPARQPGFMEPQTGPMGVATAGFGLVQPRPPLEPSPTGRHRGVRAVQQQLAYARATGHAMAAMPSSQETAEAVPKGAMGNMGSVPPQPPPQDAGGAPDHSMLYYYGQIHMYEQDGGLENLGSCQVMRSQPPQPQACQDSIQPQPLPSPGVNQVSSTVDSQLLEAPQIDFDAIMDDGDHSSLFSGALSPSLLHSLSQNSSRLTTPRNSLTLPSIPAGISNMAVGDMSSMLTSLAEESKFLNMMT T31665 TARGETID T31665 T31665 FORMERID TTDR01419 T31665 UNIPROID TFE2_HUMAN-PBX1_HUMAN T31665 TARGNAME E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA) T31665 GENENAME TCF3-PBX1 T31665 TARGTYPE Literature-reported T31665 SYNONYMS Transcription factor 3-Homeobox protein PRL (mRNA) T31665 FUNCTION E2A-PBX1 perturbs signaling pathways upstream of PLC2 and renders leukemias amenable to targeted therapeutic inhibition. T31665 BIOCLASS mRNA target T31665 SEQUENCE MNQPQRMAPVGTDKELSDLLDFSMMFPLPVTNGKGRPASLAGAQFGGSGLEDRPSSGSWGSGDQSSSSFDPSRTFSEGTHFTESHSSLSSSTFLGPGLGGKSGERGAYASFGRDAGVGGLTQAGFLSGELALNSPGPLSPSGMKGTSQYYPSYSGSSRRRAADGSLDTQPKKVRKVPPGLPSSVYPPSSGEDYGRDATAYPSAKTPSSTYPAPFYVADGSLHPSAELWSPPGQAGFGPMLGGGSSPLPLPPGSGPVGSSGSSSTFGGLHQHERMGYQLHGAEVNGGLPSASSFSSAPGATYGGVSSHTPPVSGADSLLGSRGTTAGSSGDALGKALASIYSPDHSSNNFSSSPSTPVGSPQGLAGTSQWPRAGAPGALSPSYDGGLHGLQSKIEDHLDEAIHVLRSHAVGTAGDMHTLLPGHGALASGFTGPMSLGGRHAGLVGGSHPEDGLAGSTSLMHNHAALPSQPGTLPDLSRPPDSYSGLGRAGATAAASEIKREEKEDEENTSAADHSEEEKKELKAPRARTSPDEDEDDLLPPEQKAEREKERRVANNARERLRVRDINEAFKELGRMCQLHLNSEKPQTKLLILHQAVSVILNLEQQVRERNLNPKAACLKRREEEKVSGVVGDPQMVLSAPHPGLSEAHNPAGHMMDEQPRLMHSHAGVGMAGHPGLSQHLQDGAGGTEGEGGRKQDIGDILQQIMTITDQSLDEAQARKHALNCHRMKPALFNVLCEIKEKTVLSIRGAQEEEPTDPQLMRLDNMLLAEGVAGPEKGGGSAAAAAAAAASGGAGSDNSVEHSDYRAKLSQIRQIYHTELEKYEQACNEFTTHVMNLLREQSRTRPISPKEIERMVSIIHRKFSSIQMQLKQSTCEAVMILRSRFLDARRKRRNFNKQATEILNEYFYSHLSNPYPSEEAKEELAKKCGITVSQVSNWFGNKRIRYKKNIGKFQEEANIYAAKTAVTATNVSAHGSQANSPSTPNSAGSSSSFNMSNSGDLFMSVQSLNGDSYQGAQVGANVQSQVDTLRHVISQTGGYSDGLAASQMYSPQGISANGGWQDATTPSSVTSPTEGPGSVHSDTSN T31665 DRUGINFO D02PGM ISIS 16124 Investigative T31665 DRUGINFO D06LWP ISIS 16112 Investigative T31665 DRUGINFO D09EQS ISIS 16123 Investigative T31665 DRUGINFO D0KF3D ISIS 16108 Investigative T31665 DRUGINFO D0Z6AS ISIS 16121 Investigative T13059 TARGETID T13059 T13059 FORMERID TTDR00056 T13059 UNIPROID PRP8_YEAST T13059 TARGNAME Fungal Pre-mRNA splicing factor PRP8 (Fung PRP8) T13059 GENENAME Fung PRP8 T13059 TARGTYPE Literature-reported T13059 SYNONYMS Prp8 intein; PRP8; Intein (PRP8) T13059 FUNCTION Functions as a scaffold that mediates the ordered assembly of spliceosomal proteins and snRNAs. Required for association of BRR2 with the spliceosomal U5 snRNP, and the subsequent assembly of the U4/U6-U5 tri-snRNP complex. Functions as scaffold thatpositions spliceosomal U2, U5 and U6 snRNAs at splice sites on pre-mRNA substrates, so that splicing can occur. Interacts with both the 5' and the 3' splice site, as well as the branch region. Has a role in branch site-3' splice site selection. Associates with the branch site-3' splice 3'-exon region. Also has a role in cell cycle. T13059 PDBSTRUC 6J6Q; 6J6N; 6J6H; 6J6G; 6EXN T13059 SEQUENCE MSGLPPPPPGFEEDSDLALPPPPPPPPGYEIEELDNPMVPSSVNEDTFLPPPPPPPSNFEINAEEIVDFTLPPPPPPPGLDELETKAEKKVELHGKRKLDIGKDTFVTRKSRKRAKKMTKKAKRSNLYTPKAEMPPEHLRKIINTHSDMASKMYNTDKKAFLGALKYLPHAILKLLENMPHPWEQAKEVKVLYHTSGAITFVNETPRVIEPVYTAQWSATWIAMRREKRDRTHFKRMRFPPFDDDEPPLSYEQHIENIEPLDPINLPLDSQDDEYVKDWLYDSRPLEEDSKKVNGTSYKKWSFDLPEMSNLYRLSTPLRDEVTDKNYYYLFDKKSFFNGKALNNAIPGGPKFEPLYPREEEEDYNEFNSIDRVIFRVPIRSEYKVAFPHLYNSRPRSVRIPWYNNPVSCIIQNDEEYDTPALFFDPSLNPIPHFIDNNSSLNVSNTKENGDFTLPEDFAPLLAEEEELILPNTKDAMSLYHSPFPFNRTKGKMVRAQDVALAKKWFLQHPDEEYPVKVKVSYQKLLKNYVLNELHPTLPTNHNKTKLLKSLKNTKYFQQTTIDWVEAGLQLCRQGHNMLNLLIHRKGLTYLHLDYNFNLKPTKTLTTKERKKSRLGNSFHLMRELLKMMKLIVDTHVQFRLGNVDAFQLADGIHYILNHIGQLTGIYRYKYKVMHQIRACKDLKHIIYYKFNKNLGKGPGCGFWQPAWRVWLNFLRGTIPLLERYIGNLITRQFEGRSNEIVKTTTKQRLDAYYDLELRNSVMDDILEMMPESIRQKKARTILQHLSEAWRCWKANIPWDVPGMPAPIKKIIERYIKSKADAWVSAAHYNRERIKRGAHVEKTMVKKNLGRLTRLWIKNEQERQRQIQKNGPEITPEEATTIFSVMVEWLESRSFSPIPFPPLTYKNDTKILVLALEDLKDVYASKVRLNASEREELALIEEAYDNPHDTLNRIKKYLLTQRVFKPVDITMMENYQNISPVYSVDPLEKITDAYLDQYLWYEADQRKLFPNWIKPSDSEIPPLLVYKWTQGINNLSEIWDVSRGQSAVLLETTLGEMAEKIDFTLLNRLLRLIVDPNIADYITAKNNVVINFKDMSHVNKYGLIRGLKFASFIFQYYGLVIDLLLLGQERATDLAGPANNPNEFMQFKSKEVEKAHPIRLYTRYLDRIYMLFHFEEDEGEELTDEYLAENPDPNFENSIGYNNRKCWPKDSRMRLIRQDVNLGRAVFWEIQSRVPTSLTSIKWENAFVSVYSKNNPNLLFSMCGFEVRILPRQRMEEVVSNDEGVWDLVDERTKQRTAKAYLKVSEEEIKKFDSRIRGILMASGSTTFTKVAAKWNTSLISLFTYFREAIVATEPLLDILVKGETRIQNRVKLGLNSKMPTRFPPAVFYTPKELGGLGMISASHILIPASDLSWSKQTDTGITHFRAGMTHEDEKLIPTIFRYITTWENEFLDSQRVWAEYATKRQEAIQQNRRLAFEELEGSWDRGIPRISTLFQRDRHTLAYDRGHRIRREFKQYSLERNSPFWWTNSHHDGKLWNLNAYRTDVIQALGGIETILEHTLFKGTGFNSWEGLFWEKASGFEDSMQFKKLTHAQRTGLSQIPNRRFTLWWSPTINRANVYVGFLVQLDLTGIFLHGKIPTLKISLIQIFRAHLWQKIHESIVFDICQILDGELDVLQIESVTKETVHPRKSYKMNSSAADITMESVHEWEVSKPSLLHETNDSFKGLITNKMWFDVQLRYGDYDSHDISRYVRAKFLDYTTDNVSMYPSPTGVMIGIDLAYNMYDAYGNWFNGLKPLIQNSMRTIMKANPALYVLRERIRKGLQIYQSSVQEPFLNSSNYAELFNNDIKLFVDDTNVYRVTVHKTFEGNVATKAINGCIFTLNPKTGHLFLKIIHTSVWAGQKRLSQLAKWKTAEEVSALVRSLPKEEQPKQIIVTRKAMLDPLEVHMLDFPNIAIRPTELRLPFSAAMSIDKLSDVVMKATEPQMVLFNIYDDWLDRISSYTAFSRLTLLLRALKTNEESAKMILLSDPTITIKSYHLWPSFTDEQWITIESQMRDLILTEYGRKYNVNISALTQTEIKDIILGQNIKAPSVKRQKMAELEAARSEKQNDEEAAGASTVMKTKTINAQGEEIVVVASADYESQTFSSKNEWRKSAIANTLLYLRLKNIYVSADDFVEEQNVYVLPKNLLKKFIEISDVKIQVAAFIYGMSAKDHPKVKEIKTVVLVPQLGHVGSVQISNIPDIGDLPDTEGLELLGWIHTQTEELKFMAASEVATHSKLFADKKRDCIDISIFSTPGSVSLSAYNLTDEGYQWGEENKDIMNVLSEGFEPTFSTHAQLLLSDRITGNFIIPSGNVWNYTFMGTAFNQEGDYNFKYGIPLEFYNEMHRPVHFLQFSELAGDEELEAEQIDVFS T92128 TARGETID T92128 T92128 FORMERID TTDI02654 T92128 UNIPROID ID1_HUMAN T92128 TARGNAME ID1 messenger RNA (ID1 mRNA) T92128 GENENAME ID1 T92128 TARGTYPE Literature-reported T92128 SYNONYMS bHLHb24 (mRNA); Inhibitor of differentiation 1 (mRNA); Inhibitor of DNA binding 1 (mRNA); ID (mRNA); DNA-binding protein inhibitor ID-1 (mRNA); Class B basic helix-loop-helix protein 24 (mRNA) T92128 FUNCTION Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Inhibits skeletal muscle and cardiac myocyte differentiation. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. T92128 BIOCLASS mRNA target T92128 SEQUENCE MKVASGSTATAAAGPSCALKAGKTASGAGEVVRCLSEQSVAISRCAGGAGARLPALLDEQQVNVLLYDMNGCYSRLKELVPTLPQNRKVSKVEILQHVIDYIRDLQLELNSESEVGTPGGRGLPVRAPLSTLNGEISALTAEAACVPADDRILCR T48548 TARGETID T48548 T48548 FORMERID TTDR01093 T48548 UNIPROID ARRB1_HUMAN; ARRB2_HUMAN T48548 TARGNAME Beta-arrestin messenger RNA (ARRB mRNA) T48548 GENENAME ARRB1; ARRB2 T48548 TARGTYPE Literature-reported T48548 SYNONYMS Non-visual arrestin; Beta-arrestin; Arrestin beta; ARR T48548 FUNCTION The extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G-proteins. Functions in regulating agonist-mediated G-protein coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes. During homologous desensitization, beta-arrestins bind to the GPRK-phosphorylated receptor and sterically preclude its coupling to the cognate G-protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adapter protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). T48548 BIOCLASS mRNA target T48548 SEQUENCE MGDKGTRVFKKASPNGKLTVYLGKRDFVDHIDLVDPVDGVVLVDPEYLKERRVYVTLTCAFRYGREDLDVLGLTFRKDLFVANVQSFPPAPEDKKPLTRLQERLIKKLGEHAYPFTFEIPPNLPCSVTLQPGPEDTGKACGVDYEVKAFCAENLEEKIHKRNSVRLVIRKVQYAPERPGPQPTAETTRQFLMSDKPLHLEASLDKEIYYHGEPISVNVHVTNNTNKTVKKIKISVRQYADICLFNTAQYKCPVAMEEADDTVAPSSTFCKVYTLTPFLANNREKRGLALDGKLKHEDTNLASSTLLREGANREILGIIVSYKVKVKLVVSRGGLLGDLASSDVAVELPFTLMHPKPKEEPPHREVPENETPVDTNLIELDTNDDDIVFEDFARQRLKGMKDDKEEEEDGTGSPQLNNR T03571 TARGETID T03571 T03571 FORMERID TTDI02387 T03571 UNIPROID CTCFL_HUMAN T03571 TARGNAME BORIS messenger RNA (CTCFL mRNA) T03571 GENENAME CTCFL T03571 TARGTYPE Literature-reported T03571 SYNONYMS Zinc finger protein CTCF-T (mRNA); Transcriptional repressor CTCFL (mRNA); Cancer/testis antigen 27 (mRNA); CTCF-like protein (mRNA); CTCF paralog (mRNA); CT27 (mRNA); CCCTC-binding factor (mRNA); Brother of the regulator of imprinted sites (mRNA); BORIS (mRNA) T03571 FUNCTION Plays a key role in gene imprinting in male germline, by participating in the establishment of differential methylation at the IGF2/H19 imprinted control region (ICR). Directly binds the unmethylated H19 ICR and recruits the PRMT7 methyltransferase, leading to methylate histone H4 'Arg-3' to form H4R3sme2. This probably leads to recruit de novo DNA methyltransferases at these sites. Seems to act as tumor suppressor. In association with DNMT1 and DNMT3B, involved in activation of BAG1 gene expression by binding to its promoter. Required for dimethylation of H3 lysine 4 (H3K4me2) of MYC and BRCA1 promoters. Testis-specific DNA binding protein responsible for insulator function, nuclear architecture and transcriptional control, which probably acts by recruiting epigenetic chromatin modifiers. T03571 BIOCLASS mRNA target T03571 SEQUENCE MAATEISVLSEQFTKIKELELMPEKGLKEEEKDGVCREKDHRSPSELEAERTSGAFQDSVLEEEVELVLAPSEESEKYILTLQTVHFTSEAVELQDMSLLSIQQQEGVQVVVQQPGPGLLWLEEGPRQSLQQCVAISIQQELYSPQEMEVLQFHALEENVMVASEDSKLAVSLAETTGLIKLEEEQEKNQLLAERTKEQLFFVETMSGDERSDEIVLTVSNSNVEEQEDQPTAGQADAEKAKSTKNQRKTKGAKGTFHCDVCMFTSSRMSSFNRHMKTHTSEKPHLCHLCLKTFRTVTLLRNHVNTHTGTRPYKCNDCNMAFVTSGELVRHRRYKHTHEKPFKCSMCKYASVEASKLKRHVRSHTGERPFQCCQCSYASRDTYKLKRHMRTHSGEKPYECHICHTRFTQSGTMKIHILQKHGENVPKYQCPHCATIIARKSDLRVHMRNLHAYSAAELKCRYCSAVFHERYALIQHQKTHKNEKRFKCKHCSYACKQERHMTAHIRTHTGEKPFTCLSCNKCFRQKQLLNAHFRKYHDANFIPTVYKCSKCGKGFSRWINLHRHSEKCGSGEAKSAASGKGRRTRKRKQTILKEATKGQKEAAKGWKEAANGDEAAAEEASTTKGEQFPGEMFPVACRETTARVKEEVDEGVTCEMLLNTMDK T20722 TARGETID T20722 T20722 FORMERID TTDI01539 T20722 UNIPROID E2AK1_HUMAN; E2AK2_HUMAN; E2AK3_HUMAN; E2AK4_HUMAN T20722 TARGNAME EIF protein kinase messenger RNA (EIFK mRNA) T20722 GENENAME EIF2AK1; EIF2AK2; EIF2AK3; EIF2AK4 T20722 TARGTYPE Literature-reported T20722 SYNONYMS eIF-2A kinase; Eukaryotic translation initiation factor 2-alpha kinase T20722 FUNCTION A kinase enzyme that phosphorylates eIF-2. These are all responsible for the phosphorylation of the alpha subunit of eIF-2 at serine 51, one of the best-characterized mechanisms for down-regulating protein synthesis in eukaryotes in response to various cellular stress response's. T20722 BIOCLASS mRNA target T20722 SEQUENCE MQGGNSGVRKREEEGDGAGAVAAPPAIDFPAEGPDPEYDESDVPAEIQVLKEPLQQPTFPFAVANQLLLVSLLEHLSHVHEPNPLRSRQVFKLLCQTFIKMGLLSSFTCSDEFSSLRLHHNRAITHLMRSAKERVRQDPCEDISRIQKIRSREVALEAQTSRYLNEFEELAILGKGGYGRVYKVRNKLDGQYYAIKKILIKGATKTVCMKVLREVKVLAGLQHPNIVGYHTAWIEHVHVIQPRADRAAIELPSLEVLSDQEEDREQCGVKNDESSSSSIIFAEPTPEKEKRFGESDTENQNNKSVKYTTNLVIRESGELESTLELQENGLAGLSASSIVEQQLPLRRNSHLEESFTSTEESSEENVNFLGQTEAQYHLMLHIQMQLCELSLWDWIVERNKRGREYVDESACPYVMANVATKIFQELVEGVFYIHNMGIVHRDLKPRNIFLHGPDQQVKIGDFGLACTDILQKNTDWTNRNGKRTPTHTSRVGTCLYASPEQLEGSEYDAKSDMYSLGVVLLELFQPFGTEMERAEVLTGLRTGQLPESLRKRCPVQAKYIQHLTRRNSSQRPSAIQLLQSELFQNSGNVNLTLQMKIIEQEKEIAELKKQLNLLSQDKGVRDDGKDGGVG T81227 TARGETID T81227 T81227 FORMERID TTDI01702 T81227 UNIPROID HV551_HUMAN; HV5X1_HUMAN T81227 TARGNAME Immunoglobulin heavy variable 5 (IGHV5) T81227 GENENAME IGHV5-10-1; IGHV5-51 T81227 TARGTYPE Literature-reported T81227 SYNONYMS Immunoglobulin heavy variable 5 T81227 FUNCTION V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen. T81227 SEQUENCE MGSTAILALLLAVLQGVCAEVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAR T42413 TARGETID T42413 T42413 FORMERID TTDI01400 T42413 UNIPROID A0A0G4DCU0_HYPRU T42413 TARGNAME Trichoderma L-Lysine alpha-oxidase (HYPRU LysOX) T42413 GENENAME HYPRU LysOX T42413 TARGTYPE Literature-reported T42413 SYNONYMS L-Lysine alpha-oxidase T42413 FUNCTION An antitumor enzyme of Trichoderma harzianum. Inhibit highly infectious viruses INSV and TRSV, Mycoplasma hominis, and tick-borne encephalitis virus. T42413 SEQUENCE MDNVDFAESVRTRWARRLIREKVAKELNILTERLGEVPGIPPPREGRFLGGGYSHDNLPSDPLYSSIKPALLKEAPRAEEELPPRKVCIVGAGVSGLYIAMILDDLKIPNLTYDIFESSSRTGGRLYTHHFTDAKHDYYDIGAMRYPDIPSMKRTFNLFKRTGMPLIKYYLDGENTPQLYNNHFFAKGVVDPYMVSVANGGTVPDDVVDSVGEKLQQAFGYYKEKLAEDFDKGFDELMLVDDMTTREYLKRGGPKGEAPKYDFFAIQWMETQNTGTNLFDQAFSESVIDSFDFDNPTKPEWYCIEGGTSLLVDAMKETLVHKVQNNKRVEAISIDLDAPDDGNMSVKIGGKDYSGYSTVFNTTALGCLDRMDLRGLNLHPTQADAIRCLHYDNSTKVALKFSYPWWIKDCGITCGGAASTDLPLRTCVYPSYNLGDTGEAVLLASYTWSQDATRIGSLVKDAPPQPPKEDELVELILQNLARLHAEHMTYEKIKEAYTGVYHAYCWANDPNVGGAFALFGPGQFSNLYPYLMRPAAGGKFHIVGEASSVHHAWIIGSLESAYTAVYQFLYKYKMWDYLRLLLERWQYGLQELETGKHGTAHLQFILGSLPKEYQVKI T95640 TARGETID T95640 T95640 FORMERID TTDR01318 T95640 UNIPROID A0A1C7BG45_PSEAI T95640 TARGNAME Pseudomonas Protein KerV (Pseudo KerV) T95640 GENENAME Pseudo KerV T95640 TARGTYPE Literature-reported T95640 SYNONYMS KerV protein T95640 FUNCTION A methyltransferase, well-conserved across numerous Proteobacteria, including both well-known and emerging pathogens. T95640 SEQUENCE MNEPQAFAQTDAEWLASINRARDWFQGPLGSLMLAEERRLLCDELTRYFGGYLVHYGPHAELPPSTGQIQRGVRLGPPLPGVDIACEEGAWPLSEHAADVVLLQHGLDFCLSPHRLLREAARTVRPGGHLLLIGINPWSLWGIRHYFAGDALRQARCIPPSRACDWLNLLGFALEKRRFGCYRPPLASAAWQSRLARLERWGDAWQSSGAGFYLLVARKLVVGLRPLRQSKREPRGQLVPMPVAKVSRRDSEI T55817 TARGETID T55817 T55817 FORMERID TTDNR00689 T55817 UNIPROID A0A1D8PIG5_CANAL T55817 TARGNAME Candida Co-chaperone SGT1 (Candi SGT1) T55817 GENENAME Candi SGT1 T55817 TARGTYPE Literature-reported T55817 SYNONYMS orf19.4089; CAALFM_C209270CA T55817 FUNCTION Involved in ubiquitination and subsequent proteasomal degradation of target proteins. Required for both entry into S phase and kinetochore function. Also involved in cyclic AMP (cAMP) pathway, possibly by participating in the assembly or the conformational activation of specific multiprotein complexes. T55817 SEQUENCE MAIEQFITKGDDALKSKDYLGAISYYSQAIKENPQAFSPYLKRSTAYQKLKNNDKAKADISSAFSIATEKGKRVDIGLCYFKLGLVYYQEKKVKLSLTQFEKAVEYDCKEPTLSMWKAKAEYDLKNHPEWNVEGDKEEDDDIDLVLGVENEYTQSMANTEKDKSHEPKIVELDANEESSEKKSNQESTSSAPAAQATTQAPKSTNVDVINKIAPLNVKFRDDWYQSNEEVIITIYAKKVNEEKLKVEFDTNSVCISFPSAAASEYKYYLDPLFAEIVPSESKYKVYSTKLEITLKKKDANKWPELEKQAVEGVTDNQDKDKKVDPSELVYPTSSKKKINWNNFKIDDDDKEEGNENDFFRKIFKDVDEDSRRAMMKSYVQSNGTVLTTSWDEAKDKEFEVLPPDGMEVKKWDT T22135 TARGETID T22135 T22135 FORMERID TTDNR00755 T22135 UNIPROID A0A2X2N8M2_STAAU T22135 TARGNAME Staphylococcus Pmt ABC transporter (Stap-coc Pmt) T22135 GENENAME Stap-coc Pmt T22135 TARGTYPE Literature-reported T22135 SYNONYMS Predicted membrane-bound dolichyl-phosphate-mannose-protein mannosyltransferase T22135 FUNCTION A general export system for membrane-damaging peptides, secreting host-derived AMPs in addition to the bacterial PSM cytotoxins. Defends the bacteria from killing by important human AMPs and elimination by human neutrophils. T22135 SEQUENCE MTAPVPLLPAPEERSTRYGQLRDRLLRDPDWGRAIRWLAPLVITAIAALLRLINVAHPHQLAFDETYYVKDAWSLWTLGYEGTWGENANDAFITLQQLPLSEQGAFIVHPPLGKWLIALGMAIGGPDNSAGWRLATALLGTASVLLVYLIARRLSGSVVVASVAGTLLAIDGLSIVMSRIALLDGILTFFVLLGVLFVIIDRQRTIPVLERRDPDKPDPFWGPVLWRRPWLIAAGTALGAASAVKWSGLYVLAGFGLYVVVTDALARRRAGVVLWPTGAAFRQGPVSFVLLVFPALAVYLISWTGWLVTAGGYDRQSDPNPLIALWKYHESMLGFHVGLTRGHPYASPAWEWPLLLRPTAVWVDSDPTGCGTDHCIGVISAIPNPLIWYAGVAAAIYLLYRLVRGWITRRPVGPELSIPLVGLAVTYVPWLMFPDRTIFQFYTVVMMPFLVIALAMTLRIIAGTREDPLHRRQSGERTVMIFLAFVVLVSAFFLPLWTGMSVPYEFWLLHNWLPGWV T89185 TARGETID T89185 T89185 FORMERID TTDI01440 T89185 UNIPROID PM2P1_HUMAN; PM2P2_HUMAN; PM2P3_HUMAN T89185 TARGNAME Postmeiotic segregation increased 2-like protein (PMS2L) T89185 GENENAME PMS2P1; PMS2P2; PMS2P3 T89185 TARGTYPE Literature-reported T89185 SYNONYMS Putative postmeiotic segregation increased 2-like protein; Putative postmeiotic segregation increased 2 pseudogene; Postmeiotic segregation increased protein; PMS2L; PMS2-related protein; PMS T89185 FUNCTION Expressed ubiquitously except in the heart. Analysis of the proteins interacting with PMS2Ls may lead to the elucidation of the function of PMS2Ls or of the downstream pathway in the MMR system. T89185 SEQUENCE MVTMCGGHRPENFLHQVLTEFGEELAGEGKSEVGGGAPRSYLQVASAECWAAAPAVHVGEPVHAGGLHTERGADPVIGLYLVHRGGACQTPTVGNRQTPTLGIHARPRRRATTSLLTLLLAFGKNAVRCALIGPGSLTSRTRPLTEPLGEKERREVFFPPRPERVEHNVESSRWEPRRRGACGSRGGNFPSPRGGSGVASLERAESSSTEPAKAIKPIDRKSVHQICSGPVVPSLSTAVKELVENSLDAGATNIDLKLKDYGVDLIEVSGNGCGVEEENFEGLTLKHHTSKIQEFADLPQVETFGFRGEALSSLCALSDVTISTCHVSAKVGTRLVFDHYGKIIQKTPYPHPRGMTVSVKQLFSTLPVHHKEFQRNIKKKRACFPFAFCRDCQFPEASPAMLPVQPAELTPRSTPPHPCSLEDNVITVFSSVKNGPGSSR T58028 TARGETID T58028 T58028 FORMERID TTDI01521 T58028 UNIPROID LIRA5_HUMAN; LIRB5_HUMAN T58028 TARGNAME Leukocyte Ig-like receptor-5 (LILR5) T58028 GENENAME LILRA5; LILRB5 T58028 TARGTYPE Literature-reported T58028 SYNONYMS ILT-11 T58028 FUNCTION May play a role in triggering innate immune responses. Does not seem to play a role for any class I MHC antigen recognition. T58028 SEQUENCE MAPWSHPSAQLQPVGGDAVSPALMVLLCLGLSLGPRTHVQAGNLSKATLWAEPGSVISRGNSVTIRCQGTLEAQEYRLVKEGSPEPWDTQNPLEPKNKARFSIPSMTEHHAGRYRCYYYSPAGWSEPSDPLELVVTGFYNKPTLSALPSPVVTSGENVTLQCGSRLRFDRFILTEEGDHKLSWTLDSQLTPSGQFQALFPVGPVTPSHRWMLRCYGSRRHILQVWSEPSDLLEIPVSGAADNLSPSQNKSDSGTASHLQDYAVENLIRMGMAGLILVVLGILIFQDWHSQRSPQAAAGR T11858 TARGETID T11858 T11858 FORMERID TTDI03212 T11858 UNIPROID GBRR3_HUMAN T11858 TARGNAME GABA(A) receptor rho3 (GABRR3) T11858 GENENAME GABRR3 T11858 TARGTYPE Literature-reported T11858 SYNONYMS Gamma-aminobutyric acid receptor subunit rho-3; GABA(C) receptor3; GABA(A) receptor subunit rho-3 T11858 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. T11858 SEQUENCE MVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTCKQETRMKKDDSTKARPQKYEQLLHIEDNDFAMRPGFGGSPVPVGIDVHVESIDSISETNMDFTMTFYLRHYWKDERLSFPSTANKSMTFDHRLTRKIWVPDIFFVHSKRSFIHDTTMENIMLRVHPDGNVLLSLRITVSAMCFMDFSRFPLDTQNCSLELESYAYNEDDLMLYWKHGNKSLNTEEHMSLSQFFIEDFSASSGLAFYSSTGWYNRLFINFVLRRHVFFFVLQTYFPAILMVMLSWVSFWIDRRAVPARVSLGITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYAAVNYLTTVEERKQFKKTGKISRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFMRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYILFNLFYWGVYV T11858 DRUGINFO D0A6RM trans-3-ACPBPA Investigative T11858 DRUGINFO D0B0WU cis-3-ACPBPA Investigative T11858 DRUGINFO D0C7PZ 5-Me-IAA Investigative T11858 DRUGINFO D0OY1R aza-THIP Investigative T11858 DRUGINFO D0U4HM TPMPA Investigative T11858 DRUGINFO D0WV8K (+/-)-cis-2-CAMP Investigative T11858 DRUGINFO D0VW5M piperidine-4-sulphonic acid Investigative T11858 DRUGINFO D0AC2H isonipecotic acid Investigative T11858 DRUGINFO D0P0TI TBPS Investigative T86074 TARGETID T86074 T86074 FORMERID TTDR00059 T86074 UNIPROID C4QPC8_SCHMA T86074 TARGNAME Schistosoma P2X receptor (sch P2X) T86074 GENENAME sch P2X T86074 TARGTYPE Literature-reported T86074 SYNONYMS p2X receptor subunit (AJ703803) T86074 FUNCTION A non-vertebrate ATP-gated ion channel. T86074 SEQUENCE MYFKGDSEFLGLKQCAREQMVKGIAVLFEYETPKLVQISNIKIGVTQRLLQLVILIYVVCWVMIYEKGYQENDIAKSAVTTKVKGVGFTNFSHIPGIGMRSWDVADYIVPPLENNALFVITNLVKTERQSLSKCQESSWVPEAACYKDSDCKPYFISHLGNGAHTGKCIIKPGNDIGSCEIYSWCPLENDTLPLGRKSFLFPMVYNYTLLIKNDINFEKFGIHRRNIQNWASKKFLRTCLYNKTDPENRFCPIFQFGTIFEEANVDQSIFISGGVIGIDIDWKCDLDWDVQYCNPTYSFRRLDDAHAKIASGFNFR T88838 TARGETID T88838 T88838 UNIPROID TEG7_HCMVM T88838 TARGNAME Cytomegalovirus Phosphorylated tegument protein UL51 homolog (CMV pUL71) T88838 GENENAME CMV pUL71 T88838 TARGTYPE Literature-reported T88838 SYNONYMS Tegument protein UL51 homolog T88838 FUNCTION Plays several roles during the time course of infection, including egress of virus particles from the perinuclear space and secondary envelopment of cytoplasmic capsids that bud into specific trans-Golgi network (TGN)-derived membranes. T88838 SEQUENCE MQLAQRLCELLMCRRKAAPVADYVLLQPSEDVELRELQAFLDENFKQLEITPADLRTFSRDTDVVNHLLKLLPLYRQCQSKCAFLKGYLSEGCLPHTRPAAEVECKKSQRILEALDILILKLVVGEFAMSEADSLEMLLDKFSTDQASLVEVQRVMGLVDMDCEKSAYMLEAGAAATVAPPTPPAVVQGESGVREDGETVAAVSAFACSSVSDSLIPEETGVTRPMMSLAHINTVSCPTVMRFDQRLLEEGDEEDEVTVMSPSPEPVQQQPPVEPVQQQPQGRGSHRRRYKESAPQETLPTNHEREILDLMRHSPDVPREAVMSPTMVTIPPPQIPFVGSARELRGVKKKKPTAAALLSSA T33712 TARGETID T33712 T33712 FORMERID TTDI01372 T33712 UNIPROID G0TQ18_MYCCP T33712 TARGNAME Mycobacterium Shikimate kinase (MycB aroK) T33712 GENENAME MycB aroK T33712 TARGTYPE Literature-reported T33712 SYNONYMS Shikimate kinase; MycB SK T33712 FUNCTION Catalyzes the specific phosphorylation of the 3-hydroxyl group of shikimic acid using ATP as a cosubstrate. T33712 SEQUENCE MAPKAVLVGLPGSGKSTIGRRLAKALGVSLLDTDVAIEQRTGRSIADIFATDGEQEFRRIEEDVVRAALADHDGVLSLGGGAVTSPGVRAALAGHTVVYLEISAAEGVRRTGGNTVRPLLAGPDRAEKYRALMAKRAPLYRRVATMRVDTNRRNPGAVVRYILSRLQVPSPSEAAT T20256 TARGETID T20256 T20256 FORMERID TTDNR00684 T20256 UNIPROID HAX1_HUMAN T20256 TARGNAME HCLS1-associated protein X-1 (HAX1) T20256 GENENAME HAX1 T20256 TARGTYPE Literature-reported T20256 SYNONYMS HSP1BP-1; HS1BP1; HS1-binding protein 1; HS1-associating protein X-1; HAX-1 T20256 FUNCTION Slows down the rate of inactivation of KCNC3 channels. Promotes GNA13-mediated cell migration. Involved in the clathrin-mediated endocytosis pathway. May be involved in internalization of ABC transporters such as ABCB11. May inhibit CASP9 and CASP3. Promotes cell survival. May regulate intracellular calcium pools. Recruits the Arp2/3 complex to the cell cortex and regulates reorganization of the cortical actin cytoskeleton via its interaction with KCNC3 and the Arp2/3 complex. T20256 SEQUENCE MSLFDLFRGFFGFPGPRSHRDPFFGGMTRDEDDDEEEEEEGGSWGRGNPRFHSPQHPPEEFGFGFSFSPGGGIRFHDNFGFDDLVRDFNSIFSDMGAWTLPSHPPELPGPESETPGERLREGQTLRDSMLKYPDSHQPRIFGGVLESDARSESPQPAPDWGSQRPFHRFDDVWPMDPHPRTREDNDLDSQVSQEGLGPVLQPQPKSYFKSISVTKITKPDGIVEERRTVVDSEGRTETTVTRHEADSSPRGDPESPRPPALDDAFSILDLFLGRWFRSR T80858 TARGETID T80858 T80858 FORMERID TTDI03239 T80858 UNIPROID GPR31_HUMAN T80858 TARGNAME G-protein coupled receptor 31 (GPR31) T80858 GENENAME GPR31 T80858 TARGTYPE Literature-reported T80858 SYNONYMS 12-HETER; 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor; 12-(S)-HETE receptor T80858 FUNCTION High-affinity receptor for 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12-S-HETE). 12-(S)-HETE is an arachidonic acid metabolite secreted by platelets and tumor cells, and known to induce endothelial cells retraction allowing invasive cell access to the subendothelial matrix, which is a critical step for extravasation or metastasis. Ligand-binding lead to activation of ERK1/2 (MAPK3/MAPK1), MEK, and NF-kappa-B. T80858 SEQUENCE MPFPNCSAPSTVVATAVGVLLGLECGLGLLGNAVALWTFLFRVRVWKPYAVYLLNLALADLLLAACLPFLAAFYLSLQAWHLGRVGCWALHFLLDLSRSVGMAFLAAVALDRYLRVVHPRLKVNLLSPQAALGVSGLVWLLMVALTCPGLLISEAAQNSTRCHSFYSRADGSFSIIWQEALSCLQFVLPFGLIVFCNAGIIRALQKRLREPEKQPKLQRAQALVTLVVVLFALCFLPCFLARVLMHIFQNLGSCRALCAVAHTSDVTGSLTYLHSVLNPVVYCFSSPTFRSSYRRVFHTLRGKGQAAEPPDFNPRDSYS T80858 DRUGINFO D0Z5QA 12S-HETE Investigative T47498 TARGETID T47498 T47498 FORMERID TTDI03193 T47498 UNIPROID EAA5_HUMAN T47498 TARGNAME Excitatory amino acid transporter 5 (SLC1A7) T47498 GENENAME SLC1A7 T47498 TARGTYPE Literature-reported T47498 SYNONYMS Solute carrier family 1 member 7; Retinal glutamate transporter; EAAT5 T47498 FUNCTION Transports L-glutamate; the L-glutamate uptake is sodium- and voltage-dependent and chloride-independent. Its associated chloride conductance may participate in visual processing. T47498 SEQUENCE MVPHAILARGRDVCRRNGLLILSVLSVIVGCLLGFFLRTRRLSPQEISYFQFPGELLMRMLKMMILPLVVSSLMSGLASLDAKTSSRLGVLTVAYYLWTTFMAVIVGIFMVSIIHPGSAAQKETTEQSGKPIMSSADALLDLIRNMFPANLVEATFKQYRTKTTPVVKSPKVAPEEAPPRRILIYGVQEENGSHVQNFALDLTPPPEVVYKSEPGTSDGMNVLGIVFFSATMGIMLGRMGDSGAPLVSFCQCLNESVMKIVAVAVWYFPFGIVFLIAGKILEMDDPRAVGKKLGFYSVTVVCGLVLHGLFILPLLYFFITKKNPIVFIRGILQALLIALATSSSSATLPITFKCLLENNHIDRRIARFVLPVGATINMDGTALYEAVAAIFIAQVNNYELDFGQIITISITATAASIGAAGIPQAGLVTMVIVLTSVGLPTDDITLIIAVDWALDRFRTMINVLGDALAAGIMAHICRKDFARDTGTEKLLPCETKPVSLQEIVAAQQNGCVKSVAEASELTLGPTCPHHVPVQVEQDEELPAASLNHCTIQISELETNV T47498 DRUGINFO D07CIW [3H]ETB-TBOA Investigative T47498 DRUGINFO D07GUB DL-TBOA Investigative T47498 DRUGINFO D08CAB D-aspartic acid Investigative T00488 TARGETID T00488 T00488 FORMERID TTDI03434 T00488 UNIPROID P2Y10_HUMAN T00488 TARGNAME P2Y purinoceptor 10 (P2RY10) T00488 GENENAME P2RY10 T00488 TARGTYPE Literature-reported T00488 SYNONYMS Putative P2Y purinoceptor 10; P2Y10; P2Y-like receptor T00488 FUNCTION Putative receptor for purines coupled to G-proteins. T00488 SEQUENCE MANLDKYTETFKMGSNSTSTAEIYCNVTNVKFQYSLYATTYILIFIPGLLANSAALWVLCRFISKKNKAIIFMINLSVADLAHVLSLPLRIYYYISHHWPFQRALCLLCFYLKYLNMYASICFLTCISLQRCFFLLKPFRARDWKRRYDVGISAAIWIVVGTACLPFPILRSTDLNNNKSCFADLGYKQMNAVALVGMITVAELAGFVIPVIIIAWCTWKTTISLRQPPMAFQGISERQKALRMVFMCAAVFFICFTPYHINFIFYTMVKETIISSCPVVRIALYFHPFCLCLASLCCLLDPILYYFMASEFRDQLSRHGSSVTRSRLMSKESGSSMIG T00488 DRUGINFO D0G6XT dioctanoylglycerol pyrophosphate Investigative T00488 DRUGINFO D0X0UR LPA Investigative T49208 TARGETID T49208 T49208 FORMERID TTDI03209 T49208 UNIPROID GBRP_HUMAN T49208 TARGNAME GABA(A) receptor pi (GABRP) T49208 GENENAME GABRP T49208 TARGTYPE Literature-reported T49208 SYNONYMS Gamma-aminobutyric acid receptor subunit pi; GABA(A) receptor subunit pi T49208 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone. T49208 SEQUENCE MNYSLHLAFVCLSLFTERMCIQGSQFNVEVGRSDKLSLPGFENLTAGYNKFLRPNFGGEPVQIALTLDIASISSISESNMDYTATIYLRQRWMDQRLVFEGNKSFTLDARLVEFLWVPDTYIVESKKSFLHEVTVGNRLIRLFSNGTVLYALRITTTVACNMDLSKYPMDTQTCKLQLESWGYDGNDVEFTWLRGNDSVRGLEHLRLAQYTIERYFTLVTRSQQETGNYTRLVLQFELRRNVLYFILETYVPSTFLVVLSWVSFWISLDSVPARTCIGVTTVLSMTTLMIGSRTSLPNTNCFIKAIDVYLGICFSFVFGALLEYAVAHYSSLQQMAAKDRGTTKEVEEVSITNIINSSISSFKRKISFASIEISSDNVDYSDLTMKTSDKFKFVFREKMGRIVDYFTIQNPSNVDHYSKLLFPLIFMLANVFYWAYYMYF T49208 DRUGINFO D0P0TI TBPS Investigative T39811 TARGETID T39811 T39811 FORMERID TTDI01376 T39811 UNIPROID DHSD_HUMAN T39811 TARGNAME Succinate dehydrogenase (SDHD) T39811 GENENAME SDHD T39811 TARGTYPE Literature-reported T39811 SYNONYMS Succinate-ubiquinone reductase membrane anchor subunit; Succinate-ubiquinone oxidoreductase cytochrome b small subunit; Succinate dehydrogenase complex subunit D; Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial; SDH4; QPs3; CybS; CII-4 T39811 FUNCTION Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q). T39811 SEQUENCE MAVLWRLSAVCGALGGRALLLRTPVVRPAHISAFLQDRPIPEWCGVQHIHLSPSHHSGSKAASLHWTSERVVSVLLLGLLPAAYLNPCSAMDYSLAAALTLHGHWGLGQVVTDYVHGDALQKAAKAGLLALSALTFAGLCYFNYHDVGICKAVAMLWKL T92477 TARGETID T92477 T92477 FORMERID TTDR00893 T92477 UNIPROID SOCS3_HUMAN T92477 TARGNAME Suppressor of cytokine signaling 3 (SOCS3) T92477 GENENAME SOCS3 T92477 TARGTYPE Literature-reported T92477 SYNONYMS STAT-induced STAT inhibitor 3; STAT induced STAT inhibitor 3; SSI3; SSI-3; SOCS-3; Cytokine-inducible SH2 protein 3; CIS3; CIS-3 T92477 FUNCTION SOCS3 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity. Suppresses fetal liver erythropoiesis. Regulates onset and maintenance of allergic responses mediated by T-helper type 2 cells. Regulates IL-6 signaling in vivo. Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize IL6ST. SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. T92477 SEQUENCE MVTHSKFPAAGMSRPLDTSLRLKTFSSKSEYQLVVNAVRKLQESGFYWSAVTGGEANLLLSAEPAGTFLIRDSSDQRHFFTLSVKTQSGTKNLRIQCEGGSFSLQSDPRSTQPVPRFDCVLKLVHHYMPPPGAPSFPSPPTEPSSEVPEQPSAQPLPGSPPRRAYYIYSGGEKIPLVLSRPLSSNVATLQHLCRKTVNGHLDSYEKVTQLPGPIREFLDQYDAPL T53070 TARGETID T53070 T53070 FORMERID TTDR00906 T53070 UNIPROID UN13B_HUMAN T53070 TARGNAME Protein unc-13 homolog B (UNC13B) T53070 GENENAME UNC13B T53070 TARGTYPE Literature-reported T53070 SYNONYMS UNC13B; Munc13-2; Munc13-1 T53070 FUNCTION Plays a role in vesicle maturation during exocytosis as a target of thediacylglycerol second messenger pathway. Is involved in neurotransmitter release by acting in synaptic vesicle priming prior to vesicle fusion and participates in the activity- depending refilling ofreadily releasable vesicle pool (RRP). Essential for synaptic vesicle maturation in a subset of excitatory/glutamatergic but not inhibitory/GABA-mediated synapses. T53070 SEQUENCE MSLLCVRVKRAKFQGSPDKFNTYVTLKVQNVKSTTVAVRGDQPSWEQDFMFEISRLDLGLSVEVWNKGLIWDTMVGTVWIALKTIRQSDEEGPGEWSTLEAETLMKDDEICGTRNPTPHKILLDTRFELPFDIPEEEARYWTYKWEQINALGADNEYSSQEESQRKPLPTAAAQCSFEDPDSAVDDRDSDYRSETSNSFPPPYHTASQPNASVHQFPVPVRSPQQLLLQGSSRDSCNDSMQSYDLDYPERRAISPTSSSRYGSSCNVSQGSSQLSELDQYHEQDDDHRETDSIHSCHSSHSLSRDGQAGFGEQEKPLEVTGQAEKEAACEPKEMKEDATTHPPPDLVLQKDHFLGPQESFPEENASSPFTQARAHWIRAVTKVRLQLQEIPDDGDPSLPQWLPEGPAGGLYGIDSMPDLRRKKPLPLVSDLSLVQSRKAGITSAMATRTSLKDEELKSHVYKKTLQALIYPISCTTPHNFEVWTATTPTYCYECEGLLWGIARQGMRCSECGVKCHEKCQDLLNADCLQRAAEKSCKHGAEDRTQNIIMAMKDRMKIRERNKPEIFEVIRDVFTVNKAAHVQQMKTVKQSVLDGTSKWSAKITITVVCAQGLQAKDKTGSSDPYVTVQVSKTKKRTKTIFGNLNPVWEEKFHFECHNSSDRIKVRVWDEDDDIKSRVKQRLKRESDDFLGQTIIEVRTLSGEMDVWYNLEKRTDKSAVSGAIRLQISVEIKGEEKVAPYHVQYTCLHENLFHYLTDIQGSGGVRIPEARGDDAWKVYFDETAQEIVDEFAMRYGIESIYQAMTHFACLSSKYMCPGVPAVMSTLLANINAYYAHTTASTNVSASDRFAASNFGKERFVKLLDQLHNSLRIDLSTYRNNFPAGSPERLQDLKSTVDLLTSITFFRMKVQELQSPPRASQVVKDCVKACLNSTYEYIFNNCHDLYSRQYQLKQELPPEEQGPSIRNLDFWPKLITLIVSIIEEDKNSYTPVLNQFPQELNVGKVSAEVMWHLFAQDMKYALEEHEKDHLCKSADYMNLHFKVKWLHNEYVRDLPVLQGQVPEYPAWFEQFVLQWLDENEDVSLEFLRGALERDKKDGFQQTSEHALFSCSVVDVFTQLNQSFEIIRKLECPDPSILAHYMRRFAKTIGKVLMQYADILSKDFPAYCTKEKLPCILMNNVQQLRVQLEKMFEAMGGKELDLEAADSLKELQVKLNTVLDELSMVFGNSFQVRIDECVRQMADILGQVRGTGNASPDARASAAQDADSVLRPLMDFLDGNLTLFATVCEKTVLKRVLKELWRVVMNTMERMIVLPPLTDQTGTQLIFTAAKELSHLSKLKDHMVREETRNLTPKQCAVLDLALDTIKQYFHAGGNGLKKTFLEKSPDLQSLRYALSLYTQTTDTLIKTFVRSQTTQGSGVDDPVGEVSIQVDLFTHPGTGEHKVTVKVVAANDLKWQTAGMFRPFVEVTMVGPHQSDKKRKFTTKSKSNNWAPKYNETFHFLLGNEEGPESYELQICVKDYCFAREDRVLGLAVMPLRDVTAKGSCACWCPLGRKIHMDETGLTILRILSQRSNDEVAREFVKLKSESRSTEEGS T60362 TARGETID T60362 T60362 FORMERID TTDI03569 T60362 UNIPROID TAAR5_HUMAN T60362 TARGNAME Trace amine receptor 5 (TAAR5) T60362 GENENAME TAAR5 T60362 TARGTYPE Literature-reported T60362 SYNONYMS hTaar5; Trace amine-associated receptor 5; TaR-5; Putative neurotransmitter receptor; PNR T60362 FUNCTION Olfactory receptor specific for trimethylamine, a trace amine. Also activated at lower level by dimethylethylamine. Trimethylamine is a bacterial metabolite found in some animal odors, and to humans it is a repulsive odor associated with bad breath and spoiled food. This receptor is probably mediated by the G(s)-class of G-proteins which activate adenylate cyclase. T60362 SEQUENCE MRAVFIQGAEEHPAAFCYQVNGSCPRTVHTLGIQLVIYLACAAGMLIIVLGNVFVAFAVSYFKALHTPTNFLLLSLALADMFLGLLVLPLSTIRSVESCWFFGDFLCRLHTYLDTLFCLTSIFHLCFISIDRHCAICDPLLYPSKFTVRVALRYILAGWGVPAAYTSLFLYTDVVETRLSQWLEEMPCVGSCQLLLNKFWGWLNFPLFFVPCLIMISLYVKIFVVATRQAQQITTLSKSLAGAAKHERKAAKTLGIAVGIYLLCWLPFTIDTMVDSLLHFITPPLVFDIFIWFAYFNSACNPIIYVFSYQWFRKALKLTLSQKVFSPQTRTVDLYQE T60362 DRUGINFO D04DOV trimethylamine Investigative T60362 DRUGINFO D0S5DR dimethylethylamine Investigative T77344 TARGETID T77344 T77344 FORMERID TTDR00833 T77344 UNIPROID LSM1_HUMAN T77344 TARGNAME Small nuclear ribonuclear CaSm (LSM1) T77344 GENENAME LSM1 T77344 TARGTYPE Literature-reported T77344 SYNONYMS LSM1; Cancer-associated Sm-like (CaSm) oncogene; Cancer-associated Sm-like; CaSm T77344 FUNCTION Plays a role in replication-dependenthistone mRNA degradation. Binds specifically to the 3'-terminal U-tract of U6 snRNA. T77344 SEQUENCE MNYMPGTASLIEDIDKKHLVLLRDGRTLIGFLRSIDQFANLVLHQTVERIHVGKKYGDIPRGIFVVRGENVVLLGEIDLEKESDTPLQQVSIEEILEEQRVEQQTKLEAEKLKVQALKDRGLSIPRADTLDEY T56588 TARGETID T56588 T56588 FORMERID TTDI03225 T56588 UNIPROID NMDE4_HUMAN T56588 TARGNAME Glutamate receptor ionotropic NMDA 2D (GluN2D) T56588 GENENAME GRIN2D T56588 TARGTYPE Literature-reported T56588 SYNONYMS NR2D; NMDAR2D; N-methyl D-aspartate receptor subtype 2D; Glutamate receptor ionotropic, NMDA 2D; Glutamate [NMDA] receptor subunit epsilon-4; GluN2D; EB11 T56588 FUNCTION Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition. T56588 SEQUENCE MRGAGGPRGPRGPAKMLLLLALACASPFPEEAPGPGGAGGPGGGLGGARPLNVALVFSGPAYAAEAARLGPAVAAAVRSPGLDVRPVALVLNGSDPRSLVLQLCDLLSGLRVHGVVFEDDSRAPAVAPILDFLSAQTSLPIVAVHGGAALVLTPKEKGSTFLQLGSSTEQQLQVIFEVLEEYDWTSFVAVTTRAPGHRAFLSYIEVLTDGSLVGWEHRGALTLDPGAGEAVLSAQLRSVSAQIRLLFCAREEAEPVFRAAEEAGLTGSGYVWFMVGPQLAGGGGSGAPGEPPLLPGGAPLPAGLFAVRSAGWRDDLARRVAAGVAVVARGAQALLRDYGFLPELGHDCRAQNRTHRGESLHRYFMNITWDNRDYSFNEDGFLVNPSLVVISLTRDRTWEVVGSWEQQTLRLKYPLWSRYGRFLQPVDDTQHLTVATLEERPFVIVEPADPISGTCIRDSVPCRSQLNRTHSPPPDAPRPEKRCCKGFCIDILKRLAHTIGFSYDLYLVTNGKHGKKIDGVWNGMIGEVFYQRADMAIGSLTINEERSEIVDFSVPFVETGISVMVARSNGTVSPSAFLEPYSPAVWVMMFVMCLTVVAVTVFIFEYLSPVGYNRSLATGKRPGGSTFTIGKSIWLLWALVFNNSVPVENPRGTTSKIMVLVWAFFAVIFLASYTANLAAFMIQEEYVDTVSGLSDRKFQRPQEQYPPLKFGTVPNGSTEKNIRSNYPDMHSYMVRYNQPRVEEALTQLKAGKLDAFIYDAAVLNYMARKDEGCKLVTIGSGKVFATTGYGIALHKGSRWKRPIDLALLQFLGDDEIEMLERLWLSGICHNDKIEVMSSKLDIDNMAGVFYMLLVAMGLSLLVFAWEHLVYWRLRHCLGPTHRMDFLLAFSRGMYSCCSAEAAPPPAKPPPPPQPLPSPAYPAPRPAPGPAPFVPRERASVDRWRRTKGAGPPGGAGLADGFHRYYGPIEPQGLGLGLGEARAAPRGAAGRPLSPPAAQPPQKPPPSYFAIVRDKEPAEPPAGAFPGFPSPPAPPAAAATAVGPPLCRLAFEDESPPAPARWPRSDPESQPLLGPGAGGAGGTGGAGGGAPAAPPPCRAAPPPCPYLDLEPSPSDSEDSESLGGASLGGLEPWWFADFPYPYAERLGPPPGRYWSVDKLGGWRAGSWDYLPPRSGPAAWHCRHCASLELLPPPRHLSCSHDGLDGGWWAPPPPPWAAGPLPRRRARCGCPRSHPHRPRASHRTPAAAAPHHHRHRRAAGGWDLPPPAPTSRSLEDLSSCPRAAPARRLTGPSRHARRCPHAAHWGPPLPTASHRRHRGGDLGTRRGSAHFSSLESEV T56588 DRUGINFO D03UNN L-689560 Terminated T56588 DRUGINFO D0Z8YM QNZ 46 Investigative T56588 DRUGINFO D0HF0A DQP-1105 Investigative T56588 DRUGINFO D02PXN N1-dansyl-spermine Investigative T56588 DRUGINFO D03XLS d-CCPene Investigative T56588 DRUGINFO D04NPE UBP141 Investigative T56588 DRUGINFO D08RVB LY233053 Investigative T56588 DRUGINFO D0FT0J d-AP5 Investigative T56588 DRUGINFO D00ZKW [3H]CPP Investigative T56588 DRUGINFO D06GKL 2-Methylamino-succinic acid(NMDA) Investigative T56588 DRUGINFO D07COG [3H]MDL105519 Investigative T56588 DRUGINFO D08UDC [3H]CGP39653 Investigative T56588 DRUGINFO D0B5ZA homoquinolinic acid Investigative T56588 DRUGINFO D0D2ZH [3H]dizocilpine Investigative T56588 DRUGINFO D0F5ZW CGP61594 Investigative T56588 DRUGINFO D0FW8K (RS)-(tetrazol-5-yl)glycine Investigative T56588 DRUGINFO D0KO6Y [3H]CGS19755 Investigative T56588 DRUGINFO D0OT9B L-aspartic acid Investigative T56588 DRUGINFO D08CAB D-aspartic acid Investigative T06800 TARGETID T06800 T06800 FORMERID TTDR00493 T06800 UNIPROID SOCS1_HUMAN T06800 TARGNAME Suppressor of cytokine signaling 1 (SOCS1) T06800 GENENAME SOCS1 T06800 TARGTYPE Literature-reported T06800 SYNONYMS Tec-interacting protein 3; TIP3; TIP-3; STAT-induced STAT inhibitor 1; STAT induced STAT inhibitor 1; SSI1; SSI-1; SOCS-1; JAK-binding protein; JAB T06800 FUNCTION SOCS1 is involved in negative regulation of cytokines that signal through the JAK/STAT3 pathway. Through binding to JAKs, inhibits their kinase activity. In vitro, also suppresses Tec protein-tyrosine activity. Appears to be a major regulator of signaling by interleukin 6 (IL6) and leukemia inhibitory factor (LIF). Regulates interferon-gamma mediated sensory neuron survival. Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize JAK2. SOCS1 appears to be a negative regulator in IGF1R signaling pathway. SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. T06800 SEQUENCE MVAHNQVAADNAVSTAAEPRRRPEPSSSSSSSPAAPARPRPCPAVPAPAPGDTHFRTFRSHADYRRITRASALLDACGFYWGPLSVHGAHERLRAEPVGTFLVRDSRQRNCFFALSVKMASGPTSIRVHFQAGRFHLDGSRESFDCLFELLEHYVAAPRRMLGAPLRQRRVRPLQELCRQRIVATVGRENLARIPLNPVLRDYLSSFPFQI T21715 TARGETID T21715 T21715 FORMERID TTDI00202 T21715 UNIPROID MSI1H_HUMAN T21715 TARGNAME RNA-binding protein Musashi-1 (MSI1) T21715 GENENAME MSI1 T21715 TARGTYPE Literature-reported T21715 SYNONYMS RNA-binding protein Musashi homolog 1; Musashi-1 T21715 FUNCTION Regulates expression of the NOTCH1 antagonist NUMB. Binds RNA containing the sequence 5'-GUUAGUUAGUUAGUU-3' and other sequences containing the pattern 5'-[GA]U(1-3)AGU-3'. May play a role in the proliferation and maintenance of stem cells in the central nervous system. RNA binding protein that regulates the expression of target mRNAs at the translation level. T21715 SEQUENCE METDAPQPGLASPDSPHDPCKMFIGGLSWQTTQEGLREYFGQFGEVKECLVMRDPLTKRSRGFGFVTFMDQAGVDKVLAQSRHELDSKTIDPKVAFPRRAQPKMVTRTKKIFVGGLSVNTTVEDVKQYFEQFGKVDDAMLMFDKTTNRHRGFGFVTFESEDIVEKVCEIHFHEINNKMVECKKAQPKEVMSPTGSARGRSRVMPYGMDAFMLGIGMLGYPGFQATTYASRSYTGLAPGYTYQFPEFRVERTPLPSAPVLPELTAIPLTAYGPMAAAAAAAAVVRGTGSHPWTMAPPPGSTPSRTGGFLGTTSPGPMAELYGAANQDSGVSSYISAASPAPSTGFGHSLGGPLIATAFTNGYH T76540 TARGETID T76540 T76540 FORMERID TTDR01327 T76540 UNIPROID SPY1_HUMAN T76540 TARGNAME Sprouty homolog 1 (SPRY-1) T76540 GENENAME SPRY1 T76540 TARGTYPE Literature-reported T76540 SYNONYMS Spry-1; Protein sprouty homolog 1 T76540 FUNCTION May function as an antagonist of fibroblast growth factor (FGF) pathways and may negatively modulate respiratory organogenesis. T76540 SEQUENCE MDPQNQHGSGSSLVVIQQPSLDSRQRLDYEREIQPTAILSLDQIKAIRGSNEYTEGPSVVKRPAPRTAPRQEKHERTHEIIPINVNNNYEHRHTSHLGHAVLPSNARGPILSRSTSTGSAASSGSNSSASSEQGLLGRSPPTRPVPGHRSERAIRTQPKQLIVDDLKGSLKEDLTQHKFICEQCGKCKCGECTAPRTLPSCLACNRQCLCSAESMVEYGTCMCLVKGIFYHCSNDDEGDSYSDNPCSCSQSHCCSRYLCMGAMSLFLPCLLCYPPAKGCLKLCRRCYDWIHRPGCRCKNSNTVYCKLESCPSRGQGKPS T94627 TARGETID T94627 T94627 FORMERID TTDI03552 T94627 UNIPROID S28A2_HUMAN T94627 TARGNAME Solute carrier family 28 member 2 (SLC28A2) T94627 GENENAME SLC28A2 T94627 TARGTYPE Literature-reported T94627 SYNONYMS hCNT2; Sodium/purine nucleoside co-transporter; Sodium/nucleoside cotransporter 2; Sodium-coupled nucleoside transporter 2; SPNT; Na(+)/nucleoside cotransporter 2; Concentrative nucleoside transporter 2; CNT2; CNT 2 T94627 FUNCTION Sodium-dependent and purine-selective transporter. Exhibits the transport characteristics of the nucleoside transport system cif or N1 subtype (N1/cif) (selective for purine nucleosides and uridine). Plays a critical role in specific uptake and salvage of purine nucleosides in kidney and other tissues. T94627 SEQUENCE MEKASGRQSIALSTVETGTVNPGLELMEKEVEPEGSKRTDAQGHSLGDGLGPSTYQRRSRWPFSKARSFCKTHASLFKKILLGLLCLAYAAYLLAACILNFQRALALFVITCLVIFVLVHSFLKKLLGKKLTRCLKPFENSRLRLWTKWVFAGVSLVGLILWLALDTAQRPEQLIPFAGICMFILILFACSKHHSAVSWRTVFSGLGLQFVFGILVIRTDLGYTVFQWLGEQVQIFLNYTVAGSSFVFGDTLVKDVFAFQALPIIIFFGCVVSILYYLGLVQWVVQKVAWFLQITMGTTATETLAVAGNIFVGMTEAPLLIRPYLGDMTLSEIHAVMTGGFATISGTVLGAFIAFGVDASSLISASVMAAPCALASSKLAYPEVEESKFKSEEGVKLPRGKERNVLEAASNGAVDAIGLATNVAANLIAFLAVLAFINAALSWLGELVDIQGLTFQVICSYLLRPMVFMMGVEWTDCPMVAEMVGIKFFINEFVAYQQLSQYKNKRLSGMEEWIEGEKQWISVRAEIITTFSLCGFANLSSIGITLGGLTSIVPHRKSDLSKVVVRALFTGACVSLISACMAGILYVPRGAEADCVSFPNTSFTNRTYETYMCCRGLFQSTSLNGTNPPSFSGPWEDKEFSAMALTNCCGFYNNTVCA T94627 DRUGINFO D05TGQ PMID25815140C48 Investigative T97897 TARGETID T97897 T97897 FORMERID TTDR00727 T97897 UNIPROID PLIN1_HUMAN T97897 TARGNAME Lipid droplet-associated protein (PLIN1) T97897 GENENAME PLIN1 T97897 TARGTYPE Literature-reported T97897 SYNONYMS PLIN1; PERI T97897 FUNCTION Modulator of adipocyte lipid metabolism. Coats lipid storage droplets to protect them from breakdown by hormone- sensitive lipase (HSL). Its absence may result in leanness. Plays a role in unilocular lipid droplet formation by activating CIDEC. Their interaction promotes lipid droplet enlargement and directional net neutral lipid transfer. May modulate lipolysis and triglyceride levels. T97897 SEQUENCE MAVNKGLTLLDGDLPEQENVLQRVLQLPVVSGTCECFQKTYTSTKEAHPLVASVCNAYEKGVQSASSLAAWSMEPVVRRLSTQFTAANELACRGLDHLEEKIPALQYPPEKIASELKDTISTRLRSARNSISVPIASTSDKVLGAALAGCELAWGVARDTAEFAANTRAGRLASGGADLALGSIEKVVEYLLPPDKEESAPAPGHQQAQKSPKAKPSLLSRVGALTNTLSRYTVQTMARALEQGHTVAMWIPGVVPLSSLAQWGASVAMQAVSRRRSEVRVPWLHSLAAAQEEDHEDQTDTEGEDTEEEEELETEENKFSEVAALPGPRGLLGGVAHTLQKTLQTTISAVTWAPAAVLGMAGRVLHLTPAPAVSSTKGRAMSLSDALKGVTDNVVDTVVHYVPLPRLSLMEPESEFRDIDNPPAEVERREAERRASGAPSAGPEPAPRLAQPRRSLRSAQSPGAPPGPGLEDEVATPAAPRPGFPAVPREKPKRRVSDSFFRPSVMEPILGRTHYSQLRKKS T47966 TARGETID T47966 T47966 FORMERID TTDR00465 T47966 UNIPROID GBG7_HUMAN T47966 TARGNAME GN-binding protein G(I)/G(S)/G(O) gamma-7 (GNG7) T47966 GENENAME GNG7 T47966 TARGTYPE Literature-reported T47966 SYNONYMS Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7; GNGT7; G protein gamma 7 T47966 FUNCTION The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction. Plays a role in the regulation of adenylyl cyclase signaling in certain regions of the brain. Plays a role in the formation or stabilzation of a G protein heterotrimer (G(olf) subunit alpha-beta-gamma-7) that is required for adenylyl cyclase activity in the striatum. Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. T47966 SEQUENCE MSATNNIAQARKLVEQLRIEAGIERIKVSKAASDLMSYCEQHARNDPLLVGVPASENPFKDKKPCIIL T91373 TARGETID T91373 T91373 UNIPROID DPM1_HUMAN; DPM2_HUMAN; DPM3_HUMAN T91373 TARGNAME Dolichol phosphate mannose synthase (DPMS) T91373 GENENAME DPM1; DPM2; DPM3 T91373 TARGTYPE Literature-reported T91373 SYNONYMS Mannose-P-dolichol synthase; MPD synthase; Dolichyl-phosphate beta-D-mannosyltransferase; Dolichol-phosphate mannosyltransferase; Dolichol-phosphate mannose synthase; DPM synthase T91373 FUNCTION Synthesize dolichol-phosphate mannose (Dol-P-Man) from GDP-mannose and dolichol-phosphate on the cytosolic side of the ER. Dolichol-phosphate mannose serves as a donor of mannosyl residues on the lumenal side of the endoplasmic reticulum (ER). Lack of Dol-P-Man results in defective surface expression of GPI-anchored proteins. T91373 SEQUENCE MASLEVSRSPRRSRRELEVRSPRQNKYSVLLPTYNERENLPLIVWLLVKSFSESGINYEIIIIDDGSPDGTRDVAEQLEKIYGSDRILLRPREKKLGLGTAYIHGMKHATGNYIIIMDADLSHHPKFIPEFIRKQKEGNFDIVSGTRYKGNGGVYGWDLKRKIISRGANFLTQILLRPGASDLTGSFRLYRKEVLEKLIEKCVSKGYVFQMEMIVRARQLNYTIGEVPISFVDRVYGESKLGGNEIVSFLKGLLTLFATT T95997 TARGETID T95997 T95997 FORMERID TTDI03579 T95997 UNIPROID S19A2_HUMAN T95997 TARGNAME Solute carrier family 19 member 2 (SLC19A2) T95997 GENENAME SLC19A2 T95997 TARGTYPE Literature-reported T95997 SYNONYMS Thiamine transporter 1; Thiamine carrier 1; ThTr1; ThTr-1; TRMA; THT1; TC1 T95997 FUNCTION High-affinity transporter for the intake of thiamine. T95997 SEQUENCE MDVPGPVSRRAAAAAATVLLRTARVRRECWFLPTALLCAYGFFASLRPSEPFLTPYLLGPDKNLTEREVFNEIYPVWTYSYLVLLFPVFLATDYLRYKPVVLLQGLSLIVTWFMLLYAQGLLAIQFLEFFYGIATATEIAYYSYIYSVVDLGMYQKVTSYCRSATLVGFTVGSVLGQILVSVAGWSLFSLNVISLTCVSVAFAVAWFLPMPQKSLFFHHIPSTCQRVNGIKVQNGGIVTDTPASNHLPGWEDIESKIPLNMEEPPVEEPEPKPDRLLVLKVLWNDFLMCYSSRPLLCWSVWWALSTCGYFQVVNYTQGLWEKVMPSRYAAIYNGGVEAVSTLLGAVAVFAVGYIKISWSTWGEMTLSLFSLLIAAAVYIMDTVGNIWVCYASYVVFRIIYMLLITIATFQIAANLSMERYALVFGVNTFIALALQTLLTLIVVDASGLGLEITTQFLIYASYFALIAVVFLASGAVSVMKKCRKLEDPQSSSQVTTS T95997 DRUGINFO D07TYL [3H]thiamine Investigative T14144 TARGETID T14144 T14144 FORMERID TTDR00460 T14144 UNIPROID OPHN1_HUMAN T14144 TARGNAME Oligophrenin-1 (OPHN1) T14144 GENENAME OPHN1 T14144 TARGTYPE Literature-reported T14144 SYNONYMS Oligophrenin1; OPHN1 T14144 FUNCTION Stimulates GTP hydrolysis of members of the Rho family. Its action on RHOA activity and signaling is implicated in growth and stabilization of dendritic spines, and therefore in synaptic function. Critical for the stabilization of AMPA receptors at postsynaptic sites. Critical for the regulation of synaptic vesicle endocytosis at presynaptic terminals. Required for the localization of NR1D1 to dendrites, can suppress its repressor activity and protect it fromproteasomal degradation. T14144 SEQUENCE MGHPPLEFSDCYLDSPDFRERLKCYEQELERTNKFIKDVIKDGNALISAMRNYSSAVQKFSQTLQSFQFDFIGDTLTDDEINIAESFKEFAELLNEVENERMMMVHNASDLLIKPLENFRKEQIGFTKERKKKFEKDGERFYSLLDRHLHLSSKKKESQLQEADLQVDKERHNFFESSLDYVYQIQEVQESKKFNIVEPVLAFLHSLFISNSLTVELTQDFLPYKQQLQLSLQNTRNHFSSTREEMEELKKRMKEAPQTCKLPGQPTIEGYLYTQEKWALGISWVKYYCQYEKETKTLTMTPMEQKPGAKQGPLDLTLKYCVRRKTESIDKRFCFDIETNERPGTITLQALSEANRRLWMEAMDGKEPIYHSPITKQQEMELNEVGFKFVRKCINIIETKGIKTEGLYRTVGSNIQVQKLLNAFFDPKCPGDVDFHNSDWDIKTITSSLKFYLRNLSEPVMTYRLHKELVSAAKSDNLDYRLGAIHSLVYKLPEKNREMLELLIRHLVNVCEHSKENLMTPSNMGVIFGPTLMRAQEDTVAAMMNIKFQNIVVEILIEHFGKIYLGPPEESAAPPVPPPRVTARRHKPITISKRLLRERTVFYTSSLDESEDEIQHQTPNGTITSSIEPPKPPQHPKLPIQRSGETDPGRKSPSRPILDGKLEPCPEVDVGKLVSRLQDGGTKITPKATNGPMPGSGPTKTPSFHIKRPAPRPLAHHKEGDADSFSKVRPPGEKPTIIRPPVRPPDPPCRAATPQKPEPKPDIVAGNAGEITSSVVASRTRFFETASRKTGSSQGRLPGDES T16336 TARGETID T16336 T16336 FORMERID TTDI03240 T16336 UNIPROID GPR32_HUMAN T16336 TARGNAME G-protein coupled receptor 32 (GPR32) T16336 GENENAME GPR32 T16336 TARGTYPE Literature-reported T16336 SYNONYMS Probable G-protein coupled receptor 32 T16336 FUNCTION Orphan receptor. T16336 SEQUENCE MNGVSEGTRGCSDRQPGVLTRDRSCSRKMNSSGCLSEEVGSLRPLTVVILSASIVVGVLGNGLVLWMTVFRMARTVSTVCFFHLALADFMLSLSLPIAMYYIVSRQWLLGEWACKLYITFVFLSYFASNCLLVFISVDRCISVLYPVWALNHRTVQRASWLAFGVWLLAAALCSAHLKFRTTRKWNGCTHCYLAFNSDNETAQIWIEGVVEGHIIGTIGHFLLGFLGPLAIIGTCAHLIRAKLLREGWVHANRPKRLLLVLVSAFFIFWSPFNVVLLVHLWRRVMLKEIYHPRMLLILQASFALGCVNSSLNPFLYVFVGRDFQEKFFQSLTSALARAFGEEEFLSSCPRGNAPRE T16336 DRUGINFO D0V8YH RvD1-ME Investigative T16336 DRUGINFO D0P0KG [3H]resolvin D1 Investigative T16336 DRUGINFO D0R1FZ LXA4 Investigative T01151 TARGETID T01151 T01151 FORMERID TTDI00193 T01151 UNIPROID SPAG6_HUMAN T01151 TARGNAME Sperm-associated antigen 6 (SPAG6) T01151 GENENAME SPAG6 T01151 TARGTYPE Literature-reported T01151 SYNONYMS Sperm flagellar protein; SPAG6; Repro-SA-1; Protein PF16 homolog T01151 FUNCTION Important for structural integrity of the central apparatus in the sperm tail andfor flagellar motility. T01151 SEQUENCE MSQRQVLQVFEQYQKARTQFVQMVAELATRPQNIETLQNAGVMSLLRTLLLDVVPTIQQTAALALGRLANYNDDLAEAVVKCDILPQLVYSLAEQNRFYKKAAAFVLRAVGKHSPQLAQAIVDCGALDTLVICLEDFDPGVKEAAAWALRYIARHNAELSQAVVDAGAVPLLVLCIQEPEIALKRIAASALSDIAKHSPELAQTVVDAGAVAHLAQMILNPDAKLKHQILSALSQVSKHSVDLAEMVVEAEIFPVVLTCLKDKDEYVKKNASTLIREIAKHTPELSQLVVNAGGVAAVIDCIGSCKGNTRLPGIMMLGYVAAHSENLAMAVIISKGVPQLSVCLSEEPEDHIKAAAAWALGQIGRHTPEHARAVAVTNTLPVLLSLYMSTESSEDLQVKSKKAIKNILQKCTYLPALEPFLYDAPPNILKHVVGQFSKVLPHDSKARRLFVTSGGLKKVQEIKAEPGSLLQEYINSINSCYPEEIVRYYSPGYSDTLLQRVDSYQPLNN T55948 TARGETID T55948 T55948 FORMERID TTDI01533 T55948 UNIPROID S22A3_HUMAN T55948 TARGNAME Organic cation transporter 3 (OCT3) T55948 GENENAME SLC22A3 T55948 TARGTYPE Literature-reported T55948 SYNONYMS Solute carrier family 22 member 3; Extraneuronal monoamine transporter; EMTH T55948 FUNCTION Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain. T55948 SEQUENCE MPSFDEALQRVGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGTQPDHYWCRGPSAAALAERCGWSPEEEWNRTAPASRGPEPPERRGRCQRYLLEAANDSASATSALSCADPLAAFPNRSAPLVPCRGGWRYAQAHSTIVSEFDLVCVNAWMLDLTQAILNLGFLTGAFTLGYAADRYGRIVIYLLSCLGVGVTGVVVAFAPNFPVFVIFRFLQGVFGKGTWMTCYVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFIPNWQGIQLAITLPSFLFLLYYWVVPESPRWLITRKKGDKALQILRRIAKCNGKYLSSNYSEITVTDEEVSNPSFLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGIIGGNLYIDFFISGVVELPGALLILLTIERLGRRLPFAASNIVAGVACLVTAFLPEGIAWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAVWLELPLIIFGILASICGGLVMLLPETKGIALPETVDDVEKLGSPHSCKCGRNKKTPVSRSHL T08350 TARGETID T08350 T08350 FORMERID TTDI01508 T08350 UNIPROID RNH2A_HUMAN; RNH2B_HUMAN; RNH2C_HUMAN T08350 TARGNAME Ribonuclease H2 (RNase H2) T08350 GENENAME RNASEH2A; RNASEH2B; RNASEH2C T08350 TARGTYPE Literature-reported T08350 SYNONYMS Ribonuclease H; RNase H; Aicardi-Goutieres syndrome protein; AGS T08350 FUNCTION Subunit of RNase HII, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids. Participates in DNA replication, possibly by mediating the removal of lagging-strand Okazaki fragment RNA primers during DNA replication. Mediates the excision of single ribonucleotides from DNA:RNA duplexes. T08350 SEQUENCE MDLSELERDNTGRCRLSSPVPAVCRKEPCVLGVDEAGRGPVLGPMVYAICYCPLPRLADLEALKVADSKTLLESERERLFAKMEDTDFVGWALDVLSPNLISTSMLGRVKYNLNSLSHDTATGLIQYALDQGVNVTQVFVDTVGMPETYQARLQQSFPGIEVTVKAKADALYPVVSAASICAKVARDQAVKKWQFVEKLQDLDTDYGSGYPNDPKTKAWLKEHVEPVFGFPQFVRFSWRTAQTILEKEAEDVIWEDSASENQEGLRKITSYFLNEGSQARPRSSHRYFLERGLESATSL T58548 TARGETID T58548 T58548 FORMERID TTDNR00754 T58548 UNIPROID STC2_HUMAN T58548 TARGNAME Stanniocalcin-2 (STC2) T58548 GENENAME STC2 T58548 TARGTYPE Literature-reported T58548 SYNONYMS Stanniocalcin-related protein; STCRP; STC-related protein; STC-2 T58548 FUNCTION Has an anti-hypocalcemic action on calcium and phosphate homeostasis. T58548 SEQUENCE MCAERLGQFMTLALVLATFDPARGTDATNPPEGPQDRSSQQKGRLSLQNTAEIQHCLVNAGDVGCGVFECFENNSCEIRGLHGICMTFLHNAGKFDAQGKSFIKDALKCKAHALRHRFGCISRKCPAIREMVSQLQRECYLKHDLCAAAQENTRVIVEMIHFKDLLLHEPYVDLVNLLLTCGEEVKEAITHSVQVQCEQNWGSLCSILSFCTSAIQKPPTAPPERQPQVDRTKLSRAHHGEAGHHLPEPSSRETGRGAKGERGSKSHPNAHARGRVGGLGAQGPSGSSEWEDEQSEYSDIRR T20594 TARGETID T20594 T20594 FORMERID TTDI01507 T20594 UNIPROID RRF_STRCO T20594 TARGNAME Streptomyces Ribosome recycling factor (Stre frr) T20594 GENENAME Stre frr T20594 TARGTYPE Literature-reported T20594 SYNONYMS Ribosome-releasing factor; Ribosome-recycling factor; RRF T20594 FUNCTION Responsible for the release of ribosomes from messenger RNA at the termination of protein biosynthesis. May increase the efficiency of translation by recycling ribosomes from one round of translation to another. T20594 SEQUENCE MIEETLLEAEEKMEKAVVVAKEDFAAIRTGRAHPAMFNKIVAEYYGAPTPINQLASFSVPEPRMAVVTPFDKTALRNIEQAIRDSDLGVNPSNDGNIIRVTFPELTEERRREYIKVAKAKGEDAKVSIRSVRRKAKDSIDKMVKDGEVGEDEGRRAEKELDDTTAKYVAQVDELLKHKEAELLEV T34064 TARGETID T34064 T34064 FORMERID TTDI03422 T34064 UNIPROID SO2B1_HUMAN T34064 TARGNAME Organic anion transporter B (SLCO2B1) T34064 GENENAME SLCO2B1 T34064 TARGTYPE Literature-reported T34064 SYNONYMS Solute carrier organic anion transporter family member 2B1; Solute carrier family 21 member 9; SLC21A9; Organic anion transporter polypeptide-related protein 2; OATPRP2; OATPB; OATP2B1; OATP-RP2; OATP-B; KIAA0880 T34064 FUNCTION Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost. T34064 SEQUENCE MGPRIGPAGEVPQVPDKETKATMGTENTPGGKASPDPQDVRPSVFHNIKLFVLCHSLLQLAQLMISGYLKSSISTVEKRFGLSSQTSGLLASFNEVGNTALIVFVSYFGSRVHRPRMIGYGAILVALAGLLMTLPHFISEPYRYDNTSPEDMPQDFKASLCLPTTSAPASAPSNGNCSSYTETQHLSVVGIMFVAQTLLGVGGVPIQPFGISYIDDFAHNSNSPLYLGILFAVTMMGPGLAFGLGSLMLRLYVDINQMPEGGISLTIKDPRWVGAWWLGFLIAAGAVALAAIPYFFFPKEMPKEKRELQFRRKVLAVTDSPARKGKDSPSKQSPGESTKKQDGLVQIAPNLTVIQFIKVFPRVLLQTLRHPIFLLVVLSQVCLSSMAAGMAIFLPKFLERQFSITASYANLLIGCLSFPSVIVGIVVGGVLVKRLHLGPVGCGALCLLGMLLCLFFSLPLFFIGCSSHQIAGITHQTSAHPGLELSPSCMEACSCPLDGFNPVCDPSTRVEYITPCHAGCSSWVVQDALDNSQVFYTNCSCVVEGNPVLAGSCDSTCSHLVVPFLLLVSLGSALACLTHTPSFMLILRGVKKEDKTLAVGIQFMFLRILAWMPSPVIHGSAIDTTCVHWALSCGRRAVCRYYNNDLLRNRFIGLQFFFKTGSVICFALVLAVLRQQDKEARTKESRSSPAVEQQLLVSGPGKKPEDSRV T34064 DRUGINFO D04AXP [3H]estrone-3-sulphate Investigative T95621 TARGETID T95621 T95621 UNIPROID ZWINT_HUMAN T95621 TARGNAME ZW10 interactor (ZWINT) T95621 GENENAME ZWINT T95621 TARGTYPE Literature-reported T95621 SYNONYMS Zwint-1; ZW10-interacting protein 1 T95621 FUNCTION Part of the MIS12 complex, which is required for kinetochore formation and spindle checkpoint activity. Required to target ZW10 to the kinetochore at prometaphase. T95621 SEQUENCE MEAAETEAEAAALEVLAEVAGILEPVGLQEEAELPAKILVEFVVDSQKKDKLLCSQLQVADFLQNILAQEDTAKGLDPLASEDTSRQKAIAAKEQWKELKATYREHVEAIKIGLTKALTQMEEAQRKRTQLREAFEQLQAKKQMAMEKRRAVQNQWQLQQEKHLQHLAEVSAEVRERKTGTQQELDRVFQKLGNLKQQAEQERDKLQRYQTFLQLLYTLQGKLLFPEAEAEAENLPDDKPQQPTRPQEQSTGDTMGRDPGVSFKAVGLQPAGDVNLP T71859 TARGETID T71859 T71859 FORMERID TTDI02486 T71859 UNIPROID WISP1_HUMAN T71859 TARGNAME WNT1-inducible-signaling pathway protein 1 (WISP1) T71859 GENENAME WISP1 T71859 TARGTYPE Literature-reported T71859 SYNONYMS Wnt-1-induced secreted protein; WISP1; WISP-1; CCN family member 4 T71859 FUNCTION Downstream regulator in the Wnt/Frizzled-signalingpathway. Associated with cell survival. Attenuates p53-mediated apoptosis in response to DNA damage through activation of AKT kinase. Up-regulates the anti-apoptotic Bcl-X(L) protein. Adheres to skinand melanoma fibroblasts. In vitro binding to skin fibroblasts occurs through the proteoglycans, decorin and biglycan. T71859 SEQUENCE MRWFLPWTLAAVTAAAASTVLATALSPAPTTMDFTPAPLEDTSSRPQFCKWPCECPPSPPRCPLGVSLITDGCECCKMCAQQLGDNCTEAAICDPHRGLYCDYSGDRPRYAIGVCAQVVGVGCVLDGVRYNNGQSFQPNCKYNCTCIDGAVGCTPLCLRVRPPRLWCPHPRRVSIPGHCCEQWVCEDDAKRPRKTAPRDTGAFDAVGEVEAWHRNCIAYTSPWSPCSTSCGLGVSTRISNVNAQCWPEQESRLCNLRPCDVDIHTLIKAGKKCLAVYQPEASMNFTLAGCISTRSYQPKYCGVCMDNRCCIPYKSKTIDVSFQCPDGLGFSRQVLWINACFCNLSCRNPNDIFADLESYPDFSEIAN T89530 TARGETID T89530 T89530 FORMERID TTDI01343 T89530 UNIPROID RPA1_HUMAN; RPA2_HUMAN T89530 TARGNAME DNA-directed RNA polymerase I (RNAP I) T89530 GENENAME POLR1A; POLR1B T89530 TARGTYPE Literature-reported T89530 SYNONYMS RPA; RNA polymerase I T89530 FUNCTION DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic core component of RNA polymerase I which synthesizes ribosomal RNA precursors. Forms the polymerase active center together with the second largest subunit. A single stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol I. Pol I is composed of mobile elements and RPA1/RPA2 is part of the core element with the central large cleft and probably a clamp element that moves to open and close the cleft T89530 SEQUENCE MLISKNMPWRRLQGISFGMYSAEELKKLSVKSITNPRYLDSLGNPSANGLYDLALGPADSKEVCSTCVQDFSNCSGHLGHIELPLTVYNPLLFDKLYLLLRGSCLNCHMLTCPRAVIHLLLCQLRVLEVGALQAVYELERILNRFLEENPDPSASEIREELEQYTTEIVQNNLLGSQGAHVKNVCESKSKLIALFWKAHMNAKRCPHCKTGRSVVRKEHNSKLTITFPAMVHRTAGQKDSEPLGIEEAQIGKRGYLTPTSAREHLSALWKNEGFFLNYLFSGMDDDGMESRFNPSVFFLDFLVVPPSRYRPVSRLGDQMFTNGQTVNLQAVMKDVVLIRKLLALMAQEQKLPEEVATPTTDEEKDSLIAIDRSFLSTLPGQSLIDKLYNIWIRLQSHVNIVFDSEMDKLMMDKYPGIRQILEKKEGLFRKHMMGKRVDYAARSVICPDMYINTNEIGIPMVFATKLTYPQPVTPWNVQELRQAVINGPNVHPGASMVINEDGSRTALSAVDMTQREAVAKQLLTPATGAPKPQGTKIVCRHVKNGDILLLNRQPTLHRPSIQAHRARILPEEKVLRLHYANCKAYNADFDGDEMNAHFPQSELGRAEAYVLACTDQQYLVPKDGQPLAGLIQDHMVSGASMTTRGCFFTREHYMELVYRGLTDKVGRVKLLSPSILKPFPLWTGKQVVSTLLINIIPEDHIPLNLSGKAKITGKAWVKETPRSVPGFNPDSMCESQVIIREGELLCGVLDKAHYGSSAYGLVHCCYEIYGGETSGKVLTCLARLFTAYLQLYRGFTLGVEDILVKPKADVKRQRIIEESTHCGPQAVRAALNLPEAASYDEVRGKWQDAHLGKDQRDFNMIDLKFKEEVNHYSNEINKACMPFGLHRQFPENSLQMMVQSGAKGSTVNTMQISCLLGQIELEGRRPPLMASGKSLPCFEPYEFTPRAGGFVTGRFLTGIKPPEFFFHCMAGREGLVDTAVKTSRSGYLQRCIIKHLEGLVVQYDLTVRDSDGSVVQFLYGEDGLDIPKTQFLQPKQFPFLASNYEVIMKSQHLHEVLSRADPKKALHHFRAIKKWQSKHPNTLLRRGAFLSYSQKIQEAVKALKLESENRNGRSPGTQEMLRMWYELDEESRRKYQKKAAACPDPSLSVWRPDIYFASVSETFETKVDDYSQEWAAQTEKSYEKSELSLDRLRTLLQLKWQRSLCEPGEAVGLLAAQSIGEPSTQMTLNTFHFAGRGEMNVTLGIPRLREILMVASANIKTPMMSVPVLNTKKALKRVKSLKKQLTRVCLGEVLQKIDVQESFCMEEKQNKFQVYQLRFQFLPHAYYQQEKCLRPEDILRFMETRFFKLLMESIKKKNNKASAFRNVNTRRATQRDLDNAGELGRSRGEQEGDEEEEGHIVDAEAEEGDADASDAKRKEKQEEEVDYESEEEEEREGEENDDEDMQEERNPHREGARKTQEQDEEVGLGTEEDPSLPALLTQPRKPTHSQEPQGPEAMERRVQAVREIHPFIDDYQYDTEESLWCQVTVKLPLMKINFDMSSLVVSLAHGAVIYATKGITRCLLNETTNNKNEKELVLNTEGINLPELFKYAEVLDLRRLYSNDIHAIANTYGIEAALRVIEKEIKDVFAVYGIAVDPRHLSLVADYMCFEGVYKPLNRFGIRSNSSPLQQMTFETSFQFLKQATMLGSHDELRSPSACLVVGKVVRGGTGLFELKQPLR T95605 TARGETID T95605 T95605 FORMERID TTDI03412 T95605 UNIPROID NTR2_HUMAN T95605 TARGNAME Neurotensin receptor type 2 (NTSR2) T95605 GENENAME NTSR2 T95605 TARGTYPE Literature-reported T95605 SYNONYMS NTR2; NT-R-2; Levocabastine-sensitive neurotensin receptor T95605 FUNCTION Receptor for the tridecapeptide neurotensin. It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. T95605 SEQUENCE METSSPRPPRPSSNPGLSLDARLGVDTRLWAKVLFTALYALIWALGAAGNALSAHVVLKARAGRAGRLRHHVLSLALAGLLLLLVGVPVELYSFVWFHYPWVFGDLGCRGYYFVHELCAYATVLSVAGLSAERCLAVCQPLRARSLLTPRRTRWLVALSWAASLGLALPMAVIMGQKHELETADGEPEPASRVCTVLVSRTALQVFIQVNVLVSFVLPLALTAFLNGVTVSHLLALCSQVPSTSTPGSSTPSRLELLSEEGLLSFIVWKKTFIQGGQVSLVRHKDVRRIRSLQRSVQVLRAIVVMYVICWLPYHARRLMYCYVPDDAWTDPLYNFYHYFYMVTNTLFYVSSAVTPLLYNAVSSSFRKLFLEAVSSLCGEHHPMKRLPPKPQSPTLMDTASGFGDPPETRT T95605 DRUGINFO D0OF3B xenin Investigative T95605 DRUGINFO D09RSL JMV458 Investigative T57907 TARGETID T57907 T57907 FORMERID TTDI02396 T57907 UNIPROID BY55_HUMAN T57907 TARGNAME Natural killer cell receptor BY55 (CD160) T57907 GENENAME CD160 T57907 TARGTYPE Literature-reported T57907 SYNONYMS CD160 antigen; BY55 T57907 FUNCTION Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3-kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells. Receptor for both classical and non-classical MHC class I molecules. In the context of acute viral infection, recognizes HLA-C and triggers NK cell cytotoxic activity, likely playing a role in anti-viral innate immune response. On CD8+ T cells, binds HLA-A2-B2M in complex with a viral peptide and provides a costimulatory signal to activated/memory T cells. Upon persistent antigen stimulation, such as occurs during chronic viral infection, may progressively inhibit TCR signaling in memory CD8+ T cells, contributing to T cell exhaustion. On endothelial cells, recognizes HLA-G and controls angiogenesis in immune privileged sites. Receptor or ligand for TNF superfamily member TNFRSF14, participating in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. Upon ligation of TNFRSF14, provides stimulatory signal to NK cells enhancing IFNG production and anti-tumor immune response. On activated CD4+ T cells, interacts with TNFRSF14 and downregulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response. In the context of bacterial infection, acts as a ligand for TNFRSF14 on epithelial cells, triggering the production of antimicrobial proteins and proinflammatory cytokines. CD160 antigen: Receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. T57907 SEQUENCE MLLEPGRGCCALAILLAIVDIQSGGCINITSSASQEGTRLNLICTVWHKKEEAEGFVVFLCKDRSGDCSPETSLKQLRLKRDPGIDGVGEISSQLMFTISQVTPLHSGTYQCCARSQKSGIRLQGHFFSILFTETGNYTVTGLKQRQHLEFSHNEGTLSSGFLQEKVWVMLVTSLVALQAL T28012 TARGETID T28012 T28012 FORMERID TTDI00178 T28012 UNIPROID RECK_HUMAN T28012 TARGNAME Suppressor of tumorigenicity 15 protein (ST15) T28012 GENENAME RECK T28012 TARGTYPE Literature-reported T28012 SYNONYMS hRECK; Reversion-inducing cysteine-rich protein with Kazal motifs T28012 FUNCTION Plays a key role in Wnt7-specific responses: required for central nervous system (CNS) angiogenesis and blood-brain barrier regulation. Acts as a Wnt7-specific coactivator of canonical Wnt signaling by decoding Wnt ligands: acts by interacting specifically with the disordered linker region of Wnt7, thereby conferring ligand selectivity for Wnt7. ADGRA2 is then required to deliver RECK-bound Wnt7 to frizzled by assembling a higher-order RECK-ADGRA2-Fzd-LRP5-LRP6 complex. Also acts as a serine protease inhibitor: negatively regulates matrix metalloproteinase-9 (MMP9) by suppressing MMP9 secretion and by direct inhibition of its enzymatic activity. Also inhibits metalloproteinase activity of MMP2 and MMP14 (MT1-MMP). Functions together with ADGRA2 to enable brain endothelial cells to selectively respond to Wnt7 signals (WNT7A or WNT7B). T28012 SEQUENCE MATVRASLRGALLLLLAVAGVAEVAGGLAPGSAGALCCNHSKDNQMCRDVCEQIFSSKSESRLKHLLQRAPDYCPETMVEIWNCMNSSLPGVFKKSDGWVGLGCCELAIALECRQACKQASSKNDISKVCRKEYENALFSCISRNEMGSVCCSYAGHHTNCREYCQAIFRTDSSPGPSQIKAVENYCASISPQLIHCVNNYTQSYPMRNPTDSLYCCDRAEDHACQNACKRILMSKKTEMEIVDGLIEGCKTQPLPQDPLWQCFLESSQSVHPGVTVHPPPSTGLDGAKLHCCSKANTSTCRELCTKLYSMSWGNTQSWQEFDRFCEYNPVEVSMLTCLADVREPCQLGCRNLTYCTNFNNRPTELFRSCNAQSDQGAMNDMKLWEKGSIKMPFINIPVLDIKKCQPEMWKAIACSLQIKPCHSKSRGSIICKSDCVEILKKCGDQNKFPEDHTAESICELLSPTDDLKNCIPLDTYLRPSTLGNIVEEVTHPCNPNPCPANELCEVNRKGCPSGDPCLPYFCVQGCKLGEASDFIVRQGTLIQVPSSAGEVGCYKICSCGQSGLLENCMEMHCIDLQKSCIVGGKRKSHGTSFSIDCNVCSCFAGNLVCSTRLCLSEHSSEDDRRTFTGLPCNCADQFVPVCGQNGRTYPSACIARCVGLQDHQFEFGSCMSKDPCNPNPCQKNQRCIPKPQVCLTTFDKFGCSQYECVPRQLACDQVQDPVCDTDHMEHNNLCTLYQRGKSLSYKGPCQPFCRATEPVCGHNGETYSSVCAAYSDRVAVDYYGDCQAVGVLSEHSSVAECASVKCPSLLAAGCKPIIPPGACCPLCAGMLRVLFDKEKLDTIAKVTNKKPITVLEILQKIRMHVSVPQCDVFGYFSIESEIVILIIPVDHYPKALQIEACNKEAEKIESLINSDSPTLASHVPLSALIISQVQVSSSVPSAGVRARPSCHSLLLPLSLGLALHLLWTYN T27418 TARGETID T27418 T27418 FORMERID TTDI00019 T27418 UNIPROID APCL_HUMAN T27418 TARGNAME Adenomatous polyposis coli 2 (APC2) T27418 GENENAME APC2 T27418 TARGTYPE Literature-reported T27418 SYNONYMS Adenomatous polyposis coli proteinlike; Adenomatous polyposis coli protein-like; Adenomatous polyposis coli protein 2; APClike; APCL; APC-like T27418 FUNCTION May also function in Wnt signaling by promoting the rapid degradation of CTNNB1. Stabilizes microtubules and may regulate actin fiber dynamics through the activation of Rho family GTPases. T27418 SEQUENCE MASSVAPYEQLVRQVEALKAENSHLRQELRDNSSHLSKLETETSGMKEVLKHLQGKLEQEARVLVSSGQTEVLEQLKALQMDITSLYNLKFQPPTLGPEPAARTPEGSPVHGSGPSKDSFGELSRATIRLLEELDRERCFLLNEIEKEEKEKLWYYSQLQGLSKRLDELPHVETQFSMQMDLIRQQLEFEAQHIRSLMEERFGTSDEMVQRAQIRASRLEQIDKELLEAQDRVQQTEPQALLAVKSVPVDEDPETEVPTHPEDGTPQPGNSKVEVVFWLLSMLATRDQEDTARTLLAMSSSPESCVAMRRSGCLPLLLQILHGTEAAAGGRAGAPGAPGAKDARMRANAALHNIVFSQPDQGLARKEMRVLHVLEQIRAYCETCWDWLQARDGGPEGGGAGSAPIPIEPQICQATCAVMKLSFDEEYRRAMNELGGLQAVAELLQVDYEMHKMTRDPLNLALRRYAGMTLTNLTFGDVANKATLCARRGCMEAIVAQLASDSEELHQVVSSILRNLSWRADINSKKVLREAGSVTALVQCVLRATKESTLKSVLSALWNLSAHSTENKAAICQVDGALGFLVSTLTYKCQSNSLAIIESGGGILRNVSSLVATREDYRQVLRDHNCLQTLLQHLTSHSLTIVSNACGTLWNLSARSARDQELLWDLGAVGMLRNLVHSKHKMIAMGSAAALRNLLAHRPAKHQAAATAVSPGSCVPSLYVRKQRALEAELDARHLAQALEHLEKQGPPAAEAATKKPLPPLRHLDGLAQDYASDSGCFDDDDAPSSLAAAAATGEPASPAALSLFLGSPFLQGQALARTPPTRRGGKEAEKDTSGEAAVAAKAKAKLALAVARIDQLVEDISALHTSSDDSFSLSSGDPGQEAPREGRAQSCSPCRGPEGGRREAGSRAHPLLRLKAAHASLSNDSLNSGSASDGYCPREHMLPCPLAALASRREDPRCGQPRPSRLDLDLPGCQAEPPAREATSADARVRTIKLSPTYQHVPLLEGASRAGAEPLAGPGISPGARKQAWLPADHLSKVPEKLAAAPLSVASKALQKLAAQEGPLSLSRCSSLSSLSSAGRPGPSEGGDLDDSDSSLEGLEEAGPSEAELDSTWRAPGATSLPVAIPAPRRNRGRGLGVEDATPSSSSENYVQETPLVLSRCSSVSSLGSFESPSIASSIPSEPCSGQGSGTISPSELPDSPGQTMPPSRSKTPPLAPAPQGPPEATQFSLQWESYVKRFLDIADCRERCRLPSELDAGSVRFTVEKPDENFSCASSLSALALHEHYVQQDVELRLLPSACPERGGGAGGAGLHFAGHRRREEGPAPTGSRPRGAADQELELLRECLGAAVPARLRKVASALVPGRRALPVPVYMLVPAPAPAQEDDSCTDSAEGTPVNFSSAASLSDETLQGPPRDQPGGPAGRQRPTGRPTSARQAMGHRHKAGGAGRSAEQSRGAGKNRAGLELPLGRPPSAPADKDGSKPGRTRGDGALQSLCLTTPTEEAVYCFYGNDSDEEPPAAAPTPTHRRTSAIPRAFTRERPQGRKEAPAPSKAAPAAPPPARTQPSLIADETPPCYSLSSSASSLSEPEPSEPPAVHPRGREPAVTKDPGPGGGRDSSPSPRAAEELLQRCISSALPRRRPPVSGLRRRKPRATRLDERPAEGSRERGEEAAGSDRASDLDSVEWRAIQEGANSIVTWLHQAAAATREASSESDSILSFVSGLSVGSTLQPPKHRKGRQAEGEMGSARRPEKRGAASVKTSGSPRSPAGPEKPRGTQKTTPGVPAVLRGRTVIYVPSPAPRAQPKGTPGPRATPRKVAPPCLAQPAAPAKVPSPGQQRSRSLHRPAKTSELATLSQPPRSATPPARLAKTPSSSSSQTSPASQPLPRKRPPVTQAAGALPGPGASPVPKTPARTLLAKQHKTQRSPVRIPFMQRPARRGPPPLARAVPEPGPRGRAGTEAGPGARGGRLGLVRVASALSSGSESSDRSGFRRQLTFIKESPGLRRRRSELSSAESAASAPQGASPRRGRPALPAVFLCSSRCEELRAAPRQGPAPARQRPPAARPSPGERPARRTTSESPSRLPVRAPAARPETVKRYASLPHISVARRPDGAVPAAPASADAARRSSDGEPRPLPRVAAPGTTWRRIRDEDVPHILRSTLPATALPLRGSTPEDAPAGPPPRKTSDAVVQTEEVAAPKTNSSTSPSLETREPPGAPAGGQLSLLGSDVDGPSLAKAPISAPFVHEGLGVAVGGFPASRHGSPSRSARVPPFNYVPSPMVVAATTDSAAEKAPATASATLLE T19027 TARGETID T19027 T19027 FORMERID TTDI00057 T19027 UNIPROID CCNE2_HUMAN T19027 TARGNAME G1/S-specific cyclin-E2 (CCNE2) T19027 GENENAME CCNE2 T19027 TARGTYPE Literature-reported T19027 SYNONYMS G1/Sspecific cyclinE2 T19027 FUNCTION Essential for the control of the cell cycle at the late G1 and early S phase. T19027 SEQUENCE MSRRSSRLQAKQQPQPSQTESPQEAQIIQAKKRKTTQDVKKRREEVTKKHQYEIRNCWPPVLSGGISPCIIIETPHKEIGTSDFSRFTNYRFKNLFINPSPLPDLSWGCSKEVWLNMLKKESRYVHDKHFEVLHSDLEPQMRSILLDWLLEVCEVYTLHRETFYLAQDFFDRFMLTQKDINKNMLQLIGITSLFIASKLEEIYAPKLQEFAYVTDGACSEEDILRMELIILKALKWELCPVTIISWLNLFLQVDALKDAPKVLLPQYSQETFIQIAQLLDLCILAIDSLEFQYRILTAAALCHFTSIEVVKKASGLEWDSISECVDWMVPFVNVVKSTSPVKLKTFKKIPMEDRHNIQTHTNYLAMLEEVNYINTFRKGGQLSPVCNGGIMTPPKSTEKPPGKH T01865 TARGETID T01865 T01865 FORMERID TTDR00598 T01865 UNIPROID O97467_PLAFA T01865 TARGNAME Plasmodium Hexose transporter 1 (Malaria ht1) T01865 GENENAME Malaria ht1 T01865 TARGTYPE Literature-reported T01865 SYNONYMS ht1; Putative sugar transporter; Hexose transporter T01865 FUNCTION High-affinity glucose transporter. T01865 SEQUENCE MTKSSKDICSENEGKKNGKSGFFSTSFKYVLSACIASFIFGYQVSVLNTIKNFIVVEFEWCKGEKDRLNCSNNTIQSSFLLASVFIGAVLGCGFSGYLVQFGRRLSLLIIYNFFFLVSILTSITHHFHTILFARLLSGFGIGLVTVSVPMYISEMTHKDKKGAYGVMHQLFITFGIFVAVMLGLAMGEGPKADSTEPLTSFAKLWWRLMFLFPSVISLIGILALVVFFKEETPYFLFEKGRIEESKNILKKIYETDNVDEPLNAIKEAVEQNESAKKNSLSLLSALKIPSYRYVIILGCLLSGLQQFTGINVLVSNSNELYKEFLDSHLITILSVVMTAVNFLMTFPAIYIVEKLGRKTLLLWGCVGVLVAYLPTAIANEINRNSNFVKILSIVATFVMIISFAVSYGPVLWIYLHEMFPSEIKDSAASLASLVNWVCAIIVVFPSDIIIKKSPSILFIVFSVMSILTFFFIFFFIKETKGGEIGTSPYITMEERQKHMTKSVV T01865 DRUGINFO D08MTN Glucose analogue Investigative T33318 TARGETID T33318 T33318 FORMERID TTDR01026 T33318 UNIPROID MAS_HUMAN T33318 TARGNAME Angiotensin-(1-7) receptor (MAS1) T33318 GENENAME MAS1 T33318 TARGTYPE Literature-reported T33318 SYNONYMS MAS T33318 FUNCTION Receptor for angiotensin 1-7 (By similarity). Acts specifically as a functional antagonist of AGTR1 (angiotensin-2 type 1 receptor), although it up-regulates AGTR1 receptor levels. Positive regulation of AGTR1 levels occurs through activation of the G-proteins GNA11 and GNAQ, and stimulation of the protein kinase C signaling cascade. The antagonist effect on AGTR1 function is probably due to AGTR1 being physically altered by MAS1. T33318 SEQUENCE MDGSNVTSFVVEEPTNISTGRNASVGNAHRQIPIVHWVIMSISPVGFVENGILLWFLCFRMRRNPFTVYITHLSIADISLLFCIFILSIDYALDYELSSGHYYTIVTLSVTFLFGYNTGLYLLTAISVERCLSVLYPIWYRCHRPKYQSALVCALLWALSCLVTTMEYVMCIDREEESHSRNDCRAVIIFIAILSFLVFTPLMLVSSTILVVKIRKNTWASHSSKLYIVIMVTIIIFLIFAMPMRLLYLLYYEYWSTFGNLHHISLLFSTINSSANPFIYFFVGSSKKKRFKESLKVVLTRAFKDEMQPRRQKDNCNTVTVETVV T43850 TARGETID T43850 T43850 FORMERID TTDI01642 T43850 UNIPROID ENV_HV1H2-HEMA_I34A1 T43850 TARGNAME Virus fusion protein HIV gp41-influenza HA (HIV gp41-Influ HA) T43850 GENENAME HIV gp41-Influ HA T43850 TARGTYPE Literature-reported T43850 SYNONYMS Virus fusion protein Env polyprotein-influenza Hemagglutinin T43850 FUNCTION Functions as a passive -helical anchor of the protein to the virus envelope during its merger with the cell membrane T43850 SEQUENCE KLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKMKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI T56636 TARGETID T56636 T56636 FORMERID TTDR00055 T56636 UNIPROID TAT_HV1H2-TAR RNA T56636 TARGNAME Human immunodeficiency virus Tat-TAR RNA interaction (HIV Tat-TAR PPI) T56636 GENENAME HIV Tat-TAR PPI T56636 TARGTYPE Literature-reported T56636 SYNONYMS HIV Protein Tat-TAR RNA interaction T56636 FUNCTION Inhibit Tat-dependent transcription of HIV DNA. T56636 SEQUENCE MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKE T56636 DRUGINFO D0K5EP 2'-O-Methyl G-Clamp Containing Oligonucleotides Investigative T71317 TARGETID T71317 T71317 FORMERID TTDI00120 T71317 UNIPROID AP2A_HUMAN T71317 TARGNAME AP-2 transcription factor (TFAP2A) T71317 GENENAME TFAP2A T71317 TARGTYPE Literature-reported T71317 SYNONYMS Transcription factor AP-2-alpha; TFAP2; Activator protein 2; Activating enhancer-binding protein 2-alpha; AP2TF; AP2-alpha; AP-2 T71317 FUNCTION AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. AP-2-alpha is the only AP-2 protein required for early morphogenesis of the lens vesicle. Together with the CITED2 coactivator, stimulates the PITX2 P1 promoter transcription activation. Associates with chromatin to the PITX2 P1 promoter region. Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. T71317 SEQUENCE MLWKLTDNIKYEDCEDRHDGTSNGTARLPQLGTVGQSPYTSAPPLSHTPNADFQPPYFPPPYQPIYPQSQDPYSHVNDPYSLNPLHAQPQPQHPGWPGQRQSQESGLLHTHRGLPHQLSGLDPRRDYRRHEDLLHGPHALSSGLGDLSIHSLPHAIEEVPHVEDPGINIPDQTVIKKGPVSLSKSNSNAVSAIPINKDNLFGGVVNPNEVFCSVPGRLSLLSSTSKYKVTVAEVQRRLSPPECLNASLLGGVLRRAKSKNGGRSLREKLDKIGLNLPAGRRKAANVTLLTSLVEGEAVHLARDFGYVCETEFPAKAVAEFLNRQHSDPNEQVTRKNMLLATKQICKEFTDLLAQDRSPLGNSRPNPILEPGIQSCLTHFNLISHGFGSPAVCAAVTALQNYLTEALKAMDKMYLSNNPNSHTDNNAKSSDKEEKHRK T67883 TARGETID T67883 T67883 FORMERID TTDI02505 T67883 UNIPROID PGS2_HUMAN T67883 TARGNAME Decorin (DCN) T67883 GENENAME DCN T67883 TARGTYPE Literature-reported T67883 SYNONYMS SLRR1B; PGS2; PG40; PG-S2; Bone proteoglycan II T67883 FUNCTION May affect the rate of fibrils formation. T67883 SEQUENCE MKATIILLLLAQVSWAGPFQQRGLFDFMLEDEASGIGPEVPDDRDFEPSLGPVCPFRCQCHLRVVQCSDLGLDKVPKDLPPDTTLLDLQNNKITEIKDGDFKNLKNLHALILVNNKISKVSPGAFTPLVKLERLYLSKNQLKELPEKMPKTLQELRAHENEITKVRKVTFNGLNQMIVIELGTNPLKSSGIENGAFQGMKKLSYIRIADTNITSIPQGLPPSLTELHLDGNKISRVDAASLKGLNNLAKLGLSFNSISAVDNGSLANTPHLRELHLDNNKLTRVPGGLAEHKYIQVVYLHNNNISVVGSSDFCPPGHNTKKASYSGVSLFSNPVQYWEIQPSTFRCVYVRSAIQLGNYK T36508 TARGETID T36508 T36508 FORMERID TTDR01300 T36508 UNIPROID CH10_HELPY T36508 TARGNAME Helicobacter pylori Heat shock protein A (HELPY HspA) T36508 GENENAME HELPY HspA T36508 TARGTYPE Literature-reported T36508 SYNONYMS Protein Cpn10; Heat shock protein 10; HELPY 10 kDa chaperonin; GroES protein T36508 FUNCTION Binds to Cpn60 in the presence of Mg-ATP and suppresses the ATPase activity of the latter. T36508 SEQUENCE MKFQPLGERVLVERLEEENKTSSGIIIPDNAKEKPLMGVVKAVSHKISEGCKCVKEGDVIAFGKYKGAEIVLDGTEYMVLELEDILGIVGSGSCCHTGNHDHKHAKEHEACCHDHKKH T40683 TARGETID T40683 T40683 FORMERID TTDI02418 T40683 UNIPROID BXA1_CLOBH; BXB_CLOBO; BXE_CLOBO T40683 TARGNAME Clostridium botulinum Botulinum neurotoxin (CB bot) T40683 GENENAME CB botA; CB botB; CB botE T40683 TARGTYPE Literature-reported T40683 SYNONYMS Botulinum neurotoxin; Bontoxilysin; BoNT T40683 FUNCTION Inhibits acetylcholine release. The botulinum toxin binds with high affinity to peripheral neuronal presynaptic membrane to the secretory vesicle protein SV2. It binds directly to the largest luminal loop of SV2A, SV2B and SV2C. It is then internalized by receptor-mediated endocytosis. The C-terminus of the heavy chain (H) is responsible for the adherence of the toxin to the cell surface while the N-terminus mediates transport of the light chain from the endocytic vesicle to the cytosol. After translocation, the light chain (L) hydrolyzes the 197-Gln-|-Arg- 198 bond in SNAP-25, thereby blocking neurotransmitter release. Inhibition of acetylcholine release results in flaccid paralysis, with frequent heart or respiratory failure. T40683 SEQUENCE MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL T09067 TARGETID T09067 T09067 FORMERID TTDR00286 T09067 UNIPROID CALCB_HUMAN T09067 TARGNAME Calcitonin gene-related peptide 2 (CALCB) T09067 GENENAME CALCB T09067 TARGTYPE Literature-reported T09067 SYNONYMS Calcitonin gene-related peptide II; CGRP-II; CALC2; Beta-type CGRP; Beta-CGRP T09067 FUNCTION CGRP induces vasodilation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role. T09067 SEQUENCE MGFRKFSPFLALSILVLYQAGSLQAAPFRSALESSPDPATLSKEDARLLLAALVQDYVQMKASELKQEQETQGSSSAAQKRACNTATCVTHRLAGLLSRSGGMVKSNFVPTNVGSKAFGRRRRDLQA T96669 TARGETID T96669 T96669 FORMERID TTDI02596 T96669 UNIPROID CLUS_HUMAN T96669 TARGNAME Clusterin (CLU) T96669 GENENAME CLU T96669 TARGTYPE Literature-reported T96669 SYNONYMS Testosteronerepressed prostate message 2; Testosterone-repressed prostate message 2; TRPM-2; NA1/NA2; Ku70binding protein 1; Ku70-binding protein 1; KUB1; Complementassociated protein SP40,40; Complement-associated protein SP-40,40; Complement cytolysis inhibitor; Clusterin alpha chain; CLI; Apolipoprotein J; ApoJ; Apo-J; Agingassociated gene 4 protein; Aging-associated gene 4 protein; AAG4 T96669 FUNCTION Prevents stress-induced aggregation of blood plasma proteins. Inhibits formation of amyloid fibrils by APP, APOC2, B2M, CALCA, CSN3, SNCA and aggregation-prone LYZ variants (in vitro). Does not require ATP. Maintains partially unfolded proteins in a state appropriate for subsequent refolding by other chaperones, such as HSPA8/HSC70. Does not refold proteins by itself. Binding to cell surface receptors triggers internalization of the chaperone-client complex and subsequent lysosomal or proteasomal degradation. Secreted isoform 1 protects cells against apoptosis and against cytolysis by complement. Intracellular isoforms interact with ubiquitin and SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complexes and promote the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes proteasomal degradation of COMMD1 and IKBKB. Modulates NF-kappa-B transcriptional activity. Nuclear isoforms promote apoptosis. Mitochondrial isoforms suppress BAX-dependent release of cytochrome c into the cytoplasm and inhibit apoptosis. Plays a role in the regulation of cell proliferation. Isoform 1 functions as extracellular chaperone that prevents aggregation of nonnative proteins. T96669 SEQUENCE MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSNQGSKYVNKEIQNAVNGVKQIKTLIEKTNEERKTLLSNLEEAKKKKEDALNETRESETKLKELPGVCNETMMALWEECKPCLKQTCMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHMLDVMQDHFSRASSIIDELFQDRFFTREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNFHAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKDQCDKCREILSVDCSTNNPSQAKLRRELDESLQVAERLTRKYNELLKSYQWKMLNTSSLLEQLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEVSRKNPKFMETVAEKALQEYRKKHREE T02723 TARGETID T02723 T02723 FORMERID TTDR00427 T02723 UNIPROID IRF1_HUMAN T02723 TARGNAME Interferon regulatory factor 1 (IRF1) T02723 GENENAME IRF1 T02723 TARGTYPE Literature-reported T02723 SYNONYMS IRF-1 T02723 FUNCTION These include the regulation of IFN and IFN-inducible genes, host response to viral and bacterial infections, regulation of many genes expressed during hematopoiesis, inflammation, immune responses and cell proliferation and differentiation, regulation of the cell cycle and induction of growth arrest and programmed cell death following DNA damage. Stimulates both innate and acquired immune responses through the activation of specific target genes and can act as a transcriptional activator and repressor regulating target genes by binding to an interferon-stimulated response element (ISRE) in their promoters. Its target genes for transcriptional activation activity include: genes involved in anti-viral response, such as IFN-alpha/beta, DDX58/RIG-I, TNFSF10/TRAIL, OAS1/2, PIAS1/GBP, EIF2AK2/PKR and RSAD2/viperin; antibacterial response, such as NOS2/INOS; anti-proliferative response, such as p53/TP53, LOX and CDKN1A; apoptosis, such as BBC3/PUMA, CASP1, CASP7 and CASP8; immune response, such as IL7, IL12A/B and IL15, PTGS2/COX2 and CYBB; DNA damage responses and DNA repair, such as POLQ/POLH; MHC class I expression, such as TAP1, PSMB9/LMP2, PSME1/PA28A, PSME2/PA28B and B2M and MHC class II expression, such as CIITA. Represses genes involved in anti-proliferative response, such as BIRC5/survivin, CCNB1, CCNE1, CDK1, CDK2 and CDK4 and in immune response, such as FOXP3, IL4, ANXA2 and TLR4. Stimulates p53/TP53-dependent transcription through enhanced recruitment of EP300 leading to increased acetylation of p53/TP53. Plays an important role in immune response directly affecting NK maturation and activity, macrophage production of IL12, Th1 development and maturation of CD8+ T-cells. Also implicated in the differentiation and maturation of dendritic cells and in the suppression of regulatory T (Treg) cells development. Acts as a tumor suppressor and plays a role not only in antagonism of tumor cell growth but also in stimulating an immune response against tumor cells. Transcriptional regulator which displays a remarkable functional diversity in the regulation of cellular responses. T02723 SEQUENCE MPITRMRMRPWLEMQINSNQIPGLIWINKEEMIFQIPWKHAAKHGWDINKDACLFRSWAIHTGRYKAGEKEPDPKTWKANFRCAMNSLPDIEEVKDQSRNKGSSAVRVYRMLPPLTKNQRKERKSKSSRDAKSKAKRKSCGDSSPDTFSDGLSSSTLPDDHSSYTVPGYMQDLEVEQALTPALSPCAVSSTLPDWHIPVEVVPDSTSDLYNFQVSPMPSTSEATTDEDEEGKLPEDIMKLLEQSEWQPTNVDGKGYLLNEPGVQPTSVYGDFSCKEEPEIDSPGGDIGLSLQRVFTDLKNMDATWLDSLLTPVRLPSIQAIPCAP T33895 TARGETID T33895 T33895 FORMERID TTDI01654 T33895 UNIPROID MTDC_HUMAN; MTD2L_HUMAN T33895 TARGNAME NAD-dependent methylenetetrahydrofolate dehydrogenase (NMD) T33895 GENENAME MTHFD2; MTHFD2L T33895 TARGTYPE Literature-reported T33895 SYNONYMS Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase T33895 FUNCTION Although its dehydrogenase activity is NAD-specific, it can also utilize NADP at a reduced efficiency. T33895 SEQUENCE MAATSLMSALAARLLQPAHSCSLRLRPFHLAAVRNEAVVISGRKLAQQIKQEVRQEVEEWVASGNKRPHLSVILVGENPASHSYVLNKTRAAAVVGINSETIMKPASISEEELLNLINKLNNDDNVDGLLVQLPLPEHIDERRICNAVSPDKDVDGFHVINVGRMCLDQYSMLPATPWGVWEIIKRTGIPTLGKNVVVAGRSKNVGMPIAMLLHTDGAHERPGGDATVTISHRYTPKEQLKKHTILADIVISAAGIPNLITADMIKEGAAVIDVGINRVHDPVTAKPKLVGDVDFEGVRQKAGYITPVPGGVGPMTVAMLMKNTIIAAKKVLRLEEREVLKSKELGVATN T97201 TARGETID T97201 T97201 FORMERID TTDR00844 T97201 UNIPROID LEUK_HUMAN T97201 TARGNAME Leukosialin (SPN) T97201 GENENAME SPN T97201 TARGTYPE Literature-reported T97201 SYNONYMS Sialophorin; Leukocyte sialoglycoprotein; Leucocyte sialoglycoprotein; Galactoglycoprotein; GPL115; GALGP; CD43 antigen; CD43 T97201 FUNCTION Positively regulates T-cell trafficking to lymph-nodes via its association with ERM proteins (EZR, RDX and MSN). Negatively regulates Th2 cell differentiation and predisposes the differentiation of T-cells towards a Th1 lineage commitment. Promotes the expression of IFN-gamma by T-cells during T-cell receptor (TCR) activation of naive cells and induces the expression of IFN-gamma by CD4(+) T-cells and to a lesser extent by CD8(+) T-cells. Plays a role in preparing T-cells for cytokine sensing and differentiation into effector cells by inducing the expression of cytokine receptors IFNGR and IL4R, promoting IFNGR and IL4R signaling and by mediating the clustering of IFNGR with TCR. Acts as a major E-selectin ligand responsible for Th17 cell rolling on activated vasculature and recruitment during inflammation. Mediates Th17 cells, but not Th1 cells, adhesion to E-selectin. Acts as a T-cell counter-receptor for SIGLEC1. Predominant cell surface sialoprotein of leukocytes which regulates multiple T-cell functions, including T-cell activation, proliferation, differentiation, trafficking and migration. T97201 SEQUENCE MATLLLLLGVLVVSPDALGSTTAVQTPTSGEPLVSTSEPLSSKMYTTSITSDPKADSTGDQTSALPPSTSINEGSPLWTSIGASTGSPLPEPTTYQEVSIKMSSVPQETPHATSHPAVPITANSLGSHTVTGGTITTNSPETSSRTSGAPVTTAASSLETSRGTSGPPLTMATVSLETSKGTSGPPVTMATDSLETSTGTTGPPVTMTTGSLEPSSGASGPQVSSVKLSTMMSPTTSTNASTVPFRNPDENSRGMLPVAVLVALLAVIVLVALLLLWRRRQKRRTGALVLSRGGKRNGVVDAWAGPAQVPEEGAVTVTVGGSGGDKGSGFPDGEGSSRRPTLTTFFGRRKSRQGSLAMEELKSGSGPSLKGEEEPLVASEDGAVDAPAPDEPEGGDGAAP T36325 TARGETID T36325 T36325 FORMERID TTDI02089 T36325 UNIPROID H13_HUMAN T36325 TARGNAME Histone H1s-2 (H1.3) T36325 GENENAME HIST1H1D T36325 TARGTYPE Literature-reported T36325 SYNONYMS Histone H1s2; Histone H1c; HIST1H1D T36325 FUNCTION Histone H1 protein binds to linker DNA between nucleosomes forming the macromolecular structure known as the chromatin fiber. Histones H1 are necessary for the condensation of nucleosome chains into higher-order structured fibers. Acts also as a regulator of individual gene transcription through chromatin remodeling, nucleosome spacing and DNA methylation. T36325 SEQUENCE MSETAPLAPTIPAPAEKTPVKKKAKKAGATAGKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKAASGEGKPKAKKAGAAKPRKPAGAAKKPKKVAGAATPKKSIKKTPKKVKKPATAAGTKKVAKSAKKVKTPQPKKAAKSPAKAKAPKPKAAKPKSGKPKVTKAKKAAPKKK T71190 TARGETID T71190 T71190 FORMERID TTDNC00407 T71190 UNIPROID STMN1_HUMAN T71190 TARGNAME Stathmin-1 (STMN1) T71190 GENENAME STMN1 T71190 TARGTYPE Literature-reported T71190 SYNONYMS pp19; pp17; Stathmin; Protein Pr22; Prosolin; Phosphoprotein p19; Oncoprotein 18; OP18; Metablastin; Leukemia-associated phosphoprotein p18; LAP18; C1orf215 T71190 FUNCTION Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules. Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis. Involved in the control of the learned and innate fear (By similarity). T71190 SEQUENCE MASSDIQVKELEKRASGQAFELILSPRSKESVPEFPLSPPKKKDLSLEEIQKKLEAAEERRKSHEAEVLKQLAEKREHEKEVLQKAIEENNNFSKMAEEKLTHKMEANKENREAQMAAKLERLREKDKHIEEVRKNKESKDPADETEAD T94115 TARGETID T94115 T94115 FORMERID TTDR00621 T94115 UNIPROID SYN1_HUMAN; SYN2_HUMAN; SYN3_HUMAN T94115 TARGNAME Synapsin (SYN) T94115 GENENAME SYN1; SYN2; SYN3 T94115 TARGTYPE Literature-reported T94115 SYNONYMS Synapsin T94115 FUNCTION Neuronal phosphoprotein that coats synaptic vesicles, binds to the cytoskeleton, and is believed to function in the regulation of neurotransmitter release. The complex formed with NOS1 and CAPON proteins is necessary for specific nitric-oxid functions at a presynaptic level. May be involved in the regulation of noradrenaline secretion, neurotransmitter release and synaptogenesis. T94115 SEQUENCE MNYLRRRLSDSNFMANLPNGYMTDLQRPQPPPPPPGAHSPGATPGPGTATAERSSGVAPAASPAAPSPGSSGGGGFFSSLSNAVKQTTAAAAATFSEQVGGGSGGAGRGGAASRVLLVIDEPHTDWAKYFKGKKIHGEIDIKVEQAEFSDLNLVAHANGGFSVDMEVLRNGVKVVRSLKPDFVLIRQHAFSMARNGDYRSLVIGLQYAGIPSVNSLHSVYNFCDKPWVFAQMVRLHKKLGTEEFPLIDQTFYPNHKEMLSSTTYPVVVKMGHAHSGMGKVKVDNQHDFQDIASVVALTKTYATAEPFIDAKYDVRVQKIGQNYKAYMRTSVSGNWKTNTGSAMLEQIAMSDRYKLWVDTCSEIFGGLDICAVEALHGKDGRDHIIEVVGSSMPLIGDHQDEDKQLIVELVVNKMAQALPRQRQRDASPGRGSHGQTPSPGALPLGRQTSQQPAGPPAQQRPPPQGGPPQPGPGPQRQGPPLQQRPPPQGQQHLSGLGPPAGSPLPQRLPSPTSAPQQPASQAAPPTQGQGRQSRPVAGGPGAPPAARPPASPSPQRQAGPPQATRQTSVSGPAPPKASGAPPGGQQRQGPPQKPPGPAGPTRQASQAGPVPRTGPPTTQQPRPSGPGPAGRPKPQLAQKPSQDVPPPATAAAGGPPHPQLNKSQSLTNAFNLPEPAPPRPSLSQDEVKAETIRSLRKSFASLFSD T25670 TARGETID T25670 T25670 FORMERID TTDI01828 T25670 UNIPROID TNNI1_HUMAN; TNNI2_HUMAN; TNNI3_HUMAN T25670 TARGNAME Troponin I (TNNI) T25670 GENENAME TNNI1; TNNI2; TNNI3 T25670 TARGTYPE Literature-reported T25670 SYNONYMS Troponin I T25670 FUNCTION Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. T25670 SEQUENCE MPEVERKPKITASRKLLLKSLMLAKAKECWEQEHEEREAEKVRYLAERIPTLQTRGLSLSALQDLCRELHAKVEVVDEERYDIEAKCLHNTREIKDLKLKVMDLRGKFKRPPLRRVRVSADAMLRALLGSKHKVSMDLRANLKSVKKEDTEKERPVEVGDWRKNVEAMSGMEGRKKMFDAAKSPTSQ T09742 TARGETID T09742 T09742 FORMERID TTDI01431 T09742 UNIPROID GGT1_HUMAN; GGT2_HUMAN T09742 TARGNAME Gamma glutamyltranspeptidase (GGT) T09742 GENENAME GGT1; GGT2 T09742 TARGTYPE Literature-reported T09742 SYNONYMS Gamma-glutamyltranspeptidase; Gamma-glutamyltransferase; GGT T09742 FUNCTION GGT1 cleaves the gamma-glutamyl bond of extracellular glutathione (gamma-Glu-Cys-Gly), glutathione conjugates, and other gamma-glutamyl compounds. The metabolism of glutathione releases free glutamate and the dipeptide cysteinyl-glycine, which is hydrolyzed to cysteine and glycine by dipeptidases. In the presence of high concentrations of dipeptides and some amino acids, it can also catalyze a transpeptidation reaction, transferring the gamma-glutamyl moiety to an acceptor amino acid to form a new gamma-glutamyl compound. However GGT2 lack catalytic activity due to its inability to undergo the autocatalytic cleavage needed to produce a mature, enzymatically active heterodimer. T09742 SEQUENCE MKKKLVVLGLLAVVLVLVIVGLCLWLPSASKEPDNHVYTRAAVAADAKQCSKIGRDALRDGGSAVDAAIAALLCVGLMNAHSMGIGGGLFLTIYNSTTRKAEVINAREVAPRLAFATMFNSSEQSQKGGLSVAVPGEIRGYELAHQRHGRLPWARLFQPSIQLARQGFPVGKGLAAALENKRTVIEQQPVLCEVFCRDRKVLREGERLTLPQLADTYETLAIEGAQAFYNGSLTAQIVKDIQAAGGIVTAEDLNNYRAELIEHPLNISLGDVVLYMPSAPLSGPVLALILNILKGYNFSRESVESPEQKGLTYHRIVEAFRFAYAKRTLLGDPKFVDVTEVVRNMTSEFFAAQLRAQISDDTTHPISYYKPEFYTPDDGGTAHLSVVAEDGSAVSATSTINLYFGSKVRSPVSGILFNNEMDDFSSPSITNEFGVPPSPANFIQPGKQPLSSMCPTIMVGQDGQVRMVVGAAGGTQITTATALAIIYNLWFGYDVKRAVEEPRLHNQLLPNVTTVERNIDQAVTAALETRHHHTQIASTFIAVVQAIVRTAGGWAAASDSRKGGEPAGY T15811 TARGETID T15811 T15811 FORMERID TTDI00090 T15811 UNIPROID SRCH_HUMAN T15811 TARGNAME Histidine-rich calcium binding protein (HRC) T15811 GENENAME HRC T15811 TARGTYPE Literature-reported T15811 SYNONYMS Sarcoplasmic reticulum histidine-rich calcium-binding protein; HRC T15811 FUNCTION May play a role in the regulation of calcium sequestration or release in the SR of skeletal and cardiac muscle. T15811 SEQUENCE MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNSTGVAGLSEEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVSKEYGHLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEETGHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDESSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEERREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQEYGNYQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQHCQFCYLCPLVCETVCAPGSYVDYFSSSLYQALADMLETPEP T99665 TARGETID T99665 T99665 FORMERID TTDI03210 T99665 UNIPROID GBRR1_HUMAN T99665 TARGNAME GABA(A) receptor rho1 (GABRR1) T99665 GENENAME GABRR1 T99665 TARGTYPE Literature-reported T99665 SYNONYMS Gamma-aminobutyric acid receptor subunit rho-1; GABA(C) receptor1; GABA(A) receptor subunit rho-1 T99665 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission. T99665 SEQUENCE MLAVPNMRFGIFLLWWGWVLATESRMHWPGREVHEMSKKGRPQRQRREVHEDAHKQVSPILRRSPDITKSPLTKSEQLLRIDDHDFSMRPGFGGPAIPVGVDVQVESLDSISEVDMDFTMTLYLRHYWKDERLSFPSTNNLSMTFDGRLVKKIWVPDMFFVHSKRSFIHDTTTDNVMLRVQPDGKVLYSLRVTVTAMCNMDFSRFPLDTQTCSLEIESYAYTEDDLMLYWKKGNDSLKTDERISLSQFLIQEFHTTTKLAFYSSTGWYNRLYINFTLRRHIFFFLLQTYFPATLMVMLSWVSFWIDRRAVPARVPLGITTVLTMSTIITGVNASMPRVSYIKAVDIYLWVSFVFVFLSVLEYAAVNYLTTVQERKEQKLREKLPCTSGLPPPRTAMLDGNYSDGEVNDLDNYMPENGEKPDRMMVQLTLASERSSPQRKSQRSSYVSMRIDTHAIDKYSRIIFPAAYILFNLIYWSIFS T99665 DRUGINFO D0O9UH CACA Investigative T99665 DRUGINFO D0A6RM trans-3-ACPBPA Investigative T99665 DRUGINFO D0B0WU cis-3-ACPBPA Investigative T99665 DRUGINFO D0C7PZ 5-Me-IAA Investigative T99665 DRUGINFO D0OY1R aza-THIP Investigative T99665 DRUGINFO D0U4HM TPMPA Investigative T99665 DRUGINFO D0WV8K (+/-)-cis-2-CAMP Investigative T99665 DRUGINFO D0VW5M piperidine-4-sulphonic acid Investigative T99665 DRUGINFO D0AC2H isonipecotic acid Investigative T99665 DRUGINFO D0P0TI TBPS Investigative T36423 TARGETID T36423 T36423 FORMERID TTDR00386 T36423 UNIPROID CRHBP_HUMAN T36423 TARGNAME Corticotropin-releasing factor binding protein (CRHBP) T36423 GENENAME CRHBP T36423 TARGTYPE Literature-reported T36423 SYNONYMS Corticotropin-releasing hormone-binding protein; Corticotropin-releasing factor-binding protein; CRH-BP; CRFBP; CRF-binding protein; CRF-BP T36423 FUNCTION May prevent inappropriate pituitary-adrenal stimulation in pregnancy. Binds CRF and inactivates it. T36423 SEQUENCE MSPNFKLQCHFILIFLTALRGESRYLELREAADYDPFLLFSANLKRELAGEQPYRRALRCLDMLSLQGQFTFTADRPQLHCAAFFISEPEEFITIHYDQVSIDCQGGDFLKVFDGWILKGEKFPSSQDHPLPSAERYIDFCESGLSRRSIRSSQNVAMIFFRVHEPGNGFTLTIKTDPNLFPCNVISQTPNGKFTLVVPHQHRNCSFSIIYPVVIKISDLTLGHVNGLQLKKSSAGCEGIGDFVELLGGTGLDPSKMTPLADLCYPFHGPAQMKVGCDNTVVRMVSSGKHVNRVTFEYRQLEPYELENPNGNSIGEFCLSGL T23409 TARGETID T23409 T23409 FORMERID TTDR00052 T23409 UNIPROID GA45A_HUMAN; GA45B_HUMAN; GA45G_HUMAN T23409 TARGNAME Growth arrest and DNA-damage-inducible protein (GADD45) T23409 GENENAME GADD45A; GADD45B; GADD45G T23409 TARGTYPE Literature-reported T23409 SYNONYMS Growth arrest and DNA damage-inducible protein GADD45; DNA damage-inducible transcript protein; DDIT T23409 FUNCTION Involved in the regulation of growth and apoptosis. Mediates activation of stress-responsive MTK1/MEKK4 MAPKKK. T23409 SEQUENCE MTLEEFSAGEQKTERMDKVGDALEEVLSKALSQRTITVGVYEAAKLLNVDPDNVVLCLLAADEDDDRDVALQIHFTLIQAFCCENDINILRVSNPGRLAELLLLETDAGPAASEGAEQPPDLHCVLVTNPHSSQWKDPALSQLICFCRESRYMDQWVPVINLPER T65906 TARGETID T65906 T65906 FORMERID TTDI02648 T65906 UNIPROID CD24_HUMAN T65906 TARGNAME Small cell lung carcinoma cluster 4 antigen (CD24) T65906 GENENAME CD24 T65906 TARGTYPE Literature-reported T65906 SYNONYMS Signal transducer CD24; CD24A T65906 FUNCTION Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Modulates B-cell activation responses. Promotes AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells. In association with SIGLEC10 may be involved in the selective suppression of the immune response to danger-associated molecular patterns (DAMPs) such as HMGB1, HSP70 and HSP90. Plays a role in the control of autoimmunity. May have a pivotal role in cell differentiation of different cell types. T65906 SEQUENCE MGRAMVARLGLGLLLLALLLPTQIYSSETTTGTSSNSSQSTSNSGLAPNPTNATTKAAGGALQSTASLFVVSLSLLHLYS T65906 DRUGINFO D0FZ7D BsAb cG7-MICA Investigative T25705 TARGETID T25705 T25705 FORMERID TTDI03200 T25705 UNIPROID FPR3_HUMAN T25705 TARGNAME N-formyl peptide receptor 3 (FPR3) T25705 GENENAME FPR3 T25705 TARGTYPE Literature-reported T25705 SYNONYMS Formyl peptide receptor-like 2; FPRL2; FPRH1; FMLP-related receptor II; FMLP-R-II T25705 FUNCTION Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophils chemotactic factors. Binding of FMLP to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. T25705 SEQUENCE METNFSIPLNETEEVLPEPAGHTVLWIFSLLVHGVTFVFGVLGNGLVIWVAGFRMTRTVNTICYLNLALADFSFSAILPFRMVSVAMREKWPFGSFLCKLVHVMIDINLFVSVYLITIIALDRCICVLHPAWAQNHRTMSLAKRVMTGLWIFTIVLTLPNFIFWTTISTTNGDTYCIFNFAFWGDTAVERLNVFITMAKVFLILHFIIGFSVPMSIITVCYGIIAAKIHRNHMIKSSRPLRVFAAVVASFFICWFPYELIGILMAVWLKEMLLNGKYKIILVLINPTSSLAFFNSCLNPILYVFMGRNFQERLIRSLPTSLERALTEVPDSAQTSNTDTTSASPPEETELQAM T25705 DRUGINFO D09TXO humanin Preclinical T25705 DRUGINFO D0R1FZ LXA4 Investigative T12974 TARGETID T12974 T12974 FORMERID TTDI00127 T12974 UNIPROID HMGB2_HUMAN T12974 TARGNAME High-mobility group protein B2 (HMGB2) T12974 GENENAME HMGB2 T12974 TARGTYPE Literature-reported T12974 SYNONYMS High mobility group protein B2; High mobility group protein 2; HMG2; HMG-2 T12974 FUNCTION May act in a redox sensitive manner. In the nucleus is an abundant chromatin-associated non-histone protein involved in transcription, chromatin remodeling and V(D)J recombination and probably other processes. Binds DNA with a preference to non-canonical DNA structures such as single-stranded DNA. Can bent DNA and enhance DNA flexibility by looping thus providing a mechanism to promote activities on various gene promoters by enhancing transcription factor binding and/or bringing distant regulatory sequences into close proximity. Involved in V(D)J recombination by acting as a cofactor of the RAG complex: acts by stimulating cleavage and RAG protein binding at the 23 bp spacer of conserved recombination signal sequences (RSS). Proposed to be involved in the innate immune response to nucleic acids by acting as a promiscuous immunogenic DNA/RNA sensor which cooperates with subsequent discriminative sensing by specific pattern recognition receptors. In the extracellular compartment acts as a chemokine. Promotes proliferation and migration of endothelial cells implicating AGER/RAGE. Has antimicrobial activity in gastrointestinal epithelial tissues. Involved in inflammatory response to antigenic stimulus coupled with proinflammatory activity. Involved in modulation of neurogenesis probably by regulation of neural stem proliferation. Involved in articular cartilage surface maintenance implicating LEF1 and the Wnt/beta-catenin pathway. Multifunctional protein with various roles in different cellular compartments. T12974 SEQUENCE MGKGDPNKPRGKMSSYAFFVQTCREEHKKKHPDSSVNFAEFSKKCSERWKTMSAKEKSKFEDMAKSDKARYDREMKNYVPPKGDKKGKKKDPNAPKRPPSAFFLFCSEHRPKIKSEHPGLSIGDTAKKLGEMWSEQSAKDKQPYEQKAAKLKEKYEKDIAAYRAKGKSEAGKKGPGRPTGSKKKNEPEDEEEEEEEEDEDEEEEDEDEE T97960 TARGETID T97960 T97960 UNIPROID NKG2D_HUMAN-ULBP1_HUMAN/ULBP2_HUMAN/ULBP3_HUMAN T97960 TARGNAME NKG2D-NKG2D ligand interaction (NKG2D-NKG2DL PPI) T97960 GENENAME KLRK1-ULBP1/ULBP2/ULBP3 T97960 TARGTYPE Literature-reported T97960 SYNONYMS NK cell receptor D-NKG2D ligand interaction T97960 FUNCTION Inhibits the outgrowth of naturally arising low-grade B cell lymphoma In vivo. T97960 SEQUENCE MGWIRGRRSRHSWEMSEFHNYNLDLKKSDFSTRWQKQRCPVVKSKCRENASPFFFCCFIAVAMGIRFIIMVAIWSAVFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTVMAAAASPAFLLCLPLLHLLSGWSRAGWVDTHCLCYDFIITPKSRPEPQWCEVQGLVDERPFLHYDCVNHKAKAFASLGKKVNVTKTWEEQTETLRDVVDFLKGQLLDIQVENLIPIEPLTLQARMSCEHEAHGHGRGSWQFLFNGQKFLLFDSNNRKWTALHPGAKKMTEKWEKNRDVTMFFQKISLGDCKMWLEEFLMYWEQMLDPTKPPSLAPGTTQPKAMATTLSPWSLLIIFLCFILAGR T52651 TARGETID T52651 T52651 FORMERID TTDI02576 T52651 UNIPROID MAP4_HUMAN T52651 TARGNAME Microtubule-associated protein 4 (MAP4) T52651 GENENAME MAP4 T52651 TARGTYPE Literature-reported T52651 SYNONYMS Microtubuleassociated protein 4; MAP4 T52651 FUNCTION Non-neuronal microtubule-associated protein. Promotes microtubule assembly. T52651 SEQUENCE MADLSLADALTEPSPDIEGEIKRDFIATLEAEAFDDVVGETVGKTDYIPLLDVDEKTGNSESKKKPCSETSQIEDTPSSKPTLLANGGHGVEGSDTTGSPTEFLEEKMAYQEYPNSQNWPEDTNFCFQPEQVVDPIQTDPFKMYHDDDLADLVFPSSATADTSIFAGQNDPLKDSYGMSPCNTAVVPQGWSVEALNSPHSESFVSPEAVAEPPQPTAVPLELAKEIEMASEERPPAQALEIMMGLKTTDMAPSKETEMALAKDMALATKTEVALAKDMESPTKLDVTLAKDMQPSMESDMALVKDMELPTEKEVALVKDVRWPTETDVSSAKNVVLPTETEVAPAKDVTLLKETERASPIKMDLAPSKDMGPPKENKKETERASPIKMDLAPSKDMGPPKENKIVPAKDLVLLSEIEVAQANDIISSTEISSAEKVALSSETEVALARDMTLPPETNVILTKDKALPLEAEVAPVKDMAQLPETEIAPAKDVAPSTVKEVGLLKDMSPLSETEMALGKDVTPPPETEVVLIKNVCLPPEMEVALTEDQVPALKTEAPLAKDGVLTLANNVTPAKDVPPLSETEATPVPIKDMEIAQTQKGISEDSHLESLQDVGQSAAPTFMISPETVTGTGKKCSLPAEEDSVLEKLGERKPCNSQPSELSSETSGIARPEEGRPVVSGTGNDITTPPNKELPPSPEKKTKPLATTQPAKTSTSKAKTQPTSLPKQPAPTTIGGLNKKPMSLASGLVPAAPPKRPAVASARPSILPSKDVKPKPIADAKAPEKRASPSKPASAPASRSGSKSTQTVAKTTTAAAVASTGPSSRSPSTLLPKKPTAIKTEGKPAEVKKMTAKSVPADLSRPKSTSTSSMKKTTTLSGTAPAAGVVPSRVKATPMPSRPSTTPFIDKKPTSAKPSSTTPRLSRLATNTSAPDLKNVRSKVGSTENIKHQPGGGRAKVEKKTEAAATTRKPESNAVTKTAGPIASAQKQPAGKVQIVSKKVSYSHIQSKCGSKDNIKHVPGGGNVQIQNKKVDISKVSSKCGSKANIKHKPGGGDVKIESQKLNFKEKAQAKVGSLDNVGHLPAGGAVKTEGGGSEAPLCPGPPAGEEPAISEAAPEAGAPTSASGLNGHPTLSGGGDQREAQTLDSQIQETSI T90682 TARGETID T90682 T90682 FORMERID TTDI03211 T90682 UNIPROID GBRR2_HUMAN T90682 TARGNAME GABA(A) receptor rho2 (GABRR2) T90682 GENENAME GABRR2 T90682 TARGTYPE Literature-reported T90682 SYNONYMS Gamma-aminobutyric acid receptor subunit rho-2; GABA(C) receptor2; GABA(A) receptor subunit rho-2 T90682 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission. T90682 SEQUENCE MPYFTRLILFLFCLMVLVESRKPKRKRWTGQVEMPKPSHLYKKNLDVTKIRKGKPQQLLRVDEHDFSMRPAFGGPAIPVGVDVQVESLDSISEVDMDFTMTLYLRHYWKDERLAFSSASNKSMTFDGRLVKKIWVPDVFFVHSKRSFTHDTTTDNIMLRVFPDGHVLYSMRITVTAMCNMDFSHFPLDSQTCSLELESYAYTDEDLMLYWKNGDESLKTDEKISLSQFLIQKFHTTSRLAFYSSTGWYNRLYINFTLRRHIFFFLLQTYFPATLMVMLSWVSFWIDRRAVPARVSLGITTVLTMTTIITGVNASMPRVSYVKAVDIYLWVSFVFVFLSVLEYAAVNYLTTVQERKERKLREKFPCMCGMLHSKTMMLDGSYSESEANSLAGYPRSHILTEEERQDKIVVHLGLSGEANAARKKGLLKGQTGFRIFQNTHAIDKYSRLIFPASYIFFNLIYWSVFS T90682 DRUGINFO D0A6RM trans-3-ACPBPA Investigative T90682 DRUGINFO D0B0WU cis-3-ACPBPA Investigative T90682 DRUGINFO D0C7PZ 5-Me-IAA Investigative T90682 DRUGINFO D0OY1R aza-THIP Investigative T90682 DRUGINFO D0U4HM TPMPA Investigative T90682 DRUGINFO D0WV8K (+/-)-cis-2-CAMP Investigative T90682 DRUGINFO D0VW5M piperidine-4-sulphonic acid Investigative T90682 DRUGINFO D0AC2H isonipecotic acid Investigative T90682 DRUGINFO D0P0TI TBPS Investigative T40569 TARGETID T40569 T40569 FORMERID TTDI01344 T40569 UNIPROID MPIP1_HUMAN; MPIP2_HUMAN; MPIP3_HUMAN T40569 TARGNAME Dual specificity phosphatase Cdc25 (CDC25) T40569 GENENAME CDC25A; CDC25B; CDC25C T40569 TARGTYPE Literature-reported T40569 SYNONYMS M-phase inducer phosphatase T40569 FUNCTION A dual-specificity phosphatase first isolated from the yeast Schizosaccharomyces pombe as a cell cycle defective mutant. As with other cell cycle proteins or genes such as Cdc2 and Cdc4, the "cdc" in its name refers to "cell division cycle". Dual-specificity phosphatases are considered a sub-class of protein tyrosine phosphatases. By removing inhibitory phosphate residues from target cyclin-dependent kinases (Cdks), Cdc25 proteins control entry into and progression through various phases of the cell cycle, including mitosis and S ("Synthesis") phase. T40569 SEQUENCE MELGPEPPHRRRLLFACSPPPASQPVVKALFGASAAGGLSPVTNLTVTMDQLQGLGSDYEQPLEVKNNSNLQRMGSSESTDSGFCLDSPGPLDSKENLENPMRRIHSLPQKLLGCSPALKRSHSDSLDHDIFQLIDPDENKENEAFEFKKPVRPVSRGCLHSHGLQEGKDLFTQRQNSAPARMLSSNERDSSEPGNFIPLFTPQSPVTATLSDEDDGFVDLLDGENLKNEEETPSCMASLWTAPLVMRTTNLDNRCKLFDSPSLCSSSTRSVLKRPERSQEESPPGSTKRRKSMSGASPKESTNPEKAHETLHQSLSLASSPKGTIENILDNDPRDLIGDFSKGYLFHTVAGKHQDLKYISPEIMASVLNGKFANLIKEFVIIDCRYPYEYEGGHIKGAVNLHMEEEVEDFLLKKPIVPTDGKRVIVVFHCEFSSERGPRMCRYVRERDRLGNEYPKLHYPELYVLKGGYKEFFMKCQSYCEPPSYRPMHHEDFKEDLKKFRTKSRTWAGEKSKREMYSRLKKL T56290 TARGETID T56290 T56290 FORMERID TTDI00134 T56290 UNIPROID HXA11_HUMAN T56290 TARGNAME Homeobox protein Hox-A11 (HOXA11) T56290 GENENAME HOXA11 T56290 TARGTYPE Literature-reported T56290 SYNONYMS Homeobox protein HoxA11; Homeobox protein Hox1I; Homeobox protein Hox-1I; HOX1I T56290 FUNCTION Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. T56290 SEQUENCE MDFDERGPCSSNMYLPSCTYYVSGPDFSSLPSFLPQTPSSRPMTYSYSSNLPQVQPVREVTFREYAIEPATKWHPRGNLAHCYSAEELVHRDCLQAPSAAGVPGDVLAKSSANVYHHPTPAVSSNFYSTVGRNGVLPQAFDQFFETAYGTPENLASSDYPGDKSAEKGPPAATATSAAAAAAATGAPATSSSDSGGGGGCRETAAAAEEKERRRRPESSSSPESSSGHTEDKAGGSSGQRTRKKRCPYTKYQIRELEREFFFSVYINKEKRLQLSRMLNLTDRQVKIWFQNRRMKEKKINRDRLQYYSANPLL T97413 TARGETID T97413 T97413 FORMERID TTDI01337 T97413 UNIPROID BRS3_HUMAN T97413 TARGNAME Bombesin-like receptor 3 (BRS3) T97413 GENENAME BRS3 T97413 TARGTYPE Literature-reported T97413 SYNONYMS Bombesin receptor subtype-3; BRS-3 T97413 FUNCTION Role in sperm cell division, maturation, or function. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. T97413 SEQUENCE MAQRQPHSPNQTLISITNDTESSSSVVSNDNTNKGWSGDNSPGIEALCAIYITYAVIISVGILGNAILIKVFFKTKSMQTVPNIFITSLAFGDLLLLLTCVPVDATHYLAEGWLFGRIGCKVLSFIRLTSVGVSVFTLTILSADRYKAVVKPLERQPSNAILKTCVKAGCVWIVSMIFALPEAIFSNVYTFRDPNKNMTFESCTSYPVSKKLLQEIHSLLCFLVFYIIPLSIISVYYSLIARTLYKSTLNIPTEEQSHARKQIESRKRIARTVLVLVALFALCWLPNHLLYLYHSFTSQTYVDPSAMHFIFTIFSRVLAFSNSCVNPFALYWLSKSFQKHFKAQLFCCKAERPEPPVADTSLTTLAVMGTVPGTGSIQMSEISVTSFTGCSVKQAEDRF T97413 DRUGINFO D04JSE MK-7725 Investigative T59577 TARGETID T59577 T59577 FORMERID TTDI03237 T59577 UNIPROID GP183_HUMAN T59577 TARGNAME EBV-induced G-protein coupled receptor 2 (GPR183) T59577 GENENAME GPR183 T59577 TARGTYPE Literature-reported T59577 SYNONYMS hEBI2; G-protein coupled receptor 183; Epstein-Barr virus-induced G-protein coupled receptor 2; EBI2 T59577 FUNCTION G-protein coupled receptor expressed in lymphocytes that acts as a chemotactic receptor for B-cells, T-cells, splenic dendritic cells, monocytes/macrophages and astrocytes (By similarity). Receptor for oxysterol 7-alpha,25-dihydroxycholesterol (7-alpha,25-OHC) and other related oxysterols. Mediates cell positioning and movement of a number of cells by binding the 7-alpha,25-OHC ligand that forms a chemotactic gradient (By similarity). Binding of 7-alpha,25-OHC mediates the correct localization of B-cells during humoral immune responses (By similarity). Guides B-cell movement along the B-cell zone-T-cell zone boundary and later to interfollicular and outer follicular regions (By similarity). Its specific expression during B-cell maturation helps position B-cells appropriately for mounting T-dependent antibody responses (By similarity). Collaborates with CXCR5 to mediate B-cell migration; probably by forming a heterodimer with CXCR5 that affects the interaction between of CXCL13 and CXCR5. Also acts as a chemotactic receptor for some T-cells upon binding to 7-alpha,25-OHC ligand (By similarity). Promotes follicular helper T (Tfh) cells differentiation by positioning activated T-cells at the follicle-T-zone interface, promoting contact of newly activated CD4 T-cells with activated dendritic cells and exposing them to Tfh-cell-promoting inducible costimulator (ICOS) ligand (By similarity). Expression in splenic dendritic cells is required for their homeostasis, localization and ability to induce B- and T-cell responses: GPR183 acts as a chemotactic receptor in dendritic cells that mediates the accumulation of CD4(+) dendritic cells in bridging channels (By similarity). Regulates migration of astrocytes and is involved in communication between astrocytes and macrophages. Promotes osteoclast precursor migration to bone surfaces (By similarity). Signals constitutively through G(i)-alpha, but not G(s)-alpha or G(q)-alpha. Signals constitutively also via MAPK1/3 (ERK1/2) (By similarity). T59577 SEQUENCE MDIQMANNFTPPSATPQGNDCDLYAHHSTARIVMPLHYSLVFIIGLVGNLLALVVIVQNRKKINSTTLYSTNLVISDILFTTALPTRIAYYAMGFDWRIGDALCRITALVFYINTYAGVNFMTCLSIDRFIAVVHPLRYNKIKRIEHAKGVCIFVWILVFAQTLPLLINPMSKQEAERITCMEYPNFEETKSLPWILLGACFIGYVLPLIIILICYSQICCKLFRTAKQNPLTEKSGVNKKALNTIILIIVVFVLCFTPYHVAIIQHMIKKLRFSNFLECSQRHSFQISLHFTVCLMNFNCCMDPFIYFFACKGYKRKVMRMLKRQVSVSISSAVKSAPEENSREMTETQMMIHSKSSNGK T59577 DRUGINFO D02JXQ 7alpha,25-dihydroxycholesterol Investigative T59577 DRUGINFO D04BOQ 7alpha,27-dihydroxycholesterol Investigative T59577 DRUGINFO D0FB7S 7beta-hydroxycholesterol Investigative T59577 DRUGINFO D0H7NV 7beta, 27-dihydroxycholesterol Investigative T59577 DRUGINFO D0K5QH 7alpha-hydroxycholesterol Investigative T59577 DRUGINFO D0L7PI 7beta, 25-dihydroxycholesterol Investigative T59577 DRUGINFO D06OVX 25-hydroxycholesterol Investigative T59577 DRUGINFO D0H2YM 27-hydroxycholesterol Investigative T49085 TARGETID T49085 T49085 FORMERID TTDI00156 T49085 UNIPROID SOX5_HUMAN T49085 TARGNAME Transcription factor SOX-5 (SOX5) T49085 GENENAME SOX5 T49085 TARGTYPE Literature-reported T49085 SYNONYMS SRY-box 5; LAMSHF; L-SOX5F; L-SOX5B; L-SOX5 T49085 FUNCTION Activates transcription of COL2A1 and AGC1 in vitro. Binds specifically to the DNA sequence 5'-AACAAT-3'. T49085 SEQUENCE MLTDPDLPQEFERMSSKRPASPYGEADGEVAMVTSRQKVEEEESDGLPAFHLPLHVSFPNKPHSEEFQPVSLLTQETCGHRTPTSQHNTMEVDGNKVMSSFAPHNSSTSPQKAEEGGRQSGESLSSTALGTPERRKGSLADVVDTLKQRKMEELIKNEPEETPSIEKLLSKDWKDKLLAMGSGNFGEIKGTPESLAEKERQLMGMINQLTSLREQLLAAHDEQKKLAASQIEKQRQQMELAKQQQEQIARQQQQLLQQQHKINLLQQQIQVQGQLPPLMIPVFPPDQRTLAAAAQQGFLLPPGFSYKAGCSDPYPVQLIPTTMAAAAAATPGLGPLQLQQLYAAQLAAMQVSPGGKLPGIPQGNLGAAVSPTSIHTDKSTNSPPPKSKDEVAQPLNLSAKPKTSDGKSPTSPTSPHMPALRINSGAGPLKASVPAALASPSARVSTIGYLNDHDAVTKAIQEARQMKEQLRREQQVLDGKVAVVNSLGLNNCRTEKEKTTLESLTQQLAVKQNEEGKFSHAMMDFNLSGDSDGSAGVSESRIYRESRGRGSNEPHIKRPMNAFMVWAKDERRKILQAFPDMHNSNISKILGSRWKAMTNLEKQPYYEEQARLSKQHLEKYPDYKYKPRPKRTCLVDGKKLRIGEYKAIMRNRRQEMRQYFNVGQQAQIPIATAGVVYPGAIAMAGMPSPHLPSEHSSVSSSPEPGMPVIQSTYGVKGEEPHIKEEIQAEDINGEIYDEYDEEEDDPDVDYGSDSENHIAGQAN T62977 TARGETID T62977 T62977 FORMERID TTDR00067 T62977 UNIPROID RBBA_ECOLI T62977 TARGNAME Bacterial Ribosomal ATPase RbbA (Bact rbbA) T62977 GENENAME Bact rbbA T62977 TARGTYPE Literature-reported T62977 SYNONYMS Ribosome-associated ATPase; Ribosomal bound ATPase T62977 FUNCTION Exhibits an intrinsic ATPase activity that is stimulated by both 70S ribosomes and 30S ribosomal subunits. Could be involved in protein-chain elongation and in release of deacyl-tRNA from ribosomes after peptide bond synthesis. Stimulates the synthesis of polyphenylalanine in vitro. T62977 SEQUENCE MTHLELVPVPPVAQLAGVSQHYGKTVALNNITLDIPARCMVGLIGPDGVGKSSLLSLISGARVIEQGNVMVLGGDMRDPKHRRDVCPRIAWMPQGLGKNLYHTLSVYENVDFFARLFGHDKAEREVRINELLTSTGLAPFRDRPAGKLSGGMKQKLGLCCALIHDPELLILDEPTTGVDPLSRSQFWDLIDSIRQRQSNMSVLVATAYMEEAERFDWLVAMNAGEVLATGSAEELRQQTQSATLEEAFINLLPQAQRQAHQAVVIPPYQPENAEIAIEARDLTMRFGSFVAVDHVNFRIPRGEIFGFLGSNGCGKSTTMKMLTGLLPASEGEAWLFGQPVDPKDIDTRRRVGYMSQAFSLYNELTVRQNLELHARLFHIPEAEIPARVAEMSERFKLNDVEDILPESLPLGIRQRLSLAVAVIHRPEMLILDEPTSGVDPVARDMFWQLMVDLSRQDKVTIFISTHFMNEAERCDRISLMHAGKVLASGTPQELVEKRGAASLEEAFIAYLQEAAGQSNEAEAPPVVHDTTHAPRQGFSLRRLFSYSRREALELRRDPVRSTLALMGTVILMLIMGYGISMDVENLRFAVLDRDQTVSSQAWTLNLSGSRYFIEQPPLTSYDELDRRMRAGDITVAIEIPPNFGRDIARGTPVELGVWIDGAMPSRAETVKGYVQAMHQSWLQDVASRQSTPASQSGLMNIETRYRYNPDVKSLPAIVPAVIPLLLMMIPSMLSALSVVREKELGSIINLYVTPTTRSEFLLGKQLPYIALGMLNFFLLCGLSVFVFGVPHKGSFLTLTLAALLYIIIATGMGLLISTFMKSQIAAIFGTAIITLIPATQFSGMIDPVASLEGPGRWIGEVYPTSHFLTIARGTFSKALDLTDLWQLFIPLLIAIPLVMGLSILLLKKQEG T62977 DRUGINFO D0S6RD Hygromycin B Investigative T13175 TARGETID T13175 T13175 FORMERID TTDI02556 T13175 UNIPROID WNT5A_HUMAN T13175 TARGNAME Wnt-5a protein (WNT5A) T13175 GENENAME WNT5A T13175 TARGTYPE Literature-reported T13175 SYNONYMS Protein Wnt-5a T13175 FUNCTION Can activate or inhibit canonical Wnt signaling, depending on receptor context. In the presence of FZD4, activates beta-catenin signaling. In the presence of ROR2, inhibits the canonical Wnt pathway by promoting beta-catenin degradation through a GSK3-independent pathway which involves down-regulation of beta-catenin-induced reporter gene expression. Suppression of the canonical pathway allows chondrogenesis to occur and inhibits tumor formation. Stimulates cell migration. Decreases proliferation, migration, invasiveness and clonogenicity of carcinoma cells and may act as a tumor suppressor. Mediates motility of melanoma cells. Required during embryogenesis for extension of the primary anterior-posterior axis and for outgrowth of limbs and the genital tubercle. Inhibits type II collagen expression in chondrocytes. Ligand for members of the frizzled family of seven transmembrane receptors. T13175 SEQUENCE MKKSIGILSPGVALGMAGSAMSSKFFLVALAIFFSFAQVVIEANSWWSLGMNNPVQMSEVYIIGAQPLCSQLAGLSQGQKKLCHLYQDHMQYIGEGAKTGIKECQYQFRHRRWNCSTVDNTSVFGRVMQIGSRETAFTYAVSAAGVVNAMSRACREGELSTCGCSRAARPKDLPRDWLWGGCGDNIDYGYRFAKEFVDARERERIHAKGSYESARILMNLHNNEAGRRTVYNLADVACKCHGVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMRLNSRGKLVQVNSRFNSPTTQDLVYIDPSPDYCVRNESTGSLGTQGRLCNKTSEGMDGCELMCCGRGYDQFKTVQTERCHCKFHWCCYVKCKKCTEIVDQFVCK T82979 TARGETID T82979 T82979 FORMERID TTDR00631 T82979 UNIPROID MTSA_STREE T82979 TARGNAME Streptococcus Metal-transporter protein PsaA (Stre-coc psaA) T82979 GENENAME Stre-coc psaA T82979 TARGTYPE Literature-reported T82979 SYNONYMS Pneumococcal surface adhesin A T82979 FUNCTION Part of an ATP-driven transport system for manganese. Also act as an adhesin which is involved on adherence to extracellular matrix. It is an important factor in pathogenesis and infection. T82979 SEQUENCE MKKIASVLALFVALLFGLLACSKGTSSKSSSDKLKVVTTNSILADITKNIAGDKIELHSIVPVGQDPHEYEPLPEDVKKTSQADLIFYNGINLETGGNAWFTKLVKNANKVENKDYFAASDGVEVIYLEGQNQAGKEDPHAWLNLENGIIYAKNIAKQLIAKDPKNKDFYEKNLAAYTEKLSKLDQEAKQAFNNIPAEKKMIVTSEGCFKYFSKAYGVPSAYIWEINTEVEGTPEQIKTLLEKLRQTKVPSLFVESSVDERPMKTVSKDSNIPIFAKIFTDSIAKEGEEGDSYYSMMKWNLEKIAEGLNK T51569 TARGETID T51569 T51569 FORMERID TTDR00807 T51569 UNIPROID MUC18_HUMAN T51569 TARGNAME Cell surface glycoprotein MUC18 (MCAM) T51569 GENENAME MCAM T51569 TARGTYPE Literature-reported T51569 SYNONYMS S-endo 1 endothelial-associated antigen; Melanoma-associated antigen MUC18; Melanoma-associated antigen A32; Melanoma cell adhesion molecule; Melanoma adhesion molecule; MUC18; Cell surface glycoprotein P1H12; CD146 antigen; CD146 T51569 FUNCTION Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration. Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. T51569 SEQUENCE MGLPRLVCAFLLAACCCCPRVAGVPGEAEQPAPELVEVEVGSTALLKCGLSQSQGNLSHVDWFSVHKEKRTLIFRVRQGQGQSEPGEYEQRLSLQDRGATLALTQVTPQDERIFLCQGKRPRSQEYRIQLRVYKAPEEPNIQVNPLGIPVNSKEPEEVATCVGRNGYPIPQVIWYKNGRPLKEEKNRVHIQSSQTVESSGLYTLQSILKAQLVKEDKDAQFYCELNYRLPSGNHMKESREVTVPVFYPTEKVWLEVEPVGMLKEGDRVEIRCLADGNPPPHFSISKQNPSTREAEEETTNDNGVLVLEPARKEHSGRYECQGLDLDTMISLLSEPQELLVNYVSDVRVSPAAPERQEGSSLTLTCEAESSQDLEFQWLREETGQVLERGPVLQLHDLKREAGGGYRCVASVPSIPGLNRTQLVNVAIFGPPWMAFKERKVWVKENMVLNLSCEASGHPRPTISWNVNGTASEQDQDPQRVLSTLNVLVTPELLETGVECTASNDLGKNTSILFLELVNLTTLTPDSNTTTGLSTSTASPHTRANSTSTERKLPEPESRGVVIVAVIVCILVLAVLGAVLYFLYKKGKLPCRRSGKQEITLPPSRKSELVVEVKSDKLPEEMGLLQGSSGDKRAPGDQGEKYIDLRH T93848 TARGETID T93848 T93848 UNIPROID MAGA2_HUMAN T93848 TARGNAME Melanoma-associated antigen 2 (MAGEA2) T93848 GENENAME MAGEA2 T93848 TARGTYPE Literature-reported T93848 SYNONYMS MAGEA2B; MAGEA2A; MAGE2; MAGE-2 antigen; Cancer/testis antigen 1.2; CT1.2 T93848 FUNCTION Represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation. Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. T93848 SEQUENCE MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQQTASSSSTLVEVTLGEVPAADSPSPPHSPQGASSFSTTINYTLWRQSDEGSSNQEEEGPRMFPDLESEFQAAISRKMVELVHFLLLKYRAREPVTKAEMLESVLRNCQDFFPVIFSKASEYLQLVFGIEVVEVVPISHLYILVTCLGLSYDGLLGDNQVMPKTGLLIIVLAIIAIEGDCAPEEKIWEELSMLEVFEGREDSVFAHPRKLLMQDLVQENYLEYRQVPGSDPACYEFLWGPRALIETSYVKVLHHTLKIGGEPHISYPPLHERALREGEE T13484 TARGETID T13484 T13484 FORMERID TTDI03358 T13484 UNIPROID LPAR6_HUMAN T13484 TARGNAME Lysophosphatidic acid receptor 6 (LPAR6) T13484 GENENAME LPAR6 T13484 TARGTYPE Literature-reported T13484 SYNONYMS RB intron encoded G-protein coupled receptor; Purinergic receptor 5; P2Y5; P2Y purinoceptor 5; P2RY5; Oleoyl-L-alpha-lysophosphatidic acid receptor; LPA-6; LPA receptor 6 T13484 FUNCTION Binds to oleoyl-L-alpha-lysophosphatidic acid (LPA). Intracellular cAMP is involved in the receptor activation. Important for the maintenance of hair growth and texture. T13484 SEQUENCE MVSVNSSHCFYNDSFKYTLYGCMFSMVFVLGLISNCVAIYIFICVLKVRNETTTYMINLAMSDLLFVFTLPFRIFYFTTRNWPFGDLLCKISVMLFYTNMYGSILFLTCISVDRFLAIVYPFKSKTLRTKRNAKIVCTGVWLTVIGGSAPAVFVQSTHSQGNNASEACFENFPEATWKTYLSRIVIFIEIVGFFIPLILNVTCSSMVLKTLTKPVTLSRSKINKTKVLKMIFVHLIIFCFCFVPYNINLILYSLVRTQTFVNCSVVAAVRTMYPITLCIAVSNCCFDPIVYYFTSDTIQNSIKMKNWSVRRSDFRFSEVHGAENFIQHNLQTLKSKIFDNESAA T13484 DRUGINFO D0X0UR LPA Investigative T31227 TARGETID T31227 T31227 FORMERID TTDI03238 T31227 UNIPROID GPR3_HUMAN T31227 TARGNAME G protein-coupled receptor 3 (GPR3) T31227 GENENAME GPR3 T31227 TARGTYPE Literature-reported T31227 SYNONYMS G-protein coupled receptor 3; ACCA orphan receptor; ACCA T31227 FUNCTION Orphan receptor with constitutive G(s) signaling activity that activate cyclic AMP. Has a potential role in modulating a number of brain functions, including behavioral responses to stress (By similarity), amyloid-beta peptide generation in neurons and neurite outgrowth (By similarity). Maintains also meiotic arrest in oocytes (By similarity). T31227 SEQUENCE MMWGAGSPLAWLSAGSGNVNVSSVGPAEGPTGPAAPLPSPKAWDVVLCISGTLVSCENALVVAIIVGTPAFRAPMFLLVGSLAVADLLAGLGLVLHFAAVFCIGSAEMSLVLVGVLAMAFTASIGSLLAITVDRYLSLYNALTYYSETTVTRTYVMLALVWGGALGLGLLPVLAWNCLDGLTTCGVVYPLSKNHLVVLAIAFFMVFGIMLQLYAQICRIVCRHAQQIALQRHLLPASHYVATRKGIATLAVVLGAFAACWLPFTVYCLLGDAHSPPLYTYLTLLPATYNSMINPIIYAFRNQDVQKVLWAVCCCCSSSKIPFRSRSPSDV T31227 DRUGINFO D0N0GJ diphenyleneiodonium chloride Investigative T00569 TARGETID T00569 T00569 FORMERID TTDI03417 T00569 UNIPROID SO1A2_HUMAN T00569 TARGNAME Sodium-independent organic anion transporter (SLCO1A2) T00569 GENENAME SLCO1A2 T00569 TARGTYPE Literature-reported T00569 SYNONYMS Solute carrier organic anion transporter family member 1A2; Solute carrier family 21 member 3; SLC21A3; Organic anion-transporting polypeptide 1; OATP1A2; OATP-A; OATP-1; OATP T00569 FUNCTION Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin. T00569 SEQUENCE MGETEKRIETHRIRCLSKLKMFLLAITCAFVSKTLSGSYMNSMLTQIERQFNIPTSLVGFINGSFEIGNLLLIIFVSYFGTKLHRPIMIGIGCVVMGLGCFLKSLPHFLMNQYEYESTVSVSGNLSSNSFLCMENGTQILRPTQDPSECTKEVKSLMWVYVLVGNIVRGMGETPILPLGISYIEDFAKFENSPLYIGLVETGAIIGPLIGLLLASFCANVYVDTGFVNTDDLIITPTDTRWVGAWWFGFLICAGVNVLTAIPFFFLPNTLPKEGLETNADIIKNENEDKQKEEVKKEKYGITKDFLPFMKSLSCNPIYMLFILVSVIQFNAFVNMISFMPKYLEQQYGISSSDAIFLMGIYNLPPICIGYIIGGLIMKKFKITVKQAAHIGCWLSLLEYLLYFLSFLMTCENSSVVGINTSYEGIPQDLYVENDIFADCNVDCNCPSKIWDPVCGNNGLSYLSACLAGCETSIGTGINMVFQNCSCIQTSGNSSAVLGLCDKGPDCSLMLQYFLILSAMSSFIYSLAAIPGYMVLLRCMKSEEKSLGVGLHTFCTRVFAGIPAPIYFGALMDSTCLHWGTLKCGESGACRIYDSTTFRYIYLGLPAALRGSSFVPALIILILLRKCHLPGENASSGTELIETKVKGKENECKDIYQKSTVLKDDELKTKL T00569 DRUGINFO D09VQM naringin Investigative T00569 DRUGINFO D04AXP [3H]estrone-3-sulphate Investigative T37360 TARGETID T37360 T37360 FORMERID TTDI03230 T37360 UNIPROID GPR12_HUMAN T37360 TARGNAME G-protein coupled receptor 12 (GPR12) T37360 GENENAME GPR12 T37360 TARGTYPE Literature-reported T37360 SYNONYMS G-protein coupled receptor 12 T37360 FUNCTION Promotes neurite outgrowth and blocks myelin inhibition in neurons (By similarity). Receptor with constitutive G(s) signaling activity that stimulates cyclic AMP production. T37360 SEQUENCE MNEDLKVNLSGLPRDYLDAAAAENISAAVSSRVPAVEPEPELVVNPWDIVLCTSGTLISCENAIVVLIIFHNPSLRAPMFLLIGSLALADLLAGIGLITNFVFAYLLQSEATKLVTIGLIVASFSASVCSLLAITVDRYLSLYYALTYHSERTVTFTYVMLVMLWGTSICLGLLPVMGWNCLRDESTCSVVRPLTKNNAAILSVSFLFMFALMLQLYIQICKIVMRHAHQIALQHHFLATSHYVTTRKGVSTLAIILGTFAACWMPFTLYSLIADYTYPSIYTYATLLPATYNSIINPVIYAFRNQEIQKALCLICCGCIPSSLAQRARSPSDV T37360 DRUGINFO D0J4NQ sphingosylphosphorylcholine Investigative T08446 TARGETID T08446 T08446 FORMERID TTDI03052 T08446 UNIPROID S6A12_HUMAN T08446 TARGNAME Na(+)/Cl(-) betaine/GABA transporter (SLC6A12) T08446 GENENAME SLC6A12 T08446 TARGTYPE Literature-reported T08446 SYNONYMS Solute carrier family 6 member 12; Sodium- and chloride-dependent betaine transporter; BGT-1 T08446 FUNCTION Transports betaine and GABA. May have a role in regulation of GABAergic transmission in the brain through the reuptake of GABA into presynaptic terminals, as well as in osmotic regulation. T08446 SEQUENCE MDGKVAVQECGPPAVSWVPEEGEKLDQEDEDQVKDRGQWTNKMEFVLSVAGEIIGLGNVWRFPYLCYKNGGGAFFIPYFIFFFVCGIPVFFLEVALGQYTSQGSVTAWRKICPLFQGIGLASVVIESYLNVYYIIILAWALFYLFSSFTSELPWTTCNNFWNTEHCTDFLNHSGAGTVTPFENFTSPVMEFWERRVLGITSGIHDLGSLRWELALCLLLAWVICYFCIWKGVKSTGKVVYFTATFPYLMLVILLIRGVTLPGAYQGIIYYLKPDLFRLKDPQVWMDAGTQIFFSFAICQGCLTALGSYNKYHNNCYKDCIALCFLNSATSFVAGFVVFSILGFMSQEQGVPISEVAESGPGLAFIAFPKAVTMMPLSQLWSCLFFIMLIFLGLDSQFVCVECLVTASIDMFPRQLRKSGRRELLILTIAVMCYLIGLFLVTEGGMYIFQLFDYYASSGICLLFLSLFEVVCISWVYGADRFYDNIEDMIGYRPWPLVKISWLFLTPGLCLATFLFSLSKYTPLKYNNVYVYPPWGYSIGWFLALSSMVCVPLFVVITLLKTRGPFRKRLRQLITPDSSLPQPKQHPCLDGSAGRNFGPSPTREGLIAGEKETHL T08446 DRUGINFO D0P3KI NNC052090 Investigative T08446 DRUGINFO D02SDM LU32-176B Investigative T08446 DRUGINFO D0H2HC (R/S) EF-1500 Investigative T08446 DRUGINFO D0I7AL (R)-EF-1520 Investigative T08446 DRUGINFO D0WT5D (S)-EF-1520 Investigative T30163 TARGETID T30163 T30163 FORMERID TTDI03192 T30163 UNIPROID EAA4_HUMAN T30163 TARGNAME Excitatory amino acid transporter 4 (SLC1A6) T30163 GENENAME SLC1A6 T30163 TARGTYPE Literature-reported T30163 SYNONYMS Solute carrier family 1 member 6; Sodium-dependent glutamate/aspartate transporter; EAAT4 T30163 FUNCTION Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport (By similarity). Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate (Probable). T30163 SEQUENCE MSSHGNSLFLRESGQRLGRVGWLQRLQESLQQRALRTRLRLQTMTLEHVLRFLRRNAFILLTVSAVVIGVSLAFALRPYQLTYRQIKYFSFPGELLMRMLQMLVLPLIVSSLVTGMASLDNKATGRMGMRAAVYYMVTTIIAVFIGILMVTIIHPGKGSKEGLHREGRIETIPTADAFMDLIRNMFPPNLVEACFKQFKTQYSTRVVTRTMVRTENGSEPGASMPPPFSVENGTSFLENVTRALGTLQEMLSFEETVPVPGSANGINALGLVVFSVAFGLVIGGMKHKGRVLRDFFDSLNEAIMRLVGIIIWYAPVGILFLIAGKILEMEDMAVLGGQLGMYTLTVIVGLFLHAGIVLPLIYFLVTHRNPFPFIGGMLQALITAMGTSSSSATLPITFRCLEEGLGVDRRITRFVLPVGATVNMDGTALYEALAAIFIAQVNNYELNLGQITTISITATAASVGAAGIPQAGLVTMVIVLTSVGLPTEDITLIIAVDWFLDRLRTMTNVLGDSIGAAVIEHLSQRELELQEAELTLPSLGKPYKSLMAQEKGASRGRGGNESAM T30163 DRUGINFO D04MSI threo-3-methylglutamate Investigative T30163 DRUGINFO D07CIW [3H]ETB-TBOA Investigative T30163 DRUGINFO D07GUB DL-TBOA Investigative T30163 DRUGINFO D08CAB D-aspartic acid Investigative T97135 TARGETID T97135 T97135 FORMERID TTDI02532 T97135 UNIPROID NEST_HUMAN T97135 TARGNAME Nestin (NES) T97135 GENENAME NES T97135 TARGTYPE Literature-reported T97135 SYNONYMS Nbla00170 T97135 FUNCTION Promotes the disassembly of phosphorylated vimentin intermediate filaments (IF) during mitosis and may play a role in the trafficking and distribution of IF proteins and other cellular factors to daughter cells during progenitor cell division. Required for survival, renewal and mitogen-stimulated proliferation of neural progenitor cells. Required for brain and eye development. T97135 SEQUENCE MEGCMGEESFQMWELNRRLEAYLARVKALEEQNELLSAELGGLRAQSADTSWRAHADDELAALRALVDQRWREKHAAEVARDNLAEELEGVAGRCQQLRLARERTTEEVARNRRAVEAEKCARAWLSSQVAELERELEALRVAHEEERVGLNAQAACAPRCPAPPRGPPAPAPEVEELARRLGEAWRGAVRGYQERVAHMETSLGQARERLGRAVQGAREGRLELQQLQAERGGLLERRAALEQRLEGRWQERLRATEKFQLAVEALEQEKQGLQSQIAQVLEGRQQLAHLKMSLSLEVATYRTLLEAENSRLQTPGGGSKTSLSFQDPKLELQFPRTPEGRRLGSLLPVLSPTSLPSPLPATLETPVPAFLKNQEFLQARTPTLASTPIPPTPQAPSPAVDAEIRAQDAPLSLLQTQGGRKQAPEPLRAEARVAIPASVLPGPEEPGGQRQEASTGQSPEDHASLAPPLSPDHSSLEAKDGESGGSRVFSICRGEGEGQIWGLVEKETAIEGKVVSSLQQEIWEEEDLNRKEIQDSQVPLEKETLKSLGEEIQESLKTLENQSHETLERENQECPRSLEEDLETLKSLEKENKELLKDVEVVRPLEKEAVGQLKPTGKEDTQTLQSLQKENQELMKSLEGNLETFLFPGTENQELVSSLQENLESLTALEKENQEPLRSPEVGDEEALRPLTKENQEPLRSLEDENKEAFRSLEKENQEPLKTLEEEDQSIVRPLETENHKSLRSLEEQDQETLRTLEKETQQRRRSLGEQDQMTLRPPEKVDLEPLKSLDQEIARPLENENQEFLKSLKEESVEAVKSLETEILESLKSAGQENLETLKSPETQAPLWTPEEINQGAMNPLEKEIQEPLESVEVNQETFRLLEEENQESLRSLGAWNLENLRSPEEVDKESQRNLEEEENLGKGEYQESLRSLEEEGQELPQSADVQRWEDTVEKDQELAQESPPGMAGVENEDEAELNLREQDGFTGKEEVVEQGELNATEEVWIPGEGHPESPEPKEQRGLVEGASVKGGAEGLQDPEGQSQQVGAPGLQAPQGLPEAIEPLVEDDVAPGGDQASPEVMLGSEPAMGESAAGAEPGPGQGVGGLGDPGHLTREEVMEPPLEEESLEAKRVQGLEGPRKDLEEAGGLGTEFSELPGKSRDPWEPPREGREESEAEAPRGAEEAFPAETLGHTGSDAPSPWPLGSEEAEEDVPPVLVSPSPTYTPILEDAPGPQPQAEGSQEASWGVQGRAEALGKVESEQEELGSGEIPEGPQEEGEESREESEEDELGETLPDSTPLGFYLRSPTSPRWDPTGEQRPPPQGETGKEGWDPAVLASEGLEAPPSEKEEGEEGEEECGRDSDLSEEFEDLGTEAPFLPGVPGEVAEPLGQVPQLLLDPAAWDRDGESDGFADEEESGEEGEEDQEEGREPGAGRWGPGSSVGSLQALSSSQRGEFLESDSVSVSVPWDDSLRGAVAGAPKTALETESQDSAEPSGSEEESDPVSLEREDKVPGPLEIPSGMEDAGPGADIIGVNGQGPNLEGKSQHVNGGVMNGLEQSEEVGQGMPLVSEGDRGSPFQEEEGSALKTSWAGAPVHLGQGQFLKFTQREGDRESWSSGED T93580 TARGETID T93580 T93580 FORMERID TTDI03512 T93580 UNIPROID RGS4_HUMAN T93580 TARGNAME Regulator of G-protein signaling 4 (RGS4) T93580 GENENAME RGS4 T93580 TARGTYPE Literature-reported T93580 SYNONYMS RGP4 T93580 FUNCTION Activity on G(z)-alpha is inhibited by phosphorylation of the G-protein. Activity on G(z)-alpha and G(i)-alpha-1 is inhibited by palmitoylation of the G-protein. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form. T93580 SEQUENCE MCKGLAGLPASCLRSAKDMKHRLGFLLQKSDSCEHNSSHNKKDKVVICQRVSQEEVKKWAESLENLISHECGLAAFKAFLKSEYSEENIDFWISCEEYKKIKSPSKLSPKAKKIYNEFISVQATKEVNLDSCTREETSRNMLEPTITCFDEAQKKIFNLMEKDSYRRFLKSRFYLDLVNPSSCGAEKQKGAKSSADCASLVPQCA T93580 DRUGINFO D05AMQ thiadiazolidinone (TDZD) deriv. 6 Investigative T93580 DRUGINFO D0C2GR CCG-50014 Investigative T93580 DRUGINFO D0M5DR RGS4 inhibitor 13 Investigative T16459 TARGETID T16459 T16459 FORMERID TTDR00475 T16459 UNIPROID CDN1C_HUMAN T16459 TARGNAME CDK inhibitor 1C p57Kip2 (CDKN1C) T16459 GENENAME CDKN1C T16459 TARGTYPE Literature-reported T16459 SYNONYMS P57KIP2; P57(KIP2); KIP2; Cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase inhibitor 1C T16459 FUNCTION Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life. Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. T16459 SEQUENCE MSDASLRSTSTMERLVARGTFPVLVRTSACRSLFGPVDHEELSRELQARLAELNAEDQNRWDYDFQQDMPLRGPGRLQWTEVDSDSVPAFYRETVQVGRCRLLLAPRPVAVAVAVSPPLEPAAESLDGLEEAPEQLPSVPVPAPASTPPPVPVLAPAPAPAPAPVAAPVAAPVAVAVLAPAPAPAPAPAPAPAPVAAPAPAPAPAPAPAPAPAPAPDAAPQESAEQGANQGQRGQEPLADQLHSGISGRPAAGTAAASANGAAIKKLSGPLISDFFAKRKRSAPEKSSGDVPAPCPSPSAAPGVGSVEQTPRKRLR T12290 TARGETID T12290 T12290 FORMERID TTDR00985 T12290 UNIPROID GNAQ_HUMAN T12290 TARGNAME Guanine nucleotide-binding alpha-q (GNAQ) T12290 GENENAME GNAQ T12290 TARGTYPE Literature-reported T12290 SYNONYMS GNAQ; G alphaq; G alpha(q) T12290 FUNCTION Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. Regulates B-cell selection and survival and is required to prevent B-cell-dependent autoimmunity. Regulates chemotaxis of BM-derived neutrophils and dendritic cells (in vitro). T12290 SEQUENCE MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKSTFIKQMRIIHGSGYSDEDKRGFTKLVYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKVSAFENPYVDAIKSLWNDPGIQECYDRRREYQLSDSTKYYLNDLDRVADPAYLPTQQDVLRVRVPTTGIIEYPFDLQSVIFRMVDVGGQRSERRKWIHCFENVTSIMFLVALSEYDQVLVESDNENRMEESKALFRTIITYPWFQNSSVILFLNKKDLLEEKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATDTENIRFVFAAVKDTILQLNLKEYNLV T56104 TARGETID T56104 T56104 FORMERID TTDR01299 T56104 UNIPROID SERPH_HUMAN T56104 TARGNAME Rheumatoid arthritis-related antigen RA-A47 (SERPINH1) T56104 GENENAME SERPINH1 T56104 TARGTYPE Literature-reported T56104 SYNONYMS Serpin H1; SERPINH2; PIG14; HSP47; Colligin; Collagen-binding protein; Cell proliferation-inducing gene 14 protein; CBP2; CBP1; AsTP3; Arsenic-transactivated protein 3; 47 kDa heat shock protein T56104 FUNCTION Binds specifically to collagen. Could be involved as a chaperone in the biosynthetic pathway of collagen. T56104 SEQUENCE MRSLLLLSAFCLLEAALAAEVKKPAAAAAPGTAEKLSPKAATLAERSAGLAFSLYQAMAKDQAVENILVSPVVVASSLGLVSLGGKATTASQAKAVLSAEQLRDEEVHAGLGELLRSLSNSTARNVTWKLGSRLYGPSSVSFADDFVRSSKQHYNCEHSKINFRDKRSALQSINEWAAQTTDGKLPEVTKDVERTDGALLVNAMFFKPHWDEKFHHKMVDNRGFMVTRSYTVGVMMMHRTGLYNYYDDEKEKLQIVEMPLAHKLSSLIILMPHHVEPLERLEKLLTKEQLKIWMGKMQKKAVAISLPKGVVEVTHDLQKHLAGLGLTEAIDKNKADLSRMSGKKDLYLASVFHATAFELDTDGNPFDQDIYGREELRSPKLFYADHPFIFLVRDTQSGSLLFIGRLVRPKGDKMRDEL T69091 TARGETID T69091 T69091 FORMERID TTDI03435 T69091 UNIPROID P2RX1_HUMAN T69091 TARGNAME P2X purinoceptor 1 (P2RX1) T69091 GENENAME P2RX1 T69091 TARGTYPE Literature-reported T69091 SYNONYMS Purinergic receptor 1; P2X1 T69091 FUNCTION Ligand-gated ion channel with relatively high calcium permeability. Binding to ATP mediates synaptic transmission between neurons and from neurons to smooth muscle. Seems to be linked to apoptosis, by increasing the intracellular concentration of calcium in the presence of ATP, leading to programmed cell death (By similarity). T69091 SEQUENCE MARRFQEELAAFLFEYDTPRMVLVRNKKVGVIFRLIQLVVLVYVIGWVFLYEKGYQTSSGLISSVSVKLKGLAVTQLPGLGPQVWDVADYVFPAQGDNSFVVMTNFIVTPKQTQGYCAEHPEGGICKEDSGCTPGKAKRKAQGIRTGKCVAFNDTVKTCEIFGWCPVEVDDDIPRPALLREAENFTLFIKNSISFPRFKVNRRNLVEEVNAAHMKTCLFHKTLHPLCPVFQLGYVVQESGQNFSTLAEKGGVVGITIDWHCDLDWHVRHCRPIYEFHGLYEEKNLSPGFNFRFARHFVENGTNYRHLFKVFGIRFDILVDGKAGKFDIIPTMTTIGSGIGIFGVATVLCDLLLLHILPKRHYYKQKKFKYAEDMGPGAAERDLAATSSTLGLQENMRTS T69091 DRUGINFO D03EEO MRS 2219 Investigative T69091 DRUGINFO D0B7MW NF023 Investigative T69091 DRUGINFO D0D9AA NF449 Investigative T69091 DRUGINFO D0Q1BD Ip5I Investigative T69091 DRUGINFO D01VVM TNP-ATP Investigative T69091 DRUGINFO D06HDW BzATP Investigative T69091 DRUGINFO D0UG4S L-betagamma-meATP Investigative T48166 TARGETID T48166 T48166 FORMERID TTDI00152 T48166 UNIPROID HMGA2_HUMAN T48166 TARGNAME High mobility group protein HMGI-C (HMGA2) T48166 GENENAME HMGA2 T48166 TARGTYPE Literature-reported T48166 SYNONYMS High mobility group AThook protein 2; High mobility group AT-hook protein 2; HMGIC T48166 FUNCTION Functions in cell cycle regulation through CCNA2. Plays an important role in chromosome condensation during the meiotic G2/M transition of spermatocytes. Plays a role in postnatal myogenesis, is involved in satellite cell activation. Functions as a transcriptional regulator. T48166 SEQUENCE MSARGEGAGQPSTSAQGQPAAPAPQKRGRGRPRKQQQEPTGEPSPKRPRGRPKGSKNKSPSKAAQKKAEATGEKRPRGRPRKWPQQVVQKKPAQEETEETSSQESAEED T06064 TARGETID T06064 T06064 FORMERID TTDI03375 T06064 UNIPROID TXTP_HUMAN T06064 TARGNAME Mitochondrial citrate transporter (SLC25A1) T06064 GENENAME SLC25A1 T06064 TARGTYPE Literature-reported T06064 SYNONYMS Tricarboxylate transport protein, mitochondrial; Tricarboxylate carrier protein; Solute carrier family 25 member 1; SLC20A3; Citrate transport protein; CTP T06064 FUNCTION Citrate transporter that mediates the exchange of mitochondrial citrate for cytosolic malate. Also able to mediate the exchange of citrate for isocitrate, phosphoenolpyruvate, cis- but not trans-aconitate and to a lesser extend maleate and succinate. Important for the bioenergetics of hepatic cells as it provides a carbon source for fatty acid and sterol biosyntheses, and NAD(+) for the glycolytic pathway. Required for proper neuromuscular junction formation (Probable). T06064 SEQUENCE MPAPRAPRALAAAAPASGKAKLTHPGKAILAGGLAGGIEICITFPTEYVKTQLQLDERSHPPRYRGIGDCVRQTVRSHGVLGLYRGLSSLLYGSIPKAAVRFGMFEFLSNHMRDAQGRLDSTRGLLCGLGAGVAEAVVVVCPMETIKVKFIHDQTSPNPKYRGFFHGVREIVREQGLKGTYQGLTATVLKQGSNQAIRFFVMTSLRNWYRGDNPNKPMNPLITGVFGAIAGAASVFGNTPLDVIKTRMQGLEAHKYRNTWDCGLQILKKEGLKAFYKGTVPRLGRVCLDVAIVFVIYDEVVKLLNKVWKTD T06064 DRUGINFO D05UYC 1,2,3-benzenetricarboxylic acid Investigative T59690 TARGETID T59690 T59690 FORMERID TTDR00628 T59690 UNIPROID MNN9_CANAL T59690 TARGNAME Candida Mannan polymerase complex MNN9 (Candi MNN9) T59690 GENENAME Candi MNN9 T59690 TARGTYPE Literature-reported T59690 SYNONYMS MNN9; C. albicans MNN9 T59690 FUNCTION Required for the addition of the long alpha 1,6-mannose backbone ofN-linked glycans on cell wall and periplasmic proteins. T59690 SEQUENCE MVHYRNRYLNYIRRKPLALLAPITLLVVIYFYFFSAHGFSSNKQKYNYNKKSRGWFYKNRDTVILKDLPKNHISHYDLNKLTASKDALNKREEVLILTPMSKFLPEYWENINKLTYDHSLISLGFIFPRTTQGDDALKELENALKKTKREKRLNFKKITILRQDSNSLQSQLEKDRHAFKVQKERRSMMALARNSLVFSTILPSTSWVLWLDADIVETPVTLIQDLTGHNKPVVSANVHQRFINQDTKQPDIRPYDFNNWVESEEGLKLAASLPDDEIIVEGYSEMVTHRALMAHFYDPKGDPSTEMTLDGVGGGAVMVKADVHRDGAMFPSFPFYHLIETEGFAKMAKRLGYEVYGLPNYLVFHYNE T90652 TARGETID T90652 T90652 UNIPROID SYRC_HUMAN-MD1L1_HUMAN T90652 TARGNAME Fusion protein RARS-MAD1L1 (RARS-MAD1L1) T90652 GENENAME RARS-MAD1L1 T90652 TARGTYPE Literature-reported T90652 SYNONYMS Fusion protein CArginyl-tRNA synthetase and MAD1-like protein 1 T90652 FUNCTION RARS-MAD1L1 overexpression increased cell proliferation, colony formation, and tumorigenicity in vitro, and the silencing of endogenous RARS-MAD1L1 reduced cancer cell growth and colony formation in vitro. In addition, RARS-MAD1L1 increased the side population (SP) ratio and induced chemo- and radioresistance. Furthermore RARS-MAD1L1 interacted with AIMP2, which resulted in activation of FUBP1/c-Myc pathway. T90652 SEQUENCE MEDLGENTMVLSTLRSLNNFISQRVEGGSGLDISTSAPGSLQMQYQQSMQLEERAEQIRSKSHLIQVEREKMQMELSHKRARVELERAASTSARNYEREVDRNQELLTRIRQLQEREAGAEEKMQEQLERNRQCQQNLDAASKRLREKEDSLAQAGETINALKGRISELQWSVMDQEMRVKRLESEKQELQEQLDLQHKKCQEANQKIQELQASQEARADHEQQIKDLEQKLSLQEQDAAIVKNMKSELVRLPRLERELKQLREESAHLREMRETNGLLQEELEGLQRKLGRQEKMQETLVGLELENERLLAKLQSWERLDQTMGLSIRTPEDLSRFVVELQQRELALKDKNSAVTSSARGLEKARQQLQEELRQVSGQLLEERKKRETHEALARRLQKRVLLLTKERDGMRAILGSYDSELTPAEYSPQLTRRMREAEDMVQKVHSHSAEMEAQLSQALEELGGQKQRADMLEMELKMLKSQSSSAEQSFLFSREEADTLRLKVEELEGERSRLEEEKRMLEAQLERRALQGDYDQSRTKVLHMSLNPTSVARQRLREDHSQLQAECERLRGLLRAMERGGTVPADLEAAAASLPSSKEVAELKKQVESAELKNQRLKEVFQTKIQEFRKACYTLTGYQIDITTENQYRLTSLYAEHPGDCLIFKATSPSGSKMQLLETEFSHTVGELIEVHLRRQDSIPAFLSSLTLELFSRQTVAMDVLVSECSARLLQQEEEIKSLTAEIDRLKNCGCLGASPNLEQLQEENLKLKYRLNILRKSLQAERNKPTKNMINIISRLQEVFGHAIKAAYPDLENPPLLVTPSQQAKFGDYQCNSAMGISQMLKTKEQKVNPREIAENITKHLPDNECIEKVEIAGPGFINVHLRKDFVSEQLTSLLVNGVQLPALGENKKVIVDFSSPNIAKEMHVGHLRSTIIGESISRLFEFAGYDVLRLNHVGDWGTQFGMLIAHLQDKFPDYLTVSPPIGDLQVFYKESKKRFDTEEEFKKRAYQCVVLLQGKNPDITKAWKLICDVSRQELNKIYDALDVSLIERGESFYQDRMNDIVKEFEDRGFVQVDDGRKIVFVPGCSIPLTIVKSDGGYTYDTSDLAAIKQRLFEEKADMIIYVVDNGQSVHFQTIFAAAQMIGWYDPKVTRVFHAGFGVVLGEDKKKFKTRSGETVRLMDLLGEGLKRSMDKLKEKERDKVLTAEELNAAQTSVAYGCIKYADLSHNRLNDYIFSFDKMLDDRGNTAAYLLYAFTRIRSIARLANIDEEMLQKAARETKILLDHEKEWKLGRCILRFPEILQKILDDLFLHTLCDYIYELATAFTEFYDSCYCVEKDRQTGKILKVNMWRMLLCEAVAAVMAKGFDILGIKPVQRM T05324 TARGETID T05324 T05324 FORMERID TTDNR00672 T05324 UNIPROID XPO2_HUMAN T05324 TARGNAME Exportin-2 (CSE1L) T05324 GENENAME CSE1L T05324 TARGTYPE Literature-reported T05324 SYNONYMS Importin-alpha re-exporter; Exp2; Chromosome segregation 1-like protein; Cellular apoptosis susceptibility protein; CSE1L T05324 FUNCTION Export receptor for importin-alpha. Mediates importin- alpha re-export fromthe nucleus to the cytoplasm after import substrates (cargos) have been released into the nucleoplasm. In the nucleus binds cooperatively to importin-alpha and to the GTPase Ran in its active GTP-bound form. Docking of this trimeric complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the importin-alpha from the export receptor. CSE1L/XPO2 then return to the nuclear compartment and mediate another round of transport. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasmand nucleus. . T05324 SEQUENCE MELSDANLQTLTEYLKKTLDPDPAIRRPAEKFLESVEGNQNYPLLLLTLLEKSQDNVIKVCASVTFKNYIKRNWRIVEDEPNKICEADRVAIKANIVHLMLSSPEQIQKQLSDAISIIGREDFPQKWPDLLTEMVNRFQSGDFHVINGVLRTAHSLFKRYRHEFKSNELWTEIKLVLDAFALPLTNLFKATIELCSTHANDASALRILFSSLILISKLFYSLNFQDLPEFFEDNMETWMNNFHTLLTLDNKLLQTDDEEEAGLLELLKSQICDNAALYAQKYDEEFQRYLPRFVTAIWNLLVTTGQEVKYDLLVSNAIQFLASVCERPHYKNLFEDQNTLTSICEKVIVPNMEFRAADEEAFEDNSEEYIRRDLEGSDIDTRRRAACDLVRGLCKFFEGPVTGIFSGYVNSMLQEYAKNPSVNWKHKDAAIYLVTSLASKAQTQKHGITQANELVNLTEFFVNHILPDLKSANVNEFPVLKADGIKYIMIFRNQVPKEHLLVSIPLLINHLQAESIVVHTYAAHALERLFTMRGPNNATLFTAAEIAPFVEILLTNLFKALTLPGSSENEYIMKAIMRSFSLLQEAIIPYIPTLITQLTQKLLAVSKNPSKPHFNHYMFEAICLSIRITCKANPAAVVNFEEALFLVFTEILQNDVQEFIPYVFQVMSLLLETHKNDIPSSYMALFPHLLQPVLWERTGNIPALVRLLQAFLERGSNTIASAAADKIPGLLGVFQKLIASKANDHQGFYLLNSIIEHMPPESVDQYRKQIFILLFQRLQNSKTTKFIKSFLVFINLYCIKYGALALQEIFDGIQPKMFGMVLEKIIIPEIQKVSGNVEKKICAVGITKLLTECPPMMDTEYTKLWTPLLQSLIGLFELPEDDTIPDEEHFIDIEDTPGYQTAFSQLAFAGKKEHDPVGQMVNNPKIHLAQSLHKLSTACPGRVPSMVSTSLNAEALQYLQGYLQAASVTLL T29594 TARGETID T29594 T29594 FORMERID TTDR00915 T29594 UNIPROID BI1_HUMAN T29594 TARGNAME Testis-enhanced gene transcript protein (TMBIM6) T29594 GENENAME TMBIM6 T29594 TARGTYPE Literature-reported T29594 SYNONYMS Testis enhanced gene transcript; TMBIM6; BI-1 T29594 FUNCTION Suppressor of apoptosis. Modulates unfolded protein response signaling. Modulate ER calcium homeostasis by acting as a calcium-leak channel. T29594 SEQUENCE MNIFDRKINFDALLKFSHITPSTQQHLKKVYASFALCMFVAAAGAYVHMVTHFIQAGLLSALGSLILMIWLMATPHSHETEQKRLGLLAGFAFLTGVGLGPALEFCIAVNPSILPTAFMGTAMIFTCFTLSALYARRRSYLFLGGILMSALSLLLLSSLGNVFFGSIWLFQANLYVGLVVMCGFVLFDTQLIIEKAEHGDQDYIWHCIDLFLDFITVFRKLMMILAMNEKDKKKEKK T60042 TARGETID T60042 T60042 FORMERID TTDR00438 T60042 UNIPROID MAZ_HUMAN T60042 TARGNAME Serum amyloid A-activating factor-1 (MAZ) T60042 GENENAME MAZ T60042 TARGTYPE Literature-reported T60042 SYNONYMS Zinc finger protein 801; ZNF801; ZF87; Transcription factor Zif87; SAF-1; Purine-binding transcription factor; Pur-1; Myc-associated zinc finger protein; MAZI T60042 FUNCTION May function as a transcription factor with dual roles in transcription initiation and termination. Binds to two sites, ME1a1 and ME1a2, within the MYC promoter having greater affinity for the former. Also binds to multiple G/C-rich sites within the promoter of the Sp1 family of transcription factors. Regulates inflammation-induced expression of serum amyloid A proteins. T60042 SEQUENCE MFPVFPCTLLAPPFPVLGLDSRGVGGLMNSFPPPQGHAQNPLQVGAELQSRFFASQGCAQSPFQAAPAPPPTPQAPAAEPLQVDLLPVLAAAQESAAAAAAAAAAAAAVAAAPPAPAAASTVDTAALKQPPAPPPPPPPVSAPAAEAAPPASAATIAAAAATAVVAPTSTVAVAPVASALEKKTKSKGPYICALCAKEFKNGYNLRRHEAIHTGAKAGRVPSGAMKMPTMVPLSLLSVPQLSGAGGGGGEAGAGGGAAAVAAGGVVTTTASGKRIRKNHACEMCGKAFRDVYHLNRHKLSHSDEKPYQCPVCQQRFKRKDRMSYHVRSHDGAVHKPYNCSHCGKSFSRPDHLNSHVRQVHSTERPFKCEKCEAAFATKDRLRAHTVRHEEKVPCHVCGKMLSSAYISDHMKVHSQGPHHVCELCNKGTGEVCPMAAAAAAAAAAAAAAVAAPPTAVGSLSGAEGVPVSSQPLPSQPW T45357 TARGETID T45357 T45357 FORMERID TTDI02641 T45357 UNIPROID BTG1_HUMAN T45357 TARGNAME B-cell translocation gene 1 protein (BTG1) T45357 GENENAME BTG1 T45357 TARGTYPE Literature-reported T45357 SYNONYMS Protein BTG1 T45357 FUNCTION Anti-proliferative protein. T45357 SEQUENCE MHPFYTRAATMIGEIAAAVSFISKFLRTKGLTSERQLQTFSQSLQELLAEHYKHHWFPEKPCKGSGYRCIRINHKMDPLIGQAAQRIGLSSQELFRLLPSELTLWVDPYEVSYRIGEDGSICVLYEASPAGGSTQNSTNVQMVDSRISCKEELLLGRTSPSKNYNMMTVSG T72269 TARGETID T72269 T72269 FORMERID TTDR01290 T72269 UNIPROID EF1A1_HUMAN; EF1A2_HUMAN T72269 TARGNAME Elongation factor 1A (EF1A) T72269 GENENAME EEF1A1; EEF1A2 T72269 TARGTYPE Literature-reported T72269 SYNONYMS eEF1A; Eukaryotic elongation factor 1 A; Elongation factor 1-alpha; Elongation factor; EF-1-alpha T72269 FUNCTION This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. T72269 SEQUENCE MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVLDKLKAERERGITIDISLWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAAGVGEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPPYSQKRYEEIVKEVSTYIKKIGYNPDTVAFVPISGWNGDNMLEPSANMPWFKGWKVTRKDGNASGTTLLEALDCILPPTRPTDKPLRLPLQDVYKIGGIGTVPVGRVETGVLKPGMVVTFAPVNVTTEVKSVEMHHEALSEALPGDNVGFNVKNVSVKDVRRGNVAGDSKNDPPMEAAGFTAQVIILNHPGQISAGYAPVLDCHTAHIACKFAELKEKIDRRSGKKLEDGPKFLKSGDAAIVDMVPGKPMCVESFSDYPPLGRFAVRDMRQTVAVGVIKAVDKKAAGAGKVTKSAQKAQKAK T72269 DRUGINFO D0OQ1I Narciclasine Investigative T23311 TARGETID T23311 T23311 FORMERID TTDI03208 T23311 UNIPROID GBRE_HUMAN T23311 TARGNAME GABA(A) receptor epsilon (GABRE) T23311 GENENAME GABRE T23311 TARGTYPE Literature-reported T23311 SYNONYMS Gamma-aminobutyric acid receptor subunit epsilon; GABA(A) receptor subunit epsilon T23311 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. T23311 SEQUENCE MLSKVLPVLLGILLILQSRVEGPQTESKNEASSRDVVYGPQPQPLENQLLSEETKSTETETGSRVGKLPEASRILNTILSNYDHKLRPGIGEKPTVVTVEISVNSLGPLSILDMEYTIDIIFSQTWYDERLCYNDTFESLVLNGNVVSQLWIPDTFFRNSKRTHEHEITMPNQMVRIYKDGKVLYTIRMTIDAGCSLHMLRFPMDSHSCPLSFSSFSYPENEMIYKWENFKLEINEKNSWKLFQFDFTGVSNKTEIITTPVGDFMVMTIFFNVSRRFGYVAFQNYVPSSVTTMLSWVSFWIKTESAPARTSLGITSVLTMTTLGTFSRKNFPRVSYITALDFYIAICFVFCFCALLEFAVLNFLIYNQTKAHASPKLRHPRINSRAHARTRARSRACARQHQEAFVCQIVTTEGSDGEERPSCSAQQPPSPGSPEGPRSLCSKLACCEWCKRFKKYFCMVPDCEGSTWQQGRLCIHVYRLDNYSRVVFPVTFFFFNVLYWLVCLNL T23311 DRUGINFO D0P0TI TBPS Investigative T90665 TARGETID T90665 T90665 UNIPROID DLG4_HUMAN-NOS1_HUMAN T90665 TARGNAME PSD95-nNOS interaction (PSD95-nNOS PPI) T90665 GENENAME DLG4-NOS1 T90665 TARGTYPE Literature-reported T90665 SYNONYMS Disks large homolog 4-Constitutive NOS interaction T90665 FUNCTION Functions as a novel molecular target to modulate conditioned fear: relevance to PTSD. T90665 SEQUENCE MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQAGDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTIRVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAPRPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQVDRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANNSLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFVRLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGVISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEYEEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIVSYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSSMDCLCIVTTKKYRYQDEDTPPLEHSPAHLPNQANSPPVIVNTDTLEAPGYELQVNGTEGEMEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRLRVNDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIKLIKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAVNSVGLEDVMHEDAVAALKNTYDVVYLKVAKPSNAYLSDSYAPPDITTSYSQHLDNEISHSSYLGTDYPTAMTPTSPRRYSPVAKDLLGEEDIPREPRRIVIHRGSTGLGFNIVGGEDGEGIFISFILAGGPADLSGELRKGDQILSVNGVDLRNASHEQAAIALKNAGQTVTIIAQYKPEEYSRFEAKIHDLREQLMNSSLGSGTASLRSNPKRGFYIRALFDYDKTKDCGFLSQALSFRFGDVLHVIDASDEEWWQARRVHSDSETDDIGFIPSKRRVERREWSRLKAKDWGSSSGSQGREDSVLSYETVTQMEVHYARPIIILGPTKDRANDDLLSEFPDKFGSCVPHTTRPKREYEIDGRDYHFVSSREKMEKDIQAHKFIEAGQYNSHLYGTSVQSVREVAEQGKHCILDVSANAVRRLQAAHLHPIAIFIRPRSLENVLEINKRITEEQARKAFDRATKLEQEFTECFSAIVEGDSFEEIYHKVKRVIEDLSGPYIWVPARERL T90665 DRUGINFO D00SBX ZL006 Investigative T37328 TARGETID T37328 T37328 FORMERID TTDR00599 T37328 UNIPROID P90582_PLAFA T37328 TARGNAME Plasmodium Histidine-rich protein II (Malaria HRP II) T37328 GENENAME Malaria HRP II T37328 TARGTYPE Literature-reported T37328 SYNONYMS Histidine-rich protein II T37328 FUNCTION Functions as a diagnostic and prognostic marker for falciparum malaria. T37328 SEQUENCE MVSFSKNKVLSAAVFASVLLLDNNNSAFNNNLCSKNAKGLNLNKRLLHETQAHVDDAHHAHHVADAHHAHHAADAHHAHHAADAHHAHHAADAHHAHHAADAHHAHHAAYAHHAHHAADAHHAHHASDAHHAADAHHAAYAHHAHHAADAHHAHHASDAHHAADAHHAAYAHHAHHAADAHHAADAHHATDAHHAHHAADARHATDAHHAADAHHATDAHHAADAHHAADAHHATDAHHAADAHHATDAHHAADAHHAADAHHATDAHHAHHAADAHHAAAHHATDAHHATDAHHAAAHHEAATHCLRH T26381 TARGETID T26381 T26381 FORMERID TTDI00239 T26381 UNIPROID PIMA_MYCTU T26381 TARGNAME Mycobacterium Phosphatidyl-myo-inositol mannosyltransferase (MycB pimA) T26381 GENENAME MycB pimA T26381 TARGTYPE Literature-reported T26381 SYNONYMS Phosphatidylinositol alpha-mannosyltransferase; Phosphatidyl-myo-inositol mannosyltransferase; PI alpha-mannosyltransferase; Guanosine diphosphomannose-phosphatidyl-inositol alpha-mannosyltransferase; GDP-mannose-dependent alpha-(1-2)-phosphatidylinositol mannosyltransferase; Alpha-mannosyltransferase T26381 FUNCTION Involved in the biosynthesis of phosphatidyl-myo-inositol mannosides (PIM) which are early precursors in the biosynthesis of lipomannans (LM) and lipoarabinomannans (LAM). Catalyzes the addition of a mannosyl residue from GDP-D-mannose (GDP-Man) to the position 2 of the carrier lipid phosphatidyl-myo-inositol (PI) to generate a phosphatidyl-myo-inositol bearing an alpha-1,2-linked mannose residue (PIM1). PimA plays an essential role for growth in macrophages and during both the acute and chronic phases of infection. T26381 SEQUENCE MRIGMICPYSFDVPGGVQSHVLQLAEVMRTRGHLVSVLAPASPHAALPDYFVSGGRAVPIPYNGSVARLRFGPATHRKVKKWLAHGDFDVLHLHEPNAPSLSMLALNIAEGPIVATFHTSTTKSLTLTVFQGILRPMHEKIVGRIAVSDLARRWQMEALGSDAVEIPNGVDVDSFASAARLDGYPRQGKTVLFLGRYDEPRKGMAVLLDALPKVVQRFPDVQLLIVGHGDADQLRGQAGRLAAHLRFLGQVDDAGKASAMRSADVYCAPNTGGESFGIVLVEAMAAGTAVVASDLDAFRRVLRDGEVGHLVPVDPPDLQAAALADGLIAVLENDVLRERYVAAGNAAVRRYDWSVVASQIMRVYETVAGSGAKVQVAS T17362 TARGETID T17362 T17362 FORMERID TTDR01181 T17362 UNIPROID Q01680_PNECA T17362 TARGNAME Fungal Plasma membrane H(+)-ATPase (Fung pma) T17362 GENENAME Fung pma T17362 TARGTYPE Literature-reported T17362 SYNONYMS Plasma membrane H(+)-ATPase T17362 FUNCTION Essential to fungal cell physiology, being required for the formation of a large electrochemical proton gradient and the maintenance of intracellular pH. T17362 SEQUENCE DDIDALIDDLESQDGDQEDNIEDTEFQSQRQVPEELLATDTRIGLTSQEVINRRKKYGLNKMKEEKENMIIKFLMYFVGPIQFVMEAAAILAAGLQDWVEFGVICALLLLNAFVGFIQEFQAGSIVDELKKTLALKATVLRDGRLIDIEAEEVVPGDILQLEEGSIVPADGRIVTEEAYLQVDQSAITGESLAVDIHKGDSIYSSSVAKPGETFMVVTATGDRT T65239 TARGETID T65239 T65239 FORMERID TTDI03027 T65239 UNIPROID RHAG_HUMAN T65239 TARGNAME Ammonium transporter Rh type A (RHAG) T65239 GENENAME RHAG T65239 TARGTYPE Literature-reported T65239 SYNONYMS Rhesus blood group-associated glycoprotein; Rhesus blood group-associated ammonia channel; Rhesus blood group family type A glycoprotein; Rh50A; Rh type A glycoprotein; Rh family type A glycoprotein; RH50; Erythrocyte plasma membrane 50 kDa glycoprotein; Erythrocyte membrane glycoprotein Rh50; CD241 T65239 FUNCTION Associated with rhesus blood group antigen expression. May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane. Involved in ammonia transport across the erythrocyte membrane. Seems to act in monovalent cation transport. T65239 SEQUENCE MRFTFPLMAIVLEIAMIVLFGLFVEYETDQTVLEQLNITKPTDMGIFFELYPLFQDVHVMIFVGFGFLMTFLKKYGFSSVGINLLVAALGLQWGTIVQGILQSQGQKFNIGIKNMINADFSAATVLISFGAVLGKTSPTQMLIMTILEIVFFAHNEYLVSEIFKASDIGASMTIHAFGAYFGLAVAGILYRSGLRKGHENEESAYYSDLFAMIGTLFLWMFWPSFNSAIAEPGDKQCRAIVNTYFSLAACVLTAFAFSSLVEHRGKLNMVHIQNATLAGGVAVGTCADMAIHPFGSMIIGSIAGMVSVLGYKFLTPLFTTKLRIHDTCGVHNLHGLPGVVGGLAGIVAVAMGASNTSMAMQAAALGSSIGTAVVGGLMTGLILKLPLWGQPSDQNCYDDSVYWKVPKTR T65239 DRUGINFO D0JS4B [14C]methylamine Investigative T04599 TARGETID T04599 T04599 FORMERID TTDR00991 T04599 UNIPROID IRF8_HUMAN T04599 TARGNAME Interferon consensus sequence binding protein (IRF8) T04599 GENENAME IRF8 T04599 TARGTYPE Literature-reported T04599 SYNONYMS Interferon regulatory factor 8; Interferon consensus sequence-binding protein; IRF-8; ICSBP1; ICSBP; H-ICSBP T04599 FUNCTION Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)). Plays a negative regulatory role in cells of the immune system. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF8 and activation of genes. Positively regulates macroautophagy in dendritic cells. Plays a role as a transcriptional activator or repressor. T04599 SEQUENCE MCDRNGGRRLRQWLIEQIDSSMYPGLIWENEEKSMFRIPWKHAGKQDYNQEVDASIFKAWAVFKGKFKEGDKAEPATWKTRLRCALNKSPDFEEVTDRSQLDISEPYKVYRIVPEEEQKCKLGVATAGCVNEVTEMECGRSEIDELIKEPSVDDYMGMIKRSPSPPEACRSQLLPDWWAQQPSTGVPLVTGYTTYDAHHSAFSQMVISFYYGGKLVGQATTTCPEGCRLSLSQPGLPGTKLYGPEGLELVRFPPADAIPSERQRQVTRKLFGHLERGVLLHSSRQGVFVKRLCQGRVFCSGNAVVCKGRPNKLERDEVVQVFDTSQFFRELQQFYNSQGRLPDGRVVLCFGEEFPDMAPLRSKLILVQIEQLYVRQLAEEAGKSCGAGSVMQAPEEPPPDQVFRMFPDICASHQRSFFRENQQITV T22547 TARGETID T22547 T22547 FORMERID TTDR01126 T22547 UNIPROID REL_HUMAN T22547 TARGNAME Proto-oncogene c-Rel (REL) T22547 GENENAME REL T22547 TARGTYPE Literature-reported T22547 SYNONYMS C-Rel T22547 FUNCTION NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator. Proto-oncogene that may play a role in differentiation and lymphopoiesis. T22547 SEQUENCE MASGAYNPYIEIIEQPRQRGMRFRYKCEGRSAGSIPGEHSTDNNRTYPSIQIMNYYGKGKVRITLVTKNDPYKPHPHDLVGKDCRDGYYEAEFGQERRPLFFQNLGIRCVKKKEVKEAIITRIKAGINPFNVPEKQLNDIEDCDLNVVRLCFQVFLPDEHGNLTTALPPVVSNPIYDNRAPNTAELRICRVNKNCGSVRGGDEIFLLCDKVQKDDIEVRFVLNDWEAKGIFSQADVHRQVAIVFKTPPYCKAITEPVTVKMQLRRPSDQEVSESMDFRYLPDEKDTYGNKAKKQKTTLLFQKLCQDHVETGFRHVDQDGLELLTSGDPPTLASQSAGITVNFPERPRPGLLGSIGEGRYFKKEPNLFSHDAVVREMPTGVSSQAESYYPSPGPISSGLSHHASMAPLPSSSWSSVAHPTPRSGNTNPLSSFSTRTLPSNSQGIPPFLRIPVGNDLNASNACIYNNADDIVGMEASSMPSADLYGISDPNMLSNCSVNMMTTSSDSMGETDNPRLLSMNLENPSCNSVLDPRDLRQLHQMSSSSMSAGANSNTTVFVSQSDAFEGSDFSCADNSMINESGPSNSTNPNSHGFVQDSQYSGIGSMQNEQLSDSFPYEFFQV T22284 TARGETID T22284 T22284 FORMERID TTDR00779 T22284 UNIPROID ICA69_HUMAN T22284 TARGNAME Islet cell autoantigen p69 (ICA1) T22284 GENENAME ICA1 T22284 TARGTYPE Literature-reported T22284 SYNONYMS P69; Islet cell autoantigen 1; ICAp69; ICA69; ICA1 T22284 FUNCTION May play a role in neurotransmitter secretion. T22284 SEQUENCE MSGHKCSYPWDLQDRYAQDKSVVNKMQQKYWETKQAFIKATGKKEDEHVVASDADLDAKLELFHSIQRTCLDLSKAIVLYQKRICFLSQEENELGKFLRSQGFQDKTRAGKMMQATGKALCFSSQQRLALRNPLCRFHQEVETFRHRAISDTWLTVNRMEQCRTEYRGALLWMKDVSQELDPDLYKQMEKFRKVQTQVRLAKKNFDKLKMDVCQKVDLLGASRCNLLSHMLATYQTTLLHFWEKTSHTMAAIHESFKGYQPYEFTTLKSLQDPMKKLVEKEEKKKINQQESTDAAVQEPSQLISLEEENQRKESSSFKTEDGKSILSALDKGSTHTACSGPIDELLDMKSEEGACLGPVAGTPEPEGADKDDLLLLSEIFNASSLEEGEFSKEWAAVFGDGQVKEPVPTMALGEPDPKAQTGSGFLPSQLLDQNMKDLQASLQEPAKAASDLTAWFSLFADLDPLSNPDAVGKTDKEHELLNA T90408 TARGETID T90408 T90408 UNIPROID VP30_EBOZM-NCAP_EBOZM T90408 TARGNAME Ebola virus VP30-NP interaction (EV VP30-NP PPI) T90408 GENENAME EV VP30-NP PPI T90408 TARGTYPE Literature-reported T90408 SYNONYMS Ebola VP30-Nucleocapsid protein interaction T90408 FUNCTION Plays both essential and inhibitory roles in Ebola virus RNA synthesis. T90408 SEQUENCE MEASYERGRPRAARQHSRDGHDHHVRARSSSRENYRGEYRQSRSASQVRVPTVFHKKRVEPLTVPPAPKDICPTLKKGFLCDSSFCKKDHQLESLTDRELLLLIARKTCGSVEQQLNITAPKDSRLANPTADDFQQEEGPKITLLTLIKTAEHWARQDIRTIEDSKLRALLTLCAVMTRKFSKSQLSLLCETHLRREGLGQDQAEPVLEVYQRLHSDKGGSFEAALWQQWDRQSLIMFITAFLNIALQLPCESSAVVVSGLRTLVPQSDNEEASTNPGTCSWSDEGTPMDSRPQKIWMAPSLTESDMDYHKILTAGLSVQQGIVRQRVIPVYQVNNLEEICQLIIQAFEAGVDFQESADSFLLMLCLHHAYQGDYKLFLESGAVKYLEGHGFRFEVKKRDGVKRLEELLPAVSSGKNIKRTLAAMPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHAEQGLIQYPTAWQSVGHMMVIFRLMRTNFLIKFLLIHQGMHMVAGHDANDAVISNSVAQARFSGLLIVKTVLDHILQKTERGVRLHPLARTAKVKNEVNSFKAALSSLAKHGEYAPFARLLNLSGVNNLEHGLFPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAATEAEKQLQQYAESRELDHLGLDDQEKKILMNFHQKKNEISFQQTNAMVTLRKERLAKLTEAITAASLPKTSGHYDDDDDIPFPGPINDDDNPGHQDDDPTDSQDTTIPDVVVDPDDGSYGEYQSYSENGMNAPDDLVLFDLDEDDEDTKPVPNRSTKGGQQKNSQKGQHIEGRQTQSRPIQNVPGPHRTIHHASAPLTDNDRRNEPSGSTSPRMLTPINEEADPLDDADDETSSLPPLESDDEEQDRDGTSNRTPTVAPPAPVYRDHSEKKELPQDEQQDQDHTQEARNQDSDNTQSEHSFEEMYRHILRSQGPFDAVLYYHMMKDEPVVFSTSDGKEYTYPDSLEEEYPPWLTEKEAMNEENRFVTLDGQQFYWPVMNHKNKFMAILQHHQ T69413 TARGETID T69413 T69413 FORMERID TTDI01336 T69413 UNIPROID SOS1_HUMAN; SOS2_HUMAN T69413 TARGNAME Son of sevenless (SOS) T69413 GENENAME SOS1; SOS2 T69413 TARGTYPE Literature-reported T69413 SYNONYMS Son of sevenless homolog; SOS T69413 FUNCTION Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity. T69413 SEQUENCE MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS T96859 TARGETID T96859 T96859 FORMERID TTDNR00758 T96859 UNIPROID TICN1_HUMAN T96859 TARGNAME Testican-1 (SPOCK1) T96859 GENENAME SPOCK1 T96859 TARGTYPE Literature-reported T96859 SYNONYMS SPOCK1; Protein SPOCK T96859 FUNCTION May play a role in cell-cell and cell-matrix interactions. May contribute to various neuronal mechanisms in the central nervous system. T96859 SEQUENCE MPAIAVLAAAAAAWCFLQVESRHLDALAGGAGPNHGNFLDNDQWLSTVSQYDRDKYWNRFRDDDYFRNWNPNKPFDQALDPSKDPCLKVKCSPHKVCVTQDYQTALCVSRKHLLPRQKKGNVAQKHWVGPSNLVKCKPCPVAQSAMVCGSDGHSYTSKCKLEFHACSTGKSLATLCDGPCPCLPEPEPPKHKAERSACTDKELRNLASRLKDWFGALHEDANRVIKPTSSNTAQGRFDTSILPICKDSLGWMFNKLDMNYDLLLDPSEINAIYLDKYEPCIKPLFNSCDSFKDGKLSNNEWCYCFQKPGGLPCQNEMNRIQKLSKGKSLLGAFIPRCNEEGYYKATQCHGSTGQCWCVDKYGNELAGSRKQGAVSCEEEQETSGDFGSGGSVVLLDDLEYERELGPKDKEGKLRVHTRAVTEDDEDEDDDKEDEVGYIW T10798 TARGETID T10798 T10798 FORMERID TTDNR00738 T10798 UNIPROID Q0PCM2_PLAVI T10798 TARGNAME Plasmodium Serine repeat antigen 4 (Malaria PvSERA4) T10798 GENENAME Malaria PvSERA4 T10798 TARGTYPE Literature-reported T10798 SYNONYMS Serine repeat antigen 4 T10798 FUNCTION Constitutes major substrates of SUB1, may lead to the identification of parasite and/or host cell substrates and the underlying molecular mechanisms of proteolysis. T10798 SEQUENCE FNLDMPLATHSINKDPEISDYYLKNSSDYYENLYYKKFQGSGATGGAGKQWVQGASTVYGQEGDPKVADEAGGEAAQSITTHSRAEPAGDAPPSGPLHAGTDSEQGEGTGPTDGEGPTRVVDEKAQAGGPLTSPGTLQDAVAPGGPQGPPEQGSPGPQLPPVQPTAPVPPVLPVPPAAPLPDAPTNSTVPTTESDVKEVLH T86062 TARGETID T86062 T86062 FORMERID TTDR01072 T86062 UNIPROID SCAP_HUMAN T86062 TARGNAME SREBP cleavage-activating protein (SCAP) T86062 GENENAME SCAP T86062 TARGTYPE Literature-reported T86062 SYNONYMS SREBPcleavage-activating protein; SREBP-cleavage activating protein; SCAP T86062 FUNCTION Escort protein required for cholesterol as well as lipid homeostasis. Regulates export of the SCAP/SREBF complex from the ER upon low cholesterol. Formation of a ternary complex with INSIG at high sterol concentrations leads to masking of an ER-export signal in SCAP and retention of the complex in the ER. Low sterol concentrations trigger release of INSIG, a conformational change in the SSC domain of SCAP, unmasking of the ER export signal, recruitment into COPII-coated vesicles, transport to the Golgi complex, proteolytic cleavage of SREBF in the Golgi, release of the transcription factor fragmentof SREBF from the membrane, its import into the nucleus and up-regulation of LDLR, INSIG1 and the mevalonate pathway. T86062 SEQUENCE MTLTERLREKISRAFYNHGLLCASYPIPIILFTGFCILACCYPLLKLPLPGTGPVEFTTPVKDYSPPPVDSDRKQGEPTEQPEWYVGAPVAYVQQIFVKSSVFPWHKNLLAVDVFRSPLSRAFQLVEEIRNHVLRDSSGIRSLEELCLQVTDLLPGLRKLRNLLPEHGCLLLSPGNFWQNDWERFHADPDIIGTIHQHEPKTLQTSATLKDLLFGVPGKYSGVSLYTRKRMVSYTITLVFQHYHAKFLGSLRARLMLLHPSPNCSLRAESLVHVHFKEEIGVAELIPLVTTYIILFAYIYFSTRKIDMVKSKWGLALAAVVTVLSSLLMSVGLCTLFGLTPTLNGGEIFPYLVVVIGLENVLVLTKSVVSTPVDLEVKLRIAQGLSSESWSIMKNMATELGIILIGYFTLVPAIQEFCLFAVVGLVSDFFLQMLFFTTVLSIDIRRMELADLNKRLPPEACLPSAKPVGQPTRYERQLAVRPSTPHTITLQPSSFRNLRLPKRLRVVYFLARTRLAQRLIMAGTVVWIGILVYTDPAGLRNYLAAQVTEQSPLGEGALAPMPVPSGMLPPSHPDPAFSIFPPDAPKLPENQTSPGESPERGGPAEVVHDSPVPEVTWGPEDEELWRKLSFRHWPTLFSYYNITLAKRYISLLPVIPVTLRLNPREALEGRHPQDGRSAWPPPGPIPAGHWEAGPKGPGGVQAHGDVTLYKVAALGLATGIVLVLLLLCLYRVLCPRNYGQLGGGPGRRRRGELPCDDYGYAPPETEIVPLVLRGHLMDIECLASDGMLLVSCCLAGHVCVWDAQTGDCLTRIPRPGRQRRDSGVGSGLEAQESWERLSDGGKAGPEEPGDSPPLRHRPRGPPPPSLFGDQPDLTCLIDTNFSAQPRSSQPTQPEPRHRAVCGRSRDSPGYDFSCLVQRVYQEEGLAAVCTPALRPPSPGPVLSQAPEDEGGSPEKGSPSLAWAPSAEGSIWSLELQGNLIVVGRSSGRLEVWDAIEGVLCCSSEEVSSGITALVFLDKRIVAARLNGSLDFFSLETHTALSPLQFRGTPGRGSSPASPVYSSSDTVACHLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFRLEDSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWDVLTGSRVSHVFAHRGDVTSLTCTTSCVISSGLDDLISIWDRSTGIKFYSIQQDLGCGASLGVISDNLLVTGGQGCVSFWDLNYGDLLQTVYLGKNSEAQPARQILVLDNAAIVCNFGSELSLVYVPSVLEKLD T99829 TARGETID T99829 T99829 FORMERID TTDNR00677 T99829 UNIPROID FOXC1_HUMAN T99829 TARGNAME Forkhead box protein C1 (FOXC1) T99829 GENENAME FOXC1 T99829 TARGTYPE Literature-reported T99829 SYNONYMS Forkhead-related transcription factor 3; Forkhead-related protein FKHL7; FREAC3; FREAC-3; FKHL7 T99829 FUNCTION Acts either as a transcriptional activator or repressor. Binds to the consensus binding site 5'-[G/C][A/T]AAA[T/C]AA[A/C]-3' in promoter of target genes. Upon DNA-binding, promotes DNA bending. Acts as a transcriptional coactivator. Stimulates Indian hedgehog (Ihh)-induced target gene expression mediated by the transcription factor GLI2, and hence regulates endochondral ossification. Acts also as a transcriptional coregulator by increasing DNA-binding capacity of GLI2 in breast cancer cells. Regulates FOXO1 through binding to a conserved element, 5'-GTAAACAAA-3' in its promoter region, implicating FOXC1 as an important regulator of cell viability and resistance to oxidative stress in the eye. Cooperates with transcription factor FOXC2 in regulating expression of genes that maintain podocyte integrity. Promotes cell growth inhibition by stopping the cell cycle in the G1 phase through TGFB1-mediated signals. Involved in epithelial-mesenchymal transition (EMT) induction by increasing cell proliferation, migration and invasion. Involved in chemokine CXCL12-induced endothelial cell migration through the control of CXCR4 expression. Plays a role in the gene regulatory network essential for epidermal keratinocyte terminal differentiation. Essential developmental transcriptional factor required for mesoderm-derived tissues, such as the somites, skin, bone and cartilage. Positively regulates CXCL12 and stem cell factor expression in bone marrow mesenchymal progenitor cells, and hence plays a role in the development and maintenance of mesenchymal niches for haematopoietic stem and progenitor cells (HSPC). Plays a role in corneal transparency by preventing both blood vessel and lymphatic vessel growth during embryonic development in a VEGF-dependent manner. Involved in chemokine CXCL12-induced endothelial cell migration through the control of CXCR4 expression. May function as a tumor suppressor. DNA-binding transcriptional factor that plays a role in a broad range of cellular and developmental processes such as eye, bones, cardiovascular, kidney and skin development. T99829 SEQUENCE MQARYSVSSPNSLGVVPYLGGEQSYYRAAAAAAGGGYTAMPAPMSVYSHPAHAEQYPGGMARAYGPYTPQPQPKDMVKPPYSYIALITMAIQNAPDKKITLNGIYQFIMDRFPFYRDNKQGWQNSIRHNLSLNECFVKVPRDDKKPGKGSYWTLDPDSYNMFENGSFLRRRRRFKKKDAVKDKEEKDRLHLKEPPPPGRQPPPAPPEQADGNAPGPQPPPVRIQDIKTENGTCPSPPQPLSPAAALGSGSAAAVPKIESPDSSSSSLSSGSSPPGSLPSARPLSLDGADSAPPPPAPSAPPPHHSQGFSVDNIMTSLRGSPQSAAAELSSGLLASAAASSRAGIAPPLALGAYSPGQSSLYSSPCSQTSSAGSSGGGGGGAGAAGGAGGAGTYHCNLQAMSLYAAGERGGHLQGAPGGAGGSAVDDPLPDYSLPPVTSSSSSSLSHGGGGGGGGGGQEAGHHPAAHQGRLTSWYLNQAGGDLGHLASAAAAAAAAGYPGQQQNFHSVREMFESQRIGLNNSPVNGNSSCQMAFPSSQSLYRTSGAFVYDCSKF T68876 TARGETID T68876 T68876 FORMERID TTDI03221 T68876 UNIPROID GRIK3_HUMAN T68876 TARGNAME Glutamate receptor ionotropic kainate 3 (GluK3) T68876 GENENAME GRIK3 T68876 TARGTYPE Literature-reported T68876 SYNONYMS Glutamate receptor ionotropic, kainate 3; Glutamate receptor 7; GluR7; GluR-7; GluK3; Excitatory amino acid receptor 5; EAA5 T68876 FUNCTION Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds domoate > kainate >> L-glutamate = quisqualate >> AMPA = NMDA. T68876 SEQUENCE MTAPWRRLRSLVWEYWAGLLVCAFWIPDSRGMPHVIRIGGIFEYADGPNAQVMNAEEHAFRFSANIINRNRTLLPNTTLTYDIQRIHFHDSFEATKKACDQLALGVVAIFGPSQGSCTNAVQSICNALEVPHIQLRWKHHPLDNKDTFYVNLYPDYASLSHAILDLVQYLKWRSATVVYDDSTGLIRLQELIMAPSRYNIRLKIRQLPIDSDDSRPLLKEMKRGREFRIIFDCSHTMAAQILKQAMAMGMMTEYYHFIFTTLDLYALDLEPYRYSGVNLTGFRILNVDNPHVSAIVEKWSMERLQAAPRSESGLLDGVMMTDAALLYDAVHIVSVCYQRAPQMTVNSLQCHRHKAWRFGGRFMNFIKEAQWEGLTGRIVFNKTSGLRTDFDLDIISLKEDGLEKVGVWSPADGLNITEVAKGRGPNVTDSLTNRSLIVTTVLEEPFVMFRKSDRTLYGNDRFEGYCIDLLKELAHILGFSYEIRLVEDGKYGAQDDKGQWNGMVKELIDHKADLAVAPLTITHVREKAIDFSKPFMTLGVSILYRKPNGTNPSVFSFLNPLSPDIWMYVLLAYLGVSCVLFVIARFSPYEWYDAHPCNPGSEVVENNFTLLNSFWFGMGSLMQQGSELMPKALSTRIIGGIWWFFTLIIISSYTANLAAFLTVERMESPIDSADDLAKQTKIEYGAVKDGATMTFFKKSKISTFEKMWAFMSSKPSALVKNNEEGIQRALTADYALLMESTTIEYVTQRNCNLTQIGGLIDSKGYGIGTPMGSPYRDKITIAILQLQEEDKLHIMKEKWWRGSGCPEEENKEASALGIQKIGGIFIVLAAGLVLSVLVAVGEFVYKLRKTAEREQRSFCSTVADEIRFSLTCQRRVKHKPQPPMMVKTDAVINMHTFNDRRLPGKDSMACSTSLAPVFP T68876 DRUGINFO D0K5UI UBP310 Investigative T68876 DRUGINFO D0K6AF dysiherbaine Investigative T68876 DRUGINFO D0S8AN SYM2081 Investigative T68876 DRUGINFO D04PFN [3H]kainate Investigative T18571 TARGETID T18571 T18571 FORMERID TTDI02642 T18571 UNIPROID BAGE1_HUMAN T18571 TARGNAME B melanoma antigen 1 (BAGE) T18571 GENENAME BAGE T18571 TARGTYPE Literature-reported T18571 SYNONYMS Cancer/testis antigen 2.1; CT2.1; BAGE1; B melanoma antigen; Antigen MZ2BA; Antigen MZ2-BA T18571 FUNCTION Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. T18571 SEQUENCE MAARAVFLALSAQLLQARLMKEESPVVSWRLEPEDGTALCFIF T33902 TARGETID T33902 T33902 FORMERID TTDI03234 T33902 UNIPROID GPR17_HUMAN T33902 TARGNAME Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) T33902 GENENAME GPR17 T33902 TARGTYPE Literature-reported T33902 SYNONYMS UDP/CysLT receptor; R12; G-protein coupled receptor 17 T33902 FUNCTION Dual specificity receptor for uracil nucleotides and cysteinyl leukotrienes (CysLTs). Signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and CysLTs following ischemia. T33902 SEQUENCE MSKRSWWAGSRKPPREMLKLSGSDSSQSMNGLEVAPPGLITNFSLATAEQCGQETPLENMLFASFYLLDFILALVGNTLALWLFIRDHKSGTPANVFLMHLAVADLSCVLVLPTRLVYHFSGNHWPFGEIACRLTGFLFYLNMYASIYFLTCISADRFLAIVHPVKSLKLRRPLYAHLACAFLWVVVAVAMAPLLVSPQTVQTNHTVVCLQLYREKASHHALVSLAVAFTFPFITTVTCYLLIIRSLRQGLRVEKRLKTKAVRMIAIVLAIFLVCFVPYHVNRSVYVLHYRSHGASCATQRILALANRITSCLTSLNGALDPIMYFFVAEKFRHALCNLLCGKRLKGPPPSFEGKTNESSLSAKSEL T33902 DRUGINFO D00DPX ASN04421891 Investigative T33902 DRUGINFO D07ZGV ASN04450772 Investigative T33902 DRUGINFO D0J4RI ASN06917370 Investigative T33902 DRUGINFO D0KI5P ASN02563583 Investigative T33902 DRUGINFO D0Z2TV ASN04885796 Investigative T33902 DRUGINFO D03YBH LTD4 Investigative T33902 DRUGINFO D07MIE UDP-glucose Investigative T33902 DRUGINFO D0EW6H LTC4 Investigative T33902 DRUGINFO D0C0KJ LTE4 Investigative T70685 TARGETID T70685 T70685 FORMERID TTDR00752 T70685 UNIPROID MOBP_HUMAN T70685 TARGNAME Myelin-associated/oligodendrocyte basic protein (MOBP) T70685 GENENAME MOBP T70685 TARGTYPE Literature-reported T70685 SYNONYMS Myelin-associated oligodendrocyte basic protein T70685 FUNCTION May play a role in compacting or stabilizing the myelin sheath, possibly by binding the negatively charged acidic phospholipids of the cytoplasmic membrane. T70685 SEQUENCE MSQKPAKEGPRLSKNQKYSEHFSIHCCPPFTFLNSKKEIVDRKYSICKSGCFYQKKEEDWICCACQKTRTSRRAKSPQRPKQQPAAPPAVVRAPAKPRSPPRSERQPRSPPRSERQPRSPPRSERQPRSPPRSERQPRPRPEVRPPPAKQRPPQKSKQQPRSSPLRGPGASRGGSPVKASRFW T02259 TARGETID T02259 T02259 FORMERID TTDI02413 T02259 UNIPROID RUNX2_HUMAN T02259 TARGNAME Runt-related transcription factor 2 (RUNX2) T02259 GENENAME RUNX2 T02259 TARGTYPE Literature-reported T02259 SYNONYMS SL3/AKV core-binding factor alpha A subunit; SL3-3 enhancer factor 1 alpha A subunit; Polyomavirus enhancer-binding protein 2 alpha Asubunit; Polyomavirus enhancer-binding protein 2 alpha A subunit; PEBP2A; PEBP2-alpha A; PEA2-alpha A; Osteoblast-specific transcription factor 2; Oncogene AML-3; OSF2; OSF-2; Core-binding factor subunit alpha-1; CBFA1; CBF-alpha-1; Acute myeloid leukemia 3 protein; AML3 T02259 FUNCTION Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE). Inhibits KAT6B-dependent transcriptional activation. Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. T02259 SEQUENCE MASNSLFSTVTPCQQNFFWDPSTSRRFSPPSSSLQPGKMSDVSPVVAAQQQQQQQQQQQQQQQQQQQQQQQEAAAAAAAAAAAAAAAAAVPRLRPPHDNRTMVEIIADHPAELVRTDSPNFLCSVLPSHWRCNKTLPVAFKVVALGEVPDGTVVTVMAGNDENYSAELRNASAVMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKVTVDGPREPRRHRQKLDDSKPSLFSDRLSDLGRIPHPSMRVGVPPQNPRPSLNSAPSPFNPQGQSQITDPRQAQSSPPWSYDQSYPSYLSQMTSPSIHSTTPLSSTRGTGLPAITDVPRRISDDDTATSDFCLWPSTLSKKSQAGASELGPFSDPRQFPSISSLTESRFSNPRMHYPATFTYTPPVTSGMSLGMSATTHYHTYLPPPYPGSSQSQSGPFQTSSTPYLYYGTSSGSYQFPMVPGGDRSPSRMLPPCTTTSNGSTLLNPNLPNQNDGVDADGSHSSSPTVLNSSGRMDESVWRPY T03317 TARGETID T03317 T03317 FORMERID TTDR00981 T03317 UNIPROID LY6D_HUMAN T03317 TARGNAME Lymphocyte antigen 6D (LY6D) T03317 GENENAME LY6D T03317 TARGTYPE Literature-reported T03317 SYNONYMS LY6D; E48 antigen; Desmoglein III (dg4) T03317 FUNCTION May act as a specification marker at earliest stage specification of lymphocytes between B- and T-cell development. Marks the earliest stage of B-cell specification. T03317 SEQUENCE MRTALLLLAALAVATGPALTLRCHVCTSSSNCKHSVVCPASSRFCKTTNTVEPLRGNLVKKDCAESCTPSYTLQGQVSSGTSSTQCCQEDLCNEKLHNAAPTRTALAHSALSLGLALSLLAVILAPSL T72267 TARGETID T72267 T72267 FORMERID TTDI03236 T72267 UNIPROID GPR18_HUMAN T72267 TARGNAME N-arachidonyl glycine receptor (GPR18) T72267 GENENAME GPR18 T72267 TARGTYPE Literature-reported T72267 SYNONYMS NAGly receptor; GPCRW; G-protein coupled receptor 18 T72267 FUNCTION Receptor for endocannabinoid N-arachidonyl glycine (NAGly). However, conflicting results about the role of NAGly as an agonist are reported. Can also be activated by plant-derived and synthetic cannabinoid agonists. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. May contribute to regulation of the immune system. Is required for normal homeostasis of CD8+ subsets of intraepithelial lymphocytes (IELs) (CD8alphaalpha and CD8alphabeta IELs)in small intstine by supporting preferential migration of CD8alphaalpha T-cells to intraepithelial compartment over lamina propria compartment, and by mediating their reconstitution into small intestine after bone marrow transplant (By similarity). Plays a role in hypotensive responses, mediating reduction in intraocular and blood pressure (By similarity). Mediates NAGly-induced process of reorganization of actin filaments and induction of acrosomal exocytosis. T72267 SEQUENCE MITLNNQDQPVPFNSSHPDEYKIAALVFYSCIFIIGLFVNITALWVFSCTTKKRTTVTIYMMNVALVDLIFIMTLPFRMFYYAKDEWPFGEYFCQILGALTVFYPSIALWLLAFISADRYMAIVQPKYAKELKNTCKAVLACVGVWIMTLTTTTPLLLLYKDPDKDSTPATCLKISDIIYLKAVNVLNLTRLTFFFLIPLFIMIGCYLVIIHNLLHGRTSKLKPKVKEKSIRIIITLLVQVLVCFMPFHICFAFLMLGTGENSYNPWGAFTTFLMNLSTCLDVILYYIVSKQFQARVISVMLYRNYLRSMRRKSFRSGSLRSLSNINSEML T72267 DRUGINFO D01ZHW N-arachidonoylglycine Investigative T72267 DRUGINFO D02HDI arachidonylcyclopropylamide Investigative T72267 DRUGINFO D06NAM O-1602 Investigative T72267 DRUGINFO D0S3UM abnormal cannabidiol Investigative T96242 TARGETID T96242 T96242 UNIPROID FAT1_HUMAN T96242 TARGNAME Protocadherin Fat 1 (FAT1) T96242 GENENAME FAT1 T96242 TARGTYPE Literature-reported T96242 SYNONYMS Protocadherin Fat 1, nuclear form; Protein fat homolog; Cadherin-related tumor suppressor homolog; Cadherin family member 7; CDHF7 T96242 FUNCTION Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact. T96242 SEQUENCE MGRHLALLLLLLLLFQHFGDSDGSQRLEQTPLQFTHLEYNVTVQENSAAKTYVGHPVKMGVYITHPAWEVRYKIVSGDSENLFKAEEYILGDFCFLRIRTKGGNTAILNREVKDHYTLIVKALEKNTNVEARTKVRVQVLDTNDLRPLFSPTSYSVSLPENTAIRTSIARVSATDADIGTNGEFYYSFKDRTDMFAIHPTSGVIVLTGRLDYLETKLYEMEILAADRGMKLYGSSGISSMAKLTVHIEQANECAPVITAVTLSPSELDRDPAYAIVTVDDCDQGANGDIASLSIVAGDLLQQFRTVRSFPGSKEYKVKAIGGIDWDSHPFGYNLTLQAKDKGTPPQFSSVKVIHVTSPQFKAGPVKFEKDVYRAEISEFAPPNTPVVMVKAIPAYSHLRYVFKSTPGKAKFSLNYNTGLISILEPVKRQQAAHFELEVTTSDRKASTKVLVKVLGANSNPPEFTQTAYKAAFDENVPIGTTVMSLSAVDPDEGENGYVTYSIANLNHVPFAIDHFTGAVSTSENLDYELMPRVYTLRIRASDWGLPYRREVEVLATITLNNLNDNTPLFEKINCEGTIPRDLGVGEQITTVSAIDADELQLVQYQIEAGNELDFFSLNPNSGVLSLKRSLMDGLGAKVSFHSLRITATDGENFATPLYINITVAASHKLVNLQCEETGVAKMLAEKLLQANKLHNQGEVEDIFFDSHSVNAHIPQFRSTLPTGIQVKENQPVGSSVIFMNSTDLDTGFNGKLVYAVSGGNEDSCFMIDMETGMLKILSPLDRETTDKYTLNITVYDLGIPQKAAWRLLHVVVVDANDNPPEFLQESYFVEVSEDKEVHSEIIQVEATDKDLGPNGHVTYSIVTDTDTFSIDSVTGVVNIARPLDRELQHEHSLKIEARDQAREEPQLFSTVVVKVSLEDVNDNPPTFIPPNYRVKVREDLPEGTVIMWLEAHDPDLGQSGQVRYSLLDHGEGNFDVDKLSGAVRIVQQLDFEKKQVYNLTVRAKDKGKPVSLSSTCYVEVEVVDVNENLHPPVFSSFVEKGTVKEDAPVGSLVMTVSAHDEDARRDGEIRYSIRDGSGVGVFKIGEETGVIETSDRLDRESTSHYWLTVFATDQGVVPLSSFIEIYIEVEDVNDNAPQTSEPVYYPEIMENSPKDVSVVQIEAFDPDSSSNDKLMYKITSGNPQGFFSIHPKTGLITTTSRKLDREQQDEHILEVTVTDNGSPPKSTIARVIVKILDENDNKPQFLQKFYKIRLPEREKPDRERNARREPLYHVIATDKDEGPNAEISYSIEDGNEHGKFFIEPKTGVVSSKRFSAAGEYDILSIKAVDNGRPQKSSTTRLHIEWISKPKPSLEPISFEESFFTFTVMESDPVAHMIGVISVEPPGIPLWFDITGGNYDSHFDVDKGTGTIIVAKPLDAEQKSNYNLTVEATDGTTTILTQVFIKVIDTNDHRPQFSTSKYEVVIPEDTAPETEILQISAVDQDEKNKLIYTLQSSRDPLSLKKFRLDPATGSLYTSEKLDHEAVHQHTLTVMVRDQDVPVKRNFARIVVNVSDTNDHAPWFTASSYKGRVYESAAVGSVVLQVTALDKDKGKNAEVLYSIESGNIGNSFMIDPVLGSIKTAKELDRSNQAEYDLMVKATDKGSPPMSEITSVRIFVTIADNASPKFTSKEYSVELSETVSIGSFVGMVTAHSQSSVVYEIKDGNTGDAFDINPHSGTIITQKALDFETLPIYTLIIQGTNMAGLSTNTTVLVHLQDENDNAPVFMQAEYTGLISESASINSVVLTDRNVPLVIRAADADKDSNALLVYHIVEPSVHTYFAIDSSTGAIHTVLSLDYEETSIFHFTVQVHDMGTPRLFAEYAANVTVHVIDINDCPPVFAKPLYEASLLLPTYKGVKVITVNATDADSSAFSQLIYSITEGNIGEKFSMDYKTGALTVQNTTQLRSRYELTVRASDGRFAGLTSVKINVKESKESHLKFTQDVYSAVVKENSTEAETLAVITAIGNPINEPLFYHILNPDRRFKISRTSGVLSTTGTPFDREQQEAFDVVVEVTEEHKPSAVAHVVVKVIVEDQNDNAPVFVNLPYYAVVKVDTEVGHVIRYVTAVDRDSGRNGEVHYYLKEHHEHFQIGPLGEISLKKQFELDTLNKEYLVTVVAKDGGNPAFSAEVIVPITVMNKAMPVFEKPFYSAEIAESIQVHSPVVHVQANSPEGLKVFYSITDGDPFSQFTINFNTGVINVIAPLDFEAHPAYKLSIRATDSLTGAHAEVFVDIIVDDINDNPPVFAQQSYAVTLSEASVIGTSVVQVRATDSDSEPNRGISYQMFGNHSKSHDHFHVDSSTGLISLLRTLDYEQSRQHTIFVRAVDGGMPTLSSDVIVTVDVTDLNDNPPLFEQQIYEARISEHAPHGHFVTCVKAYDADSSDIDKLQYSILSGNDHKHFVIDSATGIITLSNLHRHALKPFYSLNLSVSDGVFRSSTQVHVTVIGGNLHSPAFLQNEYEVELAENAPLHTLVMEVKTTDGDSGIYGHVTYHIVNDFAKDRFYINERGQIFTLEKLDRETPAEKVISVRLMAKDAGGKVAFCTVNVILTDDNDNAPQFRATKYEVNIGSSAAKGTSVVKVLASDADEGSNADITYAIEADSESVKENLEINKLSGVITTKESLIGLENEFFTFFVRAVDNGSPSKESVVLVYVKILPPEMQLPKFSEPFYTFTVSEDVPIGTEIDLIRAEHSGTVLYSLVKGNTPESNRDESFVIDRQSGRLKLEKSLDHETTKWYQFSILARCTQDDHEMVASVDVSIQVKDANDNSPVFESSPYEAFIVENLPGGSRVIQIRASDADSGTNGQVMYSLDQSQSVEVIESFAINMETGWITTLKELDHEKRDNYQIKVVASDHGEKIQLSSTAIVDVTVTDVNDSPPRFTAEIYKGTVSEDDPQGGVIAILSTTDADSEEINRQVTYFITGGDPLGQFAVETIQNEWKVYVKKPLDREKRDNYLLTITATDGTFSSKAIVEVKVLDANDNSPVCEKTLYSDTIPEDVLPGKLIMQISATDADIRSNAEITYTLLGSGAEKFKLNPDTGELKTSTPLDREEQAVYHLLVRATDGGGRFCQASIVLTLEDVNDNAPEFSADPYAITVFENTEPGTLLTRVQATDADAGLNRKILYSLIDSADGQFSINELSGIIQLEKPLDRELQAVYTLSLKAVDQGLPRRLTATGTVIVSVLDINDNPPVFEYREYGATVSEDILVGTEVLQVYAASRDIEANAEITYSIISGNEHGKFSIDSKTGAVFIIENLDYESSHEYYLTVEATDGGTPSLSDVATVNVNVTDINDNTPVFSQDTYTTVISEDAVLEQSVITVMADDADGPSNSHIHYSIIDGNQGSSFTIDPVRGEVKVTKLLDRETISGYTLTVQASDNGSPPRVNTTTVNIDVSDVNDNAPVFSRGNYSVIIQENKPVGFSVLQLVVTDEDSSHNGPPFFFTIVTGNDEKAFEVNPQGVLLTSSAIKRKEKDHYLLQVKVADNGKPQLSSLTYIDIRVIEESIYPPAILPLEIFITSSGEEYSGGVIGKIHATDQDVYDTLTYSLDPQMDNLFSVSSTGGKLIAHKKLDIGQYLLNVSVTDGKFTTVADITVHIRQVTQEMLNHTIAIRFANLTPEEFVGDYWRNFQRALRNILGVRRNDIQIVSLQSSEPHPHLDVLLFVEKPGSAQISTKQLLHKINSSVTDIEEIIGVRILNVFQKLCAGLDCPWKFCDEKVSVDESVMSTHSTARLSFVTPRHHRAAVCLCKEGRCPPVHHGCEDDPCPEGSECVSDPWEEKHTCVCPSGRFGQCPGSSSMTLTGNSYVKYRLTENENKLEMKLTMRLRTYSTHAVVMYARGTDYSILEIHHGRLQYKFDCGSGPGIVSVQSIQVNDGQWHAVALEVNGNYARLVLDQVHTASGTAPGTLKTLNLDNYVFFGGHIRQQGTRHGRSPQVGNGFRGCMDSIYLNGQELPLNSKPRSYAHIEESVDVSPGCFLTATEDCASNPCQNGGVCNPSPAGGYYCKCSALYIGTHCEISVNPCSSKPCLYGGTCVVDNGGFVCQCRGLYTGQRCQLSPYCKDEPCKNGGTCFDSLDGAVCQCDSGFRGERCQSDIDECSGNPCLHGALCENTHGSYHCNCSHEYRGRHCEDAAPNQYVSTPWNIGLAEGIGIVVFVAGIFLLVVVFVLCRKMISRKKKHQAEPKDKHLGPATAFLQRPYFDSKLNKNIYSDIPPQVPVRPISYTPSIPSDSRNNLDRNSFEGSAIPEHPEFSTFNPESVHGHRKAVAVCSVAPNLPPPPPSNSPSDSDSIQKPSWDFDYDTKVVDLDPCLSKKPLEEKPSQPYSARESLSEVQSLSSFQSESCDDNGYHWDTSDWMPSVPLPDIQEFPNYEVIDEQTPLYSADPNAIDTDYYPGGYDIESDFPPPPEDFPAADELPPLPPEFSNQFESIHPPRDMPAAGSLGSSSRNRQRFNLNQYLPNFYPLDMSEPQTKGTGENSTCREPHAPYPPGYQRHFEAPAVESMPMSVYASTASCSDVSACCEVESEVMMSDYESGDDGHFEEVTIPPLDSQQHTEV T76678 TARGETID T76678 T76678 FORMERID TTDI03295 T76678 UNIPROID ITPR2_HUMAN T76678 TARGNAME IP3 receptor isoform 2 (IP3R2) T76678 GENENAME ITPR2 T76678 TARGTYPE Literature-reported T76678 SYNONYMS Type 2 inositol 1,4,5-trisphosphate receptor; Type 2 InsP3 receptor; InsP3R2; Inositol 1,4,5-trisphosphate receptor type 2; IP3R 2 T76678 FUNCTION Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium. This release is regulated by cAMP both dependently and independently of PKA (By similarity). T76678 SEQUENCE MTEKMSSFLYIGDIVSLYAEGSVNGFISTLGLVDDRCVVHPEAGDLANPPKKFRDCLFKVCPMNRYSAQKQYWKAKQAKQGNHTEAALLKKLQHAAELEQKQNESENKKLLGEIVKYSNVIQLLHIKSNKYLTVNKRLPALLEKNAMRVSLDAAGNEGSWFYIHPFWKLRSEGDNIVVGDKVVLMPVNAGQPLHASNIELLDNPGCKEVNAVNCNTSWKITLFMKYSSYREDVLKGGDVVRLFHAEQEKFLTCDEYEKKQHIFLRTTLRQSATSATSSKALWEIEVVHHDPCRGGAGQWNSLFRFKHLATGNYLAAELNPDYRDAQNEGKNVRDGVPPTSKKKRQAGEKIMYTLVSVPHGNDIASLFELDATTLQRADCLVPRNSYVRLRHLCTNTWVTSTSIPIDTDEERPVMLKIGTCQTKEDKEAFAIVSVPLSEVRDLDFANDANKVLATTVKKLENGTITQNERRFVTKLLEDLIFFVADVPNNGQEVLDVVITKPNRERQKLMREQNILAQVFGILKAPFKEKAGEGSMLRLEDLGDQRYAPYKYMLRLCYRVLRHSQQDYRKNQEYIAKNFCVMQSQIGYDILAEDTITALLHNNRKLLEKHITAKEIETFVSLLRRNREPRFLDYLSDLCVSNTTAIPVTQELICKFMLSPGNADILIQTKVVSMQADNPMESSILSDDIDDEEVWLYWIDSNKEPHGKAIRHLAQEAKEGTKADLEVLTYYRYQLNLFARMCLDRQYLAINQISTQLSVDLILRCVSDESLPFDLRASFCRLMLHMHVDRDPQESVVPVRYARLWTEIPTKITIHEYDSITDSSRNDMKRKFALTMEFVEEYLKEVVNQPFPFGDKEKNKLTFEVVHLARNLIYFGFYSFSELLRLTRTLLAILDIVQAPMSSYFERLSKFQDGGNNVMRTIHGVGEMMTQMVLSRGSIFPMSVPDVPPSIHPSKQGSPTEHEDVTVMDTKLKIIEILQFILSVRLDYRISYMLSIYKKEFGEDNDNAETSASGSPDTLLPSAIVPDIDEIAAQAETMFAGRKEKNPVQLDDEGGRTFLRVLIHLIMHDYPPLLSGALQLLFKHFSQRAEVLQAFKQVQLLVSNQDVDNYKQIKADLDQLRLTVEKSELWVEKSSNYENGEIGESQVKGGEEPIEESNILSPVQDGTKKPQIDSNKSNNYRIVKEILIRLSKLCVQNKKCRNQHQRLLKNMGAHSVVLDLLQIPYEKNDEKMNEVMNLAHTFLQNFCRGNPQNQVLLHKHLNLFLTPGLLEAETMRHIFMNNYHLCNEISERVVQHFVHCIETHGRHVEYLRFLQTIVKADGKYVKKCQDMVMTELINGGEDVLIFYNDRASFPILLHMMCSERDRGDESGPLAYHITLVELLAACTEGKNVYTEIKCNSLLPLDDIVRVVTHDDCIPEVKIAYVNFVNHCYVDTEVEMKEIYTSNHIWKLFENFLVDMARVCNTTTDRKHADIFLEKCVTESIMNIVSGFFNSPFSDNSTSLQTHQPVFIQLLQSAFRIYNCTWPNPAQKASVESCIRTLAEVAKNRGIAIPVDLDSQVNTLFMKSHSNMVQRAAMGWRLSARSGPRFKEALGGPAWDYRNIIEKLQDVVASLEHQFSPMMQAEFSVLVDVLYSPELLFPEGSDARIRCGAFMSKLINHTKKLMEKEEKLCIKILQTLREMLEKKDSFVEEGNTLRKILLNRYFKGDYSIGVNGHLSGAYSKTAQVGGSFSGQDSDKMGISMSDIQCLLDKEGASELVIDVIVNTKNDRIFSEGIFLGIALLEGGNTQTQYSFYQQLHEQKKSEKFFKVLYDRMKAAQKEIRSTVTVNTIDLGNKKRDDDNELMTSGPRMRVRDSTLHLKEGMKGQLTEASSATSKAYCVYRREMDPEIDIMCTGPEAGNTEEKSAEEVTMSPAIAIMQPILRFLQLLCENHNRELQNFLRNQNNKTNYNLVCETLQFLDCICGSTTGGLGLLGLYINEKNVALVNQNLESLTEYCQGPCHENQTCIATHESNGIDIIIALILNDINPLGKYRMDLVLQLKNNASKLLLAIMESRHDSENAERILFNMRPRELVDVMKNAYNQGLECDHGDDEGGDDGVSPKDVGHNIYILAHQLARHNKLLQQMLKPGSDPDEGDEALKYYANHTAQIEIVRHDRTMEQIVFPVPNICEYLTRESKCRVFNTTERDEQGSKVNDFFQQTEDLYNEMKWQKKIRNNPALFWFSRHISLWGSISFNLAVFINLAVALFYPFGDDGDEGTLSPLFSVLLWIAVAICTSMLFFFSKPVGIRPFLVSIMLRSIYTIGLGPTLILLGAANLCNKIVFLVSFVGNRGTFTRGYRAVILDMAFLYHVAYVLVCMLGLFVHEFFYSFLLFDLVYREETLLNVIKSVTRNGRSIILTAVLALILVYLFSIIGFLFLKDDFTMEVDRLKNRTPVTGSHQVPTMTLTTMMEACAKENCSPTIPASNTADEEYEDGIERTCDTLLMCIVTVLNQGLRNGGGVGDVLRRPSKDEPLFAARVVYDLLFYFIVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVSFEEHIKSEHNMWHYLYFIVLVKVKDPTEYTGPESYVAQMIVEKNLDWFPRMRAMSLVSNEGDSEQNEIRSLQEKLESTMSLVKQLSGQLAELKEQMTEQRKNKQRLGFLGSNTPHVNHHMPPH T76678 DRUGINFO D06YZB inositol 2,4,5-trisphosphate Investigative T76678 DRUGINFO D06KHR decavanadate Investigative T59856 TARGETID T59856 T59856 FORMERID TTDNC00593 T59856 UNIPROID GPNMB_HUMAN T59856 TARGNAME Transmembrane glycoprotein NMB (GPNMB) T59856 GENENAME GPNMB T59856 TARGTYPE Literature-reported T59856 SYNONYMS NMB; Hematopoietic growth factor inducible neurokinin-1 type; HGFIN T59856 FUNCTION Could be a melanogenic enzyme. T59856 SEQUENCE MECLYYFLGFLLLAARLPLDAAKRFHDVLGNERPSAYMREHNQLNGWSSDENDWNEKLYPVWKRGDMRWKNSWKGGRVQAVLTSDSPALVGSNITFAVNLIFPRCQKEDANGNIVYEKNCRNEAGLSADPYVYNWTAWSEDSDGENGTGQSHHNVFPDGKPFPHHPGWRRWNFIYVFHTLGQYFQKLGRCSVRVSVNTANVTLGPQLMEVTVYRRHGRAYVPIAQVKDVYVVTDQIPVFVTMFQKNDRNSSDETFLKDLPIMFDVLIHDPSHFLNYSTINYKWSFGDNTGLFVSTNHTVNHTYVLNGTFSLNLTVKAAAPGPCPPPPPPPRPSKPTPSLATTLKSYDSNTPGPAGDNPLELSRIPDENCQINRYGHFQATITIVEGILEVNIIQMTDVLMPVPWPESSLIDFVVTCQGSIPTEVCTIISDPTCEITQNTVCSPVDVDEMCLLTVRRTFNGSGTYCVNLTLGDDTSLALTSTLISVPDRDPASPLRMANSALISVGCLAIFVTVISLLVYKKHKEYNPIENSPGNVVRSKGLSVFLNRAKAVFFPGNQEKDPLLKNQEFKGVS T72595 TARGETID T72595 T72595 FORMERID TTDI03224 T72595 UNIPROID NMDE3_HUMAN T72595 TARGNAME Glutamate receptor ionotropic NMDA 2C (GluN2C) T72595 GENENAME GRIN2C T72595 TARGTYPE Literature-reported T72595 SYNONYMS NR2C; NMDAR2C; N-methyl D-aspartate receptor subtype 2C; Glutamate receptor ionotropic, NMDA 2C; Glutamate [NMDA] receptor subunit epsilon-3; GluN2C T72595 FUNCTION Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition (Probable). Plays a role in regulating the balance between excitatory and inhibitory activity of pyramidal neurons in the prefrontal cortex. Contributes to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning (By similarity). T72595 SEQUENCE MGGALGPALLLTSLFGAWAGLGPGQGEQGMTVAVVFSSSGPPQAQFRARLTPQSFLDLPLEIQPLTVGVNTTNPSSLLTQICGLLGAAHVHGIVFEDNVDTEAVAQILDFISSQTHVPILSISGGSAVVLTPKEPGSAFLQLGVSLEQQLQVLFKVLEEYDWSAFAVITSLHPGHALFLEGVRAVADASHVSWRLLDVVTLELGPGGPRARTQRLLRQLDAPVFVAYCSREEAEVLFAEAAQAGLVGPGHVWLVPNLALGSTDAPPATFPVGLISVVTESWRLSLRQKVRDGVAILALGAHSYWRQHGTLPAPAGDCRVHPGPVSPAREAFYRHLLNVTWEGRDFSFSPGGYLVQPTMVVIALNRHRLWEMVGRWEHGVLYMKYPVWPRYSASLQPVVDSRHLTVATLEERPFVIVESPDPGTGGCVPNTVPCRRQSNHTFSSGDVAPYTKLCCKGFCIDILKKLARVVKFSYDLYLVTNGKHGKRVRGVWNGMIGEVYYKRADMAIGSLTINEERSEIVDFSVPFVETGISVMVARSNGTVSPSAFLEPYSPAVWVMMFVMCLTVVAITVFMFEYFSPVSYNQNLTRGKKSGGPAFTIGKSVWLLWALVFNNSVPIENPRGTTSKIMVLVWAFFAVIFLASYTANLAAFMIQEQYIDTVSGLSDKKFQRPQDQYPPFRFGTVPNGSTERNIRSNYRDMHTHMVKFNQRSVEDALTSLKMGKLDAFIYDAAVLNYMAGKDEGCKLVTIGSGKVFATTGYGIAMQKDSHWKRAIDLALLQFLGDGETQKLETVWLSGICQNEKNEVMSSKLDIDNMAGVFYMLLVAMGLALLVFAWEHLVYWKLRHSVPNSSQLDFLLAFSRGIYSCFSGVQSLASPPRQASPDLTASSAQASVLKMLQAARDMVTTAGVSSSLDRATRTIENWGGGRRAPPPSPCPTPRSGPSPCLPTPDPPPEPSPTGWGPPDGGRAALVRRAPQPPGRPPTPGPPLSDVSRVSRRPAWEARWPVRTGHCGRHLSASERPLSPARCHYSSFPRADRSGRPFLPLFPELEDLPLLGPEQLARREALLHAAWARGSRPRHASLPSSVAEAFARPSSLPAGCTGPACARPDGHSACRRLAQAQSMCLPIYREACQEGEQAGAPAWQHRQHVCLHAHAHLPFCWGAVCPHLPPCASHGSWLSGAWGPLGHRGRTLGLGTGYRDSGGLDEISRVARGTQGFPGPCTWRRISSLESEV T72595 DRUGINFO D03UNN L-689560 Terminated T72595 DRUGINFO D0HF0A DQP-1105 Investigative T72595 DRUGINFO D02PXN N1-dansyl-spermine Investigative T72595 DRUGINFO D03XLS d-CCPene Investigative T72595 DRUGINFO D04NPE UBP141 Investigative T72595 DRUGINFO D08RVB LY233053 Investigative T72595 DRUGINFO D0FT0J d-AP5 Investigative T72595 DRUGINFO D00ZKW [3H]CPP Investigative T72595 DRUGINFO D06GKL 2-Methylamino-succinic acid(NMDA) Investigative T72595 DRUGINFO D07COG [3H]MDL105519 Investigative T72595 DRUGINFO D08UDC [3H]CGP39653 Investigative T72595 DRUGINFO D0B5ZA homoquinolinic acid Investigative T72595 DRUGINFO D0D2ZH [3H]dizocilpine Investigative T72595 DRUGINFO D0F5ZW CGP61594 Investigative T72595 DRUGINFO D0FW8K (RS)-(tetrazol-5-yl)glycine Investigative T72595 DRUGINFO D0KO6Y [3H]CGS19755 Investigative T72595 DRUGINFO D0OT9B L-aspartic acid Investigative T72595 DRUGINFO D08CAB D-aspartic acid Investigative T87588 TARGETID T87588 T87588 FORMERID TTDI03222 T87588 UNIPROID GRIK4_HUMAN T87588 TARGNAME Glutamate receptor ionotropic kainate 4 (GluK4) T87588 GENENAME GRIK4 T87588 TARGTYPE Literature-reported T87588 SYNONYMS KA1; Glutamate receptor ionotropic, kainate 4; Glutamate receptor KA-1; GluK4; GRIK; Excitatory amino acid receptor 1; EAA1 T87588 FUNCTION Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. T87588 SEQUENCE MPRVSAPLVLLPAWLVMVACSPHSLRIAAILDDPMECSRGERLSITLAKNRINRAPERLGKAKVEVDIFELLRDSEYETAETMCQILPKGVVAVLGPSSSPASSSIISNICGEKEVPHFKVAPEEFVKFQFQRFTTLNLHPSNTDISVAVAGILNFFNCTTACLICAKAECLLNLEKLLRQFLISKDTLSVRMLDDTRDPTPLLKEIRDDKTATIIIHANASMSHTILLKAAELGMVSAYYTYIFTNLEFSLQRMDSLVDDRVNILGFSIFNQSHAFFQEFAQSLNQSWQENCDHVPFTGPALSSALLFDAVYAVVTAVQELNRSQEIGVKPLSCGSAQIWQHGTSLMNYLRMVELEGLTGHIEFNSKGQRSNYALKILQFTRNGFRQIGQWHVAEGLSMDSHLYASNISDTLFNTTLVVTTILENPYLMLKGNHQEMEGNDRYEGFCVDMLKELAEILRFNYKIRLVGDGVYGVPEANGTWTGMVGELIARKADLAVAGLTITAEREKVIDFSKPFMTLGISILYRVHMGRKPGYFSFLDPFSPGVWLFMLLAYLAVSCVLFLVARLTPYEWYSPHPCAQGRCNLLVNQYSLGNSLWFPVGGFMQQGSTIAPRALSTRCVSGVWWAFTLIIISSYTANLAAFLTVQRMDVPIESVDDLADQTAIEYGTIHGGSSMTFFQNSRYQTYQRMWNYMYSKQPSVFVKSTEEGIARVLNSNYAFLLESTMNEYYRQRNCNLTQIGGLLDTKGYGIGMPVGSVFRDEFDLAILQLQENNRLEILKRKWWEGGKCPKEEDHRAKGLGMENIGGIFVVLICGLIVAIFMAMLEFLWTLRHSEATEVSVCQEMVTELRSIILCQDSIHPRRRRAAVPPPRPPIPEERRPRGTATLSNGKLCGAGEPDQLAQRLAQEAALVARGCTHIRVCPECRRFQGLRARPSPARSEESLEWEKTTNSSEPE T87588 DRUGINFO D09KRH domoic acid Investigative T87588 DRUGINFO D0K6AF dysiherbaine Investigative T87588 DRUGINFO D0S8AN SYM2081 Investigative T87588 DRUGINFO D04PFN [3H]kainate Investigative T90843 TARGETID T90843 T90843 FORMERID TTDI02060 T90843 UNIPROID ENOX2_HUMAN T90843 TARGNAME Tumor-associated hydroquinone oxidase (tNOX) T90843 GENENAME ENOX2 T90843 TARGTYPE Literature-reported T90843 SYNONYMS Tumorassociated hydroquinone oxidase; Protein disulfidethiol oxidoreductase; EctoNOX disulfidethiol exchanger 2; Ecto-NOX disulfide-thiol exchanger 2; Cytosolic ovarian carcinoma antigen 1; COVA1; APK1 antigen T90843 FUNCTION Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 22 minutes and play a role in control of the ultradian cellular biological clock. May be involved in cell growth. T90843 SEQUENCE MQRDFRWLWVYEIGYAADNSRTLNVDSTAMTLPMSDPTAWATAMNNLGMAPLGIAGQPILPDFDPALGMMTGIPPITPMMPGLGIVPPPIPPDMPVVKEIIHCKSCTLFPPNPNLPPPATRERPPGCKTVFVGGLPENGTEQIIVEVFEQCGEIIAIRKSKKNFCHIRFAEEYMVDKALYLSGYRIRLGSSTDKKDTGRLHVDFAQARDDLYEWECKQRMLAREERHRRRMEEERLRPPSPPPVVHYSDHECSIVAEKLKDDSKFSEAVQTLLTWIERGEVNRRSANNFYSMIQSANSHVRRLVNEKAAHEKDMEEAKEKFKQALSGILIQFEQIVAVYHSASKQKAWDHFTKAQRKNISVWCKQAEEIRNIHNDELMGIRREEEMEMSDDEIEEMTETKETEESALVSQAEALKEENDSLRWQLDAYRNEVELLKQEQGKVHREDDPNKEQQLKLLQQALQGMQQHLLKVQEEYKKKEAELEKLKDDKLQVEKMLENLKEKESCASRLCASNQDSEYPLEKTMNSSPIKSEREALLVGIISTFLHVHPFGASIEYICSYLHRLDNKICTSDVECLMGRLQHTFKQEMTGVGASLEKRWKFCGFEGLKLT T30219 TARGETID T30219 T30219 FORMERID TTDI03067 T30219 UNIPROID C3AR_HUMAN T30219 TARGNAME C3a anaphylatoxin chemotactic receptor (C3AR1) T30219 GENENAME C3AR1 T30219 TARGTYPE Literature-reported T30219 SYNONYMS HNFAG09; C3a-R; C3R1; C3AR; AZ3B T30219 FUNCTION Receptor for the chemotactic and inflammatory peptide anaphylatoxin C3a. This receptor stimulates chemotaxis, granule enzyme release and superoxide anion production. T30219 SEQUENCE MASFSAETNSTDLLSQPWNEPPVILSMVILSLTFLLGLPGNGLVLWVAGLKMQRTVNTIWFLHLTLADLLCCLSLPFSLAHLALQGQWPYGRFLCKLIPSIIVLNMFASVFLLTAISLDRCLVVFKPIWCQNHRNVGMACSICGCIWVVAFVMCIPVFVYREIFTTDNHNRCGYKFGLSSSLDYPDFYGDPLENRSLENIVQPPGEMNDRLDPSSFQTNDHPWTVPTVFQPQTFQRPSADSLPRGSARLTSQNLYSNVFKPADVVSPKIPSGFPIEDHETSPLDNSDAFLSTHLKLFPSASSNSFYESELPQGFQDYYNLGQFTDDDQVPTPLVAITITRLVVGFLLPSVIMIACYSFIVFRMQRGRFAKSQSKTFRVAVVVVAVFLVCWTPYHIFGVLSLLTDPETPLGKTLMSWDHVCIALASANSCFNPFLYALLGKDFRKKARQSIQGILEAAFSEELTRSTHCPSNNVISERNSTTV T30219 DRUGINFO D01OIJ PMID25259874C21 Investigative T30219 DRUGINFO D01QQD PMID25259874C4 Investigative T30219 DRUGINFO D0S8NM SB290157 Investigative T90334 TARGETID T90334 T90334 UNIPROID Q16ME2_AEDAE T90334 TARGNAME Yellow fever mosquito Eggshell organizing factor 1 (YFM EOF1) T90334 GENENAME YFM EOF1 T90334 TARGTYPE Literature-reported T90334 SYNONYMS AAEL012336-PA T90334 FUNCTION Plays an essential role in the formation and melanization of the eggshell. T90334 SEQUENCE MEESQQLQFPIRGNNNNKPLNVSGGNDGSGQFTDSGYTSYHSISASGSVARSVLATIEEDNEADSSFEEARSSEDIFQMGGGSNVLTPTTAASIERISNFHLTTPNSTGKPVGQHRGLVRKPTFDNLFEQYTPKKADYGPPCRTTQTPVRSDRKVELGSQTPRKNKASAKRKLGEFREKLYSDGDALELAPSRDLNDSLEGDCKKLDQEDISPIYHTKRRRSSVIDLIRSSTPKTASLRSNFHVEVRENIDWDAVQQGKASGRGGKSRALRKFQSFSPSKMHSYKKRDVLQEKSVIANRRAPFQRQDALRQVSLEQDLSKQSTPQKAQESSLDKSFELPLEGLITPSKQSNLGVLLDAPILVQPSSEADFKESDLEQQISQIPSFEECAYPQTPSKQTLSLDDSGVIRHAPVCTEVNKSIPSILGTESPSFVSLSIPKTPTSTNKSRNRLKRLSSTKKDKPRSKPPSPIHRAQPFIPGTYRRPSYVNVERLNILKWLNEHDKDALGIVLDYLNDSDLVRVVRVSTGWRDIIEHHRPSYRRLRAHFAREKEVKENLSFPSFVSREGSLLGKTGGSLLSSFGDSSKEIAVSLPRQPFSLCNSIDSNQSVGGELRRSGSVQRSPPVSPSKRKFRENQKIASHLKKSERLKPCPRCEKPSRVVLTKSSIKLAMATGSLDSSTTRTVASGKLDRSYTLPDSLMGSSATSMIAAAALDCTSTTIGSPQSPTNPDRIRRNLFSTSLLPRSQSVDARTPVTRSPRRRRSTDVQGSSASLLERKNGKTKSAEAIQCDYAVCSGKNCGFMFCIKCLCEYHPSSVCKDLAPNSPSKEDEPAHNVACSKQSRRSLLRLRK T57843 TARGETID T57843 T57843 FORMERID TTDR00660 T57843 UNIPROID LY6K_HUMAN T57843 TARGNAME Lymphocyte antigen 6K (LY6K) T57843 GENENAME LY6K T57843 TARGTYPE Literature-reported T57843 SYNONYMS Ly-6K; CO16 T57843 FUNCTION Required for sperm migration into the oviduct and male fertility by controlling binding of sperm to zona pellucida (By similarity). May play a role in cell growth. T57843 SEQUENCE MALLALLLVVALPRVWTDANLTARQRDPEDSQRTDEGDNRVWCHVCERENTFECQNPRRCKWTEPYCVIAAVKIFPRFFMVAKQCSAGCAAMERPKPEEKRFLLEEPMPFFYLKCCKIRYCNLEGPPINSSVFKEYAGSMGESCGGLWLAILLLLASIAAGLSLS T83064 TARGETID T83064 T83064 FORMERID TTDR00997 T83064 UNIPROID GBLP_LEIMA T83064 TARGNAME Leishmania Guanine nucleotide-binding protein (Leishm LACK) T83064 GENENAME Leishm LACK T83064 TARGTYPE Literature-reported T83064 SYNONYMS Guanine nucleotide-binding protein subunit beta-like protein; Antigen LACK T83064 FUNCTION Involved as modulators or transducers in various transmembrane signaling systems. T83064 SEQUENCE MNYEGHLKGHRGWVTSLACPQQAGSYIKVVSTSRDGTVISWKANPDRHSVDSDYGLPNHRLEGHTGFVSCVSLAHATDYALTASWDRSIRMWDLRNGQCQRKFLKHTKDVLAVAFSPDDRLIVSAGRDNVIRVWNVAGECMHEFLRDGHEDWVSSICFSPSLEHPIVVSGSWDNTIKVWNVNGGKCERTLKGHSNYVSTVTVSPDGSLCASGGKDGAALLWDLSTGEQLFKINVESPINQIGFSPNRFWMCVATERSLSVYDLESKAVIAELTPDGAKPSECISIAWSADGNTLYSGHKDNLIRVWSISDAE T39684 TARGETID T39684 T39684 FORMERID TTDR00914 T39684 UNIPROID DQB2_HUMAN T39684 TARGNAME Leukocyte antigen class II (HLA-DQB2) T39684 GENENAME HLA-DQB2 T39684 TARGTYPE Literature-reported T39684 SYNONYMS MHC class II antigen DQB2; HLA-DXB; HLA class II histocompatibility antigen, DX beta chain; HLA class II histocompatibility antigen, DQ beta 2 chain T39684 FUNCTION Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. T39684 SEQUENCE MSWKMALQIPGGFWAAAVTVMLVMLSTPVAEARDFPKDFLVQFKGMCYFTNGTERVRGVARYIYNREEYGRFDSDVGEFQAVTELGRSIEDWNNYKDFLEQERAAVDKVCRHNYEAELRTTLQRQVEPTVTISPSRTEALNHHNLLVCSVTDFYPAQIKVRWFRNDQEETAGVVSTSLIRNGDWTFQILVMLEITPQRGDIYTCQVEHPSLQSPITVEWRAQSESAQSKMLSGIGGFVLGLIFLGLGLIIRHRGQKGPRGPPPAGLLH T26923 TARGETID T26923 T26923 FORMERID TTDR01111 T26923 UNIPROID Q2L8D9_HUMAN T26923 TARGNAME Abeta-binding alcohol dehydrogenase (ABAD) T26923 GENENAME ABAD T26923 TARGTYPE Literature-reported T26923 SYNONYMS Amyloid beta-binding alcohol dehydrogenase T26923 FUNCTION A direct molecular link from Abeta to mitochondrial toxicity. An ABAD peptide specifically inhibits ABAD-Abeta interaction and suppresses Abeta-induced apoptosis and free-radical generation in neurons. T26923 SEQUENCE MAAACRSVK T97858 TARGETID T97858 T97858 FORMERID TTDI01463 T97858 UNIPROID GAPN_STREI T97858 TARGNAME Streptococcus Triosephosphate dehydrogenase (Stre gapN) T97858 GENENAME Stre gapN T97858 TARGTYPE Literature-reported T97858 SYNONYMS Triosephosphate dehydrogenase; Non-phosphorylating glyceraldehyde 3-phosphate dehydrogenase; NADP-dependent glyceraldehyde-3-phosphate dehydrogenase; Glyceraldehyde-3-phosphate dehydrogenase [NADP(+)]; GAPN T97858 FUNCTION Catalyzes the irreversible NADP-dependent oxidation of glyceraldehyde-3-phosphate to 3-phosphoglycerate. Is not able to use NAD instead of NADP. May play an important role in NADPH production in S.equinus. T97858 SEQUENCE MTKQYKNYVNGEWKLSKEEIKIYAPATGEELGSVPAMSQEEVDYVYASAKAAQKAWRALSYVERAEYLHKAADILMRDAEKIGAVLSKEIAKGYKSAVGEVIRTAEIINYAAEEGVRLEGEVLEGGSFDPASKKKIAIVRREPVGLVLAISPFNYPINLAGSKIAPALISGNVVALKPPTQGSISGLLLAEAFAEAGLPAGVFNTITGRGSVIGDYIVEHEAVNYINFTGSTPVGEHIGHLAGMRPIMLELGGKDSAIILEDADLDLAAKNIVAGAYGYSGQRCTAVKRVLVMDSIADKLVEKVSALVNNLTVGMPEDNADITPLIDTKAADYVEGLIKDAQEKGAKEVISFKREGNLISPVLFDNVTTDMRLAWEEPFGPVLPFIRVNSVEEAIEISNKSEYGLQASVFTNNFPLAFKIAEQLEVGTVHINNKTQRGTDNFPFLGAKKSGAGVQGVKYSIEAMTTVKSTVFDIAK T80966 TARGETID T80966 T80966 FORMERID TTDI00133 T80966 UNIPROID AX2R_HUMAN T80966 TARGNAME Annexin II receptor (ANXA2R) T80966 GENENAME ANXA2R T80966 TARGTYPE Literature-reported T80966 SYNONYMS Annexin2 receptor; AXIIR; ANXA2R T80966 FUNCTION May act as a receptor for annexin II on marrow stromal cells to induce osteoclast formation. T80966 SEQUENCE MEQHFLGCVKRAWDSAEVAPEPQPPPIVSSEDRGPWPLPLYPVLGEYSLDSCDLGLLSSPCWRLPGVYWQNGLSPGVQSTLEPSTAKPTEFSWPGTQKQQEAPVEEVGQAEEPDRLRLQQLPWSSPLHPWDRQQDTEVCDSGCLLERRHPPALQPWRHLPGFSDCLEWILRVGFAAFSVLWACCSRICGAKQP T32938 TARGETID T32938 T32938 FORMERID TTDI03500 T32938 UNIPROID S36A2_HUMAN T32938 TARGNAME Solute carrier family 36 member 2 (SLC36A2) T32938 GENENAME SLC36A2 T32938 TARGTYPE Literature-reported T32938 SYNONYMS Tramdorin-1; TRAMD1; Proton/amino acid transporter 2; Proton-coupled amino acid transporter 2; PAT2 T32938 FUNCTION Involved in a pH-dependent electrogenic neuronal transport and sequestration of small amino acids. Transports glycine and proline. Inhibited by sarcosine (By similarity). T32938 SEQUENCE MSVTKSTEGPQGAVAIKLDLMSPPESAKKLENKDSTFLDESPSESAGLKKTKGITVFQALIHLVKGNMGTGILGLPLAVKNAGILMGPLSLLVMGFIACHCMHILVKCAQRFCKRLNKPFMDYGDTVMHGLEANPNAWLQNHAHWGRHIVSFFLIITQLGFCCVYIVFLADNLKQVVEAVNSTTNNCYSNETVILTPTMDSRLYMLSFLPFLVLLVLIRNLRILTIFSMLANISMLVSLVIIIQYITQEIPDPSRLPLVASWKTYPLFFGTAIFSFESIGVVLPLENKMKNARHFPAILSLGMSIVTSLYIGMAALGYLRFGDDIKASISLNLPNCWLYQSVKLLYIAGILCTYALQFYVPAEIIIPFAISRVSTRWALPLDLSIRLVMVCLTCLLAILIPRLDLVISLVGSVSGTALALIIPPLLEVTTFYSEGMSPLTIFKDALISILGFVGFVVGTYQALDELLKSEDSHPFSNSTTFVR T32938 DRUGINFO D0OX9Q NOX-200 Terminated T32938 DRUGINFO D09BNS 5-hydroxy-L-tryptophan Investigative T47510 TARGETID T47510 T47510 FORMERID TTDI02644 T47510 UNIPROID AMOT_HUMAN T47510 TARGNAME Angiomotin (AMOT) T47510 GENENAME AMOT T47510 TARGTYPE Literature-reported T47510 SYNONYMS KIAA1071 T47510 FUNCTION Appears to regulate endothelial cell migration and tube formation. May also play a role in the assembly of endothelial cell-cell junctions. Plays a central role in tight junction maintenance via the complex formed with ARHGAP17, which acts by regulating the uptake of polarity proteins at tight junctions. T47510 SEQUENCE MRNSEEQPSGGTTVLQRLLQEQLRYGNPSENRSLLAIHQQATGNGPPFPSGSGNPGPQSDVLSPQDHHQQLVAHAARQEPQGQEIQSENLIMEKQLSPRMQNNEELPTYEEAKVQSQYFRGQQHASVGAAFYVTGVTNQKMRTEGRPSVQRLNPGKMHQDEGLRDLKQGHVRSLSERLMQMSLATSGVKAHPPVTSAPLSPPQPNDLYKNPTSSSEFYKAQGPLPNQHSLKGMEHRGPPPEYPFKGMPPQSVVCKPQEPGHFYSEHRLNQPGRTEGQLMRYQHPPEYGAARPAQDISLPLSARNSQPHSPTSSLTSGGSLPLLQSPPSTRLSPARHPLVPNQGDHSAHLPRPQQHFLPNQAHQGDHYRLSQPGLSQQQQQQQQQHHHHHHHQQQQQQQPQQQPGEAYSAMPRAQPSSASYQPVPADPFAIVSRAQQMVEILSDENRNLRQELEGCYEKVARLQKVETEIQRVSEAYENLVKSSSKREALEKAMRNKLEGEIRRMHDFNRDLRERLETANKQLAEKEYEGSEDTRKTISQLFAKNKESQREKEKLEAELATARSTNEDQRRHIEIRDQALSNAQAKVVKLEEELKKKQVYVDKVEKMQQALVQLQAACEKREQLEHRLRTRLERELESLRIQQRQGNCQPTNVSEYNAAALMELLREKEERILALEADMTKWEQKYLEENVMRHFALDAAATVAAQRDTTVISHSPNTSYDTALEARIQKEEEEILMANKRCLDMEGRIKTLHAQIIEKDAMIKVLQQRSRKEPSKTEQLSCMRPAKSLMSISNAGSGLLSHSSTLTGSPIMEEKRDDKSWKGSLGILLGGDYRAEYVPSTPSPVPPSTPLLSAHSKTGSRDCSTQTERGTESNKTAAVAPISVPAPVAAAATAAAITATAATITTTMVAAAPVAVAAAAAPAAAAAPSPATAAATAAAVSPAAAGQIPAAASVASAAAVAPSAAAAAAVQVAPAAPAPVPAPALVPVPAPAAAQASAPAQTQAPTSAPAVAPTPAPTPTPAVAQAEVPASPATGPGPHRLSIPSLTCNPDKTDGPVFHSNTLERKTPIQILGQEPDAEMVEYLI T93722 TARGETID T93722 T93722 FORMERID TTDI01252 T93722 UNIPROID FNDC1_HUMAN T93722 TARGNAME Activation-associated cDNA protein (FNDC1) T93722 GENENAME FNDC1 T93722 TARGTYPE Literature-reported T93722 SYNONYMS MEL4B3; KIAA1866; Fibronectin type III domain-containing protein 1; FNDC2; Expressed in synovial lining protein T93722 FUNCTION May be an activator of G protein signaling. T93722 SEQUENCE MAPEAGATLRAPRRLSWAALLLLAALLPVASSAAASVDHPLKPRHVKLLSTKMGLKVTWDPPKDATSRPVEHYNIAYGKSLKSLKYIKVNAETYSFLIEDVEPGVVYFVLLTAENHSGVSRPVYRAESPPGGEWIEIDGFPIKGPGPFNETVTEKEVPNKPLRVRVRSSDDRLSVAWKAPRLSGAKSPRRSRGFLLGYGESGRKMNYVPLTRDERTHEIKKLASESVYVVSLQSMNSQGRSQPVYRAALTKRKISEEDELDVPDDISVRVMSSQSVLVSWVDPVLEKQKKVVASRQYTVRYREKGELARWDYKQIANRRVLIENLIPDTVYEFAVRISQGERDGKWSTSVFQRTPESAPTTAPENLNVWPVNGKPTVVAASWDALPETEGKVKEYILSYAPALKPFGAKSLTYPGDTTSALVDGLQPGERYLFKIRATNRRGLGPHSKAFIVAMPTTSKADVEQNTEDNGKPEKPEPSSPSPRAPASSQHPSVPASPQGRNAKDLLLDLKNKILANGGAPRKPQLRAKKAEELDLQSTEITGEEELGSREDSPMSPSDTQDQKRTLRPPSRHGHSVVAPGRTAVRARMPALPRREGVDKPGFSLATQPRPGAPPSASASPAHHASTQGTSHRPSLPASLNDNDLVDSDEDERAVGSLHPKGAFAQPRPALSPSRQSPSSVLRDRSSVHPGAKPASPARRTPHSGAAEEDSSASAPPSRLSPPHGGSSRLLPTQPHLSSPLSKGGKDGEDAPATNSNAPSRSTMSSSVSSHLSSRTQVSEGAEASDGESHGDGDREDGGRQAEATAQTLRARPASGHFHLLRHKPFAANGRSPSRFSIGRGPRLQPSSSPQSTVPSRAHPRVPSHSDSHPKLSSGIHGDEEDEKPLPATVVNDHVPSSSRQPISRGWEDLRRSPQRGASLHRKEPIPENPKSTGADTHPQGKYSSLASKAQDVQQSTDADTEGHSPKAQPGSTDRHASPARPPAARSQQHPSVPRRMTPGRAPQQQPPPPVATSQHHPGPQSRDAGRSPSQPRLSLTQAGRPRPTSQGRSHSSSDPYTASSRGMLPTALQNQDEDAQGSYDDDSTEVEAQDVRAPAHAARAKEAAASLPKHQQVESPTGAGAGGDHRSQRGHAASPARPSRPGGPQSRARVPSRAAPGKSEPPSKRPLSSKSQQSVSAEDDEEEDAGFFKGGKEDLLSSSVPKWPSSSTPRGGKDADGSLAKEEREPAIALAPRGGSLAPVKRPLPPPPGSSPRASHVPSRLPPRSAATVSPVAGTHPWPQYTTRAPPGHFSTTPMLSLRQRMMHARFRNPLSRQPARPSYRQGYNGRPNVEGKVLPGSNGKPNGQRIINGPQGTKWVVDLDRGLVLNAEGRYLQDSHGNPLRIKLGGDGRTIVDLEGTPVVSPDGLPLFGQGRHGTPLANAQDKPILSLGGKPLVGLEVIKKTTHPPTTTMQPTTTTTPLPTTTTPRPTTATTRRTTTTRRTTTRRPTTTVRTTTRTTTTTTPTPTTPIPTCPPGTLERHDDDGNLIMSSNGIPECYAEEDEFSGLETDTAVPTEEAYVIYDEDYEFETSRPPTTTEPSTTATTPRVIPEEGAISSFPEEEFDLAGRKRFVAPYVTYLNKDPSAPCSLTDALDHFQVDSLDEIIPNDLKKSDLPPQHAPRNITVVAVEGCHSFVIVDWDKATPGDVVTGYLVYSASYEDFIRNKWSTQASSVTHLPIENLKPNTRYYFKVQAQNPHGYGPISPSVSFVTESDNPLLVVRPPGGEPIWIPFAFKHDPSYTDCHGRQYVKRTWYRKFVGVVLCNSLRYKIYLSDNLKDTFYSIGDSWGRGEDHCQFVDSHLDGRTGPQSYVEALPTIQGYYRQYRQEPVRFGNIGFGTPYYYVGWYECGVSIPGKW T41075 TARGETID T41075 T41075 FORMERID TTDR01319 T41075 UNIPROID RABL3_HUMAN T41075 TARGNAME Rab-like protein 3 (RABL3) T41075 GENENAME RABL3 T41075 TARGTYPE Literature-reported T41075 SYNONYMS Rab-like protein 3 T41075 FUNCTION GTPase activity, intracellular protein transport, Rab protein signal transduction T41075 SEQUENCE MASLDRVKVLVLGDSGVGKSSLVHLLCQNQVLGNPSWTVGCSVDVRVHDYKEGTPEEKTYYIELWDVGGSVGSASSVKSTRAVFYNSVNGIIFVHDLTNKKSSQNLRRWSLEALNRDLVPTGVLVTNGDYDQEQFADNQIPLLVIGTKLDQIHETKRHEVLTRTAFLAEDFNPEEINLDCTNPRYLAAGSSNAVKLSRFFDKVIEKRYFLREGNQIPGFPDRKRFGAGTLKSLHYD T72032 TARGETID T72032 T72032 FORMERID TTDI03250 T72032 UNIPROID GPC6A_HUMAN T72032 TARGNAME G-protein coupled receptor GPCR33 (GPRC6A) T72032 GENENAME GPRC6A T72032 TARGTYPE Literature-reported T72032 SYNONYMS hGPRC6A; hGPCR33; G-protein coupled receptor family C group 6 member A T72032 FUNCTION Receptor activated by amino acids with a preference for basic amino acids such as L-Lys, L-Arg and L-ornithine but also by small and polar amino acids. The L-alpha amino acids respond is augmented by divalent cations Ca(2+) and Mg(2+). Activated by extracellular calcium and osteocalcin. Seems to act through a G(q)/G(11) and G(i)-coupled pathway. Mediates the non-genomic effects of androgens in multiple tissue. May coordinate nutritional and hormonal anabolic signals through the sensing of extracellular amino acids, osteocalcin, divalent ions and its responsiveness to anabolic steroids. T72032 SEQUENCE MAFLIILITCFVIILATSQPCQTPDDFVAATSPGHIIIGGLFAIHEKMLSSEDSPRRPQIQECVGFEISVFLQTLAMIHSIEMINNSTLLPGVKLGYEIYDTCTEVTVAMAATLRFLSKFNCSRETVEFKCDYSSYMPRVKAVIGSGYSEITMAVSRMLNLQLMPQVGYESTAEILSDKIRFPSFLRTVPSDFHQIKAMAHLIQKSGWNWIGIITTDDDYGRLALNTFIIQAEANNVCIAFKEVLPAFLSDNTIEVRINRTLKKIILEAQVNVIVVFLRQFHVFDLFNKAIEMNINKMWIASDNWSTATKITTIPNVKKIGKVVGFAFRRGNISSFHSFLQNLHLLPSDSHKLLHEYAMHLSACAYVKDTDLSQCIFNHSQRTLAYKANKAIERNFVMRNDFLWDYAEPGLIHSIQLAVFALGYAIRDLCQARDCQNPNAFQPWELLGVLKNVTFTDGWNSFHFDAHGDLNTGYDVVLWKEINGHMTVTKMAEYDLQNDVFIIPDQETKNEFRNLKQIQSKCSKECSPGQMKKTTRSQHICCYECQNCPENHYTNQTDMPHCLLCNNKTHWAPVRSTMCFEKEVEYLNWNDSLAILLLILSLLGIIFVLVVGIIFTRNLNTPVVKSSGGLRVCYVILLCHFLNFASTSFFIGEPQDFTCKTRQTMFGVSFTLCISCILTKSLKILLAFSFDPKLQKFLKCLYRPILIIFTCTGIQVVICTLWLIFAAPTVEVNVSLPRVIILECEEGSILAFGTMLGYIAILAFICFIFAFKGKYENYNEAKFITFGMLIYFIAWITFIPIYATTFGKYVPAVEIIVILISNYGILYCTFIPKCYVIICKQEINTKSAFLKMIYSYSSHSVSSIALSPASLDSMSGNVTMTNPSSSGKSATWQKSKDLQAQAFAHICRENATSVSKTLPRKRMSSI T72032 DRUGINFO D01XPY L-citrulline Phase 3 T72032 DRUGINFO D03ZNB L-ornithine Investigative T72032 DRUGINFO D07TMZ L-lysine Investigative T72032 DRUGINFO D0T6GM L-serine Investigative T72032 DRUGINFO D0HS5P calindol Investigative T75307 TARGETID T75307 T75307 FORMERID TTDR01152 T75307 UNIPROID Q69128_EBVG T75307 TARGNAME Epstein-Barr virus Nuclear antigen gene (EBV NA) T75307 GENENAME EBV NA T75307 TARGTYPE Literature-reported T75307 SYNONYMS EBV Uncharacterized protein T75307 FUNCTION A multifunctional, dimeric viral protein associated with EpsteinBarr virus (EBV). The only EBV protein found in all EBV-related malignancies. T75307 SEQUENCE MSDEGPGTGPGNGLGEKGDTSGPEGSGGSGPQRRGGDNHGRGRGRGRGRGGGRPGAPG T36721 TARGETID T36721 T36721 FORMERID TTDR00515 T36721 UNIPROID Q69133_EBVG T36721 TARGNAME Epstein-Barr virus Latent membrane protein 2A (EBV LMP2A) T36721 GENENAME EBV LMP2A T36721 TARGTYPE Literature-reported T36721 SYNONYMS Latent membrane protein 2A T36721 FUNCTION A virally encoded membrane protein that is expressed in EBV latent infection and in most of the tumors associated with EBV infection. T36721 SEQUENCE PMGAGPPSPGGDPDGDDGGNNSQYPSASGSSGNTPTPPNDEERESNEEPPPPYEDLDWGNGDRHSDYQPLGNQDPSLYLGLQHDGNDGLPPPPYSPRDDSSQHIYEEAGRGSMNPVC T93727 TARGETID T93727 T93727 FORMERID TTDI02416 T93727 UNIPROID SFRP4_HUMAN T93727 TARGNAME Secreted frizzled related protein-4 (SFRP4) T93727 GENENAME SFRP4 T93727 TARGTYPE Literature-reported T93727 SYNONYMS sFRP-4; Secreted frizzled-related protein 4; FrpHE; Frizzled protein, human endometrium T93727 FUNCTION Soluble frizzled-related proteins (sFRPS) function as modulators of Wnt signaling through direct interaction with Wnts. They have a role in regulating cell growth and differentiation in specific cell types. SFRP4 plays a role in bone morphogenesis. May also act as a regulator of adult uterine morphology and function. May also increase apoptosis during ovulation possibly through modulation of FZ1/FZ4/WNT4 signaling. Has phosphaturic effects by specifically inhibiting sodium-dependent phosphate uptake. T93727 SEQUENCE MFLSILVALCLWLHLALGVRGAPCEAVRIPMCRHMPWNITRMPNHLHHSTQENAILAIEQYEELVDVNCSAVLRFFLCAMYAPICTLEFLHDPIKPCKSVCQRARDDCEPLMKMYNHSWPESLACDELPVYDRGVCISPEAIVTDLPEDVKWIDITPDMMVQERPLDVDCKRLSPDRCKCKKVKPTLATYLSKNYSYVIHAKIKAVQRSGCNEVTTVVDVKEIFKSSSPIPRTQVPLITNSSCQCPHILPHQDVLIMCYEWRSRMMLLENCLVEKWRDQLSKRSIQWEERLQEQRRTVQDKKKTAGRTSRSNPPKPKGKPPAPKPASPKKNIKTRSAQKRTNPKRV T94485 TARGETID T94485 T94485 FORMERID TTDR01135 T94485 UNIPROID ANO7_HUMAN T94485 TARGNAME Prostate cancer-associated protein 5 (NGEP) T94485 GENENAME ANO7 T94485 TARGTYPE Literature-reported T94485 SYNONYMS Transmembrane protein 16G; TMEM16G; PCANAP5; New gene expressed in prostate; NGEP; IPCA-5; Dresden transmembrane protein of the prostate; D-TMPP; Anoctamin-7 T94485 FUNCTION Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylserine, phosphatidylcholine and galactosylceramide (By similarity). Does not exhibit calcium-activated chloride channel (CaCC) activity. May play a role in cell-cell interactions. T94485 SEQUENCE MRMAATAWAGLQGPPLPTLCPAVRTGLYCRDQAHAERWAMTSETSSGSHCARSRMLRRRAQEEDSTVLIDVSPPEAEKRGSYGSTAHASEPGGQQAAACRAGSPAKPRIADFVLVWEEDLKLDRQQDSAARDRTDMHRTWRETFLDNLRAAGLCVDQQDVQDGNTTVHYALLSASWAVLCYYAEDLRLKLPLQELPNQASNWSAGLLAWLGIPNVLLEVVPDVPPEYYSCRFRVNKLPRFLGSDNQDTFFTSTKRHQILFEILAKTPYGHEKKNLLGIHQLLAEGVLSAAFPLHDGPFKTPPEGPQAPRLNQRQVLFQHWARWGKWNKYQPLDHVRRYFGEKVALYFAWLGFYTGWLLPAAVVGTLVFLVGCFLVFSDIPTQELCGSKDSFEMCPLCLDCPFWLLSSACALAQAGRLFDHGGTVFFSLFMALWAVLLLEYWKRKSATLAYRWDCSDYEDTEERPRPQFAASAPMTAPNPITGEDEPYFPERSRARRMLAGSVVIVVMVAVVVMCLVSIILYRAIMAIVVSRSGNTLLAAWASRIASLTGSVVNLVFILILSKIYVSLAHVLTRWEMHRTQTKFEDAFTLKVFIFQFVNFYSSPVYIAFFKGRFVGYPGNYHTLFGVRNEECAAGGCLIELAQELLVIMVGKQVINNMQEVLIPKLKGWWQKFRLRSKKRKAGASAGASQGPWEDDYELVPCEGLFDEYLEMVLQFGFVTIFVAACPLAPLFALLNNWVEIRLDARKFVCEYRRPVAERAQDIGIWFHILAGLTHLAVISNAFLLAFSSDFLPRAYYRWTRAHDLRGFLNFTLARAPSSFAAAHNRTCRYRAFRDDDGHYSQTYWNLLAIRLAFVIVFEHVVFSVGRLLDLLVPDIPESVEIKVKREYYLAKQALAENEVLFGTNGTKDEQPEGSELSSHWTPFTVPKASQLQQ T32232 TARGETID T32232 T32232 FORMERID TTDR01305 T32232 UNIPROID NCLX_HUMAN T32232 TARGNAME Sodium/potassium/calcium exchanger 6 (SLC8B1) T32232 GENENAME SLC8B1 T32232 TARGTYPE Literature-reported T32232 SYNONYMS Solute carrier family 8 member B1; Solute carrier family 24 member 6; Sodium/calcium exchanger protein, mitochondrial; Na(+)/K(+)/Ca(2+)-exchange protein 6; NCKX6; Mitochondrial sodium/calcium exchanger protein T32232 FUNCTION Mitochondrial sodium/calcium antiporter that mediates sodium-dependent calcium efflux from mitochondrion, by mediating the exchange of 3 sodium ions per 1 calcium ion. Plays a central role in mitochondrial calcium homeostasis by mediating mitochondrial calcium extrusion: calcium efflux is essential for mitochondrial function and cell survival, notably in cardiomyocytes (By similarity). Regulates rates of glucose-dependent insulin secretion in pancreatic beta-cells during the first phase of insulin secretion: acts by mediating efflux of calcium from mitochondrion, thereby affecting cytoplasmic calcium responses. Required for store-operated Ca(2+) entry (SOCE) and Ca(2+) release-activated Ca(2+) (CRAC) channel regulation: sodium transport by SLC8B1 leads to promote calcium-shuttling that modulates mitochondrial redox status, thereby regulating SOCE activity. Involved in B-lymphocyte chemotaxis (By similarity). Able to transport Ca(2+) in exchange of either Li(+) or Na(+), explaining how Li(+) catalyzes Ca(2+) exchange. In contrast to other members of the family its function is independent of K(+). T32232 SEQUENCE MAGRRLNLRWALSVLCVLLMAETVSGTRGSSTGAHISPQFPASGVNQTPVVDCRKVCGLNVSDRCDFIRTNPDCHSDGGYLDYLEGIFCHFPPSLLPLAVTLYVSWLLYLFLILGVTAAKFFCPNLSAISTTLKLSHNVAGVTFLAFGNGAPDIFSALVAFSDPHTAGLALGALFGAGVLVTTVVAGGITILHPFMAASRPFFRDIVFYMVAVFLTFLMLFRGRVTLAWALGYLGLYVFYVVTVILCTWIYQRQRRGSLFCPMPVTPEILSDSEEDRVSSNTNSYDYGDEYRPLFFYQETTAQILVRALNPLDYMKWRRKSAYWKALKVFKLPVEFLLLLTVPVVDPDKDDQNWKRPLNCLHLVISPLVVVLTLQSGTYGVYEIGGLVPVWVVVVIAGTALASVTFFATSDSQPPRLHWLFAFLGFLTSALWINAAATEVVNILRSLGVVFRLSNTVLGLTLLAWGNSIGDAFSDFTLARQGYPRMAFSACFGGIIFNILVGVGLGCLLQISRSHTEVKLEPDGLLVWVLAGALGLSLVFSLVSVPLQCFQLSRVYGFCLLLFYLNFLVVALLTEFGVIHLKSM T43778 TARGETID T43778 T43778 FORMERID TTDI01346 T43778 UNIPROID PHLB3_HUMAN T43778 TARGNAME Pleckstrin homology-like domain B 3 (PHLDB3) T43778 GENENAME PHLDB3 T43778 TARGTYPE Literature-reported T43778 SYNONYMS Pleckstrin homology-like domain family B member 3 T43778 FUNCTION Binds to MDM2 and facilitates MDM2-mediated ubiquitination and degradation of p53. Promotes cell growth and inhibits apoptosis. Plays an oncogenic role by in part inhibiting p53 activity in a feedback fashion. T43778 SEQUENCE MGTRSSPEEGTPPPLVPECDVEVQPQGHPEESREQEASEVLAEPSSRGGAEQQAEEEEVGEGSSTESSRDAPEATPPIAMAATPPASTSSREGVRGAARRLQGQQLEALTRVALMEQRVKELQRQRKELRIEMEVEVALLRGELAGERVAARREEEQLRELLEQQAASEQRGRQQREQEQRRLSQERDRLEGLRQRLRKAQGQLDSQPEDQRERLLQGVQEMREQLDVAQRAYEDLEFQQLERESRQEEEDRDSPGPQVPDPKVQELQASMAQHRRGALQHRIRVLEEQLKSLGEQMAAESRGLSRKKEEALQALSQERSRLLELNCLQGTPGGDFSEPNPALTKLLFTQKTDRQLLVLQDAVAHSAATPTSSCLFSVHSSLQGSIGLQRTGSLPRKRGERGSQRGSPRPLSFHCTESLEASALPPAVGDSGRYPLYQLLNCGRGNSCGAIHPDIAHMERLLQQAMAERERLLKAREGTRRGTEGSSGPAVPAITAPPTPPHPPGPRILDLRQHLEGWGHNPENCPHVQVSGCCCRGPLVKMGGRIKTWRKRWFCFDRQARRLAYYADKEETKLKGVIYFQAIEEVYYDHLRCAFKSPNPRLTFCVKTYERLFYMVAPSPEAMRIWMDVIVTAADENHAP T57923 TARGETID T57923 T57923 FORMERID TTDR01219 T57923 UNIPROID FIP1_HUMAN-PGFRA_HUMAN T57923 TARGNAME Fusion protein FIP1L1-PDGFR alpha (FIP1L1-PDGFRA) T57923 GENENAME RHE-CD140a T57923 TARGTYPE Literature-reported T57923 SYNONYMS Fusion protein RHE-CD140a T57923 FUNCTION Provides a molecular explanation for the pathogenesis of approximately half of the patients with the hypereosinophilic syndrome (HES). T57923 SEQUENCE MSAGEVERLVSELSGGTGGDEEEEWLYGGPWDVHVHSDLAKDLDENEVERPEEENASANPPSGIEDETAENGVPKPKVTETEDDSDSDSDDDEDDVHVTIGDIKTGAPQYGSYGTAPVNLNIKTGGRVYGTTGTKVKGVDLDAPGSINGVPLLEVDLDSFEDKPWRKPGADLSDYFNYGFNEDTWKAYCEKQKRIRMGLEVIPVTSTTNKITAEDCTMEVTPGAEIQDGRFNLFKVQQGRTGNSEKETALPSTKAEFTSPPSLFKTGLPPSRNSTSSQSQTSTASRKANSSVGKWQDRYGRAESPDLRRLPGAIDVIGQTITISRVEGRRRANENSNIQVLSERSATEVDNNFSKPPPFFPPGAPPTHLPPPPFLPPPPTVSTAPPLIPPPGFPPPPGAPPPSLIPTIESGHSSGYDSRSARAFPYGNVAFPHLPGSAPSWPSLVDTSKQWDYYARREKDRDRERDRDRERDRDRDRERERTRERERERDHSPTPSVFNSDEERYRYREYAERGYERHRASREKEERHRERRHREKEETRHKSSRSNSRRRHESEEGDSHRRHKHKKSKRSKEGKEAGSEPAPEQESTEATPAEMGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVAAAVLVLLVIVIISLIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKKELDIFGLNPADESTRSYVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKNLLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYIIPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDSSDLVEDSFL T38041 TARGETID T38041 T38041 FORMERID TTDR01286 T38041 UNIPROID CSPG4_HUMAN T38041 TARGNAME Chondroitin sulfate proteoglycan 4 (CSPG4) T38041 GENENAME CSPG4 T38041 TARGTYPE Literature-reported T38041 SYNONYMS Melanoma-associated chondroitin sulfate proteoglycan; Melanoma chondroitin sulfate proteoglycan; MCSP; Chondroitin sulfate proteoglycan NG2 T38041 FUNCTION Proteoglycan playing a role in cell proliferation and migration which stimulates endothelial cells motility during microvascular morphogenesis. May also inhibit neurite outgrowth and growth cone collapse during axon regeneration. Cell surface receptor for collagen alpha 2(VI) which may confer cells ability to migrate on that substrate. Binds through its extracellular N-terminus growth factors, extracellular matrix proteases modulating their activity. May regulate MPP16-dependent degradation and invasion of type I collagen participating in melanoma cells invasion properties. May modulate the plasminogen system by enhancing plasminogen activation and inhibiting angiostatin. Functions also as a signal transducing protein by binding through its cytoplasmic C-terminus scaffolding and signaling proteins. May promote retraction fiber formation and cell polarization through Rho GTPase activation. May stimulate alpha-4, beta-1 integrin-mediated adhesion and spreading by recruiting and activating a signaling cascade through CDC42, ACK1 and BCAR1. May activate FAK and ERK1/ERK2 signaling cascades. T38041 SEQUENCE MQSGPRPPLPAPGLALALTLTMLARLASAASFFGENHLEVPVATALTDIDLQLQFSTSQPEALLLLAAGPADHLLLQLYSGRLQVRLVLGQEELRLQTPAETLLSDSIPHTVVLTVVEGWATLSVDGFLNASSAVPGAPLEVPYGLFVGGTGTLGLPYLRGTSRPLRGCLHAATLNGRSLLRPLTPDVHEGCAEEFSASDDVALGFSGPHSLAAFPAWGTQDEGTLEFTLTTQSRQAPLAFQAGGRRGDFIYVDIFEGHLRAVVEKGQGTVLLHNSVPVADGQPHEVSVHINAHRLEISVDQYPTHTSNRGVLSYLEPRGSLLLGGLDAEASRHLQEHRLGLTPEATNASLLGCMEDLSVNGQRRGLREALLTRNMAAGCRLEEEEYEDDAYGHYEAFSTLAPEAWPAMELPEPCVPEPGLPPVFANFTQLLTISPLVVAEGGTAWLEWRHVQPTLDLMEAELRKSQVLFSVTRGARHGELELDIPGAQARKMFTLLDVVNRKARFIHDGSEDTSDQLVLEVSVTARVPMPSCLRRGQTYLLPIQVNPVNDPPHIIFPHGSLMVILEHTQKPLGPEVFQAYDPDSACEGLTFQVLGTSSGLPVERRDQPGEPATEFSCRELEAGSLVYVHRGGPAQDLTFRVSDGLQASPPATLKVVAIRPAIQIHRSTGLRLAQGSAMPILPANLSVETNAVGQDVSVLFRVTGALQFGELQKQGAGGVEGAEWWATQAFHQRDVEQGRVRYLSTDPQHHAYDTVENLALEVQVGQEILSNLSFPVTIQRATVWMLRLEPLHTQNTQQETLTTAHLEATLEEAGPSPPTFHYEVVQAPRKGNLQLQGTRLSDGQGFTQDDIQAGRVTYGATARASEAVEDTFRFRVTAPPYFSPLYTFPIHIGGDPDAPVLTNVLLVVPEGGEGVLSADHLFVKSLNSASYLYEVMERPRHGRLAWRGTQDKTTMVTSFTNEDLLRGRLVYQHDDSETTEDDIPFVATRQGESSGDMAWEEVRGVFRVAIQPVNDHAPVQTISRIFHVARGGRRLLTTDDVAFSDADSGFADAQLVLTRKDLLFGSIVAVDEPTRPIYRFTQEDLRKRRVLFVHSGADRGWIQLQVSDGQHQATALLEVQASEPYLRVANGSSLVVPQGGQGTIDTAVLHLDTNLDIRSGDEVHYHVTAGPRWGQLVRAGQPATAFSQQDLLDGAVLYSHNGSLSPRDTMAFSVEAGPVHTDATLQVTIALEGPLAPLKLVRHKKIYVFQGEAAEIRRDQLEAAQEAVPPADIVFSVKSPPSAGYLVMVSRGALADEPPSLDPVQSFSQEAVDTGRVLYLHSRPEAWSDAFSLDVASGLGAPLEGVLVELEVLPAAIPLEAQNFSVPEGGSLTLAPPLLRVSGPYFPTLLGLSLQVLEPPQHGALQKEDGPQARTLSAFSWRMVEEQLIRYVHDGSETLTDSFVLMANASEMDRQSHPVAFTVTVLPVNDQPPILTTNTGLQMWEGATAPIPAEALRSTDGDSGSEDLVYTIEQPSNGRVVLRGAPGTEVRSFTQAQLDGGLVLFSHRGTLDGGFRFRLSDGEHTSPGHFFRVTAQKQVLLSLKGSQTLTVCPGSVQPLSSQTLRASSSAGTDPQLLLYRVVRGPQLGRLFHAQQDSTGEALVNFTQAEVYAGNILYEHEMPPEPFWEAHDTLELQLSSPPARDVAATLAVAVSFEAACPQRPSHLWKNKGLWVPEGQRARITVAALDASNLLASVPSPQRSEHDVLFQVTQFPSRGQLLVSEEPLHAGQPHFLQSQLAAGQLVYAHGGGGTQQDGFHFRAHLQGPAGASVAGPQTSEAFAITVRDVNERPPQPQASVPLRLTRGSRAPISRAQLSVVDPDSAPGEIEYEVQRAPHNGFLSLVGGGLGPVTRFTQADVDSGRLAFVANGSSVAGIFQLSMSDGASPPLPMSLAVDILPSAIEVQLRAPLEVPQALGRSSLSQQQLRVVSDREEPEAAYRLIQGPQYGHLLVGGRPTSAFSQFQIDQGEVVFAFTNFSSSHDHFRVLALARGVNASAVVNVTVRALLHVWAGGPWPQGATLRLDPTVLDAGELANRTGSVPRFRLLEGPRHGRVVRVPRARTEPGGSQLVEQFTQQDLEDGRLGLEVGRPEGRAPGPAGDSLTLELWAQGVPPAVASLDFATEPYNAARPYSVALLSVPEAARTEAGKPESSTPTGEPGPMASSPEPAVAKGGFLSFLEANMFSVIIPMCLVLLLLALILPLLFYLRKRNKTGKHDVQVLTAKPRNGLAGDTETFRKVEPGQAIPLTAVPGQGPPPGGQPDPELLQFCRTPNPALKNGQYWV T96398 TARGETID T96398 T96398 UNIPROID ARAID_HUMAN T96398 TARGNAME Apoptosis-related protein 3 (ATRAID) T96398 GENENAME ATRAID T96398 TARGTYPE Literature-reported T96398 SYNONYMS p18; C2orf28 T96398 FUNCTION Promotes osteoblast cell differentiation and terminal mineralization. Plays a role in inducing the cell cycle arrest via inhibiting CCND1 expression in all-trans-retinoic acid (ATRA) signal pathway. T96398 SEQUENCE MAPHDPGSLTTLVPWAAALLLALGVERALALPEICTQCPGSVQNLSKVAFYCKTTRELMLHARCCLNQKGTILGLDLQNCSLEDPGPNFHQAHTTVIIDLQANPLKGDLANTFRGFTQLQTLILPQHVNCPGGINAWNTITSYIDNQICQGQKNLCNNTGDPEMCPENGSCVPDGPGLLQCVCADGFHGYKCMRQGSFSLLMFFGILGATTLSVSILLWATQRRKAKTS T58513 TARGETID T58513 T58513 FORMERID TTDR01307 T58513 UNIPROID OLFM4_HUMAN T58513 TARGNAME Olfactomedin 4 (OLFM4) T58513 GENENAME OLFM4 T58513 TARGTYPE Literature-reported T58513 SYNONYMS hOLfD; hGC-1; UNQ362/PRO698; Olfactomedin-4; OLM4; GW112; G-CSF-stimulated clone 1 protein; Antiapoptotic protein GW112 T58513 FUNCTION May promote proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. In myeloid leukemic cell lines, inhibits cell growth and induces cell differentiation and apoptosis. May play a role in the inhibition of EIF4EBP1 phosphorylation/deactivation. Facilitates cell adhesion, most probably through interaction with cell surface lectins and cadherin. T58513 SEQUENCE MRPGLSFLLALLFFLGQAAGDLGDVGPPIPSPGFSSFPGVDSSSSFSSSSRSGSSSSRSLGSGGSVSQLFSNFTGSVDDRGTCQCSVSLPDTTFPVDRVERLEFTAHVLSQKFEKELSKVREYVQLISVYEKKLLNLTVRIDIMEKDTISYTELDFELIKVEVKEMEKLVIQLKESFGGSSEIVDQLEVEIRNMTLLVEKLETLDKNNVLAIRREIVALKTKLKECEASKDQNTPVVHPPPTPGSCGHGGVVNISKPSVVQLNWRGFSYLYGAWGRDYSPQHPNKGLYWVAPLNTDGRLLEYYRLYNTLDDLLLYINARELRITYGQGSGTAVYNNNMYVNMYNTGNIARVNLTTNTIAVTQTLPNAAYNNRFSYANVAWQDIDFAVDENGLWVIYSTEASTGNMVISKLNDTTLQVLNTWYTKQYKPSASNAFMVCGVLYATRTMNTRTEEIFYYYDTNTGKEGKLDIVMHKMQEKVQSINYNPFDQKLYVYNDGYLLNYDLSVLQKPQ T70119 TARGETID T70119 T70119 FORMERID TTDI01744 T70119 UNIPROID TBA1A_HUMAN; TBA1B_HUMAN T70119 TARGNAME Tubulin alpha (TUBA) T70119 GENENAME TUBA1A; TUBA1B T70119 TARGTYPE Literature-reported T70119 SYNONYMS Tubulin alpha-1 chain; Alpha-tubulin T70119 FUNCTION Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. T70119 SEQUENCE MRECISIHVGQAGVQIGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFNTFFSETGAGKHVPRAVFVDLEPTVIDEVRTGTYRQLFHPEQLITGKEDAANNYARGHYTIGKEIIDLVLDRIRKLADQCTGLQGFLVFHSFGGGTGSGFTSLLMERLSVDYGKKSKLEFSIYPAPQVSTAVVEPYNSILTTHTTLEHSDCAFMVDNEAIYDICRRNLDIERPTYTNLNRLIGQIVSSITASLRFDGALNVDLTEFQTNLVPYPRIHFPLATYAPVISAEKAYHEQLSVAEITNACFEPANQMVKCDPRHGKYMACCLLYRGDVVPKDVNAAIATIKTKRTIQFVDWCPTGFKVGINYQPPTVVPGGDLAKVQRAVCMLSNTTAIAEAWARLDHKFDLMYAKRAFVHWYVGEGMEEGEFSEAREDMAALEKDYEEVGVDSVEGEGEEEGEEY T24938 TARGETID T24938 T24938 FORMERID TTDR01335 T24938 UNIPROID Q76SY1_WEEV T24938 TARGNAME Western equine encephalitis virus Envelope glycoprotein E1 (WEEV E1) T24938 GENENAME WEEV E1 T24938 TARGTYPE Literature-reported T24938 SYNONYMS Envelope glycoprotein E1 T24938 FUNCTION A class II membrane fusion protein, containing a hydrophobic fusion peptide conserved among the alphaviruses. Induced a strong WEEV-specific T cell response. T24938 SEQUENCE RASNCAYGHIPISIDIPDAAFVRSSESPTILEVSCTVADCIYSADFGGSLTLQYKADREGHCPVHSHSTTAVLKEATTHVTATGSITLHFSTSSPQANFIVSLCGKKTTCNAECKPPADHIIGEPHKVDQEFQAAVSKTSWNWLLALFGGASSLIVVGLIVLVCSSMLINTRR T25728 TARGETID T25728 T25728 FORMERID TTDI03467 T25728 UNIPROID S29A4_HUMAN T25728 TARGNAME Solute carrier family 29 member 4 (SLC29A4) T25728 GENENAME SLC29A4 T25728 TARGTYPE Literature-reported T25728 SYNONYMS hENT4; Plasma membrane monoamine transporter; PSEC0113; PMAT; Equilibrative nucleoside transporter 4; ENT4 T25728 FUNCTION Functions as a polyspecific organic cation transporter, efficiently transporting many organic cations such as monoamine neurotransmitters 1-methyl-4-phenylpyridinium and biogenic amines including serotonin, dopamine, norepinephrine and epinephrine. May play a role in regulating central nervous system homeostasis of monoamine neurotransmitters. May be involved in luminal transport of organic cations in the kidney and seems to use luminal proton gradient to drive organic cation reabsorption. Does not seem to transport nucleoside and nucleoside analogs such as uridine, cytidine, thymidine, adenosine, inosine, guanosine, and azidothymidine. In adenosine is efficiently transported but in a fashion highly sensitive to extracellular pH, with maximal activity in the pH range 5.5 to 6.5. Glu-206 is essential for the cation selectivity and may function as the charge sensor for cationic substrates. Transport is chloride and sodium-independent but appears to be sensitive to changes in membrane potential. Weakly inhibited by the classical inhibitors of equilibrative nucleoside transport, dipyridamole, dilazep, and nitrobenzylthioinosine. May play a role in the regulation of extracellular adenosine concentrations in cardiac tissues, in particular during ischemia. T25728 SEQUENCE MGSVGSQRLEEPSVAGTPDPGVVMSFTFDSHQLEEAAEAAQGQGLRARGVPAFTDTTLDEPVPDDRYHAIYFAMLLAGVGFLLPYNSFITDVDYLHHKYPGTSIVFDMSLTYILVALAAVLLNNVLVERLTLHTRITAGYLLALGPLLFISICDVWLQLFSRDQAYAINLAAVGTVAFGCTVQQSSFYGYTGMLPKRYTQGVMTGESTAGVMISLSRILTKLLLPDERASTLIFFLVSVALELLCFLLHLLVRRSRFVLFYTTRPRDSHRGRPGLGRGYGYRVHHDVVAGDVHFEHPAPALAPNESPKDSPAHEVTGSGGAYMRFDVPRPRVQRSWPTFRALLLHRYVVARVIWADMLSIAVTYFITLCLFPGLESEIRHCILGEWLPILIMAVFNLSDFVGKILAALPVDWRGTHLLACSCLRVVFIPLFILCVYPSGMPALRHPAWPCIFSLLMGISNGYFGSVPMILAAGKVSPKQRELAGNTMTVSYMSGLTLGSAVAYCTYSLTRDAHGSCLHASTANGSILAGL T25728 DRUGINFO D0I5YK decynium 22 Investigative T13937 TARGETID T13937 T13937 FORMERID TTDS00222 T13937 UNIPROID Q7X2I2_MYCTX T13937 TARGNAME Mycobacterium DNA-dependent RNA polymerase beta (MycB rpoB) T13937 GENENAME MycB rpoB T13937 TARGTYPE Literature-reported T13937 SYNONYMS DNA-dependent RNA polymerase beta subunit T13937 FUNCTION Transcribes the message carried by DNA. Has important implications in transcriptional regulation. T13937 SEQUENCE TVPGGVEVPVETDDIDHFGNRRLRTVGELIQNQIRVGMSRMERVVRERMTTQDVEAITPQTLINIRPVVAAIKEFFGTSQLSQFMDQNNPLSGLTHKRRLWALGPGGLSRERAGLEVRDVHPS T31935 TARGETID T31935 T31935 FORMERID TTDI03499 T31935 UNIPROID S36A1_HUMAN T31935 TARGNAME Solute carrier family 36 member 1 (SLC36A1) T31935 GENENAME SLC36A1 T31935 TARGTYPE Literature-reported T31935 SYNONYMS hPAT1; Proton/amino acid transporter 1; Proton-coupled amino acid transporter 1; PAT1 T31935 FUNCTION Neutral amino acid/proton symporter. Has a pH-dependent electrogenic transport activity for small amino acids such as glycine, alanine and proline. Besides small apolar L-amino acids, it also recognizes their D-enantiomers and selected amino acid derivatives such as gamma-aminobutyric acid (By similarity). T31935 SEQUENCE MSTQRLRNEDYHDYSSTDVSPEESPSEGLNNLSSPGSYQRFGQSNSTTWFQTLIHLLKGNIGTGLLGLPLAVKNAGIVMGPISLLIIGIVAVHCMGILVKCAHHFCRRLNKSFVDYGDTVMYGLESSPCSWLRNHAHWGRRVVDFFLIVTQLGFCCVYFVFLADNFKQVIEAANGTTNNCHNNETVILTPTMDSRLYMLSFLPFLVLLVFIRNLRALSIFSLLANITMLVSLVMIYQFIVQRIPDPSHLPLVAPWKTYPLFFGTAIFSFEGIGMVLPLENKMKDPRKFPLILYLGMVIVTILYISLGCLGYLQFGANIQGSITLNLPNCWLYQSVKLLYSIGIFFTYALQFYVPAEIIIPFFVSRAPEHCELVVDLFVRTVLVCLTCILAILIPRLDLVISLVGSVSSSALALIIPPLLEVTTFYSEGMSPLTIFKDALISILGFVGFVVGTYEALYELIQPSNAPIFINSTCAFI T31935 DRUGINFO D00ZYK indole-3-propionic acid Investigative T31935 DRUGINFO D09BNS 5-hydroxy-L-tryptophan Investigative T82309 TARGETID T82309 T82309 FORMERID TTDR01330 T82309 UNIPROID KCNKI_HUMAN T82309 TARGNAME TWIK-related spinal cord potassium channel (TRESK) T82309 GENENAME KCNK18 T82309 TARGTYPE Literature-reported T82309 SYNONYMS TWIK-related individual potassium channel; TRIK; TRESK; Potassium channel subfamily K member 18 T82309 FUNCTION Outward rectifying potassium channel. Produces rapidly activating outward rectifier K(+) currents. May function as background potassium channel that sets the resting membrane potential. Channel activity is directly activated by calcium signal. Activated by the G(q)-protein coupled receptor pathway. The calcium signal robustly activates the channel via calcineurin, whereas the anchoring of 14-3-3/YWHAH interferes with the return of the current to the resting state after activation. Inhibited also by arachidonic acid and other naturally occurring unsaturated free fatty acids. Channel activity is also enhanced by volatile anesthetics, such as isoflurane. Appears to be the primary target of hydroxy-alpha-sanshool, an ingredient of Schezuan pepper. May be involved in the somatosensory function with special respect to pain sensation (By similarity). T82309 SEQUENCE MEVSGHPQARRCCPEALGKLFPGLCFLCFLVTYALVGAVVFSAIEDGQVLVAADDGEFEKFLEELCRILNCSETVVEDRKQDLQGHLQKVKPQWFNRTTHWSFLSSLFFCCTVFSTVGYGYIYPVTRLGKYLCMLYALFGIPLMFLVLTDTGDILATILSTSYNRFRKFPFFTRPLLSKWCPKSLFKKKPDPKPADEAVPQIIISAEELPGPKLGTCPSRPSCSMELFERSHALEKQNTLQLPPQAMERSNSCPELVLGRLSYSIISNLDEVGQQVERLDIPLPIIALIVFAYISCAAAILPFWETQLDFENAFYFCFVTLTTIGFGDTVLEHPNFFLFFSIYIIVGMEIVFIAFKLVQNRLIDIYKNVMLFFAKGKFYHLVKK T82309 DRUGINFO D01ZMR Calcineurin Investigative T61909 TARGETID T61909 T61909 FORMERID TTDI00092 T61909 UNIPROID DAAM2_HUMAN T61909 TARGNAME Disheveled-associated activator of morphogenesis 2 (DAAM2) T61909 GENENAME DAAM2 T61909 TARGTYPE Literature-reported T61909 SYNONYMS KIAA0381; Disheveledassociated activator of morphogenesis 2 T61909 FUNCTION Acts downstream of Wnt ligands and upstream of beta-catenin (CTNNB1). Required for canonical Wnt signaling pathway during patterning in the dorsal spinal cord by promoting the aggregation of Disheveled (Dvl) complexes, thereby clustering and formation of Wnt receptor signalosomes and potentiating Wnt activity. During dorsal patterning of the spinal cord, inhibits oligodendrocytes differentiation via interaction with PIP5K1A. Also regulates non-canonical Wnt signaling pathway. Acts downstream of PITX2 in the developing gut and is required for left/right asymmetry within dorsal mesentery: affects mesenchymal condensation by lengthening cadherin-based junctions through WNT5A and non-canonical Wnt signaling, inducing polarized condensation in the left dorsal mesentery necessary to initiate gut rotation. Together with DAAM1, required for myocardial maturation and sarcomere assembly. Key regulator of the Wnt signaling pathway, which is required for various processes during development, such as dorsal patterning, determination of left/right symmetry or myelination in the central nervous system. T61909 SEQUENCE MAPRKRSHHGLGFLCCFGGSDIPEINLRDNHPLQFMEFSSPIPNAEELNIRFAELVDELDLTDKNREAMFALPPEKKWQIYCSKKKEQEDPNKLATSWPDYYIDRINSMAAMQSLYAFDEEETEMRNQVVEDLKTALRTQPMRFVTRFIELEGLTCLLNFLRSMDHATCESRIHTSLIGCIKALMNNSQGRAHVLAQPEAISTIAQSLRTENSKTKVAVLEILGAVCLVPGGHKKVLQAMLHYQVYAAERTRFQTLLNELDRSLGRYRDEVNLKTAIMSFINAVLNAGAGEDNLEFRLHLRYEFLMLGIQPVIDKLRQHENAILDKHLDFFEMVRNEDDLELARRFDMVHIDTKSASQMFELIHKKLKYTEAYPCLLSVLHHCLQMPYKRNGGYFQQWQLLDRILQQIVLQDERGVDPDLAPLENFNVKNIVNMLINENEVKQWRDQAEKFRKEHMELVSRLERKERECETKTLEKEEMMRTLNKMKDKLARESQELRQARGQVAELVAQLSELSTGPVSSPPPPGGPLTLSSSMTTNDLPPPPPPLPFACCPPPPPPPLPPGGPPTPPGAPPCLGMGLPLPQDPYPSSDVPLRKKRVPQPSHPLKSFNWVKLNEERVPGTVWNEIDDMQVFRILDLEDFEKMFSAYQRHQKELGSTEDIYLASRKVKELSVIDGRRAQNCIILLSKLKLSNEEIRQAILKMDEQEDLAKDMLEQLLKFIPEKSDIDLLEEHKHEIERMARADRFLYEMSRIDHYQQRLQALFFKKKFQERLAEAKPKVEAILLASRELVRSKRLRQMLEVILAIGNFMNKGQRGGAYGFRVASLNKIADTKSSIDRNISLLHYLIMILEKHFPDILNMPSELQHLPEAAKVNLAELEKEVGNLRRGLRAVEVELEYQRRQVREPSDKFVPVMSDFITVSSFSFSELEDQLNEARDKFAKALMHFGEHDSKMQPDEFFGIFDTFLQAFSEARQDLEAMRRRKEEEERRARMEAMLKEQRERERWQRQRKVLAAGSSLEEGGEFDDLVSALRSGEVFDKDLCKLKRSRKRSGSQALEVTRERAINRLNY T36576 TARGETID T36576 T36576 FORMERID TTDI02581 T36576 UNIPROID C163A_HUMAN T36576 TARGNAME Hemoglobin scavenger receptor (CD163) T36576 GENENAME CD163 T36576 TARGTYPE Literature-reported T36576 SYNONYMS sCD163; Soluble CD163; Scavenger receptor cysteine-rich type 1 protein M130; M130 T36576 FUNCTION May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells. Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. T36576 SEQUENCE MSKLRMVLLEDSGSADFRRHFVNLSPFTITVVLLLSACFVTSSLGGTDKELRLVDGENKCSGRVEVKVQEEWGTVCNNGWSMEAVSVICNQLGCPTAIKAPGWANSSAGSGRIWMDHVSCRGNESALWDCKHDGWGKHSNCTHQQDAGVTCSDGSNLEMRLTRGGNMCSGRIEIKFQGRWGTVCDDNFNIDHASVICRQLECGSAVSFSGSSNFGEGSGPIWFDDLICNGNESALWNCKHQGWGKHNCDHAEDAGVICSKGADLSLRLVDGVTECSGRLEVRFQGEWGTICDDGWDSYDAAVACKQLGCPTAVTAIGRVNASKGFGHIWLDSVSCQGHEPAIWQCKHHEWGKHYCNHNEDAGVTCSDGSDLELRLRGGGSRCAGTVEVEIQRLLGKVCDRGWGLKEADVVCRQLGCGSALKTSYQVYSKIQATNTWLFLSSCNGNETSLWDCKNWQWGGLTCDHYEEAKITCSAHREPRLVGGDIPCSGRVEVKHGDTWGSICDSDFSLEAASVLCRELQCGTVVSILGGAHFGEGNGQIWAEEFQCEGHESHLSLCPVAPRPEGTCSHSRDVGVVCSRYTEIRLVNGKTPCEGRVELKTLGAWGSLCNSHWDIEDAHVLCQQLKCGVALSTPGGARFGKGNGQIWRHMFHCTGTEQHMGDCPVTALGASLCPSEQVASVICSGNQSQTLSSCNSSSLGPTRPTIPEESAVACIESGQLRLVNGGGRCAGRVEIYHEGSWGTICDDSWDLSDAHVVCRQLGCGEAINATGSAHFGEGTGPIWLDEMKCNGKESRIWQCHSHGWGQQNCRHKEDAGVICSEFMSLRLTSEASREACAGRLEVFYNGAWGTVGKSSMSETTVGVVCRQLGCADKGKINPASLDKAMSIPMWVDNVQCPKGPDTLWQCPSSPWEKRLASPSEETWITCDNKIRLQEGPTSCSGRVEIWHGGSWGTVCDDSWDLDDAQVVCQQLGCGPALKAFKEAEFGQGTGPIWLNEVKCKGNESSLWDCPARRWGHSECGHKEDAAVNCTDISVQKTPQKATTGRSSRQSSFIAVGILGVVLLAIFVALFFLTKKRRQRQRLAVSSRGENLVHQIQYREMNSCLNADDLDLMNSSENSHESADFSAAELISVSKFLPISGMEKEAILSHTEKENGNL T31603 TARGETID T31603 T31603 FORMERID TTDI00190 T31603 UNIPROID LAP4B_HUMAN T31603 TARGNAME Lysosome-associated transmembrane 4b-35 protein (LAPTM4B) T31603 GENENAME LAPTM4B T31603 TARGTYPE Literature-reported T31603 SYNONYMS Lysosome-associated transmembrane protein 4-beta; Lysosomal-associated transmembrane protein 4B T31603 FUNCTION Required for optimal lysosomal function. Blocks EGF-stimulated EGFR intraluminal sorting and degradation. Conversely by binding with the phosphatidylinositol 4,5-bisphosphate, regulates its PIP5K1C interaction, inhibits HGS ubiquitination and relieves LAPTM4B inhibition of EGFR degradation. Recruits SLC3A2 and SLC7A5 (the Leu transporter) to the lysosome, promoting entry of leucine and other essential amino acid (EAA) into the lysosome, stimulating activation of proton-transporting vacuolar (V)-ATPase protein pump (V-ATPase) and hence mTORC1 activation. Plays a role as negative regulator of TGFB1 production in regulatory T cells. Binds ceramide and facilitates its exit from late endosome in order to control cell death pathways. T31603 SEQUENCE MTSRTRVTWPSPPRPLPVPAAAAVAFGAKGTDPAEARSSRGIEEAGPRAHGRAGREPERRRSRQQRRGGLQARRSTLLKTCARARATAPGAMKMVAPWTRFYSNSCCLCCHVRTGTILLGVWYLIINAVVLLILLSALADPDQYNFSSSELGGDFEFMDDANMCIAIAISLLMILICAMATYGAYKQRAAWIIPFFCYQIFDFALNMLVAITVLIYPNSIQEYIRQLPPNFPYRDDVMSVNPTCLVLIILLFISIILTFKGYLISCVWNCYRYINGRNSSDVLVYVTSNDTTVLLPPYDDATVNGAAKEPPPPYVSA T78127 TARGETID T78127 T78127 FORMERID TTDI03369 T78127 UNIPROID S47A2_HUMAN T78127 TARGNAME Multidrug and toxin extrusion protein 2 (MATE2) T78127 GENENAME SLC47A2 T78127 TARGTYPE Literature-reported T78127 SYNONYMS hMATE-2; Solute carrier family 47 member 2; MATE2; MATE-2; Kidney-specific H(+)/organic cation antiporter T78127 FUNCTION Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, and ganciclovir. Responsible for the secretion of cationic drugs across the brush border membranes. T78127 SEQUENCE MDSLQDTVALDHGGCCPALSRLVPRGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCGHLGKVELASVTLAVAFVNVCGVSVGVGLSSACDTLMSQSFGSPNKKHVGVILQRGALVLLLCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQGWLKGQEEESPFQTPGLSILHPSHSHLSRASFHLFQKITWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQDWGPFFSLAVPSMLMICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYMIPLGLSIGVCVRVGMALGAADTVQAKRSAVSGVLSIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVFEAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLGMLACVFLATAAFVAYTARLDWKLAAEEAKKHSGRQQQQRAESTATRPGPEKAVLSSVATGSSPGITLTTYSRSECHVDFFRTPEEAHALSAPTSRLSVKQLVIRRGAALGAASATLMVGLTVRILATRH T78127 DRUGINFO D06PZZ [14C]TEA Investigative T69336 TARGETID T69336 T69336 FORMERID TTDR00863 T69336 UNIPROID S22AG_HUMAN T69336 TARGNAME Solute carrier family 22 member 16 (SLC22A16) T69336 GENENAME SLC22A16 T69336 TARGTYPE Literature-reported T69336 SYNONYMS Organic cation/carnitine transporter 6; Organic cation transporter OKB1; Fly-like putative transporter 2; Flipt 2; FLIPT2; Carnitine transporter 2; CT2 T69336 FUNCTION High affinity carnitine transporter; the uptake is partially sodium-ion dependent. Thought to mediate the L-carnitine secretion mechanism from testis epididymal epithelium into the lumen which is involved in the maturation of spermatozoa. Also transports organic cations such as tetraethylammonium (TEA) and doxorubicin. The uptake of TEA is inhibited by various organic cations. The uptake of doxorubicin is sodium-independent. T69336 SEQUENCE MGSRHFEGIYDHVGHFGRFQRVLYFICAFQNISCGIHYLASVFMGVTPHHVCRPPGNVSQVVFHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKKEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYFSDRLGRRVVLWATSSSMFLFGIAAAFAVDYYTFMAARFFLAMVASGYLVVGFVYVMEFIGMKSRTWASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGRYEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLTVWLIWFTGSLGFYSFSLNSVNLGGNEYLNLFLLGVVEIPAYTFVCIAMDKVGRRTVLAYSLFCSALACGVVMVIPQKHYILGVVTAMVGKFAIGAAFGLIYLYTAELYPTIVRSLAVGSGSMVCRLASILAPFSVDLSSIWIFIPQLFVGTMALLSGVLTLKLPETLGKRLATTWEEAAKLESENESKSSKLLLTTNNSGLEKTEAITPRDSGLGE T15552 TARGETID T15552 T15552 FORMERID TTDI03096 T15552 UNIPROID CTSR3_HUMAN T15552 TARGNAME Cation channel sperm-associated protein 3 (CatSper3) T15552 GENENAME CATSPER3 T15552 TARGTYPE Literature-reported T15552 SYNONYMS One-repeat calcium channel-like protein; CatSper3; Ca(v)-like protein T15552 FUNCTION Voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte. T15552 SEQUENCE MSQHRHQRHSRVISSSPVDTTSVGFCPTFKKFKRNDDECRAFVKRVIMSRFFKIIMISTVTSNAFFMALWTSYDIRYRLFRLLEFSEIFFVSICTSELSMKVYVDPINYWKNGYNLLDVIIIIVMFLPYALRQLMGKQFTYLYIADGMQSLRILKLIGYSQGIRTLITAVGQTVYTVASVLLLLFLLMYIFAILGFCLFGSPDNGDHDNWGNLAAAFFTLFSLATVDGWTDLQKQLDNREFALSRAFTIIFILLASFIFLNMFVGVMIMHTEDSIRKFERELMLEQQEMLMGEKQVILQRQQEEISRLMHIQKNADCTSFSELVENFKKTLSHTDPMVLDDFGTSLPFIDIYFSTLDYQDTTVHKLQELYYEIVHVLSLMLEDLPQEKPQSLEKVDEK T15552 DRUGINFO D03BSR NNC55-0396 Investigative T15552 DRUGINFO D0JF0W PGF1alpha Investigative T02328 TARGETID T02328 T02328 UNIPROID TM219_HUMAN T02328 TARGNAME IGF-binding protein 3 receptor (TMEM219) T02328 GENENAME TMEM219 T02328 TARGTYPE Literature-reported T02328 SYNONYMS Transmembrane protein 219; Insulin-like growth factor-binding protein 3 receptor; IGFBP-3R T02328 FUNCTION Cell death receptor specific for IGFBP3, may mediate caspase-8-dependent apoptosis upon ligand binding. T02328 SEQUENCE MGNCQAGHNLHLCLAHHPPLVCATLILLLLGLSGLGLGSFLLTHRTGLRSPDIPQDWVSFLRSFGQLTLCPRNGTVTGKWRGSHVVGLLTTLNFGDGPDRNKTRTFQATVLGSQMGLKGSSAGQLVLITARVTTERTAGTCLYFSAVPGILPSSQPPISCSEEGAGNATLSPRMGEECVSVWSHEGLVLTKLLTSEELALCGSRLLVLGSFLLLFCGLLCCVTAMCFHPRRESHWSRTRL T29363 TARGETID T29363 T29363 FORMERID TTDI00161 T29363 UNIPROID TXND6_HUMAN T29363 TARGNAME Thioredoxin-like protein 2b (NME9) T29363 GENENAME NME9 T29363 TARGTYPE Literature-reported T29363 SYNONYMS Txl-2; Thioredoxin-like protein 2; Thioredoxin domain-containing protein 6; NME9 T29363 FUNCTION May be a regulator of microtubule physiology. T29363 SEQUENCE MGSRKKEIALQVNISTQELWEEMLSSKGLTVVDVYQGWCGPCKPVVSLFQKMRIEVGLDLLHFALAEADRLDVLEKYRGKCEPTFLFYAGGELVAVVRGANAPLLQKTILDQLEAEKKVLAEGRERKVIKDEALSDEDECVSHGKNNGEDEDMVSSERTCTLAIIKPDAVAHGKTDEIIMKIQEAGFEILTNEERTMTEAEVRLFYQHKAGEEAFEKLVHHMCSGPSHLLILTRTEGFEDVVTTWRTVMGPRDPNVARREQPESLRAQYGTEMPFNAVHGSRDREDADRELALLFPSLKFSDKDTEAPQGGEAEATAGPTEALCFPEDVD T81547 TARGETID T81547 T81547 FORMERID TTDR00899 T81547 UNIPROID S13A5_HUMAN T81547 TARGNAME Solute carrier family 13 member 5 (SLC13A5) T81547 GENENAME SLC13A5 T81547 TARGTYPE Literature-reported T81547 SYNONYMS Sodium-coupled citrate transporter; SLC13A5; NaCT; Na(+)-coupled citrate transporter; Human sodium-coupled citrate transporter T81547 FUNCTION High-affinity sodium/citrate cotransporter that mediates citrate entry into cells. The transport process is electrogenic; it is the trivalent form of citrate rather than the divalent form that is recognized as a substrate. May facilitate the utilization of circulating citrate for the generation of metabolic energy and for the synthesis of fatty acids and cholesterol. T81547 SEQUENCE MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIET T22641 TARGETID T22641 T22641 FORMERID TTDR01002 T22641 UNIPROID Q89857_BDV1 T22641 TARGNAME Borna disease virus Glycoprotein p56 (BoDV p56) T22641 GENENAME BoDV p56 T22641 TARGTYPE Literature-reported T22641 SYNONYMS Glycoprotein T22641 FUNCTION Required for neuronal dissemination of Borna disease virus T22641 SEQUENCE MQPSMSFLIGFGTLVLVLSARTFDLQGLSCNTDSTPGLIDLEIRRLCHTPTENVISCEVSYLNHTTISLPAVHTSCLKYHCKTYWGFFGSYSADRIINRYTGTVKGCLNNSAPEDPFECNWFYCCSAITTEICRCSITNVTVAVQTFPPFMYCSFADCSTVSQQELESGKAMLSDGSTLTYTPYILQSEVVNKTLNGTILCNSSSKIVSFDEFRRSYSLTNGSYQSSSINVTCANYTSSCRPRLKRRRRDTQQIEYLVHKLRPTLKDAWEDCEILQSLLLGVFGTGIASASQFLRSWLNHPDIIGYIVNGVGVVWQCHRVNVTFMTWNESTYYPPVDYNGRKYFLNDEGRLQTNTPEARPGLKRVMWFGRYFLGTVGSGVKPRRIRYNKTSHDYHLEEFEASLNMTPQTSIASGHETDPINHAYGTQADLLPYTRSSNITSTDTGSGWVHIGLPSFAFLNPLGWLRDLLAWAAWLGGVLYLISLCVSLPASFARRRRLGRWQE T14224 TARGETID T14224 T14224 FORMERID TTDR00402 T14224 UNIPROID Q8B6C3_9REOV T14224 TARGNAME Virus Capsid glycoprotein VP7 (Viru VP7) T14224 GENENAME Viru VP7 T14224 TARGTYPE Literature-reported T14224 SYNONYMS Outer capsid glycoprotein VP7 T14224 FUNCTION Rotavirus attachment and entry into the host cell probably involves multiple sequential contacts between the outer capsid proteins VP4 and VP7, and the cell receptors. T14224 SEQUENCE MVCTTLYTVCAILFILFIYILFFRKMFHLITDTLIVMLILSNCVEWSQCQMFIDDIYYNGNVETIINSTDPFNVESLCIYFPNAVVGSQGPGKSDGHLNDGNYAQTIATLFETKGFPKGSIILKTYTQTSDFINSVEMTCSYNIVIIPDSPNDSESIEQIAEWILNVWKCDDMNLEIYTYEQIGINNLWAAFGSDCDISVCPLDTTSNGIGCSPASTETYEVVSNDTQLALINVVDNVRHRIQMNTAQCKLKNCIKGEARLNTALIRISTSSSFDNSLSPLNNGQTTRSFKINAKKWWTIFYTIIDYINTIVQAMTPRHRAIYPEGWMLRYA T62936 TARGETID T62936 T62936 FORMERID TTDR00685 T62936 UNIPROID YYAP1_HUMAN T62936 TARGNAME Hepatocellular carcinoma-associated protein (HCAP) T62936 GENENAME YY1AP1 T62936 TARGTYPE Literature-reported T62936 SYNONYMS YY1AP; YY1-associated protein 1; Hepatocellular carcinoma-associated protein 2; Hepatocellular carcinoma susceptibility protein; HCCA2; HCCA1 T62936 FUNCTION Enhances transcription activation by YY1. Plays a role in cell cycle regulation. Associates with the INO80 chromatin remodeling complex, which is responsible for transcriptional regulation, DNA repair, and replication. T62936 SEQUENCE MEEEASRSAAATNPGSRLTRWPPPDKREGSAVDPGKRRSLAATPSSSLPCTLIALGLRHEKEANELMEDLFETFQDEMGFSNMEDDGPEEEERVAEPQANFNTPQALRFEELLANLLNEQHQIAKELFEQLKMKKPSAKQQKEVEKVKPQCKEVHQTLILDPAQRKRLQQQMQQHVQLLTQIHLLATCNPNLNPEASSTRICLKELGTFAQSSIALHHQYNPKFQTLFQPCNLMGAMQLIEDFSTHVSIDCSPHKTVKKTANEFPCLPKQVAWILATSKVFMYPELLPVCSLKAKNPQDKILFTKAEDNKYLLTCKTARQLTVRIKNLNMNRAPDNIIKFYKKTKQLPVLGKCCEEIQPHQWKPPIEREEHRLPFWLKASLPSIQEELRHMADGAREVGNMTGTTEINSDQGLEKDNSELGSETRYPLLLPKGVVLKLKPVADRFPKKAWRQKRSSVLKPLLIQPSPSLQPSFNPGKTPAQSTHSEAPPSKMVLRIPHPIQPATVLQTVPGVPPLGVSGGESFESPAALPAMPPEARTSFPLSESQTLLSSAPVPKVMMPSPASSMFRKPYVRRRPSKRRGARAFRCIKPAPVIHPASVIFTVPATTVKIVSLGGGCNMIQPVNAAVAQSPQTIPIATLLVNPTSFPCPLNQPLVASSVSPLIVSGNSVNLPIPSTPEDKAHMNVDIACAVADGENAFQGLEPKLEPQELSPLSATVFPKVEHSPGPPPVDKQCQEGLSENSAYRWTVVKTEEGRQALEPLPQGIQESLNNSSPGDLEEVVKMEPEDATEEISGFL T54473 TARGETID T54473 T54473 FORMERID TTDI03452 T54473 UNIPROID S15A3_HUMAN T54473 TARGNAME Solute carrier family 15 member 3 (SLC15A3) T54473 GENENAME SLC15A3 T54473 TARGTYPE Literature-reported T54473 SYNONYMS Peptide/histidine transporter 2; Peptide transporter 3; PTR3; PHT2; Osteoclast transporter; OCTP T54473 FUNCTION Proton oligopeptide cotransporter. Transports free histidine and certain di- and tripeptides (By similarity). T54473 SEQUENCE MPAPRAREQPRVPGERQPLLPRGARGPRRWRRAAGAAVLLVEMLERAAFFGVTANLVLYLNSTNFNWTGEQATRAALVFLGASYLLAPVGGWLADVYLGRYRAVALSLLLYLAASGLLPATAFPDGRSSFCGEMPASPLGPACPSAGCPRSSPSPYCAPVLYAGLLLLGLAASSVRSNLTSFGADQVMDLGRDATRRFFNWFYWSINLGAVLSLLVVAFIQQNISFLLGYSIPVGCVGLAFFIFLFATPVFITKPPMGSQVSSMLKLALQNCCPQLWQRHSARDRQCARVLADERSPQPGASPQEDIANFQVLVKILPVMVTLVPYWMVYFQMQSTYVLQGLHLHIPNIFPANPANISVALRAQGSSYTIPEAWLLLANVVVVLILVPLKDRLIDPLLLRCKLLPSALQKMALGMFFGFTSVIVAGVLEMERLHYIHHNETVSQQIGEVLYNAAPLSIWWQIPQYLLIGISEIFASIPGLEFAYSEAPRSMQGAIMGIFFCLSGVGSLLGSSLVALLSLPGGWLHCPKDFGNINNCRMDLYFFLLAGIQAVTALLFVWIAGRYERASQGPASHSRFSRDRG T54473 DRUGINFO D07UTZ [3H]histidine Investigative T54473 DRUGINFO D0XT2X [14C]histidine Investigative T09132 TARGETID T09132 T09132 FORMERID TTDI00184 T09132 UNIPROID TENS4_HUMAN T09132 TARGNAME C-terminal tensin-like protein (Cten) T09132 GENENAME TNS4 T09132 TARGTYPE Literature-reported T09132 SYNONYMS Tensin-4; TNS4 T09132 FUNCTION May be involved in cell migration, cartilage development and in linking signal transduction pathways to the cytoskeleton. May promote apoptosis, via its cleavage by caspase-3. T09132 SEQUENCE MSQVMSSPLLAGGHAVSLAPCDEPRRTLHPAPSPSLPPQCSYYTTEGWGAQALMAPVPCMGPPGRLQQAPQVEAKATCFLPSPGEKALGTPEDLDSYIDFSLESLNQMILELDPTFQLLPPGTGGSQAELAQSTMSMRKKEESEALDIKYIEVTSARSRCHDGPQHCSSPSVTPPFGSLRSGGLLLSRDVPRETRSSSESLIFSGNQGRGHQRPLPPSEGLSPRPPNSPSISIPCMGSKASSPHGLGSPLVASPRLEKRLGGLAPQRGSRISVLSASPVSDVSYMFGSSQSLLHSSNSSHQSSSRSLESPANSSSSLHSLGSVSLCTRPSDFQAPRNPTLTMGQPRTPHSPPLAKEHASSCPPSITNSMVDIPIVLINGCPEPGSSPPQRTPGHQNSVQPGAASPSNPCPATRSNSQTLSDAPFTTCPEGPARDMQPTMKFVMDTSKYWFKPNITREQAIELLRKEEPGAFVIRDSSSYRGSFGLALKVQEVPASAQSRPGEDSNDLIRHFLIESSAKGVHLKGADEEPYFGSLSAFVCQHSIMALALPCKLTIPQRELGGADGASDSTDSPASCQKKSAGCHTLYLSSVSVETLTGALAVQKAISTTFERDILPTPTVVHFKVTEQGITLTDVQRKVFFRRHYPLTTLRFCGMDPEQRKWQKYCKPSWIFGFVAKSQTEPQENVCHLFAEYDMVQPASQVIGLVTALLQDAERM T12623 TARGETID T12623 T12623 FORMERID TTDR01288 T12623 UNIPROID DYNAP_HUMAN T12623 TARGNAME Dynactin-associated protein (DYNAP) T12623 GENENAME DYNAP T12623 TARGTYPE Literature-reported T12623 SYNONYMS Full; C18orf26 T12623 FUNCTION Plays a role in the regulation of cell proliferation. Promotes activation of the AKT1 signaling pathway. Promotes phosphorylation of AKT1 at 'Ser-473'. T12623 SEQUENCE MVADIKGNEQIEKYSWREACDTGSSRMDRKHGKYILNVEHSENQPPITHPNDQEAHSSICWCLPSNDITSDVSPNLTGVCVNPGILAHSRCLQSESCNTQVKEYCRNDWSMWKVFLACLLACVIMTAIGVLIICLVNNKGSANSSIVIQLSTNDGECVTVKPGTPSPACPPTMTTTSTVPASTATESTTSTATAATTSTEPITVAPTDHL T09063 TARGETID T09063 T09063 FORMERID TTDI03453 T09063 UNIPROID S15A4_HUMAN T09063 TARGNAME Solute carrier family 15 member 4 (SLC15A4) T09063 GENENAME SLC15A4 T09063 TARGTYPE Literature-reported T09063 SYNONYMS SLC15A4 T09063 FUNCTION Proton oligopeptide cotransporter. Transports free histidine and certain di- and tripeptides. T09063 SEQUENCE MEGSGGGAGERAPLLGARRAAAAAAAAGAFAGRRAACGAVLLTELLERAAFYGITSNLVLFLNGAPFCWEGAQASEALLLFMGLTYLGSPFGGWLADARLGRARAILLSLALYLLGMLAFPLLAAPATRAALCGSARLLNCTAPGPDAAARCCSPATFAGLVLVGLGVATVKANITPFGADQVKDRGPEATRRFFNWFYWSINLGAILSLGGIAYIQQNVSFVTGYAIPTVCVGLAFVVFLCGQSVFITKPPDGSAFTDMFKILTYSCCSQKRSGERQSNGEGIGVFQQSSKQSLFDSCKMSHGGPFTEEKVEDVKALVKIVPVFLALIPYWTVYFQMQTTYVLQSLHLRIPEISNITTTPHTLPAAWLTMFDAVLILLLIPLKDKLVDPILRRHGLLPSSLKRIAVGMFFVMCSAFAAGILESKRLNLVKEKTINQTIGNVVYHAADLSLWWQVPQYLLIGISEIFASIAGLEFAYSAAPKSMQSAIMGLFFFFSGVGSFVGSGLLALVSIKAIGWMSSHTDFGNINGCYLNYYFFLLAAIQGATLLLFLIISVKYDHHRDHQRSRANGVPTSRRA T09063 DRUGINFO D07UTZ [3H]histidine Investigative T09063 DRUGINFO D0XT2X [14C]histidine Investigative T66479 TARGETID T66479 T66479 FORMERID TTDI01520 T66479 UNIPROID LIRA3_HUMAN; LIRB3_HUMAN T66479 TARGNAME Leukocyte Ig-like receptor-3 (LILR3) T66479 GENENAME LILRA3; LILRB3 T66479 TARGTYPE Literature-reported T66479 SYNONYMS Monocyte inhibitory receptor; Leukocyte immunoglobulin-like receptor; LIR; Immunoglobulin-like transcript; ILT; CD85 antigen-like family member; CD85 T66479 FUNCTION Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes. Acts as soluble receptor for class I MHC antigens. Binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. T66479 SEQUENCE MTPILTVLICLGLSLDPRTHVQAGPLPKPTLWAEPGSVITQGSPVTLRCQGSLETQEYHLYREKKTALWITRIPQELVKKGQFPILSITWEHAGRYCCIYGSHTAGLSESSDPLELVVTGAYSKPTLSALPSPVVTSGGNVTIQCDSQVAFDGFILCKEGEDEHPQCLNSHSHARGSSRAIFSVGPVSPSRRWSYRCYGYDSRAPYVWSLPSDLLGLLVPGVSKKPSLSVQPGPVVAPGEKLTFQCGSDAGYDRFVLYKEWGRDFLQRPGRQPQAGLSQANFTLGPVSRSYGGQYTCSGAYNLSSEWSAPSDPLDILITGQIRARPFLSVRPGPTVASGENVTLLCQSQGGMHTFLLTKEGAADSPLRLKSKRQSHKYQAEFPMSPVTSAHAGTYRCYGSLSSNPYLLTHPSDPLELVVSGAAETLSPPQNKSDSKAGE T32434 TARGETID T32434 T32434 FORMERID TTDI03094 T32434 UNIPROID CTSR1_HUMAN T32434 TARGNAME Cation channel sperm-associated protein 1 (CatSper1) T32434 GENENAME CATSPER1 T32434 TARGTYPE Literature-reported T32434 SYNONYMS hCatSper; CatSper1 T32434 FUNCTION Voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte. T32434 SEQUENCE MDQNSVPEKAQNEADTNNADRFFRSHSSPPHHRPGHSRALHHYELHHHGVPHQRGESHHPPEFQDFHDQALSSHVHQSHHHSEARNHGRAHGPTGFGLAPSQGAVPSHRSYGEDYHDELQRDGRRHHDGSQYGGFHQQSDSHYHRGSHHGRPQYLGENLSHYSSGVPHHGEASHHGGSYLPHGPNPYSESFHHSEASHLSGLQHDESQHHQVPHRGWPHHHQVHHHGRSRHHEAHQHGKSPHHGETISPHSSVGSYQRGISDYHSEYHQGDHHPSEYHHGDHPHHTQHHYHQTHRHRDYHQHQDHHGAYHSSYLHGDYVQSTSQLSIPHTSRSLIHDAPGPAASRTGVFPYHVAHPRGSAHSMTRSSSTIRSRVTQMSKKVHTQDISTKHSEDWGKEEGQFQKRKTGRLQRTRKKGHSTNLFQWLWEKLTFLIQGFREMIRNLTQSLAFETFIFFVVCLNTVMLVAQTFAEVEIRGEWYFMALDSIFFCIYVVEALLKIIALGLSYFFDFWNNLDFFIMAMAVLDFLLMQTHSFAIYHQSLFRILKVFKSLRALRAIRVLRRLSFLTSVQEVTGTLGQSLPSIAAILILMFTCLFLFSAVLRALFRKSDPKRFQNIFTTIFTLFTLLTLDDWSLIYMDSRAQGAWYIIPILVIYIIIQYFIFLNLVITVLVDSFQTALFKGLEKAKQERAARIQEKLLEDSLTELRAAEPKEVASEGTMLKRLIEKKFGTMTEKQQELLFHYLQLVASVEQEQQKFRSQAAVIDEIVDTTFEAGEEDFRN T32434 DRUGINFO D05SRQ HC-056456 Investigative T32434 DRUGINFO D03BSR NNC55-0396 Investigative T32434 DRUGINFO D0JF0W PGF1alpha Investigative T96542 TARGETID T96542 T96542 UNIPROID SHCBP_HUMAN T96542 TARGNAME SHC SH2 domain-binding protein 1 (SHCBP1) T96542 GENENAME SHCBP1 T96542 TARGTYPE Literature-reported T96542 SYNONYMS PAL T96542 FUNCTION May play a role in signaling pathways governing cellular proliferation, cell growth and differentiation. May be a component of a novel signaling pathway downstream of Shc. Acts as a positive regulator of FGF signaling in neural progenitor cells. T96542 SEQUENCE MADGSLTGGGLEAAAMAPERMGWAVEQELASLEKGLFQDEDSCSDCSYRDKPGSSLQSFMPEGKTFFPEIFQTNQLLFYERFRAYQDYILADCKASEVQEFTAEFLEKVLEPSGWRAVWHTNVFKVLVEITDVDFAALKAVVRLAEPYLCDSQVSTFTMECMKELLDLKEHRLPLQELWVVFDDSGVFDQTALAIEHVRFFYQNIWRSWDEEEEDEYDYFVRCVEPRLRLHYDILEDRVPSGLIVDYHNLLSQCEESYRKFLNLRSSLSNCNSDSEQENISMVEGLKLYSEMEQLKQKLKLIENPLLRYVFGYQKNSNIQAKGVRSSGQKITHVVSSTMMAGLLRSLLTDRLCQEPGEEEREIQFHSDPLSAINACFEGDTVIVCPGHYVVHGTFSIADSIELEGYGLPDDIVIEKRGKGDTFVDCTGADIKISGIKFVQHDAVEGILIVHRGKTTLENCVLQCETTGVTVRTSAEFLMKNSDLYGAKGAGIEIYPGSQCTLSDNGIHHCKEGILIKDFLDEHYDIPKISMVNNIIHNNEGYGVVLVKPTIFSDLQENAEDGTEENKALKIQTSGEPDVAERVDLEELIECATGKMELCARTDPSEQVEGNCEIVNELIAASTQKGQIKKKRLSELGITQADDNLMSQEMFVGIVGNQFKWNGKGSFGTFLF T04497 TARGETID T04497 T04497 FORMERID TTDI03466 T04497 UNIPROID PKR2_HUMAN T04497 TARGNAME Prokineticin receptor 2 (PKR2) T04497 GENENAME PROKR2 T04497 TARGTYPE Literature-reported T04497 SYNONYMS PKR2; PK-R2; GPRg2; GPR73b; GPR73L1; G-protein coupled receptor I5E; G-protein coupled receptor 73-like 1 T04497 FUNCTION Receptor for prokineticin 2. Exclusively coupled to the G(q) subclass of heteromeric G proteins. Activation leads to mobilization of calcium, stimulation of phosphoinositide turnover and activation of p44/p42 mitogen-activated protein kinase. T04497 SEQUENCE MAAQNGNTSFTPNFNPPQDHASSLSFNFSYGDYDLPMDEDEDMTKTRTFFAAKIVIGIALAGIMLVCGIGNFVFIAALTRYKKLRNLTNLLIANLAISDFLVAIICCPFEMDYYVVRQLSWEHGHVLCASVNYLRTVSLYVSTNALLAIAIDRYLAIVHPLKPRMNYQTASFLIALVWMVSILIAIPSAYFATETVLFIVKSQEKIFCGQIWPVDQQLYYKSYFLFIFGVEFVGPVVTMTLCYARISRELWFKAVPGFQTEQIRKRLRCRRKTVLVLMCILTAYVLCWAPFYGFTIVRDFFPTVFVKEKHYLTAFYVVECIAMSNSMINTVCFVTVKNNTMKYFKKMMLLHWRPSQRGSKSSADLDLRTNGVPTTEEVDCIRLK T04497 DRUGINFO D03TIA PKR-A Investigative T04497 DRUGINFO D02VQO triazine compound PC10 Investigative T32912 TARGETID T32912 T32912 FORMERID TTDI02357 T32912 UNIPROID CTCFL_HUMAN T32912 TARGNAME Transcriptional repressor CTCFL (CTCFL) T32912 GENENAME CTCFL T32912 TARGTYPE Literature-reported T32912 SYNONYMS Zinc finger protein CTCF-T; Cancer/testis antigen 27; CTCF-like protein; CTCF paralog; CT27; CCCTC-binding factor; Brother of the regulator of imprinted sites; BORIS T32912 FUNCTION Plays a key role in gene imprinting in male germline, by participating in the establishment of differential methylation at the IGF2/H19 imprinted control region (ICR). Directly binds the unmethylated H19 ICR and recruits the PRMT7 methyltransferase, leading to methylate histone H4 'Arg-3' to form H4R3sme2. This probably leads to recruit de novo DNA methyltransferases at these sites. Seems to act as tumor suppressor. In association with DNMT1 and DNMT3B, involved in activation of BAG1 gene expression by binding to its promoter. Required for dimethylation of H3 lysine 4 (H3K4me2) of MYC and BRCA1 promoters. Testis-specific DNA binding protein responsible for insulator function, nuclear architecture and transcriptional control, which probably acts by recruiting epigenetic chromatin modifiers. T32912 SEQUENCE MAATEISVLSEQFTKIKELELMPEKGLKEEEKDGVCREKDHRSPSELEAERTSGAFQDSVLEEEVELVLAPSEESEKYILTLQTVHFTSEAVELQDMSLLSIQQQEGVQVVVQQPGPGLLWLEEGPRQSLQQCVAISIQQELYSPQEMEVLQFHALEENVMVASEDSKLAVSLAETTGLIKLEEEQEKNQLLAERTKEQLFFVETMSGDERSDEIVLTVSNSNVEEQEDQPTAGQADAEKAKSTKNQRKTKGAKGTFHCDVCMFTSSRMSSFNRHMKTHTSEKPHLCHLCLKTFRTVTLLRNHVNTHTGTRPYKCNDCNMAFVTSGELVRHRRYKHTHEKPFKCSMCKYASVEASKLKRHVRSHTGERPFQCCQCSYASRDTYKLKRHMRTHSGEKPYECHICHTRFTQSGTMKIHILQKHGENVPKYQCPHCATIIARKSDLRVHMRNLHAYSAAELKCRYCSAVFHERYALIQHQKTHKNEKRFKCKHCSYACKQERHMTAHIRTHTGEKPFTCLSCNKCFRQKQLLNAHFRKYHDANFIPTVYKCSKCGKGFSRWINLHRHSEKCGSGEAKSAASGKGRRTRKRKQTILKEATKGQKEAAKGWKEAANGDEAAAEEASTTKGEQFPGEMFPVACRETTARVKEEVDEGVTCEMLLNTMDK T38183 TARGETID T38183 T38183 FORMERID TTDR00577 T38183 UNIPROID VANG1_HUMAN T38183 TARGNAME Vang-like protein 1 (VANGL1) T38183 GENENAME VANGL1 T38183 TARGTYPE Literature-reported T38183 SYNONYMS Van Gogh-like protein 1; Strabismus 2; STB2; Loop-tail protein 2 homolog; LPP2 T38183 FUNCTION Invovled in multicellular organism development, Wnt signaling pathway and planar cell polarity pathway. T38183 SEQUENCE MDTESTYSGYSYYSSHSKKSHRQGERTRERHKSPRNKDGRGSEKSVTIQPPTGEPLLGNDSTRTEEVQDDNWGETTTAITGTSEHSISQEDIARISKDMEDSVGLDCKRYLGLTVASFLGLLVFLTPIAFILLPPILWRDELEPCGTICEGLFISMAFKLLILLIGTWALFFRKRRADMPRVFVFRALLLVLIFLFVVSYWLFYGVRILDSRDRNYQGIVQYAVSLVDALLFIHYLAIVLLELRQLQPMFTLQVVRSTDGESRFYSLGHLSIQRAALVVLENYYKDFTIYNPNLLTASKFRAAKHMAGLKVYNVDGPSNNATGQSRAMIAAAARRRDSSHNELYYEEAEHERRVKKRKARLVVAVEEAFIHIQRLQAEEQQKAPGEVMDPREAAQAIFPSMARALQKYLRITRQQNYHSMESILQHLAFCITNGMTPKAFLERYLSAGPTLQYDKDRWLSTQWRLVSDEAVTNGLRDGIVFVLKCLDFSLVVNVKKIPFIILSEEFIDPKSHKFVLRLQSETSV T68834 TARGETID T68834 T68834 FORMERID TTDI03427 T68834 UNIPROID OXER1_HUMAN T68834 TARGNAME Oxoeicosanoid receptor 1 (OXER1) T68834 GENENAME OXER1 T68834 TARGTYPE Literature-reported T68834 SYNONYMS TG1019; GPR170; G-protein coupled receptor TG1019; G-protein coupled receptor R527; G-protein coupled receptor 170; 5-oxo-ETE G-protein coupled receptor T68834 FUNCTION Receptor for eicosanoids and polyunsaturated fatty acids such as 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-OXO-ETE), 5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HPETE) and arachidonic acid. Seems to be coupled to the G(i)/G(o), families of heteromeric G proteins. T68834 SEQUENCE MLCHRGGQLIVPIIPLCPEHSCRGRRLQNLLSGPWPKQPMELHNLSSPSPSLSSSVLPPSFSPSPSSAPSAFTTVGGSSGGPCHPTSSSLVSAFLAPILALEFVLGLVGNSLALFIFCIHTRPWTSNTVFLVSLVAADFLLISNLPLRVDYYLLHETWRFGAAACKVNLFMLSTNRTASVVFLTAIALNRYLKVVQPHHVLSRASVGAAARVAGGLWVGILLLNGHLLLSTFSGPSCLSYRVGTKPSASLRWHQALYLLEFFLPLALILFAIVSIGLTIRNRGLGGQAGPQRAMRVLAMVVAVYTICFLPSIIFGMASMVAFWLSACRSLDLCTQLFHGSLAFTYLNSVLDPVLYCFSSPNFLHQSRALLGLTRGRQGPVSDESSYQPSRQWRYREASRKAEAIGKLKVQGEVSLEKEGSSQG T68834 DRUGINFO D05LJD 5-oxo-C20:3 Investigative T68834 DRUGINFO D07TXF 5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid Investigative T68834 DRUGINFO D0D2MN 5-oxo-12-HETE Investigative T68834 DRUGINFO D0JH4U 5-oxo-15-HETE Investigative T68834 DRUGINFO D0T0HS Gue1654 Investigative T68834 DRUGINFO D0US4S [3H]5-oxo-ETE Investigative T68834 DRUGINFO D0XL8C 5-oxo-ODE Investigative T68834 DRUGINFO D0Z6SY 5-oxo-20-HETE Investigative T68834 DRUGINFO D0Q2LG 5S-HPETE Investigative T68834 DRUGINFO D07CJR 5S-HETE Investigative T86817 TARGETID T86817 T86817 FORMERID TTDI03557 T86817 UNIPROID S38A5_HUMAN T86817 TARGNAME Solute carrier family 38 member 5 (SLC38A5) T86817 GENENAME SLC38A5 T86817 TARGTYPE Literature-reported T86817 SYNONYMS System N transporter 2; Sodium-coupled neutral amino acid transporter 5; SNAT5; SN2; PP7194; JM24 T86817 FUNCTION Functions as a sodium-dependent amino acid transporter which countertransport protons. Mediates the saturable, pH-sensitive, and electrogenic cotransport of several neutral amino acids including glycine, asparagine, alanine, serine, glutamine and histidine with sodium. T86817 SEQUENCE MELQDPKMNGALPSDAVGYRQEREGFLPSRGPAPGSKPVQFMDFEGKTSFGMSVFNLSNAIMGSGILGLAYAMAHTGVIFFLALLLCIALLSSYSIHLLLTCAGIAGIRAYEQLGQRAFGPAGKVVVATVICLHNVGAMSSYLFIIKSELPLVIGTFLYMDPEGDWFLKGNLLIIIVSVLIILPLALMKHLGYLGYTSGLSLTCMLFFLVSVIYKKFQLGCAIGHNETAMESEALVGLPSQGLNSSCEAQMFTVDSQMSYTVPIMAFAFVCHPEVLPIYTELCRPSKRRMQAVANVSIGAMFCMYGLTATFGYLTFYSSVKAEMLHMYSQKDPLILCVRLAVLLAVTLTVPVVLFPIRRALQQLLFPGKAFSWPRHVAIALILLVLVNVLVICVPTIRDIFGVIGSTSAPSLIFILPSIFYLRIVPSEVEPFLSWPKIQALCFGVLGVLFMAVSLGFMFANWATGQSRMSGH T86817 DRUGINFO D07UTZ [3H]histidine Investigative T86817 DRUGINFO D0XT2X [14C]histidine Investigative T97314 TARGETID T97314 T97314 FORMERID TTDI01480 T97314 UNIPROID NRG4_HUMAN T97314 TARGNAME Neuregulin 4 (NRG4) T97314 GENENAME NRG4 T97314 TARGTYPE Literature-reported T97314 SYNONYMS Pro-neuregulin-4, membrane-bound isoform; Pro-NRG4 T97314 FUNCTION Low affinity ligand for the ERBB4 tyrosine kinase receptor. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. Does not bind to the ERBB1, ERBB2 and ERBB3 receptors (By similarity). T97314 SEQUENCE MPTDHEEPCGPSHKSFCLNGGLCYVIPTIPSPFCRCVENYTGARCEEVFLPGSSIQTKSNLFEAFVALAVLVTLIIGAFYFLCRKGHFQRASSVQYDINLVETSSTSAHHSHEQH T95730 TARGETID T95730 T95730 UNIPROID SCG3_HUMAN T95730 TARGNAME Secretogranin-3 (SCG3) T95730 GENENAME SCG3 T95730 TARGTYPE Literature-reported T95730 SYNONYMS SgIII; Secretogranin III T95730 FUNCTION endoplasmic reticulum lumen, extracellular region, secretory granule lumen, RNA binding, cellular protein metabolic process, platelet degranulation, post-translational protein modification. T95730 SEQUENCE MGFLGTGTWILVLVLPIQAFPKPGGSQDKSLHNRELSAERPLNEQIAEAEEDKIKKTYPPENKPGQSNYSFVDNLNLLKAITEKEKIEKERQSIRSSPLDNKLNVEDVDSTKNRKLIDDYDSTKSGLDHKFQDDPDGLHQLDGTPLTAEDIVHKIAARIYEENDRAVFDKIVSKLLNLGLITESQAHTLEDEVAEVLQKLISKEANNYEEDPNKPTSWTENQAGKIPEKVTPMAAIQDGLAKGENDETVSNTLTLTNGLERRTKTYSEDNFEELQYFPNFYALLKSIDSEKEAKEKETLITIMKTLIDFVKMMVKYGTISPEEGVSYLENLDEMIALQTKNKLEKNATDNISKLFPAPSEKSHEETDSTKEEAAKMEKEYGSLKDSTKDDNSNPGGKTDEPKGKTEAYLEAIRKNIEWLKKHDKKGNKEDYDLSKMRDFINKQADAYVEKGILDKEEAEAIKRIYSSL T74607 TARGETID T74607 T74607 FORMERID TTDI03174 T74607 UNIPROID RPGF4_HUMAN T74607 TARGNAME Rap guanine nucleotide exchange factor 4 (EPAC2) T74607 GENENAME RAPGEF4 T74607 TARGTYPE Literature-reported T74607 SYNONYMS cAMP-regulated guanine nucleotide exchange factor II; cAMP-GEFII; Exchange protein directly activated by cAMP 2; Exchange factor directly activated by cAMP 2; EPAC2; EPAC 2; CGEF2 T74607 FUNCTION Guanine nucleotide exchange factor (GEF) for RAP1A, RAP1B and RAP2A small GTPases that is activated by binding cAMP. Seems not to activate RAB3A. Involved in cAMP-dependent, PKA-independent exocytosis through interaction with RIMS2 (By similarity). T74607 SEQUENCE MVAAHAAHSSSSAEWIACLDKRPLERSSEDVDIIFTRLKEVKAFEKFHPNLLHQICLCGYYENLEKGITLFRQGDIGTNWYAVLAGSLDVKVSETSSHQDAVTICTLGIGTAFGESILDNTPRHATIVTRESSELLRIEQKDFKALWEKYRQYMAGLLAPPYGVMETGSNNDRIPDKENTPLIEPHVPLRPANTITKVPSEKILRAGKILRNAILSRAPHMIRDRKYHLKTYRQCCVGTELVDWMMQQTPCVHSRTQAVGMWQVLLEDGVLNHVDQEHHFQDKYLFYRFLDDEHEDAPLPTEEEKKECDEELQDTMLLLSQMGPDAHMRMILRKPPGQRTVDDLEIIYEELLHIKALSHLSTTVKRELAGVLIFESHAKGGTVLFNQGEEGTSWYIILKGSVNVVIYGKGVVCTLHEGDDFGKLALVNDAPRAASIVLREDNCHFLRVDKEDFNRILRDVEANTVRLKEHDQDVLVLEKVPAGNRASNQGNSQPQQKYTVMSGTPEKILEHFLETIRLEATLNEATDSVLNDFIMMHCVFMPNTQLCPALVAHYHAQPSQGTEQEKMDYALNNKRRVIRLVLQWAAMYGDLLQEDDVSMAFLEEFYVSVSDDARMIAALKEQLPELEKIVKQISEDAKAPQKKHKVLLQQFNTGDERAQKRQPIRGSDEVLFKVYCMDHTYTTIRVPVATSVKEVISAVADKLGSGEGLIIVKMSSGGEKVVLKPNDVSVFTTLTINGRLFACPREQFDSLTPLPEQEGPTVGTVGTFELMSSKDLAYQMTIYDWELFNCVHELELIYHTFGRHNFKKTTANLDLFLRRFNEIQFWVVTEICLCSQLSKRVQLLKKFIKIAAHCKEYKNLNSFFAIVMGLSNVAVSRLALTWEKLPSKFKKFYAEFESLMDPSRNHRAYRLTVAKLEPPLIPFMPLLIKDMTFTHEGNKTFIDNLVNFEKMRMIANTARTVRYYRSQPFNPDAAQANKNHQDVRSYVRQLNVIDNQRTLSQMSHRLEPRRP T74607 DRUGINFO D00EHP HJC 0350 Investigative T74607 DRUGINFO D0WW2X ESI-09 Investigative T95359 TARGETID T95359 T95359 FORMERID TTDR01322 T95359 UNIPROID Q8Z939_SALTI T95359 TARGNAME Salmonella typhi 27-kDa outer membrane protein T2544 (SALTI STY0351) T95359 GENENAME SALTI STY0351 T95359 TARGTYPE Literature-reported T95359 SYNONYMS Possible outer membrane adhesin T95359 FUNCTION Plays a major role in bacterial adhesion to the host through high-affinity binding to laminin. T95359 SEQUENCE MKNFFAVCIIPLVVTWSATASAKEGIYITGKAGTSVVNVYGINSTFSQEEIVNGHATLPDRTKGVFGGGVAIGYDFYDPFQLPVRLELDTTFRGETDAKGGQDIIAFGQPVHINVKNQVRMTTYIVNGYYDFHNSTAFTPYISAGVGLAHVKLSNNTIPVGFGINETLSASKNNFAWGAGIGAKYAVTDNIMIDASYKYINAGKVSISKNHYAGDEHTAYDADTKAASNDFMLGITYAF T86226 TARGETID T86226 T86226 FORMERID TTDR01278 T86226 UNIPROID AQP3_HUMAN T86226 TARGNAME Aquaporin 3 (AQP3) T86226 GENENAME AQP3 T86226 TARGTYPE Literature-reported T86226 SYNONYMS Aquaporin-3; Aquaglyceroporin-3; AQP-3 T86226 FUNCTION Water channel required to promote glycerol permeability and water transport across cell membranes. Acts as a glycerol transporter in skin and plays an important role in regulating SC (stratum corneum) and epidermal glycerol content. Involved in skin hydration, wound healing, and tumorigenesis. Provides kidney medullary collecting duct with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient. Slightly permeable to urea and may function as a water and urea exit mechanism in antidiuresis in collecting duct cells. It may play an important role in gastrointestinal tract water transport and in glycerol metabolism (By similarity). T86226 SEQUENCE MGRQKELVSRCGEMLHIRYRLLRQALAECLGTLILVMFGCGSVAQVVLSRGTHGGFLTINLAFGFAVTLGILIAGQVSGAHLNPAVTFAMCFLAREPWIKLPIYTLAQTLGAFLGAGIVFGLYYDAIWHFADNQLFVSGPNGTAGIFATYPSGHLDMINGFFDQFIGTASLIVCVLAIVDPYNNPVPRGLEAFTVGLVVLVIGTSMGFNSGYAVNPARDFGPRLFTALAGWGSAVFTTGQHWWWVPIVSPLLGSIAGVFVYQLMIGCHLEQPPPSNEEENVKLAHVKHKEQI T22368 TARGETID T22368 T22368 FORMERID TTDI02451 T22368 UNIPROID NELL1_HUMAN T22368 TARGNAME Nel-related protein 1 (NELL1) T22368 GENENAME NELL1 T22368 TARGTYPE Literature-reported T22368 SYNONYMS NELL1; NEL-like protein 1 T22368 FUNCTION Plays a role in the control of cell growth and differentiation. Promotes osteoblast cell differentiation and terminal mineralization. T22368 SEQUENCE MPMDLILVVWFCVCTARTVVGFGMDPDLQMDIVTELDLVNTTLGVAQVSGMHNASKAFLFQDIEREIHAAPHVSEKLIQLFRNKSEFTILATVQQKPSTSGVILSIRELEHSYFELESSGLRDEIRYHYIHNGKPRTEALPYRMADGQWHKVALSVSASHLLLHVDCNRIYERVIDPPDTNLPPGINLWLGQRNQKHGLFKGIIQDGKIIFMPNGYITQCPNLNHTCPTCSDFLSLVQGIMDLQELLAKMTAKLNYAETRLSQLENCHCEKTCQVSGLLYRDQDSWVDGDHCRNCTCKSGAVECRRMSCPPLNCSPDSLPVHIAGQCCKVCRPKCIYGGKVLAEGQRILTKSCRECRGGVLVKITEMCPPLNCSEKDHILPENQCCRVCRGHNFCAEGPKCGENSECKNWNTKATCECKSGYISVQGDSAYCEDIDECAAKMHYCHANTVCVNLPGLYRCDCVPGYIRVDDFSCTEHDECGSGQHNCDENAICTNTVQGHSCTCKPGYVGNGTICRAFCEEGCRYGGTCVAPNKCVCPSGFTGSHCEKDIDECSEGIIECHNHSRCVNLPGWYHCECRSGFHDDGTYSLSGESCIDIDECALRTHTCWNDSACINLAGGFDCLCPSGPSCSGDCPHEGGLKHNGQVWTLKEDRCSVCSCKDGKIFCRRTACDCQNPSADLFCCPECDTRVTSQCLDQNGHKLYRSGDNWTHSCQQCRCLEGEVDCWPLTCPNLSCEYTAILEGECCPRCVSDPCLADNITYDIRKTCLDSYGVSRLSGSVWTMAGSPCTTCKCKNGRVCCSVDFECLQNN T94942 TARGETID T94942 T94942 FORMERID TTDI02442 T94942 UNIPROID PRG4_HUMAN T94942 TARGNAME Proteoglycan 4 (PRG4) T94942 GENENAME PRG4 T94942 TARGTYPE Literature-reported T94942 SYNONYMS Superficial zone proteoglycan; Proteoglycan 4 C-terminal part; PRG4; Megakaryocyte-stimulating factor; Lubricin T94942 FUNCTION Isoform F plays a role as a growth factor acting on the primitive cells of both hematopoietic and endothelial cell lineages. T94942 SEQUENCE MAWKTLPIYLLLLLSVFVIQQVSSQDLSSCAGRCGEGYSRDATCNCDYNCQHYMECCPDFKRVCTAELSCKGRCFESFERGRECDCDAQCKKYDKCCPDYESFCAEVHNPTSPPSSKKAPPPSGASQTIKSTTKRSPKPPNKKKTKKVIESEEITEEHSVSENQESSSSSSSSSSSSTIRKIKSSKNSAANRELQKKLKVKDNKKNRTKKKPTPKPPVVDEAGSGLDNGDFKVTTPDTSTTQHNKVSTSPKITTAKPINPRPSLPPNSDTSKETSLTVNKETTVETKETTTTNKQTSTDGKEKTTSAKETQSIEKTSAKDLAPTSKVLAKPTPKAETTTKGPALTTPKEPTPTTPKEPASTTPKEPTPTTIKSAPTTPKEPAPTTTKSAPTTPKEPAPTTTKEPAPTTPKEPAPTTTKEPAPTTTKSAPTTPKEPAPTTPKKPAPTTPKEPAPTTPKEPTPTTPKEPAPTTKEPAPTTPKEPAPTAPKKPAPTTPKEPAPTTPKEPAPTTTKEPSPTTPKEPAPTTTKSAPTTTKEPAPTTTKSAPTTPKEPSPTTTKEPAPTTPKEPAPTTPKKPAPTTPKEPAPTTPKEPAPTTTKKPAPTTPKEPAPTTPKETAPTTPKKLTPTTPEKLAPTTPEKPAPTTPEELAPTTPEEPTPTTPEEPAPTTPKAAAPNTPKEPAPTTPKEPAPTTPKEPAPTTPKETAPTTPKGTAPTTLKEPAPTTPKKPAPKELAPTTTKEPTSTTSDKPAPTTPKGTAPTTPKEPAPTTPKEPAPTTPKGTAPTTLKEPAPTTPKKPAPKELAPTTTKGPTSTTSDKPAPTTPKETAPTTPKEPAPTTPKKPAPTTPETPPPTTSEVSTPTTTKEPTTIHKSPDESTPELSAEPTPKALENSPKEPGVPTTKTPAATKPEMTTTAKDKTTERDLRTTPETTTAAPKMTKETATTTEKTTESKITATTTQVTSTTTQDTTPFKITTLKTTTLAPKVTTTKKTITTTEIMNKPEETAKPKDRATNSKATTPKPQKPTKAPKKPTSTKKPKTMPRVRKPKTTPTPRKMTSTMPELNPTSRIAEAMLQTTTRPNQTPNSKLVEVNPKSEDAGGAEGETPHMLLRPHVFMPEVTPDMDYLPRVPNQGIIINPMLSDETNICNGKPVDGLTTLRNGTLVAFRGHYFWMLSPFSPPSPARRITEVWGIPSPIDTVFTRCNCEGKTFFFKDSQYWRFTNDIKDAGYPKPIFKGFGGLTGQIVAALSTAKYKNWPESVYFFKRGGSIQQYIYKQEPVQKCPGRRPALNYPVYGETTQVRRRRFERAIGPSQTHTIRIQYSPARLAYQDKGVLHNEVKVSILWRGLPNVVTSAISLPNIRKPDGYDYYAFSKDQYYNIDVPSRTARAITTRSGQTLSKVWYNCP T22603 TARGETID T22603 T22603 FORMERID TTDI01426 T22603 UNIPROID Q95VF2_LEIDO T22603 TARGNAME Leishmania Elongation factor 1-alpha (Leishm EF1A) T22603 GENENAME Leishm EF1A T22603 TARGTYPE Literature-reported T22603 SYNONYMS Leishmania Elongation factor 1A T22603 FUNCTION This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. T22603 SEQUENCE MGKDKVHMNLVVVGHVDAGKSTATGHLIYKCGGIDKRTIEKFEKEAAEIGKASFKYAWVLDKLKAERERGITIDIALWKFESPKSVFTIIDAPGHRDFIKNMITGTSQADAAILMIDSTHGGFEAGISKDGQTREHALLAFTLGVKQMVVCCNKMDDKTVTYAQSRYDEISKEVGAYLKRVGYNPEKVRFIPISGWQGDNMIERSDNMPWYKGPTLLDALDMLEPPVRPVDKPLRLPLQDVYKIGGIGTVPVGRVETGIMKPGDVVTFAPANVTTEVKSIEMHHEQLAEAQPGDNVGFNVKNVSVKDIRRGNVCGNSKNDPPKEAADFTAQVIVLNHPGQISNGYAPVLDCHTSHIACRFAEIESKIDRRSGKELEKNPKAIKSGDAAIVKMVPQKPMCVEVFNDYAPLGRFAVRDMRQTVAVGIIKGVNKKEGSGGKVTKAAAKAAKK T13252 TARGETID T13252 T13252 FORMERID TTDI03556 T13252 UNIPROID S38A4_HUMAN T13252 TARGNAME Solute carrier family 38 member 4 (SLC38A4) T13252 GENENAME SLC38A4 T13252 TARGTYPE Literature-reported T13252 SYNONYMS System N amino acid transporter 3; System A amino acid transporter 3; Sodium-coupled neutral amino acid transporter 4; SNAT4; Na(+)-coupled neutral amino acid transporter 4; NAT3; Amino acid transporter A3; ATA3 T13252 FUNCTION Sodium-dependent amino acid transporter. Mediates electrogenic symport of neutral amino acids and sodium ions. Has a broad specificity, with a preference for Ala, followed by His, Cys, Asn, Ser, Gly, Val, Thr, Gln and Met. May mediate sodium-independent transport of cationic amino acids, such as Arg and Lys. Amino acid uptake is pH-dependent, with low transport activities at pH 6.5, intermediate at pH 7.0 and highest between pH 7.5 and 8.5. T13252 SEQUENCE MDPMELRNVNIEPDDESSSGESAPDSYIGIGNSEKAAMSSQFANEDTESQKFLTNGFLGKKKLADYADEHHPGTTSFGMSSFNLSNAIMGSGILGLSYAMANTGIILFIIMLLAVAILSLYSVHLLLKTAKEGGSLIYEKLGEKAFGWPGKIGAFVSITMQNIGAMSSYLFIIKYELPEVIRAFMGLEENTGEWYLNGNYLIIFVSVGIILPLSLLKNLGYLGYTSGFSLTCMVFFVSVVIYKKFQIPCPLPVLDHSVGNLSFNNTLPMHVVMLPNNSESSDVNFMMDYTHRNPAGLDENQAKGSLHDSGVEYEAHSDDKCEPKYFVFNSRTAYAIPILVFAFVCHPEVLPIYSELKDRSRRKMQTVSNISITGMLVMYLLAALFGYLTFYGEVEDELLHAYSKVYTLDIPLLMVRLAVLVAVTLTVPIVLFPIRTSVITLLFPKRPFSWIRHFLIAAVLIALNNVLVILVPTIKYIFGFIGASSATMLIFILPAVFYLKLVKKETFRSPQKVGALIFLVVGIFFMIGSMALIIIDWIYDPPNSKHH T09266 TARGETID T09266 T09266 FORMERID TTDI02439 T09266 UNIPROID PAQR1_HUMAN; PAQR2_HUMAN T09266 TARGNAME Adiponectin receptor (ADIPOR) T09266 GENENAME ADIPOR1; ADIPOR2 T09266 TARGTYPE Literature-reported T09266 SYNONYMS Progestin and adipoQ receptor family member; PAQR; Adiponectin receptor protein T09266 FUNCTION Receptor for globular and full-length adiponectin (APM1), an essential hormone secreted by adipocytes that acts as an antidiabetic. Probably involved in metabolic pathways that regulate lipid metabolism such as fatty acid oxidation. Mediates increased AMPK, PPARA ligand activity, fatty acid oxidation and glucose uptake by adiponectin. Has some high-affinity receptor for globular adiponectin but low-affinity receptor for full-length adiponectin. T09266 SEQUENCE MSSHKGSVVAQGNGAPASNREADTVELAELGPLLEEKGKRVIANPPKAEEEQTCPVPQEEEEEVRVLTLPLQAHHAMEKMEEFVYKVWEGRWRVIPYDVLPDWLKDNDYLLHGHRPPMPSFRACFKSIFRIHTETGNIWTHLLGFVLFLFLGILTMLRPNMYFMAPLQEKVVFGMFFLGAVLCLSFSWLFHTVYCHSEKVSRTFSKLDYSGIALLIMGSFVPWLYYSFYCSPQPRLIYLSIVCVLGISAIIVAQWDRFATPKHRQTRAGVFLGLGLSGVVPTMHFTIAEGFVKATTVGQMGWFFLMAVMYITGAGLYAARIPERFFPGKFDIWFQSHQIFHVLVVAAAFVHFYGVSNLQEFRYGLEGGCTDDTLL T97322 TARGETID T97322 T97322 FORMERID TTDI03424 T97322 UNIPROID SO4A1_HUMAN T97322 TARGNAME Organic anion transporter E (SLCO4A1) T97322 GENENAME SLCO4A1 T97322 TARGTYPE Literature-reported T97322 SYNONYMS Solute carrier organic anion transporter family member 4A1; Solute carrier family 21 member 12; Sodium-independent organic anion transporter E; SLC21A12; POAT; Organic anion-transporting polypeptide E; Organic anion transporter polypeptide-related protein 1; OATPRP1; OATPE; OATP4A1; OATP1; OATP-RP1; OATP-E; Colon organic anion transporter T97322 FUNCTION Mediates the Na(+)-independent transport of organic anions such as the thyroid hormones T3 (triiodo-L-thyronine), T4 (thyroxine) and rT3, and of estrone-3-sulfate and taurocholate. T97322 SEQUENCE MPLHQLGDKPLTFPSPNSAMENGLDHTPPSRRASPGTPLSPGSLRSAAHSPLDTSKQPLCQLWAEKHGARGTHEVRYVSAGQSVACGWWAFAPPCLQVLNTPKGILFFLCAAAFLQGMTVNGFINTVITSLERRYDLHSYQSGLIASSYDIAACLCLTFVSYFGGSGHKPRWLGWGVLLMGTGSLVFALPHFTAGRYEVELDAGVRTCPANPGAVCADSTSGLSRYQLVFMLGQFLHGVGATPLYTLGVTYLDENVKSSCSPVYIAIFYTAAILGPAAGYLIGGALLNIYTEMGRRTELTTESPLWVGAWWVGFLGSGAAAFFTAVPILGYPRQLPGSQRYAVMRAAEMHQLKDSSRGEASNPDFGKTIRDLPLSIWLLLKNPTFILLCLAGATEATLITGMSTFSPKFLESQFSLSASEAATLFGYLVVPAGGGGTFLGGFFVNKLRLRGSAVIKFCLFCTVVSLLGILVFSLHCPSVPMAGVTASYGGSLLPEGHLNLTAPCNAACSCQPEHYSPVCGSDGLMYFSLCHAGCPAATETNVDGQKVYRDCSCIPQNLSSGFGHATAGKCTSTCQRKPLLLVFIFVVIFFTFLSSIPALTATLRCVRDPQRSFALGIQWIVVRILGGIPGPIAFGWVIDKACLLWQDQCGQQGSCLVYQNSAMSRYILIMGLLYKVLGVLFFAIACFLYKPLSESSDGLETCLPSQSSAPDSATDSQLQSSV T97322 DRUGINFO D04AXP [3H]estrone-3-sulphate Investigative T59136 TARGETID T59136 T59136 FORMERID TTDNR00725 T59136 UNIPROID PINX1_HUMAN T59136 TARGNAME PIN2/TERF1-interacting telomerase inhibitor 1 (PINX1) T59136 GENENAME PINX1 T59136 TARGTYPE Literature-reported T59136 SYNONYMS TRF1-interacting protein 1; Protein 67-11-3; Pin2-interacting protein X1; Liver-related putative tumor suppressor; LPTS; LPTL T59136 FUNCTION Mediates TRF1 and TERT accumulation in nucleolus and enhances TRF1 binding to telomeres. Inhibits telomerase activity. May inhibit cell proliferation and act as tumor suppressor. Microtubule-binding protein essential for faithful chromosome segregation. T59136 SEQUENCE MSMLAERRRKQKWAVDPQNTAWSNDDSKFGQRMLEKMGWSKGKGLGAQEQGATDHIKVQVKNNHLGLGATINNEDNWIAHQDDFNQLLAELNTCHGQETTDSSDKKEKKSFSLEEKSKISKNRVHYMKFTKGKDLSSRSKTDLDCIFGKRQSKKTPEGDASPSTPEENETTTTSAFTIQEYFAKRMAALKNKPQVPVPGSDISETQVERKRGKKRNKEATGKDVESYLQPKAKRHTEGKPERAEAQERVAKKKSAPAEEQLRGPCWDQSSKASAQDAGDHVQPPEGRDFTLKPKKRRGKKKLQKPVEIAEDATLEETLVKKKKKKDSK T52719 TARGETID T52719 T52719 FORMERID TTDI01710 T52719 UNIPROID PAGE5_HUMAN T52719 TARGNAME Prostate-associated gene 5 protein (PAGE5) T52719 GENENAME PAGE5 T52719 TARGTYPE Literature-reported T52719 SYNONYMS PAGE-5; P antigen family member 5; GAGEE1; G antigen family E member 1; Cancer/testis antigen 16.1; CT16.1 T52719 FUNCTION A member of family of proteins that are expressed in a variety of tumors and in some fetal and reproductive tissues. The encoded protein may protect cells from programmed cell death. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found. T52719 SEQUENCE MQAPWAGNRGWAGTREEVRDMSEHVTRSQSSERGNDQESSQPVGPVIVQQPTEEKRQEEEPPTDNQGIAPSGEIKNEGAPAVQGTDVEAFQQELALLKIEDAPGDGPDVREGTLPTFDPTKVLEAGEGQL T57253 TARGETID T57253 T57253 FORMERID TTDI01728 T57253 UNIPROID MRGX1_HUMAN T57253 TARGNAME Mas-related G protein-coupled receptor X1 (MRGX1) T57253 GENENAME MRGPRX1 T57253 TARGTYPE Literature-reported T57253 SYNONYMS Sensory neuron-specific G-protein coupled receptor 3/4; SNSR4; SNSR3; Mas-related G-protein coupled receptor member X1; MRGX1 T57253 FUNCTION Orphan receptor. Probably involved in the function of nociceptive neurons. May regulate nociceptor function and/or development, including the sensation or modulation of pain. Potently activated by enkephalins including BAM22 (bovine adrenal medulla peptide 22) and BAM (8-22). BAM22 is the most potent compound and evoked a large and dose-dependent release of intracellular calcium in stably transfected cells. G(alpha)q proteins are involved in the calcium-signaling pathway. Activated by the antimalarial drug, chloroquine. May mediate chloroquine-induced itch, in a histamine-independent manner. T57253 SEQUENCE MDPTISTLDTELTPINGTEETLCYKQTLSLTVLTCIVSLVGLTGNAVVLWLLGCRMRRNAFSIYILNLAAADFLFLSGRLIYSLLSFISIPHTISKILYPVMMFSYFAGLSFLSAVSTERCLSVLWPIWYRCHRPTHLSAVVCVLLWALSLLRSILEWMLCGFLFSGADSAWCQTSDFITVAWLIFLCVVLCGSSLVLLIRILCGSRKIPLTRLYVTILLTVLVFLLCGLPFGIQFFLFLWIHVDREVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQRQNRQNLKLVLQRALQDASEVDEGGGQLPEEILELSGSRLEQ T96179 TARGETID T96179 T96179 UNIPROID G137A_HUMAN T96179 TARGNAME Integral membrane protein GPR137 (GPR137) T96179 GENENAME GPR137 T96179 TARGTYPE Literature-reported T96179 SYNONYMS Transmembrane 7 superfamily member 1-like 1 protein; TM7SF1L1; GPR137A; C11orf4 T96179 FUNCTION It is a peptide which displays four putative transmembrane domains and is predicted to have a cytoplasmic localization. The receptor is available in the following formats: stable over-expression cell line, membrane preparation, or purified receptor in HEK293 or CHO. T96179 SEQUENCE MESNLSGLVPAAGLVPALPPAVTLGLTAAYTTLYALLFFSVYAQLWLVLLYGHKRLSYQTVFLALCLLWAALRTTLFSFYFRDTPRANRLGPLPFWLLYCCPVCLQFFTLTLMNLYFAQVVFKAKVKRRPEMSRGLLAVRGAFVGASLLFLLVNVLCAVLSHRRRAQPWALLLVRVLVSDSLFVICALSLAACLCLVARRAPSTSIYLEAKGTSVCQAAAMGGAMVLLYASRACYNLTALALAPQSRLDTFDYDWYNVSDQADLVNDLGNKGYLVFGLILFVWELLPTTLLVGFFRVHRPPQDLSTSHILNGQVFASRSYFFDRAGHCEDEGCSWEHSRGESTRCQDQAATTTVSTPPHRRDPPPSPTEYPGPSPPHPRPLCQVCLPLLAQDPGGRGYPLLWPAPCCSCHSELVPSP T69476 TARGETID T69476 T69476 FORMERID TTDI03095 T69476 UNIPROID CTSR2_HUMAN T69476 TARGNAME Cation channel sperm-associated protein 2 (CatSper2) T69476 GENENAME CATSPER2 T69476 TARGTYPE Literature-reported T69476 SYNONYMS CatSper2 T69476 FUNCTION Voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte. T69476 SEQUENCE MAAYQQEEQMQLPRADAIRSRLIDTFSLIEHLQGLSQAVPRHTIRELLDPSRQKKLVLGDQHQLVRFSIKPQRIEQISHAQRLLSRLHVRCSQRPPLSLWAGWVLECPLFKNFIIFLVFLNTIILMVEIELLESTNTKLWPLKLTLEVAAWFILLIFILEILLKWLSNFSVFWKSAWNVFDFVVTMLSLLPEVVVLVGVTGQSVWLQLLRICRVLRSLKLLAQFRQIQIIILVLVRALKSMTFLLMLLLIFFYIFAVTGVYVFSEYTRSPRQDLEYHVFFSDLPNSLVTVFILFTLDHWYALLQDVWKVPEVSRIFSSIYFILWLLLGSIIFRSIIVAMMVTNFQNIRKELNEEMARREVQLKADMFKRQIIQRRKNMSHEALTSSHSKIEDSSRGASQQRESLDLSEVSEVESNYGATEEDLITSASKTEETLSKKREYQSSSCVSSTSSSYSSSSESRFSESIGRLDWETLVHENLPGLMEMDQDDRVWPRDSLFRYFELLEKLQYNLEERKKLQEFAVQALMNLEDK T69476 DRUGINFO D03BSR NNC55-0396 Investigative T69476 DRUGINFO D0JF0W PGF1alpha Investigative T63393 TARGETID T63393 T63393 FORMERID TTDI03429 T63393 UNIPROID OXGR1_HUMAN T63393 TARGNAME Oxoglutarate receptor (OXGR1) T63393 GENENAME OXGR1 T63393 TARGTYPE Literature-reported T63393 SYNONYMS P2Y15; P2Y-like nucleotide receptor; P2Y-like GPCR; P2Y purinoceptor 15; P2RY15; GPR99; GPR80; G-protein coupled receptor 99; G-protein coupled receptor 80; Alpha-ketoglutarate receptor 1; 2-oxoglutarate receptor 1 T63393 FUNCTION Receptor for alpha-ketoglutarate. Seems to act exclusively through a G(q)-mediated pathway (By similarity). T63393 SEQUENCE MNEPLDYLANASDFPDYAAAFGNCTDENIPLKMHYLPVIYGIIFLVGFPGNAVVISTYIFKMRPWKSSTIIMLNLACTDLLYLTSLPFLIHYYASGENWIFGDFMCKFIRFSFHFNLYSSILFLTCFSIFRYCVIIHPMSCFSIHKTRCAVVACAVVWIISLVAVIPMTFLITSTNRTNRSACLDLTSSDELNTIKWYNLILTATTFCLPLVIVTLCYTTIIHTLTHGLQTDSCLKQKARRLTILLLLAFYVCFLPFHILRVIRIESRLLSISCSIENQIHEAYIVSRPLAALNTFGNLLLYVVVSDNFQQAVCSTVRCKVSGNLEQAKKISYSNNP T63393 DRUGINFO D09KQZ alpha-ketoglutaric acid Investigative T63393 DRUGINFO D0C0KJ LTE4 Investigative T96273 TARGETID T96273 T96273 FORMERID TTDI03554 T96273 UNIPROID S38A2_HUMAN T96273 TARGNAME Solute carrier family 38 member 2 (SLC38A2) T96273 GENENAME SLC38A2 T96273 TARGTYPE Literature-reported T96273 SYNONYMS System N amino acid transporter 2; System A transporter 1; System A amino acid transporter 2; Sodium-coupled neutral amino acid transporter 2; SNAT2; SAT2; Protein 40-9-1; KIAA1382; Amino acid transporter A2; ATA2 T96273 FUNCTION Functions as a sodium-dependent amino acid transporter. Mediates the saturable, pH-sensitive and electrogenic cotransport of neutral amino acids and sodium ions with a stoichiometry of 1:1. May function in the transport of amino acids at the blood-brain barrier and in the supply of maternal nutrients to the fetus through the placenta. T96273 SEQUENCE MKKAEMGRFSISPDEDSSSYSSNSDFNYSYPTKQAALKSHYADVDPENQNFLLESNLGKKKYETEFHPGTTSFGMSVFNLSNAIVGSGILGLSYAMANTGIALFIILLTFVSIFSLYSVHLLLKTANEGGSLLYEQLGYKAFGLVGKLAASGSITMQNIGAMSSYLFIVKYELPLVIQALTNIEDKTGLWYLNGNYLVLLVSLVVILPLSLFRNLGYLGYTSGLSLLCMVFFLIVVICKKFQVPCPVEAALIINETINTTLTQPTALVPALSHNVTENDSCRPHYFIFNSQTVYAVPILIFSFVCHPAVLPIYEELKDRSRRRMMNVSKISFFAMFLMYLLAALFGYLTFYEHVESELLHTYSSILGTDILLLIVRLAVLMAVTLTVPVVIFPIRSSVTHLLCASKDFSWWRHSLITVSILAFTNLLVIFVPTIRDIFGFIGASAASMLIFILPSAFYIKLVKKEPMKSVQKIGALFFLLSGVLVMTGSMALIVLDWVHNAPGGGH T95783 TARGETID T95783 T95783 UNIPROID RSF1_HUMAN T95783 TARGNAME Remodeling and spacing factor 1 (RSF1) T95783 GENENAME RSF1 T95783 TARGTYPE Literature-reported T95783 SYNONYMS p325 subunit of RSF chromatin-remodeling complex; XAP8; Rsf-1; Hepatitis B virus X-associated protein; HBXAP; HBV pX-associated protein 8 T95783 FUNCTION Required for assembly of regular nucleosome arrays by the RSF chromatin-remodeling complex (PubMed:12972596). Facilitates transcription of hepatitis B virus (HBV) genes by the pX transcription activator. In case of infection by HBV, together with pX, it represses TNF-alpha induced NF-kappa-B transcription activation. Represses transcription when artificially recruited to chromatin by fusion to a heterogeneous DNA binding domain (PubMed:11944984, PubMed:11788598). T95783 SEQUENCE MATAAAAAAVMAPPGCPGSCPNFAVVCSFLERYGPLLDLPELPFPELERVLQAPPPDVGNGEVPKELVELHLKLMRKIGKSVTADRWEKYLIKICQEFNSTWAWEMEKKGYLEMSVECKLALLKYLCECQFDDNLKFKNIINEEDADTMRLQPIGRDKDGLMYWYQLDQDHNVRMYIEEQDDQDGSSWKCIVRNRNELAETLALLKAQIDPVLLKNSSQQDNSSRESPSLEDEETKKEEETPKQEEQKESEKMKSEEQPMDLENRSTANVLEETTVKKEKEDEKELVKLPVIVKLEKPLPENEEKKIIKEESDSFKENVKPIKVEVKECRADPKDTKSSMEKPVAQEPERIEFGGNIKSSHEITEKSTEETEKLKNDQQAKIPLKKREIKLSDDFDSPVKGPLCKSVTPTKEFLKDEIKQEEETCKRISTITALGHEGKQLVNGEVSDERVAPNFKTEPIETKFYETKEESYSPSKDRNIITEGNGTESLNSVITSMKTGELEKETAPLRKDADSSISVLEIHSQKAQIEEPDPPEMETSLDSSEMAKDLSSKTALSSTESCTMKGEEKSPKTKKDKRPPILECLEKLEKSKKTFLDKDAQRLSPIPEEVPKSTLESEKPGSPEAAETSPPSNIIDHCEKLASEKEVVECQSTSTVGGQSVKKVDLETLKEDSEFTKVEMDNLDNAQTSGIEEPSETKGSMQKSKFKYKLVPEEETTASENTEITSERQKEGIKLTIRISSRKKKPDSPPKVLEPENKQEKTEKEEEKTNVGRTLRRSPRISRPTAKVAEIRDQKADKKRGEGEDEVEEESTALQKTDKKEILKKSEKDTNSKVSKVKPKGKVRWTGSRTRGRWKYSSNDESEGSGSEKSSAASEEEEEKESEEAILADDDEPCKKCGLPNHPELILLCDSCDSGYHTACLRPPLMIIPDGEWFCPPCQHKLLCEKLEEQLQDLDVALKKKERAERRKERLVYVGISIENIIPPQEPDFSEDQEEKKKDSKKSKANLLERRSTRTRKCISYRFDEFDEAIDEAIEDDIKEADGGGVGRGKDISTITGHRGKDISTILDEERKENKRPQRAAAARRKKRRRLNDLDSDSNLDEEESEDEFKISDGSQDEFVVSDENPDESEEDPPSNDDSDTDFCSRRLRRHPSRPMRQSRRLRRKTPKKKYSDDDEEEESEENSRDSESDFSDDFSDDFVETRRRRSRRNQKRQINYKEDSESDGSQKSLRRGKEIRRVHKRRLSSSESEESYLSKNSEDDELAKESKRSVRKRGRSTDEYSEADEEEEEEEGKPSRKRLHRIETDEEESCDNAHGDANQPARDSQPRVLPSEQESTKKPYRIESDEEEDFENVGKVGSPLDYSLVDLPSTNGQSPGKAIENLIGKPTEKSQTPKDNSTASASLASNGTSGGQEAGAPEEEEDELLRVTDLVDYVCNSEQL T55201 TARGETID T55201 T55201 FORMERID TTDR01127 T55201 UNIPROID VGPCR_HHV8P T55201 TARGNAME Herpesvirus G-protein coupled receptor (KSHV vGPCR) T55201 GENENAME KSHV vGPCR T55201 TARGTYPE Literature-reported T55201 SYNONYMS viral G-protein coupled receptor; vGPCR; Protein ORF74 T55201 FUNCTION Receptor that signals constitutively via several signaling pathways including PI3K/AKT as well as mitogen- and stress-activated/MAP kinases. Promotes host cell proliferation and survival, modulates cell migration, stimulates angiogenesis, and recruits inflammatory cells, both in expressing cells and in neighboring cells. Maintains chronic activation of NF-kappa-B via interaction with host CADM1. T55201 SEQUENCE MAAEDFLTIFLDDDESWNETLNMSGYDYSGNFSLEVSVCEMTTVVPYTWNVGILSLIFLINVLGNGLVTYIFCKHRSRAGAIDILLLGICLNSLCLSISLLAEVLMFLFPNIISTGLCRLEIFFYYLYVYLDIFSVVCVSLVRYLLVAYSTRSWPKKQSLGWVLTSAALLIALVLSGDACRHRSRVVDPVSKQAMCYENAGNMTADWRLHVRTVSVTAGFLLPLALLILFYALTWCVVRRTKLQARRKVRGVIVAVVLLFFVFCFPYHVLNLLDTLLRRRWIRDSCYTRGLINVGLAVTSLLQALYSAVVPLIYSCLGSLFRQRMYGLFQSLRQSFMSGATT T75351 TARGETID T75351 T75351 FORMERID TTDI03555 T75351 UNIPROID S38A3_HUMAN T75351 TARGNAME Solute carrier family 38 member 3 (SLC38A3) T75351 GENENAME SLC38A3 T75351 TARGTYPE Literature-reported T75351 SYNONYMS Sodium-coupled neutral amino acid transporter 3; SNAT3; SN1; Na(+)-coupled neutral amino acid transporter 3; N-system amino acid transporter 1; G17 T75351 FUNCTION Sodium-dependent amino acid/proton antiporter. Mediates electrogenic cotransport of glutamine and sodium ions in exchange for protons. Also recognizes histidine, asparagine and alanine. May mediate amino acid transport in either direction under physiological conditions. May play a role in nitrogen metabolism and synaptic transmission. T75351 SEQUENCE MEAPLQTEMVELVPNGKHSEGLLPVITPMAGNQRVEDPARSCMEGKSFLQKSPSKEPHFTDFEGKTSFGMSVFNLSNAIMGSGILGLAYAMANTGIILFLFLLTAVALLSSYSIHLLLKSSGVVGIRAYEQLGYRAFGTPGKLAAALAITLQNIGAMSSYLYIIKSELPLVIQTFLNLEEKTSDWYMNGNYLVILVSVTIILPLALMRQLGYLGYSSGFSLSCMVFFLIAVIYKKFHVPCPLPPNFNNTTGNFSHVEIVKEKVQLQVEPEASAFCTPSYFTLNSQTAYTIPIMAFAFVCHPEVLPIYTELKDPSKKKMQHISNLSIAVMYIMYFLAALFGYLTFYNGVESELLHTYSKVDPFDVLILCVRVAVLTAVTLTVPIVLFPVRRAIQQMLFPNQEFSWLRHVLIAVGLLTCINLLVIFAPNILGIFGVIGATSAPFLIFIFPAIFYFRIMPTEKEPARSTPKILALCFAMLGFLLMTMSLSFIIIDWASGTSRHGGNH T58130 TARGETID T58130 T58130 FORMERID TTDI03356 T58130 UNIPROID LPAR4_HUMAN T58130 TARGNAME Lysophosphatidic acid receptor 4 (LPAR4) T58130 GENENAME LPAR4 T58130 TARGTYPE Literature-reported T58130 SYNONYMS Purinergic receptor 9; P2Y9; P2Y5-like receptor; P2Y purinoceptor 9; P2RY9; LPA4; LPA-4; LPA receptor 4; GPR23; G-protein coupled receptor 23 T58130 FUNCTION Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. Transduces a signal by increasing the intracellular calcium ions and by stimulating adenylyl cyclase activity. The rank order of potency for agonists of this receptor is 1-oleoyl- > 1-stearoyl- > 1-palmitoyl- > 1-myristoyl- > 1-alkyl- > 1-alkenyl-LPA. T58130 SEQUENCE MGDRRFIDFQFQDSNSSLRPRLGNATANNTCIVDDSFKYNLNGAVYSVVFILGLITNSVSLFVFCFRMKMRSETAIFITNLAVSDLLFVCTLPFKIFYNFNRHWPFGDTLCKISGTAFLTNIYGSMLFLTCISVDRFLAIVYPFRSRTIRTRRNSAIVCAGVWILVLSGGISASLFSTTNVNNATTTCFEGFSKRVWKTYLSKITIFIEVVGFIIPLILNVSCSSVVLRTLRKPATLSQIGTNKKKVLKMITVHMAVFVVCFVPYNSVLFLYALVRSQAITNCFLERFAKIMYPITLCLATLNCCFDPFIYYFTLESFQKSFYINAHIRMESLFKTETPLTTKPSLPAIQEEVSDQTTNNGGELMLESTF T58130 DRUGINFO D05TVG [1-bromo-(3S)-hydrox-4-(palmitoyloxy)butyl]phosphate Investigative T58130 DRUGINFO D0X0UR LPA Investigative T15888 TARGETID T15888 T15888 FORMERID TTDI03108 T15888 UNIPROID CML1_HUMAN T15888 TARGNAME Chemerin receptor (CMKLR1) T15888 GENENAME CMKLR1 T15888 TARGTYPE Literature-reported T15888 SYNONYMS G-protein coupled receptor DEZ; G-protein coupled receptor ChemR23; DEZ; Chemokine-like receptor 1; CHEMR23 T15888 FUNCTION Receptor for the chemoattractant adipokine chemerin/RARRES2 and for the omega-3 fatty acid derived molecule resolvin E1. Interaction with RARRES2 induces activation of intracellular signaling molecules, such as SKY, MAPK1/3 (ERK1/2), MAPK14/P38MAPK and PI3K leading to multifunctional effects, like, reduction of immune responses, enhancing of adipogenesis and angionesis. Resolvin E1 down-regulates cytokine production in macrophages by reducing the activation of MAPK1/3 (ERK1/2) and NF-kappa-B. Positively regulates adipogenesis and adipocyte metabolism. Acts as a coreceptor for several SIV strains (SIVMAC316, SIVMAC239, SIVMACL7E-FR and SIVSM62A), as well as a primary HIV-1 strain (92UG024-2). T15888 SEQUENCE MRMEDEDYNTSISYGDEYPDYLDSIVVLEDLSPLEARVTRIFLVVVYSIVCFLGILGNGLVIIIATFKMKKTVNMVWFLNLAVADFLFNVFLPIHITYAAMDYHWVFGTAMCKISNFLLIHNMFTSVFLLTIISSDRCISVLLPVWSQNHRSVRLAYMACMVIWVLAFFLSSPSLVFRDTANLHGKISCFNNFSLSTPGSSSWPTHSQMDPVGYSRHMVVTVTRFLCGFLVPVLIITACYLTIVCKLQRNRLAKTKKPFKIIVTIIITFFLCWCPYHTLNLLELHHTAMPGSVFSLGLPLATALAIANSCMNPILYVFMGQDFKKFKVALFSRLVNALSEDTGHSSYPSHRSFTKMSSMNERTSMNERETGML T15888 DRUGINFO D01IUB [3H]resolvin E1 Investigative T54982 TARGETID T54982 T54982 FORMERID TTDI03480 T54982 UNIPROID SC6A7_HUMAN T54982 TARGNAME Sodium-dependent proline transporter (SLC6A7) T54982 GENENAME SLC6A7 T54982 TARGTYPE Literature-reported T54982 SYNONYMS Solute carrier family 6 member 7; PROT T54982 FUNCTION Terminates the action of proline by its high affinity sodium-dependent reuptake into presynaptic terminals. T54982 SEQUENCE MKKLQGAHLRKPVTPDLLMTPSDQGDVDLDVDFAAHRGNWTGKLDFLLSCIGYCVGLGNVWRFPYRAYTNGGGAFLVPYFLMLAICGIPLFFLELSLGQFSSLGPLAVWKISPLFKGAGAAMLLIVGLVAIYYNMIIAYVLFYLFASLTSDLPWEHCGNWWNTELCLEHRVSKDGNGALPLNLTCTVSPSEEYWSRYVLHIQGSQGIGSPGEIRWNLCLCLLLAWVIVFLCILKGVKSSGKVVYFTATFPYLILLMLLVRGVTLPGAWKGIQFYLTPQFHHLLSSKVWIEAALQIFYSLGVGFGGLLTFASYNTFHQNIYRDTFIVTLGNAITSILAGFAIFSVLGYMSQELGVPVDQVAKAGPGLAFVVYPQAMTMLPLSPFWSFLFFFMLLTLGLDSQFAFLETIVTAVTDEFPYYLRPKKAVFSGLICVAMYLMGLILTTDGGMYWLVLLDDYSASFGLMVVVITTCLAVTRVYGIQRFCRDIHMMLGFKPGLYFRACWLFLSPATLLALMVYSIVKYQPSEYGSYRFPPWAELLGILMGLLSCLMIPAGMLVAVLREEGSLWERLQQASRPAMDWGPSLEENRTGMYVATLAGSQSPKPLMVHMRKYGGITSFENTAIEVDREIAEEEESMM T54982 DRUGINFO D02KNP LP-403812 Investigative T54982 DRUGINFO D0M6UK PMID25037917C58 Investigative T70633 TARGETID T70633 T70633 FORMERID TTDI03562 T70633 UNIPROID SUCR1_HUMAN T70633 TARGNAME Succinate receptor (SUCNR1) T70633 GENENAME SUCNR1 T70633 TARGTYPE Literature-reported T70633 SYNONYMS Succinate receptor 1; P2Y purinoceptor 1-like; GPR91; G-protein coupled receptor 91 T70633 FUNCTION Receptor for succinate. T70633 SEQUENCE MLGIMAWNATCKNWLAAEAALEKYYLSIFYGIEFVVGVLGNTIVVYGYIFSLKNWNSSNIYLFNLSVSDLAFLCTLPMLIRSYANGNWIYGDVLCISNRYVLHANLYTSILFLTFISIDRYLIIKYPFREHLLQKKEFAILISLAIWVLVTLELLPILPLINPVITDNGTTCNDFASSGDPNYNLIYSMCLTLLGFLIPLFVMCFFYYKIALFLKQRNRQVATALPLEKPLNLVIMAVVIFSVLFTPYHVMRNVRIASRLGSWKQYQCTQVVINSFYIVTRPLAFLNSVINPVFYFLLGDHFRDMLMNQLRHNFKSLTSFSRWAHELLLSFREK T70633 DRUGINFO D02FGK PMID21571530C5g Investigative T70633 DRUGINFO D0GC5Y PMID21571530C7e Investigative T87661 TARGETID T87661 T87661 FORMERID TTDI03235 T87661 UNIPROID GP174_HUMAN T87661 TARGNAME G-protein coupled receptor 174 (GPR174) T87661 GENENAME GPR174 T87661 TARGTYPE Literature-reported T87661 SYNONYMS Probable G-protein coupled receptor 174 T87661 FUNCTION Putative receptor for purines coupled to G-proteins. T87661 SEQUENCE MPANYTCTRPDGDNTDFRYFIYAVTYTVILVPGLIGNILALWVFYGYMKETKRAVIFMINLAIADLLQVLSLPLRIFYYLNHDWPFGPGLCMFCFYLKYVNMYASIYFLVCISVRRFWFLMYPFRFHDCKQKYDLYISIAGWLIICLACVLFPLLRTSDDTSGNRTKCFVDLPTRNVNLAQSVVMMTIGELIGFVTPLLIVLYCTWKTVLSLQDKYPMAQDLGEKQKALKMILTCAGVFLICFAPYHFSFPLDFLVKSNEIKSCLARRVILIFHSVALCLASLNSCLDPVIYYFSTNEFRRRLSRQDLHDSIQLHAKSFVSNHTASTMTPELC T87661 DRUGINFO D0M8IT lysophosphatidylserine Investigative T69393 TARGETID T69393 T69393 FORMERID TTDI03245 T69393 UNIPROID GPR63_HUMAN T69393 TARGNAME G-protein coupled receptor 63 (GPR63) T69393 GENENAME GPR63 T69393 TARGTYPE Literature-reported T69393 SYNONYMS Probable G-protein coupled receptor 63; PSP24B; PSP24-beta; PSP24-2 T69393 FUNCTION Orphan receptor. May play a role in brain function. T69393 SEQUENCE MVFSAVLTAFHTGTSNTTFVVYENTYMNITLPPPFQHPDLSPLLRYSFETMAPTGLSSLTVNSTAVPTTPAAFKSLNLPLQITLSAIMIFILFVSFLGNLVVCLMVYQKAAMRSAINILLASLAFADMLLAVLNMPFALVTILTTRWIFGKFFCRVSAMFFWLFVIEGVAILLIISIDRFLIIVQRQDKLNPYRAKVLIAVSWATSFCVAFPLAVGNPDLQIPSRAPQCVFGYTTNPGYQAYVILISLISFFIPFLVILYSFMGILNTLRHNALRIHSYPEGICLSQASKLGLMSLQRPFQMSIDMGFKTRAFTTILILFAVFIVCWAPFTTYSLVATFSKHFYYQHNFFEISTWLLWLCYLKSALNPLIYYWRIKKFHDACLDMMPKSFKFLPQLPGHTKRRIRPSAVYVCGEHRTVV T69393 DRUGINFO D07KBZ dioleoylphosphatidic acid Investigative T69393 DRUGINFO D02UUO dihydrosphingosine-1-phosphate Investigative T55932 TARGETID T55932 T55932 FORMERID TTDI03580 T55932 UNIPROID S19A3_HUMAN T55932 TARGNAME Solute carrier family 19 member 3 (SLC19A3) T55932 GENENAME SLC19A3 T55932 TARGTYPE Literature-reported T55932 SYNONYMS Thiamine transporter 2; ThTr2; ThTr-2 T55932 FUNCTION Mediates high affinity thiamine uptake, probably via a proton anti-port mechanism. Has no folate transport activity. T55932 SEQUENCE MDCYRTSLSSSWIYPTVILCLFGFFSMMRPSEPFLIPYLSGPDKNLTSAEITNEIFPVWTYSYLVLLLPVFVLTDYVRYKPVIILQGISFIITWLLLLFGQGVKTMQVVEFFYGMVTAAEVAYYAYIYSVVSPEHYQRVSGYCRSVTLAAYTAGSVLAQLLVSLANMSYFYLNVISLASVSVAFLFSLFLPMPKKSMFFHAKPSREIKKSSSVNPVLEETHEGEAPGCEEQKPTSEILSTSGKLNKGQLNSLKPSNVTVDVFVQWFQDLKECYSSKRLFYWSLWWAFATAGFNQVLNYVQILWDYKAPSQDSSIYNGAVEAIATFGGAVAAFAVGYVKVNWDLLGELALVVFSVVNAGSLFLMHYTANIWACYAGYLIFKSSYMLLITIAVFQIAVNLNVERYALVFGINTFIALVIQTIMTVIVVDQRGLNLPVSIQFLVYGSYFAVIAGIFLMRSMYITYSTKSQKDVQSPAPSENPDVSHPEEESNIIMSTKL T55932 DRUGINFO D07TYL [3H]thiamine Investigative T38428 TARGETID T38428 T38428 FORMERID TTDI00021 T38428 UNIPROID FOXQ1_HUMAN T38428 TARGNAME Forkhead box protein Q1 (FOXQ1) T38428 GENENAME FOXQ1 T38428 TARGTYPE Literature-reported T38428 SYNONYMS Hepatocyte nuclear factor 3 forkhead homolog 1; HNF3/forkheadlike protein 1; HNF-3/forkhead-like protein 1; HFH1; HFH-1 T38428 FUNCTION Plays a role in hair follicle differentiation. T38428 SEQUENCE MKLEVFVPRAAHGDKQGSDLEGAGGSDAPSPLSAAGDDSLGSDGDCAANSPAAGGGARDTQGDGEQSAGGGPGAEEAIPAAAAAAVVAEGAEAGAAGPGAGGAGSGEGARSKPYTRRPKPPYSYIALIAMAIRDSAGGRLTLAEINEYLMGKFPFFRGSYTGWRNSVRHNLSLNDCFVKVLRDPSRPWGKDNYWMLNPNSEYTFADGVFRRRRKRLSHRAPVPAPGLRPEEAPGLPAAPPPAPAAPASPRMRSPARQEERASPAGKFSSSFAIDSILRKPFRSRRLRDTAPGTTLQWGAAPCPPLPAFPALLPAAPCRALLPLCAYGAGEPARLGAREAEVPPTAPPLLLAPLPAAAPAKPLRGPAAGGAHLYCPLRLPAALQAASVRRPGPHLPYPVETLLA T02343 TARGETID T02343 T02343 FORMERID TTDS00511 T02343 UNIPROID Q9F0I5_PAEMA T02343 TARGNAME Bacterial Cycloinulo-oligosaccharide fructanotransferase (Bact cft) T02343 GENENAME Bact cft T02343 TARGTYPE Literature-reported T02343 SYNONYMS Cycloinulo-oligosaccharide fructanotransferase T02343 FUNCTION Converts inulin into cyclooligosaccharides (cyclofructans) consisting of 6 to 8 molecules of (21)linked cyclic Dfructofuranose through intramolecular transfructosylation. T02343 SEQUENCE MRKVKRGKCWISGMVIWAMVLQLVVPGISVASENRTVAGETLIPKNDVKSSVTDAIYQIKNIPQNDMGLSVTDSVYQIRNPGFETGDLTGWTVIKGDAFGPNSVTDETTWWAEKIPYNQEGAYHLNGWKYDESATGVLRSSTFELGGSGGISFKLGGAKNPDKVFINIVEVDTGQVIARYGNSAFADVGFPDPAQGMRLANMVQYKADLSTQLGKKLYVEVVDNATSDWGVIFADAFSMYHESEPAEGIVATDIKPDFKRYEIDNPSFETGNLDGWTVEEDAFEVTDEAHASKEGNFYAKSSLQGKGSITSNTFTLQGTGTINFTVLDILKPENAYVALFDANSNTLLMKTGNVSANEKISWKVQEHYNKKLYVKVVDHSNEASIAVDSFQASDRGTIFYLNLDEGAGKKALEKVHNLRHDVNYVFNNARYMASKDPRWTPRGIKGGALLFDGSSNYIEVNANVTVPVSDALTIEAWVAPRSYEWGDGNKLSAIVNQSDQDKAEGFSLGMYRHGTWSMQVGIGGQWIQVWVKDHPLEKYKWNYVAATFSKEDGKIKLYLNGEEVASQATPVNVPITPSTESLIIGKNNKPVELAGVFSFNMFSGLLDEVKLHNKALTNQEILAGYESVKALHGGSIPKIPNADIDEDPSVFDGDQHRPQYHAMPPQNWMNEAHAPIYYNGKYHLFYQHNPQGPFWHQIHWGHWVSDDMVNWENVRPALAPEAGTLDPDGTWSGSAAYDRNGNPVLFYTAGNDSLSPNQRTGLATPADLSDPYLEKWEKYPKPVTEQNGKGIHNEFRDPFVWYDKEVDKWYQLVTSGLPDFSSGTALVYVSDDMYNWKYKGPLYVSDRIRYPELGTVWELPVLLPLGTDSTGKQKYIFMINPHEKPEHVPPANDVQRDVEVFYWIGTWDRDNFKFIPDQEAPSKMDVGDGYLTAESGLVTPDGRTVVFSMVQNVRTPQAEYQSGWAHNLSLPVSLSLDKYDKLHIEPIKELQSLRGEKWVDFSDKNLESANQLIKNVKGDMLEIVMEIDPREAQKFGLKVRRSEKGQEETLIYYDKKNGTFNVDRTKSSIDPDVRVDGIQGGYVDLEGENLKLHIFLDRSVIEAFANYKKKLTTRVYVGRYDSLGLQIWADGDINIKSMQVWDMNALTGKPAAPVYVPDKWDNSVYKDITELPNHDFATGDLTGWMTEGDAFQNVHVTNTQFFWDNIFFNPSHKIPGSYHLWGFNEQAGGDSLTGALRSQNFVLGGNGKINFLISGGRDIDRLYVALVRASDDKELFKETATNYEEYQRKIWDATDYIGEELYIKVVDHSKGGFGHINVDDFNVPVQVKKKTNN T37505 TARGETID T37505 T37505 FORMERID TTDI03249 T37505 UNIPROID GPR88_HUMAN T37505 TARGNAME Striatum-specific G-protein coupled receptor (GPR88) T37505 GENENAME GPR88 T37505 TARGTYPE Literature-reported T37505 SYNONYMS STRG; Probable G-protein coupled receptor 88 T37505 FUNCTION Probable G-protein coupled receptor implicated in a large repertoire of behavioral responses that engage motor activities, spatial learning, and emotional processing. May play a role in the regulation of cognitive and motor function. T37505 SEQUENCE MTNSSSTSTSSTTGGSLLLLCEEEESWAGRRIPVSLLYSGLAIGGTLANGMVIYLVSSFRKLQTTSNAFIVNGCAADLSVCALWMPQEAVLGLLPTGSAEPPADWDGAGGSYRLLRGGLLGLGLTVSLLSHCLVALNRYLLITRAPATYQALYQRRHTAGMLALSWALALGLVLLLPPWAPRPGAAPPRVHYPALLAAAALLAQTALLLHCYLGIVRRVRVSVKRVSVLNFHLLHQLPGCAAAAAAFPGAQHAPGPGGAAHPAQAQPLPPALHPRRAQRRLSGLSVLLLCCVFLLATQPLVWVSLASGFSLPVPWGVQAASWLLCCALSALNPLLYTWRNEEFRRSVRSVLPGVGDAAAAAVAATAVPAVSQAQLGTRAAGQHW T37505 DRUGINFO D0O6ZN PMID24793972C2 Investigative T04210 TARGETID T04210 T04210 FORMERID TTDI03407 T04210 UNIPROID NMUR2_HUMAN T04210 TARGNAME Neuromedin-U receptor 2 (NMUR2) T04210 GENENAME NMUR2 T04210 TARGTYPE Literature-reported T04210 SYNONYMS TGR1; NMU2R; NMU-R2; G-protein coupled receptor TGR-1; G-protein coupled receptor FM-4 T04210 FUNCTION Receptor for the neuromedin-U and neuromedin-S neuropeptides. T04210 SEQUENCE MSGMEKLQNASWIYQQKLEDPFQKHLNSTEEYLAFLCGPRRSHFFLPVSVVYVPIFVVGVIGNVLVCLVILQHQAMKTPTNYYLFSLAVSDLLVLLLGMPLEVYEMWRNYPFLFGPVGCYFKTALFETVCFASILSITTVSVERYVAILHPFRAKLQSTRRRALRILGIVWGFSVLFSLPNTSIHGIKFHYFPNGSLVPGSATCTVIKPMWIYNFIIQVTSFLFYLLPMTVISVLYYLMALRLKKDKSLEADEGNANIQRPCRKSVNKMLFVLVLVFAICWAPFHIDRLFFSFVEEWSESLAAVFNLVHVVSGVFFYLSSAVNPIIYNLLSRRFQAAFQNVISSFHKQWHSQHDPQLPPAQRNIFLTECHFVELTEDIGPQFPCQSSMHNSHLPAALSSEQMSRTNYQSFHFNKT T04210 DRUGINFO D00EFA R-PSOP Investigative T04210 DRUGINFO D0I0LW PMID24999562C6b Investigative T79780 TARGETID T79780 T79780 FORMERID TTDI03410 T79780 UNIPROID NPFF1_HUMAN T79780 TARGNAME Neuropeptide FF receptor 1 (NPFFR1) T79780 GENENAME NPFFR1 T79780 TARGTYPE Literature-reported T79780 SYNONYMS RFamide-related peptide receptor OT7T022; NPFF1; GPR147; G-protein coupled receptor 147 T79780 FUNCTION Receptor for NPAF (A-18-F-amide) and NPFF (F-8-F-amide) neuropeptides, also known as morphine-modulating peptides. Can also be activated by a variety of naturally occurring or synthetic FMRF-amide like ligands. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. T79780 SEQUENCE MEGEPSQPPNSSWPLSQNGTNTEATPATNLTFSSYYQHTSPVAAMFIVAYALIFLLCMVGNTLVCFIVLKNRHMHTVTNMFILNLAVSDLLVGIFCMPTTLVDNLITGWPFDNATCKMSGLVQGMSVSASVFTLVAIAVERFRCIVHPFREKLTLRKALVTIAVIWALALLIMCPSAVTLTVTREEHHFMVDARNRSYPLYSCWEAWPEKGMRRVYTTVLFSHIYLAPLALIVVMYARIARKLCQAPGPAPGGEEAADPRASRRRARVVHMLVMVALFFTLSWLPLWALLLLIDYGQLSAPQLHLVTVYAFPFAHWLAFFNSSANPIIYGYFNENFRRGFQAAFRARLCPRPSGSHKEAYSERPGGLLHRRVFVVVRPSDSGLPSESGPSSGAPRPGRLPLRNGRVAHHGLPREGPGCSHLPLTIPAWDI T79780 DRUGINFO D05NKX 1DMe Investigative T79780 DRUGINFO D08UWO RF9 Investigative T83143 TARGETID T83143 T83143 FORMERID TTDI03110 T83143 UNIPROID SC5A7_HUMAN T83143 TARGNAME High affinity choline transporter 1 (CHT) T83143 GENENAME SLC5A7 T83143 TARGTYPE Literature-reported T83143 SYNONYMS Solute carrier family 5 member 7; Hemicholinium-3-sensitive choline transporter; CHT1; CHT T83143 FUNCTION Transmembrane transporter that imports choline from the extracellular space into the neuron with high affinity. Choline uptake is the rate-limiting step in acetylcholine synthesis. Sodium ion- and chloride ion-dependent. T83143 SEQUENCE MAFHVEGLIAIIVFYLLILLVGIWAAWRTKNSGSAEERSEAIIVGGRDIGLLVGGFTMTATWVGGGYINGTAEAVYVPGYGLAWAQAPIGYSLSLILGGLFFAKPMRSKGYVTMLDPFQQIYGKRMGGLLFIPALMGEMFWAAAIFSALGATISVIIDVDMHISVIISALIATLYTLVGGLYSVAYTDVVQLFCIFVGLWISVPFALSHPAVADIGFTAVHAKYQKPWLGTVDSSEVYSWLDSFLLLMLGGIPWQAYFQRVLSSSSATYAQVLSFLAAFGCLVMAIPAILIGAIGASTDWNQTAYGLPDPKTTEEADMILPIVLQYLCPVYISFFGLGAVSAAVMSSADSSILSASSMFARNIYQLSFRQNASDKEIVWVMRITVFVFGASATAMALLTKTVYGLWYLSSDLVYIVIFPQLLCVLFVKGTNTYGAVAGYVSGLFLRITGGEPYLYLQPLIFYPGYYPDDNGIYNQKFPFKTLAMVTSFLTNICISYLAKYLFESGTLPPKLDVFDAVVARHSEENMDKTILVKNENIKLDELALVKPRQSMTLSSTFTNKEAFLDVDSSPEGSGTEDNLQ T83143 DRUGINFO D05AFI [3H]hemicholinium-3 Investigative T18616 TARGETID T18616 T18616 FORMERID TTDI03357 T18616 UNIPROID LPAR5_HUMAN T18616 TARGNAME Lysophosphatidic acid receptor 5 (LPAR5) T18616 GENENAME LPAR5 T18616 TARGTYPE Literature-reported T18616 SYNONYMS LPA-5; LPA receptor 5; GPR93; GPR92; G-protein coupled receptor 93; G-protein coupled receptor 92 T18616 FUNCTION Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. T18616 SEQUENCE MLANSSSTNSSVLPCPDYRPTHRLHLVVYSLVLAAGLPLNALALWVFLRALRVHSVVSVYMCNLAASDLLFTLSLPVRLSYYALHHWPFPDLLCQTTGAIFQMNMYGSCIFLMLINVDRYAAIVHPLRLRHLRRPRVARLLCLGVWALILVFAVPAARVHRPSRCRYRDLEVRLCFESFSDELWKGRLLPLVLLAEALGFLLPLAAVVYSSGRVFWTLARPDATQSQRRRKTVRLLLANLVIFLLCFVPYNSTLAVYGLLRSKLVAASVPARDRVRGVLMVMVLLAGANCVLDPLVYYFSAEGFRNTLRGLGTPHRARTSATNGTRAALAQSERSAVTTDATRPDAASQGLLRPSDSHSLSSFTQCPQDSAL T18616 DRUGINFO D01STE alkyl glycerol phosphate 18:1 Investigative T18616 DRUGINFO D0GH9J octyl thiophosphatidic acid Investigative T18616 DRUGINFO D01ZHW N-arachidonoylglycine Investigative T18616 DRUGINFO D0X0UR LPA Investigative T15822 TARGETID T15822 T15822 FORMERID TTDI01446 T15822 UNIPROID S6A17_HUMAN T15822 TARGNAME Neurotransmitter transporter NTT4 (SLC6A17) T15822 GENENAME SLC6A17 T15822 TARGTYPE Literature-reported T15822 SYNONYMS Solute carrier family 6 member 17; Sodium-dependent neutral amino acid transporter SLC6A17; Sodium-dependent neurotransmitter transporter NTT4; NTT4 T15822 FUNCTION Functions as a sodium-dependent vesicular transporter selective for proline, glycine, leucine and alanine. In contrast to other members of this neurotransmitter transporter family, does not appear to be chloride-dependent (By similarity). T15822 SEQUENCE MPKNSKVTQREHSSEHVTESVADLLALEEPVDYKQSVLNVAGEAGGKQKAVEEELDAEDRPAWNSKLQYILAQIGFSVGLGNIWRFPYLCQKNGGGAYLVPYLVLLIIIGIPLFFLELAVGQRIRRGSIGVWHYICPRLGGIGFSSCIVCLFVGLYYNVIIGWSIFYFFKSFQYPLPWSECPVVRNGSVAVVEAECEKSSATTYFWYREALDISDSISESGGLNWKMTLCLLVAWSIVGMAVVKGIQSSGKVMYFSSLFPYVVLACFLVRGLLLRGAVDGILHMFTPKLDKMLDPQVWREAATQVFFALGLGFGGVIAFSSYNKQDNNCHFDAALVSFINFFTSVLATLVVFAVLGFKANIMNEKCVVENAEKILGYLNTNVLSRDLIPPHVNFSHLTTKDYMEMYNVIMTVKEDQFSALGLDPCLLEDELDKSVQGTGLAFIAFTEAMTHFPASPFWSVMFFLMLINLGLGSMIGTMAGITTPIIDTFKVPKEMFTVGCCVFAFLVGLLFVQRSGNYFVTMFDDYSATLPLTLIVILENIAVAWIYGTKKFMQELTEMLGFRPYRFYFYMWKFVSPLCMAVLTTASIIQLGVTPPGYSAWIKEEAAERYLYFPNWAMALLITLIVVATLPIPVVFVLRHFHLLSDGSNTLSVSYKKGRMMKDISNLEENDETRFILSKVPSEAPSPMPTHRSYLGPGSTSPLETSGNPNGRYGSGYLLASTPESEL T30844 TARGETID T30844 T30844 FORMERID TTDI03553 T30844 UNIPROID S38A1_HUMAN T30844 TARGNAME Solute carrier family 38 member 1 (SLC38A1) T30844 GENENAME SLC38A1 T30844 TARGTYPE Literature-reported T30844 SYNONYMS System N amino acid transporter 1; System A amino acid transporter 1; Sodium-coupled neutral amino acid transporter 1; SNAT1; SAT1; NAT2; N-system amino acid transporter 2; Amino acid transporter A1; ATA1 T30844 FUNCTION Functions as a sodium-dependent amino acid transporter. Mediates the saturable, pH-sensitive and electrogenic cotransport of glutamine and sodium ions with a stoichiometry of 1:1. May also transport small zwitterionic and aliphatic amino acids with a lower affinity. May supply glutamatergic and GABAergic neurons with glutamine which is required for the synthesis of the neurotransmitters glutamate and GABA. T30844 SEQUENCE MMHFKSGLELTELQNMTVPEDDNISNDSNDFTEVENGQINSKFISDRESRRSLTNSHLEKKKCDEYIPGTTSLGMSVFNLSNAIMGSGILGLAFALANTGILLFLVLLTSVTLLSIYSINLLLICSKETGCMVYEKLGEQVFGTTGKFVIFGATSLQNTGAMLSYLFIVKNELPSAIKFLMGKEETFSAWYVDGRVLVVIVTFGIILPLCLLKNLGYLGYTSGFSLSCMVFFLIVVIYKKFQIPCIVPELNSTISANSTNADTCTPKYVTFNSKTVYALPTIAFAFVCHPSVLPIYSELKDRSQKKMQMVSNISFFAMFVMYFLTAIFGYLTFYDNVQSDLLHKYQSKDDILILTVRLAVIVAVILTVPVLFFTVRSSLFELAKKTKFNLCRHTVVTCILLVVINLLVIFIPSMKDIFGVVGVTSANMLIFILPSSLYLKITDQDGDKGTQRIWAALFLGLGVLFSLVSIPLVIYDWACSSSSDEGH T00088 TARGETID T00088 T00088 FORMERID TTDR01119 T00088 UNIPROID PIGU_HUMAN T00088 TARGNAME GPI transamidase component PIG-U (PIGU) T00088 GENENAME PIGU T00088 TARGTYPE Literature-reported T00088 SYNONYMS UNQ3055/PRO9875; Phosphatidylinositol-glycan biosynthesis, class U protein; PIGU; PIG-U; Cell division cycle protein 91-like 1; CDC91L1; CDC91-like 1 protein T00088 FUNCTION Component of the GPI transamidase complex. May be involved in the recognition of either the GPI attachment signal or the lipid portion of GPI. T00088 SEQUENCE MAAPLVLVLVVAVTVRAALFRSSLAEFISERVEVVSPLSSWKRVVEGLSLLDLGVSPYSGAVFHETPLIIYLFHFLIDYAELVFMITDALTAIALYFAIQDFNKVVFKKQKLLLELDQYAPDVAELIRTPMEMRYIPLKVALFYLLNPYTILSCVAKSTCAINNTLIAFFILTTIKGSAFLSAIFLALATYQSLYPLTLFVPGLLYLLQRQYIPVKMKSKAFWIFSWEYAMMYVGSLVVIICLSFFLLSSWDFIPAVYGFILSVPDLTPNIGLFWYFFAEMFEHFSLFFVCVFQINVFFYTIPLAIKLKEHPIFFMFIQIAVIAIFKSYPTVGDVALYMAFFPVWNHLYRFLRNIFVLTCIIIVCSLLFPVLWHLWIYAGSANSNFFYAITLTFNVGQILLISDYFYAFLRREYYLTHGLYLTAKDGTEAMLVLK T83382 TARGETID T83382 T83382 FORMERID TTDI03406 T83382 UNIPROID NMUR1_HUMAN T83382 TARGNAME Neuromedin-U receptor 1 (NMUR1) T83382 GENENAME NMUR1 T83382 TARGTYPE Literature-reported T83382 SYNONYMS NMU-R1; GPR66; G-protein coupled receptor FM-3; G-protein coupled receptor 66 T83382 FUNCTION Receptor for the neuromedin-U and neuromedin-S neuropeptides. T83382 SEQUENCE MTPLCLNCSVLPGDLYPGGARNPMACNGSAARGHFDPEDLNLTDEALRLKYLGPQQTELFMPICATYLLIFVVGAVGNGLTCLVILRHKAMRTPTNYYLFSLAVSDLLVLLVGLPLELYEMWHNYPFLLGVGGCYFRTLLFEMVCLASVLNVTALSVERYVAVVHPLQARSMVTRAHVRRVLGAVWGLAMLCSLPNTSLHGIRQLHVPCRGPVPDSAVCMLVRPRALYNMVVQTTALLFFCLPMAIMSVLYLLIGLRLRRERLLLMQEAKGRGSAAARSRYTCRLQQHDRGRRQVTKMLFVLVVVFGICWAPFHADRVMWSVVSQWTDGLHLAFQHVHVISGIFFYLGSAANPVLYSLMSSRFRETFQEALCLGACCHRLRPRHSSHSLSRMTTGSTLCDVGSLGSWVHPLAGNDGPEAQQETDPS T83382 DRUGINFO D0M9DD PMID24999562C8d Investigative T38464 TARGETID T38464 T38464 FORMERID TTDNR00761 T38464 UNIPROID LY9_HUMAN T38464 TARGNAME T-lymphocyte surface antigen Ly-9 (LY9) T38464 GENENAME LY9 T38464 TARGTYPE Literature-reported T38464 SYNONYMS Signaling lymphocytic activation molecule 3; SLAMF3; SLAM family member 3; Lymphocyte antigen 9; LY9; Cell surface molecule Ly-9 T38464 FUNCTION May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. T38464 SEQUENCE MVAPKSHTDDWAPGPFSSKPQRSQLQIFSSVLQTSLLFLLMGLRASGKDSAPTVVSGILGGSVTLPLNISVDTEIENVIWIGPKNALAFARPKENVTIMVKSYLGRLDITKWSYSLCISNLTLNDAGSYKAQINQRNFEVTTEEEFTLFVYEQLQEPQVTMKSVKVSENFSCNITLMCSVKGAEKSVLYSWTPREPHASESNGGSILTVSRTPCDPDLPYICTAQNPVSQRSSLPVHVGQFCTDPGASRGGTTGETVVGVLGEPVTLPLALPACRDTEKVVWLFNTSIISKEREEAATADPLIKSRDPYKNRVWVSSQDCSLKISQLKIEDAGPYHAYVCSEASSVTSMTHVTLLIYRRLRKPKITWSLRHSEDGICRISLTCSVEDGGNTVMYTWTPLQKEAVVSQGESHLNVSWRSSENHPNLTCTASNPVSRSSHQFLSENICSGPERNTKLWIGLFLMVCLLCVGIFSWCIWKRKGRCSVPAFCSSQAEAPADTPEPTAGHTLYSVLSQGYEKLDTPLRPARQQPTPTSDSSSDSNLTTEEDEDRPEVHKPISGRYEVFDQVTQEGAGHDPAPEGQADYDPVTPYVTEVESVVGENTMYAQVFNLQGKTPVSQKEESSATIYCSIRKPQVVPPPQQNDLEIPESPTYENFT T29712 TARGETID T29712 T29712 FORMERID TTDI02554 T29712 UNIPROID PLAC1_HUMAN T29712 TARGNAME Placenta specific protein 1 (PLAC1) T29712 GENENAME PLAC1 T29712 TARGTYPE Literature-reported T29712 SYNONYMS Placentaspecific protein 1; PLAC1 T29712 FUNCTION May play a role in placental development. T29712 SEQUENCE MKVFKFIGLMILLTSAFSAGSGQSPMTVLCSIDWFMVTVHPFMLNNDVCVHFHELHLGLGCPPNHVQPHAYQFTYRVTECGIRAKAVSQDMVIYSTEIHYSSKGTPSKFVIPVSCAAPQKSPWLTKPCSMRVASKSRATAQKDEKCYEVFSLSQSSQRPNCDCPPCVFSEEEHTQVPCHQAGAQEAQPLQPSHFLDISEDWSLHTDDMIGSM T17555 TARGETID T17555 T17555 FORMERID TTDNR00745 T17555 UNIPROID ENK5_HUMAN; ENK6_HUMAN T17555 TARGNAME Endogenous retrovirus group K Env polyprotein (ENK) T17555 GENENAME ERVK-5; ERVK-6 T17555 TARGTYPE Literature-reported T17555 SYNONYMS HERV-envelope protein; HERV-K provirus ancestral Env polyprotein; HERV-K envelope protein; Envelope polyprotein; Endogenous retrovirus group K member Env polyprotein; ERVK T17555 FUNCTION Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. This endogenous envelope protein has lost its original fusogenic properties. T17555 SEQUENCE MVTPVTWMDNPIEVYVNDSVWVPGPTDDRCPAKPEEEGMMINISIVYRYPPICLGRAPGCLMPAVQNWLVEVPTVSPNSRFTYHMVSGMSLRPRVNYLQDFSYQRSLKFRPKGKPCPKEIPKESKNTEVLVWEECVANSAVILQNNEFGTIIDWAPRGQFYHNCSGQTQSCPSAQVSPAVDSDLTESLDKHKHKKLQSFYPWEWGEKGISTPRPEIISPVSGPEHPELWRLWPDTTLEFGLEIKL T02565 TARGETID T02565 T02565 FORMERID TTDI03419 T02565 UNIPROID SO1B3_HUMAN T02565 TARGNAME Liver organic anion transporter 2 (SLCO1B3) T02565 GENENAME SLCO1B3 T02565 TARGTYPE Literature-reported T02565 SYNONYMS Solute carrier organic anion transporter family member 1B3; Solute carrier family 21 member 8; SLC21A8; Organic anion-transporting polypeptide 8; Organic anion transporter 8; OATP8; OATP1B3; OATP-8; Liver-specific organic anion transporter 2; LST2; LST-2 T02565 FUNCTION Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver. T02565 SEQUENCE MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGIIMKISITQIERRFDISSSLAGLIDGSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCLLMGTGSILTSLPHFFMGYYRYSKETHINPSENSTSSLSTCLINQTLSFNGTSPEIVEKDCVKESGSHMWIYVFMGNMLRGIGETPIVPLGISYIDDFAKEGHSSLYLGSLNAIGMIGPVIGFALGSLFAKMYVDIGYVDLSTIRITPKDSRWVGAWWLGFLVSGLFSIISSIPFFFLPKNPNKPQKERKISLSLHVLKTNDDRNQTANLTNQGKNVTKNVTGFFQSLKSILTNPLYVIFLLLTLLQVSSFIGSFTYVFKYMEQQYGQSASHANFLLGIITIPTVATGMFLGGFIIKKFKLSLVGIAKFSFLTSMISFLFQLLYFPLICESKSVAGLTLTYDGNNSVASHVDVPLSYCNSECNCDESQWEPVCGNNGITYLSPCLAGCKSSSGIKKHTVFYNCSCVEVTGLQNRNYSAHLGECPRDNTCTRKFFIYVAIQVINSLFSATGGTTFILLTVKIVQPELKALAMGFQSMVIRTLGGILAPIYFGALIDKTCMKWSTNSCGAQGACRIYNSVFFGRVYLGLSIALRFPALVLYIVFIFAMKKKFQGKDTKASDNERKVMDEANLEFLNNGEHFVPSAGTDSKTCNLDMQDNAAAN T02565 DRUGINFO D0I3LQ [3H]estradiol-17beta-glucuronide Investigative T55465 TARGETID T55465 T55465 FORMERID TTDNR00710 T55465 UNIPROID NRN1_HUMAN T55465 TARGNAME Neuritin (NRN1) T55465 GENENAME NRN1 T55465 TARGTYPE Literature-reported T55465 SYNONYMS NRN T55465 FUNCTION Promotes neurite outgrowth and especially branching of neuritic processes in primary hippocampal and cortical cells. T55465 SEQUENCE MGLKLNGRYISLILAVQIAYLVQAVRAAGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGAKDMWDKLRKESKNLNIQGSLFELCGSGNGAAGSLLPAFPVLLVSLSAALATWLSF T27170 TARGETID T27170 T27170 FORMERID TTDI00119 T27170 UNIPROID SCUB2_HUMAN T27170 TARGNAME Signal peptide CUB-EGF-like-domain containing 2 (SCUBE2) T27170 GENENAME SCUBE2 T27170 TARGTYPE Literature-reported T27170 SYNONYMS Signal peptide, CUB and EGF-like domain-containing protein 2; Scube/You; Protein CEGP1; CEGP1 T27170 FUNCTION Lipid-binding protein required for SHH long-range signaling by binding to the dually lipid-modified SHH (ShhNp) and by promoting ShhNp mobilization, solubilization and release from the cell membrane. Acts by enhancing the proteolytic processing (shedding) of the lipid-modified N- and C- terminal of ShhNp at the cell surface. Synergizes with DISP1 to increase SHH secretion. Probable cell surface coreceptor for VEGFR2 involved in VEGFR2-mediated angiogenesis. T27170 SEQUENCE MGVAGRNRPGAAWAVLLLLLLLPPLLLLAGAVPPGRGRAAGPQEDVDECAQGLDDCHADALCQNTPTSYKCSCKPGYQGEGRQCEDIDECGNELNGGCVHDCLNIPGNYRCTCFDGFMLAHDGHNCLDVDECLENNGGCQHTCVNVMGSYECCCKEGFFLSDNQHTCIHRSEEGLSCMNKDHGCSHICKEAPRGSVACECRPGFELAKNQRDCILTCNHGNGGCQHSCDDTADGPECSCHPQYKMHTDGRSCLEREDTVLEVTESNTTSVVDGDKRVKRRLLMETCAVNNGGCDRTCKDTSTGVHCSCPVGFTLQLDGKTCKDIDECQTRNGGCDHFCKNIVGSFDCGCKKGFKLLTDEKSCQDVDECSLDRTCDHSCINHPGTFACACNRGYTLYGFTHCGDTNECSINNGGCQQVCVNTVGSYECQCHPGYKLHWNKKDCVEVKGLLPTSVSPRVSLHCGKSGGGDGCFLRCHSGIHLSSDVTTIRTSVTFKLNEGKCSLKNAELFPEGLRPALPEKHSSVKESFRYVNLTCSSGKQVPGAPGRPSTPKEMFITVEFELETNQKEVTASCDLSCIVKRTEKRLRKAIRTLRKAVHREQFHLQLSGMNLDVAKKPPRTSERQAESCGVGQGHAENQCVSCRAGTYYDGARERCILCPNGTFQNEEGQMTCEPCPRPGNSGALKTPEAWNMSECGGLCQPGEYSADGFAPCQLCALGTFQPEAGRTSCFPCGGGLATKHQGATSFQDCETRVQCSPGHFYNTTTHRCIRCPVGTYQPEFGKNNCVSCPGNTTTDFDGSTNITQCKNRRCGGELGDFTGYIESPNYPGNYPANTECTWTINPPPKRRILIVVPEIFLPIEDDCGDYLVMRKTSSSNSVTTYETCQTYERPIAFTSRSKKLWIQFKSNEGNSARGFQVPYVTYDEDYQELIEDIVRDGRLYASENHQEILKDKKLIKALFDVLAHPQNYFKYTAQESREMFPRSFIRLLRSKVSRFLRPYK T96393 TARGETID T96393 T96393 UNIPROID ARHG3_HUMAN T96393 TARGNAME Rho guanine nucleotide exchange factor 3 (ARHGEF3) T96393 GENENAME ARHGEF3 T96393 TARGTYPE Literature-reported T96393 SYNONYMS XPLN; Exchange factor found in platelets and leukemic and neuronal tissues T96393 FUNCTION Acts as guanine nucleotide exchange factor (GEF) for RhoA and RhoB GTPases. T96393 SEQUENCE MVAKDYPFYLTVKRANCSLELPPASGPAKDAEEPSNKRVKPLSRVTSLANLIPPVKATPLKRFSQTLQRSISFRSESRPDILAPRPWSRNAAPSSTKRRDSKLWSETFDVCVNQMLTSKEIKRQEAIFELSQGEEDLIEDLKLAKKAYHDPMLKLSIMTEQELNQIFGTLDSLIPLHEELLSQLRDVRKPDGSTEHVGPILVGWLPCLSSYDSYCSNQVAAKALLDHKKQDHRVQDFLQRCLESPFSRKLDLWNFLDIPRSRLVKYPLLLREILRHTPNDNPDQQHLEEAINIIQGIVAEINTKTGESECRYYKERLLYLEEGQKDSLIDSSRVLCCHGELKNNRGVKLHVFLFQEVLVITRAVTHNEQLCYQLYRQPIPVKDLLLEDLQDGEVRLGGSLRGAFSNNERIKNFFRVSFKNGSQSQTHSLQANDTFNKQQWLNCIRQAKETVLCAAGQAGVLDSEGSFLNPTTGSRELQGETKLEQMDQSDSESDCSMDTSEVSLDCERMEQTDSSCGNSRHGESNV T88944 TARGETID T88944 T88944 FORMERID TTDI03524 T88944 UNIPROID RL3R1_HUMAN T88944 TARGNAME Relaxin-3 receptor 1 (RXFP3) T88944 GENENAME RXFP3 T88944 TARGTYPE Literature-reported T88944 SYNONYMS Somatostatin- and angiotensin-like peptide receptor; SALPR; Relaxin family peptide receptor 3; RLN3R1; RLN3 receptor 1; G-protein coupled receptor GPCR135; G protein-coupled receptor SALPR T88944 FUNCTION Receptor for RNL3/relaxin-3. Binding of the ligand inhibit cAMP accumulation. T88944 SEQUENCE MQMADAATIATMNKAAGGDKLAELFSLVPDLLEAANTSGNASLQLPDLWWELGLELPDGAPPGHPPGSGGAESADTEARVRILISVVYWVVCALGLAGNLLVLYLMKSMQGWRKSSINLFVTNLALTDFQFVLTLPFWAVENALDFKWPFGKAMCKIVSMVTSMNMYASVFFLTAMSVTRYHSVASALKSHRTRGHGRGDCCGRSLGDSCCFSAKALCVWIWALAALASLPSAIFSTTVKVMGEELCLVRFPDKLLGRDRQFWLGLYHSQKVLLGFVLPLGIIILCYLLLVRFIADRRAAGTKGGAAVAGGRPTGASARRLSKVTKSVTIVVLSFFLCWLPNQALTTWSILIKFNAVPFSQEYFLCQVYAFPVSVCLAHSNSCLNPVLYCLVRREFRKALKSLLWRIASPSITSMRPFTATTKPEHEDQGLQAPAPPHAAAEPDLLYYPPGVVVYSGGRYDLLPSSSAY T88944 DRUGINFO D0CE5B 135PAM1 Investigative T16923 TARGETID T16923 T16923 FORMERID TTDI02399 T16923 UNIPROID CNTLN_HUMAN T16923 TARGNAME Centrosomal protein (CNTLN) T16923 GENENAME CNTLN T16923 TARGTYPE Literature-reported T16923 SYNONYMS Centlein; C9orf39; C9orf101 T16923 FUNCTION Required for centrosome cohesion and recruitment of CEP68 to centrosomes. T16923 SEQUENCE MAARSPPSPHPSPPARQLGPRSPRVGRGAEVHAMRSEASGFAGAAREVVADESDKIWVGEEGSGGRRGPGGAAPAHAPLLSAPMGSRRLEGISVEEAMVTRTQLLEEELSSLKEELALCQADKEFVWSLWKRLQVTNPDLTQVVSLVVEREKQKSEAKDRKVLEILQVKDAKIQEFEQRESVLKQEINDLVKRKIAVDEENAFLRKEFSDLEKKFKDKSQEIKDTKECVQNKEEQNRLVIKNLEEENKKLSTRCTDLLNDLEKLRKQEAHLRKEKYSTDAKIKTFEDNLIEARKEVEVSQSKYNALSLQLSNKQTELIQKDMDITLVRKELQELQNLYKQNSTHTAQQAELIQQLQVLNMDTQKVLRNQEDVHTAESISYQKLYNELHICFETTKSNEAMLRQSVTNLQDQLLQKEQENAKLKEKLQESQGAPLPLPQESDPDYSAQVPHRPSLSSLETLMVSQKSEIEYLQEKLKIANEKLSENISANKGFSRKSIMTSAEGKHKEPPVKRSRSLSPKSSFTDSEELQKLRKAERKIENLEKALQLKSQENDELRDAHEKRKERLQMLQTNYRAVKEQLKQWEEGSGMTEIRKIKRADPQQLRQEDSDAVWNELAYFKRENQELMIQKMNLEEELDELKVHISIDKAAIQELNRCVAERREEQLFRSGEDDEVKRSTPEKNGKEMLEQTLQKVTELENRLKSFEKRSRKLKEGNKKLMKENDFLKSLLKQQQEDTETREKELEQIIKGSKDVEKENTELQVKISELETEVTSLRRQVAEANALRNENEELINPMEKSHQSADRAKSEMATMKVRSGRYDCKTTMTKVKFKAAKKNCSVGRHHTVLNHSIKVMSNVFENLSKDGWEDVSESSSDSEAQTSQTLGTIIVETSQKISPTEDGKDQKESDPTEDSQTQGKEIVQTYLNIDGKTPKDYFHDKNAKKPTFQKKNCKMQKSSHTAVPTRVNREKYKNITAQKSSSNIILLRERIISLQQQNSVLQNAKKTAELSVKEYKEVNEKLLHQQQVSDQRFQTSRQTIKKLNLDLAGLRKEKEDLLKKLESSSEITSLAEENSQVTFPRIQVTSLSPSRSMDLEMKQLQYKLKNATNELTKQSSNVKTLKFELLAKEEHIKEMHEKISRMERDITMKRHLIEDLKFRQKVNLESNKSFSEMLQNLDKKVKTLTEECSNKKVSIDSLKQRLNVAVKEKSQYEQMYQKSKEELEKKDLKLTLLVSRISETESAMAEIETAASKQLQELALQSEQVLEGAQKTLLLANEKVEEFTTFVKALAKELQNDVHVVRRQIRELKKMKKNRDACKTSTHKAQTLAASILNISRSDLEEILDTEDQVEIEKTKIDAENDKEWMLYIQKLLEGQSLTLSPRLKCNGAIVAHQNLRLPDSSSSASAS T67246 TARGETID T67246 T67246 FORMERID TTDI02488 T67246 UNIPROID STAB1_HUMAN T67246 TARGNAME Stabilin-1 (STAB1) T67246 GENENAME STAB1 T67246 TARGTYPE Literature-reported T67246 SYNONYMS STAB1; MS-1 antigen; Fasciclin, EGF-like, laminin-type EGF-like and link domain-containing scavenger receptor 1; FEEL-1 T67246 FUNCTION Acts as a scavenger receptor for acetylated low density lipoprotein. Binds to both Gram-positive and Gram-negative bacteria and may play a role in defense against bacterial infection. When inhibited in endothelial tube formation assays, there is a marked decreasein cell-cell interactions, suggesting a role in angiogenesis. Involved in the delivery of newly synthesized CHID1/SI-CLP from the biosynthetic compartment to the endosomal/lysosomal system. T67246 SEQUENCE MAGPRGLLPLCLLAFCLAGFSFVRGQVLFKGCDVKTTFVTHVPCTSCAAIKKQTCPSGWLRELPDQITQDCRYEVQLGGSMVSMSGCRRKCRKQVVQKACCPGYWGSRCHECPGGAETPCNGHGTCLDGMDRNGTCVCQENFRGSACQECQDPNRFGPDCQSVCSCVHGVCNHGPRGDGSCLCFAGYTGPHCDQELPVCQELRCPQNTQCSAEAPSCRCLPGYTQQGSECRAPNPCWPSPCSLLAQCSVSPKGQAQCHCPENYHGDGMVCLPKDPCTDNLGGCPSNSTLCVYQKPGQAFCTCRPGLVSINSNASAGCFAFCSPFSCDRSATCQVTADGKTSCVCRESEVGDGRACYGHLLHEVQKATQTGRVFLQLRVAVAMMDQGCREILTTAGPFTVLVPSVSSFSSRTMNASLAQQLCRQHIIAGQHILEDTRTQQTRRWWTLAGQEITVTFNQFTKYSYKYKDQPQQTFNIYKANNIAANGVFHVVTGLRWQAPSGTPGDPKRTIGQILASTEAFSRFETILENCGLPSILDGPGPFTVFAPSNEAVDSLRDGRLIYLFTAGLSKLQELVRYHIYNHGQLTVEKLISKGRILTMANQVLAVNISEEGRILLGPEGVPLQRVDVMAANGVIHMLDGILLPPTILPILPKHCSEEQHKIVAGSCVDCQALNTSTCPPNSVKLDIFPKECVYIHDPTGLNVLKKGCASYCNQTIMEQGCCKGFFGPDCTQCPGGFSNPCYGKGNCSDGIQGNGACLCFPDYKGIACHICSNPNKHGEQCQEDCGCVHGLCDNRPGSGGVCQQGTCAPGFSGRFCNESMGDCGPTGLAQHCHLHARCVSQEGVARCRCLDGFEGDGFSCTPSNPCSHPDRGGCSENAECVPGSLGTHHCTCHKGWSGDGRVCVAIDECELDMRGGCHTDALCSYVGPGQSRCTCKLGFAGDGYQCSPIDPCRAGNGGCHGLATCRAVGGGQRVCTCPPGFGGDGFSCYGDIFRELEANAHFSIFYQWLKSAGITLPADRRVTALVPSEAAVRQLSPEDRAFWLQPRTLPNLVRAHFLQGALFEEELARLGGQEVATLNPTTRWEIRNISGRVWVQNASVDVADLLATNGVLHILSQVLLPPRGDVPGGQGLLQQLDLVPAFSLFRELLQHHGLVPQIEAATAYTIFVPTNRSLEAQGNSSHLDADTVRHHVVLGEALSMETLRKGGHRNSLLGPAHWIVFYNHSGQPEVNHVPLEGPMLEAPGRSLIGLSGVLTVGSSRCLHSHAEALREKCVNCTRRFRCTQGFQLQDTPRKSCVYRSGFSFSRGCSYTCAKKIQVPDCCPGFFGTLCEPCPGGLGGVCSGHGQCQDRFLGSGECHCHEGFHGTACEVCELGRYGPNCTGVCDCAHGLCQEGLQGDGSCVCNVGWQGLRCDQKITSPQCPRKCDPNANCVQDSAGASTCACAAGYSGNGIFCSEVDPCAHGHGGCSPHANCTKVAPGQRTCTCQDGYMGDGELCQEINSCLIHHGGCHIHAECIPTGPQQVSCSCREGYSGDGIRTCELLDPCSKNNGGCSPYATCKSTGDGQRTCTCDTAHTVGDGLTCRARVGLELLRDKHASFFSLRLLEYKELKGDGPFTIFVPHADLMSNLSQDELARIRAHRQLVFRYHVVGCRRLRSEDLLEQGYATALSGHPLRFSEREGSIYLNDFARVVSSDHEAVNGILHFIDRVLLPPEALHWEPDDAPIPRRNVTAAAQGFGYKIFSGLLKVAGLLPLLREASHRPFTMLWPTDAAFRALPPDRQAWLYHEDHRDKLAAILRGHMIRNVEALASDLPNLGPLRTMHGTPISFSCSRTRAGELMVGEDDARIVQRHLPFEGGLAYGIDQLLEPPGLGARCDHFETRPLRLNTCSICGLEPPCPEGSQEQGSPEACWRFYPKFWTSPPLHSLGLRSVWVHPSLWGRPQGLGRGCHRNCVTTTWKPSCCPGHYGSECQACPGGPSSPCSDRGVCMDGMSGSGQCLCRSGFAGTACELCAPGAFGPHCQACRCTVHGRCDEGLGGSGSCFCDEGWTGPRCEVQLELQPVCTPPCAPEAVCRAGNSCECSLGYEGDGRVCTVADLCQDGHGGCSEHANCSQVGTMVTCTCLPDYEGDGWSCRARNPCTDGHRGGCSEHANCLSTGLNTRRCECHAGYVGDGLQCLEESEPPVDRCLGQPPPCHSDAMCTDLHFQEKRAGVFHLQATSGPYGLNFSEAEAACEAQGAVLASFPQLSAAQQLGFHLCLMGWLANGSTAHPVVFPVADCGNGRVGIVSLGARKNLSERWDAYCFRVQDVACRCRNGFVGDGISTCNGKLLDVLAATANFSTFYGMLLGYANATQRGLDFLDFLDDELTYKTLFVPVNEGFVDNMTLSGPDLELHASNATLLSANASQGKLLPAHSGLSLIISDAGPDNSSWAPVAPGTVVVSRIIVWDIMAFNGIIHALASPLLAPPQPQAVLAPEAPPVAAGVGAVLAAGALLGLVAGALYLRARGKPMGFGFSAFQAEDDADDDFSPWQEGTNPTLVSVPNPVFGSDTFCEPFDDSLLEEDFPDTQRILTVK T38157 TARGETID T38157 T38157 FORMERID TTDI03420 T38157 UNIPROID SO1C1_HUMAN T38157 TARGNAME Organic anion transporter F (SLCO1C1) T38157 GENENAME SLCO1C1 T38157 TARGTYPE Literature-reported T38157 SYNONYMS Thyroxine transporter; Solute carrier organic anion transporter family member 1C1; Solute carrier family 21 member 14; SLC21A14; Organic anion-transporting polypeptide 14; Organic anion transporter polypeptide-related protein 5; OATPRP5; OATPF; OATP1C1; OATP14; OATP-F; OATP-14; OAT-RP-5 T38157 FUNCTION Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a significant role in regulating T4 flux into and out of the brain (By similarity). T38157 SEQUENCE MDTSSKENIQLFCKTSVQPVGRPSFKTEYPSSEEKQPCCGELKVFLCALSFVYFAKALAEGYLKSTITQIERRFDIPSSLVGVIDGSFEIGNLLVITFVSYFGAKLHRPKIIGAGCVIMGVGTLLIAMPQFFMEQYKYERYSPSSNSTLSISPCLLESSSQLPVSVMEKSKSKISNECEVDTSSSMWIYVFLGNLLRGIGETPIQPLGIAYLDDFASEDNAAFYIGCVQTVAIIGPIFGFLLGSLCAKLYVDIGFVNLDHITITPKDPQWVGAWWLGYLIAGIISLLAAVPFWYLPKSLPRSQSREDSNSSSEKSKFIIDDHTDYQTPQGENAKIMEMARDFLPSLKNLFGNPVYFLYLCTSTVQFNSLFGMVTYKPKYIEQQYGQSSSRANFVIGLINIPAVALGIFSGGIVMKKFRISVCGAAKLYLGSSVFGYLLFLSLFALGCENSDVAGLTVSYQGTKPVSYHERALFSDCNSRCKCSETKWEPMCGENGITYVSACLAGCQTSNRSGKNIIFYNCTCVGIAASKSGNSSGIVGRCQKDNGCPQMFLYFLVISVITSYTLSLGGIPGYILLLRCIKPQLKSFALGIYTLAIRVLAGIPAPVYFGVLIDTSCLKWGFKRCGSRGSCRLYDSNVFRHIYLGLTVILGTVSILLSIAVLFILKKNYVSKHRSFITKRERTMVSTRFQKENYTTSDHLLQPNYWPGKETQL T38157 DRUGINFO D04AXP [3H]estrone-3-sulphate Investigative T96236 TARGETID T96236 T96236 UNIPROID FOXJ2_HUMAN T96236 TARGNAME Forkhead box protein J2 (FOXJ2) T96236 GENENAME FOXJ2 T96236 TARGTYPE Literature-reported T96236 SYNONYMS Fork head homologous X; FHX T96236 FUNCTION Transcriptional activator. Able to bind to two different type of DNA binding sites. Isoform FOXJ2.L behaves as a more potent transactivator than FOXJ2.S. T96236 SEQUENCE MASDLESSLTSIDWLPQLTLRATIEKLGSASQAGPPGSSRKCSPGSPTDPNATLSKDEAAVHQDGKPRYSYATLITYAINSSPAKKMTLSEIYRWICDNFPYYKNAGIGWKNSIRHNLSLNKCFRKVPRPRDDPGKGSYWTIDTCPDISRKRRHPPDDDLSQDSPEQEASKSPRGGVAGSGEASLPPEGNPQMSLQSPTSIASYSQGTGSVDGGAVAAGASGRESAEGPPPLYNTNHDFKFSYSEINFQDLSWSFRNLYKSMLEKSSSSSQHGFSSLLGDIPPSNNYYMYQQQQPPPPQQQQQQQQPPQPPPQQSQPQQQQAPAQGPSAVGGAPPLHTPSTDGCTPPGGKQAGAEGYGPPPVMAMHPPPLQHGGYHPHQHHPHSHPAQQPPPPQPQAQGQAPINNTGFAFPSDWCSNIDSLKESFKMVNRLNWSSIEQSQFSELMESLRQAEQKNWTLDQHHIANLCDSLNHFLTQTGHVPPQGGTHRPPAPARIADSCALTSGKQESAMSQVNSYGHPQAPHLYPGPSPMYPIPTQDSAGYNRPAHHMVPRPSVPPPGANEEIPDDFDWDLIT T82922 TARGETID T82922 T82922 FORMERID TTDI03567 T82922 UNIPROID TAAR3_HUMAN T82922 TARGNAME Trace amine receptor 3 (TAAR3) T82922 GENENAME TAAR3P T82922 TARGTYPE Literature-reported T82922 SYNONYMS hTaar3; TaR-3; TAAR3; Putative trace amine-associated receptor 3; GPR57; G-protein coupled receptor 57 T82922 FUNCTION G protein-coupled receptor activity, trace-amine receptor activity, sensory perception of chemical stimulus T82922 SEQUENCE MDLTYIPEDLSSCPKFVNKILSSHQPLFSCPGDNVFGYDWSHDYPLFGNLVIMVSISHFKQLHSPTNFLILSMATTDFLLGFVIMPYSIMRSVESCWYFGDGFCKFHTSFDMMLRLTSIFHLCSIAIDRFYAVCYPLHYTTKMTNSTIKQLLAFCWSVPALFSFGLVLSEADVSGMQSYKILVACFNFCALTFNKFWGTILFTTCFFTPGSIMVGIYGKIFIVSKQHARVISHVPENTKGAVKKHLSKKKDRKAAKTLGIVMGVFLACWLPCFLAVLIDPYLDYSTPILILDLLVWLRYFNSTCNPLIHGFFNPWFQKAFKYIVSGKIFSSHSETANLFPEAH T82922 DRUGINFO D0XO7J isoamylamine Investigative T84019 TARGETID T84019 T84019 FORMERID TTDI02632 T84019 UNIPROID CLCF1_HUMAN T84019 TARGNAME Cardiotrophin-like cytokine factor 1 (CLCF1) T84019 GENENAME CLCF1 T84019 TARGTYPE Literature-reported T84019 SYNONYMS Novel neurotrophin1; NNT1; CLCF1; Bcellstimulating factor 3; BSF3 T84019 FUNCTION Cytokine with B-cell stimulating capability. Binds to and activates the ILST/gp130 receptor. T84019 SEQUENCE MDLRAGDSWGMLACLCTVLWHLPAVPALNRTGDPGPGPSIQKTYDLTRYLEHQLRSLAGTYLNYLGPPFNEPDFNPPRLGAETLPRATVDLEVWRSLNDKLRLTQNYEAYSHLLCYLRGLNRQAATAELRRSLAHFCTSLQGLLGSIAGVMAALGYPLPQPLPGTEPTWTPGPAHSDFLQKMDDFWLLKELQTWLWRSAKDFNRLKKKMQPPAAAVTLHLGAHGF T73533 TARGETID T73533 T73533 FORMERID TTDI02650 T73533 UNIPROID KAAG1_HUMAN T73533 TARGNAME Kidney associated antigen 1 (KAAG1) T73533 GENENAME KAAG1 T73533 TARGTYPE Literature-reported T73533 SYNONYMS RU2AS; RU2 antisense gene protein; Kidney-associated antigen 1 T73533 FUNCTION Invovled in immune response. T73533 SEQUENCE MDDDAAPRVEGVPVAVHKHALHDGLRQVAGPGAAAAHLPRWPPPQLAASRREAPPLSQRPHRTQGAGSPPETNEKLTNPQVKEK T99255 TARGETID T99255 T99255 FORMERID TTDI03423 T99255 UNIPROID SO3A1_HUMAN T99255 TARGNAME Organic anion transporter D (SLCO3A1) T99255 GENENAME SLCO3A1 T99255 TARGTYPE Literature-reported T99255 SYNONYMS Solute carrier organic anion transporter family member 3A1; Solute carrier family 21 member 11; Sodium-independent organic anion transporter D; SLC21A11; PGE1 transporter; Organic anion-transporting polypeptide D; Organic anion transporter polypeptide-related protein 3; OATPRP3; OATPD; OATP3A1; OATP-RP3; OATP-D T99255 FUNCTION Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate. Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS. T99255 SEQUENCE MQGKKPGGSSGGGRSGELQGDEAQRNKKKKKKVSCFSNIKIFLVSECALMLAQGTVGAYLVSVLTTLERRFNLQSADVGVIASSFEIGNLALILFVSYFGARGHRPRLIGCGGIVMALGALLSALPEFLTHQYKYEAGEIRWGAEGRDVCAANGSGGDEGPDPDLICRNRTATNMMYLLLIGAQVLLGIGATPVQPLGVSYIDDHVRRKDSSLYIGILFTMLVFGPACGFILGSFCTKIYVDAVFIDTSNLDITPDDPRWIGAWWGGFLLCGALLFFSSLLMFGFPQSLPPHSEPAMESEQAMLSEREYERPKPSNGVLRHPLEPDSSASCFQQLRVIPKVTKHLLSNPVFTCIILAACMEIAVVAGFAAFLGKYLEQQFNLTTSSANQLLGMTAIPCACLGIFLGGLLVKKLSLSALGAIRMAMLVNLVSTACYVSFLFLGCDTGPVAGVTVPYGNSTAPGSALDPYSPCNNNCECQTDSFTPVCGADGITYLSACFAGCNSTNLTGCACLTTVPAENATVVPGKCPSPGCQEAFLTFLCVMCICSLIGAMAQTPSVIILIRTVSPELKSYALGVLFLLLRLLGFIPPPLIFGAGIDSTCLFWSTFCGEQGACVLYDNVVYRYLYVSIAIALKSFAFILYTTTWQCLRKNYKRYIKNHEGGLSTSEFFASTLTLDNLGRDPVPANQTHRTKFIYNLEDHEWCENMESVL T99255 DRUGINFO D04AXP [3H]estrone-3-sulphate Investigative T75962 TARGETID T75962 T75962 FORMERID TTDI00114 T75962 UNIPROID STML2_HUMAN T75962 TARGNAME Stomatin-like protein 2 (STOML2) T75962 GENENAME STOML2 T75962 TARGTYPE Literature-reported T75962 SYNONYMS Stomatin-like protein 2, mitochondrial; SLP2; SLP-2; Paratarg-7; Paraprotein target 7; HSPC108; EPB72-like protein 2 T75962 FUNCTION Stimulates cardiolipin biosynthesis, binds cardiolipin-enriched membranes where it recruits and stabilizes some proteins including prohibitin and may therefore act in the organization of functional microdomains in mitochondrial membranes. Through regulation of the mitochondrial function may play a role into several biological processes including cell migration, cell proliferation, T-cell activation, calcium homeostasis and cellular response to stress. May play a role in calcium homeostasis through negative regulation of calcium efflux from mitochondria. Required for mitochondrial hyperfusion a pro-survival cellular response to stress which results in increased ATP production by mitochondria. May also regulate the organization of functional domains at the plasma membrane and play a role in T-cell activation through association with the T-cell receptor signaling complex and its regulation. Mitochondrial protein that probably regulates the biogenesis and the activity of mitochondria. T75962 SEQUENCE MLARAARGTGALLLRGSLLASGRAPRRASSGLPRNTVVLFVPQQEAWVVERMGRFHRILEPGLNILIPVLDRIRYVQSLKEIVINVPEQSAVTLDNVTLQIDGVLYLRIMDPYKASYGVEDPEYAVTQLAQTTMRSELGKLSLDKVFRERESLNASIVDAINQAADCWGIRCLRYEIKDIHVPPRVKESMQMQVEAERRKRATVLESEGTRESAINVAEGKKQAQILASEAEKAEQINQAAGEASAVLAKAKAKAEAIRILAAALTQHNGDAAASLTVAEQYVSAFSKLAKDSNTILLPSNPGDVTSMVAQAMGVYGALTKAPVPGTPDSLSSGSSRDVQGTDASLDEELDRVKMS T52112 TARGETID T52112 T52112 FORMERID TTDR00994 T52112 UNIPROID Q9UK79_HUMAN T52112 TARGNAME Neuro/glioblastoma derived oncogene (Herstatin) T52112 GENENAME HER-2 T52112 TARGTYPE Literature-reported T52112 SYNONYMS V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (Avian), isoform CRA_a; Herstatin; ERBB2 T52112 FUNCTION An autoinhibitor of the ErbB family consisting of subdomains I and II of the human epidermal growth factor receptor 2 (ErbB-2) extracellular domain and a novel C-terminal domain encoded by an intron. Binds to human epidermal growth factor receptor 2 and to the epidermal growth factor receptor (EGFR), blocking receptor oligomerization and tyrosine phosphorylation. T52112 SEQUENCE MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARGTHSLPPRPAAVPVPLRMQPGPAHPVLSFLRPSWDLVSAFYSLPLAPLSPTSVPISPVSVGRGPDPDAHVAVDLSRYEG T26741 TARGETID T26741 T26741 FORMERID TTDR00480 T26741 UNIPROID TBX21_HUMAN T26741 TARGNAME T-box transcription factor TBX21 (TBX21) T26741 GENENAME TBX21 T26741 TARGTYPE Literature-reported T26741 SYNONYMS Transcription factor TBLYM; TBX21; T-cell-specific T-box transcription factor T-bet; T-box protein 21; T-bet T26741 FUNCTION Transcription factor that controls the expression of the TH1 cytokine, interferon-gamma. Initiates TH1 lineage development from naive TH precursor cells both by activating TH1 genetic programs and by repressing the opposing TH2 programs. T26741 SEQUENCE MGIVEPGCGDMLTGTEPMPGSDEGRAPGADPQHRYFYPEPGAQDADERRGGGSLGSPYPGGALVPAPPSRFLGAYAYPPRPQAAGFPGAGESFPPPADAEGYQPGEGYAAPDPRAGLYPGPREDYALPAGLEVSGKLRVALNNHLLWSKFNQHQTEMIITKQGRRMFPFLSFTVAGLEPTSHYRMFVDVVLVDQHHWRYQSGKWVQCGKAEGSMPGNRLYVHPDSPNTGAHWMRQEVSFGKLKLTNNKGASNNVTQMIVLQSLHKYQPRLHIVEVNDGEPEAACNASNTHIFTFQETQFIAVTAYQNAEITQLKIDNNPFAKGFRENFESMYTSVDTSIPSPPGPNCQFLGGDHYSPLLPNQYPVPSRFYPDLPGQAKDVVPQAYWLGAPRDHSYEAEFRAVSMKPAFLPSAPGPTMSYYRGQEVLAPGAGWPVAPQYPPKMGPASWFRPMRTLPMEPGPGGSEGRGPEDQGPPLVWTEIAPIRPESSDSGLGEGDSKRRRVSPYPSSGDSSSPAGAPSPFDKEAEGQFYNYFPN T58264 TARGETID T58264 T58264 FORMERID TTDI03583 T58264 UNIPROID TPC1_HUMAN T58264 TARGNAME Two pore calcium channel protein 1 (TPC1) T58264 GENENAME TPCN1 T58264 TARGTYPE Literature-reported T58264 SYNONYMS Voltage-dependent calcium channel protein TPC1; TPC1; KIAA1169 T58264 FUNCTION Nicotinic acid adenine dinucleotide phosphate (NAADP) receptor that may function as one of the major voltage-gated Ca(2+) channels (VDCC) across the lysosomal and endosomal membrane. T58264 SEQUENCE MAVSLDDDVPLILTLDEGGSAPLAPSNGLGQEELPSKNGGSYAIHDSQAPSLSSGGESSPSSPAHNWEMNYQEAAIYLQEGENNDKFFTHPKDAKALAAYLFAHNHLFYLMELATALLLLLLSLCEAPAVPALRLGIYVHATLELFALMVVVFELCMKLRWLGLHTFIRHKRTMVKTSVLVVQFVEAIVVLVRQMSHVRVTRALRCIFLVDCRYCGGVRRNLRQIFQSLPPFMDILLLLLFFMIIFAILGFYLFSPNPSDPYFSTLENSIVSLFVLLTTANFPDVMMPSYSRNPWSCVFFIVYLSIELYFIMNLLLAVVFDTFNDIEKRKFKSLLLHKRTAIQHAYRLLISQRRPAGISYRQFEGLMRFYKPRMSARERYLTFKALNQNNTPLLSLKDFYDIYEVAALKWKAKKNREHWFDELPRTALLIFKGINILVKSKAFQYFMYLVVAVNGVWILVETFMLKGGNFFSKHVPWSYLVFLTIYGVELFLKVAGLGPVEYLSSGWNLFDFSVTVFAFLGLLALALNMEPFYFIVVLRPLQLLRLFKLKERYRNVLDTMFELLPRMASLGLTLLIFYYSFAIVGMEFFCGIVFPNCCNTSTVADAYRWRNHTVGNRTVVEEGYYYLNNFDNILNSFVTLFELTVVNNWYIIMEGVTSQTSHWSRLYFMTFYIVTMVVMTIIVAFILEAFVFRMNYSRKNQDSEVDGGITLEKEISKEELVAVLELYREARGASSDVTRLLETLSQMERYQQHSMVFLGRRSRTKSDLSLKMYQEEIQEWYEEHAREQEQQRQLSSSAAPAAQQPPGSRQRSQTVT T58264 DRUGINFO D01ZCI phosphatidyl (3,5) inositol biphosphate Investigative T58674 TARGETID T58674 T58674 FORMERID TTDI00115 T58674 UNIPROID APEL_HUMAN T58674 TARGNAME APJ endogenous ligand (Apelin) T58674 GENENAME APLN T58674 TARGTYPE Literature-reported T58674 SYNONYMS Apelin13; APEL T58674 FUNCTION Drives internalization of the apelin receptor. Apelin-36 dissociates more hardly than (pyroglu)apelin-13 from APLNR. Hormone involved in the regulation of cardiac precursor cell movements during gastrulation and heart morphogenesis. Has an inhibitory effect on cytokine production in response to T-cell receptor/CD3 cross-linking; the oral intake of apelin in the colostrum and the milk might therefore modulate immune responses in neonates. Plays a role in early coronary blood vessels formation. Mediates myocardial contractility in an ERK1/2-dependent manner. May also have a role in the central control of body fluid homeostasis by influencing vasopressin release and drinking behavior. Endogenous ligand for the apelin receptor (APLNR). T58674 SEQUENCE MNLRLCVQALLLLWLSLTAVCGGSLMPLPDGNGLEDGNVRHLVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF T47818 TARGETID T47818 T47818 FORMERID TTDI03044 T47818 UNIPROID S6A14_HUMAN T47818 TARGNAME Amino acid transporter ATB0+ (SLC6A14) T47818 GENENAME SLC6A14 T47818 TARGTYPE Literature-reported T47818 SYNONYMS Solute carrier family 6 member 14; Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) T47818 FUNCTION Mediates the uptake of a broad range of neutral and cationic amino acids (with the exception of proline) in a Na(+)/Cl(-)-dependent manner. T47818 SEQUENCE MDKLKCPSFFKCREKEKVSASSENFHVGENDENQDRGNWSKKSDYLLSMIGYAVGLGNVWRFPYLTYSNGGGAFLIPYAIMLALAGLPLFFLECSLGQFASLGPVSVWRILPLFQGVGITMVLISIFVTIYYNVIIAYSLYYMFASFQSELPWKNCSSWSDKNCSRSPIVTHCNVSTVNKGIQEIIQMNKSWVDINNFTCINGSEIYQPGQLPSEQYWNKVALQRSSGMNETGVIVWYLALCLLLAWLIVGAALFKGIKSSGKVVYFTALFPYVVLLILLVRGATLEGASKGISYYIGAQSNFTKLKEAEVWKDAATQIFYSLSVAWGGLVALSSYNKFKNNCFSDAIVVCLTNCLTSVFAGFAIFSILGHMAHISGKEVSQVVKSGFDLAFIAYPEALAQLPGGPFWSILFFFMLLTLGLDSQFASIETITTTIQDLFPKVMKKMRVPITLGCCLVLFLLGLVCVTQAGIYWVHLIDHFCAGWGILIAAILELVGIIWIYGGNRFIEDTEMMIGAKRWIFWLWWRACWFVITPILLIAIFIWSLVQFHRPNYGAIPYPDWGVALGWCMIVFCIIWIPIMAIIKIIQAKGNIFQRLISCCRPASNWGPYLEQHRGERYKDMVDPKKEADHEIPTVSGSRKPE T47818 DRUGINFO D0OX9Q NOX-200 Terminated T15161 TARGETID T15161 T15161 FORMERID TTDI03213 T15161 UNIPROID GBRT_HUMAN T15161 TARGNAME GABA(A) receptor theta (GABRQ) T15161 GENENAME GABRQ T15161 TARGTYPE Literature-reported T15161 SYNONYMS Gamma-aminobutyric acid receptor subunit theta; GABA(A) receptor subunit theta T15161 FUNCTION GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. T15161 SEQUENCE MGIRGMLRAAVILLLIRTWLAEGNYPSPIPKFHFEFSSAVPEVVLNLFNCKNCANEAVVQKILDRVLSRYDVRLRPNFGGAPVPVRISIYVTSIEQISEMNMDYTITMFFHQTWKDSRLAYYETTLNLTLDYRMHEKLWVPDCYFLNSKDAFVHDVTVENRVFQLHPDGTVRYGIRLTTTAACSLDLHKFPMDKQACNLVVESYGYTVEDIILFWDDNGNAIHMTEELHIPQFTFLGRTITSKEVYFYTGSYIRLILKFQVQREVNSYLVQVYWPTVLTTITSWISFWMNYDSSAARVTIGLTSMLILTTIDSHLRDKLPNISCIKAIDIYILVCLFFVFLSLLEYVYINYLFYSRGPRRQPRRHRRPRRVIARYRYQQVVVGNVQDGLINVEDGVSSLPITPAQAPLASPESLGSLTSTSEQAQLATSESLSPLTSLSGQAPLATGESLSDLPSTSEQARHSYGVRFNGFQADDSIFPTEIRNRVEAHGHGVTHDHEDSNESLSSDERHGHGPSGKPMLHHGEKGVQEAGWDLDDNNDKSDCLAIKEQFKCDTNSTWGLNDDELMAHGQEKDSSSESEDSCPPSPGCSFTEGFSFDLFNPDYVPKVDKWSRFLFPLAFGLFNIVYWVYHMY T15161 DRUGINFO D0P0TI TBPS Investigative T63465 TARGETID T63465 T63465 FORMERID TTDI03231 T63465 UNIPROID GP132_HUMAN T63465 TARGNAME G2 accumulation protein (GPR132) T63465 GENENAME GPR132 T63465 TARGTYPE Literature-reported T63465 SYNONYMS Probable G-protein coupled receptor 132; G2A T63465 FUNCTION May be a receptor for oxidized free fatty acids derived from linoleic and arachidonic acids such as 9-hydroxyoctadecadienoic acid (9-HODE). Activates a G alpha protein, most likely G alpha(q). May be involved in apoptosis. Functions at the G2/M checkpoint to delay mitosis. May function as a sensor that monitors the oxidative states and mediates appropriate cellular responses such as secretion of paracrine signals and attenuation of proliferation. May mediate ths accumulation of intracellular inositol phosphates at acidic pH through proton-sensing activity. T63465 SEQUENCE MCPMLLKNGYNGNATPVTTTAPWASLGLSAKTCNNVSFEESRIVLVVVYSAVCTLGVPANCLTAWLALLQVLQGNVLAVYLLCLALCELLYTGTLPLWVIYIRNQHRWTLGLLACKVTAYIFFCNIYVSILFLCCISCDRFVAVVYALESRGRRRRRTAILISACIFILVGIVHYPVFQTEDKETCFDMLQMDSRIAGYYYARFTVGFAIPLSIIAFTNHRIFRSIKQSMGLSAAQKAKVKHSAIAVVVIFLVCFAPYHLVLLVKAAAFSYYRGDRNAMCGLEERLYTASVVFLCLSTVNGVADPIIYVLATDHSRQEVSRIHKGWKEWSMKTDVTRLTHSRDTEELQSPVALADHYTFSRPVHPPGSPCPAKRLIEESC T63465 DRUGINFO D0SZ4T 9-hydroxyoctadecadienoic acid Investigative T58890 TARGETID T58890 T58890 FORMERID TTDI03312 T58890 UNIPROID S12A4_HUMAN T58890 TARGNAME Solute carrier family 12 member 4 (SLC12A4) T58890 GENENAME SLC12A4 T58890 TARGTYPE Literature-reported T58890 SYNONYMS hKCC1; KCC1; Erythroid K-Cl cotransporter 1; Electroneutral potassium-chloride cotransporter 1 T58890 FUNCTION Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral Cl(-) exit in NaCl absorbing epithelia (By similarity). Isoform 4 has no transport activity. T58890 SEQUENCE MPHFTVVPVDGPRRGDYDNLEGLSWVDYGERAELDDSDGHGNHRESSPFLSPLEASRGIDYYDRNLALFEEELDIRPKVSSLLGKLVSYTNLTQGAKEHEEAESGEGTRRRAAEAPSMGTLMGVYLPCLQNIFGVILFLRLTWMVGTAGVLQALLIVLICCCCTLLTAISMSAIATNGVVPAGGSYFMISRSLGPEFGGAVGLCFYLGTTFAAAMYILGAIEILLTYIAPPAAIFYPSGAHDTSNATLNNMRVYGTIFLTFMTLVVFVGVKYVNKFASLFLACVIISILSIYAGGIKSIFDPPVFPVCMLGNRTLSRDQFDICAKTAVVDNETVATQLWSFFCHSPNLTTDSCDPYFMLNNVTEIPGIPGAAAGVLQENLWSAYLEKGDIVEKHGLPSADAPSLKESLPLYVVADIATSFTVLVGIFFPSVTGIMAGSNRSGDLRDAQKSIPVGTILAIITTSLVYFSSVVLFGACIEGVVLRDKYGDGVSRNLVVGTLAWPSPWVIVIGSFFSTCGAGLQSLTGAPRLLQAIAKDNIIPFLRVFGHGKVNGEPTWALLLTALIAELGILIASLDMVAPILSMFFLMCYLFVNLACAVQTLLRTPNWRPRFKYYHWALSFLGMSLCLALMFVSSWYYALVAMLIAGMIYKYIEYQGAEKEWGDGIRGLSLSAARYALLRLEEGPPHTKNWRPQLLVLLKLDEDLHVKYPRLLTFASQLKAGKGLTIVGSVIQGSFLESYGEAQAAEQTIKNMMEIEKVKGFCQVVVASKVREGLAHLIQSCGLGGMRHNSVVLGWPYGWRQSEDPRAWKTFIDTVRCTTAAHLALLVPKNIAFYPSNHERYLEGHIDVWWIVHDGGMLMLLPFLLRQHKVWRKCRMRIFTVAQMDDNSIQMKKDLAVFLYHLRLEAEVEVVEMHNSDISAYTYERTLMMEQRSQMLRQMRLTKTEREREAQLVKDRHSALRLESLYSDEEDESAVGADKIQMTWTRDKYMTETWDPSHAPDNFRELVHIKPDQSNVRRMHTAVKLNEVIVTRSHDARLVLLNMPGPPRNSEGDENYMEFLEVLTEGLERVLLVRGGGREVITIYS T58890 DRUGINFO D0K9KZ DIOA Investigative T73859 TARGETID T73859 T73859 FORMERID TTDI03241 T73859 UNIPROID GPR34_HUMAN T73859 TARGNAME G-protein coupled receptor 34 (GPR34) T73859 GENENAME GPR34 T73859 TARGTYPE Literature-reported T73859 SYNONYMS Probable G-protein coupled receptor 34 T73859 FUNCTION Orphan receptor. T73859 SEQUENCE MRSHTITMTTTSVSSWPYSSHRMRFITNHSDQPPQNFSATPNVTTCPMDEKLLSTVLTTSYSVIFIVGLVGNIIALYVFLGIHRKRNSIQIYLLNVAIADLLLIFCLPFRIMYHINQNKWTLGVILCKVVGTLFYMNMYISIILLGFISLDRYIKINRSIQQRKAITTKQSIYVCCIVWMLALGGFLTMIILTLKKGGHNSTMCFHYRDKHNAKGEAIFNFILVVMFWLIFLLIILSYIKIGKNLLRISKRRSKFPNSGKYATTARNSFIVLIIFTICFVPYHAFRFIYISSQLNVSSCYWKEIVHKTNEIMLVLSSFNSCLDPVMYFLMSSNIRKIMCQLLFRRFQGEPSRSESTSEFKPGYSLHDTSVAVKIQSSSKST T73859 DRUGINFO D0M8IT lysophosphatidylserine Investigative T55968 TARGETID T55968 T55968 FORMERID TTDI01476 T55968 UNIPROID SPEG_STRP1 T55968 TARGNAME Streptococcus Exotoxin type G (Stre-coc speG) T55968 GENENAME Stre-coc speG T55968 TARGTYPE Literature-reported T55968 SYNONYMS SPE G; Pyrogenic exotoxin G; Exotoxin type G T55968 FUNCTION Mitogenic for human peripheral blood lymphocytes. T55968 SEQUENCE MKTNILTIIILSCVFSYGSQLAYADENLKDLKRSLRFAYNITPCDYENVEIAFVTTNSIHINTKQKRSECILYVDSIVSLGITDQFIKGDKVDVFGLPYNFSPPYVDNIYGGIVKHSNQGNKSLQFVGILNQDGKETYLPSEAVRIKKKQFTLQEFDFKIRKFLMEKYNIYDSESRYTSGSLFLATKDSKHYEVDLFNKDDKLLSRDSFFKRYKDNKIFNSEEISHFDIYLKTH T75947 TARGETID T75947 T75947 FORMERID TTDNR00637 T75947 UNIPROID ADIP_HUMAN T75947 TARGNAME SSX2-interacting protein (SSX2IP) T75947 GENENAME SSX2IP T75947 TARGTYPE Literature-reported T75947 SYNONYMS KIAA0923; Afadin- and alpha-actinin-binding protein; Afadin DIL domain-interacting protein; ADIP T75947 FUNCTION May connect the nectin-afadin and E-cadherin-catenin system through alpha-actinin and may be involved in organization of the actin cytoskeleton at AJs through afadin and alpha-actinin. Involved in cell movement: localizes at the leading edge of moving cells in response to PDGF and is required for the formation of the leading edge and the promotion of cell movement, possibly via activation of Rac signaling. Acts as a centrosome maturation factor, probably by maintaining the integrity of the pericentriolar material and proper microtubule nucleation at mitotic spindle poles. The function seems to implicate at least in part WRAP73; the SSX2IP:WRAP73 complex is proposed to act as regulator of spindle anchoring at the mitotic centrosome. Involved in ciliogenesis. It is required for targeted recruitment of the BBSome, CEP290, RAB8, and SSTR3 to the cilia. Belongs to an adhesion system, which plays a role in the organization of homotypic, interneuronal and heterotypic cell-cell adherens junctions (AJs). T75947 SEQUENCE MGDWMTVTDPGLSSESKTISQYTSETKMSPSSLYSQQVLCSSIPLSKNVHSFFSAFCTEDNIEQSISYLDQELTTFGFPSLYEESKGKETKRELNIVAVLNCMNELLVLQRKNLLAQENVETQNLKLGSDMDHLQSCYSKLKEQLETSRREMIGLQERDRQLQCKNRNLHQLLKNEKDEVQKLQNIIASRATQYNHDMKRKEREYNKLKERLHQLVMNKKDKKIAMDILNYVGRADGKRGSWRTGKTEARNEDEMYKILLNDYEYRQKQILMENAELKKVLQQMKKEMISLLSPQKKKPRERVDDSTGTVISDVEEDAGELSRESMWDLSCETVREQLTNSIRKQWRILKSHVEKLDNQVSKVHLEGFNDEDVISRQDHEQETEKLELEIQQCKEMIKTQQQLLQQQLATAYDDDTTSLLRDCYLLEEKERLKEEWSLFKEQKKNFERERRSFTEAAIRLGLERKAFEEERASWLKQQFLNMTTFDHQNSENVKLFSAFSGSSDWDNLIVHSRQPQKKPHSVSNGSPVCMSKLTKSLPASPSTSDFCQTRSCISEHSSINVLNITAEEIKPNQVGGECTNQKWSVASRPGSQEGCYSGCSLSYTNSHVEKDDLP T95922 TARGETID T95922 T95922 UNIPROID RP3A_HUMAN T95922 TARGNAME Rabphilin-3A (RPH3A) T95922 GENENAME RPH3A T95922 TARGTYPE Literature-reported T95922 SYNONYMS KIAA0985; Exophilin-1 T95922 FUNCTION Protein transport. Probably involved with Ras-related protein Rab-3A in synaptic vesicle traffic and/or synaptic vesicle fusion. Could play a role in neurotransmitter release by regulating membrane flow in the nerve terminal. T95922 SEQUENCE MTDTVFSNSSNRWMYPSDRPLQSNDKEQLQAGWSVHPGGQPDRQRKQEELTDEEKEIINRVIARAEKMEEMEQERIGRLVDRLENMRKNVAGDGVNRCILCGEQLGMLGSACVVCEDCKKNVCTKCGVETNNRLHSVWLCKICIEQREVWKRSGAWFFKGFPKQVLPQPMPIKKTKPQQPVSEPAAPEQPAPEPKHPARAPARGDSEDRRGPGQKTGPDPASAPGRGNYGPPVRRASEARMSSSSRDSESWDHSGGAGDSSRSPAGLRRANSVQASRPAPGSVQSPAPPQPGQPGTPGGSRPGPGPAGRFPDQKPEVAPSDPGTTAPPREERTGGVGGYPAVGAREDRMSHPSGPYSQASAAAPQPAAARQPPPPEEEEEEANSYDSDEATTLGALEFSLLYDQDNSSLQCTIIKAKGLKPMDSNGLADPYVKLHLLPGASKSNKLRTKTLRNTRNPIWNETLVYHGITDEDMQRKTLRISVCDEDKFGHNEFIGETRFSLKKLKPNQRKNFNICLERVIPMKRAGTTGSARGMALYEEEQVERVGDIEERGKILVSLMYSTQQGGLIVGIIRCVHLAAMDANGYSDPFVKLWLKPDMGKKAKHKTQIKKKTLNPEFNEEFFYDIKHSDLAKKSLDISVWDYDIGKSNDYIGGCQLGISAKGERLKHWYECLKNKDKKIERWHQLQNENHVSSD T90818 TARGETID T90818 T90818 FORMERID TTDI03411 T90818 UNIPROID NPFF2_HUMAN T90818 TARGNAME Neuropeptide FF receptor 2 (NPFFR2) T90818 GENENAME NPFFR2 T90818 TARGTYPE Literature-reported T90818 SYNONYMS Neuropeptide G-protein coupled receptor; NPGPR; NPFF2; GPR74; G-protein coupled receptor HLWAR77; G-protein coupled receptor 74 T90818 FUNCTION Receptor for NPAF (A-18-F-amide) and NPFF (F-8-F-amide) neuropeptides, also known as morphine-modulating peptides. Can also be activated by a variety of naturally occurring or synthetic FMRF-amide like ligands. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. T90818 SEQUENCE MNSFFGTPAASWCLLESDVSSAPDKEAGRERRALSVQQRGGPAWSGSLEWSRQSAGDRRRLGLSRQTAKSSWSRSRDRTCCCRRAWWILVPAADRARRERFIMNEKWDTNSSENWHPIWNVNDTKHHLYSDINITYVNYYLHQPQVAAIFIISYFLIFFLCMMGNTVVCFIVMRNKHMHTVTNLFILNLAISDLLVGIFCMPITLLDNIIAGWPFGNTMCKISGLVQGISVAASVFTLVAIAVDRFQCVVYPFKPKLTIKTAFVIIMIIWVLAITIMSPSAVMLHVQEEKYYRVRLNSQNKTSPVYWCREDWPNQEMRKIYTTVLFANIYLAPLSLIVIMYGRIGISLFRAAVPHTGRKNQEQWHVVSRKKQKIIKMLLIVALLFILSWLPLWTLMMLSDYADLSPNELQIINIYIYPFAHWLAFGNSSVNPIIYGFFNENFRRGFQEAFQLQLCQKRAKPMEAYALKAKSHVLINTSNQLVQESTFQNPHGETLLYRKSAEKPQQELVMEELKETTNSSEI T90818 DRUGINFO D05NKX 1DMe Investigative T90818 DRUGINFO D08UWO RF9 Investigative T47438 TARGETID T47438 T47438 FORMERID TTDNC00378 T47438 UNIPROID BACE2_HUMAN; PEN2_HUMAN; APH1A_HUMAN; APH1B_HUMAN T47438 TARGNAME Amyloid precursor protein secretase (Secretase) T47438 GENENAME BACE2; PSENEN; APH1A; APH1B T47438 TARGTYPE Literature-reported T47438 SYNONYMS Secretase T47438 FUNCTION Enzymes that "snip" pieces off a longer protein that is embedded in the cell membrane. Among other roles in the cell, secretases act on the amyloid precursor protein (APP) to cleave the protein into three fragments. Sequential cleavage by -secretase (BACE) and -secretase produces the amyloid- peptide fragment that aggregates into clumps called "plaques" in the brains of Alzheimer's disease patients. T47438 SEQUENCE MGALARALLLPLLAQWLLRAAPELAPAPFTLPLRVAAATNRVVAPTPGPGTPAERHADGLALALEPALASPAGAANFLAMVDNLQGDSGRGYYLEMLIGTPPQKLQILVDTGSSNFAVAGTPHSYIDTYFDTERSSTYRSKGFDVTVKYTQGSWTGFVGEDLVTIPKGFNTSFLVNIATIFESENFFLPGIKWNGILGLAYATLAKPSSSLETFFDSLVTQANIPNVFSMQMCGAGLPVAGSGTNGGSLVLGGIEPSLYKGDIWYTPIKEEWYYQIEILKLEIGGQSLNLDCREYNADKAIVDSGTTLLRLPQKVFDAVVEAVARASLIPEFSDGFWTGSQLACWTNSETPWSYFPKISIYLRDENSSRSFRITILPQLYIQPMMGAGLNYECYRFGISPSTNALVIGATVMEGFYVIFDRAQKRVGFAASPCAEIAGAAVSEISGPFSTEDVASNCVPAQSLSEPILWIVSYALMSVCGAILLVLIVLLLLPFRCQRRPRDPEVVNDESSLVRHRWK T83320 TARGETID T83320 T83320 FORMERID TTDI03313 T83320 UNIPROID S12A7_HUMAN T83320 TARGNAME Solute carrier family 12 member 7 (SLC12A7) T83320 GENENAME SLC12A7 T83320 TARGTYPE Literature-reported T83320 SYNONYMS KCC4; K-Cl cotransporter 4; Electroneutral potassium-chloride cotransporter 4 T83320 FUNCTION Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear. Important for the survival of cochlear outer and inner hair cells and the maintenance of the organ of Corti. May be required for basolateral Cl(-) extrusion in the kidney and contribute to renal acidification (By similarity). T83320 SEQUENCE MPTNFTVVPVEAHADGGGDETAERTEAPGTPEGPEPERPSPGDGNPRENSPFLNNVEVEQESFFEGKNMALFEEEMDSNPMVSSLLNKLANYTNLSQGVVEHEEDEESRRREAKAPRMGTFIGVYLPCLQNILGVILFLRLTWIVGVAGVLESFLIVAMCCTCTMLTAISMSAIATNGVVPAGGSYYMISRSLGPEFGGAVGLCFYLGTTFAGAMYILGTIEIFLTYISPGAAIFQAEAAGGEAAAMLHNMRVYGTCTLVLMALVVFVGVKYVNKLALVFLACVVLSILAIYAGVIKSAFDPPDIPVCLLGNRTLSRRSFDACVKAYGIHNNSATSALWGLFCNGSQPSAACDEYFIQNNVTEIQGIPGAASGVFLENLWSTYAHAGAFVEKKGVPSVPVAEESRASALPYVLTDIAASFTLLVGIYFPSVTGIMAGSNRSGDLKDAQKSIPTGTILAIVTTSFIYLSCIVLFGACIEGVVLRDKFGEALQGNLVIGMLAWPSPWVIVIGSFFSTCGAGLQSLTGAPRLLQAIARDGIVPFLQVFGHGKANGEPTWALLLTVLICETGILIASLDSVAPILSMFFLMCYLFVNLACAVQTLLRTPNWRPRFKFYHWTLSFLGMSLCLALMFICSWYYALSAMLIAGCIYKYIEYRGAEKEWGDGIRGLSLNAARYALLRVEHGPPHTKNWRPQVLVMLNLDAEQAVKHPRLLSFTSQLKAGKGLTIVGSVLEGTYLDKHMEAQRAEENIRSLMSTEKTKGFCQLVVSSSLRDGMSHLIQSAGLGGLKHNTVLMAWPASWKQEDNPFSWKNFVDTVRDTTAAHQALLVAKNVDSFPQNQERFGGGHIDVWWIVHDGGMLMLLPFLLRQHKVWRKCRMRIFTVAQVDDNSIQMKKDLQMFLYHLRISAEVEVVEMVENDISAFTYERTLMMEQRSQMLKQMQLSKNEQEREAQLIHDRNTASHTAAAARTQAPPTPDKVQMTWTREKLIAEKYRSRDTSLSGFKDLFSMKPDQSNVRRMHTAVKLNGVVLNKSQDAQLVLLNMPGPPKNRQGDENYMEFLEVLTEGLNRVLLVRGGGREVITIYS T83320 DRUGINFO D0K9KZ DIOA Investigative T39753 TARGETID T39753 T39753 FORMERID TTDR00541 T39753 TARGNAME Hepatitis C virus Nucleoside triphosphatase (HCV NTP) T39753 TARGTYPE Literature-reported T39753 SYNONYMS Nucleoside-triphosphatase; Nucleoside triphosphate phosphohydrolase; NTPase; MJ0226 T39753 FUNCTION Pyrophosphatase that hydrolyzes non-canonical purine nucleotides such as XTP and ITP to their respective monophosphate derivatives. Probably excludes non-canonical purines from DNA precursor pool, thus preventing their incorporation into DNA and avoiding chromosomal lesions. T21196 TARGETID T21196 T21196 FORMERID TTDR00775 T21196 TARGNAME Monosialic ganglioside 2 (GM2) T21196 TARGTYPE Literature-reported T21196 SYNONYMS Gamma-M2; GM2 T21196 FUNCTION Crystallins are the dominant structural components of the vertebrate eye lens. T91031 TARGETID T91031 T91031 TARGNAME Epstein-Barr virus microRNA miR-BART1 (EBV MIRBART1) T91031 TARGTYPE Literature-reported T91031 BIOCLASS Non-coding RNA target T82849 TARGETID T82849 T82849 FORMERID TTDI01406 T82849 TARGNAME H19 imprinted maternally expressed transcript (H19) T82849 TARGTYPE Literature-reported T82849 BIOCLASS Non-coding RNA target T61881 TARGETID T61881 T61881 FORMERID TTDI00039 T61881 TARGNAME HOXA distal transcript antisense RNA (HOTTIP) T61881 TARGTYPE Literature-reported T61881 BIOCLASS Non-coding RNA target T37498 TARGETID T37498 T37498 FORMERID TTDI00177 T37498 TARGNAME Long intergenic noncoding RNA AATBC (lincRNA AATBC) T37498 TARGTYPE Literature-reported T37498 BIOCLASS Non-coding RNA target T90764 TARGETID T90764 T90764 TARGNAME Long intergenic noncoding RNA p21 (lincRNA p21) T90764 TARGTYPE Literature-reported T90764 BIOCLASS Non-coding RNA target T04431 TARGETID T04431 T04431 FORMERID TTDI00175 T04431 TARGNAME microRNA hsa-miR-100 (MIR100) T04431 TARGTYPE Literature-reported T04431 BIOCLASS Non-coding RNA target T64947 TARGETID T64947 T64947 FORMERID TTDI00143 T64947 TARGNAME microRNA hsa-miR-101 (MIR101) T64947 TARGTYPE Literature-reported T64947 BIOCLASS Non-coding RNA target T45122 TARGETID T45122 T45122 FORMERID TTDI00225 T45122 TARGNAME microRNA hsa-miR-105 (MIR105) T45122 TARGTYPE Literature-reported T45122 BIOCLASS Non-coding RNA target T53611 TARGETID T53611 T53611 FORMERID TTDI00201 T53611 TARGNAME microRNA hsa-miR-107 (MIR107) T53611 TARGTYPE Literature-reported T53611 BIOCLASS Non-coding RNA target T51677 TARGETID T51677 T51677 FORMERID TTDI02668 T51677 TARGNAME microRNA hsa-miR-10b (MIR10b) T51677 TARGTYPE Literature-reported T51677 BIOCLASS Non-coding RNA target T62451 TARGETID T62451 T62451 FORMERID TTDI00113 T62451 TARGNAME microRNA hsa-miR-1207-5p (MIR1207-5p) T62451 TARGTYPE Literature-reported T62451 BIOCLASS Non-coding RNA target T63799 TARGETID T63799 T63799 FORMERID TTDI01304 T63799 TARGNAME microRNA hsa-miR-122 (MIR122) T63799 TARGTYPE Literature-reported T63799 BIOCLASS Non-coding RNA target T04345 TARGETID T04345 T04345 FORMERID TTDI00048 T04345 TARGNAME microRNA hsa-miR-1269a (MIR1269a) T04345 TARGTYPE Literature-reported T04345 BIOCLASS Non-coding RNA target T95748 TARGETID T95748 T95748 FORMERID TTDI00117 T95748 TARGNAME microRNA hsa-miR-1271 (MIR1271) T95748 TARGTYPE Literature-reported T95748 BIOCLASS Non-coding RNA target T17838 TARGETID T17838 T17838 FORMERID TTDI00150 T17838 TARGNAME microRNA hsa-miR-1280 (MIR1280) T17838 TARGTYPE Literature-reported T17838 BIOCLASS Non-coding RNA target T31926 TARGETID T31926 T31926 FORMERID TTDI00206 T31926 TARGNAME microRNA hsa-miR-129-5p (MIR129-5p) T31926 TARGTYPE Literature-reported T31926 BIOCLASS Non-coding RNA target T06870 TARGETID T06870 T06870 FORMERID TTDI00163 T06870 TARGNAME microRNA hsa-miR-130b (MIR130b) T06870 TARGTYPE Literature-reported T06870 BIOCLASS Non-coding RNA target T00704 TARGETID T00704 T00704 FORMERID TTDI00243 T00704 TARGNAME microRNA hsa-miR-132 (MIR132) T00704 TARGTYPE Literature-reported T00704 BIOCLASS Non-coding RNA target T38740 TARGETID T38740 T38740 FORMERID TTDI00073 T38740 TARGNAME microRNA hsa-miR-133a (MIR133a) T38740 TARGTYPE Literature-reported T38740 BIOCLASS Non-coding RNA target T40971 TARGETID T40971 T40971 FORMERID TTDI00220 T40971 TARGNAME microRNA hsa-miR-134 (MIR134) T40971 TARGTYPE Literature-reported T40971 BIOCLASS Non-coding RNA target T70791 TARGETID T70791 T70791 FORMERID TTDI00211 T70791 TARGNAME microRNA hsa-miR-143 (MIR143) T70791 TARGTYPE Literature-reported T70791 BIOCLASS Non-coding RNA target T62818 TARGETID T62818 T62818 FORMERID TTDI00015 T62818 TARGNAME microRNA hsa-miR-144 (MIR144) T62818 TARGTYPE Literature-reported T62818 BIOCLASS Non-coding RNA target T65256 TARGETID T65256 T65256 FORMERID TTDI02670 T65256 TARGNAME microRNA hsa-miR-146a (MIR146a) T65256 TARGTYPE Literature-reported T65256 BIOCLASS Non-coding RNA target T68299 TARGETID T68299 T68299 FORMERID TTDI00110 T68299 TARGNAME microRNA hsa-miR-148a (MIR148a) T68299 TARGTYPE Literature-reported T68299 BIOCLASS Non-coding RNA target T15386 TARGETID T15386 T15386 FORMERID TTDI00241 T15386 TARGNAME microRNA hsa-miR-152 (MIR152) T15386 TARGTYPE Literature-reported T15386 BIOCLASS Non-coding RNA target T09162 TARGETID T09162 T09162 FORMERID TTDI00097 T09162 TARGNAME microRNA hsa-miR-181a (MIR181a) T09162 TARGTYPE Literature-reported T09162 BIOCLASS Non-coding RNA target T63102 TARGETID T63102 T63102 FORMERID TTDI00014 T63102 TARGNAME microRNA hsa-miR-181c (MIR181c) T63102 TARGTYPE Literature-reported T63102 BIOCLASS Non-coding RNA target T27276 TARGETID T27276 T27276 FORMERID TTDI02671 T27276 TARGNAME microRNA hsa-miR-182 (MIR182) T27276 TARGTYPE Literature-reported T27276 BIOCLASS Non-coding RNA target T17579 TARGETID T17579 T17579 FORMERID TTDI00085 T17579 TARGNAME microRNA hsa-miR-183 (MIR183) T17579 TARGTYPE Literature-reported T17579 BIOCLASS Non-coding RNA target T34022 TARGETID T34022 T34022 FORMERID TTDI00216 T34022 TARGNAME microRNA hsa-miR-185 (MIR185) T34022 TARGTYPE Literature-reported T34022 BIOCLASS Non-coding RNA target T93941 TARGETID T93941 T93941 FORMERID TTDI00093 T93941 TARGNAME microRNA hsa-miR-188 (MIR188) T93941 TARGTYPE Literature-reported T93941 BIOCLASS Non-coding RNA target T52864 TARGETID T52864 T52864 FORMERID TTDI00136 T52864 TARGNAME microRNA hsa-miR-18a (MIR18a) T52864 TARGTYPE Literature-reported T52864 BIOCLASS Non-coding RNA target T01141 TARGETID T01141 T01141 FORMERID TTDR01304 T01141 TARGNAME microRNA hsa-miR-191 (MIR191) T01141 TARGTYPE Literature-reported T01141 BIOCLASS Non-coding RNA target T01141 DRUGINFO D0IC2O Anti-miR-191 modified oligonucleotide Investigative T35385 TARGETID T35385 T35385 FORMERID TTDI00016 T35385 TARGNAME microRNA hsa-miR-194 (MIR194) T35385 TARGTYPE Literature-reported T35385 BIOCLASS Non-coding RNA target T90109 TARGETID T90109 T90109 TARGNAME microRNA hsa-miR-197-3p (MIR197-3p) T90109 TARGTYPE Literature-reported T90109 BIOCLASS Non-coding RNA target T00064 TARGETID T00064 T00064 FORMERID TTDI00234 T00064 TARGNAME microRNA hsa-miR-199a (MIR199a) T00064 TARGTYPE Literature-reported T00064 BIOCLASS Non-coding RNA target T96068 TARGETID T96068 T96068 FORMERID TTDI00032 T96068 TARGNAME microRNA hsa-miR-200c (MIR200c) T96068 TARGTYPE Literature-reported T96068 BIOCLASS Non-coding RNA target T97940 TARGETID T97940 T97940 FORMERID TTDI00221 T97940 TARGNAME microRNA hsa-miR-205 (MIR205) T97940 TARGTYPE Literature-reported T97940 BIOCLASS Non-coding RNA target T78052 TARGETID T78052 T78052 FORMERID TTDI00070 T78052 TARGNAME microRNA hsa-miR-206 (MIR206) T78052 TARGTYPE Literature-reported T78052 BIOCLASS Non-coding RNA target T85293 TARGETID T85293 T85293 FORMERID TTDI02672 T85293 TARGNAME microRNA hsa-miR-21 (MIR21) T85293 TARGTYPE Literature-reported T85293 BIOCLASS Non-coding RNA target T54024 TARGETID T54024 T54024 FORMERID TTDI00162 T54024 TARGNAME microRNA hsa-miR-210 (MIR210) T54024 TARGTYPE Literature-reported T54024 BIOCLASS Non-coding RNA target T25381 TARGETID T25381 T25381 FORMERID TTDI00187 T25381 TARGNAME microRNA hsa-miR-212 (MIR212) T25381 TARGTYPE Literature-reported T25381 BIOCLASS Non-coding RNA target T81158 TARGETID T81158 T81158 FORMERID TTDI00060 T81158 TARGNAME microRNA hsa-miR-214 (MIR214) T81158 TARGTYPE Literature-reported T81158 BIOCLASS Non-coding RNA target T78745 TARGETID T78745 T78745 FORMERID TTDI00055 T78745 TARGNAME microRNA hsa-miR-218 (MIR218) T78745 TARGTYPE Literature-reported T78745 BIOCLASS Non-coding RNA target T43071 TARGETID T43071 T43071 FORMERID TTDI00209 T43071 TARGNAME microRNA hsa-miR-22 (MIR22) T43071 TARGTYPE Literature-reported T43071 BIOCLASS Non-coding RNA target T86185 TARGETID T86185 T86185 FORMERID TTDI00172 T86185 TARGNAME microRNA hsa-miR-223-3p (MIR223-3p) T86185 TARGTYPE Literature-reported T86185 BIOCLASS Non-coding RNA target T90106 TARGETID T90106 T90106 TARGNAME microRNA hsa-miR-23a (MIR23a) T90106 TARGTYPE Literature-reported T90106 BIOCLASS Non-coding RNA target T29413 TARGETID T29413 T29413 FORMERID TTDI00167 T29413 TARGNAME microRNA hsa-miR-26a (MIR26a) T29413 TARGTYPE Literature-reported T29413 BIOCLASS Non-coding RNA target T84409 TARGETID T84409 T84409 FORMERID TTDI02673 T84409 TARGNAME microRNA hsa-miR-296 (MIR296) T84409 TARGTYPE Literature-reported T84409 BIOCLASS Non-coding RNA target T77895 TARGETID T77895 T77895 FORMERID TTDI00020 T77895 TARGNAME microRNA hsa-miR-29c (MIR29c) T77895 TARGTYPE Literature-reported T77895 BIOCLASS Non-coding RNA target T60392 TARGETID T60392 T60392 FORMERID TTDI00171 T60392 TARGNAME microRNA hsa-miR-302a (MIR302a) T60392 TARGTYPE Literature-reported T60392 BIOCLASS Non-coding RNA target T43065 TARGETID T43065 T43065 FORMERID TTDI00107 T43065 TARGNAME microRNA hsa-miR-30a (MIR30a) T43065 TARGTYPE Literature-reported T43065 BIOCLASS Non-coding RNA target T20736 TARGETID T20736 T20736 FORMERID TTDI00135 T20736 TARGNAME microRNA hsa-miR-30d (MIR30d) T20736 TARGTYPE Literature-reported T20736 BIOCLASS Non-coding RNA target T61334 TARGETID T61334 T61334 FORMERID TTDI00056 T61334 TARGNAME microRNA hsa-miR-30d-5p (MIR30d-5p) T61334 TARGTYPE Literature-reported T61334 BIOCLASS Non-coding RNA target T35475 TARGETID T35475 T35475 FORMERID TTDI00125 T35475 TARGNAME microRNA hsa-miR-329 (MIR329) T35475 TARGTYPE Literature-reported T35475 BIOCLASS Non-coding RNA target T64374 TARGETID T64374 T64374 FORMERID TTDI02674 T64374 TARGNAME microRNA hsa-miR-33 (MIR33) T64374 TARGTYPE Literature-reported T64374 BIOCLASS Non-coding RNA target T21479 TARGETID T21479 T21479 FORMERID TTDI00049 T21479 TARGNAME microRNA hsa-miR-371-5p (MIR371-5p) T21479 TARGTYPE Literature-reported T21479 BIOCLASS Non-coding RNA target T65323 TARGETID T65323 T65323 FORMERID TTDI00180 T65323 TARGNAME microRNA hsa-miR-373 (MIR373) T65323 TARGTYPE Literature-reported T65323 BIOCLASS Non-coding RNA target T36512 TARGETID T36512 T36512 FORMERID TTDI00025 T36512 TARGNAME microRNA hsa-miR-375 (MIR375) T36512 TARGTYPE Literature-reported T36512 BIOCLASS Non-coding RNA target T51878 TARGETID T51878 T51878 FORMERID TTDI00131 T51878 TARGNAME microRNA hsa-miR-429 (MIR429) T51878 TARGTYPE Literature-reported T51878 BIOCLASS Non-coding RNA target T89002 TARGETID T89002 T89002 TARGNAME microRNA hsa-miR-451 (MIR451) T89002 TARGTYPE Literature-reported T89002 BIOCLASS Non-coding RNA target T09050 TARGETID T09050 T09050 FORMERID TTDI00203 T09050 TARGNAME microRNA hsa-miR-455 (MIR455) T09050 TARGTYPE Literature-reported T09050 BIOCLASS Non-coding RNA target T62602 TARGETID T62602 T62602 FORMERID TTDNR00704 T62602 TARGNAME microRNA hsa-miR-486 (MIR486) T62602 TARGTYPE Literature-reported T62602 BIOCLASS Non-coding RNA target T90444 TARGETID T90444 T90444 FORMERID TTDI00231 T90444 TARGNAME microRNA hsa-miR-492 (MIR492) T90444 TARGTYPE Literature-reported T90444 BIOCLASS Non-coding RNA target T44467 TARGETID T44467 T44467 FORMERID TTDI00124 T44467 TARGNAME microRNA hsa-miR-509 (MIR509) T44467 TARGTYPE Literature-reported T44467 BIOCLASS Non-coding RNA target T61101 TARGETID T61101 T61101 FORMERID TTDI00036 T61101 TARGNAME microRNA hsa-miR-572 (MIR572) T61101 TARGTYPE Literature-reported T61101 BIOCLASS Non-coding RNA target T20572 TARGETID T20572 T20572 FORMERID TTDI00051 T20572 TARGNAME microRNA hsa-miR-621 (MIR621) T20572 TARGTYPE Literature-reported T20572 BIOCLASS Non-coding RNA target T84602 TARGETID T84602 T84602 FORMERID TTDI00099 T84602 TARGNAME microRNA hsa-miR-664 (MIR664) T84602 TARGTYPE Literature-reported T84602 BIOCLASS Non-coding RNA target T88995 TARGETID T88995 T88995 TARGNAME microRNA hsa-miR-7 (MIR7) T88995 TARGTYPE Literature-reported T88995 BIOCLASS Non-coding RNA target T88910 TARGETID T88910 T88910 TARGNAME microRNA hsa-miR-709 (MIR709) T88910 TARGTYPE Literature-reported T88910 BIOCLASS Non-coding RNA target T13247 TARGETID T13247 T13247 FORMERID TTDI00147 T13247 TARGNAME microRNA hsa-miR-9 (MIR9) T13247 TARGTYPE Literature-reported T13247 BIOCLASS Non-coding RNA target T82013 TARGETID T82013 T82013 FORMERID TTDI00018 T82013 TARGNAME microRNA hsa-miR-939 (MIR939) T82013 TARGTYPE Literature-reported T82013 BIOCLASS Non-coding RNA target T32618 TARGETID T32618 T32618 FORMERID TTDI00179 T32618 TARGNAME microRNA hsa-miR-96 (MIR96) T32618 TARGTYPE Literature-reported T32618 BIOCLASS Non-coding RNA target T22072 TARGETID T22072 T22072 FORMERID TTDI00044 T22072 TARGNAME Small nucleolar RNA 40 (snoRNA40) T22072 TARGTYPE Literature-reported T22072 BIOCLASS Non-coding RNA target T56412 TARGETID T56412 T56412 FORMERID TTDI00009 T56412 TARGNAME Small nucleolar RNA 78 (snoRNA78) T56412 TARGTYPE Literature-reported T56412 BIOCLASS Non-coding RNA target T46863 TARGETID T46863 T46863 FORMERID TTDI01537 T46863 TARGNAME Cyclic nucleotide (CN) T46863 TARGTYPE Literature-reported T46863 SYNONYMS cNMP T76634 TARGETID T76634 T76634 FORMERID TTDR00439 T76634 TARGNAME Endotoxin (LPS) T76634 TARGTYPE Literature-reported T76634 SYNONYMS Endotoxin (lipopolysaccharide) T35667 TARGETID T35667 T35667 FORMERID TTDR00944 T35667 TARGNAME High density lipoprotein (HDL) T35667 TARGTYPE Literature-reported T35667 SYNONYMS HDL T67046 TARGETID T67046 T67046 FORMERID TTDR00161 T67046 TARGNAME Platelet activating factor (PAF) T67046 TARGTYPE Literature-reported T67046 SYNONYMS PAF T67046 DRUGINFO D0J6VN Indol-3-carbinol Preclinical T67046 DRUGINFO D01WJV F-0401 Terminated T67046 DRUGINFO D0Q8YA UR-12670 Terminated T67046 DRUGINFO D0R7MN SRI 63-441 Terminated T67046 DRUGINFO D0X9MW SCH 44643 Investigative T10277 TARGETID T10277 T10277 FORMERID TTDI00063 T10277 TARGNAME HOX transcript antisense RNA (HOTAIR) T10277 TARGTYPE Literature-reported T03276 TARGETID T03276 T03276 FORMERID TTDR01140 T03276 TARGNAME Human immunodeficiency virus RNA (HIV RNA) T03276 TARGTYPE Literature-reported T76563 TARGETID T76563 T76563 FORMERID TTDR00204 T76563 TARGNAME Human immunodeficiency virus TAR RNA (HIV TAR-RNA) T76563 TARGTYPE Literature-reported T76563 DRUGINFO D0I6YL Chimeric small nucleolar RNA-TAR decoy Investigative T76563 DRUGINFO D0K9CL 2,4-diaminoquinozalines and quinoxaline-2,3-diones Investigative T76563 DRUGINFO D08ZHT Diazaborines Investigative T98648 TARGETID T98648 T98648 FORMERID TTDNC00659 T98648 TARGNAME Lactobacillus 16S rRNA (Lacto 16RNA) T98648 TARGTYPE Literature-reported T42789 TARGETID T42789 T42789 FORMERID TTDR00749 T42789 TARGNAME G-quadruplex DNA (GQDNA) T42789 TARGTYPE Literature-reported T99170 TARGETID T99170 T99170 FORMERID TTDR00382 T99170 TARGNAME Intermediate-density lipoprotein (IDL) T99170 TARGTYPE Literature-reported T98886 TARGETID T98886 T98886 FORMERID TTDNC00679 T98886 TARGNAME Potassium-competitive acid (PCA) T98886 TARGTYPE Literature-reported T65505 TARGETID T65505 T65505 FORMERID TTDI01210 T65505 TARGNAME Src tyrosine kinase signaling pathway (Src pathway) T65505 TARGTYPE Literature-reported T00576 TARGETID T00576 T00576 TARGNAME Amine oxidase (AO) T00576 TARGTYPE Literature-reported T00576 SYNONYMS Amine oxidase (copper-containing); AOC T25889 TARGETID T25889 T25889 FORMERID TTDR00979 T25889 TARGNAME Adenylate cyclase (ADCY) T25889 TARGTYPE Literature-reported T25889 SYNONYMS Adenylyl cyclase; ATP pyrophosphate-lyase T25889 FUNCTION Catalyzes the formation of the second messenger cAMP from ATP. Its transcript is probably degraded by endoribonuclease LS (rnlA), decreasing cAMP levels and the negative regulator Crp- cAMP, which then induces its own transcription again. T25889 BIOCLASS Phosphorus-oxygen lyase T25889 DRUGINFO D0D8KI Ad5-AC6 Terminated T25889 DRUGINFO D00PZE 2-hydroxy-17beta-estradiol Investigative T25889 DRUGINFO D00QYO 2,5-didesoxy-3-ATP Investigative T25889 DRUGINFO D0C6LS Adenosine-5'-Rp-Alpha-Thio-Triphosphate Investigative T25889 DRUGINFO D0E0OJ DEOXYADENOSINE Investigative T25889 DRUGINFO D0Z3KV NSC-270718 Investigative T25889 DRUGINFO D00QLM [3H]alphabeta-meATP Investigative T25889 DRUGINFO D09KUE NSC-88915 Investigative T25889 DRUGINFO D0UB2J [3H]cAMP Investigative T25889 DRUGINFO D03RFA N6-CYCLOPENTYLADENOSINE Investigative T05127 TARGETID T05127 T05127 FORMERID TTDR01442 T05127 TARGNAME Cytochrome P450 2B2 (CYP2B2) T05127 TARGTYPE Literature-reported T05127 SYNONYMS Cytochrome P450E; Cytochrome P450 PB4; Cyp2b2; Cyp2b-2; CYPIIB2 T05127 FUNCTION Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. T05127 BIOCLASS Paired donor oxygen oxidoreductase T55114 TARGETID T55114 T55114 FORMERID TTDR01011 T55114 TARGNAME Cation channel sperm-associated protein (CatSper) T55114 TARGTYPE Literature-reported T55114 SYNONYMS Chemokine (C-C motif) receptor T55114 FUNCTION Voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte. Activated by extracellular progesterone and prostaglandins following the sequence: progesterone > PGF1-alpha = PGE1 > PGA1 > PGE2 >> PGD2. The primary effect of progesterone activation is to shift voltage dependence towards more physiological, negative membrane potentials; it is not mediated by metabotropic receptors and second messengers. Sperm capacitation enhances the effect of progesterone by providing additional negative shift. Also activated by the elevation of intracellular pH. T55114 DRUGINFO D03BSR NNC55-0396 Investigative T55114 DRUGINFO D0JF0W PGF1alpha Investigative T71054 TARGETID T71054 T71054 FORMERID TTDI01772 T71054 TARGNAME C-C chemokine receptor (CCR) T71054 TARGTYPE Literature-reported T71054 SYNONYMS Chemokine (C-C motif) receptor T71054 FUNCTION Receptor for a C-C type chemokine. Binds to MIP-1-alpha, MIP-1-delta, RANTES, and MCP-3 and, less efficiently, to MIP-1- beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. Responsible for affecting stem cell proliferation. T71054 DRUGINFO D06QRP CP-481,715 Investigative T71054 DRUGINFO D0B3PC UCB35625 Investigative T71054 DRUGINFO D0S8QZ PMID12614873C2b-1 Investigative T71054 DRUGINFO D0Y5NT VT-224 Investigative T71054 DRUGINFO D09PZD viral macrophage inflammatory protein-II Investigative T14263 TARGETID T14263 T14263 FORMERID TTDR00358 T14263 TARGNAME Phospholipase D (PLD) T14263 TARGTYPE Literature-reported T14263 SYNONYMS PLD-A; PLD; Choline phosphatase T14263 BIOCLASS Phosphoric diester hydrolase T14263 DRUGINFO D07RPV HALOPEMIDE Investigative T44150 TARGETID T44150 T44150 FORMERID TTDS00179 T44150 TARGNAME Prolyl hydroxylase (PH) T44150 TARGTYPE Literature-reported T44150 SYNONYMS Procollagen-proline,2-oxoglutarate-4-dioxygenase alpha; 4-PH alpha T44150 BIOCLASS Paired donor oxygen oxidoreductase T97769 TARGETID T97769 T97769 FORMERID TTDC00278 T97769 TARGNAME Inflammatory cytokine messenger RNA (Cytokine mRNA) T97769 TARGTYPE Literature-reported T97769 SYNONYMS mRNA of Inflammatory cytokine T97769 BIOCLASS mRNA target T59099 TARGETID T59099 T59099 FORMERID TTDR01024 T59099 TARGNAME Anandamide amidase (ANA) T59099 TARGTYPE Literature-reported T59099 SYNONYMS Arachidonylethanolamide synthase; Anandamide synthase T59099 BIOCLASS Carbon-nitrogen hydrolase T42951 TARGETID T42951 T42951 FORMERID TTDR00798 T42951 TARGNAME Calprotectin (CP) T42951 TARGTYPE Literature-reported T42951 SYNONYMS S100A9/S100A8; MRP8/MRP14 complex; MRP-8/MRP-14; Leucocyte protein L1; L1 protein; L1 antigen; Cytosolic protein complex L1 T42951 FUNCTION Expressed by macrophages in chronic inflammations. Also expressed in epithelial cells constitutively or induced during dermatoses. May interact with components of the intermediate filaments in monocytes and epithelial cells. T97288 TARGETID T97288 T97288 FORMERID TTDR01052 T97288 TARGNAME Homocitrate synthase (HCS) T97288 TARGTYPE Literature-reported T97288 SYNONYMS Homocitrate synthetase; Acetyl-coenzyme A:2-ketoglutarate C-acetyl transferase; 2-hydroxybutane-1,2,4-tricarboxylate 2-oxoglutarate-lyase (CoA-acetylating) T97288 BIOCLASS Acyltransferase T82514 TARGETID T82514 T82514 FORMERID TTDI01759 T82514 TARGNAME Neurokinin receptor (NKR) T82514 TARGTYPE Literature-reported T82514 FUNCTION This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K. T82514 DRUGINFO D0V3QE NSL-036 Terminated T35264 TARGETID T35264 T35264 FORMERID TTDR01196 T35264 TARGNAME P2Y purinoceptor (P2RY) T35264 TARGTYPE Literature-reported T35264 SYNONYMS Platelet adenosine diphosphatereceptor; P2Y receptor; Adenosine diphosphate (ADP) receptor; Adenosine 5'-Diphosphate Receptor; ADP receptor T35264 BIOCLASS GPCR rhodopsin T35264 DRUGINFO D0V4GQ Adenosine-5'-O-(2-thiodiphosphate) Investigative T59174 TARGETID T59174 T59174 FORMERID TTDI01757 T59174 TARGNAME Sodium/hydrogen exchanger (SLC) T59174 TARGTYPE Literature-reported T59174 FUNCTION Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction. T59174 DRUGINFO D05DNA FR-183998 Terminated T59174 DRUGINFO D0F1PH Rimeporide Investigative T46508 TARGETID T46508 T46508 FORMERID TTDR00516 T46508 TARGNAME Voltage-gated potassium channel (VGKC) T46508 TARGTYPE Literature-reported T46508 BIOCLASS Voltage-gated ion channel T46508 DRUGINFO D08KCZ (2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE Investigative T46508 DRUGINFO D0K7LF Tetrabutylammonium Ion Investigative T29460 TARGETID T29460 T29460 FORMERID TTDR00648 T29460 TARGNAME CoA-independent transacylase (CIT) T29460 TARGTYPE Literature-reported T29460 SYNONYMS Glycerophospholipid arachidonoyl-transferase(CoA-independent); Coenzyme A-independent transacylase; CoA-IT; 1-alkylglycerophosphocholine Acyltransferase T29460 BIOCLASS Acyltransferase T08149 TARGETID T08149 T08149 FORMERID TTDI01270 T08149 TARGNAME Lentivirus messenger RNA (Lentivirus mRNA) T08149 TARGTYPE Literature-reported T08149 SYNONYMS mRNA of Lentivirus T08149 BIOCLASS mRNA target T20537 TARGETID T20537 T20537 FORMERID TTDR00552 T20537 TARGNAME Protein kinase A alpha messenger RNA (PKA-alpha mRNA) T20537 TARGTYPE Literature-reported T20537 SYNONYMS mRNA of PKA alpha T20537 BIOCLASS mRNA target T20537 DRUGINFO D0G1ML (35)S-labeled oligonucleotide Investigative T91382 TARGETID T91382 T91382 FORMERID TTDR00344 T91382 TARGNAME Protein kinase A Ri alpha messenger RNA (PKA-Ri-alpha mRNA) T91382 TARGTYPE Literature-reported T91382 SYNONYMS mRNA of PKA Ri alpha T91382 BIOCLASS mRNA target T91382 DRUGINFO D0G1ML (35)S-labeled oligonucleotide Investigative T18170 TARGETID T18170 T18170 FORMERID TTDR00378 T18170 TARGNAME Protein kinase A1 messenger RNA (PKA mRNA) T18170 TARGTYPE Literature-reported T18170 SYNONYMS mRNA of PKA T18170 BIOCLASS mRNA target T04144 TARGETID T04144 T04144 FORMERID TTDR00128 T04144 TARGNAME Protein kinase C messenger RNA (PKC mRNA) T04144 TARGTYPE Literature-reported T04144 SYNONYMS mRNA of PKC T04144 BIOCLASS mRNA target T44620 TARGETID T44620 T44620 FORMERID TTDR01274 T44620 TARGNAME Acid-sensing ion channel (ASIC) T44620 TARGTYPE Literature-reported T44620 BIOCLASS Amiloride-sensitive sodium channel T38528 TARGETID T38528 T38528 FORMERID TTDI01601 T38528 TARGNAME AdoHcy hydrolase (SAHase) T38528 TARGTYPE Literature-reported T38528 SYNONYMS AdoHcyase T38528 DRUGINFO D0I7TN 3-DEAZAADENOSINE Terminated T67286 TARGETID T67286 T67286 FORMERID TTDR01267 T67286 TARGNAME Beta-lactoglobulin 1 (BetaL1) T67286 TARGTYPE Literature-reported T67286 FUNCTION Primary component of whey, it binds retinol and is probably involved in the transport of that molecule. T68544 TARGETID T68544 T68544 FORMERID TTDI01802 T68544 TARGNAME Estrogen-related receptor (ESRR) T68544 TARGTYPE Literature-reported T68544 FUNCTION Binds to an ERR-alpha response element (ERRE) containinga single consensus half-site, 5'-TNAAGGTCA-3'. Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces theexpression of PERM1 in the skeletal muscle. T23342 TARGETID T23342 T23342 FORMERID TTDI02001 T23342 TARGNAME GDNF receptor complexes (GDNFR) T23342 TARGTYPE Literature-reported T23342 FUNCTION Receptor for GDNF. Mediates the GDNF-induced autophosphorylation and activation of the RET receptor. T42436 TARGETID T42436 T42436 FORMERID TTDI01724 T42436 TARGNAME Interleukin receptor (ILR) T42436 TARGTYPE Literature-reported T42436 SYNONYMS Interleukin receptor T44788 TARGETID T44788 T44788 FORMERID TTDR00285 T44788 TARGNAME Large subunit Cp complex Cdc68p (CDC68) T44788 TARGTYPE Literature-reported T44788 SYNONYMS Cdc68p; CDC68 T26428 TARGETID T26428 T26428 FORMERID TTDR00131 T26428 TARGNAME Melanin-concentrating hormone receptor (MCHR) T26428 TARGTYPE Literature-reported T26428 SYNONYMS MCH receptor T26428 DRUGINFO D00AQY IDDB-41331 Preclinical T01853 TARGETID T01853 T01853 FORMERID TTDR00150 T01853 TARGNAME Mitogen-activated protein kinase kinase (MAPKK) T01853 TARGTYPE Literature-reported T01853 BIOCLASS Kinase T01853 DRUGINFO D0GD8Y U0126 Investigative T61862 TARGETID T61862 T61862 FORMERID TTDI01818 T61862 TARGNAME Relaxin receptor (RXFP) T61862 TARGTYPE Literature-reported T61862 FUNCTION Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activity of a phosphodiesterase that degrades cAMP. T39845 TARGETID T39845 T39845 FORMERID TTDR00933 T39845 TARGNAME TNF receptor-associated factor (TRAF) T39845 TARGTYPE Literature-reported T39845 SYNONYMS TRAF; TNF-receptor-associated factor T86882 TARGETID T86882 T86882 FORMERID TTDI01810 T86882 TARGNAME Tumor suppressor candidate (TUSC) T86882 TARGTYPE Literature-reported T86882 SYNONYMS Candidate tumor suppressor protein T44833 TARGETID T44833 T44833 FORMERID TTDI01688 T44833 TARGNAME Tumor-associated peptide (TAP) T44833 TARGTYPE Literature-reported T44833 SYNONYMS Tumor associated peptide T14191 TARGETID T14191 T14191 FORMERID TTDR00496 T14191 TARGNAME Voltage-gated potassium channel Kv1 (KCNA) T14191 TARGTYPE Literature-reported T14191 BIOCLASS Voltage-gated ion channel T67172 TARGETID T67172 T67172 FORMERID TTDI03617 T67172 TARGNAME Volume regulated chloride channel (VRAC) T67172 TARGTYPE Literature-reported T67172 BIOCLASS Chloride channel T67172 DRUGINFO D00BEA 1,9-dideoxyforskolin Investigative T67172 DRUGINFO D02EPD diBA-(5)-C4 Investigative T67172 DRUGINFO D02MYV IAA-94 Investigative T67172 DRUGINFO D0J3QC DCPIB Investigative T67172 DRUGINFO D0Z4AU GTPgammaS Investigative T67172 DRUGINFO D0O6KR 9-anthroic acid Investigative T67172 DRUGINFO D08DQL NPPB Investigative T67172 DRUGINFO D0PW7B DIDS Investigative T22912 TARGETID T22912 T22912 FORMERID TTDR00787 T22912 TARGNAME Endothelium-derived hyperpolarizing factor (EDHF) T22912 TARGTYPE Literature-reported T22912 SYNONYMS EDHF T38988 TARGETID T38988 T38988 FORMERID TTDR00946 T38988 TARGNAME Glycoprotein Ib-IX-V receptor (GPIbIXV) T38988 TARGTYPE Literature-reported T38988 SYNONYMS Glycoprotein Ib-IX-V; Glycoprotein (GP) Ib-IX-V; GP Ib-IX-V T26862 TARGETID T26862 T26862 FORMERID TTDR01205 T26862 TARGNAME Leukotriene E4 receptor (LTE4R) T26862 TARGTYPE Literature-reported T26862 SYNONYMS LTE4 receptor T96547 TARGETID T96547 T96547 TARGNAME Nerve/glial antigen-2 (NG2) T96547 TARGTYPE Literature-reported T96547 SYNONYMS Tubulin protein T18401 TARGETID T18401 T18401 FORMERID TTDR00694 T18401 TARGNAME Tumor-associated carbohydrate antigen KH-1 (KH-1) T18401 TARGTYPE Literature-reported T18401 SYNONYMS Antigen KH-1 T80180 TARGETID T80180 T80180 FORMERID TTDI01199 T80180 TARGNAME Carcinogenesis (Tumorigenesis) T80180 TARGTYPE Literature-reported T80180 SYNONYMS Biogenesis of tumor T89440 TARGETID T89440 T89440 TARGNAME CXCL5/CXCR2 axis (CXCL5/CXCR2 axis) T89440 TARGTYPE Literature-reported T89440 SYNONYMS C-X-C motif chemokine 5/C-X-C motif chemokine receptor 2 axis T55234 TARGETID T55234 T55234 FORMERID TTDR01115 T55234 TARGNAME Cyclin E/cdk2 pathway (CCNE2/CDK2 pathway) T55234 TARGTYPE Literature-reported T55234 SYNONYMS Cyclin E/CDK2 pathway signalling T06446 TARGETID T06446 T06446 FORMERID TTDI01171 T06446 TARGNAME Leukotriene biosynthesis (LT synth) T06446 TARGTYPE Literature-reported T06446 SYNONYMS Leukotriene synthesis T06446 DRUGINFO D04LBJ ASOBAMAST Investigative T69141 TARGETID T69141 T69141 FORMERID TTDR00098 T69141 TARGNAME Monoamine uptake (MA uptake) T69141 TARGTYPE Literature-reported T69141 SYNONYMS Monoamine(MA) uptake T69141 DRUGINFO D0A0KE Norzimelidine Investigative T69141 DRUGINFO D0L4CI Desmethylclomipramine Investigative T98600 TARGETID T98600 T98600 FORMERID TTDR00079 T98600 TARGNAME Permeability pathway (NP pathway) T98600 TARGTYPE Literature-reported T98600 SYNONYMS NPPs T98600 DRUGINFO D0K3SI Decyltrimethylammonium Investigative T98600 DRUGINFO D02COM 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30) Investigative T98600 DRUGINFO D08DQL NPPB Investigative T16132 TARGETID T16132 T16132 FORMERID TTDI01281 T16132 TARGNAME TNF alpha synthesis (TNFA synthesis) T16132 TARGTYPE Literature-reported T16132 SYNONYMS Tumor necrosis factor alpha synthesis T62648 TARGETID T62648 T62648 FORMERID TTDI01193 T62648 TARGNAME Tumour metastasis (Tmet) T62648 TARGTYPE Literature-reported T62648 SYNONYMS Metastasis; Cancer metastasis T53255 TARGETID T53255 T53255 FORMERID TTDI01384 T53255 TARGNAME Adrenomedullin receptor (AMR) T53255 TARGTYPE Literature-reported T55352 TARGETID T55352 T55352 FORMERID TTDI00191 T55352 TARGNAME Amyloid precursor protein (APP) T55352 TARGTYPE Literature-reported T55352 DRUGINFO DPYA76 SHR‐1707 Phase 1 T98519 TARGETID T98519 T98519 FORMERID TTDNC00480 T98519 TARGNAME Anaphase-promoting complex (APC/C) T98519 TARGTYPE Literature-reported T61732 TARGETID T61732 T61732 FORMERID TTDI01729 T61732 TARGNAME Aspartic protease (ASPP) T61732 TARGTYPE Literature-reported T75907 TARGETID T75907 T75907 FORMERID TTDI01822 T75907 TARGNAME ATP synthase (ATPS) T75907 TARGTYPE Literature-reported T75907 DRUGINFO DW4O2J J147 Phase 1 T57781 TARGETID T57781 T57781 FORMERID TTDR00003 T57781 TARGNAME ATP-sensitive potassium channel (KATP channel) T57781 TARGTYPE Literature-reported T74864 TARGETID T74864 T74864 FORMERID TTDI01823 T74864 TARGNAME Bacterial ATP synthase (Bact atps) T74864 TARGTYPE Literature-reported T09495 TARGETID T09495 T09495 FORMERID TTDI01896 T09495 TARGNAME Bacterial Transpeptidase (Bact TPP) T09495 TARGTYPE Literature-reported T90244 TARGETID T90244 T90244 TARGNAME Bilophila glycyl radical enzyme (GRE) T90244 TARGTYPE Literature-reported T03888 TARGETID T03888 T03888 FORMERID TTDNC00386 T03888 TARGNAME Catenin (CTNN) T03888 TARGTYPE Literature-reported T47215 TARGETID T47215 T47215 FORMERID TTDR00566 T47215 TARGNAME Cholecystokinin receptor (CCKR) T47215 TARGTYPE Literature-reported T47215 DRUGINFO D06JVU A-68552 Terminated T47215 DRUGINFO D0O7PT Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] Investigative T70410 TARGETID T70410 T70410 FORMERID TTDR01188 T70410 TARGNAME Corticosteroid receptor (CCR) T70410 TARGTYPE Literature-reported T47409 TARGETID T47409 T47409 FORMERID TTDI01624 T47409 TARGNAME C-X-C chemokine receptor (CXCR) T47409 TARGTYPE Literature-reported T40098 TARGETID T40098 T40098 FORMERID TTDI01641 T40098 TARGNAME Cytochrome P450 3 (CYP3) T40098 TARGTYPE Literature-reported T94620 TARGETID T94620 T94620 FORMERID TTDI01418 T94620 TARGNAME Death associated protein kinase (DAPK) T94620 TARGTYPE Literature-reported T39549 TARGETID T39549 T39549 FORMERID TTDI01692 T39549 TARGNAME Deoxyribonuclease (DNASE) T39549 TARGTYPE Literature-reported T68302 TARGETID T68302 T68302 FORMERID TTDNC00544 T68302 TARGNAME DNA methyltransferase (DNMT) T68302 TARGTYPE Literature-reported T12811 TARGETID T12811 T12811 FORMERID TTDI01513 T12811 TARGNAME DNA-binding protein inhibitor (ID) T12811 TARGTYPE Literature-reported T39664 TARGETID T39664 T39664 FORMERID TTDI01673 T39664 TARGNAME Estradiol 17 beta-dehydrogenase (17-beta-HSD) T39664 TARGTYPE Literature-reported T39664 DRUGINFO D0T5ZC BAY-50-9062 Terminated T29653 TARGETID T29653 T29653 FORMERID TTDI01302 T29653 TARGNAME Gluten (GLEN) T29653 TARGTYPE Literature-reported T86609 TARGETID T86609 T86609 FORMERID TTDI01675 T86609 TARGNAME Glycoside hydrolase (GlyH) T86609 TARGTYPE Literature-reported T86609 DRUGINFO D03MFV MNLP-18 Preclinical T00803 TARGETID T00803 T00803 FORMERID TTDI01470 T00803 TARGNAME GPCR frizzled protein unspecific (GPCRF) T00803 TARGTYPE Literature-reported T05241 TARGETID T05241 T05241 FORMERID TTDI01436 T05241 TARGNAME GPCR rhodopsin protein unspecific (GPCRA) T05241 TARGTYPE Literature-reported T36309 TARGETID T36309 T36309 FORMERID TTDR00781 T36309 TARGNAME Guanosine phosphotransferase (GPTase) T36309 TARGTYPE Literature-reported T17666 TARGETID T17666 T17666 FORMERID TTDI01640 T17666 TARGNAME Hematopoietic protein-tyrosine phosphatase (PTPN) T17666 TARGTYPE Literature-reported T96281 TARGETID T96281 T96281 FORMERID TTDI01676 T96281 TARGNAME Hepatitis C virus Envelope glycoprotein (HCV Env) T96281 TARGTYPE Literature-reported T96281 DRUGINFO D0VV3O GNI-104 Terminated T79716 TARGETID T79716 T79716 FORMERID TTDI01639 T79716 TARGNAME Hydroxylase (HYL) T79716 TARGTYPE Literature-reported T23286 TARGETID T23286 T23286 FORMERID TTDI01733 T23286 TARGNAME Immunoglobulin gamma Fc receptor (FCGR) T23286 TARGTYPE Literature-reported T40183 TARGETID T40183 T40183 FORMERID TTDI01840 T40183 TARGNAME Inflammatory cytokine (IC) T40183 TARGTYPE Literature-reported T92195 TARGETID T92195 T92195 FORMERID TTDI01483 T92195 TARGNAME Ligand-gated ion channel (LGIC) T92195 TARGTYPE Literature-reported T02709 TARGETID T02709 T02709 FORMERID TTDI01368 T02709 TARGNAME Lysine-specific histone demethylase (LSD) T02709 TARGTYPE Literature-reported T30519 TARGETID T30519 T30519 FORMERID TTDR00431 T30519 TARGNAME Monocyte derived cytokine (MDC) T30519 TARGTYPE Literature-reported T66451 TARGETID T66451 T66451 FORMERID TTDI01455 T66451 TARGNAME Mothers against decapentaplegic homolog (SMAD) T66451 TARGTYPE Literature-reported T65594 TARGETID T65594 T65594 FORMERID TTDI01687 T65594 TARGNAME Motoneuronotrophic factor (MNTF) T65594 TARGTYPE Literature-reported T51975 TARGETID T51975 T51975 FORMERID TTDI01462 T51975 TARGNAME NEDD4-like E3 ubiquitin-protein ligase WWP (WWP) T51975 TARGTYPE Literature-reported T21903 TARGETID T21903 T21903 FORMERID TTDI01385 T21903 TARGNAME Opsin (OP) T21903 TARGTYPE Literature-reported T54940 TARGETID T54940 T54940 FORMERID TTDI01428 T54940 TARGNAME Plasmodium Cysteine protease falcipain (Malaria CPF) T54940 TARGTYPE Literature-reported T54940 DRUGINFO D04ZIJ Pepstatin Terminated T54940 DRUGINFO D08KCA Leupeptin Investigative T97822 TARGETID T97822 T97822 FORMERID TTDI01611 T97822 TARGNAME Prostaglandin synthetase (PGS) T97822 TARGTYPE Literature-reported T97822 DRUGINFO D0E9NJ PARCETASAL Investigative T59909 TARGETID T59909 T59909 FORMERID TTDI01564 T59909 TARGNAME Protein prenyl transferase (PPTF) T59909 TARGTYPE Literature-reported T59909 DRUGINFO D03GQH B-581 Terminated T59234 TARGETID T59234 T59234 FORMERID TTDI01437 T59234 TARGNAME Stretch-gated ion channel (MSC) T59234 TARGTYPE Literature-reported T39135 TARGETID T39135 T39135 FORMERID TTDR00366 T39135 TARGNAME Sulfur mustard-stimulated protease (SMSP) T39135 TARGTYPE Literature-reported T39135 DRUGINFO D0G6OU Ca(2+) chelator Investigative T39135 DRUGINFO D0O5VI EGTA Investigative T71446 TARGETID T71446 T71446 FORMERID TTDI01727 T71446 TARGNAME Transporter unspecfic (TP) T71446 TARGTYPE Literature-reported T71446 DRUGINFO D0A7NI LIM-5310 Investigative T04524 TARGETID T04524 T04524 FORMERID TTDI01659 T04524 TARGNAME Type II transmembrane serine proteases (TTSP) T04524 TARGTYPE Literature-reported T06124 TARGETID T06124 T06124 FORMERID TTDI01622 T06124 TARGNAME Acetaminophen binding protein 58kDa (ABP58) T06124 TARGTYPE Literature-reported T01246 TARGETID T01246 T01246 FORMERID TTDNR00705 T01246 TARGNAME Ascaris NADH-fumarate reductase (Asc OSM) T01246 TARGTYPE Literature-reported T20210 TARGETID T20210 T20210 FORMERID TTDI02376 T20210 TARGNAME Feto-acinar pancreatic protein (FAPP) T20210 TARGTYPE Literature-reported T20210 DRUGINFO D0F6HW IPH-4201 Terminated T66315 TARGETID T66315 T66315 FORMERID TTDI01342 T66315 TARGNAME Imidazoline I2 receptor (I2R) T66315 TARGTYPE Literature-reported T90207 TARGETID T90207 T90207 TARGNAME Mechanistic target of rapamycin complex 3 (mTORC3) T90207 TARGTYPE Literature-reported T07209 TARGETID T07209 T07209 FORMERID TTDI01881 T07209 TARGNAME Streptococcus Capsular antigen (Stre CA) T07209 TARGTYPE Literature-reported T12598 TARGETID T12598 T12598 FORMERID TTDI01202 T12598 TARGNAME Mitochondrial membrane (MIM) T12598 TARGTYPE Literature-reported T83040 TARGETID T83040 T83040 FORMERID TTDI01540 T83040 TARGNAME Advanced glycation end-product pathway (AGE pathway) T83040 TARGTYPE Literature-reported T49958 TARGETID T49958 T49958 FORMERID TTDI01399 T49958 TARGNAME Autophagy (AUT) T49958 TARGTYPE Literature-reported T03938 TARGETID T03938 T03938 FORMERID TTDR00063 T03938 TARGNAME Axon loss (AXL) T03938 TARGTYPE Literature-reported T46371 TARGETID T46371 T46371 FORMERID TTDI01408 T46371 TARGNAME Bacterial Quorum sensing (Bact BQS) T46371 TARGTYPE Literature-reported T47782 TARGETID T47782 T47782 FORMERID TTDR01235 T47782 TARGNAME Catecholamine uptake (CA uptake) T47782 TARGTYPE Literature-reported T47782 DRUGINFO D03HKV Metanephrine Investigative T06707 TARGETID T06707 T06707 FORMERID TTDI01544 T06707 TARGNAME Energy metabolism (Energy metab) T06707 TARGTYPE Literature-reported T98559 TARGETID T98559 T98559 FORMERID TTDI01203 T98559 TARGNAME Ergosterol synthesis (EG synth) T98559 TARGTYPE Literature-reported T93405 TARGETID T93405 T93405 FORMERID TTDI01842 T93405 TARGNAME Glutamate release (GLU rele) T93405 TARGTYPE Literature-reported T58371 TARGETID T58371 T58371 FORMERID TTDI01266 T58371 TARGNAME Glycolysis (GLYS) T58371 TARGTYPE Literature-reported T53443 TARGETID T53443 T53443 FORMERID TTDI01231 T53443 TARGNAME Hepatic oligosaccharide/glycolipid storage (HOGS) T53443 TARGTYPE Literature-reported T70193 TARGETID T70193 T70193 FORMERID TTDI01335 T70193 TARGNAME Heterotrimeric G-protein signaling pathway (HGP pathway) T70193 TARGTYPE Literature-reported T99976 TARGETID T99976 T99976 FORMERID TTDI01273 T99976 TARGNAME Human immunodeficiency virus Cell fusion (HIV CF) T99976 TARGTYPE Literature-reported T42261 TARGETID T42261 T42261 FORMERID TTDI01286 T42261 TARGNAME IKB-beta-NFKB signaling pathway (IKBB-NFKB pathway) T42261 TARGTYPE Literature-reported T83371 TARGETID T83371 T83371 FORMERID TTDI01831 T83371 TARGNAME Inflammatory mediator release (IM rele) T83371 TARGTYPE Literature-reported T87128 TARGETID T87128 T87128 FORMERID TTDI01212 T87128 TARGNAME Interleukin-12 signaling pathway (IL12 pathway) T87128 TARGTYPE Literature-reported T63205 TARGETID T63205 T63205 FORMERID TTDI01679 T63205 TARGNAME Ligand-nuclear hormone receptor interaction (LNHRI) T63205 TARGTYPE Literature-reported T88072 TARGETID T88072 T88072 FORMERID TTDI00068 T88072 TARGNAME LPS-miR-34a-CCL22 axis (LmCa) T88072 TARGTYPE Literature-reported T23461 TARGETID T23461 T23461 FORMERID TTDI01223 T23461 TARGNAME Mast cell degranulation pathway (MCD pathway) T23461 TARGTYPE Literature-reported T88582 TARGETID T88582 T88582 FORMERID TTDNC00678 T88582 TARGNAME Non-steroidal androgen synthesis (NSAD synth) T88582 TARGTYPE Literature-reported T21987 TARGETID T21987 T21987 FORMERID TTDI01194 T21987 TARGNAME Plasmodium Gametocytogenesis (Plasm Gamet) T21987 TARGTYPE Literature-reported T15197 TARGETID T15197 T15197 FORMERID TTDI01172 T15197 TARGNAME Potential penetration (PP) T15197 TARGTYPE Literature-reported T15197 DRUGINFO D06UOL PIROTIODECANE Investigative T46188 TARGETID T46188 T46188 FORMERID TTDI01216 T46188 TARGNAME Pro-inflammatory autologous messenger (PAM) T46188 TARGTYPE Literature-reported T82070 TARGETID T82070 T82070 FORMERID TTDI01184 T82070 TARGNAME Prostaglandin metabolism (PG metab) T82070 TARGTYPE Literature-reported T79533 TARGETID T79533 T79533 FORMERID TTDI01307 T79533 TARGNAME Protein phosphorylation (PP) T79533 TARGTYPE Literature-reported T52144 TARGETID T52144 T52144 FORMERID TTDI01887 T52144 TARGNAME Protein translation (hPT) T52144 TARGTYPE Literature-reported T90645 TARGETID T90645 T90645 TARGNAME S100A6/p38/MAPK signaling pathway (SpM pathway) T90645 TARGTYPE Literature-reported T48872 TARGETID T48872 T48872 FORMERID TTDNC00405 T48872 TARGNAME Sonic hedgehog pathway (Shh pathway) T48872 TARGTYPE Literature-reported T21262 TARGETID T21262 T21262 FORMERID TTDI01854 T21262 TARGNAME Thyroid hormone synthesis (TH synth) T21262 TARGTYPE Literature-reported T68371 TARGETID T68371 T68371 FORMERID TTDI01365 T68371 TARGNAME TLR signaling pathway (TLR pathway) T68371 TARGTYPE Literature-reported T98056 TARGETID T98056 T98056 FORMERID TTDI01214 T98056 TARGNAME Tumor necrosis factor synthesis (TNF synth) T98056 TARGTYPE Literature-reported T48436 TARGETID T48436 T48436 FORMERID TTDNC00488 T48436 TARGNAME Ubiquitin-proteasome pathway (UP pathway) T48436 TARGTYPE Literature-reported T17893 TARGETID T17893 T17893 FORMERID TTDI01305 T17893 TARGNAME mRNA-decapping enzyme (DCP) T17893 TARGTYPE Literature-reported T47583 TARGETID T47583 T47583 UNIPROID WRN_HUMAN T47583 TARGNAME Werner syndrome ATP-dependent helicase (WRN) T47583 GENENAME WRN T47583 TARGTYPE Literature-reported T47583 SYNONYMS DNA helicase, RecQ-like type 3; RecQ3; Exonuclease WRN; RecQ protein-like 2 T47583 FUNCTION Multifunctional enzyme that has both magnesium and ATP-dependent DNA-helicase activity and 3'->5' exonuclease activity towards double-stranded DNA with a 5'-overhang. Has no nuclease activity towards single-stranded DNA or blunt-ended double-stranded DNA. Binds preferentially to DNA substrates containing alternate secondary structures, such as replication forks and Holliday junctions. May play an important role in the dissociation of joint DNA molecules that can arise as products of homologous recombination, at stalled replication forks or during DNA repair. Alleviates stalling of DNA polymerases at the site of DNA lesions. Important for genomic integrity. Plays a role in the formation of DNA replication focal centers; stably associates with foci elements generating binding sites for RP-A (By similarity). Plays a role in double-strand break repair after gamma-irradiation. T47583 ECNUMBER EC 3.1.-.- T47583 SEQUENCE MSEKKLETTAQQRKCPEWMNVQNKRCAVEERKACVRKSVFEDDLPFLEFTGSIVYSYDASDCSFLSEDISMSLSDGDVVGFDMEWPPLYNRGKLGKVALIQLCVSESKCYLFHVSSMSVFPQGLKMLLENKAVKKAGVGIEGDQWKLLRDFDIKLKNFVELTDVANKKLKCTETWSLNSLVKHLLGKQLLKDKSIRCSNWSKFPLTEDQKLYAATDAYAGFIIYRNLEILDDTVQRFAINKEEEILLSDMNKQLTSISEEVMDLAKHLPHAFSKLENPRRVSILLKDISENLYSLRRMIIGSTNIETELRPSNNLNLLSFEDSTTGGVQQKQIREHEVLIHVEDETWDPTLDHLAKHDGEDVLGNKVERKEDGFEDGVEDNKLKENMERACLMSLDITEHELQILEQQSQEEYLSDIAYKSTEHLSPNDNENDTSYVIESDEDLEMEMLKHLSPNDNENDTSYVIESDEDLEMEMLKSLENLNSGTVEPTHSKCLKMERNLGLPTKEEEEDDENEANEGEEDDDKDFLWPAPNEEQVTCLKMYFGHSSFKPVQWKVIHSVLEERRDNVAVMATGYGKSLCFQYPPVYVGKIGLVISPLISLMEDQVLQLKMSNIPACFLGSAQSENVLTDIKLGKYRIVYVTPEYCSGNMGLLQQLEADIGITLIAVDEAHCISEWGHDFRDSFRKLGSLKTALPMVPIVALTATASSSIREDIVRCLNLRNPQITCTGFDRPNLYLEVRRKTGNILQDLQPFLVKTSSHWEFEGPTIIYCPSRKMTQQVTGELRKLNLSCGTYHAGMSFSTRKDIHHRFVRDEIQCVIATIAFGMGINKADIRQVIHYGAPKDMESYYQEIGRAGRDGLQSSCHVLWAPADINLNRHLLTEIRNEKFRLYKLKMMAKMEKYLHSSRCRRQIILSHFEDKQVQKASLGIMGTEKCCDNCRSRLDHCYSMDDSEDTSWDFGPQAFKLLSAVDILGEKFGIGLPILFLRGSNSQRLADQYRRHSLFGTGKDQTESWWKAFSRQLITEGFLVEVSRYNKFMKICALTKKGRNWLHKANTESQSLILQANEELCPKKLLLPSSKTVSSGTKEHCYNQVPVELSTEKKSNLEKLYSYKPCDKISSGSNISKKSIMVQSPEKAYSSSQPVISAQEQETQIVLYGKLVEARQKHANKMDVPPAILATNKILVDMAKMRPTTVENVKRIDGVSEGKAAMLAPLLEVIKHFCQTNSVQTDLFSSTKPQEEQKTSLVAKNKICTLSQSMAITYSLFQEKKMPLKSIAESRILPLMTIGMHLSQAVKAGCPLDLERAGLTPEVQKIIADVIRNPPVNSDMSKISLIRMLVPENIDTYLIHMAIEILKHGPDSGLQPSCDVNKRRCFPGSEEICSSSKRSKEEVGINTETSSAERKRRLPVWFAKGSDTSKKLMDKTKRGGLFS T47583 DRUGINFO DF5LB8 NSC 19630 Investigative T50261 TARGETID T50261 T50261 UNIPROID Family T50261 TARGNAME PI3-kinase (PIK3C) T50261 TARGTYPE Literature-reported T50261 DRUGINFO DHG36S ETP-45658 Investigative T74839 TARGETID T74839 T74839 UNIPROID CDK13_HUMAN T74839 TARGNAME Cyclin-dependent kinase 13 (CDK13) T74839 GENENAME CDK13 T74839 TARGTYPE Literature-reported T74839 SYNONYMS CDC2-related protein kinase 5; Cell division cycle 2-like protein kinase 5; Cell division protein kinase 13; hCDK13; Cholinesterase-related cell division controller T74839 FUNCTION Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at 'Lys-50' and 'Lys-51', thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef. T74839 BIOCLASS Kinase T74839 ECNUMBER EC 2.7.11.22 T74839 SEQUENCE MPSSSDTALGGGGGLSWAEKKLEERRKRRRFLSPQQPPLLLPLLQPQLLQPPPPPPPLLFLAAPGTAAAAAAAAAASSSCFSPGPPLEVKRLARGKRRAGGRQKRRRGPRAGQEAEKRRVFSLPQPQQDGGGGASSGGGVTPLVEYEDVSSQSEQGLLLGGASAATAATAAGGTGGSGGSPASSSGTQRRGEGSERRPRRDRRSSSGRSKERHREHRRRDGQRGGSEASKSRSRHSHSGEERAEVAKSGSSSSSGGRRKSASATSSSSSSRKDRDSKAHRSRTKSSKEPPSAYKEPPKAYREDKTEPKAYRRRRSLSPLGGRDDSPVSHRASQSLRSRKSPSPAGGGSSPYSRRLPRSPSPYSRRRSPSYSRHSSYERGGDVSPSPYSSSSWRRSRSPYSPVLRRSGKSRSRSPYSSRHSRSRSRHRLSRSRSRHSSISPSTLTLKSSLAAELNKNKKARAAEAARAAEAAKAAEATKAAEAAAKAAKASNTSTPTKGNTETSASASQTNHVKDVKKIKIEHAPSPSSGGTLKNDKAKTKPPLQVTKVENNLIVDKATKKAVIVGKESKSAATKEESVSLKEKTKPLTPSIGAKEKEQHVALVTSTLPPLPLPPMLPEDKEADSLRGNISVKAVKKEVEKKLRCLLADLPLPPELPGGDDLSKSPEEKKTATQLHSKRRPKICGPRYGETKEKDIDWGKRCVDKFDIIGIIGEGTYGQVYKARDKDTGEMVALKKVRLDNEKEGFPITAIREIKILRQLTHQSIINMKEIVTDKEDALDFKKDKGAFYLVFEYMDHDLMGLLESGLVHFNENHIKSFMRQLMEGLDYCHKKNFLHRDIKCSNILLNNRGQIKLADFGLARLYSSEESRPYTNKVITLWYRPPELLLGEERYTPAIDVWSCGCILGELFTKKPIFQANQELAQLELISRICGSPCPAVWPDVIKLPYFNTMKPKKQYRRKLREEFVFIPAAALDLFDYMLALDPSKRCTAEQALQCEFLRDVEPSKMPPPDLPLWQDCHELWSKKRRRQKQMGMTDDVSTIKAPRKDLSLGLDDSRTNTPQGVLPSSQLKSQGSSNVAPVKTGPGQHLNHSELAILLNLLQSKTSVNMADFVQVLNIKVNSETQQQLNKINLPAGILATGEKQTDPSTPQQESSKPLGGIQPSSQTIQPKVETDAAQAAVQSAFAVLLTQLIKAQQSKQKDVLLEERENGSGHEASLQLRPPPEPSTPVSGQDDLIQHQDMRILELTPEPDRPRILPPDQRPPEPPEPPPVTEEDLDYRTENQHVPTTSSSLTDPHAGVKAALLQLLAQHQPQDDPKREGGIDYQAGDTYVSTSDYKDNFGSSSFSSAPYVSNDGLGSSSAPPLERRSFIGNSDIQSLDNYSTASSHSGGPPQPSAFSESFPSSVAGYGDIYLNAGPMLFSGDKDHRFEYSHGPIAVLANSSDPSTGPESTHPLPAKMHNYNYGGNLQENPSGPSLMHGQTWTSPAQGPGYSQGYRGHISTSTGRGRGRGLPY T74839 DRUGINFO D7RK2M THZ531 Investigative